"META CUI","META CUI TERM","NCIt CODE","NCIt TERM","NCIt TERM Synonyms","ICDO-3 CODE","ICDO-3 TERM","SNOMED CT CODE","SNOMED CT TERM","MedDRA CODE","MedDRA TERM","LOINC CODE","LOINC TERM","HGNC CODE","HGNC TERM","ICD-10-CM CODE","ICD-10-CM TERM","UBERON CODE","UBERON TERM","OMOP CODE","OMOP TERM","MED-RT CODE","MED-RT TERM","ICD-10-PCS CODE","ICD-10-PCS TERM","NCBI CODE","NCBI TERM","HPO CODE","HPO TERM","HCPCS CODE","HCPCS TERM","GO CODE","GO TERM","META CUI Term Type","ICDO-3 Term Type","SNOMED CT Term Type","MedDRA Term Type","LOINC Term Type","HGNC Term Type","ICD-10-CM Term Type","MED-RT Term Type","ICD-10-PCS Term Type","OMOP Term Type","NCBI Term Type","HPO Term Type","HCPCS Term Type","GO Term Type"
"C0324451","Silky Terrier","C53944","A fine-boned, moderately low-set, long-haired terrier. It is compact but lightly built with erect, v-shaped ears. It has fine, shiny hair and no undercoat. The coat may be blue and fire red, or blue with tan markings. The average height is 9-10 inches and the average weight range is 8-11 pounds.","Silky Terrier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816724","Sixty","C105792","A natural number greater than fifty-nine and less than sixty-one and the quantity that it denotes.","Sixty | 60",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508189","Number of Weeks Since Last Cigarette","C127067","A question about the number of weeks since an individual last smoked a cigarette.","Number of Weeks Since Last Cigarette | Number of weeks since last cigarette",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334037","Classic Hodgkin Lymphoma Post-Transplant Lymphoproliferative Disorder","C7243","A lymphoproliferative disorder that fulfills the criteria for classic Hodgkin lymphoma and arises as a result of post-transplant immunosuppression therapy. It is most often seen in renal transplant patients.","Classic Hodgkin Lymphoma Post-Transplant Lymphoproliferative Disorder | Classic Hodgkin Lymphoma PTLD | Classic Hodgkin Lymphoma Type PTLD | Classic Hodgkin Lymphoma Type Post-Transplant Lymphoproliferative Disorder | Classic Hodgkin Lymphoma Type Post-Transplant Lymphoproliferative Disorder | Classical Hodgkin Lymphoma Post-Transplant Lymphoproliferative Disorder | Classical Hodgkin Lymphoma Type PTLD | Classical Hodgkin Lymphoma Type Post-Transplant Lymphoproliferative Disorder | Classical Hodgkin Lymphoma Type Post-Transplant Lymphoproliferative Disorder | Hodgkin Lymphoma PTLD | Hodgkin Lymphoma Post-Transplant Lymphoproliferative Disorder | Hodgkin lymphoma - like PTLD | Hodgkin lymphoma-like post-transplant lymphoproliferative disorder | Hodgkin's Lymphoma PTLD | Hodgkin's Lymphoma Post-Transplant Lymphoproliferative Disorder | Hodgkin-Like Post-Transplant Lymphoproliferative Disorder",,,,,,,,,,,,,,,"37203817","Classical Hodgkin lymphoma type posttransplant lymphoproliferative disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555584","Mannitol Measurement","C154742","The determination of the amount of mannitol present in a sample.","Mannitol Measurement | MANNITOL | Mannitol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1171936","Exosome Complex Component RRP46, Human","C113292","Exosome complex component RRP46 (235 aa, ~25 kDa) is encoded by the human EXOSC5 gene. This protein is involved in RNA metabolism.","Exosome Complex Component RRP46 | Chronic Myelogenous Leukemia Tumor Antigen 28 | EXOSC5 | Exosome Complex Exonuclease RRP46 | Exosome Component 5 | Exosome Component Rrp46 | Ribosomal RNA-Processing Protein 46 | p12B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513477","Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic c.394_395CG>TC","C131094","A complex substitution where the nucleotide sequence at positions 394 and 395 of the coding sequence of the IDH1 gene has changed from cytosine-guanine to thymine-cytosine.","IDH1 NM_005896.3:c.394_395delinsTC | IDH c.394_395CG>TC | IDH c.394_395delCGinsTC | IDH1 NM_005896.3:c.394_395delCGinsTC | IDH1 NM_005896.3:c.394_395delCGinsTC | IDH1 c.394_395CG>TC | IDH1 c.394_395delCGinsTC | Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic c.394_395CG>TC | Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic c.394_395delCGinsTC | Isocitrate Dehydrogenase 1 (NADP+), Soluble c.394_395CG>TC | Isocitrate Dehydrogenase 1 (NADP+), Soluble c.394_395delCGinsTC | NM_005896.3:c.394_395CG>TC | NM_005896.3:c.394_395delCGinsTC | NM_005896.3:c.394_395delinsTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550995","CD40L-Fc Fusion Protein MEDI5083","C148416","A fusion protein composed of CD40 ligand (CD40L; CD154; TRAP; TNFSF5) fused to a modified immunoglobulin (Ig) Fc fragment, with potential immunostimulating activity. Upon administration of the CD40L-Fc fusion protein MEDI5083, the CD40L moiety specifically targets, binds to, and activates CD40, a cell surface receptor that belongs to the tumor necrosis factor (TNF) receptor family and is expressed on various immune cells, such as B-lymphocytes, monocytes, and dendritic cells (DCs). Activation of CD40 induces proliferation and activation of B-lymphocytes, shifts the induction of suppressive macrophages towards immunostimulatory macrophages, activates monocyte-derived DCs (moDCs), and leads to the secretion of inflammatory cytokines, which activates the immune system to induce the proliferation and activation of cytotoxic T-lymphocytes (CTLs) against tumor cells. Altogether, this may cause tumor cell lysis.","CD40L-Fc Fusion Protein MEDI5083 | MEDI 5083 | MEDI-5083 | MEDI5083",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971806","Cathinone","C166812","No value exists.","Cathinone | CATHINONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0557849","Inner City","C18067","The older and more populated and (usually) poorer central section of a city.","Inner City | Inner Cities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336577","HTATIP2 protein, human","C26315","Oxidoreductase HTATIP2 (242 aa, ~27 kDa) is encoded by the human HTATIP2 gene. This protein plays a role in the modulation of redox reactions, apoptosis, and tumor formation.","Oxidoreductase HTATIP2 | 30 kDa HIV-1 TAT-Interacting Protein | HIV-1 TAT Interactive Protein 2, 30-kD | HIV-1 TAT-Interacting Protein 30-kD | HIV-1 TAT-Interactive Protein 2 | HTATIP2 | HTATIP2 Protein | TAT-Interacting Protein (30kD) | TAT-Interacting Protein TIP30",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708204","Gene_Found_In_Organism","C43781","A role used to specify the organism of origin for a gene. It may be used to differentiate genes with the same name and functions that originate from different organisms. The domain and range for this role are 'Gene' and 'Organism', respectively.","Gene_Found_In_Organism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982070","Carcinoma of the Conjunctiva TNM Finding v7","C88586","A finding about one or more characteristics of carcinoma of the conjunctiva, following the rules of the TNM AJCC v7 classification system.  No stage grouping is presently recommended for carcinoma of the conjunctiva.  (from AJCC 7th Ed.)","Carcinoma of the Conjunctiva TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825646","Razaxaban Hydrochloride","C81464","The hydrochloride salt form of razaxaban, an orally active, 1,2-benzisoxazole-containing, inhibitor of coagulation factor Xa (activated factor X) with anticoagulant activity. Razaxaban forms an isoxazole-ring opened, stable, benzamidine metabolite which is subsequently excreted through the bile.","Razaxaban Hydrochloride | RAZAXABAN HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1299469","Fractional Flow Reserve of Vessel","C99533","A lesion-specific measure of stenosis severity within a blood vessel.","Fractional Flow Reserve of Vessel | Fractional Flow Reserve",,,,,,,,,,,,,,,"4161982","Fractional flow reserve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2240534","Zinc Lactate","C84249","No value exists.","Zinc Lactate | ZINC LACTATE | Zinc, Bis(2-(Hydroxy-Kappa-O)Propanoato-Kappa-O)-, (T-4)- | Zinc, Bis(Lactato)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003320","Antigen","C268","Any substance, generally a protein, that stimulates the immune system and elicits an immune response.  Recognition by the immune system elicits either a T-lymphocyte response, recognizing processed antigens, or a B-lymphocyte response, producing antibodies that bind to unprocessed antigens.","Antigen | Antigens | antigen",,,,,,,,,,,,,,,"4324558","Antigen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1515974","Anatomic Site","C13717","Named locations of or within the body.","Anatomic Site | Anatomic Location | Anatomic Sites | Anatomical Location | Anatomical_Location | CDISC | LOC | Location | Site | Topographic (Anatomic) Site | Topographic Site",,,,,,,,,,,,,,,"42539300","Anatomic location (property)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516308","Case Report Form","C40988","A printed, optical, or electronic document designed to record all of the clinical study-required information stipulated in the protocol to be reported to the sponsor on each clinical trial subject.","Case Report Form | CRF | CRF/ eCRF | Sample CRF/eCRF | Sample Case Report Form | case record form | case report form (CRF)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272706","Interval","C25543","The period of time or the distance separating two instances, events, or occurrences.","Interval | ",,,,,,,,,,,,,,,"4294905","Interval",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021853","Intestine","C12736","The portion of the gastrointestinal tract between the stomach and the anus. It includes the small intestine and large intestine.","Intestine | Bowel | Bowel | INTESTINE | Intestinal structure (body structure) | Intestinal tract, NOS | Intestines | bowel | intestine",,,,,,,,,,,,,,,"37158173|4034270","Intestinal|Intestinal structure",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0557514","Registrar","C25357","A person responsible for keeping official records.","Registrar | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3282337","Cell","C12508","The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid.","Cell | Cell Type | Cell Types | Cells | Cellular | Normal Cell | cell | {Cells}",,,,,,,,,,,,,,,"4195765","Cell structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205210","Clinical","C25398","Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity.","Clinical | clinical",,,,,,,,,,,,,,,"4241440","Clinical",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0858246","Hypoglycemia","C3126","Abnormally low level of glucose in the blood.","Hypoglycemia | hypoglycemia",,,,,,,,,,,,,,,"24609","Hypoglycemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1521902","To specify","C25685","Be specific about something; define clearly.","Specify | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439805","Tumor Debulking","C15749","The surgical removal of as much of a malignant tumor as is reasonably possible. This procedure increases the effectiveness of the subsequent administration of chemotherapy and/or radiation therapy.","Tumor Debulking | Debulking | Debulking | Debulking Procedure | Debulking Surgery | debulking | tumor debulking",,,,,,,,,,,,,,,"4114685|4120657","Debulking - action|Interventional debulking surgery",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0237096","Residence","C25273","Any address at which a person dwells more than temporarily.","Residence | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333348","Inflammatory","C25535","Relating to inflammation.","Inflammatory | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042149","Uterus","C12405","A hollow, thick-walled, muscular organ located within the pelvic cavity of a woman. Within the uterus the fertilized egg implants and the fetus develops during pregnancy.","Uterus | Genital System, Female, Uterus | UTERUS | Uterine | Uterine structure (body structure) | Utero | Uterus, NOS | Womb | uterus | womb",,,,,,,,,,,,,"UBERON:0000995","uterus","4149192","Uterine structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015799","Male Feminization","C26773","The development of secondary female sex characteristics in males.","Feminization | Feminization in Boys | Male Feminization",,,,,,,,,,,,,,,"4140373|4305196","Feminized male|Abnormal development of female secondary sexual characteristics",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0010435","Cuba","C16477","An island between the Caribbean Sea and the North Atlantic Ocean, 150 km south of Key West, Florida.","Cuba | 192 | CU | CUB | CUBA",,,,,,,,,,,,,,,"4075639","Cuba",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030428","Paraguay","C16953","A country in central South America, northeast of Argentina.","Paraguay | 600 | PARAGUAY | PRY | PY",,,,,,,,,,,,,,,"4072764","Paraguay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004781","Basal Ganglia","C12447","Clusters of neurons comprising the globus pallidus, putamen, caudate, nucleus accumbens, substantia nigra and subthalamic nucleus. They are involved with high level aspects of inhibitory motor activity in coordination with the excitation commands issued from the cerebellum.","Basal Ganglia | BASAL GANGLIA | BRAIN, BASAL GANGLIA | Basal ganglia | collection of basal ganglia","C71.0","Basal ganglia",,,,,,,,,,,,,"4137619","Basal ganglion structure",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0007095","Carcinoid Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0347984","During","C25490","At some point in a given period of time.","During | DURING | Over",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1542147","Main","C25562","Most important; principal.","Main | Predominant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1261188","Swab","C17627","A tuft of material on the end of a stick for applying solutions and suspensions","Swab | SWAB",,,,,,,,,,,,,,,"4255049","Swab",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710539","UniGene (experimental system)","C43563","An experimental system for automatically partitioning GenBank sequences into a non-redundant set of gene-oriented clusters. Each UniGene cluster contains sequences that represent a unique gene, as well as related information such as the tissue types in which the gene has been expressed and map location.  It is provided as a web application from the National Center for Biotechnology Information (NCBI).","UniGene | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518905","Party Role","C41108","This object connects the party (organization or person) with the animal model.","Party Role | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706959","Biosequence","C43380","A BioSequence is an object representation of a DNA, RNA, or protein sequence.  It can be represented by a Clone, Gene, or the sequence. (caMAGE)","Biosequence | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704991","Sequence Feature","C47853","An identifiable region or site of interest in a sequence.","Sequence Feature | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086282","Family Member","C41256","Any of the individuals who are descended from a common progenitor, related by marriage or other legal tie, or by a feeling of closeness.","Family Member | FAMILY MEMBER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0058731","Doxycycline Hyclate","C29007","The hyclate salt form of doxycycline, a synthetic, broad-spectrum tetracycline antibiotic exhibiting antimicrobial activity. Doxycycline hyclate binds reversibly to the 30S ribosomal subunit, possibly to the 50S ribosomal subunit as well, thereby blocking the binding of aminoacyl-tRNA to the mRNA-ribosome complex. This leads to an inhibition of protein synthesis. In addition, this agent has exhibited inhibition of collagenase activity.","Doxycycline Hyclate | DOXYCYCLINE HYCLATE | Doryx | doxycycline hyclate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1142985","Ezetimibe","C47529","An azetidinone derivative and a cholesterol absorption inhibitor with lipid-lowering activity. Ezetimibe appears to interact physically with cholesterol transporters at the brush border of the small intestine and inhibits the intestinal absorption of cholesterol and related phytosterols. As a result, ezetimibe causes a decrease in the level of blood cholesterol or an increase in the clearance of cholesterol from the bloodstream. Overall, the following effects observed are a reduction of hepatic cholesterol stores and a reduction of total cholesterol, LDL cholesterol, and other triglycerides in the blood.","Ezetimibe | 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone | EZETIMIBE | Ezedoc | Zetia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0795571","Dextroamphetamine-Amphetamine","C26643","A combination of two synthetic agents with central nervous system stimulant activity.  Both agents are non-catecholamine, sympathomimetic agents that elevate blood pressure and cause bronchodilation.  These agents are commonly abused psychostimulant drugs that induce psychologic dependence manifested by elevated mood, increased wakefulness, concentration, physical performance and a feeling of well-being.  Tolerance to various effects develops unequally, so that tachycardia and enhanced alertness diminish while psychotoxic effects (hallucinations and delusions) may occur. (NCI04)","Dextroamphetamine-Amphetamine | Adderall | Adderall XR | dextroamphetamine-amphetamine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033348","Programming Languages","C47903","A formal language in which computer programs are written. The definition of a particular language consists of both syntax (how the various symbols of the language may be combined) and semantics (the meaning of the language constructs).","Programming Language | Language",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279567","Breast Paget Disease with Invasive Ductal Carcinoma","C7951","Paget disease involving the skin overlying the mammary gland, accompanied by invasive ductal breast carcinoma.","Breast Paget Disease with Invasive Ductal Carcinoma | Paget Disease and Infiltrating Duct Carcinoma of Breast | Paget Disease of the Breast with Invasive Ductal Carcinoma | Paget Disease of the Breast with Invasive Ductal Carcinoma | Paget disease and infiltrating duct carcinoma of breast | Paget's Disease and Infiltrating Ductal Carcinoma of Breast | Paget's Disease and Infiltrating Ductal Carcinoma of the Breast | Paget's Disease and Invasive Ductal Carcinoma of Breast | Paget's Disease and Invasive Ductal Carcinoma of the Breast | Paget's Disease of Breast with Infiltrating Ductal Carcinoma | Paget's Disease of Breast with Invasive Ductal Carcinoma | Paget's Disease of the Breast with Infiltrating Ductal Carcinoma | Paget's Disease of the Breast with Invasive Ductal Carcinoma | Paget's Disease of the Breast with Invasive Ductal Carcinoma","8541/3","Paget disease and infiltrating duct carcinoma of breast",,,,,,,,,,,,,"4220365","Paget's disease and infiltrating duct carcinoma of breast",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0028040","Nicotine","C691","A plant alkaloid, found in the tobacco plant, and addictive central nervous system (CNS) stimulant that causes either ganglionic stimulation in low doses or ganglionic blockage in high doses. Nicotine acts as an agonist at the nicotinic cholinergic receptors in the autonomic ganglia, at neuromuscular junctions, and in the adrenal medulla and the brain. Nicotine's CNS-stimulating activities may be mediated through the release of several neurotransmitters, including acetylcholine, beta-endorphin, dopamine, norepinephrine, serotonin, and ACTH. As a result, peripheral vasoconstriction, tachycardia, and elevated blood pressure may be observed with nicotine intake. This agent may also stimulate the chemoreceptor trigger zone, thereby inducing nausea and vomiting.","Nicotine | (-)-Nicotine | (S)-3-(1-Methyl-2-pyrrolidinyl)pyridine | 1-Methyl-2-(3-pyridyl)pyrrolidine | NIC | NICOTINE | beta-Pyridyl-alpha-N-methylpyrrolidine | nicotine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0595451","Intrapleural Route of Administration","C38259","Administration of a drug within the pleural cavity. The intrapleural drug administration usually results in both local and systemic drug action.","Intrapleural Route of Administration | I-PLEURAL | INTRAPLEURAL | Intrapleural | Intrapleural use",,,,,,,,,,,,,,,"4156707","Intrapleural",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025826","Methyltestosterone","C648","A methylated synthetic androgen receptor agonist with anabolic effects. Methyltestosterone, mimicking testosterone, binds to cytosolic androgen receptors, and the subsequent nuclear transfer of the ligand-receptor complex induces transcription initiation of androgen responsive genes. The gene products are responsible for normal growth and development of male sex organs and secondary sex characteristics. The agent also causes retention of nitrogen, sodium, potassium, phosphorus, as well as calcium.","Methyltestosterone | (17Beta)-17-hydroxy-17-methylandrost-4-en-3-one | 17 Alpha-methyl-delta4-androsten-17beta-ol-4-one | 17-Methyltestosterone | Android | Eldec | Ero Test | Estratest | Glosso-Sterandryl | METHYLTESTOSTERONE | Malogen | Metandren | Methitest | Methyltestosteronum | Neohombreol M | Orchisterone-M | Oreton Methyl | Oreton methyl | Testomet | Testotonic B | Testovis | Testred | Virilon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324316","Border Terrier","C53714","A small terrier with a coarse, wiry double coat and small ears, which fold forward into a \'V\' shape. The coat may be red, blue and tan, tan, or grizzle and tan. The average height range is 11-16 inches and the average weight range is 11-16 pounds.","Border Terrier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001737","Africa","C26272","The continent located south of Europe and bordered to the west by the South Atlantic and to the east by the India Ocean.","Africa | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1947940","Oil Dosage Form","C42965","A solution or suspension that is hydrophobic, soluble in organic solvents, and liquid at ambient temperature.","Oil Dosage Form | OIL | Oil | Oil Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1337602","Delayed Release Tablet Dosage Form","C42905","A tablet that has been coated with a substance that is designed to impede the immediate release of the active and/or inert ingredient(s) after administration.","Delayed Release Tablet Dosage Form | DELAYED RELEASE TABLET | DR Tab | Delayed Release Tablet | Delayed Release Tablet Dose Form | Gastro-resistant tablet | TAB DR | TABLET, DELAYED RELEASE | Tablet, Delayed Release | Tablet, Gastro-Resistant | Tablet, delayed release",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441635","Segment","C45312","One of the parts into which something naturally divides.","Segment | SEGMENT",,,,,,,,,,,,,,,"4136397","Segment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0359627","Gold","C2392","An element with atomic symbol Au, atomic number 79, and atomic weight 197.","Gold | Au | GOLD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0151744","Ischemic Heart Disease","C50625","A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries, to obstruction by a thrombus, or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (myocardial infarction).","Ischemic Heart Disease | IHD",,,,,,,,,,,,,,,"4185932","Ischemic heart disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021061","Immunology Test","C16723","Laboratory test involving interaction of antigens with specific antibodies.","Immunology Test | Immunologic Technique | Immunological Laboratory Method | immunoassay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019761","HLA-DQ Antigen","C62792","HLA-DQ antigen is a class of glycoproteins that consist of dimers of alpha and beta subunits, which are encoded by the polymorphic human genes HLA-DQA1 and HLA-DQB1, respectively. This protein complex is expressed primarily in lymphoid cells and function to present antigens for CD4+ T lymphocytes. Certain HLA-DQ protein variants are associated with susceptibility to insulin-dependent diabetes mellitus and several autoimmune diseases.","HLA-DQ Antigen | ",,,,,,,,,,,,,,,"4302467","HLA-DQ antigen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033578","Prostate Neoplasm","C3343","A benign, borderline, or malignant neoplasm that affects the prostate gland.  Representative examples include benign prostate phyllodes tumor, prostatic intraepithelial neoplasia, prostate carcinoma, and prostate sarcoma.","Prostate Neoplasm | Neoplasm of Prostate | Neoplasm of the Prostate | Prostate Tumor | Tumor of Prostate | Tumor of the Prostate",,,,,,,,,,,,,,,"4129902","Neoplasm of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0053963","Bouin's Fixative","C63349","A tissue fixative consisting of formaldehyde, glacial acetic acid, and picric acid. It provides particularly excellent preservation of nuclei and chromosomes.","Bouin's Fixative | Bouin's Fluid | Bouin's Solution",,,,,,,,,,,,,,,"4203528","Bouin fluid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4225533","Clear Cell Renal Cell Carcinoma","C4033","A malignant epithelial neoplasm of the kidney characterized by the presence of lipid-containing clear cells within a vascular network.  The tumor may metastasize to unusual sites and late metastasis is common.","Clear Cell Renal Cell Carcinoma | CCRCC | Clear Cell Adenocarcinoma of Kidney | Clear Cell Adenocarcinoma of the Kidney | Clear Cell Adenocarcinoma, Kidney | Clear Cell Carcinoma of Kidney | Clear Cell Carcinoma of the Kidney | Clear Cell RCC | Clear Cell Renal Cell Cancer | Conventional (Clear Cell) Renal Cell Adenocarcinoma | Conventional (Clear Cell) Renal Cell Carcinoma | Conventional (Clear Cell) Renal Cell Carcinoma | Conventional Renal Cell Carcinoma | Grawitz Tumor | Grawitz tumor | Hypernephroid tumor | Hypernephroma | Kidney Clear Cell Adenocarcinoma | Kidney Clear Cell Carcinoma | RCC, clear cell adenocarcinoma | Renal Clear Cell Adenocarcinoma | Renal Clear Cell Carcinoma | Renal cell carcinoma, clear cell adenocarcinoma | hypernephroma","8311/1","Hypernephroid tumor",,,,,,,,,,,,,"37152522|4110880","Clear cell renal cell carcinoma|Clear cell carcinoma of kidney",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0039097","Synovial Fluid","C33718","A viscid fluid secreted by the synovial membrane, serving as a lubricant.","Synovial Fluid | FLUID, SYNOVIAL | Fluid, Joint | Fluid, synovial (Joint fluid) | SYNOVIAL FLUID | Synovia",,,,,,,,,,,,,,,"4246175","Synovial fluid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002393","Alveoloplasty","C63753","Surgical preparation of the alveolar ridges, commonly used for the reception of dentures.","Alveoloplasty | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707340","Centroid","C47930","A point that is the center of mass of an object of uniform density or the geometric center of a planar object.","Centroid | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043127","West Virginia","C43473","A state in the mid-atlantic United States. Its capital is Charleston.","West Virginia | US: West Virginia | WV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0220748","Cartilage Hair Hypoplasia","C61245","A rare autosomal recessive inherited disorder caused by mutation in the gene for RNAase RMRP. It is characterized by short-limb dwarfism, presence of fine sparse hair, and T-and B-cell immunodeficiency.","Cartilage Hair Hypoplasia | ",,,,,,,,,,,,,,,"4298801","Metaphyseal chondrodysplasia, McKusick type",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0376495","Retreatments","C54055","The repeated act of the dispensing, applying, or tendering of something to another after an initial treatment.","Retreatment | Readministration | Reapplication | Reintroduction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206034","Randomized Clinical Trial","C15417","Assignment of subjects by chance to groups that receive different treatments.","Randomized Clinical Trial | Randomized | Randomized Clinical Trials | randomized clinical trial",,,,,,,,,,,,,,,"608164","Randomized clinical trial",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524691","Dental Post","C66863","A rod that a dentist has positioned and then cemented in the canal space in a tooth's root.","Dental Post | ",,,,,,,,,,,,,,,"4031749","Dental pin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1520228","101 Mouse","C14567","Inbr: 66. Genet: A^w. Origin: Dunn, 1936. (Jackson Labs/Festing)","101 Mouse | 101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025923","Mice, Inbred DBA","C37402","definition pending","DBA Mouse | DBA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880720","False Discovery Rate","C64214","A statistical method used for multiple testing corrections to control the expected proportion of false positives (Type I error) among rejected tests or hypotheses.  It is less stringent than other multiple testing corrections and thereby, will allow a percentage of false positives.","False Discovery Rate | FDR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881639","Median Baseline Removal Method","C64240","Method for identifying invariant set normalization baseline using median expression values. Defined in the documents available at http://bioconductor.org/packages/1.9/bioc/html/affy.html.","Median Baseline Removal Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0457933","Apartment","C62140","A room or suite of rooms designed as a residence and generally located in a building occupied by more than one household used as an element of an address.","Apartment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL599759","CD19 molecule, human","C38894","B-lymphocyte antigen CD19 (556 aa, ~61 kDa) is encoded by the human CD19 gene. This protein is involved in enhancing B-cell receptor-dependent signaling.","B-Lymphocyte Antigen CD19 | B-Lymphocyte Surface Antigen B4 | B4 | CD19 | CD19 Antigen | CD19 Antigen | Differentiation Antigen CD19 | Leu-12 | T-Cell Surface Antigen Leu-12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347828","Comet Scoring Engine","C68827","A private scoring engine developed by the Fred Hutchinson Cancer Research Institute that can match tandem mass spectra with peptide sequences.","Comet Scoring Engine | Comet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024496","Main Bronchus","C12284","One of two major branches of the trachea. Bifurcation of the trachea at the carina forms the left main bronchus and the right main bronchus.","Main Bronchus | Main bronchus | Main bronchus structure (body structure) | Mainstem bronchus | main bronchus",,,,,,,,,,,,,,,"4008013","Main bronchus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348956","Heterogeneous Echotexture","C69214","A description of heterogeneous density elements seen in a tissue composition image obtained by sonography.","Heterogeneous Echotexture | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012817","Diverticulum","C26753","A pouch formed at a weakened area of wall in a hollow organ structure.","Diverticulum | DIVERTICULUM | diverticulum",,,,,,,,,,,,,,,"4150051","Diverticulum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1532563","Millimole per Liter","C64387","A unit of concentration (molarity unit) equal to one thousandth of a mole (10E-3 mole) of solute per one liter of solution.","Millimole per Liter | Attomole per Femtoliter | Femtomole per Picoliter | Micromole per Milliliter | Millimolar | Millimole/Liter | Mole per Cubic Meter | Nanomole per Microliter | Picomole per Nanoliter | Yoctomole per Zeptoliter | Zeptomole per Attoliter | amol/fL | fmol/pL | mcmol/mL | micromole(s)/millilitre | millimole per liter | millimole(s)/litre | mmol/L | mmol/l | mol/m3 | nmol/uL | pmol/nL | umol/mL | umol/ml | ymol/zL | zmol/aL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0203065","Esophagography","C38112","The process of obtaining contrast esophagrams.","Esophagography | Barium Swallow | Contrast Esophagraphy | ESOPHAGOGRAPHY | barium swallow",,,,,,,,,,,,,,,"4059066|4113928","Barium swallow|Contrast radiography of esophagus",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0079225","Dextran Sulfate Sodium","C1284","A long chain polymer of sulfated glucose with strong hydrophilic properties that binds to various membranes. Dextran sulfate has been shown to inhibit the binding of HIV-1 to CD4+ T lymphocytes by specific binding of virion-associated gp120.","Dextran Sulfate Sodium | DEXTRAN SULFATE SODIUM (5000 MW) | Dextran Sulfate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704973","Nucleic Acid Strand","C45831","A single chain of nucleotides.","Nucleic Acid Strand | Strand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346753","Amplitude","C70831","The magnitude of an oscillation.","Amplitude | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347593","Certified Family Nurse Practitioner","C71287","A registered nurse who has additional education and training in a specialty area such as family practice and who is accredited through the national board exam.","Certified Family Nurse Practitioner | CFNP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512015","Doctor of Chiropractic","C39380","The Doctor of Chiropractic degree is a degree awarded for graduates who have completed a medical doctoral program in accredited chiropractic college. The academic and clinical training include, but are not limited to, the use of current diagnostic and therapeutic procedures that specifically involve the adjustment and manipulation of the articulations and adjacent tissues of the human body, particularly of the spinal column. State laws, as well as the nation's antitrust laws, may allow Doctors of Chiropractic to utilize ancillary health care procedures commonly referred to as being in the common domain.","Doctor of Chiropractic | Chiropractic Physician | D.C. | D.C.M. | DC | DCM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346486","Authorization for Release of Confidential Health Information Indicator","C70966","An indicator that can be set or unset in order to signal whether a signed authorization from a patient, or his legal representative, or clinical study participant for the use or disclosure of oral, written, or electronic form of confidential health information that identifies the individual and relates to the medical history, diagnosis, treatment, or prognosis of his condition has been obtained.","Authorization for Release of Confidential Health Information Indicator | Indicator of Authorization for Release of Confidential Health Information",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348331","Dose Regimen","C71137","A treatment plan that specifies the amount, schedule, and the duration of intervention(s).","Dose Regimen | DOSRGM | dose schedule | doseRegimen | dose_schedule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348114","SLM1 Linkage Map","C70944","A human linkage map generated from unpublished data from Affymetrix and Dr. Aravinda Chakravarti's group at Johns Hopkins University, based on genotypes for 2022 microsatellite markers and 6205 SNPs.","SLM1 Linkage Map | SLM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881838","Millimole per Minute per Thousand Pascal per Liter","C67423","A SI-coherent unit for measuring a pulmonary diffusing capacity adjusted for lung volume and expressed in units of a substance flow rate (in millimoles per minute) per unit of pressure (in kilopascals) per unit of alveolar volume equal to one liter.","Millimole per Minute per Thousand Pascal per Liter | Millimole per Minute per Kilopascal per Liter | Millimole/Minute/10^3 Pascal/Liter | millimole per minute per thousand Pascal per liter | mmol/min/10E3Pa/L | mmol/min/kPa/L | mmol/min/kPa/l",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018592","Happiness","C72670","The feeling of being pleased and content.","Happiness | Happy",,,,,,,,,,,,,,,"4011528","Cheerful mood",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0049832","7-Aminoactinomycin D","C72904","A fluorescent nucleic acid dye which selectively binds GC sequences in double-stranded DNA. It has a molecular weight of 1270.5, an absorbance maximun at 546 nm, and emission maximum at 647 nm. It is commonly used to discriminate viable from non-viable cells.","7-Aminoactinomycin D | 7-AAD | 7-AMINOACTINOMYCIN D | 7-Amino-AMD | 7-Amino-Actinomycin D | 7AAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024876","Masseter Muscle","C13074","A muscle of mastication originating from the zygomatic arch.","Masseter Muscle | MASSETER MUSCLE | MUSCLE, MASSETER | Masseter muscle structure (body structure) | Masticatory Muscle",,,,,,,,,,,,,,,"4195588","Masseter muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0724139","Atropine/Hyoscyamine/Methenamine/Methylene Blue/Phenyl Salicylate/Benzoic Acid","C29532","A combination preparation of methenamine, methylene blue, benzoic acid, phenyl salicylate, atropine sulfate, and hyoscyamine sulfate, with anti-inflammatory, antispasmodic and analgesic properties. Methenamine hydrolyzes into formaldehyde in acidic urine, thereby providing mild antiseptic effect. Methylene blue also exerts mild antiseptic activity and may inhibit bacterial proliferation. Benzoic acid exerts mild antibacterial and antifungal activities and helps maintain an acidic pH in the urine necessary for the degradation of methenamine to formaldehyde. Phenyl salicylate exerts mild analgesic, antipyretic and anti-inflammatory actions. Atropine sulfate and hyoscyamine sulfate are antimuscarinic agents that prevent smooth muscle spasms by antagonizing actions of acetylcholine. Urised is used for the relief of symptoms associated with urinary tract infections or diagnostic procedures.","Atropine/Hyoscyamine/Methenamine/Methylene Blue/Phenyl Salicylate/Benzoic Acid | Urised | Urised",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035237","Respiratory System","C12779","The organs involved in the exchange of carbon dioxide and oxygen including the trachea, bronchi, and lung parenchyma.","Respiratory System | Body System, Pulmonary | Organ System, Pulmonary | Pulmonary Body System | Pulmonary Organ System | RESPIRATORY SYSTEM | Respiratory | respiratory system | respiratory tract",,,,,,,,,,,,,,,"4065366","Structure of respiratory system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026222","Missouri","C43492","A state in the central midwest United States. Its capital is Jefferson City.","Missouri | MO | US: Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4017789","Thrombocytopenic Purpura","C26870","Purpura associated with a reduction in circulating blood platelets which can result from a variety of factors.","Thrombocytopenic Purpura | ",,,,,,,,,,,,,,,"4119134","Thrombocytopenic purpura",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2349146","Web Site","C67518","A collection of web pages and other files.","Web Site | Internet Website | Website | website | www-website",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512484","Home Page","C19467","The introductory page of a website; its navigational starting point.","Home Page | Homepage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698703","Pacific States Census Division","C76346","A census division of the United States consisting of Alaska, California, Hawaii, Oregon, and Washington.","Pacific States Census Division | Census Division 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004036","Aspergillus flavus","C77181","A species of mold fungus in the phylum Ascomycota that is associated with aspergillosis of the lungs.","Aspergillus flavus | ASPERGILLUS FLAVUS",,,,,,,,,,,,,,,"4281672","Aspergillus flavus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1948045","Once","C64576","One time.","Once | ONCE",,,,,,,,,,,,,,,"4141105","Single event",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883051","Sodium Lactate, D-","C61718","The sodium salt of the dextro isomer of lactic acid with alkalinizing and electrolyte replenishing property. Upon metabolism, sodium lactate D is converted to bicarbonate, thereby increasing plasma bicarbonate, which facilitates removal of hydrogen ion and lactate from blood stream and leads to raised blood pH.","Sodium Lactate, D- | SODIUM LACTATE, D-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0194073","Kidney Biopsy","C51699","Removal of tissue from the kidney, for microscopic examination.","Kidney Biopsy | Biopsy of Kidney | Renal Biopsy",,,,,,,,,,,,,,,"4217034","Kidney biopsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014124","Endocardium","C13004","The layer of endothelial cells and connective tissue lining the chambers of the heart.","Endocardium | ENDOCARDIUM | Endocardial",,,,,,,,,,,,,,,"4242718","Endocardium structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2697938","Longitudinal Relaxation Time","C80363","The time it takes for the net nuclear spin in the plane that is parallel to the magnetic field of a spectrometer to return to its equilibrium value.","Longitudinal Relaxation Time | 1/R1 | Spin-Lattice Relaxation Time | T1 | T1 Relaxation Time | T1 Signal | T1 Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513893","National Comprehensive Cancer Network","C39471","An alliance of 19 leading US cancer centers, an authoritative source of information to help patients and health professionals make informed decisions about cancer care. Through the collective expertise of its member institutions, the NCCN develops, updates, and disseminates a complete library of clinical practice guidelines. These guidelines are the standard for clinical policy in oncology.","National Comprehensive Cancer Network | NCCN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825197","Intersection of set of elements","C80456","The set of elements common to two or more sets.","Intersection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3550343","Trismus","C78651","Lack of ability to open the mouth fully due to decreased range of motion of the muscles of mastication. It may be a symptom of tetanus.","Trismus | ",,,,,,,,,,,,,,,"4339090","Trismus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0853620","Abnormal Blood Prolactin","C78217","A laboratory test result which indicates abnormal levels of prolactin hormone in the blood.","Abnormal Blood Prolactin | Blood prolactin abnormal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1561643","Chronic Kidney Disease","C80078","Impairment of the renal function secondary to chronic kidney damage persisting for three or more months.","Chronic Kidney Disease | CKD - Chronic Kidney Disease | Chronic Renal Disease | Chronic Renal Failure | Chronic Renal Insufficiency | Chronic kidney disease | Chronic kidney disease, unspecified | Chronic_Renal_Disease",,,,,,,,,,,,,,,"46271022","Chronic kidney disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014356","Enterocolitis","C79573","An inflammatory process affecting the small intestine and colon. Causes include viruses, bacteria, radiation, and antibiotics use.","Enterocolitis | ",,,,,,,,,,,,,,,"4184503","Enterocolitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1560030","Deep Connective Tissue Fibrosis","C78301","Fibrotic degeneration of the deep connective tissues.","Deep Connective Tissue Fibrosis | Fibrosis deep connective tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521597","Ileal Hemorrhage","C78353","Bleeding originating from the ileal wall.","Ileal Hemorrhage | Ileal hemorrhage",,,,,,,,,,,,,,,"4318829","Ileal hemorrhage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0863127","Chemotherapy-Related Leukemia","C80691","A leukemia arising as a result of the mutagenic effect of chemotherapy agents that are used for the treatment of a malignant tumor.","Chemotherapy-Related Leukemia | Leukemia secondary to oncology chemotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL411815","Lower Gastrointestinal Hemorrhage","C78438","Bleeding from the lower gastrointestinal tract (small intestine, large intestine, and anus).","Lower Gastrointestinal Hemorrhage | Intestinal Hemorrhage | Lower gastrointestinal hemorrhage",,,,,,,,,,,,,,,"4338544","Lower gastrointestinal hemorrhage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0241136","Skin Pain","C78516","Painful sensation in the skin.","Skin Pain | Pain of skin",,,,,,,,,,,,,,,"4115411","Pain of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3809615","Renal Stone","C26807","Crystals in the pelvis of the kidney.","Renal Stone | Kidney Calculus | Kidney Stone | Renal Calculus | Renal calculi",,,,,,,,,,,,,,,"201620","Kidney stone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0226742","Superior Mesenteric Vein","C33687","A vein that follows the path of the superior mesenteric artery and joins with the splenic vein to form the hepatic portal vein.","Superior Mesenteric Vein | ",,,,,,,,,,,,,,,"4236320","Structure of superior mesenteric vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0851401","Maternal Complication of Pregnancy","C35594","The development of a problematic medical situation that occurs during pregnancy.","Maternal Complication of Pregnancy | Maternal Disorder | Maternal Pregnancy Complication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827406","Craniospinal","C84352","Relating to the cranium and the spinal column.","Craniospinal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513899","National Institute of Drug Abuse","C19757","An institute within the National Institutes of Health with the mission to lead the nation in bringing the power of science to bear on drug abuse and addiction. This charge has two critical components, the strategic support and conduct of research across a broad range of disciplines and the rapid and effective dissemination and use of the results of that research to significantly improve prevention, treatment and policy as it relates to drug abuse and addiction.","National Institute on Drug Abuse | NIDA | National Institute of Drug Abuse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516379","Center Core Grants","C20014","Supports centralized resources and facilities shared by investigators with existing funded research projects. The overall goal is to increase the effectiveness, capabilities, or productivity of current projects; to stimulate cooperative approaches; and/or to promote new research directions through multi-disciplinary or regional collaborations.","Center Core Grants | P30 Mechanism | P30 Program",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825829","XML Metadata Interchange","C81932","A use of the Extensible Markup Language (XML) that is intended to provide a standard way for programmers and other users to exchange information about metadata. Specifically, XMI is intended to help programmers using the Unified Modeling Language (UML) with different languages and development tools to exchange their data models with each other.","XMI | XML Metadata Interchange",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827425","Imaging Signal","C84384","The measured value of a response in a recorded image produced by the intensity, abundance, or concentration of source materials.","Imaging Signal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0771371","Motherwort","C87565","An herbal remedy containing parts of Leonurus cardiaca, a perennial plant in the mint family Lamiaceae. The parts used are the aerial parts, root, flowers and/or seeds depending on the remedy. The herb contains the alkaloids stachydrine and leonurinine, glycosides, diterpinoids, flavonoids, tannins, volatile oils, and vitamin A.","Motherwort | Lion's Ear | Lion's Tail",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709158","Neonatal Hearing Impairment","C50667","An abnormality that affects hearing within the first month after birth. It may or may not result in hearing loss.","Neonatal Hearing Impairment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0150141","Bathing","C86050","The act of immersing the body in water or sunshine.","Bathing | Bathe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710173","Lung Basaloid Squamous Cell Carcinoma","C45507","A morphologic variant of squamous cell lung carcinoma characterized by nuclear palisading.","Lung Basaloid Squamous Cell Carcinoma | Basaloid Squamous Cell Lung Carcinoma | Basaloid Squamous Cell Lung Carcinoma | Lung Basaloid Squamous Cell  Carcinoma | Squamous Cell Lung Carcinoma, Basaloid Variant | Squamous Cell Lung Carcinoma, Basaloid Variant",,,,,,,,,,,,,,,"37165766|45768919","Basaloid squamous cell carcinoma of lung|Primary basaloid squamous cell carcinoma of lung",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0585291","Four Times Daily","C64530","Four times per day.","Four Times Daily | 4 times daily | 4 times per day | Four times a day | QID | quarter in die",,,,,,,,,,,,,,,"4145078","Four times daily",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL449145","Between","C94545","The space or interval separating two things.","Between | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0563634","Microgranular Acute Promyelocytic Leukemia","C27757","Acute promyelocytic leukemia in which the promyelocytes in the peripheral blood have paucity or absence of cytoplasmic granules and characteristic bilobed nuclei.","Microgranular Acute Promyelocytic Leukemia | Hypogranular Acute Promyelocytic Leukemia | M3 Variant | M3v",,,,,,,,,,,,,,,"4112803","Acute promyelocytic leukemia - hypogranular variant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2983608","Good Laboratory Practice Type","C90389","A classification of the good laboratory practices employed in a study.","Good Laboratory Practice Type | GLPTYP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982579","Thyroid Cancer pT1b TNM Finding v7","C89149","Thyroid cancer with a tumor size of more than 1 cm but not more than 2 cm in greatest dimension, limited to the thyroid gland. (from AJCC 7th Ed.)","Thyroid Cancer pT1b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333296","Diffuse Large B-Cell Lymphoma Activated B-Cell Type","C36081","A biologic subset of diffuse large B-cell lymphomas with a unique molecular signature or expression profile.  It represents approximately 30% of diffuse large B-cell lymphomas, and is characterized by the expression of CD44, PKCbeta1, Cyclin D2, BCL-2, and IRF4/MUM1 genes.  Morphologically, these lymphomas are either centroblastic or immunoblastic (ratio 2:1).  Patients with this type of diffuse large B-cell lymphoma are reported to have a less favorable outcome compared to those with a germinal center B-cell expression profile, with a 5-year survival rate of 35% and a median survival of 2 years.","Diffuse Large B-Cell Lymphoma Activated B-Cell Type | ABC DLBCL | ABC-DLBCL | Activated B-Cell-Like Diffuse Large B-Cell Lymphoma | Activated B-Cell-Like Diffuse Large B-Cell Lymphoma | DLBCL Activated B-Cell Type | Diffuse Large B-Cell Lymphoma Non-GC/ABC | Diffuse Large B-Cell Lymphoma Non-Germinal Center/Activated B-Cell Type | Diffuse Large B-Cell Lymphoma with an Activated B-Cell Expression Profile | Non-GC/ABC DLBCL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439541","Black","C48323","Of darkest color; producing or reflecting comparatively little light and having no predominant hue; being the color of coal or carbon.","Black | BLACK",,,,,,,,,,,,,,,"4153955","Black color",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2987200","PrepaCyte-CB","C95518","A proprietary system for processing and storing total nucleated cells from human umbilical cord blood before banking.","PrepaCyte-CB | PrepaCyte",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013274","Patent Ductus Arteriosus","C84492","A congenital defect characterized by the failure of the ductus arteriosus to close soon after birth. As a consequence, blood from the aorta mixes with blood from the pulmonary artery. If untreated, it may lead to congestive heart failure.","Patent Ductus Arteriosus | PDA",,,,,,,,,,,,,,,"315922","Patent ductus arteriosus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4230036","Anencephaly","C84560","A rare neural tube defect during pregnancy, resulting in the absence of a large portion of the brain and skull in the fetus.","Anencephaly | ANENCEPHALY | Anencephalus",,,,,,,,,,,,,,,"377368","Anencephalus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1168173","Cogan-Reese Syndrome","C84644","A very rare syndrome characterized by eye abnormalities that lead to vision impairment. These abnormalities include iris atrophy, decreased corneal endothelium, iris nodules, adhesion of the iris to the lens and glaucoma.","Cogan-Reese Syndrome | ",,,,,,,,,,,,,,,"4228180","Cogan-Reese syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016395","Focal Dermal Hypoplasia","C84715","A genetic multisystem disorder caused by mutations in the PORCN gene. It is characterized by atrophy and hypoplasia of skin, eye defects, face defects, skeletal abnormalities, and limb malformations.","Focal Dermal Hypoplasia | ",,,,,,,,,,,,,,,"4006455","Focal dermal hypoplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1096100","Iridocorneal Endothelial Syndrome","C84792","A group of disorders characterized by the presence of an abnormal inner layer of the cornea. This abnormality results in iris distortion, corneal swelling, pupil distortion, and glaucoma. It usually affects only one eye.","Iridocorneal Endothelial Syndrome | ",,,,,,,,,,,,,,,"4305300","Iridocorneal endothelial syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4229622","Neonatal Respiratory Distress Syndrome","C27560","A condition beginning in the first day of life that results from inadequate surfactant production, causing increased work of breathing and impaired gas exchange.","Respiratory Distress Syndrome | Neonatal Respiratory Distress | Neonatal Respiratory Distress Syndrome | Neonatal Respiratory Distress Syndrome | Newborn Respiratory Distress Syndrome | RDS | Respiratory Distress Syndrome in the Newborn | Respiratory Distress Syndrome of Newborns",,,,,,,,,,,,,,,"258866","Respiratory distress syndrome in the newborn",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030486","Paraplegia","C50687","Complete paralysis of the lower half of the body including both legs, often caused by damage to the spinal cord.","Paraplegia | Paraplegia, unspecified",,,,,,,,,,,,,,,"192606","Paraplegia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041915","Urachal Cyst","C85216","A cyst that develops from the remnants of the urachus. Since urachal cysts are non-communicating, they are usually asymptomatic unless infected.","Urachal Cyst | ",,,,,,,,,,,,,,,"4066019","Allantoic cyst",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041633","Umbilical Cord","C34320","Extraembryonic structure that connects the fetus to the placenta. It contains two arteries and one vein.","Umbilical Cord | UMBILICAL CORD | chorda umbilicalis | funiculus umbilicalis | umbilical cord",,,,,,,,,,,,,"UBERON:0002331","umbilical cord","4106710","Umbilical cord structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1999666","Retinoic Acid Receptor Beta, Human","C29764","Retinoic acid receptor beta (455 aa, ~50 kDa) is encoded by the human RARB gene. This protein plays a role in the modulation of retinoic acid-dependent gene expression.","Retinoic Acid Receptor Beta | HBV-Activated Protein | Hepatitis B Virus Activated Protein | NR1B2 | Nuclear Receptor Subfamily 1 Group B Member 2 | RAR-Beta | RAR-Epsilon | RARB | Retinoic Acid Receptor Beta 2 | Retinoic Acid Receptor Beta 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012863","Topoisomerase II","C18434","Topoisomerase II catalyzes relaxation of supercoiled DNA molecules, catenation, decatenation, knotting, and unknotting of circular DNA.  The topoisomerase II reaction appears to involve crossing-over of two DNA segments.  Human cells contain two topoisomerase II isozymes: alpha and beta from distinct genes.  DNA topoisomerase II alpha is associated with the Pol II holoenzyme and is required for chromatin-dependent co-activation.  Transcription results in superhelical tension; topoisomerase II relaxation activity is essential for productive RNA synthesis on nucleosomal DNA.  (from OMIM 126430 and NCI)","Topoisomerase II | DNA Topoisomerase II | TOP2 | Topo II | Topoisomerase 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016540","Forehead","C89803","The part of the face between the eyebrows and the normal hairline.","Forehead | FOREHEAD | forehead",,,,,,,,,,,,,"UBERON:0008200","forehead","4203933","Forehead structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512970","Intrapulmonary bronchus","C12930","A bronchial branch that is located within the lung tissue.","Intrapulmonary Bronchus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334001","Atypical Glandular Hyperplasia","C8356","Proliferation of glandular epithelial cells associated with the presence of cytologic atypia and architectural growth pattern changes.","Atypical Glandular Hyperplasia | ",,,,,,,,,,,,,,,"4067899","Atypical glandular hyperplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1335902","Salivary Gland Inverted Ductal Papilloma","C35835","A very rare benign tumor of the minor salivary glands, characterized by a luminal papillary proliferation that arises at the junction of the salivary gland duct and the oral mucosal surface epithelium and expands as a nodular mass into the lamina propria.  It presents as an asymptomatic mucosal swelling.","Salivary Gland Inverted Ductal Papilloma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031707","Phosphorus Metabolic Disorder","C97095","A metabolic disorder that affects the phosphate homeostasis.","Phosphorus Metabolic Disorder | ",,,,,,,,,,,,,,,"435788","Disorder of phosphorus metabolism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3273528","Business and Financial Operations Occupations","C97627","A class of professional or vocational positions of employment that involve business or financial operations.","Business and Financial Operations Occupations | Business and Finance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0447661","Subareolar Region","C62225","The area of the chest beneath the areola of the nipple.","Subareolar Region | ",,,,,,,,,,,,,,,"4076129","Subareolar region",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0337486","Biological Mother","C96580","A female who contributes to the genetic makeup of her offspring from the fertilization of her ovum.","Biological Mother | MOTHER, BIOLOGICAL | Mother | Natural Mother",,,,,,,,,,,,,,,"4277283","Natural mother",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0277638","Accidental Death","C90351","An indication that the subject's death was due to a mishap.","Accidental Death | ACCIDENTAL DEATH",,,,,,,,,,,,,,,"4302017","Accidental death",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0060934","Gadopentetate Dimeglumine","C2588","A gadolinium complex of diethylenetriamine pentaacetic acid with ionic paramagnetic properties. Gadopentetate dimeglumine may provide contrast enhancement during magnetic resonance imaging (MRI) of intracranial lesions with abnormal vascularity or of abnormalities in the blood-brain barrier (BBB). (NCI04)","Gadopentetate Dimeglumine | GADOPENTETATE DIMEGLUMINE | Gadolinium DTPA | Gd-DTPA | Magnevist | Meglumine Gadopentetate | SH L 451 A | ZK 93035 | gadopentetate dimeglumine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420865","TP53BP1 Gene","C88925","This gene may play a role in the modulation of the response to DNA damage.","TP53BP1 Gene | TP53BP1 | Tumor Protein p53 Binding Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
,,"C91300","Dipeptidyl peptidase 4 (766 aa, ~88 kDa) is encoded by the human DPP4 gene. This protein is involved in proteolytic regulation of T cell activation.","Dipeptidyl Peptidase 4 | ADABP | ADCP-2 | Adenosine Deaminase Complexing Protein 2 | CD26 | CD26 Antigen | DPP IV | DPP4 | Dipeptidyl Peptidase IV | Dipeptidyl-Peptidase 4 | Dipeptidyl-Peptidase IV | EC 3.4.14.5 | T-Cell Activation Antigen CD26 | TP103",,,,,,,,,,,,,,,"4266535","Dipeptidyl peptidase IV",,,,,,,,,,,,,,,,,,,,,,"--"
"C3274666","Functional Assessment of Human Immunodeficiency Virus Infection","C99297","A questionnaire designed to measure the quality of life of adults living with HIV infection. This instrument is based on the FACT-G questionnaire.","Functional Assessment of Human Immunodeficiency Virus Infection | FAHI | FAHI Questionnaire | Functional Assessment of HIV Infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280028","Refractory Anemia with Excess Blasts in Transformation","C27080","Refractory anemia with excess blasts in transformation (RAEB-T) is characterised by dysplastic features of the myeloid and usually erythroid progenitor cells in the bone marrow and an increased number of myeloblasts in the peripheral blood.  The peripheral blood blast count ranges from 20% to 30%.  RAEB-T used to be a subcategory of myelodysplastic syndromes in the past.  Recently, the term has been eliminated from the WHO based classification of myelodysplastic syndromes.  The reason is that the percentage of peripheral blood blasts required for the diagnosis of acute myeloid leukemia has been reduced to 20%.  The elimination of the RAEB-T term by the WHO experts has created confusion and ongoing arguments.  Currently, according to WHO classification, the vast majority of RAEB-T cases are best classified as acute leukemias (acute leukemias with multilineage dysplasia following myelodysplastic syndrome).  A minority of cases are part of RAEB-2.","Refractory Anemia with Excess Blasts in Transformation | ","9984/3","Refractory anemia with excess blasts in transformation",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C3274720","FIGO Staging System and Modified World Health Organization [WHO] Prognostic Scoring System for Gestational Trophoblastic Neoplasms","C99408","A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk.","FIGO Staging System and Modified World Health Organization [WHO] Prognostic Scoring System for Gestational Trophoblastic Neoplasms | Modified WHO Prognostic Scoring System as adopted by FIGO for Gestational Trophoblastic Neoplasms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983255","Colorectal Cancer pM1a TNM Finding v7","C89957","Colorectal cancer with metastasis confined to one organ or site (e.g., liver, lung, ovary, nonregional node). (from AJCC 7th Ed.)","Colorectal Cancer pM1a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709488","Patient Navigator","C48832","Persons who are trained to guide and support those requiring assistance obtaining medical care. Such persons are sensitive to socio-economic factors within the community and provide a variety of services. Their primary responsibilities are to assist patients that have an abnormal examination or a positive finding to navigate through the health care system.","Patient Navigator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1328109","TGFa-PE38 Immunotoxin","C29483","A recombinant, chimeric toxin composed of human transforming growth factor alpha (TGF-alpha) fused to a fragment of Pseudomonas exotoxin (PE38) without its cell-binding domain.  The TGF-alpha moiety of the agent attaches to tumor cells expressing the epithelial growth factor receptor (EGFR); the exotoxin induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis. (NCI04)","TGFa-PE38 Immunotoxin | Cervene | TGFa-PE38 Immunotoxin | TGFa-PE38 Immunotoxin  | TP-38 | TP-38 immunotoxin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520221","Zinc-Binding, DNA-Binding Motif","C13427","Zinc-binding, DNA-binding motifs in proteins contain amino acids that are folded into a single DNA-binding structural unit around a zinc atom.","Zinc-Binding, DNA-Binding Motif | Zinc Finger | Zinc Finger Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1565874","CHUK protein, human","C42328","Inhibitor of nuclear factor kappa-B kinase subunit alpha (745 aa, ~85 kDa) is encoded by the human CHUK gene. This protein is involved in the positive regulation of nuclear factor kappa-B signaling.","Inhibitor of Nuclear Factor Kappa-B Kinase Subunit Alpha | CHUK | Conserved Helix-Loop-Helix Ubiquitous Kinase | Conserved Helix-Loop-Helix Ubiquitous Kinase | EC 2.7.11.10 | I Kappa-B Kinase Alpha | I-Kappa-B Kinase 1 | I-Kappa-B Kinase Alpha | I-Kappa-B Kinase-Alpha | IKBKA | IKK-A | IKK-Alpha | IKK1 | IKKA | IKappaB Kinase | IkB Kinase Alpha Subunit | Inhibitor of Nuclear Factor Kappa-B Kinase Alpha Subunit | NFKBIKA | Nuclear Factor NF-Kappa-B Inhibitor Kinase Alpha | Nuclear Factor NFKappaB Inhibitor Kinase Alpha | TCF-16 | Transcription Factor 16",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL599544","RB1 protein, human","C17394","Retinoblastoma-associated protein (928 aa, ~106 kDa) is encoded by the human RB1 gene. This protein plays a role in the regulation of cell cycle progression.","Retinoblastoma-Associated Protein | P105-RB | PP110 | RB Protein | RB Transcriptional Corepressor 1 | RB1 | Rb | Retinoblastoma Associated Protein | Retinoblastoma Protein | Retinoblastoma Suspectibility Protein | Retinoblastoma protein 1 | p105-Rb | p110-RB1 | pRb | pp110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982875","Cervical Cancer cT4 TNM Finding v7","C89495","Cervical cancer invades mucosa of bladder or rectum, and/or extends beyond true pelvis (bullous edema is not sufficient to classify a tumor as T4). (from AJCC 7th Ed.)","Cervical Cancer cT4 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0304915","Delta-Tocopherol","C63645","The orally bioavailable delta form of the naturally-occurring fat-soluble vitamin E, mostly found in soybean and corn oils, with potential antioxidant activity. Although the exact mechanism of action of this tocopherol has yet to be fully identified, delta-tocopherol appears to have the ability to scavenge free radicals, thereby protecting cells against oxidative damage.","Delta-Tocopherol | .DELTA.-TOCOPHEROL | 2,8-dimethyl-2-(4,8,12-trimethyltridecyl)chroman-6-ol | Delta-tocopherol | [2R-[2R*(4R*,8R*)]]-3,4-Dihydro-2,8-dimethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-ol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1506533","XPA protein, human","C21564","DNA repair protein complementing XP-A cells (273 aa, ~31 kDa) is encoded by the human XPA gene. This protein is involved in DNA excision repair.","DNA Repair Protein Complementing XP-A Cells | XPA | Xeroderma Pigmentosum Complementation Group A Protein | Xeroderma Pigmentosum Complementation Group A Protein | Xeroderma Pigmentosum Group A Complementing Protein | Xeroderma Pigmentosum Group A-Complementing Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641193","Feel that Treatment has Left Body Less Whole","C103308","A question about whether an individual feels or felt that treatment has left their body less whole.","Feel that Treatment has Left Body Less Whole | Have you been feeling that your treatment has left your body less whole | Have you been feeling that your treatment has left your body less whole?",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229685","Splenic Hilum","C33601","The area of the spleen through which the vessels and nerves enter or exit the organ.","Splenic Hilum | SPLEEN, HILUM | Structure of hilum of spleen (body structure)",,,,,,,,,,,,,,,"4261652","Structure of hilum of spleen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032981","Third Trimester","C92896","The period of gestation that ranges from the 28th week of pregnancy until delivery.","Third Trimester | ",,,,,,,,,,,,,,,"4112238","Third trimester",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1413931","ACE Gene","C91295","This gene plays a role in vasoconstriction.","ACE Gene | ACE | Angiotensin I Converting Enzyme Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641747","Limited in Doing Work or Daily Activities","C104285","A question about whether an individual limits or was limited in performing work or daily activities.","Limited in Doing Work or Daily Activities | Were you limited in doing either your work or other daily activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641808","Does Not Feel Self-Conscious When Eating","C104448","A question about whether an individual does not feel or didn't feel self conscious when eating.","Does Not Feel Self-Conscious When Eating | I do not feel self-conscious when I eat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418404","PDCD4 Gene","C94698","This gene may be involved in apoptosis and translation.","PDCD4 Gene | PDCD4 | Programmed Cell Death 4 (Neoplastic Transformation Inhibitor) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642231","Disturbed Sleep at its Worst","C105530","A question about an individual's disturbed sleep at its worst.","Disturbed Sleep at its Worst | Your disturbed sleep at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415932","IGFBP7 Gene","C73532","This gene may play a role in growth factor signal modulation and tumor suppression.","IGFBP7 Gene | IGFBP7 | Insulin-Like Growth Factor Binding Protein 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829473","JAK2 NP_004963.1:p.M929I","C105916","A change in the amino acid residue at position 929 in the tyrosine-protein kinase JAK2 protein where methionine has been replaced by isoleucine.","JAK2 NP_004963.1:p.M929I | JAK2 M929I | JAK2 Met929Ile | JAK2 NP_004963.1:p.Met929Ile | JAK2 p.M929I | JAK2 p.Met929Ile | Janus Kinase 2 M929I | Janus Kinase 2 Met929Ile | NP_004963.12:p.Met929Ile | NP_004963.1:p.M929I | Tyrosine-Protein Kinase JAK2 M929I | Tyrosine-Protein Kinase JAK2 Met929Ile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026683","Mucous Cyst","C83177","A mucous containing cyst arising from the minor salivary glands in the oral cavity.","Mucous Cyst | Mucocele",,,,,,,,,,,,,,,"4055737","Mucous cyst",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152173","Ventricular Flutter","C50800","A disorder characterized by an electrocardiographic finding of a high ventricular rate (180 to 250 beats per minute) with a regular rhythm and large oscillating sine wave-like complexes occurring as a result of QRS complexes and T waves being merged. The P wave is not visible.","Ventricular Flutter | VFl",,,,,,,,,,,,,,,"433225","Ventricular flutter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1419243","RAD52 Gene","C106263","This gene is involved in both double-strand break repair and homologous recombination.","RAD52 Gene | RAD52 | RAD52 Homolog (S. cerevisiae) Gene | RAD52 Homolog, DNA Repair Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829832","Has Cancer Other than Basal Cell Skin Cancer","C106387","A question about whether an individual has or had cancer other than basal cell skin cancer.","Has Cancer Other than Basal Cell Skin Cancer | Has the patient had cancer (other than basal cell skin cancer)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830268","FACT-L Questionnaire","C106400","A subscale complement to the FACT-G developed specifically for evaluating quality of life of lung cancer patients. It may also be useful to assess quality of life in patients with other lung diseases.","FACT-L Questionnaire | FACT-L | FACT-L  | Functional Assessment of Cancer Therapy Lung Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813323","Fatigue Severity Scale","C106621","A numeric scale to assess the severity of an individual's fatigue over the past week while performing a variety of usual tasks.","Fatigue Severity Scale | FSS | FSS01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412805","BMP4 Gene","C95041","This gene is involved in bone development and signaling.","BMP4 Gene | BMP4 | Bone Morphogenetic Protein 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828012","Sitting and Talking to Someone","C106689","A question about an individual's activity of sitting and talking to someone.","Sitting and Talking to Someone Question | Sitting and Talking to Someone | Sitting and Talking to Someone | Sitting and talking to someone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830449","Distress over Family Problem of Dealing with Children","C107175","A question about an individual's distress related to their family problems dealing with children.","Distress over Family Problem of Dealing with Children | Family Problems Dealing with children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026955","Mycotoxin","C674","Mycotoxins are toxic, secondary metabolites of low molecular weight produced by naturally occurring fungi.  Mycotoxins are neither infectious nor contagious, but can occur on a herd-wide basis.","Mycotoxin | Fungal Toxin",,,,,,,,,,,,,,,"4262940","Mycotoxin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829280","Limited in Ability to do Leisure or Recreational Activities Because of Neck or Shoulder","C107235","A question about whether an individual is or was limited in doing leisure or recreational activities because of their neck or shoulder.","Limited in Ability to do Leisure or Recreational Activities Because of Neck or Shoulder | Have you been limited in your ability to do leisure or recreational activities because of your neck or shoulder | Limited in Ability to do Leisure or Recreational Activities Because of Neck or Shoulder ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420277","SNCAIP Gene","C102936","This gene is involved in the modulation of ubiquitination.","SNCAIP Gene | SNCAIP | Synuclein, Alpha Interacting Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054450","Calcineurin","C17275","Ubiquitous heterodimeric human Calcineurin is Ca(2+)/calmodulin-regulated protein phosphatase involved in many biologic activities as a modifier of phosphorylation status. Composed of widely expressed or tissue-restricted 55-60-kDa calmodulin-binding catalytic subunit (PPP Phosphatase/PP-2B Family) and conserved 19-kD Ca(2+)-sensitive regulatory subunit, Calcineurin appears to regulate glycolytic metabolism, nuclear translocation of NFATC1 transcription factor, sperm motility, and dopaminergic signal transduction and NMDA receptor-dependent synaptic plasticity. (NCI)","Calcineurin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517415","Gain of Chromosome 6p","C36633","A chromosomal abnormality that refers to the gain of genetic material in the short arm of chromosome 6.","Gain of Chromosome 6p | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL406855","Bone Marrow Failure","C80693","The inability of the bone marrow to produce hematopoietic elements.","Bone Marrow Failure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887537","Partner","C100128","A person that is associated with another person in some manner or action.","Partner | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0194907","Orchiopexy","C111066","A surgical procedure in which an undescended testis is fixated inside the scrotum.","Orchiopexy | ",,,,,,,,,,,,,,,"4310552","Orchidopexy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829737","Have You Generally Enjoyed the Things You Do","C111704","A question about whether an individual has or had generally enjoyed the things they do.","Have You Generally Enjoyed the Things You Do | Have you generally enjoyed the things you do",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828651","Past Seven Days Decreased Appetite Interfering with Usual or Daily Activities","C112169","A question about how much an individual's decreased appetite interfered with usual or daily activities over the past seven days.","Past Seven Days Decreased Appetite Interfering with Usual or Daily Activities | Over the past seven days how much did decreased appetite INTERFERE with your usual or daily activities | Past Seven Days Loss of Appetite Interfering with Usual or Daily Activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454438","CD23 Expressing Cell Count","C111149","The determination of the amount of CD23 expressing cells per unit present in a sample.","CD23 Expressing Cell Count | FCER2 Expressing Cell Count | Low Affinity Immunoglobulin Epsilon Fc Receptor Expressing Cell Count",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413397","CHN2 Gene","C113547","This gene is involved in both the proliferation and migration of smooth muscle cells.","CHN2 Gene | CHN2 | Chimerin 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266153","Ovarian Serous Adenocarcinofibroma","C67092","A malignant neoplasm of the ovary with an invasive epithelial component and a fibrotic stroma. The epithelial component is characterized by the presence of malignant epithelial cells of serous type, forming glandular, papillary, and solid patterns.","Ovarian Serous Adenocarcinofibroma | Serous adenocarcinofibroma","9014/3","Serous adenocarcinofibroma",,,,,,,,,,,,,"4029681","Serous adenocarcinofibroma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0206667","Adrenal Cortical Adenoma","C9003","A benign neoplasm that can arise from any of the adrenal cortical layers.  It can be associated with the overproduction of glucocorticoids (Cushing's syndrome), androgenic or estrogenic steroids (adrenogenital syndrome), or mineralocorticoids (Conn's syndrome). (Sternberg Diagnostic Surgical Pathology, 3rd ed.)","Adrenal Cortical Adenoma | ADENOMA, ADRENOCORTICAL, BENIGN | Adenoma of Adrenal Cortex | Adenoma of Adrenal Gland | Adenoma of the Adrenal Cortex | Adenoma of the Adrenal Gland | Adrenal Adenoma | Adrenal Cortex Adenoma | Adrenal Cortex Adenoma | Adrenal Cortical Adenoma | Adrenal Gland Adenoma | Adrenocortical Adenoma | Benign Adenoma of Adrenal Gland | Benign Adenoma of the Adrenal Gland | Benign Adrenal Adenoma | Benign Adrenal Gland Adenoma | Cortical Cell Adenoma","8370/0","Adrenal cortical adenoma, NOS",,,,,,,,,,,,,"4116195","Adrenal cortical adenoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C3888388","Usually","C114711","A response indicating that something happens or happened most of the time.","Usually | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272860","Perpendicular","C96557","At a right angle to a given line or plane.","Perpendicular | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3475697","Expect My Health to Get Worse","C114918","A question about whether an individual expects their health to get worse.","Expect My Health to Get Worse | I expect my health to get worse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898853","How Helpful has Knowing Your Prognosis Been for Maintaining Hope","C115457","A question about helpful it's been to a person to know about the patient's prognosis in maintaining hope.","How Helpful has Knowing Your Prognosis Been for Maintaining Hope | How helpful has knowing about their prognosis been for your loved one in maintaining hope | How helpful has knowing about your prognosis been for maintaining hope",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426079","DOCK8 Gene","C116053","This gene plays a role in guanine nucleotide exchange for CDC42.","DOCK8 Gene | DOCK8 | Dedicator of Cytokinesis 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708384","Hospital Service Technician","C53433","A person trained to provide technical advice and assistance concerning the routine maintenance and service of hospital equipment.","Hospital Service Technician | HOSPITAL SERVICE TECHNICIAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708556","Intraoperative Pain","C50619","Pain occurring during a surgical operation.","Intraoperative Pain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707380","Child Intoxication With Breast Implant Material Ingredients","C50493","Children affected by toxins may be due to silicone breast implants and their effects on unborn children and from breastfeeding.","Child Intoxication With Breast Implant Material Ingredients | Toxins In Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007166","Low Cardiac Output","C50641","A below normal volume of blood pumped from the right or left ventricle of the heart per unit time.","Low Cardiac Output | ",,,,,,,,,,,,,,,"4313695","Decreased cardiac output",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0679401","Blood Vessel Perforation","C50804","Damage to a blood vessel resulting from a full thickness disruption in the integrity of the vessel wall.","Blood Vessel Perforation | Blood Vessel Rupture | Perforation of Vessels | Rupture of Vessel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520399","11q22.3","C13799","A chromosome band present on 11q","11q22.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333357","ERCC3 Gene","C20556","This gene is involved in DNA excision repair and transcription.","ERCC3 Gene | ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit Gene | ERCC3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984775","Design Error","C92042","The device had faulty (incomplete or incorrect) software design.","Design Error | Device Design Error Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984843","Device Software Livelock Evaluation Result","C92112","The device software failed because two or more processes compete with each other such that the program does not perform as intended.","Device Software Livelock Evaluation Result | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896674","FACT-BRM Questionnaire","C118267","A subscale complement to the FACT-G developed specifically for evaluating the potential side effects of biological response modifiers on cancer patients.","FACT-BRM Questionnaire | FACT-BRM | Functional Assessment of Cancer Therapy Biological Response Modifiers Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827358","FGFR1 Gene Rearrangement","C84273","Rearrangement of the FGFR1 gene resulting in translocations with an 8p11 breakpoint. It has been described in hematologic malignancies presenting as myeloproliferative neoplasms or acute leukemias.","FGFR1 Gene Rearrangement | BFGFR Gene Rearrangement | CD331 Gene Rearrangement | CEK Gene Rearrangement | FGFBR Gene Rearrangement | FGFR-1 Gene Rearrangement | FLG Gene Rearrangement | FLT-2 Gene Rearrangement | FLT2 Gene Rearrangement | FMS-Like Tyrosine Kinase 2 Gene Rearrangement | Fibroblast Growth Factor Receptor 1 Gene Rearrangement | KAL2 Gene Rearrangement | N-SAM Gene Rearrangement | OGD Gene Rearrangement | Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1822720","SHROOM2 Gene","C118551","This gene may play a role in the modulation of cell morphology.","SHROOM2 Gene | SHROOM2 | Shroom Family Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891557","Anti-CD20 Antibody","C118798","Any antibody that recognizes B-lymphocyte antigen CD20 protein.","Anti-CD20 Antibody | Anti-B-Lymphocyte Antigen CD20 Antibody | B-Lymphocyte Antigen CD20 Antibody | CD20 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521533","6p21","C13603","A chromosome band present on 6p","6p21 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898032","Pain Interference Score 0","C120149","A subjective score of 0 on a scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.","Pain Interference Score 0 | BPI Pain Interference Score 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897572","Slight Problems Performing Usual Activities","C120237","A response indicating that an individual has or had slight problems with performing their usual activities.","Slight Problems Performing Usual Activities | I have slight problems doing my usual activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348869","Glycome","C69306","The collective identity of the entirety of carbohydrates (glycans) in an organism.","Glycome | Glycomic Profile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053963","Symbol Span Subtest (WMS-IV)","C120351","A subtest of the Wechsler Memory Scale, 4th Edition. The subject is briefly shown a series of abstract symbols on a page and then asked to select the symbols from an array of symbols, in the same order they were previously presented.","Symbol Span Subtest (WMS-IV) | Symbol Span | WMS-IV Symbol Span",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3260745","Tense When Talking Because of Voice","C120512","A question about how often an individual is tense when talking to others because of their voice.","Tense When Talking Because of Voice | I'm tense when talking to others because of my voice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414084","DMP1 Gene","C95575","This gene plays a role in osteoblast differentiation and ossification.","DMP1 Gene | DMP1 | Dentin Matrix Acidic Phosphoprotein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050584","Toronto Extremity Salvage Score, Upper Extremity","C121219","A self-administered questionnaire designed to assess physical disability for patients undergoing upper limb salvage surgery for musculoskeletal tumors.","Toronto Extremity Salvage Score, Upper Extremity | TESS | TESS Upper | TESS Upper Extremity | Toronto Extremity Salvage Score | Toronto Extremity Salvage Score (TESS) Upper Extremity | Upper Extremity Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055211","Composite Score","C121197","A single value that is calculated from multiple scores. This composite score can then be used as a single variable in further analysis and comparison.","Composite Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055081","Edema Rating 1","C121311","Mild edema (slight but definite).","Edema Rating 1 | Stern's Edema Rating 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919507","FGF7 Gene","C18570","This gene plays a role in cellular biogenesis, growth, organization and proliferation. It is also involved in the inhibition of apoptosis.","FGF7 Gene | FGF7 | Fibroblast Growth Factor 7 (Keratinocyte Growth Factor) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0303267","Nickel Compound","C44407","A strong, corrosion and heat resistant, inorganic substance that contains the metallic element nickel. Nickel compounds are used in industry for electroplating, nickel-alloy production, stainless steel production, in batteries, in electronics, in the ceramic industry and as catalysts. Exposure to nickel compounds affects the kidneys and respiratory tract and is associated with developing lung and nasal cancer. (NCI05)","Nickel Compound | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050130","Cognitive Function Subordinate Domain","C122365","The collection of PROMIS item scales that assess perceived difficulties in intellectual processes, capabilities, and deficits.","PROMIS Cognitive Function Subordinate Domain | Cognitive Function | Cognitive Function Item Bank | Cognitive Function Subordinate Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0556615","Paint Thinner","C122494","Any of the solvents used to thin oil-based paints or clean up after their use. These include mineral spirits, acetone, mineral turpentine, true turpentine, naphtha, toluene, methyl ethyl ketone, dimethylformamide, 2-butoxyethanol, ethylbenzene, xylene, n-butyl acetate, and butan-1-ol. Exposure to paint thinner vapors may be hazardous.","Paint Thinner | Paint Thinners | Paint derivatives",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054812","Health Problems Effect on Work Score 5","C123299","A subjective score of 5 on a scale that ranges from 0: Health problems had no effect on my work to 10: Health problems completely prevented me from working.","Health Problems Effect on Work Score 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983321","Gastrointestinal Stromal Tumor pT3 TNM Finding v7","C90050","Gastrointestinal stromal tumor with tumor size more than 5 cm, but not more than 10 cm, in greatest dimension. (from AJCC 7th Ed.)","Gastrointestinal Stromal Tumor pT3 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981411","Stage II Gastric Gastrointestinal Stromal Tumor","C87827","Stage II includes: (T1, N0, M0, Mitotic rate: High); (T2, N0, M0, Mitotic rate: High); (T4, N0, M0, Mitotic rate: Low). T1: Tumor 2 cm or less in greatest dimension.  T2: Tumor more than 2 cm, but not more than 5 cm, in greatest dimension.  T4: Tumor more than 10 cm in greatest dimension. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage II Gastric Gastrointestinal Stromal Tumor AJCC v7 | Stage II Gastric (Stomach) Gastrointestinal Stromal Tumor (GIST) | Stage II Gastric Gastrointestinal Stromal Tumor | Stage II Gastric Gastrointestinal Stromal Tumor AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983384","Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor Clinical Distant Metastasis TNM Finding v7","C90126","A clinical finding about one or more characteristics of duodenum/ampulla/jejunum/ileum neuroendocrine tumor, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.","Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor Clinical Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538994","Treatment Epoch","C101526","A period in a clinical study during which subjects receive therapeutic treatment.","Treatment Epoch | TREATMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086394","Have Nausea Feel Pretty Sick","C124156","A response indicating that when an individual has or had nausea, they felt pretty sick.","Have Nausea Feel Pretty Sick | When I have nausea, I feel pretty sick",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514394","Preneoplastic Change","C20204","Any alteration in cell state that promotes or renders a cell or cell population more vulnerable or prone to malignant conversion or transformation. (NCI)","Preneoplastic Change | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335500","Breast Fibrocystic Change, Proliferative Type without Atypia","C5204","Breast fibrocystic change characterized by the presence of epithelial cell hyperplasia.  There is no evidence of epithelial atypia.","Breast Fibrocystic Change, Proliferative Type without Atypia | Proliferating Breast Lesion without Atypia | Proliferating Lesion of Breast without Atypia | Proliferating Lesion of the Breast without Atypia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279392","Ovarian mixed epithelial carcinoma","C40090","A malignant mixed epithelial neoplasm that arises from the ovary and is composed predominantly of serous and endocervical-type mucinous cells.","Ovarian Seromucinous Carcinoma | Malignant Ovarian Mixed Epithelial Tumor","8474/3","Seromucinous carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C4086666","One of Three Patients Will Need Diapers Due to Very Poor Urine Control After Surgery for Prostate Cancer","C124812","A question about whether an individual thinks that one of three patients who has surgery will need diapers due to very poor control of urine after surgery.","One of Three Patients Will Need Diapers Due to Very Poor Urine Control After Surgery for Prostate Cancer | One of three patients who has surgery will need diapers due to very poor control of urine after surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086949","Very Slow Growing","C124822","An indication that something is growing at a very slow rate.","Very Slow Growing | Very Slow Growth Rate | Very slow growing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086180","Choosing Without Pressure From Others","C125090","A question about an individual's assessment of whether they are choosing or chose without pressure from others.","Choosing Without Pressure From Others | I am choosing without pressure from others",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086211","Concern About Your Drinking","C125122","A question about whether anyone has expressed concern about an individual's drinking.","Concern About Your Drinking | Has anyone expressed concern about your drinking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086266","Escalation","C125176","An increase in extent or intensity; to become more serious.","Escalation | Escalate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084723","How Much Distress Constipation","C125358","A question about an individual's distress from their constipation.","How Much Distress Constipation | Constipation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086239","Did Not Feel Like Eating, Appetite Poor","C125370","A question about whether an individual does or did not feel like eating and their appetite was poor.","Did Not Feel Like Eating, Appetite Poor | I did not feel like eating; my appetite was poor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086737","People Disliked Me","C125381","A question about whether an individual feels or felt that people disliked them.","People Disliked Me | I felt that people disliked me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086964","Willing to Try Medical Test or Treatment if Experts Had Conflicting Opinions","C125568","A question about an individual's agreement that if experts had conflicting opinions about a medical test or treatment, they would still be willing to try it.","Willing to Try Medical Test or Treatment if Experts Had Conflicting Opinions | If experts had conflicting opinions about a medical test or treatment, I would still be willing to try it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086948","Very Much Worse","C125630","A subjective response indicating that something is very much worse.","Very Much Worse | Very Much Worsened | Very much worse | Very much worsened",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814447","Hydrogen Peroxide Sterilization","C101689","A sterilization process that uses hydrogen peroxide to kill microorganisms.","Hydrogen Peroxide Sterilization | Hydrogen Peroxide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504743","Dusting or Polishing Furniture or a Polishing Car","C126162","A question about an individual's ability to dust or polish furniture or polish a car.","Dusting or Polishing Furniture or a Polishing Car Question | Dusting or Polishing Furniture or a Polishing Car | Dusting or Polishing Furniture or a Polishing Car | Dusting/polishing furniture or polishing car",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417599","NAPA Gene","C126466","This gene is involved in vesicular transport between the endoplasmic reticulum and the Golgi.","NAPA Gene | NAPA | NSF Attachment Protein Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503782","Severity Score 4","C126671","A subjective score of 4 on a severity scale that ranges from 0: Not at all severe to 10: most severe.","Severity Score 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003956","Ascending Aorta","C32150","The portion of the aorta that emerges from the left ventricle and precedes the aortic arch.","Ascending Aorta | ASCENDING AORTA | Ascending aorta structure (body Structure)",,,,,,,,,,,,,,,"4183988","Ascending aorta structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508225","Full of Energy","C126946","A response indicating that an individual is or was full of energy.","Full of Energy | Full of energy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508847","FIGO Stage IIIB Ovarian Cancer","C128092","Ovarian cancer with macroscopic, extrapelvic, peritoneal metastasis equal or less than 2 cm +/- positive retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen. (FIGO 2014)","FIGO Stage IIIB Ovarian Cancer 2014 | FIGO Stage IIIB Ovarian Cancer | FIGO Stage IIIB Ovarian Cancer | FIGO Stage IIIB Ovarian Carcinoma | FIGO Stage IIIB Ovarian Carcinoma 2014",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509257","Worst Severity Past Seven Days Problems with Tasting Food or Drink","C128128","A question about the worst severity of an individual's problems with tasting food or drink during the past seven days.","Worst Severity Past Seven Days Problems with Tasting Food or Drink | In the last 7 days, what was the severity of your problems with tasting food or drink at their worst | Worst Severity of Problems with Tasting Food or Drink Past Seven Days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509256","Worst Severity Past Seven Days Heartburn","C128130","A question about the worst severity of an individual's heartburn during the past seven days.","Worst Severity Past Seven Days Heartburn | In the last 7 days, what was the severity of your heartburn at its worst | Worst Severity of Heartburn Past Seven Days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1999257","ZGLP1 Gene","C103979","This gene is involved in transcriptional repression.","ZGLP1 Gene | ZGLP1 | Zinc Finger, GATA-Like Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416985","MAGEC1 Gene","C104524","This gene may play a role in embryonal development, tumor transformation, or tumor progression.","MAGEC1 Gene | MAGE Family Member C1 Gene | MAGEC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1969043","SGMS2 Gene","C105024","This gene is involved in cell growth.","SGMS2 Gene | SGMS2 | Sphingomyelin Synthase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698310","B Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified","C80326","B lymphoblastic leukemias/lymphomas characterized by the absence of recurrent genetic abnormalities.","B Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified | B Lymphoblastic Leukemia/Lymphoma, NOS | B lymphoblastic leukemia/lymphoma, NOS | B-Lymphoblastic Leukemia/Lymphoma, NOS | B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified","9811/3","B lymphoblastic leukemia/lymphoma, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C1413189","CCR3 Gene","C129062","This gene plays a role in the migration of eosinophils.","CCR3 Gene | C-C Motif Chemokine Receptor 3 Gene | CCR3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034094","Pulmonary Artery Wedge Pressure","C129955","The pressure measured by wedging a pulmonary catheter with an inflated balloon into a small pulmonary arterial branch.","Pulmonary Artery Wedge Pressure | Mean pulmonary capillary wedge pressure | PAOP | PAWP | PCWP | Pulmonary Arterial Wedge Pressure | Pulmonary Artery Occlusion Pressure | Pulmonary Capillary Wedge Pressure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333340","EPHB2 Gene","C24367","This gene plays a role in intracellular calcium regulation and spinal morphogenesis.","EPHB2 Gene | EPH Receptor B2 Gene | EPHB2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334082","IFNAR2 Gene","C37277","This gene is involved in tyrosine-kinase signal transduction that elicits signaling events in the Jak/Stat and IRS pathways.","IFNAR2 Gene | IFNAR2 | Interferon (Alpha, Beta and Omega) Receptor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3658266","Castration-Resistant Prostatic Cancer","C130234","Prostate carcinoma that grows and continues to spread despite the surgical removal of the testes or medical intervention to block androgen production.","Castration-Resistant Prostate Carcinoma | CRPC | Castration-Resistant Prostate Cancer | Metastatic Castration-Resistant Prostate Carcinoma",,,,,,,,,,,,,,,"4141960","Hormone refractory prostate cancer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1413234","CD68 Gene","C88921","This gene may be involved in macrophage homing, selectin recognition and pathogen uptake.","CD68 Gene | CD68 | CD68 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2610961","Mitotic Catastrophe","C129398","Programmed cell death that occurs during mitosis caused by various types of cellular damage that lead to the failure of cell cycle checkpoint(s). Micronucleation and multinuceation can occur in cells undergoing this process.","Mitotic Catastrophe | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513108","GvHD Final Lung Score 1","C131045","FEV1 is 60 to 79 percent and lung symptoms are none or mild.","GvHD Final Lung Score 1 | Graft versus Host Disease GvHD Final Lung Score 1 | Score 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514090","How Much Pleasure Sex Life Gives","C131159","A question about how much pleasure an individual gets from their sex.","How Much Pleasure Sex Life Gives | How much pleasure has your sex life given you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514613","Bothered by Sore Muscles","C131392","A question about whether an individual is or was bothered by sore muscles.","Bothered by Sore Muscles | Bothered by Muscle Soreness | Have you, during the past week, been bothered by sore muscles",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2217645","stage IIIC testicular cancer","C6367","Stage IIIC includes: (Any pT/TX, N1-3, M0, S3); (Any pT/TX, Any N, M1a, S3); (Any pT/TX, Any N, M1b, Any S).  N1: Metastasis with a lymph node mass 2 cm or less in greatest dimension; or multiple lymph nodes, none more than 2cm in greatest dimension.  N2: Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or multiple lymph nodes, any one mass greater than 2 cm but not more than 5 cm in greatest dimension.  N3: Metastasis with a lymph node mass more than 5 cm in greatest dimension. M0: No distant metastasis. M1a: Non-regional nodal or pulmonary metastasis.  M1b: Distant metastasis other than to non-regional lymph nodes and lung.  S3: LDH more than 10 x N (N indicates the upper limit of normal for the LDH assay) or hCG more than 50,000 or AFP more than 10,000. (AJCC 6th and 7th eds.)","Stage IIIC Testicular Cancer AJCC v6 and v7 | Stage IIIC | Stage IIIC Cancer of Testis | Stage IIIC Cancer of the Testis | Stage IIIC Testicular Cancer | Stage IIIC Testicular Cancer | Stage IIIC Testicular Cancer AJCC v6 | Stage IIIC Testicular Cancer AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514363","RAD51 Gene Mutation","C131795","A change in the nucleotide sequence of the RAD51 gene.","RAD51 Gene Mutation | BRCC5 Gene Mutation | FANCR Gene Mutation | HRAD51 Gene Mutation | HsRad51 Gene Mutation | RAD51 Homolog (S. cerevisiae) Gene Mutation | RAD51 Recombinase Gene Mutation | RAD51, S. cerevisiae, Homolog of A Gene Mutation | RAD51A Gene Mutation | RECA Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514585","Have Darker or Lighter Skin than Normal","C131697","A question about whether an individual's skin looks or looked darker or lighter than normal.","Have Darker or Lighter Skin than Normal | Does any part of your skin look darker or lighter than normal | Skin Darker or Lighter than Normal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707004","Breast Cancer pM0 TNM Finding","C49008","Breast cancer in which there is no evidence of distant metastasis. (from AJCC 6th Ed.)","Breast Cancer pM0 TNM Finding | pM0 Breast Cancer | pM0 Breast Carcinoma | pM0 Cancer of Breast | pM0 Cancer of the Breast | pM0 Carcinoma of Breast | pM0 Carcinoma of the Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0684084","Skin Tissue","C33563","Tissue composed of three layers- epidermis, dermis and subcutis which protect underlying muscles and organs. Skin is used for insulation, vitamin D production, sensation, and excretion through sweat.","Skin Tissue | Human Skin | SKIN TISSUE",,,,,,,,,,,,,,,"4152569","Skin tissue",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1171324","B-Cell Depletion Therapy","C70546","No Value Exists","B-Cell Depletion Therapy | B-Lymphocyte Depletion Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348918","HLA-A3 Positive Cells Present","C69409","A laboratory test result indicating the presence of HLA-A*03 positive cells in a tissue sample.","HLA-A3 Positive Cells Present | HLA-A*03 Positive | HLA-A*03 Positive Cells Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521329","Human Cytomegalovirus Envelope Glycoprotein B","C132331","Envelope glycoprotein B (906 aa; ~102 kDa) is encoded by the human cytomegalovirus gB gene, which is located within the open reading frame (ORF) UL55. This protein is involved in host cell entry, cell to-cell virus transmission, and fusion of infected cells.","Human Cytomegalovirus Envelope Glycoprotein B | CMV Envelope Glycoprotein B | CMV Glycoprotein B | CMV gB protein | Envelope Glycoprotein B | Glycoprotein B | HCMV gB | HHV5 Envelope Glycoprotein B | Human Cytomegalovirus Glycoprotein B | Human Herpesvirus 5 Glycoprotein B | gB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537768","MIR124-2 Gene","C132887","This gene may be involved in gene expression regulation in neurons.","MIR124-2 Gene | MIR124-2 | MicroRNA 124-2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273085","PIK3CA Gene Amplification","C96864","A molecular genetic abnormality indicating the presence of multiple copies of the PIK3CA (phosphatidyl inositol 3-kinase) gene.","PIK3CA Gene Amplification | PI3K Gene Amplification | PI3K-Alpha Gene Amplification | PI3KCA Gene Amplification | PIK3-Alpha Gene Amplification | Phosphatidylinositol 3-Kinase, Catalytic Subunit Gene Amplification | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Gene Amplification | Phosphoinositide-3-Kinase, Catalytic, Alpha Polypeptide Gene Amplification | p110-Alpha Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519764","Curie Extension Score","C133467","A score assigned to a Curie body segment to indicate the quantity of metastases.","Curie Extension Score | Curie Method | Curie mIBG-Scoring System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520211","RET Gene Amplification","C133677","A molecular genetic abnormality indicating the presence of multiple copies of the RET gene.","RET Gene Amplification | Ret Proto-Oncogene Amplification | Ret Proto-Oncogene Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522087","Deleterious CDK12 Gene Mutation","C134505","A change in the nucleotide sequence of the CDK12 gene that is associated with increased risk of disease.","Deleterious CDK12 Gene Mutation | Deleterious CDC2 Related Protein Kinase 7 Gene Mutation | Deleterious CRK7 Gene Mutation | Deleterious CRKR Gene Mutation | Deleterious CRKRS Gene Mutation | Deleterious Cdc2-Related Kinase, Arginine/Serine-Rich Gene Mutation | Deleterious Cyclin Dependent Kinase 12 Gene Mutation | Deleterious Cyclin-Dependent Kinase 12 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522776","Cortical Cataract Grade 2","C135198","A stage of cortical cataract characterized by 10-50% of the intrapupillary space obscured by opacity. (Modified LOCS II)","Cortical Cataract Grade 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522963","Quite a Bit of Urinary Frequency or Urgency; Need to be Near Bathroom Most of the Time","C135607","A response indicating that an individual feels or felt quite a bit of urinary frequency or urgency, making it necessary to be near a bathroom most of the time.","Quite a Bit of Urinary Frequency or Urgency; Need to be Near Bathroom Most of the Time | Quite a bit of urinary frequency or urgency; need to be near a bathroom most of the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1291185","Microbial DNA","C129660","DNA that originates from a microbe.","Microbial DNA | Microbe DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0680190","Weekend","C137684","The time period comprising Saturday and Sunday, and sometimes considered to include Friday night.","Weekend | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525081","Blasts Under 30 Percent of Bone Marrow Nucleated Cells","C138057","A semi-quantitative microscopic finding indicating that less than 30 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts Under 30 Percent of Bone Marrow Nucleated Cells | Blasts Less Than 30 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525099","How True Since Illness","C138138","A question about how true something is since an individual's illness.","How True Since Illness | How true is this now, since your illness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525836","Cordonnier Grade 1 Clinically Documented Infection not Requiring Inpatient Management","C138315","Any clinically documented infection not requiring inpatient management.","Cordonnier Grade 1 Clinically Documented Infection not Requiring Inpatient Management | Grade 1 Clinically Documented Infection not Requiring Inpatient Management",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879259","Capecitabine/Oxaliplatin","C11635","No Value Exists","Capecitabine/Oxaliplatin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538180","R-Hyper-CVAD Regimen","C140104","A regimen consisting of cyclophosphamide, vincristine, doxorubicin and dexamethasone, administered on a hyperfractionated schedule, plus rituximab that may be used to treat HIV-related B-cell lymphoma, Burkitt lymphoma, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, and acute lymphoblastic leukemia (ALL).","R-Hyper-CVAD Regimen | Hyper-CVAD Plus Rituximab | R-HCVAD | R-Hyper-CVAD | R-HyperCVAD | Rituximab Plus HyperCVAD | Rituximab and Hyperfractionated Cyclophosphamide-Vincristine-Adriamycin-Dexamethasone Regimen | Rituximab-HyperCVAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525106","Magnetic Resonance Whole Body Diffusion-Weighted Imaging","C138131","A non-ionizing radiation imaging modality for quantitative assessment of disease burden and therapy response. WB-DWI uses the apparent diffusion coefficient (ADC) measurement to detect and quantify disease. ADC is influenced by tissue microarchitecture and may be altered in a disease state.","Magnetic Resonance Whole Body Diffusion-Weighted Imaging | Magnetic Resonance Whole-Body Diffusion-Weighted Imaging | WB DW MRI | WB-DWI | Whole Body Magnetic Resonance Imaging Using Diffusion-Weighted Images | Whole-Body Diffusion-Weighted MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538894","How Often Experienced Swelling of Arm on Side You Had Breast Surgery","C140772","A question about how often an individual has experienced swelling of the arm on the side they had breast surgery.","How Often Experienced Swelling of Arm on Side You Had Breast Surgery | Swelling of the arm (lymphedema) on the side(s) that you had your breast surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035522","Rib Fracture","C34990","A traumatic or pathologic injury to the rib in which the continuity of the rib is broken.","Rib Fracture | Fracture of Rib",,,,,,,,,,,,,,,"4142905","Fracture of rib",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL523037","NRAS Exon 4 Mutation","C135720","A molecular genetic abnormality indicating the presence of a mutation in exon 4 of the NRAS gene.","NRAS Exon 4 Mutation | N-RAS Exon 4 Mutation | NRAS Exon 4 Gene Mutation | Neuroblastoma RAS Viral Oncogene Homolog Exon 4 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538279","Prostate Cancer cT1b TNM Finding v8","C140132","Prostate cancer in which the tumor is an incidental histologic finding in more than 5% of tissue resected. (from AJCC 8th Ed.)","Prostate Cancer cT1b TNM Finding v8 | Prostate Carcinoma cT1b TNM Finding v8 | T1b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539607","Depression Score 2","C141598","A subjective score of 2 on a depression scale that ranges from 0: No Depression to 10: Worst Possible Depression.","Depression Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539671","Other Problem Score 8","C141643","A subjective score of 8 on a scale that ranges from 0: No Other Problem to 10: Worst Possible Other Problem.","Other Problem Score 8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541641","Hyperkeratosis, CTCAE","C143246","A disorder characterized by a thickening of the outer layer of the skin.","Hyperkeratosis, CTCAE | Hyperkeratosis | Hyperkeratosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545954","Acute Kidney Injury, CTCAE","C143262","A disorder characterized by the acute loss of renal function (within 2 weeks) and is traditionally classified as pre-renal (low blood flow into kidney), renal (kidney damage) and post-renal causes (ureteral or bladder outflow obstruction).","Acute Kidney Injury, CTCAE | Acute Kidney Injury | Acute kidney injury | Acute kidney injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544687","Back Pain, CTCAE_5","C146739","A disorder characterized by a sensation of marked discomfort in the back region.","Back Pain, CTCAE 5.0 | Back Pain | Back pain | Back pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541782","Cervicitis Infection, CTCAE","C143362","A disorder characterized by an infectious process involving the uterine cervix.","Cervicitis Infection, CTCAE | Cervicitis Infection | Cervicitis infection | Cervicitis infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541742","Duodenal Infection, CTCAE","C143415","A disorder characterized by an infectious process involving the duodenum.","Duodenal Infection, CTCAE | Duodenal Infection | Duodenal infection | Duodenal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544692","External Ear Pain, CTCAE_5","C146745","A disorder characterized by a sensation of marked discomfort in the external ear region.","External Ear Pain, CTCAE 5.0 | External Ear Pain | External ear pain | External ear pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544669","Gastrointestinal Fistula, CTCAE_5","C146637","A disorder characterized by an abnormal communication between any part of the gastrointestinal system and another organ or anatomic site.","Gastrointestinal Fistula, CTCAE 5.0 | Gastrointestinal Fistula | Gastrointestinal fistula | Gastrointestinal fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541878","Hyperparathyroidism, CTCAE","C143557","A disorder characterized by an increase in production of parathyroid hormone by the parathyroid glands. This results in hypercalcemia (abnormally high levels of calcium in the blood).","Hyperparathyroidism, CTCAE | Hyperparathyroidism | Hyperparathyroidism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541960","Intraoperative Endocrine Injury, CTCAE","C143601","A finding of damage to the endocrine gland during a surgical procedure.","Intraoperative Endocrine Injury, CTCAE | Intraoperative Endocrine Injury | Intraoperative endocrine injury | Intraoperative endocrine injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541922","Libido Decreased, CTCAE","C143649","A disorder characterized by a decrease in sexual desire.","Libido Decreased, CTCAE | Libido Decrease (Priority 2) | Libido Decreased | Libido decreased | Libido decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542002","Nail Ridging, CTCAE","C143697","A disorder characterized by vertical or horizontal ridges on the nails.","Nail Ridging, CTCAE | Nail Ridging | Nail ridging | Nail ridging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541965","Pelvic Floor Muscle Weakness, CTCAE","C143739","A disorder characterized by a reduction in the strength of the muscles of the pelvic floor.","Pelvic Floor Muscle Weakness, CTCAE | Pelvic Floor Muscle Weakness | Pelvic floor muscle weakness | Pelvic floor muscle weakness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542051","Presyncope, CTCAE","C143778","A disorder characterized by an episode of lightheadedness and dizziness which may precede an episode of syncope.","Presyncope, CTCAE | Presyncope | Presyncope",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542023","Rhinitis Infective, CTCAE","C143819","A disorder characterized by an infectious process involving the nasal mucosal.","Rhinitis Infective, CTCAE | Rhinitis Infective | Rhinitis infective | Rhinitis infective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542116","Stoma Site Infection, CTCAE","C143860","A disorder characterized by an infectious process involving a stoma (surgically created opening on the surface of the body).","Stoma Site Infection, CTCAE | Stoma Site Infection | Stoma site infection | Stoma site infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550644","BLADDER INCONTINENCE","C146786","A disorder characterized by inability to control the flow of urine from the bladder.","Urinary Incontinence, CTCAE 5.0 | Urinary Incontinence | Urinary Incontinence (Priority 1) | Urinary incontinence | Urinary incontinence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542163","Vulval Infection, CTCAE","C143943","A disorder characterized by an infectious process involving the vulva.","Vulval Infection, CTCAE | Vulval Infection | Vulval infection | Vulval infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544809","ALK NP_004295.2:p.F1245L","C146876","A change in the amino acid residue at position 1245 in the ALK tyrosine kinase receptor protein where phenylalanine has been replaced by leucine.","ALK NP_004295.2:p.F1245L | ALK F1245L | ALK NP_004295.2:p.Phe1245Leu | ALK Phe1245Leu | ALK Tyrosine Kinase Receptor F1245L | ALK Tyrosine Kinase Receptor Phe1245Leu | ALK p.F1245L | ALK p.Phe1245Leu | Anaplastic Lymphoma Kinase F1245L | Anaplastic Lymphoma Kinase Phe1245Leu | CD246 Antigen F1245L | CD246 Antigen Phe1245Leu | NP_004295.2:p.F1245L | NP_004295.2:p.Phe1245Leu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555051","Wind River Arapaho","C43893","A person having origins in the original Wind River Arapaho people.","Wind River Arapaho | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413096","CALR Gene","C95313","This gene plays a role in calcium binding and protein folding.","CALR Gene | CALR | Calreticulin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541470","CSMD3 Gene","C143042","This gene plays a role in neuronal development.","CSMD3 Gene | CSMD3 | CUB and Sushi Multiple Domains 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0751995","PDGFB Gene","C18278","This gene is involved in cellular growth and proliferation. It is also plays a role in intercellular signaling.","PDGFB Gene | PDGFB | Platelet Derived Growth Factor Subunit B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424132","MAML2 Gene","C95456","This gene plays a role in transcriptional regulation and signal transduction.","MAML2 Gene | MAML2 | Mastermind Like Transcriptional Coactivator 2 Gene | Mastermind-Like 2 (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420613","TBX3 Gene","C101638","This gene is involved in both transcriptional repression and limb development.","TBX3 Gene | T-Box 3 Gene | TBX3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1567121","AEG35156","C49180","A second-generation synthetic antisense oligonucleotide with potential antineoplastic activity. AEG35156 selectively blocks the cellular expression of X-linked inhibitor of apoptosis protein (XIAP), a pivotal inhibitor of apoptosis that is overexpressed in many tumors. This agent reduces total levels of XIAP in tumor cells, working synergistically with cytotoxic drugs to overcome tumor cell resistance to apoptosis. XIAP interferes with both the intrinsic and extrinsic program-death signaling pathways, which may render tumor cells resistant to apoptosis.","XIAP Antisense Oligonucleotide AEG35156 | AEG 35156 | AEG-35156 | AEG35156 | AEG35156 | GEM640",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524655","Rituximab and Hyaluronidase Human","C136821","A combination preparation of rituximab, a genetically engineered chimeric murine/human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against the CD20 antigen, and the recombinant form of the human enzyme hyaluronidase, with antineoplastic activity. Upon subcutaneous administration of rituximab and hyaluronidase human, the hyaluronidase reversibly depolymerizes the polysaccharide hyaluronan in the subcutaneous tissue. This increases the permeability of the subcutaneous tissue and enhances the absorption of rituximab into the systemic circulation. In turn, rituximab targets and binds to CD20 expressed on tumor cells, and induces tumor cell lysis primarily through the induction of complement dependent cytotoxicity (CDC) and antibody-dependent cell mediated cytotoxicity (ADCC).  When administered subcutaneously, hyaluronidase, an endoglycosidase, increases the dispersion and absorption of co-administered drugs.  CD20 is expressed on the surface of pre-B and mature B-lymphocytes, and is overexpressed in a variety of B-cell malignancies.","Rituximab and Hyaluronidase Human | Rituxan Hycela | Rituximab Plus Hyaluronidase | Rituximab and hyaluronidase human | Rituximab/Hyaluronidase | Rituximab/Hyaluronidase Human",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550839","PSA Level 0.2 to Two","C148234","A blood concentration of prostate specific antigen between 0.2 and 2 ng/mL.","PSA Level 0.2 to Two | PSA Level 0.2 to 2 | PSA Level Between 0.2 and 2 | PSA Level Between 0.2 and Two",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550914","Area of Affected Breast Oversensitive","C148273","A question about whether the area of an individual's affected breast is or was oversensitive.","Area of Affected Breast Oversensitive | Area of Affected Breast Overly Sensitive | Was the area of your affected breast oversensitive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524854","Pathologic Stage IIC Cutaneous Melanoma AJCC v8","C137669","Stage IIC includes: T4b, N0, M0. T4b: Tumor measuring more than 4.0 mm in thickness. Ulceration status: With ulceration.  N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","Pathologic Stage IIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIC Melanoma of the Skin AJCC v8 | Stage IIC | Stage IIC Cutaneous (Skin) Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0555051","Cohabitee Left Home","C150729","An indication that an individual who is or was living with another person left their shared home.","Cohabitee Left Home | Cohabitee left home",,,,,,,,,,,,,,,"4172700","Cohabitee left home",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552379","KDM6A Gene Mutation","C150649","A change in the nucleotide sequence of the KDM6A gene.","KDM6A Gene Mutation | KABUK2 Gene Mutation | Lysine (K)-Specific Demethylase 6A Gene Mutation | Lysine Demethylase 6A Gene Mutation | UTX Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554502","DNMT3 Family","C153274","A family of proteins involved in methylation of DNA. There are three proteins in this family. DNA (cytosine-5)-methyltransferase (DNMT) 3A and DNMT3B are DNA methyltransferases that catalyze the methylation of hemimethylated and unmethylated CpG at the same rate. DNMT3-like (DNMT3L) has no enzymatic activity; instead this protein interacts with other members of the family and regulates their enzymatic activity.","DNMT3 Family | DNA (Cytosine-5)-Methyltransferase 3 | DNA (Cytosine-5)-Methyltransferase 3 Family | DNMT3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554918","Humor is Major Ingredient in Doctor's Treatment of Patient","C153544","A question about whether humor is a major ingredient in the doctor's treatment of the patient.","Humor is Major Ingredient in Doctor's Treatment of Patient | Humor is a major ingredient in the doctor's treatment of the patient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526592","Nine Times Per Day","C139182","Nine times per day.","Nine Times Per Day | 9 TIMES PER DAY | 9 Times Daily",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054693","Ivy Incision Method","C122167","A method for assessing bleeding time in which the individual wears a blood pressure cuff inflated to 40mmHg, a controlled incision (10mm long x 1mm deep)is made on the volar surface of the arm, and blood is drawn off of the incision site with blotting paper every 30 seconds until bleeding stops.","Ivy Incision Method | IVY INCISION METHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226037","Circumflex Branch of the Left Coronary Artery","C12874","An artery arising from the bifurcation of the left coronary artery that runs along the coronary grove with branches supplying the atria and ventricles.","Circumflex Branch of the Left Coronary Artery | Circumflex Branch of Left Coronary Artery | LEFT CIRCUMFLEX CORONARY ARTERY",,,,,,,,,,,,,,,"4211970","Structure of circumflex coronary artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0229095","Vitreous Chamber","C33885","The largest space within the eye which is bounded by the lens and the retina and filled with the gelatinous vitreous humor.","Vitreous Chamber | EYE, VITREOUS CHAMBER | Postremal Chamber",,,,,,,,,,,,,,,"4096320","Vitreous cavity structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1185904","Right Cusp of the Pulmonary Valve","C127675","The cusp of the pulmonic valve attached to the right side of the cardiac septum.","Right Cusp of the Pulmonary Valve | PULMONARY VALVE, RIGHT CUSP | Pulmonary Valve, Right Semilunar Cusp",,,,,,,,,,,,,,,"4325585","Structure of right cusp of pulmonic valve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521201","Left Lung, Inferior Lobe, Posterior Basal Segment","C132396","The posterior basal segment of the inferior lobe of the left lung.","Left Lung, Inferior Lobe, Posterior Basal Segment | LUNG, LEFT, INFERIOR LOBE, POSTERIOR BASAL SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509327","Scaphoid-Trapezium Joint","C127678","A condyloid synovial joint within the wrist connecting the scaphoid bone to the trapezium bone.","Scaphoid-Trapezium Joint | SCAPHOID-TRAPEZIUM JOINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699019","Red Blood Cell Cast Measurement","C74772","The determination of the amount of red blood cell casts present in a urine sample.","Red Blood Cell Cast Measurement | CSRBC | Erythrocyte Casts | RBC Casts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879757","Lymphocytes Atypical/Leukocytes","C64819","The determination of the ratio of atypical lymphocytes to leukocytes in a blood sample. The measurement may be expressed as either a ratio or a percentage.","Atypical Lymphocyte to Leukocyte Ratio Measurement | Atypical Lymphocyte to Leukocyte Ratio | LYMATLE | Lymphocytes Atypical/Leukocytes | Lymphocytes, Variant/Leukocytes | Reactive Lymphocytes/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552583","Protein Excretion Rate","C150822","A determination of the amount of total protein being excreted in a biological specimen over a defined period of time.","Protein Excretion Rate | PROTEXR | Total Protein Excretion Rate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054696","Islet Cell Cytoplasmic IgG Antibody Measurement","C122126","The determination of the amount of islet cell cytoplasmic IgG antibody present in a sample.","Islet Cell Cytoplasmic IgG Antibody Measurement | ICAIGGAB | Islet Cell Cytoplasmic IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827551","Virtual Pixel","C114237","A type of pixel created from overlying two adjacent real pixels to create an additional virtual image of a pixel that is visible to the human eye.","Virtual Pixel | VIRTUAL PIXEL | {VIRTUAL PIXEL}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697780","Interleukin 30 Measurement","C74828","The determination of the amount of interleukin 30 present in a sample.","Interleukin 30 Measurement | INTLK30 | Interleukin 30",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813128","Factor XIII Measurement","C112277","The determination of the amount of factor XIII present in a sample.","Factor XIII Measurement | FACTXIII | Factor XIII | Fibrin Stabilizing Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526631","Linear Foot Pound","C139134","A unit of energy that equals the work required to move one pound a distance of one foot in the direction of the applied force.","Linear Foot Pound | Linear Foot-pound | Linear Pounds Feet | Linear ft*LB | Linear ft*lbf | [lbf_av] | pound foot | {Linear ft*LB}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346524","100 International Units per Milliliter","C71185","A unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one hundred international units per one milliliter of system volume.","100 International Units per Milliliter | 10*2.[IU]/mL | 10*2.[IU]/ml | 10*2.[iU]/mL | 10*2.[iU]/ml | 100 IU/mL | 100 International units/Milliliter | 100IU/Milliliter | 10^2 IU/mL | 10^2.[IU]/mL | 10^2.[IU]/ml | 10^2.[iU]/mL | 10^2.[iU]/ml | 10^5 IU/L | Hundred International Units per Milliliter | One Hundred International Units per Milliliter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897400","T Wave Duration Single Beat","C117813","An electrocardiographic interval measured from the onset of the T wave to the offset of the T wave of a single beat utilizing one or more leads. (CDISC)","T Wave Duration Single Beat | T Wave Duration, Single Beat | TWDURSB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274426","Normoblast to Total Cell Ratio Measurement","C98764","The determination of the ratio of normoblasts compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Normoblast to Total Cell Ratio Measurement | BLSTNMCE | Normoblasts to Total Cells Ratio Measurement | Normoblasts/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042879","Vitamin K Measurement","C74907","The determination of the amount of Vitamin K present in a sample.","Vitamin K Measurement | Naphthoquinone | VITK | Vitamin K",,,,,,,,,,,,,,,"4020127","Vitamin K measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0428623","Immunoglobulin G to Albumin Ratio Measurement","C147372","The determination of the ratio of IgG compared to albumin present in a sample. The measurement may be expressed as a ratio or percentage.","Immunoglobulin G to Albumin Ratio Measurement | IGGALB | IgG to Albumin Ratio Measurement | IgG/Albumin | Immunoglobulin G/Albumin",,,,,,,,,,,,,,,"4353607","Albumin/immunoglobulin G ratio measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540364","Scaphoid-Trapezoid Joint","C142316","The articulation of the scaphoid and trapezoid bones in the wrist.","Scaphoid-Trapezoid Joint | SCAPHOID-TRAPEZOID JOINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897102","Exposure as Collected Location","C117488","The site in or on the body at which the exposure as collected test or result is performed or collected.","Exposure as Collected Location | ECLOC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826902","Laboratory Test Method","C83312","A systematic course of action that is performed in order to complete a laboratory test.","Laboratory Test Method | LAB_METHOD | LBMETHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523460","Alanine Aminopeptidase Measurement","C100430","The determination of the amount of alanine aminopeptidase present in a sample.","Alanine Aminopeptidase Measurement | AAP | Alanine Aminopeptidase",,,,,,,,,,,,,,,"4018060","Alanine aminopeptidase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011947","Dialysis Fluid","C106515","The fluid which runs through a dialysis machine and captures, for discard or analysis, the excess water and waste from the blood stream through diffusion and ultrafiltration.","Dialysis Fluid | DIALYSIS FLUID | Dialysate",,,,,,,,,,,,,,,"4021071|4305215","Dialysis fluid|Dialysis fluid",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3541318","Soluble Transferrin Receptor Measurement","C100438","The determination of the amount of soluble transferrin receptor present in a sample.","Soluble Transferrin Receptor Measurement | SLTFRNRC | Soluble Transferrin Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827512","Neutrophilic Myelocyte Count","C84823","The determination of the number of neutrophilic myelocytes in a blood sample.","Neutrophilic Myelocyte Count | NEUTMY | Neutrophilic Myelocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538799","Prostaglandin E1 Measurement","C103434","The determination of the amount of the prostaglandin E1 in a sample.","Prostaglandin E1 Measurement | PGE1 | Prostaglandin E1",,,,,,,,,,,,,,,"4019991","Prostaglandin E1 measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898885","High Absorption Reticulocytes to Total Reticulocytes Ratio Measurement","C116189","The determination of the ratio of high absorption reticulocytes compared to total reticulocytes present in a sample. The measurement may be expressed as a ratio or percentage.","High Absorption Reticulocytes to Total Reticulocytes Ratio Measurement | High Absorption Retic/Reticulocytes | RETIHRTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523852","Proline Measurement","C122141","The determination of the amount of proline present in a sample.","Proline Measurement | PRO | Proline",,,,,,,,,,,,,,,"4019989","Proline measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202036","Gastrin Measurement","C74858","The determination of the amount of gastrin hormone present in a sample.","Gastrin Measurement | GASTRIN | Gastrin",,,,,,,,,,,,,,,"4336961","Gastrin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513749","Weed Mix Pollen Antigen IgG Antibody Measurement","C130107","A measurement of the weed mix pollen antigen IgG antibody in a biological specimen.","Weed Mix Pollen Antigen IgG Antibody Measurement | C130107 | Weed Mix Pollen Antigen IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540297","Streptococcus pneumoniae Serotype 20 IgG Antibody Measurement","C142268","The determination of the amount of Streptococcus pneumoniae serotype 20 IgG antibody present in a sample.","Streptococcus pneumoniae Serotype 20 IgG Antibody Measurement | C142268 | S. pneumonia Sero 20 IgG AB | S. pneumoniae Sero 20 IgG AB | Streptococcus pneumoniae Serotype 20 IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023117","Micro-Latex Particle-Mediated Immunoassay","C142341","An assay technique used to test a individual's antigen-antibody immune response, which involves coating microbeads of latex with pathogen-specific antigens or antibodies, mixing them with the subject's fluid of interest, and then observing for any agglutination.","Micro-Latex Particle-Mediated Immunoassay | Latex Agglutination | Latex Fixation | MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY",,,,,,,,,,,,,,,"4184471|45766315","Latex agglutination test|Latex agglutination test",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3242399","Global Medical Device Nomenclature","C154416","A system of internationally agreed generic descriptors used to identify all medical device products.","Global Medical Device Nomenclature | GMDN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555411","Telephonic Format with Interactive Voice Response Technology","C154499","A questionnaire or measure that is administered via telephone, using interactive voice response technology.","Telephonic Format with Interactive Voice Response Technology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555517","Prescribing Domain","C154633","Provider orders for medication dispensing and/or administration. These orders may take place in any setting, including the inpatient or outpatient basis.","Prescribing Domain | PRESCRIBING | Prescribing Table",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520852","Pathologic Stage IA Esophageal Adenocarcinoma AJCC v8","C133415","Stage IA includes: (T1a, N0, M0, G1); (T1a, N0, M0, GX). T1a: Tumor invades the lamina propria or muscularis mucosae. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well-differentiated. GX: Grade cannot be assessed. (AJCC 8th ed.)","Pathologic Stage IA Esophageal Adenocarcinoma AJCC v8 | IA | Stage IA Esophageal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831330","Blood Product Collection","C112932","Any process that harvests blood or blood products for clinical or manufacturing purposes.","Blood Product Collection | Collection, Blood Products",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524718","Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8","C136888","Stage IIIB includes: T1-4, N1b-3, M0. T1: Maximum clinical tumor diameter equal to or less than 2 cm. T2: Maximum clinical tumor diameter more than 2 cm but equal to or less than 5 cm. T3: Maximum clinical tumor diameter more than 5 cm. T4: Primary tumor invades fascia, muscle, cartilage, or bone. N1b: Clinically and/or radiologically detected regional lymph node metastasis, microscopically confirmed. N2: In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) without lymph node metastasis. N3: In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) with lymph node metastasis. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)","Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8 | Pathologic Stage IIIB Neuroendocrine Carcinoma of the Skin AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563025","Moderate to Severe Pain or Discomfort that Prevented Some Activities","C156181","A response indicating that an individual has or had moderate to severe pain or discomfort that prevented some activities.","Moderate to Severe Pain or Discomfort that Prevented Some Activities | Moderate to severe pain or discomfort that prevented some activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563038","Limitations in Use of Hands or Fingers; Requires Help for Most Tasks","C156194","A response indicating that an individual has limitations in the use of their hands or fingers that requires the help of another person for most tasks, even with use of special tools.","Limitations in Use of Hands or Fingers; Requires Help for Most Tasks | Limitations in the use of hands or fingers, required the help of another person for most tasks (not independent even with use of special tools)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL441272","Paraíba","C156327","A state in the Northeast Region of Brazil. Its capital is Joao Pessoa.","Paraiba | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563171","Milligram Iron per Gram Liver (Dry Weight)","C156448","A measurement of iron in the liver expressed as a ratio of milligrams of iron to grams of dry weight of the liver sample.","Milligram Iron per Gram Liver (Dry Weight) | mg Fe/g (dry weight) | mg Fe/g liver (dry weight) | mg iron per g liver (dry weight) | mg iron per gram liver (dry weight)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520483","Pathologic Stage IIIC Gastric Cancer AJCC v8","C133667","Stage IIIC includes: (T3, N3b, M0); (T4a, N3b, M0); (T4b, N3a, M0); (T4b, N3b, M0). T3: Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. T4a: Tumor invades the serosa (visceral peritoneum). T4b: Tumor invades adjacent structures/organs. N3a: Tumor with metastasis in seven to fifteen regional lymph nodes. N3b: Tumor with metastasis in sixteen or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Pathologic Stage IIIC Gastric Cancer AJCC v8 | IIIC | Pathologic Stage IIIC Gastric Carcinoma AJCC v8 | Stage IIIC Gastric (Stomach) Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522061","Hepatocellular Carcinoma pT1b TNM Finding v8","C134475","Hepatocellular carcinoma with solitary tumor larger than 2 cm without vascular invasion. (from AJCC 8th Ed.)","Hepatocellular Carcinoma pT1b TNM Finding v8 | Liver Cell Carcinoma pT1b TNM Finding v8 | pT1b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522098","Stage IA Hepatocellular Carcinoma AJCC v8","C134517","Stage IA includes: T1a, N0, M0. T1a: Solitary tumor equal to or less than 2 cm.  N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IA Hepatocellular Carcinoma AJCC v8 | IA | Stage IA Hepatocellular Cancer | Stage IA Liver Cell Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935806","Maternally Derived Graft Versus Host Disease","C156790","Graft versus host disease (GVHD) that occurs in an infant as the result of engraftment of maternal lymphocytes, resulting from in utero maternal-fetal cellular trafficking.","Maternally Derived Graft Versus Host Disease | Maternally Derived GVHD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935876","Activating PPM1D Gene Mutation","C156761","A change in the nucleotide sequence of the PPM1D gene that results in constitutive activation of protein phosphatase 1D and its downstream signaling pathways.","Activating PPM1D Gene Mutation | Activating IDDGIP Gene Mutation | Activating PP2C-DELTA Gene Mutation | Activating Protein Phosphatase 1D Gene Mutation | Activating Protein Phosphatase 1D Magnesium-Dependent, Delta Isoform Gene Mutation | Activating Protein Phosphatase 2C, Delta Isoform Gene Mutation | Activating Protein Phosphatase, Mg2+/Mn2+ Dependent 1D Gene Mutation | Activating WIP1 Gene Mutation | Activating Wild-Type p53-Induced Phosphatase 1 Gene Mutation | PPM1D Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1552679","Organization Name","C93874","A textual identifier for an organization.","Organization Name | Organization | Organization.name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936950","Hearing Handicap Inventory Screening Questionnaire for Adults","C157368","A 10-item questionnaire, derived from the Hearing Handicap Inventory for the Elderly, developed to assess how adult individuals under 65 perceive the social and emotional effects of hearing loss.","Hearing Handicap Inventory Screening Questionnaire for Adults | HHIA-S | Hearing Handicap Inventory for Adults, Screening Version",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540344","Non-Target Lesion Worsening Indicator","C142364","An indication as to whether a non-target lesion is showing signs of worsening.","Non-Target Lesion Worsening Indicator | NTLWIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889269","Disease Response Assessment Test","C117404","A character or string that represents the long name of the disease response assessment.","Disease Response Assessment Test | RSTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935767","Metabolite Ratio for Maximum Concentration","C156569","The ratio of metabolite maximum concentration to the parent analyte maximum concentration.","Metabolite Ratio for Maximum Concentration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898871","Hour Times Milligram Per Milliliter Per Milligram Per Gram Per Day","C117921","Hour times milligram per milliliter, divided by milligram per gram per day.","Hour Times Milligram Per Milliliter Per Milligram Per Gram Per Day | h*mg/mL/(mg/g/day) | h.mg/mL/(mg/g/d) | h.mg/ml/(mg/g/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981438","Clinical Events Sequence Number","C87854","A number that identifies the ordering relations (in time, space, etc.) in a set of clinical events.","Clinical Events Sequence Number | CESEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981498","Microbiology Specimen Reference Identifier","C87914","A character or string used to name, or characterize a microbiology specimen reference.","Microbiology Specimen Reference Identifier | MBREFID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899220","Exposure as Collected End Day","C117499","The final day of the exposure collection period.","Exposure as Collected End Day | ECENDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829031","Minute Times Mole Per Liter Per Gram","C112346","Minutes times moles per liter, divided by grams.","Minute Times Mole Per Liter Per Gram | min*mol/L/g | min.mol/L/g | min.mol/l/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899195","Exposure as Collected Total Daily Dose","C117484","A specified quantity of a therapeutic agent of the collected exposure, during a one-day period.","Exposure as Collected Total Daily Dose | ECDOSTOT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826917","Medical History Body System or Organ Class","C83327","The body system or organ class that pertains to a medical history.","Medical History Body System or Organ Class | MHBODSYS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937277","Myokine","C157583","A family of soluble proteins that are synthesized and secreted by muscle cells in response to muscle contraction and may drive autocrine, paracrine and endocrine signaling pathways in cells expressing myokine receptors.","Myokine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639709","Current Opioid Misuse Measure Questionnaire","C100764","A standardized rating scale developed and copyrighted by Inflexxicon, Inc. which is used to aid clinicians in determining if a patient may be improperly using opioids for the treatment of pain. This instrument consists of 17 questions which can be completed by the patient. Each question is rated on a scale of 0-4 with 0 being 'never' and 4 being 'very often'. A score equal to or greater than 9 indicates possible misuse.","Current Opioid Misuse Measure Questionnaire | COMM | COMM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054719","Influenza Hemagglutinin 1 Specific IgG Antibody Secreting Cell Count","C120622","The determination of the number of influenza hemagglutinin 1 specific IgG antibody secreting cells present in a sample.","Influenza Hemagglutinin 1 Specific IgG Antibody Secreting Cell Count | H1 Specific IgG ASCs | H1 Specific IgG Antibody Secreting Cells | H1IGGASC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898169","Nanomole per Liter per Microgram per Kilogram per Day","C119464","A unit of concentration equal to nanomoles per liter, divided by micrograms per kilogram per day.","Nanomole per Liter per Microgram per Kilogram per Day | Micromole per Liter per Milligram per Kilogram per Day | nmol/L/(ug/kg/d) | nmol/L/(ug/kg/day) | nmol/l/(ug/kg/d) | umol/L/(mg/kg/d) | umol/L/(mg/kg/day) | umol/l/(mg/kg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335323","Papillary Duct Hyperplasia of the Breast","C5200","Benign papillary proliferation within the ductal system of the breast parenchyma.","Breast Papillary Ductal Hyperplasia | Papillary Breast Hyperplasia | Papillary Duct Hyperplasia of Breast | Papillary Duct Hyperplasia of the Breast | Papillary Ductal Breast Hyperplasia | Papillary Ductal Breast Hyperplasia | Papillary Hyperplasia of Breast | Papillary Hyperplasia of the Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552607","Clostridium difficile tcdA DNA Measurement","C150859","The determination of the amount of tcdA DNA produced by Clostridium difficile present in a sample.","Clostridium difficile tcdA DNA Measurement | CDFTCDAD | Clostridium difficile Toxin A DNA Measurement | Clostridium difficile tcdA DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086722","Palpable State","C124449","A condition or state of the tumor with regards to its palpability status at a particular point in time.","Palpable State | PALPSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346597","J Point Elevation","C71030","An electrocardiographic finding of a significant elevation above the baseline of the J point. (CDISC)","J Point Elevation | J POINT ELEVATION | J point elevation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640888","Old or Age Indeterminate Posterior Myocardial Infarction by ECG Finding","C102691","An electrocardiographic finding in leads V1 or V2 of an initial R wave duration greater than or equal to 40 ms, R wave greater than S wave, and upright T wave, which is suggestive of myocardial infarction of the posterior wall of the left ventricle, without evidence of current or ongoing acute infarction. Evidence of inferior or lateral myocardial infarction is usually also present. (CDISC)","Old or Age Indeterminate Posterior Myocardial Infarction by ECG Finding | OLD OR AGE INDETERMINATE POSTERIOR WALL MYOCARDIAL INFARCTION | Old Or Age Indeterminate Posterior Wall Myocardial Infarction | Old or Age Indeterminate Posterior Myocardial Infarction by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574297","Basque Language","C153911","A language isolate spoken in the Basque country of Spain and France. Basque is unrelated to the other languages of Europe or to any other known living language.","Basque Language | Basque | EUS",,,,,,,,,,,,,,,"4175770","Basque language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937579","Activating NOTCH3 Mutation","C158058","A change in the nucleotide sequence of the NOTCH3 gene that that results in constitutive activation of both neurogenic locus notch homolog protein 3 and its downstream signaling pathways.","Activating NOTCH3 Mutation | Activating CADASIL Gene Mutation | Activating CASIL Gene Mutation | Activating IMF2 Gene Mutation | Activating NOTCH3 Gene Mutation | Activating Notch (Drosophila) Homolog 3 Gene Mutation | Activating Notch 3 Gene Mutation | Activating Notch Homolog 3 Gene Mutation | NOTCH3 Activating Gene Mutation | NOTCH3 Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509734","Cross-sectional Diameter at End Ventricular Systole","C127546","The cross sectional diameter measured at end ventricular systole.","Cross-sectional Diameter at End Ventricular Systole | CSDIAEVS | Cross-sec Diameter, EVS | Cross-sectional Diameter, End Ventricular Systole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0807481","Pressure Half Time","C147156","The amount of time required for the maximum transvalvular pressure gradient to decrease to one half of its initial value.","Pressure Half Time | PRESHT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545162","Valve Area","C147158","The quantitative measurement of the surface area of a valve.","Valve Area | VLVAREA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087058","Non-Quantifiable MRD Positivity","C124431","Presence of non-quantifiable residual disease based on laboratory techniques.","Non-Quantifiable Measurable Residual Disease Positivity | NON-QUANTIFIABLE MRD POSITIVITY | Non-Quantifiable MRD Positivity | Non-Quantifiable Minimal Residual Disease Positivity | Non-Quantifiable Minimal Residual Disease Positivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL497939","Pancreatic Intraductal Papillary-Mucinous Neoplasm, Low Grade","C41249","A non-invasive pancreatic intraductal papillary mucinous neoplasm characterized by the presence of neoplastic epithelial cells that form a single layer and are well polarized.  The neoplastic cells exhibit small and uniform nuclei, mild pleomorphism, and rare mitotic figures.","Pancreatic Intraductal Papillary-Mucinous Neoplasm, Low Grade | Pancreatic Intraductal Papillary Mucinous Neoplasm with Low Grade Dysplasia | Pancreatic Intraductal Papillary-Mucinous Adenoma | Pancreatic Intraductal Papillary-Mucinous Neoplasm with Low Grade Dysplasia | Pancreatic Intraductal Papillary-Mucinous Neoplasm with Low Grade Dysplasia | Pancreatic Intraductal Papillary-Mucinous Neoplasm, Low-Grade",,,,,,,,,,,,,,,"4029011|43021773","Intraductal papillary-mucinous adenoma|Intraductal papillary mucinous adenoma of pancreas",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL538334","Testicular Cancer Clinical TNM Finding v8","C140187","A clinical finding about one or more characteristics of testicular cancer, following the rules of the TNM AJCC v8 classification system.","Testicular Cancer Clinical TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538311","Stage 0 Testicular Cancer AJCC v8","C140226","Stage 0 includes: pTis, N0, M0, S0. pTis: Testicular cancer with a finding of germ cell neoplasia in situ. N0: Testicular cancer with no regional lymph node metastasis. M0: Testicular cancer without evidence of distant metastasis. S0: Marker study levels within normal limits. (AJCC 8th ed.)","Stage 0 Testicular Cancer AJCC v8 | Stage 0 Testicular Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951296","Coordinate, Arrange, and Manage Child's Medical Services","C159376","A question about an individual coordinating, arranging, and managing their child's medical services.","Coordinate, Arrange, and Manage Child's Medical Services | Coordinating, arranging, and managing medical services (examples include: scheduling appointments, locating equipment and negotiating services)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951490","Wheelchair Independent, Greater Than 50 Yards","C159469","A response indicating that an individual is independent with use of a wheelchair, including corners, and can move more than 50 yards.","Wheelchair Independent, Greater Than 50 Yards | wheelchair independent, including corners, greater than  50 yards | wheelchair independent, including corners, greater than 50 yards",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969066","Global Complete Response in Lymph Nodes","C159958","All lymph nodes are now 1.5 cm or less in greatest transverse (long axis) diameter by method used to assess lymph nodes at baseline or biopsy negative for lymphoma; in addition, lymph nodes that were N3 classification and 1.5 cm or less in their long axis and more than 1 cm in their short axis at baseline, must now be 1 cm or less in their short axis or biopsy negative for lymphoma.","Global Complete Response in Lymph Nodes | CR | Complete Response | Complete Response in Lymph Nodes | Lymph Node Complete Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985500","Child-life Worker","C93222","A professional who is responsible for making a child's hospital and treatment experience less scary.","Child-life Worker | child-life worker",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710096","Sinonasal Undifferentiated Carcinoma","C54294","A rare, highly aggressive carcinoma that arises from the sinonasal tract.  It is characterized by the presence of small to medium size malignant cells.  The prognosis is poor.","Sinonasal Undifferentiated Carcinoma | Sinonasal Anaplastic Carcinoma | Undifferentiated Sinonasal Cancer",,,,,,,,,,,,,,,"44783808","Undifferentiated carcinoma of nasal sinus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827011","Substance Use Group Identifier","C83422","A character or string that represents a substance usage group.","Substance Use Group Identifier | SUGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935829","Current Smoker Includes Daily and Non-daily Smokers","C156827","An indication that an individual is a current smoker that may or may not smoke daily.","Current Smoker Includes Daily and Non-daily Smokers | Current smoker Includes daily and non-daily smokers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827003","Substance Use Class Code","C83414","A character or string that represents a substance use class.","Substance Use Class Code | SUCLASCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970754","Informed Consent Time","C162171","The time of informed consent collection.","Informed Consent Time | Demographics Time of Informed Consent | RFICTIM | Time of Informed Consent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970955","10-2 Visual Field Testing","C162463","A test for visual field defects that tests the central 10 degrees, creating 68 points with 2 degrees between points. It is most often used on patients with conditions that affect central vision (e.g., macular degeneration, diabetic retinopathy) or when only a small amount of central vision remains (e.g., end-stage glaucoma).","10-2 Visual Field Testing | 10-2 Visual Field | 10-2 Visual Field Test | Central 10-2 Visual Field Testing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545686","Hormone Therapy Agent","C147908","Any agent that can alter hormone levels or modulate hormone effects.","Hormone Therapy Agent | Hormonal Therapy Agent | Hormone Therapy | Hormone Therapy Drug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0178830","Reproductive System Neoplasm","C3674","A benign or malignant, primary or metastatic neoplasm affecting the male and female reproductive system.","Reproductive System Neoplasm | Neoplasm of Reproductive System | Neoplasm of the Reproductive System | Reproductive Neoplasm | Reproductive System Tumor | Reproductive Tumor | Tumor of Reproductive System | Tumor of the Reproductive System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038874","Supratentorial Neoplasm","C3397","A benign or malignant neoplasm that occurs within the intracranial cavity above the tentorium cerebelli.","Supratentorial Neoplasm | Brain Neoplasms, Supratentorial | Neoplasm of uncertain behavior of brain, supratentorial | Supratentorial Neoplasms | Supratentorial Tumor | Supratentorial Tumors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951178","Highest grade","C159309","A directive to choose the highest grade of pancreatin intraepithelial neoplasia.","Highest Grade Pancreatic Intraepithelial Neoplasia | Highest Grade | Highest grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973114","Highest Grade","C162674","A morphologic grade that refers to the maximum grade that a malignant tumor can exhibit  (usually grade III or IV-poorly differentiated).","Highest Grade | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951177","Date of Surgical Procedure","C159308","A question about the date on which a surgical procedure was performed.","Date of Surgical Procedure | Date of Surgery/Procedure | Date of surgery | date of surgery | date_of_surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973372","EGFR Exon 20 Tyrosine Kinase Inhibitor Resistant Mutation","C163018","A molecular genetic abnormality indicating the presence of secondary mutations in exon 20 of the EGFR gene that result in the translation of an epidermal growth factor receptor protein that is resistant to tyrosine kinase inhibitor therapies.","EGFR Exon 20 Tyrosine Kinase Inhibitor Resistant Mutation | EGFR Exon 20 Resistance Mutation | EGFR Exon 20 TKI-Resistant Mutation | ERBB Exon 20 TKI-Resistant Mutation | ERBB1 Exon 20 TKI-Resistant Mutation | Epidermal Growth Factor Receptor Gene Exon 20 TKI-Resistant Mutation | HER1 Exon 20 TKI-Resistant Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521954","Colorectal Cancer pN2 TNM Finding v8","C134176","Colorectal cancer in which four or more regional lymph nodes are positive. (from AJCC 8th Ed.)","Colorectal Cancer pN2 TNM Finding v8 | Colorectal Carcinoma pN2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977508","Epstein-Barr Virus Reactivation","C164202","The switching of latent Epstein-Barr virus to a lytic infection.","Epstein-Barr Virus Reactivation | EBV Reactivation | HHV-4 Reactivation | HHV4 Reactivation | Human Herpesvirus 4 Reactivation | Human Herpesvirus-4 Reactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225579","Laryngeal Posterior Commissure","C164282","The posterior surface of the glottic opening at the level of the vocal cords.","Laryngeal Posterior Commissure | GLOTTIS, POSTERIOR COMMISSURE | Posterior Glottic Commissure",,,,,,,,,,,,,,,"4218094","Structure of posterior commissure of larynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL978422","Data Custodian","C165210","The person responsible for a specific data set.","Data Custodian | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978568","CDH1 Pathogenic or Likely Pathogenic Gene Mutation","C165503","A change in the nucleotide sequence of the CDH1 gene that is associated with a pathogenic or likely pathogenic prognosis.","CDH1 Pathogenic or Likely Pathogenic Gene Mutation | CD324 Pathogenic or Likely Pathogenic Variation | CDH1 PLPV | CDH1 Pathogenic or Likely Pathogenic Gene Variant | CDH1 Pathogenic or Likely Pathogenic Gene Variation | CDH1 Pathogenic or Likely Pathogenic Variant | CDHE Pathogenic or Likely Pathogenic Variation | Cadherin 1 PLPV | Cadherin 1 Pathogenic or Likely Pathogenic Variation | Cadherin-1 PLPV | Cadherin-1 Pathogenic or Likely Pathogenic Variation | E-Cadherin PLPV | E-Cadherin Pathogenic or Likely Pathogenic Variation | ECAD Pathogenic or Likely Pathogenic Variation | UVO Pathogenic or Likely Pathogenic Variation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972402","FLT3 NP_004110.2:p.M664I","C167173","A change in the amino acid residue at position 664 in the receptor-type tyrosine-protein kinase FLT3 protein where methionine has been replaced by isoleucine.","FLT3 NP_004110.2:p.M664I | CD135 Antigen M664I | CD135 Antigen Met664Ile | FLT3 M664I | FLT3 Met664Ile | FLT3 NP_004110.2:p.Met664Ile | FLT3 p.M664I | FLT3 p.Met664Ile | Fetal Liver Kinase-2 M664I | Fetal Liver Kinase-2 Met664Ile | Flt-3 Receptor M664I | Flt-3 Receptor Met664Ile | Fms-Related Tyrosine Kinase 3 M664I | Fms-Related Tyrosine Kinase 3 Met664Ile | M664I | NP_004110.2:p.M664I | NP_004110.2:p.Met664Ile | Receptor-Type Tyrosine-Protein Kinase FLT3 M664I | Receptor-Type Tyrosine-Protein Kinase FLT3 Met664Ile | Stem Cell Tyrosine Kinase 1 M664I | Stem Cell Tyrosine Kinase 1 Met664Ile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274188","EGFR NP_005219.2:p.L861R","C98499","A change in the amino acid residue at position 861 in the epidermal growth factor receptor protein where leucine has been replaced by arginine.","EGFR NP_005219.2:p.L861R | EGFR L861R | EGFR Leu861Arg | EGFR NP_005219.2:p.Leu861Arg | EGFR p.L861R | EGFR p.Leu861Arg | Epidermal Growth Factor Receptor L861R | Epidermal Growth Factor Receptor Leu861Arg | NP_005219.2:p.L861R | NP_005219.2:p.Leu861Arg | Proto-Oncogene c-ErbB-1 L861R | Proto-Oncogene c-ErbB-1 Leu861Arg | Receptor Tyrosine-Protein Kinase erbB-1 L861R | Receptor Tyrosine-Protein Kinase erbB-1 Leu861Arg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978987","Cat Dander IgG Antibody RAST Score Measurement","C165914","A classification of the amount of Felis cattus dander IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Cat Dander IgG Antibody RAST Score Measurement | C165914 | Cat Dander IgG AB RAST Score | Felis cattus Dander IgG Antibody RAST Score Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979139","Progranulin Measurement","C165964","The determination of the amount of progranulin present in a sample.","Progranulin Measurement | GRN | Pro-Granulin Measurement | Pro-Granulins Measurement | Progranulin | Progranulins Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1379034","Symptoms Extent Score 3","C168712","A subject score of 3 on a symptoms extent scale that ranges from 0: Not at All to 4: Very Bothered.","Symptoms Extent Score 3 | 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979251","Mouse Protection Assay","C166066","An assay method that is used for the detection of neutralizing antibodies in serum by determining the ability of the serum to prevent the death of mice that are exposed to a lethal dose of toxin.","Mouse Protection Assay | MOUSE PROTECTION ASSAY | MPA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382620","Blasts 5-20 Percent of Bone Marrow Nucleated Cells","C170401","A semi-quantitative microscopic finding indicating that between 5 and 20 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 5-20 Percent of Bone Marrow Nucleated Cells | Blasts Between 5 and 20 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018023","Nodular Goiter","C131437","Goiter characterized by discrete tissue mass(es) that may or may not produce thyroid hormones.","Nodular Goiter | Nodular Hyperplasia | Thyroid Nodular Hyperplasia",,,,,,,,,,,,,,,"4171549","Nodular goiter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0278602","Internal Medicine Physician","C17832","A physician specializing in the non-surgical treatment of adult disease.","Internal Medicine Physician | INTERNIST | Internist | Internist | internist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041712","United States Environmental Protection Agency","C17236","The EPA is the US Government's watchdog agency responsible for controlling the pollution of air and water, pesticides, radiation hazards and noise pollution. The agency is also involved in research to examine the effects of pollution. (EPA Terminology Reference System)","Environmental Protection Agency | EPA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976728","Fusarium proliferatum IgE Antibody Measurement","C163527","The determination of the amount of Fusarium proliferatum IgE antibody present in a sample.","Fusarium proliferatum IgE Antibody Measurement | C163527 | Fusarium proliferatum IgE Antibody | Gibberella intermedia IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979074","HIV-2 RNA Measurement","C166045","The determination of the amount of HIV-2 RNA present in a sample.","HIV-2 RNA Measurement | HIV-2 RNA | HIV2RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406648","Skin Condition Makes Showing Affection Difficult","C172773","A response indicating that an individual's skin condition makes showing affection difficult.","Skin Condition Makes Showing Affection Difficult | My skin condition makes showing affection difficult",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969755","Malignant Lesion","C160776","A lesion characterized by the presence of a malignant cellular population.","Malignant Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406962","Worry that Breast Cancer Recurrence Would Keep Me from Fulfilling Important Roles","C172908","A question about whether an individual worries that recurrence of their breast cancer would keep them from fulfilling important roles.","Worry that Breast Cancer Recurrence Would Keep Me from Fulfilling Important Roles | Keep me from fulfilling important roles (in my job or at home)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407427","Ethylbenzene","C173418","An aromatic hydrocarbon composed of a benzene ring linked to an ethyl group. Ethylbenzene is a constituent of petroleum and coal tar and is used as either a petroleum additive or a chemical intermediate in the production of polystyrene. High level exposure to airborne ethylbenzene is associated with eye and throat irritation.","Ethylbenzene | Benzene, Ethyl- | ETHYLBENZENE | Ethyl Benzene | Ethylbenzol | Phenylethane",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406662","Cancer Antigen 242 Measurement","C172526","The determination of the amount of cancer antigen 242 in a sample.","Cancer Antigen 242 Measurement | CA242 Measurement | CA242AG | Cancer Antigen 242 | Carbohydrate Antigen 242",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416484","ITGA2 Gene","C174143","This gene plays a role in cell adhesion to laminin, collagen, collagen C-propeptides, fibronectin and E-cadherin.","ITGA2 Gene | ITGA2 | Integrin Subunit Alpha 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522216","Stage IIIA Gallbladder Cancer AJCC v8","C134673","Stage IIIA includes: T3, N0, M0. T3: Tumor perforating the serosa (visceral peritoneum) and/or directly invading the liver and/or one other adjacent organ or structure, such as the stomach, duodenum, colon, pancreas, omentum, or extrahepatic bile ducts. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIA Gallbladder Cancer AJCC v8 | Stage IIIA Gallbladder Cancer | Stage IIIA Gallbladder Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412628","Exceed","C175323","To go beyond some value, or to be greater than or superior to something.","Exceed | Exceeded | Exceeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411718","Chylomicron Triglyceride Measurement","C174302","A measurement of the chylomicron triglyceride in a sample.","Chylomicron Triglyceride Measurement | CHLMCRNT | Chylomicron Triglyceride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555425","H3C13 Gene","C154647","This gene is involved in DNA compaction.","H3C13 Gene | H3 Clustered Histone 13 Gene | H3C13 | HIST2H3D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424242","CARD9 Gene","C131148","This gene is involved in both innate immunity and apoptosis regulation.","CARD9 Gene | CARD9 | Caspase Recruitment Domain Family Member 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642453","Nanogram per Mole","C176386","A unit of mass commonly used to express the molar mass of a substance in nanogram(s) per mole.","Nanogram per Mole | fg/umol | ng/mol | pg/mmol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642493","Hour Times Microgram Per Gram","C176356","Hours times micrograms per gram","Hour Times Microgram Per Gram | h*mg/kg | h*ng/mg | h*ug/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642588","NEMO Deleted Exon 5 Autoinflammatory Syndrome","C176752","An autoinflammatory syndrome caused by either gain-of-function splice site variants in the IKBKG gene resulting in a deletion in the C-terminal domain of the NEMO (NF-kappa-B essential modulator) protein or by increased expression of an isoform lacking the domain encoded by exon 5. It is clinically distinct from the immunodeficiency syndromes caused by loss-of-function IKBKG mutations and has features more characteristic of chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE).","NEMO Deleted Exon 5 Autoinflammatory Syndrome | IKBKG/NEMO NDAS | NDAS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642664","Severe Combined Immunodeficiency due to RAG2 Deficiency","C176607","An autosomal recessive condition caused by mutation(s) in the RAG2 gene, encoding V(D)J recombination-activating protein 2. It is characterized by severe combined immunodeficiency that is both T-cell and B-cell negative.","Severe Combined Immunodeficiency due to RAG2 Deficiency | RAG2 Deficiency | SCID-RAG2 | Severe Combined Immunodeficiency, T cell-Negative, B cell-Negative, RAG2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643152","ERBB2 NP_004439.2:p.V697L","C177501","A change in the amino acid residue at position 697 in the receptor tyrosine-protein kinase erbB-2 protein where valine has been replaced by leucine.","ERBB2 NP_004439.2:p.V697L | Activating V697L Mutation | ERBB2 NP_004439.2:p.Val697Leu | ERBB2 V697L | ERBB2 Val697Leu | ERBB2 p.V697L | ERBB2 p.Val697Leu | HER2 V697L | HER2 V697L Mutation | HER2 Val697Leu | NP_004439.2:p.V697L | NP_004439.2:p.Val697Leu | Proto-Oncogene Neu V697L | Proto-Oncogene Neu Val697Leu | Receptor Tyrosine-Protein Kinase erbB-2 V697L | Receptor Tyrosine-Protein Kinase erbB-2 Val697Leu | Tyrosine Kinase-Type Cell Surface Receptor HER2 V697L | Tyrosine Kinase-Type Cell Surface Receptor HER2 Val697Leu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648016","Brain Metastasis Velocity Greater Than or Equal to 4 per Year","C178514","A finding indicating that the average number of new brain metastases per year after stereotactic radiosurgery is greater than or equal to 4.","Brain Metastasis Velocity Greater Than or Equal to 4 per Year | BMV Greater than or Equal to 4 | BMV Greater than or Equal to 4 per Year | Brain Metastasis Velocity Greater Than or Equal to 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648529","Diffusion Weighted MRI with Background Subtraction","C179061","An application of diffusion weighted imaging where the measured signal is attenuated by random molecular motion of water molecules.","Diffusion Weighted MRI with Background Subtraction | DWIBS | Diffusion Weighted Imaging with Background Subtraction | Diffusion Weighted Imaging with Background Suppression | Diffusion weighted with background subtraction (DWIBS) MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519952","Head and Neck Cancer pN3 TNM Finding v8","C132651","Head and neck cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastases in a single ipsilateral lymph node larger than 3 cm and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes, any with ENE(+). (from AJCC 8th Ed.)","Head and Neck Cancer pN3 TNM Finding v8 | pN3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519788","Cutaneous Squamous Cell Carcinoma of the Head and Neck cN3 TNM Finding v8","C133220","Cutaneous squamous cell carcinoma of the head and neck with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in any lymph node(s) and clinically overt ENE(+). (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck cN3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433488","Oral Aminolevulinic Acid Hydrochloride","C99763","A powder for an oral solution comprised of the hydrochloride salt of 5-aminolevulinic acid (ALA) with a potential application for photodynamic therapy. After oral administration, ALA is converted intracellularly into the photosensitizer protoporphyrin IX (PpIX). Upon exposure to light of appropriate wavelength (violet to blue range), excited PpIX emits a characteristic red fluorescence which could facilitate guided resection, and generates excited singlet oxygen molecules that could kill cells when appropriate laser dosage is applied. ALA is preferentially taken up by and accumulates in many types of cancer cells compared to normal, healthy cells. Consequently, cancer cells can be visualized and can be distinguished from normal, healthy cells.","Oral Aminolevulinic Acid Hydrochloride | 5-ALA fluorescence | 5-Aminolevulinic Acid Hydrochloride | 5-Aminolevulinic Acid Hydrochloride, Oral | Gleolan | Gliolan | Oral 5-ALA | Oral ALA HCl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663356","RPA2 Gene Mutation","C180780","A change in the nucleotide sequence of the RPA2 gene.","RPA2 Gene Mutation | REPA2 Gene Mutation | RP-A p32 Gene Mutation | RP-A p34 Gene Mutation | RPA32 Gene Mutation | RPA34 Gene Mutation | Replication Protein A2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663494","Presymptomatic","C180882","Occurring during, or related to, the time before symptoms appear.","Presymptomatic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0331865","Mile British","C71182","A traditional unit of distance equal to 5280 feet of Old British Imperial System, used before 1959 when the unified international definitions for units of British Imperial system were established.","Mile British | British Imperial Mile | British Mile | Mile of Old British Imperial System | [mi_br] | mile | terrestrial mile Imperial unit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1770646","Imaging Mass Cytometry","C182027","A proprietary method that combines laser ablation of tissue specimens with secondary ion mass spectrometry to image antibodies tagged with isotopically pure elemental metal reporters. This technique allows for in situ characterization of the specimen while preserving its tissue architecture and cellular morphology.","Imaging Mass Cytometry | IMC | IMC Assay | Imaging Mass Cytometry Assay | Imaging Mass Spectrometry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664607","20(S)-Hydroxycholesterol Measurement","C181420","The determination of the amount of 20(S)-hydroxycholesterol present in a sample.","20(S)-Hydroxycholesterol Measurement | 20(S)-Hydroxycholesterol | 20-Alpha-Hydroxycholesterol | CHOLH20S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664624","Hyperchromic Erythrocytes to Erythrocytes Ratio Measurement","C181408","The determination of the ratio of hyperchromic erythrocytes compared to total erythrocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Hyperchromic Erythrocytes to Erythrocytes Ratio Measurement | HRRBCRBC | Hyperchromic Erythrocytes/Erythrocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771709","Would Do Better in Gym Class if Could Hear Better","C183203","A question about whether an individual feels that they would do better in gym class if they could hear better.","Would Do Better in Gym Class if Could Hear Better | I would do better in gym class (physical education, PE) if I could hear better",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771618","Vulvar Assessment Scale","C183355","A four-item clinician-administered measure that utilizes a four-point rating scale to assess a patient's perception of dryness, soreness, irritation, and pain for their vulvar area.","Vulvar Assessment Scale | VuAS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023186","Learning Disorder","C89334","A group of disorders that affect a person's ability to learn or process specific types of information which is in contrast to his/her apparent level of intellect.","Learning Disorder | Learning Disability",,,,,,,,,,,,,,,"4085156","Developmental academic disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1773128","Sickle Cell Pain Burden Interview","C185078","A 7-item, interviewer-administered questionnaire designed to assess the impact of pain on physical, social, and emotional aspects of daily function in the past month for an individual with sickle cell disease. Each item is scored using a 5-point Likert rating scale, with a final summed score rating the overall severity of pain burden.","Sickle Cell Pain Burden Interview | SCPBI | Sickle Cell Pain Burden Interview (SCPBI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773455","Contralateral Routing of Signal Device","C185115","A type of hearing aid designed for individuals with unilateral hearing loss that transmits sound from the abnormally functioning ear to the normally functioning ear without amplification using wired, wireless, or transcranial conduction.","Contralateral Routing of Signal Device | CROS Device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772712","Helicobacter pylori DNA Measurement","C184666","The determination of the amount of Helicobacter pylori DNA in a biological sample.","Helicobacter pylori DNA Measurement | HPYDNA | Helicobacter pylori DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778491","BRCA Gene Mutation Negative","C185883","A genetic finding indicating that BRCA family gene mutations have not been detected in a sample.","BRCA Gene Mutation Negative | BRCA Family Gene Mutation Negative | BRCA Family Mutation Negative | BRCA Gene Family Mutation Negative | BRCA Mutation Negative | BRCA Wild Type | BRCA Wild-Type | BRCA Wildtype | BRCA wt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337436","Galactose Measurement","C81308","The measurement of the amount of galactose in a biologic specimen.","Galactose Measurement | GAL | Galactose",,,,,,,,,,,,,,,"4189516","Galactose measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1778362","Oropharyngeal Soft Tissue","C186128","The soft tissue in the middle part of the pharynx, which includes the soft palate, tonsils, base of the tongue, and the sides and back walls of the throat.","Oropharyngeal Soft Tissue | OROPHARYNGEAL SOFT TISSUE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778734","Trichomonas RNA Measurement","C186189","The determination of the amount of RNA from any member of the genus Trichomonas in a biological sample.","Trichomonas RNA Measurement | TRICHRNA | Trichomonas RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639150","CDISC Questionnaire BPI Short Form Test Name Terminology","C100163","Test names of questionnaire questions associated with the short-form brief pain inventory for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire BPI Short Form Test Name Terminology | BPI2TN | Brief Pain Inventory Short Form Questionnaire Test Name | QS-BPI Short Form TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639223","CDISC ADAS-Cog - Ideational Praxis: Address","C100236","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Ideational praxis task for address the envelop to yourself.","CDISC ADAS-Cog - Ideational Praxis: Address | ADCIP04 | Ideational Praxis: Address",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639380","EQ-5D-3L - EQ VAS Score","C100397","The EuroQol (European Quality of Life) Five Dimension Three Level Scale (EQ-5D-3L) Indicate on this scale how good or bad your own health is today, in your opinion.","EQ-5D-3L - EQ VAS Score | EQ5D01-EQ VAS Score | EQ5D0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639506","MMSE - Question 4","C100558","The Mini-Mental State Examination (MMSE) Question 4.","MMSE - Question 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639482","MDS-UPDRS - Movements Interfere with Ratings","C100534","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) If yes, did these movements interfere with your ratings?","MDS-UPDRS - Movements Interfere with Ratings | UPD2-Movements Interfere Ratings | UPD2DB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639527","MMSE - Question 8","C100579","The Mini-Mental State Examination (MMSE) Question 8.","MMSE - Question 8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639808","SOAPP-R - How Often Mood Swings","C100870","Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often do you have mood swings?","SOAPP-R - How Often Mood Swings | SOAPR1-How Often Mood Swings | SOAPR101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639939","C-SSRS Baseline - Most Lethal Suicide Attempt Date","C101007","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Most lethal actual attempt date.","C-SSRS Baseline - Most Lethal Suicide Attempt Date | CSS01-Most Lethal Attempt Date | CSS0122A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538863","SRSF2 wt Allele","C101111","Human SRSF2 wild-type allele is located in the vicinity of 17q25.1 and is approximately 4 kb in length. This allele, which encodes serine/arginine-rich splicing factor 2 protein, is involved in the regulation of RNA splicing.","SRSF2 wt Allele | PR264 | SC-35 | SC35 | SFRS2 | SFRS2A | SRp30b | Serine and Arginine Rich Splicing Factor 2 wt Allele | Serine/Arginine-Rich Splicing Factor 2 Gene | Splicing Factor, Arginine/Serine-Rich 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640021","Bilateral Anophthalmos","C101187","A rare congenital abnormality characterized by the complete absence of ocular tissue in both orbits.","Bilateral Anophthalmos | Anophthalmos, Bilateral",,,,,,,,,,,,,,,"3657765","Bilateral anophthalmos of eyes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3537292","Forkhead Box Protein O6, human","C101412","Forkhead box protein O6 (492 aa, ~51 kDa) is encoded by the human FOXO6 gene. This protein may play a role in the positive regulation of transcription.","Forkhead Box Protein O6 | FOXO6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3852612","FLT3/KIT Kinase Inhibitor AKN-028","C101520","An orally bioavailable protein tyrosine kinase inhibitor for FMS-related tyrosine kinase 3 (FLT3; STK1) and stem cell factor receptor (SCFR; KIT), with potential antineoplastic activity. FLT3/KIT kinase inhibitor AKN-028 binds to and inhibits both the wild-type and mutated forms of FLT3 and SCFR. This may result in an inhibition of tumor cell proliferation in cancer cell types that overexpress these receptor tyrosine kinases.","FLT3/KIT Kinase Inhibitor AKN-028 | AKN-028 | BVT-II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1665663","Probable Ubiquitin Carboxyl-Terminal Hydrolase FAF-X, Human","C101576","Probable ubiquitin carboxyl-terminal hydrolase FAF-X (2570 aa, ~292 kDa) is encoded by the human USP9X gene. This protein plays a role in the modulation of post-translational protein modification.","Probable Ubiquitin Carboxyl-Terminal Hydrolase FAF-X | Deubiquitinating Enzyme FAF-X | EC 3.4.19.12 | Fat Facets In Mammals | Fat Facets Protein Related, X-Linked | Fat Facets Protein-Related, X-Linked | USP9X | Ubiquitin Thioesterase FAF-X | Ubiquitin Thiolesterase FAF-X | Ubiquitin-Specific Processing Protease FAF-X | Ubiquitin-Specific Protease 9, X Chromosome | Ubiquitin-Specific-Processing Protease FAF-X | hFAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640770","SOWS Subjective (Handelsman) - My Nose is Running","C102413","Subjective Opiate Withdrawal Scale (SOWS Subjective) My nose is running.","SOWS Subjective (Handelsman) - My Nose is Running | SOWSA1-My Nose is Running | SOWSA105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640488","HAMA - Gastrointestinal Symptoms","C102083","Hamilton Anxiety Rating Scale (HAMA) Gastrointestinal symptoms; difficulty swallowing, wind abdominal pain, burning sensations, abdominal fullness, nausea, vomiting, borborygmi, looseness of bowels, loss of weight, constipation.","HAMA - Gastrointestinal Symptoms | HAMA1-Gastrointestinal Symptoms | HAMA111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540802","ACE2 wt Allele","C102528","Human ACE2 wild-type allele is located in the vicinity of Xp22 and is approximately 41 kb in length. This allele, which encodes angiotensin-converting enzyme 2 protein, is involved in both peptide hormone-processing and vasodilation.","ACE2 wt Allele | ACEH | Angiotensin I Converting Enzyme (Peptidyl-Dipeptidase A) 2 Gene | Angiotensin I Converting Enzyme 2 wt Allele | DKFZp434A014 | UNQ868/PRO1885",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438125","Brontictuzumab","C103274","A humanized monoclonal antibody directed against the Notch-1 receptor with potential antineoplastic activity. Upon administration, brontictuzumab binds to Notch-1 on the cell surface, thereby inhibiting Notch-mediated signaling and tumor cell proliferation. Notch 1, a type 1 transmembrane protein belonging to the Notch family, functions as a receptor for membrane bound ligands and has various roles during development; dysregulated Notch signaling is associated with increased cell growth and chemoresistance in cancers.","Brontictuzumab | BRONTICTUZUMAB | Immunoglobulin G2-lambda, Anti-(homo Sapiens Notch1 (Notch 1, Translocation-associated Notch-1, TAN-1,Tan1)), Humanized Monoclonal Antibody | OMP-52M51",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641296","CDISC Questionnaire PHQ-9 Test Code Terminology","C103481","Test codes of questionnaire questions associated with the 9 item patient health questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire PHQ-9 Test Code Terminology | PHQ01TC | Patient Health Questionnaire - 9 Item Questionnaire Test Code | QS-PHQ-9 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540637","SNCAIP wt Allele","C102937","Human SNCAIP wild-type allele is located in the vicinity of 5q23.2 and is approximately 153 kb in length. This allele, which encodes synphilin-1 protein, plays a role in the regulation of protein ubiquitination. Mutation of the gene may be associated with Parkinson disease.","SNCAIP wt Allele | SYPH1 | Sph1 | Synuclein, Alpha Interacting Protein wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1456377","TFCP2 Gene","C101800","This gene plays a role in the positive regulation of transcription.","TFCP2 Gene | TFCP2 | Transcription Factor CP2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424490","ZFPM2 Gene","C102764","This gene plays a role in both cardiac development and transcriptional regulation.","ZFPM2 Gene | ZFPM2 | Zinc Finger Protein, Multitype 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540688","NCI CTEP SDC Breast Neoplasm Category Terminology","C103013","Breast Neoplasm is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Breast Neoplasm Category Terminology | Breast Neoplasm | NCI CTEP Simple Disease Classification Breast Neoplasm Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641422","NPI - Anxiety Distress","C103616","Neuropsychiatric Inventory (NPI) Anxiety: How emotionally distressing do you find this behavior?","NPI - Anxiety Distress | NPI1-Anxiety Distress | NPI1E10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537450","B4GALT1 wt Allele","C104852","Human B4GALT1 wild-type allele is located in the vicinity of 9p13 and is approximately 63 kb in length. This allele, which encodes beta-1,4-galactosyltransferase 1 protein, is involved in lactose synthesis. Mutation of the gene is associated with congenital disorder of glycosylation type 2D.","B4GALT1 wt Allele | B4GAL-T1 | CDG2D | GGTB2 | GT1 | GTB | UDP-Gal:BetaGlcNAc Beta 1,4- Galactosyltransferase, Polypeptide 1 wt Allele | beta4Gal-T1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641930","CDISC Questionnaire PI v1 Test Code Terminology","C105134","Test codes of questionnaire questions associated with the Pain Intensity (PI) version 1 for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire PI v1 Test Code Terminology | PI01TC | Pain Intensity Questionnaire Test Code | QS-PI TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642084","ADCS-ADL - Make a Meal or Snack at Home","C105305","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, did the subject make him/herself a meal or snack at home?","ADCS-ADL - Make a Meal or Snack at Home | ADL01-Make a Meal | ADL0113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641876","Dead End Protein Homolog 1","C104882","Dead end protein homolog 1 (353 aa, ~39 kDa) is encoded by the human DND1 gene. This protein is involved in miRNA-mediated gene suppression.","Dead End Protein Homolog 1 | RNA-Binding Motif, Single-Stranded-Interacting Protein 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641997","C-SSRS Baseline/Screening Version Phase 1 Study - Description of Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act (Lifetime)","C105218","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Description of active suicidal ideation with any methods (not plan) without intent to act.","C-SSRS Baseline/Screening Version Phase 1 Study - Description of Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act (Lifetime) | CSS03-Idea, No Intent, No Plan, Describe | CSS0303C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641952","DAD - Prepare the Water, Towels, and Soap for Washing, Taking a Bath or Shower","C105173","Disability Assessment for Dementia (DAD) Prepare the water, towels, and soap for washing, taking a bath or a shower?","DAD - Prepare the Water, Towels, and Soap for Washing, Taking a Bath or Shower | DAD01-Prepare For Washing Bath Shower | DAD0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640360","ADNI AVLT - List A Recall 4 Word 9","C101955","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 4, Word 9.","ADNI AVLT - List A Recall 4 Word 9 | AVL01-List A Recall 4 Word 9 | AVL01060",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539573","HES6 wt Allele","C104534","Human HES6 wild-type allele is located in the vicinity of 2q37.3 and is approximately 2 kb in length. This allele, which encodes transcription cofactor HES-6 protein, is involved in the regulation of gene expression.","HES6 wt Allele | HES-6 | Hairy and Enhancer of Split 6 (Drosophila) wt Allele | bHLHb41 | bHLHc23",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537304","CKS1B protein, human","C104982","Cyclin-dependent kinases regulatory subunit 1 (79 aa, ~10 kDa) is encoded by the human CKS1B gene. This protein plays a role in the regulation of cell cycle progression as an essential cofactor for cyclin dependent kinases.","Cyclin-Dependent Kinases Regulatory Subunit 1 | CDC2-Associated Protein CKS1 | CDC28 Protein Kinase 1 | CDC28 Protein Kinase 1B | CKS-1 | CKS1B | Cell Division Control Protein CKS1 | NB4 Apoptosis/Differentiation Related Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640438","ADNI AVLT - List A Recognition Intrusions","C102033","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of intrusions on recognition test.","ADNI AVLT - List A Recognition Intrusions | AVL01-List A Recognition Intrusions | AVL01138",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827384","Philips Pinnacle","C105677","A proprietary radiation therapy planning system developed by the Philips corporation.","Philips Pinnacle | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418724","PODXL Gene","C106447","This gene plays a role in the modulation of cell migration.","PODXL Gene | PODXL | Podocalyxin-Like Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831679","ADCS-ADL MCI - Select or Ask for Something to Read","C106918","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, did subject usually select or ask for something to read?","ADCS-ADL MCI - Select or Ask for Something to Read | ADL03-Select/Ask for Something to Read | ADL0313A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830866","C-SSRS Baseline/Screening Version - Non-Specific Active Suicidal Thoughts (Past X Months)","C106711","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Have you actually had any thoughts of killing yourself? (Past X Months).","C-SSRS Baseline/Screening Version - Non-Specific Active Suicidal Thoughts (Past X Months) | CSS04-Non-Spec Suicid Thought-P_M | CSS0402B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831606","ADCS-ADL Severe Dementia - Watch Television","C106987","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) In the past 4 weeks, did subject watch television?","ADCS-ADL Severe Dementia - Watch Television | ADL02-Watch Television | ADL0208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540592","FBXO32 wt Allele","C104222","Human FBXO32 wild-type allele is located in the vicinity of 8q24.13 and is approximately 43 kb in length. This allele, which encodes f-box only protein 32, is involved in protein ubiquitination and degradation.","FBXO32 wt Allele | ATROGIN1 | F-Box Protein 32 wt Allele | FLJ3242 | Fbx32 | MAFbx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541249","GAGE5 wt Allele","C104481","Human GAGE5 wild-type allele is located within Xp11.4-p11.2 and is approximately 7 kb in length. This allele, which encodes G antigen 5 protein, may be involved in tumor recognition.","GAGE5 wt Allele | CT4.5 | Cancer/Testis Antigen Family 4, Member 5 Gene | G Antigen 5 wt Allele | GAGE-5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829891","HAQ-DI With VAS - Able to Get In and Out of Bed","C106812","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Arising: are you able to get in and out of bed?","HAQ-DI With VAS - Able to Get In and Out of Bed | HAQ01-Get In and Out of Bed | HAQ0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641578","C-SSRS Since Last Visit - Wish to be Dead or go to Sleep and not Wake Up","C103772","Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Have you wished you were dead or wished you could go to sleep and not wake up?","C-SSRS Since Last Visit - Wish to be Dead or go to Sleep and not Wake Up | CSS02-Wish to be Dead | CSS0201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830915","C-SSRS Already Enrolled Subjects - Reasons For Most Severe Ideation (Prior to Study Entry)","C107054","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) What sort of reasons did you have for thinking about wanting to die or killing yourself? Was it to end the pain or stop the way you were feeling (in other words you couldn't go on living with this pain or how you were feeling) or was it to get attention, revenge or a reaction from others? Or both? (Prior to Study Entry).","C-SSRS Already Enrolled Subjects - Reasons For Most Severe Ideation (Prior to Study Entry) | CSS05-Most Severe Idea, Reasons-Prior | CSS0511A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813674","Lee County, MS","C109129","No value exists.","Lee County, MS | Lee County | Lee County, Mississippi | MS081",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831462","Assumption Parish, LA","C108804","No value exists.","Assumption Parish, LA | Assumption Parish | Assumption Parish, Louisiana | LA007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812233","McIntosh County, OK","C109864","No value exists.","McIntosh County, OK | McIntosh County | McIntosh County, Oklahoma | OK091",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815617","Loving County, TX","C110361","No value exists.","Loving County, TX | Loving County | Loving County, Texas | TX301",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811867","Berrien County, MI","C108929","No value exists.","Berrien County, MI | Berrien County | Berrien County, Michigan | MI021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829450","Juab County, UT","C110476","No value exists.","Juab County, UT | Juab County | Juab County, Utah | UT023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814098","Lincoln County, MN","C109042","No value exists.","Lincoln County, MN | Lincoln County | Lincoln County, Minnesota | MN081",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811275","Montgomery County, NY","C109544","No value exists.","Montgomery County, NY | Montgomery County | Montgomery County, New York | NY057",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813683","Chesterfield County, SC","C110016","No value exists.","Chesterfield County, SC | Chesterfield County | Chesterfield County, South Carolina | SC025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831311","Botetourt County, VA","C110519","No value exists.","Botetourt County, VA | Botetourt County | Botetourt County, Virginia | VA023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812235","McIntosh County, ND","C109703","No value exists.","McIntosh County, ND | McIntosh County | McIntosh County, North Dakota | ND051",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811338","Van Buren County, TN","C110203","No value exists.","Van Buren County, TN | TN175 | Van Buren County | Van Buren County, Tennessee",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813696","Pendleton County, KY","C108776","No value exists.","Pendleton County, KY | KY191 | Pendleton County | Pendleton County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814829","Sullivan County, MO","C109275","No value exists.","Sullivan County, MO | MO211 | Sullivan County | Sullivan County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812340","Butler County, OH","C109739","No value exists.","Butler County, OH | Butler County | Butler County, Ohio | OH017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811274","Montgomery County, NC","C109639","No value exists.","Montgomery County, NC | Montgomery County | Montgomery County, North Carolina | NC123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827673","Vaccination Site on Body ICSR Terminology","C105691","Terminology used in Individual Case Safety Reports to specify an anatomic site where a vaccination was administered.","Vaccination Site on Body ICSR Terminology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811835","Douglas County, SD","C110070","No value exists.","Douglas County, SD | Douglas County | Douglas County, South Dakota | SD043",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831112","ChIP-On-Chip","C106050","A molecular genetic technique that combines chromatin immunoprecipitation (ChIP) with DNA microarray technology to find candidate binding sites of DNA-associated proteins in a biological specimen. First, crosslinked protein-DNA complexes are isolated using ChIP. Next, the crosslinks are broken, the proteins are removed and the purified DNA is amplified, denatured and labeled with a fluorescent tag. The labeled, denatured DNA fragments are applied to a DNA microarray where they can hybridize to their complementary DNA sequence. After hybridization occurs, the microarray chip is imaged and the captured fluorescence signals from the array are normalized and subjected to statistical analysis. Finally, validated positive spots on the microarray can predict which DNA sequences interact with the protein of interest.","ChIP-On-Chip | ChIP-Chip | Chromatin Immunoprecipitation-On-Chip",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815117","Carroll County, TN","C110124","No value exists.","Carroll County, TN | Carroll County | Carroll County, Tennessee | TN017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831496","AQ20 - Feeling of Chest Heaviness","C112547","Airway Questionnaire 20 (AQ20) Do you have a feeling of chest heaviness?","AQ20 - Feeling of Chest Heaviness | AQ01-Feeling of Chest Heaviness | AQ0119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828188","Serrated Lesion of the Mouse Intestinal Tract","C107673","A large intestinal glandular mucosal lesion in the mouse characterized by epithelial infoldings and ectopic crypt formation.","Serrated Lesion of the Mouse Intestinal Tract | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714956","NPR1 wt Allele","C112514","Human NPR1 wild-type allele is located within 1q21-q22 and is approximately 15 kb in length. This allele, which encodes atrial natriuretic peptide receptor 1 protein, is involved in both natriuretic peptide binding and GTP metabolism.","NPR1 wt Allele | ANPRA | ANPa | GUC2A | GUCY2A | NPRA | Natriuretic Peptide Receptor A/Guanylate Cyclase A (Atrionatriuretic Peptide Receptor A) wt Allele | RP11-354A16.3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830210","FAMS - Trouble Concentrating","C112585","Functional Assessment of Multiple Sclerosis (FAMS) Thinking and Fatigue: I have trouble concentrating.","FAMS - Trouble Concentrating | FAMS01-I Have Trouble Concentrating | FAMS0135",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816453","Dickkopf-Related Protein 2","C111880","Dickkopf-related protein 2 (259 aa, ~28 kDa) is encoded by the human DKK2 gene. This protein plays a role in the inhibition of the Wnt signaling pathway.","Dickkopf-Related Protein 2 | Dickkopf 2 | Dickkopf Related Protein-2 | Dickkopf-2 | Dkk-2 | hDkk-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815631","Baker County, GA","C108078","No value exists.","Baker County, GA | Baker County | Baker County, Georgia | GA007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814059","Stafford County, KS","C108668","No value exists.","Stafford County, KS | KS185 | Stafford County | Stafford County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813214","Washington County, ID","C108282","No value exists.","Washington County, ID | ID087 | Washington County | Washington County, Idaho",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813213","Washington County, KS","C108676","No value exists.","Washington County, KS | KS201 | Washington County | Washington County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3255749","Chinese Cinnamon Leaf Oil","C107287","The essential oil of Cinnamomum cassia. Cinnamon leaf oil is used primarily in aromatherapy.","Chinese Cinnamon Leaf Oil | CHINESE CINNAMON LEAF OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829977","Glades County, FL","C108028","No value exists.","Glades County, FL | FL043 | Glades County | Glades County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810680","Miami County, IN","C108436","No value exists.","Miami County, IN | IN103 | Miami County | Miami County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828241","Santa Barbara County, CA","C107915","No value exists.","Santa Barbara County, CA | CA083 | Santa Barbara County | Santa Barbara County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828236","Sarasota County, FL","C108065","No value exists.","Sarasota County, FL | FL115 | Sarasota County | Sarasota County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830144","FGFR2 NM_000141.4:c.1124A>G","C107594","A nucleotide substitution at position 1124 of the coding sequence of the FGFR2 gene where adenine has been mutated to guanine.","FGFR2 NM_000141.4:c.1124A>G | BEK c.1124A>G | CD332 c.1124A>G | ECT1 c.1124A>G | FGFR2 c.1124A>G | Fibroblast Growth Factor Receptor 2 c.1124A>G | K-SAM c.1124A>G | KGFR c.1124A>G | NM_000141.4:c.1124A>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0061299","Glaucarubolone","C1114","A polycyclic lactone quassinoid phytochemical isolated from the seeds of Hannoa undulata and other plant species with potential antineoplastic activity.  This agent also has antiviral and antitumor properties. (NCI04)","Glaucarubolone | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815235","KIAA0202","C114431","Human SEPTIN8 wild-type allele is located in the vicinity of 5q31.1 and is approximately 56 kb in length. This allele, which encodes septin-8 protein, is involved in cytoskeletal filament assembly.","SEPTIN8 wt Allele | KIAA0202 | SEP2 | SEPT8 | SEPT8 wt Allele | Septin 8 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830675","C-SSRS Screening - Active Suicidal Ideation with Some Intent to Act, without Specific Plan","C111466","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Have you had these thoughts and had some intention of acting on them?","C-SSRS Screening - Active Suicidal Ideation with Some Intent to Act, without Specific Plan | CSS09-Idea, Intent, No Plan | CSS0904",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0851252","Breech Extraction","C114136","The delivery of a breech-presenting fetus with that is manually pulled through the birth canal.","Breech Extraction | BREECH EXTRACTION",,,,,,,,,,,,,,,"4213387","Breech extraction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829329","Laramie County, WY","C110818","No value exists.","Laramie County, WY | Laramie County | Laramie County, Wyoming | WY021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829079","MHIS-NACC - Stepwise Deterioration","C112619","Modified Hachinski Ischemic Scale-NACC Version (MHIS-NACC) Stepwise deterioration (re: cognitive status).","MHIS-NACC - Stepwise Deterioration | MHIS01-Stepwise Deterioration | MHIS0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0255567","vasodilator-stimulated phosphoprotein","C112144","Vasodilator-stimulated phosphoprotein (380 aa, ~40 kDa) is encoded by the human VASP gene. This protein is involved in both cell motility and cell adhesion.","Vasodilator-Stimulated Phosphoprotein | VASP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813985","Grant County, WA","C110654","No value exists.","Grant County, WA | Grant County | Grant County, Washington | WA025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828608","Pepin County, WI","C110782","No value exists.","Pepin County, WI | Pepin County | Pepin County, Wisconsin | WI091",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830832","C-SSRS Children's Baseline - First Suicide Attempt Date","C111561","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Initial/first attempt date.","C-SSRS Children's Baseline - First Suicide Attempt Date | CSS06-First Attempt Date | CSS0620A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454148","JAK Inhibitor INCB047986","C111761","An orally bioavailable inhibitor of Janus-associated kinases (JAK), with potential antineoplastic activity. Upon oral administration, INCB047986 specifically binds to and inhibits the phosphorylation of JAK, which affects JAK-dependent signaling and may lead to an inhibition of cellular proliferation in JAK-overexpressing tumor cells. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","JAK Inhibitor INCB047986 | INCB 047986 | INCB-047986 | INCB047986",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2977407","Dichorionic Diamniotic Twin Pregnancy","C112855","A pregnancy involving two fetuses that each have separate chorions and amniotic sacs.","Dichorionic Diamniotic Twin Pregnancy | ",,,,,,,,,,,,,,,"43021054","Dichorionic diamniotic twin pregnancy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3827571","VFQ25-Self Administered Format - Often Irritable Because of Eyesight","C112811","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Well-Being or Distress: I am often irritable because of my eyesight.","VFQ25-Self Administered Format - Often Irritable Because of Eyesight | VFQ2-Often Irritable Because Eyesight | VFQ2A12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898535","MPAI-4 - Abilities: Verbal Communication","C115857","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Verbal communication: Problems expressing or understanding language.","MPAI-4 - Abilities: Verbal Communication | MPAI1-Verbal Communication | MPAI107A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898754","Institutional Review Board Independent Ethics Committee Documentation of Non-Voting Status Document","C115695","Documentation verifying investigator, sub-investigator, or other party of the clinical trial has not voted, if they are members of the Institutional Review Board or Independent Ethics Committee.","Institutional Review Board Independent Ethics Committee Documentation of Non-Voting Status | IRB or IEC Documentation of Non-Voting Status | IRB-IEC Docn noVote | IRB-IEC Documentation of Non-Voting Status | IRB/IEC Documentation of Non-Voting Status | Institutional Review Board Independent Ethics Committee Documentation of Non-Voting Status Document | Institutional Review Board Independent Ethics Committee Documentation of Non-voting Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828796","Non-Sterile Volumetric Powder Filling Method","C112997","A process that fills a dosage unit with a powder by volume using gravity flow, which is not performed under sterile conditions.","Non-Sterile Volumetric Powder Filling Method | Filling, Nonsterile, Powder, Volumetric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001622","Hypercortisolemia","C113208","Abnormally high level of cortisol in the blood.","Hypercortisolemia | Cortisol Excess",,,,,,,,,,,,,,,"195212|438123","Hypercortisolism|Adrenocortical hyperfunction",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1424214","USH1G Gene","C114406","This gene plays a role in both sight and hearing.","USH1G Gene | USH1G | Usher Syndrome 1G (Autosomal Recessive) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827644","VFQ25-Interviewer Administered Format - Difficulty Doing Work or Hobbies","C112734","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Difficulty With Activities: How much difficulty do you have doing work or hobbies that require you to see well up close, such as cooking, sewing, fixing things around the house, or using hand tools? Would you say:","VFQ25-Interviewer Administered Format - Difficulty Doing Work or Hobbies | VFQ1-Difficulty Doing Work/Hobbies | VFQ106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827162","Anti-c-Met Monoclonal Antibody ARGX-111","C113802","A human monoclonal antibody targeting c-Met, with potential antineoplastic activity. Anti-c-Met monoclonal antibody ARGX-111 binds to c-Met, and blocks both ligand-dependent and -independent activation of c-Met-mediated signaling pathways. In addition, this agent enhances antibody dependent cellular cytotoxicity (ADCC). This leads to a reduction in cell proliferation of c-Met-expressing cancer cells. c-Met, a receptor tyrosine kinase overexpressed in certain cancer cell types, is involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors. Compared to other c-Met targeting monoclonal antibodies, ARGX-111 shows increased antibody circulation time, enhanced tissue distribution and increased efficacy. ARGX-111 is obtained through active immunization with C-met antigen in Camelids and utilizes the Camelid V-domains fused with human antibody backbones.","Anti-c-Met Monoclonal Antibody ARGX-111 | ARGX-111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420327","SOX4 Gene","C112919","This gene plays a role in the positive regulation of transcription.","SOX4 Gene | SOX4 | SRY (Sex Determining Region Y)-Box 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889120","HS3ST1 wt Allele","C118217","Human HS3ST1 wild-type allele is located in the vicinity of 4p16 and is approximately 37 kb in length. This allele, which encodes heparan sulfate glucosamine 3-O-sulfotransferase 1 protein, plays a role in the synthesis of heparan sulfate.","HS3ST1 wt Allele | 3OST | 3OST1 | H3ST1 | Heparan Sulfate (Glucosamine) 3-O-Sulfotransferase 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889450","SLC2A3 wt Allele","C115021","Human SLC2A3 wild-type allele is located in the vicinity of 12p13.3 and is approximately 17 kb in length. This allele, which encodes solute carrier family 2, facilitated glucose transporter member 3 protein, is involved in glucose transport.","SLC2A3 wt Allele | GLUT3 | Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 3 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899439","Date and Time of Death","C117450","The date or date and time of death.","Date and Time of Death | DTHDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899799","CHART-SF Interview Version - Hours of Homemaking per Week","C118008","Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) How many hours per week do you spend in active homemaking including parenting, housekeeping, and food preparation?","CHART-SF Interview Version - Hours of Homemaking per Week | CHSF1-Hours of Homemaking per Week | CHSF109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898901","Healthy Term Newborn","C114930","An age group comprised of infants delivered after full 37 weeks gestation whose 5 minute Apgar score was above 7, has no major congenital anomalies and was discharged home with mother without any additional diagnoses except for physiologic hyperbilirubinemia.","Healthy Term Newborn | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889468","MXRA5 wt Allele","C115378","Human MXRA5 wild-type allele is located in the vicinity of Xp22.33 and is approximately 38 kb in length. This allele, which encodes matrix-remodeling-associated protein 5, may be involved in extracellular matrix modeling.","MXRA5 wt Allele | DKFZp564I1922 | Matrix-Remodelling Associated 5 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889426","Content Type Requirement","C115762","A directive on whether a Content Type is necessary for a particular activity.","Content Type Requirement | Requirement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898988","IC50 Fold Change from Reference","C116249","A fold change based on a concentration of a specific drug expected to produce 50% inhibition of the standard growth of a viral organism, or of a biological/biochemical reaction. It is a ratio calculated by the IC50 Treatment Result divided by the IC50 Reference Control Result.","Viral Half Maximal Inhibitory Concentration Fold Change from Reference Measurement | IC50 Fold Change from Reference",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472323","Anagrelide Prolonged-release Formulation","C114497","A prolonged-release tablet formulation containing the quinazoline anagrelide, with antiplatelet activity. Although the exact mechanism of action through which anagrelide exerts its effect has yet to be fully elucidated, this agent inhibits the maturation of megakaryocytes into platelets, which reduces platelet production. Anagrelide also inhibits cyclic AMP phosphodiesterase III (PDEIII), which prevents PDEIII-mediated platelet aggregation. This may prevent essential thrombocythemia and thrombosis.","Anagrelide Prolonged-release Formulation | Anagrelide Retard",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890747","CYP7B1 wt Allele","C114942","Human CYP7B1 wild-type allele is located in the vicinity of 8q21.3 and is approximately 211 kb in length. This allele, which encodes 25-hydroxycholesterol 7-alpha-hydroxylase enzyme, is involved in cholesterol catabolism. Mutation of the gene is associated with autosomal recessive spastic paraplegia 5A and congenital bile acid synthesis defect 3.","CYP7B1 wt Allele | CBAS3 | CP7B | Cytochrome P450, Family 7, Subfamily B, Polypeptide 1 wt Allele | Cytochrome P450, Subfamily VIIB (Oxysterol 7 Alpha-Hydroxylase), Polypeptide 1 Gene | SPG5A | Spastic Paraplegia 5A (Autosomal Recessive) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473907","gallium Ga 68 OPS202","C116710","A radioconjugate consisting of the somatostatin antagonistic peptide OPS202 that is labeled with the positron-emitting radionuclide gallium Ga 68, which may be used as a somatostatin receptor (SSTR) imaging agent in conjunction with positron emission tomography (PET) to image neuroendocrine tumors (NETs). Gallium Ga 68 satoreotide trizoxetan binds to SSTR subtype 2 present on the cell membranes of many types of NETs. This allows for visualization of SSTR-positive cells upon imaging. SSTR subtypes have been shown to be present in large numbers on NETs and their metastases, while most other normal tissues express low levels of SSTR subtypes.","Gallium Ga 68 Satoreotide Trizoxetan | 68Ga-NODAGA-JR11 | 68Ga-OPS202 | Gallium Ga 68 NODAGA-JR11 | Gallium Ga 68 OPS202 | SATOREOTIDE TRIZOXETAN GALLIUM GA-68",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL413572","Real-Time Position-Tracking Imaging","C116497","An imaging technique that allows for the real-time tracking of an in vivo medical device, allowing for better control, positioning, and use of the device.","Real-Time Position-Tracking Imaging | Marker Tracking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433763","Lipid Encapsulated Anti-PLK1 siRNA TKM-PLK1","C116889","short interfering RNAs (siRNAs) directed against polo-like kinase 1 (PLK1, STPK13), with potential antineoplastic activity. Upon administration of lipid-encapsulated anti-PLK1 siRNA TKM-PLK1, siRNA binds to PLK1 mRNA, which results in the inhibition of both the translation and expression of the PLK1 protein. Blockage of PLK1 expression prevents proper tumor cell mitosis, causes cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of PLK1-overexpressing tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase crucial in the regulation of mitosis; its expression is upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation. The pegylated lipid bilayer of SNALP provides stability and protects siRNA degradation; it facilitates uptake into the cell and release from endosomes.","Lipid Encapsulated Anti-PLK1 siRNA TKM-PLK1 | PLK1 SNALP | PLK1424 | TKM-080301 | TKM-PLK1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL416282","Secretin-Enhanced Magnetic Resonance Imaging","C116459","An imaging technique that requires the intravenous administration of secretin immediately prior to a magnetic resonance cholangiopancreatography, allowing for a qualitative assessment of exocrine pancreatic function.","Secretin-Enhanced Magnetic Resonance Imaging | Secretin-Enhanced MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898589","Link Group Identifier","C117049","A sequence of characters used to link multiple records to a single finding.","Link Group Identifier | LNKGRP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0067533","Carboxyphenyl Retinamide","C1169","A synthetic phenylretinamide analogue of retinol (vitamin A) with potential antineoplastic and chemopreventive activities.  Carboxyphenyl retinamide induces cell differentiation and inhibits tumor cell growth and carcinogenesis.  This agent may also induce cell cycle arrest in the G1 phase in some cancer cell types. (NCI04)","Carboxyphenyl Retinamide | 4-carboxyphenyl retinamide | N-(4-Carboxyphenyl)retinamide | N-(4-carboxyphenyl)retinamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899081","Frank Umbilical Cord Prolapse","C117318","A situation in which the umbilical cord is prolapsed through the cervix and into the vagina.","Frank Umbilical Cord Prolapse | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897352","Total Protein Urine Excretion Rate","C117848","A determination of the amount of total protein being excreted in urine over a defined period of time.","Total Protein Urine Excretion Rate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538187","ZNF395 Gene","C117258","This gene may be involved in transcriptional regulation.","ZNF395 Gene | ZNF395 | Zinc Finger Protein 395 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889825","Sequence of Planned Assessment Schedule","C117298","A number that identifies the ordering relations in time of the schedules for planned assessments in a trial.","Sequence of Planned Assessment Schedule | ORDER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014571","Epiphysiolysis","C118382","Abnormal separation of an epiphysis from the shaft of a bone.","Epiphysiolysis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898630","Laboratory Test Results Laterality","C119848","A qualifier for the side of the body the laboratory test is performed.","Laboratory Test Results Laterality | LBLAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899625","Cidan Herbal Capsule","C118451","A capsule-based formulation containing artificial bezoar, Strychni pulveratum (strychnos powder), camphol alcohol (borneol or borneo camphor) and extracts from Zedoary rhizome (Rhizoma curcumae), Pseudobulbus cremastrae seu pleiones (dried pseudobulb of Cremastra appendiculata), Yatantzu (seed of Brucca javanica), beehive, Bombyx mori (Bombyx batryticatus or silkworm), Danshen (dried root of Salvia miltiorrhiza or red sage root), Radix astragali, and Angelica, with potential antineoplastic activity. Upon oral administration of the cidan herbal capsule, the active ingredients in the plant extracts may induce tumor cell apoptosis and reduce tumor cell proliferation.","Cidan Herbal Capsule | Zedoary rhizome/Pseudobulbus cremastrae seu pleiones/Yatantzu/Strychni pulveratum/Beehive/Artificial Bezoar/Bombyx mori/Danshen Root/Radix astragali/Angelica/Camphol Alcohol Capsule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890721","TRIP13 wt Allele","C118329","Human TRIP13 wild-type allele is located in the vicinity of 5p15.33 and is approximately 27 kb in length. This allele, which encodes pachytene checkpoint protein 2 homolog protein, plays a role in chromosome recombination in meiosis.","TRIP13 wt Allele | 16E1BP | PCH2 | Thyroid Hormone Receptor Interactor 13 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896633","CDISC Questionnaire CCQ 1 Week Version Test Code Terminology","C119066","Test codes of questionnaire questions associated with the Clinical COPD Questionnaire 1 Week Version (CCQ 1 Week Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire CCQ 1 Week Version Test Code Terminology | CCQ02TC | Clinical COPD Questionnaire 1 Week Version Questionnaire Test Code | QS-CCQ 1 Week Version TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825502","ATG16L1 Gene","C119723","This gene plays a role in the regulation of autophagy.","ATG16L1 Gene | ATG16L1 | Autophagy Related 16-Like 1 (S. cerevisiae) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897302","Tumor Findings Sponsor Defined Identifier","C119941","One or more sponsor defined characters used to identify, name, or characterize the tumor findings assessment.","Tumor Findings Sponsor Defined Identifier | TFSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899908","Brilacidin Oral Rinse","C120043","An oral rinse containing brilacidin, a defensin mimetic, with potential antimicrobial and anti-mucositic activities. Upon rinsing with the brilacidin oral rinse, brilacidin imitates defensin as a human host defense protein (HDP), and binds to and disrupts the bacterial cell membrane. This causes bacterial cell membrane lysis and leakage of cellular cytoplasmic contents. This inhibits bacterial activity and may prevent or treat radiation-induced mucositis. Defensins, a family of antimicrobial and cytotoxic peptides expressed mainly by epithelial cells and neutrophils, play a key role in the natural human innate immunity against pathogens.","Brilacidin Oral Rinse | PMX30063 Oral Rinse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899607","Clinical Observations Location","C119804","The site in or on the body at which the clinical observation is made.","Clinical Observations Location | CLLOC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897466","Study Day of Tumor Findings","C119928","The study day that a tumor findings assessment is performed.","Study Day of Tumor Findings | TFDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0243069","Hypoplasia","C120893","Incomplete or underdevelopment of a tissue or organ.","Hypoplasia | HYPOPLASIA",,,,,,,,,,,,,,,"4208403","Hypoplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054659","Left Ventricular Maximum Positive dP/dt","C120916","The maximum rate of positive pressure (systolic) change within the left ventricle during a unit time.","Left Ventricular Maximum Positive dP/dt | +dPdt | DPDTMAX | dPdt Maximum | dPdt Maximum; +dPdt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899044","Gallium Ga 68-NOTA-NFB","C120105","A radioconjugate composed of a derivative of the CXCR4 peptide antagonist T140, in which the N-terminal 4-fluoro-benzoyl group (NFB) is substituted with the chelating agent 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA) and radiolabeled with gallium Ga 68, with potential CXCR4 imaging activity during positron emission topography (PET). Upon administration, gallium Ga 68-NOTA-NFB selectively binds to CXCR4 and CXCR4-expressing tumor cells can then be visualized upon PET imaging. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis, and is upregulated in several tumor cell types. CXCR4 expression is correlated with tumor aggressiveness and high metastatic potential. Unmodified T140 binds non-specifically to red blood cells (RBCs); replacing the fluoro-benzoyl group with NOTA (NOTA-NFB) prevents the RBC binding almost entirely, while only minimally reducing the binding to CXCR4-positive tumor cells.","Gallium Ga 68-NOTA-NFB | 68Ga-NOTA-NFB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055346","British Isles Lupus Assessment Group Index","C121352","An organ-specific assessment intended as a clinical decision tool. It evaluates specific manifestations over the previous four weeks in a total of eight organs systems, nine in the revised Index: constitutional, mucocutaneous, neuropsychiatric, musculoskeletal, cardiorespiratory, gastrointestinal, ophthalmic, renal, and hematological. Activity in each organ system is scored from most active disease to no previous activity.","British Isles Lupus Assessment Group Index | BILAG Index",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266158","Nongerminomatous Germ Cell Tumor","C121619","A term that refers to teratoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, or mixed forms of these tumors.","Nongerminomatous Germ Cell Tumor | Germ cell tumor, nonseminomatous | Non-dysgerminomatous Germ Cell Tumor | Non-germinomatous Germ Cell Tumor | Non-seminomatous Germ Cell Tumor | Nongerminomatous Germ Cell Tumor Including Central Nervous System","9065/3","Germ cell tumor, nonseminomatous",,,,,,,,,,,,,"4030137","Germ cell tumor, nonseminomatous",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1856716","Isolated Follicle Stimulating Hormone Deficiency","C121142","Subnormal concentration of follicle stimulating hormone (FSH), associated with mutations in the FSHB gene, encoding follitropin subunit beta.","Isolated Follicle Stimulating Hormone Deficiency | ",,,,,,,,,,,,,,,"42538310","Isolated follicle stimulating hormone deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003077","Anisakis","C122043","A genus of parasitic nematode in the family Anisakidae. Members of the genus cause anisakiasis in humans. Their life cycle involves fish, crustaceans, and marine mammals. Humans become infested by eating infested fish.","Anisakis | ANISAKIS",,,,,,,,,,,,,,,"4261667","Anisakis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032302","Mycoplasmal Pneumonia","C122526","Pneumonia caused by Mycoplasma pneumoniae. Signs and symptoms include productive cough, fever, chills, shortness of breath, and chest pain.","Mycoplasmal Pneumonia | ",,,,,,,,,,,,,,,"440431","Mycoplasma pneumonia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4049726","STK35 wt Allele","C122739","Human STK35 wild-type allele is located in the vicinity of 20p13 and is approximately 75 kb in length. This allele, which encodes serine/threonine-protein kinase 35 protein, may be a regulator of actin stress fibers in nonmuscle cells.","STK35 wt Allele | CLIK-1 | CLIK1 | PDIK1 | STK35L1 | Serine/Threonine Kinase 35 wt Allele | bA550O8.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055096","EXACT - Have Chest Discomfort","C123673","Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT) Did you have chest discomfort today?","EXACT - Have Chest Discomfort | EXACT1-Chest Discomfort | EXACT105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1306587","Acute Encephalopathy","C122815","A life-threatening disorder characterized by delirium, seizures, and neuromuscular changes.","Acute Encephalopathy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054414","Neisseria gonorrhoeae, Beta-lactamase Positive","C123526","Any bacterial species identified as Neisseria gonorrhoeae that produces the enzyme beta-lactamase.","Neisseria gonorrhoeae, Beta-lactamase Positive | NEISSERIA GONORRHOEAE, BETA-LACTAMASE POSITIVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055330","CRQ-SAS First Administration Version - Energy","C121020","Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) How much energy have you had in the last 2 weeks?","CRQ-SAS First Administration Version - Energy | CRQ01-Energy | CRQ0111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055480","Allogeneic BK-specific Cytotoxic T-lymphocytes","C123277","Allogeneic cytotoxic T-lymphocytes (CTLs) that are specifically reactive to BK virus (BKV), with potential antiviral activity. Upon infusion of allogeneic BK-specific CTLs into immunocompromised patients who were infected with BKV after allogeneic stem cell transplantation, these cells exert a specific CTL response against BKV, thereby killing and eliminating the BKV-infected cells. BKV is a member of the polyomavirus family that may cause mild symptoms in normal, healthy people; however, BKV infection can lead to severe disease in immunocompromised patients.","Allogeneic BK-specific Cytotoxic T-lymphocytes | Allogeneic BK-CTLs | Allogeneic BK-specific CTLs | Allogeneic BK-specific Cytotoxic T Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055569","AVLT-REY - List B Word 8","C123707","The Rey Auditory Verbal Learning TEST (AVLT-REY) List B, Word 8.","AVLT-REY - List B Word 8 | AVL02-List B Word 8 | AVL0225",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503996","Serine/Threonine-Protein Kinase TAO1","C125175","Serine/threonine-protein kinase TAO1 (1001 aa, ~116 kDa) is encoded by the human TAOK1 gene. This protein plays a role in protein phosphorylation and the propagation of intracellular signals.","Serine/Threonine-Protein Kinase TAO1 | EC 2.7.11.1 | Kinase From Chicken Homolog B | MARK Kinase 3 | MARKK | Microtubule Affinity Regulating Kinase Kinase | PSK-2 | PSK2 | Prostate-Derived STE20-Like Kinase 2 | Prostate-Derived Sterile 20-Like Kinase | Prostate-Derived Sterile 20-Like Kinase 2 | STE20-Like Kinase PSK2 | Serine/Threonine Protein Kinase TAO1 Homolog | TAOK1 | Thousand and One Amino Acid Protein 1 | Thousand and One Amino Acid Protein Kinase 1 | hKFC-B | hTAOK1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086279","Experimental Organism Mesenchymal Proliferative Lesion","C124611","A benign neoplasm arising from the submucosa and composed of large eosinophilic epithelioid and spindle cells. (INHAND)","Experimental Organism Mesenchymal Proliferative Lesion | MESENCHYMAL PROLIFERATIVE LESION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503065","anti-TIM-3 monoclonal antibody MBG453","C124850","An inhibitor of the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sabatolimab binds to TIM-3 expressed on certain immune cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis resulting in a reduction in tumor growth. TIM-3, a transmembrane protein expressed on certain T-cells, is associated with tumor-mediated immune suppression.","Sabatolimab | Anti-TIM-3 Monoclonal Antibody MBG453 | Anti-TIM3 Checkpoint Inhibitor MBG453 | MBG 453 | MBG453 | SABATOLIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504218","PI3K-gamma inhibitor IPI-549","C125471","An orally bioavailable, highly selective small molecule inhibitor of the gamma isoform of phosphoinositide-3 kinase (PI3K-gamma) with potential immunomodulating and antineoplastic activities. Upon administration, eganelisib prevents the activation of the PI3K-gamma-mediated signaling pathways, which may lead to a reduction in cellular proliferation in PI3K-gamma-expressing tumor cells. In addition, this agent is able to modulate anti-tumor immune responses and inhibit tumor-mediated immunosuppression. Unlike other isoforms of PI3K, the gamma isoform is overexpressed in certain tumor cell types and immune cells; its expression increases tumor cell proliferation and survival. By selectively targeting the gamma isoform, PI3K signaling in normal, non-neoplastic cells is minimally or not affected, which results in a reduced side effect profile.","Eganelisib | EGANELISIB | IPI 549 | IPI-549",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504409","PHQ Screener Version Questionnaire Question","C125754","A question associated with the PHQ Screener Version questionnaire.","PHQ Screener Version Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474107","Inosine 5'-monophosphate Dehydrogenase Inhibitor FF-10501-01","C122835","An orally bioavailable inhibitor of inosine 5'- monophosphate dehydrogenase (IMPDH), with potential antineoplastic activity. Upon administration, IMPDH inhibitor FF-10501-01 competitively inhibits the enzyme IMPDH, thereby preventing the conversion of inosine monophosphate to xanthosine monophosphate. This inhibits the synthesis of guanine nucleotides, deprives cancer cells of guanosine triphosphate (GTP), disrupts DNA and RNA synthesis, and decreases tumor cell proliferation. Tumor cells are highly susceptible to IMPDH inhibition because they are rapidly dividing cells that are dependent on rapid DNA synthesis, which requires a high concentration of nucleotides. IMPDH, an enzyme that catalyzes the rate-limiting step in the synthesis of guanosine triphosphate (GTP), is overexpressed in numerous tumor cell types.","Inosine 5'-monophosphate Dehydrogenase Inhibitor FF-10501-01 | FF-10501 | FF-10501-01 | IMPDH Inhibitor FF-10501",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3544179","Accidental Drug Ingestion","C122722","The unintentional consumption of a drug.","Accidental Drug Ingestion | Accidental Medicine Ingestion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049880","PTPRB wt Allele","C122910","Human PTPRB wild-type allele is located within 12q15-q21 and is approximately 121 kb in length. This allele, which encodes receptor-type tyrosine-protein phosphatase beta protein, plays a role in both the removal of phosphate groups from phosphotyrosine and blood vessel maintenance.","PTPRB wt Allele | HPTP-BETA | HPTPB | PTPB | Protein Tyrosine Phosphatase, Receptor Type, B wt Allele | Protein Tyrosine Phosphatase, Receptor Type, Beta Polypeptide Gene | Protein-Tyrosine Phosphatase, Receptor-Type, B Gene | R-PTP-BETA | VEPTP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507916","anti-IL-15 monoclonal antibody AMG 714","C126841","A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human pro-inflammatory cytokine interleukin-15 (IL-15), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon administration, ordesekimab binds to and neutralizes IL-15, thereby preventing IL-15-mediated pro-inflammatory signaling. By inhibiting IL-15-mediated immune responses, ordesekimab decreases natural killer (NK) cell activation and proliferation, reduces T-cell infiltration, increases T-cell apoptosis, and may prevent the growth of IL-15-driven cancer cells. IL-15 plays a key role in inflammation and is associated with a variety of autoimmune and inflammatory disorders as well as with cell proliferation in certain cancer types, such as T-cell lymphomas. IL-15 is required for the proliferation of certain T-cells and NK cells.","Ordesekimab | AMG 714 | AMG714 | Anti-IL-15 Monoclonal Antibody AMG 714 | HUMAX-IL 15 | HuMab-IL15 AMG 714 | ORDESEKIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507986","ROBO3 wt Allele","C126778","Human ROBO3 wild-type allele is located in the vicinity of 11q24.2 and is approximately 16 kb in length. This allele, which encodes roundabout homolog 3 protein, plays a role in axon guidance and neurite outgrowth. Mutation of the gene is associated with horizontal gaze palsy with progressive scoliosis.","ROBO3 wt Allele | FLJ21044 | HGPPS | HGPS | Horizontal Gaze Palsy With Progressive Scoliosis Gene | RB-Inhibiting Gene 1 | RBIG1 | RIG1 | Retinoblastoma Inhibiting Gene 1 | Roundabout (Axon Guidance Receptor, Drosophila) Homolog 3 Gene | Roundabout Guidance Receptor 3 wt Allele | Roundabout, Axon Guidance Receptor, Homolog 3 (Drosophila) Gene | Roundabout, Axon Guidance Receptor, Homolog 3 Gene | Roundabout, Drosophila, Homolog of, 3 Gene | Scoliosis Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1080699","Sporidiobolus","C127300","A genus of anamorphic fungi in the phylum Basidiomycota that produce bilaterally symmetrical ballistoconidia and have CoQ 10 or CoQ 10(H2) as their major ubiquinone.","Sporidiobolus | ",,,,,,,,,,,,,,,"35624643","Sporidiobolus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508205","SDHA Protein Variant","C126832","A variation in the amino acid sequence for the succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial protein.","SDHA Protein Variant | Succinate Dehydrogenase [Ubiquinone] Flavoprotein Subunit, Mitochondrial Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508828","FACT-P Version 4 Questionnaire Question","C127365","A question associated with the FACT-P Version 4 questionnaire.","FACT-P Version 4 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086685","PANSS - Anxiety","C124762","Positive and Negative Syndrome Scale (PANSS) Temperature - Anxiety.","PANSS - Anxiety | PANSS1-Anxiety | PANSS116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086690","PANSS - Disorientation","C124770","Positive and Negative Syndrome Scale (PANSS) Temperature - Disorientation.","PANSS - Disorientation | PANSS1-Disorientation | PANSS124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498408","Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107","C124054","A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with six synthetic glioblastoma (GBM) peptides: absent in melanoma 2 (AIM-2), melanoma-associated antigen 1 (MAGE-1), tyrosinase-related protein 2 (TRP-2), glycoprotein 100 (gp100), epidermal growth factor receptor 2 (HER-2), interleukin-13 receptor subunit alpha-2 (IL-13Ra2), with potential immunostimulatory and antineoplastic activities. Mononuclear cells obtained via leukapheresis are differentiated into DCs, and pulsed with the GBM-associated peptides. Upon administration, multi-glioblastoma-peptide-targeting autologous DC vaccine ICT-107 exposes the immune system to GBM-associated antigens, which activates a specific cytotoxic T-lymphocyte (CTL) response against GBM cells. This leads to GBM cell lysis. The six peptides are derived from tumor associated antigens (TAA) expressed on GBM cells and cancer stem cells (CSCs). GBM stem-like cells contain a specific range of antigens that are essential for the neoplastic growth and survival of GBM cells.","Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107 | ICT-107 | Multi-glioblastoma-peptide-pulsed Autologous DC Vaccine ICT-107 | Multi-glioblastoma-peptide-targeting Autologous DC Vaccine ICT-107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509088","GAIA Level 2 Dysfunctional First Stage of Labor","C128718","GAIA Level 2 Dysfunctional First Stage of Labor is defined by progress of less than 0.5 cm of cervical dilation per hour, for at least 4 hours, in women with established labor (i.e. have regular contractions and cervical dilation of at least 4 cm) without certainty of ruptured membranes.","GAIA Level 2 Dysfunctional First Stage of Labor | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Dysfunctional First Stage of Labor | Level 2 Dysfunctional First Stage of Labor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0857836","JC Virus Infection","C128830","An infection that is caused by JC virus.","JC Virus Infection | JC Polyomavirus Infection | JCV Infection | John Cunningham Virus Infection | Polyomavirus JC Infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268119","Molybdenum Cofactor Deficiency","C129076","An autosomal recessive condition that is caused by mutation(s) in the MOCS1 gene, encoding molybdenum cofactor biosynthesis protein 1. it is characterized by poor feeding, encephalopathy, seizures and dysmorphic facial features.","Molybdenum Cofactor Deficiency | ",,,,,,,,,,,,,,,"4106562","Combined molybdoflavoprotein enzyme deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4273550","Central Zone of Left Half Prostate","C128587","The portion of the central zone of the prostate that is located to the anatomical left of center.","Central Zone of Left Half Prostate | Base L CZ",,,,,,,,,,,,,,,"37396912","Central zone of left half prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512407","FACIT-F Version 4 - I Am Able to Enjoy Life","C129133","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Functional Well-Being: I am able to enjoy life.","FACIT-F Version 4 - I Am Able to Enjoy Life | FAC071-I Am Able to Enjoy Life | FAC07123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417563","MYO1F Gene","C126620","This gene plays a role in the movement of intracellular components.","MYO1F Gene | MYO1F | Myosin IF Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504496","PHQ Screener Version - Last 2 Weeks, Trouble Falling or Staying Asleep","C125844","Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 2 weeks, how often have you been bothered by trouble falling or staying asleep, or sleeping too much?","PHQ Screener Version - Last 2 Weeks, Trouble Falling or Staying Asleep | PHQ03-Last 2 Week Trouble Falling Asleep | PHQ0302C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037857","Spermatid","C12604","An immature male germ cell that is formed by meiotic division of a secondary spermatocyte. Spermatids develop into spermatozoa.","Spermatid | Spermatids | Spermatoblast | Spermatoblasts | Spermoblast",,,,,,,,,,,,,,,"4243152","Spermatid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1454968","Platelet Membrane Glycoprotein 1b Alpha Chain, Human","C126548","Platelet glycoprotein Ib alpha chain (652 aa, ~72 kDa) is encoded by the human GP1BA gene. This protein plays a role in von Willebrand factor binding.","Platelet Membrane Glycoprotein 1b Alpha Chain | Antigen CD42b-Alpha | CD42b Antigen | CD42b-Alpha | GP-Ib Alpha | GPIb-Alpha | GPIbA | Glycoprotein Ibalpha | Platelet Membrane Glycoprotein 1b-Alpha Subunit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504480","Expanded DRS-PI Survivor Version - Work With Frequent Supervision and Support","C125828","Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) How certain are you that you can be able to work at home or in a special setting like a sheltered workshop in which the work is very routine and there is very frequent supervision and support?","Expanded DRS-PI Survivor Version - Work With Frequent Supervision and Support | ED2-Work With Frequent Support | ED208_7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513325","QIDS-C - Suicidal Ideation","C130405","Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Suicidal ideation.","QIDS-C - Suicidal Ideation | QIDSC1-Suicidal Ideation | QIDSC112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514130","IDS-SR - Aches and Pains","C130577","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Aches and pains.","IDS-SR - Aches and Pains | IDSR1-Aches and Pains | IDSR125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2747816","Severe Malaria","C128372","Acute malaria with signs of organ dysfunction, severe anemia (hemoglobin less than 5 g/dL or hematocrit less than 15%) and/or hyperparasitemia (greater than 5% of red blood cells infected).","Severe Malaria | Complicated Malaria",,,,,,,,,,,,,,,"602743","Complicated malaria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509578","Anaplastic Glioma","C127816","A group of malignant gliomas that includes anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and anaplastic ependymoma.","WHO Grade 3 Glioma | Anaplastic Glioma | WHO Grade III Glioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513920","FACT-LYM Version 4 - Get Emotional Support From Family","C130511","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Social/Family Well-Being: I get emotional support from my family.","FACT-LYM Version 4 - Get Emotional Support From Family | FAC018-Get Emotional Support From Family | FAC01809",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508829","FAT4 wt Allele","C128255","Human FAT4 wild-type allele is located in the vicinity of 4q28.1 and is approximately 177 kb in length. This allele, which encodes protocadherin Fat 4 protein, is involved in cell polarity. Mutation of the gene is associated with Hennekam lymphangiectasia-lymphedema syndrome 2 and Van Maldergem syndrome 2.","FAT4 wt Allele | CDHF14 | CDHR11 | FAT Atypical Cadherin 4 wt Allele | FAT Tumor Suppressor Homolog 4 (Drosophila) Gene | FAT Tumor Suppressor, Drosophila, Homolog of, 4 Gene | FAT-J | FATJ | HKLLS2 | NBLA00548 | VMLDS2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512516","Specimen Isolation","C128947","The act of separating a sub-component from the original collected specimen.","Specimen Isolation | ISOLATING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0319579","Microsporum gypseum","C127736","A species of soil-associated keratinophilic fungi in the phylum Ascomycota with a world-wide distribution. This species is known for causing diseases on human skin, particularly associated with rural and agricultural workers.","Microsporum gypseum | Arthroderma gypseum | Gymnoascus gypseus | MICROSPORUM GYPSEUM | Nannizzia gypsea",,,,,,,,,,,,,,,"4011241","Microsporum gypseum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040934","Trichophyton mentagrophytes","C127753","A species of zoophilic fungi in the phylum Ascomycota with a worldwide distribution and a wide range of animal hosts. This species causes inflammatory skin or scalp lesions in humans.","Trichophyton mentagrophytes | Microsporum mentagrophytes | TRICHOPHYTON MENTAGROPHYTES",,,,,,,,,,,,,,,"4185703","Trichophyton mentagrophytes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021770","Intermediate Filament","C13248","A class of tough protein filaments (including keratin filaments, neurofilaments, desmin, and vimentin) that measure 8-10 nm in thickness and comprise part of the cytoskeleton of the cytoplasm of most eukaryotic cells; so named because they are intermediate in thickness between actin filaments and microtubules.","Intermediate Filament | ",,,,,,,,,,,,,,,"4062913","9 nm filaments",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512340","Anti-FLT3 Monoclonal Antibody 4G8-SDIEM","C129376","A human, Fc-optimized, immunoglobulin G1 (IgG1) monoclonal antibody directed against the FLT3 tyrosine kinase receptor (CD135), with potential antineoplastic activity. Upon binding to FLT3, anti-FLT3 monoclonal antibody 4G8-SDIEM blocks FLT3 ligand binding to FLT3 and subsequent phosphorylation of FLT3, which may result in the inhibition of FLT3-mediated signal transduction pathways. In addition, this agent may stimulate an anti-FLT3 antibody-dependent cell-mediated cytotoxicity (ADCC) against FLT3-expressing tumor cells, which may lead to the inhibition of cellular proliferation and decreased survival in FLT3-expressing cells. FLT3 (FLK2), a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias.","Anti-FLT3 Monoclonal Antibody 4G8-SDIEM | 4G8-SDIEM | FLYSYN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520360","ATLD","C132224","An autosomal recessive condition caused by mutation(s) in the MRE11A gene, encoding double-strand break repair protein MRE11. It is characterized by progressive cerebellar degeneration resulting in ataxia and oculomotor apraxia.","Ataxia-Telangiectasia-Like Disorder 1 | ATLD | ATLD1 | Ataxia-Telangiectasia-Like Disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512673","Astatine-211 Alpha Radiation","C129638","Alpha rays produced by the decay of astatine-211.","Astatine-211 Alpha Radiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513808","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.895G>C Mutation","C130213","A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where guanine has been substituted with cytosine at nucleotide position 895 of the ABL1 gene. This mutation is associated with imatinib- and dasatinib-resistant leukemias.","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.895G>C Mutation | BCR/ABL Fusion Gene with NM_005157.4:c.895G>C | BCR/ABL Fusion Gene with NM_005157.5:c.895G>C | BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.895G>C | BCR/ABL1 Fusion Gene with NM_005157.4:c.895G>C | BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.895G>C Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513283","Q-LES-Q - Thought Clearly About Work","C130637","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: thought clearly about work?","Q-LES-Q - Thought Clearly About Work | QLES1-Thought Clearly About Work | QLES131",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513908","FACT-LEU Version 4 - Satisfied With How I Am Coping","C130429","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Emotional Well-Being: I am satisfied with how I am coping with my illness.","FACT-LEU Version 4 - Satisfied With How I Am Coping | FAC017-Satisfied With How I Am Coping | FAC01716",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513731","WHODAS 2.0 36-item Version Self-administered - Problem Doing Things for Relaxation","C130845","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days: How much of a problem did you have in doing things by yourself for relaxation or pleasure?","WHODAS 2.0 36-item Version Self-administered - Problem Doing Things for Relaxation | WD7-Problem Doing Things for Relaxation | WD7D6_8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1317543","Immature Monocyte","C13120","A cell derived from a myeloid stem cell. It is the representation of one stage of monocyte development.","Immature Monocyte | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514513","Factor XIII Deficiency","C131633","A coagulation disorder characterized by the partial or complete absence of factor XIII activity in the blood.","Factor XIII Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521746","Small Intestine Cancer TNM Finding v8","C133825","A finding about one or more characteristics of small intestine cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to carcinomas of the nonampullary duodenum, jejunum, and ileum. Only adenocarcinomas are assigned a stage group. Nonadenocarcinomas arising in the small intestine should have a TNM assigned but are not assigned a stage classification. (from AJCC 8th Ed.)","Small Intestine Cancer TNM Finding v8 | Small Intestine Carcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522144","Intrahepatic Bile Duct Cancer Pathologic Primary Tumor TNM Finding v8","C134586","A pathologic finding about one or more characteristics of intrahepatic bile duct cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Intrahepatic Bile Duct Cancer Pathologic Primary Tumor TNM Finding v8 | Intrahepatic Bile Duct Cancer Pathologic Primary Tumor Status (pT) | Intrahepatic Bile Duct Carcinoma Pathologic Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519889","HAQ-DI Without VAS - Open a New Milk Carton","C132579","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Eating: Are you able to open a new milk carton?","HAQ-DI Without VAS - Open a New Milk Carton | HAQ02-Open a New Milk Carton | HAQ0207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521284","Worst Observed Case Imputation Technique","C132343","A data imputation technique that populates analysis values with the worst recorded outcome within a subject.","Worst Observed Case Imputation Technique | WOC | Worst Observed Case",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521122","Small Intestinal Myeloid Sarcoma","C132260","A myeloid sarcoma that affects the small intestine. It often presents with abdominal pain and obstruction.","Small Intestinal Myeloid Sarcoma | Myeloid Sarcoma of the Small Intestine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342142","Iodine-Induced Hyperthyroidism","C131860","Iodine-induced hyperthyroidism.","Iodine-Induced Hyperthyroidism | Jod-Basedow | Jod-Basedow | Jod-Basedow Phenomenon | Jod-Basedow Syndrome",,,,,,,,,,,,,,,"4129357","Iodine-induced hyperthyroidism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514712","Small Integral Membrane Protein 24","C131751","Small integral membrane protein 24 (130 aa, ~15 kDa) is encoded by the human SMIM24 gene. This protein has no known function.","Small Integral Membrane Protein 24 | MAP17-Related Dimer | SMIM24 | Transmembrane Protein C19orf77 | Transmembrane Protein HSPC323",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520541","Supraglottic Cancer pT2 TNM Finding v8","C133103","Supraglottic cancer with tumor invading the mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis (e.g., mucosa of base of the tongue, vallecula, medial wall of pyriform sinus) without fixation of the larynx. (from AJCC 8th Ed.)","Supraglottic Cancer pT2 TNM Finding v8 | Supraglottic Carcinoma pT2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520816","Maxillary Sinus Cancer pT4a TNM Finding v8","C133039","Maxillary sinus cancer with moderately advanced local disease. Tumor invades anterior orbital contents, skin of cheek, pterygoid plates, infratemporal fossa, cribriform plate, sphenoid or frontal sinuses. (from AJCC 8th Ed.)","Maxillary Sinus Cancer pT4a TNM Finding v8 | Maxillary Sinus Carcinoma pT4a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520742","Lip and Oral Cavity Cancer pN2 TNM Finding v8","C132705","Lip and oral cavity cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE (-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, ENE(-). (from AJCC 8th Ed.)","Lip and Oral Cavity Cancer pN2 TNM Finding v8 | Lip and Oral Cavity Carcinoma pN2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520004","Hypopharyngeal Cancer Pathologic Primary Tumor TNM Finding v8","C132926","A pathologic finding about one or more characteristics of hypopharyngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Hypopharyngeal Cancer Pathologic Primary Tumor TNM Finding v8 | Hypopharyngeal Carcinoma Pathologic Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015394","Eye Bank","C133320","A facility whose operations include collection, processing and distribution of ocular tissues.","Eye Bank | Eye bank",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521858","Analytical Procedure Linearity","C134033","The ability (within a given range) to obtain test results which are directly proportional to the concentration (amount) of analyte in a sample.","Analytical Procedure Linearity | Linearity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522023","Stage III Rectal Cancer AJCC v8","C134297","Stage III includes: IIIA: (T1-T2, N1/N1c, M0); (T1, N2a, M0); IIIB: (T3-T4a, N1/N1c, M0); (T2-T3, N2a, M0); (T1-T2, N2b, M0); IIIC: (T4a, N2a, M0); (T3-T4a, N2b, M0); (T4b, N1-N2, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). T4b: Tumor directly invades or adheres to adjacent organs or structures. N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N1c: No regional lymph nodes are positive, but there are tumor deposits in the subserosa, mesentery, or nonperitonealized pericolic, or perirectal/mesorectal tissues. N2: Four or more regional lymph nodes are positive. N2a: Four to six regional lymph nodes are positive. N2b: Seven or more regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Rectal Cancer AJCC v8 | Stage III Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521829","Experimentally Determined Chemical Structure","C133995","Chemical structure derived from an investigative process using instrumentation.","Experimentally Determined Chemical Structure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519706","ALX 148","C132851","A variant of signal regulatory protein alpha (SIRPa) that antagonizes the human cell surface antigen CD47, with potential phagocytosis-inducing, immunostimulating and antineoplastic activities. Upon administration, evorpacept binds to CD47 expressed on tumor cells and prevents the interaction of CD47 with its ligand SIRPa, a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of the pro-phagocytic signal calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor cytotoxic T-lymphocyte (CTL) immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","Evorpacept | ALX 148 | ALX-148 | ALX148 | CD47 Antagonist ALX148 | CD47/SIRPa-blocking Agent ALX148 | EVORPACEPT | LGGL-ALX-148 | SIRPa Variant ALX148",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521900","Appendix Carcinoma by AJCC v8 Stage","C134117","A term that refers to the staging of appendiceal carcinoma according to the American Joint Committee on Cancer, 8th edition. This staging system applies to carcinomas of the appendix, including high-grade neuroendocrine carcinomas, mixed adenoneuroendocrine carcinomas, and goblet cell carcinoids. Well-differentiated neuroendocrine tumors (carcinoids) are staged according to the classification for neuroendocrine tumors of the appendix. (from AJCC 8th Ed.)","Appendix Carcinoma by AJCC v8 Stage | Appendiceal Carcinoma by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523824","Maternal Embryonic Leucine Zipper Kinase","C134700","Maternal embryonic leucine zipper kinase (651 aa, ~75 kDa) is encoded by the human MELK gene. This protein plays a role in the mediation of protein phosphorylation that regulates cell cycle, cell death and cell proliferation.","Maternal Embryonic Leucine Zipper Kinase | Protein Kinase Eg3 | Protein Kinase PK38 | Tyrosine-Protein Kinase MELK | hMELK | hPK38 | pEg3 Kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522719","Appendix Neuroendocrine Tumor cM1 TNM Finding v8","C135134","Appendix neuroendocrine tumor with distant metastasis. (from AJCC 8th Ed.)","Appendix Neuroendocrine Tumor cM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522172","Mirasol-treated Allogeneic Platelets","C134620","A preparation of allogeneic platelets that have been treated with Mirasol, a proprietary pathogen reduction technology (PRT) system, and can potentially be used to improve symptoms associated with thrombocytopenia. Upon apheresis, platelets are treated with the patented PRT system, which includes treatment of the platelets with riboflavin (vitamin B2) and broad-spectrum ultraviolet (UV) light. The treatment causes irreversible changes to the RNA and DNA of a broad range of pathogens, including viruses, bacteria, parasites and white blood cells (WBCs), which prevents them from replicating and causing disease. After ex vivo treatment and upon transfusion, the Mirasol-treated allogeneic platelets may reduce thrombocytopenia and prevent bleeding. By preventing the replication of contaminating pathogens, Mirasol treatment improves transfusion safety. Inactivation of WBCs may reduce transfusion reactions and immunological complications in patients.","Mirasol-treated Allogeneic Platelets | Allogeneic MIR PLTs | Allogeneic Mirasol PRT-treated Platelets | Allogeneic Mirasol Platelets",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522708","Stage II Jejunal Neuroendocrine Tumor AJCC v8","C135121","Stage II includes: (T2, N0, M0); (T3, N0, M0). T2: Tumor invading muscularis propria or measuring more than 1 cm in size. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Jejunal Neuroendocrine Tumor AJCC v8 | Stage II Jejunal Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523182","LEC-5 Standard Version - Unwanted Sex Experience: Witnessed","C135869","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Other unwanted or uncomfortable sexual experience: Witnessed it.","LEC-5 Standard Version - Unwanted Sex Experience: Witnessed | LEC01-Unwanted Sex Experience: Witnessed | LEC0109B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523142","LEC-5 Standard Version - Fire or Explosion: Job","C135829","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Fire or explosion: Part of my job.","LEC-5 Standard Version - Fire or Explosion: Job | LEC01-Fire or Explosion: Job | LEC0102D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523410","PODCI Adolescent Parent-Reported Version - Friends Limited by: Fear","C136097","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 60 above, was your child's activity limited by: Fear the other kids won't like him/her?","PODCI Adolescent Parent-Reported Version - Friends Limited by: Fear | PODCI2-Friends Limited by: Fear | PODCI264",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523510","PODCI Adolescent Self-Reported Version - Pain During the Last Week","C136197","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) How much pain have you had during the last week?","PODCI Adolescent Self-Reported Version - Pain During the Last Week | PODCI3-Pain During the Last Week | PODCI372",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523689","Pleural Malignant Mesothelioma cM1 TNM Finding v8","C136383","Pleural malignant mesothelioma with distant metastasis. (from AJCC 8th Ed.)","Pleural Malignant Mesothelioma cM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523225","LEC-5 Standard Version - Serious Injury Caused: Learned","C135912","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Serious injury, harm, or death you caused to someone else: Learned about it.","LEC-5 Standard Version - Serious Injury Caused: Learned | LEC01-Serious Injury Caused: Learned | LEC0116C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523132","PGI Generic Modification Version - Improvement","C135819","Patient Global Impression Generic Modification Version (PGI Generic Modification Version) Compared to <previously assessed protocol specified time point> how much has your condition improved?","PGI Generic Modification Version - Improvement | PGI01-Improvement | PGI0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524960","TMSB4X wt Allele","C137960","Human TMSB4X wild-type allele is located in the vicinity of Xp22.2 and is approximately 2 kb in length. This allele, which encodes thymosin beta-4 protein, is involved in the inhibition of actin polymerization.","TMSB4X wt Allele | FX | PTMB4 | TB4X | THYB4 | TMSB4 | Thymosin Beta 4, X-Linked wt Allele | Thymosin, Beta 4, X Chromosome Gene | Thymosin, Beta-4 Gene | Thymosin, Beta-4, X Chromosome Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525751","PedsQL Neuromuscular Module Version 3.0 Teen Report Questionnaire Question","C138284","A question associated with the PedsQL Neuromuscular Module Version 3.0 Teen Report questionnaire.","PedsQL Neuromuscular Module Version 3.0 Teen Report Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520636","15q22-q24","C13711","A chromosome band present on 15q","15q22-q24 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524933","Computed Tomography of the Chest and Abdomen with Contrast","C137884","Computed tomography of the chest and abdomen with the use of a contrast agent to enhance the image.","Computed Tomography of the Chest and Abdomen with Contrast | Chest/Abdominal CT with Contrast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526125","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Get Sores and/or Rashes","C138667","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: I get sores and/or rashes.","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Get Sores and/or Rashes | PQL16-Get Sores and/or Rashes | PQL1603",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526361","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard to Breathe","C138807","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to breathe.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard to Breathe | PQL08-Hard to Breathe | PQL0801",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520753","17p13.2","C13877","A chromosome band present on 17p","17p13.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523007","CDISC Questionnaire PGI Generic Modification Version Test Code Terminology","C135688","Test codes of questionnaire questions associated with the Patient Global Impression Generic Modification Version (PGI Generic Modification Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PGI Generic Modification Version Test Code Terminology | PGI01TC | Patient Global Impression Generic Modification Version Questionnaire Test Code | QS-PGI Generic Modification Version TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525927","PUL 1.2 - Shoulder Abduction Above Height","C138369","Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Shoulder abduction above shoulder height.","PUL 1.2 - Shoulder Abduction Above Height | PUL01-Shoulder Abduction Above Shldr Hgt | PUL01C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523028","PODCI Pediatric Parent-Reported Version Questionnaire Question","C135709","A question associated with the PODCI Pediatric Parent-Reported Version questionnaire.","PODCI Pediatric Parent-Reported Version Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525884","PUL 1.2 - Total Score","C138396","Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Total Score.","PUL 1.2 - Total Score | PUL01-Total Score | PUL0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520206","YDYVHL Motif","C14055","YDYVHL (tyrosine-aspartic acid-tyrosine-valine-histidine-leucine) is a preferred substrate sequence by focal adhesion kinase.  The phosphorylated YDYVHL containing protein recruits src family kinases, which can then phosphorylate other tyrosine residues within the peptide. (NCI)","YDYVHL Motif | YDYVHL Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526855","Unintended Emission","C139490","Problems due to unintended emission of electromagnetic energy by the device.","Unintended Emission | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519124","SAM Domain","C13960","The approximately 70 amino acid SAM (Sterile Alpha Motif) domain has been identified in over 400 different proteins with diverse cellular function, from yeast to man. SAM domains have been implicated in mediating protein-protein interaction via the formation of homo and hetero-typic oligomers. The residues at the interface of the EphA4 and EphB2 SAM domain homodimers have been mapped, but the factors that determine specificity remain to be determined. (Pawson Lab, SLRI, Mount Sinai Hospital, 2003)","SAM Domain | SAM Motif | Sterile Alpha Domain | Sterile Alpha Motif",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537946","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pT1b TNM Finding v8","C139829","Uterine corpus leiomyosarcoma or endometrial stromal sarcoma with tumor limited to the uterus, measuring more than 5 cm in greatest dimension. (from AJCC 8th Ed.)","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pT1b TNM Finding v8 | Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma FIGO Stage IB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521692","8p11","C13893","A chromosome band present on 8p","8p11 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538383","Kidney Cancer pTX TNM Finding v8","C140283","Kidney cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Kidney Cancer pTX TNM Finding v8 | Kidney Carcinoma pTX TNM Finding v8 | pTX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518833","PWWP Domain","C14044","Around 70 amino acids and weakly conserved, the PWWP Domain is named after a conserved Pro-Trp-Trp-Pro motif often found as multiple copies in proteins that contain chromatin-association domains or in cell growth and differentiation transcription factors, such as WHSC1 (C-terminus) and ASH1/Trithorax Group proteins. Although its function is unknown, the amino acid composition suggests that it may be involved in protein-protein interactions. The domain N-terminal half resembles a barrel-like five-stranded structure; the C-terminal half contains a five-helix bundle. The halves form a module that exhibits positive electrostatic potential. Alone, the domain binds DNA in vitro, probably through its basic surface. (NCI)","PWWP Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538178","CDKN2B Antisense RNA 1","C140090","CDKN2B antisense RNA 1 (~4 kb) is encoded by the human CDKN2B-AS1 gene. This non-coding RNA plays a role in the modulation of the expression of genes in the CDKN2B-CDKN2A gene cluster.","CDKN2B Antisense RNA 1 | Antisense Noncoding RNA in the INK4 Locus | Antisense RNA in the INK4 Locus | CDKN2B Antisense RNA | CDKN2B-AS1 | Non-Protein Coding RNA 89 | Prostate Cancer Associated Transcript 12 | p15 Antisense RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537929","Uterine Corpus Adenosarcoma cM1 TNM Finding v8","C139846","Uterine corpus adenosarcoma with distant metastasis (excluding adnexa, pelvic, and abdominal tissues). (from AJCC 8th Ed.)","Uterine Corpus Adenosarcoma cM1 TNM Finding v8 | Uterine Corpus Adenosarcoma FIGO Stage IVB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538567","Eyelid Carcinoma cM1 TNM Finding v8","C140474","Eyelid carcinoma with distant metastasis. (from AJCC 8th Ed.)","Eyelid Carcinoma cM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521309","3q21-q28","C13781","A chromosome band present on 3q","3q21-q28 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539512","Milademetan","C141432","An orally available MDM2 (murine double minute 2) antagonist with potential antineoplastic activity. Upon oral administration, milademetan binds to, and prevents the binding of MDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This results in the restoration of p53 signaling and leads to the p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein and a negative regulator of the p53 pathway, is overexpressed in cancer cells; it has been implicated in cancer cell proliferation and survival.","Milademetan | 2,6-Anhydro-5-((((3'R,4'S,5'R)-6''-chloro-4'-(2-chloro-3-fluoro-4-pyridinyl)-1'',2''-dihydro-4,4-dimethyl-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-3,4,5-trideoxy-L-erythro-hexonamide | DS-3032 | MILADEMETAN | RAIN-32",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540238","ZNF292 wt Allele","C142227","Human ZNF292 wild-type allele is located in the vicinity of 6q14.3 and is approximately 111 kb in length. This allele, which encodes zinc finger protein 292, is involved in transcriptional regulation. Mutations in the gene may be associated with gastric cancer, colorectal cancer and chronic lymphocytic leukemia.","ZNF292 wt Allele | KIAA0530 | Nbla00365 | ZFP292 | ZN-16 | ZN16 | Zn-15 | bA393I2.3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540036","DRRI-2 - E: Saw Americans Had Been Wounded","C141934","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I saw Americans or allies after they had been severely wounded or disfigured.","DRRI-2 - E: Saw Americans Had Been Wounded | DRRI1-E: Saw Americans Had Been Wounded | DRRI1E07",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539768","VALG Clinical Classification Question","C141674","A question associated with the VALG clinical classification.","VALG Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538825","Retinoblastoma HX Finding v8","C140727","Unknown or insufficient evidence of a constitutional RB1 gene mutation. (from AJCC 8th Ed.)","Retinoblastoma HX Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539866","IPAQ Long Last 7 Days Telephone Format Version - Vigorous Leisure Minutes per Day","C141832","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days doing vigorous physical activities in your leisure time?: Minutes per day.","IPAQ Long Last 7 Days Telephone Format Version - Vigorous Leisure Minutes per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520678","16p11.2","C13930","A chromosome band present on 16p","16p11.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520764","17q11.2-q21.1","C13901","A chromosome band present on 17q","17q11.2-q21.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539736","4-Stair Ascend - Time to Do 4-Stair Ascend","C141706","Four Stair Ascend Test (4 Stair Ascend) Time taken to ascend 4 stairs.","4-Stair Ascend - Time to Do 4-Stair Ascend | A4STR1-Time to Do 4-Stair Ascend | A4STR102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542244","Grade 1 Bloating, CTCAE","C143999","No change in bowel function or oral intake","Grade 1 Bloating, CTCAE | Grade 1 Bloating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542735","Grade 2 Bruising, CTCAE","C144562","Generalized","Grade 2 Bruising, CTCAE | Grade 2 Bruising",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543326","Grade 3 Blood and Lymphatic System Disorders - Other, Specify, CTCAE","C145162","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL","Grade 3 Blood and Lymphatic System Disorders - Other, Specify, CTCAE | Grade 3 Blood and lymphatic system disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542892","Grade 2 Forced Expiratory Volume Decreased, CTCAE","C144673","FEV1 60-69%","Grade 2 Forced Expiratory Volume Decreased, CTCAE | Grade 2 Forced expiratory volume decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542931","Grade 2 INR Increased, CTCAE","C144766",">1.5-2.5; >1.5-2.5 x baseline if on anticoagulation; dose adjustment indicated","Grade 2 INR Increased, CTCAE | Grade 2 INR increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543303","Grade 3 Cecal Hemorrhage, CTCAE","C145187","Transfusion indicated; invasive intervention indicated; hospitalization","Grade 3 Cecal Hemorrhage, CTCAE | Grade 3 Cecal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542410","Grade 1 Irregular Menstruation, CTCAE","C144221","Intermittent/irregular menses for no more than 3 consecutive menstrual cycles","Grade 1 Irregular Menstruation, CTCAE | Grade 1 Irregular menstruation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543013","Grade 2 Kyphosis, CTCAE","C144804","Moderate accentuation; limiting instrumental ADL","Grade 2 Kyphosis, CTCAE | Grade 2 Kyphosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542559","Grade 1 Pleuritic Pain, CTCAE","C144341","Mild pain","Grade 1 Pleuritic Pain, CTCAE | Grade 1 Pleuritic pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542591","Grade 1 Trochlear Nerve Disorder, CTCAE","C144446","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Trochlear Nerve Disorder, CTCAE | Grade 1 Trochlear nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542970","Grade 2 Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other, Specify, CTCAE","C144862","Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL","Grade 2 Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other, Specify, CTCAE | Grade 2 Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4042170","68Ga-pentixafor","C141632","A radioconjugate composed of a synthetic, cyclic pentapeptide analog of stromal-cell derived factor-1 (SDF-1 or CXCL12), which is a ligand for chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), that is radiolabeled, via the macrocyclic chelating agent dodecanetetraacetic acid (DOTA), with the radioisotope gallium Ga 68 (Ga68; 68Ga), with potential use for imaging CXCR4-expressing cells upon positron emission tomography (PET)/computed tomography (CT). Upon administration of 68Ga pentixafor, the pentixafor moiety targets and binds to CXCR4-expressing cancer cells. Upon PET/CT, CXCR4-expressing cancer cells can be visualized and the expression status of the receptor can be assessed. CXCR4, a marker of poorly differentiated cells, is overexpressed on various cancer cells, and plays a key role in tumor growth, progression, invasiveness and metastasis.","Gallium Ga 68 Boclatixafortide | 68GA-CPCR4-2 | 68Ga Pentixafor | CPCR4-2 GA-68 | GALLIUM (68GA) BOCLATIXAFORTIDE | Ga-68 Pentixafor | Ga68 Pentixafor | Gallium (68GA) Boclatixafortide | Gallium Ga 68 Pentixafor | Gallium Ga 68 Pentixafor | PENTIXAFOR GALLIUM GA-68 | Pentixafor Gallium GA-68 | [68Ga] Pentixafor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539146","Medullary Thyroid Carcinoma pT4 TNM Finding v8","C141031","Advanced disease. (from AJCC 8th Ed.)","Medullary Thyroid Carcinoma pT4 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517371","GTP Binding Domain","C14082","Associated with binding and hydrolysis of GTP, the highly conserved GTP-Binding Domain is typically found in signaling RAS-related proteins of the small GTPase superfamily. (NCI)","GTP Binding Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543375","Grade 3 Edema Limbs, CTCAE","C145244",">30% inter-limb discrepancy in volume; gross deviation from normal anatomic contour; limiting self care ADL","Grade 3 Edema Limbs, CTCAE | Grade 3 Edema limbs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542587","Grade 1 Urostomy Obstruction, CTCAE","C144458","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Urostomy Obstruction, CTCAE | Grade 1 Urostomy obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544958","RNF43 NM_017763.5:c.380G>C","C146972","A nucleotide substitution at position 380 of the coding sequence of the RNF453 gene where guanine has been mutated to cytosine.","RNF43 NM_017763.5:c.380G>C | NM_017763.5:c.380G>C | RNF124 c.380G>C | RNF43 c.380G>C | Ring Finger Protein 43 Gene c.380G>C | URCC c.380G>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544915","TP53 NM_000546.5:c.742C>T","C146904","A nucleotide substitution at position 742 of the coding sequence of the TP53 gene where cytosine has been mutated to thymine.","TP53 NM_000546.5:c.742C>T | LFS1 c.742C>T | Li-Fraumeni Syndrome c.742C>T | NM_000546.5:c.742C>T | P53 c.742C>T | TP53 c.742C>T | Tumor Protein p53 c.742C>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544898","TP53 NM_000546.5:c.818G>T","C146919","A nucleotide substitution at position 818 of the coding sequence of the TP53 gene where guanine has been mutated to thymine.","TP53 NM_000546.5:c.818G>T | LFS1 c.818G>T | Li-Fraumeni Syndrome c.818G>T | NM_000546.5:c.818G>T | P53 c.818G>T | TP53 c.818G>T | Tumor Protein p53 c.818G>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545557","FACIT-Dyspnea 10 Item Short Form - Part II: Walk Up 20 Stairs","C147665","Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part II Functional Limitation. Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Walking up 20 stairs (2 flights) without stopping.","FACIT-Dyspnea 10 Item Short Form - Part II: Walk Up 20 Stairs | FAC084-Part II: Walk Up 20 Stairs | FAC08423",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513859","NSF/N Mice","C14363","No value exists.","NSF/N Mice | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206745","Knock-Out Mouse","C14339","Informal term for the generation of a mutant mouse in which the function of a particular gene has been completely eliminated, also called a null mouse.","Knock-Out Mouse | Knockout Mouse | Mouse, Knockout | Null Mouse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541499","Anhydrous, Pinacidil","C143025","No value exists.","Pinacidil Anhydrous | 2-Cyano-3-(4-pyridinyl)-1-(1,2,2-trimethylpropyl)guanidine | Guanidine, N-cyano-N'-4-pyridinyl-N''-(1,2,2-trimethylpropyl)- | PINACIDIL ANHYDROUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540744","Letrozole/Palbociclib Regimen","C142859","A regimen consisting of letrozole and palbociclib that can be used in the treatment of breast cancer.","Letrozole/Palbociclib Regimen | Femara/Ibrance | Letrozole + Palbociclib | Letrozole and Palbociclib | Letrozole-Palbociclib | Letrozole-Palbociclib Regimen | Letrozole/Palbociclib | Palbociclib + Letrozole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515161","TGF-Beta-Null Mice","C14345","No value exists.","TGF-Beta-Null Mice | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543669","Grade 3 Sleep Apnea, CTCAE","C145622","Oxygen desaturation; associated with pulmonary hypertension; medical intervention indicated; limiting self care ADL","Grade 3 Sleep Apnea, CTCAE | Grade 3 Sleep apnea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544072","Grade 4 Osteonecrosis of Jaw, CTCAE","C146018","Life-threatening consequences; urgent intervention indicated","Grade 4 Osteonecrosis of Jaw, CTCAE | Grade 4 Osteonecrosis of jaw",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544531","Grade 5 Radiation Recall Reaction (Dermatologic), CTCAE","C146513","Death","Grade 5 Radiation Recall Reaction (Dermatologic), CTCAE | Grade 5 Radiation recall reaction (dermatologic)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544498","Grade 5 Intraoperative Hemorrhage, CTCAE","C146396","Death","Grade 5 Intraoperative Hemorrhage, CTCAE | Grade 5 Intraoperative hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551399","Implant in pre-filled syringe","C149561","Medicinal product consisting of an implant presented in a pre-filled syringe.","Implant in Pre-filled Syringe Dosage Form | Implant in Pre-filled Syringe | Implant in pre-filled syringe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551613","Powder for Epilesional Solution Dosage Form","C149825","Solid sterile preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain an epilesional solution.","Powder for Epilesional Solution Dosage Form | Powder for epilesional solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551970","Maximum Inflated Stent Diameter","C150197","Maximum diameter to which a stent can be distended.","Maximum Inflated Stent Diameter | Maximum Stent Diameter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551501","Oculonasal","C149702","Relating to the eyes and nares of a bird as the intended site of administration.","Oculonasal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544221","Grade 4 Stoma Site Infection, CTCAE","C146135","Life-threatening consequences; urgent intervention indicated","Grade 4 Stoma Site Infection, CTCAE | Grade 4 Stoma site infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543569","Grade 3 Malaise, CTCAE","C145452","Uneasiness or lack of well being limiting self-care ADL","Grade 3 Malaise, CTCAE | Grade 3 Malaise",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545605","TSCC - Can't Stop Thinking About Sex","C147745","Trauma Symptom Checklist for Children (TSCC) Can't stop thinking about sex.","TSCC - Can't Stop Thinking About Sex | TSCC01-Can't Stop Thinking About Sex | TSCC0147",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544842","Mediastinal Germ Cell Tumor N1 TNM Finding","C146844","Mediastinal germ cell tumor with metastasis in regional lymph nodes. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)","Mediastinal Germ Cell Tumor N1 TNM Finding | Thymic Germ Cell Tumor N1 TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544137","Grade 4 Rhabdomyolysis, CTCAE","C146099","Life-threatening consequences; dialysis","Grade 4 Rhabdomyolysis, CTCAE | Grade 4 Rhabdomyolysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544340","Grade 5 Enterocolitis, CTCAE","C146294","Death","Grade 5 Enterocolitis, CTCAE | Grade 5 Enterocolitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543848","Grade 3 Vascular Disorders - Other, Specify, CTCAE","C145711","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL","Grade 3 Vascular Disorders - Other, Specify, CTCAE | Grade 3 Vascular disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543892","Grade 4 Conjunctivitis Infective, CTCAE","C145803","Life-threatening consequences; urgent intervention indicated","Grade 4 Conjunctivitis Infective, CTCAE | Grade 4 Conjunctivitis infective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543640","Grade 3 Pancreatic Enzymes Decreased, CTCAE","C145513","Sequelae of absorption deficiency","Grade 3 Pancreatic Enzymes Decreased, CTCAE | Grade 3 Pancreatic enzymes decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553477","Rafigrelide","C152145","No value exists.","Rafigrelide | RAFIGRELIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1438514","SHANK2 protein, human","C147944","SH3 and multiple ankyrin repeat domains protein 2 (1470 aa, ~159 kDa) is encoded by the human SHANK2 gene. This protein is involved in organization of both the structure and function of the synaptic junction.","SH3 and Multiple Ankyrin Repeat Domains Protein 2 | Cortactin Binding Protein 1 | Cortactin SH3 Domain-Binding Protein | Cortactin-Binding Protein 1 | GKAP/SAPAP Interacting Protein | Proline-Rich Synapse Associated Protein 1 | Proline-Rich Synapse-Associated Protein 1 | SHANK2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3661282","Vortioxetine","C152917","No value exists.","Vortioxetine | VORTIOXETINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551141","mTORC 1/2 Inhibitor LXI-15029","C148528","An orally bioavailable inhibitor of raptor-mammalian target of rapamycin (mTOR) complex 1 (mTOR complex 1; mTORC1) and rictor-mTOR complex 2 (mTOR complex 2; mTORC2), with potential antineoplastic activity. Upon oral administration, mTORC1/2 inhibitor LXI-15029 binds to the kinase domain of mTOR and inhibits both mTORC1 and mTORC2, in an ATP-competitive manner. This inhibits mTOR-mediated signaling and leads to both an induction of apoptosis and a decrease in the proliferation of mTORC1/2-expressing tumor cells. mTOR is a serine/threonine kinase that is upregulated in certain tumor cell types. It plays an important role in the PI3K/Akt/mTOR signaling pathway, which is often deregulated in cancer cells and promotes cell growth, survival, and resistance to chemotherapy and radiotherapy.","mTORC 1/2 Inhibitor LXI-15029 | LXI-15029 | LXI15029 | MTI-31 | SCC-31",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043479","Zimeldine","C152954","No value exists.","Zimeldine | ZIMELDINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553333","Quingestrone","C152126","No value exists.","Quingestrone | 3-(Cyclopentyloxy)pregna-3,5-dien-20-one | 3-Cyclopentyloxy-3,5-pregnadien-20-on | QUINGESTRONE | W-3399",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551275","Dredging Container","C149445","Container for a pharmaceutical form to be applied by dredging.","Dredging Container | Dredging container",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552436","Anti-MiHA Donor T-lymphocytes","C148500","A preparation of allogeneic, donor-derived T-lymphocytes that are specific for a unique set of minor histocompatibility complex antigens (MiHA) exclusively found on the surface of malignant cells, with potential immunomodulating and antineoplastic activities. T-lymphocytes are derived from an allogeneic hematopoietic cell transplant (AHCT) donor. Ex vivo, these T-cells are exposed to and primed against a select set of host-specific hematopoietic tissue-restricted MiHAs that are expressed on leukemic cells. Then the cells are subsequently expanded. After AHCT and infusion of the anti-MiHA T-lymphocytes, these cells target and bind to MiHA antigens expressed on the host's leukemia cells, thereby killing these cancer cells. MiHA are small, cell-surface peptides that are associated with graft-versus-host disease (GvHD). The selected set of MiHAs is expressed mainly, or only, by hematopoietic cells, and overexpressed on leukemic cells.","Anti-minor Histocompatibility Complex Donor T-Lymphocytes | Anti-MiHA Donor T-lymphocytes | Anti-MiHA T Cells | GLIDE | GLIDE Cells | GLIDE T-lymphocytes | Guided Lymphocyte Immunopeptide Derived Expansion Against MiHAs Cells | Guided Lymphocyte Immunopeptide Derived Expansion Cells | MiHA T-lympocytes | MiHA-specific T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551577","Oromucosal Ointment Dosage Form","C149736","Semi-solid multidose preparation consisting of an ointment intended for oromucosal use. It is applied to the oral cavity or onto a specific part of the oral cavity, to obtain a local effect","Oromucosal Ointment Dosage Form | Oromucosal ointment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550900","Refractory Leiomyosarcoma","C148294","Leiomyosarcoma that does not respond to treatment.","Refractory Leiomyosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551061","Gallium Ga 68-P16-093","C148484","A radioconjugate composed of a human prostate specific membrane antigen (PSMA)-targeting ligand (P16-093) conjugated to the radioisotope gallium Ga 68, via the acyclic radiometal chelator N,N'-bis [2-hydroxy-5-(carboxyethyl)benzyl] ethylenediamine-N,N'-diacetic acid (HBED-CC), with potential use as a tracer for PSMA-expressing tumors during positron emission tomography (PET). Upon intravenous administration of the gallium Ga 68 P16-093, the P16-093 moiety targets and binds to PSMA-expressing tumor cells. During PET imaging, PSMA-expressing tumor cells can be detected. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.","Gallium Ga 68-P16-093 | Ga-68 P16-093 | Ga-68 PSMA-093 | Ga-68 PSMA-93 | Gallium-68-P16 093 | [68Ga] HBED-CC-PHENOXY-PSMA | [68Ga]P16-093",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552922","FACT/GOG-NTX Version 4 - I Get Support From My Friends","C151205","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Social/Family Well-Being: I get support from my friends.","FACT/GOG-NTX Version 4 - I Get Support From My Friends | FAC057-I Get Support From My Friends | FAC05710",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552669","ERT - Number Stimuli Portraying Anger","C150938","Emotion Recognition Test (ERT) Number of stimuli defined as portraying anger.","ERT - Number Stimuli Portraying Anger | EMO1-Number Stimuli Portraying Anger | EMO107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552901","Paced Tapping - Maximum Interval Tone Trial","C151056","Paced Tapping Test (Paced Tapping) The maximum intertap interval within the tone-tapping phase of Trial n (in milliseconds).","Paced Tapping - Maximum Interval Tone Trial | PTAP1-Maximum Interval Tone Trial | PTAP112B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552979","FACT-Taxane Version 4 - My Work Is Fulfilling","C151134","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Functional Well-Being: My work (include work at home) is fulfilling.","FACT-Taxane Version 4 - My Work Is Fulfilling | FAC063-My Work Is Fulfilling | FAC06322",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555434","Histone H2A-Bbd Type 2/3","C154656","Histone H2A-Bbd type 2/3 (115 aa, ~13 kDa) is encoded by the human H2AB2 and H2AB3 genes. This protein plays a role in the promotion of gene expression.","Histone H2A-Bbd Type 2/3 | H2A Barr Body Deficient | H2A Barr Body-Deficient | H2A.B | H2A.Bbd | H2AB2/3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007625","Cell-free System","C15201","An in vitro biosystem created through the mixing of isolated subcellular fractions and/or purified enzymes and coenzymes. Cell-free systems can be used for studying biological reactions or in biomanufacturing.","Cell-free System | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552516","Mutation-Positive Lynch Syndrome","C150715","A finding of Lynch syndrome in which one is identified as a carrier or obligate carrier of a pathogenic mutation(s) in one of several DNA mismatch repair genes, including MLH1, MSH2/EPCAM, MSH6 or PMS2.","Mutation-Positive Lynch Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518489","Nutrition, Fats, Unsaturated","C15233","Role of unsaturated fats in cancer causation or prevention and in general health.","Nutrition, Fats, Unsaturated | Lipid Nutrition, Unsaturated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553771","Streptovarycin","C152439","No value exists.","Streptovarycin | STREPTOVARYCIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028719","Nutritional Requirements","C15287","The protein, carbohydrates, fats and cofactors required to maintain a healthy body","Nutritional Requirements | ",,,,,,,,,,,,,,,"4191598","Nutrient requirement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL553298","NOP10 Gene","C152090","This gene plays a role in both ribosome biogenesis and telomere maintenance.","NOP10 Gene | NOP10 | NOP10 Ribonucleoprotein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553061","SIQ - Thought Way People Kill Themselves","C151344","Suicidal Ideation Questionnaire (SIQ) I thought about ways people kill themselves.","SIQ - Thought Way People Kill Themselves | SIQ01-Thought Way People Kill Themselves | SIQ0119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552173","A-101 Topical Solution","C150374","A proprietary topical formulation consisting of a high-concentration of hydrogen peroxide (H2O2), with potential keratolytic activity. Upon administration of the A-101 topical solution to an affected area of skin, the hydrogen peroxide penetrates into the cells, increases oxygen content, produces reactive oxygen species (ROS), causes oxidative stress and induces apoptosis through oxidative damage. This may clear the affected skin cells and remove common warts (verruca vulgaris) or seborrheic keratosis (SK).","A-101 Topical Solution | A-101 | A-101 Solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552935","FACT/GOG-NTX Version 4 - I Am Able to Enjoy Life","C151218","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Functional Well-Being: I am able to enjoy life.","FACT/GOG-NTX Version 4 - I Am Able to Enjoy Life | FAC057-I Am Able to Enjoy Life | FAC05723",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574438","Duala Language","C153904","A dialect cluster of the Bantu language family spoken by the Duala and Mungo peoples of Cameroon.","Duala Language | DUA | Diwala | Douala | Duala | Dualla | Dwala | Dwela",,,,,,,,,,,,,,,"4175930","Duala language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554977","Irinotecan/Panitumumab/Vemurafenib Regimen","C153482","A regimen consisting of irinotecan, panitumumab and vemurafenib that can be used for the treatment of colon cancer.","Irinotecan/Panitumumab/Vemurafenib Regimen | Irinotecan + Panitumumab + Vemurafenib | Irinotecan + Panitumumab + Vemurafenib Regimen | Irinotecan + Panitumumab Regimen | Irinotecan-Panitumumab-Vemurafenib | Irinotecan-Panitumumab-Vemurafenib Regimen | Irinotecan/Panitumumab/Vemurafenib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554510","ficolin P35-related protein, human","C153282","Ficolin-2 (313 aa, ~34 kDa) is encoded by the human FCN2 gene. This protein is involved in calcuim-dependent binding to carbohydrates.","Ficolin-2 | 37 kDa Elastin-Binding Protein | Collagen/Fibrinogen Domain-Containing Protein 2 | EBP-37 | FCN2 | Ficolin 2 | Ficolin B | Ficolin-B | Ficolin-Beta | Hucolin | L-Ficolin | Serum Lectin p35",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554303","Macy Catheter","C153164","A catheter designed for drug administration through a rectal route of delivery. It is specifically designed for rectal administration of liquid medication, especially when a patient is unable to take medications orally.","Macy Catheter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL025702","Problem Solving Skills Training","C153258","Cognitive-behavioral interventions designed to adapt to the needs of patients to improve their problem-solving skills and alleviate stress.","Problem-Solving Skills Training | PSST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555355","Antibody-drug Conjugate SC-005","C154558","An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against a tumor-associated antigen (TAA) linked to a currently undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of SC-005 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an unknown mechanism of action.","Antibody-drug Conjugate SC-005 | SC 005 | SC-005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555725","Grade 4 Neonatal Pulmonary Hemorrhage, AE","C155215","A pulmonary hemorrhage adverse event in a newborn characterized by life-threatening respiratory and/or hemodynamic compromise.","Grade 4 Neonatal Pulmonary Hemorrhage, AE | Grade 4 Neonatal Pulmonary Hemorrhage | Grade 4 Neonatal Pulmonary Hemorrhage, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280118","Infection Prophylaxis and Management","C15511","Treat infections with antibacterial, antifungal, antiparasite or antiviral drugs","Infection Prophylaxis and Management | Infectious Diseases / Treatment, General | Treatment of Infectious Disease | infectious diseases treatment | management, infection prophylaxis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555362","Nintedanib Esylate","C154570","The esylate salt form of nintedanib, an orally bioavailable, indolinone-derived inhibitor of multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs), with potential antiangiogenic, antifibrotic and antineoplastic activities. Upon administration, nintedanib selectively binds to and inhibits vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), and colony stimulating factor 1 receptor (CSF1R) tyrosine kinases, which may result in the induction of endothelial cell apoptosis, the reduction in tumor vasculature, the inhibition of tumor cell proliferation and migration, and antifibrotic activity in pulmonary fibrosis. In addition, nintedanib also binds to and inhibits members of the Src family of tyrosine kinases, including Src, Lck and Lyn, and fms-like tyrosine kinase 3 (FLT-3). VEGFR, FGFR, PDGFR and CSF1R RTKs play key roles in tumor angiogenesis, tumor cell proliferation and metastasis, as well as pulmonary fibrosis.","Nintedanib Esylate | Methyl (3Z)-3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino) (phenyl)methylidene)-2-oxo-2,3-dihydro-1H-indole-6-carboxylate Ethanesulfonate | NINTEDANIB ESYLATE | Nintedanib Ethanesulfonate | Ofev",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555307","H3/c Gene Mutation","C154312","A change in the sequence of the HIST1H3C gene.","H3C3 Gene Mutation | H3 Clustered Histone 3 Gene Mutation | H3/c Gene Mutation | H3FC Gene Mutation | H3c Gene Mutation | HIST1H3C Gene Mutation | Histone Cluster 1 H3 Family Member C Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555791","Grade 1 Neonatal Hypotension, AE","C155157","An adverse event in a newborn characterized by transient (less than 60 minutes), asymptomatic hypotension; not affecting perfusion; not requiring intervention.","Grade 1 Neonatal Hypotension, AE | Grade 1 Neonatal Hypotension | Grade 1 Neonatal Hypotension, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556201","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Carrying Less Than 5 Lbs","C155571","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Carrying something weighing less than 5 lbs (about 2 kg, like a houseplant) from one room to another.","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Carrying Less Than 5 Lbs | FAC100-Limit: Carrying Less Than 5 Lbs | FAC10090",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555841","CDRS-R - Difficulty Having Fun","C155331","Children's Depression Rating Scale, Revised (CDRS-R) Difficulty having fun.","CDRS-R - Difficulty Having Fun | CDRS1-Difficulty Having Fun | CDRS102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563085","Carboplatin/Trastuzumab Regimen","C156373","A regimen consisting of carboplatin and trastuzumab that may be used for the treatment of HER-2 (EGFR2; ErbB2)-positive breast cancer.","Carboplatin/Trastuzumab Regimen | Carboplatin-Trastuzumab | Carboplatin-Trastuzumab Regimen | Carboplatin/Trastuzumab | Trastuzumab-Carboplatin | Trastuzumab/Carboplatin | Trastuzumab/Carboplatin Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555863","CDRS-R - Depressed Facial Affect","C155357","Children's Depression Rating Scale, Revised (CDRS-R) Depressed facial affect.","CDRS-R - Depressed Facial Affect | CDRS1-Depressed Facial Affect | CDRS115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4024223","Spinal Hemangioblastoma","C155948","A hemangioblastoma that arises from the spinal cord.","Spinal Hemangioblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563073","Docetaxel/Vandetanib Regimen","C156355","A regimen consisting of docetaxel and vandetanib that may be useful in the treatment of a variety of cancers, such as breast and non-small cell lung cancers.","Docetaxel/Vandetanib Regimen | Docetaxel and Vandetanib | Docetaxel-Vandetanib | Docetaxel/Caprelsa | Docetaxel/Vandetanib | Vandetanib/Docetaxel | Vandetanib/Docetaxel Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935991","Glasdegib Maleate","C156894","The maleate salt form of glasdegib, an orally bioavailable small-molecule, smoothened (SMO) receptor inhibitor, with potential antineoplastic activity. Upon oral administration, glasdegib targets, binds to and inhibits the activity of SMO. This inhibits the activity of the Hedgehog (Hh) signaling pathway and inhibits the growth of tumor cells in which this pathway is aberrantly activated. SMO, a transmembrane protein, is involved in Hh signal transduction. The Hh signaling pathway plays an important role in cellular growth, differentiation, repair, and cancer stem cell (CSC) survival. Constitutive activation of Hh pathway signaling has been observed in various types of malignancies and is associated with uncontrolled cellular proliferation in a variety of cancers.","Glasdegib Maleate | 1-((2R,4R)-2-(1H-Benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea Maleate | Daurismo | GLASDEGIB MALEATE | PF 04449913 Maleate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935847","PVRIG wt Allele","C156799","Human PVRIG wild-type allele is located in the vicinity of 7q22.1 and is approximately 5 kb in length. This allele, which encodes transmembrane protein PVRIG, may be involved in immune checkpoint signaling.","PVRIG wt Allele | C7orf15 | CD112R | Chromosome 7 Open Reading Frame 15 Gene | MGC2463 | PVR Related Immunoglobulin Domain Containing wt Allele | Poliovirus Receptor Related Immunoglobulin Domain Containing Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935999","Natural Gas","C156874","A naturally occurring gas consisting of a hydrocarbon mixture that is primarily methane, but may include varying amounts of other higher alkanes and a small percentage of carbon dioxide, nitrogen, hydrogen sulfide, or helium. Natural gas is a fossil fuel used as a source of energy for heating, cooking, electricity generation, and transportation. It is also used in the manufacture of plastics and other commercially important organic chemicals.","Natural Gas | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563139","Thyroid Gland Solitary Fibrous Tumor","C156349","A rare solitary fibrous tumor that arises from the thyroid gland.","Thyroid Gland Solitary Fibrous Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937522","Colorectal Cancer Surgery","C157824","Any of a number of surgical procedures that can be done on the colon, rectum and/or anus.","Colorectal Cancer Surgery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937724","CDISC ADaM Geriatric Depression Scale Short Form Questionnaire Parameter Code Terminology","C158114","Terminology associated with the Geriatric Depression Scale Short Form questionnaire parameter code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Analysis Data Model (ADaM).","CDISC ADaM Geriatric Depression Scale Short Form Questionnaire Parameter Code Terminology | ADaM-GDS02PC | GDS02PC | Geriatric Depression Scale Short Form Questionnaire Parameter Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1308914","ONECUT2 protein, human","C157290","One cut domain family member 2 (504 aa, ~54 kDa) is encoded by the human ONECUT2 gene. This protein is involved in transcriptional regulation and liver development.","One Cut Domain Family Member 2 | HNF-6-Beta | Hepatocyte Nuclear Factor 6-Beta | OC-2 | ONECUT-2 Homeodomain Transcription Factor | ONECUT2 | One Cut Homeobox 2 | Onecut 2 | Transcription Factor ONECUT-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978141","MR Imaging Acquisition Protocol Element Inversion Recovery Indicator","C164861","No value exists.","MR Imaging Acquisition Protocol Element Inversion Recovery Indicator | MRImagingAcquisitionProtocolElement.inversionRecoveryIndicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3150926","Congenital Dyserythropoietic Anemia Type IV","C157148","An autosomal dominant sub-type of congenital dyserythropoietic anemia caused by mutation(s) in the KLF1 gene, encoding Krueppel-like factor 1.","Congenital Dyserythropoietic Anemia Type IV | CDAN4",,,,,,,,,,,,,,,"36714288","Congenital dyserythropoietic anemia type IV",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556021","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking Up 30 Stairs Why Not","C155519","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking up 30 stairs (3 flights) without stopping. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking Up 30 Stairs Why Not | FAC100-Sev: Walking Up 30 Stairs Why Not | FAC10038",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937602","Perivascular Epithelioid Cell Tumor of the Kidney","C158032","An angiomyolipoma that arises from the kidney and is composed exclusively or predominantly of epithelioid cells. It is often associated with cytologic atypia and may recur or metastasize.","Kidney Epithelioid Angiomyolipoma | Epithelioid Angiomyolipoma/Epithelioid PEComa of the Kidney | Kidney EAML | Kidney Epithelioid Type Angiomyolipoma | PEComa of the Kidney | Perivascular Epithelioid Cell Tumor of the Kidney | Renal Epithelioid Angiomyolipoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556291","KIT NM_000222.2:c.1939C>T","C155682","A nucleotide substitution at position 1939 of the coding sequence of the KIT gene where cytosine has been mutated to thymine.","KIT NM_000222.2:c.1939C>T | CD117 c.1939C>T | KIT Proto-Oncogene Tyrosine Protein Kinase c.1939C>T | KIT c.1939C>T | NM_000222.2:c.1939C>T | c-KIT c.1939C>T | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.1939C>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937904","Major Histocompatibility Complex Tested Indicator","C158347","An indication as to whether the study subject has had its major histocompatibility complex characterized.","Major Histocompatibility Complex Tested Indicator | MHC Tested Indicator | MHCIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562785","Diagnostic Fiberoptic Endoscopic Examination","C155920","A diagnostic procedure in which a fiberoptic endoscope is used.","Diagnostic Fiberoptic Endoscopic Examination | Fiberoptic Endoscopic Examination | Fiberoptic Endoscopy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978069","Performed Genetic Observation Result Genetic Target","C164933","No value exists.","Performed Genetic Observation Result Genetic Target | PerformedGeneticObservationResult.geneticTarget",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951580","Chemical/Occupational Exposure Present","C159577","An indication that a history of chemical/occupational exposures exists.","Chemical/Occupational Exposure Present | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518509","Nutrition, Vitamins","C16016","No value exists.","Nutrition, Vitamins | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969881","CDISC Therapeutic Area User Guide Response Terminology","C160925","Terminology associated with the CDISC therapeutic area user guide response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Therapeutic Area User Guide Response Terminology | CDISC Therapeutic Area User Guide Response | CTAUGRS | SDTM-CTAUGRS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1744560","Bulbar Urethra","C160607","The portion of the penile urethra that spans the bulb of the penis.","Bulbar Urethra | Bulbar Portion of the Urethra",,,,,,,,,,,,,,,"4309235","Structure of bulbar urethra",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL951416","HD Chest","C159518","A proprietary combination of PET/CT hardware and software designed to provide relatively motion-free images with higher count statistics for improved image quality and small lesion conspicuity. Using a highly automated, amplitude-based gating technology, HD Chest adapts to every patients breathing and automatically selects the optimal data range with the least amount of motion and the highest count statistics, producing images the chest and upper abdomen in high-definition without respiratory motion.","HD Chest | HD Chest System | High Definition Chest Software",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969591","Regular Smokeless Tobacco Use for Six Weeks or More Positive","C160471","A response that the individual used smokeless tobacco regularly for six weeks or longer.","Regular Smokeless Tobacco Use for Six Weeks or More Positive | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969800","Intermediate CALGB Criteria","C160758","A rating for AML by CALGB which indicates the outlook on the patient recovery can be considered between favorable and poor.","Intermediate CALGB Criteria | Intermediate/Normal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969483","Capecitabine/Cisplatin/Trastuzumab Regimen","C160551","A regimen consisting of capecitabine, cisplatin and trastuzumab that can be used in the treatment of esophageal and esophagogastric junction, and gastric cancers.","Capecitabine/Cisplatin/Trastuzumab Regimen | Capecitabine and Cisplatin (CX) and Trastuzumab | Capecitabine and Cisplatin (CX) and Trastuzumab-anns | Capecitabine and Cisplatin (CX) and Trastuzumab-dkst | Capecitabine and Cisplatin (CX) and Trastuzumab-dttb | Capecitabine and Cisplatin (CX) and Trastuzumab-herw | Capecitabine and Cisplatin (CX) and Trastuzumab-pkrb | Capecitabine and Cisplatin (CX) and Trastuzumab-qyyp | Capecitabine and Cisplatin (CX) and Trastuzumab-strf | Capecitabine and Cisplatin (CX) and Trastuzumab-zerc | Capecitabine-Cisplatin-Trastuzumab | Capecitabine/Cisplatin/Trastuzumab | Xeloda/Platinol/Herceptin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938152","Left Ventricular Remodeling","C157906","A change in the function, shape or size of the left ventricle, which can be either physiological or pathological. A decline in performance is the result.","Left Ventricular Remodeling | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969765","Autologous Anti-mesothelin TRuC T-cells TC-210","C160780","A preparation of autologous T-lymphocytes that have been genetically engineered to express a single-domain antibody that recognizes human mesothelin, fused to the N-terminus of the CD3-epsilon T-cell receptor (TCR) subunit which, upon expression is incorporated into the endogenous TCR complex, with potential antineoplastic activity. Upon administration, gavocabtagene autoleucel specifically target and bind to mesothelin-expressing tumor cells. This leads to T-cell activation and T-cell mediated lysis of mesothelin-expressing tumor cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types. Compared to chimeric antigen receptor (CAR) T-cells, TRuCs may be associated with less pro-inflammatory cytokine secretion and fewer adverse effects without compromising therapeutic efficacy.","Gavocabtagene Autoleucel | Autologous Anti-mesothelin T-cell Receptor Fusion Construct T-cells TC-210 | Autologous Anti-mesothelin TRuC T-cells TC-210 | GAVOCABTAGENE AUTOLEUCEL | Gavo-cel | TC 210 | TC-210 | TC-210 T Cells | TC210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969514","Apalutamide/Leuprolide Regimen","C160520","A regimen consisting of apalutamide and leuprolide that can be used for the treatment of prostate cancer.","Apalutamide/Leuprolide Regimen | Apalutamide-Leuprolide | Apalutamide/Leuprolide | Leuprolide-Apalutamide | Leuprolide-Apalutamide Regimen | Leuprolide/Apalutamide Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936883","Hereditary Adrenal Gland Pheochromocytoma","C157248","A hereditary adrenal gland pheochromocytoma caused by mutations in SDHB, SDHC, and SDHD genes.","Hereditary Adrenal Gland Pheochromocytoma | Familial Adrenal Gland Pheochromocytoma | Familial Adrenal Gland Pheochromocytoma | Hereditary Adrenal Gland Pheochromocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969527","High-dose Cytarabine/Rituximab Regimen","C160538","A regimen consisting of high-dose cytarabine and rituximab that may be used in the treatment of Burkitt lymphoma and mantle cell lymphoma (MCL).","High-dose Cytarabine/Rituximab Regimen | Cytarabine-Rituximab | Cytosar-U/Rituxan | HD AraC/Rituximab | HD Cytarabine/Rituximab | High-dose Cytarabine/Rituximab | R-HiDAC | R-HiDAC (rituximab-abbs) | R-HiDAC (rituximab-arrx) | R-HiDAC (rituximab-blit) | R-HiDAC (rituximab-pvvr) | R-HiDAC (rituximab-rite) | R-HiDAC (rituximab-rixa) | R-HiDAC (rituximab-rixi)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973104","Recurrent Childhood Malignant Neoplasm","C162702","The reemergence of a childhood malignant neoplasm after a period of remission.","Recurrent Childhood Malignant Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971106","30 Day Prior Medications","C162526","A header in a CPTAC document regarding medication use 30 days prior.","30 Day Prior Medications | Medications, vitamins, supplements administered within the 30 days prior to the CPTAC III specimen collection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002979","Digital Subtraction Angiography","C16291","A technique which subtracts two images that are obtained before and after contrast media is administered to the patient for the purpose of studying blood vessels.","Digital Subtraction Angiography | Angiography, Digital Subtraction | DS | Medical Imaging, Digital Subtraction Angiography",,,,,,,,,,,,,,,"4194013","Digital subtraction angiography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL973239","Refractory Rhabdoid Tumor of the Kidney","C162731","A rhabdoid tumor of the kidney that does not respond to treatment.","Refractory Rhabdoid Tumor of the Kidney | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971131","Penile Lymphoma","C162548","A lymphoma that arises from penile skin, subcutis, corpora cavernosa, and spongiosum. Diffuse large B-cell lymphoma is the most common primary penile lymphoma. (WHO 2016)","Penile Lymphoma | Lymphoma of the Penis | Primary Penile Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971022","Patient-derived WT1/PRAME/Survivin-specific Cytotoxic T-lymphocytes","C162624","A preparation of autologous cytotoxic T-lymphocytes (CTLs) specifically reactive to the tumor associated antigens (TAAs) human Wilms tumor protein (WT1), preferentially expressed antigen of melanoma (PRAME, melanoma antigen preferentially expressed in tumors; Opa-interacting protein 4), and survivin (baculoviral IAP repeat-containing protein 5), with potential antineoplastic activities. Upon collection, expansion, and stimulation with antigen presenting cells pulsed with an overlapping peptide library spanning the TAAs, the multi-antigen associated CTLs are re-introduced into the patient and may induce a CTL-mediated response against tumor cells expressing WT1, PRAME, or survivin, potentially leading to tumor cell lysis and inhibition of tumor cell proliferation. WT1, PRAME, and survivin, are expressed on certain tumor cell types and play key role in tumor cell proliferation and survival.","Patient-derived WT1/PRAME/Survivin-specific Cytotoxic T-lymphocytes | Autologous Tumor Antigen Associated Cytotoxic T-Lymphocytes | Patient-derived Multi-antigen Associated Cytotoxic T-lymphocytes | Patient-derived WT1/PRAME/Survivin-specific T-lymphocytes | TAA-T | TAATs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518498","Nutrition, Protein/Amino Acids","C15920","Role of proteins and amino acids in cancer causation or prevention and in general health.","Nutrition, Protein/Amino Acids | Protein/Amino Acid Nutrition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971192","Other Non-Neoplastic Finding","C159869","A selection that the choice was identified in the study but is not present in the form.","Other Non-Neoplastic Finding | Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951446","Core Biopsy of Bone","C159487","The removal of  bone marrow tissue using a needle with a relatively large diameter, for microscopic examination.","Core Biopsy of Bone | Bone Marrow Core Biopsy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951181","Penile Adenosquamous Carcinoma","C159248","An extremely rare carcinoma that arises from the penis and is characterized by the presence of glandular and squamous components.","Penile Adenosquamous Carcinoma | Adenosquamous Carcinoma of the Penis | Adenosquamous Carcinoma of the Penis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978319","Statistical Analysis Plan Version Description","C165104","No value exists.","Statistical Analysis Plan Version Description | StatisticalAnalysisPlanVersion.description",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977827","Sequence Read Count","C164667","The number of sequencing reaction results that were pooled to assemble a sequence for a genomic region of interest.","Sequence Read Count | Read Count | total reads | total_reads",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978020","Performed Imaging Study Subject Weight","C164950","No value exists.","Performed Imaging Study Subject Weight | PerformedImagingStudy.subjectWeight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977705","Identifier Reader Type Code","C164538","A coded value specifying the type of device required to read the identifying number.","Identifier Reader Type Code | identifierReaderTypeCode",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977525","Accepted Indicator","C164437","An indication as to whether the outcome of the assessment or observation is considered acceptable for usage, among the several assessments provided.","Accepted Indicator | acceptedIndicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013845","Electron Spin Resonance Spectroscopy","C16534","A spectrometric method, based on measurement of electron spins and magnetic moments, for detecting and estimating free radicals in reactions and in biological systems.","Electron Spin Resonance Spectroscopy | ESR | ESR Spectroscopy | Electron Paramagnetic Resonance | Electron Spin Resonance | Spectroscopy, ESR | Spectroscopy, Electron Spin Resonance",,,,,,,,,,,,,,,"4150977","Electron spin resonance measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL978100","Performed Activity Medical History Indicator","C164902","No value exists.","Performed Activity Medical History Indicator | PerformedActivity.medicalHistoryIndicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978466","Hanoverian Scenthound","C165350","A calm and assured scent hound with strong loyalty to the hunter in charge. The body is lean and muscular, and the head is slightly wrinkled with a serious expression. The coat is short and primarily red, but can vary from a pale fawn color to a dark brindle. The average height range is 19-21 inches and the average weight range is 79-99 pounds.","Hanoverian Scenthound | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977606","General Statistical Consideration","C164387","Careful thought or deliberation related to the planned conduct of statistical analyses.","General Statistical Consideration | GeneralStatisticalConsideration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978076","Performed Genetic Observation Genetic Region of Interest","C164926","No value exists.","Performed Genetic Observation Genetic Region of Interest | PerformedGeneticObservation.geneticRegionOfInterest",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970301","EORTC QLQ-C15-PAL Version 1 - Did You Feel Tense","C161671","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Palliative Care Version 1.0 (EORTC QLQ-C15-PAL Version 1) During the past week: Did you feel tense?","EORTC QLQ-C15-PAL Version 1 - Did You Feel Tense | EOR02-Did You Feel Tense | EOR0213",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970129","Prostate Carcinoma Metastatic in the Pelvic Cavity","C161584","A carcinoma that arises from the prostate gland and has spread to the pelvic cavity.","Prostate Carcinoma Metastatic in the Pelvic Cavity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970443","BPRS 1988 Version - Unusual Thought Content","C161755","Brief Psychiatric Rating Scale 1988 Version (BPRS 1988 Version) Unusual thought content.","BPRS 1988 Version - Unusual Thought Content | BPRS01-Unusual Thought Content | BPRS0115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970067","CDISC Traumatic Brain Injury Therapeutic Area User Guide Version 1.0","C161453","The 1.0 version of the CDISC Traumatic Brain Injury therapeutic area user guide.","CDISC Traumatic Brain Injury Therapeutic Area User Guide Version 1.0 | Traumatic Brain Injury Therapeutic Area User Guide v1.0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970356","Hydrazide Beads","C161863","Superparamagnetic silica particles coated with hydrazide used in affinity chromatography for the isolation of glycosylated proteins and peptides from a biological sample.","Hydrazide Beads | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1291166","Increased Porphyrin","C161557","Increase in the amount of porphyrin.","Increased Porphyrin | PORPHYRIN, INCREASED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971515","Coumermycin Sodium","C166516","No value exists.","Coumermycin Sodium | COUMERMYCIN SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973042","Continuous Heart Murmur","C167446","A heart murmur that occurs throughout both systole and diastole.","Continuous Heart Murmur | Continuous | Continuous Murmur",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972057","NOTCH1 NP_060087.3:p.G1196D","C167067","A change in the amino acid residue at position 1196 in the neurogenic locus notch homolog protein 1 where glycine has been replaced by aspartic acid.","NOTCH1 NP_060087.3:p.G1196D | NOTCH1 G1196D | NOTCH1 Gly1196Asp | NOTCH1 NP_060087.3:p.Gly1196Asp | NOTCH1 p.G1196D | NOTCH1 p.Gly1196Asp | NP_060087.3:p.G1196D | NP_060087.3:p.Gly1196Asp | Neurogenic Locus Notch Homolog Protein 1 G1196D | Neurogenic Locus Notch Homolog Protein 1 Gly1196Asp | TAN-1 G1196D | TAN-1 Gly1196Asp | TAN1 G1196D | TAN1 Gly1196Asp | Translocation-Associated Notch Protein TAN-1 G1196D | Translocation-Associated Notch Protein TAN-1 Gly1196Asp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0771339","calteridol","C166724","No value exists.","Calteridol | CALTERIDOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971721","Citenamide","C166472","No value exists.","Citenamide | CITENAMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972197","Isalmadol","C166951","No value exists.","Isalmadol | ISALMADOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971908","Decitropine","C166657","No value exists.","Decitropine | DECITROPINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977295","Locally Advanced Parathyroid Gland Carcinoma","C163958","A parathyroid gland carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Parathyroid Gland Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976947","Radiation Combined Injury Indicator","C163571","An indication as to whether the radiation injury is combined with infectious, physical, thermal, and/or chemical trauma.","Radiation Combined Injury Indicator | CIRNRIND | Combined Injury (Rad and Non-Rad) Ind | Combined Injury (Radiation and Non-Radiation) Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977244","Cetuximab Biobetter HLX07","C163981","A glycoengineered humanized version of the monoclonal antibody of cetuximab, with potential antineoplastic activity. Upon intravenous administration, pimurutamab selectively targets and binds to the extracellular domain of the epidermal growth factor receptor (EGFR), thereby preventing the activation and subsequent dimerization of the receptor. This may prevent EGFR-mediated signaling and inhibit EGFR-dependent tumor cell proliferation.  In addition, the glyco-optimization promotes antibody-dependent cell-mediated cytotoxicity (ADCC). EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surfaces of certain tumor types.","Pimurutamab | Anti-EGFR Monoclonal Antibody HLX-07 | Cetuximab Biobetter HLX07 | HLX 07 | HLX-07 | HLX07 | PIMURUTAMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976883","Carbophenothion","C163637","A synthetic organophosphate acetylcholinesterase inhibitor and neurotoxin that is used as a pesticide. It is characterized as a persistent and highly toxic off-white to yellow/brown liquid with a mild rotten egg odor, and exposure occurs by inhalation, ingestion, or contact.","Carbophenothion | CARBOPHENOTHION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977284","PARTNER-DDS - Diabetes and Me: Moderate","C163937","Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) Diabetes and me: Moderate distress or greater? (mean score > 2).","PARTNER-DDS - Diabetes and Me: Moderate | DDS03-Diabetes and Me: Moderate | DDS0333",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976955","Passive Recreation","C163789","Outdoor recreational activities, such as nature observation, hiking, and canoeing or kayaking, that require a minimum of facilities or development and that have minimal environmental impact on the recreational site.","Passive Recreation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382341","Lesofavumab","C170110","No value exists.","Lesofavumab | LESOFAVUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1379020","FLT4 Protein Variant","C169092","A variation in the amino acid sequence for the vascular endothelial growth factor receptor 3 protein.","FLT4 Protein Variant | FMS-Like Tyrosine Kinase 4 Protein Variant | FMS-Related Tyrosine Kinase 4 Protein Variant | Tyrosine-Protein Kinase Receptor FLT4 Protein Variant | VEGFR-3 Protein Variant | VEGFR3 Protein Variant | Vascular Endothelial Growth Factor Receptor 3 Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378863","LMP7 Inhibitor M3258","C169060","An orally bioavailable, potent, selective, reversible inhibitor of the large multifunctional peptidase 7 (LMP7, Beta5i, PSMB8), a chymotrypsin-like, proteolytic subunit of the immunoproteasome, with potential antineoplastic activity. Upon oral administration, LMP7 inhibitor M3258 targets and inhibits the proteolytic activity of the LMP7 subunit of immunoproteasome, thereby blocking its deubiquitylating activity. This blocks the ubiquitin proteasome degradation pathway, prevents the degradation of defective proteins, and leads to an accumulation of poly-ubiquitylated proteins. This induces the unfolded protein response (UPR) and results in both the induction of tumor cell apoptosis and the inhibition of tumor cell growth. Proteasomes are large multi-subunit protease complexes that degrade unneeded or damaged proteins that have been ubiquitinated, thereby restoring protein homeostasis. Unlike the constitutive proteasome, which is expressed in most tissues, immunoproteasome is specifically present in normal and malignant hematopoietic cells, including multiple myeloma. Immunoproteasome degrades ubiquitinated proteins, generates peptides for presentation on MHC class I, and plays a key role in the adaptive immune response and inflammatory diseases.","LMP7 Inhibitor M3258 | Immunoproteasome Inhibitor M3258 | M 3258 | M-3258 | M3258",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382279","Idazoxan","C170049","No value exists.","Idazoxan | IDAZOXAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383092","EORTC QLQ-CR29 Version 2.1 - Men: Difficulty Getting Erection","C170689","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Colorectal Cancer Module Version 2.1 (EORTC QLQ-CR29 Version 2.1) During the past 4 weeks: For men only: Did you have difficulty getting or maintaining an erection?","EORTC QLQ-CR29 Version 2.1 - Men: Difficulty Getting Erection | EOR06-Men: Difficulty Getting Erection | EOR0657",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015283","Exocytosis","C16568","Cellular release of secretory products from within membrane-limited vesicles or granules.","Exocytosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972336","Modified Vaccinia Ankara-vectored HPV16/18 Vaccine JNJ-65195208","C167362","A booster cancer vaccine comprised of a modified, replication-defective, vaccinia virus Ankara (MVA) Bavarian Nordic (MVA-BN) strain encoding the oncogenic human papillomavirus types 16 (HPV16) and 18 (HPV18), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration of MVA-vectored HPV16/18 vaccine JNJ-65195208, and after the administration of the prime vaccine(s) adenovirus serotype 26 (Ad26)-expressing HPV16 vaccine JNJ-63682918 and/or Ad26-expressing HPV18 vaccine JNJ-63682931, this vaccine further stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16/18 proteins, resulting in tumor cell lysis. HPV16/18 infection plays a key role in the development of a variety of cancers.","Modified Vaccinia Ankara-vectored HPV16/18 Vaccine JNJ-65195208 | JNJ 65195208 | JNJ-65195208 | JNJ65195208 | MVA BN HPV16/18 JNJ-65195208 | MVA-HPV16/18 Vaccine JNJ-65195208 | MVA-vectored HPV16/18 Vaccine JNJ-65195208 | MVA-vectored Vaccine JNJ-65195208 | MVA.HPV16/18 JNJ-65195208 | Modified Vaccinia Ankara-HPV16/18 JNJ-65195208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971358","FACT-COG Version 3 - Problems Interfered Ability Enjoy","C166315","Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Impact on Quality of Life: These problems have interfered with my ability to do things I enjoy.","FACT-COG Version 3 - Problems Interfered Ability Enjoy | FAC075-Problems Interfered Ability Enjoy | FAC07536",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971362","FACT-COG Version 3 - Cognitive Abilities Score","C166319","Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Abilities: Subscale score.","FACT-COG Version 3 - Cognitive Abilities Score | FAC075-Cognitive Abilities Score | FAC07540",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971466","Chemotherapeutic Cycle End Date","C166206","The date on which a chemotherapeutic cycle is ended.","Chemotherapeutic Cycle End Date | date of cycle end | date_of_cycle_end",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978707","ICDC MISC Breeds","C165518","A breed designation assigned by the American Kennel Club while the breed is awaiting acceptance into the AKC Registry.","ICDC MISC Breeds | MISC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1456858","Thoracic Region","C168691","The part of the body located between the cervical and lumbar spinal regions.","Thoracic Region | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406713","Likert Scale 3-Point","C172597","A questionnaire, rating and scale (QRS) data type using a 3-point Likert Scale.","Likert Scale 3-Point | LIKERT SCALE 3-POINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378626","NT5C2 Gene Mutation","C168695","A change in the nucleotide sequence of the NT5C2 gene.","NT5C2 Gene Mutation | 5'-Nucleotidase, Cytosolic II Gene Mutation | NT5B Gene Mutation | NT5CP Gene Mutation | PNT5 Gene Mutation | cN-II Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972491","Point of Maximum Impulse","C168089","A clinical finding demonstrating the pulsation associated with the contraction of the systemic ventricle. Typically associated with the apex of the heart. (ACC/AHA)","Point of Maximum Impulse | PMI | Point of Maximal Impulse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972702","Quality of Palpitations","C168413","The characteristics of the palpitations as described by the patient. (ACC/AHA)","Quality of Palpitations | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972845","Family History of Cardiovascular Disease or Cardiovascular Disease Risk Factors","C168492","A history of a first-degree relative with cardiovascular disease or cardiovascular disease risk factors.","Family History of Cardiovascular Disease or Cardiovascular Disease Risk Factors | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378654","Eligibility for Surgery","C168732","A question pertaining to a patient's eligibility to undergo a surgical procedure.","Eligibility for Surgery | Patient Eligibility for Surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378968","CNS Involvement Table","C168901","A table of data specifically regarding central nervous system involvement.","CNS Involvement Table | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382916","Locally Advanced Endometrial Carcinoma","C170461","Endometrial carcinoma that has spread to nearby tissues or lymph nodes.","Locally Advanced Endometrial Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972643","Medication for Kawasaki Disease","C168324","The medication(s) given to the patient for treatment of Kawasaki disease.","Medication for Kawasaki Disease | Intervention for Kawasaki Disease, Medications",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382928","Skin Spindle Cell/Pleomorphic Lipoma","C170474","A spindle cell/pleomorphic lipoma arising from the skin.","Skin Spindle Cell/Pleomorphic Lipoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972660","No History of Gestational Complication","C168345","An indication that the patient's mother did not have a gestational complication while pregnant with the patient.","No History of Gestational Complication | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382680","Mitemcinal Fumarate","C170187","No value exists.","Mitemcinal Fumarate | MITEMCINAL FUMARATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383145","USP6 Gene Rearrangement","C170735","A molecular abnormality indicating rearrangement of the USP6 gene.","USP6 Gene Rearrangement | HRP1 Gene Rearrangement | TRE17 Gene Rearrangement | TRE2 Gene Rearrangement | TRESMCR Gene Rearrangement | Tre-2 Gene Rearrangement | Ubiquitin Specific Peptidase 6 Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382517","Pegacaristim","C170293","No value exists.","Pegacaristim | PEGACARISTIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405508","SAS Clinical Classification Question","C171415","A question associated with the SAS clinical classification.","SAS Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1611088","Calcium Carbimide","C171758","No value exists.","Calcium Carbimide | CALCIUM CARBIMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406051","Axelopran","C171856","No value exists.","Axelopran | AXELOPRAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039980","Thoracic Injury","C171204","Trauma to the chest.","Thoracic Injury | Chest Injury | Injury to Thorax",,,,,,,,,,,,,,,"4094683","Chest injury",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1405374","Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma","C171158","Ann Arbor Stage II diffuse large B-cell lymphoma with a mass of nodes with one diameter more than 10cm or a mediastinal mass larger than one third of the transthoracic width. (Cotswolds modification)","Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405346","Lactobacillus Probiotic BSL_PS6","C171095","A probiotic composed of a strain of the Gram-positive, naturally-occurring bacterium Lactobacillus, with potential antimicrobial, immunomodulatory and protective activities. Upon oral administration of the Lactobacillus probiotic BSL_PS6, the Lactobacillus strain may improve digestion and help maintain adequate colonization of the gastrointestinal (GI) tract by modulating the composition of the normal microflora. During colonization of the GI tract, this bacterium adheres to human intestinal epithelial cells, and activates intestinal epithelial proliferation. This promotes the formation and maintenance of a protective barrier, thereby preventing the attachment of harmful pathogens. The Lactobacillus produces an acidic environment that is unfavorable for pathogens, thereby further protecting the intestinal mucosa against pathogen-induced damage and a loss of integrity of the intestinal mucosal barrier. Dietary supplementation with this bacterium may decrease intestinal inflammation and enhance intestinal immune responses.","Lactobacillus Probiotic BSL_PS6 | BSL PS6 | BSLPS6 | BSL_PS6 | Lactobacillus Supplement BSL_PS6 | Lactobacillus-based Probiotic BSL_PS6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405407","Estimated Copy Number 5 Percent Confidence Interval","C171184","The lower limit of the 95 percent confidence interval for the estimated copy number.","Estimated Copy Number 5 Percent Confidence Interval | Copy Number 5 Percent Confidence Interval | copy number ci 5 | copy_number_ci_5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383295","Study Data Tabulation Reference Time Point","C171030","The description of a time point that acts as a fixed reference for a series of planned time points, used for study data tabulation.","Study Data Tabulation Reference Time Point | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406580","AGE_AT_LAB","C172691","Age of subject (in days) when the laboratory test was performed.","Age in Days at Time of Laboratory Test | AGE_AT_LAB | Age at Time of Laboratory Test | Age in Days at Laboratory Test | Age in Days at Time of Lab Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2720530","Manometer Device","C172005","A component designed to measure pressure.","Manometer Device | Manometer",,,,,,,,,,,,,,,"45768351","Manometer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1406574","Liver Mixed Adenoneuroendocrine Carcinoma","C172718","A carcinoma that arises from the liver and is characterized by the presence of a malignant glandular epithelial component and a malignant neuroendocrine component.  At least 30 percent of either component should be present for the diagnosis to be made.","Liver Mixed Adenoneuroendocrine Carcinoma | Liver MANEC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406576","Liver Neuroendocrine Tumor G2","C172720","A well-differentiated, intermediate-grade neuroendocrine neoplasm that arises from the liver. The mitotic count is 2-20 per 2 mm2 and/or the Ki-67 index is 3 to 20%.","Liver Neuroendocrine Tumor G2 | Hepatic Neuroendocrine Tumor G2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406754","Digestive System Leiomyosarcoma","C172951","A leiomyosarcoma arising from an anatomic site in the digestive system.","Digestive System Leiomyosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407193","Anti-CD3/Anti-5T4 Bispecific Antibody GEN1044","C173369","A recombinant immunoglobulin G1 (IgG1) bispecific antibody targeting both the human T-cell surface antigen CD3 and oncofetal antigen 5T4, with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD3/anti-5T4 bispecific antibody GEN1044 simultaneously targets and binds to CD3 expressed on T-cells and 5T4 expressed on tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the 5T4-expressing tumor cells. 5T4, a transmembrane glycoprotein, is overexpressed by a variety of cancer cell types; its expression is correlated with increased invasiveness.","Anti-CD3/Anti-5T4 Bispecific Antibody GEN1044 | Anti-CD3/5T4 Bispecific Antibody GEN1044 | DuoBody-CD3x5T4 | GEN 1044 | GEN-1044 | GEN1044",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407324","How Helpful Question","C173563","A question about how helpful something is for an individual.","How Helpful Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406816","MATCH Arm EAY131-Z1M","C173044","The unique identifier assigned to the arm of the Molecular Analysis for Therapy Choice (MATCH) phase II clinical trial that is investigating treatment with nivolumab and relatlimab in patients with progressive neoplastic disease following immune checkpoint inhibitor therapies targeting either PD1 (PDCD1) or PD-L1 (CD247) that are LAG3 positive and have mismatch repair deficiency.","MATCH Arm EAY131-Z1M | EAY131-Z1M | Z1M",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3553328","UV-SENSITIVE SYNDROME 3","C173107","An autosomal recessive condition caused by mutation(s) in the UVSSA gene, encoding UV-stimulated scaffold protein A. it is characterized by cutaneous photosensitivity and slight dyspigmentation, without an increased risk of skin tumors.","UV-Sensitive Syndrome 3 | UVSS3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407217","Distress Over Physical Problem","C173350","A question about an individual's feelings of distress over a physical problem.","Distress Over Physical Problem | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407142","Number of Evaluated HLAs","C173301","The number of human leukocyte antigens that were evaluated.","Number of Evaluated HLAs | NUMBER_HLA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0311242","Gingival Cyst","C173836","An odontogenic cyst found in the alveolar mucosa. (WHO 2017)","Gingival Cyst | ",,,,,,,,,,,,,,,"4240955","Gingival odontogenic cyst",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1407825","Metastatic Vulvar Squamous Cell Carcinoma","C174201","Vulvar squamous cell carcinoma that has spread from its original site of growth to another anatomic site.","Metastatic Vulvar Squamous Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407787","Multi-antigen-directed Autologous T-cells NEXI-002","C174128","A preparation of autologous T-cells targeting several multiple myeloma (MM)-associated antigens, with potential immunomodulating and antineoplastic activities. Peripheral blood mononuclear cells (PBMC) from the patient are collected and ex vivo exposed to nanoparticles that mimic antigen-presenting cells (APCs) loaded with multiple MM-associated antigens, including Wilms' tumor 1 (WT1), CD138 (syndecan-1; SDC1), cancer-testis antigen NY-ESO-1 and CS1 (CD319; CRACC; SLAMF7), and are further enriched and expanded ex-vivo before being re-introduced into the patient. Upon administration, the multi-antigen-directed autologous T-cells NEXI-002 are re-introduced into the patient, where they target and kill tumor cells expressing these antigens.","Multi-antigen-directed Autologous T-cells NEXI-002 | Autologous MM-associated Antigens Specific T Cells NEXI-002 | NEXI 002 | NEXI-002 | NEXI-002 T Cells | NEXI002 | TAA Primed Antigen-specific CD8+ T Cells NEXI-002",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0080059","Proto-Oncogene c-Src","C17389","Proto-oncogene tyrosine-protein kinase Src (536 aa, ~60 kDa) is encoded by the human SRC gene. This protein is involved in both receptor-mediated signal transduction and tyrosine phosphorylation.","Proto-Oncogene Tyrosine-Protein Kinase Src | EC 2.7.10.2 | Proto-Oncogene c-Src | SRC | p60-SRC | p60-Src | p60src | pp60c-src",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412309","Azemiglitazone","C175055","No value exists.","Azemiglitazone | AZEMIGLITAZONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412175","Azeliragon","C174675","An orally bioavailable inhibitor of the receptor for advanced glycation end-products (RAGE), with potential antineoplastic activity. Upon oral administration, azeliragon targets and binds to RAGE, thereby preventing binding of RAGE ligands to RAGE, and prevents RAGE-mediated signaling, This may inhibit proliferation and induce apoptosis of tumor cells in which the RAGE pathway is overactivated. RAGE, a receptor belonging to the immunoglobulin superfamily, plays a key role in inflammation and is overexpressed in a variety of cancers. It plays a key role in tumor cell proliferation, survival and metastasis.","Azeliragon | AZELIRAGON | Azeliragon  | PF-04494700 | TTP488",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412348","Guancydine","C175080","No value exists.","Guancydine | GUANCYDINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1504824","SLC5A5 protein, human","C17536","Sodium/iodide cotransporter (643 aa, ~69 kDa) is encoded by the human SLC5A5 gene. This protein is involved in sodium-dependent iodide transport in the thyroid gland.","Sodium/Iodide Cotransporter | NIS | Na(+)/I(-) Cotransporter | Na(+)/I(-) Symporter | SLC5A5 | Sodium-Iodide Symporter | Solute Carrier Family 5 Member 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412385","Isecarosmab","C175097","No value exists.","Isecarosmab | ISECAROSMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411873","Lanraplenib","C174607","An orally available inhibitor of spleen tyrosine kinase (Syk), with potential immunomodulating and antineoplastic activities. Upon oral administration, lanraplenib binds to and inhibits the activity of Syk. This inhibits B-cell receptor (BCR) signaling, which leads to the inhibition of B-cell activation, and prevents tumor cell activation, migration, adhesion and proliferation. Syk, a non-receptor cytoplasmic, BCR-associated tyrosine kinase, is expressed in hematopoietic tissues and is often overexpressed in hematopoietic malignancies; it plays a key role in B-cell receptor signaling.","Lanraplenib | GS-9876 | LANRAPLENIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412316","Response System Version","C175042","The version of the response system.","Response System Version | RESPONSE_SYSTEM_VERSION | Response Criteria Version",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0122269","T-Cell Leukemia Homeobox Protein 1, Human","C17497","T-cell leukemia homeobox protein 1 (330 aa, ~34 kDa) is encoded by the human TLX1 gene. This protein plays a role in the modulation of transcription.","T-Cell Leukemia Homeobox Protein 1 | HOX11 | HOX11 Protein | Homeo Box 11 | Homeobox Protein HOX11 | Homeobox Protein Hox-11 | Proto-Oncogene Tcl-3 | T-Cell Leukemia 3 Protein | T-Cell Leukemia/Lymphoma Protein 3 | TCL3 Protein | TLX1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412273","Gemibotulinumtoxin A","C174763","No value exists.","Gemibotulinumtoxin A | GEMIBOTULINUMTOXIN A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413159","Pamufetinib","C175733","No value exists.","Pamufetinib | PAMUFETINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642504","ITCH wt Allele","C176436","Human ITCH wild-type allele is located in the vicinity of 20q11.22 and is approximately 178 kb in length. This allele, which encodes E3 ubiquitin-protein ligase Itchy homolog protein, plays a role in the regulation of ubiquitinated protein degradation of inflammatory pathway proteins. Mutation of the gene is associated with multisystem autoimmune disease with facial dysmorphism (ADMFD).","ITCH wt Allele | ADMFD | AIF4 | AIP4 | Itchy (Mouse Homolog) E3 Ubiquitin Protein Ligase Gene | Itchy E3 Ubiquitin Protein Ligase Homolog (Mouse) Gene | Itchy E3 Ubiquitin Protein Ligase Homolog Gene | Itchy E3 Ubiquitin Protein Ligase wt Allele | Itchy E3 Ubiquitin Protein Ligase, Mouse, Homolog of Gene | NAPP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413371","SF-36 v2.0 Acute - General Health 0-100 Score","C176166","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) General health 0-100 score.","SF-36 v2.0 Acute - General Health 0-100 Score | SF364-General Health 0-100 Score | SF36415",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413076","Open or Controlled Data Access Indicator","C175887","Specifies whether the data in a repository is open access or controlled access.","Open or Controlled Data Access Indicator | Data Access Level",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL517775","Primary Breast Angiosarcoma","C176251","An angiosarcoma that arises from the breast parenchyma and is not associated with radiation exposure.","Primary Breast Angiosarcoma | Primary Angiosarcoma of the Breast",,,,,,,,,,,,,,,"36717175","Primary angiosarcoma of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1413335","SF-36 v1.0 Acute - Mental Component Score","C176138","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) Mental component score.","SF-36 v1.0 Acute - Mental Component Score | SF362-Mental Component Score | SF36229",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642797","Hpk1 Inhibitor CFI-402411","C176963","An orally bioavailable inhibitor of the serine/threonine enzyme hematopoietic progenitor kinase-1 (Hpk1; Hpk-1; mitogen-activated protein kinase kinase kinase kinase 1; MAP4K1), with potential immunostimulating and antineoplastic activities. Upon oral administration, Hpk1 inhibitor CFI-402411 targets, binds to and inhibits the activity of Hpk1. This inhibits Hpk1-mediated signaling pathways and inhibits the proliferation of Hpk1-expressing tumor cells. In addition, CFI-402411 prevents Hpk1-mediated immunosuppression by preventing the inhibition of T cell receptors (TCR) signaling and effector T-cells, disrupting abnormal cytokine expression, and abrogating the immunosuppressive tumor microenvironment (TME). This may activate a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Hpk1 is expressed in hematopoietic cells and a negative regulator of TCR and T- and B-cell activation.","Hpk1 Inhibitor CFI-402411 | CFI 402411 | CFI-402411 | CFI402411 | Hematopoietic Progenitor Kinase 1 Inhibitor CFI-402411 | Hpk-1 Inhibitor CFI-402411",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643023","P2X Purinoreceptor Antagonist","C177180","Any agent that binds to and inhibits the activity of the P2X purinoreceptor.","P2X Purinoreceptor Antagonist | P2X Antagonist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643487","Medical Order","C177532","Diagnostic or treatment directives generated by a physician or physician assistant that commands the execution of specific activities to be performed or delivered as part of a diagnostic or therapeutic regimen of a patient.","Medical Order | Order",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0259927","Experimental Hematology","C17819","Basic research in the field of hematology.","Experimental Hematology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0431391","Hemimegalencephaly","C177779","A rare congenital condition in which one half of the brain is abnormally large. It is characterized by developmental delay and severe seizures.","Hemimegalencephaly | Unilateral Megalencephaly",,,,,,,,,,,,,,,"4102689","Hemimegalencephaly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1647532","SF12 v2.0 Acute - Have You Felt Calm and Peaceful","C177879","Short Form 12 Health Survey Acute, US Version 2.0 Questionnaire (SF12 v2.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - have you felt calm and peaceful?","SF12 v2.0 Acute - Have You Felt Calm and Peaceful | SF124-Have You Felt Calm and Peaceful | SF12406A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0729582","Floating-Harbor Syndrome","C175241","An autosomal dominant condition caused by mutation(s) in the SRCAP gene, encoding helicase SRCAP. It is characterized by proportionate short stature, delayed bone age, delayed speech development, and typical facial features.","Floating-Harbor Syndrome | FLHS",,,,,,,,,,,,,,,"4208782","Floating-Harbor syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1412147","Lanraplenib Succinate","C174889","The succinate salt form of lanraplenib, an orally available inhibitor of spleen tyrosine kinase (Syk), with potential immunomodulating and antineoplastic activities. Upon oral administration, lanraplenib binds to and inhibits the activity of Syk. This inhibits B-cell receptor (BCR) signaling, which leads to the inhibition of B-cell activation, and prevents tumor cell activation, migration, adhesion and proliferation. Syk, a non-receptor cytoplasmic, BCR-associated tyrosine kinase, is expressed in hematopoietic tissues and is often overexpressed in hematopoietic malignancies; it plays a key role in B-cell receptor signaling.","Lanraplenib Succinate | LANRAPLENIB SUCCINATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643432","Ovarian Surface Involvement Indicator","C177600","An indication as to whether the surface of the ovary shows evidence of disease.","Ovarian Surface Involvement Indicator | ovarian surface involvement | ovarian_surface_involvement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412096","Octenidine","C174821","No value exists.","Octenidine | OCTENIDINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3710898","CPB2 protein, human","C178158","Carboxypeptidase B2 (423 aa, ~48 kDa) is encoded by the human CPB2 gene. This protein is involved in the cleavage of C-terminal arginine or lysine residues from biologically active peptides and partially degraded fibrin.","Carboxypeptidase B2 | CPB2 | Carboxypeptidase U | EC 3.4.17.20 | Plasma Carboxypeptidase B | TAFI | Thrombin-Activable Fibrinolysis Inhibitor | Thrombin-Activatable Fibrinolysis Inhibitor | pCPB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662178","SARS Coronavirus 2 Spike Glycoprotein Variant Positive","C179605","An indication that expression of SARS coronavirus 2 spike glycoprotein with an amino acid variation has been detected in a sample.","SARS Coronavirus 2 Spike Glycoprotein Variant Positive | SARS Coronavirus 2 S Protein Variant Positive | SARS Coronavirus 2 Spike Glycoprotein Substitution Detected | SARS Coronavirus 2 Spike Glycoprotein Substitution Present | SARS2 Spike Glycoprotein Variant Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648216","HIV Molecular Test Result Provenance","C178937","The origin of a human immunodeficiency virus molecular test result.","HIV Molecular Test Result Provenance | HIV_Molecular_Test_Result_Provenance | Human Immunodeficiency Virus Molecular Test Result Provenance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661892","Cultured Lentinula edodes Mycelia Extract","C179283","An orally bioavailable capsule-based formulation of a standardized extract of cultured Lentinula edodes (Shiitake mushroom) mycelia (ECLM), which is high in the polysaccharides beta- and alpha-glucans, with potential antioxidant, immunomodulating and antineoplastic activities. Upon oral administration, the cultured Lentinula edodes mycelia extract activates the immune system, by binding to toll-like receptors (TLRs), specifically TLR-4, and induces the activation of dendritic cells (DCs), natural killer (NK) cells, macrophages and T-cells and the release of cytokines. This may clear human papillomavirus (HPV) infections.","Cultured Lentinula edodes Mycelia Extract | ACTIVE HEXOSE CORRELATED COMPOUND | AHCC | Cultured Lentinula edodes Mycelia Extract AHCC | ECLM | L. edodes Mycelia Extract AHCC | Lentinula edodes Mycelia Extract | Standardized Extract of Cultured Lentinula edodes Mycelia | Yinuojin Ruanjiaonang",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662168","T-regulatory Cell-enriched Donor Cells","C179619","A preparation of donor-derived T-cells that have been enriched with donor T-regulatory (Treg) cells, with potential immunomodulating activity. Upon administration of the Treg cell-enriched donor cells prior to hematopoietic stem cell transplantation (HSCT), the donor cells may induce tolerance to HSCT and may reduce risk of relapse and graft-versus-host-disease (GVHD) in hematologic malignancies.","T-regulatory Cell-enriched Donor Cells | Treg Cell-enriched Donor Cells | Treg-enriched Donor Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422619","SRR Gene","C178583","This gene plays a role in the conversion of L-serine to D-serine.","SRR Gene | SRR | Serine Racemase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376427","Rehabilitation Nursing","C17959","Rehabilitation nursing is a specialty devoted to assisting individuals of all ages and cultural backgrounds to accomplish the tasks of daily living to their greatest potential and return to their premorbid lifestyle. (ARN)","Rehabilitation Nursing | Restorative Nursing",,,,,,,,,,,,,,,"37158274","Rehabilitation nursing",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3279775","MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 1","C176896","An autosomal recessive condition caused by mutation(s) in the PIGN gene, encoding GPI ethanolamine phosphate transferase 1. Though the phenotype is variable, it may be characterized by neonatal hypotonia, lack of psychomotor development, seizures, dysmorphic features, and variable congenital anomalies involving the cardiac, urinary, and gastrointestinal systems.","Multiple Congenital Anomalies-Hypotonia-Seizures Syndrome 1 | GPIBD3 | Glycosylphosphatidylinositol Biosynthesis Defect 3 | MCAHS1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642827","Inbakicept","C177093","No value exists.","Inbakicept | INBAKICEPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661938","Ovarian Leiomyoma","C179360","A benign smooth muscle neoplasm arising from the ovary. It is usually characterized by the presence of spindle cells with cigar-shaped nuclei, interlacing fascicles, and a whorled pattern. Variants with increased cellularity, increased mitotic activity, myxoid changes, or epithelioid morphology have also been reported.","Ovarian Leiomyoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662052","PDGFRA NP_006197.1:p.K385X","C179243","A change in the amino acid residue at position 385 in the platelet-derived growth factor receptor alpha protein where lysine has been replaced by another amino acid.","PDGFRA NP_006197.1:p.K385X | CD140a Antigen K385X | CD140a Antigen Lys385Xxx | NP_006197.1:p.K385X | NP_006197.1:p.Lys385Xxx | PDGFR-Alpha K385X | PDGFR-Alpha Lys385Xxx | PDGFRA K385 Mutant | PDGFRA K385 Mutation | PDGFRA K385X | PDGFRA K385X Mutation | PDGFRA Lys385Xxx | PDGFRA NP_006197.1:p.Lys385Xxx | PDGFRA p.K385 Mutation | PDGFRA p.K385X | PDGFRA p.Lys385Xxx | Platelet-Derived Growth Factor Receptor Alpha K385X | Platelet-Derived Growth Factor Receptor Alpha Lys385Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643277","Seminoma International Germ Cell Tumor Consensus Risk Classification, Intermediate","C177314","The intermediate prognosis category refers to any primary site and nonpulmonary visceral metastases and normal AFP, any hCG, any LDH.","Seminoma International Germ Cell Tumor Consensus Risk Classification, Intermediate | Seminoma IGCCC, Intermediate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663490","Cervical Mucoepidermoid Carcinoma","C180878","A rare carcinoma that arises from the cervix. It is characterized by the presence of squamous cells, mucus producing cells, and cells of intermediate type.","Cervical Mucoepidermoid Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664347","EORTC QLQ-C30 Version 3 - EOR01-FS:Physical Functioning","C181143","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) Functional scale: physical functioning.","EORTC QLQ-C30 Version 3 - EOR01-FS:Physical Functioning | EOR01-FS:Physical Functioning | EOR0132",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663682","Anti-BCMA Antibody-drug Conjugate","C181108","Any antibody-drug conjugate (ADC) that targets human B-cell maturation antigen (BCMA).","Anti-BCMA Antibody-drug Conjugate | Anti-BCMA ADC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663694","Number of Peripancreatic Lymph Nodes Examined","C181083","The number of peripancreatic nodes that were examined.","Number of Peripancreatic Lymph Nodes Examined | Number of Peripancreatic Lymph Nodes Tested | peripancreatic lymph nodes tested | peripancreatic_lymph_nodes_tested",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663012","SF12 v1.0 Acute - SF-6D_R2 Score","C180456","Short Form 12 Health Survey Acute, US Version 1.0 Questionnaire (SF12 v1.0 Acute) SF-6D_R2 (utility index release 2) score.","SF12 v1.0 Acute - SF-6D_R2 Score | SF122-SF-6D_R2 (Util Index Rel 2) Score | SF12210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647854","Genetic Predisposition to Hematopoietic Disorder","C178384","The predisposition of an individual to develop a hematopoietic disorder based on their heredity.","Genetic Predisposition to Hematopoietic Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648290","SAA2 wt Allele","C178654","Human SAA2 wild-type allele is located in the vicinity of 11p15.1 and is approximately 10 kb in length. This allele, which encodes serum amyloid A-2 protein, plays a role in inflammation.","SAA2 wt Allele | Amyloid A, Serum, 2 Gene | SAA | SAA1 | Serum Amyloid A2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648103","CDK9 Inhibitor KB-0742","C178463","An orally bioavailable, selective inhibitor of the serine/threonine cyclin-dependent kinase 9 (CDK9), the catalytic subunit of the RNA polymerase II (RNA Pol II) elongation factor positive transcription elongation factor b (PTEF-b; PTEFb), with potential antineoplastic activity. Upon oral administration, istisociclib targets, binds to and blocks the phosphorylation and kinase activity of CDK9, thereby preventing PTEFb-mediated activation of RNA Pol II, leading to the inhibition of gene transcription of various anti-apoptotic proteins and oncogenic transcription factors including MYC and androgen receptor (AR). This induces cell cycle arrest and apoptosis and prevents tumor cell proliferation. CDK9 regulates elongation of transcription through phosphorylation of RNA Pol II at serine 2 (p-Ser2-RNAPII), and is an important cofactor for various oncogenic transcription factors. It is upregulated in various tumor cell types and plays a key role in the regulation of Pol II-mediated transcription of anti-apoptotic proteins. Tumor cells are dependent on anti-apoptotic proteins for their survival.","Istisociclib | CDK9 Inhibitor KB-0742 | CDK9 Inhibitor KB-0742 | Cyclin-dependent Kinase 9 Inhibitor KB-0742 | ISTISOCICLIB | KB 0742 | KB-0742 | KB0742",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648411","Mibavademab","C179103","No value exists.","Mibavademab | MIBAVADEMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663408","Pelgifatamab Corixetan","C180654","No value exists.","Pelgifatamab Corixetan | PELGIFATAMAB CORIXETAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663468","BLU 263","C180833","An orally bioavailable protein tyrosine kinase inhibitor of the mutated form of the tumor-associated antigen (TAA) mast/stem cell factor receptor c-Kit (SCFR), D816V, with potential antineoplastic activity. Upon oral administration, elenestinib binds to and inhibits the specific c-Kit mutant D816V. This may result in an inhibition of cell proliferation in mast cells that overexpress this c-Kit mutation. D816V, a mutation in which the amino acid asparagine aspartic acid at position 816 in the mast/stem cell growth factor receptor Kit protein is replaced by valine, may drive mastocytosis and other mast cell disorders.","Elenestinib | BLU 263 | BLU-263 | BLU263 | D816V-mutant KIT Inhibitor BLU-263 | ELENESTINIB | KIT D816V Mutant-selective Inhibitor BLU-263 | KIT D816V Mutant-selective Inhibitor BLU-263",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773251","Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 40","C182733","Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 40 - Disabled; requires special care and assistance.","Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 40 | 40 | KPSS0101-40",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771226","Kurtzke Functional System Scores KFSS103 Standardized Character Result 3","C182810","Kurtzke Functional System Scores KFSS103 Standardized Character Result 3 - Severe nystagmus, marked extraocular weakness, or moderate disability of other cranial nerves.","Kurtzke Functional System Scores KFSS103 Standardized Character Result 3 | 3 | KFSS103-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1770963","International Prostate Symptom Score IPS0101 Through IPS0106 Original Result - Almost Always","C182639","International Prostate Symptom Score IPS0101 Through IPS0106 Original Result - Almost always.","International Prostate Symptom Score IPS0101 Through IPS0106 Original Result - Almost Always | Almost Always | IPS0101 through IPS0106-Almost Always",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771231","Kurtzke Functional System Scores KFSS104 Standardized Character Result 1","C182823","Kurtzke Functional System Scores KFSS104 Standardized Character Result 1 - Vibration or figure-writing decrease only, in one or two limbs.","Kurtzke Functional System Scores KFSS104 Standardized Character Result 1 | 1 | KFSS104-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771119","Abnormal Sensation of Face and Limbs","C182425","Sensations of the face and limbs that are not considered normal.","Abnormal Sensation of Face and Limbs | Abnormal sensation of face and limbs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771257","Kurtzke Functional System Scores KFSS105 Standardized Character Result 2","C182840","Kurtzke Functional System Scores KFSS105 Standardized Character Result 2 - Moderate hesitancy, urgency, retention of bowel or bladder, or rare urinary incontinences.","Kurtzke Functional System Scores KFSS105 Standardized Character Result 2 | 2 | KFSS105-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1770971","International Prostate Symptom Score IPS0109 Original Result - Mostly dissatisfied","C182662","International Prostate Symptom Score IPS0109 Original Result - Mostly dissatisfied.","International Prostate Symptom Score IPS0109 Original Result - Mostly dissatisfied | IPS0109-Mostly dissatisfied | Mostly dissatisfied",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662668","FACT-BP Version 4 - How Many Places in Body Felt Pain","C180023","Functional Assessment of Cancer Therapy-Bone Pain Version 4 (FACT-BP Version 4) for patients with bone pain: In how many places in your body have you felt bone pain.","FACT-BP Version 4 - How Many Places in Body Felt Pain | FAC074-How Many Places in Body Felt Pain | FAC07401",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662639","Uterine Ligament Ependymoma","C179928","A rare neoplasm that arises from the broad or other uterine ligaments and shows ependymal differentiation.","Uterine Ligament Ependymoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662926","EGFR/CD3-targeting T-cell Engaging Molecule TAK-186","C180595","A T-cell engaging bispecific antibody and Conditional Bispecific Redirected Activation (COBRA) protein targeting both the tumor-associated antigen (TAA) epidermal growth factor receptor (EGFR; HER1; ErbB1) and the T-cell surface antigen CD3, and containing a protease cleavable linker and a human serum albumin (HSA) binding part, with potential immunostimulating and antineoplastic activities. Upon administration, EGFR/CD3-targeting T-cell engaging moleculeTAK-186 is cleaved by proteases in the tumor microenvironment (TME). Upon cleavage, TAK-186 dimerizes to form the active molecule and binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and EGFR on EGFR-expressing tumor cells. This activates and redirects CTLs to EGFR-expressing tumor cells, leading to CTL-mediated killing of EGFR-expressing tumor cells. EGFR, upregulated and/or mutated in a variety of tumor cell types, plays a key role in tumor cell proliferation. The albumin-binding domain targets and binds to serum albumin, thereby extending the serum half-life of the inactivated TAK-186. Upon cleavage of the HSA-binding component, the activated TAK-186 dimer will be eliminated after cancer cell killing; this improves the safety profile of this agent by reducing its ability to cause damage to healthy cells.","EGFR/CD3-targeting T-cell Engaging Molecule TAK-186 | CD19 x CD3 T-BsAb TNB-486 | COBRA Protein MVC-101 | Conditionally Active T- cell Engager MVC-101 | EGFR x CD3 Conditional Bispecific Redirected Activation Protein MVC-101 | EGFR/CD3-engaging Conditionally Active Bispecific Antibody MVC-101 | MVC 101 | MVC-101 | MVC101 | TAK 186 | TAK-186 | TAK186",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662501","PT01-Bloating Frequency","C180061","Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events Item Library Version 1.0 (PRO-CTCAE V1.0) In the last 7 days, how often did you have bloating of the abdomen (belly)?","PRO-CTCAE V1.0 - Bloating Frequency | PRO-CTCAE V1.0 Version Date 4/26/2020 - Bloating Frequency | PT01-Bloating Frequency | PT01013A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663047","Beta Tubulin Polymerization Inhibitor CCI-001","C180528","A colchicine derivative and beta tubulin polymerization inhibitor, with potential antineoplastic activity. Upon administration, beta tubulin polymerization inhibitor CCI-001 targets, binds to and inhibits beta-III tubulin (TUBB3), and prevents tubulin polymerization and destabilizes microtubules, ultimately leading to cell cycle arrest, blockage of cell division and an induction of cell death in cancer cells. TUBB3, overexpressed in many cancers, is associated with poor outcomes and a reduced response to taxane-based microtubule-targeting antineoplastic agents.","Beta Tubulin Polymerization Inhibitor CCI-001 | CCI 001 | CCI-001 | CCI001 | Colchicine Derivative CCI-001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663135","Combat Exposure Scale CES0104 Original Result - 26-50%","C180278","Combat Exposure Scale CES0104 Original Result - 26-50%.","Combat Exposure Scale CES0104 Original Result - 26-50% | 26-50% | CES0104-26-50%",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664728","Daunorubicin/Methotrexate/Pegaspargase/Prednisone/Vincristine Regimen","C181654","A regimen consisting of daunorubicin, methotrexate, pegaspargase, prednisone and vincristine that can be used for the treatment of acute lymphoblastic leukemia (ALL).","Daunorubicin/Methotrexate/Pegaspargase/Prednisone/Vincristine Regimen | Daunorubicin-Methotrexate-Pegaspargase-Prednisone-Vincristine | Daunorubicin-Methotrexate-Pegaspargase-Prednisone-Vincristine Regimen | Daunorubicin/Methotrexate/Pegaspargase/Prednisone/Vincristine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772633","CDISC SDTM Holter ECG Read Method Response Terminology","C184330","Terminology associated with the holter ECG read method response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Holter ECG Read Method Response Terminology | HEGRDMTH | Holter ECG Read Method Response | SDTM-HEGRDMTH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664827","CRISPR-Cas9 Engineered TGFbRII-deleted Anti-EGFR CAR T-cells","C182002","A preparation of human T-lymphocytes genetically engineered to express an anti-epidermal growth factor receptor (EGFR) chimeric antigen receptor (CAR) gene and gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to disrupt expression of transforming growth factor-beta receptor II (TGFbRII), with potential immunostimulatory and antineoplastic activities. Upon administration, the CRISPR-Cas9 engineered TGFbRII-deleted anti-EGFR CAR T-cells target and bind to the EGFR antigen on tumor cell surfaces; subsequently, EGFR-expressing tumor cells may be lysed. EGFR, overexpressed by a variety of cancer cell types, plays a key role in tumor cell proliferation, tumor angiogenesis and radio- and chemoresistance. By knocking out the expression of TGFbRII, the immunosuppressive cytokine TGF-beta is unable to bind to the T-cells and prevent the activation of the T-cells. TGF-beta contributes to the immunosuppressive nature of the tumor microenvironment (TME), and plays a key role in promoting tumor initiation, metastasis, and suppressing anti-tumor immunity.","CRISPR-Cas9 Engineered TGFbRII-deleted Anti-EGFR CAR T-cells | TGFbR-KO CAR-EGFR T Cells | TGFbeta Receptor II-Knockout EGFR CAR T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664735","SSRP1 wt Allele","C181636","Human SSRP1 wild-type allele is located in the vicinity of 11q12.1 and is approximately 10 kb in length. This allele, which encodes FACT complex subunit SSRP1 protein, plays a role in the regulation of mRNA elongation, DNA replication and DNA repair.","SSRP1 wt Allele | Chromatin-Specific Transcription Elongation Factor, 80-kD Gene | Cisplatin-DNA SSRP Gene | FACT | FACT, 80-kD Subunit Gene | FACT80 | Structure Specific Recognition Protein 1 wt Allele | T160",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812299","FOSL1 Gene","C18415","This gene plays a role in osteoclast differentiation and transcriptional activation.","FOSL1 Gene | FOS Like 1, AP-1 Transcription Factor Subunit Gene | FOS-Like Antigen 1 Gene | FOSL1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772939","Emprumapimod","C184878","No value exists.","Emprumapimod | EMPRUMAPIMOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1770655","Nucleotide Sequencing Site Name","C182036","The name of the site that performed nucleotide sequencing on a sample.","Nucleotide Sequencing Site Name | Nucleotide Sequencing Center Name | sequencing center | sequencing_center",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664798","Age in Years of Patient Relative at Cancer Diagnosis","C181704","The age in years at which the relative of a subject was first diagnosed with cancer.","Age in Years of Patient Relative at Cancer Diagnosis | relationship age at diagnosis | relationship_age_at_diagnosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2976209","MLST8 protein, human","C181675","Target of rapamycin complex subunit LST8 (326 aa, ~36 kDa) is encoded by the human MLST8 gene. This protein plays a role in cell processes that are mediated by serine/threonine-protein kinase mTOR signaling pathways.","Target of Rapamycin Complex Subunit LST8 | G Protein Beta Subunit Like | G Protein Beta Subunit-Like | G Protein Beta Subunit-Like Protein | G-Beta-Like Protein | Gable | MTOR Associated Protein LST8 | Mammalian Lethal With SEC13 Protein 8 | Protein GbetaL | TORC Subunit LST8 | mLST8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1770694","Cardiomyopathy, Familial Hypertrophic, 3","C182076","An autosomal dominant subtype of familial hypertrophic cardiomyopathy caused by mutation(s) in the TPM1 gene, encoding tropomyosin alpha-1 chain.","Familial Hypertrophic Cardiomyopathy Type 3 | CMH3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664668","HCMI Catalog Reference Number","C181735","The reference number used in the Human Cancer Models Initiative (HCMI) catalog.","HCMI Catalog Reference Number | catalog reference | catalog_reference",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1770660","Number of Recovered Cells Expected","C182045","The number of cells one expected to recover during single cell isolation.","Number of Recovered Cells Expected | number expect cells | number_expect_cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1770828","Spinal Leptomeningeal Distant Disease Type","C182219","An indication the distant disease type is spinal/leptomeningeal.","Spinal Leptomeningeal Distant Disease Type | Spinal leptomeningeal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778253","Leuprolide Acetate for Injectable Suspension TOL2506","C185872","A subcutaneous injectable suspension formulation containing the acetate salt form of leuprolide, a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH), with potential antineoplastic activity. Upon subcutaneous administration of the leuprolide acetate for injectable suspension TOL2506, leuprolide binds to and activates the gonadotropin-releasing hormone receptor (GnRHR). The continuous stimulation of GnRHR by leuprolide results in both the desensitization of pituitary GnRHR and the inhibition of pituitary secretion of the gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH). In males, this results in a significant decline in testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression. In females, this decreases estradiol production and level, suppresses ovarian function and may inhibit proliferation of estrogen receptor (ER)-positive breast cancer.","Leuprolide Acetate for Injectable Suspension TOL2506 | TOL 2506 | TOL-2506 | TOL2506",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516247","Carbohydrate Chemistry","C18677","Chemistry of molecules having the form Cn(H2O)n","Carbohydrate Chemistry | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513397","Molecular Medicine","C18885","The branch of medicine that tries to understand disease processes by understanding the way that genes, proteins, and molecules interact; also concerned with genetically based treatments.","Molecular Medicine | molecular medicine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778692","Treatment Free Epoch","C186262","A period in a study immediately following the end of treatment during which the subject(s) is no longer receiving investigational therapy or treatment and is not being assessed.","Treatment Free Epoch | TREATMENT FREE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778642","HL Concomitant Medication Table","C186329","Terminology created by EVS and PCDC to support the HL Concomitant Medication Table.","HL Concomitant Medication Table | Concomitant Medication Table | Hodgkin's Lymphoma Concomitant Medication Table",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772359","FACIT-Searchable Item Library Adult Version - Pain/Soreness/Aches in Some Muscles","C184037","Functional Assessment of Chronic Illness Therapy-Searchable Item Library Adult Version (FACIT-Searchable Item Library Adult Version) I feel pain, soreness or aches in some of my muscles.","FACIT-Searchable Item Library Adult Version - Pain/Soreness/Aches in Some Muscles | FSIL-Pain/Soreness/Aches in Some Muscles | FSIL0420",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772445","FACIT-Searchable Item Library Adult Version - Had Change in the Way Food Tastes","C183999","Functional Assessment of Chronic Illness Therapy-Searchable Item Library Adult Version (FACIT-Searchable Item Library Adult Version) I have had a change in the way food tastes.","FACIT-Searchable Item Library Adult Version - Had Change in the Way Food Tastes | FSIL-Had Change in the Way Food Tastes | FSIL0382",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772590","FACIT-Searchable Item Library Adult Version - Recommend This Treatment to Others","C184277","Functional Assessment of Chronic Illness Therapy-Searchable Item Library Adult Version (FACIT-Searchable Item Library Adult Version) Would you recommend this treatment to others with your illness?","FACIT-Searchable Item Library Adult Version - Recommend This Treatment to Others | FSIL-Recommend This Treatment to Others | FSIL0660",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772484","Natural Killer T-Lymphocyte Count","C184426","The determination of the number of the natural killer T-lymphocytes in a sample.","Natural Killer T-Lymphocyte Count | NK TLym | NK Tlym | NKT | Natural Killer T-Cells | Natural Killer T-Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772420","FACIT-Searchable Item Library Adult Version - I Have Pain","C183978","Functional Assessment of Chronic Illness Therapy-Searchable Item Library Adult Version (FACIT-Searchable Item Library Adult Version) I have pain.","FACIT-Searchable Item Library Adult Version - I Have Pain | FSIL-I Have Pain | FSIL0361",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772274","FACIT-Searchable Item Library Adult Version - I Have Trouble Learning New Tasks","C184092","Functional Assessment of Chronic Illness Therapy-Searchable Item Library Adult Version (FACIT-Searchable Item Library Adult Version) I have trouble learning new tasks or directions.","FACIT-Searchable Item Library Adult Version - I Have Trouble Learning New Tasks | FSIL-I Have Trouble Learning New Tasks | FSIL0475",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1721338","17beta-hydroxysteroid dehydrogenase type 12, human","C184998","Very-long-chain 3-oxoacyl-CoA reductase (312 aa, ~34 kDa) is encoded by the human HSD17B12 gene. This protein is involved in fatty acid elongation and estrogen synthesis.","Very-Long-Chain 3-Oxoacyl-CoA Reductase | 17-Beta-HSD 12 | 17-Beta-Hydroxysteroid Dehydrogenase 12 | 3-Ketoacyl-CoA Reductase | EC 1.1.1.330 | EC 1.1.1.62 | Estradiol 17-Beta-Dehydrogenase 12 | HSD17B12 | Hydroxysteroid 17-Beta Dehydrogenase 12 | KAR | Short Chain Dehydrogenase/Reductase Family 12C Member 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771815","FACIT-Searchable Item Library Adult Version - I Feel Depressed about Bone Pain","C183694","Functional Assessment of Chronic Illness Therapy-Searchable Item Library Adult Version (FACIT-Searchable Item Library Adult Version) I feel depressed about my bone pain.","FACIT-Searchable Item Library Adult Version - I Feel Depressed about Bone Pain | FSIL-I Feel Depressed about Bone Pain | FSIL0077",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426838","SIPA1L1 Gene","C185754","This gene plays a role in the activation of the small GTPase RAP2A.","SIPA1L1 Gene | SIPA1L1 | Signal Induced Proliferation Associated 1 Like 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332006","ACF complex","C20154","The Drosophila gene Acf1 encodes ATP-dependent chromatin assembly factor large subunit, a component of the chromatin assembly complex involved in chromatin assembly/disassembly.  Acf1 contains a PHD-finger and is able to modulate the internucleosomal spacing of chromatin by an ATP-dependent mechanism.  Similar sequences have been identified in Caenorhabditis elegans, Homo sapiens, Mus musculus, and Saccharomyces cerevisiae.  (from FlyBase 0027620 and NCI)","ACF complex | ACF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1722213","LRRK1 protein, human","C185556","Leucine-rich repeat serine/threonine-protein kinase 1 (2015 aa, ~225 kDa) is encoded by the human LRRK1 gene. This protein is involved in serine/threonine phosphorylation and osteoclast resorption of bone.","Leucine-Rich Repeat Serine/Threonine-Protein Kinase 1 | EC 2.7.11.1 | LRRK1 | Leucine Rich Repeat Kinase 1 | Leucine-Rich Repeat Kinase 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335241","PPP2CA Gene","C20398","This gene plays a role in the inhibition of the G2-M transition in the cell cycle.","PPP2CA Gene | PPP2CA | Protein Phosphatase 2 (Formerly 2A), Catalytic Subunit, Alpha Isoform Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773703","Biopsy of Distant Site for Staging","C185530","The biopsy of a site distant to the primary site to determine the stage of disease.","Biopsy of Distant Site for Staging | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778976","Nivolumab/Relatlimab-rmbw","C186440","An injectable fixed-dose combination formulation composed of nivolumab, a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), and relatlimab-rmbw, a human IgG4 monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration of nivolumab and relatlimab-rmbw, nivolumab binds to and blocks the activation of PD-1 by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This prevents PD-1-mediated signaling and PD-1-mediated inhibition of the immune response. Relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs) and prevents LAG-3 binding to major histocompatibility complex (MHC) class II. This prevents LAG-3-mediated signaling and LAG-3-mediated inhibition of the immune response. Together, blocking these two immune checkpoints re-activates the immune system, increases cytotoxic T-lymphocytes (CTLs) proliferation and activation, and leads to a reduction in tumor growth. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity. LAG-3 expression on TILs is associated with tumor-mediated immune suppression.","Nivolumab/Relatlimab-rmbw | BMS 986213 | BMS-986213 | BMS986213 | Nivolumab and Relatlimab | Nivolumab and Relatlimab-rmbw | Nivolumab and relatlimab | Nivolumab-Relatlimab-rmbw | Nivolumab/Relatlimab-rmbw Injectable Formulation | Opdivo/Relatlimab-rmbw | Opdualag | Relatlimab-rmbw and Nivolumab | Relatlimab-rmbw-Nivolumab | Relatlimab-rmbw/Nivolumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773126","ZDHHC20 wt Allele","C185082","Human ZDHHC20 wild-type allele is located in the vicinity of 13q12.11 and is approximately 87 kb in length. This allele, which encodes palmitoyltransferase ZDHHC20 protein, plays a role in lipoprotein synthesis.","ZDHHC20 wt Allele | 4933421L13Rik | DHHC-20 | DHHC20 | FLJ25952 | Zinc Finger DHHC-Type Containing 20 Gene | Zinc Finger DHHC-Type Palmitoyltransferase 20 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778531","Effector Helper T-Lymphocyte Count","C185924","The determination of the number of helper effector T-lymphocytes in a sample.","Effector Helper T-Lymphocyte Count | T-Lymphocytes Helper Effector | TLHE | TLym Help Eff",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0963824","MGN3","C1879","An arabinoxylane polysaccharide composed of the hemicellulose-Beta extract of rice bran, treated with enzymes from Shiitake mushrooms, that exerts antitumor and antiviral activity by increasing the level of natural killer cells activation. (NCI)","Arabinoxylan Compound MGN3 | Arabinoxylan Compound | Biobran | MGN3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773936","CIDEB wt Allele","C185584","Human CIDEB wild-type allele is located in the vicinity of 14q12 and is approximately 6 kb in length. This allele, which encodes cell death activator CIDE-B protein, plays a role in the positive regulation of apoptosis and assembly and host cell entry for hepatatis C virus. Mutation of the gene may increase the risk of alcohol-related liver disease and non-alcoholic fatty liver disease.","CIDEB wt Allele | CIDE-B | Cell Death Inducing DFFA Like Effector B wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516916","Epidemiology, Tobacco, Alcohol, Drugs","C18774","The consideration of tobacco, alcohol, or drug use as variables in disease incident, transmission, and control.","Epidemiology, Tobacco, Alcohol, Drugs | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517021","Exploratory/Developmental Grant for Diagnostic Cancer Imaging","C19262","The Diagnostic Imaging Program (DIP), of the Division of Cancer Treatment and Diagnosis (DCTD) solicits exploratory/developmental (R21) grants that articulate highly innovative research concepts in diagnostic cancer imaging to provide investigators with the initial resources required to accomplish feasibility and pilot testing of innovative ideas. The R21 mechanism will provide investigators at all career levels with a defined level of funding adequate for the initial feasibility testing of high risk/high impact concepts and, if the concepts are viable, for the generation of experimental preliminary data. This would render the investigators competitive for funding through the research project grant (R01) and/or First Independent Research Support and Transition (FIRST) (R29) award mechanisms, thus potentially leading to the establishment of new research programs in areas that might have previously remained unexplored.","Exploratory/Developmental Grant for Diagnostic Cancer Imaging | R21 Award",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514808","Reduction of Opportunistic Illness","C18994","Undertake epidemiologic research to reduce or prevent the occurrence of OIs in HIV-infected persons.","Reduction of Opportunistic Illness | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512007","DNase-I Footprinting","C19898","A DNA footprinting method which is commonly used for analyzing specific protein-DNA interactions. In this technique, a restriction fragment containing a specific binding site is labeled at one end and digested with DNAseI. The result is a ladder of bands, representing the various sites at which DNase I cuts. The distribution of radioactivity is visualized by autoradiography.","DNase-I Footprinting | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513823","NCI Director's Consumer Liaison Group","C19227","The Director's Consumer Liaison Group (DCLG) is a group of fifteen members of the cancer advocacy community who were convened to help NCI increase the representation of the cancer advocacy community on NCI advisory committees, and increase their involvement in program and policy development.  DCLG members will interact directly with the scientific community at NCI on a wide range of programs and issues. The DCLG will also help NCI to widen the pool of qualified consumer-advocates who can be called upon to serve on NCI advisory committees and other groups. (2/99)","NCI Director's Consumer Liaison Group | DCLG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516734","Community Oncology and Rehabilitation Branch","C19280","Part of the Division of Cancer Prevention.  Develops programs to improve clinical oncology in community settings and coordinates community oncology program activities with the activities of other research programs of the National Cancer Program; Promotes interaction between community oncologists and regional or national clinical cooperative groups; Stimulates psychosocial and physical rehabilitation research; Develops and conducts research on the management of cancer pain; develops research in the area of supportive care for patients and families; Studies the impact of cancer control programs on the community; and Conducts preliminary Phase II cancer control) studies of education, attitudes, and behavior of physicians, nurses, and other health professionals to serve as the basis for subsequent cancer control studies.","Community Oncology and Rehabilitation Branch | CORB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518515","Nutritional Toxin","C1923","Toxins present in food or water.","Nutritional Toxin | Dietary Toxin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514299","Preclinical Models for Human Cancers Working Group","C19523","No value exists.","Preclinical Models for Human Cancers Working Group | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334914","NURF","C19801","The Drosophila NURF complex catalyzes nucleosome sliding.  The Nurf301 subunit contains a bromodomain transcription factor domain, a zinc finger binding domain, nuclear localization signals, and motifs associated with rapid protein degradation.  The HMGA/HMGI(Y)-like domain of Nurf301 facilitates nucleosome sliding.  Nurf301 also interacts with sequence-specific transcription factors, providing a basis for targeted recruitment of the NURF complex to specific genes.  (from OMIM 601819, SWISS-PROT Q24572, O77460, Q24368, and NCI)","NURF | Nucleosome Remodeling Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519135","SF-12","C20079","A 12 question subset of the SF-36.  Designed to be administered in a shorter time.","SF-12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519238","Senior Scientist Award","C20034","The Senior Scientist Award (K05) provides stability of support to outstanding scientists who have demonstrated a sustained, high level of productivity and whose expertise, research accomplishments, and contributions to the field have been and will continue to be critical to the mission of the particular NIH center or institute.  The award provides salary support for award periods of five years as a means of enhancing the individual recipient's skills and dedication to his/her area of research.","Senior Scientist Award | K05 Award",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511673","DNA Interstrand Cross-Link Repair","C20225","DNA interstrand cross-links (ICLs) are very toxic to dividing cells, because they induce mutations, chromosomal rearrangements and cell death. A number of multi-step DNA repair pathways including nucleotide excision repair, homologous recombination and post-replication/translesion repair all impinge on their repair.","DNA Interstrand Cross-Link Repair | Repair of DNA Interstrand Cross-Links",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334752","Microfilament Gene","C20746","A gene that encodes cytoskeletal microfilament proteins.","Microfilament Gene | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521990","Hot Spots (Area of Increased Mortality)","C19744","A center of high activity within a larger area of low activity. The term is applied to different things in different areas of study.","Hot Spot | Hot Spots (Area of Increased Mortality)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512132","ES03","C20251","Provider: ES Cell International Pte Ltd., Melbourne, Australia. Information from provider and not independently verified by NIH: Cells are positive for cell markers Oct-4, SSEA-4, TRA-1-60, GCTM-2, and alkaline phosphatase activity; Cells are negative for cell marker SSEA-1; Give rise to teratomas containing derivatives of three germ layers in SCID mice; Differentiate in vitro into extraembryonic and somatic cell lineages; Neural progenitor cells may be isolated from differentiating ES cell cultures and induced to form mature neurons; Available for distribution. This cell line meets the criteria for the use of human embryonic stem cells by federally funded researchers.","ES03 | HES-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335783","Ribonucleotide Reductase Subunit","C21212","Encoded by Ribonucleotide Reductase Subunit Genes (RRM1 and RRM2), the M1 Chain and M2 Chain subunits compose Ribonucleoside-Diphosphate Reductase, a heterodimeric cytoplasmic enzyme essential in dividing cells that reduces ribonucleotides to deoxyribonucleotide precursors for DNA synthesis in S phase. Enzyme activity closely correlates with the cellular rate of growth and appears to vary with the cell cycle. A substrate site and catalytic site regulate enzyme activity. Allosteric control by deoxynucleoside triphosphates and by ATP bound to M1 prevents DNA replication and cell proliferation. An M1 catalytic site only forms in the presence of M2. M2 synthesis is cell-cycle dependent. p53 regulates ribonucleotide reductase by interaction with p53R2 as well as the M2 subunit. (NCI)","Ribonucleotide Reductase Subunit | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1450831","TNF Receptor-Associated Factor 4, Human","C21163","TNF receptor-associated factor 4 (470 aa, ~54 kDa) is encoded by the human TRAF4 gene. This protein plays a role in the modulation of TNF receptor superfamily-dependent signaling.","TNF Receptor-Associated Factor 4 | Cysteine-Rich Domain Associated With RING And Traf Domains Protein 1 | Cysteine-Rich Domain Associated With Ring and TRAF Domains | MLN 62 | MLN62 Protein | Malignant 62 | Metastatic Lymph Node Gene 62 Protein | RING Finger Protein 83 | TRAF4 | TRAF4 Protein | Tumor Necrosis Receptor-Associated Factor 4 | Tumor Necrosis Receptor-Associated Factor 4A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518661","Other Mouse Melanoma","C21797","No value exists.","Other Mouse Melanoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521890","Mouse Subependymal Giant Cell Astrocytoma","C21943","No value exists.","Mouse Subependymal Giant Cell Astrocytoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514220","Poorly-differentiated Squamous Cell Carcinoma of the Mouse Skin","C21809","No value exists.","Poorly-differentiated Squamous Cell Carcinoma of the Mouse Skin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038931","OR Nursing","C20879","Nursing that is concerned with patient care during the preoperative, intraoperative, and postoperative phases of surgery.","OR Nursing | Operating Room Nursing | Perioperative Nursing | Surgical Nursing",,,,,,,,,,,,,,,"37158273","Perioperative nursing",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517537","Gerontological Nurse Specialist","C20837","Clinical specialists in gerontological nursing are experts in providing, directing, and influencing the care of older adults and their families and significant others in a variety of settings. Clinical specialists demonstrate an in-depth understanding of the dynamics of aging, as well as of the interventions necessary for health promotion and management of health status alterations. Clinical specialists provide comprehensive gerontological nursing services independently or collaboratively with multidisciplinary teams. Through theory and research; clinical specialists advance the health care of older adults and the specialty of gerontological nursing. Clinical specialists are engaged in practice, case management, education, consultation, research, and administration. (ANCC)","Gerontological Nurse Specialist | Clinical Specialist in Gerontological Nursing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516500","Chondroma of the Mouse Skeletal System, NOS","C22966","No value exists.","Chondroma of the Mouse Skeletal System, NOS | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333254","DRD4 Gene","C24351","This gene plays a role in G protein-coupled receptor signal transduction and inhibits adenylyl cyclase activity.","DRD4 Gene | DRD4 | Dopamine Receptor D4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522273","Kidney - Cortex - Renal Tubule - Collecting Duct (MMHCC)","C22734","No value exists.","Mouse Collecting Duct | Kidney - Cortex - Renal Tubule - Collecting Duct (MMHCC) | Mouse Collecting Tube | Mouse Collecting Tubule | Mouse Renal Collecting Tubule | Mouse Renal Tubule Collecting Duct | Mouse Straight Tube",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513517","Mouse Cancer-Related Conditions","C23987","No value exists.","Mouse Cancer-Related Conditions | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518936","Pedunculated Tubular Adenoma of the Mouse Intestinal Tract","C22140","No value exists.","Pedunculated Tubular Adenoma of the Mouse Intestinal Tract | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513596","Mouse Gastric Pylorus Carcinoma","C24233","No value exists.","Mouse Gastric Pylorus Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522355","Malignant Mouse Thyroid Neoplasm","C24164","No value exists.","Malignant Mouse Thyroid Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522218","Mouse Testicular Germ Cell","C22179","No value exists.","Mouse Testicular Germ Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336984","DCAF5 Gene","C24263","This gene plays a role in signal transduction.","DCAF5 Gene | DCAF5 | DDB1 and CUL4 Associated Factor 5 Gene | WDR22",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522159","Mouse Chordoid Meningioma","C22024","No value exists.","Mouse Chordoid Meningioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515495","9p12-p11","C25124","A chromosome band present on 9p","9p12-p11 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334469","SMAD6 Gene","C24567","This gene is involved in signal transduction and regulation of transcription. It also plays a role in development.","SMAD6 Gene | SMAD Family Member 6 Gene | SMAD6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333731","GPR17 protein, human","C26196","Uracil nucleotide/cysteinyl leukotriene receptor (367 aa, ~41 kDa) is encoded by the human GPR17 gene. This protein plays a role in ligand-dependent G protein-coupled receptor signaling.","Uracil Nucleotide/Cysteinyl Leukotriene Receptor | G Protein-Coupled Receptor 17 | G-Protein Coupled Receptor 17 | GPR17 | P2Y-Like Receptor | Probable P2Y Purinoceptor GPR17 | R12 | UDP/CysLT Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1307877","CMKLR1 protein, human","C25985","Chemerin-like receptor 1 (373 aa, ~42 kDa) is encoded by the human CMKLR1 gene. This protein plays a role in chemoattraction, adipogenesis, angiogenesis, and bone development.","Chemerin-Like Receptor 1 | CMKLR1 | Chemerin Receptor | Chemokine-Like Receptor 1 | Chemokine-Like Receptor 1 | G Protein-Coupled Receptor ChemR23 | G Protein-Coupled Receptor DEZ | G-Protein Coupled Receptor ChemR23 | G-Protein Coupled Receptor DEZ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0950979","Arzoxifene Hydrochloride","C2460","The hydrochloride salt of arzoxifene, a synthetic aromatic derivative with anti-estrogenic properties. Arzoxifene binds to estrogen receptors as a mixed estrogen agonist/antagonist. In comparison to other selective estrogen receptor modulators (SERMs), arzoxifene exhibits greater bioavailability and higher anti-estrogenic potency in the breast than raloxifene; it exhibits reduced estrogenicity in the uterus compared with either tamoxifen or raloxifene. This agent may have beneficial effects on bone and the cardiovascular system.","Arzoxifene Hydrochloride | 2-(4-Methoxyphenyl)-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]benzo[b]thiophene-6-ol hydrochloride | ARZOXIFENE HYDROCHLORIDE | Arzoxifene.HCl | Arzoxifenehydrochloride | LY353381 Hydrochloride | LY353381 hydrochloride | LY353381.HCL | LY353381.HCl | SERM-3 | SERM3 | arzoxifene hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0380931","FASTK protein, human","C26133","Fas-activated serine/threonine kinase (549 aa, ~61 kDa) is encoded by the human FASTK gene. This protein plays a role in tyrosine phosphorylation, RNA splicing and apoptosis regulation.","Fas-Activated Serine/Threonine Kinase | EC 2.7.11.8 | FAST Kinase | FASTK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520063","Von Willebrand Factor A Domain","C26043","The type A domain (vWF) of the von Willebrand factor, a large multimeric glycoprotein found in blood plasma, is the prototype for a protein superfamily. Von Willebrand Factor A Domain is found in various plasma proteins and other extracellular proteins. Although the majority of VWA-containing proteins are extracellular, the most ancient ones present in all eukaryotes are all intracellular proteins involved in functions such as transcription, DNA repair, ribosomal and membrane transport and the proteasome. A common feature appears to be involvement in multiprotein complexes. Proteins that incorporate vWF domains participate in numerous biological events (e.g. cell adhesion, migration, homing, pattern formation, and signal transduction), involving interaction with a large array of ligands. A number of human diseases arise from mutations in VWA domains. (From Interpro IPR002035)","Von Willebrand Factor A Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1311255","ING1 protein, human","C26291","Inhibitor of growth protein 1 (422 aa, ~47 kDa) is encoded by the human ING1 gene. This protein is involved in the regulation of the cell cycle.","Inhibitor of Growth Protein 1 | ING1 | Inhibitor of Growth 1 | Inhibitor of Growth Family Member 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513775","Mustard Prodrug","C2129","A mustard compound that gets converted to an active mustard alkylating agent at a tumor site, causing DNA cross-linking. These compounds may be used in antibody-directed enzyme prodrug therapy (ADEPT).","Mustard Prodrug | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3849574","Ephrin Type-B Receptor 2, Human","C26166","Ephrin type-B receptor 2 (1055 aa, ~117 kDa) is encoded by the human EPHB2 gene. This protein is involved in ephrin-B binding, neuronal morphology and tyrosine phosphorylation.","Ephrin Type-B Receptor 2 | DRT | Developmentally-Regulated EPH-Related Tyrosine Kinase | EC 2.7.1.112 | EC 2.7.10.1 | EK5 | ELK-Related Tyrosine Kinase | EPH Tyrosine Kinase 3 | EPH-Like Kinase 5 | EPHB2 | ERK | EphB2 | EphB2 Protein | Ephrin Receptor EphB2 | Receptor Protein-Tyrosine Kinase HEK5 | Renal Carcinoma Antigen NY-REN-47 | Tyrosine-Protein Kinase Receptor EPH-3 | Tyrosine-Protein Kinase TYRO5 | hEK5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0149524","Acute Prostatitis","C26935","An acute inflammatory process that affects the prostate gland.  It is caused by bacteria, most often Escherichia coli, Proteus mirabilis, Klebsiella, and Pseudomonas aeruginosa.","Acute Prostatitis | ",,,,,,,,,,,,,,,"193522","Acute prostatitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1335992","Small Intestinal Somatostatin-Producing Neuroendocrine Tumor","C27453","A somatostatin-producing neuroendocrine tumor that arises from the small intestine.","Small Intestinal Somatostatin-Producing Neuroendocrine Tumor | Small Intestinal Somatostatin Producing Tumor | Small Intestinal Somatostatin-Producing NET",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0745541","Knee Fracture","C27201","A traumatic break in one or more of the bones that compose the knee joint.","Knee Fracture | ",,,,,,,,,,,,,,,"618877","Fracture of knee",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0767190","MRVI1 protein, human","C28521","Inositol 1,4,5-triphosphate receptor associated 1 (904 aa, ~98 kDa) is encoded by the human IRAG1 gene. This protein is involved in the regulation of inositol trisphosphate-dependent calcium mobilization.","Inositol 1,4,5-Triphosphate Receptor Associated 1 | IP3R-Associated cGMP Kinase Substrate | IRAG1 | Inositol 1,4,5-Triphosphate Receptor-Associated cGMP Kinase Substrate | Inositol 1,4,5-Triphosphate-Associated cGMP Kinase Substrate | Inositol 1,4,5-Trisphosphate Receptor-Associated cGMP Kinase Substrate | JAW1-Related Protein | JAW1-Related Protein MRVI1 | MRVI1 | Protein MRVI1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519769","Unconjugated Myeloma Ig Id","C2822","A vaccine consisting of myeloma-specific immunoglobulin that is not conjugated to a carrier molecule.  Vaccination with unconjugated myeloma Ig Id may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against myeloma cells, resulting in decreased tumor growth. (NCI04)","Unconjugated Myeloma Ig Id | Unconjugated Myeloma Immunoglobulin Idiotype | Unconjugated Myleoma Immunoglobulin IG ID Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511985","Disease Morphology Qualifier","C28099","No value exists.","Disease Morphology Qualifier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335105","Old Burn Scar-Related Neoplasm","C27771","No value exists.","Old Burn Scar-Related Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0687391","Dark-Field Microscope","C28366","No value exists.","Dark-Field Microscope | dark-field microscope",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0154089","Penile Carcinoma In Situ","C27790","Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  cN0: No palpable or visibly enlarged inguinal lymph nodes.  pN0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Penile Carcinoma In Situ | Bowen Disease of the Penis | Bowen's Disease of Penis | Bowen's Disease of the Penis | Carcinoma in situ of Penis | Carcinoma in situ of penis | Carcinoma in situ of the Penis | Erythroplasia of Queyrat | Grade III Penile Intraepithelial Neoplasia | Grade III Squamous Intraepithelial Lesion of Penis | Grade III Squamous Intraepithelial Lesion of the Penis | Penile Carcinoma In Situ AJCC v7 | Queyrat Erythroplasia | Queyrat erythroplasia | Queyrat's Erythroplasia | stage 0 penile carcinoma in situ","8080/2","Queyrat erythroplasia",,,,,,,,,,,,,"193162|4080063|4162546|4162685|4163101|4266796","Carcinoma in situ of penis|Queyrat's erythroplasia|Bowenoid papulosis of penis|Bowen's disease of penis|Queyrat's erythroplasia|Penile intraepithelial neoplasia grade III",,,,,,,,,,,,,"--","--",,,,,,,,"--|--|--|--|--|--"
"C1520761","17q11.1","C24972","A chromosome band present on 17q","17q11.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708849","M A Radiolabeled T101 Human T-LYMP","C29181","A radiolabeled murine monoclonal antibody (also known as T101) directed against T65, an antigen found on cutaneous T cell lymphoma (CTCL) cells and chronic lymphocytic leukemia (CLL) cells as well as normal T lymphocytes. T101 labeled with 131I, 125I, or 111In has potential use in the radioimaging of CTCL.  M A radiolabeled T101 human T-lymph may induce a cytotoxic T-cell response against T65-expressing T cells. (NCI04)","M A Radiolabeled T101 Human T-LYMP | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1442790","DLG1 protein, human","C29569","Disks large homolog 1 (904 aa, ~100 kDa) is encoded by the human DLG1 gene. This protein plays a role in protein localization.","Disks Large Homolog 1 | Presynaptic Protein SAP97 | SAP-97 | SAP97 | Synapse-Associated Protein 97 | hDlg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514498","Prophyllin CCC","C29389","A topical emollient ointment, by Rystan Company, containing sodium propionate and chlorophyllin copper complex. Chlorophyllin copper complex deodorizes the skin whereas sodium propionate has antifungal activity.","Prophyllin CCC | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333673","GH1 Gene","C30154","This gene is involved in the control of body growth. It also plays a role in protein synthesis as well as in cell differentiation, growth and proliferation.","GH1 Gene | GH1 | Growth Hormone 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280744","Previously Treated Myelodysplastic Syndrome","C27702","A myelodysplastic syndrome for which a patient has received treatment in the past.","Previously Treated Myelodysplastic Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334586","Gastric Sarcoma","C27439","A sarcoma that arises from the stomach. Representative examples include Kaposi sarcoma, leiomyosarcoma, and liposarcoma.","Gastric Sarcoma | Malignant Gastric Soft Tissue Neoplasm | Malignant Soft Tissue Neoplasm of Stomach | Malignant Soft Tissue Neoplasm of the Stomach",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521471","Systemic Lupus Erythematosus Rash","C27171","A rash associated with systemic lupus erythematosus.","Systemic Lupus Erythematosus Rash | ",,,,,,,,,,,,,,,"4319305","Rash of systemic lupus erythematosus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332920","Cervical Non-Neoplastic Disorder","C27622","A non-neoplastic disorder that affects the cervix. Representative examples include endometriosis and cervicitis.","Cervical Non-Neoplastic Disorder | Cervical Non-Neoplastic Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0067813","N-amyl-N-methylnitrosamine","C29825","A synthetic or natural carcinogenic compound found in a variety of smokes and industrial products, N-Amyl-N-Methylnitrosoamine is used in biomedical research to induce experimental hepatocarcinogenesis, probably through abnormal DNA methylation. (NCI04)","N-Amyl-N-Methylnitrosoamine | AMN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1848337","Rickets","C26878","Bone softening and weakening usually caused by deficiency or impaired metabolism of vitamin D. Deficiency of calcium, magnesium, or phosphorus may also cause rickets. It predominantly affects children who suffer from severe malnutrition. It manifests with bone pain, fractures, muscle weakness, and skeletal deformities.","Rickets | rachitis | rickets",,,,,,,,,,,,,,,"4189941","Rickets",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512982","Mandibular prominence","C34204","An embryonic structure developing from the lower part of the first pharyngeal arch, which gives rise to the mandible.","Mandibular Prominence | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0228237","Superior Temporal Sulcus","C33700","A groove or cleft that divides the outer surface of the temporal lobe running parallel to the horizontal portion of the fissure of Sylvius.","Superior Temporal Sulcus | ",,,,,,,,,,,,,,,"4176117","Structure of superior temporal sulcus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227557","Right Hepatic Duct","C33476","The duct that drains bile from the right lobe of the liver into the common hepatic duct.","Right Hepatic Duct | ",,,,,,,,,,,,,,,"4299923","Structure of right hepatic duct",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227265","Valve of Kerckring","C33850","Circularly arranged folds of the mucosa and submucosa of the small intestine, which extend into the lumen, and which function to increase the absorptive surface area. They are most prominent in the jejunum and proximal ileum, and are generally absent in the proximal duodenum and distal ileum.","Valve of Kerckring | Circular Fold",,,,,,,,,,,,,,,"4309368","Structure of Kerckring's valve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0456936","terminal sulcus of thalamus","C33657","A V-shaped groove on the dorsal surface of the tongue with the apex of the V located at the foramen caecum; it demarcates the anterior two-thirds of the tongue from the posterior one-third.","Sulcus Terminalis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517292","Foramen Primum","C34178","A temporary passageway enabling oxygenated blood to pass from the right to the left atrium in the embryonic heart. An opening between the free edge of the septum primum and the AV cushions that allows blood to flow directly between the right and left atrium, and which is closed by the union of the septum primum with the septum intermedium.","Foramen Primum | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335142","NR0B2 protein, human","C34000","Nuclear receptor subfamily 0 group B member 2 (257 aa, ~28 kDa) is encoded by the human NR0B2 gene. This protein plays a role in the negative regulation of transcription.","Nuclear Receptor Subfamily 0 Group B Member 2 | NR0B2 | Orphan Nuclear Receptor SHP | SHP | SHP1 | Short Heterodimer Partner | Small Heterodimer Partner",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008523","Choroid Neoplasm","C2949","A benign or malignant neoplasm that affects the choroid.","Choroid Neoplasm | Choroid Tumor | Choroidal Neoplasm | Choroidal Tumor | Neoplasm of Choroid | Neoplasm of the Choroid | Tumor of Choroid | Tumor of the Choroid",,,,,,,,,,,,,,,"4130669","Neoplasm of choroid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001940","Alcohol-Induced Wernicke-Korsakoff's Syndrome","C34366","A syndrome which occurs in individuals with a history of alcohol abuse. It is caused by prolonged alcohol-induced neurological damage and malnutrition including vitamin and electrolyte deficiencies. Clinical signs include altered mental status, visual impairment and decreased muscle coordination. The clinical course varies and is, in part, dependent upon the severity of symptoms at presentation. The prognosis is poor and worsens if alcohol abuse continues.","Alcohol-Induced Wernicke-Korsakoff's Syndrome | Alcohol-Induced Amnestic Syndrome | Alcoholic Korsakoff's Psychosis",,,,,,,,,,,,,,,"374623","Alcohol amnestic disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0076316","Tetrandrine","C28952","A natural, bis-benzylisoquinoline alkaloid isolated from the root of the plant Radix stephania tetrandrae.  Tetrandrine non-selectively inhibits calcium channel activity and induces G1 blockade of the G1 phase of the cell cycle and apoptosis in various cell types, resulting in immunosuppressive, anti-proliferative and free radical scavenging effects. This agent also increases glucose utilization by enhancing hepatocyte glycogen synthesis, resulting in the lowering of plasma glucose. (NCI04)","Tetrandrine | (1beta)-6,6',7,12-tetramethoxy-2,2'-dimethylberbaman | (S,S)-Tetrandrine | Berbaman, 6, 6',7,12-trtramethoxy-2,2'-dimethyl-, (1beta)-(PM)-(9CI) | D-tetrandrine | Pheanthine | Sinomenine A | TETRANDRINE, (+)- | Tetrandrin | Tetrandrine, D-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333276","Dermal Growth Pattern","C35896","No value exists.","Dermal Growth Pattern | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335443","Poorly Differentiated Lesion","C36132","A lesion comprised of neoplastic cells that generally have lost most of the morphological features that are indicative of normal cells.","Poorly Differentiated Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1291044","Integumentary System Finding","C36281","Symptoms, physical examination results, and/or laboratory test results related to the integumentary system.","Integumentary System Finding | Dermatological | INTEGUMENTARY SYSTEM | Skin Finding",,,,,,,,,,,,,,,"444112","Integumentary system finding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1335900","Salivary Gland Epithelial-Myoepithelial Carcinoma","C35701","A carcinoma that arises from the salivary glands, most often the parotid gland.  It presents as a slow growing and painless mass.  It is characterized by the presence of duct-like structures lined by two layers of cells, an inner layer composed of epithelial-type cells and an outer layer composed of clear, myoepithelial-type cells.","Salivary Gland Epithelial-Myoepithelial Carcinoma | Salivary Gland Epithelial Myoepithelial Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0154016","Benign Ureter Neoplasm","C3617","A neoplasm that arises from the ureter and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Ureter Neoplasm | Benign Neoplasm of Ureter | Benign Neoplasm of the Ureter | Benign Tumor of Ureter | Benign Tumor of the Ureter | Benign Ureter Tumor | Benign Ureteral Neoplasm | Benign Ureteral Tumor | Benign Ureteric Neoplasm | Benign Ureteric Neoplasm NOS",,,,,,,,,,,,,,,"198103","Benign neoplasm of ureter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1515784","t(7;14)(q35;q32.1)","C36519","No value exists.","t(7;14)(q35;q32.1) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513973","Neoplastic Glandular Cell","C36763","No value exists.","Neoplastic Glandular Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332442","Early Onset Breast Ovarian Cancer Syndrome","C36100","An autosomal dominant inherited syndrome caused by deleterious mutations in the BRCA1 gene. Patients are at high risk of developing breast cancer, ovarian cancer, and other cancers including cervical, endometrial, fallopian tube, and colon cancer.","BRCA1-Associated Hereditary Breast and Ovarian Cancer Syndrome | BRCA1 Syndrome | Early Onset Breast Ovarian Cancer Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332975","Childhood Intracranial Neoplasm","C35876","A neoplasm that arises within the skull and occurs during childhood.","Childhood Intracranial Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021868","Intracellular Membrane","C32876","A thin pliable sheet separating organelles from the protoplasm.","Intracellular Membrane | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226356","Glomerular Capillary","C32684","Tiny blood vessels located within Bowman's capsule, which combine in networks to form a glomerulus.","Glomerular Capillary | ",,,,,,,,,,,,,,,"4196473","Glomerular capillaries structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0226408","Lumbar Artery","C33013","Any of the four or five pairs of arteries arising from the left or right side of the aorta in the lumbar region.","Lumbar Artery | ",,,,,,,,,,,,,,,"4144813","Structure of lumbar artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512225","Glycogen Inclusion","C32690","A stainable aggregation of glycogen in the cytoplasm.","Glycogen Inclusion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162405","Lymphatic Capillary","C33037","Tiny vessels with porous walls that join to form the lymphatic vessels.","Lymphatic Capillary | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1182701","Hair Follicle Isthmus","C32709","The middle segment of a hair follicle that extends from the insertion of the erector pili muscle to the entrance of the sebaceous gland duct.","Hair Follicle Isthmus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517747","Lateral Infratentorial Cistern","C32939","A lateral infratentorial subarachnoid cistern.","Lateral Infratentorial Cistern | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518130","KMT2A-EEN Fusion Protein Expression","C38393","No value exists.","KMT2A-EEN Fusion Protein Expression | MLL-EEN Fusion Protein Expression | MLL-SH3GL1 Fusion Protein Expression | MLL/EEN Fusion Protein Expression | MLL/SH3GL1 Fusion Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515261","Telomere Pathway","C39247","No value exists.","Telomere Pathway | Telomeres, Telomerase, Cellular Aging, and Immortality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518522","OX40 Signaling Pathway","C39175","No value exists.","OX40 Signaling Pathway | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0968917","Traumeel S","C38683","Diluted extracts isolated from plants and minerals, including belladonna, arnica, St. Johns wort, and Echinacea.  As a homeopathic mouth rinse preparation, Traumeel S exhibits antiinflammatory activity; the mechanism of action has not been fully elucidated.  This agent may reduce the severity and duration of treatment-related stomatitis. (NCI04)","Traumeel S | TRS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511046","Barrier Animal Facility Shared Resource","C39329","The Animal Barrier Shared Resource provides for acquisition and maintenance of both pathogen-free and infected laboratory animals, including immunodeficient strains, while permitting supervised access for investigators, stable husbandry conditions, and individualized daily health care for animals. The Resource implements methods that allow maximal retention of animals when an infectious agent is detected in a barrier room. These include static microisolator housing, handling animals with disinfected forceps, opening animal cages only in a hood, cage-by-cage testing and requiring that full barrier garb be worn by all persons entering animal rooms.","Barrier Animal Facility Shared Resource | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0149640","Cecum Carcinoma","C3491","A malignant epithelial neoplasm that arises from the cecum and invades through the muscularis mucosa into the submucosa.  The vast majority are adenocarcinomas.","Cecum Carcinoma | Carcinoma of Cecum | Carcinoma of the Cecum | Cecal Cancer | Cecal Carcinoma | Cecum Cancer",,,,,,,,,,,,,,,"4116240","Carcinoma of cecum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1510836","Agrin Pathway","C38975","No value exists.","Agrin Pathway | Agrin in Postsynaptic Differentiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1328144","OSI-7904L","C38694","A liposome-encapsulated formulation of the benzoquinazoline folate analog OSI-7904 with antineoplastic activity. As a thymidylate synthase inhibitor, OSI-7904 noncompetitively binds to thymidylate synthase, resulting in inhibition of thymine nucleotide synthesis and DNA replication. Liposome encapsulation improves the efficacy and increases the half-life of OSI-7904. (NCI04)","Liposome-encapsulated OSI-7904 | GS7904L | OSI-7904 | OSI-7904L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0343585","Mite-Borne Hemorrhagic Fever","C35410","No value exists.","Mite-Borne Hemorrhagic Fever | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516666","Clonal BCL6 Gene Rearrangement","C36449","No value exists.","Clonal BCL6 Gene Rearrangement | Clonal BCL-6 Gene Rearrangement | Monoclonal BCL-6 Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042376","Vascular Headache","C35118","Headache caused by abnormal functioning of the vascular system.","Vascular Headache | ",,,,,,,,,,,,,,,"4134454","Vascular headache",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020610","Hypogalactia","C34717","Decreased secretion of breast milk.","Hypogalactia | ",,,,,,,,,,,,,,,"4062551","Decreased lactation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333636","Foveolar Hyperplasia","C35826","A hyperplasia of the gastric foveolar epithelium.","Foveolar Hyperplasia | ",,,,,,,,,,,,,,,"40493284","Foveolar hyperplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036415","Sclerema Neonatorum","C35009","A diffuse hardening of skin and subcutaneous adipose tissue, associated with minimal inflammation without fat necrosis, that typically affects critically ill preterm neonates during the first week of life.","Sclerema Neonatorum | ",,,,,,,,,,,,,,,"136530","Sclerema neonatorum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0161026","Foreign Body in Penis","C35253","Extraneous material located within the penis.","Foreign Body in Penis | ",,,,,,,,,,,,,,,"202002","Foreign body in penis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0393761","Middle Insomnia","C35582","Difficulty maintaining sleep.","Middle Insomnia | ",,,,,,,,,,,,,,,"4282607","Middle insomnia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0675974","tanespimycin","C37899","A benzoquinone antineoplastic antibiotic derived from the antineoplastic antibiotic geldanamycin.  Tanespimycin binds to and inhibits the cytosolic chaperone functions of heat shock protein 90 (HSP90).  HSP90 maintains the stability and functional shape of many oncogenic signaling proteins; the inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins that may be overexpressed by tumor cells.","Tanespimycin | 17-(Allylamino)-17-demethoxygeldanamycin | 17-AAG | 17-Allylamino-17-demethoxygeldanamycin | 17-Demethoxy-17-(2-propenylamino)geldanamycin | 17-N-allylamino-17-demethoxy geldanamycin | 17-N-allylamino-17-demethoxygeldanamycin | Geldanamycin, 17-allylamino-17-demethoxy- | KOS-953 | TANESPIMYCIN | tanespimycin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519792","Unicystic Lesion","C41423","No value exists.","Unicystic Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515020","Subependymal Tissue","C41448","Tissue located below the ependyma lining the ventricles of the brain and central canal of the spinal cord. It is a dense feltwork of glial processes and is believed to contain neural stem cells.","Subependymal Tissue | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707398","Well-Circumscribed Lesion","C41457","No value exists.","Well-Circumscribed Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513487","Monovacuolated Lipoblast","C36972","No value exists.","Monovacuolated Lipoblast | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516629","Clinical Research Support Shared Resource","C39360","The Clinical Research Shared Resource provides Cancer Center investigators with assistance in identification of prospective patients and determination of patient interest and eligibility to participate in clinical trials, in procurement and maintenance of the informed consent process, coordination of follow-up visits in conformance with protocol, hospital admission and discharge planning, coordination and safe administration of investigational agents, toxicity monitoring and reporting in compliance within Cancer Center and FDA regulations and the guidelines of GCP.","Clinical Research Support Shared Resource | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0262518","HODGKIN'S DISEASE STAGE IIIA","C3914","No value exists.","Ann Arbor Stage IIIA Hodgkin Lymphoma | Hodgkin's Disease Stage IIIA | Hodgkin's Lymphoma Stage IIIA | Stage IIIA Hodgkin Lymphoma | Stage IIIA Hodgkin's Disease | Stage IIIA Hodgkin's Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600151","SLC25A6 protein, human","C37303","ADP/ATP translocase 3 (298 aa, ~33 kDa) is encoded by the human SLC25A6 gene. This protein is involved in both the regulation of apoptosis and the exchange of cytoplasmic ADP for mitochondrial ATP across the inner mitochondrial membrane.","ADP/ATP Translocase 3 | ADP,ATP Carrier Protein 3 | ADP,ATP Carrier Protein, Isoform T2 | ADP,ATP Carrier Protein, Liver | ADP-ATP Translocase-3 | ADP/ATP Carrier 3 | ADP/ATP Carrier Protein 3 | ADP/ATP Translocator of Liver | ANT 2 | ANT 3 | Adenine Nucleotide Translocator 3 | Adenine Nucleotide Translocator-3 | Liver ADP-ATP Carrier Protein-T2 | Liver ADP-ATP Translocator | Mitochondrial Adenine Nucleotide Translocator Solute Carrier Family 25 Member-6 | SLC25A6 | Solute Carrier Family 25 Member 6 | Solute Carrier Family 25 Member-A6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512125","Erythropoietin Signaling Pathway","C39067","No value exists.","EPO Signaling Pathway | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513615","Mouse Ito Cell Tumor, Benign","C38751","No value exists.","Mouse Ito Cell Tumor, Benign | Lipoma of Mouse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279818","Recurrent Laryngeal Carcinoma","C4034","The reemergence of laryngeal carcinoma after a period of remission.","Recurrent Laryngeal Carcinoma | Recurrent Carcinoma of Larynx | Recurrent Carcinoma of the Larynx | Recurrent Laryngeal Cancer | Recurrent Laryngeal Throat Cancer | Recurrent Larynx Cancer | Recurrent Larynx Carcinoma | Relapsed Carcinoma of Larynx | Relapsed Carcinoma of the Larynx | Relapsed Laryngeal Carcinoma | Relapsed Larynx Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514415","Preventive Community Trial","C39497","The Preventive Community Trial is a controlled study that involves administration of preventive program or/and preventive treatments in community.","Preventive Community Trial | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0438967","Tokelauan","C43836","Denotes the inhabitants of Tokelau, a person from there, or their descendants elsewhere.","Tokelauan | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642330","Vaginal Low Grade Endometrioid Stromal Sarcoma","C40271","An infiltrating sarcoma that arises from the vagina.  It is characterized by the presence of cells that resemble endometrial stromal cells.","Vaginal Low Grade Endometrioid Stromal Sarcoma | Endometrioid Stromal Sarcoma of the Vagina | Low Grade Endometrioid Stromal Sarcoma of the Vagina | Vaginal Endometrioid Stromal Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513146","Mesenteric Gastrointestinal Stromal Tumor","C40339","A gastrointestinal stromal tumor that arises from the mesentery. This is an extragastrointestinal tumor, meaning that it does not arise directly from the gastrointestinal tract.","Mesenteric Gastrointestinal Stromal Tumor | Mesenteric EGIST | Mesenteric Extragastrointestinal Stromal Tumor | Mesenteric Gastrointestinal Stromal Tumor (GIST)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2211850","Vulvar Basaloid Carcinoma","C40286","A squamous cell carcinoma that arises from the vulva and is characterized by the presence of nests of malignant basaloid cells with a scant amount of cytoplasm.","Vulvar Basaloid Squamous Cell Carcinoma | Vulvar Basaloid Carcinoma | Vulvar Basaloid Carcinoma | Vulvar Basaloid Squamous Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1536526","Penile Bowenoid Papulosis","C39963","A cutaneous, usually multifocal lesion in the penis characterized by the presence of verrucous papules.  It is caused by human papillomavirus infection.  Morphologically there is bowenoid dysplasia present.  Progression to invasive carcinoma is infrequent.","Penile Bowenoid Papulosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0745390","Intrauterine Mass","C39663","No value exists.","Intrauterine Mass | Mass of Uterine Body | Mass of Uterine Corpus | Mass of the Uterine Body | Mass of the Uterine Corpus | Uterine Body Mass | Uterine Corpus Mass",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0265985","Congenital Dermal Melanocytosis","C3945","A congenital mark on the skin near the base of the spine, consisting of scattered ectopic melanocytes in the dermis, that enlarges for a short time after birth and disappears during childhood.","Congenital Dermal Melanocytosis | Blue Sacral Spot | CDM | Dermal Melanocytosis | Mongolian Macula | Mongolian Spot | Mongolian Spot",,,,,,,,,,,,,,,"4225530","Mongolian spot",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0238032","Breast Hamartoma","C40401","A benign, circumscribed and usually encapsulated lesion of the breast.  It contains all the components of the breast tissue.","Breast Hamartoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517616","JAZF1-SUZ12 Fusion Protein Expression","C40161","No value exists.","JAZF1-SUZ12 Fusion Protein Expression | JAZF1-JJAZ1 Fusion Protein Expression | JAZF1/JJAZ1 Fusion Protein Expression | JAZF1/SUZ12 Fusion Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516249","Carbohydrate Processing Inhibition","C40641","Carbohydrate Processing Inhibition consists of interference with, or restraint of, activities involved in assembly of carbohydrate-linked structures on cell surfaces, such as inhibition of enzymes responsible for the formation of these structures.  Since evidence indicates that carbohydrate structures are involved in intercellular communication, inhibition potentially results in decreased cancer cell growth, invasiveness, and metastasis.","Carbohydrate Processing Inhibition | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520884","1: 158288316-158302322","C42251","Physical location of FCGR2A_Gene","1: 158288316-158302322 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520720","17: 31353125-31348777","C41860","Physical location of CCL15_Gene","17: 31353125-31348777 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521242","3: 114734183-114830960","C42280","Physical location of FLJ20174_Gene","3: 114734183-114830960 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520611","15: 57184612-57204536","C41882","Physical location of CCNB2_Gene","15: 57184612-57204536 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707692","Designation Class Scheme Item","C42675","A class that serves to allow many to many relationships between Designation and ClassSchemeClassSchemeItem, providing uniqueness to the CS/CSI pairing to an Designation.","Designation Class Scheme Item | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0991582","Sublingual Tablet Dosage Form","C42751","A tablet intended for administration under the tongue.","Sublingual Tablet Dosage Form | SL Tab | Sublingual Tablet | Sublingual Tablet Dose Form | Sublingual tablet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521430","5: 134102105-134115746","C41821","Physical location of CAMLG_Gene","5: 134102105-134115746 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706691","Accepted_Therapeutic_Use_For","C43676","Indicates a disease or condition for which this drug is an accepted treatment.  Used in Chemicals and Drug Kind.","Accepted_Therapeutic_Use_For | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708213","Gene_Product_Has_Associated_Anatomy","C43792","A role used to specify physical structures or typical subcellular locations of a gene product. The domain and range for this role are 'Gene Product' and 'Anatomic Structure, System, or Substance', respectively.","Gene_Product_Has_Associated_Anatomy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521516","6: 32114061-32117396","C42103","Physical location of CYP21A2_Gene","6: 32114061-32117396 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551621","Pipestone Sioux","C44154","A person having origins in the original Pipestone Sioux people.","Pipestone Sioux | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709270","North Central States","C43449","The area in the United States comprised of the following states: Michigan, Ohio, Indiana, Kentucky.","North Central States | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707785","Disease_May_Have_Normal_Cell_Origin","C43769","A role used to represent that a normal cell type will only be the type of origin in some cases of the disease. The domain and the range for this role are 'Disease, Disorder or Finding' and 'Anatomic Structure, System, or Substance', respectively.","Disease_May_Have_Normal_Cell_Origin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711303","Malignant Sebocyte","C43339","No value exists.","Malignant Sebocyte | Malignant Sebaceous Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707683","Derived Unit of International System of Units","C42534","Derived units of the International System of Units (Systeme International d'Unites, SI) are those formed by combining base SI units according to the algebraic relations linking the corresponding quantities. The names and symbols of some of the units thus formed can be replaced by special names and symbols which can themselves be used to form expressions and symbols of other derived units.","Derived Unit of International System of Units | Derived SI Unit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553250","Oscarville","C44616","A person having origins in the original Oscarville people.","Oscarville | Oscarville | Oscarville | Oscarville Traditional Village",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708242","Glandular Epithelial Tissue","C45715","No value exists.","Glandular Epithelial Tissue | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708142","GPC3 Gene Inactivation","C45668","No value exists.","GPC3 Gene Inactivation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710950","2: 219570760-219584156","C45083","Physical location of WNT10A_Gene","2: 219570760-219584156 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551591","Ely","C44558","A person having origins in the original Ely people.","Ely | Ely | Ely | Ely Shoshone Tribe of Nevada",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706717","Adenosine to Guanosine Transition Abnormality","C45640","A point mutation involving the substitution of Guanosine (a purine base) for Adenosine (a purine base) in a DNA sequence from eukaryotic or prokaryotic organisms. This abnormality can be either heritable or occur somatically.","Adenosine to Guanosine Transition Abnormality | Adenosine to Guanosine Mutation | Adenosine to Guanosine Transition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0071500","Polyacrylamide Gel","C45309","An electrophoresis gel composed of polyacrylamide in an aqueous buffer.","Polyacrylamide Gel | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705207","Recombinant Human Endostatin","C45515","A recombinant human proteolytic fragment of the C-terminal end of type XVIII collagen. Endostatin induces microvascular endothelial cell apoptosis and inhibits endothelial proliferation and angiogenesis, which may result in a reduction in tumor burden. This agent also may decrease hepatic metastasis by inhibiting proinflammatory cytokines and vascular cell adhesion molecule (VCAM)-dependent cell attachment to the hepatic microvasculature.  (NCI04)","Recombinant Human Endostatin | ENDOSTATIN | Endostar | Endostatin | N-Terminal-MGGSHHHHH-Endostatin (Human Recombinant) | Recombinant Endostatin | endostatin | rhEndostatin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551538","Zia","C44848","A person having origins in the original Zia people.","Zia | Pueblo of Zia, New Mexico | Zia | Zia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0546853","Brompheniramine Maleate","C47422","The maleate salt form of brompheniramine, an alkylamine derivative and a histamine antagonist with anticholinergic and sedative properties. Brompheniramine maleate competes with histamine for the H1 receptor. This diminishes the actions of histamine on effector cells and decreases the histamine-mediated symptoms of allergic reaction such as bronchoconstriction, vasodilation, increased capillary permeability and spasmodic contractions of gastrointestinal smooth muscle.","Brompheniramine Maleate | 2-(p-Bromo-alpha-(2-(dimethylamino)ethyl)benzyl)pyridine Maleate | 2-Pyridinepropanamine, gamma-(4-Bromophenyl)-N,N-dimethyl-,(Z)-butenedioate(1:1) | 2-Pyridinepropanamine, gamma-(4-bromophenyl)-N,N-dimethyl-, (Z)-butenedioate (1:1) | Allent | BROMPHENIRAMINE MALEATE | Dimetane | Drauxin | Ilvin | Nagemid | Parabromdylamine Maleate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0349535","Intestinal Neuroendocrine Tumor G1","C4637","A well-differentiated, low-grade neuroendocrine neoplasm that arises from the small or large intestine. The mitotic count is less than 2 per 2 mm2 and the Ki-67 index is less than 3%.","Intestinal Neuroendocrine Tumor G1 | Carcinoid Tumor of Intestine | Carcinoid Tumor of the Intestine | Intestinal Carcinoid Tumor | Intestinal NET G1 | Intestine Carcinoid Tumor",,,,,,,,,,,,,,,"194307","Carcinoid tumor of intestine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0595398","Balsalazide Disodium","C47409","The disodium salt form of balsalazide, an aminosalicylate and oral prodrug that is enzymatically cleaved in the colon to produce the anti-inflammatory agent mesalazine. Mesalazine acts locally on the mucosa of the colon where it diminishes inflammation by blocking the production of arachidonic acid metabolites, including leukotrienes, prostaglandins and hydroxyeicosatetraenoic acids, and other inflammatory agents. Balsalazide disodium is used to treat chronic inflammatory bowel disease.","Balsalazide Disodium | BALSALAZIDE DISODIUM | Benzoic Acid, 5-((1E)-(4-(((2-Carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxy-, Disodium Salt | Colazal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707238","CYP3A5*9 Allele","C46024","Human CYP3A5*9 allele is located in the vicinity of 7q21.1 and is approximately 32 kb in length. This allele, a variant form of the human CYP3A5 wild-type allele, encodes cytochrome P450 3A5*9 protein. The CYP3A5*9 allele exhibits a clinically-relevant SNP (g.19386G>A) in exon 10 that results in an A337T coding change. This alteration in protein sequence decreases the enzymatic activity of the cytochrome P450 3A5*9 protein.","CYP3A5*9 Allele | CYP3A5*9 | CYP3A5, A337T | CYP3A5, g.19386G>A | Cytochrome P450, Family 3, Subfamily A, Polypeptide 5*9 Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0554632","Anogenital Human Papillomavirus Infection","C4820","No value exists.","Anogenital Human Papillomavirus Infection | Anogenital Human Papilloma Virus Infection",,,,,,,,,,,,,,,"4116193","Anogenital human papillomavirus infection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0733811","Methylergonovine Maleate","C47618","The maleate salt of methylergonovine, a semi-synthetic ergot alkaloid with vasoconstrictive and uterotonic effects. Methylergonovine stimulates serotoninergic and dopaminergic receptors as well as inhibits the release of endothelial-derived relaxation factor. This results in arterial vasoconstriction and increased uterine smooth muscle contractions.","Methylergonovine Maleate | Ergoline-8-carboxamide, 9,10-didehydro-N-((1S)-1-(hydroxymethyl)propyl)-6-methyl-,(8beta)-,(2Z)-2-butenedioate(1:1)(salt) | METHYLERGONOVINE MALEATE | Maleic Acid, Methyl Ergonovine | Methergine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709154","Nasopharyngeal Paraganglioma","C48316","An extra-adrenal paraganglioma arising from the nasopharynx and nose.  Epistaxis or nasal obstruction are common presenting symptoms.","Nasopharyngeal Paraganglioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030829","Penicillin G Benzathine","C47657","The long-acting benzathine salt form of penicillin G, a broad-spectrum penicillin antibiotic. Penicillin G benzathine binds to penicillin binding proteins (PBP), the enzymes that catalyze the synthesis of peptidoglycan, a critical component of the bacterial cell wall. This leads to the interruption of cell wall synthesis, consequently leading to bacterial cell growth inhibition and cell lysis.","Penicillin G Benzathine | Benzathine Benzylpenicillin Tetrahydrate | Benzylpenicillin Benzathine Hydrate | Bicillin | PENICILLIN G BENZATHINE | Permapen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551744","Nikolai","C44776","A person having origins in the original Nikolai people.","Nikolai | Nikolai | Nikolai | Nikolai Village",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705462","EPHX1 wt Allele","C49357","Human EPHX1 wild-type allele is located in the vicinity of 1q42.1 and is approximately 35 kb in length. This allele, which encodes epoxide hydrolase 1 protein, is involved in the metabolism of both arene and aliphatic epoxides. Certain allelic variants of the EPHX1 gene confer susceptibility to lymphoproliferative disorders. Specific inherited defects in this gene also cause familial hypercholanemia. An EPHX1 low-activity genotype is associated with decreased risk of lung cancer.","EPHX1 wt Allele | EPHX | EPOX | Epoxide Hydrolase 1, Microsomal (Xenobiotic) wt Allele | MEH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707545","Skin Fibrous Histiocytoma, Fibroblastic Variant","C49076","A variant of fibrous histiocytoma of the skin characterized by the presence of spindle-shaped fibrohistiocytic cells and associated acanthosis.","Skin Fibroblastic Fibrous Histiocytoma | Cutaneous Fibrous Histiocytoma, Fibroblastic Variant | Dermatofibroma, Fibroblastic Variant | Fibroblastic Dermatofibroma | Skin Fibrous Histiocytoma, Fibroblastic Variant | Skin Fibrous Histiocytoma, Fibroblastic Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711358","Cervix Epithelium","C49218","The varied epithelium of the cervix; which is composed of nonkeratinized stratified squamous cells distally, and simple columnar cells proximally.","Cervix Epithelium | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707057","Bubble Detector","C50354","A device designed to signal the presence of bubbles in a system.","Bubble Detector Device | Bubble Detector | Bubble Sensor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0870768","Keyboard","C50018","A device consisting of mechanical keys that are pressed to create input to a computer.","Keyboard Device | Keyboard | Keyboard/Keypad",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708191","Gas Scavenger","C49967","A device designed to remove certain gases from a gas stream or environment.","Gas Scavenging Device | Gas Scavenger | Gas Scavenging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709140","NRCAM wt Allele","C51184","Human NRCAM wild-type allele is located within 7q31.1-q31.2 and is approximately 309 kb in length. This allele, which encodes neuronal cell adhesion molecule protein, is involved in cellular adhesion in nerve cells.","NRCAM wt Allele | KIAA0343 | Neuronal Cell Adhesion Molecule wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707116","CDK5 wt Allele","C49458","Human CDK5 wild-type allele is located within 7q36 and is approximately 4 kb in length. This allele, which encodes cyclin-dependent kinase 5 protein, is involved in cell cycle regulation.","CDK5 wt Allele | Cell Division Kinase 5 Gene | Cyclin-Dependent Kinase 5 wt Allele | PSSALRE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0751606","Adult Acute Lymphocytic Leukemia","C4967","An acute lymphoblastic leukemia occurring during adulthood.","Adult Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia (ALL) | Adult ALL | Adult Acute Lymphocytic Leukemia | Adult Acute Lymphogenous Leukemia | Adult Acute Lymphoid Leukemia | Adult Precursor Lymphoblastic Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709004","Meter Needle","C50082","A needle-shaped part designed to indicate a position on a scale.","Meter Needle Device | Meter Needle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708979","Membrane Breakage","C50649","No value exists.","Membrane Breakage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706165","GRK1 wt Allele","C51307","Human GRK1 wild-type allele is located within 13q34 and is approximately 4 kb in length. This allele, which encodes rhodopsin kinase protein, plays a role in the deactivation of rhodopsin. Heritable defects in the GRK1 gene cause Oguchi disease 2.","GRK1 wt Allele | G Protein-Coupled Receptor Kinase 1 wt Allele | RHOK | RK | Rhok Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706645","ADORA1 wt Allele","C51396","Human ADORA1 wild-type allele is located in the vicinity of 1q32.1 and is approximately 77 kb in length. This allele, which encodes adenosine A1 receptor protein, plays a role in the regulation of G protein receptor signal transduction and affects several biological processes.","ADORA1 wt Allele | Adenosine A1 Receptor wt Allele | RDC7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707995","FABP4 wt Allele","C51243","Human FABP4 wild-type allele is located within 8q21 and is approximately 5 kb in length. This allele, which encodes fatty acid-binding protein, adipocyte, is involved in the regulation oflipid transport protein in adipocytes.","FABP4 wt Allele | A-FABP | AFABP | ALBP | Fatty Acid Binding Protein 4, Adipocyte wt Allele | HEL-S-104 | aP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708082","Foot Digit 2 Phalanx","C52779","A bone in the second toe from the medial side of the foot.","Foot Digit 2 Phalanx | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708561","Intrinsic Tongue Muscle Transverse Component","C52706","The intrinsic muscles spanning the length of the tongue that move the tip of the tonge up and down.","Intrinsic Tongue Muscle Transverse Component | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333989","Familial meningioma","C5301","A meningioma that is transmitted from the parents to an offspring.","Hereditary Meningioma | Familial Meningioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0580876","Superior Suprarenal Artery","C52736","Either of two arteries (left and right) arising from the inferior phrenic artery that supply the corresponding adrenal gland.","Superior Suprarenal Artery | ",,,,,,,,,,,,,,,"4240428","Structure of superior suprarenal artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0447128","Digital Vein","C53043","Any vein containing deoxygenated blood that is located in a finger or toe.","Digital Vein | ",,,,,,,,,,,,,,,"4055911","Venous structure of digit",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333777","Gastric Lipoma","C5258","A rare benign adipose tissue neoplasm of the stomach. Clinical presentation includes obstruction and gastrointestinal bleeding. Gastric lipomas occur as solitary lesions most frequently in the antrum.","Gastric Lipoma | Lipoma of Stomach | Lipoma of the Stomach",,,,,,,,,,,,,,,"36713371","Lipoma of stomach",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705673","AKAP9 wt Allele","C52456","Human AKAP9 wild-type allele is located within 7q21-q22 and is approximately 170 kb in length. This allele, which encodes A-kinase anchor protein 9, is involved in the regulation of both glutamate receptor and potassium channel signaling pathways through the alteration of the cellular location of protein kinase A.","AKAP9 wt Allele | A Kinase (PRKA) Anchor Protein (Yotiao) 9 Gene | A Kinase (PRKA) Anchor Protein 9 Gene | A-Kinase Anchor Protein 9 wt Allele | AKAP-9 | AKAP350 | AKAP450 | CG-NAP | CGNAP | HYPERION | KIAA0803 | LQT11 | MU-RMS-40.16A | PPP1R45 | PRKA9 | YOTIAO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707755","Diode","C49922","An electronic component designed to pass current in one direction only.","Diode Device | Diode",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706206","Brake Device","C49849","A device designed to slow or stop a moving part.","Brake Device | Brake",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706201","Receiver","C50133","An electronic device designed to capture an incoming electromagnetic signal and convert it to an audible or visual signal.","Receiver Device | Receiver",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705978","NFKBIB wt Allele","C52885","Human NFKBIB wild type allele is located in the vicinity of 19q13.1 and is approximately 3 kb in length. This allele, which encodes NF-kappa-B inhibitor beta protein, is involved in the attenuation of the nuclear factor kappa B complex signaling pathway.","NFKBIB wt Allele | IKBB | Inhibitor of Kappa Light Chain Gene Enhancer in B Cells, Beta Gene | NFKB Inhibitor Beta wt Allele | Nuclear Factor of Kappa Light Polypeptide Gene Enhancer in B-Cells Inhibitor, Beta Gene | TRIP9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346949","STAP1 wt Allele","C52495","Human STAP1 wild-type allele is located in the vicinity of 4q13.2 and is approximately 48 kb in length. This allele, which encodes signal-transducing adaptor protein 1, is involved in the progression of B cell antigen receptor signaling.","STAP1 wt Allele | BCR Downstream Signaling 1 Gene | BRDG1 | STAP-1 | Signal Transducing Adaptor Family Member 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475829","Clear Cell Odontogenic Carcinoma","C54300","A usually aggressive malignant neoplasm arising from tooth-forming tissues. It more often affects older females and more frequently occurs in the mandible. It is characterized by the presence of malignant epithelial cells with clear cytoplasm and a fibrotic stroma formation. It may recur and metastasize. Metastases may occur in the lymph nodes, lungs, and bones. Treatment of choice is resection with clean margins.","Clear Cell Odontogenic Carcinoma | Clear Cell Ameloblastoma | Clear Cell Odontogenic Tumor | Clear cell odontogenic carcinoma | Clear cell odontogenic tumor",,,,,,,,,,,,,,,"37116966","Clear cell odontogenic carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1559080","Grade 3 Weight Loss, CTCAE","C55319",">=20% from baseline; tube feeding or TPN indicated","Grade 3 Weight Loss, CTCAE | Grade 3 Weight loss",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556313","Grade 4 Restrictive Cardiomyopathy, CTCAE","C55042","Refractory heart failure or other poorly controlled cardiac symptoms","Grade 4 Restrictive Cardiomyopathy, CTCAE | Grade 4 Restrictive cardiomyopathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1561329","Grade 4 Hydrocephalus, CTCAE","C55405","Life-threatening consequences; urgent intervention indicated","Grade 4 Hydrocephalus, CTCAE | Grade 4 Hydrocephalus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0348026","Intent For Diagnosis","C54415","The use of a particular medical device, medication or treatment to help establish the presence or absence of a disease or condition.","Intent For Diagnosis | Diagnostic Intent | Intent For Diagnostic",,,,,,,,,,,,,,,"4129646","Diagnostic intent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704719","INHBA wt Allele","C52047","Human INHBA wild-type allele is located within 7p15-p13 and is approximately 11 kb in length. This allele, which encodes inhibin beta A chain protein, plays a role in the inhibition of follitropin secretion in the pituitary gland in is involved in the regulation of diverse cellular functions.","INHBA wt Allele | EDF | FRP | Inhibin, Beta A (Activin A, Activin AB Alpha Polypeptide) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710290","TGFA wt Allele","C51524","Human TGFA wild-type allele is located within 2p13 and is approximately 107 kb in length. This allele, which encodes transforming growth factor alpha protein, plays a role in mitogenic responses.","TGFA wt Allele | Transforming Growth Factor Alpha wt Allele | Transforming Growth Factor, Alpha Gene | Transforming Growth Factor, Alpha wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0192881","Ileocolectomy","C51793","Surgical removal of part or all of the ileum, and part or all of the colon.","Ileocolectomy | ",,,,,,,,,,,,,,,"4078310","Ileocolic resection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709819","RNA Transport Gene","C54549","A gene that encodes a protein which facilitates the transport of some form of RNA from one subcellular compartment to another.","RNA Transport Gene | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556238","Grade 2 Ventricular Flutter, CTCAE","C54837","No value exists.","Grade 2 Ventricular Flutter, CTCAE | Grade 2 Ventricular flutter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880840","Form FDA 1572","C54623","A federal form that is the statement of the investigator that he will abide by the federal guidelines set forth in the Code of Federal Regulations for the use of drugs in an investigational setting.","Form FDA 1572 | 1572 | 1572 form | FDA Form 1572 | Form 1572 | Form FDA 1572-Statement of Investigator | Informed Consent Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963169","Death Due to Multi-Organ Failure Not Associated with More Specific Term, CTCAE","C55283","No value exists.","Death Due to Multi-Organ Failure Not Associated with More Specific Term, CTCAE | Multi-organ failure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556306","Grade 2 Pulmonary Hypertension, CTCAE","C55013","Moderate dyspnea, cough; requiring evaluation by cardiac catheterization and medical intervention","Grade 2 Pulmonary Hypertension, CTCAE | Grade 2 Pulmonary hypertension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705447","EGFL6 wt Allele","C54439","Human EGFL6 wild-type allele is located within Xp22 and is approximately 64 kb in length. This allele, which encodes EGF-Like Protein 6, is involved in cell cycle.","EGFL6 wt Allele | DKFZP564P2063 | DKFZP564P2063 Gene | EGF Repeat-Containing Protein 6 Gene | EGF-Like 6 | EGF-Like 6 Gene | EGF-Like-Domain, Multiple 6 wt Allele | EGFL6 | Epidermal Growth Factor-Like Protein 6 Gene | MAEG | MAM Domain- and EGF Domain-Containing Gene | MAM- and EGF-Containing Gene | W80",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707875","Early Stromal Invasion Present","C54212","No value exists.","Early Stromal Invasion Present | Superficial Invasion Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022267","Isoxsuprine","C61795","A benzyl alcohol derivative with vasodilator activity. The mechanism of action of isoxsuprine hydrochloride is controversial, because isoxsuprine has beta-adrenergic activities that could not be offset by beta-adrenergic blockers. Although stimulation of the beta adrenergic receptor increases blood flow to produce vasodilatation, this agent may also have direct effects on the contractility of smooth muscle. Additionally, isoxsuprine causes relaxation of uterine smooth muscle and may also produce positive inotropic and chronotropic effects on the myocardium.","Isoxsuprine | ISOXSUPRINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1559770","CTCAE Grade 3 Scrotum infection with normal ANC or Grade 1 or 2 neutrophils","C59583","No value exists.","Grade 3 Scrotum Infection with Normal Absolute Neutrophil Count or Grade 1 or 2 Neutrophils, CTCAE | CTCAE Grade 3 Scrotum infection with normal ANC or Grade 1 or 2 neutrophils | Grade 3 Scrotum infection with normal ANC or Grade 1 or 2 neutrophils",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1558754","Grade 3 Small Bowel NOS Intra-Operative Injury, CTCAE","C58848","No value exists.","Grade 3 Small Bowel NOS Intra-Operative Injury, CTCAE | Grade 3 Small bowel NOS intra-operative injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007552","Cefoperazone","C61663","A semisynthetic, broad-spectrum, third-generation cephalosporin with antibacterial activity. Cefoperazone binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.","Cefoperazone | CEFOPERAZONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1560948","CTCAE Grade 3 Infection - Other","C59545","No value exists.","Grade 3 Other Infection, CTCAE | CTCAE Grade 3 Infection - Other | Grade 3 Infection - Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879801","Benign Basal Cell Tumor of the Rat Forestomach","C63885","No value exists.","Benign Basal Cell Tumor of the Rat Forestomach | Rat Forestomach Benign Basal Cell Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881202","Inductively-Coupled Plasma Optical Emission Spectrometer","C62338","A spectrometer in which a sample is introduced, either by spraying or ultrasonic nebulization, into inductively-coupled plasma generated from argon gas. This process excites dissolved metals, thereby causing them to emit radiation in both the UV and visible spectrum. The emitted radiation is dispersed by a grating monochrometer and detected with photomultiplier tubes.","Inductively-Coupled Plasma Optical Emission Spectrometer | ICP Optical Emission Spectrometer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556960","CTCAE Grade 2 Mediastinum NOS infection with normal ANC or Grade 1 or 2 neutrophils","C59285","No value exists.","Grade 2 Mediastinum Infection NOS with Normal Absolute Neutrophil Count or Grade 1 or 2 Neutrophils, CTCAE | CTCAE Grade 2 Mediastinum NOS infection with normal ANC or Grade 1 or 2 neutrophils | Grade 2 Mediastinum NOS infection with normal ANC or Grade 1 or 2 neutrophils",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881357","Large Adenocarcinoma Cell with Eosinophilic Cytoplasm","C61110","No value exists.","Large Adenocarcinoma Cell with Eosinophilic Cytoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1560941","CTCAE Grade 2 Wound infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L)","C59404","No value exists.","Grade 2 Wound Infection Documented Clinically or Microbiologically with Grade 3 or 4 Neutrophils, CTCAE | CTCAE Grade 2 Wound infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) | Grade 2 Wound infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556776","CTCAE Grade 3 Cornea infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L)","C59455","No value exists.","Grade 3 Cornea Infection Documented Clinically or Microbiologically with Grade 3 or 4 Neutrophils, CTCAE | CTCAE Grade 3 Cornea infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) | Grade 3 Cornea infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0872894","Ganirelix Acetate","C61774","The acetate salt form of ganirelix, a synthetic decapeptide with high antagonistic activity against naturally occurring gonadotropin-releasing hormone (GnRH). Ganirelix directly competes with the GnRH for receptor binding in the anterior pituitary gland, thus induces a rapid and reversible suppression of the release of follicle stimulating hormone (FSH) and luteinizing hormone (LH). This agent is used for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation, and in combination with other hormones for retrieval of the mature follicles for in-vitro fertilization.","Ganirelix Acetate | GANIRELIX ACETATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1559665","CTCAE Grade 3 Nerve-peripheral infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L)","C59558","No value exists.","Grade 3 Peripheral Nerve Infection Documented Clinically or Microbiologically with Grade 3 or 4 Neutrophils, CTCAE | CTCAE Grade 3 Nerve-peripheral infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) | Grade 3 Nerve-peripheral infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883239","Supraglottic Cancer pN3 TNM Finding v6 and v7","C64749","Supraglottic cancer with metastasis in a lymph node, more than 6 cm in greatest dimension. (from AJCC 6th and 7th Eds.)","Supraglottic Cancer pN3 TNM Finding v6 and v7 | Supraglottic Cancer pN3 TNM Finding | Supraglottic Cancer pN3 TNM Finding v6 | Supraglottic Cancer pN3 TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881953","Nanobomb","C62367","An explosive device comprised of carbon nanotubes. These nanoscale devices have desirable optical and thermal properties that can be exploited for novel cancer therapeutics. The ability to manipulate these properties facilitates a controlled, localized activation and clearance mechanism of diseased or abnormal cells.","Nanobomb | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1559625","CTCAE Grade 3 Lymphatic infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L)","C59517","No value exists.","Grade 3 Lymphatic Infection Documented Clinically or Microbiologically with Grade 3 or 4 Neutrophils, CTCAE | CTCAE Grade 3 Lymphatic infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) | Grade 3 Lymphatic infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881939","NANOG wt Allele","C61134","Human NANOG wild-type allele is located in the vicinity of 12p13.31 and is approximately 7 kb in length. This allele, which encodes homeobox protein NANOG, plays a role in both the modulation of transcription by RNA polymerase II and the establishment of embryonic stem cell pleuripotency.","NANOG wt Allele | FLJ12581 | FLJ40451 | Homeobox Transcription Factor Nanog-Delta 48 Gene | Nanog Homeobox wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1558726","Salivary Duct Intra-Operative Injury Adverse Event","C59082","No value exists.","Salivary Duct Intra-Operative Injury, CTCAE | Salivary duct intra-operative injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0055797","CISCA Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029193","Metaproterenol","C61834","No value exists.","Metaproterenol | METAPROTERENOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1559765","CTCAE Grade 3 Salivary gland infection with normal ANC or Grade 1 or 2 neutrophils","C59580","No value exists.","Grade 3 Salivary Gland Infection with Normal Absolute Neutrophil Count or Grade 1 or 2 Neutrophils, CTCAE | CTCAE Grade 3 Salivary gland infection with normal ANC or Grade 1 or 2 neutrophils | Grade 3 Salivary gland infection with normal ANC or Grade 1 or 2 neutrophils",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881626","Maxillary Sinus Cancer pT3 TNM Finding v6 and v7","C64758","Maxillary sinus cancer with tumor invading any of the following: bone of the posterior wall of maxillary sinus, subcutaneous tissues, floor or medial wall of orbit, pterygoid fossa, or ethmoid sinuses. (from AJCC 6th and 7th Eds.)","Maxillary Sinus Cancer pT3 TNM Finding v6 and v7 | Maxillary Sinus Cancer pT3 TNM Finding | Maxillary Sinus Cancer pT3 TNM Finding v6 | Maxillary Sinus Cancer pT3 TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1558519","CTCAE Grade 3 NERVES: CN II (optic) intra-operative injury","C58769","No value exists.","Grade 3 Cranial Nerve II Intra-Operative Injury, CTCAE | CTCAE Grade 3 NERVES: CN II (optic) intra-operative injury | Grade 3 NERVES: CN II (optic) intra-operative injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1558260","CTCAE Grade 4 Artery-extremity (lower) intra-operative injury","C58946","No value exists.","Grade 4 Lower Extremity Artery Intra-Operative Injury, CTCAE | CTCAE Grade 4 Artery-extremity (lower) intra-operative injury | Grade 4 Artery-extremity (lower) intra-operative injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831771","V930 Vaccine","C61069","A novel cancer vaccine designed to treat HER-2- and/or CEA-expressing cancers.","V930 Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1378107","FIGO Stage III Carcinoma of the Fallopian Tube","C8722","Stage III includes: (T3, N0, M0); IIIA (T3a, N0, M0); IIIB (T3b, N0, M0); IIIC (T3c, N0, M0).  T3: Tumor involves one or both fallopian tubes, with peritoneal implants outside the pelvis.  T3a: Microscopic peritoneal metastasis outside the pelvis.  T3b: Macroscopic peritoneal metastasis outside the pelvis 2cm or less in greatest dimension.  T3c: Peritoneal metastasis more than 2cm in diameter. (AJCC 6th ed.)","Stage III Fallopian Tube Cancer AJCC v6 | AJCC Stage III Fallopian Tube Cancer v6 | FIGO Stage III Carcinoma of Fallopian Tube | FIGO Stage III Carcinoma of the Fallopian Tube AJCC v6 | FIGO Stage III Fallopian Tube Carcinoma | Fallopian Tube Cancer Stage III AJCC v6 | Stage III Fallopian Tube Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981336","Metrizoate Calcium","C87702","No value exists.","Metrizoate Calcium | Benzoic Acid, 3-(Acetylamino)-5-(Acetylmethylamino)-2,4,6-Triiodo-, Calcium Salt (2:1) | Calcium Metrizoate | METRIZOATE CALCIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0814766","Attributable Risk","C67360","Part of a risk that is identified as due to exposure to a defined factor.","Attributable Risk | attributable risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348620","Suspension for Reconstitution Dosage Form","C69027","A suspension mixed with a liquid to form a solution or suspension before administration.","Suspension for Reconstitution Dosage Form | Susp for Reconstitution | Suspension for Reconstitution | Suspension for Reconstitution Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1017328","Streptococcus gallolyticus","C86791","A species of facultatively anaerobic, Gram positive, cocci shaped bacteria in the phylum Firmicutes. This species is positive for gallate degradation, esculin hydrolysis and Lancefield group D and negative for catalase, hemolysis, growth in 6.5% NaCl and pyrrolidonylarylamidase. It can ferment cellobiose, fructose, galactose, glucose, lactose, maltose, mannose, melibiose and trehalose but not ribose or sorbitol. S. gallolyticus is commensal in the human alimentary tract and is a pathogen that can cause septicemia and endocarditis.","Streptococcus gallolyticus | STREPTOCOCCUS GALLOLYTICUS",,,,,,,,,,,,,,,"4015114","Streptococcus gallolyticus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1881123","IPA Liver Cancer Regimen","C67296","A regimen consisting of ifosfamide, cisplatin and doxorubicin, used in the neoadjuvant setting for the treatment of advanced-stage, childhood hepatoblastoma.","IPA Liver Cancer Regimen | HB-89 Regimen | IPA | IPA Regimen | Ifosfamide-Platinol-Adriamycin Liver Cancer Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349044","Unit of Entropy","C70446","A unit used to express the number of microscopic configurations resulting in the observed macroscopic description of the thermodynamic system that represents the amount of uncertainty which remains about a system, after its observable macroscopic properties have been taken into account.","Unit of Entropy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0644519","Visnadine","C87287","No value exists.","Visnadine | 3,4,5-Trihydroxy-2,2-Dimethyl-6-Chromanacrylic Acid D-Lactone 4-Acetate 3-(2-Methylbutyrate). | VISNADINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827854","Liter per Mole","C85680","Liters per mole.","Liter per Mole | L/mol | l/mol | mL/mmol | uL/umol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347331","Naturally Occurring Folate","C68512","No value exists.","Naturally Occurring Folate | Food Folate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0320062","Alternaria alternata","C87529","No value exists.","Alternaria alternata | ALTERNARIA ALTERNATA | Alternaria fasciculata | Alternaria rugosa | Alternaria tenuis | Macrosporium fasciculatum | Torula alternata | Ulocladium consortiale",,,,,,,,,,,,,,,"4280575","Alternaria alternata",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1003853","Clostridiaceae","C85986","A taxonomic family of bacterium in the phylum Firmicutes that includes the genera Alkaliphilus, Clostridium and Lutispora, among others.","Clostridiaceae | ",,,,,,,,,,,,,,,"4314746","Clostridiaceae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1541273","Recurrent Marginal Zone Lymphoma","C68684","The reemergence of marginal zone lymphoma after a period of remission.","Recurrent Marginal Zone Lymphoma | Recurrent Marginal Zone B-Cell Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349100","Valid Biomarker","C68763","No value exists.","Valid Biomarker | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981761","Mycosis Fungoides and Sezary Syndrome N0 TNM Finding v7","C88237","No clinically abnormal peripheral lymph nodes; biopsy not required.  Note: for node, abnormal peripheral lymph node(s) indicates any palpable peripheral node that on physical examination is firm, irregular, clustered, fixed or 1.5 cm or larger in diameter.  Node groups examined on physical examination include cervical, supraclavicular, epitrochlear, axillary, and inguinal.  Central nodes, which are not generally amenable to pathologic assessment, are not currently considered in the nodal classification unless used to establish N3 histopathology.  (from AJCC 7th Ed.)","Mycosis Fungoides and Sezary Syndrome N0 TNM Finding v7 | Mycosis Fungoides and Sézary Syndrome N0 TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0317883","Neisseria mucosa","C86606","A species of aerobic, Gram-negative, diplococci shaped bacteria assigned to the phylum Proteobacteria. This species is catalase and oxidase positive, non-hemolytic, produces a yellowish pigment, reduces both nitrate and nitrite, synthesizes polysaccharides, and produces acid from glucose, maltose, fructose, and sucrose, but not mannose or lactose. N. mucosa is commensal in the human nasopharynx and is rarely pathogenic.","Neisseria mucosa | NEISSERIA MUCOSA",,,,,,,,,,,,,,,"4305338","Neisseria mucosa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348309","Docosapentaenoic Acid n-6","C68348","A polyunsaturated very long-chain fatty acid with a 22-carbon backbone and 5 double bonds, originating from the 6th, 9th, 12th, 15th and 18th positions from the methyl end.","Docosapentaenoic Acid n-6 | Fatty acid 22:5 n-6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346602","Joule per Kilogram","C70439","A unit of specific energy defined as the energy equal to one joule in the mass of matter equal to one kilogram.","Joule per Kilogram | J/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827920","Observed Mean Residence Time Infinity","C85769","The observed mean residence time (MRT) extrapolated to infinity.","Observed Mean Residence Time Infinity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0602975","Citenazone","C87472","A thiosemicarbazone derivative with activity against variola virus.","Citenazone | 2-((5-Cyano-2-thienyl)methylene)hydrazinecarbothioamide | 5-Cyanthiophene-2-aldehydethiosemicarbazone | 5-Formyl-2-Thiophenecarbonitrile Thiosemicarbazone | CITENAZONE | HOE 105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881701","Device Markings/Labeling Problem","C62976","Problem associated with the written, printed or graphic material accompanying or affixed to the device or any of its packaging. This includes verbal instructions relating to identification, technical description, and usage provided by a medical device manufacturers. Problems can include but are not limited to this material being unclear, missing, worn out, incorrect or inaccurate.","Device Markings/Labeling Problem | Device Markings/Labelling Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0056301","Cupric Sulfate","C65354","No value exists.","Cupric Sulfate | Blue Copperas | Blue Vicking | Bluestone | CUPRIC SULFATE | Copper(II) Sulfate, Pentahydrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881697","Medical Device Inoperable","C62979","No value exists.","Medical Device Inoperable | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0063440","Impromidine","C65902","No value exists.","Impromidine | IMPROMIDINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882093","No Marking on Medical Device","C62901","No value exists.","No Marking on Medical Device | Markings Are not Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880367","Ditiomustine","C65443","A nitrosourea compound with alkylating activity. Ditiomustine crosslinks DNA, resulting in the inhibition of DNA replication and eventually cellular proliferation.","Ditiomustine | DITIOMUSTINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882374","Piclonidine","C66381","No value exists.","Piclonidine | PICLONIDINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0770998","Halethazole","C65837","No value exists.","Halethazole | 5-Chloro-2-[p-(diethylaminoethoxy)phenyl]benzothiazole | Episol | HALETHAZOLE | Haletazole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880265","Defective Device","C63250","Problem associated with having flaws or dimensional deviations greater than acceptable for the intended use of the device.","Defective Device | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0628458","Histapyrrodine","C65855","No value exists.","Histapyrrodine | HISTAPYRRODINE | N-Benzyl-N-(2-(1-pyrrolidinyl)ethyl)anilin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336233","Stage IIIB Squamous Cell Carcinoma of Lung","C6690","Stage IIIB includes: (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IIIB Lung Squamous Cell Carcinoma AJCC v7 | Stage IIIB Squamous Cell Carcinoma of Lung | Stage IIIB Squamous Cell Carcinoma of the Lung | Stage IIIB Squamous Cell Lung Cancer | Stage IIIB Squamous Cell Lung Carcinoma | Stage IIIB Squamous Cell Lung Carcinoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879611","Adenoma of the Rat Oviduct","C63963","No value exists.","Adenoma of the Rat Oviduct | Rat Oviduct Adenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0065834","Mebhydrolin","C66059","No value exists.","Mebhydrolin | MEBHYDROLIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0065884","Iodamide Meglumine","C65929","No value exists.","Iodamide Meglumine | IODAMIDE MEGLUMINE",,,,,,,,,,,,,,,"4133970","Iodamide meglumine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1881744","Medical Device Shelf Life Exceeded","C62926","No value exists.","Medical Device Shelf Life Exceeded | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880302","Diagnostic Laboratory Biomarker Analysis","C64900","No value exists.","Diagnostic Laboratory Biomarker Analysis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0045686","Piridronic Acid","C66420","A synthetic pyridinyl bisphosphonate with anti-resorptive activity. Although the exact mechanism of action has yet to be fully elucidated, piridronic acid likely binds to hydroxyapatite crystals in the bone matrix and inhibits farnesyl pyrophosphate synthase, an enzyme that plays an important role in the mevalonate pathway. This inhibits the formation of isoprenoid metabolites that are substrates for protein prenylation. This prevents farnesylation and geranylgeranylation of proteins essential for osteoclast function, leading to the induction of apoptosis and eventually, osteoclast-cell death. By preventing osteoclast-mediated bone resorption, piridronic acid decreases bone turnover and stabilizes the bone matrix.","Piridronic Acid | 2-(2-Pyridyl)ethylidine-1,1-bisphosphonate | PIRIDRONIC ACID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0637817","Etazepine","C65556","No value exists.","Etazepine | ETAZEPINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0139597","Pyrvinium Pamoate","C66499","The pamoate salt of pyrvinium, a quinoline-derived cyanine dye and an mitochondrial oxidative phosphorylation (OxPhos) inhibitor, with anthelmintic and potential antineoplastic activities. Upon administration, pyrvinium pamoate may inhibit mitochondrial OxPhos and mitochondrial respiration, decreases mitochondrial function, prevents tumor cell metabolism and deprives tumor cells of energy, thereby preventing tumor cell proliferation and leading to tumor cell death in some types of cancer cells. Mitochondrial OxPhos is overactivated in cancer cells and plays a key role in tumor cell proliferation. Drug resistant tumor cells are very susceptible to decreased mitochondrial OxPhos as they cannot easily compensate for the decrease in mitochondrial function by increasing glycolysis.","Pyrvinium Pamoate | 6-(Dimethylamino)-2-(2-(2,5-dimethyl-1-phenylpyrrol-3-yl)vinyl)-1-methylquinolinium 4,4'-methylenebis(3-hydroxy-2-naphthoate) (2:1) | PYRVINIUM PAMOATE | Quinolinium, 6-(Dimethylamino)-2-(2-(2,5-dimethyl-1-phenyl-1h-pyrrol-3-yl)ethenyl)-1-methyl-, Salt with 4,4'-Methylenebis(3-hydroxy-2-naphthalenecarboxylic Acid) (2:1)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879827","Benign Sertoli Cell Tumor of the Rat Ovary","C63970","No value exists.","Benign Sertoli Cell Tumor of the Rat Ovary | Rat Ovary Benign Sertoli Cell Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0070313","Pentifylline","C66344","No value exists.","Pentifylline | PENTIFYLLINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0056727","Drofenine","C65484","No value exists.","Drofenine | DROFENINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881755","Device or Device Quality Issue","C62948","A difficulty with the quality of part of the device or the device itself.","Device or Device Quality Issue | Product Quality Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0546866","Gentamicin Sulfate","C65803","The sulfate salt form of gentamycin, a broad-spectrum aminoglycoside antibiotic complex produced by the fermentation of Micromonospora purpurea or M. echinospora, with antibacterial activity. Gentamicin is a thermostable complex containing the gentamicins C1, C1a, C2, C2a and C2b.","Gentamicin Sulfate | GENTAMICIN SULFATE | Gentamicin C | Sch 9724",,,,,,,,,,,,,,,"4331157","Gentamicin sulfate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1880148","Communication or Transmission Problem","C63271","Problem associated with a device sending or receiving signals or data. This includes transmission among internal components of the device to which the device is intended to communicate.","Communication or Transmission Problem | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334249","Non-Keratinizing Small Cell Squamous Cell Carcinoma","C65175","A squamous cell carcinoma composed of small atypical cells without morphologic evidence of keratin production.","Non-Keratinizing Small Cell Squamous Cell Carcinoma | Epidermoid carcinoma, small cell, nonkeratinizing | Squamous cell carcinoma, small cell, nonkeratinizing","8073/3","Squamous cell carcinoma, small cell, nonkeratinizing",,,,,,,,,,,,,"4147603","Squamous cell carcinoma, small cell, nonkeratinizing",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1879770","BEP regimen","C63488","A regimen consisting of bleomycin, etoposide and cisplatin that may be used for the treatment of gestational trophoblastic neoplasia (GTN),  malignant sex cord-stromal tumors, ovarian and testicular cancer, including ovarian and testicular germ cell tumors (GCTs).","BEP Regimen | Adult BEP | Adult BEP Regimen | BEP | BEP regimen | Bleomycin-Etoposide-Cisplatin Regimen | Bleomycin-Etoposide-Platinol Regimen | Bleomycin/Etoposide/Platinum | PEB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0146712","Dipenine Bromide","C65418","No value exists.","Dipenine Bromide | 2,2-Dicyclopentylacetic Acid 2'-diethylaminoethyl Ester Ethobromide | DIPONIUM BROMIDE | Diponium Bromide | HL 267 | SA-267 | Spaston",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333595","Fallopian Tube Papillary Adenocarcinoma","C6267","An adenocarcinoma that arises from the fallopian tube and is characterized by a papillary architectural pattern.","Fallopian Tube Papillary Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881990","Nasal Cavity and Ethmoid Sinus Cancer Pathologic TNM Finding v6","C65033","A pathologic finding about one or more characteristics of nasal cavity and ethmoid sinus cancer, following the rules of the TNM AJCC v6 classification system.","Nasal Cavity and Ethmoid Sinus Cancer Pathologic TNM Finding v6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0066032","Mesudipine","C66102","No value exists.","Mesudipine | MESUDIPINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347850","Application Network Problem","C64349","Problem associated with the deviations from documented system specifications that affects overall system performance and/or the performance of an individual medical device connected to that system.","Application Network Problem | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333748","Gallbladder Lymphoma","C5734","A lymphoma that arises from the gallbladder, with the bulk of the tumor located at this site.","Gallbladder Lymphoma | Lymphoma of Gallbladder | Lymphoma of the Gallbladder | Primary Gallbladder Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1557108","CTCAE Grade 5 Wound infection with unknown ANC","C60114","No value exists.","Grade 5 Wound Infection with Unknown Absolute Neutrophil Count, CTCAE | CTCAE Grade 5 Wound infection with unknown ANC | Grade 5 Wound infection with unknown ANC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335994","Small Intestinal Fibrosarcoma","C5336","A usually aggressive malignant neoplasm arising from the small intestine.  It is characterized by the presence of spindle-shaped fibroblasts and collagenous stroma formation in a herringbone growth pattern.","Small Intestinal Fibrosarcoma | Fibrosarcoma of Small Bowel | Fibrosarcoma of Small Intestine | Fibrosarcoma of the Small Bowel | Fibrosarcoma of the Small Intestine | Fibrosarcoma, Small Intestine | Small Bowel Fibrosarcoma | Small Intestine Fibrosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1558025","Grade 1 Ureter Perforation, CTCAE","C56794","No value exists.","Grade 1 Ureter Perforation, CTCAE | Grade 1 Ureter perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1561168","CTCAE Grade 4 Pancreas infection with unknown ANC","C59784","No value exists.","Grade 4 Pancreas Infection with Unknown Absolute Neutrophil Count, CTCAE | CTCAE Grade 4 Pancreas infection with unknown ANC | Grade 4 Pancreas infection with unknown ANC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556597","Grade 2 Biliary Tree Perforation, CTCAE","C57279","No value exists.","Grade 2 Biliary Tree Perforation, CTCAE | Grade 2 Biliary tree perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880107","Clinical Trial Agreement","C60777","Documentation detailing the agreement of the clinical trial requirements between the sponsor or representative of the sponsor and the investigator or institution.","Clinical Trial Agreement Documentation | Clin Trial Agrmnt | Clinical Study Agreement | Clinical Trial Agreement | Clinical Trial Agreement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1557750","Trachea Obstruction and Stenosis, CTCAE","C58206","No value exists.","Trachea Obstruction and Stenosis, CTCAE | Trachea obstruction/stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1560760","Grade 3 Uterine Hemorrhage, CTCAE","C56428","Transfusion indicated; invasive intervention indicated; hospitalization","Grade 3 Uterine Hemorrhage, CTCAE | Grade 3 Uterine hemorrhage | Grade 3 Uterus hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1557089","Vagina Infection with Unknown Absolute Neutrophil Count, CTCAE","C60286","No value exists.","Vagina Infection with Unknown Absolute Neutrophil Count, CTCAE | Vagina infection with unknown ANC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556532","Grade 4 Stomach Necrosis, CTCAE","C57648","No value exists.","Grade 4 Stomach Necrosis, CTCAE | Grade 4 Stomach necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1557574","Grade 1 Rectum Pain, CTCAE","C56206","No value exists.","Grade 1 Rectum Pain, CTCAE | Grade 1 Rectum pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556598","Grade 3 Biliary Tree Perforation, CTCAE","C57403","No value exists.","Grade 3 Biliary Tree Perforation, CTCAE | Grade 3 Biliary tree perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1560704","Grade 2 Renal Hemorrhage, CTCAE","C56350","Analgesics and hematocrit monitoring indicated","Grade 2 Renal Hemorrhage, CTCAE | Grade 2 Kidney hemorrhage | Grade 2 Renal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334377","Laryngeal Sarcoma","C6020","A rare sarcoma that arises from soft tissue or hyaline cartilage of the larynx.","Laryngeal Sarcoma | Larynx Sarcoma | Sarcoma of Larynx | Sarcoma of the Larynx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1561240","CTCAE Grade 5 Extremity-lower soft tissue necrosis","C58361","No value exists.","Grade 5 Lower Extremity Soft Tissue Necrosis, CTCAE | CTCAE Grade 5 Extremity-lower soft tissue necrosis | Grade 5 Extremity-lower soft tissue necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556666","CTCAE Grade 5 Hepatobiliary/Pancreas - Other","C56595","No value exists.","Grade 5 Other Hepatobiliary and Pancreas, CTCAE | CTCAE Grade 5 Hepatobiliary/Pancreas - Other | Grade 5 Hepatobiliary/Pancreas - Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1558317","Grade 1 Brain Intra-Operative Injury, CTCAE","C58481","No value exists.","Grade 1 Brain Intra-Operative Injury, CTCAE | Grade 1 Brain intra-operative injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1560622","Grade 4 Esophagus Hemorrhage, CTCAE","C56442","No value exists.","Grade 4 Esophagus Hemorrhage, CTCAE | Grade 4 Esophagus hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708236","Geographic Area Level Statistic","C53185","No value exists.","Geographic Area Level Statistic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1559471","Grade 5 Cecum Ulcer, CTCAE","C57674","No value exists.","Grade 5 Cecum Ulcer, CTCAE | Grade 5 Cecum ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1557831","Grade 5 Kidney Fistula, CTCAE","C57015","No value exists.","Grade 5 Kidney Fistula, CTCAE | Grade 5 Kidney fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1168200","Stage IVB Gallbladder Cancer AJCC v7","C5742","Stage IVB includes: (Any T, N2, M0); (Any T, Any N, M1).  N2: Metastases to periaortic, pericaval, superior mesenteric artery, and/or celiac artery lymph nodes.  M0: No distant metastasis.  M1: Distant metastasis. (from AJCC 7th Ed.)","Stage IVB Gallbladder Cancer AJCC v7 | Gallbladder Cancer Stage IVB AJCC v7 | Gallbladder Carcinoma Stage IVB AJCC v7 | Stage IVB Carcinoma of Gallbladder AJCC v7 | Stage IVB Carcinoma of the Gallbladder AJCC v7 | Stage IVB Gallbladder Cancer | Stage IVB Gallbladder Carcinoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556626","Grade 2 Respiratory Tract Hemorrhage NOS, CTCAE","C56367","No value exists.","Grade 2 Respiratory Tract Hemorrhage NOS, CTCAE | Grade 2 Respiratory tract hemorrhage NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1561114","CTCAE Grade 5 Lymphatic infection with unknown ANC","C59991","No value exists.","Grade 5 Lymphatic Infection with Unknown Absolute Neutrophil Count, CTCAE | CTCAE Grade 5 Lymphatic infection with unknown ANC | Grade 5 Lymphatic infection with unknown ANC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1561245","CTCAE Grade 5 Extremity-upper soft tissue necrosis","C58375","No value exists.","Grade 5 Upper Extremity Soft Tissue Necrosis Adverse Event, CTCAE | CTCAE Grade 5 Extremity-upper soft tissue necrosis | Grade 5 Extremity-upper soft tissue necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1558944","Grade 2 Tumor Flare, CTCAE","C56613","No value exists.","Grade 2 Tumor Flare, CTCAE | Grade 2 Tumor flare",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1558061","Renal or Genitourinary Other, CTCAE","C57075","No value exists.","Renal or Genitourinary Other, CTCAE | Renal/Genitourinary - Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1557443","CTCAE Grade 3 Dental/teeth/peridontal pain","C56053","No value exists.","Grade 3 Dental and Teeth and Peridontal Pain, CTCAE | CTCAE Grade 3 Dental/teeth/peridontal pain | Grade 3 Dental/teeth/peridontal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0392777","Poikiloderma","C53975","A localized skin condition commonly associated with sun exposure that is characterized by variegated discoloration, telangiectasia and atrophy.","Poikiloderma | ",,,,,,,,,,,,,,,"4289297|4298710","Poikiloderma|Poikiloderma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1558092","Genitourinary Stoma Stricture or Stenosis, CTCAE","C57066","No value exists.","Genitourinary Stoma Stricture or Stenosis, CTCAE | Stoma GU stricture/stenosis (including anastomotic)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1559557","CTCAE Grade 5 Eye NOS infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L)","C59945","No value exists.","Grade 5 Eye Infection NOS Documented Clinically or Microbiologically with Grade 3 or 4 Neutrophils, CTCAE | CTCAE Grade 5 Eye NOS infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) | Grade 5 Eye NOS infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1560519","CTCAE Grade 3 Stoma GI leak (including anastomotic)","C57444","No value exists.","Grade 3 Gastrointestinal Stoma Leak, CTCAE | CTCAE Grade 3 Stoma GI leak (including anastomotic) | Grade 3 Stoma GI leak (including anastomotic)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1557154","CTCAE Grade 2 Lymphatics - Other","C55697","No value exists.","Grade 2 Other Lymphatics, CTCAE | CTCAE Grade 2 Lymphatics - Other | Grade 2 Lymphatics - Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007192","Alcoholic Cardiomyopathy","C53653","A dilated cardiomyopathy which is associated with consumption of large amounts of alcohol over a period of years.","Alcoholic Cardiomyopathy | Alcoholic cardiomyopathy",,,,,,,,,,,,,,,"37164777","Alcoholic cardiomyopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1560247","Grade 4 Splenic Function, CTCAE","C55976","No value exists.","Grade 4 Splenic Function, CTCAE | Grade 4 Splenic function",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1560873","CTCAE Grade 4 Spinal cord (myelitis) infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L)","C59833","No value exists.","Grade 4 Spinal Cord Infection Documented Clinically or Microbiologically with Grade 3 or 4 Neutrophils, CTCAE | CTCAE Grade 4 Spinal cord (myelitis) infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) | Grade 4 Spinal cord (myelitis) infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1558296","Biliary Tree Left Hepatic Duct Intra-Operative Injury Adverse Event","C58419","No value exists.","Biliary Tree Left Hepatic Duct Intra-Operative Injury, CTCAE | Biliary tree-left hepatic duct intra-operative injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1559581","CTCAE Grade 4 Ileum infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L)","C59725","No value exists.","Grade 4 Ileum Infection Documented Clinically or Microbiologically with Grade 3 or 4 Neutrophils, CTCAE | CTCAE Grade 4 Ileum infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) | Grade 4 Ileum infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0068740","Nifurmazole","C84016","No value exists.","Nifurmazole | NIFURMAZOLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826530","MIR516A2 Pre-miRNA","C82837","MIR516A2 is an oligoribonucleotide that is encoded by the human MIR516A2 gene and has a role in the regulation of gene expression.","MIR516A2 Pre-miRNA | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826200","Clinical Study Safety Issue and Lack of Effectiveness","C82455","No value exists.","Clinical Study Safety Issue and Lack of Effectiveness | Both Safety and LOEE Issue (Clinical Studies)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825313","Computer Grid","C80698","An interconnected computer network whose combined resources may be harnessed to work on difficult problems.","Grid | Computer Grid | Device Grid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0993224","Medronate Disodium","C76571","No value exists.","Medronate Disodium | Cis-mdp | Disodium Dihydrogen Methylenediphosphonate | Disodium Methylene Diphosphonate | MEDRONATE DISODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825583","Napamezole Hydrochloride","C81333","No value exists.","Napamezole Hydrochloride | NAPAMEZOLE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0075541","Sulfatolamide","C76983","A combination of two sulfonamide antibacterials, sulfathiourea and mafenide, used in the treatment of gynecological infections.","Sulfatolamide | Marbadal | SULFATOLAMIDE | Sulfathiourea-mafenide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025805","Nordefrin","C81340","No value exists.","Nordefrin | (+/-)-Cobefrin | 1,2-benzenediol, 4-((1R,2S)-2-amino-1-hydroxypropyl)-, Rel- | NORDEFRIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0769436","Deferitrin","C76597","No value exists.","Deferitrin | 4-Hydroxydesazadesferrithiocin | DEFERITRIN | GT-56-252",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827163","Guafecainol","C83738","No value exists.","Guafecainol | GUAFECAINOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827100","Captamine","C83585","No value exists.","Captamine | 2-(Dimethylamino)-Ethanethiol | CAPTAMINE | Ethanethiol, 2-(Dimethylamino)- | N-(2-Mercaptoethyl)Dimethylamine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0752345","High-Density Polyethylene","C83759","No value exists.","High Density Polyethylene | HDPE | HIGH DENSITY POLYETHYLENE | Polyethylene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054318","(AA).ACADS.0","C82876","Short-chain specific acyl-CoA dehydrogenase, mitochondrial (412 aa, ~44 kDa) is encoded by the human ACADS gene. This protein plays a role in the oxidation of lipids.","Short-Chain Specific Acyl-CoA Dehydrogenase, Mitochondrial | ACADS | Butyryl-CoA Dehydrogenase | EC 1.3.99.2 | EC1.3.99.2 | SCAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698537","Bone Marrow, Scapula","C77689","Bone marrow in the scapula.","Bone Marrow, Scapula | BONE MARROW, SCAPULA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537774","MIR127 Gene","C80754","This gene is involved in the regulation of gene expression and plays a role in the development of hepatocellular, colon, bladder, breast and prostate carcinomas.","MIR127 Gene | MIR127 | MicroRNA 127 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0262965","Chlormadinone","C83620","No value exists.","Chlormadinone | 10H-Phenothiazine-10-Ethanaminium, N,N,N,Alpha-Tetramethyl- | 17-(Hydroxy)-6-Chloropregna-4,6-Diene-3,20-Dione | 6-Chloro-6-Dehydro-17Alpha-Hyroxyprogesterone | CHLORMADINONE | Pregna-4,6-Diene-3,20-Dione, 17-(Hydroxy)-6-Chloro-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278839","Recurrent Skin Carcinoma","C7903","A carcinoma of the skin that has recurred after a period of remission.","Recurrent Skin Carcinoma | Recurrent Cancer of Skin | Recurrent Cancer of the Skin | Recurrent Carcinoma of Skin | Recurrent Carcinoma of the Skin | Recurrent Cutaneous Carcinoma | Recurrent Skin Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825741","Indeterminate Dendritic Cell Tumor","C81767","A very rare dendritic cell tumor composed of spindle to ovoid cells with a phenotype that is similar to the Langerhans cells.  Patients usually present with cutaneous papules, nodules, and plaques.  Systemic symptoms are usually absent.  The clinical course is variable.","Indeterminate Dendritic Cell Tumor | IDCT | Indeterminate Cell Histiocytosis | Indeterminate Dendritic Cell Histiocytosis | Indeterminate Dendritic Cell Histiocytosis | Indeterminate Dendritic Cell Tumor | Indeterminate Dendritic Cell Tumor | Indeterminate dendritic cell tumor",,,,,,,,,,,,,,,"36715591|45773117","Indeterminate dendritic cell neoplasm|Indeterminate dendritic cell tumor",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2827367","ZFPM1 wt Allele","C84287","Human ZFPM1 wild-type allele is located in the vicinity of 16q24.2 and is approximately 82 kb in length. This allele, which encodes zinc finger protein ZFPM1, plays a critical role in erythroid and megakaryocytic cell differentiation and transcription.","ZFPM1 wt Allele | FOG | FOG1 | ZNF408 | ZNF89A | Zinc Finger Protein, Multitype 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698731","CLPTM1L wt Allele","C79774","Human CLPTM1L wild-type allele is located within 5pter-p15.3 and is approximately 27 kb in length. This allele, which encodes cleft lip and palate transmembrane protein 1-like protein, may be involved in the regulation of apoptosis. Polymorphism may contribute to lung cancer risk.","CLPTM1L wt Allele | CLPTM1-Like wt Allele | CRR9 | Cisplatin Resistance Related Protein Gene | DKFZp666M1010 | DKFZp761M2324 | FLJ14400 | FLJ32533",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL408683","HLA-A*2402-Restricted URLC10 Peptides Vaccine","C82421","A cancer vaccine containing HLA-A*2402-restricted epitope peptides URLC10 (up-regulated lung cancer 10) with potential immunostimulatory and antineoplastic activities. Upon administration, HLA-A*2402-restricted URLC10 peptides vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against URLC10-expressing tumor cells. URLC10, a tumor associated antigen, is often overexpressed in lung, esophageal and gastric cancers. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity.","HLA-A*2402-Restricted URLC10 Peptides Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008221","Clomethiazole","C80664","No value exists.","Clomethiazole | CLOMETHIAZOLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826898","Laboratory Test End Date Time","C83308","The date and time a laboratory test has concluded.","Laboratory Test End Date Time | LBENDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0064324","Kebuzone","C79126","No value exists.","Kebuzone | 1,2-Diphenyl-4-(3'-oxobutyl)-3,5-dioxopyrazolidine | Chepirol | KEBUZONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0051706","Ammonium Bicarbonate","C82279","No value exists.","Ammonium Bicarbonate | AMMONIUM BICARBONATE | Ammonium Hydrogen Carbonate | Monoammonium Carbonate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334207","Intermediate Blood Vessel Neoplasm","C7391","A borderline blood vessel neoplasm that can be locally aggressive, and may metastasize on rare occasions.","Intermediate Blood Vessel Neoplasm | Intermediate Blood Vessel Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031586","Phorbol Ester","C742","Polycyclic compound isolated from croton oil in which two hydroxyl groups on neighboring carbon atoms are esterified to fatty acids. The commonest of these derivatives is phorbol myristoyl acetate (PMA). Potent co carcinogens or tumor promotors, they are diacyl glycerol analogs and activate protein kinase C irreversibly.","Phorbol Ester | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1075765","Aristolochia clematitis","C72249","No value exists.","Aristolochia clematitis | ARISTOLOCHIA CLEMATITIS WHOLE | Aristolochia clematitis L. | Asarabacca | Birthwort",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699840","EDDP Measurement","C75353","The determination of the amount of EDDP, the primary metabolite of methadone, present in a sample.","EDDP Measurement | 2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine Measurement | 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine | EDDP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0070233","Adicillin","C72659","No value exists.","Adicillin | (2S,5R,6R)-6-{[(5R)-5-Amino-5-carboxypentanoyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid | (D-4-Amino-4-carboxybutyl)penicillinic Acid | ADICILLIN | Cephalosporin N | Penicillin N | Synnematin B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1504927","Dabuzalgron Hydrochloride","C75037","No value exists.","Dabuzalgron Hydrochloride | DABUZALGRON HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1018254","Ceanothus americanus","C72280","No value exists.","Ceanothus americanus | CEANOTHUS AMERICANUS WHOLE | Jersey Tea | Red Root | Wild Snowball",,,,,,,,,,,,,,,"4052902","Ceanothus americanus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448941","Growth Hormone Measurement","C75386","The determination of the amount of growth hormone (GH) present in a sample.","Growth Hormone Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0886513","Echinacea purpurea","C72304","No value exists.","Echinacea purpurea | ECHINACEA PURPUREA WHOLE | Echinacea purpurea (L.) Moench | Rudbeckia purpurea L., nom. cons.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699867","Elucaine","C75092","No value exists.","Elucaine | ELUCAINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448937","ALX4 protein, human","C74967","Homeobox protein aristaless-like 4 (411 aa, ~44 kDa) is encoded by the human ALX4 gene. This protein is involved in the regulation of transcription during skull and limb development.","Homeobox Protein Aristaless-Like 4 | ALX4 | Aristaless-Like 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348903","Guarana Flavor","C73393","A characteristic of a medicinal product, specifying that its most predominant agreeable savor detected by the unified sensation of taste and olfactory receptors resembles guarana.","Guarana Flavor | GUARANA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054091","Bromebric Acid","C72089","A derivative of bromoacrylic acid with cytostatic and antineoplastic activity. Bromebric acid appears to inhibit purine synthesis, oxidative phosphorylation and DNA synthesis. This agent inhibits tumor cell growth and causes cell cycle arrest. This agent may also have some use in the phrophylaxis of migraine.","Bromebric Acid | (E)-3-p-Anisoyl-3-bromoacrylic Acid | BROMEBRIC ACID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348860","Glenvastatin","C73064","No value exists.","Glenvastatin | GLENVASTATIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0949905","Impatiens balsamina","C72525","No value exists.","Impatiens balsamina | Garden Balsam | IMPATIENS BALSAMINA WHOLE | Rose Balsam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1504982","PAX2 protein, human","C73692","Paired box protein PAX-2 (417 aa, ~45 kD) is encoded by the human PAX2 gene. This soluble, nuclear protein plays a role in transcription by RNA polymerase II and cellular proliferation.","Paired Box Protein Pax-2 | PAX-2 | PAX2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335181","Ovarian Solid Teratoma","C7285","A mature teratoma that arises from the ovary and presents as a large solid mass.  It contains multiple cysts that vary in size.  Small foci of hemorrhage are also present.","Ovarian Solid Teratoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699554","Dalbraminol","C74200","No value exists.","Dalbraminol | DALBRAMINOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347236","Butafosfan","C73233","No value exists.","Butafosfan | (1-(Butylamino)-1-methylethyl)phosphinic Acid | BUTAFOSFAN | C7H18NO2P | Coforta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL383504","Anti-CD45 Monoclonal Antibody AHN-12","C74009","A high affinity IgG1 monoclonal antibody with potential immunotherapeutic activity. Anti-CD45 monoclonal antibody AHN-12 recognizes CD45, a transmembrane protein tyrosine phosphatase that is expressed on the surface of normal and malignant hematopoietic cells.","Anti-CD45 Monoclonal Antibody AHN-12 | AHN-12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346637","Lactose Unit","C73565","A unit of measurement for the activity of lactase enzyme which is expressed as the amount of enzyme that hydrolyzes one microequivalent (uEq) of galactosidic linkage per one minute at a pH of 4.5 and at 37 degrees Celsius.","Lactose Unit | LacU | lactose unit(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL383468","Autologous Dendritic Cell-Adenovirus CCL21 Vaccine","C74015","A cancer vaccine comprised of autologous dendritic cells (DCs) that have been transduced ex vivo with an adenoviral vector containing the CCL21 gene with potential immunostimulatory and antineoplastic activities. Upon intratumoral administration, autologous dendritic cell-adenovirus CCL21 vaccine expresses the chemokine CCL21, which may induce an antitumoral cytotoxic immune response in the tumor microenvironment. CCL21 [chemokine (C-C motif) ligand 21] has been shown to attract antigen presenting cells (APCs), like leukocytes and DCs, and natural killer (NK) cells and their T-cell effectors to induce a cytotoxic immune response.","Autologous Dendritic Cell-Adenovirus CCL21 Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333502","Extragonadal Seminoma","C7327","No value exists.","Extragonadal Seminoma | Extragonadal Primary Seminoma | Primary Extragonadal Seminoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0075227","Stepronin","C74264","No value exists.","Stepronin | STEPRONIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347059","Marketed as Bulk Inactive Ingredient","C73587","A category specifying that a product is marketed as a bulk inactive ingredient.","Marketed as Bulk Inactive Ingredient | BULK INACTIVE INGREDIENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL383544","DEPDC1/MPHOSH1 Peptide Vaccine","C74023","A cancer vaccine containing HLA-A*2402-restricted epitopes derived from DEP domain containing 1 (DEPDC1) and M phase phosphoprotein 1 (MPHOSPH1) with potential immunostimulatory and antineoplastic activities. Upon administration, DEPDC1/MPHOSH1 peptide vaccine may elicit a specific cytotoxic T lymphocyte (CTL) response against tumor cells expressing DEPDC1 and MPHOSPH1, tumor antigens that are overexpressed in bladder cancer cells.","DEPDC1/MPHOSH1 Peptide Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0066477","Melperone","C73293","No value exists.","Melperone | MELPERONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347800","Clinical Study by Organizational Parameters","C70824","No value exists.","Clinical Study by Organizational Parameters | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3485069","Frangula alnus bark extract","C73888","No value exists.","Frangula alnus Bark | European Alder Buckthorn Bark | FRANGULA ALNUS BARK | Frangulae Cortex | Glossy Buckthorn Bark",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0074391","Sertaconazole","C75206","A synthetic imidazole derivative, containing a benzothiophene ring, with antifungal, antibacterial, anti-inflammatory and anti-pruritic activity. Besides its ability to inhibit the synthesis of ergosterol, the benzothiophene ring of sertaconazole is able to insert into the fungal cell wall instead of tryptophan. This increases the permeability of the cell wall. In addition, sertaconazole suppresses the release of cytokines.","Sertaconazole | SERTACONAZOLE | [R,S]-(+/-)-1-{2,4-Dichlor-beta-[(7-chlorbenzo[b]thien-3-yl)methoxy]phenethyl}imidazol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0453264","Poppy Seed","C73910","No value exists.","Poppy Seed | POPPY SEED | Ying Su Qiao | Ying Su Zi",,,,,,,,,,,,,,,"4039035","Poppy seed",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698979","Capobenate Sodium","C79711","No value exists.","Capobenate Sodium | 6-((3,4,5-Trimethoxybenzoyl)amino)hexanoic Acid Sodium Salt | C-3 Sodium Salt | CAPOBENATE SODIUM | Sodium 6-(3,4,5-trimethoxybenzamido)hexanoate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0062687","Hexylene Glycol","C77469","No value exists.","Hexylene Glycol | HEXYLENE GLYCOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028058","Nictitating Membrane","C77657","A translucent membrane present in the eye of some animals, also called the third eyelid. It is part of the conjunctiva and protects the eye from debris and dry air.","Nictitating Membrane | MEMBRANE, NICTITATING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825187","Septal Ablation","C80439","A cardiac catheterization procedure to relieve symptoms in patients with severe obstructive hypertrophic cardiomyopathy. A catheter is used to inject alcohol into a septal artery supplying the heart muscle responsible for the obstruction, destroying the muscle tissue and relieving the obstruction.","Septal Ablation | SEPTAL ABLATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278773","Localized Unresectable Adult Primary Liver Cancer","C7878","A localized hepatocellular carcinoma or intrahepatic cholangiocarcinoma that occurs during adulthood and it is not amenable to surgical resection.","Localized Unresectable Adult Liver Carcinoma | Localized Non-Resectable Adult Liver Cancer | Localized Non-Resectable Adult Liver Carcinoma | Localized Unresectable Adult Primary Cancer of Liver | Localized Unresectable Adult Primary Cancer of the Liver | Localized Unresectable Adult Primary Liver Cancer | Unresectable Liver Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699118","Rubella Virus Antigen, A","C75816","No value exists.","Rubella Virus Antigen, A | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL378326","Recurrent Childhood Spinal Cord Neoplasm","C71712","The reemergence of a spinal cord neoplasm in childhood after a period of remission.","Recurrent Childhood Spinal Cord Neoplasm | Recurrent Childhood Spinal Cord Tumor | Recurrent Spinal Cord Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2076600","H1N1 Influenza","C80444","An acute viral respiratory infection caused by a strain of influenza virus which is endemic in swine (pigs). Rarely reported in humans prior to 2009, the disease is caused by a mutated strain of swine influenza A (H1N1) virus. It is highly contagious and spreads mainly through coughing and sneezing. Signs and symptoms include fever, chills, coughing, sore throat headache, muscle ache, and generalized weakness. Antiviral medications are most effective in the first two days of the illness.","H1N1 Influenza | H1N1 Flu | H1N1 Virus Infection | Influenza A (H1N1) | Influenza A (H1N1) Virus Infection | Swine Flu | Swine Influenza | Swine flu",,,,,,,,,,,,,,,"40484544","Influenza due to Influenza A virus subtype H1N1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2700279","Withdrawal Request","C79193","No value exists.","Withdrawal Request | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698419","NR0B1 wt Allele","C75865","Human NR0B1 wild-type allele is located within Xp21.3-p21.2 and is approximately 5 kb in length. This allele, which encodes nuclear receptor subfamily 0 group B member 1 protein, is involved in the regulation of both transcription and receptor-mediated signal transduction. Mutations in the gene are associated with both X-linked congenital adrenal hypoplasia and hypogonadotropic hypogonadism. A duplication part of the short arm of the X chromosome, which contains this gene, in XY individuals is linked to dosage-sensitive sex reversal.","NR0B1 wt Allele | AHC | AHCH | AHX | DAX-1 | DAX1 | DSS | Dosage-Sensitive Sex Reversal Gene | GTD | HHG | NROB1 | Nuclear Receptor Subfamily 0, Group B, Member 1 wt Allele | SRXY22",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0729015","Cefadroxil Anhydrous","C79562","The anhydrous form of cefadroxil, a semisynthetic first-generation cephalosporin with antibacterial activity. Cefadroxil binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.","Cefadroxil Anhydrous | (6R,7R)-7-((R)-2-Amino-2-(p-hydroxyphenyl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic Acid | BL-S 578 | CEFADROXIL ANHYDROUS | Oracefal | S-578",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279659","Extrahepatic Bile Duct Adenocarcinoma","C7975","An adenocarcinoma arising from the epithelium of the extrahepatic bile ducts.  Signs and symptoms include abdominal pain, anorexia, jaundice, pruritus, nausea and vomiting, and weight loss.","Extrahepatic Bile Duct Adenocarcinoma | Adenocarcinoma of Extrahepatic Bile Duct | Adenocarcinoma of the Extrahepatic Bile Duct",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0854960","Stage I Vulvar Cancer AJCC v6","C7854","Stage I includes: T1, N0, M0. T1: Tumor confined to the vulva or vulva and perineum, 2cm or less in greatest dimension. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th ed.).","Stage I Vulvar Cancer AJCC v6 | AJCC Stage I Vulvar Cancer AJCC v6 | FIGO Stage I Carcinoma of Vulva AJCC v6 | FIGO Stage I Carcinoma of the Vulva AJCC v6 | FIGO Stage I Vulva Carcinoma AJCC v6 | FIGO Stage I Vulvar Carcinoma AJCC v6 | Stage I Vulva Cancer AJCC v6 | Stage I Vulval Cancer AJCC v6 | Stage I Vulval Carcinoma AJCC v6 | Stage I Vulvar Cancer | Stage I Vulvar Carcinoma AJCC v6 | Vulvar Cancer Stage I AJCC v6 | stage I vulvar cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0951496","minaprine hydrochloride","C80005","No value exists.","Minaprine Hydrochloride | MINAPRINE HYDROCHLORIDE | Minaprine Dihydrochloride | Morpholine, 4-(2-((4-methyl-6-phenyl-3-pyridazinyl)amino)ethyl)-, Dihydrochloride | N-(4-Methyl-6-phenyl-3-pyridazinyl)-4-morpholineethanamine Dihydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699786","Distribution Data","C79247","No value exists.","Distribution Data | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698646","Octabenzone","C74364","No value exists.","Octabenzone | OCTABENZONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388508","PPE-Expressing Replication-Defective HSV-1 Vector NP2","C79845","A replication-defective (ICP4-deleted) herpes simplex virus type 1 (HSV-1) viral vector expressing the human preproenkephalin A (PPE) gene with potential antinociceptive activity. Upon intradermal administration, PPE-expressing replication-defective HSV-1 vector NP2 is transported by retrograde axonal transport to the dorsal root ganglion (DRG) and becomes dormant. In the DRG, the vector transduces sensory neurons with high efficiency, delivering the engineered PPE gene; transduced neurons then express the protein proenkephalin A, the precursor for Met- and Leu-enkephalin. After proteolytic cleavage from proenkephalin A in the DRG neuronal cytosol, transgene-mediated Met- and Leu-enkephalin bind to mu and gamma- opioid receptors, which may result in the inhibition of nociceptive neurotransmission.","PPE-Expressing Replication-Defective HSV-1 Vector NP2 | NP2 | Preproenkephalin-Expressing Replication-Defective Herpes Simplex Virus-1 Vector NP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0075651","Supidimide","C74382","No value exists.","Supidimide | SUPIDIMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0612052","Clemeprol","C79858","No value exists.","Clemeprol | 3-(3-Chlorphenyl)-1-(dimethylamino)-3-phenyl-2-propanol | BRL 14342 | CLEMEPROL | m-Chloro-alpha-((dimethylamino)methyl)-beta-phenylphenetyl Alcohol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698697","PLP1 wt Allele","C75898","Human PLP1 wild-type allele is located in the vicinity of Xq22 and is approximately 16 kb in length. This allele, which encodes myelin proteolipid protein, plays a role in the modulation of neuronal development and function. Mutation of the gene is associated with both Pelizaeus-Merzbacher disease and spastic paraplegia type 2.","PLP1 wt Allele | MMPL | PLP | PLP/DM20 | PMD | Proteolipid Protein 1 (Pelizaeus-Merzbacher Disease, Spastic Paraplegia 2, Uncomplicated) wt Allele | SPG2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0492524","Analytical Balance","C80370","An instrument that is able to determine the mass of a sample with a high degree of precision.","Analytical Balance | ",,,,,,,,,,,,,,,"45767733","Analytical balance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0058133","Aldioxa","C76519","No value exists.","Aldioxa | ALDIOXA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697964","MID1 wt Allele","C75731","Human MID1 wild-type allele is located in the vicinity of Xp22.2 and is approximately 388 kb in length. This allele, which encodes E3 ubiquitin-protein ligase Midline-1 protein, plays a role in the modulation of microtubule organization. Mutations in this gene may be associated with the X-linked form of Opitz syndrome.","MID1 wt Allele | BBBG1 | FXY | Finger on X and Y, Mouse, Homolog of Gene | GBBB1 | MIDIN | Midline 1 (Opitz/BBB Syndrome) Gene | Midline 1 RING Finger Gene | Midline 1 wt Allele | OGS1 | OS | OSX | RNF59 | TRIM18 | XPRF | ZNFXY | Zinc Finger on X and Y, Mouse, Homolog of Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698099","Amphenidone","C76934","No value exists.","Amphenidone | AMPHENIDONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0347012","Metastatic Malignant Neoplasm in the Urethra","C7573","A malignant neoplasm that has spread to the urethra from another anatomic site.","Metastatic Malignant Neoplasm in the Urethra | Metastasis to the Urethra | Metastatic Malignant Neoplasm to the Urethra | Metastatic Neoplasm to the Urethra",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698430","Nardeterol","C76541","No value exists.","Nardeterol | NARDETEROL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698998","Carfimate","C76095","No value exists.","Carfimate | CARFIMATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL387011","Perianal Gland","C77620","A gland located in the area around the anus.","Perianal Gland | GLAND, PERIANAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0496815","Malignant Labia Minora Neoplasm","C7637","A malignant neoplasm that affects the labia minora.","Malignant Labia Minora Neoplasm | Malignant Labia Minora Tumor | Malignant Neoplasm of Labia Minora | Malignant Neoplasm of the Labia Minora | Malignant Tumor of Labia Minora | Malignant Tumor of the Labia Minora | Malignant neoplasm of labium minus",,,,,,,,,,,,,,,"4181352","Malignant neoplasm of labia minora",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1998822","Test Result Report","C70950","An account of the outcome of an analysis or test.","Test Result Report | test value | test_value",,,,,,,,,,,,,,,"46272695","Informing health care professional of test result",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4014749","Proptosis","C87114","Abnormal protrusion of one or both eyes from the socket; causes include hyperthyroidism (particularly Graves disease); bleeding behind the eye; infection, inflammation, or tumors of the orbit; and vascular disorders.","Proptosis | Exophthalmos",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040382","Tolperisone","C84219","No value exists.","Tolperisone | TOLPERISONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1021722","Bergeyella","C86188","A genus of aerobic, Gram-negative, rod shaped bacterium assigned to the phylum Bacteroidetes and the family Flavobacteriaceae.","Bergeyella | BERGEYELLA",,,,,,,,,,,,,,,"4021699","Bergeyella",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2981651","Number of Units Returned","C88077","No value exists.","Number of Units Returned | NUMBER OF UNITS RETURNED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825776","MIR1-1 wt Allele","C81861","The human MIR1-1 wild-type allele is located in the vicinity of 20q13.33 and is 70 bases in length. This allele, which encodes MIR1-1 RNA, plays roles in lung and liver cancers, as well as cardiomyopathy, cardiac hypertrophy and coronary artery disease.","MIR1-1 wt Allele | MIRN1-1 | MicroRNA 1-1 | hsa-miR-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981673","Stage IIB Ampulla of Vater Cancer AJCC v7","C88099","Stage IIB includes: (T1, N1, M0); (T2, N1, M0); (T3, N1, M0).  T1: Tumor limited to ampulla of Vater or sphincter of Oddi.  T2: Tumor invades the duodenal wall.  T3: Tumor invades the pancreas.  N1: Regional lymph node metastasis.  M0: No distant metastasis. (from AJCC 7th Ed.)","Stage IIB Ampulla of Vater Cancer AJCC v7 | Stage IIB Ampulla of Vater Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041236","Trypsin","C84232","No value exists.","Trypsin | TRYPSIN, UNSPECIFIED FORM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825965","CTAG1A wt Allele","C82109","Human CTAG1A wild-type allele is located in the vicinity of Xq28 and is approximately 2 kb in length. This allele, which encodes cancer/testis antigen 1 protein, may play a role in both spermatogeneis and development of the testes. Aberrant expression of this gene is associated with incontinentia pigmenti.","CTAG1A wt Allele | CTAG | CTAG1 | Cancer/Testis Antigen 1-A Gene | Cancer/Testis Antigen 1A wt Allele | ESO1 | LAGE-2 | LAGE2A | NY-ESO-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981943","Bone Cancer pM1b TNM Finding v7","C88442","Bone cancer with metastasis to other distant sites. (from AJCC 7th Ed.)","Bone Cancer pM1b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0058517","Dixanthogen","C80602","No value exists.","Dixanthogen | DIXANTHOGEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828060","Salmonella Serotype Choleraesuis","C86915","Any bacterial organism that can be assigned to the genus Salmonella with serotype Choleraesuis.","Salmonella Serotype Choleraesuis | SALMONELLA SEROTYPE CHOLERAESUIS | Salmonella enterica subsp. enterica serovar Choleraesuis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0445728","Lactobacillus johnsonii","C86481","A species of facultatively anaerobic, Gram positive, rod shaped bacteria in the phylum Firmicutes. This species is nonmotile, catalase negative, produces acid from trehalose, nonsporeforming and produces lactic acid. L. johnsonii is a commensal organism of the upper gastrointestinal tract with probiotic activity.","Lactobacillus johnsonii | LACTOBACILLUS JOHNSONII",,,,,,,,,,,,,,,"4034763","Lactobacillus johnsonii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0063269","Ibuterol","C83775","No value exists.","Ibuterol | IBUTEROL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981975","Skin Squamous Cell Carcinoma or Other Skin Carcinomas Pathologic Primary Tumor TNM Finding v7","C88474","A pathologic finding about one or more characteristics of skin squamous cell carcinoma or other skin carcinomas, following the rules of the TNM AJCC v7 classification system as they pertain to staging of the primary tumor.  It excludes cutaneous squamous cell carcinoma of the eyelid and Merkel cell carcinoma.  The TNM pathologic and clinical primary tumor classifications of skin squamous cell carcinoma or other skin carcinomas are the same. (from AJCC 7th Ed.)","Skin Squamous Cell Carcinoma or Other Skin Carcinomas Pathologic Primary Tumor TNM Finding v7 | Cutaneous Squamous Cell Carcinoma or Other Cutaneous Carcinomas Pathologic Primary Tumor TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280365","Recurrent Oral Cavity Verrucous Carcinoma","C8214","Reemergence of verrucous carcinoma of the oral cavity after a period of remission.","Recurrent Oral Cavity Verrucous Carcinoma | Recurrent Mouth Verrucous Carcinoma | Recurrent Oral Cavity Verrucous Cancer | Recurrent Verrucous Carcinoma of Mouth | Recurrent Verrucous Carcinoma of Oral Cavity | Recurrent Verrucous Carcinoma of the Mouth | Recurrent Verrucous Carcinoma of the Oral Cavity | Relapsed Mouth Verrucous Carcinoma | Relapsed Oral Cavity Verrucous Carcinoma | Relapsed Verrucous Carcinoma of Mouth | Relapsed Verrucous Carcinoma of Oral Cavity | Relapsed Verrucous Carcinoma of the Mouth | Relapsed Verrucous Carcinoma of the Oral Cavity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981707","Stage IIB Uveal Melanoma AJCC v7","C88136","Stage IIB includes: (T2b, N0, M0); (T3a, N0, M0).  T2b: Ciliary body and choroid: Tumor size category 2 with ciliary body involvement.  T3a: Iris: Tumor confluent with or extending into the ciliary body, choroid, or both, with sclera extension and secondary glaucoma. Ciliary body and choroid: Tumor size category 3 without ciliary body involvement and extraocular extension. N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)","Stage IIB Uveal Melanoma AJCC v7 | IIB | Stage IIB Uveal Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828143","Incorrect Protocol Artifact","C87047","An image of reduced quality resulting from the use of the wrong instructions.","Incorrect Protocol Artifact | Incorrect Protocol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827057","Villus Tip","C83469","The distal end of a villus.","Villus Tip | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981989","Skin Squamous Cell Carcinoma or Other Skin Carcinomas pN2b TNM Finding v7","C88488","Skin squamous cell carcinoma or other skin carcinomas with metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension. (from AJCC 7th Ed.)","Skin Squamous Cell Carcinoma or Other Skin Carcinomas pN2b TNM Finding v7 | Cutaneous Squamous Cell Carcinoma or Other Cutaneous Carcinomas pN2b TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1219896","Microbacterium paraoxydans","C86512","A species of aerobic, Gram positive, coryneform bacteria assigned to the phylum Actinobacteria. This species is motile, nonfermentative, forms yellow pigmented colonies, catalase positive, oxidase negative and hydrolyzes esculin and gelatin. M. paraoxydans is pathogenic and one of the most common species of Microbacterium to be isolated from clinical specimens.","Microbacterium paraoxydans | MICROBACTERIUM PARAOXYDANS",,,,,,,,,,,,,,,"4189491","Microbacterium paraoxydans",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL408801","Flow Rate Unit","C82579","The unit of measure for the rate of infusion.","Flow Rate Unit | FLRTU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL413040","Ailanthus altissima Pollen","C85091","No value exists.","Ailanthus altissima Pollen | AILANTHUS ALTISSIMA POLLEN",,,,,,,,,,,,,,,"43020823","Ailanthus altissima pollen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4014896","Heterotaxy","C87083","The abnormal arrangement or position of thoracic and/or abdominal organs in relation to each other, often occurring in a right/left transposition.","Heterotaxy | Heterotaxia",,,,,,,,,,,,,,,"4032917","Situs ambiguus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0075591","Sulforidazine","C84185","No value exists.","Sulforidazine | SULFORIDAZINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0277873","Nasal Flaring","C87099","Enlargement of the nostrils during breathing; although there are many possible causes, it can be a sign of respiratory distress in young infants.","Nasal Flaring | ",,,,,,,,,,,,,,,"4087171","Nasal flaring",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1722375","Lemuteporfin","C83869","No value exists.","Lemuteporfin | LEMUTEPORFIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274127","PIK3CA NM_006218.1:c.1625A>T","C98479","A nucleotide substitution at position 1625 of the coding sequence of the PIK3CA gene where adenine has been mutated to thymine.","PIK3CA NM_006218.1:c.1625A>T | NM_006218.1:c.1625A>T | PI3K c.1625A>T | PIK3CA c.1625A>T | Phosphoinositide-3-Kinase, Catalytic, Alpha Polypeptide c.1625A>T | p110-alpha c.1625A>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273812","UQCRH wt Allele","C98091","Human UQCRH wild-type allele is located in the vicinity of 1p34.1 and is approximately 13 kb in length. This allele, which encodes cytochrome b-c1 complex subunit 6, mitochondrial protein, is involved in aerobic respiration. A complex rearrangement involving a paracentric inversion of chromosome 22q12 followed by translocation t(1;22)(p34;q12) results in the fusion of this gene to both the EWSR1 gene and the PATZ1 gene. These fusions are associated with small round cell sarcoma.","UQCRH wt Allele | MGC111572 | QCR6 | UQCR8 | Ubiquinol-Cytochrome C Reductase Hinge Protein wt Allele | Ubiquinol-Cytochrome C Reductase, Complex III Subunit VIII Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274328","EGFR NM_005228.3:c.2311_2312ins12","C98653","An insertion of 12 nucleotides, TGGCCACCCCCA, between position 2311 and 2312 of the coding sequence of the EGFR gene.","EGFR NM_005228.3:c.2311_2312ins12 | EGFR NM_005228.3:c.2311_2312insTGGCCACCCCCA | EGFR c.2311_2312ins12 | EGFR c.2311_2312insTGGCCACCCCCA | ERBB c.2311_2312ins12 | ERBB1 c.2311_2312ins12 | Epidermal Growth Factor Receptor Gene c.2311_2312ins12 | HER1 c.2311_2312ins12 | NM_005228.3:c.2311_2312ins12 | NM_005228.3:c.2311_2312insTGGCCACCCCCA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3275042","Abandoned Lead","C99906","The cardiac lead has been left in situ but is not in use. (ACC)","Abandoned Lead | ABANDONED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2750033","Neonatal Hypoglycemia","C99237","Blood glucose concentration below the lower limit of established reference ranges in a newborn.","Neonatal Hypoglycemia | ",,,,,,,,,,,,,,,"23034","Neonatal hypoglycemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0209851","heterogeneous nuclear ribonucleoprotein A2-B1, human","C97498","Heterogeneous nuclear ribonucleoproteins A2/B (353 aa, ~37 kDa) is encoded by the human HNRNPA2B1 gene. This protein is involved in both RNA splicing and transport.","Heterogeneous Nuclear Ribonucleoprotein A2/B1 | HNRNPA2B1 | Heterogeneous Nuclear Ribonucleoprotein A2 | Heterogeneous Nuclear Ribonucleoprotein B1 | Nuclear Ribonucleoprotein Particle A2 Protein | hnRNP A2/B1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273836","MIA wt Allele","C98125","Human MIA wild-type allele is located within 19q13.32-q13.33 and is approximately 2 kb in length. This allele, which encodes melanoma-derived growth regulatory protein, is involved in the modulation of melanoma cell proliferation.","MIA wt Allele | CD-RAP | Melanoma Inhibitory Activity wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539748","SEPTIN5 Gene","C97727","This gene plays a role in cell division.","SEPTIN5 Gene | SEPT5 | SEPT5 Gene | SEPTIN5 | Septin 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3552405","Ear Skin Tag","C98919","A small preauricular skin tag.","Ear Tag | Periauricular Tag",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273277","SOX8 wt Allele","C97204","Human SOX8 wild-type allele is located in the vicinity of 16p13.3 and is approximately 5 kb in length. This allele, which encodes transcription factor SOX-8 protein, plays a role in both embryonic development and the positive regulation of transcription.","SOX8 wt Allele | MGC24837 | SRY (Sex Determining Region Y)-Box 8 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0266172","Small Intestine Atresia","C98828","A congenital malformation characterized by the absence of a normal opening in a part of the small intestine.","Small Intestine Atresia | Atresia of Small Intestine | Atresia of the Small Intestine | Congenital Small Intestine Atresia",,,,,,,,,,,,,,,"4222795","Congenital atresia of small intestine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3275010","CARS/ALK Fusion Protein","C99872","A fusion protein (680 aa, ~75 kDa) that is encoded by the CARS/ALK fusion gene. This protein contains 606 amino acids from the N-terminus of the cysteinyl-tRNA synthetase, cytoplasmic protein and the cytoplasmic domain of the ALK tyrosine kinase receptor protein.","CARS/ALK Fusion Protein | CARS-ALK Fusion Protein | CARS1::ALK Fusion Protein | CARS::ALK Fusion Protein | Cysteinyl--tRNA Synthetase, Cytoplasmic/ALK Tyrosine Kinase Receptor Fusion Protein | Cysteinyl-tRNA Synthetase, Cytoplasmic/ALK Tyrosine Kinase Receptor Fusion Protein | Cysteinyl-tRNA Synthetase, Cytoplasmic::ALK Tyrosine Kinase Receptor Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274232","EGFR NP_005219.2:p.E746_P753del","C98544","A deletion of eight amino acids from the epidermal growth factor receptor protein from the glutamic acid at position 746 through the proline at position 753.","EGFR NP_005219.2:p.E746_P753del | EGFR E746_P753del | EGFR NP_005219.2:p.Glu746_Pro753del | EGFR p.E746_P753del | Epidermal Growth Factor Receptor E746_P753del | NP_005219.2:p.Glu746_Pro753del | Proto-Oncogene c-ErbB-1 E746_P753del | Receptor Tyrosine-Protein Kinase erbB-1 E746_P753del",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0604284","Metizoline","C99577","No value exists.","Metizoline | 1H-Imidazole, 4,5-dihydro-2-((2-methylbenzo(b)thien-3-yl)methyl)- | METIZOLINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273416","CHN1 wt Allele","C97443","Human CHN1 wild-type allele is located in the vicinity of 2q31.1 and is approximately 206 kb in length. This allele, which encodes N-chimaerin protein, plays a role in the modulation of signaling. Mutation of the gene is associated with Duane retraction syndrome 2. A translocation of this gene and the TAF15 gene may be associated with extraskeletal myxoid chondrosarcoma.","CHN1 wt Allele | ARHGAP2 | CHN | Chimerin (Chimaerin) 1 Gene | Chimerin 1 (GTPase-Activating Protein, Rho, 2) Gene | Chimerin 1 wt Allele | DURS2 | Duane Retraction Syndrome 2 Gene | N-Chimerin Gene | RHOGAP2 | RhoGAP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL430317","Pseudomonas aeruginosa Preparation","C97662","A preparation containing the inactivated Pseudomonas aeruginosa with potential immunomodulating activity. Upon inoculation, Pseudomonas aeruginosa preparation may stimulate the immune system, increasing macrophage and natural killer cell activity; it may be used thereby in cancer adjuvant treatments, and it may reduce the incidence of infection.","Pseudomonas aeruginosa Preparation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414197","DUX4 Gene","C97463","This gene plays a role in transcriptional regulation.","DUX4 Gene | DUX4 | Double Homeobox 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985262","Malt Flavor","C92710","A characteristic of a medicinal product, specifying that its most predominant agreeable savor detected by the unified sensation of taste and olfactory receptors resembles malt.","Malt Flavor | MALT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419043","PSME3 Gene","C95862","This gene is involved in cell cycle regulation.","PSME3 Gene | PSME3 | Proteasome (Prosome, Macropain) Activator Subunit 3 (PA28 Gamma; Ki) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984232","Ether Lipid Metabolism Pathway","C91416","No value exists.","Ether Lipid Metabolism Pathway | Ether lipid metabolism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983861","Teglarinad","C90746","A water-soluble prodrug of a pyridyl cyanoguanidine compound and an inhibitor of nicotinamide phosphoribosyltransferase (NAMPT) with potential antineoplastic activity. Teglarinad is rapidly converted in the bloodstream into an active compound through hydrolytic cleavage of the carbonate ester bond. The activated form inhibits NAMPT, thereby inhibiting nicotinamide adenine dinucleotide (NAD+) biosynthesis and induces a rapid decline in intracellular NAD+ followed by ATP reduction. As NAD+ is essential for tumor cell growth, inhibition of NAMPT induces tumor cell death. NAMPT is an essential enzyme in the synthesis of NAD+ and is upregulated in some cancers.","Teglarinad | Pyridinium, 4-[[[[6-(4-chlorophenoxy)hexyl]amino](cyanoamino)methylene]amino]-1-(3-oxo-2,4,7,10,13,16-hexaoxaheptadec-1-yl)- | TEGLARINAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983422","Ankyrin Repeat and BTB/POZ Domain-Containing Protein 2","C90177","Ankyrin repeat and BTB/POZ domain-containing protein 2 (839 aa, ~93 kDa) is encoded by the human ABTB2 gene. This protein may play a role in the growth of hepatocytes.","Ankyrin Repeat and BTB/POZ Domain-Containing Protein 2 | ABTB2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0426178","Compound Fetal Presentation","C92756","A presentation of the fetal hand or arm before the fetal vertex.","Compound Fetal Presentation | Compound Presentation",,,,,,,,,,,,,,,"4052737","Compound presentation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2983544","PLAC8 wt Allele","C90306","Human PLAC8 wild-type allele is located in the vicinity of 4q21.22 and is approximately 24 kb in length. This allele, which encodes placenta-specific gene 8 protein, may play a role in the modulation of dendritic cell activity.  Aberrant expression of the gene may be involved in leukemia relapse.","PLAC8 wt Allele | C15 | Onzin | Placenta-Specific 8 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984154","Omega-Oxidation of Fatty Acids Pathway","C91313","No value exists.","Omega-Oxidation of Fatty Acids Pathway | Omega Oxidation | Omega Oxidation Pathway",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985682","Study Resource Relationship","C93471","The association between a resource and the study on which it is used.","Study Resource Relationship | StudyResource",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0076667","Tienoxolol","C90801","No value exists.","Tienoxolol | TIENOXOLOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273068","Thrombocyte Differentiation","C96834","A biological process that refers to the maturation of thrombocytes.","Thrombocyte Differentiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011757","Developmental Coordination Disorder","C92561","A disorder characterized by an impairment in the development of an individual's motor coordination skills; this impairment in motor development is not due to a medical condition.","Developmental Coordination Disorder | Clumsy Child Syndrome | Development Coordination Disorder | Developmental Dyspraxia",,,,,,,,,,,,,,,"440388","Developmental coordination disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0132841","Norletimol","C90814","No value exists.","Norletimol | NORLETIMOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205320","Pedunculate","C97129","Having a narrow part by which some larger part is attached.","Pedunculate | Pedunculated | pedunculated",,,,,,,,,,,,,,,"4096718","Pedunculated",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2985186","anti-CTGF monoclonal antibody FG-3019","C92577","A human monoclonal antibody targeting connective tissue growth factor (CTGF) with potential anti-fibrotic and antineoplastic activities. Pamrevlumab binds to CTGF thereby preventing the binding of the ligand to the receptor and subsequent receptor activation. As CTGF enhances the production of collagen and fibronectin, FG-319 may prevent and reverse fibrosis. In addition, FG-3019 may prevent tumor cell proliferation in CTGF-expressing tumor cells. CTGF, a member of the CCN family (CTGF, CYR61/CEF and NOV), is expressed in a variety of tumor cell types and is involved in processes such as cell proliferation, cell migration, cell adhesion, differentiation and angiogenesis.","Pamrevlumab | Anti-Connective Tissue Growth Factor Monoclonal Antibody FG-3019 | FG-3019 | FG3019 | PAMREVLUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2344045","Lexidronam","C90830","A phosphonate analog of ethylenediaminetetraacetic acid (EDTA), with chelating activity. Lexidronam binds to and associates with hydroxyapatite crystals concentrated in areas of bone turnover. It has been used as a radiopharmaceutical in complexes with radioactive metals to selectively deliver cytotoxic radiation to osteoblastic bone metastases.","Lexidronam | EDTMP | Ethylenediamine Tetra(methylene Phosphonic Acid) | LEXIDRONAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986287","Study Legal Sponsor Primary Indicator","C94089","Specifies whether this is the main or principal study legal sponsor.","Study Legal Sponsor Primary Indicator | StudyLegalSponsor.primaryIndicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982560","Mucosal Melanoma of the Head and Neck Pathologic TNM Finding v7","C89130","A pathologic finding about one or more characteristics of mucosal melanoma of the head and neck, following the rules of the TNM AJCC v7 classification system.","Mucosal Melanoma of the Head and Neck Pathologic TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0855186","Recurrent Bladder Squamous Cell Carcinoma","C8902","The reemergence of bladder squamous cell carcinoma after a period of remission.","Recurrent Bladder Squamous Cell Carcinoma | Recurrent Bladder Epidermoid Carcinoma | Recurrent Epidermoid Carcinoma of Bladder | Recurrent Epidermoid Carcinoma of Urinary Bladder | Recurrent Epidermoid Carcinoma of the Bladder | Recurrent Epidermoid Carcinoma of the Urinary Bladder | Recurrent Squamous Cell Carcinoma of Bladder | Recurrent Squamous Cell Carcinoma of Urinary Bladder | Recurrent Squamous Cell Carcinoma of the Bladder | Recurrent Squamous Cell Carcinoma of the Urinary Bladder | Recurrent Urinary Bladder Epidermoid Carcinoma | Recurrent Urinary Bladder Squamous Cell Carcinoma | Relapsed Bladder Epidermoid Carcinoma | Relapsed Bladder Squamous Cell Carcinoma | Relapsed Epidermoid Carcinoma of Bladder | Relapsed Epidermoid Carcinoma of Urinary Bladder | Relapsed Epidermoid Carcinoma of the Bladder | Relapsed Epidermoid Carcinoma of the Urinary Bladder | Relapsed Squamous Cell Carcinoma of Bladder | Relapsed Squamous Cell Carcinoma of Urinary Bladder | Relapsed Squamous Cell Carcinoma of the Bladder | Relapsed Squamous Cell Carcinoma of the Urinary Bladder | Relapsed Urinary Bladder Epidermoid Carcinoma | Relapsed Urinary Bladder Squamous Cell Carcinoma | Squamous Cell Carcinoma of Bladder, Recurrent | Squamous Cell Carcinoma of the Bladder, Recurrent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982571","Mucosal Melanoma of the Head and Neck Clinical TNM Finding v7","C89141","A clinical finding about one or more characteristics of mucosal melanoma of the head and neck, following the rules of the TNM AJCC v7 classification system.","Mucosal Melanoma of the Head and Neck Clinical TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1154183","Mucosal Spray","C91149","A spray intended for administration to the mucosa.","Mucosal Spray Dosage Form | Mucosal Spray | Mucosal Spray Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982481","Stage IV Hypopharyngeal Carcinoma AJCC v7","C89047","Stage IV includes: IVA: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB: (T4b, Any N, M0); (Any T, N3, M0); IVC: (Any T, Any N, M1).  T4a: Tumor with moderately advanced local disease.  Tumor invades the thyroid/cricoid cartilage, hyoid bone, thyroid gland, or central compartment soft tissue.  Central compartment soft tissue includes prelaryngeal strap muscles and subcutaneous fat.  T1: Tumor limited to one subsite of hypopharynx and/or 2 cm or less in greatest dimension.  T2: Tumor invades more than one subsite of the hypopharynx or an adjacent site, or measures more than 2 cm but not more than 4 cm in greatest diameter without fixation of hemilarynx.  T3: Tumor measuring more than 4 cm in greatest dimension or tumor with fixation of hemilarynx or extension to esophagus.  T4b: Tumor with very advanced local disease.  Tumor invades prevertebral fascia, encases carotid artery, or involves mediastinal structures.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. N2: Tumor with metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. N3: Metastasis in a lymph node more than 6 cm in greatest dimension.  M0: No distant metastasis.  M1: Distant metastasis. (AJCC 7th ed.)","Stage IV Hypopharyngeal Carcinoma AJCC v7 | Stage IV Hypopharyngeal Carcinoma | Stage IV Hypopharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006759","Calisthenics","C94739","A system of free movements designed to develop muscular tone and promote physical fitness.","Calisthenics | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527196","Recombinant Transforming Growth Factor-Beta","C898","A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine transforming growth factor-beta (TGF-beta) with proapoptotic and antineoplastic properties. TGF-beta may suppress tumor cell growth by decreasing the expression of cyclin D1, a cell cycle regulatory protein, and downregulating the expression of the oncogene c-myc. This agent is also involved in T cell-mediated immunosuppression by CD4+CD25+ T cells, which permits cancer cells to evade immune surveillance. (NCI04)","Recombinant Transforming Growth Factor-Beta | Bone-Derived Transforming Growth Factor | TGF-Beta | Therapeutic Milk Growth Factor | Therapeutic TGF B | Therapeutic TGF-Beta | rTGF-Beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0053731","Tesmilifene Hydrochloride","C952","No value exists.","Tesmilifene Hydrochloride | BMS-217380-01 | BMY-33419 | Bis(diphenylphosphine)ethane | DPPE | TESMILIFENE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985741","Companion Code","C93534","A coded value specifying the type of ancillary entity or event to the primary entity or event.","Companion Code | companionCode",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0740421","Surgical Menopause","C94256","Menopause that is induced by the surgical removal of the ovaries.","Surgical Menopause | surgical menopause",,,,,,,,,,,,,,,"4154697","Postsurgical menopause",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0236800","Panic Disorder with Agoraphobia","C97194","A disorder in which an individual experiences recurrent, unexpected panic attacks and persistent concern about having additional panic attacks. Agoraphobia is a component of this disorder.","Panic Disorder with Agoraphobia | ",,,,,,,,,,,,,,,"4147466","Panic disorder with agoraphobia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2985656","Notification Receiver","C93444","A person or organization that is the target of a notification.","Notification Receiver | NotificationReceiver",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006370","Binge Eating","C97162","Recurrent episodes of over-eating.","Binge Eating | ",,,,,,,,,,,,,,,"37160425","Binge eating behavior",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2985661","Study Oversight Authority","C93450","An organization with monitoring, regulatory, or supervisory authority over biomedical research at the local, regional, national, or international level for a particular study.","Study Oversight Authority | Study Oversight Entity | StudyOversightAuthority",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273115","Gallbladder Neuroendocrine Neoplasm","C96917","A neoplasm with neuroendocrine differentiation that arises from the gallbladder. It includes neuroendocrine tumors (well-differentiated neuroendocrine neoplasms) and neuroendocrine carcinomas (poorly differentiated neuroendocrine neoplasms).","Gallbladder Neuroendocrine Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274839","C-C Motif Chemokine 28","C99633","C-C motif chemokine 28 (127 aa, ~14 kDa) is encoded by the human CCL28 gene. This protein is involved in the mediation of chemotaxis.","C-C Motif Chemokine 28 | CCL28 | MEC | Mucosae-Associated Epithelial Chemokine | Protein CCK1 | Small-Inducible Cytokine A28",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273117","Gallbladder Neuroendocrine Carcinoma","C96919","An aggressive high-grade carcinoma with neuroendocrine differentiation that arises from the gallbladder. It is composed of malignant small or large cells. The mitotic count is more than 20 per 2 mm2 and/or the Ki-67 index is more than 20%.","Gallbladder Neuroendocrine Carcinoma | Gallbladder G3 | Gallbladder High Grade Neuroendocrine Carcinoma | Gallbladder NEC | Gallbladder Neuroendocrine Cancer | Gallbladder Poorly Differentiated Endocrine Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1504558","Subependymal Hemorrhage","C99065","Bleeding within the subependymal germinal matrix.","Subependymal Hemorrhage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL429014","Dexpanthenol Mouthwash","C96233","A mouthwash containing 5% dexpanthenol, the alcoholic analogue of the dextrorotatory isomer of pantothenic acid with potential antimucositis activity. Although the exact mechanism remains to be elucidated, upon rinsing with this solution dexpanthenol is converted to pantothenic acid (vitamin B5) which is required for coenzyme A synthesis as well as for the metabolism of proteins, carbohydrates, and fats. Coenzyme A is involved in fatty acids and sphingolipids synthesis crucial for cell membrane integrity. This mouthwash may have a protective and healing effect on the oral mucosa, may improve hydration and may potentially prevent or reduce radiation/chemotherapy-induced mucositis.","Dexpanthenol Mouthwash | 5% Dexpanthenol Mouthwash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0314653","Proposita","C94482","No value exists.","Proposita | proposita",,,,,,,,,,,,,,,"4142049","Proposita",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2987074","Biologic Handling Code","C95351","A coded value specifying the handling of a biologic.","Biologic Handling Code | Biologic.handlingCode",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986093","Performed Activity Actual Duration","C93895","The period of time over which the activity is performed.","Performed Activity Actual Duration | PerformedActivity.actualDuration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987174","VHL-Associated Pancreatic Serous Adenoma","C95476","A serous adenoma that develops in a patient with Von Hippel-Lindau syndrome.  Usually there are multiple serous adenomas present of the macrocystic type.","Von Hippel Lindau Syndrome-Associated Pancreatic Serous Adenoma | VHL-Associated Pancreatic Serous Adenoma | Von Hippel-Lindau Syndrome-Associated Pancreatic Serous Adenoma | Von Hippel-Lindau Syndrome-Associated Pancreatic Serous Adenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273136","Intrahepatic Bile Duct Intraductal Papillary Neoplasm with an Associated Invasive Carcinoma","C96949","A papillary neoplasm that arises from the epithelium of the intrahepatic bile ducts and it is associated with an invasive carcinomatous component.  The carcinomatous component is an intrahepatic cholangiocarcinoma.","Intrahepatic Bile Duct Intraductal Papillary Neoplasm with an Associated Invasive Carcinoma | Intrahepatic Bile Duct IPN with an Associated Invasive Carcinoma | Intrahepatic Bile Duct Papillary Neoplasm with an Associated Invasive Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986678","stage II childhood non-Hodgkin lymphoma","C94792","Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE).","Ann Arbor Stage II Childhood Non-Hodgkin Lymphoma | Stage II Childhood Non-Hodgkin Lymphoma | stage II childhood non-Hodgkin lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272586","Push-Pull Dispensing Plastic Container Closure","C96132","A two-piece dispensing closure that includes a base member the lower portion of which is designed to attach and seal securely to a container finish and the upper portion of which is designed to receive a dispensing spout member. The spout member may be moved upward and downward to open and close the dispensing passageway.","Push-Pull Dispensing Plastic Container Closure | Push-pull (Dispensing), Plastic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272819","Dysplasia-Associated Lesion or Mass","C96495","A term that refers to raised and dysplastic large intestinal lesions in patients with a history of ulcerative colitis.  Grossly, these lesions present as polyps, plaques, or patches in areas affected by ulcerative colitis.  The presence of these lesions is associated with the development of adenocarcinomas.  Colectomy is indicated when they are detected.","Dysplasia-Associated Lesion or Mass | DALM | Dysplasia-Associated Large Intestinal Lesion or Mass",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0092881","Fluorodeoxygalactose F-18","C94212","A radioconjugate containing the D-galactose analogue 2-deoxy-2-fluoro-D-galactose (FDGal) labeled with the positron-emitting radioactive isotope fluorine F18, used for imaging upon positron emitting tomography (PET). With cell uptake much higher in tumor cells compared to normal cells, the F18 moiety of fluorodeoxygalactose F-18 can be visualized upon PET imaging and this agent can be used as a tracer for the evaluation of galactose tumor uptake and metabolism.","Fluorodeoxygalactose F-18 | 18-F-deoxy-galactose | 2-deoxy-2-[18F]fluoro-D-galactose | FDGal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273483","Golgi-Associated PDZ and Coiled-Coil Motif-Containing Protein","C97548","Golgi-associated PDZ and coiled-coil motif-containing protein (462 aa, ~51 kDa) is encoded by the human GOPC gene. This protein plays a role in protein trafficking.","Golgi-Associated PDZ and Coiled-Coil Motif-Containing Protein | CFTR-Associated Ligand | Fused in Glioblastoma | GOPC | PDZ Protein Interacting Specifically with TC10 | PIST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273174","Internet Promotion","C97002","No value exists.","Internet Promotion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272622","Darkly Pigmented Melanophages Present","C96173","A morphologic finding indicating the presence of darkly stained macrophages that contain melanin.","Darkly Pigmented Melanophages Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272516","TLR9 wt Allele","C96047","Human TLR9 wild-type allele is located in the vicinity of 3p21.3 and is approximately 5 kb in length. This allele, which encodes toll-like receptor 9 protein, is involved in the modulation of signaling and the inflammatory response.","TLR9 wt Allele | CD289 | Toll-Like Receptor 9 wt Allele | UNQ5798/PRO19605",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985893","Time Frame Text","C93693","A character string that identifies time point(s) at which an event or activity occurrs.","Time Frame Text | timeFrameText",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273091","Gestaclone","C96873","No value exists.","Gestaclone | 17beta-Acetyl-6-chloro-1beta,1a,2beta,8beta,9alpha,10,11,12,13,14alpha,15,16beta,16a,17-tetradecahydro-10beta,13beta-dimethyl-3H- | 6-Chloro-1alpha,2alpha:16alpha,17-bismethylene-4,6-pregnadiene-3,20-dione | GESTACLONE | SH 1040",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827666","Van Wert County, OH","C109811","No value exists.","Van Wert County, OH | OH161 | Van Wert County | Van Wert County, Ohio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828469","Production of In Vitro Diagnostics","C113049","The production an in vitro testing system or kit to detect viral or bacterial agents in donor blood.","Production of In Vitro Diagnostics | In Vitro Diagnostics Production | Production, in Vitro Diagnostic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1559885","CTCAE Grade 2 Artery infection with unknown ANC","C59183","No value exists.","Grade 2 Artery Infection with Unknown Absolute Neutrophil Count, CTCAE | CTCAE Grade 2 Artery infection with unknown ANC | Grade 2 Artery infection with unknown ANC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640048","Perforation due to Lead","C101246","Penetration of a lead through a systemic vein, coronary vein, or the myocardium. (ACC)","Perforation due to Lead | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899871","C-SSRS Lifetime/Recent Version - Most Lethal Suicide Attempt Actual Lethality/Medical Damage","C118074","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Most lethal attempt actual lethality/medical damage.","C-SSRS Lifetime/Recent Version - Most Lethal Suicide Attempt Actual Lethality/Medical Damage | CSS11-Most Lethal Attempt Damage | CSS1122B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1558628","CTCAE Grade 2 NERVES: Thoracodorsal intra-operative injury","C58605","No value exists.","Grade 2 Thoracodorsal Nerve Intra-Operative Injury, CTCAE | CTCAE Grade 2 NERVES: Thoracodorsal intra-operative injury | Grade 2 NERVES: Thoracodorsal intra-operative injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439331","Millimole Per Mole of Creatinine","C105511","A unit of substance concentration defined as the concentration of millimoles of solute per mole of creatinine.","Millimole Per Mole of Creatinine | mmol/mol Creatinine | mmol/mol{Creatinine}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830745","C-SSRS Children's Since Last Visit - Most Severe Ideation","C111438","Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Most severe ideation.","C-SSRS Children's Since Last Visit - Most Severe Ideation | CSS08-Most Severe Ideation | CSS0806",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526114","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard Ask Doctors and Nurses Questions","C138558","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: It is hard for my child to ask the doctors and nurses questions.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard Ask Doctors and Nurses Questions | PQL13-Hard Ask Doctors/Nurses Questions | PQL1319",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814507","Giles County, VA","C110542","No value exists.","Giles County, VA | Giles County | Giles County, Virginia | VA071",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815226","Todd County, KY","C108790","No value exists.","Todd County, KY | KY219 | Todd County | Todd County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1559653","Neck Infection Documented Clinically or Microbiologically with Grade 3 or 4 Neutrophils NOS, CTCAE","C60187","No value exists.","Neck Infection Documented Clinically or Microbiologically with Grade 3 or 4 Neutrophils NOS, CTCAE | Neck NOS infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1559636","CTCAE Grade 4 Meninges (meningitis) infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L)","C59759","No value exists.","Grade 4 Meninges Infection Documented Clinically or Microbiologically with Grade 3 or 4 Neutrophils, CTCAE | CTCAE Grade 4 Meninges (meningitis) infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) | Grade 4 Meninges (meningitis) infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336342","Stage IVA Laryngeal Cancer AJCC v7","C6005","Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); T4a: Supraglottis: Moderately advanced local disease.  Tumor invades through the thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck including deep extrinsic muscle of the tongue, strap muscles, thyroid, or esophagus). Glottis: Moderately advanced local disease. Tumor invades through the outer cortex of the thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck including deep extrinsic muscles of the tongue, strap muscles, thyroid, or esophagus). Subglottis: Moderately advanced local disease.  Tumor invades cricoid or thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck including deep extrinsic muscles of the tongue, strap muscles, thyroid, or esophagus).  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension.  N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IVA Laryngeal Cancer AJCC v7 | Laryngeal Cancer Stage IVA | Stage IVA Carcinoma of Larynx | Stage IVA Carcinoma of the Larynx | Stage IVA Laryngeal Cancer | Stage IVA Laryngeal Carcinoma | Stage IVA Laryngeal Throat Cancer | Stage IVA Larynx Carcinoma | stage IVA laryngeal cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553241","Hematologic Neoplasm with Germline Predisposition without a Constitutional Disorder Affecting Multiple Organ Systems","C151897","Familial hematologic neoplasms associated with germline mutations without a preexisting disorder or organ dysfunction.","Hematologic Neoplasm with Germline Predisposition without a Constitutional Disorder Affecting Multiple Organ Systems | Hematologic Neoplasm with Germline Predisposition without a Preexisting Disorder or Organ Dysfunction | Myeloid Neoplasm with Germline Predisposition without a Preexisting Disorder or Organ Dysfunction | Myeloid Neoplasms with Germline Predisposition without a Preexisting Disorder or Organ Dysfunction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522300","Mouse Squamous Cell Neoplasm","C24012","No value exists.","Mouse Squamous Cell Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0157259","Arrest of Labor in Active Phase","C114868","More than or equal to 6 cm dilation with membrane rupture and one of the following: 4 hours or more of adequate contractions (e.g. more than 200 Montevideo units), 6 hours or more of inadequate contractions and no cervical change.","Arrest of Labor in Active Phase | Active Phase Arrest | Prolonged Active Phase of Labor | Prolonged First Stage of Labor",,,,,,,,,,,,,,,"4080668|441362","Arrested active phase of labor|Prolonged first stage of labor",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1511195","Bladder Muscularis Mucosa","C32207","A thin layer of smooth muscle within the bladder lamina propria.","Bladder Muscularis Mucosa | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525771","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Questionnaire Question","C138272","A question associated with the PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen questionnaire.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388361","Recurrent Childhood Subependymal Giant Cell Astrocytoma","C115380","The reemergence of subependymal giant cell astrocytoma in childhood after a period of remission.","Recurrent Childhood Subependymal Giant Cell Astrocytoma | Recurrent Subependymal Giant Cell Astrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514172","Pleomorphic Epithelial Cell","C37170","No value exists.","Pleomorphic Epithelial Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520369","11p15.2-p15.1","C13894","A chromosome band present on 11p","11p15.2-p15.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543212","Grade 2 Subcutaneous Emphysema, CTCAE","C145025","Moderate; minimal, local or noninvasive intervention indicated","Grade 2 Subcutaneous Emphysema, CTCAE | Grade 2 Subcutaneous emphysema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510723","Abnormal Erythroid Precursor","C37053","No value exists.","Abnormal Erythroid Precursor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2752275","PPAR Signaling Pathway","C91497","No value exists.","PPAR Signaling Pathway | PPAR signaling pathway | Peroxisome Proliferator-Activated Receptor Signaling Pathway",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555184","Lenni Lenape","C44890","A person having origins in the original Lenni-Lenape people.","Lenni-Lenape | Lenni Lenape | Lenni Lenape | Lenni-Lenape | Lenni-Lenape",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520745","Lip and Oral Cavity Cancer pN2c TNM Finding v8","C132708","Lip and oral cavity cancer with metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Lip and Oral Cavity Cancer pN2c TNM Finding v8 | Lip and Oral Cavity Carcinoma pN2c TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1561356","Grade 1 Agitation, CTCAE","C55436","Mild mood alteration","Grade 1 Agitation, CTCAE | Grade 1 Agitation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543292","Grade 3 Conjunctivitis, CTCAE","C145208","Symptomatic with marked decrease in visual acuity (best corrected visual acuity worse than 20/40 or more than 3 lines of decreased vision from known baseline, up to 20/200); limiting self care ADL","Grade 3 Conjunctivitis, CTCAE | Grade 3 Conjunctivitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1559141","CTCAE Grade 3 Pruritus/itching","C57965","Widespread and constant; limiting self care ADL or sleep; systemic corticosteroid or immunosuppressive therapy indicated","Grade 3 Pruritus, CTCAE | CTCAE Grade 3 Pruritus/itching | Grade 3 Pruritus | Grade 3 Pruritus/itching",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543320","Grade 3 Bronchial Infection, CTCAE","C145172","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Bronchial Infection, CTCAE | Grade 3 Bronchial infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1557507","Grade 3 Middle Ear Pain, CTCAE","C56128","No value exists.","Grade 3 Middle Ear Pain, CTCAE | Grade 3 Middle ear pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542259","Grade 1 Anorectal Infection, CTCAE","C143981","Localized, local intervention indicated","Grade 1 Anorectal Infection, CTCAE | Grade 1 Anorectal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1558615","CTCAE Grade 4 NERVES: Recurrent laryngeal intra-operative injury","C58878","No value exists.","Grade 4 Recurrent Laryngeal Nerve Intra-Operative Injury, CTCAE | CTCAE Grade 4 NERVES: Recurrent laryngeal intra-operative injury | Grade 4 NERVES: Recurrent laryngeal intra-operative injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542456","Grade 1 Pancreatic Duct Stenosis, CTCAE","C144312","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Pancreatic Duct Stenosis, CTCAE | Grade 1 Pancreatic duct stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556731","CTCAE Grade 3 Bone (osteomyelitis) infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L)","C59428","No value exists.","Grade 3 Bone Infection Documented Clinically or Microbiologically with Grade 3 or 4 Neutrophils, CTCAE | CTCAE Grade 3 Bone (osteomyelitis) infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) | Grade 3 Bone (osteomyelitis) infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542457","Grade 1 Pancreatic Enzymes Decreased, CTCAE","C144313","<LLN and asymptomatic","Grade 1 Pancreatic Enzymes Decreased, CTCAE | Grade 1 Pancreatic enzymes decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0055918","Clomacran","C80670","No value exists.","Clomacran | CLOMACRAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1850674","Minicore Myopathy with External Ophthalmoplegia","C150608","An autosomal recessive condition caused by mutation(s) in the RYR1 gene, encoding ryanodine receptor 1. It may be characterized clinically by neonatal hypotonia, delayed motor development, and generalized muscle weakness, and amyotrophy. Pathologically, the absence of mitochondria and focal disorganization of the sarcomere appear as 'minicores' on ATPase staining as a result of focal defects in oxidative activity.","Minicore Myopathy with External Ophthalmoplegia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519073","Physical Chemical Technique","C19236","Techniques based on the principles of physical and chemical science, for the study of biological problems.","Physical Chemical Technique | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242949","Spinach","C72012","No value exists.","Spinach | SPINACH",,,,,,,,,,,,,,,"4103779","Spinach",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL970042","US FDA HIV Technical Specifications Guidance v1.0","C161473","The 1.0 version of the FDA HIV Technical Specifications Guidance.","US FDA HIV Technical Specifications Guidance v1.0 | HIV Technical Specifications Guidance v1.0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977187","Ovarian Capsule Ruptured","C164044","A microscopy finding indicating that a portion of the ovarian capsule in a biopsy has ruptured.","Ovarian Capsule Ruptured | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648223","Initials of Person Making Aliquot","C178944","The initials of the person's name who portioned off the aliquot.","Initials of Person Making Aliquot | Aliquot_Initials",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648498","Target Biospecimen is Bronchoalveolar Lavage","C178993","A question regarding whether the target biospecimen is bronchoalveolar lavage fluid.","Target Biospecimen is Bronchoalveolar Lavage | Target_biospecimen_is_Bronchoalveolar_lavage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035260","Physical Restraint","C158344","A material item that is placed on the body in order to restrict movement.","Physical Restraint | PHYSICAL",,,,,,,,,,,,,,,"4302381","Physical restraint",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL935736","Immunoglobulin-Like Domain-Containing Receptor 2","C156669","Immunoglobulin-like domain-containing receptor 2 (639 aa, ~71 kDa) is encoded by the human ILDR2 gene. This protein may play a role in insulin secretion, immunomodulation, signaling and cellular stress responses.","Immunoglobulin-Like Domain-Containing Receptor 2 | ILDR2 | Immunoglobulin Like Domain Containing Receptor 2 | Immunoglobulin-Like Domain Containing Receptor 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662324","Ratio Result Type","C179809","An indication of a relationship in quantity, amount, or size between two entities or activities.","Ratio Result Type | RATIO | Ratio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1770974","International Prostate Symptom Score IPS0109 Original Result - Delighted","C182658","International Prostate Symptom Score IPS0109 Original Result - Delighted.","International Prostate Symptom Score IPS0109 Original Result - Delighted | Delighted | IPS0109-Delighted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378887","Mismatch at Both HLA Alleles","C168820","A mismatch exists at both alleles.","Mismatch at Both HLA Alleles | Two Alleles Mismatched",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378923","AGE_AT_COURSE_START","C168850","Age of subject (in days) at the start of the course of treatment.","Age in Days at Start of Treatment Course | AGE_AT_COURSE_START | Age at Start of Treatment Course",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0290923","Tumor Protein p53 Binding Protein 2","C17912","Apoptosis-stimulating of p53 protein 2 (1128 aa, ~126 kDa) is encoded by the human TP53BP2 gene. This protein plays a role in cell cycle arrest and the regulation of cellular tumor antigen p53-dependent apoptosis.","Apoptosis-Stimulating of p53 Protein 2 | 53BP2 | BCL-2 Binding Protein | Bbp | Renal Carcinoma Antigen NY-REN-51 | TP53BP2 | Tumor Protein p53 Binding Protein 2 | p53-Binding Protein 2 | p53BP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773047","Aguracingene Cadoparvovec","C184851","No value exists.","Aguracingene Cadoparvovec | AGURACINGENE CADOPARVOVEC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007280","Carotid Bruit","C168039","An innocent murmur with a medium pitched, harsh character heard at the right or left upper sternal border, supraclavicular region, or anterior portion of the lower neck that disappears with bilateral shoulder hyperextension. (ACC/AHA)","Carotid Bruit | Carotid bruit",,,,,,,,,,,,,,,"4304563","Carotid bruit",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0948444","Mitochondrial DNA Variation","C181352","Any inheritable mutation that appears in mitochondrial DNA that is transmitted to the progeny with some frequency.","Mitochondrial DNA Variation | MITOCHONDRIAL VARIATION | Mitochondrial DNA Mutation | Mitochondrial Mutation | mtDNA Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411675","Sign or Symptom Leading to Discontinuation","C174281","The signs and/or symptoms that result in the discontinuation of treatment or intervention.","Sign or Symptom Leading to Discontinuation | SSDISC | Sign/Symptom Leading to Discontinuation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412450","Praliciguat","C174906","No value exists.","Praliciguat | PRALICIGUAT | Praliciguat ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019534","Canonical HMG Protein","C16677","The High Mobility Group (HMG) proteins were originally isolated from mammalian cells, named according to their electrophoretic mobility in polyacrylamide gels, and were arbitrarily classed as a specific type of non-histone proteins based on the observation that they are ubiquitous to mammalian cells, that they share certain physical properties, and that they are associated with isolated chromatin. Those mammalian proteins considered to be Canonical HMG proteins are now subdivided into 3 superfamilies: the HMGB (formerly HMG-1/-2) family, the HMGN (formerly HMG-14/-17) family, and the HMGA (formerly HMG-I/Y/C) family.  Each HMG family has a characteristic functional sequence motif. (www.informatics.jax.org/mgihome/nomen/genefamilies/hmgfamily.shtml)","Canonical HMG Protein | Archetypal HMG Protein | HMG Motif Protein | HMG Nuclear Protein | HMG Protein | High Mobility Group Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537833","MIR197 Gene","C81785","This gene is involved in the regulation of gene expression and plays a role in the development of follicular thyroid carcinoma.","MIR197 Gene | MIR197 | MicroRNA 197 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982604","Penile Cancer pT3 TNM Finding v7","C89174","Penile cancer with tumor invading urethra. (from AJCC 7th Ed.)","Penile Cancer pT3 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1558103","CTCAE Grade 5 Testes stricture/stenosis (including anastomotic)","C57031","No value exists.","Grade 5 Testes Stricture or Stenosis, CTCAE | CTCAE Grade 5 Testes stricture/stenosis (including anastomotic) | Grade 5 Testes stricture/stenosis (including anastomotic)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0861834","Recurrent Malignant Duodenal Neoplasm","C9263","The reemergence of a malignant duodenal neoplasm after a period of remission.","Recurrent Malignant Duodenal Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030454","Paramethasone","C66309","No value exists.","Paramethasone | PARAMETHASONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985338","Uterine Involution","C92909","Atrophy or reduction of the size of the uterine corpus.","Uterine Involution | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1559894","Bladder Infection with Unknown Absolute Neutrophil Count, CTCAE","C59132","No value exists.","Bladder Infection with Unknown Absolute Neutrophil Count, CTCAE | Bladder infection with unknown ANC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982445","Oropharyngeal Cancer Pathologic TNM Finding v7","C88998","A pathologic finding about one or more characteristics of oropharyngeal cancer, following the rules of the TNM AJCC v7 classification system.  The pathologic staging requires the use of all information obtained in clinical staging and in histologic study of the surgically resected specimens.  (from AJCC 7th Ed.)","Oropharyngeal Cancer Pathologic TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347684","Prizidilol Hydrochloride","C73812","No value exists.","Prizidilol Hydrochloride | PRIZIDILOL HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983676","Test Facility Location","C90468","The geographic area in which a test is conducted.","Test Facility Location | TSTFLOC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348049","DNMT1 wt Allele","C73655","Human DNMT1 wt allele is located in the vicinity of 19p13.2 and is approximately 62 kb in length. This allele, which encodes DNA (Cytosine-5)-Methyltransferase 1, is involved in epigenetic modification of chromatin DNA and control of gene expression.","DNMT1 wt Allele | CXXC-Type Zinc Finger Protein 9 | DNA (Cytosine-5)-Methyltransferase 1 wt Allele | DNA Methyltransferase HsaI | DNA Methyltransferase HsaI Gene | DNA Mtase HsaI | DNA Mtase HsaI Gene | DNMT1 | M.HsaI | MCMT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983085","GNAQ Gene Expression Analysis","C89711","A laboratory assay to determine the status of the GNAQ gene which encodes guanine nucleotide-binding protein G(q) subunit alpha.","GNAQ Gene Expression Analysis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522160","Leukocyte - Myelocyte (Granulocyte) (MMHCC)","C22590","No value exists.","Mouse Granulocyte | Mouse Granular Leukocyte",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983263","CDISC SEND Death Diagnosis Test Name Terminology","C89965","The terminology that includes concepts relevant to the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND) death diagnosis test names.","CDISC SEND Death Diagnosis Test Name Terminology | DDTEST | Death Diagnosis Test Name | SEND-DDTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513549","Mouse Endometrial Endometrioid Adenocarcinoma","C24092","No value exists.","Mouse Endometrial Endometrioid Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0115685","elliptinium","C90495","A derivative of the alkaloid ellipticine isolated from species of the plant family Apocynaceae, including Bleekeria vitensis, a plant with anti-cancer properties.  As a topoisomerase II inhibitor and intercalating agent, elliptinium stabilizes the cleavable complex of topoisomerase II and induces DNA breakages, thereby inhibiting DNA replication and RNA and protein synthesis.","Elliptinium | 9-Hydroxy-2,5,11-trimethyl-6H-pyrido[4,3-b]carbazolium | 9-Hydroxy-2-methylellipticinium | ELLIPTINIUM | N-2-Methyl-9-hydroxyellipticinium | NMHE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778464","Central Memory Cytotoxic T-Lymphocyte Subpopulation Count","C185982","The determination of the number of a subpopulation of cytotoxic central memory T-lymphocytes in a sample.","Central Memory Cytotoxic T-Lymphocyte Subpopulation Count | T-Lymphocytes Cytotoxic Central Memory Sub-Population | TLCCMS | TLym Cytx Cen Mem Sub",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984120","Zinc Finger Protein PLAGL2","C91259","Zinc finger protein PLAGL2 (496 aa, ~55 kDa) is encoded by the human PLAGL2 gene. This protein is involved in DNA binding, transcription and Wnt signaling pathways.","Zinc Finger Protein PLAGL2 | Pleiomorphic Adenoma-Like Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336710","Testicular Germ Cell Neoplasia In Situ with Extratubular Extension","C7326","A malignant neoplasm that arises from the testis and is characterized by the presence of large germ cells with abundant cytoplasm in the seminiferous tubules, associated with an invasive germ cell tumor in the adjacent tissues.","Testicular Germ Cell Neoplasia In Situ with Extratubular Extension | Testicular Intratubular Germ Cell Neoplasia with Extratubular Extension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983990","Gliamilide","C91020","A sulfonamide derivative with antihyperglycemic activity. Like sulfonylureas, gliamilide is able to lower blood glucose levels by increasing the release of insulin from pancreatic beta cells.","Gliamilide | CP-27,634 | GLIAMILIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0537079","Premafloxacin","C66464","No value exists.","Premafloxacin | 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-{3-[1-(methylamino)ethyl]-1-pyrrolidinyl}-4-oxo-3-quinolinecarboxylic acid | PD-140288 | PREMAFLOXACIN | U-95376A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279541","Hodgkin's disease, nodular sclerosis, adult","C9126","Nodular sclerosis classic Hodgkin lymphoma occurring in adults.","Adult Nodular Sclerosis Classic Hodgkin Lymphoma | Adult Hodgkin's Nodular Sclerosis | Adult NSHD | Adult Nodular Sclerosis Classical Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin's Disease | Adult Nodular Sclerosis Hodgkin's Lymphoma | Nodular Sclerosis Classical Hodgkin Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0066605","Mitoclomine","C66164","An aromatic nitrogen mustard derivative with potential antineoplastic activity. Mitoclomine alkylates DNA and appears to concentrate primarily in the spleen and thymus where it causes lymphocyte depletion.","Mitoclomine | MITOCLOMINE | N,N-bis(2-chloroethyl)4-amino-2-methyl-1-methoxy-naphthalene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333971","Liver Mesenchymal Hamartoma","C5751","A multicystic mesenchymal tumor that arises from the liver during fetal development. It is the third most common pediatric liver tumor following hepatoblastoma and infantile hemangioma. Cytogenetic and molecular studies have revealed the presence of chromosomal rearrangements involving chromosome 19q13.4 or androgenetic-biparental mosaicism. These findings support the evidence that it is a neoplastic process and not only a developmental process. Clinically, it usually presents as an abdominal mass associated with abdominal distention. Morphologically, it consists of hypocellular fibromyxoid stroma and bland spindle cell proliferation. It generally has a benign clinical course. Following resection, the prognosis is good.","Liver Mesenchymal Hamartoma | HMH | Hepatic Mesenchymal Hamartoma | Liver MH | Mesenchymal Hamartoma of Liver | Mesenchymal Hamartoma of the Liver",,,,,,,,,,,,,,,"37395823","Mesenchymal hamartoma of liver",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0675272","Albaconazole","C72952","No value exists.","Albaconazole | 7-Chloro-3-[(2R,3R)-3-(2,4-difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]quinazolin-4-one | ALBACONAZOLE | UR-9825",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1560484","CTCAE Grade 3 Large bowel leak (including anastomotic)","C57461","No value exists.","Grade 3 Large Bowel Leak, CTCAE | CTCAE Grade 3 Large bowel leak (including anastomotic) | Grade 3 Large bowel leak (including anastomotic)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL428964","Arnica montana Flower","C72490","No value exists.","Arnica montana Flower | ARNICA MONTANA FLOWER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1558110","Urethra Stricture or Stenosis, CTCAE","C57093","No value exists.","Urethra Stricture or Stenosis, CTCAE | Urethera stricture/stenosis (including anastomotic)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516907","Epidemiological Factors","C19291","The identifiable and quantifiable things which contribute to the establishment and transmission of disease.","Epidemiological Factors | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1557714","Grade 3 Tracheal Fistula, CTCAE","C58119","Invasive intervention indicated","Grade 3 Tracheal Fistula, CTCAE | Grade 3 Trachea fistula | Grade 3 Tracheal fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881358","Large Mass","C62217","No value exists.","Large Mass | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882820","Rat Histopathology Diagnoses for Proliferative Changes","C60311","No value exists.","Rat Histopathology Diagnoses for Proliferative Changes | Rat Histopathologic Diagnoses | Rat Pathologic Diagnoses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1792254","Able to Pay for Daily Housing Expenses","C187311","A question about whether an individual is or was able to pay for their daily housing expenses.","Able to Pay for Daily Housing Expenses Question | Able to Pay for Daily Housing Expenses | Able to Pay for Daily Housing Expenses | During the past year, were you able to pay for your daily housing expenses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1779250","DHODH Inhibitor RP7214","C187040","An orally available inhibitor of dihydroorotate dehydrogenase (DHODH), with potential antineoplastic, anti-inflammatory and antiviral activities. Upon oral administration, DHODH inhibitor RP7214 specifically targets, binds to and prevents the activation of DHODH, thereby preventing the fourth enzymatic step in de novo pyrimidine synthesis. This prevents uridine monophosphate (UMP) formation, DNA synthesis, cell division and cellular proliferation, promotes cell differentiation, causes cell cycle arrest and induces apoptosis in susceptible tumor cells. In addition, by preventing DHODH activity in host cells, RP7214 may reduce the ability of certain viruses, such as SARS-CoV-2, to replicate, thereby reducing viral load and infection. Also, by preventing pyrimidine synthesis, RP7214 causes anti-inflammatory and immunomodulatory effects by decreasing the activation and expansion of pro-inflammatory Th1 effectors and promoting the differentiation of immunomodulatory Th2 cells, and decreasing the production of various pro-inflammatory cytokines. RP7214 could potentially attenuate the excessive production of inflammatory cytokines and the cytokine-mediated inflammatory symptoms, which are seen in certain viral infections. DHODH, a mitochondrial enzyme, catalyzes the conversion of dihydroorotate (DHO) to orotate in the endogenous synthesis of UMP.","DHODH Inhibitor RP7214 | Dihydro-orotate Dehydrogenase Inhibitor RP7214 | Dihydroorotate Dehydrogenase Inhibitor RP7214 | RP 7214 | RP-7214 | RP7214",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447689","inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein, human","C186686","Elongator complex protein 1 (1332 aa, ~150 kDa) is encoded by the human ELP1 gene. This protein is involved in tRNA metabolism.","Elongator Complex Protein 1 | ELP1 | Elongator Acetyltransferase Complex Subunit 1 | IKK Complex-Associated Protein | IkappaB Kinase Complex-Associated Protein | p150",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778799","Stage IIA1 Cervical Cancer FIGO 2009","C186629","Cervical carcinoma limited to the upper two-thirds of the vagina and is equal or less than 4 cm in diameter. (FIGO 2009)","Stage IIA1 Cervical Cancer FIGO 2009 | Stage IIA1 Cervical Carcinoma FIGO 2009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1779228","SSX1 Gene Rearrangement","C186986","A molecular abnormality indicating rearrangement of the SSX1 gene.","SSX1 Gene Rearrangement | CT5.1 Gene Rearrangement | SSRC Gene Rearrangement | SSX Family Member 1 Gene Rearrangement | SSX Gene Rearrangement | SSX1 Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1779234","TAL1 Gene Rearrangement","C186992","A molecular abnormality indicating rearrangement of the TAL1 gene.","TAL1 Gene Rearrangement | SCL Gene Rearrangement | T-Cell Acute Lymphocytic Leukemia 1 Gene Rearrangement | TAL bHLH Transcription Factor 1, Erythroid Differentiation Gene Rearrangement | TAL1 Rearrangement | TCL5 Gene Rearrangement | bHLHa17 Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1779021","MECOM Gene Rearrangement","C186908","A molecular abnormality indicating rearrangement of the MECOM gene.","MECOM Gene Rearrangement | EVI1 Gene Rearrangement | Ecotropic Viral Integration Site 1 Gene Rearrangement | KMT8E Gene Rearrangement | MDS1 Gene Rearrangement | MDS1 and EVI1 Complex Locus Gene Rearrangement | MDS1-EVI1 Gene Rearrangement | MECOM Rearrangement | PRDM3 Gene Rearrangement | RUSAT2 Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1792847","How Often Eat Cookies, Cake, Pie, or Brownies","C188108","A question about how often an individual eats or ate cookies, cake, pie, or brownies.","How Often Eat Cookies, Cake, Pie, or Brownies | How often did you eat cookies, cake, pie or brownies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1792121","MAPK1 NP_002736.3:p.E322K","C187409","A change in the amino acid residue at position 322 in the dual specificity mitogen-activated protein kinase 1 protein where glutamic acid has been replaced by lysine.","MAPK1 NP_002736.3:p.E322K | ERK-2 E322K | ERK-2 Glu322Lys | Extracellular Signal-Regulated Kinase 2 E322K | Extracellular Signal-Regulated Kinase 2 Glu322Lys | MAP Kinase Isoform p42 E322K | MAP Kinase Isoform p42 Glu322Lys | MAPK 1 E322K | MAPK 1 Glu322Lys | MAPK1 E322K | MAPK1 Glu322Lys | MAPK1 NP_002736.3:p.Glu322Lys | MAPK1 p.E322K | MAPK1 p.Glu322Lys | Mitogen-Activated Protein Kinase 1 E322K | Mitogen-Activated Protein Kinase 1 Glu322Lys | NP_002736.3:p.E322K | NP_002736.3:p.Glu322Lys | p42-MAPK E322K | p42-MAPK Glu322Lys | p42MAPK E322K | p42MAPK Glu322Lys",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1792565","Numerical Rating Scale 7-Point","C187967","A questionnaire, rating and scale (QRS) data type using a 7-point numerical rating scale (NRS).","Numerical Rating Scale 7-Point | NRS 7-Point | NUMERICAL RATING SCALE 7-POINT | Numeric Rating Scale 7-Point",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1792390","CAPS DSM-5 With DSM IV Scoring 2016 Version - DSM-5 Criterion C Score","C187613","Clinician-Administered PTSD Scale (Current) DSM-5 With DSM IV Scoring 2016 Version (CAPS DSM-5 With DSM IV Scoring 2016 Version) DSM-5 criterion C score.","CAPS DSM-5 With DSM IV Scoring 2016 Version - DSM-5 Criterion C Score | CAP01-DSM-5 Criterion C Score | CAP0143",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1792538","Clinician-Administered PTSD Scale (Current) DSM-5 With DSM IV Scoring 2016 Version Clinical Classification","C187509","A 30-item structured interview used to make a current (past month) diagnosis of PTSD, make a lifetime diagnosis of PTSD, and assess PTSD symptoms over the past week.","Clinician-Administered PTSD Scale (Current) DSM-5 With DSM IV Scoring 2016 Version Clinical Classification | CAP01 | CAPS DSM-5 WITH DSM IV SCORING 2016 VERSION | CAPS DSM-5 With DSM IV Scoring 2016 Version | CAPS-5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1792205","Anti-mesothelin CAR Vector-transduced T-lymphocytes","C187372","A preparation of genetically modified T-lymphocytes transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) specific for the human tumor-associated antigen (TAA) mesothelin (MSLN), with potential immunomodulating and antineoplastic activities. Upon administration, the anti-MSLN CAR vector-transduced T-lymphocytes specifically target and kill MSLN-expressing tumor cells. MSLN, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types.","Anti-mesothelin CAR Vector-transduced T-lymphocytes | Anti-MSLN CAR-T Cells | HuCART-meso",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1792118","Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma","C187400","Hormone receptor-positive breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.","Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma | Locally Advanced Unresectable Hormone Receptor Positive Breast Adenocarcinoma | Locally Advanced Unresectable Hormone Receptor Positive Breast Carcinoma | Locally Advanced Unresectable Hormone Receptor-Positive Breast Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1792633","Urologist 1","C187891","An urologist performing the assessment who is given the designation of one.","Urologist 1 | UROLOGIST 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1792660","Atypical Mononuclear Cells to Leukocytes Ratio Measurement","C187791","The determination of the ratio of the atypical mononuclear cells to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Atypical Mononuclear Cells to Leukocytes Ratio Measurement | MNCATLE | Mononuclear Cells Atypical/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1792028","Anti-HJV Monoclonal Antibody DISC-0974","C187120","A humanized monoclonal antibody directed against the bone morphogenetic proteins (BMPs) co-receptor hemojuvelin (HJV), with potential to treat anemia of inflammation and other forms of anemia. Upon subcutaneous administration, anti-HJV monoclonal antibody DISC-0974 targets and binds to HJV, preventing it from binding to the hepcidin regulatory ligands BMPs and inhibiting the HJV-mediated signaling pathway. This suppresses hepcidin synthesis and increases iron availability, which may normalize plasma iron levels and increase erythropoiesis. HJV is required for hepcidin production. Hepcidin plays a key role in the homeostasis of systemic iron by restricting iron absorption and inhibiting ferroportin-mediated iron export; it is upregulated during acute and chronic inflammation in response to cytokines and, in certain cancers, may contribute to cancer-associated anemia.","Anti-HJV Monoclonal Antibody DISC-0974 | Anti-Hemojuvelin Monoclonal Antibody DISC-0974 | DISC 0974 | DISC-0974 | DISC0974",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1793054","Blast Phase Primary Myelofibrosis","C188318","Transformation of primary myelofibrosis into acute myeloid leukemia, typically via accelerated phase primary myelofibrosis. Myeloblasts account for 20% or more of the peripheral blood white cells or the nucleated cells in the bone marrow.","Blast Phase Primary Myelofibrosis | Leukemic Transformation of Primary Myelofibrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1793710","Neurogenic Differentiation Factor 1 Overexpression","C188758","An indication that overexpression of neurogenic differentiation factor 1 has been detected in a sample.","Neurogenic Differentiation Factor 1 Overexpression | NEUROD1 Overexpression Positive | NEUROD1 Transcription Factor Overexpression Positive | Overexpression of Neurogenic Differentiation Factor 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1794285","ALKAL2 wt Allele","C189095","Human ALKAL2 wild-type allele is located in the vicinity of 2p25.3 and is approximately 9 kb in length. This allele, which encodes ALK and LTK ligand 2 protein, is involved in neural development and receptor tyrosine kinase binding.","ALKAL2 wt Allele | ALK and LTK Ligand 2 wt Allele | AUGA | Augmentor, Alpha Gene | Augmentor-Alpha Gene | FAM150B | Family with Sequence Similarity 150 Member B Gene | Family with Sequence Similarity 150, Member B Gene | PRO1097 | RGPG542 | UNQ542/PRO1097",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1794133","ALK-Rearranged Renal Cell Carcinoma","C189249","An extremely rare renal cell carcinoma characterized by the presence of chromosomal translocations involving the chromosome 2p23 breakpoint that result in gene fusions between the anaplastic lymphoma kinase gene (ALK) and various gene partners.","ALK-Rearranged Renal Cell Carcinoma | ALK-RCC | Anaplastic Lymphoma Kinase Rearrangement-Associated Renal Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1794549","Focus Forming Unit per Milliliter","C189650","A derived concentration unit expressed as focus forming units per milliliter.","Focus Forming Unit per Milliliter | FFU/mL | Focus Forming Units per Milliliter | Focus Forming Units/mL | [FFU]/mL | [FFU]/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1793931","Recurrent B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","C189042","The reemergence of B acute lymphoblastic leukemia, Philadelphia chromosome negative, after a period of remission.","Recurrent B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1793762","EGFR NP_005219.2:p.D761Y","C188697","A change in the amino acid residue at position 761 in the epidermal growth factor receptor protein where aspartic acid has been replaced by tyrosine.","EGFR NP_005219.2:p.D761Y | EGFR Asp761Tyr | EGFR D761Y | EGFR D761Y Mutation | EGFR NP_005219.2:p.Asp761Tyr | EGFR p.Asp761Tyr | EGFR p.D761Y | Epidermal Growth Factor Receptor Asp761Tyr | Epidermal Growth Factor Receptor D761Y | NP_005219.2:p.Asp761Tyr | NP_005219.2:p.D761Y | Proto-Oncogene c-ErbB-1 Asp761Tyr | Proto-Oncogene c-ErbB-1 D761Y | Receptor Tyrosine-Protein Kinase erbB-1 Asp761Tyr | Receptor Tyrosine-Protein Kinase erbB-1 D761Y",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1793946","Childhood Chondrosarcoma","C189027","A rare chondrosarcoma that occurs during childhood.","Childhood Chondrosarcoma | Pediatric Chondrosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1793638","Autologous Muscle-derived Cells for Gastrointestinal Repair","C188383","A preparation of autologous human muscle-derived stem cells (MDSCs), that can potentially be used for engraftment purposes for gastrointestinal (GI) repair (GIR). Upon administration, autologous muscle-derived cells (AMDC) for GI repair (AMDC-GIR) differentiate and self-renew. This allows for certain damaged GI tissues to be repaired.","Autologous Muscle-derived Cells for Gastrointestinal Repair | AMDC-GIR | AMDCs for GIR | Autologous Muscle Derived Stem Cells for GIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1794167","GBP1 wt Allele","C189204","Human GBP1 wild-type allele is located in the vicinity of 1p22.2 and is approximately 13 kb in length. This allele, which encodes guanylate-binding protein 1, is involved in interferon-dependent antimicrobial responses.","GBP1 wt Allele | GBP-1 | Guanylate Binding Protein 1 wt Allele | Guanylate Binding Protein 1, Interferon-Inducible Gene | Guanylate Binding Protein 1, Interferon-Inducible, 67kDa Gene | Guanylate-Binding Protein 1, Interferon-Inducible, 67-kD Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1794172","COVID-19 Vaccine Administered","C189190","A question about which COVID-19 vaccine was administered.","COVID-19 Vaccine Administered | SARS-CoV-2 Vaccine Administered | SARS-CoV-2 Vaccine Type | SARS-CoV-2 vaccine type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1793971","Childhood Diffuse Intrinsic Pontine Glioma","C188924","A diffuse intrinsic pontine glioma that occurs during childhood.","Childhood Diffuse Intrinsic Pontine Glioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1794379","Predicted Diplotype","C189449","A description of the inferred nucleotide sequence at one or more paired loci.","Predicted Diplotype | Inferred Diplotype | PREDICTED DIPLOTYPE | Predicted Haplotype Pair",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3261571","How Much Current Difficulty Getting Things Organized","C190221","A question about how much difficulty an individual currently has or had getting things organized.","How Much Current Difficulty Getting Things Organized | How much difficulty do you currently have getting things organized",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1799602","PAX5 Gene Alteration Positive","C190880","A finding indicating that mutation, underexpression, overexpression, amplification or rearrangement of the PAX5 gene has been detected in a sample.","PAX5 Gene Alteration Positive | ALL3 Gene Alteration Positive | BSAP Gene Alteration Positive | PAX5alt | Paired Box Gene 5 Alteration Positive | Paired Box Gene 5 Gene Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1905611","Very Bad Experience","C192136","A response indicating that an individual's experience with something was very bad.","Very Bad Experience | Very bad",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1799110","ADAMTS10 wt Allele","C190635","Human ADAMTS10 wild-type allele is located in the vicinity of 19p13.2 and is approximately 30 kb in length. This allele, which encodes a disintegrin and metalloproteinase with thrombospondin motifs 10 protein, is involved in the organization of connective tissue microfibrils. Mutations in the gene may be associated with autosomal recessive Weill-Marchesani syndrome.","ADAMTS10 wt Allele | A Disintegrin-Like and Metalloprotease (Reprolysin Type) with Thrombospondin Type 1 Motif, 10 Gene | A Disintegrin-Like and Metalloprotease with Thrombospondin Type 1 Motif, 10 Gene | ADAM Metallopeptidase with Thrombospondin Type 1 Motif 10 wt Allele | ADAM-TS10 | ADAMTS-10 | WMS | WMS1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1798985","AARS2 wt Allele","C190306","Human AARS2 wild-type allele is located in the vicinity of 6p21.1 and is approximately 15 kb in length. This allele, which encodes alanine-tRNA ligase, mitochondrial protein, is involved in the synthesis of tRNA(Ala). Mutation of the gene is associated with both combined oxidative phosphorylation deficiency 8 and progressive leukoencephalopathy with ovarian failure.","AARS2 wt Allele | AARSL | Alanyl tRNA Ligase 2, Mitochondrial Gene | Alanyl tRNA Synthetase Like Gene | Alanyl-tRNA Synthetase 2, Mitochondrial wt Allele | COXPD8 | KIAA1270 | LKENP | MT-ALARS | MTALARS | bA444E17.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1798905","Refractory T-Cell and NK-Cell Neoplasm","C190401","T-cell and NK-cell neoplasm that is resistant to treatment.","Refractory T-Cell and NK-Cell Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1798619","International Intraocular Retinoblastoma Classification","C189851","A classification system for intraocular retinoblastoma based on the intraocular tumor size, location, extend of serous fluid, and presence of subretinal or vitreous seeds.","International Intraocular Retinoblastoma Classification | ICRB | IIRC | International Classification for Intraocular Retinoblastoma | International Classification of Retinoblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1799661","VHI - Part I-F Subtotal","C191193","Voice Handicap Index (VHI) Part I-F subtotal.","VHI - Part I-F Subtotal | VHI01-Part I-F Subtotal | VHI0131",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1798858","Androgenetic-Biparental Mosaicism","C190025","The presence of cells with complete paternal uniparental disomy.","Androgenetic-Biparental Mosaicism | Androgenetic/Biparental Mosaicism | Androgenic-Biparental Mosaicism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1799189","Fulimetibant","C190503","No value exists.","Fulimetibant | FULIMETIBANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1799078","GNAQ/GNA11 Antagonist DYP688","C190696","An antagonist of guanine nucleotide-binding protein G(q) subunit alpha (GNAQ)/ guanine nucleotide-binding protein subunit alpha-11 (GNA11), with potential antineoplastic activity. Upon administration, GNAQ/GNA11 antagonist DYP688 inhibits the activity of GNAQ/GNA11 and prevents GNAQ/GNA11-mediated signaling. This may prevent proliferation in tumors overexpressing and/or harboring mutations of GNAQ/GNA11. GNAQ and GNA11 are involved in carcinogenesis and are mutated in certain melanomas.","GNAQ/GNA11 Antagonist DYP688 | DYP 688 | DYP-688 | DYP688",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1799673","PASI Bozek Version - Lower Extremities: Sum of Symptom Scores","C191149","Psoriasis Area and Severity Index Bozek Version (PASI Bozek Version) Lower Extremities: Sum of symptom scores.","PASI Bozek Version - Lower Extremities: Sum of Symptom Scores | PASI05-Low Extrem: Sum of Symptom Scores | PASI0526",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL791557","unwinding protein 1, human","C189949","Heterogeneous nuclear ribonucleoprotein A1 (372 aa, ~39 kDa) is encoded by the human HNRNPA1 gene. This protein plays a key role in the regulation of alternative splicing.","Heterogeneous Nuclear Ribonucleoprotein A1 | HNRNPA1 | Helix-Destabilizing Protein | Heterogeneous Nuclear Ribonucleoprotein Core Protein A1 | Nuclear Ribonucleoprotein Particle A1 Protein | Single-Strand DNA-Binding Protein UP1 | Single-Strand RNA-Binding Protein | hnRNP A1 | hnRNP Core Protein A1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1799015","Childhood Pilomatricoma","C190279","A pilomatricoma that occurs during childhood.","Childhood Pilomatricoma | Pediatric Pilomatricoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1798448","Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Original Result - Cannot be Assessed Adequately Because of Severe Formal Thought Disorder, Uncooperativeness, or Marked Evasiveness/Guardedness; or Not Assessed","C189710","Brief Psychiatric Rating Scale-Anchored BPRSA101, BPRSA102, BPRSA105, BPRSA108, BPRSA109, BPRSA110, BPRSA111, BPRSA112, and BPRSA115 Original Result - Cannot be assessed adequately because of severe formal thought disorder, uncooperativeness, or marked evasiveness/guardedness; or not assessed.","Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Original Result - Cannot be Assessed Adequately Because of Severe Formal Thought Disorder, Uncooperativeness, or Marked Evasiveness/Guardedness; or Not Assessed | BPRSA1SET1-Cannot be assessed adequately because of severe formal thought disorder, uncooperativeness, or marked evasiveness/guardedness; or Not assessed | Cannot be assessed adequately because of severe formal thought disorder, uncooperativeness, or marked evasiveness/guardedness; or Not assessed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1453712","RAE1 protein, human","C189955","mRNA export factor RAE1 (368 aa, ~41 kDa) is encoded by the human RAE1 gene. This protein plays a role in attaching cytoplasmic mRNA-containing riboprotein complexes to the cytoskeleton.","mRNA Export Factor RAE1 | RAE1 | Rae1 Protein Homolog | Ribonucleic Acid Export Protein 1 | mRNA Export Protein RAE1 | mRNA-Associated Protein MRNP 41 | mRNA-Associated Protein Mrnp 41",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1912600","Progastrin","C192657","Progastrin (80 aa, ~9 kDa) is encoded by the human GAST gene. This protein is involved in the secretion of digestive factors by the gastrointestinal system. Circulating progastrin is associated with tumorigenesis.","Progastrin | HPG80 | hPG80 | progastrin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1905017","Clinical Frailty Scale Category 4","C191489","A Clinical Frailty Scale category that indicates that an individual is living with very mild frailty. Previously denoted as 'vulnerable', this category marks the transition from complete independence. Although not dependent on others for daily help, symptoms often limit activities. A common complaint is being 'slowed up' or being tired during the day.","Clinical Frailty Scale Category 4 | 4 (vulnerable)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1904846","Central Memory Helper T-Lymphocyte Subpopulation to Central Memory Helper T-Lymphocyte Ratio Measurement","C191253","The determination of the ratio of T-lymphocytes helper central memory sub-population to T-lymphocytes helper central memory present in a sample. The measurement may be expressed as a ratio or percentage.","Central Memory Helper T-Lymphocyte Subpopulation to Central Memory Helper T-Lymphocyte Ratio Measurement | T-Lymphocytes Helper Central Memory Sub-Population/T-Lymphocytes Helper Central Memory | TLHCMSP | TLym Help Cen Mem Sub/TLymHCM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1905105","Electrophysiological Procedures Terminology","C191399","Terminology from the American College of Cardiology (ACC)/American Heart Association (AHA) describing the potential electrophysiological procedures that may be utilized during COVID-19 infection (from 2022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards. Bozkurt B et al. Circ Cardiovasc Qual Outcomes. 2022; 15:e000111).","Electrophysiological Procedures Terminology | Electrophysiological Procedures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1904910","Regulatory Cytotoxic T-Lymphocyte Subpopulation to Cytotoxic T-Lymphocyte Ratio Measurement","C191208","The determination of the ratio of T-lymphocytes cytotoxic regulatory sub-population to T-lymphocytes cytotoxic present in a sample. The measurement may be expressed as a ratio or percentage.","Regulatory Cytotoxic T-Lymphocyte Subpopulation to Cytotoxic T-Lymphocyte Ratio Measurement | T-Lymphocytes Cytotoxic Regulatory Sub-Population/T-Lymphocytes Cytotoxic | TLCRSTLC | TLym Cytx Reg Sub/TLym Cytx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1904840","Regulatory Memory Helper T-Lymphocyte to Regulatory Helper T-Lymphocyte Ratio Measurement","C191267","The determination of the ratio of T-lymphocytes helper regulatory memory to T-lymphocytes helper regulatory present in a sample. The measurement may be expressed as a ratio or percentage.","Regulatory Memory Helper T-Lymphocyte to Regulatory Helper T-Lymphocyte Ratio Measurement | T-Lymphocytes Helper Regulatory Memory/T-Lymphocytes Helper Regulatory | TLHRMTHR | TLym Help Reg Mem/TLymHR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411089","Non-Invasive Papillary Urothelial Carcinoma, Low Grade","C191673","A non-invasive papillary urothelial carcinoma characterized by minimal cytologic atypia and infrequent mitotic figures (usually limited to the lower half of the tumor). It usually occurs in the urinary bladder, but it can arise from other sites in the urinary tract. This type of carcinoma recurs frequently, may invade the urinary tract wall, and has a low risk of progression.","Non-Invasive Papillary Urothelial Carcinoma, Low Grade | Non-Invasive Papillary Urothelial Carcinoma, Low-Grade",,,,,,,,,,,,,,,"3661794","Non-invasive papillary urothelial carcinoma, low-grade",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1905404","Refractory Extrapulmonary Large Cell Neuroendocrine Carcinoma","C191986","Extrapulmonary large cell neuroendocrine carcinoma that is resistant to treatment.","Refractory Extrapulmonary Large Cell Neuroendocrine Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1905447","SPOP Gene Mutation","C191947","A change in the nucleotide sequence of the SPOP gene.","SPOP Gene Mutation | BTBD32 Gene Mutation | Speckle Type BTB/POZ Protein Gene Mutation | Speckle-Type POZ Protein Gene Mutation | TEF2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1912554","Medication Dose Unit of Measure","C192240","The unit of measure that is associated with the dose of an administered medicine.","Medication Dose Unit of Measure | Medication Dosage Units | medication units of measure | medication_units_of_measure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1912857","MET/CEP7 Ratio Greater than or Equal to 4","C192796","An indication that the ratio of fluorescence in situ hybridization (FISH) signals for the MET gene versus the chromosome 7 centromere marker CEP7 is greater than or equal to 4. This result implies MET gene amplification is present.","MET/CEP7 Ratio Greater than or Equal to 4 | MET/CEP7 Greater than or Equal to 4 | MET/CEP7 Greater than or Equal to Four | MET/CEP7 Ratio Greater than or Equal to Four",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1770377","Cyclin-Dependent Kinase 4 Inhibitor","C192741","Any agent that inhibits the serine/threonine kinase cyclin-dependent kinase 4 (CDK4).","Cyclin-Dependent Kinase 4 Inhibitor | CDK4 Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1894281","HIF-2alpha Inhibitor","C192728","Any agent that inhibits the protein hypoxia inducible factor (HIF)-2alpha.","HIF-2alpha Inhibitor | HIF-2a Inhibitor | Hypoxia-inducible Factor-2 Alpha Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1912457","Plan Treated in Session Number","C192329","A particular plan that is treated within a specified session for a course of radiation therapy.","Plan Treated in Session Number | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1912502","Immunotherapeutic Agent Dosage Unit","C192286","The unit of measure that is associated with the dose of an administered immunotherapeutic agent.","Immunotherapeutic Agent Dosage Unit | Immunotherapy Drug Dosage Unit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1913825","Localized PRETEX II Hepatoblastoma","C198012","PRETEXT II hepatoblastoma confined to the liver including regional lymph nodes. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)","Localized PRETEXT II Hepatoblastoma | Hepatoblastoma Localized PRETEXT II | Localized PRETEX II Hepatoblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2889054","Reiter's Disease, Left Elbow","C196974","Evidence of Reiter's disease in the left elbow.","Reiter's Disease, Left Elbow | Reiter's disease, left elbow",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1913478","Monoplegia of Lower Limb following Non-Traumatic Subarachnoid Hemorrhage Affecting Left Non-Dominant Side","C196295","Evidence of monoplegia of lower limb following non-traumatic subarachnoid hemorrhage affecting left non-dominant side.","Monoplegia of Lower Limb following Non-Traumatic Subarachnoid Hemorrhage Affecting Left Non-Dominant Side | Monoplegia of lower limb following non-traumatic subarachnoid hemorrhage affecting left non-dominant side",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2889556","Juvenile Rheumatoid Arthritis with Systemic Onset, Left Elbow","C197378","Evidence of juvenile rheumatoid arthritis with systemic onset in the left elbow.","Juvenile Rheumatoid Arthritis with Systemic Onset, Left Elbow | Juvenile rheumatoid arthritis with systemic onset, left elbow",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1914287","Chromosome Region 8q23.3-24.13 Deletion in Blood or Tissue by FISH","C193886","A fluorescent in situ hybridization-based procedure that detects chromosome region 8q23.3-24.13 deletions in a blood or tissue specimen.","Chromosome Region 8q23.3-24.13 Deletion in Blood or Tissue by FISH | Chromosome region 8q23.3-24.13 deletion in Blood or Tissue by FISH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2882063","Other Rheumatic Tricuspid Valve Diseases","C196086","Evidence of other rheumatic tricuspid valve diseases not specified elsewhere.","Other Rheumatic Tricuspid Valve Diseases | Other rheumatic tricuspid valve diseases",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2197979","Alcohol Dependence, in Remission","C195551","Evidence of alcohol dependence, in remission.","Alcohol Dependence, in Remission | Alcohol dependence, in remission",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1914603","Gamma-Enolase [Mass/Volume] in Serum or Plasma by Immunoassay","C193716","A quantitative immunoassay that measures the concentration (mass/volume) of gamma-enolase in a serum or plasma specimen.","Gamma-Enolase [Mass/Volume] in Serum or Plasma by Immunoassay | Enolase.neuron specific [Mass/volume] in Serum or Plasma by Immunoassay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2889779","Displacement of Heart Valve Prosthesis, Initial Encounter","C197758","Evidence of displacement of heart valve prosthesis, initial encounter.","Displacement of Heart Valve Prosthesis, Initial Encounter | Displacement of heart valve prosthesis, initial encounter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3263803","Unspecified Malignant Neoplasm Skin of Right Lower Limb, Including Hip","C194216","Evidence of unspecified malignant neoplasm skin of the right lower limb including the hip.","Unspecified Malignant Neoplasm Skin of Right Lower Limb, Including Hip | Unspecified malignant neoplasm of skin of right lower limb, including hip",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2882406","Cerebral Infarction due to Unspecified Occlusion or Stenosis of Unspecified Anterior Cerebral Artery","C196249","Evidence of cerebral infarction due to an unspecified occlusion or stenosis of an unspecified anterior cerebral artery.","Cerebral Infarction due to Unspecified Occlusion or Stenosis of Unspecified Anterior Cerebral Artery | Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2882741","Other Atherosclerosis of Native Arteries of Extremities, Bilateral Legs","C196510","Evidence of other atherosclerosis of native arteries of extremities in both legs not specified elsewhere.","Other Atherosclerosis of Native Arteries of Extremities, Bilateral Legs | Other atherosclerosis of native arteries of extremities, bilateral legs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2882815","Atherosclerosis of Autologous Vein Bypass Graft(s) of the Extremities with Rest Pain, Right Leg","C196563","Evidence of atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain in the right leg.","Atherosclerosis of Autologous Vein Bypass Graft(s) of the Extremities with Rest Pain, Right Leg | Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, right leg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1913948","Oxidized Low Density Lipoprotein Cholesterol","C198267","A type of low density lipoprotein cholesterol that is oxidized.","Oxidized Low Density Lipoprotein Cholesterol | OXIDIZED LOW DENSITY LIPOPROTEIN CHOLESTEROL | Ox-LDL | Oxidized LDL Cholesterol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0348637","Occlusion and Stenosis of Other Precerebral Arteries","C196270","Evidence of occlusion and stenosis of other precerebral arteries.","Occlusion and Stenosis of Other Precerebral Arteries | Occlusion and stenosis of Other precerebral arteries",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2842058","Merkel Cell Carcinoma of Unspecified Part of Face","C194271","Evidence of Merkel cell carcinoma of unspecified part of face.","Merkel Cell Carcinoma of Unspecified Part of Face | Merkel cell carcinoma of unspecified part of face",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2874747","Inhalant Abuse with Intoxication, Uncomplicated","C195782","Evidence of inhalant abuse with intoxication, uncomplicated.","Inhalant Abuse with Intoxication, Uncomplicated | Inhalant abuse with intoxication, uncomplicated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0155889","Mushroom-Worker's Lung","C197937","A hypersensitivity pneumonitis associated with the inhalation of fungal spores that are released during mushroom cultivation.","Mushroom-Worker's Lung | Mushroom-worker's lung",,,,,,,,,,,,,,,"433233","Mushroom workers' lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1914723","Cancer Antigen 15-3 [Presence] in Serum or Plasma","C193546","A procedure that detects cancer antigen 15-3 in serum or plasma specimens.","Cancer Antigen 15-3 [Presence] in Serum or Plasma | Cancer Ag 15-3 [Presence] in Serum or Plasma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1914269","PDGFRB Gene Rearrangements [Interpretation] in Blood or Tissue by FISH Narrative","C193839","An interpretative narrative applied to a fluorescent in situ hybridization-based procedure that detects PDGFRB gene rearrangements in a blood or tissue specimen.","PDGFRB Gene Rearrangements [Interpretation] in Blood or Tissue by FISH Narrative | PDGFRB gene rearrangements [Interpretation] in Blood or Tissue by FISH Narrative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0153422","Malignant Neoplasm of Lesser Curvature of Stomach, Unspecified","C194069","Evidence of a malignant neoplasm of the lesser curvature of stomach.","Malignant Neoplasm of Lesser Curvature of Stomach, Unspecified | Malignant neoplasm of lesser curvature of stomach, unspecified",,,,,,,,,,,,,,,"4149837","Malignant tumor of lesser curve of stomach",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2874094","Type 2 Diabetes Mellitus with Proliferative Diabetic Retinopathy with Macular Edema","C195352","Evidence of type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema.","Type 2 Diabetes Mellitus with Proliferative Diabetic Retinopathy with Macular Edema | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1913119","Northeastern State","C193400","A US state in the northeastern region of the country.","Northeastern State | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4267950","Diabetes Mellitus due to Underlying Condition with Diabetic Macular Edema, Resolved following Treatment, Right Eye","C195099","Evidence of diabetes mellitus due to underlying condition with diabetic macular edema which is resolved following treatment in the right eye.","Diabetes Mellitus due to Underlying Condition with Diabetic Macular Edema, Resolved following Treatment, Right Eye | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0837004","Type 1 Diabetes Mellitus with Diabetic Cataract","C195284","Evidence of type 1 diabetes mellitus with diabetic cataract.","Type 1 Diabetes Mellitus with Diabetic Cataract | Type 1 diabetes mellitus with diabetic cataract",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2874082","Type 2 Diabetes Mellitus with Unspecified Diabetic Retinopathy without Macular Edema","C195321","Evidence of type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema.","Type 2 Diabetes Mellitus with Unspecified Diabetic Retinopathy without Macular Edema | Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2874794","Other Psychoactive Substance Abuse with Intoxication with Perceptual Disturbance","C195813","Evidence of other psychoactive substance abuse with intoxication with perceptual disturbance not specified elsewhere.","Other Psychoactive Substance Abuse with Intoxication with Perceptual Disturbance | Other psychoactive substance abuse with intoxication with perceptual disturbance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0837060","Other Specified Diabetes Mellitus with Ketoacidosis without Coma","C195409","Evidence of other specified diabetes mellitus with ketoacidosis without coma not specified elsewhere.","Other Specified Diabetes Mellitus with Ketoacidosis without Coma | Other specified diabetes mellitus with ketoacidosis without coma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2887466","Other Asthma","C196783","Evidence of other asthma not specified elsewhere.","Other Asthma | Other asthma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2889426","Rheumatoid Bursitis, Unspecified Hand","C197264","Evidence of rheumatoid bursitis in an unspecified hand.","Rheumatoid Bursitis, Unspecified Hand | Rheumatoid bursitis, unspecified hand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2909675","Diseases of the Nervous System Complicating Childbirth","C197739","Evidence of diseases of the nervous system complicating childbirth.","Diseases of the Nervous System Complicating Childbirth | Diseases of the nervous system complicating childbirth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1913833","y-Stage I","C197988","Stage I determined following chemotherapy and/or radiation.","y-Stage I | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1913224","Tanner Scale Girl TANN0101 Standardized Character Result Stage 5","C193293","Tanner Scale Girl TANN0101 Standardized Character Result Stage 5 - Stage 5: Mature stage; projection of papilla only, due to recession of the areola to the general contour of the breast.","Tanner Scale Girl TANN0101 Standardized Character Result Stage 5 | Stage 5 | TANN0101-Stage 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1913635","Rheumatoid Arthritis of Multiple Sites with Involvement of Organs and Systems","C197177","Evidence of rheumatoid arthritis of multiple sites with involvement of organs and systems.","Rheumatoid Arthritis of Multiple Sites with Involvement of Organs and Systems | Rheumatoid arthritis of multiple sites with involvement of organs and systems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1914419","Cancer Antigen 125 [Units/Volume] in Aspirate","C193984","A quantitative procedure that measures the concentration (units/volume) of cancer antigen 125 in an aspirate.","Cancer Antigen 125 [Units/Volume] in Aspirate | Cancer Ag 125 [Units/volume] in Aspirate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1913045","Supraglottic Space","C192940","The space that is bordered laterally by the quadrangular membrane and the laryngeal surface of the epiglottic cartilage, and extends from adjacent to the supraglottic mucosal surface to above the lower edge of the vestibular ligaments.","Supraglottic Space | Structure of supraglottic space (body structure)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1264191","Malignant Immunoproliferative Disease, Unspecified","C194803","Evidence of a malignant immunoproliferative disease.","Malignant Immunoproliferative Disease, Unspecified | Malignant immunoproliferative disease, unspecified",,,,,,,,,,,,,,,"4003834","Malignant immunoproliferative disease (clinical)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2882569","Aphasia following Cerebral Infarction","C196360","Evidence of aphasia following cerebral infarction.","Aphasia following Cerebral Infarction | Aphasia following cerebral infarction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1913241","CDISC ADaM National Early Warning Score 2 Clinical Classification Parameter Code Terminology","C193278","Terminology associated with the National Early Warning Score 2 Clinical Classification parameter code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Analysis Data Model (ADaM).","CDISC ADaM National Early Warning Score 2 Clinical Classification Parameter Code Terminology | ADaM-NEWS1PC | NEWS1PC | National Early Warning Score 2 Clinical Classification Parameter Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2861664","Carcinoma in Situ of Left Bronchus and Lung","C194872","Evidence of carcinoma in situ of the left bronchus and lung.","Carcinoma in Situ of Left Bronchus and Lung | Carcinoma in situ of left bronchus and lung",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2874045","Type 1 Diabetes Mellitus with Diabetic Neuropathy, Unspecified","C195290","Evidence of type 1 diabetes mellitus with diabetic neuropathy.","Type 1 Diabetes Mellitus with Diabetic Neuropathy, Unspecified | Type 1 diabetes mellitus with diabetic neuropathy, unspecified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4268024","Type 1 Diabetes Mellitus with Moderate Nonproliferative Diabetic Retinopathy without Macular Edema, Left Eye","C195245","Evidence of type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema in the left eye.","Type 1 Diabetes Mellitus with Moderate Nonproliferative Diabetic Retinopathy without Macular Edema, Left Eye | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475534","Anemia in Neoplastic Disease","C194994","Evidence of anemia in neoplastic disease.","Anemia in Neoplastic Disease | Anemia in neoplastic disease",,,,,,,,,,,,,,,"441258","Anemia in neoplastic disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1913861","Billion Copies per Milliliter","C198386","The unit of concentration expressed as the number of 10 to the ninth power copies in unit volume equal to one milliliter. (NCI)","Billion Copies per Milliliter | 10*9.{copies}/mL | 10*9.{copies}/ml | 10^9 copies/mL | 10^9.{copies}/mL | 10^9.{copies}/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2893389","Gonococcal Spondylopathy","C194011","Any joint disease within the vertebrae attributed to a gonococcal infection.","Gonococcal Spondylopathy | Gonococcal spondylopathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0496843","Malignant Neoplasm of Craniopharyngeal Duct","C194435","Evidence of a malignant neoplasm of the craniopharyngeal duct.","Malignant Neoplasm of Craniopharyngeal Duct | Malignant neoplasm of craniopharyngeal duct",,,,,,,,,,,,,,,"4095305","Malignant tumor of craniopharyngeal duct",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4268090","Type 2 Diabetes Mellitus with Severe Nonproliferative Diabetic Retinopathy without Macular Edema, Bilateral","C195350","Evidence of type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema that is bilateral.","Type 2 Diabetes Mellitus with Severe Nonproliferative Diabetic Retinopathy without Macular Edema, Bilateral | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2889619","Other Juvenile Arthritis, Right Knee","C197437","Evidence of other juvenile arthritis in the right knee not specified elsewhere.","Other Juvenile Arthritis, Right Knee | Other juvenile arthritis, right knee",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2903660","Pre-Existing Type 1 Diabetes Mellitus, in Pregnancy, Second Trimester","C197648","Evidence of pre-existing type 1 diabetes mellitus in the in pregnancy in the second trimester.","Pre-Existing Type 1 Diabetes Mellitus, in Pregnancy, Second Trimester | Pre-existing type 1 diabetes mellitus, in pregnancy, second trimester",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2889261","Rheumatoid Myopathy with Rheumatoid Arthritis of Unspecified Ankle and Foot","C197130","Evidence of rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot.","Rheumatoid Myopathy with Rheumatoid Arthritis of Unspecified Ankle and Foot | Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1913510","Hemiplegia following Unspecified Cerebrovascular Disease Affecting Left Dominant Side","C196458","Evidence of hemiplegia following unspecified cerebrovascular disease affecting left dominant side.","Hemiplegia following Unspecified Cerebrovascular Disease Affecting Left Dominant Side | Hemiplegia following unspecified cerebrovascular disease affecting left dominant side",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2882960","Atherosclerosis of Non-Biological Bypass Graft(s) of the Extremities with Gangrene, Right Leg","C196662","Evidence of atherosclerosis of non-biological bypass graft(s) of the extremities with gangrene in the right leg.","Atherosclerosis of Non-Biological Bypass Graft(s) of the Extremities with Gangrene, Right Leg | Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, right leg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4268033","Type 1 Diabetes Mellitus with Severe Nonproliferative Diabetic Retinopathy without Macular Edema, Bilateral","C195256","Evidence of type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema that is bilateral.","Type 1 Diabetes Mellitus with Severe Nonproliferative Diabetic Retinopathy without Macular Edema, Bilateral | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1914229","BCL2 Gene Rearrangements [Presence] in Blood or Tissue by FISH","C193830","A fluorescent in situ hybridization-based procedure that detects BCL2 gene rearrangements in a blood or tissue specimen.","BCL2 Gene Rearrangements [Presence] in Blood or Tissue by FISH | BCL2 gene rearrangements [Presence] in Blood or Tissue by FISH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1906351","Feel Regret About Getting Genetic Test Results","C198904","A question about whether an individual is feeling regret about getting their genetic test results.","Feel Regret About Getting Genetic Test Results | Feeling regret about getting my test results",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1906258","Vocational Education Teacher","C198819","Occupations held by individuals who teach or provide instruction in vocational or occupational subjects to adults and senior students in secondary schools, colleges and institutions of further education.","Vocational Education Teacher | Vocational education teachers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1905855","Site Specific Immunomodulator QBECO","C198697","A formulation composed of components of the inactivated bacteria Escherichia coli (E. coli), with potential immunomodulating activity. Upon subcutaneous administration, site specific immunomodulator (SSI) QBECO stimulates the innate immune system by recruiting and activating M1 macrophages. This may restore the unhealthy and altered gut microbiome, restore the function in the gastrointestinal (GI) tact, restore the immune system and rebuild normal barrier function. In addition, by enhancing and optimizing immune function, cancer cell proliferation may be inhibited and GI tract-related inflammatory diseases may be treated.","Site Specific Immunomodulator QBECO | E. coli-based Formulation QBECO | QBECO | SSI QBECO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1906291","BCOR/RARA Fusion Protein","C198852","A fusion protein encoded by the BCOR/RARA fusion gene. This protein is comprised of most of the amino acids in the BCL-6 corepressor protein, including its N-terminal BCL6 binding domain and three Ankyrin repeats, fused to the C-terminal transactivation, DNA binding, dimerization and ligand binding domains of the retinoic acid receptor alpha protein.","BCOR/RARA Fusion Protein | BCL-6 Corepressor/Retinoic Acid Receptor Alpha Fusion Protein | BCOR-RARA Fusion Protein | BCOR::RARA Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1906202","CD99 Antibody","C199270","Any antibody that recognizes CD99 antigen protein.","CD99 Antibody | 12E7 Antibody | Anti-CD99 Antibody | Anti-CD99 Antigen Antibody | CD99 Antigen Antibody | E2 Antigen Antibody | Protein MIC2 Antibody | T-Cell Surface Glycoprotein E2 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1906400","Focal Extracapsular Extention","C198968","A morphological finding indicating that the tumor cell invasion outside the lymph node capsule was less than or equal to 1 mm.","Focal Extracapsular Extention | Focal | Focal ECE | Focal ECS | Focal Extracapsular Spread",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0223335","T9 Vertebral Body","C199359","The body of the ninth thoracic vertebra.","T9 Vertebral Body | Structure of body of ninth thoracic vertebra (body structure)",,,,,,,,,,,,,,,"4142914","Structure of body of ninth thoracic vertebra",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1906819","NRAS NM_002524.5:c.38G>A","C199448","A nucleotide substitution at position 38 of the coding sequence of the NRAS gene where guanine has been mutated to adenine.","NRAS NM_002524.5:c.38G>A | N-ras c.38G>A | NM_002524.5:c.38G>A | NRAS c.38G>A | NRAS1 c.38G>A | Neuroblastoma RAS Viral (v-ras) Oncogene Homolog c.38G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1906479","Fazamorexant","C199047","No value exists.","Fazamorexant | FAZAMOREXANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0223230","T2 Vertebral Body","C199348","The body of the second thoracic vertebra.","T2 Vertebral Body | Structure of body of second thoracic vertebra (body structure)",,,,,,,,,,,,,,,"4178873","Structure of body of second thoracic vertebra",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1907005","GenBody COVID-19 Ag Home Test","C200171","A COVID-19 home test kit manufactured by GenBody Diagnostics, Inc. It is intended for persons age 14 years and older and children age 2 years and older when collected by an adult.","GenBody COVID-19 Ag Home Test | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1906682","Skin-Homing Helper Effector Memory T-Lymphocyte Count","C199793","The determination of the skin-homing helper effector memory T-lymphocytes present in a sample.","Skin-Homing Helper Effector Memory T-Lymphocyte Count | T-Lymphocytes Helper Effector Memory Skin-Homing | THEMSH | TLym Help Eff Mem SH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1907067","Pancreatic Cystic Lesion","C200231","A lesion that arises from the exocrine pancreas and contains sac-like spaces. This category includes cysts, pseudocysts, and cystic neoplasms.","Pancreatic Cystic Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0317734","Saccharopolyspora rectivirgula","C199976","Any bacterial organism that can be assigned to the species Saccharopolyspora rectivirgula.","Saccharopolyspora rectivirgula | Micropolyspora faeni | Micropolyspora rectivirgula | SACCHAROPOLYSPORA RECTIVIRGULA | Thermopolyspora polyspora | Thermopolyspora rectivirgula",,,,,,,,,,,,,,,"4034922","Saccharopolyspora rectivirgula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1906935","Anti-FAP Antibody-drug Conjugate OMTX705","C199584","An antibody-drug conjugate (ADC) composed of OMTX005, a humanized monoclonal antibody directed against fibroblast activation protein (FAP), conjugated to the cytotoxic tubulysin TAM470, with potential antineoplastic activity. Upon administration of anti-FAP ADC OMTX705, the anti-FAP monoclonal antibody moiety targets and binds to FAP expressed on cancer-associated fibroblasts (CAFs) in the tumor stroma. Upon binding, internalization and linker cleavage, the cytotoxic moiety is released, which binds to tubulin and inhibits microtubule polymerization. This results in G2/M phase arrest and the apoptosis of FAP-expressing CAFs. FAP, a membrane-bound serine protease overexpressed on CAFs, is minimally expressed on normal, healthy cells.","Anti-FAP Antibody-drug Conjugate OMTX705 | Anti-FAP ADC OMTX705 | OMTX 705 | OMTX-705 | OMTX705",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1906635","Skin-Homing Cytotoxic Effector Memory T-Lymphocyte Subpopulation Count","C199740","The determination of a sub-population of skin-homing cytotoxic effector memory T-lymphocytes present in a sample.","Skin-Homing Cytotoxic Effector Memory T-Lymphocyte Subpopulation Count | T-Lymphocytes Cytotoxic Effector Memory Skin-Homing Sub-Population | TCEMSHS | TLym Cytx Eff Mem SH Sub",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1907341","Recurrent Adnexal Carcinoma","C200065","The reemergence of adnexal carcinoma after a period of remission.","Recurrent Adnexal Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086287","Extended Release Chewable Tablet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1907534","Anti-CD123/CD16A Bispecific Antibody AFM28","C200544","A human, tetravalent, bispecific immunoglobulin G1 (IgG1)-single chain variable fragment (scFv) fusion antibody targeting both the tumor-associated antigen (TAA) CD123 and the human low affinity immunoglobulin G (IgG) Fc region receptor IIIA (FCGR3A; CD16A), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD123/CD16A bispecific antibody AFM28 simultaneously targets and binds to CD16A expressed on natural killer (NK) cells and macrophages, and to CD123 on CD123-expressing tumor cells, thereby selectively cross-linking CD123-expressing tumor cells with NK cells and macrophages. This may result in NK cell and macrophage activation, induce antibody-dependent cellular cytotoxicity (ADCC), and eventually causes tumor cell lysis. CD123 is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells. CD16A is specifically expressed on the surface of NK cells and macrophages.","Anti-CD123/CD16A Bispecific Antibody AFM28 | AFM 28 | AFM-28 | AFM28 | Bispecific Antibody Anti-CD123/Anti-CD16A AFM28 | Bispecific Innate Cell Engager AFM28 | ICE AFM28",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1907140","NR2E1 wt Allele","C200335","Human NR2E1 wild-type allele is located in the vicinity of 6q21 and is approximately 23 kb in length. This allele, which encodes nuclear receptor subfamily 2 group E member 1 protein, is involved in vision and behavior.","NR2E1 wt Allele | Nuclear Receptor Subfamily 2 Group E Member 1 wt Allele | Nuclear Receptor Subfamily 2, Group E, Member 1 Gene | TLL | TLX | Tailless Gene | Tailless, Drosophila, Homolog of Gene | Tailless-Related Receptor Gene | XTLL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1915223","FACIT-Searchable Item Library Pediatric Version Child - Hard for Me Concentrate School","C200967","Functional Assessment of Chronic Illness Therapy-Searchable Item Library Pediatric Version Child Perspective (FACIT-Searchable Item Library Pediatric Version) It is hard for me to concentrate in school.","FACIT-Searchable Item Library Pediatric Version Child - Hard for Me Concentrate School | FSLP-C: Hard for Me Concentrate School | FSLP0047",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1915381","Interpretation Not Provided","C200704","An indication that the interpretation of the reported results or observations was not provided.","Interpretation Not Provided | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1915156","Oncolytic VSV-GP BI 1821736","C200910","An oncolytic virus derived from the vesicular stomatitis virus (VSV), a single-stranded RNA virus, and containing a genetically modified glycoprotein (GP) and a human CD80 (B7.1) Fc fragment, with potential immunomodulating and antineoplastic activities. Upon administration, oncolytic VSV-GP BI 1821736 preferentially replicates in tumor cells, and induces VSV-mediated cytolytic activity towards the tumor cells. Viral infection also stimulates the immune system to recognize these same tumor cells, leading to immune-mediated killing of both infected and non-infected tumor cells, thereby further killing tumor cells. In addition, BI 1821736 secretes CD80, which targets and binds to CD28, and in the presence of antigenic T-cell receptor (TCR) signaling leads to the co-stimulation of T-cell responses including the activation of naive and memory T-cells. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells.","Oncolytic VSV-GP BI 1821736 | BI 1821736 | BI-1821736 | BI1821736 | Oncolytic VSV-GP-huCD80Fc BI 1821736 | VSV-GP BI 1821736",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1915257","FACIT-Searchable Item Library Pediatric Version Child - I Was Too Tired to Eat","C201001","Functional Assessment of Chronic Illness Therapy-Searchable Item Library Pediatric Version Child Perspective (FACIT-Searchable Item Library Pediatric Version) I was too tired to eat.","FACIT-Searchable Item Library Pediatric Version Child - I Was Too Tired to Eat | FSLP-C: I Was Too Tired to Eat | FSLP0081",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1915233","FACIT-Searchable Item Library Pediatric Version Child - I Switch From Good to Bad Moods","C200993","Functional Assessment of Chronic Illness Therapy-Searchable Item Library Pediatric Version Child Perspective (FACIT-Searchable Item Library Pediatric Version) I often switch from good moods to bad moods.","FACIT-Searchable Item Library Pediatric Version Child - I Switch From Good to Bad Moods | FSLP-C: I Switch From Good to Bad Moods | FSLP0073",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1920817","Age at Last Known Survival","C201612","The age of an individual at the time of their last known survival.","Age at Last Known Survival | Age at Last Known Survival | Age at Last Known Survival Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221291","Aleukemic Myeloid leukemia","C201127","Myeloid leukemia presenting with leukemic infiltration of tissues and normal or decreased leukocyte count in the peripheral blood.","Aleukemic Myeloid Leukemia | Aleukemic Granulocytic Leukemia | Aleukemic Myelogenous Leukemia | Aleukemic Myeloid leukemia | Aleukemic myelogenous leukemia | Aleukemic myeloid leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1920599","Kinase Inhibitor TQB3912","C201292","An orally bioavailable small molecule protein kinase inhibitor, with potential antineoplastic activity. Upon oral administration, kinase inhibitor TQB3912 may target, bind to and inhibit the activity of a protein kinase that plays an important role in tumor cell survival, proliferation, migration, and differentiation.","Kinase Inhibitor TQB3912 | Protein Kinase Inhibitor TQB3912 | TQB 3912 | TQB-3912 | TQB3912",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1920519","Anti-CD70 CAR T Cells Preparation","C201176","Any preparation of chimeric antigen receptor (CAR) expressing T-lymphocytes that targets the tumor-associated antigen (TAA) CD70.","Anti-CD70 CAR T Cells Preparation | Anti-CD70 CAR T Cell Preparation | Anti-CD70 CAR T Cells | Anti-CD70 CAR T-cells | Anti-CD70 CAR-T Cells | CD70-targeting CAR-T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1920649","SARS Coronavirus 2 XBB.1.5.70","C201246","A sublineage variant of the XBB.1.5 recombinant lineage of SARS coronavirus 2. This lineage has the same amino acid variations as XBB.1.5 but also harbors the amino acid substitutions A4068S in the ORF1a protein and both L455F and F456L in the spike glycoprotein.","SARS Coronavirus 2 XBB.1.5.70 | Omicron | SARS Coronavirus 2 Variant Lineage XBB.1.5.70 | SARS-CoV-2 XBB.1.5.70 | SARS2 XBB.1.5.70 | XBB.1.5.70",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0678000","Amifostine/Irinotecan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279841","Cisplatin/Hydrazine Sulfate/Vinblastine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677832","Cladribine/Idarubicin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280642","Asparaginase/Cyclophosphamide/Cytarabine/Mercaptopurine/Methotrexate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1327931","Cyclophosphamide/Doxorubicin/Leucovorin Calcium/Methotrexate/Methylprednisolone/Rituximab/Vincristine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279853","Cisplatin/Doxorubicin/Melphalan/Teniposide regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281731","Cisplatin/Docetaxel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281483","Cytarabine/Etoposide/Ifosfamide/Methotrexate/Prednisolone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1134554","Carboplatin/Epoetin alfa/Paclitaxel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1134498","Bevacizumab/Fluorouracil/Leucovorin Calcium/Oxaliplatin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796553","Amifostine/Bleomycin/Cisplatin/Etoposide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1327764","Flu Matrix/gp100 Antigen/Keyhole Limpet Hemocyanin/MAGE-3/MART-1 Antigen/NY-ESO-B/Tyrosinase Peptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0935885","Dexamethasone/Isotretinoin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448602","Bortezomib/Doxorubicin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280942","Carboplatin/Cytarabine/Dexamethasone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278533","Bleomycin/Lomustine/Methotrexate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516064","Astler-Coller B2 Rectal Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0078138","Carmustine/Dexamethasone/Doxorubicin/Melphalan/Vincristine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334025","High Risk Gastric Gastrointestinal Stromal Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0678056","Busulfan/Cyclophosphamide/Anti-Thymocyte Globulin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516577","Cisplatin/Dacarbazine/Interferon-alpha/Tamoxifen/Tumor Infiltrating Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448651","Vinorelbine/Zosuquidar Trihydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1168204","Stage IVA Pancreatic Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278728","Cisplatin/Mitolactol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1921423","Pineoblastoma miRNA Processing Altered 1","C201967","Pineoblastoma characterized by alterations in genes involved in miRNA biogenesis (DICER1, DROSHA, and DGCR8). It may manifest as a sporadic tumor or part of DICER1 syndrome. It affects children.","Pineoblastoma miRNA Processing Altered 1 | PB-miRNA1 | Pineoblastioma-miRNA1 | Pineoblastoma miRNA Processing Altered Group 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1921415","Functional Tests Supplemental Qualifiers Dataset","C201981","A dataset containing supplemental information, specifically non-standard variables, to parent records in the functional tests domain.","Functional Tests Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1318968","Preoperative Diagnosis","C202031","A diagnosis made on the basis of signs, symptoms, and testing and indicating the need for surgery.","Preoperative Diagnosis | ",,,,,,,,,,,,,,,"4236135","Pre-op diagnosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1920901","SARS Coronavirus 2 XBB.1.16.15","C201869","A sublineage variant of the XBB.1.16 recombinant lineage of SARS coronavirus 2. This lineage has the same amino acid variations as XBB.1.16 but harbors two additional amino acid substitutions in the spike glycoprotein, K147N and P521S.","SARS Coronavirus 2 XBB.1.16.15 | Omicron | SARS Coronavirus 2 Variant Lineage XBB.1.16.15 | SARS-CoV-2 XBB.1.16.15 | SARS2 XBB.1.16.15 | XBB.1.16.15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426729","GPR143 Gene","C201704","This gene is involved in G protein-coupled receptor signaling mediated by binding of tyrosine and dopamine.","GPR143 Gene | G Protein-Coupled Receptor 143 Gene | GPR143",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1920906","Hexokinase-4","C201645","Hexokinase-4 (465 aa, ~52 kDa) is encoded by the human GCK gene. This protein plays a role in the synthesis of hexose-6-phosphates.","Hexokinase-4 | EC 2.7.1.1 | GCK | Glucokinase | HK IV | HK4 | Hexokinase 4 | Hexokinase D | Hexokinase Type IV | Hexokinase-D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0432214","Osteoarthritis with Mild Chondrodysplasia","C202115","An autosomal dominant condition caused by mutation(s) in the COL2A1 gene, encoding collagen alpha-1(II) chain. It is characterized by osteoarthritis and mild chondrodysplasia.","Osteoarthritis with Mild Chondrodysplasia | OSCDP",,,,,,,,,,,,,,,"4113607","Namaqualand hip dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1921222","Allogeneic Anti-CD19 Gamma-delta CAR-T Cells UTAA09","C202226","A preparation of a subset of allogeneic T-lymphocytes that express only gamma chain and delta chain T-cell receptors (TCRs) and that are transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19, with potential immunomodulating and antineoplastic activities. Upon administration, allogeneic anti-CD19 gamma-delta CAR-T cells UTAA09 specifically target and bind to tumor cells expressing CD19, thereby inducing selective toxicity in CD19-expressing tumor cells. Gamma delta T-lymphocytes play a key role in the activation of the immune system and do not require major histocompatibility complex (MHC)-mediated antigen presentation to exert their cytotoxic effect. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.","Allogeneic Anti-CD19 Gamma-delta CAR-T Cells UTAA09 | Allogeneic Anti-CD19 CAR Gamma Delta T-cells UTAA09 | Allogeneic Anti-CD19 CAR gdT-cells UTAA09 | UTAA 09 | UTAA-09 | UTAA09",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1921477","Odontogenic Fibroma, Granular Cell Subtype","C202079","A central odontogenic fibroma composed of granular cells admixed with odontogenic epithelium.","Odontogenic Fibroma, Granular Cell Subtype | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1921540","Eyelash Cleanser Cosmetic Product","C202731","Eyelash cleanser intended for use as an eye cosmetic.","Eyelash Cleanser Cosmetic Product | Eyelash cleansers [Eye makeup preparations (other than children's eye makeup preparations)]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1922153","CD73 Inhibitor","C203020","Any small molecule inhibitor of the enzyme cluster of differentiation (CD) 73 (CD73; 5'-nucleotidase).","CD73 Inhibitor | 5'-Nucleotidase Inhibitor | : 5'-Nucleotidase Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1922026","Foregut Neuroendocrine Tumor G3","C203260","A well-differentiated, high-grade neuroendocrine neoplasm that arises from the esophagus, stomach, or duodenum. The mitotic count is more than 20 per 2 mm2 and/or the Ki-67 index is more than 20%.","Foregut Neuroendocrine Tumor G3 | Foregut NET G3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1921941","Ensitrelvir Fumarate","C203176","No value exists.","Ensitrelvir Fumarate | ENSITRELVIR FUMARATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1921650","Beard Softener Cosmetic Product","C202815","A product intended to be used to soften beard hair prior to shaving.","Beard Softener Cosmetic Product | Beard softeners [Shaving preparations]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1921964","Monlunabant","C203199","No value exists.","Monlunabant | MONLUNABANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1922300","Lepodisiran","C203143","No value exists.","Lepodisiran | LEPODISIRAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL763853","Not listed","C203644","Not included on a list of items.","Not Listed | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1922546","Emergency Room Critical Care Facility","C203743","An intensive care unit associated with an emergency room or emergency department.","Emergency Room Critical Care Facility | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1926535","Sleep Disorder Diagnostic Clinic","C203869","A medical facility that specializes in diagnosing sleep disorders.","Sleep Disorder Diagnostic Clinic | Sleep Disorder Clinic | Sleep Disorder Diagnostic Center | Sleep Disorder Diagnostic Clinic or Center",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1922541","Topical Mechlorethamine Regimen","C203697","A regimen consisting of topical mechlorethamine that can be used for the treatment of mycosis fungoides/Sezary syndrome and primary cutaneous CD30+ T-cell lymphoproliferative disorders.","Topical Mechlorethamine Regimen | Mechlorethamine monotherapy | Valchlor Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1922649","Thrombocytopenic Disorder","C203448","A disorder of platelets characterized by a finding of low platelet concentrations (thrombocytopenia) typically below 50,000 platelets per microliter of blood.","Thrombocytopenic Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1926280","Cisplatin/Dexamethasone/Gemcitabine/Pegaspargase Regimen","C203986","A regimen consisting of cisplatin, dexamethasone, gemcitabine and pegaspargase that may be used in the treatment of T-cell lymphoma.","Cisplatin/Dexamethasone/Gemcitabine/Pegaspargase Regimen | Cisplatin-Dexamethasone-Gemcitabine-Pegaspargase | Cisplatin/Dexamethasone/Gemcitabine/Pegaspargase | DDGP | DDGP Regimen | Dexamethasone/Cisplatin/Gemcitabine/Pegaspargase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1926552","NDP wt Allele","C203900","Human NDP wild-type allele is located in the vicinity of Xp11.3 and is approximately 25 kb in length. This allele, which encodes norrin protein, is involved in G protein-coupled receptor-dependent activation of the Wnt signaling pathway. Mutations in the gene are associated with Norrie disease and X-linked exudative vitreoretinopathy.","NDP wt Allele | EVR2 | Exudative Vitreoretinopathy 2 (X-Linked) Gene | FEVR | ND | NDP, Norrin Cystine Knot Growth Factor Gene | NORRIN | Norrie Disease (Pseudoglioma) Gene | Norrin Cystine Knot Growth Factor NDP wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1926469","PQ/CMC Ingredient Location Terminology","C203777","A category of terminology used to qualify the information pertaining to the location of an ingredient within a product in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.","PQ/CMC Ingredient Location Terminology | Pharmaceutical Quality/CMC Ingredient Location Terminology | Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Ingredient Location Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1910606","Specialist in homeopathy (occupation)","C205077","An individual who specialized in an alternative medical practice that uses diluted substances that cause illness or may mimic the symptoms thereof. A fundamental premise of homeopathy is that 'like cures like.'","Homeopath | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1926869","Anti-EphA5/MMAE Antibody-drug Conjugate MBRC-101","C204349","An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody against the tyrosine kinase receptor ephrin type-A receptor 5 (EPH receptor A5; EphA5) and conjugated, via a protease-cleavable linker, to the auristatin derivative and microtubule disrupting agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of anti-EphA5/MMAE ADC MBRC-101, the monoclonal antibody moiety targets and binds to EphA5 expressed on tumor cells. Upon binding, internalization, and proteolytic cleavage, MMAE is released. MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. This induces cell death in EphA5-expressing cancer cells. EphA5, a member of the ephrin family of receptor tyrosine kinases (RTKs) involved in axonal guidance during embryonic development, is overexpressed by a variety of cancer cell types.","Anti-EphA5/MMAE Antibody-drug Conjugate MBRC-101 | Anti-EphA5 ADC MBRC-101 | Anti-EphA5/MMAE ADC MBRC-101 | MBRC 101 | MBRC-101 | MBRC101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1926656","B-Lymphocyte to Non-TNK Leukocyte Ratio Measurement","C204589","The determination of the ratio of B-lymphocytes to leukocytes that are not T cells or natural killer cells present in a sample. The measurement may be expressed as a ratio or percentage.","B-Lymphocyte to Non-TNK Leukocyte Ratio Measurement | B-Lymphocytes/Non-TNK Leukocytes | BLym/Non-TNK Leuk | C204589",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1927091","Sepsis-related Organ Failure Assessment SOFA0103 Standardized Character Result 0","C204282","Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0103 Standardized Character Result 0 - Bilirubin less than 1.2 mg/dL; less than 20 umol/L.","Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0103 Standardized Character Result 0 | 0 | SOFA0103-0 | Sepsis-related Organ Failure Assessment SOFA0103 Standardized Character Result 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418568","PIGN gene","C204487","This gene plays a role in glycosylphosphatidylinositol-anchor biosynthesis.","PIGN Gene | PIGN | Phosphatidylinositol Glycan Anchor Biosynthesis Class N Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1927042","Anti-CLDN18.2/CD47 Bispecific Antibody AK132","C204802","A bispecific antibody directed against both the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18) and the human cell surface antigen CD47, with potential immunostimulating, phagocytosis-inducing and antineoplastic activities. Upon administration of anti-CLDN18.2/CD47 bispecific antibody AK132, the anti-CLDN18.2 moiety selectively targets and binds to CLDN18.2 on CLDN18.2-expressing tumor cells, thereby improving the binding of the anti-CD47 moiety to the CLDN18.2-expressing tumor cells. The CD47 binding by AK132 blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of the CLDN18.2-expressing tumor cells. Additionally, blocking CD47 signaling activates an anti-tumor T-lymphocyte immune response and T-cell-mediated killing of CLDN18.2-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is widely expressed on normal, healthy cells, such as red blood cells (RBCs) and platelets, and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate. CLDN18.2, a tight junction protein and stomach-specific isoform of Claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa. Co-targeting CD47 and CLDN18.2 may limit the binding of AK132 to CD47 on healthy hematopoietic stem cells (HSCs) and may minimize any associated adverse effects.","Anti-CLDN18.2/CD47 Bispecific Antibody AK132 | AK 132 | AK-132 | AK132 | Anti-CD47/Anti-CLDN18.2 Bispecific Antibody AK132 | Anti-CLDN18.2/Anti-CD47 Bispecific Antibody AK132 | Anti-Claudin18.2/CD47 Bispecific Antibody AK132 | CD47 x CLDN18.2 Bispecific Antibody AK132 | CLDN18.2 x CD47 Bispecific Antibody AK132",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1926689","Tobacco Ingredients Domain","C204614","A special-purpose domain that provides an identifier for each unique tobacco ingredient (IGDCMPID) in a tobacco product, and lists those tobacco ingredients and their attributes that contribute to their uniqueness.","Tobacco Ingredients Domain | IT | Tobacco Ingredients",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1927383","RBP2 wt Allele","C204937","Human RBP2 wild-type allele is located in the vicinity of 3q23 and is approximately 28 kb in length. This allele, which encodes retinol-binding protein 2, is involved in the intracellular localization of retinol and other retinoids.","RBP2 wt Allele | CRABP-II | CRBP2 | CRBPII | RBPC2 | Retinol Binding Protein 2 wt Allele | Retinol Binding Protein 2, Cellular Gene | Retinol-Binding Protein 2, Cellular Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1927558","Intraperitoneal Carboplatin/Paclitaxel/Intraperitoneal Paclitaxel Regimen","C205282","A regimen consisting of intraperitoneal (IP) carboplatin, intravenous (IV) paclitaxel, and IP paclitaxel that may be used for the treatment of ovarian, fallopian tube, and primary peritoneal cancers.","Intraperitoneal Carboplatin/Paclitaxel/Intraperitoneal Paclitaxel Regimen | Carboplatin IP/Paclitaxel/Paclitaxel IP | IP Carboplatin-IV Paclitaxel-IP Paclitaxel | IP Carboplatin/IV Paclitaxel/IP Paclitaxel | IP Carboplatin/Paclitaxel/IP Paclitaxel | IV Paclitaxel/IP Carboplatin/IP Paclitaxel | IV Paclitaxel/Intraperitoneal Carboplatin/Intraperitoneal Paclitaxel | Intraperitoneal Carboplatin/Paclitaxel/Intraperitoneal Paclitaxel | Paclitaxel/Intraperitoneal Carboplatin/Intraperitoneal Paclitaxel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1927649","Agender","C205469","Having no gender.","Agender | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1531245","REEP1 protein, human","C204949","Receptor expression-enhancing protein 1 (201 aa, ~22 kDa) is encoded by the human REEP1 gene. This protein is involved in the localization of odorant receptors and the formation and remodeling of the endoplasmic reticulum.","Receptor Expression-Enhancing Protein 1 | REEP1 | Receptor Expression Enhancing Protein 1 | Spastic Paraplegia 31 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1928633","Bothered by Involuntary Urination when Laughing or Coughing","C206502","A question about whether an individual is or was bothered by involuntary urination when laughing or coughing.","Bothered by Involuntary Urination when Laughing or Coughing | Involuntary urination when laughing or coughing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1928302","Health Disparity Question","C205636","A question about factors of, or contributing to, health disparities.","Health Disparity Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1928345","REPS2 wt Allele","C205708","Human REPS2 wild-type allele is located in the vicinity of Xp22.2 and is approximately 250 kb in length. This allele, which encodes RalBP1-associated Eps domain-containing protein 2, plays a role in the Ral signaling pathway and ligand-dependent receptor mediated endocytosis.","REPS2 wt Allele | POB1 | Partner of RALBP1 Gene | RALBP1 Associated Eps Domain Containing 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1928281","Pain and Swelling at Injection Site, PRO-CTCAE","C206004","Pain and inflammation at injection site as recorded on the PRO-CTCAE questionnaire.","Pain and Swelling at Injection Site, PRO-CTCAE | PRO-CTCAE, Pain and Swelling at Injection Site | Pain and Inflammation at Injection Site, PRO-CTCAE | Pain and swelling at injection site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1928392","SH3BP2 Gene Mutation","C205777","A change in the nucleotide sequence of the SH3BP2 gene.","SH3BP2 Gene Mutation | 3BP-2 Gene Mutation | 3BP2 Gene Mutation | SH3 Domain Binding Protein 2 Gene Mutation | SH3-Domain Binding Protein 2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1928582","Anti-ENPP3/Anti-CD3 Bispecific Antibody JNJ-87890387","C206251","A human bispecific antibody directed against both ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3; NPP3; B10; PDNP3; CD203c; PD-IBETA) and the T-cell surface antigen CD3, with potential immunostimulatory and antineoplastic activities. Upon administration, anti-ENPP3/anti-CD3 bispecific antibody JNJ-87890387 targets and binds to ENPP3 expressed on tumor cells and CD3 expressed on T-cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against ENPP3-expressing tumor cells. While normally expressed at low levels on tubules of the kidney cortex and by some cells in gastrointestinal, adrenal, and endometrial tissues, the type II transmembrane glycoprotein ENPP3 is overexpressed in various cancers including most renal neoplasms and some liver cancers.","Anti-ENPP3/Anti-CD3 Bispecific Antibody JNJ-87890387 | Anti-ENPP3/Anti-CD3 Bispecific ENPP3 T-cell Redirector JNJ-87890387 | Anti-ENPP3/Anti-CD3 T-cell Redirector JNJ-87890387 | Anti-ENPP3/CD3 Bispecific Antibody JNJ-87890387 | Anti-ENPP3/CD3 Bispecific ENPP3 T-cell Redirector JNJ-87890387 | ENPP3 x CD3 Bispecific Antibody JNJ-87890387 | JNJ 87890387 | JNJ-87890387 | JNJ87890387 | T-cell Engager JNJ-87890387 | TCE JNJ-87890387",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1928943","Mycosis Fungoides-Like Cutaneous Reactive T-Cell Rich Lymphoid Proliferation","C206350","A cutaneous reactive T-cell rich lymphoid proliferation characterized by the presence of intraepidermal lymphocytes that exhibit irregular nuclear contours.","Mycosis Fungoides-Like Cutaneous Reactive T-Cell Rich Lymphoid Proliferation | MF-Like rT-LP | Mycosis Fungoides-Like Reactive T-Cell Rich Lymphoid Proliferation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1928681","Device Provides Unintelligible Message","C206565","The device provides an unintelligible or incomprehensible message such as an apparently random string of characters.","Device Provides Unintelligible Message | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1928957","Unresectable Anaplastic Astrocytoma","C206427","An anaplastic astrocytoma that is not amenable to surgical resection.","Unresectable Anaplastic Astrocytoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1928815","Lung Cancer, Biomarker Reporting CAP Synoptic Pathology Report","C206662","A surgical pathology template that was developed by the College of American Pathologists (CAP) and refers to biomarker reporting on lung cancer.","Lung Cancer, Biomarker Reporting CAP Synoptic Pathology Report | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1928808","IgM Lambda","C206702","An immunoglobin of the mu isotype with lambda light chains.","IgM Lambda | Immunoglobulin M Lambda",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0547070","Ablation Therapy","C20985","Removal, separation, detachment, extirpation, or eradication of a body part, pathway, or function by surgery, chemical destruction, morbid process, or noxious substance.","Ablation Therapy | ABLATION | Ablation | Ablation | Ablation, NOS | Catheter Ablation | Local Ablation Therapy | Local Ablative Therapy | ablation",,,,,,,,,,,,,,,"4117507","Ablation - action",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332008","ACRBP Gene","C20754","This gene plays a role in the compartmentalization of acrosomal matrix and is associated with a number of cancers.","ACRBP Gene | ACRBP | Acrosin Binding Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0149615","Allogeneic Bone Marrow Transplantation","C15369","A clinical treatment in which a patient receives bone marrow from a compatible, but not genetically identical, donor.","Allogeneic Bone Marrow Transplantation | Allo BMT | Allogeneic BMT | Allogeneic Blood and Marrow Transplantation | allogeneic bone marrow transplantation",,,,,,,,,,,,,,,"4242257","Allogeneic bone marrow transplantation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1520575","Chromosome 14 Short Arm","C13537","Proximal (short) arm of chromosome 14","14p | Chromosome 14 Proximal Arm | Chromosome 14 Short Arm | Chromosome 14p",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022265","Isotretinoin","C603","A naturally-occurring retinoic acid with potential antineoplastic activity. Isotretinoin binds to and activates nuclear retinoic acid receptors (RARs); activated RARs serve as transcription factors that promote cell differentiation and apoptosis. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization.","Isotretinoin | 13-cRA | 13-cis Retinoic Acid | 13-cis retinoic acid | 13-cis-Retinoate | 13-cis-Retinoic Acid | 13-cis-Vitamin A Acid | 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-cis-4-trans-6-trans-8-trans-nonatetraenoic Acid | Absorica | Accure | Accutane | Amnesteem | Cistane | Claravis | ISOTRETINOIN | Isotretinoinum | Isotrex | Isotrexin | Myorisan | Neovitamin A | Neovitamin A Acid | Oratane | Retinoicacid-13-cis | Ro 4-3780 | Ro-4-3780 | Roaccutan | Roaccutane | Roacutan | Sotret | ZENATANE | cis-Retinoic Acid | isotretinoin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1140694","Bioinformatics","C17964","Bioinformatics derives knowledge from computer analysis of biological data. These can consist of the information stored in the genetic code, but also experimental results from various sources, patient statistics, and scientific literature. Research in bioinformatics includes method development for storage, retrieval, and analysis of the data. Bioinformatics is a rapidly developing branch of biology and is highly interdisciplinary, using techniques and concepts from informatics, statistics, mathematics, chemistry, biochemistry, physics, and linguistics. It has many practical applications in different areas of biology and medicine. (M. Nilges and Jens P. Linge, Unite de Bio-informatique Structurale, Institut Pasteur, Paris)","Bioinformatics | Computational Biology | bioinformatics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0087178","Youth","C17471","The time of life between childhood and maturity.  This period overlaps with adolescence.","Youth | Youth 10-21",,,,,,,,,,,,,,,"4329455","Adolescence period",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516889","Environmental or Occupational Exposure","C19447","The exposure to potentially harmful agents in the environment or to work-related environmental factors.","Environmental or Occupational Exposure | Environmental and Occupational Exposure | Environmental and Occupational Exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510686","ADME Study","C15967","A group of pharmacokinetic parameters commonly investigated during preclinical drug development.","ADME Study | ADME | Absorption, Distribution, Metabolism and Excretion | Absorption, Distribution, Metabolism, and Excretion Study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0178602","Dose","C25488","A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","Dose | DOSE | Dosage | Dose Level | Dose per Administration | Doses | TRTDOS | dose | dose level | dose_level | treatment dose | treatment_dose | {Dose}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1442065","Address","C25407","A standardized representation of the location of a person, business, building, or organization.","Address | Physical Address | physicalAddress",,,,,,,,,,,,,,,"4265448","Address",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024204","Lymph Node","C12745","A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.","Lymph Node | LYMPH NODE | Lymph Gland | Lymph Node(s) | Lymph Node, NOS | Lymph Nodes | Lymph node, NOS | Lymph nodes | Lymphatic Gland | Reticuloendothelial System, Lymph Node | Structure of lymph node (body structure) | lymph gland | lymph node",,,,,,,,,,,,,"UBERON:0000029","lymph node","4241958","Structure of lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332002","ABCG2 Gene","C20808","This gene plays a role in xenobiotic transport and multi-drug resistance.","ABCG2 Gene | ABCG2 | ATP-Binding Cassette, Sub-Family G (WHITE), Member 2 (Junior Blood Group)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524832","Thoracic Surgical Procedure","C15655","Any surgery performed inside the thoracic cavity.","Thoracic Surgical Procedure | Chest Surgery | Thoracic Surgery | Thoracic Surgical Procedures | Thoracic Surgical Procedures",,,,,,,,,,,,,,,"4300244","Surgical procedure on thorax",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0012155","Diet","C15222","The customary allowance of food and drink taken by a person or an animal from day to day, particularly one especially planned to meet specific requirements of the individual, including or excluding certain items of food; a prescribed course of eating and drinking in which the amount and kind of food, as well as the times at which it is to be taken, are regulated for therapeutic purposes or selected with reference to a particular state of health.","Diet | Dietary | diet",,,,,,,,,,,,,,,"4222559","Dietary finding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3554541","Peritoneal Effusion","C2885","The accumulation of fluid in the peritoneal cavity, which may be serous, hemorrhagic, or the result of tumor metastasis to the peritoneum.","Peritoneal Effusion | Ascites | Ascites | INCREASING ABDOMINAL DISTENTION OR ASCITES | PERITONEAL_EFFUSION | ascites",,,,,,,,,,,,,,,"200528","Ascites",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3275765","Arrhythmia","C2881","Any variation from the normal rate or rhythm (which may include the origin of the impulse and/or its subsequent propagation) in the heart.","Arrhythmia | Cardiac Arrhythmia",,,,,,,,,,,,,,,"44784217","Cardiac arrhythmia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3539080","Application Dosing Unit","C25397","A dosing measurement based on the application unit.","Application Unit | APPLICATION | Application | Application | Application Dosing Unit | Applicator | application | {APPLICATION} | {Application}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003618","Appetite","C25152","The natural recurring desire for food.","Appetite | appetite",,,,,,,,,,,,,,,"4143454","Food appetite",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023487","Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA","C3182","An acute promyelocytic leukemia characterized by the reciprocal balanced translocation t(15;17)(q24.1;q21.2) that results in the fusion of the promyelocytic leukemia (PML) gene and retinoic acid receptor-α (RARA) gene. The t(15;17)(q24.1;q21.2) with the resulting PML-RARA fusion gene occurs in over 95% of cases of acute promyelocytic leukemia. The remainder of the cases show variant RARA gene translocations with other genes.","Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA | AML with t(15;17)(q22;q12) | AML with t(15;17)(q24.1;q21.2) | APL | APL | APML | APML - Acute promyelocytic leukemia | Acute Promyelocytic Leukemia | Acute Promyelocytic Leukemia with PML-RARA | Acute Promyelocytic Leukemia with PML-RARA | Acute Promyelocytic Leukemia with PML::RARA | Acute Promyelocytic Leukemia with t(15;17)(q22;q12); PML-RARA | Acute Promyelocytic Leukemia with t(15;17)(q22;q12); PML-RARA | Acute Promyelocytic Leukemia with t(15;17)(q22;q12); PML/RARA | Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA Fusion | Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML::RARA | Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML::RARA Fusion | Acute promyelocytic leukaemia, PML-RAR-alpha | Acute promyelocytic leukaemia, t(15;17)(q22;q11-12) | Acute promyelocytic leukemia | FAB M3 | M3 | M3 OR Acute Promyelocytic Leukemia with t(15;17)(q22;q12); PML-RARA | M3 OR Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA | Promyelocytic Leukemia | acute promyelocytic leukemia | promyelocytic leukemia","9866/3","Acute promyelocytic leukemia, t(15;17)(q22;q11-12)",,,,,,,,,,,,,"4002497|4103718","Acute promyelocytic leukemia, FAB M3|Acute promyelocytic leukemia with PML::RARA fusion",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0003241","Antibody","C16295","A type of protein made by B lymphocytes in response to a foreign substance (antigen). Each antibody only binds to a specific antigen, helping to destroy the antigen directly or by assisting white blood cells to destroy the antigen.","Antibody | Ab | Antibodies | antibody",,,,,,,,,,,,,,,"4288455","Antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003232","Antibiotic","C258","Substances naturally produced by microorganisms or their derivatives that selectively target microorganisms not humans. Antibiotics kill or inhibit the growth of microorganisms by targeting components of the microbial cell absent from human cells, including bacterial cell walls, cell membrane, and 30S or 50S ribosomal subunits. These substances are used in the treatment of bacterial and other microbial infections.","Antibiotic | Antibiotic Agents | Antibiotic Drugs | Antibiotic Therapy | Antibiotics | Antimicrobial | Antimicrobial Agent | antibiotic | antimicrobial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522577","follow-up","C16033","The process by which information about the health status of an individual is obtained after a study has officially closed; an activity that continues something that has already begun or that repeats something that has already been done.","Follow-Up | Active Follow-up | CLSFUP | Clinical Signs Follow-up | Follow Up | Follow-up | Follow-up | Followed | Followup | follow up | follow-up | follow_up",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1442488","Baseline","C25213","A starting point to which things may be compared.","Baseline | baseline",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519543","Tobacco Use and Related Risk Factors, Surveillance","C15987","Research studies that assess trends in tobacco-related risk factors, behaviors and health services to determine changes over time and the influence of these trends on cancer incidence, morbidity, mortality and survival.  (NCI/TRIP)","Tobacco Use and Related Risk Factors, Surveillance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040223","Time","C25207","The continuum of experience in which events pass from the future through the present to the past.","Time | T | Time Dimension",,,,,,,,,,,,,,,"4256606","Time",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0392747","Change","C25446","The act of alteration or modification; changed or altered in form or character.","Change | Adapt | Adapted | Changed | Modification | Modified",,,,,,,,,,,,,,,"4348027","Changing",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005516","Biological Markers","C16342","A characteristic that can be objectively measured and serves as an indicator for normal biologic processes, pathogenic processes, state of health or disease, the risk for disease development and/or prognosis, or responsiveness to a particular therapeutic intervention.","Biomarker | Biological Marker | Biological Markers | Biomarkers | Molecular Marker | Signature Molecule | biological marker | biomarker | marker | molecular marker | signature molecule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0346053","Atypical Fibroxanthoma","C4246","An intermediate cutaneous mesenchymal neoplasm of uncertain differentiation, usually affecting the actinic-damaged skin of the elderly.  The tumor presents as a single cutaneous nodule which is often ulcerated.  Microscopically, it is characterized by the presence of highly atypical cytologic features, pleomorphism and abundant mitotic figures. The vast majority of patients have an excellent prognosis following conservative therapy. Recurrences are infrequent, and metastasis is rare.","Atypical Fibroxanthoma | AFX | Atypical Cutaneous Fibroxanthoma | Atypical Fibrous Histiocytoma | Atypical Fibroxanthoma of Skin | Atypical Fibroxanthoma of the Skin | Atypical Skin Fibroxanthoma | Atypical fibrous histiocytoma | Atypical fibroxanthoma | Malignant Fibrous Histiocytoma of Skin | Skin Malignant Fibrous Histiocytoma | Superficial Malignant Fibrous Histiocytoma","8830/1","Atypical fibrous histiocytoma",,,,,,,,,,,,,"4096931","Atypical fibrous histiocytoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0936012","Analysis","C25391","Examination and interpretation; the process of identifying an issue to be understood and addressed, modelling the issue, investigating the model results, interpreting the results, and possibly making a recommendation. The concept also refers to the examination and study of a whole in terms of the parts composing it.","Analysis | ANALYSIS | Analytical | Analyze | Analyzed | analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002771","Analgesic Agent","C241","Compounds that alleviate pain without loss of consciousness.  Analgesics act by various mechanisms including binding with opioid receptors and decreasing inflammation.  Choice of analgesic may be determined by the type of pain.  These compounds include opioid, non-opioid and adjuvant analgesic agents.","Analgesic Agent | Analgesic Drugs | Analgesics | Analgesics | Anodynes | Antinociceptive Agents | Pain-relief Medication | analgesic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227423","Anal Margin","C25419","The transitional zone between the moist, hairless, modified skin of the anal canal and the perianal skin.","Anal Margin | ANAL VERGE | Anal Verge | Anal Verge",,,,,,,,,,,,,,,"37151557|4222564","Structure of anal verge|Structure of transition zone of anal mucous membrane",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0002199","Recombinant Interferon Alfa","C225","A class of naturally-isolated or recombinant therapeutic peptides used as antiviral and anti-tumor agents.  Alpha interferons are cytokines produced by nucleated cells (predominantly natural killer (NK) leukocytes) upon exposure to live or inactivated virus, double-stranded RNA or bacterial products.  These agents bind to specific cell-surface receptors, resulting in the transcription and translation of genes containing an interferon-specific response element.  The proteins so produced mediate many complex effects, including antiviral effects (viral protein synthesis); antiproliferative effects (cellular growth inhibition and alteration of cellular differentiation); anticancer effects (interference with oncogene expression); and immune-modulating effects (natural killer cell activation, alteration of cell surface antigen expression, and augmentation of lymphocyte and macrophage cytotoxicity). (NCI04)","Recombinant Interferon Alfa | Alferon | Alpha Interferon | Alpha Interferon | Interferon Alfa | Leukocyte Interferon | Lymphoblast Interferon | Lymphoblastoid Interferon | alpha-Interferon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3550748","Acute Lymphoblastic Leukemia","C3167","Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","Acute Lymphoblastic Leukemia | ALL | ALL | ALL - Acute Lymphocytic Leukemia | ALL_TYPE | Acute Lymphoblastic Leukemia (ALL) | Acute Lymphocytic Leukaemia | Acute Lymphocytic Leukemia | Acute Lymphocytic Leukemias | Acute Lymphogenous Leukemia | Acute Lymphoid Leukemia | Acute lymphatic leukemia | Acute lymphoblastic leukemia | Acute lymphoblastic leukemia (ALL) | Acute lymphoblastic leukemia, NOS | Acute lymphoblastic leukemia, precursor cell type | Acute lymphocytic leukemia | Acute lymphoid leukemia | LEUKEMIA, LYMPHOBLASTIC, MALIGNANT | Lymphoblastic Leukemia | Lymphoblastic leukemia, NOS | Precursor Cell Lymphoblastic Leukemia | Precursor Lymphoblasic Leukemia | Precursor Lymphoblastic Leukemia | Precursor cell lymphoblastic leukemia, NOS | acute lymphoblastic leukemia | acute lymphocytic leukemia","9835/3","Precursor cell lymphoblastic leukemia, NOS",,,,,,,,,,,,,"4030260","Precursor cell lymphoblastic leukemia",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0001962","Alcohol","C2190","A volatile liquid prepared by fermentation of certain carbohydrates. Alcohol acts as a central nervous system (CNS) depressant, a diuretic, and a disinfectant. Although the exact mechanism of CNS depression is unknown, alcohol may act by inhibiting the opening of calcium channels, mediated by the binding of the inhibitory neurotransmitter gamma-amino butyric acid (GABA) to GABA-A receptors, or through inhibitory actions at N-methyl-D-aspartate (NMDA)-type glutamate receptors. Alcohol inhibits the production of antidiuretic hormone, thereby producing diuresis that may lead to dehydration. This agent kills organisms by denaturing their proteins.","Alcohol | ALCOHOL | Absolute Ethanol | Absolute ethanol | ETHANOL | Ethanol | Ethyl Alcohol | Methylcarbinol | alcohol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448743","Agent","C1708","An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","Agent | agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0729594","Axillary Lymph Node","C12904","One of approximately 20-30 lymph nodes in chain formation that traverse the concavity of the underarm to the clavicle.","Axillary Lymph Node | ALN | AXILLARY LYMPH NODE | Axillary Lymph Nodes | Axillary Node | Axillary Node | Axillary Nodes | Axillary lymph node structure (body structure) | Axillary lymph nodes | LYMPH NODE, AXILLARY | Lymph Node(s) Axilla | Lymph Node, Axillary | Lymph nodes of axilla or arm | axillary lymph node",,,,,,,,,,,,,,,"4239187","Axillary lymph node structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4018906","Axilla","C12674","The underside concavity where the arm and the shoulder are joined.","Axilla | AXILLA | Armpit | Underarm | arm pit | armpit | axilla | axillary region | regio axillaris",,,,,,,,,,,,,"UBERON:0009472","axilla","4238919","Axillary region structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004398","Autopsy","C25153","A postmortem examination of the body that includes an examination of the internal organs and structures after dissection to determine the cause of death and the nature of pathological changes.","Autopsy | AUTOPSY",,,,,,,,,,,,,,,"4162299","Autopsy examination",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0333828","Auer Rod","C25287","Rod-shaped structures of uncertain nature in the cytoplasm of immature myeloid cells, especially myeloblasts, in acute myelocytic leukemia; may be an abnormal form of lysosomes; they contain peroxidase and acid phosphatase, and stain red by azure-eosin stains.","Auer Rod | Auer Body | Auer Rods",,,,,,,,,,,,,,,"37111564","Auer rod",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040845","Tretinoin","C900","A naturally-occurring acid of retinol. Tretinoin binds to and activates retinoic acid receptors (RARs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, and inhibition of tumorigenesis.  This agent also inhibits telomerase, resulting in telomere shortening and eventual apoptosis of some tumor cell types.  The oral form of tretinoin has teratogenic and embryotoxic properties.","Tretinoin | (All-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic Acid | 2,4,6,8-Nonatetraenoic acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)- | ATRA | ATRA | Aberel | Airol | Aknoten | All-trans Retinoic Acid | All-trans Vitamin A Acid | All-trans retinoic acid | Avita | Cordes Vas | Dermairol | Epi-Aberel | Eudyna | Renova | Retin-A | Retin-A MICRO | Retin-A-Micro | Retinoic Acid | Retisol-A | Ro 5488 | Stieva-A | Stieva-A Forte | TRETINOIN | Trans Retinoic Acid | Trans Vitamin A Acid | Tretinoinum | Vesanoid | Vitamin A Acid | Vitamin A acid | Vitamin A acid, all-trans- | Vitinoin | all trans-Retinoic acid | all-trans retinoic acid | all-trans-Retinoic acid | all-trans-Vitamin A acid | beta-Retinoic Acid | retinoic acid | trans-Retinoic Acid | trans-Retinoic acid | tretinoin | vitamin A acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449438","Status","C25688","A condition or state at a particular time.","Status | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1305855","Body Mass Index","C16358","An individual's weight in kilograms divided by the square of the height in meters.","Body Mass Index | BMI | Body mass index | Quetelet Index | Vital Signs – BMI | bmi | body mass index",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3833417","Moderate Exercise","C39772","20-60 minutes of exercise which elevates your heart rate to 60-80% of your maximum heart rate performed at least 3-4 times per week.","Moderate Exercise | Moderate Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018684","Health","C25178","Refers to a person's state of physical, mental and social well-being; usually it refers specifically to the state of being in good health, a state of complete physical, mental and social well-being, and does not consist only of the absence of disease or infirmity. In any organism health constitutes a form of homeostasis with inputs and outputs of energy and mass in approximate equilibrium allowing for growth and continued survival. In humans, a subjective feeling of well-being coming from somatic and cognitive perceptions is considered an essential component of health.","Health | Well-being",,,,,,,,,,,,,,,"4139825","Health",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030193","Pain","C3303","The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.","Pain | General Pain | Pain (Various)",,,,,,,,,,,,,,,"4329041","Pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL963711","MKI67 protein, human","C17675","Antigen KI-67 protein (3256 aa, ~359 kDa) is encoded by the human MKI67 gene. This protein is required for cell proliferation.","Antigen KI-67 | Antigen Identified by Monoclonal Antibody Ki-67 | KIA | Ki-67 Antigen | Ki67 | MIB-1 | MKI67 | MKI67 Protein | Proliferation-Related Ki-67 Antigen | Proliferation-Related Ki-67 Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515031","Subsegmental Lymph Node","C28745","The lymph nodes around the subsegmental bronchi.","Subsegmental Lymph Node | Subsegmental Lymph Node Station",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0260515","Family Cancer History","C29878","A record of a patient's medical background regarding the cancer and cancer-related problems of blood relatives.","Family Cancer History | Family History of Cancer | relative with cancer history | relative_with_cancer_history",,,,,,,,,,,,,,,"4171594","Family history of cancer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1412614","Review","C42729","The act of appraisal, evaluation, or analysis.","Review | review",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023884","Liver","C12392","A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate.","Liver | Body System, Hepatic | Gastrointestinal Tract, Liver | Hepatic Body System | Hepatic Organ System | LIVER | Liver structure (body structure) | Organ System, Hepatic | liver",,,,,,,,,,,,,"UBERON:0002107","liver","4009105","Liver structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022100","Lavage","C38068","Washing out a hollow organ (especially the stomach) by flushing with a fluid.","Lavage | Irrigation | LAVAGE | Wash",,,,,,,,,,,,,,,"4194653","Irrigation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0521116","Current","C25471","Occurring in or belonging to the present time.","Current | CURRENT",,,,,,,,,,,,,,,"4034855","Current",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0543414","Tobacco Use","C18059","Use of tobacco in any form, e.g., smoking, chewing or sniffing.","Tobacco Use | Tobacco Consumption | Tobacco, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796494","Lobe","C13393","A portion of an organ, such as the liver, lung, breast, or brain.","Lobe | lobe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517806","Leukemic Cell","C25553","Malignant hematopoietic cell originating in the clonal proliferation of myeloid or lymphoid precursor that undergoes an aberrant and poorly regulated process of organogenesis resulted in arrested maturation and cell capacity for unlimited self-renewal.","Leukemic Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221198","Lesion","C3824","A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","Lesion | GROSS LESION | LESION | Visible Lesion | lesion",,,,,,,,,,,,,,,"40599742","Lesion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022885","Laboratory Procedure","C25294","Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","Laboratory Procedure | Lab Test | Lab Tests | Laboratory Test | Test | Test | Tests | lab exam | lab_exam | laboratory test | laboratory_test",,,,,,,,,,,,,,,"4028908","Laboratory procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3888414","Title","C19067","An identifying designation.","Title | title",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079419","TP53 Gene","C17359","This gene plays a critical role in cell cycle regulation and has tumor suppressor activity.","TP53 Gene | P53 | TP53 | Tumor Protein P53 (Li-Fraumeni Syndrome) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520224","Zubrod Performance Status","C25400","A scale used to assess how a patient's disease is progressing and assess how the disease affects the daily living abilities of the patient.","Zubrod Performance Status | Zubrod | Zubrod Score | Zubrod Score Performance Status",,,,,,,,,,,,,,,"4308014","ECOG performance status",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704254","Medical Image","C19477","Any record of a medical imaging event whether physical or electronic.","Medical Image | Image",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019638","Histology","C16681","The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.","Histology | HISTOLOGY | Microanatomy | histology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512429","High-Dose Chemotherapy with Autologous Stem Cell Transplant","C38722","Treatment with chemotherapy drugs at levels that will also destroy the bone marrow, followed by infusion of stem cells to reconstitute the immune system.","High-Dose Chemotherapy with Stem Cell Support | HDC/ASCT | High-Dose Chemotherapy with Autologous Stem Cell Transplant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018417","Gynecology","C16658","The branch of medicine that deals with the diseases and hygiene of women.","Gynecology | GYN",,,,,,,,,,,,,,,"4215123","Gynecology",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1798377","progesterone receptor","C17075","Progesterone receptor (933 aa, ~99 kDa) is encoded by the human PGR gene. This protein is involved in the regulation of transcription.","Progesterone Receptor | NR3C3 | Nuclear Receptor Subfamily 3 Group C Member 3 | PGR | PR | PRB | PgR | Pr | Progesterone Receptor B | Progesterone Receptor Isoform B | progesterone receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001625","Adrenal Gland","C12666","A flattened, roughly triangular body resting upon the upper end of each kidney; it is one of the ductless glands furnishing internal secretions (epinephrine and norepinephrine from the medulla and steroid hormones from the cortex).","Adrenal Gland | ADRENAL GLAND | Adrenal | Adrenal Glands | Adrenal gland | Adrenal gland, NOS | Adrenal structure (body structure) | Adrenals | GLAND, ADRENAL | adrenal gland | glandula adrenalis | glandula suprarenalis | suprarenal gland",,,,,,,,,,,,,"UBERON:0002369","adrenal gland","4051774","Adrenal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1521800","Adverse Drug Experience Report","C25410","Written notification to the FDA that a subject has experienced an adverse event.","Adverse Drug Experience Report | Adverse Drug Report | Adverse Event Report | Adverse Experience Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030279","Pancreatectomy","C15294","Surgical removal of part or all of the pancreas.","Pancreatectomy | Excision of the Pancreas | Pancreas Excision | pancreatectomy",,,,,,,,,,,,,,,"4141456","Pancreatectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0877248","Adverse Event","C41331","Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).","Adverse Event | ADVERSE EVENT | ADVERSE_EVENT | AE | Adverse Experience | AdverseEvent | adverse event | adverse event (AE) | adverse experience | adverse_event | side effects",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0872252","Proteomics","C20085","The global analysis of cellular proteins. Proteomics uses a combination of sophisticated techniques including two-dimensional (2D) gel electrophoresis, image analysis, mass spectrometry, amino acid sequencing, and bio-informatics to resolve comprehensively, to quantify, and to characterize proteins. The application of proteomics provides major opportunities to elucidate disease mechanisms and to identify new diagnostic markers and therapeutic targets.","Proteomics | Proteomic Research | Proteomics Research | proteomics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4231128","Psoriasis","C3346","An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.","Psoriasis | psoriasis",,,,,,,,,,,,,,,"140168","Psoriasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519255","Serious Adverse Event","C41335","Any expected or unexpected adverse event, related or unrelated to the intervention, occurring at any agent dose, any phase of product or procedure testing, that results in any of the following outcomes: death, a life-threatening adverse event, requires inpatient hospitalization (not required as part of the treatment) or prolongation of existing hospitalization, a persistent or significant disability or incapacity, or cancer, or a congenital anomaly or birth defect. Important medical events that may not result in the listed outcomes may be considered as serious when, based upon appropriate medical judgment, they represent significant hazards or potentially serious harm to the research subject or others and may require medical intervention to prevent one of the outcomes listed in this definition.","Serious Adverse Event | SAE | SERIOUS ADVERSE EVENT | Serious Adverse Event (SAE) | serious adverse event (SAE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0396670","Isolated Chemotherapeutic Limb Perfusion","C15393","A procedure used to deliver anticancer drugs directly to an arm or leg but not to the rest of the body. The flow of blood to and from the limb is temporarily stopped with a tourniquet (a tight band around the limb). Catheters (small, flexible tubes) attached to a pump are put into an artery and a vein in the limb so that blood can be circulated through the pump into the limb. Anticancer drugs are injected into the catheters. Wrapping the limb in a heated blanket or warming the drugs or blood may help the drugs work better.","Isolated Chemotherapeutic Limb Perfusion | Isolated Limb Perfusion (ILP) | Limb Perfusion | Limb Perfusion | isolated limb infusion | isolated limb perfusion | limb perfusion",,,,,,,,,,,,,,,"4019656|4050634","Isolated limb perfusion|Perfusion of limb",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0162678","Neurofibromatosis","C6727","An autosomal dominant hereditary neoplastic syndrome. Two distinct clinicopathological entities are recognized: neurofibromatosis type 1 and neurofibromatosis type 2. Neurofibromatosis type 1 is associated with the presence of cafe-au-lait cutaneous lesions, multiple neurofibromas, malignant peripheral nerve sheath tumors, optic nerve gliomas, and bone lesions. Neurofibromatosis type 2 is associated with the presence of schwannomas, meningiomas, and gliomas.","Neurofibromatosis | Neurofibromatosis Syndrome | Neurofibromatosis, NOS",,,,,,,,,,,,,,,"4219205","Neurofibromatosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519316","Signature","C25678","Individual's name or personal mark, used to sign documents and employed to signify that the writing which precedes accords with one's wishes and intentions; having a handwritten signature.","Signature | Signed | signatureText",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028661","Nurse","C20821","A professional healthcare provider who has graduated from an accredited nursing program, has passed the state exam for licensure, and been registered or licensed to practice by a state authority.  Nurses are educationally prepared as functional (LPN/LVN) or professional (RN).","Nurse | NURSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919689","Donor Lymphocyte Infusion","C16145","The infusion of donor lymphocytes following hematopoietic stem cell transplantation for the purpose of augmenting the host immune response or preventing the rejection of the graft.","Donor Lymphocyte Infusion | DLI | Donor Leukocyte Infusion | donor lymphocyte infusion",,,,,,,,,,,,,,,"604320","Infusion of donor leukocytes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021079","Immunosuppressive Therapy","C15261","deliberate suppression of immune system function for experimental or therapeutic purposes.","Immunosuppressive Therapy | Anti-Rejection Therapy | Immunosuppression | immunosuppression | immunosuppressive therapy",,,,,,,,,,,,,,,"4314777","Immunosuppressive therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0856825","Acute Graft Versus Host Disease","C4980","A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, usually affecting the skin, liver, and GI tract. The onset is usually within one hundred days of transplantation or immunologic manipulation.","Acute Graft Versus Host Disease | Acute | Acute GVHD | Fulminant Graft Versus Host Disease | GVHD, acute | Graft versus host disease, acute",,,,,,,,,,,,,,,"439416","Acute graft-versus-host disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009647","Conditioning","C41258","Generally refers to relative simple learning situations in which a stimulus initially incapable of evoking a certain response acquires the ability to do so by repeated pairing with another stimulus that does elicit the response.","Conditioning | Conditioned | conditioned response",,,,,,,,,,,,,,,"4302321","Conditioning",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0867389","Chronic Graft Versus Host Disease","C4981","A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, and may affect multiple organs with manifestations similar to autoimmune diseases. The onset is usually within three years of transplantation or immunologic manipulation.","Chronic Graft Versus Host Disease | Chronic | Chronic GVHD | GVHD, chronic | Graft versus host disease, chronic",,,,,,,,,,,,,,,"434314","Chronic graft-versus-host disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026606","Physical Activity","C17708","Any form of exercise or movement. Physical activity may include planned activity such as walking, running, basketball, or other sports. Physical activity may also include other daily activities such as household chores, yard work, walking the dog, etc.","Physical Activity | ",,,,,,,,,,,,,,,"4195380","Physical activity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034394","Questionnaires","C17048","A predetermined set of questions.","Questionnaire | Questionnaires | questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0750480","Count","C25463","Determining the number or amount of something.","Count | NUMBER | Num | Number Count | count",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0741302","atypia morphology","C9478","The condition of being irregular or not conforming to type.","Atypia | Atypia (Y/N) | Atypical | atypia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201913","Total Bilirubin Measurement","C38037","The measurement of the total amount of bilirubin present in a particular substrate. The substrate most often tested is blood, but other fluids extracted from the body may be used periodically depending on the purpose of the test.","Total Bilirubin Measurement | BILI | Bilirubin | Total Bilirubin | Total Bilirubin | Total Bilirubin Level",,,,,,,,,,,,,,,"4230543","Bilirubin, total measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024819","Marital Status","C25188","A demographic parameter indicating a person's current conjugal status.","Marital Status | MARISTAT | Marital or partnership status | MaritalStatus | MaritalStatusUB92 | marital status | marital_status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023610","Gonadotrophin Releasing Hormone","C2270","Specifically expressed in hypothalamic neurons as a preproprotein, Gonadotropin Releasing Hormones (GnRH Family) are secreted into the median eminence capillary plexus, bind to receptors on anterior pituitary gonadotrophs, and stimulate the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to control female reproduction.","Gonadotrophin Releasing Hormone | AY-24031 | D-His-6-Pro-8-NEt-LHRH | Follicle Stimulating Hormone-Releasing Factor | GN-RH | GnRH | Gonadoliberin | Gonadorelin | Gonadorelinum | Hoe- 471 | LH-RF | LH-RH | LH/FSH-RF | LH/FSH-RH | LHRH | Luliberin | Luteinising Hormone-Releasing Factor | Luteinizing Hormone-Releasing Factor | Luteinizing Hormone-Releasing Hormone | gonadotropin-releasing hormone | luteinizing hormone-releasing hormone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279025","Hormone Therapy","C15445","Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level.","Hormone Therapy | Chemotherapy-Hormones/Steroids | Endocrine Therapy | Endocrine Therapy | Hormonal | Hormonal Therapy | Hormonal therapy | Hormone Therapy | Hormones | endocrine therapy | hormonal therapy | hormone therapy | hormone treatment",,,,,,,,,,,,,,,"4061650","Hormone therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0419095","External Beam Radiation Therapy","C15751","Radiation therapy in which high-energy beams are delivered to the tumor from outside of the body.","External Beam Radiation Therapy | Definitive Radiation Therapy | EBRT | EXTERNAL BEAM RADIATION THERAPY | External Beam RT | External Beam Radiation | External Beam Radiotherapy | External Beam Radiotherapy (conventional) | External Radiation Therapy | External beam radiotherapy | Radiation, External Beam | Teleradiotherapy | Teletherapy | Teletherapy Radiation | external radiation | external-beam radiation",,,,,,,,,,,,,,,"4141448","External beam radiation therapy procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023779","Lipid","C616","A class of hydrocarbon-containing organic compounds. Lipids are insoluble in water but soluble in nonpolar solvents and play important roles in living organisms: these roles include functioning as energy storage molecules, serving as structural components of cell membranes, and constituting important signaling molecules. Lipids can be subdivided into 2 groups: fatty acids and glycerides.","Lipid | Lipids",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003280","Anticoagulant Agent","C263","Any agent capable of preventing blood clot formation.","Anticoagulant Agent | Anticoagulant Drugs | Anticoagulant medication administered for VTE prophylaxis | Anticoagulants | Anticoagulation Therapy | anticoagulant | blood thinner",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005821","Platelet","C12520","An irregular, disc-shaped element in the blood that assists in blood clotting. Platelets are not blood cells, they are fragments of large bone marrow cells called megakaryocytes.","Platelet | Bizzozero Corpuscle | Deetjen Body | PLATELET | Platelets | Reticuloendothelial System, Platelets | Thrombocyte | Thrombocytes | platelet | thrombocyte",,,,,,,,,,,,,,,"4039428","Platelet",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004057","Aspirin","C287","An orally administered non-steroidal antiinflammatory agent. Acetylsalicylic acid binds to and acetylates serine residues in cyclooxygenases, resulting in decreased synthesis of prostaglandin, platelet aggregation, and inflammation. This agent exhibits analgesic, antipyretic, and anticoagulant properties.","Aspirin | 2-(Acetyloxy)benzoic Acid | ASA | ASPIRIN | Acetylsalicylic Acid | Acetylsalicylic Acid | Acetylsalicylic acid | Aspergum | Ecotrin | Empirin | Entericin | Extren | Measurin | aspirin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0555952","Colorectal","C13363","Relating to the colon and rectum, or to the entire large bowel.","Colorectal | Colon or Rectum | colorectal",,,,,,,,,,,,,,,"4141331","Colorectal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013658","Education Level","C17953","An indication of the years of schooling completed in graded public, private, or parochial schools, and in colleges, universities, or professional schools.","Education Level | EDULEVEL | Education | Education Level Completed | Educational Attainment | Educational Level | Level of Education Attained | education level | education_level",,,,,,,,,,,,,,,"4022643|4144287","Educational achievement|Schooling",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0014003","Employed","C25172","The state of being engaged in an activity or service for wages or salary.","Employed | Employment | Employment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475455","T Category","C25728","One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","T Category | T | T Classification | T Stage | T Stage",,,,,,,,,,,,,,,"4193505","T category",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519429","Southwest Oncology Group","C25699","An NCI-sponsored cooperative group, an adult cancer clinical trials organization, one of the largest in the world. The group was established in 1956 and is headquartered in San Antonio, TX. Its network consists of almost 4,000 of the physicians at 283 institutions throughout the US and Canada. The major goal of the SWOG since 1990 has been to enroll more women and minority patients in cancer treatment and control research trials.","Southwest Oncology Group | SWOG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707044","Brief Symptom Inventory 18","C43524","The Brief Symptom Inventory 18 (BSI 18) assessment gathers patient-reported data to help measure psychological distress and psychiatric disorders in medical and community populations.","Brief Symptom Inventory 18 | BSI 18 | BSI-18 | BSI181",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708760","Lowest","C43517","In the lowest position, nearest the ground, at the bottom; minimal in magnitude, lowest in rank or importance; an extreme state of adversity.","Lowest | NADIR | Nadir",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522410","Highest","C25525","Approaching or constituting a maximum; the highest point (of something).","Highest | Apex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521895","Principal Investigator","C19924","An investigator who is responsible for all aspects of the conduct of a study.","Principal Investigator | AdministrativeMemberPI | PI | PRINCIPAL INVESTIGATOR | Principal Investigators | principal investigator | principal investigators | principal_investigator | principal_investigators",,,,,,,,,,,,,,,"35625739","Principal investigator",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1412919","Surgical margins","C41227","One of the criteria for assessment of the effectiveness of given surgical procedure in achieving the local control of a neoplasm and the adequacy of tumor removal. It is defined by the tissue plane through which the dissection has been done and the actual or potential neoplastic tissue which has been left outside the boundary of a resected specimen within the patient. There are four types of surgical margins: intracapsular or intralesional, marginal, wide, and radical.","Surgical Margin | MARGINS | Margin | Margins | Surgical Margins | margin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709790","Qualification","C43608","The action of verifying that a person, process, product or piece of equipment is suitable for a particular postition or task.","Qualification | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512203","Glucksberg Scale","C42297","The Glucksberg scale is a severity index for grading acute graft-versus-host disease (GVHD) after allogeneic marrow transplantation. This index is based on the results of an analysis in which distinct patterns in the peak severity of GVHD involvement in the skin, liver, and gut were correlated with the risks of transplant-related mortality (TRM) and treatment failure (defined as relapse or death).","Glucksberg Scale | Glucksberg | Glucksberg GVHD Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332162","Onset","C25279","The start, beginning, or early stages.","Onset | ",,,,,,,,,,,,,,,"4152896|4297758","Onsets|Onset of",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0037303","Skull","C12789","The bones that form the head, made up of the bones of the braincase and face.","Skull | BONE, SKULL | Bone structure of cranium (body structure) | Bone, Skull | Cranium | SKULL | Skull Bone | skull",,,,,,,,,,,,,"UBERON:0003128","skull","4230029","Bone structure of cranium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037949","Vertebral Column","C12998","A series of bones, muscles, tendons, and other tissues reaching from the base of the skull to the tailbone. The vertebral column forms the axis of the skeleton and encloses as well as protects the spinal cord and the fluid surrounding the spinal cord.","Vertebral Column | SPINAL COLUMN | Spinal Column | Spine | VERTEBRAL COLUMN | Vertebral column | backbone | spinal column | spine | vertebral column",,,,,,,,,,,,,"UBERON:0001130","vertebral column","4227378","Structure of vertebral column",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205145","Site","C37901","A position in relation to its surroundings.","Site | Sites",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1141639","Human Chorionic Gonadotropin","C2275","A sialoglycoprotein hormone secreted by the placenta and maintains the corpus luteum at the beginning of the gestation period.","Human Chorionic Gonadotropin | hCG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512288","Gynecologic Oncology Group","C25521","A non-profit NCI-supported organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of gynecologic malignancies. Approximately 45 individual clinical trials are active at any one time within GOG.","Gynecologic Oncology Group | GOG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL415042","Diagnostic","C25482","Characteristic or indicative of a condition.","Diagnostic | DIAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796392","Bevacizumab","C2039","A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","Bevacizumab | ABP 215 | ABP-215 | ABP215 | Alymsys | Anti-VEGF | Anti-VEGF Humanized Monoclonal Antibody | Anti-VEGF Monoclonal Antibody SIBP04 | Anti-VEGF rhuMAb | Avastin | Avzivi | Aybintio | BAT 1706 | BAT-1706 | BAT1706 | BAT1706 Biosimilar | BEVACIZUMAB | BP102 | BP102 Biosimilar | Bevacizumab Biosimilar ABP 215 | Bevacizumab Biosimilar BAT1706 | Bevacizumab Biosimilar BEVZ92 | Bevacizumab Biosimilar BI 695502 | Bevacizumab Biosimilar CBT 124 | Bevacizumab Biosimilar CT-P16 | Bevacizumab Biosimilar FKB238 | Bevacizumab Biosimilar GB-222 | Bevacizumab Biosimilar HD204 | Bevacizumab Biosimilar HLX04 | Bevacizumab Biosimilar IBI305 | Bevacizumab Biosimilar LY01008 | Bevacizumab Biosimilar MB02 | Bevacizumab Biosimilar MIL60 | Bevacizumab Biosimilar MYL-1402O | Bevacizumab Biosimilar Mvasi | Bevacizumab Biosimilar QL 1101 | Bevacizumab Biosimilar QL1101 | Bevacizumab Biosimilar RPH-001 | Bevacizumab Biosimilar SCT501 | Bevacizumab Biosimilar Zirabev | Bevacizumab awwb | Bevacizumab-adcd | Bevacizumab-awwb | Bevacizumab-aybi | Bevacizumab-bvzr | Bevacizumab-equi | Bevacizumab-maly | Bevacizumab-onbe | Bevacizumab-tnjn | CT P16 | CT-P16 | CTP16 | Equidacent | FKB 238 | FKB-238 | FKB238 | HD204 | Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer | MB 02 | MB-02 | MB02 | MYL-1402O | Mvasi | Onbevzi | Oyavas | PF 06439535 | PF-06439535 | PF06439535 | QL1101 | Recombinant Humanized Anti-VEGF Monoclonal Antibody | SCT501 | SIBP 04 | SIBP-04 | SIBP04 | Vegzelga | Vegzelma | Zirabev | bevacizumab | rhuMab-VEGF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0543467","Surgical Procedure","C15329","A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.","Surgical Procedure | Operation | SURGERY | Surgery | Surgery Type | Surgery, NOS | Surgical | Surgical Intervention | Surgical Interventions | Surgical Procedures | Surgically | Type of Surgery | surgery",,,,,,,,,,,,,,,"4301351","Surgical procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334044","Dysplasia","C4086","A usually neoplastic transformation of the cell, associated with altered architectural tissue patterns. The cellular changes include nuclear and cytoplasmic abnormalities. Molecular genetic abnormalities are also often found and, in some instances, may lead to cancer.","Dysplasia | Dyscrasia | Dysplastic | dyscrasia | dysplasia | dysplasia type | dysplasia_type",,,,,,,,,,,,,,,"4093447","Dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0079399","Gender","C17357","Characteristics of people that are socially constructed, including norms, behaviors, and roles based on sex. As a social construct, gender varies from society to society and can change over time. (Adapted from WHO.)","Gender | gender",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3151392","Squamous Cell Carcinoma","C2929","A carcinoma arising from squamous epithelial cells.  Morphologically, it is characterized by the proliferation of atypical, often pleomorphic squamous cells.  Squamous cell carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Well differentiated carcinomas are usually associated with keratin production and the presence of intercellular bridges between adjacent cells.  Representative examples are lung squamous cell carcinoma, skin squamous cell carcinoma, and cervical squamous cell carcinoma.","Squamous Cell Carcinoma | CARCINOMA, SQUAMOUS CELL, MALIGNANT | Epidermoid Carcinoma | Epidermoid Cell Cancer | Epidermoid carcinoma, NOS | Malignant Epidermoid Cell Neoplasm | Malignant Epidermoid Cell Tumor | Malignant Squamous Cell Neoplasm | Malignant Squamous Cell Tumor | SCC | Squamous Carcinoma | Squamous Cell Cancer | Squamous Cell Carcinoma, NOS | Squamous Cell Carcinoma, Not Otherwise Specified | Squamous Cell Carcinoma, conventional | Squamous Cell Epithelioma | Squamous carcinoma | Squamous cell carcinoma, NOS | Squamous cell epithelioma | epidermoid carcinoma | squamous cell carcinoma","8070/3","Squamous cell carcinoma, NOS",,,,,,,,,,,,,"37156145|4300118","Squamous cell carcinoma|Squamous cell carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0021368","Inflammation","C3137","A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.","Inflammation | INFLAMMATION | Inflammatory Finding | inflammation",,,,,,,,,,,,,,,"4119715","Inflammation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0314732","Infectious Agent","C14316","Any organism, such as a virus, parasite, or bacterium, that is capable of invading body tissues and multiplying.","Infectious Agent | Infectious Agents | Infective Agent | infectiousAgent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1533685","Injection Route of Administration","C28160","Administration of a drug into a location within the body; this can be achieved either through an established access or via a needle.","Injection Route of Administration | Injectable | Injection | Injection | Injection Procedure | Injection Procedure | injection",,,,,,,,,,,,,,,"4044190|4241075|42538189","Injection - action|Injection|Inject",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C0007344","Castration","C15198","Surgical removal of the ovaries or testes.","Surgical Castration | Castration | castration | surgical castration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006823","Canada","C16380","A country in northern North America, bordering the North Atlantic Ocean on the east, North Pacific Ocean on the west, and the Arctic Ocean on the north, north of the conterminous US.","Canada | 124 | CA | CAN | CANADA",,,,,,,,,,,,,,,"4075635","Canada",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709882","Regional Tumor Implant","C45217","Tumor implant developed regionally to the primary site of cancer.","Regional Tumor Implant | Regional Implant | Regional Implant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1138603","Provider","C37900","One that makes something available.","Provider | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512248","Gracely Pain Unpleasantness Scale","C42299","A visual analog scale of 0 to 20 used by a subject to define their pain unpleasantness experience.  Together with the intensity scale these tools serve to differentiate the patient's sensory perception of pain intensity from their affective experience of the pain's 'unpleasant' quality.","Gracely Pain Unpleasantness Scale | Gracely Pain Discomfort Scale | Gracely Pain Effect Scale | Gracely Unpleasantness Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017446","Geographic Locations","C16632","Any demarcated area of the Earth; may be determined by both natural and human boundaries.","Geographic Area | Area | Geographic Location | Geographic Region | Region",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1623258","Electrocardiography","C38053","A procedure that displays the electrical activity of the heart.","Electrocardiography | ECG | EKG",,,,,,,,,,,,,,,"4163951","Electrocardiographic procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519225","Seed Implantation","C16219","A type of cancer treatment using radioactive seeds or pellets, that are implanted into the affected organ, and which act as an encapsulated radiation source within the cancerous tissue while limiting the exposure to sorrounding tissues.","Seed Implantation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1524106","Chairperson","C42301","The officer who presides at the meetings of an organization, committee, or other organizational structure.","Chairperson | Chair | Chairman | Chairwoman",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516164","Cancer Biology","C18666","The study of the origins, growth, and treatment of any of various types of malignant neoplasms, most of which invade surrounding tissues, may metastasize to several sites, and are likely to recur after attempted removal and to cause death of the patient unless adequately treated; especially, any such carcinoma or sarcoma, but in ordinary usage, especially the former.","Cancer Biology | Biology of Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439603","Temporal Frequency","C25515","The number of occurrences of something within a given time period.","Temporal Frequency | EVENTFRQ | Event Frequency | Frequency | Frequency | frequency",,,,,,,,,,,,,,,"4156186","Frequencies",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015392","Eye","C12401","The organ of sight or vision.","Eye | EYE | Eye, NOS | Eyeball | Ocular | Ophthalmic | Optic | Structure of eye proper (body structure) | eye | ophthalmic",,,,,,,,,,,,,"UBERON:0000970","eye","4305329","Eye structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1739039","Epidermal Growth Factor Receptor, Human","C17068","Epidermal growth factor receptor (1210 aa, ~134 kDa) is encoded by the human EGFR gene. This protein plays a role in cell-cell adhesion, cell migration, cell proliferation and signal transduction.","Epidermal Growth Factor Receptor | Cell Growth Inhibiting Protein 40 | Cell Proliferation-Inducing Protein 61 | EC 2.7.10.1 | EGF Receptor | EGFR | ERBB Protein | Epidermal Growth Factor Receptor Protein-Tyrosine Kinase | Erb-B2 Receptor Tyrosine Kinase 1 | ErbB1 | HER-1 | HER1 | Proto-Oncogene c-erbB-1 | Receptor Tyrosine-Protein Kinase erbB-1 | Urogastrone Receptor | c-erbB-1 | epidermal growth factor receptor | erbB-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333400","Gadolinium-Enhancing Lesion","C28746","A well-defined area of unequivocally increased signal intensity on MRI or CT scan images compared with the normal-appearing surrounding tissues, following intravenous injection of gadolinium-based contrast material.","Gadolinium-Enhancing Lesion | Enhancing Lesion | Gd-Enhancing Lesion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013893","Eligibility Determination","C25171","The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","Eligibility Determination | Eligibility | Protocol Screening",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013227","Medication","C459","A drug product that contains one or more active and/or inactive ingredients; it is intended to treat, prevent or alleviate the symptoms of disease. This term does not refer to the individual ingredients that make up the product.","Medication | Drug | Drug Product | Medication Name | Medications | Medicine | drug product | medication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011627","Dermatology","C16500","The branch of medicine focused on the study of the skin, and responsible for the medical management of its associated diseases.","Dermatology | ",,,,,,,,,,,,,,,"4214566","Dermatology",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042036","Urine","C13283","The fluid that is excreted by the kidneys.  It is stored in the bladder and discharged through the urethra.","Urine | URINE | Urinary System, Urine | urine",,,,,,,,,,,,,,,"4299925","Urine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037793","Specimen Processing","C41604","The process of preparing a sample or portion of a sample for storage, preservation, or further analysis.","Specimen Processing | ",,,,,,,,,,,,,,,"4243140","Specimen processing",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0446516","Arm","C32141","The portion of the upper extremity between the shoulder and the elbow. For clinical purposes this term is also used to refer to the whole superior limb.","Arm | ARM | Brachium | Upper Arm",,,,,,,,,,,,,,,"4165266","Upper arm structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025260","Memory","C37992","The power of retaining and recalling past experience, something that is remembered.","Memory | ",,,,,,,,,,,,,,,"4116469","Memory function",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL415222","Concomitant","C25730","Accessory, accompanying especially in a subordinate or incidental way, occurring or existing during the same period of time.","Concomitant | concomitant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0973231","Bicarbonate Ion","C37918","A polyatomic ion whose formula is HCO3-.","Bicarbonate Ion | BICARBONATE ION | Bicarbonate | Bicarbonate | Hydrogen Carbonate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332307","Type","C25284","Something distinguishable as an identifiable class based on common qualities.","Type | Kind | TYPE | type",,,,,,,,,,,,,,,"4259643","Type",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522326","Treating","C25705","Providing treatment for.","Treating | Treated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514463","Prior Therapy","C16124","Prior action or administration of therapeutic agents that produced an effect that is intended to alter or stop a pathologic process.","Prior Therapy | Former Therapy | Prior Treatment | previously treated | previously_treated | prior therapy | prior treatment | prior_therapy | prior_treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516607","Clinical Data Update System","C19992","A system to standardize and streamline data reporting and reduce administration needs.  This system achieves rapid, accurate, and secure capture of clinical trial data with minimal effort. Successfully captures the majority of trial data within hours of submission. (Bypass Budget 2001 & 2002)","Clinical Data Update System | CDUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887460","Cardiovascular","C25292","Pertaining to the heart or blood vessels.","Cardiovascular | cardiovascular",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040405","Computed Tomography","C17204","A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.","Computed Tomography | CAT | CAT Scan | CAT scan | CT | CT SCAN | CT Scan | CT scan | Computed Axial Tomography | Computerized Axial Tomography | Computerized Tomography | Computerized Tomography (CT) scan | Computerized axial tomography (procedure) | computed tomography | computerized axial tomography | computerized tomography | tomography",,,,,,,,,,,,,,,"4300757","Computed tomography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0454664","Country","C25464","A collective generic term that refers here to a wide variety of dependencies, areas of special sovereignty, uninhabited islands, and other entities in addition to the traditional countries or independent states.","Country | COUNTRY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3243597","Aliquot","C25414","Pertaining to a portion of the whole; any one of two or more samples of something, of the same volume or weight.","Aliquot | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516637","Clinical Trial Eligibility Criteria","C16112","Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","Clinical Trial Eligibility Criteria | Eligibility Criteria for Clinical Trials | Study Eligibility Criteria | Trial Eligibility Criteria | eligibility criteria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456079","Level","C25554","A position on a scale measuring intensity, quality, or amount.","Level | Degree",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009924","Contrast Agent","C390","Substances administered during imaging procedures that allows delineation of internal structures. Contrast agents appear opaque due to the difference in absorption of X-rays or other electromagnetic waves and surrounding tissue.","Contrast Agent | Contrast | Contrast Drugs | Contrast Medium | contrast material",,,,,,,,,,,,,,,"4253618|4299338","Contrast media|Contrast media",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0332281","Associated","C25281","Joined in some kind of relationship.","Associated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015672","Fatigue","C3036","Overall tiredness and lack of energy.","Fatigue | FATIGUE | Fatigue (lassitude) | Lack of Energy | fatigue",,,,,,,,,,,,,,,"4223659","Fatigue",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512693","Inclusion","C25532","Medical and/or social characteristics which are necessary for a subject to be allowed to participate in a clinical study, as outlined in the study protocol. Meeting inclusion criteria is not a sufficient condition for entry or recruitment of a subject into the study. Characteristics limiting the eligibility of a subject for the clinical study must be considered.","Inclusion Criteria | INCLUSION | Inclusion | inclusion criteria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014136","Endocrine System","C12705","The body system that comprises the organs and glands that produce hormones that are secreted into the blood and control physiological functions that include reproduction, growth and development, metabolism, and stress responses.","Endocrine System | Body System, Endocrine/Metabolic | Endocrine | Endocrine/Metabolic Body System | Endocrine/Metabolic Organ System | Hormonal System | Metabolic/Endocrine Body System | Organ System, Endocrine/Metabolic | endocrine system",,,,,,,,,,,,,,,"4034504","Structure of endocrine system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0349707","Aspiration","C15631","Procedure using suction, usually with a thin needle and syringe, to remove bodily fluid or tissue.","Aspiration | ASPIRATION | aspiration",,,,,,,,,,,,,,,"4033232","Aspiration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1285578","Finding","C3367","Clinical, laboratory or molecular evidence, or absence of evidence of disease.","Finding | Observable Entity | finding",,,,,,,,,,,,,,,"4181663","Observable entity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032520","Polymerase Chain Reaction","C17003","A method for amplifying a DNA base sequence using multiple rounds of heat denaturation of the DNA and annealing of oligonucleotide primers complementary to flanking regions in the presence of a heat-stable polymerase.  This results in duplication of the targeted DNA region. Newly synthesized DNA strands can subsequently serve as additional templates for the same primer sequences, so that successive rounds of primer annealing, strand elongation, and dissociation produce rapid and highly specific amplification of the desired sequence. PCR also can be used to detect the existence of the defined sequence in a DNA sample.","Polymerase Chain Reaction | PCR | POLYMERASE CHAIN REACTION | polymerase chain reaction",,,,,,,,,,,,,,,"4120014","Polymerase chain reaction technique",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032246","Ploidy","C17001","The number of chromosome sets per cell.","Ploidy | DNA Content | DNA Ploidy | ploidy",,,,,,,,,,,,,,,"4338964","Ploidy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021430","Informed Consent","C16735","Consent by a patient to a surgical or medical procedure or participation in a clinical study after achieving an understanding of the relevant medical facts and the risks involved.","Informed Consent | Formal Consent | INFORMED CONSENT OBTAINED | informed consent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205476","Medical","C25261","Relating to the study or practice of medicine.","Medical | ",,,,,,,,,,,,,,,"4250324","Medical",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018957","Hematopoietic System","C12909","The bodily system of organs and tissues, primarily the bone marrow, spleen, tonsils, and lymph nodes, involved in the production of blood.","Hematopoietic System | Body System, Hematologic | Hematologic Body System | Hematologic Organ System | Hematopoietic Body System | Hematopoietic system, NOS | Organ System, Hematologic | hematopoietic system",,,,,,,,,,,,,,,"4210988","Hematopoietic system structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0522510","Intensity","C25539","The degree or magnitude of strength, energy, or feeling.","Intensity | Intense",,,,,,,,,,,,,,,"765415","Intensities",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1513040","Measurable","C37894","Capable of being measured.","Measurable | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0450429","Location","C25341","A position, site, or point in space where something can be found.","Location | LOC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516048","Assessment","C25217","The final result of a determination of the value, significance, or extent of.","Assessment | Assess | Assessed | Assessed | Study Assessment | Study Observation | assessment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513882","National Cancer Institute","C19202","The Federal Government's principal agency for cancer research. NCI conducts, coordinates, and funds cancer research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer. Part of the National Institutes of Health of the United States Department of Health and Human Services.","National Cancer Institute | NCI | NCI Organization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027468","United States National Institutes of Health","C16895","A federal agency in the U.S. that conducts biomedical research in its own laboratories; supports the research of non-Federal scientists in universities, medical schools, hospitals, and research institutions throughout the country and abroad; helps in the training of research investigators; and fosters communication of medical information. Access the National Institutes of Health Web site at http://www.nih.gov.","National Institutes of Health | NIH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0497254","Musculoskeletal","C25348","Pertaining to the muscles and skeleton.","Musculoskeletal | musculoskeletal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0680264","payment","C25371","A sum of money paid.","Payment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206065","Karnofsky Performance Status","C28013","An index designed for classifying patients 16 years of age or older by their functional impairment.","Karnofsky Performance Status | KARNOFSKY | KPS | Karnofsky | Karnofsky Scale | Performance Status Score: Karnofsky Score | karnofsky performance status | karnofsky_performance_status",,,,,,,,,,,,,,,"4169154","Karnofsky performance status",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0178784","Organ","C13018","A unique macroscopic (gross) anatomic structure that performs specific functions. It is composed of various tissues.  An organ is part of an anatomic system or a body region. Representative examples include the heart, lung, liver, spleen, and uterus.","Organ | Organs | organ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034510","Race","C17049","A geographic ancestral origin category that is assigned to a population group based mainly on physical characteristics that are thought to be distinct and inherent.","Race | Patient Reported Race | RACE | Racial Group | race",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034107","Pulse taking","C25749","The rhythmic wave within the arteries occurring with each contraction of the left ventricle.","Pulse | pulse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522449","Radiation Therapy","C15313","Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","Radiation Therapy | Cancer Radiotherapy | ENERGY_TYPE | Energy Type | Irradiate | Irradiated | Irradiation | Name of Radiation Therapy Course | RADIATION | RADIOTHERAPY | RT | Radiation | Radiation Therapy, NOS | Radiotherapeutics | Radiotherapy | Therapy, Radiation | irradiated | irradiation | radiation therapy | radiotherapy",,,,,,,,,,,,,,,"4029715","Radiation oncology AND/OR radiotherapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1318309","Core Biopsy","C15680","The removal of a tissue sample using a needle with a relatively large diameter, for microscopic examination.","Core Biopsy | BIOPSY, CORE | CNB | Core Needle | Core Needle Biopsy | Needle Biopsy | core biopsy | core needle biopsy",,,,,,,,,,,,,,,"4321878","Core needle biopsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0521346","Respiratory","C25656","Pertaining to respiration.","Respiratory | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035203","Respiration","C17091","Distinct from cell or tissue respiration, Respiration is the act of breathing with the lungs and consists of inspiration, or taking ambient air into the lungs, and expiration, or expelling modified air that contains more carbon dioxide than the air taken in. (NCI)","Respiration | Breathing",,,,,,,,,,,,,,,"4123008|4300515","Inhaling and exhaling|Respiratory function",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0012634","Disease or Disorder","C2991","Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","Disease or Disorder | Condition | Diagnosis | Disease | Disease or Disorder, Non-Neoplastic | Diseases | Diseases and Disorders | Diseases and Disorders | Disorder | Disorders | Other Disease | condition | disease | disease term | disease type | disease_term | disease_type | disorder",,,,,,,,,,,,,,,"4274025","Disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0600091","Identifier","C25364","One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.","Identifier | Descriptor | Designation | Designator | ID | id | identifier",,,,,,,,,,,,,,,"4038694","Identifier",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0439673","Unknown","C17998","Not known, observed, recorded; or reported as unknown by the data contributor.","Unknown | Not Known | U | UNK | UNKNOWN | Unknown/Not Stated | {Unknown}",,,,,,,,,,,,,,,"4129922","Unknown",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0376315","Form","C19464","A printed or electronic document with spaces to be filled out.","Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038952","Continuance of life","C17177","Continuance of life or existence especially under adverse conditions; includes methods and philosophy of survival.","Survival | Survivorship | Survivorship Issues | survivorship",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514989","Strenuous Exercise","C39773","20-60 minutes of exercise which elevates your heart rate to 80-90% of your maximum heart rate performed at least 3-4 times per week.","Strenuous Exercise | Strenuous Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449416","Source","C25683","Where something is available or from where it originates.","Source | source",,,,,,,,,,,,,,,"42539462","Source (property)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519683","Tumor Leakage","C40417","The loss of a fluid from a tumor. This can occur under normal circumstances or during biopsy or other surgical procedure.","Tumor Leakage | Tumor Spillage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0684224","Report","C25375","A short textual account; having provided a short account.","Report | Reported | report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1524119","Urinary","C25711","Urinary; of or relating to urine, of or relating to the urinary system, or of or relating to the function or production or secretion of urine.","Urinary | urinary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017337","Gene","C16612","A functional unit of heredity which occupies a specific position on a particular chromosome and serves as the template for a product that contributes to a phenotype or a biological function.","Gene | Genes | gene",,,,,,,,,,,,,,,"4281995","Gene",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0444667","Whole","C25326","Including all components without exception; constituting the full amount or extent or duration; complete.","Whole | ENTIRE | Entire | Entire (qualifier value)",,,,,,,,,,,,,,,"4114660","Entire",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0012854","DNA","C449","A long linear double-stranded polymer formed from nucleotides attached to a deoxyribose backbone and found in the nucleus of a cell; associated with the transmission of genetic information.","DNA | D | DOUBLE STRANDED DNA | Deoxyribonucleic Acid | Deoxyribonucleic acid | Double-stranded DNA | deoxyribonucleic acid | ds-DNA | dsDNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027361","Person","C25190","A human being.","Person | Individual",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439596","Cycle","C25472","An event or sequence of events that constitute a round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence.","Cycle | Cycles | Cyclic | Cyclical | cycle | {Cycle}",,,,,,,,,,,,,,,"4185742","Cyclic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1515022","Submission","C25694","Something submitted for the judgment or consideration of others.","Submission | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040300","Tissue","C12801","An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function.","Tissue | Normal | Normal Tissue | TISSUE | Tissue, NOS | Tissues | tissue",,,,,,,,,,,,,,,"4310109","Body tissue structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085205","Fax","C25210","Fax is short for facsimile, a telecommunications technology used to transfer copies of documents using devices operating over the telephone network.  It is used to refer both to the activity and the resulting document.","Fax | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518546","Off Study","C29851","No longer participating in a study; not being followed and will not be retreated.","Off Study | Off-Study | Study | off study | off_study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714787","Central Nervous System","C12438","The part of the nervous system that consists of the brain, spinal cord, and meninges.","Central Nervous System | CENTRAL NERVOUS SYSTEM | CNS | Central nervous system | Nervous System, CNS | central nervous system | systema nervosum centrale",,,,,,,,,,,,,"UBERON:0001017","central nervous system","4063669","Structure of central nervous system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019993","Hospitalization","C25179","The condition of being treated as a patient in a hospital.","Hospitalization | HOSPITALIZATION | Hospitalized",,,,,,,,,,,,,,,"4214577","Inpatient care",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0700219","Cigarette smoking behavior","C18270","Inhaling smoke from tobacco in the form of a cigarette.","Cigarette Smoking | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1264639","Date and Time","C37939","An expression of both date and time that an event has happened or will happen.","Date and Time | Date/Time | Date/Time",,,,,,,,,,,,,,,"4041097","Date-time",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522619","Esophageal","C37950","Of or relating to the esophagus.","Esophageal | esophageal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677453","Cigarette","C1802","Finely cut tobacco encased in a wrapper of thin paper and rolled for smoking.","Cigarette | CIGARETTES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511503","Convolution Kernel","C41832","An algorithm used to reconstruct imaging data.  Convolution kernels can be used to filter images to smooth them and reduce noise or to enhance edges or other image features.","Convolution Kernel | convolutionKernel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006644","Caffeine","C328","A methylxanthine alkaloid found in the seeds, nuts, or leaves of a number of plants native to South America and East Asia that is structurally related to adenosine and acts primarily as an adenosine receptor antagonist with psychotropic and anti-inflammatory activities. Upon ingestion, caffeine binds to adenosine receptors in the central nervous system (CNS), which inhibits adenosine binding. This inhibits the adenosine-mediated downregulation of CNS activity; thus, stimulating the activity of the medullary, vagal, vasomotor, and respiratory centers in the brain. This agent also promotes neurotransmitter release that further stimulates the CNS. The anti-inflammatory effects of caffeine are due the nonselective competitive inhibition of phosphodiesterases (PDEs). Inhibition of PDEs raises the intracellular concentration of cyclic AMP (cAMP), activates protein kinase A, and inhibits leukotriene synthesis, which leads to reduced inflammation and innate immunity.","Caffeine | 1,3,7-trimethylxanthine | 3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione | CAF | CAFFEINE | Methyltheobromine | Theine | Trimethylxanthine | caffeine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014868","Esophagitis","C9224","An acute or chronic inflammatory process affecting the esophageal wall.","Esophagitis | esophagitis",,,,,,,,,,,,,,,"30753","Esophagitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005558","Biopsy","C15189","The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.","Biopsy | BIOPSY | BIOPSY_TYPE | Bx | biopsy",,,,,,,,,,,,,,,"4311405","Biopsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1801960","Vascular","C13311","Relating to or containing blood vessels.","Vascular | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0518214","Quality of Life","C17047","The subjective measurement of an individual's sense of well-being and ability to enjoy life. The concept holds varying meanings for different people and may evolve over time. For some individuals it implies autonomy, empowerment, capability, and choice; for others, security, social integration, or freedom from stress or illness.","Quality of Life | QOL | Quality of Life (QOL) | Quality-of-Life | quality of life | quality of life (QoL)",,,,,,,,,,,,,,,"4234649","Quality of life satisfaction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710661","Washout Period","C42872","A period of time to allow one agent to clear the body before another agent can be safely introduced.  Washout periods vary depending on the agents involved.","Washout Period | Agent Washout | WASHOUT | Washout | wash-out | washout period",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024485","Magnetic Resonance Imaging","C16809","Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.","Magnetic Resonance Imaging | MR | MR Imaging | MRI | MRI Scan | MRIs | Magnetic Resonance | Magnetic Resonance Imaging (MRI) | Magnetic Resonance Imaging Scan | Magnetic resonance imaging (procedure) | Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance | NMR Imaging | NMRI | Nuclear Magnetic Resonance Imaging | Structural MRI | magnetic resonance imaging | nuclear magnetic resonance imaging | sMRI",,,,,,,,,,,,,,,"4013636|4207313","Magnetic resonance imaging|Magnetic resonance imaging - action",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL357394","Education","C16529","The activities of educating or instructing or teaching; activities that impart knowledge or skill.","Education | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037441","Social Work (discipline)","C17142","Social work; any of various services designed to aid the poor and aged and to increase the welfare of children. (WordNet)","Social Work | Social Service | social service",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0151313","Peripheral Sensory Neuropathy","C3501","Inflammation or degeneration of the sensory nerves.","Peripheral Sensory Neuropathy | Peripheral sensory neuropathy | Sensory Neuropathy",,,,,,,,,,,,,,,"37312197","Peripheral sensory neuropathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024117","Chronic Obstructive Pulmonary Disease","C3199","A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.","Chronic Obstructive Pulmonary Disease | COLD | COPD | Chronic Obstructive Airways Disease | Chronic Obstructive Airways Disease | Chronic Obstructive Lung Disease | Chronic Obstructive Pulmonary Disease (COPD) | Chronic obstructive pulmonary disease, unspecified | Obstructive Lung Disease | chronic obstructive pulmonary disease",,,,,,,,,,,,,,,"255573","Chronic obstructive lung disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007272","Common Carotid Artery","C12687","One of two arteries that supply oxygenated blood to the head and neck; the left common carotid branches from the aorta and the right common carotid from the innominate (brachiocephalic artery).","Common Carotid Artery | ARTERY, CAROTID | CAROTID ARTERY | Carotid | Carotid Artery | Carotid Artery | Carotid artery structure (body structure) | carotid artery",,,,,,,,,,,,,,,"4286359","Carotid artery structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0449238","Duration","C25330","The period of time during which something continues.","Duration | TIME | Time | Time Duration | duration",,,,,,,,,,,,,,,"42538822","Duration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0678446","Cigar","C1813","A compact roll of tobacco leaves prepared for smoking.","Cigar | CIGARS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439994","Tobacco Smoke","C829","Smoke from burning tobacco (cigarettes, cigars, or pipes) and exhaled by a smoker.  Tobacco smoke contains nicotine, a stimulant, and other biologically active chemicals having carcinogenic properties.","Tobacco Smoke | Smoke | Tobacco smoke, NOS",,,,,,,,,,,,,,,"4010813","Tobacco smoke",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522275","Lansky Play-Performance Status","C38144","The play-performance scale for children is a parent-rated instrument which records usual play activity as the index of performance.  It is similar to the Karnofsky Performance Scale for adults.","Lansky Play-Performance Status | LANSKY | Lansky | Lansky Play Score | Lansky Play-Performance Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1273518","Responsible Person","C25657","A person worthy of responsibility or trust or one held accountable.","Responsible Person | Custodian | Person Responsible | Responsible",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441938","Supratentorial","C12923","Having to do with the upper part of the brain.","Supratentorial | supratentorial",,,,,,,,,,,,,,,"4121200","Supratentorial",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0375111","Neoplasm","C3262","A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","Neoplasm | Neoplasia | Neoplasm, NOS | Neoplasms, NOS | Neoplastic Disease | Neoplastic Growth | Other Neoplasm | Tumor, NOS | neoplasia | neoplasm | tumor",,,,,,,,,,,,,,,"4030314","Neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2243117","Echocardiogram (image)","C37945","An image of the heart produced by ultrasonography.","Echocardiogram Recording | Echocardiogram | Echocardiogram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040288","Tissue Donor","C25168","Someone who gives blood or tissue or an organ to be used in another person.","Tissue Donor | DONOR, TISSUE | Donor | Donor | donor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0742078","Brain Mass","C35509","A benign or malignant solid pathologic process involving the brain and/or the meninges.","Brain Mass | ",,,,,,,,,,,,,,,"4173938","Mass lesion of brain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4228319","Immunodeficiency","C39725","A disorder in which the immune system is unable to mount an adequate immune response.","Immunodeficiency | Immunodeficient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019682","Human Immunodeficiency Virus","C14219","The virus isolated and recognized as the etiologic agent of AIDS. HIV-1 is classified as a lentivirus, a subtype of retroviruses.","Human Immunodeficiency Virus | HIV | HUMAN IMMUNODEFICIENCY VIRUS | Virus-HIV | human immunodeficiency virus",,,,,,,,,,,,,,,"4078242","Human immunodeficiency virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0522224","Paralysis","C3310","Partial or complete loss of function of one or more muscles. It is usually caused by damage to the nervous system.","Paralysis | Paralytic Syndrome | paralysis",,,,,,,,,,,,,,,"440377","Paralysis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030580","Parotid Gland","C12427","The largest of the three paired salivary glands, located in front of the ear.","Parotid Gland | GLAND, SALIVARY, PAROTID | PAROTID GLAND | Parotid | Parotid Salivary Gland | Parotid gland | Parotid gland structure (body structure) | parotid | parotid gland",,,,,,,,,,,,,"UBERON:0001831","parotid gland","4166063","Parotid gland structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040132","Thyroid Gland","C12400","An endocrine gland located at the base of the neck that produces and secretes thyroxine and other hormones. Thyroxine is important for metabolic control.","Thyroid Gland | GLAND, THYROID | Head and Neck, Thyroid | THYROID GLAND | Thyroid | Thyroid gland | Thyroid structure (body structure) | Total Thyroid | thyroid | thyroid gland",,,,,,,,,,,,,"UBERON:0002046","thyroid gland","4321375","Thyroid structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040113","Thymus Gland","C12433","A bi-lobed organ surrounded by a connective tissue capsule. It is located in the upper anterior portion of the chest, behind the sternum. It is composed predominantly of lymphocytes and fewer epithelial cells. Connective tissue septa separate the lobes into lobules. The lobules contain an outer portion (cortical zone) which is rich in lymphocytes and an inner portion (medullary zone) which is rich in epithelial cells. It is an organ essential for the development of the immune system. Its function is the maturation of the progenitor lymphoid cells to thymocytes and subsequently to mature T-cells. It reaches its greatest weight at puberty and subsequently begins to involute.","Thymus Gland | Reticuloendothelial System, Thymus | THYMUS | THYMUS GLAND | Thymus | Thymus gland structure (body structure) | thymus | thymus gland | thymus organ",,,,,,,,,,,,,"UBERON:0002370","thymus","4321259","Thymus gland structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1773628","Submandibular Salivary Gland","C12233","One of a pair of major salivary glands located below the floor of the mouth.","Submandibular Salivary Gland | GLAND, SALIVARY, SUBMANDIBULAR | Gland, Salivary, Mandibular | SUBMANDIBULAR GLAND | Submandibular | Submandibular Gland | Submandibular Gland | Submandibular gland | Submandibular salivary gland structure (body structure) | Submaxillary Gland | mandibular gland | mandibular salivary gland | submandibular gland | submandibular salivary gland",,,,,,,,,,,,,"UBERON:0001736","submandibular gland","4299196","Submandibular salivary gland structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0368761","Hematopoietic Blast Cell","C12918","A precursor cell which gives rise to a fully differentiated cell of hematopoietic lineage.","Hematopoietic Blast Cell | Blast Cell | Blast Cell | Blast Cells | Blasts | blast",,,,,,,,,,,,,,,"4207315","Blast cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032112","Plasma Cell","C12486","A fully mature B-Cell that produces a specific antibody.","Plasma Cell | Plasma Cells | Plasmacytes | Plasmocyte | plasma cell | plasmacyte | plasmacytic",,,,,,,,,,,,,,,"4034507","Plasma cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0259749","Autonomic Neuropathy","C27033","An inherited or acquired peripheral neuropathy affecting the autonomic nervous system. It results in disruption of the involuntary body functions. Inherited causes include Fabry disease and porphyrias. Acquired causes include diabetes, uremia, hepatic disorders, vitamin deficiencies, toxins, and drug toxicities.","Autonomic Neuropathy | ",,,,,,,,,,,,,,,"4080146","Autonomic neuropathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041364","Tumor Lysis Syndrome","C3425","A condition of metabolic abnormalities that result from a spontaneous or therapy-related cytolysis of tumor cells. Tumor lysis syndrome typically occurs in aggressive, rapidly proliferating lymphoproliferative disorders. Burkitt lymphoma and T cell acute lymphoblastic leukemia are commonly associated with this syndrome. Metabolic abnormalities include hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia and may result in renal failure, multiple organ failure, and death.","Tumor Lysis Syndrome | Tumor lysis syndrome | tumor lysis syndrome",,,,,,,,,,,,,,,"4079687","Tumor lysis syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0225870","Interventricular Septum","C32874","The wall that separates the left and right ventricles of the heart.","Interventricular Septum | Heart, Ventricular Septum | INTERVENTRICULAR SEPTUM | Interventricular Septal Wall | Ventricular Septum",,,,,,,,,,,,,,,"4243341","Interventricular septum structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005437","Bilirubin","C305","A dark orange, yellow pigment that is the product of the breakdown of iron in the blood; it is conjugated in the liver and excreted in the bile.","Bilirubin | BILIRUBIN | Indirect Bilirubin | Unconjugated Bilirubin | bilirubin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015733","Feces","C13234","The material discharged from the bowel during defecation.  It consists of undigested food, intestinal mucus, epithelial cells, and bacteria.","Feces | FECES | Fecal | Gastrointestinal Tract, Feces | STOOL | Stool | Stool = Fecal | feces | stool",,,,,,,,,,,,,,,"4214692","Feces",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518348","Non-CTC","C40973","Designates that a term or concept does not use the NCI Common Toxicity Criteria as a reference.","Non-CTC | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707901","Eligibility Waiver","C42580","An approved exemption to the requirement for a participant to meet eligibility criteria prior to study enrollment.  A sponsor-approved waiver is necessary when a subject fails to meet enrollment criteria, but wishes to be accrued to the trial.","Eligibility Waiver | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512247","Gracely Pain Intensity Scale","C42298","A visual analog scale of 0 to 20, used by a subject to define their pain intensity experience.  Together with the unpleasantness scale these tools serve to differentiate the patient's sensory perception of pain intensity from their affective experience of the pain's 'unpleasant' quality.","Gracely Pain Intensity Scale | Gracely Intensity Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512338","Head, Ears, Eyes, Nose and Throat","C42300","HEENT is the Head, Ears, Eyes, Nose and Throat, and is referred to as a body system on a physical or medical examination.  The term is typically used as 'HEENT' in a physician or caregiver notes.","Head, Ears, Eyes, Nose and Throat | Eyes/Ears/Nose/Throat | HEENT | HEENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516378","Celsius Scale","C41151","The temperature scale defined by the values 0 degree Celsius for the freezing point of water and 100 degrees Celsius for the boiling point of water.  The Celsius degree (C) is the same size as a Kelvin and equal to (F - 32)/1.8.","Celsius Scale | Celsius | Centigrade Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL018710","Solitary Plasmacytoma","C6932","A localized malignant neoplasm that arises in the bony skeleton or soft tissue. It is composed of clonal (malignant) plasma cells forming a tumor mass.","Solitary Plasmacytoma | Solitary plasmacytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3644160","Immunoglobulin","C572","Any of the structurally related glycoproteins that function as antibodies. They are divided into five classes (IGA, IGD, IGE, IGG, IGM) on the basis of structure and biological activity.","Immunoglobulin | Ig | Immune Globulin | Immunoglobulins | Immunoglobulins / Antibodies | immunoglobulin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001924","Albumin","C214","A family of globular proteins found in many plant and animal tissues that tend to bind a wide variety of ligands.  Albumin is the main protein in blood plasma.  Low serum levels occur in conditions associated with malnutrition, inflammation and liver and kidney diseases.","Albumin | Albumin: | albumin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4014080","Osteoporosis","C3298","A condition of reduced bone mass, with decreased cortical thickness and a decrease in the number and size of the trabeculae of cancellous bone (but normal chemical composition), resulting in increased fracture incidence. Osteoporosis is classified as primary (Type 1, postmenopausal osteoporosis; Type 2, age-associated osteoporosis; and idiopathic, which can affect juveniles, premenopausal women, and middle-aged men) and secondary osteoporosis (which results from an identifiable cause of bone mass loss).","Osteoporosis | osteoporosis",,,,,,,,,,,,,,,"80502","Osteoporosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0600688","Toxicity","C27990","The finding of bodily harm due to the poisonous effects of something.","Toxicity | TOX | toxicity",,,,,,,,,,,,,,,"442562","Poisoning",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522465","Tomogram","C25221","A radiograph obtained by tomography.","Tomogram | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040329","Tobacco","C891","The dried cured leaves of the tobacco plant, Nicotiana tabacum, used for smoking, chewing, or snuff.  Tobacco contains nicotine, a stimulant, and other biologically active ingredients having carcinogenic properties.","Tobacco | TOBACCO | TOBACCO LEAF | tobacco",,,,,,,,,,,,,,,"4219336","Tobacco",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041618","Ultrasound Imaging","C17230","The use of high-frequency sound waves to generate images of the body.","Ultrasound Imaging | 2-Dimensional Grayscale Ultrasound Imaging | 2-Dimensional Ultrasound Imaging | 2D-US | ULTRASOUND | US | Ultrasonography | Ultrasonography | Ultrasound | Ultrasound Imaging | Ultrasound Imaging | Ultrasound Test | Ultrasound, Medical | ultrasonography | ultrasound",,,,,,,,,,,,,,,"4037672","Ultrasonography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0806909","Maximum","C25564","The largest possible quantity or degree.","Maximum | MAX | MAXIMUM | Maximal | Maximum Value | maximum",,,,,,,,,,,,,,,"4162389","Max",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041365","Tumor Marker","C17220","A substance present in or produced by a tumor or by the host, that can be used for differentiating neoplastic from normal tissue based on measurements in body fluids, secretions, cells, and/or tissues. Markers are used in diagnosis, staging and prognosis of cancer, provide an estimation of tumor burden, and serve for monitoring effects of therapy, detecting recurrence, localization of tumors, and screening in general populations.","Tumor Marker | Tumor Markers | tumor marker",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL414711","Administration","C25409","The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.","Administration | Treatment | administration | administration (substance)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042232","Vagina","C12407","The female genital canal, extending from the uterus to the vulva.","Vagina | Genital System, Female, Vagina | VAGINA | Vagina, NOS | Vaginal structure (body structure) | birth canal | vagina",,,,,,,,,,,,,"UBERON:0000996","vagina","4296022","Vaginal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042209","Vaccine Therapy","C15347","Immunotherapy using a preparation that usually contains a complex mixture of disease-related antigens, immunopotentiating agents, and immunomodulators, which stimulate the immune system to destroy pathogenic microorganisms or tumor cells.","Vaccine Therapy | vaccine therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042210","Vaccine","C923","Preparations containing substances with antigenic properties administered to activate the immune system, thereby inducing an immune response.","Vaccine | Vaccine Therapy | vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042077","Urology","C17243","The medical specialty concerned with the study, diagnosis, and treatment of diseases of the genitourinary tract.","Urology | Urologic",,,,,,,,,,,,,,,"4215134","Urology",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0203057","Upper Gastrointestinal Series","C17639","An x-ray examination of the esophagus, stomach and first part of the small intestine following coating with barium solution via ingestion.","Upper Gastrointestinal Series | Barium-Swallow X-ray | Upper GI | Upper GI | Upper GI Series | Upper Gastrointestinal Tract Radiography | upper GI series | upper gastrointestinal series",,,,,,,,,,,,,,,"4345928","Upper gastrointestinal tract series",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332114","MANF Gene","C21317","This gene is involved in the regulation of both function and survival of dopaminergic neurons.","MANF Gene | ARMET Gene | MANF | Mesencephalic Astrocyte-Derived Neurotrophic Factor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3263723","Injury","C3671","Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.","Injury | Trauma | Traumatic Injury | Wound | Wound | trauma | wound",,,,,,,,,,,,,,,"440921","Traumatic injury",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005847","Blood Vessel","C12679","A tubular structure through which the blood circulates in the body. Blood vessels constitute a network composed of arteries, arterioles, capillaries, venules, and veins.","Blood Vessel | BLOOD VESSEL | Human Blood Vessel | VESSEL, BLOOD | Vessel | Vessel | blood vessel",,,,,,,,,,,,,"UBERON:0001981","blood vessel","4242893","Blood vessel structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1622418","Cellular Vesicle","C27089","A closed structure surrounded by a single membrane.","Cellular Vesicle | Vesicle | Vesicle | vesicle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773619","Adipose Tissue","C12472","A specialized form of connective tissue consisting primarily of adipocytes (fat cells), surrounded by a meshwork of collagen fibers.","Adipose Tissue | ADIPOSE TISSUE | Adipose | Body Fat | Fat Tissue | Human Adipose Tissue | adipose tissue | fat | fat tissue | fatty tissue",,,,,,,,,,,,,"UBERON:0001013","adipose tissue","4210045","Adipose tissue",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333084","Colon Neuroendocrine Tumor G1","C5497","A well-differentiated, low-grade neuroendocrine neoplasm that arises from the colon. The mitotic count is less than 2 per 2 mm2 and the Ki-67 index is less than 3%.","Colon Neuroendocrine Tumor G1 | Carcinoid Tumor of Colon | Carcinoid Tumor of the Colon | Colon Carcinoid Tumor | Colon Carcinoid Tumor | Colon NET G1 | Colonic Carcinoid Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516463","Chemopreventive Agent","C1892","A natural or synthetic substance, such as a drug, vitamin, hormone, plant product or food supplement, that may reduce the risk of developing or recurrence of tumor formation. Chemopreventive agent may work at different stages and may inhibit the initiation, promotion, transformation, and/or progression of the malignant process.","Chemopreventive Agent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0370003","Specimen","C19157","A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.","Specimen | Research Specimen | Sample",,,,,,,,,,,,,,,"4048506","Specimen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0489786","Height","C25347","The vertical measurement or distance from the base to the top of an object; the vertical dimension of extension.","Height | HEIGHT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0370199","Aspirate","C13347","Fluid withdrawn from a body cavity, organ, cyst, or tumor.","Aspirate | ASPIRATE | aspirate",,,,,,,,,,,,,,,"4001224","Specimen obtained by aspiration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0596130","Attribution","C25358","To assign to a cause or source.","Attribution | Attributable | attributable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006141","Breast","C12971","One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.","Breast | BREAST | Breast structure (body structure) | Breast, NOS | Breasts | breast",,,,,,,,,,,,,,,"4298444","Breast structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0441471","Event","C25499","Something that happens at a given place and time.","Event | ",,,,,,,,,,,,,,,"4156363","Event",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1514254","Postal Code","C25621","Any system designed to expedite the sorting and delivery of mail by assigning a series of alphanumeric codes to each delivery area. Also used to refer to any individual delivery area code.","Postal Code | Postal code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1948053","Period","C25616","An interval of time.","Period | Epoch | Time Period",,,,,,,,,,,,,,,"4152525","Time periods",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013220","Drug Tolerance","C21130","A reduction in the sensitivity to a drug following its repeated administration, in which increased doses are required to produce the same magnitude of effect previously produced by a smaller dose. This increase in dose may be necessitated by changes in the metabolism of the drug, or a cellular, physiological or behavioral adaptation to the effects of the drug.","Drug Tolerance | Tolerance | Tolerance | drug tolerance",,,,,,,,,,,,,,,"4036424|4338356","Drug tolerance|Drug tolerance",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL938196","Multiple","C17648","Having, relating to, or consisting of more than one individual, element, part, or other component; manifold.","Multiple | MULTIPLE | Multi",,,,,,,,,,,,,,,"4112104","Multiple",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0521362","Gastrointestinal","C13359","Pertaining to the stomach and intestines.","Gastrointestinal | GI | Gastroenteral | gastrointestinal",,,,,,,,,,,,,,,"42539750","Gastroenteral",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011438","Dentistry","C16497","A clinical specialty responsible for the maintenance of teeth and the oral cavity, and for the medical management of any diseases or disorders associated with these tissues.","Dentistry | ",,,,,,,,,,,,,,,"36716228","Dentistry",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0439231","Month","C29846","One of the 12 divisions of a year as determined by a calendar. It corresponds to the unit of time of approximately to one cycle of the moon's phases, about 30 days or 4 weeks.","Month | MONTH | MONTHS | Months | mo | month",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040426","Tooth","C12506","The hard bonelike structures in the jaws of vertebrates; primarily used for eating.","Tooth | TOOTH | Teeth",,,,,,,,,,,,,,,"4244368","Tooth structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009797","Consent Forms","C16468","A document explaining all the relevant information to assist an individual in understanding the expectations and risks in making a decision about a procedure. This document is presented to and signed by the individual or guardian.","Consent Form | IC Form | ICF | Informed Consent Document | Informed Consent Form | consent form | informed consent form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516236","Cancer Trials Support Unit","C20090","Streamlines and centralizes administrative, financial, and data collection tasks. The submission and development of ideas for protocols are made easier through electronic forms, templates, and databases.","Cancer Trials Support Unit | CTSU | Clinical Trials Support Unit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449913","System","C25700","A group of independent but interrelated elements comprising a unified whole.","System | system",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024687","Mandible","C12290","The lower jaw bone holding the lower teeth.","Mandible | BONE, MANDIBLE | Bone structure of mandible (body structure) | Bone, Mandibular | Inferior Maxillary Bone | Lower Jaw | MANDIBLE | Mandibular | inferior maxillary bone | mammaliam mandible | mandible | mandibulla",,,,,,,,,,,,,"UBERON:0001684","mandible","4240393","Bone structure of mandible",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024947","Maxilla","C26470","The upper jawbone in vertebrates; it is fused to the cranium.","Maxilla | BONE, MAXILLA | Bone structure of maxilla (body structure) | MAXILLA | Maxillary | Upper Jaw | maxilla",,,,,,,,,,,,,"UBERON:0002397","maxilla","4324391","Bone structure of maxilla",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005767","Blood","C12434","A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.","Blood | BLOOD | Peripheral Blood | Reticuloendothelial System, Blood | Whole Blood | blood | peripheral blood | portion of blood | vertebrate blood",,,,,,,,,,,,,"UBERON:0000178","blood","4226865","Blood",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005854","Blood - brain barrier anatomy","C13194","The mechanism for restricting the passage of charged ions and large molecules from the blood into the brain and central nervous system (CNS) by employing a unique capillary bed with tight junctions between the endothelial cells.","Blood-Brain Barrier | BBB | Blood Brain Barrier | blood-brain barrier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0053065","Beauvericin","C1011","A cyclic hexadepsipeptide antibiotic and mycotoxin isolated from the fungus Beauveria bassiana and various Fusarium fungal species.  As a potassium-specific ionophore, beauvericin A increases intracellular calcium concentrations and triggers DNA fragmentation and apoptosis through a calcium dependent caspase 3-sensitive pathway.  This agent has been studied as a potential antineoplastic agent. (NCI04)","Beauvericin | BEAUVERICIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332351","Atypical Lymphocytes Present in Peripheral Blood","C36249","A variation of lymphocytes found in a peripheral blood smear that are larger, with abundant cytoplasm, and having nuclei with multiple nucleoli.","Atypical Lymphocytes Present in Peripheral Blood | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205436","Second","C25666","Coming next after the first in position in space or time or degree or magnitude.","Second | 2nd | Second Ordinal | Secondary",,,,,,,,,,,,,,,"4217781","Second",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1861853","Malignant Neoplasm","C9305","A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","Malignant Neoplasm | CA | Cancer | Malignancy | Malignant Growth | Malignant Neoplastic Disease | Malignant Tumor | NEOPLASM, MALIGNANT | Neoplasm, malignant | Tumor, malignant, NOS | Unclassified tumor, malignant | cancer | malignancy","8000/3","Neoplasm, malignant",,,,,,,,,,,,,"37153816|443392","Malignant neoplasm|Malignant neoplastic disease",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0079189","Cytokine","C20464","A class of soluble glycoproteins which act nonenzymatically through specific receptors to regulate immune responses. Cytokines are derived from both immune and non-immune cells and are intercellular mediators that differ from hormones in that they are produced by a number of tissue or cell types rather than by specialized glands.","Cytokine | Cytokines | cytokine",,,,,,,,,,,,,,,"4328107","Cytokine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1336928","VAV Family Gene","C20408","VAV Family Genes (VAV1, VAV2, and VAV3) encode VAV proteins that respond to similar cell surface receptor tyrosine kinases as GEFs for Rho/Rac family GTPases, which activate pathways leading to actin cytoskeletal rearrangements, transcriptional alterations, cell differentiation, and/or cell proliferation. VAV proteins contain CH, DH, PH, SH2, SH3, and zinc-dependent phorbol-ester and DAG binding domains. VAV1 is expressed exclusively in hematopoietic cells, while VAV2 and VAV3 are more broadly expressed. (NCI)","VAV Family Gene | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0349532","Gastric Lymphoma","C4636","An extranodal lymphoma that arises from the stomach with the bulk of the mass located in the stomach.  The vast majority of cases are diffuse large B-cell lymphomas and B-cell lymphomas of the mucosa-associated lymphoid tissue.","Gastric Lymphoma | Lymphoma of Stomach | Lymphoma of the Stomach | Primary Gastric Lymphoma",,,,,,,,,,,,,,,"4174765","Gastric lymphoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206117","Gap Junction","C13312","Intercellular connections comprised of complexes of connexin family proteins that permit the transfer of cytoplasmic ions and molecules between connected cells. Each cell contains a hemichannel made up of homo- or hetero-hexamers of connexins.","Gap Junction | Communicating Junction | Low-resistance Junction | Nexus | Nexus Junction",,,,,,,,,,,,,,,"4240181","Gap junction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005595","Aves","C14189","A taxonomic class of egg-laying, endothermic vertebrates. The forelimbs of these bipedal animals have been modified to form wings. Modern birds have beaks with no teeth and their bodies are covered in feathers.","Aves | Avian | Bird | Bird | Birds",,,,,,,,,,,,,,,"4302848","Bird",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1521827","Preparation","C25625","The act or process of making something ready.","Preparation | PREP | Prepare | Prepared | Set Up | Setup",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0220784","Anatomic","C25421","Relating to anatomy.","Anatomic | Anatomical | anatomic",,,,,,,,,,,,,,,"4263486","Anatomic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016263","Flow Cytometry","C16585","A technique for counting, examining and sorting microscopic particles suspended in a stream of fluid.","Flow Cytometry | FLOW CYTOMETRY | flow cytometry",,,,,,,,,,,,,,,"4276031|45769412","Flow cytometry|Flow cytometry",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0009392","Colony Stimulating Factor","C20586","A substance that stimulates the production of blood cells. Colony-stimulating factors include granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and promegapoietin.","Colony Stimulating Factor | CSF | Colony-Stimulating Factors | MGI-1 | MGI-1 Protein | Myeloid Cell-Growth Inducer | colony-stimulating factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003947","Asbestos","C284","One of a number of fibrous magnesium and calcium silicate minerals processed for thermal insulation and fireproofing.  Asbestos is considered to be an environmental carcinogen; chronic inhalation of fine asbestos dust causes pulmonary asbestosis and may induce lung neoplasms.  Chronic ingestion of asbestos may induce gastrointestinal neoplasms. (NCI04)","Asbestos | asbestos",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2917212","Negative Regulation of Coagulation","C16299","Events or activities that prevent or inhibit coagulation.","Negative Regulation of Coagulation | Anticoagulation | Anticoagulation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001430","Adenoma","C2855","A neoplasm that arises from the glandular epithelium. It may be encapsulated or non-encapsulated. The neoplastic glandular epithelial cells may or may not display cellular atypia or dysplasia. Representative examples include gastrointestinal tract adenomas, thyroid gland follicular adenomas, and pituitary neuroendocrine tumors/adenomas. The vast majority are benign.","Adenoma | ADENOMA, BENIGN | Adenoma, NOS | adenoma","8140/0","Adenoma, NOS",,,,,,,,,,,,,"37156908","Adenoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C3554470","Nausea","C3258","Upper abdominal discomfort associated with an urge to vomit.","Nausea | nausea",,,,,,,,,,,,,,,"31967","Nausea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1521991","Molecular","C25574","Relating to or produced by or consisting of molecules.","Molecular | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085390","Li-Fraumeni Syndrome","C3476","An autosomal dominant cancer predisposition syndrome caused by germline mutations of the TP53 gene. It is associated with breast carcinoma, choroid plexus carcinoma, adrenal cortex carcinoma, astrocytic tumors, medulloblastoma, soft tissue sarcoma, osteosarcoma, and leukemia.","Li-Fraumeni Syndrome | Li-Fraumeni | Li-Fraumeni Familial Cancer Susceptibility Syndrome | Li-Fraumeni Syndrome, TP53-Associated | Li-Fraumeni syndrome | TP53-Associated Li-Fraumeni Syndrome",,,,,,,,,,,,,,,"4323645","Li-Fraumeni syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4011784","Dysuria","C2999","Pain or discomfort during urination.","Dysuria | ",,,,,,,,,,,,,,,"197684","Dysuria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4230442","Dyspnea","C2998","An uncomfortable sensation of difficulty breathing. It may present as an acute or chronic sign of an underlying respiratory or heart disorder.","Dyspnea | DYSPNEA | Presence and severity of dyspnea | Shortness Of Breath | Shortness of Breath | Shortness of breath | Shortness_of_breath | dyspnea",,,,,,,,,,,,,,,"312437","Dyspnea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3280227","Dysphagia","C2980","A symptom referring to difficulty in swallowing. It may be observed in patients with stroke, motor neuron disorders, cancer of the throat or mouth, head and neck injuries, Parkinson disease, and multiple sclerosis.","Dysphagia | Difficulty Swallowing | Difficulty swallowing | Dysphagia/ Odynophagia | dysphagia",,,,,,,,,,,,,,,"31317","Dysphagia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3553767","Pulmonary Emphysema","C3348","A subcategory of chronic obstructive pulmonary disease (COPD). It occurs in people who smoke and suffer from chronic bronchitis. It is characterized by inflation of the alveoli, alveolar wall damage, and reduction in the number of alveoli, resulting in difficulty breathing.","Pulmonary Emphysema | EMPHYSEMA | Emphysema | Emphysema | Emphysema, unspecified",,,,,,,,,,,,,,,"261325","Pulmonary emphysema",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013832","Electrolytes","C464","Substances that ionize into anions and cations in body fluids.  Electrolytes regulate nerve and muscle function and water distribution between cells, plasma, and interstitial fluid.  Imbalances can cause serious physiologic effects, including seizures, cardiac arrhythmias and convulsions.","Electrolytes | electrolytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700377","Measurement of Left Ventricular Ejection Fraction","C37946","A measure of how much blood the left ventricle of the heart pumps out with each contraction. With each beat, a normal heart ejects about one-half to two-thirds of the blood in its left chamber.","Measurement of Left Ventricular Ejection Fraction | Ejection Fraction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014876","Esophagus","C12389","The portion of the digestive canal between the pharynx and stomach. It is about 25 cm long and consists of three parts: the cervical part, from the cricoid cartilage to the thoracic inlet; thoracic part, from thoracic inlet to the diaphragm; and abdominal part, below the diaphragm to the cardiac opening of the stomach.","Esophagus | ESOPHAGUS | Esophageal structure (body structure) | Esophagus, NOS | Gastrointestinal Tract, Esophagus | Oesophagus | esophagus | gullet",,,,,,,,,,,,,"UBERON:0001043","esophagus","4140098","Esophageal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1798376","Estrogen Receptor","C17069","Widely expressed human Estrogen Receptors (NR3 Family) are cytoplasmic hormone-activated receptors that act as nuclear transcription factors composed of an N-terminal transcription activation/modulation domain, a DNA-binding domain, and a C-terminal steroid-binding domain. Binding to DNA as a homo- or heterodimer, ESR interacts with NCOA3, NCOA5, and NCOA6 coactivators. Hormone-ESR complexes appear to recognize discrete upstream target ERE DNA sequences to regulate gene expression, cell proliferation, and differentiation. DNA-binding is lost in the absence of ligand. (NCI)","Estrogen Receptor Family | ER | ER | ER Family | Estradiol Receptor | Estrogen Receptor | Estrogen Receptor Family Protein | NR3A | Nuclear Receptor Subfamily 3 Group A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519355","Slice","C25682","A thin flat piece cut off of some object; anything resembling such an object.","Slice | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205549","Series","C25674","A group or succession of objects, substances, or events arranged in regular order in space or time, connected by a like relation, or forming a kind of chain.","Series | ",,,,,,,,,,,,,,,"4045420","Series",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0337611","Contact Person","C25461","A person acting as a channel for communication between groups or on behalf of a group.","Contact Person | Contact | Contact | Contact person | PointOfContact",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1457887","Symptom","C4876","Subjective evidence of disease perceived by the patient.","Symptom | SYMPTOM | symptom",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205161","Abnormal","C25401","Deviating in any way from the state, position, structure, condition, behavior, or rule which is considered a norm.","Abnormal | ABNORMAL | abnormal | deviant",,,,,,,,,,,,,,,"4135493","Abnormal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034656","Randomization","C25196","The allocation of individuals to groups by chance, especially in order to control the variables in an experiment.","Randomization | RANDOM | RANDOMIZED_STATUS | Randomized | Trial is Randomized | randomization | randomized",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516915","Epidemiology, Race/Ethnic Origin","C18773","The consideration of race and/or ethnic origin as variables in disease incident, transmission, and control.","Epidemiology, Race/Ethnic Origin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0545082","Visit","C25716","The act of going to see some person or place or thing; it can cover a short or long period but refers to a non-permanent arrangement.","Visit | Visits",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0679646","Participant","C29867","Someone who takes part in an activity.","Participant | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522240","Process","C29862","A sequence of events which produces some outcome.","Process | Processed",,,,,,,,,,,,,,,"36714664|4190745","Process|Process",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0023087","Laser Surgery","C15268","A type of operation using the cutting powers of laser beams from various sources. The use of a laser either to vaporize surface lesions or to make bloodless cuts in tissue.","Laser Surgery | Clinical, Surgery, Laser | Conventional Laser Therapy | Laser | laser surgery",,,,,,,,,,,,,,,"4261829","Laser surgery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023089","Laser","C16782","An acronym for light amplification by stimulated emission of radiation; an optical device that produces an intense monochromatic beam of coherent light.","Laser | Electromagnetic, Laser | Radiation, Laser | laser",,,,,,,,,,,,,,,"4046730","Laser device",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0441633","Scanning","C17999","The data or image obtained by gathering information with a sensing device.","Scan | Scans | scan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516588","City of Hope Mayday Pain Resource Center Patient Pain Questionnaire","C21153","A 16 item ordinal scale that measures a patient's knowledge and experience in managing chronic cancer pain. There is also a Family Pain Questionnaire that measures the family caretaker's knowledge and experience.","City of Hope Mayday Pain Resource Center Patient Pain Questionnaire | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0582103","Medical Examination","C25305","An appraisal or evaluation of a patient's condition by a clinician that is based on a physical exam, medical history, and the patient's account of symptoms.","Medical Examination | Exam | Exam | Examination | Health Assessment | Health Examination | Health Status Assessment | Medical Assessment | Medical Exam | Medical Inspection",,,,,,,,,,,,,,,"4026914","Medical assessment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0220825","Evaluation","C25214","Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","Evaluation | Evaluate | Evaluated | Evaluation Procedure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521738","Field","C25507","An area of database record, or graphical user interface form, into which a particular item of data is entered.","Data Field | Field | Field | field",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015967","Fever","C3038","Elevation of body temperature above normal due to inflammatory or immune responses.","Fever | FEVER | Pyrexia | fever",,,,,,,,,,,,,,,"437663","Fever",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015671","Father","C25174","A male parent.","Father | FATHER",,,,,,,,,,,,,,,"4283070","Father",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0241889","Family Medical History","C17726","A record of a patient's background regarding health and disease events of blood relatives. A patient's family medical history may be important in diagnosing existing conditions.","Family Medical History | Epidemiology, Family Medical History | FAMILY_HISTORY | Family History | Family History | Family History of | family history | family medical history",,,,,,,,,,,,,,,"4167217","Family history of clinical finding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015576","Family","C25173","A domestic group, or a number of domestic groups linked through descent (demonstrated or stipulated) from a common ancestor, marriage, or adoption.","Family | Familial | Family Group | familial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521761","Factor","C25506","Anything that contributes causally to a result.","Factor | Determinant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017420","Genitalia","C25177","The external sex organs.","Genitalia | GENITALIA",,,,,,,,,,,,,,,"4076121","Structure of anatomical reproductive system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017296","Gene Therapy","C15238","Application of genetic material (usually DNA) into cells in order to permanently correct an inherited disease or acquired disease.","Gene Therapy | DNA Therapy | GENETIC | Gene Transfer Procedure | Gene transfer | Intervention, Genetic | Molecular Biology, Gene Therapy | gene therapy",,,,,,,,,,,,,,,"4190434","Gene therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0542341","Function","C25518","The normal action performed by a structure or device.","Function | Functional",,,,,,,,,,,,,,,"4086154","Function",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704353","Fluid","C25278","A continuous amorphous substance that tends to flow and to conform to the outline of its container (i.e., a liquid or a gas).  Also used as an adjective to describe something with properties like that of a fluid.","Fluid | fluid",,,,,,,,,,,,,,,"4140681","Liquid substance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018943","Hematology (discipline)","C16673","The branch of medicine that deals with the blood and blood-forming organs and the diseases thereof.","Hematology | Hematologic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018787","Heart","C12727","A hollow organ located slightly to the left of the middle portion of the chest. It is composed of muscle and it is divided by a septum into two sides: the right side which receives de-oxygenated blood from the body and the left side which sends newly oxygenated blood to the body. Each side is composed of two chambers: the atrium (receiving blood) and ventricle (ejecting blood).","Heart | Cardiac | HEART | Heart structure (body structure) | chambered heart | heart | vertebrate heart",,,,,,,,,,,,,"UBERON:0000948","heart","4217142","Heart structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018670","Head","C12419","The anterior and superior part of a human bearing the mouth, the brain and sensory organs.","Head | HEAD | head",,,,,,,,,,,,,,,"4287390","Head structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512335","Harvest Procedure","C37963","Remove from a culture or a living or dead body, as for the purposes of transplantation.","Harvest Procedure | Harvest | Harvest",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205480","Gynecologic","C28016","Of or relating to or practicing gynecology; pertaining to the health issues of women.","Gynecologic | GYN | gynecologic",,,,,,,,,,,,,,,"4254102","Gynecologic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018284","Growth Factor","C20424","Growth Factors are extracellular signaling molecules (ligands) involved in control of target cell proliferation, cell survival, and cell differentiation. (NCI)","Growth Factor | Growth Agents | Growth Factors | Growth Factors, Proteins | Mitogen | growth factor",,,,,,,,,,,,,,,"4216038","Growth factor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1257890","Population Group","C17005","A group of individuals united by a common factor (e.g., geographic location, ethnicity, disease, age, gender)","Population Group | Group | Group | Population | Subpopulation | population | population group | population_group",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018183","Granulocyte","C12530","A type of leukocyte with a multilobed nucleus and cytoplasmic granules. The unique morphology of the nucleus has led to their also being known as polymorphonuclear leukocytes (PMLs or PMNs). Granulocytes are subdivided according to the staining properties of their granules into eosinophils (red with acidic dye), basophils (blue with basic dye), and neutrophils (not amenable to staining with either acidic or basic dyes).","Granulocyte | GRANULOCYTE | Granular Leukocyte | Granular Leukocytes | Granulocytes | Granulocytic | Granulocytic Cell | PMN | Polymorphonuclear Cell | Polymorphonuclear Leukocytes | granular leukocyte | granulocyte | polymorphonuclear leukocyte",,,,,,,,,,,,,,,"4169076","Granulocytic cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3203027","Gleason Score for Prostate Cancer","C28084","The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.","Gleason Score for Prostate Cancer | Gleason Score | Gleason Score | Gleason Sum | Gleason score | gleason score | gleason_score",,,,,,,,,,,,,,,"4025371","Gleason grading system for prostatic cancer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020564","Hypertrophy","C3124","Abnormal enlargement of a body part or organ.","Hypertrophy | HYPERTROPHY",,,,,,,,,,,,,,,"4210465","Hypertrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4014808","Hypertension","C3117","Blood pressure that is abnormally high.","Hypertension | HTN | High Blood Pressure | High Blood Pressure/ Hypertension | High blood pressure | Vascular Hypertensive Disorder | Vascular hypertensive disorder | high blood pressure | hypertension",,,,,,,,,,,,,,,"316866","Hypertensive disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019994","Hospital","C16696","An institution that provides medical, surgical, or psychiatric care and treatment for the sick or the injured.","Hospital | HOSPITAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512416","HercepTest","C25524","An FDA approved test for the evaluation of HER2 protein overexpression in breast tumors.  It provides semi-quantitative results of p185HER2 (HER2 gene) overexpression in Bouin or formalin-fixed, routinely processed, paraffin-embedded breast cancer tissues by light microscopy.","HercepTest | Herceptest",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242957","ERBB2 Gene","C17756","This gene plays a role in cellular proliferation and is involved in the oncogenic process through amplification and/or overexpression in several cancers.","ERBB2 Gene | ERBB2 | Erb-b2 Receptor Tyrosine Kinase 2 Gene | HER2 | HER2/Neu | HER2/neu | NEU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4014769","Hepatomegaly","C3100","Abnormal enlargement of the liver.","Hepatomegaly | hepatomegaly",,,,,,,,,,,,,,,"197676","Large liver",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205054","Hepatic","C13308","Pertaining to, affecting, or associated with the liver.","Hepatic | hepatic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019079","Hemoptysis","C3094","Coughing up blood from the respiratory tract.","Hemoptysis | Coughing up Blood | hemoptysis",,,,,,,,,,,,,,,"261687","Hemoptysis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512814","Intensity-Modulated Radiation Therapy","C16135","An advanced form of 3-Dimensional Conformal Radiation Therapy (3D CRT) that involves the use of varying intensities of small radiation beams to produce dosage distributions that are more precise than those possible with 3D CRT.","Intensity-Modulated Radiation Therapy | IMRT | IMRT | INTENSITY-MODULATED RADIATION THERAPY | Intensity Modulated RT | Intensity modulated radiation therapy (procedure) | Intensity-Modulated Radiotherapy | Radiation, Intensity-Modulated Radiotherapy | intensity-modulated radiation therapy",,,,,,,,,,,,,,,"40480519","Intensity modulated radiation therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021083","Immunotherapy","C15262","Therapy designed to induce changes in a patient's immune status in order to treat disease.","Immunotherapy | IMMUNOTHERAPY | Immunological | Immunological Therapy | Immunologically Directed Therapy | immunotherapy",,,,,,,,,,,,,,,"4295112","Immunological therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0456570","Immunophenotype","C20072","The characterization of a set of cells according to the antigens expressed.","Immunophenotype | Immune Cell Phenotype | Immune Phenotype | Immunotype | immunophenotyping",,,,,,,,,,,,,,,"4079309","Immunotype",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020986","Immunochemistry","C16713","The field of chemistry concerned with chemical processes in immunology (such as chemical studies of antigens and antibodies).","Immunochemistry | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018704","Healthcare Facility","C21541","The buildings and organizations where healthcare services are provided.","Healthcare Facility | HEALTH FACILITY | Health Care Facility | HealthcareFacility | Institution | Institution | healthcare facility | institution (medical)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023418","Leukemia","C3161","A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","Leukemia | Blood (Leukemia) | LEUKEMIA, MALIGNANT | Leukemia NOS | Leukemia, Disease | Leukemia, NOS | Leukemias | Leukemias, General | leukemia","9800/3","Leukemia, NOS",,,,,,,,,,,,,"317510","Leukemia",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0279563","Breast Lobular Carcinoma In Situ","C4018","A non-invasive adenocarcinoma of the breast characterized by a proliferation of monomorphic cells completely filling the lumina.  The overall lobular architecture is preserved.  It is frequently multifocal (90% in some series) and bilateral.  It seldom becomes invasive; however there is an increased risk of infiltrating ductal adenocarcinoma.","Breast Lobular Carcinoma In Situ | LCIS | LCIS, NOS | Lobular Breast Carcinoma In Situ | Lobular Breast Carcinoma In Situ | Lobular Ca in situ of Breast | Lobular Ca in situ of the Breast | Lobular Carcinoma In Situ (LCIS) | Lobular Carcinoma In Situ of the Breast | Lobular Carcinoma In Situ of the Breast (LCIS) | Lobular Carcinoma in situ | Lobular Carcinoma in situ of Breast | Lobular carcinoma in situ | Lobular carcinoma in situ of breast | Lobular carcinoma in situ of unspecified breast | Lobular carcinoma in situ, NOS | Non-Infiltrating Lobular Breast Carcinoma | Non-Infiltrating Lobular Carcinoma | Non-Infiltrating Lobular Carcinoma of Breast | Non-Infiltrating Lobular Carcinoma of the Breast | Non-Invasive Lobular Breast Carcinoma | Non-Invasive Lobular Carcinoma of Breast | Non-Invasive Lobular Carcinoma of the Breast | lobular carcinoma in situ","8520/2","Lobular carcinoma in situ, NOS",,,,,,,,,,,,,"4001315|40480680|4298197","Lobular carcinoma in situ of breast|Classic lobular carcinoma in situ|Lobular carcinoma in situ",,,,,,,,,,,,,"--","--",,,,,,,,"--|--|--"
"CL505165","Late Adverse Effect","C4808","Any symptom or condition which is a result of a medical intervention but arises months or years after it.","Late Adverse Effect | Adverse Late Effects | LE | Late Adverse Reaction | Late Effects | late effects",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023078","Larynx","C12420","The cartilaginous structure of the respiratory tract between the pharynx and the trachea. It contains elastic vocal cords required for sound production.","Larynx | Head and Neck, Larynx | LARYNX | Laryngeal structure (body structure) | Larynx, NOS | larynx | voice box",,,,,,,,,,,,,"UBERON:0001737","larynx","4262229","Laryngeal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1261273","Karyotype","C25215","The chromosomal morphology and number in somatic cells of an individual.","Karyotype | ",,,,,,,,,,,,,,,"42539007","Karyotype",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0086911","Institutional Review Board","C16741","A specially constituted independent review body comprised of medical, scientific and non-scientific members established and designated by an entity to ensure the protection of the rights, safety and well-being of human subjects recruited to participate in biomedical or behavioral research according to the requirements outlined in Title 38, part 16 (same as Title 45, part 46 and Title 21, part 56) of the U.S. Code of Federal Regulations. IRB responsibilities include reviewing, approving, and providing continuing review of trial protocol and amendments and of the methods and material(s) to be used in obtaining and documenting informed consent of the trial. Other equivalent committees with the same or similar functions are also considered to be IRBs.","Institutional Review Board | Human Subjects Protection Review Board | Human Subjects Protection and Institutional Review Board | IRB | IRB | Institutional Review Board (IRB) | committee for the protection of human subjects | independent ethics committee | independent review board | institutional review board (IRB)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035173","Research Personnel","C17089","People engaged in research.","Research Personnel | Investigator | Personnel | ResearchStaff",,,,,,,,,,,,,,,"35625940","Researcher",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205284","Margin","C25563","A boundary line or the area immediately inside the boundary.","Margin | Marginal",,,,,,,,,,,,,,,"4011562","Marginal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018563","Hand","C32712","The distal portion of the upper extremity. It consists of the carpus, metacarpus, and digits.","Hand | HAND | forelimb autopod | forelimb autopodium | hand | hand region | manus | terminal segment of free upper limb",,,,,,,,,,,,,"UBERON:0002398","manus","4310976","Hand structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005682","Bladder","C12414","The distensible sac-like organ that functions as a reservoir of urine, collecting from the kidneys and eliminating via the urethra.","Bladder | BLADDER | Bladder, NOS | URINARY BLADDER | Urinary Bladder | Urinary System, Bladder | Urinary bladder structure (body structure) | bladder | urinary bladder | vesica urinaria",,,,,,,,,,,,,"UBERON:0001255","urinary bladder","4232481","Urinary bladder structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0879602","Autologous Dendritic Cells/Candida Albicans Skin Test Reagent/CD40-Ligand/gp100 Antigen/Interferon Gamma/Interleukin-4/MART-1 Antigen/Sargramostim/Tyrosinase Peptide","C11855","A combination of agents containing autologous dendritic cells, Candida albicans skin test reagent, CD40-ligand, gp100 antigen, interferon gamma, interleukin-4, MART-1 antigen, sargramostim and tyrosinase peptide.","Autologous Dendritic Cells/Candida Albicans Skin Test Reagent/CD40-Ligand/gp100 Antigen/Interferon Gamma/Interleukin-4/MART-1 Antigen/Sargramostim/Tyrosinase Peptide | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439228","Day","C25301","The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.","Day | DAY | DAYS | Days | d | day | days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005479","Biomaterials","C16338","Any substance other than pharmacologic substance that can be applied in biomedical research or in constructing artificial organs, devices, or prostheses that can be introduced into the human body.","Biomedical Material | Biomaterial | Biomaterials",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0442504","Place","C25319","The particular portion of space occupied by a physical object or intended for a physical object.","Place | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522602","Indicator","C25180","An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","Indicator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704327","Bone Sarcoma","C9312","A sarcoma that arises from the bone.  Representative examples are osteosarcoma and chondrosarcoma.","Bone Sarcoma | Osseous Sarcoma | Sarcoma of Bone | Sarcoma of the Bone | Skeletal Sarcoma",,,,,,,,,,,,,,,"40491441","Sarcoma of bone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005953","Bone Marrow","C12431","The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.","Bone Marrow | BONE MARROW | Bone marrow | Bone marrow structure (body structure) | Marrow | Reticuloendothelial System, Bone Marrow | bone marrow | medulla ossea | medulla ossium",,,,,,,,,,,,,"UBERON:0002371","bone marrow","4029619","Bone marrow structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0262950","Bone","C12366","The structural organ comprised of specialized connective tissue that forms the skeletal components of the body.","Bone | BONE | Bone, NOS | Bones | Osseous | bone element",,,,,,,,,,,,,,,"4154333","Bone structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1268086","Body","C13041","The entire physical structure of an organism. It is composed of anatomic systems, regions, cavities, and spaces.","Body | BODY | Body structure (body structure) | Entire body as a whole (body structure) | Whole Body",,,,,,,,,,,,,,,"4048384","Body structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005961","Bone Marrow Transplantation","C15194","A procedure to replace diseased bone marrow with transplanted healthy bone marrow cells.","Bone Marrow Transplantation | BMT | BMT | BONE MARROW TRANSPLANT | Blood and Bone Marrow Transplant | Bone Marrow | Bone Marrow Grafting | Bone Marrow Transplant | Bone marrow transplant | Marrow Transplantation | bone marrow transplantation",,,,,,,,,,,,,,,"4028623","Transplantation of bone marrow",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0842093","Bone Marrow Stem Cell Transplantation","C25437","A procedure to replace diseased or pathologic bone marrow with transplanted healthy bone marrow stem cells.","Bone Marrow Stem Cell Transplantation | BMSCT | BMSCT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0728938","Partial","C25378","Being or affecting only a part of something.","Partial | PARTIAL | Partial (qualifier value)",,,,,,,,,,,,,,,"4116993","Partial",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205394","Other","C17649","Different than the one(s) previously specified or mentioned.","Other | OT | OTHER | Other or Miscellaneous",,,,,,,,,,,,,,,"9177","Other",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0337527","Brother","C25289","A male sibling.","Brother | ",,,,,,,,,,,,,,,"4322005","Brother",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006255","Bronchus","C12683","Tubular structure in continuation with the trachea, serving as air passage. It terminates in the lung (terminal bronchiole).","Bronchus | BRONCHUS | Bronchi | Bronchial structure (body structure) | bronchi | bronchial trunk | bronchus",,,,,,,,,,,,,"UBERON:0002185","bronchus","4317407","Bronchial structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006290","Bronchoscopy","C16366","Endoscopic examination of the tracheobronchial tree.","Bronchoscopy | bronchoscopy",,,,,,,,,,,,,,,"4032404","Bronchoscopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1511333","Bronchoscopist","C25753","A specially trained physician with expertise in the application of bronchoscopic techniques for diagnostic and treatment purposes. Types of procedures and interventions performed by a bronchoscopist include, but are not limited to, evaluation of the air passages of the lung (e.g. localization of tumor or areas of dysplasia) and other chest organs and tissues (e.g. ultrasound localization of mediastinal nodes); treatment of airway obstruction by tumors or foreign bodies, removal of secretions and bronchioalveolar lavage, laser therapy, cryotherapy, brachytherapy, and stenting.","Bronchoscopist | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511325","Breslow Thickness","C25734","The measurement in millimeters of the vertical thickness of primary cutaneous melanoma.  Breslow thickness is measured from the granular layer of the epidermis, or the ulcer base (if ulcerated), to the deepest tumor cells.  It is used in staging of melanoma. (NCI)","Breslow Thickness | BRESLOW DEPTH | Breslow | Breslow | Breslow Thickness (use thickest if multiple) | Breslow's Thickness | breslow thickness | breslow_thickness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439793","Severity","C25676","Used of the degree of something undesirable e.g. pain or weather; also, strictness.","Severity | SEV | Severity/Intensity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006104","Brain","C12439","An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium.","Brain | BRAIN | Brain structure (body structure) | Brain, NOS | CNS-Brain | Nervous System, Brain | brain",,,,,,,,,,,,,"UBERON:0000955","brain","4133034","Brain structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006098","Brachytherapy","C15195","A type of radiation therapy in which radioactive material is placed inside the body, into a tumor or body cavity.","Brachytherapy | BRACHYTHERAPY | Brachytherapy | Brachytherapy, NOS | Internal Radiation | Internal Radiation Brachytherapy | Internal Radiation Therapy | Internal Radiation Therapy | Radiation Brachytherapy | Radiation, Internal | brachytherapy | internal radiation | radiation brachytherapy",,,,,,,,,,,,,,,"40317890","Brachytherapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0237753","Number","C25337","A numeral or string of numerals expressing value, quantity, or identification.","Number | Numeric | Numerical | number | {Number}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1507394","Clinical Study Protocol","C25320","A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the study, but these could be represented in other protocol referenced documents.","Clinical Study Protocol | Clinical Trial Protocol | Full Protocol | Prot | Protocol | Protocol | Protocol Amendment | Study Protocol | StudyProtocol | protocol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1148475","Complementary and alternative medicine","C15178","A group of diverse medical and health care systems, practices, and products that are not presently considered to be part of conventional medicine. Complementary medicine as being used together with conventional medicine, whereas alternative medicine is used in place of conventional medicine. The National Center for Complementary and Alternative Medicine (NCCAM) groups CAM practices into four domains, recognizing there can be some overlap: mind-body medicine; biologically based practices, manipulative and body-based practices, and energy medicine. In addition, NCCAM studies CAM whole medical systems, which cut across all domains.","Complementary and Alternative Medicine | Alternative Therapy | CAM | CAM | Complementary and Integrative Health | alternative medicine | complementary and alternative medicine | complementary medicine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514391","Premalignant","C25624","Descriptive of a condition that may or is likely to become cancerous.","Premalignant | Pre-Malignant | Precancerous | precancerous | premalignant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0807321","Pathology Report","C28277","A report that provides a description of the gross and microscopic examination of the specimen and is used to make a diagnosis and to determine treatment. It defines which structures and organs of the body are involved by the tumor, verifies the primary site of the cancer and describes the extent to which it has spread.","Pathology Report | Histology Report | Histopathology Report | pathology report | pathology_report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0681850","Study Subject","C41189","A matter or an individual that is observed, analyzed, examined, investigated, experimented upon, or/and treated in the course of a particular study.","Study Subject | STUDY SUBJECT | SUBJECT | Study Participant | StudySubject | Subject",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527391","Chest","C25389","The anterior side of the thorax from the neck to the abdomen. The shape of the chest is often regarded as potential insight into a disease process, as in the case of barrel chest and respiratory dysfunction.","Chest | CHEST | breast | mammary part of chest | mammary region",,,,,,,,,,,,,"UBERON:0001443","breast","4199473","Thoracic structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0392920","Chemotherapy","C15632","The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","Chemotherapy | CHEMO | CHEMOTHERAPY | Chemo | Chemotherapy (NOS) | Chemotherapy, Cancer, General | chemotherapy",,,,,,,,,,,,,,,"4273629","Chemotherapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007996","Chemistry","C16414","The science of the composition, structure, properties, and reactions of matter, especially of atomic and molecular systems.","Chemistry | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007806","Cerebrospinal Fluid","C12692","The fluid that is contained within the brain ventricles, the subarachnoid space and the central canal of the spinal cord.","Cerebrospinal Fluid | CEREBROSPINAL FLUID | CSF | Cerebral Spinal Fluid | Cerebral spinal fluid | Cerebrospinal fluid | FLUID, CEREBROSPINAL | cerebral spinal fluid | cerebrospinal fluid",,,,,,,,,,,,,"UBERON:0001359","cerebrospinal fluid","4278997","Cerebrospinal fluid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007097","Carcinoma","C2916","A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","Carcinoma | CARCINOMA, MALIGNANT | Carcinoma, NOS | Epithelial Carcinoma | Epithelial tumor, malignant | Epithelioma Malignant | Malignant Epithelial Neoplasm | Malignant Epithelial Tumor | Malignant Epithelioma | Other Carcinoma | carcinoma | epithelial carcinoma","8010/3|8011/3","Carcinoma, NOS|Epithelioma, malignant",,,,,,,,,,,,,"36716620|37156933","Malignant epithelial neoplasm|Carcinoma",,,,,,,,,,,,,"--","--|--",,,,,,,,"--|--"
"C0023473","Chronic Myeloid Leukemia, BCR-ABL1 Positive","C3174","A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","Chronic Myeloid Leukemia, BCR-ABL1 Positive | BCR-ABL Positive Chronic Myelogenous Leukemia | CML | CML - Chronic Myelogenous Leukemia | Chronic Granulocytic Leukemia | Chronic Myelocytic Leukemia | Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia (CML) | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Myelogenous Leukemia, BCR::ABL1 Positive | Chronic Myelogenous Leukemias | Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, BCR::ABL1 Positive | Chronic myelogenous leukemia, BCR-ABL positive | Hematopoeitic - Chronic Myelocytic Leukemia (CML) | chronic granulocytic leukemia | chronic myelogenous leukemia | chronic myeloid leukemia","9863/3|9875/3","Chronic myeloid leukemia, NOS|Chronic myelogenous leukemia, BCR/ABL positive",,,,,,,,,,,,,"134603","Chronic myeloid leukemia",,,,,,,,,,,,,"--","--|--",,,,,,,,"--"
"C0023434","Chronic Lymphocytic Leukemia","C3163","The most common type of chronic lymphoid leukemia.  It comprises 90% of chronic lymphoid leukemias in the United States.  Morphologically, the neoplastic cells are small, round B-lymphocytes.  This type of leukemia is not considered to be curable with available therapy. (WHO, 2001)","Chronic Lymphocytic Leukemia | B Cell CLL | B Cell Chronic Lymphocytic Leukemia | B Cell Lymphocytic Leukemia | B-Cell CLL | B-Cell Chronic Lymphocytic Leukemia | B-Cell Chronic Lymphoid Leukemia | B-Cell Lymphocytic Leukemia | BCLL | CLL | CLL | Chronic B-Cell Lymphocytic Leukemia | Chronic Lymphocytic Leukemia (CLL) | Chronic lymphatic leukemia | Chronic lymphocytic leukemia | Chronic lymphocytic leukemia, NOS | Hematopoeitic - Chronic Lymphocytic Leukemia (CLL) | chronic lymphocytic leukemia",,,,,,,,,,,,,,,"4180093","B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0851135","Carcinoma In Situ","C2917","A malignant epithelial neoplasm which is confined to the epithelial layer without evidence of further tissue invasion.","Carcinoma In Situ | CARCINOMA, IN SITU, MALIGNANT | CIS | CIS | Carcinoma in situ | Carcinoma in situ, unspecified | Epithelial Tumor, In situ, Malignant | Intraepithelial Carcinoma | Non-invasive Carcinoma | Preinvasive | Preinvasive Cancer | carcinoma in situ | stage 0 disease","8010/2","Carcinoma in situ, NOS",,,,,,,,,,,,,"37156895|433435","Carcinoma in situ|Carcinoma in situ",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0700589","Contraception","C37932","The prevention of conception or impregnation by the use of devices or drugs or surgery.","Contraception | Birth Control | birth control",,,,,,,,,,,,,,,"4305272","Contraception care",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0947611","Comment","C25393","A written explanation, observation or criticism added to textual material.","Comment | Comments | Comments | Remark | Remarks | comment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009368","Colon","C12382","The part of the large intestine measured from the cecum to the rectum consisting of ascending, transverse, descending and sigmoid portions. The purpose of the colon is to remove water from digested food prior to excretion.","Colon | COLON | Colon structure (body structure) | Colon, NOS | LARGE INTESTINE, COLON | colon | large bowel",,,,,,,,,,,,,"UBERON:0001155","colon","4215634","Colon structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010709","Cyst","C2978","A sac-like closed membranous structure that may be empty or contain fluid or amorphous material.","Cyst | CYST | Cyst(s) | cyst",,,,,,,,,,,,,,,"4209224|4279699","Cyst|Cyst",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0010453","Culture","C16478","A pattern of learned beliefs, values, and behavior that are shared within a group. It includes language, styles of communication, practices, customs, and views on roles and relationships.","Culture | Cultural | Culturally | culture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516627","Clinical Research Associate","C25465","A person who is employed by a study sponsor or by a contract research organization (CRO), operates independently from the clinical study site and functions as a monitor, and/or auditor, and/or a project director within a particular trial or institution.","Clinical Research Associate | AdministrativeMemberCRA | CLINICAL RESEARCH ASSOCIATE | CRA | CRA | Research Associate | clinical research associate (CRA)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677874","Complete Remission","C4870","The disappearance of all signs of cancer in response to treatment.","Complete Remission | CR | CR | CR-Complete Response | Cancer in complete remission(finding) | Cancer-Free | Complete Response | Complete response | complete remission | complete response",,,,,,,,,,,,,,,"4014046","In full remission",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007124","Breast Ductal Carcinoma In Situ","C2924","A breast carcinoma entirely confined to the mammary ducts. It is also known as DCIS. There is no evidence of invasion of the basement membrane. Currently, it is classified into three categories: High-grade DCIS, intermediate-grade DCIS and low-grade DCIS. In this classification the DCIS grade is defined by a combination of nuclear grade, architectural growth pattern and presence of necrosis. The size of the lesion as well as the grade and the clearance margins play a major role in dictating the most appropriate therapy for DCIS.","Breast Ductal Carcinoma In Situ | Breast Ductal Carcinoma In Situ, NOS | Breast Ductal Carcinoma In Situ, Not Otherwise Specified | DCIS | DCIS, NOS | Ductal Breast Carcinoma In Situ | Ductal Breast Carcinoma In Situ | Ductal Carcinoma In Situ | Ductal Carcinoma In Situ (DCIS) | Ductal Carcinoma In Situ of Breast | Ductal Carcinoma In Situ of the Breast | Ductal carcinoma in situ | Intraductal Breast Carcinoma | Intraductal Carcinoma | Intraductal Carcinoma of Breast | Intraductal Carcinoma of the Breast | Intraductal carcinoma in situ of breast | Intraductal carcinoma in situ of unspecified breast | Non-Infiltrating Ductal Adenocarcinoma of Breast | Non-Infiltrating Ductal Adenocarcinoma of the Breast | Non-Infiltrating Ductal Breast Adenocarcinoma | Non-Infiltrating Ductal Breast Carcinoma | Non-Infiltrating Ductal Carcinoma of Breast | Non-Infiltrating Ductal Carcinoma of the Breast | Non-Infiltrating Intraductal Adenocarcinoma | Non-Infiltrating Intraductal Adenocarcinoma of Breast | Non-Infiltrating Intraductal Adenocarcinoma of the Breast | Non-Infiltrating Intraductal Breast Adenocarcinoma | Non-Infiltrating Intraductal Carcinoma | Non-Invasive Ductal Adenocarcinoma of Breast | Non-Invasive Ductal Adenocarcinoma of the Breast | Non-Invasive Ductal Breast Adenocarcinoma | Non-Invasive Ductal Breast Carcinoma | Non-Invasive Ductal Carcinoma of Breast | Non-Invasive Ductal Carcinoma of the Breast | Non-Invasive Intraductal Adenocarcinoma of Breast | Non-Invasive Intraductal Adenocarcinoma of the Breast | Non-Invasive Intraductal Breast Adenocarcinoma | ductal carcinoma in situ | intraductal carcinoma","8500/2","Intraductal carcinoma, noninfiltrating, NOS",,,,,,,,,,,,,"4001670","Ductal carcinoma in situ of breast",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0337552","Daughter","C25165","A female human offspring.","Daughter | ",,,,,,,,,,,,,,,"4308126","Natural daughter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1511726","Data","C25474","A collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn.","Data | Data Point | Datum | data",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0814048","Cytometry","C25386","The measurement of physical and /or chemical characteristics of cells, or, by extension, of other biological particles.","Cytometry | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010819","Cytology","C16491","The light microscopic study of normal and abnormal cells in fine needle aspirates (FNAs), body cavity fluids, and smears.","Cytology | Histology, Cytology | cytology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010802","Cytogenetics","C16487","The branch of biology that studies the cellular aspects of heredity, especially the chromosomes. Includes the study of disease states caused by numerical and structural chromosome abnormalities.","Cytogenetics | Cytogenetic | cytogenetics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0553652","Cystoscopy","C16482","Endoscopic examination of the urinary bladder or urethra.","Cystoscopy | CS | CYSTOSCOPY | cystoscopy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010651","Cystectomy","C15217","The surgical removal of the urinary bladder; or the surgical removal of a cyst..","Cystectomy | cystectomy",,,,,,,,,,,,,,,"4029571","Bladder excision",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0678257","Description","C25365","A written or verbal account, representation, statement, or explanation of something.","Description | DESCR | Desc | Description  | Descriptive | Descriptor | description",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011065","Dead","C28554","The cessation of life.","Dead | DEAD | DEATH | DIED | Death | Death | Death (event) | Death NOS | Deceased | Died | EXPIRED | EXPIRED/DEATH | Loss of Life | Patient Deceased | dead | deceased",,,,,,,,,,,,,,,"434489","Dead",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0012739","Disseminated Intravascular Coagulation","C2992","A pathological process where the blood starts to coagulate throughout the whole body. This depletes the body of its platelets and coagulation factors, and there is an increased risk of hemorrhage.","Disseminated Intravascular Coagulation | Consumptive Coagulopathy | DIC | DIC | Disseminated Intravascular Coagulation (DIC) | Disseminated intravascular coagulation",,,,,,,,,,,,,,,"436093","Disseminated intravascular coagulation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011980","Diaphragm","C12702","Fibromuscular tissue that separates the thoracic from the abdominal cavity. It increases the volume of the thoracic cavity through contractions, thus facilitating respiration.","Diaphragm | DIAPHRAGM | Diaphragm structure (body structure) | MUSCLE, DIAPHRAGM | diaphragm | diaphragm muscle | diaphragm of thorax | thoracic diaphragm","C49.3","Diaphragm",,,,,,,,,,,"UBERON:0001103","diaphragm","4236847","Diaphragm structure",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0011900","Diagnosis","C15220","The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","Diagnosis | DIAGNOS | DIAGNOSIS | Diagnosed | Diagnostic | Diagnostic intent | Dx | diagnose | diagnosis",,,,,,,,,,,,,,,"4234469","Diagnosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013604","Edema","C3002","Accumulation of an excessive amount of fluid in cells or intercellular tissues.","Edema | EDEMA | Swelling/ Edema | edema",,,,,,,,,,,,,,,"4196943|433595","Edema|Edema",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C4227552","Lymphoma","C3208","A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","Lymphoma | LYMPHOMA, MALIGNANT | Lymphoma (Hodgkin and Non-Hodgkin) | Lymphoma (Hodgkin's and Non-Hodgkin's) | Lymphoma, NOS | Lymphomatous | Malignant Lymphoma | lymphoma","9590/3","Malignant lymphoma, NOS",,,,,,,,,,,,,"432571","Malignant lymphoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0024235","Lymphatic System","C12746","The anatomic system that includes the lymph nodes, lymphoid tissues in various organs (spleen, thymus, tonsils, gastrointestinal tract), and lymphatic vessels.  It is part of the immune system that offers protection against infections.","Lymphatic System | Lymphatic | Lymphatics | Lymphatics | Lymphoid System | Reticuloendothelial System, Lymphatic System | lymphatic system",,,,,,,,,,,,,,,"4233942","Structure of lymphatic system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024109","Lung","C12468","One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.","Lung | LUNG | Lung structure (body structure) | Lung, NOS | Lungs | Respiratory System, Lung | lung | pulmo",,,,,,,,,,,,,"UBERON:0002048","lung","4213162","Lung structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0921005","Lobule","C12990","A subdivision of a lobe.","Lobule | lobule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025329","Menstrual Cycle","C16838","The Menstrual Cycle involves regularly recurring hormonal changes and physiologic endometrial changes during the reproductive period in human females, and some primates, and culminates in partial sloughing of the endometrium (menstruation) in the absence of fertilization. For most women, one cycle takes 28 days. (NCI)","Menstrual Cycle | menstrual cycle",,,,,,,,,,,,,,,"35626259","Onset of menstrual cycle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025344","Menstruation","C3232","The normal physiologic discharge through the vagina of blood and mucosal tissues from the nonpregnant uterus.","Menstruation | Menses | Menses | Menstrual | menstrual period | menstruation",,,,,,,,,,,,,,,"4088436","Menstruation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0680022","Member","C25368","One of the persons who compose a social group, especially an individual who has joined and participates in a group organization.","Member | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025202","Melanoma","C3224","A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","Melanoma | MELANOMA, MALIGNANT | Malignant Melanoma | Melanoma, NOS | melanoma","8720/3","Malignant melanoma, NOS",,,,,,,,,,,,,"37151860|4162276","Malignant melanoma|Malignant melanoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0025065","Mediastinoscopy","C16829","A surgical procedure during which a mediastinoscope is inserted into the thorax to view the its contents for diagnostic and/or therapeutic purposes.","Mediastinoscopy | Diagnostic Mediastinoscopy | Endoscopic Exploration of Mediastinum | MEDIASTINOSCOPY | mediastinoscopy",,,,,,,,,,,,,,,"4128302","Mediastinoscopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3463824","Myelodysplastic Syndrome","C3247","A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","Myelodysplastic Syndrome | Dysmyelopoietic Syndrome | Hematopoeitic - Myelodysplastic Syndrome (MDS) | MDN | MDS | MDS | Myelodysplasia | Myelodysplastic Neoplasm | Myelodysplastic Syndrome/Neoplasm | Myelodysplastic Syndromes | Myelodysplastic syndrome | Myelodysplastic syndrome, NOS | Myelodysplastic syndrome, unspecified | Oligoblastic Leukemia | Preleukemia | Smoldering Leukemia | myelodysplasia | myelodysplastic syndromes | preleukemia | smoldering leukemia",,,,,,,,,,,,,,,"138994|4028877","Myelodysplastic syndrome (clinical)|Myelodysplastic neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0226896","Oral Cavity","C12421","The cavity located at the upper end of the alimentary canal, behind the teeth and gums that is bounded on the outside by the lips, above by the hard and soft palates and below by the tongue.","Oral Cavity | BODY CAVITY, ORAL | Buccal | Buccal Cavity | Buccal cavity | Mouth | Mouth | Mouth, NOS | ORAL CAVITY | Oral | Oral cavity structure (body structure) | Orally | buccal cavity | cavity of mouth | mouth | oral cavity | regio oralis",,,,,,,,,,,,,"UBERON:0000167 || UBERON:0000165","mouth || oral cavity","4253672","Oral cavity structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026591","Mother","C25189","A female parent.","Mother | MOTHER",,,,,,,,,,,,,,,"4248584","Mother",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0700619","Science of Morphology","C17943","The science of the form and structure of organisms (plants, animals, and other forms of life), or of their parts, and the study or science of the same.  In pathology, the specific appearance of cells and tissues (normal and abnormal) under the light or electron microscope.","Morphology | MORPHOLOGY | Morph | morphology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026249","Mitogens","C660","A soluble substance, usually a protein, that induces mitosis in resting cells, thereby causing cell proliferation.","Mitogen | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513276","Micrometastasis","C38486","Metastasis in the form of small clusters of malignant cells identifiable only under the microscope.","Micrometastasis | Micromet | Micrometastases | Micromets | micrometastases",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027627","Metastasis","C19151","The spread or migration of cancer cells from one part of the body (the organ in which it first appeared) to another. The secondary tumor contains cells that are like those in the original (primary) tumor.","Metastasis | Metastasize | Tumor Cell Migration | metastasis | metastasize",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025519","Intermediary Metabolic Process","C21198","All the reactions in an organism concerned with storing and generating metabolic energy and with the biosynthesis of low-molecular weight compounds, energy-storage compounds, and basic materials needed for important life processes. It does not include nucleic acid and protein synthesis.","Intermediary Metabolic Process | Intermediary Metabolism | Metabolism | Metabolism | metabolism",,,,,,,,,,,,,,,"4172770","General metabolic function",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028109","Nipple","C12299","The pigmented protuberance on the surface of the breast through which milk is drawn from the breast.","Nipple | NIPPLE | nipple",,,,,,,,,,,,,,,"4082856","Nipple structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0442874","Neuropathy","C4731","A disorder affecting the cranial nerves or the peripheral nervous system. It manifests with pain, tingling, numbness, and muscle weakness. It may be the result of physical injury, toxic substances, viral diseases, diabetes, renal failure, cancer, and drugs.","Neuropathy | neuropathy",,,,,,,,,,,,,,,"4301699","Neuropathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027763","Nervous System","C12755","The entire nerve apparatus, composed of a central part, the brain and spinal cord, and a peripheral part, the cranial and spinal nerves, autonomic ganglia, and plexuses.","Nervous System | Body System, Neurologic | Nervous system, NOS | Neurologic | Neurologic Body System | Neurologic Organ System | Organ System, Neurologic | nervous system",,,,,,,,,,,,,,,"4096246","Structure of nervous system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027740","Nerve","C12466","Part of the peripheral nervous system composed of bundles of nerve fibers running to various organs and tissues of the body using chemical and electrical signals to transmit sensory and motor information from one body part to another.","Nerve | NERVE | nerve",,,,,,,,,,,,,,,"4147841","Nerve structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027530","Neck","C13063","The region that connects the head to the rest of the body.","Neck | Cervical | NECK | Neck, NOS | neck",,,,,,,,,,,,,"UBERON:0000974","neck","4260843","Neck structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026764","Plasma Cell Myeloma","C3242","A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","Multiple Myeloma | Kahler disease | MYELOMA, PLASMA CELL, MALIGNANT | Multiple Myeloma | Multiple Myeloma/Plasma Cell Myeloma | Multiple myeloma | Myeloma | Myeloma | Myeloma, NOS | Myelomatosis | Plasma Cell Myeloma | Plasma Cell Myeloma | Plasma Cell Myeloma/Multiple Myeloma | Plasma cell myeloma | multiple myeloma | myeloma | myelomatosis | plasma cell myeloma",,,,,,,,,,,,,,,"37151852|437233","Plasma cell myeloma|Multiple myeloma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1367456","ACP3 Gene","C26507","This gene is involved in the dephosphorylation of a wide range of substrates under acidic conditions including alkyl, aryl, and acyl orthophosphate monoesters, phosphorylated proteins and phospholipids.","ACP3 Gene | ACP3 | ACPP | ACPP Gene | ACPP Gene | Acid Phosphatase 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028677","Nursing","C16926","Nursing encompasses autonomous and collaborative care of individuals of all ages, families, groups and communities, sick or well and in all settings. Nursing includes the promotion of health, prevention of illness, and the care of ill, disabled and dying people. Advocacy, promotion of a safe environment, research, participation in shaping health policy and in patient and health systems management, and education are also key nursing roles. (ICN 2002)","Nursing | Discipline of Nursing | Nursing Field | Nursing Profession",,,,,,,,,,,,,,,"36717536","Nursing",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007131","Lung Non-Small Cell Carcinoma","C2926","A group of at least three distinct histological types of lung cancer, including non-small cell squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Non-small cell lung carcinomas have a poor response to conventional chemotherapy.","Lung Non-Small Cell Carcinoma | NSCLC | NSCLC | NSCLC - Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer NOS | Non-Small Cell Cancer of Lung | Non-Small Cell Cancer of the Lung | Non-Small Cell Carcinoma of Lung | Non-Small Cell Carcinoma of the Lung | Non-Small Cell Lung Cancer | Non-Small Cell Lung Carcinoma | Non-Small Cell Lung Carcinoma | Non-small cell lung cancer, NOS | non-small cell lung cancer",,,,,,,,,,,,,,,"4115276","Non-small cell lung cancer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1527124","Nottingham Score","C25595","A numeric representation combining three histologic reporting elements, tubule formation, nuclear pleomorphism and mitotic count, to determine the grade of breast cancer. The Nottingham Score is a factor in determining the Nottingham Prognostic Index.","Nottingham Score | Modified Bloom-Richardson-Elston Grading System | Nottingham Histologic Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028429","Nose","C12756","A structure of special sense serving as an organ of the sense of smell and as an entrance to the respiratory tract.","Nose | NOSE | Nasal structure (body structure)",,,,,,,,,,,,,,,"4164276","Nasal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028259","Nodule","C3280","A small lump, swelling or collection of tissue.","Nodule | NODULE | nodule",,,,,,,,,,,,,,,"4101098","Nodule",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518544","Off Treatment","C25601","When a patient is not receiving therapy they are considered off treatment.  In clinical trials, a dosing schedule may require a patient to stop medication for a period of time, then resume, such as 28 days on and 7 days off.","Off Treatment | Off-Treatment | off treatment | off_treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4228768","Bone Paget Disease","C3292","A disease of bone that initially results in the excessive resorption of bone (by osteoclasts) followed by the replacement of normal bone marrow with vascular and fibrous tissue.","Bone Paget Disease | Bone Paget's Disease | Osseous Paget's Disease | Osteitis Deformans | Paget disease of bone | Paget's Disease | Paget's Disease | Paget's Disease of Bone | Paget's Disease of the Bone | Pagets Disease (Bone) | osteitis deformans",,,,,,,,,,,,,,,"75910","Osteitis deformans",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029939","Ovary","C12404","One of the paired female reproductive glands containing the ova or germ cells; the ovary's stroma is a vascular connective tissue containing numbers of ovarian follicles enclosing the ova.","Ovary | Genital System, Female, Ovary | OVARY | Ovarian structure (body structure) | Ovaries | Ovary, NOS | animal ovary | female gonad | female organism genitalia gonad | female organism genitalia gonada | female organism reproductive system gonad | female organism reproductive system gonada | female reproductive system gonad | female reproductive system gonada | genitalia of female organism gonad | genitalia of female organism gonada | gonad of female organism genitalia | gonad of female organism reproductive system | gonad of female reproductive system | gonad of genitalia of female organism | gonad of reproductive system of female organism | gonada of female organism genitalia | gonada of female organism reproductive system | gonada of female reproductive system | gonada of genitalia of female organism | gonada of reproductive system of female organism | ovary | ovum-producing ovary | reproductive system of female organism gonad | reproductive system of female organism gonada",,,,,,,,,,,,,"UBERON:0000992","ovary","4049448","Ovarian structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205494","Neurologic","C25262","Pertaining to nerves or the nervous system.","Neurologic | Neuro | Neurological | neurologic",,,,,,,,,,,,,,,"4002560","Neurologic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0521367","Oropharynx","C12762","The part of the pharynx between the soft palate and the upper portion of the epiglottis.","Oropharynx | OROPHARYNX | Oropharyngeal structure (body structure) | Oropharynx, NOS | oral part of pharynx | oropharynx",,,,,,,,,,,,,"UBERON:0001729","oropharynx","4151149","Oropharyngeal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039476","Temperature","C25206","A measure of the average kinetic energy of a system of particles. Temperature may be quantified, in the context of thermodynamics, as the potential of one system to transfer thermal energy to another system until both systems reach a state of thermal equilibrium.","Temperature | TEMP | Temperatures (Optional) | temperature",,,,,,,,,,,,,,,"36716470|45771331","Temperature|Temperature",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1522486","Professional Organization or Group","C19711","A formal group of people that exists to further a particular profession.","Professional Organization or Group | ORG | Organization | Organization | Organizational | Other Agency or Organization | Outside Bodies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029189","Orchiectomy","C15288","Surgical removal of one or both testicles.","Orchiectomy | Castration | Male Castration | Male Gonadectomy | Testis Removed | orchidectomy | orchiectomy",,,,,,,,,,,,,,,"4341536","Total orchidectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030797","Pelvis","C12767","The bony, basin-shaped structure formed by the hipbones and the base of the backbone supporting the lower limbs in humans.","Pelvis | BODY CAVITY, PELVIC | PELVIS | Pelvic | Pelvic Cavity | Pelvic Region | Pelvis, NOS | lesser pelvis | pelvic | pelvic region | pelvic region of trunk | pelvis | pelvis region | true pelvis",,,,,,,,,,,,,"UBERON:0001270 || UBERON:0002355","pelvic region of trunk","4044034","Pelvic region",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1335499","Progressive Disease","C35571","A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","Progressive Disease | Disease Progression | PD | PD | PD-Progressive Disease | PROGRESSIVE DISEASE | Progressive disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518999","Peripheral Blood Stem Cell","C12946","An immature (progenitor) cell circulating in the peripheral blood.  It has the capacity for replication and differentiation to mature blood cells.","Peripheral Blood Stem Cell | PBSC | PBSC | PERIPHERAL BLOOD STEM CELL | Peripheral Blood Stem Cells | Peripheral Stem Cells | peripheral stem cell",,,,,,,,,,,,,,,"4305523","Peripheral blood stem cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030705","Patient","C16960","A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","Patient | LAY USER/PATIENT | PATIENT | PT | Patients | patient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030664","Pathology","C18189","The medical science, and specialty practice, concerned with all aspects of disease, but with special reference to the essential nature, causes, and development of abnormal conditions, as well as the structural and functional changes that result from the disease processes. Informally used to mean the result of such an examination.","Pathology | Pathological",,,,,,,,,,,,,,,"4215127","Pathology",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334866","Pathologist","C17723","Any physician whose career is devoted to the study of pathology.","Pathologist | PATHOLOGIST | pathologist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032584","Polyp","C3340","A usually exophytic mass attached to the underlying tissue by a broad base or a thin stalk.  Polyps can be neoplastic or non-neoplastic.  Neoplastic polyps usually represent proliferations of the epithelium, and are commonly seen in the gastrointestinal tract.  Polyps of the gastrointestinal tract are often called adenomas, are associated with dysplasia, and may eventually transform into carcinomas.  Non-neoplastic polyps may be inflammatory, degenerative, or the result of malformations.","Polyp | polyp",,,,,,,,,,,,,,,"4187628|4209223","Polyp|Polyp",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0032225","Pleura","C12469","The tissue that lines the wall of the thoracic cavity and the surface of the lungs.","Pleura | PLEURA | PLEURAL TISSUE | Pleura, NOS | Pleural | Pleural Tissue | pleura | wall of pleural sac",,,,,,,,,,,,,"UBERON:0000977","pleura","4150673","Pleural structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL473981","Placebo","C753","An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","Placebo | PLCB | placebo | placebo therapy | sham therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0994475","Pill Dosage Form","C25394","A solid composed of a small, round object composed of active and/or inert ingredient(s).","Pill Dosage Form | PILL | Pill | Pill Dose Form | Pills",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031831","Physician","C25741","A doctor; a person who has been educated, trained, and licensed to practice the art and science of medicine; a practitioner of medicine, as contrasted with a surgeon.","Physician | DR | Doctor | Medical Doctor | Medical Doctors | PHYSICIAN | physician",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031153","Peritoneum","C12770","The tissue that lines the wall of the abdominal cavity, intestine, mesentery, and pelvic organs. It consists of the parietal peritoneum and the visceral peritoneum.","Peritoneum | Human Peritoneal Membrane | PERITONEUM | Peritoneum, NOS | peritoneum",,,,,,,,,,,,,"UBERON:0002358","peritoneum","4035784","Peritoneum (serous membrane) structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0597198","Performance","C25361","A manner of functioning or operating.","Performance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1280477","Progress","C25630","The act of moving forward toward a goal.","Progress | ",,,,,,,,,,,,,,,"4090959","Progressing to",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0521210","Polypectomy","C25349","Complete or partial removal of a polypoid lesion from the mucosal surface.","Polypectomy | POLYPECTOMY",,,,,,,,,,,,,,,"4217766","Resection of polyp",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0138741","prostate specific antigen, human","C17525","Prostate-specific antigen (261 aa, ~29 kDa) is encoded by the human KLK3 gene. This protein plays a role in both proteolysis and seminal fluid liquefaction.","Prostate-Specific Antigen | Antigen, Prostate-Specific | EC 3.4.21.77 | Gamma-Seminoprotein | KLK3 | Kallikrein-3 | P-30 Antigen | PSA | PSA | Prostate Specific Antigen | Prostate Specific Antigen Preproprotein | Prostate-Specific Antigen (PSA) | Semenogelase | Seminin | prostate-specific antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033684","Protein","C17021","A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence.","Protein | Protein (NOS) | Proteins | protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033573","Prostatectomy","C15307","Surgical removal of part or all of the prostate.","Prostatectomy | prostatectomy",,,,,,,,,,,,,,,"4235738","Prostatectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033572","Prostate Gland","C12410","The walnut shaped accessory sex gland of the male reproductive system. It is located in the pelvis just below the bladder, surrounding the prostatic part of the urethra. The prostate gland secretes a fluid which is part of the semen.","Prostate Gland | GLAND, PROSTATE | Genital System, Male, Prostate | PROSTATE GLAND | Prostate | Prostate | Prostate gland | Prostatic Gland | Prostatic structure (body structure) | male prostate | prostate | prostate gland",,,,,,,,,,,,,"UBERON:0002367","prostate gland","4165732","Prostatic structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034599","Radiology","C17059","The branch of medical science dealing with the medical use of X-rays or other penetrating radiation.","Radiology | Radiologic | Radiology, General | radiology",,,,,,,,,,,,,,,"4192877","Radiology - specialty",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0260194","Radiologist","C17824","A physician who specializes in the diagnostic and/or therapeutic uses of radiation.","Radiologist | RADIOLOGIST | radiologist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1265611","Quantity","C25256","How much there is of something that you can measure; the total amount or number.","Quantity | Amount | How Many | How Much | quantity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0080103","Relative","C21480","A person related by blood or marriage.","Relative | RELATIVE | Relation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514821","Registration","C25646","The act of listing or recording officially; officially qualified or enrolled.","Registration | Registered | Registering | registration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034896","Rectum","C12390","The terminal portion of the gastrointestinal tract, extending from the rectosigmoid junction to the anal canal.","Rectum | Hemorrhoidal | LARGE INTESTINE, RECTUM | RECTUM | Rectum structure (body structure) | Rectum, NOS | rectum | terminal portion of intestine",,,,,,,,,,,,,"UBERON:0001052","rectum","4144541","Rectum structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL317975","Renal","C25225","Of or pertaining to the kidney.","Renal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0599161","Reverse Transcriptase-Polymerase Chain Reaction","C18136","A laboratory procedure in which an RNA strand is first transcribed into a DNA complement and then subjected to PCR amplification. Transcribing an RNA strand into a DNA complement is termed reverse transcription and is done by the enzyme reverse transcriptase.","Reverse Transcriptase-Polymerase Chain Reaction | REVERSE TRANSCRIPTASE PCR | RT-PCR | RT-PCR | Reverse Transcription Polymerase Chain Reaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0871261","Response process","C25755","Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","Response | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0728940","Excision","C15232","The surgical removal of a lesion, often as part of a biopsy and with healthy margins.","Excision | Abscission | EXCISION | Excisional | Extirpation | Surgical Removal | excision",,,,,,,,,,,,,,,"4279903","Excision",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0677944","Sentinel Lymph Node","C12947","The first lymph node that is affected by cancer spread from the primary site.  Sentinel lymph node biopsy is part of the staging work-up to determine early metastasis to regional lymph nodes in patients with breast carcinoma or melanoma.","Sentinel Lymph Node | SLN | Sentinel Node | Sentinel Node | sentinel lymph node",,,,,,,,,,,,,,,"37151986","Sentinel lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522472","section sample","C25668","A very thin slice (of tissue or mineral or other substance) for examination under a microscope.","Section | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677946","Stable Disease","C18213","A disease that is neither decreasing nor increasing in extent or severity.","Stable Disease | SD | SD | SD-Stable Disease | Stable disease | stable disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0149925","Lung Small Cell Carcinoma","C4917","A highly aggressive carcinoma with neuroendocrine differentiation that arises from the lung. It is characterized by the presence of malignant small cells and more than 10 mitoses per 2 mm2. Necrosis is frequently seen. Metastatic disease is usually present at the time of diagnosis.","Lung Small Cell Carcinoma | Lung Oat Cell Carcinoma | Lung Small Cell Neuroendocrine Carcinoma | Oat Cell Carcinoma of Lung | Oat Cell Carcinoma of the Lung | Oat Cell Lung Carcinoma | SCLC | Small Cell Carcinoma of Lung | Small Cell Carcinoma of the Lung | Small Cell Lung Cancer | Small Cell Lung Carcinoma | Small Cell Lung Carcinoma | Small Cell Neuroendocrine Carcinoma of Lung | Small Cell Neuroendocrine Carcinoma of the Lung | Small cell lung cancer | small cell lung cancer",,,,,,,,,,,,,,,"4110591|4112739","Small cell carcinoma of lung|Oat cell carcinoma of lung",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1261473","Sarcoma","C9118","A usually aggressive malignant neoplasm of the soft tissue or bone. It arises from muscle, fat, fibrous tissue, bone, cartilage, and blood vessels. Sarcomas occur in both children and adults. The prognosis depends largely on the degree of differentiation (grade) of the neoplasm. Representative subtypes are liposarcoma, leiomyosarcoma, osteosarcoma, and chondrosarcoma.","Sarcoma | Mesenchymal Tumor, Malignant | Mesenchymal tumor, malignant | SAR | SARCOMA, MALIGNANT | Sarcoma of Soft Tissue and Bone | Sarcoma of the Soft Tissue and Bone | Sarcoma, NOS | Sarcoma, Not Otherwise Specified | sarcoma","8800/3","Sarcoma, NOS",,,,,,,,,,,,,"4311439","Sarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0085405","Salvage Therapy","C15359","Performing a salvage procedure is the last resort. The clinical situation involves either ongoing life support measures, life support measures for more than 60 seconds during the prior 10 minutes, or unanticipated institution of extracorporeal circulatory support. (ACC)","Salvage Therapy | SALVAGE | Salvage | salvage therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337514","Sister","C25680","A female sibling.","Sister | ",,,,,,,,,,,,,,,"4101245","Sister",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037047","Sibling","C25204","A person's brother or sister.","Sibling | SIBLING | Sib | Siblings | Siblings | sibling",,,,,,,,,,,,,,,"4292398","Sibling",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037004","Shoulder","C25203","The region of the body between the neck and the upper arm.","Shoulder | SHOULDER | shoulder | shoulder region",,,,,,,,,,,,,"UBERON:0001467","shoulder","4061541","Shoulder region structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1335957","Left Ventricular Fractional Shortening","C38020","The fraction of the left ventricle diastolic dimension that is lost during systole; the measurement is calculated using the following formula: (end-diastolic dimension - end-systolic dimension) / end-diastolic dimension; the quotient is then multiplied by one hundred to be expressed as a percent.","Left Ventricular Fractional Shortening | LVFS | Shortening Fraction | Shortening Fraction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519267","Serum Immunologic","C25675","Pertaining to serologic tests to determine the presence of immunologic factors or evidence of an immune response.","Serum Immunologic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162801","Sequence Analysis","C17565","The determination of the sequence of component residues in a macromolecule, e.g. amino acids in a protein or nucleotide bases in DNA/RNA or the computational analysis performed to determine the similarities between nonidentical proteins or molecules of DNA or RNA.","Sequence Analysis | Sequencing | Sequencing, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021852","Small Intestine","C12386","The section of the intestines between the pylorus and cecum. The small intestine is approximately 20 feet long and consists of the duodenum, the jejunum, and the ileum. Its main function is to absorb nutrients from food as the food is transported to the large intestine.","Small Intestine | Gastrointestinal Tract, Small Intestine | SMALL INTESTINE | Small Bowel | Small intestine | Small intestine, NOS | Structure of small intestine (body structure) | small bowel | small intestine",,,,,,,,,,,,,"UBERON:0002108","small intestine","4146765","Structure of small intestine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1123023","Skin","C12470","An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages.","Skin | Human Skin | Integument | SKIN | Skin structure (body structure) | Skin, NOS | Skin, total | entire skin | skin of body | skin organ",,,,,,,,,,,,,"UBERON:0000014 || UBERON:0002097","skin of body","4219601","Skin structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037995","Splenectomy","C15328","Surgical removal of part or all of the spleen.","Splenectomy | splenectomy",,,,,,,,,,,,,,,"4125482","Splenectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037993","Spleen","C12432","An organ that is part of the hematopoietic and immune systems. It is composed of the white pulp and the red pulp and is surrounded by a capsule. It is located in the left hypochondriac region. Its functions include lymphocyte production, blood cell storage, and blood cell destruction.","Spleen | Reticuloendothelial System, Spleen | SPLEEN | Splenic | Splenic structure (body structure) | spleen | splenic",,,,,,,,,,,,,"UBERON:0002106","spleen","4302605","Splenic structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037925","Spinal Cord","C12464","The elongated, approximately cylindrical part of the central nervous system of vertebrates that lies in the vertebral canal and from which the spinal nerves emerge.","Spinal Cord | Medulla Spinalis | SPINAL CORD | Spinal cord | Spinal cord structure (body structure) | spinal cord",,,,,,,,,,,,,"UBERON:0002240","spinal cord","4099912","Spinal cord structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037683","Son","C25205","A male human offspring.","Son | ",,,,,,,,,,,,,,,"4279757","Son",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2211494","Soft Tissue Sarcoma","C9306","A malignant neoplasm arising from muscle tissue, adipose tissue, blood vessels, fibrous tissue, or other supportive tissues excluding the bones.","Soft Tissue Sarcoma | Connective Tissue Sarcoma | Non-Rhabdo. soft tissue sarcoma | Non-Rhabdomyosarcoma soft tissue sarcoma, NOS | Sarcoma of Soft Tissue | Sarcoma of the Soft Tissue | Soft tissue sarcoma | soft tissue sarcoma",,,,,,,,,,,,,,,"40486638|4314042","Sarcoma of connective tissue|Sarcoma of soft tissue",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0453996","Tobacco Smoking","C17934","The act of puffing and/or inhaling smoke from a lit cigarette, cigar, or pipe.","Tobacco Smoking | Smoking | Smoking | Tobacco, Smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008972","Clinical Research","C15206","Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research.","Clinical Study | CLINICAL STUDY | Clinical Research | Clinical Studies | Study | clinical study | study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0185792","Sternotomy","C25220","Incision into or through the sternum.","Sternotomy | ",,,,,,,,,,,,,,,"4100637","Sternotomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038128","Stain","C841","A dye or other coloring material that is used in microscopy to make structures visible.","Stain | ",,,,,,,,,,,,,,,"4246690","Stain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1300072","Neoplasm Stage","C16899","The extent of a cancer in the body.","Neoplasm Stage | STAGE | Stage | Stage | Tumor Stage | stage",,,,,,,,,,,,,,,"4161178","Tumor stage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4014771","Splenomegaly","C3384","Abnormal enlargement of the spleen.","Splenomegaly | splenomegaly",,,,,,,,,,,,,,,"200527","Splenomegaly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0582175","Surgeon","C18071","A physician who treats disease, injury, and deformity by operation or manipulation that involves gaining access to the patient's body by incisional access.","Surgeon | surgeon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521721","Support","C37902","Moral, psychological, physical, or financial aid or assistance; approval.","Support | Supported | Supporting | Supportive | Supportive - procedure intent",,,,,,,,,,,,,,,"4161275","Supportive - procedure intent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242295","Dietary Supplement","C1505","Oral preparations containing dietary ingredient(s) intended to supplement the diet.  Dietary ingredients include vitamins, minerals, herbs, amino acids, extracts and metabolites.","Dietary Supplement | DIETARY SUPPLEMENT | Dietary Supplements | Nutritional Supplement | Supplement | Supplements | Supplements | dietary supplement | nutritional supplement | supplemental nutrition",,,,,,,,,,,,,,,"4190196","Nutritional supplement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1515021","Subgroup","C25693","A subdivision of a larger group with members often exhibiting similar characteristics.","Subgroup | Subset",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001779","Age","C25150","How long something has existed; elapsed time since birth.","Age | AGE | Aged | Chronological Age | Postnatal Age | age",,,,,,,,,,,,,,,"4314456","Current chronological age",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042567","Vertebrata","C14282","A subphylum of animals consisting of those having a bony or cartilaginous vertebral column.","Vertebrata | Vertebrate | Vertebrate | Vertebrate Animals | Vertebrates",,,,,,,,,,,,,,,"4308966","Subphylum Vertebrata",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0280988","Macrophage Colony-Stimulating Factor/Monoclonal Antibody R24","C15537","Surgical opening of the mediastinum.","Macrophage Colony-Stimulating Factor/Monoclonal Antibody R24 | M-CSF/MOAB R24 | Thoracotomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039989","Thoracoscopy","C17196","Endoscopic examination of the thoracic cavity.","Thoracoscopy | Pleuroscopy | thoracoscopy",,,,,,,,,,,,,,,"4032774","Thoracoscopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0700621","Tamoxifen Citrate","C855","The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC.","Tamoxifen Citrate | (Z)-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine 2-Hydroxy-1,2,3-propanetricarboxylate | (Z)-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine citrate | 1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene Citrate | Apo-Tamox | Clonoxifen | Dignotamoxi | Ebefen | Emblon | Estroxyn | Fentamox | Gen-Tamoxifen | Genox | ICI 46,474 | ICI 46474 | ICI-46474 | ICI46474 | Jenoxifen | Kessar | Ledertam | Lesporene | Nolgen | Noltam | Nolvadex | Nolvadex-D | Nourytam | Novo-Tamoxifen | Novofen | Noxitem | Oestrifen | Oncotam | PMS-Tamoxifen | Soltamox | TAM | TAMOXIFEN CITRATE | Tamax | Tamaxin | Tamifen | Tamizam | Tamofen | Tamoxasta | Tamoxifen | Tamoxifen citrate | Tamoxifeni Citras | Zemide | tamoxifen citrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515119","Systemic Therapy","C15698","Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.","Systemic Therapy | systemic therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332835","Graft","C12981","Tissue or organ transplanted from a donor to a recipient.","Graft | Transplant | Transplant | graft",,,,,,,,,,,,,,,"4088199","Transplant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522702","Chromosomal Translocation Process","C25756","Any type of genetic recombination involving exchange of DNA between non-homologous chromosomes, which often occurs as the result of non-homologous end-joining of broken DNA strands. Chromosomal translocation is involved in repairing broken DNA and in maintaining cell viability at the expense of long term genomic stability. This process is is associated with particular types of leukemia, infertility and Down Syndrome.","Chromosomal Translocation Process | Translocation | Translocation | translocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4013416","Diabetes Mellitus","C2985","A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization.","Diabetes Mellitus | DM | Diabetes | Diabetes mellitus | Diabetes_Mellitus | diabetes | diabetes mellitus",,,,,,,,,,,,,,,"201820","Diabetes mellitus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034897","Recurrence","C3352","Happening again (especially at regular intervals).","Recurrence | recur",,,,,,,,,,,,,,,"4078193","Recurrence",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL031853","Radiosurgery","C15696","A surgical procedure to treat cancer cells that use high energy beams.","Radiosurgery | Ablation, Radiosurgical | Radiation Surgery | Radiation Surgery | radiation surgery | radiosurgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034541","Radiosensitizing Agent","C798","An agent that makes tumor cells more sensitive to radiation therapy.","Radiosensitizing Agent | Radiation Sensitizers | Radiation-Sensitizing Agents | Radiation-Sensitizing Drugs | Radiosensitizers | Radiosensitizing Drugs | radiosensitizer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032131","Plasmacytoma","C9349","A malignant neoplasm characterized by the presence of a monoclonal population of plasma cells forming a tumor mass.","Plasmacytoma | Plasmacytoma, NOS | plasmacytoma","9731/3","Plasmacytoma, NOS",,,,,,,,,,,,,"4216139","Plasmacytoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0443268","Nodal","C25323","Of or pertaining to a node, any bulge or swelling of an anatomical structure or part.","Nodal | ",,,,,,,,,,,,,,,"4137819","Nodal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027540","Necrotic Process","C16897","A cell death process that is morphologically characterized by a gain in cell volume (oncosis), swelling of organelles, plasma membrane rupture and subsequent loss of intracellular contents.","Necrotic Process | NECROSIS | Necrosis | Necrosis | necrosis",,,,,,,,,,,,,,,"4280654","Necrosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040590","Tracheotomy","C15341","Creation of a surgical opening into the trachea.","Tracheotomy | TRACHEOSTOMY | Tracheostomy | Tracheostomy | Tracheostomy Procedure | tracheostomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677965","Video-Assisted Surgery","C15702","Endoscopic surgical procedures performed with visualization via video transmission.","Video-Assisted Surgery | video-assisted resection | video-assisted surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039597","Testis","C12412","Either of the paired male reproductive glands that produce the male germ cells and the male hormones.","Testis | Genital System, Male, Testis | TESTIS | Testes | Testicle | Testicles | Testis structure (body structure) | Testis, NOS | gonad of male genitalia | gonad of male reproductive system | male gonad | testicle | testis",,,,,,,,,,,,,"UBERON:0000473","testis","4238088","Testis structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037817","Speech","C38025","The exchange of spoken words.","Speech | Talk | Talking",,,,,,,,,,,,,,,"4337391","Speaking",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4229310","Asthma","C28397","A chronic respiratory disease manifested as difficulty breathing due to the narrowing of bronchial passageways.","Asthma | asthma",,,,,,,,,,,,,,,"317009","Asthma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4230730","Vomiting","C3442","Forceful ejection of the contents of the stomach through the mouth.","Vomiting | Emesis | emesis | vomit",,,,,,,,,,,,,,,"441408","Vomiting",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4011582","Vitiligo","C26915","Generalized well circumscribed patches of leukoderma that are generally distributed over symmetric body locations and is due to autoimmune destruction of melanocytes.","Vitiligo | ",,,,,,,,,,,,,,,"138502","Vitiligo",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1510899","Animal Testing","C16087","The use of animals for testing the safety and efficacy of drugs or treatments.","Animal Testing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3551869","Congestive Heart Failure","C3080","Failure of the heart to pump a sufficient amount of blood to meet the needs of the body tissues, resulting in tissue congestion and edema. Signs and symptoms include shortness of breath, pitting edema, enlarged tender liver, engorged neck veins, and pulmonary rales.","Congestive Heart Failure | CHF | Cardiac Failure Congestive | Congestive Heart Failure (CHF) | Congestive heart failure | Heart Failure/Congestive Heart Failure | congestive heart failure",,,,,,,,,,,,,,,"319835","Congestive heart failure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2749421","Muscle Cramp","C34827","A sustained, sudden and involuntary contraction of a muscle or group of muscles.","Muscle Cramp | Cramp | Cramp(s) /Muscle Spasm(s) | Muscle Cramping | Spasm | cramp",,,,,,,,,,,,,,,"75635","Cramp",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0178913","Blood Sample","C17610","A small volume of blood removed for testing or storage.","Blood Sample | Blood | Blood Draw | Blood Specimen | blood draw",,,,,,,,,,,,,,,"4001225","Blood specimen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0728747","Trastuzumab","C1647","A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)","Trastuzumab | ABP 980 | ALT02 | Anti-ERB-2 | Anti-HER2/c-erbB2 Monoclonal Antibody | Anti-c-ERB-2 | Anti-c-erbB2 Monoclonal Antibody | Anti-erbB-2 | Anti-erbB2 Monoclonal Antibody | Anti-p185-HER2 | Biceltis | CANMab | CT-P06 | CT-P6 | HER2 Monoclonal Antibody | HLX 02 | HLX-02 | HLX02 | Herceptin | Herceptin Biosimilar PF-05280014 | Herceptin Trastuzumab Biosimilar PF-05280014 | Hercessi | Herclon | Hertraz | Herwenda | Herzuma | Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman p185(Sup c-erbB2) Receptor), Disulfide with Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer | Kanjinti | MoAb HER2 | Monoclonal Antibody HER2 | Monoclonal Antibody c-erb-2 | Ogivri | Ontruzant | PF 05280014 | PF-05280014 | PF05280014 | QL 1701 | QL-1701 | QL1701 | RO0452317 | SB3 | TRASTUZUMAB | Trastuzumab Biosimilar ABP 980 | Trastuzumab Biosimilar ALT02 | Trastuzumab Biosimilar CT-P6 | Trastuzumab Biosimilar HLX02 | Trastuzumab Biosimilar PF-05280014 | Trastuzumab Biosimilar QL1701 | Trastuzumab Biosimilar SB3 | Trastuzumab Biosimilar SIBP-01 | Trastuzumab-anns | Trastuzumab-dkst | Trastuzumab-dttb | Trastuzumab-herw | Trastuzumab-pkrb | Trastuzumab-qyyp | Trastuzumab-strf | Trastuzumab-zerc | Trazimera | Zercepac | c-erb-2 Monoclonal Antibody | rhuMAb HER2 | trastuzumab | trastuzumab biosimilar EG12014",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332479","CARDIAC SCHWANNOMA, BENIGN","C5358","A benign peripheral nervous system neoplasm that is composed of well-differentiated Schwann cells and affects the heart.","Cardiac Schwannoma | Benign Cardiac Neurilemmoma | Benign Cardiac Schwannoma | Benign Cardiac Schwannoma | Benign Heart Neurilemmoma | Benign Heart Schwannoma | Benign Neurilemoma of Heart | Benign Neurilemoma of the Heart | CARDIAC SCHWANNOMA, BENIGN | Schwannoma, Endocardial, Benign",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL024405","Mammogram","C20178","A low voltage X-ray photograph of the breast generally done to detect breast cancer. This method is also valuable in diagnosis of benign abnormal conditions of the breast such as fibroadenoma, mastitis, abscess, and cysts.","Mammogram | mammogram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043100","Weight","C25208","The vertical force exerted by a mass as a result of gravity.","Weight | WEIGHT",,,,,,,,,,,,,,,"37111521","Weight",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL102947","Investigator","C25936","An individual who conducts scientific research. In a clinical setting this individual actually conducts and/or supervises the clinical investigation and study-related procedures.  The investigator monitors the safety of the trial subjects and investigational staff (under whose immediate direction an agent is administered or dispensed to a subject).  The investigator collects and analyses data and study documents, and provides reports in compliance with applicable requirements.","Investigator | INVESTIGATOR | Researcher | StudyInvestigator | investigator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1285529","Purpose","C25634","What something is used for; reason or intention.","Purpose | purpose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002059","Alkaline Phosphatase","C16276","An enzyme that catalyses the cleavage of inorganic phosphate non-specifically from a wide variety of phosphate esters and having a high (greater than 8) pH optimum.","Alkaline Phosphatase | ALKP | ALP | AP | Alk Phos | AlkPhos | Phosphatase, Alkaline",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL026906","Testosterone","C2299","A hormone made mainly in the testes (part of the male reproductive system). It is needed to develop and maintain male sex characteristics, such as facial hair, deep voice, and muscle growth. Testosterone may also be made in the laboratory and is used to treat certain medical conditions.","Testosterone | (17Beta)-17-hydroxyandrost-4-en-3-one | Delta4-androsten-17beta-ol-3-one | Trans-Testosterone | testosterone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3280935","Myocardial Infarction","C27996","Gross necrosis of the myocardium, as a result of interruption of the blood supply to the area, as in coronary thrombosis.","Myocardial Infarction | Heart Attack | MI | Myocardial Infarct | Myocardial infarction",,,,,,,,,,,,,,,"4329847","Myocardial infarction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1510458","Caprine Species","C14210","Any of various hollow-horned, bearded ruminant mammals of the genus Capra, originally of mountainous areas of the Old World, especially any of the domesticated forms of C. hircus, raised for wool, milk, and meat. (from American Heritage Dictionary on line)","Goat | Caprine Species | GOAT | Mammals, Goats",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024203","Lymphadenectomy","C15275","Surgical removal of lymph nodes, usually done to assess the spread of cancer.","Lymphadenectomy | LYMPHADENECTOMY | Lymph Node Dissection | Lymph Node Excision | excision of the lymph node | lymph node dissection | lymph node excision | lymphadenectomy",,,,,,,,,,,,,,,"4238646","Excision of lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034595","Radioisotope","C799","A version of a chemical element that has an unstable nucleus and emits radiation during its decay to a stable form. (online dictionary)","Radioisotope | RADIOISOTOPE | Radionuclide | radioisotope | radionuclide",,,,,,,,,,,,,,,"4232493","Radioactive isotope",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0012544","Biphosphonate","C443","A drug or substance used to treat hypercalcemia (abnormally high blood calcium) and bone pain caused by some types of cancer. Forms of bisphosphonates are also used to treat osteoporosis and for bone imaging. Bisphosphonates inhibit a type of bone cell that breaks down bone.","Biphosphonate | Diphosphonate | Diphosphonates | bisphosphonate | diphosphonate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0262926","Personal Medical History","C18772","A record of a patient's background regarding health and the occurrence of disease events of the individual. In addition, personal medical history may be a variable in epidemiologic studies.","Personal Medical History | General Medical History | History | MEDICAL_HISTORY | Medical History | PMH | Past Medical History | Personal History | personal health record | personal history | personal medical history",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011008","Date","C25164","The particular day, month and year an event has happened or will happen.","Date | Date (MM/DD/YYYY) | Dated | date",,,,,,,,,,,,,,,"4260905","Date",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018494","Hair","C32705","The filamentous outgrowth of the epidermis.","Hair | HAIR",,,,,,,,,,,,,,,"4300948","Hair structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162703","Pain Threshold","C21085","The minimum level of stimulation of a body part that a person will perceive as being noxious or unpleasant. (Taber's)","Pain Threshold | pain threshold",,,,,,,,,,,,,,,"4092327","Pain threshold",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022877","Laboratory","C37984","A facility equipped and competent to conduct scientific experiments, observations, tests, investigations, and/or to manufacture chemicals or medical products.","Laboratory | LABORATORY | Lab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001617","Corticosteroid","C2322","Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).","Corticosteroid | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242656","Disease Progression","C17747","A process that manifests as the worsening of a disease over time.","Disease Progression | PROGRESSION | Progression | Progression observed | disease progression | progression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0949626","Second Look Surgery","C15317","Surgery performed after cancer treatment to assess the results of prior treatment and to plan possible future treatment.","Second-Look Surgery | Reoperation | Repeat Surgery | Second Look | Surgical Revision | second-look surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0277556","Recurrent Disease","C38155","The return of a disease after a period of remission.","Recurrent Disease | DISEASE RELAPSE | RECURRENT DISEASE | RELAPSED DISEASE | Recurrence | Relapse | Relapse, Site Not Specified | Relapsed Disease | relapse",,,,,,,,,,,,,,,"440059","Recurrent disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0442045","Visceral","C25315","Of, or relating to, or affecting the internal organs.","Visceral | visceral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225317","Soft Tissue","C12471","A general term comprising tissue that is not hardened or calcified; including muscle, fat, blood vessels, nerves, tendons, ligaments and fascia.","Soft Tissue | SOFT TISSUE | soft tissue",,,,,,,,,,,,,,,"4338971","Soft tissue",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024886","Total Mastectomy","C15281","A surgical procedure involving the removal of the entire breast tissue, nipple and a portion of the overlying skin, while leaving the axillary contents intact.","Total Mastectomy | Simple Mastectomy | simple mastectomy | total mastectomy",,,,,,,,,,,,,,,"4066543","Simple mastectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009376","Colon Polyp","C2954","A polypoid lesion that arises from the colon and protrudes into the lumen.  This group includes adenomatous polyps, serrated polyps, and hamartomatous polyps.","Colon Polyp | Colon Polyps | Colonic Polyp | Polyp of Colon | Polyp of the Colon | colon polyp",,,,,,,,,,,,,,,"4285898","Polyp of colon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0684249","Lung Carcinoma","C4878","A carcinoma originating in the lung. Lung carcinomas usually arise from the epithelium that lines the bronchial tree (bronchogenic carcinomas), and are classified as small cell or non-small cell carcinomas. Non-small cell lung carcinomas are usually adenocarcinomas, squamous cell carcinomas, or large cell carcinomas. Metastatic carcinomas to the lung are also common, and can be difficult to distinguish from primary tumors.","Lung Carcinoma | Cancer of Lung | Cancer of the Lung | Carcinoma of Lung | Carcinoma of the Lung | Lung Cancer | Lung Cancer (all types) | Lung cancer, NOS | lung cancer",,,,,,,,,,,,,,,"40492938","Carcinoma of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0184661","Intervention or Procedure","C25218","An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects.","Clinical Intervention or Procedure | Intervention | Intervention Strategies | Intervention or Procedure | Intervention or Procedure | Interventional | Interventional Procedure Type | Procedure | Procedure | intervention | interventionDescription | procedure | study intervention | treatment type | treatment_type",,,,,,,,,,,,,,,"4322976","Procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013849","E-mail","C25170","E-mail is short for 'electronic mail' and refers to composing, sending, and receiving messages over electronic communication systems. Most e-mail systems use the Internet.","E-mail | E-MAIL | Electronic Mail | Email",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0422202","Notification","C25297","Informing by words.","Notification | NOTIFICATION | Notify",,,,,,,,,,,,,,,"4088396","Notifications",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1148523","Birth","C25155","The event of being born.","Birth | Born | Delivery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514893","physiologic resolution","C25655","Return to the normal structure and/or function, e.g. the subsidence of a pathologic process, as the subsidence of an inflammatory lesion or new growth.","Physiologic Resolution | Pathologic Process Resolution | Pathology Resolution | Pathology Resolution | Resolution | Resolution of Pathologic Process | Resolved",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0750729","Course","C25379","Passage through time; duration; a systematic or/and orderly succession; a sequence, e.g. course of treatment; a mode of action or behavior; natural development, typical manner of proceeding.","Course | course | {Course}",,,,,,,,,,,,,,,"4123545","Courses",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0348080","Condition","C25457","A state of being, such as a state of health.","Condition | Conditions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0392360","Reason","C25638","An explanation of the cause of some phenomenon or action.","Reason | Rationale",,,,,,,,,,,,,,,"4044935","Indication of",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519269","Serving","C26359","An individual portion of food or drink.","Serving | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036919","Seychelles","C17129","A country in eastern Africa, comprised of a group of islands in the Indian Ocean, northeast of Madagascar and east of Kenya.","Seychelles | 690 | SC | SEYCHELLES | SYC",,,,,,,,,,,,,,,"4072111","Seychelles",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0879626","Side Effect","C2861","The term was used in various ways in the past, to describe unintended effects of medical intervention, usually negative (unfavourable), but also positive (favourable) ones. It is recommended that this term no longer be used and particularly should not be regarded as synonymous with adverse event or adverse reaction.","Side Effect | side effect | side effects",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448866","Positive","C25246","Involving advantage or good.","Positive | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032961","Pregnancy","C25742","The state or condition of having a developing embryo or fetus in the body (uterus), after union of an ovum and spermatozoon, during the period from conception to birth.","Pregnancy | Gestation | PREGNANCY | pregnancy",,,,,,,,,,,,,,,"4128331","Pregnancy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022337","Jamaica","C16763","An island in the Caribbean Sea, south of Cuba, between the Cayman Islands and Haiti.","Jamaica | 388 | JAM | JAMAICA | JM",,,,,,,,,,,,,,,"4072762","Jamaica",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021267","Industry","C25181","The people or companies engaged in a particular kind of commercial enterprise; the organized action of making of goods and services for sale.","Industry | Industrial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162788","In Situ Hybridization","C17562","Use of a DNA or RNA probe to detect the presence of complementary sequences in chromosomes, cells, or tissues.","In Situ Hybridization | Genetics, in situ Hybridization | IN SITU HYBRIDIZATION | ISH | in situ Hybridization | in situ Hybridization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518965","Performance Status","C20641","A measure of how well a patient is able to perform ordinary tasks and carry out daily activities.","Performance Status | Performance Status Assessment | performance status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079946","National origin","C28407","System of classification based on nation from which a person originates, regardless of the nation in which he/she currently resides.","National Origin | NATORIG | Origin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028811","Occupation","C25193","The principal activity that a person does to earn money.","Occupation | EMPJOB | Employee Job | Employment Category | Job | OCCUPATION | Occupation Type | Type of Work | occupation type | occupation_type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025723","Methylation","C16848","The covalent chemical or biochemical addition of a methyl group(s) to a compound. (NCI)","Methylation | methylation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009458","Communications Media","C19442","Any mechanism of mass communication.","Media | Communications Media | Forms of Communication | Medium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0806887","Maiden Name","C25381","A woman's surname before marriage.","Maiden Name | Maiden",,,,,,,,,,,,,,,"4307270|764223","Maiden name|Maiden name",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1519384","Smoking History","C29719","A record of an individual's background in regard to smoking tobacco. This would include such factors as start date, end date (if applicable), number of cigarette smoked, attempts to quit, and others.","Tobacco Smoking History | Smoking History | Smoking History",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0191321","Punch Biopsy","C28743","Removal of a disk of skin tissue, for microscopic examination, using a punch.","Punch Biopsy | BIOPSY, PUNCH | Punch Biopsy of Skin | punch biopsy",,,,,,,,,,,,,,,"4227733","Punch biopsy of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1514743","Reader of medical images","C28747","The specific medical individual, usually a radiologist, who looks at and interprets a medical image.","Reader | READER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513041","Measurable Disease","C8507","A finding indicating that a subject has one or more measurable pathological lesions.","Measurable Disease | Measurable_Disease | measurable disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031809","Physical Examination","C20989","A systemic evaluation of the body and its functions using visual inspection, palpation, percussion and auscultation. The purpose is to determine the presence or absence of physical signs of disease or abnormality for an individual's health assessment.","Physical Examination | Assessment | Assessment | General Examination | PHYSICAL EXAM | PHYSICAL EXAMINATION | Physical | Physical Assessment | Physical Exam | Physical exam | Physical examination procedure (procedure) | assessment | physical exam | physical examination | physical_exam",,,,,,,,,,,,,,,"4240345","Physical examination",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005507","Bioassay","C16341","A laboratory test or analysis of the biological activity of a substance performed by studying its effect on an organism or in a test tube under controlled conditions.","Bioassay | Assay | Assay | bioanalytical assays",,,,,,,,,,,,,,,"4242576","Bioassay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1510825","Affiliate","C25412","A formal association between entities.","Affiliation | Affiliate | Affiliate | Affiliated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039986","Thoracic Surgery","C17195","A branch of medicine dealing with the use of surgery to treat diseases of the chest and lungs.","Thoracic Surgery | Surgery, Thoracic",,,,,,,,,,,,,,,"4252365","Thoracic surgery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005773","Peripheral Blood Cell","C12519","A general term describing the three cellular components of blood (white blood cells, red blood cells, and platelets), all which are made in the bone marrow. (Lymphoma Information Network Glossary)","Peripheral Blood Cell | ",,,,,,,,,,,,,,,"4272801","Blood cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0044663","10-Deacetyltaxol","C957","An analog of paclitaxel with antineoplastic activity.  10-Deacetyltaxol binds to and stabilizes the resulting microtubules, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and apoptosis.","10-Deacetyltaxol | 10-DEACETYLPACLITAXEL | 10-Deacetylpaclitaxel | benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332022","ADAM Family Gene","C20791","ADAMs (A Disintegrin and Metalloproteinase Domain) are membrane-anchored proteases that regulate cell behavior by proteolytically modifying the cell surface and extracellular matrix. Currently, the ADAM family has 29 members, although the function of most ADAM gene products is unknown. The ADAM gene products with known functions act in a highly diverse set of biological processes, including fertilization, neurogenesis, myogenesis, embryonic TGF-alpha release and the inflammatory response. (from J Cell Biol 2002;159:893-902 and NCI)","ADAM Family Gene | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1008132","Hyssopus officinalis","C74490","No value exists.","Hyssopus officinalis | BECLOMETHASONEDIPROPIONATE 84 MCG/ACTUAT | HYSSOPUS OFFICINALIS WHOLE | Thymus Hyssopus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537772","MIR125B2 Gene","C80752","This gene is involved in the regulation of gene expression and plays a role in the development of hepatocellular carcinoma.","MIR125B2 Gene | MIR125B2 | MicroRNA 125b-2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1528071","Uracil-DNA Glycosylase, Human","C106308","Uracil-DNA glycosylase (313 aa, ~35 kDa) is encoded by the human UNG gene. This protein plays a role in DNA metabolism.","Uracil-DNA Glycosylase | EC 3.2.2.27 | Embryonic Fluid | UDG | UDG1A | UDG1N | UNG | UNG2 | Uracil-DNA Glycosylase 2 | Uracil-DNA Glycosylase Isoform 2 | Uracil-DNA Glycosylase, Nuclear Isoform",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1327819","Golnerminogene Pradenovec","C26444","A recombinant agent consisting of a genetically-modified adenovirus 5 vector encoding the protein cytokine tumor necrosis factor (TNF) alpha. TNF exhibits potent anti-tumor cytolytic properties; the adenovirus 5 vector efficiently infects tumor cells, delivering tumor-specific TNF.","Golnerminogene Pradenovec | ADgv EGR.TNF.11D | Ad 5-TNF Alpha | Adenovirus 5-Tumor Necrosis Factor Alpha | Bone of atlas | TNFerade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347263","CD5 wt Allele","C73122","Human CD5 wild-type allele is located in the vicinity of 11q13 and is approximately 25 kb in length. This allele, which encodes T-cell surface glycoprotein CD5 protein, may play a role in the modulation of T-cell proliferation.","CD5 wt Allele | CD5 Antigen (p56-62) Gene | CD5 Molecule wt Allele | LEU1 | Ly1, Mouse, Homolog of Gene | PROTEIN 15 GM | T1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704258","Abnormality","C9440","A condition that differs from the usual physical or mental state.","Abnormality | ANOMALY | Anomaly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0444454","Access","C25396","The right to obtain or make use of or take advantage of something (as services or membership); the right to enter.  Also, an act or means of approaching.","Access | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510755","Accession Number (identifier)","C25402","A control number unique to an object.  It is used to identify the object among other objects in a collection.","Accession Number | ACSN | Accession | Accession ID | accessionNumberText",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510756","Accrual","C25403","The process of obtaining subjects for a study.","Accrual | accrual",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796366","11q","C13389","Distal (long) arm of chromosome 11","11q | Chromosome 11 Distal Arm | Chromosome 11 Long Arm | Chromosome 11q",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3549435","Vestibular Schwannoma","C3276","A benign peripheral nerve sheath neoplasm that arises from the vestibular division of the vestibulocochlear nerve (eight cranial nerve) in the auditory canal or within the labyrinth. It is composed almost entirely of differentiated neoplastic Schwann cells.","Vestibular Schwannoma | Acoustic Neurilemmoma | Acoustic Neuroma | Acoustic Schwannoma | Acoustic Schwannoma | Acoustic neuroma | Neurilemoma, Acoustic | Neuroma, Acoustic | Vestibular Neurilemmoma",,,,,,,,,,,,,,,"4131769","Acoustic neuroma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085196","Oxidopamine","C1316","An antagonist of the neurotransmitter dopamine with potential antineoplastic activity. 6-Hydroxydopamine (6-HOD) can be taken up by selective adrenergic terminals, thereby causing acute degeneration of adrenergic terminals that leads to depletion of norepinephrine, and of dopamine in the dopamine-sensitive sites. This agent is auto-oxidated at physiological pH that leads to the formation of reactive free radicals, thereby leading to cytotoxicity in neural cells.  6-Hydroxydopamine is often used to induce CNS and sympathetic neural lesions that model aging and various nervous disorders in animal systems.","Oxidopamine | 2,4,5-Trihydroxyphenethylamine | 5-(2-Aminoethyl)-1,2,4-benzenetriol | 6-Hydroxydopamine | 6-Hydroxydopamine | 6-OHDA | OXIDOPAMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334066","17-Beta-Hydroxysteroid Dehydrogenase 7","C26314","3-keto-steroid reductase (341 aa, ~38 kDa) is encoded by the human HSD17B7 gene. This protein is involved in estrogen biosynthesis.","3-Keto-Steroid Reductase | 17 Beta-Hydroxysteroid Dehydrogenase Type 7 | 17 Beta-Hydroxysteroid Dehydrogenase Type VII | 17-Beta-HSD 7 | 17-Beta-Hydroxysteroid Dehydrogenase 7 | 17-Beta-Hydroxysteroid Dehydrogenase 7 | EC 1.1.1.270 | EC 1.1.1.51 | EC 1.1.1.62 | Estradiol 17 Beta-Dehydrogenase 7 | Estradiol 17-Beta-Dehydrogenase 7 | HSD17B7 | Hydroxysteroid (17-Beta) Dehydrogenase 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1292724","Approach","C25424","A way of entering or leaving.","Approach | ",,,,,,,,,,,,,,,"4014165","Procedural approach",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522508","Details","C25480","Particulars considered individually and in relation to a whole.","Details | Detail | Detailed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205540","Approval","C25425","Acceptance as satisfactory by an authoritative body; established by authority; given authoritative approval.","Approval | Approve | Approved | Approved",,,,,,,,,,,,,,,"4317974","Approved",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0700364","Appearance","C25377","The outward or visible aspect of a person or thing.","Appearance | APPEAR | APPEARANCE | Aper",,,,,,,,,,,,,,,"37397753|45766147","Appearance|Appearance",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0002938","Aneuploidy","C2873","A chromosomal abnormality in which there is an addition or loss of chromosomes within a set (e.g., 23 + 22 or 23 + 24).","Aneuploidy | Aneuploid | aneuploidy",,,,,,,,,,,,,,,"4196629","Aneuploidy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1510826","Affiliated","C25413","To be associated with; this is usually used as a description of the relationship of a person to an institution.","Affiliated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0425382","Adopted","C25290","Having been legally made a member of a family.","Adopted | ",,,,,,,,,,,,,,,"4050948","Adopted",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0809949","Admission","C25385","The condition of being allowed to enter; the activity of admitting someone to something.","Admission | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3266814","Action","C25404","A thing done.","Action | Generic Action",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332479","Shape","C25677","The spatial arrangement of something as distinct from its substance.","Shape | SHAPE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519453","Spiculate","C28749","Covered with or having small needlelike structures (spicules) or fine fleshy points.","Spiculate | Spiculation | Spiculation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515010","Subcategory","C25692","A subdivision that has common differentiating characteristics within a larger category.","Subcategory | SCAT | SubCategory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511481","Consent","C25460","Permission to do something.","Consent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704444","Multiplicative Product","C40352","A quantity obtained by multiplication.","Multiplicative Product | Mathematical Product | Product | Product",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205039","Bronchial","C25222","Of, or pertaining to, the bronchus.","Bronchial | bronchial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006893","Cabo Verde","C16382","A group of islands in the North Atlantic Ocean, west of Senegal.","Cabo Verde | 132 | CABO VERDE | CAPE VERDE | CPV | CV | Cape Verde | Cape Verde",,,,,,,,,,,,,,,"37162466","Cabo Verde",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0752218","EF-Hand Domain","C13956","Forming a single Ca2+-binding site in many calcium-binding proteins, the basic EF-Hand Domain consists of a conserved 12-residue loop region between two perpendicular 10-12 residue alpha helices (helix-loop-helix). Ca2+ interacts with loop residues in a pentagonal bipyramidal configuration; each loop residue is important for Ca2+ coordination. Loop residues 1, 3, 5, 7, 9, and 12 (invariant Glu or Asp) are directly necessary for Ca2+ binding. Amino-acid variations at positions 1, 3, 5, 7, and 9 alter ion affinity. Single or multiple domains cause structural/functional variations. EF-hand Proteins are grouped into either regulatory/signaling or structural/buffering/transport categories. Ca2+ binding to regulatory proteins induces conformational/functional change; Ca2+ binding to structural proteins seems to provide a Ca2+ buffer. (NCI)","EF-Hand Domain | EF Hand | EF-Hand | EF-Hand Calcium-Binding Motif | EF-Hand Motif",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332304","Laterality","C25185","Dominant use or manifestations of one side of the body versus the other; referring to a side of the body or of a structure.","Laterality | LAT | Lateral (levels 2-5) | laterality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1561607","Overall","C25605","Including everything.","Overall | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511938","Histopathologic Grade differentiation","C18314","In cancer, refers to how mature (developed) the cancer cells are in a tumor. Differentiated tumor cells resemble normal cells and tend to grow and spread at a slower rate than undifferentiated or poorly differentiated tumor cells, which lack the structure and function of normal cells and grow uncontrollably.","Cellular Differentiation | Differentiation | Differentiation | differentiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514984","Stratification Factors","C16153","Selected pre-treatment factors by which patients are segregated to assure equal balance of these factors before randomization to the intervention arms of a clinical protocol.","Stratification Factors | STRATFCT | Stratification Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0184898","Surgical Incision","C15384","An intentional cut made to an individual's body with the intent of performing a diagnostic or therapeutic intervention.","Surgical Incision | Incision | Incisional | Otomy | incision",,,,,,,,,,,,,,,"4147894","Incision",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038894","Surgery","C17173","The branch of medical science that treats disease or injury by operative procedures.","Surgery | Surgical Profession | Surgical Specialties | Surgical Specialty",,,,,,,,,,,,,,,"4215265","Surgical specialty",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706077","Users","C42745","An individual who uses a computer, program, network, or related service for work or entertainment.","System User | User | User | Users",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0542560","Academic degree","C25354","An award conferred by a college, university, or other postsecondary education institution as official recognition for the successful completion of a program of studies.","Academic Degree | Degree",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042721","Viral Hepatitis","C35124","An acute or chronic inflammation of the liver parenchyma caused by viruses. Representative examples include hepatitis A, B, and C, cytomegalovirus hepatitis, and herpes simplex hepatitis.","Viral Hepatitis | Hepatitis viral",,,,,,,,,,,,,,,"4291005","Viral hepatitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029118","Opportunistic Infection","C3289","Infection caused by an organism that is capable of causing disease in immunocompromised patients only (e.g. HIV-positive or transplanted patients).--2004","Opportunistic Infection | OI | opportunistic infection",,,,,,,,,,,,,,,"4247535","Opportunistic infectious disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0231220","Symptoms (functional concept)","C25269","Exhibiting the symptoms of a particular disease.","Symptomatic | Currently has symptoms | Is_Symptomatic | SYMPTOMS | symptomatic",,,,,,,,,,,,,,,"4142947","Symptomatic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0920269","Microsatellite Instability","C36318","Genomic instability associated with the presence of hypermutability in specific genetic marker regions resulting from defective DNA mismatch repair.","Microsatellite Instability | MSI | MSI Positive | MSI Present | Microsatellite Instability Positive | Microsatellite Instability Present | microsatellite instability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519815","Upper Limit of Normal","C25706","The top value of the range of statistical characteristics that are supposed to represent accepted standard, non-pathological pattern for particular laboratory result or other quantitative parameter.","Upper Limit of Normal | ULN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706423","Inductive Resistance","C43548","An opposition to the flow of electric current resulting from inductance and capacitance (rather than resistance).","Reactance | Inductive Resistance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524869","Loss of Heterozygosity","C18016","A genetic variation where gain, loss, or exchange of DNA results in monoallelic loss of function mutations in a diploid cell. In the context of tumor suppressor genes, where a single copy is sufficient for functionality, loss of function for the second allele is associated with tumorigenesis.","Loss of Heterozygosity | LOH | loss of heterozygosity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0000833","Abscess","C26686","An inflammatory process characterized by the accumulation of pus within a newly formed tissue cavity which is the result of a bacterial, fungal, or parasitic infection or the presence of a foreign body.","Abscess | ABSCESS | abscess",,,,,,,,,,,,,,,"4195605|444202","Abscess morphology|Abscess",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0270612","Leukoencephalopathy","C27059","White matter changes first described in children with leukemia, associated with radiation and chemotherapy injury, often associated with methotrexate; pathologically characterised by diffuse reactive astrocytosis with multiple areas of necrotic foci without inflammation.","Leukoencephalopathy | ",,,,,,,,,,,,,,,"4027461","Leukoencephalopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3278945","Nystagmus","C3282","Involuntary movements of the eyeballs. The presence or absence of nystagmus is often used in the diagnosis of a variety of neurological and visual disorders.","Nystagmus | ",,,,,,,,,,,,,,,"378165","Nystagmus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043352","Xerostomia","C26917","Dryness of the oral mucosa secondary to a decrease in saliva production, or a change in saliva composition.","Xerostomia | Dry Mouth | Dry mouth | xerostomia",,,,,,,,,,,,,,,"4226991","Xerostomia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1258215","Ileus","C37979","Decrease in peristalsis in the absence of a mechanical bowel obstruction.","Ileus | ileus",,,,,,,,,,,,,,,"46272242","Intestinal obstruction co-occurrent and due to decreased peristalsis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017152","Gastritis","C26780","Inflammation of the stomach.","Gastritis | gastritis",,,,,,,,,,,,,,,"201340","Gastritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1568868","Stomatitis","C26887","Inflammation of the oral mucosa due to local or systemic factors.","Stomatitis | Mucositis oral | Oral Mucositis | stomatitis",,,,,,,,,,,,,,,"138455","Stomatitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3805748","Tremor","C38038","The shaking movement of the whole body or just a certain part of it, often caused by problems of the neurons responsible for muscle action.","Tremor | Shaking | Shaking/Tremors",,,,,,,,,,,,,,,"443782","Tremor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4014404","Syncope","C35053","A spontaneous loss of consciousness caused by insufficient blood supply to the brain.","Syncope | Fainting | Syncope/Fainting",,,,,,,,,,,,,,,"135360","Syncope",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033246","Proctitis","C38011","An inflammatory process affecting the anus. It is usually caused by sexually transmitted infectious agents and/or inflammatory bowel disease.","Proctitis | proctitis | rectitis",,,,,,,,,,,,,,,"4215578","Proctitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2748942","Seizure","C2962","Sudden, involuntary skeletal muscular contractions of cerebral or brain stem origin.","Seizure | Convulsion | Convulsion/Seizure | Seizures | Unspecified convulsions | seizure",,,,,,,,,,,,,,,"377091","Seizure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4011703","Pancreatitis","C3306","Inflammation of the pancreas.","Pancreatitis | Inflammatory Pancreatic Disease | pancreatitis",,,,,,,,,,,,,,,"4192640","Pancreatitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031208","Personality","C38002","The complex of all the attributes--behavioral, temperamental, emotional and mental--that characterize a unique individual.","Personality | ",,,,,,,,,,,,,,,"4324252","Personality",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4227642","Lymphedema","C3207","Excess fluid collection in tissues, causing swelling. It is the result of obstruction of lymphatic vessels or lymph nodes.","Lymphedema | lymphedema",,,,,,,,,,,,,,,"4147210|435839","Lymphatic edema|Lymphedema",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0267537","Typhlitis","C38043","Inflammation of the cecum, usually accompanied by neutropenia.","Typhlitis | Neutropenic Colitis",,,,,,,,,,,,,,,"4189378","Typhlitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013378","Dysgeusia","C28145","Abnormal sense of taste.","Dysgeusia | Taste Disorder | dysgeusia | parageusia",,,,,,,,,,,,,,,"436235","Taste sense altered",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030252","Palpitation","C37999","An unpleasant sensation of irregular and/or forceful beating of the heart.","Palpitation | Heart Palpitations | Palpitations | palpitation",,,,,,,,,,,,,,,"315078","Palpitations",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0559522","Genital","C13348","The group of organs and glands involved with having a child. In women, these are the uterus (womb), the fallopian tubes, the ovaries, and the vagina (birth canal). The reproductive system in men includes the testes, the prostate, and the penis.","Genital | Genital structure (body structure) | genital",,,,,,,,,,,,,,,"4216845","Genital structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034033","Public Policy","C17041","The basic policy or set of policies forming the foundation of public laws, especially such policy not yet formally enunciated. (dictionary.com)","Public Policy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1838395","Pyramidal Tract Dysfunction","C43245","Dysfunction of the corticospinal (pyramidal) tracts of the spinal cord. Symptoms include increased muscle tone in the lower extremities, hyperreflexia, positive Babinski, and decreased fine motor coordination.","Pyramidal Tract Dysfunction | Dysfunction of the Pyramidal Tract | Pyramidal Tract Syndrome | Pyramidal tract syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0695347","Modality","C41147","A specific manner, characteristic, pattern of application or the employment of, any therapeutic agent or method of treatment, especially involving the physical treatment of a condition.","Modality | modality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3553523","Exostosis","C3029","Non-neoplastic overgrowth of bone.","Exostosis | Exostosis (bone)",,,,,,,,,,,,,,,"4215424|72715","External hyperostosis|Exostosis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0026649","Movement","C37994","A change in location or position.","Movement | ",,,,,,,,,,,,,,,"4113276","Movement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0175649","Prosthesis","C17598","A device which is an artificial substitute for a missing body part or function; used for functional or cosmetic reasons, or both.","Prosthesis | Prostheses | prosthesis",,,,,,,,,,,,,,,"4205702","Prosthesis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4228466","Hydrocephalus","C3111","A disorder characterized by an abnormal increase of cerebrospinal fluid in the ventricles of the brain.","Hydrocephalus | HYDROCEPHALUS | Hydrocephalus, unspecified | hydrocephalus",,,,,,,,,,,,,,,"4043738","Hydrocephalus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4013377","Encephalopathy","C26920","A functional and/or structural disorder of the brain caused by diseases (e.g. liver disease, kidney disease), medications, chemicals, and injuries.","Encephalopathy | Encephalopathy, unspecified | encephalopathy",,,,,,,,,,,,,,,"372887","Disorder of brain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0700251","Brachial Plexopathy","C27194","A brachial plexus disorder characterized by regional paresthesia, pain and muscle weakness, and limited movement in the arm or hand.","Brachial Plexopathy | Brachial Plexus Neuropathy | Brachial plexopathy | brachial plexopathy",,,,,,,,,,,,,,,"378741","Brachial plexus disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042930","Vocal Cord","C12822","A pair of small bands of muscle that stretch from the thyroid cartilage in front to the arytenoid cartilage in back of the larynx. The vocal cords help prevent food entering the lungs and produce sound through vibration.","Vocal Cord | VOCAL CORD | Vocal Cords | Vocal cord structure (body structure) | vocal cord",,,,,,,,,,,,,,,"4263612","Vocal cord structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026975","Myelitis","C26832","An inflammatory process affecting the spinal cord. Causes include viral infections, autoimmune disorders, vascular disorders, and toxic agents. Symptoms include weakness, paresthesia, sensory loss, pain, and incontinence.","Myelitis | ",,,,,,,,,,,,,,,"138965","Myelitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3808733","Retinal Detachment","C26874","An eye emergency condition which may lead to blindness if left untreated. It is characterized by the separation of the inner retina layers from the underlying pigment epithelium. Causes include trauma, advanced diabetes mellitus, high myopia, and choroid tumors. Symptoms include sudden appearance of floaters, sudden light flushes, and blurred vision.","Retinal Detachment | DETACHMENT, RETINA | Retinal detachment",,,,,,,,,,,,,,,"378414","Retinal detachment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706867","B-Symptoms","C43283","Features commonly associated with lymphoma, including fever above 38C, drenching night sweats, and weight loss of more than 10% of body mass in the previous 6 months.  B symptoms are signs of a poor prognosis in patients with lymphoma.","B-Symptoms | B Symptoms | Systemic B symptoms | ann arbor b symptom described | ann_arbor_b_symptoms_described",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016169","Fistula","C3045","Abnormal epithelial-lined communication between two anatomical structures.","Fistula | FISTULA | Pathologic Fistula | fistula",,,,,,,,,,,,,,,"4043006|4324769","Fistula|Fistula",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0006266","Bronchospasm","C34439","Sudden contraction of the smooth muscles of the bronchial wall.","Bronchospasm | ",,,,,,,,,,,,,,,"256717","Bronchospasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4227886","Uveitis","C26909","An inflammatory process affecting a part of or the entire uvea. Causes include inflammatory agents (e.g., herpes simplex, herpes zoster, leptospirosis) and systemic diseases (e.g., inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis). Patients present with pain and redness in the eye, light sensitivity, and blurred and decreased vision.","Uveitis | ",,,,,,,,,,,,,,,"4028363","Uveitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4015391","Retinal Disorder","C26875","A non-neoplastic or neoplastic disorder that affects the retina.","Retinal Disorder | Retinal Disease",,,,,,,,,,,,,,,"378416","Retinal disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010692","Cystitis","C26738","Inflammation of the urinary bladder.","Cystitis | Bladder infection",,,,,,,,,,,,,,,"195588","Cystitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021925","Intubation Procedure","C37981","The insertion of a cannula or tube into a hollow body organ.","Intubation Procedure | Intubation | Intubation",,,,,,,,,,,,,,,"4202832","Intubation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0521585","Gastrointestinal Mucositis","C3853","Inflammation of the mucous membranes lining the gastrointestinal tract.","Gastrointestinal Mucositis | Mucositis | Mucositis | mucositis",,,,,,,,,,,,,,,"437915","Gastrointestinal mucositis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018767","Hearing","C16670","The auditory faculty, the perception of sound by the ear.","Hearing | ",,,,,,,,,,,,,,,"4186287","Hearing",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1443235","First Name","C40974","A word or group of words indicating a person's first (personal or given) name; the name that precedes the surname.","First Name | Forename | Given Name | pi first name | pi_first_name",,,,,,,,,,,,,,,"4256892","Forename",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0340652","Arterial Injury","C35401","Damage to an artery from traumatic or pathologic processes.","Arterial Injury | Arterial injury",,,,,,,,,,,,,,,"4270502","Injury of artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010825","Cytomegalovirus","C14196","A genus of the family herpesviridae, subfamily betaherpesvirinae, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions.","Cytomegalovirus | CMV | CMV, CYTOMEGALOVIRUS | CYTOMEGALOVIRUS | Cytomegalovirus (CMV) Infection | HUMAN HERPESVIRUS 5 | cytomegalovirus",,,,,,,,,,,,,,,"4234496","Cytomegalovirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0150312","Present","C25626","Being or existing in a specified place or at the specified time.","Present | Found | In | PRESENT | Presence | Present (qualifier value)",,,,,,,,,,,,,,,"4181412","Present",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4229106","Pulmonary Hypertension","C3120","Increased pressure within the pulmonary circulation due to lung or heart disorder.","Pulmonary Hypertension | Pulmonary hypertension | Pulmonary hypertension, unspecified",,,,,,,,,,,,,,,"4322024","Pulmonary hypertension",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4230735","Pericarditis","C34915","An inflammatory process affecting the pericardium.","Pericarditis | ",,,,,,,,,,,,,,,"4138837","Pericarditis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006434","Burn","C34441","A traumatic injury involving interruption of tissue cohesiveness that results from exposure to caustic chemicals, extreme heat, extreme cold or excessive radiation.","Burn | Burn(s)",,,,,,,,,,,,,,,"4168004|442013","Burn injury|Burn",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0151514","Skin Atrophy","C35163","The degeneration and thinning of the epidermis and dermis. It is usually a manifestation of aging.","Skin Atrophy | Atrophic Skin | Atrophy of Skin | Skin atrophy",,,,,,,,,,,,,,,"134118","Atrophic condition of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3809449","Obesity","C3283","Having a high amount of body fat (body mass index [BMI] of 30 or more).","Obesity | Obesity, unspecified | obesity",,,,,,,,,,,,,,,"433736","Obesity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0702166","Acne","C27195","An inflammatory process of the sebaceous glands which is characterized by comedones, nodules, papules and/or pustules on the skin.","Acne | Acne Vulgaris | acne",,,,,,,,,,,,,,,"141095","Acne",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018061","Gonadotropin","C2273","Heterodimeric glycoprotein Gonadotropin consists of alpha (common)/beta (unique) protein subunits. The alpha subunit is present in other heterodimeric glycoprotein hormones. The beta subunit confers biological specificity and stimulates ovarian synthesis of steroids (progesterone) to maintain pregnancy.","Gonadotropin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001655","Corticotropin","C2282","Corticotropin (39 aa, ~5 kDa) is encoded by the human POMC gene. This protein plays a role in the stimulation of cortisol secretion by the adrenal gland.","Corticotropin | ACTH | Adrenocorticotropic Hormone | Adrenocorticotropic Hormone | Adrenocorticotropin | adrenocorticotropic hormone | corticotropin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039446","Telangiectasia","C28194","Local dilatation of small vessels resulting in red discoloration of the skin or mucous membranes.","Telangiectasia | telangiectasia",,,,,,,,,,,,,,,"4010094","Telangiectasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019112","Hemorrhoid","C26792","Dilated veins in the anal canal.","Hemorrhoid | Hemorrhoids | hemorrhoid",,,,,,,,,,,,,,,"195562","Hemorrhoids",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014335","Enteritis","C26765","Inflammation of the small intestine.","Enteritis | ",,,,,,,,,,,,,,,"201773","Enteritis of small intestine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4231189","Hyperthyroidism","C3123","Overactivity of the thyroid gland resulting in overproduction of thyroid hormone and increased metabolic rate. Causes include diffuse hyperplasia of the thyroid gland (Graves' disease), single nodule in the thyroid gland, and thyroiditis. The symptoms are related to the increased metabolic rate and include weight loss, fatigue, heat intolerance, excessive sweating, diarrhea, tachycardia, insomnia, muscle weakness, and tremor.","Hyperthyroidism | Hyperthyroid | Overactive Thyroid | hyperthyroidism | overactive thyroid",,,,,,,,,,,,,,,"4142479","Hyperthyroidism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4228758","Kyphosis","C34754","Abnormally increased curvature of the thoracic portion of the spine.","Kyphosis | KYPHOSIS",,,,,,,,,,,,,,,"4214530","Kyphosis deformity of spine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032227","Pleural Effusion","C3331","Increased amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough, and chest pain. It is usually caused by lung infections, congestive heart failure, pleural and lung tumors, connective tissue disorders, and trauma.","Pleural Effusion | PLEURAL_EFFUSION | Pleural effusion | Pleural effusion(s) | Pleural effusion, NOS | pleural effusion",,,,,,,,,,,,,,,"254061","Pleural effusion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4229632","Proteinuria","C38012","The presence of abnormal amounts of protein in the urine.","Proteinuria | ",,,,,,,,,,,,,,,"75650","Proteinuria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0151735","Injection Site Reaction","C3508","An intense reaction (usually immunologic) developing at the site of injection","Injection Site Reaction | Injection site reaction",,,,,,,,,,,,,,,"4319315","Injection site disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027059","Myocarditis","C34831","Inflammation of the muscle tissue of the heart.","Myocarditis | ",,,,,,,,,,,,,,,"314383","Myocarditis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3810134","Lymphopenia","C26823","An abnormally small number of lymphocytes in the circulating blood.","Lymphopenia | Lymphocyte count decreased | Lymphocytopenia | lymphocytic leukopenia | lymphocytopenia | lymphopenia",,,,,,,,,,,,,,,"441541","Lymphocytopenia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020649","Hypotension","C3128","Blood pressure that is abnormally low.","Hypotension | Blood pressure disorder | Low Blood Pressure | Low Blood Pressure/ Hypotension | Vascular Hypotensive Disorder | hypotension",,,,,,,,,,,,,,,"317002","Low blood pressure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020461","Hyperkalemia","C37968","Higher than normal levels of potassium in the circulating blood; associated with kidney failure or sometimes with the use of diuretic drugs.","Hyperkalemia | ",,,,,,,,,,,,,,,"434610","Hyperkalemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522135","Hypermagnesemia result","C37969","Higher than normal levels of magnesium in the circulating blood.","Hypermagnesemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2830004","Somnolence","C26754","A sleep disorder characterized by excessive sleepiness and drowsiness.","Somnolence | ",,,,,,,,,,,,,,,"4152347|4196193","Drowsy|Drowsiness",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1862666","Renal Failure","C4376","An acute or chronic condition that is characterized by the inability of the kidneys to adequately filter the blood.","Renal Failure | Kidney Failure | Renal Failure Syndrome | Renal Insufficiency | Unspecified kidney failure | kidney failure | renal failure",,,,,,,,,,,,,,,"192359","Renal failure syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3152141","Ventricular Arrhythmia","C26924","A disorder characterized by an electrocardiographic finding of an atypical cardiac rhythm resulting from a pathologic process in the cardiac ventricles.","Ventricular Arrhythmia | Ventricular arrhythmia",,,,,,,,,,,,,,,"4185572","Ventricular arrhythmia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519386","Smoking Status","C19796","An indication of a person's current tobacco and nicotine consumption as well as some indication of smoking history.","Smoking Status | Current Tobacco and Nicotine Consumption Status | tobacco smoking status | tobacco_smoking_status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439227","Hour","C25529","A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day.","Hour | HOUR | HOURS | Hours | h | hour | hr",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031256","Petechia","C3323","Purple or red hemorrhagic pinpoint spots in the skin or mucous membranes.","Petechia | Petechiae | petechiae",,,,,,,,,,,,,,,"4172626","Petechia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522136","Hypernatremia","C37970","Higher than normal levels of sodium in the circulating blood.","Hypernatremia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012833","Dizziness","C37943","A sensation of lightheadedness, unsteadiness, turning, spinning or rocking.","Dizziness | Dizzy | Lightheadedness",,,,,,,,,,,,,,,"4223938","Dizziness",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3807325","Photophobia","C28210","Increased sensitivity of the eyes to light, which can result in the avoidance of light exposure.","Photophobia | Light Sensitivity | Ocular Photosensitivity | photophobia",,,,,,,,,,,,,,,"4260194","Photophobia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032285","Pneumonia","C3333","An acute, acute and chronic, or chronic inflammation focally or diffusely affecting the lung parenchyma, due to infections (viruses, fungi, mycoplasma, or bacteria), treatment (e.g. radiation), or exposure (inhalation) to chemicals. Symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.","Pneumonia | Patient_developed_pneumonia | Pneumonia, NOS | pneumonia",,,,,,,,,,,,,,,"255848","Pneumonia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4015590","Hypertriglyceridemia","C37971","A laboratory test result indicating elevated triglyceride concentration in the blood.","Hypertriglyceridemia | High Triglycerides",,,,,,,,,,,,,,,"4120314","Hypertriglyceridemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0234621","Visual","C38059","Relating to or using sight; able to be seen.","Visual | Visualization | Visualized",,,,,,,,,,,,,,,"4113286","Visual",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3553768","Pneumothorax","C38006","Abnormal presence of air in the pleural cavity.","Pneumothorax | ",,,,,,,,,,,,,,,"253796","Pneumothorax",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3550344","Urinary Frequency","C26906","Urination at short intervals; it may result from increased urine formation, decreased bladder capacity, or lower urinary tract irritation.","Urinary Frequency | Urinary Frequency / Polyuria | Urinary frequency",,,,,,,,,,,,,,,"4012368","Increased frequency of urination",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039082","Syndrome","C28193","A group of signs, symptoms, and clinicopathological characteristics that may or may not have a genetic basis and collectively define an abnormal condition.","Syndrome | syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3553475","Pericardial Effusion","C3319","Fluid collection within the pericardial sac, usually due to inflammation.","Pericardial Effusion | FLUID, PERICARDIAL | Fluid, Pericardial | PERICARDIAL FLUID | PERICARDIAL_EFFUSION | Pericardial Fluid | Pericardial effusion | pericardial effusion",,,,,,,,,,,,,,,"4161701","Pericardial effusion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013395","Dyspepsia","C26756","An uncomfortable, often painful feeling in the stomach, resulting from impaired digestion. Symptoms include burning stomach pain, bloating, heartburn, nausea, and vomiting. Causes include gastritis, gastric ulcer, gastroesophageal reflux disease, pancreatic disease, and gallbladder disease.","Dyspepsia | Indigestion | dyspepsia",,,,,,,,,,,,,,,"439418","Indigestion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031542","Phlebitis","C38003","Inflammation of a vein.","Phlebitis | phlebitis",,,,,,,,,,,,,,,"318174","Phlebitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1861147","Hypocalcemia","C37973","Lower than normal levels of calcium in the circulating blood.","Hypocalcemia | ",,,,,,,,,,,,,,,"435510","Hypocalcemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4013574","Pulmonary Fibrosis","C26869","Chronic progressive interstitial lung disorder characterized by the replacement of the lung tissue by connective tissue, leading to progressive dyspnea, respiratory failure, or right heart failure. Causes include chronic inflammatory processes, exposure to environmental irritants, radiation therapy, autoimmune disorders, certain drugs, or it may be idiopathic (no identifiable cause).","Pulmonary Fibrosis | Pulmonary Interstitial Fibrosis | Pulmonary fibrosis | Pulmonary interstitial fibrosis",,,,,,,,,,,,,,,"4197819","Fibrosis of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033774","Pruritus","C3344","An intense itching sensation.","Pruritus | Itch | Itching | Itching (pruritus) | Itching Sensation | pruritus",,,,,,,,,,,,,,,"4169287","Itching of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0740394","Hyperuricemia","C3961","Elevated blood concentrations of uric acid.","Hyperuricemia | hyperuricemia",,,,,,,,,,,,,,,"4147761","Hyperuricemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706244","Summary","C42581","A shortened version of a speech or written text, containing only the main points.","Summary | Precis | summary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011167","Swallowing","C38028","The act of passing something through the mouth and throat into the stomach.","Swallowing | ",,,,,,,,,,,,,,,"4185237","Deglutition",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030415","Paraffin","C727","A common name for a group of high molecular weight alkane hydrocarbons with the general formula CnH2n+2, where n is between 22 and 27. Paraffin is also a technical name for an alkane in general, but in most cases it refers specifically to a linear, or normal alkane. It is mostly found as a white, odorless, tasteless, waxy solid, with a melting point between 47C and 65C. It is insoluble in water, but soluble in ether, benzene, and certain esters. Paraffin is unaffected by most common chemical reagents but oxidizes readily.","Paraffin | PARAFFIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036592","Self Care","C15324","Personal performance of activities or tasks traditionally performed by professional health care providers.","Self Care | Self-care | Selfcare",,,,,,,,,,,,,,,"4293157|45769208","Self-care interventions|Cares for self",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL448699","Primary","C25251","Occurring first in time or sequence; original; of greatest rank or importance or value.","Primary | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0460004","Head and Neck","C12418","For oncology, an area of the body generally construed to comprise the base of skull and facial bones, sinuses, orbits, salivary glands, oral cavity, oropharynx, larynx, thyroid, facial and neck musculature and lymph nodes draining these areas.","Head and Neck | H and N | HEAD AND NECK | Head & Neck | craniocervical region",,,,,,,,,,,,,,,"4300167","Structure of head and/or neck",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002978","angiogram","C16290","An image of blood vessels.","Angiogram | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004927","Behavior","C16326","The actions or reactions of an object or organism, usually in relation to the environment or surrounding world of stimuli.","Behavior | Attitude | Behavioral | Conduct",,,,,,,,,,,,,,,"4309063","Behavior finding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0439230","Week","C29844","Any period of seven consecutive days.","Week | WEEK | WEEKS | week | wk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3806976","Hypokalemia","C37974","Lower than normal levels of potassium in the circulating blood.","Hypokalemia | ",,,,,,,,,,,,,,,"437833","Hypokalemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1969971","Insomnia","C28286","A sleep disorder characterized by difficulty in falling asleep and/or remaining asleep.","Insomnia | insomnia",,,,,,,,,,,,,,,"436962","Insomnia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040053","Thrombosis","C26891","The formation of a blood clot in the lumen of a vessel or heart chamber; causes include coagulation disorders and vascular endothelial injury.","Thrombosis | ",,,,,,,,,,,,,,,"4130722|4231363","Thrombosis|Thrombosis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3887515","Genitourinary","C25350","Of or related to the genital and urinary organs or their functions.","Genitourinary | Genitourinary, NOS | Urogenital",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0151723","Hypomagnesemia","C37975","Lower than normal levels of magnesium in the circulating blood.","Hypomagnesemia | ",,,,,,,,,,,,,,,"4098604","Hypomagnesemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042267","Vaginitis","C26911","A non-infectious or infectious inflammatory process affecting the vagina.","Vaginitis | Vaginal Inflammation | Vaginal inflammation",,,,,,,,,,,,,,,"4149084","Vaginitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023764","Lipase","C37988","Lipase; an enzyme secreted in the digestive tract that catalyzes the breakdown of fats into individual fatty acids that can be absorbed into the bloodstream.","Lipase | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042109","Urticaria","C3432","A transient, itchy skin eruption characterized by wheals with pale interiors and red margins.","Urticaria | Hives | hives | urticaria",,,,,,,,,,,,,,,"139900|4275899","Urticaria|Urticaria",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3806485","Hypophosphatemia","C37977","Lower than normal levels of phosphates in the circulating blood.","Hypophosphatemia | ",,,,,,,,,,,,,,,"4177973","Hypophosphatemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020625","Hyponatremia","C37976","Lower than normal levels of sodium in the circulating blood.","Hyponatremia | ",,,,,,,,,,,,,,,"4232311","Hyponatremia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1547383","Person Name","C25191","A word or group of words indicating the identity of a person usually consisting of a first (personal) name and a last (family) name with an optional middle name. In some cultural traditions the family name comes first.","Person Name | Contact Name | Individual's Name | Name | Name | Name of Person | Person.name",,,,,,,,,,,,,,,"37116951","Person name (property)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516084","Attempt","C39769","An activity intended to do or accomplish something.  Routinely used as in 'number of tries to complete a procedure'.","Attempt | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030054","Oxygen","C722","An element with atomic symbol O, atomic number 8, and atomic weight 16.","Oxygen | O | OXYGEN | oxygen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439165","Percentage","C25613","A fraction or ratio with 100 understood as the denominator.","Percentage | %",,,,,,,,,,,,,,,"4041099","Percent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1521828","Rate","C25636","A measurement of degree, speed, or frequency relative to time.","Rate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519941","Validation","C16237","The act of validating; finding or testing the truth of something.","Validation | validation | validity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023516","Leukocyte","C12529","Blood cells that are devoid of hemoglobin, capable of ameboid motion and phagocytosis, and act as the principal components of the immune system.","Leukocyte | LEUKOCYTE | Leukocytes | Reticuloendothelial System, Leukocytes | WBC | WBCs | White Blood Cell | White Blood Cells | White Blood Corpuscle | White Cell | leukocyte | white blood cell",,,,,,,,,,,,,,,"4198678","Leukocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014792","Erythrocyte","C12521","A blood cell specialized for oxygen transport, having a high concentration of hemoglobin in the cytoplasm. They are biconcave, anucleate discs, with a 6-8um diameter in humans.","Erythrocyte | Blood Corpuscles | Blood Erythrocyte | ERYTHROCYTES | Erythrocytes | Erythrocytic | Normocyte | RBC | RBCs | Red Blood Cells | Red Blood Corpuscule | Red Cell | Red blood cells | Red cells | Reticuloendothelial System, Erythrocytes | erythrocyte | red blood cell",,,,,,,,,,,,,,,"4218976","Erythrocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517205","Flare","C37953","Flare; reddening of the skin spreading outward from a focus of infection or irritation; a sudden recurrence or worsening of symptoms.","Flare | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035222","Acute Respiratory Distress Syndrome","C3353","Progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. Cases of neonatal respiratory distress syndrome are not included in this definition.","Acute Respiratory Distress Syndrome | ARDS | Adult RDS | Adult Respiratory Distress Syndrome | Adult Respiratory Distress Syndrome | Adult respiratory distress syndrome",,,,,,,,,,,,,,,"4195694","Acute respiratory distress syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL524172","Secondary Malignant Neoplasm","C4968","A malignant neoplasm that arises from a pre-existing lower grade lesion, or as a result of a primary lesion that has spread to secondary sites, or due to a complication of a cancer treatment.","Secondary Malignant Neoplasm | SMN | Secondary Cancer | Secondary Malignancy | Secondary malignant neoplasm of unspecified site | secondary cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018418","Gynecomastia","C3073","A non-neoplastic focal or diffuse proliferation of glandular tissue of breast in males.","Gynecomastia | ",,,,,,,,,,,,,,,"4168447","Gynecomastia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3280417","Ataxia","C26702","Lack of coordination of muscle movements resulting in the impairment or inability to perform voluntary activities. Causes include peripheral nerve disorders, posterior column injuries, cerebral and cerebellar disorders, basal ganglia disorders, and thalamic disorders.","Ataxia | ataxia",,,,,,,,,,,,,,,"437584","Ataxia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4231170","Dry Eye Syndrome","C34553","A syndrome characterized by dryness of the cornea and conjunctiva. It is usually caused by a deficiency in tear production. Symptoms include a feeling of burning eyes and a possible foreign body presence in the eye.","Dry Eye Syndrome | Dry Eye | Dry Eye(s) | Dry eye | Keratoconjunctivitis Sicca",,,,,,,,,,,,,,,"378427","Tear film insufficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1314939","Involvement","C25548","To have a connection by participation or association or use; sharing in an activity or process.","Involvement | Involved",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4228099","Glaucoma","C26782","Increased pressure in the eyeball due to obstruction of the outflow of aqueous humor.","Glaucoma | glaucoma",,,,,,,,,,,,,,,"437541","Glaucoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0853877","Genitourinary Fistula","C9489","An abnormal tract between the urinary system and the anterior surface of the gynecologic structures. These include vesico-vaginal, urethro-vaginal, uretero-vaginal, vesico-uterine, uretero-uterine, vesico-cervical, vesico-utero-vaginal fistulae.","Genitourinary Fistula | Urogenital Fistula",,,,,,,,,,,,,,,"42536549","Fistula of genitourinary tract",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085593","Chills","C35143","Shivering or moderate tremors of the body often accompanied by a cold sensation.","Chills | Chill",,,,,,,,,,,,,,,"434490","Chill",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019046","Hemoglobin","C16676","The red respiratory protein of erythrocytes, consisting of approximately 3.8% heme and 96.2% globin (64.5 KD), which as oxyhemoglobin (HbO2) transports oxygen from the lungs to the tissues where the oxygen is readily released and HbO2 becomes Hb.","Hemoglobin | Hb | Hgb | hemoglobin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4229543","Colitis","C26723","Inflammation of the colon.","Colitis | colitis",,,,,,,,,,,,,,,"4272488","Colitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017040","Gamma-Glutamyl Transpeptidase","C37959","GGT participates in the transfer of amino acids across the cellular membrane and in glutathione metabolism. High concentrations are found in the liver, bile ducts, and the kidney.  A test that measures the amount of GGT in the blood is used to detect diseases of the liver, bile ducts, and kidney; and to differentiate liver or bile duct (hepatobiliary) disorders from bone disease.","Gamma-Glutamyl Transpeptidase | EC 2.3.2.2 | EC 3.4.19.13 | GGT | Gamma Glutamyl Transferase | Gamma-GT | Gamma-Glutamyltransferase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010200","Cough","C37935","A sudden, often repetitive, spasmodic contraction of the thoracic cavity, resulting in violent release of air from the lungs, and usually accompanied by a distinctive sound.","Cough | Coughing",,,,,,,,,,,,,,,"254761","Cough",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3551741","Constipation","C37930","Irregular and infrequent or difficult evacuation of the bowels.","Constipation | constipation",,,,,,,,,,,,,,,"75860","Constipation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3806108","Hemoglobinuria","C34677","A laboratory test result which indicates free hemoglobin in the urine.","Hemoglobinuria | ",,,,,,,,,,,,,,,"321414","Hemoglobinuria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0849974","Forced Expiratory Volume in 1 Second","C38084","A test of lung function, the FEV1 is the volume exhaled during the first second of a forced expiratory maneuver started from the level of total lung capacity. It is the most frequently used index for assessing bronchoconstriction or bronchodilatation.","Forced Expiratory Volume in 1 Second | FEV1 | FEV1%VC | Forced Expiratory Volume 1 Test | PFT/FEV1 | Pulmonary Function Test/Forced Expiratory Volume 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016382","Flushing","C26775","Reddening of the skin from a transient increase in blood flow.","Flushing | Flushed",,,,,,,,,,,,,,,"318566|4068353","Flushing|Blushing",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0011175","Dehydration","C26740","A condition resulting from the excessive loss of water from the body. It is usually caused by severe diarrhea, vomiting or diaphoresis.","Dehydration | Dehydrated | dehydration",,,,,,,,,,,,,,,"435796","Dehydration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019080","Hemorrhage","C26791","The flow of blood from a ruptured blood vessel.","Hemorrhage | Bleeding | HEMORRHAGE | Hemorrhage/Bleeding | Hemorrhage/Blood Loss/Bleeding | hemorrhage",,,,,,,,,,,,,,,"4179955|437312","Hemorrhage|Bleeding",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1859608","Hypoalbuminemia","C37972","Concentration of serum albumin below normal limits for the age related normal range.","Hypoalbuminemia | ",,,,,,,,,,,,,,,"4001047","Hypoalbuminemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020437","Hypercalcemia","C3112","Abnormally high concentration of calcium in the peripheral blood.","Hypercalcemia | hypercalcemia",,,,,,,,,,,,,,,"435511","Hypercalcemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448971","International Normalized Ratio","C25352","A system, commonly called the INR, established by the World Health Organization (WHO) and the International Committee on Thrombosis and Hemostasis for reporting the results of blood coagulation (clotting) tests. All results are standardized using the international sensitivity index (ISI) for the particular thromboplastin reagent and instrument combination utilized to perform the test; the ratio of a patient's clotting time to the lab's mean reference value is normalized against the ISI. (from medterms.com and medicine.ucsf.edu)","International Normalized Ratio | INR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023618","Libido","C37986","Sexual urge or desire.","Libido | Sex Drive | Sexual Desire | Sexual Urge | libido | sex drive | sexual drive",,,,,,,,,,,,,,,"4087316","Libido",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020517","Hypersensitivity","C3114","An immune response that occurs following exposure to an innocuous antigen, but that does not require the presence of preformed antibodies to the antigen.","Hypersensitivity | Allergic reaction | Hypersensitive | Hypersensitivity Reaction | Hypersensitivity/Allergic reaction | Sensitive | Sensitivity | hypersensitivity",,,,,,,,,,,,,,,"36683564|4223616|43530807","Allergic disorder|Hypersensitivity reaction|Allergic disposition",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C0439825","Auditory","C37915","Of or relating to the process of hearing.","Auditory | ",,,,,,,,,,,,,,,"4114509","Auditory",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2945560","Hemolysis Laboratory Result","C37965","Disruption of the integrity of the erythrocyte membrane causing release of hemoglobin.","Hemolysis | Hemolytic",,,,,,,,,,,,,,,"4250490","Hemolysis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3554472","Diarrhea","C2987","Watery bowel movements.","Diarrhea | Diarrheal Disease | Frequent Stools | Loose Stools | diarrhea",,,,,,,,,,,,,,,"196523","Diarrhea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522133","Hypercholesterolemia (finding)","C37967","A laboratory test result indicating an increased amount of cholesterol in the blood.","Hypercholesterolemia | Cholesterol high | High Cholesterol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009676","Confusion","C37928","A mental state characterized by a lack of clear and orderly thought and behavior.","Confusion | Confusion/ Disorientation | Disorientation | confusion | disorientation",,,,,,,,,,,,,,,"4164633","Clouded consciousness",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0344232","Blurred Vision","C27123","Blurred vision is the loss of visual acuity (sharpness of vision) resulting in a loss of ability to see small details. (from MedlinePlus Medical Encyclopedia)","Blurred Vision | Blurred vision",,,,,,,,,,,,,,,"4006463|4079185","Blurring of visual image|Hazy vision",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0019521","Hiccough","C37966","An involuntary contraction of the diaphragm against closed vocal cords, producing the 'hic' sound.","Hiccough | Hiccup | Hiccups | Singultus",,,,,,,,,,,,,,,"194475","Hiccoughs",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242184","Hypoxia","C3890","A decrease in the amount of oxygen in the body. Symptoms range from mild (impaired judgment, memory loss, impaired motor coordination) to severe (seizures and coma).","Hypoxia | Hypoxic | hypoxia | hypoxic",,,,,,,,,,,,,,,"4306572","Hypoxia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3809921","Infertility","C3836","Inability to conceive for at least one year after trying and having unprotected sex. Causes of female infertility include endometriosis, fallopian tubes obstruction, and polycystic ovary syndrome. Causes of male infertility include abnormal sperm production or function, blockage of the epididymis, blockage of the ejaculatory ducts, hypospadias, exposure to pesticides, and health related issues.","Infertility | Fertility Disorder | Fertility Disorders | Infertile | Sterile | Sterility | infertile | infertility | sterile",,,,,,,,,,,,,,,"4311387","Infertile",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3146298","Indication","C41184","A sign, signal, circumstance, or symptom which serves to indicate or point out the cause, pathology, treatment, or issue of an attack of disease; the basis for initiation of a treatment for a disease or of a diagnostic test (causal, or symptomatic, or disease-specific indication).","Indication | Disease/Condition Indication | INDC | Indication for Use | indication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0806140","Flow","C41141","The continuous movement characteristic of a liquid or gas.","Flow | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4015534","Hyperglycemia","C26797","Abnormally high level of glucose in the blood.","Hyperglycemia | Elevated Blood Glucose | high blood sugar | hyperglycemia",,,,,,,,,,,,,,,"4214376","Hyperglycemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0012569","Diplopia","C37941","The condition in which a single object appears as two objects. Also called 'double vision.' (from medterms.com)","Diplopia | Diplopia/Double Vision | Double Vision",,,,,,,,,,,,,,,"373474","Diplopia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0699792","Relationship","C25648","A state of connectedness between people, objects, or events; to be associated or connected with something.","Relationship | Association | Related | Related | Relations",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205272","Regular","C25647","Customary, usual, or at fixed intervals; conforming to a standard or pattern.","Regular | Regularity",,,,,,,,,,,,,,,"4072676","Regular",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL031856","Treatment Regimen","C15697","A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","Treatment Regimen | Regimen | Regimen | Treatment Protocol | Treatment Schedule | regimen | regimen or line of therapy | regimen_or_line_of_therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2004454","Recovery - healing process","C25746","A healing process and/or an outcome implying relative health.  The term is typically used in the context of direct and indirect effects of sickness or injury.","Recovery | RECOVERY | recover",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034869","Records","C25198","Anything (e.g., a document) providing permanent evidence of or information about past events.","Record | record",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035150","Reproduction","C17087","The generation of offspring by living organisms.","Reproduction | Reproductive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0849355","Removed","C25650","Taken out of, separated from, or eliminated.","Removed | Eliminated | Out | Taken Out",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0544452","Remission","C18246","An abatement in intensity or degree (as in the manifestations of a disease).","Remission | N/A - Remission | remission",,,,,,,,,,,,,,,"4172372","Remission phase",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1527428","Remaining","C25649","Enduring or persisting; residual, left over or behind.","Remaining | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035039","Religion","C17085","A personal or institutionalized system grounded in belief and reverence for a supernatural power or powers regarded as creator and governor of the universe. (from dictionary.com)","Religion | religion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449444","Route","C25169","A way of getting from one place to another; an established line of travel or access; the way a chemical or pollutant enters an organism after contact, particularly, the way of drug administration.","Route | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035820","Social Role","C25199","The action or activity assigned to or required or expected of a person or group.","Social Role | Role | Role",,,,,,,,,,,,,,,"35624280","Role",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1514918","Retrieval","C25659","The operation of accessing information or removing an item from storage.","Retrieval | RETRIEVING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1274040","Outcome","C20200","The result of an action.","Outcome | Result | Result | outcome | result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514902","Restart","C25658","To take up or begin anew; resume.","Restart | Resume",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521996","Resected","C25654","Having been removed by surgery.","Resected | resected",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545933","Sensitivity","C25201","The ability to respond to physical stimuli or to register small physical amounts or differences.","Sensitivity | Sensitive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205122","Segmental","C25238","Having naturally dividable parts; divided into sections with each section adjacent to the other.","Segmental | SEGMENTAL",,,,,,,,,,,,,,,"4269656","Segmental",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519222","Security - service","C25669","Services provided to prevent, deter, detect and/or document crime, fire, disorder or violations of company rules.","Security | Secure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519193","Scheme","C25665","An elaborate and systematic plan of action.","Scheme | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086960","Schedule (document type)","C25211","An ordered list of times at which things are planned to occur.","Schedule | Scheduled | schedule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0870078","Sampling","C25662","The selection and obtaining of small representative quantities of biological material for the purpose of analysis; also, in biomedical statistics, sampling is the selection and implementation of statistical observations in order to estimate properties of an underlying population; also, in environmental science, the collection of representative specimens analyzed to characterize site conditions.","Sampling | ",,,,,,,,,,,,,,,"4117495","Sampling - action",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3203359","Rupture","C9445","Forcible tearing or disruption of tissue.","Rupture | RUPTURE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441987","Side","C25306","One of the two lateral margins or surfaces of a body, midway between the front and back.","Side | ",,,,,,,,,,,,,,,"4112563","Side",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0229671","Serum","C13325","The clear portion of the blood that remains after the removal of the blood cells and the clotting proteins.","Serum | SERUM | Sera | serum",,,,,,,,,,,,,,,"4194767","Serum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519249","Sequence","C25673","A serial arrangement in which things follow in logical order or a recurrent pattern.","Sequence | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456389","Size","C25681","The physical magnitude of something.","Size | SIZE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037778","Medical Specialty","C17153","An area of specialized study within the broader practice of medicine and surgery.","Medical Specialty | Specialty | Specialty",,,,,,,,,,,,,,,"4215266","Medical specialty",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1301826","address line","C25690","The street name and building number where a person or organization is located.","Street Address | Address Line | STREET | Street",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514983","Stratification","C25689","The process of classifying patients into a sequence of grades or ranks as part of the randomization process or for purposes of data analysis.","Stratification | stratification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704379","Treatment Step","C16154","A specific stage of progression through a sequential treatment protocol.","Treatment Step | Step | Step | current step | current_step",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1442792","State","C25687","The way something is with respect to its main attributes.","State | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1301821","Social Security Number","C25686","A nine digit identification number resembling '123-45-6789' which is issued to an individual by the Social Security Administration of the United States federal government.","Social Security Number | SSN | SSN",,,,,,,,,,,,,,,"4162224","Social security number",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205148","Surface","C25245","The extended two-dimensional outer boundary of a three-dimensional object.","Surface | SURFACE | Surface (qualifier value)",,,,,,,,,,,,,,,"4256609","Surface",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1515051","Sum","C25697","The final aggregate amount.","Sum | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0597535","Success","C25362","An event that accomplishes its intended purpose.","Success | Successful",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449560","Subtype","C25696","A group forming a type within a larger type.","Subtype | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515023","Submitted","C25695","The act of referring for judgment or consideration by others; the act of handing over something.","Submission | Submit | Submitted | Submitted | submitted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0231174","Failure","C25745","A lack of occurrence or performance.","Failure | FAILURE | Malfunction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3808973","Fracture","C3046","A traumatic injury to the bone in which the continuity of the bone is broken.","Fracture | Bone Fracture | Bone Fracture(s) | FRACTURE | FRACTURE_SITE | Fracture of Bone",,,,,,,,,,,,,,,"4217808|75053","Fracture|Fracture of bone",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1264633","Fraction","C25514","A part, a fragment of a whole.","Fraction | Fractions",,,,,,,,,,,,,,,"4014169|4020185|4081834","Fractions of|Fraction of|Fractions",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C0524811","Dose Fractionation","C15654","Radiation therapy in which the total dose delivered is divided into several smaller, equal doses delivered over a period of several days.","Fractionated Radiotherapy | Fractionated | Fractionation | Fractionation Radiotherapy | Fractions | fractionation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522492","Formation","C25513","The act of forming something or the structure formed.","Formation | Form | Forming",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL052185","Focus","C25511","Area of greatest concentration, attention, or activity; a central point or locus, especially of an infection.","Focus | Focal | Foci | Foci | Focused",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272229","Fluorochrome Dye","C503","A class of dyes when excited by light of certain wavelengths, emit photons and become fluorescent.  Fluorescence gives fluorochromes imaging characteristics and are used to label or stain biological structures.","Fluorochrome Dye | Fluorescent Dye | Fluorochrome | Fluorophore",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554605","Biological Growth","C18825","Processes that promote either specific or nonspecific formation of additional tissue mass, typically by cell proliferation.","Generalized Growth | Growth | Growth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522242","Grouping","C25523","A system for classifying things into groups or the activity of putting things together in groups.","Grouping | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919553","Histologic Grade","C18000","The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","Histologic Grade | Grade | Grade (high/low) | Grading | HISTOLOGY_GRADE | Histology Grade | Histopathologic Grade | Histopathology Grade | OVLTGRD | Overall Tumor Grade | Tumor Grade | Tumor_Grade | grade | grading | histological grade | histological_grade",,,,,,,,,,,,,,,"4160340","Histologic grade of neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205396","Identification","C25737","The procedure of having an identity established.","Identification | Identified | Identified",,,,,,,,,,,,,,,"4302031","Identified",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021308","Infarction","C25738","A localized pathological necrosis of tissue resulting from obstruction of the blood supply usually by a thrombus, an embolus, or vascular torsion.","Infarction | INFARCT | Infarct | Infarcts",,,,,,,,,,,,,,,"4206471","Infarct",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332534","Induration","C25534","The quality of being hard, the process of hardening, or an abnormally hard spot or place, particularly of the skin.","Induration | ",,,,,,,,,,,,,,,"4165876","Induration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0918012","Index","C25390","A numerical scale used to compare variables with one another or with some reference number; a number used to select an element of a list, vector, array or other sequence.","Index | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205217","Increase","C25533","A process of becoming larger, more numerous, more important, or more likely.","Increase | Heightened | INCREASED | Increased",,,,,,,,,,,,,,,"4123515","Increase",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0336545","Therapeutic implant device","C17948","A device placed in tissue to deliver therapeutic agents at a controlled, constant release rate.","Therapeutic Implant | Drug Implant | Implant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663266","Tumor Cell Invasion","C20625","The local spread of tumor cells of a malignant neoplasm through infiltration or destruction of adjacent tissue; for epithelial neoplasms, invasion signifies infiltration beneath the epithelial basement membrane.","Tumor Cell Invasion | Invasion | Invasion | Local Tumor Invasion | Tumor Invasion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517574","Invaded","C25546","Penetrated through tissue.","Invaded | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512900","Interruption","C25542","A time interval during which there is a temporary cessation of something.","Interruption | Interrupted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1283828","Intent","C25725","An anticipated outcome that is the purpose for actions taken, thus guiding the action.","Intent | Intended | Intention",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512806","Intake","C25538","The process of taking in a substance, especially by eating or drinking, or the quantities thereof; admittance of people to a place or organization at a particular time.","Intake | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574032","Infusion Procedure","C15388","Any form of treatment that is introduced into the body via a blood vessel, a muscle, or the spinal cord.","Infusion Procedure | Infused | Infusion | Infusion | infusion",,,,,,,,,,,,,,,"4044191|4269838","Infusion - action|Infusion",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0332448","Infiltration","C25754","The process of the diffusion or accumulation in a tissue or cells of a substance not normal to it or in amounts above normal. (NCI)","Infiltration | Infiltrate | Infiltrating | Infiltration into Tissue",,,,,,,,,,,,,,,"4264333","Infiltration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009450","Infectious Disorder","C26726","A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.","Infectious Disorder | Clinical Infection | ID | INFECTION | Infection | Infection | Infectious | Infectious Disease | Infectious Diseases and Manifestations | Infectious Disorder | Unspecified Infection | infection",,,,,,,,,,,,,,,"432250","Infectious disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1444754","Length","C25334","The linear extent in space from one end of something to the other end, or the extent of something from beginning to end.","Length | LENGTH",,,,,,,,,,,,,,,"4256605","Length",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023008","Language","C16779","A systematic means of communicating by the use of sounds, symbols, or gestures.","Language | Language Name",,,,,,,,,,,,,,,"4267143","Language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205281","Invasive","C14159","Marked by a tendency to spread, especially into healthy surrounding tissue.","Invasive | ",,,,,,,,,,,,,,,"4007353","Invasive",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0947322","Manufacturer","C25392","A person, enterprise, or entity that produces finished goods.","Manufacturer | MANUF | MANUFACTURER | Make | Maker | Manufacturer Name | Manufacturing | Manufacturing Laborer | Manufacturing Labourers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205282","Malignant","C14143","Refers to abnormal cell activity manifested by decreased control over growth and function, causing tumor growth or spread into surrounding tissue and adverse effects to the host.","Malignant | MALIGNANT | malignant",,,,,,,,,,,,,,,"4066212","Malignant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517945","Loss","C25559","A gradual decline in amount or activity.","Loss | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025320","Menopause","C3231","The permanent cessation of menses, usually defined by 6 to 12 months of amenorrhea in a woman over 45 years of age.","Menopause | Menopausal | menopause",,,,,,,,,,,,,,,"4059477","Menopause",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025255","Membrane","C12749","A thin sheet or layer of pliable tissue, serving as a covering or envelope of a part, as the lining of a cavity, as a partition or septum, or to connect two structures.","Membrane | Membranous | membrane",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441712","Mechanism","C25343","The means by which an effect is obtained.","Mechanism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242485","Measurement","C25209","Annotation used to indicate the size or magnitude of something that was determined by comparison to a standard.","Measurement | MEASUREMENT | Measure | {Measure}",,,,,,,,,,,,,,,"4048365|4154182","Measurement|Measurement technique",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3161035","Model system","C16866","A representation of something, often idealized or modified to make it conceptually easier to understand.","Model | Model | Model System | Model System | Modeling System | Models | model",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513371","Mode","C25571","A particular functioning condition or arrangement.","Mode | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521174","Microcalcification","C8433","Tiny deposits of calcium in tissue.  In the breast they can be seen using mammography, and if found in clusters may be indicative of breast cancer.","Microcalcification | Microcalcifications | microcalcification",,,,,,,,,,,,,,,"4132707","Microcalcification",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0449851","Technique","C16847","A practiced and regimented skill or series of actions.","Technique | Method | Methods | Methods and Techniques | Methods, Other | Technical | Techniques",,,,,,,,,,,,,,,"4156365","Technique",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0814225","Benefit","C25387","The positive effects of something.","Benefit | Benefits | Benefits",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527178","Basis - conceptual entity","C25430","The fundamental assumptions underlying an explanation or a relation that provide the foundation for something.","Basis | Based | Basic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522496","Axis","C25154","A straight line through a body or figure that satisfies certain conditions.","Axis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521802","Study Enrollment Closure","C25366","Refers to the closing of a study to further enrollment.","Study Enrollment Closure | Closure | Study Enrollment Closed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511276","Bottom","C25440","The lowest part, side, or surface of something.","Bottom | ",,,,,,,,,,,,,,,"4226764","Bottom",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522411","Anatomic Border","C25439","The boundary of a surface or object.","Anatomic Border | Border | Border",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511253","Boost","C25438","Increase or raise.","Boost | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527021","Text","C25704","The words of something written.","Text | text",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519795","Unit of Measure","C25709","A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.","Unit of Measure | U | UOM | Unit | Unit of Measurement | Unit(s) | Units | medication units of measure | medication_units_of_measure | unit | unit(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0805701","Code","C25162","A symbol or combination of symbols which is assigned to the members of a collection.","Code | CODE | Code Name | Coding System | code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511790","Detection","C16210","The act of perceiving, discerning, discovering, or identifying.","Detection | Detected | Detected Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006935","Capsule Dosage Form","C25158","A solid contained within either a hard or soft soluble shell, usually prepared from gelatin.","Capsule Dosage Form | CAP | CAPSULE | Cap | Capsule | Capsule | Capsule Dose Form | cap | capsule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516240","Capacity","C25443","The amount that can be contained.  It can refer to the volume that can be held, such as lung capacity, or the number of people that can be contained in a room or building.","Capacity | capacityQuantity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516151","Callback","C37922","The act or an instance of returning from one location or situation to the previous one. Concept also refers to a return telephone or radio call, particularly when a survey is conducted; and to a recall of a recently sold product (e.g. pharmaceutical) by the manufacturer.","Callback | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006663","Calcification","C3672","Deposition of calcium in the tissues. It may be the result of a metabolic disorder or long-standing infection, or it may be associated with the presence of cancer.","Calcification | Calcifications | Calcium Deposits/Calcification | calcification | calcinosis | macrocalcification",,,,,,,,,,,,,,,"4112703|4280820","Pathologic calcification|Calcinosis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0005902","Body Surface Area","C25157","A measure of the 2-dimensional extent of the body surface (i.e., the skin).  Body surface area (BSA) can be calculated by mathematical formula or from a chart that relates height to weight.  BSA is often an important factor in dosing.","Body Surface Area | BSA | BSA | Vital Signs – BSA | body surface area | body_surface_area",,,,,,,,,,,,,,,"4201235","Body surface area",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008633","Chromosome","C13202","A structure found in cells that is comprised of a strand of linearized double-stranded DNA plus proteins that package the DNA in a condensed coil form and regulate chromosomal function.","Chromosome | CHROMOSOME | Chromosomal | chromosome",,,,,,,,,,,,,,,"4239232","Chromosome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008377","Cholesterol","C369","An animal sterol found in the body tissues (and blood plasma) of vertebrates. It can be found in large concentrations within the liver, spinal cord, and brain. Cholesterol is an important component of the membranes of cells, providing stability. It is the major precursor for the synthesis of vitamin D, of the various steroid hormones, including cortisol, cortisone, and aldosterone in the adrenal glands, and of the sex hormones progesterone, estrogen, and testosterone.  Cholesterol also has an important role for the brain synapses as well as in the immune system.  In conditions featuring elevated low density lipoproteins (LDL), cholesterol often forms plaque deposits in the walls of arteries, a condition known as atherosclerosis, which is a major contributor to coronary heart disease and other forms of cardiovascular disease.","Cholesterol | (-)-Cholesterol | (3beta)-Cholest-5-en-3-ol | 5-cholesten-3B-ol | CHOLESTEROL | cholesterol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521970","Characteristics","C25447","The distinguishing qualities or prominent aspect of a person, object, action, process, or substance.","Characteristic | Characteristics | Characteristics | Feature | Features | Nature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333343","Body Cavity","C25444","A natural hollow or sinus within the body.","Body Cavity | BODY CAVITY | Cavity | cavity",,,,,,,,,,,,,,,"4240527","Body cavity structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0683312","Category","C25372","A grouping of items based on some commonality or by user defined characteristics.","Category | CAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522408","Surface Coat","C25450","A thin outer layer or film covering something.","Coat | Coated | Coated | Coating | Layer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008902","Classification","C25161","A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","Classification | Classified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456387","Class","C25346","A grouping of things based on shared common attributes.","Class | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008848","City","C25160","A large and densely populated urban area; a city specified in an address.","City | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1444657","Contraindicated","C37933","State of a particular method of treatment, regimen, procedure, medication, etc. of being unsuitable and inadvisable, often because of a likely adverse reaction.","Contraindicated | ",,,,,,,,,,,,,,,"4253634","Contraindicated",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0750484","Confirmation","C25458","Having been established or verified.","Confirmation | Confirmatory | Confirmed | Confirmed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009566","Complication","C2959","Any disease or disorder that occurs during the course of, or because of, another disease, treatment, or procedure.","Complication | Complications | Medical Complication | complication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205197","Complete","C25250","To possess every necessary or normal part or component or step; having come or been brought to a conclusion.","Complete | COMPLETE | COMPLETED | Completed | Completely | Completion",,,,,,,,,,,,,,,"4112431","Complete",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516698","Collection (action)","C25453","The act of gathering things together; having been brought together in one place.","Collection | COLLECTING | Collected | Collecting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448462","Criterion","C25466","That which constitutes a standard from which a judgment can be established, a reference point against which other things can be evaluated, or a basis for comparison.","Criterion | Criteria | Criteria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0868945","Deterioration","C25751","A symptom or state of reduced quality or strength.","Deterioration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1524084","Designated","C25479","Named or selected to an assignment.","Designated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL414326","Depth","C25333","The extent downward or inward; the perpendicular measurement from the surface downward to determine deepness.","Depth | DEPTH",,,,,,,,,,,,,,,"4305307","Depth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1533157","Fixed Block","C25436","Refers to preserved specimens embedded in support material.  These are typically cut into thin slices for microscopic examination, with or without an enhancement such as staining.","Fixed Block | Block | Block | Blocks | Blocks | Tissue Block",,,,,,,,,,,,,,,"37157268","Tissue block specimen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0333562","Deposit","C9442","Accumulation of extraneous inorganic matter in tissues or cavities.","Deposit | Deposits",,,,,,,,,,,,,,,"4188078","Deposition",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205421","Delay","C25476","Time during which some action is awaited; inactivity resulting in something being put off until a later time; the state of being slower or later.","Delay | Delayed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011155","Deficit","C37940","A lack or deficiency.","Deficit | ",,,,,,,,,,,,,,,"4126680","Deficient",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1301725","Documented","C25356","Furnished with or supported by documents and documentation.","Documented | ",,,,,,,,,,,,,,,"4134747","Documented",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0012751","Distance","C25167","The space separating two objects or points.","Distance | DISTANCE",,,,,,,,,,,,,,,"4077091","Distance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0012737","Dissection","C15227","The process of cutting apart or separating tissue as, for example, in the study of anatomy or in the course of a surgical procedure.","Dissection | ",,,,,,,,,,,,,,,"4046731","Dissection procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332453","Disruption","C25486","An interruption or interference in continuity.","Disruption | perturbation",,,,,,,,,,,,,,,"4297172","Disruption",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0870432","Display - arrangement","C25485","Exhibit, present, or demonstrate for viewing.","Display | Displayable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1444662","Discontinue","C25484","To stop or end, permanently or temporarily.","Discontinue | D/C | DIS | DISCONTINUED | Discontinuation | Discontinued | Discontinued | Discontinuous | dc | disc",,,,,,,,,,,,,,,"4132627","Discontinued",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030685","Patient Discharge","C25166","The release of a patient from a course of care.","Patient Discharge | Discharge | Discharge | Discharge from Healthcare Facility | Discharged | Release",,,,,,,,,,,,,,,"4240723","Patient discharge",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0439534","Dimension","C25483","The magnitude of something in a particular direction, especially length or width or height.","Dimension | Material Properties/Measurements | SPDMSION | Spatial Dimension",,,,,,,,,,,,,,,"4116856","Dimensions",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1301886","Diameter","C25285","The length of a straight line passing through the center of a circle or sphere and connecting two points on the circumference.","Diameter | DIAMETER | diameter",,,,,,,,,,,,,,,"4305186","Diameter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1384606","Dyspareunia","C2997","Painful or difficult coitus.","Dyspareunia | ",,,,,,,,,,,,,,,"439080","Dyspareunia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205222","Dryness","C25489","The lack of natural or normal moisture.","Dryness | Dried | Dry",,,,,,,,,,,,,,,"4029792","Dry",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0702240","Elevation","C25494","The condition of being elevated.","Elevation | ",,,,,,,,,,,,,,,"4112280","Elevation - value",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3163633","Elevated","C25493","Raised or increased above normal levels or limits.","Elevated | Above Normal Range",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013746","Ejaculation","C16531","The release of semen through the penis during orgasm. (NCI)","Ejaculation | Ejaculatory | ejaculation",,,,,,,,,,,,,,,"4222436","Ejaculation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013687","Effusion","C3003","A collection of fluid in a body cavity, which may be the result of a non-neoplastic disorder (e.g. heart failure) or a tumor (e.g. carcinoma of the lung).","Effusion | EFFUSION | effusion",,,,,,,,,,,,,,,"4215818","Effusion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030847","Erection","C25740","The hardening, enlarging and rising of the penis which often occurs in the sexually aroused male.","Erection | Erectile | erection",,,,,,,,,,,,,,,"4264490","Penile erection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1521975","Entered","C37949","Having made a record of, set down in permanent form, or formally registered to participate in an activity.","Entered | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516879","Enrollment","C37948","The act of registration, entering in a list, catalog, group, study; also, the number of subjects enrolled.","Enrollment | Subject Enrollment | enroll | enrollment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349179","End Point","C25212","A place of termination or completion. This may be a primary or secondary outcome variable used to judge the effectiveness of a treatment.","End Point | End-Point | Endpoint | Endpoints | Study Endpoint | endpoint",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439792","Extent","C25332","The range, magnitude, or distance over which a thing spans an interval of distance, space, or time.","Extent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0231449","Extend","C25270","To increase in length or duration.","Extend | Extended | Extension | Extension",,,,,,,,,,,,,,,"4123531","Extended",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017262","Gene Expression","C16608","Typically involves transcription of genetically encoded information into an intermediary message (messenger RNA) and subsequent translation into a functional protein.","Gene Expression | Expressed | Expression | Expression | gene expression",,,,,,,,,,,,,,,"4232626","Gene expression",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL031047","Exposure","C17941","The act of subjecting someone or something to an influencing experience.","Exposure | exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517001","Expected","C25501","Considered likely or probable; anticipated.","Expected | Anticipated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0679138","Expectancy","C25359","Something expected, especially the value (e.g. an amount, or length of time) or probability of occurrence for a specific event based on statistical calculations.","Expectancy | Expectation",,,,,,,,,,,,,,,"4259511|4295933","Expectation|Expectations",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0680251","Exclusion Criteria","C25370","Medical and/or social characteristics that prevent a subject from being allowed to participate in a clinical study, as outlined in the study protocol.","Exclusion Criteria | EXCLUSION | Exclusion | exclusion criteria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332128","Examined","C25500","Having been subjected to inspection or evaluation.","Examined | ",,,,,,,,,,,,,,,"4274637","Examined for",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0680844","estimation <subjective>","C25498","To calculate approximately.","Estimate | ESTIMATED | Estimated | Estimated | Estimation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016184","Fixatives","C498","A compound that preserves tissues and cells for microscopic study.","Fixative | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522646","Filed","C25175","Having been placed in a file; recorded in a public office or in a court of law.","Filed | File",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3550476","Fibrosis","C3044","The formation of fibrous tissue.","Fibrosis | FIBROSIS | fibrosis",,,,,,,,,,,,,,,"4012171|4137805","Fibrosis|Fibrosis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1518311","Nevus cell","C25585","A neoplastic cutaneous melanocyte that characterizes benign and atypical cutaneous neoplastic lesions called nevi.","Nevus Cell | Nevocyte | Nevus Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205160","Negative Finding","C38757","A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.","Negative Finding | NEGATIVE | Negative | Negative | No | Normal Finding",,,,,,,,,,,,,,,"9189","Negative",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0596988","Mutant","C25360","An altered form of an individual, organism, population, or genetic character that differs from the corresponding wild type due to one or more alterations (mutations).","Mutant | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2328219","Muscle Tissue","C12435","Tissue responsible for the body movements and the shape and size changes of internal organs.  Muscle tissue is composed of specialized contractile cells.  There are two types of muscle tissue recognized: striated and smooth muscle.  The striated muscle tissue is further subdivided into skeletal, visceral striated, and cardiac muscle.","Muscle Tissue | MUSCLE TISSUE | Muscle",,,,,,,,,,,,,,,"4325458","Muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL473794","Patient Observation","C15722","Closely watching a patient's condition but not giving treatment unless there are changes in test results. Active surveillance avoids problems that may be caused by treatments such as radiation or surgery. It is used to find early signs that the condition is getting worse. During active surveillance, patients will be given certain exams and tests done on a regular schedule. It is sometimes used in prostate cancer.","Patient Observation | Active Surveillance | Observation | Observation | Watchful Waiting | active surveillance | deferred therapy | expectant management | observation | watchful waiting",,,,,,,,,,,,,,,"4304206","Patient status observation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0683525","treatment options","C25374","Alternative choices or actions.","Options | Option",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521805","Opposite","C25602","Being directly across from each other; being on the other side or direction of; the other one of a complementary pair.","Opposite | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0243132","occurrence characteristics","C25275","An instance of something happening, such as an event or incident.","Occurrence | Occurrences",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028778","Obstruction","C3284","Blockage of the normal flow of the contents of an anatomical passageway.","Obstruction | OBSTRUCTION | Obstruction/Occlusion | obstruction",,,,,,,,,,,,,,,"4093906","Obstruction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1441672","Observed","C25599","Ascertained or determined through monitoring or observation.","Observed | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030247","Palpation","C16950","A method of feeling with the hands during a physical examination. The health care provider touches and feels the patient's body to examine the size, consistency, texture, location and tenderness of an organ or body part.","Palpation | PALPATION | palpation",,,,,,,,,,,,,,,"4013065","Palpation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0549099","Perforation","C4080","A hole or opening made through a membrane or other tissue or material.","Perforation | PERFORATION | Perforated | Perforating",,,,,,,,,,,,,,,"4263947","Perforation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448467","Penetration","C25612","The act of entering into or through something.","Penetration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449774","Pattern","C25336","An arrangement of objects, facts, behaviors, or other things which have scientific, mathematical, geometric, statistical, or other meaning.","Pattern | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1301732","Plan","C25619","To devise, contrive, or form in design.","Plan | Planned | Planned | Planning",,,,,,,,,,,,,,,"4161676","Planned",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205485","Physical","C25618","Having substance or material existence; concerned with material things; of or pertaining to the body as distinguished from the mind or spirit.","Physical | ",,,,,,,,,,,,,,,"4023796","Physical",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205390","Temporal Phase","C25257","A distinguishable part, a stage in a series of events or in a process of development, e.g. any of the varying aspects or stages in course of a disease; a fraction of a cycle.","Phase | Phased | Stage | phase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0884358","Performed","C38000","Executed and carried through to completion.","Performed | PERFORMED | Perform",,,,,,,,,,,,,,,"4160030","Performed",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016538","Projections and Predictions","C25176","A prediction made by extrapolating from past observations.","Projection | Projected",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033213","Problem","C28020","A difficulty, disorder, or condition needing resolution.","Problem | Issue",,,,,,,,,,,,,,,"4206460","Problem",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033095","Pressure","C25195","The force applied to a unit area of surface.","Pressure | ",,,,,,,,,,,,,,,"36716283","Pressure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1514583","Proximity","C25633","The state or quality of being next; immediate nearness either in time, place, blood or alliance.","Proximity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514578","Province","C25632","A region, district or division of a country; a tract; a portion a state, especially one remote from the capital.","Province | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1293121","Reconstructive Surgery","C25351","Surgical restoration of function or form of a part.","Reconstructive Surgery | RECONSTRUCTION_TYPE | RECONSTRUCTIVE SURGERY | Reconstruction | Reconstruction | reconstructive surgery",,,,,,,,,,,,,,,"4045073|4045162","Reconstruction - action|Reconstruction procedure",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0034866","Recommendation","C25197","Advice telling someone what the best thing to do is.","Recommendation | Recommended",,,,,,,,,,,,,,,"619611","Recommended",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1514756","Receive","C25639","To take, accept, or get something offered.","Receive | RECEIVED | RECEIVING | Received | Received",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443286","Reaction","C25637","A response generated by a stimulus.","Reaction | REACTIV | Reactivity",,,,,,,,,,,,,,,"4136151","Reaction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0920847","Radial","C25314","Arranged like rays or radii; radiating from a common center or moving in the direction of a radius; relating to or near the radius.","Radial | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332306","Quality","C25283","An essential and distinguishing attribute of something or someone; a degree or grade of excellence or worth.","Quality | QUALITY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0349674","Scale","C25664","An ordered reference standard used to measure incremental changes.","Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527144","Therapeutic Effect","C38032","Beneficial responses or outcomes in the prevention, treatment, or progression of a disease resulting from treatment intervention. Therapeutic effect includes prevention or reduction of adverse effects. (NCI)","Therapeutic Effect | therapeutic effect | treatment effect | treatment_effect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515273","Term (temporal)","C25703","A limited period of time.","Term | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039449","Telecommunications","C17188","The use of electronic-based systems to transmit information between a source and one or more recipients.","Telecommunications | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883727","Taken","C25701","Having been accepted for some purpose; ingested as a medication.","Taken | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522485","Tracer","C2480","A substance that is identifiable by virtue of its radioactive signature, color, or other distinguishing physical property, such as a dye, radioactive isotope, or inert chemical, that is introduced into a biological or mechanical system and can be followed through the course of a process, providing information on the pattern of events in the process or on the redistribution of the parts, elements, or events involved.","Tracer | Label | Labeled | Reporter | Tag | Tag | Tagged | scan tracer used | scan_tracer_used | tracer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522605","Topography","C38034","The description of an anatomical region or of a body part.","Topography | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041582","Ulceration","C25757","The formation or development of an ulcer.","Ulceration | ULCER | Ulcerated | Ulcerating | ulceration",,,,,,,,,,,,,,,"4136248|4206914","Ulceration|Ulcer",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0042196","Vaccination","C15346","Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis or treatment.","Vaccination | vaccination",,,,,,,,,,,,,,,"4144375","Active immunization",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448551","Use","C25340","A manner, or usual, or accepted practice of using something.","Use | Usage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042034","Urination","C25744","The discharge of urine.","Urination | Micturition",,,,,,,,,,,,,,,"4176132","Urinary tract function",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519814","Update","C25710","Make current; supply with recent information or technology.","Update | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521842","Zip Code","C25720","A system designed to expedite the sorting and delivery of mail by assigning a series of numbers to each delivery area in the United States.  Also used to refer to any individual delivery area code.","Zip Code | ZIP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0487742","Width","C25345","The extent or measurement of something from side to side.","Width | WIDTH | Wideness",,,,,,,,,,,,,,,"4011463","Width",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1262477","Weight Loss","C3445","A reduction in total body weight.","Weight Loss | WEIGHT_LOSS | Weight Decrease | Weight loss",,,,,,,,,,,,,,,"37311267|4229881","Weight loss|Weight loss",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0449468","Volume","C25335","The amount of three dimensional space occupied by an object or the capacity of a space or container.","Volume | Total Volume | VOLUME | Vol",,,,,,,,,,,,,,,"4042996","Volume",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1148433","Vital Status","C25717","The state or condition of being living or deceased; also includes the case where the vital status is unknown.","Vital Status | SURVSTAT | Survival Status | Vital Status (at date of last contact) | Vital_Status | vital status | vital_status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL335552","Version","C25714","A form or variant of a type or original; one of a sequence of copies of a program, each incorporating new modifications.","Version | VERS | Versioned",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205419","Variation","C25713","An alteration or difference from a norm or standard.","Variation | Deviation | VARIATION | Variant",,,,,,,,,,,,,,,"4254208","Variant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1444637","Past","C25609","Before the present time.","Past | ",,,,,,,,,,,,,,,"4132507","Past",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1514624","Qualifying","C25635","Success in satisfying a test or requirement.","Qualifying | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035171","Research Design","C15320","A plan detailing how a study will be performed in order to represent the phenomenon under examination, to answer the research questions that have been asked, and defining the methods of data analysis. Study design is driven by research hypothesis being posed, study subject/population/sample available, logistics/resources: technology, support, networking, collaborative support, etc.","Study Design | Experiment Design | Experimental Design | Research Design | designType | study design",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439234","Year","C29848","A period of time that it takes for Earth to make a complete revolution around the sun, approximately 365 days; a specific one year period.","Year | Annum | YEAR | YEARS | Years | a | year | years",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017574","Gingivitis","C34636","A disorder involving inflammation of the gums; may affect surrounding and supporting structures of the teeth.","Gingivitis | ",,,,,,,,,,,,,,,"4281516","Gingivitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031093","Periodontium","C33304","The fibrous connective tissue surrounding the root of a tooth that separates it from and attaches it to the alveolar bone.","Periodontium | Periodontal Ligament | Periodontal Membrane",,,,,,,,,,,,,,,"4076686","Periodontal ligament",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017562","Gingiva","C32677","The soft tissue surrounding the neck of individual teeth as well as covering the alveolar bone. The tissue is fibrous and continuous with the periodontal ligament and mucosal covering.","Gingiva | GINGIVA | Gingival | Gum | Gum, NOS | gingiva | gum | gum tissue | gums",,,,,,,,,,,,,"UBERON:0001828","gingiva","4034272","Gingival structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522609","Numerical value","C25712","A numerical quantity measured or assigned or computed.","Value | Quantity Value | value",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012893","DNA Probes","C451","A piece of DNA that has been labeled, usually radioactively or with a fluorescent dye, which is used in hybridization studies.  Applications include Northern and Southern blots, in situ hybridization techniques, and diagnostic tests.  DNA probes can be highly specific or degenerate.","DNA Probes | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013855","Electrophoresis","C16536","The motion of charged particles in a colloid under the influence of an electric field; particles with a positive charge go to the cathode and negative to the anode.","Electrophoresis | ELECTROPHORESIS | Fractionation, Electrophoretic | electrophoresis",,,,,,,,,,,,,,,"4218575|45771336","Electrophoresis measurement|Electrophoresis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1524075","chain of objects","C41207","A series of objects linked, connected, or associated together in linear fashion (e.g., the assemblage of atoms, radicals and chemical groups in a chemical compound, or an assemblage of individual microorganisms).","Chain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009637","Conception","C16465","Fertilization of an ovum by a spermatozoon resulting in formation of a viable zygote.","Conception | conception",,,,,,,,,,,,,,,"4029645","Conception",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0301944","Engraftment","C37947","The establishment of viable, functional grafted tissue within the body of a host.","Engraftment | ",,,,,,,,,,,,,,,"4011061","Graft acceptance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2750272","Adenocarcinoma","C2852","A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","Adenocarcinoma | ADENOCARCINOMA, MALIGNANT | Adenocarcinoma, NOS | adenocarcinoma","8140/3","Adenocarcinoma, NOS",,,,,,,,,,,,,"37152526|40484156","Adenocarcinoma|Malignant adenomatous neoplasm",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0016384","Flutamide","C509","A toluidine derivative and a nonsteroidal antiandrogen that is structurally related to bicalutamide and nilutamide. Flutamide and its more potent active metabolite 2-hydroxyflutamide competitively block dihydrotestosterone binding at androgen receptors, forming inactive complexes which cannot translocate into the cell nucleus. Formation of inactive receptors inhibits androgen-dependent DNA and protein synthesis, resulting in tumor cell growth arrest or transient tumor regression. (NCI04)","Flutamide | 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide | 4'-Nitro-3'-trifluoromethylisobutyranilide | Alpha,alpha,alpha-trifluoro-2-methy-4'-nitro-m-propionotoluidide | Apimid | Cebatrol | Chimax | Cytomid | Drogenil | Euflex | Eulexin | Eulexine | FLUT | FLUTAMIDE | Flucinom | Flucinome | Flugerel | Fluken | Flulem | Fluta-Gry | Flutabene | Flutacan | Flutamex | Flutamin | Flutan | Flutaplex | Fugerel | Grisetin | Niftolide | Oncosal | Profamid | Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)- | Prostacur | Prostadirex | Prostica | Prostogenat | SCH 13521 | Sch 13521 | Tafenil | Tecnoflut | Testotard | flutamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016366","Fluoxymesterone","C507","A halogenated derivative of 17-alpha-methyltestosterone.  Similar to testosterone, fluoxymesterone binds to and activates specific nuclear receptors, resulting in an increase in protein anabolism, a decrease in amino acid catabolism, and retention of nitrogen, potassium, and phosphorus.  This agent also may competitively inhibit prolactin receptors and estrogen receptors, thereby inhibiting the growth of hormone-dependent tumor lines. Fluoxymesterone is approximately five times more potent than methyltestosterone. (NCI04)","Fluoxymesterone | (11Beta,17beta)-9-fluoro-11,17-dihydroxy-17-methylandrost-4-en-3-one | 11Beta,17beta-dihydroxy-9alpha-fluoro-17alpha-methyl-4-androsten-3-one | 9Alpha-fluoro-11beta-hydroxy-17alpha-methyltestosterone | Androfluorene | Android-F | Androsterolo | Androxy | FLUOXYMESTERONE | FXM | Halodrin | Halotestin | Ora Testryl | Ora-Testryl | Ora-testryl | Oratestin | Stenox | Testoral | Ultandren",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0455471","Individual Cancer History","C18849","A record of a patient's medical background regarding the occurrence of cancer and cancer-related problems.","Individual Cancer History | Cancer History | history of tumor | history_of_tumor | prior malignancy | prior_malignancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1524049","Shipping","C40353","The act or business of transporting goods.","Shipping | Product | SHIPPED | SHIPPING | Ship | Shipment | Shipped",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448716","Leakage","C40416","The unintentional discharge of a substance from a container or enclosed space.","Leakage | Spillage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1524057","Compatible","C40414","Able to exist in combination.","Compatible | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518340","No Evidence of Disease","C40413","Diagnostic tests fail to detect presence of disease.","No Evidence of Disease | NED | No Measurable Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512714","Ineligibility","C40412","The state or quality of being disqualified by law, rule, or provision.","Ineligibility | Ineligible | NOT ELIGIBLE | NOT_ELIGIBLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511554","Culture Setup","C40346","The preparation work required for doing cell or tissue culture.  This includes preparation of the medium and of the growth support material or growth chamber.","Culture Setup | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518545","Off Follow-Up","C40451","No longer participating in the follow-up phase of a study; not being followed.","Off Follow-Up | Off Follow-up",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456533","M Category","C25727","One criteria of the TNM staging system. M refers to the presence of metastasis.","M Category | M | M Category | M Classification | M Stage | M Stage",,,,,,,,,,,,,,,"4082019","M category",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1514495","Property or Attribute","C20189","A distinguishing quality or prominent aspect of a person, object, action, process, or substance.","Property or Attribute | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016832","Fungus","C14209","A kingdom of eukaryotic, heterotrophic organisms that live as saprobes or parasites, including mushrooms, yeasts, smuts, molds, etc. They reproduce either sexually or asexually, and have life cycles that range from simple to complex. Filamentous fungi refer to those that grow as multicellular colonies (mushrooms and molds).","Fungus | FUNGI | FUNGUS | Fungi | Fungi | fungus",,,,,,,,,,,,,,,"4188300","Fungi",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1301808","US State","C30010","One of the fifty states which is a member of the federation known as the United States of America. Other US geographic areas, such as Puerto Rico and the District of Columbia, are essentially equivalent to State when used in an address.","US State | State | State",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514873","Requirement","C25652","Something that is a necessary condition; something that is obligatory.","Requirement | Mandatory | Required | Required | Required (1) | Requisite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332173","Daily","C25473","Occurring or done each day.","Daily | /d | /day | Every Day | Per Day | QD | quaque die | times per day",,,,,,,,,,,,,,,"4288153","Daily",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332152","Prior","C25629","Earlier in time or order.","Prior | BEFORE | Before | Leading | Pre | Preceding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001948","Alcohol Consumption","C16273","Consumption of liquids containing ethanol, including the behaviors associated with drinking the alcohol.","Alcohol Consumption | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032273","Pneumoconiosis","C26861","An occupational lung disorder caused by inhalation of dust particles. It is characterized by bilateral interstitial lung infiltrates. Representative examples include asbestosis, silicosis, anthracosis, and talc pneumoconiosis.","Pneumoconiosis | Unspecified pneumoconiosis",,,,,,,,,,,,,,,"259044","Pneumoconiosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1510829","Age-Years","C37908","The length of a person's life, stated in years since birth.","Age-Years | Age, in Years",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515926","Alteration","C28344","The act or process of modifying something.","Alteration | alteration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008325","Cholecystitis","C34465","An acute or chronic inflammation involving the gallbladder wall. It may be associated with the presence of gallstones.","Cholecystitis | ",,,,,,,,,,,,,,,"192956","Cholecystitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001675","Adult","C17600","An age group comprised of humans who have reached reproductive age.","Adult | ADULT | Adult Human (21+) | Human, Adult",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021843","Bowel Obstruction","C9175","Blockage of the normal flow of the intestinal contents within the bowel.","Bowel Obstruction | Intestinal Obstruction",,,,,,,,,,,,,,,"193518","Intestinal obstruction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023636","License","C43611","Official or legal permission to do or own a specified thing.","License | Licensed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439659","Origin","C42703","The place where something begins or comes from in either the sense of a physical location or a metaphysical source.","Origin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1524004","Authorization documentation","C41192","Decision of the competent authorities in form of a letter, document, or verbal or electronic form, that confirms that somebody has permission to do something or be somewhere, e.g. to realize a given project.","Authorization | Allowance | Authorized | Permission | authorization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521801","Administered","C25382","The act of having given something (e.g., a medication or test).","Administered | ",,,,,,,,,,,,,,,"42538098","Administer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1510802","Adherence (attribute)","C25729","The act of abiding by a stated treatment plan or protocol.","Adherence | adherence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515882","Clinical Study Activation Date","C25405","The date on which a trial was opened to accrual.","Clinical Study Activation Date | Activation Date | Activation Date | Study Activation Date | Trial Activation Date",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282515","Chemoprevention","C15604","The use of natural or synthetic substances (e.g., drugs, vitamins, hormones, plant products) or food supplements to reduce the risk of developing a disease, to reduce the chance that disease will recur, or to delay the recurrence.","Chemoprevention | Cancer Chemoprevention | Chemoprevention of Cancer | chemoprevention",,,,,,,,,,,,,,,"605786","Chemoprevention",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011298","Demography","C16495","The statistical characterization of human populations or segments of human populations (e.g., characterization by age, sex, race, or income).","Demographics | Demographic Factor | Demographic Factors | Demography | Population Studies / Demography",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475302","Paraesophageal","C25344","Body regions near to the esophagus.","Paraesophageal | ",,,,,,,,,,,,,,,"4141301","Paraesophageal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517480","Gene Amplification Technique","C20589","This technique refers to selectively replicate DNA sequence of interest to multiple extra copies that meet the need of research or health care activity. Polymerase chain reaction (PCR), can be considered a type of man-made gene amplification process.","Gene Amplification Technique | Amplification | Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1691222","Amended","C25416","Corrected, or altered formally.","Amended | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524008","Agreement","C25369","The act of agreeing to a plan, protocol, or arrangement. Also used to describe a harmony of opinion.","Agreement | Harmony",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0470187","Availability","C25429","The quality of being obtainable or accessible and ready for use or service.","Availability | Available | Available",,,,,,,,,,,,,,,"4011951","Availability of",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004144","Atelectasis","C2888","The collapse of part or the entire lung due to airway obstruction, infection, tumor, or general anesthesia.","Atelectasis | ATELECTASIS | atelectasis",,,,,,,,,,,,,,,"261880","Atelectasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516050","Assignment","C25426","An allotting or an appointment to a particular person or use, or for a particular time or object.","Assignment | Assign | Assigned",,,,,,,,,,,,,,,"764519","Assigned",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0682125","Alaska Native","C18237","Denotes a person having origins in any indigenous people of Alaska and their descendants and who maintains tribal affiliation, or community or cultural attachment. The concept refers to population subgroups such as Eskimos, Aleuts, Inupiat, Yupik, Alutiiq, Egegik,and Pribilovian, Alaskan Athabascan, Tlingit, and Haida. The concept refers also to individuals who classify themselves as such.","Alaska Native | ALASKA NATIVE | Alaska Indian | Alaska Indians | Alaska Natives",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515834","AIDS Population","C18620","Subgroups of AIDS patients.","AIDS Population | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515835","AIDS Related Research, Women","C18621","AIDS related research with a minimum of 20% research efforts related to females 12 years of age or older. To include: Pregnant women, Women at risk of HIV infection, Transmission of HIV between heterosexual partners, Female prostitutes, Perinatal transmission of HIV. (FMB)","AIDS Related Research, Women | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520851","19p13.3-p13.2","C13762","A chromosome band present on 19p","19p13.3-p13.2 | 19p13.3-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879404","Pralatrexate","C2250","A folate analogue inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressive activities. Pralatrexate selectively enters cells expressing RFC-1; intracellularly, this agent is highly polyglutamylated and competes for the folate binding site of DHFR, blocking tetrahydrofolate synthesis, which may result in depletion of nucleotide precursors; inhibition of DNA, RNA and protein synthesis; and apoptotic tumor cell death. Efficient intracellular polyglutamylation of pralatrexate results in higher intracellular concentrations compared to non-polyglutamylated pralatrexate, which is more readily effuxed by the MRP (multidrug resistance protein) drug efflux pump. RFC-1, an oncofetal protein expressed at highest levels during embryonic development, may be over-expressed on the cell surfaces of various cancer cell types.","Pralatrexate | (2S)-2-[[4-[(1RS)-1-[(2, 4-Diaminopteridin-6-yl)methyl]but-3-ynyl]benzoyl]amino]pentanedioic Acid | 10-Propargyl-10-Deazaaminopterin | 10-Propargyl-10-Deazaaminopterin | 10-propargyl-10-deazaaminopterin | Difolta | FOLOTYN | Folotyn | N-(4-{1-[(2,4-Diaminopteridin-6-yl)methyl]but-3-yn-1-yl}benzoyl)-L-glutamic Acid | PDX | PRALATREXATE | pralatrexate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3495400","Lodenosine","C1499","A nucleoside reverse transcriptase inhibitor analog of adenosine. Lodenosine is a synthetic purine fluoro-dideoxyadenosine derivative that was rationally designed to have improved chemical and enzymatic stability. It has shown activity against clinical isolates and cell lines that are resistant to AZT, dideoxyinosine, and dideoxycytosine.","Lodenosine | 2'-Beta-Fluoro-2',3'-Dideoxyadenosine | 2'-F-dd-ara-A | 2'-F-dd-araA | 2'-FddA | 2'-Fluoro-2',3'-Dideoxyadenosine | 2'-Fluoro-2',3'-Dideoxyadenosine | 2'-beta-fluoro-2',3'-dideoxyadenosine | 9-(2,3-Dideoxy-2-fluoro-beta-D-threo-pentofuranosyl) Adenine | 9-(2,3-Dideoxy-2-fluoro-beta-D-threo-pentofuranosyl)-9H-purin-6-amine | DRG-0246 | F-ddA | LODENOSINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1450330","STAM-Binding Protein, Human","C21339","STAM-binding protein (424 aa, ~48 kDa) is encoded by the human STAMBP gene. This protein plays a role in both signaling and deubiquitination of 'Lys-63'-linked polyubiquitin chains.","STAM-Binding Protein | AMSH | AMSH Protein | Associated Molecule with the SH3 Domain of STAM | EC 3.4.19.- | Endosome-Associated Ubiquitin Isopeptidase | STAMBP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1337047","14-3-3 Family","C21256","The 14-3-3 family of proteins mediates signal transduction by binding to phosphoserine-containing proteins. Two different binding motifs, RSXpSXP and RXY/FXpSXP, are present in nearly all known 14-3-3 binding proteins. The 14-3-3 dimer binds tightly to single molecules containing tandem repeats of phosphoserine motifs, implicating bidentate association as a signaling mechanism with molecules such as Raf, BAD, and Cbl. (from OMIM)","14-3-3 Family | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520266","10q","C13531","Distal (long) arm of chromosome 10","10q | Chromosome 10 Distal Arm | Chromosome 10 Long Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520484","12q","C13533","Distal (long) arm of chromosome 12","12q | Chromosome 12 Distal Arm | Chromosome 12 Long Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026383","Macromolecular Structure","C14134","Any very large complex molecule including, proteins, nucleic acids and carbohydrates, especially refering to the particular arrangement of its component atoms and groups.","Macromolecular Structure | Molecular Structure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796371","BAT Locus","C13391","Microsatellite repeats that have been used as markers of microsatellite instability.  BAT26, a poly(A) tract in MSH2 intron 5, is one example of a BAT locus.  Presence of alterations in the BAT26 locus, detected in stool samples, may be an easy and non-invasive detection method for colorectal cancer.","BAT Locus | BAT Loci",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456532","N Category","C25580","One criteria of the TNM staging system. N refers to the extent of lymph node involvement.","N Category | N | N Category | N Classification | N Stage | N Stage",,,,,,,,,,,,,,,"4175208","N category",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0048573","4-Nitroestrone 3-Methyl Ether","C977","A synthetic derivative of estradiol. 4-nitroestrone 3-methyl ether inhibits estrogen sulfotransferase (EST), a progesterone-induced secretory endometrial enzyme which affects estrogen receptor levels.  This agent has been shown to be an effective growth inhibitor of some chemically induced animal mammary tumors. (NCI04)","4-Nitroestrone 3-Methyl Ether | 3-METHOXY-4-NITRO-ESTRA-1,3,5(10)-TRIEN-17-ONE | 3-Methoxy-4-nitro-estra-1,3,5(10)-trien-17-one | 4-Nitroestrone | 4-Nitroestrone 3-methyl ether",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0050892","adult T cell leukemia-derived factor","C991","Adult T-cell Leukemia derived factor: Human thioredoxin. A cytokine.","Thioredoxin | ATL Derived Factor (Recombinant) | Recombinant ATL Derived Factor | THIOREDOXIN | Thioredoxin Human",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002903","Anesthesia Procedure","C15181","Treatment with a pharmacological substance that produces a loss of feeling.","Anesthesia Procedure | Anesthesia | anesthesia",,,,,,,,,,,,,,,"4160439","Administration of anesthesia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0539517","714-X","C1730","A product elaborated and marketed by the private Canadian laboratory. 714-X contains trimethylbicyclonitraminoheptane chloride, a nitrogenated camphor-derivative, and mineral salts in ethanol. It is claimed to cure cancer, multiple sclerosis, fibromyalgia, AIDS and other diseases by improving the body's immune function. Few inconclusive animal studies and no human trials were conducted with the product. There is no scientific evidence that 714-X is effective in treating any type of disease. It has not been proven to be safe or effective for any use. 714-X is banned by FDA for use in the USA. In Canada 714-X is legally available on compassionate grounds only through a licensed physician.","714-X | Camphorminium Chloride | Trimethylbicyclonitraminoheptane Chloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1261253","NAT2 protein, human","C17773","Arylamine N-acetyltransferase 2 (290 aa, ~34 kDa) is encoded by the human NAT2 gene. This protein plays a role in xenobiotic metabolism.","Arylamine N-Acetyltransferase 2 | Arylamide Acetylase 2 | Arylamine Acetylase | Arylamine N-acetyltransferase | EC 2.3.1.5 | N-Acetyltransferase | N-Acetyltransferase Type 2 | NAT-2 | NAT2 | PNAT | Polymorphic Arylamine N-Acetyltransferase | Serotonin N-acetyltransferase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0000741","Abducens Nerve","C12665","A cranial nerve that supplies motor impulses to the lateral rectus muscle of the eye.","Abducens Nerve | ABDUCENS NERVE | Abducens nerve structure (body structure) | Cranial Nerve VI | Nervus Abducens | Sixth Cranial Nerve",,,,,,,,,,,,,,,"4213208","Abducens nerve structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023676","Lifestyle","C16795","A manner of living that reflects the person's values and attitudes.","Lifestyle | ",,,,,,,,,,,,,,,"4046893","Lifestyle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0279784","One or More Positive Axillary Nodes","C8032","Presence of one or more lymph nodes in the area of the armpit in which cancerous cells have been detected.","One or More Positive Axillary Nodes | 1 or More Positive Axillary Nodes | 1 or more positive axillary node | Axillary Node, 1 or More Positive | One or more positive axillary node | Positive Axillary Node, 1 or More",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520677","Chromosome 16 Short Arm","C13541","Proximal (short) arm of chromosome 16","16p | Chromosome 16 Proximal Arm | Chromosome 16 Short Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005574","Biotechnology","C16351","The field devoted to applying the techniques of biochemistry, cellular biology, biophysics, and molecular biology to addressing issues related to human beings and the environment.","Biotechnology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010762","Cytochrome P450","C16484","A family of cytochromes that are involved in electron transport and oxidative metabolism of drugs and other bioactive molecules. When the catalytic heme is reduced the absorbance peak for this protein occurs at 450 nm.","Cytochrome P450 | CYP | CYP450 | Cytochrome P-450 | Cytochrome P450 Enzyme | Cytochrome P450 Family | Cytochrome P450 Protein | Cytochrome-P450 | P450 | cytochrome P450 enzyme system",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0160814","Late Radiation Injury","C3665","Late radiation injury (LRI) is the damage to the soft tissue and bone following radiation therapy that occurs weeks and years after the radiation exposure. Pathogenesis of LRI stems from ischemia, interruption of the blood supply and direct cell damage. LRIs include but not limited to the skin atrophy, ulceration and non-healing wounds; cystitis, proctosigmoiditis, resulting to fistulas, abscesses, fibrosis and scaring; laryngitis, osteoradionecrosis; central nervous system injury, optic neuropathy.","Late Radiation Injury | ",,,,,,,,,,,,,,,"440577","Late effect of radiation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022947","Lactone Compound","C606","Cyclic esters of hydroxy carboxylic acids, containing a 1-oxacycloalkan-2-one structure, or analogues having unsaturation or heteroatoms replacing one or more carbon atoms of the ring (IUPAC).","Lactone Compound | LACTONE | Lactones",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0755562","U-0126","C1825","A synthetic organic compound that selectively inhibits the kinase activity of Mitogen-Activated Protein kinase, preventing cytokine and prostaglandin E2 production. (NCI)","U-0126 | 1,4-Diamino-2,3-dicyano-1,4- bis(2-aminophynylthio)butadiene | Bis[amino[(2-aminophenyl)thio]methylene]butanedinitrile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL357397","Posterior","C25622","Denoting the back surface of the body; at or near the hind end in quadrupeds or toward the spine in primates.","Posterior | POSTERIOR | posterior",,,,,,,,,,,,,,,"4116868","Posterior",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027270","NAD","C675","Nicotinamide Adenine Dinucleotide, a coenzyme, found in eukaryotic cells and is involved in many enzymatic reactions and the production of energy through redox reactions.","NAD | NAD+",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449820","Score","C25338","A number or range of numeric values measuring performance, function, quality, or ability.","Score | SCORE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511358","C2H2 Zinc Finger","C13294","One of three structural motifs observed in DNA binding domains of zinc proteins. Domains in DNA- and RNA-binding proteins that contain amino acids which are folded into a single structural unit around a zinc atom that links two cysteines and two histidines. Each finger is postulated to recognize a specific sequence of about five nucleotide pairs. Originally identified in the TFIIIA transcription factor, it is also known as the C2H2 zinc finger.","C2H2 Zinc Finger | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512698","Yes or No Response","C38147","A response or indicator that can have a value of either yes or no.","Yes or No Response | Ind-2 | Ind-2 | yes/no",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042682","Vindesine","C934","A synthetic derivative of vinblastine, a naturally occurring vinca alkaloid. Vindesine binds to and stabilizes tubulin, thereby interrupting tubulin polymerization and preventing the formation of the mitotic spindle and cell division; treated cells are unable to undergo mitosis and are arrested in metaphase. This agent also disrupts macromolecular synthesis. (NCI04)","Vindesine | 3-(Aminocarbonyl)-O4-deacetyl-3-de-(methoxycarbonyl)vincaleukoblastine | Compound 112531 | DAVA | DVA | Deacetyl Vinblastine Carboxamide | Deacetylvinblastine Carboxamide | Desacetylvinblastine Amide | Lilly CT-3231 | VDS | VINDESINE | vindesine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333010","Childhood Testicular Neoplasm","C5053","A neoplasm that affects the testis during childhood.","Childhood Testicular Neoplasm | Childhood Neoplasm of Testis | Childhood Neoplasm of the Testis | Pediatric Neoplasm of Testis | Pediatric Neoplasm of the Testis | Pediatric Testicular Neoplasm | Testicular Tumor, Childhood",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1524082","Derivation procedure","C41378","A drawing of fluids from one part of the body to another, to relieve symptoms, reduce the inflammation or to otherwise lessen a morbid process.","Derivation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514721","Range","C38013","The difference between the lowest and highest numerical values; the limits or scale of variation.","Range | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0222645","Axial Skeleton","C32172","The part of the skeleton that includes the skull and spinal column and sternum and ribs.","Axial Skeleton | AXIAL SKELETON",,,,,,,,,,,,,,,"4285280","Axial skeleton structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0290378","ADAM11 protein, human","C25799","Disintegrin and metalloproteinase domain-containing protein 11 (769 aa, ~83 kDa) is encoded by the human ADAM11 gene. This protein plays a role in integrin-mediated signaling.","Disintegrin and Metalloproteinase Domain-Containing Protein 11 | A Disintegrin and Metalloproteinase Domain 11 Protein | ADAM 11 | ADAM11 | ADAM11 Protein | ADAM11 Protein | MDC | Metalloproteinase-Like, Disintegrin-Like and Cysteine-Rich Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518030","Lower Limit of Normal","C25555","The lowest value of the range of statistical characteristics that are supposed to represent accepted standard, non-pathological pattern for particular laboratory result or other quantitative parameter.","Lower Limit of Normal | LLN | LLN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512699","Yes, No, or Unknown Response","C38148","A response or indicator that can have a value of yes, no, or unknown.","Yes, No, or Unknown Response | Ind-3 | Ind-3 | yes/no/unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510992","Average","C37917","A statistical calculation describing the central tendency of a set of numbers; used to interpret quantitative data.","Average | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510828","Age-Months","C37907","The length of a person's life, stated in months since birth.","Age-Months | Age, in Months",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018748","Health Services Accessibility","C15244","The ability of individuals or a population to utilize and obtain care from the health care system.","Access to Care | Health Care Access",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335754","Repair Complex","C13723","Initial or intermediate protein-DNA complexes present during the process of DNA repair.","DNA Repair Complex | Repair Complex | Repair Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018496","Cochlear Hair Cell","C12629","A type of sensory epithelial cell, located in the inner ear, that use hair-like projections called stereocilia to detect sound waves and transform them into neural signals that can be interpreted by the brain.","Cochlear Hair Cell | Corti Cell | Hair Cell",,,,,,,,,,,,,,,"4180272","Hair cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001942","Alcohol Dehydrogenase","C16272","Members of this enzyme family metabolize a wide variety of substrates, including ethanol, retinol, other aliphatic alcohols, hydroxysteroids, and lipid peroxidation products.","Alcohol Dehydrogenase | ADH | Alcohol Dehydrogenase Family | EC 1.1.1.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520254","Chromosome 10 Short Arm","C13530","Proximal (short) arm of chromosome 10","10p | Chromosome 10 Proximal Arm | Chromosome 10 Short Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1318045","AKAP13 protein, human","C21329","A-kinase anchor protein 13 (2813 aa, ~308 kDa) is encoded by the human AKAP13 gene. This protein is involved in adrenergic receptor signaling, EGFR-mediated signal transduction and guanine nucleotide exchange factor activity for transforming protein RhoA.","A-Kinase Anchor Protein 13 | A Kinase Anchor Protein 13 | A Kinase Anchor Protein 13 | A-Kinase (PRKA) Anchor Protein 13 | AKAP-13 | AKAP13 | BRX | Breast Cancer Nuclear Receptor-Binding Auxiliary Protein | Breast Cancer cDNA-Encoded Nuclear Receptor-Binding Auxillary Protein 1 | Guanine Nucleotide Exchange Factor Lbc | HT31 | Human Thyroid-Anchoring Protein 31 | LBC | LBC Oncogene | Lymphoid Blast Crisis Oncogene | Non-Oncogenic Rho GTPase-Specific GTP Exchange Factor | P47 | PRKA13 | Protein Kinase A-Anchoring Protein 13 | p47",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0149576","Posterior Cerebral Artery","C12831","The posterior cerebral artery is formed by the bifurcation of the basilar artery; it divides into three branches.","Posterior Cerebral Artery | PCA | POSTERIOR CEREBRAL ARTERY | Posterior Cerebral Arteries",,,,,,,,,,,,,,,"4323126","Structure of posterior cerebral artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1412528","ARHGEF2 Gene","C101780","This gene is involved in the modulation of GTPase signaling.","ARHGEF2 Gene | ARHGEF2 | Rho/Rac Guanine Nucleotide Exchange Factor (GEF) 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039593","Testing","C15336","A procedure for critical evaluation.","Testing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206685","Acinar Cell Carcinoma","C3768","A malignant glandular epithelial neoplasm consisting of secretory cells forming acinar patterns. Representative examples include the acinar cell carcinoma of the pancreas and the acinar adenocarcinoma of the prostate gland.","Acinar Cell Carcinoma | Acinar Adenocarcinoma | Acinar Carcinoma | Acinar Cell Adenocarcinoma | Acinar adenocarcinoma | Acinar carcinoma | Acinar cell carcinoma | Acinic Cell Adenocarcinoma | Acinic Cell Carcinoma | Acinic cell adenocarcinoma | CARCINOMA, ACINAR CELL, MALIGNANT","8550/3","Acinar cell carcinoma",,,,,,,,,,,,,"4164740","Acinar cell carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0023437","Acute Basophilic Leukemia","C3164","A rare acute myeloid leukemia in which the immature cells differentiate towards basophils.","Acute Basophilic Leukemia | Acute basophilic leukaemia | Acute basophilic leukemia | Basophilic Leukemia | Leukemia Basophilic","9870/3","Acute basophilic leukemia",,,,,,,,,,,,,"4289318","Acute basophilic leukemia",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0023440","Acute Erythroid Leukemia","C8923","An acute myeloid leukemia characterized by a predominant immature erythroid population.  There are two subtypes recognized: erythroleukemia and pure erythroid leukemia. (WHO, 2001)","Acute Erythroid Leukemia | AEL | Acute Erythroblastic Leukemia | Acute erythroid leukaemia | Erythroblastic Leukemia | FAB M6 | Fab M6 | LEUKEMIA, ERYTHROID, MALIGNANT | M6 | M6 Acute Myeloid Leukemia | M6 OR Acute Erythroid Leukemia",,,,,,,,,,,,,,,"4031360","Acute erythroid leukemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1301357","Acute Leukemia of Ambiguous Lineage","C7464","An acute leukemia in which the blasts lack sufficient evidence to classify as myeloid or lymphoid or they have morphologic and/or immunophenotypic characteristics of both myeloid and lymphoid cells. (WHO, 2001)","Acute Leukemia of Ambiguous Lineage | ALAL | Acute Leukemia of Ambiguous Lineage (ALAL) | Acute Leukemia of Indeterminate Lineage | Acute Leukemia, ambiguous lineage (mixed or biphenotypic)",,,,,,,,,,,,,,,"36715589|4287473","Acute leukemia of ambiguous lineage|Acute leukemia of ambiguous lineage",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0023462","Acute Megakaryoblastic Leukemia","C3170","An acute myeloid leukemia in which at least 50% of the blasts are of megakaryocytic lineage. (WHO, 2001)","Acute Megakaryoblastic Leukemia | AMKL | Acute M7 Myeloid Leukemia | Acute Megakaryoblastic Leukemia (FAB Type M7) | Acute Megakaryoblastic Leukemia (Fab Type M7) | Acute Megakaryocytic Leukemia | Acute megakaryoblastic leukaemia | FAB M7 | Fab M7 | LEUKEMIA, MEGAKARYOCYTIC, MALIGNANT | M7 | M7 OR Acute Megakaryoblastic Leukemia","9910/3","Acute megakaryoblastic leukemia",,,,,,,,,,,,,"4079686|4180418","Acute megakaryoblastic leukemia|Acute megakaryoblastic leukemia",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C2825116","Acute Myeloid Leukemia with Variant MLL Translocations","C6924","A term referring to acute myeloid leukemias with rearrangement of the KMT2A gene that results in translocations with various genes other than the MLLT3 (AF9) gene.","Acute Myeloid Leukemia with a Variant KMT2A Rearrangement | AML with Other KMT2A Rearrangements | AML with Variant MLL Translocations | Acute Myeloid Leukemia with 11q23 (MLL) Abnormalities | Acute Myeloid Leukemia with Other KMT2A Rearrangements | Acute Myeloid Leukemia with Variant MLL Rearrangement | Acute Myeloid Leukemia with Variant MLL Translocations | Acute Myeloid Leukemia with Variant MLL Translocations | Acute Myeloid Leukemia with a Variant MLL Rearrangement | Acute Myeloid Leukemia with a Variant MLL Translocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879321","Acute Myeloid Leukemia with Maturation","C3250","An acute myeloid leukemia (AML) characterized by blasts with evidence of maturation to more mature neutrophils. (WHO, 2001)","Acute Myeloid Leukemia with Maturation | AML with Maturation | Acute M2 Myeloid Leukemia | Acute Myeloblastic Leukemia with Maturation | Acute Myelocytic Leukemia with Maturation | Acute Myelogenous Leukemia with Maturation | Acute Myeloid Leukemia (AML-M2) | Acute myeloid leukemia with maturation | FAB M2 | M2 | M2 Acute Granulocytic Leukemia | M2 Acute Myeloblastic Leukemia | M2 Acute Myeloblastic Leukemia with Maturation | M2 Acute Myelocytic Leukemia with Maturation | M2 Acute Myelogenous Leukemia | M2 Acute Myelogenous Leukemia with Maturation | M2 Acute Myeloid Leukemia | M2 Acute Myeloid Leukemia with Maturation","9874/3","Acute myeloid leukemia with maturation",,,,,,,,,,,,,"4304051","Acute myeloid leukemia with maturation",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0026998","Acute Myeloid Leukemia without Maturation","C3249","An acute myeloid leukemia (AML) characterized by blasts without evidence of maturation to more mature neutrophils. (WHO, 2001)","Acute Myeloid Leukemia without Maturation | AML without Maturation | Acute M1 Myeloid Leukemia | Acute Myeloblastic Leukemia without Maturation | Acute Myelogenous Leukemia without Maturation | Acute Myeloid Leukemia without Maturation (FAB M1) | Acute myeloid leukemia without maturation | FAB M1 | M1 | M1 Acute Myeloblastic Leukemia | M1 Acute Myeloblastic Leukemia without Maturation | M1 Acute Myelogenous Leukemia | M1 Acute Myelogenous Leukemia without Maturation | M1 Acute Myeloid Leukemia | M1 Acute Myeloid Leukemia without Maturation","9873/3","Acute myeloid leukemia without maturation",,,,,,,,,,,,,"4304356","Acute myeloid leukemia without maturation",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0522631","Acute Myeloid Leukemia with Minimal Differentiation","C8460","An acute myeloid leukemia (AML) in which the blasts do not show evidence of myeloid differentiation by morphology and conventional cytochemistry. (WHO, 2001)","Acute Myeloid Leukemia with Minimal Differentiation | AML with Minimal Differentiation | Acute Myeloblastic Leukemia with Minimal Differentiation | Acute Myeloblastic Leukemia, Minimally Differentiated | Acute Myelogenous Leukemia with Minimal Differentiation | Acute Myeloid Leukemia with Minimal Differentiation (MO) | Acute Myeloid Leukemia, Minimally Differentiated | Acute Myeloid Leukemia, Minimally Differentiated | Acute myeloid leukemia, minimal differentiation | FAB M0 | M0 | M0 Acute Myeloblastic Leukemia | M0 Acute Myelogenous Leukemia | M0 Acute Myelogenous Leukemia with Minimal Differentiation | M0 Myeloid Leukemia | M0 Myeloid Leukemia with Minimal Differentiation","9872/3","Acute myeloid leukemia, minimal differentiation",,,,,,,,,,,,,"4304199","Acute myeloid leukemia with minimal differentiation",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0023479","Acute Myelomonocytic Leukemia","C7463","An acute leukemia characterized by the proliferation of both neutrophil and monocyte precursors.  (WHO, 2001)","Acute Myelomonocytic Leukemia | AMML | Acute M4 Myeloid Leukemia | Acute Myelomonocytic Leukemia (FAB Type M4) | Acute myelomonocytic leukemia | M4 | M4 OR Acute Myelomonocytic Leukemia",,,,,,,,,,,,,,,"4149110","Acute myelomonocytic leukemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334674","Acute Panmyelosis with Myelofibrosis","C4344","An acute myeloid leukemia characterized by bone marrow fibrosis without preexisting primary myelofibrosis.","Acute Panmyelosis with Myelofibrosis | APMF | Acute (Malignant) Myelofibrosis | Acute (Malignant) Myelosclerosis | Acute Myelofibrosis | Acute Myelosclerosis | Acute Panmyelosis | Acute myelofibrosis | Acute panmyelosis with myelofibrosis","9931/3","Acute panmyelosis with myelofibrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C0001422","Female Reproductive System Adenofibroma","C8984","A benign or borderline neoplasm characterized by the presence of connective tissue stroma and epithelial structures. It occurs in the ovary, fallopian tube, uterine corpus, and cervix.","Female Reproductive System Adenofibroma | ADENOFIBROMA, BENIGN | Adenofibroma | Benign Mixed Muellerian Tumor","9013/0","Adenofibroma, NOS",,,,,,,,,,,,,"600704","Benign adenofibroma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0001442","Adenosarcoma","C9474","A low grade malignant neoplasm characterized by the presence of a benign epithelial component (tubular and cleft-like glands) and a low grade sarcomatous component that contains varying amounts of fibrous and smooth muscle tissues. In a minority of cases, the sarcomatous component contains heterologous elements including striated muscle, cartilage, and fat. It occurs in the uterine corpus, ovary, fallopian tube, cervix, and vagina. It may recur and in a minority of cases may metastasize to distant anatomic sites.","Adenosarcoma | Mullerian Adenosarcoma | Mullerian adenosarcoma | Müllerian Adenosarcoma | adenosarcoma","8933/3","Adenosarcoma",,,,,,,,,,,,,"4135215","Adenosarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0206623","Adenosquamous Carcinoma","C3727","An invasive carcinoma composed of malignant glandular cells and malignant squamous cells.","Adenosquamous Carcinoma | Adenosquamous carcinoma | CARCINOMA, ADENOSQUAMOUS, MALIGNANT | Mixed Adenocarcinoma and Epidermoid Carcinoma | Mixed Adenocarcinoma and Epidermoid Cell Carcinoma | Mixed Adenocarcinoma and Squamous Carcinoma | Mixed Adenocarcinoma and Squamous Cell Carcinoma | Mixed adenocarcinoma and epidermoid carcinoma | Mixed adenocarcinoma and squamous cell carcinoma | adenosquamous carcinoma","8560/3","Adenosquamous carcinoma",,,,,,,,,,,,,"4241843|4298029","Adenosquamous carcinoma|Adenosquamous cell carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1440080","Alveolar","C14155","Of or relating to the alveoli.","Alveolar | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206180","Anaplastic Large Cell Lymphoma","C3720","A peripheral (mature) T-cell lymphoma, consisting of usually large anaplastic, CD30 positive cells. The majority of cases are positive for the anaplastic large cell lymphoma (ALK) protein. The most frequently seen genetic alteration is a t(2;5) translocation. Majority of patients present with advanced disease. The most important prognostic indicator is ALK positivity, which has been associated with a favorable prognosis. (WHO, 2001)","Anaplastic Large Cell Lymphoma | ALCL | Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type | Anaplastic large cell lymphoma, CD30+ | Anaplastic large cell lymphoma, NOS | CD30 Positive Anaplastic Large Cell Lymphoma | Ki-1 Lymphoma | Ki-1+ ALCL | Ki-1+ Anaplastic Large Cell Lymphoma | NHL, anaplastic large cell lymphoma | anaplastic large cell lymphoma","9714/3","Anaplastic large cell lymphoma, T-cell and Null-cell type",,,,,,,,,,,,,"4183267","Anaplastic large cell lymphoma, T cell and Null cell type",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0020981","Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type","C7528","An aggressive follicular helper T-cell lymphoma affecting lymph nodes and other sites. It is characterized by a polymorphous infiltrate and prominent proliferation of high endothelial venules and follicular dendritic cells. It is associated with EBV infection and affects mainly older adults.","Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | AILD | AILT | AITL | Angioimmunoblastic Lymphadenopathy | Angioimmunoblastic Lymphadenopathy Type T-Cell Lymphoma | Angioimmunoblastic Lymphadenopathy with Dysproteinemia | Angioimmunoblastic T-Cell Lymphoma | Angioimmunoblastic T-Cell Lymphoma | Angioimmunoblastic T-cell lymphoma | Angioimmunoblastic lymphadenopathy | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic Type (Angioimmunoblastic T-Cell Lymphoma) | Nodal T-Follicular Helper Lymphoma, Angioimmunoblastic-Type | angioimmunoblastic T-cell lymphoma | nTFHL-AI","9705/3","Angioimmunoblastic T-cell lymphoma",,,,,,,,,,,,,"4178598|4184976|4308429","Angioimmunoblastic lymphadenopathy|Angioimmunoblastic T-cell lymphoma|Angioimmunoblastic T-cell lymphoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--|--"
"C0205094","Anterior","C25231","Denoting the front surface of the body; often used to indicate the position of one structure relative to another.","Anterior | ANTERIOR | anterior",,,,,,,,,,,,,,,"4115458","Anterior",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003617","Appendix","C12380","Small tissue projection existing as a cecal diverticulum with a questionable history of vestigial versus specialized organ.","Appendix | APPENDIX | Appendix structure (body structure) | LARGE INTESTINE, APPENDIX | Vermiform Appendix | appendix | appendix vermiformis | caecal appendix | cecal appendix | vermiform appendix",,,,,,,,,,,,,"UBERON:0001154","vermiform appendix","4283683","Appendix structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227375","Ascending Colon","C12265","The first part of the colon (large intestine) that starts in the right lower quadrant of the abdomen and ends at the transverse colon in the right upper quadrant of the abdomen.","Ascending Colon | Ascending colon | Ascending colon structure (body structure) | COLON, ASCENDING | ascending colon | colon ascendens",,,,,,,,,,,,,"UBERON:0001156","ascending colon","4234702","Ascending colon structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0231221","Asymptomatic","C3833","Without clinical signs or indications that raise the possibility of a particular disorder or dysfunction.","Asymptomatic | NO SYMPTOMS | asymptomatic",,,,,,,,,,,,,,,"4309345","Asymptomatic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1779346","Atypical Chronic Myeloid Leukemia","C3519","A myelodysplastic/myeloproliferative neoplasm characterized by the presence of leukocytosis with increased numbers of neutrophils, promyelocytes, myelocytes, and metamyelocytes; blasts less than 20% in bone marrow and peripheral blood; dysgranulopoiesis; minimal or absent monocytosis; absence of eosinophilia; and presence of bone marrow hypercellularity with granulocytic proliferation and granulocytic dysplasia. Dysplasia in the erythroid and megakaryocytic lineages may be present or absent. No evidence of BCR/ABL fusion is present.","Atypical Chronic Myeloid Leukemia | Atypical CML | Atypical Chronic Myeloid Leukemia | Atypical Chronic Myeloid Leukemia | Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Atypical Chronic Myeloid Leukemia, BCR::ABL1 Negative | MDS/MPN-N | Myelodysplastic/Myeloproliferative Neoplasm with Neutrophilia | Subacute Granulocytic Leukemia | Subacute Myelogenous Leukemia | Subacute Myeloid Leukemia | Subacute granulocytic leukemia | Subacute myelogenous leukemia | Subacute myeloid leukemia | aCML","9876/3","Atypical chronic myeloid leukemia, BCR/ABL negative",,,,,,,,,,,,,"4079282","Myelodysplastic/myeloproliferative neoplasm with neutrophilia",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"CL317948","Axillary","C13351","Pertaining to the armpit area, including the lymph nodes that are located there.","Axillary | axillary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475801","B-Cell Prolymphocytic Leukemia","C4753","A malignant B-cell lymphoproliferative process affecting the blood, bone marrow, and spleen.  The B-prolymphocytes are medium-sized, round lymphoid cells with prominent nucleoli.  The B-prolymphocytes must exceed 55% of lymphoid cells in the blood.  Cases of transformed chronic lymphocytic leukemia (CLL) and CLL with increased prolymphocytes are excluded.  The prognosis is poor.  (WHO, 2001)","B-Cell Prolymphocytic Leukemia | B Prolymphocytic Leukemia | Prolymphocytic leukemia, B-cell type","9833/3","Prolymphocytic leukemia, B-cell type",,,,,,,,,,,,,"4173974","B-cell prolymphocytic leukemia",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0333990","Basal Cell Hyperplasia","C35845","A pathologic hyperplastic process characterized by the proliferation of the cells of the epithelial layer that resemble the basal cells of the lower part of the epidermis.","Basal Cell Hyperplasia | ",,,,,,,,,,,,,,,"4233228","Basal cell hyperplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205183","Benign","C14172","For neoplasms, a non-infiltrating and non-metastasizing neoplastic process that is characterized by the absence of morphologic features associated with malignancy (e.g., severe atypia, nuclear pleomorphism, tumor cell necrosis, and abnormal mitoses). For other conditions, a process that is mild in nature and not dangerous to health.","Benign | BENIGN | benign",,,,,,,,,,,,,,,"4148764","Benign",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0238767","Bilateral","C13332","Affecting both sides of the body or a matched pair of organs.","Bilateral | BILATERAL | Right and Left | Right and left (qualifier value) | bilateral",,,,,,,,,,,,,,,"4197258","Right and left",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205184","Biphasic","C25435","Occurring in or characterized by two stages or phases.","Biphasic | ",,,,,,,,,,,,,,,"4006167","Biphasic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1301363","Blastic Plasmacytoid Dendritic Cell Neoplasm","C7203","A clinically aggressive neoplasm derived from the precursors of plasmacytoid dendritic cells (also called professional type I interferon-producing cells or plasmacytoid monocytes), with a high frequency of cutaneous and bone marrow involvement and leukemic dissemination. (WHO 2017)","Blastic Plasmacytoid Dendritic Cell Neoplasm | Agranular CD4+ CD56+ Hematodermic Neoplasm/Tumor | Agranular CD4+ Natural Killer Cell Leukemia | BPDCN | Blastic NK Cell Lymphoma | Blastic NK-Cell Lymphoma | Blastic NK-Cell Lymphoma | Blastic NK-cell lymphoma | Blastic Natural Killer Leukemia/Lymphoma | Blastic plasmacytoid dendritic cell neoplasm | CD4+/CD56+ Hematodermic Neoplasm | Monomorphic NK-Cell Lymphoma",,,,,,,,,,,,,,,"40481988|40482072","Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0203668","Bone Scan","C17646","A nuclear imaging method used to evaluate pathological bone metabolism.","Bone Scan | Bone Scintigraphy | bone scan",,,,,,,,,,,,,,,"4217238","Radioisotope scan of bone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006233","Broxuridine","C318","A halogenated thymidine analogue with potential antineoplastic and radiosensitizing activities. Bromodeoxyuridine competes with thymidine for incorporation into DNA, resulting in DNA mutation and the inhibition of cell proliferation. As a radiosensitizer, this agent is associated with the inhibition of repair of radiation-induced DNA double-strand breaks.","Broxuridine | 5-BrdU | 5-Bromo-2'-deoxyuridine | 5-Bromodeoxyuridine | 5-Bromouracil Deoxyriboside | 5-Bromouracil deoxyriboside | 5-Bromouracil-2-deoxyriboside | 5-Budr | BRDU | BROXURIDINE | BrdU | Bromo Deoxyuridine | Bromodeoxyuridine | Bromodeoxyuridine | Bromouracil Deoxyriboside | Bromouracil deoxyriboside | Bromouridine | Broxine | Neomark | Neomark-BU | broxuridine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281297","Carboplatin/Paclitaxel","C10662","Definition not available.","Carboplatin/Paclitaxel | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225594","Carina","C25264","A ridge or ridge-like structure.  In humans it usually refers to the trachea.  The carina of trachea is part of the lowest tracheal cartilage which is placed between the orifices of the two bronchi.","Carina | CARINA | Carina, Tracheal | Structure of carina of trachea (body structure) | carina of trachea | carina tracheae | tracheal carina",,,,,,,,,,,,,"UBERON:0006679","carina of trachea","4102942","Structure of carina of trachea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007531","Cecum","C12381","A blind pouch-like commencement of the colon in the right lower quadrant of the abdomen at the end of the small intestine and the start of the large intestine.","Cecum | CECUM | Cecal | Cecum structure (body structure) | LARGE INTESTINE, CECUM | caecum | cecum | intestinum crassum caecum",,,,,,,,,,,,,"UBERON:0001153","caecum","4139602","Cecum structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227186","Cervical Esophagus","C12250","Clinical esophageal segment composed of skeletal muscle. It corresponds to the superior part of the upper third topographic segment of the esophagus.","Cervical Esophagus | Cervical esophagus | Cervical esophagus structure (body structure) | ESOPHAGUS, CERVICAL",,,,,,,,,,,,,,,"4244559","Cervical esophagus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008497","Choriocarcinoma","C2948","An aggressive malignant tumor arising from trophoblastic cells. The vast majority of cases arise in the uterus and represent gestational choriocarcinomas that derive from placental trophoblastic cells. Approximately half of the cases develop from a complete hydatidiform mole. A minority of cases arise in the testis or the ovaries. There is often marked elevation of human chorionic gonadotropin (hCG) in the blood. Choriocarcinomas disseminate rapidly through the hematogenous route; the lungs are most frequently affected.","Choriocarcinoma | CHORIOCARCINOMA, MALIGNANT | Choriocarcinoma, NOS | Chorioepithelioma | chorioblastoma | choriocarcinoma | chorioepithelioma | chorionic carcinoma","9100/3","Choriocarcinoma, NOS",,,,,,,,,,,,,"4092517|608185","Choriocarcinoma|Choriocarcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0001815","Primary Myelofibrosis","C2862","A chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, proliferation of atypical megakaryocytes and granulocytes in the bone marrow, anemia, splenomegaly, and extramedullary hematopoiesis. (WHO, 2001)","Primary Myelofibrosis | AMM | Agnogenic Myeloid Metaplasia | Agnogenic myeloid metaplasia | CIMF | Chronic Idiopathic Myelofibrosis | Chronic Idiopathic Myelofibrosis | Chronic idiopathic myelofibrosis | Idiopathic Bone Marrow Fibrosis | Idiopathic Myelofibrosis | Myelosclerosis with Myeloid Metaplasia | Myelosclerosis with myeloid metaplasia | PMF | Primary myelofibrosis | agnogenic myeloid metaplasia | chronic idiopathic myelofibrosis | idiopathic myelofibrosis | myelosclerosis with myeloid metaplasia","9961/3","Primary myelofibrosis",,,,,,,,,,,,,"4029668","Primary myelofibrosis",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1302547","Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","C27911","An indolent, mature B-cell neoplasm composed of small, round B-lymphocytes. When the bone marrow and peripheral blood are involved, the term chronic lymphocytic leukemia is used. The term small lymphocytic lymphoma is restricted to cases which do not show leukemic involvement of the bone marrow and peripheral blood.","Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | B-cell lymphocytic leukemia/small lymphocytic lymphoma | CLL/SLL | chronic lymphocytic leukemia/small lymphocytic lymphoma","9823/3","B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C0023480","Chronic Myelomonocytic Leukemia","C3178","A myelodysplastic/myeloproliferative neoplasm which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20 percent blasts in the bone marrow and blood, myelodysplasia, and absence of PDGFRA or PDGFRB rearrangement.","Chronic Myelomonocytic Leukemia | CMML | Chronic Myelomonocytic Leukemia (CMML) | Chronic myelomonocytic leukemia | chronic myelomonocytic leukemia","9945/3","Chronic myelomonocytic leukemia, NOS",,,,,,,,,,,,,"4030264|4133599","Chronic myelomonocytic leukemia|Chronic myelomonocytic leukemia",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1333046","Myeloproliferative Neoplasm, Not Otherwise Specified","C27350","This subgroup of myeloproliferative neoplasms includes cases which do not meet the morphologic criteria of any of the defined myeloproliferative neoplasms, or which have characteristics that overlap at least two of the myeloproliferative neoplasms.","Myeloproliferative Neoplasm, Not Otherwise Specified | CMPD, U | CMPD-U | Chronic Myeloproliferative Disease, Unclassifiable | Chronic Myeloproliferative Disease, Unclassifiable | Chronic Myeloproliferative Disorder, Unclassifiable | Chronic myeloproliferative disease, NOS | MPN, U | MPN-NOS | MPN-U | Myeloproliferative Neoplasm, NOS | Myeloproliferative Neoplasm, Unclassifiable | Myeloproliferative Neoplasm, Unclassifiable | Myeloproliferative disease, NOS | Myeloproliferative neoplasm, NOS | Unclassifiable Chronic Myeloproliferative Disease | Unclassifiable Chronic Myeloproliferative Disorder","9960/3|9975/3","Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, unclassifiable",,,,,,,,,,,,,"37158270","Myeloproliferative neoplasm unclassifiable",,,,,,,,,,,,,"--","--|--",,,,,,,,"--"
"C0023481","Chronic Neutrophilic Leukemia","C3179","A rare chronic myeloproliferative neoplasm characterized by neutrophilic leukocytosis.  There is no detectable Philadelphia chromosome or BCR/ABL fusion gene.","Chronic Neutrophilic Leukemia | Chronic neutrophilic leukemia | Neutrophilic Leukemia | chronic neutrophilic leukemia","9963/3","Chronic neutrophilic leukemia",,,,,,,,,,,,,"4029665|4097581","Chronic neutrophilic leukemia|Chronic neutrophilic leukemia",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C4228437","Cirrhosis","C2951","A disorder characterized by replacement of the liver parenchyma with fibrous tissue and regenerative nodules. It is usually caused by alcoholism, hepatitis B, and hepatitis C. Complications include the development of ascites, esophageal varices, bleeding, and hepatic encephalopathy.","Cirrhosis | Cirrhosis of the Liver | Liver Cirrhosis | Unspecified cirrhosis of liver | cirrhosis",,,,,,,,,,,,,,,"4064161","Cirrhosis of liver",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0338265","Cisplatin/Gemcitabine","C11117","Definition not available.","Cisplatin/gemcitabine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221228","Comedo","C26453","A morphologic qualifier that refers to a carcinoma with central necrosis of the tumor sheaths. The necrotic areas contain karyorrhectic/nuclear debris.","Comedo | ",,,,,,,,,,,,,,,"4100813","Comedo",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1621425","cribriform","C25731","A morphologic qualifier that refers to a carcinoma in which the tumor sheaths contain circular spaces, resulting in a sieve-like or Swiss cheese appearance.","Cribriform | cribriform",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1136033","Cutaneous Mastocytosis","C7137","Mastocytosis characterized by infiltration of the skin by mast cells.","Cutaneous Mastocytosis | CM | Cutaneous (Skin) Mastocytosis | Cutaneous mastocytosis",,,,,,,,,,,,,,,"4246283|45766622","Cutaneous mastocytosis|Cutaneous mastocytosis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1301364","Dendritic Cell Tumor, Not Otherwise Specified","C27260","A dendritic cell neoplasm that does not fall into well-defined categories or shows hybrid features.","Dendritic Cell Tumor, Not Otherwise Specified | Dendritic Cell Sarcoma, NOS | Dendritic Cell Sarcoma, not Otherwise Specified | Sarcoma of dendritic cells (accessory cells)",,,,,,,,,,,,,,,"608013","Dendritic cell sarcoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227389","Descending Colon","C12268","The fourth portion of the large intestine (colon) that communicates with the transverse colon in the left-upper quadrant of the abdomen and the rectum below.","Descending Colon | COLON, DESCENDING | Descending colon | Descending colon structure (body structure) | colon descendens | descending colon",,,,,,,,,,,,,"UBERON:0001158","descending colon","4139456","Descending colon structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205219","Diffuse","C14175","Widely spread; not localized or confined.","Diffuse | DIFFUSE | Widespread | diffuse",,,,,,,,,,,,,,,"4055872","Diffuse",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0079744","Diffuse Large B-Cell Lymphoma","C8851","A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma.  Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.","Diffuse Large B-Cell Lymphoma | DLBCL | Diffuse Large B-Cell Lymphoma (DLBCL) | Diffuse large B-cell lymphoma | Diffuse large B-cell lymphoma, unspecified site | Non-follicular (diffuse) lymphoma, unspecified, unspecified site | diffuse large B-cell lymphoma",,,,,,,,,,,,,,,"432574","Diffuse non-Hodgkin's lymphoma, large cell (clinical)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1793019","Distant Metastasis","C18206","A biological process that involves the transfer and growth of cancer cells from the site of the primary tumor. Relocation of malignant cells during metastasis can be restricted to movement within a specific tissue/organ or may entail migration to a distal locus within the body. This phenotype is a characteristic of all malignant tumors.","Distant Metastasis | Distant | Distant Cancer | distant cancer | distant metastasis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512083","Ductal","C25732","Related to, or having the quality of, a duct.","Ductal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448355","Early Detection","C16209","Use of a device, marker, or other means for the purpose of detecting the presence of a tumor early in its development.","Early Detection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014441","ELISA","C16553","A highly sensitive technique for detecting and measuring antigens or antibodies in a solution; the solution is run over a surface to which immobilized antibodies specific to the substance have been attached, and if the substance is present, it will bind to the antibody layer, and its presence is verified and visualized with an application of antibodies that have been tagged in some way. (BioTech Life Science Dictionary)","ELISA | Enzyme-linked Immunosorbent Assay | enzyme-linked immunosorbent assay",,,,,,,,,,,,,,,"4297438","Enzyme-linked immunosorbent assay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206659","Embryonal Carcinoma","C3752","A non-seminomatous malignant germ cell tumor characterized by the presence of large germ cells with abundant cytoplasm resembling epithelial cells, geographic necrosis, high mitotic activity, and pseudoglandular and pseudopapillary structures formation. It can arise from the testis, ovary, and extragonadal sites (central nervous system and mediastinum).","Embryonal Carcinoma | CARCINOMA, EMBRYONAL, MALIGNANT | Carcinoma, Embryonal, Malignant | Embryonal carcinoma, NOS","9070/3","Embryonal carcinoma, NOS",,,,,,,,,,,,,"4102135|607975","Embryonal carcinoma|Embryonal carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0206630","Endometrioid Stromal Sarcoma","C8973","A malignant mesenchymal neoplasm that affects the uterine corpus, and rarely, the ovaries, cervix, and vagina. In the uterine corpus it is classified as low grade or high grade endometrial stromal sarcoma. In the remainder of the anatomic sites it is classified as low grade endometrioid stromal sarcoma.","Endometrioid Stromal Sarcoma | ESS | Endometrial Stromal Sarcoma | Endometrial Stromal Sarcoma | Endometrial stromal sarcoma | STROMAL SARCOMA, ENDOMETRIAL, MALIGNANT | Sarcoma, Endometrial Stromal","8930/3","Endometrial stromal sarcoma, NOS",,,,,,,,,,,,,"40491873|44783285","Sarcoma of endometrium|Endometrial stromal sarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0206687","Endometrioid Adenocarcinoma","C3769","An adenocarcinoma characterized by the presence of malignant glandular epithelial cells resembling endometrial cells. It can arise from the uterine body, ovary, fallopian tube, cervix, vagina, and uterine ligament.","Endometrioid Adenocarcinoma | Endometrioid Carcinoma | Endometrioid adenocarcinoma, NOS | Endometrioid carcinoma | Endometrioid carcinoma, NOS","8380/3","Endometrioid adenocarcinoma, NOS",,,,,,,,,,,,,"4147383","Endometrioid carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0014180","Endometrium","C12313","The mucous membrane comprising the inner layer of the uterine wall; it consists of a simple columnar epithelium and a lamina propria that contains simple tubular uterine glands. The structure, thickness, and state of the endometrium undergo marked change with the menstrual cycle.","Endometrium | ENDOMETRIUM | Tunica Mucosa | endometrium",,,,,,,,,,,,,,,"4099331","Endometrial structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014245","Endoscopic Procedure","C16546","A diagnostic or therapeutic procedure in which an endoscope is inserted in a tubular organ to examine the structural architecture and/or remove abnormal tissues.","Endoscopic Procedure | ENDOSCOPY | ES | Endoscopic | Endoscopic Examination | Endoscopy | Endoscopy | endoscopy",,,,,,,,,,,,,,,"4313889","Endoscopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0456889","Enteropathy-Associated T-Cell Lymphoma","C4737","A mature T-cell and NK-cell non-Hodgkin lymphoma of intraepithelial T-lymphocytes. It usually arises from the small intestine, most commonly the jejunum or ileum.  Other less frequent primary anatomic sites include the duodenum, stomach, colon, or outside the gastrointestinal tract. It is characterized by the presence of pleomorphic medium-sized to large T-lymphocytes with vesicular nuclei, prominent nucleoli, and moderate to abundant pale cytoplasm. It is associated with celiac disease.","Enteropathy-Associated T-Cell Lymphoma | EATL | EATL, Type I | Enteropathy Associated T-Cell Lymphoma | Enteropathy associated T-cell lymphoma | Enteropathy type intestinal T-cell lymphoma | Enteropathy-Associated T-Cell Lymphoma, Type I | Enteropathy-Type T-Cell Lymphoma | Enteropathy-type (intestinal) T-cell lymphoma | Enteropathy-type T-Cell Lymphoma",,,,,,,,,,,,,,,"37153581|4082627","Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0221908","Epithelial","C13315","A term that refers to the cells that make up the epithelial tissues.  They are found in the skin, and in the parenchyma, surface and lumen of internal organs.","Epithelial | epithelial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040028","Essential Thrombocythemia","C3407","A chronic myeloproliferative neoplasm that involves primarily the megakaryocytic lineage. It is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage. (WHO, 2008)","Essential Thrombocythemia | ET | Essential (hemorrhagic) thrombocythemia | Essential Thrombocytemia | Essential Thrombocytosis | Essential thrombocythemia | Idiopathic Thrombocythemia | Idiopathic thrombocythemia | Primary Thrombocythemia | Primary Thrombocytosis | essential thrombocythemia | essential thrombocytosis","9962/3","Essential thrombocythemia",,,,,,,,,,,,,"4028716|438383","Essential thrombocythemia|Essential thrombocythemia",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0272202","Extracutaneous Mastocytoma","C7136","A localized mast cell neoplasm involving extracutaneous sites.","Extracutaneous Mastocytoma | Extracutaneous mastocytoma",,,,,,,,,,,,,,,"4269229","Localized extracutaneous mastocytosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015560","Fallopian Tube","C12403","One of a pair of tubes that extend from the uterus to each of the ovaries. Following ovulation the egg travels down the fallopian tube to the uterus where fertilization may or may not occur.","Fallopian Tube | FALLOPIAN TUBE | Fallopian Tube, NOS | Fallopian Tubes | Fallopian tube | OVIDUCT | Oviduct | fallopian tube | mammalian oviduct | uterine tube",,,,,,,,,,,,,"UBERON:0003889","fallopian tube","4151444","Fallopian tube structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016045","Fibroma","C3041","A non-metastasizing neoplasm arising from the fibrous tissue. It is characterized by the presence of spindle-shaped fibroblasts.","Fibroma | FIBROMA, BENIGN | Fibroma, NOS","8810/0","Fibroma, NOS",,,,,,,,,,,,,"4309855","Fibroma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0016315","Fluorescence","C16586","Fluorescence is a luminescence (i.e., optical phenomenon) in cold bodies, in which a molecule absorbs a high-energy photon, and re-emits it as a lower-energy (longer-wavelength) photon. The energy difference between the absorbed and emitted photons ends up as molecular vibrations (heat).","Fluorescence | ",,,,,,,,,,,,,,,"4121029","Fluorescence microscopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205234","Focal","C28224","Limited to a specific area.","Focal | FOCAL | Localized | focal",,,,,,,,,,,,,,,"4337257","Focal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024301","Follicular Lymphoma","C3209","A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).","Follicular Lymphoma | Follicle Center Lymphoma | Follicular Centre Cell Lymphoma | Follicular Non-Hodgkin Lymphoma | Follicular Non-Hodgkin's Lymphoma | Follicular lymphoma | Follicular lymphoma, unspecified, unspecified site | LYMPHOMA, FOLLICULAR, MALIGNANT | Lymphoma, Follicular Centre Cell | follicular lymphoma","9690/3","Follicular lymphoma, NOS",,,,,,,,,,,,,"4205271","Follicular lymphoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0740422","Fundus","C13378","The bottom portion or the portion that is furthest from the opening of a hollow organ.","Fundus | Fundic | fundus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517378","Gain","C37956","Gain; to increase or the amount of increase.","Gain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017454","Georgia (Republic)","C16634","A country in southwestern Asia, bordering the Black Sea, between Turkey and Russia.","Georgia (Republic) | 268 | GE | GEO | GEORGIA | Georgia | Georgia",,,,,,,,,,,,,,,"4329171","Georgia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018206","granulosa cell tumor","C3070","A slow-growing sex cord-stromal tumor characterized by the presence of granulosa-like cells and Call-Exner bodies. It is almost always found in the ovary and rarely in the testis. There are two types of granulosa cell tumors: the adult and the juvenile.","Granulosa Cell Tumor | Granulosa Cell Neoplasm | granulosa cell tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023443","Hairy Cell Leukemia","C7402","A neoplasm of small B-lymphocytes with 'hairy' projections in bone marrow, spleen, and peripheral blood.  Most patients present with splenomegaly and pancytopenia. (WHO, 2001)","Hairy Cell Leukemia | HCL | Hairy cell leukemia | Leukemic Reticuloendotheliosis | Leukemic reticuloendotheliosis | hairy cell leukemia",,,,,,,,,,,,,,,"4038845|4182216","Hairy cell leukemia (clinical)|Hairy cell leukemia",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0227385","Hepatic Flexure","C12266","The bend of the colon at the juncture of its ascending and transverse portions.","Hepatic Flexure | Ascending Colon Hepatic Flexure | COLON, HEPATIC FLEXURE | Hepatic Flexure of Colon | Hepatic Flexure of the Colon | Hepatic flexure of colon | Right Colic Flexure | flexura coli heaptica | hepatic flexure | hepatic flexure of colon | right colic flexure",,,,,,,,,,,,,"UBERON:0022277","hepatic flexure of colon","4168005","Structure of right colic flexure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0522627","Hepatosplenic T-Cell Lymphoma","C8459","An extranodal, mature T-cell non-Hodgkin lymphoma that originates from cytotoxic T-cells, usually of gamma/delta T-cell type.  It is characterized by the presence of medium-size neoplastic lymphocytes infiltrating the hepatic sinusoids.  A similar infiltrating pattern is also present in the spleen and bone marrow that are usually involved at the time of the diagnosis.","Hepatosplenic T-Cell Lymphoma | Hepatosplenic Gamma/Delta T-Cell Lymphoma | Hepatosplenic T-cell lymphoma | Hepatosplenic gamma-delta cell lymphoma","9716/3","Hepatosplenic T-cell lymphoma",,,,,,,,,,,,,"40483374","Hepatosplenic T-cell lymphoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1561957","High","C25227","An elevated level or position or degree; greater than normal in degree or intensity or amount.","High | High-level | Higher | Highly",,,,,,,,,,,,,,,"4328749","High",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334663","Histiocytic Sarcoma","C27349","An aggressive malignant neoplasm with a poor response to therapy, usually presenting as stage III/IV disease. It is characterized by the presence of neoplastic cells with morphologic and immunophenotypic characteristics similar to those seen in mature histiocytes.","Histiocytic Sarcoma | Histiocytic sarcoma | SARCOMA, HISTIOCYTIC, MALIGNANT","9755/3","Histiocytic sarcoma",,,,,,,,,,,,,"4002494|4029172","Histiocytic sarcoma (clinical)|Histiocytic sarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0444498","In Situ","C14160","In the natural or normal place, confined to the site of origin without invasion of neighboring tissues.","In Situ | in situ",,,,,,,,,,,,,,,"4136272","In situ",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0184922","Incisional Biopsy","C15386","A surgical procedure in which part of a lesion is removed for microscopic examination.","Incisional Biopsy | BIOPSY, INCISIONAL | Biopsy, Incisional | Open Biopsy | incisional biopsy | open biopsy",,,,,,,,,,,,,,,"4321986","Incisional biopsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021747","Interferon","C20493","Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570)","Interferon | Human Fibroblast Interferon | Human Leukocyte Interferon | Human Lymphoblastoid Interferon | IFN | interferon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0349639","Juvenile Myelomonocytic Leukemia","C9233","A clonal myeloid disorder of childhood previously classified as myelodysplastic/myeloproliferative neoplasm. It is characterized by the presence of monocytic proliferation in peripheral blood, less than 20% blasts in bone marrow and peripheral blood, splenomegaly, and the absence of BCR-ABL1 fusion. Almost all patients carry mutations of the RAS pathway.","Juvenile Myelomonocytic Leukemia | Chronic Myelomonocytic Leukemia | JCML | JMML | Juvenile Chronic Myelogenous Leukemia | Juvenile Chronic Myeloid Leukemia | Juvenile Chronic Myelomonocytic Leukemia | Juvenile myelomonocytic leukemia | juvenile myelomonocytic leukemia",,,,,,,,,,,,,,,"4029178|40482847","Juvenile myelomonocytic leukemia|Juvenile myelomonocytic leukemia",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0439209","Kilogram","C28252","A basic SI unit of mass. It is defined as the mass of an international prototype in the form of a platinum-iridium cylinder kept at Sevres in France. A kilogram is equal to 1,000 grams and 2.204 622 6 pounds.","Kilogram | KILOGRAM | Kilograms | kg | kilogram | kilogram(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019621","Langerhans Cell Histiocytosis","C3107","A neoplastic proliferation of Langerhans cells which contain Birbeck granules by ultrastructural examination. Three major overlapping syndromes are recognized: eosinophilic granuloma, Letterer-Siwe disease, and Hand-Schuller-Christian disease. The clinical course is generally related to the number of organs affected at presentation. (WHO, 2001)","Langerhans Cell Histiocytosis | Histiocytosis X | LCH | Langerhans Cell Granulomatosis | Langerhans Cell Histiocytosis, NOS | Langerhans Cell Histiocytosis, Not Otherwise Specified | Langerhans cell granulomatosis | Langerhans cell histiocytosis | Langerhans cell histiocytosis, NOS",,,,,,,,,,,,,,,"4278365","Langerhans cell histiocytosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1260327","Langerhans Cell Sarcoma","C6921","A neoplastic proliferation of Langerhans cells with overtly malignant cytologic features.  It can be considered a higher grade variant of Langerhans cell histiocytosis (LCH) and it can present de novo or progress from antecedent LCH. (WHO, 2001)","Langerhans Cell Sarcoma | Langerhans cell sarcoma","9756/3","Langerhans cell sarcoma",,,,,,,,,,,,,"37110403|4029173","Langerhans cell sarcoma|Langerhans cell sarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0031150","Laparoscopy","C16969","A surgical procedure during which a laparoscope is inserted into the abdomen to view the abdominopelvic contents for diagnostic and/or therapeutic purposes.","Laparoscopy | LAPAROSCOPY | LP | Laparoscopic | laparoscopy",,,,,,,,,,,,,,,"4251314","Laparoscopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023038","Laparotomy","C15266","Creation of a surgical opening into the abdominal cavity.","Laparotomy | laparotomy",,,,,,,,,,,,,,,"4314251","Laparotomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206704","Large Cell Carcinoma","C3780","A carcinoma that is composed of malignant large epithelial cells. This category includes large cell undifferentiated carcinomas, large cell differentiated carcinomas including large cell neuroendocrine carcinomas, and giant cell carcinomas.","Large Cell Carcinoma | Carcinoma, Large Cell | large cell carcinoma","8012/3","Large cell carcinoma, NOS",,,,,,,,,,,,,"4331315","Large cell carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0205091","Left","C25229","Being or located on or directed toward the side of the body to the west when facing north.","Left | LEFT | Left (qualifier value)",,,,,,,,,,,,,,,"4300877","Left",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2739810","Lentigo Maligna Melanoma","C9151","A melanoma of the skin characterized by single cell infiltration of the papillary dermis by atypical melanocytes, in a background of lentigo maligna changes.","Lentigo Maligna Melanoma | LMM | Lentigo maligna melanoma | Malignant Lentigo Melanoma | Melanoma in Hutchinson Melanotic Freckle","8742/3","Lentigo maligna melanoma",,,,,,,,,,,,,"4116198|4195326","Lentigo maligna melanoma|Lentigo maligna melanoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0023928","Lobectomy","C15272","Surgical removal of a lobe of an organ.","Lobectomy | LOBECTOMY | lobectomy",,,,,,,,,,,,,,,"4054047","Lobectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205417","Lobular","C25557","Of or relating to or resembling a lobule.","Lobular | ",,,,,,,,,,,,,,,"4223502","Lobular",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023216","Lower Extremity","C12742","The limb that is composed of the hip, thigh, leg and foot.","Lower Extremity | LIMB, LOWER | Lower Body Extremity | Lower Limb | Lower extremity | Lower limb, NOS",,,,,,,,,,,,,,,"4267861","Lower limb structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024307","Lymphomatoid Granulomatosis","C7930","An angiocentric and angiodestructive lymphoproliferative disease involving extranodal sites, comprised of Epstein-Barr virus (EBV)-positive B-cells admixed with reactive T-cells.  Incidence is higher among adult males; patients with a history of immunodeficiency are at increased risk.  The most common site of involvement is the lung; other common sites include brain, kidney, liver, and skin.  Morphologically, three grades are recognized: grade I, II, and III.  Grade III lymphomatoid granulomatosis should be approached clinically as a subtype of diffuse large B-cell lymphoma.","Lymphomatoid Granulomatosis | LYG | Lymphomatoid granulomatosis | lymphomatoid granulomatosis",,,,,,,,,,,,,,,"37311660|4344254","Lymphomatoid granulomatosis|Lymphomatoid granulomatosis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0206182","Lymphomatoid Papulosis","C3721","A chronic, recurrent cutaneous disorder characterized by the presence of spontaneously regressing papules.  The papules are composed of an atypical lymphocytic infiltrate that contains anaplastic CD30-positive T-cells, which are found in type A and diffuse large cell type (type C) lymphomatoid papulosis.  In a small number of cases, of type B, the lymphocytic infiltrate is composed of small, cerebriform-like lymphocytes that are often negative for CD30.  The majority of cases follow a benign clinical course, but some cases are clonal and may progress to lymphoma.  Treatment options include low dose methotrexate and psoralen/UVA (PUVA).","Lymphomatoid Papulosis | LyP | Lymphomatoid papulosis",,,,,,,,,,,,,,,"4150201|4287474","Lymphomatoid papulosis|Lymphomatoid papulosis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0334634","Mantle Cell Lymphoma","C4337","A non-Hodgkin lymphoma composed of small to medium sized B-lymphocytes (centrocytes). Most patients present with advanced stage disease with lymphadenopathy, hepatosplenomegaly, and bone marrow involvement. The gastrointestinal tract is the most commonly affected extranodal site by this type of non-Hodgkin lymphoma. The vast majority of cases express the t(11;14)(q13;q32) resulting in the rearrangement of the BCL-1 gene and the overexpression of cyclin D1 mRNA.","Mantle Cell Lymphoma | Classical Mantle Cell Lymphoma | MCL | Mantle Zone Lymphoma | Mantle cell lymphoma | Mantle cell lymphoma, unspecified site | Mantle zone lymphoma | mantle cell lymphoma","9673/3","Mantle cell lymphoma",,,,,,,,,,,,,"40481901|4251953","Mantle cell lymphoma|Mantle cell lymphoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0024881","Mastectomy","C15277","Surgical removal of the breast.","Mastectomy | Mammectomy | mastectomy",,,,,,,,,,,,,,,"37164749","Excision of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1292754","Primary Mediastinal Large B-Cell Lymphoma","C9280","A large B-cell non-Hodgkin lymphoma arising in the mediastinum.  Morphologically it is characterized by a massive diffuse lymphocytic proliferation associated with compartmentalizing fibrosis.  Response to intensive chemotherapy, with or without radiotherapy, is usually good. (WHO, 2001)","Primary Mediastinal Large B-Cell Lymphoma | B-Cell Diffuse Large Cell Lymphoma of Mediastinum | B-Cell Diffuse Large Cell Lymphoma of the Mediastinum | Mediastinal (Thymic) Large B-Cell Lymphoma | Mediastinal (Thymic) Large B-Cell Lymphoma | Mediastinal (thymic) large B-cell lymphoma | Mediastinal (thymic) large B-cell lymphoma, unspecified site | Mediastinal B-Cell Diffuse Large Cell Lymphoma | Mediastinal Diffuse Large Cell Lymphoma with Sclerosis | Mediastinal large B-cell lymphoma | PMBL | PMLCL | Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Primary Mediastinal Clear Cell Lymphoma of B-Cell Type | Primary Mediastinal Large B-Cell Lymphoma | Thymic large B-cell lymphoma","9679/3","Mediastinal large B-cell lymphoma",,,,,,,,,,,,,"4028703|40481522","Mediastinal large B-cell lymphoma|Primary mediastinal (thymic) large B-cell lymphoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0025066","Mediastinum","C12748","An anatomic site along the midline and under the sternum that contains the heart and pericardium, the bases of the great vessels, the trachea and bronchi, esophagus, thymus, lymph nodes, thoracic duct, phrenic and vagus nerves, and other structures and tissues.","Mediastinum | MEDIASTINUM | Mediastinal structure (body structure) | Mediastinum, NOS | mediastinal part of chest | mediastinum",,,,,,,,,,,,,"UBERON:0003728","mediastinum","4216544","Mediastinal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018717","Medicare","C16665","The US federal health insurance program run by the Health Care Financing Administration for people 65 years of age or older, certain people with disabilities who have not reached this age, and individuals with permanent kidney failure with dialysis or a transplant.  People over 65 years old, younger disabled people, and dialysis patients are eligible for the program regardless of their income. Participating beneficiaries pay part of healthcare costs through deductible amounts. Limited monthly premiums are required from beneficiaries for non-hospital coverage.","Medicare | Medicare Program | Public Health Insurance Medicare",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513143","Mesenchymal","C25721","Refers to cells that develop into connective tissue, blood vessels, and lymphatic tissue.","Mesenchymal | mesenchymal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0444598","Middle","C25569","An intermediate part or section; an area that is approximately central within some larger region.","Middle | Middle (qualifier value)",,,,,,,,,,,,,,,"4125576","Median",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334046","Mild Dysplasia","C8362","A morphologic finding indicating the presence of mild cellular atypia associated with mild architectural changes in a tissue sample.","Mild Dysplasia | Mild",,,,,,,,,,,,,,,"4182265","Mild dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0439210","Milligram","C28253","A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce.","Milligram | MILLIGRAM | mg | milligram | milligram(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439242","Milliliter","C28254","A unit of volume equal to one millionth (10E-6) of a cubic meter, one thousandth of a liter, one cubic centimeter, or 0.061023 7 cubic inch. A cubic centimeter is the CGS unit of volume.","Milliliter | Cubic Centimeter | MILLILITER | cc | cm3 | cu cm | cubic centimeter | mL | mililiter | milliliter | millilitre(s) | ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439200","Millimeter","C28251","A metric unit of length equal to one thousandth of a meter (10E-3 meter) or approximately 0.03937 inch.","Millimeter | MILLIMETER | Millimeters | millimeter | millimeter(s) | mm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334047","Moderate Dysplasia","C8363","A morphologic finding indicating the presence of moderate cellular atypia associated with moderate architectural changes in a tissue sample.","Moderate Dysplasia | Moderate",,,,,,,,,,,,,,,"4237280","Moderate dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205616","Moderately Differentiated","C14162","Describes tumor cells that have lost some of the appearance of normal cells. They tend to grow and spread at a faster rate than well differentiated tumor cells.","Moderately Differentiated | G2 | G2 Moderately differentiated | Moderately Well Differentiated",,,,,,,,,,,,,,,"4298625","Moderately differentiated",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024883","Modified Radical Mastectomy","C15278","The surgical removal of one or both breasts, including the areola, nipple, and the majority of the axillary lymph nodes, but sparing the pectoralis major muscle.","Modified Radical Mastectomy | MODIFIED RADICAL MASTECTOMY | Modified Mastectomy | modified radical mastectomy",,,,,,,,,,,,,,,"4249113","Modified radical mastectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205186","Monophasic","C25576","Occurring in or characterized by only one phase or stage.","Monophasic | ",,,,,,,,,,,,,,,"4249905","Monophasic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007130","Mucinous Adenocarcinoma","C26712","An invasive adenocarcinoma composed of malignant glandular cells that contain intracytoplasmic mucin. Often, the infiltrating glandular structures are associated with mucoid stromal formation. It may arise from the large and small intestine, appendix, stomach, lung, ovary, breast, corpus uteri, cervix, vagina, and salivary gland.","Mucinous Adenocarcinoma | ADENOCARCINOMA, MUCINOUS, MALIGNANT | Colloid Adenocarcinoma | Colloid Carcinoma | Colloid adenocarcinoma | Colloid carcinoma | Gelatinous Adenocarcinoma | Gelatinous Carcinoma | Gelatinous adenocarcinoma | Gelatinous carcinoma | Mucinous Carcinoma | Mucinous adenocarcinoma | Mucinous carcinoma | Mucoid Adenocarcinoma | Mucoid Carcinoma | Mucoid adenocarcinoma | Mucoid carcinoma | Mucous Adenocarcinoma | Mucous Carcinoma | Mucous adenocarcinoma | Mucous carcinoma | mucinous carcinoma","8480/3","Mucinous adenocarcinoma",,,,,,,,,,,,,"4247921","Mucinous adenocarcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0026948","Mycosis Fungoides","C3246","A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei.  Patients with limited disease generally have an excellent prognosis.  In the more advanced stages, the prognosis is poor. (WHO, 2001)","Mycosis Fungoides | CTCL/ Mycosis fungoides | Cutaneous T-cell lymphoma/Mycosis fungoides | MF | Mycosis fungoides | Mycosis fungoides, unspecified site | mycosis fungoides","9700/3","Mycosis fungoides",,,,,,,,,,,,,"4040380|4233385","Mycosis fungoides (clinical)|Mycosis fungoides",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0854809","Myelodysplastic Syndrome, Unclassifiable","C8648","A subtype of myelodysplastic syndrome which initially lacks findings appropriate for classification into any other myelodysplastic category.  There are no specific morphologic findings.  The diagnosis can be made in the following instances: 1. in cases of refractory cytopenia with unilineage dysplasia or refractory cytopenia with multilineage dysplasia but with 1% blasts in the peripheral blood; 2: in cases of myelodysplastic syndrome with unilineage dysplasia which are associated with pancytopenia; 3: in cases with persistent cytopenia (s) with 1% or fewer blasts in the blood and fewer than 5% in the bone marrow, unequivocal dysplasia in less than 10% of the cells in one or more myeloid lineages, and cytogenetic abnormalities considered as presumptive evidence of myelodysplastic syndrome. (WHO, 2008)","Myelodysplastic Syndrome, Unclassifiable | MDS, U | MDS-U | Myelodysplastic syndrome, unclassifiable | Unclassifiable MDS | Unclassifiable Myelodysplastic Syndrome",,,,,,,,,,,,,,,"37167447","Unclassifiable myelodysplastic syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL414320","Myeloid Sarcoma","C3520","A tumor mass composed of myeloblasts or immature myeloid cells.  It occurs in extramedullary sites or the bone.  (WHO, 2001)","Myeloid Sarcoma | Chloroma | Extramedullary Myeloid Sarcoma | Extramedullary Myeloid Tumor | MYELOID_SARCOMA | Myeloid sarcoma | SARCOMA, MYELOID, MALIGNANT | chloroma","9930/3","Myeloid sarcoma",,,,,,,,,,,,,"140967|4148718","Myeloid sarcoma|Myeloid sarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0005560","Needle Biopsy","C15190","The removal of a tissue sample using a needle, for microscopic examination.","Needle Biopsy | Aspiration Biopsy | Puncture Biopsy | needle biopsy",,,,,,,,,,,,,,,"4044511","Needle biopsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3853545","Negative - answer","C25247","Involving disadvantage or harm.","Negative | NEG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206695","Neuroendocrine Carcinoma","C3773","An aggressive carcinoma composed of malignant cells that exhibit neuroendocrine differentiation. It is classified as small cell or large cell neuroendocrine carcinoma.","Neuroendocrine Carcinoma | High-Grade Neuroendocrine Carcinoma | Malignant Poorly Differentiated Epithelial Neuroendocrine Neoplasm | Malignant poorly differentiated neuroendocrine tumors | NEC | Neuroendocrine Cancer | Neuroendocrine cancer, NOS | Neuroendocrine carcinoma, NOS | Poorly Differentiated Epithelial Neuroendocrine Neoplasm","8246/3","Neuroendocrine carcinoma, NOS",,,,,,,,,,,,,"4102373|4184763","Neuroendocrine carcinoma|Neuroendocrine tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0855139","Nodal Marginal Zone Lymphoma","C8863","A primary nodal B-cell non-Hodgkin lymphoma which morphologically resembles lymph nodes involved by marginal zone lymphomas of extranodal or splenic types, but without evidence of extranodal or splenic disease.  (WHO, 2001)","Nodal Marginal Zone Lymphoma | Monocytoid B-Cell Lymphoma | Monocytoid B-cell lymphoma | Nodal Marginal Zone B-Cell Lymphoma | Nodal Marginal Zone B-Cell Lymphoma | Nodal marginal zone B-cell lymph. | Nodal marginal zone B-cell lymphoma | Nodal marginal zone lymphoma",,,,,,,,,,,,,,,"37118088|4079693|4265014","Nodal marginal zone B-cell lymphoma|Monocytoid B-cell lymphoma|Nodal marginal zone B-cell lymphoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C1550457","Normal","C14165","Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.","Normal | NORMAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521447","Nuclear","C13361","Pertaining to the nucleus.","Nuclear | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028977","Omentum","C33209","A fold of peritoneum originating at the stomach and supporting the viscera.","Omentum | OMENTUM | Omental Fat | omentum",,,,,,,,,,,,,"UBERON:0003688","omentum","4099608","Omentum structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0156344","Ovarian Endometriosis","C27628","A non-neoplastic disorder characterized by the growth of endometrial tissue in the ovaries.  It results in the development of blood filled ovarian cysts (chocolate cysts), and creation of scars and adhesions.","Ovarian Endometriosis | ",,,,,,,,,,,,,,,"199881","Endometriosis of ovary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205312","Papillary","C14166","Of or relating to or resembling papilla.","Papillary | ",,,,,,,,,,,,,,,"4298944","Papillary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1270947","Partial Hysterectomy","C40961","Surgical removal of part of the uterus.","Partial Hysterectomy | partial hysterectomy | subtotal hysterectomy",,,,,,,,,,,,,,,"4300373","Partial hysterectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1521733","Pathologic","C25610","Caused by or altered by or manifesting disease or pathology.","Pathologic | PATHOLOGICAL",,,,,,,,,,,,,,,"4105323","Pathologic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002997","Percutaneous Transluminal Coronary Angioplasty","C38078","A procedure to open an occluded coronary artery, performed by percutaneous introduction of a catheter into a peripheral (usually femoral) artery which is directed in a retrograde fashion to reach the diseased coronary artery.","Percutaneous Transluminal Coronary Angioplasty | PCTA | PTCA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031050","Pericardium","C13005","A conical membranous sac filled with serous fluid in which the heart as well as the roots of the aorta and other large blood vessels are contained.","Pericardium | Human Pericardium | PERICARDIUM | Pericardial structure (body structure) | pericardium",,,,,,,,,,,,,"UBERON:0002407","pericardium","4298557","Pericardial structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0442034","peritoneal","C25313","Of or pertaining to the peritoneum.","Peritoneal | peritoneal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514164","Pleomorphic","C28109","Occurring in various distinct forms.  In terms of cells, having variation in the size and shape of cells or their nuclei.","Pleomorphic | pleomorphic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032284","Pneumonectomy","C15305","The excision of part or all of a lung.","Pneumonectomy | pneumonectomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032463","Polycythemia Vera","C3336","A chronic myeloproliferative neoplasm characterized by an increased red blood cell production. The bone marrow is hypercellular due to a panmyelotic proliferation typically characterized by pleomorphic megakaryocytes. The major symptoms are related to hypertension, splenomegaly or to episodes of thrombosis and/or hemorrhage.","Polycythemia Vera | Chronic Erythremia | Polycythemia Rubra Vera | Polycythemia rubra vera | Polycythemia vera | Polycythemmia vera | polycythemia vera","9950/3","Polycythemia vera",,,,,,,,,,,,,"135214|4030270","Polycythemia vera (clinical)|Polycythemia vera",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0205617","Poorly Differentiated","C14167","Describes tumor cells that generally have lost most of the appearance of normal cells. They tend to grow and spread.","Poorly Differentiated | G3 | G3 Poorly differentiated",,,,,,,,,,,,,,,"4135617","Poorly differentiated",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268381","Primary Amyloidosis","C3819","Amyloidosis caused by monoclonal deposition of immunoglobulin light chain and, rarely, heavy chain fragments in organs and tissues. It is associated with plasma cell or B-cell lymphoproliferative disorders.","Primary Amyloidosis | Primary amyloidosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1301362","Primary Cutaneous Anaplastic Large Cell Lymphoma","C6860","An anaplastic large cell lymphoma limited to the skin at the time of diagnosis.  Most patients present with solitary or localized skin lesions, which may be tumors, nodules or papules.  The t(2;5) translocation that is present in many cases of systemic anaplastic large cell lymphoma, is not found in this disease. (WHO, 2001)","Primary Cutaneous Anaplastic Large Cell Lymphoma | ALCL, cutaneous | Anaplastic large-cell lymphoma, primary cutaneous type | C-ALCL | Primary Anaplastic Large Cell Lymphoma of Skin | Primary Anaplastic Large Cell Lymphoma of the Skin | Primary Cutaneous CD30 Positive Anaplastic Large Cell Lymphoma | Primary Cutaneous CD30+ ALCL | Primary Cutaneous CD30+ Anaplastic Large Cell Lymphoma | Primary cutaneous anaplastic large cell lymphoma",,,,,,,,,,,,,,,"4264450","Primary cutaneous anaplastic large cell lymphoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1292753","Primary Effusion Lymphoma","C6915","A large B-cell lymphoma usually presenting as a serous effusion without detectable tumor masses. It is universally associated with human herpes virus 8 (HHV8), also called Kaposi sarcoma-associated herpesvirus.  It mostly occurs in the setting of immunodeficiency. The most common sites of involvement are the pleural, pericardial, and peritoneal cavities. Rare HHV8-positive lymphomas indistinguishable from primary effusion lymphomas (PEL) present as solid tumor masses, and have been termed extracavitary PEL. The prognosis is extremely unfavorable. (WHO 2017)","Primary Effusion Lymphoma | PEL | Primary effusion lymphoma | primary effusion lymphoma","9678/3","Primary effusion lymphoma",,,,,,,,,,,,,"37017270|4028702","Primary effusion lymphoma|Primary effusion lymphoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C2709248","Pulmonary","C13304","Relating to the lungs as the intended site of administration, where the pharmaceutical product is administered, usually by inhalation, for local action in the lower respiratory tract or for systemic action after absorption via the lower respiratory tract.","Pulmonary | pulmonary",,,,,,,,,,,,,,,"42538094","Pulmonary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL429630","Recurrence (disease attribute)","C14173","Occurring again.","Recurrent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002893","Refractory Anemia","C2872","A myelodysplastic syndrome characterized mainly by dysplasia of the erythroid series.  Refractory anemia is uncommon.  It is primarily a disease of older adults.  The median survival exceeds 5 years.  (WHO, 2001)","Refractory Anemia | Aregenerative Anemia | RA | Refractory anemia | Refractory anemia, unspecified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002894","Myelodysplastic Syndrome with Excess Blasts","C7506","Myelodysplastic syndrome characterized by the presence of 5-9% blasts in bone marrow and 2-9% blasts in peripheral blood.","Myelodysplastic Syndrome with Excess Blasts | MDS-EB | MDS-EB-1 | MDS-IB | MDS-IB-1 | MDS-IB1 | Myelodysplastic Neoplasm with Increased Blasts | Myelodysplastic Syndrome with Excess Blasts-1 | Myelodysplastic Syndrome with Increased Blasts | RAEB | RAEB I | RAEB-1 | RAEB-I | Refractory Anemia with Excess Blasts | Refractory Anemia with Excess Blasts | Refractory Anemia with an Excess of Blasts | Refractory anemia with excess blasts | Refractory anemia with excess of blasts 1 | Refractory anemia with excess of blasts, unspecified",,,,,,,,,,,,,,,"136949|4028718","Myelodysplastic syndrome with excess blasts|Myelodysplastic syndrome with increased blasts",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1264195","Myelodysplastic Syndrome with Ring Sideroblasts","C4036","A myelodysplastic syndrome characterized by an anemia in which 15% or more of the erythroid precursors are ring sideroblasts.  The ring sideroblast is an erythroid precursor in which one third or more of the nucleus is encircled by granules which are positive for iron stain. (WHO, 2001)","Myelodysplastic Syndrome with Ring Sideroblasts | MDS-RS | Pure Sideroblastic Anemia | RARS | Refractory Anemia with Ring Sideroblasts | Refractory Anemia with Ring Sideroblasts | Refractory Anemia with Ringed Sideroblasts | Refractory Anemia with Ringed Sideroblasts | Refractory anemia with ring sideroblasts | Refractory anemia with ringed sideroblasts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796466","Myelodysplastic Syndrome, Not Otherwise Specified with Multilineage Dysplasia","C8574","A myelodysplastic syndrome characterized by bi-cytopenia or pancytopenia and dysplastic changes in 10% or more of the cells in two or more of the myeloid cell lines. (WHO, 2001)","Myelodysplastic Syndrome, Not Otherwise Specified with Multilineage Dysplasia | MDS, NOS with Multilineage Dysplasia | MDS-LB-MLD | MDS-MLD | Myelodysplastic Neoplasm with Low Blasts and Multilineage Dysplasia | Myelodysplastic Syndrome with Low Blasts and Multilineage Dysplasia | Myelodysplastic Syndrome with Multilineage Dysplasia | Myelodysplastic Syndrome with Multilineage Dysplasia | RCMD | Refractory Cytopenia with Multilineage Dysplasia | Refractory Cytopenia with Multilineage Dysplasia | Refractory cytopenia with multilineage dysplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205090","Right","C25228","Being or located on or directed toward the side of the body to the east when facing north.","Right | RIGHT | Right (qualifier value)",,,,,,,,,,,,,,,"4080761","Right",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205697","Sarcomatoid Carcinoma","C27004","A malignant epithelial neoplasm characterized by the presence of spindle cells and anaplastic morphologic features.  Giant cells and a sarcomatous component may also be present.","Sarcomatoid Carcinoma | CARCINOMA, SPINDLE CELL, MALIGNANT | Pseudosarcomatous Carcinoma | Pseudosarcomatous carcinoma | Sarcomatoid carcinoma | Spindle Cell Carcinoma | sarcomatoid carcinoma","8032/3|8033/3","Spindle cell carcinoma, NOS|Pseudosarcomatous carcinoma",,,,,,,,,,,,,"4045625","Pseudosarcomatous carcinoma",,,,,,,,,,,,,"--","--|--",,,,,,,,"--"
"C0036628","Seminal Vesicle","C12787","One of the two paired glands in the male genitourinary system, posterior to the bladder and superior to the prostate gland, that produces fructose-rich seminal fluid which is a component of semen. These glands join the ipsilateral ductus deferens to form the ejaculatory duct.","Seminal Vesicle | GLAND, SEMINAL VESICLE | SEMINAL VESICLE | Seminal Sacs | Seminal Vesicles | Seminal vesicle structure (body structure) | seminal vesicle","C63.7","Seminal vesicle",,,,,,,,,,,"UBERON:0000998","seminal vesicle","4277442","Seminal vesicle structure",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0796693","Sentinel Lymph Node Biopsy","C15667","Surgical removal and examination of the sentinel node, the lymph node which is first in receiving the lymphatic drainage of a specified anatomic location and is most likely to be affected by the lymphatic spread of cancer.","Sentinel Lymph Node Biopsy | SENTINEL LYMPH NODE BIOPSY | SLNB | SNB | Sentinel Node Biopsy | Sentinel node biopsy alone | sentinel lymph node biopsy",,,,,,,,,,,,,,,"4263386","Sentinel lymph node biopsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448664","Serous Adenocarcinoma","C40101","An adenocarcinoma that is characterized by the presence of papillary patterns and cellular budding. Psammoma bodies may be present.  Representative examples include cervical serous adenocarcinoma, endometrial serous adenocarcinoma, ovarian serous adenocarcinoma, and primary peritoneal serous adenocarcinoma.","Serous Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334048","Severe Dysplasia","C8364","A morphologic finding indicating the presence of severe cellular atypia associated with severe architectural changes in a tissue sample.","Severe Dysplasia | Severe",,,,,,,,,,,,,,,"4206155","Severe dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036920","Sezary Syndrome","C3366","A generalized peripheral (mature) T-cell neoplasm characterized by the presence of erythroderma, lymphadenopathy, and neoplastic, cerebriform T-lymphocytes in the blood.  Sezary syndrome is an aggressive disease. (WHO, 2001)","Sezary Syndrome | CTCL / Sezary syndrome | Cutaneous T-cell lymphoma/Sezary syndrome | Sezary disease | Sezary disease, unspecified site | Sezary syndrome | Sezary's Disease | Sézary Syndrome","9701/3","Sezary syndrome",,,,,,,,,,,,,"4170865","Sezary syndrome",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0206696","Signet Ring Cell Adenocarcinoma","C3774","A usually aggressive, poorly differentiated invasive adenocarcinoma characterized by the presence of malignant glandular cells in which the nucleus is pressed to one side by the presence of intracytoplasmic mucus. It may arise from the stomach, small and large intestine, ampulla of Vater, appendix, gallbladder, pancreas, lung, bladder, breast, and prostate gland.","Signet Ring Cell Adenocarcinoma | Signet Ring Cell Adenocarcinoma | Signet Ring Cell Carcinoma | Signet Ring Cell Carcinoma | Signet ring cell adenocarcinoma | Signet ring cell carcinoma | Signet-Ring Cell Carcinoma | signet ring cell carcinoma","8490/3","Signet ring cell carcinoma",,,,,,,,,,,,,"4227888","Signet ring cell carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0037116","Silicosis","C3369","An occupational lung disorder caused by the inhalation of silica dust. It results in the inflammation and scarring of the upper lobes of the lungs. It may be an acute or chronic disorder. In the acute form, patients develop shortness of breath, fever, and cyanosis. In the chronic form patients, develop progressive shortness of breath.","Silicosis | Pneumoconiosis due to Other dust containing silica",,,,,,,,,,,,,,,"442125","Pneumoconiosis due to silica",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0262584","Small Cell Neuroendocrine Carcinoma","C3915","An aggressive high-grade carcinoma with neuroendocrine differentiation composed of malignant small cells.","Small Cell Neuroendocrine Carcinoma | Oat Cell Cancer | Oat Cell Carcinoma | Oat cell carcinoma | SCNEC | Small Cell Cancer | Small Cell Carcinoma | Small Cell Carcinoma | Small Cell NEC | Small cell carcinoma, NOS | Small cell neuroendocrine carcinoma | oat cell cancer","8041/3|8042/3","Small cell carcinoma, NOS|Oat cell carcinoma",,,,,,,,,,,,,"36712771|4252582|4298553","Small cell carcinoma|Small cell carcinoma|Oat cell carcinoma",,,,,,,,,,,,,"--","--|--",,,,,,,,"--|--|--"
"C0227387","Splenic Flexure","C12267","The bend at the junction of the transverse and descending colon.","Splenic Flexure | COLON, SPLENIC FLEXURE | Left Colic Flexure | Splenic Flexure of Colon | Splenic flexure of colon | flexura coli splenica | left colic flexure | splenic flexure | splenic flexure of colon",,,,,,,,,,,,,"UBERON:0022276","splenic flexure of colon","4217667","Structure of left colic flexure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025570","Squamous Metaplasia","C3237","A morphologic finding indicating the transformation of glandular or transitional epithelial cells to, usually, mature squamous epithelial cells.  Representative examples include squamous metaplasia of bronchial epithelium, cervix, urinary bladder, and prostate gland.","Squamous Metaplasia | Sinonasal metaplasia",,,,,,,,,,,,,,,"4306771","Squamous metaplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205360","Stable","C30103","Subject to little fluctuation; showing little if any change.","Stable | STABLE",,,,,,,,,,,,,,,"4241442","Stable",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0441904","Staging","C15608","The process of defining at what point in the natural history of a malignant disease a patient is when a diagnosis is made.","Staging | STAGING | staging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0522624","Subcutaneous Panniculitis-Like T-Cell Lymphoma","C6918","A cytotoxic primary cutaneous T-cell lymphoma. Recent studies suggest there are at least two groups of subcutaneous panniculitis-like T-cell lymphomas, each with distinct histologic features, immunophenotypic profile, and prognosis. One group has an alpha/beta, CD8 positive phenotype, involves only subcutaneous tissues, and usually has an indolent clinical course. The second group has a gamma/delta phenotype, is CD8 negative, often co-expresses CD56, is not confined to the subcutaneous tissues, and usually has a poor prognosis. In the recent WHO-EORTC classification, the term subcutaneous panniculitis-like T-cell lymphoma is reserved for cases with an alpha/beta, CD8 positive phenotype. Cases with a gamma/delta phenotype are included in the group of cutaneous gamma/delta T-cell lymphomas.","Subcutaneous Panniculitis-Like T-Cell Lymphoma | SPTCL | Subcutaneous Panniculitis-Like T-Cell Lymphoma (Alpha/Beta Type) | Subcutaneous Panniculitis-Like T-Cell Lymphoma, Alpha/Beta Type | Subcutaneous panniculitis-like T-cell lymphoma","9708/3","Subcutaneous panniculitis-like T-cell lymphoma",,,,,,,,,,,,,"4301666|4304337","Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0446461","Supraclavicular","C25329","Positioned above the clavicle.","Supraclavicular | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL426379","Epidemiology Surveillance","C15719","The systematic collection, analysis, and interpretation of health data on an ongoing basis.","Surveillance | Epidemiology / Surveillance | surveillance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2363142","T-Cell Prolymphocytic Leukemia","C4752","An aggressive T-cell leukemia, characterized by the proliferation of small to medium sized prolymphocytes with a mature T-cell phenotype, involving the blood, bone marrow, lymph nodes, liver, spleen, and skin.  (WHO, 2001)","T-Cell Prolymphocytic Leukemia | Prolymphocytic leukemia, T-cell type | T Cell Prolymphocytic Leukemia | T Prolymphocytic Leukemia | T-Prolymphocytic Leukemia","9834/3","Prolymphocytic leukemia, T-cell type",,,,,,,,,,,,,"4029175|4079683","Prolymphocytic leukemia, T-cell type|T-cell prolymphocytic leukemia",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0039871","Thiotepa","C875","A polyfunctional, organophosphorus alkylating agent and a stable derivative of N,N',N''-triethylenephosphoramide (TEPA), with antineoplastic activity. Upon administration, thiotepa is converted into highly reactive ethylenimine groups, which covalently bind to nucleophilic groups in DNA and demonstrate a preference for the N7 position of guanine bases. This induces crosslinking of alkylated guanine bases in double-stranded DNA, interferes with both DNA replication and cell division, and results in both the induction of apoptosis and the inhibition of cell growth.","Thiotepa | 1,1',1'-phosphinothioylidynetrisaziridine | 1,1',1''-Phosphinothioyldynetrisaziridine | 1,1',1''-Phosphinothioylidynetrisaziridine | Girostan | N,N', N''-Triethylenethiophosphoramide | N,N',N''-triethylenethiophosphoramide | Oncotiotepa | SH 105 | SH-105 | SH105 | STEPA | TESPA | THIOTEPA | TIO TEF | TSPA | Tepadina | Tepylute | Tespamin | Tespamine | Thio-Tepa | Thiofosfamide | Thiofozil | Thiophosphamide | Thiophosphoamide | Thiophosphoramide | Thioplex | Thiotef | Tifosyl | Tio-tef | Triethylene Thiophosphoramide | Triethylene thiophosphoramide | Triethylenethiophosphoramide | Tris(1-aziridinyl)phosphine sulfide | WR 45312 | thiotepa | triethylenethiophosphoramide | tris(1-aziridinyl)phosphine sulfide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677962","Total Hysterectomy","C15701","A surgical procedure to remove the uterine body and cervix. -- 2004","Total Hysterectomy | Full Hysterectomy | Simple Hysterectomy | complete hysterectomy | total hysterectomy",,,,,,,,,,,,,,,"4023403","Total hysterectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007138","Transitional Cell Carcinoma","C2930","A malignant neoplasm arising from the transitional epithelium, usually affecting the urinary bladder, ureter, or renal pelvis. It may or may not have a papillary configuration. It is graded 1 to 3 or 4 according to the degree of cellular differentiation and architectural patterns. Grade 1 transitional cell carcinoma is histologically benign but it may recur. Transitional cell carcinomas may also affect the upper respiratory tract and the ovaries.","Transitional Cell Carcinoma | CARCINOMA, UROTHELIAL, MALIGNANT | Transitional Carcinoma | Transitional carcinoma | Transitional cell carcinoma | transitional cell carcinoma","8120/3","Transitional cell carcinoma, NOS",,,,,,,,,,,,,"4097829","Transitional cell carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1519630","Transurethral Resection","C15705","Surgery performed with a special instrument inserted through the urethra.","Transurethral Resection | TUR | transurethral resection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227386","Transverse Colon","C12385","The third division of the colon (large intestine). It communicates with the ascending colon in the upper right-hand quadrant of the abdomen and the descending colon in the upper left-hand quadrant.","Transverse Colon | COLON, TRANSVERSE | Transverse colon | Transverse colon structure (body structure) | colon transversum | transverse colon",,,,,,,,,,,,,"UBERON:0001157","transverse colon","4171827","Transverse colon structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0460005","Trunk","C33816","The body excluding the head and neck and limbs.","Trunk | TRUNK | Torso | thoracolumbar region | torso | trunk | trunk region",,,,,,,,,,,,,"UBERON:0002100","trunk","4042529","Trunk structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041296","Tuberculosis","C3423","A chronic, recurrent infection caused by the bacterium Mycobacterium tuberculosis. Tuberculosis (TB) may affect almost any tissue or organ of the body with the lungs being the most common site of infection. The clinical stages of TB are primary or initial infection, latent or dormant infection, and recrudescent or adult-type TB. Ninety to 95% of primary TB infections may go unrecognized. Histopathologically, tissue lesions consist of granulomas which usually undergo central caseation necrosis. Local symptoms of TB vary according to the part affected; acute symptoms include hectic fever, sweats, and emaciation; serious complications include granulomatous erosion of pulmonary bronchi associated with hemoptysis. If untreated, progressive TB may be associated with a high degree of mortality. This infection is frequently observed in immunocompromised individuals with AIDS or a history of illicit IV drug use.","Tuberculosis | Active Tuberculosis | TB | Tuberculosis Disease | tuberculosis",,,,,,,,,,,,,,,"434557","Tuberculosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332208","Tubular","C14169","Shaped like a tube; of or pertaining to a tubule.","Tubular | ",,,,,,,,,,,,,,,"4028196","Tubular",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883403","Sweat Gland Tubular Carcinoma","C3682","An aggressive adenocarcinoma that arises from the sweat glands. It usually presents as a firm, erythematous nodular lesion in the axilla. Morphologically, it is characterized by the presence of tubular structures and apocrine differentiation.","Sweat Gland Tubular Carcinoma | Sweat Gland Tubular Adenocarcinoma | Tubular Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205618","Undifferentiated","C14176","Describes tumor cells that generally have lost all of the appearance of normal cells. They tend to grow and spread quickly and aggressively.","Undifferentiated | G4 | G4 Undifferentiated | Undifferentiated Grade | Undifferentiated Histology | undifferentiated",,,,,,,,,,,,,,,"4137182","Undifferentiated",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205698","Undifferentiated Carcinoma","C3692","A usually aggressive malignant epithelial neoplasm composed of atypical cells which do not display evidence of glandular, squamous, or transitional cell differentiation.","Undifferentiated Carcinoma | Anaplastic Carcinoma | CARCINOMA, UNDIFFERENTIATED, MALIGNANT | Carcinoma, Undifferentiated | Carcinoma, anaplastic, NOS | Carcinoma, undifferentiated, NOS","8020/3|8021/3","Carcinoma, undifferentiated, NOS|Carcinoma, anaplastic, NOS",,,,,,,,,,,,,"4243327","Carcinoma, undifferentiated",,,,,,,,,,,,,"--","--|--",,,,,,,,"--"
"C0205092","Unilateral","C28012","Having to do with one side of the body.","Unilateral | UNILATERAL | Unilateral Anatomic Qualifier | unilateral | unilateral",,,,,,,,,,,,,,,"4280221","Unilateral",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1140618","Upper Extremity","C12671","The region of the body that includes the arm, the forearm, and hand.","Upper Extremity | LIMB, UPPER | Upper Body Extremity | Upper Limb | Upper extremity | Upper limb, NOS | arm",,,,,,,,,,,,,"UBERON:0001460","arm","4200396","Upper limb structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041951","Ureter","C12416","The thick-walled tube that carries urine from each kidney to the bladder.","Ureter | URETER | Ureteric structure (body structure) | ureter",,,,,,,,,,,,,"UBERON:0000056","ureter","4337115","Ureteric structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205615","Well Differentiated","C14171","Describes tumor cells that generally retain the appearance of normal cells and tend to grow and spread at a slower rate than undifferentiated or poorly differentiated tumor cells.","Well Differentiated | G1 | G1 Well differentiated",,,,,,,,,,,,,,,"4137845","Well differentiated",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0851238","Lumpectomy","C15755","The surgical removal of a discrete mass.","Lumpectomy | LUMPECTOMY | Lumpectomy of Breast | Partial Mastectomy | lumpectomy | partial mastectomy",,,,,,,,,,,,,,,"4309433","Excision of mass",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013089","Doxorubicin","C456","An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","Doxorubicin | (8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione | (8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione | 14-Hydroxydaunomycin | Adriablastin | DOXORUBICIN | Hydroxydaunomycin | Hydroxyl Daunorubicin | Hydroxyldaunorubicin | doxorubicin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010583","Cyclophosphamide","C405","A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","Cyclophosphamide | (-)-Cyclophosphamide | 1-bis(2-chloroethyl)-amino-1-oxo-2-aza-5-oxaphosphoridin monohydrate | 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate | 2-[bis(b-chloroethyl)amino]-1-oxa-3-aza-2-phosphacyclohexane-2-oxide monohydrate | 2-[di(chloroethyl)amino]-1-oxa-3-aza-2-phosphacyclohexane 2-oxide monohydrate | 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate | Asta B 518 | B 518 | B-518 | B518 | Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester monohydrate | CP monohydrate | CTX | CYCLO-cell | CYCLOPHOSPHAMIDE | Carloxan | Ciclofosfamida | Ciclofosfamide | Cicloxal | Clafen | Claphene | Cycloblastin | Cycloblastine | Cyclophospham | Cyclophosphamid monohydrate | Cyclophosphamide Monohydrate | Cyclophosphamidum | Cyclophosphan | Cyclophosphane | Cyclophosphanum | Cyclostin | Cyclostine | Cytophosphan | Cytophosphane | Cytoxan | Fosfaseron | Genoxal | Genuxal | Ledoxina | Mitoxan | N,N-bis(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide monohydrate | N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)phosphorodiamidic acid intramolecular ester monohydrate | N,N-bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide monohydrate | N,N-bis(b-chloroethyl)-N',O-trimethylenephosphoric acid ester diamide monohydrate | N,N-bis(beta-chloroethyl)-N',O-propylenephosphoric acid ester diamide monohydrate | N,N-bis(beta-chloroethyl)-N',O-trimethylenephosphoric acid ester diamide monohydrate | Neosar | Revimmune | Syklofosfamid | WR 138719 | WR- 138719 | WR-138719 | WR138719 | bis(2-chloroethyl)phosphamide cyclic propanolamide ester monohydrate | cyclophosphamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0144576","Paclitaxel","C1411","A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","Paclitaxel | 5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester with (2R,3S)-N-Benzoyl-3-phenylisoserine | Anzatax | Asotax | Bristaxol | PACLITAXEL | Praxel | Taxol | Taxol Konzentrat | [2aR-[2a Alpha,4beta,4a beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a alpha,12b alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester | paclitaxel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036588","Self","C25200","The individual as the object of his own reflective consciousness.","Self | You | Yourself",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086409","Hispanic or Latino","C17459","Includes individuals of Mexican, Puerto Rican, Salvadoran, Cuban, Dominican, Guatemalan, and other Central or South American or Spanish culture or origin.","Hispanic or Latino | HISPANIC OR LATINO | HISPANIC_OR_LATINO | Hispanic | Hispanic | Hispanic Populations | Hispanics or Latinos | Latino Population | Spanish Origin | hispanic or latino",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511035","Bachelor's Degree","C39327","Bachelor's degree is an award (baccalaureate or equivalent degree, as determined by the Secretary of the U.S. Department of Education) conferred by a college, university, or other postsecondary education institution as official recognition for the successful completion of a program of studies, that normally requires at least four years of full-time equivalent college-level work. This includes bachelor's degrees conferred in a five-year cooperative program.","Bachelor's Degree | Baccalaureate Degree",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022646","Kidney","C12415","One of the two bean-shaped organs located on each side of the spine in the retroperitoneum. The right kidney is located below the liver and the left kidney below the diaphragm. The kidneys filter and secrete metabolic products and minerals from the blood, thus maintaining homeostasis. On the superior pole of each kidney there is an adrenal gland. Each kidney and adrenal gland is surrounded by fat.","Kidney | KIDNEY | Kidney structure (body structure) | Kidney, NOS | Kidneys | Urinary System, Kidney | kidney",,,,,,,,,,,,,"UBERON:0002113","kidney","4271678","Kidney structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013852","Electron","C40428","A fundamental particle with a negative charge.","Electron | Negative Beta Particle",,,,,,,,,,,,,,,"4263200","Electron",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205288","Microscopic","C25252","Too small to be seen except under a microscope.","Microscopic | Micro | microscopic",,,,,,,,,,,,,,,"4309202","Microscopic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036525","Metastatic","C14174","A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site.","Metastatic | METASTATIC | metastatic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002805","Anastomosis (procedure)","C15609","A natural or surgically-induced connection between tubular structures in the body.","Anastomosis | ANASTOMOSIS | Anastomotic | anastomosis",,,,,,,,,,,,,,,"4117491","Anastomosis - action",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205276","Local-Regional","C25388","Of or belonging to both a local and regional area of the body.","Local-Regional | LOCOREGIONAL | Local | Locoregional | Regional",,,,,,,,,,,,,,,"4114651","Local",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0443203","Distant","C25321","Far apart in space from a point of origin on the body.","Distant | DISTANT | Distantly | Remote",,,,,,,,,,,,,,,"4128936","Distant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1514461","Prior Immunotherapy","C16168","Originally, therapeutic administration of serum or gamma globulin containing preformed antibodies produced by another individual; currently, immunotherapy includes nonspecific systemic stimulation, adjuvants, active specific immunotherapy, and adoptive immunotherapy.  New forms of immunotherapy include the use of monoclonal antibodies.  This approach has been widely adopted by cancer specialists, often in cases which fail to respond to other treatment.  Immunotherapy aims to boost immune system function, as with the administration of interferons and interleukin-2, or to attack cancerous cells directly, as with the injection of monoclonal antibodies.  Various immunotherapeutic techniques have also been employed among AIDS patients.  In addition, a number of alternative medical practices are claimed to enhance immune function, and various over-the-counter substances (e.g., goldenseal, lysine have gained popularity for this supposed property.","Prior Immunotherapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279134","Prior Radiation Therapy","C15477","An indicator that a person previously received radiation treatment for the same condition.","Prior Radiation Therapy | Prior RT | Prior Radiation | Prior Radiotherapy | previously irradiated | previously_irradiated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0392756","Reduced","C25640","Made less in size or amount or degree.","Reduced | DECREASED | Decrease | Decreased | Reduction",,,,,,,,,,,,,,,"4127781","Reduced",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0290883","Anastrozole","C1607","A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure.  As a third-generation aromatase inhibitor, anastrozole selectively binds to and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.  In estrogen-dependent breast cancers, ananstrozole may inhibit tumor growth. (NCI04)","Anastrozole | 2,2'-[5-(1H-1,2,4-Triazol-1-ylmethyl)-1,3-phenylene]di(2-methylpropionitrile) | ANASTROZOLE | Alpha,alpha,alpha', alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile | Anastrazole | Arimidex | ICI D1033 | ICI-D1033 | ZD-1033 | anastrozole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0246421","Letrozole","C1527","A nonsteroidal inhibitor of estrogen synthesis with antineoplastic activity. As a third-generation aromatase inhibitor, letrozole selectively and reversibly inhibits aromatase, which may result in growth inhibition of estrogen-dependent breast cancer cells. Aromatase, a cytochrome P-450 enzyme localized to the endoplasmic reticulum of the cell and found in many tissues including those of the premenopausal ovary, liver, and breast, catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.","Letrozole | 4,4'-(1H-1,2,4triazol-1-ylmethylene)dibenzonitrile | CGS 20267 | CGS-20267 | CGS20267 | Femara | Fempro | LETROZOLE | letrozole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704242","Gastric","C13307","Relating to the stomach.","Gastric | gastric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL053214","Pancreatic","C25726","Of or pertaining to the pancreas.","Pancreatic | pancreatic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027855","Neurology","C16908","A branch of medicine concerned with the development, anatomy, function, and dysfunction of the nervous system.","Neurology | ",,,,,,,,,,,,,,,"4192658","Neurology",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025677","Methotrexate","C642","An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","Methotrexate | 4-Amino-10-methylfolic Acid | 4-Amino-4-deoxy-10-methylpteroyl-L-glutamic Acid | Abitrexate | Alpha-Methopterin | Amethopterin | Brimexate | CL 14377 | CL-14377 | Emtexate | Emthexat | Emthexate | Farmitrexat | Fauldexato | Folex | Folex PFS | Jylamvo | Lantarel | Ledertrexate | Lumexon | METHOTREXATE | MTX | Maxtrex | Medsatrexate | Metex | Methoblastin | Methotrexate LPF | Methotrexate Methylaminopterin | Methotrexatum | Metotrexato | Metrotex | Mexate | Mexate-AQ | N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic Acid | Novatrex | Rheumatrex | Texate | Tremetex | Trexeron | Trixilem | WR-19039 | amethopterin | methotrexate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016360","Fluorouracil","C505","An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","Fluorouracil | 2,4-Dioxo-5-fluoropyrimidine | 5 FU | 5 Fluorouracil | 5 Fluorouracilum | 5-FU | 5-Fluoro-2,4(1H, 3H)-pyrimidinedione | 5-Fluoro-2,4(1H,3H)-pyrimidinedione | 5-Fluorouracil | 5-Fluracil | 5-Fu | 5-fluorouracil | 5FU | AccuSite | Adrucil | Carac | FLUOROURACIL | Fluoro Uracil | Fluouracil | Flurablastin | Fluracedyl | Fluracil | Fluril | Fluroblastin | Ribofluor | Ro 2-9757 | Ro-2-9757 | fluorouracil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0671970","Capecitabine","C1794","A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)","Capecitabine | 5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine | CAPECITABINE | Ro 09-1978/000 | Xeloda | capecitabine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0752233","Raloxifene","C1518","A selective benzothiophene estrogen receptor modulator (SERM).  Raloxifene binds to estrogen receptors (ER) as a mixed estrogen agonist/antagonist; it displays both an ER-alpha-selective partial agonist/antagonist effect and a pure ER-beta-selective antagonist effect.  This agent functions as an estrogen agonist in some tissues (bones, lipid metabolism) and as an estrogen antagonist in others (endometrium and breasts), with the potential for producing some of estrogen's beneficial effects without producing its adverse effects. (NCI04)","Raloxifene | Keoxifene | LY 139481 | RALOXIFENE | [6-Hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone | raloxifene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205373","Systemic","C13310","Affecting an entire system.","Systemic | systemic",,,,,,,,,,,,,,,"4150371","Systemic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0458083","Hormonal","C25528","Relating to hormones.","Hormonal | ",,,,,,,,,,,,,,,"4132920","Hormonal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517030","Extensive Radiation","C16230","Cancer therapy using ionizing radiation to a significant (>50%) portion of the body, e.g. craniospinal, total body irradiation, or pelvic radiation.","Extensive Radiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0745777","Lost","C25560","Parted with; no longer held or possessed; incapable of being recovered or regained.","Lost | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015780","Female","C16576","A person who belongs to the sex that normally produces ova. The term is used to indicate biological sex distinctions, or cultural gender role distinctions, or both.","Female | F | FEMALE | female",,,,,,,,,,,,,,,"4031903","Female structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0086582","Male","C20197","A person who belongs to the sex that normally produces sperm. The term is used to indicate biological sex distinctions, cultural gender role distinctions, or both.","Male | Human, Male | M | MALE | male",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1865325","Coma","C34497","A state of profound unconsciousness associated with markedly depressed cerebral activity. Causes include central nervous system damage, intoxication, and metabolic abnormalities.","Coma | Comatose | coma",,,,,,,,,,,,,,,"380834","Coma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0439810","Total","C25304","Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition.","Total | ",,,,,,,,,,,,,,,"4112438","Total",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0178539","Cellular","C37923","The degree, quality, or condition of cells that are present.","Cellularity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009498","Complement","C16459","The complement system is a complex system of serum proteins that interact in a cascade.  Many of the early components are serine proteases that activate each other sequentially. This complement system consists of three separate activation triggers: (1) Ab binding to a cell surface, (2) formation of immune complexes, and (3) a carbohydrate component of a microbe's cell membrane.  Along with this triggers, there are also two sets of mechanisms.  Both of these mechanisms, classical pathway and alternative or properdin pathway, make MAC (Membrane Attack Complex), which can lyse and destroy the cell.","Complement | ",,,,,,,,,,,,,,,"4049212","Complement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009961","Coombs Test","C25163","A hemagglutination test using anti-human globulin (antiglobulin, Coombs reagent) to detect antibodies that react with a subject's red blood cells. The test takes two forms: the direct test is used to diagnose autoimmune hemolytic anemia; the indirect test is used for prenatal Rhesus factor compatibility, blood and tissue typing, and transplant cross-matching.","Coombs Test | Coomb's test | Coombs | antiglobulin test",,,,,,,,,,,,,,,"45773009","Coombs test",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009968","Copper","C391","An element with atomic symbol Cu, atomic number 29, and atomic weight 63.","Copper | COPPER | Cu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015879","Ferritin","C16577","An iron protein complex, containing up to 23% iron, formed by the union of ferric iron with apoferritin; it is found in the intestinal mucosa, spleen, bone marrow, reticulocytes, and liver, and regulates iron storage and transport from the intestinal lumen to plasma.","Ferritin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016006","Fibrinogen","C25736","A fibrillar protein present in blood plasma; it converts to fibrin during the process of blood clot formation.","Fibrinogen | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL026873","Insulin","C2271","Insulin (51 aa, ~6 kDa) is encoded by the human INS gene. This protein is involved in the direct regulation of glucose metabolism.","Insulin | INS | INSULIN | insulin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0302583","Iron","C598","An element with atomic symbol Fe, atomic number 26, and atomic weight 55.85.","Iron | Fe | IRON | Niferex | iron",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0373658","Iron Binding Capacity","C25748","The capacity of iron-binding protein in serum (transferrin) to bind serum iron.","Iron Binding Capacity | IBC | Iron Binding Capacity Measurement",,,,,,,,,,,,,,,"4235028","Total iron binding capacity measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037473","Sodium","C830","An element with atomic symbol Na, atomic number 11, and atomic weight 23.","Sodium | Na | SODIUM | Sodium (NOS) | sodium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040679","Transferrin","C17211","Serotransferrin (698 aa, ~77 kDa) is encoded by the human TF gene. This protein is involved in iron sequestration and transport.","Serotransferrin | Beta-1 Metal-Binding Globulin | Granulocyte/Pollen-Binding Protein | Siderophilin | TF | Transferrin | Transferrin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041004","Triglycerides","C906","Fats composed of three fatty acid chains linked to a glycerol molecule.","Triglycerides | Triglyceride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1291218","Urea Nitrogen","C919","A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids.","Urea Nitrogen | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005954","Bone Marrow Biopsy","C15193","A biopsy involving the removal of a core tissue containing bone spicules and hematopoietic elements embedded in the marrow stroma.  This procedure is done in the hip area mainly for the diagnosis and evaluation of neoplastic and non-neoplastic hematopoietic disorders (e.g. anemias, leukemias, lymphomas) and the evaluation of the spread of solid tumors (e.g. carcinomas, sarcomas) and lymphomas for therapeutic purposes.","Bone Marrow Biopsy | Biopsy of Bone Marrow | Biopsy, Bone Marrow | bone marrow biopsy",,,,,,,,,,,,,,,"4120443","Bone marrow sampling",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448530","Unrelated","C25328","Not connected or associated e.g. by kinship.","Unrelated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0302350","Therapeutic","C25277","Relating to or involved in therapy.","Therapeutic | therapeutic",,,,,,,,,,,,,,,"4133895","Therapeutic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518422","Negation","C25594","An operation in which a term denies or inverts the meaning of another term or construction.","Negation | Negated | No | Non | Non- | Not | Not",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0455610","Prior Surgery","C16169","An indication that a subject has had a surgical procedure in the past.","Prior Surgery | prior surgery | prior_surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031327","Drug Kinetics","C15299","The characteristic movements of drugs within biological systems, as affected by absorption, distribution, binding, elimination, biotransformation, and excretion; particularly the rates of such movements.","Pharmacokinetics | PK | Pharmacokinetic (PK) study | pharmacokinetics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042014","Urinalysis","C17241","Laboratory analysis of urine, commonly used to aid in the diagnosis of disease or to detect the presence of a specific substance. It involves examination of the urine by physical or chemical means as well as microscopic examination that helps to screen for urinary tract infections, renal disease, and diseases of other organs, that result in abnormal metabolites (break-down products) appearing in the urine.","Urinalysis | Urine Test | urinalysis",,,,,,,,,,,,,,,"4099313","Urinalysis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522601","Cardiac","C13306","Having to do with the heart.","Cardiac | cardiac",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281265","Prior Adjuvant Chemotherapy","C15564","Definition not available.","Prior Adjuvant Chemotherapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514455","Prior Adjuvant Immunotherapy","C16157","Definition not available.","Prior Adjuvant Immunotherapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514456","Prior Adjuvant Other Therapy","C16158","Definition not available.","Prior Adjuvant Other Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0442117","Intramuscular","C27974","Within or into muscle.","Intramuscular | IM | intramuscular",,,,,,,,,,,,,,,"4116871","Intramuscular",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0150647","Intradermal","C28213","Within the skin.","Intradermal | intradermal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522229","Intravenous Bolus","C38274","A volume of drug intended to be administered into a vein at a relatively fast rate. The volume of drug and the rate of administration are specified.","Intravenous Bolus | INTRAVENOUS BOLUS | IV BOLUS | IV Bolus | Intravenous Bolus Route of Administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021440","Intravenous Infusion","C38275","Introduction of a drug directly into venous circulation over the time duration of more than 30 minutes but less than 24 hours. Method results in 100% bioavailability of the agent due to an absence of the absorption phase and provides a precise and continuous mode of drug therapy, especially for drugs with a narrow therapeutic index. To achieve the steady state quickly, the loading dose is used. Intravenously administered drug is diluted in the pooled venous blood and pumped through lungs before entering systematic circulation (lung first-pass effect). The target organ receives only the fraction of drug corresponding to the fraction of received arterial blood.","Intravenous Infusion | IVI | intravenous infusion",,,,,,,,,,,,,,,"4030886","Intravenous infusion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1511497","Continuous Intravenous Infusion","C38196","A route of administration of a fluid drug form into a vein or veins, over a time duration of equal to or more than 24 hours. Method allows to maintain steady state plasma/serum medication levels, a smaller total daily dose of drug to achieve the same pharmacodynamic endpoint in comparison with intermittent or bolus infusion, and may result in lower toxicity. The method has a positive impact on health-care costs.","Continuous Intravenous Infusion | CIV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443315","Subcutaneous","C13353","Beneath the skin.","Subcutaneous | subcutaneous",,,,,,,,,,,,,,,"35622521|4139962","Subcutaneous|Subcutaneous",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0442120","Intraperitoneal","C13352","Relating to the peritoneal cavity as the intended site of administration.","Intraperitoneal | IP | intraperitoneal",,,,,,,,,,,,,,,"37204624|4134042","Intraperitoneal|Intraperitoneal",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1512948","intrahepatic","C13808","Within the liver.","Intrahepatic | intrahepatic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332237","Topical","C13344","On the surface of the body.","Topical | topical",,,,,,,,,,,,,,,"4231622","Topical",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0442027","Oral","C25311","Of, or relating to, or affecting, or for use in the mouth.","Oral | Oral (qualifier value) | Orally | oral",,,,,,,,,,,,,,,"42538090","Oral",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1134564","Intrahepatic Infusion Procedure","C15731","Administration of a fluid form of the drug via a blood vessel into the liver over the sustained period of time.","Intrahepatic Infusion Procedure | HAI | Hepatic Arterial Infusion | Hepatic Artery Infusion | IHI | Intrahepatic Infusion | Intrahepatic Infusion | hepatic arterial infusion | intrahepatic infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0231170","Disability","C21007","Any physical or mental impairment that interferes with an individual's ability to perform desired activities.","Disability | DISABILITY | Handicap | Infirmity",,,,,,,,,,,,,,,"4052648","Disability",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3554473","Anorexia","C2875","Loss of appetite.","Anorexia | Decreased Appetite | anorexia",,,,,,,,,,,,,,,"442165","Loss of appetite",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3807341","Chest Pain","C38665","Pain in the chest.","Chest Pain | Chest_pain | thoracalgia | thoracodynia",,,,,,,,,,,,,,,"77670","Chest pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032105","Plasma","C13356","Plasma is the fluid (noncellular) portion of the circulating blood, as distinguished from the serum that is the fluid portion of the blood obtained by removal of the fibrin clot and blood cells after coagulation.","Plasma | PLASMA | plasma",,,,,,,,,,,,,,,"4178303","Plasma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518373","Non-Measurable","C25589","Not possible to be measured.","Non-Measurable | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205314","New","C25586","Having no previous example or precedent or parallel; of a kind not seen before.","New | Novel",,,,,,,,,,,,,,,"4325437","New",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL430726","Abdominal","C25342","Of, or related to, the abdomen.","Abdominal | abdominal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042993","Vulva","C12408","The external, visible part of the female genitalia surrounding the urethral and vaginal opening. The vulva includes the clitoris and inner as well as outer labia.","Vulva | External Genitalia | VULVA | Vulva, NOS | Vulval structure (body structure) | female pudendum | mammalian vulva | puboperineal region | pudendum femininum | vulva",,,,,,,,,,,,,"UBERON:0000997","mammalian vulva","4166066","Vulval structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023269","Leiomyosarcoma","C3158","An uncommon, aggressive malignant smooth muscle neoplasm, usually occurring in post-menopausal women.  It is characterized by a proliferation of neoplastic spindle cells.  Morphologic variants include epithelioid, granular cell, inflammatory and myxoid leimyosarcomas.","Leiomyosarcoma | LEIOMYOSARCOMA, MALIGNANT | Leiomyosarcoma (excluding uterine leiomyosarcoma) | Leiomyosarcoma - not uterine | Leiomyosarcoma, NOS | Leiomyosarcomas | leiomyosarcoma","8890/3","Leiomyosarcoma, NOS",,,,,,,,,,,,,"40482829","Leiomyosarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0006675","Calcium","C331","An element with atomic symbol Ca, atomic number 20, and atomic weight 40.08.","Calcium | CALCIUM | Ca | Calcium (NOS) | calcium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038056","Sputum","C13278","Material containing mucus, cellular debris, microorganisms and sometimes blood or pus.  It is ejected through the mouth from the lungs, bronchi, and trachea.","Sputum | SPUTUM | sputum",,,,,,,,,,,,,,,"4164116","Sputum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0860888","Spiral CT","C20645","A method of computed tomography (CT) that uses continuous rotation of the X-ray tube and continuous transport of the patient through the scanning aperture that allows the rapid acquisition of a volume of CT data.  Advantages over conventional CT include: rapid acquisition of a large volume of data within a single breath-hold, thus minimizing respiration artifact and misregistration between slices; the ability to reconstruct images retrospectively at any level within the scanned volume; optimization of intravenous contrast enhancement due to the short scan times; improved multi-planar and 3-D reconstruction; and the potential for radiation dose reduction.  Same as helical computed tomography. (British Journal of Radiology 1994 May;67(797):436-44)","Spiral CT | Helical CT | SCT | SPIRAL CT | Spiral Acquisition CT | Spiral Computed Tomography | Spiral Volumetric CT | Volumetric CT | helical computed tomography | spiral CT scan",,,,,,,,,,,,,,,"4019099","Spiral computed tomography scan",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3808808","Epistaxis","C26766","Bleeding from the nose.","Epistaxis | Nasal Hemorrhage | Nose Bleed | Nosebleed",,,,,,,,,,,,,,,"4096682","Bleeding from nose",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0231528","Myalgia","C27009","Painful sensation originating from a muscle or group of muscles.","Myalgia | Muscle Ache | Muscle Aches | Muscle Pain | Muscle_ache | Myalgias | myalgia",,,,,,,,,,,,,,,"442752","Muscle pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242192","Aspartate Aminotransferase","C25202","A family of pyridoxal phosphate-dependent enzymes involved in amino acid metabolism and in the urea and tricarboxylic acid cycles. Aspartate aminotransferase specifically and reversibly catalyzes the transfer of an amino group from L-aspartate to alpha-ketoglutarate forming oxaloacetate and L-glutamate.","Aspartate Aminotransferase |  AspAT | AAT | ASAT | AST | Aspartate Aminotransferase | Aspartate Transaminase | EC 2.6.1.1 | GOT | Glutamic Oxaloacetic Transaminase | SGOT | SGOT (AST) | SGOT (AST) | aspartate transaminase | serum glutamic-oxaloacetic transaminase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0231290","Post","C38008","Happening at a time subsequent to a reference time; later in time or order.","Post | AFTER | After | Status Post | Trailing",,,,,,,,,,,,,,,"4123210","After values",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001552","Pharmaceutical Adjuvants","C2140","An agent that enhances the activity or therapeutic effect of another pharmacologic substance without having much, if any, therapeutic impact by itself.","Adjuvant | ADJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522673","Adjuvant","C25722","Serving to aid or contribute; auxiliary.","Adjuvant Generic | Adjuvant | Adjuvant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205179","Advanced","C25411","Far along in course.","Advanced | ",,,,,,,,,,,,,,,"4313265","Advanced",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332601","Cushingoid","C37938","A constellation of signs and symptoms caused by an excess of glucocorticoids. Classic features include moon facies, buffalo hump, obesity, striae and adiposity.","Cushingoid | ",,,,,,,,,,,,,,,"4195232","Cushingoid facies",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL455358","Nodal Arrhythmia by ECG Finding","C27045","An electrocardiographic finding of an arrhythmia originating from within the atrioventricular node.","Nodal Arrhythmia by ECG Finding | Nodal Arrhythmia | Nodal Arrhythmia | Nodal Arrhythmia by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003708","Arachnoiditis","C37913","Inflammation of the arachnoid membrane and adjacent subarachnoid space.","Arachnoiditis | ",,,,,,,,,,,,,,,"4218912","Arachnoiditis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013491","Ecchymosis","C26758","A flat discoloration of the skin or a mucous membrane, larger in area than a petechia, caused by the extravasation of blood.","Ecchymosis | ecchymosis",,,,,,,,,,,,,,,"4118793|4300859","Ecchymosis|Ecchymosis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0242350","Erectile Dysfunction","C3133","A disorder characterized by the persistent or recurrent inability to achieve or to maintain an erection during sexual activity.","Erectile Dysfunction | Erectile Dysfunction | Erectile dysfunction | Impotence | Impotence | Impotent | Male Erectile Disorder | erectile dysfunction | impotence | impotent",,,,,,,,,,,,,,,"3655355","Erectile dysfunction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4014723","Myositis","C27578","An inflammatory process affecting the skeletal muscles. Causes include infections, injuries, and autoimmune disorders.","Myositis | ",,,,,,,,,,,,,,,"73001","Myositis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0151662","Gamma-Glutamyltransferase Increased","C26943","Increase in the level of the enzyme gamma-glutamyltransferase in the blood, which catalyzes the transfer of a gamma glutamyl group from a gamma glutamyl peptide to another peptide, aminoacids, or water.","Gamma-Glutamyltransferase Increased | GGT increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3554582","Bone Pain","C38644","Painful sensation in the bones.","Bone Pain | Bone pain | Bone pain (diffuse not joint pain or arthritis)",,,,,,,,,,,,,,,"4129418","Bone pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085610","Sinus Bradycardia","C26923","A disorder characterized by an electrocardiographic finding of abnormally slow heart rate with its origin in the sinus node. Thresholds for different age, gender, and patient populations exist. (CDISC)","Sinus Bradycardia | Sinus bradycardia",,,,,,,,,,,,,,,"4171683","Sinus bradycardia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4229471","Hypothyroidism","C26800","Abnormally low levels of thyroid hormone.","Hypothyroidism | Hypothyroid | Hypothyroidism, unspecified | hypothyroidism | underactive thyroid",,,,,,,,,,,,,,,"140673","Hypothyroidism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014742","Erythema Multiforme","C3024","A hypersensitivity reaction characterized by the sudden appearance of symmetrical cutaneous and mucocutaneous macular or papular lesions which evolve into lesions with bright red borders (target lesions). The lesions usually appear in the hands, feet, extremities, and face. Symptoms include fever, malaise, sore throat, cough, vomiting, diarrhea, arthralgia, and myalgia. Causes include infections (most commonly herpes simplex virus), drugs (e.g., sulfonamides, anticonvulsants, and antibiotics), malignancies, and collagen vascular disorders.","Erythema Multiforme | Erythema multiforme",,,,,,,,,,,,,,,"132702","Erythema multiforme",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039239","Sinus Tachycardia","C26889","A disorder characterized by an electrocardiographic finding of abnormally rapid heart rate with its origin in the sinus node. Thresholds for different age, gender, and patient populations exist. (CDISC)","Sinus Tachycardia | Sinus tachycardia",,,,,,,,,,,,,,,"4007310","Sinus tachycardia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021167","Incontinence","C3429","Involuntary passage of stool or urine from the body.","Incontinence | Urinary Incontinence | Urinary/Bowel incontinence | incontinence",,,,,,,,,,,,,,,"444035","Incontinence",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3553853","Liver Failure","C26922","A disorder characterized by the inability of the liver to metabolize chemicals in the body. Causes include cirrhosis and drug-induced hepatotoxicity. Signs and symptoms include jaundice and encephalopathy. Laboratory test results reveal abnormal plasma levels of ammonia, bilirubin, lactic dehydrogenase, and alkaline phosphatase.","Liver Failure | Hepatic Failure | Hepatic Failure | Hepatic failure",,,,,,,,,,,,,,,"4245975","Hepatic failure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4227337","Portal Hypertension","C3119","Increased blood pressure in the portal venous system. It is most commonly caused by cirrhosis. Other causes include portal vein thrombosis, Budd-Chiari syndrome, and right heart failure. Complications include ascites, esophageal varices, encephalopathy, and splenomegaly.","Portal Hypertension | Portal hypertension | portal hypertension",,,,,,,,,,,,,,,"192680","Portal hypertension",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013456","Ear Pain","C37944","Painful sensation in the ear region.","Ear Pain | Ear pain | Earache | Earache",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4076281","Aspartate Aminotransferase Increased","C26947","An increase in the level of aspartate aminotransferase in the blood.","Aspartate Aminotransferase Increased | Aspartate aminotransferase increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0151905","Alanine Aminotransferase Increased","C26948","An increase in the level of alanine aminotransferase in the blood.","Alanine Aminotransferase Increased | Alanine aminotransferase increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013295","Duodenal Ulcer","C26755","An ulcer in the duodenal wall.","Duodenal Ulcer | Duodenal ulcer",,,,,,,,,,,,,,,"4198381","Ulcer of duodenum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021833","Intestinal Fistula","C34732","An abnormal communication between the small or large intestine and another organ or cavity.","Intestinal Fistula | Fistula of Intestine",,,,,,,,,,,,,,,"196160","Fistula of intestine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0086818","Platelet Transfusion","C15366","The infusion of platelets into the bloodstream.","Platelet Transfusion | Blood Platelet Transfusion",,,,,,,,,,,,,,,"4130829","Platelet transfusion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0199962","Packed Red Blood Cell Transfusion","C15409","The intravenous administration of red blood cells (whole blood without the plasma) into an individual.","Packed Red Blood Cell Transfusion | PRBC Transfusion",,,,,,,,,,,,,,,"4108705|4323715","Intravenous blood transfusion of packed cells|Transfusion of packed red blood cells",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0016204","Flatulence","C37954","A state of excessive gas in the alimentary canal.","Flatulence | ",,,,,,,,,,,,,,,"4091513","Passing flatus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038358","Gastric Ulcer","C3388","An ulcerated lesion in the mucosal surface of the stomach. It may progress to involve the deeper layers of the gastric wall.","Gastric Ulcer | Gastric ulcer | Stomach Ulceration",,,,,,,,,,,,,,,"4265600","Gastric ulcer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0235146","Euphoric Mood","C27011","A psychological state of extreme happiness or elation.","Euphoric Mood | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4015039","Peripheral Motor Neuropathy","C3500","Inflammation or degeneration of the peripheral motor nerves.","Peripheral Motor Neuropathy | Motor Neuropathy | Peripheral motor neuropathy",,,,,,,,,,,,,,,"4319472","Peripheral motor neuropathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0155626","Acute Myocardial Infarction","C35204","Necrosis of the myocardium, as a result of interruption of the blood supply to the area. It is characterized by a severe and rapid onset of symptoms that may include chest pain, often radiating to the left arm and left side of the neck, dyspnea, sweating, and palpitations.","Acute Myocardial Infarction | ",,,,,,,,,,,,,,,"312327","Acute myocardial infarction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020546","Hypertensive Crisis","C3122","A severe, acute increase in blood pressure that may result in stroke or myocardial ischemia.","Hypertensive Crisis | Hypertensive crisis, unspecified",,,,,,,,,,,,,,,"45768449","Hypertensive crisis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4014120","Nephrotic Syndrome","C34845","A collection of symptoms that include severe edema, proteinuria, and hypoalbuminemia; it is indicative of renal dysfunction.","Nephrotic Syndrome | Nephrosis",,,,,,,,,,,,,,,"195314","Nephrotic syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002622","Amnesia","C2867","Systematic and extensive loss of memory caused by organic or psychological factors. The loss may be temporary or permanent, and may involve old or recent memories.","Amnesia | Memory Loss/Impairment",,,,,,,,,,,,,,,"439147","Amnesia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007642","Cellulitis","C26715","Inflammation of the dermis and subcutaneous tissues caused by a bacterial infection. Symptoms include erythema, edema, and pain to the affected area.","Cellulitis | cellulitis",,,,,,,,,,,,,,,"4299470|435613","Cellulitis|Cellulitis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0232970","Postmenopausal","C15421","After menopause.","Postmenopausal | POSTMENOPAUSAL | postmenopausal",,,,,,,,,,,,,,,"4295261","Postmenopausal state",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1454696","CALCA","C2281","Calcitonin (32 aa, ~3 kDa) is encoded by the human CALCA gene. This protein is involved in the modulation of blood calcium and phosphate concentrations through promoting incorporation of these ions into bone.","Calcitonin | CALCA | CALCITONIN | Calcitonin | Calcitonin Gene-Related Peptide 1 | Thyrocalcitonin | calcitonin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0076836","Toremifene","C1256","A nonsteroidal triphenylethylene antiestrogen.  Chemically related to tamoxifen, toremifene is a selective estrogen receptor modulator (SERM).  This agent binds competitively to estrogen receptors, thereby interfering with estrogen activity.  Toremifene also has intrinsic estrogenic properties, which are manifested according to tissue type or species. (NCI04)","Toremifene | (Z)-2-[4-(4-Chloro-1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine | (Z)-4-Chloro-1,2-diphenyl-1[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-butene | Farestone | TOREMIFENE | toremifene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL026899","Estrogen","C2293","A class of sex hormones associated with the development and maintenance of secondary female sex characteristics and control of the cyclical changes in the reproductive cycle. They are also required for pregnancy maintenance and have an anabolic effect on protein metabolism and water retention.","Estrogen | estrogen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033308","Progesterone","C2297","Produced in the corpus luteum and by the placenta, as an antagonist of estrogens. Promotes proliferation of uterine mucosa and the implantation of the blastocyst, prevents further follicular development.","Progesterone | Corpus Luteum Hormone | Delta4-pregnene-3,20-dione | Pregn-4-ene-3,20-dione | progesterone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3277399","Depression","C2982","A melancholy feeling of sadness and despair.","Depression | depression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282402","Hormone Replacement Therapy","C15599","Treatment with estrogens or estrogen/progesterone after menopause or ovariectomy to prevent pathological effects of decreased estrogen production.","Hormone Replacement Therapy | HRT | Hormone Replacement Rx | hormone replacement therapy | hormone replacement therapy type | hormone_replacement_therapy_type | menopausal hormone therapy",,,,,,,,,,,,,,,"4141760","Hormone replacement therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0549207","Vertebra","C12933","Any of thirty-three ring-shaped structures that form the vertebral column which surrounds and protects the spinal cord. Each vertebra consists of a bony body with its superior and inferior articular surfaces covered by hyaline cartilage. The body includes the centrum anteriorly and vertebral arch posteriorly. The articular surfaces of the vertebrae are connected by a fibrocartilaginous intervertebral disc.","Vertebra | Vertebrae",,,,,,,,,,,,,,,"4222390","Bone structure of vertebra",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0851344","Exemestane","C1097","An irreversible steroidal aromatase inhibitor, with antiestrogen and antineoplastic activities. Upon oral administration, exemestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the peripheral aromatization of androgens, including androstenedione and testosterone, to estrogens. This lowers estrogen levels in the blood circulation.","Exemestane | 6-Methyleneandrosta-1,4-diene-3,17-dione | Aromasin | EXEMESTANE | FCE-24304 | exemestane",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0077275","Triptorelin","C1267","A synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH).  Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men. (NCI04)","Triptorelin | 6-D-Tryptophan-LH-RH | 6-D-Tryptophanluteinizing Hormone-releasing Factor | AY 25650 | AY-25650 | AY25650 | CL 118532 | CL-118,532 | CL-118532 | CL118532 | Detryptoreline | TRIPTORELIN | triptorelin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0120107","Goserelin","C1374","A synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. Goserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Prolonged administration of goserelin inhibits the secretion of pituitary gonadotropin, thereby decreasing levels of testosterone (in males) and estradiol (in females).  Administration of this agent in a depot formulation may result in the regression of sex hormone-sensitive tumors and a reduction in sex organ size and function. (NCI04)","Goserelin | 6-[O-(1,1-Dimethylethyl)-D-serine]-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig) 2-(aminocarbonyl)hydrazide | GOSERELIN | ICI-118630 | goserelin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514923","Retrospective","C28010","Looking back at events that have already taken place.","Retrospective | retrospective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281189","Breast Cancer Prevention","C15553","Anything, such as drug administration or lifestyle changes, designed to inhibit the onset of breast cancer.","Breast Cancer Prevention | Prevention of Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205098","Medial","C25232","Toward the middle or inside (as opposed to lateral).","Medial | MEDIAL",,,,,,,,,,,,,,,"4112422","Medial",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205093","Lateral","C25230","Situated at or extending to the side.","Lateral | LATERAL",,,,,,,,,,,,,,,"4171348","Lateral",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0418967","Other Therapy","C15645","Definition not available.","Other Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898133","No Prior Cancer Therapy","C15903","No prior cancer treatment.","No Prior Cancer Therapy | No Prior Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516238","Cancer and Leukemia Group B","C25442","A national clinical research group - network of 29 university medical centers, over 185 community hospitals and more than almost 3000 physicians - sponsored by the NCI, with its Central Office headquartered at the University of Chicago, and its Statistical Center located at Duke University, founded in 1955 with a goal of bringing together clinical and laboratory research.","Cancer and Leukemia Group B | CALGB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512162","Eastern Cooperative Oncology Group","C25491","A cooperative group funded primarily by the NCI, one of the largest clinical cancer research organizations in the US, incorporating universities, medical centers, Community Clinical Oncology Programs, and Cooperative Group Outreach Programs with almost 6000 physicians, nurses, pharmacists, statisticians, and clinical research associates from the US, Canada, and South Africa. ECOG has more than 90 active clinical trials in all types of adult malignancies. Annual accrual is 6,000 patients, with more than 20,000 patients in follow-up.","Eastern Cooperative Oncology Group | ECOG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515944","American College of Surgeons Oncology Group","C19712","A cooperative group sponsored by the NCI whose primary goal is to evaluate surgical therapies in the management of patients with malignant solid tumors. The ACOSOG (Durham, NC) includes general and specialty surgeons, representatives of related oncologic disciplines and allied health professionals in academic medical centers and community practices throughout the US and foreign countries. The group is composed of the Administrative Coordinating Center and the Statistics and Data Coordinating. Both groups are based at the Duke Clinical Research Institute.","American College of Surgeons Oncology Group | ACOSOG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518419","North Central Cancer Treatment Group","C25581","A national clinical research group sponsored by the NCI. The research base for NCCTG is located at Mayo Clinic in Rochester, Minn. NCCTG consists of a network of more than 1,000 cancer specialists at community clinics, hospitals and medical centers in 25 states in US, two Canadian provinces and Mexico. NCCTG specializes in researching methods of treating and preventing cancer, and in researching methods to alleviate the side effects of cancer and cancer treatments.","North Central Cancer Treatment Group | NCCTG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514695","Radiation Therapy Oncology Group","C19778","A multi-institutional cooperative organization, a national cancer study research group comprised of 250 of the major research institutions nationally and in Canada, funded by NCI, headquartered in Philadelphia with almost 30 years of experience in running clinical trials. More than 40 clinical trials that involve radiation therapy either alone or in conjunction with surgery and/or chemotherapeutic drugs are active at any one time within RTOG. The group is interested in quality of life issues and their effects on the cancer patient","Radiation Therapy Oncology Group | RTOG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516477","Children's Oncology Group","C39353","An NCI-supported clinical cooperative group formed by the merger of the four national pediatric cancer research organizations: the Children's Cancer Group, the Intergroup Rhabdomyosarcoma Study Group, the National Wilms Tumor Study Group, and the Pediatric Oncology Group. The primary objective of the organization is to conduct clinical trials of new therapies for childhood and adolescent cancer. COG develops and coordinates clinical trials conducted at the 238 member institutions that include cancer centers of all major universities and teaching hospitals throughout the U.S. and Canada, as well as sites in Europe and Australia. COG members include over 5000 cancer researchers.","Children's Oncology Group | COG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516985","European Organization for Research and Treatment of Cancer","C19741","A group with aims to conduct, develop, coordinate, and stimulate laboratory and clinical research in Europe to improve the management of cancer and related problems by increasing survival but also patients' quality of life. There are more than 60 institutions and departments that have been recognized by EORTC as affiliated. These groups conduct, on a voluntary basis, laboratory research and/or clinical trials on all types of cancers using a multidisciplinary approach. EORTC maintains close working relationship with NCI and the British Cancer Research United Kingdom in London.","European Organization for Research and Treatment of Cancer | EORTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513885","National Cancer Institute of Canada Clinical Trials Group","C39467","A cooperative oncology group which carries out clinical trials in cancer therapy and supportive care across Canada and internationally. It is supported by the National Cancer Institute of Canada with funds raised by the Canadian Cancer Society.","National Cancer Institute of Canada Clinical Trials Group | NCIC CTG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3833460","National Surgical Adjuvant Breast and Bowel Project","C15818","A clinical trials cooperative group supported by the NCI. The group headquarters in Pittsburgh, Pennsylvania and has research sites at nearly 200 major medical centers, university hospitals, large oncology practice groups, and health maintenance organizations in the United States, Canada, Puerto Rico, and Australia. In addition to funding from the NCI, which the NSABP has received since it began, the NSABP also receives support from other sources for ancillary studies, training, and educational programs.","National Surgical Adjuvant Breast and Bowel Project | NSABP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518418","North American Brain Tumor Consortium","C37995","Dedicated to the development and conduct of innovative clinical trials that will ultimately result in a cure for patients with malignant brain tumors. Their goals are 1) to discover new and effective therapies for the treatment of patients with brain tumors, including anti-angiogenesis drugs, differentiating agents, anti-invasive medications, and new molecular agents such as gene therapy; 2) to develop innovative combination strategies to enhance the therapeutic effects of chemotherapy and radiation treatments; and 3) to develop and fund translational research opportunities that will bring exciting new agents and strategies from the laboratory to the clinical setting.","North American Brain Tumor Consortium | NABTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512890","International Breast Cancer Study Group","C25530","A group dedicated to innovative clinical research designed to improve the prognosis of women with breast cancer. Patients and investigators from six continents: Europe, Australia/ New Zealand, Africa, Asia, and North and South America, cooperate by participating in extensive clinical trials in the Adjuvant breast cancer setting. IBCSG has been a pioneer in research into combined hormonal therapy and chemotherapy, timing and duration of Adjuvant Therapies, and Quality of Life of breast cancer patients. (from ibcsg.org)","International Breast Cancer Study Group | IBCSG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002838","Andorra","C16289","A country in southwestern Europe, between France and Spain.","Andorra | 020 | AD | AND | ANDORRA",,,,,,,,,,,,,,,"4320322","Andorra",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041698","United Arab Emirates","C17232","A country in the Middle East, bordering the Gulf of Oman and the Persian Gulf, between Oman and Saudi Arabia.","United Arab Emirates | 784 | AE | ARE | UNITED ARAB EMIRATES",,,,,,,,,,,,,,,"4330418","United Arab Emirates",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001732","Afghanistan","C16267","A country in southern Asia, north and west of Pakistan, east of Iran.","Afghanistan | 004 | AF | AFG | AFGHANISTAN",,,,,,,,,,,,,,,"4320153","Afghanistan",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003354","Antigua and Barbuda","C16303","A group of islands in the Caribbean Sea, east of Saint Kitts and Nevis.","Antigua and Barbuda | 028 | AG | ANTIGUA AND BARBUDA | ATG",,,,,,,,,,,,,,,"4071850","Antigua and Barbuda",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003353","Anguilla","C20133","A group of islands in the Caribbean Sea, east of the Virgin Islands and north of Saint Kitts and Nevis.","Anguilla | 660 | AI | AIA | ANGUILLA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001909","Albania","C16271","A country in southeastern Europe, bordering the Adriatic and Ionian Seas, between Greece and Montenegro.","Albania | 008 | AL | ALB | ALBANIA",,,,,,,,,,,,,,,"4320165","Albania",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003798","Armenia","C16306","A country in southwestern Asia, east of Turkey and south of Georgia.","Armenia | 051 | AM | ARM | ARMENIA",,,,,,,,,,,,,,,"4330428","Armenia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003023","Angola","C16292","A country in southern Africa, bordering the South Atlantic Ocean, between Namibia and Democratic Republic of the Congo.","Angola | 024 | AGO | ANGOLA | AO",,,,,,,,,,,,,,,"4075205","Angola",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0454691","Antarctica","C18007","The continent lying mostly south of the Antarctic Circle.","Antarctica | 010 | ANTARCTICA | AQ | ATA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003761","Argentina","C16305","A country in southern South America, bordering the South Atlantic Ocean, between Chile and Uruguay.","Argentina | 032 | AR | ARG | ARGENTINA",,,,,,,,,,,,,,,"4073750","Argentina",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242536","American Samoa","C17739","A group of islands in the South Pacific Ocean, between Hawaii and New Zealand and east of Samoa.","American Samoa | 016 | AMERICAN SAMOA | AS | ASM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004348","Austria","C16312","A country in central Europe, northeast of Italy and southeast of Germany.","Austria | 040 | AT | AUSTRIA | AUT",,,,,,,,,,,,,,,"4329596","Austria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004340","Australia","C16311","The continent and country between the Indian Ocean and the South Pacific Ocean, south of Asia.","Australia | 036 | AU | AUS | AUSTRALIA",,,,,,,,,,,,,,,"4329592","Australia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0282379","Aruba","C17884","An island in the Caribbean Sea, north of Venezuela and west of Curacao.","Aruba | 533 | ABW | ARUBA | AW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006036","Bosnia and Herzegovina","C16361","A country in southeastern Europe, bordering the Adriatic Sea, between Croatia and Serbia.","Bosnia and Herzegovina | 070 | BA | BIH | BOSNIA AND HERZEGOVINA | BOSNIA-HERZEGOVINA | Bosnia-Herzegovina | Bosnia-Herzegovina",,,,,,,,,,,,,,,"4330434","Bosnia - Herzegovnia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004739","Barbados","C16324","An island between the Caribbean Sea and the North Atlantic Ocean, east of Saint Vincent and the Grenadines.","Barbados | 052 | BARBADOS | BB | BRB",,,,,,,,,,,,,,,"4072760","Barbados",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004732","Bangladesh","C16323","A country in southern Asia, bordering the Bay of Bengal, between Burma and India.","Bangladesh | 050 | BANGLADESH | BD | BGD",,,,,,,,,,,,,,,"4329584","Bangladesh",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004950","Belgium","C16329","A country in western Europe, bordering the North Sea, between France and the Netherlands.","Belgium | 056 | BE | BEL | BELGIUM",,,,,,,,,,,,,,,"4330433","Belgium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006409","Burkina Faso","C16369","A country in western Africa, between Mali and Ghana.","Burkina Faso | 854 | BF | BFA | BURKINA FASO",,,,,,,,,,,,,,,"4075209","Burkina Faso",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006368","Bulgaria","C16368","A country in southeastern Europe, bordering the Black Sea, between Romania and Turkey.","Bulgaria | 100 | BG | BGR | BULGARIA | Republic of Bulgaria",,,,,,,,,,,,,,,"4330429","Bulgaria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004684","Bahrain","C16322","An archipelago in the Persian Gulf, on the east coast of Saudi Arabia.","Bahrain | 048 | BAHRAIN | BH | BHR",,,,,,,,,,,,,,,"4329587","Bahrain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006448","Burundi","C16371","A country in central Africa, east of the Democratic Republic of the Congo and south of Rwanda.","Burundi | 108 | BDI | BI | BURUNDI",,,,,,,,,,,,,,,"4072107","Burundi",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005126","Bermuda","C16334","A group of islands in the North Atlantic Ocean, east of South Carolina.","Bermuda | 060 | BERMUDA | BM | BMU | Bermuda Islands | Bermudas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005918","Bolivia, Plurinational State of","C16359","A country in central South America, southwest of Brazil.","Bolivia, Plurinational State of | 068 | BO | BOL | BOLIVIA | BOLIVIA, PLURINATIONAL STATE OF | Bolivia | Bolivia",,,,,,,,,,,,,,,"4073751","Bolivia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006137","Brazil","C16364","A country in eastern South America, bordering the Atlantic Ocean.","Brazil | 076 | BR | BRA | BRAZIL",,,,,,,,,,,,,,,"4075645","Brazil",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004683","Bahamas","C16321","A chain of islands in the North Atlantic Ocean, southeast of Florida and north of Cuba.","Bahamas | 044 | BAHAMAS | BAHAMAS, THE | BHS | BS",,,,,,,,,,,,,,,"4072759","The Bahamas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005341","Bhutan","C16336","A country in southern Asia, between China and India, east of Nepal and north of Bangladesh.","Bhutan | 064 | BHUTAN | BT | BTN",,,,,,,,,,,,,,,"4330327","Bhutan",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1511278","Bouvet Island","C20104","An island in the South Atlantic Ocean, south-southwest of the Cape of Good Hope (South Africa).","Bouvet Island | 074 | BOUVET ISLAND | BV | BVT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006041","Botswana","C16363","A country in southern Africa, north of South Africa and east of Namibia.","Botswana | 072 | BOTSWANA | BW | BWA",,,,,,,,,,,,,,,"4072753","Botswana",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006539","Belarus","C16372","A country in eastern Europe, east of Poland and north of Ukraine.","Belarus | 112 | BELARUS | BLR | BY | Byelarus",,,,,,,,,,,,,,,"37151334","Belarus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004952","Belize","C16331","A country in central America, bordering the Caribbean Sea, between Guatemala and Mexico.","Belize | 084 | BELIZE | BLZ | BZ",,,,,,,,,,,,,,,"4330443","Belize",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009738","Congo","C16467","A country in western Africa, bordering the South Atlantic Ocean, between Gabon and the Democratic Republic of the Congo.","Congo | 178 | CG | COG | CONGO | CONGO (BRAZZAVILLE) | Republic of the Congo",,,,,,,,,,,,,,,"4072108","Republic of the Congo",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039021","Switzerland","C17181","A country in central Europe, east of France and north of Italy.","Switzerland | 756 | CH | CHE | SWITZERLAND",,,,,,,,,,,,,,,"4330427","Switzerland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009956","Cook Islands","C16469","A group of islands in the South Pacific Ocean, east of Australia, between Tonga and French Polynesia.","Cook Islands | 184 | CK | COK | COOK ISLANDS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008107","Chile","C16427","A country in southwestern South America, bordering the South Pacific Ocean, between Argentina and Peru.","Chile | 152 | CHILE | CHL | CL",,,,,,,,,,,,,,,"4073752","Chile",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006802","Cameroon","C16379","A country in western Africa, bordering the Gulf of Guinea, between Equatorial Guinea and Nigeria.","Cameroon | 120 | CAMEROON | CM | CMR",,,,,,,,,,,,,,,"4075199","Cameroon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008115","China","C16428","A country in eastern Asia, bordering the East China Sea, Korea Bay, Yellow Sea, and South China Sea, south of Kazakhstan, Mongolia and Russia.","China | 156 | CHINA | CHN | CN",,,,,,,,,,,,,,,"4329982","China",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3245499","Colombia","C16449","A country in northern South America, bordering the Caribbean Sea and the North Pacific Ocean, between Ecuador and Venezuela.","Colombia | 170 | CO | COL | COLOMBIA",,,,,,,,,,,,,,,"4073753","Colombia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010182","Costa Rica","C16470","A country in Central America, bordering both the Caribbean Sea and the North Pacific Ocean, between Nicaragua and Panama.","Costa Rica | 188 | COSTA RICA | CR | CRI",,,,,,,,,,,,,,,"4330444","Costa Rica",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010622","Cyprus","C16480","An island in the Mediterranean Sea, south of Turkey.","Cyprus | 196 | CY | CYP | CYPRUS",,,,,,,,,,,,,,,"4329599","Cyprus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206578","Czechia","C17668","A country in central Europe, southeast of Germany and southwest of Poland.","Czechia | 203 | CZ | CZE | CZECH REPUBLIC | CZECHIA | Czech Republic | Czech Republic | Czech Republic (Czechia)",,,,,,,,,,,,,,,"4320163","Czech republic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017480","Germany","C16636","A country in central Europe, bordering the Baltic Sea and the North Sea, between the Netherlands and Poland, south of Denmark.","Germany | 276 | DE | DEU | GERMANY",,,,,,,,,,,,,,,"4330424","Germany",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0012836","Djibouti","C16506","A country in eastern Africa, bordering the Gulf of Aden and the Red Sea, between Eritrea and Somalia.","Djibouti | 262 | DJ | DJI | DJIBOUTI",,,,,,,,,,,,,,,"4073739","Djibouti",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011318","Denmark","C16496","A country in northern Europe, bordering the Baltic Sea and the North Sea, consisting of a peninsula on the north coast of Germany and several major islands.","Denmark | 208 | DENMARK | DK | DNK",,,,,,,,,,,,,,,"4330435","Denmark",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013013","Dominica","C16519","An island between the Caribbean Sea and the North Atlantic Ocean, south of Guadeloupe and north of Martinique.","Dominica | 212 | DM | DMA | DOMINICA",,,,,,,,,,,,,,,"4075640","Commonwealth of Dominica",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013014","Dominican Republic","C16520","A country comprising the eastern two-thirds of the island of Hispaniola, between the Caribbean Sea and the North Atlantic Ocean, east of Haiti.","Dominican Republic | 214 | DO | DOM | DOMINICAN REPUBLIC",,,,,,,,,,,,,,,"4075641","Dominican Republic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002037","Algeria","C16274","A country in northern Africa, bordering the Mediterranean Sea, between Morocco and Tunisia.","Algeria | 012 | ALGERIA | DZ | DZA",,,,,,,,,,,,,,,"4072105","Algeria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013593","Ecuador","C16528","A country in western South America, bordering the Pacific Ocean at the Equator, between Colombia and Peru.","Ecuador | 218 | EC | ECU | ECUADOR",,,,,,,,,,,,,,,"4071854","Ecuador",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014908","Estonia","C16562","A country in eastern Europe, bordering the Baltic Sea and Gulf of Finland, between Latvia and Finland.","Estonia | 233 | EE | EST | ESTONIA",,,,,,,,,,,,,,,"4320166","Estonia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013715","Egypt","C16530","A country in northern Africa, bordering the Mediterranean Sea, east of Libya and north of Sudan.","Egypt | 818 | EG | EGY | EGYPT",,,,,,,,,,,,,,,"4073737","Egypt",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1520135","Western Sahara","C20113","A country in northern Africa, bordering the North Atlantic Ocean, between Mauritania and Morocco.","Western Sahara | 732 | EH | ESH | WESTERN SAHARA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2711724","Eritrea","C16558","A country in eastern Africa, bordering the Red Sea, between Sudan and Ethiopia.","Eritrea | 232 | ER | ERI | ERITREA",,,,,,,,,,,,,,,"40481806","Eritrea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037747","Spain","C17152","A country in southwestern Europe, bordering the Bay of Biscay, Mediterranean Sea, and North Atlantic Ocean, southwest of France.","Spain | 724 | ES | ESP | SPAIN",,,,,,,,,,,,,,,"4328760","Spain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015024","Ethiopia","C16563","A country in eastern Africa, between Somalia and Sudan.","Ethiopia | 231 | ET | ETH | ETHIOPIA",,,,,,,,,,,,,,,"4071835","Ethiopia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016132","Finland","C16584","A country in northern Europe, bordering the Baltic Sea, between Sweden and Russia.","Finland | 246 | FI | FIN | FINLAND | Republic of Finland",,,,,,,,,,,,,,,"4320323","Finland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016080","Fiji","C16582","A group of islands in the South Pacific Ocean, southwest of Wallis and Fortuna and east of Vanuatu.","Fiji | 242 | FIJI | FJ | FJI | Republic of Fiji",,,,,,,,,,,,,,,"4320159","Fiji",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015541","Faroe Islands","C16573","An island group between the Norwegian Sea and the North Atlantic Ocean, about one-half of the way from Iceland to Norway.","Faroe Islands | 234 | FAROE ISLANDS | FO | FRO | Faeroe Islands",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016674","France","C16592","A country in western Europe, bordering the Bay of Biscay and the English Channel, between Germany and Spain.","France | 250 | FR | FRA | FRANCE",,,,,,,,,,,,,,,"4320324","France",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016910","Gabon","C16596","A country in central Africa, bordering the Atlantic Ocean at the Equator, between Republic of the Congo and Equatorial Guinea.","Gabon | 266 | GA | GAB | GABON",,,,,,,,,,,,,,,"4072109","Gabon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018232","Grenada","C16647","An island between the Caribbean Sea and Atlantic Ocean, south of Saint Vincent and the Grenadines and north of Trinidad and Tobago.","Grenada | 308 | GD | GRD | GRENADA",,,,,,,,,,,,,,,"4075642","Grenada",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017516","Ghana","C26330","A country in western Africa, bordering the Gulf of Guinea, between Cote d'Ivoire and Togo.","Ghana | 288 | GH | GHA | GHANA",,,,,,,,,,,,,,,"4073745","Ghana",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017540","Gibraltar","C16638","A dependency in southwestern Europe, on the southern coast of Spain, bordering the Strait of Gibraltar.","Gibraltar | 292 | GI | GIB | GIBRALTAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018229","Greenland","C16646","An island between the Arctic Ocean and the North Atlantic Ocean, northeast of Canada.","Greenland | 304 | GL | GREENLAND | GRL",,,,,,,,,,,,,,,"37162435","Greenland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016993","The Gambia","C16598","A country in western Africa, bordering the North Atlantic Ocean and surrounded by Senegal.","The Gambia | 270 | GAMBIA | GAMBIA, THE | GM | GMB | Gambia | Gambia",,,,,,,,,,,,,,,"4329867","The Gambia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018381","Guinea","C16655","A country in western Africa, bordering the North Atlantic Ocean, between Guinea-Bissau and Sierra Leone.","Guinea | 324 | GIN | GN | GUINEA",,,,,,,,,,,,,,,"4072754","Guinea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014651","Equatorial Guinea","C16557","A country in western Africa, bordering the Gulf of Guinea, between Cameroon and Gabon; composed of a mainland portion and five inhabited islands.","Equatorial Guinea | 226 | EQUATORIAL GUINEA | GNQ | GQ",,,,,,,,,,,,,,,"4071846","Equatorial Guinea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018226","Greece","C16645","A country in southern Europe, bordering the Aegean, Ionian, and Mediterranean Seas, between Albania and Turkey.","Greece | 300 | GR | GRC | GREECE",,,,,,,,,,,,,,,"4330430","Greece",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018367","Guatemala","C16654","A country in Central America, bordering the Caribbean Sea and the North Pacific Ocean, east of Mexico and west of Belize and Honduras.","Guatemala | 320 | GT | GTM | GUATEMALA",,,,,,,,,,,,,,,"4072757","Guatemala",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018408","Guyana","C16657","A country in northern South America, bordering the North Atlantic Ocean, between Suriname and Venezuela.","Guyana | 328 | GUY | GUYANA | GY",,,,,,,,,,,,,,,"4075646","Guyana",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019907","Hong Kong","C16695","A special administrative region of China, bordering the South China Sea, east of Macao.","Hong Kong | 344 | HK | HKG | HONG KONG",,,,,,,,,,,,,,,"4072011","Hong Kong",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019905","Honduras","C16694","A country in Central America, bordering the Caribbean Sea, between Guatemala and Nicaragua.","Honduras | 340 | HN | HND | HONDURAS",,,,,,,,,,,,,,,"4075638","Honduras",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010343","Croatia","C16474","A country in southeastern Europe, bordering the Adriatic Sea, between Bosnia and Herzegovina and Slovenia.","Croatia | 191 | CROATIA | HR | HRV",,,,,,,,,,,,,,,"4329601","Croatia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018510","Haiti","C16660","A country comprising the western one-third of the island of Hispaniola, between the Caribbean Sea and the North Atlantic Ocean, west of the Dominican Republic.","Haiti | 332 | HAITI | HT | HTI | Haïti",,,,,,,,,,,,,,,"4072761","Haiti",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020174","Hungary","C16699","A country in central Europe, northwest of Romania and south of Slovakia.","Hungary | 348 | HU | HUN | HUNGARY",,,,,,,,,,,,,,,"4320164","Hungary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021247","Indonesia","C16728","A country in southeastern Asia, comprising the archipelago and islands between the Indian Ocean and the Pacific Ocean, north of Australia.","Indonesia | 360 | ID | IDN | INDONESIA",,,,,,,,,,,,,,,"4329582","Indonesia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022067","Ireland","C16757","A country in western Europe, occupying five-sixths of the island of Ireland in the North Atlantic Ocean, west of Great Britain.","Ireland | 372 | IE | IRELAND | IRL",,,,,,,,,,,,,,,"4330438","Ireland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022271","Israel","C16760","A country in the Middle East, bordering the Mediterranean Sea, between Egypt and Lebanon.","Israel | 376 | IL | ISR | ISRAEL",,,,,,,,,,,,,,,"4320157","Israel",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021201","India","C16727","A country in southern Asia, bordering the Arabian Sea and the Bay of Bengal, between Pakistan and China.","India | 356 | IN | IND | INDIA",,,,,,,,,,,,,,,"4320154","India",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022066","Iraq","C16756","A country in the Middle East, bordering the Persian Gulf, between Iran and Syria.","Iraq | 368 | IQ | IRAQ | IRQ",,,,,,,,,,,,,,,"4320308","Iraq",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022065","Iran, Islamic Republic of","C16755","A country in the Middle East, bordering the Gulf of Oman, the Persian Gulf, and the Caspian Sea, between Iraq and Pakistan.","Iran, Islamic Republic of | 364 | IR | IRAN | IRN | Iran | Iran",,,,,,,,,,,,,,,"4329588","Islamic Republic of Iran",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020750","Iceland","C16704","A country in northern Europe, island between the Greenland Sea and the North Atlantic Ocean, northwest of the UK.","Iceland | 352 | ICELAND | IS | ISL",,,,,,,,,,,,,,,"4330436","Iceland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022277","Italy","C16761","A country in southern Europe, occupying a peninsula extending into the central Mediterranean Sea, northeast of Tunisia.","Italy | 380 | IT | ITA | ITALY",,,,,,,,,,,,,,,"4328757","Italy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022418","Jordan","C16765","A country in the Middle East, northwest of Saudi Arabia.","Jordan | 400 | JO | JOR | JORDAN",,,,,,,,,,,,,,,"4320158","Jordan",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022341","Japan","C16764","A country in eastern Asia, occupying an island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula.","Japan | 392 | JAPAN | JP | JPN",,,,,,,,,,,,,,,"4329983","Japan",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022558","Kenya","C16769","A country in eastern Africa, bordering the Indian Ocean, between Somalia and Tanzania.","Kenya | 404 | KE | KEN | KENYA",,,,,,,,,,,,,,,"4075204","Kenya",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006797","Cambodia","C16378","A country in southeastern Asia, bordering the Gulf of Thailand, between Thailand, Vietnam, and Laos.","Cambodia | 116 | CAMBODIA | KH | KHM | Kampuchea",,,,,,,,,,,,,,,"4329581","Cambodia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017550","Kiribati","C16639","A group of 33 coral atolls in the Pacific Ocean, south of Hawaii and northeast of Jarvis Island.","Kiribati | 296 | KI | KIR | KIRIBATI | Republic of Kiribati",,,,,,,,,,,,,,,"4320160","Kiribati",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009490","Comoros","C16458","A group of islands in the Mozambique Channel, about two-thirds of the way between northern Madagascar and northern Mozambique, northwest of Mayotte.","Comoros | 174 | COM | COMOROS | KM",,,,,,,,,,,,,,,"4075203","Comoros",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022804","Kuwait","C16775","A country in the Middle East, bordering the Persian Gulf, between Iraq and Saudi Arabia.","Kuwait | 414 | KUWAIT | KW | KWT",,,,,,,,,,,,,,,"4329589","Kuwait",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007481","Cayman Islands","C16391","An island group in the Caribbean Sea, south of Cuba and west of Jamaica.","Cayman Islands | 136 | CAYMAN ISLANDS | CYM | KY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023190","Lebanon","C16784","A country in the Middle East, bordering the Mediterranean Sea, between Israel and Syria.","Lebanon | 422 | LB | LBN | LEBANON",,,,,,,,,,,,,,,"4329590","Lebanon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036056","Saint Lucia","C17113","An island between the Caribbean Sea and the North Atlantic Ocean, south of Martinique and north of Saint Vincent and the Grenadines.","Saint Lucia | 662 | LC | LCA | SAINT LUCIA",,,,,,,,,,,,,,,"4071852","Saint Lucia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023668","Liechtenstein","C16794","A country in central Europe, between Austria and Switzerland.","Liechtenstein | 438 | LI | LIE | LIECHTENSTEIN",,,,,,,,,,,,,,,"4330425","Liechtenstein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038088","Sri Lanka","C17163","A country in southern Asia, occupying an island in the Indian Ocean, southeast of India.","Sri Lanka | 144 | LK | LKA | SRI LANKA",,,,,,,,,,,,,,,"4320156","Sri Lanka",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023617","Liberia","C16791","A country in western Africa, bordering the North Atlantic Ocean, between Cote d'Ivoire and Sierra Leone.","Liberia | 430 | LBR | LIBERIA | LR",,,,,,,,,,,,,,,"4073747","Liberia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023376","Lesotho","C16787","A country in southern Africa, an enclave of South Africa.","Lesotho | 426 | LESOTHO | LS | LSO",,,,,,,,,,,,,,,"4075207","Lesotho",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023879","Lithuania","C16799","A country in eastern Europe, bordering the Baltic Sea, between Latvia and Russia.","Lithuania | 440 | LITHUANIA | LT | LTU",,,,,,,,,,,,,,,"4329600","Lithuania",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024176","Luxembourg","C16803","A country in western Europe, between France, Belgium, and Germany.","Luxembourg | 442 | LU | LUX | LUXEMBOURG",,,,,,,,,,,,,,,"4329602","Luxembourg",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023128","Latvia","C16783","A country in eastern Europe, bordering the Baltic Sea, between Estonia and Lithuania.","Latvia | 428 | LATVIA | LV | LVA",,,,,,,,,,,,,,,"4320319","Latvia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026544","Morocco","C16878","A country in northern Africa, bordering the North Atlantic Ocean and the Mediterranean Sea, south of Spain and between Algeria and Western Sahara.","Morocco | 504 | MA | MAR | MOROCCO",,,,,,,,,,,,,,,"4071834","Morocco",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026405","Monaco","C16874","A country in western Europe, bordering the Mediterranean Sea on the southern coast of France, near the border with Italy.","Monaco | 492 | MC | MCO | MONACO",,,,,,,,,,,,,,,"4329604","Monaco",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026374","Moldova, Republic of","C16871","A country in eastern Europe, northeast of Romania.","Moldova, Republic of | 498 | MD | MDA | MOLDOVA | MOLDOVA, REPUBLIC OF | Moldova | Moldova | Republic of Moldova",,,,,,,,,,,,,,,"4320320","Republic of Moldova",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024443","Madagascar","C16808","A country in southern Africa, occupying an island in the Indian Ocean, east of Mozambique.","Madagascar | 450 | MADAGASCAR | MDG | MG",,,,,,,,,,,,,,,"4071839","Madagascar",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2711078","Marshall Islands","C16822","A group of atolls and reefs in the North Pacific Ocean, about one-half of the way from Hawaii to Australia, south of Wake Island and north of Nauru.","Marshall Islands | 584 | MARSHALL ISLANDS | MH | MHL",,,,,,,,,,,,,,,"40479978","Marshall Islands",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024581","Mali","C16816","A country in western Africa, southwest of Algeria and east of Mauritania.","Mali | 466 | MALI | ML | MLI",,,,,,,,,,,,,,,"4072755","Mali",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006416","Myanmar","C16370","A country in southeastern Asia, bordering the Andaman Sea and the Bay of Bengal, southwest of China, between Bangladesh and Thailand.","Myanmar | 104 | BURMA | Burma | MM | MMR | MYANMAR | Republic of the Union of Myanmar | Union of Burma | Union of Myanmar",,,,,,,,,,,,,,,"4329580","Myanmar",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026410","Mongolia","C16875","A country in northern Asia, between China and Russia.","Mongolia | 496 | MN | MNG | MONGOLIA",,,,,,,,,,,,,,,"4329981","Mongolia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024403","Macau","C16807","A special administrative region of China, bordering the South China Sea, west of Hong Kong.","Macau | 446 | MAC | MACAO | MACAU | MO | Macao",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024943","Mauritania","C16826","A country in northern Africa, bordering the North Atlantic Ocean, between Senegal, Western Sahara, and Mali.","Mauritania | 478 | MAURITANIA | MR | MRT",,,,,,,,,,,,,,,"4072756","Mauritania",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026514","Montserrat","C16876","An island in the Caribbean Seas, southeast of Saint Kitts and Nevis.","Montserrat | 500 | MONTSERRAT | MS | MSR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024653","Malta","C16817","A country in southern Europe, occupying islands in the Mediterranean Sea, south of Sicily (Italy).","Malta | 470 | MALTA | MLT | MT",,,,,,,,,,,,,,,"4330437","Malta",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024944","Mauritius","C16827","A country in southern Africa, occupying an island in the Indian Ocean, off the coast of Madagascar, east of Reunion.","Mauritius | 480 | MAURITIUS | MU | MUS",,,,,,,,,,,,,,,"4072751","Mauritius",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024553","Maldives","C16815","A country in southern Asia, occupying a group of atolls in the Indian Ocean, south-southwest of India and north of the British Indian Ocean Territory.","Maldives | 462 | MALDIVES | MDV | MV",,,,,,,,,,,,,,,"4329585","Maldives",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024548","Malawi","C16813","A country in southern Africa, east of Zambia and west of Mozambique and Tanzania.","Malawi | 454 | MALAWI | MW | MWI",,,,,,,,,,,,,,,"4072113","Malawi",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025885","Mexico","C16850","A country in southern North America, bordering the North Pacific Ocean and the Gulf of Mexico, south of the US.","Mexico | 484 | MEX | MEXICO | MX",,,,,,,,,,,,,,,"4075636","Mexico",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024552","Malaysia","C16814","A country in southeastern Asia bordering Indonesia and the South China Sea, occupying a peninsula south of Thailand and the northern one-third of the island of Borneo.","Malaysia | 458 | MALAYSIA | MY | MYS",,,,,,,,,,,,,,,"4330325","Malaysia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026655","Mozambique","C16882","A country in southeastern Africa, bordering the Mozambique Channel, between South Africa and Tanzania.","Mozambique | 508 | MOZ | MOZAMBIQUE | MZ",,,,,,,,,,,,,,,"4072752","Mozambique",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027366","Namibia","C16891","A country in southwestern Africa, bordering the South Atlantic Ocean, between Angola and South Africa.","Namibia | 516 | NA | NAM | NAMIBIA",,,,,,,,,,,,,,,"4071843","Namibia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028074","Niger","C16916","A country in western Africa, southeast of Algeria and north of Nigeria.","Niger | 562 | NE | NER | NIGER",,,,,,,,,,,,,,,"4075200","Niger",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028366","Norfolk Island","C16919","A country in the Pacific, occupying an island in the South Pacific Ocean, east of Australia and between New Caledonia and New Zealand.","Norfolk Island | 574 | NF | NFK | NORFOLK ISLAND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028075","Nigeria","C16917","A country in western Africa, bordering the Gulf of Guinea, between Benin and Cameroon.","Nigeria | 566 | NG | NGA | NIGERIA",,,,,,,,,,,,,,,"4073748","Nigeria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028002","Nicaragua","C16915","A country in Central America, bordering both the Caribbean Sea and the North Pacific Ocean, between Costa Rica and Honduras.","Nicaragua | 558 | NI | NIC | NICARAGUA",,,,,,,,,,,,,,,"4072758","Nicaragua",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027778","Netherlands","C16903","A country in western Europe, bordering the North Sea, between Belgium and Germany.","Netherlands | 528 | Kingdom of the Netherlands | NETHERLANDS | NL | NLD",,,,,,,,,,,,,,,"4320169","Netherlands",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028423","Norway","C16920","A country in northern Europe, bordering the North Sea and the North Atlantic Ocean, west of Sweden.","Norway | 578 | NO | NOR | NORWAY",,,,,,,,,,,,,,,"4328758","Norway",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027689","Nepal","C16901","A country in southern Asia, between China and India, west of Bhutan.","Nepal | 524 | NEPAL | NP | NPL",,,,,,,,,,,,,,,"4330329","Nepal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027496","Nauru","C16896","A country in Oceania, occupying an island in the South Pacific Ocean, south of the Marshall Islands.","Nauru | 520 | NAURU | NR | NRU",,,,,,,,,,,,,,,"4320312","Nauru",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028219","Niue","C16918","A country in the Pacific, occupying an island in the South Pacific Ocean, east of Tonga and south of American Samoa.","Niue | 570 | NIU | NIUE | NU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027978","New Zealand","C16914","A country in the Pacific, comprised of islands in the South Pacific Ocean, southeast of Australia.","New Zealand | 554 | NEW ZEALAND | NZ | NZL",,,,,,,,,,,,,,,"4329593","New Zealand",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028971","Oman","C16933","A country in the Middle East, bordering the Arabian Sea, southeast of Saudi Arabia.","Oman | 512 | OM | OMAN | OMN",,,,,,,,,,,,,,,"4330416","Oman",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030266","Panama","C16951","A country in Central America, bordering both the Caribbean Sea and the North Pacific Ocean, between Colombia and Costa Rica.","Panama | 591 | PA | PAN | PANAMA",,,,,,,,,,,,,,,"4073749","Panama",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031238","Peru","C16972","A country in western South America, bordering the South Pacific Ocean, between Chile and Ecuador.","Peru | 604 | PE | PER | PERU",,,,,,,,,,,,,,,"4072765","Peru",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030375","Papua New Guinea","C16952","A country in southeastern Asia, comprising a group of islands and including the eastern half of the island of New Guinea, between the Coral Sea and the South Pacific Ocean, east of Indonesia.","Papua New Guinea | 598 | PAPUA NEW GUINEA | PG | PNG",,,,,,,,,,,,,,,"4320161","Papua New Guinea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031529","Philippines","C16978","A country in southeastern Asia, comprised of an archipelago between the Philippine Sea and the South China Sea, east of Vietnam.","Philippines | 608 | PH | PHILIPPINES | PHL",,,,,,,,,,,,,,,"4320305","Republic of the Philippines",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030211","Pakistan","C16949","A country in southern Asia, bordering the Arabian Sea, between India on the east and Iran and Afghanistan on the west and China in the north.","Pakistan | 586 | PAK | PAKISTAN | PK",,,,,,,,,,,,,,,"4329586","Pakistan",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032356","Poland","C17002","A country in central Europe, east of Germany.","Poland | 616 | PL | POL | POLAND",,,,,,,,,,,,,,,"4329597","Poland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034044","Puerto Rico","C17043","An island between the Caribbean Sea and the North Atlantic Ocean, east of the Dominican Republic and west of the British Virgin Islands.","Puerto Rico | 630 | PR | PRI | PUERTO RICO",,,,,,,,,,,,,,,"4072763","Puerto Rico",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032729","Portugal","C17006","A country in southwestern Europe, bordering the North Atlantic Ocean, west of Spain.","Portugal | 620 | PORTUGAL | PRT | PT",,,,,,,,,,,,,,,"4320170","Portugal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2711193","Palau","C17733","A country in the Pacific, comprising a group of islands in the North Pacific Ocean, southeast of the Philippines and northwest of Papua New Guinea.","Palau | 585 | PALAU | PLW | PW",,,,,,,,,,,,,,,"40481808","Palau",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034366","Qatar","C17045","A country in the Middle East, occupying a peninsula bordering the Persian Gulf and Saudi Arabia.","Qatar | 634 | QA | QAT | QATAR",,,,,,,,,,,,,,,"4329591","Qatar",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035826","Romania","C17108","A country in southeastern Europe, bordering the Black Sea, between Bulgaria and Ukraine.","Romania | 642 | RO | ROMANIA | ROU",,,,,,,,,,,,,,,"4330431","Romania",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035978","Rwanda","C17112","A country in central Africa, between the Democratic Republic of the Congo and Tanzania and north of Burundi.","Rwanda | 646 | RW | RWA | RWANDA",,,,,,,,,,,,,,,"4075201","Rwanda",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036243","Saudi Arabia","C17117","A country in the Middle East, bordering the Persian Gulf and the Red Sea, north of Yemen.","Saudi Arabia | 682 | SA | SAU | SAUDI ARABIA",,,,,,,,,,,,,,,"4330417","Saudi Arabia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037623","Solomon Islands","C17148","A group of islands in the South Pacific Ocean, east of Papua New Guinea.","Solomon Islands | 090 | SB | SLB | SOLOMON ISLANDS",,,,,,,,,,,,,,,"4329594","Solomon islands",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038642","Sudan","C17170","A country in northeastern Africa, bordering the Red Sea, between Egypt and Eritrea.","Sudan | 729 | 736 | Republic of the Sudan | SD | SDN | SUDAN",,,,,,,,,,,,,,,"4075198","Sudan",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038995","Sweden","C17180","A country in northern Europe, bordering the Baltic Sea, between Finland and Norway.","Sweden | 752 | SE | SWE | SWEDEN",,,,,,,,,,,,,,,"4330441","Sweden",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037173","Singapore","C17134","A country in southeastern Asia, comprised of the southern tip of the Malaysian peninsula and nearby islands between Malaysia and Indonesia.","Singapore | 702 | SG | SGP | SINGAPORE",,,,,,,,,,,,,,,"4320306","Singapore",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037334","Slovenia","C17138","A country in central Europe, bordering the Adriatic Sea, between Austria and Croatia.","Slovenia | 705 | SI | SLOVENIA | SVN",,,,,,,,,,,,,,,"4320295","Slovenia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206579","Slovakia","C17669","A country in central Europe, south of Poland and north of Hungary.","Slovakia | 703 | SK | SLOVAKIA | SVK",,,,,,,,,,,,,,,"4329598","Slovakia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037063","Sierra Leone","C17130","A country in western Africa, bordering the North Atlantic Ocean, between Guinea and Liberia.","Sierra Leone | 694 | SIERRA LEONE | SL | SLE",,,,,,,,,,,,,,,"4320148","Sierra Leone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036154","San Marino","C17115","A country in southern Europe, an enclave in central Italy.","San Marino | 674 | SAN MARINO | SM | SMR",,,,,,,,,,,,,,,"4320171","San Marino",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036644","Senegal","C17121","A country in western Africa, bordering the North Atlantic Ocean, between Guinea-Bissau and Mauritania.","Senegal | 686 | SEN | SENEGAL | SN",,,,,,,,,,,,,,,"4071848","Senegal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037640","Somalia","C17149","A country in eastern Africa, bordering the Gulf of Aden and the Indian Ocean, east of Ethiopia.","Somalia | 706 | Federal Republic of Somalia | SO | SOM | SOMALIA",,,,,,,,,,,,,,,"4075202","Somalia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013754","El Salvador","C16532","A country in Central America, bordering the North Pacific Ocean, between Guatemala and Honduras.","El Salvador | 222 | EL SALVADOR | SLV | SV",,,,,,,,,,,,,,,"4075637","El Salvador",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039138","Syrian Arab Republic","C17182","A country in the Middle East, bordering the Mediterranean Sea, between Lebanon and Turkey.","Syrian Arab Republic | 760 | SY | SYR | SYRIA | SYRIAN ARAB REPUBLIC | Syria | Syria",,,,,,,,,,,,,,,"4320310","Syrian Arab Republic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038983","Eswatini","C17179","A country in southern Africa, between Mozambique and South Africa.","Eswatini | 748 | ESWATINI | SWAZILAND | SWZ | SZ | Swaziland | Swaziland",,,,,,,,,,,,,,,"4075208","Eswatini",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007928","Chad","C16412","A country in central Africa, south of Libya, between Niger and Sudan.","Chad | 148 | CHAD | TCD | TD",,,,,,,,,,,,,,,"4073741","Chad",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040363","Togo","C17202","A country in western Africa, bordering the Gulf of Guinea, between Benin and Ghana.","Togo | 768 | TG | TGO | TOGO",,,,,,,,,,,,,,,"4320302","Togo",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039725","Thailand","C17192","A country in southeastern Asia, bordering the Andaman Sea and the Gulf of Thailand, southeast of Burma.","Thailand | 764 | TH | THA | THAILAND",,,,,,,,,,,,,,,"4320152","Thailand",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0220928","Tokelau","C17704","A group of three atolls in the South Pacific Ocean, about one-half of the way from Hawaii to New Zealand, west of Tuvalu and north of American Samoa.","Tokelau | 772 | TK | TKL | TOKELAU | Union Islands",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041403","Turkmenistan","C17223","A country in central Asia, bordering the Caspian Sea, between Iran and Kazakhstan.","Turkmenistan | 795 | TKM | TM | TURKMENISTAN",,,,,,,,,,,,,,,"4320150","Turkmenistan",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041388","Tunisia","C17221","A country in northern Africa, bordering the Mediterranean Sea, between Algeria and Libya.","Tunisia | 788 | TN | TUN | TUNISIA",,,,,,,,,,,,,,,"4075197","Tunisia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040407","Tonga","C17205","An archipelago in the South Pacific Ocean, about two-thirds of the way from Hawaii to New Zealand, southeast of Fiji.","Tonga | 776 | TO | TON | TONGA",,,,,,,,,,,,,,,"4330421","Tonga",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1452561","Timor-Leste","C17200","A country in southeastern Asia, northwest of Australia in the Lesser Sunda Islands at the eastern end of the Indonesian archipelago. East Timor includes the eastern half of the island of Timor, the Oecussi (Ambeno) region on the northwest portion of the island of Timor, and the islands of Pulau Atauro and Pulau Jaco.","Timor-Leste | 626 | East Timor | East Timor | TIMOR-LESTE | TL | TLS",,,,,,,,,,,,,,,"40479979","Timor-Leste",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041400","Turkey","C17222","A country in southeastern Europe and southwestern Asia, between the Black Sea and Mediterranean Sea, east of Greece and north of Syria.","Turkey | 792 | Republic of Turkey | TR | TUR | TURKEY | Turkiye | Turkiye Cumhuriyeti",,,,,,,,,,,,,,,"4133506","Türkiye",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041413","Tuvalu","C17225","A group of islands consisting of nine coral atolls in the South Pacific Ocean, about one-half of the way from Hawaii to Australia, west of Tokelau and north of Fiji.","Tuvalu | 798 | TUV | TUVALU | TV",,,,,,,,,,,,,,,"4320313","Tuvalu",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039260","Taiwan","C17184","A group of islands bordering the East China Sea, Philippine Sea, South China Sea, and Taiwan Strait, off the southeastern coast of China north of the Philippines.","Taiwan | 158 | TAIWAN | TW | TWN | Taiwan",,,,,,,,,,,,,,,"4178927","Taiwan",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039298","Tanzania, United Republic of","C17185","A country in eastern Africa, bordering the Indian Ocean, between Kenya and Mozambique.","Tanzania, United Republic of | 834 | TANZANIA | TANZANIA, UNITED REPUBLIC OF | TZ | TZA | Tanzania | Tanzania | United Republic of Tanzania",,,,,,,,,,,,,,,"4072112","Tanzania",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041580","Ukraine","C17229","A country in eastern Europe, bordering the Black Sea, between Poland and Russia.","Ukraine | 804 | UA | UKR | UKRAINE",,,,,,,,,,,,,,,"4320321","Ukraine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041573","Uganda","C17228","A country in eastern Africa, west of Kenya.","Uganda | 800 | UG | UGA | UGANDA",,,,,,,,,,,,,,,"4071840","Uganda",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041700","United Kingdom","C17233","A country in western Europe, comprising islands, including England, Scotland, Wales, and the northern one-sixth of the island of Ireland, between the North Atlantic Ocean and the North Sea, northwest of France.","United Kingdom | 826 | GB | GBR | UNITED KINGDOM | United Kingdom of Great Britain and Northern Ireland",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042113","Uruguay","C17244","A country in southern South America, bordering the South Atlantic Ocean, between Argentina and Brazil.","Uruguay | 858 | URUGUAY | URY | UY",,,,,,,,,,,,,,,"4075648","Uruguay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042177","Uzbekistan","C17246","A country in central Asia, north of Afghanistan, between Turkmenistan and Kazakhstan.","Uzbekistan | 860 | UZ | UZB | UZBEKISTAN",,,,,,,,,,,,,,,"4329577","Uzbekistan",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042658","Viet Nam","C17252","A country in southeastern Asia, bordering the Gulf of Thailand, Gulf of Tonkin, and South China Sea, alongside China, Laos, and Cambodia.","Viet Nam | 704 | VIET NAM | VIETNAM | VN | VNM | Vietnam | Vietnam",,,,,,,,,,,,,,,"4330326","Viet Nam",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042321","Vanuatu","C17247","A group of islands in the South Pacific Ocean, about three-quarters of the way from Hawaii to Australia.","Vanuatu | 548 | VANUATU | VU | VUT",,,,,,,,,,,,,,,"4320314","Vanuatu",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043402","Yemen","C17264","A country in the Middle East, bordering the Arabian Sea, Gulf of Aden, and Red Sea, between Oman and Saudi Arabia.","Yemen | 887 | YE | YEM | YEMEN",,,,,,,,,,,,,,,"37163159","Yemen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024974","Mayotte","C16828","A country in southern Africa, occupying an island in the Mozambique Channel, about one-half of the way from northern Madagascar to northern Mozambique, southeast of Comoros.","Mayotte | 175 | MAYOTTE | MYT | YT",,,,,,,,,,,,,,,"37396222","Mayotte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037712","South Africa","C17151","A country in southern Africa, at the southern tip of the continent of Africa.","South Africa | 710 | SOUTH AFRICA | ZA | ZAF",,,,,,,,,,,,,,,"4073743","South Africa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043445","Zambia","C17267","A country in southern Africa, east of Angola and north of Zimbabwe.","Zambia | 894 | ZAMBIA | ZM | ZMB",,,,,,,,,,,,,,,"4071838","Zambia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043476","Zimbabwe","C17268","A country in southern Africa, between South Africa and Zambia, west of Mozambique.","Zimbabwe | 716 | ZIMBABWE | ZW | ZWE",,,,,,,,,,,,,,,"4073744","Zimbabwe",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038944","Suriname","C17175","A country in northern South America, bordering the North Atlantic Ocean, between French Guiana and Guyana.","Suriname | 740 | SR | SUR | SURINAME",,,,,,,,,,,,,,,"4075647","Suriname",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042469","Venezuela, Bolivarian Republic of","C17250","A country in northern South America, bordering the Caribbean Sea and the North Atlantic Ocean, between Colombia and Guyana.","Venezuela, Bolivarian Republic of | 862 | VE | VEN | VENEZUELA | VENEZUELA, BOLIVARIAN REPUBLIC OF | Venezuela | Venezuela | Venezuela, Bolivian Republic of | Venezuela, Bolivian Republic of",,,,,,,,,,,,,,,"4075649","Bolivarian Republic of Venezuela",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037926","Spinal Cord Compression","C3380","Compression of the spinal cord.","Spinal Cord Compression | ",,,,,,,,,,,,,,,"4322945","Spinal cord compression",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0231435","Mobile","C25295","Moving or capable of moving readily.","Mobile | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205052","Rectal","C25224","Of or pertaining to the rectum.","Rectal | rectal",,,,,,,,,,,,,,,"42538095","Rectal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031066","Perineum","C33301","The area located between the anus and vulva in females, and anus and scrotum in males.","Perineum | PERINEUM | Perineal structure (body structure)",,,,,,,,,,,,,,,"4304791","Perineal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0442519","Home","C18002","A person's permanent place of residence.","Home | HOME",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL025467","Retention","C38016","The condition of remaining in a place or position or of holding within.","Retention | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1282907","Low Grade","C14161","Used to describe tumor samples that exhibit well to moderately well differentiated cells. They are generally expected to be slow growing and less aggressive.","Low Grade | Low | low grade",,,,,,,,,,,,,,,"37164079","LG",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL378245","High Grade","C14158","Used to describe tumor samples that exhibit poorly differentiated or undifferentiated cells. They are generally expected to be fast growing and aggressive.","High Grade | High | high grade",,,,,,,,,,,,,,,"37164080","HG",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205108","Distal","C25237","Situated farthest from a point of attachment or origin, as of a limb or bone; or directed away from the midline of the body.","Distal | DISTAL | Distal (qualifier value) | distal",,,,,,,,,,,,,,,"4261786","Distal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205107","Proximal","C25236","Situated nearest to a point of attachment or origin.","Proximal | PROXIMAL | Proximal (qualifier value) | proximal",,,,,,,,,,,,,,,"4226543","Proximal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0060197","Fenretinide","C1098","An orally-active synthetic phenylretinamide analogue of retinol (vitamin A) with potential antineoplastic and chemopreventive activities.  Fenretinide binds to and activates retinoic acid receptors (RARs), thereby inducing cell differentiation and apoptosis in some tumor cell types.  This agent also inhibits tumor growth by modulating angiogenesis-associated growth factors and their receptors and exhibits retinoid receptor-independent apoptotic properties. (NCI04)","Fenretinide | 4-(all-trans-retino-yl)aminophenol | 4-HPR | 4-Hydroxyphenylretinamide | All-trans-4'-Hydroxyretinanilide | FENRETINIDE | Fenretinimide | HPR-4 | McN-R-1967 | N-(4-hydroxyphenyl)retinamide | all-trans-4'-hydroxyretinanilide | all-trans-N-(4-Hydroxyphenyl)retinamide | all-trans-N-4'-hydroxyretinanilide | fenretinide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205474","Biochemical","C25434","Of or relating to biochemistry; involving chemical processes in living organisms.","Biochemical | ",,,,,,,,,,,,,,,"4214736","Biochemical",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0344211","Supportive Care","C15747","Supportive care is that which helps the patient and their family to cope with cancer and treatment of it from pre-diagnosis, through the process of diagnosis and treatment, to cure, continuing illness or death and into bereavement. It helps the patient to maximize the benefits of treatment and to live as well as possible with the effects of the disease. Supportive therapy may provide a patient with friendship, encouragement, practical advice such as access to community resources or how to develop a more active social life, vocational counseling, suggestions for minimizing friction with family members, and, above all, hope that the life of the patient may be improved. In all situations, supportive therapy involves the teaching of such life skills as managing medication, learning to socialize, handling finances, and getting a job.","Supportive Care | SUPPORTIVE CARE | Supportive Therapy | Symptom Management | Therapy, Supportive | supportive care",,,,,,,,,,,,,,,"4055254","Support",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL356891","Regional","C25643","Of or belonging to a broader area or region of the body.","Regional | REGIONAL | regional",,,,,,,,,,,,,,,"4260906","Regional",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0521316","Gallium Scan","C38087","A nuclear imaging procedure in which an isotope of gallium is used as the radiopharmaceutical. Gallium binds to transferrin, leukocyte lactoferrin, bacterial siderophores and inflammatory proteins and thereby can be used to localize foci of infection. It is also taken up by several tumors, thus gallium scintigraphy can be used for the staging of tumors.","Gallium Scan | gallium scan",,,,,,,,,,,,,,,"4336668","Gallium scan",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0441766","Stage I","C27966","Invasive cancer confined to the original anatomic site of growth without lymph node involvement.","Stage I | Stage 1",,,,,,,,,,,,,,,"4121054","Stage 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0456595","Stage IA","C27975","Invasive cancer confined to the original anatomic site of growth without lymph node involvement.  The definition of stage IA depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IA is defined as follows: T1, N0, M0. T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for bone cancer, stage IA is defined as follows: T1, N0, M0, G1, GX. T1: Tumor 8 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well differentiated-low grade. GX: Grade cannot be assessed. (partially adapted from AJCC 8th ed.)","Stage IA | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456597","Stage IB","C27976","Invasive cancer confined to the original anatomic site of growth without lymph node involvement.  The definition of stage IB depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IB is defined as follows: (T0, N1mi, M0); (T1, N1mi, M0). T0: No evidence of primary tumor. T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. N1mi: Nodal micrometastases. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for bone cancer, stage IB is defined as follows: (T2, N0, M0, G1, G2, GX); (T3, N0, M0, G1, G2, GX). T2: Tumor more than 8 cm in greatest dimension. T3: Discontinuous tumors in the primary bone site. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well differentiated-low grade. G2: Moderately differentiated-low grade. GX: Grade cannot be assessed. (partially adapted from AJCC 7th ed.)","Stage IB | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441767","Stage II","C28054","Invasive cancer more extensive than stage I, usually involving local lymph nodes without spread to distant anatomic sites.","Stage II | Stage 2",,,,,,,,,,,,,,,"4106768","Stage 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0441771","Stage III","C27970","Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites.","Stage III | Stage 3",,,,,,,,,,,,,,,"4121176","Stage 3",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0441772","Stage IV","C27971","Cancer that has spread to distant anatomic sites beyond its original site of growth.","Stage IV | Stage 4",,,,,,,,,,,,,,,"4123017","Stage 4",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0456600","Stage IVA","C27979","Cancer that has spread to distant anatomic sites beyond its original site of growth. The definition of stage IVA depends on the particular type of cancer that it refers to; for example, for bone cancer, stage IVA is defined as follows: Any T, N0, M1a, Any G. N0: No regional lymph node metastasis. M1a: Distant metastasis to lung; for vaginal cancer, stage IVA is defined as follows: T4, Any N, M0. T4: Tumor invades mucosa of the bladder or rectum and/or extends beyond the true pelvis (bullous edema is not sufficient evidence to classify a tumor as T4). M0: No distant metastasis. (partially adapted from AJCC 7th ed.)","Stage IVA | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456601","Stage IVB","C27980","Cancer that has spread to distant anatomic sites beyond its original site of growth. The definition of stage IVB depends on the particular type of cancer that it refers to; for example, for bone cancer, stage IVB is defined as follows: (Any T, N1, Any M, Any G); (Any T, Any N, M1b, Any G). N1: Regional lymph node metastasis. M1b: Metastasis to other distant sites; for vaginal cancer, stage IVB is defined as follows: Any T, Any N, M1. M1: Distant metastasis. (partially adapted from AJCC 7th ed.)","Stage IVB | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441778","Stage A","C28056","Cancer confined to the original anatomic site of growth.","Stage A | ",,,,,,,,,,,,,,,"4128451","Stage A",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0441781","Stage B","C28057","Cancer that is confined to the original anatomic site of growth but is clinically palpable.","Stage B | ",,,,,,,,,,,,,,,"4130409","Stage B",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0441785","Stage C","C28060","Cancer that has reached the muscularis propria of the colon, or cancer that has invaded the prostatic gland capsule but is confined to the periprostatic area.","Stage C | ",,,,,,,,,,,,,,,"4130410","Stage C",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0441789","Stage D","C28061","Cancer that has spread to other anatomic sites beyond the site of its original growth.","Stage D | ",,,,,,,,,,,,,,,"4164075","Stage D",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0441790","Stage D1","C28062","Prostate cancer that has spread to local lymph nodes only.","Stage D1 | ",,,,,,,,,,,,,,,"4128453","Stage D1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0441791","Stage D2","C28063","Prostate cancer that has spread to distant lymph nodes or other organs.","Stage D2 | ",,,,,,,,,,,,,,,"4127606","Stage D2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0441763","Stage 0","C28051","Cancer confined to the epithelium without invasion of the basement membrane.","Stage 0 | ",,,,,,,,,,,,,,,"4127500","Stage 0",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0441768","Stage IIA","C27967","Invasive cancer more extensive than stage I, usually involving local lymph nodes without spread to distant anatomic sites.  The definition of stage IIA depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIA is defined as follows: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0). T0: No evidence of primary tumor. T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N0: No regional lymph node metastasis. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for bone cancer, stage IIA is defined as follows: T1, N0, M0, G3, G4. T1: Tumor 8 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. G3: Poorly differentiated. G4: Undifferentiated. (partially adapted from AJCC 7th ed.)","Stage IIA | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441769","Stage IIB","C27968","Invasive cancer more extensive than stage I, usually involving local lymph nodes without spread to distant anatomic sites.  The definition of stage IIB depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIB is defined as follows: (T2, N1, MO); (T3, NO, MO). T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension. T3: Tumor more than 50 mm in greatest dimension. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N0: No regional lymph node metastasis. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for bone cancer, stage IIB is defined as follows: T2, N0, M0, G3, G4. T2: Tumor more than 8 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. G3: Poorly differentiated. G4: Undifferentiated. (partially adapted from AJCC 7th ed.)","Stage IIB | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456598","Stage IIIA","C27977","Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites. The definition of stage IIIA depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIIA is defined as follows: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0). T0: No evidence of primary tumor. T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension. T3: Tumor more than 50 mm in greatest dimension. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for cervical cancer, stage IIIA is defined as follows: T3a, N0, M0. T3a: Tumor involves lower third of vagina, no extension to pelvic wall. N0: No regional lymph node metastasis. M0: No distant metastasis. (partially adapted from AJCC 7th ed.)","Stage IIIA | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456599","Stage IIIB","C27978","Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites.  The definition of stage IIIB depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIIB is defined as follows: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules). N0: No regional lymph node metastasis. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for cervical cancer, stage IIIB is defined as follows: (T3b, Any N, M0); (T1-3, N1, M0). T3: Tumor extends to pelvic wall and/or involves lower third of vagina, and/or causes hydronephrosis or non-functioning kidney. T3b: Tumor extends to pelvic wall and/or causes hydronephrosis or non-functioning kidney. N1: Regional lymph node metastasis. M0: No distant metastasis. (partially adapted from AJCC 7th ed.)","Stage IIIB | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456608","Stage IIIC","C27982","Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites.  The definition of stage IIIC depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIIC is defined as follows: Any T, N3, M0. N3: Metastases in ipsilateral infraclavicular (level III) axillary lymph nodes(s) with or without level I, II axillary lymph node involvement; or in clinically detected ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for appendix carcinoma, stage IIIC is defined as follows: Any T, N2, M0. N2: Metastasis in four or more regional lymph nodes. M0: No distant metastasis. (partially adapted from AJCC 7th ed.)","Stage IIIC | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019004","Hemodialysis","C15248","A therapeutic procedure used in patients with kidney failure.  It involves the extracorporeal removal of harmful wastes and fluids from the blood using a dialysis machine.  Following the dialysis, the blood is returned to the body.","Hemodialysis | Artificial Kidney Dialysis | Extracorporeal Dialysis | HEMODIALYSIS | Kidney Dialysis | Renal Dialysis",,,,,,,,,,,,,,,"4120120","Hemodialysis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031139","Peritoneal Dialysis","C15297","A form of dialysis that uses the peritoneum as a membrane across which the infused diasylate exchanges nutrients for waste products that are removed when the fluid is exchanged.","Peritoneal Dialysis | ",,,,,,,,,,,,,,,"4324124","Peritoneal dialysis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0149514","Acute Bronchitis","C26932","Acute inflammation and edema of the larger bronchi caused by viruses or bacteria.  Signs and symptoms include cough, sputum production, shortness of breath, and wheezing.","Acute Bronchitis | ",,,,,,,,,,,,,,,"260139","Acute bronchitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016733","Frontal Lobe","C12352","The part of the brain located anterior to the parietal lobes at the front of each cerebral hemisphere.","Frontal Lobe | Brain, Frontal lobe | FRONTAL LOBE | Frontal lobe | Frontal lobe structure (body structure) | frontal lobe | lobi frontales | lobus frontalis",,,,,,,,,,,,,"UBERON:0016525","frontal lobe","4307223","Frontal lobe structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030560","Parietal Lobe","C12354","One of the lobes of the cerebral hemisphere located superiorly to the occipital lobe and posteriorly to the frontal lobe. Cognition and visuospatial processing are its main functions.","Parietal Lobe | Brain, Parietal lobe | PARIETAL LOBE | Parietal Lobe of the Brain | Parietal lobe | Parietal lobe structure (body structure) | parietal lobe",,,,,,,,,,,,,,,"4042920","Parietal lobe structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039485","Temporal Lobe","C12353","One of the cerebral lobes. It is located inferior to the frontal and parietal lobes and anterior to the occipital lobe.","Temporal Lobe | Brain, Temporal lobe | TEMPORAL LOBE | Temporal lobe | Temporal lobe structure (body structure) | temporal lobe",,,,,,,,,,,,,,,"4302313","Temporal lobe structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028785","Occipital Lobe","C12355","One of the four regions of cortex in each cerebral hemisphere. It is located posterior to the temporal lobe and inferior to the parietal lobe.","Occipital Lobe | Brain, Occipital lobe | OCCIPITAL LOBE | Occipital lobe | Occipital lobe structure (body structure) | occipital lobe",,,,,,,,,,,,,,,"4150041","Occipital lobe structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029130","Optic Nerve","C12761","The second cranial nerve.","Optic Nerve | NERVE, OPTIC | OPTIC NERVE | Optic nerve | Optic nerve structure (body structure) | Second Cranial Nerve | optic nerve",,,,,,,,,,,,,,,"4080374","Optic nerve structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010090","Corpus Callosum","C12446","A white matter structure within the cleft that separates the left and right cerebral hemispheres in the mammalian brain. It is composed of a wide, flat bundle of 200-250 million axonal projections.","Corpus Callosum | BRAIN, CORPUS CALLOSUM | CORPUS CALLOSUM",,,,,,,,,,,,,,,"4227439","Corpus callosum structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152279","Lateral Ventricle","C12834","The rostral extensions of the ventricular system of the brain consisting of two cavities, one on each side of the brain within the central regions of each cerebral hemisphere.  Cerebrospinal fluid flows from the lateral ventricles into the centrally third ventricle via the foramen of Monroe.","Lateral Ventricle | BRAIN VENTRICLE, LATERAL | Lateral Ventricle of Brain | Lateral Ventricles | Ventricle, Lateral | Ventricles, Lateral",,,,,,,,,,,,,,,"4280490","Lateral ventricle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007769","Aqueduct of Sylvius","C32135","A channel that connects the third and fourth ventricles of the brain.","Aqueduct of Sylvius | Cerebral Aqueduct",,,,,,,,,,,,,,,"4214611","Structure of cerebral aqueduct",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0149555","Third Ventricle","C12827","A centrally placed component of the ventricular system of the brain located in the diencephalon. Cerebrospinal fluid from the lateral ventricles flows into the third ventricle via the foramina of Monroe and exits the third ventricle via the aqueduct of Sylvius. The thalamus and hypothalamus border the lateral walls of the third ventricle.","Third Ventricle | BRAIN, THIRD VENTRICLE | Third Cerebral Ventricle | Third Ventricle of Brain | Ventricle, Third",,,,,,,,,,,,,,,"4173271","Third ventricle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0149556","Fourth Ventricle","C12828","A diamond-shaped cavity filled with cerebrospinal fluid within the pons extending between the obex in the caudal medulla and the aqueduct of Sylvius in the cerebellum.","Fourth Ventricle | BRAIN, FOURTH VENTRICLE | Fourth Ventricle of Brain | Fourth Ventricle of the Brain",,,,,,,,,,,,,,,"4261524","Fourth ventricle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007610","Nucleus","C13197","A body within the cell, surrounded by a membrane, within which lie the chromosomes, one or more nucleoli, combined with proteins, and exhibits mitosis.","Nucleus | Cell Nucleus | NUCLEUS | Nuclei | Nucleic | nucleus",,,,,,,,,,,,,,,"4223855","Nucleus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010834","Cytoplasm","C13226","That portion of the cell contained within the plasma membrane but excluding the nucleus.","Cytoplasm | Cytoplasmic | cytoplasm",,,,,,,,,,,,,,,"4267273","Cytoplasmic matrix",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205064","Cervical","C12844","Relating to a neck, or cervix, in any sense.","Cervical | cervical",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007458","Cauda Equina","C12689","The collection of spinal nerve roots, arising from lumbar pairs two through five, sacral pairs one through five, and the coccygeal nerve, that branch off the conus medullaris at the termination of the spinal cord, and float freely within the lumbar cistern before exiting the spinal column at the appropriate vertebra.","Cauda Equina | Cauda Equina Spinal Cord | Cauda equina | Cauda equina structure (body structure) | cauda equina",,,,,,,,,,,,,,,"4216565","Cauda equina structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007765","Cerebellum","C12445","The portion of the brain located at the base of the skull that is responsible for balance, equilibrium and movement.","Cerebellum | BRAIN, CEREBELLUM | Brain, Cerebellum, NOS | CEREBELLUM | Cerebellar | Cerebellar structure (body structure) | Cerebellum, NOS | cerebellum",,,,,,,,,,,,,"UBERON:0002037","cerebellum","4034048","Cerebellar structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007473","Cavernous Sinus","C12690","One of a pair of dural venous sinuses located on either side of the pituitary fossa and lateral to the sella turcica. It receives blood from the superior and inferior ophthalmic veins, and drains via the superior and inferior petrosal sinuses, as well as into the emissary vein.","Cavernous Sinus | ",,,,,,,,,,,,,,,"4077145","Structure of cavernous sinus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020663","Hypothalamus","C12458","A small, cone shaped collection of nuclei in the brain that is located below the thalamus and forms the lower side wall and floor of the third ventricle. It regulates homeostasis, the sleep-wake cycle, and metabolism, and plays a role in autonomic, endocrine, and motor function control.","Hypothalamus | BRAIN, HYPOTHALAMUS | HYPOTHALAMUS | Hypothalamic structure (body structure) | hypothalamus","C71.0","Hypothalamus",,,,,,,,,,,,,"4195703","Hypothalamic structure",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0039729","Thalamus","C12459","An ovoid mass composed predominantly of gray substance and associated laminae of white substance. The thalamus is divided into anterior, medial, and lateral parts. The function of the thalamus is to relay sensory impulses and cerebellar and basal ganglia projections to the cerebral cortex. The thalamus is positioned within the posterior part of the diencephalon forming most of each lateral wall of the third ventricle.","Thalamus | BRAIN, THALAMUS | Dorsal Thalamus | THALAMUS | dorsal plus ventral thalamus | thalamus","C71.0","Thalamus",,,,,,,,,,,,,"4175342","Thalamic structure",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0008841","Cisterna Magna","C32324","The largest of the three principle cisterns in the subarachnoid space which is located between the cerebellum and the medulla oblongata.","Cisterna Magna | Cerebellomedullary Cistern",,,,,,,,,,,,,,,"4183847","Structure of cisterna magna",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL318009","Thoracic","C13360","Having to do with the chest.","Thoracic | thoracic",,,,,,,,,,,,,,,"4120195","THO",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4228805","Yolk Sac Tumor","C3011","A non-seminomatous malignant germ cell tumor composed of primitive germ cells.  It is the most common malignant germ cell tumor in the pediatric population. It occurs in the infant testis, ovary, sacrococcygeal region, vagina, uterus, prostate, abdomen, liver, retroperitoneum, thorax, and pineal/third ventricle. The tumor mimics the yolk sac of the embryo and produces alpha-fetoprotein (AFP). Treatment includes: surgical resection, radiation, and chemotherapy. This tumor is very responsive to chemotherapy regimens that include cisplatinum.","Yolk Sac Tumor | Carcinoma, Yolk Sac | Endodermal Sinus Neoplasm | Endodermal Sinus Tumor | Endodermal sinus tumor | YOLK SAC TUMOR, MALIGNANT | Yolk Sac Neoplasm | Yolk Sac Tumor Site Unspecified | Yolk Sac Tumour Site Unspecified | Yolk sac tumor",,,,,,,,,,,,,,,"4253816|4300688","Endodermal sinus tumor|Yolk sac tumor",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0039538","Teratoma","C3403","A non-seminomatous germ cell tumor characterized by the presence of various tissues which correspond to the different germinal layers (endoderm, mesoderm, and ectoderm). It occurs in the testis, ovary, and extragonadal sites including central nervous system, mediastinum, lung, and stomach. According to the level of differentiation of the tissues which comprise the tumor, teratomas are classified as benign (grade 0 or 1), immature (grade 2), and malignant (grade 3). Grade 0 teratomas contain only mature elements; grade 1 teratomas have a limited degree of immaturity; grade 2 teratomas have a more extensive degree of immaturity; grade 3 teratomas are composed exclusively of immature tissues. The prognosis depends on patient age, tumor size and grade, and stage.","Teratoma | Teratoma, NOS | Teratoma, Not Otherwise Specified | teratoma","9080/1","Teratoma, NOS",,,,,,,,,,,,,"36713171|37156920","Teratoma|Teratoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0334524","Mixed Germ Cell Tumor","C4290","A malignant germ cell tumor characterized by the presence of at least two different germ cell tumor components. The different germ cell tumor components include choriocarcinoma, embryonal carcinoma, yolk sac tumor, teratoma, and seminoma. It occurs in the ovary, testis, and extragonadal sites including central nervous system and mediastinum.","Mixed Germ Cell Tumor | Combined Germ Cell Neoplasm | Combined Germ Cell Tumor | Mixed Germ Cell Neoplasm | Mixed germ cell tumor","9085/3","Mixed germ cell tumor",,,,,,,,,,,,,"4140097|607973","Mixed germ cell tumor|Mixed germ cell tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0085533","Adjuvant Chemotherapy","C15360","Chemotherapy that is administered subsequent to the main treatment plan to minimize or prevent disease recurrence.","Adjuvant Chemotherapy | Adjuvant",,,,,,,,,,,,,,,"37154085","Adjuvant drug therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334501","Benign Phyllodes Tumor","C4274","A benign, circumscribed fibroepithelial neoplasm arising from the breast and rarely the prostate gland. It is characterized by the presence of epithelial structures which are arranged in clefts and by a hypercellular mesenchymal stroma which is organized in leaf-like structures. There is no evidence of cellular atypia or sarcomatous features.","Benign Phyllodes Tumor | Benign Cystosarcoma Phyllodes | Benign Phyllodes Neoplasm | Cystosarcoma phyllodes, benign | Phyllodes tumor, benign","9020/0","Phyllodes tumor, benign",,,,,,,,,,,,,"4040991","Benign phyllodes tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1370913","Borderline Phyllodes Tumor","C7503","A phyllodes tumor with morphologic characteristics which are intermediate between a benign and a malignant phyllodes tumor. The stromal sarcomatous changes are of low grade and are often reminiscent of low grade fibrosarcomas.","Borderline Phyllodes Tumor | Borderline Phyllodes Neoplasm | Phyllodes tumor, borderline","9020/1","Phyllodes tumor, borderline",,,,,,,,,,,,,"4323562","Borderline phyllodes tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0007140","Carcinosarcoma","C34448","A malignant tumor composed of a mixture of carcinomatous and sarcomatous elements.","Carcinosarcoma | CARCINOSARCOMA, MALIGNANT | Carcinosarcoma, NOS | carcinosarcoma","8980/3","Carcinosarcoma, NOS",,,,,,,,,,,,,"4271564","Carcinosarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0206650","Breast Fibroadenoma","C3744","A benign tumor of the breast characterized by the presence of stromal and epithelial elements. It presents as a painless, solitary, slow growing, firm, and mobile mass. It is the most common benign breast lesion. It usually occurs in women of childbearing age. The majority of fibroadenomas do not recur after complete excision. A slightly increased risk of developing cancer within fibroadenomas or in the breast tissue of patients previously treated for fibroadenomas has been reported.","Breast Fibroadenoma | FIBROADENOMA, BENIGN | Fibroadenoma | Fibroadenoma | Fibroadenoma of Breast | Fibroadenoma of the Breast | fibroadenoma","9010/0","Fibroadenoma, NOS",,,,,,,,,,,,,"4116072|608109","Fibroadenoma of breast|Benign fibroadenoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0016048","Fibromatosis","C3042","A poorly circumscribed neoplasm arising from the soft tissues. It is characterized by the presence of spindle-shaped fibroblasts and an infiltrative growth pattern.","Fibromatosis | fibromatosis",,,,,,,,,,,,,,,"37109980|4062787","Fibromatosis|Fibromatosis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0206713","Intraductal Papilloma","C3785","An intraluminal papillary epithelial neoplasm arising within the ducts. Representative examples are the intraductal breast papilloma and the salivary gland intraductal papilloma.","Intraductal Papilloma | Duct Adenoma | Duct adenoma, NOS | Ductal Papilloma | Ductal papilloma | Intraductal papilloma | intraductal papilloma","8503/0","Intraductal papilloma",,,,,,,,,,,,,"4179640","Intraductal papilloma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1297883","Radial Scar/Complex Sclerosing Lesion","C9495","A benign breast lesion characterized by the presence of fibrosis with stellate appearance in the parenchyma.  The lesions are often multiple and bilateral.  Grossly, the lesions are irregular and firm and resemble carcinoma.  Microscopically, the stellate lesions are composed of dense, hyalinized collagen.  Entrapped in the collagen are tubules.  There is no evidence of cytologic atypia.","Radial Scar/Complex Sclerosing Lesion | Complex Sclerosing Lesion | Radial Scar | Radial Scar | Radial Sclerosing Lesion",,,,,,,,,,,,,,,"4046286","Radial scar",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013516","Echocardiography","C16525","A procedure that uses high-frequency sound waves (ultrasound) to create an image of the heart.","Echocardiography | EC | ECHOCARDIOGRAPHY | echocardiography",,,,,,,,,,,,,,,"4230911","Echocardiography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007778","Decortication","C28139","Surgical excision of a restrictive fibrinous layer overlying an organ or tissue as a result of pathologic inflammatory conditions.","Decortication | decortication",,,,,,,,,,,,,,,"4119227","Brain decortication",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3549846","Jaundice","C3143","Yellow pigmentation of the skin, mucous membranes, and the eyes due to hyperbilirubinemia. Causes include liver disease, biliary tract obstruction, and hemolysis.","Jaundice | jaundice",,,,,,,,,,,,,,,"137977","Jaundice",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0441994","Lower","C25309","The bottom one of two.","Lower | LOWER | Lower (qualifier value)",,,,,,,,,,,,,,,"4126988","Lower",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1282910","Upper","C25355","Higher in place or position; the topmost one of two.","Upper | UPPER | Upper (qualifier value) | Uppermost",,,,,,,,,,,,,,,"4130098","Upper",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1368019","Paget Disease","C7073","A malignant neoplasm composed of large cells with large nuclei, prominent nucleoli, and abundant pale cytoplasm (Paget cells).  Paget cell neoplasms include Paget disease of the nipple and extramammary Paget disease which may affect the vulva, penis, anus, skin and scrotum.","Paget Disease | Paget Cell Neoplasm | Paget's Cell Neoplasm | Paget's Disease | Paget's Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205269","Refractory","C38014","Not responding to treatment.","Refractory | Unresponsive | Unresponsive to Treatment | refractory",,,,,,,,,,,,,,,"4048615","Intractable",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512426","Heterogenous","C28361","Derived from a different origin.","Heterogenous | Heterogeneity | heterogenic | heterogenous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439662","Immune","C17997","Protected against infectious disease by either specific or non-specific mechanisms.","Immune | ",,,,,,,,,,,,,,,"4116825","Immune",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020883","Ileostomy","C15257","Surgical creation of an external opening into the ileum for fecal diversion or drainage. Loop or tube procedures are most often employed.","Ileostomy | ileostomy",,,,,,,,,,,,,,,"4199270","Ileostomy operation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009410","Colostomy","C15211","The surgical creation of an opening between the colon and the surface of the body.","Colostomy | colostomy",,,,,,,,,,,,,,,"4162987","Colostomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1521023","2-Amino-9,10-Epoxy-8-Oxodecanoic Acid","C1948","The epoxy containing amino acid of HC toxin, a histone deacetylase inhibitor.","2-Amino-9,10-Epoxy-8-Oxodecanoic Acid | AEO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521099","Chromosome 22 Short Arm","C13554","Proximal (short) arm of chromosome 22","22p | Chromosome 22 Proximal Arm | Chromosome 22 Short Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521041","Chromosome 20 Short Arm","C13550","Proximal (short) arm of chromosome 20","20p | Chromosome 20 Proximal Arm | Chromosome 20 Short Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0914050","Tyrphostin AG 1295","C2031","A member of the Tyrphostin family of tyrosine kinase inhibitors that inhibits signal transduction through platelet-derived growth factor receptor and selectively attenuates smooth muscle cell growth. (NCI)","Tyrphostin AG 1295 | 6,7-Dimethyl-2-phenylquinoxaline | AG 1295",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0836921","Tonsil","C12802","The two organs situated in the throat on either side of the narrow passage from the mouth to the pharynx. They are composed of lymphoid tissues.","Tonsil | TONSIL | Tonsillar structure (palatine) (body structure) | Tonsils | tonsil",,,,,,,,,,,,,"UBERON:0002372","tonsil",,,,,,,,,,,,,,,"--"
"C1515153","TE72","C20303","Provider: Technion University, Haifa, Israel. No information from provider. This cell line meets the criteria for the use of human embryonic stem cells by federally funded researchers.","TE72 | J 3.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008838","Cisplatin","C376","An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","Cisplatin | (SP-4-2)-Diamminedichloroplatinum | Abiplatin | Blastolem | Briplatin | CDDP | CISPLATIN | Cis-diammine-dichloroplatinum | Cis-diamminedichloridoplatinum | Cis-diamminedichloro Platinum (II) | Cis-diamminedichloroplatinum | Cis-dichloroammine Platinum (II) | Cis-platinous Diamine Dichloride | Cis-platinum | Cis-platinum II | Cis-platinum II Diamine Dichloride | Cismaplat | Cisplatina | Cisplatinum | Cisplatyl | Citoplatino | Citosin | Cysplatyna | DDP | Lederplatin | Metaplatin | Neoplatin | Peyrone's Chloride | Peyrone's Salt | Placis | Plastistil | Platamine | Platiblastin | Platiblastin-S | Platinex | Platinol | Platinol- AQ | Platinol-AQ | Platinol-AQ VHA Plus | Platinoxan | Platinum | Platinum Diamminodichloride | Platinum, Diaminedichloro-, cis- (8CI) | Platiran | Platistin | Platosin | cisplatin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038911","Plastic Surgery","C18192","The branch of surgery concerned with therapeutic or cosmetic reformation of tissue.","Plastic Surgery | ",,,,,,,,,,,,,,,"4190433","Plastic surgery - specialty",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025011","Measles morbillivirus","C14237","A morbillivirus that causes the childhood disease measles and is responsible for subacute sclerosing panencephalitis.","Measles morbillivirus | MEASLES MORBILLIVIRUS | MEASLES VIRUS | Measles Virus | Measles Virus | Rougeole Virus | Rubeola Virus | SSPEV | Subacute Sclerosing Panencephalitis Virus | measles virus",,,,,,,,,,,,,,,"4199587","Measles morbillivirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0796347","5q","C13380","Distal (long) arm of chromosome 5","5q | Chromosome 5 Distal Arm | Chromosome 5 Long Arm | Chromosome 5q",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0393034","5-Fluoropyrimidinone","C2422","A fluoronucleoside that inhibits pyrimidine synthesis, interfering with DNA synthesis.","5-Fluoropyrimidinone | 5-Fluoro-Pyrimidinone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0046319","2-Methoxyestradiol","C965","An orally bioavailable estradiol metabolite with potential antineoplastic activity.  2-Methoxyestradiol inhibits angiogenesis by reducing endothelial cell proliferation and inducing endothelial cell apoptosis.  This agent also inhibits tumor cell growth by binding to tubulin, resulting in antimitotic activity, and by inducing caspase activation, resulting in cell cycle arrest in the G2 phase, DNA fragmentation, and apoptosis. (NCI04)","2-Methoxyestradiol | (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol | 2-METHOXYESTRADIOL | 2-MeE2 | 2-MeOE2 | 2-Methoxy Estradiol | 2-methoxyestradiol | 2ME2 | Panzem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677850","Adjuvant Therapy","C15675","Any therapy that is administered to augment or stimulate other treatment modalities or to minimize or prevent disease recurrence subsequent to the main treatment plan.","Adjuvant Therapy | AJ-Adjuvant Therapy | adjunct therapy | adjunctive therapy | adjuvant therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030231","Palliative Therapy","C15292","The patient- and family-centered active holistic care of patients with advanced, progressive disease. Essential components of palliative care are: pain and symptom control, communication regarding treatment and alternatives, prognosis, and available services, rehabilitation services, care that addresses treatment and palliative concerns, intellectual, emotional, social, and spiritual needs, terminal care, support in bereavement. The goal of palliative care is an achievement of the best quality of life for patients and their families.","Palliative Therapy | Comfort Care | PA-Palliative Therapy | Palliative | Palliative Care | Palliative Treatment | Symptom Management | Symptoms Management | comfort care | palliation | palliative care | palliative therapy | symptom management",,,,,,,,,,,,,,,"4014023","Palliative care",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206681","Clear Cell Adenocarcinoma","C3766","A malignant neoplasm composed of glandular epithelial clear cells.  Various architectural patterns may be seen, including papillary, tubulocystic, and solid.","Clear Cell Adenocarcinoma | ADENOCARCINOMA, CLEAR CELL, MALIGNANT | Clear Cell Carcinoma | Clear cell adenocarcinoma, NOS | Clear cell adenocarcinoma, mesonephroid | Clear cell carcinoma | Mesonephroid Clear Cell Adenocarcinoma | Mesonephroid Clear Cell Carcinoma | clear cell adenocarcinoma | clear cell carcinoma","8310/3","Clear cell adenocarcinoma, NOS",,,,,,,,,,,,,"4148292","Clear cell adenocarcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0227666","Renal Pelvis","C12887","The funnel-shaped proximal portion of the ureter located within the kidney into which urine is secreted from the collecting duct system of the kidney.","Renal Pelvis | RENAL PELVIS | Renal pelvis | Renal pelvis structure (body structure) | renal pelvis",,,,,,,,,,,,,,,"4094242","Renal pelvis structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0729596","Inguinal Lymph Node","C32801","A superficial or deep lymph node located in the inguinal area.","Inguinal Lymph Node | INGUINAL LYMPH NODE | Inguinal | LYMPH NODE, INGUINAL | Lymph Node(s) Inguinal | Lymph Node, Inguinal | inguinal lymph node",,,,,,,,,,,,,,,"4229762","Inguinal lymph node structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL455365","Pelvic Lymph Node","C12363","Any lymph node within the abdominal pelvic region.","Pelvic Lymph Node | Lymph Node(s) Pelvic | PELVIC LYMPH NODE | Pelvic Lymph Node(s) | Pelvic Lymph Nodes | Pelvic lymph node group (body structure) | Pelvic lymph nodes | lymph node of pelvis | pelvic lymph node",,,,,,,,,,,,,"UBERON:0015876","pelvic lymph node","4181602","Pelvic lymph node structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030274","Pancreas","C12393","An organ behind the lower part of the stomach that is the shape of a fish and about the size of a hand. It is a compound gland composed of both exocrine and endocrine tissues. The endocrine pancreas makes insulin so that the body can use glucose (sugar) for energy. The exocrine pancreas makes enzymes that help the body digest food. Spread all over the pancreas are areas called the Islets of Langerhans. The cells in these areas each have a special purpose. The alpha cells make glucagon, which raises the level of glucose in the blood; the beta cells make insulin; the delta cells make somatostatin. There are also PP cells and D1 cells, about which little is known.","Pancreas | Gastrointestinal Tract, Pancreas | PANCREAS | Pancreas, NOS | Pancreatic structure (body structure) | pancreas",,,,,,,,,,,,,"UBERON:0001264","pancreas","4049768","Pancreatic structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038351","Stomach","C12391","The primary organ of food digestion. It is located under the diaphragm, between the liver and the spleen as well as between the esophagus and the small intestine.","Stomach | Gastric | Gastrointestinal Tract, Stomach | STOMACH | Stomach structure (body structure) | Stomach, NOS | stomach",,,,,,,,,,,,,"UBERON:0000945","stomach","4288283","Stomach structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825026","Heparin","C539","A sulfur-rich glycosaminoglycan with anticoagulant property. Heparin binds to antithrombin III to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors, such as factors IX, X, XI, and XII, thereby preventing the polymerization of fibrinogen to fibrin and the subsequent formation of clots.","Heparin | HEPARIN | UFH | Unfractionated Heparin | Unfractionated heparin | heparin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336895","Urothelial Hyperplasia","C27877","Hyperplasia of the transitional epithelium of the urinary tract.  Morphologically it is subdivided into flat and papillary hyperplasia. -- 2003","Urothelial Hyperplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020507","Hyperplasia","C3113","An abnormal increase in the number of cells in an organ or a tissue with consequent enlargement.","Hyperplasia | HYPERPLASIA | Hyperplastic | hyperplasia",,,,,,,,,,,,,,,"4296894","Hyperplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001002","Acetone","C29807","A colorless, volatile, flammable organic solvent.  Acetone occurs naturally in plants, trees, forest fires, vehicle exhaust and as a breakdown product of animal fat metabolism.  This agent may be normally present in very small quantities in urine and blood; larger amounts may be found in the urine and blood of diabetics.  Acetone is toxic in high doses. (NCI04)","Acetone | 2-Propanone | ACETONE | Dimethyl Formaldehyde | Methyl Ketone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205358","Soft","C25255","Lacking in hardness relatively or comparatively.","Soft | Softly",,,,,,,,,,,,,,,"4290879","Soft",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036087","Saliva","C13275","The watery fluid in the mouth made by the salivary glands. Saliva moistens food to help digestion and it helps protect the mouth against infections.","Saliva | Head and Neck, Saliva | SALIVA | saliva",,,,,,,,,,,,,,,"4120374","Saliva",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036614","Seminal Fluid","C33529","Part of the ejaculated fluid. It contains secretions from the seminal vesicles, Cowper's gland, and prostate gland.","Seminal Fluid | SEMINAL FLUID | Seminal fluid | seminal fluid",,,,,,,,,,,,,,,"4289619","Seminal fluid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0765273","Bexarotene","C1635","A synthetic retinoic acid agent with potential antineoplastic, chemopreventive, teratogenic and embryotoxic properties.  Bexarotene selectively binds to and activates retinoid X receptors (RXRs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, apoptosis of some cancer cell types, and tumor regression. (NCI04)","Bexarotene | 3-methyl TTNEB | 4-[1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]benzoic Acid | BEXAROTENE | LGD 1069 | LGD-1069 | LGD1069 | Targretin | bexarotene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003166","Anthralin","C28827","A natural anthraquinone derivative, anti-psoriatic and anti-inflammatory Anthralin (dithranol) controls skin growth by reducing DNA synthesis and mitotic activity in the hyperplastic epidermis, restoring a normal rate of cell proliferation and keratinization. Used topically in the treatment of psoriasis, dermatoses, and alopecia areata, it is also used in biomedical research due to its effect on EGFR autophosphorylation. (NCI04)","Anthralin | 1,8-Dihydroxy-9(10H)-anthracenone | ANTHRALIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007257","Carmustine","C349","An antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  This agent also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)","Carmustine | 1,3-Bis(2-chloroethyl)-1-nitrosourea | 1,3-Bis(beta-chloroethyl)-1-nitrosourea | BCNU | Becenum | Becenun | BiCNU | Bis(chloroethyl) Nitrosourea | Bis-Chloronitrosourea | CARMUSTINE | Carmubris | Carmustin | Carmustinum | FDA 0345 | N,N'-Bis(2-chloroethyl)-N-nitrosourea | N,N'-bis(2-chloroethyl)-N-nitrosourea | NSC 409962 | NSC409962 | Nitrourean | Nitrumon | SK 27702 | SRI 1720 | WR 139021 | WR-139021 | WR139021 | carmustine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600266","Mechlorethamine Hydrochloride","C627","The hydrochloride salt of mechlorethamine, a nitrogen mustard and an analogue of sulfur mustard, with antineoplastic and immunosuppressive activities. Mechlorethamine is metabolized to an unstable, highly reactive ethyleniminium intermediate that alkylates DNA, particularly the 7 nitrogen of guanine residues, resulting in DNA base pair mismatching, DNA interstrand crosslinking, the inhibition of DNA repair and synthesis, cell-cycle arrest, and apoptosis. This agent also exhibits lympholytic properties.","Mechlorethamine Hydrochloride | Bis(2-chloroethyl)methylamine Hydrochloride | Caryolysine | Chlorethamine HCl | Chlorethazine Hydrochloride | Chlormethine Hydrochloride | Chlormethine hydrochloride | Chloromethine HCl | Chloromethine Hydrochloride | Cloramin | Erasol | HN 2 Hydrochloride | MECHLORETHAMINE HYDROCHLORIDE | Mechlorethamine hydrochloride | Methylbis(beta-chloroethyl)amine Hydrochloride | Methylchlorethamine Hydrochloride | Mustargen | Mustargen HCl | Mustargen Hydrochloride | Mustargen hydrochloride | Mustine Hydrochloride | Mustine hydrochloride | N-Lost | Nitrogen Mustard | Onco-Cloramin | WR-147650 | chlorethamine hydrochloride | ethanamine,2-chloro-N-(2-chloroethyl)-N-methyl Hydrochloride | mechlorethamine HCl | mechlorethamine hydrochloride | mustine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0454529","UVA Light Therapy","C16228","Light therapy using ultraviolet radiation between 100 and 400nm.","UVA Light Therapy | UVA Phototherapy",,,,,,,,,,,,,,,"4039592","Ultraviolet A therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010592","Cyclosporine","C406","A natural cyclic polypeptide immunosuppressant isolated from the fungus Beauveria nivea. The exact mechanism of action of cyclosporine is not known but may involve binding to the cellular protein cytophilin, resulting in inhibition of the enzyme calcineurin. This agent appears to specifically and reversibly inhibit immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited with T-helper cells as the primary target. Cyclosporine also inhibits lymphokine production and release. (NCI04)","Cyclosporine | 27-400 | CYCLOSPORINE | Ciclosporin | CsA | CyA | Cyclosporin | Cyclosporin A | Cyclosporine Modified | Cyclosporine modified | Cyclosporine non-modified | Gengraf | Neoral | OL 27-400 | Sandimmune | SangCya | cyclosporine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0717758","Etanercept","C2381","A recombinant soluble dimeric fusion protein consisting of the extracellular ligand-binding region of recombinant human tumor necrosis factor (rhTNF) receptor attached to the constant (Fc) region of human immunoglobulin G (FcIgG). The receptor moiety of etanercept binds to circulating TNF (2 molecules of TNF per receptor) and inhibits its attachment to endogenous TNF cell surface receptors, thereby rendering TNF inactive and inhibiting TNF-mediated mechanisms of inflammation. (NCI04)","Etanercept | ETANERCEPT | Enbrel | TNFR:Fc | Tumor Necrosis Factor Receptor IgG Chimera | etanercept",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0666743","Infliximab","C1789","A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis. Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. (NCI04)","Infliximab | Avakine | INFLIXIMAB | Remicade | Remsima | cA2 | infliximab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0209368","Mycophenolate Mofetil","C1468","The morpholinoethyl ester of mycophenolic acid (MPA) with potent immunosuppressive properties.  Mycophenolate stops T-cell and B-cell proliferation through selective inhibition of the de novo pathway of purine biosynthesis.  In vivo, the active metabolite, MPA, reversibly inhibits inosine 5'-monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of guanine nucleotides.  MPA displays high lymphocyte specificity and cytotoxicity due to the higher dependence of activated lymphocytes on both salvage and de novo synthesis of guanine nucleotides relative to other cell types. (NCI04)","Mycophenolate Mofetil | CellCept | Cellcept | MMF | MYCOPHENOLATE MOFETIL | Mycophenolate mofetil | mycophenolate mofetil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0065767","Calcipotriene","C28900","A synthetic vitamin D derivative usually formulated for topical dermatological use, antipsoriatic Calcipotriene (calcipotriol) competes equally with active 1,25-hydroxy-2D3 (the natural form of vitamin D) for 1,25-hydroxy-2D3 receptors in regulating cell proliferation and differentiation. It induces differentiation and suppresses proliferation of keratinocytes, reversing abnormal keratinocyte changes in psoriasis, and leads to normalization of epidermal growth. (NCI04)","Calcipotriene | CALCIPOTRIENE | Calcipotriol | Dovonex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162638","Apoptosis","C17557","A form of programmed cell death that begins when a cell receives internal or external signals, then proceeds through a series of characteristic stages typically including rounding-up of the cell, retraction of pseudopods, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), and plasma membrane blebbing, and ends with the death of the cell.","Apoptosis | APOPTOSIS | Apoptotic Process | PCD | Programmed Cell Death | apoptosis | programmed cell death",,,,,,,,,,,,,,,"4048757","Apoptosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1521168","Chromosome 2 Short Arm","C13547","Proximal (short) arm of chromosome 2","2p | Chromosome 2 Proximal Arm | Chromosome 2 Short Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001483","Adenoviridae","C14179","A group of DNA containing viruses which infect mammals and are capable of causing respiratory disease, including one form of the common cold.","Adenoviridae | ADENOVIRIDAE | ADV | Adenovirus | Adenovirus | adenovirus",,,,,,,,,,,,,,,"4172988","Adenoviridae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004611","Bacteria","C14187","Unicellular, prokaryotic organisms that reproduce by cell division and usually have cell walls; can be shaped like spheres, rods or spirals and can be found in virtually any environment.","Bacteria | BACTERIA | Bacteria, Eubacteria | Bacterium | Eubacteria | bacteria",,,,,,,,,,,,,,,"4249833","Domain Bacteria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010414","Cryptococcosis","C2967","An acute or chronic, localized or disseminated infection by Cryptococcus neoformans.  Sites of involvement include the lungs, central nervous system and meninges, skin, and visceral organs.--2004","Cryptococcosis | ",,,,,,,,,,,,,,,"440035","Cryptococcosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014383","Enterovirus","C14203","A (+) strand single strand RNA virus of the picornavirus family.  Poliovirus is an enterovirus.","Enterovirus | ENTEROVIRUS",,,,,,,,,,,,,,,"4086097","Genus Enterovirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014644","Epstein-Barr Virus","C14204","A species of Herpetoviridae that is responsible for infectious mononucleosis (glandular fever). Discovered in 1964, this virus has been associated with Burkitt's lymphoma in South African children and with nasopharyngeal carcinoma in Asian populations.","Epstein-Barr Virus | EBV | EPSTEIN-BARR VIRUS | Epstein Barr Virus | Epstein-Barr virus | HHV-4 | HUMAN HERPESVIRUS 4 | Human Gammaherpesvirus 4 | Human Herpesvirus 4 | Lymphocryptovirus | Virus-Epstein-Barr",,,,,,,,,,,,,,,"4221378","Human herpesvirus 4",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014834","Escherichia coli","C14206","A common, gram negative gut bacterium that has been studied intensively by geneticists because of its small genome size, normal lack of pathogenicity, and ease of growth in the laboratory.","Escherichia coli | E. coli | ESCHERICHIA COLI",,,,,,,,,,,,,,,"4011683","Escherichia coli",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0079488","Helicobacter pylori","C14289","Bacteria that cause stomach inflammation (gastritis) and ulcers in the stomach. This bacteria is the most common cause of ulcers worldwide. It is often referred to as H. pylori. H. pylori infection is usually acquired from contaminated food and water and through person to person spread. The infection is common in crowded living conditions with poor sanitation. In countries with poor sanitation, 90% of the adult population can be infected. In the U.S., 30% of the adult population is infected. One out of six patients with H. pylori infection develops ulcers of the duodenum or the stomach. This bacteria is also believed to be associated with stomach cancer and a rare type of lymph gland tumor called gastric MALT lymphoma. Infected persons usually carry the infection indefinitely, unless treated with medications to eradicate the bacteria. (MedicineNet.com)","Helicobacter pylori | Campylobacter pylori | H. pylori | HELICOBACTER PYLORI",,,,,,,,,,,,,,,"4216359","Helicobacter pylori",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019159","Hepatitis A Infection","C3096","Acute inflammation of the liver caused by the hepatitis A virus. It is highly contagious and usually contracted through close contact with an infected individual or their feces, contaminated food or water.","Hepatitis A Infection | Acute Hepatitis A | Hepatitis A | Hepatitis A",,,,,,,,,,,,,,,"4223947","Viral hepatitis, type A",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019169","Hepatitis B Virus","C14215","Hepatitis B Virus (HBV) is the prototype of the Hepadnavirus Family.  Included in the family are the Woodchuck Hepatitis Virus (WHV) and the Duck Hepatitis B Virus (DHBV) which provide animal models of infection.  The HBV genome is a partially double stranded circular DNA.  A viral reverse transcriptase is bound to the 5' extremity of the long strand.","Hepatitis B Virus | HBV | HEPATITIS B VIRUS | Virus-Hepatitis B | hepatitis B virus",,,,,,,,,,,,,,,"4217475","Hepatitis B virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019196","Hepatitis C Infection","C3098","A viral infection caused by the hepatitis C virus.","Hepatitis C Infection | HCV Infection | Hepatitis C | Hepatitis C | Hepatitis C Virus Infection | NANBH | Non-A, Non-B Hepatitis | hepatitis C",,,,,,,,,,,,,,,"197494","Viral hepatitis C",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3806111","Hepatitis","C3095","Inflammation of the liver; usually from a viral infection, but sometimes from toxic agents.","Hepatitis | Hepatitis, NOS | Inflammatory liver disease, unspecified | hepatitis",,,,,,,,,,,,,,,"194990","Inflammatory disease of liver",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022727","Klebsiella","C28165","A genus of Gram-negative, non-motile, rod-shaped bacteria that have a polysaccharide-based capsule and are oxidase negative. Klebsiella spp. are frequent human pathogens.","Klebsiella | KLEBSIELLA",,,,,,,,,,,,,,,"4327473","Klebsiella",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030358","Papillomavirus","C14251","A genus of viruses (family Papovaviridae) containing DNA, having virions about 55 nm in diameter, and including the papilloma and warts viruses of man and other animals, some of which are associated with inductions of carcinoma.","Papillomavirus | Papilloma Virus | Virus-Papilloma",,,,,,,,,,,,,,,"4087740","Genus Papillomavirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032556","Polyomavirus","C14260","A genus of double-stranded DNA viruses. The viral particles are not enveloped and are icosahedral in structure.","Polyomavirus | POLYOMAVIRUS | Polyoma",,,,,,,,,,,,,,,"4251450","Genus Polyomavirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206545","Human Respiratory Syncytial Virus","C14267","A negative-sense, enveloped RNA virus. The virion is variable in shape and size with an average diameter of between 120 and 300 nm.","Human Respiratory Syncytial Virus | HUMAN RESPIRATORY SYNCYTIAL VIRUS | Human RSV | RSV | Respiratory Syncytial Virus | hRSV | respiratory syncytial virus",,,,,,,,,,,,,,,"4274000","Human respiratory syncytial virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043393","Yeast","C14286","Various single-celled members of the fungal families, ascomycetes, basidiomycetes and imperfect fungi that tend to be unicellular for the greater part of their life cycle.","Yeast | YEAST",,,,,,,,,,,,,,,"4132477|4265186","Yeast|Yeast",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0206076","Reproductive History","C17655","An account of all reproductive events and problems a person has experienced. An important aggregate factor in epidemiological studies of women's health.  The concept usually includes the number and timing of pregnancies and their outcomes, the incidence of breast feeding, and may include age of menarche and menopause, regularity of menstruation, fertility, gynecological or obstetric problems, or contraceptive usage.","Reproductive History | Reproductive Factors | Reproductive Issues",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511487","Constitutional","C37931","Existing as an essential characteristic.","Constitutional | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519604","Transfusion History","C30142","An account of all experiences related to the receipt of blood, WBC, platelets, and/or other blood components.","Transfusion History | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1378128","Cream Dosage Form","C28944","A semi-solid composed of an emulsion of lipids, hydrocarbons, waxes, or polyols in water.","Cream Dosage Form | CREAM | Cream | Cream Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0544341","Lotion Dosage Form","C29167","A semi-solid composed of an oil in water emulsion, with lower viscosity than cream or gel.","Lotion Dosage Form | LOTION | Lotion | Lotion Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282245","Northern Mariana Islands","C17882","A country in the Pacific, comprising islands in the North Pacific Ocean, about three-quarters of the way from Hawaii to the Philippines, north of Guam.","Northern Mariana Islands | 580 | MNP | MP | NORTHERN MARIANA ISLANDS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018309","Guam","C16652","An island in the North Pacific Ocean, about three-quarters of the way from Hawaii to the Philippines, south of the Northern Mariana Islands.","Guam | 316 | GU | GUAM | GUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0694643","Transdermal","C28017","Referring to the application of medication through the skin.","Transdermal | transdermal",,,,,,,,,,,,,,,"42539752","Transdermal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1578559","Buccal Mucosa","C12505","The mucosal membranes located on the inside of the cheek, in the buccal cavity.","Buccal Mucosa | BUCCAL MUCOSA | Buccal mucosa | Cheek mucosa | MUCOSA, BUCCAL | buccal mucosa",,,,,,,,,,,,,"UBERON:0006956","buccal mucosa","4057160","Buccal mucosa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0226901","Hard Palate","C12230","The bony anterior part of the roof of the mouth separating the nose from the mouth.","Hard Palate | HARD PALATE | Hard palate | Hard palate structure (body structure) | PALATE, HARD | hard palate | palatum durum",,,,,,,,,,,,,"UBERON:0003216","hard palate","4234542","Hard palate structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030219","Soft Palate","C12231","The muscular extension of the hard palate which comprises the posterior of the oral cavity and the floor of the nasal cavity.","Soft Palate | PALATE, SOFT | SOFT PALATE | Soft palate structure (body structure) | Soft palate, NOS | soft palate",,,,,,,,,,,,,,,"4177005","Soft palate structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027423","Nasal Cavity","C12424","The proximal portion of the respiratory passages on either side of the nasal septum lying between the floor of the cranium and the roof of the mouth and extending from the face to the pharynx. The nasal cavity is lined with ciliated mucosa, extending from the nares to the pharynx.","Nasal Cavity | BODY CAVITY, NASAL | NASAL CAVITY | Nasal Fossa | Nasal cavity | Nasal cavity structure (body structure) | cavity of nose | cavity of olfactory apparatus | nasal canal | nasal cavity | nasal conduit space | nasal fossa | olfactory chamber cavity",,,,,,,,,,,,,"UBERON:0001707","nasal cavity","4088327","Nasal cavity structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206694","Mucoepidermoid Carcinoma","C3772","A carcinoma morphologically characterized the presence of cuboidal mucous cells, goblet-like mucous cells, squamoid cells, cystic changes, and a fibrotic stromal formation. It can occur in several anatomic sites, including parotid gland, oral cavity, paranasal sinus, skin, breast, lung, larynx, and lacrimal ducts. It is classified as low or high grade.","Mucoepidermoid Carcinoma | MEC | Mucoepidermoid carcinoma | Mucoepidermoid tumor","8430/1|8430/3","Mucoepidermoid tumor|Mucoepidermoid carcinoma",,,,,,,,,,,,,"4253608","Mucoepidermoid carcinoma",,,,,,,,,,,,,"--","--|--",,,,,,,,"--"
"C0010606","Adenoid Cystic Carcinoma","C2970","A malignant tumor arising from the epithelial cells.  Microscopically, the neoplastic epithelial cells form cylindrical spatial configurations (cribriform or classic type of adenoid cystic carcinoma), cordlike structures (tubular type of adenoid cystic carcinoma), or solid structures (basaloid variant of adenoid cystic carcinoma).  Adenoid cystic carcinomas mostly occur in the salivary glands.  Other primary sites of involvement include the lacrimal gland, the larynx, and the lungs.  Adenoid cystic carcinomas spread along nerve sheaths, resulting in severe pain, and they tend to recur.  Lymph node metastases are unusual; hematogenous tumor spread is characteristic.","Adenoid Cystic Carcinoma | Adenocystic Carcinoma | Adenocystic carcinoma | Adenoid cystic carcinoma | Cylindroid Adenocarcinoma | adenoid cystic cancer","8200/3","Adenoid cystic carcinoma",,,,,,,,,,,,,"4022895","Adenoid cystic carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334392","Epithelial-Myoepithelial Carcinoma","C4199","A malignant neoplasm which occurs mostly in the major salivary glands (most frequently in the parotid gland), but also in the minor salivary glands of the oral mucosa and the tracheobronchial tree. It is characterized by the presence of ductal structures which are lined by an inner layer of cuboidal epithelial-type cells and an outer layer of myoepithelial cells with clear or eosinophilic cytoplasm.","Epithelial-Myoepithelial Carcinoma | Epithelial-myoepithelial carcinoma","8562/3","Epithelial-myoepithelial carcinoma",,,,,,,,,,,,,"4321002","Epithelial-myoepithelial carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0206703","Giant Cell Carcinoma","C3779","A malignant epithelial neoplasm composed of giant, pleomorphic cells.","Giant Cell Carcinoma | Carcinoma, Giant Cell | Giant cell carcinoma","8031/3","Giant cell carcinoma",,,,,,,,,,,,,"4175678","Giant cell carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1301194","Salivary Duct Carcinoma","C5904","An aggressive, high grade adenocarcinoma that arises from the salivary glands. It usually affects elderly males and presents as a rapidly enlarging mass. It metastasizes to regional lymph nodes and distant anatomic sites.","Salivary Duct Carcinoma | Carcinoma of Salivary Duct | Carcinoma of the Salivary Duct | High Grade Salivary Duct Carcinoma | SDC | Salivary duct carcinoma",,,,,,,,,,,,,,,"4287334","Salivary duct carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0398395","Neck Dissection","C15643","Surgery to remove lymph nodes and other tissues in the neck.","Neck Dissection | neck dissection",,,,,,,,,,,,,,,"4075296","Block dissection of cervical lymph nodes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040732","Transplantation","C15342","Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.","Transplantation | Grafting | Grafting Procedure | Surgery, Transplantation | Transplant | Transplant Procedure | Transplantation Surgery | transplantation",,,,,,,,,,,,,,,"4300185","Transplantation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017189","Gastrointestinal Tract","C34082","The upper gastrointestinal (GI) tract is comprised of mouth, pharynx, esophagus and stomach while the lower GI tract consists of intestines and anus. The primary function of the GI tract is to ingest, digest, absorb and ultimately excrete food stuff.","Gastrointestinal Tract | Alimentary Canal | Digestive Tract | GASTROINTESTINAL TRACT | Gastrointestinal tract, NOS | Gut | alimentary part of gastrointestinal system | digestive tract | digestive tube | enteric tract | gastrointestinal tract",,,,,,,,,,,,,"UBERON:0001555","digestive tract","4046957","Gastrointestinal tract structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015020","Amifostine","C488","The trihydrate form of a phosphorylated aminosulfhydryl compound. After dephosphorylation of amifostine by alkaline phosphatase to an active free sulfhydryl (thiol) metabolite, the thiol metabolite binds to and detoxifies cytotoxic platinum-containing metabolites of cisplatin and scavenges free radicals induced by cisplatin and ionizing radiation. The elevated activity of this agent in normal tissues results from both the relative abundance of alkaline phosphatase in normal tissues and the greater vascularity of normal tissues compared to tumor tissues.","Amifostine | 2-[(3-Aminopropyl)amino]ethanethiol Dihydrogen Phosphate Ester Trihydrate | AMIFOSTINE | APAETP | Amifostine Trihydrate | Aminopropylaminoethylthiophosphoric Acid Trihydrate | Cytofos | Ethiofos | Ethyol | Gammaphos | S-(N-(3-Aminopropyl)-2-aminoethyl)thiophosphoric Acid Trihydrate | S-2-(3-Aminopropylamino)ethylphosphorothioic Acid Trihydrate | WR 2721 | WR-2721 | WR2721 | YM-08310",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008059","Child","C16423","An age group comprised of individuals who are not yet an adult. The specific cut-off age will vary by purpose.","Child | CHILD | Children | Children (0-21)",,,,,,,,,,,,,,,"4285883","Child",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026933","Mycophenolic Acid","C673","An antineoplastic antibiotic derived from various Penicillium fungal species.  Mycophenolic acid is an active metabolite of the prodrug mycophenolate mofetil.  Mycophenolic acid inhibits inosine monophosphate dehydrogenase (IMPDH), preventing the formation of guanosine monophosphate and synthesis of lymphocyte DNA that results in inhibition of lymphocyte proliferation, antibody production, cellular adhesion, and migration of T and B lymphocytes.  Mycophenolic acid also has antibacterial, antifungal, and antiviral activities. (NCI04)","Mycophenolic Acid | 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (E)- | 4-Hexenoic acid, 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-, (E)- | Acide mycophenolique | Acido micofenolico | Acidum mycophenolicum | Lilly-68618 | Ly 68618 | MPA | MYCOPHENOLIC ACID | Myfortic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039736","Thalidomide","C870","A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.  Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons.  This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis.  In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis.","Thalidomide | (+)-Thalidomide | (-)-Thalidomide | .alpha.-Phthalimidoglutarimide | 2, 6-Dioxo-3-phthalimidopiperidine | 2,6-Dioxo-3-phthalimidopiperidine | 2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione | 3-Phthalimidoglutarimide | Alpha-Phthalimidoglutarimide | Contergan | Distaval | Kevadon | N-(2,6-Dioxo-3-piperidyl)phthalimide | N-Phthaloylglutamimide | N-Phthalylglutamic Acid Imide | N-Phthalylglutamic acid imide | Neurosedyn | Pantosediv | Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (+)- | Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (-)- | Sedalis | Sedoval K-17 | Sedoval K17 | Softenon | Synovir | THALIDOMIDE | Talimol | Thalomid | thalidomide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL317974","Intestinal","C25266","Of, or related to, or referring to the intestines.","Intestinal | intestinal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334660","Intravascular Large B-Cell Lymphoma","C4342","A rare extranodal B-cell non-Hodgkin lymphoma, characterized by the presence of lymphoma cells exclusively in the lumina of small vessels, particularly capillaries.  This is an extremely aggressive lymphoma which responds poorly to chemotherapy.  (WHO, 2001)","Intravascular Large B-Cell Lymphoma | Angiotropic Large Cell Lymphoma | Angiotropic Lymphoma | Angiotropic lymphoma | IVLBCL | Intravascular B-Cell Lymphoma | Intravascular B-cell lymphoma | Intravascular large B-cell lymphoma | Malignant Angioendotheliomatosis","9712/3","Intravascular large B-cell lymphoma",,,,,,,,,,,,,"4161153|608282","Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1292777","Aggressive NK-Cell Leukemia","C8647","A rare, highly aggressive, Epstein-Barr virus-associated leukemia, also known as aggressive NK-cell leukemia/lymphoma; it may represent the leukemic counterpart of nasal type extranodal NK/T-cell lymphomas. It affects primarily teenagers and young adults. It is characterized by the systemic proliferation of NK cells in the peripheral blood, bone marrow, liver, and spleen.","Aggressive NK-Cell Leukemia | Aggressive NK-Cell Leukemia/Lymphoma | Aggressive NK-cell leukaemia | NK Cell Leukemia | NK-Cell Leukemia | Natural Killer Cell Leukemia","9948/3","Aggressive NK-cell leukemia",,,,,,,,,,,,,"4029664","Aggressive NK-cell leukemia",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0677960","T-Cell Depletion Therapy","C15699","Treatment to destroy T cells, which play an important role in the immune response. Elimination of T cells from a bone marrow graft or peripheral blood stem cell graft from a donor may reduce the chance of an immune reaction against the recipient's tissues.","T-Cell Depletion Therapy | T-Cell Depletion | T-Cell Depletion | T-Lymphocyte Depletion Therapy | T-cell depletion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010405","Cryopreservation","C16475","Preservation of cells, tissues, organs, or embryos by storage at low temperatures.","Cryopreservation | Cryopreserved | Storage, Cryopreservation | cryopreservation",,,,,,,,,,,,,,,"4338536","Cryopreservation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0521026","Viral","C27985","Having to do with a virus.","Viral | viral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0442143","Paratracheal","C25317","Regions near to the trachea.","Paratracheal | ",,,,,,,,,,,,,,,"4139328","Paratracheal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1521735","Pectoral","C25611","Of or pertaining to the chest.","Pectoral | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522718","Mediastinal","C25310","Related to the mediastinum.","Mediastinal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL053209","Hilar","C25724","Refers to the area associated with the hilum.","Hilar | HILAR | hilar",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448666","Mesenteric","C25226","Of, or relating to, or located in a mesentery.","Mesenteric | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL318004","Retroperitoneal","C28256","Occurring in, or located in the retroperitoneum.","Retroperitoneal | retroperitoneal",,,,,,,,,,,,,,,"4125707","Retroperitoneal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3163632","Cranial","C37936","Of or relating to the cranium.","Cranial | CRANIAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0855095","Small Lymphocytic Lymphoma","C7540","A non-Hodgkin lymphoma composed of monomorphic small, round B-lymphocytes in the lymph nodes.  When the lymphoid process predominantly involves the bone marrow and the peripheral blood it is called chronic lymphocytic leukemia. (WHO, 2001)","Small Lymphocytic Lymphoma | B-Cell Small Lymphocytic Lymphoma | Diffuse Well Differentiated Lymphocytic Lymphoma | LYMPHOMA, SMALL LYMPHOCYTIC, MALIGNANT | Lymphoma, Lymphocytic, Malignant | SLL | Small B-Cell Lymphocytic Lymphoma | Small cell B-cell lymphoma, unspecified site | Small lymphocytic lymphoma, NOS | small lymphocytic lymphoma | well-differentiated lymphocytic lymphoma",,,,,,,,,,,,,,,"4119130","Malignant lymphoma - small lymphocytic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006413","Burkitt Lymphoma","C2912","A highly aggressive lymphoma composed of monomorphic medium-sized B-cells with basophilic cytoplasm and numerous mitotic figures.  It is often associated with the presence of Epstein-Barr virus (EBV) and is commonly seen in AIDS patients.  Three morphologic variants are recognized: classical Burkitt lymphoma, Burkitt lymphoma with plasmacytoid differentiation, and atypical Burkitt/Burkitt-like lymphoma.  All cases express the MYC translocation [t(8;14)]. (WHO, 2001)","Burkitt Lymphoma | Burkitt lymphoma, unspecified site | Burkitt's Lymphoma | Burkitt's Lymphoma | Burkitt's lymphoma | NHL, Burkitt lymphoma (BL) | Small Non-Cleaved Cell Lymphoma, Burkitt's Type","9687/3","Burkitt lymphoma, NOS",,,,,,,,,,,,,"4041800|4300163","Burkitt's lymphoma (clinical)|Burkitt lymphoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0023493","Adult T-Cell Leukemia/Lymphoma","C3184","A peripheral (mature) T-cell neoplasm linked to the human T-cell leukemia virus type 1 (HTLV-1).  Adult T-cell leukemia/lymphoma is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa.","Adult T-Cell Leukemia/Lymphoma | ATLL | Adult T Cell Lymphoma/Leukemia | Adult T-Cell Lymphoma/Leukemia | Adult T-Cell Lymphoma/Leukemia | Adult T-cell leukemia/lymphoma | Adult T-cell lymphoma/leukemia | HTLV-1 Associated Adult T-Cell Lymphoma/Leukemia | HTLV-I Associated Adult T-Cell Leukemia/Lymphoma | adult T-cell leukemia/lymphoma","9827/3","Adult T-cell leukemia/lymphoma (HTLV-1 positive)",,,,,,,,,,,,,"4003188|4300174","Adult T-cell leukemia/lymphoma|Adult T-cell leukemia/lymphoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0023185","Learning","C19369","The act, process, or experience of gaining knowledge or skill.","Learning | ",,,,,,,,,,,,,,,"4289163","Learning",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003250","Monoclonal Antibody","C20401","An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","Monoclonal Antibody | MAb | MoAB | Monoclonal Antibodies | Monoclonal Antibody Therapy | monoclonal antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021084","Immunotoxin","C575","Agents comprised of various toxic molecules (Radioactive Isotopes and Bacterial or Plant Toxins) conjugated with specific immune substances (Immunoglobulins, Monoclonal Antibodies, and Antigens) that targets affected cells allowing incorporation of the toxin into the cells.","Immunotoxin | immunotoxin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024305","Non-Hodgkin Lymphoma","C3211","Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.","Non-Hodgkin Lymphoma | NHL | NHL, NOS | Non-Hodgkin lymphoma, NOS | Non-Hodgkin lymphoma, unspecified site | Non-Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma (NHL) | non-Hodgkin lymphoma","9591/3","Malignant lymphoma, non-Hodgkin, NOS",,,,,,,,,,,,,"4038838","Non-Hodgkin's lymphoma (clinical)",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0439859","Autologous","C28000","Taken from an individual's own tissues, cells, or DNA.","Autologous | autologous",,,,,,,,,,,,,,,"4112258","Autologous",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL317990","Nasal","C27958","In reference to the nose.","Nasal | NASAL | nasal",,,,,,,,,,,,,,,"42538088","Nasal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029087","Ophthalmology","C16939","A medical specialty concerned with the structure and function of the eye and the medical and surgical treatment of its defects and diseases.","Ophthalmology | OPHTHALMOLOGY | Ophthalmologic",,,,,,,,,,,,,,,"4190430","Ophthalmology",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033909","Psychology","C17027","The study of behavior and cognition.","Psychology | ",,,,,,,,,,,,,,,"36716227","Psychology",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033873","Psychiatry","C17026","The medical specialty that deals with the medical management of mental disorders.","Psychiatry | Psychiatric",,,,,,,,,,,,,,,"4215124","Psychiatry",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1442959","Nutrition","C28294","That which is consumed to fuel necessary life processes of an organism.","Nutrition | nutrition",,,,,,,,,,,,,,,"4298503","Nutrition",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1963221","ASPIRATION","C28245","A disorder characterized by inhalation of solids or liquids into the lungs.","Aspiration, CTCAE | Aspiration | Aspiration | Aspiration Adverse Event | Aspiration/Inhalation | Inhalation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522187","Dental Route of Administration","C38197","Administration of the drug to a tooth or teeth.","Dental Route of Administration | DENTAL | Dental | Dental Route of Drug Administration | Dental use",,,,,,,,,,,,,,,"4163765|42538084","Dental|Dental",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3536910","Cyclooxygenase Inhibitor","C1323","Any agent that inhibits prostaglandin G/H synthase (cyclooxygenase or COX), an enzyme that catalyzes the production of prostanoids, including prostaglandins, prostacyclin and thromboxane, from arachidonic acid. Cyclooxygenase inhibitors are a type of non-steroidal anti-inflammatory drug.","Cyclooxygenase Inhibitor | COX Inhibitor | COX inhibitor | Clyclooxygenases Inhibitor | Cyclooxygenase Inhibitor  | Prostaglandin G/H Synthase Inhibitor | cyclooxygenase inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043668","Doxercalciferol","C2645","A synthetic analog of vitamin D with potential antineoplastic activity. In the liver, doxercalciferol is converted to its biologically active vitamin D metabolites, which control the intestinal absorption of dietary calcium, the tubular reabsorption of calcium by the kidney and, in conjunction with parathyroid hormone (PTH), the mobilization of calcium from the skeleton. Through interaction with specific receptor proteins in target tissues, these vitamin D metabolites act directly on osteoblasts to stimulate skeletal growth, and on the parathyroid glands to suppress PTH synthesis and secretion. This agent has also been shown to inhibit the growth of retinoblastomas, and may exhibit some antiproliferative activity against prostate cancer cells.","Doxercalciferol | (1alpha,3beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol | 1-Alpha-Hydroxyvitamin D2 | DOXERCALCIFEROL | Hectorol | doxercalciferol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227411","Anal Canal","C12375","The terminal section of the alimentary canal, which extends from the anorectal junction and ends at the anal opening.","Anal Canal | ANAL CANAL | Anal canal | Anal canal structure (body structure) | Functional Anal Canal | Surgical Anal Canal | anal canal",,,,,,,,,,,,,,,"4145453","Anal canal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004388","Autonomic Nervous System","C12673","The part of the nervous system of vertebrates that controls involuntary actions of the smooth muscles and heart and glands.","Autonomic Nervous System | ANS | Autonomic | Autonomic nervous system, NOS | autonomic division of peripheral nervous system | autonomic nervous system | autonomic part of peripheral nervous system | divisio autonomica systematis nervosi peripherici | involuntary nervous system | pars autonomica systematis nervosi peripherici | peripheral autonomic nervous system | visceral nervous system",,,,,,,,,,,,,"UBERON:0002410","autonomic nervous system","4218275","Autonomic nervous system structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005400","Bile Duct","C12376","Any of the ducts conveying bile between the liver and the intestine, including hepatic, cystic, and common bile duct.","Bile Duct | BILE DUCT | DUCT, BILE | bile duct","C24.0|C24.0","Bile duct, NOS|Biliary duct, NOS",,,,,,,,,,,"UBERON:0002394","bile duct","4154158","Bile duct structure",,,,,,,,,,,,,"--","--|--",,,,,,,,"--"
"C0006121","Brain Stem","C12441","Three sections, the midbrain, pons and medulla oblongata, that are located at the base of the brain. The brain stem regulates the central nervous system, and is vital as a conduit for motor and sensory innervations.","Brain Stem | BRAIN STEM | BRAIN, BRAIN STEM | Brain stem | Brain, Brain stem | Brainstem | Brainstem structure (body structure) | brain stem | brainstem | truncus encephali",,,,,,,,,,,,,"UBERON:0002298","brainstem","4049603","Brainstem structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006270","Bronchiole","C12684","The smallest subdivisions of the bronchial tree, which are both acartilagenous and aglandular.","Bronchiole | BRONCHIOLE | Bronchioles | Bronchiolus | bronchiole | lobular bronchiole",,,,,,,,,,,,,"UBERON:0002186","bronchiole","4205284","Bronchiole structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007874","Cervix Uteri","C12311","The lower part of the uterus occupying the region between the isthmus of the uterus and the vagina. It is divided into supravaginal and vaginal portions.","Cervix Uteri | CERVIX | CERVIX UTERI | Cervix | Cervix uteri | Cervix uteri structure (body structure) | Genital System, Female, Cervix | Uterine Cervix | Uterus, Cervix | canalis cervicis uteri | caudal segment of uterus | cervical canal of uterus | cervix | cervix uteri | neck of uterus | uterine cervix",,,,,,,,,,,,,"UBERON:0000002","uterine cervix","4325271","Cervix uteri structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009780","Connective Tissue","C12374","The supporting or framework tissue of the animal body, formed of fibrous and ground substance with more or less numerous cells of various kinds; it is derived from the mesenchyme, and this in turn from the mesoderm; the varieties of connective tissue are: areolar or loose; adipose; dense, regular or irregular, white fibrous; elastic; mucous; and lymphoid tissue; cartilage; and bone; the blood and lymph may be regarded as connective tissues the ground substance of which is a liquid.","Connective Tissue | CONNECTIVE TISSUE | connective tissue | portion of connective tissue | textus connectivus",,,,,,,,,,,,,"UBERON:0002384","connective tissue","4057704|4071048","Connective tissue|Connective tissue structure",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0013443","Ear","C12394","A sense organ needed for the detection of sound and for establishing balance. The outer ear consists of the auricle, the ear canal as well as the tympanic membrane. The middle ear is made up of an air-filled cavity behind the tympanic membrane that contains the ossicles (malleus, incus and stapes). The inner ear is made up of the cochlea needed for hearing and the vestibular apparatus required for balance.","Ear | EAR | Ear structure (body structure) | ear",,,,,,,,,,,,,"UBERON:0001690","ear","4037611","Ear structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014133","Endocrine Gland","C12704","Ductless glands that secrete substances which are released directly into the circulation and which influence metabolism and other body functions.","Endocrine Gland | Endocrine Organs | Endocrine gland, NOS | ductless gland | endocrine gland | glandula endocrina",,,,,,,,,,,,,"UBERON:0002368","endocrine gland","4302834","Endocrine gland structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017129","Fundus of the Stomach","C12257","The portion of the stomach that lies above the cardiac notch. It allows for the accumulation of gases produced by chemical digestion.","Fundus of the Stomach | FUNDUS OF THE STOMACH | Fundus | Fundus Of Stomach | Fundus of Stomach | Fundus of stomach | STOMACH, FUNDUS | fundus gastricus (ventricularis) | fundus of stomach | gastric fundus | stomach fundus",,,,,,,,,,,,,"UBERON:0001160","fundus of stomach","4185453","Gastric fundus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020629","Hypopharynx","C12246","The lower part of the pharynx that connects to the esophagus.","Hypopharynx | HYPOPHARYNX | Hypopharyngeal structure (body structure) | Hypopharynx, NOS | Laryngopharynx | hypopharynx | laryngeal pharynx | laryngopharynx",,,,,,,,,,,,,"UBERON:0001051","hypopharynx","4218592","Hypopharyngeal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020962","Immune System","C12735","The complex group of organs like thymus, spleen, tonsils, lymphatic system, hematopoetic system and cells like lymphocytes, granulocytes, monocytes and macrophages that defends the body against infection or disease. It consists of a complex interrelated cellular, molecular and genetic component.","Immune System | allergic/immunologic body system | allergic/immunologic organ system | body system, allergic/immunologic | immune system | immunologic/allergic organ system | organ system, allergic/immunologic",,,,,,,,,,,,,,,"4021240","Structure of immune system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0229730","Supraclavicular Lymph Node","C12903","A lymph node which is located above the clavicle.","Supraclavicular Lymph Node | Lymph Node(s) Supraclavicular | SUPRACLAVICULAR LYMPH NODE | Structure of supraclavicular lymph node (body structure) | Supraclavicular Lymph Nodes | Supraclavicular Nodes | Supraclavicular lymph nodes | nodus lymphaticus supraclavicularis axillae | supraclavicular lymph node | supraclavicular node",,,,,,,,,,,,,"UBERON:0035279","supraclavicular lymph node","4297981","Structure of supraclavicular lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027442","Nasopharynx","C12423","The part of the pharynx in the back of the throat, at and above the soft palate. The nasopharynx is continuous with the nasal passages.","Nasopharynx | NASOPHARYNX | Nasopharyngeal structure (body structure) | Nasopharynx, NOS | nasal part of pharynx | nasopharynx | rhinopharynx",,,,,,,,,,,,,"UBERON:0001728","nasopharynx","4216712","Nasopharyngeal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032005","Pituitary Gland","C12399","Pea-sized endocrine gland located at the base of the brain in the pituitary fossa. It produces and secretes hormones such as oxytocin and vasopressin, to regulate the activities of the hypothalamus.","Pituitary Gland | GLAND, PITUITARY | Hypophysis | Hypophysis Cerebri | Nervous System, Pituitary | PITUITARY GLAND | Pituitary | Pituitary gland | Pituitary structure (body structure) | glandula pituitaria | pituitary | pituitary body | pituitary gland",,,,,,,,,,,,,"UBERON:0000007","pituitary gland","4209428","Pituitary structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0311400","Metabolic","C28240","Having to do with metabolism.","Metabolic | metabolic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024202","Lymph","C13252","A clear, transparent, sometimes faintly yellow and slightly opalescent fluid that is collected from the tissues throughout the body, flows in the lymphatic vessels (through the lymph nodes), and is eventually added to the venous blood circulation. Lymph consists of a clear liquid portion, varying numbers of white blood cells (chiefly lymphocytes), and a few red blood cells.","Lymph | LYMPH | Reticuloendothelial System, Lymph | lymph | lymphatic fluid",,,,,,,,,,,,,,,"4242236","Lymph",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1452531","Tyrosine-Protein Kinase Yes, Human","C18556","Tyrosine-protein kinase Yes (543 aa, ~61 kDa) is encoded by the human YES1 gene. This protein plays a role in both receptor tyrosine kinase-mediated signaling and tyrosine phosphorylation.","Tyrosine-Protein Kinase Yes | EC 2.7.10.2 | Proto-Oncogene c-Yes | YES1 | YES1 Protein Tyrosine Kinase | c-yes Kinase | p61-YES | p61-YES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1558270","CTCAE Grade 4 Artery-hepatic intra-operative injury","C58931","testing tonight","Grade 4 Hepatic Artery Intra-Operative Injury, CTCAE | CTCAE Grade 4 Artery-hepatic intra-operative injury | CTCAE Grade 4 Hepatic Artery Intra-Operative Injury | Grade 4 Artery-hepatic intra-operative injury | Tests for Meningitis (fungal)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919524","ATM Gene","C18583","This gene is involved in apoptosis, DNA repair and cell cycle regulation.","ATM Gene | ATM | ATM Serine/Threonine Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332015","ADAM11 Gene","C20792","This gene plays a role in cell-cell and cell-matrix interactions.","ADAM11 Gene | A Disintegrin and Metalloproteinase Domain 11 Gene | ADAM11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332034","AGR2 Gene","C20755","This gene is involved in differentiation. It also plays a putative role in tumor metastasis.","AGR2 Gene | AGR2 | Anterior Gradient 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0237400","Actual","C25274","Existing in fact; real.","Actual | ACTUAL | Real",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1524062","Additional","C25406","Added; extra; further.","Additional | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205117","Adjacent","C25408","Next to or adjoining.","Adjacent | ",,,,,,,,,,,,,,,"4077456","Juxta-posed",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1523987","Alternative","C25415","Available in place of something else.","Alternative | Alternate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332194","Anterolateral","C25422","Denoting the area of the body in front and away from the middle line.","Anterolateral | ANTEROLATERAL",,,,,,,,,,,,,,,"4289848","Anterolateral",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003297","Antiemetic Agent","C267","A pharmacological agent that prevents nausea and/or vomiting.","Antiemetic Agent | Anti-emetic Agent | Antiemetic Drugs | Antiemetics | antiemetic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205111","Apical","C25423","Relating to or located at the tip (an apex).","Apical | APICAL",,,,,,,,,,,,,,,"4184475","Apical",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205182","Atypical","C25428","Varying from the norm; not conformable to the type.","Atypical | ",,,,,,,,,,,,,,,"4011080","Atypical",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0596155","Basal Cell","C12475","A cuboidal or low columnar cell in the deepest epidermal layer, stratum basale (stratum germinativum), adjacent to the basal lamina.","Skin Basal Cell | Basal Cell | Basal Cells | basal cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004827","Basophil","C12531","A type of granular leukocyte with granules that are easily stained by basic stains.","Basophil | Basophilic Granulocyte | Basophilic Leukocyte | Basophils | basophil",,,,,,,,,,,,,,,"4107371","Basophil",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004891","BCR/ABL1 Fusion Protein","C16325","A fusion protein encoded by the BCR/ABL1 fusion gene. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein.","BCR/ABL1 Fusion Protein | BCR ABL Fusion Protein | BCR-ABL Oncoprotein | BCR-ABL Oncoprotein | BCR-ABL Protein Tyrosine Kinase | BCR-ABL fusion protein | BCR-ABL1 Fusion Protein | BCR/ABL | BCR/ABL Chimeric Protein | BCR/ABL Fusion Protein | BCR/ABL Oncoprotein | BCR::ABL1 Fusion Protein | Breakpoint Cluster Region/Tyrosine-Protein Kinase ABL1 Fusion Protein | Breakpoint Cluster Region::Tyrosine-Protein Kinase ABL1 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448548","Begin","C25431","Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins.","Begin | Start",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522427","best (quality)","C25432","Having the most positive qualities.","Best | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511117","Bimanual","C25433","Relating to, or performed by, both hands.","Bimanual | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600137","Blood Urea Nitrogen","C1753","The most prevalent of nonprotein nitrogenous compounds circulating in the blood used as an indicator of liver and kidney function.","Blood Urea | BUN | Blood Urea Nitrogen | blood urea nitrogen | urea nitrogen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006610","CA-125 Antigen","C325","An antigen expressed by tissues derived from mullerian epithelium (tubal, endometrial and endocervical) or celomic epithelium (mesothelial cells of the pleura, pericardium and peritoneum).  Although its biochemical nature has not been clearly defined, CA125 has been described as a glycosylated, high-molecular-weight protein that may be released from damaged cells.  Measurable in plasma, CA125 is a sensitive, nonspecific tumor marker for ovarian cancer; as such it is much more useful for monitoring clinical responses to the treatment of ovarian cancer than for the diagnosis of ovarian cancer.  Elevated plasma CA125 may occur in association with other malignancies and non-malignant gynecologic disorders. (NCI04)","CA-125 Antigen | CA-125 | CA125 | Cancer Antigen 125 | Carbohydrate Antigen 125 | cancer antigen 125",,,,,,,,,,,,,,,"4012704","Cancer antigen 125",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006613","CA19-9 Antigen","C327","CA 19-9 is a fucosylated glycosphingolipid carbohydrate antigen that is soluble and is adsorbed to erythrocytes and to many adenocarcinomas of the digestive tract, especially pancreatic tumors. By structure CA 19-9 is related to the Lewis blood group antigens.","CA19-9 Antigen | CA-19-9 | CA19-9 | Cancer Antigen 19-9 | Carbohydrate Antigen 19-9 | SIALYL LEWIS A | SLeA | Sialyl Le(a) Antigen | Sialyl LeA | Sialyl LewisA | Sialyl-Lewis A | Sialylated Lewis (a) Antigen | Sialylated Lewis a Antigen",,,,,,,,,,,,,,,"4011160","Cancer antigen 19-9",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0175895","Calcified","C25441","Having calcium deposited on or in an anatomic structure.","Calcified | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054551","cyclophosphamide/doxorubicin/methotrexate protocol","C9535","No definition exists.","Cyclophosphamide/Doxorubicin/Methotrexate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007226","Cardiovascular System","C12686","Relating to the heart and the blood vessels or the circulation.","Cardiovascular System | Body System, Cardiovascular | CARDIOVASCULAR SYSTEM | Cardiovascular | Cardiovascular Body System | Cardiovascular Organ System | Circulatory System | Organ System, Cardiovascular | Vascular, Heart | circulatory system",,,,,,,,,,,,,,,"4014241","Structure of cardiovascular system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007082","Carcinoembryonic Antigen","C25159","A cancer-specific antigen associated with both tumors and the developing fetus. The main use of this antigen is as a tumor marker, especially with respect to intestinal cancers. Production of the antigen ceases shortly before birth, but may reappear in people who develop certain types of cancer.","Carcinoembryonic Antigen | CEA | CEA Family Protein | Carcinoembryonic Antigen Family Protein | carcinoembryonic antigen",,,,,,,,,,,,,,,"4284823","Carcinoembryonic antigen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205099","Center","C25445","A point or area that is approximately central within some larger region or structure.","Center | CENTRAL | Central | Central (qualifier value)",,,,,,,,,,,,,,,"4095408","Central",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008209","Chloride Ion","C1741","A chlorine anion that forms the negatively charged part of certain salts, including sodium and hydrogen chloride salts, and is an essential electrolyte located in all body fluids responsible for maintaining acid/base balance, transmitting nerve impulses and regulating fluid in and out of cells.","Chloride Ion | CHLORIDE ION | Chloride | Chlorine- | Cl-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205191","Chronic","C14141","Usually used to describe a condition that is persistent and long standing.","Chronic | CHRONIC | chronic",,,,,,,,,,,,,,,"4236661","Chronic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516626","Clinical/Radiologic","C25448","Something observed through clinical or radiologic examination.","Clinical/Radiologic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522666","Closest","C25449","Indicating the one of several that is the shortest distance away.","Closest | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205195","Combined","C25454","Made or joined or united into one or involving the joint activity of two or more.","Combined | ",,,,,,,,,,,,,,,"4232463","Combined",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522701","Complicating","C25455","Making more complex or intricate.","Complicating | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521115","Concurrent","C25456","Occurring or operating at the same time.","Concurrent | COINCIDENT | Co-occur | Co-occurrence | Coincident | Concurrency | Simultaneous",,,,,,,,,,,,,,,"4284984","Concurrent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0742742","Congestive","C25459","Relating to or affected by an abnormal collection of blood or other fluid.","Congestive | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441988","Contralateral","C25307","On or relating to the opposite side of the body.","Contralateral | CONTRALATERAL | contralateral",,,,,,,,,,,,,,,"4112107","Contralateral",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0700114","Coordination","C25462","The act of bringing into common action, movement, or condition.","Coordination | Coordinated | Coordinating | Coordinating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0444669","Core","C25327","The center of an object; indispensable","Core | Core (qualifier value)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522318","Coronary","C41072","Surrounding like a crown (especially of the blood vessels surrounding the heart).","Coronary | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511524","Correlative Study","C16100","A type of study that tests for a relationship between a condition and a potential causal factor of the condition.","Correlative Study | Correlative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010294","Creatinine","C399","The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.","Creatinine | CREATININE | creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0373595","Creatinine Clearance","C25747","The determination of the clearance of endogenous creatinine, used for evaluating the glomerular filtration rate.","Creatinine Clearance | CREATCLR",,,,,,,,,,,,,,,"4042762","Measurement of renal clearance of creatinine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1511545","Critical","C25467","Being in or verging on a state of crisis or emergency; urgently needed; absolutely necessary.","Critical | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516234","Cancer Therapy Evaluation Program","C15794","The program within the Division of Cancer Treatment and Diagnosis (DCTD) of the NCI which plans, assesses, and coordinates all aspects of clinical trials including extramural clinical research programs, internal resources, treatment methods and effectiveness, and compilation and exchange of data as it pertains to the development and evaluation of anticancer agents.","Cancer Therapy Evaluation Program | CTEP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511559","Cumulative","C25470","Increasing by successive addition.","Cumulative | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511636","cytotoxic","C37893","Having the ability to kill cells.","Cytotoxic | cytotoxic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511741","Declining","C25475","Becoming progressively lower, growing weaker, or going from better to worse.","Declining | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205125","Deep","C25240","Extending relatively far inward.","Deep | DEEP",,,,,,,,,,,,,,,"4196186","Deep",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221928","Dermal - anatomy qualifier","C25478","Of or relating to or located in the dermis.","Dermal | DERMAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011649","Dermoid Cyst","C9011","A mature teratoma characterized by the presence of a cyst which is lined by mature tissue resembling the epidermis and the epidermal appendages. It occurs in the ovary, testis, and extragonadal sites including central nervous system and skin.","Dermoid Cyst | Benign Cystic Teratoma | DERMOID CYST, BENIGN | Dermoid | Dermoid Tumor | Dermoid cyst, NOS | Mature Cystic Teratoma | Subcutaneous Cystic Teratoma | dermoid cyst","9084/0","Dermoid cyst, NOS",,,,,,,,,,,,,"40287650","Dermoid cyst",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0428883","Diastolic Blood Pressure","C25299","The minimum pressure exerted into the systemic arterial circulation during cardiac ventricular relaxation and filling.","Diastolic Blood Pressure | DIABP | Diastolic Pressure | Diastolic blood pressure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527180","Dominant","C25487","Exercising influence or control.","Dominant | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0849912","Emotional","C25495","Excessively affected by emotion.","Emotional | ",,,,,,,,,,,,,,,"4235387","Emotional",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516835","En Bloc","C25733","In a lump; as a whole; used to refer to autopsy techniques in which visceral organs are removed in large blocks allowing the prosector to retain a continuity in organ architecture during the subsequent dissection.","En Bloc | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227843","Endometrial","C13322","Relating to or composed of endometrium.","Endometrial | endometrial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014467","Eosinophil","C12532","Granular leukocytes with a nucleus that usually has two lobes connected by a slender thread of chromatin, and cytoplasm containing coarse, round granules that are uniform in size and stainable by eosin.","Eosinophil | Acidophilic Leukocyte | Blood Eosinophil | Eosinocyte | Eosinophilic Granulocyte | Eosinophilic Leukocyte | Eosinophils | eosinophil",,,,,,,,,,,,,,,"4032804","Eosinophil",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014762","Erythroblast","C12527","An immature, nucleated erythrocyte occupying the stage of erythropoiesis that follows formation of erythroid progenitor cells and precedes formation of reticulocytes.","Erythroblast | Erythroblasts | Nucleated Erythrocyte | Nucleated Erythrocytes | Nucleated RBC | Nucleated Red Blood Cell | Nucleated Red Blood Cells | Nucleated Red Cell | Nucleated Red Cells",,,,,,,,,,,,,,,"4223658","Erythroblast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516986","Evaluable Disease","C8503","A finding that refers to a disease that can be assessed by existing methods.","Evaluable Disease | Evaluable | evaluable disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517049","Extracapsular","C25502","Situated outside of a capsule, esp. outside the capsular ligament of a joint.","Extracapsular | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517060","Extramedullary","C25503","Outside of, or unrelated to, any medulla, especially the medulla oblongata.","Extramedullary | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517061","Extramural Activities","C18787","Research activities which take place off the NIH campus.","Extramural Activities | Extramural",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517067","Extranodal","C25504","Situated outside of a node.","Extranodal | extranodal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517078","Extraprostatic","C25505","Situated outside of the prostate.","Extraprostatic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448226","Final","C25508","Conclusive in a process or progression.","Final | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205435","First","C25509","Preceding all others in time or space or degree.","First | 1st | Initial",,,,,,,,,,,,,,,"4112230","First",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517198","Fissural","C25510","Relating to or resembling a fissure.","Fissural | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522662","sample fixation","C25219","The chemical preservation of a substance to maintain structural and/or molecular features of that substance as they exist in the living entity.","Fixation | FIXING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0059985","Fludarabine","C1094","A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  (NCI04)","Fludarabine | 2-Fluoro-9-beta-arabinofuranosyladenine | 2-Fluorovidarabine | 9-Beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine | 9-Beta-D-arabinofuranosyl-2-fluoroadenine | FLUDARABINE | Fluradosa | fludarabine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510483","Fine-Needle Aspiration","C15361","The removal of tissue or fluid with a thin needle for examination under a microscope.","Fine-Needle Aspiration | Aspirate, Fine Needle | FINE NEEDLE ASPIRATION | FNA | FNA biopsy | Fine Needle Aspiration | Fine Needle Biopsy | fine-needle aspiration biopsy",,,,,,,,,,,,,,,"4121742","Fine needle aspiration biopsy - action",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0376327","International Aspects","C17957","An indication that all or part of the research on a grant to a US institution is either conducted in a foreign country, uses foreign subjects or their tissues or medical data, or involves collaboration with foreign researchers.","Foreign Component | Foreign | Foreign Subpart | Foreign or Foreign Component | International Aspects",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517320","From","C25516","Used to indicate a specified place or time as a starting point; used to indicate a source, cause, agent, or instrument.","From | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443225","Full","C25517","Containing as much or as many as is possible or normal.","Full | ",,,,,,,,,,,,,,,"4129648","Full",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517331","Further","C25519","To or at a greater distance in time or space.","Further | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085155","Generic Drugs","C1312","A pharmaceutical product equivalent to the brand name drug in dosage, safety, strength, how it is taken, quality, performance, and intended use. The FDA bases evaluations of substitutability, or therapeutic equivalence of a generic drug on scientific evaluation. A generic drug product must contain the identical amounts of the same active ingredient(s) as the brand name product and is expected to have equal effect when substituted for the brand name product.","Generic Drug | Generic | generic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0314603","Genetic","C17938","Having to do with information that is passed from parents to offspring through genes in sperm and egg cells.","Genetic | genetic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017725","Glucose","C2831","A simple sugar monosaccharide having two isoforms, alpha and beta, with a chemical structure of C6H12O6 that acts as an energy source for both plants and animals by reacting with oxygen, generating carbon dioxide and water, and releasing energy.","Glucose | 6-(hydroxymethyl)oxane-2,3,4,5-tetrol | DEXTROSE, UNSPECIFIED FORM | glucose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439667","Granulomatous","C25302","Relating to or characterized by granulomas.","Granulomatous | ",,,,,,,,,,,,,,,"4115432","Granulomatous",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512272","Granulopenic","C25522","Relating to or resembling granulocytopenia.","Granulopenic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333850","Hairy Cell","C25288","An abnormal large leukocyte found in the blood in hairy cell leukemia; it has numerous irregular cytoplasmic villi that give it a flagellated or hairy appearance.","Hairy Cell | ",,,,,,,,,,,,,,,"4010903","Hairy cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0474824","Halo Nevus","C7602","A melanocytic nevus characterized by circumferential depigmentation. It is usually associated with a brisk lymphocytic infiltrate.","Halo Nevus | Halo nevus | Leukoderma Acquisitum Centrifugum | Perinevoid Leukoderma | Perinevoid Vitiligo | Sutton Nevus","8723/0","Halo nevus",,,,,,,,,,,,,"4134542|4302320","Halo nevus|Halo nevus",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0023821","High Density Lipoprotein","C25186","The smallest and densest lipoproteins, containing a high proportion of protein. They are synthesized in the liver as empty proteins and they pick up cholesterol and increase in size as they circulate through the bloodstream.  Because HDL can remove cholesterol from the arteries, and transport it back to the liver for excretion, they are seen as 'good' lipoproteins.","High Density Lipoprotein | HDL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229601","Hematopoietic","C13324","Pertaining to or related to the formation of blood cells.","Hematopoietic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3805433","Hematuria","C3090","Blood in the urine.","Hematuria | hematuria",,,,,,,,,,,,,,,"437038","Blood in urine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205462","Histologic","C25526","Pertaining to the combined microscopic physical features of cells and their surrounding extracellular environment in tissues.","Histologic | Histological",,,,,,,,,,,,,,,"4283982","Histologic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448463","Histologically","C25527","Involving the use of histology or histological techniques.","Histologically | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019764","HLA-DR Antigen","C16692","Encoded by multiple HLA-DRA and HLA-DRB genes in a complex variable 5 cM region of MHC between HLA-B and -D, HLA-DR Antigens are Class II histocompatibility transmembrane glycoprotein heterodimers of alpha (heavy, 35-kD) and beta (light, 27-kD) chains. Located predominantly on B cells and macrophages, HLA-DR antigens function in antigen presentation to regulatory T cells in the immune response and in self/nonself discrimination. Invariant alpha and polymorphic beta chains have glycosylated N-termini, hydrophobic membrane regions, and hydrophilic C-termini. The heterodimer consists of 4 extracellular domains; invariant alpha-1, polymorphic N-terminal beta-1, and conserved Ig-like alpha-2 and beta-2. Alpha-1 and alpha-2 contain disulfide loops. Beta-1 contains 2 small variable regions. Alpha sequences have relatively simple structure; beta chains carry the major polymorphic determinants.","HLA-DR Antigen | HLA-DR | Human Leukocyte Antigen - DR Isotype | Human Leukocyte Antigen-DR Isotype",,,,,,,,,,,,,,,"4265058","HLA-DR antigen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205126","Horizontal","C25241","Parallel to or in the plane of the horizon.","Horizontal | ",,,,,,,,,,,,,,,"4035763","Horizontal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020835","IgA","C565","IgA is the immunoglobulin subclass that is associated with antibody-mediated mucosal immunity.  It is secreted as dimers into the mucosa and is the most effective isotype at fixing complement by the alternative pathway, even though it lacks the ability to fix complement by the classical pathway. There are two subtypes in the human - IgA1 and IgA2.","IgA | Immunoglobulin A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020852","IgG","C568","An immunoglobulin isotype (subclass) that characterizes secondary immune responses.  This isotype is further broken down into several smaller subclasses (IgG1, IgG2a, IgG2b, IgG3 in the mouse; IgG1-4 in the human), and each subclass is differentially synthesized and secreted into the serum upon differential immune stimuli.","IgG | Immunoglobulin G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020861","IgM","C569","The major immunoglobulin secreted during a primary immune response.  IgM binds with low affinity but high avidity (multiple binding sites) because it not only occurs as monomers but also as pentamers and hexamers.","IgM | Immunoglobulin M",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205252","Immature","C25531","In an early period of life or development or growth.","Immature | IMMATURE | IMMATURITY",,,,,,,,,,,,,,,"4033751","Immature",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0542339","Inferior","C25353","In anatomy indicating lower than a given reference point.","Inferior | INFERIOR | Inferior (qualifier value)",,,,,,,,,,,,,,,"4134040","Inferior",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522154","Informed","C37896","Acquainted with knowledge of a subject.","Informed | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230108","Infraclavicular Region","C25268","The region below the clavicle.","Infraclavicular Region | Infraclavicular",,,,,,,,,,,,,,,"4066495","Infraclavicular region structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004048","Inspiration","C25735","Taking ambient air into the lungs; breathing in.","Inspiration | Inhalation | Inhaling | Inhaling | Inspired",,,,,,,,,,,,,,,"4033701","Inspiration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1555582","Initial (abbreviation)","C25536","The first letter of a word, especially the first letter of each word in a proper name.","Initials | Initial | Initial | initials",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021562","Inpatient","C25182","A patient who is residing in the hospital where he is being treated.","Inpatient | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519231","Self-Administered","C25670","Self given or applied.","Self-Administered | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519232","Seminal","C25671","Pertaining to or containing or consisting of semen.","Seminal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519246","Send (transmission)","C25672","Cause or enable to go or be conveyed or transmitted.","Send | Sent | Sent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376147","SGPT - Glutamate pyruvate transaminase","C25293","A family of pyridoxal phosphate-dependent enzymes involved in cellular nitrogen metabolism, amino acid metabolism, and liver gluconeogenesis. Alanine aminotransferase specifically and reversibly catalyzes the transfer of an amino group from L-alanine to alpha-ketoglutarate forming pyruvate and L-glutamate.","Alanine Aminotransferase | ALAT | ALT | Alanine Aminotransferase | Alanine Transaminase | EC 2.6.1.2 | SGPT | SGPT (ALT) | SGPT (ALT) | Serum Glutamate-Pyruvate Transaminase | Serum Glutamic-Pyruvic Transaminase | alanine transferase | serum glutamate pyruvate transaminase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1806781","Short","C25249","Having little (physical) length or seeming to be limited in (temporal) duration.","Short | SHORT | Shortest",,,,,,,,,,,,,,,"4279538","Short",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0700321","Small","C25376","Limited in number, quantity, magnitude or extent.","Small | SMALL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205555","Special","C25684","Surpassing what is common or usual or expected.","Special | ",,,,,,,,,,,,,,,"4194898","Special",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0442181","Subaortic","C25318","Below the aorta.","Subaortic | ",,,,,,,,,,,,,,,"4139466","Subaortic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1515009","Subcarinal","C25691","Below the carina.","Subcarinal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205124","Superficial","C25239","Of little substance or significance; involving only a surface.","Superficial | SUPERFICIAL | superficial",,,,,,,,,,,,,,,"4096030","Superficial",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL357421","Superior","C25235","In anatomy, indicating higher than a given reference point.","Superior | SUPERIOR | Superior (qualifier value)",,,,,,,,,,,,,,,"4138000","Superior",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0871470","Systolic Blood Pressure","C25298","The maximum pressure exerted into the systemic arterial circulation during the contraction of the left ventricle of the heart.","Systolic Blood Pressure | SYSBP | Systolic Pressure | Systolic blood pressure | systolic bp | systolic_bp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040715","Chromosomal Translocation","C3420","A genetic exchange where a piece of one chromosome is transferred to another chromosome.","Chromosomal Translocation | Chromosome Translocation | Translocation | Translocation NOS | Translocation, Chromosomal | Translocation, NOS | chromosomal translocation | chromosomal_translocation | t",,,,,,,,,,,,,,,"4049480","Chromosomal translocation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1521840","Target","C25702","An object fixed as a goal or point of examination; something to point at; a destination.","Target | Destination | Targeted | Targeting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205437","Third","C25260","Following the second position in an ordering or series; coming next after the second and just before the fourth in position.","Third | 3rd",,,,,,,,,,,,,,,"4324384","Third",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1515169","TNM Staging System","C25384","A system for clinicopathologic evaluation of tumors based on the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion), and lymph node involvement (N) and metastasis (M) each followed by a number starting at 0 for no evident metastasis; numbers used depend on the organ involved and influence the prognosis and choice of treatment.","TNM Staging System | AJCC staging system | TNM | TNM | TNM Staging | TNM staging system",,,,,,,,,,,,,,,"4219422","TNM category",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519767","Uncoated","C25707","Not having a coating.","Uncoated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519791","Unfiltered","C25708","Lacking a filter.","Unfiltered | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1508753","Urinary System","C12413","The organs involved in the creation and excretion of urine.","Urinary System | Body System, Renal/Urologic | Organ System, Renal/Urologic | Renal/Urologic Body System | Renal/Urologic Organ System | URINARY SYSTEM | Urinary Tract | Urinary system, NOS | Urologic/Renal Body System | renal system | urinary system | urinary tract",,,,,,,,,,,,,,,"4047487","Urinary system structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL318016","Vaginal","C13309","Of or relating to the vagina.","Vaginal | vaginal",,,,,,,,,,,,,,,"42538097","Vaginal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0348013","Venous","C25291","Of, or pertaining to, or contained in, or performing the function of the veins.","Venous | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448468","Vertebral","C25715","Of or relating to or constituting vertebrae.","Vertebral | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205128","Vertical","C25243","Upright in position or posture.","Vertical | ",,,,,,,,,,,,,,,"4140522","Vertical",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0443348","Viable","C25324","Capable of life or normal growth and development.","Viable | VIABLE",,,,,,,,,,,,,,,"4137186","Viable",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0442732","Vital","C18003","Necessary to maintain life. Breathing is a vital function","Vital | vital",,,,,,,,,,,,,,,"4128649","Vital",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332285","Within","C25282","On the inside; contained in.","Within | Inside | Intra",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332288","Without","C25718","Used to indicate the absence or lack of something or someone.","Without | nono",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522166","Worst","C25719","To the highest degree of inferiority or badness; the least favorable outcome.","Worst | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512855","Interlobar","C25540","Between lobes.","Interlobar | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205102","Internal","C25234","Happening or arising or located within some limits, or especially, within some surface.","Internal | Internal (qualifier value) | Internally | Intramural",,,,,,,,,,,,,,,"4127806","Internal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512888","International","C25541","Concerning or belonging to two or more nations.","International | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332286","Into","C25544","Expressing entrance, or a passing from the outside of a thing to its interior parts.","Into | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512925","Intraclavicular","C25545","Within the clavicles.","Intraclavicular | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0442124","Intravesical","C13415","Within the bladder.","Intravesical | intravesical | intravesical",,,,,,,,,,,,,,,"42538087","Intravesical",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021968","Iodine","C594","An element with atomic symbol I, atomic number 53, and atomic weight of 126.90.","Iodine | I | IODINE | iodine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441989","Ipsilateral","C25308","Having to do with the same side of the body.","Ipsilateral | IPSILATERAL | ipsilateral",,,,,,,,,,,,,,,"4112106","Ipsilateral",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205409","Isolation","C25549","A state of separation; the act of isolating something; setting something apart from others; marked by separation of or from usually contiguous elements.","Isolation | Isolated | Isolated | isolation",,,,,,,,,,,,,,,"4186921","Isolated",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0443228","Largest","C25550","Greatest in size of those under consideration.","Largest | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517741","Last","C25551","Coming after all others in time or space or degree or being the only one remaining.","Last | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022917","Lactate Dehydrogenase","C25184","A family of homotetrameric cytoplasmic enzymes involved in the conversion of L-lactate and NAD to pyruvate and NADH in the final step of anaerobic glycolysis. In vertebrates, genes for three different subunits (LDH-A, LDH-B and LDH-C) exist.","Lactate Dehydrogenase | EC 1.1.1.27 | L-(+)-Lactate Dehydrogenase | L-Lactic Acid Dehydrogenase | LDH | Lactic Acid Dehydrogenase | NAD-Lactate Dehydrogenase | lactate dehydrogenase | lactic acid dehydrogenase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023823","Low Density Lipoprotein","C25187","A lipoprotein that carries cholesterol around the body, for use by various cells.  LDL transports cholesterol to the arteries and increased levels are associated with atherosclerosis, and thus myocardial infarctions and strokes. This is why cholesterol inside LDL lipoproteins is called bad cholesterol.","Low Density Lipoprotein | LDL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522538","Leading","C25552","Be in charge of; a position of leadership.","Lead | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522010","Lobar","C25556","Of or relating to or affecting a lobe.","Lobar | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517927","Locally","C41065","To a restricted area (of the body).","Locally | Localized",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205166","Long","C25248","Of relatively great or greater than average spatial extension or temporal duration.","Long | Elongated | LONG",,,,,,,,,,,,,,,"4114661","Long",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522425","Longest","C25558","Having the greater length of two or the greatest length of several.","Longest | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205127","Longitudinal","C25242","Running lengthwise.","Longitudinal | ",,,,,,,,,,,,,,,"4304309","Longitudinal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0443252","Long-term","C25322","Involving or being in effect for a long time.","Long-Term | Long Term",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522604","Lymphatic","C25267","Of, or relating to, or produced by lymph.","Lymphatic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2939172","Lymphocytic","C13350","Of or pertaining to lymphocytes.","Lymphocytic | lymphocytic",,,,,,,,,,,,,,,"4114540","Lymphocytic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518071","Lymphoid","C13810","Referring to lymphocytes, a type of white blood cell. Also refers to tissue in which lymphocytes develop.","Lymphoid | lymphoid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518090","Lymphovascular","C25561","Of or relating to the lymphatic vessels.","Lymphovascular | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0929301","Mammary Gland","C12367","In humans, the glands of the breast, consisting of fibrous tissue connecting the lobes and fatty tissue in between the lobes.","Mammary Gland | GLAND, MAMMARY | MAMMARY GLAND | mammary gland",,,,,,,,,,,,,,,"4149965","Glandular structure of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162415","Mesenchyme","C13301","Embryonic tissue of mesodermal origin.  Develops into connective tissue, blood vessels, and lymphatic tissue.","Mesenchyme | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513155","Mesorectal","C25565","Of or relating to the fold of peritoneum, or mesentery, attached to the rectum.","Mesorectal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334023","Metaplastic","C25566","Pertaining to or characterized by metaplasia.","Metaplastic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205622","Microinvasive","C25568","Exhibiting or pertaining to microinvasion, the microscopic extension of malignant cells into adjacent tissue in carcinoma in situ.","Microinvasive | ",,,,,,,,,,,,,,,"4173160","Microinvasive tumor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1524031","Minimum","C25570","The smallest possible quantity.","Minimum | MIN | MINIMAL | MINIMUM | Minimal | Minimum Value | minimal | minimum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205430","Mixed","C25259","Involving or composed of different kinds.","Mixed | MIXED | Mist. | Mistura | Mix",,,,,,,,,,,,,,,"4095714","Mixed",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026473","Monocyte","C12547","Large, phagocytic mononuclear leukocytes produced in the vertebrate bone marrow and released into the blood; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles.","Monocyte | MONOCYTE | Monocytes | monocyte",,,,,,,,,,,,,,,"4208122","Monocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1513475","Mononuclear","C25575","Possessing a single nucleus.","Mononuclear | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205393","Most","C25258","Greatest in amount, extent, or degree; constituting a majority.","Most | Greatest | Mostly",,,,,,,,,,,,,,,"4166194","Most",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1513491","Most Recent","C25577","Nearest to the present.","Most Recent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439743","Multicentric","C25303","Having many centers. A multicentric cancer consists of a primary tumor with satellites of cancerous growth in surrounding tissues.","Multicentric | ",,,,,,,,,,,,,,,"4112105","Multicentric",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205292","Multifocal","C25253","Arising from, pertaining to, or having many locations.","Multifocal | MULTIFOCAL",,,,,,,,,,,,,,,"4181140","Multifocal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522564","Myocardial","C25578","Of or pertaining to the myocardium.","Myocardial | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521387","Myometrial","C25579","Of or pertaining to the myometrium.","Myometrial | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513884","National Cancer Institute of Canada","C25582","Acts in concert with its partner the Canadian Cancer Society, and with The Terry Fox Foundation, to provide support for cancer research and related programs undertaken at Canadian universities, hospitals and other research institutions. (www.ncic.cancer.ca)","National Cancer Institute of Canada | NCIC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448465","Nearest","C25583","Most near in time or space.","Nearest | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448527","Necrotic","C25286","Relating to or affected by necrosis.","Necrotic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600558","Neoadjuvant Therapy","C15665","Therapy administered prior to the primary treatment for the purpose of making the primary treatment more effective.","Neoadjuvant Therapy | Induction Therapy | Neo-Adjuvant | Neoadjuvant | Pre-Adjuvant | Pre-Adjuvant Therapy | Preoperative Therapy | induction therapy | neoadjuvant therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448492","Nervous","C25584","Of or relating to the nervous system.","Nervous | Nerve",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0599851","Nervous - anatomy qualifier","C25363","Of or relating to neurons or the nervous system.","Neural | neural",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027950","Neutrophil","C12533","Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes.","Neutrophil | Blood Segmented Neutrophil | Neutrophilic Granulocyte | Neutrophilic Leukocyte | Polymorphonuclear Neutrophils | neutrophil",,,,,,,,,,,,,,,"4198194","Segmented neutrophil",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518321","Newly Diagnosed","C25587","Very recently determined.","Newly Diagnosed | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518371","Non-Malignant","C25588","For neoplasms, a neoplastic process that, at the time of the pathologic diagnosis, does not show evidence of tissue infiltration and may or may not show evidence of atypical morphologic features (e.g., cellular atypia, formation of complex structures, cellular pseudostratification, and increased mitotic activity).  This term encompasses benign neoplastic processes, neoplastic processes with dysplastic features, and borderline processes.  The former do not metastasize and the latter two are associated with a future risk of stromal invasion and metastasis. For other conditions, a process that is not seriously resistant to treatment or dangerous to health.","Non-Malignant | Non Malignant | Nonmalignant | nonmalignant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448466","Non-Protocol","C25590","Treatment not specified in a protocol.","Non-Protocol | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518388","Non-Surgical","C25591","Not pertaining to or amenable to surgery.","Non-Surgical | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518389","Non-Target","C25592","Other than the one for which something is done.","Non-Target | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518392","Non-Visceral","C25593","Not relating to or affecting the internal organs.","Non-Visceral | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521739","Nutritional","C25597","Of or relating to or providing nutrition.","Nutritional | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521127","Occupational","C25600","Of or relating to the activity or business by which a person earns income.","Occupational | ",,,,,,,,,,,,,,,"4338393","Occupational",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518600","Optional","C25603","Possible but not necessary; left to personal choice.","Optional | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205313","Original","C25604","Preceding all others in time or being as first made or performed.","Original | ORIGINAL",,,,,,,,,,,,,,,"4025679","Original",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448560","Painful","C25271","Causing physical or psychological misery, pain or distress.","Painful | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0234226","Painless","C25272","Not causing physical or psychological misery, pain or distress.","Painless | ",,,,,,,,,,,,,,,"4114514","Painless",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0522499","Palpable","C25606","Capable of being handled or touched or felt.","Palpable | PALPABLE | Palpable Disease | palpable disease",,,,,,,,,,,,,,,"4014160","Palpable",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0442134","Paraaortic Region","C25316","Regions near to the aorta.","Paraaortic Region | Paraaortic | Paraaortic",,,,,,,,,,,,,,,"4081183|4126992","Para-aortic region|Para-aortic",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1518890","Parametrial","C25607","Regions near to the parametrium.","Parametrial | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0442030","Parietal","C25312","Of, or relating to, or associated with the parietal bones.","Parietal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0679823","Participation","C25608","The act of taking part in an activity.","Participation | Participating | Participating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521725","Pediatric","C39299","Having to do with children.","Pediatric | Childhood | pediatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0442135","Pericolic","C25614","Surrounding the colon.","Pericolic | Pericolonic",,,,,,,,,,,,,,,"4126059","Paracolic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518980","perineural","C25615","Surrounding a nerve.","Perineural | perineural",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205100","Peripheral","C25233","On or near an edge or constituting an outer boundary; the outer area.","Peripheral | PERIPHERAL | Peripheral (qualifier value)",,,,,,,,,,,,,,,"4031511","Peripheral",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519008","Periprostatic","C25617","Surrounding the prostate.","Periprostatic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514162","Platinum-Based","C25620","Derived from or containing platinum.","Platinum-Based | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522720","Pleural","C25223","Of or pertaining to the pleura.","Pleural | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032821","Potassium","C765","An element with atomic symbol K, atomic number 19, and atomic weight 39.10.","Potassium | K | POTASSIUM | Potassium (NOS) | potassium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514392","Premalignant Cell","C12976","Cells which show sign/s, that they can become cancerous.","Premalignant Cell | Precancerous Cells | Premalignant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205156","Previous","C25627","Occurring prior to something else.","Previous | FORMER | Former | Previously",,,,,,,,,,,,,,,"4238439","Previous",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205225","Principal","C25628","First or foremost in importance.","Principal | ",,,,,,,,,,,,,,,"4269228","Principal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0220901","prognostic","C25263","Having value for making predictions.","Prognostic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205329","Progressive","C25254","Advancing in extent or severity.","Progressive | ",,,,,,,,,,,,,,,"4114504","Progressive",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0229614","Prolymphocyte","C13119","A medium-sized round lymphocyte of B or T-cell lineage with prominent nucleoli.  It is an intermediate cell between the lymphoblast and the small, mature lymphocyte.","Prolymphocyte | ",,,,,,,,,,,,,,,"4023589","Prolymphocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030605","Activated Partial Thromboplastin Time","C38462","A measurement of the length of time that it takes for clotting to occur when activating reagents are added to a plasma specimen. The test is partial due to the absence of tissue factor (Factor III) from the reaction mixture.","Activated Partial Thromboplastin Time | APTT | Partial Thromboplastin Time | aPTT",,,,,,,,,,,,,,,"4175016","Partial thromboplastin time, activated",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332185","Recent","C25280","Near to or not long before the present.","Recent | ",,,,,,,,,,,,,,,"4274816","Recent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1514811","Bibliographic Reference","C25641","A note acknowledging a source of information or quoting a passage.","Reference | Bibliographic Reference | bibliographicDesignation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205543","Referring","C25642","Sending or directing for treatment, information, or a decision.","Referring | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700287","Reporting","C25651","The act of providing a short account.","Reporting | ",,,,,,,,,,,,,,,"4073047","Informing",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1514888","Resectable","C25653","Capable of being removed by surgery.","Resectable | resectable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1609982","Residual","C37895","Remaining or left behind.","Residual | ",,,,,,,,,,,,,,,"4276970","Residual",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1514924","Retrotracheal","C25660","Denoting the area behind the trachea.","Retrotracheal | RETROTRACHEAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704362","Reviewing","C25661","Reexamining or reconsidering.","Reviewing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332221","Satellite","C25663","Situated near; accompanying.","Satellite | ",,,,,,,,,,,,,,,"4104816","Satellite",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0175668","Secondary","C25667","Derived as a result of a primary condition; not direct or immediate; of second rank or importance or value.","Secondary | ",,,,,,,,,,,,,,,"4093903","Secondary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522541","Protocol Treatment Arm","C15538","A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","Protocol Treatment Arm | Arm | Planned Arm | Protocol Arm | TREATMENT_ARM | Treatment Arm | arm | arm (protocol) | study arm | study_arm | treatment arm | treatment_arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018133","Graft Versus Host Disease","C3063","A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.","Graft Versus Host Disease | GVHD | Graft Vs. Host Disease | Graft vs Host Disease | Graft-Versus-Host-Disease | GvHD | Runt Disease | graft-versus-host disease",,,,,,,,,,,,,,,"443216","Graft versus host disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1513492","motor movement","C28367","In medicine, having to do with the movement of body parts.","Motor | motor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0445254","Sensory","C28259","Having to do with the senses.","Sensory | sensory",,,,,,,,,,,,,,,"4136006","Sensory",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002712","Amylase","C16284","Amylase is an enzyme which helps digest glycogen and starch. It is produced mainly in the pancreas and salivary glands.","Amylase | amylase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205178","Acute","C14140","Having a severe and rapid onset of symptoms with short duration.","Acute | ACUTE | acute",,,,,,,,,,,,,,,"4156184","Acuteness",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0086543","Cataract","C26713","Partial or complete opacity of the crystalline lens of one or both eyes that decreases visual acuity and eventually results in blindness. Some cataracts appear in infancy or in childhood, but most develop in older individuals. (Sternberg Diagnostic Surgical Pathology, 3rd ed.)","Cataract | Cataracts | cataract",,,,,,,,,,,,,,,"375545","Cataract",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035455","Rhinitis","C34986","An inflammation of the mucous membrane lining the nose, usually associated with nasal discharge.","Rhinitis | ",,,,,,,,,,,,,,,"4320791","Rhinitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4014799","Arthritis","C2883","An inflammatory process affecting a joint. Causes include infection, autoimmune processes, degenerative processes, and trauma. Signs and symptoms may include swelling around the affected joint and pain.","Arthritis | arthritis",,,,,,,,,,,,,,,"4291025","Arthritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4227421","Apnea","C26698","Transient cessation of respiration.","Apnea | ",,,,,,,,,,,,,,,"321689","Apnea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4228281","Anxiety","C26696","Apprehension of danger and dread accompanied by restlessness, tension, tachycardia, and dyspnea unattached to a clearly identifiable stimulus.","Anxiety | anxiety",,,,,,,,,,,,,,,"441542","Anxiety",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022417","Joint","C13044","The connection point between two bones or skeletal elements. The joint may be fixed or movable.","Joint | Articular | Articulation | JOINT | Joint structure (body structure) | Joints | joint | skeletal joint",,,,,,,,,,,,,"UBERON:0000982","skeletal joint","4214466","Joint structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205460","Biological","C28226","Pertaining to biology or to life and living things.","Biological | Biologic | Biologically | biological",,,,,,,,,,,,,,,"4029802","Biologic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038990","Sweating","C36172","A watery secretion by the sweat glands that is primarily composed of salt, urea and minerals.","Sweating | Sweats",,,,,,,,,,,,,,,"4188566|4215206","Sweating|Sweating",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0024348","Tissue Lysis","C37889","Tissue structure disintegration and destruction due to action of endogenous or/and exogenous lytic substances which include but not limited to naturally occurring or laboratory designed proteolytic enzymes, glycosidases, detergents, pore-forming proteins, immune complexes, etc. Tissue lysis plays role in pathogenesis of a number of conditions e.g. protozoal infections, ischemic tissue injury, and autoimmune disorders. It is also used as a basis for non-surgical treatment modality to remove or minimize presence of abnormal tissue, e.g. adhesions.","Tissue Lysis | Lysis | Lysis | Lytic",,,,,,,,,,,,,,,"4155001","Lysis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2749520","Thrombocytopenia","C3408","A laboratory test result indicating that there is an abnormally small number of platelets in the circulating blood.","Thrombocytopenia | Platelet count decreased | Thrombocytopenia, unspecified | Thrombocytopenic Disorder | thrombocytopenia",,,,,,,,,,,,,,,"432870","Thrombocytopenic disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030198","Pain Assessment","C20992","The evaluation of pain complaints.  Measurements should be objective on the part of the practitioner, based on subjective information from the patient.  Measurements may also be indirect, by such assessments as respiratory rate and effort, withdrawal, guarding, or other appropriate assessment techniques.","Pain Assessment | Pain Measurement",,,,,,,,,,,,,,,"4021323","Pain assessment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516945","Epithelioid Endothelial Cell","C37093","No value exists.","Epithelioid Endothelial Cell | Histiocytoid Endothelial Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011379","Dental Material","C42634","Substances that are used in the clinical practice of dentistry for the production of fillings, restorations, impressions, and prostheses.","Dental Material | ",,,,,,,,,,,,,,,"4113902|45768309","Dental material|Dental material",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1558148","Adverse Event Associated with Secondary Malignancy","C53796","No value exists.","Adverse Event Associated with Secondary Malignancy | Inhalant Solution | SECONDARY MALIGNANCY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031845","Biological Process","C17828","An activity occurring within an organism, between organisms or among organisms and the mechanisms underlying such events.","Biological Process | Biological Function",,,,,,,,,,,,,,,"37396426","Physiological process",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518935","Pediatric Research","C26026","The scientific investigation of the distinctive health characteristics and care of children.","Pediatric Research | Amino Acids, Peptides, and Proteins",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521472","5q12.3","C25078","A chromosome band present on 5q","5q12.3 | Alanine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029235","Organism","C14250","A living entity.","Organism | BiologicEntity | Organismal | Organisms | Taxon | organism",,,,,,,,,,,,,,,"4259632","Organism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042776","Virus","C14283","An infectious agent which consists of two parts, genetic material and a protein coat. These organisms lack independent metabolism, and they must infect the cells of other types of organisms to reproduce. Most viruses are capable of passing through fine filters that retain bacteria, and are not visible through a light microscope.","Virus | VIRUS | Viruses | Viruses, General | virus",,,,,,,,,,,,,,,"4177956","Virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0686817","Prokaryote","C14263","Organisms without a cell nucleus or any other membrane-bound organelles. Most prokaryotes are bacteria but the group includes both the Bacteria and the Archaea. Eukaryota, Bacteria, and Archaea are now considered the top nodes of a three-domain taxonomy system.","Prokaryote | Prokaryotes | Prokaryotic Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032098","Plant","C14258","Any living organism that typically synthesizes its food from inorganic substances, possesses cellulose cell walls, responds slowly and often permanently to a stimulus, lacks specialized sense organs and nervous system, and has no powers of locomotion. (EPA Terminology Reference System)","Plant | Plants | Plants, General | Viridiplantae",,,,,,,,,,,,,,,"4149889","Kingdom Plantae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334606","Malignant Neoplasm by Grade","C36041","A term that refers to the categorization of malignant neoplasm by histologic grade.","Malignant Neoplasm by Grade | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1254372","Conceptual Entity","C20181","An organizational header for concepts representing mostly abstract entities.","Conceptual Entity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003842","Artery","C12372","A blood vessel that carries blood away from the heart.","Artery | ARTERY | Arterial | arterial subtree | arterial tree organ part | arteries | artery",,,,,,,,,,,,,"UBERON:0001637","artery","4199457","Arterial structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0333717","Abnormal Cell","C12913","An abnormal human cell type which can occur in either disease states or disease models.","Abnormal Cell | ",,,,,,,,,,,,,,,"4191243","Abnormal cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1510716","Abnormal Connective and Soft Tissue Cell","C36843","No value exists.","Abnormal Connective and Soft Tissue Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510719","Abnormal Endothelial Cell","C37086","No value exists.","Abnormal Endothelial Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510721","Abnormal Epithelial Cell","C36745","An epithelial cell that occurs in human disease or in models of human disease.","Abnormal Epithelial Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510725","Abnormal Hematopoietic and Lymphoid Cell","C36987","No value exists.","Abnormal Hematopoietic and Lymphoid Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510730","Abnormal Mesothelial Cell","C36829","No value exists.","Abnormal Mesothelial Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510732","Abnormal Myoepithelial Cell","C36769","No value exists.","Abnormal Myoepithelial Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0522580","Atypical Cell of Undetermined Significance","C8445","No value exists.","Atypical Cell of Undetermined Significance | Atypical Cell of Uncertain Significance",,,,,,,,,,,,,,,"4013004","Atypical cells of undetermined significance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0427528","Atypical Mononuclear Cell","C12979","No value exists.","Atypical Mononuclear Cell | ",,,,,,,,,,,,,,,"4095351","Atypical mononuclear cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0391864","Cytomegalic Cell","C36735","An abnormal cell that contains intranuclear and intracytoplasmic cytomegalovirus inclusion bodies.","Cytomegalic Cell | ",,,,,,,,,,,,,,,"4053461","Cytomegaly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023172","LE Cell","C36716","The lupus erythematosus cell, which is likely a neutrophil with denatured nuclei. It may be found in blood, bone marrow, synovial fluid, cerebrospinal fluid, pericardial and pleural effusions of individuals with lupus erythematosus.","LE Cell | Lupus Erythematosus Cell",,,,,,,,,,,,,,,"4290924","Lupus erythematosus cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1513170","Metaplastic Cell","C36786","No value exists.","Metaplastic Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0597032","Neoplastic Cell","C12922","Cells of, or derived from, a tumor.","Neoplastic Cell | Tumor Cell | Tumor cells, NOS | Tumor cells, uncertain whether benign or malignant","8001/1","Tumor cells, uncertain whether benign or malignant",,,,,,,,,,,,,"4102371|4216929","Tumor cells|Tumor cells of uncertain behavior",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0333727","Signet Ring Cell","C12487","A neoplastic cell containing cytoplasmic mucin. The presence of mucin pushes the nucleus of the cell to the periphery, assuming a configuration resembling a signet ring.","Signet Ring Cell | Signet-Ring Cell",,,,,,,,,,,,,,,"4336667","Signet ring cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017526","Giant Cell","C12607","An abnormally large cell that contains multiple nuclei and an abundant amount of cytoplasm.","Giant Cell | MULTINUCLEATED GIANT CELL | Multinucleated Giant Cell | syncytium",,,,,,,,,,,,,,,"4244853","Multinucleate giant cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0349515","Amelanotic Cutaneous Melanoma",,,,,,,,,,,,,,,,,,"4080901","Amelanotic malignant melanoma of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516354","Cell Motility Pathway","C39703","An elaboration of the known steps and interactions required to allow cell movement.","Cell Motility Pathway | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517009","Experimental Organism Diagnosis","C22187","A condition or observation that is relevant to disease states, models of disease or characterization of those conditions in a non-human organism; this includes conditions or observations in organisms used in research settings.","Experimental Organism Diagnosis | Non-Human or Experimental Organism Diagnosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515976","Anatomic Structure, System, or Substance","C12219","A human biological structure, fluid or other substance; excludes single molecular entities.","Anatomic Structure, System, or Substance | Anatomic Structures and Systems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704222","Genome Encoded Entity","C26548","A protein, RNA or a complex that contains proteins and/or RNA.","Gene Product | Genome Encoded Entity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880421","Drug, Food, Chemical or Biomedical Material","C1908","An organic or inorganic substance, element, isotope, food or other materials derived from microorganism, plant, or animal sources. They can be used for the prevention, diagnosis, treatment or research of disease states, for industrial purposes, or for the promotion or maintenance of organism viability or health.","Drug, Food, Chemical or Biomedical Material | Drug or Chemical",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002072","Alkanesulfonates","C222","An ester of alkane sulfonic acid that acts as an alkylating agent.","Alkylsulfonate Compound | Alkanesulfonates | Alkyl Sulfonates | Elimination | Sulfonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003062","Animal","C14182","A living organism that has membranous cell walls, requires oxygen and organic foods, and is capable of voluntary movement, as distinguished from a plant or mineral.","Animal | ANIMAL | Animalia | Animals | Metazoa | Metazoa Kingdom",,,,,,,,,,,,,,,"4307750","Kingdom Animalia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0376558","Alive","C37987","Showing characteristics of life; displaying signs of life.","Alive | ALIVE | Life | Live | Living | alive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0236100","Female Reproductive System Disorder","C27020","A non-neoplastic or neoplastic disorder that affects the female genital system. Representative examples of non-neoplastic disorders include infection, endometriosis, and adenomyosis. Representative examples of neoplastic disorders include germ cell tumors, carcinoma, lymphoma, and sarcoma.","Female Reproductive System Disorder | Female Reproductive System Disease | Gynecological Disorder",,,,,,,,,,,,,,,"4180154","Disorder of female reproductive system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0078262","Vinyl Carbamate","C29864","A synthetic organic compound produced in industry, Vinyl Carbamate is used in biomedical research to induce experimental (especially skin and lung) tumors in animals. Metabolism of Vinyl Carbamate leads to formation of electrophilic reactants that covalently bind to macromolecules (DNA-, RNA-, and protein-adducts) and initiate carcinogenesis. (NCI04)","Vinyl Carbamate | Metabolic Rate Alteration | VINYL CARBAMATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514644","RCAS-Ras","C29910","A recombinant retroviral virus derived from SR-A strain of Rous sarcoma virus carrying a human gene encoding the G12D mutant form of K-Ras. The viral vector, RCAS harbors a Replication Competent ALV Splice acceptor. This recombinant virus was use in animal model to study gliomagenesis.","RCAS-Ras | Organic Ion Metabolism Alteration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511219","Leukocyte Banking","C15773","The typing, separation, and storage of leukocytes for subsequent transfusion to recipients.","Leukocyte Banking | Blood Banking, Leukocyte",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706062","Biochemical Pathway","C20633","A series of biochemical reactions which occurs in a known sequence and can result in all or part of the initiation, progression or completion of a biological process or function.","Biochemical Pathway | Metabolic Network | Pathway | Pathways | molecular pathway",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086418","Human","C14225","The bipedal primate mammal, Homo sapiens; belonging to man or mankind; pertaining to man or to the race of man; use of man as experimental subject or unit of analysis in research.","Human | HUMAN | Homo sapiens | Human, General",,,,,,,,,,,,,,,"4079979|4225446","Human - origin|Homo sapiens",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1523994","Diagnostic, Therapeutic, and Research Equipment","C19238","A manufactured object that is used to perform diagnostic, therapeutic or research activities.","Diagnostic, Therapeutic, or Research Equipment | Diagnostic, Therapeutic, and Research Equipment | Diagnostic, Therapeutic, and Research Equipment | Equipment | Hardware",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511989","Disease, Disorder or Finding","C7057","A condition that is relevant to human neoplasms and non-neoplastic disorders.  This includes observations, test results, history and other concepts relevant to the characterization of human pathologic conditions.","Disease, Disorder or Finding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0442711","Protocol","C42651","A rule which guides how an activity should be performed.","Protocol | ",,,,,,,,,,,,,,,"4122869","Protocols",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024467","Magnesium","C29239","An alkaline earth metal, Magnesium is important for many biochemical functions and reactions; for bone and muscle function, protein and fatty acid formation, activation of B vitamins, blood clotting, insulin secretion, and ATP formation. More than 300 enzymes require magnesium for catalytic action. The adult daily requirement is about 300 mg/day. Magnesium is found in many green plants, vegetables, and seeds; chlorophyll is a magnesium-centered porphyrin compound. Magnesium salts are used for magnesium deficiency supplementation. (NCI04)","Magnesium | magnesium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205369","Specified","C38024","Clearly and explicitly stated.","Specified | Specific",,,,,,,,,,,,,,,"4320344","Specific",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704730","Packaging Tube","C42794","A flexible container for semisolid drug products which is flattened and crimped or sealed at one end and has a reclosable opening at the other.","Packaging Tube | TUBE | Tube | Tube",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020699","Hysterectomy","C15256","A surgical procedure to remove the uterine body (partial hysterectomy) or the uterine body and cervix (total hysterectomy).","Hysterectomy | Hysterectomy NOS | hysterectomy | hysterectomy type | hysterectomy_type",,,,,,,,,,,,,,,"4127886","Hysterectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029936","Oophorectomy","C15291","Partial or complete removal of one or both of the ovaries.","Oophorectomy | Female Castration | Ovariectomy | oophorectomy",,,,,,,,,,,,,,,"4306298","Oophorectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0995188","Cetuximab","C1723","A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors.","Cetuximab | C 225 | C-225 | C225 | CETUXIMAB | Cetuximab Biosimilar CDP-1 | Cetuximab Biosimilar CMAB009 | Cetuximab Biosimilar KL 140 | Chimeric Anti-EGFR Monoclonal Antibody | Chimeric MoAb C225 | Chimeric Monoclonal Antibody C225 | Erbitux | IMC-C225 | cetuximab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032790","Postoperative","C28006","Relating to or occurring during the period immediately following a surgical operation.","Postoperative | Post-Operative | postoperative",,,,,,,,,,,,,,,"4118656","Postoperative period",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024264","Lymphocyte","C12535","White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each); those with characteristics of neither major class are called null cells.","Lymphocyte | LYMPHOCYTE | Lymph Cell | Lymphocytes | lymphocyte",,,,,,,,,,,,,,,"4211531","Lymphocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0012881","DNA Nucleotidylexotransferase","C16509","DNA nucleotidylexotransferase (509 aa, ~59 kDa) is encoded by the human DNTT gene. This protein plays a role in DNA polymerization and specifically catalyzes the insertion of nucleotides (N regions) at the V(H)-D and D-J(H) junctions of immunoglobulin genes.","DNA Nucleotidylexotransferase | DNTT | Deoxynucleotidyl Terminal Transferase | EC 2.7.7.31 | TDT | TdT | Terminal Addition Enzyme | Terminal Deoxynucleotidyltransferase | Terminal Deoxyribonucleotidyl Transferase | Terminal Deoxyribonucleotidyl Transferase | Terminal Transferase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016504","Foot","C32622","The structure found below the ankle joint.","Foot | FOOT | Pedal | foot | hindlimb autopod | hindlimb autopodium | hindlimb distal free limb segment | pes | terminal segment of free lower limb",,,,,,,,,,,,,"UBERON:0002387","pes","4211098","Foot structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035561","Rib","C12782","Any one of the paired bones, 12 on either side, extending from the thoracic vertebrae toward the median line on the ventral aspect of the trunk. The long curved bones which form the rib cage. Generally, ribs 1 to 7 are connected to the sternum by their costal cartilages and are called true ribs, whereas ribs 8 to 12 are termed false ribs.","Rib | BONE, RIB | Bone structure of rib (body structure) | RIB | rib",,,,,,,,,,,,,"UBERON:0002228","rib","4011851","Bone structure of rib",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031253","Pesticide","C737","Any agent used to control, repel, or kill unwanted organisms.","Pesticide | Pesticides | pesticide",,,,,,,,,,,,,,,"4245743","Pesticide",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035648","Risk Factor","C17103","Any aspect of an individual's life, behavior, an environmental exposure, or an inborn or inherited characteristic that increases the likelihood of a disease, condition or injury.","Risk Factor | risk factor | risk factors | risk_factor | risk_factors",,,,,,,,,,,,,,,"4214014","Risk factor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1707689","Design","C43358","The act of working out the form of something (as by making a sketch or outline or plan) or the result of this activity.","Design | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003211","Nonsteroidal Antiinflammatory Drug","C257","A pharmacological agent that is not a steroid and has potential anti-inflammatory, analgesic, antipyretic and anti-platelet activities. Most nonsteroidal anti-inflammatory drugs (NSAIDs) act by inhibiting the conversion of arachidonic acid to the precursors of prostaglandin and thromboxane by cyclooxygenase enzymes.","Nonsteroidal Antiinflammatory Drug | NSAID | NSAID medications | NSAIDs | nonsteroidal anti-inflammatory drug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085826","Antiplatelet Agent","C1327","An agent that inhibits platelet aggregation and reduces coagulation in the circulatory system.","Antiplatelet Agent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0149783","Steroid Therapy","C15370","The use of exogenous steroids for the treatment of any disease or disorder.","Steroid Therapy | steroid therapy",,,,,,,,,,,,,,,"4180039","Administration of steroid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0392752","Localized","C14146","Restricted to the site of origin, without evidence of spread.","Localized | Localised | localized",,,,,,,,,,,,,,,"4114652","Localized",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1301048","Pancreatic Mixed Ductal Adenocarcinoma-Neuroendocrine Carcinoma","C6879","A carcinoma that arises from the pancreas and is composed of ductal adenocarcinoma and neuroendocrine carcinoma components in both the primary tumor and the metastatic sites.","Pancreatic Mixed Ductal Adenocarcinoma-Neuroendocrine Carcinoma | Mixed Ductal-Endocrine Carcinoma | Mixed Ductal-Endocrine Carcinoma | Mixed Ductal-Endocrine Carcinoma of the Pancreas | Mixed Ductal-Neuroendocrine Carcinoma of the Pancreas | Mixed Ductal-Neuroendocrine Carcinoma of the Pancreas | Mixed ductal-endocrine carcinoma | Pancreatic Mixed Ductal Adenocarcinoma-NEC | Pancreatic Mixed Ductal-Neuroendocrine Carcinoma | Pancreatic Mixed Ductal-Neuroendocrine Carcinoma",,,,,,,,,,,,,,,"3655588|4263963","Mixed ductal-neuroendocrine carcinoma of pancreas|Mixed ductal-endocrine carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0593802","Aromatase Inhibitor","C1740","Any substance that inhibits aromatase, an enzyme responsible for the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. Inhibition of aromatase results in the suppression of estrogen-regulated processes.","Aromatase Inhibitor | Androstenedione Aromatase Inhibitor | Aromatase Inhibition Therapy | Estrogen Synthase Inhibitor | Estrogen Synthetase Inhibitor | aromatase inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030761","genetic pedigree","C27957","A record of descent or ancestry, particularly of a specific condition or trait, indicating individual family members, their relationships, and their status with respect to the trait or condition.","Pedigree | Genealogical Tree | pedigree",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511297","Gail Risk Model","C19665","A computer program developed through the National Surgical Adjuvant Breast and Bowel project.  Estimates risk of breast cancer based upon current age, age at menarche, age at first live birth, number of first-degree relatives who have had breast cancer, number of breast biopsies, and number of biopsies with atypical hyperplasia.  Results are presented as risk of breast cancer, as a percentage, within the next five years or over a lifetime.","Gail Risk Model | Breast Cancer Gail Model | Breast Cancer Gail Model Risk Assessment Tool | Breast Cancer Risk Assessment Tool | Breast Cancer Risk Assessment Tool | Gail model | Gail risk model",,,,,,,,,,,,,,,"37397096","Breast Cancer Risk Assessment Tool",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162789","Fluorescence In Situ Hybridization","C17563","A physical mapping approach that uses fluorescent tags to detect hybridization of probes within metaphase chromosomes or less condensed somatic interphase chromatin. This technique can be used for identification of chromosomal abnormalities and for gene mapping.","Fluorescence In Situ Hybridization | FISH | Fluorescence in Situ Hybridization | Fluorescence in Situ Hybridization | Fluorescence in situ Hybridization | Fluorescence in situ Hybridization | fluorescence in situ hybridization",,,,,,,,,,,,,,,"4142271","Fluorescence in situ hybridization",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517050","Extracellular Domain","C13458","Any part of a transmembrane protein that projects into the environment surrounding a cell.","Extracellular Domain | External Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517878","Lifetime Risk","C19662","An estimate of cumulative risk calculated over a lifetime.","Lifetime Risk | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1176140","CYP3A4 Gene","C24328","This gene plays an role in the metabolism of numerous clinically-relevant drugs. It is also involved in the oxidation of both endogenous substrates and xenobiotics.","CYP3A4 Gene | CYP3A4 | Cytochrome P450 Family 3 Subfamily A Member 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017431","Genotype","C16631","The genetic constitution of an organism or cell, as distinct from its expressed features or phenotype.","Genotype | Genotypic | genotype",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511298","Breast Cancer Risk Factor","C20116","Any factor, such as age, ethnicity, genetic factor, family history, over-exposure to estrogen, or environmental factors, that increases a person's chance of developing breast cancer.","Breast Cancer Risk Factor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015031","Ethnic Group","C16564","A social group characterized by a distinctive social and cultural tradition that is maintained from generation to generation. Members share a common history and origin and a sense of identification with the group. They have similar and distinctive features in their lifestyle habits and shared experiences. They often have a common genetic heritage which may be reflected in their experience of health and disease.","Ethnic Group | ETHNIC | ETHNICITY | Ethnic Origin | Ethnic Origins | Ethnicity | Patient Reported Ethnicity | ethnicity",,,,,,,,,,,,,,,"4271761","Ethnic group",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1292533","Tissue Sample","C19697","A piece of tissue removed from an organism for examination, analysis, or propagation.","Tissue Sample | Tissue | Tissue Specimen | Type of tissue obtained | tissue type | tissue_type",,,,,,,,,,,,,,,"4002890","Tissue specimen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1301584","Last Name","C40975","A word or group of words indicating a person's last (family) name.","Last Name | Family Name | Surname | pi last name | pi_last_name",,,,,,,,,,,,,,,"4265883","Surname",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030551","Parent","C42709","A mother or a father; an immediate progenitor.","Parent | PARENT | Parental",,,,,,,,,,,,,,,"4232263","Parent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035668","Ribonucleic Acid","C812","Single-stranded long chain of nucleotides containing ribose. It is the end product of DNA transcription by the enzyme RNA polymerase. It is essential in protein synthesis.","Ribonucleic Acid | R | RNA | Ribonucleic acid | ribonucleic acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227963","Prostate Capsule","C13086","The membrane the surrounds the prostate gland.","Prostate Capsule | Capsule of the Prostate",,,,,,,,,,,,,,,"4247298","Structure of capsule of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031437","Phenotype","C16977","The assemblage of traits or outward appearance of an individual. It is the product of interactions between genes and between genes and the environment.","Phenotype | phenotype",,,,,,,,,,,,,,,"4215157","Phenotype",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0935916","Fulvestrant","C1379","A synthetic estrogen receptor antagonist.  Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. (NCI04)","Fulvestrant | 7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol | FULVESTRANT | Faslodex | Faslodex(ICI 182,780) | ICI 182,780 | ICI 182780 | ICI-182780 | ICI182780 | ZD 9238 | ZD-9238 | ZD9238 | fulvestrant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516654","Clinical or Research Activity","C16203","Any specific activity undertaken during the course of a clinical study or research protocol.","Clinical or Research Activity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517008","Experimental Organism Anatomical Concept","C22188","A biological structure, fluid or other substance that is present in a non-human organism; this includes anatomic entities found in organisms used in research settings. However, this grouping excludes single molecular entities.","Experimental Organism Anatomical Concept | Non-Human or Experimental Organism Anatomical Concept",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024706","Manganese","C624","An element with atomic symbol Mn, atomic number 25, and atomic weight 54.94.","Manganese | Mn",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040278","Tissue Collection","C15339","A repository of the tissue specimen, cells or cell lines, for experimental purpose. It can be from different diseases or different parts of the body.","Tissue Collection | Tissue Bank | Tissue Repository | Tissue/Specimen Collection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0179400","Box","C43178","A square or rectangular vessel, usually made of cardboard or plastic.","Box | BOX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441655","Activity","C43431","An active process; excludes processes and mechanisms which fulfill biological functions.","Activity | General activity",,,,,,,,,,,,,,,"4117957","Activity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519524","Paraffin Embedded Tissue","C19597","Tissue that is preserved and embedded in paraffin.","Paraffin Embedded Tissue | PARAFFIN-EMBEDDED | Paraffin Block | Paraffin block | Paraffin-Embedded Specimen | Tissue, Paraffin | Tissue, Paraffin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519521","Fresh Tissue","C19066","Tissue that is not frozen or embedded in preservatives","Fresh Tissue | Tissue, Fresh | Tissue, Fresh",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706163","Tree Node","C42765","A term that refers to any individual item or entity in a hierarchy or pedigree.","Tree Node | Node",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027365","Name","C42614","The words or language units by which a thing is known.","Name | name",,,,,,,,,,,,,,,"42536171","Name (property)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705630","Concept Relationship","C42727","Any of the relationships between concepts. The vertical, hierarchical relationships may be referred to as Parent, Child, Broader, Narrower, isa, inverse-isa, Super Concept, Subconcept, etc.  The horizontal named relationships include Roles and Associations.","Concept Relationship | Relationship | rel | rela",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1292718","isa Relationship","C44235","A relationship of specialization that states that a concept is a particular kind of another concept. This relationship relates concepts through logical hierarchy and forms the foundation of a taxonomy.","isa Relationship | Is-A | Parent-Child Relationship | isa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710468","Traverse Down","C44243","Specifies the default behavior of a tree search or traversal.","Traverse Down | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710054","Serial Version Unique Identifier","C42735","Maintains a reference (via a proxy to the EVSManager).","Serial Version Unique Identifier | Serial Version UID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0000723","Abbreviation","C42610","A shortened form of a word or phrase.","Abbreviation | Abbreviated | Preferred Abbreviation | Short | Short Name | abbreviation",,,,,,,,,,,,,,,"4162372","Abbreviation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710047","Semantic_Type","C42732","The semantic type describes the sort of thing or category to which a concept belongs in the context of the UMLS semantic network.","Semantic_Type | Semantic Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705811","Terminology Role Entity","C42754","A non-hierarchical, named relationship between concepts.  They are binary relationships pointing from one concept to another concept.  Roles are unidirectional and each role has a Domain and a Range; the role points from one kind, the domain, to another (or same) kind, the range.  The specific concept pointed to is considered the Role Value.","Role Entity | Role | Terminology Role",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708986","NCI Metathesaurus Concept","C42695","A terminology concept as represented in the NCI Enterprise Vocabulary Services' Metathesaurus.","Metathesaurus Concept | Concept | Meta Thesaurus Concept",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707476","UMLS Concept Unique Identifier","C42718","In the Unified Medical Language System (UMLS) of the National Library of Medicine (NLM) the concept unique identifier (CUI) is an 8-character identifier beginning with the letter 'C' and followed by 7 digits.  Each concept is assigned such a CUI.  The CUI has no intrinsic meaning but remains constant through time and across versions.","UMLS Concept Unique Identifier | CUI | Concept Unique Identifier | NLM CUI | UMLS CUI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711200","Edit Action","C42682","The type of change made to an element.","Edit Action | Change Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707688","Description Logic Concept","C42717","A terminology concept modeled in a structured and formally well-understood way using logic-based semantics which can be given by a translation into first-order predicate logic.","Description Logic Concept | Desc Logic Concept",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706214","Creation","C42620","The process by which something is brought into existence; having been brought into existence.","Creation | Create | Created | Created",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709146","Namespace","C42699","In general, a namespace is an abstract container, which is or could be filled by names, or technical terms, or words, and these represent or stand for real-world things.  A description logic terminology namespace is a collection of Kind, Role, Property and Concept definitions. As in computer programming, context namespaces are intended to allow multiple knowledge bases to reside in the same physical database. (from Apelon)","Namespace | Namespace Entity | Namespace Entity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0699032","Hierarchy","C45418","A series of ordered groupings of people or things within a system; an organization with one or a few things at the top and with several things below each other thing.","Hierarchy | Tree",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704788","Definition","C42777","A concise explanation of the meaning of a word or phrase or symbol.","Definition | Defined",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711247","Attribute Set Descriptor","C42630","A description of an attribute set.","Attribute Set Descriptor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987719","Enterprise Vocabulary","C43528","A listing of the words used in some enterprise.","Enterprise Vocabulary | Vocabulary | Vocabulary | Vocabulary Object | Vocabulary Object",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711219","Terminology Entity","C42698","Terminology entities represent the elements that form and define an ontology.","Terminology Entity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007600","Cultured Cell Line","C16403","A permanently established cell culture that will proliferate indefinitely given appropriate fresh medium and space.","Cell Line | CELL LINE | Cell Lines | Cell-Line | CellLine | cultured cell line | cultured cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448677","Supplier","C43530","Someone whose business is to supply a particular service or commodity.","Supplier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0870411","Developmental stages","C43531","A general term that usually refers to named landmark events during development of an organism.","Developmental Stage | developmental stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527094","SNP Info","C41173","Provides access to the clones and the trace files from which it was identified, the two most common substitutions at that position, the offset of the SNP in the parent sequence, and a confidence score.","SNP Info | SNP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710090","Single Nucleotide Polymorphism Database","C45369","A database repository and internet resource for a broad collection of simple genetic polymorphisms.  It is hosted by the National Center for Biotechnology Information.","Single Nucleotide Polymorphism Database | dbSNP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002085","Allele","C16277","Mutually exclusive alternative forms of the same gene occupying the same locus on homologous chromosomes, differing in nucleotide sequence and governing the same biochemical and developmental process.","Allele | Alleles | allele",,,,,,,,,,,,,,,"4235440","Genetic alleles",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205165","Minor","C45367","Lesser or smaller in amount, extent, or size.","Minor | MINOR",,,,,,,,,,,,,,,"4115473","Minor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517479","Gene Alias","C41095","This object holds alternative names for a gene.","Gene Alias | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006556","cDNA","C324","Single-stranded DNA that is complementary to messenger RNA or DNA that has been synthesized from messenger RNA by reverse transcriptase.","cDNA | Complementary DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710024","Scientific Name","C43459","The name applied to a plant, animal, or other organism, according to the Codes of Nomenclature, consisting of a Genus and species.","Scientific Name | Genus and Species Name | Scientific_Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205214","Common","C43461","Widely known or encountered; standard; of no special distinction or quality.","Common | ",,,,,,,,,,,,,,,"4218633","Common",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332838","Candidate Disease Gene","C19389","A gene proposed to have a primary role in a disease, based upon its known function in other organisms or model systems or based upon its physical proximity to markers linked to a genetic disease.","Candidate Disease Gene | Candidate Gene | Candidate Genes | Target Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004793","Nucleotide Sequence","C45374","The sequence of nucleotide residues along an RNA or DNA chain.","Nucleotide Sequence | NUCLEOTIDE SEQUENCE | Sequence",,,,,,,,,,,,,,,"4219499","Base sequence",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1514572","Protocol Association","C41112","An association class relating between Clinical Trial Protocols to Diseases.","Protocol Association | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704614","International Medical Terminology","C43557","The International Medical Terminology is a clinically validated standard terminology for the reporting of regulatory activities, originally based upon the Medical Dictionary for Drug Regulatory Affairs (MedDRA), developed under the auspices of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).","International Medical Terminology | IMT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522729","Library Protocol","C41111","Laboratory protocol used to prepare a Library.","Library Protocol | Protocol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0681494","Diagram","C43559","A drawing intended to explain how something works; a drawing showing the relation between the parts.","Diagram | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518584","Ontology","C21270","A terminology that includes explicit formal specification of how to represent the objects, concepts, relationships, and other entities that are in the terminology.","Ontology | ontology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0872147","DNA Library","C16223","A collection of DNA molecules that have been cloned in vectors.","DNA Library | Library | Library",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012906","Restriction Endonuclease","C16515","Enzymes that exhibit endonuclease activity at a specific short nucleotide sequence to cleave strands of DNA.","Restriction Endonuclease | Restriction Enzyme | fragmentation enzyme | fragmentation_enzyme",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086022","Cloning Vectors","C1329","Any DNA molecule capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. They are or are derived from plasmids, bacteriophages, or viruses and are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain genetic markers to facilitate their selective recognition.","Cloning Vector | Vector | Vectors | Vectors [Cloning Vectors]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600510","Expressed Sequence Tags","C18155","Single-pass reads of 200-800 bp that were obtained from randomly selected clones from cDNA libraries. They represent a snapshot of the genes expressed in a given tissue and/or at a given developmental stage for a given organism.","Expressed Sequence Tag | EST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708608","Keyword","C43513","A word or small set of words designed to convey the subject of a technical article.","Keyword | keywordText",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709696","Producer","C45336","A person or group that creates or manufactures something.","Producer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL415099","Histopathologic Examination","C18190","The microscopic study of characteristic tissue abnormalities by employing various cytochemical and immunocytochemical stains.","Histopathologic Examination | HISTOPATHOLOGY | Histopathologic | Histopathologic Study | Histopathological | Histopathology | Histopathology | histopathology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439806","Gross","C43566","Visible to the naked eye.","Gross | Macro | Macroscopic",,,,,,,,,,,,,,,"4116700","Gross",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021149","Incidence","C16726","The relative frequency of occurrence of something.","Incidence | incidence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038954","Survival Rate","C28192","The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.","Survival Rate | overall survival rate | survival rate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704332","Cluster","C43418","A grouping of a number of similar things.","Cluster | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706510","Gene Symbol","C43568","A unique gene name approved by an organism specific nomenclature committee.","Gene Symbol | Gene Name | Gene.symbol | Official Gene Name | gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517367","GO Ontology Object","C41169","An object providing entry to a Gene object's position in the Gene Ontology Consortium's controlled vocabularies.","GO Ontology Object | GO Ontology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707788","Disease Ontology Object","C45370","Disease objects specify a disease name and ID; disease objects also provide access to: ontological relations to other diseases; clinical trial protocols treating the disease; and specific histologies associated with instances of the disease.","Disease Ontology Object | Disease Ontology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708067","Flag","C43578","An indicator that can be set or unset in order to signal whether a particular condition is true.","Flag | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448694","Organizational Unit","C41167","Organizational unit like a laboratory, institute or consortium.","Organizational Unit | Organization | Organizational",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705823","Object Title","C42774","An official descriptive name of a document, e.g. the long name of a study protocol provided by the study sponsor.","Title | Document Title",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL414404","Document","C19498","A physical object, or electronic counterpart, that is characterized by containing writing which is meant to be human-readable.","Document | DOC | Document Type | Document Type | documentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0220965","PDQ (Physician Data Query)","C15439","An online database developed and maintained by the National Cancer Institute.  Designed to make the most current, credible, and accurate cancer information available to health professionals and the public, PDQ contains peer-reviewed summaries on cancer treatment, screening, prevention, genetics, and supportive care; a registry of cancer clinical trials from around the world; and directories of physicians, professionals who provide genetics services, and organizations that provide cancer care. Most of this information is available on the Cancer.gov Web site.  More specific information about PDQ can be found at http://cancer.gov/cancer_information/pdq/.","PDQ Information System | PDQ | Physician Data Query",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0262496","Molecular Abnormality","C36391","Any alteration in the inherited nucleic acid sequence of the genotype of an organism.","Molecular Genetic Variation | Anomaly | DNA Sequence Variation | Gene Alteration | Genetic Abnormality | Genetic Alteration | Genetic Anomaly | Molecular Abnormality | Molecular Anomaly | Molecular Genetic Abnormality | Molecular Genetic Abnormality | Molecular Genetic Anomaly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513857","NSC Number","C41243","A numeric identifier for substances submitted to the National Cancer Institute (NCI) for testing and evaluation. It is named after the Cancer Chemotherapy National Service Center (CCNSC), created in 1955, which originally ran the testing program and assigned these numbers. The testing program and repository is now run by the NCI Developmental Therapeutics Program (DTP).  Assignment of NSC numbers was never done in a way that would guarantee one and only one NSC number would be assigned to a particular substance.","NSC Number | Cancer Chemotherapy National Service Center Number | NSC Code | NSC Code | National Service Center Number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511445","CMAP Ontology ID","C41082","An object providing entry to the CMAP gene ontology.","CMAP Ontology ID | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705251","NCI Concept Code","C43516","A concept unique identifier within the NCI Enterprise Vocabulary Service's NCI Thesaurus.","NCI Concept Code | Concept Code | NCI Code | NCI Thesaurus Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017270","Population Frequency","C45373","A description of the relative rate of occurrence of specific alleles, traits, or other factors within a population of organisms.","Population Frequency | Allele Frequency | Gene Frequency",,,,,,,,,,,,,,,"4238822","Gene frequency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710568","Universal Protein Resource","C43579","UniProt (Universal Protein Resource) is the world's most comprehensive catalog of information on proteins. It is a central repository of protein sequence and function created by joining the information contained in Swiss-Prot, TrEMBL, and PIR.  The UniProt Knowledgebase (UniProt) is the central access point for extensive curated protein information, including function, classification, and cross-reference.","Universal Protein Resource | UniProt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448687","Copyright","C45337","A document or statement granting exclusive right to own, publish, and sell literary, musical, or artistic work, or intellectual property.","Copyright | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002518","Amino Acid Sequence","C13187","The sequence of amino acids along a polypeptide chain.","Amino Acid Sequence | AMINO ACID SEQUENCE | Primary Protein Structure | Protein Sequence | Protein Sequence | amino acid sequence",,,,,,,,,,,,,,,"4103075","Amino acid sequence",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1707360","Checksum","C43522","A computed value which depends on the contents of a block of data and which is transmitted or stored along with the data in order to detect corruption of the data. The receiving system recomputes the checksum based upon the received data and compares this value with the one sent with the data. If the two values are the same, the receiver has some confidence that the data was received correctly.","Checksum | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334043","Homologous Gene","C28709","A gene from one species which corresponds to a gene in another species and that is related via a common ancestral species.  These genes retain a similar sequence and function.","Homologous Gene | Gene Homolog | Homolog | Homologous | Homologous Association | Homologue | Homology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710052","Sequence Similarity","C45333","The degree of similarity between the primary sequence of two biological macromolecules.","Sequence Similarity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521913","Chromosome band","C13432","Chromosomal bands observed after staining with specific dyes.  The band pattern is the result of differential interactions between the dye and nonadjacent chromosomal regions.","Chromosome Band | Chromosomal Band | Chromosomal Bands | band | cytoband",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008630","Gene Mapping","C16438","Determination of the relative positions of genes on a DNA molecule (chromosome or plasmid) and of the distance, in linkage units or physical units, between them.","Gene Mapping | Gene Localization | Gene Mapping, Total Human and Non-Human | Genetic Mapping | Genetics, Gene Mapping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028630","Nucleotide","C709","A subunit of DNA or RNA consisting of a nitrogenous base (adenine, guanine, thymine, or cytosine in DNA; adenine, guanine, uracil, or cytosine in RNA), a phosphate molecule, and a sugar molecule (deoxyribose in DNA and ribose in RNA).","Nucleotide | Base | Nucleotides | Nucleotides | nucleotide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272693","End","C25496","The point or place at which something terminates in time, space, or extent.","End | Ended | Ending",,,,,,,,,,,,,,,"4300367","Ended",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708224","Gene Relative Location","C45377","The location of a feature (for example a SNP, repeat, etc.) relative to the coding sequence of a gene.","Gene Relative Location | Gene Relative Location Object | Gene Relative Location Object | Location on Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522642","Clone","C37925","A group of genetically identical cells, organisms, or DNA molecules.","Clone | Clonal | clone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206414","Reporter Gene","C17661","A gene which produces an easily assayed phenotype.  Often used for expression studies of heterologous promoters.","Reporter Gene | Genes, Reporter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709016","Microarray","C44282","A piece of glass or plastic on which different samples have been affixed at separate locations in an ordered manner thus forming a microscopic array.  The samples are usually DNA fragments but may also be antibodies, other proteins, or tissues.","Microarray | High-Density Microarray | MICROARRAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710360","Platform","C45378","The specific version (manufacturer, model, etc.) of a technology that is used to carry out a laboratory or computational experiment.","Technology Platform Version | Platform | Platform Version | Technology Platform | Technology Platform | platform",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0457242","Square Meter","C42569","A SI unit of area measurement equal to a square whose sides are one meter long. Square meter is equal to 10,000 square centimeters; 0.01 are; 1.196 square yards; 10.76 square feet; 1550 square inches.","Square Meter | Centare | m2 | sq. m | square meter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448695","Application Context","C41086","A designation or description of the application environment or discipline in which a name is applied or from which it originates.","Application Context | Context",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0870325","Computer Application","C42608","A program that gives a computer instructions that provide the user with tools to accomplish a task.","Computer Application | Application | application software | computer application",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706704","Active Flag","C42612","An indication of whether the item in question is an active item.","Active Flag | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011001","Data Source","C16493","The person or authoritative body who provided the information.","Data Source | DATA_SOURCE | Data Sources | data origin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706859","Authentication Policy Configuration Name","C42617","This name represents the name that should be used to get all the configuration for authentication for this application.","Authentication Policy Configuration Name | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707641","Declarative Flag","C42649","An indication of whether an application uses declarative security.","Declarative Flag | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708731","Login Name","C42694","The account name used by a person to access a computer system.","Login Name | Account Name | User ID | User Name | Username",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704729","Department","C42671","A specialized division of a large organization.","Department | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515258","Telephone Number","C40978","A sequence of decimal digits (0-9) that is used for identifying a destination telephone line or other device in a telephone network.","Telephone Number | Phone | Phone Number | Telephone",,,,,,,,,,,,,,,"37118762","Telephone number (property)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709475","Password","C42710","A secret set of characters, numbers, or symbols used as a form of authentication.","Password | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705961","E-mail Address","C42775","A text string identifier for a location to which e-mail can be delivered.","E-mail Address | E-mail | Electronic Mail Address | Email | Email Address | Email Address",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705429","User Group","C42684","A set of people who have similar interests, goals, or concerns.","User Group | Group",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706336","User Privilege","C42722","The operations and access levels which are allowed to a user (e.g Create, Read, Update, Delete).","User Privilege | Privilege",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705809","Security Role Object","C42768","This class defines the security role object in context of an application. The roles are collection of privileges.","Security Role Object | Role | Security Role",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709737","Protection Group","C42706","This class represents a Protection Group. It is nothing but a collection of protection elements. A user or a user-group can assume various roles on a protection group.","Protection Group | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708643","Large Element Count Flag","C42691","A flag indicating whether the protection group has a large number of protection elements.","Large Element Count Flag | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709736","Protection Element","C42724","A Protection Element is any resource that is protected. This way the access to different part of the data can be restricted.","Protection Element | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518526","Object Class","C41106","A set of ideas, abstractions, or things in the real world that can be identified with explicit boundaries and meaning and whose properties and behavior follow the same rules.","Object Class | Object | class",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704772","Protection Element Attribute","C42616","It is the attribute of the object which is to be protected. It along with the object id forms the unique key which can identify the protection element.","Protection Element Attribute | Attribute",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711173","Group Role Context","C42686","It is the class which hold the roles which are assumed by a particular group in the context of a protection group.","Group Role Context | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709738","Protection Group Role Context","C42725","This class establishes the relationship between protection group and roles and becomes a member for a user and a group.","Protection Group Role Context | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0522537","Xenograft","C12932","Cells, tissues, or organs from a donor that are transplanted into a recipient of another species.","Xenograft | Heterograft | Xenograft Tissue | Xenotransplant",,,,,,,,,,,,,,,"4195546","Xenograft",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0208355","20S Proteasome","C13737","The 20S proteasome, as proteolytic core of the proteasome system, is essential in ATP dependent ubiquitin protein complex degradation and in antigen processing in antigen presenting cell. It has 13-15 subunits each of which has three or four different peptidase activities. 26S proteasomes may be formed in an ATP dependent fashion from a 20S proteasome and additional components, CF1 (660 kD), CF2 (250 kD) and CF3 (600 kD). The 20S proteasome interacts with additional subunits, PA700 and PA28, to form an ATP-dependent multicatalytic proteinase complex (MPC) involved in the ATP ubiquitin degradation pathway.","20S Proteasome | 20S Catalytic Proteasome | 20S Core Proteasome | 20S Proteosome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042333","Genetic Variation","C17248","Genetic Variation consists of deviation(s) in the nucleotide sequence of the genetic material of an individual from that typical of the group to which the individual belongs, or deviation(s) in the nucleotide sequence of the genetic material of offspring from that of its parents.","Genetic Variation | Genetic Diversity | GeneticVariation | Sequence Variant | Sequence Variation | variant classification | variant_classification",,,,,,,,,,,,,,,"4271711","Genetic variation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0282641","Transgene","C22190","An engineered gene consisting at least of a regulatory element and a coding sequence; regulatory element and coding sequence can come from different species.","Transgene | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512809","Integration Type","C41099","Location of the integration of the engineered gene e.g. random or targeted.","Integration Type | Location of Integration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1363945","Therapy Object (animal model)","C41174","Pre-clinical trials experiment conducted on the animal model with the goal to reduce cancer burden.","Therapy Object | Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0681814","research study","C42790","A coordinated set of actions and observations designed to generate data, with the ultimate goal of discovery or hypothesis testing.","Experiment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079870","Site-Directed Mutagenesis","C17378","Any of several methods used to create alterations in a gene at a specific location.","Site-Directed Mutagenesis | Targeted DNA Modification | Targeted Modification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512140","ES Cell Line","C20232","Stable cell lines derived from embryonic stem cells.  They can be propagated indefinitely in the primitive undifferentiated state while remaining pluripotent.","ES Cell Line | Embryonic Stem Cell Line",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1281743","Blastocyst","C13739","An embryo made up of two groups of cells. One group will develop into the fetus and the other will become the placenta.","Blastocyst | Blastosphere | Blastula",,,,,,,,,,,,,,,"4205542","Blastocyst structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036878","Sex Distribution","C40994","A description of the distribution of a trait between sexes in a population; number of males and females in a given population.","Sex Distribution | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514856","Repository Info","C41119","An object that contains information about the availability of a particular model from the repository. A submitter of data to the cancer models database can also indicate if their model should be submitted to the repository.","Repository Info | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034987","Regulatory Element","C13734","Any DNA sequence involved in the regulation of genetic processes such as transcription and replication.","Regulatory Element | Regulatory Region",,,,,,,,,,,,,,,"4314143","Nucleic acid regulatory sequence",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704324","Scientific Publication","C19026","A class of publication in which original scientific work is described.","Scientific Publication | Publication | Published | Scientific Publications",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705102","Volume (publication)","C43320","A publication that is one of a set of several similar publications.","Volume | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704732","Page (document)","C42783","One side of one leaf (of a book or magazine or newspaper or letter etc.) or the written or pictorial matter it contains.","Page | Pages",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1138432","PubMed","C42881","A web application from the National Library of Medicine (NLM).  It provides a single query interface to over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources.","PubMed | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162443","Journal","C40976","A periodical dedicated to a particular subject.","Journal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812881","Author","C42781","The writer of a book, article, or other text.","Author | Authors | DocumentAuthor | Writer",,,,,,,,,,,,,,,"4243601","Author",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0086860","Promoter","C13297","A DNA sequence at which RNA polymerase binds and initiates transcription.","Promoter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1317574","Note","C42619","A brief written record.","Note | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006159","Breeding","C42877","The production of animals or plants by selective pairing.","Breeding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522390","Person Info","C41171","Person's first and last name and the connection to the party.","Person Info | Person",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518904","Party","C41107","An informal term specifying an organization or person.","Party | Party Name | Party Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1524067","Rodent Nomenclature Name","C41105","Official nomenclature name for mouse and rat models.","Rodent Nomenclature Name | Nomenclature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517619","Jax Info","C41101","Identification number (stock number) of strain at the Jackson Laboratory.","Jax Info | Jax Stock Number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3847505","Repository","C16143","A facility where items can be deposited for storage or safekeeping.","Repository | Bank | Repository  of Specimens and Reagents",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512710","Induced Mutation","C40987","Any mutation that occurs in response to inducing agents, including radiation, viral infection, and a broad variety of mutagenic chemicals.","Induced Mutation | Induced DNA Alteration | Induced Sequence Alteration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0487602","Staining Method","C23010","Any of the various methods that use a dye, reagent, or other material for producing coloration in tissues or microorganisms for microscopic examination.","Staining Method | STAINING | Stain | Staining | stain type | stain_type",,,,,,,,,,,,,,,"4132406","Staining method",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517524","Genotype Summary","C41098","Listing of the genetic changes made deliberately in order to generate the animal model.","Genotype Summary | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517520","Genomic Segment","C41097","Genomic segment extracted from a library e.g. BAC or YAC library to be used in the genetic manipulation of the animal model.","Genomic Segment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0302523","Observation in research","C25598","Watching something and taking note of what happens.","Observation | Inspection | OBSERVATION | Observational | Visual Inspection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0871738","Experimental Method","C43622","The use of controlled observations and measurements to test hypotheses.","Experimental Method | experimental method | experimental strategy | experimental_method | experimental_strategy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0872177","gene delivery process","C41096","Gene is delivered to specific organs or specific receptors within the animal model using viral vectors.","Gene Delivery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520007","Viral Vector","C2173","A viral gene transduction agent used to transfer genes or genetic materials, such as retroviruses and adenoviruses.","Viral Vector | viral vector",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0686732","Environmental Risk Factor","C18244","Health hazards at home, in the work place, or in nature (e.g., infectious agents, irritants, respiratory fibrotic agents, asphyxiants, allergens, metabolic poisons, physical agents, mutagens, teratogens, and carcinogens). (Winett et al: Health Psychology and Public Health)","Environmental Risk Factor | Environmental Factor",,,,,,,,,,,,,,,"4010837","Environmental risk factor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516876","Engineered Gene","C40985","A gene that has been artificially altered in sequence or structure.","Engineered Gene | Genetically Engineered Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707247","Cancer Bioinformatics Infrastructure Objects","C42878","The vision for caCORE is to provide a common data management framework that will support the consistency, clarity, and comparability of biomedical research data and information. The cancer Bioinformatics Infrastructure Objects (caBIO) model and architecture is the primary programmatic interface to caCORE. The heart of caBIO is its domain objects, each of which represents an entity found in biomedical research. These domain objects are related to each other, and examining these relationships can bring to the surface biomedical knowledge that was previously buried in the various primary data sources.","Cancer Bioinformatics Infrastructure Objects | Cancer Bioimformatics Object Model | Cancer Bioinformatics Infrastructure Object Model | caBIO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511490","Person Contact Information","C41085","Information regarding the person who is acting as a channel for communication between groups.","Person Contact Information | Contact Info | Contact Info",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549619","Fax Number","C42879","A telephone number that is used for identifying a destination fax machine in a telephone network.","Fax Number | FAX | Facsimile Number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519605","Transgene Conditionality","C41084","Indicates if a transgene or targeted modification is done conditionally (time or tissue specific).","Transgene Conditionality | Conditionality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516279","Carcinogenic Intervention","C41078","Treatment or procedure that the animal model was exposed to in order to initiate or support the development of neoplastic lesions.","Carcinogenic Intervention | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710634","Visible To","C43613","This property describes the intended viewing audience.","Visible To | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1283071","Release","C42882","To make available; set free.","Release | Released | Released | Releasing",,,,,,,,,,,,,,,"4045050","Release - action",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0012644","Animal Disease Models","C16504","Animal disease whose pathologic mechanisms are sufficiently similar to those of a human disease for the animal disease to serve as a model.","Animal Model of Disease | Animal Model | Disease Models, Animal | animal model",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710546","Uniform Resource Locator","C42743","The global address of documents and other resources on the World Wide Web.","Uniform Resource Locator | URL | uniform resource locator (URL) | uniformResourceLocator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516211","Cancer Model","C19691","Any model that can be used to study issues important in cancer such as cancer development or prediction.","Cancer Model | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448686","Abstract","C42874","A concept or idea not associated with any specific instance.","Abstract | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520210","Yeast Model System","C19617","Pathways and other molecular and cellular processes which can be manipulated in yeast, the results of which can be extrapolated to human systems.","Yeast Model System | Yeast Model",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519205","Growth Inhibition Screening Result","C41121","A Screening Result captures the results of the tens of thousands of compounds screened for their ability to inhibit the growth of selected yeast strains altered in DNA damage repair or cell cycle control.","Growth Inhibition Screening Result | Screening Result | Screening Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3463820","Inhibition","C42791","The interference with or prevention of an action or response even though the stimulus for that action or response is present.","Inhibition | Inhibiting | Inhibitory | Response Inhibition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517589","In Vivo Result","C41100","An Invivo Result captures the results of anti-tumor drug screening.","In Vivo Result | Invivo Result | Invivo Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206194","Survivor","C17659","A person who lives through affliction.","Survivor | survivor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242890","Toxicity Test","C17755","Controlled laboratory tests to determine the toxicity of a chemical to an organism in terms of specific chemical concentrations.","Toxicity Test | Toxicity Testing | Toxicity_Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517022","Expression Feature","C41164","Describes the expression pattern of a gene.","Expression Feature | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011777","Dexamethasone","C422","A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","Dexamethasone | (11Beta,16alpha)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione | 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone | 16Alpha-methyl-9alpha-fluoro-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione | 16Alpha-methyl-9alpha-fluoro-delta1-hydrocortisone | 16Alpha-methyl-9alpha-fluoroprednisolone | 9Alpha-fluoro-11beta,17alpha,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione | 9Alpha-fluoro-16alpha-methylprednisolone | 9alpha-Fluoro-16alpha- methylprednisolone | Aacidexam | Adexone | Aknichthol Dexa | Alba-Dex | Alin | Alin Depot | Alin Oftalmico | Amplidermis | Anemul mono | Auricularum | Auxiloson | Baycadron | Baycuten | Baycuten N | Cortidexason | Cortisumman | DEXAMETHASONE | Decacort | Decadrol | Decadron | Decadron DP | Decalix | Decameth | Decasone R.p. | Dectancyl | Dekacort | Deltafluorene | Deronil | Desamethasone | Desameton | Dexa-Mamallet | Dexa-Rhinosan | Dexa-Scheroson | Dexa-sine | Dexacortal | Dexacortin | Dexafarma | Dexafluorene | Dexalocal | Dexamecortin | Dexameth | Dexamethasone Intensol | Dexamethasonum | Dexamonozon | Dexapos | Dexinoral | Dexone | Dinormon | Dxevo | Fluoro-9alpha Methyl-16alpha Prednisolone | Fluorodelta | Fortecortin | Gammacorten | Hemady | Hexadecadrol | Hexadrol | LenaDex | Lokalison-F | Loverine | Methylfluorprednisolone | Millicorten | Mymethasone | Orgadrone | Spersadex | TaperDex | Visumetazone | ZoDex | dexamethasone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0076080","Temozolomide","C1244","A triazene analog of dacarbazine with antineoplastic activity.  As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of DNA replication. Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. (NCI04)","Temozolomide | 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide | 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one | CCRG-81045 | Gliotem | Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo- | M & B 39831 | M and B 39831 | Methazolastone | RP-46161 | SCH 52365 | TEMOZOLOMIDE | TMZ | Temcad | Temizole | Temodal | Temodar | Temomedac | imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo- | temozolomide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1533491","Erlotinib Hydrochloride","C2693","The hydrochloride salt of a quinazoline derivative with antineoplastic properties.  Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.","Erlotinib Hydrochloride | CP 358 | CP-358 | CP-358,774 | CP358 | Cp-358,774 | ERLOTINIB HYDROCHLORIDE | Erlotinib | N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine Monohydrochloride | OSI 774 | OSI-774 | OSI774 | Tarceva | erlotinib hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0335038","Reporter","C41191","Somebody who makes a report of any kind, e.g. a person who is authorized to gather and give a formal or official account or description of findings, events, issues and other information regarding clinical study, drug adverse effect, preclinical research results, data and safety monitoring, etc. to appropriate agency or institution.","Reporter | ",,,,,,,,,,,,,,,"4202044","Reporter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032743","Positron Emission Tomography","C17007","A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.","Positron Emission Tomography | Medical Imaging, Positron Emission Tomography | PET | PET SCAN | PET Scan | PET scan | PT | Pet Scan | Positron Emission Tomography Scan | Positron emission tomography (procedure) | Positron-Emission Tomography | positron emission tomography scan | proton magnetic resonance spectroscopic imaging",,,,,,,,,,,,,,,"4305790","Positron emission tomography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1506592","Soluble Receptor Tyrosine-Protein Kinase erbB-2, Human","C18435","Soluble receptor tyrosine-protein kinase erbB-2 is encoded by the human ERBB2 gene. This protein may be involved in binding to receptor tyrosine-protein kinase erbB-2, which leads to disruption of dimer formation, reduced receptor phosphorylation, and inhibition of cell growth.","Soluble Receptor Tyrosine-Protein Kinase erbB-2 | ERBB2 | ERBB2 ECD | ERBB2 Extracellular Domain | HER2 ECD | HER2 Extracellular Domain | Herstatin | Soluble ERBB2 | Soluble ErbB-2 | Soluble ErbB-2 | Soluble Receptor Tyrosine-Protein Kinase erbB-2 | sERBB2 | sErbB-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521425","Endocrine","C41064","Collective designation for those tissues capable of secreting hormones.","Endocrine | endocrine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0060389","Finasteride","C1099","A synthetic 4-azasteroid compound. Finasteride competitively binds to and inhibits steroid type II 5-alpha-reductase in the prostate gland, liver, and skin, thereby interfering with the enzymatic conversion of testosterone to 5-dihydrotestosterone (DHT) and reducing serum DHT levels. The reduction in serum DHT levels results in diminished stimulation of androgen receptors in the nuclei of prostate cells and, so, diminished prostate cell proliferation.","Finasteride | (5alpha,17beta)-N-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide | Chibro-Proscar | FINASTERIDE | Finastid | MK 906 | Pro-Cure | Propecia | Propeshia | Proscar | Prostide | Urprosan | finasteride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025201","Melanocyte","C12591","Epidermal dendritic pigment cells which control long-term morphological color changes by alteration in their number or in the amount of pigment they produce and store in the pigment containing organelles called MELANOSOMES. MELANOPHORES are larger cells which do not exist in mammals.","Melanocyte | Melanocytes | melanocyte",,,,,,,,,,,,,,,"4321440","Melanocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085301","Proto-Oncogene Proteins c-fos","C17439","c-FOS protein is a transcription factor critical in regulating the development of the skeleton.  c-FOS protein is a major component of the DNA-binding AP-1 transcription complex, which also includes members of the JUN family.  Each protein contains a bZIP domain and a leucine zipper domain.  FOS oncoproteins derive from mutated FOS genes.  These proteins have been found in the Finkel-Biskis-Jinkins (FBJ-MSV) and Finkel-Biskis-Reilly (FBR-MSV) murine sarcoma viruses, which induce osteogenic sarcomas in mice.  The FBJ-MSV v-fos gene encodes a 55 kD protein and the FBR-MSV v-fos gene encodes a 75 kD fusion protein.  (from OMIM 164810 and NCI)","FOS Oncoprotein | Cellular Oncogene c-FOS | FOS_Oncoprotein | G0S7 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511887","Diagnostic or Prognostic Factor","C20047","A characteristic of an organism that contributes to the diagnosis or treatment of a disease or to the prediction of clinical outcomes.","Diagnostic or Prognostic Factor | Diagnostic_or_Prognostic_Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227716","Bladder Neck","C12336","The inferior portion of the urinary bladder which is formed as the walls of the bladder converge and become contiguous with the proximal urethra.","Bladder Neck | BLADDER, NECK | Bladder neck | Cervix Vesicae | Neck | Neck of Bladder | Neck of the Bladder | neck of urinary bladder",,,,,,,,,,,,,,,"4272632","Structure of neck of urinary bladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0279492","Antiandrogen Therapy","C15481","A therapeutic regimen that utilizes pharmaceuticals to reduce serum levels of male sex hormones.","Antiandrogen Therapy | ADT | Androgen Deprivation Therapy | Androgen Deprivation Therapy (ADT) | Anti-androgen Therapy | Anti-androgen Treatment | Antiandrogen Treatment | Hormone Deprivation Therapy | Hormone-Deprivation Therapy | antiandrogen therapy",,,,,,,,,,,,,,,"45768763","Androgen deprivation therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1707532","Cross-Reference","C43621","A notation or direction at one place (as in a book or filing system) to pertinent information at another place.","Cross-Reference | Cross Reference | Xref",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242356","Databases","C15426","An information set with a regular structure.  Although it can be applied to any set of information the term was invented to refer to computerized data, and is used almost exclusively in computing.","Database | DB | Data Bank | Database, Electronic | database",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709753","Provenance","C43581","Where something originated or was nurtured in its early existence.","Provenance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705163","Data Transformation","C43582","A process whereby data is changed from one format to another.","Data Transformation | Transformation | data transformations",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332120","Evidence","C43583","Knowledge on which to base belief.","Evidence | ",,,,,,,,,,,,,,,"4089880","Evidence of",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021622","Institutes","C41206","An established society, corporation, foundation or other organization founded and united for a specific purpose, e.g. for health-related research; also used to refer to a building or buildings occupied or used by such organization.","Institution | INSTITUTION | Institute | Institutional | registering institution | registering_institution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710664","Web Service","C45412","A software-powered resource or functional component whose capabilities can be accessed at an internet URI; an automated resource accessed via the Internet.","Web Service | Web Services | Web Services",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL026523","Internet","C20342","A worldwide, decentralized network of computer networks connecting individuals and organizations to information and electronic mail services.","Internet | internet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704784","Owner","C42704","One with an interest in, dominion of, or control over an object or property.","Owner | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0746921","Lymph Node Mass","C35521","A benign or malignant solid pathologic process involving a lymph node.","Lymph Node Mass | Nodal Mass",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036916","Sexually Transmitted Disorder","C3365","A disorder acquired through sexual contact.","Sexually Transmitted Disorder | STD | STI | Sexually Transmitted Disease | Sexually Transmitted Infection | VD | Venereal Disease",,,,,,,,,,,,,,,"440647","Sexually transmitted infectious disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708063","First-Line Therapy","C45792","The preferred standard treatment for a particular condition.","First-Line Therapy | First Line Therapy | First Line Treatment | First line of therapy | First-Line Treatment | first-line therapy | primary therapy | primary treatment",,,,,,,,,,,,,,,"45769570","First line treatment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1707909","Encrypted","C45417","Having been converted from text into code so as to be unintelligible to unauthorized parties.","Encrypted | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1552663","Boolean","C45254","The type of an expression with two possible values, 'true' and 'false'.","Boolean | BL | Boolean Value",,,,,,,,,,,,,,,"605553","Boolean value",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705740","Pellet Formation","C45813","Formation by cetrifugation of a tightly packed sample in the bottom of a tube.","Pellet Formation | Pellet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704808","Lobular Cancerization","C45806","Lobular Cancerization (or cancerization of lobules, COL) is the presence in a lobule of ductal carcinoma in situ (DCIS) tumor cells with preservation of the normal lobular pattern. It appears to represents a variation in the growth pattern of DCIS, not secondary extension of DCIS into a lobule.","Lobular Cancerization | COL | Cancerization of a Lobule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516220","Cancer Prevention Trial","C15790","Clinical trials that study ways of reducing the risk of getting cancer.","Cancer Prevention Trial | Clinical Trials, Prevention",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009417","Colposcopy","C16451","Endoscopic examination of the uterine cervix and vagina.","Colposcopy | CP | colposcopy",,,,,,,,,,,,,,,"4189586","Colposcopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021344","Human Papillomavirus","C14226","A strain of papillomavirus that can infect the skin and mucous membranes of humans.","Human Papillomavirus | HPV | HUMAN PAPILLOMAVIRUS | Human Papilloma Virus | human papillomavirus",,,,,,,,,,,,,,,"4317416","Human papillomavirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519671","Cancer Biobank","C15863","A repository of biospecimens - including tissue samples, fluids such as blood, serum and urine, and molecular derivatives such as DNA, RNA and proteins pertaining to cancer research. The repository has stringent guidelines regarding the standardized collection, handling, storage and documentation of biological specimens. These guidelines enable an extensive system for specimen storage that allows for the accurate establishment of disease incidences over long periods of time.","Cancer Biobank | Cancer Biorepository | Tumor Bank | Tumor Bank",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1302362","Stage Grouping","C38027","An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","Stage Grouping | Group | Stage Group | TNM Stage Group | TNM Stage Grouping",,,,,,,,,,,,,,,"4219603","TNM stage grouping",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205370","Unspecified","C38046","Not stated explicitly or in detail.","Unspecified | None Specified | Not Assigned | Not Specified | UNSPECIFIED | unspecified",,,,,,,,,,,,,,,"4001594","Non-specific",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704620","Intersex","C45908","Refers to an individual who was born with genitalia and/or secondary sexual characteristics of indeterminate sex, or which combine features of both sexes.","Intersex | INTERSEX | Intersexed | UNDIFFERENTIATED",,,,,,,,,,,,,,,"46273637","Intersex",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019269","Hermaphrodite","C45909","An organism having both male and female sexual characteristics and organs.","Hermaphrodite | HERMAPHRODITE | Hermaphroditism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709595","Pooled Sample","C45910","A mix of specimens from multiple individuals representing multiple sex groups.","Sex Pooled Sample | Pooled Sample | Pooled Sample | Sex Pooled Specimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0459471","Interpretation","C41255","An act or process of elucidation, explication, or explanation of the meaning of an event or thing.","Interpretation | INTERPRETATION | INTP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521941","Prescription","C28180","A verbal or written order given by an authorized person instructing a patient to obtain and use a medical device, prescription or undergo a procedure.","Prescription | Prescription Use (Rx) | Rx | prescription",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1442989","Standard (qualifier)","C44275","Regularly and widely used.","Standard | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456603","Ratio","C44256","Quotient of quantities of the same kind for different components within the same system.","Ratio | RATIO | ratio | {RATIO} | {Ratio}",,,,,,,,,,,,,,,"4042999","Ratio",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1510776","Addendum","C41216","An appendage to an existing document that contains supplemental information. The parent document remains content is unaltered.","Addendum | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022116","Ischemia","C34738","Lack of blood supply to an area of the body, resulting in impairment of tissue oxygenation.","Ischemia | ischemia",,,,,,,,,,,,,,,"4200991","Ischemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028582","Nuclear Medicine","C16922","Nuclear Medicine is the branch of medicine that uses radioactive materials either to image a patient's body or to destroy diseased cells.","Nuclear Medicine | Radiology / Radiation Biology / Nuclear Medicine | Radiology-Nuclear Medicine",,,,,,,,,,,,,,,"4190438","Nuclear medicine - specialty",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1441547","Derivation","C42885","The source from which something comes or issues; to take, obtain, or receive from a source.","Derivation | DER | DERIVED | Derived | Derived",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019932","Hormone","C2315","Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various endocrine glands and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects.","Hormone | Endocrine Gland Secretion | Hormones | hormone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205489","Dermatologic","C41128","Having to do with the skin.","Dermatologic | ",,,,,,,,,,,,,,,"4277597","Dermatologic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0370231","Whole Blood","C41067","Blood that has not been separated into its various components; blood that has not been modified except for the addition of an anticoagulant.","Whole Blood | Peripheral Whole Blood | WHOLE BLOOD | Whole blood",,,,,,,,,,,,,,,"4170424","Whole blood",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001175","Acquired Immunodeficiency Syndrome","C2851","A syndrome resulting from the acquired deficiency of cellular immunity caused by the human immunodeficiency virus (HIV). It is characterized by the reduction of the Helper T-lymphocytes in the peripheral blood and the lymph nodes. Symptoms include generalized lymphadenopathy, fever, weight loss, and chronic diarrhea. Patients with AIDS are especially susceptible to opportunistic infections, tuberculosis, candida infections, and cryptococcosis), and the development of malignant neoplasms (usually non-Hodgkin lymphoma and Kaposi sarcoma). The human immunodeficiency virus is transmitted through sexual contact, sharing of contaminated needles, or transfusion of contaminated blood.","Acquired Immunodeficiency Syndrome | AIDS | Acquired Immune Deficiency | Acquired Immunodeficiency | Acquired Immunodeficiency Disease | HIV / AIDS | HIV/AIDS | acquired immunodeficiency syndrome",,,,,,,,,,,,,,,"4267414","AIDS",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706722","Administered Item","C42613","A registry item for which administrative information is recorded in an Administration Record.","Administered Item | Administered Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710679","Workflow","C42753","The operational aspect of a work procedure: how tasks are structured, who performs them, what their relative order is, how they are synchronized, how information flows to support the tasks and how tasks are being tracked.","Workflow | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205262","Hidden","C45671","Not accessible to view.","Hidden | ",,,,,,,,,,,,,,,"4246103","Occult",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710575","Unresolved Issue","C42869","Any problem that remains unresolved regarding proper documentation of the Administered Item.","Unresolved Issue | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710548","Unique","C45282","The single one of its kind.","Unique | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707531","Created By","C42628","Indicates the person or authoritative body who brought the item into existence.","Created By | Creator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205349","Modified By","C42629","Indicates the person or authoritative body who changed an item.","Modified By | Modifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516778","Conceptual Domain","C41083","The set of all possible Valid Value meanings of a Data Element Concept expressed without representation.","Conceptual Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707753","Dimensionality","C42676","The state of having dimensions; an indication of the dimensions associated with an object.","Dimensionality | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511729","Data Element Concept","C41087","A concept that can be represented in the form of a data element, described independently of any particular representation.","Data Element Concept | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511728","Data Element","C41002","A unit of data for which the definition, identification, representation and permissible values are specified by means of a set of attributes.","Data Element | data element",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516596","Classification Scheme","C41079","An arrangement or division of objects into groups based on characteristics that the objects have in common, e.g., origin, composition, structure, application, function, etc. Adds information not easily included in definitions, helps organize the registry and facilitates access to the registry.","Classification Scheme | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708631","Label Type Flag","C42854","An indicator that specifies if the classification scheme is A= alphanumeric; C=character; N=numeric.","Label Type Flag | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710611","Value Domain","C42748","Specified by a description or specification, such as a rule, a procedure, a range (i.e. interval), or by a set of permissible values.","Value Domain | VD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553726","Data Type","C42645","An indication of the form that a value will have.  Examples include string, integer, and character.","Data Type | DataType | Datatype | data type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707354","Character Set","C42631","A defined list of characters recognized by the computer hardware and software. Each character is represented by a number.","Character Set | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1301627","Format","C42761","The organization of information according to preset specifications.","Format | data format | data_format",,,,,,,,,,,,,,,"4262183","Format",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1521256","3: 384700814-38499868","C41646","Physical location of ACVR2B_Gene","3: 384700814-38499868 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708366","High Value Number","C42853","Indicates the upper limit permissible for a value.","High Value Number | Range",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516597","Classification Scheme Item","C41080","A component of content in a Classification Scheme. This may be a node in a taxonomy or ontology or a term in a thesaurus, etc.","Classification Scheme Item | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519018","Permissible Value","C41109","The exact names, codes and text that can be stored in a data field in an information management system.","Permissible Value | permissible values",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514812","Reference Document","C41117","A document that provides pertinent details for consultation about a subject.","Reference Document | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705176","Order (arrangement)","C42680","A logical or comprehensible arrangement of separate elements; a condition of regular or proper arrangement.","Order | Ordered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1264636","Property","C42605","A basic or essential attribute shared by all members of a class.","Property | ",,,,,,,,,,,,,,,"4041103","Property",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705542","Template","C45677","Something that establishes or serves as a pattern for reference; a form, mold, or pattern used as a guide to making something.","Template | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709061","Module","C42721","A self-contained component (unit or item) that is used in combination with other components.","Module | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514574","Protocol Forms Set","C41113","Protocols, with Case Report Forms included, stipulate the execution of Clinical Trials.","Protocol Forms Set | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709941","Reviewed By (qualifier)","C42728","Indicates the person or authoritative body who appraised, evaluated, or analyzed the item.","Reviewed By | Reviewer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706842","Approved By","C42615","Indicates the person or authoritative body who has given approval.","Approved By | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522634","Question","C41116","A sentence of inquiry that asks for a reply; a request for information (e.g., a formal request to a database or search engine).","Question | Query | Question Text | Question Text | Request",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514623","Qualifier (concept)","C41009","A term that helps define and render a concept unique.","Qualifier | Modifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514861","Representation Component","C41120","Mechanism by which the functional and/or presentational category of an item may be conveyed to a user. Component of a Data Element Name that describes how data are represented (i.e. the combination of a Value Domain, data type, and if necessary a unit of measure or a character set.) The Representation occupies the last position in the Data Element name (i.e. rightmost).","Representation Component | Representation | Representation Class",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519940","Valid Value","C41124","The allowable values for a given data element (question) on a Case Report Form.","Valid Value | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510813","Administered Component Designation","C41092","A name by which an Administered Component is known in a specific Context. Also a placeholder to track the usage of Administered Components by different Contexts.","Administered Component Designation | Designation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709258","Non-enumerated","C45675","Not individually specified; expressed as a descrition, text, or set of instructions.","Non-enumerated | Nonenumerated | Nonenumerated | Nonenumerated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519950","Value Meaning","C41126","The significance associated with an allowable/permissible value.","Value Meaning | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704771","Association Class","C45672","In UML modeling, an association that is also a class.  It not only connects a set of classes, but also defines a set of features that belong to the relationship itself.","Association Class | Association",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519949","Value Domain Permissible Value","C41125","This captures the many to many relationship between value domain and permissible values and allows to associate a value domain to a permissible value.","Value Domain Permissible Value | Permissible Value",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511731","Data Element Derivation","C41089","The data element component(s) used for a derived data element.","Data Element Derivation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0805874","derivation calculation","C42861","The logical, mathematical, and/or other operations specifying derivation. The rule may range from a simple operation such as subtraction to a very complex set of derivations.","Derivation Rule | Rule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707467","Concatenation Character","C42641","The symbol used to represent a linking of separate elements.","Concatenation Character | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511779","Derivation Type","C41090","The type of Derived Data Element that is being created. For example a Data Element that is derived/created by subtracting two dates represented by other data elements would be a Calculated Representation Type. Types include: Calculated, Complex Recode, Compound, Concatenation, Object Class, and Simple Recode.","Derivation Type | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0302828","Instruction [Publication Type]","C42688","A message describing how something is to be done.","Instruction | Instructions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707634","Data Element Relationship","C42644","The affiliation between two occurrences of Data Elements.","Data Element Relationship | Data Element Relationships",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707404","Classification Scheme Relationship","C42633","The affiliation between two occurrences of Classification Schemes.","Classification Scheme Relationship | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707403","Classification Scheme Item Relationship","C42632","The affiliation between two occurrences of Classification Scheme Items.","Classification Scheme Item Relationship | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449738","Direction","C42677","The spatial relation between something and the course along which it points or moves.","Direction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449822","Multiplicity","C45676","The number of values for which a given condition holds; an indication of how many objects may participate in a given relationship; the property of being multiple.","Multiplicity | multiplicity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705250","NCI Thesaurus Concept","C43821","A concept is the basic unit of information contained in the Thesaurus. They describe sets of individuals in a given domain. A concept has a name, belongs to a Namespace and exists in relation to other concepts. The vertical relationships consist of 'isa' statements that form a logical hierarchy (taxonomy or subsumption graph). In general, concepts above a given concept are referred to as superconcepts or parents and those below as subconcepts or children. In addition, there are horizontal named realationships between concepts called Roles, binary relations between concepts that provide a machine-interpretable definition of a concept and the means for discrimination of sibling concepts. A concept may also include Properties, named slots that allow attachment of external information to concepts.","NCI Thesaurus Concept | Concept | Concept | Terminology Concept",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707868","EVS Code Type","C42852","The type of EVS concept code (e.g., NCI_CONCEPT_CODE, UML_CUI).","EVS Code Type | EVS Source",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707927","Enumeration","C45674","The act of specifying individually; expressing as a list.","Enumeration | Enumerated | Enumerated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0190979","Phlebotomy","C28221","The collection of blood from a vein, most commonly via needle venipuncture.","Phlebotomy | Blood Draw | PHLEBOTOMY | Venipuncture | blood draw | phlebotomy | venipuncture",,,,,,,,,,,,,,,"4245372","Phlebotomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516044","Apoptotic","C14156","Pertaining to apoptosis.","Apoptotic | APOPTOTIC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0741847","Bypass","C15723","A surgical procedure in which the doctor creates a new pathway for the flow of body fluids.","Bypass | bypass",,,,,,,,,,,,,,,"4229451","Construction of shunt",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0059438","epigallocatechin gallate","C1088","A phenolic antioxidant found in a number of plants such as green and black tea. It inhibits cellular oxidation and prevents free radical damage to cells. It is under study as a potential cancer chemopreventive agent. (NCI)","Epigallocatechin Gallate | (-)-Epigallocatechin-3-Gallate | (2R-cis)-3,4-Dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl 3,4,5-Trihydroxybenzoate | EGCG | EPIGALLOCATECHIN GALLATE | Epigallocatechin-3-Gallate | Epigallocatechin-Gallate | Epigallocatechingallate | Tea catechin | [(2R,3R)-2-(3,4,5-trihydroxyphenyl)-5,7-dihydroxy-chroman-3-yl] 3,4,5-trihydroxybenzoate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448701","Or","C37998","An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","Or | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3281210","Malignant Breast Neoplasm","C9335","A primary or metastatic malignant neoplasm involving the breast.  The vast majority of cases are carcinomas arising from the breast parenchyma or the nipple.  Malignant breast neoplasms occur more frequently in females than in males.","Malignant Breast Neoplasm | Malignant Breast Tumor | Malignant Neoplasm of Breast | Malignant Neoplasm of the Breast | Malignant Tumor of Breast | Malignant Tumor of the Breast",,,,,,,,,,,,,,,"4112853","Malignant tumor of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0086930","Health Risk Assessment","C15367","An estimated probability that one or more adverse event(s) will occur as a result of exposure to an actual or potential hazardous situation or chemical.","Health Risk Assessment | Risk Assessment | Risk Assessment | risk assessment",,,,,,,,,,,,,,,"4024612","Risk assessment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004910","Bed Rest","C45985","Confinement of an individual to bed for therapeutic reasons.","Bed Rest | Bed Confinement | Bed rest | Confinement to Bed",,,,,,,,,,,,,,,"4021158","Bedrest",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037775","Distribution","C45273","The act of distributing or spreading or apportioning.","Distribution | Distribute | Distributed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1561954","tube","C41277","A hollow cylinder, especially one for holding or conveying liquids; anything shaped like such a hollow cylinder, e.g. an organic structure having the shape or function of a tube such as channel within a plant or animal body (e.g. fallopian tube).","Tube | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0347997","Object","C45281","Something perceptible by one or more of the senses, especially by vision or touch; a material thing.","Object | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515985","Androgen Suppression","C15676","Blockage of the production of male hormones.","Androgen Suppression | Androgen Ablation | Androgen Deprivation | Testosterone Suppression | androgen ablation | androgen deprivation | androgen suppression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037253","Skeletal System","C12788","The collection of bones and tissues, including ligaments and cartilage, that compose the rigid internal framework of the human body, and which serves a multitude of functions, including structural support, movement, protection, production of blood cells, storage of ions, and endocrine regulation.","Skeletal System | Skeleton | skeletal | skeleton",,,,,,,,,,,,,,,"4014426","Skeletal system structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0496899","Benign Brain Neoplasm","C4781","A neoplasm that arises from the brain and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Brain Neoplasm | Benign Brain Tumor | Benign Neoplasm of Brain | Benign Neoplasm of the Brain | Benign Tumor of Brain | Benign Tumor of the Brain | Benign neoplasm of brain, unspecified | Benign_Brain_Neoplasm | Brain Neoplasms, Benign",,,,,,,,,,,,,,,"379769","Benign neoplasm of brain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0681906","Patient Self-Report","C21089","Subjective reports made by a patient.","Patient Self-Report | Self Report | Self-Report | Self-Reported | subject-reported outcome (SRO)",,,,,,,,,,,,,,,"603082|764573","Self reported|Self-reported",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0042866","D Vitamin","C941","A family of lipo-soluble steroids important to the absorption, metabolism, and function of calcium and phosphorus and the growth and development of bone and tooth enamel. Found naturally in animal tissues, cholecalciferol (vitamin D3) is formed in the skin when ultraviolet light activates cholesterol conversion into vitamin D3. Ultraviolet irradiation of ergosterol (plant vitamin D) forms ergocalciferol (vitamin D2). (NCI04)","D Vitamin | 3-[2-[7a-methyl-1-(1,4,5-trimethylhex-2-enyl)-1,2,3,3a,5,6,7,7a-octahydroinden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol | VITAMIN D | Vitamin D | Vitamin D | Vitamin D Compound | Vitamin-D | vitamin D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707687","Describable Class","C43443","Abstract class that allows subclasses to inherit the association to Description, for detailed annotations such as Ontology entries and Database references, the association to Audit, for tracking changes, and the association to Security for indicating permissions. (caMAGE)","Describable Class | Describable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705683","Identifiable Class","C44469","A class that has an unambiguous reference within the scope.  It also has a potentially ambiguous name.","Identifiable Class | Identifiable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707967","Extendable Class","C45846","Abstract class that specifies for subclasses an association to NameValueTypes.  These can be used, for instance, to specify proprietary properties and in-house processing hints.","Extendable Class | Extendable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710495","Tuple","C43426","A data object containing two or more components.","Tuple | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522053","DNA Microarray format","C25922","This term describes an experiment in which probes representing genes that one wants to study are affixed to a substrate (e.g., a glass slide) and then exposed to target molecules (sometimes referred to as the sample). The level of hybridization between a specific probe and a target (typically indicated through fluorescence and measured through image analysis) indicates the level of the gene corresponding to that probe in a test solution.","DNA Microarray Analysis | DNA Microarray | DNA Microarray | Gene Microarray",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706388","Array Feature","C44283","A specific position on a microarray.","Array Feature | Feature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709534","Physical Array Design","C44180","A design that is expected to be used to manufacture physical arrays.","Physical Array Design | Physical Array Design Object | Physical Array Design Object",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708660","Layout","C43430","A plan or design of something that is laid out.","Layout | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710706","Zone","C43428","An area or region distinguished from adjacent parts by a distinctive feature or characteristic.","Zone | Zonal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0178587","Density","C45781","The amount of something per unit size.","Density | DENSITY",,,,,,,,,,,,,,,"4052433","Density",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706132","Column (arrangement)","C43379","An arrangement of objects one under another in a line.","Column | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1552846","Row (arrangement)","C43378","An arrangement of objects side by side in a line.","Row | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710137","Spacing","C45786","An intervening interval of space or time.","Spacing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441833","Group","C43359","Any number of entities (members) considered as a unit.","Group | Panel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704750","X-Dimension","C45784","The magnitude of something in a horizontal direction.","X-Dimension | X | xDimension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704671","Y-Dimension","C45785","The magnitude of something in a vertical direction.","Y-Dimension | Y | yDimension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704751","X-Coordinate","C44477","A horizontal coordinate that is used together with a vertical coordinate to specify an exact point in space.","X-Coordinate | X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704670","Y-Coordinate","C44478","A vertical coordinate that is used together with a horizontal coordinate to specify an exact point in space.","Y-Coordinate | y",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709911","Reporter Group","C44266","Allows specification of the type of Reporter Design Element. (caMAGE)","Reporter Group | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707691","Design Element","C43445","An element of an array.  This is generally of type feature but can be specified as reporters or compositeSequence for arrays that are abstracted from a physical array. (caMAGE)","Design Element | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707462","Composite Group","C43436","Allows specification of the type of Composite Design Element. (caMAGE)","Composite Group | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709878","Reference Point","C45793","A specified location to which measurements are referred.","Reference Point | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707511","Coordinate on an axis or a grid","C44465","A number or other designation that identifies a position relative to an axis or grid.","Coordinate | Coordinates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1457869","Defect","C43429","A failing or deficiency.","Defect | DEFECT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004738","Barcode","C43361","A machine-readable representation of information in a visual format on a surface.","Barcode | Bar Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708936","mark - attribute","C45787","A distinguishing symbol, a written or printed symbol, or a visible indication made on a surface.","Mark | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704322","Orientation (spatial)","C45788","Position or alignment relative to points of the compass or other specific directions.","Spatial Orientation | Orientation | Oriented",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0870840","Manufacture","C43360","The act of making something (a product) from raw materials.","Manufacture | MANUFACTURE | Manufacturing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704410","Tolerance","C43414","The allowable deviation from a standard; a permissible difference.","Tolerance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708056","Fiducial","C44467","Used as a fixed standard of reference for comparison or measurement.","Fiducial | Fiduciary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708932","Manufacture LIMS","C44470","Information on the physical production of arrays within the laboratory. (caMAGE)","Manufacture LIMS | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704781","Biologically-Derived Material","C43376","Natural substances derived from living organisms such as cells, tissues, proteins, and DNA.","Biologically-Derived Material | Biomaterial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0184066","Microplate","C43377","A flat dish with multiple individual wells that are arrayed in a standardized number, size, and arrangement.","Microplate | Microtiter Plate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708632","Labeled (qualifier)","C43386","Bearing or marked with a label or tag.","Labeled | Tagged",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706958","Biosample","C43412","BioSamples are products of treatments that are of interest.  BioSamples are often used as the sources for other biosamples.  The Type attribute describes the role the BioSample holds in the treatment hierarchy.  This type can be an extract. (caMAGE)","Biosample | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205198","Compound","C43366","A substance formed by chemical union of two or more elements or ingredients in definite proportion by weight.","Compound | compound",,,,,,,,,,,,,,,"4268167","Compound",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1697819","Solvent","C45790","A liquid that dissolves or that is capable of dissolving; the component of a solution that is present in greater amount.","Solvent | solvent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705169","Biomaterial Treatment","C43442","The process by which a biomaterial is created (from source biomaterials).  Treatments have an order and an action. (caMAGE)","Biomaterial Treatment | Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704780","Bioassay Class","C42886","An abstract class which represents both physical and computational groupings of arrays and biomaterials.","Bioassay Class | Bioassay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707420","Cluster Node","C44475","An individual component of a clustering.  May contain other nodes.","Cluster Node | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL222537","Content","C44476","Everything that is included in a collection, container, or communication.","Content | Contents | content",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709535","Physical Bioassay Object","C44181","A bioAssay created by the bioAssayCreation event (e.g. in gene expression analysis this event is represented by the hybridization event).","Physical Bioassay Object | Physical Bioassay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1548524","Uniform Resource Identifier","C42778","A character string that identifies an internet resource; URIs can be either a uniform resource locator (URL) or uniform resource name (URN).","Uniform Resource Identifier | URI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706095","Channel Object","C44170","An independent acquisition scheme, i.e., a route or conduit through which flows data consisting of one particular measurement using one particular parameter.","Channel | Acquisition Scheme | Channel Object | Channel Object",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708950","Measured Bioassay","C44471","The direct processing of information in a physical bioAssay by the featureExtraction event.  Often uses images which are referenced through the physical bioAssay.","Measured Bioassay | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707635","Data Extraction","C44285","A process whereby specific data is taken out of a larger set of data and presented in a usable format.","Data Extraction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028602","Nucleic Acid Hybridization","C16924","Laboratory procedure in which single stranded nucleic acids are allowed to interact so that complexes, or hybrids, are formed by molecules with sufficiently similar, complementary sequences. By this means the degree of sequence identity can be assessed and specific sequences detected. (From Biology-online)","Nucleic Acid Hybridization | Hybridization | Molecular Biology, Molecular Hybridization | NUCLEIC ACID HYBRIDIZATION",,,,,,,,,,,,,,,"4297703","Nucleic acid hybridization procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708464","Image Acquisition","C43385","The process by which an image is acquired or obtained.","Image Acquisition | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704774","Audit Object","C44169","Tracks information on the contact that creates or modifies an object.","Audit Object | Audit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520235","10: 123347907-123227846","C42271","Physical location of FGFR2_Gene","10: 123347907-123227846 | Security Group",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710431","Toll-Free Telephone Number","C43413","A special telephone number in which the calling party is not charged for the cost of the call. Instead, the called party pays all of the charges for the call.","Toll-Free Telephone Number | Toll-Free Number | Toll-Free Phone | Toll-Free Phone Number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709794","Quantitation Type Dimension","C44186","An ordered list of quantitationTypes.","Quantitation Type Dimension | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704815","Collection Object - UML Entity","C43446","An object that holds the values or locations of other objects.","Container Object | Collection | Collection Object | Container",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706473","Functional Map","C43434","A function such that for every element of one set there is a unique element of another set.","Functional Map | Map | Map Function",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0745732","List","C43432","A series of names, words, or other items written, printed, or imagined one after the other.","List | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711369","Quantitation Type","C43447","A method for calculating a single datum of the matrix (e.g. raw intensity, background, error).","Quantitation Type | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707633","Data Cube","C44171","A multidimensional representation of data which provides fast retrieval and drill down facilities.","Data Cube | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510941","Array","C26358","An orderly arrangement.","Array | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027965","New England States","C43439","The area in the United States comprised of the following states: Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut, and New Jersey.","New England States | CompositeSequenceDimension | New England",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709910","Reporter Dimension","C44262","Specialized DesignElementDimension to hold Reporters.","Reporter Dimension | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711346","Feature Dimension","C44284","Specialized DesignElementDimension to hold Features. (caMAGE)","Feature Dimension | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706386","Experiment Object","C44173","The Experiment is the collection of all the BioAssays that are related by the ExperimentDesign. (caMAGE)","Experiment Object | Experiment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981173","Variable Characteristic","C43371","A characteristic or attribute of an object, event, or other entity under observation that can assume more than one value and by which a classification can be assigned.","Variable Characteristic | Variable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0549193","Parameter","C44175","Any factor that defines a system and determines (or limits) its performance.","Parameter | Parameter Object | Parameter Value | VAL | parameter",,,,,,,,,,,,,,,"608007","Parameter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709744","Protocol Application Object","C44184","The use of a protocol with the requisite parameters and parameter values.","Protocol Application Object | Protocol Application | Protocol Application",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037585","Computer Program","C17146","A set of coded instructions, which a computer follows in processing data, performing an operation, or solving a logical problem, upon execution of the program.","Computer Program | Computer Software | Software | software",,,,,,,,,,,,,,,"45768388","Software",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026336","Study models","C43383","A style or design of an item.","Model | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711345","Hardware Application","C44468","The use of a piece of hardware with the requisite Parameters and ParameterValues. (caMAGE)","Hardware Application | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709463","Parameterizable Object","C44176","The Parameterizable interface encapsulates the association of Parameters with ParameterValues. (caMAGE)","Parameterizable Object | Parameterizable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709462","Parameterizable Application","C44178","The interface that is the use of a Parameterizable class. (caMAGE)","Parameterizable Application | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705654","Entry (data)","C43381","An item inserted in a written or electronic record.","Entry | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709214","Network Address","C45791","A means of identifying and locating an individual device on a communication network. This may include a name based address (e.g., ncicb.nci.nih.gov), or a numeric internet protocol address.","Network Address | IP Address | Internet Protocol Address",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709322","Ontology Entry","C44174","A single entry from an ontology or a controlled vocabulary.  For instance, category could be 'species name', value could be 'homo sapiens' and ontology would be taxonomy database, NCBI. (caMAGE)","Ontology Entry | Ontology Entry Object | Ontology Entry Object",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706687","Absolute vs Relative Indicator","C45832","An indicator that a measurement is reported as absolute or relative to some other measurement. (caMAGE)","Absolute vs Relative Indicator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439148","Unit","C44278","A single undivided thing occurring in the composition of something else.","Unit | U | Units | {Unit} | {U}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439221","Unit of Time","C42574","An indication of the type of unit of measure being used to express a time.","Unit of Time | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439196","Unit of Length","C42578","An indication of the type of unit of measure being used to express a length or distance.","Unit of Length | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439235","Unit of Temperature","C44276","An indication of the type of unit of measure being used to express a temperature.","Unit of Temperature | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3853797","Unit Quantity - Maximum number of items covered","C44258","An indication of the type of unit of measure being used to express a quantity.","Unit of Quantity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439206","Unit of Mass","C42579","An indication of the type of unit of measure being used to express a mass.","Unit of Mass | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439240","Unit of Volume","C44279","An indication of the type of unit of measure being used to express a volume.","Unit of Volume | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1446561","Concentration (quantity)","C41185","The quantity of a substance per unit volume or weight; a measure of the amount of substance present in a unit amount of mixture, particularly, the amount of solute dissolved in a solvent. The amounts can be expressed as moles, masses, volumes, or parts.","Concentration | CONC | concentration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706945","Bio Event","C44172","An abstract class to capture the concept of an event (either in the laboratory or a computational analysis). (caMAGE)","Bio Event | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707883","Editor","C43368","A person who edits material for publication; a person having managerial and sometimes policy-making responsibility for the editorial part of a publishing firm or of a newspaper, magazine, or other publication; the supervisor or conductor of a department of a newspaper, magazine, etc.","Editor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706387","Issue (document)","C43415","One of a series of documents that are published periodically.","Issue | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709767","Publisher","C43416","A person or firm engaged in publishing periodicals or books or music.","Publisher | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517495","Gene Feature","C13445","The structural elements that comprise a gene or transcription unit. Gene structures include the transcription initiation site, the protein coding sequences, intervening sequences, and the transcription termination or polyadenylation sites as well as the regulatory elements (enhancers, silencers, and the promoter) that lie outside the boundaries of the transcribed unit.","Gene Feature | Gene Organization | Gene Structure | Gene Structure/Organization | Seq Feature | Sequence Feature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521343","4: 1762854-1777829","C42272","Physical location of FGFR3_Gene","4: 1762854-1777829 | Annotation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518439","Nuclear Structure","C13446","Any structures that are enclosed within nucleus are considered nuclear structure, including any macromolecular structures. (NCI)","Nuclear Structure | Gene Feature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708040","Feature Strand Type","C45833","Indicates the direction and/or type of the SeqFeature, i.e. whether it is in the 5' or 3' direction, is double stranded, etc. (caMAGE)","Feature Strand Type | Feature_Strand_Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332232","Approximate","C45828","Not quite exact or correct; almost exact or correct.","Approximate | About | Approximately",,,,,,,,,,,,,,,"4094357","Approximate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1282913","Circle","C45789","A ring-shaped structure with every point equidistant from the center.","Circle | Circular",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706907","Background","C45782","Existing conditions, especially those that would be confused with the phenomenon to be observed or measured.","Background | Backgroud",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704211","Specialized","C44274","Developed or designed for a special activity or function.","Specialized | ",,,,,,,,,,,,,,,"4194898","Special",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710082","Signal","C43382","A detectable physical quantity or impulse (e.g., voltage, current, or magnetic field strength).","Signal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0444706","Measured","C44473","Having been determined by measurement.","Measured | ",,,,,,,,,,,,,,,"4122991","Measured",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0743559","error","C43369","A discrepancy between a computed, observed, or measured value or condition and the true, specified, or theoretically correct value or condition.","Error | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709380","P-Value","C44185","A measure of the probability that a result happened by chance. The lower the p-value, the more likely it is that the result was caused by phenomenon of interest.","P-Value | P Value | P value (probability value) | Statistical Significance | p-value | p-value (probability value)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704726","Confidence","C43367","A feeling of trust (in someone or something).","Confidence | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709643","Present/Absent Object","C44183","Indicates relative presence or absence.  From the enumeration AbsoluteCallTypeEnum (Present / Absent / Marginal / No call) or ComparisonCallTypeEnum (Increase / Marginal Increase / Decrease / Marginal Decrease / No change / No Call / Unknown), as specified by the dataType. (caMAGE)","Present/Absent Object | Presence/Absence | Present Absent | Present/Absent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0231175","Failed","C44281","Having undergone failure; did not accomplish the intended purpose.","Failed | FAIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705915","Reporter Object","C44255","A biological material (clone, oligo, etc.) on an array which will report on some biosequence or biosequences. Also refers to any substance that is identifiable by virtue of its radioactive signature, color, or other distinguishing physical property, such as a dye, radioactive isotope, or inert chemical, that is introduced into a biological or mechanical system and can be followed through the course of a process, providing information on the pattern of events in the process or on the redistribution of the parts, elements, or events involved.","Reporter Substance | Reporter | Reporter | Reporter Object | Reporter Object",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709912","Reporter Position","C44267","The location in the composite target's sequence to which a source reporter maps.  The association to MismatchInformation allows the specification, usually for control purposes, of deviations from the CompositeSequence's BioMaterial. (caMAGE)","Reporter Position | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707463","Composite Position","C43437","The location in the compositeSequence target's sequence to which a source compositeSequence maps.  The association to MismatchInformation allows the specification, usually for control purposes, of deviations from the CompositeSequence's BioMaterial. (caMAGE)","Composite Position | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707464","Composite Sequence","C43435","A collection of Reporter or CompositeSequence Design Elements, annotated through the association to BioSequence. (caMAGE)","Composite Sequence | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709041","Mismatch Information","C44474","Describes how a reporter varies from its ReporterCharacteristics sequence(s) or how a Feature varies from its Reporter sequence. (caMAGE)","Mismatch Information | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708038","Feature Information","C44291","As part of the map information, allows the association of one or more differences in the BioMaterial on a feature from the BioMaterial of the Reporter.  Useful for control purposes such as in Affymetrix probe pairs. (caMAGE)","Feature Information | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708039","Feature Reporter Map","C44466","A FeatureReporterMap is the description of how source features are transformed into a target reporter.  These would map replicate features for a reporter to the reporter. (caMAGE)","Feature Reporter Map | FeatureReporterMap",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709909","Reporter Composite Map","C44260","A ReporterCompositeMap is the description of how source Reporters are transformed into a target CompositeSequences.  For instance, several reporters that tile across a section of a chromosome could be mapped to a CompositeSequence. (caMAGE)","Reporter Composite Map | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600139","Prostate Carcinoma","C4863","One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","Prostate Carcinoma | Cancer of Prostate | Cancer of the Prostate | Carcinoma of Prostate | Carcinoma of the Prostate | Other Prostate Carcinoma | Prostate Cancer | Prostate cancer, NOS | prostate cancer",,,,,,,,,,,,,,,"4116087","Carcinoma of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1254042","Anatomical maturation","C17770","The act, or process, of natural progression in physical and psychological maturation from a previous, lower, or embryonic stage to a later, more complex, or adult stage.","Maturation | Development | Development | Developmental",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041445","Tympanic Membrane","C12502","A thin membrane that separates the external auditory canal from the middle ear. The movement of the tympanic membrane in response to air pressure changes in the external ear facilitates the transmission of sound energy by causing vibration of the ossicular chain.","Tympanic Membrane | Ear Drum | Eardrum | Membrana Tympanica | Membrane, Tympanic | TM | TYMPANIC MEMBRANE",,,,,,,,,,,,,,,"4178172","Tympanic membrane structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1524083","Undifferentiated Sex","C41438","Sex could not be determined; not uniquely defined; undifferentiated.","Undifferentiated Sex | Not Specified | Sex Not Specified | Undifferentiated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706429","Male, Self-Reported","C46107","An individual who reports to be male, the sex that ordinarily produces sperm.","Male, Self-Report | Male | Male Sex, Self Report | Male, Self-Reported",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705497","Female, Self-Report","C46108","An individual who reports to be female, the sex that ordinarily produces ova.","Female, Self-Report | Female | Female Sex, Self-Report | Female, Self-Reported",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706180","Male Gender, Self Report","C46109","The cultural, social, psychological, and behavior norms that are associated with being a man.","Male Gender | Male | Male Gender, Self Report | Male Gender, Self Reported",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448708","Female Gender","C46110","The cultural, social, psychological, and behavior norms that are associated with being a woman.","Female Gender | Female | Female Gender, Self Report | Female Gender, Self Reported",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706428","Male Phenotype","C46112","An animal who is observed by researcher or clinician to be male, the sex that ordinarily produces sperm.","Male Phenotype | MALE | Male",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705498","Female Phenotype","C46113","An animal who is observed by researcher or clinician to be female, the sex that ordinarily produces ova.","Female Phenotype | FEMALE | Female",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710693","XY Genotype","C45977","The normal genotype of a male human.","XY Genotype | 46XY | Male Genotype | XY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0450371","XX Genotype","C45976","The normal genotype of a female human.","XX Genotype | 46XX | Female Genotype | XX",,,,,,,,,,,,,,,"4130749","46XX",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705489","Transgender Woman","C46120","A person who was assigned to the male gender at birth based on physical characteristics but who self-identifies psychologically and emotionally as female.","Transgender Woman | M-to-F | M2F | MTF | Male-to-Female Transsexual | Male-to-Female Transsexual | Male-to-Female Transsexual, Self-Report | TF | TRANSGENDER WOMAN/GIRL | Trans Female | Trans Woman | Transgender Female | Transgender Female/Woman/Girl | Transgender female | Transsexual Female | Transwoman",,,,,,,,,,,,,,,"4248372","Male-to-female transsexual",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705488","Female-to-Male Transsexual, Self-Report","C46121","A person who was assigned to the female gender at birth based on physical characteristics but who self-identifies psychologically and emotionally as male.","Transgender Man | F-to-M | F2M | FTM | Female-to-Male Transsexual | Female-to-Male Transsexual | Female-to-Male Transsexual, Self-Report | TM | TRANSGENDER MAN/BOY | Trans Man | Transgender Male | Transgender Male/Man/Boy | Transgender male | Transman | Transsexual Male | Transsexual Man",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0558141","Transsexual","C46117","A person who was assigned to one sex at birth based on physical characteristics but who self-identifies psychologically and emotionally as the other.","Transsexual | Trans",,,,,,,,,,,,,,,"4231241","Transsexual",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026724","Mucosa","C13166","Mucous membrane.","Mucosa | MUCOSA | Mucosal | Mucous Membrane | mucosa | mucous membrane",,,,,,,,,,,,,,,"4212318","Mucous membrane structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206417","Peripheral Nervous System","C12465","That part of the nervous system consisting of the nerves and neurons that reside or extend outside the central nervous system.","Peripheral Nervous System | Peripheral nervous system | peripheral nervous system",,,,,,,,,,,,,,,"4148296","Peripheral nervous system structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522730","CNS (MMHCC)","C22605","The organ system of the mouse consisting of the brain and spinal cord.","Mouse Central Nervous System | CNS (MMHCC) | CNS (MMHCC)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0543478","Residual Disease","C4809","The persistence of tumor cells in the body following cancer treatment.","Residual Disease | Residual Tumor | residual disease | residual tumor | residual_disease | residual_tumor",,,,,,,,,,,,,,,"4077124","Residual tumor stage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205682","Waist-Hip Ratio","C17651","The ratio of the abdominal circumference at the navel to maximum hip and buttocks circumference; looks at the proportion of fat stored on the body around the waist and hip. Carrying extra weight around the waist is a greater health risk than carrying extra weight around the hips or thighs.","Waist-Hip Ratio | WAISTHIP | Waist to Hip Ratio",,,,,,,,,,,,,,,"4087501","Waist/hip ratio",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0677930","Primary Neoplasm","C8509","A tumor at the original site of origin.","Primary Neoplasm | Primary | Primary Tumor | primary | primary tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0164786","Proto-Oncogene Proteins c-akt","C41625","Expressed in diverse tissues, Protein Kinase B (AKT/RAC Family) is a group (Alpha, Beta and Gamma) of cytoplasmic serine/threonine enzymes that covalently transfer the terminal, gamma phosphate group from ATP to a variety of substrate proteins and regulate cell signaling responses to insulin, PDGF, and IGF1 (through PI3K) involved in cell survival, cell proliferation, differentiation, apoptosis, glycogen synthesis, and glucose uptake.","Protein Kinase B | AKT | Akt | Protein_Kinase_B | protein kinase B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414313","EGFR Gene","C17757","This gene is involved in the epidermal growth factor signal transduction pathway.","EGFR Gene | EGFR | Epidermal Growth Factor Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015295","Exon","C13231","The sequences of a gene that are present in the final, mature, spliced messenger RNA molecule from that gene.","Exon | exon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707076","CA Repeat","C45810","A dinucleotide repeat consisting of (CA/GT)n.","CA Repeat | CA/GT Repeat | GT Repeat | GT/CA Repeat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439079","Positive integer","C47801","An integer with a value greater than zero.","Non-Negative Integer | Non-Negative Integer Value | Positive Integer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439080","Ordinal Position","C46126","A number designating a place in an ordered sequence.","Ordinal Position | Ordinal | Ordinal Number | Ordinal Number | Ordinal Position Number",,,,,,,,,,,,,,,"4158499","Ordinal number",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3549709","Coronary Artery Disease","C26732","Narrowing of the coronary arteries due to fatty deposits inside the arterial walls. The diagnostic criteria may include documented history of any of the following: documented coronary artery stenosis greater than or equal to 50% (by cardiac catheterization or other modality of direct imaging of the coronary arteries); previous coronary artery bypass surgery (CABG); previous percutaneous coronary intervention (PCI); previous myocardial infarction. (ACC)","Coronary Artery Disease | CAD | Coronary Disease | Coronary Disease | Coronary artery disease | Coronary artery disorder | coronary artery disease | coronary heart disease",,,,,,,,,,,,,,,"317576","Coronary arteriosclerosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1711239","Since","C45325","Subsequent to; after.","Since | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705019","American Diabetes Association","C47836","A nonprofit health organization providing diabetes research, information and advocacy. The mission of the Association is to prevent and cure diabetes and to improve the lives of all people affected by diabetes.  To fulfill this mission, the American Diabetes Association funds research, publishes scientific findings, provides information and other services to people with diabetes, their families, health professionals and the public. The Association is also actively involved in advocating for scientific research and for the rights of people with diabetes.","American Diabetes Association | ADA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0302909","Solid","C45300","The state in which a substance has no tendency to flow under moderate stress; resists forces (such as compression) that tend to deform it; and retains a definite size and shape.","Solid | ",,,,,,,,,,,,,,,"4193245","Solid substance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0000511","4-Nitroquinoline-1-Oxide","C194","A quinoline derivative with potent tumorigenic activity. 4-nitroquinoline-1-oxide (4-NQO) potentially induces DNA damage by either binding directly to DNA and disrupting replication or through the generation of reactive oxygen species (ROS). 4-NQO is also metabolized to form other mutagenic compounds, such as 8-hydroxy-2'-deoxyguanosine.","4-Nitroquinoline-1-Oxide | 4-NQO | 4-Nitroquinoline N-oxide | 4-nitroquinoline 1-oxide | Absorption",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516329","Cell Culture System","C19147","Systems and reagents for the propagation of cells in tissue culture","Cell Culture System | Cell_Culture_System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0972569","Electrophoresis Gel","C45307","A gel matrix through which molecules are separated, usually by size or charge, under the influence of an electrical field.","Electrophoresis Gel | Electrophoresis_Gel | Gel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512520","Hybridization Array","C18842","A molecular biology device that utilizes a set of defined oligonucleotide probes, recombinant clones, or other samples attached in a specific grid arrangement to a solid support for nucleic acid hybridization assays in gene mapping studies or in determining gene sequences, sequence variations, or gene expression patterns.","Hybridization Array | Hybridization_Array",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512629","Imaging Device","C19747","A device for producing a representation or picture, usually of a part of the body, to aid in diagnosis and evaluation","Imaging Device | Imaging Tool | Imaging_Device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025080","Medical Device","C16830","Any physical object that is useful for prevention, diagnosis, monitoring, or treatment of disease or other conditions.","Medical Device | DEVICE | Device | Medical Devices | Medical_Device | medical device",,,,,,,,,,,,,,,"4272314","Biomedical device",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013058","Pharmaceutical Dosage Form","C42636","The form in which active and/or inert ingredient(s) are physically presented.","Pharmaceutical Dosage Form | DOSFRM | Dosage Form | Dose Form | Drug Dose Form | Pharmaceutical | Pharmaceutical Dose Form | Pharmaceutical Formulation | Pharmaceutical_Dosage_Form | dosage form | dose form | pharmaceutical form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704753","Storage Unit","C45322","A physical structure or device capable of holding objects or samples.","Storage Unit | Storage Device | StorageEquipment | Unit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520064","Vortex Mixer","C29544","An electrical rotator that blends or mixes substances or ingredients, in whirling or rotary motion, for homogenizing samples.","Vortex Mixer | Vortex_Mixer | Vortexer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448964","Computer System","C16462","A set of hardware and software which processes data in a meaningful way.","Computer System | Computer_System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1523997","Recombinant Corticotropin","C212","A recombinant peptide hormone chemically identical to or similar to human polypeptide hormone corticotropin (adrenocorticotropic hormone; ACTH). Secreted by the anterior pituitary gland, circulating ACTH stimulates the adrenal cortex to secrete adrenocortical steroids, especially cortisone, which elevate blood pressure in response to stress. With normally functioning adrenal glands, recombinant corticotropin could be used to achieve pharmacologic effects similar to those from cortisone administration.","Recombinant Corticotropin | ACTH | Absorption Half-Life | Acthar | Adrenocorticotropic Hormone | Adrenocorticotropin | CORTICOTROPIN | Corticotropin | Therapeutic ACTH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001551","Immunoadjuvant","C210","Adjuvants are mostly pharmacological agents of drug or biological origin used to modify the antigenicity of immunization components, i.e., to stimulate, potentiate, or depress the immune response or to inhibit or enhance specific subclasses of immunocytes.  Adjuvants augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level.  Classical agents (Freund's adjuvant, BCG, Corynebacterium parvum) contain bacterial antigens.  Some adjuvants are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1).  Their mode of action is either non-specific, resulting in increased immune responsiveness to a variety of antigens, or antigen-specific, affecting a restricted type of immune response to a narrow group of antigens.  Since adjuvants enhance the body's immune response, they can be considered a type of immune modulator.","Immunoadjuvant | Adjuvants, Immunologic | Affected by concomitant drug administration | Immunologic Adjuvant | Immunologic Adjuvants | immune adjuvant | immunological adjuvant",,,,,,,,,,,,,,,"4143851","Immunologic adjuvant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0000641","Benzo(a)pyrene-7,8-diol 9,10-Epoxide","C196","A polycyclic aromatic hydrocarbon and metabolite of benzo(a)pyrene with potent cytotoxic and mutagenic properties. Benzo(a)pyrene-7,8-diol-9,10-epoxide binds directly to DNA and disrupts DNA replication.","Benzo(a)pyrene-7,8-diol 9,10-Epoxide | 8a,9a-Dihydrobenzo(10,11)chryseno(3,4-b)oxirene-7,8-diol | Affected by food/other nutrients | BPDE | Benzo(10,11)chryseno(3,4-b)oxirene-7,8-diol, 8a,9a-dihydro-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001143","Aclarubicin","C202","An oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces galilaeus. Aclarubicin intercalates into DNA and interacts with topoisomerases I and II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine. This agent is less cardiotoxic than doxorubicin and daunorubicin.","Aclarubicin | (1R,2R,4S)-2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R,trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranosyl]-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl]oxy]-1-naphthacenecarboxylic acid methyl ester | 1-naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5, 7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-((2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl) -alpha-L-lyxo-hexopyranosyl]-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl]oxy]-, methyl ester,(1R-(1alpha,2beta,4beta))-(9CI) | ACLARUBICIN | ACM-A | Aclacinomycin | Aclacinomycin A | Aclacinomycin-A | Antibiotic MA144-A1 | MA144-A1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001455","Cyclic AMP","C208","A second messenger molecule comprised of an adenine ribonucleotide bearing a phosphate group bound to the oxygen molecules at the 3' and 5' positions of the sugar moiety. Cyclic AMP, which is synthesized from ATP by the intracellular enzyme adenylate cyclase, modulates the activity of several hormone-dependent signal transduction pathways.","Cyclic AMP | 3'5'-cyclic ester of AMP | ADENOSINE CYCLIC PHOSPHATE | Adenosine Cyclic 3',5'-(Hydrogen Phosphate) | Adenosine Cyclic 3',5'-Phosphate | Adenosine Cyclic 3',5'-Phosphate | Adenosine Cyclic 3':5'-Monophosphate | Cyclic Adenosine Monophosphate | cAMP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708092","Forced Expiratory Volume in 6 Seconds","C47843","A test of lung function, the FEV6 is the volume exhaled during six seconds of a forced expiratory maneuver started from the level of total lung capacity.","Forced Expiratory Volume in 6 Seconds | FEV6 | Forced Expiratory Volume 6 | Forced Expiratory Volume 6 Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205164","Major","C45368","Greater or bigger in amount, extent, or size.","Major | MAJOR",,,,,,,,,,,,,,,"4115472","Major",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0079083","Carboplatin","C1282","A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","Carboplatin | (SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum | 1,1-cyclobutanedicarboxylic acid platinum complex | Blastocarb | CARBOPLATIN | CBDCA | Carboplat | Carboplatin Hexal | Carboplatino | Carboplatinum | Carbosin | Carbosol | Carbotec | Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum | Displata | Ercar | JM-8 | JM8 | Nealorin | Novoplatinum | Paraplat | Paraplatin | Paraplatin AQ | Paraplatine | Platinwas | Ribocarbo | carboplatin | cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II) | cis-diammine(cyclobutanedicarboxylato)platinum II | platinum, diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828387","Method, LOINC Axis 6","C40570","The process by which an observation value was obtained.  Example methods include: weighing, use of a mass spectrometer, use of an ion sensitive electrode, and examination using a microscope.","Method, LOINC Axis 6 | LOINC Axis 6 | Method | Method LOINC Axis 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709789","QS Wave by ECG Finding","C47872","An electrocardiographic finding of a QS wave, which is atypical.","QS Wave by ECG Finding | Abnormal Q Wave | QS Wave | QS Wave | QS Wave by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006087","Brachial Artery","C12681","An artery originating at the axillary artery and branching into the radial and ulnar arteries.","Brachial Artery | ARTERY, BRACHIAL | BRACHIAL ARTERY | Brachial | Brachial artery",,,,,,,,,,,,,,,"4063510","Structure of brachial artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025102","Medical Record","C45258","A chronological written account of a patient's examination and treatment that includes the patient's medical history and complaints, the physician's physical findings, the results of diagnostic tests and procedures, and medications and therapeutic procedures.","Medical Record | From Electronic Health Record | From Medical Record | Medical Records | Medical Report",,,,,,,,,,,,,,,"4030601","Medical record",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1711359","Hepatobiliary System","C43612","The liver, gallbladder, and associated ducts, considered collectively.","Hepatobiliary System | HEPATOBILIARY SYSTEM | hepatobiliary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516077","At","C25427","Used to indicate position, location, or state.","At | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024671","Mammography","C16818","A type of radiography used specifically to examine breast tissue. The procedure utilizes a low-dose of x-rays or radiation to generate an image. A mammography exam or mammogram, is used as a screening tool to detect early breast cancer in women experiencing no symptoms and to detect and diagnose breast disease.","Mammography | MAMMOGRAPHY | MG | mammography",,,,,,,,,,,,,,,"4324693","Mammography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019929","Hormone Receptor","C28154","Ligand binding proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell.  The hormone receptor can be cytoplasmic/nuclear, or associated with the cell membrane in the case of receptors whose ligands cannot penetrate the membrane.","Hormone Receptor | hormone receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376571","BRCA1 Gene","C17965","This gene plays a role in cell cycle control, regulation of transcription and the maintenance of genomic stability. It is also involved in the inhibition of mammary cell growth.","BRCA1 Gene | BRCA1 | BRCA1, DNA Repair Associated Gene | Breast Cancer 1, Early Onset Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705484","Female-to-Male Transsexual Phenotype","C47838","An individual who was female at birth based on physical characteristics and has undergone hormonal therapy and/or surgical procedures in order to develop more male physical characteristics.","Female-to-Male Transsexual Phenotype | Female-to-Male Transsexual | Trans Man Phenotype | Transgener Man Phenotype",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705486","Male-to-Female Transsexual Phenotype","C47837","An individual who was male at birth based on physical characteristics and has undergone hormonal therapy and/or surgical procedures in order to develop more female physical characteristics.","Male-to-Female Transsexual Phenotype | Male-to-Female Transsexual | Trans Woman Phenotype | Transgender Woman Phenotype",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705487","Male-to-Female Transsexual Animal","C47917","An organism that was male at birth based on physical characteristics and has undergone hormonal therapy and/or surgical procedures in order to develop more female physical characteristics.","Male-to-Female Transsexual Animal | Male-to-Female Transsexual",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705485","Female-to-Male Transsexual Animal","C47918","An organism that was female at birth based on physical characteristics and has undergone hormonal therapy and/or surgical procedures in order to develop more male physical characteristics.","Female-to-Male Transsexual Animal | Female-to-Male Transsexual",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004475","Azacitidine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510758","Acetyl Group Shuttle Pathway","C39144","Most of the energy derived from the oxidation of glucose is not extracted directly as ATP, but as reduced NADH that transfers high-energy electrons to the electron transport chain in the inner mitochondrial membrane. This NADH comes primarily from the Krebs cycle in the mitochondrial matrix and is therefore directly accessible to electron transport. NADH generated during glycolysis cannot reach the electron transport chain directly however and there is no direct mechanism for the transfer of NADH across the mitochondrial membrane. Instead shuttle mechanisms have evolved to move the energy of reduced NADH across the membrane in the form of other reduced molecules. One shuttle is the glycerophosphate shuttle and another is the malate-aspartate shuttle. The malate-aspartate shuttle occurs in mammalian tissues. First, oxaloacetate on the cytoplasmic side is reduced by NADH, creating malate and NAD+. Malate and the electrons it carries are transported into the mitochondria across the inner mitochondrial membrane, in exchange for alpha-ketoglutarate, which is transported out of the mitochondria. Once inside, the energy in malate is extracted again by reducing NAD+ to make NADH, regenerating oxaloacetate. This NADH is then free to transfer its high energy electrons to the electron transport chain. The oxaloacetate is transaminated with glutamate to make aspartate and alpha-ketoglutarate. Aspartate is returned to the cytosol by the aspartate-glutamate transporter, which moves glutamate into the mitochondria as it transports aspartate out. The overall result is that NADH is transported into the mitochondria, and can be used to generate 3 ATP per every NADH transported in from the cytosol, a very efficient process. (BioCarta)","Acetyl Group Shuttle Pathway | Shuttle for transfer of acetyl groups from mitochondria to the cytosol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1557816","Genitourinary Fistula, CTCAE","C53824","No value exists.","Genitourinary Fistula, CTCAE | Fistula, GU | Oral Spray",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1559868","Infection Adverse Event with Unknown Absolute Neutrophil Count","C53832","No value exists.","Infection with Unknown Absolute Neutrophil Count, CTCAE | Infection with unknown ANC | Topical Spray",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1448598","SKIL protein, human","C29970","Ski-like protein (684 aa, ~77 kDa) is encoded by the human SKIL gene. This protein plays a role in the regulation of both gene transcription and signal transduction.","SKI-Like Protein | Physiological Effects | SKI-Like | SKI-Like Protein SKIL | SKI-Related Oncogene | SKI-Related Oncogene SNO Protein | SKI-Related Protein | SKIL | SNO | SNOA | SNON",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333075","Coagulation Factor Gene","C28480","Coagulation Factor Genes encode endogenous Coagulation Factors, involved in blood coagulation. (NCI)","Coagulation Factor Gene | Generalized Systemic Effects",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3657987","RPS3 protein, human","C29906","40S ribosomal protein S3 (243 aa, ~27 kDa) is encoded by the human RPS3 gene. This protein plays a role in translation and DNA repair.","40S Ribosomal Protein S3 | EC 4.2.99.18 | Organ System Specific Effects | RPS3 | Ribosomal Protein S3 | Small Ribosomal Subunit Protein uS3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152132","Hypertensive Retinopathy","C3514","Retinopathy due to hypertension.","Hypertensive Retinopathy | Hypertensive retinopathy, unspecified eye | Immunologic Diseases",,,,,,,,,,,,,,,"376965","Hypertensive retinopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0812227","Oncogene YES-1","C18349","The gene product of oncogene YES-1 is associated with tyrosine kinase activity and its amino acid sequence shows high similarity with that of SRC. Multiple copies of YES-related genes occur in the human genome. Oncogene YES-1 is located at 18p11.31-p11.21.","Oncogene YES-1 | YES-1Gene | YES1 | YES1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4015937","Acute Myeloid Leukemia","C3171","A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","Acute Myeloid Leukemia | AML | AML - Acute Myeloid Leukemia | ANLL | Acute Granulocytic Leukemia | Acute Myeloblastic Leukemia | Acute Myelocytic Leukemia | Acute Myelogenous Leukemia | Acute Myelogenous Leukemias | Acute Myeloid Leukemia (AML) | Acute Nonlymphocytic Leukemia | Acute granulocytic leukemia | Acute myeloblastic leukemia | Acute myelocytic leukemia | Acute myelogenous leukemia | Acute myeloid leukemia | Acute myeloid leukemia (AML) | Hematopoeitic - Acute Myleogenous Leukemia (AML) | acute myeloblastic leukemia | acute myelogenous leukemia | acute myeloid leukemia | acute nonlymphocytic leukemia",,,,,,,,,,,,,,,"140352","Acute myeloid leukemia, disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010711","Cytarabine","C408","An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","Cytarabine | .beta.-Cytosine arabinoside | 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone | 1-.beta.-D-Arabinofuranosylcytosine | 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone | 1-Beta-D-arabinofuranosylcytosine | 1.beta.-D-Arabinofuranosylcytosine | 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl- | 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl- | 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone | ARA-cell | Alexan | Ara-C | Arabine | Arabinofuranosylcytosine | Arabinosylcytosine | Aracytidine | Aracytin | Aracytine | Beta-Cytosine Arabinoside | Beta-cytosine Arabinoside | CHX-3311 | CYTARABINE | Cytarabinum | Cytarbel | Cytosar | Cytosar-U | Cytosine Arabinoside | Cytosine Arabinoside | Cytosine-.beta.-arabinoside | Cytosine-beta-arabinoside | Erpalfa | Starasid | Tarabine PFS | U 19920 | U-19920 | Udicil | WR-28453 | cytarabine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0220908","Disease Screening","C15419","The use of any device, marker, or other means for the purpose of detecting the presence of disease, usually in asymptomatic individuals.","Disease Screening | Disease Screening Procedure | Screening | Screening | Screening Intervention | screening",,,,,,,,,,,,,,,"4063579|4077808","Screening procedure|Screening - health check",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0332161","Attenuated","C28034","Weakened or thinned.  Attenuated strains of disease-causing bacteria and viruses are often used as vaccines.  The weakened strains are used as vaccines because they stimulate a protective immune response while causing no disease or only mild disease in the person receiving the vaccine.","Attenuated | attenuated",,,,,,,,,,,,,,,"4077409","Attenuated by",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0046056","Fludeoxyglucose F-18","C964","A positron-emitting radiopharmaceutical containing radioactive 2-deoxy-2-[18F] fluoro-D-glucose. With similar cell uptake as glucose (high in tumor cells), fludeoxyglucose F 18 is not dephosphorylated and further metabolized. (NCI04)","Fludeoxyglucose F-18 | 18FDG | 2-Deoxy-2-(18F)Fluoro-D-Glucose | 2-F18-Fluoro-2-deoxy-D-glucose | 2-F18-Fluoro-2-deoxyglucose | FDG | FLUDEOXYGLUCOSE F-18 | Fludeoxyglucose (18F) | Fludeoxyglucose F 18 | Fludeoxyglucose F18 | Fluorine-18 2-Fluoro-2-deoxy-D-Glucose | Fluorodeoxyglucose F18 | fludeoxyglucose F 18",,,,,,,,,,,,,,,"4148849","Fluorodeoxyglucose (18-F)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011923","Diagnostic Imaging","C16502","Any method that uses a visual display of structural or functional patterns of organs or tissues for diagnostic evaluation.","Diagnostic Imaging | Medical Imaging",,,,,,,,,,,,,,,"4180938","Imaging",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0069717","Oxaliplatin","C1181","An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)","Oxaliplatin | 1-OHP | Ai Heng | Aiheng | DACPLAT | Dacotin | Dacplat | Diaminocyclohexane Oxalatoplatinum | ELOXATIN | Eloxatin | Eloxatine | Elplat | JM 83 | JM-83 | JM83 | OXALIPLATIN | Oxalatoplatin | Oxalatoplatinum | RP 54780 | RP-54780 | RP54780 | SR 96669 | SR-96669 | SR96669 | [(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum | [SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum | oxalato (1R,2R-cyclohexanediamine)platinum(II) | oxalato (trans-l-1,2-diaminocyclohexane)platinum(II) | oxaliplatin | trans-l DACH oxalatoplatinum | trans-l diaminocyclohexane oxalatoplatinum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031001","Chemotherapeutic Perfusion","C15295","The process of flooding fluid through the artery to saturate the surrounding tissue. In regional perfusion, a specific area of the body (usually an arm or a leg) is targeted and high doses of anticancer drugs are flooded through the artery to reach the surrounding tissue and kill as many cancer cells as possible. Such a procedure is performed in cases where the cancer is not thought to have spread past a localized area.","Chemotherapeutic Perfusion | Perfusion | Perfusion | perfusion",,,,,,,,,,,,,,,"4044535|4338837","Perfusion - action|Perfusion",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1527048","Pre-study","C38010","Occurring before enrollment/treatment on-study.","Pre-study | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708233","Genomic Identifier","C45766","One or more characters and/or numbers that are used to identify, name, or characterize the nature, properties, or contents of genomic sequences, mRNA transcripts, protein products, or other class of entities that occurs throughout the genome.","Genomic Identifier | locus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707922","Ensembl","C45763","Ensembl is a joint project between EMBL-EBI and the Sanger Institute to develop a software system which produces and maintains automatic annotation on selected eukaryotic genomes. Ensembl is primarily funded by the Wellcome Trust.  The Ensembl Genome Browser can be accessed through www.ensembl.org.","Ensembl | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708200","GenBank Accession Number","C43685","Indicates the accession number for a Gene within the GenBank database.","GenBank Accession Number | GenBank ID | GenBank_Accession_Number | Genbank_Accession_Number_Property | NCBI GenBank ID | NCBIGBID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708201","Versioned Genbank Accession Number","C45814","A Genbank accession number with an explicit version.","Versioned Genbank Accession Number | Genbank Accession Number, Versioned",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707926","Entrez Gene","C45765","NCBI's database for gene-specific information. It focuses on the genomes that have been completely sequenced, that have an active research community to contribute gene-specific information, or that are scheduled for intense sequence analysis. The content of Entrez Gene represents the result of curation and automated integration of data from NCBI's Reference Sequence project (RefSeq), from collaborating model organism databases, and from many other databases available from NCBI.","Entrez Gene | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035696","Messenger RNA","C813","A class of RNA molecule containing protein-coding information in its nucleotide sequence that can be translated into the amino acid sequence of a protein.","Messenger RNA | MessengerRNA | mRNA | messenger RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709876","RefSeq","C45335","The Reference Sequence (RefSeq) collection aims to provide a comprehensive, integrated, non-redundant set of sequences, including genomic DNA, transcript (RNA), and protein products, for major research organisms.  RefSeq standards serve as the basis for medical, functional, and diversity studies; they provide a stable reference for gene identification and characterization, mutation analysis, expression studies, polymorphism discovery, and comparative analyses. RefSeqs are used as a reagent for the functional annotation of some genome sequencing projects, including those of human and mouse.","RefSeq | Reference Sequence Collection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517058","Extrahepatic","C28358","Located or occurring outside the liver.","Extrahepatic | extrahepatic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010408","Cryosurgery","C15215","The use of extreme cold to damage or destroy a body part, pathway, or function. The procedure is performed using small cryogenic probes during surgery, and has recently been applied to solitary sporadic renal tumor lesions.","Cryosurgery | Ablation, Cryo | CRYOABLATION | Cryoablation | cryoablation | cryosurgery | cryosurgical ablation",,,,,,,,,,,,,,,"4146273","Cryosurgery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205150","Portal","C38007","Of or pertaining to a porta, especially the porta of the liver; as, the portal vein, which enters the liver at the porta, and divides into capillaries after the manner of an artery. Portal is applied to other veins which break up into capillaries; as, the renal portal veins in the frog.","Portal | ",,,,,,,,,,,,,,,"4138838","Portal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0746922","Anatomic Node","C45804","Any bulge or swelling of an anatomical structure or part.","Node | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205681","Active Site","C47935","The catalytic site of an enzyme, the part of an enzyme where the actual enzymatic function is performed.","Active Site | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0682969","Ligand Binding Domain","C13671","A Binding Site Domain is a region of protein that physically interacts stereospecifically, and usually at high affinity, with a specific ligand, substrate, or a specific domain of some complex target biomolecule, such as a protein, lipid, carbohydrate, or nucleic acid. Typically, but not necessarily, the interaction results in protein conformational alteration and functional modification.","Ligand Binding Domain | Binding Site | Binding Site Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516143","Calcium-Binding Domain","C14114","Many calcium-binding proteins belong to the same evolutionary family and share a type of calcium-binding domain known as the EF-hand. This type of domain consists of a twelve residue loop flanked on both side by a twelve residue alpha-helical domain. In an EF-hand loop the calcium ion is coordinated in a pentagonal bipyramidal configuration. The six residues involved in the binding are in positions 1, 3, 5, 7, 9 and 12; these residues are denoted by X, Y, Z, -Y, -X and -Z. The invariant Glu or Asp at position 12 provides two oxygens for liganding Ca (bidentate ligand). (From InterPro IPR002048)","Calcium-Binding Domain | Calcium-Binding Motif",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030956","Peptide","C735","A compound of two or more amino acids where the alpha carboxyl group of one is bound to the alpha amino group of another.","Peptide | Polypeptide | peptide | polypeptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0178576","Cross link","C47936","Any covalent linkage between two polymers or between two different regions of the same polymer.","Cross Link | Cross Linked | Crosslink",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002520","Amino Acid","C231","Any organic compounds containing amino (-NH2) and carboxyl (-COOH) groups.  In biochemistry, used to refer to the twenty-plus L-alpha-amino acids found in proteins.","Amino Acid | AMINO ACIDS, SOURCE UNSPECIFIED | Amino Acids | aa | amino acid",,,,,,,,,,,,,,,"4203622","Amino acid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1511997","Disulfide Linkage","C14062","A disulfide linkage is a covalent bond between 2 sulfide atoms from the thiol group of 2 cysteine residues (S-S). They occur both interstrand and intrastrand.","Disulfide Linkage | Disulfide Bond",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511662","DNA Binding Domain","C13425","A region of a protein that interacts with DNA. Among the various recognized structural motifs present in DNA binding domains are the helix-loop-helix and the zinc-finger.","DNA Binding Domain | DNA Binding Motif | Protein Motifs, DNA-Binding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510464","Protein Structure","C13303","The amino acids and their 3-D arrangement in constituting a protein.","Protein Structure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513806","N-Glycosylation Site","C14051","A glycosylation site is an amino acid residue within a peptide that accepts oligosaccharide via amide linkage, specifically through amide nitrogen of asparagine via N-acetylglucosamine, as one of the post-translational modifications.","N-Glycosylation Site | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704821","Protein Helix","C48043","A protein secondary structure motif. Amino acids are arranged in a right-handed rod like structure stabilized by hydrogen bonds between the C=O and the N-H groups of the main chain. Types include:alpha-helix, 3.10 helix and pi-helix.","Protein Helix | Helix",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025646","Methionine","C29600","One of nine essential amino acids in humans (provided by food), Methionine is required for growth and tissue repair. A sulphur-containing amino acid, methionine improves the tone and pliability of skin, hair, and strengthens nails. Involved in many detoxifying processes, sulphur provided by methionine protects cells from pollutants, slows cell aging, and is essential for absorption and bio-availability of selenium and zinc. Methionine chelates heavy metals, such as lead and mercury, aiding their excretion. It also acts as a lipotropic agent and prevents excess fat buildup in the liver. (NCI04)","Methionine | (S)-2-Amino-4-(methyl-sulfanyl)butanoic acid | L-Methionine | METHIONINE | Met",,,,,,,,,,,,,,,"4193996","L-methionine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519613","Translation Initiation","C30023","Translation Initiation consists of cellular and enzymatic reactions that instigate the process by which polypeptides are synthesized on ribosomes from information in mRNA transcripts to specify the sequence of amino acids in the polypeptide chain.","Translation Initiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513163","Metal Binding Site","C13453","The specific parts of a protein molecule that directly participate in its interactions with a metal ion.","Metal Binding Site | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514250","Post-Translational Modification Site","C14050","A post-translational modification site refers to amino acid residues within a peptide that act as acceptors for any modifications that do not happen concurrent with translation.","Post-Translational Modification Site | Post-Translational Protein Modification Site | Posttranslational Modification Site | Posttranslational Protein Modification Site | STRUCTURAL ATTACHMENT POINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707491","Consecutive","C47939","In regular succession without gaps.","Consecutive | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3853528","Terminal","C47940","Being or situated at an end; occurring at or forming an end.","Terminal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205177","Active","C45329","Exerting influence or producing an effect.","Active | Activity",,,,,,,,,,,,,,,"9181","Active",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709708","Proprotein","C47941","An inactive protein precursor that is made active by cleavage or glycosylation.","Proprotein | Propeptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1547730","Repeat Pattern","C47942","Two or more adjacent copies of an identical pattern.","Repeat Pattern | Repeat | Repeat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0074289","Selenocysteine","C1223","An unusual amino acid of proteins, the selenium analogue of cysteine, in which a selenium atom replaces sulphur. Involved in the catalytic mechanism of seleno enzymes such as formate dehydrogenase of E. coli and mammalian glutathione peroxidase.","Selenocysteine | 3-Selenyl-L-Alanine | SELENOCYSTEINE | SeC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009671","Difference","C46003","The quality of being unlike or dissimilar.","Difference | Conflict | Different | Differential",,,,,,,,,,,,,,,"4049324","Conflict",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037081","Signal Peptide","C14090","The N-terminal sequence of a secreted protein that interacts with a signal recognition particle and is required for transport through the cell membrane.","Signal Peptide | Leader Sequence | Signal Sequence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002345","Alternate Splicing","C16280","Alternate Splicing is a process in which multiple protein isoforms or products are generated from a single gene as a result of splicing together different nonconsecutive exons during the processing of initially identical nascent transcripts of a gene into mature mRNA transcripts. An exon may be connected to any one of several alternative exons to form the mRNA and generate related proteins, often in a tissue or developmental stage specific manner.","Alternate Splicing | Alternative Splicing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600383","Beta Strand","C47945","A beta strand is an extended polypeptide chain with the sidechains pointing away from the backbone and oriented on opposite sides of the backbone from one residue to another.","Beta Strand | B-strand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710466","Transit Peptide","C47943","The N-terminal sequence of a protein that is required to direct the localization of a cytoplasmic protein to a subcellular membrane-bound organelle.","Transit Peptide | Transit Domain | Transit Peptide Domain | Transit Sequence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519623","Transmembrane Domain","C13410","The portion of an integral membrane protein crossing through the plasma lemma (cell membrane) or that of an internal vesicle. This region is highly hydrophobic, approximately 20 amino acids long, and bordered by charged amino acids.","Transmembrane Domain | TM Domain | Transmembrane Region",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709743","Protein Turn","C47946","A protein secondary structure in which the polypeptide bends back on itself and is stabilized by hydrogen bonds.","Protein Turn | Turn",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3844322","Uncertain","C47944","Not established beyond doubt; still undecided or unknown.","Uncertain | Not Certain | Uncertainty | Unsure",,,,,,,,,,,,,,,"4277602","Uncertain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1179962","Cytoplasmic organelle","C13269","A subcellular feature in the cytoplasm of a cell with a definite structure and a specific role in the function of the cell.","Cytoplasmic Organelle | Organelle | organelle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032136","Plasmid","C754","A small cellular inclusion consisting of a ring of DNA that is not in a chromosome but is capable of autonomous replication.","Plasmid | Plasmid DNA | Plasmids | pDNA",,,,,,,,,,,,,,,"4161700","Plasmid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0087066","Taxonomy","C17469","The theories and techniques of naming, describing, and classifying organisms, and the study of the relationships of taxa.","Taxonomy | Taxonomy, General",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705803","National Center for Biotechnology Information","C45799","Established in 1988 as a national resource for molecular biology information, NCBI creates public databases, conducts research in computational biology, develops software tools for analyzing genome data, and disseminates biomedical information - all for the better understanding of molecular processes affecting human health and disease.","National Center for Biotechnology Information | NCBI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710540","UniProtKB","C47851","The UniProt Knowledgebase (UniProtKB), a product of the UniProt consortium, provides a central database of protein sequences with accurate, consistent, rich sequence and functional annotation.  The UniProt Knowledgebase consists of two sections: Swiss-Prot - a section containing manually-annotated records with information extracted from literature and curator-evaluated computational analysis, and TrEMBL - a section with computationally analyzed records that await full manual annotation.","UniProtKB | UniProt Knowledgebase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551066","Unified Atomic Mass Unit","C41127","The non-SI unit of mass in terms of which the masses of individual atoms and molecules are expressed. Unified atomic mass unit is defined as one twelfth of the mass of an unbound atom of the carbon-12 nuclide, the predominant isotope of carbon, at rest and in its ground state. It is equal to 1.6606x10(E-27) kg (approximately).","Unified Atomic Mass Unit | 1.6605402 x 10-24 g | Atomic Mass Unit | D | Da | Dalton | Dalton | amu | u | unified atomic mass unit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708003","FASTA Format","C47845","A text-based format for representing either nucleotide sequences or peptide sequences. It consists of a single-line description, followed by lines of sequence data.  Sequences are represented in the standard IUPAC-IUB (International Union of Pure and Applied Chemistry-International Union of Biochemistry Commission on Biochemical Nomenclature) single letter amino acid and nucleic acid base codes. It is an extension of the FAST-P (protein) and FAST-N (nucleotide) alignment tools.","FASTA Format | FASTA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1179435","Protein Component","C45994","A protein cleavage product with a demonstrated function.","Protein Component | Component | Functional Component | Protein Functional Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514562","Protein Domain","C13379","A structurally or functionally defined protein region.","Protein Domain | Domain | Feature | Motif | Protein Feature | Protein Motif | Protein Region | Region | Signature | domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515221","Biological Taxon","C40098","Ranked categories for the classification of organisms according to their suspected evolutionary relationships.","Taxon | Biological Taxon | Taxonomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003286","Anticonvulsant Agent","C264","Medicine to stop, prevent, or control seizures (convulsions).","Anticonvulsant Agent | Anti-seizure agent | Anticonvulsant Agents | Anticonvulsants | Antiepileptic Agent | Antiepileptics | anticonvulsant | antiepileptic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710607","Vacuum-Assisted Biopsy","C47949","A minimally invasive biopsy method that uses either sterotactic mammography or ultrasound for precise positioning of a vacuum-assisted biopsy probe.","Vacuum-Assisted Biopsy | VACB | vacuum-assisted biopsy | vacuum-assisted core biopsy",,,,,,,,,,,,,,,"37206731","Vacuum assisted biopsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708928","Mammotome Clip","C47950","A biocompatible stainless steel tag placed at the site of a breast tissue sample.  It appears on a mammogram to help pinpoint an area of past concern.","Mammotome Clip | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706462","Reference Object","C48294","Something referred to; the object of a reference.","Reference Object | Reference | Referenced | Referent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706427","Concept (Terminology Entity)","C45728","An entity in a controlled vocabulary that represents a discrete unit of meaning. It serves as the 'container' for all of the terms with identical meaning (synonyms) and as a focal point for relationships to other concepts in the controlled vocabulary.","Concept | Conceptual | concept",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332255","Fragment","C48295","A part of a larger entity.","Fragment | Fragmented",,,,,,,,,,,,,,,"4104030","Fragment of",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1711330","Offset","C47923","The distance between a point and a fixed reference point; difference between a set point and the actual reading.","Offset | STOFF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707660","Deidentification","C45970","Removal of text elements that would make data individually identifiable.","Deidentification | DID | de-identification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707981","Extensible Markup Language","C45967","A general-purpose markup language for creating special-purpose markup languages. It is capable of describing many different kinds of data. Its primary purpose is to facilitate the sharing of data across different systems, particularly systems connected via the Internet.","Extensible Markup Language | XML | XML (eXtensible Markup Language)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706942","Binary","C45969","Consisting of two (e.g., units, components, elements, terms, possibilities) or based on two.","Binary | Binary Value",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705252","NCI Metathesaurus Concept Code","C45972","A concept unique identifier within the NCI Enterprise Vocabulary Service's NCI Metathesaurus.","NCI Metathesaurus Code | Concept Code | Metathesaurus Code | Metathesaurus Concept Code | NCI Metathesaurus Concept Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705848","Execution","C48293","The act of carrying out some order or instruction to accomplish an aim.","Execution | Execute | Executed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085756","Black or African American","C16352","Individuals with origins in any of the Black racial groups of Africa, including, for example, African American, Jamaican, Haitian, Nigerian, Ethiopian. and Somali.","Black or African American | African American | BLACK OR AFRICAN AMERICAN | BLACK_OR_AFRICAN_AMERICAN | black or african american",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282204","American Indian or Alaska Native","C41259","Individuals with origins in any of the original peoples of North, Central, and South America, including, for example, Navajo Nation, Blackfeet Tribe of the Blackfeet Indian Reservation of Montana, Native Village of Marrow Inupiat Traditional Government, Nome Eskimo Community, Aztec, and Maya.","American Indian or Alaska Native | AMERICAN INDIAN OR ALASKA NATIVE | AMERICAN_INDIAN_OR_ALASKA_NATIVE | First Nations | Indigenous American | Native American | Native Americans | american indian or alaska native",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0078988","Asian","C41260","Individuals with origins in any of the original peoples of Central or East Asia, Southeast Asia, or South Asia including, for example, Chinese, Asian Indian, Filipino, Vietnamese, Korean, and Japanese.","Asian | ASIAN | Asian Ancestry | Asians | asian",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513907","Native Hawaiian or Other Pacific Islander","C41219","Individuals with origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Islands, including, for example, Native Hawaiian, Samoan, Chamorro, Tongan, Fijian, and Marshallese.","Native Hawaiian or Other Pacific Islander | NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER | NATIVE_HAWAIIAN_OR_OTHER_PACIFIC_ISLANDER | Pacific Islander | native hawaiian or other pacific islander",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043157","White","C41261","Individuals with origins in any of the original peoples of Europe, including for example, English, German, Irish, Italian, Polish, and Scottish.","White | Caucasian | Caucasians | Caucasoid | Occidental | WHITE | Whites | white",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518424","Not Hispanic or Latino","C41222","A person not of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race.","Not Hispanic or Latino | NOT HISPANIC OR LATINO | NOT_HISPANIC_OR_LATINO | Non-Hispanic | Non-Hispanic or Latino | Not Hispanic/Spanish origin | not hispanic or latino",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513302","Mild Adverse Event","C41338","An experience that is usually transient, and requires no special treatment or intervention. The event does not generally interfere with usual daily activities. Includes transient laboratory test alterations.","Mild Adverse Event | 1 | CTCAE Grade 1 | Common Terminology Criteria for Adverse Events Grade 1 | Grade 1 | Grade 1 Mild Adverse Event | MILD | Standard Toxicity Grade 1 | Toxicity Value 1",,,,,,,,,,,,,,,"763790","Common terminology criteria for adverse events grade 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1513374","CTCAE Grade 2","C41339","An experience that is alleviated with simple therapeutic treatments. The event impacts usual daily activities. Includes laboratory test alterations indicating injury, but without long-term risk.","Moderate Adverse Event | 2 | CTCAE Grade 2 | Common Terminology Criteria for Adverse Events Grade 2 | Grade 2 | Grade 2 Moderate Adverse Event | MODERATE | Standard Toxicity Grade 2 | Toxicity Value 2",,,,,,,,,,,,,,,"765927","Common terminology criteria for adverse events grade 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519275","Severe Adverse Event","C41340","An adverse event experience that requires intensive therapeutic intervention and interrupts usual daily activities.","Severe Adverse Event | 3 | CTCAE Grade 3 | Common Terminology Criteria for Adverse Events Grade 3 | Grade 3 | Grade 3 Severe Adverse Event | SEVERE | Standard Toxicity Grade 3 | Toxicity Value 3",,,,,,,,,,,,,,,"763791","Common terminology criteria for adverse events grade 3",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0687695","Grade 1","C28077","A morphologic qualifier indicating that a cancerous lesion is well differentiated.","Grade 1 | 1 | G1 | GRADE 1 | Grade I",,,,,,,,,,,,,,,"40459832","Grade 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522446","Disease Grade 2","C28078","A morphologic qualifier indicating that a cancerous lesion is moderately differentiated.","Grade 2 | 2 | G2 | GRADE 2 | Grade II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0450094","Tumor Grade 3","C28079","A morphologic qualifier indicating that a cancerous lesion is poorly differentiated.","Grade 3 | 3 | G3 | GRADE 3 | Grade III",,,,,,,,,,,,,,,"37164077","G3",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0547054","Tumor Grade 4","C28082","A morphologic qualifier indicating that a cancerous lesion is undifferentiated.","Grade 4 | 4 | G4 | GRADE 4 | Grade IV",,,,,,,,,,,,,,,"37164078|4120176","G4|G4 grade",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1521826","Protocol Agent","C41161","A medical product, practice, or application that is tested in a clinical trial.","Protocol Agent | Agent | Experimental Intervention | Investigational Interventional | Investigational Therapy or Treatment | Study Agent | Study Treatment | StudyAgent | TRT | Target Product | Test Article | experimental intervention | investigational product | study agent | study treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030851","Penis","C12409","The male organ of urination and copulation.","Penis | Genital System, Male, Penis | PENIS | Penile structure (body structure) | Penis, NOS | penis",,,,,,,,,,,,,"UBERON:0000989","penis","4077311","Penile structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2338314","Genome","C16629","The complete genomic content of an organism, and possibly the full DNA sequence of that organism. It is contained in a set of chromosomes in eukaryotes, a single chromosome in bacteria, or a DNA or RNA molecule in viruses.","Genome | Genomic | genome",,,,,,,,,,,,,,,"4083139","Genome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0676494","Urinary Bladder Tumor Antigen","C1801","Bladder tumor associated antigen is a human complement factor H-related protein (hCFHrp), a glycoprotein produced by cancer cells and macrophages but not by normal epithelia. In cell culture, hCFHrp was shown to be produced by several human bladder cancer cell lines, but not by normal epithelial cell lines. By interaction with complement factor C3b, hCFH serves to inhibit the formation of a membrane attack complex, thereby preventing cell lysis. Production of bladder tumor associated antigen may confer a selective growth advantage to cancer cells in vivo by allowing the cells to evade the host immune system. Approved by FDA as a tumor marker for screening test for transitional cell carcinoma.","Urinary Bladder Tumor Antigen | BTA | Bladder Tumor-Associated Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0133195","Nuclear Matrix Protein","C17517","Proteins that give shape to the nucleus and provide support for the chromosomes.","Nuclear Matrix Protein | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517194","First Degree Relative","C21481","Any relative who is one meiosis away from a particular individual in a family; a relative with whom one half of an individual's genes is shared (i.e., parent, sibling, offspring) (from Genetics Home Reference glossary)","First Degree Relative | FDR | First Degree Relative, NOS | RELATIVE, FIRST DEGREE | first-degree relative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024121","Lung Neoplasm","C3200","A benign or malignant, primary or metastatic neoplasm involving the lungs.  Representative examples of benign neoplasms include adenoma, papilloma, chondroma, and endobronchial lipoma.  Representative examples of malignant neoplasms include carcinoma, carcinoid tumor, sarcoma, and lymphoma.","Lung Neoplasm | Lung Neoplasms | Lung Tumor | Neoplasm of Lung | Neoplasm of the Lung | Tumor of Lung | Tumor of the Lung",,,,,,,,,,,,,,,"4128888","Neoplasm of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519136","SF-36","C20078","A 36 question survey for measuring health status and outcomes from the patient's point of view. Designed for use in surveys of general and specific populations, health policy evaluations, and clinical practice and research.  Measures 8 health concepts: 1) Limitations in physical activities because of health problems, 2) Limitations in usual role activities because of physical health problems, 3) Bodily pain, 4) General health perceptions, 5) Vitality (energy and fatigue), 6) Limitations in social activities because of physical or emotional problems, 7) Limitations in usual role activities because of emotional problems, 8) Mental health (psychological distress and well-being).","SF-36 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522384","Sex","C28421","An arbitrary categorization of individuals based on the assemblage of physical properties related to reproduction, and commonly associated with the designation of such categories as female and male. This designation is based on a combination of observable information from organ inventories, morphological assessments, hormone assessments, genetic testing, observed primary and secondary sex characteristics, menstrual status, and/or obstetric history. Current sex designation may or may not be the same as an individual's sex assigned or reported at birth.","Sex | Gender | SEX | SPCU | Sex Designation | Sex Parameter for Clinical Use | Sex for Clinical Use | sex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514496","Prophylactic Cranial Irradiation","C15913","Radiation therapy to the head to reduce the risk that cancer will spread to the brain.","Prophylactic Cranial Irradiation | PCI | prophylactic cranial irradiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL414488","Healthcare Activity","C16205","The actions of prevention, treatment, and management of illness and the preservation of mental and physical well-being through the services offered by the medical and allied health professions.","Healthcare Activity | Health Care | Health Care Activity | Healthcare",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3160715","Mixed Cell Morphology","C26457","Mixed; being composed of a combination of normal and tumor cells.","Mixed (Normal and Tumor) | Mixed | Mixed (normal and tumor)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030472","Paraneoplastic Syndrome","C3311","A classification for rare disorders of diverse organ systems (endocrine, neuromuscular, gastrointestinal, renal, dermatologic, rheumatologic, hematologic) that are affected by substances secreted by a distant neoplasm but not by the action of the neoplasm itself metastasizing to that organ or tissue. Less than 1 % of neoplasms are associated with these syndromes. An immune-mediated response to neoplasm-elaborated proteins may be the cause of these syndromes. Additionally, their manifestation may signal the presence of an occult neoplasm, potentially at an earlier stage of disease thereby leading to a better clinical outcome. Constitutional signs may include fever, night sweats, anorexia and cachexia. Clinical course is usually progressive. Prognosis is variable depending on the effective treatment of the underlying neoplasm.","Paraneoplastic Syndrome | paraneoplastic syndrome",,,,,,,,,,,,,,,"4175961","Paraneoplastic syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1831915","hyperfractionation","C15745","Radiation treatments in which the total dose of radiation is divided into smaller doses and administered more than once a day.","Hyperfractioned Radiation Therapy | Hyperfractionated | Hyperfractionated Radiation | Hyperfractionated Radiation Therapy | Hyperfractionation | Hyperfractionation | accelerated-fraction radiation therapy | hyperfractionated radiation therapy | hyperfractionation | superfractionated radiation therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011443","Dentition","C13072","The development and arrangement of teeth in the mouth.","Dentition | ",,,,,,,,,,,,,,,"4075101","Dentition",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001829","Agriculture","C16270","The practice of cultivating the land or raising stock, as well as the work, business, or study of farming.","Agriculture | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551883","Mountain Village","C44606","A person having origins in the original Mountain Village people.","Mountain Village | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205146","Area","C25244","The extent of a 2-dimensional surface enclosed within a boundary.","Area | AREA",,,,,,,,,,,,,,,"4176935","Area",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1292711","Part","C45313","One of the portions into which something is regarded as divided and which together constitute a whole.","Part | Portion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514693","Radiation Oncologist","C17833","A physician who specializes in the treatment of cancer patients, using radiation as the main modality of treatment.","Radiation Oncologist | radiation oncologist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037444","Social Worker","C28190","A professionally trained person who is employed in the administration of charity, social service, and welfare. The assistance this professional provides helps disadvantaged individuals and families adjust themselves to the community. Social workers work closely with health agencies, and are often employed by the government.","Social Worker | social worker",,,,,,,,,,,,,,,"4024166","Social worker",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0225777","Parietal Pleura","C33273","The outermost of the two pleural membranes. It consists of a thin basal layer of fibrous tissue upon which sits a continuous layer of mesothelial cells. The cells function to secrete the lubricant lining the pleural cavity.","Parietal Pleura | PARIETAL PLEURA",,,,,,,,,,,,,,,"4214274","Parietal pleura structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0225776","Visceral Pleura","C33881","The layer investing the lungs and dipping into the fissures between the several lobes.","Visceral Pleura | ",,,,,,,,,,,,,,,"4218087","Visceral pleura structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007966","Cheek","C13070","The fleshy part of the face bounded by the eyes, nose, ear, and jaw line.","Cheek | CHEEK | cheek",,,,,,,,,,,,,,,"4246169","Cheek structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0279752","Premenopausal - menopausal status","C15491","Prior to menopause.","Premenopausal | PREMENOPAUSAL | premenopausal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014942","Estrone","C2294","One of three naturally occurring estrogens synthesized from androstenedione in the adrenal glands and peripheral tissues by aromatization and is the primary estrogen produced after menopause.","Estrone | 1,3,5(10)-Estratrien-3-ol-17-one | 3-Hydroxyestra-1,3,5(10)-trien-17-one",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0059668","Estrone Sulfate","C1091","An aqueous substance that is the sulfate salt form of estrone. (NCI)","Estrone Sulfate | ESTRONE SULFATE | Estrone-Sulfate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333977","Atypical Hyperplasia","C8355","A benign (noncancerous) condition in which tissue has certain abnormal features.","Atypical Hyperplasia | atypical hyperplasia",,,,,,,,,,,,,,,"4138847","Atypical hyperplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0184921","Excisional Biopsy","C15385","A surgical procedure in which an entire lesion is removed for microscopic examination.","Excisional Biopsy | BIOPSY, EXCISIONAL | Biopsy, Excisional | Excisional biopsy | excisional biopsy | surgical biopsy",,,,,,,,,,,,,,,"4228202","Excisional biopsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0949466","Western Blotting","C16357","A laboratory procedure for the detection or identification of proteins or peptides that have been separated by gel electrophoresis and transferred onto nitrocellulose or other type of paper or nylon membrane. The proteins are then detected by reaction with enzymatically labeled or radiolabeled antibody probes.","Western Blotting | Blotting, Western | Blotting, Western | WESTERN BLOT | Western Blot",,,,,,,,,,,,,,,"4175139","Western blot assay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704648","Brother - courtesy title","C48648","A courtesy title for a member of a religious order, fraternity, movement, or other group.","Brother | Br.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704647","Sister - courtesy title","C48649","A courtesy title for a member of a religious order, sorority, movement, the nursing profession, or other group.","Sister | Sis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027903","Neuropsychology","C16911","The study of how the physiology of the brain and central nervous system are related to behavior.","Neuropsychology | neuropsychology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025274","Menarche","C3228","Onset of menses.","Menarche | ",,,,,,,,,,,,,,,"4061459","Menarche",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0449243","Timing, LOINC Axis 3","C40567","The chronological relationship between when an observation is made and other relevant associated periods of time.  For example, the timing axis specifies whether a given observation represents the value of a measurement at a moment (point) in time, an average of the measurement over a period of time (24 hours, 72 hours, a nursing shift, a clinical encounter), a minimum or maximum over a period of time (24 hour maximum), or its ordinal rank within a period of time (first, second, last).","Timing, LOINC Axis 3 | LOINC Axis 3 | Timing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521929","Mouse Olfactory Neuroepithelioma","C21978","No value exists.","Mouse Olfactory Neuroepithelioma | Proteins",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1312696","Heart Fatty Acid-Binding Protein, Human","C20974","Fatty acid-binding protein, heart (133 aa, ~15 kDa) is encoded by the human FABP3 gene. This protein plays a role in the intracellular transport of long-chain fatty acids and their acyl-CoA esters.","Fatty Acid-Binding Protein, Heart | FABP3 | Fatty Acid Binding Protein 11 | Fatty Acid Binding Protein 3, Muscle And Heart (Mammary-Derived Growth Inhibitor) | Fatty Acid Binding Protein, Heart | Fatty Acid Binding Protein, Heart | Fatty Acid-Binding Protein 3 | Fatty Acid-Binding Protein 3 | Fatty Acid-Binding Protein 3, Muscle | Fatty Acid-Binding Protein, Muscle And Heart | Fatty Acid-Binding Protein, Skeletal Muscle | H-FABP | Heart Fatty Acid-Binding Protein | Heart-Type Fatty Acid-Binding Protein | M-FABP | MDGI | Mammary-Derived Growth Inhibitor | Muscle Fatty Acid-Binding Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042537","Vermont","C43462","A state in the northeastern United States. Its capital is Montpelier.","Vermont | US: Vermont | VT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0684275","Hemophilia","C3093","A deficiency or abnormality of a blood coagulation factor characterized by the tendency to hemorrhage. Hemophilia is typically a hereditary disorder but, rarely, may be acquired. Inherited coagulation factor-deficient hemophilias include hemophilia A or classic hemophilia (hereditary factor VIII deficiency) hemophilia B or Christmas disease (hereditary factor IX deficiency), and hemophilia C (hereditary factor XI deficiency). Factor VIII inhibitors may occur spontaneously as autoantibodies, resulting in acquired hemophilia known as acquired factor VIII deficiency. Approximately 10% of patients with acquired hemophilia have an underlying malignancy.","Hemophilia | Hemophiliac | hemophilia",,,,,,,,,,,,,,,"4236898","Hemophilia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0750502","Significant","C41130","A term applied to differences, correlations, cause-and-effect relationships, etc., to indicate that they are noticeable, probably too closely correlated to be attributed to chance and therefore indicating a systematic relation: substantial, fairly large; also having consequence or import, important in effect or meaning. In statistics significant ordinarily indicates a probability of not less than 95 percent, while highly significant indicates a probability of not less than 99 percent.","Significant | Significance",,,,,,,,,,,,,,,"4297215","Significant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035647","Risk","C17102","The potential future harm that may arise from some present action. It is often combined or confused with the probability of an event which is seen as undesirable.","Risk | ",,,,,,,,,,,,,,,"4147359","Risk of",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018720","Health Maintenance Organization","C15242","A type of managed health care that requires enrollees to see health care providers that are part in the plan's network; exceptions are made for emergency care.","Health Maintenance Organization | HMO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021672","Insurance","C16745","A mechanism for guarding against financial aspects of risk by making payments in the form of premiums to an insurance company, which pays an agreed-upon sum to the insured in the event of loss.","Insurance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516224","Cancer Research Network","C19720","Ten major, non-profit managed care organizations that are members of the HMO Research Network will participate in the project, known as the Cancer Research Network. A key goal of the Cancer Research Network project is identifying the patient, treatment and delivery system factors that may make a difference in health outcomes for cancer. By combining the data capacities of these large integrated health systems, researchers will be able to study health care patterns among millions of patients who mirror the diversity of the nation in terms of age, gender, income, education, cultural background and location.","Cancer Research Network | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514826","Regulatory Affairs","C18995","The business of a regulatory agency.","Regulatory Affairs | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1947939","Law (profession)","C16786","The learned profession that is mastered by graduate study in a law school and that is responsible for the judicial system.","Law | Law Profession",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516782","Conduct Clinical Trials","C15793","Conduct clinical trials and develop new trial methodologies. Trials should be designed in order to rapidly develop new therapeutic strategies, optimize clinical efficacy and proper use of available modalities, define factors that affect the success of therapeutic strategies (including the role of resistance), and advance our understanding of disease pathogenesis and progression.","Conduct Clinical Trials | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448705","Instance","C48364","An occurrence of something.","Instance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0728907","Compression","C41208","The act, process, or result of pressing together, flattening, or condensing, particularly, increasing an external physical pressure on a body structure. Also refers to the reduction in the volume of a body or substance and augmentation of its density due to pressure.","Compression | COMPRESSION | compression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709558","Pixel","C48367","The smallest resolvable rectangular area of an image, either on a screen or stored in memory.","Pixel | PIXEL | Picture Element | {PIXEL} | {Pixel}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1280412","Thickness","C41145","The dimension between two surfaces of an object, usually the smallest dimension as opposed to the width or the length: also, viscous consistency.","Thickness | THCKN | THICK | THICKNSS",,,,,,,,,,,,,,,"4081323","Thick",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1511237","Bolus Infusion Procedure","C15678","A procedure in which a single dose of a pharmalogical substance is administered, generally via injection, over a short period of time.","Bolus Infusion Procedure | Bolus | Bolus Infusion | Bolus Infusion | bolus dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708610","Kilovolt Peak","C48432","The peak accelerating voltage applied in an X-ray tube between the cathode and anode.","Kilovolt Peak | KVP | kVp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL333651","Mammary","C43595","Having to do with the breast.","Mammary | mammary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706701","Acquisition (action)","C43384","The process by which something is acquired or obtained.","Acquisition | Acquire | Obtain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705970","Electrical Current","C48434","The movement of electrical charges in a conductor.","Electrical Current | Current",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035868","Rotation","C48439","A single complete turn (axial or orbital).","Revolution | Rotation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205171","Single","C48440","Not accompanied by another or others; exclusive of anyone or anything else.","Single | Alone | Only | SINGLE | Solitary",,,,,,,,,,,,,,,"4179186","Singular",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704634","Pitch (deviation)","C48442","The degree of deviation from a horizontal plane.","Pitch | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005898","Body Region","C12680","Named areas of the body.","Body Region | Anatomic Region",,,,,,,,,,,,,,,"4199158","Body region structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL414927","Service","C47920","Work, or a product of that work, done by one person or group that benefits another.","Service | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709450","Pair","C48046","A set of two similar things considered as a unit.","Pair | Paired",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522191","Auricular Route of Administration","C38192","Administration of the drug to or by way of the ear. The drug action is mostly topical/local.","Auricular Route of Administration | AURICULAR (OTIC) | Auricular | Auricular (Otic) | Auricular use | OTIC | Otic",,,,,,,,,,,,,,,"4023156","Otic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1711246","Swallow Evaluation","C48874","The administration of liquids in assorted thicknesses to determine the ability of a patient to swallow without aspiration.  Swallow evaluation involves a variety of approaches, but may be divided into endoscopic and non-endoscopic techniques.","Swallow Evaluation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376196","Opiate","C1657","Functionally related to the poppy (Papaver somniferum) alkaloid morphine, natural or synthetic Opiates have widespread effects in the central nervous system, and on smooth muscle, due to activation of specific delta, mu, and kappa opiate receptors (each controlling different brain functions). Opiates include natural ingredients of the poppy and their derivatives - opium, morphine, codeine, and heroin. Morphine preparations are used as analgesic, sedative, or anxiolytic agent, but are also abused as street drugs. (NCI04)","Opiate | opiate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282123","Daunorubicin Hydrochloride","C1583","The hydrochloride salt of an anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis.","Daunorubicin Hydrochloride | 5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-, hydrochloride | 5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, hydrochloride, (8S-cis)-(9CI) | CERUBIDINE | Cerubidin | Cerubidine | Cloridrato de Daunorubicina | DAUNORUBICIN HYDROCHLORIDE | Daunoblastin | Daunoblastina | Daunoblastine | Daunomycin Hydrochloride | Daunomycin hydrochloride | Daunomycin, hydrochloride | Daunorubicin hydrochloride | Daunorubicin.HCl | Daunorubicini Hydrochloridum | FI-6339 | L-lyxo-Hexopyranoside, 3beta-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-metldioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-,alpha-,hydrochloride | Ondena | RP-13057 | Rubidomycin Hydrochloride | Rubilem | daunomycin hydrochloride | daunorubicin hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376563","Recombinant Granulocyte-Macrophage Colony-Stimulating Factors","C1288","A recombinant therapeutic agent which is chemically identical to or similar to the endogenous glycoprotein cytokine growth factor granulocyte-macrophage colony stimulating factor (GM-CSF). Therapeutic GM-CSF induces the clonal expansion and differentiation of progenitor blood cells and stimulates the cytotoxicity of monocytes and neutrophils, thereby restoring immune function and host antitumor immune responses and stimulating engraftment of transplanted bone marrow tissue. (NCI04)","Recombinant Granulocyte-Macrophage Colony-Stimulating Factor | CSF 39300 | CSF 39300/GM-CSF | CSF-GM (Hoechst) | Colony-Stimulating Factor, Granulocyte-Macrophage | GM CSF | GM-CSF | GM-CSF (Schering) | GMCSF | Recombinanr Colony-Stimulating Factor 2 | Recombinant Colony-Stimulating Factor 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205341","Repeat","C47886","Make or do or perform again.","Repeat | Repeatedly | Replicate",,,,,,,,,,,,,,,"4099902","Repeat",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0052416","Arsenic Trioxide","C1005","A small-molecule arsenic compound with antineoplastic activity.  The mechanism of action of arsenic trioxide is not completely understood. This agent causes damage to or degradation of the promyelocytic leukemia protein/retinoic acid receptor-alpha (PML/RARa) fusion protein; induces apoptosis in acute promyelocytic leukemia (APL) cells and in many other tumor cell types; promotes cell differentiation and suppresses cell proliferation in many different tumor cell types; and is pro-angiogenic. (NCI04)","Arsenic Trioxide | ARSENIC TRIOXIDE | ATO | Arsenic (III) Oxide | Arsenic Sesquioxide | Arsenic trioxide | Arsenous Acid | Arsenous Acid Anhydride | Arsenous Oxide | Trisenox | White Arsenic | arsenic trioxide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0000618","Mercaptopurine","C195","A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04)","Mercaptopurine | 1,7-Dihydro-6H-purine-6-thione | 1,7-Dihydro-6H-purine-6-thione Monohydrate | 3H-Purine-6-thiol | 6 MP | 6 Thiohypoxanthine | 6 Thiopurine | 6-MP | 6-Mercaptopurine | 6-Mercaptopurine Monohydrate | 6-Purinethiol | 6-Thiopurine | 6-Thioxopurine | 6H-Purine-6-thione, 1,7-dihydro- (9CI) | 7-Mercapto-1,3,4,6-tetrazaindene | Alti-Mercaptopurine | Azathiopurine | BW 57-323H | Bw 57-323H | Flocofil | Ismipur | Leukerin | Leupurin | MERCAPTOPURINE | Mercaleukim | Mercaleukin | Mercaptina | Mercapto-6-purine | Mercaptopurinum | Mercapurin | Mern | NCI-C04886 | Puri-Nethol | Purimethol | Purine, 6-mercapto- | Purine-6-thiol (8CI) | Purine-6-thiol Monohydrate | Purine-6-thiol, Monohydrate | Purine-6-thiol, monohydrate | Purinethiol | Purinethol | U-4748 | WR-2785 | mercaptopurine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516051","Association of American Cancer Institutes","C39324","Comprised of 80 of the leading academic and freestanding cancer research centers in the United States.  Almost all of the National Cancer Institute-designated centers are members and the remaining member institutions are academic-based cancer programs that receive NCI support. The AACI's mission combines those of its member institutions and the national cancer program.","Association of American Cancer Institutes | AACI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513821","NCI Center for Cancer Research","C20160","Formed in Jan, 2001 by the merger of the Division of Clinical Sciences and the Division of Basic Sciences, the Center for Cancer Research is the largest component of the National Cancer Institute's Intramural Research Program.","NCI Center for Cancer Research | Center for Cancer Research",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516587","City of Hope Comprehensive Cancer Center","C39355","The City of Hope Comprehensive Cancer Center is an independent medical and research institution dedicated to developing innovative, disease-fighting strategies in the battle against cancer. It fosters a multidisciplinary, interactive environment where basic, clinical, translational, and prevention and control scientists work closely together. The center received its NCI designation in 1981 and its designation as a comprehensive cancer center in 1998.","City of Hope Comprehensive Cancer Center | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512002","Division of Cancer Epidemiology and Genetics","C18749","The Division of Cancer Epidemiology and Genetics (DCEG) is the primary focus within the National Cancer Institute for population based research on environmental and genetics determinants of cancer. Intramural and collaborative interdisciplinary studies are conducted on the distribution, causes, and natural history of cancer, and the means for its prevention. Research areas of special interest include genetic predisposition, lifestyle factors, environmental contaminants, occupational exposures, medications, radiation and infectious agents, as well as statistics and methods development.","Division of Cancer Epidemiology and Genetics | DCEG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512161","Early Detection Research Network","C19265","Established by NCI to identify and evaluate molecular biomarkers and technologies for earlier detection and risk assessment of all major cancers. The EDRN is a national network of academic and industry investigators with expertise in laboratory and clinical sciences, biostatistics, informatics, and public health.","Early Detection Research Network | EDRN | National Detection Research Network",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518417","Norris Cotton Cancer Center","C39477","The mission of the Norris Cotton Cancer Center is to understand the causes of cancer, to translate new knowledge into better prevention and treatment, and to provide effective and compassionate clinical care that improves the lives of cancer patients and families. It is committed to providing access to research-based care, advanced technologies, and clinical trials for patients throughout northern New England. The center is affiliated with The Geisel School of Medicine at Dartmouth and the Mary Hitchcock Memorial Hospital. It was designated as an NCI cancer center in 1978 and as a comprehensive cancer center in 1980.","Norris Cotton Cancer Center | Norris Cotton Cancer Center at Dartmouth | Norris Cotton Cancer Center at the Dartmouth-Htchcock Medical Center",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519443","Specialized Program of Research Excellence","C19460","The Specialized Programs of Research Excellence (SPOREs) established by NCI to promote interdisciplinary research and to speed the bi-directional exchange between basic and clinical science to move basic research finding from the laboratory to applied settings involving patients and populations. The goal of the SPORE program is to bring to clinical care settings novel ideas that have the potential to reduce cancer incidence and mortality, improve survival, and to improve the quality of life. SPOREs are funded through specialized center grants (P50s).","Specialized Program of Research Excellence | Cancer Centers: SPORES | SPORE | SPORES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512003","Division of Cancer Prevention","C18750","Reorganized on October 1, 1997 to the extramural Division of Cancer Prevention and the extramural Division of Cancer Control and Population Science.","Division of Cancer Prevention | DCP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005791","Pheresis","C15191","A procedure that collects a component of the peripheral blood while returning the rest to the donor.","Pheresis | Apheresed | Apheresis | Blood Component Removal | Collection, Apheresis/Leukapheresis | Hemapheresis | apheresis | pheresis",,,,,,,,,,,,,,,"4132856|4236076","Apheresis|Apheresis - action",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0007471","Cauterization","C15199","To destroy tissue using a hot or cold instrument, an electrical current, or a chemical that burns or dissolves the tissue. This process may be used to kill certain types of small tumors or to seal off blood vessels to stop bleeding.","Cauterization | Cauterize | cauterize | cautery",,,,,,,,,,,,,,,"4099751","Cauterization",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152277","Incision and Drainage","C38067","A surgical procedure where a cut is made in a tissue or structure to allow the drainage of fluid.","Incision and Drainage | Incision & Drainage",,,,,,,,,,,,,,,"4211374","Incision AND drainage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034115","Paracentesis","C15310","The removal of excess fluid via needle puncture from any body cavity.","Paracentesis | paracentesis",,,,,,,,,,,,,,,"4313285","Centesis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0189477","Thoracentesis","C15392","The removal of excess fluid via needle puncture from the thoracic cavity.","Thoracentesis | Chest Aspiration | Pleural Cavity Tap | Pleural Tap | Pleurocentesis | Puncture of Pleural Cavity for Aspiration | THORACENTESIS | Thoracic Paracentesis | thoracentesis",,,,,,,,,,,,,,,"4240305","Thoracentesis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705313","Term (lexical)","C45559","A word or expression used for some particular thing.","Term | Word | term",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006147","Breast Feeding","C25596","The nursing of an infant at the mother's breast.","Breast Feeding | BREASTFEEDING | Nursing",,,,,,,,,,,,,,,"4014153","Breast fed",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019163","Hepatitis B Infection","C3097","A viral infection caused by the hepatitis B virus.","Hepatitis B Infection | Hepatitis B | Hepatitis B | Hepatitis B Virus infection | Viral Hepatitis B",,,,,,,,,,,,,,,"4281232","Type B viral hepatitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4229468","Anemia","C2869","A reduction in the number of red blood cells, the amount of hemoglobin, and/or the volume of packed red blood cells. Clinically, anemia represents a reduction in the oxygen-transporting capacity of a designated volume of blood, resulting from an imbalance between blood loss (through hemorrhage or hemolysis) and blood production. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability.","Anemia | Anemia, unspecified | anemia",,,,,,,,,,,,,,,"439777","Anemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522690","Pegylated Liposomal Doxorubicin Hydrochloride","C1555","A liposome-encapsulated preparation of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin. Doxorubicin intercalates between DNA base pairs, thereby hinders the movement of replication machinery along DNA strands, as well as blocks the activity of topoisomerase II during replication. As a result, this agent causes DNA adducts formation, renders single- and double-stranded DNA breakages that induce DNA repair and or apoptotic processes. Doxorubicin also generates reactive oxygen species that leads to cytotoxicity secondary to lipid peroxidation of cell membrane lipids. Liposomal delivery of doxorubicin HCl improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects. A liposomal formulation of doxorubicin also modulates toxicity, specifically the cardiac effects commonly seen with anthracycline antitumor drugs.","Pegylated Liposomal Doxorubicin Hydrochloride | (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-tri-hydroxy-1-methoxy-5,12-naphthacenedione Hydrochloride | ATI-0918 | Caelyx | Caelyx | DOX-SL | DOXIL | Dox-SL | Doxil | Doxilen | Doxorubicin HCl Liposomal | Doxorubicin HCl Liposome | Doxorubicin Hydrochloride Liposome | Doxorubicin Hydrochloride Liposome | Duomeisu | Evacet | LipoDox | Lipodox 50 | Liposomal Adriamycin | Liposomal Doxorubicin Hydrochloride | Liposomal-Encapsulated Doxorubicin | Pegylated Doxorubicin HCl Liposome | Pegylated Liposomal Doxorubicin | Pegylated liposomal doxorubicin | S-Liposomal Doxorubicin | Stealth Liposomal Doxorubicin | TLC D-99 | doxorubicin hydrochloride liposome | liposomal doxorubicin hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700582","Epirubicin Hydrochloride","C474","The hydrochloride salt of the 4'-epi-isomer of the anthracycline antineoplastic antibiotic doxorubicin. Epirubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis. This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.","Epirubicin Hydrochloride | (8S-cis)-10-((3-Amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione Hydrochloride | 3-Glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl-3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside Hydrochloride | EPIRUBICIN HYDROCHLORIDE | Ellence | IMI-28 | Pharmorubicin PFS | epirubicin hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700458","Mitoxantrone Hydrochloride","C665","The hydrochloride salt of an anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication.  This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair.  Mitoxantrone is less cardiotoxic compared to doxorubicin.","Mitoxantrone Hydrochloride | 1,3-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9, 10-anthracenedione Dihydrochloride | 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9, 10-anthroquinone Dihydrochloride | CL 232315 | DHAD | DHAQ | Dihydroxyanthracenedione Dihydrochloride | MITOXANTRONE HYDROCHLORIDE | Mitoxantrone Dihydrochloride | Mitoxantroni Hydrochloridum | Mitozantrone Hydrochloride | Mitroxone | Neotalem | Novantrone | Onkotrone | Pralifan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0246415","Docetaxel","C1526","A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","Docetaxel | DOCETAXEL | Docecad | N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol | RP 56976 | RP-56976 | RP56976 | Taxotere | Taxotere Injection Concentrate | [2aR-[2a alphaa,4beta,4a beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a alpha,12b alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester | docetaxel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0078257","Vinorelbine","C1275","A semisynthetic vinca alkaloid. Vinorelbine binds to tubulin and prevents formation of the mitotic spindle, resulting in the arrest of tumor cell growth in metaphase. This agent may also interfere with amino acid, cyclic AMP. and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.","Vinorelbine | 3',4'-Didehydro-4'-deoxy-C'-norvincaleukoblastine | 5'-Nor-Anhydrovinblastine | Dihydroxydeoxynorvinkaleukoblastine | VINORELBINE | nor-5'-Anhydrovinblastine | vinorelbine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0771488","Gemcitabine Hydrochloride","C961","The hydrochloride salt of an analogue of the antimetabolite nucleoside deoxycytidine with antineoplastic activity. Gemcitabine is converted intracellularly to the active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP). dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis.","Gemcitabine Hydrochloride | 1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose, hydrochloride | 2'Deoxy-2',2'-Difluorocytidine, Hydrochloride | Difluorodeoxycytidine Hydrochloride | FF 10832 | FF-10832 | FF10832 | GEMCITABINE HYDROCHLORIDE | Gemcitabine HCI | Gemzar | LY 188011 | LY-188011 | LY188011 | dFdCyd | gemcitabine hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0356588","Pamidronate Disodium","C1345","The disodium salt of the synthetic bisphosphonate pamidronate. Although its mechanism of action is not completely understood, pamidronate appears to adsorb to calcium phosphate crystals in bone, blocking their dissolution by inhibiting osteoclast-mediated bone resorption. This agent does not inhibit bone mineralization and formation.","Pamidronate Disodium | Aminomux | Aredia | GCP-23339A | PAMIDRONATE DISODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0257685","Zoledronic Acid","C1699","A synthetic imidazole bisphosphonate analog of pyrophosphate with anti-bone-resorption activity. A third-generation bisphosphonate, zoledronic acid binds to hydroxyapatite crystals in the bone matrix, slowing their dissolution and inhibiting the formation and aggregation of these crystals. This agent also inhibits farnesyl pyrophosphate synthase, an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids, donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which are important in the process of osteoclast turnover. Decreased bone turnover and stabilization of the bone matrix contribute to the analgesic effect of zoledronic acid with respect to painful osteoblastic lesions. The agent also reduces serum calcium concentrations associated with hypercalcemia.","Zoledronic Acid | Aclasta | CGP 42446 | CGP42446A | NDC-Zoledronate | Reclast | ZOL 446 | ZOLEDRONIC ACID | Zoledronate | Zoledronate | Zoledronic acid | Zometa | [1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic Acid | zoledronic acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205065","Ovarian","C28047","Having to do with the ovaries, the female reproductive glands in which the ova (eggs) are formed. The ovaries are located in the pelvis, one on each side of the uterus.","Ovarian | ovarian",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700596","Leuprolide Acetate","C1319","The acetate salt of a synthetic nonapeptide analogue of gonadotropin-releasing hormone. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.","Leuprolide Acetate | 6-D-Leucine-9-(N-ethyl-L-prolinamide)-1-9-luteinizing Hormone-releasing Factor (Pig) Monoacetate | 6-D-Leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig) Monoacetate | A 43818 | A-43818 | A43818 | Abbott 43818 | Abbott-43818 | Carcinil | Depo-Eligard | Eligard | Enanton | Enantone | Enantone-Gyn | Fensolvi | Ginecrin | LEUP | LEUPROLIDE ACETATE | Leuplin | Leuprorelin Acetate | Lucrin | Lucrin Depot | Luprodex Depot | Lupron | Lupron Depot | Lupron Depot-3 Month | Lupron Depot-4 Month | Lupron Depot-Ped | Lutrate | Procren | Procrin | Prostap | TAP 144 | TAP-144 | TAP144 | Trenantone | Uno-Enantone | Viadur | leuprolide acetate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1174732","Abarelix","C2015","A synthetic decapeptide and antagonist of naturally occurring gonadotropin-releasing hormone (GnRH). Abarelix directly and competitively binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone.  As a result, this may relieve symptoms associated with prostate hypertrophy or prostate cancer, since testosterone is required to sustain prostate growth.","Abarelix | ABARELIX | PPI-149 | Plenaxis | R-3827 | abarelix",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025175","Megestrol","C630","A synthetic derivative of progesterone with antiestrogenic activity. Megestrol binds to and activates nuclear receptors which subsequently bind to and activate target genes for transcription. As an antiestrogen, this agent may inhibit the growth-stimulating effects of estrogen on estrogen-sensitive tumor cells. In addition, megestrol stimulates appetite in cachectic subjects.","Megestrol | Compound 5071 | MEG | MEGESTROL | Pregna-4,6-diene-3,20-dione, 17-hydroxy-6-methyl- | megestrol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034036","Publication","C48471","A printed or electronic work offered for distribution.","Publication | LITERATURE | Printed Materials | Textual Matter | publication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282460","Phase 2 Clinical Trials","C15601","A clinical research protocol designed to study a biomedical or behavioral intervention in a larger group of people (several hundred), to evaluate the drug's effectiveness for a particular indication in patients with the disease or condition under study, and to determine the common short-term side effects and risks associated with the intervention.","Phase II Trial | 2 | Clinical Trials, Phase II | PHASE II TRIAL | Phase 2 | Phase 2 Study | Phase II Clinical Trial | Phase II Protocol | Phase II Study | Trial Phase 2 | phase 2 | phase II trial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0920321","Phase I Clinical Trials","C15600","A clinical research protocol designed to test a new biomedical intervention in a small group of people for the first time. A Phase I trial can be to establish the toxicity of a new treatment with escalating intensity of the treatment administered and/or to determine the side effects of a new treatment for a particular indication in subjects.","Phase I Trial | 1 | Clinical Trials, Phase I | Early-Stage Clinical Trials | PHASE I TRIAL | Phase 1 | Phase 1 Study | Phase I Clinical Trials | Phase I Protocol | Phase I Study | Trial Phase 1 | phase 1 | phase I trial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512043","Dose-Limiting","C28014","Describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment.","Dose-Limiting | dose-limiting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521808","Clinical Trials Cooperative Group","C18205","A group of researchers, cancer centers, and community doctors who provide infrastructure for studies of new cancer treatment, prevention, early detection, quality of life, and rehabilitation. (BRIDG)","Clinical Trials Cooperative Group | Clinical Cooperative Groups | Clinical Trial Groups | Clinical Trials Cooperative Groups | Cooperative Group | Cooperative Groups | CooperativeGroup | NCI clinical trials cooperative group",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706084","(City) Block","C48949","A rectangular area in a city surrounded by streets and usually containing several buildings.","Block | Geographic Block",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448741","Door","C48950","The entrance through which you enter or leave a room or building used as an element of an address.","Door | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707816","Double Dependent Locality","C48951","A locality or minor thoroughfare the address for which must be specified in relationship to a more major one.","Double Dependent Locality | Double Dependent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022130","Island","C48952","A land mass smaller than a continent that is surrounded by water.","Island | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0557759","Farm","C48953","A tract of land cultivated for the purpose of agricultural production or devoted to the raising and breeding of domestic animals.","Farm | FARM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709636","Prefecture","C48954","A district administered by a prefect (as in France or Japan).","Prefecture | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205147","Region","C41129","An area or portion of something with more or less definite boundaries designed or specified according to some established biological, administrative, economic, demographic, etc. criteria.","Region | Geographic Area (Syn: Geographic Region; Region)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708237","Sector","C48955","An area of land or sea that has been divided from other areas and is controlled by a particular country. (from Cambridge Dictionaries Online)","Sector | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714523","Section (geographic)","C48956","A distinct region or subdivision of a territorial or political area or community.","Section | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710443","Tower","C48957","A structure taller than its diameter; can stand alone or be attached to a larger building.","Tower | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0562518","Village","C48958","A community of people smaller than a town.","Village | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707260","Canton","C48959","A small administrative division of a country.","Canton | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710179","Staircase","C48960","A way of access consisting of a set of steps used as an element of an address.","Staircase | Stair | Stairway",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517586","Investigational","C28041","In the process of being studied; experimental.","Investigational | Experimental | experimental | investigational",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016094","File (record)","C42883","A set of related records (either written or electronic) kept together.","File | file",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205379","Visible","C48173","Perceptible especially by the eye; open to easy view.","Visible | ",,,,,,,,,,,,,,,"4080769","Visible",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705052","2-Dimensional","C48282","The property of being measured and described using two orthogonal directions.","2-Dimensional | 2-D | 2D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708715","Loading Technique","C48174","To fill or to place an object onto or into a structure or conveyence; in computer terms, to copy data into memory.","Loading | Load | Loaded | Loading Technique",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4048290","pH","C45997","Quantity of dimension one used to express on a scale from 0 to 14 the amount-of-substance concentration of hydrogen ion of dilute aqueous solution, calculated as the logarithm of the reciprocal of hydrogen-ion concentration in gram atoms per liter.","pH | PH | [pH] | potential of Hydrogen",,,,,,,,,,,,,,,"4099592","Hydrogen ion concentration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704688","Run action","C47911","The act of testing or performing something.","Run | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704922","Image","C48179","Any record of an imaging event whether physical or electronic.","Image | image",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473410","Label","C45561","A brief description given for purposes of identification; an identifying or descriptive marker that is attached to an object.","Label | Tag",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448711","Plug","C48223","An object designed to fill a hole tightly; anything that resembles such an object in appearance or origin.","Plug | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705203","Spot (mark)","C48039","A mark on a substance or body made by foreign matter; a blot; a place discolored.","Spot | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709843","Raw","C48188","Not processed or refined.","Raw | Unaltered | Unprocessed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709694","Processing (action)","C48177","The act of preparing or putting through a prescribed procedure.","Processing | Processing Technique | processing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705822","Transfer","C48167","The act of conveying or transporting from one place to another.","Transfer | Deliver | Delivered | Delivery | Transfer Technique | Transport",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704631","Expiration","C48573","To come to a close or end of useable period; termination.","Expiration | Expire | Expired",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705920","Species","C45293","A group of organisms that differ from all other groups of organisms and that are capable of breeding and producing fertile offspring.","Species | SPECIES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518614","Organism Strain","C14419","A population or type of organisms that is genetically different from others of the same species and possessing a set of defined characteristics.","Organism Strain | STRAIN | Strain | Strain Number | strain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0681493","Graph - visual representation","C37960","A drawing illustrating the relations between certain quantities plotted with reference to a set of axes.","Graph | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705104","Importance Weight","C48192","The relative importance granted to something.","Importance Weight | Weight | weighting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448704","Information","C48191","Knowledge derived from study, experience, or instruction that has been gathered or received by communication.","Information | Info",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL414920","Donor","C48284","One that contributes something.","Donor | DONOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205101","External","C44280","Happening or arising or located outside or beyond some limits, or especially, some surface.","External | Exogenous | External (qualifier value) | Externally | Extramural | Outside",,,,,,,,,,,,,,,"4130085","External",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1550369","Performed By","C48206","Indicates the person, group, or institution who carried out the action.","Performed By | Performer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708728","Event Log","C45279","A written record of events.","Log | Event Log",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709701","Project","C47885","Any specifically defined piece of work that is undertaken or attempted to meet a single requirement.","Project | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439265","Unit of Concentration","C48207","An indication of the type of unit of measure being used to express a concentration.","Unit of Concentration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710565","Unit of Weight","C48208","An indication of the type of unit of measure being used to express a weight.","Unit of Weight | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708635","Laboratory Information Management System","C48209","Integrated computer systems that are used in the laboratory for the management of samples, laboratory users, instruments, standards and other laboratory functions such as invoicing, plate management, and work flow automation.","Laboratory Information Management System | LIMS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708517","Input","C47905","Anything added into a sytem.","Input | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706502","Default - option","C48156","An option that is selected automatically unless an alternative is specified.","Default | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709510","Personalized","C48219","Made for or directed or adjusted to a particular individual.","Personalized | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1524072","Placement","C41148","Position or arrangement, as of the teeth; the state of being placed or arranged, as the assignment of a person to a appropriate clinical study.","Placement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677862","Biopsy Specimen","C18202","A specimen obtained by biopsy, which is a process of removing tissue from living patients for diagnostic examination.","Biopsy Specimen | Biopsy Sample | biopsy specimen",,,,,,,,,,,,,,,"4121220","Biopsy specimen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705491","Blood Oxygen Level Dependent Functional Magnetic Resonance Imaging","C49099","A magnetic resonance imaging technique that uses the difference between the magnetic signals of hemoglobin when it is carrying oxygen (oxyhemoglobin) and when it is not carrying oxygen (deoxyhemoglobin) to detect metabolic activity, and hence neurologic activity, in the brain.","Blood Oxygen Level-Dependent Functional MRI | BLOOD OXYGEN LEVEL-DEPENDENT FUNCTIONAL MRI | BOLD | BOLD fMRI | Blood Oxygen Level Dependant Imaging | Blood Oxygen Level Dependent Functional Magnetic Resonance Imaging | Blood Oxygen Level Dependent Imaging | Blood Oxygen Level Dependent Imaging | Blood Oxygen Level-Dependent fMRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038898","Digestive System Surgery","C15330","Surgery performed on any part of the digestive system.","Digestive System Surgery | OR Gastrointestinal Therapeutic Procedure | Surgery, Digestive System | Surgery, Gastrointestinal | digestive system operative procedure | digestive system surgical procedure | gastrointestinal surgical procedure | gastrointestinal system operative procedure | operative procedure on the digestive system | operative procedure on the gastrointestinal system",,,,,,,,,,,,,,,"37151633|4030654|4293902","Gastrointestinal surgery|Operative procedure on digestive system|Operation on digestive tract",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C1709792","Quantile","C48920","Division of a distribution into equal, ordered subgroups; a set of 'cut points' that divide a sample of data into groups containing (as far as possible) equal numbers of observations.","Quantile | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709593","Polynomial Degree","C48924","The highest power of any term in a polynomial.","Polynomial Degree | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449864","Threshold","C48228","The lowest limit at which something becomes detectable or relevant.","Threshold | ",,,,,,,,,,,,,,,"4043000","Threshold",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705282","Multiplier - number","C48229","A number by which another number is multiplied.","Multiplier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711260","Variance","C48918","A measure of the variability in a sample or population. It is calculated as the mean squared deviation (MSD) of the individual values from their common mean. In calculating the MSD, the divisor n is commonly used for a population variance and the divisor n-1 for a sample variance.","Variance | variance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1264641","Percentile","C48919","Any of the 99 numbered points that divide an ordered set of scores into 100 parts each of which contains one-hundredth of the total.","Percentile | Centile | PERCENTILE | Prctl",,,,,,,,,,,,,,,"4041100","Percentile",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708696","Life Sciences Identifier","C47841","A unique identifier meant to be a common way to identify and access biologically significant data, whether that data is stored in files, relational databases, in applications, or in internal or public data sources. Every LSID consists of up to five parts: the Network Identifier (NID); the root DNS name of the issuing authority; the namespace chosen by the issuing authority; the object id unique in that namespace; and an optional revision id for storing versioning information. Each part is separated by a colon.","Life Sciences Identifier | LSID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709973","Routine Option","C48925","A name/value parameter passed into an analytical routine.","Routine Option | Routine Operation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706314","Lambda (parameter)","C48926","A mixing parameter typically giving a degree of smoothing used, or a relaxation parameter defining a rate of convergence.","Lambda | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706276","Near","C48927","Not far distant in time or space or degree or circumstances.","Near | Near to | Nearby",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1442160","Cutoff","C47877","A designated limit beyond which something cannot function, must be terminated, or no longer applies.","Cutoff | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028263","Noise","C45783","Any part of a signal that is not the true or original signal but is introduced by the communication mechanism.","Noise | Data Noise | Signal Noise",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708584","JPEG","C48230","A file compression format mostly used for color and greyscale photographs.","JPEG | Joint Photographic Experts Group Format",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448746","Window","C48921","A time period, or other type of interval, during which something may be achieved, obtained or observed.","Window | Interval | Timing Window",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711300","Span - parameter","C48929","A smoothing parameter.","Span | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707429","Coefficient","C48922","A constant number that serves as a measure of some property or characteristic.","Coefficient | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705648","Dropping","C48930","Leave undone or leave out; get rid of.","Drop | Dropped | Dropping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711342","Exponent","C48923","The number of times to multiply by a number.","Exponent | Coefficient | Exponential",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706914","Base 64","C47879","A file format using 64 ASCII characters to encode the six bit binary data values 0-63. Base 64 is used when transmitting binary data through text-only media such as electronic mail.","Base 64 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710017","Scalar","C47839","Any data type that stores a single value (e.g. a number or Boolean), as opposed to an aggregate data type that has many elements.","Scalar | Scalar Value",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456148","Null","C47840","A special value that may be stored in some database columns to represent an unknown, missing, not applicable, or undefined value.","Null | None | Null Value",,,,,,,,,,,,,,,"4080894","Null",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710306","TOAST Classification","C49121","A classification of subtypes of ischemic stroke based on clinical features and the results of ancillary diagnostic studies.The TOAST classification denotes five subtypes of ischemic stroke: 1) large-artery atherosclerosis, 2) cardioembolism, 3) small-vessel occlusion, 4) stroke of other determined etiology, and 5) stroke of undetermined etiology.","TOAST Classification | Ischemic Stroke Subtype Classification | TOAST | Trial of ORG 10172 in Acute Stroke Treatment Classification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032529","Genetic Polymorphism","C17004","The regular and simultaneous occurrence of alternative nucleotide sequences at equivalent locations of the genetic material among individuals of a single interbreeding population that are not maintained by recurrent mutation. Polymorphisms may range in size from single nucleotide to large nucleotide sequence variation visible at the chromosomal level.","Genetic Polymorphism | Polymorphism | polymorphism",,,,,,,,,,,,,,,"4177328","Genetic polymorphism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706078","Accession Action","C45257","The process of increasing by addition (as to a collection or group).","Accession | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517493","Gene Physical Location","C40342","The physical location of a gene expressed as chromosome and start and end base positions.","Gene Physical Location | Gene Relative Location Object | position",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162326","DNA Sequence","C13299","The sequence of nucleotide residues along a DNA chain.","DNA Sequence | Sequence | Sequences",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514563","Protein Sequence Alteration","C21070","Any subcellular or molecular event, process, or condition that produces a divergence from the usual wild-type condition in the primary sequence of a peptide or protein molecule. (NCI)","Protein Sequence Alteration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704972","Genomic Orientation","C48673","The orientation of a genomic element on the double stranded molecule.","Genomic Orientation | Orientation | Strand | orientation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009932","Control Groups","C28143","A group used as a standard of comparison in a control experiment.","Control Group | Control | control group",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281588","Quality-of-Life Assessment","C15584","A determination of an individual's sense of well-being and ability to enjoy life.","Quality-of-Life Assessment | Quality of Life Assessment",,,,,,,,,,,,,,,"46271390","Assessment of quality of life",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332197","Absent","C48190","Not existing in a specified place at a specified time.","Absent | ABSENT | Absent (qualifier value) | Not Present",,,,,,,,,,,,,,,"4132135","Absent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709366","system output","C47906","Anything coming out of a system.","Output | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705195","set (group)","C47894","A group of things of the same kind that belong together and are so used.","Set | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205547","Routine","C47893","An unvarying or habitual method or procedure.","Routine | ",,,,,,,,,,,,,,,"4176260","Routine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704666","Hyperlink","C47919","A reference (link) from some point in one hypertext document to another document, another place in the same document, or a website.","Hyperlink | Link | www-links",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021822","Interview","C16751","A conversation with an individual regarding his or her background and other personal and professional details, opinions on specific subjects posed by the interviewer, etc.","Interview | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005525","Biological Response Modifiers","C308","Any substance that induces, enhances, restores or suppresses the host's immune system, or an agent that utilizes or is derived from a component of the immune system.","Immunotherapeutic Agent | BRM | Biological Response Modifier | Biological Response Modifier | Biomodulators | Immune Mediators | Immune Modulators | Immune Regulators | Immunomodulating Agent | Immunomodulating Agent | Immunomodulators | Immunomodulatory Agent | Immunopotentiators | Immunotherapeutic Drug | Immunotherapy | Immunotherapy Agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017163","Gastroenterology","C16603","The branch of medicine that focuses on diagnosis and treatment of conditions affecting the gastrointestinal tract.","Gastroenterology | ",,,,,,,,,,,,,,,"4214567","Gastroenterology",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021782","Internal Medicine","C16749","A medical specialty concerned with the diagnosis of diseases of the internal organs and non-surgical treatments.","Internal Medicine | General Medicine | Medicine, Internal",,,,,,,,,,,,,,,"4169306","Internal medicine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025098","Medical Oncology","C16832","The study and treatment of cancers with chemicals, biological products or immunotherapy.","Medical Oncology | Oncology, Medical",,,,,,,,,,,,,,,"4214569","Medical oncology",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524850","Neurosurgical Procedure","C15656","Any surgical procedure performed on nervous system tissue.","Neurosurgical Procedure | Neurological Surgery | Neurosurgery | Neurosurgical Procedures | Surgery, Neurological",,,,,,,,,,,,,,,"4041193","Operation on nervous system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029892","Otolaryngology","C16943","A medical specialty concerned with the study and treatment of disorders of the ear, nose, and throat.","Otolaryngology | ENT | Ear, Nose, and Throat | Oto/Rhino/Laryngology | Otorhinolaryngology",,,,,,,,,,,,,,,"4169456","Otolaryngology",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030755","Pediatrics","C16962","The branch of medicine concerned with the treatment of infants and children.","Pediatrics | Pediatric Medicine",,,,,,,,,,,,,,,"4215118","Pediatric specialty",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034019","Public Health","C17039","The science and practice of protecting and improving the health of a community, as by preventive medicine, health education, control of communicable diseases, application of sanitary measures, and monitoring of environmental hazards.","Public Health | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0243005","Radiation Oncology","C17760","The study of the effects of ionizing radiation for treatment of tumors.","Radiation Oncology | oncology, radiation",,,,,,,,,,,,,,,"4170755","Radiation oncology",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1515090","Surgical Oncology","C17839","Intervention studies in which surgery is the dominant feature to prevent, diagnose, stage, or treat cancer (except neurosurgery and eye surgery).  Includes special devices for dividing or destroying tissues, development and improvement of instruments for detection and diagnosis of tumors where surgery/biopsy is the dominant feature, cytoreductive procedures, intraoperative radiotherapy, surgical treatment of cancer and its complications, surgical supportive care, and plastic reconstructive and rehabilitation surgery.","Surgical Oncology | Complex General Surgical Oncology | oncologic surgery | oncology, surgical",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709926","Response Evaluation Criteria in Solid Tumors","C49164","Standard parameters to be used when documenting response of solid tumors to treatment; a set of published rules that define when cancer patients improve ('respond'), stay the same ('stable'), or worsen ('progression') during treatments. (from www.recist.com)","Response Evaluation Criteria in Solid Tumors | Best Overall Response (RECIST) | RECIST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0549622","Sexual Dysfunction","C3347","Disturbances in sexual desire or performance.","Sexual Dysfunction | ",,,,,,,,,,,,,,,"4237140","Abnormal sexual function",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040184","Tibia","C12800","A bone located between the femur and the tarsus, being part of the lower leg.","Tibia | BONE, TIBIA | TIBIA | shankbone | shinbone | tibia",,,,,,,,,,,,,"UBERON:0000979","tibia","4054327","Bone structure of tibia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0012132","Zalcitabine","C430","A synthetic dideoxynucleoside. After intracellular phosphorylation to its active metabolite, zalcitabine preferentially inhibits the gamma form of DNA polymerase present in tumor cell mitochondria, resulting in the inhibition of tumor cell mitochondrial DNA replication and tumor cell death. (NCI04)","Zalcitabine | 2',3'-Dideoxycytidine | Dideoxycytidine | Hivid | ZALCITABINE | ddC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030896","Pentostatin","C732","A purine nucleotide analogue antibiotic isolated from the bacterium Streptomyces antibioticus. Also known as 2'-deoxycoformycin, pentostatin binds to and inhibits adenine deaminase (ADA), an enzyme essential to purine metabolism; ADA activity is greatest in cells of the lymphoid system with T-cells having higher activity than B-cells and T-cell malignancies higher ADA activity than B-cell malignancies. Pentostatin inhibition of ADA appears to result in elevated intracellular levels of dATP which may block DNA synthesis through the inhibition of ribonucleotide reductase. This agent may also inhibit RNA synthesis and may selectively deplete CD26+ lymphocytes. (NCI04)","Pentostatin | (R)-3-(2-Deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7, 8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol | (R)-3-(2-Deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol | 2'-Deoxycoformycin | CI-825 | Co-Vidarabine | Co-vidarabine | Covidarabine | DCF | Deoxycoformycin | Nipent | PD-81565 | PENTOSTATIN | Pentostatine | pentostatin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700534","Disopyramide Phosphate","C47497","A class Ia antiarrhythmic agent with cardiac depressant properties. Disopyramide phosphate exerts its actions by blocking both sodium and potassium channels in cardiac membrane during phase 0 of the action potential. This slows the impulse conduction through the AV node and prolongs the duration of the action potential of normal cardiac cells in atrial and ventricular tissues. Disopyramide prolongs the QT interval and causes a widening of the QRS complex. It also possesses some anticholinergic and local anaesthetic properties. Disopyramide phosphate is used in the treatment of supraventricular tachycardia.","Disopyramide Phosphate | 2-(1-(Ammoniocarbonyl)-3-(diisopropylammonio)-1-phenylpropyl)pyridinium Phosphate | DISOPYRAMIDE PHOSPHATE | Norpace | Rythmodan | alpha-(2-(Diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamide Phosphate(1:1)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700450","Dobutamine Hydrochloride","C28997","The hydrochloride salt form of dobutamine, a synthetic catecholamine with direct inotropic activity. Dobutamine hydrochloride, mimics the effects of dopamine and stimulates beta-1 adrenergic receptors located in the myocardium. This leads to an increase in heart rate and force and results in an increase in cardiac output.","Dobutamine Hydrochloride | DOBUTAMINE HYDROCHLORIDE | Dobutrex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282140","Docusate Calcium","C28999","The calcium salt of docusate, a dioctyl salt and an emollient laxative with stool-softening activity. Docusate decreases surface tension and emulsification of fecal matter and allows water to penetrate and mix with stool. As a result, it softens the stool.","Docusate Calcium | DOCUSATE CALCIUM | Surfak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0243237","Docusate Sodium","C29000","The sodium salt of docusate, a dioctyl salt and an emollient laxative with stool-softening activity. Docusate decreases surface tension and emulsification of fecal matter and allows water to penetrate and mix with stool. As a result, it softens the stool.","Docusate Sodium | Colace | DOCUSATE SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0065818","Dolasetron Mesylate","C1153","An indole derivative with antiemetic activity.  As a selective serotonin receptor antagonist, dolasetron mesylate competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting. (NCI04)","Dolasetron Mesylate | Anzemet | DOLASETRON MESYLATE | MDL 73,147EF | dolasetron mesylate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0719046","Domeboro Solution","C29001","A aluminum solution with astringent, antibacterial, and antifungal properties. Domeboro solution is a commercial preparation of modified Burow's solution, (5% aluminum acetate) by Bayer.  Aluminum sulfate, the active ingredient of Domeboro, is attributed for this agent's bacteriostatic effect. Domeboro is used most often to cleanse irritated skin and soothe inflammation.","Domeboro Solution | Burow's Solution | Domeboro",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012133","Didanosine","C431","A nucleoside reverse transcriptase inhibitor analog of adenosine.","Didanosine | 2',3'-Dideoxyinosine | DIDANOSINE | Didanosine EC | Dideoxyinosine | Videx | Videx EC | ddI | didanosine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012582","Dipyridamole","C445","A synthetic agent derivative of pyrimido-pyrimidine, with antiplatelet properties.  Dipyridamole inhibits adenosine uptake by platelets and endothelial cells, triggering an accumulation of cyclic adenosine monophosphate (cAMP), and inhibiting the stimulation of platelet aggregation by agents such as platelet activating factor and collagen. (NCI04)","Dipyridamole | 2,2',2'',2''''-[(4,8-Dipiperidinopyrimido-[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetraethanol | DIPYRIDAMOLE | DP | Persantine | dipyridamole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013015","Domperidone","C454","A peripheral-specific antagonist of the dopamine receptor D2 (D2R), with antiemetic, gastrokinetic and galactagogue activities. Following administration, domperidone binds to D2R expressed by peripheral neurons; this inhibits dopamine binding and D2R-mediated signaling. Inhibition of peripheral D2R signaling prevents or relieves various gastrointestinal (GI) symptoms, such as nausea and vomiting, and may help relief reflux and symptoms of a variety of other upper GI disorders.","Domperidone | DOMPERIDONE | KW 5338 | Motilium | R 33,812",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0378883","Donnatal","C29002","A combination agent, comprised of belladonna alkaloids and Phenobarbital, with gastrointestinal anticholinergic activity. The belladonna alkaloids produce an anticholinergic effect by the competitive inhibition of acetylcholine at the parasympathetic neuro-effector junction, and the barbiturates produce a sedative effect probably as a result of their inhibition of synaptic neurotransmitters in the central nervous system (CNS).","Donnatal | Donnatol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282151","Dopamine Hydrochloride","C455","The hydrochloride salt form of dopamine, a monoamine compound with positive inotropic activity. Dopamine is a naturally occurring catecholamine formed by decarboxylation of dehydroxyphenylalanine and a precursor of norepinephrine and epinephrine. Dopamine binds to alpha-1- and beta-1- adrenergic receptors. Mediated through myocardial beta-1-adrenergic receptors, dopamine increase heart rate and force, thereby increasing cardiac output. Alpha-1-adrenergic receptor stimulation on vascular smooth muscle, leads to vasoconstriction and results in an increase in systemic vascular resistance. Stimulation of dopaminergic receptors in renal vasculature, leads to renal blood vessel dilation, and an increase in glomerular filtration rate, renal blood flow, sodium excretion, and urine output.","Dopamine Hydrochloride | DOPAMINE HYDROCHLORIDE | Dopaminergic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512042","Dorzolamide Sodium","C29004","The sodium salt of Dorzolamide.  An inhibitor of carbonic anhydrase, a zinc-containing enzyme that catalyzes the rapid conversion of carbon dioxide and water into carbonic acid, protons and bicarbonate ions.  Distributed throughout many cells and tissues, various carbonic anhydrases play important roles in mineral and metabolic homeostasis. (NCI04)","Dorzolamide Sodium | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0678136","Doxazosin Mesylate","C29005","The mesylate salt form of doxazosin, a quinazoline compound with smooth muscle relaxing activity. Doxazosin mesylate selectively antagonizes alpha-1-adrenergic receptors in smooth muscle of the bladder neck and prostate, thereby relaxing the smooth muscle and decreasing the obstruction and urethral resistance seen with benign prostate hyperplasia (BPH). This may improve BPH symptoms. This agent also blocks alpha-1-adrenergic receptors in peripheral vascular smooth muscle, which leads to vasodilatation and a subsequent decrease in peripheral vascular resistance.","Doxazosin Mesylate | Cardura | DOXAZOSIN MESYLATE | doxazosin | doxazosin mesylate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700535","Doxepin Hydrochloride","C29006","A dibenzoxepin derivative and tricyclic antidepressant with antipruritic and sedative activities. Doxepin blocks the reuptake of norepinephrine and serotonin into presynaptic terminals thereby prolonging the availability of the monoaminergic neurotransmitters within the synaptic cleft and enhancing their action leading to sedative effects. Doxepin also has antagonistic effects on histamine (H1 and H2), 5-HT2, alpha-1 adrenergic, and muscarinic receptors. The antipruritic effect of this agent is the result mediated through inhibition of histamine receptors.","Doxepin Hydrochloride | Adapin | DOXEPIN HYDROCHLORIDE | Sinequan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0771947","Doxycycline Hydrochloride","C29010","The hydrochloride salt form of doxycycline exhibiting antimicrobial activity.  Doxycycline blocks binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis.  In addition, this agent has exhibited inhibition of collagenase activity. (NCI)","Doxycycline Hydrochloride | 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, Monohydrochloride, (4S,4aR,5S,5aR,6R,12aS)- | Biocamycin | DOXYCYCLINE HYDROCHLORIDE | Deoxy-5-hydroxytetracycline Hydrochloride | Samecin | Tanamicin | Tecacin | Tetradox",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039663","Dronabinol","C867","An isomer of tetrahydrocannabinol (THC) that is the main and most active isomer found in the Cannabis sativa L. plant, with potential anti-emetic, analgesic and appetite stimulating activities. Upon administration, dronabinol, also called delta-9-THC, targets and binds to cannabinoid receptors (CBRs) located in the central nervous system (CNS). Dronabinol acts directly on the appetite and vomiting control centers in the brain to stimulate appetite and prevent emesis. In addition, this agent induces analgesia. Urine levels may be used as a marker to determine the exposure to certain preparations containing parts of the cannabis plant, such as marijuana.","Dronabinol | (-)-.DELTA.9-Tetrahydrocannabinol | Abbott 40566 | DRONABINOL | Delta 9-Tetrahydrocannabinol | Delta(9)-Tetrahydrocannibinol | Delta-9-THC | Delta-9-Tetrahydrocannabinol | Delta9-THC | Marinol | SP 104 | SP-104 | SYNDROS | THC | Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo(b,d)pyran-1-ol | Tetrahydrocannabinol | dronabinol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013136","Droperidol","C458","A butyrophenone with anti-emetic, sedative and anti-anxiety properties. Although the exact mechanism through which droperidol exerts its effects is unknown, droperidol may block dopamine receptors in the chemoreceptor trigger zone (CTZ), which may lead to its anti-emetic effect. This agent may also bind to postsynaptic gamma-aminobutyric acid (GABA) receptors in the central nervous system (CNS), which increases the inhibitory effect of GABA and leads to sedative and anti-anxiety activities.","Droperidol | DROPERIDOL | Inapsine | droperidol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0991568","Drops - Drug Form","C29012","A substance intended for administration in a drop-wise fashion.","Drop Dosage Form | Drop | Drop Dose Form | Drops | gtt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282155","Doxycycline Calcium","C29008","The calcium salt form of doxycycline exhibiting antimicrobial activity.  Doxycycline blocks binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis.  In addition, this agent has exhibited inhibition of collagenase activity. (NCI)","Doxycycline Calcium | DOXYCYCLINE CALCIUM | Vibramycin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899634","Chlorpheniramine/Methscopolamine/Phenylephrine Tablet Formulation","C29013","A commercial combination preparation, by Biovail Pharmaceuticals, containing chlorpheniramine maleate, phenylephrine hydrochloride and methscopolamine nitrate used to relieve symptoms of cold and flu. Chlorpheniramine maleate, an antihistamine, blocks the effects of histamine, thereby preventing symptoms such as sneezing and itchy, watery eyes, runny nose and itchy throat. Phenylephrine hydrochloride, a sympathomimetic agent, acts as a decongestant by inducing blood vessels constriction mediated via alpha-adrenergic receptors, thereby reducing blood flow and decreasing swelling which prevents nasal and sinus congestion. Methscopolamine nitrate, an anticholinergic agent, may reduce fluid secretions and provides a drying effect in nose, eyes and chest.","Chlorpheniramine/Methscopolamine/Phenylephrine Tablet Formulation | DuraVent DA | DuraVent DA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0754659","Dutasteride","C47503","A synthetic 4-azasteroid compound. Dutasteride competitively and specifically binds to isoenzymes 1 and 2 of 5 alpha-reductase, forming stable enzyme complexes and inhibiting the conversion of testosterone to 5 alpha-dihydrotestosterone (DHT); the reduction in DHT activity may mitigate or prevent enlargement of the prostate gland. The type 2 5 alpha-reductase isoenzyme is primarily active in the reproductive tissues, while the type 1 isoenzyme is also active in skin and the liver.","Dutasteride | Avodart | Avolve,(5alpha,17beta)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide | DUTASTERIDE | GG 745 | GG745 | alpha,alpha,alpha,alpha',alpha',alpha'-Hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide | dutasteride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1178489","Eletriptan Hydrobromide","C47508","A triptan with specific affinity for the 5-hydroxytriptamine1B/1D receptor. Eletriptan hydrobromide binds to and acts at serotonin 5-HT1B receptors located on intracranial blood vessels which leads to vasoconstriction. This drug may also exerts its effects by binding to and activating 5-HT 1D receptors on sensory nerve endings in the trigeminal system, which results in the inhibition of pro-inflammatory neuropeptide release. Eletriptan hydrobromide is used to relieve pain or symptoms associated with migraine headaches.","Eletriptan Hydrobromide | 3-[[(R)-1-Methyl-2-pyrrolidinyl]methyl]-5-[2-(phenylsulfonyl)ethyl]indole, Monohydrobromide | ELETRIPTAN HYDROBROMIDE | Relpax",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0059079","Eutectic Mixture of Local Anesthetics","C1081","A topical anesthetic cream, containing lidocaine 2.5% and prilocaine 2.5%, that provides neuralgia pain relief by causing loss of cutaneous sensation through reversible blockade of conduction in nerve fibers. (NCI)","Eutectic Mixture of Local Anesthetics | EMLA | Lidocaine-Prilocaine Eutectic Mixture | Lidocaine/Prilocaine | Oraqix",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700452","Enalapril Maleate","C468","The maleate salt form of enalapril, a dicarbocyl-containing peptide and angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. As a prodrug, enalapril is converted by de-esterification into its active form enalaprilat. Enalaprilat competitively binds to and inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the potent vasoconstrictive actions of angiotensin II and results in vasodilation. Enalapril also decreases angiotensin II-induced aldosterone secretion by the adrenal cortex, which leads to an increase in sodium excretion and subsequently increases water outflow.","Enalapril Maleate | ENALAPRIL MALEATE | Enacard | Renitec | Vasotec",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0674428","Efavirenz","C29027","A synthetic non-nucleoside reverse transcriptase (RT) inhibitor with antiviral activity. Efavirenz binds directly to the human immunodeficiency virus type 1 (HIV-1) RT, an RNA-dependent DNA polymerase, blocking its function in viral DNA replication. In combination with other antiretroviral drugs, this agent has been shown to significantly reduce HIV viral load, retarding or preventing damage to the immune system and reducing the risk of developing AIDS. Efavirenz induces activity of the cytochrome P450 system, accelerating its own metabolism.","Efavirenz | DMP-266 | EFAVIRENZ | L743726 | MK-0831 | Sustiva | efavirenz",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0058831","Dyclonine","C29015","An unclassified compound with local anesthetic effect. Dyclonine reversibly binds to activated sodium channels on the neuronal membrane, thereby decreasing the neuronal membrane's permeability to sodium ions, leading to an increased threshold for excitation. This reversibly stabilizes the membrane and inhibits depolarization, leading to the failure of a propagated action potential and subsequent conduction blockade. This results in a transient and reversible loss of sensation in a localized area of the body.","Dyclonine | 1-Propanone,1-(4-butoxyphenyl)-3-(1-piperidinyl)- | DYCLONINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206460","Enoxaparin","C1452","A low molecular weight, synthetic heparin. As an anticoagulant/antithrombotic agent, enoxaprin's mechanism of action is similar to that of heparin, although it exhibits a higher ratio of anti-Factor Xa to anti-Factor IIa activity. This agent also has anti-inflammatory properties, inhibiting monocyte adhesion to tumor necrosis factor alpha- or lipopolysaccharide-activated endothelial cells.  Compared to unfractionated heparins, the use of enoxaparin is associated with lower incidences of osteoporosis and heparin-induced thrombocytopenia. (NCI04)","Enoxaparin | ENOXAPARIN | enoxaparin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1971775","Entex Liquid Reformulated Feb 2008","C29028","A commercial combination preparation containing guaifenesin and phenylephrine hydrochloride with expectorant and decongestant activities. Guaifenesin works by drawing water into respiratory tracts, thereby reducing adhesiveness and surface tension of mucus as well as increasing hydration of mucus. This reduces the viscosity of mucus and makes the cough more productive. Phenylephrine hydrochloride, a direct-acting sympathicomimetic amine, activates alpha-adrenergic receptors in the nasal mucosa thereby causing vasoconstriction, reduces swelling of nasal mucous membranes and decreases nasal and sinus congestion.","Entex | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL026898","Epinephrine","C2292","The active sympathomimetic hormone from the adrenal medulla in most species. It stimulates both the alpha- and beta- adrenergic systems, causes systemic vasoconstriction and gastrointestinal relaxation, stimulates the heart, and dilates bronchi and cerebral vessels. It is used in asthma and cardiac failure and to delay absorption of local anesthetics.","Epinephrine | Adrenaline | adrenaline | epinephrine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0357126","Epoetin Alfa","C2695","A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine human erythropoietin (EPO). Produced primarily by cells of the peritubular capillary endothelium of the kidney in response to hypoxia, circulating EPO binds to EPO receptors on the surface of committed erythroid progenitors in the bone marrow resulting in their replication and maturation into functional erythrocytes.","Epoetin Alfa | EPO | Epoetin alfa | Epoetin alfa-epbx | Epogen | Eprex | Procrit | Retacrit | epoetin alfa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0253563","Eptifibatide","C47516","A cyclical heptapeptide with anticoagulant activity. Eptifibatide selectively and reversibly binds to and blocks the platelet glycoprotein IIb/IIIa receptor. This prevents the binding of fibrinogen, von Willebrand factor, and other adhesive ligands and leads to an inhibition of platelet aggregation and prevents thrombus development.","Eptifibatide | EPTIFIBATIDE | Integrilin | L-Cysteinamide, N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-prolyl-, cyclic(1-6)-disulfide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014695","Ergocalciferol","C29029","Vitamin D2, a fat-soluble vitamin important for many biochemical processes including the absorption and metabolism of calcium and phosphorus.  In vivo, ergocalciferol is formed after sun (ultraviolet) irradiation of plant-derived ergosterol, another form of vitamin D. Ergocalciferol is the form of vitamin D usually found in vitamin supplements. (NCI04)","Ergocalciferol | (5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol | 9,10-Secoergosta-5,7,10(19),22-tetraen-3-beta-ol | Deltalin | Drisdol | ERGOCALCIFEROL | Vitamin D | Vitamin D2 | ergocalciferol | vitamin D2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0059566","Erythromycin Stearate","C47989","The stearate salt form of erythromycin, a broad-spectrum, topical macrolide antibiotic with antibacterial activity. Erythromycin stearate diffuses through the bacterial cell membrane and reversibly binds to the 50S subunit of the bacterial ribosome. This prevents bacterial protein synthesis. Erythromycin stearate may be bacteriostatic or bactericidal in action, depending on the concentration of the drug at the site of infection and the susceptibility of the organism involved.","Erythromycin Stearate | Abboticin | ERYTHROMYCIN STEARATE | Erypar | Erythrocin Stearate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1170746","Escitalopram Oxalate","C47518","The oxalate salt of escitalopram, a pure S-enantiomer of the racemic bicyclic phthalane derivative citalopram, with antidepressant activity. As a selective serotonin reuptake inhibitor (SSRI), escitalopram blocks the reuptake of serotonin by neurons in the central nervous system (CNS), thereby potentiating CNS serotonergic activity.","Escitalopram Oxalate | 5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-,(1S)-, ethanedioate(1:1) | ESCITALOPRAM OXALATE | Lexapro | Lu 26-054-0 | escitalopram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0937622","Esomeprazole Magnesium","C29032","The magnesium salt of esomeprazole, the S-isomer of omeprazole, with gastric proton pump inhibitor activity. In the acidic compartment of parietal cells, esomeprazole is protonated and converted into the active achiral sulphenamide; the active sulphenamide forms one or more covalent disulfide bonds with the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase), thereby inhibiting its activity and the parietal cell secretion of H+ ions into the gastric lumen, the final step in gastric acid production. H+/K+ ATPase is an integral membrane protein of the gastric parietal cell.","Esomeprazole Magnesium | ESOMEPRAZOLE MAGNESIUM | ESOMEPRAZOLE MAGNESIUM TRIHYDRATE | Esomeprazole Magnesium Trihydrate | Nexium | esomeprazole magnesium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014806","Erythromycin","C476","A broad-spectrum, macrolide antibiotic with antibacterial activity. Erythromycin diffuses through the bacterial cell membrane and reversibly binds to the 50S subunit of the bacterial ribosome. This prevents bacterial protein synthesis. Erythromycin may be bacteriostatic or bactericidal in action, depending on the concentration of the drug at the site of infection and the susceptibility of the organism involved.","Erythromycin | E-Base | E-Mycin | ERYC | ERYTHROMYCIN | Ery-Tab | EryDerm | Eryc | Eryderm | Erymax | Ilotycin | RP-Mycin | Robimycin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014912","Estradiol","C2295","The most potent form of the naturally occurring steroid sex hormone in humans, produced by ovary, placenta, testis, and in small amount by adrenal cortex. Estradiol binds to a specific intracellular estrogen receptor located in female organs, breasts, hypothalamus and pituitary. The receptor-ligand complex promotes gene expression necessary for the maintenance of fertility and secondary sexual characteristics in females. In addition, estradiol exhibits mild anabolic and metabolic properties, and increases blood coagulability. Estradiol, the principal intracellular human estrogen, is substantially more active at the cellular level than its metabolites, estrone and estriol.","Estradiol | (17beta)-Estra-1,3,5(10)-triene-3,17-diol | 17 Beta-Estradiol | 17-beta-Estradiol | estradiol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015011","Ethinyl Estradiol","C486","A semisynthetic estrogen. Ethinyl estradiol binds to the estrogen receptor complex and enters the nucleus, activating DNA transcription of genes involved in estrogenic cellular responses. This agent also inhibits 5-alpha reductase in epididymal tissue, which lowers testosterone levels and may delay progression of prostatic cancer. In addition to its antineoplastic effects, ethinyl estradiol protects against osteoporosis. In animal models, short-term therapy with this agent has been shown to provide long-term protection against breast cancer, mimicking the antitumor effects of pregnancy. (NCI04)","Ethinyl Estradiol | (17alpha)-19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol | Diogyn E | Diogyn-E | ETHINYL ESTRADIOL | Estinyl | Ethinoral | Ethinylestradiol | Eticylol | Feminone | Inestra | Lynoral | Orestralyn",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1260235","Ethinyl Estradiol/Norethindrone","C29035","An oral contraceptive formulation containing the semisynthetic estrogen, ethinyl estradiol, combined with the synthetic progestin, norethindrone, with estrogenic and progestogenic activities, respectively. Ethinyl estradiol binds to and activates intracellular estrogen receptors found in the reproductive tract and other estrogen-responsive tissues. The activated complex enters the nucleus, binds to the estrogen response elements on DNA, activates the transcription of genes involved in the maintenance of the female reproductive system, inhibits the release of follicle stimulating hormone (FSH) from the anterior pituitary, and suppresses the development of the ovarian follicle. Norethindrone binds to intracellular progesterone receptors in progesterone-responsive tissues, such as the pituitary and those found in the reproductive system, and the activated ligand/receptor complex interacts with specific progesterone response elements on DNA, which results in the alteration in protein synthesis, the inhibition of ovulation, an increase in cervical mucus production, the induction of the secretory phase of the endometrial cycle, and the inhibition of luteinizing hormone (LH) release. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system and alters the structure of the endometrium to discourage implantation.","Ethinyl Estradiol/Norethindrone | Aranelle | Balziva | Brevicon | Gencept | Modicon | Norcept-E | Norethin | Norinyl | Nortrel | Ortho-Novum | Ortho-Novum 1/35 | Ovcon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0721402","Lo/Ovral","C12162","A combination of two steroid sex hormones, the semisynthetic estrogen ethinyl estradiol and the synthetic progestogen norgestrel, with contraceptive activity.  The combination of ethinyl estradiol with norgestrel suppresses the hypothalamic-pituitary system, leading to an inhibition of the release of follicle stimulating hormone (FSH), thus suppressing the development of ovarian follicles. The release of luteinizing hormone (LH) is also inhibited, thus preventing ovulation. In addition, thickening of the cervical mucus and the endometrium is promoted, thereby altering the endometrium in such a way as to discourage implantation.","Ethinyl Estradiol/Norgestrel | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0059865","Etodolac","C47526","A pyranocarboxylic acid and non-steroidal anti-inflammatory drug (NSAID) with antipyretic and analgesic activities. Etodolac inhibits the activity of cyclooxygenase I and II, thereby preventing the formation of prostaglandin which is involved in the induction of pain, fever, and inflammation. It also inhibits platelet aggregation by blocking platelet cyclooxygenase and the subsequent formation of thromboxane A2.","Etodolac | 1,3,4,9-Tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic Acid | ETODOLAC | Etodolic Acid | Lodine | Ultradol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015131","Etomidate","C47527","An imidazole derivative with short-acting sedative, hypnotic, and general anesthetic properties. Etomidate appears to have gamma-aminobutyric acid (GABA) like effects, mediated through GABA-A receptor. The action enhances the inhibitory effect of GABA on the central nervous system by causing chloride channel opening events which leads to membrane hyperpolarization.","Etomidate | 1H-Imidazole-5-Carboxylic Acid, 1-((1R)-1-phenylethyl)-, Ethyl Ester | Amidate | ETOMIDATE | R-(+)-Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0164056","Eucerin","C1425","A moisturizing skincare formulation used for various skin conditions including dry skin conditions associated with eczema, psoriasis, chapped or chafed skin. (NCI)","Eucerin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0546863","Ethambutol Hydrochloride","C29033","The hydrochloride salt form of ethambutol, an ethylenediamine derivative with antibacterial activity, specifically effective against mycobacteria. Although the exact mechanism of action of ethambutol hydrochloride is unknown, ethambutol hydrochloride inhibits the transfer of mycolic acids into the cell wall of bacteria, which impedes bacterial cell growth. This agent may also interfere with RNA synthesis or inhibit other cell metabolism, thereby preventing cell multiplication and causing cell death.","Ethambutol Hydrochloride | ETHAMBUTOL HYDROCHLORIDE | Ethambutol HCl | Myambutol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0720328","Acetaminophen/Aspirin/Caffeine","C29038","A commercial combination preparation by Novartis containing acetaminophen, aspirin, and caffeine with analgesic activity. Acetaminophen exerts antipyretic and analgesic activities by inhibiting prostaglandin synthesis while aspirin, a salicylate, inhibits cyclooxygenases (COX) with anti-inflammatory, antipyretic and analgesic properties. Caffeine is a central nervous system stimulant and causes constriction of dilated cerebral blood vessels. Excedrin is used for the relief and treatment of migraine and tension headaches.","Acetaminophen/Aspirin/Caffeine | Acetaminophen/Asprinin/Caffeine | Excedrin | Excedrin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0720319","Ex-Lax","C29037","A commercial preparation, by Novartis, with laxative activity. Ex-Lax contains anthraquinone glycosides sennosides, extracted from senna leaves. Sennosides irritate the lining of the intestine wall, thereby causing increased intestinal muscle contractions that lead to vigorous bowel movement and relief constipation.","Ex-Lax | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015620","Famotidine","C29045","A propanimidamide and histamine H2-receptor antagonist with antacid activity. As a competitive inhibitor of histamine H2-receptors located on the basolateral membrane of the parietal cell, famotidine reduces basal and nocturnal gastric acid secretion, resulting in a reduction in gastric volume, acidity, and amount of gastric acid released in response to various stimuli.","Famotidine | FAMOTIDINE | Pepcid | Pepcid AC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0304483","Fat Emulsion","C2575","A liquid composed of two immiscible substances, typically some form of fat and water. In parenteral nutrition, a fat emulsion may contain phospholipids, triglycerides and essential fatty acids (NCI04)","Fat Emulsion | FAT EMULSION, INTRAVENOUS | Intralipid | Intravenous Fat Emulsion",,,,,,,,,,,,,,,"4168305","Fat emulsion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0060103","Fazarabine","C1096","An orally-active pyrimidine analogue of an aza-substituted cytidine in which the ribose moiety is replaced by an arabinose sugar. Similar in action to cytarabine, fazarabine is phosphorylated by deoxycytidine kinase to a triphosphate form which competes with thymidine for incorporation into DNA; its incorporation into DNA inhibits DNA synthesis, resulting in tumor cell death and tumor necrosis. The presence of deoxycytidine kinase in a tumor is a determinant of tumor sensitivity to this drug. (NCI04)","Fazarabine | 1,3, 5-Triazin-2(1H)-one, 4-Amino-1-beta-D- arabinofuranosyl- (9CI) | 1,3, 5-Triazin-2(1H)-one, 4-amino-1-.beta.-D- arabinofuranosyl- (9CI) | 1-.beta.-D-Arabinofuranosyl-5-azacytosine | 1-Beta-D-arabinofuranosyl-5-azacytosine | Ara AC | FAZARABINE | Kymarabine | ara-AC | fazarabine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015772","Felodipine","C29046","A dihydropyridine calcium channel blocking agent. Felodipine inhibits the influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility. This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04)","Felodipine | FELODIPINE | Plendil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0591423","Fentanyl","C494","A synthetic, lipophilic phenylpiperidine opioid agonist with analgesic and anesthetic properties. Fentanyl selectively binds to and activates the mu-receptor in the central nervous system (CNS) thereby mimicking the effects of endogenous opiates. Activation of the mu-subtype opioid receptor stimulates the exchange of GTP for GDP on the G-protein complex and subsequently inhibits adenylate cyclase. This causes a decrease in intracellular cAMP which inhibits cAMP-mediated calcium influx into the cell via the calcium channels and thereby results in hyperpolarization and reduced neuronal excitability.","Fentanyl | Abstral | Duragesic | FENTANYL | N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0060277","Ferrous Gluconate","C29048","A form of mineral iron for oral administration, Ferrous Gluconate is absorbed in the stomach and small intestine and combines with apoferritin to form ferritin, which is stored in the liver, spleen, red bone marrow, and intestinal mucosa. Important in transport of oxygen by hemoglobin to the tissues, iron is also found in myoglobin, transferrin, and ferritin, and is as a component of many enzymes such as catalase, peroxidase, and cytochromes. (NCI04)","Ferrous Gluconate | FERROUS GLUCONATE | Fergon | Ferric gluconate | Ferrous Gluconate Dihydrate | Iron Gluconate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0060282","Ferrous Sulfate","C29049","A sulfate salt of mineral iron formulated for oral administration and used as a dietary supplement, ferrous sulfate is absorbed in the stomach and small intestine and combines with apoferritin to form ferritin, which is stored in the liver, spleen, red bone marrow, and intestinal mucosa. Important in transport of oxygen by hemoglobin to the tissues, iron is also found in myoglobin, transferrin, and ferritin, and is a component of many enzymes such as catalase, peroxidase, and cytochromes.","Ferrous Sulfate | FERROUS SULFATE | Ferrous sulfate | Iron(II) Sulfate | ferrous sulfate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0209227","Famciclovir","C29044","A diacetyl 6-deoxy prodrug analog of the antiviral agent penciclovir.  Orally administered, famciclovir in vivo is converted to penciclovir triphosphate, which is active against the Herpes viruses, including herpes simplex 1 and 2 and varicella-zoster.  This agent inhibits the replication of viral DNA by interfering competitively with DNA polymerase. (NCI04)","Famciclovir | 2-(2-(2-Amino-9H-purin-9-yl)ethyl)-1,3-propanediol Diacetate (ester) | BRL 42810 | BRL-42810 | FAMCICLOVIR | Famvir",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033228","Fenofibrate","C29047","A synthetic phenoxy-isobutyric acid derivate and prodrug with antihyperlipidemic activity. Fenofibrate is hydrolyzed in vivo to its active metabolite fenofibric acid that binds to and activates peroxisome proliferator activated receptor alpha (PPARalpha), resulting in the activation of lipoprotein lipase and reduction of the production of apoprotein C-III, an inhibitor of lipoprotein lipase activity. Increased lipolysis and a fall in plasma triglycerides, in turn, leads to the modification of the small, dense low density lipoporotein (LDL) particles into larger particles that are catabolized more rapidly due to a greater affinity for cholesterol receptors. In addition, activation of PPARalpha also increases the synthesis of apoproteins A-I, A-II, and high density lipoprotein (HDL)-cholesterol. Overall, fenofibrate reduces total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) while increasing HDL cholesterol.","Fenofibrate | FENOFIBRATE | Lofibra | TriCor | Tricor | fenofibrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0771752","Fexofenadine Hydrochloride","C29050","The hydrochloride salt form of fexofenadine, a carboxylated metabolic derivative of terfenadine and second generation, long-lasting selective histamine H1 receptor antagonist, with antihistaminic activity. Upon administration, fexofenadine competitively binds of peripheral H1-receptors in the gastrointestinal (GI) tract, blood vessels, and bronchial smooth muscle. This prevents binding of histamine to peripheral H1-receptors and prevents their activation. This prevents a histamine-mediated allergic reaction. Fexofenadine does not cross the blood-brain-barrier (BBB).","Fexofenadine Hydrochloride | Allegra | Benzeneacetic Acid, 4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethyl-, Hydrochloride | FEXOFENADINE HYDROCHLORIDE | Fexofenadine HCl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0210630","Filgrastim","C1474","A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors.","Filgrastim | FILGRASTIM | Filgrastim Biosimilar Filgrastim-sndz | Filgrastim Biosimilar Tbo-filgrastim | Filgrastim XM02 | Filgrastim-aafi | Filgrastim-ayow | Filgrastim-sndz | G-CSF | Granix | Neupogen | Neutroval | Nivestim | Nivestym | Recombinant Methionyl Human Granulocyte Colony Stimulating Factor | Releuko | Tbo-filgrastim | Tevagrastim | XM02 | Zarxio | filgrastim | r-metHuG-CSF | rG-CSF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0717309","Acetaminophen/Butalbital/Caffeine","C29051","A combination preparation of acetaminophen, butalbital, and caffeine. Acetaminophen exerts antipyretic and analgesic activities by inhibiting prostaglandin synthesis. Butalbital, a barbiturate with an intermediate duration of action, depresses the central nervous system and exerts sedative activity. Caffeine is a central nervous system stimulant and causes constriction of dilated cerebral blood vessels. This combination is used for the relief and treatment of migraine and tension headaches.","Acetaminophen/Butalbital/Caffeine | Fioricet | Fioricet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016157","Fish Oil","C497","An oil derived from the tissues of oily fish. Fish oil is considered valuable due to its high content of omega-3 fatty acids eicosapentanoic acid and docosahexaenoic acid. Such fatty acids are not actually produced in fish, but are accumulated from phytoplankton which produce omega-3 fatty acids.","Fish Oil | FISH OIL | Oil, Fish | Seafood Oil",,,,,,,,,,,,,,,"42536455","Fish oil",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0281603","Alvocidib Hydrochloride","C1571","A synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (CDKs) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis. This agent is also a competitive inhibitor of adenosine triphosphate activity.","Alvocidib Hydrochloride | (-)-2-(2-Chlorophenyl)-5,7-dihydroxy-8-[(3R,4S)-3-hydroxy-1-methyl-4-piperidinyl]-4H-1-benzopyran-4-one Hydrochloride | 4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5, 7-dihydroxy-8-(3-hydroxy-1-methyl-4-piperidinyl)-, hydrochloride, (-)-cis- | ALVOCIDIB HYDROCHLORIDE | Flavopiridol | Flavopiridol Hydrochloride | HL-275 | HMR 1275 | HMR-1275 | HMR1275 | L 868275 | L-86-8275 | L-868275 | L868275 | MDL 107,826A | MDL-107826A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0306214","Sodium Phosphate/Sodium Biphosphate Laxative","C29052","An oral hyperosmotic saline laxative containing sodium biphosphate and sodium phosphate. Sodium phosphate/sodium biphosphate oral laxative promotes retention of water in the bowel, thereby increasing stool water content and volume, which results in increased gastrointestinal motility and stool transit time and evacuation of colonic contents.","Sodium Phosphate/Sodium Biphosphate Laxative | Fleet Phospho-Soda | Fleets Phospho-Soda | Sodium Phosphate/Sodium Biphosphate Oral Laxative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0060507","Fluocinolone","C29053","A synthetic glucocorticoid with anti-inflammatory and antipruritic activities. Fluocinolone binds the glucocorticoid receptor, followed by translocation of the ligand-receptor complex to the nucleus and transcription activation of genes containing glucocorticoid-responsive elements. Lipocortin-1 is one factor induced by fluocinolone that interacts with and inhibits cytosolic phospholipase 2 alpha, thereby preventing phospholipase translocation to the perinuclear membrane and subsequent release and conversion of arachidonic acid to inflammatory prostaglandins. In addition, MAPK phosphatase 1 is induced, thereby preventing the triggering of the MAPK cascade resulting in pro-inflammatory effects via Jun N-terminal kinase and c-Jun. Finally, fluocinolone binds to and inhibits nuclear factor kappa-B directly, resulting in inhibition of cyclooxygenase 2 transcription and subsequent prostaglandin synthesis.","Fluocinolone | 6-alpha,9-Difluoro-11-beta,16-alpha-17,21-tetrahydroxypregna-1,4-diene-3,20-dione | 6-alpha-Fluorotriamcinolone | FLUOCINOLONE | Flucinolone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0616274","Fludrocortisone Acetate","C1103","The acetate salt of a synthetic fluorinated corticosteroid with antiinflammatory and antiallergic activities. As a glucocorticoid-receptor agonist, fludrocortisone binds to cytoplasmic receptors, translocates to the nucleus, and subsequently initiates the transcription of glucocorticoid-responsive genes such as lipocortins to inhibit phospholipase A2 (PLA2). Inhibition of PLA2 activity prevents the release of arachidonic acid, a precursor of eicosanoids such as prostaglandins and leukotrienes; eicosanoids are important mediators in the pro-inflammatory response mechanism. As a mineralocorticoid-receptor agonist, this agent stimulates Na+ reabsorption and water retention and K+ and H+ secretion in the distal tubules and collecting ducts of the kidney.","Fludrocortisone Acetate | FLUDROCORTISONE ACETATE | Florinef | Florinef Acetate | Florinef acetate | Fludrocortisone acetate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0060501","Flunisolide","C29054","A synthetic corticosteroid with antiinflammatory and antiallergic properties. Flunisolide is a glucocorticoid receptor agonist that binds to cytoplasmic glucocorticoid receptors and subsequently translocates to the nucleus where it initiates the transcription of glucocorticoid-responsive genes such as lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both are potent mediators of inflammation.","Flunisolide | FLUNISOLIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016298","Fluocinolone Acetonide","C29055","The acetonide salt form of fluocinolone, a synthetic fluorinated corticosteroid with antiinflammatory, antipruritic and vasoconstrictive properties. Fluocinolone is a glucocorticoid receptor agonist that binds to cytoplasmic glucocorticoid receptors and subsequently translocates to the nucleus where it initiates the transcription of glucocorticoid-responsive genes such as lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both are potent mediators of inflammation. Fluocinolone exerts its vasoconstrictive effect through inhibition of nitric oxide synthase, thereby blocking nitric oxide production and effectively diminishing the effect of nitric oxide on vascular smooth muscles leading to reduced blood flow.","Fluocinolone Acetonide | (6alpha,11beta,16alpha)-6,9-Difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione | FLUOCINOLONE ACETONIDE | fluocinolone acetonide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016299","Fluocinonide","C29056","A synthetic glucocorticoid and derivative of fluocinolone acetonide with anti-inflammatory and antipruritic activities. Fluocinonide binds the glucocorticoid receptor, followed by translocation of the ligand-receptor complex to the nucleus and transcription activation of genes containing glucocorticoid-responsive elements. Lipocortin-1 is one factor induced by fluocinonide that interacts and inhibits cytosolic phospholipase 2 alpha, thereby preventing phospholipase translocation to the perinuclear membrane and subsequent release and conversion of arachidonic acid to inflammatory prostaglandins. In addition, MAPK phosphatase 1 is induced, thereby preventing the triggering of the MAPK cascade resulting in pro-inflammatory effects via Jun N-terminal kinase and c-Jun. Finally, fluocinonide binds to and inhibits nuclear factor kappa-B directly, resulting in inhibition of cyclooxygenase 2 transcription and subsequent prostaglandin synthesis.","Fluocinonide | (6alpha,11beta,16alpha)-21-(Acetyloxy)-6,9-difluoro-11-hydroxy-16,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione | FLUOCINONIDE | Lidex | Vanos",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016351","Fluorometholone","C29058","A synthetic glucocorticoid with anti-inflammatory and anti-allergic properties. Fluorometholone exerts its effects by interacting with cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. The synthesis of certain anti-inflammatory proteins is induced while the synthesis of certain inflammatory mediators is inhibited. As a result, there is an overall reduction in chronic inflammation and autoimmune reactions.","Fluorometholone | FLUOROMETHOLONE | Fluor-Op | Oxylone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0733380","Fluoxetine Hydrochloride","C2829","The hydrochloride salt form of fluoxetine, a diphenhydramine derivative and selective serotonin reuptake inhibitor with antidepressant, anti-anxiety, antiobsessional and antibulimic activity and with potential immunomodulating activity. Upon administration, fluoxetine binds to the presynaptic serotonin (5-HT) receptor resulting in negative allosteric modulation of the receptor complex, thereby blocking recycling of serotonin by the presynaptic receptor. Inhibition of serotonin reuptake by fluoxetine enhances serotonergic function through serotonin accumulation in the synaptic space, resulting in long-term desensitization and downregulation of 5-HT receptors, preventing 5-HT-mediated signaling and leading to antidepressant, anti-anxiety, antiobsessional and antibulimic effects. In addition, fluoxetine may inhibit the expression of pro-inflammatory cytokines, including interleukin-6 (IL-6). This may prevent IL-6-mediated inflammation and cytokine storm.","Fluoxetine Hydrochloride | FLUOXETINE HYDROCHLORIDE | Prozac",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242293","Flurazepam Hydrochloride","C29060","The hydrochloride salt form of flurazepam, a member of the benzodiazepines and a long-acting depressor of the central nervous system (CNS) with sedative and hypnotic effects. Flurazepam binds to a specific site on the benzodiazepine-gamma-aminobutyric acid (GABA)-A-chloride ionophore receptor complex located on the neuronal membrane. Binding causes an allosteric modification of the receptor thereby enhancing the affinity of GABA to the receptor leading to an increase in the frequency of chloride-channel opening events, which leads to an increase in chloride ion conductance, neuronal hyperpolarization, inhibition of the action potential, and a decrease in neuronal excitability. By modulating binding of the GABA inhibitory neurotransmitter to GABA-A receptors in the ascending reticular activating system, flurazepam blocks arousal of the cortical and limbic system, thereby exerting its sedative and hypnotic effect.","Flurazepam Hydrochloride | Dalmane | FLURAZEPAM HYDROCHLORIDE | Flurazepam Dihydrochloride | ID480 | Insumin Dihydrochloride | Linzac | Lunipax | Ro 5-6901 | Somlan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016377","Flurbiprofen","C508","A derivative of propionic acid, and a phenylalkanoic acid derivative of non-steroidal antiinflammatory drugs (NSAIDs) with analgesic, antiinflammatory and antipyretic effects. Flurbiprofen non-selectively binds to and inhibits cyclooxygenase (COX). This results in a reduction of arachidonic acid conversion into prostaglandins that are involved in the regulation of pain, inflammation and fever. This NSAID also inhibits carbonic anhydrase, thereby reducing the production of hydrogen and bicarbonate ions. Upon ocular administration, flurbiprofen may reduce bicarbonate ion concentrations leading to a decrease in the production of aqueous humor, thereby lowering intraocular pressure.","Flurbiprofen | 2-Fluoro-alpha-methyl[1,1'-biphenyl]-4-acetic Acid | Ansaid | BTS 18,322 | FLURBIPROFEN | U-27,182",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0117996","Fluticasone Propionate","C29061","The propionate salt form of fluticasone, a synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, antiinflammatory and antipruritic effects. Binding and activation of the glucocorticoid receptor results in the activation of lipocortin that in turn inhibits cytosolic phospholipase A2, which triggers cascade of reactions involved in synthesis of inflammatory mediators, such as prostaglandins and leukotrienes. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.","Fluticasone Propionate | (6alpha,11beta,16alpha,17alpha)-6,9-Difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)androsta-1,4-diene-17-carbothioic Acid, S-(Fluoromethyl) Ester | FLUTICASONE PROPIONATE | Flonase | Flovent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0246203","Fluvastatin Sodium","C29062","The sodium salt of a synthetic lipid-lowering agent with potential antineoplastic activity. Fluvastatin competitively inhibits hepatic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses through the suppression of MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. Through the inhibition of mevalonate synthesis, statins, like fluvastatin, have been shown to inhibit the production of dolichol, geranylpyrophosphate (GPP) and farnesylpyrophosphate (FPP) and the isoprenylation of the intracellular G-proteins Ras and Rho, which may result in antiangiogenic, apoptotic, and antimetastatic effects in susceptible tumor cell populations.","Fluvastatin Sodium | (3R,5S,6E)-(+/-)-7-(3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoic Acid | FLUVASTATIN SODIUM | Lescol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700473","Fluvoxamine Maleate","C29063","The maleate salt form of fluvoxamine, a 2-aminoethyl oxime ether of aralkylketones, with antidepressant, antiobsessive-compulsive, and antibulimic activities. Fluvoxamine blocks serotonin reuptake by inhibiting the serotonin reuptake pump of the presynaptic neuronal membrane leading to an increase of serotonin levels within the synaptic cleft. This results in facilitated serotonergic transmission and decreased serotonin turnover leading to antidepressant and antiobsessive-compulsive effects.","Fluvoxamine Maleate | FLUVOXAMINE MALEATE | Fluoxamine | Luvox",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0731033","Leucovorin Calcium","C607","An active metabolite of folic acid (also called folinic acid and citrovorum factor), which does not require metabolism by dihydrofolate reductase, the molecular target of folate antagonist-type chemotherapeutic drugs.  Leucovorin calcium counteracts the toxic effects of these medications, 'rescuing' the patient while permitting the antitumor activity of the folate antagonist. This agent also potentiates the effects of fluorouracil and its derivatives by stabilizing the binding of the drug's metabolite to its target enzyme, thus prolonging drug activity. (NCI04)","Leucovorin Calcium | 5-Formyl Tetrahydrofolate | 5-Formyl-5,6,7,8-tetrahydrofolic Acid | 5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic Acid | Adinepar | Calcifolin | Calcium (6S)-Folinate | Calcium Folinate | Calcium Leucovorin | Calcium N-(p-((((6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamate (1:1) | Calfolex | Calinat | Cehafolin | Citofolin | Citrec | Citrovorum Factor | Cromatonbic Folinico | Dalisol | Disintox | Divical | Ecofol | Emovis | FOLI-cell | Factor, Citrovorum | Flynoken A | Folaren | Folaxin | Foliben | Folidan | Folidar | Folinac | Folinate Calcium | Folinic Acid Calcium Salt Pentahydrate | Folinic acid | Folinoral | Folinvit | Foliplus | Folix | Imo | LEUCOVORIN CALCIUM | Lederfolat | Lederfolin | Leucosar | Leucovorin | N-[4-[[(2-Amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amnio]benzoyl]-L-glutamic Acid, Calcium Salt (1:1) | N-[p-[[(2-Amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]glutamic Acid | Rescufolin | Rescuvolin | Tonofolin | Wellcovorin | citrovorum factor | folinic acid | leucovorin | leucovorin calcium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0771469","Formoterol Fumarate","C47540","The fumarate salt form of formoterol, a long-acting and selective sympathomimetic beta-receptor agonist with bronchodilator activity. Formoterol fumarate binds beta 2 adrenergic receptors in bronchial smooth muscle and stimulates intracellular adenyl cyclase, thereby increasing the production of cyclic adenosine monophosphate (cAMP). Increased cAMP levels cause relaxation of bronchial smooth muscle, improve mucociliary clearance and reduce mediator substance release in inflammatory cells, especially from mast cells. (NCI05)","Formoterol Fumarate | FORMOTEROL FUMARATE ANHYDROUS | Foradil | Formamide, N-(2-hydroxy-5-((1R)-1-hydroxy-2-(((1R)-2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)-, rel-,(E)-2-butenedioate(2:1)(salt) | Formoterol Fumarate Anhydrous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016860","Furosemide","C515","A sulfamoylanthranilic acid derivative, also known as frusemide, and potent loop diuretic. Furosemide is widely used to treat hypertension and edema. This agent is highly bound to albumin and is largely excreted unchanged in the urine.","Furosemide | FRS | FUROSEMIDE | LB 502 | LB-502 | Lasix | SK-Furosemide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0060926","Gabapentin","C1108","A synthetic analogue of the neurotransmitter gamma-aminobutyric acid with anticonvulsant activity. Although its exact mechanism of action is unknown, gabapentin appears to inhibit excitatory neuron activity. This agent also exhibits analgesic properties. (NCI04)","Gabapentin | 1-(aminomethyl)cyclohexaneacetic Acid | GABAPENTIN | Gralise | Neurontin | gabapentin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017007","Gamma Globulin","C16601","A type of globulin in plasma that in electrically charged solutions exhibits slowest colloidal mobility after that of the alpha and beta globulins. All immunoglobulins belong to this group of serum protein.","Gamma Globulin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0885057","Garlic Extract","C29069","The alcoholic extract of the bulb or whole garlic plant Allium sativum (Liliaceae) with potential antineoplastic activity. The garlic plant has long been considered a beneficial plant for health and has been used as an antihelmintic, a rubefacient, an anti-infective, and an antihypertensive. Fresh or aged, garlic extracts contain compounds such as diallyl and allyl propyl disulfides with potent antioxidant, cholesterol-lowering properties; regular ingestion may be preventative for atherosclerosis and cardiovascular diseases. (NCI04)","Garlic Extract | Allium sativum Extract | CCRIS 7640 | EINECS 232-371-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0209738","Lamivudine","C1471","A synthetic nucleoside analogue with activity against hepatitis B virus (HBV) and HIV. Intracellularly, lamivudine is phosphorylated to its active metabolites, lamiduvine triphosphate (L-TP) and lamiduvine monophosphate (L-MP).  In HIV, L-TP inhibits HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleoside analogue into viral DNA.  In HBV, incorporation of L-MP into viral DNA by HBV polymerase results in DNA chain termination. L-TP is a weak inhibitor of mammalian DNA polymerases alpha and beta, and mitochondrial DNA polymerase. (NCI04)","Lamivudine | (-)-BCH-189 | 2',3'-Dideoxy-3'-thiacytidine | 3'-Thia-2',3'-dideoxycytidine | 3TC | 4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone | Epivir | GR109714X | LAM | LAMIVUDINE | lamivudine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0214192","Aminocamptothecin","C1488","A water-insoluble camptothecin derivative.  Aminocamptothecin binds to the nuclear enzyme topoisomerase I, thereby inhibiting repair of single-strand DNA breakages.  Because the terminal lactone ring of aminocamptothecin required for the agent's antitumor activity spontaneously opens under physiological conditions to an inactive carboxy form, the drug must be administered over an extended period of time to achieve effective cytotoxicity. (NCI04)","Aminocamptothecin | 9-AC | 9-AMINOCAMPTOTHECIN | 9-Amino-20-(S)-camptothecin | 9-amino-20(S)-camptothecin | 9-amino-20-camptothecin | 9-amino-CPT | 9-amino-camptothecin | 9-aminocamptothecin | aminocamptothecin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0305093","A and D Ointment","C28794","A topical preparation containing fat-soluble vitamins A and D usually in a lanolin-petrolatum base, A and D Ointment promotes healing of minor burns, rashes, sunburn, skin irritations, and acne; and prevents diaper rash. Vitamin A is essential for diverse cellular functions, immune system functions, and maintenance of mucous membranes, while vitamin D regulates calcium and phosphorous metabolism. (NCI04)","A and D Ointment | A&D Ointment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0724515","Abacavir Sulfate","C28804","A sulfate salt form of abacavir, a nucleoside reverse transcriptase inhibitor analog of guanosine. This agent decreases HIV viral loads, retards or prevents the damage to the immune system, and reduces the risk of developing AIDS.","Abacavir Sulfate | 1592U89 | ABACAVIR SULFATE | Ziagen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1145701","Liposomal Amphotericin B","C1566","A liposome-encapsulated formulation of the polyene antifungal antibiotic amphotericin B produced by the bacterium Streptomyces nodosus with antifungal activity. Amphotericin B binds to ergosterol, an essential component of the fungal cell membrane, and alters cell membrane integrity, resulting in leakage of intracellular components and cell rupture. This agent may also induce oxidative damage in fungal cells and has been reported to stimulate host immune cells. Compared to amphotericin B alone, liposomal delivery of amphotericin B allows for a greater drug concentration in target tissues while decreasing systemic side effects.","Liposomal Amphotericin B | Abelcet | AmBisome | Amphotericin B Liposomal | Amphotericin B-Lipid Complex | Amphotericin B-Lipid Complex | DKF-5122 | L-AMB | Lipid Complex, Amphotericin B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0543447","Acebutolol Hydrochloride","C28806","The hydrochloride salt form of acebutolol, a synthetic butyranilide derivative with hypotensive and antiarrhythmic activity. Acebutolol acts as a cardioselective beta-adrenergic antagonist with little effect on bronchial receptors and has intrinsic sympathomimetic properties. Having stabilizing and quinidine-like effects on cardiac rhythm, Acebutolol is used in ventricular arrhythmias. Other indications include hypertension, alone or in combinations with other agents. (NCI04)","Acebutolol Hydrochloride | ACEBUTOLOL HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0540694","Adefovir Dipivoxil","C28811","A dipivoxil formulation of adefovir, a nucleoside reverse transcriptase inhibitor analog of adenosine with activity against hepatitis B virus (HBV), herpes virus, and human immunodeficiency virus (HIV).","Adefovir Dipivoxil | ADEFOVIR DIPIVOXIL | GS-0840 | Hepsera",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0050393","Acarbose","C983","A pseudotetrasaccharide and inhibitor of alpha-glucosidase and pancreatic alpha-amylase with antihyperglycemic activity. Acarbose binds to and inhibits alpha-glucosidase, an enteric enzyme found in the brush border of the small intestines that hydrolyzes oligosaccharides and disaccharides into glucose and other monosaccharides. This prevents the breakdown of larger carbohydrates into glucose and decreases the rise in postprandial blood glucose levels. In addition, acarbose inhibits pancreatic alpha-amylase which hydrolyzes complex starches to oligosaccharides in the small intestines.","Acarbose | ACARBOSE | Bay g 5421 | Glucobay | O-4,6-Dideoxy-4-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-D-glucose | Precose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0000970","Acetaminophen","C198","A p-aminophenol derivative with analgesic and antipyretic activities. Although the exact mechanism through which acetaminophen exert its effects has yet to be fully determined, acetaminophen may inhibit the nitric oxide (NO) pathway mediated by a variety of neurotransmitter receptors including N-methyl-D-aspartate (NMDA) and substance P, resulting in elevation of the pain threshold. The antipyretic activity may result from inhibition of prostaglandin synthesis and release in the central nervous system (CNS) and prostaglandin-mediated effects on the heat-regulating center in the anterior hypothalamus.","Acetaminophen | 4-Hydroxyacetanilide | ACETAMINOPHEN | APAP | N-(4-Hydroxyphenyl)acetamide | Paracetamol | Tylenol | acetaminophen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2351132","Acetaminophen/Codeine","C28807","A synthetic p-aminophenol derivative combined with codeine, with anti-inflammatory and analgesic activites. Acetaminophen with codeine is used against inflammatory conditions, fever, and pain. Codeine is an opium alkaloid with analgesic properties. Acetaminophen appears to inhibit prostaglandin biosynthesis in the central nervous system and less in peripheral tissues.","Acetaminophen/Codeine | Acetaminophen #3 | Acetaminophen #3 | Acetaminophen with Codeine | Tylenol with Codeine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0717366","Acetaminophen/Diphenhydramine","C28808","A synthetic p-aminophenol derivative and diphenhydramine combination with anti-inflammatory, analgesic, and anti-allergic properties. Acetaminophen Diphenhydramine is used to treat symptoms of allergies and hay fever. The active principal metabolite of phenacetin, acetaminophen appears to inhibit prostaglandin biosynthesis in the central nervous system and less in peripheral tissues. Diphenhydramine blocks histamine effects, preventing sneezing and itchy, watery eyes, as well as nasal and other allergy and hay fever symptoms. (NCI04)","Acetaminophen/Diphenhydramine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0000981","Acetazolamide","C28809","A sulfonamide derivative with diuretic, antiglaucoma, and anticonvulsant properties. Acetazolamide is a non-competitive inhibitor of carbonic anhydrase, an enzyme found in cells in the proximal tube of the kidney, the eye, and glial cells. Inhibition of this enzyme in the kidney prevents excretion of hydrogen, leading to increased bicarbonate and cation excretion and increased urinary volume, which results in an alkaline diuresis. Acetazolamide reduces the concentration of bicarbonate, resulting in a decreased synthesis of aqueous humor in the eye, thereby lowering intraocular pressure. Although its mechanism of action is unknown, acetazolamide has anti-convulsant properties resulting from indirect effects secondary to metabolic acidosis or direct effects on neuronal transmission. Acetazolamide also produces respiratory stimulant effects in response to changes to both carbon dioxide and oxygen tension levels within the lungs.","Acetazolamide | ACETAZOLAMIDE | Diacarb | Diluran | N-(5-(Aminosulfonyl)-1,3,4-thiadiazol-2-yl)acetamide | N-[5-(Aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0050559","Acitretin","C985","An orally-active metabolite of the synthetic aromatic retinoic acid agent etretinate with potential antineoplastic, chemopreventive, anti-psoratic, and embryotoxic properties.  Acitretin activates nuclear retinoic acid receptors (RAR), resulting in induction of cell differentiation, inhibition of cell proliferation, and inhibition of tissue infiltration by inflammatory cells.  This agent may also inhibit tumor angiogenesis. (NCI04)","Acitretin | (All-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic Acid | ACITRETIN | Etretin | Neotigason | Ro 10-1670 | Ro-10-1670 | Soriatane | Trimethylmethoxyphenyl-retinoic acid | acitretin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523878","Acyclovir","C205","A synthetic analog of the purine nucleoside, guanosine, with potent antiviral activity against herpes simplex viruses type 1 and 2, varicella-zoster virus and other viruses of the herpesvirus family. After conversion in vivo to the active metabolite acyclovir triphosphate by viral thymidine kinase, acyclovir competitively inhibits viral DNA polymerase by incorporating into the growing viral DNA chain and terminating further polymerization.","Acyclovir | 2-Amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one | 9-[(2-Hydroxyethoxy)-methyl]guanine | 9-[(2-Hydroxyethoxy)methyl]guanine | ACV | ACYCLOVIR | Acicloftal | Aciclovir | Aclovir | Acycloguanosine | BW-248U | Cargosil | Virorax | Wellcome-248U | Zovirax | acyclovir",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0165631","Adapalene","C28989","A topical retinoid-like compound, chemically similar to vitamin A.  Although the exact mechanism of action is unknown, adapalene binds to specific retinoic acid receptors in the nucleus, leading to specific gene expression.  This agent stimulates skin growth through modulation of cellular differentiation, inflammatory processes and keratinization of follicular epithelial cells.  Adapalene may increase dermal sensitivity to ultraviolet radiation. (NCI04)","Adapalene | 6-(3-(1-Adamantyl)-4-methoxyphenyl)-2-naphthoic acid | 6-(4-Methoxy-3-tricyclo(3.3.1.13,7)dec-1-ylphenyl)-2-naphthalenecarboxylic Acid | ADAPALENE | CD271 | Differin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001443","Adenosine","C207","A ribonucleoside comprised of adenine bound to ribose, with vasodilatory, antiarrhythmic and analgesic activities. Phosphorylated forms of adenosine play roles in cellular energy transfer, signal transduction and the synthesis of RNA.","Adenosine | ADENOSINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281666","Alitretinoin","C1574","An orally- and topically-active naturally-occurring retinoic acid with antineoplastic, chemopreventive, teratogenic, and embryotoxic activities. Alitretinoin binds to and activates nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR); these activated receptors act as transcription factors, regulating gene expression that results in the inhibition of cell proliferation, induction of cell differentiation, and apoptosis of both normal cells and tumor cells.","Alitretinoin | 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-trans-4-trans-6-cis-8-trans-nonatetraenoic Acid | 9-Cis-Retinoic Acid | 9-cRA | 9-cis Retinoic Acid | 9-cis retinoic acid | 9-cis-RA | 9-cis-Retinoic Acid | 9-cis-Retinoic Acid | ALITRETINOIN | ALRT 1057 | ALRT-1057 | ALRT1057 | LGD 1057 | LGD-1057 | LGD1057 | Panretin | Panretyn | Panrexin | Retinoicacid-9-cis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0051166","Sodium Bicarbonate/Aspirin/Citric Acid","C28867","A combination preparation containing sodium bicarbonate, aspirin and citric acid, with analgesic and acid neutralizing properties. Sodium bicarbonate and citric acid provide rapid dissolution of aspirin in water. Sodium bicarbonate also neutralizes stomach acid. Aspirin, a salicylate, binds to and blocks the activities of cyclooxygenases thereby exerting analgesic, antipyretic and anti-inflammatory effects. This preparation is used to relief pain associated with stomach acid.","Sodium Bicarbonate/Aspirin/Citric Acid | Alka Seltzer | Bicarb/ASA.Citric Acid | Bicarb/ASA/Citric Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001927","Albuterol","C215","A racemic mixture of the r-isomer levalbuterol and s-albuterol, a short-acting sympathomimetic agent with bronchodilator activity. Albuterol stimulates beta-2 adrenergic receptors in the lungs, thereby activating the enzyme adenylate cyclase that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increased cAMP concentrations relax bronchial smooth muscle, relieve bronchospasms, and reduce inflammatory cell mediator release, especially from mast cells. Albuterol although to a lesser extent, also stimulates beta-1 adrenergic receptors, thereby increasing the force and rate of myocardial contraction.","Albuterol | ALBUTEROL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700482","Alendronate Sodium","C973","The sodium salt of alendronate, a second generation bisphosphonate and synthetic analog of pyrophosphate with bone anti-resorption activity. Alendronate sodium binds to and inhibits the activity of geranyltranstransferase (farnesyl pyrophosphate synthetase), an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which is important in the process of osteoclast turnover. As a result, osteoclast activity is inhibited and bone resorption and turnover are reduced.","Alendronate Sodium | ALENDRONATE SODIUM | Adronat | Alendronic Acid Monosodium Salt Trihydrate | Alendros | Binosto | Fosamax | G-704650 | MK-217 | Onclast | alendronate sodium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510857","Allergy Shot","C28814","The injection of an allergen extract intended to increase resistance, tolerance, or immunity to the given allergens. When the allergen extract is administered in a series of increasing amounts the process is referred to as allergy therapy, immunotherapy or desensitization.","Allergy Shot | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002144","Allopurinol","C224","A structural isomer of hypoxanthine. Allopurinol inhibits xanthine oxidase, an enzyme that converts oxypurines to uric acid. By blocking the production of uric acid, this agent decreases serum and urine concentrations of uric acid, thereby providing protection against uric acid-mediated end organ damage in conditions associated with excessive production of uric acid, i.e. the massive cell lysis associated with the treatment of some malignancies. (NCI04)","Allopurinol | 1,5-Dihydro-4H-pyrazolo[3,4-d]pryimidin-4-one | 1,5-Dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one | 1H-Pyrazolo[3,4-d]pyrimidin-4-ol | 4'-HPP | 4-Hydroxypyrazolo[3,4-d]pyrimidine | ALLOPURINOL | Lopurin | Sigapurol | Zurinol | allopurinol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002333","Alprazolam","C227","A triazolobenzodiazepine agent with anxiolytic, sedative-hypnotic and anticonvulsant activities. Alprazolam binds to a specific site distinct from the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) binding site on the benzodiazepine-GABA-A-chloride ionophore receptor complex located in the limbic, thalamic and hypothalamic regions of the central nervous system (CNS). This binding causes an allosteric modification of the receptor and enhances the affinity of GABA to the receptor leading to an increase in the frequency of chloride-channel opening events. This leads to an increase in chloride ion conductance, neuronal hyperpolarization, inhibition of the action potential and leads to a decrease in neuronal excitability.","Alprazolam | ALPRAZOLAM | Apo-Alpzar | Nu-Alpraz | Xanax | alprazolam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002335","Alprostadil","C28816","The naturally occurring prostaglandin E1 (PGE1) which displays a variety of pharmacologic actions.  Alprostadil is a potent vasodilator agent that increases peripheral blood flow, inhibits platelet aggregation, and induces bronchodilation. Used in the treatment of erectile dysfunction, this agent produces corporal smooth muscle relaxation by binding to PGE receptors, resulting in the activation of adenylate cyclase and the subsequent accumulation of 3'5'-cAMP.","Alprostadil | (11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic Acid | ALPROSTADIL | Caverject | MUSE | Muse (intraurethral alprostadil suppository) | PGE1 | Prostaglandin E1 | alprostadil | prostaglandin E1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507763","Tissue-Type Plasminogen Activator","C16995","Tissue-type plasminogen activator (562 aa, ~63 kDa) is encoded by the human PLAT gene. This protein plays a role in the cleavage of plasminogen between Arg-580 and Val-581 to form the fibrinolytic enzyme plasmin.","Tissue-Type Plasminogen Activator | EC 3.4.21.68 | PLAT | T-Plasminogen Activator | TPA | Tissue Plasminogen Activator | Tissue Plasminogen Activator | t-PA | tPA | tissue plasminogen activator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700949","Amikacin Sulfate","C230","The sulfate salt of amikacin, a broad-spectrum semi-synthetic aminoglycoside antibiotic, derived from kanamycin with antimicrobial property. Amikacin irreversibly binds to the bacterial 30S ribosomal subunit, specifically in contact with 16S rRNA and S12 protein within the 30S subunit. This leads to interference with translational initiation complex and misreading of mRNA, thereby hampering protein synthesis and resulting in bactericidal effect. This agent is usually used in short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria.","Amikacin Sulfate | AMIKACIN SULFATE | Amikin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700442","Amiodarone Hydrochloride","C236","The hydrochloride salt of an iodine-rich benzofuran derivative with antiarrhythmic and vasodilatory activities. As a class III antiarrhythmic agent, amiodarone blocks the myocardial calcium, potassium and sodium channels in cardiac tissue, resulting in prolongation of the cardiac action potential and refractory period. In addition, this agent inhibits alpha- and beta-adrenergic receptors, resulting in a reduction in sympathetic stimulation of the heart, a negative chronotropic effect, and a decrease in myocardial oxygen demands. Amiodarone may cause vasodilation by stimulation of the release of nitric oxide and cyclooxygenase-dependent relaxing endothelial factors.","Amiodarone Hydrochloride | AMIODARONE HYDROCHLORIDE | Cordarone | Nexterone | amiodarone hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0733667","Amitriptyline Hydrochloride","C28819","The hydrochloride salt of the tricyclic dibenzocycloheptadiene amitriptyline with antidepressant and antinociceptive activities. Amitriptyline inhibits the re-uptake of norepinephrine and serotonin by the presynaptic neuronal membrane in the central nervous system (CNS), thereby increasing the synaptic concentration of norepinephrine and serotonin. Due to constant stimulation to these receptors, amitriptyline may produce a downregulation of adrenergic and serotonin receptors, which may contribute to the antidepressant activity. In the CNS the antinociceptive activity of this agent may involve high affinity binding to and inhibition of N-methyl-D-aspartate (NMDA) receptors and/or the enhancement of the action of serotonin at the spinal terminals of an opioid-mediated intrinsic analgesia system.","Amitriptyline Hydrochloride | AMITRIPTYLINE HYDROCHLORIDE | Elavil | Endep | amitriptyline hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282051","Amphetamine Sulfate","C28822","The sulfate salt form of amphetamine, a synthetic substance related to natural sympathomimetic amines. Amphetamine appears to exert its central nervous system (CNS) and peripheral effects indirectly by inducing the release of biogenic amines from their storage sites in nerve terminals. This agent is a commonly abused psychostimulant drug, which may be snorted, taken orally, smoked, or injected.  Amphetamine induces psychologic dependence which is manifested by elevated mood, increased wakefulness, concentration, physical performance and a feeling of well-being. With sustained use, the effects of tachycardia and enhanced alertness diminish while psychotoxic effects such as hallucinations and delusions may occur. (NCI04)","Amphetamine Sulfate | (+-)-2-Amino-1-phenylpropane Sulfate | (+-)-Amphetamine Sulfate | (+-)-Phenisopropylamine Sulfate | (+-)-alpha-Methylphenethylamine Sulfate (2:1) | (+/-)-Alpha-Methylphenethylamine Sulfate (2:1) | 1-Phenyl-2-aminopropane Sulfate | AMPHETAMINE SULFATE | Amfetamine Sulphate | Astedin | Benzedrine | Benzeneethanamine, Alpha-Methyl-, Sulphate (2:1), (+/-)- | Desoxynorephedrine Sulfate | dl-Amphetamine Sulfate | dl-Amphetamine Sulphate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002679","Amphotericin B","C238","A polyene antifungal antibiotic produced by Streptomyces nodosus, with antifungal activity. Amphotericin B binds to ergosterol, an essential component of the fungal cell membrane, thereby causing depolarization of the membrane and altering cell membrane permeability. This leads to leakage of important intracellular components, cell rupture, and eventually cell death. This agent may also induce oxidative damage in fungal cells and has been reported to stimulate host immune cells.","Amphotericin B | AMPHOTERICIN B | AmB | Amphocil | Amphotec | Amphotercin B | Amphotericin b | amphotericin B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205257","Incomplete","C49160","Not whole; lacking some necessary part or detail; unfinished.","Incomplete | INCOMPLETE",,,,,,,,,,,,,,,"4114687","Incomplete",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705116","Refuse","C49161","To decline to do, accept, give, or allow something.","Refuse | Refused",,,,,,,,,,,,,,,"40481444","Refused",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023864","Literacy","C49162","The ability to read and write.","Literacy | Literate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019453","Altretamine","C544","A synthetic cytotoxic s-triazine derivative similar in structure to alkylating agent triethylenemelamin with antineoplastic activity.  Although the precise mechanism by which altretamine exerts its cytotoxic effect is unknown, N-demethylation of altretamine may produce reactive intermediates which covalently bind to DNA, resulting in DNA damage. (NCI04)","Altretamine | 2,4,6-Tris(dimethylamino)-s-triazine | 2,4,6-tris(dimethylamino)-s-triazine | ALTRETAMINE | ENT 50852 | ENT-50852 | HMM | HXM | Hemel | Hexalen | Hexaloids | Hexamethylamine | Hexamethylmelamine | Hexastat | Hexinawas | N,N,N',N',N',N'-hexamethyl-1,3,5-triazine-2,4,6-triamine | N,n,n',N'N'-hexamethyl-1,3,5,-triazine-2,4,6,-triamine | RB-1515 | WR-95704 | altretamine | s-Triazine, 2,4,6-tris(dimethylamino)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002371","Aluminum Hydroxide","C39707","An inorganic compound containing aluminum.  Used in various immunologic preparations to improve immunogenicity, aluminum hydroxide adjuvant consists of aluminum hydroxide gel in a saline solution.  In vaccines, this agent binds to the protein conjugate, resulting in improved antigen processing by the immune system. (NCI04)","Aluminum Hydroxide | ALUMINUM HYDROXIDE | Alum Adjuvant | Aluminum hydroxide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515930","Aluminum Magnesium","C28817","A salt or hydroxide mixture of aluminum and magnesium metals used as an antacid, aluminum magnesium absorbs and neutralizes stomach acid, helping to relieve intermittent, infrequent heartburn and indigestion. Aluminum and magnesium antiacids may be used to treat symptoms of peptic ulcer, gastritis, esophagitis, hiatal hernia and gastric hyperacidity. (NCI04)","Aluminum Magnesium | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0723562","Amantadine Hydrochloride","C28818","The hydrochloride salt of amantadine, a synthetic tricyclic amine with antiviral, antiparkinsonian, and antihyperalgesic activities. Amantadine appears to exert its antiviral effect against the influenza A virus by interfering with the function of the transmembrane domain of the viral M2 protein, thereby preventing the release of infectious viral nucleic acids into host cells; furthermore, this agent prevents virus assembly during virus replication. Amantadine exerts its antiparkinsonian effects by stimulating the release of dopamine from striatal dopaminergic nerve terminals and inhibiting its pre-synaptic reuptake. This agent may also exert some anticholinergic effect through inhibition of N-methyl-D-aspartic acid (NMDA) receptor-mediated stimulation of acetylcholine, resulting in antihyperalgesia.","Amantadine Hydrochloride | AMANTADINE HYDROCHLORIDE | Amantadine HCl | Symmetrel | amantadine hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002555","Aminoglutethimide","C233","A synthetic derivative of the sedative and anticonvulsant glutethimide with anti-steroid properties.  Originally used as an anticonvulsant, aminoglutethimide also blocks adrenal steroidogenesis by inhibiting the enzymatic conversion of cholesterol to pregnenolone.  In addition, this agent blocks the peripheral aromatization of androgenic precursors to estrogens.  Aminoglutethimide does not suppress ovarian estrogen production.","Aminoglutethimide | 2-(p-Aminophenyl)-2-ethylglutarimide | 3-(4-Aminophenyl)-3-ethyl-2,6-piperidinedione | 3-Ethyl-3-(p-aminophenyl)-2,6-dioxopiperidine | AMINOGLUTETHIMIDE | Aminoblastin | BA-16038 | Ba-16038 | Cytadren | Elipten | Mamomit | Orimenten | Orimeten | Orimetene | Rodazol | alpha-(4-Aminophenyl)-alpha-ethylglutarimide | aminoglutethimide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0354468","Amlodipine Besylate","C28820","The besylate salt of amlodipine, a synthetic dihydropyridine with antihypertensive and antianginal effects. Amlodipine inhibits the influx of extracellular calcium ions into myocardial and peripheral vascular smooth muscle cells, thereby preventing vascular and myocardial contraction. This results in a dilatation of the main coronary and systemic arteries, decreased myocardial contractility, increased blood flow and oxygen delivery to the myocardial tissue, and decreased total peripheral resistance. This agent may also modulate multi-drug resistance (MDR) activity through inhibition of the p-glycoprotein efflux pump.","Amlodipine Besylate | AMLODIPINE BESYLATE | Norvasc",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0718495","Ammonium Lactate","C28821","An organic salt of ammonium (lactic acid neutralized with ammonium hydroxide), topical moisturizing Ammonium Lactate can be applied as a humectant in ichthyosis vulgaris and xerosis. Available as cream or lotion, this agent moisturizes the skin and breaks up the scales. (NCI04)","Ammonium Lactate | AMMONIUM LACTATE | Lactic Acid/Ammonium Hydroxide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002645","Amoxicillin","C237","A broad-spectrum, semisynthetic aminopenicillin antibiotic with bactericidal activity. Amoxicillin binds to and inactivates penicillin-binding protein (PBP) 1A located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall and causes cell lysis.","Amoxicillin | AMOX | AMOXICILLIN | Amoxicillin Trihydrate | Amoxil | Polymox | Trimox | Utimox | Wymox | amoxicillin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002680","Ampicillin","C239","A broad-spectrum, semi-synthetic, beta-lactam penicillin antibiotic with bactericidal activity. Ampicillin binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall and causes cell lysis. Ampicillin is stable against hydrolysis by a variety of beta-lactamases, therefore, can be used in wide range of gram-positive and -negative infections.","Ampicillin | (2S,5R,6R)-6-((R)-2-Amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid | AMPICILLIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0147814","ampicillin sodium/sulbactam sodium","C28823","A combination formulation of the sodium salts of the antibiotic ampicillin and the beta-lactamase inhibitor sulbactam with antibacterial activity. Ampicillin, a broad-spectrum, semisynthetic penicillin, binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall, thereby interfering with the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. As a result, the cell wall is weakened and the cell lyses. The sulbactam component irreversibly binds to bacterial beta-lactamase at or near its active site, thereby interfering with substrate binding and inhibiting bacterial metabolism of penicillin and cephalosporin beta-lactam antibiotics, effectively extending their antibiotic spectrum to include many beta-lactam-resistant bacteria.","Sultamicillin | Ampicillin Sodium/Sulbactam Sodium | SULTAMICILLIN | Unasyn",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0754188","Amprenavir","C28824","A synthetic derivative of hydroxyethylamine sulfonamide that selectively binds to and inhibits human immunodeficiency virus (HIV) protease.","Amprenavir | 141W94 | AMPRENAVIR | Agenerase | Carbamic acid, (3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(- phenylmethyl)propyl)-, tetrahydro-3-furanyl ester, (3S-(3R*(1S*,2R*)))- | KVX 478 | VX 478",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0051809","Anagrelide","C28825","A synthetic quinazoline derivative, Anagrelide reduces platelet production through a decrease in megakaryocyte maturation. Anagrelide inhibits cyclic AMP phosphodiesterase, as well as ADP- and collagen-induced platelet aggregation. At therapeutic doses, it does not influence white cell counts or coagulation parameters. Anagrelide is used for treatment of essential thrombocythemia to reduce elevated platelet counts and the risk of thrombosis. (NCI04)","Anagrelide | ANAGRELIDE | anagrelide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710131","Source Code","C47901","Program instructions written as an ASCII text file; must be translated by a compiler or interpreter or assembler into the object code for a particular computer before execution.","Source Code | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705596","Routine Signature","C47951","The types or domains, and order, in some representations, of inputs to and outputs from a function. (NIST)","Routine Signature | Routine Contract | Signature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709607","Postcondition","C47909","A fact that must always be true just after the execution of some section of code.","Postcondition | Post-condition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709632","Precondition","C47910","A fact that must always be true just prior to the execution of some section of code.","Precondition | Pre-condition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0525063","Benchmark","C47895","A standard by which something can be measured or judged.","Benchmark | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710663","Web Service Definition Language","C47884","An XML format for describing network services as a set of endpoints operating on messages containing either document-oriented or procedure-oriented information.","Web Service Definition Language | WSDL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710688","XML Path Language","C47883","XPath is a language that describes a way to locate and process items in Extensible Markup Language (XML) documents by using an addressing syntax based on a path through the document's logical structure or hierarchy. (from Computer, Telephony & Electronics Industry Glossary)","XML Path Language | XPath",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706852","Article","C47902","Nonfictional prose forming an independent part of a publication.","Article | Programming Language",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707059","Pre-release version of a computer program","C47904","A pre-release version of a computer program.","Build | Pre-Release Version",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709757","Pseudocode","C47900","An outline of a computer program written in plain language.","Pseudocode | Pseudo-code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0871599","Cautionary Warning","C47896","Cautionary advice about something.","Warning | Caveat | WARN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707456","Compiler","C47907","A program that decodes instructions written in a higher order language and produces an assembly language program.","Compiler | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0392366","Test","C47891","A procedure for critical evaluation; a means of determining the presence, quality, or truth of something.","Test | ",,,,,,,,,,,,,,,"4157560","Tests",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704970","Means","C47955","A way of doing something; how a result is obtained or an end is achieved.","Means | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705415","Communication Contact","C47954","A channel for communication between groups.","Communication Contact | Contact",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707959","Example","C48175","A representative form or pattern; an item of information that is representative of a type.","Example | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708476","Implementation","C47899","The act of carrying into effect.","Implementation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709324","Operating System","C47908","The low-level software which handles the interface to peripheral hardware, schedules tasks, allocates storage, and presents a default interface to the user when no application program is running.","Operating System | OS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1261552","Step","C48176","A specific stage of progression through a sequential process.","Step | ",,,,,,,,,,,,,,,"4161942","Step",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705117","Increment","C47882","The amount by which something increases.","Increment | Incremental | Step",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272460","Not Applicable","C48660","Determination of a value is not relevant in the current context.","Not Applicable | Does Not Apply | N/A | NA | NOT APPLICABLE | No Apparent Adverse Event | No unit of measure required | Not applicable | not applicable | {NA} | {Not applicable}",,,,,,,,,,,,,,,"4294169","Not applicable",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007285","Carpal Bone","C12688","Any of the small bones of the wrist joint, located between the radius and the ulna and the metacarpus.","Carpal Bone | BONE, CARPAL | CARPAL BONE | Carpus | Carpus Bone",,,,,,,,,,,,,,,"4221855","Bone structure of carpus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016277","Fluconazole","C500","A synthetic triazole with antifungal activity. Fluconazole preferentially inhibits fungal cytochrome P-450 sterol C-14 alpha-demethylation, resulting in the accumulation of fungal 14 alpha-methyl sterols, the loss of normal fungal sterols, and fungistatic activity. Mammalian cell demethylation is much less sensitive to fluconazole inhibition.","Fluconazole | Diflucan | FLUCONAZOLE | alpha-(2,4-difluorophenyl)-alpha- (1,2,4-triazol-1-ylmethyl)-1,2, 4- triazole-1-ethanol | fluconazole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1861854","Renal Cell Carcinoma","C9385","A carcinoma arising from the renal parenchyma.  There is a strong correlation between cigarette smoking and the development of renal cell carcinoma.  The clinical presentation includes : hematuria, flank pain and a palpable lumbar mass.  A high percentage of renal cell carcinomas are diagnosed when an ultrasound is performed for other purposes.  Radical nephrectomy is the standard intervention procedure.  Renal cell carcinoma is generally considered to be resistant to radiation treatment and chemotherapy.","Renal Cell Carcinoma | Adenocarcinoma of Kidney | Adenocarcinoma of the Kidney | CARCINOMA, RENAL CELL, MALIGNANT | Kidney Adenocarcinoma | RCC | Renal Cell Adenocarcinoma | Renal Cell Cancer | Renal Cell Carcinoma, Stage Unspecified | Renal cell adenocarcinoma | Renal cell carcinoma, NOS | Renal cell carcinoma, unclassified | renal cell adenocarcinoma | renal cell cancer | renal cell carcinoma",,,,,,,,,,,,,,,"4215373|45765451","Renal cell carcinoma|Renal cell carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0553257","Renal cell","C33455","A cuboidal glandular epithelial cell found in the renal cortex.","Renal Cortical Cell | Renal Cell | Renal Glandular Epithelial Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1305231","Sinus - general anatomical term","C33556","A recess, cavity, or channel.","Sinus | SINUS | sinus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266043","Sarcomatoid Renal Cell Carcinoma","C27893","A high grade carcinoma of the kidney.  It is not a distinct clinicopathological entity and includes a diverse group of renal cell carcinomas which have been transformed from a lower to a higher grade.","Sarcomatoid Renal Cell Carcinoma | RCC w/ sarcomatoid features | Renal Cell Carcinoma, Sarcomatoid | Renal cell carcinoma with sarcomatoid features | Renal cell carcinoma, sarcomatoid | Sarcomatoid Renal Cell Cancer","8318/3","Renal cell carcinoma, sarcomatoid",,,,,,,,,,,,,"4029987","Renal cell carcinoma, sarcomatoid",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0751429","Laparoscopic Surgery","C15725","Surgery done using a laparoscope.","Laparoscopic Surgery | laparoscopic surgery | laparoscopic-assisted resection | laparoscopy-assisted surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027695","Nephrectomy","C15284","A surgical procedure to completely or partially remove a kidney. With a complete nephrectomy, the attached adrenal gland, perinephric fat, and regional lymph nodes are often removed as well. With a partial nephrectomy, the removed tissue contains the tumor and a rim of normal renal parenchyma only.","Nephrectomy | nephrectomy",,,,,,,,,,,,,,,"4027426","Kidney excision",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013922","Embolism","C26759","The blockage of a blood vessel lumen by air or solid material such as blood clot or other tissues (e.g., adipose tissue, cancer cells) that have migrated from another anatomic site.","Embolism | Embolism/Embolus | embolism",,,,,,,,,,,,,,,"4185607","Embolism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043299","X-Ray Imaging","C38101","A radiographic procedure using the emission of x-rays to form an image of the structure penetrated by the radiation.","X-Ray Imaging | Conventional X-Ray | Diagnostic Radiology | Medical Imaging, X-Ray | Plain film radiographs | RG | Radiographic Imaging | Radiographic imaging procedure (procedure) | Radiography | Radiography | Static X-Ray | X-RAY | X-Ray | X-Ray | X-ray",,,,,,,,,,,,,,,"4178367","Radiographic imaging procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001632","Adrenalectomy","C15177","Surgical removal of part or all of the adrenal gland.","Adrenalectomy | Adrenal Gland Excision | Excision of Adrenal Gland | adrenalectomy",,,,,,,,,,,,,,,"4137462","Adrenalectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085973","Case Study","C15362","An uncontrolled observational study containing a detailed report of the diagnosis, treatment, and follow-up of an individual patient. Case reports also contain some demographic information about the patient (for example, age, gender, ethnic origin).","Case Study | CASE ONLY | Case Report | case report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711364","Frame of Reference","C48360","A set of ideas, as of philosophical or religious doctrine, in terms of which other ideas are interpreted or assigned meaning; a system that uses coordinates to establish position.","Frame of Reference | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711426","Tilt","C48433","The degree of deviation from a vertical plane.","Tilt | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511232","Board Certification","C19602","The process by which a person is tested and approved to practice in a specialty field, especially medicine, after successfully completing the requirements of a board of specialists in that field.","Board Certification | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708743","Lossy Compression","C48366","A data compression algorithm that reduces the amount of information in the data, rather than just the number of bits used to represent that information.","Lossy Compression | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029355","Orthopedics","C16942","The branch of surgery broadly concerned with the skeletal system (bones and joints).","Orthopedics | Orthopedic | Orthopedic Surgery | Orthopedic Surgical Profession",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518927","Pediatric Hematology/Oncology","C17844","A medical specialty that focuses on diseases and disorders of the blood and blood-forming tissues, including hematopoietic and lymphoid cell neoplasms, in children.","Pediatric Hematology/Oncology | Pediatric HemOnc | Pediatric Hematology and Oncology | hematology/oncology, pediatric | oncology/hematology, pediatric | pediatric hematology oncology | pediatric oncology/hematology",,,,,,,,,,,,,,,"37207440","Pediatric hematology oncology",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0678536","Speed","C41146","A scalar measure of the rate of movement of the object expressed either as the distance travelled divided by the time taken (average speed) or the rate of change of position with respect to time at a particular point (instantaneous speed).","Speed | SPEED",,,,,,,,,,,,,,,"3655981","Distance per time (property)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0474796","Neoplasm by Morphology","C4741","A classification system grouping neoplasms according to their cellular characteristics.","Neoplasm by Morphology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709044","Missing Value Reason","C48655","A specific reason explaining why a meaningful value is not available. A meaningful value answers the question posed by a Data Element Concept. In contrast, a Missing Value Reason answers the implicit question 'Why is there no 'meaningful' value?', when there is none.","Missing Value Reason | MVR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710268","Synoptic Surgical Pathology Report","C47867","A surgical pathology reporting template that was developed by the College of American Pathologists (CAP) and contains specific data elements in a specific format on tumors diagnosed in tissue obtained through resection or biopsy.","Synoptic Surgical Pathology Report | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710395","Three Dimensional Size","C47866","definition pending","Three Dimensional Size | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707254","Cancer TNM Finding","C48232","A cancer finding in the TNM system that is relevant to the diagnosis of cancer.","Cancer TNM Finding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707255","Cancer TNM Finding Category","C48698","definition pending","Cancer TNM Finding Category | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708231","Generic Primary Tumor TNM Finding","C48885","definition pending","Generic Primary Tumor TNM Finding | Generic_Primary_Tumor_TNM_Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708232","Generic Regional Lymph Nodes TNM Finding","C48884","definition pending","Generic Regional Lymph Nodes TNM Finding | Generic_Regional_Lymph_Nodes_TNM_Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708230","Generic Distant Metastasis TNM Finding","C48883","definition pending","Generic Distant Metastasis TNM Finding | Generic_Distant_Metastasis_TNM_Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030669","Surgical Pathology specialty","C16958","A field of anatomical pathology in which tissue or cells removed from a living organism are macroscopically and microscopically reviewed for the purpose of disease diagnosis.","Surgical Pathology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707003","Breast Cancer TNM Finding v6","C48790","A finding about one or more characteristics of breast cancer, following the rules of the TNM AJCC v6 classification system.","Breast Cancer TNM Finding v6 | Breast Cancer TNM Finding | Breast Carcinoma TNM Finding v6 | Cancer of the Breast TNM Finding v6 | Carcinoma of the Breast TNM Finding v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335447","Positive Laboratory Test Result","C35682","A laboratory test result that indicates that a specific disease, condition, or attribute being assessed is present.","Positive Laboratory Test Result | Positive | Positive Test Result | positive test result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709603","Positive Surgical Margin","C48620","Indicates the presence of tumor cells at the edge of a surgically excised specimen.","Positive Surgical Margin | Involved | Positive Margins",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709157","Uninvolved","C48621","Indicates the absence of tumor cells at the edge of a surgically excised specimen.","Negative Surgical Margin | All Margins Pathologically Negative | Clear | Clear Margin | Clear Surgical Margin | Uninvolved",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0853879","Invasive Breast Carcinoma","C9245","A carcinoma that infiltrates the breast parenchyma.  The vast majority are adenocarcinomas arising from the terminal ductal lobular unit (TDLU).  Often, the invasive adenocarcinoma co-exists with ductal or lobular carcinoma in situ.  It is the most common carcinoma affecting women.","Invasive Breast Carcinoma | Infiltrating Breast Carcinoma | Infiltrating Carcinoma of Breast | Infiltrating Carcinoma of the Breast | Invasive Breast Cancer | Invasive Carcinoma of Breast | Invasive Carcinoma of the Breast | Invasive Mammary Carcinoma | Invasive breast carcinoma | Invasive mammary carcinoma | infiltrating breast cancer | invasive breast cancer",,,,,,,,,,,,,,,"37017351","Invasive carcinoma of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1510886","Angioinvasion","C39589","A term referring to the presence of tumor emboli or tumor masses within blood vessels (arteries or veins).","Angioinvasion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2924460","Lymphatic Invasion","C47850","A term referring to the presence of tumor emboli or tumor masses within lymphatic vessels.","Lymphatic Invasion | LVI | LVSI | Lymphovascular Invasion | Lymphovascular Space Invasion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710625","Venous Invasion","C47849","A term referring to the presence of tumor emboli or tumor masses within veins.","Venous Invasion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706528","And/Or","C48928","Used to indicate that either or both of two items or options may be valid.","And/Or | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336833","Tubular Pattern","C35925","A morphological appearance characteristic of neoplasms which arise from the glandular or ductal (or both) epithelium, consisting of glandular or ductal neoplastic proliferations forming small tubules with a lumen lined by neoplastic cells.","Tubular Pattern | Tubular",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518437","Nuclear Pleomorphism","C38721","Having nuclei with various distinct forms.","Nuclear Pleomorphism | Nuclear Pleomorphism Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709047","Mitotic Count","C47864","The number of mitoses identified under the microscope in tumors.  It is one of the parameters that determine the grade of malignant tumors.  The method of counting varies, according to the specific tumor examined.  Usually the mitotic count is determined based on the number of mitoses per high power field (40X) or 10 high power fields.","Mitotic Count | Mitotic Count per 40 HPF | Mitotic Rate | Number of Mitotic Figures | mitotic count | mitotic_count",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710441","Total Nottingham Score","C48934","A scoring system used to determine the grade of invasive breast carcinoma.  The total score is determined by the summation of three values (scores), each numbered 1-3.  The three values correspond to the degree of tubular formation, the degree of nuclear pleomorphism, and the mitotic counts per 10 high power fields, respectively.  The sum of the three values produces a total score of 3-9.  Lesions with total score 3-5, are grade I; lesions with total score 6-7, are grade 2.  Lesions with total score 8-9, are grade 3.","Total Nottingham Score | Nottingham Overall Score | Overall Grade | Overall Nottingham Score | Overall Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448703","Tumor Grading System","C48224","A morphologic classification system of malignant tumors, usually relating to disease progression and clinical outcome.  It is based upon the presence or absence of several morphologic parameters, including tumor cell necrosis, cytologic atypia, nuclear pleomorphism and mitotic figures, the architectural infiltrating patterns, and the degree of tumor cell differentiation.  Malignant tumors usually are graded I-III.","Tumor Grading System | Grading System | Grading System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0151779","Cutaneous Melanoma","C3510","A primary melanoma arising from atypical melanocytes in the skin.  Precursor lesions include acquired and congenital melanocytic nevi, and dysplastic nevi.  Several histologic variants have been recognized, including superficial spreading melanoma, acral lentiginous melanoma, nodular melanoma, and lentigo maligna melanoma.","Cutaneous Melanoma | CM | Cutaneous (Skin) Melanoma | Malignant Cutaneous Melanoma | Malignant Melanoma (of Skin), Stage Unspecified | Malignant Melanoma of Skin | Malignant Melanoma of Skin Stage Unspecified | Malignant melanoma of skin, unspecified | Melanoma of Skin | Melanoma of the Skin | Skin Melanoma | Skin, Melanoma",,,,,,,,,,,,,,,"141232","Malignant melanoma of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709883","Regional Lymph Node Dissection","C48935","Surgical removal of the lymph nodes located in a particular anatomic region.  This procedure is commonly performed as a component of cancer staging.","Regional Lymph Node Dissection | regional lymph node dissection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981203","Cutaneous Melanoma TNM Finding v6","C48791","A finding about one or more characteristics of cutaneous melanoma, following the rules of the TNM AJCC v6 classification system.","Cutaneous Melanoma TNM Finding v6 | Cutaneous Melanoma TNM Finding | Cutaneous Melanoma v6 | Melanoma of Skin TNM Finding v6 | Melanoma of the Skin TNM Finding v6 | Skin Melanoma TNM Finding v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708945","Matted Lymph Nodes","C48599","Lymph nodes adherent to each other, usually a result of tumor spread.","Matted Lymph Nodes | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710016","Satellite Nodule","C48598","Additional, separate neoplastic nodules surrounding a central neoplastic lesion.","Satellite Nodule | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031911","Pigmentation","C38005","Pigmentation; the coloring of the skin, hair, mucous membranes, and retina of the eye.","Pigmentation | PIGMENT | Pigments",,,,,,,,,,,,,,,"4137823|4177036","Pigmentation|Pigment deposition",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1317608","Perineural Invasion","C48260","A morphologic finding referring to a tumor that has spread along and infiltrated nerve fibers.  The presence of perineural invasion by malignant tumor cells may represent a poor prognostic factor.","Perineural Invasion | Perineural Invasion | Perineurial Invasion | Present",,,,,,,,,,,,,,,"44783970","Perineural spread",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0079722","Tumor Infiltrating Lymphocyte","C12546","Lymphocytes that show specificity for autologous tumor cells and can infiltrate a tumor.","Tumor Infiltrating Lymphocyte | Lymphocytes, Tumor-Infiltrating | TIL | TILs | Tumor Infiltrating Lymphocytes | tumor infiltrating lymphocyte",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0684320","Regression","C18243","Return to a former state; a subsidence of the symptoms of a disease process; in cancer, a decrease in the size of a tumor or in the extent of cancer in the body.","Regression | Regressing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0184913","Re-Excision","C48600","A surgical procedure to remove the remaining abnormal tissues from the body, not completely removed in an earlier attempt.","Re-Excision | RE-EXCISION | Re-excision | Reexcision",,,,,,,,,,,,,,,"4280798","Reexcision",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708566","Invasive Prostate Carcinoma","C48596","A carcinoma that is not confined to the prostatic epithelium but has spread to the surrounding stroma of the prostate gland.  The vast majority of invasive prostate carcinomas are adenocarcinomas.","Invasive Prostate Carcinoma | Infiltrating Prostate Carcinoma | Invasive Prostate Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332326","Gleason Grading System","C28107","A grading system for prostatic carcinoma based on the microscopic glandular architectural patterns of the malignant epithelial cells. Nuclear atypia is not evaluated. It defines five patterns or grades which reflect decreasing differentiation.","Gleason Grading System | Gleason Grade | Gleason Grade for Prostate Cancer | Gleason Grade for Prostate Cancer | Grade Group",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1273604","Primary Gleason Pattern","C48603","The most prevalent Gleason pattern in a prostate biopsy or prostatectomy specimen. The Gleason score is defined by adding the most prevalent (primary) and second most prevalent (secondary) patterns.","Primary Gleason Pattern | GLEASON PRIMARY SCORE | Primary Gleason Score For Prostate Cancer | primary gleason grade | primary_gleason_grade",,,,,,,,,,,,,,,"4293445","Primary Gleason pattern",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1273605","Secondary Gleason Pattern","C48604","The second most prevalent Gleason pattern in a prostate biopsy or prostatectomy specimen. The Gleason score is defined by adding the most prevalent (primary) and second most prevalent (secondary) patterns.","Secondary Gleason Pattern | GLEASON SECONDARY SCORE | Secondary Gleason Score For Prostate Cancer | secondary gleason grade | secondary_gleason_grade",,,,,,,,,,,,,,,"4297948","Secondary Gleason pattern",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1273607","Total Gleason Score for Prostate Cancer","C48602","The value of the sum of the primary and secondary Gleason scores (range 2-10). If three patterns are identified, it is the sum of the primary pattern score and the score of the least well-differentiated pattern.","Total Gleason Score for Prostate Cancer | GLEASON TOTAL SUM | Total Gleason Score | Total Gleason Score For Prostate Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514521","Prostatic Tissue","C33414","Tissue composed of tubuloalveolar glands embedded in fibromuscular stroma. The stroma is smooth muscle separated by strands of connective tissue rich in collagenous and elastic fibers. The secretory alveoli of the prostate are irregularly shaped with papillary projections of the mucosa into the lumen of the gland.","Prostatic Tissue | Prostatic Parenchyma | ProstaticTissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014392","Enucleation","C48601","A surgical procedure by which tissue or an organ (usually containing a tumor) is removed without rupture from a specific anatomic site.","Enucleation | enucleation",,,,,,,,,,,,,,,"4213548","Enucleation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0475358","Tumor Tissue Sample","C18009","Tissue sample that contains an abnormal cellular infiltrate forming a solid mass. The abnormal cellular component can be benign or malignant. Tumor samples are obtained for microscopic examination and/or molecular analysis.","Tumor Tissue Sample | TUMOR TISSUE | Tumor | Tumor Sample | Tumor Tissue | Tumor Tissue",,,,,,,,,,,,,,,"4122248","Tumor tissue specimen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0194810","Radical Prostatectomy","C15399","The surgical removal of all of the prostate as well as some surrounding tissue, including lymph nodes.","Radical Prostatectomy | Prostatovesiculectomy | radical prostatectomy",,,,,,,,,,,,,,,"4096783","Radical prostatectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0277565","Localized Disease","C36162","A disease that is confined to a specific organ or tissue and has not spread to other anatomic sites.","Localized Disease | Local",,,,,,,,,,,,,,,"4251043","Local disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708680","Lesion by Focality","C48615","A term referring to the number of anatomic sites affected by a disease.","Lesion by Focality | Lesion By Focality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981195","Prostate Cancer TNM Finding v6","C48234","A finding about one or more characteristics of prostate cancer, following the rules of the TNM AJCC v6 classification system.","Prostate Cancer TNM Finding v6 | Cancer of the Prostate TNM Finding v6 | Carcinoma of the Prostate TNM Finding v6 | Prostate Cancer TNM Finding | Prostate Carcinoma TNM Finding v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1273608","Tertiary Gleason Pattern","C48605","Prostate carcinoma patterns occupying less than 5% of the tumor.","Tertiary Gleason Pattern | Tertiary Gleason Score for Prostate Cancer | gleason grade tertiary | gleason_grade_tertiary",,,,,,,,,,,,,,,"4298753","Tertiary Gleason pattern",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040771","Transurethral Prostatic Resection","C15343","Prostate tissue removal via a cystoscope.","Transurethral Prostatic Resection | Prostate Transurethral Resection | TURP | Transurethral Prostatectomy | Transurethral Resection (TURP) | Transurethral Resection of Prostate | Transurethral Resection of the Prostate | transurethral resection of the prostate",,,,,,,,,,,,,,,"4234536","Transurethral prostatectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0743997","Incidental Lesion Finding","C48619","An asymptomatic benign or malignant lesion discovered during an endoscopic, surgical, or radiologic procedure performed for unrelated reasons.","Incidental Lesion Finding | Incidental Finding | Incidentaloma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019139","Low Molecular Weight Heparin","C2578","Substances comprised of fragmented heparin molecules derived from unfractionated heparin that bind to antithrombin III with a molecular weight ranging from 1000 to 10,000 daltons, which causes changes in property from unfractionated heparin, including decreased protein binding, enhanced bioavailability, decreased platelet interaction, and decreased binding to thrombin.","Low Molecular Weight Heparin | LMWH | Low-molecular-weight heparin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043031","Warfarin","C945","A synthetic anticoagulant. Warfarin inhibits the regeneration of vitamin K1 epoxide and so the synthesis of vitamin K dependent clotting factors, which include Factors II, VII, IX and X, and the anticoagulant proteins C and S. This inhibition results in a sequential depression of Factors VII, IX, X and II activities. Vitamin K is an essential cofactor for the post ribosomal synthesis of the vitamin K dependent clotting factors. The vitamin promotes the biosynthesis of gamma-carboxyglutamic acid residues in these proteins which are essential for biological activity.","Warfarin | 1-(4'-Hydroxy-3'-coumarinyl)-1-phenyl-3-butanone | 3-(.alpha.-Acetonylbenzyl)-4-hydroxycoumarin | 3-(.alpha.-Phenyl-.beta.-acetylethyl)-4-hydroxycoumarin | 3-(Alpha-acetonylbenzyl)-4-hydroxycoumarin | 3-Alpha-phenyl-beta-acetylethyl-4-hydroxycoumarin | 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one | Athrombin-K | Co-Rax | Compound 42 | Rodex | WARF Compound 42 | WARF compound 42 | WARFARIN | warfarin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205258","Indeterminate","C48658","Cannot distinguish between two or more possible values in the current context.","Indeterminate | Cannot Be Determined | INDETERMINATE | Inconclusive | Indeterminant | Unable to Determine",,,,,,,,,,,,,,,"4219043","Indeterminate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0475264","Localization","C28264","The process of determining or marking the location or site of a lesion or disease.","Localization | LOCALIZATION_TECHNIQUE | localization",,,,,,,,,,,,,,,"4107450","Localization - action",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704681","Molecular Probe","C43523","General term for a piece of DNA or RNA corresponding to a gene or sequence of interest, that has been labelled either radioactively or with some other detectable molecule, such as biotin, digoxygenin or fluorescein. As stretches of DNA or RNA with complementary sequences will hybridize, a probe will label viral plaques, bacterial colonies or bands on a gel that contain the gene of interest.","Probe | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710541","UniSTS","C48815","A comprehensive database of sequence tagged sites (STSs) derived from STS-based maps and other experiments providing a unified, non-redundant view of sequence tagged sites. UniSTS integrates marker and mapping data from a variety of public resources.","UniSTS | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1138831","Gene Ontology","C43520","The Gene Ontology (GO) project is a collaborative effort to address the need for consistent descriptions of gene products in different databases.  The goal of the Gene Ontology project is to produce a controlled vocabulary that can be applied to all organisms even as knowledge of gene and protein roles in cells is accumulating and changing. GO provides three structured networks of defined terms, molecular function, biological process, and cellular component, to describe gene product attributes.","Gene Ontology | GO | GO | GO Ontology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708378","HomoloGene","C48819","A system provided by the National Center for Biotechnology Information for automated detection of homologs among the annotated genes of several completely sequenced eukaryotic genomes.","HomoloGene | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0080145","Sequence Tagged Sites","C17396","Short (200 to 500 base pairs) DNA sequence that is operationally unique and has a single occurrence in the human genome and whose location and base sequence are known and therefore they can be used as landmarks in genome mapping.","Sequence Tagged Site | STS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707520","Correlation","C48834","The degree to which two or more quantities or events are linearly associated, a statistical relation between two or more variables such that systematic changes in the value of one variable are accompanied by systematic changes in the others.","Correlation | Correlated | Correlative | correlation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0950133","Online Mendelian Inheritance In Man","C43519","This database is a catalog of human genes and genetic disorders authored and edited by Dr. Victor A. McKusick and his colleagues at Johns Hopkins and elsewhere, and developed for the World Wide Web by NCBI, the National Center for Biotechnology Information. The database contains textual information and references. It also contains copious links to MEDLINE and sequence records in the Entrez system, and links to additional related resources at NCBI and elsewhere.","Online Mendelian Inheritance in Man | OMIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0598211","GenBank","C43818","The NIH genetic sequence database, an annotated collection of all publicly available DNA sequences. GenBank records are annotated using a standard set of biological terms and show these annotations in a Feature Table.","GenBank | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0752046","Single Nucleotide Polymorphism","C18279","A variation of a single nucleotide at a specific location of the genome due to base substitution, present at an appreciable frequency between individuals of a single interbreeding population.","Single Nucleotide Polymorphism | Polymorphism, Single Base | Polymorphism, Single Nucleotide | SNP | Single-Nucleotide Polymorphisms | single nucleotide polymorphism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796419","Taxanes","C1490","A type of drug that blocks cell growth by stopping mitosis (cell division). Taxanes interfere with microtubules (cellular structures that help move chromosomes during mitosis). They are used to treat cancer. A taxane is a type of mitotic inhibitor and a type of antimicrotubule agent.","Taxane Compound | Taxanes | taxane",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0549184","None","C41132","No person or thing, nobody, not any.","None | NONE | No abnormalities related to cardiovascular diseases | None at all",,,,,,,,,,,,,,,"4124462","None",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1521743","Study Monitor","C41201","An organization, individual, group, or body responsible for the appropriate oversight and monitoring of the conduct of a clinical study.  This is done to ensure the safety of participants and the validity and integrity of the study data.","Study Monitor | Monitor | Monitor | Protocol Monitor | Trial Monitor | monitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522653","Endotracheal Route of Administration","C38208","Endotracheal drug administration involves the introduction of the agent directly through the endotracheal tube in an intubated patient. Generally this route is considered as a last resort for drug administration, and provides a fast, effective means of drug delivery in a patient who requires immediate medication. Plasma levels obtained via endotracheal administration are considerably less than those obtained with an equal dosage administered intravenously or intraosseously. Endotracheal administration must be followed by hyper-insufflation of the lungs to promote optimal drug absorption.","Endotracheal Route of Administration | E-TRACHE | ENDOTRACHEAL | ET | Endotracheal | Endotracheopulmonary use | Intratracheal | Intratracheal Route of Administration",,,,,,,,,,,,,,,"4229543","Intratracheal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448491","Cytopathology","C20611","A branch of pathology that studies and diagnoses diseases on the cellular level including the anatomy, physiology, pathology and chemistry of the cell.","Cytopathology | Cytology and Pathology | Cytopathologic | Cytopathological",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708071","Floating-Point Number","C48150","A number that can have its decimal point in any position.","Float | Float Value | Floating Point | Floating-Point Number | Floating-point",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708523","Integer (number)","C45255","A number with no fractional part, including the negative and positive numbers as well as zero.","Integer | Integer Value",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334274","Invasive Carcinoma","C9480","A carcinoma that is not confined to the epithelium, and has spread to the surrounding stroma.","Invasive Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441800","Grade","C48309","A position on a scale of intensity or amount or quality.","Grade | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513183","Metastatic Lesion","C40557","A tumor arising at a location distant to the primary lesion.","Metastatic Lesion | DISEASE BECAME METASTATIC | Metastases | Metastasis | Metastasis, NOS | Metastatic | Metastatic Disease | metastasis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708745","Low-Dose Treatment","C49341","A reduced quantity of a therapeutic agent prescribed to be taken at one time or at stated intervals.","Low-Dose Treatment | Low-Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709056","Moderate-Dose Treatment","C49342","The regular strength or dosage quantity of a therapeutic agent prescribed to be taken at one time or at stated intervals.","Moderate-Dose Treatment | Moderate-Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0149871","Deep Vein Thrombosis","C49343","A blood clot in a deep vein, predominantly in the lower extremity, but may include the pelvis or upper extremity.","Deep Vein Thrombosis | DVT | Deep Vein Thrombosis (DVT) | Deep Venous Thrombosis | deep vein thrombosis",,,,,,,,,,,,,,,"4133004","Deep venous thrombosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705190","Second Suffix","C49463","A suffix denoting the second person having the same complete name (first, middle, and family names).","Second | II | Second Suffix",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705160","III (suffix)","C49464","A suffix denoting the third person having the same complete name (first, middle, and family names).","Third | III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706303","Fourth (suffix)","C49465","A suffix denoting the fourth person having the same complete name (first, middle, and family names).","Fourth | IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708595","Junior","C49466","A suffix used to distinguish a son from his father when they have the same given name.","Junior | Jr",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705825","Senior - Suffix","C49467","A suffix used to distinguish a father from his son when they have the same given name.","Senior | Sr",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513897","National Institute of Dental and Craniofacial Research","C19755","One of the institutes that comprise the National Institutes of Health. The mission of the NIDCR is to improve oral, dental and craniofacial health through research, research training, and the dissemination of health information.","National Institute of Dental and Craniofacial Research | NIDCR | NIDR | National Institute of Dental Research",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0222595","Central Portion of the Breast","C12300","The part of the breast which is in the center.","Central Portion of the Breast | Central Portion of Breast | Central portion of breast",,,,,,,,,,,,,,,"4173884","Structure of central portion of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0222596","Upper-Inner Quadrant of the Breast","C12301","The quarter of the breast which is superior and medial.","Upper-Inner Quadrant of the Breast | Upper-Inner Quadrant of Breast | Upper-inner quadrant of breast | upper inner quadrant of breast",,,,,,,,,,,,,,,"4299233","Structure of upper inner quadrant of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0222597","Lower-Inner Quadrant of the Breast","C12302","The quarter of the breast which is inferior and medial.","Lower-Inner Quadrant of the Breast | Lower-Inner Quadrant of Breast | Lower-inner quadrant of breast | lower inner quadrant of breast",,,,,,,,,,,,,,,"4078061","Structure of lower inner quadrant of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0222598","Upper-Outer Quadrant of the Breast","C12303","The quarter of the breast which is superior and lateral.","Upper-Outer Quadrant of the Breast | Upper-outer quadrant of breast | upper outer quadrant of breast",,,,,,,,,,,,,,,"4295715","Structure of upper outer quadrant of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0222599","Lower-Outer Quadrant of the Breast","C12304","The quarter of the breast which is inferior and lateral.","Lower-Outer Quadrant of the Breast | Lower-Outer Quadrant of Breast | Lower-outer quadrant of breast | lower outer quadrant of breast",,,,,,,,,,,,,,,"4140809","Structure of lower outer quadrant of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227959","Apex of the Prostate","C13087","The lowest part of the prostate gland adjacent to the superior fascia of the urogenital diaphragm.","Apex of the Prostate | Apex | Apex of Prostate | Apical Prostate | Prostatic apex",,,,,,,,,,,,,,,"4288609","Structure of apex of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0193867","Axillary Lymph Node Dissection","C15677","Surgical removal of the lymph nodes located in the cavity beneath the junction of the arm and the thorax, or axilla (armpit).  This procedure is commonly performed as a component of cancer staging.","Axillary Lymph Node Dissection | ALND | Axillary Dissection | Axillary Lymphadenectomy | Axillary Node Dissection | Excision Axillary Lymph Nodes | axillary dissection | axillary lymph node dissection",,,,,,,,,,,,,,,"4120961","Excision of axillary lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005001","Benign Prostatic Hyperplasia","C2897","A non-cancerous nodular enlargement of the prostate gland.  It is characterized by the presence of epithelial cell nodules, and stromal nodules containing fibrous and smooth muscle elements.  It is the most common urologic disorder in men, causing blockage of urine flow.","Benign Prostatic Hyperplasia | BPH | Benign Hyperplasia of Prostate | Benign Hyperplasia of the Prostate | Benign Prostate Hyperplasia | Benign Prostatic Hyperplasia - BPH | Benign Prostatic Hypertrophy | Prostate Adenoma | Prostatic Hyperplasia | benign prostatic hyperplasia | benign prostatic hypertrophy",,,,,,,,,,,,,,,"198803","Benign prostatic hyperplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007112","Prostate Adenocarcinoma","C2919","An adenocarcinoma arising from the prostate gland.  It is one of the most common malignant tumors afflicting men.  The majority of adenocarcinomas arise in the peripheral zone and a minority occurs in the central or the transitional zone of the prostate gland.  Grading of prostatic adenocarcinoma predicts disease progression and correlates with survival.  Several grading systems have been proposed, of which the Gleason system is the most commonly used.  Gleason sums of 2 to 4 represent well-differentiated disease, 5 to 7 moderately differentiated disease and 8 to 10 poorly differentiated disease.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic adenocarcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","Prostate Adenocarcinoma | Adenocarcinoma of Prostate | Adenocarcinoma of the Prostate | PRAD | Prostate Adenocarcinoma ",,,,,,,,,,,,,,,"4161028","Adenocarcinoma of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022602","Actinic Keratosis","C3148","A precancerous lesion of the skin composed of atypical keratinocytes. It is characterized by the presence of thick, scaly patches of skin. Several histologic variants have been described, including atrophic, acantholytic, hypertrophic, proliferative, lichenoid, bowenoid, and pigmented variants.","Actinic Keratosis | AK | Actinic (Solar) Keratosis | Actinic (Solar) Keratosis | Senile Hyperkeratosis | Senile Keratosis | Solar Keratosis | actinic keratosis | senile keratosis | solar keratosis",,,,,,,,,,,,,,,"138825|4309965","Actinic keratosis|Actinic keratosis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1333299","Diffuse Pattern","C35903","A morphologic architectural pattern in which a cellular population is distributed in a relatively uniform fashion throughout a specified tissue area; not focal.","Diffuse Pattern | Diffuse Architectural Pattern | Diffuse Architecture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334819","Multifocal Lesion","C36180","A lesion arising from or having many locations.","Multifocal Lesion | Multifocal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0154084","Stage 0 Breast Cancer AJCC v6 and v7","C3641","Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage 0 Breast Cancer AJCC v6 and v7 | Breast Cancer Stage 0 | Breast Cancer in situ | Breast Carcinoma in situ | Carcinoma in situ of Breast | Carcinoma in situ of breast | Carcinoma in situ of the Breast | In situ Breast Cancer | Non-Infiltrating Breast Carcinoma | Non-Infiltrating Carcinoma of Breast | Non-Infiltrating Carcinoma of the Breast | Non-Invasive Breast Carcinoma | Non-Invasive Carcinoma of Breast | Non-Invasive Carcinoma of the Breast | Stage 0 Breast Cancer | Stage 0 Breast Cancer | Stage 0 Breast Cancer AJCC v6 | Stage 0 Breast Cancer AJCC v7 | Stage 0 Breast Carcinoma | Stage 0 Carcinoma of Breast | Stage 0 Carcinoma of the Breast | Unspecified type of carcinoma in situ of breast | Unspecified type of carcinoma in situ of unspecified breast | breast cancer in situ | stage 0 breast carcinoma in situ",,,,,,,,,,,,,,,"81250","Carcinoma in situ of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334439","Desmoplastic Melanoma","C37257","A melanoma of the skin characterized by a proliferation of atypical spindled melanocytes in the dermis, in a background of abundant collagen. It usually presents as an amelanotic raised nodular lesion.","Desmoplastic Melanoma | Desmoplastic Cutaneous (Skin) Melanoma | desmoplastic melanoma",,,,,,,,,,,,,,,"4202041|4298034","Desmoplastic melanoma, malignant|Desmoplastic malignant melanoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0346037","Acral Lentiginous Melanoma","C4022","A form of melanoma occurring most often on the plantar, palmar, subungual, and periungual skin.  It presents as a pigmented macular lesion with irregular borders.  Morphologically, it consists of atypical spindled and dendritic melanocytes.  The epidermis is often hyperplastic and there is pagetoid infiltration of the epidermis by anaplastic cells.","Acral Lentiginous Melanoma | Acral Lentiginous Malignant Melanoma | Acral Lentiginous Malignant Melanoma | Acral Melanoma | Acral lentiginous melanoma, malignant",,,,,,,,,,,,,,,"4061266|4110726","Acral lentiginous melanoma, malignant|Acral lentiginous malignant melanoma of skin",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1511281","Breast Adenocarcinoma with Spindle Cell Metaplasia","C40360","An invasive adenocarcinoma of the breast usually affecting post-menopausal women, characterized by extensive spindle cell metaplasia of the neoplastic glandular cells.","Breast Adenocarcinoma with Spindle Cell Metaplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510796","Breast Adenosquamous Carcinoma","C40361","An invasive breast carcinoma characterized by the presence of tubular and glandular neoplastic cell structures, admixed with islands of neoplastic cells showing squamous differentiation.","Breast Adenosquamous Carcinoma | Adenosquamous Breast Carcinoma | Adenosquamous Breast Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513365","Breast Carcinosarcoma","C40364","An invasive breast carcinoma characterized by the presence of a mesenchymal cellular component.  The mesenchymal cellular component ranges from cartilaginous and osseous, to purely sarcomatous.","Breast Mixed Epithelial/Mesenchymal Metaplastic Carcinoma | Breast Carcinosarcoma | Mixed Epithelial/Mesenchymal Metaplastic Breast Carcinoma | Mixed Epithelial/Mesenchymal Metaplastic Breast Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334371","Breast Secretory Carcinoma","C4189","A rare, low grade invasive adenocarcinoma of the breast characterized by the presence of cells that secrete milk-like material. Morphologically, it usually appears as a circumscribed lesion, composed of cystic spaces, tubular structures, and solid areas.","Breast Secretory Carcinoma | Cystic Hypersecretory Breast Carcinoma | Cystic Hypersecretory Carcinoma of Breast | Cystic Hypersecretory Carcinoma of the Breast | Cystic hypersecretory carcinoma | Infiltrating Cystic Hypersecretory Duct Breast Carcinoma | Invasive Cystic Hypersecretory Duct Breast Carcinoma | Juvenile Breast Carcinoma | Juvenile Carcinoma of Breast | Juvenile Carcinoma of the Breast | Juvenile Secretory Breast Carcinoma | Juvenile Secretory Carcinoma of Breast | Juvenile Secretory Carcinoma of the Breast | Juvenile carcinoma of breast | Secretory Breast Carcinoma | Secretory Breast Carcinoma | Secretory Carcinoma | Secretory Carcinoma of Breast | Secretory Carcinoma of the Breast | Secretory carcinoma of breast","8508/3","Cystic hypersecretory carcinoma",,,,,,,,,,,,,"4030119|4224593","Cystic hypersecretory carcinoma|Juvenile carcinoma of the breast",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1134719","Invasive Breast Carcinoma of No Special Type","C4194","A term that refers to a large and heterogeneous group of invasive breast carcinomas that cannot be classified morphologically as any of the special histological types. (WHO 2019)","Invasive Breast Carcinoma of No Special Type | IBC NST | Infiltrating Ductal Adenocarcinoma | Infiltrating Ductal Breast Carcinoma | Infiltrating Ductal Carcinoma | Infiltrating Ductal Carcinoma of Breast | Infiltrating Ductal Carcinoma of the Breast | Invasive Ductal Adenocarcinoma | Invasive Ductal Breast Carcinoma | Invasive Ductal Carcinoma | Invasive Ductal Carcinoma of Breast | Invasive Ductal Carcinoma of the Breast | Invasive Ductal Carcinoma, NOS | Invasive Ductal Carcinoma, NST | Invasive Ductal Carcinoma, No Specific Type | Invasive Ductal Carcinoma, Not Otherwise Specified | Invasive Ductal Carcinoma, Not Otherwise Specified | infiltrating ductal carcinoma","8500/3|8521/3","Infiltrating duct carcinoma, NOS|Infiltrating ductular carcinoma",,,,,,,,,,,,,"4237178|4242279","Infiltrating duct carcinoma of breast|Infiltrating ductular carcinoma",,,,,,,,,,,,,"--","--|--",,,,,,,,"--|--"
"C0334424","Cutaneous Nodular Melanoma","C4225","Nodular melanoma that arises from the skin. It may or may not arise from a pre-existing nevus.","Cutaneous Nodular Melanoma | Nodular Cutaneous (Skin) Melanoma | Nodular Malignant Melanoma of Skin | Nodular Malignant Melanoma of the Skin | Nodular Malignant Skin Melanoma | Nodular Melanoma | Nodular Melanoma | Nodular melanoma",,,,,,,,,,,,,,,"4061568|4112760","Nodular melanoma|Nodular malignant melanoma of skin",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0334447","Melanoma Arising in Blue Nevus","C4240","A rare melanoma which develops in a pre-existing blue nevus. It occurs more frequently on the scalp, face, orbit, back, buttocks, extremities, hands, and feet.","Melanoma Arising in Blue Nevus | Blue Nevus-Like Melanoma | Blue Nevus-Like Melanoma | Cutaneous (Skin) Melanoma Arising from Blue Nevus | MBN | Malignant Blue Nevus | Malignant Blue Nevus of Skin | Malignant Blue Nevus of the Skin | Malignant Cutaneous Blue Nevus | Malignant Skin Blue Nevus | Melanoma Arising from Blue Nevus | Melanoma Arising from Blue Nevus","8780/3","Blue nevus, malignant",,,,,,,,,,,,,"4141249|4284099","Malignant blue nevus of skin|Blue nevus, malignant",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1707042","Breast Carcinoma with Chondroid Metaplasia","C47847","An invasive carcinoma of the breast showing differentiation towards cartilaginous structures.","Breast Carcinoma with Chondroid Metaplasia | Breast Carcinoma with Cartilaginous Metaplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711312","Breast Carcinoma with Osseous Metaplasia","C47848","An invasive breast carcinoma showing differentiation towards bone structures.","Breast Carcinoma with Osseous Metaplasia | Breast Carcinoma with Osseous Metaplasia ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710051","Sentinel Lymph Node Biopsy with Axillary Lymph Node Dissection","C47854","A surgical procedure in which the sentinel node is removed followed by dissection and removal of the axillary node group.","Sentinel Lymph Node Biopsy with Axillary Lymph Node Dissection | Axillary Lymph Node Dissection with Prior Sentinel Lymph Node Biopsy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4266631","Left Breast","C47855","The hemispheric projection, including the mammary gland, located on the anterior portion of the chest, lateral to the midline, on the side of the body to the west when facing north.","Left Breast | ",,,,,,,,,,,,,,,"4197399","Left breast structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4266628","Right Breast","C47856","The hemispheric projection, including the mammary gland, located on the anterior portion of the chest, lateral to the midline, on the side of the body to the east when facing north.","Right Breast | ",,,,,,,,,,,,,,,"4248990","Right breast structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709447","Paget's Disease of the Breast without Invasive Carcinoma","C47858","Paget disease involving the skin overlying the mammary gland, without accompanying invasive ductal or lobular breast carcinoma.","Breast Paget Disease without Invasive Carcinoma | Paget Disease of the Breast without Invasive Carcinoma | Paget Disease of the Breast without Invasive Carcinoma | Paget's Disease of the Breast without Invasive Carcinoma | Tis (Paget's) | Tis (Paget)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272628","Microcalcification Present in Non-Neoplastic Tissue","C47860","A finding of microcalcifications located within tissues without neoplasm.","Microcalcification Present in Non-Neoplastic Tissue | ",,,,,,,,,,,,,,,"4296694","Microcalcifications in non-neoplastic tissue present",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709018","Microcalcification Present in Neoplastic and Non-Neoplastic Tissue","C47861","A finding of microcalcifications located within neoplastic tissue, and in tissues without neoplasm.","Microcalcification Present in Neoplastic and Non-Neoplastic Tissue | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205231","Extensive","C47863","Large in quantity, range, or spatial extent.","Extensive | ",,,,,,,,,,,,,,,"4165724","Extensive",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708074","Focal Pattern","C48606","A morphologic architectural pattern in which a cellular population is distributed in a localized or relatively uneven fashion throughout a specified tissue area; not diffuse.","Focal Pattern | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708565","Infiltrating Melanoma","C48607","A melanoma of the skin that is not confined to the dermal-epidermal junction, and has infiltrated the dermis.","Invasive Cutaneous Melanoma | Infiltrating Melanoma | Invasive Cutaneous (Skin) Melanoma | Invasive Melanoma | Invasive Skin Melanoma | Invasive Skin Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710671","Wide Skin Excision","C48608","Surgical excision of diseased skin tissue with a border of healthy tissue surrounding the lesion. It is often used as a treatment for skin cancers. The margin of the healthy tissue may range from a few millimeters for small cancers up to around 15 mm for larger cancers.","Wide Skin Excision | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707902","Elliptical Skin Excision","C48611","A surgical procedure in which the skin is cut in a geometrical fashion resembling an ellipse.","Elliptical Skin Excision | Elliptical Skin Excision ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0545071","Minimal Deviation Melanoma","C48612","A melanocytic neoplasm displaying morphologic features that are intermediate between those of benign nevus and melanoma.  It is characterized by a nodular architectural growth resembling a melanoma, and a loss of nevus cell maturation.  The melanocytic cells forming the nodular growth are uniform, and they may display a high mitotic rate, but they do not show cytologic atypia.","Minimal Deviation Melanoma | Minimal Deviation Cutaneous (Skin) Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711221","Melanoma in Congenital Melanocytic Nevus","C48613","A melanoma of the skin arising in a congenital melanocytic nevus.","Melanoma Arising in Congenital Melanocytic Nevus | Cutaneous (Skin) Melanoma in Congenital Melanocytic Nevus | Melanoma in Congenital Melanocytic Nevus | Melanoma in Congenital Melanocytic Nevus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709220","Desmoplastic Neurotropic Melanoma","C48614","A desmoplastic melanoma characterized by the presence of nerve infiltration by atypical spindled melanocytes.","Desmoplastic Neurotropic Melanoma | Neurotropic Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710544","Unifocal Lesion","C48616","A lesion arising from or having a single location.","Unifocal Lesion | Unifocal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266115","Mucosal Lentiginous Melanoma","C48622","An acral lentiginous melanoma affecting mucosal surfaces.","Mucosal Lentiginous Melanoma | Mucosal Lentiginous Malignant Melanoma | Mucosal lentiginous melanoma","8746/3","Mucosal lentiginous melanoma",,,,,,,,,,,,,"4029521","Mucosal lentiginous melanoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1707258","Cannot Be Assessed","C48657","Aspects of the context prevent the evaluation needed to determine a value.","Cannot Be Assessed | Cannot be assessed",,,,,,,,,,,,,,,"607928","Cannot be determined",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709276","Not Identified","C48661","The finding is not present, but a value of 'none' cannot be unequivocally established absence in the current context.","Not Identified | not identified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706089","Marked","C48662","A prominent or noticeable characteristic.","Marked | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709610","Posterolateral Part of the Prostate","C48663","The part of the prostate gland that is lateral and posterior.","Posterolateral Part of the Prostate | Postero-Lateral Part of the Prostate | Posterolateral Part Of The Prostate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709480","Pathologic TNM Finding","C48739","A TNM finding obtained following the microscopic examination of a specimen.","Pathologic TNM Finding | pTNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709870","Recurrent Cancer TNM Finding","C48880","TNM staging performed for recurrent cancer.","Recurrent Cancer TNM Finding | rTNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707417","Clinical TNM Finding","C48881","TNM staging performed with access to clinical information only.","Clinical TNM Finding | cTNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332167","Breast Adenoid Cystic Carcinoma","C5130","An adenoid cystic carcinoma primarily involving the breast.  Three morphologic patterns are seen: cribriform, trabecular, and solid.  The prognosis is excellent.","Breast Adenoid Cystic Carcinoma | Adenocystic Breast Carcinoma | Adenocystic Carcinoma of Breast | Adenocystic Carcinoma of the Breast | Adenoid Cystic Breast Carcinoma | Adenoid Cystic Breast Carcinoma | Adenoid Cystic Carcinoma of Breast | Adenoid Cystic Carcinoma of the Breast | Mammary Adenocystic Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332316","Breast Apocrine Carcinoma","C5141","An adenocarcinoma of the breast characterized by the presence of two intermingled cellular components: cells with abundant granular, eosinophilic cytoplasm, and cells with abundant cytoplasm containing fine empty vacuoles.","Breast Apocrine Carcinoma | Apocrine Breast Carcinoma | Apocrine Breast Carcinoma | Apocrine Carcinoma of Breast | Apocrine Carcinoma of the Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334275","Invasive Cribriform Carcinoma of Breast","C5142","An invasive adenocarcinoma of the breast with a favorable clinical outcome, characterized by the presence of a sieve-like or cribriform infiltrating pattern.","Invasive Breast Cribriform Carcinoma | Infiltrating Cribriform Breast Carcinoma | Infiltrating Cribriform Carcinoma of Breast | Infiltrating Cribriform Carcinoma of the Breast | Infiltrating Cribriform Ductal Carcinoma of Breast | Invasive Breast Cribriform Adenocarcinoma | Invasive Cribriform Breast Carcinoma | Invasive Cribriform Breast Carcinoma | Invasive Cribriform Carcinoma of Breast | Invasive Cribriform Carcinoma of the Breast | Invasive Cribriform Ductal Carcinoma of Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335519","Prostate Acinar Sarcomatoid Carcinoma","C5530","A rare acinar adenocarcinoma of the prostate gland with unfavorable prognosis. It is composed of both malignant glandular and sarcomatous components. The sarcomatous component contains a malignant spindle cell proliferation or specific mesenchymal elements including osteosarcoma, chondrosarcoma, and leiomyosarcoma.","Prostate Acinar Sarcomatoid Carcinoma | Acinar Prostate Adenocarcinoma, Sarcomatoid Variant | Acinar Prostate Adenocarcinoma, Sarcomatoid Variant | Prostate Acinar Adenocarcinoma, Sarcomatoid Variant | Prostate Carcinosarcoma | Prostate Sarcomatoid Carcinoma | Prostate Sarcomatoid acinar adenocarcinoma | Sarcomatoid Carcinoma of Prostate | Sarcomatoid Carcinoma of the Prostate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335520","Prostate Acinar Signet Ring Cell-Like Adenocarcinoma","C5535","Acinar adenocarcinoma of the prostate gland characterized by the presence of malignant cells with intracytoplasmic vacuoles that displace the nucleus to the periphery of the cell.","Prostate Acinar Signet Ring Cell-Like Adenocarcinoma | Acinar Prostate Adenocarcinoma, Signet Ring Variant | Acinar Prostate Adenocarcinoma, Signet Ring Variant | Acinar Prostate Adenocarcinoma, Signet Ring Variant   | Prostate Acinar Adenocarcinoma, Signet Ring Cell-Like | Prostate Acinar Adenocarcinoma, Signet Ring Variant | Prostate Acinar Adenocarcinoma, Signet Ring-Like Cell Variant | Prostate Acinar Adenocarcinoma, Signet-Ring Cell-Like | Prostate Acinar Adenocarcinoma, Signet-Ring-Like Cell Variant | Prostate Acinar Signet-Ring Cell-Like Adenocarcinoma | Prostate Signet Ring Cell Carcinoma | Prostate Signet ring-like cell acinar adenocarcinoma | Signet Ring Cell Carcinoma of Prostate | Signet Ring Cell Carcinoma of the Prostate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335513","Acinar Colloid Prostate Adenocarcinoma","C5537","Acinar adenocarcinoma of the prostate gland characterized by the presence of lakes of extracellular mucin. This diagnosis applies when at least 25% of the resected tumor contains extracellular mucin.","Prostate Acinar Mucinous Adenocarcinoma | Acinar Colloid Prostate Adenocarcinoma | Acinar Prostate Mucinous Adenocarcinoma | Acinar Prostate Mucinous Adenocarcinoma | Colloid Adenocarcinoma of Prostate | Colloid Adenocarcinoma of the Prostate | Colloidal Adenocarcinoma of Prostate | Colloidal Adenocarcinoma of the Prostate | Colloidal Prostate Adenocarcinoma | Mucinous Adenocarcinoma of Prostate | Mucinous Adenocarcinoma of the Prostate | Prostate Mucinous (colloid) acinar adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335503","Prostate Adenosquamous Carcinoma","C5538","An infrequent invasive carcinoma of the prostate gland characterized by the presence of both glandular and squamous neoplastic components.  It is more often located in the transitional zone of the prostate gland and it tends to rapidly metastasize to the bones.","Prostate Adenosquamous Carcinoma | Adenosquamous Carcinoma of Prostate | Adenosquamous Carcinoma of the Prostate | Prostate Adenosquamous carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1168327","High Grade Prostatic Intraepithelial Neoplasia","C5541","Prostatic intraepithelial neoplasia characterized by the presence of morphologically malignant cells lining the acini and ducts.  The malignant cells are enlarged, contain prominent nucleoli, and have increased nuclear/cytoplasmic ratio.  The malignant cells may grow within the ducts and acini in four architectural patterns: flat, tufting, micropapillary, and cribriform.  The presence of high grade prostatic intraepithelial neoplasia in needle biopsy is a risk factor for the subsequent detection of carcinoma on repeat biopsy.","High Grade Prostatic Intraepithelial Neoplasia | HGPIN | High-Grade Intraepithelial Neoplasia of Prostate | High-Grade Intraepithelial Neoplasia of the Prostate | High-Grade PIN | High-Grade Prostatic Intraepithelial Neoplasia | High-grade Prostatic Intraepithelial Neoplasia (PIN) | Prostatic intraepithelial neoplasia (high grade)",,,,,,,,,,,,,,,"40489291","High grade prostatic intraepithelial neoplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1335523","Prostatic Atypical Adenomatous Hyperplasia","C5595","A prostatic hyperplasia characterized by the presence of crowded adenomatous epithelial nodules.","Prostatic Atypical Adenomatous Hyperplasia | Atypical Adenomatous Hyperplasia (Adenosis) | Atypical Adenomatous Hyperplasia of Prostate | Atypical Adenomatous Hyperplasia of the Prostate | Atypical Adenomatous Prostate Hyperplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336863","Prostate Undifferentiated Carcinoma","C5597","An invasive prostate carcinoma characterized by the presence of undifferentiated malignant cells.","Prostate Undifferentiated Carcinoma | Undifferentiated Carcinoma of Prostate | Undifferentiated Carcinoma of the Prostate | Undifferentiated Prostate Carcinoma | Undifferentiated Prostate Carcinoma | Undifferentiated Prostatic Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1300585","Prostate Small Cell Neuroendocrine Carcinoma","C6766","A rare small cell neuroendocrine carcinoma that arises from the prostate gland.","Prostate Small Cell Neuroendocrine Carcinoma | Oat Cell Carcinoma of Prostate | Oat Cell Carcinoma of the Prostate | Prostate Oat Cell Carcinoma | Prostate Small Cell Carcinoma | Prostate Small Cell Carcinoma | Prostate Small Cell NEC | Small Cell Carcinoma of Prostate | Small Cell Carcinoma of the Prostate",,,,,,,,,,,,,,,"4288534","Small cell carcinoma of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0349672","Prostate Ductal Adenocarcinoma","C6813","A usually aggressive invasive adenocarcinoma of the prostate gland composed of large glands containing tall columnar cells.  The columnar cells have abundant cytoplasm and are reminiscent of endometrial carcinoma.  This type of adenocarcinoma has a tendency to metastasize to the lung and penis.","Prostate Ductal Adenocarcinoma | Ductal Adenocarcinoma of Prostate | Ductal Adenocarcinoma of the Prostate | Endometrioid Adenocarcinoma of Prostate | Endometrioid Adenocarcinoma of the Prostate | Endometrioid Carcinoma of Prostate | Endometrioid Carcinoma of the Prostate | Prostate Endometrioid Adenocarcinoma | Prostate Endometrioid Carcinoma | Prostate ductal Adenocarcinoma | Prostatic Endometrioid Carcinoma",,,,,,,,,,,,,,,"4082919","Endometrioid carcinoma of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027960","Melanocytic Nevus","C7570","A neoplasm composed of melanocytes that usually appears as a dark spot on the skin.","Melanocytic Nevus | Melanocytic nevus | Melanotic Nevus | Mole | Nevus | mole | nevus",,,,,,,,,,,,,,,"4271013","Melanocytic nevus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0279565","Invasive Breast Lobular Carcinoma","C7950","An infiltrating lobular adenocarcinoma of the breast.  The malignant cells lack cohesion and are arranged individually or in a linear manner (Indian files), or as narrow trabeculae within the stroma.  The malignant cells are usually smaller than those of ductal carcinoma, are less pleomorphic, and have fewer mitotic figures.","Invasive Breast Lobular Carcinoma | Classic Invasive Lobular Carcinoma | Infiltrating Lobular Adenocarcinoma | Infiltrating Lobular Breast Carcinoma | Infiltrating Lobular Carcinoma of Breast | Infiltrating Lobular Carcinoma of the Breast | Invasive Lobular Adenocarcinoma | Invasive Lobular Breast Carcinoma | Invasive Lobular Breast Carcinoma | Invasive Lobular Carcinoma | Invasive Lobular Carcinoma of Breast | Invasive Lobular Carcinoma of the Breast | Invasive Lobular Carcinoma, Classic Type | Invasive lobular carcinoma",,,,,,,,,,,,,,,"4232456","Lobular carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0860580","Breast Medullary Carcinoma","C9119","An infiltrating breast carcinoma with a relatively favorable prognosis.  It is an uncommon carcinoma, accounting for less than 1% of all infiltrating breast carcinomas.  It is well circumscribed, with soft cut surface and often of considerable size.  Microscopically, the predominant growth pattern is syncytial with broad anastomosing bands or sheets of malignant cells.  The malignant cells are round with abundant cytoplasm and vesicular nuclei.  The sheets of malignant cells are associated with a marked lymphoplasmacytic infiltrate.  Glandular or tubular structures are absent.","Breast Medullary Carcinoma | Infiltrating Medullary Carcinoma of Breast | Infiltrating Medullary Carcinoma of the Breast | Invasive Medullary Breast Carcinoma | Invasive Medullary Carcinoma of Breast | Invasive Medullary Carcinoma of the Breast | Medullary Breast Cancer | Medullary Breast Carcinoma | Medullary Breast Carcinoma | Medullary Breast Carcinoma with Lymphoid Stroma | Medullary Carcinoma of Breast | Medullary Carcinoma of the Breast | Medullary carcinoma with lymphoid stroma | medullary breast carcinoma","8512/3","Medullary carcinoma with lymphoid stroma",,,,,,,,,,,,,"4312359","Medullary carcinoma with lymphoid stroma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1334807","Breast Mucinous Carcinoma","C9131","An invasive adenocarcinoma of the breast characterized by the presence of islands of small and uniform cells, surrounded by large amounts of mucin.  Pure mucinous breast carcinomas generally have a favorable prognosis.","Breast Mucinous Carcinoma | Breast Mucinous Carcinoma | Colloid Breast Carcinoma | Colloid Carcinoma of Breast | Colloid Carcinoma of the Breast | Infiltrating Colloid Breast Carcinoma | Infiltrating Mucinous Breast Carcinoma | Invasive Colloid Breast Carcinoma | Invasive Mucinous Breast Carcinoma | Mucinous Breast Cancer | Mucinous Breast Carcinoma | Mucinous Breast Carcinoma | Mucinous Carcinoma of Breast | Mucinous Carcinoma of the Breast",,,,,,,,,,,,,,,"40480651","Mucinous carcinoma of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0279556","invasive ductal breast carcinoma with predominant intraductal component","C9132","An invasive breast carcinoma of no special type characterized by the presence of a predominant ductal carcinoma in situ component and a minor component of invasive carcinoma.","Invasive Breast Carcinoma of No Special Type with Predominant Intraductal Component | Infiltrating Ductal Breast Carcinoma with Predominant Intraductal Component | Invasive Breast Ductal Carcinoma with Predominant Intraductal Component | Invasive Breast Ductal Carcinoma with Predominant Intraductal Component | Invasive Ductal Breast Carcinoma with Predominant Intraductal Component | Invasive Ductal Breast Carcinoma with Predominant Intraductal Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812899","Breast Papillary Carcinoma","C9134","A breast carcinoma characterized by the formation of irregular, finger-like projections of fibrous stroma covered with neoplastic epithelial cells.","Breast Papillary Carcinoma | Breast Papillary  Carcinoma | Papillary Breast Cancer | Papillary Breast Carcinoma | Papillary Breast Carcinoma | Papillary Carcinoma of Breast | Papillary Carcinoma of the Breast",,,,,,,,,,,,,,,"45766426","Papillary carcinoma of the breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1328544","Breast Tubular Carcinoma","C9135","An invasive adenocarcinoma of the breast with a favorable prognosis.  It is composed of tubular structures lined by a single layer of epithelium.","Breast Tubular Carcinoma | Infiltrating Tubular Breast Carcinoma | Infiltrating Tubular Carcinoma of Breast | Infiltrating Tubular Carcinoma of the Breast | Invasive Tubular Breast Carcinoma | Invasive Tubular Carcinoma of Breast | Invasive Tubular Carcinoma of the Breast | Tubular Breast Cancer | Tubular Breast Carcinoma | Tubular Breast Carcinoma | Tubular Carcinoma of Breast | Tubular Carcinoma of the Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334438","Low-CSD Melanoma","C9152","A cutaneous melanoma that develops on sun-exposed sites with low cumulative sun damage (CSD). It typically occurs in light-skinned individuals ranging in age from young adults to the elderly. It arises from any cutaneous site, except the palms and soles.","Low-CSD Melanoma | Cutaneous Superficial Spreading Melanoma | Low Degree of Cumulative Sun Damage Melanoma | Low-CSD Melanoma/SSM | Low-CSD Melanoma/Superficial Spreading Melanoma | Non- CSD Melanoma | Non-CSD Melanoma | Pagetoid Melanoma | SSM | Superficial Spreading Cutaneous (Skin) Melanoma | Superficial Spreading Malignant Melanoma of Skin | Superficial Spreading Malignant Melanoma of the Skin | Superficial Spreading Malignant Skin Melanoma | Superficial Spreading Melanoma | Superficial Spreading Melanoma | Superficial Spreading Melanoma of Skin | Superficial Spreading Melanoma of the Skin | Superficial spreading melanoma",,,,,,,,,,,,,,,"4110725|4207824","Superficial spreading malignant melanoma of skin|Superficial spreading melanoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2349954","Withdraw (activity)","C38061","To cease active participation in; remove from active use.","Withdraw | Retire | Retired | Withdrawal | Withdrawn | Withdrawn",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012655","Susceptibility","C16505","The constitutional or inborn state disposing to a disease, group of diseases, or metabolic or structural anomaly.","Susceptibility | Predisposition | Susceptible",,,,,,,,,,,,,,,"4295266","Diathesis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517526","Geographic","C37957","Of or relating to the science of geography; determined by geography.","Geographic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705236","Protocol Deviation","C50996","A variation from processes or procedures defined in a protocol. Deviations usually do not preclude the overall evaluability of subject data for either efficacy or safety, and are often acknowledged and accepted in advance by the sponsor. (CDISC Glossary)","Protocol Deviation | DVTERM | Deviation | PROTOCOL DEVIATION | protocol deviation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001895","Alabama","C43479","A state in the southeast United States. Its capital is Montgomery.","Alabama | AL | US: Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001905","Alaska","C43506","A state in the far northwestern United States. Its capital is Juneau.","Alaska | AK | US: Alaska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003787","Arizona","C43505","A state in the southwestern United States. Its capital is Phoenix.","Arizona | AZ | US: Arizona",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003790","Arkansas","C43495","A state in the southern midwest United States. Its capital is Little Rock.","Arkansas | AR | US: Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006754","California","C43509","A state on the western coast of the United States. Its capital is Sacramento.","California | CA | US: California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009778","Connecticut","C43466","A state in the northeastern United States. Its capital is Hartford.","Connecticut | CT | US: Connecticut",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011198","Delaware","C43470","A state in the mid-atlantic United States. Its capital is Dover.","Delaware | DE | US: Delaware",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0412766","Dual X-ray Absorptiometry","C48789","A technique for scanning bone and measuring bone mineral density (BMD). A DXA scanner produces 2 X-ray beams, each with different energy levels. One beam is high energy while the other is low energy. The amount of x-rays that pass through the bone is measured for each beam. This will vary depending on the thickness of the bone. Based on the difference between the 2 beams, the bone density can be measured.","Dual X-ray Absorptiometry | BMD scan | DEXA | DEXA (Bone Density) | DEXA Scan | DEXA scan | DXA | DXA SCAN | Dual Energy X-ray Absorptiometry | Dual X-Ray Absorptiometry | Dual X-Ray Absorptometry | Dual X-ray Absorptometry | bone mineral density scan | dual energy x-ray absorptiometric scan | dual x-ray absorptiometry",,,,,,,,,,,,,,,"4086416","Dual energy X-ray absorptiometry",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709925","Response Declined","C51024","Used to indicate when a respondent makes a decision to not answer a question.","Response Declined | Asked But Declined | Declined | Declined Response | Declined to answer | Declines to disclose | Did Not Disclose | Refused to Answer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0920318","Directories as Topic","C49057","A document that points out the location of people, places, or objects.","Directory | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704449","Filter (function)","C41199","A device that removes something from whatever passes through it.","Filter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009452","Communication","C16452","The exchange of information between objects, people, or groups.","Communication | Communicative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0558295","Preference","C41187","The act, fact, or principle of giving advantages to some particular person, object, or course of action over others; designated as more desirable.","Preference | Preferred",,,,,,,,,,,,,,,"4026072","Preferences",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0699794","Rank","C48904","A relative status as compared to others within a group.","Rank | Ranking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230168","Abdomen","C12664","The cavity located between the lungs and pelvis. It contains the lower esophagus, stomach, pancreas, intestines, liver, gallbladder and spleen.","Abdomen | ABDOMINAL CAVITY | Abdomen, NOS | Abdomen, total | Abdominal Cavity | Abdominal Cavity | BODY CAVITY, ABDOMINAL | abdomen | abdominopelvic region | abdominopelvis","C76.2","Abdomen, NOS",,,,,,,,,,,"UBERON:0003684","abdomen",,,,,,,,,,,,,,,"--","--"
"C0180392","Detectors","C41276","A mechanical, electrical, or chemical device with sensor properties, that automatically identifies and records or registers a stimulus, such as change in pressure or temperature or content, movement, an electrical signal, radiation from a radioactive material or presence of subatomic particles, etc.","Detector | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036375","School","C17118","An educational institution.","School | Educational Institution | SCHOOL | Schools",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162579","Worksite","C17556","The physical location where work or employment takes place.","Worksite | Place of Work | WORKSITE | Work Place | Work Sites | Workplace",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553304","Aleutian Aleuts","C43389","A person having origins in the original Aleutian people.","Aleutian | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152035","Chinese","C43391","A person having origins in any of the original peoples of China.","Chinese | CHINESE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556094","Japanese","C43392","A person having origins in any of the original peoples of Japan..","Japanese | JAPANESE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556095","Korean","C43395","A person having origins in any of the original peoples of Korea.","Korean | KOREAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014845","Eskimo","C43390","The native people inhabiting the Arctic of northern Canada, Greenland, Alaska, or eastern Siberia. The two main groups referred to as Eskimo are the Yupik and Inuit. A third group, the Aleut, is related. In Canada and Greenland, the term Eskimo has fallen out of favor, as it is considered pejorative by the natives and has been replaced by the term Inuit.","Eskimo | Inuit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1524069","Asian Indian","C41262","A person having origins in the original peoples of the Indian sub-continent.","Asian Indian | ASIAN INDIAN | Asian Indians | Indian",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553323","Cambodian","C43399","Denotes the inhabitants of Cambodia (formerly Kampuchea), a person from there, or their descendants elsewhere.","Cambodian | CAMBODIAN | Kampuchean",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556093","Filipino","C43393","A person having origins in any of the original peoples of the Philippine Islands.","Filipino | FILIPINO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553324","Hmong","C43398","Denotes a person having origins in any of the original Hmong people originating in China around the Yellow River or Hoang Ho.","Hmong | HMONG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706999","Breast Cancer Pathologic Distant Metastasis TNM Finding v6","C48971","A pathologic finding about one or more characteristics of breast cancer, following the rules of the TNM AJCC v6 classification system as they pertain to distant metastases. TNM pathologic distant metastasis findings are based on clinical findings supplemented by histopathologic examination of one or more tissue specimens acquired during surgery.","Breast Cancer Pathologic Distant Metastasis TNM Finding v6 | Breast Cancer Pathologic Distant Metastasis TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556097","Fiji Islander","C43410","Denotes the inhabitants of Fiji, a person from there, or their descendants elsewhere.","Fiji Islander | Fijian",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553325","Laotian","C43397","Denotes the inhabitants of Laos, a person from there, or their descendants elsewhere.","Laotian | LAOTIAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0240620","Pakistani","C43427","Primarily refers to a person having origins in the original peoples of the Indian sub-continent, a subset of which formed Pakistan.  The term also refers to a person from Pakistan, whether or not ancestors were from India.","Pakistani | PAKISTANI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337910","Thai","C43400","Denotes the inhabitants of Thailand, a person from there, or their descendants elsewhere.","Thai | THAI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1561452","Vietnamese","C43396","A person having origins in any of the original peoples of Viet Nam.","Vietnamese | VIETNAMESE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0920541","Guamanian","C43404","Denotes the inhabitants of Guam, a person from there, or their descendants elsewhere.","Guamanian | GUAMANIAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556103","Samoan","C43407","A person having origins in any of the original peoples of Samoa.","Samoan | SAMOAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556108","Tongan","C43408","Denotes the inhabitants of Tonga, a person from there, or their descendants elsewhere.","Tongan | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279033","Replacement Therapy","C15471","Administration of a body substance to compensate for the loss, as from disease or surgery, of a gland or tissue that would normally produce the substance.","Replacement Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707000","Breast Cancer Pathologic Primary Tumor TNM Finding v6","C48969","A pathologic finding about one or more characteristics of breast cancer, following the rules of the TNM AJCC v6 classification system as they pertain to staging of the primary tumor. TNM pathologic primary tumor findings are based on clinical findings supplemented by histopathologic examination of one or more tissue specimens acquired during surgery.","Breast Cancer Pathologic Primary Tumor TNM Finding v6 | Breast Cancer Pathologic Primary Tumor TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707001","Breast Cancer Pathologic Regional Lymph Nodes TNM Finding v6","C48970","A pathologic finding about one or more characteristics of breast cancer, following the rules of the TNM AJCC v6 classification system as they pertain to staging of regional lymph nodes. TNM pathologic regional lymph nodes findings are based on clinical findings supplemented by histopathologic examination of one or more tissue specimens acquired during surgery.","Breast Cancer Pathologic Regional Lymph Nodes TNM Finding v6 | Breast Cancer Pathologic Regional Lymph Nodes TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981226","Cutaneous Melanoma Pathologic Distant Metastasis TNM Finding v6","C48895","A pathologic finding about one or more characteristics of cutaneous melanoma, following the rules of the TNM AJCC v6 classification system as they pertain to distant metastases. TNM pathologic distant metastasis findings are based on clinical findings supplemented by histopathologic examination of one or more tissue specimens acquired during surgery.","Cutaneous Melanoma Pathologic Distant Metastasis TNM Finding v6 | Cutaneous Melanoma Pathologic Distant Metastasis TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981225","Cutaneous Melanoma Pathologic Primary Tumor TNM Finding v6","C48894","A pathologic finding about one or more characteristics of cutaneous melanoma, following the rules of the TNM AJCC v6 classification system as they pertain to staging of the primary tumor. TNM pathologic primary tumor findings are based on clinical findings supplemented by histopathologic examination of one or more tissue specimens acquired during surgery.","Cutaneous Melanoma Pathologic Primary Tumor TNM Finding v6 | Cutaneous Melanoma Pathologic Primary Tumor TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981224","Cutaneous Melanoma Pathologic Regional Lymph Nodes TNM Finding v6","C48892","A pathologic finding about one or more characteristics of cutaneous melanoma, following the rules of the TNM AJCC v6 classification system as they pertain to staging of regional lymph nodes. TNM pathologic regional lymph nodes findings are based on clinical findings supplemented by histopathologic examination of one or more tissue specimens acquired during surgery.","Cutaneous Melanoma Pathologic Regional Lymph Nodes TNM Finding v6 | Cutaneous Melanoma Pathologic Regional Lymph Nodes TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009905","Oral Contraceptive","C389","An agent taken orally to prevent conception.","Oral Contraceptive | Oral Contraceptives",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709793","Quantitation","C48937","The act of measuring or estimating a quantity.","Quantitation | QUANTIFICATION | Quantification | Quantify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596244","Cancer Risk","C18077","The probability that exposure to some agent or substance will adversely transform cells to replicate and form a malignant tumor. (EPA Terminology Reference System)","Cancer Risk | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0679560","Genetic Testing","C15709","The process of isolating and testing the DNA of an embryo or a person to detect the presence of genetic alterations or defects that may predispose to the future development of a disease or disorder.","Genetic Testing | Genetic Analysis | Genetic Examination | Genetic Test | genetic analysis | genetic testing",,,,,,,,,,,,,,,"4237017","Genetic test",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2981223","Prostate Cancer Pathologic Distant Metastasis TNM Finding v6","C48891","A pathologic finding about one or more characteristics of prostate cancer, following the rules of the TNM AJCC v6 classification system as they pertain to distant metastases. TNM pathologic distant metastasis findings are based on clinical findings supplemented by histopathologic examination of one or more tissue specimens acquired during surgery.","Prostate Cancer Pathologic Distant Metastasis TNM Finding v6 | Prostate Cancer Pathologic Distant Metastasis TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981221","Prostate Cancer Pathologic Primary Tumor TNM Finding v6","C48889","A pathologic finding about one or more characteristics of prostate cancer, following the rules of the TNM AJCC v6 classification system as they pertain to staging of the primary tumor. TNM pathologic primary tumor findings are based on clinical findings supplemented by histopathologic examination of one or more tissue specimens acquired during surgery.","Prostate Cancer Pathologic Primary Tumor TNM Finding v6 | Prostate Cancer Pathologic Primary Tumor TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981222","Prostate Cancer Pathologic Regional Lymph Nodes TNM Finding v6","C48890","A pathologic finding about one or more characteristics of prostate cancer, following the rules of the TNM AJCC v6 classification system as they pertain to staging of regional lymph nodes. TNM pathologic regional lymph nodes findings are based on clinical findings supplemented by histopathologic examination of one or more tissue specimens acquired during surgery.","Prostate Cancer Pathologic Regional Lymph Nodes TNM Finding v6 | Prostate Cancer Pathologic Regional Lymph Nodes TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0598034","BRCA2 Gene","C18120","This gene is involved in cell cycle control, DNA repair and the maintenance of genomic stability. It also plays a role in the proliferation of embryonic cells.","BRCA2 Gene | BRCA2 | BRCA2, DNA Repair Associated Gene | Breast Cancer 2, Early Onset Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279037","Hematologic Toxicity Attenuation","C15474","A treatment designed to reduce or prevent damage to the hematologic system due to adverse events from other drug therapies.","Hematologic Toxicity Attenuation | neutropenia attenuation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520166","Xenograft Model","C19812","An experimental system in which (usually) human tumor cells are transplanted into immunocompromised mice that do not reject human cells; cells may be implanted under the skin or into the organ type in which the tumor originated. These model systems may be used for drug development and studies of molecular biological mechanisms of cancer.","Xenograft Model | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441587","Insertion","C48685","The act of putting one thing into another.","Insertion | Insert | Inserted",,,,,,,,,,,,,,,"4106470|4224420","Insertion - action|Insert",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0947647","Manipulation","C48310","Move, treat, or operate with the hands or by mechanical means, especially in a skillful manner.","Manipulation | Manipulate | Manipulative",,,,,,,,,,,,,,,"4078521","Manipulation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0598079","American Type Culture Collection","C15661","A global nonprofit bioscience organization (located at 10801 University Boulevard, Manassas, VA 20110-2209 703-365-2700) that provides biological products, technical services, and educational programs to private industry, government, and academic organizations around the world.  Biological products for academic and industrial labs, as well as educational and technical services.  For the collection, preservation and distribution of cultures of living microorganisms, viruses, DNA probes, plants, and human and animal","ATCC | American Type Culture Collection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205318","Uncontrolled","C48932","Not controlled, regulated, or constrained.","Uncontrolled | ",,,,,,,,,,,,,,,"4078213","Uncontrolled",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013153","Route of Administration","C38114","Designation of the part of the body through which or into which, or the way in which, the medicinal product is intended to be introduced. In some cases a medicinal product can be intended for more than one route and/or method of administration.","Route of Administration | Drug Administration Method | Drug Route of Administration | ROUTE | ROUTE OF ADMINISTRATION | ROUTE_DETAIL | Route of Drug Administration | route of administration | route of administration (ROA) | route_of_administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1158478","DNA Integration","C18855","Any DNA sequence rearrangement in which double-stranded DNA from a donor molecule is incorporated into host DNA by the action of an integrase, yielding a single, stable, replication-competent, double-stranded DNA product.","DNA Integration | Integration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709631","Nonclinical Study","C48678","A study performed on animal subjects to determine the toxicity of a new drug or invasive device prior to a clinical trial.","Nonclinical Study | Preclinical Study | Preclinical Study | Preclinical Testing | Preclinical Trial | nonclinical study | preclinical study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0178874","Tumor Progression","C17609","A pathologic process in which alterations at the molecular level result in a more aggressive cytologic and phenotypic profile and clinical course of a neoplasm.","Tumor Progression | Progression",,,,,,,,,,,,,,,"4168352","Tumor progression",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448706","Targeted Mutation","C48668","A mutation created in a gene at a specific location. Targeted mutations are frequently generated in the laboratory to investigate the influence of inactivation of a particular gene product.","Targeted Mutation | Targeted DNA Alteration | Targeted DNA Modification | Targeted Modification | Targeted Sequence Alteration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706509","Gene Identifier","C48664","A unique gene name within a specific repository, database, or collection.","Gene Identifier | Gene ID | Gene Name | Gene.identifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513639","Mouse Models of Human Cancer Consortium","C19750","A program to develop and refine experimental models that reflect the etiology and progression of human cancer.","Mouse Models of Human Cancer Consortium | MMHCC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026809","Mouse","C14238","Any of numerous species of small rodents belonging to the genus Mus and various related genera of the family Muridae.","Mouse | MOUSE | Mammals, Mice | Mice | Murine | Mus",,,,,,,,,,,,,,,"40492857","Mus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1272683","Request","C48312","Express the need or desire for; ask for.","Request | Requested",,,,,,,,,,,,,,,"4295934","Requested",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034037","Publishing","C48669","The act of issuing printed materials.","Publication | Published",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510893","Animal Cancer Model","C41162","An animal model which develops cancer or can be used to generate a model that develops cancer.","Animal Cancer Model | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL035566","Inherited","C28018","Transmitted through genes from parents to offspring. (genome.gov)","Inherited | Heritable | inherited",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705194","Server","C48297","A computer which provides some service for other computers connected to it via a network.","Server | Computer Server | server",,,,,,,,,,,,,,,"45761708","Computer network server",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0314627","Gene Function","C48933","A term that expresses the function of a gene product.","Gene Function | ",,,,,,,,,,,,,,,"4033693","Gene function",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017387","Genetic Engineering","C16621","The application of genetic-based biotechnology to modify the characteristics of an organism by cutting, splicing, and transferring genetic materials, especially DNA, from one or more species of organism.","Genetic Engineering | Biotechnology, Genetic Engineering | Engineered Gene | Gene Splicing | Genetically Engineered | Molecular Biology, Genetic Engineering | Recombinant DNA Technology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516998","Exogenous Factors","C19688","Environmental factors considered as variables in disease incident, transmission, and control.","Exogenous Factors | Environmental Factors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707073","CAS_Registry","C43678","Indicates the Chemical Abstracts Service number for a Chemical or Drug.","CAS_Registry | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710438","Tool Mouse","C48290","A mouse strain that does not develop tumors, but can be used in generating tumor bearing strains.","Tool Mouse | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3146294","Generation (action)","C48151","The act of bringing into being.","Generation | Generated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710032","Screening","C48261","A systematic examination or assessment.","Screening | Screening | Screening - procedure intent | Screening Generic | Screening Generic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710493","Tumor Model","C48686","Cells, tissues, or animals used to study the development and progression of cancer, and to test new treatments before they are given to humans. Animals with transplanted human tumors or other tissues are called xenograft models.","Tumor Model | tumor model",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511124","Bioassay, In Vivo","C18641","A laboratory test or analysis of the biological properties or activities of a substance performed by testing its effect on an organism.","Bioassay, In Vivo | Bioassay, in vivo | in vivo Bioassay | in vivo test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707889","Elapse","C48665","To pass by; having passed by.","Elapse | Elapsed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0087113","Treatment Effectiveness","C39546","The measure of the ability of an intervention to produce the desired beneficial clinical effect in average conditions of application, usually determined in non-randomized outcome studies. Treatment effectiveness could be affected by lack of efficacy and/or patient compliance.","Treatment Effectiveness | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1547619","Relational Operator","C48354","A boolean operator used to specify a greater-than, less-than, or equal-to relationship.","Relational Operator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366479","CASP1 Gene","C26554","This gene plays a role in apoptosis, inflammation, septic shock, and wound healing.","CASP1 Gene | CASP1 | Caspase 1, Apoptosis-Related Cysteine Protease Gene | Death",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516741","Comparative Pathology","C20631","Biological field of study concerned with the analysis of similarities and differences in specific characteristics between different diseases.","Comparative Pathology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1254351","Pharmacologic Substance","C1909","Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.","Pharmacologic Substance | Agent | DRUG | Drug | Drug Substance | Pharmaceutical Agent | Pharmaceuticals | Pharmacologic Agent | Pharmacological Substance | Product | Therapeutic Agent | drug | therapeutic agents | therapeutic_agents",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707250","Cancer Molecular Analysis Project","C48274","Through the Cancer Molecular Analysis Project (CMAP), NCI facilitates the identification and evaluation of molecular targets by integrating comprehensive molecular characterizations of cancer and making the data and infrastructure publicly accessible. CMAP permits investigators to 1) Discover molecular targets, 2) Assess their validity and interaction with other targets, 3) Determine if there are therapeutic agents that can act on specific targets, 4) Screen for possible toxicity, and 5) Determine whether there are clinical trials evaluating these agents.","Cancer Molecular Analysis Project | CMAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709079","Mouse Genome Informatics","C48299","A resource of the Jackson lab, provides integrated access to data on the genetics, genomics, and biology of the laboratory mouse.","Mouse Genome Informatics | MGI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205359","Spontaneous","C48307","Happening or arising without apparent external cause.","Spontaneous | ",,,,,,,,,,,,,,,"4196694","Spontaneous",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1546931","distributor - ParticipationType","C48289","A person or group with authority to allot or deal out or apportion.","Distributor | DISTRIBUTOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710198","Stock (in-store merchandise)","C48288","The merchandise that a shop has on hand.","Stock | Lot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710237","Subsystem","C48692","A system that is part of some larger system.","Subsystem | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707249","Cancer Models Database","C43619","The cancer Models Database (caMOD) allows researchers to retrieve and submit animal models of cancer.  caMOD currently supports the Mouse Models of Human Cancer Consortium (MMHCC).","Cancer Models Database | caMOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516333","Cell Cycle Kinetics (discipline)","C18491","Cell cycle kinetics is the rate at which a cell progresses through the cell cycle.  It is a general indication of how fast a tissue or cell sample is proliferating.  This rate is generally increased in more aggressive tumors and can be measured by various biochemical methods such as the incorporation of labeled nucleotides into replicating DNA or the level of expression of cell cycle proteins or other proliferation markers.","Cell Cycle Kinetics | Cell Kinetics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517324","Functional Imaging","C19609","The visualization of physiological, cellular or molecular processes in living tissue in real time as they take place in cells, for example, blood flow, oxygen consumption or glucose metabolism. (Bypass Budget)","Functional Imaging | Physiologic Imaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043350","Xeroradiography","C17263","A printing process of electrostatic electrophotography that uses a photoconductive insulating medium in conjunction with X-rays or gamma rays to produce latent electrostatic-charge patterns for achieving an observable pattern.","Xeroradiography | xeroradiography",,,,,,,,,,,,,,,"4331606","Xeroradiography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516610","Clinical Genetics Board Certification","C18197","The process by which a person is tested and approved to practice in the specialty field of clinical genetics.","Clinical Genetics Board Certification | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009369","Colon and Rectal Surgery","C15210","Surgical removal of part or all of the colon and/or rectum.","Colon and Rectal Surgery | colon and rectum surgery | colorectal surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0430400","Microbial Culture Procedure","C25300","Any laboratory procedure for growing microorganisms.","Microbial Culture Procedure | Culture | Culture Procedure | Culture Procedure | MICROBIAL CULTURE",,,,,,,,,,,,,,,"4098207|4189544|45771293","Culture - general|Microbial culture|Microbial culture",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C0235032","Neurotoxicity Syndrome","C27961","A group of neurologic disorders caused by damage to the nervous system following exposure to pharmacologic, biologic, and chemical agents. Examples of neurotoxins include chemotherapy agents, radiation treatment, heavy metals, pesticides, and food additives.","Neurotoxicity Syndrome | Neurotoxicity | Neurotoxicity | neurotoxicity",,,,,,,,,,,,,,,"4024301","Neurotoxicity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0439857","Dependence","C35458","The psychological or physiological need to take a substance in order to experience its effects or to avoid the effects of its absence.","Dependence | ",,,,,,,,,,,,,,,"4113279","Dependence",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011854","Type 1 Diabetes Mellitus","C2986","A chronic condition characterized by minimal or absent production of insulin by the pancreas.","Type 1 Diabetes Mellitus | Diabetes Mellitus (Type I) | Diabetes, Type I | Diabetes, Type I+A3139:G3152 | IDDM | Immune Mediated Diabetes | Insulin Dependent Diabetes | Insulin Dependent Diabetes Mellitus | Insulin Dependent Diabetes Mellitus | Juvenile Diabetes | Type 1 Diabetes | Type I Diabetes | Type I Diabetes Mellitus | Type I Diabetes mellitus | Type I diabetes",,,,,,,,,,,,,,,"201254","Type 1 diabetes mellitus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1409894","Sphincter","C28381","A circular band of muscle that functions to regulate the size of an orifice in the body.","Sphincter | sphincter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0678594","Structure","C41186","The components and their relationship and manner of arrangement in constituting a whole.","Structure | Structural",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036864","Sex Behavior","C17127","Behaviors involved with sexual arousal and/or intercourse.","Sex Behavior | Sex | Sexual | Sexual Behavior | Sexually",,,,,,,,,,,,,,,"4238766","Sexual behavior",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0000729","Abdominal Cramp","C34331","An involuntary muscular contraction involving a muscle of the abdomen or of a hollow organ within the abdomen.","Abdominal Cramp | Abdominal Cramps",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709318","Oncotype DX Breast Cancer Assay","C52159","A diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is validated for use in breast cancer patients whose disease is newly diagnosed, stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen.","Oncotype DX Breast Cancer Assay | Oncotype DX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1301820","Obtain","C52349","To come into possession of something.","Obtain | Obtained",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079104","Pap Smear","C17348","A biospecimen collection and staining procedure in which secretions and superficial cells of the cervix are collected and stained with the Papanicolaou stain followed by microscopic examination to identify the presence of abnormal cells.","Pap Smear | Cervical Smear Preparation | Cervical Smear Procedure | PAP SMEAR | Pap Smear | Pap Smear Procedure | Pap Test | Pap smear | Pap test | Papanicolaou Smear Procedure | Papanicolaou Smear Procedure | Papanicolaou Test | Vaginal Smears",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1135868","Gestational Trophoblastic Tumor","C4699","A diverse group of pregnancy-related tumors characterized by excessive proliferation of trophoblasts. It includes gestational choriocarcinoma, epithelioid trophoblastic tumor, placental site trophoblastic tumor, and mixed trophoblastic tumor.","Gestational Trophoblastic Tumor | GTT | gestational trophoblastic neoplasia | gestational trophoblastic tumor",,,,,,,,,,,,,,,"43530971|43530973","Gestational trophoblastic neoplasia|Gestational trophoblastic neoplasia",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1706697","Acid Etching","C52570","The use of an acid to condition tooth structure, resulting in a superficial demineralization.","Acid Etching | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706778","Allocation","C52580","The distribution of resources over various time periods, products, operations, or investments.","Allocation | Participant Allocation | Subject Allocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0440138","Amalgam","C52583","An alloy, typically a mix of silver, tin, and mercury, used in direct dental restorations.","Amalgam | ",,,,,,,,,,,,,,,"4103628","Amalgam (silver) dental filling material",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0279516","Antibacterial Agent","C52588","A family of substances capable of destroying or inhibiting the growth of bacteria.","Antibacterial Agent | Antimicrobial Solution | antibacterial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0927218","Buccal Surface","C52589","The surface of the tooth facing or in direct contact with the oral mucosa of the cheek.","Buccal Surface | Buccal | Buccal Tooth Surface | Tooth Buccal Surface",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707064","Business Day","C52592","Any day a government or commercial enterprise is open and actively engaged in the work of that enterprise.","Business Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011334","Caries","C52593","The decay of a tooth, in which it becomes softened, discolored, and/or porous.","Caries | Cavities | Dental Caries | Dental caries | Tooth Decay",,,,,,,,,,,,,,,"4277113","Caries",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1707304","Caries Removal","C52571","Any process by which decayed tooth material is removed from the tooth.","Caries Removal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707305","Carious Dentin","C52594","Tooth decay that has invaded the dentin, creating dentin that is partially demineralized and containing mineral crystals in the tubules.","Carious Dentin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707399","Class I Restoration","C52572","Reconstruction of the occlusal surface of a tooth.","Class I Restoration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009586","Comprehensive Care","C52640","Planned, non-emergency care that includes prevention and maintance and restoration of health.","Comprehensive Care | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707489","Connectivity","C52642","The ability to make and maintain a connection between two or more points in a telecommunications systems.","Connectivity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706353","Crack","C52648","A break or fissure in a structure.","Crack | Cracked",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707676","Dental License","C52649","The legal right to practice dentistry.","Dental License | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707679","Dental Operatory","C52651","A space equiped and dedicated to the care of dental patients.","Dental Operatory | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707680","Dental Recall","C52573","A routine dental appointment for a patient of record that includes diagnostic procedures and preventive care.","Dental Recall | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036376","Dental School","C52652","A professional school offering coursework leading to a degree in the field dentistry.","Dental School | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037777","Dental Specialty","C52653","A branch of dentistry requiring advanced study.","Dental Specialty | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011441","Dentist","C52654","An individual licensed for the prevention, diagnosis, and treatment of diseases in the oral cavity, adjacent tissues, and related structures.","Dentist | DENTIST | dentist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0846817","Direct Pulp Cap","C52574","The procedure in which the exposed pulp is covered with a dressing that protects the pulp and promotes healing and repair.","Direct Pulp Cap | Direct Capping | Direct Pulp Capping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707897","Electronic Billing System","C52655","A computer-based tracking and submission system for statements, bills, invoices, and related information corresponding to the payment for goods or services.","Electronic Billing System | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707898","Electronic Health Record System","C52657","A computer-based clinical information system that is dedicated to collecting, storing, manipulating, and making available clinical information important to the delivery of patient care. The central focus of such systems is clinical data and not financial or billing information.","Electronic Health Record System | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
,,"C52641","Care necessary to treat acute pain, infection, bleeding, or trauma.","Emergency Care | ",,,,,,,,,,,,,,,"4056945","Emergency treatment",,,,,,,,,,,,,,,,,,,,,,"--"
"C0700632","Endodontic Treatment","C52575","Dental procedures to treat disease or injury to the tooth pulp, and may include palliative treatment.","Endodontic Treatment | Endodontic Procedure",,,,,,,,,,,,,,,"4208099","Endodontic procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0682295","Full Time Employment","C52658","Employed for a standard number of hours of working time, at least 50% or 20 hours per week.","Full Time Employment | FULL-TIME | Full Time | Full-Time | Full-time | Full-time Employment | Working full time | Working full-time for pay",,,,,,,,,,,,,,,"4053118","Full-time employment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704440","Geriatric","C52660","Of or related to the aged or to characteristics of the aging process.","Geriatric | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711333","Graduation","C52581","Conferral or receipt of an academic degree or diploma marking the completion of a defined set of coursework.","Graduation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708499","Indirect Pulp Cap","C52576","A procedure in which the nearly exposed pulp is covered with a protective dressing to protect the pulp from additional injury and to promote healing and repair via formation of secondary dentin.","Indirect Pulp Cap | Indirect Capping | Indirect Pulp Capping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0556656","Meeting","C52661","The act or process or an instance of coming together.","Meeting | ",,,,,,,,,,,,,,,"4045286","Meetings",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708982","Mesial Surface","C52590","That side of the tooth facing the midline.","Mesial Surface | Mesial | Mesial Tooth Surface | Tooth Mesial Surface",,,,,,,,,,,,,,,"4225600","Structure of mesial surface of tooth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709022","Microetching","C52577","A method of roughening the surface of a natural tooth or a dental restoration, most likely the inside of a metal crown or the facial side of a metal crown to prepare it for repair, utilizing a gas-impelled jet of a fine abrasive. It enhances the attachment of resin cements or restorative materials to the surface.","Microetching | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0447303","Occlusal Surface","C52591","The biting surfaces of the premolar and molar teeth.","Occlusal Surface | Occlusal | Occlusal Tooth Surface | Tooth Occlusal Surface",,,,,,,,,,,,,,,"4308425","Structure of occlusal surface of tooth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0402335","Office Manager","C52663","An employee charged with the general administrative responsibilities of any given office of a corporation or business, responsible for all paperwork, including its filing and retention over time, and the supervision of office staff.","Office Manager | ",,,,,,,,,,,,,,,"4009982","Office manager",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029981","Ownership","C52643","The legal relation in which a person or group entity has a financial interest in, dominion of, or control over an object or property.","Ownership | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709483","Patient Base","C52644","The total number of patients that have been evaluated or treated.","Patient Base | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709487","Patient Load","C52646","The number of patients who are evaluated or treated in any given period of time.","Patient Load | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709628","Practitioners Engaged in Applied Research and Learning Network","C52664","An infrastructure to conduct office-based research that will answer the questions facing general dental practitioners in the routine care of their patients.","Practitioners Engaged in Applied Research and Learning Network | PEARL | PEARL Network",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709602","Porcelain Veneer","C52584","A restoration consisting of a layer of tooth-colored porcelain material cemented to the surface of a tooth.","Porcelain Veneer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709609","Posterior Tooth","C52666","Refers to teeth and tissues towards the back of the mouth (distal to the canines): maxillary and mandibular premolars and molars. The designation of permanent posterior teeth in the Universal tooth numbering system include teeth 1 through 5 and 12 through 16 (maxillary), and 17 through 21 and 28 through 32 (mandibular); primary teeth in the Universal tooth numbering system are designated A, B, I, and J (maxillary) and K, L, S, and T (mandibular).","Posterior Tooth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709626","Practice-based Research Network","C52671","A group of practicing clinicians who link their expertise and resources in collaborative efforts to address important research questions of shared interest.","Practice-based Research Network | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033284","Professional Practice","C52673","Health care professional business directed towards treatment and care of patients.","Professional Practice | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709697","Program - framework of goals","C52647","A broad framework of goals to be achieved.","Program | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0447400","Pulp Horn","C52670","The portion of the pulp chamber that extends towards a cusp.","Pulp Horn | ",,,,,,,,,,,,,,,"4083935","Pulp horn",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034103","Pulpitis","C52595","Inflammation of the dental pulp.","Pulpitis | ",,,,,,,,,,,,,,,"437589","Pulpitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034927","Referral","C52582","Sending a patient from one practitioner to another for health care services.","Referral | Referred | referral",,,,,,,,,,,,,,,"4144684","Patient referral",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1711362","Remineralization","C52578","The restoration of lost mineral constituents to the enamel, dentin, or cementum.","Remineralization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709917","Resin Modified Glass Ionomer Liner","C52585","A dental restorative material made up of disparate or separate parts (e.g., resin and quartz particles) in a glass polyalkenoate cement (a fluoride-containing aluminosilicate glass powder) used as a liner/base for other restoration materials.","Resin Modified Glass Ionomer Liner | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711229","Resin-Based Composite","C52586","A dental restorative material made up of disparate or separate parts (e.g., resin and quartz particles).","Resin-Based Composite | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0729415","Sealant","C52587","A resinous material designed to be applied to the occlusal surfaces of posterior teeth to prevent occlusal decay by filling in the fissures and/or crevices of the tooth.","Sealant | ",,,,,,,,,,,,,,,"4299189","Sealant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710045","Self-Etching Bonding System","C52579","Using an acid to condition tooth dentin, resulting in a superficial demineralization of dentin, allowing a low-viscosity monomer to be diffused into the evacuated spaces creating micro retention that results in bond strength approaching the inherent strength of dentin itself.","Self-Etching Bonding System | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227073","Tooth 30","C52667","The first, permanent, six-year molar of the lower right arch as defined by the Universal tooth numbering system.","Tooth 30 | First Molar | Six-year Molar | Tooth #30",,,,,,,,,,,,,,,"3667179","Structure of permanent mandibular right first molar tooth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710636","Vital Tooth","C52669","A tooth with functioning pulpal tissue.","Vital Tooth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706450","Legal Adult","C52678","A person of legal age to consent to a procedure as specifed by local regulation.","Legal Adult | Adult",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033581","Prostatitis","C26866","An infectious or non-infectious inflammatory process affecting the prostate gland.","Prostatitis | prostatitis",,,,,,,,,,,,,,,"194997","Prostatitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042387","Vasectomy","C15348","Surgical removal of part or all of the vas deferens.","Vasectomy | vasectomy",,,,,,,,,,,,,,,"4330583","Vasectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1384593","Digital Rectal Examination","C17631","An examination that checks for abnormalities of organs or other structures in the pelvis and lower abdomen. During a digital rectal exam, a health professional inserts a lubricated, gloved finger of one hand into the rectum and may use the other hand to press on the lower abdomen or pelvic area.","Digital Rectal Examination | DRE | digital rectal examination",,,,,,,,,,,,,,,"4254766","Digital examination of rectum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039128","Syphilis","C35055","A contagious bacterial infection caused by the spirochete Treponema pallidum. It is a sexually transmitted disorder, although it can also be transmitted from the mother to the fetus in utero. Typically, it is initially manifested with a single sore which heals without treatment. If the infection is left untreated, the initial stage is followed by skin rash and mucous membrane lesions. A late stage follows, which is characterized by damage of the internal organs, including the nervous system.","Syphilis | ",,,,,,,,,,,,,,,"436033","Syphilis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011399","Dental Pulp","C32451","A richly vascularized and innervated connective tissue of mesodermal origin contained in the central cavity of a tooth and delimited by the dentin. It has formative, nutritive, sensory, and protective functions.","Dental Pulp | Tooth Pulp",,,,,,,,,,,,,,,"4132316","Structure of pulp of tooth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0593507","Ibuprofen","C561","A propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic effects. Ibuprofen inhibits the activity of cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. This leads to decreased prostaglandin synthesis, by prostaglandin synthase, the main physiologic effect of ibuprofen. Ibuprofen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation. (NCI05)","Ibuprofen | (.+ -.)-p-Isobutylhydratropic acid | Advil | Benzeneacetic Acid, Alpha-methyl-4-(2-methylpropyl)- | IBUPROFEN | Motrin | ibuprofen | p-Isobutylhydratropic Acid | p-Isobutylhydratropic acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162791","Guidelines","C17564","A systematic statement of policy rules or principles. Guidelines may be developed by government agencies at any level, institutions, professional societies, governing boards, or by convening expert panels.","Guideline | Guidelines | Guidelines",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085134","Smoking Cessation","C17427","Discontinuation of the habit of smoking.","Smoking Cessation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015385","Limb","C12429","A body region referring to an upper or lower extremity.","Limb | Extremities | Extremity | LIMB | Limbs | free limb | limb | pentadactyl limb | tetrapod limb",,,,,,,,,,,,,"UBERON:0002101","limb","4282006","Limb structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3887652","Pelvic Bone","C33287","The caudal portion of the trunk, bounded anteriorly and laterally by the two hip bones incorporating the socket portion of the hip joint for each leg. Posteriorly it is bounded by the sacrum and coccyx.","Pelvic Bone | BONE, PELVIS | PELVIC BONE | Structure of innominate bone and/or sacrum and/or coccyx (body structure)","C41.4","Pelvic bone",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C0205653","Adolescent","C27954","An age group comprised of juveniles between the onset of puberty and maturity; in the state of development between puberty and maturity.","Adolescent | ADOLESCENT | Adolescents",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013343","Dye","C461","Agents used to enhance the color or contrast of target materials or samples. Dyes have some affinity for their substrates and are usually applied in a solution.","Dye | Color Additive | Dye Chemicals",,,,,,,,,,,,,,,"4267888","Dye",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2939420","Metastatic Neoplasm","C3261","A tumor that has spread from its original (primary) site of growth to another site, close to or distant from the primary site.  Metastasis is characteristic of advanced malignancies, but in rare instances can be seen in neoplasms lacking malignant morphology.","Metastatic Neoplasm | Metastatic | Metastatic Tumor | Neoplasm, metastatic | Tumor, metastatic","8000/6","Neoplasm, metastatic",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C1704686","Initiation","C47938","The act of starting something; an act that sets in motion some course of events.","Initiation | Initiate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012828","Divorced","C51776","Indicates a person whose marriage has been legally dissolved and has not remarried.","Divorced | DIVORCED | Divorced Status",,,,,,,,,,,,,,,"4069297","Divorced",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL355270","Married","C51773","Indicates a person currently joined in a legally binding matrimonial union.  Classify common law marriage as married.  Includes married couples living together and not living together.","Married | MARRIED | Married Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027952","Never Married","C51774","Indicates a person who has never been married or whose marriages have been annulled.","Never Married | NEVER MARRIED | Never Married Status",,,,,,,,,,,,,,,"4053854","Single, never married",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL423159","Legally Separated","C51777","Indicates a person living apart from his/her spouse by legal arrangement.","Legally Separated | LEGALLY SEPARATED | Separated | Separated | Separated Status",,,,,,,,,,,,,,,"4027529","Separated",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206275","Widowed","C51775","Indicates a person who is no longer married because of the death of his/her spouse and has not remarried.","Widowed | WIDOWED | Widowed Status",,,,,,,,,,,,,,,"4143188","Widowed",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0683559","Domestic Partnership","C53262","Indicates a person who is a member of an unmarried couple, including same sex couples, living together in longstanding relationships, that are registered or unregistered.","Domestic Partnership | DOMESTIC PARTNER | Domestic Partner | Domestic partner",,,,,,,,,,,,,,,"4325710","Domestic partnership",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0442592","Clinic","C51282","A healthcare facility in which patients are provided routine urgent and non-urgent care.","Clinic, Walk-in, Other | CLINIC | CLINIC - WALK IN, OTHER | Clinic | Treatment Center",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0681288","Written Language","C51276","Communication by means of words or symbols traced or formed on paper or an equivalent surface.","Written Language | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0424919","Spoken Language","C51277","Language communicated by means of words or sounds uttered through the mouth or artificial device.","Spoken Language | ",,,,,,,,,,,,,,,"4052785","Language spoken",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037078","Sign Language","C51278","A system of hand gestures used for communication.","Sign Language | ",,,,,,,,,,,,,,,"40483152","Sign language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708640","Language Code","C51279","An alphanumeric system designed to identifiy languages. The ISO 639 standard includes a two letter representation and a three letter representation.","Language Code | languageCode",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448868","Preservation","C52243","The activity of protecting something from loss or danger; a process that saves organic substances from decay; to maintain or keep intact.","Preservation | Preserved",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1282914","Surrounding","C52247","Extending on all sides of simultaneously; encircling.","Surrounding | Peri | Surround | Surrounded",,,,,,,,,,,,,,,"4230826","Surrounding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3714578","Fix","C52253","Cause to be firmly attached; stick or hold together and resist separation.","Fix | Adhere | Adhered | Attach | Attached | Fixed | Immobile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0232483","Reflux","C3835","An abnormal backward flow of a body fluid.","Reflux | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042427","Holy See (Vatican City State)","C17249","An enclave of Rome (Italy).","Holy See (Vatican City State) | 336 | Holy See | Holy See | VA | VAT | VATICAN CITY | VATICAN CITY STATE | Vatican City",,,,,,,,,,,,,,,"37151054","Holy See",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002726","Amyloidosis","C2868","A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.","Amyloidosis | AMYLOID | amyloidosis",,,,,,,,,,,,,,,"432595","Amyloidosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034693","Rattus norvegicus","C14266","The common rat, Rattus norvegicus, often used as an experimental organism.","Rattus norvegicus | Common Rat | Norway Rat | RATTUS NORVEGICUS | Rat",,,,,,,,,,,,,,,"4160363","Rattus norvegicus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010980","Dapsone","C415","A synthetic derivative of diamino-sulfone with anti-inflammatory and anti-bacterial properties. As a structural analog of p-aminobenzoic acid (PABA), dapsone inhibits dihydropteroate synthase (DHPS), an enzyme important in folate synthesis, resulting in a depletion of the folate pool and a reduction in the amount of thymidylate available for DNA synthesis. Although the exact mechanism through which dapsone exerts its anti-inflammatory activity has yet to be fully elucidated, this agent interferes with the activation and oxidative damage of myeloperoxidase in neutrophils and inhibits the integrin-mediated adherence and chemotaxis of neutrophils. Dapsone's anti-inflammatory activities may contribute to the effects seen upon topical administration.","Dapsone | 1358F | 4,4'-Sulfonylbis[benzenamine] | 4,4'-Sulfonylbisbenzamine | 4,4'-Sulfonylbisbenzeneamine | 4,4'-Sulfonyldianiline | Aczone | Avlosulfon | Bis(4-aminophenyl) sulfone | Bis(4-aminophenyl)sulfone | Croysulfone | DADPS | DAPSONE | DDS | Diphenasone | Disulone | Dumitone | Eporal | Novophone | Sulfona-MAE | Sulfona-Mae | Sulphadione | Undolac | dapsone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017797","Glutamine","C522","A nonessential amino acid. Glutamine can donate the ammonia on its side chain to the formation of urea (for eventual excretion by the kidneys) and to purines (necessary for the synthesis of nucleic acids). Glutamic acid-to-glutamine conversion, in which an ammonia group is added to glutamic acid (catalyzed by glutamine synthase), is of central importance in the regulation of toxic levels of ammonia in the body. This agent is a substrate for the production of both excitatory and inhibitory neurotransmitters (glutamate and GABA) and is also an important source of energy for the nervous system. Glutamine may become a conditionally essential amino acid during certain catabolic states.","Glutamine | (S)-2-Aminopentane-dioic acid 5-amide | Endari | GLUTAMINE | GLUTAMINE,L- | Gln | GlutaSolve | Glutacerebro | Glutapak-10 | Glutaven | L-Glutamine | L-glutamine | Memoril | Nutrestore | Q. Levoglutamide | Resource Glutasolve | Sympt-X | Sympt-X G.I. | glutamine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007450","Cat","C14191","The domesticated feline mammal, Felis catus, which is kept as a house pet.","Cat | CAT | FELIS CATUS | Feline Species | Felis catus | Felis domesticus | Felis silvestris catus | Mammals, Cats",,,,,,,,,,,,,,,"40488452","Domestic cat",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021147","Incentive","C53277","A benefit, consideration, or positive motivational influence, financial or otherwise, given to induce a specific action.","Incentive | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0680827","Centralization","C53278","The act of consolidating power under a central control; the process by which the activities of an organization, particularly those regarding decision-making; become concentrated within a particular location and/or group.","Centralization | Centralized",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439598","Continue","C53279","Remain in force or carry on without letup; keep or maintain in unaltered condition; exist in time or space without stop or interruption.","Continue | CONTINUOUS | Continual | Continued | Continuing | Continuous | Continuous | Continuously | ONGO | ONGOING | Ongoing",,,,,,,,,,,,,,,"4137800","Continual",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015535","Faculty","C53281","The body of teachers and administrators at a school.","Faculty | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0679006","Decision","C53285","A position, opinion, or judgment reached on an issue under consideration.","Decision | Call",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332283","Next","C53286","Subsequent; immediately following in time or order.","Next | Followed By | Following | Subsequent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205374","Temporary","C53288","Not permanent; not lasting; lacking continuity or regularity.","Temporary | Transient | Transitory",,,,,,,,,,,,,,,"4033243","Transitory",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038908","Oral Surgery","C17174","Surgical procedures for treating diseases and disorders of the oral cavity.","Oral Surgery | Surgery, Oral",,,,,,,,,,,,,,,"4190432","Oral surgery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035452","Rheumatology","C17099","A medical specialty that deals with diagnosis and treatment of diseases and disorders of the connective tissues.","Rheumatology | ",,,,,,,,,,,,,,,"4214702","Rheumatology",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0949059","Colorectal Polyp","C5679","A polypoid lesion that arises from the colon or rectum and protrudes into the lumen.  This group includes adenomatous polyps, serrated polyps, and hamartomatous polyps.","Colorectal Polyp | Large Bowel Polyp | Large Intestine Polyp | Polyp of Large Bowel | Polyp of Large Intestine | Polyp of the Large Bowel | Polyp of the Large Intestine",,,,,,,,,,,,,,,"4164337","Polyp of large intestine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3553962","Ulcerative Colitis","C2952","An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.","Ulcerative Colitis | Colitis Ulcerative | ulcerative colitis",,,,,,,,,,,,,,,"81893","Ulcerative colitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3553281","Crohn Disease","C2965","A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.","Crohn Disease | Crohn disease | Crohn's Disease | Crohn's Disease | Regional Enteritis | regional enteritis",,,,,,,,,,,,,,,"201606","Crohn's disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032580","Familial Adenomatous Polyposis","C3339","An autosomal dominant disorder, characterized by the presence of multiple adenomas in the colon and rectum. It is caused by a germline mutation in the adenomatous polyposis coli (APC) gene which is located on the long arm of chromosome 5. The adenomas are most often tubular, and they have the tendency to progress to adenocarcinoma. They can occur throughout the colon, but they tend to concentrate in the rectum and sigmoid colon. The colorectal adenomas are detected during endoscopic examination between the age of 10 and 20 years. The adenomas increase in size and numbers with age, and there is usually progression of one or more adenomas to adenocarcinoma. The mean age of development of adenocarcinoma is about 40 years. Signs include rectal bleeding and mucousy diarrhea.","Familial Adenomatous Polyposis | APC - Adenomatous Polyposis Coli | Adenomatous Polyposis Coli | Adenomatous Polyposis Coli | Adenomatous polyposis coli | FAP | Familial Adenomatous Polyposis 1 | Familial Adenomatous Polyposis Coli | Familial Adenomatous Polyposis Syndrome | Familial polyposis coli | Hereditary Adenomatous Polyposis Coli | Polyposis Coli | familial adenomatous polyposis | familial polyposis","8220/0","Adenomatous polyposis coli",,,,,,,,,,,,,"4248251","Familial multiple polyposis syndrome",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0017097","Gardner Syndrome","C6728","A variant of familial adenomatous polyposis. It is an autosomal dominant syndrome characterized by multiple colonic polyps predisposing to carcinoma of the colon, osteomas of the skull, epidermoid cysts, and fibromas. It is associated with mutation of the APC gene.","Gardner Syndrome | Gardner's Syndrome | Gardner's Syndrome",,,,,,,,,,,,,,,"4246717","Gardner syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3554760","Stroke","C3390","A sudden loss of neurological function secondary to hemorrhage or ischemia in the brain parenchyma due to a vascular event.","Stroke | CVA | Cerebral Infarction | Cerebrovascular Accident | Cerebrovascular Accident | Stroke Syndrome | Stroke not otherwise specified | Stroke/CVA | UNDETERMINED STROKE | stroke",,,,,,,,,,,,,,,"381316","Cerebrovascular accident",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008677","Chronic Bronchitis","C26722","A type of chronic obstructive pulmonary disease characterized by chronic inflammation in the bronchial tree that results in edema, mucus production, obstruction, and reduced airflow to and from the lung alveoli.  The most common cause is tobacco smoking.  Signs and symptoms include coughing with excessive mucus production, and shortness of breath.","Chronic Bronchitis | Unspecified chronic bronchitis",,,,,,,,,,,,,,,"255841","Chronic bronchitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL415259","Gallbladder Stone","C34443","Single or multiple, ovoid or irregular, solid particles that are formed from bile, cholesterol, and calcium in the gallbladder cavity.","Gallbladder Stone | Gallbladder Calculus | cholelith | gallstone",,,,,,,,,,,,,,,"4120373","Gallstone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1306372","Mass","C43246","The amount of matter in an object.","Mass | MASS",,,,,,,,,,,,,,,"4041088","Mass",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1707835","Dynamic Optical Breast Imaging","C53402","A scan using red light instead of x-rays to differentiate between benign and malignant conditions. It measures physiological changes in the breast when the breast is gently squeezed by an air filled bag. It is relatively comfortable (compared to a mammogram).","Dynamic Optical Breast Imaging | DOBI | Dynamic Optical Breast Imaging Scan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1554065","Unified Code for Units of Measure","C53403","A code system intended to include all units of measures being contemporarily used in international science, engineering, and business. Its purpose is to facilitate unambiguous electronic communication of quantities together with their units.","Unified Code for Units of Measure | UCUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711305","Sponsor","C48355","A person or organization that supports or champions something.","Sponsor | Applicant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012813","Diverticulitis","C26752","An infection that develops in the diverticula of the intestinal tract. Signs and symptoms include abdominal pain, fever, and leukocytosis.","Diverticulitis | diverticulitis",,,,,,,,,,,,,,,"4109737|4141224","Diverticulitis|Diverticulitis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1510475","Diverticulosis","C4922","A finding indicating the presence of multiple pouches, usually in the colonic or gastric wall.","Diverticulosis | Diverticular Disorder | diverticulosis",,,,,,,,,,,,,,,"4266809|4272162","Diverticular disease|Diverticula of intestine",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3550619","Hydronephrosis","C26796","Dilation of the urinary collecting space in the kidney.","Hydronephrosis | hydronephrosis",,,,,,,,,,,,,,,"433811","Hydronephrosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008111","Chimpanzee","C14297","Pan troglodytes, an anthropoid ape that inhabits the tropical rain forests of Africa and is used for experimental purposes because of its susceptibility to some human diseases and in behavioral studies because of its high level of intelligence.","Chimpanzee | CHIMPANZEE | Chimp | Common Chimpanzee | Pan Species | Pan troglodytes",,,,,,,,,,,,,,,"4033239","Pan troglodytes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704302","Bicuspid Tooth","C32201","One of the two permanent teeth located in front of the molars and behind each cuspid. These teeth have two cusps (points) and are used to tear and grind food.","Bicuspid Tooth | Bicuspid | Premolar | Premolar Tooth | TOOTH, PREMOLAR",,,,,,,,,,,,,,,"4297143","Structure of premolar tooth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0348016","Intravenous","C13346","Into or within a vein. Intravenous usually refers to a way of giving a drug or other substance through a needle or tube inserted into a vein.","Intravenous | IV | intravenous",,,,,,,,,,,,,,,"4112421","Intravenous",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1707655","Definitely Better","C53559","Showing obvious signs of improvement.","Definitely Better | Definite Improvement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709605","Possibly Better","C53560","Showing signs suggestive of improvement.","Possibly Better | Possible Improvement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709606","Possibly Worse","C53561","Showing signs suggestive of deterioration or decline.","Possibly Worse | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707656","Definitely Worse","C53562","Showing obvious signs of deterioration or decline.","Definitely Worse | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0149543","Base of the Skull","C12493","The portion of the skull that forms the floor on which the brain lies. The internal surface of the cranial base has three large depressions that lie on different levels known as the anterior, middle, and posterior cranial fossae.","Base of the Skull | Base of Skull | SKULL, BASE",,,,,,,,,,,,,,,"4151591","Base of skull structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008913","Clavicle","C12695","One of a pair of bones linking the scapula and the sternum. The clavicle is part of the pectoral girdle.","Clavicle | BONE, CLAVICLE | Bone structure of clavicle (body structure) | CLAVICLE | Collar Bone | clavicle | clavicle bone | clavicula | collar bone | collarbone",,,,,,,,,,,,,"UBERON:0001105","clavicle bone","4197120","Bone structure of clavicle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009758","Conjunctiva","C12341","A thin, transparent tissue divided into the palpebral conjunctiva (covering the inner side of the eye lid) and the bulbar conjunctiva (covering the eyeball).","Conjunctiva | CONJUNCTIVA | conjunctiva | conjunctivae | conjunctivas | tunica conjunctiva | wall of conjunctival sac",,,,,,,,,,,,,"UBERON:0001811","conjunctiva","4105319","Conjunctival structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013303","Duodenum","C12263","A jointed tube 25-30 cm long that connects the stomach to the jejunum.","Duodenum | DUODENUM | Duodenal structure (body structure) | SMALL INTESTINE, DUODENUM | duodenum",,,,,,,,,,,,,"UBERON:0002114","duodenum","4302112","Duodenal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015811","Femur","C12717","The upper leg bone positioned between the pelvis and the knee.","Femur | BONE, FEMUR | Bone structure of femur (body structure) | Bone, Femoral | FEMUR | Femoral | femur | thigh bone",,,,,,,,,,,,,"UBERON:0000981","femur","4323581","Bone structure of femur",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016068","Fibula","C12718","The small, lateral calf bone extending from the knee to the ankle.","Fibula | BONE, FIBULA | Bone structure of fibula (body structure) | FIBULA | fibula",,,,,,,,,,,,,"UBERON:0001446","fibula","4337676","Bone structure of fibula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016129","Finger","C32608","Any of the digits of the hand.","Finger | FINGER | digit of hand | digit of manus | digitus manus | finger | fore digit | forelimb digit | hand digit | manual digit | manual digit (phalangeal portion) plus soft tissue",,,,,,,,,,,,,"UBERON:0002389","manual digit","4192373","Finger structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018246","Inguinal Region","C12726","The lower region of the anterior abdominal wall located laterally to the pubic region.","Inguinal Region | Groin | INGUINAL REGION | Inguinal | groin | groin area | groin region | iliac region | inguen | inguinal part of abdomen | inguinal region",,,,,,,,,,,,,"UBERON:0008337","inguinal part of abdomen","4098586","Inguinal region structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0559280","Anterior Wall of the Bladder","C12334","The anterior aspect of the bladder wall.","Anterior Wall of the Bladder | Anterior Wall of Bladder | Anterior wall of bladder | Wall, Anterior",,,,,,,,,,,,,,,"4179932","Structure of anterior wall of urinary bladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227965","Prostatic Duct","C13102","A small canal that receives prostatic secretions from the glandular tubules and discharges it through the prostatic portion of the urethra.","Prostatic Duct | ",,,,,,,,,,,,,,,"4142030","Prostatic duct structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1288328","Dome of the Bladder","C12332","The upper, convex surface of the bladder.","Dome of the Bladder | BLADDER, DOME | Dome | Dome of Bladder | Dome of bladder | Superior Surface of Bladder | Superior Surface of the Bladder",,,,,,,,,,,,,,,"4282252","Structure of dome of urinary bladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227701","Posterior Wall of the Bladder","C12335","The posterior aspect of the bladder wall.","Posterior Wall of the Bladder | Posterior Wall of Bladder | Posterior wall of bladder | Wall, Posterior",,,,,,,,,,,,,,,"4106318","Structure of posterior wall of urinary bladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1176383","Atazanavir Sulfate","C28835","A sulfate salt form of atazanavir, an aza-dipeptide analogue with a bis-aryl substituent on the (hydroxethyl)hydrazine moiety with activity against both wild type and mutant forms of HIV protease. Atazanavir does not elevate serum lipids, a common problem with other protease inhibitors.","Atazanavir Sulfate | ATAZANAVIR SULFATE | BMS-232632 | CGP-73547 | Reyataz",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1170741","Atomoxetine Hydrochloride","C47405","The hydrochloride salt of atomoxetine, a phenoxy-3-propylamine derivative and selective non-stimulant, norepinephrine reuptake inhibitor with cognitive-enhancing activity. Although its precise mechanism of action is unknown, atomoxetine appears to selectively inhibit the pre-synaptic norepinephrine transporter, resulting in inhibition of the presynaptic reabsorption of norepinephrine and prolongation of norepinephrine activity in the synaptic cleft. The effect on cognitive brain function may result in improved attention and decreased impulsivity and activity levels.","Atomoxetine Hydrochloride | (-)-N -Methyl-3-phenyl-3-(o-tolyloxy)-propylamine Hydrochloride | (-)-N-methyl-gamma(2-methylphenoxy)benzenepropamine Hydrochloride | ATOMOXETINE HYDROCHLORIDE | Strattera | Tomoxetine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1122758","Apolizumab","C2228","A humanized monoclonal antibody directed against 1D10, a polymorphic determinant on the HLA-DR beta chain that is expressed on normal and neoplastic B cells. Apolizumab induces complement-mediated cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and apoptosis of 1D10 antigen-positive B cells in vitro.  (NCI04)","Apolizumab | 1D10 Anti-lymphoma Antibody | APOLIZUMAB | MAbHu1D10 | MoAb Hu1D10 | MoAb: Hu1D10 | Monoclonal Antibody Hu1D10 | Monoclonal antibody 1D10 | Remitogen | apolizumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1176306","Aprepitant","C49173","A small molecule, high-affinity substance P antagonist (SPA) with antiemetic activity. Crossing the blood brain barrier, aprepitant binds selectively to the human substance P/neurokinin 1 receptor in the central nervous system (CNS), thereby inhibiting receptor binding of endogenous substance P and substance P-induced emesis. This agent has little or no affinity for serotonin type 3 (5-HT3), dopamine, and corticosteroid receptors.","Aprepitant | 5-(((2R,3S)-2-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl)-1,2-dihydro-3H-1,2,4-Triazol-3-one | APREPITANT | Aponvie | CINVANTI | Emend | L-754030 | MK 0869 | MK-0869 | MK0869 | ONO-7436 | aprepitant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0718635","Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment","C28832","A petrolatum-based ointment absorbed by dry and moist skin, petrolatum-mineral oil-lanolin-ceresin ointment is non-comedogenic, non-irritating, and non-sensitizing. It can reduce healing time of cracked, dry skin on hands, elbows, and knees, and helps prevent diaper rash. The original ointment also contained mineral oil, ceresin, lanolin alcohol. Its use is indicated in atopic dermatitis, eczema, and psoriasis when extra protection from a heavier base is needed.","Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment | Aquaphor | Aquaphor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003968","Ascorbic Acid","C285","A natural water-soluble vitamin (Vitamin C). Ascorbic acid is a potent reducing and antioxidant agent that functions in fighting bacterial infections, in detoxifying reactions, and in the formation of collagen in fibrous tissue, teeth, bones, connective tissue, skin, and capillaries. Found in citrus and other fruits, and in vegetables, vitamin C cannot be produced or stored by humans and must be obtained in the diet. (NCI04)","Ascorbic Acid | 2-(1,2-dihydroxyethyl)-4,5-dihydroxy-furan-3-one | ASCORBIC ACID | Ascorbic acid | Asorbicap | C Vitamin | C-Long | Ce-Vi-Sol | Cecon | Cenolate | Cetane | Cevalin | L-Ascorbic Acid | VIT C | Vitamin C | Vitamin-C | ascorbic acid | vitamin C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004015","Aspartic Acid","C29608","A non-essential amino acid in humans, Aspartic Acid has an overall negative charge and plays an important role in the synthesis of other amino acids and in the citric acid and urea cycles. Asparagine, arginine, lysine, methionine, isoleucine, and some nucleotides are synthesized from aspartic acid. Aspartic acid also serves as a neurotransmitter. (NCI04)","Aspartic Acid | (S)-Aminobutanedioic acid | ASPARTIC ACID | Asp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0699606","Astemizole","C28834","A synthetic piperidinyl-benzimidazol derivative with antiallergic properties, Astemizole acts as a reversible competitive inhibitor of histamine H1 receptors, with less anticholinergic effects compared to related agents. It is a long-acting, non-sedative antihistaminic used in the treatment of seasonal allergic rhinitis, asthma, allergic conjunctivitis, and chronic idiopathic urticaria. (NCI04)","Astemizole | 1-(p-Fluorobenzyl)-2-((1-(p-methoxyphenethyl)-4-piperidyl)amino)benzimidazole | 1H-Benzimidazol-2-amine, 1-((4-fluorophenyl)methyl)-N-(1-(2-(4-methoxyphenyl)eth l)-4-piperidinyl)- | ASTEMIZOLE | Hismanal | Paralergin | R 42512 | R 43,512 | Retolen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004147","Atenolol","C28836","A synthetic isopropylamino-propanol derivative used as an antihypertensive, hypotensive and antiarrhythmic Atenolol acts as a peripheral, cardioselective beta blocker specific for beta-1 adrenergic receptors, without intrinsic sympathomimetic effects. It reduces exercise heart rates and delays atrioventricular conduction, with overall oxygen requirements decreasing. (NCI04)","Atenolol | ATENOLOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0286650","Atorvastatin Calcium","C28837","The calcium salt of atorvastatin, a synthetic lipid-lowering agent. Atorvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent increases the number of LDL receptors on hepatic cell surfaces, enhancing the uptake and catabolism of LDL and reducing LDL production and the number of LDL particles, and lowers plasma cholesterol and lipoprotein levels. Like other statins, atorvastatin may also display direct antineoplastic activity, possibly by inhibiting farnesylation and geranylgeranylation of proteins such as small GTP-binding proteins, which may result in the arrest of cells in the G1 phase of the cell cycle. This agent may also sensitize tumor cells to cyctostatic drugs, possibly through the mTOR-dependent inhibition of Akt phosphorylation.","Atorvastatin Calcium | ATORVASTATIN CALCIUM TRIHYDRATE | Atorvastatin | CI-981 | Lipitor | atorvastatin calcium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0581619","Cervical Spinal Cord","C12892","The portion of the spinal cord located in the cervical region.","Cervical Spinal Cord | Cervical Portion of Spinal Cord | Cervical cord | Cervical spinal cord structure (body structure) | SPINAL CORD, CERVICAL | cervical spinal cord",,,,,,,,,,,,,,,"4183411","Cervical spinal cord structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016536","Forearm","C32628","The structure on the upper limb, between the elbow and the wrist.","Forearm | FOREARM",,,,,,,,,,,,,,,"4032953","Forearm structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016976","Gallbladder","C12377","A pear-shaped organ located under the liver that stores and concentrates bile secreted by the liver. From the gallbladder the bile is delivered through the bile ducts into the intestine thereby aiding the digestion of fat-containing foods.","Gallbladder | GALLBLADDER | Gallbladder / Biliar | Gallbladder structure (body structure) | Gastrointestinal Tract, Gall Bladder | cholecyst | gall bladder | gallbladder",,,,,,,,,,,,,"UBERON:0002110","gallbladder","4151384","Gallbladder structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015450","Face (anatomic feature)","C13071","The anterior portion of the head extending from the forehead to the chin and ear to ear. The facial structures contain the eyes, nose and mouth, cheeks and jaws.","Face | FACE | Facial | Facial region",,,,,,,,,,,,,,,"4232301","Face structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020164","Humerus","C12731","The upper arm bone between the shoulder and elbow.","Humerus | BONE, HUMERUS | Bone structure of humerus (body structure) | Bone, Humeral | HUMERUS | humeri | humerus | humerus bone",,,,,,,,,,,,,"UBERON:0000976","humerus","4224516","Bone structure of humerus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020889","Ilium","C32765","The broad, dorsal, upper, and widest of the three principal bones composing either half of the pelvis.","Ilium | BONE, ILIUM | Bone structure of ilium (body structure) | ILIUM | Iliac | iliac bone | ilium | ilium bone | os iliacum | os ilii | os ilium","C41.4","Ilium",,,,,,,,,,,"UBERON:0001273","ilium","4329573","Bone structure of ilium",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0022378","Jejunum","C12388","The portion of the small intestine that extends from the duodenum to the ileum.","Jejunum | JEJUNUM | Jejunal structure (body structure) | SMALL INTESTINE, JEJUNUM | jejunum",,,,,,,,,,,,,"UBERON:0002115","jejunum","4065077","Jejunal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024090","Lumbar Region","C34004","The region of the spine below the ribs and above the hipbones.","Lumbar Region | LUMBAR REGION",,,,,,,,,,,,,,,"4200862","Structure of lumbar region of back",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023759","Lip","C12220","Fleshy fold which surrounds the opening of the mouth.","Lip | LIP | Lip, NOS | Vermillion of the Lip | lip",,,,,,,,,,,,,"UBERON:0001833","lip","4168155","Lip structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029180","Orbit","C12347","The bony cavity of the skull which contains the eye, anterior portion of the optic nerve, ocular muscles and ocular adnexa. Seven bones contribute to the structure of the orbit: the frontal, maxillary, zygomatic, sphenoid, lacrimal, ethmoid, and palatine bones.","Orbit | BODY CAVITY, ORBITAL | Eye Socket | ORBIT | Ocular Orbit | Ocular Orbits | Ocular orbits | Orbit, NOS | Orbital Cavity | Structure of orbit proper (body structure)",,,,,,,,,,,,,,,"4179706","Structure of orbit proper",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0700374","Palate","C12229","The roof of the oral cavity. It separates the oral cavity from the nasal cavity.","Palate | PALATE | Palate, NOS | palate",,,,,,,,,,,,,,,"4249459","Palatal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704247","Peritoneal Cavity","C12769","The potential space located between the parietal and visceral layers of the peritoneum.","Peritoneal Cavity | BODY CAVITY, PERITONEAL | PERITONEAL CAVITY | peritoneal cavity",,,,,,,,,,,,,"UBERON:0001179","peritoneal cavity","4307671","Peritoneal cavity structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031354","Pharynx","C12425","A hollow tube that starts posterior to the mouth and nasal cavity and ends superior to the trachea and esophagus.","Pharynx | PHARYNX | Pharyngeal structure (body structure) | Pharynx, NOS | pharynx",,,,,,,,,,,,,"UBERON:0006562","pharynx","4207370","Pharyngeal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3669209","Sacrum","C33508","The triangular bone, made up of 5 fused bones of the spine, located in the lower area of the spine between the fifth lumbar vertebra and the coccyx.","Sacrum | SACRUM | Sacral | Sacral Region | Sacral Region | Sacral Spine | Sacrum | fused sacrum | os sacrum [vertebrae sacrales I - V] | sacrum | sacrum [sacral vertebrae I - V] | sacrum [sacral vertebrae I-V]",,,,,,,,,,,,,"UBERON:0005473","fused sacrum","4262680","Sacral region back structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036098","Salivary Gland","C12426","An exocrine gland that secretes saliva. Salivary glands are mostly located in and around the oral cavity.","Salivary Gland | GLAND, SALIVARY | Head and Neck, Salivary Glands | Major salivary gland, NOS | SALIVARY GLAND | Salivary Glands | saliva-secreting gland | salivary gland",,,,,,,,,,,,,,,"4294042","Salivary gland structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036277","Scapula","C12783","The flat triangle-shaped bone that connects the humerus with the clavicle in the back of the shoulder.","Scapula | BONE, SCAPULA | Bone structure of scapula (body structure) | SCAPULA | Shoulder Blade | scapula | scapulae | shoulder blade",,,,,,,,,,,,,"UBERON:0006849","scapula","4196209","Bone structure of scapula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030471","Paranasal Sinus","C12763","Any one of the air-filled spaces within the ethmoid, frontal, maxillary, or sphenoid bones, which communicate with the nasal cavity.","Paranasal Sinus | Accessory Sinus | Accessory Sinuses | Accessory sinus, NOS | Accessory sinuses | Nasal Sinus | Nasal Sinuses | Nasal and Sinuses | PARANASAL SINUS | Paranasal Sinuses | Paranasal sinuses | Sinuses, Nasal | Sinuses, Paranasal | paranasal sinus",,,,,,,,,,,,,"UBERON:0001825","paranasal sinus","4051578","Nasal sinus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038293","Sternum","C12793","The long, flat bone connecting with the cartilages of the first seven ribs and the clavicle.","Sternum | BONE, STERNUM | STERNUM | Sterna | breastbone | sternum | vertebrate sternum",,,,,,,,,,,,,"UBERON:0000975","sternum","4211392","Bone structure of sternum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039987","Thoracic Vertebra","C12798","One of 12 vertebrae in the human vertebral column. The thoracic vertebrae are situated between the seventh cervical vertebra down to the first lumbar vertebra.","Thoracic Vertebra | Bone structure of thoracic vertebra (body structure) | THORACIC VERTEBRA | Thoracic Vertebrae",,,,,,,,,,,,,,,"4147619","Bone structure of thoracic vertebra",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0817096","Thorax","C12799","The division of the body lying between the neck and the abdomen.","Thorax | THORAX | Thorax, NOS | anterolateral part of thorax | chest | front of thorax | pectus | ventral part of thoracic region",,,,,,,,,,,,,"UBERON:0001443","chest","4199473","Thoracic structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040408","Tongue","C12422","The muscular organ located in the floor of the mouth and serving as the principal organ of taste and modification of the voice in speech.","Tongue | Entire tongue (body structure) | TONGUE | Tongue structure (body structure) | Tongue, NOS | tongue",,,,,,,,,,,,,"UBERON:0001723","tongue","4071678","Tongue structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040578","Trachea","C12428","The fibrocartilaginous, mucous-lined tube passing from the larynx to the bronchi.","Trachea | TRACHEA | Tracheal structure (body structure) | Windpipe | cartilaginous trachea | trachea | vertebrate trachea | windpipe",,,,,,,,,,,,,"UBERON:0003126","trachea","4195956","Tracheal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0454077","Electron Beam Therapy","C15650","Radiation therapy using electron beam.","Electron Beam Therapy | ELECTRON Therapy | Electron Beam Radiation Therapy | External beam radiation therapy using electrons (procedure)",,,,,,,,,,,,,,,"4165039","External beam radiation therapy using electrons",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0600521","3-Dimensional Conformal Radiation Therapy","C16035","A process by which a dose of radiation is automatically shaped to closely conform to the entire volume of the tumor, so that surrounding normal tissue is spared and treatment toxicity is decreased.","3-Dimensional Conformal Radiation Therapy | 3-dimensional conformal radiation therapy | 3-dimensional radiation therapy | 3D CONFORMAL RADIATION THERAPY | 3D CRT | 3D Conformal | 3D radiotherapy | 3D-CRT | Conformal Therapy | Radiation Conformal Therapy | Radiation, 3D Conformal | Three dimensional external beam radiation therapy (procedure)",,,,,,,,,,,,,,,"762950","Three dimensional conformal radiotherapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0422771","African Caribbean","C41226","Denotes a person of African ancestral origins whose family settled in the Caribbean region.","African Caribbean | AFRICAN CARIBBEAN | African Caribbean Ancestry | African Caribbean Descent | Afro-Caribbean",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556107","Bangladeshi","C43671","Denotes the inhabitants of Bangladesh, a person from there, or their descendants elsewhere.","Bangladeshi | BANGLADESHI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1328050","High Dose Chemotherapy","C15807","A cancer treatment having a treatment dose that is higher than the standard dosage levels recommended on the product labeling for that chemotherapeutic agent. This dose is concurrently toxic and destroys the normal bone marrow stem cells.","High Dose Chemotherapy | high-dose chemotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709036","Minimantle Radiation Field","C53632","A radiation field that includes the bilateral cervical, supraclavicular, and axillary lymph nodes.","Minimantle Radiation Field | Minimantle | Minimantle Field",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708569","Inverted Y Radiation Field","C53634","A radiation field that covers the anterior chest well in the shape of an inverted 'Y'. It includes the inguinal, femoral, pelvic, and para-aortic nodal area.","Inverted Y Radiation Field | Inverted Y | Inverted Y Field",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1248601","Oatmeal Powder","C29298","Colloidal oatmeal, whole oats milled to a fine powder, with anti-pruritic activity. Oatmeal powder, especially when added to a warm bath, is used to provide temporary relief of itching and irritation caused by insect bites, eczema, sun burns, reactions to poisonous plants and various other skin rashes and allergies.","Oatmeal Powder | Aveeno | OATMEAL",,,,,,,,,,,,,,,"4190348","Colloidal oatmeal powder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041044","Trimethoprim-Sulfamethoxazole","C909","A synthetic combination of two antibacterial agents, trimethoprim and sulfamethoxazole. This synergistic combination, also known as Co-Trimoxazole, inhibits two sequential steps in the bacterial metabolism of folic acid. Trimethoprim is a pyrimidine inhibitor of dihydrofolate reductase; sulfamethoxazole is a sulfamide inhibitor of bacterial dihydrofolate synthase.","Trimethoprim-Sulfamethoxazole | Bactrim | Bactrim DS | Bactrimel | Centran | Centrin | Co-Trimoxazole | Cotrim | Cotrimoxazole | Eslectin | Insozalin | SMZ-TMP | Septra | Sulfamethoprim | Sulfatrim | Sulmeprim | TMP-SMX | Trimedin | Trimethoprim/Sulfamethoxazole | Trimethoprim/Sulfamethoxazole (Bactrim DS) | Trimezole | Uroplus | co-trimoxazole | trimethoprim-sulfamethoxazole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0165603","Atovaquone","C28838","A synthetic hydroxynaphthoquinone with antiprotozoal activity. Atovoquone blocks the mitochondrial electron transport at complex III of the respiratory chain of protozoa, thereby inhibiting pyrimidine synthesis, preventing DNA synthesis and leading to protozoal death.","Atovaquone | 566C80 | ATOVAQUONE | Atovoquone | BW-566C | BW-A566C | Mepron",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004259","Atropine","C28840","A synthetically-derived form of the endogenous alkaloid isolated from the plant Atropa belladonna.  Atropine functions as a sympathetic, competitive antagonist of muscarinic cholinergic receptors, thereby abolishing the effects of parasympathetic stimulation.  This agent may induce tachycardia, inhibit secretions, and relax smooth muscles. (NCI04)","Atropine | ATROPINE | Atropen | dl-Tropyl Tropate | endo-(+/-)-alpha-(Hydroxymethyl)benzeneacetic Acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl Ester",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0052657","Attapulgite","C28841","A natural clay-like mineral mixture of hydrated aluminum silicate containing magnesium, adsorbent Attapulgite (kaopectate) acts locally in the intestines to adsorb bacteria and toxins; reduce water loss; and treat diarrhea. Sometimes it is activated by heat to increase absorbency. (NCI04)","Attapulgite | ATTAPULGITE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0052796","Azithromycin","C28844","An azalide, derived from erythromycin, and a member of a subclass of macrolide antibiotics with bacteriocidal and bacteriostatic activities. Azithromycin reversibly binds to the 50S ribosomal subunit of the 70S ribosome of sensitive microorganisms, thereby inhibiting the translocation step of protein synthesis, wherein a newly synthesized peptidyl tRNA molecule moves from the acceptor site on the ribosome to the peptidyl (donor) site, and consequently inhibiting RNA-dependent protein synthesis leading to cell growth inhibition and cell death.","Azithromycin | (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy]-1-oxa-6-azacyclopentade | AZITHROMYCIN, UNSPECIFIED FORM | AzaSite | CP 62993 | N-methyl-11-aza-10-deoxy-10-dihydroerythromycin A | XZ-450 | Zithromax",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0699281","Aztreonam","C28845","A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum with bactericidal activity. Aztreonam preferentially binds to and inactivates penicillin-binding protein-3 (PBP-3), which is involved in bacterial cell wall synthesis, thereby inhibiting bacterial cell wall integrity and leading to cell lysis and death. This agent differs from other beta-lactam antibiotics because it is resistant to beta-lactamase hydrolysis, and it is usually used to treat infections caused by gram-negative aerobic microorganisms.","Aztreonam | AZTREONAM | Azactam | SQ 26,776",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004599","Bacitracin","C295","A complex of cyclic polypeptide antibiotics, mainly bacitracin A, produced by spore-forming organisms belonging to the licheniformin group of the Bacillus subtilis with antibacterial activity. Bacitracin binds to C55-isoprenyl pyrophosphate, a biphosphate lipid transport molecule that carries the building blocks of the peptidoglycan bacterial cell wall. The binding interferes with the enzymatic dephosphorylation of the C55-isoprenyl pyrophosphate and prevents peptidoglycan synthesis, thereby inhibiting bacterial cell growth.","Bacitracin | BACITRACIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043483","Bacitracin Zinc","C28857","The zinc salt form of bacitracin, a complex of cyclic polypeptide antibiotics, mainly bacitracin A, produced by spore-forming organisms belonging to the licheniformin group of the Bacillus subtilis with antibacterial activity. Bacitracin zinc binds to C55-isoprenyl pyrophosphate, a biphosphate lipid transport molecule that carries the building blocks of the peptidoglycan bacterial cell wall, thereby interfering with the enzymatic dephosphorylation of the C55-isoprenyl pyrophosphate and preventing peptidoglycan synthesis which leads to cell lysis.","Bacitracin Zinc | BACITRACIN ZINC | Ziba-Rx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0699999","Baclofen","C28858","A synthetic chlorophenyl-butanoic acid derivative used to treat spasms due to spinal cord damage and multiple sclerosis, muscle-relaxing Baclofen acts as a gamma-aminobutyric acid (GABA) agonist specific for GABA-B receptors. It acts at spinal and supraspinal sites, reducing excitatory transmission. (NCI04)","Baclofen | 4-Amino-3-(4-chlorophenyl)-butanoic Acid | BA34647 | BACLOFEN | Gablofen | Kemstro | Lioresal | baclofen | beta-(Aminomethyl)-4-chlorobenzenepropanoic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004754","Barium Sulfate","C28859","The sulfate salt of barium, an alkaline, divalent metal.  Barium sulfate is quite insoluble in water, and is used as a radiopaque agent to diagnose gastrointestinal medical conditions.  Barium sulfate is taken by mouth or given rectally. (NCI04)","Barium Sulfate | BARIUM SULFATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004906","Beclomethasone Dipropionate","C299","The dipropionate ester of a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, beclomethasone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.","Beclomethasone Dipropionate | (11beta,16beta)-9-Chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)pregna-1,4-diene-3,20-dione Dipropionate | BECLOMETHASONE DIPROPIONATE | Beclovent | Beconase | QNASL | Qvar | SCH-18020W | Vancenase | Vanceril",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0770917","Benazepril Hydrochloride","C28862","The hydrochloride salt of benazepril, a carboxyl-containing angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. As a prodrug, benazepril is metabolized to its active form benazeprilat. Benazeprilat competitively binds to and inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the potent vasoconstrictive actions of angiotensin II, resulting in vasodilation. Benazeprilat also decreases angiotensin II-induced aldosterone secretion by the adrenal cortex, which leads to an increase in sodium excretion and subsequently increases water outflow.","Benazepril Hydrochloride | BENAZEPRIL HYDROCHLORIDE | Benazepril HCl | CGS14824A | Lotensin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1298908","No","C49487","The non-affirmative response to a question.","No | N | NO | no",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1298907","Yes","C49488","The affirmative response to a question.","Yes | Y | YES | yes",,,,,,,,,,,,,,,"4188539","Yes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2963216","Vital Signs Measurement","C49672","The act of assessing an individual's current temperature, heart rate, respiratory rate, pulse oxygenation, and blood pressure.","Vital Signs Measurement | VITALS_TEST | VS | VSTEST | Vital Sign Measurement | Vital Signs | Vital Signs | Vital Signs Test | Vital Signs Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018810","Heart Rate","C49677","The number of heartbeats per unit of time, usually expressed as beats per minute.","Heart Rate | HR | Heart rate | Vital Signs – Heart Rate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0232117","Pulse Rate","C49676","The rate of the pulse as observed in an artery, expressed as beats per minute. It can be measured at several anatomic sites, including the wrist, neck, temple, groin, behind the knees, or on top of the foot.","Pulse Rate | PULSE",,,,,,,,,,,,,,,"4301868","Pulse rate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0231832","Respiratory Rate","C49678","The rate of breathing (inhalation and exhalation) measured within in a unit time, usually expressed as breaths per minute.","Respiratory Rate | RESP | RESPRATE | Respiratory rate | Vital Signs – Respiratory Rate | respiration rate | respiration_rate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706977","Body Frame Size","C49680","The categorization of a person's body frame into small, medium and large based on the measurement of wrist circumference or the breadth of the elbow.","Body Frame Size | FRMSIZE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0428886","Mean Arterial Pressure","C49679","The mean pressure of the blood within the arterial circulation. The arterial pressure may be directly measured by insertion of an intra-arterial catheter connected to a transducer. The mean arterial pressure (MAP) can be calculated by subsequent analysis of the waveform. MAP can be approximated without an invasive procedure using the following formula: diastolic pressure plus 1/3 of the pulse pressure, where pulse pressure is systolic pressure - diastolic pressure.","Mean Arterial Pressure | MAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042173","Uvula","C12232","The fleshy lobe that hangs at the back of the soft palate.","Uvula | PALATINE UVULA | Palatine Uvula | palatine uvula | uvula | uvula of palate | uvula palatina",,,,,,,,,,,,,"UBERON:0001734","palatine uvula","4095284","Uvula palatina structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0225326","Fiber","C1502","Substances in plant foods (fruits and vegetables) that are not digested or absorbed by the gastrointestinal tract.  Fiber is classified into two categories, soluble and insoluble fiber.  Due to increasing the rate of gastrointestinal digestion and possible absorption of cancer causing agents, fiber may possess chemopreventive properties. (NCI)","Fiber | Fibra",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0053229","Benzonatate","C28863","A synthetic butylamino-benzoate derivative related to tetracaine and a peripherally acting antitussive, nonnarcotic Benzonatate reduces the cough reflex by anesthetizing and depressing mechanoreceptors in the respiratory passages, lungs, and pleura. It is recommended for cough relief in the common cold, bronchitis, pneumonia, and for chronic cough such as in asthma. (NCI04)","Benzonatate | BENZONATATE | KM-65 | Tessalon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0053156","Benztropine Mesylate","C28864","A synthetic antiparkinson tertiary amine structurally related to atropine, Benztropine Mesylate acts as a central muscarinic antagonist and inhibits dopamine uptake. With antihistaminic and local anesthetic properties as well, it is indicated for symptomatic relief of parkinsonism and drug-induced extrapyramidal reactions. (NCI04)","Benztropine Mesylate | BENZTROPINE MESYLATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037540","Penicillin G Sodium","C28865","The sodium salt form of benzylpenicillin, a semi-synthetic, broad-spectrum penicillin antibiotic with bactericidal activity. Benzylpenicillin sodium binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.","Penicillin G Sodium | 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid, 3,3-dimethyl-7-oxo-6-((phenylacetyl)amino)-,(2S-(2alpha,5alpha,6beta))-, Monosodium Salt | Benzylpenicillin Sodium | Benzylpenicillin Sodium | Benzylpenicillin Sodium Salt | Novocillin | PENICILLIN G SODIUM | Penicillin | Penilaryn | Sugracillin Sodium Salt | Veticillin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0053396","Beta-Carotene","C1016","A naturally-occurring retinol (vitamin A) precursor obtained from certain fruits and vegetables with potential antineoplastic and chemopreventive activities.  As an anti-oxidant, beta carotene inhibits free-radical damage to DNA.  This agent also induces cell differentiation and apoptosis of some tumor cell types, particularly in early stages of tumorigenesis, and enhances immune system activity by stimulating the release of natural killer cells, lymphocytes, and monocytes. (NCI04)","Beta-Carotene | .beta.-Carotene | 3,7,12,16-tetramethyl-1,18-bis(2,6,6-trimethyl-1-cyclohexenyl)-octadeca-1,3,5,7,9,11,13,15,17-nonaene | BETA CAROTENE | Beta Carotene | Beta Carotene | Beta-carotene | CAROTENE, BETA | Lumitene | Solatene | beta carotene | beta-Carotene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005308","Betamethasone","C303","A synthetic glucocorticoid with metabolic, immunosuppressive and anti-inflammatory activities. Betamethasone binds to specific intracellular glucocorticoid receptors and subsequently binds to DNA to modify gene expression. The synthesis of certain anti-inflammatory proteins is induced while the synthesis of certain inflammatory mediators is inhibited.  As a result, there is an overall reduction in chronic inflammation and autoimmune reactions.","Betamethasone | BETAMETHASONE | Celestone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0106169","Bethanechol Chloride","C28866","A synthetic quaternary ammonium base derivative, parasympathomimetic Bethanechol is a slowly hydrolyzed muscarinic agonist with no nicotinic effects. Generally used to increase smooth muscle tone, Bethanechol is used to treat reflux esophagitis and to initiate urination after surgery, in urinary infections, or for enlarged prostate. It may cause hypotension, cardiac rate changes, and bronchial spasms. (NCI04)","Bethanechol Chloride | 2-[(Aminocarbonyl)oxy]-N,N,N-trimethyl-1-propanaminium Chloride | BETHANECHOL CHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0285590","Bicalutamide","C1599","A synthetic, nonsteroidal antiandrogen.  Bicalutamide competitively binds to cytosolic androgen receptors in target tissues, thereby inhibiting the receptor binding of androgens. This agent does not bind to most mutated forms of androgen receptors. (NCI04)","Bicalutamide | (+/-)-N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide | 4'-Cyano-alpha,alpha,alpha-trifuloro-3-[(p-fluorophenyl)sulfonyl]-2-methyl-m-lactotoluidide | 4-Cyano-3-trifluoromethyl-N-(3-p-fluorophenylsulfonyl-2-hydroxy-2-methylpropionyl)aniline | BICALUTAMIDE | Casodex | Cassotide | Cosudex | ICI 176,334 | ICI 176334 | N-[4-Cyano-3-(trifluoromethyl)phenyl]3-3[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-propanamide | Utamide | bicalutamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005632","Bisacodyl","C28870","A synthetic pyridinylmethylene-diacetate ester derivative stimulant laxative, Bisacodyl acts with a parasympathetic effect directly on mucosal sensory nerves, increasing peristaltic contractions. It is used for occasional constipation, in pre- and postoperative treatment, and in conditions that require facilitation of defecation. (NCI04)","Bisacodyl | BISACODYL | Dulcolax",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0053792","Bismuth Subsalicylate","C1020","A bismuth salt of salicylic acid.  Little absorbed from the gastrointestinal tract, bismuth subsalicylate exerts a local effect on the gastric mucosa, coating it and protecting it from the corrosive effects of acid and pepsin.  This agent also has local antimicrobial properties. (NCI04)","Bismuth Subsalicylate | BISMUTH SUBSALICYLATE | Bismuth subsalicylate | Pepto Bismol | Pepto-Bismol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0543473","Bisoprolol Fumarate","C28871","The fumarate salt of a synthetic phenoxy-2-propanol-derived cardioselective beta-1 adrenergic receptor antagonist with antihypertensive and potential cardioprotective activities. Devoid of intrinsic sympathomimetic activity, bisoprolol selectively and competitively binds to and blocks beta-1 adrenergic receptors in the heart, decreasing cardiac contractility and rate, reducing cardiac output, and lowering blood pressure. In addition, this agent may exhibit antihypertensive activity through the inhibition of renin secretion by juxtaglomerular epithelioid (JGE) cells in the kidney, thus inhibiting activation of the renin-angiotensin system (RAS). Bisoprolol has been shown to be cardioprotective in animal models.","Bisoprolol Fumarate | (+-)-1-((alpha-(2-Isopropoxyethoxy)-p-tolyl)oxy)-3-(isopropylamino)-2-propanol fumarate (2:1) (salt) | BISOPROLOL FUMARATE | Bisoprolol Hemifumarate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0546852","Bromocriptine Mesylate","C317","The mesylate salt of bromocriptine, a semisynthetic ergot alkaloid with dopaminergic, antidyskinetic, and antiprolactinemic activities. Bromocriptine selectively binds to and activates postsynaptic dopamine D2 receptors in the corpus striatum of the central nervous system (CNS). Activation of these D2 receptors activate inhibitory G-proteins, which inhibit adenylyl cyclase, preventing signal transduction mediated via cAMP and resulting in the inhibition of neurotransmission and an antidyskinetic effect. This agent also stimulates dopamine D2 receptors in the anterior pituitary gland, which results in the inhibition of prolactin secretion and lactation and may inhibit the proliferation of prolactin-dependent breast cancer cells.","Bromocriptine Mesylate | 2-Bromo-alpha-ergocryptine Mesylate | BROMOCRIPTINE MESYLATE | Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, monomethanesulfonate (salt), (5'alpha)- | Parlodel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0699883","Bupivacaine Hydrochloride","C28876","A long-acting, amide-type local anesthetic. Bupivicaine reversibly binds to specific sodium ion channels in the neuronal membrane, resulting in a decrease in the voltage-dependent membrane permeability to sodium ions and membrane stabilization; inhibition of depolarization and nerve impulse conduction; and a reversible loss of sensation.","Bupivacaine Hydrochloride | BUPIVACAINE HYDROCHLORIDE | Bupivacaine | Marcain | Marcaine | Sensorcaine | bupivacaine hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0383429","Alemtuzumab","C1681","A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","Alemtuzumab | ALEMTUZUMAB | Anti-CD52 Monoclonal Antibody | Campath | Campath-1H | LDP 03 | LDP-03 | LDP03 | Lemtrada | MabCampath | Monoclonal Antibody Campath-1H | alemtuzumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1318898","5 Alpha-Reductase Inhibitor","C2319","Any substance that inhibits steroid 5-alpha-reductase, an enzyme that converts testosterone into dihydrotestosterone (DHT). Since DHT has three times greater affinity for androgen receptors than testosterone, inhibition of 5-alpha-reductase results in a strong reduction in the androgenic effects of testosterone.","5 Alpha-Reductase Inhibitor | 5-alpha reductase inhibitor | Steroid 5-alpha-reductase Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0106940","Bovine Cartilage","C2418","Cartilage extracted from various parts of a cow and is proposed to stimulate the immune system and inhibit tumor cell growth.  It was used in the 1950s and 60s to enhance wound healing. (NCI)","Bovine Cartilage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054201","Budesonide","C1027","A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. Upon administration, budesonide binds to intracellular glucocorticoid receptors (GRs) and induces the expression of glucocorticoid-responsive genes that encode for anti-inflammatory mediators, such as certain anti-inflammatory cytokines, including interleukin 10 (IL-10), and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both mediators of inflammation. In addition, budesonide prevents the release of pro-inflammatory cytokines from epithelial cells and macrophages, including interleukin 6 (IL-6), IL-8, interferon-beta (IFNb), and inhibits nuclear factor kappa-B (NF-kB) activation thereby decreasing NF-kB-mediated inflammation.","Budesonide | (RS)-11beta,16alpha,17,21,-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal w/ Butyraldehyde | BUDESONIDE | Budecort | Butacort | Eltair | Nasocort | Preferid | Pregna-1,4-diene-3,20-dione,16,17-(butylidenebis(oxy))-11,21-dihydroxy-, (11beta,16alpha)- | Pulmicort | Pulmicort Turbuhaler | Rhinocort | budesonide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0701009","Bumetanide","C28875","A potent sulfamoylanthranilic acid derivative belonging to the class of loop diuretics. In the brain, bumetanide may prevent seizures in neonates by blocking the bumetanide-sensitive sodium-potassium-chloride cotransporter (NKCC1), thereby inhibiting chloride uptake thus, decreasing the internal chloride concentration in neurons and may block the excitatory effect of GABA in neonates.","Bumetanide | BUMETANIDE | Bumex | Burinex | Edemex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006674","Calcitriol","C330","A synthetic physiologically-active analog of vitamin D, specifically the vitamin D3 form.  Calcitriol regulates calcium in vivo by promoting absorption in the intestine, reabsorption in the kidneys, and, along with parathyroid hormone, regulation of bone growth.  A calcitriol receptor-binding protein appears to exist in the mucosa of human intestine. Calcitriol also induces cell cycle arrest at G0/G1 phase of the cell cycle, cell differentiation, and apoptosis, resulting in inhibition of proliferation of some tumor cell types.  This agent may be chemopreventive for colon and prostate cancers. (NCI04)","Calcitriol | (1alpha,3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol | 1,25(OH)2-D3 | 1,25-DHCC | 1,25-Dihydroxycholecalciferol | 1,25-Dihydroxycholecaliferol | CALCITRIOL | Calcijex | Rocaltrol | calcitriol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006681","Calcium Carbonate","C332","The carbonic salt of calcium (CaCO3). Calcium carbonate is used therapeutically as a phosphate buffer in hemodialysis, as an antacid in gastric hyperacidity for temporary relief of indigestion and heartburn, and as a calcium supplement for preventing and treating osteoporosis. (NCI04)","Calcium Carbonate | CALCIUM CARBONATE | calcium carbonate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006686","Calcium Chloride","C28901","A crystalline, white substance, soluble in water, Calcium Chloride is the chloride salt of calcium, a bivalent metallic element with many crucial biological roles. Calcium is a major constituent of the skeleton but plays many roles as an intracellular and plasma ion as well. In medicine, calcium chloride is also used as a 10% solution in injection, for calcium replenishment. (NCI04)","Calcium Chloride | CALCIUM CHLORIDE | Calcium Chloride Anhydrous | Calcium Chloride Dihydrate | Calcium Chloride Hexahydrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0108101","Calcium Citrate","C1355","The citrate salt of calcium. An element necessary for normal nerve, muscle, and cardiac function, calcium as the citrate salt helps to maintain calcium balance and prevent bone loss when taken orally. This agent may also be chemopreventive for colon and other cancers. (NCI04)","Calcium Citrate | 2-Hydroxy-1,2,3-propanetricarboxylic Acid, Calcium Salt (2:3) | Acicontral | CALCIUM CITRATE | Citracal | Tricalcium Citrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006699","Calcium Gluconate","C336","The gluconate salt of calcium. An element or mineral necessary for normal nerve, muscle, and cardiac function, calcium as the gluconate salt helps to maintain calcium balance and prevent bone loss when taken orally. This agent may also be chemopreventive for colon and other cancers. (NCI04)","Calcium Gluconate | CALCIUM GLUCONATE | Calcium D-gluconate | Calglucon | calcium gluconate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054480","Calcium Polycarbophil","C28902","A loosely cross-linked synthetic polycarboxylic-type hydrophilic polymer resin, laxative and anti-diarrheal Calcium Polycarbophil increases stool frequency, fecal water content, and fecal weight in a dose-dependent manner. It is used for idiopathic constipation, secretory diarrhea, and irritable bowel syndrome. (NCI04)","Calcium Polycarbophil | CALCIUM POLYCARBOPHIL | Fiberall | Fibercon | Mitrolan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0527379","Candesartan Cilexetil","C28903","A synthetic, benzimidazole-derived angiotensin II receptor antagonist prodrug with antihypertensive activity. After hydrolysis of candesartan cilexetil to candesartan during gastrointestinal absorption, candesartan selectively competes with angiotensin II for the binding of the angiotensin II receptor subtype 1 (AT1) in vascular smooth muscle, blocking angiotensin II-mediated vasoconstriction and inducing vasodilatation. In addition, antagonism of AT1 in the adrenal gland inhibits angiotensin II-stimulated aldosterone synthesis and secretion by the adrenal cortex; sodium and water excretion increase, followed by a reduction in plasma volume and blood pressure.","Candesartan Cilexetil | Atacand | Blopress | CANDESARTAN CILEXETIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006931","Capsaicin","C339","A chili pepper extract with analgesic properties.  Capsaicin is a neuropeptide releasing agent selective for primary sensory peripheral neurons.  Used topically, capsaicin aids in controlling peripheral nerve pain.  This agent has been used experimentally to manipulate substance P and other tachykinins.  In addition, capsaicin may be useful in controlling chemotherapy- and radiotherapy-induced mucositis.","Capsaicin | (E)-N-[(4-Hydroxy-3-methoxyphenyl)methyl]-8-methyl-6-nonenamide | (E)-N-[(4-hydroxy-3-methoxy-phenyl)methyl]-8-methyl-non-6-enamide | CAPSAICIN | N-(4-hydroxy-3-methoxyphenylmethyl) -8-Methyl-6-Nonenamide | capsaicin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006938","Captopril","C340","A sulfhydryl-containing analog of proline with antihypertensive activity and potential antineoplastic activity. Captopril competitively inhibits angiotensin converting enzyme (ACE), thereby decreasing levels of angiotensin II, increasing plasma renin activity, and decreasing aldosterone secretion.  This agent may also inhibit tumor angiogenesis by inhibiting endothelial cell matrix metalloproteinases (MMPs) and endothelial cell migration. Captopril may also exhibit antineoplastic activity independent of effects on tumor angiogenesis. (NCI04)","Captopril | (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline | CAPTOPRIL | Capoten | captopril",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006949","Carbamazepine","C341","A tricyclic compound chemically related to tricyclic antidepressants (TCA) with anticonvulsant and analgesic properties. Carbamazepine exerts its anticonvulsant activity by reducing polysynaptic responses and blocking post-tetanic potentiation. Its analgesic activity is not understood; however, carbamazepine is commonly used to treat pain associated with trigeminal neuralgia.","Carbamazepine | 5H-Dibenz(b,f)azepine-5-carboxamide | CARBAMAZEPINE | Epitol | Tegretol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007248","Carisoprodol","C28904","A synthetic propanediol dicarbamate derivative and an adjunct in the treatment of painful muscle spasms, Carisoprodol is a centrally acting skeletal muscle relaxant that relieves stiffness, pain, and discomfort caused by muscle injuries. Its mechanism of action is not clear yet; perhaps due to its sedative actions. (NCI04)","Carisoprodol | CARISOPRODOL | Soma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0108938","Cefpodoxime Proxetil","C28916","A third generation semi-synthetic cephalosporin and a beta-lactam antibiotic with bactericidal activity. Cefpodoxime's effect is dependent on its binding to penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. Binding results in the inhibition of the transpeptidase enzymes, thereby preventing cross-linking of the pentaglycine bridge with the fourth residue of the pentapeptide and interrupting consequent synthesis of peptidoglycan chains. As a result, cefpodoxime inhibits bacterial septum and cell wall synthesis formation.","Cefpodoxime Proxetil | CEFPODOXIME PROXETIL | Vantin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700860","Ceftazidime Sodium","C355","The sodium salt of ceftazidime, a third-generation cephalosporin antibiotic with bactericidal activity. Ceftazidime binds to and inactivates penicillin-binding proteins (PBPs), enzymes located on the inner membrane of the bacterial cell wall, resulting in the weakening of the bacterial cell wall and cell lysis. Compared to the second and first generation cephalosporins, ceftazidime is more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftazidine also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS). PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity.","Ceftazidime Sodium | CEFTAZIDIME SODIUM | Tazicef",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035750","Ceftriaxone Sodium","C817","The sodium salt form of ceftriaxone, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Ceftriaxone binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, ceftriaxone is more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftriaxone also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS).","Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Rocephin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054836","Carvedilol","C28906","A synthetic antihypertensive methoxyphenoxy- 2-propanol derivative with no intrinsic sympathomimetic activity, Carvedilol acts as a nonselective beta-adrenoceptor blocking agent (S(-) enantiomer) and as an alpha 1-adrenoceptor blocker (R(+) and S(-) enantiomers). Its acts more strongly on beta-receptors than on alpha 1-receptors, reduces peripheral vascular resistance by vasodilation, and prevents reflex tachycardia (beta-blockade) so that heart rate is either unchanged or decreased. Carvedilol also reduces renin release through beta-blockade. (NCI04)","Carvedilol | CARVEDILOL | Coreg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205705","Casanthranol","C28907","A concentrated mixture of anthranol glycosides from cascara sagrada (dried bark of Rhamnus p.) and used as a laxative in constipation and various medical conditions, stimulant laxative Casanthranol encourages bowel movements by acting on the intestinal wall to increase muscle contractions. (NCI04)","Casanthranol | CASANTHRANOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0307257","Peri-Colace","C28908","A combination of laxatives, Casanthranol Docusate is used in constipation and various medical conditions. Casanthranol is a concentrated mixture of anthranol glycosides from cascara sagrada (dried bark of Rhamnus p.) and a stimulant laxative that encourages bowel movements by acting on the intestinal wall to increase muscle contractions. A surface-active emollient, stool softener Docusate helps liquids to mix into dry stool, allowing patients to have a bowel movement without straining. (NCI04)","Casanthranol/Docusate | Peri-Colace",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205704","Frangula purshiana Bark","C28909","Used as a laxative in constipation and various medical conditions, Cascara (cascara sagrada) is dried bark of Picramnia sp. (Simarubaceae) or Rhamnus purshiana (Rhamnaceae) containing stimulant laxative anthranol glycosides that act on the intestinal wall to increase muscle contractions and encourage bowel movements. (NCI04)","Frangula purshiana Bark | Bearberry Bark | Cascara | Cascara | Cascara Bitterless Bark Extract | Cascara Fluidextract, Aromatic | FRANGULA PURSHIANA BARK | Rhamnus purshiana Bark | Sacred Bark",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0537894","Caspofungin","C28910","An antimycotic echinocandin lipopeptide, semisynthetically derived from a fermentation product of the fungus Glarea lozoyensis. Caspofungin inhibits 1,3-beta-glucan synthase, resulting in decreased synthesis of beta(1,3)-D-glucan (an essential component of the fungal cell wall), weakening of the fungal cell wall, and fungal cell wall rupture. This agent is active against Aspergillus and Candida species.","Caspofungin | CASPOFUNGIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007537","Cefaclor","C28911","A beta-lactam, second-generation cephalosporin antibiotic with bactericidal activity. Cefaclor binds to and inactivates penicillin-binding proteins (PBP) located in bacterial cytoplasmic membranes. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.","Cefaclor | CEFACLOR | Cefaclor Hydrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007538","Cefadroxil","C28912","A semi-synthetic, beta-lactam, first-generation cephalosporin antibiotic with bactericidal activity. Cefadroxil binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.","Cefadroxil | (6R,7R)-7-(((2R)-Amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic Acid | CEFADROXIL | Duricef",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007546","Cefazolin","C28913","A beta-lactam antibiotic and first-generation cephalosporin with bactericidal activity. Cefazolin binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.","Cefazolin | (6R,7R)-3-(((5-Methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(2-(1H-tetrazol-1-yl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic Acid | CEFAZOLIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0060405","Cefdinir","C28914","A semi-synthetic cephalosporin and a beta-lactam antibiotic with bactericidal activity. Cefdinir's effect is dependent on its binding to penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. Binding results in the inhibition of the transpeptidase enzymes, thereby preventing cross-linking of the pentaglycine bridge with the fourth residue of the pentapeptide and interrupting consequent synthesis of peptidoglycan chains. As a result, cefdinir inhibits bacterial septum and cell wall synthesis formation.","Cefdinir | CEFDINIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0771284","Cefepime Hydrochloride","C1041","The hydrochloride salt of a semi-synthetic, beta-lactamase-resistant, fourth-generation cephalosporin antibiotic derived from an Acremonium fungal species with broad-spectrum bactericidal activity. Administered parenterally, cefepime inhibits bacterial cell wall synthesis by binding to and inactivating penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity, resulting in a reduction of bacterial cell wall stability and cell lysis. This agent is more active against a variety of Gram-positive pathogens compared to third-generation cephalosporins.","Cefepime Hydrochloride | CEFEPIME HYDROCHLORIDE | Cefepime | Maxipime | Pyrrolidinium, 1-((7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methyl-, hydroxide, inner salt, (6R-(6alpha,7beta(Z)))-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700445","Cefotaxime Sodium","C2328","The sodium salt form of cefotaxime, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Cefotaxime sodium binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, cefotaxime sodium is more active against gram-negative bacteria and less active against gram-positive bacteria.","Cefotaxime Sodium | CEFOTAXIME SODIUM | Claforan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700446","Cefoxitin Sodium","C28915","The sodium salt form of cefoxitin, a beta-lactam, second-generation cephalosporin antibiotic with bactericidal activity. Cefoxitin sodium binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.","Cefoxitin Sodium | CEFOXITIN SODIUM | Mefoxin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0055147","Cetirizine","C1042","Cetirizine is a metabolite of hydroxyzine and a selective peripheral histamine H1-receptor antagonist. It is used for symptomatic treatment of seasonal and perennial allergic rhinitis and for chronic urticaria. (NCI)","Cetirizine | CETIRIZINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0053882","Cefprozil","C28917","A semi-synthetic cephalosporin and a beta-lactam antibiotic with bactericidal activity. Cefprozil's effect is dependent on its binding to penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. Binding results in the inhibition of the transpeptidase enzymes, thereby preventing cross-linking of the pentaglycine bridge with the fourth residue of the pentapeptide and interrupting consequent synthesis of peptidoglycan chains. As a result, cefprozil inhibits bacterial septum and cell wall synthesis formation.","Cefprozil | 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2R)-amino(4-hydroxyphenyl)acetyl)amino)-8-oxo-3-(1-propenyl)-, (6R,7R)- | BMY 28100 | CEFPROZIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0538927","Celecoxib","C1728","A nonsteroidal anti-inflammatory drug (NSAID) with a diaryl-substituted pyrazole structure. Celecoxib selectively inhibits cyclo-oxygenase-2 activity (COX-2); COX-2 inhibition may result in apoptosis and a reduction in tumor angiogenesis and metastasis.","Celecoxib | 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide | Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- | CELECOXIB | Celebrex | Elyxyb | Onsenal | SC-58635 | YM 177 | celecoxib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007716","Cephalexin","C356","A beta-lactam, first-generation cephalosporin antibiotic with bactericidal activity. Cephalexin binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to second and third generation cephalosporins, cephalexin is more active against gram-positive and less active against gram-negative organisms.","Cephalexin | CEPHALEXIN | Keflex | cephalexin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0724549","Cerivastatin Sodium","C28919","The sodium salt of cerivastatin, a synthetic lipid-lowering agent.","Cerivastatin Sodium | Baycol | CERIVASTATIN SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008161","Chloral Hydrate","C28922","A synthetic monohydrate of chloral with sedative, hypnotic, and anticonvulsive properties. Chloral hydrate is converted to the active compound trichloroethanol by hepatic alcohol dehydrogenase. The agent interacts with various neurotransmitter-operated ion channels, thereby enhancing gamma-aminobutyric acid (GABA)-A receptor mediated chloride currents and inhibiting amino acid receptor-activated ion currents. In addition, chloral hydrate enhances the agonistic effects of glycine receptors, inhibits AMPA-induced calcium influx in cortical neurons, and facilitates 5-HT 3 receptor-mediated currents in ganglionic neurons. Overall, this results in a depressive effect on the central nervous system.","Chloral Hydrate | CHLORAL HYDRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008163","Chlorambucil","C362","An orally-active antineoplastic aromatic nitrogen mustard. Chlorambucil alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  (NCI04)","Chlorambucil | .gamma.-(p-bis(2-chloroethyl)aminophenyl)butyric acid | .gamma.-[p-Di(2-chloroethyl)aminophenyl]butyric acid | .gamma.-[p-bis(2-chloroethyl)aminophenyl]butyric acid | 4-[Bis(2-chloroethyl)amino]benzenebutanoic acid | 4-[bis(2-chloroethyl)amino]benzenebutanoic acid | 4-[p-[Bis(2-chloroethyl)amino]phenyl]butyric acid | 4-[p-[bis(2-chloroethyl)amino]phenyl]butyric acid | Alti-chlorambucil | Ambochlorin | Amboclorin | Aminochlorambucil | Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]- (9CI) | Butyric acid, 4-(p-[bis(2-chloroethyl)amino]phenyl)- | Butyric acid, 4-(p-bis(2-chloroethyl)aminophenyl)- | CB 1348 | CB-1348 | CHL | CHLORAMBUCIL | Chlorambucilum | Chloraminophen | Chloraminophene | Chlorbutin | Chlorbutine | Chloroambucil | Chlorobutin | Chlorobutine | Ecloril | Elcoril | Leukeran | Leukersan | Leukoran | Linfolizin | Linfolysin | Lympholysin | N,N-Di-2-chloroethyl-.gamma.-p-aminophenylbutyric acid | N,N-di-2-chloroethyl-gamma-p-aminophenylbutyric acid | Phenylbutyric acid nitrogen mustard | WR-139013 | aminochlorambucil | benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]- (9CI) | butyric acid, 4-(p-bis(2-chloroethyl)aminophenyl) | chlorambucil | chlorbutinum | chloroambucil | gamma-(p-bis(2-chloroethyl)aminophenyl)butyric acid | gamma-[p-di(2-chloroethyl)aminophenyl]butyric acid | p-(N, N-Di-2-chloroethyl)aminophenyl butyric acid | p-(N, N-di-2-chloroethyl)aminophenyl butyric acid | p-N, N-Di-(.beta.-chloroethyl)aminophenyl butyric acid | p-N, N-di-(beta-chloroethyl)aminophenyl butyric acid | phenylbutyric acid nitrogen mustard",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008188","Chlordiazepoxide","C47443","A long-acting benzodiazepine with anxiolytic, sedative and hypnotic activity. Chlordiazepoxide exerts its effect by binding to the benzodiazepine site at the gamma-aminobutyric acid (GABA) receptor-chloride ionophore complex in the central nervous system (CNS). This leads to an increase in the opening of chloride channels, membrane hyperpolarization and increases the inhibitory effect of GABA on the CNS.","Chlordiazepoxide | 3H-1,4-Benzodiazepin-2-amine, 7-chloro-N-methyl-5-phenyl, 4-oxide | CHLORDIAZEPOXIDE | Librelease | Libritabs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0055361","Chlorhexidine Gluconate","C47974","The gluconate salt form of chlorhexidine, a biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine gluconate is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine gluconate penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.","Chlorhexidine Gluconate | CHLORHEXIDINE GLUCONATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008273","Chlorothiazide","C28924","A short-acting, benzothiadiazinesulfonamide derivative and prototypical thiazide diuretic. Chlorothiazide is excreted unchanged by the kidneys.","Chlorothiazide | CHLOROTHIAZIDE | Diuril",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0546857","Chlorpheniramine Maleate","C28925","A synthetic alkylamine derivative used in allergic reactions, hay fever, rhinitis, urticaria, and asthma, antihistamine Chlorpheniramine Maleate acts as a competitive histamine H1 receptor antagonist, and displays anticholinergic and mild sedative effects as well. (NCI04)","Chlorpheniramine Maleate | CHLORPHENIRAMINE MALEATE | Chlor-Trimeton | gamma-(4-Chlorophenyl)-N,N-dimethyl-2-pyridinepropanamine (Z)-2-butenedioate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0699065","Chlorpromazine","C367","A phenothiazine and traditional antipsychotic agent with anti-emetic activity. Chlorpromazine exerts its antipsychotic effect by blocking postsynaptic dopamine receptors in cortical and limbic areas of the brain, thereby preventing the excess of dopamine in the brain. This leads to a reduction in psychotic symptoms, such as hallucinations and delusions. Chlorpromazine appears to exert its anti-emetic activity by blocking the dopamine receptors in the chemical trigger zone (CTZ) in the brain, thereby relieving nausea and vomiting.","Chlorpromazine | 2-Chloro-10-(3-(dimethylamino)propyl)phenothiazine | CHLORPROMAZINE | Chlor-PZ | Thorazine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008294","Chlorthalidone","C47449","A long acting thiazide-like diuretic of the sulfamoylbenzamide class that is devoid of the benzothiadiazine structure. Chlorthalidone directly inhibits sodium and chloride reabsorption on the luminal membrane of the early segment in the distal convoluted tubule (DCT) in the kidney. This leads to an increase in sodium, chloride, bicarbonate, and potassium secretion resulting in the excretion of water. In addition, this agent, like other thiazide diuretics, decreases calcium and uric acid secretion. In addition, this agent inhibits many carbonic anhydrase (CA) isoenzymes. Chlorthalidone is used in the treatment of high blood pressure, edema and congestive heart failure. The elimination half-life is about 40 to 50 hours.","Chlorthalidone | Benzenesulfonamide, 2-Chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)- | Benzenesulfonamide, 2-chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)- | CHLORTHALIDONE | Chlorphthalidolone | Hygroton | Thalitone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008296","Chlorzoxazone","C28926","A benzoxazolone derivative with mild sedative and centrally-acting muscle relaxant activities. Although its exact mechanism of action is unknown, chlorzoxazone (CZ) appears to act at the spinal cord and subcortical levels of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasms. This agent is extensively hydroxylated by cytochrome P450 2E1 (CYP2E1) to 6-hydroxychlorzoxazone (HCZ),11,12 which is subsequently glucuronidated and eliminated renally. Highly selective for CYP2E1, CZ may be used as a selective probe for phenotyping CYP2E1 in humans; the ratio of HCZ-to-CZ plasma concentrations obtained 2 to 4 hours after oral administration of CZ may be used as a phenotypic measure of CYP2E1 enzymatic activity.","Chlorzoxazone | CHLORZOXAZONE | Paraflex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008466","Chondroitin Sulfate","C28141","Derivatives of chondroitin which have a sulfate moiety esterified to the galactosamine moiety of chondroitin. Chondroitin sulfate A, or chondroitin 4-sulfate, and chondroitin sulfate C, or chondroitin 6-sulfate, have the sulfate esterified in the 4- and 6-positions, respectively. Chondroitin sulfate B (beta heparin; DERMATAN SULFATE) is a misnomer and this compound is not a true chondroitin sulfate.","Chondroitin Sulfate | chondroitin sulfate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025729","Methylcellulose","C29253","The methyl ether of cellulose with laxative activity. Methylcellulose is not absorbed by the intestines and attracts large amounts of water into the colon, thereby increasing viscosity, producing a softer and bulkier stool and stimulating the constriction of intestinal smooth muscles.","Methylcellulose | Citrucel | METHYLCELLULOSE, UNSPECIFIED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516487","Chlorzoxazone/Acetaminophen","C28927","Chlorzoxazone Acetaminophen is a combination of muscle relaxant (Chlorzoxazone) and anti-inflammatory analgesic (Acetaminophen) indicated in acute painful musculoskeletal diseases. The active principal metabolite of phenacetin, Acetaminophen appears to inhibit prostaglandin biosynthesis in the central nervous system and less in peripheral tissues. With mild sedative properties, centrally acting Chlorzoxazone inhibits muscle spasm at the spinal cord and subcortical levels of the brain. (NCI04)","Chlorzoxazone/Acetaminophen | Parafon Forte",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009074","Clotrimazole","C381","A synthetic, imidazole derivate with broad-spectrum, antifungal activity. Clotrimazole inhibits biosynthesis of sterols, particularly ergosterol, an essential component of the fungal cell membrane, thereby damaging and affecting the permeability of the cell membrane. This results in leakage and loss of essential intracellular compounds, and eventually causes cell lysis.","Clotrimazole | 1-[(2-Chlorophenyl)diphenylmethyl]-1H-imidazole | CLOT | CLOTRIMAZOLE | Gyne-Lotrimin | Lotrimin | Mycelex | Mycelex Troche",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008402","Cholestyramine","C28929","An anion exchange resin with hypolipidemic activity. Cholestyramine resin adsorbs and combines with bile acids in the intestine to form an insoluble complex, which is then excreted in the feces, resulting in an increased oxidation of cholesterol to bile acids, a decrease in low density lipoprotein in the plasma, and a decrease in serum cholesterol levels.","Cholestyramine | CHOLESTYRAMINE | Cholybar | Colestyramine | Duolite AP143 Resin | Questran | Questran Light",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0286079","Cidofovir","C1600","A synthetic, acyclic, monophosphate nucleotide analog of deoxycytidine with antiviral activity, and mostly used against cytomegalovirus (CMV). After incorporation into the host cell, cidofovir is phosphorylated by pyruvate kinases to its active metabolite cidofovir diphosphate. Cidofovir diphosphate, bearing structural similarity to nucleotides, competes with deoxycytosine-5-triphosphate (dCTP) for viral DNA polymerase and gets incorporated into the growing viral DNA strands. As a result, it prevents further DNA polymerization and disrupts DNA replication of viruses.","Cidofovir | 1(3-hydroxy-2-phosphonomethoxypropyl) Cytosine | CDV | CIDOFOVIR | Cidofovir Dihydrate | DRG-0145 | GS-0504 | HPMPC | Vistide | cidofovir",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008783","Cimetidine","C374","A histamine H(2)-receptor antagonist.  Enhancing anti-tumor cell-mediated responses, cimetidine blocks histamine's ability to stimulate suppressor T lymphocyte activity and to inhibit natural killer (NK) cell activity and interleukin-2 production.  Cimetidine also may inhibit tumor growth by suppressing histamine's growth-factor activity and blocking histamine-induced stimulation of vascular endothelial growth factor (VEGF), a pro-angiogenic growth factor. (NCI04)","Cimetidine | CIMETIDINE | Guanidine, N''-Cyano-N-Methyl-N'-(2-(((5-Methyl-1H-Imidazol-4-yl)Methyl)Thio)Ethyl)- | N-Cyano-N'-methyl-N''-[2-[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]guanidine | Tagamet | cimetidine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008809","Ciprofloxacin","C375","A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication.  This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04)","Ciprofloxacin | 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic Acid | CIPROFLOXACIN | Cipro | ciprofloxacin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0072916","Cisapride","C1210","A substituted piperidinyl benzamide prokinetic agent.  Cisapride facilitates release of acetylcholine from the myenteric plexus, resulting in increased gastrointestinal motility.  In addition, cisapride has been found to act as a serotonin agonist, stimulating type 4 receptors, and a serotonin 5-HT3 receptor antagonist. (NCI)","Cisapride | CISAPRIDE | Propulsid | cis-4-Amino-5-Chloro-N-(1-(3- (p-fluorophenoxy)propyl)-3-methoxy-4- piperidyl)-o-Anisamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0724555","Citalopram Hydrobromide","C28932","The orally bioavailable hydrobromide salt of the racemic bicyclic phthalene derivative citalopram with antidepressant activity. As a selective serotonin reuptake inhibitor (SSRI), citalopram selectively inhibits the CNS neuronal reuptake of serotonin, thereby potentiating serotonergic activity in the central nervous system (CNS). This agent has minimal effects on the CNS neuronal reuptake of norepinephrine (NE) and dopamine (DA).","Citalopram Hydrobromide | 1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile Monohydrobromide | CITALOPRAM HYDROBROMIDE | Celexa | Elopram | Lu 10-171-B | Seropram | citalopram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0546859","Clomiphene Citrate","C379","The citrate salt form of clomiphene, a triphenylethylene nonsteroidal ovulatory stimulant evaluated for antineoplastic activity against breast cancer. Clomiphene has both estrogenic and anti-estrogenic activities that compete with estrogen for binding at estrogen receptor sites in target tissues.  This agent causes the release of the pituitary gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to ovulation. (NCI04)","Clomiphene Citrate | 2-[p-(2-Chloro-1,2-diphenylvinyl)phenoxy]triethylamine Citrate | 2-[p-(2-Chloro-1,2-diphenylvinyl)phenoxy]triethylamine Citrate (1:1) | CLOMIPHENE CITRATE | Clomid | Clomiphene | Serophene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0056077","Coenzyme Q10","C916","A naturally occurring benzoquinone important in electron transport in mitochondrial membranes. Coenzyme Q10 functions as an endogenous antioxidant; deficiencies of this enzyme have been observed in patients with many different types of cancer and limited studies have suggested that coenzyme Q10 may induce tumor regression in patients with breast cancer. This agent may have immunostimulatory effects. (NCI04)","Coenzyme Q10 | 2-(3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecanyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione | Co-Q10 | CoQ10 | Coenzyme-Q | Q10 | UBIDECARENONE | Ubidecarenone | Ubiquinone 10 | coenzyme Q10 | ubiquinone | vitamin Q10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0717880","Lamivudine/Zidovudine","C28939","A combination of two synthetic nucleoside analogues with synergistic antiviral properties.  Lamivudine is phosphorylated intracellularly to its active 5'-triphosphate metabolite, lamivudine triphosphate (L-TP); zidovudine is phosphorylated to its active 5'-triphosphate metabolite, zidovudine triphosphate (ZDV-TP). These active metabolites inhibit human immunodeficiency virus (HIV) viral reverse transcriptase (RT) by incorporating into viral DNA and terminating viral DNA chain elongation. (NCI04)","Lamivudine/Zidovudine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0055856","Clarithromycin","C1054","A semisynthetic 14-membered ring macrolide antibiotic.  Clarithromycin binds to the 50S ribosomal subunit and inhibits RNA-dependent protein synthesis in susceptible organisms.  Clarithromycin has been shown to eradicate gastric MALT (mucosa-associated lymphoid tissue) lymphomas, presumably due to the eradication of tumorigenic Helicobacter pylori infection. This agent also acts as a biological response modulator, possibly inhibiting angiogenesis and tumor growth through alterations in growth factor expression. (NCI04)","Clarithromycin | 6-O-Methylerythromycin | Abbott-56268 | Biaxin | CLARITHROMYCIN | clarithromycin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008947","Clindamycin","C377","A semisynthetic broad spectrum antibiotic produced by chemical modification of the parent compound lincomycin. Clindamycin dissociates peptidyl-tRNA from the bacterial ribosome, thereby disrupting bacterial protein synthesis. (NCI04)","Clindamycin | 7-Chloro-7-deoxylincomycin | CLINDAMYCIN | Cleocin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0055895","Clobetasol Propionate","C28934","The propionate salt form of clobetasol, a topical synthetic corticosteroid with anti-inflammatory, anti-pruritic, and vasoconstrictive properties. Clobetasol propionate exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators. Specifically, clobetasol propionate appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from membrane phospholipids by phospholipase A2.","Clobetasol Propionate | CLOBETASOL PROPIONATE | Olux-E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009011","Clonazepam","C28935","A synthetic benzodiazepine derivative used for myotonic or atonic seizures, absence seizures, and photosensitive epilepsy, anticonvulsant Clonazepam appears to enhance gamma-aminobutyric acid receptor responses, although its mechanism of action is not clearly understood. It is seldom effective in generalized tonic-clonic or partial seizures. (NCI04)","Clonazepam | CLONAZEPAM | Klonopin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009014","Clonidine","C380","An imidazoline derivate and centrally-acting alpha-adrenergic agonist, with antihypertensive activity. Clonidine binds to and stimulates central alpha-2 adrenergic receptors, thereby reducing the amount of norepinephrine (NE) release and thus decreasing sympathetic outflow to the heart, kidneys, and peripheral vasculature. The reduction in sympathetic outflow leads to decreased peripheral vascular resistance, decreased blood pressure, and decreased heart rate. In addition, clonidine binds to imidazoline receptor subtype 1 (I1), which may also contribute to a reduction in blood pressure.","Clonidine | CLONIDINE | Catapres-TTS | N-(2,6-Dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine | clonidine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0633084","Clopidogrel Bisulfate","C2673","A thienopyridine with antiplatelet activity. Clopidogrel bisulfate irreversibly alters the platelet receptor for adenosine diphosphate (ADP), thereby blocking the binding of ADP to its receptor, inhibiting ADP-mediated activation of the glycoprotein complex GPIIb/IIIa, and inhibiting fibrinogen binding to platelets and platelet adhesion and aggregation. (NCI04)","Clopidogrel Bisulfate | CLOPIDOGREL BISULFATE | Plavix",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009079","Clozapine","C28936","A synthetic dibenzo-diazepine derivative, atypical antipsychotic Clozapine blocks several neurotransmitter receptors in the brain (dopamine type 4, serotonin type 2, norepinephrine, acetylcholine, and histamine receptors). Unlike traditional antipsychotic agents, it weakly blocks dopamine type 2 receptors. It relieves schizophrenic symptoms (hallucinations, delusions, dementia). (NCI04)","Clozapine | 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine | CLOZAPINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009214","Codeine","C383","A naturally occurring phenanthrene alkaloid and opioid agonist with analgesic, antidiarrheal and antitussive activities. Codeine mimics the actions of endogenous opioids by binding to the opioid receptors at many sites within the central nervous system (CNS). Stimulation of mu-subtype opioid receptors results in a decrease in the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline; in addition, the codeine metabolite morphine induces opening of G-protein-coupled inwardly rectifying potassium (GIRK) channels and blocks the opening of N-type voltage-gated calcium channels, resulting in hyperpolarization and reduced neuronal excitability. Stimulation of gut mu-subtype opioid receptors results in a reduction in intestinal motility and delayed intestinal transit times. Antitussive activity is mediated through codeine's action on the cough center in the medulla.","Codeine | CODEINE | Codeine Phosphate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009262","Colchicine","C385","An alkaloid isolated from Colchicum autumnale with anti-gout and anti-inflammatory activities. The exact mechanism of action by which colchicines exerts its effect has not been completely established. Colchicine binds to tubulin, thereby interfering with the polymerization of tubulin, interrupting microtubule dynamics, and disrupting mitosis. This leads to an inhibition of migration of leukocytes and other inflammatory cells, thereby reducing the inflammatory response to deposited urate crystals.  Colchicine may also interrupt the cycle of monosodium urate crystal deposition in joint tissues, thereby also preventing the resultant inflammatory response. Overall, colchicine decreases leukocyte chemotaxis/migration and phagocytosis to inflamed areas, and inhibits the formation and release of a chemotactic glycoprotein that is produced during phagocytosis of urate crystals.","Colchicine | (S)-N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)acetamide | COLCHICINE | Colcrys | Mitigare | colchicine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900124","Acetaminophen-based Oral Cough and Cold Preparation","C28940","A combination preparation containing the analgesic acetaminophen and a combination of one or more of the following agents: an antihistamine (chlorpheniramine maleate or brompheniramine maleate), the expectorant guaifenesin, the antitussive dextromethorphan maleate and/or the decongestant pseudoephedrine hydrochloride or phenylephrine hydrochloride. These preparations are used to relieve symptoms of cold, cough and flu.","Acetaminophen-based Oral Cough and Cold Preparation | Comtrex | Comtrex | Tylenol Multi Symptom",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0056391","Cortisone Acetate","C1058","The acetate salt form of cortisone, a synthetic or semisynthetic analog of the naturally occurring cortisone hormone produced by the adrenal glands with anti-inflammatory and immunomodulating properties. Cortisone acetate diffuses through the cell membrane and binds to nuclear glucocorticoid receptors. The receptor-ligand complex binds to promotor regions of certain genes and initiates RNA transcription. This results in an induction of synthesis of certain anti-inflammatory proteins while inhibiting the synthesis of certain inflammatory mediators.","Cortisone Acetate | 21-(Acetyloxy)-17-hydroxypregn-4-ene-3,11,20-trione | 6alpha,9Difluoro-11beta,17,21-trihydroxypregna-1,4- diene-3,20-dione 21-acetate 17- Butyrate | CORTISONE ACETATE | Cortisone acetate | Cortogen | Cortone | Cortone acetate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0936050","Cranberry","C28943","Fruit of the Cranberry plant, a Native American wetland plant, can be consumed whole or made into food products such as jellies and juices. Prevention of urinary tract infections by cranberries has been documented. Natural, unprocessed cranberries contain anthocyanidins, which prevent Escherichia coli, the typical cause urinary tract infections, from attaching to the urinary tract wall. Anthocyanidins are potent antioxidant substances. (NCI04)","Cranberry | CRANBERRY",,,,,,,,,,,,,,,"4026203","Cranberries",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0873188","Creatine Monohydrate","C28945","The monohydrate form of creatine similar or identical to endogenous creatine produced in the liver, kidneys, and pancreas. Creatine, in phosphate form, helps supply energy to muscle cells for contraction. After intense effort, when ATP deposits are depleted, creatine phosphate donates phosphate groups toward the fast synthesis of ATP. Dietary supplementation with creatine may improve muscle wasting associated with cancer and other chronic diseases.","Creatine Monohydrate | CREATINE MONOHYDRATE | Creatine Supplement | Creatine Supplement | N-(Aminoiminomethyl)-N-methylglycine Monohydrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012694","Cromolyn Sodium","C28946","The sodium salt form of cromolyn, a mast cell stabilizer with anti-inflammatory activity. Cromolyn sodium probably interferes with the antigen-stimulated calcium transport across the mast cell membrane, thereby inhibiting mast cell release of histamine, leukotrienes, and other substances that cause hypersensitivity reactions. Cromolyn sodium also inhibits eosinophil chemotaxis.","Cromolyn Sodium | 5,5'-[(2-Hydroxy-1,3-propanediyl)bis(oxy)]bis[4-oxo-4H-1-benzopyran-2-carboxylic Acid], Disodium Salt | CROMOLYN SODIUM | DSCG | Disodium Cromoglycate | Intal | Nasalcrom | Sodium Cromoglycate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773629","Vitamin B 12","C939","An essential nutrient and natural water-soluble vitamin of the B-complex family that must combine with an intrinsic factor for absorption by the intestine, Vitamin B12 (cyanocobalamin) is necessary for hematopoiesis, neural metabolism, DNA and RNA production, and carbohydrate, fat, and protein metabolism. B12 improves iron functions in the metabolic cycle and assists folic acid in choline synthesis. B12 metabolism is interconnected with that of folic acid. Vitamin B12 deficiency causes pernicious anemia, megaloblastic anemia, and neurologic lesions.","Cobalamin | B12 Vitamin | COBALAMIN | Cobalamin (1+) | VIT B12 | Vitamin B-12 | Vitamin B12 | Vitamin B12 | Vitamin-B12 | cobalamin | vitamin B12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0056732","Cyclobenzaprine","C28947","A centrally acting skeletal muscle relaxant with antidepressant activity. The exact mechanism of action of cyclobenzaprine has not been fully determined, but this drug seems to primarily act at the brain stem to reduce tonic somatic motor activity, influencing both gamma and alpha motor neurons leading to a reduction in muscle spasms.","Cyclobenzaprine | Amrix | CYCLOBENZAPRINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0587081","Laboratory Test Result","C36292","The outcome of a laboratory test.","Laboratory Test Result | LAB_RESULT | Lab Findings | Lab Value | Laboratory Finding | Laboratory Report | Labs | TEST RESULT | Test Result | test result | test_result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012203","Diethylstilbestrol","C433","A synthetic, nonsteroidal form of estrogen. A well-known teratogen and carcinogen, diethylstilbestrol inhibits the hypothalamic-pituitary-gonadal axis, thereby blocking the testicular synthesis of testosterone, lowering plasma testosterone, and inducing a chemical castration.","Diethylstilbestrol | (E)-4,4'-(1,2-diethyl-1,2-ethenediyl)bisphenol | .alpha., .alpha.'-Diethylstilbenediol | 3, 4-Bis(p-hydroxyphenyl)-3-hexene | 3,4-Bis(p-hydroxyphenyl)-3-hexene | 3-Hexene,3,4-bis(p-hydroxyphenyl)- | 4,4'-Dihydroxy-.alpha., .beta.-diethylstilbene | 4,4'-Dihydroxy-alpha,beta-diethylstilbene | Acnestrol | Alpha,alpha'-diethylstilbenediol | Antigestil | Apstil | Boestrol | Bufon | Cyren A | DES | DIETHYLSTILBESTROL | Diastyl | Diethylstilbenediol | Diethylstilbestrolum | Diethylstilboestrol | Distilbene | Domestrol | Estrobene | Estromenin | Estrosyn | Fonatol | Grafestrol | Makarol | Microest | Milestrol | Neo-Oestronol I | Oestrogenine | Oestromenin | Oestromensyl | Oestromon | Palestrol | Serral | Sexocretin | Sibol | Stilbestrol | Stilbetin | Stilboefral | Stilboestroform | Stilboestrol | Stilkap | Synestrin | Synthoestrin | Trans-bis-(hydroxy-4-phenyl)-3,4 hexene-3 | Vagestrol | diethylstilbestrol | diethylstilbestrol (DES)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011185","Prasterone","C2265","A synthetic form of dehydroepiandrosterone with potential chemopreventive activity.  Produced endogenously, dehydroepiandrosterone (DHEA) is an intermediate in the conversion of cholesterol to androgens and estrogens.  Although the mechanisms of action of exogenously administered DHEA have not been fully illuminated, they may result in both direct and indirect physiologic effects. Direct effects include GABA-a receptor complex and NMDA receptor modulation, and enhanced pancreatic beta cell insulin secretion and antiglucocorticoid activities. (NCI04)","Prasterone | 17-Hormoforin | 3beta-Hydroxyandrost-5-en-17-one | 5,6-Dehydroisoandrosterone | DHEA | Dehydroepiandrosterone | Dehydroisoandrosterone | Diandron | Fidelin | GL701 | PRASTERONE | Therapeutic Dehydroepiandrosterone | Therapeutic Dehydroepiandrosterone | dehydroepiandrosterone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448577","Deodorized Tincture of Opium","C28968","An opium tincture with antidiarrheal activity. The opiate morphine, in deodorized tincture of opium, increases the tone of the smooth muscle in the intestines. It stops the normal movement and slows down the passage of intestinal contents. This allows water to be absorbed from the liquid stool thereby decreasing diarrhea.","Deodorized Tincture of Opium | DTO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206461","Dalteparin","C1453","A low molecular weight, synthetic heparin. As an anticoagulant/antithrombotic agent, dalteparin binds to antithrombin and enhances the inhibition of Factor Xa. Compared to unfractionated heparins, the use of dalteparin is associated with lower incidences of osteoporosis and heparin-induced thrombocytopenia. (NCI04)","Dalteparin | DALTEPARIN | dalteparin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0663182","Daclizumab","C1569","A recombinant monoclonal antibody interleukin-2 receptor antagonist.  Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway.","Daclizumab | Anti-Tac | Anti-Tac Humanized Monoclonal Antibody | Anti-Tac Monoclonal Antibody | DACLIZUMAB | Dacliximab | Humanized Anti-Tac Monoclonal Antibody | Monoclonal Antibody Anti-Tac | Zenapax | daclizumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0717670","Denileukin Diftitox","C1476","A cytotoxic recombinant fusion protein consisting of the human cytokine interleukin-2 (IL-2) fused to diphtheria toxin fragments A and B, containing both the catalytic and translocation domains, with potential antineoplastic activity. Upon administration, the IL-2 moiety of denileukin difitox targets and binds to IL-2 receptors. After internalization by IL-2 receptor-expressing cells via endocytosis, denileukin difitox is proteolytically cleaved. This releases the catalytic domain of the toxin moiety, which catalyzes the transfer of the ADP-ribose moiety of NAD to a diphthamide residue of elongation factor 2 (EF-2). This covalent modification inactivates EF-2 and disrupts polypeptide chain elongation, resulting in an inhibition of translation and cell death.","Denileukin Diftitox | DAB(389)-Interleukin-2 | DAB(389)IL-2 | DAB-IL2 | DAB389 Interleukin-2 | DAB389 Interleukin-2 Immunotoxin | DAB389IL-2 | DAB389IL2 | DABIL2 | DENILEUKIN DIFTITOX | Denileukin Diftitox-cxdl | Denileukin diftitox | Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein E7777 | E7777 | Interleukin-2 Fusion Protein | Interleukin-2 Fusion Toxin | LY 335348 | LY-335348 | LY335348 | Lymphir | Ontak | Remitoro | denileukin diftitox",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0353453","Danaparoid Sodium","C28971","The sodium salt form of danaparoid, a synthetic low molecular weight heparin (LMWH) derived from porcine gut mucosa with anticoagulant activity. Danaparoid sodium binds to antithrombin III and inhibits the activity of activated factor X (factor Xa) and, to a lesser extent, activated factor II (thrombin) thereby preventing fibrin formation. Compared to heparin, danaparoid sodium exhibits a much higher ratio of anti-factor Xa activity to anti-factor IIa activity (22:1).","Danaparoid Sodium | DANAPAROID SODIUM | Orgaran",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010961","Danazol","C414","A synthetic androgen derived from ethinyl testosterone.  Danazol indirectly reduces estrogen production by decreasing pituitary secretion of follicle-stimulating hormone and luteinizing hormone, and binds to sex hormone receptors in target tissues, thereby exhibiting antiestrogenic, anabolic and weakly androgenic effects. (NCI04)","Danazol | (17Alpha)-pregna-2,4-dien-20-yno[2,3-d]-isoxazol-17-ol | (17alpha)-Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol | 1-Ethynyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-10a,12a-dimethyl-1H-cyclopental[7,8]phenanthro[3,2-d]isoxazol-1-ol | 17Alpha-ethynyl-17beta-hydroxy-4-androsteno[2,3-d]isoxazole | Bonzol | Chronogyn | Cyclomen | DAN | DANAZOL | Danocrine | Danol | Danoval | Ladogal | Win 17757 | Win-17757 | Winobanin | danazol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0937950","Darbepoetin Alfa","C1878","A recombinant analog of the endogenous cytokine erythropoietin, an erythropoiesis-stimulating protein.  Due to the addition of two carbohydrate chains, darbepoetin alfa exhibits a three-fold greater half-life than does erythropoietin.  Similar to erythropoietin, darbopoietin alfa binds to and activates epoetin receptors, thereby inducing the differentiation and maturation of erythrocyte progenitors, stimulating endothelial cell proliferation, and stimulating B-cell proliferation and immunoglobulin production. (NCI04)","Darbepoetin Alfa | Aranesp | DARBEPOETIN ALFA | Darbepoetin alfa | NESP | Nespo | Novel Erythropoiesis Stimulating Protein | darbepoetin alfa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0719665","Dayquil","C28973","A daytime non-drowsy preparation used to relieve common cold and flu symptoms. Dextromethorphan, one of the active ingredients, exerts its activity by raising the threshold for coughing in the cough center. Another ingredient of Dayquil, phenylephrine, a post-synaptic alpha-adrenergic receptor agonist, induces vasoconstriction, and thereby reduces blood flow, decreases swelling and prevents nasal and sinus congestion.","Dayquil | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0049065","Decitabine","C981","A cytidine antimetabolite analogue with potential antineoplastic activity. Decitabine incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. (NCI04)","Decitabine | 2'-Deoxy-5-azacytidine | 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one | 5-Aza-2'-deoxycytidine | 5-Aza-2'deoxycytidine | 5-Aza-2-deoxycytidine | 5-Azadeoxycytidine | DECITABINE | Dacogen | Decitabine for Injection | Deoxyazacytidine | Dezocitidine | decitabine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0543492","Delavirdine Mesylate","C28974","A mesylate salt form of delavirdine, a synthetic, non-nucleoside reverse transcriptase inhibitor. In combination with other anti-retroviral drugs, this agent has been shown to reduce HIV viral load and increase CD4 leukocyte counts in patients. As an inhibitor of the cytochrome P450 system, delavirdine may result in increased serum levels of co-administered protease inhibitors metabolized by the cytochrome P450 system.","Delavirdine Mesylate | DELAVIRDINE MESYLATE | Delavirdine Monomethanesulfonate | Piperazine, 1-(3-((1-Methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulfonyl)amino)-1H-indol-2-yl)carbonyl)-, Monomethanesulfonate | Rescriptor | U 90152 | U-90 | U-90152 | U90 | U90152",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004963","Diphenhydramine Hydrochloride","C300","The hydrochloride salt form of diphenhydramine, an ethanolamine and first-generation histamine antagonist with anti-allergic activity. Diphenhydramine hydrochloride competitively blocks H1receptors, thereby preventing the actions of histamine on bronchial smooth muscle, capillaries, and gastrointestinal (GI) smooth muscle. This prevents histamine-induced bronchoconstriction, vasodilation, increased capillary permeability, and GI smooth muscle spasms.","Diphenhydramine Hydrochloride | Benadryl | Bendylate | DIPHENHYDRAMINE HYDROCHLORIDE | Diphenhydramine hydrochloride | Diphenhydramine.HCl | Eldadryl | SK-Diphenhydramine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012265","Digoxin","C28990","A cardiac glycoside. Digoxin inhibits the sodium potassium adenosine triphosphatase (ATPase) pump, thereby increasing intracellular calcium and enhancing cardiac contractility.  This agent also acts directly on the atrioventricular node to suppress conduction, thereby slowing conduction velocity.  Apparently due to its effects on intracellular calcium concentrations, digoxin induces apoptosis of tumor cells via a pathway involving mitochondrial cytochrome c and caspases 8 and 3. (NCI04)","Digoxin | 12beta-Hydroxydigitoxin | 3beta,12beta,14-Trihydroxy-5beta,14beta-card-20(22)-enolid-3-tridigitoxosid | Cardiogoxin | DIGOXIN | Digoxigenin-tridigitoxosid | Lanoxin | digoxin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700940","Diltiazem Hydrochloride","C398","A benzothiazepine calcium channel blocking agent. Diltiazem hydrochloride inhibits the transmembrane influx of extracellular calcium ions into select myocardial and vascular smooth muscle cells, causing dilatation of coronary and systemic arteries and decreasing myocardial contractility.  Because of its vasodilatory activity, this agent has been shown to improve the microcirculation in some tumors, thereby potentially improving the delivery of antineoplastic agents to tumor cells. (NCI04)","Diltiazem Hydrochloride | Cardizem | DILTIAZEM HYDROCHLORIDE | Diltiazem HCl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012381","Dimenhydrinate","C28992","An ethanolamine and first-generation histamine antagonist with anti-allergic activity. Dimenhydrinate competitively blocks H1 receptors, thereby preventing the actions of histamine on bronchial smooth muscle, capillaries and gastrointestinal (GI) smooth muscle. This prevents histamine-induced bronchoconstriction, vasodilation, increased capillary permeability, GI smooth muscle spasm.","Dimenhydrinate | DIMENHYDRINATE | Dramamine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0114064","Dimetapp","C28993","A commercial combination preparation, by Wyeth, containing brompheniramine maleate and phenylpropanolamine hydrochloride, with antihistaminergic and vasoconstrictive properties. Brompheniramine maleate, a propylamine antihistamine binds to and blocks H1 receptors thereby preventing the actions of histamine. Phenylpropanolamine hydrochloride is a decongestant that causes constriction of blood vessels mediated through its alpha-adrenergic signaling, thereby reducing blood flow and improving nasal air flow. Dimetapp is used to relieve nasal congestion and to treat rhinitis.","Dimetapp | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0058379","Diphencyprone","C28994","A synthetic, potent allergic contact sensitizer with potential immunostimulatory activity. After sensitization process by repeated topical application of diphencyprone to a specific area, further application of this agent to the affected area may stimulate an immune response and may potentially be useful to clear the affected area from infection or cancer.","Diphencyprone | DIPHENCYPRONE | DPCP | Diphenylcyclopropenone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0048470","Argatroban","C28833","A synthetic derivative of L-arginine with antithrombotic activity. Argatroban is a univalent and direct inhibitor of fibrin-bound thrombin. This agent reversibly binds to the thrombin active site thereby preventing the thrombin-dependent reactions, which include conversion of fibrinogen to fibrin; the activation of factors V, VIII and XI; the activation of protein C; and platelet aggregation. Argatroban is highly selective for thrombin and is able to inhibit the action of both free and clot-associated thrombin. As a result, stabilization of blood clots and coagulation is inhibited.","Argatroban | 1-[5-guanidino-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methyl-piperidine-2-carboxylic acid | ARGATROBAN | Argipidine | MD-805",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282145","Diphenoxylate Hydrochloride","C28995","The hydrochloride salt form of diphenoxylate, a piperidine derivate, chemically related to narcotic meperidine, with antidiarrheal activity and devoid of central nervous system (CNS) activity. Diphenoxylate acts on opioid receptors in the gastrointestinal tract, thereby decreasing gastrointestinal motility and causing constipation or preventing diarrhea.","Diphenoxylate Hydrochloride | DIPHENOXYLATE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013090","Doxycycline","C457","A synthetic, broad-spectrum tetracycline antibiotic exhibiting antimicrobial activity. Doxycycline binds to the 30S ribosomal subunit, possibly to the 50S ribosomal subunit as well, thereby blocking the binding of aminoacyl-tRNA to the mRNA-ribosome complex. This leads to an inhibition of protein synthesis. In addition, this agent has exhibited inhibition of collagenase activity.","Doxycycline | DOXYCYCLINE | Doxycycline Monohydrate | doxycycline",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0546862","Econazole Nitrate","C47506","An imidazole derivative and broad-spectrum antimycotic agent with fungistatic properties. Econazole nitrate inhibits biosynthesis of ergosterol, thereby damaging the fungal cell wall membrane and altering its permeability which leads to a loss of essential intracellular components. In addition, econazole nitrate inhibits biosynthesis of triglycerides and phospholipids and inhibits oxidative and peroxidative enzyme activity which may contribute to cellular necrosis and cell death. Econazole nitrate is also active against some gram positive bacteria. This antifungal agent is used in the treatment various dermatomycoses.","Econazole Nitrate | 1-[2-{(4-chloro-phenyl)methoxy}-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole Mononitrate | ECONAZOLE NITRATE | Ifenec | Pevaryl | R 14827 | Spectazole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0908935","Desloratadine","C47474","A long-acting piperidine derivate with selective H1 antihistaminergic and non-sedating properties. Desloratadine diminishes the typical histaminergic effects on H1-receptors in bronchial smooth muscle, capillaries and gastrointestinal smooth muscle, including vasodilation, bronchoconstriction, increased vascular permeability, pain, itching and spasmodic contractions of gastrointestinal smooth muscle. Desloratadine is used to provide symptomatic relieve of allergic symptoms.","Desloratadine | 5H-Benzo(5,6)cyclohepta(1,2-b)pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)- | Clarinex | DESLORATADINE | Sch 34117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0701195","Desmopressin Acetate","C47475","An analogue of the hormone vasopressin with antidiuretic and antihemorrhagic properties. Desmopressin acetate has selective affinity for the V2 receptor and acts on the distal kidney tubule by increasing the cellular permeability thereby stimulating water reabsorption. This antidiuretic agent is used in the treatment of central diabetes insipidus. An unrelated action of desmopressin acetate is to increases circulating factor VIII and is used in patients with haemophilia and von Willebrand's disease.","Desmopressin Acetate | 1-(3-Mercaptopropionic acid)-8-D-arginine Vasopression Monoacetate | Concentraid | DDAVP | DESMOPRESSIN ACETATE | Octostim | Stimate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011812","Dextroamphetamine","C28981","A synthetic substance related to natural sympathomimetic amines and the synthetic agent amphetamine. In the central nervous system (CNS), dextroamphetamine induces the release of dopamine within the mesocorticolimbic system, a major component of the brain reward system, resulting in measurable behavioral changes such as euphoria. As a CNS stimulant, this agent may increase blood pressure and reduce appetite. Similar to other amphetamines, dextroamphetamine has a high potential for abuse, dependence, and addiction if used in large doses over extended periods of time. (NCI04)","Dextroamphetamine | (+)-Amphetamine | DEXTROAMPHETAMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0350422","Dextromethorphan Hydrobromide","C423","The hydrobromide salt form of dextromethorphan, a synthetic, methylated dextrorotary analogue of levorphanol, a substance related to codeine and a non-opioid derivate of morphine. Dextromethorphan exhibits antitussive activity and is devoid of analgesic or addictive property. This agent crosses the blood-brain-barrier and activates sigma opioid receptors on the cough center in the central nervous system, thereby suppressing the cough reflex.","Dextromethorphan Hydrobromide | DEXTROMETHORPHAN HYDROBROMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012010","Diazepam","C28982","A benzodiazepine derivative with anti-anxiety, sedative, hypnotic and anticonvulsant properties. Diazepam potentiates the inhibitory activities of gamma-aminobutyric acid (GABA) by binding to the GABA receptor, located in the limbic system and the hypothalamus. This increases the frequency of chloride channel opening, allowing the flow of chloride ions into the neuron and ultimately leading to membrane hyperpolarization and a decrease in neuronal excitability.","Diazepam | 7-Chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one | DIAZEPAM | Valium | diazepam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012050","Dibucaine","C28984","A quinoline derivative and amino amide with anesthetic activity. Dibucaine reversibly binds to and inactivates sodium channels in the neuronal cell membrane. Inhibition of sodium channels prevents the depolarization of nerve cell membranes and inhibits subsequent propagation of impulses along the course of the nerve, thereby limiting the excitation of nerve endings. This results in loss of sensation.","Dibucaine | Cinchocaine | DIBUCAINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012091","Diclofenac","C28985","A nonsteroidal benzeneacetic acid derivative with anti-inflammatory activity.  As a nonsteroidal anti-inflammatory drug (NSAID), diclofenac binds and chelates both isoforms of cyclooxygenase (COX-1 and-2), thereby blocking the conversion of arachidonic acid to pro-inflammatory-proprostaglandins.  This agent also may inhibit COX-2-mediated tumor angiogenesis.  When inhibiting COX-2, diclofenac may be effective in relieving pain and inflammation; when inhibiting COX-1, it may produce unacceptable gastrointestinal side effects.  This agent may be more active against COX-2 than several other carboxylic acid-containing NSAIDs. (NCI04)","Diclofenac | 2-[(2,6-Dichlorophenyl)amino]benzeneacetic Acid | DICLOFENAC | diclofenac",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012093","Dicloxacillin","C28986","A broad-spectrum, semi-synthetic, beta-lactam, penicillin antibiotic with bactericidal and beta-lactamase resistant activity. Dicloxacillin binds to penicillin binding proteins (PBP) located on the inner membrane of the bacterial cell wall.  It also inhibits the cross-linkage of peptidoglycan, a critical component of bacterial cell walls. This leads to the inhibition of bacterial cell wall synthesis and eventually causes cell lysis.","Dicloxacillin | 3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolylpenicillin | DICLOXACILLIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0733440","Fosinopril Sodium","C47542","The sodium salt of fosinopril, a phosphinic acid-containing angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. Fosinopril sodium is an ester prodrug that is hydrolysed by esterases to its active metabolite fosinoprilat. Fosinoprilat specifically and competitively inhibits angiotensin-converting enzyme thereby decreasing the formation of the potent vasoconstrictor angiotensin II, resulting in diminished vasopressor activity. In addition, angiotensin II-mediated aldosterone secretion by adrenal cortex is decreased, which results in a decrease of sodium retention and an increase of serum potassium. (NCI05)","Fosinopril Sodium | Eliten | FOSINOPRIL SODIUM | L-proline, 4-Cyclohexyl-1-[[[2-methyl-1-(1-oxopropoxy) propoxyl](4-phenylbutyl) phosphinyl]acetyl]-,Sodium Salt, trans- | Monopril | Newace",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016410","Folic Acid","C510","A collective term for pteroylglutamic acids and their oligoglutamic acid conjugates. As a natural water-soluble substance, folic acid is involved in carbon transfer reactions of amino acid metabolism, in addition to purine and pyrimidine synthesis, and is essential for hematopoiesis and red blood cell production. (NCI05)","Folic Acid | 2-[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]aminopentanedioic acid | FA | FOLIC ACID | Ffolate | Folacin | Folic acid | N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid | N-[4-[[(2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic Acid | Pteroylmonoglutamic Acid | Vitamin B9 | Vitamin Bc | folic acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0146934","Foscarnet Sodium","C1193","The trisodium salt of a synthetic organic analogue of inorganic pyrophosphate with antiviral activity. Foscarnet selectively blocks the pyrophosphate binding site of herpesvirus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases. This agent does not require phosphorylation by thymidine kinase (TK) or other kinases and therefore is active in vitro against herpes simplex virus (HSV) TK deficient mutants and cytomegalovirus (CMV) UL97 mutants. Because foscarnet crosses the blood brain barrier, it may be used in the treatment of viral infections of the CNS.","Foscarnet Sodium | FOSCARNET SODIUM | Foscavir | Phosphonoformate Trisodium | foscarnet sodium | phosphonoformate trisodium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017066","Ganciclovir","C517","A synthetic guanine derivative with antiviral activity.  As the active metabolite of ganciclovir, ganciclovir-5-triphosphate (ganciclovir-TP) appears to inhibit viral DNA synthesis by competitive inhibition of viral DNA polymerases and incorporation into viral DNA, resulting in eventual termination of viral DNA elongation.","Ganciclovir | 2'-Nor-2'-deoxyguanosine | 2'NDG | 2-Amino-1,9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-6H-purin-6-one | 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine | Cymevan | DHPG | GANCICLOVIR | GCV | Nordeoxyguanosine | Virgan | ganciclovir",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0753645","Gatifloxacin","C29070","A synthetic 8-methoxyfluoroquinolone with antibacterial activity against a wide range of gram-negative and gram-positive microorganisms. Gatifloxacin exerts its effect through inhibition of DNA gyrase, an enzyme involved in DNA replication, transcription and repair, and inhibition of topoisomerase IV, an enzyme involved in partitioning of chromosomal DNA during bacterial cell division.","Gatifloxacin | 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid | AM-1155 | BMS-206584-01 | GATIFLOXACIN | Gatiflo | Tequin | Zymar",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017245","Gemfibrozil","C29071","A fibric acid derivative with hypolipidemic effects. Gemfibrozil interacts with peroxisome proliferator-activated receptors (PPARalpha) resulting in PPARalpha-mediated stimulation of fatty acid oxidation and an increase in lipoprotein lipase (LPL) synthesis. This enhances triglyceride-rich lipoprotein clearance and reduces the expression of apolipoprotein C-III (apoC-III). The reduction in hepatic production of apoC-III results in subsequent reduction of serum levels of very-low-density-lipoprotein cholesterol (VLDL-C). In addition, gemfibrozil-mediated PPARalpha stimulation of apoA-I and apoA-II expression results in an increase in high-density lipoprotein cholesterol (HDL-C).","Gemfibrozil | GEMFIBROZIL | Lopid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017436","Gentamicin","C519","A broad-spectrum aminoglycoside antibiotic produced by fermentation of Micromonospora purpurea or M. echinospora. Gentamicin is an antibiotic complex consisting of four major (C1, C1a, C2, and C2a) and several minor components. This agent irreversibly binds to the bacterial 30S ribosomal subunit. Specifically, this antibiotic is lodged between 16S rRNA and S12 protein within the 30S subunit. This leads to interference with translational initiation complex, misreading of mRNA, thereby hampering protein synthesis and resulting in bactericidal effect. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses.","Gentamicin | GENTAMICIN | Garamicin | Garamycin | Genoptic | Genoptic S.O.P. | Gentamycin | Gentamycin Complex | U-Gencin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005770","Blood Banks","C51963","An establishment that collects, tests, processes, and stores blood and its components intended for transfusion or for further manufacture into products used for biological therapies.","Blood Bank | BLOOD BANK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704640","Matrix Array","C45802","A rectangular array of elements (or entries) set out by rows and columns.","Matrix | Matrix Array",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704725","Statistical Confidence","C49020","The statistical calculation of the percentage likelihood for a given set of data to have a given statistical value.","Statistical Confidence | Confidence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706241","Low Complexity Region","C49032","A protein region consisting of a very small variety of residues, including homopolymeric runs, short-period repeats, and more subtle overrepresentation of one or a few residues. (from BioInformatics Glossary: big.mcw.edu)","Low Complexity Region | LCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512488","Homologous Protein","C40992","A protein similar in structure and evolutionary origin to a protein in another species.","Homologous Protein | Protein Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709461","Paralogous Gene","C49108","A gene related to a similar gene by duplication within a genome.","Paralogous Gene | Paralog | Paralogous Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706765","Alignment","C49033","The act of adjusting or aligning objects in relation to each other; the result of this activity.","Alignment | Aligned",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205280","Identical","C49034","Exactly alike; incapable of being perceived as different; being the exact same one; coinciding exactly when superimposed; having properties with uniform values along all axes.","Identical | ",,,,,,,,,,,,,,,"4067323","Identical",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512489","Homology Modeling","C19234","An approach to modeling a protein structure based on an initial sequence alignment to a protein with a known 3D structure.  After evaluating and resolving structural irregularities in the initial model, it may be further refined using energy minimization and other procedures.","Homology Modeling | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600115","Molecular Modeling","C18148","The computer simulation of chemical structures or processes; allows for the exploration, visualization, and manipulation of molecular structures and properties.","Molecular Modeling | Nucleic Acid Biochemistry, Molecular Modeling | Protein/Amino Acid Biochemistry, Molecular Modeling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708585","JPred","C49036","A consensus protein secondary structure prediction server; http://barton.ebi.ac.uk/servers/jpred.html.","JPred | Jpred",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704769","Programming Parameter","C48913","A value that is passed to a routine.","Programming Parameter | Argument | Input Parameter | Parameter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0950143","Swiss-Prot","C43819","Swiss-Prot is a protein knowledgebase established in 1986 and maintained collaboratively, since 1987, by the Department of Medical Biochemistry of the University of Geneva (now the Swiss Institute of Bioinformatics) and the EMBL Data Library.  It is a curated protein sequence database which strives to provide a high level of annotation (such as the description of the function of a protein, its domains structure, post-translational modifications, variants, etc.), a minimal level of redundancy and high level of integration with other databases.","Swiss-Prot | Swissprot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162807","Secondary Protein Structure","C13302","The specific 3-dimensional folded protein structure that is determined by the hydrogen bonds formed between amino acids in the polypeptide chain.","Secondary Protein Structure | Secondary Structure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705293","SEG Algorithm","C49037","A computer algorithm that provides a general method for partitioning the globular and non-globular regions of a protein sequence.","SEG Algorithm | SEG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162847","Protein Folding","C17568","The change in structure whereby a polypeptide assumes its functional shape or conformation. This is a process that occurs during either protein biosynthesis or protein reconstitution. Polypeptide chains assume their correct three-dimensional conformation through discrete intermediate (primary, secondary, and tertiary) structures prior to the development final quaternary structure.","Protein Folding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711223","TmHMM Algorithm","C49038","A computer algorithm that predicts trans-membrane helices based on the hidden Markov model.","TmHMM Algorithm | TmHMM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705318","Protein Data Bank","C49039","A worldwide repository for the processing and distribution of 3-D biological macromolecular structure data.","Protein Data Bank | PDB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708011","FFAS Algorithm","C49040","A profile-profile alignment algorithm that make structural predictions using sequence information.","FFAS Algorithm | FFAS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710083","SignalP Algorithm","C49043","An algorithm that predicts the presence and location of signal peptide cleavage sites in amino acid sequences. It incorporates a prediction of cleavage sites and a signal peptide/non-signal peptide prediction based on a combination of several artificial neural networks and hidden Markov models.","SignalP Algorithm | SignalP | SignalP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705945","COILS Program","C49044","A program that compares a sequence to a database of known parallel two-stranded coiled-coils and derives a similarity score. By comparing this score to the distribution of scores in globular and coiled-coil proteins, the program then calculates the probability that the sequence will adopt a coiled-coil conformation.","COILS Program | COILS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708374","HmmPfam Algorithm","C49045","A program that searches Hidden Markov Models from the PFAM database for significantly similar sequence matches to the input protein sequence.","HmmPfam Algorithm | HmmPfam | HmmPfam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710576","Unsolved","C49049","Lacking a solution, explanation, or answer.","Unsolved | Not Solved",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709915","Residue","C48795","A single unit within a polymer; a recognizable molecular fragment embedded in a larger molecule.","Residue | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709393","PDB BLAST","C49050","A protein profile search method designed to find distant homologs.","PDB BLAST | PDB-BLAST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516692","Coiled-Coil Domain","C13967","A domain that stabilizes alpha helices in proteins through a very efficient burial of hydrophobic side chains so that polar water molecules do not access them. As a result, the helices are quite stable. In fact, many structural proteins (keratins, tropomyosin, laminin) that have to bear considerable stress have a coiled-coil domain. Two basic essential features are common: (1) the overall secondary structure is alpha helical, (2) the hydrophobic residues are arranged on one side of the helices. The typical positioning of the hydrophobic residues in the coiled-coil domain can be often recognized from primary structure of the protein. The helices can be parallel or antiparallel. The former is common when the helices belong to different polypeptides and the latter prevails in coiled coils made up from a single polypeptide chain. The number of helices in the coil varies usually between 2 and 4.","Coiled-Coil Domain | 4-3 Hydrophobic Repeat | Coiled Coil | Coiled Coil Domain | Coiled-Coil | Left-Handed Twist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242596","Measurable Residual Disease","C3896","Evidence for remaining tumor following treatment that is only apparent using highly sensitive techniques.","Measurable Residual Disease | Detectable Residual Disease | MRD | Measurable Residual Disease | Minimal Residual Disease | Minimal Residual Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0061323","Glimepiride","C29073","A long-acting, third-generation sulfonylurea with hypoglycemic activity. Compared to other generations of sulfonylurea compounds, glimepiride is very potent and has a longer duration of action. This agent is metabolized by CYP2C9 and shows peroxisome proliferator-activated receptor gamma (PPARgamma) agonistic activity.","Glimepiride | Amaryl | GLIMEPIRIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017642","Glipizide","C29074","A short-acting, second-generation sulfonylurea with hypoglycemic activity. Glipizide is rapidly absorbed, has a very quick onset of action and a short half-life. This agent is extensively metabolized in the liver and the metabolites as well as the unchanged form are excreted in the urine.","Glipizide | GLIPIZIDE | Glucotrol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017720","Glucosamine Sulfate","C29075","An amino sugar (2-amino, 2-deoxyglucose) in cell membranes, Glucosamine Sulfate is believed to play a role in cartilage formation and repair. Long-term glucosamine sulfate treatment retards progression of knee osteoarthritis; the mechanism appears to involve glucosamine's role as an essential substrate for glycosaminoglycans and hyaluronic acid, needed for formation of the joint proteoglycan structural matrix. (NCI04)","Glucosamine Sulfate | GLUCOSAMINE SULFATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017628","Glyburide","C29076","A sulfonamide urea derivative with antihyperglycemic activity that can potentially be used to decrease cerebral edema. Upon administration, glyburide binds to and blocks the sulfonylurea receptor type 1 (SUR1) subunit of the ATP-sensitive inwardly-rectifying potassium (K(ATP)) channels on the membranes of pancreatic beta cells. This prevents the inward current flow of positively charged potassium (K+) ions into the cell, and induces a calcium ion (Ca2+) influx through voltage-sensitive calcium channels, which triggers exocytosis of insulin-containing granules. In addition, glyburide also inhibits the SUR1-regulated nonselective cation (NC) Ca-ATP channel, melastatin 4 (transient receptor potential cation channel subfamily M member 4; (TRPM4)), thereby preventing capillary failure and brain swelling. SUR1-TRPM4 channels are formed by co-assembly of SUR1 with TRPM4 in neurons, astrocytes, and capillary endothelium during cerebral ischemia. Upon ischemia-induced ATP depletion, channels open which results in sodium influx, cytotoxic edema formation, capillary fragmentation and necrotic cell death. SUR1-TRPM4 is not expressed in normal, uninjured tissues.","Glyburide | Diabeta | GLYBURIDE | Glibenclamide | Micronase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017861","Glycerin","C29077","A trihydroxyalcohol with localized osmotic diuretic and laxative effects. Glycerin elevates the blood plasma osmolality thereby extracting water from tissues into interstitial fluid and plasma. This agent also prevents water reabsorption in the proximal tubule in the kidney leading to an increase in water and sodium excretion and a reduction in blood volume. Administered rectally, glycerin exerts a hyperosmotic laxative effect by attracting water into the rectum, thereby relieving constipation. In addition, glycerin is used as a solvent, humectant and vehicle in various pharmaceutical preparations.","Glycerin | 1,2,3-Propanetriol | GLYCERIN | Glycerol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017970","Glycopyrrolate","C29078","A synthetic quaternary ammonium that is an anticholinergic agent with antispasmodic activity. Glycopyrrolate competitively binds to peripheral muscarinic receptors in the autonomic effector cells of, and inhibits cholinergic transmission in smooth muscle, cardiac muscle, the sinoatrial (SA) node, the atrioventricular (AV) node, exocrine glands and in the autonomic ganglia. Blockage of cholinergic transmission, in smooth muscle cells located in the gastrointestinal tract and the bladder, causes smooth muscle relaxation and prevents the occurrence of painful spasms. In addition, glycopyrrolate inhibits the release of gastric, pharyngeal, tracheal, and bronchial secretions.","Glycopyrrolate | GLYCOPYRROLATE | Glycopyrronium Bromide | Pyrrolidinium, 3-((Cyclopentylhydroxyphenylacetyl)oxy)-1,1-dimethyl-, Bromide | Robinul | Robinul Forte",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527251","Glyoktyl","C29079","A Danish brand name for a laxative product containing glycerin and docusate sodium.  As a hyperosmotic laxative, glycerin draws water into the bowel from surrounding tissues, thereby softening the stool and increasing bowel action.  Docusate sodium acts as a surface-active agent (emollient) that promotes the mixing of intestinal liquid and dry stool. (NCI04)","Glyoktyl | Glycerin/Docusate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0543476","Granisetron Hydrochloride","C1353","The hydrochloride salt of an indazole derivative with antiemetic properties. As a selective serotonin receptor antagonist, granisetron competitively blocks the action of serotonin at 5-hydroxytryptamine3 (5-HT3) receptors, resulting in the suppression of chemotherapy- and radiotherapy-induced nausea and vomiting.","Granisetron Hydrochloride | Endo-N-(9-methyl-9-azabicyclo [3.3.1] non-3-yl)-1-methyl-1H-indazole-3-carboxamide Hydrochloride | GRANISETRON HYDROCHLORIDE | Kytril | granisetron hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018305","Guaifenesin","C29081","A glyceryl guaiacolate with expectorant effects. Guaifenesin increases respiratory tract mucus secretions, acts as an irritant to gastric vagal receptors and recruits efferent parasympathetic reflexes that cause glandular exocytosis. This agent reduces the viscosity of mucus secretion by reducing adhesiveness and surface tension as well as increasing hydration of mucus. Guaifenesin promotes the efficiency of the mucociliary mechanism important in removing accumulated secretions from the upper and lower airway.","Guaifenesin | 3-(o-Methoxyphenoxy)-1,2-propanediol | GUAIFENESIN | Glyceryl Guaiacolate | Humibid | Mucinex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973052","ginseng","C26651","The aromatic root of the perennial herb Panax quinquefolius, native to eastern North America. American ginseng, used in Chinese traditional medicine and available as a nutritional supplement, is classified as an adaptogenic herb with multiple effects, many of which are regulatory in nature. It contains a complex mixture of saponin glycosides, also known as ginsenosides or panaxosides. Although the mechanism of action is unclear, this agent is reported to enhance the immune system and reduce fatigue.","American Ginseng | AMERICAN GINSENG | Ginseng | Ginseng | Ginseng Root | Panax quinquifolius | ginseng",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038317","Steroid Compound","C843","Compounds possessing the skeleton of cyclopenta[a]phenanthrene or a skeleton derived therefrom by one or more bond scissions or ring expansions or contractions. Methyl groups are normally present at C-10 and C-13. An alkyl side chain may also be present at C-17.  They include cholesterol, numerous hormones, precursors of certain vitamins, bile acids, alcohols (STEROLS), and certain natural drugs and poisons.","Steroid Compound | Steroid | Steroids | steroid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012984","Dog","C14201","The domestic dog, Canis familiaris.","Dog | CANIS FAMILIARIS | Canine | Canine Species | Canis canis | Canis domesticus | Canis familiaris | Canis lupus familiaris | DOG | Mammals, Dogs",,,,,,,,,,,,,,,"40491509","Domestic dog",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1521726","Partial Remission","C18058","A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","Partial Remission | Cancer in partial remission (finding) | PR | PR-Partial Response | Partial Response | Partial response | partial remission | partial response",,,,,,,,,,,,,,,"4014045","In partial remission",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016564","Formaldehyde","C29744","A colorless poisonous gas synthesized by the oxidation of methanol and used as an antiseptic, disinfectant, histologic fixative, and general-purpose chemical reagent for laboratory applications. Formaldehyde is readily soluble in water and is commonly distributed as a 37% solution in water; formalin, a 10% solution of formaldehyde in water, is used as a disinfectant and to preserve biological specimens. Environmentally, formaldehyde may be found in the atmosphere, smoke from fires, automobile exhaust and cigarette smoke. Small amounts are produced during normal metabolic processes in most organisms, including humans.","Formaldehyde | FORMALDEHYDE | Formalin | Formic Aldehyde | Formol | Methanal | Methyl Aldehyde | Oxomethane | formaldehyde",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704758","Action Taken with Study Treatment","C49499","Describes changes made with respect to the specific therapy under study","Action Taken with Study Treatment | ACN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707810","Dose Increased","C49503","An indication that a medication schedule was modified by addition; either by changing the frequency, strength or amount.","Dose Increased | DOSE INCREASED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1449512","Dose Reduced","C49505","An indication that a medication schedule was modified by subtraction, either by changing the frequency, strength or amount.","Dose Reduced | DOSE REDUCED | Dose Reduction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707812","Dose Not Changed","C49504","An indication that a medication schedule was continued without modification.","Dose Not Changed | DOSE NOT CHANGED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707820","Drug Interrupted","C49501","An indication that a medication schedule was modified by temporarily terminating a prescribed regimen of medication.","Drug Interrupted | DRUG INTERRUPTED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707825","Drug Withdrawn","C49502","An indication that a medication schedule was modified through termination of a prescribed regimen of medication.","Drug Withdrawn | DRUG WITHDRAWN | Discontinued | discontinue (study treatment)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL414978","Entity","C51070","An independently existing thing (living or nonliving).","Entity | Item | Thing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079170","County","C49292","A region created by territorial division for the purpose of local government.","County | Parish",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512181","Electro-osmosis Route of Administration","C38633","Administration of drug by way of diffusion, through a membrane in an electric field. Electro-osmosis describes the active transport of non-ionized solutes associated with the bulk flow of fluid in the direction of the counter-ions that occurs with iontophoretic transport of other, ionized solutes. Using this method, even a neutral compound can be administered. Method can be used for local and systemic drug delivery.","Electro-osmosis Route of Administration | EL-OSMOS | ELECTRO-OSMOSIS | Electro-Osmosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522196","Enteral Route of Administration","C38209","Administration of a substance by the way of the gastrointestinal tract, usually for systemic action. Drug bioavailability can be affected due to enzymatic degradation by intestinal tissues and microbes, and first-pass hepatic metabolism.","Enteral Route of Administration | Digestive Tract Route of Administration | ENTER | ENTERAL | Enteral | Gastroenteral use",,,,,,,,,,,,,,,"35622589|4167540","Enteral|Enteral",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1522201","Extracorporeal Circulation Route of Administration","C38212","Drug administration outside of the body. Concept refers to a number of techniques and procedures including extracorporeal photopheresis, ultraviolet blood irradiation and extracorporeal detoxification methods with drug administration, etc.","Extracorporeal Circulation Route of Administration | EXTRACORPOREAL | Extracorporeal | Extracorporeal use | X-CORPOR",,,,,,,,,,,,,,,"37018288","Extracorporeal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205535","Inhalation Route of Administration","C38216","Administration of medication via the respiratory tract, usually by oral or nasal inhalation, for local or systemic effect.","Inhalation Route of Administration | INH | INHALATION | Inhalation | Inhalation use | RESPIR | RESPIRATORY (INHALATION) | Respiratory (Inhalation) | Respiratory tract route of adminstration | inhalation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512919","Intracavernous Route of Administration","C38230","Administration of a drug within a pathologic cavity.","Intracavernous Route of Administration | I-CAVERN | INTRACAVERNOUS | Intracavernous | Intracavernous use",,,,,,,,,,,,,,,"4157757","Intracavernous",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1521952","Intracavitary Route of Administration","C38231","Administration of medication within any natural, non-pathologic cavity, such as that of cervix, uterus, or penis.","Intracavitary Route of Administration | Body Cavity Route of Administration | I-CAVIT | INTRACAVITARY | Intracavitary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522518","Intraurethral Route of Administration","C38271","Administration of a drug directly into the urethra.","Intraurethral Route of Administration | URETH | URETHRAL | Urethral | Urethral Route of Administration | Urethral use",,,,,,,,,,,,,,,"4233974","Urethral",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1700702","Iontophoresis Route of Administration","C38203","Ion transfer of topical solution into the epidermis and mucous membranes of body by continuous direct current. Can be used for local and systemic drug delivery. Concept does not refer to ion exchange, air ionization, and phonophoresis.","Iontophoresis Route of Administration | ION | IONTOPHORESIS | Iontophoresis",,,,,,,,,,,,,,,"4045089","Iontophoresis - action",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1640372","Laryngeal Route of Administration","C38282","Administration of a drug directly upon the larynx.","Laryngeal Route of Administration | LARYN | LARYNGEAL | Laryngeal | Laryngopharyngeal use",,,,,,,,,,,,,,,"4170440","Laryngeal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1513727","Mucosal Route of Administration","C38283","Administration of a substance to the mucosa; often resulting in systemic action due to absorption.","Mucosal Route of Administration | T-MUCOS | TRANSMUCOSAL | Transmucosal | Transmucosal Route of Administration",,,,,,,,,,,,,,,"4232601","Transmucosal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522019","Nasal Route of Administration","C38284","Administration of a drug by the way of the nose. This often results in systemic action of the agent due to absorption through the nasal mucosa. The richly supplied vascular nature of the nasal mucosa coupled with its high drug permeation makes the nasal route of administration attractive for many drugs, including proteins and peptides.","Nasal Route of Administration | Intranasal Route of Administration | NASAL | Nasal | Nasal use",,,,,,,,,,,,,,,"4262914","Nasal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522230","Ophthalmic Route of Administration","C38287","Administration of medication to the external surfaces of the eye.","Ophthalmic Route of Administration | OPHTH | OPHTHALM | OPHTHALMIC | Ocular route of administration | Ocular use | Ophthalmic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527415","Oral Route of Administration","C38288","The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.","Oral Route of Administration | Intraoral Route of Administration | ORAL | Oral | Oral use | Orally | PO | Per Os",,,,,,,,,,,,,,,"4132161","Oral",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1521979","Other Route of Administration","C38290","Route of drug administration not specified on this list.","Other Route of Administration | OTHER | Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518896","Parenteral Route of Administration","C38291","Administration of a substance by some means other than through the gastrointestinal tract: usually through injection, infusion, or implantation. Predominantly, the drug action is systemic, but in some cases, it is confined to local area.","Parenteral Route of Administration | PAREN | PARENTERAL | Parenteral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527425","Rectal Route of Administration","C38295","The introduction of a substance into the gastrointestinal tract by the way of the rectum, usually for systemic action. Depending on the molecular structure, drugs cross the rectal wall via either intercellular or tight junctions interconnecting the mucosal cells. Drug absorption is usually around 50% of normal oral dose. Due to the drainage pattern of the rectal veins, the hepatic first-pass effect tends to increase as the dosage form is placed deeper into the rectum. Solid suppositories represent greater than 98% of all rectal dosage forms.","Rectal Route of Administration | Per Rectum | RECTAL | Rectal | Rectal use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705512","Route of Administration Not Applicable","C48623","The route of drug administration is not applicable.","Route of Administration Not Applicable | NA | NOT APPLICABLE | Route of administration not applicable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522168","Topical Route of Administration","C38304","The application of a drug to a certain area of the skin or mucous membrane (including the intra-organ application), or other tissue locally, so that the agent will take effect on the surface and/or on the underlying tissues.","Topical Route of Administration | T | TOP | TOPIC | TOPICAL | Topical",,,,,,,,,,,,,,,"4263689","Topical",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040652","Transdermal Route of Administration","C38305","Administration of a substance through the dermal layer of the skin into the systemic circulation by diffusion.","Transdermal Route of Administration | Cutaneous Route of Administration | Percutaneous Route of Administration | T-DERMAL | TRANSDERMAL | Transdermal | Transdermal use",,,,,,,,,,,,,,,"4262099","Transdermal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522232","Transplacental Route of Administration","C38307","Administration of a drug to an embryo in utero via systemic administration of the substance to the pregnant mother. Drugs cross the placenta through passive diffusion, active transport, pinocytosis and filtration. The properties of drugs that determine placental transfer by passive diffusion include molecular weight, pKa, lipid solubility and protein binding. Drugs with molecular weight of over 500 D are transferred incompletely. Drug metabolism and uptake can be altered by placental enzymes.","Transplacental Route of Administration | T-PLACENT | TRANSPLACENTAL | Transplacental",,,,,,,,,,,,,,,"40487858","Transplacental",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522233","Transtracheal Route of Administration","C38308","Administration of a drug through the wall of the trachea.","Transtracheal Route of Administration | T-TRACHE | TRANSTRACHEAL | Transtracheal",,,,,,,,,,,,,,,"40491832","Transtracheal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522234","Transtympanic Route of Administration","C38309","Administration of a drug across or through the tympanic cavity. This method reduces the total dose of medication, and allows high concentrations of drug to be delivered directly to the target tissue, while reducing systemic effects. Transtympanic medication can be administered through a needle puncture of the eardrum. If multiple injections are required, a myringotomy tube can be inserted.","Transtympanic Route of Administration | T-TYMPAN | TRANSTYMPANIC | Transtympanic",,,,,,,,,,,,,,,"40491830","Transtympanic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519757","Unassigned Route of Administration","C38310","Route of administration has not yet been assigned.","Unassigned Route of Administration | UNAS | UNASSIGNED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521803","Unknown Route of Drug Administration","C38311","The route of drug administration is unknown.","Unknown Route of Administration | UNKNOWN | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522613","Ureteral Route of Administration","C38312","Administration of a drug into the ureter.","Ureteral Route of Administration | URETER | URETERAL | Ureter | Ureteral",,,,,,,,,,,,,,,"4304571","Ureteral",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522570","Vaginal Route of Administration","C38313","Administration of a drug into the vagina. The medication usually has the form of a solution, tablet, cream, gel, or suppository. The drug is slowly absorbed through the vaginal wall with predominantly local, but some systemic effects.","Vaginal Route of Administration | VAG | VAGIN | VAGINAL | Vaginal | Vaginal use",,,,,,,,,,,,,,,"4057765","Vaginal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705586","Adverse Event Outcome","C49489","A condition or event that is attributed to the adverse event and is the result or conclusion of the adverse event.","Adverse Event Outcome | ADVERSE EVENT OUTCOME | AEOUT | AE_OUTCOME | AdverseEventOutcomeAssessment | OUTCOME ATTRIBUTED TO ADVERSE EVENT | outcome (of adverse event)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709863","RECOVERED/RESOLVED","C49498","One of the possible results of an adverse event outcome that indicates that the event has improved or recuperated.","Recovered from Adverse Event | Patient recovered | RECOVERED/RESOLVED | Recovered | Recovered or Resolved",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709864","Recovering or Resolving","C49496","One of the possible results of an adverse event outcome that indicates that the event is improving.","Recovering or Resolving | RECOVERING/RESOLVING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709862","RECOVERED/RESOLVED WITH SEQUELAE","C49495","One of the possible results of an adverse event outcome where the subject recuperated but retained pathological conditions resulting from the prior disease or injury.","Recovered from Adverse Event with Sequelae | RECOVERED/RESOLVED WITH SEQUELAE | Recovered With Sequelae | Recovered or Resolved with Sequelae | Recovered with Sequelae",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1136114","Institutional Animal Care and Use Committees","C19487","A self-regulating entity mandated by federal law to be established at an institution that uses laboratory animals for research or instructional purposes to oversee and evaluate all aspects of the institution's animal use and care program.","Institutional Animal Care and Use Committee | IACUC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037267","Integumentary System","C12907","The enveloping membrane of the body; includes, in addition to the epidermis and dermis, all the derivatives of the epidermis, e.g., hairs, nails, sudoriferous and sebaceous glands.","Integumentary System | Body System, Dermatologic | Dermatologic Body System | Dermatologic Organ System | Integumentary | Organ System, Dermatologic",,,,,,,,,,,,,,,"4170047","Structure of integumentary system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522188","Buccal Route of Administration","C38193","Administration of a substance through the mucosal membrane on the inside of the cheek or the back of the mouth. Buccal route bypasses first pass metabolism and avoids pre-systemic elimination in the gastrointestinal tract. The buccal environment is well supplied with both vascular and lymphatic drainage and is well suited for a retentive device. This is a feasible alternative for systemic delivery of orally inefficient drugs, such as peptide and protein drug molecules.","Buccal Route of Administration | BUCC | BUCCAL | Buccal | Buccal use",,,,,,,,,,,,,,,"4181897","Buccal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522409","Oropharyngeal Route of Administration","C38289","Administration of a drug directly to the mouth and pharynx.","Oropharyngeal Route of Administration | ORO | OROPHARYNGEAL | Oropharyngeal | Oropharyngeal use",,,,,,,,,,,,,,,"4303277","Oropharyngeal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001565","Sublingual Route of Administration","C38300","Administration of a drug beneath the tongue. The route provides rapid absorption, the drug immediately enters the bloodstream without first passing through the intestinal wall and liver. However, most drugs cannot be taken this way because they may be absorbed incompletely or erratically.","Sublingual Route of Administration | SL | SUBLINGUAL | Sublingual | Sublingual use",,,,,,,,,,,,,,,"42538333|4292110","Sublingual|Sublingual",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1522483","Conjunctival Route of Administration","C38194","Administration of a drug to the conjunctiva, the most frequently used mode of ocular drug delivery. Advantages of this topical route include direct, localized delivery to the target tissue, good accessibility into the intraocular environment owing to membrane permeability and large intercellular spaces, avoidance of hepatic first-pass metabolism, convenience, and relative painlessness. Limitations include rapid drug elimination due to lacrimation and nasolacrimal drainage, drug binding to, and metabolism by, tear proteins, and target non-specificity as a result of systemic absorption through the nasal mucosa and conjunctival vasculature.","Conjunctival Route of Administration | CONJUNC | CONJUNCTIVAL | Conjunctival",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522447","Cutaneous Route of Administration","C38675","Administration to the skin.","Cutaneous Route of Administration | CUTAN | CUTANEOUS | Cutaneous | Cutaneous use | Dermal",,,,,,,,,,,,,,,"40490507","Cutaneous",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1524042","Endocervical Route of Administration","C38205","Administration of the drug within the canal of the cervix uteri.","Endocervical Route of Administration | E-CERVIC | EC | ENDOCERVICAL | Endocervical | Endocervical use | Intracervical Route of Administration",,,,,,,,,,,,,,,"4186831","Endocervical",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522228","Intrauterine Route of Administration","C38272","The administration of a drug within the uterus.","Intrauterine Route of Administration | I-UTER | INTRAUTERINE | Intrauterine | Intrauterine use",,,,,,,,,,,,,,,"4269621","Intrauterin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522448","Intravesical Route of Administration","C38278","The administration of a drug within the urinary bladder.","Intravesical Route of Administration | I-VESIC | INTRAVESICAL | Intravesical | Intravesical use",,,,,,,,,,,,,,,"4186838","Intravesical",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517556","Intrasinal Route of Administration","C38262","The administration of a drug through the nasal sinuses.","Intrasinal Route of Administration | I-SINAL | INTRASINAL | Intrasinal | Sinus Route of Administration",,,,,,,,,,,,,,,"4169440","Intrasinal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1298993","Endosinusial Route of Administration","C38206","Administration of the drug within the nasal sinuses.","Endosinusial Route of Administration | E-SINUS | ENDOSINUSIAL | ES | Endosinusial | Endosinusial use",,,,,,,,,,,,,,,"4157756","Endosinusial",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0592511","Epidural Route of Administration","C38210","Administration of the drug in the epidural space, usually at the lumbar level of the spine. The drug must initially cross the dura mater before exerting its effect on the nervous system components. The drug is also subject to uptake into the rich epidural plexus of veins. Uptake and distribution after epidural administration resembles that seen after intramuscular injection. The portion of drug that is not taken into the vascular compartment is available to cross the dura. Hydrophilicity is a major component in the pharmacokinetics of drug transfer into the subdural space.","Epidural Route of Administration | EPIDUR | EPIDURAL | Epidural | Epidural use",,,,,,,,,,,,,,,"4225555","Epidural",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522199","Extraamniotic Route of Administration","C38211","Administration of the drug to the outside of the membrane enveloping the fetus.","Extraamniotic Route of Administration | EXTRA-AMNIOTIC | Extra-Amniotic | Extraamniotic use | X-AMNI",,,,,,,,,,,,,,,"4130086|4186833","Extra-amniotic|Extra-amniotic",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1524112","Administration via Hemodialysis","C38200","Method of administering the drug through hemodialysate fluid.","Administration via Hemodialysis | Administration Via Hemodialysis | HEMO | HEMODIALYSIS | Haemodialysis | Hemodialysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1523986","Infiltration Route of Administration","C38215","Route of drug administration that results in substances passing into tissue spaces or intracellularly.","Infiltration Route of Administration | INFIL | INFILTRATION | Infiltration",,,,,,,,,,,,,,,"37397638","Infiltration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522203","Interstitial Route of Administration","C38219","Drug administration to or in the interstices of a tissue.","Interstitial Route of Administration | INTERSTIT | INTERSTITIAL | Interstitial",,,,,,,,,,,,,,,"4327128","Interstitial",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512911","Intraabdominal Route of Administration","C38220","Administration of the drug within the abdominal cavity, typically as a loco-regional therapy for disease confined to the abdomen.","Intraabdominal Route of Administration | I-ABDOM | INTRA-ABDOMINAL | Intra-Abdominal",,,,,,,,,,,,,,,"4304882","Intraabdominal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512912","Intraamniotic Route of Administration","C38221","Administration of the drug within the amnion.","Intraamniotic Route of Administration | I-AMNI | INTRA-AMNIOTIC | Intra-Amniotic | Intraamniotic use",,,,,,,,,,,,,,,"4163767","Intraamniotic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522204","Intraarticular Route of Administration","C38223","Administration of the drug within a joint.","Intraarticular Route of Administration | I-ARTIC | INTRA-ARTICULAR | Intra-Articular | Intraarticular use",,,,,,,,,,,,,,,"3655016|4006860","Intraarticular|Intra-articula",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1319199","Intrabiliary Route of Administration","C38224","Administration within the biliary system for selective delivery of the agent to targeted hepatobiliary tissues and cell types, the goal of which is utilization of optimal therapeutic dosages combined with a reduction in systemic toxicity. Strategies for improving the tissue specificity include the use of tissue-specific ligands and the focal administration of drugs. Focal delivery has been primarily directed at uptake by the hepatocyte basolateral membrane and has included direct intraparenchymal injection, portal venous infusion, hepatic arterial infusion, and surgical systems for temporarily isolating the liver from the vasculature.","Intrabiliary Route of Administration | I-BILI | INTRABILIARY | Intrabiliary",,,,,,,,,,,,,,,"4223965","Intrabiliary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512914","Intrabronchial Route of Administration","C38225","Administration of a drug within a bronchus or bronchi. The intrabronchial drug delivery can be used for both local and systemic drug action.","Intrabronchial Route of Administration | I-BRONCHI | INTRABRONCHIAL | Intrabronchial",,,,,,,,,,,,,,,"4303263","Intrabronchial",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522205","Intrabursal Route of Administration","C38226","Administration of a drug within a bursal cavity.","Intrabursal Route of Administration | I-BURSAL | INTRABURSAL | Intrabursal | Intrabursal use",,,,,,,,,,,,,,,"4163768","Intrabursal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522207","Intracardiac Route of Administration","C38227","Administration of a drug within the heart.","Intracardiac Route of Administration | I-CARDI | INTRACARDIAC | Intracardiac | Intracardiac use",,,,,,,,,,,,,,,"4156705","Intracardiac",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512917","Intracartilaginous Route of Administration","C38228","Administration of a drug within a cartilage.","Intracartilaginous Route of Administration | I-CARTIL | INTRACARTILAGINOUS | Intracartilaginous | Intracartilaginous use",,,,,,,,,,,,,,,"4303676","Intracartilaginous",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512918","Intracaudal Route of Administration","C38229","Administration of a drug within the cauda equina.","Intracaudal Route of Administration | I-CAUDAL | INTRACAUDAL | Intracaudal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522211","Intracerebral Route of Administration","C38232","Administration of a drug within the cerebrum, directly into brain tissue, usually by injection or direct application.","Intracerebral Route of Administration | I-CERE | INTRACEREBRAL | Intracerebral | Intracerebral use",,,,,,,,,,,,,,,"40488317","Intracerebral",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512927","Intracorneal Route of Administration","C38234","Administration of a drug within the eye cornea.","Intracorneal Route of Administration | I-CORNE | INTRACORNEAL | Intracorneal | Intracorneal use",,,,,,,,,,,,,,,"4305690","Intracorneal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512966","Intraovarian Route of Administration","C38256","Administration of a drug within the ovary or ovaries.","Intraovarian Route of Administration | I-OVAR | INTRAOVARIAN | Intraovarian",,,,,,,,,,,,,,,"4306657","Intraovarian",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512930","Intracorpus Cavernosum Route of Administration","C38235","Administration of medication within the dilatable venous spaces of the cavernous tissue of the penis.","Intracorpus Cavernosum Route of Administration | I-CORPOR | INTRACORPORUS CAVERNOSUM | Intracavernous use | Intracorporus Cavernosum Route of Administration | Intracorporus cavernosum of penis route of administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512936","Intraductal Route of Administration","C38240","Administration of a drug within the duct of a gland.","Intraductal Route of Administration | I-DUCTAL | INTRADUCTAL | Intraductal",,,,,,,,,,,,,,,"4170083","Intraductal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512934","Intradiscal Route of Administration","C38239","Administration of a drug within a fibrocartilaginous intervertebral disc.","Intradiscal Route of Administration | I-DISCAL | INTRADISCAL | Intradiscal | Intradiscal use",,,,,,,,,,,,,,,"4163769","Intradiscal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512939","Intradural Route of Administration","C38242","Administration of a drug within or beneath the dura mater.","Intradural Route of Administration | I-DURAL | INTRADURAL | Intradural",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512958","Intrameningeal Route of Administration","C38254","The administration of a drug within meningeal membranes.","Intrameningeal Route of Administration | I-MENIN | INTRAMENINGEAL | Intrameningeal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518532","Occlusive Dressing Technique","C38286","Administration of a substance by the topical route that is then covered by a dressing which occludes the area of drug application.","Occlusive Dressing Technique | OCCLUS | OCCLUSIVE DRESSING TECHNIQUE",,,,,,,,,,,,,,,"40490870","Occlusive dressing technique",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1515025","Submucosal Route of Administration","C38301","Administration of a drug beneath the mucous membrane.","Submucosal Route of Administration | S-MUCOS | SUBMUCOSAL | Submucosal | Submucosal use",,,,,,,,,,,,,,,"4169634","Submucosal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1556154","Intramuscular Route of Administration","C28161","Intramuscular injection is a route of drug administration via injection into muscle tissue. Aqueous or oleaginous solutions and emulsions or suspensions may be administered. Absorption rates, delay in availability of the drug to the systemic circulation, and duration of effect are perfusion-limited, depend on molecular size of the agent, volume, and osmolarity of the drug solution, fat content of the injection site, and patient physical activity.","Intramuscular Route of Administration | IM | INTRAMUSCULAR | Intramuscular | Intramuscular Injection | Intramuscular use | intramuscular injection",,,,,,,,,,,,,,,"4302612","Intramuscula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0595826","Retrobulbar Route of Administration","C38296","The introduction of a substance behind the pons or behind the eyeball.","Retrobulbar Route of Administration | RETRO | RETROBULBAR | Retrobulbar | Retrobulbar use",,,,,,,,,,,,,,,"4303673","Retrobulba",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522223","Intraocular Route of Administration","C38255","Administration of a drug within the eye. Intraocular drugs are almost always used for their local effects.","Intraocular Route of Administration | I-OCUL | INTRAOCULAR | Intraocular | Intraocular use",,,,,,,,,,,,,,,"4157760","Intraocula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522192","Soft Tissue Route of Administration","C38198","The introduction of a substance into any soft tissue.","Soft Tissue Route of Administration | SOFT TIS | SOFT TISSUE | Soft Tissue Route Of Administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556144","Subconjunctival Route of Administration","C38298","The introduction of a substance beneath the conjunctiva.","Subconjunctival Route of Administration | S-CONJUNC | SUBCONJUNCTIVAL | Subconjunctival | Subconjunctival use",,,,,,,,,,,,,,,"4163770","Subconjunctival",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1515008","Subarachnoid Route of Administration","C38297","The introduction of a substance beneath the arachnoidal membrane","Subarachnoid Route of Administration | S-ARACH | SUBARACHNOID | Subarachnoid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2960678","Periodontal Route of Administration","C38294","Administration of a substance within the tissues surrounding a tooth or teeth.","Periodontal Route of Administration | P-ODONT | PERIODONTAL | Periodontal | Periodontal use",,,,,,,,,,,,,,,"37153642|40490866","Periodontal|Periodontal",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1517571","Intraventricular Route of Administration","C38277","Administration of a drug directly into a cerebral ventricle, commonly using a reservoir. This allows a more even distribution of drug through the cerebrospinal fluid (CSF) and is particularly useful in the treatment of certain types of cancers.","Intraventricular Route of Administration | I-VENTRIC | INTRAVENTRICULAR | Intraventricular",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522217","Intraluminal Route of Administration","C38251","Administration of a drug within the cavity or channel of a tubular structure or tubular organ.","Intraluminal Route of Administration | I-LUMIN | INTRALUMINAL | Intraluminal",,,,,,,,,,,,,,,"4292410","Intraluminal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512957","Intramedullary Route of Administration","C38253","Administration of a drug within the marrow cavity of a bone. The essential premise for intraosseous administration is a functioning medullary cavity. The route is considered reasonably safe and permits rapid achievement of satisfactory plasma concentrations of therapeutic agent. The route is used for blood transfusion or fluid therapy when other routes are awkward, as in neonates.","Intramedullary Route of Administration | I-MEDUL | INTRAMEDULLARY | Intramedullary",,,,,,,,,,,,,,,"4246511","Intramedullary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2960799","Intrapericardial Route of Administration","C38257","Administration of a drug within the pericardium. Intrapericardial application of therapeutic agents provides a strategy for site-specific treatment of heart or coronary diseases. The magnitude of the local advantage depends on substance exchange between the local and the blood compartments and on substance elimination from these compartments.","Intrapericardial Route of Administration | I-PERICARD | INTRAPERICARDIAL | Intrapericardial | Intrapericardial use",,,,,,,,,,,,,,,"40492305","Intrapericardial",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522583","Intraperitoneal Route of Administration","C38258","Administration of a drug via injection or infusion of a substance into the peritoneum, where it is absorbed by the lining.","Intraperitoneal Route of Administration | I-PERITON | INTRAPERITONEAL | IP | Intraperitoneal | Intraperitoneal Infusion | Intraperitoneal use | intraperitoneal infusion | peritoneal infusion",,,,,,,,,,,,,,,"4243022","Intraperitoneal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512969","Intraprostatic Route of Administration","C38260","Administration of a drug within the prostate gland.","Intraprostatic Route of Administration | I-PROSTAT | INTRAPROSTATIC | Intraprostatic | Intraprostatic use",,,,,,,,,,,,,,,"4171725","Intraprostatic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522224","Intrapulmonary Route of Administration","C38261","Administration of a substance in the form gas, aerosol, emulsion, or liquid (during partial and tidal liquid ventilation), or fine powder into the lung, often with systemic action. Method limitations: insufficient drug delivery to peripheral lung regions, the inability to quantify the actually administered dose, and non-homogeneous distribution.","Intrapulmonary Route of Administration | I-PULMON | INTRAPULMONARY | Intrapulmonary | Intrapulmonary use",,,,,,,,,,,,,,,"4169270","Intrapulmonary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522227","Intraspinal Route of Administration","C38263","The administration of a drug within the vertebral column. High therapeutic ratio is based on drug delivery directly to central nervous system sites of action.","Intraspinal Route of Administration | I-SPINAL | INTRASPINAL | Intraspinal",,,,,,,,,,,,,,,"4302788","Intraspinal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0595620","Intratendinous Route of Administration","C38265","The administration of an agent within a tendon. The route is used for local therapy in various conditions of the tendinous or bursal structures such as tendinitis, tenosynovitis, epicondylitis, etc. Depending on indications and the drug, injection could be done into the tendon sheath or into the substance of the tendon.","Intratendinous Route of Administration | I-TENDIN | INTRATENDINOUS | Intratendinous",,,,,,,,,,,,,,,"4303939","Intratendinous",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517559","Intratesticular Route of Administration","C38266","The administration of a drug within the testicle.","Intratesticular Route of Administration | I-TESTIC | INTRATESTICULAR | Intratesticular",,,,,,,,,,,,,,,"4171067","Intratesticula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0677897","Intrathecal Route of Administration","C38267","Administration of drugs directly into spinal subarachnoid space in the cerebrospinal fluid, at any level of the cerebrospinal axis, including injection into the cerebral ventricles, in order to bypass the blood-brain barrier and achieve local, rapid effects on the meninges or cerebrospinal axis.","Intrathecal Route of Administration | INTRATHECAL | IT | Intrathecal | Intrathecal use",,,,,,,,,,,,,,,"4217202","Intrathecal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517563","Intratubular Route of Administration","C38268","The administration of a drug within the tubules of an organ.","Intratubular Route of Administration | I-TUBUL | INTRATUBULAR | Intratubular",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517565","Intratumoral Route of Administration","C38269","The administration of a drug within or introduced directly into a tumor. Method allows to achieve high concentration of the agent in the tumor and delay drug release in systemic circulation.","Intratumoral Route of Administration | I-TUMOR | INTRATUMOR | Intratumor | Intratumor Route of Administration | Intratumoral | Intratumoral use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517566","Intratympanic Route of Administration","C38270","The administration of a drug directly into the tympanic cavity has high safety profile and allows delivering high concentrations of the agent to the inner ear end organ. Perfusion is performed under the surgical microscope by inserting the needle in the posterior-inferior aspect of the tympanic membrane.","Intratympanic Route of Administration | I-TYMPAN | INTRATYMPANIC | Intratympanic",,,,,,,,,,,,,,,"4168656","Intratympanic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512956","Intralymphatic Route of Administration","C38252","Administration of a drug within the lymphatic system: into the lymph nodes or/and the lymph vessels.","Intralymphatic Route of Administration | I-LYMPHAT | INTRALYMPHATIC | Intralymphatic | Intralymphatic use",,,,,,,,,,,,,,,"4157759","Intralymphatic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512955","Intralesional Route of Administration","C38250","Administration of a drug within or introduced directly into a localized lesion. Method allows to achieve high concentration of the agent in the lesion and delay drug release in systemic circulation.","Intralesional Route of Administration | I-LESION | INTRALESIONAL | Intralesional | Intralesional use",,,,,,,,,,,,,,,"4157758","Intralesional",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2960476","Intravascular Route of Administration","C38273","The administration of an agent within a vessel or vessels.","Intravascular Route of Administration | I-VASC | INTRAVASCULAR | Intravascular",,,,,,,,,,,,,,,"40492287","Intravascula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1521919","Irrigation Route of Administration","C38281","Administration of a drug by bathing or flushing open wounds, body cavities or surfaces.","Irrigation Route of Administration | IRRIG | IRRIGATION | Irrigation | Irrigation-Route of Administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522726","Intravenous Route of Administration","C38276","Administration of a drug within or into a vein or veins. Introduction of the drug directly into venous circulation results in 100% bioavailability due to an absence of the absorption phase, provides a precise and continuous mode of drug therapy, especially for drugs with a narrow therapeutic index.","Intravenous Route of Administration | INTRAVENOUS | IV | Intravenous | Intravenous use | Intravenously",,,,,,,,,,,,,,,"4171047","Intravenous",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1621368","Intravenous Drip","C38279","The administration of a drug within or into a vein or veins over a sustained period of time. A slow, continuous drip avoids excessively high transient peak plasma levels.","Intravenous Drip | INTRAVENOUS DRIP | IV DRIP | IV Drip",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1561451","Intraarterial Route of Administration","C38222","The administration of a substance directly into an artery.","Intraarterial Route of Administration | I-ARTER | I-arter | IA | INTRA-ARTERIAL | Intra Arterial Route of Administration | Intra-Arterial | Intra-Arterial Route of Administration | Intra-arterial Route of Administration | Intraarterial | Intraarterial Infusion | Intraarterial Injection | Intraarterial use",,,,,,,,,,,,,,,"4240824","Intra-arterial",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522438","Subcutaneous Route of Administration","C38299","Drug administration beneath the skin. It provides for relatively slow, sustained release of the drug. The rate of absorption into the blood is perfusion-limited, proportional to the amount of drug at the site and can be enhanced by chemical or physical stimulation of blood flow. Subcutaneous administration minimizes the risks associated with intravascular injection: for subcutaneous infusions, external and implantable pumps are used.","Subcutaneous Route of Administration | SC | SUBCUTANEOUS | Subcutaneous | Subcutaneous use | Subdermal Route of Administration",,,,,,,,,,,,,,,"4142048","Subcutaneous",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518982","Perineural Route of Administration","C38293","Administration of a substance within the tissues surrounding a nerve or nerves.","Perineural Route of Administration | P-NEURAL | PERINEURAL | Perineural | Perineural use",,,,,,,,,,,,,,,"4157761","Perineural",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518975","Peridural Route of Administration","C38677","The administration of a drug via injection or infusion into the epidural space, the area immediately adjacent to the outside surface of the dura mater of the spinal cord.","Peridural Route of Administration | P-DURAL | PERIDURAL | Peridural",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0595695","Periarticular Route of Administration","C38292","Administration of a substance within the tissues surrounding a joint.","Periarticular Route of Administration | P-ARTIC | PERIARTICULAR | Periarticular | Periarticular use",,,,,,,,,,,,,,,"4156708","Periarticula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522243","Percutaneous Route of Administration","C38676","Administration of a drug by the way of absorption through the skin, usually for systemic action. The route allows sustained therapeutic plasma drug levels and avoids first pass effect. Simplicity of administration tends to result in high patient compliance.","Percutaneous Route of Administration | PERCUT | PERCUTANEOUS | Percutaneous | percutaneous",,,,,,,,,,,,,,,"4177987","Percutaneous",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1636191","Intracoronal Dental Route of Administration","C38217","Administration of a drug within a crown of tooth.","Intracoronal Dental Route of Administration | I-CORONAL | INTRACORONAL, DENTAL | Intracoronal, Dental",,,,,,,,,,,,,,,"4303667","Intracoronal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512937","Intraduodenal Route of Administration","C38241","Administration of a drug within the duodenum.","Intraduodenal Route of Administration | I-DUOD | INTRADUODENAL | Intraduodenal",,,,,,,,,,,,,,,"4302354","Intraduodenal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2959898","Intraesophageal Route of Administration","C38245","Administration of a drug within the esophagus.","Intraesophageal Route of Administration | I-ESO | INTRAESOPHAGEAL | Intraesophageal",,,,,,,,,,,,,,,"40492284","Intraesophageal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512953","Intraileal Route of Administration","C38249","Administration of a drug within the distal portion of the small intestine, from the jejunum to the cecum.","Intraileal Route of Administration | I-ILE | INTRAILEAL | Intraileal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0694637","Nasogastric Route of Administration","C38285","Administration of a drug through the nose and into the stomach, usually by means of a tube.","Nasogastric Route of Administration | NASOGASTRIC | NG | Nasogastric",,,,,,,,,,,,,,,"4132711","Nasogastric",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0694754","Intrasynovial Route of Administration","C38264","The administration of a drug within the synovial cavity of a joint.","Intrasynovial Route of Administration | I-SYNOV | INTRASYNOVIAL | Intrasynovial",,,,,,,,,,,,,,,"4302352","Intrasynovial",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0595836","Endothoracic Route of Administration","C38207","Administration of a drug within the thorax (internal to the ribs).","Endothoracic Route of Administration | I-THORAC | INTRATHORACIC | Intrathoracic | Intrathoracic Route of Administration",,,,,,,,,,,,,,,"4167393","Intrathoracic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512941","Intraepidermal Route of Administration","C38243","Administration of a drug within the superficial epithelial layer of the skin.","Intraepidermal Route of Administration | I-EPIDERM | INTRAEPIDERMAL | Intraepidermal | Intraepidermal use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517572","Intravitreal Route of Administration","C38280","The administration of a drug within the vitreous body of the eye.","Intravitreal Route of Administration | I-VITRE | INTRAVITREAL | Intravitreal | Intravitreal Injection | Intravitreal use",,,,,,,,,,,,,,,"4302785","Intravitreal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0595454","Intracoronary Route of Administration","C38218","Administration of a drug within the coronary arteries supplying blood to the tissues of the heart.","Intracoronary Route of Administration | I-CORONARY | INTRACORONARY | Intracoronary | Intracoronary use",,,,,,,,,,,,,,,"4186836","Intracoronary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522215","Intragastric Route of Administration","C38246","Administration of a drug within the stomach, e.g. via gavage or via gastrostomy.","Intragastric Route of Administration | Gastric use | I-GASTRIC | INTRAGASTRIC | Intragastric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4227880","Skin Rash","C39594","Any change in the skin which affects its appearance or texture. A rash may be localized to one part of the body, or affect all the skin. Rashes may cause the skin to change color, itch, become warm, bumpy, dry, cracked or blistered, swell and may be painful.","Skin Rash | Cutaneous Eruption | Rash | Rashes | Skin Eruption | Skin rash",,,,,,,,,,,,,,,"140214","Eruption",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3808574","Respiratory Distress","C27165","A pathological increase in the effort and frequency of breathing movements.","Respiratory Distress | Difficulty_breathing | Respiratory distress",,,,,,,,,,,,,,,"4158346","Respiratory distress",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705232","Death Related to Adverse Event","C48275","The termination of life associated with an adverse event.","Death Related to Adverse Event | 5 | AESDTH | CTCAE Grade 5 | Common Terminology Criteria for Adverse Events Grade 5 | FATAL | Fatal | Grade 5 | Grade 5 Death Related to Adverse Event | Standard Toxicity Grade 5 | Toxicity Value 5",,,,,,,,,,,,,,,"40459836|765766","Grade 5|Common terminology criteria for adverse events grade 5",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1709277","NOT RECOVERED/NOT RESOLVED","C49494","One of the possible results of an adverse event outcome that indicates that the event has not improved or recuperated.","Not Recovered from Adverse Event | NOT RECOVERED/NOT RESOLVED | Not Recovered | Not Recovered or Not Resolved | Not Yet Recovered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554601","Therapeutic Corticosteroid","C211","Any steroid hormone made in the adrenal cortex (the outer part of the adrenal gland). They are also made in the laboratory. Corticosteroids have many different effects in the body, and are used to treat many different conditions. They may be used as hormone replacement, to suppress the immune system, and to treat some side effects of cancer and its treatment. Corticosteroids are also used to treat certain lymphomas and lymphoid leukemias.","Therapeutic Corticosteroid | Corticosteroids | corticosteroid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0854619","Single Agent Systemic Chemotherapy","C15756","Systemic chemotherapy with a single agent regimen. All routes of administration are acceptable as long as the agent is intended for systemic therapy.","Single Agent Systemic Chemotherapy | Chemotherapy Single Agent Systemic | Chemotherapy single agent systemic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517499","Gene Transfer","C20185","Incorporation of new DNA into an organism's cells, usually by a vector such as a modified virus. Used in gene therapy.(From Human Genome Project Information).","Gene Transfer | gene transfer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026845","Muscle","C13056","One of the contractile organs of the body.","Muscle | MUSCLE | Muscular | Skeletal and/or smooth muscle structure (body structure)",,,,,,,,,,,,,,,"4325458","Muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021791","International System of Units","C42541","The International System of Units (Systeme International d'Unites, SI) is a decimal system of weights and measures derived from and extending the metric system of units established through the Treaty of the Meter (Convention du Metre) signed in Paris in 1875 and currently signed by 48 nations including all the major industrialized countries. The SI is maintained by the International Bureau of Weights and Measures (BIPM, for Bureau International des Poids et Mesures), and is updated every few years by an international conference, the General Conference on Weights and Measures (CGPM, for Conference Generale des Poids et Mesures). SI has a short list of base units defined in an absolute way without referring to any other units: the metre, the kilogram, the second, the ampere, the kelvin, the mole, and the candela. The base units are consistent with the part of the metric system called the MKS system.","International System of Units | Modern Metric System | SI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512924","Intracisternal Route of Administration","C38233","Administration of a drug directly into the cerebrospinal fluid of the brain ventricles. It could be performed by direct injection into the cisterna magna or via permanently positioned tube.","Intracisternal Route of Administration | I-CISTERN | INTRACISTERNAL | Intracisternal | Intracisternal use",,,,,,,,,,,,,,,"4305993","Intracisternal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522475","Intradermal Route of Administration","C38238","Intradermal injection is a method of drug administration within the substance of the skin, particularly the dermis.","Intradermal Route of Administration | DL | I-DERMAL | I-dermal | IC | ID | INTRADERMAL | Intracutaneous | Intradermal | Intradermal Injection | Intradermal use",,,,,,,,,,,,,,,"4156706","Intradermal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512947","Intragingival Route of Administration","C38247","Administration of a drug within the gingivae.","Intragingival Route of Administration | I-GINGIV | INTRAGINGIVAL | Intragingival",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042615","Veterinary Medicine (discipline)","C17251","The practice of medicine as applied to non-human animals.","Veterinary Medicine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511510","Cooperative Group Program","C16008","NCI-sponsored program that promotes and supports clinical trials in cancer treatment, (largely combined modality approaches); cancer prevention, and early detection within setting of a Cooperative Group.","Cooperative Group Program | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278627","Oncology","C17837","The study of tumors encompassing the physical, chemical, and biologic properties.","Oncology | Cancer, Oncology | Oncologic | oncology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020281","Hydrogen Peroxide","C28156","A peroxide and oxidizing agent with disinfectant, antiviral and anti-bacterial activities. Upon rinsing and gargling or topical application, hydrogen peroxide exerts its oxidizing activity and produces free radicals which leads to oxidative damage to proteins and membrane lipids. This may inactivate and destroy pathogens and may prevent spreading of infection.","Hydrogen Peroxide | Dihydrogen Dioxide | Dihydrogen Peroxide | H2O2 | HOOH | HYDROGEN PEROXIDE | Hydrogen Dioxide | hydrogen peroxide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0699178","Hydralazine Hydrochloride","C551","The hydrochloride salt of hydralazine, a phthalazine derivative with antihypertensive and potential antineoplastic activities. Hydralazine alters intracellular calcium release and interferes with smooth muscle cell calcium influx, resulting in arterial vasodilatation. This agent also inhibits the phosphorylation of myosin protein and chelation of trace metals required for smooth muscle contraction, resulting in an increase in heart rate, stroke volume and cardiac output. In addition to its cardiovascular effects, hydralazine inhibits DNA methyltransferase, which may result in inhibition of DNA methylation in tumor cells.","Hydralazine Hydrochloride | Apresoline | Apressin | HYDRALAZINE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0546868","Hydrocodone Bitartrate","C29099","The bitartrate salt form of hydrocodone, a semisynthetic hydrogenated codeine derivative and opioid agonist with analgesic and antitussive effects. Hydrocodone primarily binds to and activates the mu-opioid receptor in the central nervous system (CNS). This leads to analgesia, euphoria, respiratory depression, miosis, decreased gastrointestinal motility, cough suppression and physical dependence. Hydrocodone is converted to hydromorphone by the cytochrome P450 enzyme CYP2D6.","Hydrocodone Bitartrate | HYDROCODONE BITARTRATE | Hycodan | hydrocodone bitartrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0717804","Guaifenesin/Pseudoephedrine","C29084","A combination preparation containing guaifenesin and the indirect-acting sympathicomimetic agent pseudoephedrine with expectorant and decongestant activities, respectively. Guaifenesin works by drawing water into respiratory tracts, by which reducing adhesiveness and surface tension of mucus as well as increasing hydration of mucus, thereby reducing the viscosity of mucus and making cough more productive. Pseudoephedrine displaces norepinephrine from storage vesicles in presynaptic neurons, thereby releasing norepinephrine into the neuronal synapses where it stimulates primarily alpha-adrenergic receptors in the nasal mucosa, thereby producing vasoconstriction, reduces swelling of nasal mucous membranes and decreasing nasal and sinus congestion.","Guaifenesin/Pseudoephedrine | Guaifenisin/Pseudoephedrine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0717689","Guaifenesin-DM","C29083","A combination preparation containing guaifenesin and the opioid agonist dextrometorphan with expectorant and antitussive activities, respectively. Guaifenesin works by drawing water into respiratory tracts, by which reducing adhesiveness and surface tension of mucus as well as increasing hydration of mucus, thereby reducing the viscosity of mucus and making cough more productive. Dextrometorphan, a synthetic, methylated dextrorotary analogue of levorphanol, exhibits antitussive activity by activating opioid receptors in the cough center in the central nervous system, thereby raising the threshold for coughing.","Guaifenesin-DM | Guaifenesin-Dextromethorphan | Guaifenisin-DM | Robitussin DM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018546","Haloperidol","C537","A phenylbutylpiperadine derivative with antipsychotic, neuroleptic, and antiemetic activities. Haloperidol competitively blocks postsynaptic dopamine (D2) receptors in the mesolimbic system of the brain, thereby eliminating dopamine neurotransmission and leading to antidelusionary and antihallucinagenic effects. Antagonistic activity mediated through D2 dopamine receptors in the chemoreceptive trigger zone (CTZ) accounts for its antiemetic activity.","Haloperidol | 4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone | HALOPERIDOL | Haldol | McN-JR-1625 | R 1625 | R-1625 | haloperidol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037513","Heparin Sodium","C833","The sodium salt form of heparin.  As a glycosaminoglycan anticoagulant, heparin sodium binds to antithrombin III to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin. (NCI)","Heparin Sodium | HEPARIN SODIUM | Hep-Lock | Heparin sodium | Lipo-Hepin | Sodium heparin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0170300","Hepatitis A Vaccine","C29090","An inactivated virus vaccine that provides active immunization against hepatitis A virus (HAV). Immunization with hepatitis A vaccine induces the formation of anti-HAV antibodies which provide protection against hepatitis A infection.","Hepatitis A Vaccine | Havrix | Hepatitis A Vaccine, Inactivated | Vaqta | hepatitis A vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3644158","Hepatitis B Vaccine","C29091","A non-infectious mixture containing recombinant hepatitis B surface antigen (HBsAg) in a liquid vehicle. Immunization with the hepatitis B vaccine induces the formation of specific anti-hepatitis B antibodies and an active immunity against hepatitis B infection.","Hepatitis B Vaccine | ENGERIX-B | Hepatitis B Vaccine (Recombinant) | RECOMBIVAX HB | Recombinant Hepatitis B Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019497","Hexylresorcinol","C29092","A substituted phenol with bactericidal, antihelminthic and potential antineoplastic activities. Hexylresorcinol is used as an antiseptic in mouthwashes and skin wound cleansers. Hexylresorcinol may also inhibit oxidative DNA damage by enhancing the activity of antioxidant enzymes, including glutathione peroxidase and glutathione reductase, which facilitate scavenging reactive oxygen molecules by glutathione (GSH).","Hexylresorcinol | 4-Hexylresorcinol | HEXYLRESORCINOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020261","Hydrochlorothiazide","C29098","A short acting thiazide diuretic. Hydrochlorothiazide (HCTZ) is widely used to treat hypertension and edema. This agent's metabolite appears to preferentially bind to and accumulate in red blood cells. This agent is primarily excreted by the kidneys.","Hydrochlorothiazide | 6-Chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide | HYDROCHLOROTHIAZIDE | Hydrodiuril",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020402","Hydroxyurea","C560","A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle.  This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. (NCI04)","Hydroxyurea | Droxia | HYDROXYUREA | Hydrea | Hydroxycarbamide | Litalir | Onco-Carbide | Onco-carbide | Oncocarbide | Oxeron | SQ 1089 | SQ-1089 | Syrea | WR 83799 | hydroxyurea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020404","Hydroxyzine","C29103","A piperazine derivative with antihistamine, antiemetic, and anxiolytic properties. Hydroxyzine's antihistaminic effect is due to its metabolite, cetirizine, a potent H1 receptor antagonist and selective inhibitor of peripheral H1 receptors. This agent competes with histamine for binding at H1-receptor sites on the effector cell surface. The sedative properties of hydroxyzine occur as a result of suppression of certain subcortical regions of the brain. Secondary to its central anticholinergic actions, hydroxyzine may be effective as an antiemetic.","Hydroxyzine | HYDROXYZINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596004","Hyoscyamine","C29104","A belladonna alkaloid derivative and the levorotatory form of racemic atropine isolated from the plants Hyoscyamus niger or Atropa belladonna, which exhibits anticholinergic activity. Hyoscyamine functions as a non-selective, competitive antagonist of muscarinic receptors, thereby inhibiting the parasympathetic activities of acetylcholine on the salivary, bronchial, and sweat glands, as well as the eye, heart, bladder, and gastrointestinal tract. These inhibitory effects cause a decrease in saliva, bronchial mucus, gastric juices, and sweat. Furthermore, its inhibitory action on smooth muscle prevents bladder contraction and decreases gastrointestinal motility.","Hyoscyamine | (-)-Atropine | (S)-Atropine | Benzeneacetic acid, alpha-(hydroxymethyl)-, 8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, (3(S)-endo)- | HYOSCYAMINE | Hyoscyamine Sulfate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020933","Imipenem","C570","A broad-spectrum, semi-synthetic beta-lactam carbapenem derived from thienamycin, produced by Streptomyces cattleya. Imipenem binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes that are involved in the last stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. This inactivation results in the weakening of the bacterial cell wall and eventually causes cell lysis. Imipenem has the greatest affinity for PBP 1A, 1B, and 2, and its lethal effect is related to binding to PBP 2 and 1B. This antibiotic is active against a wide range of gram-positive and gram-negative organisms and is stable in the presence of beta-lactamases. (NCI05)","Imipenem | 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic Acid, 6-(1-Hydroxyethyl)-3-((2-((iminomethyl)amino)ethyl)thio)-7-oxo-, Monohydrate, (5R-(5alpha,6alpha(R*)))- | IMIPENEM | Imipemide | MK-0787 | imipenem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512679","Immutol","C29117","A purified Norwegian Beta-Glucan (NBG), extracted from the cell walls of baker's yeast. Used as an immunostimulant in complementary medicine, NBG binds specifically to receptors found on the surface of specialized macrophages, granulocytes and natural killer cells and may stimulate these cells to become more active in engulfing and digesting foreign antigens; NBG also induces the production of cytokines that further augment the host immune response to foreign antigens. Use of this agent may enhance overall resistance to infectious agents and promote wound healing and tissue repair. (NCI04)","Immutol | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1444156","Anatolian Shepherd Dog","C54047","A large dog similar to the Great Pyrenees and the Kuvasz, but more slender with a large head and a large and blunt muzzle that is a bit shorter than the skull. Triangular, pendant ears are small with rounded tips. The back is short relative to leg length. The short or rough double coat is generally fawn with a black mask. The average height range is 26-30 inches and the average weight range is 90-150 pounds.","Anatolian Shepherd Dog | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1296824","Black Russian Terrier","C54048","A rare Russian breed that is robust, strong, large, stable, and alert. The head is powerfully built with a broad skull and a long head. A mustache and beard add to the squaring off of the muzzle. It has large and powerful jaws with a coarse, waterproof coat that covers the legs with 2 to 4 inches hair. The very large, bear-like feet are fully covered with hair and have tough, black, thick pads. The average height range is 27-30 inches and the average weight range is 80-130 pounds.","Black Russian Terrier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1296838","Canaan Dog","C54049","A sturdy, medium-sized, squarely proportioned herding dog with a bushy tail carried curled over the back when the dog is alert. The ears have a broad base and a rounded tip, and are set high. The straight, harsh, double coat lies flat and may be solid black, brown, and white, or in a patched pattern of white with black or brown. The average height range is 19-24 inches and weight is 35-55 pounds.","Canaan Dog | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1296905","Glen of Imaal Terrier","C54051","A sturdy dog that resembles the Welsh Corgi - a short legged dog that is low to the ground with a long body. It has a harsh, shaggy, medium-length coat that comes in many colors including red, blue, brindle, or wheaten. The ears are half-pricked or half-rose shaped. The average height is 14 inches and the average weight range is 34-36 pounds.","Glen of Imaal Terrier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1269310","Neapolitan Mastiff","C54052","The Neapolitan Mastiff is a muscular dog with a rather rectangular body, massive head, and wrinkled face. The facial wrinkles continue under the chin and down the neck. It has a short, harsh, dense, and smooth coat. The most common coat color is blue, though black is the next most common color. Chocolate dogs are rare. It can be either solid or brindle. The average height range is 24-30 inches and weight is up to 165 pounds.","Neapolitan Mastiff | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324432","Nova Scotia Duck Tolling Retriever","C54053","A well-muscled dog that is medium to heavy boned and resembles a small golden retriever. The coat is dense, and may be various shades of red and orange. It usually has small white markings on the feet, chest, tail, tip, and sometimes face. It may have a slight wave on its back, but the coat is otherwise straight. The ears are triangular and set high and are well back from the skull. The average height range is 17-21 inches and the average weight range is 37-51 pounds.","Nova Scotia Duck Tolling Retriever | Nova Scotia Duck-Tolling Retriever",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709588","Polish Lowland Sheepdog","C54054","A medium-sized, strong and muscular herding dog with characteristically long, hanging hair that covers the eyes. The profuse hair on the forehead, cheeks, and chin make the head look bigger than it actually is. It is doubled-coated and the body is covered with a long, dense, shaggy, thick coat that is reasonably straight. The undercoat is soft and dense. Ears are heart-shaped, drop, and set moderately high. The average height range is 17-20 inches and the average weight range is 30-50 pounds.","Polish Lowland Sheepdog | PON | Polski Owczarek Nizinny",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711211","German Pinscher","C54050","The German Pinscher, also called the Standard Pinscher, is a medium-sized, tall terrier with a smooth, glossy coat that comes in red fawn, black and tan, and dark brown with yellow markings. Black with tan markings is the most common. The ears have a natural fold when they are uncropped. Cropped ears are high set. The body is well-muscled with a straight back. The average height range is 16-19 inches and the average weight range is 25-35 pounds.","German Pinscher | Standard Pinscher",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448810","Bank","C54129","An officially chartered institution empowered to receive deposits, make loans, and provide checking and savings account services, all at a profit.","Bank | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0683756","Business Organization","C54128","A structure through which enterprises cooperate systematically to conduct activities for profit.","Business Organization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705158","Controlled Foreign Corporation","C54130","An offshore company in which a U.S. person owns 10 percent or more of a foreign corporation or in which 50 percent or more of the total voting stock is owned by U.S. shareholders collectively or 10 percent or more of the voting control is owned by U.S. persons which is treated by the IRS as a U.S. tax reporting entity.","Controlled Foreign Corporation | CFC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0683757","Company (organization)","C54131","Any formal business entity for profit, which may be a corporation, a partnership, association or individual proprietorship.","Company | Business",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0683758","Corporation","C54132","An organization formed with state governmental approval to act as an artificial person to carry on business (or other activities), which can sue or be sued, and (unless it is non-profit) can issue shares of stock to raise funds with which to start a business or increase its cap","Corporation | Corp.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708229","General Partnership","C54133","An association of two or more peoplecarrying on a business with the goal of earning a profit.","General Partnership | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708377","Homeowners Association","C54141","An organization comprised of all owners of units in the development.","Homeowners Association | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708593","Joint Stock Company","C54134","A company which has some features of a corporation and some features of a partnership. The company sells fully transferable stock, but all shareholders have unlimited liability.","Joint Stock Company | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704741","Limited Company","C54135","A business structure used in Europe and Canada, in which shareholder responsibility for company debt is limited to the amount he/she has invested in the company.","Limited Company | LC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708702","Limited Liability Partnership","C54136","A type of company, authorized only in certain states, whose owners and managers receive the limited liability and (usually) tax benefits of an S Corporation without having to conform to the S corporation restrictions.","Limited Liability Partnership | LLP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708705","Limited Partnership","C54137","A business organization with one or more general partners, who manage the business and assume legal debts and obligations, and one or more limited partners, who are liable only to the extent of their investments. Limited partners also enjoy rights to the partnership's cash flow, but are not liable for company obligations.","Limited Partnership | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709100","Mutual","C54142","Referring to anything in which both parties have reciprocal rights, understanding or agreement.","Mutual | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711206","Partnership","C54138","A business enterprise entered into for profit which is owned by more than one person, each of whom is a 'partner.'","Partnership | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0680946","Subsidiary","C54139","A company for which a majority of the voting stock is owned by a holding company.","Subsidiary | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710522","US Public Institution","C54140","A legal entity in the United States which is controlled by the state. Typically a public institution will have a board of trustees who govern the institution and the members of the board are public officials who are appointed by the state (typically a person in the executive branch such as a state governor) for a fixed term of years.","US Public Institution | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707416","Clinical Resource Contractor","C54146","A person, group, or organization that agrees to furnish something of, relating to, or connected with a clinic that can be used for support or help at a specified price.","Clinical Resource Contractor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707518","Correctional Institute",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707500","Contract Research Organization","C54148","A commercial organization contracted by a client to perform one or more research-related functions.","Contract Research Organization | CRO | Contract Research Organization (CRO) | contract research organization (CRO)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0815266","Drug Company","C54149","A company licensed to discover, develop, market and distribute drugs.","Drug Company | Pharmaceutical Company",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1274022","Employer","C54144","A person or entity which hires the services of another.","Employer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551340","guarantor","C54150","A person or entity that agrees to be responsible for another's debt or performance under a contract, if the other fails to pay or perform.","Guarantor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709482","Patient Advocacy Group","C54151","An organization that works to safeguard patients through effective mediation assuring access to care, maintenance of employment and preservation of their financial stability.","Patient Advocacy Group | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711214","Pharmacy Distribution Center","C54152","A place where drugs are received from manufacturer and stored for future shipment to other sites.","Pharmacy Distribution Center | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709695","Procurement","C54153","The process of obtaining services, supplies, and equipment in conformance with applicable laws and regulations.","Procurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520061","Volunteer Group","C19440","A group of individuals who voluntarily enter into an agreement to form a body (or organization) to accomplish a purpose.","Volunteer Group | Voluntary Association",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018759","Health Status (individual)","C16669","The state of a subject's mental or physical condition.","Health Status | General Health Status",,,,,,,,,,,,,,,"4247398","Health status",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027552","Need","C41204","Anything that is necessary but lacking; the psychological feature that arouses an organism to action toward a desired goal; the reason for the action; that which gives purpose and direction to behavior.","Need | Needs",,,,,,,,,,,,,,,"4256472","Needed",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013453","External Ear","C12292","The external part of the ear.","External Ear | Auricle | EAR, OUTER | Ear, External | External ear | PINNA | Pinna | auricle | auricle of ear | auricle of external ear | auricula | auris externa | pinna | pinna of ear",,,,,,,,,,,,,"UBERON:0001757","pinna","4153243","External ear structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0717367","Hydrocodone/Acetaminophen","C29100","A combination preparation of the analgesic acetaminophen and the semisynthetic opioid agonist hydrocodone with analgesic and antitussive activities. Acetaminophen exerts its analgesic activity by inhibiting prostaglandin synthesis while hydrocodone exerts its analgesic activity by binding to the mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids.","Hydrocodone/Acetaminophen | Lorcet | Vicodin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700533","Hydromorphone Hydrochloride","C436","The hydrochloride salt form of hydromorphone, the hydrogenated ketone of morphine, a semi-synthetic opioid with analgesic effects. Hydromorphone selectively binds the mu-opioid receptor which is linked through G-proteins. Binding stimulates the exchange of guanosine triphosphate (GTP) for guanosine diphosphate (GDP) on the G-protein complex and interacts with and inhibits adenylate cyclase located at the inner surface of the plasma membrane. This leads to a reduction in intracellular cyclic 3',5'-adenosine monophosphate (cAMP). Further, voltage-gated potassium channels are activated, thereby causing hyperpolarization and reducing neuronal excitability. In addition, the opening of voltage-gated calcium channels is inhibited, thereby leading to an inhibition of calcium entry and a reduction in the release of various neurotransmitters, including GABA, vasopressin, somatostatin, insulin and glucagons.","Hydromorphone Hydrochloride | Dilaudid | Dilaudid HP | Dimorphone | Exalgo | HYDROMORPHONE HYDROCHLORIDE | Hydromorphone | Hydrostat | Hymorphan | Laudicon | Novolauden",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596007","Hydroxychloroquine Sulfate","C29101","A synthetic derivative of quinolyl with chemotherapeutic and antibiotic properties, Hydroxychloroquine Sulfate acts against erythrocytic malarial parasites (Plasmodium vivax, ovale, and malariae) by concentrating in food vacuoles. It inhibits plasmodial heme polymerase and acts through other unknown mechanisms. Hydroxychloroquine also has anti-inflammatory properties and is used in the treatment of rheumatoid arthritis and lupus erythematosus. (NCI04)","Hydroxychloroquine Sulfate | HYDROXYCHLOROQUINE SULFATE | Plaquenil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021186","Indapamide","C29119","An indole derivative of chlorosulphonamide and a sulfamyl diuretic with antihypertensive activity. Indapamide may interact directly with the subunits of delayed rectifier potassium channels, thereby blocking both slow and rapid K+ (IKs and IKr) currents through the channels. Through the homeostasis mechanism in balancing total ion concentration (Ca++, Na+), it reduces vascular hyperreactivity and peripheral and arterial vascular resistance, possibly by inhibiting transmembrane ionic influx, probably calcium ions, and stimulating prostaglandin E2 synthesis, thereby causing vasodilatation. Indapamide exerts its diuretic effect by inhibiting reabsorption of sodium and chloride, primarily as a result of action on the cortical diluting segment of the renal distal tubule, thereby promoting urinary excretion of water and electrolytes.","Indapamide | INDAPAMIDE | Lozol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021547","Inositol","C28163","A natural sugar found in cell membrane phospholipids, plasma lipoproteins, and (as the phosphate form) in the nucleus with potential chemopreventive properties. As one of a number of intracellular phosphate compounds, inositol is involved in cell signaling and may stimulate tumor cell differentiation. (NCI04)","Inositol | Cyclohexanehexol | INOSITOL | cis-1,2,3,5-trans-4,6-Cyclohexanehexol | inositol | myo-Inositol | myoinositol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021641","Human Insulin Regular","C29125","A recombinant form of the naturally occurring human pancreatic hormone insulin. Upon administration, regular insulin mimics the action of endogenous human insulin and binds to insulin receptors located on muscle and fat cells. This both facilitates the cellular uptake of glucose and lowers blood glucose levels. In addition, insulin inhibits the liver's conversion of stored glycogen into glucose, which also decreases blood glucose levels. Insulin also inhibits lipolysis in adipose tissue, inhibits proteolysis, and enhances protein synthesis.","Insulin, Regular | Humulin R | Novolin R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041616","Insulin, Ultralente","C29126","A long-acting form of crystalline insulin often used in combination with a short-acting insulin in the treatment of diabetes mellitus.  Administered once daily, this type of insulin may be derived from porcine, bovine, or recombinant sources.  Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats; it has anabolic effects on many types of tissues. (NCI04)","Insulin, Ultralente | Humulin U | Insulin Zinc Injectable Suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512802","Insulin, 70/30","C29121","A mixture of two types of insulin consisting of 70 percent long-acting insulin suspension and 30 percent rapid-acting insulin.  Typically administered twice a day, insulin 70/30 controls postprandial glycemia and allows convenient mealtime dosing. The long-acting insulin component controls blood glucose levels between meals. Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats; it has anabolic effects on many types of tissues. (NCI04)","Insulin, 70/30 | Humulin 70/30 | Novolin 70/30",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL414513","Interferon beta","C20495","Interferon beta (187 aa, ~22 kDa) is encoded by the human IFNB1 gene. This protein plays a role in interferon signaling and host defense.","Interferon Beta | Beta Interferon | Beta-Interferon | Endogenous Interferon Beta | Fibroblast Interferon | IFN-Beta | IFNB1 | Interferon Beta 1 | Interferon Beta, Natural | Interferon, Beta | Natural human interferon beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1610033","Interferon Alpha, Human","C20494","A class of interferon (leukocyte interferon) produced predominantly by B lymphocytes.  Located in a cluster on 9p22 there are at least 13 functional genes and 1 pseudogene.","Interferon Alpha | Human leukocyte interferon | IFN Alpha | alpha interferon | leukocyte interferon | lymphoblast interferon | lymphoblastoid interferon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021745","Interferon Gamma","C20496","Interferon gamma (166 aa, ~19 kDa) is encoded by the human IFNG gene. This protein is involved in antiviral activity, macrophage activation, antiproliferative activity and immunopotentiation.","Interferon Gamma | Gamma Interferon | Gamma-Interferon | IFN-Gamma | IFN-II | IFN-g | IFNG | Immune Interferon | Interferon Type II | Interferon-Gamma | Type II Interferon | interferon, gamma | lFN-Gamma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022026","Iopamidol","C47567","An organic iodine compound and used as a non-ionic water soluble radiographic contrast medium. Iopamidol blocks x-rays as they pass through the body, thereby allowing body structures not containing iodine to be visualized. The degree of opacity produced by iopamidol is directly proportional to the total amount of the iodinated contrast agent in the path of the x-rays. The visualization of body structures is dependent upon the distribution and elimination of iopamidol. (NCI05)","Iopamidol | (S)-N,N'-bis(2-Hydroxy-1-(hydroxymethyl)ethyl)-2,4,6-triiodo-5-lactamidoisophthalamide | 1,3-Benzenedicarboxamide, N,N'-bis(2-hydroxy-1-(hydroxymethyl)ethyl)-5-((2-hydroxy-1-oxopropyl)amino)-2,4,6-triiodo- | IOPAMIDOL | Isovue | Niopam | Solutrast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700580","Ipratropium Bromide","C29128","The bromide salt form of ipratropium, a synthetic derivative of the alkaloid atropine with anticholinergic properties. Ipratropium antagonizes the actions of acetylcholine at parasympathetic, postganglionic, effector-cell junctions. When inhaled, ipratropium binds competitively to cholinergic receptors in the bronchial smooth muscle thereby blocking the bronchoconstrictor actions of the acetylcholine mediated vagal impulses. Inhibition of the vagal tone leads to dilation of the large central airways resulting in bronchodilation.","Ipratropium Bromide | (8R)-3alpha-Hydroxy-8-isopropyl-1alpha H,5alphaH-tropanium Bromide (+-)-tropate Monohydrate | Atrovent | Atrovent HFA | IPRATROPIUM BROMIDE | Ipratropium Bromide Hydrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0717386","Ipratropium/Albuterol","C29129","A combination of albuterol and ipratropium with a bronchodilatory effect. Albuterol stimulates beta-2 adrenergic receptors in the lungs, thereby activating the enzyme adenylate cyclase that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'- adenosine monophosphate (cAMP). This results in the relaxation of bronchial smooth muscle, relieve of bronchospasms, and reduction of inflammatory cell mediator release. Ipratropium is a synthetic quaternary ammonium compound and a competitive muscarinic acetylcholine (Ach) receptor antagonist. This agent inhibits vagally mediated reflexes by antagonizing the action of Ach and consequently, prevents the increase in intracellular cyclic guanosine monophosphate, which is a result of ACh interacting with the muscarinic receptor on bronchial smooth muscle.","Ipratropium/Albuterol | Combivent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0595301","Irbesartan","C29130","A nonpeptide angiotensin II antagonist with antihypertensive activity. Irbesartan selectively and competitively blocks the binding of angiotensin II to the angiotensin I receptor. Angiotensin II stimulates aldosterone synthesis and secretion by adrenal cortex, which decreases the excretion of sodium and increases the excretion of potassium. Angiotensin II also acts as a vasoconstrictor in vascular smooth muscle. (NCI05)","Irbesartan | Avapro | IRBESARTAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020268","Therapeutic Hydrocortisone","C555","A synthetic or semisynthetic analog of natural hydrocortisone hormone produced by the adrenal glands with primary glucocorticoid and minor mineralocorticoid effects. As a glucocorticoid receptor agonist, hydrocortisone promotes protein catabolism, gluconeogenesis, capillary wall stability, renal excretion of calcium, and suppresses immune and inflammatory responses. (NCI04)","Therapeutic Hydrocortisone | (11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione | Aeroseb-HC | Barseb HC | Barseb-HC | Cetacort | Cort-Dome | Cortef | Cortenema | Cortifan | Cortisol | Cortispray | Cortril | Dermacort | Domolene | Eldecort | HYDROCORTISONE | Hautosone | Heb-Cort | Hydrocortisone | Hydrocortone | Hytone | Komed-HC | Nutracort | Proctocort | Rectoid | hydrocortisone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512541","Hydroxypropyl Methylcellulose D","C29102","A semisynthetic, high viscosity polymer used as a food additive which may have the ability to lower total cholesterol and low-density lipoprotein cholesterol (LDL-C).","Hydroxypropyl Methylcellulose D | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021755","Interleukin-1","C20506","Interleukin-1 (endogenous pyrogen), produced primarily by monocytes, is an important pro-inflammatory cytokine that mediates the acute phase host response.  The biologic activities of IL1 are properties of a protein derived from a larger precursor.  Inflammation causes induction of COX2, leading to release of prostanoids, which sensitize peripheral nociceptor terminals and produce local pain hypersensitivity.  Inflammation also generates sensitivity in neighboring tissue, muscle and joint pain, fever, lethargy, and anorexia.  COX2 induction in regions of the CNS is mediated by IL1B.  Interleukin-1-beta also stimulates bone resorption.  IL1RN is a competitive inhibitor of IL1B.  Mature IL1-beta levels are a sensitive and specific indicator of caspase-1 activation.  (from OMIM 147720 and NCI)","Interleukin-1 | IL-1 | IL1 | IL1B | Lymphocyte Activating Factor | Lymphocyte-Stimulating Hormone | Macrophage Cell Factor | interleukin-1",,,,,,,,,,,,,,,"4178276","Interleukin-1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0123759","Interleukin-12","C20514","Exhibiting a broad range of biological activities on T and natural killer cells, Interleukin-12 is a disulfide-bonded heterodimeric cytokine composed of a 35-kD IL12A subunit (IL-6 Superfamily) and a 40-kDa IL12B subunit (Type I Cytokine Receptor 3 Family). IL12 stimulates T-cell-independent production of IFN-gamma by PBMCs, enhances NK cell lytic activity, acts as a growth factor for T- and NK-cells, and is important for Th1 and Th2 cell differentiation. Lymphocyte responses to IL12 require NOS2A and are mediated by STAT4 activator of transcription. (NCI)","Interleukin-12 | CLMF | Cytotoxic Lymphocyte Maturation Factor | IL-12 | IL-12 p70 | IL-12p70 | IL12 | Interleukin 12 | NKSF | Natural Killer Cell Stimulatory Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1698754","Interleukin-6, Human","C20451","Interleukin-6 (212 aa, ~24 kDa) is encoded by the human IL6 gene. This protein is involved in signaling affecting a wide variety of cell types including monocytes, lymphocytes, hepatocytes and nerve cells.","Interleukin-6 | B Cell Differentiation Factor 2 | B-Cell Differentiation Factor | B-Cell Stimulatory Factor 2 | B-Cell Stimulatory Factor-2 | BSF-2 | BSF2 | CDF | CTL Differentiation Factor | HGF | HPGF | HSF | Hepatocyte Stimulating Factor | Hepatocyte Stimulatory Factor | Hybridoma Growth Factor | IFN Beta 2 | IFN-Beta-2 | IFNB2 | IL-6 | IL6 | IL6 Protein | Interferon Beta-2 | Interferon, Beta-2 | Interleukin 6 | Interleukin BSF-2 | Myeloid Differentiation Inducing Protein | Plasmacytoma Growth Factor | Sigosix | interleukin-6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0733696","Imipenem-Cilastatin Sodium","C2338","A parenteral antibiotic preparation containing imipenem and cilastatin sodium with bactericidal activity. Imipenem, a broad spectrum beta-lactam antibiotic, binds to penicillin-binding proteins (PBP) on the inner membrane of the bacterial cell wall, thereby interfering with the cross-linkage of peptidoglycan chains critical for bacterial cell wall strength and rigidity. Cilastatin sodium is added to reduce breakdown of imipenem by kidney dehydropeptidase.  This agent is effective against both gram positive and negative bacteria and is often used in treating severe infections caused by multiresistant organisms.","Imipenem-Cilastatin Sodium | Imipenem/Cilastatin Sodium | Primaxin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0589978","Imipramine Hydrochloride","C29116","The hydrochloride salt form of imipramine, a synthetic tricyclic derivative, antidepressant Imipramine enhances monoamine neurotransmission in certain areas of the brain. It also induces sedation through histamine 1 receptor blockage; hypotension through beta-adrenergic blockage; and diverse parasympatholytic effects. Imipramine has less sedative effect than other members of its therapeutic family. It is used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. (NCI04)","Imipramine Hydrochloride | IMIPRAMINE HYDROCHLORIDE | Tofranil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700483","Indinavir Sulfate","C1662","A synthetic antiviral agent. Indinavir selectively binds to the active site of human immunodeficiency virus (HIV) protease and inhibits its activity, preventing the protease-mediated cleavage of gag-pol viral polyproteins; as a result immature, noninfectious virions are produced.","Indinavir Sulfate | Crixivan | D-erythro-Pentonamide, 2,3,5-trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-, monohydrate, (1(1S,2R),5(S))-, sulfate (1:1) (salt) | DRG-0233 | INDINAVIR SULFATE | L-735,524 | MK-639",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021246","Indomethacin","C576","A synthetic nonsteroidal indole derivative with anti-inflammatory activity and chemopreventive properties. As a nonsteroidal anti-inflammatory drug (NSAID), indomethacin inhibits the enzyme cyclooxygenase, thereby preventing cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines. This agent also may inhibit the expression of multidrug-resistant protein type 1, resulting in increased efficacies of some antineoplastic agents in treating multi-drug resistant tumors. In addition, indomethacin activates phosphatases that inhibit the migration and proliferation of cancer cells and downregulates survivin, which may result in tumor cell apoptosis. (NCI04)","Indomethacin | 1-(4-chlorobenzoyl)-5-methoxy- 2-methyl-1-H-indole-3-acetic acid | INDOMETHACIN | Indocin | Indometacin | indomethacin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1702044","IL2 protein, human","C20507","Interleukin-2 (153 aa, ~18 kDa) is encoded by the human IL2 gene. This protein is involved in T-cell proliferation, leukocyte stimulation and immune responses.","Interleukin-2 | ETAF | Epidermal Thymocyte Activating Factor | IL-2 | IL2 | IL2 Protein | Interleukin 2 | Interleukin 2 Precursor | Interleukin II | Lymphocyte Mitogenic Factor | Mitogenic Factor | Ro-236019 | T Cell Growth Factor | T-Cell Growth Factor | TCGF | TSF | Thymocyte Stimulating Factor | hIL-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0071304","Isradipine","C47577","A dihydropyridine calcium channel blockers with antihypertensive and vasodilator activities. Isradipine blocks the calcium entry through the calcium ion channels of coronary and peripheral vascular smooth muscle, thereby dilating coronary arteries and peripheral arterioles. This increases oxygen delivery due to an increased blood flow and reduces oxygen requirements due to decrease in total peripheral resistance. (NCI05)","Isradipine | 3,5-Pyridinedicarboxylic Acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, Methyl 1-methylethyl Ester | Dynacirc | ISRADIPINE | Isopropyl methyl(+-)-4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate | Lomir",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0939237","Lopinavir/Ritonavir","C2096","A fixed combination of two protease inhibitors, lopinavir and ritonavir, used to treat human immunodeficiency virus (HIV) infection. The ritonavir in the combination drug increases the concentration and biological half-life of lopinavir but is not present in sufficient concentration to act as a protease inhibitor.","Lopinavir/Ritonavir | Kaletra | lopinavir/ritonavir",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022209","Isoniazid","C600","A synthetic derivative of nicotinic acid with anti-mycobacterial properties.  Although its mechanism of action is still unclear, isoniazid appears to block the synthesis of mycolic acids, major components of the mycobacterial cell wall. This agent is only active against actively growing mycobacteria because, as a pro-drug, it requires activation in susceptible mycobacterial species. Isoniazid also interferes with mycobacterial metabolism of vitamin B6.  Resistance occurs due to decreased bacterial wall penetration. (NCI04)","Isoniazid | ISONIAZID | Isonicotinic Acid Hydrazide | Isonicotinyl Hydrazine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282210","Isoproterenol Hydrochloride","C29133","The hydrochloride salt form of isoproterenol, a synthetic catechol compound and potent beta adrenergic agonist with peripheral vasodilator, bronchodilator, and cardiac stimulating properties. Isoproterenol exerts its effect on the beta-1 adrenergic receptors in the myocardium, thereby increasing heart rate and cardiac output. In addition, isoproterenol acts on beta-2 adrenergic receptors in bronchiolar and vascular smooth muscle, thereby causing smooth muscle relaxation.","Isoproterenol Hydrochloride | 4-[1-Hydroxy-2-[(1-methylethyl)amino]ethyl]-1,2-benzenediol Hydrochloride | ISOPROTERENOL HYDROCHLORIDE | Isuprel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022252","Isosorbide Dinitrate","C29134","The dinitrate salt form of isosorbide, an organic nitrate with vasodilator activity. Isosorbide dinitrate relaxes vascular smooth muscle by formation of the free radical nitric oxide (NO), which is identical to the endothelium-derived relaxing factor (EDRF). NO activates guanylyl cyclase, thereby increasing the synthesis of cGMP within smooth muscle, resulting in dephosphorylation of light chain myosin and relaxation of peripheral arteries and veins. In addition, isosorbide dinitrate relaxes coronary arteries, thereby increasing the blood circulation through the ischemic area. (NCI05)","Isosorbide Dinitrate | ISOSORBIDE DINITRATE | Isordil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0064113","Itraconazole","C1138","A synthetic triazole agent with antimycotic properties. Formulated for both topical and systemic use, itraconazole preferentially inhibits fungal cytochrome P450 enzymes, resulting in a decrease in fungal ergosterol synthesis.  Because of its low toxicity profile, this agent can be used for long-term maintenance treatment of chronic fungal infections. (NCI04)","Itraconazole | (+-)-1-sec-Butyl-4-(p-(4-(p-(((2R*,4S*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-delta(sup 2)-1,2,4-triazolin-5-one | ITRACONAZOLE | Lozanoc | Oriconazole | R 51,211 | Sporanox | itraconazole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524079","IV Fluid","C29107","A sterile liquid preparation infused into a vein.  IV fluid is prescribed as a replacement of fluid, electrolytes, calories, vitamins, and other nutritional substances.  In addition, IV fluids are used to administer blood products and medications such as chemotherapy.  Examples of IV fluids include Normal Saline, Ringers Solution, and Lactated Ringers Solution. (NCI)","IV Fluid | Intravenous Fluid",,,,,,,,,,,,,,,"4042177","Intravenous fluid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022625","Ketoconazole","C605","A synthetic derivative of phenylpiperazine with broad antifungal properties and potential antineoplastic activity.  Ketoconazole inhibits sterol 14-a-dimethylase, a microsomal cytochrome P450-dependent enzyme, thereby disrupting synthesis of ergosterol, an important component of the fungal cell wall. (NCI04)","Ketoconazole | Cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazole-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine | Fungarest | Fungoral | KETOCONAZOLE | Ketoderm | Ketoisdin | Nizoral | Orifungal M | Panfungol | R-41400 | Xolegel | ketoconazole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022635","Ketoprofen","C47578","A propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic effects. Ketoprofen inhibits the activity of the enzymes cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. The resulting decrease in prostaglandin synthesis, by prostaglandin synthase, is responsible for the therapeutic effects of ibuprofen. Ketoprofen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation.","Ketoprofen | Benzeneacetic Acid, 3-benzoyl-alpha-methyl- | Capisten | KETOPROFEN | Orudis | Oruvail | Propionic Acid, 2-(3-benzoylphenyl)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0073631","Ketorolac","C1219","A synthetic pyrrolizine carboxylic acid derivative with anti-inflammatory, analgesic, and antipyretic activities. Ketorolac non-selective inhibits the enzymes cyclooxygenase 1 (COX-1) and COX-2. The inhibition of COX-2, up-regulated at sites of inflammation, prevents conversion of arachidonic acid to pro-inflammatory prostaglandins. The inhibition of COX-1 by this agent prevents the normal steady-state production of prostaglandins that play housekeeping roles in the protection of the gastrointestinal tract, the regulation of renal blood flow, and platelet aggregation. As a result, the inhibition of COX-1 may be associated with gastrointestinal toxicity, nephrotoxicity, and the inhibition of platelet aggregation.","Ketorolac | KETOROLAC | ketorolac",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022860","Labetalol","C29146","A third generation selective alpha-1-adrenergic antagonist and non-selective beta-adrenergic antagonist with vasodilatory and antihypertensive properties. Labetalol competitively binds to alpha-1-adrenergic receptors in vascular smooth muscle, thereby inhibiting the adrenergic stimulation of endothelial cell function and vasoconstriction in peripheral blood vessels. This agent also binds to beta-receptors in the bronchial and vascular smooth muscle, resulting in a decrease in adrenergic stimulation. The result is a decrease in resting and exercise heart rates, cardiac output, and in both systolic and diastolic blood pressure, thereby resulting in vasodilation, and negative chronotropic and inotropic cardiac effects.","Labetalol | LABETALOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022957","Lactulose","C29148","A disaccharide (sugar) synthesized from fructose and galactose, Lactulose is used to treat constipation and some liver diseases. Nondigestible in mammals, lactulose passes unabsorbed down to the large intestine where resident bacteria consume it and produce lactic, acetic, and formic acids, which draw fluid into the bowel to soften the stool (laxative effect). Acidification of the colon contents attracts ammonia from the bloodstream, assisting stool excretion; helpful in liver failure when ammonia cannot be detoxified. (NCI04)","Lactulose | 4-O-beta-D-Galactopyranosyl-D-fructofuranose | Cephulac | Chronulac | LACTULOSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0878244","Laetrile","C29149","Originally, the name laetrile was the contraction of laevo-mandelonitrile glucoside, a cyanogenic glycoside found naturally in some plants.  Over the years the meaning of laetrile has changed.  There are now preparations called Laetrile where amygdalin is the major constituent.  Laetrile and amygdalin are often used interchangeably, but are different agents.  Cyanide and benzaldehyde are metabolites of both laetrile and amygdalin.  Both metabolites may possess antineoplastic properties.  Laetrile has been used as an anticancer treatment in humans worldwide, but scientific evidence does not support its effectiveness.  It is not approved for use in the United States. (NCI04)","Laetrile | Beta-D-Glucopyranosiduronic acid, alpha-cyanobenzyl | Cyanophenylmethyl-beta-D-glucopyranosiduronic acid | L-Mandelonitrile-beta-glucuronoside | Laetrille | Laetrille | Mandelonitrile-beta-glucuronide | Vitamin B17 | laetrile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0064636","Lamotrigine","C38703","A synthetic phenyltriazine with antiepileptic and analgesic properties.  Lamotrigine enhances the action of gamma-aminobutyric acid, an inhibitory neurotransmitter, which may result in a reduction of pain-related transmission of signals along nerve fibers. This agent may also inhibit voltage-gated sodium channels, suppress glutamate release, and inhibit serotonin reuptake. (NCI04)","Lamotrigine | LAMOTRIGINE | Lamictal | lamotrigine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0050940","Lansoprazole","C29150","A substituted benzimidazole prodrug with selective and irreversible proton pump inhibitor activity. Lansoprazole prodrug is converted to an active sulfonamide derivative in the acidic environment of the gastric parietal cell; the sulfonamide derivative binds to the gastric proton pump H+/K+ ATPase and forms a stable disulfide bond with the sulfhydryl group near the potassium-binding site on the luminal side, resulting in inactivation of the ATPase and a reduction in gastric acid secretion. This agent does not have anticholinergic or histamine H2 -receptor antagonistic properties.","Lansoprazole | LANSOPRAZOLE | Prevacid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0593887","Latanoprost","C29151","A prostaglandin F2alpha analogue and a prostanoid selective FP receptor agonist with an ocular hypertensive effect. Latanoprost increases uveoscleral outflow and thereby reduces intraocular pressure.","Latanoprost | LATANOPROST | Xalatan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0733383","Levamisole Hydrochloride","C610","The hydrochloride salt of the synthetic imidazothiazole derivative levamisole with anthelminthic and immunomodulating activities. In immunosuppressed states, levamisole may restore immune function by: 1) stimulating antibody formation, 2) stimulating T-cell activation and proliferation, 3) potentiating monocyte and macrophage phagocytosis and chemotaxis and 4) increasing neutrophil mobility, adherence, and chemotaxis.","Levamisole Hydrochloride | (S)-2,3,5,6-Tetrahydro-6-phenylimidazo[2,1-b]thiazole Monohydrochloride | Ascaridil | Cloridrato de Levamizol | Decaris | Ergamisol | Ergamisole | ICI-59623 | Immunol | Ketrax | LEVAMISOLE HYDROCHLORIDE | Levamisole | R 12564 | R-12564 | RP-20605 | Solaskil | Tramisol | Trimisol | l-Tetramisole Hydrochloride | l-Tetramisole hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448740","Levarterenol Bitartrate Anhydrous","C29152","The anhydrous bitartrate salt form of levarterenol, the levorotatory isomer of norepinephrine with a vasoconstrictor effect. Levarterenol binds to alpha and beta-1 receptor sites of sympathetic effector cells, thereby causing vasoconstriction of the radial smooth muscle of the arteries, arterioles, and veins and increasing myocardial contractility, heart rate, automaticity, and artrioventricular (AV) conduction, respectively. Stimulation of the beta-2 adrenergic receptors causes bronchiolar and vascular smooth muscle dilatation.","Levarterenol Bitartrate Anhydrous | Levarterenol Bitartrate | NOREPINEPHRINE BITARTRATE ANHYDROUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0377265","Levetiracetam","C47581","A pyrrolidine with antiepileptic activity. The exact mechanism through which levetiracetam exerts its effects is unknown but does not involve inhibitory and excitatory neurotransmitter activity. Stereoselective binding of levetiracetam was confined to synaptic plasma membranes in the central nervous system with no binding occurring in peripheral tissue. Levetiracetam inhibits burst firing without affecting normal neuronal excitability, which suggests that it may selectively prevent hyper-synchronization of epileptiform burst firing and propagation of seizure activity.","Levetiracetam | (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide | 1-Pyrrolidineacetamide, Alpha-ethyl-2-oxo-,(S)- | Keppra | LEVETIRACETAM | levetiracetam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700541","Ketamine Hydrochloride","C29142","The hydrochloride salt of a synthetic derivative of cyclohexanone with analgesic and anesthetic activities. Although its mechanism of action is not well understood, ketamine appears to non-competitively block N-methyl-D-aspartate (NMDA) receptors and may interact with opioid mu receptors and sigma receptors, thereby reducing pain perception, inducing sedation, and producing dissociative anesthesia.","Ketamine Hydrochloride | KETAMINE HYDROCHLORIDE | Ketalar | Ketamine | Ketamine HCl | ketamine hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0083183","Lactase","C29147","Formulated in various oral forms for use in lactose intolerance, Lactase Enzyme (Lactaid) is a dietary supplement that breaks down lactose (milk sugar) in dairy foods. It prevents gas, diarrhea, and bloating caused by consumption from dairy foods in people that lack the natural lactase enzyme. (NCI04)","Lactase | LACTASE | Lactaid | Lactase Enzyme | Lactase Enzyme | lactase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0087163","Levocarnitine","C26657","An amino acid derivative.  Levocarnitine facilitates long-chain fatty acid entry into mitochondria, delivering substrate for oxidation and subsequent energy production. Fatty acids are utilized as an energy substrate in all tissues except the brain. (NCI04)","Levocarnitine | Carnitor | L-carnitine | LEVOCARNITINE | levocarnitine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0591174","Levobunolol Hydrochloride","C29153","The hydrochloride salt form of levobunolol, a naphthalenone and non-cardioselective adrenergic beta-receptor antagonist with anti-glaucoma activity. Upon administration in the eye, levobunolol blocks beta-adrenergic receptors, thereby causing vasoconstriction. Levobunolol also decreases ciliary's body production of aqueous humor, leading to a decrease in aqueous humor.","Levobunolol Hydrochloride | Betagan | LEVOBUNOLOL HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079691","Levothyroxine Sodium","C888","The sodium salt of levothyroxine, a synthetic levoisomer of thyroxine (T4) that is similar to the endogenous hormone produced by the thyroid gland. In peripheral tissues, levothyroxine is deiodinated by 5'-deiodinase to form triiodothyronine (T3). T3 enters the cell and binds to nuclear thyroid hormone receptors; the activated hormone-receptor complex in turn triggers gene expression and produces proteins required in the regulation of cellular respiration; thermogenesis; cellular growth and differentiation; and the metabolism of proteins, carbohydrates and lipids. T3 also exhibits cardiostimulatory effects.","Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Levothroid | Levothyroxine sodium | Sodium levothyroxine | Synthroid | Therapeutic Levothyroxine | Thyroid hormone replacement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0546869","Lidocaine Hydrochloride","C48000","The hydrochloride salt form of lidocaine, an aminoethylamide and a prototypical member of the amide class anesthetics. Lidocaine interacts with voltage-gated Na+ channels in the nerve cell membrane and blocks the transient increase in permeability of excitable membranes to Na+. This prevents the generation and conduction of nerve impulses and produces a reversible loss of sensation. Lidocaine hydrochloride also exhibits class IB antiarrhythmic effects. The agent decreases the flow of sodium ions into myocardial tissue, especially on the Purkinje network, during phase 0 of the action potential, thereby decreasing depolarization, automaticity and excitability.","Lidocaine Hydrochloride | 2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide Monohydrochloride | LIDOCAINE HYDROCHLORIDE | Xylocaine | Xylocitin | Xylotox",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0546882","Liothyronine Sodium","C2581","The sodium salt form of liothyronine, a synthetic form of the levorotatory isomer of the naturally occurring thyroid hormone triiodothyronine (T3). Liothyronine sodium binds to nuclear thyroid receptors which then bind to thyroid hormone response elements of target genes. As a result, liothyronine sodium induces gene expression that is required for normal growth and development. Liothyronine sodium is more potent and has a more rapid action than thyroxine (T4).","Liothyronine Sodium | Cytomel | LIOTHYRONINE SODIUM | Triostat | liothyronine sodium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282386","Levofloxacin","C1586","A broad-spectrum, third-generation fluoroquinolone antibiotic and optically active L-isomer of ofloxacin with antibacterial activity. Levofloxacin diffuses through the bacterial cell wall and acts by inhibiting DNA gyrase (bacterial topoisomerase II), an enzyme required for DNA replication, RNA transcription, and repair of bacterial DNA. Inhibition of DNA gyrase activity leads to blockage of bacterial cell growth.","Levofloxacin | (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic Acid Hydrate (2:1) | 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic Acid, 9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, Hydrate (2:1), (S)- | LEVOFLOXACIN | Levaquin | Levofloxacin Hydrate | Quixin | levofloxacin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517867","Lidobenalox","C29155","An oral suspension of viscous lidocaine, diphenhydramine (Benadryl) and aluminum and magnesium hydroxides (Maalox). This agent possesses anesthetic, antihistamine, and antacid properties. (NCI04)","Lidobenalox | Lidobenalox Solution | Lidocain,Viscous/Benadryl/Maalox",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0876068","Lidocaine Patch","C29988","A transdermal patch containing a 5 percent aqueous base solution of the synthetic amide-type anesthetic lidocaine with analgesic activity. Upon topical application and transdermal delivery, the active ingredient lidocaine binds to and blocks voltage-gated sodium channels in the neuronal cell membrane; lidocaine-mediated stabilization of neuronal membranes inhibits the initiation and conduction of nerve impulses and produces a reversible local anesthesia.","Lidocaine Patch | Lidoderm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0360097","Lidocaine Topical","C29989","A synthetic aminoethylamide with local anesthetic activity applied topically to either the skin or mucous membranes. Lidocaine stabilizes the neuronal cell membrane by binding to and inhibiting voltage-gated sodium channels, thereby inhibiting the initiation and conduction of nerve impulses and producing a reversible loss of sensation.","Lidocaine Topical | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1251135","Lidocaine Oral Solution","C29987","A synthetic aminoethylamide with anesthetic activity applied topically to the mucous membranes in the mouth and/or throat. Lidocaine stabilizes the neuronal cell membrane by binding to and inhibiting voltage-gated sodium channels, thereby inhibiting the initiation and conduction of nerve impulses and producing a reversible loss of sensation. Lidocaine oral solution applied to specific areas in the mouth and/or throat is used to provide relief of pain and discomfort during dental procedures and due to irritated or inflamed mucous membranes of the mouth and pharynx.","Lidocaine Oral Solution | Viscous Lidocaine HCl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0663241","Linezolid","C29158","A synthetic oxazolidinone derivative, Linezolid selectively inhibits an early step in bacterial protein synthesis and affects blood pressure through monoamine oxidase inhibition. It is effective against Gram-positive organisms, including methicillin-resistant Staphylococcus aureus strains, coagulase-negative Staphylococci, vancomycin-resistant Enterococci, and penicillin-resistant Streptococcus pneumoniae strains. (NCI04)","Linezolid | LINEZOLID | Zyvox",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0065374","Lisinopril","C29159","An orally bioavailable, long-acting angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. Lisinopril, a synthetic peptide derivative, specifically and competitively inhibits ACE, which results in a decrease in the production of the potent vasoconstrictor angiotensin II and, so, diminished vasopressor activity. In addition, angiotensin II-stimulated aldosterone secretion by the adrenal cortex is decreased which results in a decrease in sodium and water retention and an increase in serum potassium.","Lisinopril | LISINOPRIL | N2-[(1S)-1-Carboxy-3-phenylpropyl]-L-lysyl-L-proline, Dihydrate | Prinivil | Zestril | lisinopril",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085217","Lithium Carbonate","C1318","The carbonate salt of lithium, a soft alkali metal, with antimanic and hematopoietic activities. Lithium interferes with transmembrane sodium exchange in nerve cells by affecting sodium, potassium-stimulated adenosine triphosphatase (Na+, K+-ATPase); alters the release of neurotransmitters; affects cyclic adenosine monophosphate (cAMP) concentrations; and blocks inositol metabolism resulting in depletion of cellular inositol and inhibition of phospholipase C-mediated signal transduction. The exact mechanism through which lithium exerts its mood-stabilizing effect has not been established. In addition, lithium stimulates granulocytopoiesis and appears to increase the level of pluripotent hematopoietic stem cells by stimulating the release of hematopoietic cytokines and/or directly acting on hematopoietic stem cells.","Lithium Carbonate | Escalith | Eskalith | LITHIUM CARBONATE | Lithane | Lithium | Lithium carbonate | Lithobid | Lithonate | Lithotabs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023992","Loperamide","C618","A synthetic agent chemically related to the opiates with anti-diarrheal properties.  Loperamide decreases gastro-intestinal motility by effects on the circular and longitudinal muscles of the intestine. Part of its anti-diarrheal effect may be due to a reduction of gastro-intestinal secretion produced by opioid receptor binding in the intestinal mucosa. (NCI04)","Loperamide | LOPERAMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0674432","Lopinavir","C2095","A peptidomimetic HIV protease inhibitor that retains activity against HIV protease with the Val 82 mutation. Lopinavir is less affected by binding to serum proteins than the structurally-related drug ritonavir.","Lopinavir | ABT-378/r | LOPINAVIR | lopinavir",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0065180","Loratadine","C29162","A piperidine histamine H1-receptor antagonist with anti-allergic properties and without sedative effects. Loratadine blocks the H1 histamine receptor and prevents the symptoms that are caused by histamine activity on capillaries, bronchial smooth muscle, and gastrointestinal smooth muscle, including vasodilatation, increased capillary permeability, bronchoconstriction, and spasmodic contraction of gastrointestinal smooth muscle. Loratadine does not cross the blood-brain barrier and does not cause central nervous system effects.","Loratadine | 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-, Ethyl Ester | Claritin | LORATADINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0699194","Lorazepam","C619","A benzodiazepine with anxiolytic, anti-anxiety, anticonvulsant, anti-emetic and sedative properties. Lorazepam enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid on the GABA receptors by binding to a site that is distinct from the GABA binding site in the central nervous system. This leads to an increase in chloride channel opening events, a facilitation of chloride ion conductance, membrane hyperpolarization, and eventually inhibition of the transmission of nerve signals, thereby decreasing nervous excitation.","Lorazepam | 7-Chloro-5-(2-chlorophenyl)-1, 3-Dihydro-3-Hydroxy-1,4- Benzodiazepin-2-one | Ativan | LORAZEPAM | lorazepam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700492","Losartan Potassium","C29165","The potassium salt of losartan, a non-peptide angiotensin II receptor antagonist with antihypertensive activity. Losartan selectively and competitively binds to the angiotensin II receptor (type AT1) and blocks the binding of angiotensin II to the receptor, thus promoting vasodilatation and counteracting the effects of aldosterone. Converted from angiotensin I by angiotensin-converting enzyme (ACE), angiotensin II stimulates the adrenal cortex to synthesize and secrete aldosterone, decreasing sodium excretion and increasing potassium excretion, and acts as a vasoconstrictor in vascular smooth muscle.","Losartan Potassium | 2-Butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol, Monopotassium Salt | Cozaar | LOSARTAN POTASSIUM | losartan | losartan potassium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024027","Lovastatin","C620","A lactone metabolite isolated from the fungus Aspergillus terreus with cholesterol-lowering and potential antineoplastic activities. Lovastatin is hydrolyzed to the active beta-hydroxyacid form, which competitively inhibits 3-hydroxyl-3-methylgutarylcoenzyme A (HMG-CoA) reductase, an enzyme involved in cholesterol biosynthesis. In addition, this agent may induce tumor cell apoptosis and inhibit tumor cell invasiveness, possibly by inhibiting protein farnesylation and protein geranylgeranylation, and may arrest cells in the G1 phase of the cell cycle. The latter effect sensitizes tumor cells to the cytotoxic effects of ionizing radiation.","Lovastatin | (2S)-2-Methylbutanoic Acid, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl Ester | LOVASTATIN | Lovastatin Sodium | Mevacor | Mevinolin | Monacolin K | lovastatin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897599","Skin Care Product","C29169","Any skin care product containing humectants, emollients and emulsifiers with moisturizing activity. These products increase the skin's hydration and are used to soften and protect dry skin.","Skin Care Product | Lubriderm | Lubriderm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0065223","Vaginal Lubricant","C29170","A vaginal lubricant containing a mixture of polyethylene glycols, glycerol and caprylic/capric triglyceride used to relieve discomfort due to vaginal dryness when applied intravaginally.","Vaginal Lubricant | Lubrin | Lubrin",,,,,,,,,,,,,,,"45759569","Vaginal lubricant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043328","Lutein","C1965","Lutein (LOO-teen) is a oxygenated carotenoid found in vegetables and fruits.  lutein is found in the macula of the eye, where it is believed to act as a yellow filter. Lutein acts as an antioxidant, protecting cells against the damaging effects of free radicals.","Lutein | (3R,3'R,6'R)-beta,epsilon-Carotene-3,3'-diol | 4-[18-(4-hydroxy-2,6,6-trimethyl-1-cyclohex-2-enyl)-3,7,12,16-tetramethyl-octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-3,5,5-trimethyl-cyclohex-3-en-1-ol | Adaptinol | All-Trans-Lutein | LUT | LUTEIN | Leutin | Xanthophyll | Xanthophylls",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0065331","Lycopene","C2226","A linear, unsaturated hydrocarbon carotenoid, the major red pigment in fruits such as tomatoes, pink grapefruit, apricots, red oranges, watermelon, rosehips, and guava.  As a class, carotenoids are pigment compounds found in photosynthetic organisms (plants, algae, and some types of fungus), and are chemically characterized by a large polyene chain containing 35-40 carbon atoms; some carotenoid polyene chains are terminated by two 6-carbon rings.  In animals, carotenoids such as lycopene may possess antioxidant properties which may retard aging and many degenerative diseases.  As an essential nutrient, lycopene is required in the animal diet. (NCI04)","Lycopene | 2,6,10,14,19,23,27,31-octamethyldotriaconta-2,6,8,10,12,14,16,18,20,22,24,26,30-tridecaene | LYCOPENE | Lyc-O-Mato | all-trans-Lycopene | lycopene | psi,psi-Carotene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024337","Lysine","C29171","One of nine essential amino acids in humans required for growth and tissue repair, Lysine is supplied by many foods, especially red meats, fish, and dairy products. Lysine seems to be active against herpes simplex viruses and present in many forms of diet supplements. The mechanism underlying this effect is based on the viral need for amino acid arginine; lysine competes with arginine for absorption and entry into cells. Lysine inhibits HSV growth by knocking out arginine. (NCI04)","Lysine | (S)-2,6-Diaminohexanoic acid | LYSINE | Lys",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0065461","Aluminum Hydroxide/Magnesium Hydroxide","C1149","An oral suspension containing aluminum hydroxide and magnesium hydroxide, with antacid effects. Aluminum hydroxide and magnesium hydroxide neutralizes or reduces gastric acid, thereby relieving symptoms associated with indigestion, gastritis, and gastroesophageal disease (GERD). Combined with other liquid ingredients (such as lidocaine and diphenhydramine), this antacid provides relief for painful stomatitis, mucositis, and esophagitis associated with both chemotherapy and radiation therapy.","Aluminum Hydroxide/Magnesium Hydroxide | Maalox | Maalox | Mylanta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518153","Magic Mouthwash","C29238","A combination preparation of mouth rinsing suspension containing an antacid, an antihistamine and an anesthetic agent. Usually, magic mouthwash consists of lidocaine for its anesthetic activity, the antihistamine diphenhydramine and the antacids aluminum hydroxide and/or magnesium hydroxide. Sucralfate, an anti-ulcer agent, can be added to the mouthwash to form a protective coating over the lesion areas by binding to the proteins at the inflamed mucous lining. In addition, the antimycotic agent nystatin is often added to stop fungal growth. Magic mouthwash is used to treat chemotherapy- and/or radiation-induced oral mucositis.","Magic Mouthwash | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024472","Magnesium Chloride","C29240","Magnesium Chloride was used as a laxative. An alkaline earth metal, magnesium is important for many biochemical functions and reactions; for bone and muscle function, protein and fatty acid formation, activation of B vitamins, blood clotting, insulin secretion, and ATP formation. More than 300 enzymes require magnesium for catalytic action. The adult daily requirement is about 300 mg/day. Magnesium is found in many green plants, vegetables, and seeds; chlorophyll is a magnesium-centered porphyrin compound. Magnesium salts are used for magnesium deficiency supplementation. (NCI04)","Magnesium Chloride | MAGNESIUM CHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0126774","Magnesium Citrate","C29241","The citrate salt of the element magnesium with cathartic activity. The cathartic action of magnesium cations appears to result, in part, from osmotically mediated water retention, which subsequently stimulates peristalsis. In addition, magnesium ions may also stimulate the activity of nitric oxide (NO) synthase and increase the biosynthesis of the phospholipid proinflammatory mediator platelet activating factor (PAF) in the gut. NO may stimulate intestinal secretion via prostaglandin- and cyclic GMP-dependent mechanisms while PAF produces significant stimulation of colonic secretion and gastrointestinal motility.","Magnesium Citrate | Citramag | Citrate of Magnesia | CitroMag | Citroma | MAGNESIUM CITRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024476","Magnesium Hydroxide","C29262","A solution of magnesium hydroxide with antacid and laxative properties. Milk of magnesium exerts its antacid activity in low doses such that all hydroxide ions that enter the stomach are used to neutralize stomach acid. This agent exerts its laxative effect in higher doses so that hydroxide ions are able to move from the stomach to the intestines where they attract and retain water, thereby increasing intestinal movement (peristalsis) and inducing the urge to defecate.","Magnesium Hydroxide | MAGNESIUM HYDROXIDE | Milk of Magnesia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024477","Magnesium Oxide","C29242","The oxide salt of magnesium with antacid, laxative and vascular smooth muscle relaxant activities. Magnesium combines with water to form magnesium hydroxide which reacts chemically to neutralize or buffer existing quantities of stomach acid; stomach-content and intra-esophageal pH rise, resulting in a decrease in pepsin activity. This agent's laxative effect is the result, in part, of osmotically mediated water retention, which subsequently stimulates peristalsis. In addition, magnesium ions may behave as calcium antagonists in vascular smooth muscle.","Magnesium Oxide | MAGNESIUM OXIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024480","Magnesium Sulfate","C623","A magnesium salt of sulfuric acid, that can be used to normalize magnesium levels in the body, and to prevent seizures in eclampsia and preeclampsia. Magnesium is a divalent cation essential for a number of biochemical processes involved in nerve signaling, bone mineralization and muscle contractions. About 350 enzymes involved in glycolysis and the Krebs cycle, formation of cyclic-AMP and ATP, cellular signal transduction and protein and nucleic acid synthesis are dependent on magnesium. Magnesium blocks neuromuscular transmission and decreases the amount of acetylcholine liberated at the end plate by the motor nerve impulse, thereby preventing convulsions and seizures.","Magnesium Sulfate | MAGNESIUM SULFATE, UNSPECIFIED FORM | Magnesium SO4 | Magnesium Sulfate whiskers | Magnesium sulfate | magnesium sulfate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1659099","Mannitol","C625","A naturally occurring alcohol found in fruits and vegetables and used as an osmotic diuretic. Mannitol is freely filtered by the glomerulus and poorly reabsorbed from the renal tubule, thereby causing an increase in osmolarity of the glomerular filtrate. An increase in osmolarity limits tubular reabsorption of water and inhibits the renal tubular reabsorption of sodium, chloride, and other solutes, thereby promoting diuresis. In addition, mannitol elevates blood plasma osmolarity, resulting in enhanced flow of water from tissues into interstitial fluid and plasma.","Mannitol | D-Mannitol | MANNITOL | Mannitol, D- | Osmitrol | Resectisol | mannitol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0813211","Hydrochlorothiazide-Triamterene","C1388","A combination drug containing hydrochlorothiazide and triamterene used as a diuretic.","Hydrochlorothiazide-Triamterene | Maxzide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025147","Medroxyprogesterone","C629","A synthetic derivative of progesterone administered as an acetate salt (medroxyprogesterone acetate) with antiestrogenic activity. As a do all progestins, medroxyprogesterone binds to and activates nuclear receptors which subsequently bind to and activate target genes for transcription. As an antiestrogen, this agent may inhibit the growth-stimulating effects of estrogen on estrogen-sensitive tumor cells. (NCI04)","Medroxyprogesterone | (6Alpha)-17-hydroxy-6-methylpregn-4-ene-3,20-dione | 17Alpha-hydroxy-6alpha-methylprogesterone | 6Alpha-methyl-17alpha-hydroxyprogesterone | 6Alpha-methyl-4-pregnen-17alpha-ol-3,20-dione | Curretab | MEDROXYPROGESTERONE | Medroxyprogesterone acetate | medroxyprogesterone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012005","Diatrizoate Meglumine","C29247","The meglumine salt form of diatrizoate, an organic, iodinated, radiopaque X-ray contrast medium used in diagnostic radiography. The iodine moiety of diatrizoate meglumine is not penetrable by X-rays, therefore blocks the X-ray film exposure by radiation. This makes it possible to distinguish on X-ray film, body parts that contain diatrizoate meglumine from body parts that do not contain this agent and allows for visualization of different body structures.","Diatrizoate Meglumine | 1-Deoxy-1-(methylamino)-D-glucitol 3,5-diacetamido-2,4,6-triiodobenzoate (Salt) | 1-Deoxy-1-(methylamino)-D-glucitol 3,5-diacetamido-2,4,6-triiodobenzoate (salt) | Benzoic Acid, 3,5-Bis(Acetylamino)-2,4,6-Triiodo-, Compd. With 1-Deoxy-1-(Methylamino)-D-Glucitol (1:1) | Cardiografin | DIATRIZOATE MEGLUMINE | Meglumine Amidotrizoate | Meglumine Amidotrizoate | Meglumine Diatrizoate",,,,,,,,,,,,,,,"4264184","Meglumine diatrizoate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025219","Melatonin","C2267","A hormone involved in sleep regulatory activity, and a tryptophan-derived neurotransmitter, which inhibits the synthesis and secretion of other neurotransmitters such as dopamine and GABA. Melatonin is synthesized from serotonin intermediate in the pineal gland and the retina where the enzyme 5-hydroxyindole-O-methyltransferase, that catalyzes the last step of synthesis, is found. This hormone binds to and activates melatonin receptors and is involved in regulating the sleep and wake cycles. In addition, melatonin possesses antioxidative and immunoregulatory properties via regulating other neurotransmitters.","Melatonin | 5-Methoxy-N-acetyltryptamine | N-Acetyl-5-methoxytryptamine | N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide | N-[2-(5-methoxyindol-3-yl)ethyl]acetamide | melatonin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0066005","Meropenem","C1160","A broad-spectrum carbapenem with antibacterial properties, synthetic Meropenem inhibits cell wall synthesis in gram-positive and gram-negative bacteria. It penetrates cell walls and binds to penicillin-binding protein targets. Meropenem acts against aerobes and anaerobes including Klebsiella, E. coli, Enterococcus, Clostridium sp.. (NCI04)","Meropenem | MEROPENEM | Meropenem Trihydrate | Merrem I.V. | SM-7338",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0127615","Mesalamine","C29249","An agent derived from sulfasalazine, an antiinflammatory agent.  Mesalamine may reduce inflammation through inhibition of cyclooxygenase and prostaglandin production. Following rectal or oral administration, only a small amount of mesalamine is absorbed; the remainder, acting topically, reduces bowel inflammation, diarrhea, rectal bleeding and stomach pain. (NCI04)","Mesalamine | 5-ASA | 5-Amino-2-hydroxybenzoic Acid | 5-Aminosalicylic Acid | Apriso | Asacol | Lialda | MESALAMINE | Mesalazine | Pentasa | Rowasa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0000294","Mesna","C192","A sulfhydryl compound that is used to reduce the incidence of hemorrhagic cystitis associated with certain chemotherapeutic agents.  Mesna is converted to a free thiol compound in the kidney, where it binds to and inactivates acrolein and other urotoxic metabolites of ifosfamide and cyclophosphamide, thereby reducing their toxic effects on the urinary tract during urinary excretion. (NCI04)","Mesna | 2-Mercaptoethanesulfonate, Sodium Salt | 2-Mercaptoethanesulfonic Acid Sodium Salt | Ausobronc | D-7093 | Filesna | MESNA | Mercaptoethane Sulfonate | Mercaptoethanesulfonate | Mesnex | Mesnil | Mesnum | Mexan | Mistabron | Mistabronco | Mitexan | Mucofluid | Mucolene | Sodium 2-Mercaptoethane Sulfonate | Sodium 2-Mercaptoethanesulphonate | UCB 3983 | Uromitexan | Ziken | mesna",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025644","Methimazole","C641","A thioamide inhibitor of the enzyme thyroid peroxidase (TPO), with antithyroid activity. Upon administration, methimazole inhibits the metabolism of iodide and the iodination of tyrosine residues in the thyroid hormone precursor thyroglobulin by TPO; this prevents the synthesis of the thyroid hormones triiodothyronine (T3) and thyroxine (T4).","Methimazole | METHIMAZOLE | Tapazole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025659","Methocarbamol","C29252","A carbamate with centrally acting muscle relaxant properties. Though the exact mechanism of action of methocarbamol was not established, it's postulated to be via a mechanism similar of carbamate, inhibition of acetylcholinesterase at synapses in the autonomic nervous system, neuromuscular junction, and central nervous system. Methocarbamol has no direct effect on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.","Methocarbamol | METHOCARBAMOL | Robaxin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025815","Methylprednisolone","C647","A synthetic corticosteroid with anti-inflammatory and immunomodulating properties.  Methylprednisolone binds to and activates specific nuclear receptors, resulting in altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","Methylprednisolone | (6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione | 6Alpha-Methylprednisolone | Adlone | Caberdelta M | DepMedalone | Depo Moderin | Depo-Nisolone | Duralone | Emmetipi | Esametone | Firmacort | METHYLPREDNISOLONE | Medlone 21 | Medrate | Medrol | Medrol Veriderm | Medrone | Mega-Star | Meprolone | Methylprednisolonum | Metilbetasone Solubile | Metrocort | Metypresol | Metysolon | Predni-M-Tablinen | Prednilen | Radilem | Sieropresol | Solpredone | Summicort | Urbason | Veriderm Medrol | Wyacort | methylprednisolone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025854","Metolazone","C650","A long acting, quinazoline-based sulfonamide thiazide-like, diuretic. Similar to the thiazides, metolazone acts on the distal convoluted tubule (DCT) and inhibits the sodium-chloride symporter, thereby preventing sodium and chloride reabsorption and excretion of water.","Metolazone | 2-Methyl-3-o-tolyl-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone | 7-Chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulfonamide | 7-Chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-6-quinazolinesulfonamide | Diulo | METOLAZONE | Metenix | Mykrox | SR-720-22 | Xuret | Zaroxolyn",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0724633","Metoprolol Succinate","C29254","The succinate salt form of metoprolol, a cardioselective competitive beta-1 adrenergic receptor antagonist with antihypertensive properties and devoid of intrinsic sympathomimetic activity. Metoprolol succinate antagonizes beta 1-adrenergic receptors in the myocardium, thereby reducing the rate and force of myocardial contraction, and consequently a diminished cardiac output. This agent may also reduce the secretion of renin with subsequent reduction in levels of angiotensin II thus decreasing sympathetic activation, including vasoconstriction, aldosterone secretion.","Metoprolol Succinate | METOPROLOL SUCCINATE | Metoprolol succinate | Toprol XL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700548","Metoprolol Tartrate","C29255","The tartrate salt form of metoprolol, a cardioselective competitive beta-1 adrenergic receptor antagonist with antihypertensive properties and devoid of intrinsic sympathomimetic activity. Metoprolol tartrate antagonizes beta 1-adrenergic receptors in the myocardium, thereby reducing the rate and force of myocardial contraction, and consequently a diminished cardiac output. This agent may also reduce the secretion of renin with subsequent reduction in levels of angiotensin II thus decreasing sympathetic activation, including vasoconstriction, aldosterone secretion.","Metoprolol Tartrate | Lopressor | METOPROLOL TARTRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025872","Metronidazole","C651","A synthetic nitroimidazole derivative with antiprotozoal and antibacterial activities. Although its mechanism of action is not fully elucidated, un-ionized metronidazole is readily taken up by obligate anaerobic organisms and is subsequently reduced by low-redox potential electron-transport proteins to an active, intermediate product. Reduced metronidazole causes DNA strand breaks, thereby inhibiting DNA synthesis and bacterial cell growth.","Metronidazole | Flagyl | Flagyl I.V. RTU | METRONIDAZOLE | Tricom | metronidazole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1302063","Amlodipine Besylate/Benazepril Hydrochloride","C29168","Having a substantial blood pressure lowering capability, Amlodipine Besylate Benazepril Hydrochloride contains a dihydropyridine calcium blocker (amlodipine) and an angiotensin-converting enzyme (ACE) inhibitor (benazepril). A long-acting calcium channel antagonist, Amlodipine inhibits transmembrane calcium influx into vascular smooth muscle. Blocking ACE, Benazepril decreases vasopressive plasma angiotensin II. (NCI04)","Amlodipine Besylate/Benazepril Hydrochloride | Lotrel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282227","Meclizine Hydrochloride","C29245","The hydrochloride salt form of meclizine, a synthetic piperazine with anti-emetic, sedative and histamine H1 antagonistic properties. Meclizine hydrochloride blocks the H1 histamine receptor and prevents the symptoms that are caused by histamine activity on capillaries, bronchial and gastrointestinal smooth muscles, including vasodilation, increased capillary permeability, bronchoconstriction, and spasmodic contraction of gastrointestinal smooth muscles. Meclizine hydrochloride may exert its antiemetic effects by its anticholinergic actions or due to a direct effect on the medullary chemoreceptive trigger zone.","Meclizine Hydrochloride | 1-[(4-Chlorophenyl)phenylmethyl]-4-[(3-methylphenyl)methyl]piperazine Dihydrochloride Monohydrate | Antivert | Bonine | MECLIZINE HYDROCHLORIDE | Meclizine Dihydrochloride Monohydrate | Meclizine HCl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0065864","Medroxyprogesterone Acetate","C1155","A synthetic, acetate derivative of the sex hormone progesterone.  Medroxyprogesterone 17-acetate (NCI04)","Medroxyprogesterone Acetate | (6alpha)-17-(Acetyloxy)-6-methylpregn-4-ene-3,20-dione | 17-(Acetyloxy)-6alpha-methylpregn-4-ene-3,20-dione | 17-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione Acetate | 17Alpha-acetoxy-6alpha-methylprogesterone | 6-Alpha-methyl-17alpha-acetoxyprogesterone | Amen | Aragest | Ciclotal | Clinofem | Clinovir | Cycrin | Depo-Clinovir | Depo-Provera | Depo-provera | Depot-Medroxyprogestereone Acetate | Farlutal | G-Farlutal | Gestapuran | Hysron | Lutoral | MEDROXYPROGESTERONE ACETATE | MPA | Medroxyprogesterone 17-Acetate | Medroxyprogesterone 17-Acetate | Medroxyprogesterone acetate | Medroxyprogesteroni Acetas | Methylacetoxyprogesterone | Metipregnone | Nadigest | Nadigest (vet) | Nidaxin | Nidaxin (vet) | Oragest | Perlutex | Prodasone | Provera | Sodelut G | Veramix | medroxyprogesterone acetate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0353148","Meperidine Hydrochloride","C635","The hydrochloride salt of a synthetic piperidine ester with opioid analgesic activity. Meperidine mimics the actions of endogenous neuropeptides via opioid receptors such as the mu-opioid receptor, thereby producing characteristic morphine-like effects including analgesia, euphoria, sedation, respiratory depression, miosis, bradycardia and physical dependence.","Meperidine Hydrochloride | Demerol | MEPERIDINE HYDROCHLORIDE | Meperidine | meperidine hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033979","Psyllium Husk","C29250","The husk of the dried ripe seeds of the Plantago psyllium, P. Indica, P. Ovata, and P. Arenaria plants with laxative and cholesterol lowering activities. The husks contain mucilage that swells on exposure to water and provides an indigestible mucilaginous mass in the intestines, thereby causing lubrication, contraction of the smooth muscles of the intestinal walls, and thus stimulating bowel movement. Psyllium husk is rich in soluble fiber and has a cholesterol-lowering effect.","Psyllium Husk | Isogel | Ispaghula | Metamucil | PSYLLIUM HUSK | Plantaglucide | Psyllium | Psyllium Gum | Psyllium Hydrophilic Mucilloid | Psyllium Seed Husk | psyllium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0770893","Metformin Hydrochloride","C29251","The hydrochloride salt of the biguanide metformin with antihyperglycemic and potential antineoplastic activities. Metformin inhibits complex I (NADPH:ubiquinone oxidoreductase) of the mitochondrial respiratory chain, thereby increasing the cellular AMP to ATP ratio and leading to activation of AMP-activated protein kinase (AMPK) and regulating AMPK-mediated transcription of target genes. This eventually prevents hepatic gluconeogenesis, enhances insulin sensitivity and fatty acid oxidation and ultimately leads to a decrease in glucose levels. Metformin may exert antineoplastic effects through AMPK-mediated or AMPK-independent inhibition of mammalian target of rapamycin (mTOR), which is up-regulated in many cancer tissues. Furthermore, this agent also inhibits tumor cell migration and invasion by inhibiting matrix metalloproteinase-9 (MMP-9) expression which is mediated through the suppression of transcription activator protein-1 (AP-1) activation.","Metformin Hydrochloride | 1,1-Dimethylbiguanide Hydrochloride | APO-Metformin | Cidophage | Dimefor | Glifage | Glucoformin | Glucophage | Glucophage ER | METFORMIN HYDROCHLORIDE | Metformin HCl | N,N-Dimethylimidodicarbonimidic Diamide Monohydrochloride | Riomet | Siofor | metformin hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700545","Methylphenidate Hydrochloride","C646","The hydrochloride salt of the synthetic central nervous system stimulant methylphenidate. Methylphenidate appears to activate the brain stem arousal system and cortex to produce its stimulant effect and, in some clinical settings, may improve cognitive function.","Methylphenidate Hydrochloride | Concerta | METHYLPHENIDATE HYDROCHLORIDE | Quillivant XR | Ritalin | alpha-Phenyl-2-piperidineacetic Acid Methyl Ester Hydrochloride | methylphenidate hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0887128","Metoclopramide Hydrochloride","C649","The hydrochloride salt of the substituted benzamide metoclopramide, a para-aminobenzoic acid (PABA) derivative that is structurally related to procainamide, with gastroprokinetic and antiemetic activities. Metoclopramide binds to dopamine 2 (D2) receptors in the peripheral nervous system (PNS), antagonizing dopamine-mediated relaxation of gastrointestinal smooth muscle and promoting gastroprokinesis; the pyloric sphincter and the duodenal bulb are relaxed, peristalsis of the duodenum and jejunum increase, and gastric emptying and intestinal transit accelerate. This agent may also increase the resting tone of the lower esophagus sphincter (LES), preventing acid reflux. In the central nervous system (CNS), metoclopramide antagonizes D2 dopamine receptors in the chemoreceptive trigger zone (CTZ) of the medulla, thereby preventing nausea and vomiting.","Metoclopramide Hydrochloride | METOCLOPRAMIDE HYDROCHLORIDE | Reglan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0543459","Mexiletine Hydrochloride","C652","The hydrochloride salt form of mexiletine, a local anesthetic and antiarrhythmic (Class IB) agent structurally related to lidocaine. Mexiletine exerts its antiarrhythmic effect by inhibiting the inward sodium current in cardiac cells, thereby reducing the rate of rise of the cardiac action potential (phase 0) and decreases automaticity in the Purkinje fibers. This slows nerve impulses in the heart and stabilizes the heartbeat. Mexiletine's anesthetic activity is due to its ability to block sodium influx in peripheral nerves, thereby reducing the rate and intensity of pain impulses reaching the central nervous system.","Mexiletine Hydrochloride | 1-(2,6-Dimethylphenoxy)-2-propanamine Hydrochloride | 1-Methyl-2-(2,6-xylyloxy)ethylamine Hydrochloride | Ko 1173 Cl | MEXILETINE HYDROCHLORIDE | Mexitil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0937640","Milk Thistle","C29261","A substance derived from any of several Old World coarse prickly-leaved shrubs and subshrubs including the plant Silybum marianum.  Milk thistle's active chemical component is silymarin, which is a combination of flavonoids such as silibinin, dehydrosilibinin, silychristin and silydianin.  These compounds are antioxidants and may alter the membrane structure of the liver cell, thereby blocking the absorption of toxins; they may also stimulate the production of new liver cells. In addition, milk thistle may increase cellular adenosine triphosphate (ATP) levels, exhibiting dose-dependent cardiac myocyte cytoprotection against doxorubicin.  The silibinin component of milk thistle has been shown to inhibit growth factor receptor-mediated mitogenic and cell survival signaling, thereby inhibiting tumor growth. (NCI04)","Milk Thistle | MILK THISTLE | milk thistle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600487","Milrinone Lactate","C29263","The lactate salt form of milrinone, a cardiovascular bipyridine agent and phosphodiesterase (PDE) III inhibitor, with positive inotropic and vasodilator activities.  Upon administration, milrinone selectively inhibits PDE-mediated degradation of cyclic adenosine monophosphate (cAMP) in the heart and vascular muscles, thereby increasing cAMP and activates protein kinase A (PKA). This leads to phosphorylation of calcium ion channels and improve myocardium contractile force. Milrinone also causes vasodilation in arteriolar and venous vascular smooth muscle.","Milrinone Lactate | MILRINONE LACTATE | Primacor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026156","Mineral Oil","C29264","A mixture of liquid paraffinic, naphthenic and polycyclic aromatic hydrocarbons obtained from petroleum in which the amount and types of aromatic hydrocarbons is dependent on the treatment process. Untreated and mildly treated mineral oils contain the highest amount of aromatic and unsaturated compounds and are primarily used as a lubricant base oil to produce further refined oil products. Exposure to these types of mineral oils can cause rapid respiration, cyanosis, tachycardia and low-grade fever. Untreated and mildly treated mineral oils are strongly associated with an increased risk of scrotal and skin cancer but can also cause gastrointestinal, rectal, bladder and certain respiratory-tract cancers. (NCI05)","Mineral Oil | Heavy Liquid Petrolatum | Heavy Mineral Oil | Liquid Paraffin | Liquid Petrolatum | MINERAL OIL | Paraffin Oil | Paraffin, Liquid | Paraffinum Liquidum | White Mineral Oil | mineral oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0049506","Mirtazapine","C29265","A synthetic tetracyclic derivative of the piperazino-azepines with antidepressant activity. Although its mechanism of action is unknown, mirtazapine enhances central adrenergic and serotonergic transmission, possibly by acting as an antagonist at central presynaptic alpha 2 adrenergic inhibitory autoreceptors and heteroreceptors. This agent is a potent antagonist of 5-hydroxytryptamine type 2 (5-HT2), 5-HT3, and histamine 1 (H1) receptors, and a moderate antagonist of peripheral alpha 1 adrenergic and muscarinic receptors.","Mirtazapine | MIRTAZAPINE | Remeron | mirtazapine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085174","Misoprostol","C1313","A synthetic analog of natural prostaglandin E1. It produces a dose-related inhibition of gastric acid and pepsin secretion, and enhances mucosal resistance to injury. It is an effective anti-ulcer agent and also has oxytocic properties.","Misoprostol | (11alpha,13E)-(+-)-11,16-Dihydroxy-16-methyl-9-oxo-prost-13-en-1-oic Acid Methyl Ester | Cytotec | MISOPROSTOL | Methyl (11alpha,13E)-11,16-Dihydroxy-16-methyl-9-oxoprost-13-en-1-oate | SC-29333 | misoprostol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026256","Mitotane","C664","A synthetic derivative of the insecticide dichlorodiphenyl trichloroethane (DDT) with anti-adrenocorticoid properties.  Following its metabolism in the adrenal cortex to a reactive acyl chloride intermediate, mitotane covalently binds to adrenal proteins, specifically inhibiting adrenal cortical hormone production. (NCI04)","Mitotane | (o,p)-DDD | 1, 1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane | 1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane | 1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene | 2, 2-Bis(2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane | 2, 4'-Dichlorodiphenyldichloroethane | 2,2-Bis(2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane | 2,4'-Dichlorodiphenyldichloroethane | 2-(2-Chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethane | CB 313 | CB-313 | Chloditan | Chlodithane | DDD | Ethane, 2-(o-chlorophenyl)-2-(p-chlorophenyl)-1,1-dichloro- | Khloditan | Lisodren | Lysodren | MITOTANE | Mytotan | Ortho,para-DDD | WR-13045 | mitotane | o,p' - DDD | o,p'-DDD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0066677","Modafinil","C26661","A synthetic central nervous system stimulant with wakefulness-promoting activity. Modafinil appears to inhibit dopamine reuptake, resulting in an increase in extracellular dopamine.  This agent exhibits pronounced wakefulness-promoting activity (without sympathomimetic activity) and may improve cognitive function in certain clinical settings. (NCI04)","Modafinil | MODAFINIL | Provigil | modafinil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0066700","Mometasone Furoate","C29268","The furoate ester form of mometasone, a synthetic topical glucocorticoid receptor (GR) agonist with anti-inflammatory, anti-pruritic and vasoconstrictive properties. Upon administration, mometasone binds to cytoplasmic GRs and subsequently activates GR-mediated gene expression. This results in the synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators. Specifically, mometasone appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from phospholipid membrane by phospholipase A2.","Mometasone Furoate | (11beta,16alpha)-9,21-Dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methylpregna-1,4-diene-3,20-dione | Elocon | MOMETASONE FUROATE | Nasonex | Propel | Sch-32088 | mometasone furoate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0380447","Montelukast Sodium","C47625","The orally bioavailable monosodium salt of montelukast, a selective cysteinyl leukotriene receptor antagonist with anti-inflammatory and bronchodilating activities. Montelukast selectively and competitively blocks the cysteinyl leukotriene 1 (CysLT1) receptor, preventing binding of the inflammatory mediator leukotriene D4 (LTD4). Inhibition of LTD4 activity results in inhibition of leukotriene-mediated inflammatory events including: migration of eosinophils and neutrophils; adhesion of leukocytes to vascular endothelium, monocyte and neutrophil aggregation; increased airway edema; increased capillary permeability; and bronchoconstriction. The CysLT1 receptor is found in a number of tissues including spleen, lung, placenta, small intestine, and nasal mucosa, and in a variety of cell types including monocyte/macrophages, mast cells, eosinophils, CD34-positive hemopoietic progenitor cells, neutrophils and endothelial cells.","Montelukast Sodium | Cyclopropaneacetic Acid, 1-((((1R)-1-(3-((1E)-2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)-, Monosodium Salt | MK 476 | MONTELUKAST SODIUM | Montair | Plenair | Singulair | montelukast sodium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0722208","Morphine Sulfate","C669","The sulfate salt of morphine, an opiate alkaloid isolated from the plant Papaver somniferum and produced synthetically. Morphine binds to and activates specific opiate receptors (delta, mu and kappa), each of which are involved in controlling different brain functions. In the central nervous and gastrointestinal systems, this agent has widespread effects including analgesia, anxiolysis, euphoria, sedation, respiratory depression, and gastrointestinal system smooth muscle contraction.","Morphine Sulfate | Avinza | Infumorph | Kadian | MORPHINE SULFATE | MS Contin | MSir | Morphine | Oramorph | Oramorph SR | Roxanol | Statex SR | morphine sulfate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085259","Mupirocin","C29271","A natural crotonic acid derivative extracted from Pseudomonas fluorescens. Mupirocin inhibits bacterial protein synthesis by specific reversible binding to bacterial isoleucyl tRNA synthase. With excellent activity against gram-positive staphylococci and streptococci, it is primarily used for treatment of primary and secondary skin disorders, nasal infections, and wound healing. (NCI04)","Mupirocin | MUPIROCIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0883242","Mycophenolate","C29272","The morpholinoethyl ester of mycophenolic acid (MPA).  As an immunosuppressive agent in vivo, the active metabolite mycophenolate reversibly inhibits inosine 5'-monophosphate dehydrogenase (IMPDH), an enzyme involved in the de novo synthesis of guanine nucleotides, thereby retarding T-cell and B-cell proliferation.  MPA displays high lymphocyte specificity and cytotoxicity because lymphocyte metabolism is highly dependent on both salvage and de novo synthesis of guanine nucleotides. (NCI04)","Mycophenolate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0701331","Nabumetone","C47627","A naphthylalkanone and non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Nabumetone is a prodrug that upon hepatic catalysis converts into the active moiety 6-methoxy-2-naphthylacetic acid (6MNA). 6MNA inhibits the activity of the enzymes cyclo-oxygenase I and II, resulting in decreased formation of precursors of prostaglandins and thromboxanes. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of nabumetone. The formation of thromboxane A2, by thromboxane synthase, is also decreased and results in an inhibition of platelet aggregation.","Nabumetone | 4-(6-Methoxy-2-naphthalenyl)-2-butanone | NABUMETONE | Relafen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027302","Nadolol","C29280","A non-selective beta-adrenergic antagonist with antihypertensive and antiarrhythmic activities. Nadolol competitively blocks beta-1 adrenergic receptors located in the heart and vascular smooth muscle, inhibiting the activities of the catecholamines epinephrine and norepinephrine and producing negative inotropic and chronotropic effects. This agent exhibits antiarrhythmic activity via the impairment of atrioventricular (AV) node conduction and a corresponding reduction in sinus rate. In the kidney, inhibition of the beta-2 receptor within the juxtaglomerular apparatus results in the inhibition of renin production and a subsequent reduction in angiotensin II and aldosterone levels, thus inhibiting angiotensin II-dependent vasoconstriction and aldosterone-dependent water retention.","Nadolol | Corgard | NADOLOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700017","Naproxen","C680","A propionic acid derivative and a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Naproxen inhibits the activity of the enzymes cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of naproxen. Naproxen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation.","Naproxen | 6-Methoxy-alpha-methyl-2-naphthaleneacetic Acid | NAPROXEN | Naprosyn | RS-3540 | d-2-(6-Methoxy-2-naphthyl)propionic Acid | naproxen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0525005","Nelfinavir","C29285","A synthetic antiviral agent that selectively binds to and inhibits human immunodeficiency virus (HIV) protease. Nelfinavir has activity against HIV 1 and 2.","Nelfinavir | NELFINAVIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054410","Neomycin/Polymyxin B/Bacitracin Zinc","C29286","A combination preparation containing the aminoglycoside antibiotic neomycin sulfate, the polypeptide antibiotic polymyxin B sulfate and bacitracin zinc, with topical antibacterial activity. Polymyxin B sulfate, a polypeptide produced by Bacillus polymyxa, binds to negatively charged phospholipids in the cell membrane, thereby altering the permeability of the bacterial cytoplasmic membrane. Neomycin sulfate, an aminoglycoside antibiotic, irreversibly binds to the bacterial 30S ribosomal subunit, thereby preventing mRNA from binding to the 30S subunit, causes misreading and inhibits protein synthesis.","Neomycin/Polymyxin B/Bacitracin Zinc | Neomycin/Polymyxin B/Bacitracin Zinc Ointment | Neosporin Cream | Neosporin Original",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828836","Neomycin/Polymyxin B/Bacitracin Zinc Ophthalmic Ointment","C29287","A sterile combination preparationscontaining neomycin sulfate, polymyxin B sulfate and bacitracin zinc, as the main active ingredients, for ophthalmic treatments. Polymyxin B sulfate, a polypeptide produced by Bacillus polymyxa, binds to the negatively charged phospholipids in the cell membrane, thereby altering the permeability of the bacterial cytoplasmic membrane. Neomycin sulfate, an aminoglycoside antibiotic, irreversibly binds to the bacterial 30S subunit proteins and 16S rRNA of ribosome, thereby causing misreading and inhibiting protein synthesis which results in bactericidal effect.","Neomycin/Polymyxin B/Bacitracin Zinc Ophthalmic Ointment | Neosporin Ophthalmic | Neosporin Ophthalmic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0132326","Nevirapine","C29277","A benzodiazepine non-nucleoside reverse transcriptase inhibitor. In combination with other antiretroviral drugs, nevirapine reduces HIV viral loads and increases CD4 counts, thereby retarding or preventing the damage to the immune system and reducing the risk of developing AIDS.","Nevirapine | 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one | BI-RG-587 | BIRG 0587 | NEVIRAPINE | NVP | Viramune",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027996","Niacin","C689","A water-soluble vitamin belonging to the vitamin B family, which occurs in many animal and plant tissues, with antihyperlipidemic activity. Niacin is converted to its active form niacinamide, which is a component of the coenzymes nicotinamide adenine dinucleotide (NAD) and its phosphate form, NADP. These coenzymes play an important role in tissue respiration and in glycogen, lipid, amino acid, protein, and purine metabolism. Although the exact mechanism of action by which niacin lowers cholesterol is not fully understood, it may act by inhibiting the synthesis of very low density lipoproteins (VLDL), inhibiting the release of free fatty acids from adipose tissue, increasing lipoprotein lipase activity, and reducing the hepatic synthesis of VLDL-C and LDL-C.","Niacin | 3-Pyridinecarboxylic Acid | NIACIN | Nicotinamide | Nicotinic Acid | Nicotinic Acid Amide | Nicotinic acid | Vitamin B-3 | Vitamin B3 | niacin | nicotinic acid | vitamin B3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0358855","Nicotine Patch","C17955","A transdermal patch containing the alkaloid nicotine with nicotine replacement activity. Upon administration of the patch, nicotine is slowly released into the bloodstream and, although nicotine binds to nicotinic cholinergic receptors at the autonomic ganglia, adrenal medulla and at neuromuscular junctions as well, the binding of nicotine to the receptors in the central nervous system (CNS) appears to be responsible for the addictive nature of nicotine. Binding to CNS nicotinic acetylcholine receptors causes the release of the neurotransmitter dopamine which appears to be responsible for the addiction of nicotine. Administration of nicotine may prevent nicotine craving and may help with the withdrawal symptoms associated with smoking cessation.","Nicotine Patch | NicoDerm CQ | Nicotine Skin Patch | Nicotine Transdermal Patch | nicotine patch",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028066","Nifedipine","C29290","A dihydropyridine calcium channel blocking agent. Nifedipine inhibits the transmembrane influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility. This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04)","Nifedipine | Adalat | NIFEDIPINE | Procardia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439677","Myeloid","C13349","A type of white blood cell. Neutrophils, eosinophils, and basophils are granulocytes.","Myeloid | myeloid",,,,,,,,,,,,,,,"4116826","Myeloid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040052","Thrombopoietin","C20441","Thrombopoietin (353 aa, ~38 kDa) is encoded by the human THPO gene. This protein is involved in both megakaryocyte differentiation and platelet activation.","Thrombopoietin | C-MPL Ligand | MGDF | ML | MPL Ligand | Megakaryocyte Colony Stimulating Factor | Megakaryocyte Colony-Stimulating Factor | Megakaryocyte Growth and Development Factor | Megakaryocyte Stimulating Factor | Myeloproliferative Leukemia Virus Oncogene Ligand | Prepro-Thrombopoietin | THPO | TPO | TSF | thrombopoietin",,,,,,,,,,,,,,,"4088069","Thrombopoietin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008625","Cytogenetic Abnormality","C2950","An irregularity in the number or structure of chromosomes, usually in the form of a gain (duplication), loss (deletion), exchange (translocation), or alteration in sequence (inversion) of genetic material.","Cytogenetic Abnormality | Aberrant Chromosome | Chromosomal Aberration | Chromosomal Abnormalities | Chromosomal Abnormality | Chromosomal Alterations | Chromosome Aberration | Chromosome Abnormality | Chromosome Alterations | Chromosome Anomalies | Cytogenetic Aberration | Cytogenetic Analysis Abnormality Type | Genomic Structural Variation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010828","Cytopenia","C2979","A laboratory test result indicating an abnormally low quantity of circulating blood cells.","Cytopenia | cytopenia",,,,,,,,,,,,,,,"4179922","Cytopenia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704632","Disease Response","C50995","The molecular/pathological and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","Disease Response | Disease Response to Treatment | Disease Status | RESPONSE | Response | Response | Response to Treatment | Treatment Response | disease response | disease_response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014822","Erythropoietin","C20429","Erythropoietin (193 aa, ~21 kDa) is encoded by the human EPO gene. This protein plays a role in both erythropoiesis and the maintenance of red blood cell volume.","Erythropoietin | EPO | Epoetin | Erythrocyte Colony Stimulating Factor | Erythropoeitin | Hematopoietin | Hemopoietin | erythropoietin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028833","Octreotide","C711","A synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Similar to somatostatin, this agent also suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.","Octreotide | D-Phenylalanyl-L-cysteinyl-L-phenyl-alanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide Cyclic (2->7)-Disulfide | D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol Cyclic (2->7)-Disulfide | D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hyroxymethyl)propyl]-L-cysteinamide, Cyclic (2->7)-disulfide | OCTREOTIDE | SMS 201 995 | SMS 201995 | SMS-201-995 | SMS201995 | octreotide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514462","Prior Limited Radiation","C15905","Cancer therapy using ionizing radiation to a limited (< 50%) portion of the body.","Prior Limited Radiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0000924","Accident","C34340","An unforeseen and unplanned event or circumstance frequently causing loss or injury.","Accident | Accidental",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038435","Stress","C35041","The negative mental, emotional, and physical reactions that occur when environmental stressors are perceived as exceeding the individual's adaptive capacities.","Stress | stress",,,,,,,,,,,,,,,"4136014|4251306","Stress|Stress",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C4013417","Sleep Disorder","C3376","A change from the patient's baseline sleeping pattern, in the hours slept and/or an alteration/dysfunction in the stages of sleep.","Sleep Disorder | Sleep Disorders | Sleep Disturbance | Sleep Dysfunction | Sleep disturbance | parasomnia | sleep disorder",,,,,,,,,,,,,,,"435524","Sleep disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025361","Mental Process","C16840","Any cognitive activity.","Mental Process | ",,,,,,,,,,,,,,,"4085511|4259259","Thought process|Form of thinking",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1709114","NCI Enterprise Vocabulary Services","C43515","The NCI EVS is set of services and resources that address NCI's needs for controlled vocabulary. The EVS Project is a collaborative effort of the Center for Bioinformatics and the NCI Office of Communications. The NCI Thesaurus, which is a biomedical thesaurus created specifically to meet the needs of the NCI, is produced by the NCI EVS project. The NCI Thesaurus is provided under an open content license.  The EVS Project also produces the NCI Metathesaurus, which is based on NLM's Unified Medical Language System Metathesaurus supplemented with additional cancer-centric vocabulary. In addition the EVS Project provides NCI with licenses for MedDRA, SNOMED, ICD-O-3, and other proprietary vocabularies.","NCI Enterprise Vocabulary Services | EVS | Enterprise Vocabulary Services | Enterprise Vocabulary System | NCI EVS | NCI Enterprise Vocabulary Services (EVS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711365","Limited Radiation Therapy","C54225","Cancer therapy using ionizing radiation to < 50% of the body.","Limited Radiation Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039869","Thinking","C54226","Mental activity, not predominantly perceptual, by which one apprehends some aspect of an object or situation based on past learning and experience.","Thinking | Thought | Thoughts",,,,,,,,,,,,,,,"4230784","Thinking",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704610","Data Value","C49100","The information contained in a data field. It may represent a numeric quantity, a textual characterization, a date or time measurement, or some other state, depending on the nature of the attribute.","Data Value | Value",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709299","Object Class Relationship","C42702","A description of the affiliation between two occurrences of Object Classes.","Object Class Relationship | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031336","Pharmacy (field)","C16976","The science of preparing and dispensing drugs.","Pharmaceutics | Pharmaceutical | Pharmacy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677881","Cytotoxic Chemotherapy","C15681","A drug therapy that is used to destroy cancer cells.","Cytotoxic Chemotherapy | Cytotoxic | Cytotoxic Therapy | cytotoxic chemotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0153690","Metastatic Malignant Neoplasm in the Bone","C3580","The spread of a malignant neoplasm from a primary site to the skeletal system.  The majority of metastatic neoplasms to the bone are carcinomas.","Metastatic Malignant Neoplasm in the Bone | Bone Metastases | Bone Metastasis | Metastases to bone, NOS | Metastatic Cancer to the Bone | Metastatic Malignant Neoplasm to the Bone | Metastatic Malignant Neoplasm to the Bone | Metastatic Neoplasm to the Bone | Metastatic Tumor to the Bone | Secondary malignant neoplasm of bone | bone metastasis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0220650","Metastatic Malignant Neoplasm in the Brain","C3813","A malignant neoplasm that has spread to the brain from another anatomic site or system. The majority are carcinomas (usually lung or breast carcinomas).","Metastatic Malignant Neoplasm in the Brain | Brain Metastases | Brain Metastasis | Metast. to brain parenchyma, NOS | Metastases to brain parenchyma, NOS | Metastatic Malignant Neoplasm to the Brain | Metastatic Malignant Neoplasm to the Brain | Metastatic Neoplasm to the Brain | Metastatic Tumor to the Brain | Secondary malignant neoplasm of brain | brain metastasis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230139","Thoracic Cavity","C12905","The cavity in the vertebrate body enclosed by the ribs between the diaphragm and the neck and containing the lungs and heart.","Thoracic Cavity | BODY CAVITY, THORACIC | THORACIC CAVITY",,,,,,,,,,,,,,,"4184181","Thoracic cavity structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0686619","Metastatic Malignant Neoplasm in the Lymph Nodes","C4904","The spread of a malignant neoplasm from its original site of growth to lymph nodes.","Metastatic Malignant Neoplasm in the Lymph Nodes | Metastases to Lymph Nodes | Metastasis to Lymph Node | Metastatic Malignant Neoplasm in Lymph Node | Metastatic Malignant Neoplasm in Lymph Node | Metastatic Malignant Neoplasm in the Lymph Nodes | Metastatic Malignant Neoplasm to the Lymph Node | Metastatic Malignant Neoplasm to the Lymph Nodes | Metastatic Neoplasm to the Lymph Node | Metastatic Tumor to Lymph Node",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0870186","Avoidance","C54264","A conscious or unconscious refusal to encounter situations, activities, or objects; the act or practice of keeping away from or withdrawing from something.","Avoidance | avoidance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013987","Emotion","C54266","That aspect of consciousness devoted to affect or feeling; a strong feeling, aroused mental state, or intense state of drive or unrest directed toward a definite object, with physiological, somatic, and behavioral components.","Emotion | Emotional | Emotions",,,,,,,,,,,,,,,"4112897","Emotion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013117","Dreaming","C54268","A mental phenomenon occurring during sleep in which images, emotions, and thoughts are experienced with a sense of reality; occurs during REM sleep.","Dreaming | Dream | Dreams",,,,,,,,,,,,,,,"4215467","Dream",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709896","Reminder","C54270","A thing that causes someone to remember something.","Reminder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0233754","Derealization","C54271","A feeling of altered reality characterized by a feeling of unreality, or being unreal.","Derealization | Derealisation",,,,,,,,,,,,,,,"4233346","Derealization",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0441469","Picture","C54273","A visual representation of an object, scene, person or abstraction.","Picture | Photograph",,,,,,,,,,,,,,,"4121556","Picture",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709287","Numb (emotional response)","C54275","Emotionally unresponsive.","Numb | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0387926","Atrasentan Hydrochloride","C1779","The orally available hydrochloride salt of pyrrolidine-3-carboxylic acid with potential antineoplastic activity.  As a selective antagonist of the endothelin-A (ETA) receptor, atrasentan binds selectively to the ETA receptor, which may result in inhibition of endothelin-induced angiogenesis and tumor cell proliferation.","Atrasentan Hydrochloride | (+)-A 127722 | (2R,3R,4S)-4-(1,3-Benzodioxo-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)-3-pyrrolidinecarboxylic Acid Monohydrochloride | ABT-627 | ATRASENTAN HYDROCHLORIDE | Xinlay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011946","Dialysis","C15221","A procedure to remove toxic substances from the blood that is used in patients with end-stage chronic kidney disease or acute kidney failure. This includes hemodialysis and peritoneal dialysis.","Dialysis | Dialysis Procedure | Dialysis Therapy | dialysis",,,,,,,,,,,,,,,"4032243|4146536","Dialysis procedure|Renal dialysis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0205322","Persistent","C43623","Retained; never-ceasing.","Persistent | PERSISTENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030660","Pathologic Process","C16956","A biologic function or a process having an abnormal or deleterious effect at the subcellular, cellular, multicellular, or organismal level.","Pathologic Process | Pathological Process",,,,,,,,,,,,,,,"4203278","Pathological process",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026447","Monkey","C14243","Any haplorhine primate not belonging to the family Tarsiidae, Hylobatidae, Pongidae, or Hominidae; this does not correspond to any taxon. This group is divided into Old World monkeys (Cercopithecidae) and New World monkeys (Callitrichidae and Cebidae).  Many types are used as an experimental model for human disease and drug testing.","Monkey | MONKEY | Monkeys",,,,,,,,,,,,,,,"4204367","Monkey",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0584876","Foot Phalanx","C52772","A bone of the toe.","Foot Phalanx | FOOT PHALANX | Foot Phalanges | Phalanges of Foot | Phalanx of Foot | Phalanx of the Foot",,,,,,,,,,,,,,,"4232620","Bone structure of phalanx of foot",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0263772","Hip Osteoarthritis","C34876","Osteoarthritis of the hip joint.","Hip Osteoarthritis | ",,,,,,,,,,,,,,,"4079749","Osteoarthritis of hip",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013862","Polyacrylamide Gel Electrophoresis","C16539","Analytical and separative procedures in which molecules, particularly proteins or nucleic acids, are separated by their different electrophoretic mobilities in a hydrated gel. The gel suppresses convective mixing of the fluid phase through which the electrophoresis takes place and contributes molecular sieving. For proteins, commonly carried out in the presence of the anionic detergent sodium dodecylsulphate (SDS). SDS denatures proteins so that noncovalently associating sub unit polypeptides migrate independently and by binding to the proteins confers a net negative charge roughly proportional to the chain weight.","Polyacrylamide Gel Electrophoresis | Electrophoresis, Polyacrylamide Gel | Fractionation, Polyacrylamide Gel | PAGE",,,,,,,,,,,,,,,"4098364","Polyacrylamide gel electrophoresis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1711349","Extraskeletal","C54379","Outside of or excluding the skeleton.","Extraskeletal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511484","Consolidation Therapy","C15679","Treatment that is given after initial therapy to kill any remaining cancer cells.","Consolidation Therapy | Consolidation | Post Remission Therapy | Postremission Therapy | consolidation therapy | intensification therapy | postremission therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0430292","Immunofixation","C54536","An enhancement of immunoelectrophoresis in which a series of post-electrophoretic gel slabs are layered with cellulose-acetate gels saturated with specific antibodies. The resulting antigen-antibody complexes fixed on the second gel may then be stained, allowing sensitive and specific qualitative visual identification of paraproteins by electrophoretic position. It can be used to identify specific proteins in the blood or urine. It has greatest application in the identification and monitoring of monoclonal proteins that are produced in conditions like Waldenstom's macroglobulinaemia and multiple myeloma.","Immunofixation | IFE | IMMUNOFIXATION ELECTROPHORESIS | Immunofixation Electrophoresis",,,,,,,,,,,,,,,"4098368|45769417","Immunofixation|Immunofixation",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1533699","Gemtuzumab Ozogamicin","C1806","A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin.  In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04)","Gemtuzumab Ozogamicin | CDP-771 | CMA-676 | Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody | GEMTUZUMAB OZOGAMICIN | Gemtuzumab ozogamicin | Mylotarg | WAY-CMA-676 | gemtuzumab | gemtuzumab ozogamicin | hP67.6-Calicheamicin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1317659","M Protein","C17788","A protein complex comprised of two heavy chains and two light chains. Monoclonal immunoglobulin (M protein) is found in abundance in patients who have multiple myeloma. The protein is not produced in response to an antigen, but it is expressed in malignant plasma cells and excreted into the blood and urine.","M Protein | M Component | M Proteins | M protein | M-Protein | Monoclonal immunoglobulin | Myeloma Protein | Paraprotein | Spike Protein | monoclonal protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021036","Immunoglobulin Light Chain, Kappa","C16718","Immunoglobulin Light Chain Kappa is one of two Ig light chain types. Each Ig molecule is typically composed of two heavy chains and two light chains. Ig kappa light chains contain a variable and a constant region. Kappa light chains are encoded by multiple V, J, and C gene segments, which are separated in the genomes of cells undifferentiated with regard to antibody gene expression. Diversity in the kappa light chain V region arises during differentiation of an activated (kappa-type) antibody-producing B-cell from variable recombination of kappa V genes with kappa J genes and somatic point mutation, which plays a major role in antibody diversity. (from OMIM and NCI)","Immunoglobulin Light Chain, Kappa | IGK | Ig Kappa Chain | Ig Light Chain Kappa | Immunoglobulin Kappa | Immunoglobulin Kappa Chain | Immunoglobulin Kappa Light Chain | Immunoglobulin Kappa Light-Chain | Kappa Light Chain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021037","Immunoglobulin Light Chain, Lambda","C16719","Immunoglobulin Light Chain Lambda is one of two Ig light chain types. Each Ig molecule is typically composed of two heavy chains and two light chains but Ig lambda light chains contain a variable and a constant region. Lambda light chains are encoded by multiple V, J, and C gene segments, which are separated in the genomes of cells undifferentiated with regard to antibody gene expression. During differentiation of an activated (lambda-type) antibody-producing B-cell, diversity in the lambda light chain V region arises from variable recombination of lambda V genes with lambda J genes and somatic point mutation, which plays a major role in antibody diversity. (from OMIM 147220 and NCI)","Immunoglobulin Light Chain, Lambda | IGL | Ig Lambda Chain | Ig Light Chain Lambda | Immunoglobulin Lambda | Immunoglobulin Lambda Chain | Immunoglobulin Lambda Light Chain | Immunoglobulin Lambda Light-Chain | Lambda Light Chain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1621812","Metaphase Process","C16846","The second phase of mitosis, in which the chromosomes line up across the equatorial plane of the spindle prior to separation.","Metaphase Process | Metaphase | Metaphase | Mitotic Metaphase",,,,,,,,,,,,,,,"4253365","Metaphase",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085669","Acute Leukemia","C9300","A clonal (malignant) hematopoietic disorder with an acute onset, affecting the bone marrow and the peripheral blood.  The malignant cells show minimal differentiation and are called blasts, either myeloid blasts (myeloblasts) or lymphoid blasts (lymphoblasts).","Acute Leukemia | acute leukemia","9801/3","Acute leukemia, NOS",,,,,,,,,,,,,"138708|4080746","Acute leukemia|Acute leukemia",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0087111","Therapeutic Procedure","C49236","Medical care intended to treat or cure a condition or lessen its symptoms. This includes the administration of drugs, surgical procedures, physical or psychotherapy, or the use of therapeutic devices.","Therapeutic Procedure | TREAT | TX | Therapeutic | Therapeutic Interventions | Therapeutic Method | Therapeutic Technique | Therapy | Treatment | any therapy | any_therapy | therapy | treatment | treatment or therapy | treatment_or_therapy",,,,,,,,,,,,,,,"4172515","Therapeutic procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0259785","Anaplastic (Malignant) Meningioma","C4051","A WHO grade III meningioma characterized by the presence of malignant morphologic features, including malignant cytology and a very high mitotic index (20 or more mitoses per ten high power fields).","Anaplastic (Malignant) Meningioma | Anaplastic Meningioma | Malignant Meningioma | Meningioma, Malignant | Meningioma, anaplastic | Meningioma, malignant | malignant meningioma","9530/3","Meningioma, malignant",,,,,,,,,,,,,"4301120","Meningioma, malignant",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C4012135","Meningioma","C3230","A generally slow growing tumor attached to the dura mater. It is composed of neoplastic meningothelial (arachnoidal) cells. It typically occurs in adults, often women and it has a wide range of histopathological appearances. Of the various subtypes, meningothelial, fibrous and transitional meningiomas are the most common. Most meningiomas are WHO grade 1 tumors, and some are WHO grade 2 or 3 tumors. Most subtypes share a common clinical behavior, although some subtypes are more likely to recur and follow a more aggressive clinical course. (Adapted from WHO)","Meningioma | Meningioma, NOS | Meningiomas | meningioma","9530/0","Meningioma, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C1546437","No Information Available","C53269","Information regarding the subject is unknown or inaccessible at this time.","No Information Available | Data Not Available | Information Not Available | NI | NO ANSWER PROVIDED | NO INFORMATION | No Data | No Data Available | No Information | Unclassified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332880","Central Nervous System Germ Cell Tumor","C5461","A unique group of rare tumors of the central nervous system that affect mainly children and adolescents. Their morphologic and biologic profile corresponds to that of homologous germ cell tumors that arise in the gonads and in other extragonadal sites. Representative examples include: germinoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, and teratoma.","Central Nervous System Germ Cell Tumor | CNS Germ Cell Neoplasm | CNS Germ Cell Tumor | Central Nervous System Germ Cell Neoplasm | Germ Cell Neoplasm of CNS | Germ Cell Neoplasm of Central Nervous System | Germ Cell Neoplasm of the CNS | Germ Cell Neoplasm of the Central Nervous System | Germ Cell Tumor of CNS | Germ Cell Tumor of Central Nervous System | Germ Cell Tumor of the CNS | Germ Cell Tumor of the Central Nervous System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205851","Germ Cell Tumor","C3708","A benign or malignant, gonadal or extragonadal neoplasm that originates from germ cells. Representative examples include teratoma, seminoma, embryonal carcinoma, and yolk sac tumor.","Germ Cell Tumor | Germ Cell Neoplasm | Germ Cell Neoplasms | Germ cell tumor, NOS | Neoplasm of Germ Cell | Neoplasm of the Germ Cell | Tumor of Germ Cell | Tumor of the Germ Cell | germ cell tumor",,,,,,,,,,,,,,,"4151356|4294433","Germinoma|Germ cell tumor",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0010268","Cranial Nerve","C12700","Any of the 12 paired nerves that originate in the brain stem.","Cranial Nerve | CRANIAL NERVE | Cranial nerve, NOS | NERVE, CRANIAL | Nerve(s) Cranial | cranial nerve | cranial neural tree organ",,,,,,,,,,,,,"UBERON:0001785","cranial nerve","4098198","Cranial nerve structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0228126","Leptomeninges","C32979","The two innermost layers of tissue that cover the brain and spinal cord, the arachnoid mater and the pia mater.","Leptomeninges | CNS-Leptom | LEPTOMENINGES | Leptomeningeal | leptomeningeal | leptomeninges | leptomeninx",,,,,,,,,,,,,"UBERON:0000391","leptomeninx","4280956","Leptomeninges structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0521407","Subependymal","C28050","Describes the layer of cells just under the ependyma (the thin membrane that lines the fluid-filled spaces in the brain and spinal cord).","Subependymal | subependymal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0581620","Thoracic Spinal Cord","C12894","The portion of the spinal cord located in the thoracic region.","Thoracic Spinal Cord | SPINAL CORD, THORACIC | Thoracic Portion of Spinal Cord | Thoracic spinal cord structure (body structure) | thoracic spinal cord",,,,,,,,,,,,,,,"4176257","Thoracic spinal cord structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085203","Stereotactic Radiosurgery","C15358","A non-surgical procedure that was developed to deliver one or several maximum dose targeted radiation treatments for cancers in the brain or spine.","Stereotactic Radiosurgery | SRS | Stereotactic External Beam Irradiation | Stereotactic Radiation Therapy | Stereotactic Radiotherapy | stereotactic external-beam radiation therapy | stereotactic radiation therapy | stereotactic radiosurgery | stereotaxic radiation therapy | stereotaxic radiosurgery",,,,,,,,,,,,,,,"4021989","Stereotactic radiosurgery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0442893","Systemic Disease","C9229","A clinical course finding indicating that a disease presents with systemic manifestations.","Systemic Disease | Systemic Disorder | systemic disease",,,,,,,,,,,,,,,"4206788","Systemic disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007787","Transient Ischemic Attack","C50781","A brief attack (from a few minutes to an hour) of cerebral dysfunction of vascular origin, with no persistent neurological deficit.","Transient Ischemic Attack | TIA | Transient Ischemic Attacks | Transient cerebral ischemic attack, unspecified | Transient ischemic attack | Transient ischemic attacks",,,,,,,,,,,,,,,"373503","Transient cerebral ischemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002962","Angina","C51221","Paroxysms of chest pain due to reduced oxygen to the heart.","Angina | Angina pectoris | Chest pain - cardiac",,,,,,,,,,,,,,,"321318","Angina pectoris",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0012108","Dictionaries as Topic","C49461","No Value Exists","Dictionary | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1140263","Medical Dictionary for Regulatory Activities Terminology (MedDRA)","C43820","An international medical terminology designed to support the classification, retrieval, presentation, and communication of medical information throughout the medical product regulatory cycle. MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. The MedDRA Maintenance and Support Services Organization holds a contract with the International Federation of Pharmaceutical Manufacturers Associations to maintain and support the implementation of the terminology.","MedDRA | MedDRA | MedDRA (Medical Dictionary for Regulatory Activities) | Medical Dictionary for Regulatory Activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1140123","WHO Adverse Reaction Terminology","C49468","A terminology for coding clinical information in relation to drug therapy, used throughout the WHO Program by member countries and around the world by pharmaceutical companies and clinical research organisations. It has been developed over more than thirty years to serve as a basis for rational coding of adverse reaction terms.","World Health Organization Adverse Reaction Terminology | WHO Adverse Reaction Terminology | WHO-ART | WHOART | World Health Organization Adverse Reaction Terms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710681","World Health Organization Drug Dictionary","C49475","A reference source of drugs and drug associated information maintained by the World Health Organization.","World Health Organization Drug Dictionary | WHODD | WHODrug Global",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1623497","Systematized Nomenclature of Medicine Clinical Terms","C49469","Published by the College of American Pathologists, the Systematized Nomenclature of Medicine Clinical Terms is a combination of content of SNOMED Reference Terminology and READ codes.","Systematized Nomenclature of Medicine Clinical Terms | SNOMED CT | SNOMED CT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1140097","COSTART","C49471","A terminology developed and used by the Food and Drug Administration (FDA) for the coding, filing and retrieving of post marketing adverse reaction reports.","Thesaurus of Adverse Reaction Term Coding Symbols | COSTART | Coding Symbols for a Thesaurus of Adverse Reaction Terms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0870733","International Classification of Diseases","C49474","A system of categories to which morbid entries are assigned according to established criteria. Included is the entire range of conditions in a manageable number of categories, grouped to facilitate mortality reporting. It is produced by the World Health Organization. The Clinical Modifications, produced by the United States Dept. of Health and Human Services, are larger extensions used for morbidity and general epidemiological purposes, primarily in the U.S.","International Classification of Diseases | ICD | ICD Version",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1136323","Logical Observation Identifiers Names and Codes","C49476","Published by The Regenstrief Institute, the Logical Observation Identifiers Names and Codes covers clinical and clinical laboratory terminology.","Logical Observation Identifiers Names and Codes | LOINC | LOINC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705762","Submission Domain Abbreviation","C49558","A unique, 2-character domain code used in the regulatory submission process.  The domain abbreviation is used consistently throughout the submission, i.e. in the dataset name, as the value of the domain variable within the dataset, and as a prefix for most variable names in the dataset. (CDISC Glossary)","Submission Domain Abbreviation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704642","Analysis Dataset Domain","C49563","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to the analysis of a dataset.","Analysis Dataset Domain | AD | Analysis Dataset | Analysis Dataset Submission Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705413","Adverse Event Domain","C49562","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to an adverse event.","Adverse Event Domain | AE | Adverse Event Submission Domain | Adverse Events | Adverse Experiences",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704773","Autopsy Domain","C49565","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to autopsy.","Autopsy Domain | Autopsy Submission Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706430","Biopsy Domain","C49567","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to biopsy.","Biopsy Domain | Biopsy Submission Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704651","Bone Mineral Density Data Domain","C49566","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to bone mineral density data.","Bone Measurements Domain | Bone Mineral Density Data Domain | Bone Mineral Density Data Submission Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282411","CO","C49569","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to comments.","Comment Domain | CO | Comment Submission Domain | Comments",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704627","Concomitant Medication Submission Domain","C49568","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to concomitant medication administration.","Concomitant Medication Domain | CM | Concomitant Medication Submission Domain | Concomitant/Prior Medications",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704791","Demographics Domain","C49572","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to demographics.","Demographics Domain | DM | Demographics | Demographics Submission Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705348","Disease Characteristics Domain","C49570","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to disease characteristics.","Disease Characteristics Domain | Disease Characteristics Submission Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705555","Disposition Domain","C49576","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to disposition.","Disposition Domain | DS | Disposition | Disposition Submission Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704643","DA","C49578","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to drug and other product accountability.","Product Accountability Domain | DA | Drug Accountability Domain | Drug Accountability Submission Domain | Product Accountability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704645","Protocol Deviations Domain","C49585","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to protocol deviations.","Protocol Deviations Domain | DV | Protocol Deviations | Protocol Deviations Submission Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705651","Electrocardiogram Domain","C49626","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to electrocardiogram.","Electrocardiogram Domain | ECG Test Results | EG | Electrocardiogram Submission Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704279","Electroencephalogram Domain","C49625","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to electroencephalogram.","Electroencephalogram Domain | Electroencephalogram Submission Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704625","Exposure Domain","C49587","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to exposure.","Exposure Domain | EX | Exposure | Exposure Submission Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704682","Stress Exercise Test Data Domain","C49614","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to stress exercise test data.","Stress Exercise Test Data Domain | Exercise Test Data Submission Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705495","Family History Domain","C49588","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to family history.","Family History Domain | Family History Submission Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704738","Healthcare Resource Utilization Domain","C49589","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to healthcare resource utilization.","Healthcare Resource Utilization Domain | Healthcare Resource Utilization Submission Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705214","Laboratory Data Domain","C49592","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to laboratory data.","Laboratory Data Domain | LB | Laboratory Data Submission Domain | Laboratory Test Results",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706380","Meal Data Domain","C49604","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to meal data.","Meal Data Domain | ML | Meal Data | Meal Data Submission Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706181","Microbiology Specimen Domain","C49602","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to microbiology specimen.","Microbiology Specimen Domain | MB | Microbiology Domain | Microbiology Specimen | Microbiology Submission Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704706","Medical History Domain","C49603","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to subject medical history.","Medical History Domain | MH | Medical History | Medical History Submission Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705272","Organ Measurement Domain","C49605","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to organ measurement.","Organ Measurement Domain | OM | Organ Measurement Submission Domain | Organ Measurements",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706367","Pharmacokinetic Concentration Domain","C49606","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to pharmacokinetic concentration.","Pharmacokinetic Concentration Domain | PC | Pharmacokinetic Concentration Submission Domain | Pharmacokinetics Concentrations",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1744699","Physical Exam Domain","C49608","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to physical exam.","Physical Exam Domain | PE | Physical Exam Submission Domain | Physical Examination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705911","Pharmacokinetic Parameters Domain","C49607","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to pharmacokientic parameters.","Pharmacokinetic Parameters Domain | PP | Pharmacokinetic Parameters Submission Domain | Pharmacokinetics Parameters",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706422","Questionnaire Domain","C49609","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to questionnaire.","Questionnaire Domain | QS | Questionnaire Submission Domain | Questionnaires",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706465","Subject Characteristics Domain","C49610","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to subject characteristics.","Subject Characteristics Domain | SC | Subject Characteristics | Subject Characteristics Submission Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705196","Surgery Domain","C49611","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to surgery.","Surgery Domain | Surgery Submission Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705200","Skin Test Domain","C49612","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to skin test.","Skin Test Domain | Skin Test Submission Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704626","Sleep Polysomnography Domain","C49613","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to polysomnography.","Sleep Polysomnography Domain | Polysomnography Submission Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705189","Subject Element Domain","C49616","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to subject element.","Subject Element Domain | SE | Subject Element Submission Domain | Subject Elements",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704677","Subject Visits Domain","C49617","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to subject visit.","Subject Visits Domain | SV | Subject Visits | Subject Visits Submission Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705534","Substance Use Domain","C49615","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to substance use.","Substance Use Domain | SU | Substance Use | Substance Use Submission Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705538","Trial Arms Domain","C49618","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to trial arm.","Trial Arms Domain | TA | Trial Arms | Trial Arms Submission Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705540","Trial Elements Domain","C49619","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to trial element.","Trial Elements Domain | TE | Trial Elements | Trial Elements Submission Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704756","Trial Inclusion and Exclusion Criteria Submission Domain","C49620","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to trial inclusion and exclusion criteria.","Trial Inclusion and Exclusion Criteria Domain | TI | Trial Inclusion and Exclusion Criteria Submission Domain | Trial Inclusion/Exclusion Criteria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704705","Trial Visits Domain","C49621","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to trial visit.","Trial Visits Domain | TV | Trial Visits | Trial Visits Submission Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704629","Vital Signs Domain","C49622","A subject domain used for storing information regarding a patient's vital status (such as height, weight, and blood pressure).","Vital Signs Domain | VS | VT | Vital Signs | Vital Signs Submission Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704618","Trial Summary Domain","C53483","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to trial summary.","Trial Summary Domain | TS | Trial Summary | Trial Summary Submission Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520143","Whole-Brain Radiotherapy","C16187","Radiation treatment modality used as major component in treatment of primary and metastatic brain tumors. This is a standard treatment for multiple brain metastases.","Whole-Brain Radiotherapy | WBRT | whole-brain radiation therapy | whole-brain radiotherapy",,,,,,,,,,,,,,,"764407","Whole brain radiation therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0282282","Palliative Surgery","C17883","Surgery that does not alter the course of a disease, but improves the quality of life.","Palliative Surgery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018981","Hematopoietic and Lymphatic System Disorder","C35814","A non-neoplastic or neoplastic disorder that affects the hematopoietic and lymphatic system.","Hematopoietic and Lymphatic System Disorder | Hematopoietic and Lymphoid System Disease | Hematopoietic and Lymphoid System Disorder | Hematopoietic and Lymphoid System Disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018799","Heart Disorder","C3079","A non-neoplastic or neoplastic disorder that affects the heart and/or the pericardium. Representative examples include endocarditis, pericarditis, atrial myxoma, cardiac myeloid sarcoma, and pericardial malignant mesothelioma.","Heart Disorder | Cardiac Disease | Heart Disease | Heart trouble | Unspecified Heart Problem",,,,,,,,,,,,,,,"321588","Heart disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448747","Congenital, Familial and Genetic Disorder Class","C49399","A class of disorders that encompasses conditions resulting from a congenital, familial hereditary trait or genetic abnormality as is manifested by a characteristic set of symptoms and signs.","Congenital, Familial and Genetic Disorder Class | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448763","Ear and Labyrinth Disorder Class","C49400","Any deviation from the normal structure or function of the ear or labyrinth that is manifested by a characteristic set of symptoms and signs.","Ear and Labyrinth Disorder Class | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014130","Endocrine System Disorder","C3009","A non-neoplastic or neoplastic disorder that affects the endocrine system. Representative examples of non-neoplastic disorders include diabetes mellitus, hyperthyroidism, and adrenal gland insufficiency. Representative examples of neoplastic disorders include carcinoid tumor, neuroendocrine carcinoma, and pheochromocytoma.","Endocrine System Disorder | Disorder of Endocrine System | Endocrine Disease | Endocrine Disorder | Endocrine Disorder | Endocrinopathy | Thyroid or other glandular disorders",,,,,,,,,,,,,,,"31821","Disorder of endocrine system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015397","Eye Disorder","C26767","A non-neoplastic or neoplastic disorder that affects the eye. Representative examples include conjunctivitis, glaucoma, cataract, conjunctival squamous cell carcinoma, uveal melanoma, and retinoblastoma.","Eye Disorder | Eye Disease",,,,,,,,,,,,,,,"375252","Disorder of eye",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017178","Digestive System Disorder","C2990","A non-neoplastic or neoplastic disorder that affects the gastrointestinal tract, anus, liver, biliary system, and pancreas.","Digestive System Disorder | Digestive Disease | Digestive System Disease | Disorder of Digestive System | GI Disorder | Gastrointestinal Disorder | Gastrointestinal Disorder | Gastrointestinal System Disease | Gastrointestinal System Disorder | Unspecified Gastrointestinal Problem | stomach or intestinal disorder",,,,,,,,,,,,,,,"4000610","Disorder of gastrointestinal tract",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448764","General Disorders and Administration Site Conditions Class","C49401","A class of disorders that encompasses conditions of a general kind that result from a disease, the treatment of disease or administration of treatment at a particular site and are manifested by a characteristic set of symptoms and signs.","General Disorders and Administration Site Conditions Class | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0267792","Hepatobiliary Disorder","C3959","A non-neoplastic or neoplastic disorder that affects the liver, bile ducts, and gallbladder. Representative examples of non-neoplastic disorders include hepatitis, cirrhosis, cholangitis, and cholecystitis. Representative examples of neoplastic disorders include hepatocellular adenoma, hepatocellular carcinoma, and cholangiocarcinoma.","Hepatobiliary Disorder | Liver Disease | Liver and Biliary Disease | Liver and Biliary Disorder | Liver and Biliary System Disorder | Liver and Biliary Tract Disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4227548","Immune System Disorder","C3507","A disorder resulting from an abnormality in the immune system.","Immune System Disorder | Disorder of Immune System | Immune Disorder | Immune Disorders | Immune Dysfunction | Immune disorder, NOS | Immunologic Disorder | Unspecified Immune System Problem",,,,,,,,,,,,,,,"432596","Immune defect",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448765","Injury, Poisoning and Procedural Complication Class","C49402","A class of disorders that encompasses conditions resulting from an injury, poisoning or procedure.","Injury, Poisoning and Procedural Complication Class | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448246","Investigation","C41198","The act or process of a systematic and thorough examination; research, study; the process of inquiring into or following up, intended to develop facts.","Investigation | Investigation Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448767","Metabolism and Nutrition Disorder Class","C49403","A class of disorders that encompasses conditions occurring as a result of metabolic dysfunction or deviation from the normal nutritional requirements.","Metabolism and Nutrition Disorder Class | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333150","Connective and Soft Tissue Disorder","C27574","A non-neoplastic or neoplastic disorder that affects the connective and soft tissue.","Connective and Soft Tissue Disorder | Connective and Soft Tissue Disease | Connective and Soft Tissue Diseases",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027765","Nervous System Disorder","C26835","A non-neoplastic or neoplastic disorder that affects the brain, spinal cord, or peripheral nerves.","Nervous System Disorder | Disorder of Nervous System | Neurologic Disorder | Neurological Disorder | Unspecified Nervous System Problem",,,,,,,,,,,,,,,"376337","Disorder of nervous system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448768","Pregnancy, Puerperium and Perinatal Condition Class","C49404","A class of conditions associated with pregnancy, puerperium and perinatal status.","Pregnancy, Puerperium and Perinatal Condition Class | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004936","Psychiatric Disorder","C2893","A disorder characterized by behavioral and/or psychological abnormalities, often accompanied by physical symptoms. The symptoms may cause clinically significant distress or impairment in social and occupational areas of functioning. Representative examples include anxiety disorders, cognitive disorders, mood disorders and schizophrenia.","Psychiatric Disorder | Mental Disorder | Mental Dysfunction | Mental Illness | Psychiatric Disease | Psychiatric disorder",,,,,,,,,,,,,,,"432586","Mental disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042075","Urinary System Disorder","C3430","A non-neoplastic or neoplastic disorder affecting the urinary system.","Urinary System Disorder | Disorder of Urinary System | Urinary Tract Disease | Urinary Tract Disorder | Urinary Tract Disorder | Urologic Disorder | Urological Disorders | urinary tract disorder",,,,,,,,,,,,,,,"75865","Disorder of the urinary system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448769","Reproductive System and Breast Disorder Class","C49405","Any deviation from the normal structure or function of the reproductive system or breast that is manifested by a characteristic set of symptoms and signs.","Reproductive System and Breast Disorder Class | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0851355","Respiratory and Thoracic Disorder","C27669","A non-neoplastic or neoplastic disorder that affects the respiratory system or the thoracic organs.","Respiratory and Thoracic Disorder | Respiratory and Thoracic Disease | Respiratory, Thoracic, and Mediastinal Disease | Respiratory, Thoracic, and Mediastinal Disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037274","Skin Disorder","C3371","Any deviation from the normal structure or function of the skin or subcutaneous tissue that is manifested by a characteristic set of symptoms and signs.","Skin Disorder | Cutaneous Disorder | Dermatologic Disorder | Disorder of Skin | Skin Diseases and Manifestations | Skin Disorders",,,,,,,,,,,,,,,"4317258","Disorder of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0851364","Social Circumstances","C20188","Pertaining to the demographic and psychosocial environment in which a person lives.","Social Circumstances | social circumstances",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042373","Vascular Disorder","C35117","A non-neoplastic or neoplastic disorder affecting the arteries, veins, or lymphatic vessels. Examples include vasculitis, thrombophlebitis, arteriosclerosis, lymphedema, hemangioma, and angiosarcoma.","Vascular Disorder | Unspecified Vascular Problem | Vascular Disease | Vascular disease",,,,,,,,,,,,,,,"443784","Vascular disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706086","Both","C49636","One and the other; relating to or being two in conjunction.","Both | BOTH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521158","Recurrent Neoplasm","C4798","The reemergence of a neoplasm after a period of remission.","Recurrent Neoplasm | Neoplasm Recurrence | Recurrence | Recurrent | Recurrent Tumor | Recurrent tumor | recurrence",,,,,,,,,,,,,,,"4097297","Recurrent neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516691","Cognitive","C37926","Of or being or relating to or involving cognition.","Cognitive | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709849","reason off study","C49627","The reason that a subject was discontinued from a study.","Reason for Study Discontinuation | Reason for Non-Completion | Reason for Non-Completion | reason off study | reason_off_study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0235828","Lack of Efficacy","C48226","The lack of expected or desired effect related to a therapy.","Lack of Efficacy | Efficacy Lack | LACK OF EFFICACY | TREATMENT FAILURE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1302313","Lost To Follow-Up","C48227","The loss or lack of continuation of subject participation after a study has officially closed.","Lost To Follow-Up | LOST TO FOLLOW-UP | Lost To Follow-up | Lost To Follow-up | Lost to Follow-up | Lost to follow-up (finding) | Yes | lost to follow-up",,,,,,,,,,,,,,,"4163894","Lost to follow-up",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709261","Non-Compliance With Study Drug","C49631","An indication that a subject has not agreed with or followed the instructions related to the study medication.","Non-Compliance With Study Drug | NON-COMPLIANCE WITH STUDY DRUG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709536","Physician Decision","C48250","A position, opinion or judgment reached after consideration by a physician with reference to subject.","Physician Decision | PHYSICIAN DECISION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710476","Trial Screen Failure","C49628","The failure of a potential subject of meeting one or more criteria required for participation in a trial.","Trial Screen Failure | Failure to Meet Inclusion/Exclusion Criteria | SCREEN FAILURE | screen failure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710224","Study Terminated By Sponsor","C49632","An indication that a clinical study was stopped by its sponsor.","Study Terminated By Sponsor | STUDY TERMINATED BY SPONSOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710348","Technical Problem","C49633","A problem with some technical aspect of a clinical study, usually related to an instrument.","Technical Problem | TECHNICAL PROBLEMS | Technical Difficulty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710677","Withdrawal by Subject","C49634","An indication that a study participant has removed themself from the study or from one or more segments of the study.","Withdrawal by Subject | Dropout | Subject Dropped Out | Subject Withdrawal | WITHDRAWAL BY SUBJECT | withdraw | withdrawal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023730","Linear Accelerator","C28169","A type of particle accelerator that generates ionizing radiation by colliding subatomic particles traveling at high speeds along a straight chamber. This creates high-energy radiation that may be used to treat cancer.","Linear Accelerator | LINAC | LINEAR ACCELERATOR | Linac | MeV linear accelerator | linac | linear accelerator | mega-voltage linear accelerator",,,,,,,,,,,,,,,"4142633","Linear accelerator",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1514120","Nerve-Sparing Prostatectomy","C16218","A type of surgical prostatectomy which attempts to spare the nerves that control erection.","Nerve-Sparing Prostatectomy | Nerve-Sparing Surgery | nerve-sparing radical prostatectomy | nerve-sparing surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0549177","Large","C49508","Of considerable or relatively great size, extent, or capacity.","Large | LARGE | Larger",,,,,,,,,,,,,,,"4116858","Large",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221099","Impairment","C21055","Loss or abnormality of psychological, physiological, or anatomic structure or function.","Impairment | Impaired | impairment",,,,,,,,,,,,,,,"4125554","Impaired",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704434","Unit","C50329","A largely self-contained device designed to be incorporated into a larger device.","Unit Device | Device Unit | Unit | Unit Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0542479","Energy, Physics","C48058","The capacity of a physical system to do work.","Energy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004916","Bed","C50367","A structure that permits a subject to recline; it can be used for sleeping or for positioning a subject for a procedure.","Bed | ",,,,,,,,,,,,,,,"4044565","Bed",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518823","PSA Velocity","C20119","A type of PSA assay which compares changes in PSA levels over time. A sharp rise in the PSA level raises the suspicion of cancer. (from Cancer Information Service)","PSA Velocity | PSA kinetics | PSA velocity | Prostate Specific Antigen Velocity | Prostate-specific antigen kinetics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086330","Gamma Knife Radiosurgery","C15382","A treatment using gamma rays, a type of high-energy radiation that can be tightly focused on small tumors or other lesions in the head or neck, so very little normal tissue receives radiation. The gamma rays are aimed at the tumor from many different angles at once, and deliver a large dose of radiation exactly to the tumor in one treatment session. This procedure is a type of stereotactic radiosurgery. Gamma Knife therapy is not a knife and is not surgery. Gamma Knife is a registered trademark of Elekta Instruments, Inc.","Gamma Knife | Gamma Knife Radiosurgery | Gamma Knife therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043309","X-Ray","C17262","Ionizing electromagnetic radiation having a wavelength that is shorter than ultraviolet radiation and longer than gamma radiation.","X-Ray | Radiation, X-Rays | X-RAY | X-radiation | x-ray",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537125","Life Threatening or Disabling Adverse Event","C41337","Any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.","Life Threatening or Disabling Adverse Event | 4 | CTCAE Grade 4 | Common Terminology Criteria for Adverse Events Grade 4 | Grade 4 | Grade 4 Life Threatening or Disabling Adverse Event | LIFE THREATENING | Life Threatening Adverse Event | Standard Toxicity Grade 4 | Toxicity Value 4",,,,,,,,,,,,,,,"765765","Common terminology criteria for adverse events grade 4",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1456501","Preventive","C28005","Evidence of preventive.","Preventive | Preventive - intent | preventive",,,,,,,,,,,,,,,"4044554","Preventive intent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334972","Nodular Pattern","C35899","A morphologic architectural pattern characterized by the presence of proliferating non-neoplastic or neoplastic cells forming single or multiple nodules within a lesion.","Nodular Pattern | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883411","Tumor Replacement","C54692","The process whereby normal tissue cells and structures are replaced by tumor cells.","Tumor Replacement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL343029","Percent Unit","C48570","A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred).","Percent Unit | % | PERCENT | Percent | Percentage | Unit of Percent | percent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475210","Centimeter","C49668","A basic unit of length in the former CGS version of metric system, equal to one hundredth of a meter or approximately 0.393 700 787 inch.","Centimeter | Centimeters | centimeter | cm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704777","Balloon Device","C49837","Any of various types of bags designed to be distended.","Balloon Device | Balloon | Balloon Device Component | Balloon Device Component",,,,,,,,,,,,,,,"4145297","Medical balloon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518654","Other Imaging Modalities","C19343","Imaging methods not listed.","Other Imaging Modalities | Medical Imaging, Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706749","Age Unit","C50400","Those units of time that are routinely used to express the age of a person or thing.","Age Unit | AGEU | Unit of Age",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707739","Dictionary Name","C50399","A name given to a reference source that lists words and gives their meaning.","Dictionary Name | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704854","No Yes Response","C49486","A response or indicator that can have a value of yes, no, unknown, or not applicable.","Yes, No, Unknown, or Not Applicable Response | Ind-4 | Ind-4 | Y/N/U/NA | Yes, No, Unknown, or Not Applicable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2960324","Transrectal Ultrasound","C18315","A procedure that uses sound waves to create a video image of the pelvic organs and tissues. A small, lubricated probe placed into the rectum releases sound waves, which create echoes as they enter a pelvic organ. The echoes that bounce back are sent to a computer that translates the pattern of echoes into a picture of the specific organ under examination.  This procedure is most often used to evaluate the prostate gland.","Transrectal Ultrasound | ERUS | TRUS | endorectal ultrasound | transrectal ultrasound",,,,,,,,,,,,,,,"40486003","Ultrasonography by transrectal approach",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710569","Universally Unique Identifier","C54100","A 128 bit identifier. Depending on the mechanism used to generate it, it is either guaranteed to be different from all other UUIDs/GUIDs generated until 3400 AD or extremely likely to be different. Its relatively small size lends itself well to sorting, ordering, and hashing of all sorts, storing in databases, simple allocation, and ease of programming in general.","Universally Unique Identifier | GUID | Globally Unique Identifier | UUID | Unique Universal Identifier | Universal Identifier | Universal Unique Identifier | uuid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439617","Revision","C54087","An act of alteration involving reconsideration and modification.","Revision | Revise | Revised",,,,,,,,,,,,,,,"4116366","Revision - value",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710255","Surgical Pathology Report","C45260","A pathology report based upon samples obtained by or during surgery.","Surgical Pathology Report | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708381","Honest Broker","C54088","An individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly.  The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a 're-identification code'), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.","Honest Broker | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709334","Ordering Physician","C54089","The physician who has ordered diagnostic tests, services, items (e.g., durable medical equipment), or supplies for a patient or study subject.","Ordering Physician | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705191","Section (object)","C54091","One of several parts or pieces that fit with others to constitute a whole object; a self-contained part of a larger composition (written or musical).","Section | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705175","Order","C54092","A commercial document used to request someone to supply something in return for payment and providing specifications and quantities.","Order | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708059","Fill","C54093","Execute or satisfy a request or order; supply or furnish.","Fill | Filled",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002812","Topology","C54101","The study of anatomy based on regions or divisions of the body and emphasizing the relations between various structures (muscles and nerves and arteries etc.) in that region.","Topology | Regional Anatomy | Topographic Anatomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229962","Body Part","C32221","Any part of an organism.","Body Part | Body Structure",,,,,,,,,,,,,,,"4190005","Body part structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708320","Handle - program access","C54106","A number or token that lets a program access a resource. Programs often receive a handle in response to a request for a resource, and then they use the handle when they need to access the resource. When the program uses the handle, the value of the handle tells the system which resource, from the pool of resources maintained by the system, to use.","Handle | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0678367","public entity","C49060","Not private; open to or concerning the people as a whole.","Public | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550398","Private","C54104","Not public; kept secret or restricted.","Private | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710218","Structured Query Language","C54108","An industry-standard language for creating, updating and, querying relational database management systems.","Structured Query Language | SQL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332353","Atypical Small Acinar Proliferation of the Prostate Gland","C37268","Focal proliferation of small acinar glandular cells in the prostate gland with cytologic changes ranging from atypia to highly suggestive of malignancy.","Atypical Small Acinar Proliferation of the Prostate Gland | ASAP | Prostatic Atypical Small Acinar Proliferation",,,,,,,,,,,,,,,"37209512","Atypical small acinar proliferation of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0678222","Breast Carcinoma","C4872","A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","Breast Carcinoma | Breast Cancer | Breast cancer, NOS | Cancer of Breast | Cancer of the Breast | Carcinoma of Breast | Carcinoma of the Breast | Mammary Carcinoma | breast cancer",,,,,,,,,,,,,,,"4116071","Carcinoma of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0439223","Millisecond","C41140","A unit of time equal to one thousandth of a second (10E-3 second).","Millisecond | Msec | millisecond | ms | msec",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519043","Phase I/II Trial","C15693","A clinical research protocol designed to study the safety, dosage levels and response to new treatment. Phase I/II trials combine a Phase I and a Phase II trial of the same treatment into a single protocol.","Phase I/II Trial | 1-2 | PHASE I/II TRIAL | Phase I/II trial | Trial Phase 1-2 | Trial Phase 1/2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282461","Phase 3 Clinical Trials","C15602","A clinical research protocol designed to investigate the efficacy of the biomedical or behavioral intervention in large groups of human subjects (from several hundred to several thousand), to confirm efficacy, to monitor adverse reactions to the new medication or treatment regimen with respect to long-term use and by comparing the intervention to other standard or experimental interventions as well as to a placebo.","Phase III Trial | 3 | Clinical Trials, Phase III | PHASE III TRIAL | Phase 3 | Phase 3 Study | Phase III Clinical Trial | Phase III Protocol | Phase III Study | Phase III Trials | Trial Phase 3 | phase 3 | phase III trial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282462","Phase 4 Clinical Trials","C15603","A randomized, controlled trial that is designed to evaluate the long-term safety and efficacy of a drug for a given indication. Often they are designed to study side effects that may have become apparent after the phase III study was completed.","Phase IV Trial | 4 | Clinical Trials, Phase IV | PHASE IV TRIAL | Phase 4 Study | Phase IV Clinical Trials | Phase IV Study | Trial Phase 4 | phase 4 | phase IV trial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1271104","Blood Pressure Finding","C54707","A test result that reports the diastolic and systolic pressure of the blood.","Blood Pressure Finding | Blood Pressure | Blood Pressure Result",,,,,,,,,,,,,,,"4214962","Blood pressure finding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882358","Phase 0 Trial","C54721","A clinical trial that uses an investigational agent that is available only in very limited quantities and which has never previously given to humans or for which there is extremely limited human experience. Phase 0 clinical trials are intended to enable researchers to understand the path of the drug in the body and its efficacy. Adverse event reporting in Phase 0 trials is expedited.","Phase 0 Trial | 0 | EARLY PHASE I | Early Phase I | PHASE 0 TRIAL | Phase 0 | Pre-Clinical Trial | Pre-clinical Trial | Trial Phase 0 | phase 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439482","Hertz","C42545","A SI derived unit of frequency; equal to one oscillation (one cycle) per second.","Hertz | Cycle per Second | Cycle/Second | Cycle/s | Herz | Hz | cycle/sec | hertz | {cycle}/s",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033110","Preventive Medicine","C17011","A branch of medicine that focuses on disease prevention.","Preventive Medicine | Community Medicine",,,,,,,,,,,,,,,"4249864","Preventive medicine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221456","Physicist","C53446","An individual trained and qualified to advise, administer, supervise, or perform research or other professional and scientific work in the investigation and application of the relations between space, time, matter, and energy in the areas of mechanics, sound, optics, heat, electricity, magnetism, radiation, or atomic and nuclear phenomena.","Physicist | PHYSICIST",,,,,,,,,,,,,,,"4025373","Physicist",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709627","Practitioner","C51845","A person engaged in the work of a profession or occupation.","Practitioner | practitioner",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0450059","Population Member","C51844","An individual of a group united by a common factor; a person in a defined cohort or group of people.","Population Member | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709699","Program Specialist","C51850","A professional with expertise in a scientific discipline, that can provide insight and advice to the program staff.","Program Specialist | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709703","Project Officer","C51852","A staff member who coordinates the substantive aspects of a contract from planning a request for proposals to oversight after award.","Project Officer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711222","Protocol Author","C51853","A person who is the writer of a structured research study.","Protocol Author | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0175838","Audiologist","C51804","A trained non-medical health professional who specializes in the identification, testing, habilitation and rehabilitation of hearing loss and other auditory and balance disorders. Particularly, an audiologist may be involved in diagnostic and screening procedures to determine hearing deficits, as well as in assessment of amplification devices and instruction in their care, training in speechreading, and may serve as consultant to government and industry on issues concerning environmental, noise-induced hearing loss. Certification requirements for clinical audiology professional are currently defined at a single level - Certificate of Clinical Competency.","Audiologist | AUDIOLOGIST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706179","Magnifier","C50043","An optical device designed to enlarge an image.","Magnifier Device | Magnifier | Magnifier Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677517","Fluoride Ion","C28149","Considered a trace element, fluoride is any combination of elements containing the fluorine atom in the -1 oxidation state (fluoride ion).  Due to its reactivity, fluorine is found in nature as fluorine compounds or fluorides.  Fluoride inhibits various enzyme systems, erythrocyte glycolysis and binds Ca++, causing anticoagulation and other toxic effects.  In addition, fluoride is a mitogen for osteoblasts and stimulates bone formation. (NCI)","Fluoride Ion | F- | FLUORIDE ION | Fluoride | Fluoride | Fluorine- | fluoride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336538","Supratentorial Embryonal Tumor, Not Otherwise Specified","C6968","A central nervous system embryonal tumor, not otherwise specified arising from the supratentorial region.","Supratentorial Embryonal Tumor, Not Otherwise Specified | CNS/Supratentorial PNET | Supratent. primitive neuro. tumor | Supratentorial Embryonal Tumor, NOS | Supratentorial PNET | Supratentorial Primitive Neuroectodermal Tumor | Supratentorial Primitive Neuroectodermal Tumor | Supratentorial primitive neuroectodermal tumor",,,,,,,,,,,,,,,"44782471","Supratentorial primitive neuroectodermal tumor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334586","Pleomorphic Xanthoastrocytoma","C4323","A WHO grade 2 astrocytic tumor with a relatively favorable prognosis.  It is characterized by pleomorphic and lipidized cells expressing GFAP often surrounded by a reticulin network and eosinophilic granular bodies. It presents in the superficial cerebral hemispheres and involves the meninges. It typically affects children and young adults.","Pleomorphic Xanthoastrocytoma | PXA | Pleomorphic Xantho-Astrocytoma | Pleomorphic xanthoastrocytoma","9424/3","Pleomorphic xanthoastrocytoma",,,,,,,,,,,,,"4302038","Pleomorphic xanthoastrocytoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0025149","Medulloblastoma","C3222","A malignant, invasive embryonal neoplasm arising from the cerebellum or posterior fossa. It occurs predominantly in children and has the tendency to metastasize via the cerebrospinal fluid pathways. Signs and symptoms include truncal ataxia, disturbed gait, lethargy, headache, and vomiting. There are four histologic variants: classic medulloblastoma, large cell/anaplastic medulloblastoma, desmoplastic/nodular medulloblastoma, and medulloblastoma with extensive nodularity.","Medulloblastoma | CNS, medulloblastoma | MEDULLOBLASTOMA, MALIGNANT | Medulloblastomas | medulloblastoma",,,,,,,,,,,,,,,"40481031","Medulloblastoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205898","Pineoblastoma","C9344","A poorly differentiated malignant embryonal neoplasm arising from the pineal region.  It usually occurs in children and it is characterized by the presence of small immature neuroepithelial cells.  It may follow an aggressive clinical course.","Pineoblastoma | PINEOBLASTOMA, MALIGNANT | PNET of Pineal Gland | PNET of the Pineal Gland | Pineal Gland PNET | Pineal Gland Primitive Neuroectodermal Neoplasm | Pineal Gland Primitive Neuroectodermal Tumor | Pineal PNET | Pineal Primitive Neuroectodermal Neoplasm | Pineal Primitive Neuroectodermal Tumor | Pineoblastoma (WHO Grade 4) | Pineoblastoma (WHO Grade IV) | Primitive Neuroectodermal Neoplasm of Pineal Gland | Primitive Neuroectodermal Neoplasm of the Pineal Gland | Primitive Neuroectodermal Tumor of Pineal Gland | Primitive Neuroectodermal Tumor of the Pineal Gland | pineoblastoma","9362/3","Pineoblastoma",,,,,,,,,,,,,"35614931|4135326","Pineoblastoma|Pineoblastoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0334580","Protoplasmic Astrocytoma","C4320","A rare variant of diffuse astrocytoma. It is predominantly composed of neoplastic astrocytes showing a small cell body with few, flaccid processes with a low content of glial filaments and scant GFAP expression. This lesion is not well defined and is considered by some authors as an occasional histopathological feature rather than a reproducibly identifiable variant. When occurring in children, this neoplasm may be difficult to separate from pilocytic juvenile astrocytoma. (Adapted from WHO)","Protoplasmic Astrocytoma | Protoplasmic astrocytoma","9410/3","Protoplasmic astrocytoma",,,,,,,,,,,,,"4208378","Protoplasmic astrocytoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334581","Gemistocytic Astrocytoma","C4321","A rare variant of diffuse astrocytoma. It is characterized by the presence of a conspicuous, though variable, fraction of gemistocytic neoplastic astrocytes. Gemistocytes are round to oval astrocytes with abundant, glassy, non-fibrillary cytoplasm which appears to displace the dark, angulated nucleus to the periphery of the cell. To make the diagnosis of gemistocytic astrocytoma, gemistocytes should amount to more than approximately 20% of all tumor cells. (Adapted from WHO)","Gemistocytic Astrocytoma | Gemistocytic astrocytoma | Gemistocytoma",,,,,,,,,,,,,,,"4250157","Gemistocytic astrocytoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334579","Anaplastic Astrocytoma","C9477","A diffusely infiltrating, WHO grade 3 astrocytoma with focal or dispersed anaplasia, and a marked proliferative potential. It may arise from a low-grade astrocytoma, but it can also be diagnosed at first biopsy, without indication of a less malignant precursor lesion. It has an intrinsic tendency for malignant progression to glioblastoma. (WHO)","Anaplastic Astrocytoma | Anaplastic astrocytoma | Astrocytoma, anaplastic | Grade 3 Astrocytic Neoplasm | Grade 3 Astrocytic Tumor | Grade 3 Astrocytoma | Grade III Astrocytic Neoplasm | Grade III Astrocytic Tumor | Grade III Astrocytoma | High Grade Astrocytoma | High-Grade Astrocytoma | High-grade astrocytoma, NOS | Malignant Astrocytoma",,,,,,,,,,,,,,,"4206182","Astrocytoma, anaplastic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334588","Giant Cell Glioblastoma","C4325","A rare histological variant of glioblastoma with a predominance of bizarre, multinucleated giant cells, an occasionally abundant stromal reticulin network, and a high frequency of TP53 mutations. (WHO)","Giant Cell Glioblastoma | Giant cell glioblastoma","9441/3","Giant cell glioblastoma",,,,,,,,,,,,,"4195300","Giant cell glioblastoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0205768","Subependymal Giant Cell Astrocytoma","C3696","A benign, slowly growing tumor (WHO grade I) typically arising in the wall of the lateral ventricles and composed of large ganglioid astrocytes. It is the most common CNS neoplasm in patients with tuberous sclerosis complex and typically occurs during the first two decades of life. (WHO)","Subependymal Giant Cell Astrocytoma | SEGA | Subependymal Giant Cell Astrocytic Neoplasm | Subependymal Giant Cell Astrocytic Tumor | Subependymal giant cell astrocytoma","9384/1","Subependymal giant cell astrocytoma",,,,,,,,,,,,,"4049007|42709927","Subependymal giant cell astrocytoma|Subependymal giant cell astrocytoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0280788","Anaplastic Ependymoma","C4049","A WHO grade 3 malignant glioma of ependymal origin with accelerated growth and an unfavorable clinical outcome, particularly in children. It is characterized by high mitotic activity, often accompanied by microvascular proliferation and pseudo-palisading necrosis. (Adapted from WHO)","Anaplastic Ependymoma | Anaplastic Ependymal Neoplasm | Anaplastic Ependymal Tumor | Ependymoma with Anaplasia | Ependymoma, anaplastic | Malignant Ependymoma | Undifferentiated Ependymal Neoplasm | Undifferentiated Ependymal Tumor | Undifferentiated Ependymoma | WHO Grade 3 Ependymal Neoplasm | WHO Grade 3 Ependymal Tumor | WHO Grade III Ependymal Neoplasm | WHO Grade III Ependymal Tumor","9392/3","Ependymoma, anaplastic",,,,,,,,,,,,,"4066105|608134","Ependymoma, anaplastic|Malignant ependymoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0431108","Anaplastic Oligoastrocytoma","C6959","An oligoastrocytoma characterized by the presence of increased cellularity, nuclear atypia, pleomorphism, and high mitotic activity.","Anaplastic Oligoastrocytoma | Anaplastic Mixed Glioma | Anaplastic oligoastrocytoma | WHO Grade 3 Mixed Glioma | WHO Grade III Mixed Glioma",,,,,,,,,,,,,,,"4102390","Anaplastic oligoastrocytoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334590","Anaplastic Oligodendroglioma","C4326","A WHO grade 3 oligodendroglioma with focal or diffuse malignant morphologic features (prominent nuclear pleomorphism, mitoses, and increased cellularity).","Anaplastic Oligodendroglioma | Anaplastic oligodendroglioma | Malignant Oligodendroglioma | Oligodendroglioma, Malignant | Oligodendroglioma, anaplastic | Undifferentiated Oligodendroglioma | WHO Grade 3 Oligodendroglial Neoplasm | WHO Grade 3 Oligodendroglial Tumor | WHO Grade III Oligodendroglial Neoplasm | WHO Grade III Oligodendroglial Tumor",,,,,,,,,,,,,,,"4150348","Oligodendroglioma, anaplastic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0280785","Diffuse Astrocytoma","C7173","A low-grade (WHO grade 2) astrocytic neoplasm. It is characterized by diffuse infiltration of neighboring central nervous system structures. These lesions typically affect young adults and have a tendency for progression to anaplastic astrocytoma and glioblastoma. Based on the IDH genes mutation status, diffuse astrocytomas are classified as IDH-mutant, IDH-wildtype, and not otherwise specified.","Diffuse Astrocytoma | ASTROCYTOMA, DIFFUSE, MALIGNANT | Astrocytoma, Diffuse | Diffuse astrocytoma | Grade 2 Astrocytic Neoplasm | Grade 2 Astrocytic Tumor | Grade 2 Astrocytoma | Grade II Astrocytic Neoplasm | Grade II Astrocytic Tumor | Grade II Astrocytoma | Low-grade astrocytoma, NOS | WHO Grade 2 Astrocytoma | WHO Grade II Astrocytoma",,,,,,,,,,,,,,,"4288097","Diffuse astrocytoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206726","Gliosarcoma","C3796","A rare histological variant of glioblastoma (WHO grade IV) characterized by a biphasic tissue pattern with alternating areas displaying glial and mesenchymal differentiation (WHO).","Gliosarcoma | Glioblastoma with a Sarcomatous Component | gliosarcoma","9442/3","Gliosarcoma",,,,,,,,,,,,,"4148715","Gliosarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0014474","Ependymoma","C3017","A WHO grade 2, slow growing tumor of children and young adults, usually located intraventricularly. It is the most common ependymal neoplasm. It often causes clinical symptoms by blocking cerebrospinal fluid pathways. Key histological features include perivascular pseudorosettes and ependymal rosettes. (WHO)","Ependymoma | CNS, ependymoma | Ependymoma, NOS | WHO Grade 2 Ependymal Neoplasm | WHO Grade 2 Ependymal Tumor | WHO Grade II Ependymal Neoplasm | WHO Grade II Ependymal Tumor | ependymoma","9391/3","Ependymoma, NOS",,,,,,,,,,,,,"40482745","Ependymoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334582","Fibrillary Astrocytoma","C4322","The most frequent histological variant of diffuse astrocytoma. It is predominantly composed of fibrillary neoplastic astrocytes. Nuclear atypia is a diagnostic criterion but mitotic activity, necrosis and microvascular proliferation are absent.  The occasional or regional occurrence of gemistocytic neoplastic cells is compatible with the diagnosis of fibrillary astrocytoma. (WHO)","Fibrillary Astrocytoma | Fibrillary astrocytoma | Fibrous astrocytoma","9420/3","Fibrillary astrocytoma",,,,,,,,,,,,,"4325285","Fibrillary astrocytoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334583","Pilocytic Astrocytoma","C4047","A WHO grade 1, relatively circumscribed, slowly growing, often cystic astrocytoma occurring in children and young adults.  Histologically it is characterized by a biphasic pattern with compacted bipolar cells associated with Rosenthal fibers and multipolar cells associated with microcysts and eosinophilic bodies/hyaline droplets. (WHO)","Pilocytic Astrocytoma | Grade 1 Astrocytic Neoplasm | Grade 1 Astrocytic Tumor | Grade 1 Astrocytoma | Grade I Astrocytic Neoplasm | Grade I Astrocytic Tumor | Grade I Astrocytoma | Pilocytic astrocytoma","9421/1","Pilocytic astrocytoma",,,,,,,,,,,,,"4029182","Pilocytic astrocytoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0205769","Myxopapillary Ependymoma","C3697","A slow growing, WHO grade I glioma which generally occurs in young adults.  It arises almost exclusively in the conus medullaris, cauda equina, and filum terminale of the spinal cord. It generally has a favorable prognosis and is characterized histologically by tumor cells arranged in a papillary manner around vascularized mucoid stromal cores. (Adapted from WHO).","Myxopapillary Ependymoma | EPENDYMOMA, BENIGN | Myxopapillary ependymoma","9394/1","Myxopapillary ependymoma",,,,,,,,,,,,,"4037299","Myxopapillary ependymoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0206725","Subependymoma","C3795","A benign, slow growing neoplasm which is typically attached to a ventricular wall. It is composed of glial tumor cell clusters embedded in an abundant fibrillary matrix with frequent microcystic change. Some lesions have the histological features of both subependymoma and ependymoma. It is often detected incidentally and has a very favorable prognosis. (Adapted from WHO.)","Subependymoma | SUBEPENDYMOMA, BENIGN | Subependymal Astrocytoma | Subependymal Glioma | Subependymal glioma | WHO Grade 1 Ependymal Neoplasm | WHO Grade 1 Ependymal Tumor | WHO Grade I Ependymal Neoplasm | WHO Grade I Ependymal Tumor | Who Grade I Ependymal Neoplasm | Who Grade I Ependymal Tumor","9383/1","Subependymoma",,,,,,,,,,,,,"4163959","Subependymal glioma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C4012134","Choroid Plexus Papilloma","C3698","A benign, slow growing tumor which may cause symptoms by blocking cerebrospinal fluid pathways.  It is characterized by the presence of delicate fibrovascular connective tissue fronds covered by a single layer of epithelial cells.  Mitotic activity is extremely low.  Surgical resection is usually curative. (Adapted from WHO)","Choroid Plexus Papilloma | Choroid plexus papilloma, NOS | PAPILLOMA, CHOROID PLEXUS, BENIGN | Papilloma of Choroid Plexus | Papilloma of the Choroid Plexus","9390/0","Choroid plexus papilloma, NOS",,,,,,,,,,,,,"608014","Benign choroid plexus papilloma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0431109","Choroid Plexus Carcinoma","C4715","A malignant neoplasm arising from the choroid plexus.  It shows anaplastic features and usually invades neighboring brain structures. Cerebrospinal fluid metastases are frequent. (Adapted from WHO)","Choroid Plexus Carcinoma | Anaplastic Choroid Plexus Papilloma | CARCINOMA, CHOROID PLEXUS, MALIGNANT | Cancer of Choroid Plexus | Cancer of the Choroid Plexus | Carcinoma of Choroid Plexus | Carcinoma of the Choroid Plexus | Choroid Plexus Cancer | Choroid plexus carcinoma | Choroid plexus papilloma, anaplastic | Choroid plexus papilloma, malignant","9390/3","Choroid plexus carcinoma",,,,,,,,,,,,,"4339415|607987","Choroid plexus carcinoma|Choroid plexus carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0334587","Astroblastoma, MN1-Altered","C4324","A rare glial neoplasm characterized by structural rearrangements of the MN1 gene at chromosome band 22q12.1. It is usually found in the cerebral hemispheres of young adults and children and predominantly affects females. Morphologically, it consists of elongated glial cells with abundant eosinophilic cytoplasm and GFAP-positive processes, arranged perivascularly.","Astroblastoma, MN1-Altered | Astroblastoma | Astroblastoma","9430/3","Astroblastoma",,,,,,,,,,,,,"4172159","Astroblastoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"CL378224","Gangliocytoma","C6934","A well differentiated, slow growing neuroepithelial neoplasm composed of neoplastic, mature ganglion cells.","Gangliocytoma | ",,,,,,,,,,,,,,,"4029202","Gangliocytoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206716","Ganglioglioma","C3788","A well differentiated, slow growing neuroepithelial neoplasm composed of neoplastic, mature ganglion cells and neoplastic glial cells. Some gangliogliomas show anaplastic features in their glial component and are considered to be WHO grade III. Rare cases of newly diagnosed gangliogliomas with grade IV (glioblastoma) changes in the glial component have also been reported. (Adapted from WHO)","Ganglioglioma | Ganglioglioma, NOS","9505/1","Ganglioglioma, NOS",,,,,,,,,,,,,"37019038","Ganglioglioma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0917890","Pineocytoma","C6966","A WHO grade 1 slow growing tumor, more frequently affecting young adults. It is composed of small, uniform, mature cells resembling pineocytes with occasional large pineocytomatous rosettes. It may show a wide range of divergent phenotypes, including neuronal, glial, melanocytic, photoreceptor and mesenchymal differentiation. Pineocytoma generally has a relatively favorable prognosis. (Adapted from WHO)","Pineocytoma | Benign Pinealoma | Benign neoplasm of pineal gland | PINEOCYTOMA, BENIGN | Pinealocytoma | Pineocytoma (WHO Grade 1) | Pineocytoma (WHO Grade I) | pineocytoma","9361/1","Pineocytoma",,,,,,,,,,,,,"4228357","Pineocytoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0391826","Dysplastic Cerebellar Gangliocytoma","C8419","A benign, WHO grade I cerebellar mass, which occurs in young adults and is composed of dysplastic ganglion cells.  It is the major CNS manifestation of Cowden disease, an autosomal dominant condition that causes a variety of hamartomas and neoplasms.","Dysplastic Cerebellar Gangliocytoma | Dysplastic Cerebellar Gangliocytoma (Lhermitte-Duclos Disease) | Dysplastic Gangliocytoma of Cerebellum | Dysplastic Gangliocytoma of the Cerebellum | Dysplastic gangliocytoma of cerebellum (Lhermitte-Duclos) | Lhermitte-Duclos Disease","9493/0","Dysplastic gangliocytoma of cerebellum (Lhermitte-Duclos)",,,,,,,,,,,,,"4194773","Lhermitte-Duclos disease",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0457179","Desmoplastic Infantile Astrocytoma","C9476","A WHO grade I large cystic tumor that occurs almost exclusively in infants, with a prominent desmoplastic stroma having a neuroepithelial population consisting mainly of neoplastic astrocytes. It involves the superficial cerebral cortex and leptomeninges, and often attaches to the dura. Although clinically it presents as large tumor, it generally has a good prognosis following surgical resection. (Adapted from WHO)","Desmoplastic Infantile Astrocytoma | DIA | Desmoplastic Astrocytoma of Infancy | Desmoplastic infantile astrocytoma","9412/1","Desmoplastic infantile astrocytoma",,,,,,,,,,,,,"4029035","Desmoplastic infantile astrocytoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1266177","Dysembryoplastic Neuroepithelial Tumor","C9505","A glial-neuronal neoplasm located in the cortex. It occurs in children and young adults with a long-standing history of partial seizures. A histologic hallmark of this tumor is the 'specific glioneuronal element', characterized by columns, made up of bundles of axons, oriented perpendicularly to the cortical surface. (Adapted from WHO)","Dysembryoplastic Neuroepithelial Tumor | DNET | DNT | Dysembryoplastic Neuroepithelial Neoplasm | Dysembryoplastic neuroepithelial tumor","9413/0","Dysembryoplastic neuroepithelial tumor",,,,,,,,,,,,,"37018866|4028698","Dysembryoplastic neuroepithelial tumor|Dysembryoplastic neuroepithelial tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0431112","Anaplastic Ganglioglioma","C4717","A WHO grade III neuroepithelial neoplasm composed of neoplastic, mature ganglion cells and anaplastic glial cells. The anaplastic changes in the glial component and high MIB-1 and TP53 labeling indices may indicate aggressive behavior. However, the correlation of histological anaplasia with clinical outcome is inconsistent. (Adapted from WHO)","Anaplastic Ganglioglioma | Ganglioglioma, anaplastic","9505/3","Ganglioglioma, anaplastic",,,,,,,,,,,,,"603173","Anaplastic ganglioglioma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0206719","Central Neurocytoma","C3791","An intraventricular neuronal neoplasm composed of uniform round cells with neuronal differentiation. It is typically located in the lateral ventricles in the region of the foramen of Monro. It generally affects young adults and has a favorable prognosis. (Adapted from WHO)","Central Neurocytoma | Central Neurocytoma (WHO Grade 2) | Central Neurocytoma (WHO Grade II) | Central neurocytoma","9506/1","Central neurocytoma",,,,,,,,,,,,,"4030272","Central neurocytoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1370507","Cerebellar Liponeurocytoma","C6905","A rare, WHO grade II cerebellar neoplasm which shows consistent neuronal, variable astrocytic and focal lipomatous differentiation. It occurs in adults, has a low proliferative potential and usually has a favorable prognosis. (Adapted from WHO)","Cerebellar Liponeurocytoma | Cerebellar Liponeurocytoma (WHO Grade 2) | Cerebellar Liponeurocytoma (WHO Grade II) | Cerebellar liponeurocytoma | Lipomatous Medulloblastoma | Lipomatous medulloblastoma",,,,,,,,,,,,,,,"37118772|37396694","Cerebellar liponeurocytoma|Cerebellar liponeurocytoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2751421","Neuroblastoma","C3270","A malignant neuroblastic tumor characterized by the presence of neuroblastic cells, the absence of ganglion cells, and the absence of a prominent Schwannian stroma formation.","Neuroblastoma | NEUROBLASTOMA, MALIGNANT | Neural Crest Tumor, Malignant | Neuroblastoma (NBL) | Neuroblastoma (Schwannian Stroma-Poor) | Neuroblastoma (Schwannian Stroma-poor) | Neuroblastoma, NOS | neuroblastoma","9500/3","Neuroblastoma, NOS",,,,,,,,,,,,,"4333766|4337398","Neuroblastoma|Neuroblastoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0206717","Olfactory Neuroblastoma","C3789","A rare neuroectodermal tumor originating from olfactory receptor cells in the sinonasal tract. In rare cases, it can be ectopic and originate from other sites such as the sellar region. Microscopically, it is characterized by neuroblastic differentiation with occasional formation of rosettes. If the tumor is not resected at an early stage, the prognosis is usually poor.","Olfactory Neuroblastoma | Esthesioneuroblastoma | Esthesioneuroepithelioma | Olfactory Esthesioneuroblastoma | Olfactory Neuroepithelioma | Olfactory neuroblastoma | Olfactory neuroepithelioma","9522/3|9523/3","Olfactory neuroblastoma|Olfactory neuroepithelioma",,,,,,,,,,,,,"4295574|4306965","Esthesioneuroblastoma|Olfactory neuroblastoma",,,,,,,,,,,,,"--","--|--",,,,,,,,"--|--"
"C0559460","Adrenal Gland Neuroblastoma","C4827","A neuroblastoma arising from the adrenal gland.","Adrenal Gland Neuroblastoma | Adrenal Neuroblastoma | Neuroblastoma of Adrenal | Neuroblastoma of Adrenal Gland | Neuroblastoma of the Adrenal | Neuroblastoma of the Adrenal Gland",,,,,,,,,,,,,,,"4085559","Adrenal neuroblastoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031941","Pineal Parenchymal Cell Neoplasm","C6965","A neoplasm that arises from pinealocytes in the pineal gland. This category includes pineocytomas, pineal parenchymal tumors of intermediate differentiation, and pineoblastomas.","Pineal Parenchymal Cell Neoplasm | Neoplasm of Pineal Gland | Neoplasm of the Pineal Gland | Pineal Gland Neoplasm | Pineal Gland Tumor | Pineal Parenchymal Cell Tumor | Pineal Parenchymal Neoplasm | Pineal Parenchymal Tumor | Pineal parenchymal tumor | Pineocytic Neoplasm | Pineocytic Tumor | Tumor of Pineal Gland | Tumor of the Pineal Gland",,,,,,,,,,,,,,,"4131120|4234744","Neoplasm of pineal gland|Pinealoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0700367","Embryonal Tumor with Multilayered Rosettes, C19MC-Altered","C4915","An aggressive embryonal tumor with multilayered rosettes characterized by the presence of amplification of the C19MC region on chromosome 19 (19q13.42).","Embryonal Tumor with Multilayered Rosettes, C19MC-Altered | ETMR, C19MC-Altered | Embryonal Tumor with Abundant Neuropil and True Rosettes | Embryonal Tumor with Multilayered Rosettes | Embryonal Tumor with Multilayered Rosettes with C19MC Amplification | Embryonal tumor with multilayered rosettes C19MC-altered | Ependymoblastoma | Ependymoblastoma",,,,,,,,,,,,,,,"37396184","Ependymoblastoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0751291","Desmoplastic Nodular Medulloblastoma","C4956","A medulloblastoma characterized by the presence of nodular, collagenous areas which do not contain reticulin, surrounded by hypercellular areas which contain an intercellular reticulin fiber network.","Desmoplastic/Nodular Medulloblastoma | Desmoplastic Medulloblastoma | Desmoplastic Medulloblastoma | Desmoplastic Nodular Medulloblastoma | Desmoplastic medulloblastoma | Desmoplastic nodular medulloblastoma","9471/3","Desmoplastic nodular medulloblastoma",,,,,,,,,,,,,"4137141","Desmoplastic medulloblastoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1266180","Large Cell Medulloblastoma","C6904","A medulloblastoma composed of large cells with prominent nucleoli and a larger amount of cytoplasm in contrast with the cells of the classic medulloblastoma.","Large Cell Medulloblastoma | Large cell medulloblastoma","9474/3","Large cell medulloblastoma",,,,,,,,,,,,,"4028699","Large cell medulloblastoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0205833","Medullomyoblastoma","C3706","A rare malignant embryonal neoplasm arising from the cerebellum.  It is characterized by the morphologic features of a medulloblastoma and the presence of a striated muscle component.  Its clinical behavior is similar to medulloblastoma.","Medullomyoblastoma | Medullomyoblastoma | Medullomyoblastoma with Myogenic Differentiation | Medullomyoblastoma with Myogenic Differentiation","9472/3","Medullomyoblastoma",,,,,,,,,,,,,"4078469","Medullomyoblastoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1275668","Melanocytic Medulloblastoma","C9497","A rare malignant embryonal neoplasm characterized by the presence of small cells which resemble the cells of classic medulloblastoma and a minor population of melanin-forming neuroepithelial cells.  It usually has an unfavorable clinical course.","Melanocytic Medulloblastoma | Medulloblastoma with Melanotic Differentiation | Medulloblastoma with Melanotic Differentiation | Melanotic Medulloblastoma | Melanotic Medulloblastoma | Melanotic medulloblastoma",,,,,,,,,,,,,,,"4287481","Medulloblastoma, melanotic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206718","Ganglioneuroblastoma","C3790","A malignant neuroblastic tumor characterized by the presence of neuroblastic cells, ganglion cells, and a stroma with Schwannian differentiation constituting more than fifty-percent of the tumor volume.  There are two histologic subtypes identified: ganglioneuroblastoma, intermixed and ganglioneuroblastoma, nodular.","Ganglioneuroblastoma | GANGLIONEUROBLASTOMA, MALIGNANT","9490/3","Ganglioneuroblastoma",,,,,,,,,,,,,"37016149|4287382","Ganglioneuroblastoma|Ganglioneuroblastoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1266184","Atypical Teratoid/Rhabdoid Tumor","C6906","An aggressive malignant embryonal neoplasm arising from the central nervous system. It is composed of cells with a large eccentric nucleus, prominent nucleolus, and abundant cytoplasm. Mutations of the SMARCB1 gene or very rarely SMARCA4 (BRG1) gene are present. The vast majority of cases occur in childhood. Symptoms include lethargy, vomiting, cranial nerve palsy, headache, and hemiplegia.","Atypical Teratoid/Rhabdoid Tumor | AT/RT | ATRT | ATT/RHT | Atypical Teratoid/Rhabdoid Tumor (WHO Grade 4) | Atypical Teratoid/Rhabdoid Tumor (WHO Grade IV) | Atypical teratoid/rhabdoid tumor | CNS Rhabdoid Neoplasm | CNS Rhabdoid Tumor | Central Nervous System Rhabdoid Neoplasm | Central Nervous System Rhabdoid Tumor | Malignant Brain Rhabdoid Neoplasm | Malignant Brain Rhabdoid Tumor | Malignant Rhabdoid Neoplasm of Brain | Malignant Rhabdoid Neoplasm of the Brain | Malignant Rhabdoid Tumor of Brain | Malignant Rhabdoid Tumor of the Brain | Primary Malignant Brain Rhabdoid Neoplasm | Primary Malignant Brain Rhabdoid Tumor | Primary Malignant Rhabdoid Neoplasm of Brain | Primary Malignant Rhabdoid Neoplasm of the Brain | Primary Malignant Rhabdoid Tumor of Brain | Primary Malignant Rhabdoid Tumor of the Brain | Rhabdoid Neoplasm of CNS | Rhabdoid Neoplasm of Central Nervous System | Rhabdoid Neoplasm of the CNS | Rhabdoid Neoplasm of the Central Nervous System | Rhabdoid Tumor of CNS | Rhabdoid Tumor of Central Nervous System | Rhabdoid Tumor of the CNS | Rhabdoid Tumor of the Central Nervous System | atypical teratoid/rhabdoid tumor","9508/3","Atypical teratoid/rhabdoid tumor",,,,,,,,,,,,,"4029656","Atypical teratoid/rhabdoid tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0027809","Schwannoma","C3269","A benign, usually encapsulated slow growing tumor composed of Schwann cells.  It affects peripheral and cranial nerves.  It recurs infrequently and only rare cases associated with malignant transformation have been reported.","Schwannoma | Benign Neurilemmoma | Benign Schwannoma | Neurilemmoma | Neurinoma | SCHWANNOMA, BENIGN | Schwannoma (WHO Grade I) | Schwannoma (Who Grade I) | Schwannoma, NOS | schwannoma",,,,,,,,,,,,,,,"40384902|4321755","Schwannoma|Schwannoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0085167","Granular Cell Tumor","C3474","An unusual benign or malignant neoplasm characterized by the presence of neoplastic large polygonal cells with granular, eosinophilic cytoplasm which contains abundant lysosomes. It was originally thought to be a tumor originating from muscle cells and was named granular cell myoblastoma. Subsequent studies have suggested a derivation from Schwann cells. It affects females more often than males and it usually presents as a solitary mass. A minority of patients have multiple tumors. It can arise from many anatomic sites including the posterior pituitary gland, skin, oral cavity, esophagus, stomach, heart, mediastinum, and breast.","Granular Cell Tumor | Abrikossoff Tumor | Abrikossoff's Tumor | Granular Cell Myoblastoma | Granular Cell Nerve Sheath Tumor | Granular Cell Schwannoma | Granular cell tumor, NOS","9580/0","Granular cell tumor, NOS",,,,,,,,,,,,,"4005360|4301640","Granular cell tumor|Granular cell tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0010276","Craniopharyngioma","C2964","A benign, partly cystic, epithelial tumor of the sellar region, presumably derived from Rathke pouch epithelium. It affects mainly children and young adults. There are two clinicopathological forms: adamantinomatous craniopharyngioma and papillary craniopharyngioma. The most significant factor associated with recurrence is the extent of surgical resection, with lesions greater than 5 cm in diameter carrying a markedly worse prognosis. (Adapted from WHO)","Craniopharyngioma | Benign neoplasm of craniopharyngeal duct | CRANIOPHARYNGIOMA, BENIGN | Craniopharyngeal Tumor | Craniopharyngioma (WHO Grade 1) | Craniopharyngioma (WHO Grade I) | Cystoma | Neoplasm of Rathke's Pouch | Rathke Pouch Neoplasm | Rathke Pouch Tumor | Rathke pouch tumor | Rathke's Pouch Neoplasm | Rathke's Pouch Tumor | Tumor of Rathke's Pouch | craniopharyngioma","9350/1","Craniopharyngioma",,,,,,,,,,,,,"4099351|4220185","Craniopharyngioma|Craniopharyngioma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0431129","Adamantinomatous Craniopharyngioma","C4726","A craniopharyngioma consisting of broad strands, cords and bridges of a multistratified squamous epithelium with peripheral palisading of nuclei. Diagnostic features include nodules of compact 'wet' keratin and dystrophic calcification. (Adapted from WHO)","Adamantinomatous Craniopharyngioma | ACP | Adamantinous Craniopharyngioma | Adamantinous Craniopharyngioma | Adamantinous Neoplasm of Rathke's Pouch | Adamantinous Rathke's Pouch Neoplasm | Adamantinous Rathke's Pouch Tumor | Adamantinous Tumor of Rathke's Pouch | Craniopharyngioma, adamantinomatous","9351/1","Craniopharyngioma, adamantinomatous",,,,,,,,,,,,,"4028695","Craniopharyngioma, adamantinomatous",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0476073","Papillary Neoplasm","C36031","A benign, intermediate, or malignant neoplasm characterized by the formation of papillary structures.","Papillary Neoplasm | Papillary Tumor | papillary tumor",,,,,,,,,,,,,,,"40482256","Papillary neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017636","Glioblastoma","C3058","The most malignant astrocytic tumor (WHO grade 4).  It is composed of poorly differentiated neoplastic astrocytes and is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation, and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. (Adapted from WHO)","Glioblastoma | CNS, glioblastoma (GBM) | GBM | GBM (Glioblastoma) | Glioblastoma Multiforme | Glioblastoma multiforme | Spongioblastoma Multiforme | Spongioblastoma multiforme | glioblastoma | glioblastoma multiforme","9440/3","Glioblastoma, NOS",,,,,,,,,,,,,"40571980","Glioblastoma multiforme",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334576","Gliomatosis Cerebri","C4318","A diffuse glial tumor which infiltrates the brain extensively, involving more than two lobes. It is frequently bilateral and often extends to the infratentorial structures, even to the spinal cord. It is probably of astrocytic origin, although GFAP expression may be scant or absent. (Adapted from WHO.)","Gliomatosis Cerebri | Astrocytosis cerebri | Gliomatosis | Gliomatosis cerebri","9381/3","Gliomatosis cerebri",,,,,,,,,,,,,"4094384","Gliomatosis cerebri",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0008196","Chlorhexidine","C364","A biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.","Chlorhexidine | CHLORHEXIDINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882536","Radiation Field","C54648","The area of the body exposed to radiation during radiation therapy.","Radiation Field | treatment field",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1295725","Perpendicular Axis","C54649","A straight line through a body or figure that is at a right angle to a given line or plane.","Perpendicular Axis | Perpendicular",,,,,,,,,,,,,,,"4038108","Perpendicular axis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1881275","Isocenter","C54651","Either a point at which there is a maximum or minimum of a radiation dose or the center point of a radiation field where the origin of the coordinate system is (x, y, z) = (0, 0, 0).","Isocenter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882534","Radiation Arc","C54652","The path or area of the body covered by a moving source of radiation during treatment.","Radiation Arc | Arc",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881277","Isodose","C54654","A radiation dose of equal intensity applied to more than one body area; of or relating to points or zones in a medium that receive equal doses of radiation.","Isodose | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553028","Mega","C54653","A prefix indicating a quantity of one million, 10E6.","Mega | M | Mega- | [M] | mega | mega-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005771","Blood Cell Count","C28133","The determination of the number of red blood cells, white blood cells, and platelets in a biospecimen.","Blood Cell Count | CBC | Complete Blood Count | FBC | Full Blood Count | blood cell count | complete blood count",,,,,,,,,,,,,,,"4339397","Blood cell count",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333899","HLA-A Gene","C28585","This gene is involved in immune responses and histocompatibility processes.","HLA-A Gene | HLA-A | Major Histocompatibility Complex, Class I, A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890174","Decreased Biochemical Activity","C45423","A quantitative reduction in a measurable amount of a specific function or role performed by a biological entity in a biophysical process, biochemical reaction, or biochemical process compared to the level of activity exhibited by that same biological entity in the majority of healthy individuals in a reference population.","Decreased Biochemical Activity | Decreased Activity | Decreased Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0442040","Salivary","C38017","Salivary; of or relating to saliva.","Salivary | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511562","Curative Surgery","C38047","Surgery which cures disease.","Curative Surgery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439502","Volt","C42551","A SI derived unit of electric potential and electromotive force, equal to the difference of electric potential between two points on a conducting wire carrying a constant current of one ampere when the power dissipated between the points is one watt, equivalent to the potential difference across a resistance of one ohm when one ampere of current flows through it.","Volt | V | volt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711421","Account Administrator","C51795","A person who is responsible for establishing and managing user accounts. Duties include accepts/rejects membership to an account, assigns and edits access permissions and resets/revokes user passwords.","Account Administrator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706713","Address Module Coordinator","C51796","A person who coordinates and manages address and contact information for an organization.","Address Module Coordinator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706709","AdEERS Contact","C51797","A person responsible within the Cooperative Group and/or a particular clinical trial for the completion and filing of reports (along with any supporting documentation) on adverse events to NCI and FDA via web-based Adverse Event Expedited Reporting System (AdEERS).","AdEERS Contact | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1550497","Admitting Physician","C51798","The physician responsible for the admission of a patient to a hospital or other inpatient health institution. The admitting physician evaluates patients, makes admitting decisions and assesses diagnostic and treatment plans.","Admitting Physician | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706738","Adverse Event Coordinator","C51799","A designated person who is trained and responsible for coordinating adverse event review, tracking, surveillance and reporting activities within a clinical institution or clinical trial.","Adverse Event Coordinator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706750","Agent Expert","C51800","A scientist or other professional who is an independent, non-participant in the agent development effort. The person is responsible for contributing expert advice on the scientific design and on the conduct of the research regarding the investigational agent.","Agent Expert | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706752","Agent Inspector","C51801","An authorized person who is appointed to audit and officially inspect the warehousing, prescribing, dispensing, distribution, administration and documentation practices related to utilization of investigational agent(s) within a clinical study or/and institution, in order to confirm the strict drug(s) accountability and to ensure patients safety and the clinical site compliance with protocol(s) and federal drug laws and regulations.","Agent Inspector | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706221","Associate - assistant","C51802","A person who is an assistant or subordinate to another professional, e.g. research associate functioning under the general supervision of the appointed investigator.","Associate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1320929","Attending Physician","C51803","The physician responsible for the administration and medical care a patient receives. The physician may have the added responsibility of supervising resident physicians or medical students, and involving consulting physicians in the prescribed plan of care.","Attending Physician | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706996","Branch Chief","C51805","A professional that is responsible for the direction and supervision of a division within a larger or more complex organization.","Branch Chief | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707121","CDU Web Contact","C51806","A person within a Cooperative Group, institution, clinical site, or/and particular study responsible for completion and submission of clinical trial data to the NCI via the web-based Clinical Data Update System (CDUS).","CDU Web Contact | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707338","Central Reviewer","C51807","A single person who critically evaluates and reports on laboratory test results, protocols, or other data.","Central Reviewer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707123","CEP Member","C51808","A member of the multidisciplinary Concept Evaluation Panel (CEP) organized under the leadership of the NCI Cancer Therapy Evaluation Program to evaluate Phase III clinical trial proposals. Membership includes NCI staff and representatives of NCI-sponsored Cooperative Groups and Cancer Centers, as well as other sources. Two-thirds of the CEP members (clinicians, basic scientists, statisticians, other oncology professionals, and patient advocates) are not affiliated with NCI.","CEP Member | Concept Evaluation Panel Member",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707358","Checklist Completer","C51809","A person that is responsible for the completion of forms that contain a list of information regarding procedure or content validation.","Checklist Completer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707359","Checklist Supervisor","C51810","A person who is responsible for directing personnel involved with the coordination and completion of forms that contain a list of information regarding procedure or content validation.","Checklist Supervisor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707414","Clinical Coordinator","C51811","A person to whom a clinical investigator delegates a few of the routine administrative requirements of a protocol. The duties and responsibilities of a clinical research coordinator may vary across different infrastructures. Generally, the coordinator manages the subject's clinical trial participation and provides a vital linkage between the subject, the investigator, and the sponsor.","Clinical Coordinator | CLINICAL RESEARCH COORDINATOR | CRC | Clinical Research Coordinator | Clinical Research Coordinator (CRC) | clinical coordinator | clinical research coordinator (CRC) | research coordinator | study coordinator | trial coordinator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707421","Co-Investigator","C51812","One of two or more scientists working together on a research project. A person that equally contributes to the preparation of the protocol, and shares the responsibilities of this position, including medical monitoring (particularly toxicity/safety), liaison with statisticians over analysis, and the generation of a report containing the results.","Co-Investigator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707422","Co-Project Officer","C51819","One of two or more people who has authority concerning the content, organization, or administration of a clinical trial or other work.","Co-Project Officer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707452","Community Educator","C51813","A person that provides coordination between physicians, hospital staff, and administration in the implementation of programs that are to develop and deliver a range of education and information to both patients and healthcare personnel.","Community Educator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707473","Concept Review Chair","C51814","The presiding officer who examines abstract or generic ideas generalized from particular instances.","Concept Review Chair | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1441532","Consulting Physician","C51815","A physician that has expertise in a specific medical disciple that can offer expertise or advice to other physicians and healthcare providers.","Consulting Physician | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711170","Contract Officer","C51816","A person with the authority to enter into, administer, and/or terminate contracts and make related determinations and findings.","Contract Officer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707499","Contract Principal Investigator","C51817","A scientist or health care professional that has a financial agreement, as outlined in a binding statement of work, with the sponsor to bear full and ultimate responsibility for the scientific, administrative, ethical, legal, technical, and fiscal aspects of the study, and for day-to-day management of the scientific project, as well as for documenting and reporting its results.","Contract Principal Investigator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711160","Coordinating Investigator","C51818","A research scientist whose task is to see that work, or events, goes harmoniously.","Coordinating Investigator | coordinating investigator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707636","Data Manager","C51820","A person primarily responsible for database creation, data collection, validation, integration, coding, review, quality evaluation, and archiving, as well as for preparation of reports and data displays.","Data Manager | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707803","Division Head","C51821","The official that is responsible for the administrative, research and medical activities within a clinical program or subdivision of organization such as a hospital. A division head is responsible for the overall direction in the conduct of research; provision and coordination of training and education; operations, staffing, and maintenance of the facilities.","Division Head | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707818","Drug Company Contact","C51822","A person who acts as a channel for communication with a commercial enterprise which produces substances intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease.","Drug Company Contact | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0599987","Employee","C51823","A person working for another person or a business firm on a full- or part-time basis and who receives payment for this work.","Employee | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707957","Evaluator - personnel","C51824","A person who determines the significance, worth, or condition of something by careful appraisal and study.","Evaluator | Assessor | EVAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708251","Grant Investigator","C51825","An individual designated by the grantee to take part in the conduction of the study or to participate in a scientific activity being supported by the grant.","Grant Investigator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711341","Group Coordinator","C51827","A person that is responsible for the integration and interaction of work or events from an assembly of different people with diverse interests and operations.","Group Coordinator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023226","Guardian","C51828","An individual who is authorized under applicable State or local law to consent on behalf of a child or incapable person to general medical care including participation in clinical research.","Guardian | GUARDIAN | Legal Guardian",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708634","Laboratory Director","C51829","A person who plans, organizes, coordinates and oversees the overall operation of laboratory activities. The laboratory director establishes policies and procedures that govern the utilization of community laboratory services, and ensures that the laboratory and support personnel receive the appropriate training associated with the work involved.","Laboratory Director | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708252","Grant Principal Investigator","C51826","An individual designated by the grantee to direct the project or activity being supported by the grant. He or she is responsible for the scientific, legal, administrative, and technical aspects of the grant and accountable to the grantee for the proper conduct of the project or activity. The Principle Investigator (PI) must have a formal written appointment with the applicant organization, which must be in the form of an official relationship between the parties, but need not involve a salary or other form of remuneration. The PI is a member of the grantee team responsible for ensuring compliance with the financial and administrative aspects of the award and with organizational as well as Federal requirements.","Grant Principal Investigator | Grant PI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018724","Health Care Provider","C16666","Persons who provides health care as part of their job responsibilities: or a person or organization who is licensed to supply health care.","Health Care Provider | Healthcare Provider | HealthcareProvider | healthcare provider",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1112870","Aerosol Dosage Form","C42887","Contents packaged under pressure that are released upon activation of an appropriate valve system.","Aerosol Dosage Form | AER | AEROSOL | Aer | Aerosol | Aerosol Dose Form | aer",,,,,,,,,,,,,,,"4178742","Drug aerosol",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706744","Aerosol Foam Dosage Form","C42888","A foam that is packaged under pressure and released upon activation of an appropriate valve system.","Aerosol Foam Dosage Form | AER FOAM | AEROSOL, FOAM | Aer Foam | Aerosol Foam | Aerosol Foam Dose Form | Aerosol, Foam | Aerosol, foam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1720286","Metered Aerosol Dosage Form","C42960","An aerosol contained in a device with valves that permits the release of a specified quantity of active and/or inert ingredient(s) upon activation.","Metered Aerosol Dosage Form | AER MET | AEROSOL, METERED | Aerosol, Metered | Metered Aer | Metered Aerosol | Metered Aerosol Dose Form",,,,,,,,,,,,,,,"4221787","Metered aerosol",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709616","Powder Aerosol Dosage Form","C42971","A powder composed of active and/or inert ingredient(s) and packaged under pressure. Ingredients are released upon activation of an appropriate valve system.","Powder Aerosol Dosage Form | AER PWD | AEROSOL, POWDER | Aer Pwd | Aerosol Powder | Aerosol, Powder | Powder Aerosol | Powder Aerosol Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706745","Aerosol Spray Dosage Form","C42889","A spray that is packaged under pressure and released upon activation of an appropriate valve system.","Aerosol Spray Dosage Form | AER SPRAY | AEROSOL, SPRAY | Aer Spray | Aerosol Spray | Aerosol Spray Dose Form | Aerosol, Spray | Aerosol, spray",,,,,,,,,,,,,,,"4228261","Aerosol spray",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1270980","Laboratory Technologist","C51830","A technically trained person who performs laboratory activities and provides laboratory analysis according to laboratory policies, procedures and protocols.","Laboratory Technologist | Lab Tech | Laboratory Technician",,,,,,,,,,,,,,,"4297246","Laboratory technologist",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708662","Lead Drug Monitor","C51831","The primary individual who over a period of time checks on and maintains continuous observation of state, condition, situation, or process relating to substances intended for use in diagnosis, cure, mitigation, treatment, or prevention of disease as a check on output, efficiency, conduct, etc. and warns of faults, or gives advice and instruction by way of reporting or caution.","Lead Drug Monitor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708677","Legal Representative of the Sponsor","C51832","An individual with expertise in the law who provides legal counsel and representation to the individual, company, institution, or organization taking responsibility for the initiation, management, and financing of a study.","Legal Representative of the Sponsor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708691","Letter of Intent Review Chair","C51833","A person who presides over a review committee or panel, which evaluates letters of intent (LOI) for clinical trials.","Letter of Intent Review Chair | LOI Review Chair",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708857","Mail to Contact","C51835","A person to whom mail is to be sent.","Mail to Contact | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708968","Medical Monitor","C51836","A person employed by the sponsor or clinical research organization with medical authority for evaluating the safety aspects of a clinical trial.","Medical Monitor | medical monitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334903","Neuropathologist","C51837","A pathologist with additional training/certification in neuropathology.","Neuropathologist | Pathology Neuropathology | neuropathologist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709473","Participant Chief","C51838","The head of a body of persons who takes part in an activity.","Participant Chief | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708856","Mail Contact","C51834","The person who is responsible for correspondence handled in a postal system, such as letters and packages.","Mail Contact | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709513","Pharmaceutical Liaison","C51839","A person who initiates and maintains a contact or connection pertaining to pharmacy.","Pharmaceutical Liaison | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031323","Pharmacist","C51840","A person trained in pharmacy that prepares and dispenses drugs prescribed by physicians and health practitioners. The responsibilities include instructing patients on the use, hazards, interactions, and side effects of any drug dispensed.","Pharmacist | PHARMACIST | pharmacist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0260120","Pharmacologist","C51841","A physician, scientist, or healthcare provider that investigates the mechanisms underlying the effects of drugs and chemicals on biological or living systems. This knowledge is employed to help design and evaluate drugs for the prevention and treatment of disease.","Pharmacologist | ",,,,,,,,,,,,,,,"4135807","Pharmacologist",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709411","PMB Drug Company Contact","C51843","The drug company employee who is authorized to serve as a primary contact between the company and NCI CTEP Pharmaceutical Management Branch (PMB) regarding pharmaceutical issues (drug acquisition, quality, supply, inventory management, distribution, etc.) pertaining to the investigational agent utilized in the NCI-sponsored clinical trial.","PMB Drug Company Contact | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1320721","Practitioner Assigned","C51846","A person professionally engaged medical practice who is appointed to a post or duties.","Practitioner Assigned | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709652","Primary CDUS Contact","C51847","A primary person within the Cooperative Group, institution, clinical site, or/and particular study that is responsible for the clinical trial data completion and submission to NCI via Clinical Data Update System (CDUS).","Primary CDUS Contact | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709667","Primary Shipping Designee","C51848","The principal person of contact who denotes where and to whom pharmaceuticals are to be shipped. The person of contact is assigned by the principal investigator and registered with the NCI CTEP Pharmaceutical Management Branch (PMB) as with a distributor of (investigational new drugs (INDs) for all NCI-sponsored trials. In addition, this person is authorized to place orders for investigational agents with PMB, requests drug transfers, and maintains drug inventory documentation at the clinical site. Investigational agents are shipped from the PMB directly to the institution or the investigator's practice site where the agent will be prepared and administered.","Primary Shipping Designee | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709698","Program Director","C51849","A professional who holds a leadership administrative, research, or academic position within a scientific program. A program director is responsible for the overall direction in the conduct of research; provision and coordination of training and education; operations, staffing, and maintenance of research facilities; development of new research activities; developing and maintaining relationships with other agencies, programs, scientific centers and departments, as well as with communities.","Program Director | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709702","Project Coordinator","C51851","A staff member who is responsible for the overall integration and interaction of different people and different components of subject matter associated with a specific project.","Project Coordinator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709745","Protocol Chair","C51854","A person at the primary location of research that retains the responsibility for regulation compliance and ensures the proper administration of the objectives, study design, and methodology of study.","Protocol Chair | Protocol Chairperson",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709746","Protocol Chair at an Organization","C51855","A person at a business or administrative group that retains the responsibility for regulation compliance and ensures the proper administration of the objectives, study design, and methodology of study.","Protocol Chair at an Organization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711377","Protocol Lead Investigator","C51856","Primary clinical researcher of a clinical trial, ultimately responsible for all aspects in the conduct of a study, but has special responsibility with regard to the implementation and administration of the study design, and methodology of a trial.","Protocol Lead Investigator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709748","Protocol Review Chair","C51857","The presiding officer of a meeting, organization, or committee that is responsible for the analysis and evaluation of the detailed plan that sets forth the objectives, study design, and methodology for a clinical trial.","Protocol Review Chair | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709749","Protocol Specialist","C51858","A staff member assigned primary responsibility for fulfilling core responsibilities for a specific study. Manages the protocol development and review process, working closely with the Protocol Chair and the study team to develop the protocol and prepare responses. Coordinates the protocol development and study implementation teams throughout study development and conduct.","Protocol Specialist | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709879","Referring Pathologist","C51859","A pathologist that directs a patient to an additional source of medical expertise for assistance, examination, information, or treatment.","Referring Pathologist | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709880","Referring Physician","C51860","A physician that directs a patient to an additional source of medical expertise for assistance, examination, information, or treatment.","Referring Physician | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709885","Registration Coordinator","C51861","A person that is responsible for the integration and collation of subject information and participation throughout the duration of the clinical trial, and subsequent follow-up.","Registration Coordinator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272239","Regulatory Contact","C51862","A person that is responsible for ensuring compliance with government regulations and interacts with the regulatory agencies regarding toxicity, protocol administration, and drug approval procedures.","Regulatory Contact | Regulatory Coordinator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709914","Research Clinician","C51863","A physician who is involved in the treatment and observation of patients as part of a systematic investigation.","Research Clinician | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0687693","Research Nurse","C51864","A nurse who is involved in the treatment and observation of patients as part of a systematic investigation.","Research Nurse | Study Nurse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709938","Review Liaison","C51865","A person that maintains communication between the investigators that submit funding proposals and the officials in charge of review at the institution that fund the proposals.","Review Liaison | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709939","Review Specialist","C51866","An individual with expertise in one or more scientific disciples that can evaluate and review scientific data and funding proposals.","Review Specialist | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709943","Reviewing Radiologist","C51868","A radiologist that formally inspects and verifies diagnoses, clinical data, treatment plans, and grant or scientific proposals.","Reviewing Radiologist | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708969","Medical Physicist","C51842","A healthcare professional or scientist with knowledge and competence in health physics including but not limited to nuclear medicine, radiotherapy, radiology and various aspects of physiological monitoring and investigation.","Medical Physicist | ",,,,,,,,,,,,,,,"37158085","Medical physicist",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709942","Reviewing Pathologist","C51867","A pathologist that inspects and verifies diagnoses, clinical data, grant or scientific proposals.","Reviewing Pathologist | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710023","Scientific Monitor","C51869","An individual with expertise in one or more scientific disciples that can evaluate and review scientific data generated during a study. The individual reviews study records to determine that a study is being conducted in accordance with the protocol and works with the clinical research coordinator to check all data and documentation from the study.","Scientific Monitor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710039","Secondary CDUS Contact","C51870","A subordinate person within the Cooperative Group, institution, clinical site, or/and particular study that is responsible for the clinical trial data completion and submission to NCI via Clinical Data Update System (CDUS).","Secondary CDUS Contact | Secondary Clinical Data Update System Contact",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710075","Shipping Designee","C51871","A person of contact that denotes where, and to whom pharmaceuticals are to be shipped. The person is assigned by the principal investigator and registered with the NCI CTEP Pharmaceutical Management Branch (PMB) as a distributor of investigational new drugs (INDs) for all NCI-sponsored trials. Additionally, this person is authorized to place orders for investigational agents with PMB, requests drug transfers, and maintains drug inventory documentation at the clinical site. Investigational agents are shipped from the PMB directly to the institution or the investigator's practice site where the agent will be prepared and administered.","Shipping Designee | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710100","Site Coordinator","C51872","The staff member at an organization who is responsible for program management of the study and functions as the primary contact for the organization.","Site Coordinator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710101","Site Investigator","C51873","An investigator designated to a specific study location.","Site Investigator | site investigator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710102","Site Leader","C51874","A person in charge of a group at the location of a research project.","Site Leader | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711237","Site Representative Investigator","C51875","The investigator who officially represents a clinical site that participates in a multicentral clinical trial. The responsibilities of the official include the management of site compliance with rules and regulations and attention to personnel and patient requisites.","Site Representative Investigator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334957","Statistician","C51877","A person responsible for the compilation, organization, and analysis of mathematical data.","Statistician | STATISTICIAN",,,,,,,,,,,,,,,"4024156","Statistician",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710219","Study Chair","C51878","A person who is responsible for providing overall management for the operation of the study, and for reporting to the Data and Safety Monitoring Board. The continual review of the data by an independent individual or DSMB assures the investigator(s) that the trial can continue without jeopardizing patient safety.","Study Chair | STUDY CHAIR | Study Chairperson | Study Director",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710220","Study Coordinator","C51880","A person who handles most of the administrative responsibilities of a clinical study, acts as liaison between investigative site and sponsor, and reviews all data and records before a monitor's visit.","Study Coordinator | StudyResearchCoordinator",,,,,,,,,,,,,,,"35625680","Study coordinator",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710470","Treating Physician","C51883","The physician who directly administers medical aid to a patient or study subject.","Treating Physician | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710161","Sponsor Medical Expert","C51876","A physician or health care provider selected by the sponsor to be readily available to advise clinical trial officials on trial related medical questions or problems.","Sponsor Medical Expert | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710227","Subject Recruiter","C51881","A person whose task is to identify and enroll individuals into a research study.","Subject Recruiter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710231","Submitting Pathologist","C51882","A pathologist that submits a proposal or letter of intent to participate in a study or who submits results or diagnoses for use in a study.","Submitting Pathologist | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705908","Veterinary Patient","C53691","A non-human animal that is a subject in a study.","Veterinary Patient | Patient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031133","Peristalsis","C16968","A series of coordinated, rhythmic muscle contractions that occur throughout the length of the gastrointestinal tract and in the ureters. The body utilizes alternating muscles that contract and relax to move fluids and solids from one cavity to another.","Peristalsis | peristalsis",,,,,,,,,,,,,,,"4154727","Peristalsis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704650","Breed (group)","C53692","A group of animals homogeneous in appearance and other characteristics that distinguish it from other animals of the same species.","Breed | BREED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324297","Affenpinscher","C53933","A small version of a working terrier with a harsh, shaggy coat, and longer hair all over the face. The coat is usually black or dark grey, but tan and red are also possible. The average height is 10-15 inches and weight is 7-8 pounds.","Affenpinscher | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324298","Afghan Hound","C53911","A sighthound that is tall and slender with a long, narrow, refined head and powerful jaws. The occiput is prominent. The long coat is usually the color of sand with a darker face and ear fringes. The average height range is 27-29 inches and the average weight range is 58-64 pounds.","Afghan Hound | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324299","Airedale Terrier","C53711","A large terrier with a harsh wiry coat, a long flat head, and a deep chest. The coat is usually tan with black (or dark grizzle) markings. The average height range is 22-24 inches and the average weight range is 40-65 pounds.","Airedale Terrier | Airedale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706757","Akita","C53762","A powerful, solid, well-proportioned and distinctive looking dog that is strong and muscular with a flat, heavy head and strong, short muzzle. The head is broad and shaped like a blunt triangle. Coat colors are pure white, red, sesame, and brindle. The average height range is 24-28 inches and the average weight range is 75-120 pounds.","Akita | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324301","Alaskan Malamute","C53760","A large, strong dog with a thick, coarse double coat and a plumed tail held over its back. The feet are furry and have tough pads. The coat averages 1-3 inches in length and can be white, black and white, wolf grey, wolf sable (red undercoat with dark grey outer coat), or red, often with darker highlights and sometimes with a dark mask or cap. The average height range is 22-26 inches and the average weight range is 70-95 pounds.","Alaskan Malamute | Malamute",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324362","American eskimo dog","C53845","A white spitz-type dog with a wedge-shaped head and a muzzle and skull of about the same length. It has erect triangular-shaped ears and a heavily plumed tail curled over its back. The profuse coat is always white, or white with biscuit or cream markings. This dog can be a toy, miniature, or standard. The average height range is 9-19 inches and the average weight range is 6-35 pounds.","American Eskimo Dog | Eskimo Dog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324369","American Foxhound","C53924","A large hound with broad, pendant ears and a short, hard coat. It is taller than most hounds. The coat may be any color. The average height range is 21-25 inches and the average weight range is 65-75 pounds.","American Foxhound | Foxhound (American)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324455","American Water Spaniel","C53880","An active, muscular, and hardy dog with a broad skull and a crisp-textured, tightly curled or wavy outer coat lined with a protective undercoat. Coat colors can include liver or chocolate. The average height range is 15-18 inches and the average weight range is 25-45 pounds.","American Water Spaniel | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706791","American Staffordshire Terrier","C53734","A very muscular, stocky dog with a broad, powerful head, short muzzle, and very strong jaws. The coat is made up of thick, short, shiny hair. The average height range is 16-19 inches and the average weight range is 57-67 pounds.","American Staffordshire Terrier | Staffordshire Terrier (American)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324303","Australian Cattle Dog","C53740","A sturdy, compact, well-muscled, and powerful working dog. The head is broad and slightly rounded between the widely set, moderately pointed pricked ears. Coat colors may be blue or red speckled, and the blue  speckled coat can have black, blue or tan markings on the head, with tan points. The average height range is 17-20 inches and the average weight range is 30-35 pounds.","Australian Cattle Dog | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1296811","Australian Shepherd","C53741","A medium-sized dog with a weather resistant coat of medium texture and moderate length. An identifying characteristic is a natural or docked bobtail. The coat can be blue merle, red (liver) merle, solid black, or solid red (liver), with or without white markings and/or tan (copper) points. The average height range is 18-23 inches and the average weight range is 40-65 pounds.","Australian Shepherd | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324302","Australian Terrier","C53712","One of the smallest of the terriers, this is a sturdy, short legged, little dog with a rough-textured, weatherproof coat that is about 2-3 inches in length. The coat can be solid red, sandy, or dark or silvery blue, with tan markings on the head and legs. The average height range is 9-11 inches and the average weight range is 9-14 pounds.","Australian Terrier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324304","Basenji","C53912","A small, elegant, athletic hound about the size of a fox terrier, with a smooth shiny coat of copper, red, black and tan, or black and brindle. The Basenji does not bark, but makes a sound described as something between a chortle and a yodel, as well as many other vocalizations. The average height range is 15-17 inches and the average weight range is 20-26 pounds.","Basenji | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324305","Basset Hound","C53896","A hound with a large head and a rounded skull. The body has loose-fitted skin that falls in folds on the head and very long, velvety ears. The coat is short. The body shape is longer than it is tall and the legs are very short. The average height range is 11-15 inches and the average weight range is 45-65 pounds.","Basset Hound | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324306","Beagle","C53897","The Beagle is a hardy, sturdy squarely-built, small hound, with a short coat in tri-color, red and white, orange and white, or lemon and white. The ears are long, wide, and pendant. The average height range is 13-16 inches and the average weight range is 20-25 pounds.","Beagle | BEAGLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324337","Bearded Collie","C53743","A medium-sized herding dog with a shaggy coat. This breed has a broad head, short muzzle, and a shaggy coat all over the body, even under the chin. The color of the coat changes several times over the life of the dog. The adult coats may be any of the four colors, black, brown, blue, or fawn. The average height range is 20-22 inches and the average weight range is 40-60 pounds.","Bearded Collie | Collie (Bearded)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324307","Bedlington Terrier","C53713","A terrier that resembles a lamb, with a pear-shaped head, arched back, and a thick, curly double coat that can be blue, liver, or sandy color. The average height range is 15-17 inches and the average weight range is 18-23 pounds.","Bedlington Terrier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324310","Belgian Malinois","C53758","A muscular dog that is not heavy. It has short, erect ears and a short-haired coat that is fawn to red to mahogany with black tips, mask, and ears. There may be some white on the chest and feet. The average height range is 22-26 inches and the average weight range is 55-65 pounds.","Belgian Malinois | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324311","Belgian Sheepdog","C53742","A muscular black dog that is not heavy with triangular, erect ears. It may be completely black, or may be black with a small to moderate white patch or strip on fore chest, between pads of feet, on tips of hind toes, on chin, and on muzzle (frost may be white or grey). The coat is very full and moderately long, with a ruff around the neck and extra feathering on the underside, legs, and tail. The average height range is 22-26 inches and the average weight range is 55-65 pounds.","Belgian Sheepdog | Belgian Shepherd",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324312","Belgian Tervuren","C53759","A slender dog that is squarely proportioned and solidly muscled, but not bulky. The erect ears are equilateral triangles. The harsh coat is medium to long, with a dense under coat and a straight, black-tipped, outer coat that produces a characteristic black overlay. The average height range is 22-26 inches and the average weight range is 60-75 pounds.","Belgian Tervuren | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324313","Bernese Mountain Dog","C53761","A sturdy, heavy dog, with a weather-resistant, tri-color double coat. The dog has a white blaze on the chest, white on the head and toes, and rust markings over each eye, on the cheeks, sides of the chest, under the tail, and on each leg. The broad head has a slight furrow down the middle. The medium-sized triangular ears are pendant. The average height range is 23-28 inches and the average weight range is 80-110 pounds.","Bernese Mountain Dog | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324314","Bichon Frise","C53856","A friendly, sociable, and cute dog with a loosely curled double coat consisting of a textured outer coat lined with a soft, fine, silky undercoat that is virtually hypo-allergenic. It is usually white with the occasional buff spot. The average height range is 9-12 inches and the average weight range is 7-18 pounds.","Bichon Frise | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324343","Black and Tan Coonhound","C53921","A large, powerful working hound with long pendent ears. The short, sleek, black coat has tan markings on the muzzle, limbs, and chest. The droop of loosely fitting skin and extensive ear leather give the Black and Tan a distinctive quality. The average height range is 23-27 inches and the average weight range is 50-75 pounds.","Black and Tan Coonhound | Coonhound",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324315","Bloodhound","C53898","A powerful, massive hound with a long muzzle, drooping ears, and loose, wrinkled skin. A short, fairly hard coat of hair covers the body and can be black and tan, liver and tan, or red and tawny. The average height range is 23-27 inches and the average weight range is 80-110 pounds.","Bloodhound | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1296845","Border Collie","C53744","A medium sized dog with a body that is slightly longer than tall, and a fairly wide skull. The ears are usually half-perked. The coat colors can be black and white, tri-color, red and white, black and grey, or all black. The average height range is 18-22 inches and the average weight range is 27-45 pounds.","Border Collie | Collie (Border)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324317","Borzoi","C53913","A tall dog with a long, thin, narrow head and curved back. The chest is narrow, but very deep. The longish silky coat may be wavy or have large curls, with a heavy mane at the neck. The colors may be white, golden, tan, or grey with black markings, in either solid or mixed colors. The average height range is 26-28 inches and the average weight range is 60-105 pounds.","Borzoi | Russian Wolfhound",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324318","Boston Terrier","C53846","A compact and well-muscled dog with a broad face, flat head and short, wide muzzle. The hair is short and may be brindle and white, black and white, or brown and white. The average height range is 15-17 inches and the average weight range is 10-25 pounds.","Boston Terrier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324319","Flanders Cattle Dog","C53748","A powerful dog with a massive and heavily-coated head with a thick beard and mustache, and shaggy eyebrows. It has a double coat, and the rough, shaggy-looking outer coat is harsh and dry to the touch. The steel-wool hair may be black, fawn, grey, or brindle. The average height range is 22-28 inches and the average weight range is 60-90 pounds.","Bouvier des Flandres | Bouviers Des Flandres | Flanders Cattle Dog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324320","Boxer","C53763","A powerful and compact dog with a close-fitting coat that may be fawn, brindle, white, or various shades of red with white markings. Its head is in proportion to its body and is lean and unwrinkled. Its lower jaw extends beyond its upper one, curving upward. The average height range is 21-25 inches and the average weight range is 53-70 pounds.","Boxer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324321","Briard","C53749","A large, muscular herding dog with a coarse, long, slightly wavy double coat. Briards are generally black, grey, or tawny, and have a shaggy beard, eyebrows, and mustache. The average height range is 22-27 inches and the average weight range is 75 pounds.","Briard | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324456","Brittany","C53879","A vigorous, medium-sized, leggy dog with a fairly short, lightly feathered single coat. Coat color may be orange and white, liver and white, black and white, liver tri-color, or black tricolor. The high-set ears are short with a triangular shape, slightly fringed, and hanging close to the head. The average height range is 17-21 inches and the average weight range is 30-40 pounds.","Brittany | Brittany Spaniel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707056","Brussels Griffon","C53925","A sturdy toy dog of square proportions with a domed head, undershot jaw, and a very short nose. There are two types: Rough Coated (harsh wiry and dense), and Smooth-Coated or Petit Brabancon variety (short, straight, glossy). Griffon coats may be red, a mixture of red-brown and black, black and tan, or solid black. The average height range is 7-8 inches and the average weight range is 6-12 pounds.","Brussels Griffon | Belgian Griffon | Brussels Griffon (coat not specified)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324322","Bull Terrier","C53736","A thick-set muscular, well-proportioned dog with a short, dense coat that may be pure white, black, brindle, red, fawn, or tri-color. Its most distinctive feature is its head, which is almost flat at the top, sloping evenly down to the end of the nose. There are standard and miniature breeds. The average height range is 10-24 inches and the average weight range is 24-80 pounds.","Bull Terrier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324327","Bulldog","C53847","A small dog in stature, but wide and compact, with a thick, massive head. The skin on the skull and forehead should fall in dense folds. The ears should be small and thin, and folded back in the form of a rose. The coat may be red, fawn, brindle, pale yellow, washed-out red, or white. The average height range is 12-16 inches and the average weight range is 49-55 pounds.","Bulldog | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324328","Bullmastiff","C53764","A very powerfully built dog with a broad wrinkled head and a fairly short, square, dark muzzle. The v-shaped wide-set ears are pendant and dark colored. It has a short, slightly rough coat that comes in brindle, fawn, or red, often with black markings on the head. The average height range is 24-27 inches and the average weight range is 100-133 pounds.","Bullmastiff | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324329","Cairn Terrier","C53715","A hardy little dog with a foxlike expression. It has a compact body with small, pointy, and erect ears. It has an abundant shaggy outer coat with a soft downy undercoat. The coat may be red, brindle, blackish, sand, or various shades of grey. The average height range is 9-13 inches and the average weight range is 13-18 pounds.","Cairn Terrier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324479","Cardigan Welsh Corgi","C53751","A long, low dog with very large erect ears, a broad flat skull, and a long, low-set tail. It tends to be heavier than the Pembroke Welsh Corgi. Its double coat has a harsh medium length outer coat lined with a soft, dense undercoat. Colors may be brindle, blue merle, black, black and tan, black and brindle, sable, or red, often with white markings. The average height range is 10-13 inches and the average weight range is 25-30 pounds.","Cardigan Welsh Corgi | Corgi - Cardigan Welsh | Welsh Corgi (Cardigan)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324330","Cavalier King Charles Spaniel","C53928","A small spaniel with dark, round eyes that are large but not prominent. The ears are long with abundant feathering, and it has a silky coat, sometimes with a slight waviness that may be ruby, black and tan, tri-color, or Blenheim (chestnut on a pearly-white background) in color. The average height range is 12-12 inches and the average weight range is 10-18 pounds.","Cavalier King Charles Spaniel | King Charles Spaniel (Cavalier)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324427","Chesapeake Bay Retriever","C53869","A powerful, muscular retriever with a slightly wavy, rather short coat. Both the outer coat and dense wooly undercoat are oily for water-repellence. The coat may be a shade of brown, red, or tan, ranging from a dead-grass-straw color to a deep dark brown with red overtones. The average height range is 21-26 inches and the average weight range is 55-80 pounds.","Chesapeake Bay Retriever | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324331","Chihuahua (mammal)","C53929","A tiny dog with a big personality, an apple-shaped head, and a short pointed muzzle. It has round, large, very dark eyes and trademark large ears. The body is stout, and longer than it is tall. Besides the common short-haired variety, there is also a long-haired type. Colors include fawn, sand, chestnut, silver and steel blue, black, tan, and parti-color. The average height range is 6-9 inches and the average weight range is 2-6 pounds.","Chihuahua | Chihuahua (coat not specified)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1296839","Chinese Crested","C53947","A sweet and slender dog with spotted pink skin. There are two distinct varieties: one is hairless except for its feet, head, and tail, and is called the Hairless. The other is called the Powder Puff and has a long coat. Coats may be numerous colors, and can be solid, mixed, or spotted all over. The average height is 12 inches and weight is not over 10 pounds.","Chinese Crested | Chinese Crested (coat not specified)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1296872","Chinese Shar-Pei","C53850","A heavily wrinkled dog with a large head, though dogs with smaller heads and tighter looking skins do occur in this breed. Puppies have more wrinkles than adults. Shar-Peis slowly loose their wrinkles as they get older. There are three coat varieties: horse-coat, brush-coat, and a rare bear-coat. The unusual horse-coat is rough to the touch, prickly, and off-standing. The brush-coated variety has longer hair and a smoother feel. The coat on either variety can be up to one inch in length. Coat colors include all solid colors and sables. The average height range is 18-20 inches and the average weight range is 40-55 pounds.","Chinese Shar-Pei | Shar-Pei",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324335","Chow Chow","C53851","A bright, serious, muscular dog with a dense, furry, and profuse coat. Its two most distinctive features are its blue-black tongue and its almost straight hind legs, which causes it to have a stilted gait.  Its dense furry coat is profuse and comes in two varieties, smooth and rough. The most common colors are solid red, black, blue, cinnamon, and cream, but it can also be tan, grey, or (rarely) white. The ears are small and rounded and there is a large ruff behind the head, which gives it a lion like appearance. The average height range is 18-22 inches and the average weight range is 45-70 pounds.","Chow Chow | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324457","Clumber Spaniel","C53881","A massive dog with a broad, deep chest. It has a broad square head, with short, straight, and strong-boned limbs. Its hair is thick and straight. Coat color is predominantly white, with either lemon or orange markings. The average height range is 16-20 inches and the average weight range is 55-85 pounds.","Clumber Spaniel | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707427","Cocker Spaniel","C53882","A spaniel with a sturdy, compact body and a chiseled head. It has strong, moderately bent, muscular quarters. It is capable of considerable speed, combined with endurance.","Cocker Spaniel | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324336","Collie","C53745","An active and agile, long-coated sheepdog. It has a lean, blunted, wedge-shaped head that is flat on top. The trim, but muscular, body is slightly longer than it is tall. In the Rough variety, an abundant double coat forms a mane around the neck and chest. The Smooth variety has a one-inch coat that needs very little grooming. Coats may be sable and white, tri-color (black, white and tan), blue merle, or predominantly white with sable, tri-color, or blue merle markings. The average height range is 22-26 inches and the average weight range is 56-75 pounds.","Collie | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324428","Curly-Coated Retriever","C53870","A large, athletic retriever with a distinctive crisp curly coat. The thick black or liver-colored coat of tight curls protects the dog from brambles and icy water. The smallish ears are pendant. The average height range is 25-27 inches and the average weight range is 65-80 pounds.","Curly-Coated Retriever | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324348","Dachshund","C53899","An elongated, vigorous, muscular dog with short legs. This breed has a long muzzle and robust jaws with extremely strong canine teeth. There are two sizes of Dachshund: standard and miniature. Both sizes have three coat varieties: the short-haired, the wired-haired, and the long-haired. Solid-colored Dachshunds may be tan or yellow. Bi-color Dachshunds may be deep black, brown, or grey with areas of bright chestnut. There are also piebald, speckle-streaked, or harlequin varieties. The average height range is 5-9 inches and the average weight range is 5-32 pounds.","Dachshund | Dachshund (size and coat not specified)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324355","Dalmatian","C53852","A symmetrical, muscular, medium-sized dog with superior endurance. It has a short, hard, dense coat of pure white with characteristic black or liver colored spots randomly splashed over it. The spots can be black, brown (liver), lemon, dark blue, tri colored, brindled, solid white, or sable. The average height range is 20-24 inches and the average weight is 55 pounds.","Dalmatian | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324356","Dandie Dinmont Terrier","C53716","A terrier that is longer than it is tall with short and muscular legs. The solid head is covered with a distinctive topknot. The unique crisp-textured coat contains a mixture of harsh and soft hair. Its coat may be pepper or mustard colored. The topknot and furnishings on pepper Dandies are silver and on mustard Dandies are cream colored. The average height range is 8-11 inches and the average weight range is 18-24 pounds.","Dandie Dinmont Terrier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324358","Doberman Pinscher","C53767","A muscular and very powerful dog. Its hard, short-haired, close-fitting coat may be black, black and tan, blue-grey, red, or fawn and white. The hair is short, thick, and tight to its body. The ears are usually cropped and then taped for a couple of months to make them stand up. If left natural the ears develop somewhat like a hound. The average height range is 24-28 inches and the average weight range is 66-88 pounds.","Doberman Pinscher | Doberman",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324468","English cocker spaniel","C53884","An alert, compactly built, medium-sized dog with long ears. The feet are round and cat-like with tight, arched toes. It has hair of medium length. The coat may be solid black, liver, red, or parti-color combinations of white with black, liver, or red markings or ticking. The average height range is 14-17 inches and the average weight range is 26-34 pounds.","English Cocker Spaniel | Cocker Spaniel (English)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324370","English Foxhound","C53923","A clean-cut, athletic hound, with a long muzzle and wide skull. The ears lay flat to the head. The short, hard coat is usually tri-color (black, white and tan), or bi-color with a white background. The average height range is 21-25 inches and the average weight range is 65-70 pounds.","English Foxhound | Foxhound (English)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324445","English Setter","C53875","A slim setter with a speckled coat. The long hair is flat and a bit wavy. The coat may be white with blue, lemon, orange, or brown speckling. Some dogs are tri-color (blue, white and brown). The moderately long pendant ears have a velvety tip. The average height range is 23-27 inches and the average weight range is 45-80 pounds.","English Setter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324462","English Springer spaniel","C53888","A compact, medium-sized dog with long pendant ears. The medium-length coat is flat or wavy and feathered, and may be liver and white, black and white, blue, or liver roan. The average height range is 18-21 inches and the average weight range is 40-55 pounds.","English Springer Spaniel | Springer Spaniel (English)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324360","English Toy Spaniel","C53950","A small, square spaniel with a deep, pug nose. The long feathered ears are pendant and hang along its cheeks. The soft coat is well feathered and may be one of four color varieties: King Charles (black and tan), Ruby (solid red, sometimes with a few white hairs or small white patch on the chest), Blenheim (white with red markings, often with a red 'thumb print' centered on the top of the head), or Prince Charles (tri-color: white with black and tan markings). The average height is 10 inches and the average weight range is 9-12 pounds.","English Toy Spaniel | King Charles Spaniel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324463","Field Spaniel","C53885","A moderately-sized spaniel, slightly heavier and longer in body than the Cocker. The nose is large, with very open nostrils. The silky coat is generally a solid color, either liver or black. Some dogs have tan markings, and some are roan (speckled). The legs, chest, ears, tail, and undersides are abundantly feathered. The average height is 18 inches and the average weight range is 35-50 pounds.","Field Spaniel | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324364","Finnish Spitz","C53853","A dog that resembles a fox with a pointed muzzle and perked ears. It has thick, erect, medium-length hair with a thick under-layer of straight hair. Its plumed tail curls up over the back and down the side. The feet are round and cat-like. The coat color may be red-brown, or a yellowish-red with some white markings. The average height range is 15-20 inches and the average weight range is 31-35 pounds.","Finnish Spitz | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324429","Flat-Coated Retriever","C53871","A black or liver-colored retriever with a sleek, medium-length, thick coat and well-feathered legs, tail, and chest. The moderately small ears lay flat against the head. The chest is deep and wide. The average height is 22-23 inches and the average weight range is 60-70 pounds.","Flat-Coated Retriever | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324372","French Bulldog","C53849","A sturdy bulldog with large, erect, rounded bat ears, a flat muzzle, and a pug nose. The square flat head is not as massive as the English Bulldog's. The forehead is rounded. The dog is pear-shaped, with the shoulders wider than the tail area. The short coat comes in brindle, fawn, white, or combinations of brindle or fawn with white. The average height is 12 inches and the average weight range is 19-28 pounds.","French Bulldog | Bulldog (French)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324373","German Shepherd Dog","C53753","A well proportioned and very strong shepherd with a sturdy, muscular, slightly elongated body with a light but solid bone structure. It has round feet with very hard soles. The coat is black and tan, sable, or all black. The average height range is 22-26 inches and the average weight range is 77-85 pounds.","German Shepherd Dog | Alsatian | German Shepherd",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324415","German Shorthaired Pointer","C53867","A clean-cut, well-balanced, hunting dog with a chiseled head and large nose. The muzzle is long, but not pointed, and it has a short, dense coat that comes in solid liver or liver and white, patched, ticked, or roan. The average height range is 21-25 inches and the average weight range is 45-70 pounds.","German Shorthaired Pointer | Pointer (German Shorthaired)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324416","German Wirehaired Pointer","C53868","A dog with a coarse, wiry, weather-resistant coat with a thick undercoat. The coat is basically water-repellent and protects it from brambles. The beard, forehead hair, and whiskers protect the face. The color is liver and white, spotted, roan, or ticked. The pendent ears hang down limply beside the head. The average height range is 22-26 inches and the average weight range is 60-70 pounds.","German Wirehaired Pointer | Pointer (German Wirehaired)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324374","Great Dane","C53768","A giant dog with a long narrow head and ears that are either left natural or cropped long, pointed, and carried erect. All Danes have short, thick, close-fitting hair. The color of the coat indicates the variety: fawn, brindle, black, blue, mantle harlequin, and sometimes merle. The average height range is 28-34 inches and the average weight range is 100-200 pounds.","Great Dane | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324440","Giant Schnauzer","C53770","A large, compact dog with bushy eyebrows, whiskers, and a beard. It has a harsh, wiry outer coat and a dense, soft undercoat that comes in solid black or salt and pepper. The average height range is 23-28 inches and the average weight range is 55-80 pounds.","Giant Schnauzer | Schnauzer (Giant) | Schnauzer - Giant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324430","Golden Retriever","C53872","A sturdy, well-proportioned dog with a feathered, medium-length, cream to golden-colored coat. The outer coat is water-repellent and the undercoat is dense. The ears are medium-sized and pendant. Its neck and thighs are muscular and the chest is broad. The average height range is 20-24 inches and the average weight range is 55-80 pounds.","Golden Retriever | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324446","Gordon Setter","C53876","A black and tan setter with a feathered coat and a long, chiseled, and massive head. The coat color should always be black with clearly differentiated tan markings. The long, slightly pointed ears hang flat beside the head. Feet are cat-like, with arched toes, and the breed is well furnished with hair. The average height range is 23-27 inches and the average weight range is 45-80 pounds.","Gordon Setter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324375","Great Pyrenees","C53766","A very large dog with a solid muscular body. The long, coarse, outer coat is either straight or slightly wavy, while the undercoat is soft and thick. Coat colors may be solid white, or white with patches of tan, wolf-grey, or pale yellow. The medium-sized ears are triangular and pendant. The average height range is 25-40 inches and weight is at least 85 pounds.","Great Pyrenees | Pyrenees",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1296801","Greater Swiss Mountain Dog","C53769","A large, strong, muscular, draft dog. The head is large with a broad, flat skull and pendant, medium-sized, triangular ears. The coat is a tri-color double coat (black with rust and white markings). The average height range is 23.5-28.5 inches and the average weight range is 130-135 pounds.","Greater Swiss Mountain Dog | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324376","Greyhound","C53914","A sleek, contoured dog built for speed with a very deep chest and a flexible, curved spine. The head is long and the skull is wide between the ears. The small rose ears are folded back. The coat is short and smooth and may be any dog color. The average height range is 27-30 inches and the average weight range is 60-70 pounds.","Greyhound | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324380","Harrier dog","C53907","The Harrier is similar to the English Foxhound, but smaller. A muscular hunting hound with a short, hard coat that is usually lemon and white, red and white, or white and tan. The rounded ears are pendant. The feet are tight and cat-like, and the front toes may turn inward. The average height range is 19-21 inches and the average weight range is 40-60 pounds.","Harrier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708329","Havanese","C53934","The Havanese gives a rugged impression of a little dog; it is sturdy and not fragile. It is a double-coated breed with soft hair, both on the outer and undercoat. The profuse coat varies from wavy to curly and may be any color, including cream, gold, white, silver, blue, or black. The average height range is 8-11 inches and the average weight range is 7-13 pounds.","Havanese | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324381","Ibizan Hound","C53915","An agile, deer-like, athletic hound that has a long, arched neck, long wedge-shaped head, and very large, triangular ears which stand up when the dog is alert. The rose or flesh-colored nose has a slightly convex shape called 'Roman nose'. There are three varieties of Ibizan: smooth-haired, long-haired, and wire-haired. Colors are white and red, white and tan, or solid white or red. The average height range is 22-29 inches and the average weight range is 42-55 pounds.","Ibizan Hound | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324447","Irish Setter","C53877","A swift runner with an acute sense of smell. It has a feathered, silky coat that may be shades of chestnut to mahogany, sometimes with splashes of white on the chest and feet. The feet are well covered with hair. The chest is narrow. The average height range is 24-28 inches and the average weight range is 55-75 pounds.","Irish Setter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324383","Irish Terrier","C53719","A medium-sized, well-proportioned terrier with long whiskers, a bearded muzzle with powerful jaws, and bushy eyebrows. The ears are v-shaped and fold forward. The rough looking wiry outer jacket is lined with a softer undercoat. The coat is solid colored and may be red, golden, or wheaten. The average height is 18 inches and the average weight range is 25-27 pounds.","Irish Terrier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324465","Irish Water Spaniel","C53889","The largest of the spaniels with a solid brown (leaning to purple), crisp-textured, and curly coat. The long ears are covered with curls. The outer coat is lined with a dense undercoat, which helps insulate the dog in even the coldest water. Webbed feet assist in swimming. The average height range is 20-23 inches and the average weight range is 45-65 pounds.","Irish Water Spaniel | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324382","Irish Wolfhound","C53916","The Irish Wolfhound is a massive, muscular dog, and is one of the tallest breeds in the world. It can reach the size of a small pony and has a rough, shaggy coat and wiry bushy eyebrows. Colors include grey, brindle, red, black, or white; however, grey is the most common color. The paws are large and round, with arched toes and strong, curved nails. The average height range is 28-35 inches and the average weight range is 105-120 pounds.","Irish Wolfhound | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324384","Italian Greyhound","C53935","A miniature greyhound with a long head thinning gradually to a pointed muzzle with narrow ears that fold back along the head, but rise perpendicular to the head when the dog is alert. It has a high stepping gait and a short, sleek coat in solid grey, slate grey, cream, red, fawn, black, or blue - often broken up with white markings on the chest and feet, or white with color markings. The average height range is 12-15 inches and the average weight range is 6-10 pounds.","Italian Greyhound | Greyhound (Italian)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324387","Japanese Chin","C53932","A small spaniel with a short, broad face, and a soft, feathered coat. A thick ruff covers the neck and chest. The nose is wide and the nostrils open. The upside-down, v-shaped ears are well covered with hair. The coat may be white with colored patches, most often black, but is sometimes red, yellow, orange, sable, or brindle. The average height range is 7-11 inches and the weight is up to 9 pounds.","Japanese Chin | Japanese Spaniel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324389","Keeshond","C53854","A compact little dog with a strong resemblance to its ancestor the Samoyed due to its oblique chestnut eyes and erect triangular ears. It has a cream or pale grey undercoat and an outer coat that may be shades of grey with black tips and stands away from the body. The markings are quite definite and there are distinctive pale 'spectacles' around the eyes. The average height range is 17-19 inches and the average weight range is 35-45 pounds.","Keeshond | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324390","Kerry Blue Terrier","C53723","A well-built, muscular, medium-sized dog with true terrier style and character. It has a long head with abundant whiskers, beard, and eyebrows. The ears are v-shaped and crease above the skull to fall toward the outside corner of the eye. The coat is black at birth but changes color through one or more transitions. The mature color varies in color from slate blue to light grey. The average height range is 17.5-20 inches and the average weight range is 33-40 pounds.","Kerry Blue Terrier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324391","Komondor","C53779","A massive dog totally covered with a felted and corded coat, which is 8 to 11 inches long, and is always white. It has a large head and generally massive bone structure. The average height is a minimum 25.5 inches and the weight is a maximum 125 pounds.","Komondor | Hungarian Sheepdog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324392","Kuvasz","C53771","A well-proportioned, white sheepdog. The medium-boned dog is muscular, but not bulky. The ears are folded and close to the head. Though the coat is white, the skin is generally dark. The coat is medium-length, either straight or quite wavy, with a thick undercoat. It forms an abundant mane around the neck and chest. The average height range is 26-30 inches and the average weight range is 70-115 pounds.","Kuvasz | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324431","Labrador retriever","C53873","A solid, muscular dog, with a short, hard, water-resistant double coat that does not have any waves. The coat may be solid black, yellow, or chocolate. There is also said to be a rare silver or grey color. The medium-sized ears are pendant. The webbed feet aid in swimming. The average height range is 21-24 inches and the average weight range is 55-75 pounds.","Labrador Retriever | Lab | Labrador",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324393","Lakeland Terrier","C53724","A solid, squarely proportioned dog similar to the Welsh Terrier, but a bit smaller. The hard outer coat with its undercoat liner protects the dog from brambles and bad weather. The long head has bushy hair on the foreface and the v-shaped ears fold over. Puppies are often born dark, but the adult may be many combinations of black, black and tan, reddish, red grizzle, wheat, liver and blue, grizzle, or grizzle and tan. The maximum height is 14.5 inches and the average weight range is 15-17 pounds.","Lakeland Terrier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324394","Lhasa Apso","C53855","A shaggy dog with a long, heavy, double coat draping over his entire body to the floor that resembles a small version of the Old English Sheepdog. Gold, cream, and honey are the most popular coat colors, but the coat may also be smoke, dark-grizzle, slate, or a multi-color assortment of brown, white and black. The coat is straight, hard, and heavy. Its neck has an abundant scarf of hair, and its tail is feathered and carried over its back. The average height is 10-11 inches and the average weight range is 13-15 pounds.","Lhasa Apso | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708746","Löwchen","C53857","A short and well proportioned dog with a short head and pendant, feathered ears. The hair is long and wavy, but not curly. The colors are white, black, and lemon. The average height range is 10-13 inches and the average weight range is 9-18 pounds.","Lowchen | Little Lion Dog | Low Chen | Löwchen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324395","Maltese","C53936","A small, hardy companion dog with a thick, heavy coat that hangs straight to the ground on each side of a center part line. The color is pure white or sometimes light ivory. The long pendant ears and tail are thickly covered with hair. The average height range is 8-10 inches and the average weight range is 6.5-9 pounds.","Maltese | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324397","Standard Manchester Terrier","C53725","A small, compact, agile dog with a long tapering head. The ears are v-shaped, and may be naturally folded over, pricked up, or cropped (in the toy variety, the ears must be naturally erect). The coat colors are black and tan.  The average height is 15-16 inches and the average weight is 17-18 pounds.","Standard Manchester Terrier | Manchester Terrier (standard) | Manchester Terrier - Standard",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324399","Mastiff","C53773","A massive, powerful and muscular dog. It is one of the heaviest breeds; a male Mastiff can exceed 200 pounds. It has a short coat and small ears. There is a black mask around the eyes and nose no matter what the general coat color. The short coat may be golden fawn, light fawn, brindle, silver, tiger, or apricot. The average height range is 27-30 inches and the average weight range is 150-160 pounds.","Mastiff | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1269315","Miniature Bull Terrier","C53737","A thick-set muscular, well-proportioned dog with a short, dense coat that may be pure white, black, brindle, red, fawn, or tri-color. Its most distinctive feature is its head, which is almost flat at the top, sloping evenly down to the end of the nose. The average height range is 10-14 inches and the average weight range is 24-33 pounds.","Miniature Bull Terrier | Bull Terrier (miniature)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324401","Miniature Pinscher","C53938","A small, compact, muscular dog with square proportions and well-chiseled lines. It has a short coat that may be red, but may also be black and tan or chocolate. The dog has an unusual high stepping gait. The average height range is 10-12 inches and the average weight range is 8-10 pounds.","Miniature Pinscher | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324439","Miniature Schnauzer","C53728","A small, squarely-proportioned dog with a long head, bushy beard, mustache, and eyebrows. The v-shaped ears fold forward when left natural or are cropped to a point and stand erect. Coat colors include salt and pepper, black, white, or a harsh black and silver outer coat with a soft undercoat. The average height range is 12-14 inches and the average weight range is 10-15 pounds.","Miniature Schnauzer | Schnauzer (miniature) | Schnauzer - Miniature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1269316","Mongrel","C53951","A dog of undetermined or mixed breed.","Mixed Breed | MONGREL | Mix Breed | Mix Breed | Mongrel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324402","Newfoundland dog","C53765","A strong, massive dog with a broad heavy head and webbed feet. The water-repellent long outer coat is flat, oily, and slightly wavy with a thick oily undercoat. The small triangular ears are pendant. The coat is most often black (sometimes with a little white on the feet, end of the tail, or chest), black with blue highlights, bronze, or sometimes also brown or grey and Landseer (White with black markings). The average height range is 25-29 inches and the average weight range is 100-150 pounds.","Newfoundland | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324403","Norfolk Terrier","C53726","Among the smallest of the working terriers, this dog has a short, strong, sturdy body with strongly boned legs and a foxlike muzzle with large solid teeth. The coat is wiry and straight and may be red, wheaten, tan, black and tan, or grizzle - occasionally with white markings. The ears are hanging and tight to the cheeks. The average height is 10 inches and the average weight range is 10-12 pounds.","Norfolk Terrier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324404","Norwegian Elkhound","C53906","The Norwegian Elkhound is a hardy, medium-sized Spitz-type dog, sturdy and squarely built with great stamina. The head is broad and wedge-shaped. The paws are small and tight with thick pads. The stand-off double coat has a distinctive grey color with a lighter undercoat and undersides. A distinct characteristic of the Norwegian Elkhound is the absence of 'dog odor'. The average height range is 18-21 inches and the average weight range is 40-60 pounds.","Norwegian Elkhound | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324405","Norwich Terrier","C53727","Among the smallest of the working terriers, this dog has a short, strong, sturdy body with strongly boned legs and a foxlike muzzle. Their coats are wiry and straight and may be red, wheaten, tan, black and tan, or grizzle, occasionally with white markings. The average height is 10 inches and the average weight range is 10-12 pounds.","Norwich Terrier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324406","Old English Sheepdog","C53755","A large, squarely proportioned, agile dog with a profuse, shaggy coat. The body is stocky, well-balanced, and muscular. Topline slopes upward from the withers to the loin. This unusual topline is an important breed characteristic. Coat colors are blue, grey, blue grey, or blue merle, often with white markings, or white with markings of the darker colors. It has a distinctive low-pitched, loud-ringing bark. The average height range is 20-24 inches and the average weight range is 60-65 pounds.","Old English Sheepdog | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709358","Otterhound","C53908","A large rough-coated dog with a shaggy face and bushy eyebrows. Under the long, oily outer coat is a dense wooly undercoat for protection in frigid water. The ears are long and dangling and the tail curves up like a saber. The coat is usually grizzle or wheaten with black markings. Like many other pack hounds, the feet are webbed for swimming. The average height range is 24-26 inches and the average weight range is 66-115 pounds.","Otterhound | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324408","Papillon","C53939","A small, frisky spaniel with a long coat and a long, plumed tail which is carried curled over the back. The coat is white with patches of any color, except liver. It has butterfly ears that are carried either erect or drooping. The average height range is 8-11 inches and the average weight range is 7-10 pounds.","Papillon | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324409","Pekingese","C53940","A compact, stocky toy dog with a long, straight-flowing coat that has profuse feathering and may be any color. It has a broad head with large, slightly prominent eyes, and drooping heart-shaped, long feathering ears. The average height range is 6-9 inches and the average weight range is 8-10 pounds.","Pekingese | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324480","Pembroke Welsh Corgi","C53752","A long, low dog with large erect ears, a broad flat skull, and a foxlike head. It has a soft, water-resistant coat that may be red, sable, fawn, or black and tan, usually with white markings. The average height range is 10-12 inches and the average weight range is 24-30 pounds.","Pembroke Welsh Corgi | Corgi - Pembroke Welsh | Welsh Corgi (Pembroke)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324410","Petit Basset Griffon Vendeen","C53909","A small dog with an unkempt, wiry double coat with shaggy eyebrows, beard and mustache. Coats may be white with markings, or any of the following colors: black, orange, yellow, tri-color and grizzle. It is about 50% longer than tall. The tail tapers and is carried high and alert. The average height range is 13-15 inches and the average weight range is 31-40 pounds.","Petit Basset Griffon Vendeen | Petit Basset Griffon Vendéen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324411","Pharaoh Hound","C53917","An athletic sight hound with a wedge-shaped, chiseled head, large, erect ears, and a powerful jaw. The flat skull and muzzle are long and slim. The coat is short and glossy and may be red or tan, often with white markings. It may also have a white tip on the tail, a white star on the chest, white on toes, and/or a thin white line down the center of the face. The average height range is 21-25 inches and the average weight range is 45-55 pounds.","Pharaoh Hound | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704636","Pointer","C48909","An address or abstract location where a specified object can be found.","Pointer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709594","Pomeranian","C53941","A tiny dog with a wedge-shaped head and pointed erect ears. The profuse stand-off double coat includes an abundant ruff around the neck and chest area. The Pomeranians also boast a distinctive feathered tail that fans forward over the back. Coats may be any solid color, but the most common are red, orange, white or cream, blue, brown, or black. Sometimes the coat is parti-colored (white with colored markings), black and tan, wolf, or orange sable. The average height range is 7-12 inches and the average weight range is 3-7 pounds.","Pomeranian | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324418","Poodle","C53858","A dog with a profuse, wiry curly coat that may be one of three varieties, toy, miniature, and standard. The head and muzzle are long and the ears are wide and hang close to the head. Coats are any solid color, for example: black, blue, silver, grey, cream, apricot, red, white, brown, or cafe-au-lait. The average height range for all varieties is 10-15+ inches and the average weight range is 10-70 pounds.","Poodle | Poodle - Unspecified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324422","Portuguese Water Dog","C53774","A hardy, muscular, medium-sized dog. The single-layered, non-shedding, virtually hypo-allergenic coat may be black, white, brown, parti-color (white with dark spots), black or brown with white markings, silver fox, or grey. The coat varies from a flat, wavy, shiny type to a thick, open curl, to a tight curl. It has more webbing between the toes than many other breeds, which aids in swimming. The heart-shaped ears hang down beside the head. The average height range is 17-22 inches and the average weight range is 35-55 pounds.","Portuguese Water Dog | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709768","Pug","C53942","The Pug has a square, thickset, stocky compact, body, with a sleek, soft coat that comes in apricot, fawn, black or silver - all with a short, flat, black muzzle and velvety ears. It has prominent eyes and a slightly undershot bite. The tail lays in a tight curl or a double curl on the back. The average height range is 10-14 inches and the average weight range is 13-20 pounds.","Pug | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324425","Puli","C53754","An ancient breed of Hungarian sheep dog. It is medium-sized and sturdy, with a unique, corded coat. A full adult coat can reach to the ground. The coat colors can be black, any shade of grey, apricot (with or without a black mask), or the rarer white. Their body shape is square and, though fine-boned, fairly muscular. The average height range is 14.5-17.5 inches and the average weight range is 20-35 pounds.","Puli | Hungarian Water Dog | Pulik",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324433","Rhodesian Ridgeback","C53910","A large, muscular hound with the most unique characteristic being a clearly defined symmetrical ridge running the length of its back, formed by hair that grows in the opposite direction from the rest of its coat. The short, sleek coat may be light to dark wheaten, sometimes with small white markings on the chest and feet. The average height range is 24-27 inches and the average weight range is 65-90 pounds.","Rhodesian Ridgeback | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324434","Rottweiler","C53775","A massive dog with a powerful body. Muscular and athletic, it has a broad head and rounded forehead. The coat is short, hard, and thick. It is black with brown markings on the cheeks and muzzle, paws and legs. A red color with brown markings also exists. The average height range is 22-27 inches and the average weight range is 85-130 pounds.","Rottweiler | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324469","Saint Bernard","C53776","A very large, strong, muscular dog, with a powerful head. There are two types of coat: rough and smooth; both are very dense and may be white with markings in tan, red, mahogany, brindle, or  black in various combinations. The face and ears are usually shaded with black. The feet are large with strong well-arched toes, making the Saint Bernard's sure-footed in the snow and ice. The average height range is 25.5-27.5 inches and the average weight range is 110-200 pounds.","Saint Bernard | St. Bernard",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324436","Samoyed","C53777","A strong, active dog with a compact muscular body that indicates this breed's strength. Its coat is thick and harsh, not wavy, with a thick, soft undercoat, which protects it against the arctic cold. The thick, silver-tipped coat comes in white, biscuit, yellow, or cream. It has a wedge-shaped head with strong jaws. The average height range is 19-23.5 inches and the average weight range is 35-65 pounds.","Samoyed | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324437","Schipperke","C53862","A small, thickset, tail-less dog with a thick double coat and a ruff around the neck. In color, the Schipperke is solid black; however, the coat may also be one of a range of tans and fawns. The head is wedge-shaped with a pointed muzzle, like a fox. The small, erect ears are triangular in shape. The average height range is 10-13 inches and the average weight range is 12-18 pounds.","Schipperke | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324441","Standard Schnauzer","C53772","A medium-sized, rugged, robust dog with bushy eyebrows, whiskers, and a beard. The feet are small and cat-like with arched toes. It has a harsh, wiry outer coat and dense, soft undercoat. The coat may be salt and pepper or solid black. The average height range is 17-20 inches and the average weight range is 30-45 pounds.","Standard Schnauzer | Schnauzer (standard) | Schnauzer - Standard",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324357","Scottish Deerhound","C53919","A tall and slim sight hound with a saggy, long coat, beard, mustache and mane. The harsh, wiry coat comes in various shades of grey (blue-grey is preferred), fawn, or brindle, with dark ears, and a tapering dark muzzle. It may have some white on the chest, feet, and tail. The soft ears lie back against the head unless the dog is excited, in which case, they become half-perked. The average height range is 28-32 inches and the average weight range is 75-110 pounds.","Scottish Deerhound | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324442","Scottish Terrier","C53729","A sturdy little dog with short legs. The coat is compact, course, and hard as bristles with a soft undercoat that protects it thoroughly from bad weather. It may be black, wheaten, or brindle of any color. It has sharply pricked ears, a large nose, and large teeth. The average height is 10-11 inches and the average weight range is 19-23 pounds.","Scottish Terrier | Scottie",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324443","Sealyham Terrier","C53730","A terrier with a large nose and powerful jaws with very long canines. Its front legs are short and straight and its the hind legs are powerful and muscular. The coat is bristly, coarse, and long and may be white or yellowish-white. The height is not more than 12 inches and weight is not more than 20 pounds.","Sealyham Terrier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324448","Shetland Sheepdog","C53756","A strong, lightly built dog, with a long, wedge-shaped head. Its coat is rough with a soft undercoat. It has a lion-like mane and frill around the neck, and the coat may be blue merle or sable and black with various amounts of white and/or tan. Ears are small and flexible with dropping tips. The average height range is 12-15 inches and the average weight range is 12-18 pounds.","Shetland Sheepdog | Collie (miniature) | Sheltie",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1296870","Shiba Inu","C53865","A small, compact, furry dog with a pointed face, broad forehead, and triangular prick ears. It has a Spitz-like tail curling over the back. The double coat is most often red, or red with a little black overlay, or black with tan markings. The dog should have white or cream-colored markings on the cheeks and sides of the muzzle, throat, underside, and chest. White is also possible on the legs, tail tip, and above the eyes. The average height range is 13-16 inches and the average weight range is 18-30 pounds.","Shiba Inu | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324449","Shih Tzu","C53943","A small, sturdy dog with a double coat of long hair lined with a woolly undercoat. It has large, round eyes and pendant ears. The head is rounded, with a profuse beard and mustache, short hairy muzzle, and black nose (except in liver-colored dogs which have liver noses). The maximum height is 11 inches and the average weight range is 9-16 pounds.","Shih Tzu | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710079","Siberian Husky","C53778","A strong, compact, working dog with high set and erect ears. The large 'snow shoe' feet have hair between the toes for gripping on ice. It has a thick, wooly undercoat and soft outer coat. Coat colors include black and white, grey and white, sable and white, agouti and white, and white. The face mask and underbody are usually white. The average height range is 20-23.5 inches and the average weight range is 35-60 pounds.","Siberian Husky | Husky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324452","Skye Terrier","C53731","A long and low terrier with a soft undercoat and a long, stiff, and straight outer coat. The colors of its coat are either grey-blue, dove, or cream, always with black ears. A small amount of white may be found on the chest. The hair shields and protects the eyes and forehead. It has either upright or falling-down ears (although, falling-down ears are rare). Its tail is pendent and never curled. The hare-like feet are long and large, pointing straight forward. The average height is 10 inches and weight is 25 pounds.","Skye Terrier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324435","Saluki","C53918","A slim, greyhound-like dog with long feathering on the ears and tail. They have an unusual gait when they are at top speed: all four of their legs are in the air at the same time. The coat may be black and tan, fawn, white, cream, gold and red, or combinations of these colors. Some Salukis have a patch of white in the middle of the forehead. The ears are long and hanging and the neck is flexible. The feet are thickly haired between the toes for protection from rough terrain. The average height range is 23-28 inches and the average weight range is 29-66 pounds.","Saluki | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324366","Smooth Fox Terrier","C53717","A little dog with a short white coat and black or brown markings. It has a flat, tapering, narrow skull, and ears that fold forward making 'V' shaped flaps. It has strong jaws and well-developed teeth. The average height range is 13-16 inches and the average weight range is 13-20 pounds.","Smooth Fox Terrier | Fox Terrier (Smooth)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324453","Soft Coated Wheaten Terrier","C53732","A medium-sized, compact, and squarely proportioned dog. The head is shaped like a rectangle, and is long, with a short, strong muzzle. Jaws are able to seize and grip prey well with large teeth. Puppies are born black, but lighten to the final adult wheaten color by about two years of age. The average height range is 17-20 inches and the average weight range is 30-45 pounds.","Soft Coated Wheaten Terrier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710155","Spinone Italiano","C53892","A large, rugged dog of distinctive appearance with a long head and hanging ears. Its body is strong-boned, of square build, and has a deep chest. Its coat protects it from the water and freezing temperatures. The average height range is 22.5-27.5 inches and the average weight range is 61-85 pounds.","Spinone Italiano | Italian Griffon | Italian Spinone | Spinone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324325","Staffordshire Bull Terrier","C53733","A powerful and muscular dog that is very strong for its size, with a broad head and very strong jaws. The ears are either rose or half-pricked. The short coat is soft and close, and may be black, blue, fawn, or brindle, often with white markings. The average height range is 13-16 inches and the average weight range is 23-38 pounds.","Staffordshire Bull Terrier | Staffordshire Terrier | Staffordshire Terrier (region not specified)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324466","Sussex Spaniel","C53878","A strong, massive dog with loose skin and heavy long ears that are somewhat reminiscent of a Basset Hound. The coat is flat or slightly wavy without being curled and comes in a golden-liver color. The legs, undersides, and tail are feathered. The average height range is 15-16 inches and the average weight range is 40-44 pounds.","Sussex Spaniel | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324471","Tibetan Spaniel","C53863","A small dog that looks like a Pekingese, but with a slightly longer face, less profuse coat, and no extra skin around the eyes. It has a plumed tail curled over his back, feathered pendent ears, and a soft, medium-length flat coat. The average height is 10 inches and the average weight range is 9-15 pounds.","Tibetan Spaniel | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324472","Tibetan Terrier","C53864","A medium-sized squarely proportioned dog that looks more like a sheepdog than a terrier. It has a fine outer coat that is straight or wavy, and a soft, wooly undercoat. The coat is long, but should not touch the ground. The feathered tail is heavily furnished and carried over the back. This breed's unique, large, flat feet are well furnished with hair and produce a snowshoe effect that provides traction and flotation in snow. The average height range is 14-17 inches and the average weight range is 18-30 pounds.","Tibetan Terrier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324368","Toy Fox Terrier","C53945","This tiny terrier has dark, round eyes and v-shaped, erect ears. The coat is short and thick, and may be white with black and tan or tan markings. The average height is 10 inches and the average weight range is 3.5-7 pounds.","Toy Fox Terrier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324473","Vizsla","C53890","A sleek, muscular, medium-sized hunting dog with a short coat. It has a lean, chiseled head with a long, tapering muzzle and round-tipped ears that are pendant and rather long. The coat can be solid golden rust in different shadings, and is short and abundant. The average height range is 20-26 inches and the average weight range is 40-60 pounds.","Vizsla | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324476","Weimaraner","C53891","A sleek, moderately large, athletic dog with a short, fine, smooth grey coat. The head is long and aristocratic with moderately long, pendant ears. They have has webbed feet for swimming. The average height range is 22-27 inches and the average weight range is 50-70 pounds.","Weimaraner | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324467","Welsh Springer Spaniel","C53887","A compact, medium-sized dog with a medium-length, dark red and white coat that is straight or slightly wavy with feathering on the chest, undersides, legs, and tail. The longish pendant ears are fringed with hair, somewhat like a setter's. The average height range is 16-19 inches and the average weight range is 35-45 pounds.","Welsh Springer Spaniel | Springer Spaniel (Welsh)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324477","Welsh Terrier","C53738","A compact and rugged-looking terrier, with a wiry coat. The head is long, flat and rectangular, with a square muzzle, bushy eyebrows, mustache, and beard. The v-shaped ears fold forward. The cat-like feet are small and rounded. The coat may be black and tan and grizzle. Puppies are born all black. The extremities then lighten gradually, leaving a black 'jacket'. The maximum height is 15 inches and the average weight range is 20-21 pounds.","Welsh Terrier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324481","West Highland White Terrier","C53739","A sturdy, hardy, compact little terrier with a two inch, all-white coat that is uncurled with a soft, dense undercoat. The ears are small, pointed, and erect. The average height range is 9-12 inches and the average weight range is 13-22 pounds.","West Highland White Terrier | Westie",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324482","Whippet","C53920","Similar to a small greyhound, this breed is slender, but hardy with a fine, dense coat that comes in many colors: brindle, black, red, fawn,  white, or slate blue, either solid-colored or mixed. It has small rose-shaped ears. The average height range is 17-19 inches and the average weight range is 12-28 pounds.","Whippet | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324367","Wire Fox Terrier","C53718","A small, strong dog with a wiry coat with black or brown markings that was once a mainstay of British foxhunts. Today, this breed is a handsome and amusing companion and master show dog.  Their coat is dense and wiry with a predominant white color, and brindle, red, liver, or slate blue markings. The average height is 15.5 inches and the average weight range is 15-18 pounds.","Wire Fox Terrier | Fox Terrier (Wire) | Wire-haired Fox Terrier | Wirehaired Fox Terrier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324379","Wirehaired Pointing Griffon","C53874","A rough-coated, medium-sized dog. It has a large, long head, square muzzle, and soft, thick, bushy eyebrows, beard and mustache. It has a straight, hard, wiry outer coat which is lined with a fine but thick downy undercoat. The coat comes in silver or steel-grey with chestnut or roam markings, or in solid chestnut. The average height range is 20-24 inches and the average weight range is 50-60 pounds.","Wirehaired Pointing Griffon | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324483","Yorkshire Terrier","C53946","A small terrier with an ultra long, fine coat. It has a flat head, medium-sized length muzzle, and v-shaped, erect or semi-erect ears. It is steel blue on the body and tail, and tan elsewhere. Puppies are usually black and tan. The average height range is 6-7 inches and the average weight is 7 pounds.","Yorkshire Terrier | Yorkie",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1458155","Breast Neoplasm","C2910","A benign or malignant neoplasm of the breast parenchyma. It can originate from the ducts, lobules or the breast adipose tissue. Breast neoplasms are much more common in females than males.","Breast Neoplasm | Breast Tumor | Neoplasm of Breast | Neoplasm of the Breast | Tumor of Breast | Tumor of the Breast",,,,,,,,,,,,,,,"81251","Neoplasm of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706758","Akrotiri","C49344","A British Overseas Territory comprising a peninsula on the southern coast of Cyprus.","Akrotiri | 900 | AKROTIRI | Akrotiri Sovereign Base Area | QZ | Western Sovereign Base Area | XQZ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004486","Azerbaijan","C16316","A country in southwestern Asia, bordering the Caspian Sea, between Iran and Russia.","Azerbaijan | 031 | AZ | AZE | AZERBAIJAN",,,,,,,,,,,,,,,"4320316","Azerbaijan",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005005","Benin","C16333","A country in western Africa, bordering the North Atlantic Ocean, between Nigeria and Togo.","Benin | 204 | BEN | BENIN | BENIN REPUBLIC | BJ | Benin Republic | Benin Republic | Bénin | Bénin Republic | DHY | DY | Dahomey | Kingdom of Dahomey",,,,,,,,,,,,,,,"4071845","Benin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006196","British Indian Ocean Territory","C16365","An archipelago in the Indian Ocean, south of Africa, about one-half the way from Africa to Indonesia and south of the Maldives.","British Indian Ocean Territory | 086 | BRITISH INDIAN OCEAN TERRITORY | IO | IOT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205999","British Virgin Islands","C17653","A group of islands between the Caribbean Sea and the North Atlantic Ocean, east of the US Virgin Islands.","Virgin Islands, British | 092 | British Virgin Islands | British Virgin Islands | VG | VGB | VIRGIN ISLANDS, BRITISH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006320","Brunei Darussalam","C16367","A country in southeastern Asia, bordering the South China Sea and surrounded by Malaysia.","Brunei Darussalam | 096 | BN | BRN | BRUNEI | BRUNEI DARUSSALAM | Brunei",,,,,,,,,,,,,,,"4329579","Brunei Darussalam",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007673","Central African Republic","C16409","A country in central Africa, north of Democratic Republic of the Congo, between Cameroon and South Sudan.","Central African Republic | 140 | CAF | CENTRAL AFRICAN REPUBLIC | CF",,,,,,,,,,,,,,,"4073740","Central African Republic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006888","Christmas Island","C44482","An Australian-administered island in the eastern Indian Ocean south of Java, Indonesia.","Christmas Island | 162 | CHRISTMAS ISLAND | CX | CXR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009212","Cocos (Keeling) Islands","C16445","A group of islands in the Indian Ocean, south of Indonesia and west of Christmas Island.","Cocos (Keeling) Islands | 166 | CC | CCK | COCOS (KEELING) ISLANDS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022326","Cote d'Ivoire","C16762","A country in western Africa, bordering the North Atlantic Ocean, between Ghana and Liberia.","Cote d'Ivoire | 384 | CI | CIV | COTE D'IVOIRE | CÔTE D'IVOIRE | Côte d'Ivoire | Ivory Coast",,,,,,,,,,,,,,,"4073746","Cote d'Ivoire",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1707730","Dhekelia","C49345","A British Overseas Territory on the southeast coast of Cyprus.","Dhekelia | 907 | DHEKELIA | Dhekelia Sovereign Base Area | Eastern Sovereign Base Area | XD | XXD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0349396","Falkland Islands (Malvinas)","C17954","A group of islands in the South Atlantic Ocean, east of southern Argentina.","Falkland Islands (Malvinas) | 238 | FALKLAND ISLANDS | FALKLAND ISLANDS (ISLAS MALVINAS) | FALKLAND ISLANDS (MALVINAS) | FK | FLK | Falkland Islands | Falkland Islands | Islas Malvinas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016703","French Guiana","C16593","A country in northern South America, bordering the North Atlantic Ocean, between Brazil and Suriname.","French Guiana | 254 | FRENCH GUIANA | GF | GUF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016704","French Polynesia","C16594","An archipelago in the South Pacific Ocean, east of the Cook Islands.","French Polynesia | 258 | FRENCH POLYNESIA | PF | PYF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018301","Guadeloupe","C16651","A group of islands in the Caribbean Seas, southeast of Montserrat.","Guadeloupe | 312 | GLP | GP | GUADELOUPE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515101","Svalbard and Jan Mayen","C17178","A group of islands between the Arctic Ocean, Barents Sea, Greenland Sea, and Norwegian Sea, northeast of Iceland and north of Norway.","Svalbard and Jan Mayen | SJM | SVALBARD AND JAN MAYEN | Svalbard & Jan Mayen Islands",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018387","Guinea-Bissau","C16656","A country in western Africa, bordering the North Atlantic Ocean, between Guinea and Senegal.","Guinea-Bissau | 624 | GNB | GUINEA-BISSAU | GW",,,,,,,,,,,,,,,"4075212","Guinea-Bissau",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512358","Heard Island and McDonald Islands","C20106","A group of islands in the Indian Ocean, about two-thirds of the way from Madagascar to Antarctica, southeast of the French Southern and Antarctic Islands.","Heard Island and McDonald Islands | 334 | HEARD ISLAND AND MCDONALD ISLANDS | HM | HMD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022132","Isle of Man","C44480","An island in the Irish Sea, between Great Britain and Ireland.","Isle of Man | 833 | IM | IMN | ISLE OF MAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022537","Kazakhstan","C20107","A country in central Asia, northwest of China and south of Russia.","Kazakhstan | 398 | KAZ | KAZAKHSTAN | KZ | Kazakstan",,,,,,,,,,,,,,,"4329574","Kazakhstan",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022773","Korea, Republic of","C16774","A country in eastern Asia, occupying the southern half of the Korean Peninsula, bordering the Sea of Japan and the Yellow Sea.","Korea, Republic of | 410 | KOR | KOREA, REPUBLIC OF | KOREA, SOUTH | KR | Republic of Korea | SOUTH KOREA | South Korea | South Korea",,,,,,,,,,,,,,,"4330323","South Korea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022772","Korea, Democratic People's Republic of","C16773","A country in eastern Asia, occupying the northern half of the Korean Peninsula, bordering the Korea Bay and the Sea of Japan, between China and South Korea.","Korea, Democratic People's Republic of | 408 | KOREA, DEMOCRATIC PEOPLE'S REPUBLIC OF | KOREA, NORTH | KP | NORTH KOREA | North Korea | North Korea | PRK",,,,,,,,,,,,,,,"4320304","Democratic People's Republic of Korea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022718","Kyrgyzstan","C16771","A country in central Asia, between southern Kazakhstan and western China.","Kyrgyzstan | 417 | KG | KGZ | KYRGYZSTAN",,,,,,,,,,,,,,,"4320303","Kyrgyzstan",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023634","Libya","C16793","A country in northern Africa, bordering the Mediterranean Sea, between Egypt and Algeria.","Libya | 434 | LBY | LIBYA | LY | Libyan Arab Jamahiriya | Libyan Arab Jamahiriya",,,,,,,,,,,,,,,"4072106","Libya",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0700290","North Macedonia","C17654","A country in southeastern Europe, north of Greece, between Albania and Bulgaria.","North Macedonia | 807 | MACEDONIA, THE FORMER YUGOSLAV REPUBLIC OF | MK | MKD | Macedonia | Macedonia (Republic) | Macedonia, Former Yugoslav Republic of | Macedonia, the Former Yugoslav Republic of | Macedonia, the Former Yugoslav Republic of | NORTH MACEDONIA | REPUBLIC OF MACEDONIA | Republic of Macedonia | Republic of Macedonia | The Former Yugoslav Republic of Macedonia",,,,,,,,,,,,,,,"4208477","North Macedonia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0454677","Martinique","C16823","An island between the Caribbean Sea and the North Atlantic Ocean, south of Dominica and north of Saint Lucia.","Martinique | 474 | MARTINIQUE | MQ | MTQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027779","Netherlands Antilles","C16904","A group of islands in the Caribbean, formerly an autonomous Caribbean country within the Kingdom of the Netherlands and now a constituent of the Kingdom.","Netherlands Antilles | NN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027964","New Caledonia","C16913","A country in the Pacific, comprised of islands in the South Pacific Ocean, east of Australia.","New Caledonia | 540 | NC | NCL | NEW CALEDONIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282244","Micronesia, Federated States of","C17881","An island group in the North Pacific Ocean, about three-quarters of the way from Hawaii to Indonesia, west of the Marshall Islands and north of the Solomon Islands.","Micronesia, Federated States of | 583 | FM | FSM | Federated States of Micronesia | Federated States of Micronesia | MICRONESIA, FEDERATED STATES OF",,,,,,,,,,,,,,,"40479631","Federated States of Micronesia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035373","Reunion","C17095","A country in southern Africa, occupying an island in the Indian Ocean, east of Madagascar and west of Mauritius.","Reunion | 638 | RE | REU | REUNION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035970","Russian Federation","C17111","A country in northern Asia, bordering the Arctic Ocean, between Europe and the North Pacific Ocean.","Russian Federation | 643 | RU | RUS | RUSSIA | RUSSIAN FEDERATION | Russia | Russia",,,,,,,,,,,,,,,"37162241","Russian Federation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038108","Saint Helena, Ascension and Tristan da Cunha","C17164","A group of islands in the South Atlantic Ocean, about midway between South America and Africa, west of Angola and South Africa.","Saint Helena, Ascension and Tristan da Cunha | 654 | SAINT HELENA | SAINT HELENA, ASCENSION AND TRISTAN DA CUNHA | SAINT HELENA, ASCENSION, AND TRISTAN DA CUNHA | SH | SHN | Saint Helena | Saint Helena",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282380","Saint Kitts and Nevis","C17885","A group of islands in the Caribbean Sea, east of the Virgin Islands and south of Anguilla.","Saint Kitts and Nevis | 659 | KN | KNA | SAINT KITTS AND NEVIS",,,,,,,,,,,,,,,"4071851","Saint Kitts and Nevis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038111","Saint Pierre and Miquelon","C17165","A country in northern North America, comprised of islands in the North Atlantic Ocean, south of Newfoundland (Canada).","Saint Pierre and Miquelon | 666 | PM | SAINT PIERRE AND MIQUELON | SPM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036057","Saint Vincent and the Grenadines","C17114","A group of islands between the Caribbean Sea and the North Atlantic Ocean, south of Saint Lucia and north of Granada.","Saint Vincent and the Grenadines | 670 | SAINT VINCENT AND THE GRENADINES | VC | VCT",,,,,,,,,,,,,,,"4075643","Saint Vincent and the Grenadines",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242537","Samoa","C17740","A group of islands in the South Pacific Ocean, about half way from Hawaii to New Zealand, west of American Samoa.","Samoa | 882 | SAMOA | WS | WSM",,,,,,,,,,,,,,,"4330422","Samoa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036183","Sao Tome and Principe","C17116","A country in western Africa, comprised of islands in the Gulf of Guinea, straddling the Equator, west of Gabon.","Sao Tome and Principe | 678 | SAO TOME AND PRINCIPE | ST | STP | São Tomé and Príncipe",,,,,,,,,,,,,,,"4071847","Sao Tome and Principe",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519428","South Georgia and the South Sandwich Islands","C20111","A group of islands in the South Atlantic Ocean, east of the Falkland Islands.","South Georgia and the South Sandwich Islands | 239 | GS | SGS | SOUTH GEORGIA AND SOUTH SANDWICH ISLANDS | SOUTH GEORGIA AND THE SOUTH SANDWICH ISLANDS | South Georgia and the South Sandwich",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039247","Tajikistan","C17183","A country in central Asia, south of Kyrgyzstan and west of China.","Tajikistan | 762 | TAJIKISTAN | TJ | TJK",,,,,,,,,,,,,,,"4329576","Tajikistan",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041061","Trinidad and Tobago","C17217","A group of islands between the Caribbean Sea and the North Atlantic Ocean, off the northeast coast of Venezuela.","Trinidad and Tobago | 780 | TRINIDAD AND TOBAGO | TT | TTO",,,,,,,,,,,,,,,"4075644","Trinidad and Tobago",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041405","Turks and Caicos Islands","C17224","Two island groups in the North Atlantic Ocean, southeast of The Bahamas and north of Haiti.","Turks and Caicos Islands | 796 | TC | TCA | TURKS AND CAICOS ISLANDS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041703","United States","C17234","A country in North America, between Canada and Mexico, bordering both the North Atlantic Ocean and the North Pacific Ocean.","United States | 840 | UNITED STATES | US | USA | United States of America",,,,,,,,,,,,,,,"4330442","United States of America",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042752","Virgin Islands, U.S.","C17255","A group of islands between the Caribbean Sea and the North Atlantic Ocean, east of Puerto Rico and west of the British Virgin Islands.","Virgin Islands, U.S. | 850 | U.S. Virgin Islands | United States Virgin Islands | United States Virgin Islands | VI | VIR | VIRGIN ISLANDS, U.S. | Virgin Islands",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043021","Wallis and Futuna","C17259","A group of islands in the South Pacific Ocean, about two-thirds of the way from Hawaii to New Zealand, northeast of Fiji and west of American Samoa.","Wallis and Futuna | 876 | WALLIS AND FUTUNA | WF | WLF | Wallis and Futuna Islands | Wallis and Futuna Islands",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282111","Internet","C20461","A computer network consisting of a collection of internet sites that offer text and graphics and sound and animation resources through the hypertext transfer protocol.","World Wide Web | WWW | Web",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0991503","Chewable Bar Dosage Form","C42892","A bar designed to be chewed to release active and/or inert ingredient(s).","Chewable Bar Dosage Form | BAR CHEW | BAR, CHEWABLE | Bar, Chewable | Bar, chewable | Chew Bar | Chewable Bar | Chewable Bar Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0991566","Bead Dosage Form","C42890","A solid in the shape of a small sphere.","Bead Dosage Form | BEAD | Bead | Bead Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0179376","Bottle","C43169","A vessel with a narrow neck designed to accept a specific closure.","Bottle | BOTTLE",,,,,,,,,,,,,,,"4238725","Bottle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1707969","Extended Release Bead Implant Dosage Form","C43451","A solid in the shape of a small sphere intended to be embedded securely in the body and designed to release active and/or inert ingredient(s) at a controlled, prolonged rate so as to reduce dosing frequency.","Extended Release Bead Implant Dosage Form | BEAD IMP ER | BEAD, IMPLANT, EXTENDED RELEASE | Bead, Implant, Extended Release | Bead, implant, extended release | ER Bead Implant | Extended Release Bead Implant | Extended Release Bead Implant Dose Form | XR Bead Implant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707424","Coated Capsule Dosage Form","C42895","A capsule that contains an additional outer layer over the capsule shell.","Coated Capsule Dosage Form | CAP COATED | CAPSULE, COATED | Capsule, Coated | Capsule, coated | Coated Cap | Coated Capsule | Coated Capsule Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707970","Extended Release Coated Capsule Dosage Form","C42917","A capsule covered with a thin layer of substance and is designed to release active and/or inert ingredient(s) at a controlled, prolonged rate so as to reduce dosing frequency.","Extended Release Coated Capsule Dosage Form | CAP COATED ER | CAPSULE, COATED, EXTENDED RELEASE | Capsule, Coated, Extended Release | Capsule, coated, extended release | ER Coated Cap | Extended Release Coated Capsule | Extended Release Coated Capsule Dose Form | XR Coated Cap",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707425","Coated Pellet in Capsule Dosage Form","C42896","A capsule composed of small globular masses covered with an outer shell.","Coated Pellet in Capsule Dosage Form | CAP COATED PELLETS | CAPSULE, COATED PELLETS | Capsule, Coated Pellets | Capsule, coated pellets | Coated Pellet in Capsule | Coated Pellet in Capsule Dose Form | Coated Pellets in Capsule Dosage Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707665","Delayed Release Capsule Dosage Form","C42902","A capsule covered with a substance that is designed to impede the immediate release of the active and/or inert ingredient(s) after administration.","Delayed Release Capsule Dosage Form | CAP DR | CAPSULE, DELAYED RELEASE | Capsule, Delayed Release | Capsule, delayed release | DELAYED RELEASE CAPSULE | DR Cap | Delayed Release Capsule | Delayed Release Capsule Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707667","Delayed Release Pellet in Capsule Dosage Form","C42904","A capsule composed of active and/or inert ingredient(s) small, spherical structures that have been coated with a substance that is designed to impede the immediate release of the active and/or inert ingredient(s) after administration.","Delayed Release Pellet in Capsule Dosage Form | CAP DR PELLETS | CAPSULE, DELAYED RELEASE PELLETS | Capsule, Delayed Release Pellets | Capsule, delayed release pellets | DR Cap Pellet | Delayed Release Pellet in Capsule | Delayed Release Pellet in Capsule Dose Form | Delayed Release Pellets in Capsule Dosage Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0991505","Extended Release Capsule Dosage Form","C42916","A capsule designed to release active and/or inert ingredient(s) at a controlled, prolonged rate so as to reduce dosing frequency.","Extended Release Capsule Dosage Form | CAP ER | CAPSULE, EXTENDED RELEASE | Capsule, Extended Release | Capsule, extended release | ER Cap | EXTENDED RELEASE CAPSULE | Extended Release Capsule | Extended Release Capsule Dose Form | XR Cap",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707973","Extended Release Film Coated Capsule Dosage Form","C42928","A capsule covered with a thin layer of water soluble or insoluble polymer and is designed to release active and/or inert ingredient(s) at a controlled, prolonged rate so as to reduce dosing frequency.","Extended Release Film Coated Capsule Dosage Form | CAP FILM COATED ER | CAPSULE, FILM COATED, EXTENDED RELEASE | Capsule, Film Coated, Extended Release | Capsule, film coated, extended release | ER Film Coated Cap | Extended Release Film Coated Capsule | Extended Release Film Coated Capsule Dose Form | XR Film Coated Cap",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708199","Gelatin Coated Capsule Dosage Form","C42936","A capsule covered with a thin layer of gelatin.","Gelatin Coated Capsule Dosage Form | CAP GELATIN COATED | CAPSULE, GELATIN COATED | Capsule, Gelatin Coated | Capsule, gelatin coated | Gelatin Coated Cap | Gelatin Coated Capsule | Gelatin Coated Capsule Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708712","Liquid Filled Capsule Dosage Form","C42954","A capsule composed of liquid covered with an outer shell, which is usually prepared from gelatin.","Liquid Filled Capsule Dosage Form | CAP LIQ FILLED | CAPSULE, LIQUID FILLED | Capsule, Liquid Filled | Capsule, liquid filled | Liq Cap | Liquid Filled Capsule | Liquid Filled Capsule Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL347258","Cement Dosage Form","C45414","A base composed of bonding agents intermingled with active and/or inert ingredient(s), which rapidly hardens into a firm mass upon application.","Cement Dosage Form | CEMENT | Cement | Cement Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704760","Cigarette Dosage Form","C42678","A solid composed of active and/or inert ingredient(s) wrapped in a paper cylinder whereby one end is burned. The ingredient is released in a smoke form, which is inhaled.","Cigarette Dosage Form | CIGARETTE | Cig | Cigarette | Cigarette Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704638","Cone Dosage Form","C42900","A solid with a shape bounded by a circular base converging upon a single vertex.","Cone Dosage Form | CONE | Cone | Cone Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707972","Extended Release Core Dosage Form","C42919","A solid or liquid core composed of active and/or inert ingredient(s) enclosed by a polymer coated shell. It is designed to release active and/or inert ingredient(s) at a controlled, prolonged rate so as to reduce dosing frequency.","Extended Release Core Dosage Form | CORE ER | CORE, EXTENDED RELEASE | Core, Extended Release | Core, extended release | ER Core | Extended Release Core | Extended Release Core Dose Form | XR Core",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707974","Patch - Extended Release Film","C42920","A film that is designed to release active and/or inert ingredient(s) at a controlled, prolonged rate so as to reduce dosing frequency.","Extended Release Film Dosage Form | ER Film | Extended Release Film | Extended Release Film Dose Form | FILM ER | FILM, EXTENDED RELEASE | Film, Extended Release | Film, extended release | XR Film",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710127","Soluble Film Dosage Form","C42984","A film that will dissolve in a liquid solvent to form a solution.","Soluble Film Dosage Form | FILM SOLUBLE | FILM, SOLUBLE | Film, Soluble | Film, soluble | Soluble Film | Soluble Film Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705851","Extract Dosage Form","C42929","A distillate composed of active and/or inert ingredient(s) extracted from plant or animal matter, and represented in concentrated form.","Extract Dosage Form | EXTRACT | Extract | Extract Dose Form | extract",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704673","Gas Dosage Form","C42933","An elastic aeriform fluid in which the molecules are separated from one another and have freedom of movement.","Gas Dosage Form | GAS | Gas | Gas Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL333316","Gel Dosage Form","C42934","A semi-solid composed of a solid, three dimensional, cross linked matrix of polymers within a liquid, yielding a jelly-like material unable to flow at steady state.","Gel Dosage Form | GEL | Gel | Gel Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0787889","Dentifrice Gel Dosage Form","C42906","A gel intended for use in the oral cavity to clean the teeth and maintain oral hygiene.","Dentifrice Gel Dosage Form | Dent Gel | Dental gel | Dentifrice Gel | Dentifrice Gel Dose Form | GEL DENT | GEL, DENTIFRICE | Gel, Dentifrice | Gel, dentifrice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881293","Jelly Dose Form","C42948","A semi-solid composed of suspensions of active and/or inert ingredient(s) in any type of highly viscous material, including gelatin or gel. The structural matrix of the jelly contains high levels of liquid.","Jelly Dosage Form | JELLY | Jelly | Jelly Dose Form | Jelly Gel Dosage Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704445","Generator Dosage Form","C48193","An apparatus that converts solutions, suspensions or solids, composed of active and/or inert ingredient(s) into a vapor or gas by heat or chemical reaction.","Generator Dosage Form | GENERATOR | Generator | Generator Dose Form | Radionuclide generator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1337528","Globule Dosage Form","C42937","A solid composed of sucrose, lactose or other polysaccharides formed into small globular pellets impregnated with active and/or inert ingredient(s).","Globule Dosage Form | GLOBULE | Globule | Globule Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705210","Graft Dosage Form","C45416","A solid composed of a piece of skin or other tissue intended for implantation into or on the body.","Graft Dosage Form | GRAFT | Graft | Graft Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0993609","Granule Dosage Form","C42938","A solid composed of small particles or grains.","Granule Dosage Form | GRAN | GRANULE | GRANULES | Gran | Granule | Granule Dose Form | Granules",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1273633","Effervescent Granules Dosage Form","C42909","A granule composed of active and/or inert ingredient(s), and a mixture of acids and sodium bicarbonate, which release carbon dioxide when dissolved in water.","Effervescent Granules Dosage Form | Effervescent Granule | Effervescent Granule Dosage Form | Effervescent Granule Dose Form | Effervescent granules | Effvsct Gran | GRAN EFFRV | GRANULE, EFFERVESCENT | Granule, Effervescent | Granule, effervescent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707666","Delayed Release Granule Dose Form","C42903","A solid composed of small particles or grains and have been coated with a substance that is designed to impede the immediate release of the active and/or inert ingredient(s) after administration.","Delayed Release Granules Dosage Form | DELAYED RELEASE GRANULES | DR Gran | Delayed Release Granule | Delayed Release Granule Dosage Form | Delayed Release Granule Dose Form | GRAN DR | GRANULE, DELAYED RELEASE | Gastro-resistant granules | Granule, Delayed Release | Granule, delayed release",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708254","Granule for Solution Dosage Form","C42939","A granule intended for administration as a solution.","Granule for Solution Dosage Form | GRAN F/SOL | GRANULE, FOR SOLUTION | Gran for Sol | Granule For Solution Dosage Form | Granule for Solution | Granule for Solution Dose Form | Granule, for Solution | Granule, for solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708255","Granule for Suspension Dosage Form","C42940","A granule intended for administration as a suspension.","Granule for Suspension Dosage Form | GRAN F/SUS | GRANULE, FOR SUSPENSION | Gran for Susp | Granule For Suspension Dosage Form | Granule for Suspension | Granule for Suspension Dose Form | Granule, for Suspension | Granule, for suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL333307","Extended Release Granule for Suspension Dosage Form","C42921","A granule intended for administration as a suspension and designed to release active and/or inert ingredient(s) at a controlled, prolonged rate so as to reduce dosing frequency.","Extended Release Granule for Suspension Dosage Form | ER Gran for Susp | Extended Release Granule For Suspension Dosage Form | Extended Release Granule for Suspension | Extended Release Granule for Suspension Dose Form | Extended Release for Suspension | GRAN F/SUSP ER | GRANULE, FOR SUSPENSION, EXTENDED RELEASE | Granule, for Suspension, Extended Release | Granule, for suspension, extended release | XR Gran for Susp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1378701","Gum Dosage Form","C42941","A semi-solid composed of a sticky, mucilaginous polysaccharide.","Gum Dosage Form | GUM | Gum | Gum Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1321911","Chewing Gum","C42894","A semi-solid composed of synthetic, polymerized polysaccharide and flavorings, intended to be chewed to release active and/or inert ingredient(s).","Chewing Gum Dosage Form | Chewing Gum | Chewing Gum Dose Form | GUM CHEWING | GUM, CHEWING | Gum, Chewing | Gum, chewing | Medicated chewing-gum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709916","Resin Gum Dosage Form","C42978","A semi-solid composed of a mixture of gum and a plant based hydrocarbon.","Resin Gum Dosage Form | GUM RESIN | GUM, RESIN | Gum, Resin | Gum, resin | Resin Gum | Resin Gum Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704229","Implant Dosage Form","C42942","A solid intended for insertion securely within the body.","Implant Dosage Form | IMP | IMPLANT | Imp | Implant | Implant Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0598322","Inhalant dose form","C42944","Vaporized active and/or inert ingredient(s) intended for administration by inhalation.","Inhalant Dosage Form | INHALANT | Inh | Inhalant | Inhalant Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0991512","Injectable Suspension Dosage Form","C42995","A suspension intended for injection.","Injectable Suspension Dosage Form | INJ SUSP | INJECTION, SUSPENSION | Inj Susp | Injectable Suspension | Injectable Suspension Dose Form | Injection, Suspension | Injection, suspension | Suspension for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1720590","Injectable Sonicated Suspension Dosage Form","C42988","A suspension intended for injection and is sonicated while a gas is bubbled through the suspension resulting in the creation of microspheres by the solid particles.","Injectable Sonicated Suspension Dosage Form | INJ SUSP SON | INJECTION, SUSPENSION, SONICATED | Inj Sonicated Susp | Injectable Sonicated Suspension | Injectable Sonicated Suspension Dose Form | Injection, Suspension, Sonicated | Injection, suspension, sonicated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1720257","Injectable Liposomal Suspension Dosage Form","C42951","A suspension composed of active and/or inert ingredient(s) encapsulated in liposomes and intended for injection.","Injectable Liposomal Suspension Dosage Form | INJ SUSP LIPOS | INJECTION, SUSPENSION, LIPOSOMAL | Inj Liposomal Susp | Injectable Liposomal Suspension | Injectable Liposomal Suspension Dose Form | Injection, Suspension, Liposomal | Injection, suspension, liposomal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1720330","Injectable Extended Release Suspension Dosage Form","C42926","A suspension intended for injection that is designed to release active and/or inert ingredient(s) at a controlled, prolonged rate so as to reduce dosing frequency.","Injectable Extended Release Suspension Dosage Form | ER Inj Susp | INJ SUSP ER | INJECTION, SUSPENSION, EXTENDED RELEASE | Injectable Extended Release Suspension | Injectable Extended Release Suspension Dose Form | Injection, Suspension, Extended Release | Injection, suspension, extended release | XR Inj Susp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086466","Injectable Dosage Form","C42946","A substance intended for injection.","Injectable Dosage Form | INJ | INJECTION | Inj | Injectable | Injectable Dose Form | Injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272885","Emulsion for Injection Dosage Form","C42914","An emulsion intended for injection.","Emulsion for Injection Dosage Form | Emulsion for Injection | Emulsion for Injection Dose Form | Emulsion for injection | INJ EMULSION | INJECTION, EMULSION | Injection, Emulsion | Injection, emulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708708","Injectable Lipid Complex Dosage Form","C42950","A substance composed of complexed active and/or inert ingredient(s) with natural or synthetic lipids that is intended for injection.","Injectable Lipid Complex Dosage Form | INJ LIPID COMPLEX | INJECTION, LIPID COMPLEX | Inj Lipid Complex | Injectable Lipid Complex | Injectable Lipid Complex Dose Form | Injection, Lipid Complex | Injection, lipid complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1378554","Crystals","C42901","A solid that consists of naturally produced angular solids composed of singular, repeating units that are systematically arranged in an evenly spaced lattice.","Crystal Dosage Form | CRYSTAL | Crystal | Crystal Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706355","Culture Dose Form","C45415","A solution, suspension or semi-solid composed of media conducive to microbial growth.","Culture Dosage Form | CULTURE | Culture | Culture Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705368","Diaphragm Dosage Form","C47890","A dome-shaped insert with a springy, flexible rim intended to be inserted into the vagina and positioned behind the pelvic bone to completely cover the cervix.","Vaginal Diaphragm Dosage Form | DIAPHRAGM | Diaphragm | Diaphragm Dosage Form | Vag Diaphragm | Vaginal Diaphragm | Vaginal Diaphragm Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0993608","Disk Drug Form","C43525","A flat, circular shaped form composed of a solid or powder that contains active and/or inert ingredient(s).","Disc Dosage Form | DISC | Disc | Disc Dose Form | Disk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1509132","Douche","C42679","A substance intended for use as a vaginal irrigant.","Douche Dosage Form | DOUCHE | Douch | Douche | Douche Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705365","Dressing Dosage Form","C42763","A substance intended for administration in or on a wound.","Dressing Dosage Form | DRESSING | Dressing | Dressing Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0678430","Elixir Dosage Form","C42912","A solution composed of a clear, sweetened hydroalcoholic liquid in which active and/or inert ingredient(s) are dissolved.","Elixir Dosage Form | ELIXIR | Elix | Elixir | Elixir Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0259862","Emulsion Dosage Form","C42913","A semi-solid composed of at least two immiscible liquids, one of which is dispersed as droplets within the other liquid, and stabilized with one or more emulsifying agents.","Emulsion Dosage Form | EMULSION | Emulsion | Emulsion Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0993595","Enema","C42915","A solution or suspension intended for administration into the rectum.","Enema Dosage Form | ENEMA | Enema | Enema Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704608","Film Dosage Form","C42932","A thin layer of water soluble or insoluble polymer intended to coat the site of administration.","Film Dosage Form | FILM | Film | Film Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1720318","Powder for Injectable Extended Release Suspension Dosage Form","C42977","A powder intended for injection following reconstitution to form a suspension that is designed to release active and/or inert ingredient(s) at a controlled, prolonged rate so as to reduce dosing frequency.","Powder for Injectable Extended Release Suspension Dosage Form | INJ PWD F/SUSP ER | INJECTION, POWDER, FOR SUSPENSION, EXTENDED RELEASE | Injection, Powder for Suspension, Extended Release | Injection, powder, for suspension, extended release | Powder For Injectable Extended Release Suspension Dosage Form | Powder for Injectable Extended Release Suspension | Powder for Injectable Extended Release Suspension Dose Form | Pwd for Inj ER Susp | Pwd for Inj XR Susp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1720024","Lyophilized Powder for Injectable Liposomal Suspension Dosage Form","C42959","A freeze dried powder composed of active and/or inert ingredient(s) encapsulated in liposomes and intended for injection following reconstitution with a suitable solvent to form a suspension.","Lyophilized Powder for Injectable Liposomal Suspension Dosage Form | INJ PWD LYO F/LS | INJECTION, POWDER, LYOPHILIZED, FOR LIPOSOMAL SUSPENSION | Injection, Powder, Lyophilized, for Liposomal Suspension | Injection, powder, lyophilized, for liposomal suspension | Lyophilized Powder For Injectable Liposomal Suspension Dosage Form | Lyophilized Powder for Injectable Liposomal Suspension | Lyophilized Powder for Injectable Liposomal Suspension Dose Form | Lyophilized Pwd for Inj Liposomal Susp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272888","Powder for Injectable Suspension Dosage Form","C42976","A powder intended for injection following reconstitution to form a suspension.","Powder for Injectable Suspension Dosage Form | INJ PWD F/SUSP | INJECTION, POWDER, FOR SUSPENSION | Injection, Powder, for Suspension | Injection, powder, for suspension | Powder For Injectable Suspension Dosage Form | Powder for Injectable Suspension | Powder for Injectable Suspension Dose Form | Powder for suspension for injection | Pwd for Inj Susp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272887","Powder for Injectable Solution Dosage Form","C42974","A powder intended for injection following reconstitution to form a solution.","Powder for Injectable Solution Dosage Form | INJ PWD F/SOL | INJECTION, POWDER, FOR SOLUTION | Injection, Powder, for Solution | Injection, powder, for solution | Powder For Injectable Solution Dosage Form | Powder for Injectable Solution | Powder for Injectable Solution Dose Form | Powder for solution for injection | Pwd for Inj Sol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0991511","Injectable Solution Dosage Form","C42945","A solution intended for injection.","Injectable Solution Dosage Form | INJ SOL | INJECTION, SOLUTION | Inj Sol | Injectable Solution | Injectable Solution Dose Form | Injection, Solution | Injection, solution | Solution for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272891","Concentrated Injectable Solution Dosage Form","C42899","A concentrate which is usually diluted prior to administration by injection.","Concentrated Injectable Solution Dosage Form | Conc Inj Sol | Concentrate for Injectable Solution Dosage Form | Concentrated Injectable Solution | Concentrated Injectable Solution Dose Form | INJ SOL CONC | INJECTION, SOLUTION, CONCENTRATE | Injection, Solution, Concentrate | Injection, solution, concentrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707976","Extended Release Insert Dosage Form","C42922","An insert designed to release active and/or inert ingredient(s) at a controlled, prolonged rate so as to reduce dosing frequency.","Extended Release Insert Dosage Form | ER Insert | Extended Release Insert | Extended Release Insert Dose Form | INSERT ER | INSERT, EXTENDED RELEASE | Insert, Extended Release | Insert, extended release | XR Insert",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706306","Intrauterine Device Dosage Form","C47915","A solid intended for placement within the uterine cavity where active and/or inert ingredient(s) are released from an apparatus at a controlled rate.","Intrauterine Device Dosage Form | INTRAUTERINE DEVICE | IUD | Intrauterine Device | Intrauterine Device Dose Form | Intrauterine device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0593225","Irrigant Dosage Form","C42947","A solution or suspension used to bathe or flush open wounds or body cavities.","Irrigant Dosage Form | IRRIGANT | Irrigant | Irrigant Dose Form | Irrigation solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704742","Kit Dosage Form","C47916","A collection of materials that are used together to orchestrate dosage administration.","Kit Dosage Form | KIT | Kit | Kit Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707678","Dental Liner Dosage Form","C45413","A resinous film-forming agent dissolved in a solvent or a calcium hydroxide suspension within a synthetic resin solution, which rapidly hardens into a firm mass upon administration.","Dental Liner Dosage Form | Dental Liner | Dental Liner Dose Form | LINER DENTAL | LINER, DENTAL | Liner, Dental | Liner, dental",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023742","Liniment Dosage Form","C42949","A semi-solid with viscosity similar to that of a lotion, which is intended for topical use and must be rubbed into the site of administration to release the active and/or inert ingredient(s).","Liniment Dosage Form | LINIMENT | Liniment | Liniment Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL337470","Lipstick Dosage Form","C42952","A solid or semi-solid with a waxy consistency in the shape of a stick and intended for use on the lips.","Lipstick Dosage Form | LIPSTICK | Lipstick | Lipstick Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1697794","Liquid Dosage Form","C42953","A substance in the fluid state of matter having no fixed shape but a fixed volume.","Liquid Dosage Form | LIQ | LIQUID | Liq | Liquid | Liquid Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0991564","Lozenge Dosage Form","C42955","A solid composed of active and/or inert ingredient(s), sweeteners, other flavorings and mucilage, intended for oral administration.","Lozenge Dosage Form | LOZENGE | Lozenge | Lozenge Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700468","Mouthwash Dosage Form","C29269","A solution or suspension intended for oral administration, for its deodorizing or antiseptic effects in the oral cavity. Usually, the mouthwash is swished around the mouth and expelled.","Mouthwash Dosage Form | MOUTHWASH | Mouthwash | Mouthwash Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705113","Dosage Form Not Applicable","C48624","An indication that the dosage form is not relevant or appropriate.","Dosage Form Not Applicable | NA | NOT APPLICABLE | Not Applicable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028912","Ointment Dosage Form","C42966","A semi-solid, viscous in texture, that may be composed of a variety of bases including hydrocarbons, emulsifiers or vegetable oils, and mixed with active and/or inert ingredient(s).","Ointment Dosage Form | OINTMENT | Oint | Ointment | Ointment Dose Form | oint | ointment | unguent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706363","Packing Dosage Form","C47887","A solid composed of a material that contains active and/or inert ingredient(s) which is intended to be placed in a cavity or depression within the body.","Packing Dosage Form | PACKING | Packing | Packing Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1321899","Paste","C42967","A semi-solid composed of a large proportion of solids and finely dispersed active and/or inert ingredient(s) in a fat-based vehicle.","Paste Dosage Form | PASTE | Paste | Paste Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0787888","Dentifrice Paste Dosage Form","C42907","A paste of mild abrasives, detergents, flavoring agents, binders, fluoride, and other active and/or inert ingredient(s).","Dentifrice Paste Dosage Form | Dent Paste | Dental paste | Dentifrice Paste | Dentifrice Paste Dose Form | PASTE DENT | PASTE, DENTIFRICE | Paste, Dentifrice | Paste, dentifrice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0994894","Patch Dosage Form","C42968","A solid composed of an impermeable occlusive backing and a formulation matrix in which the active and/or inert ingredient(s) are dissolved or dispersed; possibly includes an adhesive layer.","Patch Dosage Form | PATCH | Patch | Patch Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707977","Extended Release Patch Dosage Form","C42923","A patch designed to release active and/or inert ingredient(s) at a controlled, prolonged rate so as to reduce dosing frequency.","Extended Release Patch Dosage Form | ER Patch | Extended Release Patch | Extended Release Patch Dose Form | PATCH ER | PATCH, EXTENDED RELEASE | Patch, Extended Release, Electrically Controlled | Patch, extended release | XR Patch",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707893","Electrically Controlled Extended Release Patch Dosage Form","C42911","A patch that composed of active and/or inert ingredient(s) whose release is controlled by electronic impulses that release ingredients at a controlled, prolonged rate so as to reduce dosing frequency.","Electrically Controlled Extended Release Patch Dosage Form | Electrically Controlled ER Patch | Electrically Controlled Extended Release Patch | Electrically Controlled Extended Release Patch Dose Form | Electrically Controlled XR Patch | PATCH ER ELCON | PATCH, EXTENDED RELEASE, ELECTRICALLY CONTROLLED | Patch, Extended Release, Electrically Controlled | Patch, extended release, electrically controlled",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0993610","Pellet Dosage Form","C42969","A solid composed of a small granular or compressed mass that contains highly purified active and/or inert ingredient(s).","Pellet Dosage Form | PELLET | Pellet | Pellet Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708475","Implantable Pellet Dosage Form","C42943","A pellet intended for insertion securely within the body.","Implantable Pellet Dosage Form | Imp Pellet | Implantable Pellet | Implantable Pellet Dose Form | PELLET IMP | PELLET, IMPLANTABLE | Pellet, Implantable | Pellet, implantable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707971","Extended Release Coated Pellet Dosage Form","C42918","A pellet covered with a thin layer of substance that is designed to release active and/or inert ingredient(s) at a controlled, prolonged rate so as to reduce dosing frequency.","Extended Release Coated Pellet Dosage Form | ER Coated Pellet | Extended Release Coated Pellet | Extended Release Coated Pellet Dose Form | Extended Release Coated Pellets Dosage Form | PELLETS COATED ER | PELLETS, COATED, EXTENDED RELEASE | Pellets, Coated, Extended Release | Pellets, coated, extended release | XR Coated Pellet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL337367","Plaster Dosage Form","C42970","A semi-solid composed of a soft, smooth mass with relatively thick consistency and strong adhesiveness that becomes solid when dry.","Plaster Dosage Form | PLASTER | Plaster | Plaster Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL414914","Poultice Dosage Form","C47913","A semi-solid composed of a soft, moist mass that is made by wetting an absorbent solid substance.","Poultice Dosage Form | POULTICE | Poultice | Poultice Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032861","Powder Dosage Form","C42972","A solid composed of a mixture of dry, finely divided active and/or inert ingredient(s).","Powder Dosage Form | POWDER | PWD | Powder | Powder Dose Form | Pwd",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0787890","Dentifrice Powder Dosage Form","C42908","A powder composed of a mild abrasives, detergents, flavoring agents, binders, fluoride, and other active and/or inert ingredient(s).","Dentifrice Powder Dosage Form | Dent Pwd | Dental powder | Dentifrice Powder | Dentifrice Powder Dose Form | POWDER, DENTIFRICE | PWD DENT | Powder, Dentifrice | Powder, dentifrice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709619","Powder for Solution Dosage Form","C42973","A powder that yields a solution following reconstitution with an appropriate liquid.","Powder for Solution Dosage Form | POWDER FOR SOLUTION | POWDER, FOR SOLUTION | PWD F/SOL | Powder for Solution | Powder for Solution Dose Form | Powder, for Solution | Powder, for solution | Pwd for Sol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709620","Powder for Suspension Dosage Form","C42975","A powder that forms a suspension when reconstituted with a liquid solution.","Powder for Suspension Dosage Form | POWDER, FOR SUSPENSION | PWD F/SUSP | Powder for Suspension | Powder for Suspension Dose Form | Powder, for Suspension | Powder, for suspension | Pwd for Susp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709007","Metered Powder Dosage Form","C42961","A powder contained in a device with valves that permits the dispensing of active and/or inert ingredient(s) upon activation.","Metered Powder Dosage Form | Metered Powder | Metered Powder Dose Form | Metered Pwd | POWDER, METERED | PWD MET | Powder, Metered | Powder, metered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1701810","Rinse Dosage Form","C42979","A solution or suspension intended for irrigation purposes.","Rinse Dosage Form | RINSE | Rinse | Rinse Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710011","Salve Dosage Form","C42980","A semi-solid composed of a thick, fat or wax-based ointment or cerate with a consistency somewhere between an ointment and a plaster.","Salve Dosage Form | SALVE | Salve | Salve Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704277","Shampoo Dosage Form","C42981","A solution or suspension composed of an anionic surfactant and intended for administration to the hair and/or scalp.","Shampoo Dosage Form | SHAMPOO | Shampoo | Shampoo Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710070","Shampoo Suspension Dosage Form","C42982","A suspension composed of anionic surfactant and intended for administration to the hair and/or scalp.","Shampoo Suspension Dosage Form | SHAMPOO SUSP | SHAMPOO, SUSPENSION | Shampoo Susp | Shampoo Suspension | Shampoo Suspension Dose Form | Shampoo, Suspension | Shampoo, suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705308","Soap Dosage Form","C42983","An anionic surfactant for cleansing.","Soap Dosage Form | SOAP | Soap | Soap Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1382100","Solution Dosage Form","C42986","A clear, homogeneous liquid composed of one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents.","Solution Dosage Form | SOL | SOLUTION | Sol | Solution | Solution Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707468","Concentrated Solution Dosage Form","C42898","A concentrate which is usually diluted prior to administration and exists as a solution in its final form.","Concentrated Solution Dosage Form | Conc Sol | Concentrate for Solution Dosage Form | Concentrated Solution | Concentrated Solution Dose Form | SOL CONC | SOLUTION, CONCENTRATE | Solution, Concentrate | Solution, concentrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710128","Solution for Slush Dosage Form","C42987","A solution composed of an iced saline slurry with or without active and/or inert ingredient(s) intended to induce regional hypothermia from the point of administration.","Solution for Slush Dosage Form | SOL F/SLUSH | SOLUTION, FOR SLUSH | Sol for Slush | Solution For Slush Dosage Form | Solution for Slush | Solution for Slush Dose Form | Solution, for Slush | Solution, for slush",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708198","Extended Release Gel Forming Solution Dosage Form","C42935","A solution that becomes gelatinous upon administration and is designed to release active and/or inert ingredient(s) at a controlled, prolonged rate so as to reduce dosing frequency.","Extended Release Gel Forming Solution Dosage Form | ER Gel Sol | Extended Release Gel Forming Solution | Extended Release Gel Forming Solution Dose Form | SOL GF ER | SOLUTION, GEL FORMING, EXTENDED RELEASE | Solution, Gel Forming, Extended Release | Solution, gel forming, extended release | XR Gel Sol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705741","Sponge Dosage Form","C47912","A solid composed of a porous, interlacing, absorbent, usually shape retaining material, such as cellulose wood fibers or plastic polymer form.","Sponge Dosage Form | SPONGE | Sponge | Sponge Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1154182","Spray Dosage Form","C42989","A solution or suspension composed of active and/or inert ingredient(s) in oil or water, typically dispensed from an atomizer or nebulizer.","Spray Dosage Form | SPRAY | Spray | Spray Dose Form",,,,,,,,,,,,,,,"4226794|42539118","Spray dose form|Spray",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1709008","Metered Spray Dosage Form","C42962","A spray contained in a device with valves that permits the dispensing of a specified quantity of active and/or inert ingredient(s) upon activation.","Metered Spray Dosage Form | Metered Spray | Metered Spray Dose Form | SPRAY MET | SPRAY, METERED | Spray, Metered | Spray, metered",,,,,,,,,,,,,,,"4145844","Metered spray",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710170","Spray Suspension Dosage Form","C42990","A spray composed of a suspension that contains active and/or inert ingredient(s).","Spray Suspension Dosage Form | SPRAY SUSP | SPRAY, SUSPENSION | Spray Susp | Spray Suspension | Spray Suspension Dose Form | Spray, Suspension | Spray, suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706582","Stick Dosage Form","C42991","A solid composed active and/or inert ingredient(s) in a long, slender cylindrical shape.","Stick Dosage Form | STICK | Stick | Stick Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3241918","Strip Dosage Form","C47914","A solid composed of active and/or inert ingredient(s) in a long narrow piece of material.","Strip Dosage Form | STRIP | Strip | Strip Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707978","Extended Release Suppository Dosage Form","C42924","A suppository that is designed to release active and/or inert ingredient(s) at a controlled, prolonged rate so as to reduce dosing frequency.","Extended Release Suppository Dosage Form | ER Supp | Extended Release Suppository | Extended Release Suppository Dose Form | SUPP ER | SUPPOSITORY, EXTENDED RELEASE | Suppository, Extended Release | Suppository, extended release | XR Supp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038854","Suppository Dosage Form","C42993","A solid or semi-solid composed of active and/or inert ingredient(s) in a wax, fat or a glycerin gelatin jelly and that is conical or oval in shape. It is intended to be inserted into a body orifice.","Suppository Dosage Form | SUPP | SUPPOSITORY | Supp | Suppository | Suppository Dose Form | supp | suppository",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038960","Suspension Dosage Form","C42994","Insoluble solid particles composed of active and/or inert ingredient(s) that are dispersed in a liquid.","Suspension Dosage Form | Ready to Use Suspension | SUSP | SUSPENSION | Susp | Suspension | Suspension Dose Form | susp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0991508","Extended Release Suspension Dosage Form","C42925","A suspension that is designed to release active and/or inert ingredient(s) at a controlled, prolonged rate so as to reduce dosing frequency.","Extended Release Suspension Dosage Form | ER Susp | Extended Release Suspension | Extended Release Suspension Dose Form | SUSP ER | SUSPENSION, EXTENDED RELEASE | Suspension, Extended Release | Suspension, extended release | XR Susp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706068","Suture Dosage Form","C47889","A solid composed of fibrous strands of material that are used to bind wound edges together.","Suture Dosage Form | SUTURE | Suture | Suture Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706069","Swab Dosage Form","C47898","A solid composed of a small piece of absorbent material attached to one end of a small stick.","Swab Dosage Form | SWAB | Swab | Swab Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0991550","Syrup Dosage Form","C42996","A solution or suspension composed of a viscid vehicle that contains a high concentration of sucrose or other sugars and active and/or inert ingredient(s).","Syrup Dosage Form | SYRUP | Syrup | Syrup Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039225","Tablet Dosage Form","C42998","A solid composed of a mixture of that active and/or inert ingredient(s) are pressed or compacted together, usually in the form of a relatively flat and round, square or oval shape.","Tablet Dosage Form | TAB | TABLET | Tab | Tablet | Tablet Dose Form | tab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1273644","Effervescent Tablet Dosage Form","C42910","A tablet composed of active and/or inert ingredient(s), and a mixture of acids and sodium bicarbonate, which release carbon dioxide when dissolved in water.","Effervescent Tablet Dosage Form | EFFERVESCENT TABLET | Effervescent Tablet | Effervescent Tablet Dose Form | Effervescent tablet | Effvsct Tab | TAB EFFRV | TABLET, EFFERVESCENT | Tablet, Effervescent | Tablet, effervescent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0360714","HMG-CoA Reductase Inhibitor","C1655","Any substance that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis. Inhibition of HMG-CoA reductase acts to lower plasma cholesterol and lipoprotein levels.","HMG-CoA Reductase Inhibitor | HMG-CoA reductase inhibitor | Hydroxymethylglutaryl CoenzymeA Reductase Inhibitors | Statin | hydroxymethylglutaryl-coenzyme A reductase inhibitor | statin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0304290","Chewable Tablet Dosage Form","C42893","A tablet that must be chewed to release the active and/or inert ingredient(s).","Chewable Tablet Dosage Form | Chew Tab | Chewable Tablet | Chewable Tablet Dose Form | Chewable tablet | TAB CHEW | TABLET, CHEWABLE | Tablet, Chewable | Tablet, chewable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1273642","Coated Tablet Dosage Form","C42897","A tablet whose outer shell is covered with a substance.","Coated Tablet Dosage Form | Coated Tab | Coated Tablet | Coated Tablet Dose Form | Coated tablet | TAB COATED | TABLET, COATED | Tablet, Coated | Tablet, coated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710340","Delayed Release Particle Tablet Dosage Form","C42997","A tablet composed of individual fragments have been coated with a substance that is designed to impede the immediate release of the active and/or inert ingredient(s) after administration.","Delayed Release Particle Tablet Dosage Form | DR Particle Tab | Delayed Release Particle Tablet | Delayed Release Particle Tablet Dose Form | Delayed Release Particles Tablet Dosage Form | TAB DR PARTICLES | TABLET, DELAYED RELEASE PARTICLES | Tablet, Delayed Release Particles | Tablet, delayed release particles",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0991507","Extended Release Tablet Dosage Form","C42927","A tablet designed to release active and/or inert ingredient(s) at a controlled, prolonged rate so as to reduce dosing frequency.","Extended Release Tablet Dosage Form | ER Tab | EXTENDED RELEASE TABLET | Extended Release Tablet | Extended Release Tablet Dose Form | Prolonged-release tablet | TAB ER | TABLET, EXTENDED RELEASE | Tablet, Extended Release | Tablet, Prolonged Release | Tablet, extended release | XR Tab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1273643","Film Coated Tablet Dosage Form","C42931","A tablet covered with a thin layer of water soluble or insoluble polymer.","Film Coated Tablet Dosage Form | Film Coated Tab | Film Coated Tablet | Film Coated Tablet Dose Form | Film-coated tablet | TAB FILM COATED | TABLET, FILM COATED | Tablet, Film Coated | Tablet, film coated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708060","Film Coated Extended Release Tablet Dosage Form","C42930","A tablet covered with a thin layer of water soluble or insoluble polymer and is designed to release active and/or inert ingredient(s) at a controlled, prolonged rate so as to reduce dosing frequency.","Film Coated Extended Release Tablet Dosage Form | Film Coated ER Tab | Film Coated Extended Release Tablet | Film Coated Extended Release Tablet Dose Form | Film Coated XR Tab | TAB FILM COATED ER | TABLET, FILM COATED, EXTENDED RELEASE | Tablet, Film Coated, Extended Release | Tablet, film coated, extended release",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709088","Multilayered Tablet Dosage Form","C42964","A tablet composed of active and/or inert ingredient(s) that have been compressed to form a tablet that contains multiple layers.","Multilayered Tablet Dosage Form | Multilayered Tab | Multilayered Tablet | Multilayered Tablet Dose Form | TAB MULTILAYER | TABLET, MULTILAYER | Tablet, Multilayer | Tablet, multilayer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709087","Multilayered Extended Release Tablet Dosage Form","C42963","A tablet composed of active and/or inert ingredient(s) that have been compressed into multiple layers and is designed to release active and/or inert ingredient(s) at a controlled, prolonged rate so as to reduce dosing frequency.","Multilayered Extended Release Tablet Dosage Form | Multilayered ER Tab | Multilayered Extended Release Tablet | Multilayered Extended Release Tablet Dose Form | Multilayered XR Tab | TAB MULTILAYER ER | TABLET, MULTILAYER, EXTENDED RELEASE | Tablet, Multilayer, Extended Release | Tablet, multilayer, extended release",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710341","Orally Disintegrating Tablet Dosage Form","C42999","A tablet which disintegrates and dissolves quickly (usually within a matter of seconds) in the mouth. Additional water to complete dissolution is not necessary.","Orally Disintegrating Tablet Dosage Form | Orally Disintegrating Tablet | Orodispersible tablet | TAB ORALLY DIS | TABLET, ORALLY DISINTEGRATING | Tablet, Orally Disintegrating | Tablet, orally disintegrating | orally Dis Tab | orally Disintegrating Tablet Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1273629","Soluble Tablet Dosage Form","C42985","A tablet that will dissolve in a liquid solvent to form a solution.","Soluble Tablet Dosage Form | Sol Tab | Soluble Tablet | Soluble Tablet Dose Form | Soluble tablet | TAB SOLUBLE | TABLET, SOLUBLE | Tablet, Soluble | Tablet, soluble",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710240","Sugar Coated Tablet Dosage Form","C42992","A tablet covered with sugar.","Sugar Coated Tablet Dosage Form | Sugar Coated Tab | Sugar Coated Tablet | Sugar Coated Tablet Dose Form | TAB SUGAR COATED | TABLET, SUGAR COATED | Tablet, Sugar Coated | Tablet, sugar coated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704612","Tampon Dosage Form","C47892","A solid composed of a plug made from absorbent material.","Tampon Dosage Form | TAMPON | Tampon | Tampon Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704747","Tape Dosage Form","C47897","A solid composed of narrow woven fabric or a narrow extruded synthetic material, usually with an adhesive on one or both sides.","Tape Dosage Form | TAPE | Tape | Tape Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0991583","Tincture Dosage Form","C43000","A solution composed of an alcoholic extract or solution of nonvolatile active and/or inert ingredient(s).","Tincture Dosage Form | TINCTURE | Tinct | Tincture | Tincture Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705355","Troche Dosage Form","C43001","A solid discoid composed of active and/or inert ingredient(s) in a suitably flavored base, that dissolves when sucked in the mouth.","Troche Dosage Form | TROCHE | Troche | Troche Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704754","Unassigned Dosage Form","C43002","An indication that the dosage form has yet to be assigned.","Unassigned Dosage Form | UNASSIGNED | Unassigned | Unassigned Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0991560","Oral Wafer","C43003","A solid composed of a thin slice of material that contain active and/or inert ingredient(s).","Wafer Dosage Form | WAFER | Wafer | Wafer Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707315","Category for Inclusion and or Exclusion","C49480","A collection of criteria on which subjects are evaluated and that must be met by all study subjects.","Category for Inclusion and or Exclusion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704712","Can - object","C43180","A cylindrical vessel, usually made of metal.","Can | CAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272696","Not Done","C49484","Indicates a task, process or examination that has either not been initiated or not been completed.","Not Done | NOT DONE",,,,,,,,,,,,,,,"4301433","Not done",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448227","Caudad","C60642","Backwards; in a direction toward the tail or posterior extremity of the body.","Caudad | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205096","Cephalad","C60645","Forwards; towards the head or anterior extremity of the body.","Cephalad | ",,,,,,,,,,,,,,,"4283694","Cephalic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710068","Sex of Study Group","C49696","The specific sex, either male, female, or mixed of the subject group being studied.","Sex of Study Group | SEXPOP | Sex of Participants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883168","Stationary Beam Radiation Therapy","C60646","Radiation therapy without displacement of one or more mechanical axes relative to the patient during irradiation.","Stationary Beam Radiation Therapy | Fixed Beam | Fixed Beam Radiation | Fixed Beam Radiation Therapy | Stationary Beam Radiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439536","Medium","C49507","Mid-way between small and large in number, quantity, magnitude or extent.","Medium | MEDIUM",,,,,,,,,,,,,,,"4116857","Medium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016234","Flexible Fiberoptic Sigmoidoscopy","C51588","Examination of the luminal surface of the sigmoid colon, using a flexible fiberoptic endoscope.","Flexible Fiberoptic Sigmoidoscopy | ",,,,,,,,,,,,,,,"4196378","Flexible fiberoptic sigmoidoscopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709891","Relation to Reference Period","C49638","An abstraction belonging to or characteristic of a point or period to something that refers or points to an interval of time characterized by the occurrence of a certain condition, event, or phenomenon.","Relation to Reference Period | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707834","During or After","C49640","Within a certain period of time or after a certain point or period in time.","During or After | DURING/AFTER | During Or After",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027362","Age Related Group","C20587","Subgroups of populations based on age.","Age Related Group | Age Group | Age Group",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708480","In Utero","C49641","The period of time during which the embryo or fetus is present in the uterus of the female. Also describes the location of the embryo or fetus as being in the uterus in contrast to outside the uterus (ex utero).","In Utero | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021294","Preterm Infant","C49642","An age group comprised of infants less than 37 weeks, 0 days gestational age.","Preterm Infant | Premature Infant | Preterm Newborn Infant",,,,,,,,,,,,,,,"4217564","Premature infant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021289","Newborn","C16731","An age group comprised of infants during the first month after birth.","Newborn | NEONATE | Neonatal | Neonate",,,,,,,,,,,,,,,"4046034","Newborn",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708505","Infant And Toddler","C49643","An age group comprised of individuals between 28 days to 23 months of age.","Infant And Toddler | Infant And Toddler (28 Days to 23 Months)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707381","Children 2-11 Years Old","C49683","An age group comprised of individuals between 2 to 11 years of age.","Children 2-11 Years Old | Children (2-11)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706730","Adult 18-65 Years Old","C49685","An age group comprised of individuals from 18 years to 65 years of age.","Adult 18-65 Years Old | Adult (18-65)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825054","Elderly","C16268","An age group comprised of individuals 65 years of age and older.","Elderly | Aged 65 and Over | ELDERLY | Elderly (Over 65) | Senior Citizen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879526","Aberrant Crypt Foci","C60536","A larger than normal, microscopically elevated colonic crypt that may contain dysplastic epithelium.  It is considered as a possible precursor of colonic adenoma and carcinoma.","Aberrant Crypt Focus | ACF | Aberrant Crypt Foci | aberrant crypt foci",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882499","Provisional Registration","C60537","The act of enrolling, contingent upon satisfactory results obtained from additional screening.","Provisional Registration | Pre-Registration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707504","Control Type (study treatment comparator)","C49647","A characteristic of a treatment regimen employed as a comparator against which the study treatment is evaluated.","Control Type | TCNTRL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706408","Placebo Control","C49648","Use of an inactive compound identical in appearance to drug or treatment being tested in experimental research, which may or may not be known to the physician and/or subject, administered to distinguish between drug action and suggestive effect of the drug or treatment under study. The effects of the active drug or treatment are compared to the effects of the placebo.","Placebo Control | PLACEBO | Placebo | Placebo Comparator | placebo-controlled",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706449","Active Control","C49649","The use of a pharmacologic substance as a control within a treatment regimen where the pharmacologic properties of that substance are relevant to the condition being treated.","Active Control | ACTIVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707731","Diagnosis Group","C49650","A grouping of individuals on the basis of a shared procedure or disease, or lack thereof (e.g. healthy volunteers, type 2 diabetic subjects, subjects with renal cell cancer).  Standardized naming systems are available that define the groups within which a subject should be placed.","Diagnosis Group | TDIGRP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708335","Healthy Subject","C49651","An individual who is or becomes a participant in a research study and has no significant health-related issues.","Healthy Subject | Healthy Volunteer | healthy volunteer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710474","Trial Indication Type","C49652","The planned purpose of the therapy, device, or agent under study in the clinical study.","Clinical Study by Intent | Clinical Study Intent | Study Intent | TINDTP | Trial Indication Type | Trial Indication Type | Trial Intent | Trial Intent Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704656","Diagnosis Study","C49653","A type of study designed to evaluate method(s) aimed at identifying a disease or condition.","Diagnosis Study | DIAGNOSIS | Diagnostic Study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705416","Cure Study","C49654","A type of study protocol designed to evaluate intervention(s) aimed to cure a disease or condition.","Cure Study | CURE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706601","Adverse Effect Mitigation Study","C49655","A type of study designed to identify actions necessary to eliminate or reduce the risk to human life or well-being as a result of a particular medication, treatment regimen, procedure, or any other medical intervention.","Adverse Effect Mitigation Study | MITIGATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3161471","Treatment Study","C49656","A type of study protocol designed to evaluate intervention(s) for disease treatment.","Treatment Study | TREATMENT | Therapy Trial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706420","Prevention Study","C49657","A type of study protocol designed to evaluate intervention(s) for disease prevention.","Prevention Study | PREVENTION | Preventive Clinical Trial | Prophylaxis Study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710473","Trial Blinding Schema","C49658","The type of experimental design used to describe the level of awareness of the study subjects and/ or study personnel as it relates to the respective intervention(s) or assessments being observed, received or administered.","Trial Blinding Schema | Blinding Schema | Study Blinding Design | Study Blinding Schema | Study Masking Design | TBLIND | Trial Blinding Design | Trial Masking Design",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709323","Open Label Study","C49659","A type of study that stipulates both the health provider and the subject be aware of the drug or treatment assignment.","Open Label Study | OPEN LABEL | open label study | open-label | open-label study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242570","Single Blind Study","C28233","A type of study that stipulates the subject to be unaware of the drug or treatment assignment.","Single Blind Study | SINGLE BLIND | Single Masked | Single-Masked | single blind study | single-blind study | single-masked study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710065","Severity/Intensity Scale for Adverse Events","C49705","A scale that defines the degree or state of disease existing in a patient as a result of the occurrence of an adverse event.","Severity/Intensity Scale for Adverse Events | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516728","Common Terminology Criteria for Adverse Events","C49704","A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","Common Terminology Criteria for Adverse Events | CTC | CTCAE | CTCAE (Common Terminology Criterion for Adverse Events) | CTCAE Grades | Common Toxicity Criteria | Common Toxicity Criteria for Adverse Events | Standard Toxicity Grade",,,,,,,,,,,,,,,"46272971","Common Terminology Criteria for Adverse Events",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710475","Trial Phase","C48281","Clinical trials are broken into three or four phases: Phase I tests a new drug or treatment for safety in a small group; Phase II expands the study to a larger group of people; Phase III expands the study to an even larger group of people to measure whether the treatment actually benefits patients, and whether its benefits exceed its risks; and Phase IV takes place after the drug or treatment has been licensed and marketed.","Trial Phase | STUDY_PHASE | TPHASE | Trial Phase Classification | Trial Phase Classification | phase | phase (of clinical development)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706446","Trial Phase 2A","C49686","A clinical research protocol generally referred to as a pilot or feasibility trial that aims to prove the concept of the new intervention in question.","Phase IIa Trial | 2A | PHASE IIA TRIAL | Phase II A Trial | Trial Phase 2A | Trial Phase IIA | phase 2a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706096","Phase II B Trial","C49688","A clinical research protocol generally referred to as a well-controlled and pivotal trial that aims to prove the mechanism of action of the new intervention in question. A pivotal study will generally be well-controlled, randomized, of adequate size, and whenever possible, double-blind.","Phase IIb Trial | 2B | PHASE IIB TRIAL | Phase II B Trial | Trial Phase 2B | Trial Phase IIB | phase 2b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519042","Phase II/III Trial","C15694","A type of clinical study that combines elements characteristic of traditional Phase II and Phase III trials.","Phase II/III Trial | 2-3 | PHASE II/III TRIAL | Trial Phase 2-3 | Trial Phase 2/3 | phase II/III trial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706447","Trial Phase 3A","C49687","A classification typically assigned retrospectively to a Phase III trial after regulatory authorities determined the need for a Phase III B trial.","Phase IIIa Trial | 3A | PHASE IIIA TRIAL | Phase IIIA Trial | Trial Phase 3A | Trial Phase IIIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706097","Trial Phase 3B","C49689","A type of Phase III trial executed near the time of approval to elicit additional findings. This type of trial may be required as a condition of regulatory authority approval.","Phase IIIb Trial | 3B | PHASE IIIB TRIAL | Phase III B Trial | Trial Phase 3B | Trial Phase IIIB | phase 3b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706448","Trial Phase 5","C47865","Postmarketing surveillance is sometimes referred to as Phase V. See outcomes research.","Phase V Trial | 5 | PHASE V TRIAL | Trial Phase 5 | phase 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710478","Trial Summary Parameter","C49691","Individual characteristics of a clinical trial, e.g. description of trial design, trial blinding schema, and primary objective of trial.","Trial Summary Parameter | TSPARM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0680731","Clinical Trial Type","C49660","The type of clinical trial performed e.g. efficacy, safety.","Trial Type | Clinical Study by Product, Procedure, or Method Tested | TTYPE | Trial Scope | clinical trial type | clinical_trial_type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710375","Test Product Added to Existing Treatment","C49703","An indication that an investigational drug or substance has been added to the existing treatment regimen.","Test Product Added to Existing Treatment | ADDON | Added on to Existing Treatments",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706739","Adverse Event Dictionary","C49700","A reference source that provides meanings of words related to adverse events.","Adverse Event Dictionary | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707819","Drug Dictionary","C49701","A reference source that provides meanings of words related to drugs.","Drug Dictionary | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708967","Medical History Dictionary","C49702","A reference source that provides meanings of words related to medical history.","Medical History Dictionary | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710222","Study Stop Rule","C49698","The rule, regulation and/or condition that determines the point in time when a clinical trial will be terminated.","Study Stop Rule | STOPRULE | Study Stop Rules | Study Stop Rules",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709559","Planned Maximum Age of Subjects","C49694","The anticipated maximum age of the subjects to be entered in a clinical trial.","Planned Maximum Age of Subjects | AGEMAX | Maximum Age",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709560","Planned Minimum Age of Subjects","C49693","The anticipated minimum age of the subjects to be entered in a clinical trial.","Planned Minimum Age of Subjects | AGEMIN | Minimum Age",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706316","Length of Trial","C49697","The anticipated length of a clinical trial measured as a unit of time.","Trial Length | LENGTH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709561","Planned Subject Number","C49692","The number of subjects entered in a clinical trial.","Planned Subject Number | Anticipated Enrollment | Number of Study Subjects | PLANSUB | Planned Enrollment | Planned Number of Participants | Planned Number of Subjects | Target Accrual | Target Enrollment | target enrollment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705824","Trial Title","C49802","The name of a clinical trial.","Trial Title | Official Study Title | Study Title | TITLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705187","Safety Study","C49667","A study of the relative safety of treatment of a disease. Usually this is a Phase I or II trial.","Safety Study | SAFETY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707887","Efficacy Study","C49666","A study of the relative therapeutic efficacy of treatment of a disease. Usually this is a Phase II or III study.","Efficacy Study | EFFICACY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2355581","Therapeutic Equivalency Study","C49665","A study most often used to compare the efficacy of different formulations to treat a given disease.  It is the testing of an old versus a new formulation in healthy volunteers or subjects with the disease under study and usually in one dose.","Therapeutic Equivalency Study | BIO-EQUIVALENCE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706947","Bioavailability Study","C49664","A study of the degree to which, or rate at which, a drug or other substance is absorbed or becomes available at the site of physiological activity after administration.","Bioavailability Study | BIO-AVAILABILITY | BIOAVAILABILITY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL354156","Pharmacokinetic Study","C49663","A study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body.","Pharmacokinetic Study | PHARMACOKINETIC | PK Study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709518","Pharmacodynamic Study","C49662","A study of the biochemical and physiological effect of a drug and the mechanism of drug action and the relationship between drug concentration and effect.","Pharmacodynamic Study | PHARMACODYNAMIC | Pharmacodynamic (PD) study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709519","Pharmacogenomic Study","C49661","A study of identification and analysis of genomic variations that affect the efficacy of a drug. Pharmacogenomic studies can potentially be predictive of an individual's drug-response or adverse reactions or susceptibility to iatrogenic disorders, and may also reveal new targets that can help in the design of new drugs.","Pharmacogenomic Study | PHARMACOGENOMIC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519031","Pharmacoeconomic Study","C39493","A study that assesses the value associated with a given drug in therapeutic and economic terms. This type of study is multidisciplinary in nature and takes into consideration the social and economic costs (resource utilization costs including direct, indirect, and intangible costs) of drug therapy in addition to its direct therapeutic benefits. Analyses relate the difference in therapeutic benefits to the difference in costs between treatment alternatives.","Pharmacoeconomic Study | PHARMACOECONOMIC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710566","Units for Vital Signs Results","C49675","The unit used to record and describe the result of a test investigating a vital sign.","Units for Vital Signs Results | VITALS_RESULT_UNIT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456689","Kilogram per Square Meter","C49671","The SI derived unit of spread rate of a substance by mass, used also as a measure of area density and as a dose calculation unit.","Kilogram per Square Meter | Kilogram Per Square Meter | Kilogram per Meter Squared | Kilogram/Square Meter | kg/m2 | kg/mg2 | kilogram per meter squared | kilogram(s)/square meter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439237","Degree Celsius","C42559","A unit of temperature of the temperature scale designed so that the freezing point of water is 0 degrees and the boiling point is 100 degrees at standard atmospheric pressure. The current official definition of the Celsius sets 0.01 C to be at the triple point of water and a degree to be 1/273.16 of the difference in temperature between the triple point of water and absolute zero. One degree Celsius represents the same temperature difference as one Kelvin.","Degree Celsius | C | Cel | Celsius | Celsius Degree | Degree C | Degree Centigrade | celsius temperature | degree Celsius",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456628","Degree Fahrenheit","C44277","A unit of temperature of the temperature scale designed so that the freezing point of water is 32 degrees and the boiling point is 212 degrees, placing the boiling and melting points of water 180 degrees apart. One degree Fahrenheit is 5/9ths of a kelvin (or of a degree Celsius), and minus 40 degrees Fahrenheit is equal to minus 40 degrees Celsius.","Degree Fahrenheit | Degree F | F | Fahrenheit | [degF] | degree Fahrenheit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439386","Breaths per Minute","C49674","The number of breaths (inhalation and exhalation) taken per minute time.","Breaths per Minute | Breaths/Minute | bpm | breaths/min | cycles/min | {BREATHS}/min | {breaths}/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439208","Gram","C48155","The metric unit of mass equal to one thousandth of a kilogram. One gram equals approximately 15.432 grains or 0.035 273 966 ounce.","Gram | GRAM | g | gm | gram | gram(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0560037","Ohm","C42554","A unit of electrical resistance equal to the resistance between two points on a conductor when a potential difference of one volt between them produces a current of one ampere. Ohm is also used to measure impedance and reactance for complex resistance. A measurement in ohms is the reciprocal of a measurement in siemens.","Ohm | ohm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439219","Pound","C48531","The traditional unit of mass. By international agreement, one avoirdupois pound is equal to exactly 0.453 592 37 kilogram, 16 ounces, or 1.215 28 troy pounds.","Pound | Avoirdupois Pound | LB | POUND | Pounds | [lb_av] | lb | lb_av | pound",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439204","Inch","C48500","A traditional unit of length equal to 1/12 of a foot or 2.54 centimeters.","Inch | INCH | Inch International | Inches | [in_i] | in | inch",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448531","Millimeter of Mercury","C49670","A non-SI unit of pressure equal to 133,332 Pa or 1.316E10-3 standard atmosphere. Use of this unit is generally deprecated by ISO and IUPAC.","Millimeter of Mercury | Torr | millimeter of mercury | mmHG | mmHg | mm[Hg]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439385","Beats per Minute","C49673","The number of heartbeats measured per minute time.","Beats per Minute | BPM | Beats/Minute | Heart Beats per Minute | beat/min | beats/min | bpm | {BEATS}/min | {beats}/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709367","Oval","C48345","The shape of either an oval or an ellipse.  See also TEAR.","Oval | OVAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523207","Hematoxylin and Eosin Staining Method","C23011","Hematoxylin-and-eosin, or H&E, is a routine staining procedure of tissue sections. This staining method uses two separate dyes, one staining the nucleus and the other staining the cytoplasm and connective tissue. Hematoxylin is a dark purplish dye that stains the chromatin (nuclear material) within the nucleus. Eosin is an orangish-pink to red dye that stains the cytoplasmic material including connective tissue and collagen.","Hematoxylin and Eosin Staining Method | H and E | H and E Staining | H and E Staining Method | H&E | H&E Stain | H&E Staining | H&E Staining Method | HEMATOXYLIN AND EOSIN STAIN | Haemotoxylin and Eosin (H&E) | Hematoxylin and Eosin | Hematoxylin and Eosin Staining",,,,,,,,,,,,,,,"4014506","Hematoxylin and eosin stain method",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013230","Investigational New Drug","C49135","A new drug or biological drug that is used in a clinical investigation. The term also includes a biological product that is used in vitro for diagnostic purposes.","Investigational New Drug | IND | Investigational Agent | Investigational Drug | experimental drug | investigational agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1327622","Regulatory Process","C48805","A process that acts to control the rate or manner in which another process progresses or a product is formed.","Regulatory Process | Regulation | Regulation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL333395","Pouch","C43200","A flexible container used to protect or hold one or more doses of a drug product (e.g. a pouch into which oral contraceptive blister packs are inserted, and an overwrap pouch for large volume parenterals).","Pouch | POUCH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227822","Parametrium","C12320","The subserous connective tissue of the pelvic floor of the supracervical portion of the uterus. The parametrium extends laterally between the layers of the broad ligament.","Parametrium | PARAMETRIUM | Parametrium, NOS | Structure of parametrium (body structure)",,,,,,,,,,,,,,,"4163989","Structure of parametrium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512268","Grants and Contracts, NIH","C18820","Monetary awards made by NIH for research and support services.","Grants and Contracts, NIH | NIH, Grants and Contracts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880644","Extramural Nodule","C60696","A small aggregate of cells found in adipose tissues, particularly those attached to the colon where the architectural details of the lymph node cannot be identified with certainty under the microscope.  It may represent a lymph node completely replaced by metastatic cancer.","Extramural Nodule | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879550","Activity Code","C60756","The designated category assigned by the National Institutes of Health to a specific funding mechanism for an extramural research activity.","Activity Code | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0429170","Active Caries","C60712","Tooth decay that is increasing in size or scope.","Active Caries | ",,,,,,,,,,,,,,,"46270633","Active caries",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1879673","Air-Drying","C60713","Drying by exposure to forced air.","Air-Drying | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0876934","Neuropathology","C18479","The branch of pathology concerned with diseases and disorders of the nervous system.","Neuropathology | ",,,,,,,,,,,,,,,"4215130","Neuropathology",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0457166","Class V Surface","C60748","The gingival margins of the tooth surfaces.","Class V Surface | Class V | Tooth Class V Surface",,,,,,,,,,,,,,,"4080722","Class 5",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0949177","White Spot Lesion","C60714","A chalky white area that appears on a tooth surface indicating the presence of decalcified enamel and the potential to advance to cavitation.","White Spot Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011330","Dental Calculus","C60715","Mineralized deposit that forms on the teeth or dental prostheses.","Dental Calculus | ",,,,,,,,,,,,,,,"4069451","Dental calculus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1880281","Dental Explorer","C60716","A dental hand-held instrument that is used for exploring the tooth surface.","Dental Explorer | ",,,,,,,,,,,,,,,"45771935","Dental explorer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011360","Dental Fissure","C60717","Grooves or clefts in the surface of a tooth.","Dental Fissure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0399059","Dental Restoration","C60718","Replacement or reconstruction of a lost tooth structure.","Dental Restoration | ",,,,,,,,,,,,,,,"4071006","Restoration of tooth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011413","Permanent Dental Restoration","C60719","A replacement for a lost tooth structure designed for continued or prolonged use.","Permanent Dental Restoration | Final Dental Restoration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011414","Temporary Dental Restoration","C60720","Reconstruction of a tooth or part of a tooth which is designed to seal the tooth and maintain its position until a permanent restoration is done.","Temporary Dental Restoration | Temporization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880284","Dental Treatment Plan","C60747","An outline of the clinical steps in the care of a dental patient that may include specific services to be delivered, the frequency of services, expected duration/timing, and costs.","Dental Treatment Plan | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0493998","Fiber Optic Transilluminator","C60721","A light, with glass or plastic fibers which have special optical properties usually attached to a dental handpiece that is intended to illuminate oral structures.","Fiber Optic Transilluminator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1184544","Gingival Margin","C60722","The crest of the gingiva surrounding a tooth.","Gingival Margin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881363","Laser Fluorescence","C60724","A method used to aid in the detection of tooth decay by measuring fluorescence using a laser.","Laser Fluorescence | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029164","Oral Hygiene","C60725","The practice of keeping the mouth, teeth, and gums clean and healthy to prevent disease, as by regular brushing and flossing and visits to a dentist.","Oral Hygiene | Dental Hygiene",,,,,,,,,,,,,,,"37397340","Mouth care",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011389","Dental Plaque","C60726","A biofilm that contains numerous microorganisms that adheres to the teeth.","Dental Plaque | Plaque | Plaque",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448814","Radiograph","C60727","An image produced on a radiosensitive surface by x-ray radiation that has penetrated and passed through a structure.","Radiograph | Image | RT Image | RTIMAGE | Radiogram | Radiographs | Radiotherapy Image | X-ray",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227056","Tooth 19","C60728","The first, permanent, six-year molar of the lower left arch as defined by the Universal tooth numbering system.","Tooth 19 | First Molar | Six-year Molar | Tooth #19",,,,,,,,,,,,,,,"3667180","Structure of permanent mandibular left first molar tooth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1881197","Individualized","C60729","Made for or directed or adjusted to a particular individual.","Individualized | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0543488","Interest","C60730","A state of curiosity or concern about or attention to something.","Interest | ",,,,,,,,,,,,,,,"4023037","Interested",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1828381","Advising","C60731","The act of giving information, suggestion, or recommendation to a group or individual.","Advising | ",,,,,,,,,,,,,,,"4310149","Recommendation - action",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026369","Third Molar","C60732","Any one of the rearmost molars on each side of the upper and lower jaw in humans.","Third Molar | Wisdom Tooth | third molar | wisdom tooth",,,,,,,,,,,,,,,"4243795","Structure of permanent third molar tooth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0348070","Permanent Tooth","C33313","Any of the 32 teeth that replace the deciduous teeth of early childhood.","Permanent Tooth | ",,,,,,,,,,,,,,,"4243781","Structure of permanent tooth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2746058","BlackBerry Device","C60790","A wireless handheld device from Research In Motion (RIM) that supports e-mail, mobile telephone, text messaging, web browsing and other wireless information services.","BlackBerry | BlackBerry Device | BlackBerry PDA | BlackBerry Personal Digital Assistant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880669","Facsimile Machine","C60789","A machine which scans and transmits via telephone, fixed graphic material including pictures, text, or images.","Facsimile Machine | Facsimile | Fax | Fax Machine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1136360","Mobile Telephone","C60786","Mobile communications system that uses a combination of radio wave transmission and conventional telephone switching to permit telephone communication to and from mobile users within a specified area.","Mobile Telephone | Mobile Phone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1136359","Cellular Phone","C60787","A hand-held mobile radiotelephone for use in an area divided into small sections (cells), each with its own short-range transmitter/receiver","Cellular Telephone | Cell | Cell Phone | Cell-phone | Cellphone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882977","Satellite Telephone","C60788","A mobile phone that communicates directly with orbiting communications satellites. Depending on the architecture of a particular system, coverage may include the entire Earth, or only specific regions.","Satellite Telephone | Satellite Phone | Satphone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0445078","Magnifier","C60803","An optical device that enlarges the apparent size of an image or object.","Magnifier | ",,,,,,,,,,,,,,,"4142852","Optical near vision magnifier",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023416","Leukapheresis","C15269","A procedure that collects white blood cells from the peripheral blood while returning the rest to the donor.","Leukapheresis | LEUKAPHERESIS | Leukocyte Adsorptive Apheresis | Leukocytopheresis | Therapeutic Leukopheresis | White Blood Cell Reduction Apheresis | leukapheresis",,,,,,,,,,,,,,,"4298124","Leukopheresis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332575","Erythema","C26901","Red discoloration of the skin caused by infectious agents, inflammation, drug hypersensitivity, or underlying disease.","Erythema | Redness | erythema",,,,,,,,,,,,,,,"137193|4323847","Erythema|Erythema",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0024808","Marijuana","C26659","Any part of, or extract from, the female hemp plant Cannabis sativa.  Marijuana contains cannabinoids, substances with hallucinogenic, psychoactive, and addictive properties.  This agent has potential use for treating cancer pain and cachexia. (NCI04)","Marijuana | CANNABIS SATIVA SUBSP. INDICA TOP | Cannabis | marijuana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0594375","Irinotecan Hydrochloride","C1381","The hydrochloride salt of a semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.  Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme.  One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death.  Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.","Irinotecan Hydrochloride | CPT 11 | CPT-11 | CPT11 | Campto | Camptosar | Camptothecin 11 | Camptothecin-11 | IRINOTECAN HYDROCHLORIDE | Irinomedac | Irinotecan Hydrochloride Trihydrate | Irinotecan Monohydrochloride Trihydrate | U 101440E | U-101440E | U101440E | irinotecan hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086996","Socioeconomic Factors","C17468","Characteristics of a person such as education and occupation, used to describe the person's position in stratification systems, access to services, etc.","Socioeconomic Factors | Measured Social Factor | Socioeconomic Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523807","Oxygen Saturation Measurement","C60832","The measurement of the ratio of oxygenated hemoglobin to total hemoglobin in the blood.","Oxygen Saturation Measurement | Blood Oxygen Saturation | Hemoglobin Saturation | Hemoglobin Saturation Measurement | O2 Saturation | OXYSAT | Oximetry | Oxygen Content Measurement | Oxygen Saturation | Oxygen Saturation | Vital Signs – Oxygen Saturation | oxygen saturation test",,,,,,,,,,,,,,,"4020553","Oxygen saturation measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0718407","Miconazole Nitrate","C29257","The nitrate salt form of miconazole, an antifungal synthetic derivative of imidazole and used in the treatment of candidal skin infections, Miconazole selectively affects the integrity of fungal cell membranes, high in ergosterol content and different in composition from mammalian cells membranes. (NCI04)","Miconazole Nitrate | 1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole Mononitrate | MICONAZOLE NITRATE | Micatin | Monistat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522685","Mouse Plasmacytoma","C21631","No Value Exists","Mouse Plasmacytoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796350","18q","C13383","Distal (long) arm of chromosome 18","18q | Chromosome 18 Distal Arm | Chromosome 18 Long Arm | Chromosome 18q",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205344","Absolute","C45829","Complete and without restriction or qualification; something that does not depend on anything else; not relative.","Absolute | ABSOLUTE | Absolute Value",,,,,,,,,,,,,,,"4210327","Absolute",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0444505","Peak","C48054","The most extreme possible amount or value; the highest point.","Peak | ",,,,,,,,,,,,,,,"4114683","Peak",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037354","Smallpox","C35027","A condition that is caused by infection with Variola, and that is characterized by small, raised bumps.","Smallpox | ",,,,,,,,,,,,,,,"134573","Smallpox",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0257766","SILV protein, human","C41037","Melanocyte protein PMEL (661 aa, ~70 kDa) is encoded by the human PMEL gene. This protein plays a role in melanogenesis.","Melanocyte Protein PMEL | 95 kDa Melanocyte-Specific Secreted Glycoprotein | ME20 | ME20-M | ME20-M/ME20-S | ME20M | ME20M/ME20S | Melanocyte Lineage-Specific Antigen gp100 | Melanocyte Lineage-Specific Antigen gp100 | Melanocyte Protein 17 | Melanocyte Protein MEL17 | Melanocyte Protein Mel 17 | Melanocyte Protein PMEL17 | Melanocyte Protein Pmel 17 | Melanocyte Protein Pmel 17 | Melanocytes Lineage-Specific Antigen gp100 | Melanoma-Associated ME20 Antigen | Melanosomal Matrix Protein17 | P1 | P100 | PMEL | PMEL17 | Premelanosome Protein | SI | SIL | SILV | Silver Homolog | Silver Like | Silver Locus Protein Homolog | gp100",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221912","Cutaneous","C13316","Involving the skin.","Cutaneous | cutaneous",,,,,,,,,,,,,,,"42538083","Cutaneous",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266071","Pancreatic Intraductal Papillary-Mucinous Neoplasm","C38342","A usually slow-growing epithelial neoplasm with ductal differentiation that arises from the exocrine pancreas and grows mostly within the pancreatic ducts. Grossly, it is characterized by the presence of intraductal masses. Morphologically, there is proliferation of mucin-producing cells within the pancreatic ducts, intraductal accumulation of mucin, and a papillary growth pattern. It may be associated with the presence of an invasive carcinoma. It usually occurs in older patients. Signs and symptoms include epigastric pain, weight loss, jaundice, chronic pancreatitis, and diabetes mellitus.","Pancreatic Intraductal Papillary-Mucinous Neoplasm | Pancreatic IPMN | Pancreatic Intraductal Papillary-Mucinous Tumor",,,,,,,,,,,,,,,"37111370","Intraductal papillary mucinous neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708943","Match","C54116","An exact duplicate; coinciding in characteristics; similar or consistent.","Match | Matched | Matching",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879893","Bone Conduction Assessment","C60916","A test of the transmission of sound to the inner ear through the bones of the skull. This testing can measure functionality of the inner ear independent of the functionality of the outer and middle ears.","Bone Conduction Assessment | Bone Conduction Hearing Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883165","Static Admittance","C60917","The maximum compliance (mobility) of the middle ear system (i.e., the greatest amount of acoustic energy absorbed by the middle ear system (the vertical peak of the tympanogram tracing).","Static Admittance | Tympanic Static Admittance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0680063","Offspring","C42708","A first-generation, biological descendant of any age.","Offspring | Biological Child | CHILD, BIOLOGICAL | Child | Children | Human, Child | Progeny | progeny",,,,,,,,,,,,,,,"4051272","Child of",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1559081","Adverse Event Associated with Death","C53787","An adverse event resulting in death.","Adverse Event Associated with Death | DEATH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018681","Headache","C34661","Pain in various parts of the head, not confined to the area of distribution of any nerve.","Headache | Cephalalgia | Cephalgia | Headaches",,,,,,,,,,,,,,,"378253","Headache",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004604","Back Pain","C41830","Painful sensation in the back region.","Back Pain | Back pain",,,,,,,,,,,,,,,"134736","Backache",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3805780","Arthralgia","C50464","Pain in a joint.","Arthralgia | Arthrodynia | Joint Pain | arthralgia",,,,,,,,,,,,,,,"77074","Joint pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0915342","FOLFOX Regimen","C11197","One of several chemotherapy regimens that include leucovorin calcium (calcium folinate), 5-fluorouracil and oxaliplatin and which may be used in the treatment of advanced-stage and metastatic colorectal cancer. FOLFOX regimens differ in agent dosing and administration schedule and include FOLFOX 4, FOLFOX 6, modified FOLFOX 6 (mFOLFOX 6) and FOLFOX 7.","FOLFOX Regimen | CF/5-FU/L-OHP | FOLFOX | FOLFOX chronotherapy | FOLFOX regimen | Fluorouracil/Leucovorin Calcium/Oxaliplatin | Fluorouracil/Leucovorin Calcium/Oxaliplatin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0184301","Vial","C41275","A small, often stoppered glass or plastic bottle for holding fluids.","Vial | Phial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707246","Cancer Bioinformatics Grid","C49046","A voluntary network or grid connecting individuals and institutions to enable the sharing of data and tools, creating a World Wide Web of cancer research. The goal is to speed the delivery of innovative approaches for the prevention and treatment of cancer. The infrastructure and tools created by caBIG also have broad utility outside the cancer community. caBIG is being developed under the leadership of the National Cancer Institute's Center for Bioinformatics.","Cancer Bioinformatics Grid | caBIG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707248","NCI Cancer Imaging Program","C49047","The mission of the Cancer Imaging Program, National Cancer Institute, is to promote and support Cancer-related basic, translational and clinical research in imaging sciences and technology, and integration and application of these imaging discoveries and developments to the understanding of cancer biology and to the clinical management of cancer and cancer risk.","Cancer Imaging Program | CIP | National Cancer Institute Cancer Imaging Program",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1631280","Quadrant","C61106","One quarter of a circle. In anatomy, one part of an area divided into quarters for descriptive purposes.","Quadrant | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514559","Protein Overexpression","C18211","Synthesis of excess polypeptide within the cell. Overexpression is often due to the amplification or deregulation of the gene which encodes the gene product.","Protein Overexpression | Overexpression | overexpress",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1171892","Vascular Endothelial Growth Factor A, Human","C20450","Vascular endothelial growth factor A (232 aa, ~27 kDa) is encoded by the human VEGFA gene. This protein plays a role in both cell proliferation and angiogenesis.","Vascular Endothelial Growth Factor A | VEGF | VEGF-A | VEGF121 | VEGF145 | VEGF148 | VEGF165 | VEGF183 | VEGF189 | VEGF206 | VPF | Vascular Endothelial Growth Factor | Vascular Endothelial Growth Factor | Vascular Permeability Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0215848","Hypoxia-Inducible Factor 1","C17690","Hypoxia-inducible factor-1 (HIF1) is a transcription factor found in mammalian cells cultured under reduced oxygen tension that plays an essential role in cellular and systemic homeostatic responses to hypoxia. HIF1 is a heterodimer composed of a 120-kD HIF1-alpha subunit complexed with a 91- to 94-kD HIF1-beta subunit.","Hypoxia-Inducible Factor-1 | HIF-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280449","Secondary Acute Myeloid Leukemia","C25765","An acute myeloid leukemia arising from prior myelodysplastic syndrome, myeloproliferative neoplasm, or myelodysplastic/myeloproliferative neoplasm, or as a result of previous exposure to alkylating agents or topoisomerase II inhibitors.","Secondary Acute Myeloid Leukemia | SECONDARY_AML | Secondary AGL | Secondary AML | Secondary Acute Granulocytic Leukemia | Secondary Acute Myeloblastic Leukemia | Secondary Acute Myelogenous Leukemia | Secondary Acute Myeloid Leukemia (AML)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0555047","Marriage","C48033","The social institution involving legal and/or religious sanction whereby men and women are joined together for the purpose of founding a family unit; the state of being a married couple.","Marriage | Marital | Married",,,,,,,,,,,,,,,"4052602","Marriage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018956","Hematopoietic Stem Cell","C12551","Primitive blood cells derived from embryonic mesenchyme capable of differentiating into any of the blood cell line progenitor cells (erythroblasts, young granulocytic series cells, megakaryocytes, etc.)","Hematopoietic Stem Cell | Ferrata cell | HPC | HSC | HSCs | Hematohistioblast | Hematopoietic Progenitor Cell | Hematopoietic Progenitor Cells | Hematopoietic Stem Cells | Hemohistioblast",,,,,,,,,,,,,,,"4301929","Hematopoietic stem cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041971","Urethra Neoplasm","C3428","A benign or malignant neoplasm that affects the urethra.  Urethral carcinoma is a representative example.","Urethra Neoplasm | Neoplasm of Urethra | Neoplasm of the Urethra | Neoplasms. Urethra | Tumor of Urethra | Tumor of the Urethra | Tumors. Urethra | Urethra Neoplasms | Urethra Tumor | Urethra Tumors | Urethral Neoplasm | Urethral Neoplasms | Urethral Tumor | Urethral Tumors",,,,,,,,,,,,,,,"4131001","Neoplasm of urethra",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709900","Renal Pelvis and Ureter","C54419","The upper tract of the renal system. The renal pelvis is the large cavity in the middle of each kidney. Urine drains from each kidney through a long tube called the ureter, into the bladder, where it is stored until it is passed from the body through the urethra.","Renal Pelvis and Ureter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004285","Audiology","C61153","The study of hearing, including the diagnosis and treatment of hearing defects.","Audiology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0870883","Metabolite","C61154","Any substance involved in metabolism, either as a product of metabolism or as necessary for metabolism.","Metabolite | metabolite",,,,,,,,,,,,,,,"35624497","Metabolite",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1336528","Superficial Lesion","C36109","A lesion with limited invasion of deeper tissues.","Superficial Lesion | Superficial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882454","Preparative Regimen","C61155","The chemotherapy or radiation given prior to blood, marrow, cord blood transplant, or cell infusion to kill diseased cells and make space for the healthy new graft and/or suppress the immune system so rejection does not occur.","Preparative Regimen | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1184738","Regional Lymph Node","C49018","A lymph node that drains lymph from a region of interest.","Regional Lymph Node | LYMPH NODE, REGIONAL | Lymph Node(s) Regional | Lymph Node, Regional | REGIONAL LYMPH NODE | Regional Lymph Nodes | Regional lymph node | regional lymph node",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1301355","Myelodysplastic/Myeloproliferative Neoplasm","C27262","A category of clonal hematopoietic disorders that have both myelodysplastic and myeloproliferative features at the time of initial presentation.","Myelodysplastic/Myeloproliferative Neoplasm | MDS-MPD | MDS/MPD | MDS/MPN | MPD-MDS | MPD/MDS | Myelodysplastic/Myeloproliferative Disease | Myelodysplastic/Myeloproliferative Disease | Myelodysplastic/Myeloproliferative Diseases | Myelodysplastic/Myeloproliferative Disorder | Myelodysplastic/Myeloproliferative Disorders | Myeloproliferative/Myelodysplastic Disorders | Myeloproliferative/Myelodysplastic Syndromes",,,,,,,,,,,,,,,"40492268|4265010","Myelodysplastic/myeloproliferative disease|Myelodysplastic/myeloproliferative disease",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3554554","Aplastic Anemia","C2870","Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors.","Aplastic Anemia | Aplastic anemia, unspecified | aplastic anemia",,,,,,,,,,,,,,,"137829","Aplastic anemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4013832","Autoimmune Disease","C2889","A disorder resulting from loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to his own tissue constituents. It may be systemic (e.g., systemic lupus erythematosus), or organ specific, (e.g., thyroiditis).","Autoimmune Disease | Autoimmune Disorder | Autoimmune disease | Autoimmune disorder | Autoimmune_condition | autoimmune disease",,,,,,,,,,,,,,,"434621","Autoimmune disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0151854","Abnormal Platelet","C37038","A platelet characterized by a structural or functional abnormality.","Abnormal Platelet | Atypical Platelet",,,,,,,,,,,,,,,"4133293","Abnormal platelet",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0278845","Graft versus host disease prophylaxis/therapy","C15448","Therapy to prevent or treat graft vs host disease.","Graft Versus Host Disease Prophylaxis/Therapy | GVHD prophylaxis/therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336527","Non-Muscle Invasive Bladder Carcinoma","C27474","An infiltrating carcinoma of the bladder that has not invaded into the bladder muscularis propria.","Non-Muscle Invasive Bladder Carcinoma | NMIBC | Non-Muscle Invasive Bladder Cancer | Superficial Bladder Cancer | Superficial Bladder Cancer | Superficial Bladder Carcinoma | Superficial Bladder Carcinoma | Superficial Urinary Bladder Cancer | Superficial Urinary Bladder Carcinoma",,,,,,,,,,,,,,,"4322388","Carcinoma of urinary bladder, superficial",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1642967","Diagnostic Procedure","C18020","Any procedure or test to diagnose a disease or disorder.","Diagnostic Procedure | DIAGNOSTIC TEST | Diagnostic | Diagnostic Method | Diagnostic Technique | Diagnostic Test | Evaluation Basis of Disease Status | diagnostic procedure | diagnostic technique",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510898","Animal Sources","C18634","Indicates that a product is derived from an animal.","Animal Sources | Animal-derived indirectly | Derivation, Extraction, Animal Source",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007584","Cell Count","C48938","A procedure to determine the number of cells in a sample.","Cell Count | CELL COUNT | CELLS | Cells | Total Cells | cell count | cell_count",,,,,,,,,,,,,,,"4038498","Cell count",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL000755","Preventive Intervention","C15843","Therapeutic, nutritional, environmental, social and/or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease.","Preventive Intervention | PREVENTATIVE | PRYLX | Prevention | Prevention Measures | Prophylactic | Prophylaxis | prevention | prophylaxis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710187","Statement","C49154","A verbal and/or written message that asserts, affirms, or declares something.","Statement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705273","Mathematical Operator","C54025","A symbol or mathematical function that represents a specific action. For example, a plus sign (+) is an operator that represents addition. The basic mathematic operators are + addition, - subtraction,* multiplication,/ division. In addition to these operators, many programs and programming languages recognize other operators that allow you to manipulate numbers and text in more sophisticated ways. For example, Boolean operators enable you to test the truth or falsity of conditions, and relational operators let you compare one value to another.","Mathematical Operator | Function | Operator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0347982","Mole per Liter","C48555","A unit of concentration (molarity unit) equal to one mole of solute per one liter of solution.","Mole per Liter | MOLAR | Millimole per Milliliter | Molar | Molarity-Based Dosing Unit | millimole(s)/millilitre | mmol/mL | mmol/ml | mol/L | mol/l | mole per liter | mole(s)/litre",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040435","Dental Disorder","C35077","A non-neoplastic or neoplastic (benign or malignant) disorder affecting the teeth.","Dental Disorder | Dental Condition | Tooth Disorder",,,,,,,,,,,,,,,"4122115","Tooth disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706256","Clinical Study Case","C49152","A problem requiring investigation.","Case | Clinical Study Case | case",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009219","Coding","C45971","The activity of implementing rules that are used to map the elements of one set onto the elements of another set, usually on a one-to-one basis.","Coding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0312586","Polyclonal Antibody","C61381","A heterogeneous antibody derived from a host organism, typically produced by immunization of a suitable mammal with an antigen which induces B-lymphocytes to produce IgG immunoglobulins specific for the antigen. The resulting collection of antibodies have specificity for different epitopes of the antigen.","Polyclonal Antibody | ",,,,,,,,,,,,,,,"4148844","Polyclonal antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0065879","Megestrol Acetate","C1156","The acetate salt form of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone with potential anti-estrogenic and antineoplastic activity. Mimicking the action of progesterone, megestrol acetate binds to and activates nuclear progesterone receptors in the reproductive system, and causes the ligand-receptor complex to be translocated to the nucleus where it binds to and promotes expression of target genes. This leads to an alteration in protein synthesis, which modulates cell growth of reproductive tissues. Due to the negative feedback mechanism seen with progesterone, megestrol also blocks luteinizing hormone (LH) release from the pituitary gland, thereby leading to an inhibition of ovulation and an alteration in the cervical mucus and endometrium. Furthermore, without stimulation of LH, estrogen release from the ovaries is stopped, hence impedes the growth of estrogen-sensitive tumor cells.","Megestrol Acetate | (9beta,10alpha)-17-(Acetyloxy)-6-methylpregna-4,6-diene-3,20-dione | 17 Alpha-acetoxy-6-methylpregna-4,6-diene-3,20-dione | 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione Acetate | 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate | 17.alpha.-Acetoxy-6-methylpregna-4,6-diene-3,20-dione | 6-Dehydro-6-methyl-17 alpha-acetoxyprogesterone | 6-Dehydro-6-methyl-17.alpha.-acetoxyprogesterone | 6-Methyl-6-dehydro-17.alpha.-acetoxyprogesterone | 6-Methyl-delta-4,6-pregnadien-17 alpha-ol-3,20-dione Acetate | BDH 1298 | BDH-1298 | MEGESTROL ACETATE | Maygace | Megace | Megestat | Megestil | Niagestin | Ovaban | Pallace | SC 10363 | SC-10363",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026019","Electron Microscopy","C16854","Any form of microscopy in which the interactions of electrons with the specimens are used to provide information about the final structure of that specimen.","Electron Microscopy | ",,,,,,,,,,,,,,,"4250635","Electron microscopic study",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0444440","Internal Mammary Lymph Node","C32853","Any of the lymph nodes of the breast located under the ribcage, near the sternum.","Internal Mammary Lymph Node | INTERNAL MAMMARY LYMPH NODE | Internal mammary lymph node group (body structure) | LYMPH NODE, MAMMARY GLAND | Lymph Node(s) Internal Mammary | Structure of parasternal lymph node (body structure) | internal mammary lymph node | nodus parasternale | parasternal lymph node | parasternal node",,,,,,,,,,,,,"UBERON:0035219","parasternal lymph node","4219616","Structure of parasternal lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705492","Missing","C54031","Not existing; not able to be found.","Missing | Missed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004448","Awareness","C54070","Knowing that something exists, or having knowledge or experience of a particular thing; having special interest in or experience of something and so being well informed of what is happening in that subject at the present time.","Awareness | Aware",,,,,,,,,,,,,,,"4207026","Cognitive function: awareness",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1555721","Substitution - ActClass","C54071","The act of putting one thing or person in the place of another.","Substitution | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009669","confidentiality","C16466","Treatment of information so that it is not divulged in ways that are inconsistent with the understanding of the original disclosure. Particularly, the ethical principle or legal right that a physician or other health professional will hold secret all information relating to a patient, unless the patient gives consent permitting disclosure.","Confidentiality | confidentiality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518000","Lot (entire collection)","C41396","A defined quantity of manufactured material or product produced in a single manufacturing process or series of process steps so that it reasonably is expected to be homogeneous.","Lot | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448538","Stability","C54072","The quality of being free from change or variation or not taking part readily in chemical change.","Stability | Stable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021162","Income","C41150","A gain or recurrent benefit during a period of time, usually measured in money that derives from capital or labor.","Income | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020052","Household","C41194","A social unit comprised of one or more individuals living together (all of whom need not be related) in the same dwelling, who aggregate and share their incomes.","Household | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1550720","Prefix","C54066","An affix occurring at or before the beginning of a word or name.","Prefix | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448742","Suffix","C49106","An affix occurring at the end of a word, word base, phrase, or name.","Suffix | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029247","Nonprofit Organization","C54073","An organization whose primary objective is to support some issue or matter of private interest or public concern for non-commercial purposes. Nonprofits generally do not operate to generate profit, and this characteristic is popularly considered to be the defining characterisitic of such organizations. However, a non-profit organization may accept, hold and disburse money and other things of value. It may also legally and ethically trade at a profit. The extent to which it can generate income may be constrained, or the use of those profits may be restricted.","Nonprofit Organization | Commercial Organization | NPO | Non-profit | Non-profit Organization | Nonprofit | Nonprofit Group | Not for Profit Organization",,,,,,,,,,,,,,,"762943","Non-profit organization",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1301860","Legal","C54074","To meet the requirements under law; not in violation of law or anything related to the law.","Legal | ",,,,,,,,,,,,,,,"4134564","Legal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039371","Taxes","C54075","A charge against a citizen's person or property or activity for the support of government.","Tax | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707806","Domain Name","C54076","An internet address in alphabetic form. Domain names must have at least 2 parts: the part on the left which names the organization, and the part on the right which identifies the highest subdomain, such as the country (e.g., fr for France, uk for United Kingdom) or the type of organization (e.g., com for commercial, edu for educational).","Domain Name | domain name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707626","DUNS Number","C54080","The Dun and Bradstreet D-U-N-S Number is a non-indicative, nine-digit number assigned to each business location in the D&B database having a unique, separate, and distinct operation, and is maintained solely by D&B. The D&B D-U-N-S Number is used by industries and organizations around the world as a global standard for business identification and tracking.","DUNS Number | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1321605","Patient Compliance","C39490","The extent to which a patient conforms to medical advice regarding prescribed regimen, lifestyle, dietary changes, follow-up schedule and other recommendations.","Patient Compliance | Compliance | Compliant | compliance",,,,,,,,,,,,,,,"4234517","Compliance behavior",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516720","Commercial or Non-CTEP IND Agent","C38471","An investigational new drug that does not come from the CTEP program.","Commercial or Non-CTEP IND Agent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0681842","Prediction","C54156","An extrapolation of given data into the future.","Prediction | Predicted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085425","AdEERS","C17443","A Web application developed for the electronic submission of Expedited Reports to the NCI for serious and/or unexpected Adverse Events, deaths, and other events defined in the NCI Guidelines: Adverse Event Reporting Requirements for NCI Investigational Agents","Adverse Drug Event Reporting System | AdEERS | Adverse Drug Experience Reporting System | Adverse Drug Experience Reporting System | Adverse Event Expedited Reporting System | Adverse Event Reporting System | CTEP AERS | CTEP Adverse Event Reporting System | Cancer Therapy Evaluation Program Adverse Event Reporting System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041714","Food and Drug Administration","C17237","One of the agencies of the U.S. Department of Health and Human Services. It assures the safety of foods and cosmetics, and the safety and efficacy of pharmaceuticals, biological products, radiation emitting products, medical devices, and also, animal feed and drugs.","Food and Drug Administration | FDA | Food and Drug Administration (FDA)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009361","Colloids","C32345","A mixture of microscopic particles suspended in some sort of liquid medium.","Colloid | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522669","Recombinant Tumor Necrosis Factor-Alpha","C913","A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine tumor necrosis factor-alpha with antineoplastic properties.  Tumor necrosis factor-alpha binds to and activates 'death receptors' on the cell surface, resulting in apoptosis and cell death by the p53-independent extrinsic pathway. This agent also disrupts tumor vascularization. (NCI04)","Recombinant Tumor Necrosis Factor-Alpha | Cachectin | SONERMIN | TNF-Alpha | TNFA | Tumor Necrosis Factor (TNF-alpha)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3839366","Perimenopausal","C15692","Describes the time in a woman's life as she approaches menopause. This is usually three to five years before menopause and is often marked by irregular menstrual periods and many of the symptoms of menopause, including hot flashes, mood swings, night sweats, vaginal dryness, trouble concentrating, and infertility.","Perimenopausal | Menopause Transitional Phase | PERIMENOPAUSAL | perimenopausal",,,,,,,,,,,,,,,"45757505","Perimenopausal state",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882142","Office of Biotechnology Activities","C61428","An office within the National Institutes of Health that monitors scientific progress in basic and clinical research involving recombinant DNA and human gene transfer, advises federal departments and agencies on ways to minimize the possibility that knowledge and technologies emanating from vitally important biological research will be misused to threaten public health or national security, provides policy advice to the Department of Health and Human Services on the broad array of complex medical, ethical, legal, and social issues raised by the development and use of genetic technologies and Xenotransplantation.","Office of Biotechnology Activities | OBA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039590","Testicular Neoplasm","C3404","A benign or malignant neoplasm that affects the testis.  Representative examples include fibroma, thecoma, benign Sertoli cell tumor, seminoma, embryonal carcinoma, sarcoma, leukemia, and lymphoma.","Testicular Neoplasm | Neoplasm of Testis | Neoplasm of the Testis | Testicular Tumor | Tumor of Testis | Tumor of the Testis",,,,,,,,,,,,,,,"4129900","Neoplasm of testis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003461","Anus","C43362","The lower opening of the digestive tract, lying in the cleft between the buttocks, through which fecal matter is extruded.","Anus | ANUS | Anal | Anus, NOS | LARGE INTESTINE, ANUS | anal | anal opening | anal orifice | anus | opening of terminal part of digestive tract | opening of terminal part of digestive tractanal orifice",,,,,,,,,,,,,"UBERON:0001245","anus","4202233","Anal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883163","Standard Industrial Classification","C61433","A code scheme established to promote uniformity and comparability of data collected and published by agencies within the U.S. government, state agencies, trade associations, and research organizations. It was developed as an establishment based industry classification system that classified each establishment (defined as a single physical location at which economic activity occurs) according to its primary activity. The SIC covered the entire field of economic activities by defining industries in accordance with the composition and structure of the economy. It has been replaced by the North American Industry Classification System (NAICS).","Standard Industrial Classification | SIC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242793","Disease-Free Survival","C17751","The length of time after treatment for a specific disease during which a patient survives with no sign of recurrence of the disease.","Disease-Free Survival | Disease Free | disease-free survival",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0150098","Data Set","C47824","A collection of related data records.","Data Set | Dataset | dataset",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448842","North American Industry Classification System","C61432","The North American Industry Classification System (NAICS) was developed as the standard for use by Federal statistical agencies in classifying business establishments for the collection, analysis, and publication of statistical data related to the business economy of the U.S. It was developed in cooperation with the statistical agencies of Canada and Mexico to establish a 3-country standard that allows for a high level of comparability in business statistics among the three countries. It replaces the Standard Industrial Classification (SIC).","North American Industry Classification System | NAICS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706085","Block Dosage Form","C42891","A solid or semi-solid in the shape of a square or rectangle.","Block Dosage Form | BLOCK | Block | Block Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880111","Cloth Dosage Form","C60884","A solid composed active and/or inert ingredient(s) in a woven absorbent material.","Cloth Dosage Form | CLOTH | Cloth | Cloth Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880165","Concentrate Dosage Form","C60891","A solution or suspension composed of active and/or inert ingredient(s) with increased strength in a reduced volume, which is usually diluted prior to administration.","Concentrated Dosage Form | CONC | CONCENTRATE | Conc | Concentrate | Concentrate Dosage Form | Concentrated | Concentrated Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879759","Augmented Cream Dosage Form","C60897","A cream that is modified to enhance the release of active and/or inert ingredient(s).","Augmented Cream Dosage Form | Aug Cream | Augmented Cream | Augmented Cream Dose Form | CREAM AUG | CREAM, AUGMENTED | Cream, Augmented | Cream, augmented",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085104","Drug Delivery Systems","C17423","Modern technology, distributed with or as a part of a drug product that allows for the uniform release or targeting of drugs to the body.","Drug Delivery System | DDS | DRUG DELIVERY SYSTEM | Drug Delivery | Drug Delivery Systems | Drug delivery system | SYSTEM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880639","Extended Release Fiber Dosage Form","C60926","A solid in the shape of a slender, elongated thread that is designed to release active and/or inert ingredient(s) at a controlled, prolonged rate so as to reduce dosing frequency.","Extended Release Fiber Dosage Form | ER Fiber | Extended Release Fiber | Extended Release Fiber Dose Form | FIBER ER | FIBER, EXTENDED RELEASE | Fiber, Extended Release | Fiber, extended release | XR Fiber",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880396","Dosage Form for Solution","C60927","A substance intended for administration as a solution.","Dosage Form for Solution | Dosage Form For Solution | Dose Form for Solution | FOR SOL | FOR SOLUTION | For Solution | For solution | for Sol | for Solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880397","Dosage Form for Suspension","C60928","A substance intended for administration as a suspension.","Dosage Form for Suspension | Dosage Form For Suspension | Dose Form for Suspension | FOR SUSP | FOR SUSPENSION | For Suspension | For suspension | for Susp | for Suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880638","Extended Release Dosage Form for Suspension","C60929","A substance that forms a suspension upon reconstitution and designed to release active and/or inert ingredient(s) at a controlled, prolonged rate so as to reduce dosing frequency.","Extended Release Dosage Form for Suspension | ER for Susp | Extended Release Dosage Form For Suspension | Extended Release Dose Form for Suspension | Extended Release for Suspension | FOR SUSP ER | FOR SUSPENSION, EXTENDED RELEASE | For Suspension, Extended Release | For suspension, extended release | XR for Susp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1720499","Metered Gel Dosage Form","C60930","A gel contained in a device with valves that permits the release of a uniform dose of gel that composed of active and/or inert ingredient(s) upon activation.","Metered Gel Dosage Form | GEL MET | GEL, METERED | Gel, Metered | Gel, metered | Metered Gel | Metered Gel Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881214","Liposomal Injection Dosage Form","C60931","A substance composed of active and/or inert ingredient(s) encapsulated in liposomes and intended for injection.","Liposomal Injection Dosage Form | INJ LIPOS | INJECTABLE, LIPOSOMAL | Injectable, Liposomal | Injectable, liposomal | Liposomal Inj | Liposomal Injection | Liposomal Injection Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1743766","Insert Dosage Form","C60933","A solid or semi-solid intended for administration within the body.","Insert Dosage Form | INSERT | Insert | Insert Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1720232","Extended Release Liquid Dosage Form","C60934","A solution or suspension that is designed to release active and/or inert ingredient(s) at a controlled, prolonged rate so as to reduce dosing frequency.","Extended Release Liquid Dosage Form | ER Liq | Extended Release Liquid | Extended Release Liquid Dose Form | LIQ ER | LIQUID, EXTENDED RELEASE | Liquid, Extended Release | Liquid, extended release | XR Liq",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879760","Augmented Lotion Dosage Form","C60957","A lotion that is modified to enhance the release of active and/or inert ingredient(s).","Augmented Lotion Dosage Form | Aug Lotion | Augmented Lotion | Augmented Lotion Dose Form | LOTION AUG | LOTION, AUGMENTED | Lotion, Augmented | Lotion, augmented",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881454","Lotion Shampoo Dosage Form","C60958","A lotion composed of anionic surfactant intended for administration to the hair or scalp.","Lotion Shampoo Dosage Form | LOTION SHAMPOO | LOTION/SHAMPOO | Lotion Shampoo | Lotion Shampoo Dose Form | Lotion/Shampoo | Lotion/shampoo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879761","Augmented Ointment Dosage Form","C60984","An ointment that is modified to enhance the release of active and/or inert ingredient(s).","Augmented Ointment Dosage Form | Aug Oint | Augmented Ointment | Augmented Ointment Dose Form | OINTMENT AUG | OINTMENT, AUGMENTED | Ointment, Augmented | Ointment, augmented",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1720601","Pastille Dosage Form","C60985","A solid or semi-solid composed of a lozenge, that contains active and/or inert ingredient(s) that dissolves when sucked in the mouth.","Pastille Dosage Form | PASTILLE | Pastille | Pastille Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882953","Ring Dosage Form","C60988","A solid composed active and/or inert ingredient(s) of in the shape of a hoop.","Ring Dosage Form | RING | Ring | Ring Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880935","Gel Forming Drop Solution Dosage Form","C60994","A solution intended for administration in a drop-wise fashion; it becomes gelatinous upon administration.","Gel Forming Drop Solution Dosage Form | Gel Forming Drop Solution | Gel Forming Drop Solution Dose Form | Gel Forming Drops Solution Dosage Form | Gel Forming Gtt Sol | SOL GF DROPS | SOLUTION, GEL FORMING / DROPS | SOLUTION, GEL FORMING/DROPS | Solution, Gel Forming/Drops | Solution, gel forming / drops",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880415","Drop Solution Dosage Form","C60992","A solution intended for administration in a drop-wise fashion.","Drop Solution Dosage Form | Drop Sol | Drop Solution | Drop Solution Dose Form | Drops Solution Dosage Form | Gtt Sol | SOL DROPS | SOLUTION/ DROPS | SOLUTION/DROPS | Solution/ drops | Solution/Drops",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880416","Drop Suspension Dosage Form","C60995","A suspension intended for administration in a drop-wise fashion.","Drop Suspension Dosage Form | Drop Suspension | Drop Suspension Dose Form | Drops Susp | Drops Suspension Dosage Form | Gtt Susp | SUSP DROPS | SUSPENSION/DROPS | Suspension/Drops | Suspension/drops",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553202","Tablet Coated Particle Dosage Form","C60997","A tablet composed of a conglomerate of particles that contains active and/or inert ingredient(s) that have been individually covered with a coating.","Tablet Coated Particle Dosage Form | TAB COATED PART | TABLET, COATED PARTICLES | Tablet Coated Particle | Tablet Coated Particle Dose Form | Tablet Coated Particles Dosage Form | Tablet, Coated Particles | Tablet, coated particles",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1273630","Tablet For Suspension Dosage Form","C61005","A tablet that changes into a suspension when added to a liquid solution.","Tablet for Suspension Dosage Form | TAB DISP | TAB FOR SUSP | TABLET FOR SUSPENSION | TABLET, FOR SUSPENSION | Tab Disp | Tab for Susp | Tablet For Suspension | Tablet For Suspension Dosage Form | Tablet for Suspension | Tablet for Suspension Dose Form | Tablet, for Suspension | Tablet, for suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883262","Tablet for Solution Dosage Form","C61004","A tablet that changes into a solution when added to a liquid solvent.","Tablet for Solution Dosage Form | TAB FOR SOL | TABLET, FOR SOLUTION | Tab for Sol | Tablet For Solution Dosage Form | Tablet for Solution | Tablet for Solution Dose Form | Tablet, for Solution | Tablet, for solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883263","Orally Disintegrating Delayed Release Tablet Dosage Form","C61006","A tablet that disintegrates rapidly, usually within a matter of seconds, when placed upon the tongue but is also designed to impede the immediate release of the active and/or inert ingredient(s) after administration.","Orally Disintegrating Delayed Release Tablet Dosage Form | Orally Disintegrating Delayed Release Tablet | TAB ORALLY DIS DR | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE | Tablet Orally Disintegrating Delayed Release Dosage Form | Tablet, Orally Disintegrating, Delayed Release | Tablet, orally disintegrating, delayed release | orally Disintegrating DR Tab | orally Disintegrating Delayed Release Tablet Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0232278","S3 Gallop","C61455","A finding which can be heard on auscultation of the heart in the setting of congestive heart failure. The sound of the S3 gallop, which immediately follows the second heart sound (S2) is thought to be produced by the sound of blood flowing into a noncompliant ventricle.","S3 Gallop | S3 | S3 GALLOP | S3 Heart Sound | Third Heart Sound | Third heart sound (S3) | Ventricular Gallop",,,,,,,,,,,,,,,"4175984","Protodiastolic gallop",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4013302","Cardiomegaly","C61453","Abnormal enlargement of the heart.","Cardiomegaly | Cardiomegaly, chamber enlargement",,,,,,,,,,,,,,,"314658","Cardiomegaly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0240859","Basilar Rales","C61454","Abnormal breath sounds (crackles) heard on auscultation only in the bases of the lungs. They indicate inflammation, fluid, or infection in the air sacs of the lung.","Basilar Rales | Basal Crepitations | Crackles | Crepitations | Rales",,,,,,,,,,,,,,,"4113000","Basal crepitations",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041348","Tubulin","C17219","Microtubules of the eukaryotic cytoskeleton perform essential and diverse functions and are composed of a heterodimer of alpha and beta tubulin. The genes encoding these microtubule constituents are part of the tubulin superfamily, which is composed of six distinct families. Genes from the alpha, beta and gamma tubulin families are found in all eukaryotes. The alpha and beta tubulins represent the major components of microtubules, while gamma tubulin plays a critical role in the nucleation of microtubule assembly. There are multiple alpha and beta tubulin genes and they are highly conserved among and between species. (from LocusLink)","Tubulin | tubulin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026255","Mitosis","C16864","The usual process of somatic reproduction of cells consisting of a sequence of modifications of the nucleus that result in the formation of two daughter cells with exactly the same chromosome and DNA content as that of the original cell. It is the process by which the body grows and replaces cells and is divided into four phases. In Prophase, paired chromosomes form, nuclear membrane disappears, the achromatic spindle appears, and polar bodies form. In Metaphase, chromosomes are arranged in the equatorial plane of the central spindle to form the monaster and chromosomes separate into exactly similar halves. In Anaphase, the two groups of daughter chromosomes separate and move along the fibers of the central spindle, each toward one of the asters, forming the diaster. In Telophase, the daughter chromosomes resolve themselves into a reticulum, the daughter nuclei are formed, and the cytoplasm divides forming two complete daughter cells.","Mitosis | Mitotic Process | mitosis | mitotic cycle",,,,,,,,,,,,,,,"4290076","Mitosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0232478","Ingestion","C28229","The act of taking food, medicines, and other substances into the body by mouth.","Ingestion | ingestion",,,,,,,,,,,,,,,"4008101","Ingestion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL353521","Lethargic","C50412","Characterized by a lack of vitality or energy.","Lethargic | Lethargy | Stuporous | Torpid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032219","Pleomorphism","C17000","Having different forms at different stages of the life cycle.","Pleomorphism | ",,,,,,,,,,,,,,,"4169885","Pleomorphism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007133","Papillary Carcinoma","C2927","A malignant epithelial neoplasm characterized by a papillary growth pattern. A papillary carcinoma may be composed of glandular cells (papillary adenocarcinoma), squamous cells (papillary squamous cell carcinoma), or transitional cells (papillary transitional cell carcinoma). Bladder carcinoma is a representative example of papillary transitional cell carcinoma.","Papillary Carcinoma | ","8050/3","Papillary carcinoma, NOS",,,,,,,,,,,,,"4093456","Papillary carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0035253","Resting","C28185","Freedom from activity.","Resting | Rest",,,,,,,,,,,,,,,"4121040","Rest",,,,,,,,,,,,,"--",,,,,,,,,"--"
,,"C61483","The motivational and/or affective state of annoyance resulting from being blocked, thwarted, disappointed or defeated.","Frustration | Frustrated",,,,,,,,,,,,,,,"4074627","Feeling frustrated",,,,,,,,,,,,,,,,,,,,,,"--"
"C1261045","Sacral Vertebra","C12853","One of the usually five fused vertebrae forming the triangular bone just below the lumbar vertebrae.","Sacral Vertebra | SACRAL VERTEBRA | Sacral Vertebrae | Sacral vertebra structure (body structure)",,,,,,,,,,,,,,,"4314430","Sacral vertebra structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0935882","Antisense Therapy","C16236","Treatment using nucleic acid oligomers to bind to specific mRNA to deter protein production and alter disease process.","Antisense Therapy | Antisense | Antisense Oligonucleotide Therapy | antisense oligonucleotide therapy | antisense therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0223865","Great Trochanter","C32698","A large, irregular, quadrilateral area of bone found at the neck of the femur.","Great Trochanter | GREAT TROCHANTER",,,,,,,,,,,,,,,"4148293","Structure of greater trochanter of femur",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4015486","Atrial Fibrillation","C50466","A disorder characterized by an electrocardiographic finding of a supraventricular arrhythmia characterized by the replacement of consistent P waves by rapid oscillations or fibrillatory waves that vary in size, shape and timing and are accompanied by an irregular ventricular response. (CDISC)","Atrial Fibrillation | AF | AFib | Atrial fibrillation",,,,,,,,,,,,,,,"313217","Atrial fibrillation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007430","Catheterization","C38045","A technique in which a hollow, flexible tube is used to drain body fluids or to introduce fluids into the body, or to examine or widen a narrowed vein or artery.","Catheterization | Catheter Insertion",,,,,,,,,,,,,,,"4164278","Catheterization",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007222","Cardiovascular Disorder","C2931","A non-neoplastic or neoplastic disorder affecting the heart or the vessels (arteries, veins and lymph vessels). Representative examples of non-neoplastic cardiovascular disorders are endocarditis and hypertension. Representative examples of neoplastic cardiovascular disorders are endocardial myxoma and angiosarcoma.","Cardiovascular Disorder | Cardiovascular Disease | Cardiovascular Disease (CVD) | Cardiovascular Disorder, NOS | Cardiovascular_Disease | Disorder of Cardiovascular System | Unspecified disorder of circulatory system",,,,,,,,,,,,,,,"134057","Disorder of cardiovascular system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0177804","Bone Mineral Density Test","C61545","A scanning procedure used to measure calcium and other minerals present in bone.","Bone Mineral Density Test | BMD | Bone Density Test | Bone Mineral Density | bone density | bone mass | bone mineral density",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042789","Sight","C38533","The faculty of vision, the perception of objects by the eye.","Sight | Ocular | Vision",,,,,,,,,,,,,,,"4094031","Visual function",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0262544","Lumbar Vertebral Fracture","C27035","A fracture of one of the lumbar vertebra.","Lumbar Vertebral Fracture | ",,,,,,,,,,,,,,,"4129394","Fracture of lumbar spine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242606","Oxidative Stress","C17741","A disturbance in the prooxidant-antioxidant balance in favor of the former, leading to potential damage. Indicators of oxidative stress include damaged DNA bases, protein oxidation products, and lipid peroxidation products.  The damage to biological tissues is caused by superoxide and other free radicals generated by many factors, including exposure to alcohol, medications, trauma, cold, toxins, and radiation or by antimicrobial cellular immunity, metabolic abnormality, or 'normal' aging; not synonymous with hypoxia or hyperoxia.  Oxidative stress promotes a range of degenerative disorders, including cancer, diabetes, premature aging, Alzheimer's, and many others.","Oxidative Stress | oxidative stress",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881379","Lineage","C60792","Descent in a line from a common progenitor or source.","Lineage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015815","Femoral Neck","C61563","The short, constricted portion of the thigh bone between the femur head and the trochanter.","Femoral Neck | FEMORAL NECK | Femoral Neck  | Neck of Femur | Structure of neck of femur (body structure)",,,,,,,,,,,,,,,"4105581","Structure of neck of femur",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001271","Actin","C16258","A globular subunit of microfilaments, highly conserved Actin is one of the most abundant proteins in eukaryotic cells. Monomeric actin, a slow ATPase composed of a 375 amino acid polypeptide chain, interacts with one molecule of ATP or ADP and contains high affinity and low affinity binding sites for divalent cations. Actin can quickly assemble into long microfilament polymers. In conjunction with myosin, actin is responsible for the contraction and relaxation of muscle.","Actin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1568555","Glutathione Peroxidase 1","C60309","Glutathione peroxidase 1 (203 aa, ~22 kDa) is encoded by the human GPX1 gene. This protein plays a role in glutathione metabolism, peroxide reduction and hemoglobin homeostasis.","Glutathione Peroxidase 1 | Cellular Glutathione Peroxidase | EC 1.11.1.9 | GPX1 | GPX1 Protein | GPx-1 | GSHPx-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1136257","Systematized Nomenclature of Medicine","C53489","A multiaxial, hierarchical classification system for diseases in man developed by the College of American Pathologists.","Systematized Nomenclature of Medicine | SNOMED | SNOMED (Systematized Nomenclature of Medicine)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017393","Genetic Marker","C16622","A segment of DNA with an identifiable physical location on a chromosome and whose inheritance can be followed.","Genetic Marker | genetic marker",,,,,,,,,,,,,,,"4049517","Genetic marker",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1314792","Etiology","C16390","The cause of a disease or abnormal condition.","Etiology | Causation | Cause | etiology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021798","Interphase Process","C16750","The interval between two successive cell divisions during which the chromosomes are not individually distinguishable. Interphase is considered the resting stage of the cell.","Interphase Process | Interphase | Interphase",,,,,,,,,,,,,,,"4238996","Interphase",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009247","Cohort Study","C15208","A research study that compares a particular outcome (such as lung cancer) in groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke compared with those who do not smoke).","Cohort Study | COHORT | cohort study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008659","Human Chromosome 17","C13212","The designation for each member of the seventeenth largest human autosomal chromosome pair. Chromosome 17 spans more than 81 million base pairs and represents between 2.5 and 3% of the total DNA in normal diploid cells.","Human Chromosome 17 | Chromosome 17 | Chromosome 17 | chr17",,,,,,,,,,,,,,,"4163254","Chromosome pair 17",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512894","International Prognostic Index","C20118","A list of five factors that help doctors assess how a non-Hodgkin lymphoma patient might respond to a certain treatment or predict the risk of disease recurrence and survival following therapy.  The factors are: 1) patient's age, 2) stage of disease: an indication of how localized or widespread is the disease, 3) LDH levels: serum levels often correlate with the amount of tumor in the body, 4) the number of extranodal, non-lymphatic sites found, 5) the patient's overall health. (from Lymphoma Research Foundation of America glossary (www.lymphoma.org))","International Prognostic Index | IPI | international prognostic index | international_prognostic_index",,,,,,,,,,,,,,,"37396673","International Prognostic Index",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0278956","performance status 2","C17846","Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours (Eastern Cooperative Oncology Group)","Zubrod Performance Status 2 | Karnofsky 60-70 | Performance Status 2 | Performance Status 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278957","Zubrod Performance Status 3","C17847","Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. (Eastern Cooperative Oncology Group)","Zubrod Performance Status 3 | Karnofsky 40-50 | Performance Status 3 | Performance Status 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278958","Zubrod Performance Status 4","C17848","Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair (Eastern Cooperative Oncology Group)","Zubrod Performance Status 4 | Karnofsky 20-30 | Performance Status 4 | Performance Status 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025568","Metaplasia","C3236","Transformation of a mature, normal cell or groups of mature cells to other forms of mature cells.  The capacity for malignant transformation of metaplastic cells is a subject of controversy.","Metaplasia | METAPLASIA | Metaplastic Change | metaplasia",,,,,,,,,,,,,,,"4070551","Metaplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883178","Subclone","C62037","A DNA clone generated by transferring a cloned DNA fragment from one plasmid to another.","Subclone | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879851","Bitewing Radiograph","C62057","A radiographic film that is positioned in the mouth by biting on a central tab or positioning wing.  Coronal images of the maxillary and mandibular teeth are recorded.","Bitewing Radiograph | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882337","Periodontal Probe","C62058","A calibrated dental instrument used to measure periodontal pocket depth and/or clinical attachment level at various locations around the teeth. May also be used for other measurements in the mouth.","Periodontal Probe | ",,,,,,,,,,,,,,,"45758179","Periodontal probe",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1549534","Mastication","C62062","The process by which food is torn or crushed by the teeth.","Mastication | Chew | Chewing | Masticate",,,,,,,,,,,,,,,"4003394","Mastication",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1880280","Dental Bonding Agent","C62092","An adhesive used to bond various materials to a tooth.","Dental Bonding Agent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515851","AML1-ETO Fusion Protein Expression","C37218","Expression of a fusion protein that results from a t(8;21)(q22;q22) translocation, which involves the human genes RUNX1 and RUNX1T1 and is associated with acute myeloid leukemia.","AML1-ETO Fusion Protein Expression | AML1/ETO Fusion Protein Expression | CBFalpha2-ETO Fusion Protein Expression | RUNX1-RUNX1T1 Fusion Protein Expression | RUNX1/RUNX1T1 Fusion Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516132","BCR-ABL1 Fusion Protein Expression","C36715","Bcr/abl is the gene rearrangement that is associated primarily with the disease chronic myelogenous leukemia and less frequently with acute lymphoblastic leukemia.  This rearrangement results in the formation of the BCR-ABL1 fusion protein.","BCR-ABL1 Fusion Protein Expression | BCR-ABL | BCR-ABL1 Fusion Protein Positive | BCR/ABL1 Fusion Protein Expression | BCR/ABL1 Fusion Protein Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515674","p190 Fusion Protein Expression","C36714","Expression of a fusion protein with an apparent molecular weight of 190 kilodaltons that results from a fusion of the human genes BCR and ABL1.","p190 Fusion Protein Expression | p190 BCR-ABL1 Fusion Protein Expression | p190 BCR/ABL1 Fusion Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515675","p210 Fusion Protein Expression","C36712","Expression of a fusion protein with an apparent molecular weight of 210 kilodaltons that results from a fusion of the human genes BCR and ABL1.","p210 Fusion Protein Expression | p210 BCR-ABL1 Fusion Protein Expression | p210 BCR/ABL1 Fusion Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515676","p230 Fusion Protein Expression","C36713","Expression of a fusion protein with an apparent molecular weight of 230 kilodaltons that results from a fusion of the human genes BCR and ABL1.","p230 Fusion Protein Expression | p230 BCR-ABL1 Fusion Protein Expression | p230 BCR/ABL1 Fusion Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515155","ETV6-RUNX1 Fusion Protein Expression","C37227","Expression of a fusion protein containing the helix-loop-helix domain encoded by the human ETV6 gene and the DNA-binding and transactivation domains encoded by the human RUNX1 gene as a result of a t(12;21)(p13; q22) translocation.","ETV6-RUNX1 Fusion Protein Expression | ETV6-CBFalpha2 Fusion Protein Expression | ETV6/RUNX1 Fusion Protein Expression | TEL-AML1 Fusion Protein Expression | TEL-AML1 Fusion Protein Expression | TEL/AML1 Fusion Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518798","PML-RARA Fusion Protein Expression","C37223","Expression of a fusion protein that results from a fusion of the human genes PML and RARA.","PML-RARA Fusion Protein Expression | PML-RAR | PML-RARa Fusion Protein Expression | PML-RARalpha Fusion Protein Expression | PML-RARalpha Fusion Protein Expression | PML/RARA Fusion Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518796","ZBTB16-RARA Fusion Protein Expression","C37220","A fusion protein encoded by a t(15;17) translocation, which involves the human genes ZBTB16 and RARA and is characteristic of acute promyelocytic leukemia. It is a transcriptional repressor with both gain-of-function and dominant-negative properties, resulting in transcriptional repression of retinoic acid and non-retinoic acid target genes and culminating in differentiation arrest.","ZBTB16-RARA Fusion Protein Expression | PLZF-RARalpha Fusion Protein Expression | PLZF-RARalpha Fusion Protein Expression | PLZF/RARA Fusion Protein Expression | ZBTB16/RARA Fusion Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512110","TCF3-PBX1 Fusion Protein Expression","C37226","Expression of a fusion protein that results from a t(1;19)(q23;p13) translocation, which involves the human genes E2A and PBX1 and is associated with B lymphoblastic leukemias.","TCF3-PBX1 Fusion Protein Expression | E2A-PBX1 Fusion Protein Expression | E2A-PBX1 Fusion Protein Expression | E2A/PBX1 Fusion Protein Expression | TCF3/PBX1 Fusion Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512144","EVI1/RUNX1 Fusion Protein Expression","C41074","Expression of a fusion protein that results from a t(3;21)(q26;q22) translocation, which involves the human genes MECOM and RUNX1 and is associated with chronic myelogenous leukemia.","MECOM-RUNX1 Fusion Protein Expression | EVI1-AML1 Fusion Protein Expression | EVI1-AML1 Fusion Protein Expression | EVI1/RUNX1 Fusion Protein Expression | MECOM-RUNX1 Fusion Protein Expression | MECOM/RUNX1 Fusion Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518128","MLL-AF4 Fusion Protein Expression","C37228","Expression of a fusion protein that results from the insertion mutation ins(5;11)(q31;q13q23), which involves the human genes KMT2A and AFF1 and is associated with acute lymphoblastic leukemia.","KMT2A-AFF1 Fusion Protein Expression | KMT2A-AF4 Fusion Protein Expression | KMT2A-AF4 Fusion Protein Expression | MLL-AF4 Fusion Protein Expression | MLL-AF4 Fusion Protein Expression | MLL-AFF1 Fusion Protein Expression | MLL-FEL Fusion Protein Expression | MLL/AF4 Fusion Protein Expression | MLL/AFF1 Fusion Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518129","MLL-AF9 Fusion Protein Expression","C38390","Expression of a fusion protein that results from a t(9;11)(p22;q23) translocation, which involves the human genes KMT2A and MLLT3 and is associated with many leukemias.","MLLT3-KMT2A Fusion Protein Expression | MLL-AF9 Fusion Protein Expression | MLL-AF9 Fusion Protein Expression | MLL-MLLT3 Fusion Protein Expression | MLL/AF9 Fusion Protein Expression | MLL/MLLT3 Fusion Protein Expression | MLLT3--KMT2A Fusion Protein Expression | MLLT3-MLL Fusion Protein Expression | MLLT3-MLL Fusion Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511408","CBFB-MYH11 Fusion Protein Expression","C37219","Expression of a fusion protein that results from an inversion or translocation, which involves the human genes CBFB and MYH11 and is associated with acute myeloid leukemias.","CBFB-MYH11 Fusion Protein Expression | CBFB/MYH11 Fusion Protein Expression | CBFbeta-MYH11 Fusion Protein Expression | CBFbeta-MYH11 Fusion Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707677","Dental Liner Material","C42795","Material applied to the dental tissue or to the tissue side of a denture to provide biological, chemical and physical protection.","Dental Liner | Dental Liner Material",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL364833","Sitting","C62122","The state or act of one who sits; the posture of one who occupies a seat.","Sitting | SITTING | Seated | Sit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600199","Cavity Liner","C62126","A material placed between the restoration and the tooth surface.","Cavity Liner | Liner",,,,,,,,,,,,,,,"45762071","Dental cavity liner",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1707793","Dispensing Bottle","C43170","A bottle that is used by the pharmacist to dispense the prescribed medication. It includes preparations for which a dropper accompanies the bottle.","Dispensing Bottle | BOTTLE, DISPENSING | Bottle, Dispensing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556084","French","C43854","Denotes the inhabitants of France, a person from there, or their descendants elsewhere.","French | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0277785","Dysfunction","C53526","Disturbance, impairment or abnormality of function.","Dysfunction | dysfunction",,,,,,,,,,,,,,,"4302528","Functional disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448715","Unifocal","C47862","Arising from, pertaining to, or having a single location.","Unifocal | ",,,,,,,,,,,,,,,"4126041","Unifocal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448710","Relative Value","C45830","Considered in comparison with something else; dependent on or interconnected with something else; not absolute.","Relative Value | Relative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039336","Gustation","C20620","The faculty of taste, distinguishing substances by means of the taste buds.","Gustation | Taste",,,,,,,,,,,,,,,"4265873|4296465","Taste, function|Finding of sense of taste",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2364135","Discomfort","C50535","A feeling of mental or physical uneasiness, pain, or distress.","Discomfort | ",,,,,,,,,,,,,,,"4090431","Discomfort",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0234421","Consciousness","C37929","The state of being alert, oriented, and responsive to the environment.","Consciousness | Conscious",,,,,,,,,,,,,,,"4024715","Consciousness related finding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3150182","Irritability","C50623","Excited response to stimuli.","Irritability | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0055633","Chromogranin A","C17284","Chromogranin-A (457 aa, ~51 kDa) is encoded by the human CHGA gene. This protein plays a role in the modulation of both blood pressure and pancreatic release of insulin.","Chromogranin-A | CHGA | CgA | Chromogranin A | Chromogranin A | PSP | Parathyroid Secretory Protein 1 | Pituitary Secretory Protein I | SP-I | Secretory Protein I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517488","Gene Family","C26004","A set of genes coding for diverse proteins which, by virtue of their high degree of sequence similarity, are believed to have evolved from a single ancestral gene.","Gene Family | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0679214","symbol","C54191","An arbitrary sign (written or printed) that has acquired a conventional significance.","Symbol | symbol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1285573","Genotyping","C45447","The determination of the DNA sequence of an individual.","Genotyping | GENOTYPE | Genotype Analysis | Genotype Assay",,,,,,,,,,,,,,,"4181037|45769413","Genotype determination|Genotype determination",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0039985","Chest Radiography","C38103","An x-ray examination of the chest.","Chest Radiography | Chest X-ray | Chest radiography | chest x-ray",,,,,,,,,,,,,,,"4163872","Plain chest X-ray",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009264","Cold","C62180","Having less heat energy than the object against which it is compared; the absence of heat.","Cold | Cold Temperature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0444519","Hot","C62181","Having more heat energy than the object against which it is compared.","Hot | Hot Temperature",,,,,,,,,,,,,,,"4141161","Hot",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1537081","sweet flavor","C62182","Having or resembling the taste of sugar.","Sweet | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0234830","Articulation","C62183","Movements of the mouth and airway that produce speech; the act of vocal expression.","Articulation | ",,,,,,,,,,,,,,,"42536485","Vocal articulation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0870433","Dissatisfaction","C62184","The feeling of being displeased and discontent.","Dissatisfaction | Dissatisfied",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882997","Self-conscious","C62186","Excessively and uncomfortably conscious of your appearance or behavior.","Self-conscious | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0679112","Embarrassment","C62187","An unpleasant emotional state experienced upon having an inadequacy, guilt, or socially unacceptable act or trait witnessed by or revealed to others.","Embarrassment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0522165","Relaxation","C62188","A state of refreshing tranquility; freedom from work, strain, or responsibility.","Relaxation | Relax | Relaxed",,,,,,,,,,,,,,,"4009706","Feeling calm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034786","Androgen Receptor","C17063","Androgen receptor (919 aa, ~99 kDa) is encoded by the human AR gene. This protein plays a role in the modulation of steroid-dependent gene transcription.","Androgen Receptor | AR | DHTR | Dihydrotestosterone Receptor | NR3C4 | Nuclear Receptor Subfamily 3 Group C Member 4",,,,,,,,,,,,,,,"4279150","Androgen receptor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0200728","Tissue Preparation or Processing Technique","C49337","Any of the steps that convert a fresh tissue to a specimen ready for microscopy.","Tissue Preparation or Processing Technique | Tissue Preparation | Tissue Processing Technique | Tissue Processing Technique",,,,,,,,,,,,,,,"4027857","Tissue processing technique",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332218","Difficulty","C62189","Something not easily done, accomplished, comprehended, or solved.","Difficulty | Difficult",,,,,,,,,,,,,,,"4200246","Difficult",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1711202","Stereotactic Biopsy","C51654","A biopsy procedure that uses 3-dimensional imaging to localize a lesion and guide the removal of a tissue sample.","Stereotactic Biopsy | stereotactic biopsy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029144","Optics","C16940","The branch of physics that describes the behavior and properties of light and the interaction of light with matter.","Optics | Optical",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0182400","Probe Device","C50121","A device designed to reach into a location for manipulating or sensing.","Probe Device | Device Probe | Probe | Probe Device Component",,,,,,,,,,,,,,,"4253067","Probe",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011429","Dentin","C32453","The hard portion of the tooth surrounding the pulp, covered by enamel on the crown and cementum on the root. Dentin is harder and denser than bone but softer than enamel.","Dentin | ",,,,,,,,,,,,,,,"4224331","Dentin structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020361","5-Hydroxyindoleacetic Acid","C28157","A breakdown product of serotonin that is excreted in the urine. Serotonin is a hormone found at high levels in many body tissues. Serotonin and 5HIAA are produced in excess amounts by carcinoid tumors, and levels of these substances may be measured in the urine to test for carcinoid tumors.","5-Hydroxyindoleacetic Acid | 5-HIAA | 5-HYDROXYINDOLE-3-ACETIC ACID | 5-hydroxyindoleacetic acid",,,,,,,,,,,,,,,"4122840","5-hydroxyindole acetic acid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0056097","Cold Agglutinin","C62221","An autoantibody against a red blood cell surface antigen that causes the cells to clump when the blood is cooled below the normal body temperature (the clumping is most pronounced at temperatures below 78 degrees). Presence of cold agglutinins may be indicative of mycoplasmal pneumonia, mononucleosis, mumps, measles, scarlet fever, some parasitic infections, cirrhosis of the liver, and some types of hemolytic anemia.","Cold Agglutinin | ",,,,,,,,,,,,,,,"4266493","Cold agglutinin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1880904","Gamma-Enolase","C62216","Gamma-enolase (434 aa, ~47 kDa) is encoded by the human ENO2 gene. This protein is involved in glycolysis, neurotrophy and neuroprotection.","Gamma-Enolase | 2-Phospho-D-Glycerate Hydro-Lyase | EC 4.2.1.11 | ENO2 | Enolase 2 | NSE | Neural Enolase | Neuron-Specific Enolase | Phosphopyruvate Hydratase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1381542","70% Ethyl Alcohol","C62218","An aqueous dilution of ethanol containing 70% ethanol by volume.","70% Ethyl Alcohol | 70% Ethanol | Alcohol, Ethyl 70% | Ethyl Alcohol, 70%",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0183957","Tissue Processor","C62219","An automated system used to process tissue specimens for examination through fixation, dehydration, and infiltration.","Tissue Processor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880198","Cure (remedy)","C62220","Serving or tending to restore health; a remedy.","Cure | CURATIVE | Curative | Curative - procedure intent | Cured | cure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2004491","Scar","C34483","A permanent mark left on the skin in the process of wound healing.","Scar | SCAR | Scar (morphologic abnormality) | Scarring",,,,,,,,,,,,,,,"4050007|4169984","Scar|Scar",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0949307","Formaldehyde Solution","C62229","A saturated solution of formaldehyde, water, and typically another agent, most commonly methanol. In its typical form, formalin is 37% formaldehyde by weight (40% by volume), 6-13% methanol, and the rest water.","Formaldehyde Solution | FORMALDEHYDE SOLUTION | Formalin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448846","Potential","C62230","The likelihood or possibility that a specific state or condition will exist or that an action will occur.","Potential | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0809762","Abstractor","C62231","A person who retrieves and summarizes information.","Abstractor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0559956","Replacement","C53610","The act of removing one thing and putting another thing in its place.","Replacement | REPLACEMENT | Replaced",,,,,,,,,,,,,,,"4086536","Replacement - action",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1412043","HUGO","C48690","An international organization of scientists involved in human genetics. Established in 1989 by a collection of the world's leading human geneticists, the primary ethos of the Human Genome Organisation is to promote and sustain international collaboration in the field of human genetics.","Human Genome Organisation | HUGO | Human Genome Organization | Human Genome Organization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706202","Search - action","C54117","The activity of looking thoroughly in order to find something or someone; an operation that determines whether one or more of a set of items has a specified property.","Search | Searched",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600678","Abstract Summary","C60765","A written summary of the important points of a scientific article.","Abstract | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0080142","Self-Examination","C15353","The inspection of one's own body, usually for signs of disease.","Self-Examination | Self-Surveillance",,,,,,,,,,,,,,,"4249868","Self-examination",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1456711","Sun Exposure","C17725","The exposure to incident light from the sun.","Sun Exposure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038818","Sunscreen","C851","A photoprotective topical substance for the skin that helps protect the skin against harmful UV radiation from the sun.","Sunscreen | Sunblock | sunscreen",,,,,,,,,,,,,,,"4190206","Sunscreen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3281209","Skin Carcinoma","C4914","A carcinoma that arises from the skin.  Representative examples are basal cell carcinoma and squamous cell carcinoma.","Skin Carcinoma | Carcinoma of Skin | Carcinoma of the Skin | Non-Melanoma Cancer of Skin | Non-Melanoma Cancer of the Skin | Non-Melanoma Skin Cancer | Non-melanoma Skin Cancer | Skin Cancer, Non-Melanoma | nonmelanoma skin cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706302","Phlebotomist","C53421","A person trained to collect blood for transfusion, analysis, or experimental testing.","Phlebotomist | PHLEBOTOMIST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883385","Treatment Assent","C62283","Agreement for treatment by a primary participant or recipient who is unable to legally consent to treatment; applies to minor children and adults lacking capacity to consent for themselves. In these circumstances agreement/assent will come from the participant and formal consent will come from a parent or a legally authorized representative.","Treatment Assent | Assent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880285","Dentin Desensitizer","C62293","A substance applied directly to the surface of a tooth to reduce sensitivity.","Dentin Desensitizer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152276","Granulocytic Sarcoma","C35815","A tumor mass composed of myeloblasts, neutrophils and neutrophil precursors.  Granulocytic sarcoma is the most common type of myeloid sarcoma.  (WHO, 2001)","Granulocytic Sarcoma | Granulocytic sarcoma | SARCOMA, GRANULOCYTIC, MALIGNANT | granulocytic sarcoma",,,,,,,,,,,,,,,"4148718","Myeloid sarcoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1881083","Hyperocclusion","C62294","Contact of a tooth or restoration such that it encrouches on the interocclusal freeway space.","Hyperocclusion | ",,,,,,,,,,,,,,,"44782491","Hyperocclusion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1947975","Sedative Filling (dental material)","C62295","A restoration intended to relieve pain.","Sedative Filling | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881073","Hybrid Composite","C62296","A tooth restorative material that contains both microfill composites and macrofill composites, and contains a range of particle sizes between .6 and 1 micron in diameter.","Hybrid Composite | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0673997","Flowable Composite","C62297","A tooth restorative material that is formulated to create a loose, free-flowing mix.","Flowable Composite | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880282","Dental Percussion Procedure","C62298","A diagnostic test performed on a tooth by tapping on the crown with a dental instrument.","Dental Percussion | PERCUSSION | Percussion | Percussion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0341000","Occlusal Adjustment","C62300","Reshaping a tooth surface to modify the dental occlusion.","Occlusal Adjustment | ",,,,,,,,,,,,,,,"4122351","Occlusal adjustment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011382","Dental Occlusion","C62301","The spatial relation of the upper and lower teeth when the jaws are closed.","Dental Occlusion | Bite | Occlusion",,,,,,,,,,,,,,,"4099234","Dental occlusion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1879688","Ambient","C62306","In or of the immediately surrounding area; relating to the immediate surroundings of something.","Ambient | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL369385","Ulcer","C3426","A circumscribed inflammatory and often suppurating lesion on the skin or an internal mucous surface resulting in necrosis of tissue.","Ulcer | ULCER | Ulcerated | Ulceration | Ulcerative | Ulcers | ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1959609","Erosion","C50443","An eating away or breakdown of any type of external or internal human tissue including but not limited to skin, teeth, mucosa, or somatic, which involves only the outer tissue layer. When tissue surrounds an implanted device, the tissue breakdown may result in migration and loss of the implant material and may result in further complications such as infection or abscess.","Erosion | EROSION",,,,,,,,,,,,,,,"4049449","Superficial ulcer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205251","Low","C54722","A minimum level or position or degree; less than normal in degree, intensity or amount.","Low | Low-level",,,,,,,,,,,,,,,"4267416","Low",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1515724","t(15;17)(q22;q12)","C27758","A chromosomal translocation associated with creation of a fusion between the PML and RARA genes. It is seen in variants of acute promyelocytic leukemia.","t(15;17)(q24;q21) | t(15;17)(q22;q12) | t(15;17)(q22;q12) | t(15;17)(q22;q12) PML::RARA | t(15;17)(q22;q21) | t(15;17)(q24.1;q21.2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018926","Hematemesis","C37964","Vomiting blood.","Hematemesis | ",,,,,,,,,,,,,,,"26727","Hematemesis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882162","Oral Health Impact Profile","C62359","Measures a person's perceptions of the social impact of oral disorders on their well-being; measures self-reported dysfunction, discomfort and disability attributed to oral conditions.","Oral Health Impact Profile | Health Profile | OHIP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0445204","Preoperative","C54732","Relating to or occurring during the period immediately before a surgical operation.","Preoperative | Pre-Operative | Pre-operative",,,,,,,,,,,,,,,"4119031","Preoperative",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709566","Platelet Count 20000","C53266","Indicates a platelet count of at least 20,000 per cubic millimeter.","Platelet Count 20000 | Platelet Count 20,000 per cubic millimeter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709567","Platelet Count 50000","C53267","Indicates a platelet count of at least 50,000 per cubic millimeter.","Platelet Count 50000 | Platelet Count 50,000 per cubic millimeter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709854","Recipient","C53268","A person who gets something.","Recipient | recipient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0472699","Hematopoietic Cell Transplantation","C15431","A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases.","Hematopoietic Cell Transplantation | HCT | HEMATOPOIETIC STEM CELL TRANSPLANT | HSCT | Hematopoietic Stem Cell Infusion | Hematopoietic Stem Cell Transplantation | SCT | Stem Cell Transplant | Stem Cell Transplantation | Stem Cell Transplantation, NOS | stem cell transplantation",,,,,,,,,,,,,,,"4120445","Hemopoietic stem cell transplant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1511983","Disease Marker","C18329","Specific molecular signature of disease, physiological measurement, genotype structural or functional characteristic, metabolic changes, or other determinant that may simplify the diagnostic process, make diagnoses more accurate, distinguish different causes of disease, or enable physicians to make diagnoses before symptoms appear and to track disease progression.","Disease Marker | Marker, Disease | Markers, Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514474","Prognostic Factor","C18959","The general personal and health characteristics that have a bearing on the course of a disease and its eventual outcome.","Prognostic Factor | General Prognostic Factor | Prognostic/Survival Factor | prognostic factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0200633","Neutrophil Count","C51950","A test to determine the number of neutrophils in a sample of blood.","Neutrophil Count | Neutrophils",,,,,,,,,,,,,,,"4148615","Neutrophil count",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709221","Neutrophil Count 1000","C53271","Indicates a neutrophil count of at least 1000 per cubic millimeter.","Neutrophil Count 1000 | ANC Greater than or Equal to 1000 per Cubic Millimeter | ANC Greater than or Equal to 1000 per Microliter | ANC Greater than or Equal to 1000/mm3 | ANC Greater than or Equal to 1000/uL | Absolute Neutrophil Count Greater than or Equal to 1000 per Cubic Millimeter | Absolute Neutrophil Count Greater than or Equal to 1000 per Microliter | Absolute Neutrophil Count Greater than or Equal to 1000/mm3 | Absolute Neutrophil Count Greater than or Equal to 1000/ul | Neutrophil Count 1000 per cubic millimeter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001288","Activity of Daily Living","C53291","Those physical activities which are required for our daily existence. These include personal maintenance activities and activities for maintenance of our living space, as well as activities related to independent living.","Activity of Daily Living | ADL | Daily Activity | Household Activity | Household Activity | activities of daily living",,,,,,,,,,,,,,,"4043369","Activity of daily living",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024826","Marketing","C53292","The commercial processes involved in promoting and selling and distributing a product or service.","Marketing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008109","Chimera organism","C14194","An organism with tissues derived from two or more genotypes; composed of parts that are of different origin.","Chimera | Chimeric | chimeric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704814","Item Collection","C45261","A group of items of the same type, gathered for display or study.","Item Collection | Collection | Collection Object",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1524020","Radiation Ionizing Radiotherapy","C15846","The use of ionizing radiation to kill cancer cells","Radiation Ionizing Radiotherapy | Radiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708062","Finished Pharmaceutical Product","C42639","A pharmaceutical product that has undergone all stages of production and testing, including packaging in its final container and labelling.","Finished Pharmaceutical Product | Pharmaceutical Product | pharmaceutical product",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705275","Operator - device","C48036","A person that operates some apparatus or machine.","Operator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0587894","Maintenance","C53297","The act of sustaining something in its current form or proper condition; upkeep.","Maintenance | Maintain",,,,,,,,,,,,,,,"4299719","Maintenance - action",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1555310","holder - ParticipationType","C53299","A person who has physical possession or legal rights to something.","Holder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880177","Contribution","C61412","The part played by somebody or something in bringing about an end or result.","Contribution | Contibution | Contribute | Contributing | Contributory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705922","Pharmaceutical Strength","C53294","The content of an active ingredient expressed quantitatively per dosage unit, per unit of volume, or per unit of weight, according to the pharmaceutical dose form.","Pharmaceutical Strength | PSTRG | Strength | strength",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1550600","Ingredient","C51981","That which enters into a compound, or is a component part of any combination or mixture; an element; a constituent.","Ingredient | ingredient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511229","Blood and Blood Products","C19448","Whole blood or any of the components into which it can be separated.","Blood and Blood Products | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281342","Bone Marrow Ablation","C15569","The destruction of bone marrow using radiation or drugs.","Bone Marrow Ablation | bone marrow ablation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010406","Cryoprotective Agent","C53306","A substance that is used to protect from the effects of freezing, largely by preventing large ice crystals from forming.","Cryoprotective Agent | Cryoprotectant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019629","Histocompatibility Antigens Class I","C20706","Found on virtually every cell, MHC (Major Histocompatibility, HLA) Class-I (Antigens) Proteins consist of noncovalently bound polymorphic 44-kDa MHC membrane glycoprotein and nonpolymorphic 12-kDa b2-microglobulin. The HLA antigens are encoded by closely linked multiallelic genes of the HLA (MHC) complex, a region containing several genetic loci (HLA-A, -B, -C, -DP, -DQ, -DR, -MB, -MT, and -Te).","MHC Class I Protein | Class I MHC Protein | Complex Class 1 | Histocompatibility Antigen, Class I | Human Leukocyte Antigen | MHC Class I Molecule | Major Histocompatibility Complex Class 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0486616","Composition","C53414","The way in which something is made, especially in terms of its different parts; its constituents.","Composition | COMPOS | composition",,,,,,,,,,,,,,,"37116946","Composition (property)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1707432","Collection Facilitator","C53426","A substance used to increase the quality or quantity of a sample harvest.","Collection Facilitator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038528","Cell Fraction","C17169","Components of a cell produced by various separation techniques which, though they disrupt the delicate anatomy of a cell, preserve the structure and physiology of its functioning constituents for biochemical and ultrastructural analysis.","Cell Fraction | Fraction",,,,,,,,,,,,,,,"4236042","Subcellular structure, isolated by fractionation technique",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2355611","Suppressor effector T lymphocyte","C12544","T-lymphocytes that respond to signals from suppressor-inducer T-cells by inhibiting either cell-mediated immunity or antibody production by B-cells.","Suppressor-Effector T-Lymphocyte | Suppressor T Lymphocyte | Suppressor-Effector T-Cells | Suppressor-Effector T-Lymphocytes | T Suppressor Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332140","Clinical Diagnosis","C15607","A diagnosis made from a study of the signs and symptoms of a disease.","Clinical Diagnosis | ",,,,,,,,,,,,,,,"4309119","Clinical diagnosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0439211","Microgram","C48152","A metric unit of mass equal to one millionth of a gram or one thousandth of a milligram.","Microgram | MICROGRAM | mcg | microgram | microgram(s) | ug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439243","Microliter","C48153","A unit of volume accepted for use with the SI and equal to one millionth of a liter (10E-6 liter).","Microliter | (10E-3m)3 | (10^-3m)3 | 10E-6 L | Cubic Millimeter | MICROLITER | cu mm | mcL | microliter | microlitre(s) | mm3 | uL | ul",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707450","Common Security Module","C53639","Provides caBIG application developers with powerful security tools to allow application developers to integrate security with minimal coding effort.","Common Security Module | CSM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704775","Audit","C45269","A methodical examination or review of a condition or situation.","Audit | audit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079021","Biohazardous Substance","C1281","A biological or chemical substance that exerts toxic or pathologic effects on living entities.","Biohazardous Substance | Biohazard | Biohazard Substance",,,,,,,,,,,,,,,"4252719","Biohazardous material",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0439232","Minute","C48154","A unit measure of time equal to 60 seconds.","Minute | MINUTE | min | minute",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709160","Neoplastic","C45315","Exhibiting characteristics of independently proliferating cells, notably altered morphology, growth characteristics, and/or biochemical and molecular properties.","Neoplastic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1382104","Gel physical state","C45297","Jelly like material formed by the coagulation of a colloidal liquid.","Gel | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708639","Lane","C45311","A defined path with physical dimensions through which an object or substance may traverse.","Lane | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706688","Absorbance at 260nm","C48169","The quantity of 260nm light that is not transmitted through a substance or solution.","Absorbance at 260nm | A260 | OD260",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706689","Absorbance at 280nm","C48170","The quantity of 280nm light that is not transmitted through a substance or solution.","Absorbance at 280nm | A280 | OD280",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035705","28S Ribosomal RNA","C48171","The largest of the three RNA components of the mammalian ribosome.","28S Ribosomal RNA | 28S RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035703","18S Ribosomal RNA","C48172","The second largest of the three RNA components of the mammalian ribosome.","18S Ribosomal RNA | 18S RNA | 18S rRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705248","Component (part)","C48792","An artifact that is one of the individual parts of which a composite entity is made up; especially a part that can be separated from or attached to a system.","Element | Component | Element Part",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0180098","Container","C43186","An object that can be used to hold things.","Container | CONTAINER",,,,,,,,,,,,,,,"45768321","Container",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448709","Freezing","C48160","The act or event which causes the transition from a liquid to solid matter phase when the temperature is lowered.","Freezing | FREEZING | Freeze | Freeze Technique | Frozen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007703","Centrifugation","C16410","A process where a rotating machine exposes a specimen to centrifugal force. This process can be used to remove moisture from a specimen, to subject an organism to increased gravitational forces, or to separate the components of heterogeneous mixtures based on density differences.","Centrifugation | CENTRIFUGATION | CENTRIFUGING | Centifugation | Fractionation, Centrifugation",,,,,,,,,,,,,,,"4309809","Centrifugation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0086323","G Force","C48162","Inertial force produced by accelerations or gravity, expressed in gravitational units; one G is equal to the pull of gravity at the earth's surface at sea level and 45 degrees North latitude (32.1725 ft/sec2; 980.621 cm/sec2).","G Force | g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707903","Embedding","C48163","To surround an object with a firm chemical substance such as wax or resin, in order to perform cutting of thin sections for microscopic examination.","Embedding | EMBEDDING | Embed | Embed | Embed Technique | Embedded",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705217","Medium (Substance)","C48164","A substance holding another substance in solution or suspension.","Medium | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710378","Thaw","C48165","The process whereby heat changes something from a solid to a liquid.","Thaw | THAWING | Thaw Technique",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707797","Disposal","C48166","The act or means of getting rid of something.","Disposal | Disposal Technique | Dispose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707252","Cancer Research Group","C48168","A collection of scientist and/or clinician users with a common research objective related to diagnosis and treatment of cancer.","Cancer Research Group | CRG | Cancer Group",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881447","Los Angeles Classification System","C62423","A classification system for the endoscopic assessment of reflux esophagitis based on the number and extent of mucosal breaks and their relationships to the mucosal folds and esophageal circumference.","Los Angeles Classification System | LA Classification System | Los Angeles Classification System for endoscopic assessment of reflux esophagitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0243098","Funding","C17769","A sum of money or other resources set aside for a specific purpose.","Funding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883701","LA Grade A","C62424","One or more mucosal breaks no longer than 5 mm, none of which extends between the tops of the mucosal folds.","LA Grade A | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881342","LA Grade B","C62425","One or more mucosal breaks more than 5 mm long, none of which extends between the tops of two mucosal folds.","LA Grade B | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881343","LA Grade C","C62426","Mucosal breaks that extend between the tops of two or more mucosal folds, but which involve less than 75% of the esophageal circumference.","LA Grade C | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881344","LA Grade D","C62427","Mucosal breaks which involve at least 75% of the esophageal circumference.","LA Grade D | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512989","Map Location Object","C41175","Physical map location of a Gene, expressed as either a cytological chromosomal band or by chromosome, start point and end point.","Map Location Object | Map Location",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335144","Orthologous Gene","C28708","A gene from one species which corresponds to a gene in another species that is related via a common ancestral species (a homologous gene), but which has evolved to become different from the gene of the other species.","Orthologous Gene | Ortholog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709346","Orthologous","C48811","Occurring in one species but corresponding to one in another species that is related via a common ancestral species.","Orthologous | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518425","Not Otherwise Specified","C19594","Not characterized in any other way.","Not Otherwise Specified | NOS | Not Specified | Not otherwise specified | {NOS}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520598","14q31.1","C13866","A chromosome band present on 14q","14q31.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0520510","Material","C48187","The tangible substance that goes into the makeup of a physical object.","Material | ",,,,,,,,,,,,,,,"4124783","Material",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006560","C-Reactive Protein","C60651","C-reactive protein (224 aa, ~25 kDa) is encoded by the human CRP gene. This protein is cleaved during biological activation and is associated with host defense mechanisms and inflammatory responses.","C-Reactive Protein | C-Reactive Protein [Precursor] | CRP | Pentraxin 1 | Pentraxin 1, Short",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705606","Text Line","C49259","Text consisting of a row of words written across a page or computer screen.","Text Line | Text",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036581","Selenium","C825","A nonmetallic chemical element found in trace amounts in human body. Selenium primarily occurs in vivo as selenocompounds, mostly selenoproteins such as glutathione peroxidase and thioredoxin reductase (enzymes responsible for detoxification). Alone or in combination with Vitamin E, selenocompounds act as antioxidants. These agents scavenge free radicals; prevent blood clots by inhibiting platelet aggregation; strengthen the immune system; and have been shown, in some instances, to inhibit chromosomal damage and mutations. Exhibiting chemopreventive activity, selenocompounds also inhibit the induction of protein kinase C.","Selenium | SELENIUM | Se | selenium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1446409","Positive Finding","C38758","A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.","Positive Finding | EXPRESSED | POSITIVE | Positive | positive test result",,,,,,,,,,,,,,,"9191","Positive",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205076","Chest Wall","C62484","The total system of structures outside the lungs that move as a part of breathing; it includes all structures from the skin to the parietal pleura.","Chest Wall | CHEST WALL | Chest wall | Chest wall structure (body structure) | THORACIC WALL | Thoracic Wall | chest wall",,,,,,,,,,,,,"UBERON:0016435","chest wall","4193513","Chest wall structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512413","HER2/Neu Status","C16152","The presence or absence of Her2/Neu on a tissue sample.","HER2/Neu Status | ERBB2 Status | Her2/Neu Status | Her2/Neu Value",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278947","Prior Biologic Therapy","C15452","Previous biologic therapy administered as treatment.","Prior Biologic Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278960","History of myocardial infarction within 6 months","C17849","An event in a personal medical history indicating that a myocardial infartion has occurred during the previous 6 months.","History of Myocardial Infarction Within 6 Months | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018944","Hematoma","C50579","A localized collection of blood, usually clotted, in an organ, space, or tissue, due to a break in the wall of a blood vessel.","Hematoma | HEMATOMA | hematoma",,,,,,,,,,,,,,,"4147001|4299449","Hematoma|Hematoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0262627","Seroma","C50739","A collection of serum in the body.","Seroma | ",,,,,,,,,,,,,,,"37018844|4209136","Seroma|Seroma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0259768","Wound Dehiscence","C50863","Splitting of the sutured margins of a surgical wound. Risk factors include diabetes mellitus, obesity, and advanced age.","Wound Dehiscence | Wound Disruption | Wound dehiscence",,,,,,,,,,,,,,,"4253777|439981","Wound dehiscence|Wound dehiscence",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0600593","Health Insurance Portability and Accountability Act","C62504","United States legislation enacted in 1996 that aims to provide health data privacy and security.","Health Insurance Portability and Accountability Act | HIPAA | Kassebaum Kennedy Act | PL 104-191 | Public Law 104-191 | United States Health Insurance Portability and Accountability Act",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882474","Program Office","C62519","An administrative unit established to oversee efforts that transcend organizational boundaries.","Program Office | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0346040","Stage 0 Cutaneous Melanoma AJCC v6 and v7","C8423","Stage 0 includes: Tis, N0, M0.  Tis: Melanoma in situ.  N0: No regional lymph node metastases.  M0: No detectable evidence of distant metastases. (from AJCC 6th and 7th Eds.)","Stage 0 Cutaneous Melanoma AJCC v6 and v7 | Cutaneous Melanoma in situ | Malignant Cutaneous Melanoma in situ | Malignant Skin Melanoma in situ | Melanoma In Situ | Melanoma in situ | Melanoma in situ of Skin | Melanoma in situ of skin | Melanoma in situ of the Skin | Skin Melanoma in situ | Stage 0 Cutaneous (Skin) Melanoma | Stage 0 Cutaneous Melanoma | Stage 0 Malignant Cutaneous Melanoma | Stage 0 Malignant Melanoma | Stage 0 Malignant Skin Melanoma | Stage 0 Melanoma | Stage 0 Melanoma of Skin | Stage 0 Melanoma of the Skin | Stage 0 Skin Melanoma | Stage 0 Skin Melanoma AJCC v6 | Stage 0 Skin Melanoma AJCC v6 and v7 | Stage 0 Skin Melanoma AJCC v7 | melanoma in situ | stage 0 melanoma","8720/2","Melanoma in situ",,,,,,,,,,,,,"4031756|4301009","Melanoma in situ of skin (clinical)|Melanoma in situ",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1140621","Leg","C32974","The portion of the lower extremity between the knee and the ankle. For clinical purposes this term is also used to refer to the whole inferior limb.","Leg | LEG | leg | tetrapod leg",,,,,,,,,,,,,"UBERON:0000978","leg","4107527","Lower leg structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706864","Autopsy TNM Finding","C48882","TNM staging performed on autopsy.","Autopsy TNM Finding | aTNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013231","Over the Counter Product","C54068","A medicine or device that can be bought without a doctor's order or prescription.","Over the Counter Product | Nonprescription | OTC | Over the Counter | Over the Counter (OTC) | Over-the-Counter | Over-the-Counter Product | nonprescription | over-the-counter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3552261","Liver and Intrahepatic Bile Duct Disorder","C3196","A non-neoplastic or neoplastic disorder that affects the liver parenchyma and intrahepatic bile ducts. Representative examples of non-neoplastic disorders include hepatitis, cirrhosis, cholangitis, and polycystic liver disease. Representative examples of neoplastic disorders include hepatocellular adenoma, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, lymphoma, and angiosarcoma.","Liver and Intrahepatic Bile Duct Disorder | Hepatic Disorder | Hepatic Disorder | Liver Disease | Liver Disorder | Liver disease | Liver disease, unspecified",,,,,,,,,,,,,,,"194984","Disease of liver",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448837","National","C61423","Relating to, concerned with, limited to, owned by, or in the interests of a particular nation.","National | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041735","Veterans Administration","C17239","A government-run comprehensive benefit system for veterans and for their families, caregivers, and survivors.","Department of Veterans Affairs | Department of Veterans Affairs | VA | Veterans Administration | Veterans Administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003364","Antihypertensive Agent","C270","Any substance used in the treatment of acute or chronic hypertension regardless of pharmacological mechanism. Antihypertensive agents include diuretics, alpha-adrenergic and beta-adrenergic antagonists, angiotensin-converting enzyme inhibitors, calcium channel blockers, ganglionic blockers, and vasodilator agents.","Antihypertensive Agent | Antihypertensive Drugs | Antihypertensives | Hypotensive Agents | Hypotensive Drugs | Hypotensives",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706860","Authoritative","C45338","Sanctioned by established authority; having authority or ascendancy or influence; of recognized authority or excellence..","Authoritative | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518470","Number of Prior Chemotherapies","C16159","Number of prior chemotherapy regimens: If a patient has received a chemotherapy regimen, provide the number of different single or multi agent chemotherapy regimens the patient has received.  A regimen is described as a distinctive collection of agent(s) and/or modalities to be utilized together during a cycle or course of therapy.  A chemotherapy regimen may have been discontinued for any reason (e.g. completion of therapy, toxicity, disease progression).  If the planned treatment is ABVD/MOPP code as one chemotherapy regimen.","Number of Prior Chemotherapies | Multiple Agents Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515830","AIDS Malignancy Consortium","C19707","Established in 1995 to carry out Phase I and II studies of innovative therapies for AIDS malignancies.","AIDS Malignancy Consortium | AMC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596087","Angiogenesis Inhibitor","C1742","An agent or endogenous substance that inhibits the formation of capillaries from existing blood vessels. In cancer therapy, angiogenesis inhibitors preferentially target the new blood vessels that tumors require for oxygen and nutrition, thereby inhibiting the growth and spread of these tumors.","Angiogenesis Inhibitor | Angiogenesis Antagonists | Angiogenesis Blockers | Angiogenesis Inhibitors | Anti-Angiogenic Agents | Antiangiogenesis Agents | Antiangiogenic Agent | angiogenesis inhibitor | antiangiogenic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005527","Biological Therapy","C15187","A type of treatment that uses substances derived from or made by living organisms to treat disease; this includes both naturally occurring and synthetic products.","Biological Therapy | BRM therapy | Biological Agent Therapy | Biological Agents | Biological Response Modifier Therapy | Biological Response Modifiers Therapy | Biologics Therapies | Biotherapy | biological response modifier therapy | biological therapy | biotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511146","Biological Immunotherapy","C15972","The use of biological agents to enhance the host immune system.","Biological Immunotherapy | Cancer Biologics and Immunotherapy for Brain Tumors | Immunotherapy-Biological",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0746319","Positive Lymph Node","C27296","The presence of metastatic cancer cells in a lymph node.","Positive Lymph Node | Positive | node-positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3550888","Tooth Crowding","C62542","The condition when the summation of the mesio distal width of the teeth is larger than the arch perimeter.","Tooth Crowding | Crowding",,,,,,,,,,,,,,,"438792","Crowding of teeth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0441330","Intraoral Appliance","C62543","Any device worn within the mouth that can be removed and is not primarily designed to replace teeth.","Intraoral Appliance | ",,,,,,,,,,,,,,,"4157530","Intraoral device",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882338","Periodontal Probing","C62544","The act of inserting a periodontal probe between the gingival tissues and the tooth.","Periodontal Probing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006430","Burning Mouth Syndrome","C62545","A condition characterized by a burning or tingling sensation on the lips, tongue, or entire mouth.","Burning Mouth Syndrome | Oral Dysesthesia | Oral dysesthesia",,,,,,,,,,,,,,,"4163277","Burning mouth syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038363","Canker Sore","C62546","A recurrent disease of the oral mucosa of unknown etiology. It is characterized by small white ulcerative lesions, single or multiple, round or oval, lasting for 7-14 days and healing without scarring.","Canker Sore | Aphthous Stomatitis | Aphthous Ulcer | Aphthous stomatitis",,,,,,,,,,,,,,,"138463","Aphthous ulcer of mouth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031094","Periodontal Pocket","C62547","An abnormal deepening of a gingival sulcus associated with destruction of the supporting periodontal tissue.","Periodontal Pocket | PERIODONTAL POCKET",,,,,,,,,,,,,,,"4033622","Periodontal pocket",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034104","Pulpotomy","C62549","Surgical amputation of the coronal portion of the dental pulp.","Pulpotomy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705872","RANGAP1 wt Allele","C52550","Human RANGAP1 wild-type allele is located in the vicinity of 22q13 and is approximately 57 kb in length. This allele, which encodes Ran GTPase-activating protein 1, plays a role in initiation of Ran-mediated cellular processes including protein synthesis, DNA duplication and cell cycle progression.","RANGAP1 wt Allele | Fug1 | GTPase-Activating Protein, RAN, 1 Gene | KIAA1835 | MGC20266 | Pulpectomy | RANGAP | Ran GTPase Activating Protein 1 wt Allele | SD | Segregation Distorter Gene | Segregation Distorter Homolog (Drosophila) Gene | Segregation Distorter Homolog Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225392","Nasal Mucus","C52551","A network of dental practices that will establish the infrastructure to perform a wide variety of oral health research studies in Idaho, Montana, Oregon, Utah and Washington.","Nasal Mucus | Practice-Based Research Collaborative in Evidence-Based Dentistry",,,,,,,,,,,,,,,"4294392","Nasal mucus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2314896","Hereditary Atypical Mole Melanoma Syndrome","C27264","An autosomal dominant hereditary neoplastic syndrome caused by mutation(s) in the CDKN2A gene. It is characterized by the presence of multiple melanocytic nevi, some of which are atypical, and a family history of melanoma. Patients are at an increased risk of developing melanoma and other malignancies, including pancreatic, breast, and lung carcinoma.","Hereditary Atypical Mole Melanoma Syndrome | FAMM Syndrome | FAMMM syndrome | Familial Atypical Mole Melanoma Syndrome | Familial Atypical Mole Melanoma Syndrome | Familial atypical multiple mole melanoma (FAMMM) | familial atypical multiple mole melanoma syndrome",,,,,,,,,,,,,,,"4112850","B-K mole (nevus) syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033251","Proctoscopy","C17012","Endoscopic examination of the rectum.","Proctoscopy | proctoscopy",,,,,,,,,,,,,,,"4171571","Proctoscopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037075","Sigmoidoscopy","C17131","Endoscopic examination of the luminal surface of the sigmoid colon.","Sigmoidoscopy | Proctosigmoidoscopy | proctosigmoidoscopy | sigmoidoscopy",,,,,,,,,,,,,,,"4087381","Sigmoidoscopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0279637","Anal Carcinoma","C9291","A carcinoma that arises from the anal canal or perianal area (anal margin). Histologic types include squamous cell carcinoma and adenocarcinoma.","Anal Carcinoma | Anal Cancer | Anal Cancer (all types) | Anal cancer | Anal cancer, NOS | Cancer of Anus | Cancer of the Anus | Carcinoma of Anus | Carcinoma of the Anus | anal cancer",,,,,,,,,,,,,,,"4116241","Squamous cell carcinoma of anal margin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL415251","Lymphangiogram","C16805","An x-ray image of the lymphatic system using a radiopaque imaging agent.","Lymphangiogram | lymphangiogram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449067","Coding Region","C48691","The sequences on a gene or messenger RNA that are translated into protein.","Coding Region | Coding Feature | Coding Sequence | Protein Coding Region | Protein Coding Sequence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704659","Fellowship for the Interpretation of Genomes","C48833","A non-profit organization specializing in bioinformatics tool development and comparative genomics research.","Fellowship for the Interpretation of Genomes | FIG | fellowship for the interpretation of genomes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1948049","Cell (compartment)","C48694","Any small compartment.","Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706074","Data Table","C48693","A set of data arranged in rows and columns.","Data Table | Table",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705810","Generic Role","C48835","The usual or expected function of something; the part something plays in an action or event.","Role | Functional Role | Generic Role | Role, Generic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706814","Annotation","C44272","An explanatory or critical comment, or other in-context information (e.g., pattern, motif, link), that has been associated with data or other types of information.","Annotation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282503","Controlled Vocabulary","C48697","A set of terms that are selected and defined based on the requirements set out by the user group, usually a set of vocabulary is chosen to promote consistency across data collection projects.","Controlled Vocabulary | Controlled Terminology | controlled terminology | controlled vocabulary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3266841","Temporary Tooth","C33745","Any of the teeth of the first dentition, which are usually shed and replaced by the permanent teeth.","Temporary Tooth | Deciduous Tooth | Primary Tooth",,,,,,,,,,,,,,,"37156718|4068082","Structure of deciduous teeth|Structure of deciduous tooth",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0019345","Cold Sore","C34695","A lesion caused by type 1 or type 2 herpes simplex virus, involving the oralfacial region.","Cold Sore | ",,,,,,,,,,,,,,,"4033227","Herpes labialis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153446","Malignant Anal Neoplasm","C7379","A primary or metastatic malignant neoplasm that affects the anal canal or perianal skin.  Representative examples include carcinomas, lymphomas, and melanomas.","Malignant Anal Neoplasm | Malignant Anal Tumor | Malignant Neoplasm of Anus | Malignant Neoplasm of the Anus | Malignant Tumor of Anus | Malignant Tumor of the Anus | Malignant neoplasm of anus, unspecified",,,,,,,,,,,,,,,"4180911","Malignant tumor of anus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518045","Lymph Node Drainage","C18209","The flow of fluids and lymphocytes in the lymphatic vessels, which are concentrated from tissue fluids, into a particular lymph node. Once the fluid has transited the lymph node, it is returned to the blood via the lymphatic system.","Lymph Node Drainage | lymph node drainage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880279","Dental Base","C62564","Material used on the surfaces of a prepared cavity for protection and insulation of the tooth tissues prior to placement of a restoration.","Dental Base | Base",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0450433","Bonding Restorative Material","C62566","An adhesive restorative material, available in a number of shades to match patients' teeth, used for restoring teeth, correcting tooth discolorations, or cosmetic tooth enhancements.","Bonding Restorative Material | Bonding Material",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085275","Dental Dam","C62567","A thin sheet of rubber that is fitted over the mouth and perforated to expose certain teeth that acts as a moisture barrier during dental procedures.","Dental Dam | Rubber Dam",,,,,,,,,,,,,,,"4104081","Dental rubber dam",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882110","Non-Carious Tissue Change","C62568","An abnormal tissue change in a tooth that does not involve caries.","Non-Carious Tissue Change | Non-Carious | Non-carious Tissue Change",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705483","Pathname","C47922","The specification of a node (file or directory) in a hierarchical file system, usually specified by listing the nodes top-down.","Pathname | File Path | Path | file location | file_location",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475371","T0 TNM Finding","C48719","A primary tumor TNM finding indicating that there is no evidence of primary tumor.","T0 TNM Finding | T0 | T0 Cancer Stage Finding | T0 Primary Tumor Finding | T0 Primary Tumor Stage Finding | T0 Stage | T0 Stage Finding | T0 Stage Finding | T0 TNM Finding | T0 Tumor Finding | T0 Tumor Stage | Tumor Stage T0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332377","TX TNM Finding","C48737","A primary tumor TNM finding indicating that the status of the primary tumor cannot be assessed.","TX TNM Finding | TX | TX Cancer Stage Finding | TX Primary Tumor Finding | TX Primary Tumor Stage Finding | TX Stage | TX Stage Finding | TX Stage Finding | TX TNM Finding | TX Tumor Finding | TX Tumor Stage | Tumor Stage TX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475413","pTis TNM Finding","C48738","A term that refers to a TNM finding of a primary tumor microscopically defined as carcinoma in situ.","pTis TNM Finding | Stage Tis | Tis | Tis Cancer Stage Finding | Tis Primary Tumor Finding | Tis Primary Tumor Stage Finding | Tis Stage | Tis Stage Finding | Tis Stage Finding | Tis TNM Finding | Tis TNM Finding | Tis Tumor Finding | Tis Tumor Stage | Tumor Stage Tis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475372","T1 Stage Finding","C48720","A clinical and/or pathologic primary tumor TNM finding indicating that the cancer is limited to the site of growth.","T1 TNM Finding | T1 | T1 Cancer Stage Finding | T1 Primary Tumor Finding | T1 Primary Tumor Stage Finding | T1 Stage | T1 Stage Finding | T1 Stage Finding | T1 TNM Finding | T1 Tumor Finding | T1 Tumor Stage | Tumor Stage T1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475373","T2 Stage Finding","C48724","A general term that refers to a TNM finding of primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to primary tumor that is more than 2.0 cm, but not more than 5.0 cm in greatest dimension; for cutaneous melanoma it refers to primary tumor that is 1.01 to 2 mm in thickness, with or without ulceration; for colorectal cancer it refers to primary tumor with invasion into the muscularis propria; and for bladder cancer it refers to primary tumor with invasion into the muscle layer.","T2 TNM Finding | T2 | T2 Cancer Stage Finding | T2 Primary Tumor Finding | T2 Primary Tumor Stage Finding | T2 Stage | T2 Stage Finding | T2 Stage Finding | T2 TNM Finding | T2 Tumor Finding | T2 Tumor Stage | Tumor Stage T2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475374","T3 Stage Finding","C48728","A clinical and/or pathologic primary tumor TNM finding usually indicating that the cancer is locally invasive, without infiltration of adjacent structures.","T3 TNM Finding | T3 | T3 Cancer Stage Finding | T3 Primary Tumor Finding | T3 Primary Tumor Stage Finding | T3 Stage | T3 Stage Finding | T3 Stage Finding | T3 TNM Finding | T3 Tumor Finding | T3 Tumor Stage | Tumor Stage T3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475751","T4 TNM Finding","C48732","A clinical and/or pathologic primary tumor TNM finding indicating direct invasion of adjacent structures by cancer.","T4 TNM Finding | T4 | T4 Cancer Stage Finding | T4 Primary Tumor Finding | T4 Primary Tumor Stage Finding | T4 Stage | T4 Stage Finding | T4 Stage Finding | T4 TNM Finding | T4 Tumor Finding | T4 Tumor Stage | Tumor Stage T4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441959","N0 TNM Finding","C48705","A regional lymph node TNM finding indicating that there is no evidence of regional lymph node metastasis.","N0 TNM Finding | Lymph Node Stage N0 | N0 | N0 Cancer Stage Finding | N0 Lymph Node Finding | N0 Lymph Node Stage | N0 Node Finding | N0 Node Stage | N0 Regional Lymph Node Stage Finding | N0 Regional Lymph Nodes Finding | N0 Stage | N0 Stage Finding | N0 Stage Finding | N0 TNM Finding | Node Stage N0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441962","N1 Stage Finding","C48706","A general term that refers to a TNM finding of cancer metastases usually in a limited number of regional lymph nodes. The definition of N1 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to micrometastases or metastases in 1-3 axillary lymph nodes; for cutaneous melanoma it refers to metastasis in 1 regional lymph node; for colorectal cancer it refers to metastases in 1-3 regional lymph nodes; and for bladder cancer it refers to metastasis in 1 regional lymph node in the true pelvis.","N1 TNM Finding | Lymph Node Stage N1 | N1 | N1 Cancer Stage Finding | N1 Lymph Node Finding | N1 Lymph Node Stage | N1 Node Finding | N1 Node Stage | N1 Regional Lymph Node Stage Finding | N1 Regional Lymph Nodes Finding | N1 Stage | N1 Stage Finding | N1 Stage Finding | N1 TNM Finding | Node Stage N1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441960","N2 TNM Finding","C48786","A general term that refers to a TNM finding of cancer metastases in several regional lymph nodes. The definition of N2 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in 4-9 axillary lymph nodes; for cutaneous melanoma it refers to metastases in 2-3 regional lymph nodes; for colorectal cancer it refers to metastases in 4 or more regional lymph nodes; and for bladder cancer it refers to metastases in multiple regional lymph nodes in the true pelvis.","N2 TNM Finding | Lymph Node Stage N2 | N2 | N2 Cancer Stage Finding | N2 Lymph Node Finding | N2 Lymph Node Stage | N2 Node Finding | N2 Node Stage | N2 Regional Lymph Node Stage Finding | N2 Regional Lymph Nodes Finding | N2 Stage | N2 Stage Finding | N2 Stage Finding | N2 TNM Finding | Node Stage N2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441961","N3 TNM Finding","C48714","A general term that refers to a TNM finding of cancer metastases in multiple lymph nodes. The definition of N3 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in 10 or more axillary lymph nodes; for cutaneous melanoma it refers to metastases in 4 or more regional lymph nodes; for gastric cancer it refers to metastases in 7 or more regional lymph nodes; and for bladder cancer it refers to metastases in common iliac lymph nodes.","N3 TNM Finding | Lymph Node Stage N3 | N3 | N3 Cancer Stage Finding | N3 Lymph Node Finding | N3 Lymph Node Stage | N3 Node Finding | N3 Node Stage | N3 Regional Lymph Node Stage Finding | N3 Regional Lymph Nodes Finding | N3 Stage | N3 Stage Finding | N3 Stage Finding | N3 TNM Finding | Node Stage N3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0445085","NX TNM Finding","C48718","A regional lymph node TNM finding indicating that the status of regional lymph nodes cannot be assessed.","NX TNM Finding | Lymph Node Stage NX | NX | NX Cancer Stage Finding | NX Lymph Node Finding | NX Lymph Node Stage | NX Node Finding | NX Node Stage | NX Regional Lymph Node Stage Finding | NX Regional Lymph Nodes Finding | NX Stage | NX Stage Finding | NX Stage Finding | NX TNM Finding | Node Stage NX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0445034","M0 TNM Finding","C48699","A distant metastasis TNM finding indicating that there is no evidence of distant metastasis.","M0 TNM Finding | M0 | M0 Cancer Finding | M0 Cancer Stage Finding | M0 Distant Metastasis Finding | M0 Distant Metastasis Stage Finding | M0 Finding | M0 Metastasis Finding | M0 Metastasis Stage | M0 Stage | M0 Stage Finding | M0 Stage Finding | M0 TNM Finding | Metastasis Stage M0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441971","M1 TNM Finding","C48700","A clinical and/or pathologic distant metastasis TNM finding indicating the spread of cancer to distant anatomic sites.","M1 TNM Finding | M1 | M1 Cancer Stage Finding | M1 Distant Metastasis Finding | M1 Distant Metastasis Stage Finding | M1 Finding | M1 Metastasis Finding | M1 Metastasis Stage | M1 Stage | M1 Stage Finding | M1 Stage Finding | M1 TNM Finding | Metastasis Stage M1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0445039","MX TNM Finding","C48704","A distant metastasis TNM finding indicating that the status of distant metastasis cannot be assessed.","MX TNM Finding | MX | MX Cancer Stage Finding | MX Distant Metastasis Finding | MX Distant Metastasis Stage Finding | MX Metastasis Finding | MX Metastasis Stage | MX Stage | MX Stage Finding | MX Stage Finding | MX TNM Finding | Metastasis Stage MX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0154064","Stage 0 Anal Canal Cancer AJCC v6 and v7","C7794","Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th Eds.)","Stage 0 Anal Canal Cancer AJCC v6 and v7 | Anal Canal Carcinoma in situ | Stage 0 Anal Canal Cancer | Stage 0 Anal Canal Cancer | Stage 0 Anal Canal Cancer AJCC v6 | Stage 0 Anal Canal Cancer AJCC v7 | Stage 0 Anal Canal Carcinoma AJCC v6 and v7 | Stage 0 Anal Carcinoma AJCC v6 and v7 | stage 0 anal carcinoma in situ",,,,,,,,,,,,,,,"436671|78110","Carcinoma in situ of anal canal|Carcinoma in situ of anus",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0278499","Stage I Anal Canal Cancer AJCC v6 and v7","C9037","Stage I includes: T1, N0, M0.  T1: Tumor 2 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th Eds.)","Stage I Anal Canal Cancer AJCC v6 and v7 | Stage I Anal Canal Cancer | Stage I Anal Canal Cancer | Stage I Anal Canal Cancer AJCC v6 | Stage I Anal Canal Cancer AJCC v7 | Stage I Anal Canal Carcinoma AJCC v6 and v7 | Stage I Anal Carcinoma AJCC v6 and v7 | stage I anal cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278500","Stage II Anal Canal Cancer AJCC v6 and v7","C7775","Stage II includes: (T2, N0, M0); (T3,N0, M0).  T2: Tumor more than 2 cm but not more than 5 cm in greatest dimension.  T3: Tumor more than 5 cm in greatest dimension. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th Eds.)","Stage II Anal Canal Cancer AJCC v6 and v7 | Stage II Anal Canal Cancer | Stage II Anal Canal Cancer | Stage II Anal Canal Cancer AJCC v6 | Stage II Anal Canal Cancer AJCC v7 | Stage II Anal Canal Carcinoma AJCC v6 and v7 | Stage II Anal Carcinoma AJCC v6 and v7 | stage II anal cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278563","Stage IIIA Anal Canal Cancer AJCC v6 and v7","C5925","Stage IIIA includes: (T1, N1, M0); (T2, N1, M0); (T3, N1, M0); (T4, N0, M0). T1: Tumor 2 cm or less in greatest dimension.  T2: Tumor more than 2 cm but not more than 5 cm in greatest dimension.  T3: Tumor more than 5 cm in greatest dimension.  T4: Tumor of any size that invades adjacent organ(s).  N1: Metastasis in perirectal lymph node(s).  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th Eds.)","Stage IIIA Anal Canal Cancer AJCC v6 and v7 | Stage IIIA Anal Canal Cancer | Stage IIIA Anal Canal Cancer | Stage IIIA Anal Canal Cancer AJCC v6 | Stage IIIA Anal Canal Cancer AJCC v7 | Stage IIIA Anal Canal Carcinoma AJCC v6 and v7 | Stage IIIA Anal Cancer | Stage IIIA Anal Carcinoma AJCC v6 and v7 | stage IIIA anal cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278564","Stage IIIB Anal Canal Cancer AJCC v6 and v7","C5926","Stage IIIB includes: (T4, N1, M0); (Any T, N2, M0); (Any T, N3, M0). T4: Tumor of any size that invades adjacent organ(s).  N1: Metastasis in perirectal lymph node(s).  N2: Metastasis in unilateral internal iliac and/or inguinal lymph node(s).  N3: Metastasis in perirectal and inguinal lymph nodes and/or bilateral internal iliac and/or inguinal lymph nodes. M0: No distant metastasis. (AJCC 6th and 7th Eds.)","Stage IIIB Anal Canal Cancer AJCC v6 and v7 | Stage IIIB Anal Canal Cancer | Stage IIIB Anal Canal Cancer | Stage IIIB Anal Canal Cancer AJCC v6 | Stage IIIB Anal Canal Cancer AJCC v7 | Stage IIIB Anal Canal Carcinoma AJCC v6 and v7 | Stage IIIB Anal Cancer | Stage IIIB Anal Carcinoma AJCC v6 and v7 | stage IIIB anal cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0861424","Stage IV Anal Canal Cancer AJCC v6 and v7","C6873","Stage IV includes: (Any T, Any N, M1).  M1: Distant metastasis. (AJCC 6th and 7th Eds.)","Stage IV Anal Canal Cancer AJCC v6 and v7 | Stage IV Anal Canal Cancer | Stage IV Anal Canal Cancer | Stage IV Anal Canal Cancer AJCC v6 | Stage IV Anal Canal Cancer AJCC v7 | Stage IV Anal Canal Carcinoma AJCC v6 and v7 | Stage IV Anal Carcinoma AJCC v6 and v7 | stage IV anal cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705057","Circumferential Resection Margin","C46085","The non-peritonealised bare area of rectum, comprising anterior and posterior segments, when submitted as a surgical specimen resulting from excision of cancer of the rectum.","Circumferential Resection Margin | CRM | Circumferential | Circumferential Margin | Circumferential Radial Margin | Lateral Resection Margin | Mesorectal Resection Margin | Radial Margin | Radial Resection Margin | circumferential resection margin | circumferential_resection_margin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2004062","History of previous events","C54625","The aggregate of past events; the continuum of events occurring in succession leading from the past to the present; a record or narrative description of past events.","History | Historical",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376209","Adjustment","C49157","The act of making necessary corrections or modifications.","Adjustment | Adjusted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280470","Anal Basaloid Carcinoma","C8256","An anal squamous cell carcinoma characterized by the presence of malignant cells with hyperchromatic nuclei and peripheral nuclear palisading.","Anal Basaloid Carcinoma | Anal Basaloid Carcinoma | Anal Basaloid Carcinoma | Anal Basaloid Squamous Cell Carcinoma | Anal Basaloid Squamous Cell Carcinoma | Basaloid Carcinoma of Anus | Basaloid Carcinoma of the Anus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412036","Anal Squamous Cell Carcinoma","C9161","A squamous cell carcinoma (SCC) arising from the anal canal or the anal margin (perianal skin). Human papillomavirus is detected in the majority of cases. Homosexual HIV-positive men have an increased risk of developing anal squamous cell carcinoma in comparison to the general male population. Symptoms include anal pruritus, discomfort when sitting, pain, change in bowel habit, and bleeding. The prognosis is generally better for anal margin SCC than for anal canal SCC.","Anal Squamous Cell Carcinoma | Anal Squamous Cell Cancer | Epidermoid Anal Carcinoma | Epidermoid Carcinoma of Anus | Epidermoid Carcinoma of the Anus | Squamous Cell Anal Carcinoma | Squamous Cell Carcinoma of Anus | Squamous Cell Carcinoma of the Anus | Squamous cell carcinoma - anus | Squamous cell carcinoma of the anus",,,,,,,,,,,,,,,"4116241","Squamous cell carcinoma of anal margin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334273","Anal Canal Cloacogenic Carcinoma","C8255","An anal carcinoma arising from the transitional zone of the anal canal.","Anal Canal Cloacogenic Carcinoma | Anal Canal Cloacogenic Cancer | Anal Canal Transitional Zone Carcinoma | Anal Cloacogenic Carcinoma | Anal Cloacogenic Carcinoma | Cloacogenic Anal Carcinoma | Cloacogenic Carcinoma | Cloacogenic Carcinoma of Anus | Cloacogenic Carcinoma of the Anus | Cloacogenic carcinoma","8124/3","Cloacogenic carcinoma",,,,,,,,,,,,,"4223836","Cloacogenic carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1512863","Intermediate Grade","C28083","A term referring to the degree of differentiation of a malignant neoplasm and indicating that it is moderately differentiated.","Intermediate Grade | Medium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388664","Psychometrics","C17034","The science of measuring 'psychological' aspects of a person such as knowledge, skills, abilities, or personality. Measurement of these unobservable phenomena is difficult and much of the research and accumulated art of this discipline is designed to reliably define and then quantify.","Psychometrics | psychometrics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205199","Composite","C61520","Consisting of separate interconnected parts.","Composite | ",,,,,,,,,,,,,,,"4034846","Composite",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005740","Bleomycin","C313","A mixture of glycopeptide antineoplastic antibiotics isolated from the bacterium Streptomyces verticillus. Bleomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation.","Bleomycin | BLEO | BLEOMYCIN | BLM | Bleo | bleomycin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006463","Busulfan","C321","A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04)","Busulfan | 1, 4-Bis[methanesulfonoxy]butane | 1,4-Bis(methanesulfonoxy)butane | 1,4-Bitanediol Dimethanesulfonate Esters | 1,4-Butanediol Dimethylsulfonate | 1,4-Di(methanesulfonyloxy)butane | 1,4-Di(methylsulfonyloxy)butane | BUS | BUSULFAN | Busilvex | Bussulfam | Busulfanum | Busulfex | Busulphan | CB 2041 | CB-2041 | GT 41 | GT-41 | Glyzophrol | Joacamine | Methanesulfonic Acid Tetramethylene Ester | Methanesulfonic acid, tetramethylene ester | Mielucin | Misulban | Misulfan | Mitosan | Myeleukon | Myeloleukon | Myelosan | Mylecytan | Myleran | Sulfabutin | Tetramethylene Bis(methanesulfonate) | Tetramethylene bis[methanesulfonate] | WR-19508 | busulfan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0092801","Cladribine","C1336","A purine nucleoside antimetabolite analogue. Cladribine triphosphate, a phosphorylated metabolite of cladribine, incorporates into DNA, resulting in single-strand breaks in DNA, depletion of nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP), and apoptosis.  Because this agent is resistant to adenosine deaminase, an enzyme that inactivates some antineoplastic agents, it is selectively toxic to lymphocytes and monocytes which exhibit little deoxynucleotide deaminase activity. (NCI04)","Cladribine | 2-CdA | 2-Chloro-2-Deoxyadenosine | 2-Chlorodeoxyadenosine | 2CDA | CLADRIBINE | CdA | Cladribina | Leustat | Leustatin | Leustatine | RWJ-26251 | cladribine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282564","Anthracycline Antineoplastic Antibiotic","C1594","An antineoplastic antibiotic that is structurally similar to the benzoquinone ansamycin antibiotic geldanamycin. A geldanamycin analogue binds to HSP90, a chaperone protein that aids in the assembly, maturation, and folding of proteins. Subsequently, the function of HSP90 is inhibited, leading to the degradation and depletion of client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction.","Anthracycline Antineoplastic Antibiotic | Anthracycline Antibiotic | Anthracyclines | Chemotherapy, Cancer, Anthracyclines | anthracycline",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015133","Etoposide","C491","A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","Etoposide | 4'-Demethylepipodophyllotoxin 9-[4,6-O-ethylidene-beta-D-glucopyranoside] | 9-[(4,6-O-Ethylidene-beta-D-glucopyranosyl]oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one | Demethyl Epipodophyllotoxin Ethylidine Glucoside | EPEG | ETOPOSIDE | Lastet | Toposar | VP 16 | VP 16-213 | VP 16213 | VP-16 | VP-16-213 | VP-16213 | VP16 | VP16213 | Vepesid | etoposide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020823","Ifosfamide","C564","A synthetic analogue of the nitrogen mustard cyclophosphamide with antineoplastic activity. Ifosfamide alkylates and forms DNA crosslinks, thereby preventing DNA strand separation and DNA replication.  This agent is a prodrug that must be activated through hydroxylation by hepatic microsomal enzymes. (NCI04)","Ifosfamide | 2-oxo-N,3-bis-(2-chloroethyl) tetrahydro-2H-1,3,2-oxazaphosphorin- 2-amine | 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorin-2-oxide | Asta Z 4942 | Asta Z-4942 | Cyfos | Holoxan | Holoxane | IFO | IFO-Cell | IFOSFAMIDE | IFX | Ifex | Ifolem | Ifomida | Ifomide | Ifosfamidum | Ifoxan | Iphosphamid | Iphosphamide | Iso-Endoxan | Isoendoxan | Isophosphamide | MJF 9325 | MJF-9325 | Mitoxana | N,3-bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide | Naxamide | Seromida | Tronoxal | Z 4942 | Z-4942 | ifosfamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517560","Intrathecal Chemotherapy","C15750","Chemotherapy delivered via the spinal canal.","Intrathecal Chemotherapy | intrathecal chemotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0939537","Imatinib Mesylate","C1687","The mesylate salt of imatinib, a tyrosine kinase inhibitor with antineoplastic activity. Imatinib binds to an intracellular pocket located within tyrosine kinases (TK), thereby inhibiting ATP binding and preventing phosphorylation and the subsequent activation of growth receptors and their downstream signal transduction pathways. This agent inhibits TK encoded by the bcr-abl oncogene as well as receptor TKs encoded by the c-kit and platelet-derived growth factor receptor (PDGFR) oncogenes. Inhibition of the bcr-abl TK results in decreased proliferation and enhanced apoptosis in malignant cells of Philadelphia-positive (Ph+) hematological malignancies such as CML and ALL; effects on c-kit TK activity inhibit mast-cell and cellular proliferation in those diseases overexpressing c-kit, such as mastocytosis and gastrointestinal stromal tumor (GIST).","Imatinib Mesylate | 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate | CGP 57148 | CGP 57148B | CGP-57148 | CGP-57148B | CGP57148 | CGP57148B | Gleevec | Glivec | IMATINIB MESYLATE | Imarech | Imat | STI 571 | STI-571 | STI571 | imatinib mesylate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025241","Melphalan","C633","A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.","Melphalan | 4-[bis(2-chloroethyl)amino]-L-phenylalanine | Alanine Nitrogen Mustard | CB-3025 | L-PAM | L-Phenylalanine Mustard | L-Phenylalanine mustard | L-Sarcolysin | L-Sarcolysin Phenylalanine mustard | L-Sarcolysine | L-sarcolysin | MELPHALAN | Melphalan for Injection-Hepatic Delivery System | Melphalanum | Phenylalanine Mustard | Phenylalanine Nitrogen Mustard | Phenylalanine nitrogen mustard | Sarcoclorin | Sarkolysin | WR-19813 | melphalan | p-di(chloroethyl)amino-L-phenylalanine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026259","Mitoxantrone","C62050","An anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication.  This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair.  Mitoxantrone is less cardiotoxic compared to doxorubicin.","Mitoxantrone | 1,3-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9, 10-anthracenedione | 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9, 10-anthroquinone | Dihydroxyanthracenedione | MITOXANTRONE | Mitozantrone | mitoxantrone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028210","Nitrosourea Compound","C699","Any of a class of alkylating agents that contain both a nitroso group and a urea. They are lipophilic and can cross the blood-brain barrier.","Nitrosourea Compound | Nitrosourea Compounds | Nitrosoureas | nitrosourea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039512","Teniposide","C857","A semisynthetic derivative of podophyllotoxin with antineoplastic activity. Teniposide forms a ternary complex with the enzyme topoisomerase II and DNA, resulting in dose-dependent single- and double-stranded breaks in DNA, DNA: protein cross-links, inhibition of DNA strand religation, and cytotoxicity. This agent acts in the late S or early G phase of the cell cycle. (NCI04)","Teniposide | 4'-Demethylepipodophyllotoxin 9-(4,6-O-2-Thenylidene-beta-D-glucopyranoside) | 4'-Demethylepipodophyllotoxin-beta-D-thenylidine Glucoside | EPT | PTG | TENIPOSIDE | Thenylidene Lignan | VM 26 | VM-26 | VM26 | Vehem | Vumon | [5R-[5Alpha,5a beta,8a alpha, 9beta(R*)]]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-(2-thienylmethylene)-beta-D-glucopyranosyl]oxy]furo[3',4':6,7]-naphtho[2,3-d]-1,3-dioxol-6(5aH)-one | teniposide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0305055","Anti-Thymocyte Globulin","C278","Purified gamma globulin, with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","Anti-Thymocyte Globulin | ATG | ATS | Antithymocyte Globulin | Antithymocyte Globulin | Antithymocyte Serum | antithymocyte globulin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020789","Idarubicin","C562","A semisynthetic 4-demethoxy analogue of the antineoplastic anthracycline antibiotic daunorubicin. Idarubicin intercalates into DNA and interferes with the activity of topoisomerase II, thereby inhibiting DNA replication, RNA transcription and protein synthesis. Due to its high lipophilicity, idarubicin penetrates cell membranes more efficiently than other anthracycline antibiotic compounds.","Idarubicin | (1S,3S)-3-Acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-6,11-dioxo-1-naphthacenyl-3-amino-2,3,6-trideoxy-alpha-L-hexopyranoside | (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione | 4-DMDR | 4-Demethoxydaunomycin | 4-Demethoxydaunorubicin | 4-demethoxydaunorubicin | IDARUBICIN | idarubicin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206788","Zorubicin Hydrochloride","C1458","A benzoyl-hydrazone derivative of the anthracycline antineoplastic antibiotic daunorubicin.  Zorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. (NCI04)","Zorubicin Hydrochloride | (2S-cis)-Benzoic Acid[1-[4-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3-naphthacenyl]ethylidene]hydrazide | Benzoyl Hydrazone Daunorubicin | Daunorubicin Benzoylhydrazone Hydrochloride | RP 22,050 Hydrochloride | RP 22050 | Rubidazone | ZORUBICIN HYDROCHLORIDE | Zorubicin | Zorubicin hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032952","Prednisone","C770","A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","Prednisone | .delta.1-Cortisone | 1, 2-Dehydrocortisone | 1,2-Dehydrocortisone | 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione | Adasone | Cortancyl | Dacortin | DeCortin | Decortisyl | Decorton | Delta 1-Cortisone | Delta-Dome | Deltacortene | Deltacortisone | Deltadehydrocortisone | Deltasone | Deltison | Deltra | Econosone | Liquid Pred | Lisacort | Meprosona-F | Metacortandracin | Meticorten | Ofisolona | Orasone | PRED | PREDNISONE | Panafcort | Panasol-S | Paracort | Perrigo Prednisone | Predeltin | Predicor | Predicorten | Prednicen-M | Prednicort | Prednidib | Prednilonga | Predniment | Prednisone Intensol | Prednisonum | Prednitone | Promifen | Rayos | SK-Prednisone | Servisone | Sk-Prednisone | Sterapred | prednisone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708234","Genomic Molecule Entity","C47844","The sequences, mRNA transcripts, protein products, or other genome encoded molecules of the cell.","Genomic Molecule Entity | Genomic Entity | Genomic Molecule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708247","GoMiner","C45724","GoMiner is a tool for biological interpretation of 'omic' data, including data from gene expression microarrays. Omic experiments often generate lists of dozens or hundreds of genes that differ in expression between samples, raising the question: 'What does it all mean biologically?' To answer this question, GoMiner leverages the Gene Ontology (GO) to identify the biological processes, functions and components represented in these lists. Instead of analyzing microarray results with a gene-by-gene approach, GoMiner classifies the genes into biologically coherent categories and assesses these categories. The insights gained through GoMiner can generate hypotheses to guide additional research.","GoMiner | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205557","False Positive","C45726","A test result that shows evidence of a result or condition although it is not actually present.","False Positive | False Alarm | False Discovery | Type I Error | false positive | false-positive result | false-positive test result | type 1 (or type I) error",,,,,,,,,,,,,,,"4232000","False positive",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708064","Fisher's Exact Test","C45725","A statistical test used to determine if there are nonrandom associations between two categorical variables. It is an alternative to the Chi-square test for small samples.","Fisher's Exact Test | Fisher's Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708583","JDBC Driver","C45795","An application program interface specification for connecting programs written in Java to the data in a database. It is a Java API that enables Java programs to execute SQL statements and interact with any SQL-compliant database. (netlingo.com)","JDBC Driver | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522664","filter information process","C45801","A higher-order function which takes a predicate and a list and returns those elements of the list for which the predicate is true. It is a means of narrowing the scope of a report by specifying ranges or types of data to include or exclude.","Filter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706943","BioCarta","C45727","A developer, supplier and distributor of reagents and assays for biopharmaceutical and academic research. BioCarta aims to be the leader in the development and commercialization of new technology for functional proteomics by creating an international organization geared towards identifying, acquiring, and commercializing novel products. The BioCarta web site serves as an interactive web-based resource for life scientists. Their web site provides immediate access to existing life science research and integrates new data as it emerges. Broadly, this information falls into four categories: gene function, proteomic pathways, ePosters, and research reagents. BioCarta offers an easy and dynamic forum for information exchange and collaboration between researchers, educators and students. Scientists moderate BioCarta, and the site is open and without restriction or cost to participants. (from biocarta.com/about)","BioCarta | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706232","Directed Acyclic Graph","C45803","A graph whose edges are ordered pairs of vertices or nodes and which contains no path that starts and ends at the same vertex.","Directed Acyclic Graph | DAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708992","Metadata","C52095","Data about data; information that describes another set of data.","Metadata | metadata",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708934","Mapping Table","C45794","A function, represented as a table, such that for every element of one set there is a unique element of another set.","Mapping Table | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013072","Double Blind Study","C15228","A study method in which neither the subjects nor the investigators are permitted to know which subject is receiving which treatment.","Double Blind Study | DOUBLE BLIND | Double Masked | Double-Blinded | Double-Masked | double-blind study | double-blinded",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003372","Antilymphocyte Serum","C62577","Immunoglobulins raised xenogeneically against lymphocyte populations.  It is used both as a test for histocompatibility and in conjunction with other immunosuppressive agents to suppress rejection of grafts or organ transplants.","Antilymphocyte Serum | ALG | ALS | Antilymphocyte Globulin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0343084","Capillary Leak Syndrome","C62578","A syndrome characterized by leakage of intravascular fluids into the extravascular space. This syndrome is observed in patients who demonstrate a state of generalized leaky capillaries following shock syndromes, low-flow states, ischemia-reperfusion injuries, toxemias, medications, or poisoning. It can lead to generalized edema and multiple organ failure.","Capillary Leak Syndrome | AVLS | Acute Vascular Leak Syndrome | CLS | Capillary leak syndrome | capillary leak syndrome",,,,,,,,,,,,,,,"4227747","Capillary leak syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006272","Bronchiolitis Obliterans","C62580","Inflammation of the bronchioles with obstruction by fibrous granulation tissue or bronchial exudate. It may follow inhalation of irritating gases or foreign bodies and it complicates pneumonia.","Bronchiolitis Obliterans | BO | bronchiolitis obliterans",,,,,,,,,,,,,,,"4222731","Obliterative bronchiolitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1880018","Cerebrovascular","C62581","Relating to the brain and the blood vessels that supply it.","Cerebrovascular | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333678","Chimerism","C62582","The occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from different individuals. This contrasts with mosaicism in which the different cell populations are derived from a single individual.","Chimerism | ",,,,,,,,,,,,,,,"4324254","Cellular mosaicism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0445625","Coagulase-Negative Staphylococcus","C62584","A subtype of Staphylococcus characterized by an inability to produce free plasma coagulase.","Coagulase-Negative Staphylococcus | CNS | COAGULASE NEGATIVE STAPHYLOCOCCUS",,,,,,,,,,,,,,,"4020318","Staphylococcus, coagulase negative",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1265293","Coagulase-Positive Staphylococcus","C62585","A subtype of Staphylococcus characterized by an ability to produce free plasma coagulase.","Coagulase-Positive Staphylococcus | COAGULASE POSITIVE STAPHYLOCOCCUS",,,,,,,,,,,,,,,"4132273","Staphylococcus, coagulase positive",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242770","Cryptogenic Organizing Pneumonia","C62586","A form of organizing pneumonia with a non-infectious etiology. Excessive proliferation of granulation tissue occurs in alveolar ducts and alveoli and primarily causes injury to alveolar walls, but bronchioles may be affected.","Cryptogenic Organizing Pneumonia | BOOP | Bronchiolitis Obliterans Organizing Pneumonia | COP",,,,,,,,,,,,,,,"36714118","Cryptogenic organizing pneumonia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4230370","Delayed Puberty","C62587","Unusually late sexual maturity.","Delayed Puberty | Constitutional Growth Delay | Delayed puberty | Pubertal Delay",,,,,,,,,,,,,,,"4266651","Delayed puberty",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1880741","Federal Wide Assurance","C62588","Under the Department of Health and Human Services (DHHS) human subjects protection regulations (at 45 C.F.R. 46.103), every institution engaged in human subjects research that is funded or conducted by DHHS must obtain an Assurance Of Compliance approved by the Office for Human Research Protections (OHRP). This Assurance Of Compliance, when granted, is called a Federalwide Assurance. Both 'awardee' institutions and collaborating 'performance site' institutions must file Assurances.","Federal Wide Assurance | FWA | Federalwide Assurance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085498","Gram Positive Bacillus","C62589","Any rod shaped bacteria that has a peptidoglycan rich cell wall that stains dark purple with the Gram staining technique.","Gram Positive Bacillus | GPR | GRAM-POSITIVE BACILLUS | Gram-Positive Rod | Gram-Positive Rod",,,,,,,,,,,,,,,"4306758","Gram-positive bacillus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1504431","Idiopathic Pneumonia Syndrome","C62590","An inflammatory lung disease characterized by diffuse interstitial pneumonitis and alveolitis leading to interstitial fibrosis in the absence of an identifiable infectious agent.","Idiopathic Pneumonia Syndrome | IPS | idiopathic pneumonia syndrome",,,,,,,,,,,,,,,"36712839","Idiopathic pneumonia syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4012739","Hypopituitarism","C62591","A condition of diminution or cessation of secretion of one or more hormones from the anterior pituitary gland. This may result from surgical or radiation ablation, non-secretory pituitary neoplasms, metastatic tumors, infarction, pituitary apoplexy, infiltrative or granulomatous processes, and other conditions.","Hypopituitarism | Pituitary Insufficiency",,,,,,,,,,,,,,,"4254542","Hypopituitarism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2939186","Mood Alteration","C62592","A change in disposition or state of mind.","Mood Alteration | ",,,,,,,,,,,,,,,"4167815","Disturbance in mood",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882036","National Marrow Donor Program","C62593","A non-profit organization based in Minneapolis, MN, that facilitates hematopoietic cell transplants and cellular therapies for patients by connecting patients, doctors, donors and researchers to the resources they need.","National Marrow Donor Program | NMDP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882357","Pharyngeal/Respiratory Flora","C62594","The bacteria and other microorganisms that normally inhabit the pharynx or respiratory tract.","Pharyngeal/Respiratory Flora | Pharyngeal Flora | Pharyngeal/Respiratory Microbiome | Pharyngeal/Respiratory Microbiota | Pharyngeal/Respiratory Microflora | Respiratory Flora",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL365148","Retinopathy","C62601","Any non-neoplastic pathologic conditions of the retina, including non-neoplastic structural anomalies.","Retinopathy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0948387","Secondary Adrenal Insufficiency","C62602","A hormonal disorder that occurs when lack of corticotropin-releasing hormone (CRH) secretion from the hypothalamus or adrenocorticotropic hormone (ACTH) secretion from the pituitary is responsible for hypofunction of the adrenal cortex.","Secondary Adrenal Insufficiency | Central Adrenal Insufficiency | Central Hypoadrenalism",,,,,,,,,,,,,,,"4042063","Hypocortisolism secondary to another disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883169","Stem Cell Mobilization Therapy","C62604","Therapy to cause release of stem cells from the bone marrow into the peripheral blood circulation for the purpose of collection.","Stem Cell Mobilization Therapy | Chemomobilization | Hematopoietic Stem Cell Mobilization | Mobilization Therapy | Stem-cell mobilization",,,,,,,,,,,,,,,"604319","Hematopoietic stem cell mobilization",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2717961","Thrombotic Microangiopathy","C62605","A microvascular coagulopathy that may result from systemic vascular endothelial injury triggering the development of a procoagulant state, activation of the complement cascade, and microthrombi formation. Signs may include hemolytic anemia, thrombocytopenia, hypertension and renal dysfunction.","Thrombotic Microangiopathy | TMA | Thrombotic microangiopathy",,,,,,,,,,,,,,,"313800","Thrombotic microangiopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4227981","Muscle Weakness","C50658","A reduction in the strength of one or more muscles.","Muscle Weakness | ",,,,,,,,,,,,,,,"79908","Muscle weakness",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519302","Short Tandem Repeat","C13441","Area of repetitive DNA within the genome consisting of multiple, end-to-end copies of a short DNA sequence usually comprised of di-, tri-, or tetranucleotide repeat units.","Short Tandem Repeat | STR | Simple Sequence Repeat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879399","Tositumomab","C2543","A murine IgG2 monoclonal antibody directed against the CD20 antigen, found on the surface of B-cells.  Tositumomab binds to the CD20 surface membrane antigen, resulting in apoptosis, and may stimulate antitumoral cell-mediated and/or antibody-dependent cytotoxicity. (NCI04)","Tositumomab | Anti-CD20 Antibody | MoAb Anti-B1 | Monoclonal Antibody Anti-B1 | TOSITUMOMAB | anti-B1 | tositumomab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0877880","Ibritumomab Tiuxetan","C29981","An immunoconjugate of the monoclonal antibody ibritumomab conjugated with the linker-chelator tiuxetan, a high affinity, conformationally restricted chelation site for radioisotopes. When bound to indium In 111 or yttrium Y 90, ibritumomab tiuxetan, targeting the CD20 antigen on B cell surfaces, specifically delivers a potentially cytotoxic dose of radiation to B lymphocytes. Ibritumomab is a murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes.","Ibritumomab Tiuxetan | IBRITUMOMAB TIUXETAN | IDEC-129 | IDEC-2B8 | Ibritumomab tiuxetan | Zevalin | ibritumomab tiuxetan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0393022","Rituximab","C1702","A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","Rituximab | ABP 798 | ABP-798 | ABP798 | BI 695500 | BI-695500 | BI695500 | Blitzima | C2B8 Monoclonal Antibody | CT P10 | CT-P10 | CTP10 | Chimeric Anti-CD20 Antibody | GP 2013 | GP-2013 | GP2013 | IDEC 102 | IDEC-102 | IDEC-C2B8 | IDEC-C2B8 Monoclonal Antibody | IDEC102 | Ikgdar | MabThera | Mabtas | Monoclonal Antibody IDEC-C2B8 | PF 05280586 | PF-05280586 | PF05280586 | RITUXIMAB | RTXM 83 | RTXM-83 | RTXM83 | Riabni | Ritemvia | Rituxan | Rituximab ABBS | Rituximab ARRX | Rituximab Biosimilar ABP 798 | Rituximab Biosimilar BI 695500 | Rituximab Biosimilar CT-P10 | Rituximab Biosimilar GB241 | Rituximab Biosimilar GP2013 | Rituximab Biosimilar IBI301 | Rituximab Biosimilar JHL1101 | Rituximab Biosimilar PF-05280586 | Rituximab Biosimilar RTXM83 | Rituximab Biosimilar SAIT101 | Rituximab Biosimilar SIBP-02 | Rituximab PVVR | Rituximab-abbs | Rituximab-arrx | Rituximab-blit | Rituximab-pvvr | Rituximab-rite | Rituximab-rixa | Rituximab-rixi | Rixathon | Riximyo | Ruxience | Truxima | rituximab | rituximab biosimilar TQB2303 | rituximab-abbs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023972","Lomustine","C617","A nitrosourea with antineoplastic activity. Lomustine alkylates and crosslinks DNA, thereby inhibiting DNA and RNA synthesis.  This agent also carbamoylates DNA and proteins, resulting in inhibition of DNA and RNA synthesis and disruption of RNA processing.  Lomustine is lipophilic and crosses the blood-brain barrier. (NCI04)","Lomustine | 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea | 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea | 1-Nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl- | Belustin | Belustine | CCNU | Cecenu | CeeNU | Chloroethylcyclo- hexylnitrosourea | Chloroethylcyclohexylnitrosourea | Citostal | Gleostine | LOMUSTINE | Lomeblastin | Lomustinum | Lucostin | Lucostine | N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea | N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea | Prava | RB-1509 | WR-139017 | lomustine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882910","Read Permission","C62621","Permission that allows a user or program the ability to view information.","Read Permission | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883565","Write Permission","C62622","Permission that allows a user or program the ability to view information, write new information, and modify information.","Write Permission | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880863","Full Permission","C62623","Permission that allows a user or program the ability to view information, modify and add information, and delete information.","Full Permission | Delete Permission | Read/Write/Delete Permission",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013103","Drainage","C50434","The systematic withdrawal of fluids and discharges from a wound, sore or cavity.","Drainage | drain",,,,,,,,,,,,,,,"4046266","Drainage procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1879984","California Verbal Learning Test, Children's Version","C62620","Provides a short, individually administered assessment of the strategies and processes involved in learning and recall of verbal material. Assessment is made in the context of an everyday event. It measures both recall and recognition of words over a number of trials and has been found to be sensitive to memory deficits resulting from a variety of neurological conditions. It is designed for ages 5 through 16.","California Verbal Learning Test, Children's Version | CVLT-C",,,,,,,,,,,,,,,"36717696","CVLT-C (California Verbal Learning Test Children's Version)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0597530","Stressor","C54571","An agent, stimulus, activity, or event that causes stress on an organism, speeds up a reaction rate, or keeps a reaction rate the same.","Stressor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0220806","Chemical","C48807","A substance with a defined atomic or molecular structure that results from, or takes part in, reactions involving changes in its structure, composition, or properties.","Chemical | Chemically | chemical",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710230","Submitter","C54269","A person who presents or submits something (e.g., a proposal or protocol) for formal consideration or review by others.","Submitter | Submitted By",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473433","Cell Culture","C16396","General term referring to the maintenance of cell strains or lines in the laboratory.","Cell Culture | CellCulture | Expansion/Differentiation/Production, Cell Product",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705764","Doubling","C54574","A twofold increase.","Double | Doubling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708235","Genus","C45292","A taxonomic category ranking below a family (or Subfamily) and above a species and generally consisting of a group of species exhibiting similar characteristics.","Genus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897134","Biochemical Activity","C45420","A measurable amount of a specific function or role performed by a entity in a biophysical process, biochemical reaction, or biochemical process.","Biochemical Activity | Activity | Biochemical Activity Level",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376622","ABCB1 Gene","C17966","This gene plays a role in multi-drug resistance and is involved in blood-brain barrier transport.","ABCB1 Gene | ABCB1 | ATP-Binding Cassette, Sub-Family B (MDR/TAP), Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880027","Chemical Effects in Biological Systems","C54681","A data repository developed by the National Institute of Environmental Sciences (NIEHS) National Center for Toxicogenomics (NCT) to promote a systems biology approach to understand the biological effects of environmental stressors on environmentally induced toxicity and disease.  It includes studies on environmental chemicals and stressors and their effects, as well as a relational and descriptive data compendia on toxicologically important genes, groups of genes, SNPs, mutants and their attributes across species that are relevant to human health and environmental disease.","Chemical Effects in Biological Systems | CEBS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705821","Timeline","C54576","A chronological schedule of when activities or events occurred or will occur.","Timeline | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879918","CAS Number","C54682","A unique numerical identifier assigned, by the Chemical Abstract Service (CAS), a division of the American Chemical Society, to chemical compounds, polymers, biological sequences, mixtures, and alloys.","CAS Number | Chemical Abstract Service Number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705501","Chemical Formula","C48808","A representation of a substance using symbols for its constituent elements.","Chemical Formula | Formula | Molecular Formula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881233","International Chemical Identifier","C54683","A textual identifier for chemical substances designed to provide a standard and human-readable way to encode molecular information that also facilitates searches in printed and electronic data sources.","International Chemical Identifier | InCHi | InChI | InChI File (small molecule)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523831","Mechanism of Action","C54680","The mechanism by which a pharmacologically active substance produces an effect on a living organism or in a biochemical system.","Mechanism of Action | MOA | mechanism of action",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709764","PubChem","C54563","Maintained by the National Center for Biotechnology Information (NCBI).  Provides information on the chemical activity of small molecules and encompasses three primary databases:  PCSubstance, which contains over 10 million records of substance information; PCCompound, which contains over 5 million unique component structures, and PCBioAssay, which contains over 190 million bioassays and bioactivity data.","PubChem | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439861","Substance","C45306","Any matter of defined composition that has discrete existence, whose origin may be biological, mineral or chemical.","Substance | SUBSTANCE",,,,,,,,,,,,,,,"4022675","Substance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883032","Simplified Molecular Input Line Entry Specification","C54684","Specification for unambiguously describing the structure of chemical molecules using short ASCII strings. SMILES strings can be imported by most molecular editors for conversion back into two-dimensional drawings or three-dimensional models for the molecules.","Simplified Molecular Input Line Entry Specification | SMILES | Simplified Molecular Input Line Entry System | Simplified Molecular Input Line Entry System (SMILES)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1561488","HL7 2.5 Event type","C53053","A particular category of events regarded as having particular characteristics, qualities, and/or defined similarities.","Type of Event | Event Type | TYPE OF EVENT | TYPE OF REPORTABLE EVENT | Type of Reportable Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1135935","Spectral Karyotyping","C20068","A novel karyotyping procedure which is based on the simultaneous hybridization of 24 chromosome-specific painting probes labeled with different fluorochromes or fluorochrome combinations. The measurement of defined emission spectra by means of interferometer-based spectral imaging allows for the definitive discernment of all human chromosomes in different colors. (from Schrock et al., Hum Genet 1997:101:255-62)","Spectral Karyotyping | Color Karyotyping | Spectral Karyotype",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0552371","Citation","C41196","An extract or quotation from or reference to an authoritative source, e.g. a book or author, used, for example, to support an idea, theory, or argument.","Citation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448808","Syntax","C54277","A systematic or rule-based and harmonious arrangement of parts or elements.","Syntax | syntactic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448809","Disagreement","C54274","Inconsistency or lack of agreement between data, facts, claims, or opinions.","Disagreement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796358","comparative genomic analysis","C18084","Comparative genomic hybridization (CGH) is a technique that allows the detection of losses and gains in DNA copy number across the entire genome without prior knowledge of specific chromosomal abnormalities.  Comparative genomic hybridization utilizes the hybridization of differentially labeled tumor and reference DNA to generate a map of DNA copy number changes in tumor genomes. Comparative genomic hybridization is an ideal tool for analyzing chromosomal imbalances in archived tumor material and for examining possible correlations between these findings and tumor phenotypes. (from Ried et al. J Mol Med 1997 75:801-14)","Comparative Genomic Hybridization | CGH | Comparative Genome Hybridization | Comparative Genomic Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596142","Autosome","C32168","A chromosome not involved in sex determination. The diploid human genome consists of a total of 46 chromosomes which includes 22 pairs of autosomes.","Autosome | Autosomal | autosomal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035639","Supernumerary Circular Chromosome","C3360","An aberrant chromosome where the arms have fused to form a ring.","Supernumerary Circular Chromosome | Ring Chromosome | r",,,,,,,,,,,,,,,"4049814|605030","Ring chromosome|Ring chromosome",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1512486","Homogeneously Staining Region","C6832","A region on a chromosome which, when stained, is uniform in appearance. (Normally, a stained chromosome shows a banding pattern.) Homogeneously staining regions contain multiple copies of a single gene.  (Online Medical Dictionary)","Homogeneously Staining Region | hsr",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007709","Centromere","C13198","The nonstaining primary constriction of a chromosome which is the point of attachment of the spindle fiber; provides the mechanism of chromosome movement during cell division; the centromere divides the chromosome into two arms, and its position is constant for a specific chromosome: near one end (acrocentric), near the center (metacentric), or between (submetacentric).","Centromere | ",,,,,,,,,,,,,,,"4290425","Centromere",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448807","Draw","C54353","Represent by making a drawing of, as with pencil, chalk, etc. on a surface; make a mark or lines on a surface.","Draw | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439660","Hereditary","C27998","Transmitted from parent to child by information contained in the genes.","Hereditary | hereditary",,,,,,,,,,,,,,,"4114534","Hereditary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709015","MicroArray and Gene Expression","C54278","A group that aims to standardize the representation of microarray expression data that facilitates microarray information exchange between different data systems. (www.mged.org)","MicroArray and Gene Expression | MAGE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1947976","Correction (change)","C54657","The act of offering an improvement to replace a mistake; setting right; something substituted for an error.","Correction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0220647","Carcinoma of Unknown Primary","C3812","A carcinoma which has metastasized from an unknown primary anatomic site.","Carcinoma of Unknown Primary | CUP | Carcinoma of Unknown Primary Origin | Carcinoma of Unknown Primary Origin | carcinoma of unknown primary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0876929","Sentence","C62638","A set of words that is complete in itself, conveying a statement, question, exclamation, or command and typically containing an explicit or implied subject and a predicate containing a finite verb.","Sentence | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1955835","Laser Therapy","C15466","Any procedure in which an intense beam of light is used to cut, burn, or destroy tissue.","Laser Therapy | Laser Therapy and Laser Surgery | Therapy, Laser | laser therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033204","Probability","C54154","A measure of the expectation of the occurrence of a particular event.","Probability | Likelihood | Probable | probability | probabilityPercent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041980","Uric Acid","C62652","A white tasteless odorless crystalline product of protein metabolism, found in the blood and urine, as well as trace amounts found in the various organs of the body. It can build up and form stones or crystals in various disease states.","Uric Acid | 1H-Purine-2,6,8-triol | 2,6,8-Trihydroxypurine | 2,6,8-Trioxopurine | 2,6,8-Trioxypurine | 7,9-Dihydro-1H-purine-2,6,8(3H)-trione | URIC ACID | Urate | uric acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033707","Prothrombin Time","C62656","A measurement of the clotting time of plasma recalcified in the presence of excess tissue thromboplastin; it is a measure of the extrinsic pathway of coagulation. It is used to determine the clotting tendency of blood, in the measure of warfarin dosage, liver damage and vitamin K status. Factors measured are fibrinogen, prothrombin, and factors V, VII, and X.","Prothrombin Time | PT | Prothrombin Time Test",,,,,,,,,,,,,,,"4245261","Prothrombin time",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1374571","B2M protein, human","C62657","Beta-2-microglobulin protein (119 aa, ~14 kDa) is encoded by the human B2M gene. This protein plays a role in immune responses and is a key component of major histocompatibility complex class I molecules. The protein is localized to the surface of cells and is utilized as a prognostic marker in persons with cancers that involve white blood cells. The polypeptide is also used as a marker in kidney damage diagnosis and in the detection of viral infection.","Beta-2-Microglobulin | B2M | Beta-2 Microglobulin | Beta-2-Microglobin | Beta-2-Microglobulin Protein | beta-2-microglobulin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227958","Base of the Prostate","C13088","The uppermost part of the prostate gland adjacent to the bladder wall.","Base of the Prostate | Base",,,,,,,,,,,,,,,"4261841","Base of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227972","Middle Lobe of the Prostate","C13094","The upper, smaller part of the prostate between the ejaculatory ducts and the urethra.","Middle Lobe of the Prostate | Middle | PROSTATE GLAND, MIDDLE LOBE",,,,,,,,,,,,,,,"4142778","Structure of median lobe of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0087153","Ventilator","C38388","A medical device that facilitates breathing.","Ventilator | respirator | ventilator",,,,,,,,,,,,,,,"45768197","Ventilator",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705943","Class (taxonomic)","C45280","A collection of taxonomic subdivisions directly under Phylum. It is a major group of organisms, e.g. Mammalia, Reptilia, Gastropoda, Insecta, etc that contains a large number of different sublineages, but have shared characteristics in common (e.g. warm-blooded, fur, six legs etc).","Taxonomic Class | Class | Class",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708507","Infraclass","C45286","A taxonomic category of related organisms ranking below a subclass and above an order.","Infraclass | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708508","Infraorder","C45289","A taxonomic category of related organisms ranking below a suborder and above a family.","Infraorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708611","Kingdom","C45276","The highest taxonomic rank, immediately above phylum or division. There are five biological kingdoms (Monera, Protista, Plantae, Fungi, Animalia) into which organisms are grouped, based on common characteristics.","Kingdom | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705177","Order (taxonomic)","C45287","A taxonomic category between Class and Family.  It is group of organisms that although differing quite a bit among themselves still have a large degree of characteristics in common.","Order | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709533","Phylum (taxon)","C45277","A major division of a biological kingdom, consisting of closely-related classes; represents a basic fundamental pattern of organization and, presumably, a common descent.","Phylum | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448549","Subclass","C45285","A taxonomic subdivisions more specific than class but more general than order.","Subclass | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711207","Subfamily","C45291","A taxonomic category below a family.","Subfamily | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710232","Suborder","C45288","A taxonomic group that is a subdivision of an order.","Suborder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710233","Subphylum","C45278","A taxonomic group ranking between a phylum and a class.","Subphylum | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600142","Hot Flashes","C3109","A temporary feeling of intense body warmth, flushing, sometimes accompanied by sweating. A common, symptom of menopause; other conditions that can produce hot flushes include antidepressants and drugs blocking the effect of estrogens, carcinoid tumors and a sensitivity to sulfites or other food additives.","Hot Flashes | Hot Flash | Hot Flashes/Flushes | Hot flashes | hot flash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009240","Cognition","C16446","The mental process of knowing, thinking, learning and judging; the psychological result of perception and learning and reasoning.","Cognition | cognition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706910","Ball","C49835","Any device that is spherical in shape.","Ball Device | Ball | Ball Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704727","Family (taxonomic)","C45290","A taxonomic category between Order and Genus. It consists of a group of organisms among which the differences are quite minor, e.g. Equiidae - horses and their relatives.","Family | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043162","Total-Body Irradiation","C15350","A therapeutic procedure that involves the irradiation of the whole body with ionizing or non-ionizing radiation.","Total-Body Irradiation | SCT_TBI | TBI | TOTAL BODY IRRADIATION | Total Body Irradiation | Whole Body | Whole Body Irradiation | Whole-Body Irradiation | total-body irradiation",,,,,,,,,,,,,,,"4165515","Total body irradiation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519560","Total Nodal Irradiation","C15748","Radiation therapy to the mantle field, the spleen, the lymph nodes in the upper abdomen, and the lymph nodes in the pelvic area.","Total Nodal Irradiation | total nodal irradiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018067","Gonad","C12725","A reproductive system organ that produces and releases either sperm (testis) or eggs (ovary).","Gonad | GONAD | Gonadal | Gonads | gonad",,,,,,,,,,,,,,,"4183167","Gonadal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883204","Domain (trial submission dataset)","C49556","A collection of logically-related observations with a topic-specific commonality about the subjects in a trial, used in the regulatory submission process.  The logic of the relationship may relate to the scientific subject matter of the data, or to its role in the trial.  Typically, each domain is represented by a dataset, but it is possible to have information relevant to the same topicality spread among multiple datasets. (CDISC Glossary)","Submission Domain | Domain | Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882333","Periareolar","C62685","Surrounding the areola.","Periareolar | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882097","No Rank","C62686","Used to specify that the taxonomy rank is unknown.","No Rank | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880841","Forma (botanical taxonomic category below variety)","C62688","In botanical nomenclature, a rank below that of variety.","Forma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828336","Parvorder","C62689","A taxonomic category above superfamily and below infraorder.","Parvorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883071","Species Group","C62690","The taxonomic ranking including both species and subspecies.","Species Group | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883072","Species Subgroup","C62691","A taxonomic category below species group.","Species Subgroup | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883697","Subgenus","C62692","A taxonomic category directly below genus and above species.","Subgenus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883207","Subspecies","C62700","A taxonomic category below that of species.","Subspecies | subsp.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883203","Subkingdom","C62701","A taxonomic category below kingdom and above superphylum.","Subkingdom | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1948024","Tribe (taxon)","C62702","A taxonomic category below subfamily and above genus.","Tribe | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883212","Subtribe","C62703","A taxonomic category below tribe and above genus.","Subtribe | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883219","Superclass","C62704","A taxonomic rank below subphylum and above class.","Superclass | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883220","Superfamily","C62705","A taxonomic category above family and below order.","Superfamily | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883221","Superkingdom (taxonomic category)","C62706","A taxonomic category above that of Kingdom.","Superkingdom | Domain | Empire | Superregnum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883222","Superorder","C62707","A taxonomic category above order and below class.","Superorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883223","Superphylum","C62708","A taxonomic category above phylum and below subkingdom.","Superphylum | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883525","Variety (taxon)","C62709","In botanical nomenclature, a rank below subspecies but above forma.","Variety | Varietas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0204457","Wechsler Intelligence Scale for Children","C62715","An individually administered clinical instrument for assessing the cognitive ability of children aged 6 years through 16 years 11 months. It is a psychometric test that assesses a child's current cognitive abilities in both verbal and nonverbal areas, including verbal comprehension, perceptual reasoning, working memory, and processing speed. It was first published in 1949 and revised in 1974 (WISC-R). The third edition (WISC-III) was released in 1991 and the fourth edition (WISC-IV) in 2003.","Wechsler Intelligence Scale for Children | WISC | WISC-III | WISC-IV | Wechsler Intelligence Scale for Children, Fourth Edition | Wechsler Intelligence Scale for Children, Fourth Edition | Wechsler Intelligence Scale for Children, Third Edition",,,,,,,,,,,,,,,"4165605","Wechsler intelligence scale for children",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883557","Wide Range Achievement Test, 3rd Edition","C62716","Measures basic skills in reading, arithmetic, and spelling. It is a screening test that can be administered to determine if a more comprehensive achievement test is needed.","Wide Range Achievement Test, 3rd Edition | WRAT-3 | Wide Range Achievement Test, Revision 3 | Wide Range Achievement Test-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705274","Operator of Medical Device","C53272","An individual who handles and controls the functioning of medical device.","Operator of Medical Device | Device Operator | Medical Device Operator | OPERATOR OF MEDICAL DEVICE | Operator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448749","Frozen Section Diagnosis","C49338","A method for rapid diagnosis that uses a frozen tissue sample rather than a chemically fixed sample.","Frozen Section Diagnosis | Frozen Section",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0948441","Veno-Occlusive Disease","C8301","Disorder in which veins are partially or completely obstructed or the blood flow through the veins is suboptimal.--2004","Veno-Occlusive Disease | VOD | Vaso-Occlusive Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831743","Autologous Hematopoietic Stem Cell Transplantation","C16039","Stem cell transfer or transplantation in which the patient is their own donor.","Autologous Hematopoietic Stem Cell Transplantation | AHSCT | Autologous | Autologous Hematopoietic Cell Transplantation | Autologous Stem Cell Transplant | Autologous Stem Cell Transplantation | Autologous Stem Cell Transplantation | Stem Cell Transplantation, Autologous | autologous stem cell transplantation",,,,,,,,,,,,,,,"46271079","Transplantation of autologous hematopoietic stem cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2587213","Control","C61299","The act of directing or determining; regulation or maintenance of a function or action; a relation of constraint of one entity (thing or person or group) by another.","Control | Controlled | Controlling | Direct | Directed | Directing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881938","Myriad Model","C62748","A model that predicts a person's risk of hereditary breast and ovarian cancer based on family cancer history (including relatives' age at diagnosis) and ethnicity.","Myriad Model | Myriad Model for Breast Cancer Risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162371","Umbilical Cord Blood","C13300","Blood present in the umbilical vessels at the time of delivery. If cryopreserved at birth, cord blood can serve as a source of hematopoietic progenitor cells for transplantation to a patient later diagnosed and treated for a hematopoietic disorder.","Umbilical Cord Blood | CORD BLOOD | Cord Blood | Cord blood | Unmanipulated Cord Blood | umbilical cord blood",,,,,,,,,,,,,,,"4052756","Cord blood",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0750526","Today","C41134","The day that includes the present moment, as distinct from yesterday or tomorrow.","Today | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279026","Syngeneic Bone Marrow Transplantation","C15465","Bone marrow transplantation in which the donor and recipient are genetically identical.","Syngeneic Bone Marrow Transplantation | syngeneic bone marrow transplantation",,,,,,,,,,,,,,,"4121104","Syngeneic bone marrow transplant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710528","Umbilical Cord Blood Stem Cell","C43424","A stem cell obtained from the umbilical cord.","Umbilical Cord Blood Stem Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514468","product","C51980","The end result of a manufacturing process; anything that is produced.","Product | ProcessedProduct",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883469","Unstained Specimen","C62755","A specimen that is mounted for microscopic study but without preparation methods which use dyes, reagents or other materials to produce coloration in tissues or microorganisms for microscopic examination.","Unstained Specimen | Unstained Slide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3275993","Swelling","C3399","Enlargement; expansion in size; sign of inflammation","Swelling | ",,,,,,,,,,,,,,,"40484518|4275722","Swelling|Swelling",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0029445","Bone Necrosis","C34880","Death of bone tissue due to traumatic or nontraumatic causes.","Bone Necrosis | Osteonecrosis",,,,,,,,,,,,,,,"4344387","Bone necrosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1336735","Acute Myeloid Leukemia Post Cytotoxic Therapy","C8252","An acute myeloid leukemia arising as a result of the mutagenic effect of chemotherapy agents and/or ionizing radiation.  (WHO, 2001)","Acute Myeloid Leukemia Post Cytotoxic Therapy | High-Grade Treatment-Related Myeloid Neoplasm | Therapy-Related Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Treatment Related AML | Treatment Related Acute Myelogenous Leukemia | Treatment Related Acute Myeloid Leukemia | Treatment related AML | Treatment related acute myeloid leukemia | Treatment-Related AML | Treatment-Related Acute Myelogenous Leukemia | Treatment-related Acute Myeloid Leukemia | t-AML",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1321724","Alkylating Agent-Related Acute Myeloid Leukemia","C27754","Acute myeloid leukemia occurring as late complication of prior therapy with alkylating agents.","Alkylating Agent-Related Acute Myeloid Leukemia | Alkylating Agent Related Acute Myeloid Leukemia | Alkylating Agent-Related AML | Therapy-related acute myeloid leukemia, alkylating agent related",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0751366","Radiation-Related Malignant Neoplasm","C27209","A malignant neoplasm arising in a site exposed to radiation therapy.","Radiation-Related Malignant Neoplasm | Radiation-Induced Cancer | Radiation-Induced Malignant Neoplasm | Radiation-Related Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332235","Alkylating Agent-Related Myelodysplastic Syndrome","C7643","A disorder seen following cancer chemotherapy. It is the most common cause of therapy-related myelodysplastic syndromes. It typically manifests several years after initiation of single or multi-agent chemotherapy with alkylators. Mutagenic potential of alkylating agents is believed to be age and cumulative dose-dependent. Deletions in chromosomes 5 and 7 are associated with susceptibility to this disorder. Clinical signs may include fatigue, dyspnea, bruising and frequent infections. Clinical course may progress to bone marrow failure or acute myeloid leukemia that is refractory to treatment. Prognosis is dismal with survivability usually less than one year.","Alkylating Agent-Related Myelodysplastic Syndrome | Alkylating Agent Related Myelodysplastic Syndrome | Therapy-related myelodysplastic syndrome, alkylating agent related",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1292780","Myelodysplastic Syndrome Post Cytotoxic Therapy","C27722","A myelodysplastic syndrome resulting from chemotherapy or radiation therapy for cancer.","Myelodysplastic Syndrome Post Cytotoxic Therapy | MDS Post Cytotoxic Therapy | MDS-pCT | Therapy Related Myelodysplastic Syndrome | Therapy-Related MDS | Therapy-Related Myelodysplastic Syndrome | Therapy-Related Myelodysplastic Syndrome | t-MDS","9987/3","Therapy-related myelodysplastic syndrome, NOS",,,,,,,,,,,,,"45771284","Therapy-related myelodysplastic syndrome",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1336769","Topoisomerase II Inhibitor-Related Acute Myeloid Leukemia","C27755","Acute myeloid leukemias arising as a result of the mutagenic effect of therapeutic agents targeting DNA-topoisomerase II. The vast majority of patients present without a preceding myelodysplastic phase. The acute myeloid leukemias are usually of the monoblastic or myelomonocytic type. Clonal cytogenetic abnormalities are frequently present and usually involve chromosome 11q23 (MLL gene).","Topoisomerase II Inhibitor-Related Acute Myeloid Leukemia | Topoisomerase II Inhibitor Related Acute Myeloid Leukemia | Topoisomerase II Inhibitor-Related AML",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519554","Topoisomerase II Inhibitors","C1968","Any substance that inhibits topoisomerase-II, a topoisomerase that relieves torsional stress in a DNA molecule by cutting both strands of the DNA double helix. A topoisomerase II inhibitor can either stabilize the DNA-protein complex or inhibit the catalytic activity of the enzyme. Inhibition of topoisomerase-II causes DNA damage, inhibition of DNA replication, and apoptosis.","Topoisomerase-II Inhibitor | Topoisomerase-II Inhibitors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2242529","Allogeneic Hematopoietic Stem Cell Transplantation","C46089","A clinical treatment in which hematopoietic stem cells (HSCs) are transferred from one genetically dissimilar individual to another.","Allogeneic Hematopoietic Stem Cell Transplantation | Allogeneic | Allogeneic Hematopoietic Cell Transplantation | Allogeneic Stem Cell Transplantation | HSC | HSCT | Stem Cell Transplantation, Allogeneic | allogeneic stem cell transplantation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513380","Molecular Analysis","C19770","A laboratory procedure that involves the study of tissues, cells, and fluids using techniques to analyze biologically active molecules, including nucleic acids, proteins, lipids and carbohydrates, for the identification of processes, characteristics and abnormalities at the molecular level.","Molecular Analysis | Molecular Assay | Molecular Genetic Analysis | Molecular Genetic Procedure | Molecular Procedure | Molecular Test | NUCLEIC ACID BASED METHOD | molecular analysis method | molecular_analysis_method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0752095","Cytogenetic Analysis","C18280","Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.","Cytogenetic Analysis | CYEXAM | Cytogenetic Examination | Cytogenetic Techniques | Cytogenetic studies | Cytogenetics, NOS",,,,,,,,,,,,,,,"4249882","Cytogenetic procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011135","Defecation","C62787","The normal process of elimination of fecal material from the rectum.","Defecation | bowel movement | defecation",,,,,,,,,,,,,,,"4009473","Defecation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0426636","Defecation Urgency","C62788","A sudden compelling urge to defecate.","Defecation Urgency | ",,,,,,,,,,,,,,,"4216708","Urgent desire for stool",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0348374","Malignant Central Nervous System Neoplasm","C4627","A primary or metastatic malignant neoplasm involving the brain or spinal cord.  Representative examples include anaplastic astrocytoma, glioblastoma, anaplastic (malignant) meningioma, lymphoma, and metastatic carcinoma from another anatomic site.","Malignant Central Nervous System Neoplasm | CNS Cancer | CNS Malignant Neoplasms | CNS Neoplasms, Malignant | Cancer of CNS | Cancer of Central Nervous System | Cancer of the CNS | Cancer of the Central Nervous System | Central Nervous System Cancer | Central Nervous System Neoplasms, Malignant | Malignant CNS Neoplasm | Malignant CNS Neoplasms | Malignant CNS Tumor | Malignant Central Nervous System Tumor | Malignant Neoplasm of CNS | Malignant Neoplasm of Central Nervous System | Malignant Neoplasm of the CNS | Malignant Neoplasm of the Central Nervous System | Malignant Tumor of CNS | Malignant Tumor of Central Nervous System | Malignant Tumor of the CNS | Malignant Tumor of the Central Nervous System | Malignant neoplasm of central nervous system, unspecified",,,,,,,,,,,,,,,"4155285","Malignant neoplasm of central nervous system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019829","Hodgkin Lymphoma","C9357","A lymphoma characterized by the presence of relatively few malignant cells called Reed-Sternberg cells and mononuclear Hodgkin cells that are admixed with nonneoplastic inflammatory cells. The malignant cells have a distinctive immunophenotype; they are positive for CD30 and CD15 and negative for CD3, CD20, and CD45.","Hodgkin Lymphoma | HL | Hodgkin Lymphoma, NOS | Hodgkin disease | Hodgkin disease, NOS | Hodgkin lymphoma | Hodgkin lymphoma, NOS | Hodgkin lymphoma, unspecified, unspecified site | Hodgkin's Disease | Hodgkin's Lymphoma | Hodgkin's Lymphoma | Malignant lymphoma, Hodgkin","9650/3","Hodgkin lymphoma, NOS",,,,,,,,,,,,,"3661447|4038835|4038840","Hodgkin granuloma|Hodgkin's disease (clinical)|Hodgkin's sarcoma (clinical)",,,,,,,,,,,,,"--","--",,,,,,,,"--|--|--"
"C0549473","Thyroid Gland Carcinoma","C4815","A carcinoma arising from the thyroid gland. It includes the following main subtypes: follicular, papillary, medullary, poorly differentiated, and anaplastic carcinoma.","Thyroid Gland Carcinoma | Cancer of Thyroid | Cancer of the Thyroid | Carcinoma of Thyroid | Carcinoma of Thyroid Gland | Carcinoma of the Thyroid | Carcinoma of the Thyroid Gland | THCA | Thyroid Cancer | Thyroid Carcinoma | Thyroid Gland Cancer | Thyroid cancer, NOS | thyroid cancer",,,,,,,,,,,,,,,"40488900","Carcinoma of thyroid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2700375","Protozoal qualifier","C28028","Having to do with the simplest organisms in the animal kingdom. Protozoa are single-cell organisms, such as ameba, and are different from bacteria, which are not members of the animal kingdom. Some protozoa can be seen without a microscope.","Protozoal | protozoal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026946","Fungal Infection","C3245","An infection caused by a fungus.","Fungal Infection | Fungal infection | Mycosis",,,,,,,,,,,,,,,"433701","Mycosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042749","Viremia","C35125","A laboratory test result indicating the presence of a virus in the blood.","Viremia | ",,,,,,,,,,,,,,,"133327","Viremia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704861","Computer Programming Object","C45974","In object-oriented programming, an object is a self-contained entity that consists of both data and procedures to manipulate the data.","Computer Programming Object | Object",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242481","Research Activities","C15429","Systematic investigation into a subject in order to discover facts, establish or revise a theory, or develop a plan of action based on the facts discovered.","Research Activity | Research | research study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4227865","Weight Gain","C62754","An increase in total body weight.","Weight Gain | BWGAIN | Body Weight Gain | Weight Increase | Weight gain",,,,,,,,,,,,,,,"37311268|4232487","Weight gain|Weight gain",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1881024","HLA Class I Histocompatibility Antigen, Cw-1 Alpha Chain Protein","C62760","HLA class I histocompatibility antigen, C alpha chain (366 aa, ~41 kDa) is encoded by the human HLA-C gene. This protein plays a role in the presentation of foreign antigens to the immune system. This class of antigens is associated with certain disease manifestations such as spondylarthritis, psoriasis and multiple myeloma.","HLA Class I Histocompatibility Antigen, C Alpha Chain | HLA Class I Histocompatibility Antigen, C*07:02 Alpha Chain | HLA Class I Histocompatibility Antigen, C-0702 Alpha Chain | HLA Class I Histocompatibility Antigen, Cw-1 Alpha Chain Protein | HLA Class I Histocompatibility Antigen, Cw-1 Alpha Chain Protein | HLA-C | HLA-C*0702 | HLA-C*07:02 | HLA-Cw | Human Leukocyte Antigen C | Human Leukocyte Antigen C*07:02 | MHC I Antigen C | MHC I Antigen C*07:02 | MHC I Antigen Cw | MHC class I antigen Cw*1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881023","HLA Class II Histocompatibility Antigen, DRB1-4 Beta Chain Protein","C62757","HLA class II histocompatibility antigen, DRB1-4 beta chain protein (266 aa, ~30 kDa) is encoded by the human HLA-DRB1 gene. This protein is involved in both antigen presentation to regulatory T cells and in the immune response. The antigen is frequently typed for bone marrow and kidney transplantation procedures.","HLA Class II Histocompatibility Antigen, DRB1-4 Beta Chain Protein | DR-4 | DR4 | HLA Class II Histocompatibility Antigen, DRB1-4 Beta Chain | HLA-DR4 | HLA-DR4 Antigen | MHC Class I Antigen DRB1*4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881020","HLA Class I Histocompatibility Antigen, B-7 Alpha Chain","C62774","HLA class I histocompatibility antigen, B-7 alpha chain protein (362 aa, ~40 kDa) is encoded by the human HLA-B gene. This protein is involved in the presentation of foreign antigens to the immune system. It is associated with susceptibility to ankylosing spondylitis, Behcet syndrome and carbamazepine-induced Stevens-Johnson syndrome.","HLA Class I Histocompatibility Antigen, B-7 Alpha Chain | HLA-B7 Antigen | MHC Class I Antigen B*7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205488","Hematologic","C62780","Pertaining to or related to the blood and blood-forming organs.","Hematologic | ",,,,,,,,,,,,,,,"4211850","Hematologic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162481","Doppler Ultrasound","C62781","Diagnostic imaging that uses sound waves (ultrasound) applying the Doppler effect, with frequency-shifted ultrasound reflections produced by moving targets (usually red blood cells) in the bloodstream along the ultrasound axis in direct proportion to the velocity of movement of the targets, to determine both direction and velocity of blood flow.","Doppler Ultrasound | DOPPLER ULTRASOUND | Doppler",,,,,,,,,,,,,,,"35622931","Doppler ultrasound",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019168","Hepatitis B Virus HBsAg Surface Protein Antigen","C62786","Any one of the hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen.","Hepatitis B Virus HBsAg Surface Protein Antigen | HBsAg | HEPATITIS B VIRUS HBSAG SURFACE PROTEIN ANTIGEN | HEPATITIS B VIRUS SURFACE ANTIGEN | Hepatitis B Surface Antigen | Hepatitis B Surface Antigen | Hepatitis B Virus Surface Antigen",,,,,,,,,,,,,,,"4318957","Hepatitis B surface antigen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0062524","Hepatitis A Virus Antibody","C62793","An antibody produced by B lymphocytes in response to hepatitis A enteroviral infection.","Hepatitis A Virus Antibody | ",,,,,,,,,,,,,,,"4139121","Antibody to hepatitis A virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0369334","Hepatitis B Virus Surface Antibody","C62796","An antibody produced by B lymphocytes to the hepatitis B surface antigen as part of the immune response to hepatitis B viral infection.","Hepatitis B Virus Surface Antibody | Anti-HBs | Anti-HBs Antibody | Anti-Hepatitis B Virus Surface Antibody | HBsAb",,,,,,,,,,,,,,,"4220846","Antibody to hepatitis B surface antigen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0312631","Hepatitis B Virus Core Antibody","C62797","An antibody produced by B lymphocytes to the hepatitis B core antigen as part of the immune response to hepatitis B viral infection.","Hepatitis B Virus Core Antibody | HBV Core Antibody | HBcAb | anti-HBc",,,,,,,,,,,,,,,"4219058","Antibody to hepatitis B core antigen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3536718","Growth Hormone Secretion Abnormality","C62800","An abnormal production of growth hormone.","Growth Hormone Secretion Abnormality | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880997","Gonadotropin Secretion Abnormality","C62802","An abnormality of gonadotropin production resulting in abnormal levels of circulating gonadotropin.","Gonadotropin Secretion Abnormality | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707513","Copy Number","C49142","The number of molecules of a particular type on or in a cell or part of a cell. Usually applied to specific genes or to plasmids within a bacterium.","Copy Number | Copy Number Reported | LAB_SEQ_METHOD | copy number | copy_number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026237","Mitochondrion","C13258","Semiautonomous, self-reproducing organelles that occur in the cytoplasm of all cells of most, but not all, eukaryotes. Mitochondria contain distinctive ribosomes, transfer RNAs, amino acyl t-RNA synthetases, and elongation and termination factors. Mitochondria depend upon genes within the nucleus for many essential messenger RNAs. Mitochondria consist of two sets of membranes, a smooth continuous outer coat and an inner membrane arranged in tubules or more often in folds that form platelike double membranes (cristae). Mitochondria are the principal energy source of the cell and contains the cytochrome enzymes of terminal electron transport and the enzymes of the citric acid cycle, fatty acid oxidation, and oxidative phosphorylation. Mitochondria are the sites of the reactions of oxidative phosphorylation, which result in the formation of ATP.","Mitochondrion | Mitochondria | Mitochondrial | mitochondria",,,,,,,,,,,,,,,"4327481","Mitochondrion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1279919","Early","C61589","At or near the beginning of a period of time or course of events.","Early | ",,,,,,,,,,,,,,,"4130705","Early",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0871468","Synonym","C52469","A word having the same or nearly the same meaning as another word or other words in a language; a word or an expression that serves as a figurative or symbolic substitute for another.","Synonym | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001554","Administration, Management","C48905","Performing or possessing executive duties; acting as a supervisor or manager.","Administration, Management | Administration | Administration | Management",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521871","Amplification","C25418","Addition of extra material.","Amplification | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448843","Extraction","C61575","The act of pulling out, including the process of obtaining something from a mixture or compound by chemical or physical or mechanical means.","Extraction | EXTRACTING | Extracted | REMOVAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009378","Colonoscopy","C16450","Endoscopic examination of the luminal surface of the colon.","Colonoscopy | COLONOSCOPY | colonoscopy",,,,,,,,,,,,,,,"4249893","Colonoscopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0521317","Multigated Acquisition Scan","C38073","A diagnostic test used to evaluate the pumping function of the heart's ventricles. A radioactive tracer is injected into a vein and a gamma camera detects the radiation released by the tracer, with image acquisition triggered (gated) at different points of the cardiac cycle.","Multigated Acquisition Scan | Blood Pool Scan | Equilibrium Radionuclide Angiography | Gated Blood Pool Imaging | Gated Heart Pool Scan | MUGA | MUGA Scan | Multi-Gated Acquisition Scan | RNV Scan | RNVG | Radionuclide Ventriculogram Scan | Radionuclide Ventriculogram Scan | Radionuclide Ventriculography | Radionuclide ventriculography | SYMA Scanning | Synchronized Multigated Acquisition Scanning",,,,,,,,,,,,,,,"4223321","Multiple gated acquisition scanning",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162597","Stromal Cell","C12571","Connective tissue cells found in the tissue stroma of any organ.","Stromal Cell | Stromal Cells | stromal cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014597","Epithelial Cell","C12578","Any of the cells of the epithelium, which covers the body and lines its cavities and glands.","Epithelial Cell | EPITHELIAL CELL | Epithelial Cells",,,,,,,,,,,,,,,"4172959","Epithelial cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028953","Oligonucleotide","C713","A DNA polymer made up of a small number of nucleotides.","Oligonucleotide | Oligo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707925","Entrez","C45764","Entrez, the Life Sciences Search Engine, integrates the scientific literature, DNA and protein sequence databases, 3D protein structure and protein domain data, population study datasets, expression data, assemblies of complete genomes, and taxonomic information into a tightly interlinked system.  It is a product of the National Center for Biotechnology Information (NCBI).","Entrez | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705987","Pathway (interactions)","C54214","A set or series of interactions, often forming a network, which biologists have found useful to group together for organizational, historic, biophysical, or other reasons.","Pathway | Pathways",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0887889","Bacterial Artificial Chromosomes","C1860","Based upon the natural F plasmid of E. coli.  Inserts up to 300 Kb can be cloned and stably maintained as circular molecules.","Bacterial Artificial Chromosome | BAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510438","Assay","C60819","A qualitative or quantitative analysis performed to determine the amount of a particular constituent in a sample or the biological or pharmacological properties of a drug.","Assay | ASSAY | assay",,,,,,,,,,,,,,,"4156364","Assay technique",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0600600","3' Untranslated Region","C13373","Sequences on the 3' end of messenger RNAs that are not translated into protein. The 3'UTR is involved in many post-transcriptional regulatory pathways, including regulating translation efficiency, mRNA stability, and polyadenylation signals.","3' Untranslated Region | 3' UTR | 3'-UTR | 3'UTR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600493","5' Untranslated Region","C13371","Sequences on the 5' end of messenger RNAs that are not translated into protein.  5'UTR extends from the transcription start site to just before the ATG translation initiation codon.  This region contains the ribosome binding site and other transcription and translation regulating sequences.","5' Untranslated Region | 5' UTR | 5'-UTR | 5'UTR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033799","Pseudogene","C40415","Nonfunctional DNA sequences that are very similar to the sequences of known genes.  Many seem to have arisen as functional gene duplications that subsequently underwent mutation and loss of function.  Others are structurally similar to mRNA and seem to have arisen by a reverse transcription event followed by integration into the genome.  Some pseudogenes are transcribed and may play a role in regulation of its homologous gene.","Pseudogene | PSEUDOGENE",,,,,,,,,,,,,,,"4296006","Pseudogene",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705759","Gene Amplification Abnormality","C45581","An increase in the copy number of a particular gene. This type of abnormality can be either inherited or somatic.","Gene Amplification Abnormality | Amplification | Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0243095","Investigation Finding","C61036","The result of an examination or inquiry.","Investigation Finding | Finding | Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880833","Fold Change","C60693","An indication of the magnitude difference between two values specified as the number of multiples of the first value to the second value (e.g., from 10 to 20 is a 2-fold increase, from 10 to 50 is a five-fold increase).","Fold Change | Multiples of Difference",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704701","Normal, Unit of Concentration","C48554","A unit of concentration equal to one gram-equivalent of solute per one liter of solution.","Normal, Unit of Concentration | NORMAL | Normal | Normal | Normality-Based Dosing Unit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205189","Borderline","C14157","Straddling the dividing line between two categories.","Borderline | BORDERLINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205081","Moderate","C61376","The quality of being within reasonable or average limits; not excessive or extreme.","Moderate | MODERATE | Moderately | Moderation | Moderation",,,,,,,,,,,,,,,"37165778","Moderate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0442821","Strong","C62223","Having strength, power, or intensity greater than average or expected.","Strong | ",,,,,,,,,,,,,,,"4127784","Strong",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883425","Unevaluable","C62222","Unable to be evaluated.","Unevaluable | NE | NOT EVALUABLE | Non-Evaluable | Not Assessable | Not Evaluable | Not evaluable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1762617","Weak","C62224","Having strength, power, or intensity less than average or expected.","Weak | ",,,,,,,,,,,,,,,"4124461","Weak",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021044","Immunohistochemistry Staining Method","C23020","Immunohistochemical staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody and an enzyme complex with a chromogenic substrate. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. The specimen may then be counterstained and coverslipped. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.","Immunohistochemistry Staining Method | Cell/Tissue, Immunohistochemistry | IHC | Immunohistochemistry | Immunohistochemistry (IHC) | immunohistochemistry",,,,,,,,,,,,,,,"4035726|45769444","Immunohistochemistry procedure|Immunohistochemistry",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0019409","Heterogeneity","C28359","The quality or state of consisting of elements that are not of the same kind or nature.","Heterogeneity | Heterogeneous | Heterogeneous | heterogeneous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881065","Homogeneity","C61365","The quality or state of being similar or comparable in kind or nature or of being uniform throughout in composition or structure.","Homogeneity | Homogeneous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705241","Change","C54126","A change in or difference between; usually represented by the 4th letter of the greek alphabet.","Delta | Change | Difference",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334278","Invasive Lesion","C36117","A malignant cellular population that has increased in size and infiltrates the surrounding tissues.","Invasive Lesion | Invasive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007603","Plasma Membrane","C13735","The semipermeable membrane that encloses the cytoplasm of a cell.","Plasma Membrane | Cell Membrane | Plasmalemma | plasma membrane",,,,,,,,,,,,,,,"4207350","Cell membrane",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1515981","And","C37912","An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","And | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881488","Lysate","C62004","The cellular debris and fluid produced by lysis of a cell.","Lysate | Cell Lysate | LYSATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882115","Normalize","C62007","To make something conform to a standard; to remove useless or extraneous entries from a data set.","Normalize | Normalization | Normalized | Normative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0544886","Somatic Variation","C18060","Any mutation with an origin in cells that are not destined to become gametes. As a consequence, such mutations are not transmitted to progeny, though they will be transmitted during any mitosis within the individual. Somatic mutations may contribute to a broad variety of pathologies including cancer.","Somatic Variation | SOMATIC VARIATION | Somatic Mutation | Somatic Mutation | Somatic Mutation Abnormality | Somatic Variant | somatic mutation",,,,,,,,,,,,,,,"4052276","Somatic mutation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009221","Codon (nucleotide sequence)","C62019","A specific sequence of three adjacent bases on a strand of DNA or RNA that provides genetic code information for a particular amino acid.","Codon | codon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021920","Introns","C13249","Non-coding, intervening sequences of DNA that are transcribed, but are removed from within the primary gene transcript and rapidly degraded during maturation of messenger RNA.","Intron | Intervening Sequence | Intronic | intron",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883559","Wild Type","C62195","The naturally-occurring, normal, non-mutated version of a gene or genome.","Wild Type | No mutation detected | WT | Wildtype",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704241","complex (molecular entity)","C19398","A molecular entity formed by loose association involving two or more component molecular entities. The bonding between the components is normally weaker than in a covalent bond.","Complex | Complexes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079380","Frameshift Mutation","C17354","A mutation occurring within the protein-coding region of a gene which results in a shift in the reading frame of the encoded protein. Frameshift mutations often result in the premature truncation of a gene product.","Frameshift Mutation | Frameshift | Frameshift Mutation Abnormality | Frameshift Variant | Mutation, Frameshift | Reading Frame Shift Mutation | frameshift mutation | fs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881206","Inframe Mutation","C62199","A mutation occurring within the protein-coding region of a gene which results in a retention of the reading frame of the encoded protein.","Inframe Mutation | Inframe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0599155","Missense Mutation","C18133","A point mutation occurring within the protein-coding region of a gene, and which codes for a different amino acid than expected.","Missense Mutation | Exon Non-Synonymous Mutation | Exonic Non-Synonymous Mutation | Missense Mutation Abnormality | Missense Variant | Mutation, Missense | Non-Synonymous Mutation | Protein Altering Variant | Substitution | Substitution Mutation | missense mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0544885","Nonsense Mutation","C62198","A point mutation occurring within the protein-coding region of a gene, and which codes for a stop that can truncate the protein.","Nonsense Mutation | Nonsense | Premature Termination Abnormality | Premature Termination Mutation | Stop Gain | Stop Gained | nonsense mutation",,,,,,,,,,,,,,,"4209755","Nonsense mutation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519323","Silent Mutation","C20629","A point mutation occurring within the protein-coding region of a gene, and which codes for the same amino acid as expected.","Silent Mutation | Exon Synonymous Mutation | Exonic Synonymous Mutation | Mutation, Silent | Synonymous | Synonymous Mutation | Synonymous Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519478","Splice-Site Mutation","C19798","Any mutation that occurs within the discrete sequences comprising the 5' or 3' splice sites of a gene that has a spliced message. Splice-site mutation may result in a deletion or insertion of extraneous amino acids in the gene product or a change in the reading frame of the spliced message.","Splice-Site Mutation | Intron Splice Site Mutation | Intronic Splice Site Mutation | Splice | Splice Region Variant | Splice-Juction Mutation | Splice-Site Mutation Abnormality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511760","Deletion Mutation","C19296","Any rearrangement to the genomic content that results in the loss of one or more nucleotides of DNA. Deletions are generally irreversible rearrangements. They may alter the reading frame of a gene, or may result in loss of large chromosomal regions.","Deletion Mutation | A loss of any genetic material on a chromosome, ranging from loss of a single nucleotide, to loss of part or all of a gene, to loss of a visible portion of the chromosome involving multiple genes. Deletions often disrupt gene or protein function and cell function as a result. | Deletion | Deletion Abnormality | Deletion NOS | Deletion, NOS | Mutation, Deletion | del | deletion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512796","Insertion Mutation","C19295","Any rearrangement to the genomic content that adds one or more extra nucleotides into the DNA. Insertions may be reversible, particulary if caused by transposable elements. They may alter the reading frame of a gene, or may cause large scale additions of genomic DNA.","Insertion Mutation | Insertion | Insertion Mutation Abnormality | Insertion NOS | Insertion, NOS | Mutation, Insertion | ins",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162735","Point Mutation","C62200","A small-scale mutation in which a single nucleotide is exchanged for another. Mutagenic chemicals and mistakes in DNA replication may result in point mutations.","Point Mutation | point mutation",,,,,,,,,,,,,,,"43020565","Point mutation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1831593","Recombinant Human Interleukin-21","C62492","A recombinant peptide similar to or identical to endogenous human cytokine interleukin-21 (IL-21) with potential antineoplastic activity. Denenicokin binds to and activates IL-21 receptors, expressed on T-cells, B-cells, dendritic cells (DC), and natural killer (NK) cells, modulating the proliferation and/or differentiation of T and B cells, promoting T cell survival, and increasing the cytolytic activity of cytotoxic T lymphocytes (CTLs) and NK cells.","Denenicokin | DENENICOKIN | IL-21 | L-methionyl(Human Interleukin-21) | Recombinant Human Interleukin-21 | Wildtype | rIL-21 | rhIL-21",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705502","Statistical Frequency","C53988","The ratio of the number of observations in a statistical category to the total number of observations.","Statistical Frequency | Frequency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881032","Hardy-Weinberg Distribution","C62197","The ratio of genotype frequencies that evolve when mating is random and neither selection nor drift are operating. For two alleles (A and a) with frequencies p and q, there are three genotypes: AA, Aa, and aa. The Hardy-Weinberg ratio for the three is: p^2AA : 2pqAa : q^2aa. Deviation from this ratio indicates that some force is acting on the population (e.g., selection, mutation, migration, genetic drift, non-random mating).","Hardy-Weinberg Distribution | Hardy-Weinberg Ratio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019425","Heterozygosity","C45825","Having two different allelic forms of a gene, one inherited from each parent, on each of the two homologous chromosomes.","Heterozygosity | Heterozygote | Heterozygous | Heterozygous | heterozygous genotype",,,,,,,,,,,,,,,"4031674","Heterozygote",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019904","Homozygosity","C45826","Having two identical allelic forms of a gene, one inherited from each parent, on each of the two homologous chromosomes.","Homozygosity | Homozygote | Homozygous | Homozygous | homozygous genotype",,,,,,,,,,,,,,,"4329704","Homozygote",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005532","biology (field)","C16345","The scientific study of living organisms.","Biology | Biologic | Biological",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707455","Comparison","C49156","The examination of two or more people or things in order to detect similarities and differences.","Comparison | Compare | Compared | Versus | vs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0444504","Arithmetic Mean","C53319","The sum of a set of values divided by the number of values in the set.","Arithmetic Mean | MEAN, ARITHMETIC | Mean | Statistical Mean | mean",,,,,,,,,,,,,,,"4115464","Mean",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0876920","Median Statistical Measurement","C28007","The value which has an equal number of values greater and less than it.","Median | MEDIAN | Middle (qualifier value) | Statistical Median | median",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0871420","Standard Deviation","C53322","A measure of the range of values in a set of numbers. Standard deviation is a statistic used as a measure of the dispersion or variation in a distribution, equal to the square root of the arithmetic mean of the squares of the deviations from the arithmetic mean.","Standard Deviation | SD | standard deviation",,,,,,,,,,,,,,,"4297217","Standard deviation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448805","Variable","C54166","Marked by diversity or difference; liable to or capable of change.","Variable | variable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880097","Class Comparison","C61038","A type of analysis that determine the significance and/or magnitude of the difference between groups.","Class Comparison | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710191","Statistical Technique","C19044","A method of analyzing or representing statistical data; a procedure for calculating a statistic.","Statistical Technique | Statistical Method | statistical method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881925","Multiple Comparison Adjustment","C61601","A procedure used for correction of p-value due to multiple testing.","Multiple Comparison Adjustment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879830","Benjamini-Hochberg Procedure","C61596","A sequential p-value procedure that controls expected false discovery rate.","Benjamini-Hochberg Procedure | Benjamini and Hochberg Adjustment | Benjamini and Hochberg Method | Benjamini and Hochberg Procedure | Benjamini-Hochberg Adjustment | Benjamini-Hochberg Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879894","Bonferroni Adjustment","C61594","Used in multiple comparison procedures to calculate an adjusted probability, alpha (a), of comparison-wise type I error from the desired probability aFW0 of family-wise type I error. The calculation guarantees that the use of the adjusted a in pairwise comparisons keeps the actual probability aFW of family-wise type I errors not higher than the desired level, as specified by aFW0.","Bonferroni Adjustment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0870536","F-Test","C53234","A test of the hypothesis that the standard deviations of two normally distributed populations are equal, and thus that they are of comparable origin.","F-Test | F Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0871472","t-Test","C53231","A statistical hypothesis test based on a test statistic whose sampling distribution is a t-distribution.  The term 't-test' is often used in a narrower sense: it refers to a popular test aimed at testing the hypothesis that the population mean is equal to some value m (see also t-statistic). The most popular t-tests are aimed at testing the following hypotheses: 1. The population mean is as hypothesized (the population variance is not known); 2. The means of two populations are equal (the population variances are not known but equal); 3. The means of two populations are equal (the population variances are not known and not equal); 4. The correlation coefficient for two random variables is zero; 5. The slope of the population regression line is zero.","t-Test | t test | t-test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0871608","Wilcoxon Signed Rank Test","C53246","The Wilcoxon signed ranks test is aimed at testing a null hypothesis from paired replicates data - that both treatments are equivalent. This test is based on one of the two Wilcoxon rank sums as the test statistic. The Wilcoxon signed ranks test allows you to utilize information about order (rank) of the magnitude of the difference between two replicated measurements. In other words, this test gives more weight to the pairs of measurements which show higher difference. Note that this test does not use the absolute magnitude of the difference, just its rank. In other words, a difference of 4 is considered larger than a difference of 2, but not twice as large, nor 2 units larger. This is a nonparametric test.","Wilcoxon Signed Rank Test | Wilcoxon Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0429865","Principal Component Analysis","C49291","A vector space transform used to reduce the dimensionality in a dataset while retaining those characteristics of the dataset that contribute most to its variance.","Principal Component Analysis | PCA | Principal Components Analysis",,,,,,,,,,,,,,,"4090044","Principal component analysis of arterial velocity waveform",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882460","Principal Component","C60694","One of the axes representing the projection of varience resulting from principal component analysis.","Principal Component | Principle Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0699733","Device","C62103","An object contrived for a specific purpose.","Device | device",,,,,,,,,,,,,,,"4169265","Device",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709637","Preferred_Name","C43707","The word or phrase that NCI uses by preference to refer to the concept.","Preferred_Name | Preferred Name | Preferred Name | Preferred Term",,,,,,,,,,,,,,,"763778","Preferred name",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705420","Integrated Molecular Analysis of Genomes and their Expression Consortium","C45993","A group formed in 1993 by four academic groups on a collaborative basis after informal discussions led to a common vision of how to achieve an important goal in the study of the human genome: the Integrated Molecular Analysis of Genomes and their Expression. They share high-quality, arrayed cDNA libraries and place sequence, map, and expression data on the clones in these arrays into the public domain. The human and mouse genomes were the first to be studied, and the collection now contains clones from rat, zebrafish, Fugu, Xenopus and rhesus macaque. They anticipate arraying (and sharing) cDNA libraries from additional species over time. A majority of their clones are publicly available, free of any royalties, and may be used by anyone agreeing with their guidelines.","Integrated Molecular Analysis of Genomes and their Expression Consortium | I.M.A.G.E. | I.M.A.G.E. Consortium | IMAGE | IMAGE Consortium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516202","Cancer Genome Anatomy Project","C15923","The Cancer Genome Anatomy Project (CGAP) is an interdisciplinary program to establish the information and technological tools needed to decipher the molecular anatomy of a cancer cell.  The Cancer Genome Anatomy Project (CGAP) will unite the newest technologies, along with those both cost-effective and capable of high-throughput, to identify all the genes responsible for the establishment and growth of cancer.  CGAP has two overall goals: 1. Enhance discovery of the acquired and inherited molecular changes in cancer. 2. Evaluate the clinical potential of these discoveries. This requires the creation and dissemination of technologies that can read and interpret the molecular features of cancer.","Cancer Genome Anatomy Project | CGAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708141","GO Ontology Relationship","C43567","This object specifies GoOntologyrRelationship. (caBIO)","GO Ontology Relationship | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004561","B-Lymphocyte","C12474","Immunologically important lymphocyte that is not thymus-dependent, is either short-lived and naive or long-lived and of memory phenotype, and resembles the bursa-derived lymphocyte of birds in that it is responsible for the production of immunoglobulins.","B-Lymphocyte | B Cell | B Cells | B Lymphocytes | B cell | B lymphocyte | B-Cell | B-Cells | B-Lymphocytes | Bursa-Dependent Lymphocyte | Bursa-Equivalent Lymphocyte",,,,,,,,,,,,,,,"4011536","B lymphocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0887899","Myeloid Cells","C12549","Cells which include the monocytes and the granulocytes.","Myeloid Cell | Myeloid Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1321301","Peripheral Blood Mononuclear Cell","C12954","A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.","Peripheral Blood Mononuclear Cell | PBMC | PERIPHERAL BLOOD MONONUCLEAR CELL | Peripheral Blood Mononuclear cells",,,,,,,,,,,,,,,"4229415","Peripheral blood mononuclear cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039194","T-Lymphocyte","C12476","A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc.","T-Lymphocyte | T Cell | T Cells | T cell | T lymphocyte | T-Cell | T-Cells | T-Lymphocytes | Thymus Derived Lymphocyte | Thymus-Dependent Lymphocytes",,,,,,,,,,,,,,,"4238820","T lymphocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035268","Restriction fragment length polymorphism","C17093","Variation occurring within a species in the length of DNA fragments generated by a specific endonuclease. Such variations are generated by mutations that create or abolish recognition sites for these enzymes.","Restriction Fragment Length Polymorphism | Molecular Biology, Restriction Fragment Length Polymorphisms | Polymorphism, Restriction Fragment Length | RFLP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242827","Minisatellite Repeats","C13334","Tandem arrays of moderately repetitive (5-50 repeats) short (10-60 bases) DNA sequences found dispersed throughout the genome and clustered near telomeres.  Their degree of repetition is two to several hundred at each locus.  Loci number in the thousands but each locus shows a distinctive repeat unit.","Minisatellite Repeat | Minisatellite | Minisatellite Repeats | Minisatellites | VNTR | Variable Number Tandem Repeat | Variable Number of Tandem Repeats",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026780","Mumps","C29888","A contagious viral infection caused by the mumps virus. Symptoms include swollen and tender parotid glands, fever, muscle aches and fatigue. Due to vaccination programs, mumps has become a rare disease.","Mumps | Epidemic Parotitis",,,,,,,,,,,,,,,"4290000","Mumps",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0449255","Context","C63325","The universe of discourse that surrounds a language unit and helps to determine its interpretation.","Context | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0948762","Absolute Neutrophil Count","C63321","The real number of white blood cells (WBC) that are neutrophils. It is derived by multiplying the WBC count by the percent of neutrophils in the differential WBC count. The normal range for ANC is 1.5 to 8.0 (1,500 to 8,000/mm3).","Absolute Neutrophil Count | ANC | Absolute Neutrophil | NEUT | Neutrophils",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882078","Neutrophil Engraftment","C63322","An absolute neutrophil count (ANC) of 500 or more (500 or more neutrophils in a cubic millimeter of blood) for 3 days in a row is a sign of engraftment. Neutrophil engraftment can occur as early as 10 days after transplant. About 20 days is more common for patients who receive marrow or peripheral (circulating) blood cells. For patients who receive cord blood, the average time to neutrophil engraftment is between 21 and 35 days.","Neutrophil Engraftment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882407","Platelet Engraftment","C63323","A platelet count of 20,000 to 50,000 (platelets per microliter of blood) is a sign of platelet engraftment. For patients who receive marrow or peripheral blood cells, platelet engraftment often happens at the same time or a little bit after neutrophil engraftment. For patients who receive cord blood, it may be 8 weeks or longer after transplant before platelet engraftment occurs.","Platelet Engraftment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919746","Engraftment Syndrome","C63324","A toxicity of hematopoietic stem cell transplantation that manifests as fever, rash and pulmonary deterioration which becomes evident at marrow engraftment. It occurs unexpectedly and is occasionally fatal. It can occur after an autogeneic or an allogeneic hematopoietic cell transplantation.","Engraftment Syndrome | ",,,,,,,,,,,,,,,"4141365","Engraftment syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332287","With","C62355","Used to indicate the presence of something or someone.","With | Cum | c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0237876","Sharing (Social Behavior)","C38019","Have in common; held or experienced in common.","Shared | Common | SHARED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439605","Random","C60702","Governed by or depending on chance; lacking any definite plan or order or purpose.","Random | ",,,,,,,,,,,,,,,"4116363","Random",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705285","Mutation Abnormality","C45576","Any transmissible change in the genetic material of an organism, which can result from radiation, viral infection, transposition, treatment with mutagenic chemicals and errors during DNA replication or meiosis. The effects of mutation range from single base changes to loss or gain of complete chromosomes. As many of the simpler alterations to DNA may be repaired, such changes are only heritable once the change is fixed in the DNA by the process of replication. Mutations may be associated with genetic diversity or with pathologies including cancer.","Mutation Abnormality | Expression Consequence | Genetic Alteration | Genetic Change | Mutated | Mutation | Mutation NOS | Mutation, NOS | mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514485","Proliferation","C28378","Multiplying or increasing in number.","Proliferation | PROLIFERATING | Proliferating | Proliferating | proliferating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4012822","Peptic Ulcer","C3318","A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.","Peptic Ulcer | Peptic Ulcer (Ulcer) | Peptic Ulcer Disease | peptic ulcer",,,,,,,,,,,,,,,"4027663","Peptic ulcer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512804","Dihydrotestosterone","C29619","The most potent androgen, required for sex development. Dihydrotestosterone is synthesized from testosterone in the prostate gland, testes, hair follicles and adrenal glands by 5-alpha reductase. Dihydrotestosterone exerts its action similar to testosterone, which binds to and activates specific nuclear androgen receptors.  After translocation into the nucleus, the activated hormone-receptor complex binds to the androgen response elements on the DNA and activates gene expressions that are required for sex development. Dihydrotestosterone is responsible for the formation of male primary sex characteristics and most male secondary sex characteristics during puberty, such as muscular growth, facial and body hair growth, and deepening of the voice.","Dihydrotestosterone | (5alpha,17beta)-17-Hydroxyandrostan-3-one | Androstanolone | DHT | androstanolone | dihydrotestosterone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3712803","Insulin-Like Growth Factor I, Human","C16743","Insulin-like growth factor I (195 aa, ~22 kDa) is encoded by the human IGF1 gene. This protein may be involved in the regulation of glucose metabolism.","Insulin-Like Growth Factor I | IGF I | IGF-1 | IGF-I | IGF1 | Insulin-Like Growth Factor 1 | Insulin-Like Growth Factor 1 | Insulin-Like Growth Factor-I | MGF | Mechano Growth Factor | Somatomedin C | Somatomedin-C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017833","GSTP1 protein, human","C18049","Glutathione S-transferase P (210 aa, ~23 kDa) is encoded by the human GSTP1 gene. This protein plays a role in xenobiotic metabolism and the negative regulation of both cell death and cell proliferation.","Glutathione S-Transferase P | GST Class-Pi | GST-Pi | GST3 | GSTP1 | GSTP1-1 | Glutathione S-Transferase 3 | Glutathione S-Transferase Pi | Glutathione S-Transferase Pi | Glutathione S-Transferase Pi 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708739","Loss of Range of Motion","C50637","A finding that the flexibility of a joint is below the expected range of normal for that individual.","Loss of Range of Motion | Loss Of Range Of Motion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705180","Recall (activity)","C53609","A removal or correction of a marketed product that the FDA considers to be in violation of the laws it administers and against which the agency would initiate legal action, such as seizure. A recall may be a voluntary action conducted by the manufacturer, by FDA request, or by FDA order under statutory authority.","Recall | RECALL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708568","Inverse Role","C43275","An inverse role has the same basic meaning of a role entity but is expressed in the opposite direction.","Inverse Role | Inverse Role Entity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705099","Vector (data type)","C54169","A single dimensional array.","Vector | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708567","Inverse Association","C54170","An inverse association has the same basic meaning of an association but is expressed in the opposite direction.","Inverse Association | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705419","NCI Thesaurus Property","C43644","A specific terminology property present in the NCI Thesaurus.","NCI Thesaurus Property | EVS Concept Property | Property",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550459","Concept Attribute","C54176","Any of the properties, roles, or associations, that define a concept.","Concept Attribute | Attribute",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705912","Terminology Property","C43645","Properties are a convenience that allows the knowledge engineer to attach auxilary or non-semantic external information to concepts. They can be used for anything whatsoever, and have no bearing on classification and do not inherit. Often they are used for storing documentation strings and numeric codes.","Terminology Property | Property | Property",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705255","Concept History","C42687","The tracking of concept evolution over the lifetime of a vocabulary, includes concept creation, modification, merges, splits, and retirements.","Concept History | EVS Concept Object History | History | NCI Thesaurus Concept History",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706222","NCI Concept Atom","C42757","In the NCI Thesaurus an atom consists of a term string, a term type, a term source, and an optional term code.  They can be thought of as synonyms or alternative valid forms of a particular concept. This information resides in the property FULL_SYN.","NCI Concept Atom | Atom | Concept Atom",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708695","Lexical Group Unique Identifier","C54177","A unique identifier of a group of lexically equivalent atoms. For English language entries in the Metathesaurus, each string is linked to all of its lexical variants or minor variations by means of a common term identifier (LUI). In the Metathesaurus, therefore, an English 'term' is the group of all strings that are lexical variants of each other.","Lexical Group Unique Identifier | LUI | NLM LUI | UMLS LUI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706443","NCI Thesaurus Qualifier","C43647","For each property or association you assign to a concept you also can specify an established qualifier type and value. For properties, the qualifier provides additional detail regarding the nature of a concept property (e.g., a property effective date, or an indicator reflecting that the property is Current). For associations, the qualifier provides additional detail regarding the nature of the concept association (for example, the degree of accuracy of the relationship, such as Usually).","NCI Thesaurus Qualifier | Qualifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704770","NCI Thesaurus Association","C43646","An association is a non-hierarchical, named relationship between a source and target concept that does not affect classification and is not inherited by child concepts during classification.  Associations are bidirectional and have a stated inverse.  Unlike roles, associations do not have a domain or range.","NCI Thesaurus Association | Association",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706233","Silo (dataset)","C54175","A repository of customized concept terminology data from a knowledgebase.","Silo | Dataset",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439063","Alphanumeric","C63345","A term used to describe a character string containing only letters and numbers.","Alphanumeric | ",,,,,,,,,,,,,,,"4156064","Alphanumeric",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3665477","Chemotherapy Regimen or Agent Combination","C12218","A combination of multiple drugs used in standard or clinical trial treatments. The order, dosage or dosing interval of the individual ingredients may not be specified.","Chemotherapy Regimen or Agent Combination | Chemotherapy Regimen | Combination Chemotherapy Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882405","Planimeter","C63401","An instrument for measuring the area of an irregular plane figure.","Planimeter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042769","Viral Infection","C3439","Any disease caused by a virus.","Viral Infection | Other viral infection | Viral Disease | Viral Disorder",,,,,,,,,,,,,,,"440029","Viral disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516974","Estrogen Receptor Status - Clinical Trial Eligibility Criteria","C16150","The estrogen receptor level measured in a primary tumor or in metastases.  There are essentially two distinct forms of breast cancer, one that tends to have an early onset and is characterized by an ER- status, and one that tends to have a late onset and is characterized by an ER+ status.  However, these two variants tend to overlap with respect to age, so it is possible for a young woman to have a 'late-onset' form of breast cancer and for an older woman to have an 'early-onset' variant of the disease.","Estrogen Receptor Status | ER Alpha Status | ER Status | ER-Alpha Status | ERA Status | ESR Status | ESR1 Status | ESRA Status | ESTRR Status | Estrogen Receptor | Estrogen Receptor 1 Status | Estrogen Receptor Alpha Status | NR3A1 Status | Nuclear Receptor Subfamily 3 Group A Member 1 Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514471","Progesterone Receptor Status","C16149","Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards)","Progesterone Receptor Status | PgR Status | Progesterone Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880017","Central Nervous System Carcinoma","C62332","A malignant tumor arising in the epithelial cells of the brain or spinal cord.","Central Nervous System Carcinoma | Primary Central Nervous System Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085136","Central Nervous System Neoplasm","C9293","A benign or malignant, primary or metastatic neoplasm that affects the brain, meninges, or spinal cord.  Representative examples of primary neoplasms include astrocytoma, oligodendroglioma, ependymoma, and meningioma.  Representative examples of metastatic neoplasms include carcinoma and leukemia.","Central Nervous System Neoplasm | Brain/Spinal Cord Tumor | CNS Neoplasm | CNS Tumor | CNS tumor | Central Nervous System Tumor | Neoplasm of CNS | Neoplasm of Central Nervous System | Neoplasm of the Central Nervous System | Neoplasm of uncertain behavior of central nervous system, unspecified | Tumor of CNS | Tumor of Central Nervous System | Tumor of the CNS | Tumor of the Central Nervous System | central nervous system tumor",,,,,,,,,,,,,,,"4131770","Neoplasm of central nervous system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009402","Colorectal Carcinoma","C2955","A malignant epithelial neoplasm that arises from the colon or rectum and invades through the muscularis mucosa into the submucosa.  The vast majority are adenocarcinomas.","Colorectal Carcinoma | CRC | Cancer of Large Bowel | Cancer of Large Intestine | Cancer of the Large Bowel | Cancer of the Large Intestine | Carcinoma of Large Bowel | Carcinoma of Large Intestine | Carcinoma of the Large Bowel | Carcinoma of the Large Intestine | Colorectal (Colon or Rectal) Cancer | Colorectal Cancer | Colorectal cancer, NOS | Large Bowel Cancer | Large Bowel Carcinoma | Large Intestine Cancer | Large Intestine Carcinoma | colorectal cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009404","Colorectal Neoplasm","C2956","A benign or malignant neoplasm that affects the colon or rectum.  Representative examples of benign neoplasms include lipoma and leiomyoma.  Representative examples of malignant neoplasms include carcinoma, lymphoma, and sarcoma.  Colorectal adenomas always exhibit epithelial dysplasia and are considered premalignant neoplasms.","Colorectal Neoplasm | Colorectal Tumor | Large Bowel Neoplasm | Large Bowel Tumor | Large Intestinal Neoplasm | Large Intestine Neoplasm | Large Intestine Tumor | Neoplasm of Large Bowel | Neoplasm of the Large Bowel | Tumor of Large Bowel | Tumor of the Large Bowel",,,,,,,,,,,,,,,"4130514","Neoplasm of large intestine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0449830","Arrangement","C61532","The spatial property of the way in which something is placed.","Arrangement | Configuration | configuration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1947953","Stalk - anatomical structure","C62353","A slender or elongated structure that supports another usually larger structure.","Stalk | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987365","Colorectal Cancer TNM Finding v6","C60833","A finding about one or more characteristics of colorectal cancer, following the rules of the TNM AJCC v6 classification system.","Colorectal Cancer TNM Finding v6 | Colon Cancer TNM Finding v6 | Colorectal Cancer TNM Finding | Colorectal Carcinoma TNM Finding v6 | Rectal Cancer TNM Finding v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883364","Transanal Excision","C62398","Surgery for rectal cancer that spares the anus and leaves the sphincter intact. Surgery is performed through the anus and removes only the rectal tumor and small amounts of surrounding tissue.","Transanal Excision | Transanal Disc Excision | Transanal Disk Excision",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1947912","Integrity","C62446","The state of being complete or undivided, of being sound or undamaged.","Integrity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027653","Neoplasm by Site","C3263","A term that refers to the classification of a neoplastic process according to the anatomic site that is involved.","Neoplasm by Site | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3149267","Kidney Neoplasm","C3150","A benign or malignant neoplasm affecting the kidney. Representative examples of benign renal neoplasms include fibroma, lipoma, oncocytoma, and juxtaglomerular cell tumor. Representative examples of malignant renal neoplasms include renal cell carcinoma, renal pelvis carcinoma, Wilms tumor, rhabdoid tumor, sarcoma, and lymphoma.","Kidney Neoplasm | Kidney Tumor | Neoplasm of Kidney | Neoplasm of the Kidney | Renal Neoplasm | Renal Neoplasm | Renal Tumor | Renal Tumors | Tumor of Kidney | Tumor of the Kidney",,,,,,,,,,,,,,,"4131748","Neoplasm of kidney",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1300579","Fuhrman Nuclear Grade","C62411","A 4-point scale for renal cell carcinoma that indicates the level of protein synthesis activity in malignant cells based on the appearance of the nuclei. The grading ranges from I (best prognosis) to IV (worst prognosis).","Fuhrman Nuclear Grade | FUHRMAN NUCLEAR GRADE | Fuhrman Grade | Fuhrman Tumor Grade | Histologic Tumor Grade/Fuhrman Nuclear Grade",,,,,,,,,,,,,,,"4262472","Fuhrman nuclear grade",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1378703","Kidney Carcinoma","C9384","A carcinoma arising from the epithelium of the renal parenchyma or the renal pelvis.  The majority are renal cell carcinomas.  Kidney carcinomas usually affect middle aged and elderly adults.  Hematuria, abdominal pain, and a palpable mass are common symptoms.","Kidney Carcinoma | Kidney (including Renal Cell) Cancer | Kidney Cancer | Kidney cancer, NOS | Renal Cancer | Renal Carcinoma | Renal Carcinoma | kidney cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883677","Focality","C62405","The quality of having a central point of origin.","Focality | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0740457","Malignant Kidney Neoplasm","C7548","Primary or metastatic malignant neoplasm involving the kidney.","Malignant Kidney Neoplasm | Malignant Kidney Tumor | Malignant Neoplasm of Kidney | Malignant Neoplasm of the Kidney | Malignant Renal Neoplasm | Malignant Renal Neoplasm | Malignant Renal Tumor | Malignant Tumor of Kidney | Malignant Tumor of the Kidney",,,,,,,,,,,,,,,"196653","Malignant tumor of kidney",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1881468","Lung Cancer TNM Finding v6","C60959","A finding about one or more characteristics of lung cancer, following the rules of the TNM AJCC v6 classification system.","Lung Cancer TNM Finding v6 | Lung Cancer TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0235974","Pancreatic Carcinoma","C3850","A carcinoma that arises from the exocrine pancreas. The vast majority of exocrine pancreas carcinomas are adenocarcinomas. The main subtype of pancreatic adenocarcinoma is ductal adenocarcinoma, which is the most frequently seen type of pancreatic carcinoma.","Exocrine Pancreas Carcinoma | Cancer of Exocrine Pancreas | Cancer of Pancreas | Cancer of the Pancreas | Carcinoma of Exocrine Pancreas | Carcinoma of Pancreas | Carcinoma of the Pancreas | Exocrine Pancreas Cancer | Exocrine Pancreas Carcinoma | Pancreas Cancer | Pancreas Carcinoma | Pancreatic Cancer | Pancreatic Carcinoma | Pancreatic cancer (excluding Islets), NOS | Pancreatic cancer (not Islets) | exocrine cancer | pancreatic cancer",,,,,,,,,,,,,,,"4157459","Carcinoma of pancreas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0346647","Malignant Pancreatic Neoplasm","C9005","A primary or metastatic malignant tumor involving the pancreas.  Representative examples include carcinoma and lymphoma.","Malignant Pancreatic Neoplasm | Malignant Neoplasm of Pancreas | Malignant Neoplasm of the Pancreas | Malignant neoplasm of pancreas, unspecified",,,,,,,,,,,,,,,"4180793","Malignant tumor of pancreas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030297","Pancreatic Neoplasm","C3305","A benign or malignant neoplasm involving the pancreas.","Pancreatic Neoplasm | Neoplasm of Pancreas | Neoplasm of the Pancreas | Pancreas Neoplasm | Pancreas Tumor | Pancreatic Tumor | Tumor of Pancreas | Tumor of the Pancreas",,,,,,,,,,,,,,,"4129886","Neoplasm of pancreas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0228116","Cerebral Meninges","C12349","The membranes that envelop and protect the brain.","Cerebral Meninges | Cerebral meninges",,,,,,,,,,,,,,,"4231110","Structure of brain meninges",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0228174","Cerebral Hemisphere","C12351","The part of the brain that controls muscle functions and also controls speech, thought, emotions, reading, writing, and learning. The right hemisphere controls the muscles on the left side of the body, and the left hemisphere controls the muscles on the right side of the body.","Cerebral Hemisphere | BRAIN, CEREBRUM | Brain Hemisphere | Brain, Cerebrum | CEREBRUM | Cerebral | Cerebral Hemispheres | Cerebral hemisphere structure (body structure) | Cerebrum | Structure of cerebrum (body structure) | cerebral hemisphere | cerebrum","C71.0|C71.0","Cerebral hemisphere|Cerebrum",,,,,,,,,,,"UBERON:0001869","cerebral hemisphere","4157335","Cerebral hemisphere structure",,,,,,,,,,,,,"--","--|--",,,,,,,,"--"
"C0230054","Suprasellar Region","C42602","The area above or over the sella turcica.","Suprasellar Region | Structure of suprasellar region (body structure) | Suprasellar",,,,,,,,,,,,,,,"4035640","Structure of suprasellar region",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031939","Pineal Gland","C12398","A small endocrine gland in the brain, situated beneath the back part of the corpus callosum, that secretes melatonin.","Pineal Gland | GLAND, PINEAL | PINEAL GLAND | Pineal | Pineal Body | Pineal gland | Pineal structure (body structure) | corpus pineale | glandula pinealis | pineal body | pineal gland | pineal organ",,,,,,,,,,,,,"UBERON:0001905","pineal body","4164136","Pineal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007764","Cerebellopontine Angle","C54057","A region of the brain at the junction of the pons, cerebellum, and medulla. It is a frequent site of tumor formation.","Cerebellopontine Angle | ",,,,,,,,,,,,,,,"4067280","Structure of cerebellopontine angle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007799","Brain Ventricle","C12356","The four connected cavities (hollow spaces) centrally located within the brain that connect posteriorly with the central canal of the spinal cord.","Brain Ventricle | BRAIN VENTRICLE | Brain, Ventricle, NOS | Space of ventricular system of brain (body structure) | Ventricle | Ventricle of Brain | Ventricle, Brain | Ventricle, NOS | Ventricles, Brain | brain ventricle",,,,,,,,,,,,,,,"4261981","Brain ventricle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0228084","Nerve Root","C54024","The initial segment of a nerve after it has branched off from the central nervous system.","Nerve Root | NERVE ROOT | Nerve root structure (body structure)",,,,,,,,,,,,,,,"4164957","Nerve root structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883546","WHO Central Nervous System Grade I","C62394","Describes central nervous system tumors that are generally low malignancy, non-infiltrative, and slow growing. Often they can be cured by surgery alone and there is a good chance of long term survival.","WHO Central Nervous System Grade 1 | Grade I | I | WHO Central Nervous System Grade I | WHO Central Nervous System Grade I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883547","WHO Central Nervous System Grade II","C62395","Describes central nervous system tumors that are generally relatively slow growing and somewhat infiltrative. They may recur after treatment.","WHO Central Nervous System Grade 2 | Grade II | II | WHO Central Nervous System Grade II | WHO Central Nervous System Grade II | WHO Grade II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883548","WHO Central Nervous System Grade III","C62396","Describes central nervous system tumors that are generally malignant and infiltrative. They tend to recur after treatment.","WHO Central Nervous System Grade 3 | Grade III | III | WHO Central Nervous System Grade III | WHO Central Nervous System Grade III | WHO Grade III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883549","WHO Central Nervous System Grade IV","C62397","Describes central nervous system tumors that are generally highly malignant, show rapid and aggressive growth, widely infiltrative, and prone to necrosis. They often recur rapidly after treatment.","WHO Central Nervous System Grade 4 | Grade IV | IV | WHO Central Nervous System Grade IV | WHO Central Nervous System Grade IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335371","Pedunculated Lesion","C35936","A lesion connected to the underlying tissue by a small stalk.","Pedunculated Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335952","Sessile Lesion","C35935","Attached directly by the base; not having an intervening stalk.","Sessile Lesion | Sessile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205266","Intact","C62399","Undamaged in any way; whole.","Intact | ",,,,,,,,,,,,,,,"4008705","Intact",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227391","Sigmoid Colon","C12384","The portion of the colon that connects to the descending colon above and the rectum below.","Sigmoid Colon | COLON, SIGMOID | Sigmoid colon | Sigmoid colon structure (body structure) | sigmoid colon",,,,,,,,,,,,,"UBERON:0001159","sigmoid colon","4244588","Sigmoid colon structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1179187","Lamina Propria","C32918","The connective tissue coat of a mucous membrane including the epithelium and basement membrane.","Lamina Propria | lamina propria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225357","Muscularis Mucosa","C33149","A thin layer of smooth muscle fibers found as a part of the tunica mucosa in the gastrointestinal tract and urinary bladder deep to the lamina propria mucosae.","Muscularis Mucosa | ",,,,,,,,,,,,,,,"4155445","Muscularis mucosa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0225344","Submucosa","C13167","A layer of areolar tissue beneath the mucous membrane","Submucosa | submucosa",,,,,,,,,,,,,,,"4287103","Tunica submucosa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448918","Muscularis Propria","C62404","The detrusor muscle of the bladder, forming the muscular wall of the bladder, consisting of the inner longitudinal; middle circular; and outer longitudinal layers.","Muscularis Propria | Detrusor Muscle of the Bladder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0442161","Perinephric","C62408","Surrounding the kidney in whole or in part.","Perinephric | ",,,,,,,,,,,,,,,"4139331","Perinephric",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227637","Renal Capsule","C12885","A layer of dense connective tissue that covers the outer surface of each kidney.","Renal Capsule | renal capsule",,,,,,,,,,,,,,,"4049133","Structure of capsule of kidney",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042449","Vein","C12814","A blood vessel that carries blood toward the heart.","Vein | VEIN | Venous | vein | venous tree organ part",,,,,,,,,,,,,"UBERON:0001638","vein","4104340","Venous structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022663","Glomerulus","C13250","A tuft of capillaries situated at the entrance to each nephron, within the Bowman's capsule. This tuft functions as the first stage in filtering blood in the kidney.","Glomerulus | GLOMERULUS | Glomerular | Malpighian Tuft | Renal Glomerulus | renal glomerulus",,,,,,,,,,,,,,,"4195524","Glomerulus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027697","Nephritis","C26833","Inflammation of renal tissue.","Nephritis | ",,,,,,,,,,,,,,,"193253","Nephritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1881236","Interstitial Disease","C62410","A disease occurring chiefly in the connective-tissue framework of an organ.","Interstitial Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880858","Fuhrman Grade 1","C62428","Nuclei round, uniform, approximately 10 microns; nucleoli inconspicuous or absent","Fuhrman Grade 1 | Fuhrman Nuclear Grade 1 | G1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880859","Fuhrman Grade 2","C62429","Nuclei slightly irregular, approximately 15 microns; nucleoli evident.","Fuhrman Grade 2 | Fuhrman Nuclear Grade 2 | G2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880860","Fuhrman Grade 3","C62430","Nuclei very irregular, approximately 20 microns; nucleoli large and prominent.","Fuhrman Grade 3 | Fuhrman Nuclear Grade 3 | G3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880861","Fuhrman Grade 4","C62431","Nuclei bizarre and multilobated, 20 microns or greater, nucleoli prominent, chromatin clumped.","Fuhrman Grade 4 | Fuhrman Nuclear Grade 4 | G4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225752","Lung Lobe","C34021","One of the subdivisions of the lung, 2 in the left lung and 3 in the right lung.","Lung Lobe | LUNG LOBE | Structure of lobe of lung (body structure)",,,,,,,,,,,,,,,"4150049","Structure of lobe of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0225756","Upper Lobe of the Lung","C12285","The upper-most lobe of either lung.","Upper Lobe of the Lung | Lung Upper Lobe | Superior Lobe of the Lung | Upper Lobe | Upper Lobe, Lung | Upper lobe, lung | upper lobe of lung",,,,,,,,,,,,,,,"4167002","Structure of upper lobe of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0225758","Lower Lobe of the Lung","C12287","The bottom most subdivision of either the right or left lung.","Lower Lobe of the Lung | Lower Lobe | Lower Lobe, Lung | Lower lobe, lung | Lung Lower Lobe | lower lobe of lung",,,,,,,,,,,,,,,"4235763","Structure of lower lobe of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227579","Head of the Pancreas","C12269","That portion of the pancreas lying in the concavity of the duodenum.","Head of the Pancreas | Head of Pancreas | Head of pancreas | PANCREAS, HEAD | Pancreas Head | Pancreatic Head | Structure of head of pancreas (body structure) | head of pancreas",,,,,,,,,,,,,,,"4275124","Structure of head of pancreas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227582","Body of the Pancreas","C12270","The part of the pancreas from the point where it crosses the portal vein to the point where it enters the lienorenal ligament.","Body of the Pancreas | Body | Body of Pancreas | Body of pancreas | PANCREAS, BODY | Pancreas Body | Pancreatic Body | body of pancreas",,,,,,,,,,,,,,,"4223040","Structure of body of pancreas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227580","Uncinate Process of Pancreas","C62432","A portion of the pancreas that extends behind the superior mesenteric artery and superior mesenteric vein.","Uncinate Process of Pancreas | UNCINATE PROCESS OF PANCREAS | Uncinate Pancreas | Uncinate Pancreas | Uncinate Process",,,,,,,,,,,,,,,"4107217","Structure of uncinate process of pancreas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227590","Tail of the Pancreas","C12271","The left extremity of the pancreas within the lienorenal ligament.","Tail of the Pancreas | PANCREAS, TAIL | Pancreas Tail | Pancreatic Tail | Structure of tail of pancreas (body structure) | Tail | Tail of Pancreas | Tail of pancreas | tail of pancreas",,,,,,,,,,,,,,,"4248267","Structure of tail of pancreas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0450127","Allograft","C60701","A graft transferred from a donor of one species to a recipient of the same species but different genetic makeup.","Allograft | ",,,,,,,,,,,,,,,"4195128","Allograft",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0012931","Recombinant DNA","C453","Biologically active DNA which has been formed by the in vitro joining of segments of DNA from different sources usually for the purpose of genetic manipulation.","Recombinant DNA | Construct | DNA Construct | Molecular Biology, Recombinant DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515351","The Jackson Laboratory Cancer Center","C39529","The Jackson Laboratory Cancer Center conducts basic research using the mouse as a research tool. Its mission is to discover the genetic basis for preventing, treating, and curing human disease, and to enable broader research in the global biomedical community. This independent, nonprofit organization was designated as an NCI cancer center in 1983.","The Jackson Laboratory Cancer Center | JAX | JLCC | Jackson Labs | The Jackson Laboratory | The Jackson Laboratory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709142","NSC_Number","C43700","A property that stores the NSC Number identifier for substances submitted to the National Cancer Institute (NCI) Developmental Therapeutics Program (DTP) for testing and evaluation.","NSC_Number | NSC_Code | NSC_Code | NSC_Number_Property",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007090","Carcinogen","C347","Any chemical, biological or physical agents that increase the risk of neoplasms in humans or animals.  Carcinogens include natural or synthesized compounds, certain viruses, and various sources of radiation.  A carcinogen may directly alter the genetic material of cells (genotoxic), thereby initiating or promoting the process of malignant transformation; it also may induce cancers by mechanisms that do not involve a direct alteration of cellular genetic material (non-genotoxic). (NCI04)","Carcinogen | Cancer Causing Agents | carcinogen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881903","Morpholino","C60700","An antisense oligonucleotide modified to be more stable than RNA. While morpholinos have standard nucleic acid bases, those bases are bound to morpholine rings instead of deoxyribose rings and linked through phosphorodiamidate groups instead of phosphates. Morpholinos are used to inhibit translation or splicing of specific, complementary mRNAs.","Morpholino | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026769","Multiple Sclerosis","C3243","A progressive autoimmune disorder affecting the central nervous system resulting in demyelination. Patients develop physical and cognitive impairments that correspond with the affected nerve fibers.","Multiple Sclerosis | Multiple sclerosis | multiple sclerosis",,,,,,,,,,,,,,,"374919","Multiple sclerosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031036","Polyarteritis Nodosa","C26847","A necrotizing vasculitis that affects medium-sized arteries, it is usually idiopathic, and may be triggered by viral infections (Hepatitis B, also others). A multisystem disease, it most commonly affects skin (nodules, livedo reticularis) and peripheral nerves; higher morbidity is associated with gastrointestinal, central nervous system, cardiac, and/or other organ involvement. Anti-neutrophil cytoplasmic antibodies (ANCA) are typically negative.","Polyarteritis Nodosa | Classic Polyarteritis Nodosa | Classical Polyarteritis Nodosa | PAN | Panarteritis Nodosa | Periarteritis Nodosa | Polyarteritis nodosa",,,,,,,,,,,,,,,"320749","Polyarteritis nodosa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020473","Hyperlipidemia","C34707","Elevated levels of lipids in the blood.","Hyperlipidemia | ",,,,,,,,,,,,,,,"432867","Hyperlipidemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709145","Name-Value Pair","C47921","The name of a field together with the value of the field.","Name-Value Pair | Name Value | Name Value Pair | Name-Value | Name/Value | Name/Value Pair",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0450363","3-Dimensional","C18005","The property of being measured and described using three orthogonal directions.","3-Dimensional | 3-D | 3-dimensional | 3D",,,,,,,,,,,,,,,"4131156","Three-dimensional",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705178","Order (action)","C48906","The act of requesting that a person, business, or organization do or supply something.","Order | Ordered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883523","Value Meaning Not Provided","C62635","This Value Meaning was not provided and is to be manually entered.","Value Meaning Not Provided | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439300","Micromole per Liter","C48508","A unit of concentration (molarity unit) equal to one one-millionth of a mole (10E-6 mole) of solute per one liter of solution.","Micromole per Liter | Attomole per Picoliter | Femtomole per Nanoliter | MICROMOLAR | Micormolar | Micromolar | Nanomole per Milliliter | Picomole per Microliter | Zeptomole per Femtoliter | amol/pL | fmol/nL | mcmol/L | micromolar | micromole(s)/litre | micromoles per liter | nanomole(s)/millilitre | nanomoles per milliliter | nmol/mL | nmol/ml | pmol/uL | umol/L | umol/l | zmol/fL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704458","Top","C62637","The uppermost part, side, or surface of something.","Top | ",,,,,,,,,,,,,,,"4228436","Top",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0457385","Second","C42535","A unit of time, one of the seven base units of the International System of Units (Systeme International d'Unites, SI). The second is the duration of 919 263 177 0 periods of the specified light radiation corresponding to the transition between the two hyperfine levels of the caesium 133 atom in its ground state at 0 K. According to the convention, 60 seconds constitute one minute; 3,600 seconds constitute one hour.","Second | SECOND | Seconds | s | sec | second | seconds",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439201","Micron","C48510","A unit of length in metric system equal to 10E-6 meter, or micrometer.","Micron | MICRON | Micrometer | mcm | micrometer | micron | um",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475209","Meter","C41139","A unit of linear measure in the metric system, one of the seven base units of the International System of Units (Systeme International d'Unites, SI). A meter is defined as the length of the path traveled by light in a vacuum during a time interval of 1/299 792 458 of a second and is equal to 1.093 61 yards.","Meter | m | meter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439189","Mole","C42539","A unit of amount of substance, one of the seven base units of the International System of Units (Systeme International d'Unites, SI). It is the amount of substance that contains as many elementary units as there are atoms in 0.012 kg of carbon-12. When the mole is used, the elementary entities must be specified and may be atoms, molecules, ions, electrons, other particles, or specified groups of such particles.","Mole | M | MOLE | mol | mole | mole (chemical) | mole(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439191","Nanomole","C48517","A unit of amount of substance equal to 10E-9 mole.","Nanomole | NANOMOLE | nanomole | nanomole(s) | nmol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439194","Micromole","C48509","A unit of amount of substance equal to a millionth of a mole.","Micromole | MICROMOLE | mcmol | micromole | micromole(s) | umol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439190","Millimole","C48513","A unit of amount of substance equal to 0.001 mole.","Millimole | MILLIMOLE | millimole | millimole(s) | mmol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475211","Liter","C48505","The non-SI unit of volume accepted for use with the SI. One liter is equal to cubic decimeter, or one thousandth of cubic meter, or 1000 cubic centimeters, or approximately 61.023 744 cubic inches.","Liter | Cubic Decimeter | L | LITER | LT | dm3 | l | liter | litre(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439212","Nanogram","C48516","The metric unit of mass equal to one billionth of a gram (10E-9 gram) or one thousandth of a milligram.","Nanogram | NANOGRAM | nanogram | nanogram(s) | ng",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880157","Computation (action)","C61298","The act of calculating; determining something by mathematical or logical methods.","Computation | Computational | Computed | Computing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439239","Kelvin","C42537","A basic unit of thermodynamic temperature, one of the seven base units of the International System of Units (Systeme International d'Unites, SI). It is 1/273.16th of the thermodynamic temperature of the triple point of water. This sets the size of the kelvin unit for temperature differences and defines the thermodynamic temperature of an equilibrium mixture of waters ice-liquid-vapor as 273.16 K, where 0 K is the lowest possible temperature ('absolute zero').","Kelvin | Degree Kelvin | K | degree Kelvin | kelvin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007836","Certification","C43610","The process by which a person demonstrates specific knowledge, skills, or abilities in the view of a certifying body.  Similarly, the process by which a product or process can achieve certification indicating its suitability for a specific purpose.","Certification | Certified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2607871","Range of Motion","C63507","A measure of joint flexibility consisting of flexion, how far it can bend, and extension, how far it can stretch. It is usually measured by the number of degrees from the starting position of a segment to its position at the end of its arc.","Range of Motion | Joint Mobility | Joint Range of Motion | Joint Range of Movement | Mobility",,,,,,,,,,,,,,,"4264818","Range of joint movement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1879548","Active Range of Motion","C63509","A measure of how far a patient can move a body part against gravity","Active Range of Motion | AROM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079991","Passive Range of Motion","C63512","A measure of how far a joint can move when it is being manipulated by someone other than the patient.","Passive Range of Motion | PROM",,,,,,,,,,,,,,,"4058931","Passive movement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0175674","Manual","C63513","Of or related to the hands; reference to a task or activity being done by hand (as opposed as being performed with the assistance of automation or other supportive means).","Manual | MANUAL",,,,,,,,,,,,,,,"4337123","Manual",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882516","Quick Freeze","C63521","To freeze rapidly so as to preserve structure and prevent ice crystal formation.","Quick Freeze | FLASH FREEZING | Flash Freeze | Flash Frozen | Quick Frozen | Snap Freeze | Snap Frozen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882161","Optimal Cutting Temperature Compound","C63523","A solution of water soluble glycols and resins that provide a specimen support matrix for cryostat sectioning at temperatures of -10 degrees C and below.","Optimal Cutting Temperature Compound | OCT | Tissue-Tek OCT | Tissue-Tek OCT | Tissue-Tek Optimal Cutting Temperature Compound",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0547044","Lesser","C61422","Of lower rank, degree, or importance; of reduced size, extent, or degree; more limited in quantity.","Lesser | Less",,,,,,,,,,,,,,,"4137814","Lesser",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014038","Encephalitis","C26760","An inflammatory process affecting the brain parenchyma. Causes include viral infections and less frequently bacterial infections, toxins, and immune-mediated processes.","Encephalitis | ",,,,,,,,,,,,,,,"378143","Encephalitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025289","Meningitis","C26828","A disorder characterized by acute inflammation of the meninges of the brain and/or spinal cord.","Meningitis | Meningococcal Infection | meningitis",,,,,,,,,,,,,,,"435785","Meningitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882074","Neutral pH","C63342","Neither chemically acidic or basic.","Neutral pH | Neutral | Neutral | pH 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448852","Buffered","C63343","The property of being able to chemically neutralize both acids and bases thereby maintaining the original pH of the solution.","Buffered | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880351","Disabled","C63367","No longer able to be activated or utilized.","Disabled | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0066069","Methacarn","C63344","A liquid preservative for cytological materials, consisting of methanol, chloroform and glacial acetic acid in a 6:3:1 ratio. It is typically used on tissues to be paraffin-embedded and immunochemically stained and is useful for the preservation of nucleic acids in situ.","Methacarn | Methanol-Carnoy | Methanol-substituted Carnoy's Solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0520878","Short PR Interval by ECG Finding","C62246","An electrocardiographic finding of an abnormally short PR interval. Thresholds for different age, gender, and patient populations exist. (CDISC)","Short PR Interval by ECG Finding | SHORT PR INTERVAL | Short PR Interval | Short PR Interval by EKG Finding | Short PR interval | Universal Molecular",,,,,,,,,,,,,,,"4171521","Shortened PR interval",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882529","RNALater","C63348","Trade name for an aqueous, non-toxic tissue storage reagent that rapidly permeates tissues to stabilize and protect cellular RNA.","RNALater | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879533","Acceptable","C63350","Satisfying an established set of qualifying measures.","Acceptable | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205410","Sufficient","C63351","Meeting a quantitative or qualitative measure necessary for a requirement; enough to meet the needs of a situation.","Sufficient | Adequate | Satisfactory",,,,,,,,,,,,,,,"4196803","Sufficient",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1548794","Hemolyzed (Qualitative Concept)","C63352","Having been subjected to a process that has broken open red blood cells and released hemoglobin into the surrounding fluid.","Hemolyzed | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881407","Lipemic (qualifier)","C63353","Characterized by an abnormally high concentration of lipid.","Lipemic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883420","Unacceptable","C63354","Failing to satisfy an established set of qualifying measures.","Unacceptable | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883522","Vacutainer","C63362","A brand of of test tube specifically designed for venipuncture; the tube contains a vacuum allowing it to suck blood though a needle and fill itself. The tube may contain additives to facilitate downstream processing and testing of the blood samples; the tube cap is color-coded to indicate the type of additive present.","Vacutainer | Evacuated Blood Specimen Collection Tube",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1550602","additive ingredient","C63495","A substance that is added to a system or compound to improve its characteristics.","Additive | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0183212","Separators","C63363","A device for separating liquids of different specific gravities (as cream from milk) or liquids from solids.","Separator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013618","Edetic Acid","C61742","The acid form of edetate, a chelating agent with anti-hypercalcemic and anticoagulant properties. Edetic acid binds calcium and heavy metal ions, forming soluble stable complexes which are readily excreted by the kidneys. This results in a decrease in serum calcium levels. This agent is also used as an anticoagulant for blood specimens and is applied as a treatment of lead poisoning.","Edetic Acid | EDETIC ACID | EDTA | Ethylenediaminetetraacetic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376259","Citrate","C63374","A salt or ester of citric acid.","Citrate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0050552","Acid-Citrate-Dextrose","C63375","A solution of citric acid, sodium citrate, and dextrose used as an anticoagulant in the collection and preservation of whole blood.","Acid-Citrate-Dextrose | ACD | Acid Citrate Dextrose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013239","Dry Ice","C63373","A solid form of carbon dioxide used as a refrigerant. At temperatures above -78.5 degrees C and ambient pressure, it changes directly to a gas as it absorbs heat.","Dry Ice | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0232920","Sterile","C63385","Devoid of living organisms.","Sterile | Aseptic",,,,,,,,,,,,,,,"4129756","Sterile",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0083072","Isopentane","C63387","An organic, branched-chain alkane with five carbon atoms.","Isopentane | (CH3)2CHCH2CH3 | 1,1,2-Trimethylethane | 2-methylbutane | Ethyldimethylmethane | ISOPENTANE | Isoamylhydride | Methylbutane",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0597635","Vapor","C63390","The gaseous state of matter that is a solid or liquid at normal room temperature.","Vapor | ",,,,,,,,,,,,,,,"35625039","Vapor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883043","Slurry","C63391","A mixture of solid and liquid matter phases.","Slurry | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880191","Cryobath","C63392","A device designed to generate a liquid environment that is below the freezing point of normal biological tissues (usually -50 to -70 degrees celsius).","Cryobath | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0180202","Cryostat","C63393","An instrument designed to cut frozen tissue specimens on the order of micron-scale thickness, generally for the purposes of histolgical evaluation.","Cryostat | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881775","Melting Point","C63394","Determining the temperature at which a crystalline solid changes state from solid to liquid.","Melting Point Determination | Melting Point | Melting Point",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0444660","Plane","C63534","An imaginary surface formed by extension of a point through any axis or two definite points; any flat two-dimensional surface.","Plane | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708373","Hit - database search return","C54115","A positive return on a search in a database or by way of a search engine on the Internet; the request for and delivery of a file (such as a Web page) on a server.","Hit | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705919","Term Source","C43822","An indicator of the particular group or agency that supplied a specific term.","Term Source | Source | Term Source Property",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706817","Response (statement)","C49149","A statement (either spoken or written) that is made in reply to a question or request or criticism or accusation; a statement that solves a problem or explains how to solve the problem.","Answer | Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1947906","Sorting","C62803","An operation that segregates items into groups according to a specified criterion.","Sorting | Sort | Sorted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0681884","variable, characteristic, factor","C19332","The distinguishing qualities or prominent aspects of an individual person.","Personal Attribute | Personal | Subject Characteristics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881006","Grid Service","C63541","A service available on a network infrastructure that coordinates resources that are not subject to central control, using open, general purpose protocols and interfaces to deliver nontrivial qualities of services.","Grid Service | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880181","Core Grid Service","C63542","Services that are needed to maintain the running of a grid, including monitoring and discovery service, security management service (authentication and authorization), identifier naming and resolution service, query and federated query service, and workflow management service.","Core Grid Service | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879700","Analytical Grid Service","C63543","A published API which receives data in the form of objects, performs computations based upon the input data, and returns information to a client via the grid in the form of one or more objects.","Analytical Grid Service | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1306837","Papillary Renal Cell Carcinoma","C6975","Also known as chromophil carcinoma, it represents a minority of renal cell carcinomas.  It can be hereditary or sporadic.  The sporadic papillary renal cell carcinoma is characterized by trisomy of chromosomes 7, 16, and 17, and loss of chromosome Y.  The peak incidence is in the sixth and seven decades.  It is classified as type 1 or 2, based on the cytoplasmic volume and the thickness of the lining neoplastic cells. The prognosis is more favorable than for conventional (clear cell) renal cell carcinoma.","Papillary Renal Cell Carcinoma | Chromophil Carcinoma of Kidney | Chromophil Carcinoma of the Kidney | Chromophil Renal Cell Carcinoma | PRCC | Papillary (Chromophil) Renal Cell Carcinoma | Papillary RCC | Papillary Renal Cell Cancer | Papillary renal cell carcinoma",,,,,,,,,,,,,,,"37116730|37116731","Papillary renal cell carcinoma|Papillary renal cell carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1883671","Data Grid Service","C63544","A grid service that provides an API with a query method, which allows the querying of any class or attribute in the exposed model.","Data Grid Service | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546002","Sequential","C49153","An event or action that occurs successively after another.","Sequential | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707761","Directionality","C54215","Operating most effectively in a particular direction.","Directionality | DIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1547402","Data types - String","C45253","An expression consisting of a linear sequence of symbols (characters or words or phrases).","String | Character String | String Value | string",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709940","Reviewed","C45314","Having been appraised, evaluated, or analyzed.","Reviewed | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1444748","Initiator","C54190","Something that sets into motion some course of events; a device that activates or releases or causes something to happen.","Initiator | Trigger | trigger",,,,,,,,,,,,,,,"4253758","Evoked",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705914","Repeat Object","C48804","Something occurring more than once.","Repeat Object | Repeat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705711","Unified Modeling Language","C54193","A non-proprietary, third generation modelling language. The Unified Modeling Language is an open method used to specify, visualise, construct and document the artifacts of an object-oriented software-intensive system under development. The UML represents a compilation of 'best engineering practices' which have proven successful in modelling large, complex systems.","Unified Modeling Language | UML",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706937","Bidirectional","C54200","Reactive or functioning or allowing movement in two usually opposite directions.","Bidirectional | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711161","Cardinality","C54199","The number of elements in a set.","Cardinality | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017324","Generalization","C54202","The process of formulating general concepts by abstracting common properties of instances; reasoning from detailed facts to general principles.","Generalization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036612","Semantics","C54194","The meaning of a string in some language; of or relating to the study of meaning and changes of meaning.","Semantics | Semantic | semantic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704709","Computer program package","C54192","Written programs or procedures or rules and associated documentation pertaining to the operation of a computer system and that are stored in read/write memory.","Package | Program Package",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0220931","Training","C17705","To teach with hands-on experience","Training | Training Programs",,,,,,,,,,,,,,,"4040383","Functional training",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266042","Chromophobe Renal Cell Carcinoma","C4146","A type of carcinoma that comprises a minority of renal cell carcinomas.  It is characterized by loss of chromosomes 1 and Y.  Based on the cytoplasmic characteristics of the neoplastic cells, this type of carcinoma is classified as classic (typical), eosinophilic, or oncocytic.  It has a much better prognosis than other renal cell carcinomas.","Chromophobe Renal Cell Carcinoma | Chromophobe Adenocarcinoma | Chromophobe Carcinoma | Chromophobe Carcinoma of Kidney | Chromophobe Carcinoma of the Kidney | Chromophobe Cell Carcinoma of Kidney | Chromophobe Cell Carcinoma of the Kidney | Chromophobe RCC | Chromophobe Renal Cell Cancer | Chromophobe adenocarcinoma | Chromophobe carcinoma | Chromophobe cell renal carcinoma | Renal Cell Carcinoma, Chromophobe Type | Renal cell carcinoma, chromophobe type","8270/3|8317/3","Chromophobe carcinoma|Renal cell carcinoma, chromophobe type",,,,,,,,,,,,,"37116670","Chromophobe renal cell carcinoma",,,,,,,,,,,,,"--","--|--",,,,,,,,"--"
"C1266044","Collecting Duct Carcinoma","C6194","Also known as collecting duct carcinoma, this is a rare type of renal carcinoma. It arises from the collecting ducts of the renal medulla, and most authors suggest that this is an aggressive tumor.","Collecting Duct Carcinoma | BDC | Bellini Duct Carcinoma | Bellini duct carcinoma | Carcinoma of Collecting Ducts of Bellini | Carcinoma of Kidney Collecting Duct | Carcinoma of Renal Collecting Duct | Carcinoma of the Collecting Ducts of Bellini | Carcinoma of the Collecting Ducts of Bellini | Carcinoma of the Kidney Collecting Duct | Carcinoma of the Renal Collecting Duct | Collecting Duct Renal Cell Carcinoma | Collecting duct carcinoma | Collecting duct renal cancer | Kidney Collecting Duct Carcinoma | Renal Collecting Duct Carcinoma | Renal carcinoma, collecting duct type","8319/3","Collecting duct carcinoma",,,,,,,,,,,,,"4029988","Collecting duct carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"CL448841","Cytosol","C61554","The aqueous part of the cytoplasm within which various particles and organelles are suspended.","Cytosol | Cytosolic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881365","Lead Organization","C63409","The principal administrative organization responsible for the research conducted.","Lead Organization | LPO | Lead Protocol Organization | lead organization | lead_organization | program",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882297","Participating Organization","C63411","An organization associated with the Lead Organization and is active in the conduct of the research.","Participating Organization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880867","Funded Principal Investigator","C63403","The investigator named on the award document.  This investigator has full and ultimate responsibility for all research conducted under the award.","Funded Principal Investigator | Funding Principal Investigator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0161912","Partial Pancreatectomy","C51666","Surgical removal of part of the pancreas.","Partial Pancreatectomy | PARTIAL PANCREATECTOMY | Partial Excision of Pancreas",,,,,,,,,,,,,,,"4124310","Subtotal pancreatectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040511","Total Pancreatectomy","C15340","Surgical removal of the entire pancreas.","Total Pancreatectomy | TOTAL PANCREATECTOMY | Total Excision of the Pancreas | total pancreatectomy",,,,,,,,,,,,,,,"4316068","Total pancreatectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026367","Molar Tooth","C33136","A grinding tooth with a broad crown; located behind the premolars.","Molar Tooth | TOOTH, MOLAR",,,,,,,,,,,,,,,"4297315","Structure of molar tooth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0194086","Partial Nephrectomy","C51928","The surgical removal of a portion of a kidney.","Partial Nephrectomy | NSS | Nephron Sparing Surgery | partial nephrectomy",,,,,,,,,,,,,,,"4304536","Partial nephrectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0401181","Radical Nephrectomy","C51778","Surgical removal of a kidney, the adrenal gland, adjacent lymph nodes, and other surrounding tissue.","Radical Nephrectomy | radical nephrectomy",,,,,,,,,,,,,,,"4022014","Radical nephrectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708788","Lung Typical Carcinoid Tumor","C45550","A neuroendocrine tumor of the lung characterized by the absence of necrosis and the presence of less than 2 mitoses per 2 mm2.","Lung Neuroendocrine Tumor G1 | Lung NET G1 | Lung NET Grade 1 | Lung NET, Grade 1 | Lung Neuroendocrine Tumor G1 | Lung Neuroendocrine Tumor Grade 1 | Lung Neuroendocrine Tumor, Grade 1 | Lung Typical Carcinoid Tumor | Lung Typical Carcinoid Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335302","Pancreatic Ductal Adenocarcinoma","C9120","An infiltrating adenocarcinoma that arises from the epithelial cells of the pancreas.  It affects males more often than females and the patients are usually over 50 years of age.  Microscopically it is characterized by the presence of glandular (ductal) differentiation and desmoplastic stroma formation.  Signs and symptoms include pain, loss of weight, and jaundice.  It grows rapidly and is usually detected after it has metastasized to other anatomic sites.  The prognosis is usually poor.","Pancreatic Ductal Adenocarcinoma | Ductal Adenocarcinoma of Pancreas | Ductal Adenocarcinoma of the Pancreas | PDA | PDAC | Pancreas Ductal Adenocarcinoma | Pancreatic Infiltrating Duct Carcinoma, NOS | Pancreatic Infiltrating Duct Carcinoma, Not Otherwise Specified | Pancreatic Tubular Adenocarcinoma",,,,,,,,,,,,,,,"37311469","Pancreatic ductal adenocarcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333081","Pancreatic Mucinous Noncystic Carcinoma","C37214","An infiltrating pancreatic ductal adenocarcinoma, characterized by the presence of malignant cells floating in pools of mucin.  It has a more favorable prognosis than the conventional infiltrating ductal adenocarcinoma.  It often arises in association with intraductal pancreatic mucinous neoplasms and in some cases it may result in the development of pseudomyxoma peritonei.","Pancreatic Colloid Carcinoma | Colloid Carcinoma of the Pancreas | Colloid Carcinoma of the Pancreas | Colloid carcinoma (Mucinous noncystic carcinoma) | Mucinous Noncystic Carcinoma | Pancreatic Mucinous Noncystic Carcinoma | Pancreatic Mucinous Noncystic Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2007059","Pancreatic Undifferentiated Carcinoma with Osteoclast-Like Giant Cells","C5723","A rare variant of undifferentiated pancreatic carcinoma characterized by the presence of non-neoplastic osteoclast-like giant cells.","Pancreatic Undifferentiated Carcinoma with Osteoclast-Like Giant Cells | Osteoclast-like Giant Cell Neoplasm of Pancreas | Osteoclast-like Giant Cell Neoplasm of the Pancreas | Pancreatic Osteoclast-Like Giant Cell Carcinoma | Pancreatic Osteoclast-Like Giant Cell Carcinoma | Undifferentiated Pancreatic Carcinoma with Osteoclast-Like Giant Cells | Undifferentiated Pancreatic Carcinoma with Osteoclast-Like Giant Cells | Undifferentiated carcinoma with osteoclast-like giant cells",,,,,,,,,,,,,,,"37168354","Undifferentiated carcinoma with osteoclast-like giant cells of pancreas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206701","Serous Cystadenocarcinoma","C3778","A malignant serous cystic neoplasm usually involving the ovary or the pancreas. It is characterized by the presence of invasive malignant glandular epithelial cells which often form papillary structures.","Serous Cystadenocarcinoma | Serous Adenocarcinoma | Serous adenocarcinoma, NOS | Serous cystadenocarcinoma, NOS",,,,,,,,,,,,,,,"4236657","Serous cystadenocarcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518870","Pancreatic Mucinous-Cystic Neoplasm with an Associated Invasive Carcinoma","C41246","A cystic epithelial neoplasm characterized by the presence of columnar mucin-producing epithelial cells, ovarian-type stroma formation, and a focal or extensive invasive carcinomatous component.","Pancreatic Mucinous-Cystic Neoplasm with an Associated Invasive Carcinoma | Pancreatic Invasive Mucinous Cystadenocarcinoma | Pancreatic Invasive Mucinous Cystadenocarcinoma | Pancreatic Mucinous Cystic Neoplasm with an Associated Invasive Carcinoma",,,,,,,,,,,,,,,"3655584","Mucinous cystic neoplasm with invasive carcinoma of pancreas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1335304","Pancreatic Intraductal Papillary-Mucinous Carcinoma","C5725","A malignant glandular neoplasm arising from the exocrine pancreas. Microscopically it is characterized by the presence of mucoid stroma formation, papillary patterns, and cystic changes. It has been associated with KRAS and Tp53 gene mutations.","Pancreatic Intraductal Papillary-Mucinous Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266087","Pancreatic Acinar Cell Cystadenocarcinoma","C5727","A cystic adenocarcinoma characterized by the presence of relatively uniform neoplastic cells which produce pancreatic enzymes and are arranged in acinar patterns. Signs and symptoms include abdominal pain, weight loss, nausea, and diarrhea. It usually has an aggressive clinical course.","Pancreatic Acinar Cell Cystadenocarcinoma | Acinar Cell Cystadenocarcinoma | Acinar Cell Cystadenocarcinoma of Pancreas | Acinar Cell Cystadenocarcinoma of the Pancreas | Acinar cell cystadenocarcinoma","8551/3","Acinar cell cystadenocarcinoma",,,,,,,,,,,,,"4030122","Acinar cell cystadenocarcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C2063878","Mixed Carcinoid-Adenocarcinoma of the Pancreas","C6878","A carcinoma that arises from the pancreas and is composed of acinar carcinoma and neuroendocrine carcinoma components in both the primary tumor and the metastatic sites.","Pancreatic Mixed Acinar Carcinoma-Neuroendocrine Carcinoma | ACINAR-ISLET CELL TUMOR, MALIGNANT | Mixed Acinar-Endocrine Carcinoma | Mixed Acinar-Endocrine Carcinoma of the Pancreas | Mixed Acinar-Neuroendocrine Carcinoma of the Pancreas | Mixed Acinar-Neuroendocrine Carcinoma of the Pancreas | Mixed Carcinoid-Adenocarcinoma of the Pancreas | Mucinous Carcinoid Tumor of the Pancreas | Pancreatic Mixed Acinar Adenocarcinoma-Neuroendocrine Carcinoma | Pancreatic Mixed Acinar-Neuroendocrine Carcinoma | Pancreatic Mixed Acinar-Neuroendocrine Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376705","Viral Load","C51952","The number of viral particles (usually HIV) in a sample of blood plasma.","Viral Load | ",,,,,,,,,,,,,,,"37154469","Viral load",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013080","Down Syndrome","C2993","A chromosomal dysgenesis syndrome resulting from a triplication or translocation of chromosome 21. Down syndrome occurs in approximately 1:700 live births. Abnormalities are variable from individual to individual and may include mental retardation, retarded growth, flat hypoplastic face with short nose, prominent epicanthic skin folds, small low-set ears with prominent antihelix, fissured and thickened tongue, laxness of joint ligaments, pelvic dysplasia, broad hands and feet, stubby fingers, transverse palmar crease, lenticular opacities and heart disease. Patients with Down syndrome have an estimated 10 to 30-fold increased risk for leukemia; most have symptoms of Alzheimer's disease by age 40. Also known as trisomy 21 syndrome.","Down Syndrome | Down syndrome | Down's Syndrome | Trisomy 21 | Trisomy 21 (Down Syndrome) | Trisomy 21 Syndrome",,,,,,,,,,,,,,,"439125","Complete trisomy 21 syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013931","Embolization Therapy","C15230","A procedure in which substances are injected into blood vessels adjacent to a tumor for the purpose of interrupting the blood flow to the cancer cells.","Embolization Therapy | Embolization | embolization | therapy, embolization",,,,,,,,,,,,,,,"4043846|4046732","Embolization - action|Embolization procedure",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0192865","Left Colectomy","C51624","Surgical removal of the left part of the colon.","Left Colectomy | Colon Resection, Left Extended | LEFT COLECTOMY | Left Hemicolectomy",,,,,,,,,,,,,,,"4219780","Left colectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034975","Registries","C61393","An official written record of names or events or transactions.","Registry | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883655","caBIG Identifier","C63540","A globally unique identifier deployed by systems that are compatible with the caGrid.","caBIG Identifier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1547538","Facility","C62574","Services and space and equipment provided for a particular purpose; a building or place that provides a particular service or is used for a particular industry.","Facility | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039215","CD4-Positive T-Lymphocyte","C12537","A type of white blood cell that helps stimulate immune system reactions.  Helper T cells help activate cytotoxic T cells and macrophages by secreting cytokines. They also stimulate B cells to make antibodies.","CD4-Positive T-Lymphocyte | CD4 Lymphocyte | CD4 Lymphocytes | CD4+ T Cell | CD4+ T Lymphocyte | CD4+ T Lymphocytes | CD4+ T-Lymphocyte | CD4-Positive Lymphocyte | CD4-Positive Lymphocytes | CD4-Positive T-Lymphocytes | CD4-positive T lymphocyte | T4 Cell | T4 Cells | T4 Lymphocyte | T4 Lymphocytes",,,,,,,,,,,,,,,"4017426|4023904","T lymphocyte positive for CD4 antigen|Cell positive for CD4 antigen",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0018894","Helper-Inducer T-Lymphocyte","C12538","A subtype of CD4+ T lymphocyte that triggers differentiation of nearby immune cells, and initiates a variety of other immune functions, including the induction of humoral and cellular inflammatory immune responses by B and other T lymphocytes, respectively.","Helper-Inducer T-Lymphocyte | Helper T-Cell | Helper T-Cells | Helper T-Lymphocyte | Helper T-Lymphocytes | Inducer T-Lymphocyte | Inducer T-Lymphocytes | T-Lymphocyte, Helper-Inducer | helper T cell",,,,,,,,,,,,,,,"4105764|4196061","Helper T cell|Helper cell",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0242629","CD8-Positive T-Lymphocyte","C12542","A subset of T-lymphocytes that express the CD8 surface glycoprotein and bind epitopes that are part of class I histocompatibility molecules. CD8-positive T-lymphocytes include cytotoxic T-lymphocytes and CD8+ suppressor T-lymphocytes.","CD8-Positive T-Lymphocyte | CD8 Cell | CD8 Lymphocyte | CD8 Lymphocytes | CD8+ T Cell | CD8+ T Lymphocyte | CD8+ T Lymphocytes | CD8+ T-Lymphocyte | CD8-Positive Lymphocyte | CD8-Positive Lymphocytes | CD8-Positive T-Lymphocytes | T8 Cell | T8 Cells | T8 Lymphocyte | T8 Lymphocytes",,,,,,,,,,,,,,,"37115775|4035704","CD8+ cell|Lymphocyte positive for CD8 antigen",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0162556","Suppressor-Inducer T-Lymphocyte","C12541","A subtype of CD4+ T lymphocyte that triggers CD8+ T lymphocytes to inhibit the production of antibodies.","Suppressor-Inducer T-Lymphocyte | Suppressor-Inducer T-Cell | Suppressor-Inducer T-Cells | Suppressor-Inducer T-Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549728","National Provider Identifier","C54633","A unique 10-digit identification number used in the U.S. in standard healthcare transactions that identifies both individual healthcare providers and healthcare organizations","National Provider Identifier | NPI | PRN | Provider Identifier | Provider Identifier Number | Provider Number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242781","Disease Transmission","C17214","A passage or transfer, as of a disease from one individual to another.","Disease Transmission | Pathogen Transmission Route | Transmission | Transmission | Transmitted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0949765","RNA Polyadenylation","C18947","The enzymatic addition of a sequence of adenylyl residues at the 3' end of an RNA molecule.","RNA Polyadenylation | Polyadenylation | RNA Polyadenylation ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883719","Insert","C45518","Something inserted or to be inserted.","Insert | Insertion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1407029","Toxic","C28004","Having to do with poison or something harmful to the body. Toxic substances usually cause unwanted side effects. ","Toxic | toxic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0586917","Postdoctoral Scholar","C19925","A scholar or researcher who is involved in academic study beyond the level of a doctoral degree, usually a recent Ph.D. holder temporarily appointed to teach or conduct research.","Postdoctoral Scholar | Postdoc | Postdoctoral Fellow | Postdoctoral Fellow | Postdoctoral Researcher | Research Associate | Research Fellow",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515895","Allogeneic","C28343","Taken from different individuals of the same species.","Allogeneic | Allogeneic Family Related | Allogenic | allogeneic | allogenic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010482","Canine Tooth","C32258","A single-cusped (pointed) and usually single-rooted tooth located between the incisors and premolars.","Canine Tooth | CANINE TOOTH | TOOTH, CANINE",,,,,,,,,,,,,,,"4164277","Structure of canine tooth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882440","Pre-Therapy","C54734","Occurring before a therapeutic procedure.","Pre-Therapy | Before Treatment | Pre-Treatment | Pretreatment | Prior to Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038215","Science of Statistics","C17167","A branch of applied mathematics concerned with the collection and interpretation of quantitative data and the use of probability theory to estimate population parameters.","Statistics | Statistical | Statistically",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880123","Colorectal Cancer Pathologic Distant Metastasis TNM Finding v6","C60838","A pathologic finding about one or more characteristics of colorectal cancer, following the rules of the TNM AJCC v6 classification system as they pertain to distant metastases.","Colorectal Cancer Pathologic Distant Metastasis TNM Finding v6 | Colorectal Cancer Pathologic Distant Metastasis TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880125","Colorectal Cancer Pathologic Regional Lymph Nodes TNM Finding v6","C60837","A pathologic finding about one or more characteristics of colorectal cancer, following the rules of the TNM AJCC v6 classification system as they pertain to staging of regional lymph nodes.","Colorectal Cancer Pathologic Regional Lymph Nodes TNM Finding v6 | Colorectal Cancer Pathologic Regional Lymph Nodes TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880124","Colorectal Cancer Pathologic Primary Tumor TNM Finding v6","C60836","A pathologic finding about one or more characteristics of colorectal cancer, following the rules of the TNM AJCC v6 classification system as they pertain to staging of the primary tumor.","Colorectal Cancer Pathologic Primary Tumor TNM Finding v6 | Colorectal Cancer Pathologic Primary Tumor TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010412","Cryotherapy","C40030","The therapeutic use of cold or refrigeration in medicine.","Cryotherapy | CRYOTHERAPY | cryotherapy",,,,,,,,,,,,,,,"4097985|4106455","Cryotherapy|Cryotherapy - action",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1512954","Intralesional","C28040","Within a cancerous area, for example, within a tumor in the skin.","Intralesional | intralesional",,,,,,,,,,,,,,,"37206254","Intralesional",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0200932","Nucleic Acid Amplification Test","C20055","Any of various amplification and detection strategies applied to detection of virus contamination in donor blood.  Specifically designed to detect recently infected individuals during the latency period before seroconversion.","Nucleic Acid Amplification Test | NAAT | NAT | NUCLEIC ACID AMPLIFICATION TEST | Nucleic Acid Testing",,,,,,,,,,,,,,,"4239666","Nucleic acid amplification",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026879","Mutagen","C672","Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes.","Mutagen | mutagen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880611","Excellent Tissue Fixation with Well Preserved Nuclear Details","C55074","Excellent Tissue Fixation with Well Preserved Nuclear Details","Excellent Tissue Fixation with Well Preserved Nuclear Details | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880998","Good Tissue Fixation with Definable Cellular Details","C55075","Good Tissue Fixation with Definable Cellular Details","Good Tissue Fixation with Definable Cellular Details | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880716","Fair Tissue Fixation with Definable Architectural Characteristics","C55077","Fair Tissue Fixation with Definable Architectural Characteristics","Fair Tissue Fixation with Definable Architectural Characteristics | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882426","Poor Tissue Fixation with No Definable Features","C55239","Poor Tissue Fixation with No Definable Features","Poor Tissue Fixation with No Definable Features | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229096","Vitreous Humor","C13323","The clear colorless transparent jelly that fills the posterior chamber of the eyeball.","Vitreous Humor | VITREOUS HUMOR | Vitreous Fluid | vitreous humor",,,,,,,,,,,,,,,"4138900","Vitreous humor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1881465","Lung Cancer Pathologic Primary Tumor TNM Finding v6","C60983","A pathologic finding about one or more characteristics of lung cancer, following the rules of the TNM AJCC v6 classification system as they pertain to staging of the primary tumor.","Lung Cancer Pathologic Primary Tumor TNM Finding v6 | Lung Cancer Pathologic Primary Tumor TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881466","Lung Cancer Pathologic Regional Lymph Nodes TNM Finding v6","C60981","A pathologic finding about one or more characteristics of lung cancer, following the rules of the TNM AJCC v6 classification system as they pertain to staging of regional lymph nodes.","Lung Cancer Pathologic Regional Lymph Nodes TNM Finding v6 | Lung Cancer Pathologic Regional Lymph Nodes TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880616","Exocrine Pancreatic Cancer Pathologic Distant Metastasis TNM Finding v6","C60940","A pathologic finding about one or more characteristics of exocrine pancreatic cancer, following the rules of the TNM AJCC v6 classification system as they pertain to distant metastases.","Exocrine Pancreatic Cancer Pathologic Distant Metastasis TNM Finding v6 | Exocrine Pancreatic Cancer Pathologic Distant Metastasis TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880618","Exocrine Pancreatic Cancer Pathologic Regional Lymph Nodes TNM Finding v6","C60939","A pathologic finding about one or more characteristics of exocrine pancreatic cancer, following the rules of the TNM AJCC v6 classification system as they pertain to staging of regional lymph nodes.","Exocrine Pancreatic Cancer Pathologic Regional Lymph Nodes TNM Finding v6 | Exocrine Pancreatic Cancer Pathologic Regional Lymph Nodes TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880617","Exocrine Pancreatic Cancer Pathologic Primary Tumor TNM Finding v6","C60938","A pathologic finding about one or more characteristics of exocrine pancreatic cancer, following the rules of the TNM AJCC v6 classification system as they pertain to staging of the primary tumor.","Exocrine Pancreatic Cancer Pathologic Primary Tumor TNM Finding v6 | Exocrine Pancreatic Cancer Pathologic Primary Tumor TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881464","Lung Cancer Pathologic Distant Metastasis TNM Finding v6","C60982","A pathologic finding about one or more characteristics of lung cancer, following the rules of the TNM AJCC v6 classification system as they pertain to distant metastases.","Lung Cancer Pathologic Distant Metastasis TNM Finding v6 | Lung Cancer Pathologic Distant Metastasis TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519595","Transcript","C1936","The initial RNA molecule produced by transcription.","Transcript | Transcripts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0588055","Mediastinal Lymph Node","C33073","A lymph node located in the mediastinum. Mediastinal lymph nodes are arranged in three groups, one on the lateral, another on the medial, and a third on the anterior aspect of the vessels; the third group is, however, sometimes absent.","Mediastinal Lymph Node | LYMPH NODE, MEDIASTINAL | Lymph Node(s) Mediastinal | Lymph Nodes(s) Mediastinal | MEDIASTINAL LYMPH NODE | Mediastinal lymph node structure (body structure) | Mediastinal lymph nodes | mediastinal lymph node | mediastinal node",,,,,,,,,,,,,"UBERON:0002524","mediastinal lymph node","4269080","Mediastinal lymph node structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332490","Round","C48348","The shape of a circle.","Round | ROUND",,,,,,,,,,,,,,,"4177524|4227797","Round shape|Circular",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0599946","Attenuation","C61471","A weakening in force or intensity.","Attenuation | Attenuate | Attenuated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883687","Miller and Payne Classification","C63611","A classification system for grading pathological remission based purely on microscopic assessment. It classifies patients into five groups with significantly different disease-free and overall survival and grades pathological remission in both the primary tumor and the axillary lymph nodes, with comparison of negative nodes with those that have already responded to chemotherapy.","Miller and Payne Classification | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1947908","On Staff","C63614","Denotes a person of advanced education, ability, or seniority employed by an organization.","On Staff | Staff",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711375","Postcontrast","C43290","Refers to the time after a contrast agent is added in an imaging study.","Postcontrast | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0854638","Antiestrogen Therapy","C15757","Drug treatment to block the action of the female hormone estrogen.","Antiestrogen Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1698986","Storage","C60824","The act of safekeeping goods in a depository.","Storage | STORING | Store | Stored",,,,,,,,,,,,,,,"4234626","Storage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1875022","Diluent","C60823","Any liquid or solid material used to lessen the strength or flavor of a solution or mixture of another ingredient.","Diluent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002638","Amniotic Fluid","C13188","The fluid within the amniotic cavity which surrounds and protects the developing embryo. It is initially produced by the amnion and then later by the lungs and kidneys. The amount at term normally varies from 500 to 2000 ml.","Amniotic Fluid | AMNIOTIC FLUID | Amniotic fluid | Aqua Amnii | FLUID, AMNIOTIC | Human Amniotic Fluid | Liquor Amnii | Waters (Amniotic Fluid) | amniotic fluid",,,,,,,,,,,,,"UBERON:0000173","amniotic fluid","4297445","Amniotic fluid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038984","Sweat","C13280","The liquid secreted by the sweat glands, having a salty taste and a pH that varies from 4.5 to 7.5. Sweat produced by the eccrine sweat glands is clear with a faint characteristic odor, and contains water, sodium chloride, and traces of albumin, urea, and other compounds. Its composition varies with many factors, e.g., fluid intake, external temperature and humidity, and some hormonal activity. Sweat produced by the larger, deeper, apocrine sweat glands of the axillae contains, in addition, organic material which on bacterial decomposition produces an offensive odor.","Sweat | PERSPIRATION | Perspiration | SWEAT | Sweats",,,,,,,,,,,,,,,"4251945","Sweat",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026140","Mammary Gland Milk","C13257","Milk produced by female mammals for the purpose of feeding their young.","Mammary Gland Milk | BREAST MILK | Breast Milk | Breast Milk | MILK | Mammary Gland Milk | Milk",,,,,,,,,,,,,,,"4035904","Breast milk",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005388","Bile","C13192","Fluid composed of waste products, bile acids, salts, cholesterol, and electrolytes. It is secreted by the liver parenchyma and stored in the gallbladder.","Bile | BILE | Bile Fluid | Bile Juice | bile",,,,,,,,,,,,,,,"4289901","Bile",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0587267","Closed","C49070","Not affording passage or access; blocked against entry.","Closed | Close | closed",,,,,,,,,,,,,,,"4104200","Closed",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL411846","Metastatic Malignant Neoplasm in the Leptomeninges","C3814","A malignant neoplasm that has spread from its original site of growth to the leptomeninges.","Metastatic Malignant Neoplasm in the Leptomeninges | Leptomeningeal Metastases | Leptomeningeal Metastasis | Leptomeningeal metastases, NOS | Meningeal Metastasis | Metastasis to the Leptomeninges | Metastatic Malignant Neoplasm in the Meninges | Metastatic Malignant Neoplasm to the Leptomeninges | Metastatic Malignant Neoplasm to the Leptomeninges | Metastatic Neoplasm to the Leptomeninges | Metastatic Neoplasm to the Meninges | Metastatic Tumor to the Leptomeninges | carcinomatous meningitis | leptomeningeal carcinoma | leptomeningeal metastasis | meningeal metastasis | neoplastic meningitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0752151","Video-Assisted Thoracic Surgery","C63704","Thoracic surgery that is aided by the use of a video camera.","Video-Assisted Thoracic Surgery | VATS | Video-Assisted Thoroscopic Surgery | Video-assisted Thoracic Surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229743","Infraclavicular Lymph Node","C63705","A lymph node located in the area below the clavicle.","Infraclavicular Lymph Node | Deltopectoral Lymph Node | Deltopectoral Node | INFRACLAVICULAR LYMPH NODE | Infraclavicular Node | Infraclavicular Nodes | Lymph Node(s) Subclavicular | Subclavicular Lymph Node | Subclavicular Node | deltopectoral lymph node | deltopectoral node | infraclavicular lymph node | infraclavicular node | nodus lymphaticus infraclavicularis axillae",,,,,,,,,,,,,"UBERON:0035162","infraclavicular lymph node","4322036","Infraclavicular lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2585997","New Diagnosis","C54731","The novel recognition of the presence of a disease, condition, or injury based on investigation, analysis or tests for signs and symptoms.","New Diagnosis | ",,,,,,,,,,,,,,,"4262070","New diagnosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882428","Post-Therapy","C54735","Occurring after a therapeutic procedure.","Post-Therapy | After Treatment | Post-Treatment | Posttreatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882154","Operative","C54733","Occurring during or associated with a surgical procedure.","Operative | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882918","Recurrent Disease, Primary Site","C55072","Recurrence of symptoms of a disease at the original site.","Recurrent Disease, Primary Site | Primary Recurrence | Relapse, Primary Site | Relapsed Disease, Primary Site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882917","Recurrent Disease, Distant Site","C55073","Recurrence of symptoms of a disease, at a site different and away from the original site.","Recurrent Disease, Distant Site | Distant | Distant Disease | Distant Recurrence | Relapse, Distant Site | Relapsed Disease, Distant Site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705942","Clamp Device","C49872","A device designed to hold things firmly together.","Clamp Device | Clamp | Clamp Device Component",,,,,,,,,,,,,,,"4186606","Clamp",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706079","Arrival - action","C53463","The act of reaching a destination.","Arrival | Arrive | Arrived",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001963","Methyl Alcohol","C217","Used as a solvent and as an intermediate in chemical synthesis.  Component of deicing mixtures and preservatives. Toxic.","Methyl Alcohol | METHANOL | METHYL ALCOHOL | Methanol | Wood Alcohol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0598304","Microdissection","C18124","A laboratory method in which the tissue from a histology slide is dissected under a microscope to procure specific cells or cell populations.","Microdissection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448798","Hemorrhagic Change","C35380","A morphologic finding indicating a change in a tissue due to vascular injury or leakage.","Hemorrhagic Change | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883709","Damage","C61555","Physical harm reducing the value, operation, or usefulness of something.","Damage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0178932","Quality Assurance","C15381","Programs of regular assessment of medical and nursing activities to evaluate the quality of medical care including all actions taken to ensure that standards and procedures are adhered to and that delivered products or services meet performance requirements.","Quality Assurance | QA | Qaulity Assurance Activity | quality assurance | quality assurance (QA)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511548","Cryopreserved Cell","C19314","Cells which are indefinitely maintained in a viable state at extremely low temperatures.","Cryopreserved Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005775","Blood Circulation","C16353","The movement of blood to and from the heart and to the rest of the body's organs, tissues, and cells through the network of arteries, veins, and capillaries. (NCI)","Blood Circulation | Blood Flow | Bloodstream | Circulation | Circulatory | circulation",,,,,,,,,,,,,,,"4238490","Vascular flow",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007439","Indwelling Catheter","C54729","A hollow tube left implanted in a body canal or organ to provide fluid access or promote drainage.","Indwelling Catheter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0727492","Plastic Bottle","C43173","A plastic vessel with a narrow neck designed to accept a specific closure.","Plastic Bottle | BOTTLE, PLASTIC | Bottle, Plastic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0552389","Cross-section","C63795","A section created by a plane cutting a solid perpendicular to its longest axis.","Cross-section | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883531","Verumontanum Mucosal Gland Hyperplasia","C63796","A benign microacinar proliferation occurring exclusively in the verumontanum and adjacent posterior urethra where the ejaculatory ducts and utricle empty into the urethra. Crystalloids and intraluminal mucin are usually absent, but; intraluminal corpora amylacea are often present. The lining epithelium typically consists of bland cuboidal to columnar luminal cells with underlying basal cells.","Verumontanum Mucosal Gland Hyperplasia | VMGH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027625","Circulating Tumor Cell","C63797","A metastatic cancer cell found in the peripheral blood.","Circulating Tumor Cell | CIRCULATING TUMOR CELL | CTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015455","Facial Bone","C63706","Any bone that contributes to the facial structures, except those bones that are part of the braincase.","Facial Bone | Bone Face | Bone of Face | FACIAL BONE",,,,,,,,,,,,,,,"4237077","Bone structure of face",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029461","Osteoradionecrosis","C63707","Necrosis of bone following exposure to a source of radiation.","Osteoradionecrosis | ",,,,,,,,,,,,,,,"4032861","Osteoradionecrosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883021","Sextant","C63708","One sixth of a circle or disc; a sector with an angle of 60 degrees. In anatomy, the division of teeth into six parts: maxillary right, maxillary anterior, maxillary left, mandibular right, mandibular anterior, mandibular left.","Sextant | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039494","Temporomandibular Joint Disorder","C63709","A disorder that affects the masticatory muscles and temporomandibular joint.","Temporomandibular Joint Disorder | TMD",,,,,,,,,,,,,,,"74396","Temporomandibular joint disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3203360","Suppuration","C63710","A pathologic process consisting of the formation and discharge of pus.","Suppuration | ",,,,,,,,,,,,,,,"4114506|4164958","Infection - suppurative|Suppurative inflammation",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0152027","Sensory Disorder","C63711","An interruption or alteration in the sensory activity or functions of the nervous system.","Sensory Disorder | Neurosensory Disorder | Neurosensory Disorder",,,,,,,,,,,,,,,"4311114","Sensory disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1879693","American Academy of Periodontology","C63712","Association of dental professionals specializing in the prevention, diagnosis and treatment of diseases affecting the gums and supporting structures of the teeth and in the placement and maintenance of dental implants and dedicated to advocate, educate, and set standards for advancing the periodontal and general health of the public and promoting excellence in the practice of periodontics.","American Academy of Periodontology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038544","Subgingival Curettage","C63713","Removal of degenerated and necrotic epithelium and underlying connective tissue of a periodontal pocket in an effort to convert a chronic ulcerated wound to an acute surgical wound, thereby insuring wound healing and attachment or epithelial adhesion, and shrinkage of the marginal gingiva.","Subgingival Curettage | ",,,,,,,,,,,,,,,"4220704","Subgingival curettage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882339","Periodontal Scaling and Root Planing","C63714","Instrumentation of the crown and root surfaces of a tooth to remove plaque and calculus from these surfaces. It is indicated for patients with periodontal disease and is therapeutic, not prophylactic, in nature. Root planing is the definitive procedure designed for the removal of cementum and dentin that is rough, and/or permeated by calculus or contaminated with toxins or microorganisms. Some soft tissue removal occurs. This procedure may be used as a definitive treatment in stages of periodontal disease and/or as a part of pre-surgical procedures in others.","Periodontal Scaling and Root Planing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011402","Dental Pulp Capping","C63715","The application of a barrier substance to either the dentin or the dental pulp of a tooth which protects the tooth from contact with oral contaminants. This allows for recovery and restoration of the dental pulp.","Dental Pulp Capping | Dental Pulp Cap",,,,,,,,,,,,,,,"4144547","Pulp cap, direct, excluding final restoration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003571","Apicoectomy","C63716","Excision of the apical portion of a tooth root through an opening made in the overlying labial, buccal, lingual, or palatal alveolar bone.","Apicoectomy | Root Resection",,,,,,,,,,,,,,,"37161003","Excision of apex of root of tooth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882342","Periradicular","C63723","Around or surrounding a root, especially the root of a tooth.","Periradicular | Pericemental",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011373","Dental Implant","C63718","Materials placed into (endosseous) or onto (subperiosteal) the jawbone; commonly used to support a crown, bridge, artificial tooth, stabilize a diseased tooth, or to use as anchorage in orthodontic therapy.","Dental Implant | dental implant",,,,,,,,,,,,,,,"4224802","Implantable dental prosthesis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011394","Denture","C63720","An appliance used as an artificial or prosthetic replacement for missing teeth and adjacent tissues.","Denture | ",,,,,,,,,,,,,,,"4213730","Denture",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043400","White Phosphorus","C63731","The element phosphorus in its allotropic form, a soft, waxy, poisonous solid melting at 44.5 degrees C; soluble in carbon disulfide, insoluble in water and alcohol; self-igniting in air.","White Phosphorus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0336683","Munition","C63732","A complete device charged with explosives, propellants, pyrotechnics, initiating composition, or nuclear, biological, or chemical material for use in military operations, including demolitions.","Munition | Ammunition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037390","Snuff Tobacco","C63733","A fine-grain tobacco that that users hold between their lower lip and gum.","Snuff Tobacco | Dip | Snuff",,,,,,,,,,,,,,,"4218197","Snuff tobacco",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040461","Toothbrushing","C63734","The act of cleaning teeth with a brush to remove plaque and prevent tooth decay.","Toothbrushing | Brushing",,,,,,,,,,,,,,,"42872816","Brushing of teeth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1880794","Flossing","C63735","Using dental floss, a string-like device, to remove plaque and food particles from between the teeth.","Flossing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0260115","Periodontist","C63736","A dentist who specializes in the prevention, diagnosis and treatment of the hard and soft tissue supporting the teeth.","Periodontist | Surgical Dentistry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0260083","Orthodontist","C63737","A dentist specializing in the prevention, diagnosis, and treatment of malocclusions of the teeth and their surrounding structures.","Orthodontist | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011467","denturist","C63739","A dental technician who provides dentures for patients without supervision of a dentist. Their duties include taking impressions and bite registrations for preparing and repairing dentures and fitting dentures.","Denturist | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0259864","Endodontist","C63740","A dentist specializing the biology of the normal pulp, the etiology, diagnosis, prevention and treatment of diseases and injuries of the pulp and associated periradicular conditions.","Endodontist | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881144","Implant Specialist","C63741","A dentist who specializes in surgical placement of dental implants or the restoration of dental implants in the facial bones.","Implant Specialist | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882163","Oral Medicine Specialist","C63742","A dentist specializing in the diagnosis and non-surgical management of medically-related disorders or conditions affecting the oral and maxillofacial region.","Oral Medicine Specialist | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031090","Periodontal Disorder","C63743","An inflammatory process of the gingival tissues and/or periodontal membrane of the teeth, resulting in an abnormally deep gingival sulcus, possibly producing periodontal pockets and loss of alveolar bone support.","Periodontal Disorder | Periodontal Disease | Periodontal disease",,,,,,,,,,,,,,,"134398","Periodontal disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017318","General Dentistry","C63745","A dentist involved in the treatment of the oral facial disease who has not limited his/her practice to any dental specialty.","General Dentistry | General Dental Practice | General Dentistry Specialist",,,,,,,,,,,,,,,"4235266","General dental practice",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026644","Edentulous","C63746","An indication that an individual lacks teeth/dentition.","Edentulous | ",,,,,,,,,,,,,,,"4150442","Edentulous",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882340","Periodontal Treatment","C63747","Treatment of the gums, soft tissues, and bones that support the teeth.","Periodontal Treatment | Periodontal Procedure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0185216","Sequestrectomy","C63750","Removal of a fragment of dead bone separated from healthy bone as a result of injury or disease.","Sequestrectomy | ",,,,,,,,,,,,,,,"4198708","Sequestrectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1881914","Mucoperiosteal Flap","C63757","A flap of mucosal, and possibly gingival, tissue including the periosteum, reflected from bone and created in the process of conducting orthodontic surgery.","Mucoperiosteal Flap | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415562","HLA-C Gene","C62758","This gene plays a role in both immune responses and histocompatibility processes.","HLA-C Gene | HLA-C | Major Histocompatibility Complex, Class I, C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021821","Interviewer","C63759","The person who manages an interview and asks the questions.","Interviewer | INTERVIEWER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0489844","Interviewee","C63762","The person who answers the questions during an interview.","Interviewee | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205246","Generalized","C63764","Widespread, broadly dispersed, common.","Generalized | General",,,,,,,,,,,,,,,"4244571","Generalized",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1556020","Technician","C63861","A person skilled in the performance of the technical or procedural aspects of a profession.","Technician | TECHNICIAN | Technologist | technician",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227736","Prostatic Utricle","C63862","A small indentation located in the prostatic urethra, at the apex of the urethral crest, on the seminal colliculus, laterally flanked by openings of the ejaculatory ducts.","Prostatic Utricle | Utricle",,,,,,,,,,,,,,,"4222482","Structure of prostatic utricle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1881134","Image Study","C63859","A radiographic technique used to evaluate a specific anatomic location for a specific purpose.","Image Study | Imaging Study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1285092","Gland","C13319","An organ that produces and secretes hormones (e.g. endocrine gland), saliva or sweat (e.g. exocrine gland).","Gland | Glandular | gland",,,,,,,,,,,,,,,"4180501","Gland structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705938","Base - General Qualifier","C48055","The most important or necessary part of something.","Base | Based",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4227764","Osteopenia","C50910","Decreased calcification or density of bone tissue.","Osteopenia | Bone Loss | Osteopenia/ Osteoporosis | osteopenia",,,,,,,,,,,,,,,"4195039|4302453","Osteopenia|Osteopenia",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1883484","User Role Context","C63535","A class which hold the roles which are assumed by a particular group in the context of a protection group.","User Role Context | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439836","Conversion","C52566","The act of changing the nature, form, function, or purpose of something to another.","Conversion | conversion",,,,,,,,,,,,,,,"4153902","Conversions",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3808806","Leukoplakia","C3186","A white patch or plaque on a mucous membrane that cannot be characterized clinically or pathologically as any other disease. The diagnosis of leukoplakia is one of exclusion; other conditions such as candidiasis, lichen planus, leukoedema, etc., must be ruled out before a diagnosis of leukoplakia can be made. Leukoplakia may be a premalignant condition.","Leukoplakia | Keratotic Plaque | leukoplakia",,,,,,,,,,,,,,,"4167091|4176406","Leukoplakia|Leukoplakia",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0153381","Malignant Oral Cavity Neoplasm","C9314","A primary or metastatic malignant neoplasm involving the oral cavity.  The majority are squamous cell carcinomas.","Malignant Oral Cavity Neoplasm | Malignant Mouth Neoplasm | Malignant Mouth Tumor | Malignant Neoplasm of Mouth | Malignant Neoplasm of the Mouth | Malignant Oral Cavity Tumor | Malignant Tumor of Mouth | Malignant Tumor of the Mouth | Malignant neoplasm of mouth, unspecified",,,,,,,,,,,,,,,"25189","Malignant tumor of oral cavity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2711248","Osteonecrosis of Jaw","C63924","An area of necrotic bone in the mandible or maxilla.","Osteonecrosis of Jaw | Jaw Osteonecrosis | ONJ | Osteonecrosis of jaw",,,,,,,,,,,,,,,"40480852","Aseptic necrosis of bone of jaw",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1880646","FACT-BR Questionnaire","C63928","A 50-item instrument that assesses general physical, social, emotional and functional well-being, as well as brain tumor-specific concerns.","FACT-BR Questionnaire | FACT-BR | Functional Assessment of Cancer Therapy Scale-Brain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883513","Utricle-Associated Mucosal Gland Hyperplasia","C63929","A benign microacinar proliferation occurring exclusively in the area of the utricle.","Utricle-Associated Mucosal Gland Hyperplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0699790","Colon Carcinoma","C4910","A malignant epithelial neoplasm that arises from the colon and invades through the muscularis mucosa into the submucosa.  The vast majority are adenocarcinomas.","Colon Carcinoma | Carcinoma of Colon | Carcinoma of the Colon | Colon Cancer | Colonic Carcinoma | colon cancer",,,,,,,,,,,,,,,"4149847","Carcinoma of colon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4012286","Adrenocortical Insufficiency","C26691","An endocrine or hormonal disorder that occurs when the adrenal cortex does not produce enough of the hormone cortisol and in some cases, the hormone aldosterone. It may be due to a disorder of the adrenal cortex (Addison's disease or primary adrenal insufficiency) or to inadequate secretion of ACTH by the pituitary gland (secondary adrenal insufficiency).","Adrenocortical Insufficiency | Adrenal Cortical Hypofunction | Adrenal Cortical Insufficiency | Adrenal Gland Insufficiency | Adrenal Gland Insufficiency | Adrenal Insufficiency | Adrenal insufficiency | Hypocortisolemia | Hypocortisolism",,,,,,,,,,,,,,,"4035127","Hypoadrenalism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1290916","Radiologic Finding","C35869","Imaging results obtained through a radiology procedure.","Radiologic Finding | RADIOLOGIC FINDING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448690","Amendment","C41200","A change in a document made by correction, adding, substituting or omitting a certain part. Amendments are the mechanism of changes introduction, further development and improvement of previously submitted or approved clinical study protocols and proposals.","Amendment | AMENDMENT | Amend | Amended | amendment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0150108","Blinded","C49068","A characteristic of experiment design in which one or more groups involved (receiving, administering, or evaluating intervention) are unaware of which intervention any particular subject is receiving.","Blinded | Blind | Blinding | Masking | Study Blinding | Study Masking | Trial Blinding | Trial Masking | blinding | masking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707357","Checklist","C49073","A list of items required or things to be done or considered.","Checklist | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1449699","Tumor Burden","C28384","Refers to the number of cancer cells, the size of a tumor, or the amount of cancer in the body.","Tumor Burden | tumor burden | tumor load | tumor_burden",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0203597","Hyperthermia Treatment","C15415","A type of treatment in which body tissue is exposed to high temperatures to damage and kill cancer cells or to make cancer cells more sensitive to the effects of radiation and certain anticancer drugs.","Hyperthermia Treatment | Clinical Hyperthermia | Diathermy | Hyperthermia | Hyperthermia Therapy | diathermy | hyperthermia therapy",,,,,,,,,,,,,,,"4137449","Hyperthermia treatment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1707998","FACT-G Questionnaire","C45899","A general quality of life instrument intended for use with a variety of chronic illness conditions. A core instrument in the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, a system which has multiple disease-, treatment-, and condition-specific subscales to complement the FACT-G.","FACT-G Questionnaire | FACT-G | Functional Assessment of Cancer Therapy General Questionaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024985","McGill Pain Questionnaire","C21135","A questionnaire incorporating a series of adjectives to describe the characteristics and intensity of pain. The longer version of this instrument was used by Kane and colleagues to evaluate a clinical trial of hospice care. (Wales 1983)","McGill Pain Questionnaire | ",,,,,,,,,,,,,,,"4165281","McGill pain chart questionnaire",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005823","Blood Pressure","C54706","The pressure of the circulating blood against the walls of the blood vessels.","Blood Pressure | BP | blood pressure",,,,,,,,,,,,,,,"4326744","Blood pressure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704628","Hyperthermia","C50589","A condition characterized by an abnormally high body temperature. In a hyperthermic state, the hypothalamic set-point is normal but body temperature increases and overrides the ability to lose heat, resulting from exogenous heat exposure or endogenous heat production.","Hyperthermia | Elevated Core Body Temperature | hyperthermia",,,,,,,,,,,,,,,"4178904","Body temperature above reference range",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517564","Intratumoral","C28036","Within a tumor.","Intratumoral | intratumoral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1947901","Cancer Progression","C19987","A pathologic process in which alterations at the molecular level result in a more aggressive cytologic and phenotypic profile and clinical course of a malignant neoplasm.","Cancer Progression | Cancer Disease Progression | disease progression | progression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448883","Equivalent","C48793","A person or thing equal to another in value or measure or force or effect or significance etc.; being essentially equal to something.","Equivalent | EQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711374","Maximum Length Number","C42696","Indicates the greatest number of characters permissible in a value.","Maximum Length Number | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709037","Minimum Length Number","C42697","Indicates the least number of characters permissible in a value.","Minimum Length Number | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034754","Read","C48222","The act of interpreting something that is written or printed.","Read | ",,,,,,,,,,,,,,,"4175288","Reading",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002045","algorithm","C16275","A defined procedure for solving a problem. Applied to a problem-solving procedure implemented in software to be executed by a computer.","Algorithm | Algorithms | algorithm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705482","Timestamp - Data Type","C54086","A variation of the Date datatype that's useful for storing very precise datetime values, down to small fractions of seconds. The Timestamp datatype stores all the information that the Date datatype stores, but also includes fractional seconds.","Timestamp Data Type | Timestamp | Timestamp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0947630","Study","C63536","A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.","Study | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704749","Z-Coordinate","C44479","A third coordinate that is used together with horizontal (x) and vertical (y) coordinates to specify an exact point in a three dimensional space.","Z-Coordinate | z",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1948038","Markup (detection and tagging)","C63615","A process for adding information to a document or image.","Markup | markup",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1948035","Hold (action)","C62290","Contain; have within.","Hold | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880389","Domain (area of knowledge)","C62289","An area of knowledge considered as a discrete unit for some purpose.","Domain | domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881173","Inclusion Exclusion Domain","C61536","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to the violation of trial inclusion and exclusion criteria of a subject.","Inclusion Exclusion Criteria Not Met Domain | IE | Inclusion Exclusion Domain | Inclusion/Exclusion Criteria Not Met",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881819","Microbiology Susceptibility Domain","C61531","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to microbiology susceptibility tests.","Microbiology Susceptibility Domain | MS | Microbiology Susceptibility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882354","Pharmacogenomics Domain","C61529","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to pharmacogenomics.","Pharmacogenomics Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043287","Wyoming","C43500","A state in the western United States. Its capital is Cheyenne.","Wyoming | US: Wyoming | WY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042753","Virginia","C43472","A state in the mid-atlantic United States. Its capital is Richmond.","Virginia | US: Virginia | VA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042124","Utah","C43502","A state in the western United States. Its capital is Salt Lake City.","Utah | US: Utah | UT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043193","Wisconsin","C43485","A state in the northern midwest United States. Its capital is Madison.","Wisconsin | US: Wisconsin | WI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039711","Texas","C43498","A state in the southern midwest United States. Its capital is Austin.","Texas | TX | US: Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039514","Tennessee","C43476","A state in the southeastern United States. Its capital is Nashville.","Tennessee | TN | US: Tennessee",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707512","Coordinating Center","C48359","A facility that is responsible for receiving, editing, processing, analyzing, and storing data generated in a study and that, in addition, has responsibility for coordination of activities required for execution of the study.","Coordinating Center | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706203","Subject - topic","C48910","Some matter, situation, or event that is thought about, written about, or discussed.","Subject | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880229","DICOM Study","C63537","One or more series of images taken on a single visit to a medical facility.","DICOM Study | DICOM Image | Study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439580","Synchronous","C48444","Occurring at the same time or rate.","Synchronous | Synchronization | Synchronization | Synchronized",,,,,,,,,,,,,,,"4112237","Synchronous",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1711233","Security Group","C44271","A group created to indicate the access level of member individuals.","Security Group | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883015","Service-Object Pair","C63426","The information object and the service class are the two fundamental components of DICOM. Information objects define the core contents of medical imaging, and service classes define what to do with those contents. The service classes and information objects are combined to form the functional units of DICOM. This combination is called a service-object pair.","Service-Object Pair | SOP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1699030","Digital Imaging and Communications in Medicine (DICOM)","C49059","A comprehensive set of standards for communications between medical imaging devices, including handling, storing and transmitting information in medical imaging. It includes a file format definition and a network communication protocol.","DICOM | Dicom Standard | Digital Imaging and Communications in Medicine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709665","Primary Key","C49189","The attribute selected as being most important for uniquely identifying a body of information (an entity, object or record).","Primary Key | PK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707535","Curation","C48292","To organize and oversee.","Curation | Curate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020912","Optical Image Reconstruction","C19339","The process of generating an image from the raw data, or set of unprocessed measurements, made by an imaging system. (from AmershamHealth Medcyclopaedia)","Optical Image Reconstruction | Image Reconstruction | Reconstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0184486","X-Ray Tube","C48435","A vacuum tube containing a metal target onto which a beam of electrons is directed at high energy for the generation of X rays.","X-Ray Tube | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0457243","Ampere","C42536","A unit of electric current, one of the seven base units of the International System of Units (Systeme International d'Unites, SI). It is that constant current which, if maintained in two straight parallel conductors of infinite length and zero diameter separated by one meter in a vacuum, would produce between these conductors a force equal to 2x10E7 newton per meter of length. This is dependent upon the definitions of the meter, kilogram, and second. One ampere represents 6.24 x 10E18 unit electric charge carriers, such as electrons, passing a specified fixed point in one second.","Ampere | A | amp | ampere",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553035","Unit Of Measure Prefix - micro","C48438","A prefix indicating a quantity of one one-millionth, 10E-6.","Micro | [u] | micro | micro- | u",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521917","Common Data Element","C19984","Data terms or concepts that have been determined to be identical between projects or contexts.","Common Data Element | CDE | common data element (CDE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449574","Histologic Type","C61478","Refers to the type of tissue in which a tumor originated.","Histologic Type | Histopathologic Type | Histopathology Type | Histotype",,,,,,,,,,,,,,,"4154129","Histologic type of proliferative mass",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1718420","Tubule Formation","C62448","The presence of malignant tubular formations which are thought to represent malignant counterparts of the terminal ductal-lobular units of the breast.","Tubule Formation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882330","performance - action","C60778","An action that is carried out or accomplished.","Performance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1547350","Data types - Date","C48871","A string unique to a time duration of 24 hours between 2 successive midnights defined by the local time zone. The specific representation of a date will depend on which calendar convention is in force as well as local ordering conventions.","Date Data Type | Date | Date | Date Representation | Date Value | date",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333309","Distantly Metastatic Malignant Neoplasm","C35933","A malignant tumor that has spread from its original (primary) site of growth to another site distant from the primary site.","Distantly Metastatic Malignant Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880117","Collaborative Staging","C62575","A coding system for staging of cancer bringing together the principles of Summary Stage, the TNM categories and stage groupings, and the SEER Extent of Disease (EOD) coding structure, creating a carefully selected set of data items that describe how far a cancer has spread at the time of diagnosis. The Collaborative Staging System uses a modified EOD coding system, a five-field, 10 digit system: tumor size (3 digits), extension of the primary tumor (2 digits), regional lymph node involvement (highest specific lymph node chain involved by tumor) (1 digit), the number of pathologically reviewed regional lymph nodes that are positive (2 digits), and the number of pathologically examined regional lymph nodes (2 digits).","Collaborative Staging | CS | Collaborative Staging System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL107025","Metastatic Malignant Neoplasm","C36263","A malignant tumor that has spread from its original (primary) site of growth to another site close to or distant from the primary site.","Metastatic Malignant Neoplasm | Metastatic Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515946","American Joint Committee on Cancer","C39315","A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.","American Joint Committee on Cancer | AJCC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883218","Summary Staging Guide 1977","C62611","An international coding scheme for tumors. These rules governed staging for cases diagnosed before 2001.","Summary Staging Guide 1977 | SSS Manual 1977 | SSS1977",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882964","SEER Summary Staging Manual 2000","C62610","An international coding scheme for tumors. The SSS2000 is an update and clarification of the Summary Staging Guide (1977).","SEER Summary Staging Manual 2000 | SSS Manual 2000 | SSS2000",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205438","Fourth","C54566","Following the third position in an ordering or series; coming next after the third and just before the fifth in position.","Fourth | 4th",,,,,,,,,,,,,,,"4107051","Fourth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205439","Fifth","C54567","Following the fourth position in an ordering or series; coming next after the fourth and just before the sixth in position.","Fifth | 5th",,,,,,,,,,,,,,,"4136808","Fifth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205440","Sixth","C54568","Following the fifth position in an ordering or series; coming next after the fifth and just before the seventh in position.","Sixth | 6th",,,,,,,,,,,,,,,"4203150","Sixth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0441792","Edition","C62613","The form in which a text (especially a printed book) is published.","Edition | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024763","Manuals as Topic","C62612","A small handbook.","Manual | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242638","Surveillance, Epidemiology, and End Results (SEER) Program","C15432","A program of the National Cancer Institute that provides information on cancer statistics in an effort to reduce the cancer burden among the U.S. population.","Surveillance, Epidemiology, and End Results Program | SEER | SEER-Surveillance, Epidemiology, and End Results | Surveillance, Epidemiology, and End Results Program (SEER)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709246","Non-Neoplastic Disorder","C53529","Any disorder other than abnormal tissue growth resulting from uncontrolled cell proliferation.","Non-Neoplastic Disorder | NON-NEOPLASTIC | Non-Neoplastic Disease | Non-neoplastic Disorder | Non-neoplastic condition, NOS | Non-neoplastic disorder, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443196","Definitive","C62607","Supplying or being a final or conclusive settlement or result.","Definitive | DEFINITIVE",,,,,,,,,,,,,,,"4129644","Definitive",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1880022","Characterization","C62606","The act of describing distinctive characteristics or essential features.","Characterization | Characterized",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230097","Waist","C64192","The abdominal circumference at the navel.","Waist | WAIST",,,,,,,,,,,,,,,"4143910","Structure of waist (surface region)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0599755","Cohort","C61512","A group of individuals, identified by a common characteristic.","Cohort | Study Cohort | cohort",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015663","Fasting","C63663","Abstaining from food.","Fasting | Fast",,,,,,,,,,,,,,,"37312086|4060364","Fasting|Fasting",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1882331","Performing Laboratory","C64206","A laboratory providing analyses of samples collected in clinical care or research.","Performing Laboratory | PerformingLaboratory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707640","Decimal Place","C42646","An indication of the specific number of digits to be expected to the right of the decimal point in a line of numbers.","Decimal Place | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882497","Organization Assigning a Unique Protocol Identifer","C64210","The name of the organization who issued the extension or identifier.","Organization Assigning a Unique Protocol Identifer | Protocol Identifier Assigning Organization | Protocol Identifier Assigning Organization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1552667","Concept Descriptor","C64208","An assigned code from a defined code system used to represent any type of concept.","Concept Descriptor | CD | Concept Descriptor Data Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880016","Central Laboratory","C64207","A laboratory delivering the data for a particular study.","Central Laboratory | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553020","Byte","C48047","A sequence of 8 bits processed as a single unit of information.","Byte | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0218640","Lenograstim","C49234","A glycosylated form of a recombinant therapeutic agent which is chemically identical to or similar to an endogenous human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions.","Lenograstim | Glycosylated Recombinant G-CSF | Glycosylated Recombinant Granulocyte Colony-Stimulating Factor | Granocyte | LENOGRASTIM | Neutrogin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376562","Recombinant Granulocyte Colony Stimulating Factor","C1287","A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine granulocyte colony-stimulating factor (G-CSF).  Secreted by monocytes, macrophages and neutrophils and other cells after activation, G-CSF stimulates the proliferation and differentiation of hematopoietic progenitor cells committed to the neutrophil/ granulocyte lineage. (NCI04)","Recombinant Granulocyte Colony-Stimulating Factor | Recombinant Colony-Stimulating Factor 3 | Recombinant Granulocyte Colony Stimulating Factor | rhG-CSF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879629","Adjacency Matrix","C63897","A matrix with rows and columns labeled by graph vertices, with a 1 or 0 in position (vi,vj) according to whether vi and vj are adjacent or not.","Adjacency Matrix | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881934","Mutual Information Value","C63898","Expresses the extent to which the observed frequency of co-occurrence differs from that expected under the null hypothesis.","Mutual Information Value | Mutual Information Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879519","ARACNE Algorithm","C63899","An information-theoretic algorithm for reverse engineering of transcriptional networks using microarray data, specifically designed to scale up to the complexity of regulatory networks in mammalian cells, yet general enough to address a wider range of network deconvolution problems, while eliminating the majority of indirect interactions inferred by co-expression methods.","ARACNE Algorithm | Algorithm for the Reconstruction of Accurate Cellular Networks",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881303","Kernel","C63630","The central module of an operating systems, responsible for memory management, disk management, and process and task management.","Kernel | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879840","Bin","C63902","An interval into which a given data point does or does not fall.","Bin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882071","Network","C61377","An interconnected system of things or people.","Network | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1701901","Conditional","C63905","Subject to, implying, or dependent upon something else; not absolute.","Conditional | Conditionality | Contingency | Contingent | Dependent",,,,,,,,,,,,,,,"4159760","Dependent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0681921","Coefficient of Variance","C63904","The ratio of standard deviation to mean, expressed as a percentage or fraction.","Coefficient of Variance | CV | Coefficient of Variation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881045","Hierarchical Clustering","C63919","Cluster analysis that uses stepwise partitioning of objects.","Hierarchical Clustering | Hierarchical Cluster Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882996","Self-Organizing Map","C63920","A data visualization technique which reduces the dimensions of data through the use of self-organizing neural networks. SOMs scale well to large data sets, can identify local clusters in the data and organize them globally, and proceed in an unsupervised fashion.","Self-Organizing Map | SOM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1306504","Radius","C63921","A straight line from the center to the perimeter of a circle or from the center to the surface of a sphere.","Radius | ",,,,,,,,,,,,,,,"4038963","Radius",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448855","Iteration","C63922","Doing or saying again; a repeated performance.","Iteration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1449575","Microarray Analysis","C18477","Analysis using microarray technology (e.g., cDNA arrays to see gene expression or protein microarrays to profile the pattern of proteins).","Microarray Analysis | Gene Expression Profiling | Microarray | Microarray Technology | Microarray-Based Analysis | gene expression profile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882911","Reciprocal","C62766","Concerning each of two or more things, especially those given or done in return. In mathematics, used to denote different kinds of mutual relation.","Reciprocal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205187","Inoperable","C64247","Not suitable for surgery.","Inoperable | inoperable",,,,,,,,,,,,,,,"4254665","Inoperable",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0204193","Orthodontic Treatment","C64248","A dental treatment to correct malocclusions of the teeth and their surrounding structures.","Orthodontic Treatment | Orthodon Procedure | Orthodontic Treatment ",,,,,,,,,,,,,,,"4060198","Orthodontic procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0677829","Palifermin","C2455","A recombinant form of the endogenous human keratinocyte growth factor with cell growth promoting activity. Palifermin acts in the manner similar to the endogenous keratinocyte growth factor that binds to keratinocyte growth factor receptors on the epithelial cell surface in the lining of mouth and gastrointestinal tract. This results in stimulation of epithelial cell proliferation, differentiation and upregulation of cytoprotective mechanisms.","Palifermin | Growth Factor, Recombinant Human Keratinocyte | Kepivance | Keratinocyte Growth Factor, Recombinant Human | PALIFERMIN | Recombinant Human Keratinocyte Growth Factor | palifermin | rhKGF | rhu Keratinocyte Growth Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205391","Pervasive","C64249","Spread throughout a structure or area.","Pervasive | Widespread",,,,,,,,,,,,,,,"4310530","Widespread",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710622","velafermin","C48425","A recombinant human fibroblast growth factor-20 (rhFGF-20) protein with pro-proliferative activity.  Velafermin stimulates DNA synthesis and cell proliferation, specifically promoting epithelial and mesenchymal cell proliferation, and may prevent radiation or chemotherapy-induced oral mucositis.","Velafermin | CG53135 | Recombinant FGF-20 | Recombinant Human Fibroblast Growth Factor-20 | VELAFERMIN | velafermin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882925","Removable","C64250","Capable of being taken away.","Removable | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448235","Molecular Abnormality","C3910","A molecular or cytogenetic abnormality which occurs in either human disease states or disease models.","Molecular Abnormality | Chromosomal, Gene, or Protein Abnormality | Cytogenetic or Molecular Genetic Abnormality | Genetic Abnormality | MOLECULAR_ABNORMALITY | Molecular Alteration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4229995","Coagulation Disorder","C2902","A condition in which there is a deviation from or interruption of the normal coagulation properties of the blood.","Coagulation Disorder | Coagulation Defect | Coagulation defect, unspecified | Coagulopathy | Coagulopathy, specify",,,,,,,,,,,,,,,"432585","Blood coagulation disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332520","Circumference","C64265","The length of the closed curve of a circle; the size of something as given by the distance around it.","Circumference | CIRC | CIRCUMF | Circumferential",,,,,,,,,,,,,,,"4252748","Circumference",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0230069","Throat","C54272","The narrow passage from the mouth to the cavity at the back of the mouth.","Throat | THROAT | throat",,,,,,,,,,,,,"UBERON:0000341","throat","4173413","Structure of anterior portion of neck",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2749592","Subarachnoid Hemorrhage","C50757","Intracranial hemorrhage into the subarachnoid space.","Subarachnoid Hemorrhage | Subarachnoid hemorrhage",,,,,,,,,,,,,,,"432923","Subarachnoid hemorrhage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1969275","Dementia","C4786","Loss of intellectual abilities interfering with an individual's social and occupational functions. Causes include Alzheimer's disease, brain injuries, brain tumors, and vascular disorders.","Dementia | dementia",,,,,,,,,,,,,,,"4182210","Dementia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162577","Angioplasty","C51999","An endovascular procedure used to widen diseased arteries resulting in increasing blood flow through the area.","Angioplasty | angioplasty",,,,,,,,,,,,,,,"4302652","Angioplasty of blood vessel",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2749590","Hemiplegia","C64329","Paralysis of one side of the body.","Hemiplegia | ",,,,,,,,,,,,,,,"374022","Hemiplegia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0449450","Presentation","C61388","To show or display; the act of presenting something to sight or view: how something looks.","Presentation | Present | Presented | Presenting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0454270","High-Dose Rate Brachytherapy","C15651","Internal radiation treatment that targets a cancerous tissue with accurate, high doses of radiation through the use of inserted temporary implants.","High-Dose Rate Brachytherapy | Brachytherapy, High Dose | HDR | HIGH-DOSE RATE BRACHYTHERAPY | High dose brachytherapy (procedure)",,,,,,,,,,,,,,,"4038003|4216178","High dose rate brachytherapy|High dose brachytherapy",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1882485","Prominent Intraductal Component Present","C54687","A morphologic finding that indicates the presence of a substantial neoplastic cellular proliferation within a ductal structure.","Prominent Intraductal Component Present | EIC | Extensive Intraductal Component | Extensive Intraductal Component Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985790","Therapeutic Agent Research Funding","C17935","Funds allocated for basic research of the development of physical or chemical agents that may improve the health of a patient by impeding cancer or other diseases.","Therapeutic Agent Research Funding | Therapeutic Agents",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0423153","Tearing","C38031","Shedding of tears.","Tearing | Tears",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3809229","Cardiomyopathy","C34830","A disease of the heart muscle or myocardium proper. Cardiomyopathies may be classified as either primary or secondary, on the basis of etiology, or on the pathophysiology of the lesion: hypertrophic, dilated, or restrictive.","Cardiomyopathy | CARDIOMYOPATHY | Cardiomyopathy, NOS",,,,,,,,,,,,,,,"321319","Cardiomyopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085655","Polymyositis","C26925","An idiopathic inflammatory disorder affecting the muscles. It presents with symmetrical proximal muscle weakness and elevated skeletal muscle enzymes.","Polymyositis | Polymyositis, organ involvement unspecified | polymyositis",,,,,,,,,,,,,,,"80800","Polymyositis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026896","Myasthenia Gravis","C60989","A chronic autoimmune neuromuscular disorder characterized by skeletal muscle weakness. It is caused by the blockage of the acetylcholine receptors at the neuromuscular junction.","Myasthenia Gravis | myasthenia gravis",,,,,,,,,,,,,,,"76685","Myasthenia gravis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242428","Satisfaction","C62185","The feeling of being pleased and content.","Satisfaction | Satisfied",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706721","Adjuvant Radiation Therapy","C51987","Radiation therapy that is administered subsequent to the main treatment plan to minimize or prevent disease recurrence.","Adjuvant Radiation Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034131","Purified Protein Derivative","C29329","A purified protein extract derived from the bacterium Mycobacterium tuberculosis. Intradermally-administered, PPD stimulates preprimed CD4 T cells in immunologically competent subjects previously exposed to the bacterium Mycobacterium tuberculosis; these activated CD4 T cells secrete various cytokines that attract granulocytes, monocytes, and macrophages in an inflammatory response known as delayed hypersensitivity. (NCI04)","Purified Protein Derivative | PPD | PPD Tine Test | Tubersol",,,,,,,,,,,,,,,"4032570","Tuberculin purified protein derivative",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0305062","Tetanus Toxoid Vaccine","C2660","A preparation of formaldehyde-deactivated toxin isolated from the bacterium Clostridium tetani. Tetanus toxoid is used for booster injection and can stimulate the production of antitoxin antibodies. This agent may be used as an adjuvant in cancer vaccines.","Tetanus Toxoid Vaccine | TT | Tetanus Toxoid | Tetanus Toxoid | tetanus toxoid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0740858","Substance Abuse","C18272","Maladaptive pattern of drug or alcohol use that may lead to social, occupational, psychological, or physical problems.","Substance Abuse | substance abuse",,,,,,,,,,,,,,,"4279309","Substance abuse",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3257574","BCG Vaccine","C298","A vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.","BCG Vaccine | BCG | BCG (Pasteur) | BCG TICE | BCG Tice | BCG vaccine | Bacille Calmette Guerin | Bacille Calmette-Guerin Live | Bacillius Calmette-Guerin Vaccine | Bacillus Calmette Guerin | Bacillus Calmette Guerin Vaccine | Bacillus Calmette-Guerin | Bacillus Calmette-Guérin Vaccine | Cultivo BCG | ImmuCyst | Imovax BCG | Live Intravesical BCG | Monovax | Mycobacterium bovis (Strain BCG) | Oncotice | Pacis | Pastimmun | TICE BCG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1550704","Pager","C64350","A small wireless radio receiver designed to be carried by a person, to give an indication when activated by the reception of a radio signal containing its specific code, and to display a short messages in a text-only format.","Pager | Beeper",,,,,,,,,,,,,,,"45772525","Pager",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704655","modem device","C50072","An electronic device for converting between serial data from a computer and an audio signal suitable for transmission over a telephone line connected to another modem.","Modem Device | Modem | Modem Device Component | Modulator/Demodulator | modem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3554543","Lymphoproliferative Disorder","C9308","A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis).","Lymphoproliferative Disorder | Lymphoproliferative disease, NOS | Lymphoproliferative disorder, NOS | lymphoproliferative disorder","9970/1","Lymphoproliferative disorder, NOS",,,,,,,,,,,,,"4079147|4186240","Lymphoproliferative disorder|Lymphoproliferative disorder",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0037549","Sodium Salicylate","C834","The sodium salt of salicylic acid. As a nonsteroidal anti-inflammatory drug (NSAID), sodium salicylate irreversibly acetylates cyclooxygenases I and II, thereby inhibiting prostaglandin synthesis and associated inflammation and pain.  This agent may also activate mitogen-activated protein kinase (p38MAPK), thereby inducing apoptosis in cancer cells. (NCI04)","Sodium Salicylate | Benzoic acid, 2-hydroxy-, monosodium salt | SODIUM SALICYLATE | Salicylate, sodium | Sodium salicylate | sodium salicylate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003808","Alert","C64358","Condition of heightened watchfulness or preparation for action.","Alert | arousal",,,,,,,,,,,,,,,"4086843","Mentally alert",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1550227","canal (bodily passage)","C61487","A bodily passage or tube lined with epithelial cells and conveying a secretion or other substance.","Canal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2745965","Emergency","C62648","A sudden unforeseen crisis that requires immediate action.","Emergency | EMERGENCY | Emergency Situation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162409","Spouse","C62649","A person's partner in marriage.","Spouse | SPOUSE",,,,,,,,,,,,,,,"4132413","Spouse",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002092","Allergen","C62651","A substance that elicits an allergic reaction.","Allergen | allergen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009488","Comorbidity","C16457","The coexistence of two or more disease processes.","Comorbidity | Intercurrent Illness | Intercurrent illness | comorbidities | comorbidity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0460002","Organ System","C12919","An anatomical structure that consists of organs and organ subclasses responsible for certain body functions.  Representative examples are the gastrointestinal system, urinary system, and hematopoietic system.","Organ System | Body Systems | body system | body_system",,,,,,,,,,,,,,,"4237366","Body system structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0728831","Social","C62650","Relating to human society and its members.","Social | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1999262","Pack dose form","C62653","A number of individual items packaged as a unit.","Pack Dosage Form | PACK | Pack | Pack | Packs | {PACK} | {Pack}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004763","Barrett Esophagus","C2891","Esophageal lesion lined with columnar metaplastic epithelium which is flat or villiform. Barrett epithelium is characterized by two different types of cells: goblet cells and columnar cells. The symptomatology of Barrett esophagus is that of gastro-esophageal reflux. It is the precursor of most esophageal adenocarcinomas.  (WHO)","Barrett Esophagus | BE | Barrett's Esophagus | Barrett's Esophagus | Barrett's esophagus | CELLO | CLE | Columnar Epithelial-Lined Lower Esophagus | Columnar-Lined Esophagus",,,,,,,,,,,,,,,"443344","Barrett's esophagus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516737","Comorbidity Index","C19253","In epidemiology, a rating scale for comorbidity.","Comorbidity Index | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0817745","Back","C13062","The dorsal area between the base of the neck and the sacrum.","Back | BACK | back | back of body proper | dorsal part of organism | dorsum",,,,,,,,,,,,,"UBERON:0001137","dorsum",,,,,,,,,,,,,,,"--"
"C1321721","Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome","C4037","An acute myeloid leukemia developing in patients with a prior history of myelodysplastic syndrome.","Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome | AML/MDS | Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome | Acute Myeloid Leukemia with Multilineage Dysplasia following Myelodysplastic Syndrome | Acute Myeloid Leukemia with Multilineage Dysplasia following Myelodysplastic Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1292773","Acute Myeloid Leukemia with Multilineage Dysplasia","C9289","An acute myeloid leukemia arising de novo and not as a result of treatment. It is characterized by the presence of myelodysplastic features in at least 50% of the cells of at least two hematopoietic cell lines. Patients often present with severe cytopenia.","Acute Myeloid Leukemia with Multilineage Dysplasia | AML with Multilineage Dysplasia | AML-MLD | Acute myeloid leukemia with multilineage dysplasia | De Novo Acute Myeloid Leukemia with Multilineage Dysplasia | De novo Acute Myeloid Leukemia with Multilineage Dysplasia | De novo Acute Myeloid Leukemia with Multilineage Dysplasia","9895/3","Acute myeloid leukemia with multilineage dysplasia",,,,,,,,,,,,,"4029177","Acute myeloid leukemia myelodysplasia related",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0023465","Acute Monocytic Leukemia","C4861","An acute myeloid leukemia in which the majority of monocytic cells are promonocytes.  (WHO, 2001)","Acute Monocytic Leukemia | Acute Monocytic Leukemia (FAB M5b) | Acute Monocytic Leukemia (Fab M5B) | Acute monocytic leukemia | FAB M5 (includes all variants) | LEUKEMIA, MONOCYTIC, MALIGNANT | M5 | M5b | Monocytic Leukemia","9891/3","Acute monocytic leukemia",,,,,,,,,,,,,"135768|4319285","Acute monocytic leukemia|Acute monocytic leukemia",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"CL1779333","Acute Myeloid Leukemia Not Otherwise Specified","C27753","Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related.  This category includes entities classified according to the French-American-British classification scheme.","Acute Myeloid Leukemia, Not Otherwise Specified | AML not otherwise specified | AML, NOS | AML, Not Otherwise Specified | Acute Myeloid Leukemia Defined by Differentiation | Acute Myeloid Leukemia NOS | Acute Myeloid Leukemia Not Otherwise Categorized | Acute Myeloid Leukemia Not Otherwise Specified | Acute Myeloid Leukemia Not Otherwise Specified | Acute Myeloid Leukemia not Otherwise Categorized | Acute Myeloid Leukemia, Defined by Differentiation | Acute Myeloid Leukemia, NOS | Acute myeloid leukemia | Acute myeloid leukemia, NOS","9861/3","Acute myeloid leukemia, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C4227542","B Acute Lymphoblastic Leukemia","C8644","The most frequent type of acute lymphoblastic leukemia.  Approximately 75% of cases occur in children under six years of age.  This is a good prognosis leukemia.  In the pediatric age group the complete remission rate is approximately 95% and the disease free survival rate is 70%.  Approximately 80% of children appear to be cured.  In the adult age group the complete remission rate is 60-85%.  (WHO, 2001)","B Acute Lymphoblastic Leukemia | Acute B Cell Lymphocytic Leukemia | Acute B-Cell Lymphocytic Leukemia | B Cell Acute Lymphocytic Leukemia | B Cell Precursor Type Acute Leukemia | B-ALL | B-Acute Lymphoblastic Leukemia | B-Cell ALL | B-Cell Acute Lymphoblastic Leukemia | B-Cell Acute Lymphocytic Leukemia | B-Cell Lymphoblastic Leukemia | B-Cell Precursor Type Acute Leukemia | B-Cell Type Acute Leukemia | B-cell acute lymphoblastic leukemia | B-cell acute lymphocytic leukemia | B-precursor ALL | Precursor B-Cell Lymphoblastic Leukemia | Precursor B-Lymphoblastic Leukemia | Precursor B-Lymphoblastic Leukemia | Precursor B-cell lymphoblastic leukemia | Precursor B-lymphoblastic leukemia (B-precursor ALL) | precursor B-lymphoblastic leukemia",,,,,,,,,,,,,,,"4029662","Precursor B-cell lymphoblastic leukemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1961099","T Acute Lymphoblastic Leukemia","C3183","Acute lymphoblastic leukemia of T-cell origin.  It comprises about 15% of childhood cases and 25% of adult cases.  It is more common in males than females.  (WHO, 2001)","T Acute Lymphoblastic Leukemia | Acute T Cell Leukemia | Acute T Cell Lymphoblastic Leukemia | Acute T Cell Lymphocytic Leukemia | Acute T-Cell Leukemia | Acute T-Cell Lymphoblastic Leukemia | Acute T-Cell Lymphocytic Leukemia | Precursor T-Cell Lymphoblastic Leukemia | Precursor T-Lymphoblastic Leukemia | Precursor T-Lymphoblastic Leukemia | Precursor T-lymphoblastic leukemia (T-cell ALL) | T cell acute lymphoblastic leukemia | T-ALL | T-Acute Lymphoblastic Leukemia | T-Cell Acute Lymphoblastic Leukemia | T-Cell Type Acute Leukemia | T-cell ALL | T-cell acute lymphoblastic leukemia | T-cell acute lymphocytic leukemia | precursor T-lymphoblastic leukemia","9837/3","Precursor T-cell lymphoblastic leukemia",,,,,,,,,,,,,"4030261|4082462","Precursor T-cell lymphoblastic leukemia|T-cell acute lymphoblastic leukemia",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0023435","Burkitt Leukemia","C7400","The leukemic counterpart of Burkitt's lymphoma. The characteristic Burkitt cells are seen in the bone marrow and the peripheral blood. This is an aggressive leukemia.","Burkitt Leukemia | Burkitt cell leukemia | Burkitt lymphoma/leukemia | Burkitt's Cell Leukemia | Burkitt's Leukemia | Burkitt's Leukemia | Burkitt's leukemia | FAB L3 | L3 Acute Lymphoblastic Leukemia | L3 Acute Lymphocytic Leukemia | L3 Acute Lymphogenous Leukemia | L3 Acute Lymphoid Leukemia",,,,,,,,,,,,,,,"4173963|4265150|4319135","B-cell acute lymphoblastic leukemia|Burkitt lymphoma/leukemia|Burkitt cell leukemia",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C1955861","T-Cell Large Granular Lymphocyte Leukemia","C4664","A T-cell peripheral neoplasm characterized by a persistent (>6 months) increase in the number of peripheral blood large granular lymphocytes, without a clearly identified cause. (WHO, 2001)","T-Cell Large Granular Lymphocyte Leukemia | LEUKEMIA, LARGE GRANULAR LYMPHOCYTIC, MALIGNANT | LGLL | Large Cell Granular Lymphogenous Leukemia | Large Cell Granular Lymphoid Leukemia | Large Granular Lymphocytic Leukemia | Large Granular Lymphocytosis | T Gamma Lymphoproliferative Disorder | T Large Granular Lymphocyte Leukemia | T-Cell Large Granular Lymphocytic Leukemia | T-Gamma Lymphoproliferative Disorder | T-LGL leukemia | T-Large Granular Lymphocyte Leukemia | T-cell large gran. lymph. leuk. | T-cell large granular lymphocyte leukemia | T-cell large granular lymphocytic leukemia | T-cell large granular lymphocytosis | T-gamma lymphoproliferative disease | Tgamma Large Granular Lymphocyte Leukemia","9768/1|9831/3","T-gamma lymphoproliferative disease|T-cell large granular lymphocytic leukemia",,,,,,,,,,,,,"4028712|4204536|44783718","T-cell large granular lymphocytic leukemia|T-gamma lymphoproliferative disease|T-cell large granular lymphocytic leukemia",,,,,,,,,,,,,"--","--|--",,,,,,,,"--|--|--"
"C1948021","Proband (person)","C64435","The affected family member who seeks medical attention for a genetic disorder thereby bringing the family under study.","Proband | proband",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085149","Tacrolimus","C1311","A macrolide isolated from Streptomyces tsukubaensis. Tacrolimus binds to the FKBP-12 protein and forms a complex with calcium-dependent proteins, thereby inhibiting calcineurin phosphatase activity and resulting in decreased cytokine production. This agent exhibits potent immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation. Tacrolimus possesses similar immunosuppressive properties to cyclosporine, but is more potent.","Tacrolimus | FK 506 | FK-506 | FK506 | Fujimycin | Hecoria | Hexadecahydro-5,19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone | Prograf | Protopic | TACROLIMUS | Tacforius | tacrolimus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515655","In Vivo","C15744","Located or occurring in the body.","In Vivo | in vivo | in vivo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0220938","White","C48325","The achromatic color of maximum lightness; the color of objects that reflect nearly all light of all visible wavelengths; the complement or antagonist of black, the other extreme of the neutral gray series.","White | WHITE | White Color",,,,,,,,,,,,,,,"4159854","White color",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031705","Phosphorus","C47934","An element with atomic symbol P, atomic number 15, and atomic weight 30.97.","Phosphorus | P | Phosphorous (NOS) | phosphorus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376450","Transplant Conditioning","C64468","Administration of high doses of chemotherapy or radiation therapy, as well as immunosuppressive therapy, to a transplant recipient prior to a bone marrow or hematopoietic stem cell transplant.  Conditioning destroys the patient's abnormal blood cells or cancer, as well as slows the patient's immune response against the donor bone marrow (graft rejection).","Transplant Conditioning | conditioning regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023461","Mast Cell Leukemia","C3169","A variant of systemic mastocytosis with involvement of the bone marrow (20% or more mast cells) and the peripheral blood (mast cells account for 10% or more of peripheral blood white cells). (WHO, 2001)","Mast Cell Leukemia | LEUKEMIA, MAST CELL, MALIGNANT | Mast cell leukaemia","9742/3","Mast cell leukemia",,,,,,,,,,,,,"4002496|4030287","Mast cell leukemia (clinical)|Mast cell leukemia",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1292771","Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive","C9128","A chronic myeloid leukemia characterized by the t(9;22)(q34;q11) chromosomal translocation, resulting in the presence of the Philadelphia chromosome and the BCR-ABL1 fusion gene.","Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive | CML - Philadelphia chromosome | Chronic Myeloid Leukemia t(9;22) (q34;q11), BCR/ABL Positive | Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR::ABL1 Positive | Chronic granulocytic leukemia, BCR/ABL | Chronic granulocytic leukemia, Philadelphia chromosome (Ph1) positive | Chronic granulocytic leukemia, t(9;22)(q34;q11) | Chronic myelogenous leukemia, Philadelphia chromosome (Ph 1) positive | Chronic myelogenous leukemia, Philadelphia chromosome positive | Chronic myelogenous leukemia, t(9;22)(q34;q11) | Ph' Chromosome Positive Chronic Myelocytic Leukemia | Ph' Chromosome Positive Chronic Myelogenous Leukemia | Ph' Chromosome Positive Chronic Myeloid Leukemia | Ph' Positive Chronic Granulocytic Leukemia | Ph1 Chromosome Positive Chronic Myelocytic Leukemia | Ph1 Chromosome Positive Chronic Myelogenous Leukemia | Ph1 Chromosome Positive Chronic Myeloid Leukemia | Ph1 Positive Chronic Granulocytic Leukemia | Philadelphia Chromosome Positive CML | Philadelphia Chromosome Positive Chronic Granulocytic Leukemia | Philadelphia Chromosome Positive Chronic Myelocytic Leukemia | Philadelphia Chromosome Positive Chronic Myelogenous Leukemia | Philadelphia Chromosome Positive Chronic Myelogenous Leukemia | Philadelphia Chromosome Positive Chronic Myeloid Leukemia | Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia | Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia | Philadelphia Chromosome Positive, BCR::ABL1 Positive Chronic Myelogenous Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279549","Philadelphia Chromosome Negative BCR-ABL1 Positive Chronic Myelogenous Leukemia","C9129","A chronic myeloid leukemia that does not have the characteristic t(9;22)(q34;q11.2) translocation but it has either a variant translocation or a cryptic translocation that cannot be detected by conventional cytogenetic analysis.  In such cases the BCR-ABL1 fusion gene is always detected by RT-PCR, FISH, or Southern blot analysis.","Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive | Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR::ABL1 Positive | Ph Negative CML | Ph Negative Chronic Myelogenous Leukemia | Ph' Chromosome Negative Chronic Granulocytic Leukemia | Ph' Chromosome Negative Chronic Myelocytic Leukemia | Ph' Chromosome Negative Chronic Myeloid Leukemia | Ph' Negative Chronic Granulocytic Leukemia | Ph- CML | Ph- Chronic Myelogenous Leukemia | Ph1 Chromosome Negative Chronic Myelocytic Leukemia | Ph1 Chromosome Negative Chronic Myelogenous Leukemia | Philadelphia Chromosome Negative BCR-ABL1 Positive Chronic Myelogenous Leukemia | Philadelphia Chromosome Negative CML | Philadelphia Chromosome Negative Chronic Granulocytic Leukemia | Philadelphia Chromosome Negative Chronic Myelocytic Leukemia | Philadelphia Chromosome Negative Chronic Myelogenous Leukemia | Philadelphia Chromosome Negative Chronic Myelogenous Leukemia | Philadelphia Chromosome Negative Chronic Myeloid Leukemia | Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia | Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia | Philadelphia Chromosome Negative, BCR::ABL1 Positive Chronic Myelogenous Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023486","Prolymphocytic Leukemia","C3181","A mature B- or T- cell leukemia with progressive clinical course. It is characterized by the presence of medium-sized lymphocytes with visible nucleoli (prolymphocytes) in the peripheral blood, bone marrow, and spleen.","Prolymphocytic Leukemia | PLL | Prolymphocytic leukemia (B or T) | Prolymphocytic leukemia (B or T-cell) | prolymphocytic leukemia","9832/3","Prolymphocytic leukemia, NOS",,,,,,,,,,,,,"4001331|4029800","Prolymphocytic leukemia (clinical)|Prolymphocytic leukemia",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1292778","Myeloproliferative Neoplasm","C4345","A group of myeloid neoplasms that includes the following: chronic myeloid leukemia, BCR-ABL1 positive; polycythemia vera; essential thrombocythemia;  primary myelofibrosis; chronic neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified; and myeloproliferative neoplasm, unclassifiable.","Myeloproliferative Neoplasm | CMPD | Chronic Myeloproliferative Disease | Chronic Myeloproliferative Disorder | Chronic Myeloproliferative Disorder | Chronic Myeloproliferative Disorders | Chronic Myeloproliferative Neoplasm | Chronic myeloproliferative disease | Chronic myeloproliferative disease, NOS | Chronic myeloproliferative disorder | MPD | MPN | Myeloproliferative Disease | Myeloproliferative Disorder | Myeloproliferative Tumor | Myeloproliferative disease, NOS | Myeloproliferative neoplasm, NOS | myeloproliferative disorder",,,,,,,,,,,,,,,"4304484","Chronic myeloproliferative disorder (clinical)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0442031","Pericardial body location","C38001","Located around the heart or relating to or affecting the pericardium.","Pericardial | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206373","Extracorporeal Photopheresis","C62729","A procedure which combines apheresis and photodynamic therapy, resulting in blood being treated with a photosensitizing agent and subsequently irradiated with specified wavelengths of light to achieve an effect.","Extracorporeal Photopheresis | Extracorporeal Photophoresis | Photophoresis | extracorporeal photopheresis | photopheresis",,,,,,,,,,,,,,,"4309050","Extracorporeal photopheresis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0072980","Sirolimus","C1212","A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production. (NCI04)","Sirolimus | 9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,2 | AY 22989 | AY-22989 | AY22989 | RAPA | RAPAMYCIN | Rapamune | Rapamycin | SILA 9268A | SILA-9268A | SILA9268A | SIROLIMUS | WY 090217 | WY-090217 | WY090217 | rapamycin | sirolimus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042105","Ursodiol","C1818","A synthetically-derived form of ursodiol, a bile acid produced by the liver and secreted and stored in the gallbladder.  Also produced by the Chinese black bear liver, ursodiol has been used in the treatment of liver disease for centuries.  This agent dissolves or prevents cholesterol gallstones by blocking hepatic cholesterol production and decreasing bile cholesterol.  Ursodiol also reduces the absorption of cholesterol from the intestinal tract.","Ursodiol | (3alpha,5beta,7beta)-3,7-Dihydroxycholan-24-oic acid | Actigall | Deursil | UDCA | URSO | URSODIOL | Ursodeoxycholic Acid | Ursodeoxycholic acid | ursodiol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334989","Non-Melanomatous Lesion","C36114","A lesion characterized by the absence of clinical and/or morphologic criteria that are suggestive of melanoma.","Non-Melanomatous Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1136084","Plasma Cell Neoplasm","C4665","A clonal proliferation of immunoglobulin-secreting plasma cells. This category includes multiple myeloma, plasma cell leukemia, plasmacytoma, and plasma cell post-transplant lymphoproliferative disorder.","Plasma Cell Neoplasm | PLASMA CELL TUMOR, MALIGNANT | Plasma Cell Dyscrasia | Plasma Cell Tumor | Plasma Cell Tumors | Plasma cell tumor | Plasmacytic Neoplasm | Plasmacytic Tumor | Plasmacytic Tumour | plasma cell tumor",,,,,,,,,,,,,,,"37156887","Plasmacytoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334633","Lymphoplasmacytic Lymphoma","C3212","A clonal neoplasm of small B-lymphocytes, lymphoplasmacytoid cells, and plasma cells involving the bone marrow, lymph nodes, and the spleen. The majority of patients have a serum IgM paraprotein.","Lymphoplasmacytic Lymphoma | Immunocytoma, Lymphoplasmacytic Type | LYMPHOMA, LYMPHOPLASMACYTIC, MALIGNANT | Lymphoma, Plasmacytic | Lymphoplasmacytic Lymphoma/Waldenstrom's Macroglobulinemia | Lymphoplasmacytic lymphoma | Lymphoplasmacytic lymphoma (Waldenstrom macroglobulinemia) | Lymphoplasmacytoid Lymphoma | lymphoplasmacytic lymphoma",,,,,,,,,,,,,,,"4000173|4141255","Malignant lymphoma, lymphoplasmacytic|Malignant lymphoma - lymphoplasmacytic",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0023485","B Lymphoblastic Leukemia/Lymphoma","C8936","A neoplasm of lymphoblasts committed to the B-cell lineage, typically composed of small to medium-sized blast cells.  When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called B acute lymphoblastic leukemia.  When it involves nodal or extranodal sites, it is called B lymphoblastic lymphoma. (WHO, 2001)","B Lymphoblastic Leukemia/Lymphoma | B-Cell Lymphoblastic Leukemia/Lymphoma | B-Lymphoblastic Leukemia/Lymphoma | Precursor B Lymphoblastic Leukemia/Lymphoma | Precursor B-Lymphoblastic Lymphoma/Leukemia | Precursor B-Lymphoblastic Lymphoma/Leukemia",,,,,,,,,,,,,,,"37156124","B lymphoblastic leukemia lymphoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0349632","Splenic Marginal Zone Lymphoma","C4663","A B-cell non-Hodgkin lymphoma composed of small lymphocytes which surround and replace the splenic white pulp germinal centers.  It involves the spleen and splenic hilar lymph nodes, bone marrow, and often the peripheral blood.  When lymphoma cells are present in the peripheral blood, they are usually, but not always, characterized by the presence of short polar villi. (WHO)","Splenic Marginal Zone Lymphoma | Marginal Zone Lymphoma of Spleen | Marginal Zone Lymphoma of the Spleen | SLVL | SMZL | Splenic Lymphoma with Circulating Villous Lymphocytes | Splenic Marginal Zone B-Cell Lymphoma | Splenic Marginal Zone B-Cell Lymphoma | Splenic Marginal Zone B-Cell Lymphoma with Villous Lymphocytes | Splenic Marginal Zone Lymphoma with Villous Lymphocytes | Splenic marginal zone B-cell lymphoma | Splenic marginal zone lymphoma, NOS","9689/3","Splenic marginal zone B-cell lymphoma",,,,,,,,,,,,,"4029658","Splenic marginal zone B-cell lymphoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0242647","Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","C3898","An indolent, extranodal type of non-Hodgkin lymphoma composed of small B-lymphocytes (centrocyte-like cells).  The gastrointestinal tract is the most common site of involvement.  Other common sites of involvement include lung, head and neck, ocular adnexae, skin, thyroid, and breast.  Gastric involvement is associated with the presence of H. pylori infection. (WHO, 2001)","Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue | Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue | Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT-lymphoma) | Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma] | Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue | Immunocytoma | MALT Lymphoma | MALT lymphoma | MALT-lymphoma | MALToma | Mucosa-Associated Lymphoid Tissue Lymphoma | Mucosal-associated lymphoid tissue lymphoma | mucosa-associated lymphoid tissue lymphoma",,,,,,,,,,,,,,,"40482893|4173976|4265015","Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT-lymphoma)|Mucosa-associated lymphoma|Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C0079765","Grade 1 Follicular Lymphoma","C3465","A follicular lymphoma which contains up to 5 centroblasts per 40X high-power microscopic field.","Grade 1 Follicular Lymphoma | Follicular Lymphoma Grade 1 | Follicular Small Cleaved Cell Lymphoma | Follicular lymphoma grade I, unspecified site | Follicular lymphoma, grade 1 | Follicular lymphoma, small cleaved cell | Grade 1 | Grade I Follicular Lymphoma | Grade I Follicular Small Cleaved Cell Lymphoma | Poorly Differentiated Nodular Lymphocytic Lymphoma | WHO Follicular Lymphoma Histologic Grade 1 | grade 1 follicular lymphoma","9695/3","Follicular lymphoma, grade 1",,,,,,,,,,,,,"4002357|4079289|4146031|4188203","Follicular non-Hodgkin's lymphoma, small cleaved cell (clinical)|Follicular malignant lymphoma - small cleaved cell|Malignant lymphoma, lymphocytic, poorly differentiated, nodular|Follicular lymphoma, grade 1",,,,,,,,,,,,,"--","--",,,,,,,,"--|--|--|--"
"C0079758","Grade 2 Follicular Lymphoma","C8968","A follicular lymphoma which contains 6-15 centroblasts per 40X high-power microscopic field.","Grade 2 Follicular Lymphoma | Follicular Lymphoma Grade 2 | Follicular Mixed Cell Lymphoma | Follicular Mixed Lymphocytic-Histiocytic Lymphoma | Follicular lymphoma grade II, unspecified site | Follicular lymphoma, grade 2 | Grade 2 | Grade II Follicular Lymphoma | Grade II Follicular Mixed Cell Lymphoma | Nodular Mixed Lymphoma | WHO Follicular Lymphoma Histologic Grade 2 | follicular mixed cell lymphoma | grade 2 follicular lymphoma","9691/3","Follicular lymphoma, grade 2",,,,,,,,,,,,,"4001329|4097572|4146027|4173977|4204524","Follicular non-Hodgkin's lymphoma, mixed small cleaved cell and large cell (clinical)|Follicular non-Hodgkin's mixed small cleaved and large cell lymphoma|Malignant lymphoma, mixed lymphocytic-histiocytic, nodular|Follicular malignant lymphoma - mixed cell type|Follicular lymphoma, grade 2",,,,,,,,,,,,,"--","--",,,,,,,,"--|--|--|--|--"
"C0079745","Grade 3 Follicular Lymphoma","C3460","A follicular lymphoma which contains more than 15 centroblasts per 40X high-power microscopic field.","Grade 3 Follicular Lymphoma | Follicular Large Cell Lymphoma | Follicular Lymphoma Grade 3 | Follicular Lymphoma, Predominantly Large Cell | Follicular lymphoma grade III, unspecified, unspecified site | Follicular lymphoma, grade 3 | Grade 3 | Grade III Follicular Large Cell Lymphoma | Grade III Follicular Lymphoma | Nodular Histiocytic Lymphoma | WHO Follicular Lymphoma Histologic Grade 3 | follicular large cell lymphoma | grade 3 follicular lymphoma","9698/3","Follicular lymphoma, grade 3",,,,,,,,,,,,,"4003833","Follicular non-Hodgkin's lymphoma, large cell (clinical)",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1368771","Atypical Burkitt/Burkitt-Like Lymphoma","C6917","A morphologic variant of Burkitt lymphoma characterized by marked nuclear pleomorphism, abundant apoptotic debris, and the presence of tangible body macrophages.","Atypical Burkitt/Burkitt-Like Lymphoma | Atypical Burkitt's/Burkitt's-Like Lymphoma | Burkitt's-like Lymphoma | Burkitt-like Lymphoma | Burkitt-like lymphoma",,,,,,,,,,,,,,,"4300163","Burkitt lymphoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1301359","T Lymphoblastic Leukemia/Lymphoma","C8694","A neoplasm of lymphoblasts committed to the T-cell lineage, typically composed of small to medium-sized blast cells.  When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called T acute lymphoblastic leukemia.  When it involves nodal or extranodal sites it is called T lymphoblastic lymphoma. (WHO, 2001)","T Lymphoblastic Leukemia/Lymphoma | Precursor T Lymphoblastic Leukemia/Lymphoma | Precursor T Lymphoblastic Lymphoma/Leukemia | Precursor T-Lymphoblastic Lymphoma/Leukemia | Precursor T-Lymphoblastic Lymphoma/Leukemia | T lymphoblastic leukemia/lymphoma | T-Cell Lymphoblastic Leukemia/Lymphoma | T-Lymphoblastic Leukemia/Lymphoma",,,,,,,,,,,,,,,"45766617","T lymphoblastic leukemia/lymphoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0392788","Nasal Type Extranodal NK/T-Cell Lymphoma","C4684","An aggressive, predominantly extranodal, mature T-cell non-Hodgkin lymphoma. It is characterized by an often angiocentric and angiodestructive cellular infiltrate composed of EBV positive NK/T cells. The nasal cavity is the most common site of involvement. Patients often present with midfacial destructive lesions (lethal midline granuloma). The disease may disseminate rapidly to various anatomic sites including the gastrointestinal tract, skin, testis, and cervical lymph nodes. It is also known as angiocentric T-cell lymphoma. The term 'polymorphic reticulosis' has been widely used to describe the morphologic changes seen in this type of lymphoma. However, the latter term may also apply to lymphomatoid granulomatosis, which is an angiocentric and angiodestructive EBV positive B-cell lymphoproliferative disorder.","Nasal Type Extranodal NK/T-Cell Lymphoma | Angiocentric T-Cell Lymphoma | Angiocentric T-cell lymphoma | Extranodal NK/T lymphoma-nasal | Extranodal NK/T-Cell Lymphoma | Extranodal NK/T-Cell Lymphoma, Nasal Type | Extranodal NK/T-cell lymphoma, nasal type | NK/T-cell lymphoma, nasal and nasal-type | RETICULOSIS, MALIGNANT | T/NK-cell lymphoma",,,,,,,,,,,,,,,"4029170|4212994","NK/T-cell lymphoma, nasal and nasal-type|Extranodal NK/T-cell lymphoma, nasal type",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0862196","Mycosis Fungoides and Sezary Syndrome","C9265","Mature T and NK neoplasms predominantly affecting the skin and the peripheral blood.  Peripheral blood involvement by abnormal T-cells (cerebriform cells) is a late manifestation of mycosis fungoides, whereas it is the presenting finding in Sezary syndrome.","Mycosis Fungoides and Sezary Syndrome | Mycosis Fungoides and Sézary Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079774","Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","C3468","This type of lymphoma is not frequently seen in the western hemisphere. Clinically, with the exception of anaplastic large cell lymphoma, mature T- and NK-cell lymphomas are among the most aggressive of all hematopoietic neoplasms. Representative disease entities include mycosis fungoides, angioimmunoblastic T-cell lymphoma, hepatosplenic T-cell lymphoma, and anaplastic large cell lymphoma.","Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Mature T- and NK-Cell Lymphomas | Mature T-Cell Non-Hodgkin's Lymphoma | Mature T-Cell and NK-Cell Lymphoma | Mature T-Cell and NK-Cell Non-Hodgkin's Lymphoma | Mature T-and NK-Cell Lymphoma | Mature T/NK-cell lymphomas, unspecified, unspecified site | PTCL | Peripheral T-Cell Lymphoma | mature T-cell lymphoma | peripheral T-cell lymphoma",,,,,,,,,,,,,,,"37152048|434881","Peripheral T-cell lymphoma|Peripheral T-cell lymphoma (clinical)",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1336548","Systemic Anaplastic Large Cell Lymphoma","C9470","An anaplastic large cell lymphoma that is not confined to a single anatomic site and involves multiple nodal and/or extranodal sites.","Systemic Anaplastic Large Cell Lymphoma | ALCL, systemic | Anaplastic large-cell lymphoma, primary systemic type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280803","Central Nervous System Lymphoma","C9301","A non-Hodgkin or Hodgkin lymphoma that arises in the brain or spinal cord as a primary lesion. There is no evidence of lymphoma outside the central nervous system at the time of diagnosis.","Central Nervous System Lymphoma | CNS Lymphoma | Malignant Lymphomas of CNS | Malignant Lymphomas of the CNS | PCNSL | Primary CNS Lymphoma | Primary CNS lymphoma | Primary Central Nervous System Lymphoma | primary CNS lymphoma | primary central nervous system lymphoma",,,,,,,,,,,,,,,"373152","Primary central nervous system lymphoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266194","Lymphocyte-Rich Classic Hodgkin Lymphoma","C6913","A subtype of classic Hodgkin lymphoma with scattered Hodgkin and Reed-Sternberg cells and a nodular or less often diffuse cellular background consisting of small lymphocytes and with an absence of neutrophils and eosinophils. (WHO, 2008)","Lymphocyte-Rich Classic Hodgkin Lymphoma | Classical Hodgkin lymphoma, lymphocyte-rich | Hodgkin Lymphoma, Lymphocyte-Rich | Hodgkin lymphoma, lymphocyte-rich | LRCHL | Lymphocyte Rich Classical Hodgkin Lymphoma | Lymphocyte Rich Classical Hodgkin Lymphoma | Lymphocyte Rich Classical Hodgkin's Disease | Lymphocyte Rich Classical Hodgkin's Lymphoma | Lymphocyte Rich Hodgkin Lymphoma | Lymphocyte Rich Hodgkin's Disease | Lymphocyte Rich Hodgkin's Lymphoma | Lymphocyte-Rich Classical Hodgkin Lymphoma | Lymphocyte-Rich Classical Hodgkin Lymphoma | Lymphocyte-Rich Classical Hodgkin's Lymphoma | Lymphocyte-rich classical Hodgkin lymphoma, unspecified site","9651/3","Hodgkin lymphoma, lymphocyte-rich",,,,,,,,,,,,,"4028701|4038841","Hodgkin lymphoma, lymphocyte-rich|Lymphocyte-rich classical Hodgkin lymphoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0152268","Nodular Sclerosis Classic Hodgkin Lymphoma","C3518","A subtype of classic Hodgkin lymphoma characterized by collagen bands that surround at least one nodule, and Hodgkin and Reed-Sternberg cells with lacunar type morphology. (WHO, 2008)","Nodular Sclerosis Classic Hodgkin Lymphoma | Classical Hodgkin lymphoma, nodular sclerosis, NOS | Hodgkin Lymphoma, Nodular Sclerosis, NOS | Hodgkin disease, nodular sclerosis, NOS | Hodgkin's Nodular Sclerosis | NSCHL | NSHD | NSHL | Nodular Sclerosis Classical Hodgkin Lymphoma | Nodular Sclerosis Classical Hodgkin Lymphoma | Nodular Sclerosis Hodgkin Lymphoma | Nodular Sclerosis Hodgkin Lymphoma | Nodular Sclerosis Hodgkin's Disease | Nodular Sclerosis Hodgkin's Lymphoma | Nodular sclerosis classical Hodgkin lymphoma, unspecified site","9663/3","Hodgkin lymphoma, nodular sclerosis, NOS",,,,,,,,,,,,,"4038842|4179351","Hodgkin's disease, nodular sclerosis (clinical)|Hodgkin lymphoma, nodular sclerosis",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0152267","Lymphocyte-Depleted Classic Hodgkin Lymphoma","C9283","A diffuse subtype of classic Hodgkin lymphoma which is rich in Hodgkin and Reed-Sternberg cells and/or depleted in non-neoplastic lymphocytes. (WHO, 2008)","Lymphocyte-Depleted Classic Hodgkin Lymphoma | Classical Hodgkin lymphoma, lymphocyte depletion, NOS | Classical Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis | Hodgkin Lymphoma Lymphocyte Depleted | Hodgkin Lymphoma, Lymphocyte Depletion, NOS | Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis | Hodgkin lymphoma, lymphocyte depletion, reticular | Hodgkin's Disease Lymphocyte Depletion | Hodgkin's Lymphoma Lymphocyte Depleted | LDCHL | LDHL | Lymphocyte Depleted Classical Hodgkin Lymphoma | Lymphocyte Depleted Classical Hodgkin Lymphoma | Lymphocyte Depleted Classical Hodgkin's Lymphoma | Lymphocyte Depleted Hodgkin Lymphoma | Lymphocyte Depleted Hodgkin Lymphoma | Lymphocyte Depleted Hodgkin's Disease | Lymphocyte Depleted Hodgkin's Lymphoma | Lymphocyte depleted classical Hodgkin lymphoma, unspecified site | Lymphocyte-Depleted Classical Hodgkin Lymphoma | Lymphocyte-Depleted Classical Hodgkin Lymphoma | Lymphocyte-Depleted Hodgkin's Disease | Lymphocyte-Depleted Hodgkin's Lymphoma","9653/3|9654/3|9655/3","Hodgkin lymphoma, lymphocyte depletion, NOS|Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis|Hodgkin lymphoma, lymphocyte depletion, reticular",,,,,,,,,,,,,"4012175|4041798","Hodgkin lymphoma, lymphocyte depletion|Hodgkin's disease, lymphocytic depletion (clinical)",,,,,,,,,,,,,"--","--|--|--",,,,,,,,"--|--"
"C0152266","Mixed Cellularity Classic Hodgkin Lymphoma","C3517","A subtype of classic Hodgkin lymphoma with scattered Reed-Sternberg and Hodgkin cells in a diffuse or vaguely nodular mixed inflammatory background without nodular sclerosing fibrosis. (WHO, 2008)","Mixed Cellularity Classic Hodgkin Lymphoma | Hodgkin Lymphoma, Mixed Cellularity, NOS | Hodgkin's Disease Mixed Cellularity | Hodgkin's Lymphoma Mixed Cellularity | MCCHL | MCHL | Mixed Cellularity Classical Hodgkin Lymphoma | Mixed Cellularity Classical Hodgkin Lymphoma | Mixed Cellularity Hodgkin Lymphoma | Mixed Cellularity Hodgkin Lymphoma | Mixed Cellularity Hodgkin's Disease | Mixed Cellularity Hodgkin's Lymphoma | Mixed cellularity classical Hodgkin lymphoma, unspecified site","9652/3","Hodgkin lymphoma, mixed cellularity, NOS",,,,,,,,,,,,,"4038843|4216428","Hodgkin's disease, mixed cellularity (clinical)|Hodgkin lymphoma, mixed cellularity",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0280100","Solid Neoplasm","C9292","A benign or malignant neoplasm arising from tissues that do not include fluid areas.  Representative examples include epithelial neoplasms (e.g. lung carcinoma, prostate carcinoma, breast carcinoma, colon carcinoma), and neoplasms arising from the soft tissues and bones (e.g. leiomyosarcoma, liposarcoma, chondrosarcoma, osteosarcoma).  Neoplasms originating from the blood or bone marrow (leukemias and myeloproliferative disorders) are not considered solid tumors.","Solid Neoplasm | Solid Neoplasm | Solid Tumor | Solid Tumor | Solid Tumour | Solid tumor, NOS | solid tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278601","Breast Inflammatory Carcinoma","C4001","An advanced, invasive breast adenocarcinoma characterized by the presence of distinct changes in the overlying skin. These changes include diffuse erythema, edema, peau d'orange (skin of an orange) appearance, tenderness, induration, warmth, enlargement, and in some cases a palpable mass. The skin changes are the consequence of lymphatic obstruction from the underlying invasive breast adenocarcinoma. Microscopically, the dermal lymphatics show prominent infiltration by malignant cells. The invasive breast adenocarcinoma is usually of ductal, NOS type. There is not significant inflammatory cell infiltrate present, despite the name of this carcinoma.","Breast Inflammatory Carcinoma | Inflammatory Breast Cancer | Inflammatory Breast Carcinoma | Inflammatory Breast Carcinoma | Inflammatory Carcinoma of Breast | Inflammatory Carcinoma of the Breast | Inflammatory breast carcinoma | Inflammatory carcinoma | Mastitis Carcinomatosa | inflammatory breast cancer","8530/3","Inflammatory carcinoma",,,,,,,,,,,,,"4112074|4139947","Inflammatory carcinoma of breast|Inflammatory carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C3544268","Extragonadal Germ Cell Tumor","C3918","A germ cell tumor arising in an anatomic site other than the testis or ovary (e.g., central nervous system, lung, mediastinum, and retroperitoneum).","Extragonadal Germ Cell Tumor | Extragonadal GCT, NOS | Extragonadal Germ Cell Neoplasm | Extragonadal Germ Cell Neoplasms | Extragonadal germ cell tumors, NOS | Neoplasm of Extragonadal Germ Cell | Neoplasm of the Extragonadal Germ Cell | Primary Extragonadal Germ Cell Tumor | Tumor of Extragonadal Germ Cell | Tumor of the Extragonadal Germ Cell | extragonadal germ cell tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336708","Testicular Germ Cell Tumor","C8591","A germ cell tumor arising from the testis. Representative examples include teratoma, seminoma, embryonal carcinoma, and yolk sac tumor.","Testicular Germ Cell Tumor | Germ Cell Neoplasm of Testis | Germ Cell Neoplasm of the Testis | Germ Cell Tumor of Testis | Germ Cell Tumor of the Testis | TGCT | Testicular Germ Cell Neoplasm | Testicular Germ Cell Neoplasms",,,,,,,,,,,,,,,"37017324","Germ cell tumor of testis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0677886","Ovarian Carcinoma","C4908","An invasive carcinoma that arises from the surface ovarian epithelium. The vast majority of cases are adenocarcinomas. The most common sites of involvement are the contralateral ovary, peritoneal cavity, para-aortic and pelvic lymph nodes, and liver.  Lung and pleura are the most common sites of extra-abdominal spread. The primary form of therapy is surgical.  The overall prognosis of ovarian carcinoma remains poor, a direct result of its rapid growth rate and the lack of early symptoms.","Ovarian Carcinoma | Carcinoma of Ovary | Carcinoma of the Ovary | Epithelial Ovarian Cancer | Invasive Ovarian Carcinoma | Ovarian Cancer | Ovarian Epithelial Cancer | Ovarian epithelial cancer | epithelial ovarian cancer | ovarian epithelial cancer",,,,,,,,,,,,,,,"4116073","Malignant epithelial tumor of ovary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0553580","Ewing Sarcoma","C4817","A small round cell tumor that lacks morphologic, immunohistochemical, and electron microscopic evidence of neuroectodermal differentiation. It represents one of the two ends of the spectrum called Ewing sarcoma/peripheral neuroectodermal tumor. It affects mostly males under age 20, and it can occur in soft tissue or bone. Pain and the presence of a mass are the most common clinical symptoms.","Ewing Sarcoma | ES | Ewing sarcoma | Ewing tumor | Ewing's Sarcoma | Ewing's Tumor",,,,,,,,,,,,,,,"4297997","Ewing's sarcoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016057","Fibrosarcoma","C3043","A malignant mesenchymal fibroblastic neoplasm affecting the soft tissue and bone.","Fibrosarcoma | FIBROSARCOMA, MALIGNANT | Fibrosarcoma, NOS | Malignant Fibromatous Neoplasm | fibrosarcoma","8810/3","Fibrosarcoma, NOS",,,,,,,,,,,,,"40480598|4202374","Malignant fibromatous neoplasm|Fibrosarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0018923","Angiosarcoma","C3088","A malignant tumor arising from the endothelial cells of the blood vessels.  Microscopically, it is characterized by frequently open vascular anastomosing and branching channels.  The malignant cells that line the vascular channels are spindle or epithelioid and often display hyperchromatic nuclei.  Angiosarcomas most frequently occur in the skin and breast.  Patients with long-standing lymphedema are at increased risk of developing angiosarcoma.","Angiosarcoma | HEMANGIOSARCOMA, MALIGNANT | Hemangiosarcoma | Malignant Angioendothelioma | Malignant Hemangioendothelioma | angiosarcoma | hemangiosarcoma","9120/3|9130/3","Hemangiosarcoma|Hemangioendothelioma, malignant",,,,,,,,,,,,,"4297200","Angiosarcoma",,,,,,,,,,,,,"--","--|--",,,,,,,,"--"
"C0346117","Liposarcoma","C3194","A usually painless malignant tumor that arises from adipose tissue.  Microscopically, it may contain a spectrum of neoplastic adipocytes ranging from lipoblasts to pleomorphic malignant adipocytes.  Morphologic variants include: well differentiated, dedifferentiated, pleomorphic, and myxoid liposarcoma.  The metastatic potential is higher in less differentiated tumors.","Liposarcoma | LIPOSARCOMA, MALIGNANT | Liposarcoma Not Otherwise Specified | Liposarcoma, NOS | Malignant Lipomatous Neoplasm | liposarcoma","8850/3","Liposarcoma, NOS",,,,,,,,,,,,,"4110857","Liposarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0024224","Lymphangiosarcoma","C3205","A malignant neoplasm arising from the endothelial cells of the lymphatic vessels.","Lymphangiosarcoma | LYMPHANGIOSARCOMA, MALIGNANT | Lymphangioendothelial Sarcoma | Lymphangioendothelial sarcoma | Lymphangioendothelioma, malignant | Malignant Lymphangioendothelioma | lymphangiosarcoma","9170/3","Lymphangiosarcoma",,,,,,,,,,,,,"4272004|4298141","Lymphangiosarcoma|Lymphangiosarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C3489398","Peripheral Primitive Neuroectodermal Tumor","C9341","A small round cell tumor with neural differentiation arising from the soft tissues or bone.","Peripheral Primitive Neuroectodermal Tumor | Neuro-Differentiated Ewing Tumor | PPNET | Peripheral Neuroectodermal Neoplasm | Peripheral Neuroectodermal Tumor | Peripheral Neuroepithelioma | Peripheral PNET | Peripheral Primitive Neuroectodermal Neoplasm | Peripheral neuroectodermal tumor | pPNET | peripheral primitive neuroectodermal tumor",,,,,,,,,,,,,,,"4251325","Peripheral neuroectodermal tumor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1276181","Rhabdomyosarcoma","C3359","A rare aggressive malignant mesenchymal neoplasm arising from skeletal muscle. It usually occurs in children and young adults. Only a small percentage of tumors arise in the skeletal muscle of the extremities. The majority arise in other anatomic sites.","Rhabdomyosarcoma | RHABDOMYOSARCOMA, MALIGNANT | Rhabdomyosarcoma, NOS | rhabdomyosarcoma","8900/3","Rhabdomyosarcoma, NOS",,,,,,,,,,,,,"4116201|4149420","Rhabdomyosarcoma|Rhabdomyosarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0039101","Synovial Sarcoma","C3400","A malignant neoplasm characterized by the chromosomal translocation t(X;18)(p11;q11).  It can occur at any age, but mainly affects young adults, more commonly males.  Although any site can be affected, the vast majority of the cases arise in the deep soft tissues of extremities, especially around the knee.  Microscopically, synovial sarcoma is classified as monophasic (with a spindle or epithelial cell component) or biphasic (with both spindle and epithelial cell components).  Synovial sarcomas can recur or metastasize to the lungs, bones, and lymph nodes.","Synovial Sarcoma | SARCOMA, SYNOVIAL, MALIGNANT | SS | Synovial Sarcoma, NOS | Synovial Sarcoma, Not Otherwise Specified | Synovial sarcoma | Synovial sarcoma, NOS | Synovioma, NOS | synovial sarcoma","9040/3","Synovial sarcoma, NOS",,,,,,,,,,,,,"4116202|4268491","Synovial sarcoma|Synovial sarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0018671","Head and Neck Neoplasm","C3077","A benign or malignant neoplasm that affects the anatomic structures of the head and neck region.  Representative examples of benign neoplasms include salivary gland pleomorphic adenoma and nasal cavity papilloma.  Representative examples of malignant neoplasms include oral cavity squamous cell carcinoma, laryngeal squamous cell carcinoma, and salivary gland carcinoma.","Head and Neck Neoplasm | Head and Neck Neoplasm (Excluding Central Nervous System) | Head and Neck Tumor | Neoplasm of Head and Neck | Neoplasm of the Head and Neck | Tumor of Head and Neck | Tumor of the Head and Neck",,,,,,,,,,,,,,,"4111017","Neoplasm of head and neck",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038356","Gastric Neoplasm","C3387","A benign or malignant neoplasm involving the stomach.","Gastric Neoplasm | Gastric Tumor | Neoplasm of Stomach | Neoplasm of the Stomach | Stomach Neoplasm | Stomach Tumor | Tumor of Stomach | Tumor of the Stomach",,,,,,,,,,,,,,,"4131611","Neoplasm of stomach",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0854196","Hepatobiliary Neoplasm","C8614","A benign or malignant neoplasm that affects the liver parenchyma, bile ducts, and gallbladder.  Representative examples of benign neoplasms include hepatocellular adenoma, bile duct adenoma, and gallbladder lipoma.  Representative examples of malignant neoplasms include hepatocellular carcinoma, intrahepatic and extrahepatic cholangiocarcinoma, and gallbladder carcinoma.","Hepatobiliary Neoplasm | Hepatic and Biliary Neoplasms | Hepatic and Biliary Tumors | Hepatic, Biliary, and Gallbladder Neoplasms | Hepato-Biliary Neoplasm | Hepato-Biliary Neoplasm | Hepato-Biliary Tumor | Hepatobiliary Tumor | Hepatobiliary Tumors | Liver and Biliary Neoplasm | Liver and Biliary System Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030849","Penile Neoplasm","C3317","A benign, borderline, or malignant neoplasm that affects the penis.  Representative examples include penile hemangioma, penile intraepithelial neoplasia, and penile carcinoma.","Penile Neoplasm | Neoplasm of Penis | Neoplasm of the Penis | Penile Neoplasms | Penile Tumor | Tumor of Penis | Tumor of the Penis",,,,,,,,,,,,,,,"4129899","Neoplasm of penis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042995","Vulvar Neoplasm","C3443","A benign, precancerous, or malignant neoplasm that affects the vulva. Representative examples include Bartholin gland adenoma, vulvar nodular hidradenoma, vulvar intraepithelial neoplasia, vulvar carcinoma, and vulvar melanoma.","Vulvar Neoplasm | Neoplasm of Vulva | Neoplasm of the Vulva | Tumor of Vulva | Tumor of the Vulva | Vulva Neoplasm | Vulva Tumor | Vulvar Tumor",,,,,,,,,,,,,,,"4130032","Neoplasm of vulva",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007873","Cervical Neoplasm","C2940","A benign, malignant, or precancerous neoplasm that affects the cervix.","Cervical Neoplasm | Cervical Tumor | Cervix Neoplasm | Cervix Tumor | Cervix Uteri Neoplasm | Cervix Uteri Tumor | Neoplasm of Cervix | Neoplasm of Cervix Uteri | Neoplasm of Uterine Cervix | Neoplasm of the Cervix | Neoplasm of the Cervix Uteri | Neoplasm of the Uterine Cervix | Tumor of Cervix | Tumor of Cervix Uteri | Tumor of Uterine Cervix | Tumor of the Cervix | Tumor of the Cervix Uteri | Tumor of the Uterine Cervix | Uterine Cervix Neoplasm | Uterine Cervix Tumor",,,,,,,,,,,,,,,"4047648","Neoplasm of uterine cervix",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042138","Uterine Neoplasm","C3435","A benign or malignant neoplasm that affects the uterine corpus or the cervix. Representative examples of benign neoplasms include leiomyoma, adenomyoma, and endocervical polyp. Representative examples of malignant neoplasms include endometrial carcinoma, carcinosarcoma, and cervical carcinoma.","Uterine Neoplasm | Neoplasm of Uterus | Neoplasm of the Uterus | Tumor of Uterus | Tumor of the Uterus | Uterine Neoplasms | Uterine Tumor",,,,,,,,,,,,,,,"4131007","Neoplasm of uterus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042258","Vaginal Neoplasm","C3437","A benign or malignant neoplasm affecting the vagina. Representative examples of benign neoplasms include squamous papilloma and melanocytic nevus. Representative examples of malignant neoplasms include carcinoma, melanoma, and sarcoma.","Vaginal Neoplasm | Neoplasm of Vagina | Neoplasm of the Vagina | Tumor of Vagina | Tumor of the Vagina | Vagina Neoplasm | Vagina Tumor | Vaginal Tumor",,,,,,,,,,,,,,,"4131012","Neoplasm of vagina",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL505178","Wilms Tumor","C3267","An embryonal neoplasm characterized by the presence of epithelial, mesenchymal, and blastema components. The vast majority of cases arise from the kidney. A small number of cases with morphologic features resembling Wilms tumor of the kidney have been reported arising from the ovary and the cervix.","Wilms Tumor | Nephroblastoma | Wilms tumor | Wilms tumor (Nephroblastoma) | Wilms tumor (WT) | Wilms' Tumor","8960/3","Nephroblastoma, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C0035335","Retinoblastoma","C7541","A malignant tumor that originates in the nuclear layer of the retina. As the most common primary tumor of the eye in children, retinoblastoma is still relatively uncommon, accounting for only 1% of all malignant tumors in pediatric patients. Approximately 95% of cases are diagnosed before age 5. These tumors may be multifocal, bilateral, congenital, inherited, or acquired. Seventy-five percent of retinoblastomas are unilateral; 60% occur sporadically. A predisposition to retinoblastoma has been associated with 13q14 cytogenetic abnormalities. Patients with the inherited form also appear to be at increased risk for secondary nonocular malignancies such as osteosarcoma, malignant fibrous histiocytoma, and fibrosarcoma.","Retinoblastoma | RB | RETINOBLASTOMA, MALIGNANT | Retinoblastoma, NOS | retinoblastoma","9510/3","Retinoblastoma, NOS",,,,,,,,,,,,,"4062561|4158977","Retinoblastoma|Retinoblastoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0040100","Thymoma","C3411","A neoplasm arising from the epithelial cells of the thymus.  Although thymomas are usually encapsulated tumors, they may invade the capsule and infiltrate the surrounding tissues or even metastasize to distant anatomic sites.  The following morphologic subtypes are currently recognized: type A, type B, type AB, metaplastic, micronodular, microscopic, and sclerosing thymoma.  Thymomas type B are further subdivided into types B1, B2, and B3. Thymoma type B3 usually has the most aggressive clinical course.","Thymoma | Thymoma, NOS | thymoma",,,,,,,,,,,,,,,"37156936|40485495","Thymoma|Thymoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0042076","Urinary System Neoplasm","C3431","A benign or malignant, primary or metastatic neoplasm involving the urinary system (kidney, ureter, bladder, and urethra).","Urinary System Neoplasm | Neoplasm of Urinary System | Neoplasm of Urinary Tract | Neoplasm of the Urinary System | Neoplasm of the Urinary Tract | Tumor of Urinary System | Tumor of Urinary Tract | Tumor of the Urinary System | Tumor of the Urinary Tract | Urinary System Tumor | Urinary Tract Neoplasm | Urinary Tract Tumor",,,,,,,,,,,,,,,"4112878|79768","Neoplasm of urinary tract proper|Neoplasm of urinary system",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0025063","Mediastinal Neoplasm","C3221","A benign or malignant neoplasm that affects the structures of the mediastinum.  Representative examples include mediastinal lipoma, mediastinal schwannoma, thymoma, mediastinal germ cell tumor, and mediastinal lymphoma.","Mediastinal Neoplasm | Mediastinal Neoplasm NOS | Mediastinal Tumor | Neoplasm of Mediastinum | Neoplasm of the Mediastinum | Tumor of Mediastinum | Tumor of the Mediastinum",,,,,,,,,,,,,,,"4131456","Neoplasm of mediastinum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332181","Annual","C54647","Occurring or done each year.","Annual | ",,,,,,,,,,,,,,,"4180707","Annual",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883018","Severe Aplastic Anemia","C61229","Life-threatening anemia associated with a high risk of infection or bleeding.","Severe Aplastic Anemia | SAA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0348890","Idiopathic Aplastic Anemia","C61230","Aplastic anemia without a known cause.","Idiopathic Aplastic Anemia | Idiopathic Aplastic Aplasia | Idiopathic aplastic anemia",,,,,,,,,,,,,,,"4098145","Idiopathic aplastic anemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883669","Aplastic Anemia due to Hepatitis","C61231","Bone marrow failure defined as pancytopenia, secondary to hepatitis.","Aplastic Anemia due to Hepatitis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0271909","Drug-Induced Aplastic Anemia","C35343","A state of bone marrow suppression and failure that is caused by a cytotoxic or adverse immunologic response to a drug treatment, leading to a failure of production of red blood cells, white cells and platelets.","Drug-Induced Aplastic Anemia | Drug-induced aplastic anemia",,,,,,,,,,,,,,,"4146088","Aplastic anemia due to drugs",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882103","Non-Congenital Amegakaryocytosis","C61232","An acquired non-neoplastic disorder characterized by marked reduction or absence of megakaryocytes and thrombocytopenia.","Non-Congenital Amegakaryocytosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024790","Paroxysmal Nocturnal Hemoglobinuria","C61233","A rare acquired hematologic disorder characterized by hemolytic anemia, dark-colored urine due to the release of hemoglobin in the blood, and thrombosis. The episodes of hemolysis tend to occur at night. It is caused by a somatic mutation in the glycosylphosphatidylinositol biosynthesis gene.","Paroxysmal Nocturnal Hemoglobinuria | PNH | Paroxysmal Hemoglobinuria | paroxysmal nocturnal hemoglobinuria",,,,,,,,,,,,,,,"4024671","Paroxysmal nocturnal hemoglobinuria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034902","Pure Red Cell Aplasia","C34974","A disease characterized by normocytic, normochromic anemia, low hematocrit, reticulocytopenia, and selective erythroid hypoplasia.","Pure Red Cell Aplasia | PRCA",,,,,,,,,,,,,,,"140065","Pure red cell aplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1880167","Congenital Abnormalities of Erythrocyte Differentiation or Function","C61234","Inherited disorders involving abnormalities of red blood cell function, structure, or production. Some diseases in this group may be associated with bone marrow failure, neutropenia, and/or thrombocytopenia.","Congenital Abnormalities of Erythrocyte Differentiation or Function | Inherited Abnormalities of Erythrocyte Differentiation or Function",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0272170","Shwachman-Diamond Syndrome","C61235","A rare, autosomal recessive disorder characterized by exocrine pancreas insufficiency, skeletal abnormalities, bone marrow dysfunction, and an increased incidence of leukemia.","Shwachman-Diamond Syndrome | SDS | Schwachmann-Diamond Syndrome | Shwachman Syndrome | Shwachman syndrome | Shwachman-Bodian-Diamond Syndrome | Shwachman-Diamond syndrome | Shwachman-Diamond-Oski Syndrome",,,,,,,,,,,,,,,"4232178","Shwachman syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0949116","Congenital Pure Red Cell Aplasia","C61236","An inherited condition characterized by aplasia of the erythroid series only. The white cells and platelets are not affected. Patients develop anemia usually in infancy.","Diamond-Blackfan Anemia | Blackfan-Diamond anemia | Congenital Pure Red Cell Aplasia | Congenital Pure Red Cell Aplasia | DBA | Diamond Blackfan | Diamond Blackfan Anemia | Diamond-Blackfan Anemia | Diamond-Blackfan Anemia PT: Congenital Pure Red Cell Aplasia | Diamond-Blackfan anemia | congenital hypoplastic anemia | congenital pure red cell aplasia | erythrogenesis imperfecta | inherited erythroblastopenia",,,,,,,,,,,,,,,"4228194","Congenital hypoplastic anemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015625","Fanconi Anemia","C62505","An autosomal recessive genetic disorder characterized by bone marrow failure, skeletal abnormalities, and an increased incidence of the development of neoplasias.","Fanconi Anemia | Fanconi's Anemia | Fanconi's anemia | Pancytopenia, Congenital | Panmyelopathy, Fanconi | Primary Erythroid Hypoplasia",,,,,,,,,,,,,,,"4148471","Fanconi's anemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448229","Sickle Cell-Thalassemia","C61237","Hemolytic anemia, in which patients are heterozygous for both the sickle cell gene and a thalassemia gene.","Sickle Cell-Thalassemia | Sickle Cell Thalassemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002895","Sickle Cell Disease","C34383","A blood disorder characterized by the appearance of sickle-shaped red blood cells and anemia.","Sickle Cell Disease | Hb SS | Hemoglobin SS | Hemoglobin SS Disease | Sickle Cell Anemia | Sickle-cell Disorders | Sickling Disorder due to Hemoglobin S | sickle cell anemia | sickle cell disease",,,,,,,,,,,,,,,"4213628","Sickling disorder due to hemoglobin S",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039730","Thalassemia","C35069","An inherited blood disorder characterized by a decreased synthesis of one of the polypeptide chains that form hemoglobin. Anemia results from this abnormal hemoglobin formation.","Thalassemia | ",,,,,,,,,,,,,,,"30978","Thalassemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019045","Hemoglobinopathy","C3092","An inherited disorder characterized by structural alterations of a globin chain within the hemoglobin molecule.","Hemoglobinopathy | Hemoglobinopathies / Iron Metabolism",,,,,,,,,,,,,,,"432868","Hemoglobinopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268124","Adenosine Deaminase Deficiency","C3962","An autosomal recessive deficiency of the purine salvage enzyme adenosine deaminase which results in Severe Combined Immunodeficiency Disease (SCID).  The most common form of SCID, accounting for about 50% of autosomal recessive cases.  The first disease for which gene therapy was applied.","Adenosine Deaminase Deficiency | ADA-SCID | Adenosine Deaminase Severe Combined Immune Deficiency | Adenosine Deaminase Severe Combined Immunodeficiency",,,,,,,,,,,,,,,"4261471","Adenosine deaminase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883020","Severe Combined Immunodeficiency with Absence of T and B Cells","C61238","An inherited, severe immunodeficiency disorder characterized by abnormalities in the development and function of T and B cell immunity. The peripheral T and B lymphocytes are absent or in very low counts.","Severe Combined Immunodeficiency with Absence of T and B Cells | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883019","Severe Combined Immunodeficiency with Absence of T, Normal B Cells","C61239","An inherited, severe immunodeficiency disorder characterized by abnormalities in the development and function of T cell immunity. The peripheral T lymphocytes are absent or in very low counts. The B lymphocyte counts are normal.","Severe Combined Immunodeficiency with Absence of T, Normal B Cells | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1801959","Omenn Syndrome","C61240","An autosomal recessive combined immunodeficiency syndrome caused by mutations in the RAG-1 and RAG-2 genes. It is characterized by the presence of alopecia, erythroderma, desquamation, lymphadenopathy, and chronic diarrhea.","Omenn Syndrome | ",,,,,,,,,,,,,,,"4146032","Histiocytic medullary reticulosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0272167","Reticular Dysgenesis","C27070","A rare severe combined immunodeficiency disorder characterized by congenital agranulocytosis, lymphoid tissue and thymic tissue hypoplasia, and lymphopenia. Both cellular and humoral immunities are absent.","Reticular Dysgenesis | ",,,,,,,,,,,,,,,"4006469","Reticular dysgenesis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242583","Bare Lymphocyte Syndrome","C3895","A hereditary immunodeficiency disorder caused by the lack of expression of major histocompatibility complex (MHC) proteins. Signs include upper and lower respiratory tract bacterial infections, malabsorption, diarrhea, and mucocutaneous candidiasis.","Bare Lymphocyte Syndrome | ",,,,,,,,,,,,,,,"4216841","SCID (severe combined immunodeficiency) due to absent class II HLA (human leukocyte antigens)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3806381","Severe Combined Immunodeficiency","C3472","X-linked or autosomal recessive disorder characterized by defects of both humoral and cell mediated immunity, resulting in low or absent antibody levels, leukopenia, marked susceptibility to infections, and early death.--2004","Severe Combined Immunodeficiency | SCID | Severe Combined Immune Deficiency | severe combined immunodeficiency disease",,,,,,,,,,,,,,,"29783","Severe combined immunodeficiency disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004135","Ataxia Telangiectasia Syndrome","C2887","Rare hereditary disease characterized by extreme sensitivity to ionizing radiation or radiomimetic drugs because of a defect in DNA repair. AT heterozygosity is estimated to occur in more than 2% of the U.S. population; heterozygotes exhibit increased radiation sensitivity and are at increased risk for several types of cancer. The normal version of the gene that is defective in AT appears to activate the p53-dependent response to DNA damage.","Ataxia Telangiectasia Syndrome | Ataxia Telangiectasia | Ataxia-Telangiectasia Syndrome | Ataxia-telangiectasia | Louis-Bar Syndrome | ataxia-telangiectasia",,,,,,,,,,,,,,,"4285430","Ataxia-telangiectasia syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019693","HIV Infection","C3108","An infection caused by the human immunodeficiency virus.","HIV Infection | HIV | Human Immunodeficiency Virus Infection | Human Immunodeficiency Virus Infectious Disease",,,,,,,,,,,,,,,"439727","Human immunodeficiency virus infection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0012236","22q11.2 Deletion Syndrome","C2989","A congenital anomaly characterized by immunodeficiency, abnormal facies, congenital heart disease, hypocalcemia, and increased susceptibility to infections. Pathologic characteristics include conotruncal abnormalities and absence or hypoplasia of thymus and parathyroid glands. DiGeorge syndrome is associated with abnormalities of chromosome 22. Also known as DiGeorge anomaly.","22q11.2 Deletion Syndrome | 22q Deletion Syndrome(s) | 22q11 deletion | CATCH-22 | DGS1 | DiGeorge Anomaly | DiGeorge Sequence | DiGeorge Syndrome | DiGeorge Syndrome | DiGeorge Syndrome Type 1 | DiGeorge syndrome | DiGeorge's Syndrome | DiGeorge's Syndrome | FACES | Shprintzen Syndrome | Shprintzen syndrome",,,,,,,,,,,,,,,"35624485","22q11.2 deletion syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018203","Chronic Granulomatous Disease","C26788","A rare genetic disorder with a predominantly X-linked recessive pattern of inheritance resulting in impaired phagocytic clearance of bacteria and fungi. It is caused by a defect in the phagocytic NADPH oxidase (phox) complex. The phagocytes can engulf pathogens but are unable to produce the microbicidal precursors needed to destroy them. Clinical signs of severe disease present in childhood with milder forms later in life. They include recurrent infection especially pneumonia, cervical lymphadenopathy and hepatosplenomegaly. The clinical course includes the appearance of granulomata in the skin and gastrointestinal or genitourinary tracts. The clinical prognosis is dependent on effectively treating and preventing infection.","Chronic Granulomatous Disease | CGD",,,,,,,,,,,,,,,"4300478","Chronic granulomatous disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009447","Common Variable Immunodeficiency","C26725","A primary immunodeficiency characterized by low levels or absence of all the immunoglobulin classes and lack of B-lymphocytes or plasma cells. It results in recurrent bacterial infections. Complications include autoimmune phenomena and cancer development.","Common Variable Immunodeficiency | Acquired Agammaglobulinemia | Acquired Hypogammaglobulinemia | Common variable immune deficiency (CVID) | Secondary Hypogammaglobulinemia",,,,,,,,,,,,,,,"435228","Common variable agammaglobulinemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0272187","Leukocyte Adhesion Deficiency","C27874","A rare autosomal recessive immunodeficiency disorder caused by deficiency of CD18 expression. It is characterized by defects in neutrophil adhesion and bacterial infections.","Leukocyte Adhesion Deficiency | ",,,,,,,,,,,,,,,"37162286","Leukocyte adhesion deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0340970","Congenital Neutropenia","C61242","A rare congenital disorder characterized by mild or severe reduction of neutrophils in the peripheral blood and recurrent infantile infections.","Congenital Neutropenia | congenital neutropenia | genetic infantile agranulocytosis | infantile genetic agranulocytosis",,,,,,,,,,,,,,,"434895","Congenital neutropenia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882075","Neutrophil Actin Defect","C61243","A genetic disorder characterized by defective polymorphonuclear cell actin function, resulting in impaired granulocyte motility.","Neutrophil Actin Defect | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007965","Chediak-Higashi Syndrome","C2941","A rare autosomal recessive immunodeficiency disorder characterized by abnormal intracellular protein transport. Chediak-Higashi syndrome (CHS) is characterized by immune deficiency; partial oculocutaneous albinism; a bleeding disorder due to deficient platelet dense bodies; neutropenia; neutrophils with impaired chemotaxis and bactericidal activity; recurrent infection; and abnormal natural killer (NK) cell function. CHS may be associated with hepatosplenomegaly, lymphadenopathy, anemia, thrombocytopenia, roentgenologic changes in bones, lungs and heart, and skin and psychomotor abnormalities; it is often fatal in childhood as a result of infection or an accelerated lymphoma-like phase. CHS occurs in mink, cattle, and mice, as well as man.","Chediak-Higashi Syndrome | ",,,,,,,,,,,,,,,"4006317","Chédiak-Higashi syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043194","Wiskott-Aldrich Syndrome","C3448","A rare, X-linked immunodeficiency syndrome characterized by eczema, thrombocytopenia, and recurrent pyogenic infection. It is seen exclusively in young boys. Typically, IgM levels are low and IgA and IgE levels are elevated. Lymphoreticular malignancies are common.","Wiskott-Aldrich Syndrome | Aldrich syndrome | Wiskott Aldrich Syndrome | Wiskott-Aldrich syndrome",,,,,,,,,,,,,,,"440982","Wiskott-Aldrich syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0549463","X-Linked Lymphoproliferative Syndrome","C61246","An X-linked immunodeficiency syndrome that exclusively affects males, although females can be carriers. It is caused by mutation(s) in SH2D1A and/or XIAP genes and is characterized by life-threatening episodes of infectious mononucleosis, hypogammaglobulinemia, and subsequent development of lymphomas (usually B-cell lymphomas) and other lymphoproliferative disorders.","X-Linked Lymphoproliferative Syndrome | Duncan Disease | X-linked Lymphoproliferative Syndrome",,,,,,,,,,,,,,,"4298696","X-linked lymphoproliferative syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1279481","X-Linked Severe Combined Immunodeficiency","C4682","An X-linked form of severe combined immunodeficiency characterized as T-cell negative, B-cell positive, NK cell negative, and with mutations in the IL2RG gene, resulting in an impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels.","X-Linked Severe Combined Immunodeficiency | SCID, T- B+ NK-, IL2RG mutations, X-linked SCID | X-linked SCID | XL IL2RG",,,,,,,,,,,,,,,"35608121","T cell negative B cell positive severe combined immunodeficiency due to gamma chain deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1880168","Congenital Platelets Abnormality","C61247","A group of rare inherited platelet disorders that involve abnormalities of platelet function or platelet production and that usually cause moderate to severe bleeding problems.","Congenital Platelets Abnormality | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879691","Amegakaryocytosis","C61248","A non-neoplastic, congenital or non-congenital disorder charcaterized by marked reduction or absence of megakaryocytes and thrombocytopenia.","Amegakaryocytosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040015","Glanzmann Thrombasthenia","C61249","A rare, autosomal recessive inherited and less frequently acquired platelet disorder. It is characterized by deficient or dysfunctional glycoprotein IIb/IIIa complex. It leads to defective platelet aggregation, resulting in bleeding.","Glanzmann Thrombasthenia | Thrombasthenia",,,,,,,,,,,,,,,"4139942","Glanzmann's thrombasthenia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025521","Congenital Metabolic Disorder","C34816","A group of disorders present at birth that involve genetic defects leading to disturbances in carbohydrate, lipid, lysosomal storage or amino acid metabolism in the body.","Congenital Metabolic Disorder | Congenital Metabolism Disorder | Inborn Error of Metabolism | Inborn Errors of Metabolism",,,,,,,,,,,,,,,"444377","Inborn error of metabolism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3808241","Osteopetrosis","C26840","A rare genetic disorder inherited in an autosomal dominant, autosomal recessive, or X-linked recessive pattern. In the majority of cases it is caused by mutations in the CLCN7, TCIRG1, or IKBKG genes. It is characterized by excessive bone formation due to the failure of osteoclasts to resorb bone. It manifests with deformities, fractures, hepatosplenomegaly, anemia, and extramedullary hematopoiesis.","Osteopetrosis | ",,,,,,,,,,,,,,,"81403","Osteopetrosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023522","Metachromatic Leukodystrophy","C61251","An autosomal recessive inherited disorder characterized by abnormalities in the development of the myelin sheaths. It is caused by a deficiency of the enzyme arylsulfatase A. There are three forms of this disease: late infantile, juvenile, and adult. In the late infantile form symptoms include muscle weakness and rigidity, gait disturbances, developmental delays, and seizures. In the juvenile form symptoms include gait disturbances, mental deterioration and seizures. The adult form is characterized by psychotic symptoms and dementia.","Metachromatic Leukodystrophy | Metachromatic leukodystrophy",,,,,,,,,,,,,,,"4262609","Metachromatic leukodystrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162309","Adrenoleukodystrophy","C61252","A rare metabolic disorder characterized by damage of the myelin sheaths in the nervous system and degeneration of the adrenal glands. It leads to progressive neurologic disorders, adrenal insufficiency and death.","Adrenoleukodystrophy | Schilder Disease",,,,,,,,,,,,,,,"4276356","Adrenoleukodystrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023521","Krabbe Disease","C61254","A rare inherited neurodegenerative disorder that belongs to the group of leukodystrophies. It is characterized by myelin destruction, gliosis in the brain, and the presence of multinucleated globoid cells. Signs and symptoms include irritability, mental and motor developmental disturbances, muscle weakness, seizures, blindness, and deafness.","Krabbe Disease | Galactosylceramide Beta-Galactosidase Deficiency | Galactosylceramide Lipidosis | Globoid Cell Leukodystrophy | Krabbe disease",,,,,,,,,,,,,,,"4105341","Galactosylceramide beta-galactosidase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023374","Lesch-Nyhan Syndrome","C61255","An X-linked inherited syndrome caused by mutations in the gene that encodes the enzyme hypoxanthine-guanine phosphoribosyltransferase, resulting in accumulation of uric acid in the body. It affects males and is characterized by neurologic defects, moderate mental retardation, muscle hypotonia, and a tendency for self-mutilation (self-biting of lips, tongue, and fingertips).","Lesch-Nyhan Syndrome | ",,,,,,,,,,,,,,,"4016108","Lesch-Nyhan syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0751383","Neuronal Ceroid Lipofuscinosis Type 3","C61258","A condition associated with mutation(s) in the CLN3 gene, encoding battenin. The condition is one of a group of genetically heterogeneous neurodegenerative disorders, characterized by accumulation of intracellular lipopigments.","Neuronal Ceroid Lipofuscinosis Type 3 | Batten Disease | Batten Disease | CLN3",,,,,,,,,,,,,,,"4264152","Juvenile neuronal ceroid lipofuscinosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026703","Mucopolysaccharidosis","C61259","A group of autosomal recessive or X-linked inherited lysosomal storage disorders affecting the metabolism of mucopolysaccharides, resulting in the accumulation of mucopolysaccharides in the body. Signs and symptoms include organomegaly, intellectual disabilities, abnormal skeletal development, heart disorders, hearing loss, and central nervous system deficiencies.","Mucopolysaccharidosis | ",,,,,,,,,,,,,,,"433446","Mucopolysaccharidosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0086795","Hurler Syndrome","C61261","An autosomal recessive inherited disorder of mucopolysaccharide metabolism. It is the most severe form of mucopolysaccharidosis type I. It is characterized by deficiency of the enzyme alpha-L-iduronidase resulting in the accumulation of mucopolysaccharides in the tissues.","Hurler Syndrome | MPS I H | Mucopolysaccharidosis Type IH",,,,,,,,,,,,,,,"4109172|4276347","Dysostosis multiplex|Mucopolysaccharidosis, MPS-I-H",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0026708","Scheie Syndrome","C61265","An autosomal recessive disorder representing the milder form of mucopolysaccharidosis type I. It is characterized by deficiency of the enzyme alpha-L-iduronidase. Signs and symptoms include broad mouth with full lips, cloudy cornea which may lead to blindness, stiff joints, and hirsutism.","Scheie Syndrome | MPS I S",,,,,,,,,,,,,,,"4218929","Mucopolysaccharidosis, MPS-I-S",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026705","Hunter Syndrome","C61260","An X-linked, inherited lysosomal storage disease caused by the deficiency of the enzyme iduronate sulfatase that is responsible for the degradation of mucopolysaccharides.  It nearly always affects males and is characterized by the accumulation of mucopolysaccharides in various organs, resulting in mental dysfunction, enlarged abdomen, hearing loss, obstructive airway disease, heart disease, and hepatosplenomegaly.","Hunter Syndrome | Mucopolysaccharidosis Type II",,,,,,,,,,,,,,,"4323827","Mucopolysaccharidosis, MPS-II",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026706","Sanfilippo Syndrome","C61262","A rare autosomal recessive lysosomal storage disease affecting the metabolism of mucopolysaccharides. Signs and symptoms include behavioral changes, sleep disorders, mental developmental delays, and seizures.","Sanfilippo Syndrome | Mucopolysaccharidosis Type III",,,,,,,,,,,,,,,"4227905","Sanfilippo syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026707","Morquio Syndrome","C61263","A rare autosomal recessive lysosomal storage disease characterized by abnormal skeletal developments, dwarfism, heart disorders, and central nervous system deficits.","Morquio Syndrome | Mucopolysaccharidosis IV | Mucopolysaccharidosis Type IV",,,,,,,,,,,,,,,"4292105","Morquio syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026709","Maroteaux-Lamy Syndrome","C61264","A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme N-acetylgalactosamine-4-sulfatase. It is characterized by organomegaly, short stature, joint stiffness, otitis media, and respiratory illnesses.","Maroteaux-Lamy Syndrome | Mucopolysaccharidosis Type VI | Mucopolysaccharidosis VI",,,,,,,,,,,,,,,"4287262","Maroteaux-Lamy syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017205","Gaucher Disease","C61268","An inherited lysosomal storage disease caused by deficiency of the enzyme glucocerebrosidase. It results in the accumulation of a fatty substance called glucocerebroside in mononuclear cells in the bone marrow, liver, spleen, brain, and kidneys. Signs and symptoms include hepatomegaly, splenomegaly, neurologic disorders, lymphadenopathy, skeletal disorders, anemia and thrombocytopenia.","Gaucher Disease | Glucosylceramide Beta-Glucosidase Deficiency",,,,,,,,,,,,,,,"4101305","Gaucher's disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028064","Niemann-Pick Disease","C61269","An autosomal recessive inherited lysosomal storage disease characterized by deficiency of sphingomyelinase. It results in the accumulation of sphingomyelin in the liver, spleen, brain, lungs, and bone marrow. Signs and symptoms include hepatosplenomegaly, pancytopenia, ataxia, dystonia, and dementia.","Niemann-Pick Disease | Sphingomyelin/Cholesterol Lipidosis",,,,,,,,,,,,,,,"4242275","Sphingomyelin/cholesterol lipidosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020725","I-Cell Disease","C61270","An inherited lysosomal storage disease characterized by the presence of dense intracytoplasmic inclusions in mesenchymal cells, especially fibroblasts. Signs and symptoms include developmental delay, psychomotor deterioration, and growth failure.","I-Cell Disease | Inclusion-cell Disease | Mucolipidosis Type II",,,,,,,,,,,,,,,"4322172","I-cell disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043208","Wolman Disease","C61271","A very rare, autosomal recessive inherited lysosomal storage disease caused by mutations in the LIPA gene. Signs and symptoms appear in infancy and include developmental delay, vomiting, abdominal distention, hepatosplenomegaly, jaundice, anemia, steatorrhea, and calcification of the adrenal glands.","Wolman Disease | Lysosomal Acid Lipase Deficiency | Wolman's Disease",,,,,,,,,,,,,,,"4221254","Wolman's disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017919","Glycogen Storage Disease","C61272","An inherited metabolic disorder characterized either by defects in glycogen synthesis or defects in the breaking down of glycogen. It results either in the creation of abnormal forms of glycogen or accumulation of glycogen in the tissues.","Glycogen Storage Disease | Glycogen storage disease",,,,,,,,,,,,,,,"434003","Glycogen storage disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085078","Lysosomal Storage Disease","C61250","A group of autosomal recessive or X-linked inherited metabolic disorders caused by defects in the function of the lysosomes. Signs and symptoms include hepatomegaly, splenomegaly, nervous system manifestations, skeletal abnormalities, and mental deterioration. Representative examples include Gaucher disease, Niemann-Pick disease, Wolman disease, and Fabry disease.","Lysosomal Storage Disease | Disorder of Lysosomal Enzymes | Lysosomal Storage Disorder | PHOSPHOLIPIDOSIS",,,,,,,,,,,,,,,"4053270","Disorder of lysosomal enzyme",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026697","Mucolipidosis","C61267","A group of inherited lysosomal storage diseases characterized by accumulation of lipids and carbohydrates in the tissues, resulting in mental disabilities and skeletal malformations.","Mucolipidosis | ",,,,,,,,,,,,,,,"4323268","Mucolipidosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268225","Aspartylglycosaminuria","C61273","A rare autosomal recessive lysosomal disorder characterized by deficiency of N-aspartyl-beta-glucosaminidase. It is characterized by developmental delays during childhood.","Aspartylglycosaminuria | Aspartylglucosaminuria",,,,,,,,,,,,,,,"4207521","Aspartylglucosaminuria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0108779","CD3 Complex","C38897","A protein complex comprised of one T-cell surface glycoprotein CD3 delta chain (CD3D), one T-cell surface glycoprotein CD3 gamma chain (CD3G) and two T-cell surface glycoprotein CD3 epsilon chains (CD3E). CD3D, CD3G and CD3E are transmembrane proteins with one extracellular immunoglobulin domain and one intracellular ITAM domain. The CD3 complex is a T-cell co-receptor that noncovalently associates with either the disulfide bound heterodimeric alpha/beta T-cell receptor (TCR) or gamma/delta TCR and two copies of the accessory protein, T-cell surface glycoprotein CD3 zeta chain (CD247), which is a transmembrane protein with three ITAM domains. The TCR moiety of the TCR-CD3 complex binds to MHC and processed antigens on antigen presenting cells, which triggers phosphorylation of and cellular propagation of the signal by CD247 and the CD3 complex.","CD3 Complex | CD3 | T-Cell Surface Glycoprotein CD3 | T3 Complex",,,,,,,,,,,,,,,"4260837","Lymphocyte antigen CD3",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016788","Fucosidosis","C61274","An autosomal recessive lysosomal storage disease characterized by a defective alpha-L-fucosidase. It results in accumulation of fucose in the tissues. Signs and symptoms include psychomotor retardation, dysostosis multiplex, and neural disturbances.","Fucosidosis | ",,,,,,,,,,,,,,,"4277436","Fucosidosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003323","T-Cell Surface Glycoprotein CD4","C16300","T-cell surface glycoprotein CD4 (458 aa, ~51 kDa) is encoded by the human CD4 gene. This protein plays a role in antigen recognition and HIV entry.","T-Cell Surface Glycoprotein CD4 | CD4 | CD4 Antigen | CD4 Antigen | CD4 Antigen (P55) | CD4 Protein | OKT4 Antigen | T-Cell Antigen T4/Leu3 | T-Cell Surface Antigen T4/Leu-3",,,,,,,,,,,,,,,"4081164","Lymphocyte antigen CD4",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1257960","Mannosidosis","C61275","A rare autosomal recessive lysosomal storage disease characterized by a deficient activity of the enzymes alpha-D-mannosidase or beta-mannosidase. Clinical signs and symptoms include hepatomegaly, splenomegaly, hearing loss, mental retardation, skeletal abnormalities, and recurrent respiratory infections.","Mannosidosis | ",,,,,,,,,,,,,,,"4277255","Mannosidosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332717","CD8 Antigen, Beta Polypeptide 1","C17441","T-cell surface glycoprotein CD8 beta chain (210 aa, ~24 kDa) is encoded by the human CD8B gene. This protein plays a role in T-cell cytotoxicity.","T-Cell Surface Glycoprotein CD8 Beta Chain | CD8 Antigen, Beta Polypeptide 1 | CD8B | CD8B1 | CD8b Antigen | LYT3 | T-Cell Glycoprotein CD8b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706319","MS4A1 wt Allele","C51082","Human MS4A1 wild-type allele is located within 11q12 and is approximately 13 kb in length. This allele, which encodes B-lymphocyte antigen CD20 protein, plays a role in the development and differentiation of B-cells into plasma cells.","MS4A1 wt Allele | B1 | Bp35 | CD20 | LEU-16 | MS4A2 | Membrane-Spanning 4-Domains, Subfamily A, Member 1 wt Allele | S7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1999531","Neural Cell Adhesion Molecule 1, Human","C25276","Neural cell adhesion molecule 1 (761 aa, ~84 kDa) is encoded by the human NCAM1 gene. This protein is involved in the mediation of neuron-neuron adhesion.","Neural Cell Adhesion Molecule 1 | Antigen MSK39 Identified By Monoclonal Antibody 5.1H11 | CD56 | CD56 Antigen | N-CAM-1 | NCAM | NCAM-1 | NCAM1 | NKH-1 | Neural Cell Adhesion Molecule | Neural Cell Adhesion Molecule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0272199","Familial Hemophagocytic Lymphohistiocytosis","C61276","A rare, life-threatening disorder usually appearing during the first few months of life. It is caused by abnormalities in the PRF1, UNC13D, and STX11 genes. It is characterized by histiocytic proliferation and phagocytosis. Patients present with fever, lymphadenopathy, and hepatosplenomegaly.","Familial Hemophagocytic Lymphohistiocytosis | FHLH | Familiar Hemophagocytic Lymphohistiocytosis | Hemophagocytic Syndrome | Primary Hemophagocytic Lymphohistiocytosis | fHLH",,,,,,,,,,,,,,,"4161829","Familial hemophagocytic lymphohistiocytosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3554549","Hemophagocytosis","C35985","The term hemophagocytosis describes the pathologic finding of activated macrophages, engulfing erythrocytes, leukocytes, platelets, and their precursor cells. (from Medscape: Hemophagocytic Syndromes and Infection)","Hemophagocytosis | ",,,,,,,,,,,,,,,"4246857","Erythrophagocytosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003873","Rheumatoid Arthritis","C2884","A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.","Rheumatoid Arthritis | RA | Rheumatoid arthritis, unspecified | rheumatoid arthritis",,,,,,,,,,,,,,,"80809","Rheumatoid arthritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4230618","Psoriatic Arthritis","C61277","Joint inflammation associated with psoriasis.","Psoriatic Arthritis | Arthritis Psoriatica | Arthropathic psoriasis, unspecified | Psoriatic Arthropathy",,,,,,,,,,,,,,,"40319772","Psoriatic arthritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0087031","Systemic Onset Juvenile Rheumatoid Arthritis","C61278","An inflammatory disorder most often affecting children. It is characterized by the presence of arthritis, salmon-colored rash, spiking fevers, fatigue, and sore throats.","Still Disease | Juvenile rheumatoid arthritis with systemic onset, unspecified site | Still's Disease | Stills Disease | Systemic JRA | Systemic Juvenile Rheumatoid Arthritis (AQ) | Systemic Onset Juvenile Rheumatoid Arthritis | sJRA",,,,,,,,,,,,,,,"4116447","Systemic onset juvenile chronic arthritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0157917","Pauciarticular Juvenile Rheumatoid Arthritis","C61279","Juvenile rheumatoid arthritis affecting four or fewer joints, usually asymmetrically. The most commonly affected joints are the knee, elbow, wrist, and ankle.","Oligoarticular Still Disease | Oligoarticular JRA | Oligoarticular Juvenile Rheumatoid Arthritis | Oligoarticular Still's Disease | Oligoarticular Stills Disease | Pauciarticular JRA | Pauciarticular Juvenile Rheumatoid Arthritis (AQ) | Pauciarticular juvenile rheumatoid arthritis, unspecified site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0311221","Polyarticular juvenile rheumatoid arthritis","C61280","Juvenile rheumatoid arthritis affecting multiple joints, usually symmetrically. It may be associated with low grade fever, anemia, and weight loss. Patients usually test negative for rheumatoid factor.","Polyarticular Still Disease | Polyarticular JRA | Polyarticular Juvenile Rheumatoid Arthritis (AQ) | Polyarticular Still's Disease | Polyarticular Stills Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337666","Cigar Smoking","C19702","The act of inhaling smoke from dried tobacco that is rolled up and called a cigar.","Cigar Smoking | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880019","Cessation","C61497","A stopping.","Cessation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009782","Connective Tissue Disorder","C26729","A non-neoplastic or neoplastic disorder that affects the connective tissue.","Connective Tissue Disorder | Connective Tissue Disease | Connective Tissue Diseases | Connective Tissue Disorders | Disorder of Connective Tissue | Primary Disorder of Connective Tissue",,,,,,,,,,,,,,,"253549","Disorder of connective tissue",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011644","Scleroderma","C26746","A localized or systemic chronic and progressive autoimmune disorder characterized by thickening of the skin and the connective tissues. Localized scleroderma affects only the skin. Systemic scleroderma affects internal organs, including the heart, lungs, gastrointestinal tract, and kidneys.","Scleroderma | scleroderma",,,,,,,,,,,,,,,"40352976","Scleroderma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4229824","Systemic Lupus Erythematosus","C3201","An autoimmune multi-organ disease typically associated with vasculopathy and autoantibody production. Most patients have antinuclear antibodies (ANA). The presence of anti-dsDNA or anti-Smith antibodies are highly-specific.","Systemic Lupus Erythematosus | SLE | SLE - Lupus Erythematosus, Systemic | Systemic lupus erythematosus, unspecified | systemic lupus erythematosus",,,,,,,,,,,,,,,"257628","Systemic lupus erythematosus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1527336","Sjogren Syndrome","C26883","An autoimmune disorder affecting the salivary and lacrimal glands. Morphologically, it is characterized by the presence of lymphocytic and plasmacytic infiltrates which cause destruction of these glands. It results in dry mouth and dry eyes. It may be associated with the presence of other autoimmune disorders, including rheumatoid arthritis and lupus erythematosus.","Sjogren Syndrome | Sjogren syndrome | Sjogren's Syndrome | Sjogren's Syndrome | Sjögren Syndrome",,,,,,,,,,,,,,,"254443","Sjögren's syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3278909","Dermatomyositis","C26744","Inflammation of the skin and muscle.","Dermatomyositis | ",,,,,,,,,,,,,,,"80182","Dermatomyositis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085278","Antiphospholipid Syndrome","C61283","A disorder caused by the presence of autoantibodies directed against phospholipids, causing a hypercoaguable state, which may result in blood clots, stroke, heart attack, and in women, significant pregnancy-related complications, including miscarriage and still birth. The syndrome is often associated with other autoimmune disorders, most commonly lupus erythematosus, and infections, including syphilis and Lyme disease.","Antiphospholipid Syndrome | Antiphospholipid Antibody Syndrome",,,,,,,,,,,,,,,"4098292","Antiphospholipid syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042384","Vasculitis","C26912","An inflammatory process involving the wall of the vessels (large, medium, or small-sized vessels). The inflammatory process may cause necrosis or formation of granulomas in the vascular wall. It may be the result of an autoimmune disorder, infection, or malignancy. Representative examples include polyarteritis nodosa, temporal arteritis, Wegener granulomatosis, Kawasaki disease, Takayasu arteritis, and Henoch-Schonlein purpura.","Vasculitis | ",,,,,,,,,,,,,,,"4137275","Vasculitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3495801","Granulomatosis with Polyangiitis","C3444","A rare, autoimmune, systemic medium and small size vasculitis. It is characterized by the formation of necrotizing granulomas in the respiratory tract, necrotizing angiitis, and glomerulonephritis.","Granulomatosis with Polyangiitis | GPA | Wegener Granulomatosis | Wegener Granulomatosis | Wegener's Granulomatosis | Wegener's Granulomatosis",,,,,,,,,,,,,,,"313223","Granulomatosis with polyangiitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008728","Churg-Strauss Syndrome","C34481","An autoimmune necrotizing vasculitis with the formation of granulomas. It is a pulmonary and systemic vasculitis associated with eosinophilia.","Eosinophilic Granulomatosis with Polyangiitis | Allergic Granulomatosis | Allergic Granulomatous Angiitis | Churg-Strauss Syndrome | Churg-Strauss Syndrome | EGPA | Polyarteritis with lung involvement [Churg-Strauss]",,,,,,,,,,,,,,,"4305666","Eosinophilic granulomatosis with polyangiitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1956391","Temporal Arteritis","C35065","An autoimmune, systemic, giant cell granulomatous arteritis predominantly involving the arteries that supply blood to the central nervous system, head and eyes. Superficial arteries of the scalp that are involved tend to be enlarged and tender. Signs and symptoms include headaches, myalgias, visual disturbances, and skin necrosis.","Temporal Arteritis | Giant Cell Arteritis",,,,,,,,,,,,,,,"4290976","Temporal arteritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039263","Takayasu Arteritis","C35062","A large vessel vasculitis affecting the aorta and its branches. It usually affects young females. It causes vascular obstruction, resulting in asymmetric pulses.","Takayasu Arteritis | Pulseless Disease | Takayasu's Arteritis | Takayasu's Arteritis",,,,,,,,,,,,,,,"4347063|440740","Idiopathic aortitis|Takayasu's disease",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0004943","Behcet Syndrome","C34416","A rare chronic inflammatory disorder of unknown etiology. It is characterized by the development of ulcers in the mouth and genital region and uveitis. Other signs and symptoms include arthritis, deep vein thrombosis and superficial thrombophlebitis.","Behcet Syndrome | Behcet Disease | Behcet's Disease | Behcet's Syndrome | Behcet's Syndrome | Behcet's disease | Behçet Disease | Behçet Syndrome | Behçet's Syndrome | Behçet-Adamantiades Syndrome | Morbus Behçet's Syndrome | Silk Road Disease",,,,,,,,,,,,,,,"436642","Behcet's syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882233","Overlap Necrotizing Arteritis","C61282","A necrotizing arteritis that exhibits characteristic features of several distinct vascular disorders.","Overlap Necrotizing Arteritis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3277909","Necrotizing Arteritis","C61281","An arteritis characterized by the presence of inflammation and necrosis in the arterial wall.","Necrotizing Arteritis | ",,,,,,,,,,,,,,,"4270883","Necrotizing arteritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0920163","Primary Immune Thrombocytopenia","C3446","Acquired thrombocytopenia of unknown cause, characterized by immune-mediated destruction of normal platelets. It affects both children and adults. It manifests with petechiae, purpura, and overt bleeding. Based upon the duration of the disease, it is classified as newly diagnosed (from diagnosis until 3 months), persistent (3-12 months), and chronic (lasting for more than 12 months).","Primary Immune Thrombocytopenia | ITP | Idiopathic Thrombocytopenia | Idiopathic Thrombocytopenia Purpura | Idiopathic Thrombocytopenic Purpura | Idiopathic Thrombocytopenic Purpura | Immune Thrombocytopenia | Immune Thrombocytopenic Purpura | Immune thrombocytopenic purpura | idiopathic thrombocytopenic purpura | immune thrombocytopenic purpura",,,,,,,,,,,,,,,"4028065","Primary ITP (immune thrombocytopenia)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4227881","Hemolytic Anemia","C34376","Anemia resulting from the premature destruction of the peripheral blood red cells. It may be congenital or it may be caused by infections, medications, or malignancies.","Hemolytic Anemia | ",,,,,,,,,,,,,,,"435503","Hemolytic anemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0272126","Evans Syndrome","C61284","A rare, chronic and relapsing autoimmune disorder of unknown etiology, characterized by the presence of immune thrombocytopenia and autoimmune hemolytic anemia.","Evans Syndrome | Evans syndrome",,,,,,,,,,,,,,,"436956","Evans syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3810108","Intestinal Disorder","C26801","A non-neoplastic or neoplastic disorder that affects the small or large intestine.","Intestinal Disorder | ",,,,,,,,,,,,,,,"201618","Disorder of intestine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006271","Bronchiolitis","C39658","Inflammation of the bronchioles characterized by swelling of the bronchioles and mucus accumulation. It is usually caused by the respiratory syncytial virus and affects children. Signs and symptoms include coughing, wheezing, and shortness of breath.","Bronchiolitis | Wheezy Bronchitis",,,,,,,,,,,,,,,"4165112","Bronchiolitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0012240","Digestive System","C12378","The system that includes the esophagus, stomach, small and large intestine, anus, liver, biliary tract, and pancreas.","Digestive System | Body System, Gastrointestinal | GASTROINTESTINAL SYSTEM | Gastrointestinal | Gastrointestinal Body System | Gastrointestinal Organ System | Gastrointestinal System | Gastrointestinal System | Organ System, Gastrointestinal | digestive system",,,,,,,,,,,,,,,"4314892","Structure of digestive system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042066","Genitourinary System","C12810","The body system that includes all organs involved in reproduction and in the formation and voidance of urine.","Genitourinary System | GENITOURINARY SYSTEM | Genitourinary | Genitourinary Tract | Urogenital System | Urogenital Tract | genitourinary system",,,,,,,,,,,,,,,"4069509","Structure of genitourinary system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1880648","FACT-O Questionnaire","C64712","A subscale complement to the FACT-G developed specifically for evaluating quality of life of ovarian cancer patients.","FACT-O Questionnaire | FACT-O | FACT-O Questionaire | Functional Assessment of Cancer Therapy-Ovarian",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1947910","Pulse phenomenon","C64713","Any of a series of intermittent occurrences characterized by a brief, sudden change in a quantity.","Pulse | Pulsed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0392258","Dye Laser","C64722","A laser in which light is emitted by a fluorescent organic dye and which can be tuned to radiate at any of a wide range of frequencies.","Dye Laser | ",,,,,,,,,,,,,,,"4042152","Dye laser device",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014457","Eosinophilia","C3015","Abnormal high level of eosinophils in the blood.","Eosinophilia | eosinophilia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4014129","Autoantibody","C48966","An antibody acting against tissues of the organism that produces it.","Autoantibody | autoantibody",,,,,,,,,,,,,,,"4148637","Autoantibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0199176","Intent For Prophylaxis","C54404","The use of a particular medical device, medication or treatment to help reduce the risk of contracting or developing a disease or condition.","Intent For Prophylaxis | Prevention Intent | Prevention Of | Prophylaxis Intent",,,,,,,,,,,,,,,"4061660|4232816","Preventive procedure|Prophylaxis - intent",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0051761","Amphotericin B Deoxycholate","C62201","The deoxycholate salt of amphotericin B, a polyene antifungal antibiotic produced by Streptomyces nodosus, with antifungal activity. Amphotericin B binds to ergosterol, an essential component of the fungal cell membrane. This results in depolarization of the cell membrane, alterations in cell membrane permeability, leakage of important intracellular components, and cell rupture. This agent may also induce oxidative damage in fungal cells and has been reported to stimulate host immune cells.","Amphotericin B Deoxycholate | Amphotericin B-deoxycholate | Fungizone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1120386","Micafungin","C1850","A semi-synthetic echinocandin derived from a natural product of the fungus Coleophama empedri with potent antifungal activity. Micafungin, like other cyclic lipopeptides, noncompetitively inhibits the fungal specific enzyme 1,3-beta-D-glucan synthase, an enzyme essential for fungal cell wall synthesis. Inhibition of this enzyme weakens of the cell wall, thereby leading to osmotic lysis and eventually, fungal cell death.","Micafungin | FK463 | MICAFUNGIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0936148","Posaconazole","C61500","A broad-spectrum, second generation, triazole compound with antifungal activity. Posaconazole strongly inhibits 14-alpha demethylase, a cytochrome P450-dependent enzyme. Inhibition of 14-alpha-demethylase prevents the conversion of lanosterol to ergosterol, an important component of the fungal cell wall. Inhibition of ergosterol synthesis changes the fungal cell membrane composition and integrity, alters membrane permeability and eventually leads to fungal cell lysis. Compared to other azole antifungals, posaconazole is a significantly more potent inhibitor of sterol 14-alpha demethylase.","Posaconazole | Noxafil | POSACONAZOLE | SCH 56592",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0535186","Ravuconazole","C38688","A triazole with antifungal activity. Ravuconazole inhibits 14a demethylase, an enzyme involved in sterol synthesis, resulting in lysis of the fungal cell wall and fungal cell death. (NCI04)","Ravuconazole | BMS-207147 | ER-30346 | RAVUCONAZOLE | p-(2-((alphaR,betaR)-2,4-Difluoro-beta-hydroxy-alpha-methyl-beta-(1H-1,2,4-triazol-1-ylmethyl)phenethyl)-4-thiazolyl)benzonitrile | ravuconazole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0393080","Voriconazole","C1707","A synthetic triazole with antifungal activity. Voriconazole selectively inhibits 14-alpha-lanosterol demethylation in fungi, preventing the production of ergosterol, an essential constituent of the fungal cell membrane, and resulting in fungal cell lysis. (NCI04)","Voriconazole | (2R,3S)-2-(2,4-Difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol | VORICONAZOLE | Vfend | voriconazole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0909381","Valganciclovir","C2629","A synthetic prodrug of ganciclovir, a nucleoside analogue of 2'-deoxyguanosine, with antiviral activity. After phosphorylation, valganciclovir is incorporated into DNA, resulting in inhibition of viral DNA polymerase, viral DNA synthesis, and viral replication. (NCI04)","Valganciclovir | L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-3-hydroxypropyl Ester | VALGANCICLOVIR | valganciclovir",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0249458","Valacyclovir","C28235","The hydrochloride salt of the L-valyl ester of the antiviral drug acyclovir. Orally administered, valacyclovir is rapidly converted to acyclovir which inhibits viral DNA replication after further conversion to the nucleotide analog acyclovir triphosphate by viral thymidine kinase, cellular guanyl cyclase, and a number of other cellular enzymes. Acyclovir triphosphate competitively inhibits viral DNA polymerase; incorporates into and terminates the growing viral DNA chain; and inactivates viral DNA polymerase. The greater antiviral activity of acyclovir against herpes simplex virus (HSV) compared with varicella-zoster virus (VZV) is due to its more efficient phosphorylation by HSV thymidine kinase.","Valacyclovir | L-Valine ester with 9-((2-hydroxyethoxy)methyl)guanine | VALACYCLOVIR | ValACV | Valaciclovir | Zelitrex | valacyclovir",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030863","Pentamidine","C731","A synthetic derivative of amidine with antiprotozoal and antifungal activities.  Although the precise mode of action of pentamidine is unclear, it appears to interact directly with the pathogen genome by binding to AT-rich regions of duplex DNA and the minor groove of DNA, thereby interfering with DNA replication. (NCI04)","Pentamidine | Aerosolized Pentamadine | PENTAMIDINE | pentamidine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003308","Antifungal Agent","C514","Substances that treat systemic or topical infections caused by fungi. Antifungal agents kill or inhibit the growth of fungi, by various mechanisms. These mechanisms include inhibition of fungal mitosis, impairing synthesis or binding to ergosterol, inhibition of RNA or DNA synthesis, and interfering with other fungal metabolic processes.","Antifungal Agent | Antifungal | Antifungal Drug | Antifungals | antifungal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003451","Antiviral Agent","C281","Any agent that can treat or prevent viral infections by interfering with the viral replication cycle.","Antiviral Agent | Antiviral | Antivirals | antiviral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004482","Azathioprine","C290","A purine analogue with cytotoxic and immunosuppressive activity. Azathioprine is a prodrug that is converted by hepatic xanthine oxidase to its active metabolite 6-mercaptopurine (6-MP). 6-MP is further metabolized by hypoxanthine-guanine phosphoribosyltransferase (HGPRT) into 6-thioguanosine-5'-phosphate (6-thio-GMP) and 6-thioinosine monophosphate (6-thio-IMP), both inhibit nucleotide conversions and de novo purine synthesis. This leads to inhibition of DNA, RNA, and protein synthesis. As a result, cell proliferation may be inhibited, particularly in lymphocytes and leukocytes.","Azathioprine | 6-[(1-Methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-purine | AZA | AZATHIOPRINE | AZTP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015137","Etretinate","C29036","A synthetic oral retinoid that is a prodrug of acitretin.  Etretinate activates retinoid receptors, causing an induction of cell differentiation, inhibition of cell proliferation, and inhibition of tissue infiltration by inflammatory cells.  Etretinate is no longer commercially available in the U.S. due to the extended potential for teratogenic effects related to its long half-life. (NCI04)","Etretinate | (2E,4E,6E,8E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic Acid, Ethyl Ester | ETRETINATE | Ethyl-all-trans-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoate | Ro 10-9359 | Tegison | Tigason",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020336","Hydroxychloroquine","C557","A 4-aminoquinoline with immunosuppressive, antiautophagy, and antimalarial activities. Although the precise mechanism of action is unknown, hydroxychloroquine may suppress immune function by interfering with the processing and presentation of antigens and the production of cytokines. As a lysosomotropic agent, hydroxychloroquine raises intralysosomal pH, impairing autophagic protein degradation; hydroxychloroquine-mediated accumulation of ineffective autophagosomes may result in cell death in tumor cells reliant on autophagy for survival.  In addition, this agent is highly active against the erythrocytic forms of P. vivax and malariae and most strains of P. falciparum but not the gametocytes of P. falciparum.","Hydroxychloroquine | HYDROXYCHLOROQUINE | hydroxychloroquine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008996","Clofazimine","C47456","A phenazine dye with anti-mycobacterial and anti-inflammatory activities. The exact mechanism through which clofazimine exerts its effect is unknown.  However, it binds preferentially to mycobacterial DNA, thereby inhibiting DNA replication and cell growth. Clofazimine has a slow bactericidal effect on Mycobacterium leprae and is active against various other Mycobacteria.","Clofazimine | 2-Phenazinamine, 3,5-dihydro-N,5-bis(4-chlorophenyl)-3-((1-methylethyl)imino)- | 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-phenazine | CLOFAZIMINE | Lamprene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016072","Psoralen","C2586","A furocoumarin that intercalates with DNA, inhibiting DNA synthesis and cell division. Psoralen is used in Photochemotherapy with high-intensity long-wavelength UVA irradiation. Psoralens are tricyclic furocumarins and have a strong tendency to intercalate with DNA base pairs. Irradiation of nucleic acids in the presence of psoralen with long wave UV (~360 nm) results in the 2+2 cyclo- addition of either of its two photoreactive sites with 5,6-carbon bonds of pyrimidines resulting in crosslinking double-stranded nucleic acids.","Psoralen | 6-hydroxy-5-benzofuranacrylic Acid deta-lacton | Ficusin | PSORALEN | psoralen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008038","Chewing Tobacco","C361","Tobacco, in the form of a plug, usually flavored, for chewing rather than smoking.","Chewing Tobacco | Spit Tobacco",,,,,,,,,,,,,,,"4219234","Chewing tobacco",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032594","Polysaccharide","C28179","A large carbohydrate molecule. It contains many small sugar molecules that are joined chemically.","Polysaccharide | glycan | polysaccharide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020291","Hydrolysis","C16702","A chemical reaction in which a water molecule is added to a compound. This addition often involves the splitting or cleavage of the molecule. The hydroxyl group is incorporated into one fragment of the compound and the hydrogen atom in the other.","Hydrolysis | Hydrolytic Process | hydrolysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019618","Histiocytosis","C3106","A morphologic finding indicating tissue infiltration by non-neoplastic or neoplastic histiocytes.","Histiocytosis | Histiocytic Infiltrate | Histiocytic Infiltrate | Histiocytic Syndrome",,,,,,,,,,,,,,,"4130197|4264478","Histiocytic syndrome|Histiocytosis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2939461","Myeloid Neoplasm","C9290","Proliferation of myeloid cells originating from a primitive stem cell.","Myeloid Neoplasm | Myeloid Malignancy | Myeloid Tumor",,,,,,,,,,,,,,,"4212320","Myeloid neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2349952","Oropharyngeal Cancers","C9105","Carcinoma, predominantly squamous cell, arising from the epithelial cells of the oropharynx.","Oropharyngeal Carcinoma | Cancer of Oropharynx | Cancer of the Oropharynx | Carcinoma of Oropharynx | Carcinoma of the Oropharynx | Oropharyngeal Cancer | Oropharyngeal Throat Cancer | Oropharynx Carcinoma | oropharyngeal cancer",,,,,,,,,,,,,,,"40488898","Malignant epithelial neoplasm of oropharynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027543","Avascular Necrosis of Bone","C34841","Necrotic changes in the bone tissue due to interruption of blood supply. Most often affecting the epiphysis of the long bones, the necrotic changes result in the collapse and the destruction of the bone structure.","Avascular Necrosis of Bone | Avascular necrosis",,,,,,,,,,,,,,,"4287786","Avascular necrosis of bone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018050","Gonadal Disorder","C26786","A non-neoplastic or neoplastic disorder that affects the testis or the ovary.","Gonadal Disorder | Disorder of Gonads | Gonadal Disorders | Gonadal Dysfunction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714500","Human Somatotropin","C2288","Somatotropin (217 aa, ~25 kDa) is encoded by the human GH1 gene. This protein is involved in the regulation of many physiologic processes, including the growth of organs and tissues and the metabolism of amino acids and proteins.","Somatotropin | GH | GH-N | GHN | Growth Hormone | Growth Hormone | Growth Hormone 1 | Pituitary Growth Hormone | Somatotropic Hormone | growth hormone | hGHN | somatotropin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881036","Hemizygosity","C64346","Having only one copy of a particular gene or genetic region.","Hemizygosity | Hemizygous | Hemizygous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032113","Plasmapheresis","C15304","A procedure that collects plasma from the peripheral blood while returning the rest to the donor.","Plasmapheresis | Plasma Exchange | Therapeutic Plasma Exchange | Therapeutic Plasmapheresis | plasmapheresis",,,,,,,,,,,,,,,"4055766|4076662","Plasma exchange|Therapeutic plasma exchange",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1883702","Supernumerary","C63758","Exceeding the normal or usual number.","Supernumerary | Accessory | Extra | SUPERNUMERARY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0260272","Oral Surgeon","C17825","A surgeon with advanced training in treating diseases and disorders of the oral cavity.","Oral Surgeon | oral surgeon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555936","Prosthodontist","C17947","A dentist with special training in making replacements for missing teeth or other structures of the oral cavity to restore the patient's appearance, comfort, and/or health.","Prosthodontist | prosthodontist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887754","Ultrasonogram","C28455","A computerized image of internal tissues created by bouncing high-energy sound waves off internal organs.","Ultrasonogram | Sonogram | sonogram | ultrasonogram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014442","Enzyme","C16554","Molecules that catalyze a chemical reaction. They are usually proteins, although catalytic RNA and DNA molecules have been identified.","Enzyme | Enzymes | enzyme",,,,,,,,,,,,,,,"4233680","Enzyme",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1535502","Bronchoalveolar Lavage","C51913","Washing out the bronchi and alveoli by flushing with a fluid.","Bronchoalveolar Lavage | Lung lavage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0863477","Transbronchial Lung Biopsy","C51749","Removal of tissue through the bronchial wall, for microscopic examination.","Transbronchial Lung Biopsy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0175566","Open","C49069","Affording unobstructed entrance and exit; affording free passage or access; accessible to all.","Open | OPEN | Opened | open",,,,,,,,,,,,,,,"4206640|763006","Patent|Open",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0166025","Risedronate Sodium","C1528","The sodium salt of risedronic acid, a synthetic pyridinyl bisphosphonate. Risedronic acid binds to hydroxyapatite crystals in bone and inhibits osteoclast-dependent bone resorption.","Risedronate Sodium | Actonel | Monosodium (1-hydroxy-2-(3-pyridinyl)ethylidene)bisphosphonate | NE-58095 | RISEDRONATE SODIUM | Risedronate | Risendronate Sodium | risedronate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0772244","Ibandronate Sodium","C1670","The sodium salt form of ibandronic acid, a synthetic nitrogen-containing bisphosphonate. Ibandronic acid inhibits farnesyl pyrophosphate synthase, resulting in a reduction in geranylgeranyl GTPase signaling proteins and apoptosis of osteoclasts. This agent increases bone mineral density, decreases bone remodeling, inhibits osteoclast-mediated bone resorption, and reduces metastases-related and corticosteroid-related bone pain.","Ibandronate Sodium | Bondronate | Boniva | IBANDRONATE SODIUM | ibandronate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037507","Etidronate Disodium","C831","A synthetic therapeutic diphosphonate analogue of endogenous pyrophosphate. As a member of the family of drugs known as bisphosphonates, etidronate disodium differs from endogenous pyrophosphate in its resistance to enzymatic hydrolysis.  This agent adsorbs to hydroxyapatite cells and reduces the number of osteoclasts, thereby inhibiting abnormal bone resorption.  Etidronate may also directly stimulate bone formation by osteoblasts. (NCI04)","Etidronate Disodium | Calcimux | Didronel | Diphos | Disodium Dihydrogen (1-hydroxyethylidene)bis(phosphonate) | ETIDRONATE DISODIUM | Etidron",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0286030","Tiludronate Disodium","C61973","The disodium salt form of tiludronate, a first-generation, non-nitrogenous bisphosphonate analogue of endogenous pyrophosphate. Tiludronate adsorbs to hydroxyapatite cells, and although the exact mechanism through which this bisphosphonate exerts its effect has yet to be fully elucidated, tiludronate appears to inhibit protein-tyrosine-phosphatase (PTP) in osteoclasts, thereby disrupting the cytoskeletal ring structure and suppressing the bone resorbing activity of osteoclasts. In addition, tiludronate appears to inhibit the vacuolar-type proton ATPase (V-ATPase) in osteoclasts. Altogether, this may reduce the number of osteoclasts, inhibit abnormal bone resorption and reduce bone turnover.","Tiludronate Disodium | Skelid | TILUDRONATE DISODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008994","Clodronate Disodium","C1418","The disodium salt of a nitrogen-free bisphosphonate analog of naturally occurring pyrophosphate. Clodronate binds to calcium and inhibits osteoclastic bone resorption and hydroxyapatite crystal formation and dissolution, resulting in a reduction of bone turnover. This agent may control malignancy-associated hypercalcemia, inhibit osteolytic bone metastasis and decrease pain.","Clodronate Disodium | Bonefos | CL2MDP | CLODRONATE DISODIUM | Clasteon | Clodronate | Clodronic Acid Disodium Salt | Dichloromethylene Diphosphonate | Difosfonal | Loron | Mebonat | Ossiten | clodronate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206679","Human Herpesvirus 1","C14311","HSV is a nuclear replicating, icosahedral, enveloped DNA virus. The HSV envelope contains at least 8 glycoproteins. The matrix or tegument which contacts both the envelope and the capsid contains at least 15-20 proteins. There are two types of HSV - Type 1 and Type 2.  The Type 1 virus causes cold sores.  Most people get Type 1 infections during infancy or childhood. The Type 2 virus causes genital sores. Most people get Type 2 infections following sexual contact with an infected person.","Human Herpesvirus 1 | HERPES SIMPLEX VIRUS 1 | HHV-1 | HHV1 | HSV-1 | HSV1 | HUMAN HERPESVIRUS 1 | Herpes Simplex Virus | Herpes Simplex Virus 1 | Herpes Simplex Virus Type 1 | Human Alphaherpesvirus 1 | Human alphaherpesvirus 1",,,,,,,,,,,,,,,"4035979","Human alphaherpesvirus 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019381","Human Herpesvirus 6","C14218","A human herpesvirus that has been found in certain lymphoproliferative disorders, replicates in a number of different types of leukocytes, and is associated with the childhood disease roseola (exanthema subitum).","Human Herpesvirus 6 | HHV-6 | HHV6 | HUMAN HERPESVIRUS 6 | Herpes Simplex Virus 6 | Herpes Virus 6 | Human Betaherpesvirus 6 | Human Herpesvirus-6 | Human betaherpesvirus 6 | Virus-HHV6",,,,,,,,,,,,,,,"4013872","Human herpesvirus 6",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035235","Respiratory Syncytial Virus Infection","C3354","Infection with the respiratory syncytial virus, an RNA virus of the genus Pneumovirus, in the family Paramyxoviridae, which is characterized by the formation of syncytia in tissue culture. It causes minor respiratory infection with rhinitis and cough in adults, but is capable of causing severe bronchitis and bronchopneumonia in young children.","Respiratory Syncytial Virus Infection | RSV Infection",,,,,,,,,,,,,,,"437222","Respiratory syncytial virus infection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010798","Cytochromes","C16486","A family of membrane-associated, heme-containing proteins that catalyze oxidation and reduction to promote electron transport reactions.","Cytochrome | Cytochromes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0489451","Body Surface","C29667","The surface of an external body region.","Body Surface | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448689","Tracking","C45275","The act or process of following a person, animal, or object through space or time.","Tracking | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519336","Site Visit","C19032","A visit from an oversite group to a site of a study or research for fact gathering, peer review, or compliance with regulations.","Site Visit | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031752","Photometry","C65109","Measurement of the properties of light, especially luminous intensity.","Photometry | PHOTOMETRY | Photometric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242739","Nutritional Support","C15433","Administration of essential nutrients to a patient utilizing methods other than oral feedings.","Nutritional Support | Nutrition Therapy | Nutritional Care | Nutritional Therapy",,,,,,,,,,,,,,,"4132896","Nutritional support",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029473","Ostomy","C15290","Surgical creation of an opening in an organ.","Ostomy | ostomy | surgical construction of a stoma",,,,,,,,,,,,,,,"4327938","Construction of stoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1948029","Destruction (action)","C62100","The act of destroying; demolition or annihilation.","Destruction | DESTROYING | Destroy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152018","Esophageal Carcinoma","C3513","A malignant epithelial tumor arising from the esophageal mucosa. Two major histologic types of esophageal carcinoma have been described: squamous cell carcinoma and adenocarcinoma. This type of cancer is associated with excessive ethanol and cigarette usage.","Esophageal Carcinoma | Cancer of Esophagus | Cancer of the Esophagus | Carcinoma of Esophagus | Carcinoma of the Esophagus | ESCA | Esophageal Cancer | Esophageal cancer, NOS | Esophagus Carcinoma | esophageal cancer",,,,,,,,,,,,,,,"4162997","Carcinoma of esophagus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011369","Dental Hygienist","C53293","A health care professional auxiliary in dentistry trained and licensed to provide preventive, therapeutic and educational services for the control of oral diseases.","Dental Hygienist | DENTAL HYGIENIST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0836913","Fossa","C34007","A concavity in a surface, especially an anatomical depression.","Fossa | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3806995","Tracheoesophageal Fistula","C35080","A congenital or acquired abnormal communication between the trachea and the esophagus.","Tracheoesophageal Fistula | Tracheo-esophageal Fistula",,,,,,,,,,,,,,,"25582","Tracheoesophageal fistula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522721","Prostatic","C27959","Of, or pertaining to, the prostate.","Prostatic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0588054","Cervical Lymph Node","C32298","Any of the lymph nodes located in the neck.","Cervical Lymph Node | CERVICAL LYMPH NODE | Cervical Nodes | Cervical lymph node structure (body structure) | Cervical lymph nodes | LYMPH NODE, CERVICAL | Lymph Node(s) Cervical | cervical lymph node",,,,,,,,,,,,,,,"4215878","Cervical lymph node structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041967","Urethra","C12417","The tube carrying urine from the bladder to outside of the body.","Urethra | URETHRA | Urethral structure (body structure) | urethra",,,,,,,,,,,,,"UBERON:0000057","urethra","4029306","Urethral structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0184980","Endoscopic Biopsy","C15389","The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis. In the case of an endoscopic biopsy, an endoscope is used to obtain the sample.","Endoscopic Biopsy | Endoscopy and Biopsy",,,,,,,,,,,,,,,"4202517","Endoscopic biopsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0190482","Biopsy of Temporal Artery","C51932","Removal of a portion of the temporal artery for microscopic examination.","Biopsy of Temporal Artery | Temporal Artery Biopsy",,,,,,,,,,,,,,,"4248147","Biopsy of temporal artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1880202","Customize","C65167","To make according to individual requirements or specifications; to make more personalized or tailored for a specific need.","Customize | Custom | Customized",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229766","Celiac Lymph Node","C65166","A lymph node at the base of the celiac artery.","Celiac Lymph Node | CELIAC LYMPH NODE | Celiac Axis Lymph Node | Celiac Nodes",,,,,,,,,,,,,,,"4167324","Structure of celiac lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0406810","Carney Complex","C4705","An autosomal dominant disorder most often caused by mutations in the PRKAR1A gene. It is characterized by the presence of myxomas in the heart and skin, skin hyperpigmentation, increased endocrine activity and melanotic schwannomas.","Carney Complex | Atrial Myxoma with Lentigines | CNC | Carney Syndrome | Carney Syndrome | Carney complex | Carney syndrome | Carney's Syndrome | LAMB | Lentigines, Atrial Myxoma, Mucocutaneous Myoma, Blue Nevus Syndrome | Nevi, Atrial Myxoma, Skin Myxoma, Ephelides Syndrome",,,,,,,,,,,,,,,"37116686","Carney complex",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0373561","Calcium Cation","C61660","The metabolically-active portion of calcium, not bound to proteins, circulating in the blood.","Calcium Cation | CA+2 | CALCIUM CATION | Ca++ | Ca2+ | Calcium 2+ | Calcium Ion | Calcium Ion | Free Calcium | Ionized Calcium",,,,,,,,,,,,,,,"4125860","Calcium electrolyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4227559","Inflammatory Bowel Disease","C3138","A spectrum of small and large bowel inflammatory diseases of unknown etiology. It includes Crohn's disease, ulcerative colitis, and colitis of indeterminate type.","Inflammatory Bowel Disease | Autoimmune Bowel Disorder | IBD | inflammatory bowel disease",,,,,,,,,,,,,,,"4074815","Inflammatory bowel disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015259","Exercise","C16567","Activity that requires physical or mental exertion, especially when performed to develop or maintain fitness.","Exercise | Exercise Type",,,,,,,,,,,,,,,"4116678","Exercise",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0449394","Staging System","C18004","A systematic method for clinicopathologic evaluation of tumors.","Staging System | STAGE_SYSTEM | Stage System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034375","Qualitative Evaluation","C49143","A type of evaluation that is primarily descriptive and interpretative, and may or may not lend itself to quantification. Mainly concerned with the properties, the state, and the character (i.e., the nature) of phenomena. It implies an emphasis on processes and meanings that are rigorously examined, but not measured in terms of quantity, amount, or frequency. (www.unfpa.org/monitoring/toolkit/glossary.pdf and Nonprofit Good Practice Guide Glossary)","Qualitative Evaluation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443131","Accuracy","C49145","The quality of nearness to the truth or the true value.","Accuracy | Accurate",,,,,,,,,,,,,,,"4137666","Accurate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706862","Automated Neuropsychological Assessment Metrics","C49144","A computerized library of tests designed for baseline screening and serial assessment of neurocognitive function.","Automated Neuropsychological Assessment Metrics | ANAM | Automated Neuropsychological Assessment Metrics Battery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1504479","Numeric Pain Scale","C21082","A pain rating scale that attempts objectivity by reliance on a person's ability to rate pain on a scale of 0 to 5, 10, or 100, where the lowest number in the scale represents no pain and the highest number represents the worst imaginable pain.","Numeric Pain Scale | Numeric Rating Scale for Pain | Numerical Pain Scale",,,,,,,,,,,,,,,"37151627","Numeric Pain Rating Scale",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709113","NCI-Navy Medical Oncology Branch","C49105","An organizational unit in the Center for Cancer Research of the NCI, but is physically located in the National Naval Medical Center in Bethesda, adjacent to the NIH campus. It is part of the National Naval Medical Center cancer treatment program.","NCI-Navy Medical Oncology Branch | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879684","Alpha-2 Country Code","C54641","The two-letter country codes specified by the ISO 3166-1 country code standard.","Alpha-2 Country Code | ISO 3166-1 Alpha-2 Country Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0687675","Abortion Finding","C35221","The unintentional or intentional loss of a pregnancy before 22 weeks gestation.","Abortion Finding | Abortion | Abortion | Pregnancy Loss",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510831","Age at First Live Birth","C19667","The age at which a woman gave birth to her first live child.","Age at First Live Birth | Age at First Full-Term Pregnancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030563","Parity","C16955","The number of pregnancies reaching 20 weeks and 0 days of gestation or beyond, regardless of the number of fetuses or outcomes.","Parity | Maternal Parity | PARITY | Para",,,,,,,,,,,,,,,"4041279|4264419","Parity finding|Parity",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0595939","Stillbirth","C49151","A fetus of at least 20 weeks gestation, or of a birth weight of at least 350 grams if the gestational age is unknown, that is born without signs of life at the time of delivery, and with an Apgar score of zero at both one and five minutes.","Stillbirth | Intrauterine Fetal Death",,,,,,,,,,,,,,,"443213","Stillbirth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710371","Term Type","C42737","An indicator of a particular 'meaning' of a term.","Term Type | Term Group | Term Type Property | Termgroup",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205404","Serious","C54035","Causing fear or anxiety by threatening great harm; of great consequence.","Serious | Seriousness",,,,,,,,,,,,,,,"4178614","Serious",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0392367","Physical Contact","C49147","The act of touching physically; the physical coming together of two or more things.","Physical Contact | Contact",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704748","Z-Dimension","C49150","The magnitude of something in a third direction, generally representing depth.","Z-Dimension | Z | zDimension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028708","Nutritional Assessment","C15286","An in-depth evaluation of an individual's food and nutrient intake, lifestyle, and medical history designed to help the individual either maintain their health status or attain a healthier status.","Nutritional Assessment | Dietary Assessment | dietary counseling | nutritional counseling",,,,,,,,,,,,,,,"4149297","Nutritional assessment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017596","Glass","C45301","A brittle transparent solid with irregular atomic structure.","Glass | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0189485","Lung Biopsy","C51748","Removal of tissue from the lung, for microscopic examination.","Lung Biopsy | Biopsy of Lung | lung biopsy",,,,,,,,,,,,,,,"4303062","Biopsy of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516167","Cancer Burden","C16064","A measure of the incidence of cancer within the population and an estimate of the financial, emotional, or social impact it creates. The burden of disease is not borne equally by all population groups in the United State.","Cancer Burden | National Cancer Burden",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043188","Wine","C66822","An alcoholic beverage created from fermented juice of fresh grapes or of other fruit or plant products.","Wine | WINE",,,,,,,,,,,,,,,"4262278","Wine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0678403","Wine Cooler","C66823","An alcoholic beverage made from wine and fruit juice, often in combination with a carbonated beverage and sugar.","Wine Cooler | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004922","Beer","C66824","A carbonated alcoholic beverage made through the fermentation of sugars derived from malted grains; this beverage is usually flavored with hops but other herbs or fruit may be used to enhance its flavor.","Beer | ",,,,,,,,,,,,,,,"4201587","Beer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0678393","Sake - alcoholic beverage","C66825","A Japanese alcoholic beverage made from fermented rice; usually served hot.","Sake | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0301611","Liquor","C66826","An alcoholic beverage in which the initial fermentation mixture is distilled in order to concentrate the alcohol, generally resulting in a mixture that is at least 35% alcohol by volume.","Liquor | ",,,,,,,,,,,,,,,"4275752","Distilled spirits",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1947936","Glass Packaging Device","C66821","A glass container for holding liquids while drinking, or any other similar drinking vessel.","Glass | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879748","Assembly (group of parts)","C63548","A group of parts that fit together to form a self-contained unit.","Assembly | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883464","University of California at Santa Cruz","C63549","A campus of the University of California located in Santa Cruz, CA.","University of California at Santa Cruz | UC Santa Cruz | UCSC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206415","Oligonucleotide Primer","C1451","Short DNA oligonucleotide chains used to prime DNA (and in some cases RNA) synthesis.","Oligonucleotide Primer | Primer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883001","Sense Orientation","C63550","Having a DNA sequence identical to that of a messenger RNA molecule; the coding strand in double-stranded DNA.","Sense Orientation | Coding Sense | Coding Strand | Forward Sense | Forward Strand | Sense Strand | Upper Strand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879714","Antisense Orientation","C63551","Having a DNA sequence complementary to that of a messenger RNA molecule; the non-coding strand in double-stranded DNA.","Antisense Orientation | Antisense Strand | Lower Strand | Non-Coding Sense | Non-coding Strand | Reverse Sense | Reverse Strand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0080089","Reading Frames (Nucleotide Sequence)","C63552","One of the three possible ways of reading a nucleotide sequence. As the genetic code is read in nonoverlapping triplets (codons) there are three possible ways of translating a sequence of nucleotides into a protein, each with a different starting point.","Reading Frame | Frame",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521120","Obsolete","C63553","No longer in use or valid; old.","Obsolete | ",,,,,,,,,,,,,,,"9174","Obsolete",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1881884","Molecular Modeling Database","C63579","An online resource of NCBI containing 3D macromolecular structures, including proteins and polynucleotides. Each structure is linked to the rest of the NCBI databases, including sequences, bibliographic citations, taxonomic classifications, and sequence and structure neighbors.","Molecular Modeling Database | MMDB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018591","Haplotype","C63547","A way of denoting the collective genotype of a number of closely linked loci on a chromosome.","Haplotype | HAPLOTYPE | Haplo | haplotype",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883002","Sequence Chromatogram","C63580","The output of an automated sequencing run represented as peak intensities plotted against nucleotide position along a DNA strand.","Sequence Chromatogram | Sequence Trace | Trace",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883644","5' Region","C63581","Sequences immediately preceding a point of interest.","5' Region | 5' Flank | Upstream Region",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883633","3' Region","C63582","Sequences immediately following a point of interest.","3' Region | 3' Flank | Downstream Region",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010055","Coronary Artery Bypass Surgery","C51998","Surgery performed to bypass partially or completely occluded coronary arteries, thereby increasing the blood supply of the heart.","Coronary Artery Bypass Surgery | Aortocoronary Bypass | CAB | CABG | CORONARY ARTERY BYPASS GRAFT | Coronary Artery Bypass | Coronary Artery Bypass Graft | Coronary Artery Bypass Graft Surgery | Coronary Artery Bypass Grafting | Heart Bypass | aortocoronary bypass | coronary artery bypass",,,,,,,,,,,,,,,"4231998|4284104|4336464","Cardiac revascularization with bypass anastomosis|Aortocoronary artery bypass graft|Coronary artery bypass graft",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C1516119","Sorafenib","C61948","A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","Sorafenib | BA4 43 9006 | BAY 43 9006 | BAY 43-9006 | BAY 439006 | BAY-43-9006 | BAY439006 | Bay-439006 | SORAFENIB | sorafenib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1700685","Sunitinib Malate","C26673","The orally bioavailable malate salt of an indolinone-based tyrosine kinase inhibitor with potential antineoplastic activity.  Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.  This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.","Sunitinib Malate | Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1) | SU 011248 | SU 11248 | SU-011248 | SU-11248 | SU011248 | SU11248 | SUNITINIB MALATE | Sutent | sunitinib | sunitinib malate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1947934","Run By","C60820","Indicates the person or authoritative body who performed a test.","Run By | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037628","Solubility","C60821","The ability of a particular substance to dissolve in a particular solvent (yielding a saturated solution).","Solubility | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709850","Received By","C45265","Indicates the person or authoritative body who has received something.","Received By | Received by | Receiver",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882442","Precaution","C60827","A measure taken beforehand to prevent harm or secure good.","Precaution | Precautions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036043","Safety","C60828","The state of being certain that adverse effects will not be caused by some agent under defined conditions.","Safety | safety",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710183","Standard Operating Procedure","C48443","An established procedure to be followed in carrying out a given operation or in a given situation.","Standard Operating Procedure | SOP | standard operating procedures (SOPs)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448213","Instrumentation","C16742","Any object, or item of electrical or electronic equipment, which is designed to carry out a specific function or set of functions.","Instrumentation | Instrument",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1450054","Artificial nanoparticles","C62308","A small, stable particle whose size is measured in nanometers. These particles are used in various biomedical applications in which they can be utilized as drug carriers or imaging agents. Various targeting agents, such as antibodies, drugs, imaging agents, and reporters can be attached to the surface of a nanoparticle.","Nanoparticle | nanoparticle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596402","cytotoxicity","C27988","The adverse effect of some iatrogenic therapies. It is an accepted side effect in radiation therapy where the desired effect is to kill rapidly growing tumor cells.  In the killing of tumor cells, other cells that are rapidly growing e.g hair, mucous membranes are also killed.","Cytotoxicity | Lytotoxicity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596763","Immunotoxicity","C63814","Toxicity that impairs or damages the immune system.","Immunotoxicity | TOXICITY_IMMUNE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0598629","Hydrophobicity","C63813","The inherent characteristic of a molecule or substance to be immiscible in water. The property means that the moiety of interest does not dissolve in, absorb, or mix easily with water.","Hydrophobicity | Hydrophobic | Hydrophobic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1948047","Soluble (qualifier)","C64364","Capable of being dissolved in some solvent.","Soluble | soluble",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882508","Purity","C62352","A quantitative assessment of the homogeneity or uniformity of a mixture. Alternatively, purity refers to the degree of being free of contaminants or heterogeneous components.","Purity Assessment | Purity | Purity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883249","Surface Chemistry","C64351","The study of chemical reactions that occur at the interface of two phases.","Surface Chemistry | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0567416","Molecule","C63816","An aggregate of two or more atoms in a defined arrangement held together by chemical bonds.","Molecule | molecule",,,,,,,,,,,,,,,"4128355","Molecule",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1563732","Dendrimer","C62363","A polymeric molecule which has a highly-branched, three-dimensional architecture. Dendrimers are synthesized from monomers and new branches are added in discrete steps to form a tree-like architecture. A high level of synthetic control is achieved through step-wise reactions and purification at each step to regulate the size, architecture, functionality and monodispersity of the molecules. These polymers have desirable pharmacokinetic properties and a polyvalent array of surface groups that make them potential drug delivery vesicles.","Dendrimer | Cascade Molecule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1253959","Anatomic Branch","C61482","A part of a forking structure; a division or offshoot from a main stem.","Branch | BRANCHED | Bifurcated | Forked",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0597177","Particle","C63850","An object with finite mass and size parameters.","Particle | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025552","Metal","C637","Electropositive chemical elements characterised by ductility, malleability, luster, and conductance of heat and electricity. They can replace the hydrogen of an acid and form bases with hydroxyl radicals.","Metal | Metals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032521","Polymer","C48803","A substance made up of variable numbers of repeating structural units linked through covalent bonds.","Polymer | POLYMER SUBSTANCE | Polymeric | Polymeric Macromolecules | Polymers | polymer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023828","Liposome","C18208","Substances composed of layers of lipid that form hollow microscopic spheres within which drugs or agents could be contained for enhanced safety and efficacy.","Liposome | liposomal | liposome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0314672","Polymerization","C34072","The act or process of changing to a polymeric form. Polymerization consists of reactions that form a compound (polymer), usually of high molecular weight, by combination of simpler molecules (monomers).","Polymerization | Polymerized",,,,,,,,,,,,,,,"4139761","Polymerization",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516451","Chemical Modifier","C1932","A chemical that influences the properties of another chemical or biological function. (NCI)","Chemical Modifier | Modifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1138408","Carbon Nanotube","C62389","Fullerene-like nanostructures that consist of graphene cylinders. The ends of the construct are closed with pentagonal-shaped rings.","Carbon Nanotube | Nanotube",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007009","Carbon","C63798","A nonmetalic tetravalent element with symbol C, atomic number 6, and atomic weight 12.","Carbon | Elemental Carbon",,,,,,,,,,,,,,,"4337528","Carbon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1881985","Nanotube Chirality","C63926","A measure of the degree of geometrical symmetry in the structure of the nanotube. The resultant symmetry is quantified based upon the on the material properties of the construct.","Nanotube Chirality | Chirality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0220844","Growth","C64379","A process of becoming larger or longer or more numerous.","Growth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677535","Wall","C64373","A layer of material that encloses space or that encloses a structure.","Wall | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1258084","Quantum Dot","C62378","Nanometer-sized semiconductor particles, made of cadmium selenide (CdSe), cadmium sulfide (CdS) or cadmium telluride (CdTe) with an inert polymer coating. The semiconductor material used for the core is chosen based upon the emission wavelength range being targeted: CdS for UV-blue, CdSe for the bulk of the visible spectrum, and CdTe for far red and near-infrared. The size of the particle determines the exact color of a given quantum dot. The polymer coating protects cells from cadmium toxicity but also facilitates the attachment of a variety of targeting molecules, including monoclonal antibodies directed to tumor-specific biomarkers. Because of their small size, quantum dots can function as cell- and even molecule-specific markers that will not interfere with the normal cellular functions.","Quantum Dot | Quantum Dots",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0302934","Fullerene","C62382","One of three known pure forms of carbon that exhibits a spherical shape with a hollow interior. The number of carbon atoms comprising fullerenes is variable and several stable spherical carbon structures containing 70 or more atoms have been documented.","Fullerene | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014020","Emulsions","C63807","A suspension of liquid within another liquid or a dispersion consisting of two or more liquid phases.","Emulsion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881971","Nanoparticle Complex","C62364","A nanoparticle bound to another moiety of interest via a chemical or physical interaction.","Nanoparticle Complex | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032176","Platelet Aggregation Process","C16999","Any cell adhesion process that involves the association of platelets via adhesion molecules.","Platelet Aggregation Process | Platelet Aggregation | Platelet Aggregation",,,,,,,,,,,,,,,"4246065","Platelet aggregation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1167622","Molecular Interaction Process","C18219","Involves temporary, non-covalent binding of two or more molecules as a result of intermolecular physical forces and often involves spatial complementarity between the interacting objects.","Molecular Interaction Process | Binding | Molecular Interaction | Molecular Interaction | Physical Interaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036825","Serum Protein","C17126","Dissolved proteins of blood plasma.  These mainly consist of albumins and globulins and include antibodies and blood-clotting proteins.","Serum Protein | Plasma Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014431","Enzyme Induction","C41564","Enzyme Induction involves initiation of function of a biological molecule that possesses catalytic activity.","Enzyme Induction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1159825","Caspase Activation","C42784","Caspase Activation involves induction of the activity of intracellular cysteine endopeptidase family members kept inactive by mitochondrial surface proteins (BcL-2 Family) and involved in initial signaling and downstream proteolytic cleavages (at P1 aspartic acids) in inflammation and apoptotic cell death when signals block BcL-2 function and activators initiate caspase cascades.","Caspase Activation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516362","Cell Viability Process","C21099","A cellular process that directly affects the ability of a cell to repair damaged cell components. (NCI)","Cell Viability Process | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201610","Colony-Forming Unit-Granulocyte Macrophage Assay","C63799","A functional (qualitative) as well as quantitative assay that is utilized as an indicator of granulopoiesis reconstitution.","Colony-Forming Unit-Granulocyte Macrophage Assay | CFU-GM Assay | Colony Forming Unit Granulocyte Macrophage Assay | Colony Forming Unit-Granulocyte Macrophage Assay",,,,,,,,,,,,,,,"4264748","Colony forming unit-granulocyte/macrophage assay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031308","Phagocytosis","C26115","The process by which phagocytes engulf and digest microorganisms and cellular debris; an important defense against infection.","Phagocytosis | phagocytosis",,,,,,,,,,,,,,,"4208978","Phagocytosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008018","Chemotactic Process","C16422","The characteristic directional movement or orientation of an organism or cell along a chemical concentration gradient either toward or away from the chemical stimulus.","Chemotactic Process | Chemotaxis | Chemotaxis",,,,,,,,,,,,,,,"4286119","Chemotaxis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205263","Induction","C61367","The act of bringing about something.","Induction | Induce | Induced | Inducible | Inducing",,,,,,,,,,,,,,,"4039269","Induced",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009528","Complement Activation","C21519","Any physiologic process in which a protease directs the cleavage of complement components C4, C2, or factor B which then form the C3 and C5 convertases for the classical and lectin pathways, respectively. This process is involved in direct lysis of target cells, immune adherence and phagocytosis of pathogens, and recruitment and activation of immunocompetent cells.","Complement Activation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1155064","NK Cell Activation","C19940","NK Cell Activation involves interaction with virus-infected or transformed cells by diverse adhesion or co-stimulatory molecules and release of cytokines, chemokines, and lethal chemicals from granules.","NK Cell Activation | Natural Killer Cell Activation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1947904","Attachment (action)","C61470","The act of affixing one thing to another.","Attachment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0597357","Receptor","C18106","A protein located on the cell surface, or in the cytoplasm, that binds to a specific signaling factor, such as a hormone, antigen, or neurotransmitter, causing a conformational and functional change in the receptor molecule.  The ligand-bound receptor then alters its interaction with target molecules, which leads to changes in cellular physiology through modification of the activity of one or more signal transduction pathways.","Receptor | Receptor Protein | receptor",,,,,,,,,,,,,,,"4023249","Receptor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1879547","Activation","C64382","To cause something to start or to stimulate activity.","Activation | ACTIVATED | Activate | Activated | activate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1328819","Small Molecule","C48809","A molecule with a low molecular weight that is not determined by a genome sequence.","Small Molecule | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513403","Molecular Target","C16128","Every point of difference between premalignant or malignant cells and their normal counterparts is a potential target of opportunity for drug discovery - a molecular target of prevention or treatment.","Molecular Target | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205426","Not Classified","C64486","Not arranged or included in any specific grouping.","Unclassified | Not Classified",,,,,,,,,,,,,,,"4033700","Unclassified",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021521","Inorganic Chemical","C579","A broad class of substances, principally from mineral sources of non-biological origin, encompassing all those that do not include carbon and its derivatives as their principal elements.","Inorganic Chemical | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029224","Organic Chemical","C718","Molecule that contains atoms of the element carbon, usually combined with itself and with atoms of one or more other element such as hydrogen, oxygen, nitrogen, sulfur, phosphorus, chlorine, or fluorine. Excludes carbides, carbonates and carbon oxides.","Organic Chemical | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439855","Complex","C47881","Hard, involved or complicated, elaborate, having many parts.","Complex | ",,,,,,,,,,,,,,,"4013723","Complex",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0599894","cellular targeting","C64542","The process of directing an agent to a specific anatomic location.","Targeting | Targeted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028580","Nuclear Magnetic Resonance","C16921","A physical phenomenon involving the interaction of atomic nuclei placed in an external magnetic field with an applied electromagnetic field oscillating at a particular frequency. Magnetic conditions within the material are measured by monitoring the radiation absorbed and emitted by the atomic nuclei. It is the underlying principle of Magnetic Resonance Imaging (MRI).","Nuclear Magnetic Resonance | Magnetic Resonance | NMR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034519","Electromagnetic Radiation","C17050","The radiation of energy as transverse waves produced by moving charges.","Electromagnetic Radiation | EMR | Radiation | Radiation, Electromagnetic | Radiation-Total | electromagnetic radiation | radiation | radiation (unspecified type)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1456803","Ultrasonics (sound)","C64384","High frequency sound, generally with a frequency greater than 20,000 Hz.","Ultrasound | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041625","Ultraviolet Radiation","C17231","The invisible ultraviolet spectrum makes up one specific portion of sunlight. This unique portion accounts for three percent of all solar radiation reaching the earth. UV radiation causes many health problems.","Ultraviolet Radiation | Radiation, UV | Sun/Ultra-Violet Rays | UV | UV Radiation | UV radiation | ultraviolet radiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883676","Positive Control","C64356","A control sample that is known to produce a positive result if the test is working as expected.","Positive Control | POSITIVE CONTROL | Postive_Control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1382110","Powder","C45302","A solid substance in the form of tiny loose particles; a solid that has been pulverized.","Powder | ",,,,,,,,,,,,,,,"42710000","Powder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0302908","Liquid","C45298","A substance in the fluid state of matter having no fixed shape but a fixed volume.","Liquid | ",,,,,,,,,,,,,,,"4140681|42537331","Liquid substance|Liquid",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0596383","Copolymer","C63800","A chemical structure with a high molecular weight that is comprised of two or more monomer subunits. The monomers can be of the same or different composition.","Copolymer | Heteropolymer | copolymer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0444626","Crystal","C61303","A solid formed by the solidification of a chemical and having a highly regular atomic structure.","Crystal | CRYSTALS | Crystal Formation | Crystalline | Crystallized",,,,,,,,,,,,,,,"4138135","Crystal - natural material",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1948066","Fibril","C63809","A small slender fiber or filament","Fibril | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880194","Cube - faceted volume","C63804","An object that is comprised of six regular, solid, congruent square faces and has three equal axes at right angles to each other.","Cube | Cubic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708361","Hexagon","C48343","A six-sided polygon.","Hexagon | HEXAGON (6 sided) | Hexagonal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205271","Irregular","C63815","Lacking perfect symmetry or evenness.","Irregular | ",,,,,,,,,,,,,,,"4175788","Irregular",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882041","Needle Shape","C63846","The geometry of an object that resembles a needle, meaning that it has a long slender cylindrical shape.","Needle Shape | Needle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882135","Oblate","C63847","The geometry of an object that is shaped like a spheroid compressed at the poles.","Oblate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1947942","Rod Shape","C64352","An object resembling a slender bar.","Rod | Rod Shape",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332501","Sphere","C64353","A solid or hollow three-dimensional object bounded by a closed surface such that every point on the surface is equidistant from the center.","Sphere | Spherical",,,,,,,,,,,,,,,"4145295","Spherical shape",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883283","Tetrahedron","C63856","The geometry of an object which is comprised of a polyhedron containing four faces.","Tetrahedron | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883284","Tetrapod","C63857","The geometry of an object that consists of four rods in a tetrahedral arrangement.","Tetrapod | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205119","Triangle","C48353","A three-sided polygon.","Triangle | TRIANGLE | Triangular",,,,,,,,,,,,,,,"4099031","Triangular",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1947977","Ellipse","C64362","A closed plane curve resulting from the intersection of a circular cone and a plane cutting completely through it, especially a plane not parallel to the base.","Ellipse | Elliptical",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205114","Cylinder","C63806","A surface formed by circles of a given radius that are contained in a plane perpendicular to a given axis, whose centers align on the axis.","Cylinder | Cylindrical",,,,,,,,,,,,,,,"4164585","Cylindrical",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1880490","Ellipsoid","C64363","A surface whose plane sections are all ellipses or circles.","Ellipsoid | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0999699","Guinea Pig","C14211","The domesticated guinea pig, Cavia porcellus.","Guinea Pig | CAVIA PORCELLUS | Cavia porcellus | GUINEA PIG | Mammals, Guinea Pigs",,,,,,,,,,,,,,,"4052896","Domestic Guinea pig",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018557","Hamster","C14212","Any member of four genera of the rodent family Cricetidae; short-tailed Old World burrowing rodents with large cheek pouches.","Hamster | HAMSTER | Mammals, Hamsters | Mesocricetus",,,,,,,,,,,,,,,"4213421","Hamster",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007452","Cow","C14192","Domesticated ungulates that are raised for beef, dairy products, and leather, and used for labor.","Cow | BOVINE | Bos bovis | Bos primigenius taurus | Bos taurus | Bovine | Bovine Species | Cattle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019944","Horse","C14222","The domestic horse, Equus caballus.","Horse | Equine | Equine Species | Equus caballus | HORSE",,,,,,,,,,,,,,,"4149492","Horse",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1123019","Sheep","C14273","Any one of several species of ruminants of the genus Ovis, native of the higher mountains of both hemispheres, but most numerous in Asia; the domestic sheep, Ovis aries.","Sheep | Ovine | SHEEP",,,,,,,,,,,,,,,"4116827|4301952","Ovine|Genus Ovis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1136016","Sus scrofa domestica","C14280","The domestic pig Sus scrofa domestica.","Sus scrofa domestica | Domestic Pig | Pig",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043457","Zebrafish","C14287","Brachydanio rerio, species of small freshwater aquarium fish with a transparent embryo making it possible to follow progeny of single cells until quite late stages of development. This, together with the availability of mutant lines make it an important preparation for the study of vertebrate cell lineage and developmental biology.","Zebrafish | Brachydanio rerio | Cyprinus rerio | DANIO RERIO | Danio frankei | Danio rerio | Zebra danio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880402","Double-Walled Nanotube","C62390","A carbon nanotube comprised of two layers of graphitic carbon.","Double-Walled Nanotube | DWNT | Double Walled Nanotube",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883034","Single-Walled Nanotube","C62392","A carbon nanotube comprised of a single layer of graphitic carbon. These tubes may be metallic or semi-conducting depending on the chirality of the tube.","Single-Walled Nanotube | SWNT | Single Walled Nanotube",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881922","Multi-Walled Nanotube","C62391","A nanotube consisting of single-walled nanotubes layered inside each other.","Multi-Walled Nanotube | MWNT | Multi Walled Nanotube",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1948022","Shell (rigid covering)","C64372","A rigid covering that envelops an object.","Shell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596260","Carboxyl Group","C64369","The univalent radical -COOH; present in and characteristic of organic acids.","Carboxyl Group | Carboxy | Carboxyl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700307","hydroxyl group","C64370","The monovalent group -OH in such compounds as bases and some acids and alcohols.","Hydroxyl Group | Hydroxy | Hydroxyl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596072","Amine Group","C64371","The univalent hydrocarbon radical -NH2.","Amine Group | Amine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019204","Hepatocellular Carcinoma","C3099","A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.","Hepatocellular Carcinoma | CARCINOMA, HEPATOCELLULAR, MALIGNANT | Carcinoma of Liver Cells | Carcinoma of the Liver Cells | HCC | Hepatocellular Cancer | Hepatocellular carcinoma | Hepatoma | LIHC | Liver Cell Cancer (Hepatocellular Carcinoma) | Liver Cell Carcinoma | Liver cell carcinoma | Primary Carcinoma of Liver Cells | Primary Carcinoma of the Liver Cells | hepatocellular carcinoma | hepatoma","8170/3","Hepatocellular carcinoma, NOS",,,,,,,,,,,,,"4001171|4101758","Liver cell carcinoma|Hepatocellular carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0022674","Renal Tubule","C49274","The anatomical segment of the kidney that is comprised of both the nephron and associated collecting tubules. These tubules or tubes contain fluid that has been filtered through the glomerulus.","Renal Tubule | ",,,,,,,,,,,,,,,"4241597","Renal tubule structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705162","Transducer","C50226","An electrical device that converts one form of energy into another.","Transducer Device | Device Transducer | Transducer | Transducer Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038951","Survey","C17176","A document used in a method of data collection that involves interviewing (or giving questionnaires to) a representative and often large group of people.","Survey | Survey Instrument | survey",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054953","Hematopoietic Progenitor Cell Antigen CD34","C17280","Hematopoietic progenitor cell antigen CD34 (385 aa, ~41 kDa) is encoded by the human CD34 gene. This protein plays a role in cell-cell adhesion and may have a role in leukocyte migration.","Hematopoietic Progenitor Cell Antigen CD34 | CD34 | CD34 Antigen | CD34 antigen | HPCA1 | gp105-120",,,,,,,,,,,,,,,"4233215","Lymphocyte antigen CD34",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022688","Natural Killer Cell","C12536","Natural killer cells are cells that resemble large granular lymphocytes.  They do not express markers of either T or B cell lineage. They are positive for CD16, CD56, and CD 94.  These cells do possess Fc receptors for IgG and can kill target cells using antibody-dependent cell-mediated cytotoxicity. They can also use perforin to kill cells in the absence of antibody and killing may occur without previous sensitization.","Natural Killer Cell | Killer Cell | Killer Cells | NATURAL KILLER CELL | NK | NK Cell | NK Cells | NK cell | NK-Cell | NK-LGL | killer cell | natural killer cell",,,,,,,,,,,,,,,"4125090","NK-cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0483203","NRBC - Nucleated red blood cell present result","C35471","A morphologic finding indicating the presence of nucleated red cells in the peripheral blood.","Nucleated Red Blood Cells Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011305","Dendrite","C32447","A long, branching outgrowth or extension from a neuron, that carries electrical signals from synapses to the cell body; any structure that resembles a dendrite.","Dendrite | Dendritic",,,,,,,,,,,,,,,"4236181","Dendrite",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016030","Fibroblast","C12482","A connective tissue cell that makes and secretes collagen proteins.","Fibroblast | FIBROBLAST | Fibroblasts | fibroblast",,,,,,,,,,,,,,,"4200843","Fibroblast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0545406","Abutment","C66853","The tooth, teeth, or implant that supports a fixed bridge or removable prosthesis.","Abutment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879715","Apical Endodontic Surgery","C66854","Creation of a visual window of the apex of the root that includes retrofilling the apical portion of the root canal.","Apical Endodontic Surgery | Tooth Extraction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880862","Full Crown","C66855","A dental restoration completely covering the aspect of the tooth normally covered by enamel.","Full Crown | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881364","Lateral Condensation","C66856","An endodontic filling technique which compresses the filling material, gutta percha, parallel to the long tooth axis in the root canal.","Lateral Condensation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0597428","Sedimentation procedure","C54178","The act or process of settling particles by mechanical means from a state of suspension in air or water.","Sedimentation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510827","Affinity","C20604","The strength of noncovalent chemical binding between two substances as measured by the dissociation constant of the complex.","Affinity | affinity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023206","Lectin","C16785","Proteins that specifically bind to the branching sugar molecules of glycoproteins and glycolipids on cell surfaces to cause biochemical changes. They are often classified according to either the saccharide or sugar specificity.","Lectin | lectin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040549","Toxin","C894","A chemical, physical, or biological agent that causes disease or some alteration of the normal structure and function of an organism. Usually refers to poisonous substance produced during the metabolism and growth of certain microorganisms and some higher plant and animal species, or any poisonous isomer, homolog, or derivative of such a substance. It causes either permanent or reversible injury to the health of a living thing on contact or absorption, typically by interacting with biological macromolecules such as enzymes and receptors. Onset of effects may be immediate or delayed, and impairments may be slight or severe. (NCI)","Toxin | Toxins | toxin",,,,,,,,,,,,,,,"4214011","Toxin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516809","Elutriative Centrifugation","C18798","Separation of particles on the basis of their differential sedimentation rate.","Elutriative Centrifugation | Fractionation, Centrifugation, Elutriation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205352","Simple","C47880","Easy, not involved or complicated, not elaborate, having few parts.","Simple | ",,,,,,,,,,,,,,,"4028981","Simple",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0253527","MTA Cement","C66857","A cement like material used for apical seals and as a reparative material for perforation of the tooth root.","MTA Cement | Mineral Tri-oxide Aggregate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011459","Overdenture","C66858","A complete denture with additional support from remaining teeth that have been reshaped or altered prosthetically to permit the denture to fit over them.","Overdenture | ",,,,,,,,,,,,,,,"4175548","Overdenture",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882295","Partial Crown","C66859","A dental restoration incompletely covering the aspect of the tooth normally covered by enamel.","Partial Crown | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0729269","Periapical","C66860","At or around the apex of the root of a tooth.","Periapical | ",,,,,,,,,,,,,,,"4207304","Periapical",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882989","Secondary Caries","C66861","A carious lesion adjacent to an existing restoration.","Secondary Caries | ",,,,,,,,,,,,,,,"46270631","Secondary caries",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883308","Thermal Fill","C66862","An endodontic filling material which is comprised of gutta percha around a plastic core.","Thermal Fill | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883359","Tooth Canal","C66864","The anatomic space in the root of a tooth that contains nerves, blood vessels, and connective tissue.","Tooth Canal | Canal of Tooth | TOOTH CANAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226993","Crown","C32375","The portion of the tooth covered by enamel.","Crown | Corona Dentis | Crown of Tooth | Crown of the Tooth | Tooth Crown",,,,,,,,,,,,,,,"4328094","Structure of crown of tooth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001166","Acoustic","C16256","Having to do with sound or hearing.","Acoustic | acoustic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708511","Inheritance Mode","C45827","The manner in which a particular genetic trait or disorder is passed from one generation to the next.","Inheritance Mode | Inheritance Pattern | Mode of Inheritance | mode of inheritance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443299","Separate","C63803","Independent; not united or joint.","Separate | ",,,,,,,,,,,,,,,"4139956","Separate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0438154","Electrocardiographic Finding","C41328","Graphic representation and categorization of the electrical vectors produced by the depolarization and repolarization of myocardial tissue.","Electrocardiographic Finding | ECG Finding | Electrocardiographic Findings | ecg",,,,,,,,,,,,,,,"4156045","ECG finding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4017737","Atrial Flutter","C51224","A disorder characterized by an electrocardiographic finding of an organized, regular atrial rhythm with atrial rate of 240-340 beats per minute. Multiple P waves typically appear in the inferior leads in a saw tooth-like pattern between the QRS complexes. (CDISC)","Atrial Flutter | Atrial flutter",,,,,,,,,,,,,,,"314665","Atrial flutter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4227386","Wolff-Parkinson-White Syndrome","C35132","A cardiac conduction disorder characterized by an electrocardiographic finding of ventricular pre-excitation, which is a short PR interval and a long QRS interval with a delta wave. Most individuals are asymptomatic; however they can experience periods of palpitations, shortness of breath or syncope during tachycardic episodes.","Wolff-Parkinson-White Syndrome | WOLFF-PARKINSON-WHITE SYNDROME | WPW | Wolff-Parkinson-White syndrome",,,,,,,,,,,,,,,"4253363","Wolff-Parkinson-White pattern",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037052","Sick Sinus Syndrome","C62244","A constellation of signs and symptoms which may include syncope, fatigue, dizziness, and alternating periods of bradycardia and atrial tachycardia, which is caused by sinoatrial node dysfunction.","Sick Sinus Syndrome | SSS | Sick sinus syndrome",,,,,,,,,,,,,,,"4261842","Sick sinus syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035204","Respiratory System Disorder","C26871","A non-neoplastic or neoplastic disorder that affects the respiratory system. Representative examples include pneumonia, chronic obstructive pulmonary disease, pulmonary failure, lung adenoma, lung carcinoma, and tracheal carcinoma.","Respiratory System Disorder | Disorder of Respiratory System | Respiratory Disorder | Respiratory Disorder | Unspecified Respiratory Problem",,,,,,,,,,,,,,,"320136","Disorder of respiratory system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085430","Blood Transfusion","C15192","The injection of whole blood or a blood component directly into the bloodstream.","Blood Transfusion | BLOOD TRANSFUSION | Blood Component Transfusion | Transfusion | Transfusion of Blood Products | blood transfusion | transfusion",,,,,,,,,,,,,,,"4024656|4184733","Transfusion of blood product|Transfusion of blood component",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C4227545","Eczema","C3001","A form of dermatitis characterized by red, itchy, scaly, or crusty patches that can be chronic or intermittent.","Eczema | Atopic Dermatitis | Eczematous Dermatitis | eczema",,,,,,,,,,,,,,,"133835","Eczema",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0443146","Autoimmune","C37916","Pertaining to autoimmunity.","Autoimmune | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032181","Platelet Count","C51951","The determination of the number of platelets in a biospecimen.","Platelet Count | Anucleated Thrombocytes | PLAT | Platelet count | Platelets",,,,,,,,,,,,,,,"4267147","Platelet count",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883073","Electromagnetic Spectrum","C63808","A charted band of wavelengths of electromagnetic vibrations.","Electromagnetic Spectrum | Spectral | Spectrum | Spectrum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0058187","1,1-Dimethylhydrazine","C1072","A clear, colorless, flammable, hygroscopic liquid with a fishy smell that emits toxic fumes of nitrogen oxides when heated to decomposition, and turns yellow upon contact with air. 1,1-Dimethylhydrazine is mainly used as a high-energy fuel in jets and rockets, but is also used in chemical synthesis, in photography and to control the growth of vegetation. This substance is also found in tobacco products. Exposure to 1,1-dimethylhydrazine results in irritation of skin, eyes and mucous membranes, and can affect liver and central nervous system. 1,1-Dimethylhydrazine is reasonably anticipated to be a human carcinogen. (NCI05)","1,1-Dimethylhydrazine | 1,1-DIMETHYLHYDRAZINE | Dimazine | Dimethylhydrazine | UDMH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987634","Receptor Agonist","C1514","An agent that has affinity for a receptor and intrinsic activity at that receptor.","Agonist | RECEPTOR AGONIST | Receptor Agonist | agonist",,,,,,,,,,,,,,,"36675081","Receptor agonist",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002063","Alkalosis","C37909","An abnormally high alkalinity (low hydrogen-ion concentration) of the blood and other body tissues.","Alkalosis | ",,,,,,,,,,,,,,,"438730","Alkalosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0700624","Allergic","C37910","Pertaining to, caused by, affected with or of the nature of allergy.","Allergic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515941","American College of Radiology","C39314","An FDA-designated accrediting body that includes radiologists, radiation oncologists and medical physicists. The ACR focuses its activity on making imaging safe, effective and accessible trough its accreditation programs, research, and development of guidelines for quality imaging, and education.","American College of Radiology | ACR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706668","sipuleucel-T","C1985","A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells.  Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP. (NCI05)","Sipuleucel-T | APC 8015 | APC-8015 | APC8015 | APC8015 Vaccine | APC8015 Vaccine | PA2024 (PAP/GM-CSF)-Loaded Dendritic Cell Vaccine | Provenge | SIPULEUCEL-T | SipT | sipuleucel-T | sipuleucel-t",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4227418","Atrioventricular Block by ECG Finding","C26703","An electrocardiographic finding of delayed or blocked cardiac electrical impulse conduction from the atria to the ventricles at the level of the atrioventricular node.","Atrioventricular Block by ECG Finding | AV Block | AV block | Atrioventricular Block | Atrioventricular Block | Atrioventricular Block by EKG Finding",,,,,,,,,,,,,,,"316135","Atrioventricular block",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242444","Population at Risk","C17734","Population groups with an increased likelihood of a disease or other health issue, eg smoking, drug use, teen pregnancy.","At-Risk Population | Population at Risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516086","Attenuated Live Virus Vaccine","C1920","Live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strains capable of inducing protective immunity. Live-attenuated vaccines are used when a CD8+ T Cell (cellular cytotoxicity) response is desired.","Attenuated Live Virus Vaccine | Live Attenuated Viral Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3536735","Basal Body","C32183","A centriole-containing organelle that serves as the base and nucleation site for microtubules that form cilia or flagella.","Basal Body | Kinetosome",,,,,,,,,,,,,,,"4281549","Basal body of cilium or flagellum, not bacterial",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009938","Bruise/contusion intact skin","C37921","Injury of the soft tissues or bone without breaking the skin that is characterized by blood leakage into the surrounding area.","Bruise | Bruise/Contusion | Bruising",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516147","Calendar","C19459","A list or register of events; a tabular array of the days.","Calendar | Calendars",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0920425","Cancer Therapeutic Procedure","C16212","Any intervention for management of a malignant neoplasm.","Cancer Therapeutic Procedure | Cancer Therapy | Cancer Treatment | Cancer Treatment | Cancer_Treatment | Malignant Neoplasm Therapy | Malignant Neoplasm Treatment | anticancer therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007269","Carotene","C350","The general name for a group of pigments found in green, yellow, and leafy vegetables, and yellow fruits. The pigments are fat-soluble, unsaturated aliphatic hydrocarbons functioning as provitamins and are converted to vitamin A through enzymatic processes in the intestinal wall.","Carotene | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704387","Clonality","C18304","Related by descent from a single progenitor cell.","Clonality | Clonal | clonality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4011653","Conjunctivitis","C34504","Inflammation of the conjunctiva of the eye.","Conjunctivitis | Pink Eye | conjunctivitis",,,,,,,,,,,,,,,"379019","Conjunctivitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205202","Corrected","C37934","Having had errors or mistakes removed.","Corrected | ",,,,,,,,,,,,,,,"4143923","Corrected",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010803","Cytokeratin","C20693","Cytokeratins are a family of cysteine-rich fibrous structural proteins that form tough filaments or sheets. These proteins are the main component of intermediate filaments in the epidermis, hair, nails, horny tissues, and the organic matrix of tooth enamel.","Cytokeratin | Keratin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011306","Dendritic Cells","C12583","Immunocompetent cells of the lymphoid and hemopoietic systems and skin. They function morphologically and phenotypically by presenting or processing antigens, thereby stimulating cellular immunity. They represent the most potent antigen-presenting cells and, therefore, play a critical role in the primary T cell immune response.","Dendritic Cell | Dendritic Cells | dendritic cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511789","Desmoplastic","C41603","This term refers to the growth of fibrous or connective tissue. Some tumors elicit a desmoplastic reaction, the pervasive growth of dense fibrous tissue around the tumor. Scar tissue (adhesion) within the abdomen after abdominal surgery is another type of desmoplastic reaction. (MedicineNet.com)","Desmoplastic | Desmoplastic Reaction | desmoplastic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511980","Disease Grade Qualifier","C28076","A term that refers to the cellular differentiation of a malignant cellular infiltrate. A cancer is defined through grades I-IV (or 1-4), or as well, moderately, poorly differentiated or undifferentiated.","Disease Grade Qualifier | tumor grade | tumor_grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556083","English","C43853","Denotes the inhabitants of England, a person from there, or their descendants elsewhere.","English | ENGLISH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014412","Environmental Exposure","C16552","Exposure to potentially harmful chemical, physical, or biological agents via the environment.","Environmental Exposure | Environmental Exposures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1526986","Epidural Chemotherapy","C15683","Having to do with the space between the wall of the spinal canal and the covering of the spinal cord. An epidural injection is given into this space.","Epidural Chemotherapy | Epidural",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015426","Eyelid","C12713","A thin membrane of skin with the purpose of covering and protecting an eye.","Eyelid | EYELID | Palpebra | eyelid",,,,,,,,,,,,,,,"4196657","Eyelid structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017471","Germ Cell","C12597","Gametes, also known as sex cells or germ cells, are the cells that come together during fertilization or conception in organisms that reproduce sexually.  Their genetic complement consists of a single set of unpaired chromosomes.","Germ Cell | Gamete | Gametes | Germ Cells | Reproductive Cells | Sex Cell | Sexual Cell | germ cell | reproductive cell",,,,,,,,,,,,,,,"37219293","Germ cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1505203","HP protein, human","C37962","Haptoglobin (406 aa, ~45 kDa) is encoded by the human HP gene. This protein plays a role in tight junction disassembly, intestinal permeability, heme iron recycling, antimicrobial activity and the regulation of hydrogen peroxide catabolism.","Haptoglobin | HP | Zonulin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0220847","Hepatitis C Virus","C14312","A small, enveloped, positive sense single strand RNA virus in the family Flaviviridae. The genome consists of a single RNA molecule with a single open reading frame.","Hepatitis C Virus | HCV | HEPATITIS C VIRUS | Hepatitis C | Virus-Hepatitis C",,,,,,,,,,,,,,,"4268323","Hepatitis C virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020843","IgD","C566","An immunoglobulin isotype (subclass).  This isotype is expressed on naive B cells along with IgM.  Little is known about its physiologic role.","IgD | Immunoglobulin D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020846","IgE","C567","An immunoglobulin isotype (subclass).  This isotype has the unique ability to bind with high affinity to IgE receptors (FceRI) on mast cells and basophils and induce degranulation and cytokine production by these cells when they are crosslinked by antigen.  In addition to a central role in atopy and allergic responses, it has been speculated that IgE-mediated mast cell degranulation, by its release of mediators that increase vascular permeability, has an important role in the initiation of immune response in general.","IgE | Immunoglobulin E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704382","Imaging Technology","C18843","Any of a number of technologies that permits the visualization and acquisition of images into a physical or electronic record.","Imaging Technology | Imaging | Imaging Technologies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4229712","Lordosis","C34787","Abnormally increased curvature of the lumbar portion of the spinal column.","Lordosis | LORDOSIS",,,,,,,,,,,,,,,"37162301|73012","Hyperlordosis deformity of lumbar spine|Lordosis deformity of spine",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1334467","Lymphoplasmacytic Infiltrate","C35984","A finding referring to the presence of a cellular infiltrate that is composed of lymphocytes and plasma cells in a tissue sample.","Lymphoplasmacytic Infiltrate | LPI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439680","Lytic","C27963","Having to do with lysis. In biology, lysis refers to the disintegration of a cell by disruption of its plasma membrane. Lysis can be caused by chemical or physical means (e.g., high-energy sound waves) or by a virus infection.","Lytic | Lytic (related to plasma membrane) | lytic",,,,,,,,,,,,,,,"4114503","Lytic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0231218","Malaise","C3832","A feeling of general discomfort or uneasiness, an out-of-sorts feeling.","Malaise | ",,,,,,,,,,,,,,,"4272240","Malaise",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1513186","Metastatic/Recurrent","C25567","Refers to a tumor that has spread to anatomic sites away from the original site of growth or has reappeared in any anatomic site. The vast majority of such tumors are malignant.","Metastatic/Recurrent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513354","Mitotic","C37993","Pertaining to mitosis.","Mitotic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027912","Neuroendocrine System","C12945","A system of neurosecretory neurons that release hormones to the circulatory system.","Neuroendocrine System | Neuroendocrine | Neurosecretory System | neuroendocrine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0392209","Nutritional Status","C17993","The state of the body as influenced by the diet and the ability of the diet to maintain an overall healthy condition.","Nutritional Status | nutritional status",,,,,,,,,,,,,,,"4337839","Nutritional status",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518543","Off","C40450","No longer planned or scheduled (said of events).","Off | ",,,,,,,,,,,,,,,"4227075","Off",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029127","Optic Disc","C12760","A portion of the retina at which the axons of the ganglion cells exit the eyeball to form the optic nerve. No light-sensitive photoreceptors are contained within this portion of the retina.","Optic Disc | OPTIC DISC | Optic Disk | Optic Nerve Head | Optic Papilla",,,,,,,,,,,,,,,"4217170","Optic disc structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029921","Outpatient","C28293","A patient who comes to a healthcare facility for diagnosis or treatment but is not admitted for an overnight stay.","Outpatient | outpatient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031526","Philadelphia Chromosome","C28452","A translocation between chromosomes 9 and 22. It is the hallmark for chronic myelogenous leukemia (CML).","Philadelphia Chromosome | Ph | Philadelphia Translocation | Philadelphia chromosome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031837","Physics","C16989","The study of those aspects of nature which can be understood in a fundamental way in terms of elementary principles and laws; the laws and properties of matter, and the forces acting upon it.","Physics | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032718","Portal Vein","C33343","A short thick trunk vein that transports blood containing the absorbed products of digestion from the intestine directly to the liver.","Portal Vein | Hepatic Portal Vein | PORTAL VEIN | Portal vein structure (body structure) | VEIN, PORTAL | hepatic portal vein | portal vein",,,,,,,,,,,,,,,"4138976","Portal vein structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033416","Promyelocyte","C13114","A cell of the bone marrow that is derived from myeloblasts and will give rise to myelocytes, precursors of myeloid cells and neutrophil granulocytes.","Promyelocyte | ",,,,,,,,,,,,,,,"4184786","Promyelocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1305636","Pubic Hair","C33424","Hair growing in the pubic area.","Pubic Hair | ",,,,,,,,,,,,,,,"4105058","Entire hair of pubis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034108","Pulse Oximetry","C38085","A non-invasive method that provides estimates of arterial oxyhemoglobin saturation by utilizing selected wavelengths of light to determine the saturation of oxyhemoglobin.","Pulse Oximetry | PULSE OXIMETRY | pulse ox | pulse_ox",,,,,,,,,,,,,,,"4098046|45773001","Pulse oximetry|Pulse oximetry",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1527121","Radiolabeled","C18138","Any compound that has been joined with a radioactive substance.","Radiolabeled | radiolabeled",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514715","Rai Staging System","C20115","A staging system for Chronic Lymphocytic Leukemia.  Stage 0: absolute lymphocytosis (>15,000 per cubic millimeter) without adenopathy, hepatosplenomegaly, anemia, or thrombocytopenia; Stage I: absolute lymphocytosis with lymphadenopathy without hepatosplenomegaly, anemia, or thrombocytopenia; Stage II: absolute lymphocytosis with either hepatomegaly or splenomegaly, with or without lymphadenopathy; Stage III: absolute lymphocytosis and anemia (hemoglobin <11 g/dL) with or without lymphadenopathy, hepatomegaly, or splenomegaly; Stage IV: absolute lymphocytosis and thrombocytopenia (<100,000 per cubic millimeter) with or without lymphadenopathy, hepatomegaly, splenomegaly, or anemia.  (from OncoLink)","Rai Staging System | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514882","NCI Annual Fact Book","C19471","An annual report, compiled and published by the staff of the financial management branch, detailing how the NCI distributed its budget among the various research programs and funding mechanisms. It also contains funding policies influencing grant awards, and comparisons with prior year allocations.","NCI Annual Fact Book | Research Project Summaries | Research Project Summaries",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0080129","S Phase Process","C17395","Phase of the cell cycle following G1 and preceding G2 when the entire DNA content of the nucleus is replicated (Synthesis phase). It is achieved by bidirectional replication at multiple sites along each chromosome.","S Phase Process | S Phase | S Phase | Synthesis Period | Synthesis Phase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036410","Sclera","C12784","The white, opaque, fibrous, outer tunic of the eyeball, covering it entirely excepting the segment covered anteriorly by the cornea. It is essentially avascular but contains apertures for vessels, lymphatics, and nerves. It receives the tendons of insertion of the extraocular muscles and at the corneoscleral junction contains the canal of Schlemm. (From Cline et al., Dictionary of Visual Science, 4th ed)","Sclera | EYE, SCLERA | Human Sclera | SCLERA | White of Eye | sclera",,,,,,,,,,,,,,,"4091162","Scleral structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036690","Septicemia","C3364","The presence of pathogenic microorganisms in the blood stream causing a rapidly progressing systemic reaction that may lead to shock. Symptoms include fever, chills, tachycardia, and increased respiratory rate. It is a medical emergency that requires urgent medical attention.","Septicemia | Sepsis | Sepsis Syndrome | Systemic Sepsis | blood poisoning | sepsis | septicemia | toxemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037868","Spermatozoon","C12602","The male reproductive cell that is formed in the testicle. A sperm consists of a head, a body, and a tail that provides propulsion.","Spermatozoon | SPERMATOZOON | Sperm | Sperm Cell | Spermatic | Spermatozoa | Zoosperm | sperm",,,,,,,,,,,,,,,"4283960","Spermatozoa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0521329","Spinal","C38026","Of or relating to the spine or spinal cord.","Spinal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522565","Ventricular","C38055","Of or relating to a ventricle (of the heart or brain).","Ventricular | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042905","Vitreous Body","C33884","A clear, avascular, gelatinous body that occupies the posterior chamber of the eye.  It is bounded by the retina except anteriorly where it lies adjacent to the lens and iris.","Vitreous Body | EYE, VITREOUS",,,,,,,,,,,,,,,"4165531","Vitreous body structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013839","Electromyography","C38056","An assessment of skeletal muscle function and nerve control, obtained by recording and studying the intrinsic electrical properties of the muscles.","Electromyography | ELECTROMYOGRAPHY | EMG | EMG",,,,,,,,,,,,,,,"4179815","Electromyography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1415576","HLA-DRB1 Gene","C19409","This gene is involved in immunoregulation and antigen presentation. The gene has several hundred alleles and polymorphism typing is routinely performed for bone marrow and kidney transplantation.","HLA-DRB1 Gene | HLA-DRB1 | HLA-DRB1 | Major Histocompatibility Complex, Class II, DR Beta 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0595850","Intracranial Route of Administration","C38236","Administration of a drug within the skull.","Intracranial Route of Administration | I-CRAN | INTRACRANIAL | Intracranial | Intracranial",,,,,,,,,,,,,,,"4171079","Intracranial",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0740437","Infectious Otitis Externa","C3299","Inflammation of the anatomical structures of the outer ear and ear canal secondary to an infectious process. Bacterial etiology is most common, but fungal infection is also possible. Symptoms include erythema, edema, and pain.","Infectious Otitis Externa | External Ear Infection | External Ear Infection | Otitis Externa | Otitis Externa | Otitis externa | Outer Ear Infection | Swimmer's Ear",,,,,,,,,,,,,,,"4298713","Infection of external ear",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035440","Acute Rheumatic Heart Disease","C34985","Pancarditis, involving inflammation of the endocardium, myocardium, and epicardium. It results from an autoimmune reaction following an infection with Streptococcus pyogenes (Group A Streptococci).","Acute Rheumatic Heart Disease | Acute rheumatic heart disease, unspecified",,,,,,,,,,,,,,,"313500","Acute rheumatic heart disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1442881","SLC25A4 protein, human","C37299","ADP/ATP translocase 1 (298 aa, ~33 kDa) is encoded by the human SLC25A4 gene. This protein is involved in the transport of ADP and ATP across the mitochondrial inner membrane.","ADP/ATP Translocase 1 | ADP,ATP Carrier Protein 1 | ADP,ATP Carrier Protein, Heart/Skeletal Muscle | ADP,ATP Carrier Protein, Heart/Skeletal Muscle Isoform T1 | ADP-ATP Translocase-1 | ADP/ATP Carrier 1 | ADP/ATP Carrier Protein | ADP/ATP Translocator of Skeletal Muscle 1 | ANT | ANT1 | Adenine Nucleotide Translocator 1 | Adenine Nucleotide Translocator-1 | Adenine Nucleotide Translocator-1 | Heart-Skeletal Muscle ADP-ATP Carrier Protein-T1 | Heart/Skeletal Muscle ATP/ADP Translocator | Mitochondrial Adenine Nucleotide Translocator Solute Carrier Family 25 Member-4 | SLC25A4 | Skeletal Muscle Adenine Nucleotide Translocator-1 | Solute Carrier Family 25 Member 4 | T1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278766","Allopurinol Sodium","C2564","The sodium form of allopurinol, which is a structural isomer of hypoxanthine. Allopurinol inhibits xanthine oxidase, an enzyme that converts oxypurines to uric acid. By blocking the production of uric acid, this agent decreases serum and urine concentrations of uric acid, thereby providing protection against uric acid-mediated end organ damage in conditions associated with excessive production of uric acid, i.e. the massive cell lysis associated with the treatment of some malignancies. (NCI04)","Allopurinol Sodium | 1,5-Dihydro-4H-pyrazolo[3,4-d]pryimidin-4-one Monosodium Salt | 1H-Pyrazolo(3,4-d)pyrimidin-4-ol Monosodium Salt | ALLOPURINOL SODIUM | Adenock | Allo-Puren | Allozym | Allural | Aloprim | Aloral | Alositol | Anoprolin | Anzief | Apulonga | Apurin | Apurol | BW 56158 | BW-56158 | Bleminol | Bloxanth | Caplenal | Cellidrin | Cosuric | Dabroson | Embarin | Epidropal | Foligan | Geapur | Gichtex | Hamarin | Hexanurat | Ketanrift | Ketobun-A | Ledopur | Lopurin | Lysuron | Miniplanor | Monarch | Nektrohan | Remid | Riball | Sodium allopurinol | Suspendol | Takanarumin | Urbol | Uricemil | Uripurinol | Urosin | Urtias | Xanturat | Zyloprim | Zyloric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324875","Armadillo","C14185","Any of several small, burrowing, chiefly nocturnal mammals with body covered with strong horny plates.","Armadillo | Dasypodidae | Mammals, Armadillos",,,,,,,,,,,,,,,"4025700","Dasypodidae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015028","Ethmoid Sinus","C12276","A sinus of the meatuses of the nasal cavity.","Ethmoid Sinus | ETHMOID SINUS | Ethmoid sinus | Ethmoid sinus structure (body structure) | Sinus, Ethmoid | ethmoid sinus",,,,,,,,,,,,,,,"4182234","Ethmoid sinus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017287","Gene Rearrangement Process","C16611","Any DNA sequence rearrangement that results in the creation of a novel protein-coding capacity. Within certain genes, gene rearrangement is a normal part of development, facilitating the affinity maturation of B and T lymphocytes as well as class switching of immunoglobulins.","Gene Rearrangement Process | Gene Rearrangement",,,,,,,,,,,,,,,"4183442","Gene re-arrangement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017681","Glottis","C12724","The space in which the vocal cords are located.","Glottis | GLOTTIS | Glottis structure (body structure) | glottis",,,,,,,,,,,,,"UBERON:0002486","glottis","4047227","Glottis structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024957","Maxillary Sinus","C12275","A pyramidal-shaped, thin-walled, air-filled cavity located in the maxilla. It is lined by mucus membrane and periosteum (mucoperiosteum) which contains cilia. It is adjacent to the nasal cavity and communicates with the middle meatus of the nose. It is the largest paranasal sinus and is composed of three recesses: alveolar, zygomatic, and infraorbital.","Maxillary Sinus | Antrum Highmori | Antrum of Highmore | Antrum of Highmori | Antrum, Maxillary | Apertura Sinus Maxillaris | MAXILLARY SINUS | Maxillary sinus | Maxillary sinus structure (body structure) | Sinus(es), Maxillary | Sinus, Maxillary | antrum of Highmore | maxillary sinus | sinus maxilliaris",,,,,,,,,,,,,"UBERON:0001764","maxillary sinus","4050631","Maxillary sinus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1514253","Postal","C38009","Of or relating to the system for delivering mail.","Postal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456475","Subglottis","C12280","The area of the larynx below the vocal cords down to the trachea.","Subglottis | SUBGLOTTIS | infraglottic part of larynx | subglottic larynx | subglottic region | subglottis",,,,,,,,,,,,,"UBERON:0036068","subglottis","4002724","Subglottis structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0225574","Supraglottis","C12279","The upper part of the larynx, including the epiglottis; the area above the vocal cords.","Supraglottis | SUPRAGLOTTIS | supraglottic larynx | supraglottic part of larynx | supraglottis",,,,,,,,,,,,,"UBERON:0036263","supraglottic part of larynx","4001049","Supraglottis structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1556156","Caloric Intake","C28135","Refers to the number of calories (energy content) consumed.","Caloric Intake | caloric intake",,,,,,,,,,,,,,,"4022856","Nutrient intake",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0681263","Spatial Design","C41149","Refers to the ways in which objects or bodies are placed in space and in relation to each other.","Spatial Design | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520227","101/H Mouse","C37318","definition pending","101/H Mouse | 101/H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520229","101/Rl Mouse","C37319","definition pending","101/Rl Mouse | 101/Rl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520439","129 Mouse","C15151","Inbr and colour depends on substrain (see below). Origin: Dunn 1928 from crosses of coat colour stocks from English fanciers and a chinchilla stock from Castle. This strain has a common origin with strain 101. Most substrains carry the white-bellied agouti gene AW though only a subset have the agouti pattern as many carry albino or chinchilla and/or the pink-eyed dilution gene, p, which is derived from Asian mice of the Mus musculus type (see also strains SJL, P/J and FS/Ei). (Jackson Labs/Festing)","129 Mouse | 129",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520440","129/Sv Mouse","C37320","Derived by Dunn (1928) from a mouse/chinchilla cross, the 129/Sv substrain has been recognized as a member of the Parental subgroup of substrains. Strain 129/SvJ was genetically contaminated in 1978 by an unknown strain and differs from other 129 substrains at 25% of SSLP genetic markers, therefore a nomenclature re-designation of 129cX/Sv has been suggested.","129/Sv Mouse | 129/SV | 129/Sv",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520413","129P1/Re Mouse","C37321","definition pending","129P1/Re Mouse | 129P1/Re",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520412","129P1/ReJ Mouse","C37322","definition pending","129P1/ReJ Mouse | 129P1/ReJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520411","129P1/ReJLacFib Mouse","C37323","definition pending","129P1/ReJLacFib Mouse | 129P1/ReJLacFib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520415","129P2/Ola Mouse","C37324","definition pending","129P2/Ola Mouse | 129P2/Ola",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520414","129P2/OlaHsd Mouse","C37325","definition pending","129P2/OlaHsd Mouse | 129P2/OlaHsd",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520416","129P2/SvOla Mouse","C37326","definition pending","129P2/SvOla Mouse | 129P2/SvOla",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520418","129P3/J Mouse","C37327","definition pending","129P3/J Mouse | 129P3/J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520417","129P3/JEmsJ Mouse","C37328","definition pending","129P3/JEmsJ Mouse | 129P3/JEmsJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520422","129P4/Rr Mouse","C37329","definition pending","129P4/Rr Mouse | 129P4/Rr",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520419","129P4/RrJ Mouse","C37330","definition pending","129P4/RrJ Mouse | 129P4/RrJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520420","129P4/RrRkJ Mouse","C37331","definition pending","129P4/RrRkJ Mouse | 129P4/RrRkJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520421","129P4/RrSv Mouse","C37332","definition pending","129P4/RrSv Mouse | 129P4/RrSv",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520434","129S/Sv Mouse","C37333","definition pending","129S/Sv Mouse | 129S/Sv",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520433","129S/SvEv Mouse","C37334","definition pending","129S/SvEv Mouse | 129S/SvEv",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520424","129S1/Sv Mouse","C37335","definition pending","129S1/Sv Mouse | 129S1/Sv",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520423","129S1/SvImJ Mouse","C37336","definition pending","129S1/SvImJ Mouse | 129S1/SvImJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520426","129S2/SvPas Mouse","C37337","definition pending","129S2/SvPas Mouse | 129S2/SvPas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520425","129S2/SvPasIco Mouse","C37338","definition pending","129S2/SvPasIco Mouse | 129S2/SvPasIco",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520427","129S3/SvImJ Mouse","C37339","definition pending","129S3/SvImJ Mouse | 129S3/SvImJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520429","129S4/SvJae Mouse","C37340","definition pending","129S4/SvJae Mouse | 129S4/SvJae",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520428","129S4/SvJaeSor Mouse","C37341","definition pending","129S4/SvJaeSor Mouse | 129S4/SvJaeSor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520430","129S5/SvEvBrd Mouse","C37342","definition pending","129S5/SvEvBrd Mouse | 129S5/SvEvBrd",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520431","129S6/SvEvTac Mouse","C37343","definition pending","129S6/SvEvTac Mouse | 129S6/SvEvTac",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520432","129S7/SvEvBrd Mouse","C37344","definition pending","129S7/SvEvBrd Mouse | 129S7/SvEvBrd",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520436","129T2/SvEms Mouse","C37345","definition pending","129T2/SvEms Mouse | 129T2/SvEms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520435","129T2/SvEmsJ Mouse","C37346","definition pending","129T2/SvEmsJ Mouse | 129T2/SvEmsJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520438","129X1/Sv Mouse","C37347","definition pending","129X1/Sv Mouse | 129X1/Sv",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520437","129X1/SvJ Mouse","C14579","definition pending","129X1/SvJ Mouse | 129X1/SvJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522424","A Mouse","C37348","definition pending","A Mouse | A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510706","A/He Mouse","C14652","definition pending","A/He Mouse | A/He",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510705","A/HeJ Mouse","C37349","definition pending","A/HeJ Mouse | A/HeJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510707","A/J Mouse","C14650","Derived by Strong (1921) from a cross between the Cold Spring harbor and Bagg Albino stocks. The A strain mouse has an albino coat (genotype a,b,c) and is susceptible to carcinogen-induced lung adenomas and cleft palate formation in response to cortisone. Also, the strain has defective macrophage function reminiscent of lps mutation common to other strains. The A strain has intermediate breeding performance with a high ratio of females at birth and a low litter size at weaning.","A/J Mouse | A/J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510708","A/JOlaHsd Mouse","C37350","definition pending","A/JOlaHsd Mouse | A/JOlaHsd",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510709","A/WySnJ Mouse","C37351","definition pending","A/WySnJ Mouse | A/WySnJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510677","A2G Mouse","C14647","definition pending","A2G Mouse | A2G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510680","ABH Mouse","C14983","definition pending","ABH Mouse | ABH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510681","ABP/LeJ Mouse","C37352","definition pending","ABP/LeJ Mouse | ABP/LeJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510687","AEJ/Gn Mouse","C37353","definition pending","AEJ/Gn Mouse | AEJ/Gn",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025918","AKR Mouse","C37354","definition pending","AKR Mouse | AKR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515841","AKR/J Mouse","C14505","Originally disseminated by Detweiler and carried by Furth (1928-1936) and the Rockefeller Institute for subsequent generations. The AKR mouse has an albino coat (genotype a, B, c) and is highly susceptible to leukemias. The strain is viremic from birth in that all tissues express the AKV retrovirus and copies of the AKV genome are integrated in the mouse genome, which is associated with leukemia development. The AKR strain is also a source of the Thy1.1 thymocyte antigen, which is expressed on thymocyte, bone marrow and T cell progenitors and is used as a marker for a variety of stem cells. The strain has a low reproductive performance with small litter sizes at birth and weaning.","AKR/J Mouse | AKR/J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515842","AKR/N Mouse","C37355","definition pending","AKR/N Mouse | AKR/N",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1523976","ALR Mouse","C37356","definition pending","ALR Mouse | ALR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510704","AU/SsJ Mouse","C14639","definition pending","AU/SsJ Mouse | AU/SsJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025919","BALB/c Mouse","C37357","Derived from albino mice stocks originally disseminated by Bagg (1913) to Snell in 1932 that has an albino coat with genotype A,b,c. The BALB/c mouse develops plasmacytomas upon injection with mineral oil, which form the mouse cell component of the mouse-human hybrid cells that are used in the production of monoclonal antibodies. This strain exhibits excellent breeding performance and a long life span which contribute to its being one of the most highly utilized of all available mouse strains.","BALB/c Mouse | BALB/C | BALB/c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516109","BALB/cAnPt Mouse","C37358","definition pending","BALB/cAnPt Mouse | BALB/cAnPt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516111","BALB/cBy Mouse","C37359","definition pending","BALB/cBy Mouse | BALB/cBy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516110","BALB/cByJ Mouse","C37360","definition pending","BALB/cByJ Mouse | BALB/cByJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516112","BALB/cCrl Mouse","C37361","definition pending","BALB/cCrl Mouse | BALB/cCrl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516113","BALB/cHeA Mouse","C37362","definition pending","BALB/cHeA Mouse | BALB/cHeA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516114","BALB/cJ Mouse","C14657","definition pending","BALB/cJ Mouse | BALB/cJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516115","BALB/cRl Mouse","C37363","definition pending","BALB/cRl Mouse | BALB/cRl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516139","BDP/J Mouse","C14595","definition pending","BDP/J Mouse | BDP/J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511028","BTBR Mouse","C37364","definition pending","BTBR Mouse | BTBR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511027","BTBRTF Mouse","C37365","definition pending","BTBRTF Mouse | BTBRTF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511031","BUB/BnJ Mouse","C14987","definition pending","BUB/BnJ Mouse | BUB/BnJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025920","C3H Mouse","C37366","definition pending","C3H Mouse | C3H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511366","C3H/He Mouse","C37367","Derived from the C3H progenitor strain that was passed to Heston in 1941. The C3H/He mouse has an agouti coat color, genotype +, rd and is wild type at the lps locus.","C3H/He Mouse | C3H/He",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511361","C3H/HeH Mouse","C37368","definition pending","C3H/HeH Mouse | C3H/HeH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511362","C3H/HeJ Mouse","C37369","Derived from the C3H progenitor strain that was passed to Heston in 1941 and to Jackson Lab in 1947. The C3H/HeJ mouse has an agouti coat color (genotype +, rd) and 90% of non-fostered offspring developed mammary tumors by 11 months or age. Fostered offspring have a high incidence of hepatomas.","C3H/HeJ Mouse | C3H/HeJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511363","C3H/HeN Mouse","C37370","definition pending","C3H/HeN Mouse | C3H/HeN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511364","C3H/HeOuJ Mouse","C37371","definition pending","C3H/HeOuJ Mouse | C3H/HeOuJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511365","C3H/HeSnJ Mouse","C37372","definition pending","C3H/HeSnJ Mouse | C3H/HeSnJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511367","C3H/Rl Mouse","C37373","definition pending","C3H/Rl Mouse | C3H/Rl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511368","C3HeB/FeJ Mouse","C37374","definition pending","C3HeB/FeJ Mouse | C3HeB/FeJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025921","C57BL Mouse","C37375","definition pending","C57BL Mouse | C57BL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511377","C57BL/10 Mouse","C37376","Derived by Little (1921) from A Lathrop stocks and separated out before 1937. The C57BL/10 strain carries a Y chromosome of Asian Mus musculus origin and a LINE-1 element from Mus spretus, suggesting that up to 6.5% of the genome is Mus spretus in origin. Substrain C57BL/10 differs from other substrains at multiple loci, including H9, Igh2 and Lv, on chromosome 4 and has a high incidence of spontaneous mutations. The mouse model has a 30% spontaneous tumor formation in both sexes, these tumors are comprised mostly of lymphomas. The C57BL/10 strain exhibits good reproductive performance.","C57BL/10 Mouse | C57BL/10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511373","C57BL/10J Mouse","C37377","definition pending","C57BL/10J Mouse | C57BL/10J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511374","C57BL/10ScSnJ Mouse","C37378","definition pending","C57BL/10ScSnJ Mouse | C57BL/10ScSnJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511376","C57BL/10Sn Mouse","C37379","definition pending","C57BL/10Sn Mouse | C57BL/10Sn",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521751","C57BL/6 Mouse","C14424","Derived by Little (1921) from A Lathrop stocks and separated out before 1937, the C57BL/6 mouse has a black coat and is one of the most widely used inbred strains. It accounts for 14% of all mouse inbred strain laboratory usage. The strain carries a Y chromosome of Asian Mus musculus origin and a LINE-1 element from Mus spretus, suggesting that up to 6.5% of the genome is Mus spretus in origin. Substrain C57BL/6 differs from other substrains at multiple loci, including H9, Igh2 and Lv, on chromosome 4. This mouse model is prone to the development of fatty lesions in the aorta similar to atheromatous plaque in humans, as well as hyperglycemia, hyperinsulinemia, hypercholesterolemia and non-insulin-dependent diabetes mellitus in response to a high fat diet. The C57BL/6 strain exhibits good reproductive performance and hermaphroditism in this substrain has been shown to occur.","C57BL/6 Mouse | B6 | C57BL/6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511379","C57BL/6By Mouse","C37381","definition pending","C57BL/6By Mouse | C57BL/6By",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511378","C57BL/6ByJ Mouse","C37382","definition pending","C57BL/6ByJ Mouse | C57BL/6ByJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511380","C57BL/6JEiJ Mouse","C37383","definition pending","C57BL/6JEiJ Mouse | C57BL/6JEiJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511381","C57BL/6JN Mouse","C37384","definition pending","C57BL/6JN Mouse | C57BL/6JN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511382","C57BL/6N Mouse","C37385","definition pending","C57BL/6N Mouse | C57BL/6N",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511383","C57BL/6Pas Mouse","C37386","definition pending","C57BL/6Pas Mouse | C57BL/6Pas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511384","C57BL/Ka Mouse","C37387","definition pending","C57BL/Ka Mouse | C57BL/Ka",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511372","C57BLKS Mouse","C14545","definition pending","C57BLKS Mouse | C57BLKS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511371","C57BLKS/J Mouse","C37388","definition pending","C57BLKS/J Mouse | C57BLKS/J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511385","C57BR Mouse","C37389","definition pending","C57BR Mouse | C57BR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511386","C57BR/cdJ Mouse","C37390","definition pending","C57BR/cdJ Mouse | C57BR/cdJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511388","C57L Mouse","C37391","definition pending","C57L Mouse | C57L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511387","C57L/J Mouse","C14519","definition pending","C57L/J Mouse | C57L/J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511390","C58 Mouse","C37392","definition pending","C58 Mouse | C58",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511389","C58/J Mouse","C14515","definition pending","C58/J Mouse | C58/J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511400","CASA/RkJ Mouse","C37393","definition pending","CASA/RkJ Mouse | CASA/RkJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511402","CAST/Ei Mouse","C14867","definition pending","CAST/Ei Mouse | CAST/Ei",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511401","CAST/EiJ Mouse","C37394","definition pending","CAST/EiJ Mouse | CAST/EiJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025922","CBA Mouse","C37395","definition pending","CBA Mouse | CBA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511405","CBA/Ca Mouse","C37396","The CBA mouse from Strong (1920) was disseminated to Jackson Laboratory and then onto Haldane and Gruneberg (1932) and finally onto Carter (1947). The CBA/Ca female mice have long life spans whilst males have short life spans. Both males and females have high ceruloplasmin levels. The CBA/Ca substrain is used most commonly in British scientific and pre-clinical trial research.","CBA/Ca Mouse | CBA/CA | CBA/Ca",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511403","CBA/CaH Mouse","C37397","definition pending","CBA/CaH Mouse | CBA/CaH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511404","CBA/CaJ Mouse","C37398","definition pending","CBA/CaJ Mouse | CBA/CaJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511407","CBA/N Mouse","C37400","definition pending","CBA/N Mouse | CBA/N",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511436","CE/J Mouse","C15109","definition pending","CE/J Mouse | CE/J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511471","CZECHII Mouse","C37401","definition pending","CZECHII Mouse | CZECHII",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511646","DBA/1 Mouse","C14606","Derived from crosses made by Little in 1929-1930 between DBA progenitors. The DBA/1 mouse has a q H2 haplotype and carries the Cdh23^ahl mutation that results in progressive hearing loss after 10 months of age. The DBA/1 and DBA/2 mice differ at loci Car2, Ce2, Hc, H2, If1, Lsh, Tla, and Qa3. The strain is commonly used as a model for rheumatoid arthritis as it mimics hallmarks of the human disease when immunized with type II collagen.","DBA/1 Mouse | DBA/1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511647","DBA/1J Mouse","C37403","definition pending","DBA/1J Mouse | DBA/1J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511648","DBA/1LacJ Mouse","C37404","definition pending","DBA/1LacJ Mouse | DBA/1LacJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511649","DBA/2 Mouse","C14604","Derived from crosses made by Little in 1929-1930 between DBA progenitors. The DBA/2 mouse has a d H2 haplotype and carries the Cdh23ahl mutation that results in a progressive hearing loss beginning at 3-4 weeks of age and severe hearing loss after 3 months of age. Alleles GpnmbR150X and Tyrp1isa contribute to an eye phenotype that closely resembles human hereditary glaucoma. The DBA/2 mouse strain shows severe intolerance to alcohol and morphine and is naturally CD94 deficient.","DBA/2 Mouse | DBA/2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511650","DBA/2N Mouse","C37405","definition pending","DBA/2N Mouse | DBA/2N",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511653","DDK Mouse","C14766","definition pending","DDK Mouse | DDK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511654","DDY Mouse","C14777","definition pending","DDY Mouse | DDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511708","DW/J Mouse","C15031","definition pending","DW/J Mouse | DW/J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517101","FVB Mouse","C37406","definition pending","FVB Mouse | FVB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517102","FVB/N Mouse","C14474","NIH general purpose Swiss mice were selected for resistance or sensitivity to histamine challenge following pertussis vaccination. The sensitive strain, HFSF/N, was subsequently found to have the Fv1b allele, which sensitizes the mice to B strain Friend Leukemia virus. The FVB/N strain has an albino coat with genotype A,B,c,D,P, and has a vigorous reproductive performance. This strain is commonly used in the generation of transgenic mice due to the fact that the pronuclei of FVB/N fertilized oocytes are prominent, which allows for ease of microinjection.","FVB/N Mouse | FVB/N",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512321","HRS/J Mouse","C37407","definition pending","HRS/J Mouse | HRS/J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512607","I/LnJ Mouse","C14594","definition pending","I/LnJ Mouse | I/LnJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025925","ICR Mouse","C37408","definition pending","ICR Mouse | ICR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517689","LG/J Mouse","C15043","definition pending","LG/J Mouse | LG/J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517698","LP/J Mouse","C37409","definition pending","LP/J Mouse | LP/J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517699","LT/SvJ Mouse","C37410","definition pending","LT/SvJ Mouse | LT/SvJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518112","MA/MyJ Mouse","C14512","definition pending","MA/MyJ Mouse | MA/MyJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518135","MOLD/RkJ Mouse","C37411","definition pending","MOLD/RkJ Mouse | MOLD/RkJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518136","MOLF/EiJ Mouse","C37412","definition pending","MOLF/EiJ Mouse | MOLF/EiJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518139","MRL/MpJ Mouse","C37413","definition pending","MRL/MpJ Mouse | MRL/MpJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518140","MSM/Ms Mouse","C37414","definition pending","MSM/Ms Mouse | MSM/Ms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513839","NFS/N Mouse","C37415","definition pending","NFS/N Mouse | NFS/N",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513843","NIH Mouse","C14476","definition pending","NIH Mouse | NIH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513846","NMRI Mouse","C37416","Derived from a Swiss type mouse that C. Lynch passed onto Poiley at NIH in 1937. This strain, then known as NIH/PI, was maintained as an inbred strain and was passed onto the Naval Medical Research Institute at F51. The NMRI mouse has a white coat color (albino) with genotype A/a, TyrC.","NMRI Mouse | NMRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085243","Mice, Inbred NOD","C37417","definition pending","NOD Mouse | NOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513851","NOD/Lt Mouse","C37418","definition pending","NOD/Lt Mouse | NOD/Lt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513850","NOD/LtJ Mouse","C37419","definition pending","NOD/LtJ Mouse | NOD/LtJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513853","NON Mouse","C14460","definition pending","NON Mouse | NON",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513854","NOR Mouse","C37420","definition pending","NOR Mouse | NOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025926","NZB Mouse","C37421","definition pending","NZB Mouse | NZB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513862","NZB/BlNJ Mouse","C37422","definition pending","NZB/BlNJ Mouse | NZB/BlNJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513863","NZC Mouse","C37423","definition pending","NZC Mouse | NZC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513864","NZO/HlLt Mouse","C37424","definition pending","NZO/HlLt Mouse | NZO/HlLt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513867","NZW Mouse","C37425","definition pending","NZW Mouse | NZW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513866","NZW/LacJ Mouse","C37426","definition pending","NZW/LacJ Mouse | NZW/LacJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518517","O20/A Mouse","C37427","definition pending","O20/A Mouse | O20/A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518835","P/J Mouse","C14598","definition pending","P/J Mouse | P/J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518788","PERA/EiJ Mouse","C37428","definition pending","PERA/EiJ Mouse | PERA/EiJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518797","PL/J Mouse","C15049","definition pending","PL/J Mouse | PL/J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518832","PWK Mouse","C37429","definition pending","PWK Mouse | PWK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514639","RBF/DnJ Mouse","C37430","definition pending","RBF/DnJ Mouse | RBF/DnJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514647","RF/J Mouse","C14683","definition pending","RF/J Mouse | RF/J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514653","RIII Mouse","C37431","definition pending","RIII Mouse | RIII",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514652","RIII/2J Mouse","C37432","definition pending","RIII/2J Mouse | RIII/2J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514651","RIIIS/J Mouse","C37433","definition pending","RIIIS/J Mouse | RIIIS/J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519132","SEA/GnJ Mouse","C37434","definition pending","SEA/GnJ Mouse | SEA/GnJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519133","SEG Mouse","C37435","definition pending","SEG Mouse | SEG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519137","SF/CamEiJ Mouse","C37436","definition pending","SF/CamEiJ Mouse | SF/CamEiJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519146","SJL Mouse","C37437","definition pending","SJL Mouse | SJL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519145","SJL/J Mouse","C14448","definition pending","SJL/J Mouse | SJL/J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519147","SKIVE Mouse","C37438","definition pending","SKIVE Mouse | SKIVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519148","SM/J Mouse","C14612","definition pending","SM/J Mouse | SM/J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519151","SPE/Pas Mouse","C37439","definition pending","SPE/Pas Mouse | SPE/Pas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519152","SPRET/EiJ Mouse","C37440","definition pending","SPRET/EiJ Mouse | SPRET/EiJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519162","ST/bJ Mouse","C37441","definition pending","ST/bJ Mouse | ST/bJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519161","STS/A Mouse","C37442","definition pending","STS/A Mouse | STS/A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519165","SWR Mouse","C37443","definition pending","SWR Mouse | SWR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519164","SWR/J Mouse","C14427","definition pending","SWR/J Mouse | SWR/J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519166","SWV Mouse","C15062","definition pending","SWV Mouse | SWV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520112","WMP Mouse","C37444","definition pending","WMP Mouse | WMP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520205","YBR Mouse","C14510","definition pending","YBR Mouse | YBR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520204","YBR/Ki Mouse","C37445","definition pending","YBR/Ki Mouse | YBR/Ki",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511406","CBA/J Mouse","C37399","Developed by Strong (1920), the CBA/J mouse was disseminated to Andervont (1947) and then to Jackson Laboratory (1948). The CBA/J strain carries the gene for retinal degeneration (rd) and has a high gross tumor incidence, including lymphoma, hepatoma, and mammary tumors. The CBA/J mice exhibit an intermediate life span with good breeding performance.","CBA/J Mouse | CBA/J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512692","Inbred Strain","C28422","A strain that has been maintained by sibling (sister x brother) matings for 20 or more consecutive generations. (from JAX Strain Information)","Inbred Strain | Inbred",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1947989","Colony (cells or organisms)","C61515","A group of cells or organisms grown from a single progenitor.","Colony | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710709","Zygosity","C45824","The genetic condition of a zygote, especially with respect to its being a homozygote or a heterozygote.","Zygosity | zygosity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512571","Hypothesis","C28362","A tentative proposal made to explain certain observations or facts that requires further investigation to be verified.","Hypothesis | hypothesis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880120","Colony Management System","C64342","A multi-user relational database management system for managing animal colonies in a research environment.","Colony Management System | CMS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024779","Map","C43433","A usually 2-dimensional diagrammatic representation of an object or area.","Map | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376298","Consensus","C64197","Agreement as the result of multiple results or opinions.","Consensus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880149","Comparative Marker Selection","C64198","An algorithm for assigning significance values to genes being tested for their ability to discriminate between microarray samples.","Comparative Marker Selection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880170","Consensus Clustering","C64199","A method to represent the consensus across multiple runs of a clustering algorithm, to determine the number of clusters in the data, and to assess the stability of the discovered clusters. The method can also be used to represent the consensus over multiple runs of a clustering algorithm with random restart (such as K-means, model-based Bayesian clustering, SOM, etc.), so as to account for its sensitivity to the initial conditions. It also provides for a visualization tool to inspect cluster number, membership, and boundaries.","Consensus Clustering | Consensus Clustering Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881786","Merge","C64266","To join, combine, or mix together.","Merge | Merged",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0868941","Data Processing","C47925","A series of operations on data by a computer in order to retrieve or transform or classify information.","Data Processing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883661","log2","C64200","The log base 2 value of argument X.","log2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439093","Greater Than","C61584","A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status.","Greater Than | GT | Greater than | MT | MT (more than) | More Than",,,,,,,,,,,,,,,"4172704",">",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0439092","Less Than","C61585","A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status.","Less Than | LT | LT (less than) | Less than | Lesser Than",,,,,,,,,,,,,,,"4171756","<",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1880728","Family-Wise Error Rate","C64215","A statistical method used for multiple testing corrections to control the expected proportion of false positives (Type I error) among rejected tests or hypotheses.  It is more stringent than other multiple testing corrections and thereby, will allow very few false positives.","Family-Wise Error Rate | FWER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883663","maxT","C64216","A statisical test to adjust the p-value for multiple comparisons.","maxT | maxT Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882511","Q-Value","C64217","The minimum False Discovery Rate (FDR) value required for a test to be considered significant.","Q-Value | Q Value",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706515","Matrix substance","C45805","Ground substance in which things are embedded or that fills a space (e.g., extracellular matrix or nuclear matrix).","Matrix | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879779","Balanced Permutation","C64218","A method for reducing bias in which half of the treatment arrays swap with half of the control arrays in each permutation.","Balanced Permutation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882348","Permutation","C64219","A set of elements are rearranged or reindexed in various and different orders. In the rearrangement process, none of the elements are lost, added, or changed.","Permutation | Arrangement number | Order",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882542","Random Seed","C64220","A number (or vector) used to generate random numbers in a system.","Random Seed | Random Number Seed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1948044","Smoothing (statistical technique)","C64202","The process by which a data set is simplified to reduce irregularities.","Smoothing | Smoothed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0237913","Statistical Test","C53228","A test used to determine the statistical significance of an observation.","Statistical Test | Hypothesis Test | Statistical Hypothesis Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883413","Two-Sided Test","C64267","A statistical hypothesis test that controls directional errors if rejection of a hypothesis is the result of a directional decision.  The two-sided test has less statistical power than the one-sided test.","Two-Sided Test | 2-Sided Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882111","Non-negative Matrix Factorization","C64257","A pattern recognition alogrithm that identifies patterns that together explain the data as a linear combination of expression signatures.","Non-negative Matrix Factorization | NMF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879679","All-Pairs Comparison","C64268","A type of class comparison used when more than two classes are present in which each class is compared individually to each of the other classes.  For example, Class A is compared to Class B, then compared to Class C; Class B is then compared to Class C, etc.","All-Pairs Comparison | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882147","One-Versus-All Comparison","C64269","A type of class comparison used when more than two classes are present in which each class is compared to the other classes as a group.  For example Class A is compared to Classes B, C, and D; Class B is compared to Classes A, C, and D, etc.","One-Versus-All Comparison | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880356","Discretize","C64270","A method to normalize data.  In this normalization process, each value subtracts the column mean and is divided by the column standard deviation.","Discretize | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028908","Oil","C66934","Any of numerous unctuous combustible substances that are liquid or can be liquefied easily on warming, are soluble in ether but not in water, and leave a greasy stain on paper or cloth.","Oil | Oily",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1535514","European","C43851","Denotes the inhabitants of any of the countries of Europe, a person from there, or their descendants elsewhere.","European | EUROPEAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1947986","Negative Control","C64357","A control sample where a negative result is expected, to help correlate a positive result with the variable being tested.","Negative Control | NEGATIVE CONTROL | Negative_Control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810300","Hypogammaglobulinemia","C26931","A decreased level of serum immunoglobulins. It may be inherited or acquired. It is caused by decreased or inefficient production of immunoglobulins from B cells or by a decrease in the numbers of B cells themselves. Low levels of immunoglobulins will affect the immune system's ability to combat bacterial infection. Supplementation of immunoglobulins is needed to prevent worsening outcomes.","Hypogammaglobulinemia | Agammaglobulinemia | hypogammaglobulinemia",,,,,,,,,,,,,,,"440072","Hypogammaglobulinemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883398","Triple Blind Study","C66959","A study in which knowledge of the treatment assignments are concealed from the people who organize and analyze the data of a study as well as from subjects and investigators.","Triple Blind Study | Triple-Blind Study | Triple-Blinded | triple-blind study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880647","FACT-E Questionnaire","C66958","A subscale complement to the FACT-G developed specifically for evaluating the quality of life of esophageal cancer patients.","FACT-E Questionnaire | FACT-E | Functional Assessment of Cancer Therapy Scale-Esophageal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880594","European Quality of Life Five Dimension Three Level Questionnaire","C66957","A standardized rating scale which is used as a measure of health outcome. This instrument is a descriptive system consisting of 5 dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. Each dimension has 3 levels ranging from no problem to extreme problem or incapable, which are assessed by the patient.","European Quality of Life Five Dimension Three Level Questionnaire | EQ-5D-3L | EQ5D01 | EuroQOL Questionnaire | European Quality of Life Five Dimension Three Level Scale Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706613","Not Stated","C43234","Not provided or available.","Not Reported | NOT REPORTED | NOT_REPORTED | Not Stated | Not reported | Not specified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510715","Abnormal Cells Present","C42076","Abnormal Cells Present","Abnormal Cells Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040452","Root","C33446","The part of a tooth below the neck of the tooth which is covered by cementum.","Root | Radix Dentis | Root of Tooth | Root of the Tooth | Tooth Root",,,,,,,,,,,,,,,"4225908","Tooth root structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011331","Dental Procedure","C38052","Any of the dental diagnostic, preventive, and restorative services provided to meet the needs of a patient.","Dental Procedure | ",,,,,,,,,,,,,,,"4024741","Dental care",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020242","Hydrocarbon","C552","A group of organic compounds that consist of only hydrogen (H) and carbon (C) atoms and are involved in energy production. They may be cyclic or non-cyclic compounds. They may have double bonds, single bonds or both with carbon forming the backbone.","Hydrocarbon | Hydrocarbons | hydrocarbon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028158","Nitrogen","C61863","An element with atomic symbol N, atomic number 7, and atomic weight 14.01.","Nitrogen | NITROGEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0182981","Restorative Material","C62565","A dental material used to fill cavities and create a new tooth surface.","Restorative Material | Dental Restorative Material",,,,,,,,,,,,,,,"45763785","Dental restorative material",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512612","Ideal","C28741","Conforming to an ultimate standard of perfection or excellence.","Ideal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0000925","Cut","C50518","A wound or cleft resulted from tissue separation into parts or laid open or penetrated with a sharp edge or instrument.","Cut | ",,,,,,,,,,,,,,,"4047081|4155044","Incised wound - morphology|Incised wound",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL378249","Nutrition, Calories","C15646","Role of caloric intake in cancer causation or prevention and in general health.","Nutrition, Calories | calorie",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201802","Specific Gravity","C64832","The density (mass per unit volume) of any material divided by that of water at a standard temperature.","Specific Gravity | SPGRAV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881306","Ketone Measurement","C64854","A quantitative measurement of the amount of ketones present in a sample.","Ketone Measurement | KETONES | Ketones",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086243","Epipodophyllotoxin Compound","C1331","An alkaloid isolated or derived synthetically from Podophyllum peltatum that can bind to and inhibit topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.","Epipodophyllotoxin Compound | epipodophyllotoxin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152036","Immunology","C18011","The study of the immune system and its reaction to pathogens, as well as its malfunctions (autoimmune diseases, allergies, rejection of organ transplants).","Immunology | Immunologic | Immunology (Including BRMP) | Immunology (NCI Program) | immunology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040441","Tooth Fracture","C50777","Broken tooth affecting any portion of tooth: root fracture, crown-root, broken tooth (crown fracture), chipped tooth. A crown fracture can involve the pulp. Tooth fracture sequelae range in severity from cosmetic defects to tooth death. Involvement of the pulp is a more important indicator of severity of tooth fracture than is the amount of the tooth affected.","Tooth Fracture | Crack | Fracture of Tooth",,,,,,,,,,,,,,,"4264073","Fracture of tooth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704243","Greater","C61421","Notable in size, number, measure, magnitude, degree, or effectiveness.","Greater | Great",,,,,,,,,,,,,,,"4139823","Greater",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882518","Quinolone Antibiotic","C795","The basic structure of quinolone is nalidixic acid that has limited therapeutic value.  However, the development of fluorinated quinolones led to new derivative compounds with broad antibacterial activity.  Both DNA gyrase and topoisomerase IV are targets of quinolones.","Quinolone Antibiotic | Quinolone Compound",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030842","Penicillin Antibiotic","C1500","Any beta-lactam antibiotic derived from Penicillium fungi with bactericidal activity. Penicillin antibiotics bind to and inactivate penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall, eventually causing cell lysis.","Penicillin Antibiotic | penicillin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL557638","Cephalosporin Antibiotic","C357","A synthetic or semi-synthetic beta-lactam antibiotic derived from Acremonium (Cephalosporium) fungi with bactericidal activity. Cephalosporin antibiotics bind to and inactivate penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall, eventually causing cell lysis.","Cephalosporin Antibiotic | Cephalosporins | cephalosporin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938164","Beta-Lactam Antibiotic","C260","A compound with a four member amide ring (beta-lactam), where one member is the amide nitrogen and another is the carbonyl carbon, with bactericidal activity. Beta-lactam antibiotics act by disrupting the synthesis of the peptidoglycan layer of the bacterial cell wall.","Beta-Lactam Antibiotic | Lactam Antibiotics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3536841","Aminoglycoside Antibiotic","C2363","Any antibiotic containing amino-modified sugars originally isolated from various Streptomyces and Micromonospora species. Aminoglycoside antibiotics bind to the 16S RNA of the bacterial 30S ribosomal subunit, inhibiting translation and protein synthesis. Aminoglycoside use is associated with ototoxicity, neurotxicity and nephrotoxicity.","Aminoglycoside Antibiotic | Aminoglycoside Agents | Aminoglycoside Drugs | Aminoglycosides | aminoglycoside antibiotic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL557616","Tetracycline Antibiotic","C1595","Any of a group of broad spectrum naphthacene antibiotics isolated from various species of Streptomyces or produced semisynthetically. In bacteria, tetracycline antibiotics block binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis. (NCI05)","Tetracycline Antibiotic | Tetracycline Antibiotics | Tetracyclines",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1948051","Checked-In","C66995","The state of an object when it has been placed in its designated storage location.","Checked-In | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880026","Checked-Out","C66996","The state of an object when it has been removed from its designated storage location.","Checked-Out | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882294","Partial Blind Study","C67020","A study in which the subject, the investigator, or anyone assessing the outcome is aware of the assignment in at least one treatment group but unaware of the treatment assignment(s) in one or more other treatment groups.","Partial Blind Study | Partial Blind",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515942","American College of Radiology Imaging Network","C19603","An infrastructure for multi-institutional clinical trials of imaging and related disciplines applied to cancer. The group has been in operation since March 1999. It does not have a continuing membership.","American College of Radiology Imaging Network | ACRIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882950","Reviewer (person)","C54634","A person with a responsibility for examining something to make sure that it is adequate, accurate, or correct.","Reviewer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1135159","COMT Gene","C18589","This gene is involved in the metabolism of catecholamine drugs and neurotransmitters.","COMT Gene | COMT | Catechol-O-Methyltransferase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448967","Convention","C61300","Something regarded as a normative example.","Convention | Classic | Classical | Conventional",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511314","Breast Imaging Reporting and Data System","C38071","The Breast Imaging Reporting and Data System (BI-RADS) Atlas is a quality assurance guide to standardize breast-imaging reporting and to facilitate outcome monitoring. The atlas contains a guide to standardized mammographic reporting, including a breast-imaging lexicon of terminology, a report organization and assessment structure and coding system.","Breast Imaging Reporting and Data System | BI-RADS | BIRAD | BIRADS | Breast Imaging Reporting and Data System Atlas | Mammogram, BIRAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018795","Cardiac Catheterization","C38044","A procedure in which a thin plastic tube (catheter) is inserted into an artery or vein in the arm or leg and then advanced into the chambers of the heart or into the coronary arteries. Catheterization can measure blood pressure within the heart and how much oxygen is in the blood. It's also used to get information about the pumping ability of the heart muscle. Catheters are also used to inject dye into the coronary arteries. Catheters with a balloon on the tip are used in the procedure called percutaneous transluminal coronary angioplasty.","Cardiac Catheterization | CARDIAC CATHETERIZATION | Cardiac catheterization",,,,,,,,,,,,,,,"4223020","Cardiac catheterization",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710578","Upload","C48914","To transfer a file or program to a central computer from a smaller computer or a computer at a remote location.","Upload | Uploaded",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0549179","Priority","C48911","A status established by order of importance or urgency.","Priority | Precedence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707391","Choose (action)","C48912","Select from a group.","Choose | Choice | Chose | Chosen | Elected | Election | Pick | Picked | Select | Selected | Selection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711420","ASCII","C45533","The worldwide standard for the code numbers used by computers to represent all the uppercase and lowercase Latin letters, numbers, punctuation, and other symbols. There are 128 standard ASCII codes, each of which can be represented by a 7 digit binary number: 0000000 through 1111111.","ASCII | American Standard Code for Information Interchange",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514307","Predictive Value","C16238","An expression of the likelihood that a given test result correlates with the presence or absence of disease.","Predictive Value | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516251","Carbon Monoxide Diffusing Capability Test","C38083","A measurement of carbon monoxide (CO) transfer from inspired gas to pulmonary capillary blood. During the test, the subject inspires a gas containing CO and one or more tracer gases to allow determination of the gas exchanging capability of the lungs.","Carbon Monoxide Diffusing Capability Test | DLCO | Diffusion Capacity of Lung for CO | Diffusion Capacity of the Lung for Carbon Monoxide | PFT/DLCO | Pulmonary Function Test/Carbon Monoxide Diffusing Capability | TLCO | Transfer Factor of Lung for CO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201916","Direct Bilirubin Measurement","C64481","The bilirubin is bound to glucuronide to form conjugated bilirubin (direct bilirubin). Direct Bilirubin measurement is accomplished by a colorimetric method. Direct Bilirubin in biological fluids reacts with sulfanilic acid at acidic pH to produce a red colored complex. The optical density of produced color has a direct relationship with Direct Bilirubin concentration in the solution.","Direct Bilirubin Measurement | BILDIR | Direct Bilirubin",,,,,,,,,,,,,,,"4216632","Bilirubin, direct measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0376545","Hematopoietic and Lymphoid Cell Neoplasm","C27134","A neoplasm that arises from hematopoietic and lymphoid cells. Representative examples include myeloproliferative neoplasms, myelodysplastic syndromes, leukemias, Hodgkin lymphomas, and non-Hodgkin lymphomas.","Hematopoietic and Lymphoid Cell Neoplasm | HEMOLYMPHORETICULAR TUMOR, MALIGNANT | Hematologic Cancer | Hematologic Malignancy | Hematologic Neoplasm | Hematological Neoplasm | Hematopoietic Cancer | Hematopoietic Neoplasm | Hematopoietic Neoplasms Including Lymphomas | Hematopoietic and Lymphoid Neoplasm | Hematopoietic malignancy, NOS | Malignant Hematologic Neoplasm | Malignant Hematopoietic Neoplasm | Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified | hematologic cancer",,,,,,,,,,,,,,,"4044013|4185782|4212193","Hematologic neoplasm|Hematopoietic neoplasm|Malignant hematopoietic neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C0474535","Erythrocyte Mean Corpuscular Hemoglobin Concentration","C64798","The mean cell hemoglobin concentration (MCHC), which is the average concentration of hemoglobin in a given volume of blood. The MCHC is a calculated value derived from the measurement of hemoglobin and the hematocrit.","Erythrocyte Mean Corpuscular Hemoglobin Concentration | Ery. Mean Corpuscular HGB Concentration | MCHC",,,,,,,,,,,,,,,"4290193","Mean corpuscular hemoglobin concentration determination",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0369183","Erythrocyte Mean Corpuscular Hemoglobin","C64797","The mean cell hemoglobin (MCH), which is the average amount of hemoglobin in the average red cell. The MCH is a calculated value derived from the measurement of hemoglobin and the red cell count.","Erythrocyte Mean Corpuscular Hemoglobin | Ery. Mean Corpuscular Hemoglobin | MCH",,,,,,,,,,,,,,,"4182871","Mean corpuscular hemoglobin determination",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1948043","Erythrocyte Mean Corpuscular Volume","C64799","The mean cell volume is the average volume of a red blood cell. This is a calculated value derived from the hematocrit and the red cell count.","Erythrocyte Mean Corpuscular Volume | Ery. Mean Corpuscular Volume | Erythrocytes Mean Corpuscular Volume | MCV | RBC Mean Corpuscular Volume",,,,,,,,,,,,,,,"4016239","Erythrocyte mean corpuscular volume determination",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4014900","Kidney Disorder","C3149","A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).","Kidney Disorder | Kidney Disease | Kidney Disease | Kidney disease | Renal Disease | Renal Disorder | Renal Disorder | Renal Disorder, NOS",,,,,,,,,,,,,,,"198124","Kidney disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019704","Human Immunodeficiency Virus 1","C14220","Any viral organism that can be assigned to the species Human Immunodeficiency virus 1.","Human Immunodeficiency Virus 1 | HIV-1 | HUMAN IMMUNODEFICIENCY VIRUS 1 | Human Immunodeficiency Virus, Type 1 | LAV-1",,,,,,,,,,,,,,,"4230974","Human immunodeficiency virus type I",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019707","Human Immunodeficiency Virus 2","C14221","Any viral organism that can be assigned to the species Human Immunodeficiency virus 2.","Human Immunodeficiency Virus 2 | HIV-2 | HUMAN IMMUNODEFICIENCY VIRUS 2 | Human Immunodeficiency Virus, Type 2 | LAV-2",,,,,,,,,,,,,,,"4262565","Human immunodeficiency virus type 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0537026","UGT1A1 Gene","C20128","This gene is involved in controlling serum levels of bilirubin and in glucuronidation.","UGT1A1 Gene | UDP Glucuronosyltransferase Family 1 Member A1 Gene | UGT1A1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035286","Reticulocyte","C12528","Immature erythrocytes that have just undergone extrusion of their cell nucleus. They still contain some organelles that gradually decrease in number as the cells mature.","Reticulocyte | RETICULOCYTES | Reticulocytes",,,,,,,,,,,,,,,"4199752","Reticulocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1879653","Bioconductor caAffy Constant Normalization","C63930","A method to scale Affymetrix arrays, as defined in documents available at http://bioconductor.org/packages/1.9/bioc/html/affy.html","Bioconductor caAffy Constant Normalization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879654","Bioconductor caAffy Contrasts Normalization","C63931","A method to normalize intensities using the contrasts method, as defined in documents available at http://bioconductor.org/packages/1.9/bioc/html/affy.html","Bioconductor caAffy Contrasts Normalization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879657","Bioconductor caAffy Invariant Set Normalization","C63932","A method to normalize arrays in an AffyBatch using an invariant set, as defined in documents available at http://bioconductor.org/packages/1.9/bioc/html/affy.html","Bioconductor caAffy Invariant Set Normalization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879659","Bioconductor caAffy Loess Normalization","C63933","A method to normalize Affymetrix arrays using loess, as defined in documents available at http://bioconductor.org/packages/1.9/bioc/html/affy.html","Bioconductor caAffy Loess Normalization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879664","Bioconductor caAffy Q-Spline Normalization","C63934","A method to normalize Affymetrix arrays to each other or to a set of target intensities, as defined in documents available at http://bioconductor.org/packages/1.9/bioc/html/affy.html","Bioconductor caAffy Q-Spline Normalization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879665","Bioconductor caAffy Quantiles Normalization","C63935","A method for normalization based upon quantiles. This function normalizes a matrix of probe level intensities.  Defined in documents available at http://bioconductor.org/packages/1.9/bioc/html/affy.html","Bioconductor caAffy Quantiles Normalization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879666","Bioconductor caAffy Quantiles Robust Normalization","C63936","A method for normalization based upon the concept of a quantile-quantile plot extended to n dimensions.  Defined in documents available at http://bioconductor.org/packages/1.9/bioc/html/affy.html","Bioconductor caAffy Quantiles Robust Normalization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879649","Bioconductor caAffy Average Difference Probe Summary Method","C64222","Summarizes probe sets by computing the average difference between all PM and MM probes in a probe set. Defined in the documents available at http://bioconductor.org/packages/1.9/bioc/html/affy.html","Bioconductor caAffy Average Difference Probe Summary Method | Average Difference | Average Difference Probe Summary Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879658","Bioconductor caAffy Li Wong Probe Summary Method","C64223","Summarizes probe sets using the model described in Li and Wong (2001) to a probe set with I chips and J probes. Defined in the documents available at http://bioconductor.org/packages/1.9/bioc/html/affy.html","Bioconductor caAffy Li Wong Probe Summary Method | Li Wong | Li Wong Probe Summary Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879660","Bioconductor caAffy MAS Probe Summary Method","C64224","Summarizes probe sets using the robust average 1-step Tukey biweight algorithm. Defined in the documents available at http://bioconductor.org/packages/1.9/bioc/html/affy.html","Bioconductor caAffy MAS Probe Summary Method | MAS | MAS Probe Summary Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879661","Bioconductor caAffy Median Polish Probe Summary Method","C64225","Summarizes probe sets using Tukey's median polish procedure. Defined in the documents available at http://bioconductor.org/packages/1.9/bioc/html/affy.html.","Bioconductor caAffy Median Polish Probe Summary Method | Median Polish | Median Polish Probe Summary Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879662","Bioconductor caAffy Player Out Probe Summary Method","C64226","Summarizes probe sets using the 'player out' statistical algorithm. Defined in the documents available at http://bioconductor.org/packages/1.9/bioc/html/affy.html.","Bioconductor caAffy Player Out Probe Summary Method | Player Out | Player Out Probe Summary Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882928","Variance Criterion","C64229","Method for removing extreme values from a set, based upon its variance.  Defined in documents available at http://bioconductor.org/packages/1.9/bioc/html/affy.html","Variance Criterion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831839","oral fludarabine phosphate","C64338","An oral formulation of the phosphate salt of fludarabine, a synthetic purine nucleoside analogue antimetabolite with antineoplastic activity. Fudarabine is preferentially transported into malignant cells and metabolized by deoxycytidine kinase to its active form, 2-fluoro-ara-ATP; 2-fluoro-ara-ATP competes directly with deoxyadenosine triphosphate (dATP) and inhibits alpha DNA polymerase, RNA reductase, and DNA primase, which may result in inhibition of DNA synthesis and cell death.","Oral Fludarabine Phosphate | Fludara Oral | Mean Criterion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882927","Mean Criterion","C64228","Method for removing extreme values from a set, based upon its deviation from the mean.  Defined in documents available at http://bioconductor.org/packages/1.9/bioc/html/affy.html","Mean Criterion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881492","MAS Probe Correction Method","C64231","Correct perfect match (PM) probe levels using the ideal mismatch algorithm. Defined in the documents available at http://bioconductor.org/packages/1.9/bioc/html/affy.html.","MAS Probe Correction Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882259","PM Only Probe Correction Method","C64232","Make no adjustment to the perfect match (PM) probe levels. Defined in the documents available at http://bioconductor.org/packages/1.9/bioc/html/affy.html","PM Only Probe Correction Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883211","Subtract MM Probe Correction Method","C64233","Correct perfect match (PM) probe levels by subtracting mismatch (MM) probe levels. Defined in the documents available at http://bioconductor.org/packages/1.9/bioc/html/affy.html.","Subtract MM Probe Correction Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881491","MAS Background Correction Method","C64237","This is an implementation of the Affymetrix (2002) MAS algorithm for background correction, which divides each chip into regions, uses a threshold to identify a 'background' level of expression, and subtracts this from both MM and PM probes.","MAS Background Correction Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882528","RMA Background Correction Method","C64235","Perform RMA background correction. Defined in the documents available at http://bioconductor.org/packages/1.9/bioc/html/affy.html.","RMA Background Correction Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882527","RMA2 Background Correction Method","C64236","Perform a modified version of RMA background correction. Defined in the documents available at http://bioconductor.org/packages/1.9/bioc/html/affy.html.","RMA2 Background Correction Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881866","Mismatch Probe","C64213","A 25 nucleotide probe with a sequence mismatch to its target at position 13 used for measuring non-specific binding in analysis of Affymetrix arrays.","Mismatch Probe | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882328","Perfect Match Probe","C64212","A 25 nucleotide probe with an exact sequence match to its target used in analysis of Affymetrix arrays.","Perfect Match Probe | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883357","Together","C63802","In conjunction with; combined.","Together | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881633","Mean Baseline Removal Method","C64239","Method for identifying invariant set normalization baseline using mean expression values. Defined in the documents available at http://bioconductor.org/packages/1.9/bioc/html/affy.html.","Mean Baseline Removal Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882501","Pseudo Mean Baseline Removal Method","C64242","Method for identifying invariant set normalization baseline using psuedo mean expression values. Defined in the documents available at http://bioconductor.org/packages/1.9/bioc/html/affy.html.","Pseudo Mean Baseline Removal Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882502","Pseudo Median Baseline Removal Method","C64241","Method for identifying invariant set normalization baseline using psuedo median expression values. Defined in the documents available at http://bioconductor.org/packages/1.9/bioc/html/affy.html.","Pseudo Median Baseline Removal Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883656","caExpresso Analytic Service","C64244","The underlying Bioconductor routine.","caExpresso Analytic Service | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879650","Background Correction Method","C64234","A method to adjust detector intensities to correct for background variation in intensities.","Background Correction Method | Background Correction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879663","Probe Correction Method","C64230","A method for correcting perfect match (PM) probe expression levels. Defined in the documents available at http://bioconductor.org/packages/1.9/bioc/html/affy.html","Probe Correction Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882462","Probe Summary Method","C64221","Method for summarizing expression values of all probes in a probe set. Defined in the documents available at http://bioconductor.org/packages/1.9/bioc/html/affy.html","Probe Summary Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1554990","Portable Document Format","C63805","An open file format created and controlled by Adobe Systems, for representing two-dimensional documents in a device independent and resolution independent fixed-layout document format. Each PDF file encapsulates a complete description of a 2D document that includes the text, fonts, images, and 2D vector graphics that compose the document. PDF files do not encode information that is specific to the application software, hardware, or operating system used to create or view the document. This feature ensures that a valid PDF will render exactly the same regardless of its origin or destination (but depending on font availability when fonts are not encapsulated in the file).","Portable Document Format | PDF | pdf",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882926","Remove Extremes","C64227","Method for removing extreme values from a set.  Defined in documents available at http://bioconductor.org/packages/1.9/bioc/html/affy.html","Remove Extremes | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880241","caDNAcopy Analytic Service","C64245","Segments DNA copy number data using circular binary segmentation to detect regions with abnormal copy number.","caDNAcopy Analytic Service | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0237881","Statistical Significance","C61040","In statistics, a number that expresses the probability that the result of a given experiment or study could have occurred purely by chance. This number can be a margin of error or it can indicate a confidence level.","Statistical Significance | Significance | Statistically Significant | significant | statistical significance | statistically significant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883675","Change-Point Analysis","C64211","Methods for determining whether a change has taken place, when it has taken place, the confidence level indicating the likelihood that a change occurred, and the confidence interval indicating when the change occurred.","Change-Point Analysis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880951","Genomic Feature Physical Location","C64389","The physical location on a specified chromosome of a feature or area of interest expressed as a base pair position.","Genomic Feature Physical Location | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705291","Mass-to-Charge Ratio","C48049","The abbreviation m/z is used to denote the dimensionless quantity formed by dividing the mass number of an ion by its charge number. It has long been called the mass-to-charge ratio although m is not the ionic mass nor is z a multiple or the elementary (electronic) charge e. (from IUPAC Compendium)","Mass-to-Charge Ratio | m/z | mz",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883658","caPROcess Analytic Service","C64246","Performs peak identification for a collection of SELDI-TOF protein mass spectrometry samples.","caPROcess Analytic Service | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027569","Neighborhood","C64203","A surrounding or nearby region.","Neighborhood | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879568","Iobenguane I-131","C970","An I 131 radioiodinated synthetic analogue of the neurotransmitter norepinephrine. Iobenguane localizes to adrenergic tissue and, in radioiodinated forms, may be used to image or eradicate tumor cells that take up and metabolize norepinephrine.","Iobenguane I-131 | (131)I-MIBG | 131I-MIBG | I 131 Meta-iodobenzylguanidine | I-131 Metaiodobenzylguanidine | IOBENGUANE I-131 | Iobenguane (131I) | Iobenguane I 131 | Iodine I 131 Metaiodobenzylguanidine | Iodine I 131 Metaiodobenzylguanidine | MIBG I-131 | Raiatt MIBG-I 131 | iodine I 131 metaiodobenzylguanidine",,,,,,,,,,,,,,,"4217741","Iobenguane (131-I)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017004","Gamma Camera","C16600","An instrument used in medicine to produce images of internal organs after the injection of a radioactive drug into the body, where the drug releases gamma rays. It is used especially in medical diagnostic scanning. (Encarta Dictionary and Merriam-Webster Online Dictionary)","Gamma Camera | ",,,,,,,,,,,,,,,"4127639","Gamma camera",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0106132","Choriogonadotropin Subunit Beta 3","C17479","Choriogonadotropin subunit beta 3 (165 aa, ~18 kDa) is encoded by the human CGB3, CGB5, and CGB8 genes. This protein is involved in the regulation of steroid synthesis during pregnancy.","Choriogonadotropin Subunit Beta 3 | CG-Beta | CGB3 | Choriogonadotropin Beta Chain | Choriogonadotropin Subunit Beta | Choriogonadotropin Subunit Beta | Chorionic Gonadotrophin Beta Subunit | Chorionic Gonadotropin Beta 3 Subunit | Chorionic Gonadotropin Beta Chain | Chorionic Gonadotropin Beta Polypeptide | Chorionic Gonadotropin Chain Beta | Chorionic Gonadotropin, Beta Chain | Chorionic Gonadotropin, Beta Polypeptide 3 | Human Chorionic Gonadotropin Beta Subunit | Human Chorionic Gonadotropin Beta Subunit | beta-hCG | beta-human chorionic gonadotropin | hCG-Beta | hCGBeta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1307640","AFP protein, human","C16278","Alpha-fetoprotein (609 aa, ~69 kDa) is encoded by the human AFP gene. This protein plays a role in the binding to copper, nickel, bilirubin and fatty acids in the fetal circulation.","Alpha-Fetoprotein | AFP | Alpha Fetal Protein | Alpha Fetoprotein | Alpha-1-Fetoprotein | Alpha-Fetoglobulin | alpha-Fetoprotein | alpha-fetoprotein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205473","Serological","C41264","Pertaining to the in vitro reactions and properties of immune sera, particularly, the concept refers to the use of such reactions to measure serum titers of antibody against infectious and non-infectious agents (serologic tests), to the clinical correlations of the antibody titer, and to the use of serologic reactions to detect antigens.","Serological | Serologic",,,,,,,,,,,,,,,"4099605","Serologic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0241329","Tahitian","C43406","Denotes the inhabitants of Tahiti, a person from there, or their descendants elsewhere.","Tahitian | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553343","Chamorran","C43403","Denotes any of the indigenous Chamorro people of Guam and the Mariana Islands or persons of that ancestry.","Chamorran | CHAMORRO | Chamorro",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337920","Native Hawaiian","C43394","A person having origins in any of the original peoples of Hawaii.","Native Hawaiian | Hawaiian | Hawaiian | NATIVE HAWAIIAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553350","Papua New Guinean","C43411","Denotes the inhabitants of Papua New Guinea, a person from there, or their descendants elsewhere.","Papua New Guinean | New Guinean | New Guinean",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1947967","Call (Instruction)","C64924","Send a message or attempt to reach someone by radio, phone, etc.","Call | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0872272","Software Development","C67226","The design and writing of computer programs. Software development includes the design of the user interface and the program architecture as well as programming the source code. A somewhat broader scope of computer programming or a specialty of project managing.","Software Development | Computer Software Development | Software Developer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883060","Software Maintenance","C67227","All program coding after initial deployment to correct coding errors, enhance the functionality of the software, and perfect the functioning of the software.","Software Maintenance | SOFTWARE UPDATE | Software Maintainer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0259990","Oncologist","C17821","A physician who specializes in the diagnosis and treatment of cancer.","Oncologist | ONCOLOGIST | oncologist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0815319","Geographic Information Systems","C15754","A system of hardware, software, and geographic data designed to capture, store, update, manipulate, analyze and display data that are linked to location.","Geographic Information System | GIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883657","caGrid","C67252","The underlying services oriented architecture that supports caBIG. caGrid defines two types of 'grid services' that can be registered as nodes on the grid: Data Services and Analytical Services. caGrid provides a standard infrastructure for bioinformaticians to advertise their services thru common metadata defined in Unified Modeling Language (UML) domain information model. caGrid infrastructure also provides strong semantic specification thru binding to description logic terminology concepts that can be used by users to discover new and interesting scientific information using semantically aware searches.","caGrid | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205449","Three","C66834","A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one.","Three | 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1947907","biologic consumption","C66715","The bodily process of taking in and using up something, especially the eating or drinking of something.","Consumption | CONSUMING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3553274","Abdominal Pain","C26682","Painful sensation in the abdominal region.","Abdominal Pain | Abdominal pain | Abdominal_pain",,,,,,,,,,,,,,,"200219","Abdominal pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0746883","Febrile Neutropenia","C35665","Neutropenia associated with fever, the latter indicating the presence of an infection.","Febrile Neutropenia | Febrile neutropenia | Neutropenic Fever | febrile neutropenia",,,,,,,,,,,,,,,"4250734","Febrile neutropenia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021081","Immunosuppressant","C574","Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of suppressor T-cell populations or by inhibiting the activation of helper cells. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of interleukins and other cytokines are emerging.","Immunosuppressant | Immunosuppressive Agents | immunosuppressant | immunosuppressive | immunosuppressive treatment type | immunosuppressive_treatment_type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205447","One","C66832","The smallest natural number and quantity it denotes: a single entity, unit, or object.","One | 1 | 1* | ONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880359","Dispense","C64658","Give or apply.","Dispense | disp.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708698","LED","C49923","A type of diode designed to emit light when a current passes through it.","Light Emitting Diode Device | LED | LED (Light Emitting Diode) | Light Emitting Diode | Light Emitting Diode Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043047","Water","C65147","H2O, a clear, colorless, odorless, tasteless liquid that freezes into ice below 0 degrees centigrade and boils above 100 degrees centigrade.","Water | WATER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020746","Ice","C67342","Water frozen in the solid state.","Ice | Frozen Water | Water Ice | Wet Ice",,,,,,,,,,,,,,,"4232960","Ice",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1881345","LED Therapy","C67341","The use of LED light or radiation for treatment of various conditions including skin treatments and chemotherapy.","LED Therapy | LED therapy | Light-Emitting Diode Therapy | light-emitting diode therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710382","Therapy-Related Toxicity","C42607","The finding of bodily harm due to the poisonous effects associated with the action or administration of therapeutic agents.","Therapy-Related Toxicity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882504","Pseudomembrane Formation","C67353","Formation of membrane-like structures consisting of coagulated exudate that is loosely adherent to an inflamed tissue.","Pseudomembrane Formation | Pseudomembrane",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3552576","Kaposi Sarcoma","C9087","A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).","Kaposi Sarcoma | KS | Kaposi sarcoma | Kaposi's Sarcoma | Kaposi's sarcoma | Kaposi's sarcoma, unspecified | Multiple Hemorrhagic Sarcoma | Multiple hemorrhagic sarcoma","9140/3","Kaposi sarcoma",,,,,,,,,,,,,"434584","Kaposi's sarcoma (clinical)",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0687133","Drug Interaction","C54708","Alteration of the disposition and/or effect of a drug, owing to the presence of another factor such as a second drug, or food.","Drug Interaction | INTERACTION | drug interaction",,,,,,,,,,,,,,,"4196500","Medication interaction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1879774","BRCAPRO","C67371","A statistical model used to assess the probability that an individual carries a germline deleterious mutation of the BRCA1 and BRCA2 genes, based on family history of breast and ovarian cancer, including male breast cancer and bilateral synchronous and asynchronous diagnoses.","BRCAPRO | BRCAPro",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707405","Claus Model","C45991","The Claus model predicts the probability of a woman's risk for developing breast cancer based on her family history. It focuses solely on family history to estimate the probability that a woman will develop breast cancer. Using this model requires providing information about first-degree and second-degree relatives who have had breast cancer. It factors in the ages at which these relatives were diagnosed. It can also include breast cancer history on the father's side of the family as well. It's main advantage is its expanded inclusion of family history information. It is limited in that it can be used only with women who have at least one first- or second-degree relative with breast cancer. Also, it does not take into account other risk factors such as the presence of atypical hyperplasia, age of first menstrual period, or age of first live birth.","Claus Model | Claus Breast Cancer Risk Assessment Model | Claus model",,,,,,,,,,,,,,,"37397095","Claus Model",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0597526","Stoichiometry","C18110","The relation between the quantities of substances that take part in a reaction or form a compound (typically a ratio of whole integers).","Stoichiometry | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705536","Summation (document)","C48794","A concluding part of a speech or argument containing a summary of principal points.","Summation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704735","Regulator","C48806","Something that controls the rate or manner in which a process progresses or a product is formed.","Regulator | Regulatory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511131","Biochemical Reaction","C19899","A chemical process, typically mediated by an enzyme, in which one or more substances (a substrate) are transformed by covalent modification into another substance(s) (a product) or in which the state of a substance is transformed.","Biochemical Reaction | Biochemical Reactions | Enzymatic Reaction | biochemical reactions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0175921","Catalyst","C48810","A substance that initiates or accelerates a chemical reaction without itself being affected.","Catalyst | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085862","Independence","C61366","Freedom from control or influence of another or others factors.","Independence | Independent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1261287","Stenosis","C50754","Narrowing or stricture of a vessel, duct or canal.","Stenosis | Stricture",,,,,,,,,,,,,,,"4100082|45769800","Stricture|Narrowing",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0585297","Four Times Weekly","C64531","Four times per week.","Four Times Weekly | 4 TIMES PER WEEK | 4 times per week | Four times a week | QIS",,,,,,,,,,,,,,,"4144039","Four times weekly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1880609","Every Two Months","C64536","Every two months.","Every Two Months | Every two months | Q2M",,,,,,,,,,,,,,,"40484206","Every two months",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0585333","Every Three Weeks","C64535","Every three weeks.","Every Three Weeks | EVERY 3 WEEKS | Every 3 weeks | Every third week | Q3S",,,,,,,,,,,,,,,"4196987","Triweekly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332179","Every Three Months","C64537","Every three months.","Every Three Months | Every 3 months | Q3M",,,,,,,,,,,,,,,"4107703","Trimonthly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1275551","Every Three Days","C64533","Every three days.","Every Three Days | Every 3 days | Q3D",,,,,,,,,,,,,,,"4262457","Every three days",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1275555","Every Four Weeks","C64529","Every four weeks.","Every Four Weeks | EVERY 4 WEEKS | Every 4 weeks | Every four weeks | Q4S",,,,,,,,,,,,,,,"4288394","Every four weeks",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0585338","Every Four Months","C64538","Every four months.","Every Four Months | Every 4 months | Q4M",,,,,,,,,,,,,,,"4145092","Every four months",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1275554","Every Four Days","C64534","Every four days.","Every Four Days | Every 4 days | Q4D",,,,,,,,,,,,,,,"4288392","Every four days",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0278838","Recurrent Prostate Carcinoma","C7902","The reemergence of prostate carcinoma after a period of remission.","Recurrent Prostate Carcinoma | Recurrent Cancer of Prostate | Recurrent Cancer of the Prostate | Recurrent Prostate Cancer | Recurrent Prostate Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521750","Combination Chemotherapy","C191","Treatment using more than one anticancer drug.","Combination Chemotherapy | Chemotherapy, Combination | Combination Drug Therapy | Drug Therapy, Combination | combination chemotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3809384","Oral Candidiasis","C28137","Infection of the mucosal lining of the mouth with the fungus Candida albicans.","Oral Candidiasis | Thrush",,,,,,,,,,,,,,,"29735","Candidiasis of mouth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882134","Object Property","C62498","A named data value associated with an object.","Computer Programming Object Property | Object Property | Property",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705917","heirarchal root","C45800","Concepts in a hierarchy are often said to be in a tree.  A root refers to a concept that is considered as the top node for a specific purpose.","Tree Root | Root",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880158","Computational Proteomics Analysis System","C62487","A suite of database and analysis tools for managing proteomics data; built on LabKey, the open source platform for science developed in partnership with the Fred Hutchison Cancer Research Center.","Computational Proteomics Analysis System | CPAS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810255","Tinnitus","C50772","Abnormal perception of sounds experienced by an individual in the absence of auditory stimulation.","Tinnitus | Tinnitus Aurium | tinnitus",,,,,,,,,,,,,,,"377575","Tinnitus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0079490","Hematopoietic Cell Growth Factors","C20427","Endogenous growth factors which promote the development of blood cells.","Hematopoietic Growth Factor | Hematopoietic Cytokine | hematopoietic growth factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0064294","Fibroblast Growth Factor 7","C20436","Fibroblast growth factor 7 (194 aa, ~23 kDa) is encoded by the human FGF7 gene. This protein is involved in embryonic development, cell proliferation, cell differentiation, branch formation and keratinocyte growth.","Fibroblast Growth Factor 7 | FGF-7 | FGF7 | HBGF-7 | Heparin-Binding Growth Factor 7 | KGF | Keratinocyte Growth Factor | keratinocyte growth factor",,,,,,,,,,,,,,,"4217256","Keratinocyte growth factor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153564","Lung Kaposi Sarcoma","C3551","A Kaposi sarcoma arising from the lung.","Lung Kaposi Sarcoma | Kaposi's Sarcoma of Lung | Kaposi's Sarcoma of the Lung | Kaposi's sarcoma of unspecified lung | Lung Kaposi's Sarcoma | Pulmonary Kaposi's Sarcoma",,,,,,,,,,,,,,,"254583","Kaposi's sarcoma of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333776","Gastric Kaposi's Sarcoma","C5529","A Kaposi sarcoma arising from the stomach.","Gastric Kaposi Sarcoma | Gastric Kaposi's Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026636","Oral Cavity Disorder","C27641","A non-neoplastic or neoplastic disorder affecting the oral cavity.","Oral Cavity Disorder | Oral Cavity Disease",,,,,,,,,,,,,,,"4042502","Disease of mouth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1707335","Census Tract Level Statistic","C53188","No Value Exists","Census Tract Level Statistic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0203418","Transvaginal Ultrasound","C17644","A technique in which sound waves are sent out by an ultrasound probe that has been inserted in the vagina and a computer uses the ultrasound echoes to create an image of the female genital tract. The test can be performed to evaluate women with infertility problems, abnormal bleeding, sources of unexplained pain, congenital malformations of the uterus and ovaries, and possible tumors and infection.","Transvaginal Ultrasound | TRANSVAGINAL ULTRASOUND | TVS | TVU | transvaginal sonography | transvaginal ultrasound",,,,,,,,,,,,,,,"4027510","Transvaginal echography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016741","Frozen Sections","C67462","A thin slice of tissue cut from a frozen specimen, often used for rapid microscopic diagnosis.","Frozen Section | Frozen Tissue Section",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882347","Permanent Section","C67463","A thin slice of fixative-preserved tissue mounted on a slide for microscopic examination.","Permanent Section | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555581","Address Part Type - census tract","C67490","Relatively permanent statistical subdivisions of a county used by the U.S. Bureau of the Census for purposes of population enumeration. Each tract has a unique identification number consisting of a 4-digit basic number and a 2-digit suffix of the form 1234.56.","Census Tract | Block Numbering Area | Census Tract and Block Numbering Area",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706543","CD52 wt Allele","C51036","Human CD52 wild-type allele is located within 1p36 and is approximately 3 kb in length. This allele, which encodes CAMPATH-1 antigen immunoprotein, plays a role in inflammatory response and carbohydrate trafficking; however, neither role has been substantiated.","CD52 wt Allele | CD52 Antigen (CAMPATH-1 Antigen) Gene | CD52 Molecule wt Allele | CDW52 | CDW52 wt Allele | HE5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938172","Two","C66833","A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.","Two | 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1506770","Lapatinib","C26653","A synthetic, orally-active quinazoline with potential antineoplastic properties. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.","Lapatinib | GSK572016 | GW 2016 | GW 572016 | GW-572016 | GW2016 | GW572016 | LAPATINIB | lapatinib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348250","Dextran-Albumin Solution","C67499","An osmotically neutral fluid generally consisting of 7.5-10% Dextran-40 and 5% human albumin in saline.","Dextran-Albumin Solution | Dextran 40 and 5% Albumin in Normal Saline",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348732","Gantry","C67506","A spanning framework used to support machinery, including that for mounting a device to be moved in a circular path.","Gantry | ",,,,,,,,,,,,,,,"45772858","Gantry",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031325","Pharmacogenetics","C16973","The investigation of the impact of individual gene variations on drug responses.","Pharmacogenetics | PGt | pharmacogenetics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415561","HLA-B Gene","C62778","This gene plays a role in both immune responses and histocompatibility processes.","HLA-B Gene | HLA-B | Major Histocompatibility Complex, Class I, B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516476","Children's Cancer Group","C39352","An NCI-supported clinical cooperative group dedicated to conduct clinical research on childhood cancer, in 2001 was merged with the National Wilms Tumor Study Group, the Pediatric Oncology Group and the Intergroup Rhabdomyosarcoma Study Group to form a new national organization, the Children's Oncology Group.","Children's Cancer Group | CCG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1273870","Management","C61372","The act of conducting, controlling or supervising something.","Management | Managed | Managing | Oversight | Supervision",,,,,,,,,,,,,,,"4001217","Management procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516514","Chromogenic in situ Hybridization","C40960","A laboratory procedure that combines the sequence-specific detection aspects of FISH with the simple detection methods of immunohistochemistry. Briefly, sequence-specific probes are hybridized to cells fixed on slides and the sequestered probe is visualized by a peroxidase reaction. It has the advantage of being a less costly assay that does not require fluorescence microscopy with results that are stable over time.","Chromogenic In Situ Hybridization | CISH | Chromogenic in Situ Hybridization | Chromogenic in situ Hybridization | Chromogenic in situ Hybridization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026499","Monosomy","C3239","A chromosomal abnormality consisting of the absence of one chromosome from the normal diploid number.","Monosomy | ",,,,,,,,,,,,,,,"4311407","Monosomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1514212","Polysomy","C36331","The condition of having additional copies of a chromosome present in a cell.","Polysomy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710201","Storage Medium","C48445","Any media or device used for storing data.","Storage Medium | Storage Media",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378607","Six","C66837","A natural number greater than 5 and less than 7 and the quantity that it denotes: the sum of five and one.","Six | 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554673","Reading (datum presentation)","C48356","A datum that is presented to a user by a meter or similar instrument.","Reading | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086696","Therapy-Related Neoplasm","C3487","The development of a neoplasm in response to medical or surgical treatment, induced by the treatment itself.","Therapy-Related Neoplasm | Therapy Related Neoplasm | Therapy Related Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027666","Radiation-Related Neoplasm","C3265","A neoplasm that develops as a result of exposure to radiation.","Radiation-Related Neoplasm | Radiation Induced Neoplasm | Radiation-Induced Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825086","Blood Type","C61009","The specific reaction pattern of erythrocytes of an individual to the antisera of one blood group; e.g., the ABO blood group consists of four major blood types: O, A, B, and AB. This classification depends on the presence or absence of two major antigens: A or B. Type O occurs when neither is present and type AB when both are present. The blood type is the genetic phenotype of the individual for one blood group system and may be determined using different antisera available for testing.","Blood Type | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011015","Daunorubicin","C62091","An anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis.","Daunorubicin | (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione | 5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)- | DAUNOMYCIN | DAUNORUBICIN | DNR | Daunomycin | Daunorrubicina | L-lyxo-Hexopyranoside, 3beta-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-metldioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-,alpha- | Leukaemomycin C | RUBOMYCIN C | Rubidomycin | Rubomycin C | daunomycin | daunorubicin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0887947","Highly Active Antiretroviral Therapy","C16165","Drug therapy which targets retrovirus function by multiple mechanisms.","Highly Active Antiretroviral Therapy | HAART | On_HAART_Therapy | haart treatment indicator | haart_treatment_indicator | highly active antiretroviral therapy",,,,,,,,,,,,,,,"4166414","Highly active anti-retroviral therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512892","International Classification of Disease for Oncology","C37978","The International Classification of Diseases for Oncology has been used for nearly 25 years as a tool for coding diagnoses of neoplasms in tumor and cancer registrars and in pathology laboratories. ICD-O is a dual classification with coding systems for both topography and morphology. The topography code describes the site of origin of the neoplasm. The morphology code describes the characteristics of the tumor itself, including its cell type and biologic activity. (from Amazon.com)","International Classification of Diseases for Oncology | ICD-O | ICDO-3 | International Classification of Disease for Oncology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035403","Rh Factor","C67517","A family of 45 different antigens on the surface of red cells that are controlled by 2 closely linked genes on chromosome 1.","Rh Factor | ",,,,,,,,,,,,,,,"4061678","Antigen in Rh blood group system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004268","Attention Concentration","C41209","The act or process of concentrating, focusing the attention and mental energy on a single object to the exclusion of others.","Attention Concentration | Attention | Concentration",,,,,,,,,,,,,,,"4195864","Attention",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1511521","Core Facility","C15896","Shared facilities which provide services of a particular area of expertise.","Core Facility | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016884","Future","C67527","A time that is yet to come.","Future | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0231241","Fluctuate","C67528","To be unstable, having ups and downs.","Fluctuate | Fluctuating | Fluctuation",,,,,,,,,,,,,,,"4113281","Fluctuating",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1547671","Override","C67529","To take precedence over and countermand, thereby allowing an activity to continue despite a warning or error.","Override | Over-ride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519620","Translational Research","C15862","Studies designed to translate basic science findings into clinically useful tools and applications and to ensure that new treatments and research knowledge reach the patients or populations for whom they are intended and are implemented correctly.","Translational Research | Translational Research Enterprise | Translational Science | translational research",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882459","Primary Sampling Unit","C67108","A designated geographic area consisting of either metropolitan areas containing a central city of 50,000 or larger population, or counties or groups of counties containing small cities and rural areas.","Primary Sampling Unit | PSU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032854","Poverty","C17009","A subjective and comparative term describing a lack of sufficient wealth (usually understood as capital, money, material goods, or resources especially natural resources) to live what is understood in a society as a 'normal' life: for instance, to be capable of raising a healthy family, and especially educating children and participating in society. A person living in this condition of poverty is said to be poor. The meaning of 'sufficient' varies widely across the different political and economic areas of the world.","Poverty | Low Income | Poor",,,,,,,,,,,,,,,"4015401","Financially poor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1880252","Data Not Releasable","C67110","Data that can not be released due to confidentiality issues or for other reasons.","Data Not Releasable | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881928","Multiracial","C67109","Having ancestors of several or various races.","Multiracial | Multirace",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881927","Multiple Hispanic","C67111","A person living in the United States of Mexican, Puerto Rican, Cuban, Central or South American, or other Spanish culture or origin. The concept does not include Brazilian Americans or Portuguese Americans.","Multiple Hispanic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034043","Puerto Rican","C67112","A person of Puerto Rican culture or origin, regardless of race.","Puerto Rican | PUERTO RICAN | Puertorican",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0240339","Mexican","C67113","Denotes a person from or of Mexico.","Mexican | MEXICAN | Mexicano",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025884","Mexican American","C67114","Denotes an american citizen of Mexican descent.","Mexican American | MEXICAN AMERICAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010436","Cuban or Cuban American","C67115","Denotes a person from or of Cuba or an American citizen of Cuban descent.","Cuban or Cuban American | CUBAN AMERICAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388698","Dominican","C67117","Denotes the inhabitants of the Dominican Republic, a person from there, or their descendants elsewhere.","Dominican | DOMINICAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0238914","Central American","C67118","Denotes a person from the area between north and south America including persons from Belize, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama, and the Panama Canal zone.","Central American | CENTRAL AMERICAN | Cental American",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3161473","Spanish","C67120","Denotes a person from Spain or of Spanish descent.","Spanish | SPANISH | Spaniard",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882118","Not Ascertained","C67119","Not learned, discovered, or determined with certainty.","Not Ascertained | Not Determined",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0557286","No Formal Schooling","C67122","Indicates that a person has never attended an educational program or formal schooling.","No Formal Schooling | Never Attended | Never Attended School",,,,,,,,,,,,,,,"4074913","No formal education",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883619","1st Grade Completion","C67123","Indicates that 1st grade is the highest level of educational achievement.","1st Grade Completion | 1st Grade | Completed 1st Grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883622","2nd Grade Completion","C67124","Indicates that 2nd grade is the highest level of educational achievement.","2nd Grade Completion | 2nd Grade | Completed 2nd Grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883635","3rd Grade Completion","C67125","Indicates that 3rd grade is the highest level of educational achievement.","3rd Grade Completion | 3rd Grade | Completed 3rd Grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883642","4th Grade Completion","C67126","Indicates that 4th grade is the highest level of educational achievement.","4th Grade Completion | 4th Grade | Completed 4th Grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883646","5th Grade Completion","C67127","Indicates that 5th grade is the highest level of educational achievement.","5th Grade Completion | 5th Grade | Completed 5th Grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883649","6th Grade Completion","C67128","Indicates that 6th grade is the highest level of educational achievement.","6th Grade Completion | 6th Grade | Completed 6th Grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883651","7th Grade Completion","C67129","Indicates that 7th grade is the highest level of educational achievement.","7th Grade Completion | 7th Grade | Completed 7th Grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883653","8th Grade Completion","C67130","Indicates that 8th grade is the highest level of educational achievement.","8th Grade Completion | 8th Grade | Completed 8th Grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883654","9th Grade Completion","C67131","Indicates that 9th grade is the highest level of educational achievement.","9th Grade Completion | 9th Grade | Completed 9th Grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883613","10th Grade Completion","C67132","Indicates that 10th grade is the highest level of educational achievement.","10th Grade Completion | 10th Grade | Completed 10th Grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883614","11th Grade Completion","C67133","Indicates that 11th grade is the highest level of educational achievement.","11th Grade Completion | 11th Grade | Completed 11th Grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883615","12th Grade Completion, No Diploma","C67134","Indicates that a person was in school through 12th grade but they did not receive a high school diploma.","12th Grade Completion, No Diploma | 12th Grade | 12th Grade Completion | 12th Grade Completion, No Diploma  | 12th Grade, No Diploma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880947","General Equivalency Diploma Completion","C67135","Indicates that a person has received a General Equivalency Diploma in lieu of a high school diploma.","General Equivalency Diploma Completion | GED | GED or Equivalent | General Equivalency Diploma | General Equivalency Diploma Received",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0870649","High School Completion","C67136","Indicates that a person has attended high school and has received a high school diploma.","High School Completion | High School | High School Diploma Received | High School Graduate | High school completion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883065","Some College Completion","C67137","Indicates that a person has attended college but that they did not receive any degree.","Some College Completion | College no degree | Some College | Some College Attendence | Some College, No Degree",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883542","Vocational Program Completion","C67141","Indicates that a person has attended or received a degree from an occupational, technical, or vocational program as their highest level of educational achievement.","Vocational Program Completion | Associates degree vocational | Vocational Degree | Vocational Degree Completion | Vocational Degree Received",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879750","Associate Academic Degree Completion","C67140","Indicates that a person has received a degree from a 2 year college program.","Associate Academic Degree Completion | Academic Associate Degree | Associate Degree | Associate Degree Completion | Associate Degree Received | Associates degree academic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513010","Master's Degree","C39453","The Master's Degree is an award that requires the successful completion of a program of study of at least the full-time equivalent of 1 but not more than two academic years of work beyond the bachelor's degree.","Master's Degree | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882471","Professional Doctorate","C67143","A doctorate awarded in certain fields where most holders of the degree are not engaged primarily in scholarly research and academic activities, but rather in a profession, such as law, medicine, music, or ministry.","Professional Doctorate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882934","Research Doctorate","C67144","A doctorate nearly always awarded in recognition of academic research that is of a publishable standard (even if not actually published) and that represents at least a modest contribution to human knowledge. The research is usually assessed by submission and defense of a doctoral thesis or dissertation, though in some cases a coherent body of published literature can be accepted instead.","Research Doctorate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880386","Does Not Know","C67142","The answer is not known by the person answering.","Does Not Know | Don't Know | Don't know - can't remember | I do not know",,,,,,,,,,,,,,,"764572","Don't know",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3266136","Current Every Day Smoker","C67145","Indicates a person who has smoked at least 100 cigarettes in his or her lifetime and who currently smokes every day.","Current Every Day Smoker | Current every day smoker | Daily Smoker | Every Day Smoker | Every day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880200","Current Some Day Smoker","C67146","Indicates a person who has smoked at least 100 cigarettes in his or her lifetime, who smokes now, but does not smoke every day.","Current Some Day Smoker | Chipper | Current some day smoker | Non-Daily Smoker | Occasional Smoker | Some Day Smoker | Some days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337671","Former Smoker","C67148","A person who has quit smoking at the time of the interview but has smoked at least 100 cigarettes in their life.","Former Smoker | Former smoker | Prior Smoker",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883049","Smoker, Current Status Unknown","C67150","Indicates a person who is known to have smoked but whose current smoking status is unknown.","Smoker, Current Status Unknown | Smoker, current status unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883465","Unknown If Ever Smoked","C67151","Indicates that a person's smoking status is unknown.","Unknown If Ever Smoked | Unknown if ever smoked",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032343","Poisoning","C34933","Injury to the body or interference of normal body functions by a substance that is swallowed, inhaled, injected, or absorbed.","Poisoning | ",,,,,,,,,,,,,,,"442562","Poisoning",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710631","Verbatim","C54032","In precisely the same words used by a writer or speaker.","Verbatim | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1441506","Calculation","C54125","The procedure or activity of determining something by mathematical or logical methods.","Calculation | CALCULATION | Calculate | Calculated",,,,,,,,,,,,,,,"45765839","Calculation technique",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034625","Radium","C2391","An element with atomic symbol Ra, atomic number of 88, and atomic weight 226.0","Radium | RADIUM | Ra",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019552","Hip","C64193","The lateral prominence of the pelvis from the waist to the thigh.","Hip | HIP | hip | hip region | regio coxae",,,,,,,,,,,,,"UBERON:0001464","hip","4107083","Hip region structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0439152","Milliequivalent","C48512","A unit of relative amount of a substance equal to one thousandth of an equivalent weight.","Milliequivalent | MILLIEQUIVALENT | mEq | meq | milliequivalent | milliequivalent(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439547","Timepoint","C68568","A specific point in the time continuum, including those established relative to an event.","Timepoint | Point in Time | Time Point",,,,,,,,,,,,,,,"4152519","Points in time",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021034","Immunoglobulin Heavy Chain","C16717","A protein complex that consists of two heavy chains (gamma, alpha, delta, epsilon or mu). The larger of the two immunoglobulin chain types determines the immunoglobulin class (G, A, D, E or M, respectively). The heavy chain molecules exhibit the same structure and composition, which consists of constant, variable, and hypervariable regions.","Immunoglobulin Heavy Chain | IGH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021038","Immunoglobulin Light Chain","C16720","A protein complex that consists of two light chains (kappa and lambda). The light chain molecules are of the same structure and composition, consisting of constant, variable, and hypervariable regions.","Immunoglobulin Light Chain | Ig Light Chain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880593","Euclidean Distance Measurement","C65170","A generalization of the Pythagorean theorem to more than two coordinates. It is what would be obtained if the distance between two points were measured with a ruler: the 'intuitive' idea of distance.","Euclidean Distance Measurement | 2-norm Distance | Euclidean Distance | Euclidiean Distance Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883070","Spearman Rank-Order Correlation","C65171","A distribution-free analog of correlation analysis. Like regression, it can be applied to compare two independent random variables, each at several levels (which may be discrete or continuous). Unlike regression, Spearman's rank correlation works on ranked (relative) data, rather than directly on the data itself.","Spearman Rank-Order Correlation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0871052","Pearson Correlation Coefficient","C65172","A measure of the correlation of two variables X and Y measured on the same object or organism, that is, a measure of the tendency of the variables to increase or decrease together. It is defined as the sum of the products of the standard scores of the two measures divided by the degrees of freedom.","Pearson Correlation Coefficient | Pearson Product-moment Correlation Coefficient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883037","Single Linkage Cluster Analysis","C65177","A clustering method in which the distance between two clusters is determined by the distance of the two closest objects (nearest neighbors) in the different clusters.","Single Linkage Cluster Analysis | Nearest Neighbor | Single Linkage | Single Linkage Clustering",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879763","Average Linkage Cluster Analysis","C65183","A clustering method that determines the mean distance between all possible inter- or intra-cluster pairs.","Average Linkage Cluster Analysis | Average Linkage | Average Linkage Clustering",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880153","Complete Linkage Cluster Analysis","C65185","A clustering method in which the distance between two clusters is determined by the greatest distance between any two objects in the different clusters (furthest neighbors).","Complete Linkage Cluster Analysis | Complete Linkage | Complete Linkage Clustering | Furthest Neighbor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028688","Nursing Home","C53533","A residential health care facility for persons with chronic illness or disability.","Nursing Home | NURSING HOME | nursing home",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019947","Hospice","C53532","An establishment that provides palliative and supportive care for terminally ill patients and their families via physical, psychological, social and other forms of care.","Hospice | HOSPICE | Hospice Facility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042462","Vendors","C68608","A person or agency that promotes or exchanges goods or services for money; a seller.","Vendor | Seller | VENDOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347839","Commission on Cancer","C68607","A consortium of professional organizations dedicated to improving survival and quality of life for cancer patients through standard-setting, prevention, research, education, and the monitoring of comprehensive quality care.","Commission on Cancer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513784","Myeloablative Chemotherapy","C16231","The administration of high-dose chemotherapy, with or without total body irradiation, to eradicate the underlying disease and/or ablate the immune system of the patient.","Myeloablative Chemotherapy | myeloablative chemotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439583","Overnight","C65019","Occurring between nightfall and dawn.","Overnight | ",,,,,,,,,,,,,,,"4116375","Overnight",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0694888","PTEN Gene","C18256","This gene plays a role in signal transduction and apoptosis. It is also involved in the regulation of cell cycle progression.","PTEN Gene | PTEN | Phosphatase and Tensin Homolog Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448881","Military","C68638","The armed forces of a country.","Military | Armed Forces",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349972","Mother-in-law","C68639","The mother of your spouse.","Mother-in-law | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349973","Father-in-law","C68640","The father of your spouse.","Father-in-law | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348609","Supplement","C68641","Something added to complete a thing, make up for a deficiency, or extend or strengthen the whole; serving to complete or make an addition.","Supplement | Supplemental",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1627936","Latitude","C68642","The angular distance north or south between an imaginary line around a heavenly body parallel to its equator and the equator itself.","Latitude | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1657623","Longitude","C68643","An imaginary great circle on the surface of a heavenly body passing through the poles at right angles to the equator.","Longitude | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025071","Medicaid","C68633","A joint federal and state program that provides assistance with healthcare costs to people with low income and limited resources. Medicaid is run by state and local governments within federal guidelines. Healthcare bills are paid from federal, state and local tax funds. The eligibility for the program does not depend on a person's age. Participating beneficiaries usually pay no part of costs for covered healthcare expenses except a small co-payment required in some cases.","Medicaid | Medicaid Program | Public Health Insurance Medicaid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005528","Transport Process","C21079","Any subcellular or molecular process involved in translocation of a biological entity, such as a macromolecule, from one site or compartment to another.","Transport Process | Molecular Transport | Transport | Transport Reaction",,,,,,,,,,,,,,,"4238821","Biological transport",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL793064","Spontaneous Abortion","C34336","Fetal loss at less than 20 weeks of gestation.","Spontaneous Abortion | Miscarriage",,,,,,,,,,,,,,,"4067106","Miscarriage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3146284","Therapeutic Abortion Finding","C34338","An abortion performed on the individual due to a harmful medical condition caused by pregnancy.","Therapeutic Abortion Finding | Therapeutic Abortion | Therapeutic Abortion",,,,,,,,,,,,,,,"4204840","Therapeutic termination of pregnancy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004286","Audiometric Test","C38036","Testing conducted utilizing a manual or microprocessor audiometer to test for hearing loss.","Audiometric Test | AUDIOMETRY | Audiometric Testing | Audiometry | Hearing Test",,,,,,,,,,,,,,,"4071702","Audiometric test",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0276535","AIDS-Related Kaposi Sarcoma","C3992","The most aggressive form of Kaposi sarcoma. It presents in patients who are infected with the human immunodeficiency virus. It can affect the skin and internal organs.","AIDS-Related Kaposi Sarcoma | AIDS Related Kaposi's Sarcoma | AIDS, Kaposi's Sarcoma | AIDS-Related Kaposi's Sarcoma | AIDS-related Kaposi sarcoma | Autoimmune Deficiency Syndrome-Related Kaposi Sarcoma | Epidemic Kaposi's Sarcoma | Kaposi's Sarcoma AIDS Related | Kaposi's Sarcoma Epidemic Type",,,,,,,,,,,,,,,"434584","Kaposi's sarcoma (clinical)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825032","Withdrawal","C41341","A social or emotional detachment, pathological retreat from objective reality, interpersonal contact and social involvement, as in some forms of schizophrenia, depression, or schizoid, avoidant, or schizotypal personality disorders.","Withdrawal | Withdrawn",,,,,,,,,,,,,,,"4084560","Withdrawn",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704649","Transport Device","C50233","Any device designed to move something.","Transport Device | Transport | Transport Device Component",,,,,,,,,,,,,,,"4236220","Transport",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031774","Phrenic Nerve","C52813","Either of a pair of nerves that arise in the cervical plexus and provide innervation of the diaphragm.","Phrenic Nerve | PHRENIC NERVE",,,,,,,,,,,,,,,"4177178","Structure of phrenic nerve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1559198","Adverse Event Associated with Endocrine","C53801","no definition","Adverse Event Associated with the Endocrine System | Adverse Event Associated with Endocrine | ENDOCRINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963249","Tinnitus, CTCAE_3","C54959","no definition","Tinnitus, CTCAE 3.0 | Tinnitus | Tinnitus Adverse Event | Tinnitus, CTCAE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439851","Direct","C62254","As an immediate result; having nothing intervening; without deviation or interruption.","Direct | Directly",,,,,,,,,,,,,,,"4114684","Direct",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332296","Empty","C63628","Holding or containing nothing.","Empty | Free",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018935","Hematocrit Measurement","C64796","A measure of the volume of red blood cells expressed as a percentage of the total blood volume. Normal in males is 43-49%, in females 37-43%.","Hematocrit Measurement | EVF | Erythrocyte Volume Fraction | HCT | Hematocrit | Hematocrit | PCV | Packed Cell Volume",,,,,,,,,,,,,,,"4094760|4151358","Packed cell volume measurement|Hematocrit determination",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0523826","Phosphate Measurement","C64857","A quantitative measurement of the amount of phosphate present in a sample.","Phosphate Measurement | Inorganic Phosphate | PHOS | Phosphate | Phosphorus",,,,,,,,,,,,,,,"4017907","Phosphate measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0444868","All","C64916","To a complete degree or to the full or entire extent.","All | ALL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443144","At Rest","C64920","A period of being still or inactive.","At Rest | ",,,,,,,,,,,,,,,"4137022","At rest",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205087","Late","C64998","Being or occurring at an advanced period of time or after a usual or expected time.","Late | ",,,,,,,,,,,,,,,"4128643","Late",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1947925","Stop (Instruction Imperative)","C65125","Put an end to a state or an activity.","Stop | Cease | Quit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079427","Tumor Suppressor Gene","C17362","Tumor Suppressor Genes encode proteins whose functions inhibit expression of tumorigenic phenotypes by holding cellular proliferation in check. When inactivated or lost, a barrier to normal proliferation is removed and deregulated growth is possible. (NCI)","Tumor Suppressor Gene | Anti-Oncogene | Antioncogene | Tumor Suppressor | Tumor Suppressors | antioncogene | tumor suppressor gene",,,,,,,,,,,,,,,"4299771","Antioncogene",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1947917","Occlusion","C50678","Obstruction or a closure of hollow organ, passageway or vessel; also the transient approximation of the edges of a natural opening; imperforation.","Occlusion | Occlusal | Occlusive",,,,,,,,,,,,,,,"4135610","Occluded",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043432","Yttrium","C28199","An element with atomic symbol Y, atomic number 39, and atomic weight 88.91.","Yttrium | Y | YTTRIUM | yttrium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600596","DNA Microarray Chip","C18158","An orderly array of DNA samples affixed to a support.  Using robots thousands of samples can be arrayed on a single chip. The chip is used in various types of hybridization experiments.","DNA Microarray Chip | Chip | DNA Chip | DNA MICROARRAY | DNA Microarray | Gene Chip | Gene Expression Array",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242618","Sample Size","C53190","1. A subset of a larger population, selected for investigation to draw conclusions or make estimates about the larger population. 2. The number of subjects in a clinical trial. 3. Number of subjects required for primary analysis.","Sample Size | sample size",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347294","Mosteller Body Surface Area Formula","C68646","The formula to calculate body surface area as described by RD Mosteller. It is mathematically defined as: BSA (m^2) = ([Height(cm) x Weight(kg)]/3600)^0.5; e.g. BSA = SQRT((cm x kg)/3600)","Mosteller Body Surface Area Formula | Mosteller | Mosteller BSA Formula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348353","Dubois and Dubois Body Surface Area Formula","C68647","The formula to calculate body surface area as described by D and EF DuBois. It is mathematically defined as: BSA (m^2) = 0.20247 x [Height(m)^0.725] x [Weight(kg)^0.425]","Dubois and Dubois Body Surface Area Formula | Dubois and Dubois | Dubois and Dubois BSA Formula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348939","Haycock Body Surface Area Formula","C68648","The formula to calculate body surface area as described by GB Haycock et al. It is mathematically defined as: BSA (m^2) = 0.024265 x [Height(cm)^0.3964] x [Weight(kg)^0.5378]","Haycock Body Surface Area Formula | Haycock | Haycock BSA Formula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348739","Gehan and George Body Surface Area Formula","C68649","The formula to calculate body surface area as described by EA Gehan and SL George. It is mathematically defined as: BSA (m^2) = 0.0235 x Height(cm)^0.42246 x Weight(kg)^0.51456","Gehan and George Body Surface Area Formula | Gehan and George | Gehan and George BSA Formula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347048","Boyd Body Surface Area Formula","C68650","The formula to calculate body surface area as described by E Boyd. It is mathematically defined as: BSA (m^2) = 0.0003207 x [Height(cm)^0.3] x [Weight(g)^(0.7285 - (0.0188 x LOG(g))]","Boyd Body Surface Area Formula | Boyd | Boyd BSA Formula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023733","Linear Regression","C68651","The formula to calculate body surface area as described by John D. Current. It is mathematically defined as: BSA (m^2) = 1321 + 0.3433 x Weight(g)","Linear Regression Body Surface Area Formula for Infants and Children | Linear Regression | Linear Regression BSA Formula for Infants and Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347040","Body Surface Area Formula for Cats","C68653","The formula to calculate body surface area in cats. It is mathematically defined as: BSA (m^2) = (10.1 x Weight(g)^2/3)/1000","Body Surface Area Formula for Cats | BSA Formula for Cats | Feline | Feline BSA Formula | Felis domesticus BSA Formula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1450294","Nomogram Chart","C68654","A graphical calculating device or a two-dimensional diagram designed to allow the approximate graphical computation of a function.","Nomogram Chart | Nomogram | nomogram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347041","Body Surface Area Formula for Dogs","C68652","The formula to calculate body surface area in dogs. It is mathematically defined as: BSA (m^2) = (10.0 x Weight(g)^2/3)/1000","Body Surface Area Formula for Dogs | BSA Formula for Dogs | Canine | Canine BSA Formula | Canis (lupus) familiaris BSA Formula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085141","Indian Health Service","C68716","An agency within the Department of Health and Human Services. It is responsible for providing comprehensive health services to American Indians and Alaska Natives through IHS and tribally contracted hospitals, health centers, school health centers, and health stations.","Indian Health Service | IHS | Indian Health Service or Tribe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512062","Liposome-Encapsulated Doxorubicin Citrate","C61317","A formulation of the citrate salt of the antineoplastic anthracycline antibiotic doxorubicin, encapsulated within liposomes, with antitumor activity. Doxorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and RNA synthesis. This agent also interacts with cell membrane lipids causing lipid peroxidation. Liposomal delivery of doxorubicin improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects while lowering the toxicity profile.","Liposome-Encapsulated Doxorubicin Citrate | DOXORUBICIN CITRATE | Myocet | Non-pegylated liposomal doxorubicin | liposome-encapsulated doxorubicin citrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1144149","Lenalidomide","C2668","A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.","Lenalidomide | 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione | CC 5013 | CC-5013 | CC5013 | CDC 501 | LENALIDOMIDE | Revlimid | lenalidomide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337664","Smoker","C68751","A person who inhales or has inhaled combustible products of organic material during their lifetime.","Smoker | Current or Former Smoker",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1306898","Milliunit","C67315","A quantity equivalent to the one thousandth unit (10E-3 unit).","Milliunit | MilliUnit | mU | milliunit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938174","Five","C66836","A natural number greater than 4 and less than 6 and the quantity that it denotes: the sum of four and one.","Five | 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704680","Staining (finding)","C50753","Discoloration of patient tissue(s) produced by absorption of, or contact with, foreign matter, such as with medical dyes.","Staining | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0125090","L-Selectin","C17512","L-selectin (372 aa, ~42 kDa) is encoded by the human SELL gene. This protein plays a role in leukocyte adhesion and rolling.","L-Selectin | CD62 Antigen Ligand | CD62 Antigen-Like Family Member L | CD62L | CD62L Antigen | LAM-1 | LECAM1 | Leukocyte Adhesion Molecule 1 | Leukocyte Surface Antigen Leu-8 | Leukocyte-Endothelial Cell Adhesion Molecule 1 | Lymph Node Homing Receptor | Lymphocyte Adhesion Molecule 1 | Pln Homing Receptor | SELL | Selectin L | Selectin L | TQ1 | gp90-MEL",,,,,,,,,,,,,,,"4011784","Lymphocyte antigen CD62L",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003402","Antioxidant","C275","A group of organic or inorganic substances capable of preventing the genotoxic and carcinogenic effects of free-radical compounds. Antioxidants bind to and neutralize ('scavenge') free radicals, thereby transforming them into non-toxic compounds and blocking their genotoxic and carcinogenic effects. This class of agents includes the vitamins C and E, the carotenoids, and selenium. Organic antioxidants are found in high concentrations in fruits, seeds and vegetables.","Antioxidant | antioxidant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0537670","Oprelvekin","C1303","A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin 11 (IL-11). Secreted by bone marrow stromal cells and a number of mesenchymal cells, IL-11 binds to and activates its cell-surface receptor, promoting primary and secondary immune responses, modulating antigen-specific antibody reactions, and preventing apoptotic cell death.  This agent also stimulates the T-cell-dependent development of IgG-secreting B-cells in spleen cell cultures and may be an important regulator of megakaryocytopoiesis. (NCI04)","Oprelvekin | Adipogenesis Inhibitory Factor | IL-11 | Interleukin 11 | Interleukin-11 | Interleukin-11-Recombinant | Neumega | OPRELVEKIN | Recombinant Human Interleukin-11 | Recombinant Interleukin-11 | oprelvekin | recombinant human interleukin-11 | rhIL-11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL387764","Cardioprotective Agent","C2079","An agent that prevents damage to the heart, thereby protecting myocardial function.","Cardioprotective Agent | Cardiovascular Agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0451022","Beck Depression Inventory","C40438","A twenty-one question survey completed by a patient, with each answer scored on a scale of 0 to 3, designed to measure presence of depression.","Beck Depression Inventory | ",,,,,,,,,,,,,,,"4167608","Beck depression inventory",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025284","Meningeal Neoplasm","C3229","A benign or malignant neoplasm that affects the meninges.  The majority of the neoplasms arise from meningothelial cells and are called meningiomas.  Non-meningothelial cell neoplasms include mesenchymal, non-meningothelial tumors, hemangiopericytomas, and melanocytic lesions.","Meningeal Neoplasm | Meningeal Neoplasms | Meningeal Tumor | Meninges Neoplasm | Meninges Tumor | Neoplasm of Meninges | Neoplasm of the Meninges | Neoplasm of uncertain behavior of meninges, unspecified | Tumor of Meninges | Tumor of the Meninges",,,,,,,,,,,,,,,"4133829","Meningeal neoplasm (morphology)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1259807","CCNE1 protein, human","C21414","G1/S-specific cyclin-E1 (401 aa, ~47 kDa) is encoded by the human CCNE1 gene. This protein is involved in the progression of the cell cycle between the G1 and S phases.","G1/S-Specific Cyclin-E1 | CCNE1 | Cyclin E | Cyclin E1 | Cyclin E1 | Cyclin Es | Cyclin Et | Cyclin-E1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887551","Memory Dysfunction","C46084","Interference or disruption of memory processes. Memory dysfunction refers to the inability to store and retrieve information. This term encompasses a large number of problems and issues associated with intellectual functioning. 2005","Memory Dysfunction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553019","bit - unit of measure","C63625","A binary digit, the smallest unit of storage.","Bit | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707144","CPU (central processing unit of computer system)","C50332","The part of a computer which controls all the other parts. Designs vary widely but, in general, the CPU consists of the control unit, the arithmetic and logic unit (ALU) and memory (registers, cache, RAM and ROM) as well as various temporary buffers and other logic.","Central Processing Unit of Computer Device | CPU | Central Processing Unit | Central Processing Unit | Central Processing Unit of Computer Device Component | Processor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879980","Memory Cache","C63626","RAM memory that is set aside as a specialized buffer storage that is continually updated; used to optimize data transfers between system elements with different characteristics.","Memory Cache | Cache | Cache | cache",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553029","Kilo","C48436","A prefix indicating a quantity of one thousand, 10E3.","Kilo | [k] | k | kilo | kilo-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880108","Clock Speed","C63627","The fundamental rate in cycles per second at which a computer performs its most basic operations such as adding two numbers or transfering a value from one register to another.","Clock Speed | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882467","Processor Core","C64194","An integrated circuit design, usually for a microprocessor, which includes only the CPU and which is intended to form part of a complete circuit design which incorporates other circuits on the same chip such as cache, memory management unit, I/O ports and timers.","Processor Core | Core",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883173","Streaming SIMD Extensions","C64195","A central controller which broadcasts an instruction stream to all the processing elements.","Streaming SIMD Extensions | SSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883067","Space - property","C63629","An empty area; an area set apart or available for use.","Space | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882350","Persistent Memory Device","C64579","Any memory device that retains its stored data when the power is switched off.","Persistent Memory Device | Non-volatile Storage Device | Persistent Memory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881002","Graphics Processing Unit","C64196","A microprocessor specifically designed for processing 3D graphics data.","Graphics Processing Unit | GPU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706377","Memory","C50047","Any device that can hold data in machine-readable format.","Memory Device | Memory | Memory Device Component | Memory/Storage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015641","Fascia","C13108","A sheet or band of fibrous connective tissue enveloping, separating, or binding together muscles, organs, and other soft structures of the body.","Fascia | FASCIA | Human Fascia",,,,,,,,,,,,,,,"4224342","Structure of fascia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347984","Rural-Urban Continuum Code","C68926","A code from a classification scheme that distinguishes metropolitan counties by the population size of their metro area, and nonmetropolitan counties by degree of urbanization and adjacency to a metro area or areas.","Rural-Urban Continuum Code | Continuum COde",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0231303","Distress","C37942","A state of physiological or psychological stress that cannot be compensated for by normal adaptive measures.","Distress | distress",,,,,,,,,,,,,,,"4239819","Distress",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021585","Insect","C14227","A taxonomic class of arthropods that includes praying mantises, dragonflies, grasshoppers, true bugs, flies, bees, wasps, ants, butterflies, moths, and beetles.","Insect | Insecta | Invertebrates, Insects",,,,,,,,,,,,,,,"4304482","Class Insecta",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0439852","Indirect","C62255","Not as a direct effect or consequence; having intervening factors or persons or influences.","Indirect | ",,,,,,,,,,,,,,,"4115455","Indirect",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0108747","Fc-Gamma Receptor III","C17487","A family of low affinity receptors that bind to the Fc region of gamma immunoglobulin (IgG) monomers and aggregates. These receptors are expressed on the surface of natural killer cells, neutrophils, monocytes and macrophages. IgG binding initiates antibody-dependent cellular cytotoxicity and induces phagocytosis of antigen-antibody complexes.","Fc-Gamma Receptor III | CD16 | CD16 Antigen | CD16 Protein | FCG3 | FCGR3 | Fc Gamma Receptor III | Fc-Gamma RIII | FcRIII",,,,,,,,,,,,,,,"4078554","Lymphocyte antigen CD16",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0851286","Staff","C63612","The employees of an organization; personnel who assist their superior in carrying out an assigned task.","Staff | OrganizationStaff",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518549","Budget and Financial Management Office","C19207","Responsible for a broad range of Office of the Director strategic and financial management activities.","Budget and Financial Management Office | BFMO | Office of Budget and Financial Management | Office of Budget and Financial Management",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1260957","Blue","C48333","The hue of that portion of the visible spectrum lying between green and indigo, evoked in the human observer by radiant energy with wavelengths of approximately 420 to 490 nanometers; any of a group of colors that may vary in lightness and saturation, whose hue is that of a clear daytime sky.","Blue | BLUE",,,,,,,,,,,,,,,"4236881","Blue color",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1881109","ICD-O-3_Code","C66766","Indicates the matching ICD-O-3 code for the NCI Thesaurus concept.","ICD-O-3_Code | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0687673","Registered Nurse","C20824","Registered Nurse (R.N.) - a nurse who has graduated from an accredited registered nursing program, has passed the state exam for licensure, and been registered and licensed to practice by a state authority.  R.N.s receive educational preparation through hospital-based diploma programs, community/junior college associate's degree programs, baccalaureate programs, or combinations thereof.","Registered Nurse | R.N. | RN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0684004","Licensed Practical Nurse","C20822","Licensed Practical Nurse - a professional healthcare provider who has graduated from an accredited licensed practical nursing program, has passed the state exam for licensure, and been licensed to practice by a state authority.","Licensed Practical Nurse | LPN | LVN | Licensed Vocational Nurse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028657","Nurse Practitioner","C20852","A registered nurse (RN) with advanced training in diagnosing and treating illness.  NPs are master's degree prepared health experts that focus on helping patients achieve total health and prevent disease.  NPs focus on disease prevention, wellness, and patient education.  NPs prescribe medications, treat illness, and perform physical examinations.  NPs can function independently of physician intervention, but require a practice agreement with a physician. NPs are licensed by a state authority.","Nurse Practitioner | NP | nurse practitioner",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031833","Physician Assistant","C53423","A person trained and qualified to provide comprehensive diagnostic, preventive, and therapeutic medical care and services to patients under the guidance of the physician. A scope of physician assistant professional activity does not include the full range of interpretation of medical findings requiring the full professional background of the licensed physician. PAs are licensed by a state authority.","Physician Assistant | PA | PHYSICIAN ASSISTANT | physician assistant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512018","Doctor of Medicine","C39383","The Doctor of Medicine degree is the first-professional postgraduate degree that requires completion of a program that meets all of the following criteria: completion of the academic requirements to begin practice in the profession; at least 2 years of college work prior to entering the program; and a total of at least 6 academic years of college work to complete a program of studies in any branch of medical science, including prior required college work plus the length of the professional program itself. The academic standard is equivalent to Ph.D. science.","Doctor of Medicine | M.D. | MD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028655","Certified Nurse Midwife","C20830","A licensed health care practitioner educated in the two disciplines of nursing and midwifery. CNMs provide primary health care to women of childbearing age including: prenatal care, labor and delivery care, care after birth, gynecological exams, newborn care, assistance with family planning decisions, preconception care, menopausal management and counseling in health maintenance and disease prevention.","Certified Nurse Midwife | CNM | Nurse Midwife",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205238","True","C68850","Conforming to facts, reality or definitive criteria.","True | T",,,,,,,,,,,,,,,"4135944","True",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205237","False","C68851","Not in accordance with facts, reality or definitive criteria.","False | F",,,,,,,,,,,,,,,"4272339","False",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1547703","Room","C69074","An area within a building enclosed by walls and floor and ceiling.","Room | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229635","Metamyelocyte","C13116","A cell derived from a promyelocyte and differentiates into a neutrophil. It is nonproliferative and is usually found in bone marrow. Its nucleus is indented and the chromatin clumped and dense.","Metamyelocyte | ",,,,,,,,,,,,,,,"4307366","Metamyelocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0369715","Myelocyte","C13115","A cell derived from a promyelocyte. It differentiates into a metamyelocyte. It has a diameter of 10-18 micrometer, and an oval or round nucleus with finely granulated chromatin.","Myelocyte | ",,,,,,,,,,,,,,,"4027902","Myelocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0229655","Monoblast","C13014","A cell derived from a myeloid progenitor cell. It differentiates into a promonocyte. It is about 12 to 20 micrometer in diameter, has a round to oval nucleus with fine, lightly dispersed chromatin and one to four nucleoli. The cytoplasm is agranular, stains moderately to lightly basophilic, and often has an intensely stained periphery and a prominent perinuclear zone. Monoblasts are found in bone marrow and never appear in the normal peripheral blood.","Monoblast | ",,,,,,,,,,,,,,,"4202669","Monoblast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2350175","Erythroid Progenitor Cells","C12526","A unipotent hematopoietic progenitor cell derived from myeloid stem cells that is committed to the erythrocyte cell lineage.","Erythroid Stem Cell | EPC | Erythroid Precursor Cell | Erythroid Precursor Cells | Erythroid Progenitor Cell | Erythroid Progenitor Cells | Erythroid Stem Cells | Erythropoietic Progenitor Cell | Erythropoietic Progenitor Cells | Erythropoietic Stem Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3495095","Lithium Cation","C69075","A monovalent cation that is metabolized much like sodium and is important in many cellular functions inside or on the surface of cells.","Lithium Cation | LITHIUM CATION | Li+ | Lithium Ion | Lithium Ion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347299","Multidimensional","C67503","Having or involving or marked by several dimensions or aspects, generally indicating dimensionalities beyond 3D.","Multidimensional | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706463","Resolution Property","C47876","The size of the smallest element that can be separated from neighboring elements.","Resolution | Resolution Property",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0146283","TP53 protein, human","C17387","Cellular tumor antigen p53 (393 aa, ~44 kDa) is encoded by the human TP53 gene. This protein plays a role in the regulation of both the cell cycle and apoptosis.","Cellular Tumor Antigen p53 | Antigen NY-CO-13 | P53 | P53 Protein | Phosphoprotein P53 | Phosphoprotein p53 | TP53 | Transformation-Related Protein 53 | Tumor Protein p53 | Tumor Protein p53 | Tumor Suppressor p53 | p53 | p53 Tumor Suppressor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1430988","PTEN protein, human","C18181","Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (403 aa, ~47 kDa) is encoded by the human PTEN gene. This protein plays a role in signaling and as both a dual-specificity phosphoprotein phosphatase and a lipid phosphatase.","Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN | EC 3.1.3.16 | EC 3.1.3.48 | EC 3.1.3.67 | Mitochondrial PTENalpha | Mitochondrial Phosphatase and Tensin Protein Alpha | Mutated in Multiple Advanced Cancers 1 | PTEN | PTEN Tyrosine Phosphatase | PTEN Tyrosine Phosphatase | PTEN tyrosine phosphatase | Phosphatase and Tensin Homolog | Phosphatase and Tensin-Like Protein | Phosphatidylinositol-3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN | Phosphatidylinositol-3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025166","Megakaryocyte","C12553","Very large bone marrow cells which release mature blood platelets.","Megakaryocyte | Megakaryocytes | Megakaryocytic | Megalokaryocyte",,,,,,,,,,,,,,,"4126455","Megakaryocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1291081","Metabolic Pathway","C18611","An elaboration of the known steps and interactions for the metabolism of a compound.","Metabolic Pathway | Metabolic Pathways | Metabolism",,,,,,,,,,,,,,,"4045228","Metabolic pathway",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0439202","Nanometer","C67328","A metric unit of length equal to one billionth of a meter (10E-9 meter). Nanometer is used as a unit for light wavelength measurement.","Nanometer | nanometer | nanometer of light | nm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439224","Microsecond","C69149","A unit of time equal to one millionth of a second.","Microsecond | us | usec",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347516","Picometer","C69148","A metric unit of length equal to one trillionth of a meter (10E-12 meter).","Picometer | pm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348667","Femtometer","C69147","A metric unit of length equal to one quadrillionth of a meter (10E-15 meter).","Femtometer | Fermi | fm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2355595","Bishop - Courtesy Title","C69162","A courtesy title for a person who supervises a number of local churches or a diocese, being in the Greek, Roman Catholic, Anglican, and other churches a member of the highest order of the ministry.","Bishop | Bish.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0558269","Chaplain","C69163","A courtesy title for an ecclesiastic attached to the chapel of a royal court, college, etc., or to a military unit.","Chaplain | Ch. | chaplain",,,,,,,,,,,,,,,"4026056","Chaplain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348314","Doctor - Title","C69164","A courtesy title for a person who has received a doctorate degree or who practices medicine.","Doctor | Dr.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348513","Father - courtesy title","C69165","A courtesy title of reverence, as for church dignitaries, officers of monasteries, monks, confessors, and especially priests.","Father | Fr.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347167","Mr. - Title","C69166","A courtesy title for a man.","Mister | Mr.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349206","Miss - Title","C69167","A courtesy title for an unmarried woman.","Miss | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349188","Mrs - title","C69168","A courtesy title prefixed to the name of a married woman.","Mrs | Mistress | Mrs.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349943","Ms. - Title","C69169","A courtesy title used before the name of a woman without making a distinction between married and unmarried status.","Ms | Ms.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0599518","Professor","C69170","A courtesy title for a teacher of the highest academic rank in a college or university.","Professor | Prof.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0684010","Rabbi","C69171","A courtesy title of respect for the leader of a Jewish congregation, the chief religious official of a synagogue, or a Jewish scholar or teacher.","Rabbi | R.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347961","Reverend","C69172","A courtesy title of respect applied or prefixed to the name of a member of the clergy or a religious order.","Reverend | Rev.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2917383","Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor","C2167","Any agent that inhibits the activity of the epidermal growth factor receptor (EGFR) tyrosine kinase.","Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | EGFR Blocker | EGFR Inhibitor | EGFR Tyrosine Kinase Inhibitor | EGFR Tyrosine Kinase Inhibitors | EGFR-TK Inhibitor | Epidermal Growth Factor Receptor Inhibitor | Epidermal Growth-Factor Receptor Inhibitors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280573","cytarabine/daunorubicin protocol","C10271","No Value Exists","Cytarabine/Daunorubicin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348938","Hash Value","C68725","An irreversible unique number generated from a string of text. The hash value is calculated so that it's unlikely, but not impossible, for some other text string to result in the same hash value, but the calculation guarantees that the same string will always produce the same hash value.","Hash Value | Hash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2350015","Data Type -Character","C68805","Any single letter, number, or symbol.","Character | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0871421","Z-Score","C68741","A method for converting an individual score into a standard form. The z-score indicates how far and in what direction an item deviates from its distribution's mean, expressed in units of standard deviation. Calculation of a z-score requires knowledge about the population's standard deviation and mean.","Z-Score | Standard Score | Z SCORE | Z Score | ZScore",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347074","Mascot Scoring Engine","C68826","A proprietary scoring engine from Matrix Science that can match tandem mass spectra with peptide sequences.","Mascot Scoring Engine | Mascot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0424215","Identity","C68806","The set of characteristics by which a thing or person is recognized or known and that constitutes it's individuality or set inclusion.","Identity | ",,,,,,,,,,,,,,,"4085191","Sense of identity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022023","Ions","C597","An atom or molecule having a positive or negative charge owing to the loss or gain of one or more electrons.","Ion | Ions | ion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708939","Mass Spectrometry Markup Language","C47924","An XML based common file format for mass spectrometry data.","Mass Spectrometry Extensible Markup Language | Mass Spectrometry Extensible Markup Language | Mass Spectrometry Markup Language | MzXML | mzXML",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0563548","Charge","C48050","The quantity of unbalanced electricity in a body (either positive or negative) and construed as an excess or deficiency of electrons.","Charge | Charged",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880257","Decimal Ratio","C67272","A ratio expressed in base 10 notation.","Decimal Ratio | decimal ratio | {Decimal Ratio}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439187","Part Per Million","C48523","A unit of proportion equal to 10E-6.","Part Per Million | PART PER MILLION | PPM | Part per Million | Per Million | [ppm] | part per million | parts per million | ppm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439539","Heavy","C68807","Of comparatively great physical weight or density.","Heavy | ",,,,,,,,,,,,,,,"4235147","Heavy (weight)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347468","PeptideProphet","C68809","A software package for the statistical validation of peptide identifications made by tandem mass spectrometry (MS/MS) and database searching.","PeptideProphet | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709634","Precursor","C48044","A substance from which another substance is formed.","Precursor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012630","Discriminant Function Analysis","C68834","A statistical technique used to determine which variables discriminate between two or more naturally groups and to determine whether groups differ with regard to the mean of a variable.","Discriminant Function Analysis | Discriminant Function",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0597304","Proteolysis","C18105","Proteolysis typically involves hydrolysis of specific peptide bond(s) with formation of smaller polypeptides in a target protein during maturation or modification of functional activity. The process may be catalyzed by proteolytic enzymes, by acids, or by bases.","Proteolysis | Protein Cleavage | Proteolytic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348822","Tryptic Digestion","C68835","A technique for proteolysis of proteins into peptides at lysine or arginine by treatment with the pancreatic enzyme trypsin.","Tryptic Digestion | Trypsin Digestion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439844","Cover","C68811","Span a region or interval of distance, space or time.","Cover | Coverage | Covered",,,,,,,,,,,,,,,"4114510","Covered",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0599748","Tandem Mass Spectrometry","C18142","Mass spectrometers coupled in series.  The targeted compound is selectively ionized, and its characteristic ions are separated from others in the mixture in the first mass spectrometer. The selected primary ions are then decomposed by collision, and from the resulting products the final mass analyzer selects secondary ions characteristic of the targeted compound. Tandem mass spectrometry can achieve specificities and sensitivities equivalent of those of methods such as radioimmunoassay and gas chromatography/mass spectrometry, while performing analyses in much shorter times.","Tandem Mass Spectrometry | MS 2 | MS/MS | MS2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348185","Sequest Scoring Engine","C68825","A proprietary scoring engine from Thermo Fisher Scientific that can match tandem mass spectra with peptide sequences.","Sequest Scoring Engine | Sequest",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348012","Cross-Correlation","C68833","A statistical measure timing the movements and proximity of alignment between two different information sets of a series of information. A function of the relative time between the signals, it is a measure of similarity of two signals, commonly used to find features in an unknown signal by comparing it to a known one.","Cross-Correlation | Cross Correlation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347703","ProteinProphet","C68813","A software model that has as input the list of peptides assigned to MS/MS spectra and corresponding probabilities that those peptide assignments are correct. Different peptide identifications corresponding to the same protein are combined together to estimate the probability that their corresponding protein is present in the sample. This protein grouping information is then employed to adjust the individual peptide probabilities.","ProteinProphet | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349182","Correct","C68815","Free from error; especially conforming to fact or truth.","Correct | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349185","Signal Sensitivity","C68816","A measure of the minimum change in an input signal that an instrument can detect.","Sensitivity | Signal Sensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0183396","Mass Spectrometers (device)","C47875","An instrument that determines the exact mass of charged particles or ions by measuring the flight path through a set of magnetic and electric fields.","Mass Spectrometer | MS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348167","Search Engine","C68817","A computer program that retrieves documents or files or data from a database or from a computer network.","Search Engine | Search Program | Search Tool",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349162","X Tandem Scoring Engine","C68818","An open source scoring engine from The Global Proteome Machine Organization that can match tandem mass spectra with peptide sequences.","X Tandem Scoring Engine | X Tandem | X Tandem | X!Tandem | X!Tandem Scoring Engine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346898","B-Ion","C68840","In tandem mass spectrometry, the set of amino end (n-terminus) ions created from a peptide.","B-Ion | B-ion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349165","Y-Ion","C68841","In tandem mass spectrometry, the set of carboxyl end (c-terminus) ions created from a peptide.","Y-Ion | Y-ion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348941","Header of a document","C68829","A line of text serving to indicate what the passage below it is about.","Header | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205412","Inadequate","C69177","Not meeting a quantitative or qualitative measure necessary for a requirement.","Inadequate | Insufficient",,,,,,,,,,,,,,,"4215915","Inadequate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706501","Cuff Device","C49900","A bandlike device or structure that encircles a body part or another device.","Cuff Device | Cuff | Cuff | Cuff Device Component",,,,,,,,,,,,,,,"4154014","Device cuff",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0439214","Femtogram","C64552","The metric unit of mass equal to one quadrillionth of a gram (10E-15 gram).","Femtogram | fg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439213","Picogram","C64551","The metric unit of mass equal to one trillionth of a gram (10E-12 gram).","Picogram | pg | picogram | picogram(s) | picograms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475213","Femtoliter","C64780","The non-SI unit of volume accepted for use with the SI equal to one quadrillionth of a liter (10E-15 liter).","Femtoliter | Cubic Micrometer | Cubic Micron | fL | femtoliter | fl | um3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439241","Deciliter","C64697","The unit of volume equal to one tenth of a liter. Accepted for use with the SI.","Deciliter | DECILITER | dL | deciliter | dl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883351","To","C65107","Used as a function word to indicate direction, purpose, or movement.","To | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825139","Acute Myeloid Leukemia, Myelodysplasia-Related","C7600","An acute myeloid leukemia with at least 20% blasts in the bone marrow or blood, and either a previous history of myelodysplastic syndrome, multilineage dysplasia or myelodysplastic syndrome-related cytogenetic abnormalities.  There is no history of prior cytotoxic therapy for an unrelated disorder, and there is absence of the molecular abnormalities that are present in acute myeloid leukemia with recurrent genetic abnormalities.","Acute Myeloid Leukemia, Myelodysplasia-Related | AML with Myelodysplasia-Related Changes | AML with Myelodysplasia-related Changes | AML with myelodysplasia-related changes | AML-MRC | Acute Myeloid Leukemia with Multilineage Dysplasia | Acute Myeloid Leukemia with Myelodysplasia-Related Changes | Acute Myeloid Leukemia with Myelodysplasia-Related Changes | Acute myeloid leukemia with myelodysplasia-related changes","9895/3","Acute myeloid leukemia with myelodysplasia-related changes",,,,,,,,,,,,,"40483761","Acute myeloid leukemia with myelodysplasia-related changes",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0522630","Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11","C9287","An acute myeloid leukemia with monocytic and granulocytic differentiation and the presence of a characteristically abnormal eosinophil component in the bone marrow.  This type of acute myeloid leukemia has a favorable prognosis.  (WHO, 2001)","Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 | AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 | AML with inv(16)(p13q22) or t(16;16) (p13.1;q22), (CBFB/MYH11) | Acute Myeloid Leukemia with Abnormal Marrow Eosinophils | Acute Myeloid Leukemia with Abnormal Marrow Eosinophils | Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 Fusion | Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 | Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::MYH11 Fusion | Acute Myeloid Leukemia, CBF-beta/MYH11 | Acute Myeloid Leukemia, CBFB-MYH11 | Acute myeloid leukemia, CBF-beta/MYH11","9871/3","Acute myeloid leukemia with abnormal marrow eosinophils",,,,,,,,,,,,,"4304355","Acute myeloid leukemia with CBFB::MYH11 fusion",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1292774","Acute Myeloid Leukemia with t(8;21)(q22; q22.1); RUNX1-RUNX1T1","C9288","An acute myeloid leukemia with t(8;21)(q22; q22.1) giving rise to RUNX1/RUNX1T1 fusion transcript and showing maturation in the neutrophil lineage. The bone marrow and the peripheral blood show large myeloblasts with abundant basophilic cytoplasm, often containing azurophilic granules. This type of AML is associated with good response to chemotherapy and high complete remission rate.","Acute Myeloid Leukemia with t(8;21)(q22; q22.1); RUNX1-RUNX1T1 | AML with t(8;21)(q22;q22), RUNX1 RUNX1T1 | AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 | AML with t(8;21)(q22;q22.1); RUNX1-RUNX1T1 | Acute Myeloid Leukemia with t(8;21)(q22; q22.1); RUNX1-RUNX1T1 Fusion | Acute Myeloid Leukemia with t(8;21)(q22; q22.1); RUNX1::RUNX1T1 | Acute Myeloid Leukemia with t(8;21)(q22; q22.1); RUNX1::RUNX1T1 Fusion | Acute Myeloid Leukemia with t(8;21)(q22;q22) | Acute Myeloid Leukemia with t(8;21)(q22;q22)(AML1(CBFa)/ETO) | Acute Myeloid Leukemia with t(8;21)(q22;q22)(AML1(CBFa)/ETO) | Acute Myeloid Leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1 | Acute Myeloid Leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1 | Acute Myeloid Leukemia with t(8;21); (q22; q22.1); RUNX1-RUNX1T1 | Acute Myeloid Leukemia with t(8;21); (q22; q22.1); RUNX1-RUNX1T1 Fusion | Acute Myeloid Leukemia with t(8;21); (q22; q22.1); RUNX1::RUNX1T1 Fusion | Acute Myeloid Leukemia with t(8;21); (q22;q22.1); RUNX1-RUNX1T1 | Acute Myeloid Leukemia, t(8;21)(q22;q22) | Acute myeloid leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1","9896/3","Acute myeloid leukemia, t(8;21)(q22;q22)",,,,,,,,,,,,,"606958","Acute myeloid leukemia with t(8;21)(q22;q22) RUNX1-RUNX1T1",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C3831784","Acute Monoblastic and Monocytic Leukemia","C7318","Acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage, including monoblasts, promonocytes, and monocytes. Bleeding disorders are common presenting features.","Acute Monoblastic and Monocytic Leukemia | Acute Monoblastic Leukemia and Acute Monocytic Leukemia | Acute Monoblastic/Monocytic Leukemia | Acute Myeloid Leukemia M5 | Acute monoblastic and monocytic leukemia | FAB M5 (includes all variants) | M5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515809","t(9;22)(q34.1;q11.2)","C13271","A translocation between chromosomes 9 and 22 that is associated with the Philadelphia chromosome.","t(9;22)(q34.1;q11.2) | t(9;22)(q34;q11) | t(9;22)(q34;q11) | t(9;22)(q34;q11.2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515739","t(1;19)(q23;p13.3)","C27715","A chromosomal abnormality consisting of the translocation of 19p13.3 with 1q23, resulting in the fusion of the TCF3 (E2A) gene with the PBX1 gene.","t(1;19)(q23;p13.3) | TCF3-PBX1 t(1;19) | t(1;19) (q23;p13.3); PBX/E2A | t(1;19)(q23;p13.3); PBX/E2A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515749","t(21;22)(q22;q12)","C36367","A chromosomal translocation associated with Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor and Olfactory Neuroblastoma.","t(21;22)(q22;q12) | t(21;22) EWS-ERG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023464","Acute Biphenotypic Leukemia","C4673","An acute leukemia of ambiguous lineage characterized by blasts which coexpress myeloid and T or B lineage antigens or concurrent B and T lineage antigens.  (WHO, 2001)","Acute Biphenotypic Leukemia | Acute biphenotypic leukemia","9805/3","Acute biphenotypic leukemia",,,,,,,,,,,,,"4028711|4081867","Acute biphenotypic leukemia|Acute biphenotypic leukemia",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0560008","Nanoliter","C69188","A unit of volume equal to one billionth of a liter (10E-9 liter).","Nanoliter | nL | nanolitre(s) | nl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700176","Picoliter","C69189","A unit of volume equal to one trillionth of a liter (10E-12 liter).","Picoliter | pL | pl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439195","Femtomole","C68854","A unit of amount of substance equal to one quadrillionth of a mole (10E-15 mole).","Femtomole | fmol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439192","Picomole","C65045","A unit of amount of substance equal to a trillionth (10E-12) of a mole.","Picomole | picomole | pmol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439193","Attomole","C68855","A unit of amount of substance equal to one quintillionth of a mole (10E-18 mole).","Attomole | amol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205544","Cancel","C63471","Postpone indefinitely or annul something that was scheduled.","Cancel | Cancelation | Canceled",,,,,,,,,,,,,,,"4233952","Canceled",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709305","Occur (action)","C54069","Come to pass.","Occur | Happen | Happened | Occurred | Take Place | Took Place",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704685","Follow-Up Report","C53579","A report that comes some time after an initial study and report.","Follow-Up Report | FOLLOW-UP | Follow-Up",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448793","B-Cell Non-Hodgkin Lymphoma","C3457","The most common type of non-Hodgkin lymphoma.  It includes the most frequently seen morphologic variants which are: diffuse large B-cell lymphoma, follicular lymphoma, small lymphocytic lymphoma and marginal zone B-cell lymphoma.","B-Cell Non-Hodgkin Lymphoma | B-Cell Non Hodgkin's Lymphoma | B-Cell Non-Hodgkin's Lymphoma | B-cell lymphoma | Lymphomas Non-Hodgkin's B-Cell | Non-Hodgkin's B-Cell Lymphoma | Non-Hodgkin's Lymphoma B-Cell | Unspecified B-cell lymphoma, unspecified site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079772","T-Cell Non-Hodgkin Lymphoma","C3466","A non-Hodgkin lymphoma of T-cell lineage. It includes the T lymphoblastic lymphoma and the mature T- and NK-cell lymphomas.","T-Cell Non-Hodgkin Lymphoma | Non-Hodgkin's T-Cell Lymphoma | T Cell Lymphoma | T-Cell Lymphoma | T-Cell Non-Hodgkin's Lymphoma | T-Cell and NK-Cell Non-Hodgkin Lymphoma | T-Cell and NK-Cell Non-Hodgkin's Lymphoma | T-cell lymphoma",,,,,,,,,,,,,,,"4003183","T-cell lymphoma (clinical)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2853959","Peripheral T-Cell Lymphoma, Not Otherwise Specified","C4340","A group of peripheral T-cell lymphomas that do not meet the criteria for any other category of specifically defined entities of peripheral T-cell lymphoma.","Peripheral T-Cell Lymphoma, Not Otherwise Specified | Mature T-Cell Lymphoma, NOS | PTCL, NOS | PTCL-NOS | Peripheral T-Cell Lymphoma, NOS | Peripheral T-Cell Lymphoma, Unclassifiable | Peripheral T-cell lymphoma, NOS | Peripheral T-cell lymphoma, not classified, unspecified site | Unspecified Peripheral T-Cell Lymphoma","9702/3","Mature T-cell lymphoma, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C1707541","Cutaneous Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type","C45271","Follicular helper T-cell lymphoma, angioimmunoblastic-type affecting the skin.","Cutaneous Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | Cutaneous Angioimmunoblastic T-Cell Lymphoma | Cutaneous Angioimmunoblastic T-Cell Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332146","Acute Adult T-Cell Leukemia/Lymphoma","C36265","The most common variant of adult T-cell leukemia/lymphoma.  It is characterized by systemic disease with a leukemic phase, generalized lymphadenopathy, and skin lesions.  Hypercalcemia is commonly seen.","Acute Adult T-Cell Leukemia/Lymphoma | Acute Adult T-Cell Lymphoma/Leukemia | Acute Adult T-Cell Lymphoma/Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0855197","Malignant Testicular Germ Cell Tumor","C9063","A malignant germ cell tumor that arises from the testis. It predominantly affects young men. Seminoma is the most frequently seen malignant testicular germ cell tumor, followed by embryonal carcinoma and yolk sac tumor.","Malignant Testicular Germ Cell Tumor | Malignant Germ Cell Neoplasm of Testis | Malignant Germ Cell Neoplasm of the Testis | Malignant Germ Cell Tumor of Testis | Malignant Germ Cell Tumor of the Testis | Malignant Testicular Germ Cell Neoplasm | Testicular Cancer | Testicular Germ Cell Cancer | Testicular ca. (no germ/tropho.) | Testicular cancer (excluding germ cell or trophoblastic cancer) | testicular cancer",,,,,,,,,,,,,,,"37017381","Malignant germ cell tumor of testis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0585474","Ewing Sarcoma of Bone","C4835","A small round cell bone tumor that lacks morphologic, immunohistochemical, and electron microscopic evidence of neuroectodermal differentiation.  It represents one of the two ends of the spectrum called Ewing sarcoma/peripheral neuroectodermal tumor.  It often affects the diaphysis or metaphyseal-diaphyseal portion of long bones.  Clinical findings include pain and a mass in the involved area.  Fever, anemia, leukocytosis, and an increased sedimentation rate are often seen.  X-ray examination reveals osteolytic lesions.  The prognosis depends on the stage, anatomic location, and size of the tumor.","Ewing Sarcoma of Bone | Bone Ewing's Sarcoma | Ewing's Sarcoma of Bone | Ewing's Sarcoma, Osseous | Osseous Ewing's Sarcoma | Osseous Ewing's Tumor | Skeletal Ewing's Sarcoma | Skeletal Ewing's Tumor",,,,,,,,,,,,,,,"4144193","Ewing's sarcoma of bone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0279980","Extraskeletal Ewing Sarcoma","C7135","A rare malignant neoplasm of the soft tissues. It is typically a disease of children and young adults. Most commonly occurs in the paravertebral region, chest wall, pelvis and lower extremities. Treatment includes local excision with consideration for post-operative chemotherapy and/or radiotherapy.","Extraskeletal Ewing Sarcoma | EES | EOE | Extra-Osseous Ewing's Sarcoma | Extraosseous Ewing Sarcoma | Extraosseous Ewing Sarcoma | Extraosseous Ewing's Sarcoma | Extraosseous Ewing's Tumor | Extraskeletal Ewing sarcoma | Extraskeletal Ewing's Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0445247","Same","C64637","Equal, or closely similar or comparable, in kind or quality or quantity or degree.","Same | Idem | SAME",,,,,,,,,,,,,,,"4119043","Same",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1176309","Bortezomib","C1851","A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","Bortezomib | BORTEZOMIB | LDP 341 | LDP-341 | LDP341 | MLN 341 | MLN-341 | MLN341 | PS 341 | PS-341 | PS341 | Velcade | [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid | bortezomib | velcade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013216","Pharmacotherapy","C15986","Treatment of disease through the use of drugs.","Pharmacotherapy | Drug Therapy | Pharmaceutical Therapy | Pharmaceutical Therapy, NOS | Pharmacological Treatment | Pharmacological Treatments | Treatment With Medication | drug therapy",,,,,,,,,,,,,,,"4216752","Drug therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0278685","Stage I Ovarian Cancer AJCC v6 and v7","C7829","Stage I includes: T1, N0, M0. T1: Tumor limited to ovaries (one or both).  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)","Stage I Ovarian Cancer AJCC v6 and v7 | AJCC Stage I Ovarian Cancer | FIGO Stage I Cancer of Ovary | FIGO Stage I Cancer of the Ovary | FIGO Stage I Carcinoma of Ovary | FIGO Stage I Carcinoma of the Ovary | FIGO Stage I Ovarian Cancer | FIGO Stage I Ovarian Carcinoma | Ovarian Cancer Stage I | Stage I Ovarian Cancer | Stage I Ovarian Cancer | Stage I Ovarian Cancer AJCC v6 | Stage I Ovarian Cancer AJCC v7 | Stage I Ovarian Carcinoma | Stage I Ovarian Epithelial Cancer | stage I ovarian epithelial cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336121","Stage IA Ovarian Cancer","C5220","Stage IA includes: T1a, N0, M0.  T1a: Tumor limited to one ovary; capsule intact, no tumor on ovarian surface.  No malignant cells in ascites or peritoneal washings.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage IA Ovarian Cancer AJCC v6 and v7 | AJCC Stage IA Ovarian Cancer | FIGO Stage IA Cancer of Ovary | FIGO Stage IA Cancer of the Ovary | FIGO Stage IA Carcinoma of Ovary | FIGO Stage IA Carcinoma of the Ovary | FIGO Stage IA Ovarian Cancer | FIGO Stage IA Ovarian Carcinoma | Ovarian Cancer Stage IA | Stage IA Ovarian Cancer | Stage IA Ovarian Cancer | Stage IA Ovarian Cancer AJCC v6 | Stage IA Ovarian Cancer AJCC v7 | Stage IA Ovarian Epithelial Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336141","Ovarian Cancer Stage IB","C5221","Stage IB includes: T1b, N0, M0. T1b: Tumor limited to both ovaries; capsules intact, no tumor on ovarian surface.  No malignant cells in ascites or peritoneal washings.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage IB Ovarian Cancer AJCC v6 and v7 | AJCC Stage IB Ovarian Cancer | FIGO Stage IB Cancer of Ovary | FIGO Stage IB Cancer of the Ovary | FIGO Stage IB Carcinoma of Ovary | FIGO Stage IB Carcinoma of the Ovary | FIGO Stage IB Ovarian Cancer | FIGO Stage IB Ovarian Carcinoma | Ovarian Cancer Stage IB | Stage IB Ovarian Cancer | Stage IB Ovarian Cancer | Stage IB Ovarian Cancer AJCC v6 | Stage IB Ovarian Cancer AJCC v7 | Stage IB Ovarian Epithelial Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336150","AJCC Stage IC Ovarian Cancer","C5222","Stage IC includes: T1c, N0, M0. T1c: Tumor limited to one or both ovaries with any of the following: capsule ruptured, tumor on ovarian surface, malignant cells in ascites or peritoneal washings.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage IC Ovarian Cancer AJCC v6 and v7 | AJCC Stage IC Ovarian Cancer | FIGO Stage IC Cancer of Ovary | FIGO Stage IC Cancer of the Ovary | FIGO Stage IC Carcinoma of Ovary | FIGO Stage IC Carcinoma of the Ovary | FIGO Stage IC Ovarian Cancer | FIGO Stage IC Ovarian Carcinoma | Ovarian Cancer Stage IC | Stage IC Ovarian Cancer | Stage IC Ovarian Cancer | Stage IC Ovarian Cancer AJCC v6 | Stage IC Ovarian Cancer AJCC v7 | Stage IC Ovarian Epithelial Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278686","Stage II Ovarian Cancer AJCC v6 and v7","C7830","Stage II includes: T2, N0, M0.  T2: Tumor involves one or both ovaries with pelvic extension and/or implants.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage II Ovarian Cancer AJCC v6 and v7 | AJCC Stage II Ovarian Cancer | FIGO Stage II Cancer of Ovary | FIGO Stage II Cancer of the Ovary | FIGO Stage II Carcinoma of Ovary | FIGO Stage II Carcinoma of the Ovary | FIGO Stage II Ovarian Cancer | FIGO Stage II Ovarian Carcinoma | Ovarian Cancer Stage II | Stage II Ovarian Cancer | Stage II Ovarian Cancer | Stage II Ovarian Cancer AJCC v6 | Stage II Ovarian Cancer AJCC v7 | Stage II Ovarian Carcinoma | Stage II Ovarian Epithelial Cancer | stage II ovarian epithelial cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336169","AJCC Stage IIA Ovarian Cancer","C5223","Stage IIA includes: T2a, N0, M0.  T2a: Extension and/or implants on uterus and/or tube(s). No malignant cells in ascites or peritoneal washings.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage IIA Ovarian Cancer AJCC V6 and v7 | AJCC Stage IIA Ovarian Cancer | FIGO Stage IIA Cancer of Ovary | FIGO Stage IIA Cancer of the Ovary | FIGO Stage IIA Carcinoma of Ovary | FIGO Stage IIA Carcinoma of the Ovary | FIGO Stage IIA Ovarian Cancer | FIGO Stage IIA Ovarian Carcinoma | Ovarian Cancer Stage IIA | Stage IIA Ovarian Cancer | Stage IIA Ovarian Cancer | Stage IIA Ovarian Cancer AJCC V6 | Stage IIA Ovarian Cancer AJCC v7 | Stage IIA Ovarian Epithelial Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336192","Ovarian Cancer Stage IIB","C5224","Stage IIB includes: T2b N0, M0.  T2b: Extension and/or implants on other pelvic tissues.  No malignant cells in ascites or peritoneal washings.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage IIB Ovarian Cancer AJCC v6 and v7 | AJCC Stage IIB Ovarian Cancer | FIGO Stage IIB Cancer of Ovary | FIGO Stage IIB Cancer of the Ovary | FIGO Stage IIB Carcinoma of Ovary | FIGO Stage IIB Carcinoma of the Ovary | FIGO Stage IIB Ovarian Cancer | FIGO Stage IIB Ovarian Carcinoma | Ovarian Cancer Stage IIB | Stage IIB Ovarian Cancer | Stage IIB Ovarian Cancer | Stage IIB Ovarian Cancer AJCC v6 | Stage IIB Ovarian Cancer AJCC v7 | Stage IIB Ovarian Epithelial Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336199","Stage IIC Ovarian Carcinoma","C5225","Stage IIC includes: T2c, N0, M0.  T2c: Pelvic extension and/or implants (T2a or T2b) with malignant cells in ascites or peritoneal washing.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage IIC Ovarian Cancer AJCC v6 and v7 | AJCC Stage IIC Ovarian Cancer | FIGO Stage IIC Cancer of Ovary | FIGO Stage IIC Cancer of the Ovary | FIGO Stage IIC Carcinoma of Ovary | FIGO Stage IIC Carcinoma of the Ovary | FIGO Stage IIC Ovarian Cancer | FIGO Stage IIC Ovarian Carcinoma | Ovarian Cancer Stage IIC | Stage IIC Ovarian Cancer | Stage IIC Ovarian Cancer | Stage IIC Ovarian Cancer AJCC v6 | Stage IIC Ovarian Cancer AJCC v7 | Stage IIC Ovarian Epithelial Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278687","Stage III Ovarian Cancer AJCC v6 and v7","C7831","Stage III includes: T3, N0, M0.  T3: Tumor involves one or both ovaries with microscopically confirmed peritoneal metastasis outside pelvis.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage III Ovarian Cancer AJCC v6 and v7 | AJCC Stage III Ovarian Cancer | FIGO Stage III Cancer of Ovary | FIGO Stage III Cancer of the Ovary | FIGO Stage III Carcinoma of Ovary | FIGO Stage III Carcinoma of the Ovary | FIGO Stage III Ovarian Cancer | FIGO Stage III Ovarian Carcinoma | Ovarian Cancer Stage III | Stage III Ovarian Cancer | Stage III Ovarian Cancer | Stage III Ovarian Cancer AJCC v6 | Stage III Ovarian Cancer AJCC v7 | Stage III Ovarian Carcinoma | Stage III Ovarian Epithelial Cancer | stage III ovarian epithelial cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336212","Stage IIIA Ovarian Carcinoma","C6258","Stage IIIA includes: T3a, N0, M0.  T3a: Microscopic peritoneal metastasis beyond pelvis (no macroscopic tumor). N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage IIIA Ovarian Cancer AJCC v6 and v7 | AJCC Stage IIIA Ovarian Cancer | FIGO Stage IIIA Cancer of Ovary | FIGO Stage IIIA Cancer of the Ovary | FIGO Stage IIIA Carcinoma of Ovary | FIGO Stage IIIA Carcinoma of the Ovary | FIGO Stage IIIA Ovarian Cancer | FIGO Stage IIIA Ovarian Carcinoma | Ovarian Cancer Stage IIIA | Stage IIIA Ovarian Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Ovarian Cancer AJCC v6 | Stage IIIA Ovarian Cancer AJCC v7 | Stage IIIA Ovarian Epithelial Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336227","Stage IIIB Ovarian Carcinoma","C6259","Stage IIIB includes: T3b, N0, M0.  T3b: Macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage IIIB Ovarian Cancer AJCC v6 and v7 | AJCC Stage IIIB Ovarian Cancer | FIGO Stage IIIB Cancer of Ovary | FIGO Stage IIIB Cancer of the Ovary | FIGO Stage IIIB Carcinoma of Ovary | FIGO Stage IIIB Carcinoma of the Ovary | FIGO Stage IIIB Ovarian Cancer | FIGO Stage IIIB Ovarian Carcinoma | Ovarian Cancer Stage IIIB | Stage IIIB Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIB Ovarian Cancer AJCC v6 | Stage IIIB Ovarian Cancer AJCC v7 | Stage IIIB Ovarian Epithelial Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336237","Stage IIIC Ovarian Cancer","C6260","Stage IIIC includes: (T3c, N0, M0); (Any T, N1, M0). T3c: Peritoneal metastasis beyond pelvis more than 2cm in greatest dimension and/or regional lymph node metastasis. N0: No regional lymph node metastasis.  N1: Regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage IIIC Ovarian Cancer AJCC v6 and v7 | AJCC Stage IIIC Ovarian Cancer | FIGO Stage IIIC Cancer of Ovary | FIGO Stage IIIC Cancer of the Ovary | FIGO Stage IIIC Carcinoma of Ovary | FIGO Stage IIIC Carcinoma of the Ovary | FIGO Stage IIIC Ovarian Cancer | FIGO Stage IIIC Ovarian Carcinoma | Ovarian Cancer Stage IIIC | Stage IIIC Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IIIC Ovarian Cancer AJCC v6 | Stage IIIC Ovarian Cancer AJCC v7 | Stage IIIC Ovarian Epithelial Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278688","Stage IV Ovarian Cancer AJCC v6 and v7","C7832","Stage IV includes: Any T, Any N, M1.  M1: Distant metastasis (excludes peritoneal metastasis). (AJCC 6th and 7th eds.)","Stage IV Ovarian Cancer AJCC v6 and v7 | AJCC Stage IV Ovarian Cancer | FIGO Stage IV Cancer of Ovary | FIGO Stage IV Cancer of the Ovary | FIGO Stage IV Carcinoma of Ovary | FIGO Stage IV Carcinoma of the Ovary | FIGO Stage IV Ovarian Cancer | FIGO Stage IV Ovarian Carcinoma | Ovarian Cancer Stage IV | Stage IV Ovarian Cancer | Stage IV Ovarian Cancer | Stage IV Ovarian Cancer AJCC v6 | Stage IV Ovarian Cancer AJCC v7 | Stage IV Ovarian Carcinoma | Stage IV Ovarian Epithelial Cancer | stage IV ovarian epithelial cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882212","Ovarian Cancer pT0 TNM Finding v6","C60902","Ovarian cancer with no evidence of a primary tumor. (from AJCC 6th Ed.)","Ovarian Cancer pT0 TNM Finding v6 | Ovarian Cancer pT0 TNM Finding | pT0 Cancer of Ovary v6 | pT0 Cancer of the Ovary v6 | pT0 Carcinoma of Ovary v6 | pT0 Carcinoma of the Ovary v6 | pT0 Ovarian Cancer v6 | pT0 Ovarian Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882213","Ovarian Cancer pT1 TNM Finding v6","C60904","Ovarian cancer with tumor confined to one or both ovaries. (from AJCC 6th Ed.)","Ovarian Cancer pT1 TNM Finding v6 | Ovarian Cancer pT1 TNM Finding | pT1 Cancer of Ovary v6 | pT1 Cancer of the Ovary v6 | pT1 Carcinoma of Ovary v6 | pT1 Carcinoma of the Ovary v6 | pT1 Ovarian Cancer v6 | pT1 Ovarian Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882214","Ovarian Cancer pT1a TNM Finding v6","C60905","Ovarian cancer with tumor in one ovary with capsule intact, no tumor on ovarian surface and no malignant cells in either ascites or peritoneal washings. The presence of ascites does not affect staging unless malignant cells are present. (from AJCC 6th Ed.)","Ovarian Cancer pT1a TNM Finding v6 | Ovarian Cancer pT1a TNM Finding | pT1a Cancer of Ovary v6 | pT1a Cancer of the Ovary v6 | pT1a Carcinoma of Ovary v6 | pT1a Carcinoma of the Ovary v6 | pT1a Ovarian Cancer v6 | pT1a Ovarian Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882215","Ovarian Cancer pT1b TNM Finding v6","C60906","Ovarian cancer with tumor in both ovaries with capsule intact, no tumor on ovarian surface and no malignant cells in either ascites or peritoneal washings. The presence of ascites does not affect staging unless malignant cells are present. (from AJCC 6th Ed.)","Ovarian Cancer pT1b TNM Finding v6 | Ovarian Cancer pT1b TNM Finding | pT1b Cancer of Ovary v6 | pT1b Cancer of the Ovary v6 | pT1b Carcinoma of Ovary v6 | pT1b Carcinoma of the Ovary v6 | pT1b Ovarian Cancer v6 | pT1b Ovarian Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882216","Ovarian Cancer pT1c TNM Finding v6","C60907","Ovarian cancer involving one or both ovaries with either a ruptured capsule, or tumor on the ovarian surface, or presence of malignant cells in either ascites or peritoneal washings. (from AJCC 6th Ed.)","Ovarian Cancer pT1c TNM Finding v6 | Ovarian Cancer pT1c TNM Finding | pT1c Cancer of Ovary v6 | pT1c Cancer of the Ovary v6 | pT1c Carcinoma of Ovary v6 | pT1c Carcinoma of the Ovary v6 | pT1c Ovarian Cancer v6 | pT1c Ovarian Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882217","Ovarian Cancer pT2 TNM Finding v6","C60908","Ovarian cancer involving one or both ovaries with pelvic extension and/or implants. (from AJCC 6th Ed.)","Ovarian Cancer pT2 TNM Finding v6 | Ovarian Cancer pT2 TNM Finding | pT2 Cancer of Ovary v6 | pT2 Cancer of the Ovary v6 | pT2 Carcinoma of Ovary v6 | pT2 Carcinoma of the Ovary v6 | pT2 Ovarian Cancer v6 | pT2 Ovarian Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882218","Ovarian Cancer pT2a TNM Finding v6","C60909","Ovarian cancer involving one or both ovaries with extension or implants on uterus and/or fallopian tubes and without malignant cells in ascites or peritoneal washings. (from AJCC 6th Ed.)","Ovarian Cancer pT2a TNM Finding v6 | Ovarian Cancer pT2a TNM Finding | pT2a Cancer of Ovary v6 | pT2a Cancer of the Ovary v6 | pT2a Carcinoma of Ovary v6 | pT2a Carcinoma of the Ovary v6 | pT2a Ovarian Cancer v6 | pT2a Ovarian Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882219","Ovarian Cancer pT2b TNM Finding v6","C60910","Ovarian cancer involving one or both ovaries with extension or implants on pelvic tissues other than the uterus or fallopian tubes, and without malignant cells in ascites or peritoneal washings. (from AJCC 6th Ed.)","Ovarian Cancer pT2b TNM Finding v6 | Ovarian Cancer pT2b TNM Finding | pT2b Cancer of Ovary v6 | pT2b Cancer of the Ovary v6 | pT2b Carcinoma of Ovary v6 | pT2b Carcinoma of the Ovary v6 | pT2b Ovarian Cancer v6 | pT2b Ovarian Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882220","Ovarian Cancer pT2c TNM Finding v6","C60911","Ovarian cancer involving one or both ovaries with extension or implants on the uterus and/or fallopian tubes, or other pelvic tissues, with malignant cells in either ascites or peritoneal washings. (from AJCC 6th Ed.)","Ovarian Cancer pT2c TNM Finding v6 | Ovarian Cancer pT2c TNM Finding | pT2c Cancer of Ovary v6 | pT2c Cancer of the Ovary v6 | pT2c Carcinoma of Ovary v6 | pT2c Carcinoma of the Ovary v6 | pT2c Ovarian Cancer v6 | pT2c Ovarian Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882221","Ovarian Cancer pT3 TNM Finding v6","C60912","Ovarian cancer involving one or both ovaries with microscopic or macroscopic peritoneal metastasis beyond the pelvis. (from ACJCC 6th Ed.)","Ovarian Cancer pT3 TNM Finding v6 | Ovarian Cancer pT3 TNM Finding | pT3 Cancer of Ovary v6 | pT3 Cancer of the Ovary v6 | pT3 Carcinoma of Ovary v6 | pT3 Carcinoma of the Ovary v6 | pT3 Ovarian Cancer v6 | pT3 Ovarian Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882222","Ovarian Cancer pT3a TNM Finding v6","C60913","Ovarian cancer involving one or both ovaries with microscopically confirmed peritoneal metastasis beyond the pelvis. (from AJCC 6th Ed.)","Ovarian Cancer pT3a TNM Finding v6 | Ovarian Cancer pT3a TNM Finding | pT3a Cancer of Ovary v6 | pT3a Cancer of the Ovary v6 | pT3a Carcinoma of Ovary v6 | pT3a Carcinoma of the Ovary v6 | pT3a Ovarian Cancer v6 | pT3a Ovarian Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882223","Ovarian Cancer pT3b TNM Finding v6","C60914","Ovarian cancer involving one or both ovaries with macroscopic peritoneal metastasis beyond the pelvis, with tumor size of 2 cm or less in greatest dimension. (from AJCC 6th Ed.)","Ovarian Cancer pT3b TNM Finding v6 | Ovarian Cancer pT3b TNM Finding | pT3b Cancer of Ovary v6 | pT3b Cancer of the Ovary v6 | pT3b Carcinoma of Ovary v6 | pT3b Carcinoma of the Ovary v6 | pT3b Ovarian Cancer v6 | pT3b Ovarian Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882224","Ovarian Cancer pT3c TNM Finding v6","C60915","Ovarian cancer involving one or both ovaries with macroscopic peritoneal metastasis beyond the pelvis, with tumor size of more than 2 cm in greatest dimension. (from AJCC 6th Ed.)","Ovarian Cancer pT3c TNM Finding v6 | Ovarian Cancer pT3c TNM Finding | pT3c Cancer of Ovary v6 | pT3c Cancer of the Ovary v6 | pT3c Carcinoma of Ovary v6 | pT3c Carcinoma of the Ovary v6 | pT3c Ovarian Cancer v6 | pT3c Ovarian Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882225","Ovarian Cancer pTX TNM Finding v6","C60901","Ovarian cancer in which the primary tumor cannot be assessed. (from AJCC 6th Ed.)","Ovarian Cancer pTX TNM Finding v6 | Ovarian Cancer pTX TNM Finding | pTX Cancer of Ovary v6 | pTX Cancer of the Ovary v6 | pTX Carcinoma of Ovary v6 | pTX Carcinoma of the Ovary v6 | pTX Ovarian Cancer v6 | pTX Ovarian Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225757","Middle Lobe of the Right Lung","C12286","The smallest lobe of the right lung, situated above the oblique fissure and below the horizontal fissure.","Middle Lobe of the Right Lung | LUNG, RIGHT MIDDLE LOBE | Lung Middle Lobe | Middle Lobe | Middle Lobe of Lung | Middle lobe, lung | RML | Right Middle Lobe, Lung",,,,,,,,,,,,,,,"4247919","Structure of middle lobe of right lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1948020","Overlap","C54669","The phenomenon of coinciding partially or wholly; extending over and covering a part of.","Overlap | Overlapping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0000934","Acclimatization","C68767","The physiological process through which an organism grows accustomed to a new environment.","Acclimatization | Acclimation | Climate Adaptation | Climate Adapted",,,,,,,,,,,,,,,"4246097","Acclimation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0234402","Stimulus","C41210","An environmental event, agent, act, or influence that can be detected by a receptor in the body and will invariably produce a reaction in a living organism, e.g. change in the behavior, functional or trophic reaction.","Stimulus | Stimuli",,,,,,,,,,,,,,,"4231303","Stimulus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL427986","Body Fluid or Substance","C13236","Material produced by living organisms; it can be a necessary constituent of, or product of an organismal process.","Body Fluid or Substance | Body Fluids and Substances | Body Fluids or Substances | FLUID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011121","Decontamination","C68769","To rid of contamination.","Decontamination | DECONTAMINATING | Decontaminate",,,,,,,,,,,,,,,"4260064","Decontamination",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0200765","Image Processing","C17606","The use of data processing systems to analyze, enhance, interpret or display digital images.","Image Processing | Image Analysis",,,,,,,,,,,,,,,"4076808","Image analysis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1511160","Biomolecule Separation Technology","C18653","Techniques for separating biomolecules from suspensions or mixtures, based on physical and chemical properties. Such techniques include ion exchange columns, gel filtration methods, affinity chromatography, HPLC, aqueous two phase partitioning, and membrane separation.","Biomolecule Separation Technology | Biomolecule Separations Technology | Biomolecule Separations Technology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518613","Organism Modification","C22489","Techniques used for deliberately altering the genetic material of an organism in order to make them capable of making new substances or performing new or different functions.","Organism Modification | Genetic Modification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1439852","Incubated","C15685","Grown in the laboratory under controlled conditions. For example, white blood cells can be grown in special conditions so that they attack specific cancer cells when returned to the body.","Incubated | incubated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987620","Inoculation","C68774","To implant microbes or infective materials, introduce immune serum, vaccines of various kinds, and other antigenic materials for preventive, curative, or experimental purposes.","Inoculation | Inoculate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346678","Linear Amplification Technique","C68778","Various methods for amplification of nucleic acid sequences by making many copies off the same template.","Linear Amplification Technique | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028606","Nucleic Acids","C706","Type of substance that may be described as a linear sequence of nucleosides typically linked through phosphate esters.","Nucleic Acids | NUCLEIC ACID SUBSTANCE | Nucleic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349200","Pool (action)","C68779","Combine together into a single unit, group, or sample.","Pool | POOLING | Pooled | Pooling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514402","Preservation Technique","C19232","Procedures utilized to save substances from decay. Some preservation procedures are meant to maintain cells, tissues, or organisms in a viable state.","Preservation Procedure | Preservation | Preservation Method | Preservation Technique | preservation method | preservation_method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0243114","purification aspects","C68780","The process of removing impurities.","Purification | Purified | Purify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035380","Reverse Transcription Process","C17097","The action of copying RNA into DNA by reverse transcriptase.","Reverse Transcription Process | Reverse Transcription | Reverse Transcription | reverse transcription",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL370083","Sacrifice","C68781","To kill an experimental animal.","Sacrifice | Destroy | Kill",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1534709","Split","C54572","To separate or divide into distinct parts or portions.","Split | Bifid | SPLIT | Splitting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348531","Starve","C68782","To deprive an organism of food or nutrients.","Starve | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040669","Transfection","C17209","The process of introduction of DNA into a recipient eukaryote cell and its subsequent integration into the recipient cell's chromosomal DNA, so that the cells or progeny may express the integrated donor gene.","Transfection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441648","Wash (cleansing action)","C65077","Cleanse with a cleaning agent, such as soap, and water.","Wash | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439091","Greater Than or Equal To","C61583","A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest exceeds the other object in one of these ways.","Greater Than or Equal To | GE | Greater than or equal to | NLT | NLT (not less than) | Not Less Than",,,,,,,,,,,,,,,"4171755",">=",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0439807","Radical","C68786","Directed to the root or source of a morbid process; to remove the root of a disease or all diseased tissue, as radical surgery.","Radical | ",,,,,,,,,,,,,,,"4112436","Radical",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041687","Unilateral Oophorectomy","C29892","Surgery to remove one ovary.","Unilateral Oophorectomy | Unilateral Ovariectomy | ovariectomy - unilateral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036132","Salpingo-Oophorectomy","C15323","Surgical removal of the fallopian tube(s) and ovary(ies).","Salpingo-Oophorectomy | salpingo-oophorectomy",,,,,,,,,,,,,,,"4021363","Salpingo-oophorectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0195495","Bilateral Salpingectomy with Oophorectomy","C51765","Surgery to remove both fallopian tubes, as well as both ovaries.","Bilateral Salpingectomy with Oophorectomy | bilateral salpingo-oophorectomy",,,,,,,,,,,,,,,"4107080","Excision of bilateral fallopian tubes and ovaries",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0812449","Omentectomy","C51787","Partial or complete resection of the omentum.","Omentectomy | Epiploectomy | Resection of Omentum | omentectomy",,,,,,,,,,,,,,,"4300662","Omentectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0741614","Intestine Resection","C51652","Surgical removal of part or all of the intestine.","Intestine Resection | Bowel Resection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1947911","combination of objects","C61517","A collection of things that have been assembled together to form a new whole.","Combination | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015258","Exenteration","C68790","Removal of internal organs and tissues, usually radical removal of the contents of a body cavity.","Exenteration | Evisceration | exenteration",,,,,,,,,,,,,,,"4032155|4106054","Evisceration|Exenteration - action",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0919267","Ovarian Neoplasm","C4984","A benign, borderline, or malignant neoplasm involving the ovary.","Ovarian Neoplasm | Neoplasm of Ovary | Neoplasm of the Ovary | Ovarian Tumor | Ovarian Tumors | Tumor of Ovary | Tumor of the Ovary",,,,,,,,,,,,,,,"4047650","Neoplasm of ovary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL938173","Four","C66835","A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one.","Four | 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514691","Radiation Non-Ionizing, Diagnostic Imaging","C18981","The use of non-ionizing radiation such as X-rays to obtain internal images of the body","Radiation Non-Ionizing, Diagnostic Imaging | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514690","Radiation Ionizing, Diagnostic Imaging","C18980","A technique for medical imaging that uses ionizing radiation like X-rays and gamma rays. Both x-rays and gamma rays are high energy, short wavelength electromagnetic radiation that are capable of penetrating and passing through most tissues. The technique is highly useful to determine the presence or absence of a specific medical condition.","Radiation Ionizing, Diagnostic Imaging | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0740294","Biopsy of Brain","C51766","Removal of brain tissue for microscopic examination.","Biopsy of Brain | Brain Biopsy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517925","Local Therapy","C15687","Any therapeutic procedure that targets, or is restricted to, a specific anatomical location.","Local Therapy | Localized Therapy | local therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0260055","Liquid Nitrogen","C68796","Nitrogen in a liquid state, having been super-cooled to -196 degrees Celsius.","Liquid Nitrogen | LN2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810371","Malignant Ovarian Neoplasm","C7431","A primary or metastatic malignant neoplasm involving the ovary. Most primary malignant ovarian neoplasms are either carcinomas (serous, mucinous, or endometrioid adenocarcinomas) or malignant germ cell tumors. Metastatic malignant neoplasms to the ovary include carcinomas, lymphomas, and melanomas.","Malignant Ovarian Neoplasm | Cancer of Ovary | Cancer of the Ovary | Malignant Neoplasm of Ovary | Malignant Neoplasm of the Ovary | Malignant Ovarian Tumor | Malignant Tumor of Ovary | Malignant Tumor of the Ovary | Malignant neoplasm of unspecified ovary | Ovarian Cancer | Ovarian cancer, NOS | ovarian cancer",,,,,,,,,,,,,,,"4181351","Malignant tumor of ovary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1711411","Verification","C45513","Support or establish by evidence or proof.","Verification | Verified | Verify | verification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879849","Biospecimen Core Resource Facility","C63636","A central facility to qualify, quality assure, and distribute human biomolecules in support of the development of the Cancer Genome Atlas (TCGA). Standard procedures will be used for all steps, including informed consent, clinical data collection, sample collection, pathology review, biomolecule extractions, quality control, laboratory data collection, and biomolecule distribution. The BCR will minimize the variability introduced by the collection, processing, and handling of tissues.","Biospecimen Core Resource | BCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882531","RNA Integrity Number","C63637","A numerical assessment of the integrity of RNA based on the entire electrophoretic trace of the RNA sample, including the presence or absence of degradation products.","RNA Integrity Number | RIN | rin | rna integrity number | rna_integrity_number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518435","Nuclear Grade","C18513","An evaluation of the size and shape of the nucleus in tumor cells and the percentage of tumor cells that are in the process of dividing or growing. Cancers with low nuclear grade grow and spread less quickly than cancers with high nuclear grade.","Nuclear Grade | nuclear grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014257","Endothelium","C12481","The layer of cells that lines the cavities of the heart and of the blood vessels (Endothelium, Vascular) and lymph vessels (Endothelium, Lymphatic), and the serous cavities of the body, originating from the mesoderm.","Endothelium | Endothelial",,,,,,,,,,,,,,,"4098413","Structure of endothelium tissue",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347442","Palisading Necrosis","C68752","A morphologic appearance consisting of small, irregular regions of necrosis surrounded by dense accumulations of tumor cells; the tumor cells are more densely packed at the edge of the necrosis than in other regions of the tumor and thus appear to 'palisade' around the necrotic zone.","Palisading Necrosis | Palisading",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439294","Kilogram per Cubic Meter","C42576","A SI derived unit of mass concentration defined as the concentration of one kilogram of a substance per unit volume of the mixture equal to one cubic meter, or the concentration of one milligram of a substance per unit volume of the mixture equal to one milliliter, or one gram of a substance per one liter of the mixture. It is also a unit of mass density (volumic mass) defined as the density of substance which mass equal to one milligram occupies the volume one milliliter.","Kilogram per Cubic Meter | Gram per Cubic Decimeter | Gram per Liter | Kilogram/Cubic Meter | Microgram per Microliter | Milligram per Milliliter | g/L | g/dm3 | g/l | gram per liter | gram(s)/litre | kg/m3 | kilogram per meter cubed | kilogram(s)/cubic meter | mg/mL | mg/ml | microgram(s)/microlitre | milligram per milliliter | milligram(s)/millilitre | ug/uL | ug/ul",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333735","Gemistocytic Neoplastic Astrocyte","C37132","A pathologic astrocyte in which the cell body swells and contains glial filaments and an eccentric nucleus; seen particularly in demyelinating and neoplastic conditions.","Gemistocytic Neoplastic Astrocyte | Gemistocyte | Gemistocytic Astrocyte | Reactive Astrocyte",,,,,,,,,,,,,,,"4207823","Gemistocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347390","Oligodendroglial Component Present","C68766","A tumor component characterized by the presence of a diffuse, homogeneous population of tumor cells (oligodendroglial cells) with round nuclei and clear cytoplasm.  The infiltrate has a honeycomb appearance.  An oligodendroglial component can be seen in central nervous system tumors including glioblastomas and mixed gliomas.","Oligodendroglial Component Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL963933","GFAP protein, human","C68804","Glial fibrillary acidic protein (432 aa, ~50 kDa) is encoded by the human GFAP gene. This protein may be involved in both neuronal maintenance and astrocyte morphology and motility.","Glial Fibrillary Acidic Protein | GFAP | GFAP Alpha | GFAP-Alpha | GFAP-alpha | GFAP-alpha Isoform | GFAPa | GLIAL FIBRILLARY ACIDIC PROTEIN ALPHA SUBUNIT | Glial Fibrillary Acidic Protein Alpha Isoform",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0872291","Timespan","C68594","The period of time between two dates or events or between the beginning and end of something.","Timespan | Time Frame | Time Interval",,,,,,,,,,,,,,,"4250771","Time frame",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883710","Clamping Activity","C63659","To fasten, grip, or support with or as if with a clamp.","Clamping | Clamp | Clamping Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1318551","Myelodysplastic Syndrome/Acute Myeloid Leukemia","C7168","A myelodysplastic syndrome characterized by the presence of dysplasia in one or more hematopoietic cell lineages and 10-19% blasts in bone marrow or peripheral blood.","Myelodysplastic Syndrome/Acute Myeloid Leukemia | MDS with Increased Blasts-2 | MDS-EB-2 | MDS-EB2 | MDS-IB-2 | MDS-IB2 | MDS/AML | Myelodysplastic Syndrome with Excess Blasts-2 | Myelodysplastic Syndrome with Excess Blasts-2 | RAEB II | RAEB-2 | RAEB-2 | RAEB-II | Refractory anemia with excess of blasts 2",,,,,,,,,,,,,,,"4187355|4288089","Myelodysplastic syndrome with excess blasts-2|Myelodysplastic neoplasm with increased blasts-2",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1301356","Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia","C27726","A myelodysplastic syndrome characterized by bi-cytopenia or pancytopenia, dysplastic changes in 10% or more of the cells in two or more of the myeloid cell lines, and 15% or more ring sideroblasts in the bone marrow.  (WHO, 2001)","Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia | MDS-RS-MLD | RCMD-RS | Refractory Cytopenia with Multilineage Dysplasia and Ring Sideroblasts | Refractory Cytopenia with Multilineage Dysplasia and Ring Sideroblasts | Refractory Cytopenia with Multilineage Dysplasia and Ringed Sideroblasts | Refractory Cytopenia with Multilineage Dysplasia and Ringed Sideroblasts | Refractory cytopenia with multilineage dysplasia and ring sideroblasts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1292779","Myelodysplastic Syndrome with del(5q)","C6867","A myelodysplastic syndrome characterized by a deletion between bands q31 and 33 on chromosome 5.  The number of blasts in the bone marrow and blood is <5%.  The bone marrow is usually hypercellular or normocellular with increased number of often hypolobated megakaryocytes.  The peripheral blood shows macrocytic anemia.  This syndrome occurs predominantly but not exclusively in middle age to older women.  The prognosis is good and transformation to acute leukemia is rare.  (WHO, 2001)","Myelodysplastic Syndrome with del(5q) | 5Q minus syndrome | 5Q- syndrome | 5q- Syndrome | MDS-del(5q) | Myelodysplastic Neoplasm with Low Blasts and 5q Deletion | Myelodysplastic Syndrome Associated with Isolated del (5q) Chromosome Abnormality | Myelodysplastic Syndrome Associated with Isolated del (5q) Chromosome Abnormality | Myelodysplastic Syndrome with 5q Deletion | Myelodysplastic Syndrome with Isolated Del (5Q) | Myelodysplastic Syndrome with Isolated del(5q) | Myelodysplastic Syndrome with Isolated del(5q) | Myelodysplastic syndrome with 5q deletion (5q-) syndrome | Myelodysplastic syndrome with isolated del (5q) | Myelodysplastic syndrome with isolated del (5q) chromosomal abnormality",,,,,,,,,,,,,,,"136950|4030266","Myelodysplastic syndrome with isolated del(5q)|Myelodysplastic syndrome with isolated del (5q)",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0346421","Chronic Eosinophilic Leukemia, Not Otherwise Specified","C4563","A rare myeloproliferative neoplasm characterized by a clonal proliferation of eosinophilic precursors resulting in persistently increased numbers of eosinophils in the blood, marrow and peripheral tissues.  Since acute eosinophilic leukemia is at best exceedingly rare, the term eosinophilic leukemia is normally used as a synonym for chronic eosinophilic leukemia.  In cases in which it is impossible to prove clonality and there is no increase in blast cells, the diagnosis of 'idiopathic hypereosinophilic syndrome' is preferred.  (WHO, 2001)","Chronic Eosinophilic Leukemia, Not Otherwise Specified | CEL | CEL, NOS | CEL/Hypereosinophilic syndrome | Chronic Eosinophilic Leukemia | Chronic Eosinophilic Leukemia | Chronic Eosinophilic Leukemia, NOS | Chronic eosinophilic leukemia, NOS | Chronic eosinophilic leukemia/hypereosinophilic syndrome | Eosinophilic Leukemia | Eosinophilic leukemia | chronic eosinophilic leukemia",,,,,,,,,,,,,,,"4091925|4211647","Chronic eosinophilic leukemia|Chronic eosinophilic leukemia",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1334291","JAK2 Gene","C24529","This gene is involved in erythropoiesis and signal transduction.","JAK2 Gene | JAK2 | Janus Kinase 2 (A Protein Tyrosine Kinase) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1455147","Dasatinib","C38713","An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases.  Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with a variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.","Dasatinib | 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate | BMS 354825 | BMS-354825 | BMS354825 | DASATINIB | Dasatinib Hydrate | Dasatinib Monohydrate | Sprycel | dasatinib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1721377","Nilotinib","C48375","An orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl protein of the Bcr-Abl fusion protein, resulting in the inhibition of the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R) and c-kit, a receptor tyrosine kinase mutated and constitutively activated in most gastrointestinal stromal tumors (GISTs). With a binding mode that is energetically more favorable than that of imatinib, nilotinib has been shown to have an approximately 20-fold increased potency in kinase and proliferation assays compared to imatinib.","Nilotinib | 4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide | AMN 107 Base Form | NILOTINIB | nilotinib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015282","Exocrine Gland","C12712","A gland from which secretions reach a free surface of the body by ducts.","Exocrine Gland | Apocrine | Apocrine Gland | apocrine gland",,,,,,,,,,,,,,,"4180625","Exocrine gland structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030489","Paraproteinemia","C27468","A plasma cell disorder in which an abnormal amount of a single immunoglobulin is present in the serum. Paraproteinemias may be seen in conjunction with various carcinomas, chronic inflammatory and infectious conditions, and other diseases. --2004","Paraproteinemia | ",,,,,,,,,,,,,,,"4149022","Monoclonal gammopathy of undetermined significance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036429","Sclerosis","C69309","A pathological hardening or thickening of tissue, especially that of the interstitial substance.","Sclerosis | Sclerotic",,,,,,,,,,,,,,,"4184624","Sclerosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348529","Standardized Uptake Value","C69310","An effectively dimensionless measure of regional tracer uptake calculated as the activity concentration within a 2D region of interest (ROI) or 3D volume of interest (VOI) measured on a PET image (nCi1mL) / [injected dose (nCi) / body weight (g)].","Standardized Uptake Value | Differential Absorption Ratio | Differential Uptake Ratio | Distribution Activity Ratio | SUV | Standard Uptake Value | Standardized Uptake Ratio | imaging suv | imaging_suv",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013770","Elbow Joint","C32497","A type of hinge joint located between the forearm and upper arm.","Elbow Joint | ELBOW JOINT | Elbow | Elbow joint structure (body structure) | Elbow region structure (body structure) | JOINT, ELBOW",,,,,,,,,,,,,,,"4061414","Elbow joint structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022359","Jaw Bone","C48821","The bones of the skull that frame the mouth and serve to open it; the bones that hold the teeth.","Jaw Bone | JAW | Jaw | Jaw | jaw | jaw skeleton | mandibular arch skeleton",,,,,,,,,,,,,"UBERON:0001708","jaw skeleton",,,,,,,,,,,,,,,"--"
"C0022745","Knee Joint","C32898","A joint connecting the lower part of the femur with the upper part of the tibia. The lower part of the femur and the upper part of the tibia are attached to each other by ligaments. Other structures of the knee joint include the upper part of the fibula, located below and parallel to the tibia, and the patella which moves as the knee bends.","Knee Joint | Femorotibial Joint | JOINT, FEMOROTIBIAL | Joint, Stifle | KNEE JOINT | Knee | Knee region structure (body structure) | Tibiofemoral Joint | knee | knee region",,,,,,,,,,,,,"UBERON:0001465","knee","4169744","Knee joint structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023474","Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","C3175","A phase of chronic myeloid leukemia, BCR-ABL1 positive in which the peripheral blood smear shows leukocytosis with neutrophils in different stages of maturation, less than 2% blasts, and normal or increased platelet count. Most patients have mild anemia. The bone marrow is hypercellular due to increased numbers of neutrophils and their precursors, and blasts usually account for fewer than 5% of the marrow cells. Megakaryocytes are smaller than normal and have hypolobated nuclei. The spleen is enlarged due to infiltration of the cords of the red pulp by granulocytes.","Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | Chronic Phase CML | Chronic Phase Chronic Granulocytic Leukemia | Chronic Phase Chronic Myelocytic Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Phase Chronic Myelogenous Leukemia, BCR::ABL1 Positive | Chronic Phase Chronic Myeloid Leukemia | Chronic Phase Chronic Myeloid Leukemia, BCR::ABL1 Positive | chronic phase chronic myelogenous leukemia",,,,,,,,,,,,,,,"4188975","Chronic phase chronic myeloid leukemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005699","Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","C9110","An advanced phase of chronic myeloid leukemia.  It is characterized by: 1.  the presence of blasts in the peripheral blood or bone marrow that are at least 20% of the peripheral blood white cells or of the nucleated cells in the bone marrow respectively, or 2. an extramedullary proliferation of blasts, and/or 3. when there are large aggregates and clusters of blasts in the bone marrow biopsy specimen (adapted from WHO, 2001).","Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | Blast Phase CML | Blast Phase Chronic Granulocytic Leukemia | Blast Phase Chronic Myelocytic Leukemia | Blast Phase Chronic Myelogenous Leukemia | Blast Phase Chronic Myelogenous Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blast Phase Chronic Myelogenous Leukemia, BCR::ABL1 Positive | Blast Phase Chronic Myeloid Leukemia | Blast Phase Chronic Myeloid Leukemia, BCR::ABL1 Positive | Blastic Phase CML | Blastic Phase Chronic Granulocytic Leukemia | Blastic Phase Chronic Myelocytic Leukemia | Blastic Phase Chronic Myelogenous Leukemia | Blastic Phase Chronic Myeloid Leukemia | blast crisis | blastic phase chronic myelogenous leukemia",,,,,,,,,,,,,,,"4081695|4211481","Blast crisis|Blastic phase chronic myeloid leukemia",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0023472","Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","C3173","A phase of chronic myeloid leukemia characterized by one or more of the following: 1) Myeloblasts accounting for 10-19% of the peripheral blood white cells or of the nucleated cells in the bone marrow, 2) peripheral blood basophils at least 20%, 3) persistent thrombocytopenia that is unrelated to therapy, 4) persistent thrombocytosis despite adequate therapy, 5) increasing white blood cell count and increasing spleen size unresponsive to therapy, and/or evidence of clonal evolution. (WHO, 2001)","Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | Accelerated Phase CML | Accelerated Phase Chronic Granulocytic Leukemia | Accelerated Phase Chronic Myelocytic Leukemia | Accelerated Phase Chronic Myelogenous Leukemia | Accelerated Phase Chronic Myelogenous Leukemia | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Accelerated Phase Chronic Myelogenous Leukemia, BCR::ABL1 Positive | Accelerated Phase Chronic Myeloid Leukemia | Accelerated Phase Chronic Myeloid Leukemia, BCR::ABL1 Positive | Aggressive-Phase CML | Aggressive-Phase Chronic Myelocytic Leukemia | Aggressive-Phase Chronic Myelogenous Leukemia | Aggressive-Phase Chronic Myeloid Leukemia | accelerated phase chronic myelogenous leukemia",,,,,,,,,,,,,,,"4187635","Accelerated phase chronic myeloid leukemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0183427","Sphygmomanometer","C69317","An instrument used for non-invasive determination of arterial blood pressure, generally consisting of an inflatable cuff and a pressure readout device, classically, a column of mercury.","Sphygmomanometer | ",,,,,,,,,,,,,,,"4216003","Sphygmomanometer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348537","Stethescope","C69320","A medical instrument for listening to the sounds generated inside the body.","Stethescope | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346879","Auscultatory Blood Pressure Monitor","C69318","An instrument for blood pressure monitoring consisting of a sphygmomanometer and a stethoscope to hear blood flow.","Auscultatory Blood Pressure Monitor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347412","Oscillometric Blood Pressure Monitor","C69319","An instrument for blood pressure monitoring consisting of a sphygmomanometer and an electronic pressure sensor (transducer) that detects blood flow by the presence of ocillations in the cuff pressure.","Oscillometric Blood Pressure Monitor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448879","Local","C67263","Of or belonging to a restricted area or locality.","Local | LOCAL | Local-Regional | Regional",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831742","Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation","C62714","A modification of the standard method of allogeneic hematopoietic stem cell transplantation developed to allow for the therapy to be extended to a patient population that is unable to tolerate treatment with the conventional procedure due to its toxicity.","Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation | NST | Non-Myeloablative | Non-myeloablative allogeneic transplant | Nonmyeloablative Stem Cell Transplantation | Stem Cell Transplantation, Non-Myeloablative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1306673","Stage","C48308","Any distinct time period in a sequence of events.","Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278485","Stage I Breast Cancer AJCC v6","C7767","Stage 1 includes T1, NO, MO.  T1: Tumor 2.0 cm or less in greatest dimension.  T1mic: Microinvasion 0.1 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th Ed.)-2003","Stage I Breast Cancer AJCC v6 | Breast Cancer Stage I AJCC v6 | Breast Carcinoma Stage I AJCC v6 | Stage I Breast Cancer | Stage I Breast Cancer | Stage I Breast Carcinoma AJCC v6 | stage I breast cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278486","Stage II Breast Cancer AJCC v6 and v7","C7768","Stage II includes: IIA: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0) and IIB: (T2, N1, M0); (T3, N0, M0).  T0: No evidence of primary tumor.  T1: Tumor 2.0 cm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 2.0 cm but not more than 5.0 cm in greatest dimension.  T3: Tumor more than 5.0 cm in greatest dimension.  N1: Metastasis to movable ipsilateral axillary lymph node(s).  M0: No distant metastasis.  (AJCC 6th and 7th Eds.)","Stage II Breast Cancer AJCC v6 and v7 | Breast Cancer Stage II | Carcinoma of Breast Stage II | Carcinoma of the Breast Stage II | Stage II Breast Cancer | Stage II Breast Cancer | Stage II Breast Cancer AJCC v6 | Stage II Breast Cancer AJCC v7 | Stage II Breast Carcinoma | stage II breast cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278487","Stage III Breast Cancer AJCC v6","C7769","Stage III is divided into two stages IIIA and IIIB.  Stage IIIA includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0).  Stage IIIB includes: (T4, any N, M0).  T4: Tumor of any size with direct extension to (a) chest wall or (b) skin.  N2: Metastases in ipsilateral axillary lymph nodes fixed or matted, or in clinically apparent ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastasis.  N3: Metastasis in ipsilateral infraclavicular lymph nodes(s) with or without axillary lymph node involvement, or in clinically apparent ipsilateral internal mammary lymph node(s); and in the presence of clinically evident axillary lymph node metastasis or metastasis in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement.  M0: No distant metastasis.  (AJCC 6th Ed.)","Stage III Breast Cancer AJCC v6 | Breast Cancer Stage III AJCC v6 | Breast Carcinoma Stage III AJCC v6 | Stage III Breast Cancer | Stage III Breast Cancer | Stage III Breast Carcinoma AJCC v6 | stage III breast cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009194","Coccyx","C12696","A small bone located at the bottom of the spine. The coccyx is a result of 3-5 fused rudimentary vertebrae.","Coccyx | COCCYX | coccygeal skeleton | coccygeal vertebrae I-IV | coccyx | fused caudal vertebrae | fused caudal vertebral column | os coccygis | tailbone | vertebrae coccygeae I-IV","C41.4","Coccyx",,,,,,,,,,,"UBERON:0001350","coccyx","4276201","Bone structure of coccyx",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0728985","Cervical Spine","C69313","The set of vertebrae immediately caudal to the skull.","Cervical Spine | C Spine | CERVICAL SPINE | cervical region of vertebral column",,,,,,,,,,,,,,,"4046743","Structure of cervical vertebral column",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3887615","Lumbar Spine","C69314","Those vertebrae between the ribs and the pelvis, L1-L5 in man.","Lumbar Spine | L Spine | LUMBAR SPINE | Lumbar | lumbar region of vertebral column",,,,,,,,,,,,,,,"4045660","Lumbar spine structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0581269","Thoracic Spine","C69315","The vertebrae of the thoracic spine, numbered one through twelve in man.","Thoracic Spine | T Spine | THORACIC SPINE | axial skeleton thoracic region | columna vertebralis thoracicus | thoracic region of vertebral column | thoracic spine | thoracic vertebrae series | thoracic vertebral column",,,,,,,,,,,,,"UBERON:0006073","thoracic region of vertebral column","4047490","Thoracic spine structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0302600","Angiogenic Process","C17932","A process that results in the development of new blood vessels.","Angiogenic Process | Angiogenesis | Angiogenesis | Angiogenic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0876994","Cardiotoxicity","C27994","Toxicity that impairs or damages the heart. This condition is often caused by the administration of a pharmaceutical agent that initiates a poisonous or toxic response in cardiac tissue.","Cardiotoxicity | Cardiac Toxicity | Toxicity, Cardiac | cardiotoxicity",,,,,,,,,,,,,,,"3655437","Cardiotoxicity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003087","Ankle Joint","C32078","A gliding joint between the distal ends of the tibia and fibula and the proximal end of the talus.","Ankle Joint | ANKLE JOINT | Ankle | Ankle | ankle joint",,,,,,,,,,,,,"UBERON:0001488","ankle joint","4289928","Ankle joint structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705253","Logical Condition","C47953","An assumption on which rests the validity or effect of something else.","Logical Condition | Condition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0470166","Message","C62608","A usually short communication transmitted by words, signals, or other means from one person, station, or group to another.","Message | message",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346639","Lansky Performance Status 0","C70538","Unresponsive.","Lansky Performance Status 0 | 0 | Performance Status 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346640","Lansky Performance Status 10","C70539","No play; does not get out of bed.","Lansky Performance Status 10 | 10 | Performance Status 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346642","Lansky Performance Status 20","C70540","Often sleeping; play entirely limited to very passive activities.","Lansky Performance Status 20 | 20 | Performance Status 20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346643","Lansky Performance Status 30","C70541","In bed; needs assistance even for quiet play.","Lansky Performance Status 30 | 30 | Performance Status 30",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346644","Lansky Performance Status 40","C70542","Mostly in bed; participates in quiet activities.","Lansky Performance Status 40 | 40 | Performance Status 40",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346645","Lansky Performance Status 50","C69421","Gets dressed, but lies around much of the day; no active play, able to participate in all quiet play and activities.","Lansky Performance Status 50 | 50 | Performance Status 50",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346646","Lansky Performance Status 60","C69422","Up and around, but minimal active play; keeps busy with quieter activities.","Lansky Performance Status 60 | 60 | Performance Status 60",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346647","Lansky Performance Status 70","C69423","Both greater restriction of and less time spent in play activity.","Lansky Performance Status 70 | 70 | Performance Status 70",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346648","Lansky Performance Status 80","C69424","Active, but tires more quickly.","Lansky Performance Status 80 | 80 | Performance Status 80",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346649","Lansky Performance Status 90","C69425","Minor restrictions in physically strenuous activity.","Lansky Performance Status 90 | 90 | Performance Status 90",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346641","Lansky Performance Status 100","C69426","Full active, normal.","Lansky Performance Status 100 | 100 | Performance Status 100",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3853577","Feed (action)","C69427","To move something gradually into or through.","Feed | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0489636","R-R Interval","C69284","The time measurement between the R wave of successive heartbeats as measured in milliseconds.","R-R Interval | R-R Interval | R-R Wave Period | RR Interval | RR Interval",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347112","Methylation Site","C68801","A sequence in DNA that can be recognized by a specific methylase enzyme and that contains the specific base target for methyl transfer.","Methylation Site | DNA Methylation Site | Methylase Recognition Site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035359","Retroperitoneum","C12298","The back of the abdomen where the kidneys lie and the great blood vessels run.","Retroperitoneum | RETROPERITONEUM | Retroperitoneal Cavity | Retroperitoneal Space | retroperitoneal space | retroperitoneum | spatium retroperitoneale",,,,,,,,,,,,,"UBERON:0003693","retroperitoneal space","4220536","Retroperitoneal compartment structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025474","Mesentery","C33103","A double layer of peritoneum that attaches to the back wall of the abdominal cavity and supports the small intestines.","Mesentery | MESENTERY | Mesenteric Membrane | generic mesentery | mesenteric membrane | mesentery | mesentery (generic)",,,,,,,,,,,,,"UBERON:0002095","mesentery","4233095","Mesentery structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1879647","Alpha1 Significance","C67050","The significance level for the detection p-value in an absolute analysis.","Alpha1 Significance | Alpha1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879648","Alpha2 Significance","C67051","The second significance level for the detection p-value in an absolute analysis.","Alpha2 Significance | Alpha2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1947974","Tau - Statistical Technique","C67052","The difference, alpha2 minus alpha1.","Tau | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1947916","Scaling","C67036","The act of altering the size of an object.","Scaling | Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879656","Corner Plus","C67053","The average cell intensity for the sense probe cells used in the grid alignment process.","Corner Plus | Corner + | Corner P",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879655","Corner Minus","C67054","The average cell intensity for the antisense probe cells used in the grid alignment process.","Corner Minus | Corner - | Corner M",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879652","Central Minus","C67055","The average cell intensity for the nine probe cells that compose the cross at the center of the antisense probe array.","Central Minus | Central - | Central M",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1947914","Marginal (quality)","C67037","Of questionable or minimal quality; just barely adequate or within a lower limit.","Marginal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882932","Representation (action)","C67045","An activity that stands as an equivalent of something or results in an equivalent; typical of, or the same as, others in a larger group of people or things.","Representation | Represent | Representational | Representative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336964","Villous Pattern","C36121","A morphological appearance resembling the villi seen on the mucosa of the small bowel","Villous Pattern | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026682","Mucin","C16883","An albuminoid substance containing mucopolysaccharides and protein which is contained in mucus, and gives to the latter secretion its peculiar ropy character. It is found in all the secretions from mucous glands, and also between the fibres of connective tissue, as in tendons.","Mucin | Mucus Glycoprotein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709218","Neuroendocrine Differentiation","C43574","A finding in a tissue sample indicating the presence of epithelial cells that express neuroendocrine markers by immunohistochemistry (e.g., chromogranin A and neuron-specific enolase) and/or neurosecretory granules by electron microscopy.","Neuroendocrine Differentiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880189","Crohn Disease-like Reaction","C67077","A distinctive Crohn's disease-like reaction (CLR) consisting of discrete lymphoid aggregates, some with germinal centers, and surrounding stellate fibrosis commonly found around colorectal adenocarcinomas in the absence of clinical or pathologic evidence of prior Crohn's disease.","Crohn Disease-Like Reaction | CLR | Crohn Disease-like Reaction | Crohn disease-like reaction | Crohn's Disease-Like Reaction | Crohn's Disease-like Reaction | Crohn's-Like Lymphoid Reaction | Crohn-Like Reaction | Crohn-like reaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521157","Tumor Vascular Invasion","C35939","A term referring to the presence of tumor emboli or tumor masses within any circulatory vessel.","Tumor Vascular Invasion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879766","BAT25","C67062","A mononucleotide repeat that serves as a marker for microsatellite instability in colorectal cancers.","BAT25 | BAT25 poly(A) Repeat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879767","BAT26","C67063","A mononucleotide repeat that serves as a marker for microsatellite instability in colorectal cancers.","BAT26 | BAT-26 | BAT26 poly(A) Repeat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1327772","D2S123","C67064","A dinucleotide repeat on chromosome 2 that serves as a marker for microsatellite instability in colorectal cancers.","D2S123 | D2S123 Dinucleotide Repeat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1327771","D5S346","C67065","A dinucleotide repeat on chromosome 5 that serves as a marker for microsatellite instability in colorectal cancers.","D5S346 | D5S346 Dinucleotide Repeat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880219","D17S250","C67067","A dinucleotide repeat on chromosome 17 that serves as a marker for microsatellite instability in colorectal cancers.","D17S250 | D17S250 Dinucleotide Repeat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL414336","Microsatellite Repeat","C13338","A variety of simple di-, tri-, tetra-, and pentanucleotide tandem repeats that are dispersed in the euchromatic arms of most chromosomes.","Microsatellite Repeat | Microsatellite | Microsatellite Repeats | Microsatellites | microsatellite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347315","NCI Criterion","C69132","Criteria established for assigning high-frequency microsatellite instability (MSI-H) in cancers requiring that at least two of five markers (BAT25, BAT26, D2S123, D5S346, D17S250) score positive for MSI.","NCI Criterion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883705","Paty Criterion","C67068","Criteria established for assigning high-frequency microsatellite instability (MSI-H) in cancers requiring that at least two of three markers (BAT25, BAT26, D2S123) score positive for MSI.","Paty Criterion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882979","Scientific Control","C64355","Methodology that tests integrity in experiments by isolating variables as dictated by the scientific method in order to make a conclusion about such variables. In a controlled experiment, two virtually identical experiments are conducted, but the factor being tested is varied in only one of them. This serves to isolate any causal phenomena.","Scientific Control | Blank Sample | Control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1948031","Batch (group)","C67073","A quantity of people or things treated or regarded as a group, especially when subdivided from a larger group.","Batch | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0927195","Stroma","C67387","The non-neoplastic connective tissue of an organ.","Stroma | Non-neoplastic Connective Tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881879","Modified Partitioning Around Medoids","C67094","A classification algorithm based on the robust classification method called partitioning around medoids. MPAM includes terms in the objective function to penalize the small between-group distances. The resulting average silhouette width is a useful measure of classification quality.","Modified Partitioning Around Medoids | MPAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519210","Second Degree Relative","C19811","Any relative who is two meioses away from a particular individual in a family; a relative with whom one quarter of an individual's genes is shared (i.e., grandparent, grandchild, uncle, aunt, nephew, niece, half-sibling) (from Genetics Home Reference glossary)","Second Degree Relative | RELATIVE, SECOND DEGREE | SDR | second-degree relative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706801","Amsterdam Criteria","C46069","Research criteria established for defining Hereditary Non-Polyposis Colorectal Cancer (HNPCC) families as established by the International Collaborative Group (ICG) meeting in Amsterdam in 1990: 1. One member diagnosed with colorectal cancer before age 50; 2. Two affected generations; 3. Three affected relatives, 1 of them a first-degree relative of the other 2; 4. Familial adenomatous polyposis should be excluded; 5. Tumors should be verified by pathological examination.","Amsterdam Criteria | Amsterdam Criteria I | Amsterdam Criteria I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879699","Amsterdam Criteria II","C67074","Additional criteria for defining Hereditary Non-Polyposis Colorectal Cancer (HNPCC) families designed to accommodate the range of cancers that can be present in HNPCC families: 1. There should be at least 3 relatives with an HNPCC-associated cancer (colorectal cancer, cancer of the endometrium, small bowel, ureter, or renal pelvis); 2. One should be a first-degree relative of the other 2; 3. At least 2 successive generations should be affected; 4. At least 1 should be diagnosed before age 50; 5. Familial adenomatous polyposis should be excluded in the colorectal cancer cases; 6. Tumors should be verified by pathological examination.","Amsterdam Criteria II | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881865","Mismatch","C67078","A failure to correspond or match; to match unsuitably or inaccurately.","Mismatch | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009085","statistical cluster","C63918","Methods for grouping objects into subsets such that those within each cluster are more closely related to one another than objects assigned to different clusters.","Cluster Analysis | Clustering | Clustering Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0056912","CpG Dinucleotide","C67101","A dinucleotide consisting of cytosine followed by guanine.","CpG Dinucleotide | CpG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010843","Cytosine","C410","A pyrimidine base found in DNA and RNA that pairs with guanine.","Cytosine | 4-Amino-2(1H)-pyrimidinone | CYTOSINE | cytosine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0494165","Metastatic Malignant Neoplasm in the Liver","C4758","A malignant neoplasm that has spread to the liver from another (primary) anatomic site. Representative examples include carcinomas, lymphomas, melanomas, or sarcomas.","Metastatic Malignant Neoplasm in the Liver | Liver Metastases | Liver Metastasis | Metastases to liver, NOS | Metastatic Malignant Neoplasm to the Liver | Metastatic Malignant Neoplasm to the Liver | Metastatic Neoplasm to the Liver | Metastatic Tumor to the Liver | Secondary malignant neoplasm of liver and intrahepatic bile duct | liver metastasis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0153676","Metastatic Malignant Neoplasm in the Lung","C3577","The spread of a malignant neoplasm to the lung. This may be from a primary lung malignant neoplasm, or from a malignant neoplasm at a distant site.","Metastatic Malignant Neoplasm in the Lung | Lung Metastases | Metastases to Lung | Metastases to lung, NOS | Metastasis to Lung | Metastasis to the Lung | Metastatic Malignant Neoplasm to the Lung | Metastatic Malignant Neoplasm to the Lung | Metastatic Neoplasm to the Lung | Metastatic Tumor to the Lung | Pulmonary Metastasis | Secondary malignant neoplasm of lung | Secondary malignant neoplasm of unspecified lung | lung metastasis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0346989","Metastatic Malignant Neoplasm in the Peritoneum","C4583","The spread of a malignant neoplasm to the peritoneum from another primary anatomic site.","Metastatic Malignant Neoplasm in the Peritoneum | Metastases to peritoneum, NOS | Metastasis to the Peritoneum | Metastatic Malignant Neoplasm to the Peritoneum | Metastatic Malignant Neoplasm to the Peritoneum | Metastatic Neoplasm to the Peritoneum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0861461","Stage IV Colon Cancer AJCC v6","C3994","Stage IV includes: (Any T, Any N, M1).  M1: Distant metastasis. (AJCC 6th ed.)","Stage IV Colon Cancer AJCC v6 | AJCC Stage IV Colon Cancer v6 | Astler-Coller D Colon Carcinoma | Colon Cancer Stage IV AJCC v6 | Colon Cancer, Stage IV AJCC v6 | Dukes D Carcinoma of Colon | Dukes D Carcinoma of the Colon | Dukes D Colon Carcinoma | Dukes D Colonic Carcinoma | Stage IV Carcinoma of Colon AJCC v6 | Stage IV Carcinoma of the Colon AJCC v6 | Stage IV Colon Cancer | Stage IV Colon Cancer | Stage IV Colon Carcinoma AJCC v6 | Stage IV Colonic Carcinoma AJCC v6",,,,,,,,,,,,,,,"4312001","Carcinoma of colon, stage IV",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0376452","DNA Methylation","C17961","The process by which methyl groups are added to nucleotides in genomic DNA.","DNA Methylation | DNA Methylation Process | DNA methylation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883167","Station","C67102","A facility or location equipped with special equipment and/or personnel for a particular purpose.","Station | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2003901","Never","C70543","Not ever; at no time (in the past or future).","Never | NEVER | Never (0% chance)",,,,,,,,,,,,,,,"763692","Never",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334250","Non-Infiltrating Non-Comedo Ductal Carcinoma of the Breast","C5137","Breast ductal carcinoma in situ characterized by the presence of sheets of tumor cells without evidence of central necrosis or cell death.","Breast Ductal Carcinoma In Situ, Non-Comedo Type | Breast Intraductal Non-Comedo Adenocarcinoma | Breast Intraductal Non-Comedo Adenocarcinoma | Intraductal Non-Comedo Breast Adenocarcinoma | Intraductal Non-Comedo Breast Adenocarcinoma | Non-Comedo Breast Ductal Carcinoma in situ | Non-Comedo DCIS of Breast | Non-Comedo DCIS of the Breast | Non-Comedo Ductal Carcinoma in situ of Breast | Non-Comedo Ductal Carcinoma in situ of the Breast | Non-Infiltrating Non-Comedo Ductal Breast Carcinoma | Non-Infiltrating Non-Comedo Ductal Carcinoma of Breast | Non-Infiltrating Non-Comedo Ductal Carcinoma of the Breast | Non-Invasive Non-Comedo Ductal Breast Carcinoma | Non-Invasive Non-Comedo Ductal Carcinoma of Breast | Non-Invasive Non-Comedo Ductal Carcinoma of the Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334370","Comedo-Type Adenocarcinoma","C4188","A high grade carcinoma characterized by the presence of comedo-type tumor cell necrosis in which the necrotic areas are surrounded by a solid proliferation of malignant pleomorphic cells.","Comedo-Type Adenocarcinoma | Comedocarcinoma | Comedocarcinoma | Comedocarcinoma, NOS","8501/3","Comedocarcinoma, NOS",,,,,,,,,,,,,"4270137","Comedocarcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1947903","See","C64647","Perceive by sight.","See | vid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512027","Doctorate Degree","C39392","The Doctor's Degree is the highest award a student can earn for graduate study. The doctor's degree classification includes such degrees in any field.","Doctorate Degree | Doctor's Degree | Doctoral Degree | Doctorate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0000768","Congenital Abnormality","C2849","Any abnormality, anatomical or biochemical, evident at birth or during the neonatal period.","Congenital Abnormality | Birth Defect | CONGENITAL DEFECT/DEFORMITY | Congenital Anatomic Abnormality | Congenital Anatomical Abnormality | Congenital Anomalies of Fetus | Congenital Anomaly | Congenital Anomaly or Birth Defect | Congenital Defect | Congenital Defect/Deformity | Congenital Deformity | Congenital Malformation | DEFECT/DEFORMITY, CONGENITAL | SCONG",,,,,,,,,,,,,,,"4079975","Congenital malformation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3887962","Per (qualifier)","C65039","For each, generally denoting a ratio.","Per | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0819757","Lung Tissue","C33024","Tissue consisting of an external serous coat, subserous areolar tissue and lung parenchyma. The parenchyma is made up of lobules wound together by connective tissue. A primary lobule consists of a terminal bronchiole, respiratory bronchioles, and alveolar ducts, which communicate with many alveoli, each alveolus being surrounded by a network of capillary blood vessels.","Lung Tissue | Lung Parenchyma",,,,,,,,,,,,,,,"4012637","Structure of parenchyma of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348867","Global","C68846","Covering or affecting the whole of a system.","Global | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516602","Research or Clinical Assessment Tool","C20993","Any evaluation or assessment tool used to ascertain a patient's condition or diagnosis.","Research or Clinical Assessment Tool | Clinical Assessment Tool | Clinical Assessment Tool | Clinical Measure | Clinical Measure Instrument | Clinical or Research Assessment Tool",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514593","Psychological Impact","C16222","The impact of sickness on the mental wellbeing of both the patient and the patient's family.","Psychological Impact | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029016","Oncogene","C16936","A gene that normally directs cell growth. If mutated or overexpressed in a dominant fashion, it can release the cell from normal restraints on growth. It alone or in concert with other changes, converts the cell into a tumor cell. Alterations can be inherited or caused by an environmental exposure to carcinogens.","Oncogene | Cancer-Promoting Gene | oncogene",,,,,,,,,,,,,,,"4250890","Oncogene",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519817","Upper Respiratory System","C33839","The sinuses and those parts of the respiratory system above the trachea. It includes the nares, nasopharynx, oropharynx, larynx, vocal cords, glottis and upper trachea.","Upper Respiratory System | UPPER RESPIRATORY SYSTEM | Upper Airway | Upper respiratory tract, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281779","Anal Condyloma Acuminatum","C4054","A human papillomavirus-related neoplasm arising from the anus. Morphologically, it is characterized by an exophytic papillary proliferation of squamous cells and acanthosis.","Anal Condyloma Acuminatum | Anal Condyloma | Anal Condyloma | Anal Condyloma Acuminatum | Condylomata of Anus | Condylomata of the Anus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009663","Condyloma Acuminatum","C2960","A sexually transmitted papillary growth caused by the human papillomavirus. It usually arises in the skin and mucous membranes of the perianal region and external genitalia.","Condyloma Acuminatum | Condyloma | Condyloma | Condyloma Acuminata | Condyloma Acuminatum | Genital Wart | Genital Warts | Venereal Wart | condyloma | genital wart",,,,,,,,,,,,,,,"198075|4148102","Condyloma acuminatum of the anogenital region|Genital warts",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1292734","Intent To Treat","C54398","The use of a particular medical device, medication or treatment to treat a pre-existing disease or condition.","Intent To Treat | Treatment Intent | intention-to-treat | treatment intent type | treatment_intent_type",,,,,,,,,,,,,,,"4194400","Treatment intent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0432487","Post-Transplant Lymphoproliferative Disorder","C4727","Post-transplant lymphoproliferative disorder (PTLD) is a polyclonal (benign) or clonal (malignant) proliferation of lymphoid cells that develops as a consequence of immunosuppression in a recipient of a solid organ or bone marrow allograft. PTLDs comprise a spectrum ranging from early, Epstein-Barr virus (EBV)-driven polyclonal lymphoid proliferations to EBV-positive or EBV- negative lymphomas of predominantly B-cell or less often T-cell type. (WHO, 2001)","Post-Transplant Lymphoproliferative Disorder | PTLD | PTLD, NOS | Post transplant lymphoproliferative disorder, NOS | Post-transplant Lymphoproliferative Disorder | Post-transplant lymphoproliferative disorder (PTLD) | post-transplant lymphoproliferative disorder",,,,,,,,,,,,,,,"435514","Lymphoproliferative disorder following transplantation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036749","Serositis","C70428","Inflammation of a serous membrane.","Serositis | ",,,,,,,,,,,,,,,"4157025","Serositis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2346729","Ambiguity","C70429","The quality of having an uncertain or inexact meaning.","Ambiguity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938212","Arabic numeral 0","C70430","A mathematical element that when added to another number yields the same number; the cardinal number meaning one less than one.","Zero | 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0582584","Training and Education","C18074","To teach theory and hands on experience","Training and Education | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032927","Precancerous Condition","C3341","A pathological process with signs indicating it may become cancerous.  Representative examples include leukoplakia, dysplastic nevus, actinic keratosis, xeroderma pigmentosum, and intraepithelial neoplasia.","Precancerous Condition | Precancerous State | Premalignant Condition | Premalignant State",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0917927","Breast Conservation Treatment","C15280","Breast conservation treatment is defined as excision of the primary tumor and adjacent breast tissue, followed by radiation therapy.  This procedure is also referred to as lumpectomy, segmental mastectomy, or partial mastectomy. (from Consensus Statements: Treatment of Early-stage Breast Cancer, 1990)","Breast Conservation Treatment | BCS | BCT | Breast Conserving Surgery/Lumpectomy | Breast-Conserving Surgery | breast-conserving surgery | breast-sparing surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0438108","Improved Patient Condition","C50415","Evidence of improved patient condition.","Improved Patient Condition | Patient's condition improved (finding)",,,,,,,,,,,,,,,"4149524","Patient's condition improved",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1301624","Medical Contraindication","C50646","A symptom or medical condition that makes a particular treatment or procedure inadvisable because a person is likely to have a bad reaction.","Medical Contraindication | CONTRAINDICATION | Contraindication | contraindication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707033","Breast Cancer pT4 TNM Finding v6 and v7","C48985","Breast cancer with tumor of any size with direct extension to chest wall or skin, but only as described in pT4 sub-categories, in accordance with TNM guidelines. (from AJCC 6th and 7th Eds.)","Breast Cancer pT4 TNM Finding v6 and v7 | Breast Cancer pT4 TNM Finding | Breast Cancer pT4 TNM Finding | Breast Cancer pT4 TNM Finding v6 | Breast Cancer pT4 TNM Finding v7 | pT4 Breast Cancer v6 | pT4 Breast Carcinoma v6 | pT4 Cancer of Breast v6 | pT4 Cancer of the Breast v6 | pT4 Carcinoma of Breast v6 | pT4 Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0487261","Antinuclear Antibody","C70547","An autoimmune antibody that is directed against structures within the nucleus of the cell.","Antinuclear Antibody | ANA | Antinuclear Autoantibody",,,,,,,,,,,,,,,"4163958","Antinuclear antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0685938","Malignant Digestive System Neoplasm","C4890","A primary or metastatic malignant neoplasm involving any part of the digestive system.","Malignant Digestive System Neoplasm | Gastrointestinal Cancer | Gastrointestinal System Cancer | Gastrointestinal cancer, NOS | Malignant Gastrointestinal Neoplasm | Malignant Gastrointestinal Neoplasm | Malignant Gastrointestinal System Neoplasm",,,,,,,,,,,,,,,"40491001|443568","Malignant neoplasm of digestive system|Malignant neoplasm of gastrointestinal tract",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0007114","Malignant Skin Neoplasm","C2920","A primary or metastatic malignant neoplasm involving the skin. Primary malignant skin neoplasms most often are carcinomas (either basal cell or squamous cell carcinomas) or melanomas. Metastatic malignant neoplasms to the skin include carcinomas and lymphomas.","Malignant Skin Neoplasm | Malignant Neoplasm of Skin | Malignant Neoplasm of the Skin | Malignant Skin Tumor | Malignant Tumor of Skin | Malignant Tumor of the Skin | Melanoma and Non-Melanoma Skin Cancer | Skin Cancer | Skin Cancer, Including Melanoma | Skin Neoplasm, Malignant | Skin cancer, NOS | Unspecified malignant neoplasm of skin, unspecified | skin cancer",,,,,,,,,,,,,,,"4155297","Malignant neoplasm of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0076028","Technetium Tc-99m Dextran","C1243","A substance being studied as a way to find sentinel lymph nodes in some types of skin cancer and breast cancer. It contains a radioactive substance called technetium linked to a substance called dextran. Dextran helps technetium stay in blood and lymph vessels after it is injected. A machine or probe that detects radioactivity shows which lymph nodes near the tumor have technetium Tc 99m dextran in them. It is a type of radiopharmaceutical and a type of radioimaging agent.","Technetium Tc-99m Dextran | 99m-Tc-Dx | Tc 99m Dextran | Tc 99m Dextran | Tc-99m Dextran | Technetium 99m Dextran | technetium Tc 99m dextran",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704787","Definitely Related to Intervention","C53260","A characteristic used to qualify the adverse event as certainly related to the medical intervention. According to WHO causality assessment criteria of suspected adverse reactions it is applicable to a clinical event, including laboratory test abnormality, occurring in a plausible time relationship to medical intervention, and which cannot be explained by concurrent disease or other interventions. The response to withdrawal of the medical product (dechallenge) should be clinically plausible. The event must be definitive pharmacologically or phenomenologically, using a satisfactory rechallenge procedure if necessary.","Adverse Event Definitely Related to Intervention | Adverse Event Related to Intervention | Certain | Definite | Definite Attribution | Definitely | Definitely Related | Definitely Related to Intervention | Definitely Related to Intervention | Related | Related Attribution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0199850","Clinical Breast Examination","C70552","An exam of the breast performed by a health care provider to check for lumps or other changes.","Clinical Breast Examination | CBE | clinical breast exam",,,,,,,,,,,,,,,"4188188","Examination of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2346941","Accumulated X-Ray Dose Data","C69230","The total X-ray dose an individual was exposed to during a specified time period.","Accumulated X-Ray Dose Data | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347172","Acquired Image","C69244","An obtained image.","Acquired Image | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347173","Acquisition Duration","C69269","The amount of time elapsed during the capture of data.","Acquisition Duration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347174","Acquisition Protocol","C69297","A protocol for creating images or image-derived measurements.","Acquisition Protocol | Image Acquisition Protocol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348002","Age Started","C69217","The age of a person at the start of a specific event.","Age Started | age at onset | age_at_onset",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346975","Cardiac Beat Accepted","C69190","An indication that a heart beat was detected and accepted as conforming to the measurement standards.","Cardiac Beat Accepted | Beat Detected (Accepted) | Beat Detected (Accepted)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346976","Cardiac Beat Detected","C69191","An indication that a heart beat was detected and rejected as not conforming to the measurement standards.","Cardiac Beat Detected | Beat Detected (Rejected) | Beat Detected (Rejected)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346977","Beat Number","C69283","The number of a specific beat.","Beat Number | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347045","Border Definition","C69220","A description of the boundary findings or features of a sample.","Border Definition | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347046","Border Shape","C69224","A description of the boundary configuration of a sample.","Border Shape | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347050","Breast Background Echotexture","C69211","A description of general breast tissue composition as obtained by sonography.","Breast Background Echotexture | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006751","Calibration","C69187","The act of checking or adjusting (by comparison with a standard) the accuracy of a measuring instrument.","Calibration | CALIBRATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347551","Last Calibration Date","C69231","The date of the most recent calibration event for an instrument.","Last Calibration Date | Calibration Date | Calibration Date",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347552","Calibration Factor","C69285","A multiplication factor used to obtain an estimated real-world value from a measured or calculated value.","Calibration Factor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347807","Clockface or Region","C69198","A location identifier based on clockface numbering or anatomic subregion.","Clockface or Region | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347859","Content Creation Date","C69199","The date on which data creation began.","Content Creation Date | Content Date | Content Date | Created | Date Created",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347860","Content Start Time","C69200","The time data creation began.","Content Start Time | Content Time | Content Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347863","Contrast Agent Administered Identifier","C69278","An identifier for a contrast agent that was administered.","Contrast Agent Administered Identifier | Contrast | Contrast Administered | Contrast Administered Identifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347864","Contrast Agent Name","C69294","The identity of the contrast agent.","Contrast Agent Name | Contrast or Bolus Agent | Contrast/Bolus Agent | Contrast/Bolus Agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347865","Contrast Agent Finished Identifier","C69277","An identifier for a contrast agent for which administration has ended.","Contrast Agent Finished Identifier | Contrast End | Contrast End | Contrast End Identifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347866","Contrast Agent Started Identifier","C69276","An identifier for a contrast agent for which administration has started.","Contrast Agent Started Identifier | Contrast Start | Contrast Start Identifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348040","DICOM Derivation","C69271","To determine by mathematical computation.","Mathematical Derivation | Derivation | Derivation | Derived",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348041","Diffusion Anisotropy","C69227","A property of tissues such that a substance shows variable rates of diffusion in different spatial dimensions.","Diffusion Anisotropy | DICOM Diffusion Anisotropy | Diffusion Imaging | Diffusion MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348042","Parallel Lesion","C69215","An indication that the long axis of a lesion runs parallel to the skin.","Parallel Lesion | Parallel | Parallel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348043","Estimated Potential Vessel Value","C69287","Quantifiable estimate of the potential patency of a vessel in the absence of stenosis.","Estimated Potential Vessel Value | Reconstructed | Reconstructed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348044","Series - set of composite instances","C69225","A collection of images with a common element.","Image Series | Series | Series",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348103","Device Observer Manufacturer","C69251","The manufacturer of an observation device.","Device Observer Manufacturer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348104","Device Observer Model Name","C69252","The model name of the observation device.","Device Observer Model Name | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348105","Device Observer Name","C69250","The identifier of the observation device.","Device Observer Name | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348106","Device Location During Observation","C69254","Location of the automated observation device during an observation.","Device Location During Observation | Device Observer Physical Location During Observation | Device Observer Physical Location During Observation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348107","Device Observer Serial Number","C69253","The serial number of an automated observation device.","Device Observer Serial Number | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348108","Device Observer UID","C69249","A unique identifier for an automated observation device.","Device Observer UID | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348305","Distance Source to Detector","C69237","The physical distance between a radiation source and the detector plane.","Distance Source to Detector | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348343","Drug Administered Identifier","C69275","An identifier for a drug that was administered.","Drug Administered Identifier | Drug Administered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348344","Drug Finished Identifier","C69274","An identifier for a drug for which administration has ended.","Drug Finished Identifier | Drug End | Drug End Identifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348346","Drug Started Identifier","C69273","An identifier for a drug for which administration has started.","Drug Started Identifier | Drug Start | Drug Start Identifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348354","Duration of Administration","C69282","The amount of time elapsed during the administration of an agent.","Duration of Administration | Administration Duration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348440","End Procedure Action Item","C69264","Indicates the ending action of a procedure.","End Procedure Action Item | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348485","X-Ray Exposure Time","C69234","The cumulative time a subject was exposed to X-rays.","X-Ray Exposure Time | Exposure Time | Exposure Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348694","Focal Spot Size","C69242","The size of the focal spot created by an X-ray tube.","Focal Spot Size | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348705","For Attenuation Correction","C69286","The referenced information was used to correct the data for differential attenuation through different anatomic tissue.","For Attenuation Correction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348711","Frame of Reference Identity","C69296","There is a defined equivalence between the Frame of Reference of the Registration SOP instance and the Frame of Reference of the referenced images.","Frame of Reference Identity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348988","Homogeneous Fat Echotexture","C69212","A description of homogeneous fat lobules seen in a tissue composition image obtained by sonography.","Homogeneous Fat Echotexture | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348989","Homogeneous Fibroglandular Echotexture","C69213","A description of homogeneous fibroglandular elements seen in a tissue composition image obtained by sonography.","Homogeneous Fibroglandular Echotexture | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348992","Horizontal Pixel Spacing","C69201","The horizontal distance between the centers of adjacent pixels in an image.","Horizontal Pixel Spacing | PIXSPCX | X-axis Pixel Spacing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346468","Image Acquired","C69265","An indication that an image has been successfully captured and saved.","Image Acquired | Image Acquisition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346470","Image Laterality","C69202","An indication of the laterality of a body part.","Image Laterality | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346471","Image Type","C69268","A category of image.","Image Type | image type included | image_type_included",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346472","Image View","C69203","An indication of the orientation of the image plane.","Image View | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346473","Image View Modifier","C69204","Modifier for Image View.","Image View Modifier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346903","Lossy Compressed Image","C69270","An image that has been encoded using a lossy compression algorithm.","Lossy Compressed Image | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347372","Number of Frames","C69267","The total number of frames in a multiframe image.","Number of Frames | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347453","Patient Alert","C69272","Patient is awake and mentally responsive.","Patient Alert | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347454","Patient Allergic to Contrast Media","C69197","Patient identified to be at risk for an allergic reaction to contrast media.","Patient Allergic to Contrast Media | Patient Allergic to Media or Contrast | Patient Allergic to Media/Contrast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347455","Patient Orientation Column","C69205","The orientation of the patient relative to the image plane designated in the anatomical direction of the column axis.","Patient Orientation Column | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347456","Patient Orientation Row","C69206","The orientation of the patient relative to the image plane designated in the anatomical direction of the row axis.","Patient Orientation Row | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0683521","Patient Physiological Condition","C69192","A description of the physiological status of a patient.","Patient Physiological Condition | Patient State | Patient State",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347457","Patient Table Relationship","C69236","The orientation of a patient in relation to the head of the table.","Patient Table Relationship | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347480","Performed Procedure Step SOP Class UID","C69262","The unique identifier for a performed procedure step class.","Performed Procedure Step SOP Class UID | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347481","Performed Procedure Step SOP Instance UID","C69261","The unique identifier for an instance of a performed procedure step.","Performed Procedure Step SOP Instance UID | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347489","Person Observer","C69245","The name of the individual witnessing an event.","Person Observer | Person",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347490","Observer Organization","C69246","The affiliated organization of an observer.","Observer Organization | Person Observer Organization Name | Person Observer's Organization Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347491","Person Observer Role in Organization","C69247","An indication of the organizational role of a human observer.","Person Observer Role in Organization | Person Observer's Role in the Organization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347492","Person Observer Role in Procedure","C69248","An indication of the procedural role of a human observer.","Person Observer Role in Procedure | Person Observer's Role in this Procedure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347640","Positioner Primary Angle","C69222","Position of an object in reference to a patient, from the right anterior oblique to left anterior oblique direction.","Positioner Primary Angle | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347641","Positioner Secondary Angle","C69223","Position of an object in reference to a patient, from the caudal to cranial direction.","Positioner Secondary Angle | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347647","Post-intervention","C69196","Indicates that the imaging procedure was performed immediately after a non-surgical intervention.","Post-intervention | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347660","Pre-Medication","C69295","A medication that is administered prior to a procedure.","Pre-Medication | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347663","Pre-intervention Imaging","C69195","Indicates that the imaging procedure was performed immediately prior to a non-surgical intervention.","Pre-intervention Imaging | Pre-intervention | Pre-intervention",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0552579","Pregnancy Status","C69218","The pregnancy status of an individual.","Pregnancy Status | PREGSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347688","Digital Image Processing Equipment","C69194","Equipment used to analyze, enhance, interpret or display digital images.","Digital Image Processing Equipment | Processing Equipment | Processing Equipment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347713","Cardiac Stress Test Exercise Stage","C69193","The exercise level of a cardiac stress test.","Cardiac Stress Test Exercise Stage | Protocol Stage | Protocol Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347886","Radionuclide Residual Syringe Counts","C69293","The amount of radioactive material remaining in a syringe after administration, measured as counts per minute.","Radionuclide Residual Syringe Counts | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347887","Radionuclide Syringe Counts","C69292","The total amount of radioactive material present in a syringe prior to administration, measured as counts per minute.","Radionuclide Syringe Counts | Radionuclide_Syringe_Counts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347888","Radionuclide Total Dose","C69291","The total amount of radioisotope administered during a diagnostic or therapeutic event.","Radionuclide Total Dose | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0182638","Radiopharmaceutical Compound","C1446","An agent that contains a radioactive isotope and is used for diagnostic or therapeutic purposes.","Radiopharmaceutical Compound | Radioactive Pharmaceutical | Radiochemical | Radiopharmaceutical | Radiopharmaceutical | Radiopharmaceuticals | radioactive drug | radiopharmaceutical",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347889","Radiopharmaceutical Volume Administered","C69290","The amount of radiopharmaceutical given to a subject.","Radiopharmaceutical Volume Administered | Radiopharmaceutical Volume | Radiopharmaceutical Volume",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347894","Rate of Administration","C69281","The speed at which an action is performed.","Rate of Administration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347896","Reason For Procedure","C69216","A rationale for executing a plan of action.","Reason For Procedure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347982","Rotational Acquisition","C69229","Acquisition of an image where the X-ray source rotates around the subject.","Rotational Acquisition | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348172","Selected Region Description","C69207","The description of an identified region within an image.","Selected Region Description | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348190","Series Instance UID","C69219","A unique identifier for series of images.","Series Instance UID | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037812","Spectroscopy","C17155","The technique of measuring the emission and absorption of different wavelengths (spectra) of visible and non-visible light. This can be done via a spectroscope, which consists of a slit, prism, collimator lens, object lens, and a grating.","Spectroscopy | spectroscopy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348530","Start Procedure Action Item","C69263","Indicates the beginning action of a procedure.","Start Procedure Action Item | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348558","Study Start Date","C69208","The date on which a study began.","Study Start Date | SSTDTC | Study Date | Study Date | study start date",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040227","Time Studies","C69209","The time a study began.","Study Start Time | Study Time | Study Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348575","Subject Age","C69260","The age of a person who is the subject in a study.","Subject Age | Age | subjectAge",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348576","Subject Birth Date","C69259","The date of birth of a person who is the subject in a study.","Subject Birth Date | Patient Date of Birth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348580","Subject Name","C69257","The name of the individual of interest.","Subject Name | patient first name | patient_first_name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348584","Subject Unique Identifier","C69256","A unique identifier for a subject in a study.","Subject Unique Identifier | Subject ID | Subject Identifier | Subject UID | Subject UID | Subject.identifier | SubjectIdentifier | Unique Subject Identifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348641","Table Height Position","C69238","The elevation of a table in relation to a reference point.","Table Height Position | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348642","Table Horizontal Rotation Angle","C69239","The angle of horizontal rotation of a table.","Table Horizontal Rotation Angle | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348764","Texture Descriptor","C69221","A description of the consistency findings or features of a sample.","Texture Descriptor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349017","Undiluted Dose Administered","C69280","The amount of undiluted agent administered to a subject.","Undiluted Dose Administered | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349114","Velocity Encoded MRI","C69228","A type of magnetic resonance imaging used to determine the velocity of moving fluids.","Velocity Encoded MRI | Velocity Encoded | Velocity Encoded",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349115","Velocity Encoding Maximum Value","C69289","The maximum acceptable encoded velocity.","Velocity Encoding Maximum Value | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349116","Velocity Encoding Minimum Value","C69288","The minimum acceptable encoded velocity.","Velocity Encoding Minimum Value | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349121","Vertical Pixel Spacing","C69210","The vertical distance between the centers of adjacent pixels in an image.","Vertical Pixel Spacing | PIXSPCY | Y-axis Pixel Spacing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349139","Volume Administered","C69279","The amount of substance given a subject.","Volume Administered | VOLT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349157","X-Ray Filter Material","C69240","The type of absorbent material in an X-ray filter.","X-Ray Filter Material | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349158","X-Ray Filter Thickness Maximum","C69243","The maximum thickness of the X-ray absorbing material used in the filter.","X-Ray Filter Thickness Maximum | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349159","X-Ray Filter Thickness Minimum","C69241","The minimum thickness of the X-ray absorbing material used in the filter.","X-Ray Filter Thickness Minimum | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349160","Mean Tube Current","C69233","The mean value of the electrical current applied to an X-ray tube.","Mean Tube Current | X-Ray Tube Current | X-Ray Tube Current",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600281","Nomenclature","C48298","A system of words used in a particular discipline.","Nomenclature | Terminology | nomenclature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1947971","Give","C64974","Transfer possession of something to some person or group.","Give | Given",,,,,,,,,,,,,,,"4305522","Give",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029064","Operating Room","C53516","A room in a health care facility equipped for the performance of surgical operations and procedures.","Operating Room | OPERATING ROOM | OR | Operating Theater | Operating Theatre",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706081","Departure - action","C53464","The act of leaving a destination.","Departure | Depart | Departed | Leave | Leaving",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512346","Patient Visit","C39564","A visit by a patient or study participant to a medical professional.","Patient Visit | Healthcare Visit | Patient Encounter | Subject Visit | visit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205275","Latent","C28225","Describes a condition that is present but not active or causing symptoms.","Latent | latent",,,,,,,,,,,,,,,"4185573","Latent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205395","Miscellaneous","C69023","Diverse, mixed, consisting of an assortment of different kinds.","Miscellaneous | Misc",,,,,,,,,,,,,,,"4177792","Miscellaneous",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347880","Beam - rays of radiation or stream of particles","C70569","A group of nearly parallel rays of electromagnetic radiation or a stream of particles.","Beam | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013146","Drug Abuse","C16522","The use of a drug for a reason other than which it was intended or in a manner or in quantities other than directed.","Drug Abuse | Drug Use Disorder | Recreational Drug Use | drug abuse",,,,,,,,,,,,,,,"436954","Drug abuse",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333900","HLA-DPB1 Gene","C29953","This gene plays a critical regulatory role in antigen presentation and peptide binding specificity.","HLA-DPB1 Gene | HLA-DPB1 | Major Histocompatibility Complex, Class II, DP Beta 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710670","Whole-Abdominal Irradiation","C51991","Radiation therapy meant to expose all tissues and organs within the abdominal cavity.","Whole-Abdominal Irradiation | TOTAL ABDOMINAL IRRADIATION | WAI | Whole Abdominal Irradiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334030","Histiocytic and Dendritic Cell Neoplasm","C9294","A group of rare tumors that affect the hematopoietic and lymphoid tissues. The cells of origin are the histiocytes and accessory cells. This category includes the following: Langerhans cell histiocytosis, Langerhans cell sarcoma, indeterminate dendritic cell histiocytosis, interdigitating dendritic cell sarcoma, histiocytic sarcoma, disseminated juvenile xanthogranuloma, Erdheim-Chester disease, Rosai-Dorfman-Destombes disease, ALK-positive histiocytosis, and follicular dendritic cell sarcoma.","Histiocytic and Dendritic Cell Neoplasm | Histiocytic Neoplasm | Histiocytic and Dendritic Cell Neoplasms | Histiocytic and Dendritic Cell Neoplasms | Histiocytic and Dendritic Cell Tumors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518988","perioperative","C28374","Around the time of surgery. This usually lasts from the time the patient goes into the hospital or doctor's office for surgery until the time the patient goes home.","Perioperative | perioperative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439285","Femtomole per Liter","C68887","A unit of concentration (molarity unit) equal to one quadrillionth of a mole (10E-15 mole) of solute in one liter of solution.","Femtomole per Liter | Attomole per Milliliter | Femtomole/Liter | Yoctomole per Nanoliter | Zeptomole per Microliter | amol/mL | fmol/L | fmol/l | ymol/nL | zmol/mcL | zmol/uL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439267","Gram per Deciliter","C64783","A unit of mass concentration defined as the concentration of one gram of a substance per unit volume of the mixture equal to one deciliter (100 milliliters). The concept also refers to the metric unit of mass density (volumic mass) defined as the density of substance which mass equal to one gram occupies the volume one deciliter.","Gram per Deciliter | Gram Percent | Gram-Percent | Gram/Deciliter | g% | g/dL | g/dl | gram per deciliter | gram percent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439282","Nanomole per Liter","C67432","A unit of concentration (molarity unit) equal to one billionth of a mole (10E-9 mole) of solute in one liter of solution.","Nanomole per Liter | Attomole per Nanoliter | Femtomole per Microliter | Micromole per Cubic Meter | Nanomole/Liter | Picomole per Milliliter | Yoctomole per Femtoliter | Zeptomole per Picoliter | amol/nL | fmol/mcL | fmol/uL | nanomole per liter | nmol/L | nmol/l | pmol/mL | umol/m3 | ymol/fL | zmol/pL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439284","Picomole per Liter","C67434","A unit of concentration (molarity unit) equal to one trillionth of a mole (10E-12 mole) per one liter of solution.","Picomole per Liter | Attomole per Microliter | Femtomole per Milliliter | Nanomole per Cubic Meter | Picomole/Liter | Yoctomole per Picoliter | Zeptomole per Nanoliter | amol/mcL | amol/uL | fmol/mL | nmol/m3 | picomole per liter | pmol/L | pmol/l | ymol/pL | zmol/nL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201838","Albumin Measurement","C64431","A quantitative measurement of albumin present in a sample.","Albumin Measurement | ALB | Albumin | Albumin Level | Microalbumin",,,,,,,,,,,,,,,"4097664","Albumin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519955","Vascular Access Device Placement","C38097","A procedure that involves the insertion of a catheter in a blood vessel. It is used in patients who require prolonged treatments (e.g., chemotherapy) or infusion of nutritional substances.","Vascular Access Device Placement | Line Placement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439268","Microgram per Milliliter","C64572","A metric unit of mass concentration defined as the concentration of one gram of a substance per unit volume of the mixture equal to one cubic meter. The concept also refers to the metric unit of mass density (volumic mass) defined as the density of a substance which mass equal to one gram occupies the volume of one cubic meter.","Microgram per Milliliter | Gram per Cubic Meter | Microgram per Milliliter Class | Microgram/Milliliter | Milligram per Cubic Decimeter | Milligram per Liter | Nanogram per Microliter | g/m3 | gram(s)/cubic meter | gram/cubic meter | mcg/mL | mg/L | mg/dm3 | mg/l | microgram per milliliter | microgram(s)/millilitre | milligram per liter | milligram(s)/litre | ng/uL | ug/mL | ug/mL{class} | ug/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439271","Microgram per Deciliter","C67305","A unit of mass concentration defined as the concentration of one microgram of a substance per unit volume of the mixture equal to one deciliter. The concept also refers to the unit of mass density (volumic mass) defined as the density of substance which mass equal to one microgram occupies the volume one deciliter.","Microgram per Deciliter | Microgram/Deciliter | mcg/dL | microgram per deciliter | ug/dL | ug/dl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1145640","Central Venous Access Catheter","C17612","A venous catheter positioned with the tip in the proximal third of the superior vena cava, the right atrium, or the inferior vena cava.","Central Venous Access Catheter | Central Line Catheter | Central Venous Access Catheters | central venous access catheter",,,,,,,,,,,,,,,"4179206","Central venous catheter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1273428","Total Mesorectal Excision","C16180","Surgery for rectal cancer involving precise removal of an intact mesorectal envelope with tumor-free margins.  Associated with local recurrence rates below 5% in clinical trials.  (from Medscape)","Total Mesorectal Excision | TME",,,,,,,,,,,,,,,"4194416","Total mesorectal excision",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1880637","Exploratory Surgery","C66747","Surgery to look inside the body to help make a diagnosis.","Exploratory Surgery | exploratory surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021102","Implant","C41075","A prosthesis placed permanently in tissue.","Implant | Implantable | Implanted | implant",,,,,,,,,,,,,,,"4223622","Implant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334156","Immune System and Related Disorders","C27351","A group of non-neoplastic and neoplastic disorders resulting from the deregulation and/or deficiency of immune system functions. It includes autoimmune disorders (e.g., lupus erythematosus, dermatomyositis, rheumatoid arthritis), congenital and acquired immunodeficiency syndromes including the acquired immune deficiency syndrome (AIDS), and neoplasms (e.g., lymphomas and malignancies secondary to transplantation).","Immune System and Related Disorders | Immunodeficiency and Immunosuppression Disorders",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4014213","Raynaud Phenomenon","C50724","An episodic vasoconstriction resulting in discoloration of the skin and pain in the affected areas, often involving fingers or toes. Classically associated with triphasic color changes (white, blue, red) but may be biphasic. Often occurs in response to cold temperatures or emotional stress. May be primary or secondary to an underlying autoimmune disease.","Raynaud Phenomenon | Raynaud Disease | Raynaud's Disease | Raynaud's Phenomenon | Raynaud's Syndrome",,,,,,,,,,,,,,,"4143972","Raynaud's phenomenon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0282056","Anti-DNA Antibody","C1580","An antinuclear autoantibody directed against nuclear DNA.","Anti-DNA Antibody | ",,,,,,,,,,,,,,,"4282748","Anti DNA antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1571455","Complement C3, Human","C21527","Complement C3 (1663 aa, ~187 kDa) is encoded by the human C3 gene. This protein plays a role in complement-mediated immunity.","Complement C3 | C3 | C3 and PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 1 | Complement Component 3 | Complement Component 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201973","Creatine Kinase Measurement","C64489","A quantitative measurement of the amount of creatine kinase present in a sample.","Creatine Kinase Measurement | CK | CPK | Creatine Kinase | Creatine Phosphokinase",,,,,,,,,,,,,,,"4265595","Creatine kinase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0999806","Human Papillomavirus-16","C14338","A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce skin and mucosal epithelial lesions. Human papillomavirus-16 (HPV16) has been directly linked to cervical cancer and is significantly associated with invasiveness. Progression from low- to high-grade neoplasia is often associated with the integration of the HPV16 genome into the host chromosome.","Human Papillomavirus-16 | 16 | HPV 16 | HPV Genotype 16 | HPV-16 | HPV16 | HUMAN PAPILLOMAVIRUS TYPE 16 | High-Risk Human Papillomavirus 16 | High-Risk Human Papillomavirus Subtype 16 | High-Risk Human Papillomavirus Subtype HPV16 | High-Risk Human Papillomavirus-16 | High-Risk Subtype HPV-16 | High-Risk Subtype HPV16 | Human Papillomavirus 16 | Human Papillomavirus Genotype 16 | Human Papillomavirus Type 16 | Human Papillomavirus Type 16 | Human Papillomavirus-16 | hrHPV-16 | hrHPV16",,,,,,,,,,,,,,,"4019194","Human papillomavirus, type 16",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0999807","Human Papillomavirus-18","C14377","A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce skin and mucosal epithelial lesions. Human papillomavirus-18 (HPV18) has been directly linked to cervical cancer and plays a role in the pathogenesis of the disease. The virus integrates its DNA at specific chromosomal locations, such as 8q24 and 12q15. The use of molecular markers for HPV18 infection may allow the identification of patients with early stage cervical cancer and those at high risk for disease recurrence.","Human Papillomavirus-18 | 18 | HPV 18 | HPV Genotype 18 | HPV-18 | HPV18 | HUMAN PAPILLOMAVIRUS TYPE 18 | Human Papillomavirus Genotype 18 | Human Papillomavirus Type 18 | Human Papillomavirus Type 18 | Human Papillomavirus-18",,,,,,,,,,,,,,,"4017400","Human papillomavirus, type 18",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1515867","Acinar Salivary Gland System","C32045","The glandular portion of the salivary system whose combined secretions constitute the saliva; a clear, alkaline, somewhat viscus secretion that keeps the mouth moist and aids in swallowing and digesting food. It includes the major salivary glands - sublingual, submandibular, and parotid glands, as well as numerous minor glands.","Acinar Salivary Gland System | Ankle Joint",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415572","HLA-DQB1 Gene","C70614","This gene is involved in the mediation of antigen presentation.","HLA-DQB1 Gene | HLA-DQB1 | Major Histocompatibility Complex, Class II, DQ Beta 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009542","Complement Hemolytic Activity Assay","C70611","A screening assay for circulating complement proteins in which diluted serum samples are added to antibody-coated erythrocytes and the percentage of cell lysis is measured. The values are expressed in hemolytic complement units per milliliter (CH50), the dilution of serum required to lyse 50 percent of the erythrocytes in the assay.","Complement Hemolytic Activity Assay | CH50 | HEMOLYTIC COMPLEMENT ACTIVITY ASSAY | Total Hemolytic Activity Assay | Total Hemolytic Complement 50% | Total Hemolytic Complement Assay | Total Hemolytic Complement CH50",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009516","Complement Component-4","C70618","Complement component-4 (1744 aa, ~193 kDa) is part of the complement cascade, which mediates the innate immune response to infection. The full length protein is a precursor that is secreted as a trimeric molecule containing an alpha, beta and gamma chain. When the complement cascade is initiated, the protein is cleaved. This proteolysis releases both the alpha chain, C4 anaphylatoxin, which stimulates inflammation, and a dimer of the beta and gamma chains, which mediates the interaction between the antigen-antibody complex and other complement components.","Complement Component-4 | C4 | Complement C4",,,,,,,,,,,,,,,"4115224","Complement component C4",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2346951","Bachelor's Degree Completion","C70555","Indicates that a person has received a degree for successful completion of a program of studies that normally requires at least 4-5 years of full-time equivalent college-level work.","Bachelor's Degree Completion | Bachelor's Degree | Bachelor's Degree Received | Bachelor's degree",,,,,,,,,,,,,,,"37171568","Bachelor's degree achieved",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348318","Academic Doctorate Degree Completion","C70557","Indicates that a person has received a degree for completion of the highest award earned for graduate study.","Academic Doctorate Degree Completion | Doctoral Degree | Doctoral Degree Completion | Doctoral Degree Received | Doctorate Degree | Doctorate Degree Completion | Doctorate Degree Received | Doctorate degree",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347079","Master's Degree Completion","C70556","Indicates that a person has received a degree for completion of at least one year of prescribed study beyond the bachelor's degree.","Master's Degree Completion | Master's Degree | Master's Degree Received | Master's degree",,,,,,,,,,,,,,,"37171569","Master's degree achieved",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347690","Professional Doctorate Degree Completion","C70558","Indicates that a person has received a degree allowing them to practice a profession, such as law, medicine, music, or ministry.","Professional Doctorate Degree Completion | Professional Doctoral Degree | Professional Doctoral Degree Completion | Professional Doctoral Degree Received | Professional Doctorate Degree | Professional Doctorate Degree Received | Professional degree",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0578822","Home School Completion","C70434","Indicates that a person was instructed in an educational program outside of established schools, especially in the home.","Home School Completion | Home School | Home School Attendence | Home Schooled | Home Schooling",,,,,,,,,,,,,,,"4201722","Receiving home tuition",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022262","Isotope","C47933","A form of a chemical element containing a specific number of neutrons and a specific atomic mass.","Isotope | ISOTOPE | isotope",,,,,,,,,,,,,,,"4143312","Isotope",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0580836","Old","C65010","Not new, of an earlier time.","Old | ",,,,,,,,,,,,,,,"4323831","Old",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0582802","Digit","C40186","A finger or toe in human beings or corresponding part in other vertebrates.","Digit | DIGIT | Digital",,,,,,,,,,,,,,,"4219902","Digit structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448897","Kindergarten Completion","C70432","Indicates that kindergarten is the highest level of education achievement.","Kindergarten Completion | Kindergarten | Kindergarten Only",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0681405","Preschool Completion","C70433","Indicates that preschool is the highest level of education achievement.","Preschool Completion | Preschool | Preschool Only",,,,,,,,,,,,,,,"4052781","Nursery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0080032","Malignant Pleural Effusion","C9432","A collection of fluid in the pleural cavity resulting from malignant disease. Malignant pleural effusions often contain free-floating malignant cells.","Malignant Pleural Effusion | malignant pleural effusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0220655","Malignant Pericardial Effusion","C7717","Presence of fluid in the pericardial space as a complication of malignant disease.","Malignant Pericardial Effusion | ",,,,,,,,,,,,,,,"37168001","Malignant pericardial effusion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347338","Negative Selection","C70599","The selective removal of undesired cells through recognition and elimination of cells bearing specified characteristics, leaving the target cells more highly represented in the remaining mixture.","Negative Selection | Negative Cell Enrichment | Negative Cell Fractionation | Negative Cell Selection | Negative Fraction | Negative Fractionation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348825","Tumor Purging","C70600","Removal of tumor cells from the graft.","Tumor Purging | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0302189","Cellular Therapy","C70601","Utilization of specific cells, modified or not, for treatment of diseases. Donor lymphocyte infusion is a type of cellular therapy.","Cellular Therapy | Cell Therapy | cell therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347494","Ph-/BCR+","C70602","Philadelphia chromosome abnormality; t(9;22)(q34;q11) was not found; bcr/abl gene rearrangement was found.","Ph-/BCR+ | Ph Negative/BCR Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347861","Continued Complete Response","C70603","The patient had achieved a complete response; received more therapy and continued in complete response.","Continued Complete Response | Durable Complete Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347678","Primary Refractory","C70604","Disease status just prior to the start of the preparative regimen for hematopoietic stem cell transplantation (HSCT): Primary refractory refers to never achieving a complete remission (CR) from any therapy and also not being in partial remission (PR) at the time of the last evaluation prior to HSCT.  PR could have been achieved at some point, but the recipient is no longer in PR.","Primary Refractory | Less than Partial Response to Initial Therapy | PIF Res | Primary Induction Failure-Resistant | Primary Refractory (Less than Partial Response (PR) to Initial Therapy) / Primary Induction Failure-Resistant (PIF Res)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347305","Light Chain Multiple Myeloma","C70605","A finding of multiple myeloma in which  the light chain (kappa or lambda) of the immunoglobulin is defective.","Light Chain Multiple Myeloma | Light Chain Myeloma | Multiple Myeloma-Light Chain Only",,,,,,,,,,,,,,,"4082464","Light chain myeloma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347300","IgA Multiple Myeloma","C70606","A finding of multiple myeloma in which the heavy chain of the immunoglobulin A is defective. This is the second most common type of multiple myeloma (~20%).","IgA Multiple Myeloma | IgA Type Multiple Myeloma | Multiple Myeloma-IgA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347301","IgD Multiple Myeloma","C70607","A finding of multiple myeloma in which the heavy chain of the immunoglobulin D is defective. This multiple myeloma subtype is very rare (~1%).","IgD Multiple Myeloma | IgD Type Multiple Myeloma | Multiple Myeloma-IgD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347302","IgE Multiple Myeloma","C70608","A finding of multiple myeloma in which the heavy chain of the immunoglobulin E is defective. This multiple myeloma subtype is extremely rare.","IgE Multiple Myeloma | IgE Type Multiple Myeloma | Multiple Myeloma-IgE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347303","IgG Multiple Myeloma","C70609","A finding of multiple myeloma in which the heavy chain of the immunoglobulin G is defective. This is the most common type of multiple myeloma (>50%).","IgG Multiple Myeloma | IgG Type Multiple Myeloma | Multiple Myeloma-IgG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347304","IgM Multiple Myeloma (not Waldenstrom Macroglobulinemia)","C70610","A finding of multiple myeloma in which the heavy chain of the immunoglobulin M is defective. This finding is seen in other lymphocytic/plasmacytic disorders as well, including Waldenstrom macroglobulinemia.","IgM Multiple Myeloma (not Waldenstrom Macroglobulinemia) | IgM Type Multiple Myeloma (not Waldenstrom Macroglobulinemia) | Multiple Myeloma-IgM (not Waldenstrom Macroglobulinemia)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898125","Non-Secretory Multiple Myeloma","C4734","A rare type of multiple myeloma in which the plasma cells synthesize but do not secrete immunoglobulins.  As a result, none of the immunoglobulins appear out of the normal range.  The symptoms are generally the same with those of immunoglobulin-secreting myeloma; however, the incidence of renal insufficiency is lower in non-secretory myeloma.  The diagnosis can be missed because of the absence of monoclonal immunoglobulin in the serum or urine.","Non-Secretory Multiple Myeloma | Non-Secretory Multiple Myeloma | Non-Secretory Myeloma | Non-Secretory Plasma Cell Myeloma | Non-Secretory Plasma Cell Myeloma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348798","Tolerance Induction Pre-Solid Organ Transplant","C70612","A procedure to establish immune suppression of the host in preparation for solid organ transplant to avoid organ rejection.","Tolerance Induction Pre-Solid Organ Transplant | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0340961","Acquired Pure Red Cell Aplasia","C70548","A disease characterized by normocytic, normochromic anemia, low hematocrit, reticulocytopenia and selective erythroid hypoplasia. It can occur as a chronic or acute form; the former is predominantly seen in adults and the latter in children. Pathogenesis involves immune dysfunction with antibodies directed against erythroid precursor cells or erythropoietin, or due to T-cell mediated suppression of erythropoiesis.","Acquired Pure Red Cell Aplasia | acquired pure red cell aplasia",,,,,,,,,,,,,,,"138723","Acquired red cell aplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348347","Drug/Toxin-Induced Aplastic Anemia","C70613","Bone marrow failure defined as pancytopenia, due to exposure to a known toxin or drug.","Drug/Toxin-Induced Aplastic Anemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348037","CD40 Ligand Deficiency","C61244","Patients with the X-linked hyper IgM syndrome have a deficiency of a protein, CD40 ligand that is found on the surface of T-lymphocytes. As a consequence of the deficiency of this protein, their T-lymphocytes are unable to instruct B-lymphocytes to switch their production of gamma globulins from IgM to IgG and IgA. As a result, patients have decreased levels of IgG and IgA and normal or elevated levels of IgM. In addition, since CD40 ligand is important to other functions of T-lymphocytes, they also have a defect in some of the protective functions of their T-lymphocytes.","CD40 Ligand Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348808","Total Complement Assay","C70617","An assay to determine total complement levels as a measure of complement system activation.  The complement system is a major component of innate immunity against microbes and a complement to humoral, antibody-triggered responses by the body.","Total Complement Assay | ",,,,,,,,,,,,,,,"4194779","Complement assay, total",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2346830","Anticardiolipin IgM Antibody","C70619","An IgM autoantibody directed against cardiolipin. It is associated with hemolytic anemia.","Anticardiolipin IgM Antibody | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346906","Lupus Anticoagulant Antibody","C70620","Antibodies directed against plasma proteins (such as beta-2-glycoprotein I, prothrombin, or annexin V) bound to anionic phospholipids. The anticoagulant blocks in vitro assembly of the prothrombinase complex, resulting in prolongation of in vitro clotting assays such as the activated partial thromboplastin time, the Russell viper venom time, and others. Paradoxical to these changes which suggest impaired coagulation, patients with the lupus anticoagulant have an increase in thrombotic events.","Lupus Anticoagulant Antibody | LA | LAC | Lupus Anti-Coagulant | Lupus Anti-Coagulant Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347677","Primary Induction Failure","C70622","A disease status whereby the patient does not achieve a complete remission. It may not be limited to the first/initial course of therapy; it may represent all courses.","Primary Induction Failure | Induction Failure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347498","Ph Unknown/BCR+","C70623","Philadelphia chromosome abnormality; (9;22)(q34;q11) was not tested; therefore it is not known if it was present or not; bcr/abl gene rearrangement was found.","Ph Unknown/BCR+ | Ph Unknown/BCR Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347496","Ph+/BCR Unknown","C70624","Philadelphia chromosome abnormality; t(9;22)(q34;q11) was found; bcr/abl gene rearrangement was not tested; therefore it is not known if present or not.","Ph+/BCR Unknown | Ph Positive/BCR Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023494","T-Cell Chronic Lymphocytic Leukemia","C70649","A slow-growing type of leukemia (blood cancer) in which too many lymphocytes are found in the bone marrow and/or blood.  The T-cell is specified as the defective cell line.","T-Cell Chronic Lymphocytic Leukemia | ",,,,,,,,,,,,,,,"4173955","T-cell chronic lymphocytic leukemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2346630","Lab Lupus Inhibitor Test","C70648","Laboratory test to determine whether a lupus anticoagulant is present in the subject. Presence of a lupus inhibitor is most often detected by prolongation of the activated partial thromboplastin time. Presence of a lupus anticoagulant may actually increase risk for blood clots, and may indicate presence of systemic lupus. See definition of lupus anticoagulant for more details.","Lab Lupus Inhibitor Test | Lab Lupus Inhibitor | Lab Lupus Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347497","Ph Unknown/BCR-","C70627","Philadelphia chromosome abnormality; t(9;22)(q34;q11) was not tested; therefore it is not known whether it is present or not; bcr/abl gene rearrangement was not found.","Ph Unknown/BCR- | Ph Unknown/BCR Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347499","Ph Unknown/BCR Unknown","C70628","Philadelphia chromosome abnormality; t(9;22)(q34;q11) was not tested; therefore it is not known whether it is present or not; bcr/abl gene rearrangement was not tested; therefore it is not known whether it is present or not.","Ph Unknown/BCR Unknown | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347493","Ph -/BCR-ABL-","C70629","Philadelphia chromosome abnormality; t(9;22)(q34;q11) was not found; bcr/abl gene rearrangement was not found.","Ph -/BCR-ABL- | Ph Negative/BCR-ABL Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347495","Ph-/BCR Unknown","C70630","Philadelphia chromosome abnormality; t(9;22)(q34;q11) was not found; bcr/abl gene rearrangement was not tested; therefore it is not known if present or not.","Ph-/BCR Unknown | Ph Negative/BCR Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347126","Microscopic Polyarteritis","C70549","A systemic necrotizing vasculitis that typically affects the small and medium-sized muscular arteries. In some cases, however, microscopic vessels are also affected (e.g., in the kidneys), a condition that has been called microscopic polyarteritis or polyangiitis; this disorder is felt to be more closely associated with Wegener granulomatosis than to classic polyarteritis nodosa.","Microscopic Polyarteritis | MPA | Microscopic Polyangiitis | Microscopic polyangiitis",,,,,,,,,,,,,,,"606328","Microscopic polyangiitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2346508","International Staging System for Myeloma","C70657","A method of staging myeloma published by the International Myeloma Working Group in 2003.","International Staging System for Myeloma | ISS for Myeloma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346458","ISS Stage I Plasma Cell Myeloma","C70658","Multiple myeloma with beta-2-microglobulin less than 3.5 and albumin greater than or equal to 3.5 (median survival of 62 months).  Note that the older Durie/Salmon staging system defines stage I quite differently. (PDQ)","ISS Stage I Multiple Myeloma | I | ISS Stage I Multiple Myeloma | ISS Stage I Multiple Myeloma/Plasma Cell Myeloma | ISS Stage I Plasma Cell Myeloma | ISS Stage I Plasma Cell Myeloma | International Staging System Stage I Multiple Myeloma | International Staging System Stage I Plasma Cell Myeloma | Multiple Myeloma Stage I | Stage I Multiple Myeloma | Stage I Plasma Cell Myeloma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346457","ISS Stage II Plasma Cell Myeloma","C70659","Multiple myeloma with blood levels of beta-2-microglobulin between 3.5 and 5.5 mg/L.","ISS Stage II Multiple Myeloma | II | ISS Stage II Multiple Myeloma | ISS Stage II Multiple Myeloma/Plasma Cell Myeloma | ISS Stage II Plasma Cell Myeloma | ISS Stage II Plasma Cell Myeloma | International Staging System Stage II Multiple Myeloma | International Staging System Stage II Plasma Cell Myeloma | Multiple Myeloma Stage II | Stage II Multiple Myeloma | Stage II Plasma Cell Myeloma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346456","ISS Stage III Plasma Cell Myeloma","C70660","Multiple myeloma with beta-2-microglobulin greater than or equal to 5.5 (median survival of 29 months).  Note that the older Durie/Salmon staging system defines stage III quite differently. (PDQ)","ISS Stage III Multiple Myeloma | III | ISS Stage III Multiple Myeloma | ISS Stage III Multiple Myeloma/Plasma Cell Myeloma | ISS Stage III Plasma Cell Myeloma | ISS Stage III Plasma Cell Myeloma | International Staging System Stage III Multiple Myeloma | International Staging System Stage III Plasma Cell Myeloma | Multiple Myeloma Stage III | Stage III Multiple Myeloma | Stage III Plasma Cell Myeloma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021051","Immunodeficiency Syndrome","C3131","Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral.","Immunodeficiency Syndrome | Immunodeficiency | Immunodeficiency Disorder | immunodeficiency | immunodeficiency syndrome",,,,,,,,,,,,,,,"433740","Immunodeficiency disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL070358","Arteriogram","C20607","An x-ray of arteries. The person receives an injection of a dye that outlines the vessels on the x-ray.","Arteriogram | arteriogram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003904","Arthroscopy","C38033","Endoscopic examination of a joint space.","Arthroscopy | ",,,,,,,,,,,,,,,"4028987","Arthroscopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0398523","Bone Marrow Aspiration","C15644","Aspiration of immature hematopoietic elements and blood from the bone marrow.  It is done for the evaluation of hematopoietic disorders and for the evaluation of infectious diseases and cytogenetic studies.","Bone Marrow Aspiration | bone marrow aspiration",,,,,,,,,,,,,,,"4174208","Bone marrow aspiration procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0203075","Barium Enema Injection","C1447","Injection of a barium-containing contrast medium through the anus and into the lower gastrointestinal tract so that X-rays can be taken in order to identify lesions and other abnormal growths.","Barium Enema Injection | Barium Enema | Lower GI Series | Lower Gastrointestinal Series | barium enema | lower GI series",,,,,,,,,,,,,,,"4060768|4124389","Barium enema|Lower gastrointestinal tract contrast procedure",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0456852","Image Guided Biopsy","C15652","The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis, using imaging technology.","Image Guided Biopsy | Image-Guided Biopsy | Imaging Guided Biopsy | Imaging for Biopsy",,,,,,,,,,,,,,,"4173968","Imaging guided biopsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0436196","Spectrometry","C62326","A class of analytical techniques used to measure certain physical properties such as energy, mass and wavelength via the dispersion of radiant energy or particles into a spectrum.","Spectrometry | ",,,,,,,,,,,,,,,"4058482","Spectrometry",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007820","Cerebrovascular Disorder","C2938","A disorder resulting from inadequate blood flow in the vessels that supply the brain. Representative examples include cerebrovascular ischemia, cerebral embolism, and cerebral infarction.","Cerebrovascular Disorder | Cerebrovascular Disease",,,,,,,,,,,,,,,"381591","Cerebrovascular disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2673553","Valvular Heart Disorder","C45525","Any heart disorder characterized by a defect in valve structure or function.","Valvular Heart Disorder | Disorder of Heart Valve | Heart Valve Disease | Heart Valve Disorder | Valvular Disease",,,,,,,,,,,,,,,"4281749","Heart valve disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348480","ex vivo","C70676","Outside the living body; referring to the use or positioning of an organ, tissue, or cell in an environment outside the living organism while the tissue or cells remain viable.","ex vivo | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1635169","Microliter per Milliliter","C69175","A unit of volume fraction expressed as a number of microliters of the constituent per the volume of the system represented in milliliters.","Microliter per Milliliter | Microliter/Milliliter | Milliliter per Liter | mL/L | mcL/mL | microlitre(s)/millilitre | uL/mL | uL/ml | ul/mL | ul/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709500","Percent Mass per Mass","C48528","A unit of percentage concentration expressed as a fraction of a solute by mass in the entire mass of a resulting solution. The concept also refers to the weight-weight percentage concentration given that standard values for specific gravity of the solute and the solution are used.","Percent Mass per Mass | % (W/W) | %(w/w) | %M/M | %{WeightToWeight} | %{w/w} | Gram per 100 Grams | Mass Percentage | PERCENT WEIGHT/WEIGHT | Percent Mass by Mass | Percent Weight per Weight | Percent Weight/Weight | Percent by Mass | Percent by Weight | Weight Percent | Weight-Weight Percentage | g/100 g | m/m% | percent weight/weight | w/w%",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0560267","Percent Mass per Volume","C48527","A unit of percentage concentration expressed as a fraction of a component by mass in the entire volume of a resulting mixture. The standard conditions for temperature and pressure apply. The mass-volume percentage is used for liquid solute/solution systems and systems containing solid phase components. The concept also refers to the weight-volume percentage concentration given that standard values for specific gravity of the solute are used.","Percent Mass per Volume | % (W/V) | %(w/v) | %M/V | %w/v | %{WeightToVolume} | %{w/v} | Mass-Volume Percentage | PERCENT WEIGHT/VOLUME | Percent Mass/Volume | Percent Weight per Volume | Weight-Volume Percentage | percent weight per volume | percent weight/volume",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706723","Administrative Activity","C49235","Activities involved in the performance of executive, supervisory, or managerial duties.","Administrative Activity | Administrative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346725","Alternative Hematopoietic Cell Transplantation","C70632","A procedure in which hematopoietic stem cells are given for another reason, not to reconstitute the patient's immune system.","Alternative Hematopoietic Cell Transplantation | Alternative HCT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538925","Nodular Partial Remission","C70633","Remission with persistent lymphoid nodules in the bone marrow.","Nodular Partial Remission | Nodular Partial Response | nPR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348101","Destructive Arthritis","C70634","Arthritis associated with the destruction of the cartilage and the articular surface of the bone of the joint. This process severely interferes with movement in the joint.","Destructive Arthritis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1318520","Necrotizing Vasculitis","C70635","A rare condition that involves inflammation and necrosis of the walls of the blood vessels; may occur in rheumatoid arthritis.","Necrotizing Vasculitis | ",,,,,,,,,,,,,,,"4039691","Necrotizing vasculitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205135","Extra-Articular","C70636","Pertaining to an area outside a joint.  In rheumatoid arthritis this term usually refers to tendonitis or inflammation of the heart or lung.","Extra-Articular | ",,,,,,,,,,,,,,,"4226986","Extra-articular",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348543","Stringent Complete Response (sCR) of Multiple Myeloma or Plasma Cell Leukemia","C70637","Stringent complete response (sCR) of multiple myeloma or plasma cell leukemia is characterized by complete response plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry or immunofluorescence (confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the kappa/lambda ratio. An abnormal kappa/lambda ratio by immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting the presence of an abnormal clone is kappa/lambda of > 4:1 or < 1:2.).  Stringent complete response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy stringent complete response requirements.","Stringent Complete Response (sCR) of Multiple Myeloma or Plasma Cell Leukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349122","Very Good Partial Response of Multiple Myeloma or Plasma Cell Leukemia","C70638","Very good partial response of multiple myeloma or plasma cell leukemia is characterized by serum and urine M-protein detectable by immunofixation but not on electrophoresis, or at least 90% reduction in serum M-protein and urine M-protein level < 100 mg/24 hours. Very good partial response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy very good partial response requirements.","Very Good Partial Response of Multiple Myeloma or Plasma Cell Leukemia | Very Good Partial Response (VGPR) of Multiple Myeloma or Plasma Cell Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347844","Complete Response of Multiple Myeloma or Plasma Cell Leukemia","C70639","Complete response of multiple myeloma or plasma cell leukemia is characterized by negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and less than 5% plasma cells in the bone marrow (confirmation with repeat bone marrow biopsy not needed). Complete response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy complete response requirements.","Complete Response of Multiple Myeloma or Plasma Cell Leukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347448","Partial Response of Multiple Myeloma or Plasma Cell Leukemia","C70641","Partial response of multiple myeloma or plasma cell leukemia is characterized by a 50% or greater reduction in serum M-protein, and reduction in 24-hour urinary M-protein by 90% or more or to less than 200 mg/24 hours. If the serum and urine M-protein are unmeasurable (i.e., do not meet any of the following criteria: 1. serum M-protein at least 1 g/dL; 2. urine M-protein at least 200 mg/24 hours; a 50% or more decrease in the difference between involved and uninvolved free light chain levels is required in place of the M-protein criteria (provided the serum free light chain assay shows involved level at least 10 mg/dL and the serum free light chain is abnormal). If serum and urine M-protein are unmeasurable, and serum free light assay is also unmeasurable, a 50% or more reduction in plasma cells is required in place of M-protein, provided the baseline bone marrow plasma cell percentage was 30% or more. In addition to the above listed criteria, a 50% or more reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. Partial response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy partial response requirements.","Partial Response of Multiple Myeloma or Plasma Cell Leukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348412","Stable Multiple Myeloma or Plasma Cell Leukemia","C70642","Stable multiple myeloma or plasma cell leukemia is characterized by not meeting the criteria for complete response, very good partial response, partial response or progression of disease. Stable disease requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy stable disease requirements.","Stable Multiple Myeloma or Plasma Cell Leukemia | Stable Disease of Multiple Myeloma or Plasma Cell Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347692","Progression of Multiple Myeloma or Plasma Cell Leukemia","C70643","Progression of multiple myeloma or plasma cell leukemia requires any one or more of the following: Increase of 25% or more from baseline in: serum M-component with an absolute increase 0.5 g/dL or more (for progressive disease, serum M-component increases of 1 g/dL or more are sufficient to define relapse if the starting M component is 5 g/dL or more); urine M-component with an absolute increase 200 mg. or more/ 24 hours; for recipients without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels (absolute increase more than 10 mg/dL); bone marrow plasma cell percentage (absolute percentage 10% or more); definite development of new bone lesions or soft tissue plasmacytomas, or definite increase in the size of any existing bone lesions or soft tissue plasmacytomas; development of hypercalcemia (corrected serum calcium more than 11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder. Progression of disease requires two consecutive assessments made at any time before classification as disease progression, and/or the institution of any new therapy.","Progression of Multiple Myeloma or Plasma Cell Leukemia | Progressive Disease of Multiple Myeloma or Plasma Cell Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347944","Relapse from Complete Response of Multiple Myeloma or Plasma Cell Leukemia","C70645","Relapse from complete response of multiple myeloma or plasma cell leukemia requires one or more of the following: reappearance of serum or urine M-protein by immunofixation or electrophoresis; development of 5% or more plasma cells in the bone marrow (relapse from complete response has a 5% cutoff vs.10% for other categories of relapse); appearance of any other sign of progression (e.g., new plasmacytoma, lytic bone lesion, hypercalcemia). Relapse requires two consecutive assessments made at any time before classification as relapse, and/or the institution of any new therapy.","Relapse from Complete Response of Multiple Myeloma or Plasma Cell Leukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206138","CREST Syndrome","C70646","A variant of systemic sclerosis characterized by calcinosis, Raynaud phenomenon, esophageal motility disorders, sclerodactyly, and telangiectasia.","CREST Syndrome | CR(E)ST syndrome | Limited Cutaneous Systemic Scleroderma | Limited Cutaneous Systemic Sclerosis | lSSc | lcSSc",,,,,,,,,,,,,,,"4135937","CREST syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0086981","Sicca Syndrome","C70647","A constellation of symptoms that include abnormal dryness of the mouth, eyes and other mucous membranes. The condition is seen in patients with Sjogren syndrome, sarcoidosis, amyloidosis, and deficiencies of vitamins A and C.","Sicca Syndrome | SICCA | Sicca syndrome, unspecified",,,,,,,,,,,,,,,"254443","Sjögren's syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2945599","Mild","C70666","Gentle or temperate in nature or degree.","Mild | MILD | Mildly",,,,,,,,,,,,,,,"4116992","Mild",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205082","Severe","C70667","Intensely bad or unpleasant in degree, quality or extent.","Severe | SEVERE | Severely | severe",,,,,,,,,,,,,,,"4087703","Severe",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024115","Lung Disorder","C3198","A non-neoplastic or neoplastic disorder affecting the lung. Representative examples of non-neoplastic disorders include chronic obstructive pulmonary disease and pneumonia. Representative examples of neoplastic disorders include benign processes (e.g., respiratory papilloma) and malignant processes (e.g., lung carcinoma and metastatic cancer to the lung).","Lung Disorder | Disorder of Lung | Lung Disorders | Pulmonary Disease | Pulmonary Diseases | Pulmonary Disorder | Pulmonary Disorders",,,,,,,,,,,,,,,"257907","Disorder of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882509","put - instruction imperative","C65046","Cause to be in a certain state, relationship, or location.","Put | Place",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883720","Remove","C64914","Shift the position or location of; take out of.","Remove | Removal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521125","For","C64956","The reason of something.","For | ",,,,,,,,,,,,,,,"4312863","For",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3146286","Due","C45263","Expected or scheduled.","Due | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511499","Contractor","C19461","Non-Fed. Govt companies who contract to do specific work for the Fed Govt thru the official Contracting process.","Contractor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517323","Fruit or Vegetable","C1945","Food substances obtained from plant source.","Fruit or Vegetable | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033666","Post-Translational Modification","C17019","The enzymatic processing of a polypeptide chain after translation from messenger RNA and after peptide bond formation has occurred. Examples include glycosylation, acylation, limited proteolysis, phosphorylation, isoprenylation.","Post-Translational Modification | Post Translational Modification | Post-Translational Modification Alteration | Posttranslational Modification | Protein Modification | Protein/Amino Acid Biochemistry, Post-Translational Modification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704675","Interaction","C54216","The quality, state, or process of (two or more things) acting on each other.","Interaction | Interactive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711351","Subunit","C48788","A single unit of a multimeric object.","Subunit | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348017","Curator","C69141","The person in charge of the care and superintendence of something, especially a collection.","Curator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407116","Seven","C66838","A natural number greater than 6 and less than 8 and the quantity that it denotes: the sum of six and one.","Seven | 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205454","Eight","C66839","A natural number greater than 7 and less than 9 and the quantity that it denotes: the sum of seven and one.","Eight | 8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205455","Nine","C66840","A natural number greater than 8 and less than 10 and the quantity that it denotes: the sum of nine and one.","Nine | 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205456","Ten","C69122","A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.","Ten | 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347129","Milestone","C70743","An important event in the progress, development, or history of something or in someone's life.","Milestone | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1096774","Letter","C70805","A written message addressed to a person or organization.","Letter | LETTER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279328","Hyperbaric Oxygen (substance)","C2351","Oxygen that is administered at a higher pressure compared to standard (i.e. sea-level) atmospheric pressure.  Administration of oxygen under hyperbaric conditions enhances the delivery of oxygen to hypoxic tumor cells, thereby increasing their sensitivity to radiation and chemotherapy.  In addition, hyperbaric oxygen may improve the healing of radiation-induced injuries by improving oxygen delivery to damaged tissue. (NCI04)","Hyperbaric Oxygen | hyperbaric oxygen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517569","Intraventricular","C13731","Located within a ventricle of the brain or heart.","Intraventricular | Intra-ventricular",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347712","Protocol Information Office","C70829","An office within NCI which provides administrative support for clinical trial development and tracking by abstraction of key elements into a web-based relational database, monitoring trial timelines and activity from trial proposal to close-out, supporting document review and agent meetings, and developing metrics for program evaluation.","Protocol Information Office | PIO | Protocol and Information Office",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346733","American Society of Anesthesiologists","C70825","An educational, research and scientific association of physicians organized to raise and maintain the standards of the medical practice of anesthesiology and improve the care of the patient.","American Society of Anesthesiologists | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035435","Rheumatologic Disorder","C27204","Inflammatory and degenerative diseases of connective tissue structures, such as arthritis.","Rheumatologic Disorder | Collagen Disease | Collagen Vascular Disease | Connective Tissue Disease | Inflammatory Rheumatism | Musculoskeletal Pain Disorder | Rheumatic Disease | Rheumatism | Rheumatologic Disease | collagen disease | rheumatism",,,,,,,,,,,,,,,"138845","Rheumatism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034963","Regeneration","C17083","Reproduction or reconstitution of a lost or injured part. (NCI)","Regeneration | REGENERATION",,,,,,,,,,,,,,,"4142624","Regeneration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347584","Central Institutional Review Board","C70907","Initiative sponsored by NCI in consultation with the Department of Health and Human Services Office for Human Research Protections (OHRP) designed to help reduce the administrative burden on local IRBs and investigators while continuing a high level of protection for human research participants. A local IRB's use of the CIRB facilitated review mechanism enables an investigator to enroll patients into adult and pediatric Cooperative Group clinical trials significantly faster than when employing traditional method of IRB review.","Central Institutional Review Board | CIRB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010194","Cotinine","C70941","The major metabolite of nicotine.","Cotinine | (S)-1-Methyl-5-(3-pyridinyl)-2-pyrrolidinone | 1-Methyl-5-(3-pyridinyl)-2-pyrrolidinone | COTININE | S-(-)-Cotinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0151295","Mononeuritis Multiplex","C70938","A painful asymmetric asynchronous sensory and motor peripheral neuropathy involving isolated damage to at least 2 separate nerve areas; associated with (but not limited to) systemic disorders such as diabetes, vasculitis, amyloidosis, direct tumor involvement, polyarteritis nodosa, rheumatoid arthritis, systemic lupus erythematosus, and paraneoplastic syndromes. It also may be associated with Lyme disease, Wegener's granulomatosis, Sjogren syndrome, cryoglobulinemia, hypereosinophilia, temporal arteritis, scleroderma, sarcoidosis, leprosy, acute viral hepatitis A, and acquired immunodeficiency syndrome.","Mononeuritis Multiplex | ",,,,,,,,,,,,,,,"376395","Mononeuritis multiplex",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1283169","Monitoring","C61256","The act of observing something (and sometimes keeping a record of it).","Monitoring | monitor | monitoring",,,,,,,,,,,,,,,"4231016","Monitoring - action",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332240","Idiopathic","C28242","Describes a disease of unknown cause.","Idiopathic | idiopathic",,,,,,,,,,,,,,,"4185231","Unknown (origin)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0012920","TOP1 protein, human","C16516","DNA topoisomerase 1 (765 aa, ~91 kDa) is encoded by the human TOP1 gene. This protein plays a role in the regulation of DNA topology.","DNA Topoisomerase 1 | DNA Topoisomerase I | EC 5.99.1.2 | SCL-70 | Scl-70 Antigen | Scleroderma-70 | TOP1 | Topo I | Topoisomerase (DNA) I | Topoisomerase 1 | Topoisomerase I | Topoisomerase I | Topoisomerase, DNA, I | Type I DNA Topoisomerase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0193842","Lymph Node Biopsy","C51900","A test in which a lymph node or a piece of a lymph node is removed for examination under a microscope for signs of infection or disease such as cancer.","Lymph Node Biopsy | Biopsy of Lymph Node",,,,,,,,,,,,,,,"4071443","Biopsy of lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2346829","Anticardiolipin IgG Antibody","C70990","An IgG autoantibody directed against cardiolipin. It is associated with thrombosis, spontaneous abortion, and complications during labor.","Anticardiolipin IgG Antibody | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831914","Dynamic Contrast-Enhanced Magnetic Resonance Imaging","C62665","A modification of contrast-enhanced MRI that allows observation of functional properties in addition to structural properties.","Dynamic Contrast-Enhanced Magnetic Resonance Imaging | DCE | DCE MRI | DCE-MRI | DYNAMIC CONTRAST ENHANCED MRI | Dynamic Contrast-enhanced Magnetic Resonance Imaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704746","Bioelectric Impedance Analysis","C43545","A method to assess body composition, i.e., the relative percentages of body weight comprised of fat tissue and lean body mass.  It is based on the principle that the resistance to an applied electric current is inversely related to the amount of lean body mass within the body. Impedance is greatest in fat tissue, which contains only 10-20% water, while lean body mass, which contains 70-75% water, allows the signal to pass much more easily.","Bioelectric Impedance Analysis | BIA | Bioelectric Impedance | Bioelectric Impedance Test | Bioelectrical Impedance Analysis | Bioimpedance Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710238","Subtlety Score","C45992","A subjective rating of the visibility of a lesion in a medical image, ranging from not visible to obvious.","Subtlety Score | Subtlety | Subtlety Rating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516960","Erythroid","C13805","1) Reddish in color. 2) relating to erythrocytes or their precursors.","Erythroid | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020094","HTLV-1","C14223","A human deltaretrovirus related to HTLV-2. Human T-lymphotropic virus-1 (HTLV-1) is associated with adult T-cell leukemia (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).","HTLV-1 | Adult T-cell Leukemia Lymphoma ATLL | Adult T-cell Lymphoma Virus Type 1 | HTLV-I | HUMAN T-LYMPHOTROPIC VIRUS 1 | Human T-Lymphotropic Virus 1 | Human T-Lymphotropic Virus, Type I | Virus-HTLV-I | human T-cell leukemia virus type 1 | human T-cell lymphotropic virus type 1",,,,,,,,,,,,,,,"4298313","Human T-lymphotropic virus 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020099","HTLV-2","C14224","A human deltaretrovirus related to HTLV-1. Although human T-lymphotropic virus-2 (HTVL-2) has been isolated in association with specific diseases it has not been shown to have a causal relationship with any disease.","HTLV-2 | HTLV-II | HUMAN T-LYMPHOTROPIC VIRUS 2 | Human T-Lymphotropic Virus 2 | Human T-Lymphotropic Virus, Type II | Virus-HTLV-II",,,,,,,,,,,,,,,"4147998","Human T-lymphotropic virus 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085219","HIV p24 Antigen","C17431","HIV-p24 antigen, an important core protein of the human immunodeficiency virus, is encoded by the gag gene. This protein can be detected in serum either in its free form or bound by anti-p24 antibody. Individuals who are HIV-seropositive elicit a significant immune response to p24. Thus, detection of p24 antibodies by ELISA or Western analysis is a screening method utilized to determine the presence of HIV.","HIV p24 Antigen | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005845","Blood Urea Nitrogen Measurement","C61019","A quantitative measurement of the amount of urea nitrogen present in a serum sample.","Blood Urea Nitrogen Measurement | BUN | Blood Urea Nitrogen",,,,,,,,,,,,,,,"4017361","Blood urea nitrogen measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704408","West Nile Virus Pathway","C39271","A description of the life cycle of the West Nile virus.","West Nile Virus Pathway | West Nile Virus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0067033","Myeloblastin","C17548","Myeloblastin (256 aa, ~28 kDa) is encoded by the human PRTN3 gene. This protein is involved in the proteolysis of extracellular matrix proteins.","Myeloblastin | ACPA | AGP7 | Azurophil Granule Protein 7 | C-ANCA | C-ANCA Antigen | EC 3.4.21.76 | Leukocyte Proteinase 3 | MBT | NP-4 | Neutrophil Proteinase 4 | Neutrophil Serine Proteinase | P29 | PR-3 | PR3 | PROTEINASE 3 | PRTN3 | Proteinase 3 | Proteinase 3 | Serine Proteinase, Neutrophil | Wegener Autoantigen | Wegener Granulomatosis Autoantigen | p29",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079603","Fluorescent Antibody Procedure","C17370","An immunological procedure in which the antibodies are coupled with molecules which fluoresce under ultra violet (UV) light. This makes them particularly suitable for detection of specific antigens in tissues or on cells.","Fluorescent Antibody Procedure | FLUORESCENT IMMUNOASSAY | Fluorescent Antibody Assay | Fluorescent Antibody Technique | Immunofluorescence | Immunofluorescence Assay | Immunologic, Immunofluorescence",,,,,,,,,,,,,,,"4148777|4238977|45766312","Fluorescent immunoassay|Fluorescent identification of anti-nuclear antibody|Immunofluorescence technique",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C0042338","Varicella Zoster Virus","C71091","An icosahedral, enveloped virus containing a single molecule of linear double-stranded DNA of 125000 nucleotides that infects only humans. It is the causative agent of chickenpox and shingles.","Varicella Zoster Virus | HHV-3 | HHV3 | HUMAN HERPESVIRUS 3 | Herpes Zoster Virus | Human Alphaherpesvirus 3 | Human Herpesvirus 3 | Human Herpesvirus 3 | VARICELLA ZOSTER VIRUS | VZV | Varicella-Zoster Virus 1",,,,,,,,,,,,,,,"4025840","Human alphaherpesvirus 3",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019360","Herpes Zoster","C71079","A common dermal and neurologic disorder caused by reactivation of the varicella-zoster virus that has remained dormant within dorsal root ganglia, often for decades, after the patient's initial exposure to the virus in the form of varicella (chickenpox). It is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area.","Herpes Zoster | Shingles | Zoster",,,,,,,,,,,,,,,"443943","Herpes zoster",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027021","MPO protein, human","C71145","Myeloperoxidase (745 aa, ~84 kDa) is encoded by the human MPO gene. This protein is involved in the regulation of the innate host defense through the production of hypohalous acids.","Myeloperoxidase | EC 1.11.1.7 | MPO | MYELOPEROXIDASE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708496","Yes, No, or Not Applicable Response","C49797","A response or indicator that can have a value of yes, no, or not applicable.","Yes, No, or Not Applicable Response | Ind-3b | Ind-3b | yes/no/not applicable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202155","Partial Pressure of Oxygen Measurement","C71251","Measures the pressure of oxygen dissolved in the blood and how well oxygen is able to move from the airspace of the lungs into the blood.","Partial Pressure of Oxygen Measurement | PO2 | PaO2 | Partial Pressure O2 | Partial Pressure Oxygen | Partial Pressure of Oxygen | Po2 | pO2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0150411","Arterial Blood Gas Measurement","C71252","Measures the acidity (pH) and the levels of oxygen, carbon dioxide, and bicarbonate in the blood.","Arterial Blood Gas Measurement | ABG | Blood Gas Analysis | Blood Gas Measurement",,,,,,,,,,,,,,,"4239236|4243951","Blood gases, arterial measurement|Analysis of arterial blood gases and pH",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0040440","Extraction of Tooth","C51770","The surgical removal of a tooth from its bony socket.","Extraction of Tooth | Dental Extraction | Dental extraction | Tooth Extraction",,,,,,,,,,,,,,,"4208393","Tooth extraction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0374711","Repair","C53611","The act of returning something to working order.","Repair | REPAIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887509","Rabbit","C14264","Various members of the family Leporidae, especially those of the genus Sylvilagus.","Rabbit | Mammals, Rabbits | RABBIT",,,,,,,,,,,,,,,"4228075","Rabbit",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0456607","Stage IC","C27981","A cancer stage generally indicating the local invasion of tissues by cancer at the primary site.","Stage IC | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441770","Stage IIC","C27969","A cancer stage generally indicating the invasion of adjacent structures by cancer without distant metastases.","Stage IIC | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1948054","When (temporal qualifier)","C65140","At what time, how soon, in what circumstances?","When | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013790","Electricity","C61332","A physical phenomenon associated with stationary or moving electrons and protons; energy made available by the flow of electric charge through a conductor.","Electricity | Electric | Electrical | Electrically",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448698","Added","C45330","Combined or joined to increase in size or quantity or scope.","Added | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448904","Transmission","C71292","The act of sending a message; causing a message to be transmitted.","Transmission | Transmittal | Transmitted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0743223","Disposition","C41205","The tendency of something to act in a certain manner under given circumstances resulting from natural constitution; nature; quality; orderly arrangement.","Disposition | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015895","Fertility","C16578","The ability of an individual to produce offspring.","Fertility | fertility",,,,,,,,,,,,,,,"4265450|4265865","Ability to conceive|Fertility, function",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0029045","Oocyte","C12598","The female gamete, germ cells in stages between the prophase of the first maturation division and the completion of the second maturation division.","Oocyte | Egg | Human Oocyte (Egg) | Oocytes | Ovocyte | Ovum | Unfertilized Egg",,,,,,,,,,,,,,,"4313283","Oocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013935","Embryo","C28147","An organism in its initial stage of development following fertilization. The human embryonic period lasts approximately eight weeks, during which time organogenesis takes place.","Embryo | EMBRYO | Embryologic | Human Embryo | embryo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015915","In Vitro Fertilization","C16580","Fertilization of an ovum outside of the body.","In Vitro Fertilization | Artificial Fertilization | IVF | in vitro Fertilization | in vitro fertilization",,,,,,,,,,,,,,,"4199599","In vitro fertilization",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1415578","HLA-DRB3 Gene","C71259","This gene is involved in immunoregulation and antigen presentation.","HLA-DRB3 Gene | HLA-DRB3 | HLA-DRB3 Gene  | Major Histocompatibility Complex, Class II, DR Beta 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415579","HLA-DRB4 Gene","C71261","This gene plays a role in both antigen presentation and the regulation of T-cell-mediated immunity.","HLA-DRB4 Gene | HLA-DRB4 | HLA-DRB4 Gene  | Major Histocompatibility Complex, Class II, DR Beta 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415580","HLA-DRB5 Gene","C71263","This gene is involved in the regulation of T-cell-mediated immunity and antigen presentation.","HLA-DRB5 Gene | HLA-DRB5 | HLA-DRB5 Gene  | Major Histocompatibility Complex, Class II, DR Beta 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415570","HLA-DQA1 Gene","C71265","This gene plays a role in antigen presentation and immunoregulation.","HLA-DQA1 Gene | HLA-DQA1 | HLA-DQA1 Gene  | Major Histocompatibility Complex, Class II, DQ Alpha 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415567","HLA-DPA1 Gene","C71267","This gene is involved in the regulation of both cellular immune responses and antigen presentation.","HLA-DPA1 Gene | HLA-DPA1 | HLA-DPA1 Gene  | Major Histocompatibility Complex, Class II, DP Alpha 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0062832","HLA-Bw4 Antigen","C71269","HLA-BW4 antigen is the public epitope associated with the sequence of amino acid residues at positions 77-83 in the alpha one domain of the HLA class I heavy chain. These epitopes exist on proteins encoded by certain alleles of both the human HLA-B gene and the human HLA-A gene.","HLA-Bw4 Antigen | HLA-Bw4 Antigen ",,,,,,,,,,,,,,,"4263725","HLA-Bw4 antigen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0062845","HLA-Bw6 Antigen","C71270","HLA-BW6 antigen is the public epitope associated with the sequence of amino acid residues at positions 77-83 in the alpha one domain of the HLA class I heavy chain encoded by various alleles of the human HLA-B gene.","HLA-Bw6 Antigen | HLA-Bw6 Antigen ",,,,,,,,,,,,,,,"4272261","HLA-Bw6 antigen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0246598","HLA-DR51 Antigen","C71271","HLA-DR51 antigen is a set of polymorphic glycoproteins encoded by the human HLA-DRB5 gene. This protein is the beta subunit of the major histocompatibility complex, class II DR protein, which is expressed primarily in lymphoid cells and functions to present antigens for CD4+ T lymphocytes.","HLA-DR51 Antigen | HLA Class II Histocompatibility Antigen, DRB5 Beta Chain | HLA-DR51 Antigen ",,,,,,,,,,,,,,,"4124133","Human leukocyte antigen DR51",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0062880","HLA-DR52 Antigen","C71272","HLA-DR52 antigen is a set of polymorphic glycoproteins encoded by the human HLA-DRB3 gene. This protein is the beta subunit of the major histocompatibility complex, class II DR protein, which is expressed primarily in lymphoid cells and functions to present antigens for CD4+ T lymphocytes.","HLA-DR52 Antigen | HLA Class II Histocompatibility Antigen, DRB3 Beta Chain | HLA-DR52 Antigen ",,,,,,,,,,,,,,,"4011804","HLA-DR52 antigen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0062872","HLA-DR53 Antigen","C71273","HLA-DR53 antigen is a set of polymorphic glycoproteins encoded by the human HLA-DRB4 gene. This protein is the beta subunit of the major histocompatibility complex, class II DR protein, which is expressed primarily in lymphoid cells and functions to present antigens for CD4+ T lymphocytes.","HLA-DR53 Antigen | HLA Class II Histocompatibility Antigen, DRB4 Beta Chain | HLA-DR53 Antigen ",,,,,,,,,,,,,,,"4011805","HLA-DR53 antigen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019759","HLA-DP Antigen","C71274","HLA-DP antigen is a class of glycoproteins that consist of dimers of alpha and beta subunits, which are encoded by the polymorphic human genes HLA-DPA1 and HLA-DPB1, respectively. This protein complex is expressed primarily in lymphoid cells and function to present antigens for CD4+ T lymphocytes.","HLA-DP Antigen | HLA-DP | HLA-DP Antigen ",,,,,,,,,,,,,,,"4323585","HLA-DP antigen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348930","HLA Compatibility Testing","C68707","A process in which blood or tissue samples are analyzed to determine their human leukocyte antigen (HLA) profiles so that transplant materials can be transfered into a patient with the same or similar profile.","HLA Matching | HLA Compatibility Testing | Human Leukocyte Antigen Matching",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1171194","Fertility Preservation","C71326","Methods that focus on the retention of a woman's reproductive capability.","Fertility Preservation | Fertility Preservation for Patients with Cancer",,,,,,,,,,,,,,,"4191386","Fertility care",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348520","Federal Information Processing Standards","C71327","Standards developed by the National Institute of Standards and Technology (NIST) to address Federal requirements for the interoperability of different systems, for the portability of data and software, and for computer security.","Federal Information Processing Standards | FIPS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242318","HLA Typing","C71329","A process in which blood or tissue samples are analyzed to determine their human leukocyte antigen (HLA) profiles.","HLA Typing | HLA Testing",,,,,,,,,,,,,,,"4058764","HLA tissue typing",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2584313","Discussion (communication)","C71323","An extended communication (often interactive) dealing with some particular topic.","Discussion | Discuss",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030201","Post-Operative Pain","C34887","A sensation of discomfort secondary to surgery.","Post-Operative Pain | Post Surgery Pain | Post-operative Pain | Postoperative Pain",,,,,,,,,,,,,,,"439502","Postoperative pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1642104","Anesthetic Agent","C245","A pharmacological agent that acts in a reversible fashion and can be applied either locally or systemically to cause a partial or total loss of sensation and pain or to induce unconsciousness.","Anesthetic Agent | Anaesthetic Agent | Anaesthetics | Anesthesia Agent | Anesthestic Drugs | Anesthetic | Anesthetic Drugs | Anesthetics | anesthetic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1571705","Follicle","C61362","Any small spherical group of cells containing a cavity.","Follicle | Follicular | follicle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521987","Preexisting Condition","C54056","A health condition or medical problem that was diagnosed or treated before a specific date.","Preexisting Condition | Pre-existing Condition | Pre-existing Condition",,,,,,,,,,,,,,,"4010833","Pre-existing condition",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348813","Transabdominal Ultrasound","C71375","A method of ultrasound imaging in which the ultrasound probe is pressed against the skin of the abdomen in order to create an image of the abdominal organs.","Transabdominal Ultrasound | TRANSABDOMINAL ULTRASOUND | TUS | abdominal ultrasound | transabdominal ultrasound",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600225","Graafian Follicle","C32692","Any of the fluid-filled vesicles in the mammalian ovary containing a maturing ovum.","Graafian Follicle | Antral Follicle | Mature Follicle | Secondary Ovarian Follicle | Vesicular Ovarian Follicle",,,,,,,,,,,,,,,"4274647","Vesicular ovarian follicle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034991","Rehabilitation","C15315","Restoration of the ability to function in a normal or near normal manner following disease, illness, or injury.","Rehabilitation | Physical Health Services / Rehabilitation | Rehabilitation, Medical | rehabilitation | rehabilitation therapy",,,,,,,,,,,,,,,"4180248","Rehabilitation therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028873","Odds Ratio","C16932","The ratio of the odds of an event occurring in one group to the odds of it occurring in another group, or to a sample-based estimate of that ratio.","Odds Ratio | ODDS RATIO | OR | odds ratio | relative odds",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349209","Bound (value)","C70987","A value approached but never reached.","Bound | Limit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710181","Standard Error","C53323","The standard deviations of the sample in a frequency distribution, obtained by dividing the standard deviation by the square root of the total number of cases in the frequency distribution.","Standard Error | SE | SEM | Standard Error of the Mean",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705256","ZBTB48 wt Allele","C52934","Human ZBTB48 wild-type allele is located in the vicinity of 1p36.3 and is approximately 9 kb in length. The allele, which encodes zinc finger and BTB domain containing protein 48, plays a role in RNA polymerase II-directed transcription.","ZBTB48 wt Allele | GLI-Kruppel Family Member HKR3 Gene | HKR3 | Zinc Finger and BTB domain containing 48 wt Allele | pp9964",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448877","Man","C14366","An adult, male human.","Man | Human, Male",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0887808","cDNA Microarrays","C19819","A molecular biology device that utilizes a set of defined cDNA clones attached in a specific grid arrangement to a solid support for nucleic acid hybridization assays in gene mapping studies or in determining gene sequences, sequence variations, or gene expression patterns.","cDNA Array | cDNA Microarray",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880274","Deletion","C61330","Elimination, especially by blotting out, cutting out, or erasing.","Deletion | Delete | Deleted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708472","Immunohistochemical Test","C51944","A diagnostic test in which an antibody is used to link a cellular antigen specifically to a stain that can be seen with a microscope.","Immunohistochemical Test | IHC_TEST | Immunohistochemistry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037813","Mass Spectrometry","C17156","An analytical technique wherein ions are separated according to their ratio of charge to mass. From the mass spectrum produced, the atomic weight of the particle can be deduced.","Mass Spectrometry | MASS SPECTROMETRY | MS | MS 1 | MS1 | Mass Spec | Mass Spectrum | MassSpec | Photometry/Spectrum Analysis, Mass",,,,,,,,,,,,,,,"4232957","Mass spectrometry measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348589","Subtraction process","C70590","The act of removing a part from the whole.","Subtraction | Subtract",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348741","Gel Warping Algorithm","C70591","A computer-implemented image processing method and apparatus for normalizing gel electrophoresis images. The method includes the steps of assigning tiepoints in a reference image and in one or more object images. The tiepoints in the object image are evaluated by comparison to a corresponding tiepoint in the reference image, and the location of the tiepoint in the object image is adjusted by slight movement to a location with respect to recognizable features in both the reference and object image. Warping functions are generated and then globally optimized.","Gel Warping Algorithm | Gel Electrophoresis Image Warping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710020","Scanner","C50158","An electronic device that generates a digital representation of an image for data input to a computer or a receiver designed to search for a signal within a specified frequency range.","Scanner Device | Scanner | Scanner Device Component | Scanner Device Component | scanner",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346714","Abundance","C70589","Relative degree of plentifulness.","Abundance | Abundant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3146287","Well","C70592","A cavity or vessel used to contain liquid.","Well | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0182258","Microplate Reader","C70661","An instrument for the automated determination of absorbance data from multiple samples contained in a microplate.","Microplate Reader | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1136348","Protein Microarray","C25867","A molecular biology device consisting of a set of defined proteins, protein fragments, or peptides attached in a specific grid arrangement to a solid support.","Protein Microarray | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079240","Dilute","C64657","To reduce in strength or concentration, especially by the addition of water.","Dilute | DILUTING | Dilution | Dilution | dil. | dilute",,,,,,,,,,,,,,,"37159550","Dilute",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883712","Add - instruction imperative","C64911","To join or unite with others so as to increase size, quantity, or scope.","Add | Addition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0868955","Edit","C70595","The act of preparing by correcting, revising, or adapting.","Edit | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346469","Image Feature","C70838","In image processing, a piece of information which is relevant for solving the computational task related to a certain application, either specific structures in the image itself (e.g., simple structures such as points or edges to more complex structures such as objects) or the result of a general neighborhood operation (feature extractor or feature detector) applied to the image.","Image Feature | Feature | Imaging Feature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346495","Seed entity","C70596","An initial thing from which others are generated.","Seed | Initial Seed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448553","Conjugate","C61533","A compound formed by the union of two entities or compounds.","Conjugate | Conjugated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008565","Liquid Chromatography","C16435","A type of chromatography in which separation of a mixture is achieved by passing a sample in a stream of liquid solvent through some form of material that will provide resistance by virtue of chemical interactions between the components of the sample and the material.","Liquid Chromatography | LC",,,,,,,,,,,,,,,"4199465","Liquid chromatography measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825050","Energy Absorption","C45995","The process in which radiated energy is partially or completely retained in the matter which it traverses.","Energy Absorption | Absorbance | Absorption | Absorption",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022171","Isoelectric Point","C54157","The pH at which a molecule in solution has no net charge and does not migrate in an electric field.","Isoelectric Point | pI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448272","Protein Function","C18967","The action of enzymes, regulators, chaperones etc.","Protein Function | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0335141","Manager","C70652","Someone (or something) that controls, directs, and organizes people, resources, or processes.","Manager | ",,,,,,,,,,,,,,,"4025521","Manager",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2349984","Inversion","C70653","The act of turning inside out, upside down, or end-for-end.","Inversion | Invert | Inverted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348636","Tag Image File Format","C70631","A bitmap graphics file format utilizing tagged fields.","TIFF | Tagged Image File Format",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348289","Differential In-Gel Electrophoresis","C70654","A form of gel electrophoresis where up to three different protein samples can be labeled with fluorescent dyes prior to two-dimensional electrophoresis in the same gel. After the gel electrophoresis, the gel is scanned with the excitation wavelength of each dye and the imges are superimposed, allowing detection of changes in protein abundance between samples.","Differential In-Gel Electrophoresis | DIGE | Difference Gel Electrophoresis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705246","Separation Column","C47874","A tube used in column chromatography.","Separation Column | Column",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448902","Point","C70656","The precise location of something; a spatially limited location.","Point | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707271","Carboxy-Terminal Amino Acid","C54121","The amino acid residing in the last position of a protein or peptide.","Carboxy-Terminal Amino Acid | C-Terminal | C-Terminal Amino Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706793","Amino-Terminal Amino Acid","C54120","The amino acid residing in the first position of a protein or peptide.","Amino-Terminal Amino Acid | N-Terminal Amino Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708579","Isotope-Coded Affinity Tag Protein Analysis","C54164","Recognizing that only a single tryptic peptide is needed to quantify the expression of the corresponding parent protein, the ICAT reagent was designed to affinity isolate and quantify via the use of a stable isotope the relative concentrations of cysteine-containing tryptic peptides obtained from digests of control versus experimental samples. A feature of the ICAT approach is that the in vitro incorporation of a stable isotope into one of the two samples being compared obviates the need to analyze by mass spectrometry the control and experimental samples separately. ICAT data, which is analogous to that obtained via the use of two different fluorescent dyes in DNA microarray analysis of mRNA or DIGE analysis of protein expression, provides the corresponding ratio for the level of expression of the parent protein in the control versus experimental sample.","Isotope-Coded Affinity Tag Protein Analysis | ICAT | ICAT Analysis | ICAT Profiling | Isotope-Coded Affinity Tag Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448675","Protein Cleavage","C41598","Protein Cleavage involves hydrolysis by proteolytic enzymes of specific peptide bond(s), forming smaller polypeptides in the target protein during maturation or modification of functional activity.","Protein Cleavage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026377","Conformation","C13738","The three-dimensional arrangement of something in space. Often refers to the arrangement of the side groups on a molecule which can freely rotate into different positions without breaking any bonds.","Conformation | Conformal",,,,,,,,,,,,,,,"4233666","Molecular conformation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0178812","Protonation","C54165","The addition of a proton (H+) to an atom, molecule, or ion.","Protonation | Protonated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516801","Electrospray Ionization","C19363","A procedure used in mass spectrometry analysis. Means of delivering nonvolatile analytes into the gas phase for mass analysis. Best used on molecules which are charged in solution or readily accept a charge. Particularly well suited to the analysis of biomolecules. Can be used to probe tertiary structure and non-covalent interactions (from NCSU Mass Spectrometry Facility web site)","Electrospray Ionization | ESI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347946","Relevance","C70664","The relation of something to the matter at hand.","Relevance | Relevant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347727","Quadrupole","C70689","A set of two pairs of oppositely charged rods that are used in a mass spectrometer to filter out ions by focusing them in the center of the set of poles so that the radio frequency wave passed along the rods can propagate the ions from one end of the rods to the other.","Quadrupole | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449819","Wavelength","C48158","The distance (measured in the direction of propagation) between two points in the same phase in consecutive cycles of a wave.","Wavelength | WAVLGTH",,,,,,,,,,,,,,,"4086172","Wavelength",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0549255","Excitation","C70662","The addition of energy to a system, thereby transferring it from its ground state to an excited state.","Excitation | Excite | Excited",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205554","Automatic","C70669","Operating with minimal human intervention; independent of external control.","Automatic | AUTOMATIC | Automated",,,,,,,,,,,,,,,"4306773","Automated",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2003902","Always","C70670","At all times; on every occasion.","Always | All of the Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346972","Bead","C70671","A small spherical structure or mass.","Bead | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1325742","Pore","C70672","Any tiny hole admitting passage of a liquid (fluid or gas).","Pore | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348532","Stationary Phase - Research Equipment","C70673","The non-moving substance contained in a chromatography column that causes separation.","Stationary Phase | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448901","Treat","C70742","Subject to a process with the aim of readying for some purpose, improving, or remedying a condition.","Treat | Treated | Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812409","Gradient","C70693","A graded change in the magnitude of some physical quantity or dimension.","Gradient | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348791","Time-of-Flight","C70698","In mass spectroscopy, the time required for particles (as ions) to traverse a tube of a certain length.","Time-of-Flight | TOF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347921","Reflectron","C70697","A component of a time-of-flight mass spectrometer that uses a static electric field to reverse the direction of travel of the ions entering it thereby improving mass resolution by assuring that ions of the same m/z but different kinetic energy arrive at the detector at the same time.","Reflectron | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0807955","Slope","C70744","The property possessed by a line or surface that departs from the horizontal; the tangent of the angle it forms with the positive X axis.","Slope | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009393","Color","C37927","The appearance of objects (or light sources) described in terms of a person's perception of their hue and lightness (or brightness) and saturation.","Color | COLOR",,,,,,,,,,,,,,,"37397754|45766146","Color|Color",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0876954","Contour","C70749","The outline of a part; the surface configuration.","Contour | Isocontour",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0678578","Brightness","C70753","An indication of the relative light intensity of a source or object.","Brightness | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1979874","Contrast","C70754","The degree of difference between the lightest and darkest areas of an image or object.","Contrast | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347221","Brownian Dynamics","C70775","Simulations used to describe the motion of molecules in solution, generally discounting the effects of inertia.","Brownian Dynamics | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449234","Computer Programming Object Attribute","C62618","A single data item related to a database object.","Computer Programming Object Attribute | Attribute | Object Attribute | Object Attribute | attribute (n)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349184","Force Field","C70773","The region in which a particular type of force can be observed, often viewed as a space which was modified by the sources of the force which the field represents.","Field | Force Field",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1589268","Eluent","C70796","The liquid or gas entering a chromatographic bed used to effect a separation.","Eluent | Elutant | Mobile Phase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708574","Ionization Source","C47927","A device that converts a sample into an ion stream.","Ionization Source | Ion Source",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282597","Matrix-Assisted Laser Desorption Ionization Mass Spectrometry","C48040","A mass spectrometric technique that is used for the analysis of large biomolecules. Analyte molecules are embedded in an excess matrix of small organic molecules that show a high resonant absorption at the laser wavelength used. The matrix absorbs the laser energy, thus inducing a soft disintegration of the sample- matrix mixture into free (gas phase) matrix and analyte molecules and molecular ions. In general, only molecular ions of the analyte molecules are produced and almost no fragmentation occurs. This makes the method well suited for molecular weight determinations and mixture analysis. (CHI)","Matrix-Assisted Laser Desorption Ionization Mass Spectrometry | MALDI | Matrix Assisted Laser Desorption Ionization Mass Spectrometry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0598352","Voltage","C70813","The rate at which energy is drawn from a source that produces a flow of electricity in a circuit; expressed in volts.","Voltage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348395","Electrode Grid","C70846","An electrode placed between the cathode and anode of a vacuum tube to control the flow of electrons through the tube.","Grid | Electrode Grid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596963","Polarity","C48048","The positive or negative direction of an electrical, acoustical, or magnetic force.","Polarity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006353","Buffer","C70815","An ionic compound that resists changes in its pH.","Buffer | Buffered | Buffering agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349186","Fit (action)","C70826","Satisfy a condition or restriction.","Fit | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205134","Curve","C70828","A connected set of points constituting a one-dimensional continuum.","Curve | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555688","recovery - adjustment","C70827","A getting back or regaining.","Recovery | Salvage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1178969","Cell Part","C34070","The components of the cell.","Cell Part | Cell Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516337","Cell Cycle Phase","C20180","Any one of the major conceptual divisions of the eukaryotic cell cycle, based on characteristic cytological and biochemical events, that occur in the order G1 (Gap 1)-S (Synthesis)-G2 (Gap 2)-M (Mitosis) and lead to cell division.","Cell Cycle Phase | Cell Cycle Stage | Cell Cycle Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014406","Environment","C16551","The totality of surrounding conditions.","Environment | Environmental",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337196","Collision","C48052","An accident resulting from violent impact of a moving object; an brief event in which two or more bodies come together.","Collision | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017110","Gas","C45299","A fluid in the gaseous state having neither independent shape nor volume and being able to expand indefinitely.","Gas | ",,,,,,,,,,,,,,,"42539073|4326759","Gas|Gaseous substance",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0008550","Chromatography","C16431","A technique for the separation of complex mixtures that relies on the differential affinities of substances for a gas or liquid mobile medium and for a stationary adsorbing medium through which they pass.","Chromatography | CHROMATOGRAPHY | Chromatography / Separation Science | chromatography",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002780","Analysis of Variance","C53241","A statistical technique which helps in making inference whether three or more samples might come from populations having the same mean; specifically, whether the differences among the samples might be caused by chance variation.","Analysis of Variance | ANOVA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079941","Open Reading Frames","C13292","A sequence of nucleotides in that contains no termination codons and so can potentially translate as a polypeptide chain.","Open Reading Frame | ORF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013812","Electrode Device","C49936","A conductor that is designed to make contact with part of a circuit or system.","Electrode Device | Electrode | Electrode Device Component | electrode",,,,,,,,,,,,,,,"4039956","Electrode",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2350017","Cone shape","C70849","A shape whose base is a circle and whose sides taper up to a point.","Cone | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708533","Interface","C50008","Either a program that controls a display for the user and that allows the user to interact with the system or a computer circuit consisting of the hardware and associated circuitry that links one device with another.","Interface Device | Interface | Interface Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037633","Solution","C70830","A homogeneous mixture of two or more substances; frequently (but not necessarily) a liquid solution.","Solution | ",,,,,,,,,,,,,,,"4309788","Solution",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710425","Tip Device","C50324","The extreme end of something, especially something pointed.","Tip Device | Tip | Tip Device Component",,,,,,,,,,,,,,,"45768333","Device tip",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2003858","Spray (action)","C65101","Scatter in a mass or jet of droplets.","Spray | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346586","Ion Trap","C70839","A device used to prevent ions in an electron beam from striking other apparatus.","Ion Trap | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034547","Radio Frequency","C70832","An electromagnetic wave frequency between audio and infrared.","Radio Frequency | radio wave",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348966","Hexapole","C70841","A set of three pairs of oppositely charged rods that are used in a mass spectrometer to filter out ions by focusing them in the center of the set of poles so that the radio frequency wave passed along the rods can propagate the ions from one end of the rods to the other.","Hexapole | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347766","Chromint Software","C70843","A method for detection of chromatography peaks based on the analysis of the profile of the first derivative of the signal calculated with a Savitzky-Golay filter. This provides a list of peaks and their position with typically around 25 peaks detected per electropherogram.","Chromint Software | Chromint Program",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376690","Area Under Curve","C64774","The area between the x-axis and the curve given by the integrand. It is equal to the definite integral of a function. In the field of pharmacokinetics, the area under the curve (AUC) is the area under the curve in a plot of concentration of a drug in plasma against time. AUC is usually given for the time interval zero to infinity, and other time intervals are indicated.","Area Under Curve | AUC | Area Under the Curve | Area under Curve | area under the curve | {AUC}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL375920","Vibration Response Imaging","C70582","A cavity or vessel used to contain liquid.","Vibration Response Imaging | Well",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887809","Net (qualifier)","C70842","Ultimate; final; remaining after all deductions, outlay, or loss.","Net | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348542","Streak","C70847","A marking of a different color or texture from the background.","Streak | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596801","Ionization","C48059","Any process by which a neutral atom gains or loses electrons, thus acquiring a net charge, as the dissociation of a substance in solution into ions or ion production by the passage of radioactive particles.","Ionization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527240","Derivative","C28355","In chemistry, a compound produced from or related to another.","Derivative | derivative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349986","Protein Digestion (research activity)","C70845","A technique for proteolysis of proteins into peptides by treatment with any of various enzymes.","Protein Digestion | Digestion | Digestion Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0808070","Start Date","C68616","The calendar date on which something is to start or did start.","Start Date | STDAT | Start | Starting Date",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3665596","Verrucous Lesion","C5028","A papillomavirus related epithelial overgrowth. It can be located anywhere on the body though when it involves the perineal region it is generally referred to as condyloma acuminatum.","Verrucous Lesion | Verruca | Verrucas | Wart | wart",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880121","Color Assessment","C64546","A qualitative assessment of the color of a biological specimen.","Color Assessment | COLOR | Color",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0347129","Anal Intraepithelial Neoplasia","C4595","A precancerous neoplastic intraepithelial process involving either the squamous and transitional zones of the anal canal or the perianal skin (anal margin).","Anal Intraepithelial Neoplasia | AIN | Anal Canal and Anal Margin Squamous Intraepithelial Neoplasia | Anal Canal and Perianal Squamous Intraepithelial Neoplasia | Anal Dysplasia | Anal Squamous Dysplasia | Anal Squamous Intraepithelial Neoplasia | Intraepithelial Neoplasia of Anus | Intraepithelial Neoplasia of the Anus",,,,,,,,,,,,,,,"4113117","Anal intraepithelial neoplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1549943","Associate Degree","C71340","A degree granted by a two-year college on successful completion of the undergraduates course of studies.","Associate Degree | AA | Associate of Arts | Associate's Degree | Associates Degree | Associates Degree",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549944","Associate of Applied Science","C71341","An associate's degree awarded to students who are permitted to relax some of the general education requirements in order to study more course work in their program area. This kind of degree is for students who intend to enter the work force upon graduation.","Associate of Applied Science | AAS | Associate of Arts and Sciences",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549945","Associate of Business Administration","C71342","An associate's degree awarded upon completion of a course of study usually lasting two years with a focus on business, including the processes of interchanging goods and services (buying, selling and producing), business organization, and accounting as used in profit-making and nonprofit public and private institutions and agencies.","Associate of Business Administration | ABA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549946","Associate of Engineering","C71343","An associate's degree awarded upon completion of a course of study, usually lasting two years, with a focus on engineering.","Associate of Engineering | AE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549947","Associate of Science","C71344","An associate's degree awarded upon completion of a course of study usually lasting two years with areas of concentration in mathematics, natural sciences, or technology.","Associate of Science | AS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549948","Bachelor of Arts","C71345","A bachelor's degree in the liberal arts, usually awarded for studies in the social sciences or humanities.","Bachelor of Arts | Artium Baccalaureus | BA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549949","Bachelor of Business Administration","C71346","A bachelor's degree in business studies. In most universities, the degree is conferred upon a student after four years of full-time study (120 credit hours) in one or more areas of business concentrations. The BBA program usually includes general business courses and advanced courses for specific concentrations.","Bachelor of Business Administration | BBA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346953","Bachelor of Engineering","C71347","A bachelor's degree in engineering awarded to a student after three, four or five years of studying engineering at an accredited university. It is a professional degree that involves a requirement for undertaking some engineering work.","Bachelor of Engineering | BE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346952","Bachelor of Education","C71348","A bachelor's degree in education awarded to students seeking training to become teachers in primary and secondary schools.","Bachelor of Education | BEd",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549951","Bachelor of Fine Arts","C71349","A bachelor's degree in arts awarded to students seeking a professional education in the visual or performing arts.","Bachelor of Fine Arts | BFA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549952","Bachelor of Science in Nursing","C71350","A four year academic degree in the science and principles of nursing, granted by a tertiary education university or similarly accredited school.","Bachelor of Science in Nursing | BN | BSN | Bachelor of Nursing | Bachelor of Science in Nursing (syn: Bachelor of Nursing)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549953","Bachelor of Science","C71351","A bachelor's degree, usually awarded for studies in natural science, pure science, or technology.","Bachelor of Science | BS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549954","Bachelor of Science in Law","C71352","A special-purpose degree that allows someone who has some prior studies but not achieved a bachelor's degree to resume their education and pursue the study of law towards an eventual Juris Doctor degree.","Bachelor of Science in Law | BSL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346954","Bachelor of Social Work","C71353","A bachelor's degree awarded to someone who has successfully completed undergraduate studies in psychosocial evaluation and intervention, including therapy, to effect a change in the feelings, attitudes and behavior of a client, whether an individual, group or community.","Bachelor of Social Work | BSW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549956","Bachelor of Theology","C71354","A bachelor's degree in theological disciplines. Candidates for this degree typically must complete course work in Greek or Hebrew, as well as systematic theology, biblical theology, ethics, homiletics and Christian ministry.","Bachelor of Theology | BT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348315","Doctor of Divinity","C71358","A doctoral degree in religion.","Doctor of Divinity | DD | DDiv",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549965","Doctor of Education","C71359","A professional doctorate that prepares the student for academic, administrative or specialized positions in education.","Doctor of Education | D.Ed. | Ed.D.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348316","Doctor of Social Work","C71360","A doctoral degree for experienced social work practitioners in advanced practice, research and/or policy analysis (although some DSW recipients are not social workers). Much of the course work emphasizes qualitative and quantitative analysis methods. The degree typically leads to teaching, research, leadership roles in agencies, or self-employed social work practice.","Doctor of Social Work | DSW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549972","Doctor of Law","C71361","A professional doctorate typically awarded by an accredited U.S. law school after successfully completing three years of post-graduate law study. Generally, a 4-year undergraduate degree is required to be eligible for entry into a JD program.","Doctor of Law | Doctor of Jurisprudence | JD | Juris Doctor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347076","Master of Law","C71363","An advanced law degree generally earned in a course of specialized study in law.","Master of Law | LLM | Legum Magister",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549973","Master of Arts","C71364","An academic degree in a nonscience subject, usually awarded after one or two years of postgraduate study.","Master of Arts | MA | Magister Artium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549974","Master of Civil Engineering","C71366","A postgraduate academic degree awarded after the completion of a program of one to three years in duration. This acknowledgment comprises about 4-6 years of university study in total with a professional engineering discipline that deals with the construction and design of public and private sector works such as bridges, roads, dams and buildings.","Master of Civil Engineering | MCE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549976","Master of Divinity","C71367","A master's degree in religion.","Master of Divinity | MDiv",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549977","Master of Engineering","C71368","A master's degree in engineering awarded after the completion of a program of one to three years in duration. This acknowledgment comprises about 4-6 years of university study in total with a focus in the field of engineering.","Master of Engineering | ME",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549978","Master of Education","C71369","A master's degree in education awarded after the completion of a program of one to three years in duration. This acknowledgment comprises about 4-6 years of university study in total and is a degree conferred by American and Canadian institutions for educators moving on in their field.","Master of Education | MEd",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549979","Master of Electrical Engineering","C71370","A master's degree in electrical engineering awarded after the completion of a program of one to three years in duration. This acknowledgment comprises about 4-6 years of university study in total with a focus on an engineering discipline that deals with the study and/or application of electricity, electronics and electromagnetism.","Master of Electrical Engineering | MEE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549980","Master of Fine Arts","C71371","A master's degree in an area of visual, literary or performing arts typically requiring two to three years of study beyond the bachelor level. Coursework is primarily of an applied or performing nature with the program often culminating in a major work or performance.","Master of Fine Arts | MFA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549981","Master of Mechanical Engineering","C71372","A master's degree in mechanical engineering awarded after the completion of a program of one to three years in duration. This acknowledgment comprises about 4-6 years of university study in total with the focus on an engineering discipline that involves the application of principles of physics for analysis, design, manufacturing, and maintenance of mechanical systems.","Master of Mechanical Engineering | MME",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347077","Master of Public Administration","C71373","A master's degree that focuses on public administration at the local, state/provincial, national/federal and supranational levels, as well as in the nonprofit sector.","Master of Public Administration | MPA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549982","Master of Science in Law","C71381","A postgraduate academic degree awarded after the completion of a program of one to three years in duration. This acknowledgment comprises about 4-6 years of university study in total with a focus on law.","Master of Science in Law | JSM | MSL | Master of Science of Law",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549983","Master of Science in Nursing","C71374","An advanced-level quaternary education degree for Registered Nurses focusing in one or more different advanced nursing specialties. It is required to become an advanced practice nurse and is considered an entry-level degree for nurse educators and managers. It is also a prerequisite for doctorate-level nursing education.","Master of Science in Nursing | MSN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347078","Master of Social Work","C71376","An advanced academic degree in the field of social work which is received from a graduate school that has been approved by the Council on Social Work Education. The MSW requires two years of post graduate study, in combination with one year's internship, also called field experience.","Master of Social Work | MSW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549984","Master of Theology","C71377","An advanced academic degree which is sometimes earned after (or instead of) a Master of Divinity or a Master of Theological Studies. This degree can range from a one or two year degree (30-60 credit hours) in general theological studies all the way up to a four year degree (120 credit hours) which offers specialized advanced studies in theological research.","Master of Theology | MT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549988","Doctor of Engineering","C71378","A doctoral degree awarded on the basis of advanced study and research in engineering.  It is awarded by many American universities and is equivalent to a PhD degree.","Doctor of Engineering | DEng | EngD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549989","Doctor of Science","C71379","A doctoral degree earned with the approval of a committee on the basis of original research and publications. It is awarded predominantly in doctoral level science programs such as engineering, information systems, medical and health sciences, and health economics.","Doctor of Science | ScD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348317","Doctor of Theology","C71380","A doctoral degree in theology. It is a research degree, involving the publication of an original contribution to scholarship in the form of a dissertation, that is for most purposes the equivalent of a Doctor of Philosophy in Theology or a similar discipline.","Doctor of Theology | ThD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348504","Family Practice Nurse Practitioner (occupation)","C71275","A nurse practitioner that meets the health care needs of the family by providing health assessments, direct care, and guidance, teaching, or counseling as appropriate, particularly around family self-care. The FNP typically works collaboratively with family primary care physicians and other professionals within the health care system, and is licensed to practice by a state authority.","Family Practice Nurse Practitioner | FPNP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346672","Licensed Clinical Social Worker","C71276","A social worker trained in psychotherapy who helps individuals deal with a variety of mental health and daily living problems to improve overall functioning. A social worker usually has a master's degree in social work and has studied sociology, growth and development, mental health theory and practice, human behavior/social environment, psychology, and research methods, and is licensed to practice by a state authority.","Licensed Clinical Social Worker | LCSW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1508821","Registered Dietitian","C71277","An individual who: (1) has completed the minimum of a Baccalaureate degree granted by a U.S. regionally accredited college or university, or equivalent; (2) has met current minimum academic requirements (Didactic Program in Dietetics) as approved by the Commission on Accreditation/Approval for Dietetics Education of the American Dietetic Association; (3) has completed pre-professional experience accredited/approved by the Commission on Accreditation/Approval for Dietetics Education of the American Dietetic Association; (4) has successfully completed the Registration Examination for Dietitians; (5) has the annual registration maintenance fee; and (6) has accrued 75 hours of approved continuing professional education within a specific five-year reporting period.","Registered Dietitian | Registered Dietitian Nutritionist | registered dietitian",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347929","Registered Medical Assistant (occupation)","C71278","A licensed health care worker who performs the administrative and clinical tasks that keep the offices of physicians, podiatrists, chiropractors, and other health practitioners running smoothly and is licensed by a state authority.","Registered Medical Assistant | RMA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347930","Registered Nurse Practitioner","C71279","A registered nurse who has received special training and can perform many of the duties of a physician.","Registered Nurse Practitioner | RNP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347931","Registered Pharmacist (occupation)","C71281","A person trained to formulate and dispense drugs or medications through completion of an accredited university program in pharmacy. Licensure is required upon completion of the program and prior to serving the public as a pharmacist.","Registered Pharmacist | Licensed Pharmacist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1552258","Nurse Practitioner - Acute Care","C71282","A registered nurse prepared in a graduate level acute care nurse practitioner program to provide and manage health care of acutely ill, and critically or chronically ill adult patients in a wide range of settings.","Acute Care Nurse Practitioner | ACNP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347752","Adult Nurse Practitioner","C71283","A registered nurse prepared in a graduate level adult nurse practitioner program to provide a full range of health care services on the wellness-illness health care continuum at an advanced level to adults.","Adult Nurse Practitioner | ANP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347988","Advanced Oncology Certified Nurse","C71293","A registered nurse who has worked at least 12 months out of the last 3 years as an oncology nurse. The nurse must also have worked at least 1,000 hours out of the last 2-1/2 years in the field of oncology.","Advanced Oncology Certified Nurse | AONC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347989","Advanced Oncology Certified Nurse Practitioner","C71284","A registered nurse with a master's degree or higher in nursing and a minimum of 500 hours of supervised clinical practice of oncology nursing. The AOCNP certification also requires successful completion of an accredited nurse practitioner program.","Advanced Oncology Certified Nurse Practitioner | AONC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347990","Advanced Oncology Certified Nurse Specialist","C71294","A registered nurse who has a master's degree or higher in nursing and a minimum of 500 hours of supervised clinical practice of oncology nursing.","Advanced Oncology Certified Nurse Specialist | AOCNS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347991","Advanced Practice Nurse Practitioner","C71285","A registered nurse with advanced education, knowledge, skills, and scope of practice.","Advanced Practice Nurse Practitioner | APRN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347587","Certified Adult Nurse Practitioner (occupation)","C71286","A registered nurse who has completed an advanced training program endorsed authoritatively as having met certain requirements in adult medicine.","Certified Adult Nurse Practitioner | CANP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347588","Certified Clinical Nurse Specialist","C71295","A registered nurse who has a master's or doctorate degree in a clinical field of nursing and has been certified by the Board of Registered Nursing.","Certified Clinical Nurse Specialist | CCNS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347589","Certified Clinical Research Associate","C71296","A clinical research associate or monitor with related work experience and with certification earned by passing a required program and written examination from the Association of Clinical Research Professionals (ACRP) or equivalent organization.","Certified Clinical Research Associate | CCRA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347590","Certified Clinical Research Coordinator","C71297","A clinical research coordinator or study coordinator with related work experience and with certification earned by passing a required program and written examination from the Association of Clinical Research Professionals (ACRP) or equivalent organization.","Certified Clinical Research Coordinator | CCRC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347586","Certification in Critical Care Nursing","C71298","The process of obtaining certification in critical care nursing as granted by the American Association of Critical-Care Nurses (AACN) Certification Corporation. Registered nurses who have not achieved CCRN certification status or whose CCRN status has lapsed are not authorized to use the CCRN credential.","Certification in Critical Care Nursing | CCRN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347591","Certified Clinical Research Professional","C71302","A clinical research professional (i.e., administrator, coordinator, consultant, educator, or researcher in clinical trial management) with related work experience and with certification earned by passing a required program and written examination from the Society of Clinical Research Associates (SOCRA) or equivalent organization.","Certified Clinical Research Professional | CCRP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347592","Certified Emergency Nurse","C71306","A registered nurse who has passed an examination to show possession of a body of knowledge commensurate with competent practice as awarded by The Board of Certification in Emergency Nursing.","Certified Emergency Nurse | CEM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347594","Certified Flight Registered Nurse","C71307","A registered nurses who has successfully completed the flight nurse certification examination and earned the credential of Certified Flight Registered Nurse.","Certified Flight Registered Nurse | CFRN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349938","Certified Midwife","C71308","An individual educated in the discipline of midwifery, who possesses evidence of certification according to the requirements of ACNM.","Certified Midwife | CM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347595","Certified Medical Assistant (occupation)","C71309","A medical assistant who has successfully completed an examination that earns them the credentials to become a certified medical assistant.","Certified Medical Assistant | CMA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347596","Certified Nurse Assistant","C71310","A person who has completed a brief health-care training program, and who provides support services for RNs and LPNs. Also known as an orderly or, when certified by a state agency, a certified nurse assistant.","Certified Nurse Assistant | CNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347599","Certified Nurse Practitioner","C71288","A registered nurse who meets the requirements for licensure as an advanced practice nurse. A CNP can order diagnostic tests, prescribe medications and drugs, and administer medications and drugs.","Certified Nurse Practitioner | CNP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347597","Certified Nurse Specialist","C71311","An advanced practice RN who functions as a health care provider, educator, consultant, researcher, leader/administrator and/or case manager. It is the CNS who often sets the standards for quality patient care; trouble shoots problems and crises; anticipates complications and helps to prevent their development; and views the individual, family or group within the context of a whole system. The CNS usually has a specialty practice area such as diabetes, cardiology, respiratory, pediatrics or psychiatric-mental health.","Certified Nurse Specialist | CNS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347598","Certified Pediatric Nurse","C71312","A specialized registered nurse who provides care to pediatric patients. This includes performing nursing assessments, medication and treatment interventions, and education of the patient and the family.","Certified Pediatric Nurse | CPN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3468052","Certified Pediatric Nurse Practitioner","C71289","A nurse practitioner who practices in acute or primary care. The certified pediatric nurse practitioner specializes in assessing, diagnosing, and treating pediatric patients with acute or chronic pediatric diseases.","Certified Pediatric Nurse Practitioner | CPNP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347600","Certified Pediatric Oncology Nurse","C71331","A licensed Registered Nurse who has achieved the recognition of meeting criteria necessary to be specialized in the field of Pediatric Oncology, including working at least 1 year within the past 3 years with at least 1,000 hours spent in Pediatric Oncology Nursing within the past 2 1/2 years. In addition, at least 10 continuing education hours in the field of Pediatric Oncology Nursing should have been completed over the past 3 years.","Certified Pediatric Oncology Nurse | CPON",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347602","Certified Registered Nurse (occupation)","C71332","A registered nurse who has received certification from a national nursing organization or national nurse certification organization for practice in a specialized field of professional nursing.","Certified Registered Nurse | CRN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347604","Certified Vascular Nurse","C71333","A registered nurse with a vascular specialty encompassing caring for patients with a variety of arterial, venous and lymphatic diseases.","Certified Vascular Nurse | CVN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347603","Certified Transport Registered Nurse","C71334","A licensed registered nurse with a certification that indicates specialization in providing nursing care to patients during ground transportation.","Certified Transport Registered Nurse | CTRN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549966","Diploma","C71335","A document certifying the successful completion of a course of study.","Diploma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1552262","Family Nurse Practitioner","C71290","A registered nurse with specialized and advanced education in treating all age groups. The Family Nurse Practitioner can treat both pediatric and adult members of the family who suffer from acute or chronic illnesses, as well as address psychosocial issues that may be affecting the family.","Family Nurse Practitioner | FNP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348753","Gerontological Nurse Practitioner","C71291","A registered nurse with specialization and higher level of training in treating the elderly population. This includes the management of acute and chronic illness, as well as addressing the psychosocial issues that can be present with aging. Gerontological Nurse Practitioners are employed in clinics, doctor's offices, long-term care facilities, and hospitals.","Gerontological Nurse Practitioner | GNP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347392","Oncology Certified Nurse","C71336","A licensed Registered Nurse who has been working at least 1 year within the past 3 years, with at least 1,000 hours spent in Oncology Nursing within the past 2 1/2 years and at least 10 continuing education hours in the field of Oncology Nursing completed over the past 3 years and who has passed the certification exam.","Oncology Certified Nurse | OCN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347601","Certified Physician Assistant","C71337","A Physician Assistant who has completed a defined course of study and has undergone testing by the National Commission on Certification of Physician Assistants (NCCPA).  To remain certified a physician assistant must log 100 hours of continuing medical education every two years and take the recertification exam every six years.","Certified Physician Assistant | PA-C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347693","Progressive Care Certified Nurse","C71338","A critical care nurse with specialized training in progressive care, which describes areas referred to as intermediate care units, direct observation units, step-down units, telemetry and transitional care units as well as a specific level of care.","Progressive Care Certified Nurse | PCCN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549993","Secretarial Certificate","C71339","A document certifying a person to perform routine administrative, or personal tasks for a superior, including word processing, bookkeeping, file and record keeping, and scheduling.","Secretarial Certificate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512021","Doctor of Pharmacy","C39386","A professional, postgraduate degree that requires completion of a program in pharmacy that meets all of the following criteria: completion of the academic requirements to begin practice in the profession; at least 2 years of college work prior to entering the program; eight academic semesters after admission to the School of Pharmacy that involve extensive instruction in professional pharmacy pre-clinical and clinical sciences.","Doctor of Pharmacy | Pharm.D. | PharmD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348534","Steering Committee","C71415","A committee to arrange the priorities or order of business for an organization.","Steering Committee | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079595","Imaging Technique","C17369","Any technology or method that aids in the visualization of any biological process, cell, tissue or organ for use in screening, diagnosis, surgical procedures or therapy.","Imaging Procedure | Diagnostic Imaging Technique | IMAGING_METHOD | Image Type | Imaging | Imaging (procedure) | Imaging Procedures | Imaging Technique | Imaging Technique | Medical Imaging | Type of imaging | imaging | imaging procedure | imaging type | imaging_type",,,,,,,,,,,,,,,"4081530","Imaging technique",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017349","MHC Class II Gene","C16616","A family of genes expressed mainly by antigen presenting cells that encode major histocompatibility complex proteins and are involved in the presentation of fragments from phagocytized extracellular proteins to cytotoxic lymphocytes.","MHC Class II Gene | Class II MHC | MHC Class II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017355","MHC Class I Gene","C16617","A family of genes that encode major histocompatibility complex proteins and are involved in the presentation of cytoplasmic protein fragments to cytotoxic lymphocytes.","MHC Class I Gene | Class I MHC | MHC Class I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512020","Doctor of Osteopathic Medicine","C39385","The Doctor of Osteopathic Medicine degree is the first-professional, postgraduate degree awarded to the graduates who have completed an osteopathic medicine program which is designed to prepare physicians who are especially concerned with maintaining continuing personal relationships with patients, their families and their optimum interaction with the community environmental patterns.","Doctor of Osteopathic Medicine | D.O. | DO | Doctor of Osteopathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512016","Doctor of Dental Medicine","C39381","The Doctor of Dental Medicine degree is the first-professional, postgraduate degree awarded for graduates who have completed a program of studies in dental medical science. The academic standard is equivalent to Ph.D.","Doctor of Dental Medicine | D.M.D. | DMD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704312","Health Care Professional","C53287","A person qualified to be engaged in activity directed at preservation of mental and physical health by diseases prevention and treatment as a source of livelihood.","Health Care Professional | HEALTH CARE PROFESSIONAL | Health Professional",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348494","Extramembrane Domain","C71457","Any part of a transmembrane protein that is not embedded within the membrane.","Extramembrane Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512017","Doctor of Dental Surgery","C39382","The Doctor of Dental Surgery degree is the first-professional, postgraduate degree awarded for graduates who have completed a program of studies in dental surgery.","Doctor of Dental Surgery | D.D.S. | DDS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512024","Doctor of Podiatric Medicine","C39389","The Doctor of Podiatric Medicine degree is the first-professional, postgraduate degree awarded to the graduates who have completed an podiatric medicine program which is designed to prepare physicians who prevent, diagnose, and treat diseases and disorders that affect the human foot and ankle.","Doctor of Podiatric Medicine | D.P. | D.P.M. | DP | DPM | Pod.D. | PodD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512025","Doctor of Public Health","C39390","Doctor of Public Health is an academic degree in public health. The prior degree is generally earned in the closely related professional field, e.g. medicine.","Doctor of Public Health | Dr.P.H.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512026","Doctor of Veterinary Medicine","C39391","The Doctor of Veterinary Medicine degree is a postgraduate first-professional degree awarded for graduates who have completed a program of studies in veterinary medicine.","Doctor of Veterinary Medicine | D.V.M. | DVM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513006","Master of Business Administration","C39449","Master of Business Administration is a master's degree in business.","Master of Business Administration | M.B.A. | MBA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513007","Master of Health Services Administration","C39450","Master of Health Services Administration is a master's degree in health administration and health care management.","Master of Health Services Administration | M.H.A. | M.H.S.A. | MHA | MHSA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513008","Master of Public Health","C39451","The Master's of Public Health is an academic degree awarded to graduates who have completed a program of studies in public health that usually address human population health, community program administration, research, and health policy development.","Master of Public Health | M.P.H. | MPH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513009","Master of Science","C39452","The Master of Science Degree is an academic degree in science. The degree's classification includes such degrees in any scientific field.","Master of Science | M.S. | MS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513911","Naturopathic Doctor","C39473","The Naturopathic Doctor (N.D.) degree is a degree awarded for graduates who have completed a medical doctoral program in accredited school. N.D. has a qualification of primary care physicians with a specialized focus in preventative medicine, natural therapeutics, and emphasis on holistic and nontoxic approaches to therapy and optimizing wellness.","Naturopathic Doctor | N.D. | ND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512019","Doctor of Optometry","C39384","The Doctor of Optometry degree is the first-professional, postgraduate degree awarded to the graduates who have completed a specialized four year post-baccalaureate professional program in order to become independent health care providers who examine, diagnose, treat, and manage disorders of the visual systems and diseases of the eye and associated structures.","Doctor of Optometry | OD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512022","Doctor of Philosophy","C39387","The Doctor of Philosophy degree is the highest academic degree awarded in recognition of creative scholarship and research in a field of study. The recipient of this degree must have demonstrated proficiency in a broad area of learning and the ability to critically evaluate work in the discipline. The degree is not awarded solely for completing a prescribed number of courses, but for having undertaken and completed independent work in the discipline leading to an original contribution to knowledge.","Doctor of Philosophy | Ph.D. | PhD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0586303","Certificate","C68637","A document earned by a person indicating that the person has specific knowledge, skills, or abilities in the view of a certifying body.  Similarly, a document indicating that a product or process is suitable or in working order for a specific purpose.","Certificate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1321571","Certified Registered Nurse Anesthetist","C20831","Certified Registered Nurse Anesthetist (CRNA) - a registered nurse who provides anesthetics to patients in collaboration with surgeons, anesthesiologists, dentists, podiatrists, and other qualified healthcare professionals.  CRNAs practice with a high level of autonomy in most surgical practice settings. (AANA)","Certified Registered Nurse Anesthetist | CRNA | Nurse Anesthesiologist | Nurse Anesthetist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013963","Emergency Medical Technician","C53417","A person with formal training in basic medical knowledge and skills, certified (requirements vary by state) to respond and to provide a competent prehospital care and transportation to patients in emergency situations including but not limited to medical emergencies, hazardous materials exposure, child birth, abuse, fires, flood, accidents, trauma, and psychiatric crises.","Emergency Medical Technician | EMERGENCY MEDICAL TECHNICIAN | EMT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030450","Paramedical Personnel","C53420","An individual trained and certified to provide all basic and intermediate life support measures in addition to using invasive medical procedures (including intravenous therapy, cardiac defibrillation, administering medications and solutions, and using ventilation devices) as dictated by state law and performed under medical control in case of medical emergencies, hazardous materials exposure, child birth, abuse, fires, flood, accidents, trauma, and psychiatric crises.","Paramedic | PARAMEDIC | Paramedical Practitioner | Paramedical Practitioners",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334914","Medical Assistant","C53430","A person trained to assist medical professionals.","Medical Assistant | MEDICAL ASSISTANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510818","Advanced Practice Nurse","C20825","A registered nurse, usually prepared at the master's degree level or higher, who functions within a specialty area within nursing practice.  Advanced practice nurses make independent and collaborative health care decisions. Advanced practice nurses are expert clinicians engaged in active practice. The advanced practice nurse demonstrates leadership as a consultant, educator, administrator and researcher. An important leadership function of all advanced practice nurses is participation in legislative and professional activities to promote professional advancement and health related social policies. (from AANP)","Advanced Practice Nurse | APN | advanced practice nurse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883725","Replicate","C28038","To make a copy or duplicate of something.","Replicate | Copy | Duplicate | replicate",,,,,,,,,,,,,,,"4045414","Double",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026605","Motivation","C28495","The psychological feature that arouses an organism to action toward a desired goal; the reason for the action; that which gives purpose and direction to behavior.","Motivation | Motive",,,,,,,,,,,,,,,"4239752","Motivation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347607","ChemBank","C71414","A web-based knowledge environment that includes freely available data derived from small molecules and small-molecule screens and resources for studying the data so that biological and medical insights can be gained.","ChemBank | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035149","Reproducibility","C15318","The ability to yield similar results given a set of constraints.","Reproducibility | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036773","Serum Albumin","C28187","The main protein in blood plasma. Low levels of serum albumin occur in people with malnutrition, inflammation, and serious liver and kidney disease.","Serum Albumin | serum albumin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0699889","Malignant Female Reproductive System Neoplasm","C4913","A primary or metastatic malignant neoplasm involving the female reproductive system.  Representative examples include endometrial carcinoma, cervical carcinoma, ovarian carcinoma, uterine corpus leiomyosarcoma, adenosarcoma, malignant mixed mesodermal (mullerian) tumor, and gestational choriocarcinoma.","Malignant Female Reproductive System Neoplasm | Female Reproductive Cancer | Female reprod. system cancer, NOS | Female reproductive system cancer, NOS | Gynecologic Cancer | Malignant Female Reproductive System Tumor | Malignant Gynecologic Neoplasm | Malignant Gynecologic Tumor | Malignant Neoplasm of Female Reproductive System | Malignant Neoplasm of the Female Reproductive System | Malignant Tumor of Female Reproductive System | Malignant Tumor of the Female Reproductive System | Malignant neoplasm of female genital organ, unspecified | gynecologic cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511788","Desktop Video","C19542","A videoconferencing system that can be used by an individual from a desktop computer. A desktop conferencing system consists of a computer, an attached video camera, microphone, and speakers, and a telephone or network connection.","Desktop Video | Desk Video",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347452","Paternal Relative","C71382","A person related by lineage through the father's side of the family.","Paternal Relative | Paternal",,,,,,,,,,,,,,,"764185","Paternal relative",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347083","Maternal Relative","C71383","A person related by lineage through the mother's side of the family.","Maternal Relative | Maternal",,,,,,,,,,,,,,,"764186","Maternal relative",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266852","Biological Relative","C71384","A person related by descent rather than by marriage or law.","Biological Relative | BIOLOGICALLY RELATED | Blood Relation | Blood Relative | Consanguineous Relative | Consanguinity | Natural Relative | consanguinity",,,,,,,,,,,,,,,"4053608","Blood relative",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0337471","Grandparent","C71385","A parent of your father or mother.","Grandparent | ",,,,,,,,,,,,,,,"4244389","Grandparent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0337474","Grandmother","C71386","The mother of your father or mother.","Grandmother | ",,,,,,,,,,,,,,,"4014095","Grandmother",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0337475","Grandfather","C71387","The father of your father or mother.","Grandfather | ",,,,,,,,,,,,,,,"4146527","Grandfather",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348890","Grand Relative","C71388","A relative separated by two generations.","Grand Relative | Grand Relation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337548","Grandchild","C71397","A child of your son or daughter.","Grandchild | ",,,,,,,,,,,,,,,"4311425","Grandchild",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0337573","Grandson","C71398","A male grandchild.","Grandson | ",,,,,,,,,,,,,,,"4323278","Grandson",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0337561","Granddaughter","C71399","A female grandchild.","Granddaughter | ",,,,,,,,,,,,,,,"4194989","Granddaughter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348895","Great Relative","C71389","When combined with another relation 'great' indicates an additional generation of separation between relatives.","Great Relative | Great Relation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348717","Full Sibling","C71390","A sibling with whom you share both parents.","Full Sibling | Full Relation | Full Relative | SIBLING, FULL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337505","Half Sibling","C71391","A sibling with whom you share a single parent.","Half Sibling | Half Relation | Half Relative | SIBLING, HALF | half-sibling",,,,,,,,,,,,,,,"4050684","Half-sibling",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0337531","Half Brother","C71402","A male sibling with whom you share a single parent.","Half Brother | BROTHER, HALF | Half-brother",,,,,,,,,,,,,,,"4187654","Half-brother",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0337518","Half Sister","C71403","A female sibling with whom you share a single parent.","Half Sister | Half-sister | SISTER, HALF",,,,,,,,,,,,,,,"4331453","Half-sister",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2346667","Legal Relative","C71392","Family members related by secondary marriage or other legal arrangement.","Legal Relative | Legal Relation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348710","Foster Relative","C71393","Unrelated persons who are part of the same foster family.","Foster Relative | Foster Relation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347535","Adoptive Relative","C71394","A family relation established by a legal proceeding that creates a parent-child relation between persons not related by blood.","Adoptive Relative | Adoptive Relation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348536","Step Relative","C71395","A family relation established through a subsequent marriage of your parent.","Step Relative | Step Relation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349980","In-law (relative)","C71396","A relative by marriage.","In-law | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2350007","Son-in-law","C71400","The husband of your daughter.","Son-in-law | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553705","Daughter-in-law","C71401","The wife of your son.","Daughter-in-law | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553711","Brother-in-law","C71406","A brother by marriage.","Brother-in-law | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2350006","Sister-in-law (relative)","C71407","A sister by marriage.","Sister-in-law | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337577","Uncle","C71404","The brother of your father or mother; the husband of your aunt.","Uncle | ",,,,,,,,,,,,,,,"4244225","Uncle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0337576","Aunt","C71405","The sister of your father or mother; the wife of your uncle.","Aunt | ",,,,,,,,,,,,,,,"4101465","Aunt",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0337578","Niece","C71408","A daughter of your brother or sister.","Niece | ",,,,,,,,,,,,,,,"4146371","Niece",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0337579","Nephew","C71409","A son of your brother or sister.","Nephew | ",,,,,,,,,,,,,,,"4308892","Nephew",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0337580","Cousin","C71410","A child of your aunt or uncle or their descendents.","Cousin | ",,,,,,,,,,,,,,,"4206333","Cousin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0337583","First Cousin","C71411","A child of your aunt or uncle.","First Cousin | ",,,,,,,,,,,,,,,"4165069","First cousin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348676","First Cousin Once Removed","C71412","A child of your first cousin.","First Cousin Once Removed | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2355574","Ward (person)","C71413","A person who is under the protection or in the custody of another.","Ward | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441640","Taper","C71482","To cease by degrees; decrease; diminish.","Taper | Taper Off",,,,,,,,,,,,,,,"4106473","Tapering - action",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2349022","Unique Identifier","C70663","A set of characters used as a code that is unique in the context or the system for which it is created. It serves as a means of identification and reference (often instead of a name) for an entity, person, thing, function, procedure, activity, variable, or body of data.","Unique Identifier | UI | UID | uuid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348942","Healthcare Payer","C70686","An entity, organization, government, corporation, health plan sponsor, or any other financial agent who pays a healthcare provider for the healthcare service rendered to a patient or reimburses the cost of the healthcare service.","Healthcare Payer | ",,,,,,,,,,,,,,,"762460","Healthcare payer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347027","Biospecimen Collection","C70945","The act or process of gathering biospecimens for testing, diagnostic, propagation, treatment or research purposes.","Biospecimen Collection | Biological Sample Collection | Biospecimen Collected | Specimen Collection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347111","Biospecimen Collection Method","C70700","A method or procedure by which biological material is obtained from a subject for testing, diagnostic, treatment, or research purposes.","Biospecimen Collection Method | Biological Sample Collection Method | Method of Biospecimen Collection | method of sample procurement | method_of_sample_procurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348511","Fasting Status at Specimen Collection","C70928","Indicates whether a specimen obtained from a subject that has abstained from food and possibly water for the prescribed amount of time; or from a subject who has not abstained from food or water.","Fasting Status at Specimen Collection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347525","Planned Clinical Study","C70704","A business process status of a clinical study which occurs before the study starts. A study plan on which the clinical trial is based focuses on several priority parameters that include but are not limited to the types of subjects eligible to participate in the study, targeted accrual numbers, schedules and durations of interventions, the length of the study, and the planned duration of a subject participation. These outlines are a part of a study protocol which is more a detailed and comprehensive study document.","Planned Clinical Study | Planned Clinical Trial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347798","Clinical Study Targeted Accrual","C70706","A total number of subjects needed for the entire clinical study. The final sample size documented in the study protocol.","Clinical Study Targeted Accrual | Clinical Study Target Accrual | Clinical Trial Targeted Accrual",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347527","Planned Duration of Study Subject Participation","C70707","Total estimated length of time of subject's participation in a clinical study; from the time of enrollment to the completion of follow-up as documented in the study protocol.","Planned Duration of Study Subject Participation | Planned Duration of Study Subject's Participation | Planned Length of Time of Study Subject Participation | Planned Length of Time of Study Subject's Participation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347528","Planned Intervention Duration for Study Subject","C70708","Total estimated length of time during which a clinical study subject is expected to undergo an intervention in the framework of a clinical trial.","Planned Intervention Duration for Study Subject | Planned Study Subject Intervention Duration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348587","Submission Unit Relationship","C70959","The relationship between a regulatory submission and the submission units. It might refer to a temporal or sequential relationship, or indicate the order in which submission units should be processed and evaluated.","Submission Unit Relationship | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348184","Sequence Number","C70710","A number that identifies the ordering relations (in time, space, etc.) in a set of objects or events.","Sequence Number | SEQ | sequenceNumber",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348533","Scheduled Study Activity for Study Subject","C70712","A state of an activity (such as a procedure, visit, examination, etc.), which has been assigned with the designation of a time or/and date when the activity has to be performed to a particular study subject according to the study protocol.","Scheduled Study Activity for Study Subject | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348162","Scheduled Study Activity Date and Time","C71158","An expression of both a date and time when a particular study activity assigned to be performed.","Scheduled Study Activity Date and Time | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0680846","Funding Agency","C39409","An organization that underwrites financial support for projects of a particular type. Typically, they process applications and award funds to the chosen qualified applicants.","Funding Agency | Funding Source",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456204","Biospecimen Type","C70713","The type of a material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes. This includes particular types of cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory substances.","Biospecimen Type | Biospecimen_Type | SPEC | Sample Type | Specimen Type | Type of Biospecimen | physical sample type | physical_sample_type | sample type | sample_type | specimen type | specimen_type",,,,,,,,,,,,,,,"4154128","Specimen type",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347962","Reviewable Unit","C70721","A predefined portion of an application that, by agreement between the applicant and the review division, can be submitted prior to submission of a complete application.","Reviewable Unit | ReviewableUnit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3476359","Postal Address","C70946","A physical location used by a person or organization for the purpose of receiving postal mail deliveries.","Postal Address | Mail Address | Mailing Address | postalAddress",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348559","Study Investigator Role","C71099","The responsibility of the investigator on a particular study as defined in the study protocol.","Study Investigator Role | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0806020","End Date","C68617","The calendar date on which something is to terminate or did terminate.","End Date | ENDAT | Stop | Stopping Date",,,,,,,,,,,,,,,"764408","End date",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2346578","Investigator Status in Study","C70725","A category used to describe the registration status of a clinical study investigator in a particular study.","Investigator Status in Study | Clinical Study Investigator Status in Study | Study Investigator Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346576","Investigator Signature","C70947","A textual or multimedia form of the signed name or personal mark of the investigator who is responsible for completing a particular document as a part of clinical study activity. By signing this document the investigator confirms his participation and his role in the study and assumes responsibility and accountability associated with this role.","Investigator Signature | Investigator's Signature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347526","Planned Clinical Study Activity","C70726","Any activity specified in a clinical study protocol that is anticipated to be performed during the execution of the study.","Planned Clinical Study Activity | Planned Protocol Activity | Planned Study Activity | PlannedActivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346865","Assessment of Observation Result","C70727","A critical appraisal of the evidence of the association between an assessment and the results of an observation.","Assessment of Observation Result | Observation Outcome Assessment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0587902","Information Status","C70728","A state of the information pertaining to the entity associated with a clinical study protocol indicating whether this information is active or inactive for the purpose of inclusion in the protocol planned activities.","Information Status | ",,,,,,,,,,,,,,,"4151032","Information status",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348654","Targeted Anatomic Site","C70729","An anatomic site targeted for a particular medical intervention.","Targeted Anatomic Site | Target Anatomic Site | TargetAnatomicSite | treatment anatomic site | treatment anatomic sites | treatment_anatomic_site | treatment_anatomic_sites",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349001","Human Study Subject","C70665","A living individual about whom an investigator conducting research obtains data through intervention or interaction with the individual or through identifiable private information.","Human Study Subject | Human Subject | Study Participant | Subject | human subject | subject/trial subject",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348585","Clinical Trial Subject Unique Identifier","C70731","A unique identifier assigned to each clinical trial subject to protect the subject's identity and used in lieu of the subject's name when the investigator reports adverse events and/or other trial-related data (ICH Guidelines).","Clinical Trial Subject Unique Identifier | Clinical Study Subject Unique Identifier | Subject Unique Identifier | subject identification code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347789","Clinical Study Population Subgroup","C70730","Relatively uniform groups (e.g. etiologically and pathogenetically more homogeneous, racial, ethnic, or gender-specific, or the disease- or condition-specific) of study subjects formed within a clinical study population for a separate analysis. The selection of the subgroups, methods of subgroup analysis, and anticipated difference in observation outcome(s) have to be defined and justified in the study protocol and based on known biological mechanisms, and/or findings in previous studies.","Clinical Study Population Subgroup | Study Population Subgroup | Study Subgroup | patient subgroup | patient_subgroup",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348583","Subject's Signature on Informed Consent Form","C70958","An inscription provided by a human subject on the informed consent document.  This inscription signifies the subject's intent to participate in the clinical study, and his acknowledgement and understanding of the risks involved in such participation.","Subject's Signature on Informed Consent Form | Patient Signature on Informed Consent Form | Patient's Signature on Informed Consent Form | Subject Signature on Informed Consent Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348568","Study Subject Participation Status","C70732","The status of a subject in relationship to their participation in a given clinical study, at a particular time and date.","Study Subject Participation Status | Subject Participation Status | Subject Participation Status in Clinical Study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347478","Performed Clinical Study","C70759","A business process status of a clinical study that refers to the study that started the execution of activities specified by the study protocol. The data associated with the performed study describes quantitatively and qualitatively actual observations and events occurring in the study after its approval, such as actual accrual numbers, dates of subject enrollment, etc.","Performed Clinical Study | Performed Clinical Trial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347786","Clinical Study Actual Accrual Number","C70760","A number of subjects that have been enrolled for the participation in a clinical study at a given point in time. A date for the actual accrual number must be specified.","Clinical Study Actual Accrual Number | Actual Accrual | Actual Accrual Number | Actual Accrual for Clinical Trial | Clinical Study Actual Accrual",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347785","Clinical Study Activity Relationship","C70762","The relationship between clinical study activities specified in a study protocol. It might refer to a temporal or sequential relationship, or indicate the possibility of performing a particular type of activity as a substitute for another one.","Clinical Study Activity Relationship | Study Activity Relationship",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348833","Clinical Study Activity Relationship Type","C70970","An attribute that defines the meaning and purpose of a clinical study activity relationship instance.","Clinical Study Activity Relationship Type | Type of Clinical Study Activity Relationship",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347681","Priority Number","C70763","An integer designating the relative priority of events, activities, or entities of a similar type. Lower priority number signifies higher priority value.","Priority Number | priorityNumber",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347833","Clinical Study Activity Relationship Comment","C70929","An additional description of the relationship between the clinical study activities specified in a study protocol. It might refer to a temporal or sequential relationship, or indicate the possibility of performing a particular type of activity as a substitute for another one.","Clinical Study Activity Relationship Comment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346574","Investigator Official Credentials","C70949","A textual description of the investigator's credentials including, but not limited to the degree(s), board certification(s), license(s), diploma, and other official and/or legal documents indicating that the person has specific knowledge, skills, or abilities in the view of a certifying body. It may also include granted permission(s) to perform a certain activity or hold possession of a specified thing.","Investigator Official Credentials | Investigator Certification or License | Investigator's Certification or License | Investigator's Official Credentials",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348097","Clinical Study Activity Description","C70960","A coded terminology representation of a study activity that can be planned, scheduled or performed according to the study protocol. A full representation includes a code and a corresponding textual description of the activity.","Clinical Study Activity Description | Description of Clinical Study Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347837","Study Activity Comment","C70936","An optional additional description of an activity that can be planned, scheduled or performed in the framework of a particular study. The comment is provided in a free text format.","Study Activity Comment | Comment on Study Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347181","Activity Status","C70711","A state of an activity in relation to its execution, timing, objective(s) or other quantitative or qualitative parameter(s).","Activity Status | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348834","Clinical Study Document Relationship Type","C71107","A particular category of the relationship between two items of study-related documentation.","Clinical Study Document Relationship Type | Type of Clinical Study Document Relationship",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348099","Description of Test Result","C70951","A textual representation of a laboratory test result.","Description of Test Result | Test Result Description",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347373","Numeric Test Result","C70952","A numeric representation of a test result.","Numeric Test Result | LAB_RESULT_NUMERIC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706245","Precision - characteristic","C48045","A quantitative representation of the degree of accuracy necessary for or associated with a particular action.","Precision | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348631","System of Measurement","C70767","A set of units that can be used to quantitatively specify and characterize entities, objects, phenomena, or events.","System of Measurement | Measurement System | Unit of Measure Coding Scheme | Unit of Measure System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348663","Test Reference Text List","C70935","Textual representation of a normal result of a particular test. It may consist of one word or an expression.","Test Reference Text List | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346904","Low Test Reference Range","C70934","Reported low limit of the test reference range.","Low Test Reference Range | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348973","High Test Reference Range","C70933","Reported upper limit of the test reference range.","High Test Reference Range | ORNRHI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347838","Test Result Reference Range Comment","C70930","An optional additional description of the characteristics of the laboratory test result reference range entered in a free text format. It may include specific demographic parameters, the specific instrument used to measure the value, or the specific method applied.","Test Result Reference Range Comment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346633","Laboratory Test Result Status","C70768","A qualifier used to describe the workflow progression of a laboratory observation outcome in terms of being finished, concluded, interpreted as preliminary, needed to be repeated, etc.","Laboratory Test Result Status | Lab Test Result Status | Reported Test Result Status | Test Result Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346488","Original Unit or Value of Reported Test Result Indicator","C70967","An indicator that can be set or unset in order to signal whether the observation is in the units or values as collected, or it has been converted into standardized units or values.","Original Unit or Value of Reported Test Result Indicator | Indicator of Original Unit or Value of Reported Test Result | Indicator of Original Unit or Value of Reported Test Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347378","Observation Outcome Relationship","C70776","The relationship between two or more observation outcomes. It might refer to a diverse range of relationships such as temporal, or sequential, or indicate that a test was performed to verify another test result, or designate that a test is a component of a test panel.","Observation Outcome Relationship | Test Result Relationship",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348835","Observation Result Relationship Type","C71108","A particular category of the relationship that defines the meaning and purpose of a clinical study observation result relationship instance.","Observation Result Relationship Type | Type of Observation Result Relationship",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347836","Observation Result Relationship Comment","C70931","An additional description of the relationship between two or more observation outcomes. It could refer to the temporal, or sequential relationship, or indicate that a test was performed to verify another test result, or designate that a test is a component of a test panel.","Observation Result Relationship Comment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347790","Clinical Study Site","C70777","A healthcare organization, an institution, a facility, a healthcare provider, or a part or a constituent of any of the above entities directly involved in conducting a particular clinical study.","Clinical Study Site | CLINICAL STUDY SITE | Site | Study Site | study site | study_site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347795","Study Site Role","C70781","A designation of responsibilities of a clinical site in conducting a particular clinical study.","Study Site Role | Clinical Study Site Role | Clinical Study Site by Role in Study | Clinical Study Site by Role in Study | Site Role | Site Role in Study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347791","Clinical Study Site Accrual Status","C70785","Defines the status of a clinical study site in relation to the subject enrollment at a particular time.","Clinical Study Site Accrual Status | Accrual Status of Clinical Study Site | Accrual Status of Clinical Trial Site | Accrual Status of Study Site | Site Accrual Status | Site Status of Accrual | Study Site Accrual Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348653","Targeted Accrual at Clinical Study Site","C70789","A total number of subjects needed for the entire clinical study at a particular clinical study site.","Targeted Accrual at Clinical Study Site | Clinical Study Site Targeted Accrual | Site Planned Accrual | Site Target Accrual | Study Site Target Accrual | Study Site Targeted Accrual",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346500","Institutional Review Board Approval Date","C70801","A date on which the Institutional Review Board (IRB) approved a clinical study protocol for execution at the particular institution or site. If the study receives full unconditional approval at a convened meeting, the date of IRB approval is the date of this convened meeting. If at the convened IRB meeting the study is approved subject to modifications, the date of IRB approval is the date when the requested changes are verified.","Institutional Review Board Approval Date | IRB Approval Date",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348439","End Date of Clinical Study Site Participation in Study","C71105","A calendar date specifying the end of the clinical site participation in a particular study","End Date of Clinical Study Site Participation in Study | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347794","Study Site Status","C70783","A business process state of a site in relation to its approval status, authorization for patient enrollment, and other protocol-specific activities in the framework of a particular clinical study.","Study Site Status | Clinical Study Site Status | Clinical Study Site Status | Clinical Trial Site Status | Site Status | Trial Site Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347834","Laboratory Procedure Comment","C70954","Optional additional information about a laboratory procedure that can be planned, scheduled or performed in the framework of a particular study. The comment is provided in a free text format.","Laboratory Procedure Comment | Additional Test Description",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346632","Laboratory-Generated Comment","C70932","Additional information related to the specific test that was generated in the laboratory where test had been performed. This comment is usually provided in free text format.","Laboratory-Generated Comment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348840","Telecommunication Address Type","C70955","A particular category of telecommunication address regarded as having particular characteristics, qualities, type of usage, and defined similarities.","Telecommunication Address Type | Type of Telecommunication Address",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348659","Telecommunication Address Usage Type","C70808","A normal use or purpose of the telecommunication resource of an entity.","Telecommunication Address Usage Type | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1552673","Telecommunication Address","C70806","The value for a particular telecommunication address used as the contact telecommunication information for a person or organization.","Telecommunication Address | telecomAddress",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL372179","Birth Date","C68615","The calendar date on which a person was born.","Birth Date | BD | BRTHDAT | DOB | Date of Birth | birthDate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1148348","Date of Death","C70810","The calendar date of subject's death.","Date of Death | DOD | Date of Death (If Deceased) | Death Date | deathDate",,,,,,,,,,,,,,,"4265167","Date of death",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0557163","Household Income","C70811","A demographic parameter indicating the amount of earnings made by a family.","Household Income | ",,,,,,,,,,,,,,,"4076114","Household income",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347932","Regulated Industry","C70814","A company, institution or organization that develops, manufactures, distributes or has responsibility for a regulated product.","Regulated Industry | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348098","Study Population Description","C70834","A textual description of the target study population which contains precisely defined characteristics of potential participants. This includes inclusion and exclusion criteria, the number of potential participants, conditions of recruitment and sample structure, information on vulnerable population(s) involvement in the study (if applicable).  Other available appropriate characteristics of the population from which study subjects will be recruited and to which the study results could be reasonably generalized is considered noteworthy.","Study Population Description | Description of Study Population | Study Design Population Description | Target Study Population Description | populationDescription",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348569","Study Subject Type","C70835","A target biological entity of the study.","Study Subject Type | Type of Study Subject",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347038","Blinded Clinical Study","C70840","A clinical study that is designed using a procedure in which one or more parties to the study [subject(s), investigator(s), monitor, or/and data analyst(s)] are kept unaware of the treatment assignment(s).","Blinded Clinical Study | Blind Clinical Study | Blinded Clinical Trial | Masked Clinical Study | blinded study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206012","Multicenter Trials","C16104","Clinical trial conducted according to a single protocol but at more than one site and, therefore, carried out by more than one investigator.","Multi-Institutional Clinical Trial | Central | multicenter study | multicenter trial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347892","Randomization Indicator","C70939","An indicator that can be set or unset in order to signal whether a study is randomized.","Randomization Indicator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348564","Study Protocol Confidentiality Status","C71109","A characteristic that defines how the disclosure of protocol content is controlled.","Study Protocol Confidentiality Status | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346663","Lead Protocol Agent Indicator","C71106","An indicator that can be set or unset in order to signal whether a particular agent is a primary medical product, practice, or application that is tested in a multi-agent clinical study.","Lead Protocol Agent Indicator | Lead Study Agent Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1115660","Lot Number","C70848","A distinctive alpha-numeric identification code assigned by the manufacturer or distributor to a specific quantity of manufactured material or product within a batch.","Lot Number | LOT | Lot Code | Lot Identifier | lotNumberText | medication lot number | medication_lot_number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347099","Medical Product Stability Date","C71365","A date until which the medical product retains its properties within specified limits, and resists conditions that may affect its stated performance. After it is activated, the product is considered useable during the stability period.","Medical Product Stability Date | Stability Date",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347095","Medical Product Expiration Date","C70854","A date determined by appropriate stability testing of the medical product lot, batch, or item, after which the product may not meet the appropriate regulatory agencies requirements. The expiration date must be placed on the container or label(s) of a medical product designating the time during which a batch of the product is expected to remain within the approved shelf life specifications if stored under defined conditions, and after which it may not be used (21 CFR 211.137 and 211.166).","Medical Product Expiration Date | Expiration Date | Product Expiration Date | Product.expirationDate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347379","Observation Result","C70856","An outcome of observation represented as a text, qualitative, or quantitative parameter, code, image, graph, etc.","Observation Result | RES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1302584","Date of Report","C70857","A date on which an event or observation was reported.","Date of Report | Date Of Record",,,,,,,,,,,,,,,"4161972","Date of report",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347835","Observation Result Comment","C70956","An optional additional description of the observation result provided in a free text format.","Observation Result Comment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349016","Observation Result Uncertainty","C70858","The measure of uncertainty of an observation result. Numerical value(s) indicating the reliability of the observation measurement including quantities evaluated by statistical methods and by other means.","Observation Result Uncertainty | Uncertainty of Observation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348586","Submission Unit","C70709","A collection of documents pertaining to a particular clinical study protocol and/or medical product accompanied by the associated reference information officially provided to the regulatory authority. This is usually done to comply with a specific regulatory purpose or decision.","Submission Unit | Regulatory Submission Unit | SubmissionUnit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347941","Regulatory Submission Receipt Date and Time","C70864","Physical media documenting the date and time when a regulatory submission is received in the FDA Document Room. This is an official receipt for the regulatory submission time. A submission receipt date might be different from a submission date. Submissions received outside of official hours are dated the next business day.","Regulatory Submission Receipt Date and Time | Submission Receipt Date",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348838","Regulatory Submission Unit Type","C70859","A particular category of a regulatory submission regarded as having particular characteristics, purposes, and causing different regulatory requests.","Regulatory Submission Unit Type | Submission Unit Type | Type of Regulatory Submission Unit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348588","Submission Unit Status","C70866","An attribute that indicates the status of a submission unit being referenced in relation to a regulatory assessment. The status of a submission unit is assigned by the submitting organization.","Submission Unit Status | Regulatory Submission Unit Status | Status of Regulatory Submission Unit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516606","Clinical Data","C15783","Data obtained through patient examination or treatment.","Clinical Data | Clinical | clinical data",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347934","Regulatory Application","C70868","A collection of submissions related to a particular regulated product that are grouped together for regulatory purposes and can be referenced in making one or more regulatory decisions.","Regulatory Application | Application | RegulatoryApplication | regulatory application",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348836","Regulatory Application Type","C70871","The primary category of an official application to the regulatory agency. It can cause specific types of regulatory requests.  The type of application is determined by the nature of the regulated product it supports, the phase of the product development, and other factors.","Regulatory Application Type | Application Type | Type of Application | Type of Regulatory Application",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347897","Study Administrative Activity Variance Reason","C70957","A textual explanation of the cause why a given activity or event considered as a milestone associated with a patient and/or study deviated from the expected timeline or did not occur.","Study Administrative Activity Variance Reason | Reason for Variance of Study Administrative Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347936","Regulatory Application Sponsor","C71136","The party who submits a marketing application to FDA for approval of a drug, device, or biologic product. An applicant is the person or entity who assumes responsibility for the marketing of a new medical product, including responsibility for compliance with applicable provisions of the Federal Food, Drug, and Cosmetic Act and related regulations. The sponsor is usually an individual, partnership, corporation, government agency, manufacturer or scientific institution.","Regulatory Application Sponsor | Applicant | Application Sponsor | Drug Sponsor | RegulatoryApplicationSponsor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347939","Regulatory Submission","C70885","An assembly of one or more regulatory submission units supporting a specific regulatory purpose or decision. In most cases, the compilation of the submission units is utilized in the assessment of a regulated medical product quality, safety and/or effectiveness.","Regulatory Submission | Reg Subm | Submission",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348837","Regulatory Submission Type","C70886","A particular category of a regulatory submission regarded as having particular characteristics, purposes, and causing different regulatory requests.","Regulatory Submission Type | Submission Type | Type of Regulatory Submission | submission type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347938","Regulatory Assessment","C70887","A regulatory action or inaction undertaken by the regulatory authority as a result of a submission analysis and evaluation.","Regulatory Assessment | RegulatoryAssessment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348003","Agent Administration","C70962","The act of the dispensing, applying, or tendering a medical product or other agent.","Agent Administration | Administration | administration (substance) | agent administration | agent_administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710560","Potency Unit","C48470","The basic quantity or increment used to describe the strength of a product or amount of product in a package.","Potency Unit | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882978","Schedule Frequency","C64493","A regimen for an intervention which consists of a specified number of instances within a specific time period.","Schedule Frequency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348330","Dose Description","C70961","A textual description of the agent dose level(s) or range(s) assigned to a subject according to the study protocol.","Dose Description | DOSTXT | DSTXT | doseDescription",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348070","Daily Dose","C70888","A specified quantity of a therapeutic agent to which an individual can be exposed to or was exposed to, during a one-day period.  In the clinical study protocol, the label and other documentation the type of daily dose must be specified.","Daily Dose | DOSTOT | Total Daily Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707811","Dose Modification","C54346","Change, alteration, or adjustment of a dose specified in a treatment plan or/and administered to a patient.","Dose Modification | DOSE MODIFICATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348832","Agent Dose Change Type","C70892","An attribute used to characterize a change in the agent dose regimen in the context of its relation to the original documented treatment plan.","Agent Dose Change Type | Dose Change Type | Type of Agent Dose Change",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042444","Drug Vehicle","C927","A substance used as a medium for administration of a pharmaceutical.","Drug Vehicle | Agent Vehicle | TRTV | Treatment Vehicle | Vehicle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348349","Drug Vehicle Volume","C70963","A volume of a carrier or inert medium used as a solvent in which a medicinally active agent is formulated and/or administered to the subject.","Drug Vehicle Volume | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348348","Drug Vehicle Unit of Volume","C70976","A unit used to express a volume of a carrier or inert medium in which a medicinally active agent is formulated and/or administered.","Drug Vehicle Unit of Volume | Unit of Volume for Drug Vehicle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347818","Code System","C70895","A systematized collection of concepts that define corresponding codes.","Code System | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348303","Display Name","C70896","The standardized text associated with a code in a particular code system.","Display Name | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347410","Original Text","C71138","The source text in its original format used as the basis of coding.","Original Text | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347817","Code Qualifier","C70897","Contains the value of the modified text when the original text is modified for coding purposes.","Code Qualifier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347820","Code Translation","C70898","An automated procedure that uses a specialized set of concept descriptors for conversion of the target concept descriptors into executable elements of other code systems with the equivalent semantics.","Code Translation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348554","Study Author","C70965","An individual, group, or organization primarily responsible for the content of a planned study. The author of the study is not necessarily the principal investigator. The principal investigator is not necessarily the author of the study.","Study Author | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348319","Document Detailed Description","C71140","A comprehensive narrated account of a document.","Document Detailed Description | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348322","Document Summary Description","C71141","An abstract of a document detailed description which represents its most significant information.","Document Summary Description | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348323","Document Summary Description Synopsis","C71142","A text that abstracts the salient information from the document summary description.","Document Summary Description Synopsis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347935","Regulatory Application Document Subtype","C71143","A subset category identified within a larger group of regulatory application documents. A document subtype provides more specific context for the documentation. It contains name value pairs and keywords that are used within the context of the application.","Regulatory Application Document Subtype | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348320","Document Status","C70865","A condition of a document indicating its relative position or state of affairs in relation to other documents and/or activities, especially in regard to document processing.","Document Status | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347479","Performed Clinical Study Activity","C70900","Activities specified in a clinical study protocol which have been successfully or unsuccessfully completed.","Performed Clinical Study Activity | Performed Study Activity | PerformedActivity | performed activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347572","Cause or Rationale for Missed Study Activity","C70937","A reason, motivation, and/or rationale for the activity-instance, such as the patient condition which demanded an intervention, or a patient's request to perform a procedure.","Cause or Rationale for Missed Study Activity | Missing Activity Reason",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347796","Clinical Study Sponsor","C70793","An entity such as an individual, company, institution, group, or organization which takes responsibility for the initiation, management, and/or financing of a clinical study. The sponsor does not actually conduct the investigation unless the sponsor is a sponsor-investigator. A person other than an individual (e.g., corporation or agency) that uses one or more of its own employees to conduct research it has initiated is considered to be a sponsor, and the employees are considered to be investigators. [21 CFR P.50.3(k)] [21 CFR P.50.102(j)] [21 CFR P.312.3]","Clinical Study Sponsor | CLINICAL STUDY SPONSOR | SPONSOR | Sponsor | Study Sponsor | sponsor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348839","Study Sponsor Type","C70972","An attribute used to indicate whether the sponsor assumes an ultimate responsibility for the initiation, management and/or financing of a clinical study, or provides support for these activities.","Study Sponsor Type | Type of Study Sponsor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346573","Investigational New Drug Indicator","C71144","An indicator that can be set or unset in order to signal whether an agent possesses a New Investigational Drug status.","Investigational New Drug Indicator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347852","Concomitant Agent","C70902","A pharmaceutical agent other than agent(s) tested in a given protocol that is administered to or used by a subject either prior to or during the study. Supportive care and essential ancillary medications required by a treatment regimen should be clearly identified. A protocol's complete instructions including appropriate indication, dosage, administration route, schedule, restrictions to use, and any other relevant data should be explicitly stated. Concept also refers to substance(s) used prior or during the study that are not specified by the protocol.","Concomitant Agent | CMTRT | Concomitant Medication Reported Name | Concomitant Medication or Therapy | ConcomitantAgent | MEDICATION | concomitant medications",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346498","Instance Unique Identifier","C71160","Data type unique identifier within a particular context.","Instance Unique Identifier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347975","Root Identifier","C70903","A unique identifier that guarantees the global uniqueness of the instance identifier. The root alone may be the entire instance identifier.","Root Identifier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346461","Identifier Extension","C70904","A character string as a unique identifier within the scope of the identifier root.","Identifier Extension | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346487","Displayable Identifier Indicator","C70973","An indicator that can be set or unset in order to signal whether the identifier is intended for human display and data entry as opposed to pure machine interoperation.","Displayable Identifier Indicator | Indicator of Displayable Identifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346561","phastCon","C70978","A computer program based on a two-state phylogenetic hidden Markov model (phylo-HMM) that works by fitting a phylo-HMM to the data by maximum likelihood, subject to constraints designed to calibrate the model across species groups, and then predicting conserved elements based on this model.","phastCon | phastCon Program | phastCon Software",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514586","Pseudoautosomal Region","C42296","The human Y chromosome is composed of two different parts: a pseudoautosomal region that is homologous to a region of the X chromosome and which is responsible for sex chromosome pairing and a Y-specific part that encodes the sex determining gene.  Genes within the pseudoautosomal region are not sex linked.","Pseudoautosomal Region | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043292","Human Chromosome X","C13285","The larger of the two human sex chromosomes. It is usually present singly in males and doubly in females.","Human Chromosome X | Chromosome X | Chromosome X | Human X Chromosome | X Chromosome | chrX",,,,,,,,,,,,,,,"4248722","Sex chromosome X",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519329","Single Nucleotide Polymorphism in Coding Sequence","C18518","Single Nucleotide Polymorphisms in Coding Sequences consist of a variation at an appreciable frequency between individuals of a single interbreeding population of a single nucleotide, due to base substitution, at an equivalent location within a protein-coding region of a gene that may or may not cause an amino acid change in the protein product and a detectable phenotypic effect.","Single Nucleotide Polymorphism in Coding Sequence | Single Nucleotide Polymorphism in cDNA Sequence | Single Nucleotide Polymorphisms in Coding Sequences | Single Nucleotide Polymorphisms in cDNA Sequences | cSNP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709259","Non-synonymous Coding SNP","C45397","A Non-synonymous Coding SNP consists of a variation at an appreciable frequency between individuals of a single interbreeding population of a single nucleotide, due to base substitution, at an equivalent location within a protein-coding region of a gene that causes an alteration of the translation of the affected codon into a different amino acid in the protein product. A missense non-synonymous SNP results in an amino acid change in the protein product due to a codon change, while a nonsense non-synonymous SNP results in a termination codon.","Non-synonymous Coding SNP | Coding, Non-synonymous SNP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710267","Synonymous Coding SNP","C45396","Synonymous Coding SNP consists of a variation at an appreciable frequency between individuals of a single interbreeding population of a single nucleotide, due to base substitution, at an equivalent location within a protein-coding region of a gene that causes no amino acid change in the protein product and no detectable phenotypic effect; a silent mutation.","Synonymous Coding SNP | Coding, Synonymous SNP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796346","Polymorphic Microsatellite Marker","C18299","Short repeats of nucleotide sequences present throughout the genome which exhibit variations within a population.","Polymorphic Microsatellite Marker | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346558","deCODE Map","C70942","A high resolution genetic map based on 5136 microsatellite markers in 146 Icelandic families.","deCODE Map | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347073","Marshfield Linkage Map","C70943","A microsatellite-based human genetic map based on 7740 microsatellite markers originally identified at the Marshfield Clinic.","Marshfield Linkage Map | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346505","International HapMap Project","C70979","A collaboration among scientists in Japan, the U.K., Canada, China, Nigeria, and the U.S. to develop a haplotype map of the human genome, the HapMap, which will describe the common patterns of human DNA sequence variation.","International HapMap Project | TSC | The SNP Consortium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516193","Cancer Detection","C15776","The act of discovery of a malignant neoplasm, and after treatment, the discovery of minimal residual disease.","Cancer Detection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333990","Lynch Syndrome","C8494","An autosomal dominant hereditary neoplastic syndrome characterized by the development of colorectal carcinoma and a high risk of developing endometrial carcinoma, gastric carcinoma, ovarian carcinoma, renal pelvis carcinoma, and small intestinal carcinoma. Patients often develop colorectal carcinomas at an early age (mean, 45 years). In the majority of the cases the lesions arise from the proximal colon. At the molecular level, high-frequency microsatellite instability is present.","Lynch Syndrome | Familial Non-Polyposis Colon Cancer (hMSH2, hMLH1, hPMS1, hPMS2) | Hereditary Colorectal Endometrial Cancer Syndrome | Hereditary Defective Mismatch Repair Syndrome | Hereditary Non-Polyposis Colon Cancer | Hereditary Non-Polyposis Colon Cancer (hMSH2, hMLH1, hPMS1, hPMS2) | Hereditary Nonpolyposis Colon Cancer (hMSH2, hMLH1, hPMS1, hPMS2) | Lynch syndrome",,,,,,,,,,,,,,,"37396489","Lynch syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019630","MHC Class II Protein","C20705","MHC Class-II Proteins are non-covalently linked polymorphic alpha/beta transmembrane glycoproteins. The immunological function of MHC Class-II proteins is to bind and present antigenic peptides on the surfaces of cells for recognition by the antigen-specific T cell receptors of lymphocytes. These proteins plays an important role in the mediation of immune response.","MHC Class II Protein | Class II MHC Protein | HLA | Histocompatibility Antigen, Class II | Human Leukocyte Antigen | MHC Class II Molecule | Major Histocompatibility Complex Class II | human leukocyte antigen | human lymphocyte antigen",,,,,,,,,,,,,,,"42539463","Major histocompatibility complex class II",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085076","Mammoplasty","C15354","Surgical reconstruction of the breast.","Mammoplasty | Breast Reconstruction | Breast Reconstruction | breast reconstruction",,,,,,,,,,,,,,,"4140686","Mammoplasty",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0917968","Breast Implant","C28335","A silicone gel-filled or saline-filled sac placed under the chest muscle to restore breast shape.","Breast Implant | breast implant",,,,,,,,,,,,,,,"4038538","Breast implant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0199470","Mechanical Ventilation","C70909","A method to mechanically assist or replace spontaneous breathing in patients by use of a powered device that forces oxygenated air into the lungs.","Mechanical Ventilation | MECHANICAL VENTILATION | Mechanical ventilation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206135","Platinum Compound","C1450","A chemotherapy compound that contains a platinum atom. Platinum compounds do not contain alkyl groups but do cause DNA crosslinks and adducts similar to alkylating agents. DNA crosslinks and adducts ultimately lead to the induction of apoptosis.","Platinum Compound | Platinum Agents | Platinum-Based Chemotherapeutic Agent | Platinum-Based Chemotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021699","Transmembrane Protein","C16747","A protein that is an integral membrane protein with a transmembrane region.","Transmembrane Protein | Integral Membrane Protein | Intrinsic Membrane Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242568","Biases","C28232","Any deviation of results or inferences from the truth, or processes leading to such deviation.","Bias | (research) bias | Biased | bias | bias (research)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0179196","Bag","C43167","A sac or pouch.","Bag | BAG",,,,,,,,,,,,,,,"4290599","Bag",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0324413","Pointer <dog>","C53895","A hunting dog with a powerful long neck and a well-muscled, athletic body. The medium-sized ears are pendant and somewhat pointed. The short, shiny coat is primarily white, but may be liver, lemon, black, or orange, and can be solid, patched, or speckled. The average height range is 21-24 inches and the average weight range is 44-66 pounds.","Pointer | English Pointer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831936","Ocaratuzumab","C2524","An Fc-engineered monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ocaratuzumab specifically binds to CD20 antigen (B1), preventing mitogen-induced B-cell proliferation; inhibiting B-cell differentiation; and promoting antibody-dependent cell-mediated cytotoxicity (ADCC) and apoptosis of B cells expressing CD20. The Fc portion of this monoclonal antibody has been engineered to possess a higher binding affinity for variant Fc receptors on T helper cells, resulting in an augmentation of the anti-tumor immune response. Because of Fc engineering, this agent may be significantly more potent than rituximab in inducing B cell-directed ADCC. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B cell development.","Ocaratuzumab | AME-133v | Anti-CD20 Monoclonal Antibody AME-133v | Anti-CD20 Monoclonal Antibody AME-133v | LY 2469298 | MoAb CD20 | OCARATUZUMAB | monoclonal antibody, CD20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079459","Granulocyte Colony-Stimulating Factor","C26078","Granulocyte colony-stimulating factor (207 aa, ~22 kDa) is encoded by the human CSF3 gene. This protein is involved in the regulation of the production, differentiation, and function of granulocytes.","Granulocyte Colony-Stimulating Factor | CSF3 | Colony Stimulating Factor 3 | Colony Stimulating Factor 3 | Colony-Stimulating Factor (Granulocyte) | Colony-Stimulating Factor 3 | G CSF | G-CSF | GCSF | Granulocyte Colony Stimulating Factor | Pluripoietin | granulocyte colony-stimulating factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1374956","CSF2 protein, human","C20545","Granulocyte-macrophage colony-stimulating factor (144 aa, ~16 kDa) is encoded by the human CSF2 gene. This protein plays a role in the positive regulation of the growth and differentiation of cells in the granulocyte, macrophage, eosinophil and erythrocyte lineages.","Granulocyte-Macrophage Colony-Stimulating Factor | CSF | CSF2 | Colony Stimulating Factor 2 | Colony Stimulating Factor 2 | Colony Stimulating Factor, Granulocyte-Macrophage | Colony-Stimulating Factor | Colony-Stimulating Factor 2 | GM CSF | GM-CSF | GMCSF | Granulocyte Macrophage Colony Stimulating Factor | Granulocyte Macrophage Colony-Stimulating Factor | Granulocyte-Macrophage Colony Stimulating Factor | granulocyte-macrophage colony-stimulating factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0179804","Foley Catheter","C54730","A flexible plastic tube inserted into the bladder to provide continuous urinary drainage. A balloon on the bladder end is inflated (with air or fluid) so that the catheter cannot pull out but is retained in the bladder as an 'indwelling' catheter.","Foley Catheter | ",,,,,,,,,,,,,,,"40625746","Foley catheter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034378","Quality Control","C15311","Set of measurements and inspections taken to verify that performance of equipment and procedures remains within specified limits.","Quality Control | QA Report | QC | quality control (QC)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880355","Discover","C62262","See for the first time; identify.","Discover | Discovery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL365211","Food or Food Product","C1949","Processed or unprocessed substances obtained from animal, plant, microorganism and mining source that provide nutrients for living organisms to maintain biological processes or functions.","Food or Food Product | FOOD OR FOOD PRODUCT | Food | Food Product | Food or Food Substance | Food or Food Substance | FoodProduct",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0936234","Computed Tomography Scanning Systems","C45844","CT (Computerized (Axial) Tomography) scanner is a special kind of machine which directs a series of X-ray pulses through the body, to produce detailed pictures of internal body structures.","CT Scanner | Computerized (Axial) Tomography Scanner",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007113","Rectal Carcinoma","C9382","A malignant epithelial neoplasm that arises from the rectum. The vast majority are adenocarcinomas.","Rectal Carcinoma | Cancer of Rectum | Cancer of the Rectum | Carcinoma of Rectum | Carcinoma of the Rectum | Rectal Cancer | Rectum Cancer | rectal cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034304","Pyrogen","C71583","Any substance that can cause a rise in body temperature.","Pyrogen | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4227568","Heart Failure","C50577","Inability of the heart to pump blood at an adequate rate to meet tissue metabolic requirements. Clinical symptoms of heart failure include: unusual dyspnea on light exertion, recurrent dyspnea occurring in the supine position, fluid retention or rales, jugular venous distension, pulmonary edema on physical exam, or pulmonary edema on chest x-ray presumed to be cardiac dysfunction.","Heart Failure | Cardiac Failure | HF | Heart failure | Heart failure, unspecified",,,,,,,,,,,,,,,"316139","Heart failure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0376443","Endoscopic Ultrasound","C46078","An ultrasound administered by using a tube containing flexible fibre optic wires that allows for the analysis of tissues inside the body.  Ultrasound technology utilizes high frequency waves and their echoes to produce an image. 2005","Endoscopic Ultrasound | ENDOSCOPIC ULTRASOUND | EUS | endoscopic ultrasound | endosonography",,,,,,,,,,,,,,,"42872565","Endoscopic ultrasonography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448862","Upon","C65137","Used to indicate that an event is to immediately follow another event.","Upon | On",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880151","Complement Activity Enzyme Unit","C67270","A unit for measurement of enzymatic activity of plasma and membrane-bound proteins that comprise a complement system and their split products in functional assays indicative of the activity of the classical and alternative pathways designed to ward off invading pathogens.","Complement Activity Enzyme Unit | CAE Unit | complement activity enzyme unit | {CAE Unit} | {CAE}Unit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456524","Billion Cells per Liter","C67249","A unit of cell concentration expressed as a number of cells in billions per unit volume equal to one liter.","Billion Cells per Liter | 10E6 Cells/L | 10E9 Cells/L | 10^9 Cells/L | 10^9{Cells}/L | Billion Cells/Liter | billion cells per liter | x10^9 cells/L",,,,,,,,,,,,,,,"4175206","10*9 cells/L",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1300557","Per Microliter","C67254","A volume unit equal to one microliter used as a denominator to build a derived unit expressed as a ratio.","Per Microliter | /uL | /ul | Per Cubic Millimeter | Per uL | per microliter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879838","Billion Cells","C67247","A unit of cell count expressed in billions.","Billion Cells | 10*9{Cells} | 10*9{cells} | 10E9 Cells | 10^9 Cells | 10^9 cells | 10^9{Cells} | 10^9{cells} | billion cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881070","Hundred Million Cells","C67248","A unit of cell count expressed in hundreds of millions.","Hundred Million Cells | 10E8 Cells | 10^8 Cells | 10^8{Cells} | hundred million cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883275","Ten Million Cells per Kilogram","C67260","A derived unit expressed as a number of cells in tens of millions per unit of mass equal to one kilogram.","Ten Million Cells per Kilogram | 10E7 Cells/kg | 10^7 Cells/Kilogram | 10^7 Cells/kg | 10^7{Cells}/kg | ten million cells per kilogram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881842","Million Cells per Microliter","C67251","A unit of cell concentration expressed as a number of cells in millions per unit volume equal to one microliter.","Million Cells per Microliter | 10E6 cells/uL | 10^6 Cells/uL | 10^6{Cells}/uL | Million Cells/cu mm | million cells per microliter | x10^6 cells/mcL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881840","Million Cells","C67246","A unit of cell count expressed in millions.","Million Cells | 10E6 Cells | 10^6 Cells | 10^6{Cells} | million cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883312","Thousand Cells per Microliter","C67244","A unit of cell concentration expressed as a number of cells in thousands per unit volume equal to one microliter.","Thousand Cells per Microliter | 10E3 Cells/uL | 10^3 Cells/uL | 10^3{Cells}/uL | Thousand Cells/cu mm | thousand cells per microliter | x10^3 cells/mcL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456617","Trillion Cells per Liter","C67243","A unit of cell concentration expressed as a number of cells in trillions per unit volume equal to one liter.","Trillion Cells per Liter | 10E12 Cells/L | 10^12 Cells/L | 10^12{Cells}/L | Trillion Cells/L | Trillion Cells/Liter | trillion cells per liter",,,,,,,,,,,,,,,"4079010","10*12 cells/L",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882318","Per 100 White Blood Cells","C67219","Natural number unit for measurement of portion of a particular type of blood cells (such as any type of white blood cells or nucleated red blood cells) in the total white blood cell count expressed per count of 100.","Per 100 White Blood Cells | /10*2{WBC} | /100 WBC | /10^2{WBC} | Per 100 WBC | per 100 white blood cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882326","Percent in White Blood Count Differential","C67215","A unit for percentage measurement of fraction of any type of white blood cells in the total white blood cell count differential.","Percent in White Blood Count Differential | % WBC | %/100{WBC} | Percent in White Blood Count | Percent per 100 WBC | percent per 100 WBC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439378","Cells per Microliter","C67242","A unit of cell concentration expressed as a number of cells per unit volume equal to one microliter.","Cells per Microliter | Cells/Microliter | Cells/cu mm | Cells/uL | cells per microliter | {Cells}/uL | {cells}/mm3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439417","Gram per 24 Hours","C67372","A metric mass flow rate unit equal to the rate at which mass of matter of one gram crosses a given surface or/and is transferred over a period of twenty four hours.","Gram per 24 Hours | Gram per Day | Gram/24 Hours | g/24.h | g/24h | g/d | g/day | gram per 24 hours | gram/day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880521","Enzyme Unit per Milliliter","C67367","Unit of catalytic activity concentration defined as activity equal to one enzyme unit per one milliliter of system volume.","Enzyme Unit per Milliliter | Enzyme Unit per milliliter | Enzyme Unit/Milliliter | Enzyme Unit/mL | U/mL | {Enzyme}U per mL | {Enzyme}U/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880520","Enzyme Unit per Deciliter","C67366","Unit of catalytic activity concentration defined as activity equal to one enzyme unit per one deciliter of system volume.","Enzyme Unit per Deciliter | Enzyme Unit/Deciliter | Enzyme Unit/dL | U/dL | enzyme unit per deciliter | {Enzyme}U/dL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880519","Enzyme Unit","C64778","A unit of catalytic activity measurement defined as the quantity of a particular enzyme that catalyzes the transformation of one micromole of the substrate per minute under standard conditions for specified assay system. The usage of this unit is discouraged in favor of the katal by International Federation of Clinical Chemistry and Laboratory Medicine due to lack of its coherence with the SI system. One enzyme unit is equal to 16.667 nanokatals.","Enzyme Unit | Enzyme U | U | UNIT - CATALYTIC ACTIVITY | UNITS | Unit | catalytic activity unit | enzyme unit | {Enzyme}.U",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346871","Attoliter","C67565","A unit of volume equal to one quintillionth of a liter (10E-18 liter) or one cubic micrometer.","Attoliter | (10E-6m)3 | (10^-6m)3 | 10E-18 Liter | Cubic Micrometer | Cubic Micron | Micron Cubed | aL | cubic micron | micrometer cubed | um3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009992","Copying Processes","C67336","A secondary representation, reproduction, or replica.","Copy | Copies | copies | {Copies}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242402","Opioid","C1506","A class of synthetic chemicals/drugs similar to opiates (opium derivatives) with analgesic properties.  Due to binding to opiate receptors, opioids mimic opiate activity on neurons, various cells (i.e. lymphocytes), pain suppression and other neurobehavioral activity. (NCI)","Opioid | Narcotic | narcotic | opioid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL355625","Flatus","C50569","Gas or air in the gastrointestinal tract.","Flatus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1631077","IgG Phospholipid Unit","C67347","A unit for semiquantitative measurement of IgG autoantibodies to proteins associated with negatively charged phospholipids evaluated in ELISA serum anticardiolipin or anionic phospholipid assay against an established reference standard. One IgG phospholipid unit is equivalent to one mg/mL of an affinity-purified standard IgG sample obtained from specified individuals.","IgG Phospholipid Unit | GPL U | GPL Unit | GPL unit | GPL'U | Immunoglobin G Phospholipid Units | [GPL'U]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881001","Gram per Microliter","C67301","A unit of mass concentration defined as the concentration of one gram of a substance per unit volume of the mixture equal to one microliter. The concept also refers to the unit of mass density (volumic mass) defined as the density of substance which mass equal to one gram occupies the volume one microliter.","Gram per Microliter | Gram/Microliter | Kilogram per Milliliter | Microgram per Picoliter | Milligram per Nanoliter | g/uL | gram per microliter | kg/mL | mcg/pL | mg/nL | ug/pL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439340","Kilounit per Liter","C67385","An arbitrary unit of substance concentration equal to the concentration at which one liter of mixture contains one thousand units of a substance.","Kilounit per Liter | U/mL | U/ml | Unit per Milliliter | Units per Milliliter | kU/L | kilounit per liter | unit per millilliter | unit(s)/millilitre",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439458","International Unit per Milliliter","C67377","A unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one international unit per one milliliter of system volume.","International Unit per Milliliter | IE/mL | IU/mL | IU/ml | International Unit/Milliliter | Kilo International Unit per Liter | Kilointernational Unit per Liter | [IU]/mL | [IU]/ml | [iU]/mL | [iU]/ml | iU/mL | international unit per milliliter | international unit(s)/millilitre | kIU/L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1533024","International Unit per Square Meter","C67378","A dose calculation unit expressed as a number of arbitrary units of biological activity (International Units) of substance per square meter of body surface area.","International Unit per Square Meter | IU/m2 | International Unit per Meter Squared | International Unit/Square Meter | [iU]/m2 | iU/m2 | international unit per meter squared",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439457","International Unit per Liter","C67376","Unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one international unit per one liter of the system volume.","International Unit per Liter | IE/L | IU/L | IU/l | International Unit/Liter | Microinternational Unit per Microliter | Milliinternational Unit per Milliliter | [IU]/L | [IU]/l | [iU]/L | [iU]/l | iU/L | international unit per liter | international unit(s)/litre | mIU/mL | m[IU]/mL | m[iU]/mL | milliinternational unit per milliliter | u[iU]/uL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439453","International Unit","C48579","The unitage assigned by the WHO to International Biological Standards - substances, classed as biological according to the criteria provided by WHO Expert Committee on Biological Standardization (e.g. hormones, enzymes, and vaccines), to enable the results of biological and immunological assay procedures to be expressed in the same way throughout the world. The definition of an international unit is generally arbitrary and technical, and has to be officially approved by the International Conference for Unification of Formulae.","International Unit | F2 | IE | INTERNATIONAL UNITS | IU | International Standard Unit | International Unit of Biological Activity | International Units | Unit | Unit International | [IU] | [iU] | international unit | international unit(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881192","Index Value","C67368","A statistic which assigns a single number to several individual statistics in order to quantify trends and evaluate a value or quantity as compared with a standard or a base value.","Index Value | INDEX | index value | {Index value}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1552990","High Power Field","C67274","The area visible under the maximum magnification power of the objective being used in microscopy.","High Power Field | HPF | High Powered Field | [HPF] | high power field",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439394","Liter per Second","C67390","A metric unit of volumetric flow rate defined as the rate at which one liter of matter crosses a given surface during the period of time equal to one second.","Liter per Second | L/s | L/sec | Liter/Second | l/s | liter per second",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439393","Liter per Minute","C67388","A metric unit of volumetric flow rate defined as the rate at which one liter of matter crosses a given surface during the period of time equal to one minute.","Liter per Minute | Cubic Decimeter per Minute | L/min | Liter/Minute | dm3/min | l/min | liter per minute | liters/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883713","As - qualifier","C64938","In the same amount or manner; to the same degree; in the role, function, or capacity of.","As | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242665","Wife","C71587","A female partner in marriage.","Wife | WIFE",,,,,,,,,,,,,,,"4133847","Wife",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242664","Husband","C71588","A male partner in marriage.","Husband | HUSBAND | Husbane",,,,,,,,,,,,,,,"4133846","Husband",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0439272","Milligram per Kilogram","C67401","A unit of a mass fraction expressed as a number of milligrams of substance per kilogram of mixture. The unit is also used as a dose calculation unit.","Milligram per Kilogram | Attogram per Picogram | Femtogram per Nanogram | Microgram per Gram | Milligram/Kilogram | Nanogram per Milligram | Picogram per Microgram | Yoctogram per Attogram | Zeptogram per Femtogram | ag/pg | fg/ng | mcg/g | mg/kg | mg/kilo | milligram per kilogram | milligram(s)/kilogram | ng/mg | pg/mcg | pg/ug | ug/g | yg/ag | zg/fg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439269","Milligram per Deciliter","C67015","A unit of mass concentration defined as the concentration of one milligram of a substance in unit volume of the mixture equal to one cubic deciliter or 100 cubic centimeters. It is also a unit of mass density (volumic mass) defined as the density of substance which mass equal to one milligram occupies the volume one cubic deciliter or 100 cubic centimeters.","Milligram per Deciliter | Milligram/Deciliter | mg% | mg/dL | mg/dl | milligram per 100 milliliters of solution | milligram per deciliter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439422","Milligram per 24 Hours","C67399","A unit of mass flow rate equivalent to the rate at which one thousandth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to twenty four hours. Milligram per twenty four hours is also a dose administration rate unit equal to the rate at which one thousandth of a gram of a product is administered per unit of time equal to twenty four hours.","Milligram per 24 Hours | Milligram per Day | mg/24 hr | mg/24.h | mg/24h | mg/d | mg/day | milligram per 24 hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439375","Milliequivalent per Liter","C67474","A concentration unit measured as a number of milliequivalents of solute per liter of solution.","Milliequivalent per Liter | Milliequivalent Per Liter | Milliequivalent/Liter | Millivalent per Liter | mEq/L | mEq/l | meq/L | meq/l | milliequivalent per liter | milliequivalent(s)/litre | mval/L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1300572","Milliequivalent per Kilogram","C67475","A unit of relative amount of substance content equivalent to the content at which one kilogram of mixture contains one thousandth of an equivalent of a component. The unit is also used as a dose calculation unit.","Milliequivalent per Kilogram | Milliequivalent Per Kilogram | Milliequivalent/Kilogram | mEq/kg | meq/kg | milliequivalent per kilogram | milliequivalent(s)/kilogram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1532568","Milliequivalent per Deciliter","C67473","A concentration unit measured as a number of milliequivalents of solute per deciliter of solution.","Milliequivalent per Deciliter | Milliequivalent/Deciliter | mEq/dL | meq/dL | meq/dl | milliequivalent per deciliter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439448","Milliequivalent per 24 Hours","C67471","A unit of relative amount of substance flow rate equivalent to the rate at which one thousandth of an equivalent of substance crosses a given surface or is delivered to a given object or space over a period of time equal to twenty four hours.","Milliequivalent per 24 Hours | Milliequivalent/24 Hours | Milliequivalents per Day | mEq/24h | mEq/day | meq/24.h | meq/d | milliequivalents per 24 hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1690015","Microgram per Specimen","C67358","A derived unit expressed as quantity in micrograms per specimen.","Microgram per Specimen | mcg/specimen | microgram per specimen | ug/specimen | ug/{specimen}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439275","Microgram per Liter","C67306","A unit of mass concentration defined as the concentration of one microgram of a substance per unit volume of the mixture equal to one liter. The concept also refers to the unit of mass density (volumetric mass) defined as the density of a substance which mass equal to one microgram occupies the volume of one liter.","Microgram per Liter | Microgram per Cubic Decimeter | Microgram/Liter | Milligram per Cubic Meter | Nanogram per Milliliter | Picogram per Microliter | mcg/L | mcg/dm3 | mg/m3 | microgram per liter | microgram(s)/litre | milligram(s)/cubic meter | nanogram per milliliter | ng/mL | ng/ml | pg/uL | ug/L | ug/dm3 | ug/l",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1552991","Low Power Field","C67307","The area visible in one view field of the microscope under the low magnification of the objective being used in microscopy.","Low Power Field | LPF | [LPF] | low power field",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881035","Heart Failure Prompting Medical Attention Event","C67105","Heart failure which leads an individual to seek medical attention.","Heart Failure Prompting Medical Attention Event | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085281","Addiction","C3479","Physical and/or psychological dependence to any substance.","Addiction | addiction",,,,,,,,,,,,,,,"4139144","Addiction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0456614","Million per Microliter","C67308","A derived unit expressed as a number of entities or quantity in millions per unit of volume equal to one microliter.","Million per Microliter | /pL | 1/pL | 10*12/L | 10*12/l | 10E6/uL | 10^12/L | 10^12/l | 10^6 per Microliter | 10^6/mm3 | 10^6/uL | M/cmm | M/mm3 | M/uL | MILL/CMM | Mill/mcL | Million per Cubic Millimeter | Million per millimeter cubed | T/L | TI/L | Tera/L | million per microliter",,,,,,,,,,,,,,,"4082154","10*12/L",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1881839","Million","C67238","A natural number following 999999 and preceding 1000001 and the quantity that it denotes: one thousand thousands.","Million | 1000000 | 10E6 | 10^6 | One Million | million",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881844","Million Plaque Forming Units","C67268","A measure of viable infectious entities expressed in millions in the specimen or product defined as the smallest quantity that can produce a cytopathic effect in the host cell culture challenged with the defined inoculum, visible under the microscope or/and to the naked eye as a plaque.","Million Plaque Forming Units | 10*6{PFU} | 10E6 PFU | 10^6 PFU | 10^6 Plaque Forming Units | 10^6{PFU} | One Million PFU | One Million Plaque Forming Units | million plaque forming units",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439342","Microunit per Milliliter","C67408","An arbitrary unit of substance concentration equal to the concentration at which one milliliter of mixture contains one millionth of a unit of a substance.","Microunit per Milliliter | Microunit/Milliliter | Milliunit per Liter | Nanounit per Microliter | mU/L | mU/l | microunit per milliliter | nU/uL | uU/mL | uU/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439280","Micromole per Deciliter","C67407","Unit of concentration (molarity unit) equal to one millionth of mole of a solute in one deciliter of the solution.","Micromole per Deciliter | Micromole/Deciliter | micromole per deciliter | umol/dL | umol/dl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439436","Micromole per 24 Hours","C67406","A unit of amount of substance flow rate equivalent to the rate at which one millionth of a mole of substance crosses a given surface or is delivered to a given object or space over a period of time equal to 24 hours.","Micromole per 24 Hours | Micromole per Day | mcmol/day | micromole per 24 hours | umol/24.h | umol/24h | umol/d | umol/day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439462","Microinternational Unit per Milliliter","C67405","Unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one millionth of international unit per one milliliter of system volume.","Microinternational Unit per Milliliter | Micro-International Unit per milliliter | Microinternational Unit/Milliliter | Milliinternational Unit per Liter | Nanointernational Unit per Microliter | mIE/L | mIU/L | m[iU]/L | mcIU/mL | microinternational unit per milliliter | n[iU]/uL | uIU/mL | u[IU]/mL | u[IU]/ml | u[iU]/mL | u[iU]/ml | uiU/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881832","Milligram per Milliliter per Minute","C67403","A dose calculation unit equal to mass concentration of a substance expressed in kilograms per unit volume of the mixture equal to one cubic meter per time period of one minute.","Milligram per Milliliter per Minute | Milligram/Milliliter/Minute | mg/mL/min | mg/ml/min | milligram per milliliter per minute",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021890","Intraoperative Complication","C34735","A disease or disorder that occurs during the course of a surgical procedure.","Intraoperative Complication | ",,,,,,,,,,,,,,,"42538061","Intraoperative complication",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0750557","If","C64955","A modifier term indicating a condition to follow.","If | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1955856","Stoma","C13345","A surgically created opening from an area inside the body to the outside.","Stoma | stoma",,,,,,,,,,,,,,,"4076390","Stoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013926","Air Embolism","C50455","The presence of bubbles of air in the vascular system; occurrence is related to the entry of air into the venous circulation following trauma or surgery.","Air Embolism | Aeroembolism",,,,,,,,,,,,,,,"4156949","Air embolism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0055816","citrate phosphate dextrose","C71605","A solution of citric acid, sodium citrate, monobasic sodium phosphate, and dextrose in water used as an anticoagulant in the collection and preservation of whole blood.","Citrate Phosphate Dextrose | CPD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346476","Immunomagnetic Column","C71606","A separation column that when placed in proximity to a magnet creates a high gradient magnetic field strong enough to retain cells labeled with antibodies complexed to magnetic particles.","Immunomagnetic Column | Immunomagnetic Selection Column",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881834","Milliinternational Unit per Square Meter","C67409","A dose calculation unit equal to one-thousandth (10E-3) of an arbitrary unit of biological activity (International Unit) of substance per square meter of body surface area.","Milliinternational Unit per Square Meter | Milli-International Unit per Square Meter | Milliinternational Unit/Square Meter | mIU/m2 | m[iU]/m2 | milliinternational units per meter squared",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439455","Milliinternational Unit","C67316","A unit equal to one-thousandth of an international unit.","Milliinternational Unit | Milli-International Unit | mIU | m[iU] | miU | milliinternational unit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456680","Millimeter per Hour","C67419","A unit of both speed (scalar) and velocity (vector), defined as the distance of one millimeter travelled per unit time equal to one hour.","Millimeter per Hour | Millimeter/Hour | millimeter per hour | mm/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881837","Milliliter per Minute per Millimeters of Mercury per Liter","C67418","A unit for measuring a pulmonary diffusing capacity adjusted for lung volume expressed in units of gas flow rate (in milliliters per minute) per a unit of pressure (in torrs) per one liter.","Milliliter per Minute per Millimeters of Mercury per Liter | Milliliter/Minute/Millimeters of Mercury/Liter | mL/min/mm[Hg]/L | mL/mmHg/min/L | mL/mm[Hg]/min/L | milliliter per minute per millimeter mercury per liter | ml/mm[Hg]/min/l",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881836","Milliliter per Minute per Millimeters of Mercury","C67417","A unit for measuring a pulmonary diffusing capacity expressed in units of gas flow rate (in milliliters per minute) per a unit of pressure (in torrs).","Milliliter per Minute per Millimeters of Mercury | Milliliter per Minute per Millimeters of Mercury (Torr) | Milliliter per Minute per Torr | Milliliter/Minute/Millimeters of Mercury | mL/min/mmHg | mL/min/mm[Hg] | milliliter per minute per millimeters of mercury (torr) | ml/min/mm[Hg]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881835","Milliliter per Minute per 1.73 m2 of Body Surface Area","C67412","A unit used in the calculation of a rate of the substance removal from the body (such as creatinine clearance) for the measurement of renal excretory function, with the applied correction factor for body size. It is also used as a dose delivery rate calculation unit equal to the rate, at which one milliliter of medication is delivered during a period of time equal to one minute per 1.73 square meters of body surface area.","Milliliter per Minute per 1.73 m2 of Body Surface Area | Milliliter per Minute per 1.73 Meters Squared | mL/min/(173/100).m2 | mL/min/1.73 m2 | mL/min/1.73m2 | mL/min/1.73m2{BSA} | milliliter per minute per 1.73 m2 of body surface area | milliliter per minute per 1.73 meters squared | ml/min/(173/100).m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439445","Milliliter per Minute","C64777","A metric unit of volumetric flow rate defined as the rate at which one milliliter of matter crosses a given surface during the period of time equal to one minute.","Milliliter per Minute | Milliliter/Minute | mL/min | milliliter per minute | ml/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449008","Rejected","C69304","Having been judged unacceptable.","Rejected | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347610","Chemosensitivity","C71488","Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better.","Chemosensitivity | chemosensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347585","Central Pathology Review","C71684","The process by which specimens are sent to a central lab for confirmatory analysis using standardized methods and result criteria in order to minimize inter-reviewer differences thereby improving the accuracy of pathology data.","Central Pathology Review | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519113","Routine Histology Staining Method","C23043","'Routine' histology staining generally refers to staining performed using hematoxylin and eosin. Hematoxylin stains the nuclei in cells and other cationic elements purple. Eosin is an anionic dye and binds to cytoplasmic proteins below pH6 giving a pink color. (From Biogenex)","Routine Histology Staining Method | Routine Histology Staining",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881965","Nanomole per Milligram of Protein","C67433","A unit of concentration of amount of substance of a component measured in nanomoles of the component per milligram of protein of the mixture.","Nanomole per Milligram of Protein | Nanomole/Milligram of Protein | nanomole per milligram of protein | nmol/mg{protein}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439274","Nanogram per Deciliter","C67326","A unit of mass concentration defined as the concentration of one nanogram of a substance per unit volume of the mixture equal to one deciliter. The concept also refers to the unit of mass density (volumic mass) defined as the density of substance which mass equal to one nanogram occupies the volume of one deciliter.","Nanogram per Deciliter | Nanogram/Deciliter | nanogram per deciliter | ng/dL | ng/dl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881846","Million Units per Milliliter","C67428","An arbitrary unit of substance concentration equal to the concentration at which one milliliter of mixture contains one million units of a substance.","Million Units per Milliliter | 10E6U/mL | 10^6 Million Units per Milliliter | 10^6U/mL | million units per milliliter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1552995","IgM Phospholipid Unit","C67348","A unit for semiquantitative measurement of IgM autoantibodies to proteins associated with negatively charged phospholipids evaluated in ELISA serum anticardiolipin or anionic phospholipid assay against an established reference standard. One IgM phospholipid unit is equivalent to one mg/mL of an affinity-purified standard IgM sample obtained from the specified individuals.","IgM Phospholipid Unit | Immunoglobin M Phospholipid Units | MPL U | MPL Unit | MPL unit | MPL'U | [MPL'U]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439353","Milliosmole per Kilogram","C67427","A unit of osmotic strength of solution as a measure of concentration of osmotically active particles expressed in a number of milliosmoles of solute per kilogram of solvent.","Milliosmole per Kilogram | Milliosmole/Kilogram | mOsm/kg | milliosmol(s)/kilogram | milliosmole per kilogram | mosm/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439433","Millimole per 24 Hours","C67420","A unit of amount of substance flow rate equivalent to the rate at which one thousandth of a mole of substance crosses a given surface or is delivered to a given object or space over a period of time equal to 24 hours.","Millimole per 24 Hours | Millimole per Day | Millimole/24h | millimole per 24 hours | mmol/24.h | mmol/24h | mmol/d | mmol/day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0184511","Better","C71685","In an improved condition.","Better | BETTER/IMPROVED/RECOVERING | Improved",,,,,,,,,,,,,,,"4146220","Better",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1457868","Worse","C71686","In an declined condition.","Worse | WORSE/DECLINING | WORSENED",,,,,,,,,,,,,,,"4334741","Worse",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2346711","Unchanged","C71687","The status is unaltered or similar to the previous state.","Unchanged | About The Same | About The Same | UNCHANGED | Unchanged",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041600","Ulna","C12809","One of the bones that comprise the forearm. The largest aspect articulates with the humerus at the elbow joint and the smallest portion of the ulna articulates with the carpal bones in the wrist.","Ulna | BONE, ULNA | ULNA",,,,,,,,,,,,,,,"4050857","Bone structure of ulna",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0684083","Pelvic Girdle","C33291","The basin-shaped skeletal structure that is formed by the sacrum and the ilium, ischium, and pubis of each side that supports the trunk and to which the lower extremities attach.","Pelvic Girdle | ","C41.4","Pelvic bones, sacrum, coccyx and associated joints",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C0243144","Uptake","C71688","The absorption by a tissue of some substance, food material, mineral, etc., and its permanent or temporary retention.","Uptake | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0525006","Myelopoiesis","C21143","The hematopoietic process that refers to the production of myelocytes.","Myelopoiesis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596962","Molecular Pathology (discipline)","C18098","Description of disease and disease processes based upon the underlying protein and genetic defects rather than by a description of morphology.","Molecular Pathology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333568","FLT3 Gene","C24399","This gene plays a role in hematopoiesis and may function as a growth factor receptor.","FLT3 Gene | FLT3 | FMS-Related Tyrosine Kinase 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348501","FLT3 Tyrosine Kinase Domain Point Mutation","C67495","Single nucleotide mutations in the tyrosine kinase domain encoded by the human FLT3 gene that are associated with acute myeloid leukemia and poor prognosis.","FLT3 Tyrosine Kinase Domain Point Mutation | FLT3-TKD Point Mutation | FLT3/TKD Point Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348499","FLT3 Internal Tandem Duplication","C67494","A genetic abnormality that arises from duplications of the juxtamembrane portion of the gene and results in constitutive activation of the FLT3 receptor tyrosine kinase protein in early hematopoietic progenitor cells. It is associated with acute myelogenous leukemia where it appears to correlate with a poor prognosis.","FLT3 Internal Tandem Duplication | Activating FLT3-ITD Gene Mutation | Activating FLT3-ITD Mutation | FLT3 ITD | FLT3-ITD | FLT3-ITD Activating Mutation | FLT3-ITD Mutation | FLT3/ITD Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0526371","Midostaurin","C1872","A synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors.","Midostaurin | CGP 41251 | CGP41251 | MIDOSTAURIN | N-Benzoyl-Staurosporine | N-Benzoylstaurosporine | N-benzoyl-staurosporine | PKC 412 | PKC-412 | PKC412 | Rydapt | midostaurin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706504","Bilateral Prophylactic Mastectomy","C46072","Surgical removal of both non-diseased breasts with the goal of preventing breast carcinoma.","Bilateral Prophylactic Mastectomy | BPM | Prophylactic Bilateral Mastectomy | bilateral prophylactic mastectomy",,,,,,,,,,,,,,,"37111603","Prophylactic bilateral mastectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882377","Picogram of Prostaglandin E2 per Milligram of Protein","C67476","A unit of mass fraction of Prostaglandin E2 expressed as number of picograms of Prostaglandin E2 per one milligram of total protein.","Picogram of Prostaglandin E2 per Milligram of Protein | pgPGE2/mg protein | pg{PGE2}/mg{protein} | picogram of Prostaglandin E2 per milligram of protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439297","Nanogram per Liter","C67327","A unit of mass concentration defined as the concentration of one nanogram of a substance per one liter of the mixture, or one picogram of a substance per unit volume of the mixture equal to one milliliter, or one microgram of a substance per one cubic meter of the mixture. The concept also refers to the metric unit of mass density (volumic mass) defined as the density of a substance which mass equal to one nanogram occupies the volume of one liter.","Nanogram per Liter | Femtogram per Microliter | Microgram per Cubic Meter | Nanogram per Cubic Decimeter | Nanogram/Liter | Picogram per Milliliter | fg/uL | mcg/m3 | microgram(s)/cubic meter | nanogram per liter | ng/L | ng/dm3 | ng/l | pg/mL | pg/ml | picogram per milliliter | ug/m3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439277","Picogram per Deciliter","C67331","A unit of mass concentration defined as the concentration of one picogram of a substance per unit volume of the mixture equal to one deciliter. The concept also refers to the unit of mass density (volumic mass) defined as the density of a substance which mass equal to one picogram occupies the volume of one deciliter.","Picogram per Deciliter | Picrogram/Deciliter | pg/dL | pg/dl | picogram per deciliter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883066","Source Data Not Available","C67329","Data from an original source is not present, accessible or ready for use or service.","Source Data Not Available | No Source Data | No source data | {No Srce}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439339","Unit per Liter","C67456","An arbitrary unit of substance concentration equal to the concentration at which one liter of mixture contains one unit of a substance.","Unit per Liter | Microunit per Microliter | Milliunit per Milliliter | U/L | Unit/Liter | mU/mL | milliunit per milliliter | uU/uL | unit per liter | {Unit}/L | {Unit}/l | {U}/L | {U}/l",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349975","Enhance (action)","C71607","To improve the quality of something; make better or more attractive.","Enhance | Enhanced | Enhancement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1969988","Tachycardia","C38029","An abnormally rapid heart rate. Thresholds for different age, gender, and patient populations exist.","Tachycardia | tachycardia",,,,,,,,,,,,,,,"444070","Tachycardia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1262869","Body Position","C62164","The spatial property of a body; where it is or the way in which it is situated.","Body Position | ",,,,,,,,,,,,,,,"4287468","Body position",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032987","Ectopic Pregnancy","C34945","An abnormal pregnancy in which the conception is implanted outside the endometrial cavity.","Ectopic Pregnancy | Extrauterine Pregnancy | ectopic pregnancy | extrauterine pregnancy",,,,,,,,,,,,,,,"437611","Ectopic pregnancy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883462","Unit per Microliter","C67468","An arbitrary unit of substance concentration equal to the concentration at which one microliter of mixture contains one unit of a substance.","Unit per Microliter | Kilounit per Milliliter | U/uL | Unit/Microliter | kU/mL | unit per microliter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1532637","Unit per Square Meter","C67467","A dose calculation unit expressed as a number of arbitrary units of substance per one square meter of a body surface area.","Unit per Square Meter | U/m2 | Unit per Meter Squared | Unit/Square Meter | unit per meter squared | {Unit}/m2 | {U}/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883460","Unit per 24 Hours","C67464","A unit of an activity rate expressed as a number of substance units which crosses a given surface or is delivered to a given object or space over a period of time equal to 24 hours. This unit is also used as a dose calculation unit.","Unit per 24 Hours | U/24.h | U/24h | Unit per Day | Unit/24 Hours | unit per 24 hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883314","Thousand per Square Millimeter","C67451","A derived unit expressed as number of objects in thousands per unit of area equal to one millimeter.","Thousand per Square Millimeter | 10E3/mm2 | 10^3 per Millimeter Squared | 10^3/mm2 | Thousand per Millimeter Squared | thousand per millimeter squared",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456615","Billion per Liter","C67255","A derived unit expressed as a number or quantity of objects in billions per unit of volume equal to one liter, or the equivalent in milliliters or microliters.","Billion per Liter | /nL | 1/nL | 10*9/L | 10*9/l | 10E9/L | 10^3/mm3 | 10^3/uL | 10^6/mL | 10^6/mm3 | 10^9/L | 10^9/l | Billion/Liter | G/L | GI/L | Giga per Liter | K/cumm | Million per Milliliter | Thou/mcL | Thousand per Cubic Millimeter | Thousand per Microliter | billion per liter | thousand per microliter | x10^3 per mcL",,,,,,,,,,,,,,,"4079009","10*9/L",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883310","One Thousand","C67234","A natural number following 999 and preceding 1001 and the quantity that it denotes: ten times one hundred.","Thousand | 1000 | 10E3 | 10^3 | K | M | One Thousand | thousand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882530","RNA Copy per Milliliter","C67441","A unit of concentration of RNA copies expressed as a number of copies per unit volume equal to one milliliter.","RNA Copy per Milliliter | RNA Copies per Milliliter | RNA copies per milliliter | RNA copies/Milliliter | RNA copies/mL | {RNA copies}/mL | {RNA copies}/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1533072","Nanogram per Milliliter per Hour","C67430","A dose calculation unit equal to mass concentration of a substance expressed in nanograms per unit volume of one milliliter per time period of one hour.","Nanogram per Milliliter per Hour | Nanogram/Milliliter/Hour | nanogram per milliliter per hour | ng/mL/h | ng/ml/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439421","Milligram per Hour","C66969","A unit of mass flow rate equivalent to the rate at which one thousandth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to one hour.","Milligram per Hour | Milligram/Hour | mg/h | mg/hr | milligram per hour",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439425","Microgram per Hour","C67394","A unit of mass flow rate equivalent to the rate at which one millionth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to one hour.","Microgram per Hour | Microgram/Hour | mcg/h | microgram per hour | ug/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1532569","Milliequivalent per Hour","C67472","A unit of relative amount of substance flow rate equivalent to the rate at which one thousandth of an equivalent of substance crosses a given surface or is delivered to a given object or space over a period of time equal to one hour.","Milliequivalent per Hour | Milliequivalent/Hour | Milliequivalents per Hour | mEq/h | meq/h | milliequivalent per hour",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0556643","Rad","C18064","A unit of radiation absorbed dose equal to the amount of energy from any type of ionizing radiation (e.g., alpha, beta, gamma, neutrons, etc.) deposited in any medium (e.g., water, tissue, air). A dose of one rad means the absorption of 100 ergs per gram of absorbing tissue (100 rad = 1 gray). (The U.S. Nuclear Regulatory Commission, NRC).","Rad | RAD | Radiation Absorbed Dose | rad | radiation absorbed dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0560013","Gallon US","C48580","The US unit of liquid volume legally defined as 3785.411784 milliliters (3.785 411 784 liters), or 231 cubic inches. The US gallon holds 4 liquid quarts; the gallon of water gallon weighs approximately 8.33 pounds.","Gallon US | GALLON | Gallon | Liquid Gallon US | Queen Annes Wine Gallon | [gal_us] | gal | gallon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882540","Radioactive Seed Implant Dosing Unit","C67446","A dosing unit in a form of an incapsulated radioactive material that constitutes an implantable pellet designed for brachytherapy administration.","Radioactive Seed Implant Dosing Unit | RADIOACTIVE SEED IMPLANT | Seed | Seed Implant | radioactive seed | seed | {RADIOACTIVE SEED IMPLANT} | {Seed}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439256","Joule","C42548","A unit of electrical, mechanical, and thermal energy (as well as work and quantity of heat) in the SI system, equal to the work done when the point of application of a force of one newton is displaced through a distance of one meter in the direction of the force or the work done when a current of one ampere passes through a resistance of one ohm for one second. Joule is equal to 0.23889 gram-calorie (mean).","Joule | J | Watt second | joule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1319632","International Unit per Milligram","C67380","A unit of measure of quantity of substance per unit mass, expressed in terms of International Units per milligram. (CDISC)","International Unit per Milligram | IU/mg | International Unit/Milligram | [IU]/mg | [iU]/mg | iU/mg | international unit per milligram | international unit(s)/milligram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1532633","Kilounit per Kilogram","C67382","An arbitrary unit of substance content expressed in thousands of units of biological activity per unit of mass equal to one kilogram. Kilounit per kilogram is also used as a dose calculation unit expressed in thousands of arbitrary units per one kilogram of body mass.","Kilounit per Kilogram | U/g | Unit per Gram | kU/kg | kilounit per kilogram | unit per gram | unit(s)/gram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1319267","Microgram per Square Meter","C67312","A metric unit of areal density equal to approximately 2.94935E-8 ounce per square yard. Also used as a dose calculation unit.","Microgram per Square Meter | Microgram per Meter Squared | Microgram/Square Meter | mcg/m2 | microgram per meter squared | microgram(s)/square meter | ug/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1633989","Bottle Dosing Unit","C48477","A dosing unit equal to the amount of active ingredient(s) contained in a bottle.","Bottle Dosing Unit | BO | BOTTLE | Bottle | bottle | {BOTTLE} | {Bottle}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881072","Hundred Thousand Cells per Kilogram","C67258","A derived unit expressed as a number of cells in hundreds of thousands per unit of mass equal to one kilogram.","Hundred Thousand Cells per Kilogram | 10E5 Cells/kg | 10^5 Cells/kg | 10^5{Cells}/kg | Hundred Thousand Cells/Kilogram | hundred thousand cells per kilogram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881841","Million Cells per Kilogram","C67259","A derived unit expressed as a number of cells in millions per unit of mass equal to one kilogram.","Million Cells per Kilogram | 10E6 Cells/kg | 10^6 Cells/Kilogram | 10^6 Cells/kg | 10^6{Cells}/kg | million cells per kilogram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881246","Intravenous Bag Dosing Unit","C67283","A dosing unit equal to the amount of active ingredient(s) contained in an intravenous bag.","Intravenous Bag Dosing Unit | IV Bag | intravenous bag | {IV Bag}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881831","Milligram per Inhalation","C67400","An inhalation dosing unit equal to the quantity of medicinal substance(s) expressed in milligrams delivered per a single act of taking in breath.","Milligram per Inhalation | mg/inhalation | mg/{inhalation} | milligram per inhalation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881235","International Unit per Milligram of Alpha-Tocopherol","C67381","Unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one international unit of alpha-Tocopherol per one milligram of preparation.","International Unit per Milligram of Alpha-Tocopherol | International Unit per Milligram of Alpha-TE | International Unit/Milligram of Alpha-Tocopherol | [iU]/mg alpha-Tocopherol | [iU]/mg{alpha-Tocopherol} | iU/mg alpha-TE | iU/mg alpha-Tocopherol | international units per milligram of alpha-Tocopherol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881234","International Unit of Vitamin A","C67374","An arbitrary unit of measurement of the specific biological activity of vitamin A, defined by the International Conference for Unification of Formula as equal approximately to 0.30 micrograms of all-trans retinol or to 0.60 micrograms of the provitamin A, all-trans-beta-carotene.","International Unit of Vitamin A | IU Vitamin A | [iU]{Vitamin A} | international unit of Vitamin A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882947","Retinol Activity Equivalent","C67438","An arbitrary unit for measurement of the bioefficacy of ingested provitamin A carotenoids introduced by the U.S. Institute of Medicine (IOM). For a given amount of provitamin A compounds in a mixed diet, IOM estimates that the number of retinol activity e (RAE) is half the number of RE suggested by FAO/WHO. RAE is viewed as an approximate guideline because it was defined on the basis of relatively few studies and limited data on carotenoids bioavailability and bioconversion.","Retinol Activity Equivalent | RAE | Retinol Activity Equivalent (IOM) | Vitamin A Retinol | {RAE}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0556581","Retinol Equivalent","C67436","An arbitrary unit for measurement of a vitamin A activity of provitamin A carotenoids (such as carotenes, xanthophylls, and compounds that arise from rearrangement of carotene I skeleton) in a mixed diet introduced by FAO/WHO Expert Group in 1967. The concept of the retinol equivalent (RE) is established on the following relationships among food sources of the vitamin A: one microgram of all-trans retinol is equal to one RE, one microgram of beta-carotene is equal to 0.167 RE, and one microgram of other pro-vitamin A carotenoids is equal to 0.084 RE.","Retinol Equivalent | RAE | RE | Retinol Activity Equivalent | Retinol Equivalents | retinol equivalents | {RE}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883016","Activity Session","C67447","Time, period, or term devoted to some activity.","Session | session | {Session}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706366","Patch Dosing Unit","C48524","A dosing unit equal to the amount of active ingredient(s) contained in a patch.","Patch Dosing Unit | PATCH | Patch | patch | {PATCH} | {Patch}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439391","Milliliter per Hour","C66962","A metric unit of volumetric flow rate defined as the rate at which one milliliter of matter crosses a given surface during the period of time equal to one hour.","Milliliter per Hour | Milliliter/Hour | cc/hr | cm3/h | mL/h | milliliter per hour | ml/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881833","Milligram per Week","C67404","A dose administration rate unit equal to the rate at which one thousandth of a gram of a product is delivered or administered over the time period of one week. This is also a unit of mass flow rate equivalent to the rate at which one thousandth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to one week.","Milligram per Week | Milligram/Week | mg/wk | milligram per week",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881294","Joule per Square Centimeter","C67357","A unit of radiant exposure equal to radiant energy of one joule arriving upon a surface area of one square centimeter. The unit is also used for measurement of output of the energy-emitting source.","Joule per Square Centimeter | J/cm2 | Joules per Centimeter Squared | joules per centimeter squared",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439463","International Unit per Kilogram","C67379","A unit of measure of a quantity of substance per unit mass, expressed as the quantity of substance in International Units, divided by the mass of the substance in kilograms. It is also used as a dose calculation unit expressed in International Units of biological activity per one kilogram of body mass.","International Unit per Kilogram | IU/kg | International Unit/Kilogram | [IU]/kg | [iU]/kg | iU/kg | international unit per kilogram | international unit(s)/kilogram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705211","Inhalation Dosing Unit","C48501","A dosing unit equal to the amount of active ingredient(s) contained in an inhalation.","Inhalation Dosing Unit | INH | INHALATION | Inhalation | inhalation | {INHALATION} | {Inhalation}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0556636","Gray","C18063","A SI derived unit of absorbed radiation dose. One gray is equal to an absorbed dose of one joule per kilogram of matter, or to 100 rads.","Gray | Gy | gray",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1300564","Gram per Square Meter","C67282","A metric unit of areal density defined as a spread rate at which one gram of a substance is spread over the area of one square meter. It is equal to approximately 0.029 4935 ounce per square yard. Also used as a dose calculation unit to express quantity of an agent in grams per body surface area in square meters.","Gram per Square Meter | Gram per Meter Squared | Gram/Square Meter | Milligram per Millimeter Squared | Milligram per Square Millimeter | Milligram/Square Millimeter | g/m2 | gram per meter squared | gram(s)/square meter | gsm | mg/mm2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439185","Equivalent Weight","C67273","A unit of relative amount of a substance that combines with or displaces 8.0 grams of oxygen or 1.008 gram of hydrogen. The unit is usually expressed in grams and is equal to the amount of substance that gains or loses one mole of electrons in a redox reaction, or to the amount of substances that releases or accepts one mole of hydrogen ions in a neutralization reaction; or to the amount of electrolyte that carries one mole of positive or negative charge. This is a large unit and measurements are more often done in its derivatives, e.g. in milliequivalents.","Equivalent Weight | Eq wt | Equivalents | eq | equivalent | equivalents",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL377449","Metric Drop","C48491","A unit of volume used in pharmacy and equal to 0.05 milliliter (20 drops/ml).","Metric Drop | DROPS | Drop | Drop Dosing Unit | Drop Unit | Drops | Gtt | Pharmacist's Drop | X4 | [drp] | drop(s) | gtt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700085","Curie","C48466","A unit of radioactivity in the CGS system, defined as 3.7 E10 atomic disintegrations or other nuclear transformations per second. One curie is equal to 37 gigabecquerels.","Curie | CURIE | Ci",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0556645","Centigray","C64693","The metric unit of absorbed radiation dose equal to the absorption of one hundredth of joule of radiation energy per kilogram of matter.","Centigray | cGy | centigray",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706433","Capsule Dosing Unit","C48480","A dosing unit equal to the amount of active ingredient(s) contained in a capsule.","Capsule Dosing Unit | AV | CAPSULE | Cap | Capsule | cap | capsule | {CAPSULE} | {Capsule}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879996","Caplet Dosing Unit","C64696","A dosing unit equal to the amount of active ingredient(s) contained in a caplet.","Caplet Dosing Unit | CAPLET | Caplet | caplet | {CAPLET} | {Caplet}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879839","Billion Plaque Forming Units","C67267","A measure of viable infectious entities expressed in billions in the specimen or product defined as the smallest quantity that can produce a cytopathic effect in the host cell culture challenged with the defined inoculum, visible under the microscope or/and to the naked eye as a plaque.","Billion Plaque Forming Units | 10*9{PFU} | 10E9 PFU | 10^9 PFU | 10^9{PFU} | 10^9{pfu} | Billion PFU | billion plaque forming units",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881071","Hundred Million Plaque Forming Units","C67266","A measure of viable infectious entities expressed in hundreds of millions in the specimen or product defined as the smallest quantity that can produce a cytopathic effect in the host cell culture challenged with the defined inoculum, visible under the microscope or/and to the naked eye as a plaque.","Hundred Million Plaque Forming Units | 10*8{PFU} | 10E8 PFU | 10^8 PFU | 10^8 pfu | 10^8{PFU} | 10^8{pfu} | Hundred Million PFU | hundred million plaque forming units",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883276","Ten Million Plaque Forming Units","C67265","A measure of viable infectious entities expressed in tens of millions in the specimen or product defined as the smallest quantity that can produce a cytopathic effect in the host cell culture challenged with the defined inoculum, visible under the microscope or/and to the naked eye as a plaque.","Ten Million Plaque Forming Units | 10*7{PFU} | 10E7 PFU | 10^7 PFU | 10^7{PFU} | 10^7{pfu} | Ten Million PFU | ten million plaque forming units",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881335","Kilounit","C67309","A quantity equivalent to one thousand units (10E3 units).","Kilounit | 10E3 U | 10^3 U | Kilo Unit | Kilo Units | kU | kilo units | kilounit | kunits",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439474","Kilopascal","C67284","A SI derived unit of pressure equivalent to 1000 newtons per square meter or 10000 bars or to 0.145 pound per square inch.","Kilopascal | kPa | kilopascal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0556965","Kilohertz","C67279","A unit of measure denoting the frequency equal to 1000 cycles per second meaning e.g. that the cylical waveform changes from one state to the other (from one polarity to the other) 1000 times per second.","Kilohertz | Kiloherz | kHz | kiloHertz | kilohertz | kiloherz",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881333","Kiloelectronvolt","C67276","A unit of energy equal to 1000 electronvolts, or (approximately) 1,602 177 x 10-16 joule. The unit is accepted for use with SI units.","Kiloelectronvolt | Energy Unit | KeV | keV | kiloelectronvolt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1319266","Milligram per Square Meter","C67402","A metric unit of areal density equal to approximately 2.94935E-5 ounce per square yard. Also used as a dose calculation unit.","Milligram per Square Meter | Milligram per Meter Squared | Milligram/Square Meter | mg/m2 | milligram per meter squared | milligram(s)/square meter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0560005","Millicurie","C48511","A unit of radioactivity equal to one thousandth of a curie or 37 megabecquerels, and corresponding to a radioactivity of 37 millions of atomic disintegrations per second.","Millicurie | MILLICURIE | mCi | millicurie | millicurie(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1627892","Microgram per Kilogram","C67396","A unit of a mass fraction expressed as a number of micrograms of substance per kilogram of mixture. The unit is also used as a dose calculation unit.","Microgram per Kilogram | Attogram per Nanogram | Femtogram per Microgram | Microgram/Kilogram | Nanogram per Gram | Picogram per Milligram | Yoctogram per Femtogram | Zeptogram per Picogram | ag/ng | fg/mcg | fg/ug | mcg/kg | microgram per kilogram | microgram(s)/kilogram | ng/g | pg/mg | ug/kg | yg/fg | zg/pg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0560006","Microcurie","C48507","A unit of radioactivity equal to one millionth of a curie or 37 kilobecquerels, and corresponding to a radioactivity of 37 000 atomic disintegrations per second.","Microcurie | MICROCURIE | mcCi | microcurie | microcurie(s) | uCi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881765","Megarad","C67349","A unit of absorbed radiation dose equal to one million rad (10E6 rad), or 10000 Gy (10E4 Gy).","Megarad | MRAD | Mrad | Mrd | megarad",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0556962","Megahertz","C67314","The SI derived unit of frequency; equal to one million oscillations per second or to 10E6 hertz.","Megahertz | MHz | Megaherz | megaherz",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1300574","Milliliter per Kilogram","C67411","A dose calculation unit equal to one milliliter of preparation per one kilogram of body mass.","Milliliter per Kilogram | Milliliter/Kilogram | mL/kg | milliliter per kilogram | ml/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1533107","Puff Dosing Unit","C65060","A dosing unit equal to the amount of active ingredient(s) contained in a puff.","Puff Dosing Unit | PUFF | Puff | puff | {PUFF} | {Puff} | {puff}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439472","Pound per Square Inch","C67334","A traditional unit of pressure equivalent to 6.894757 kilopascals, or 703.0696 kilograms per square meter, or 51.71507 millimeters of mercury.","Pound per Square Inch | Pounds per Square Inch | [psi] | pounds per square inch | psi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882406","Plaque Forming Unit","C67264","A measure of viable infectious entities (e.g. viral particles or group of particles) in the specimen or product defined as the smallest quantity that can produce a cytopathic effect in the host cell culture challenged with the defined inoculum, visible under the microscope and/or to the naked eye as a plaque. A number of plaque forming units (PFU) per unit volume is a conventional way to refer the titer of an infective entity in a specimen or preparation.","Plaque Forming Unit | PFU | PLAQUE-FORMING UNITS | [PFU] | plaque forming unit | plaque forming units | {PFU}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439473","Pascal","C42547","A SI derived unit of pressure equivalent to one newton per square meter or 10 bars or to 1.45x10E-4 pounds per square inch.","Pascal | P | Pa | pascal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1641805","Packet Dosing Unit","C48521","A dosing unit equal to the amount of active ingredient(s) contained in a packet.","Packet Dosing Unit | PACKET | Packet | packet | {PACKET} | {Packet} | {packet}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439218","Ounce","C48519","The traditional unit of mass. The avoirdupois ounce is equal to 1/16 pound, or 28.349 5 grams, or 0.911 457 troy ounce.","Ounce | Avoirdupois Ounce | International Ounce | OUNCE | OZ | [oz_av] | ounce | oz | oz avdp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439186","Osmole","C67330","A non-SI unit of osmotic pressure equal to that of an ideal solution of a nondissociating substance that has a concentration of one mole of solute per liter of solution.","Osmole | Osm | osm | osmole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1638318","Nanogram per Kilogram","C67429","A unit of mass fraction expressed as a number of nanograms of a substance per kilogram of the mixture. The unit is also used as a dose calculation unit.","Nanogram per Kilogram | Attogram per Microgram | Femtogram per Milligram | Nanogram/Kilogram | Picogram per Gram | Yoctogram per Picogram | Zeptogram per Nanogram | ag/mcg | ag/ug | fg/mg | nanogram per kilogram | ng/kg | pg/g | yg/pg | zg/ng",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0560007","Nanocurie","C67352","A unit of radioactivity equal to one billionth of a curie or 37 becquerels, and corresponding to radioactivity of 37 atomic disintegrations per second.","Nanocurie | nCi | nanocurie | nanocurie(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456691","Millivolt","C67324","A SI derived unit of an electric potential and electromotive force equal to one thousandth of a volt.","Millivolt | mV | millivolt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439154","Milliosmole","C67318","A unit of osmotic pressure equal to one thousandth of osmole or osmotic pressure of 0.001 molar solution of a substance that does not dissociate.","Milliosmole | mOsm | milliosmole | mosm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881847","Million Viral Particles","C67351","A unit for virus amount measurement that represents a number of viral particles (live and dead combined) expressed in millions.","Million Viral Particles | 10E6 VP | 10^6 Viral Particles | 10^6{VP} | million viral particles",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881845","Million Units","C67310","A quantity equivalent to one million units (10E6 units).","Million Units | 10*6.U | 10E6U | 10^6 Million Unit | 10^6 U | 10^6.U | 10^6U | Million U | million unit | million units",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883540","Viral Particle Unit","C67350","A unit for virus amount measurement that represents the total number of viral particles (live and dead combined).","Viral Particle Unit | VP | Viral Particle | Viral Particles | viral particles | {VP}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1300561","Unit per Kilogram","C67465","An arbitrary unit of substance content expressed in units of biological activity per unit of mass equal to one kilogram. Unit per kilogram is also used as a dose calculation unit expressed in arbitrary units per one kilogram of body mass.","Unit per Kilogram | U/kg | Unit/Kilogram | unit per kilogram | {Unit}/kg | {U}/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705354","Troche Dosing Unit","C48548","A dosing unit equal to the amount of active ingredient(s) contained in a troche.","Troche Dosing Unit | TROCHE | Troche | troche | {TROCHE} | {Troche}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883346","Tissue Culture Infectious Dose 50%","C67450","A potency unit defined as a minimal dose of infectious material at which preparation causes cytopathic effects (changes in the morphology and metabolism of tissue culture cells, indicating cell death, due to suspected infection) in the 50% of the tissue culture-containing flasks inoculated with that dilution of infectious material in the product potency assay or pathogen activity assay.","Tissue Culture Infectious Dose 50% | 50 Percent Tissue Culture Infective Dose | 50% Tissue Culture Infective Dose | TCID50 | TISSUE CULTURE INFECTIOUS DOSE 50% | Tissue Culture Infection Dose 50 | [TCID_50] | tissue culture infection dose 50 | {TCID50}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704619","Teaspoon Dosing Unit","C48544","A unit of volume used in pharmacy and equal to 5 milliliters.","Teaspoon Dosing Unit | TEASPOON | Teaspoon | Teaspoon Unit | Teaspoonful | Y3 | [tsp_us] | t | teaspoon | tsp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705223","Tablet Dosing Unit","C48542","A dosing unit equal to the amount of active ingredient(s) contained in a tablet.","Tablet Dosing Unit | TABLET | Tab | Tablet | U2 | tab | tablet | {TABLET} | {Tablet} | {tbl}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1532188","Tablespoon Dosing Unit","C48541","A unit of volume informally used in pharmacy. Under the metric system the tablespoon has been standardized at 15 milliliters in the US, Britain, Canada, and New Zealand, and at 20 milliliters in Australia and some European countries.","Tablespoon Dosing Unit | T | TABLESPOON | Tablespoon | Tablespoon Unit | Tablespoonful | Tblsp | Tbsp | Y2 | [tbs_us] | tablespoon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2315586","Suppository Dosing Unit","C48539","A dosing unit equal to the amount of active ingredient(s) contained in a suppository.","Suppository Dosing Unit | AR | SUPPOSITORY | Supp | Suppository | suppository | {SUPPOSITORY} | {Suppository}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704413","Spray Dosing Unit","C48537","A dosing unit equal to the amount of active ingredient(s) contained in a spray.","Spray Dosing Unit | SPRAY | Spray | spray | {SPRAY} | {Spray}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205170","Good","C64975","Valuable or useful or agreeable or pleasing.","Good | ",,,,,,,,,,,,,,,"4047870","Good",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518072","Lymphoid Blood-Forming Cells","C13012","A hematopoietic stem cell that is committed to differentiate into T-, B- and natural killer (NK) cells.","Lymphoid Progenitor Cell | CFU-L | CLP | Colony Forming Units - Lymphoid | Common Lymphoid Progenitor | Common Lymphoid Progenitor Cell | Lymphoid Blood-Forming Cell | Lymphoid Blood-Forming Cell | Lymphoid Blood-Forming Cells | Lymphoid Progenitor Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881193","Indirect Bilirubin Measurement","C64483","Bilirubin is in the insoluble form, unconjugated bilirubin (indirect bilirubin).The non-water soluble, free bilirubin does not react with sulfanilic acid at acidic pH to produce a red colored complex until an accelearator, alcohol, is added to the solution to perform a quantitative measurement of unconjugated bilirubin levels.","Indirect Bilirubin Measurement | BILIND | Indirect Bilirubin | Unconjugated Bilirubin Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831937","F-18 16 Alpha-Fluoroestradiol","C62541","A radiopharmaceutical consisting of an estradiol analogue radiolabeled with the positron-emitting isotope fluorine F 18. F-18 16 alpha-fluoroestradiol is actively taken up in tumor cells expressing the estrogen receptor (ER), allowing visualization of ER-positive tumor cells with positron emission tomography (PET). Uptake of this agent depends upon the ER status of target tissues.","F-18 16 Alpha-Fluoroestradiol | 16 alpha-fluroestradiol-17 beta | F-18 16 alpha-fluoroestradiol | F-18 FES | FES | FLUOROESTRADIOL F-18 | Fluorine-18 16 alpha-fluoroestradiol | Fluoroestradiol F-18",,,,,,,,,,,,,,,"619878","Fluoroestradiol (18-F)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018834","Heartburn","C34670","Abdominal discomfort with retrosternal pain usually associated with gastroesophageal reflux.","Heartburn | Heartburn/Indigestion | Pyrosis | Pyrosis/Heartburn",,,,,,,,,,,,,,,"23325","Heartburn",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3203358","Hypoventilation","C50594","A state in which there is a reduced amount of air entering the pulmonary alveoli.","Hypoventilation | ",,,,,,,,,,,,,,,"312603","Hypoventilation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1515999","Anti-inflammatory effect","C28347","Having to do with reducing inflammation.","Anti-inflammatory | anti-inflammatory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0237935","Trust","C71753","Having confidence in the reliability of people or things.","Trust | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448795","Restriction","C53452","Anything that limits; a limitation.","Restriction | Constraint | Limitation | Restricted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441463","Static","C69299","A term used to denote that something is unchanging, not dynamic.","Static | ",,,,,,,,,,,,,,,"4107125","Static",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL938198","Unremarkable","C96301","In pathology, a term that is used to describe a tissue specimen that has a normal appearance.","Unremarkable | Floating-Point Number | UNREMARKABLE",,,,,,,,,,,,,,,"4069590","Normal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882365","Phenomenon","C61380","A fact or situation that is observed to exist.","Phenomenon | Phenomena",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347745","R Programming Language","C69302","A programming language and software environment for statistical computing and graphics.","R Programming Language | GNU S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347384","Octave Programming Language","C69303","An interpreted programming language for performing numerical computations for scientific computing.","Octave Programming Language | GNU Octave",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024934","Mathematics","C16825","The study of numbers, shapes, patterns, and logical reasoning.","Mathematics | Math | Mathematical",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346556","caArray","C71459","An NCICB informatics project consisting of a microarray database and microarray data analysis and visualization tools.","caArray | Cancer Array Informatics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706391","EntrezGene_ID","C49379","Indicates the accession number for a Gene within the Entrez Gene database.","EntrezGene_ID | GeneID | Locus_ID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706317","Long Variable","C48311","A variable that is stored as a signed 64-bit (8-byte) integer.","Long | Long Data Type | Long Value | Long Variable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705765","Double Value Type","C48870","A 64-bit floating point primitive. When wrapped in an immutable Object, it is called a Double.","Double | Double Value | Double Value Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348291","Digital Object Identifier","C71462","A unique code used by publishers in the identification and exchange of the content of a digital object, such as a journal article, web document, or other item of intellectual property. The DOI consists of two parts: a prefix assigned to each publisher by the administrative DOI agency and a suffix assigned by the publisher that may be any code the publisher chooses.","Digital Object Identifier | DOI | digital object id | digital_object_id",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347026","Biospecimen","C70699","Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products.","Biospecimen | BIOSPECIMEN | Bio-Specimen | BiologicSpecimen | Biological Sample | Biological Specimen | Sample | Specimen | biospecimen | sample | specimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043125","West Nile Virus","C71877","A species of flavivirus, one of the Japanese encephalitis virus group. It can infect birds and mammals and is spread especially from birds to humans by mosquitoes. Human infection causes an illness marked by fever, headache, muscle ache, skin rash, and sometimes encephalitis or meningitis.","West Nile Virus | WEST NILE VIRUS | WNV",,,,,,,,,,,,,,,"4238052","West Nile virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1720154","Inject","C64978","Add or introduce by needle and syringe.","Inject | ",,,,,,,,,,,,,,,"4227647","Inject",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1282927","Brief","C61484","Of short duration, extent, or distance.","Brief | ",,,,,,,,,,,,,,,"4231621","Shortened",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2349995","Emission substance","C71894","A substance that is emitted or released.","Emission | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348628","Syngeneic","C71901","Denoting individuals or tissues that are genetically identical.","Syngeneic | Isogeneic | Isogenic | Syngenic | syngeneic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347643","Positive Contrast Agent","C71959","Contrast media that has a higher amplification and intensity than the surrounding tissue making the contrast look more opaque when seen in an x-ray.","Positive Contrast Agent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347337","Negative Contrast Agent","C71960","Contrast media that has a lower amplification and intensity than the surrounding tissue making the contrast look less opaque when seen in an x-ray.","Negative Contrast Agent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015809","Femoral Vein","C12716","A vein that starts within the inguinal region and extends to the lower extremities.","Femoral Vein | FEMORAL VEIN | VEIN, FEMORAL | femoral vein",,,,,,,,,,,,,"UBERON:0001361","femoral vein","4308414","Femoral vein structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038532","Subclavian Vein","C12794","The vein that drains the axillary vein and joins the internal jugular vein to form the brachiocephalic vein. The subclavian vein runs parallel to the subclavian artery.","Subclavian Vein | SUBCLAVIAN VEIN | Structure of subclavian vein (body structure)",,,,,,,,,,,,,,,"4311330","Structure of subclavian vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710021","Schedule of Controlled Substances","C48670","The abuse potential category to which an active ingredient, or combination of active ingredients, is assigned, as regulated by both the United States Drug Enforcement Administration (DEA) and the United States Food and Drug Administration.","Schedule of Controlled Substances | Structured Product Labeling and Drug Enforcement Administration Schedule of Controlled Substances",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011892","Diacetylmorphine","C424","A narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed)","Diacetylmorphine | Acetomorphine | DIAMORPHINE | Heroin | Heroin | heroin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600427","Cocaine Dependence","C34492","A psychologically and socially impaired state, with or without physiological changes, that develops as a result of using cocaine and which leads to compulsive behaviors to acquire the substance.","Cocaine Dependence | Cocaine Addiction",,,,,,,,,,,,,,,"436389","Cocaine dependence",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348625","Sweep","C72075","A movement in an arc over a specified body part or area.","Sweep | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348693","Flux","C72076","Movement of a substance through a unit area of a boundary layer or membrane per unit of time.","Flux | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0553561","Colony Forming Unit","C68742","The minimum number of separable cells which is able to produce a detectable colony of progeny. Examples of CFU usage include, but are not limited to, the measurement of the number of viable bacteria present in the environment, and the ability of stem cells to produce cells of single or multiple lineages.","Colony Forming Unit | CFU | COLONY FORMING UNITS | [CFU] | colony forming units",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346845","Approval (document)","C70799","A document containing a formal acceptance as satisfactory, and/or official agreement or permission.","Approval Document | Approval | Approval | approval letter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034386","Quarantine","C71902","Place into enforced isolation.","Quarantine | ",,,,,,,,,,,,,,,"4015846","Quarantine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205372","Tertiary","C71903","Occurring third in place, order, degree, value, or rank.","Tertiary | ",,,,,,,,,,,,,,,"4225752","Tertiary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205499","Retropubic","C71904","Denoting the area posterior to the pubic bone.","Retropubic | ",,,,,,,,,,,,,,,"4164305","Retropubic approach",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0447562","Mesorectum","C71909","The fold of peritoneum, or mesentery, attached to the upper portion of the rectum and connecting it with the sacrum.","Mesorectum | ",,,,,,,,,,,,,,,"4074966","Mesorectum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347534","Administrator (Computer)","C72011","A person who manages a computer, a network or specific software components and has rights to perform all operations.","Administrator (Computer) | Administrator | Administrator (Computer) ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348608","Supervisor (Computer)","C72024","A person who can access data but can perform only limited actions on it.","Supervisor (Computer) | Supervisor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005859","Bloom Syndrome","C2903","Bloom syndrome is an autosomal recessive disorder associated with mutations in BLM gene encoding protein that belongs to the family of DNA helicases. It is characterized by predisposition to cancer, immunodeficiency, high sensitivity to UV and genomic instability of somatic cells. (Oncogene 2001 Dec 13;20(57):8276-80)","Bloom Syndrome | Bloom syndrome | Bloom-Torre-Machacek syndrome | Congenital Telangiectatic Erythema Syndrome",,,,,,,,,,,,,,,"4185900","Bloom syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0369738","Neutrophil Band Form Count","C64830","The determination of the number of band neutrophils in a blood sample.","Neutrophil Band Form Count | Bands | NEUTB | Neutrophil Bands | Neutrophils Band Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025663","Method","C71460","A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.","Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042241","Vaginal Diaphragm","C42767","A medical contraceptive device of soft flexible material, usually of thin rubber, that is designed to cover the cervix uteri prior to sexual intercourse to prevent the entry of spermatozoa. To enhance efficacy, a spermicidal agent is often placed within the device. Antimicrobial agent(s) can also be used to prevent sexually transmitted diseases. Efficacy of vaginal diaphragm against infections is very limited.","Vaginal Diaphragm | Diaphragm",,,,,,,,,,,,,,,"4069548|45771957","Contraceptive diaphragm|Diaphragm pessary",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1144906","Condom","C28258","A contraceptive device consisting of a thin rubber or latex sheath worn over the penis during intercourse.","Condom | Prophylactic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448545","Weekly","C67069","Every week.","Weekly | /wk | EVERY WEEK | Every week | Per Week | QS",,,,,,,,,,,,,,,"4031528","Weekly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0439507","Monthly","C64498","Every month.","Monthly | /mo | /month | Every Month | Per Month | QM",,,,,,,,,,,,,,,"4230958","Monthly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0226550","Internal Jugular Vein","C32849","A continuation of the sigmoid sinus of the dura mater; joins the subclavian vein to form the brachiocephalic vein.","Internal Jugular Vein | Internal jugular vein structure (body structure)",,,,,,,,,,,,,,,"4006845","Internal jugular vein structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2350010","Alpha Value","C72484","Indicates the probability of rejecting the statistical hypothesis tested when in fact, that hypothesis is true.","Alpha | Alpha Value",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349149","Westfall Young Adjustment","C72514","An adjustment method used in multiple comparison procedures to calculate an adjusted probability. This method ranks probabilities in descending order of their absolute p-values first, then calculate the adjusted p-values by an algorithm described in Dudoit et al. 2003.","Westfall Young Adjustment | Westfall Young | Westfall Young Correction | Westfall Young Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347434","Adjusted Bonferroni Correction","C72534","A multiple comparison adjustment method where the p-values are ranked in descending order. For the highest p-value, the critical p-value becomes (alpha/n), where n is the number of outcomes being tested; for the second-highest p-value, the critical p-value will be (alpha/n-1), and so on. The stringency of this correction falls somewhere between no correction and the Standard Bonferroni.","Adjusted Bonferroni Correction | Adjusted Bonferroni | Adjusted Bonferroni Adjustment | Adjusted Bonferroni Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1292856","Stimulation","C61406","Any physical thing or event that acts to arouse action.","Stimulation | Stimulated | Stimulating",,,,,,,,,,,,,,,"4043701","Stimulation - action",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0596545","Experience","C54627","The accumulation of knowledge or skill that results from direct participation in events or activities.","Experience | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711176","Biorepository","C48800","A storage facility of biospecimens that includes tissue samples, fluids, and molecular derivatives such as DNA, RNA, and proteins. The biorepository has stringent guidelines regarding the standardized collection, handling, storage, and documentation of biological specimens.","Biorepository | Biobank | biorepository | biospecimen source | biospecimen_source",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033422","Prone Position","C62165","An anterior recumbent body position whereby the person lies on its stomach and faces downward.","Prone Position | PRONE | Prone",,,,,,,,,,,,,,,"4050473","Prone body position",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038846","Supine Position","C62167","A posterior recumbent body position whereby the person lies on its back and faces upward.","Supine Position | SUPINE | Supine | Supine position",,,,,,,,,,,,,,,"4221822","Supine body position",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0079773","Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","C3467","A T-cell non-Hodgkin lymphoma arising from the skin. Representative examples include mycosis fungoides and primary cutaneous anaplastic large cell lymphoma.","Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | CTCL | Cutaneous T Cell Lymphoma | Cutaneous T-Cell Non-Hodgkin Lymphoma | Cutaneous T-Cell Non-Hodgkin Lymphoma | Cutaneous T-Cell Non-Hodgkin's Lymphoma | Cutaneous T-cell lymphoma, unspecified, unspecified site | PCTCL | Primary Cutaneous T-Cell Non-Hodgkin's Lymphoma | Skin T-Cell Non-Hodgkin's Lymphoma | T-Cell Non-Hodgkin's Lymphoma of Skin | T-Cell Non-Hodgkin's Lymphoma of the Skin | cutaneous T-cell lymphoma","9709/3","Cutaneous T-cell lymphoma, NOS",,,,,,,,,,,,,"37151253|37151343|4266805","Cutaneous T-cell lymphoma|Primary cutaneous T-cell lymphoma|Primary cutaneous T-cell lymphoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--|--"
"C0086059","Coping Skills","C19382","Use of conscious or unconscious strategies or mechanisms in adapting to stress.","Coping Skills | Stress and Coping | Stress and Coping | coping skills",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015388","Exudate","C13233","Material, such as purulent and nonpurulent fluid, cells, or cellular debris, which has escaped from blood vessels and has been deposited in tissues or on tissue surfaces, usually as a result of inflammation.  An exudate, in contrast to a transudate, is characterized by a relatively high protein content.","Exudate | EXUDATE",,,,,,,,,,,,,,,"4082584|4172171","Exudate|Exudate",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1947930","Cleaning (activity)","C65076","The action of removing dirt, filth, or unwanted substances from.","Clean | Cleaned | Cleanse | Cleansed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030971","Perception","C16967","The process of producing an internal, conscious image through stimulating a sensory system; it involves the recognition that stimulation has occurred, and the ability to discriminate various aspects of the stimulus.","Perception | Perceived",,,,,,,,,,,,,,,"4304678","Perception",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2349993","Blackout - suspension of service","C71739","A suspension of service (especially of radio or tv broadcasting).","Blackout | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347803","Clinical Trial Epoch","C71738","A portion of a study containing one or more study segments with a consistent objective such as screening subjects or treating disease.","Clinical Trial Epoch | EPOCH | Epoch | Study Epoch | epoch",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348301","Dismiss","C71730","Bar from attention or consideration; cease to consider.","Dismiss | Dismissed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347804","Clinical Trial Period","C71737","A possibly-repeating collection of consecutive days that define the length of a Study Segment","Clinical Trial Period | Period",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1260956","Red","C48326","The hue of the long-wave end of the visible spectrum, evoked in the human observer by radiant energy with wavelengths of approximately 630 to 750 nanometers; any of a group of colors that may vary in lightness and saturation and whose hue resembles that of blood","Red | RED",,,,,,,,,,,,,,,"4159773","Red color",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332585","Pink","C48328","Any of a group of colors reddish in hue, of medium to high lightness, and of low to moderate saturation.","Pink | PINK",,,,,,,,,,,,,,,"4159775","Pink color",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3179002","Social Networking","C19035","Establishing relationships with individuals who have similar social or professional interests for the purposes of expanding knowledge and professional/social interaction. (Glanz et al: Heath Behavior & Health Education, 1990)","Social Networking | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348521","Feet First","C72675","A direction of movement in which a person's feet lead the way.","Feet First | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348940","Head First","C72676","A direction of movement in which a person's head leads the way.","Head First | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0559228","Right Lateral Decubitus Position","C62171","Lying down or reclining with the right side in a downward direction.","Right Lateral Decubitus Position | RIGHT LATERAL DECUBITUS | Right lateral decubitus",,,,,,,,,,,,,,,"4009274","Right lateral decubitus position",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0559227","Left Lateral Decubitus Position","C62172","Lying down or reclining with the left side in a downward direction.","Left Lateral Decubitus Position | LEFT LATERAL DECUBITUS | Left lateral decubitus",,,,,,,,,,,,,,,"4010960","Left lateral decubitus position",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009253","Sexual Intercourse","C72881","A sexual act where a man's penis is inserted into the woman's vagina and excited until orgasm and ejaculation occur.","Sexual Intercourse | Intercourse",,,,,,,,,,,,,,,"4120031","Intercourse",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347948","Reluctance","C72882","A certain degree of unwillingness.","Reluctance | Reluctant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026516","Mood","C72883","A relatively temporary state of feeling.","Mood | ",,,,,,,,,,,,,,,"603070","Mood",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0079382","Friend","C72884","A person whom an individual knows, likes, and trusts.","Friend | FRIEND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004271","Outlook","C72885","A habitual or characteristic mental attitude that determines how a person will interpret and respond to situations.","Outlook | Attitude",,,,,,,,,,,,,,,"4021341","Attitude",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2346501","Interference","C72886","The act of hindering or obstructing or impeding.","Interference | Interfere | Interfered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2350008","Financial","C72888","Concerning or related to monetary conditions.","Financial | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346843","Appreciation","C72889","To be fully aware of the value of something; realize fully.","Appreciation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516635","Clinical Treatment","C15786","Actual observation and treatment of disease in patients (including experimental treatment) as distinct from theoretical or experimental work.","Clinical Treatment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883254","Synthesis","C61408","The process of producing a chemical compound, usually by the union of simpler chemical compounds.","Synthesis | Derivation, Chemical Synthesis | Synthesized | Synthetic | synthetic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919453","Cancer-Predisposing Gene","C18521","Mutated forms of genes which encode proteins that are essential for the control and maintenance of normal cellular processes. Inherited or somatic mutations in the wild-type form of these genes alters control of their expression, resulting in a change in control of the cell cycle. Individuals who harbor cancer-predisposing genes require fewer somatic mutations for transformation of a particular cell, thereby predisposing them to the development of cancer.","Cancer-Predisposing Gene | Cancer Susceptibility Gene | Susceptibility Gene | predisposing mutation | susceptibility gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006002","Book","C16360","A volume made up of pages fastened along one edge and enclosed between protective covers. (from American Heritage Dictionary)","Book | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347957","Reservation (action)","C71729","The act of keeping back or setting aside for some future occasion.","Reservation | Reserve",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706839","Applicable","C44483","Having relevance; capable of being applied.","Applicable | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016911","Gadolinium","C39765","An element with atomic symbol Gd, atomic number 64, and atomic weight 157.25.","Gadolinium | GADOLINIUM | Gd | gadolinium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0869039","Unit Dose","C65135","Packaging of medication in individual servings.","Unit Dose | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027551","Needle","C69013","A sharp pointed device.","Needle | ",,,,,,,,,,,,,,,"4194531","Needle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2346874","Attractive","C73114","Pleasing to the eye or mind especially through beauty or charm.","Attractive | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349015","Unattractive","C73115","Lacking beauty or charm; not appealing to the senses.","Unattractive | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0522498","Rarely","C73116","Not often.","Rarely | Not very often | Rather Seldom | Seldom | Very seldom | rather seldom",,,,,,,,,,,,,,,"4229765","Rare",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0451156","Fagerstrom Test for Nicotine Dependence","C70989","A standard instrument for assessing the intensity of physical addiction to nicotine.","Fagerstrom Test for Nicotine Dependence | Fagerstrom Questionnaire",,,,,,,,,,,,,,,"4159696","Fagerstrom test for nicotine dependence",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221093","Hypodermic Needle","C73119","A slender, hollow needle used for injection or aspiration.","Hypodermic Needle | Injection needle",,,,,,,,,,,,,,,"4230325","Hypodermic needle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0456564","Gauge (thickness dimension)","C73120","The thickness of a wire or a similarly shaped object.","Gauge | ",,,,,,,,,,,,,,,"4079306","Gauges",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347229","Buffy Coat Preparation","C72895","A process using centrifugation of whole blood to obtain a white blood cell layer highly enriched for neutrophils, lymphocytes, monocytes and progenitor cells.","Buffy Coat Preparation | Buffy Coat Isolation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346827","Antibody Coated Plate","C72896","A plastic medium with a coating of monoclonal or polyclonal antibodies, often used to select or deplete a population of cells which are passed over the medium.","Antibody Coated Plate | Antibody-Coated Plate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348198","Sheep Red Blood Cell Rosetting","C72897","A technique for identifying and removing T lymphocytes based on their ability to form rosettes with untreated sheep erythrocytes.","Sheep Red Blood Cell Rosetting | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348230","Soybean Lectin Agglutination","C72902","A technique for removing T lymphocytes based on differential agglutination with soybean lectin.","Soybean Lectin Agglutination | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033470","Propidium Iodide","C72903","A fluorescent nucleic acid dye which binds only to double-stranded nucleic acids. It has a molecular weight of 668.4, an absorbance maximum of 535nm, and an emission maximum of 617 nm.  It is commonly used to determine the DNA content of a cell or to discriminate viable from non-viable cells.","Propidium Iodide | PROPIDIUM IODIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0107497","Butenafine","C72959","A rat IgG2b monoclonal antibody directed against the cell surface glycoprotein CD52. It is used in HCT to prevent GVHD by eliminating T cells via antibody dependent cell cytotoxicity in vivo.","Butenafine | BUTENAFINE | Campath-1G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448919","Anti-CD52 Monoclonal Antibody","C72960","Any monoclonal antibody directed against the cell surface glycoprotein CD52, regardless of the antibody type (e.g., rat, mouse, humanized).","Anti-CD52 Monoclonal Antibody | Anti-CD52 | Anti-CD52 Antibody | Anti-CD52 Monoclonal Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012403","Dimethyl Sulfoxide","C437","A highly polar organic liquid that is used widely as a chemical solvent and a free radical scavenger. It shows a range of pharmacological activity including analgesia and anti-inflammation. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect cells and tissue during cryopreservation and has been used to treat extravasation damage caused by anthracycline-based chemotherapy.","Dimethyl Sulfoxide | (DMSO) | DIMETHYL SULFOXIDE | DMSO | Demasorb | Demeso | Domoso | Dromisol | SQ 9453 | SQ-9453 | Sulfinylbismethane | dimethyl sulfoxide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1610534","CAMPATH-1 Antigen","C38908","CAMPATH-1 antigen (61 aa, ~7 kDa) is encoded by the human CD52 gene. This protein may play a role in spermatogenesis and lymphocyte biology.","CAMPATH-1 Antigen | CD52 | CD52 Antigen | CDW52 | CDW52 Antigen | CDW52 Antigen | CDw52 | Cambridge Pathology 1 Antigen | Epididymal Secretory Protein E5 | He5 | Human Epididymis-Specific Protein 5",,,,,,,,,,,,,,,"4175981","Lymphocyte antigen CDw52",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347293","Mononucleated Blood Cell","C73123","A mixture of cells possessing a single nucleus, including monocytes and lymphocytes; blood leukocytes from which granulocytes have been separated and removed.","Mononucleated Blood Cell | Mononuclear Blood Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448920","Nucleated Red Blood Cell","C73125","Red blood cells that are at the last stage of development, still containing a nucleus, that are found in the bone marrow and occasionally in the peripheral blood.","Nucleated Red Blood Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347368","Nucleated Blood Cell","C73126","The cellular material of blood consisting of white blood cells and nucleated red blood cells.","Nucleated Blood Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054964","T-Cell Surface Glycoprotein CD5","C73124","T-cell surface glycoprotein CD5 (495 aa, ~54 kDa) is encoded by the human CD5 gene. This protein may be involved in regulating the proliferation of T-cells.","T-Cell Surface Glycoprotein CD5 | CD5 | CD5 Antigen | Lymphocyte Antigen CD5 | Lymphocyte Antigen T1/Leu-1",,,,,,,,,,,,,,,"4147845","Lymphocyte antigen CD5",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0054967","T-Cell Differentiation Antigen CD6","C73129","T-cell differentiation antigen CD6 (668 aa, ~72 kDa) is encoded by the human CD6 gene. This protein plays a role in the adherence of immature thymus cells to thymic epithelial cells.","T-Cell Differentiation Antigen CD6 | CD6 Antigen | T12 | TP120",,,,,,,,,,,,,,,"4280941","Lymphocyte antigen CD6",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008976","Clinical Trial","C71104","A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.","Clinical Trial | Clinical Trials | Clinical Trials, Unspecified | Interventional Clinical Trial | Interventional Study | Trial | Trials | clinical trial | clinical_trial",,,,,,,,,,,,,,,"4002165","Clinical trial",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348127","Sachet Dosing Unit","C71324","A dosing unit equal to the amount of active ingredient(s) contained in a sachet.","Sachet Dosing Unit | SACHET | Sachet | Sachet dosing unit | {SACHET} | {Sachet}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1280500","Effect","C25492","A phenomenon that follows and is caused by some previous phenomenon.","Effect | Effects",,,,,,,,,,,,,,,"4109801","Effect",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0565944","Skin Burning Sensation","C35297","A sensation of dermal stinging or heat, not necessarily accompanied by redness or physical signs of skin irritation.","Skin Burning Sensation | ",,,,,,,,,,,,,,,"4108467|4123196|42538644","Burn of skin|Burn of skin of body region|Burning sensation of skin",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C0037313","Sleep","C73425","A natural and periodic state of rest during which consciousness of the world is suspended.","Sleep | ",,,,,,,,,,,,,,,"4123007","Sleep",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019826","Hobby","C73426","An area of interest or recreational activity that someone pursues outside their occupational duties.","Hobby | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041427","Twin","C73427","Either of two offspring born from the same pregnancy.","Twin | TWIN | Twin Sibling",,,,,,,,,,,,,,,"4013484","Twin sibling",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041429","Fraternal Twin","C73428","Either of the two offspring from separately fertilized ova during the same pregnancy.","Fraternal Twin | Dizygotic Twin | Fraternal Twin Sibling | TWIN, DIZYGOTIC",,,,,,,,,,,,,,,"4196733","Fraternal twin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041432","Identical Twin","C73429","Either of the two offspring resulting from a shared ovum.","Identical Twin | Monozygotic Twin | TWIN, MONOZYGOTIC",,,,,,,,,,,,,,,"4193698","Identical twin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883476","Upon Awakening-schedule frequency","C64921","Used to indicate that an event is to commence following the end of sleeping.","Upon Awakening | Upon Waking | Waking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL475592","Gavage","C73430","Administration of nutritional support by means of a tube passed into the stomach.","Gavage | Gastrogavage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524867","Myeloablative Agonist","C1711","A pharmacological agent that kills cells in the bone marrow.","Myeloablative Agonist | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448921","Enlargement","C73432","The act of increasing (something) in size or volume or quantity or scope.","Enlargement | ENLARGEMENT | Enlarged",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036938","Shame","C73431","A painful emotion resulting from a feeling of inadequacy, embarrassment, or guilt.","Shame | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007876","Cesarean Section","C46088","Surgical delivery of one or more intrauterine fetuses though an abdominal incision.","Cesarean Section | Abdominal Delivery | C-Section | CESAREAN SECTION | Caesarean Birth | Caesarean Section | Caesarian Section | Cesarean Birth | Cesarean Birth | Cesarean Delivery | Cesarian Section",,,,,,,,,,,,,,,"4015701","Cesarean section",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024119","Pulmonary Function Test","C38081","A broad range of tests that are performed to assess how well lungs inhale and exhale air and how efficiently they transfer oxygen into the blood.","Pulmonary Function Test | PFT | Pulmonary Function Testing | Pulmonary Function Tests | lung function test | pulmonary function test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001861","Air (atmospheric)","C73434","A mixture of gases making up the earth's atmosphere, consisting mainly of nitrogen, oxygen, argon, and carbon dioxide.","Air | AIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3149028","Gastrointestinal Stromal Tumor","C3868","A stromal tumor most commonly seen in the gastrointestinal tract. Rare cases of solitary masses in the omentum or the mesentery have also been reported (extragastrointestinal gastrointestinal stromal tumor).  It is a tumor that differentiates along the lines of interstitial cells of Cajal.  Most cases contain KIT- or PDGFRA-activating mutations. Until recently, surgery has been the only effective therapy for this tumor.  However, many patients still experience recurrence.  Conventional chemotherapy and radiation therapy have been of limited value.  A KIT tyrosine kinase inhibitor, imatinib mesylate (also known as STI-571 or Gleevec), is now effective in the treatment of relapsed and unresectable cases.","Gastrointestinal Stromal Tumor | GIST | GIST, NOS | GISTs | Gastrointestinal Stromal Neoplasm | Gastrointestinal Stromal Tumor (GIST) | Gastrointestinal stromal tumor | Gastrointestinal stromal tumor, NOS | Gastrointestinal stromal tumor, unspecified site | gastrointestinal stromal tumor",,,,,,,,,,,,,,,"4170421","Gastrointestinal stromal tumor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0677908","Maintenance Therapy","C15688","Continuation of treatment for an extended period of time to prevent relapse.","Maintenance Therapy | Maintenance | maintenance therapy",,,,,,,,,,,,,,,"4198144","Maintenance therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028773","Obstetrics","C16928","A medical-surgical specialty dealing with the care of a woman and her offspring during pregnancy, childbirth and the puerperium (the period shortly after birth).","Obstetrics | Obstetrical",,,,,,,,,,,,,,,"4235391","Obstetrics",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0218986","Aldesleukin","C1498","A recombinant analog of the endogenous cytokine interleukin-2 (IL-2) with immunoregulatory and antineoplastic activities. Aldesleukin binds to and activates the IL-2 receptor, followed by heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains; activation of the tyrosine kinase Jak3; and phosphorylation of tyrosine residues on the IL-2R beta chain, resulting in an activated receptor complex. Various cytoplasmic signaling molecules are recruited to the activated receptor complex and become substrates for regulatory enzymes that are associated with the receptor complex. This agent enhances lymphocyte mitogenesis; stimulates long-term growth of human IL-2 dependent cell lines; enhances lymphocyte cytotoxicity; induces lymphokine-activated killer (LAK) cell and natural killer (NK) cell activities; and induces expression of interferon-gamma. Aldesleukin may induce T cell-mediated tumor regression in some tumor types.","Aldesleukin | 125-L-Serine-2-133-interleukin 2 | ALDESLEUKIN | Proleukin | Recombinant Human IL-2 | Recombinant Human Interleukin-2 | aldesleukin | r-serHuIL-2 | recombinant human interleukin-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0877578","Therapy-Related Malignant Neoplasm","C4969","The development of a malignant neoplasm in response to medical or surgical treatment, induced by the treatment itself.","Therapy-Related Malignant Neoplasm | Iatrogenic Cancer | Therapy Related Cancer | Therapy Related Malignant Neoplasm | Therapy Related Malignant Neoplasm | Therapy Related Malignant Tumor | Treatment related secondary malignancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002073","Alkylating Agent","C223","Agents that replace hydrogen atom(s) in biologically active molecules with alky radical(s), hindering proper function.  Alkylating agents exhibit cytotoxic effects through the alkylation of DNA, resulting in strand cross-linking, ultimately inhibiting DNA replication and cell growth.","Alkylating Agent | Alkylating Agents | Alkylator | alkylating agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1268900","Gonadotropin-Releasing Hormone Analogue","C1910","A synthetic analogue of the endogenous hormone gonadotropin-releasing hormone (GnRH), with potential antineoplastic activity. Upon administration, GnRH analogue mimics endogenous GnRH and strongly binds to and activates pituitary GnRH receptors, which stimulates the synthesis and secretion of the gonadotropic hormones, follicle stimulating hormone (FSH) and luteinizing hormone (LH). Continuous, prolonged activation by the GnRH analogue results in pituitary GnRH receptor desensitization and receptor downregulation. This causes inhibition of pituitary gonadotropin secretion of LH and FSH. In males, the inhibition of LH secretion prevents the production and release of testosterone from Leydig cells in the testes and causes a significant decline in testosterone production that is near the levels seen after castration. This may inhibit androgen receptor-positive tumor progression. In females, this results in a decrease in estradiol production. GnRH, also called luteinizing hormone-releasing hormone (LH-RH), is normally synthesized in and secreted by the hypothalamus. Synthetic analogues of GnRH have a stronger receptor binding affinity than the endogenous form.","Gonadotropin-releasing Hormone Analog | GnRH Agonist | GnRH Analog | Gonadotropin-Releasing Hormone Agonist | Gonadotropin-Releasing Hormone Analogue | LH-RH Analogs | LH-RH agonist | LHRH Agonist | Luteinizing Hormone-Releasing Hormone Analog | Luteinizing Hormone-releasing Hormone Agonist | gonadotropin-releasing hormone agonist | luteinizing hormone-releasing hormone agonist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0301532","Multivitamin","C1654","A dietary supplement containing all or most of the vitamins that may not be readily available in the diet. Vitamins may be classified according to their solubility either in lipids (vitamins A, D, E, K, F) or in water (vitamins C, B-complex). Present in minute amounts in various foods, vitamins are essential to maintaining normal metabolism and biochemical functions. (NCI04)","Multivitamin | Geritol | Vitamin Supplements (NOS)",,,,,,,,,,,,,,,"763310","Vitamin supplement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347565","Case Sensitive","C71490","Indicates that a text matching operation distinguishes upper-case (capital) letters from lower case.","Case Sensitive | Case Sensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349021","Uniform Resource Name","C71581","A standardized name for a persistent, location-independent, resource identifier.","Uniform Resource Name | URN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1552672","Object Identifier","C71489","An integer or pointer that uniquely identifies an object.","Object Identifier | OID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349939","Deprecated - general qualifier","C71491","Used to indicate something that is tolerated or supported but not recommended (discouraged) and that may be in the process of being phased out; obsolescent.","Deprecated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346787","Anonymous","C71754","Having no known name or identity or known source.","Anonymous | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448917","Debug","C71579","Act to locate and correct errors in a computer program code.","Debug | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1302234","Fatal","C71580","Bringing death.","Fatal | Fatal (Computer Sense)",,,,,,,,,,,,,,,"4163278","Fatal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705605","Absence of Biochemical Activity","C45422","Indicates an absence of a measurable amount of a specific function or role performed by a biological entity in a biophysical process, biochemical reaction, or biochemical process.","Absence of Biochemical Activity | Inactive | Inactive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1547325","Pending","C53470","Not yet decided or settled; awaiting conclusion or confirmation.","Pending | pending",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347387","Official","C72159","Established by authority or sanction.","Official | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349099","Valid","C71756","Allowable, usable, or acceptable.","Valid | Sound | valid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346670","LexBIG","C71582","Provides externalization and support of LexGrid-based terminology software (services, persistence, tooling) developed for the Cancer Biomedical Informatics Grid (caBIG) initiative. The goal of the project is to build a vocabulary server accessed through a well-structured application programming interface (API) capable of accessing and distributing vocabularies as commodity resources.","LexBIG | Lexgrid Vocabulary Services for caBIG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205385","Ascend","C61465","To travel upward.","Ascend | Ascending",,,,,,,,,,,,,,,"4194081","Ascending",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2349992","Java Programming Language","C71585","A platform-independent object-oriented programming language used for writing applets that are downloaded from the World Wide Web by a client and run on the client's machine.","Java Programming Language | Java | Java",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL378357","Export","C71586","To transfer from a local area to an external or distant area; to move data out of one file or system with the purpose of importing it into another file or system.","Export | EXPORT | Exported",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600457","Gravida","C73435","A woman who currently is pregnant or has been in the past, irrespective of the pregnancy outcome.","Gravida | GRAVIND | Gravida Indicator | PREGNANT",,,,,,,,,,,,,,,"4060186","Gravida",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0000781","Abortus","C73436","Products of conception expelled or removed upon miscarriage or termination of a pregnancy.","Abortus | Aborted Fetus",,,,,,,,,,,,,,,"4103222","Structure of abortus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL383718","Apgar Score Finding","C73437","The numerical sum between zero and ten that is computed from individual values of zero to two that are assigned to five different areas of interest in newborn screenings. These areas are breathing, muscle tone, pulse rate, reflex irritability and skin color.","Apgar Score | ",,,,,,,,,,,,,,,"4200202","Finding of Apgar score",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348744","Gene Distance Metric","C72648","A mathematical method for calculating a relatedness score for genes.","Gene Distance Metric | Distance Metric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348205","Similarity","C72665","The quality of being alike; having characteristics in common.","Similarity | Like | Similar",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347874","Cosine Distance Method","C72662","A type of pearson measure, which considers the relative differences (e.g. A*B/Abs[A]*Abs[B]) assuming that the scale is uniform (that the distance from zero is relative). In some cases this can give better results, particularly where the data is not 'normally' distributed.","Cosine Distance Method | Cosine Distance | Cosine Similarity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347053","Manhattan Distance Method","C72664","The sum of the absolute differences between two variables (e.g. Abs[A-B]). Unlike the euclidean distance this does not give an overemphasis to greater distances. This should generally be considered the default distance measure to be used in most operations.","Manhattan Distance Method | Manhattan Distance | Manhattan Distance Metric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281176","Antibody Therapy","C15542","Treatment with injections of antibodies to directly destroy specific, usually cancerous, cells or to stimulate the immune system to destroy those cells.","Antibody Therapy | antibody therapy | passive antibody therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332170","Morning","C64934","The time period between dawn and noon.","Morning | ",,,,,,,,,,,,,,,"4252249","Morning",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4229107","Bradycardia","C37920","An abnormally slow heart rate. Thresholds for different age, gender, and patient populations exist.","Bradycardia | ",,,,,,,,,,,,,,,"4169095","Bradycardia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205131","Axial","C73439","Situated on or along or in the direction of an axis.","Axial | ",,,,,,,,,,,,,,,"4086896","Axial",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0587107","During Exercise","C64932","While exercising or working out.","During Exercise | During Workout | Morning",,,,,,,,,,,,,,,"4203112","During exercise",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0087009","Specialist Physician","C73456","A physician who receives additional education and training in one particular area of medicine.","Specialist Physician | Specialist | specialist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3845746","Loss of Consciousness","C50635","An inability to purposefully respond to stimuli.","Loss of Consciousness | Loss Of Consciousness | Loss of consciousness | UNCONSCIOUS | Unconscious | Unconscious State",,,,,,,,,,,,,,,"372448","Loss of consciousness",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519789","Unexpected Adverse Event","C41334","Any adverse event associated with a medical product or procedure that has not been previously observed, whether or not the event was anticipated because of the pharmacologic properties of the study agent or the nature of the medical procedure. This includes events that are more serious than expected or occur more frequently than expected, particularly, any adverse experience, the nature, severity or frequency of which is not consistent with the product label, or with the current investigator brochure for investigational agent; or with the risk information described in the investigational plan or protocol or consent form.","Unexpected Adverse Event | UAE | Unanticipated Adverse Event | Unexpected | unexpected adverse drug reaction | unexpected adverse event | unexpected_adverse_event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706307","Irritation","C50624","A mild inflammatory tissue reaction; it can be caused by physical contact with an irritant or can be a local response to a systemic trigger.","Irritation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348382","Effect, Appearance","C71600","An outward appearance.","Effect, Appearance | Effect | Effect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006118","Brain Neoplasm","C2907","A benign or malignant neoplasm that arises from or metastasizes to the brain.","Brain Neoplasm | Brain Neoplasms | Brain Tumor | Neoplasm of Brain | Neoplasm of the Brain | Neoplasm of unspecified behavior of brain | Tumor of Brain | Tumor of the Brain | brain tumor",,,,,,,,,,,,,,,"373724","Neoplasm of brain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020431","Hyperbaric Oxygen Therapy","C38065","The use of a pressurized chamber for the delivery of oxygen in higher concentrations for therapeutic benefit. Useful in the treatment of severe burns, peripheral vascular disease, carbon monoxide poisoning and decompression illness.","Hyperbaric Oxygen Therapy | Hyperbaric Therapy | Hyperbaric Treatment | Hyperbaric oxygen",,,,,,,,,,,,,,,"4087611","Hyperbaric oxygen therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036536","Cellular Secretion","C17119","Production by a cell or aggregation of cells (a gland) of a physiologically active substance and its movement out of the cell or organ in which it is formed.  Discharge across the cell membrane, into the intracellular space or ducts, of endogenous substances resulting from the activity of intact cells of glands, tissues, or organs.","Cellular Secretion | Secreted | Secreting | Secretion | Secretion, Cellular | Secretory | secrete",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0403673","Dry Orgasm","C4698","Male sexual climax without ejaculation.","Dry Orgasm | Retrograde Ejaculation | dry orgasm",,,,,,,,,,,,,,,"435866","Retrograde ejaculation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006325","Bruxism","C73511","Excessive clenching of the jaw and grinding of the teeth.","Bruxism | Teeth Grinding",,,,,,,,,,,,,,,"4099943","Bruxism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0183975","Toothbrush","C73512","A small implement with bristles and usually a long handle, used to clean the teeth and gums.","Toothbrush | ",,,,,,,,,,,,,,,"4066492","Toothbrush",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348095","Dental Curing","C73513","The process by which resin-based materials are polymerized to become rigid.","Dental Curing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011375","Dental Impression","C73514","A procedure used to acquire a negative reproduction of an oral structure for the purpose of producing a positive model or cast of the structure upon which restorations, prostheses, and dentures are fabricated.","Dental Impression | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227017","Dentinal Tubule","C73515","Minute branching canals in the tooth dentin that contain filamentous protoplasmic processes of the odontoblasts and extend radially from the pulp to the dentoenamel junction.","Dentinal Tubule | Dentinal Canal",,,,,,,,,,,,,,,"4248693","Dentinal tubule",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL523885","Toothpaste","C73516","A substance in paste form containing abrasives used to clean the tooth surface.","Toothpaste | ",,,,,,,,,,,,,,,"4169067","Toothpaste",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002957","Anger","C73506","An emotional state characterized by marked annoyance or hostility.","Anger | ",,,,,,,,,,,,,,,"4327815","Feeling angry",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0871641","Affection","C73508","A positive feeling of liking.","Affection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024028","Love","C73509","A strong positive emotion of affection and attraction.","Love | ",,,,,,,,,,,,,,,"4032605","Love",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0683285","Humiliation","C73510","A feeling of extreme embarrassment.","Humiliation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152030","Skin Irritation","C50743","A mild inflammatory dermal tissue reaction; it can be caused by physical contact with an irritant or can be a local response to a systemic trigger.","Skin Irritation | ",,,,,,,,,,,,,,,"4280604","Skin irritation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040802","Travel","C53462","The act of going from one place to another.","Travel | ",,,,,,,,,,,,,,,"4168974","Travel",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037361","Olfaction","C17139","The faculty of smell.","Olfaction | Olfactory | Smell | olfaction | olfactory",,,,,,,,,,,,,,,"4262169","Sense of smell, function",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332261","Spread","C61404","The act of extending over a wider scope or expanse of space or time.","Spread | Spreading",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036606","Support Groups","C17120","A group of people who provide each other moral support, information, and advice on problems relating to a shared characteristic or experience.","Support Group | Self-Help Group | support group",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332169","Daytime","C64928","The time between sunrise and sunset while it is light.","Daytime | ",,,,,,,,,,,,,,,"4101405","Daytime",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0240526","Night Time","C65001","The time in every 24 hour period when it is dark.","Night Time | Night",,,,,,,,,,,,,,,"4102546","Night time",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029260","Orgasm","C73521","The height of sexual excitement, consisting of a series of involuntary contractions of the muscles of the genitals, lower pelvis, and anus, accompanied by strong feelings of pleasure.","Orgasm | Orgasmic | orgasm",,,,,,,,,,,,,,,"4294766","Sexual orgasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0233972","Sexual Arousal","C73522","Heightened urges of sexual desires in preparation for sexual behavior.","Sexual Arousal | ",,,,,,,,,,,,,,,"4140844","Sexual excitation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL449146","Psychological Health","C16839","mental health status.","Psychological Health | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007704","Density Gradient Centrifugation","C16411","A method of separating macromolecules by either their differential rate of sedimentation in a centrifugal gradient or their differential buoyancy in a density gradient. (from biology-text.com)","Density Gradient Centrifugation | Fractionation, Density Gradient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007616","Cell Sorting","C16406","Any of various processes to isolate one or more specific cell populations from a heterogeneous mixture of cells.","Cell Sorting | Cell Isolation | Cell Separation | Cell Separation Technology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224424","Gluteus Maximus","C52560","The outermost and largest muscle of the buttocks.","Gluteus Maximus | GLUTEUS MAXIMUS",,,,,,,,,,,,,,,"4070318","Structure of gluteus maximus muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014724","Eructation","C50550","To belch, the casting of upwind from the stomach.","Eructation | Belching, Burping | Eructate",,,,,,,,,,,,,,,"4152350|4285583","Burping|Eructation",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0036421","Systemic Scleroderma","C72070","A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. The two types of systemic scleroderma, limited cutaneous and diffuse cutaneous are classified with focus on the extent of affected skin. A relationship exists between the extent of skin area affected and degree of internal organ/system involvement. Systemic scleroderma can manifest itself in pulmonary fibrosis, Raynaud's syndrome, digestive system telangiectasias, renal hypertension and/or pulmonary hypertension.","Systemic Scleroderma | Diffuse Scleroderma | Diffuse Sclerosis | SSc, Diffuse Sclerosis | Scleroderma, Diffuse | Scleroderma, Systemic | Systemic Sclerosis | Systemic sclerosis, unspecified | systemic scleroderma | systemic sclerosis",,,,,,,,,,,,,,,"134442","Systemic sclerosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010186","Financial cost","C69088","The amount paid, charged, or engaged to be paid, for purchasing goods, services and financial instruments.","Cost | Costs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1947933","care activity","C61488","The work of attending to someone or something.","Care | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1302752","Abrasion","C50449","Superficial damage to the skin caused by rubbing or scraping.","Abrasion | Skin Abrasion",,,,,,,,,,,,,,,"4219871|4271006","Abrasion|Abrasion",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0080331","Walking","C73554","The act of traveling by foot.","Walking | Ambulation | By Foot | On Foot | Walk",,,,,,,,,,,,,,,"3655979|4044711","Walking|Walking",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0536495","Moxifloxacin","C62052","A fluoroquinolone antibiotic with antibacterial activity. Moxifloxacin binds to and inhibits the bacterial enzymes DNA gyrase (topoisomerase II) and topoisomerase IV, resulting in inhibition of DNA replication and repair and cell death in sensitive bacterial species.","Moxifloxacin | MOXIFLOXACIN | moxifloxacin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0663655","Abacavir","C61523","A nucleoside reverse transcriptase inhibitor analog of guanosine. This agent decreases HIV viral loads, retards or prevents the damage to the immune system, and reduces the risk of developing AIDS.","Abacavir | 1592U89 | 2-Cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-, (1S,4R)- | ABACAVIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0050175","Adefovir","C61526","A nucleoside reverse transcriptase inhibitor analog of adenosine with activity against hepatitis B virus (HBV), herpes virus, and human immunodeficiency virus (HIV).","Adefovir | 9-(2-Phosphonylmethoxyethyl)adenine | ADEFOVIR | GS-0393 | PMEA | Phosphonylmethoxyethyl-a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002499","Amikacin","C61615","A broad-spectrum semi-synthetic aminoglycoside antibiotic, derived from kanamycin with antimicrobial property. Amikacin irreversibly binds to the bacterial 30S ribosomal subunit, specifically locking 16S rRNA and S12 protein within the 30S subunit. This leads to interference with translational initiation complex and misreading of mRNA, thereby hampering protein synthesis and resulting in bactericidal effect. This agent is usually used in short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria.","Amikacin | AMIKACIN | amikacin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0055011","Cefpodoxime","C65305","A third generation semi-synthetic cephalosporin and a beta-lactam antibiotic with bactericidal activity. Cefpodoxime's effect is dependent on its binding to penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. Binding results in the inhibition of the transpeptidase enzymes, thereby preventing cross-linking of the pentaglycine bridge with the fourth residue of the pentapeptide and interrupting consequent synthesis of peptidoglycan chains. As a result, cefpodoxime inhibits bacterial septum and cell wall synthesis formation.","Cefpodoxime | CEFPODOXIME",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007559","Ceftazidime","C66868","A beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Ceftazidime binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, ceftazidime is more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftazidine also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS).","Ceftazidime | CEFTAZIDIME | Ceftazidime Pentahydrate | Ceptaz | Fortaz | GR 20263 | LY 139381 | Pentacef | Pyridinium, 1-((7-(((2-amino-4-thiazolyl)((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, Hydroxide, Inner Salt, Pentahydrate, (6R-(6alpha,7beta(Z)))-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007561","Ceftriaxone","C62020","A beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Ceftriaxone binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, ceftriaxone is more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftriaxone also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS).","Ceftriaxone | CEFTRIAXONE | ceftriaxone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025942","Miconazole","C62048","An antifungal synthetic derivative of imidazole and used in the treatment of candidal skin infections, Miconazole selectively affects the integrity of fungal cell membranes, high in ergosterol content and different in composition from mammalian cells membranes. (NCI04)","Miconazole | 1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole | MICONAZOLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027324","Nafcillin","C62053","A semi-synthetic naphthalene and beta-lactam antibiotic with antibacterial activity. Nafcillin inhibits bacterial wall synthesis by a mechanism of action similar to penicillin. Penicillinase-resistant Nafcillin is used to treat infections caused by penicillin-resistant strains of Staphylococci. (NCI04)","Nafcillin | NAFCILLIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028156","Nitrofurantoin","C29293","A synthetic derivative of imidazolidinedione, Nitrofurantoin inhibits bacterial DNA, RNA, and cell wall protein synthesis. Activated by bacterial flavoproteins to intermediates that inactivate bacterial ribosomal proteins, Nitrofurantoin is used prophylactically as a urinary anti-infective agent against most gram-positive and gram-negative organisms and for long-term suppression of infections. (NCI04)","Nitrofurantoin | Macrobid | Macrodantin | NITROFURANTOIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028741","Nystatin","C710","A polyene macrolide antibiotic, with antifungal activity. Upon administration, nystatin binds to sterols in the fungal plasma membrane, thereby increasing membrane permeability. This leads to leakage of important intracellular components, cell rupture, and eventually fungal cell death.","Nystatin | Mycostatin | NYSTATIN | Nystex | Nystop | mycostatin | nystatin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028902","Ofloxacin","C712","A fluoroquinolone antibacterial antibiotic. Ofloxacin binds to and inhibits bacterial topoisomerase II (DNA gyrase) and topoisomerase IV, enzymes involved in DNA replication and repair, resulting in cell death in sensitive bacterial species. (NCI04)","Ofloxacin | 9-Fluoro-2,3-Dihydro-3-Methyl-10-(4-Methyl-1-Piperazinyl)-7-Oxo-7H-Pyrido(1,2,3-de)(1,4)benzoxazine-6-Carboxylic Acid, DL- | DL-8280 | Floxin | HOE 280 | OFLOXACIN | Ocuflox | ofloxacin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0874161","Oseltamivir","C62061","A synthetic derivative prodrug of ethyl ester with antiviral activity. Osetamivir blocks neuraminidases on the surfaces of influenza viruses, interfering with host cell release of complete viral particles.","Oseltamivir | OSELTAMIVIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037536","Oxacillin Sodium","C720","The sodium salt form of oxacillin, a semisynthetic penicillinase-resistant and acid-stable penicillin with an antimicrobial activity. Oxacillin binds to penicillin-binding proteins in the bacterial cell wall, thereby blocking the synthesis of peptidoglycan, a critical component of the bacterial cell wall. This leads to inhibition of cell growth and causes cell lysis.","Oxacillin Sodium | OXACILLIN SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030840","Penicillin V","C62064","A member of the penicillin family exhibiting broad-spectrum antibiotic property. Penicillin V binds to penicillin binding proteins (PBP), the enzymes that catalyze the synthesis of peptidoglycan, which is a critical component of the bacterial cell wall. This leads to the interruption of cell wall synthesis, consequently leading to bacterial cell growth inhibition and cell lysis.","Penicillin V | PENICILLIN V | Phenoxymethylpenicillin | V-Cillin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0070455","Permethrin","C29354","A synthetic pyrethroid and neurotoxin. Permethrin affects the neuronal membrane by blocking the movement of sodium ions from outside to inside the neuronal cell membrane thereby disrupting the sodium channel current that regulates the polarization of the membrane. This leads to delayed repolarization and subsequent paralysis of the nervous system. Permethrin is used to eradicate parasites such as head lice, ticks and scabies from humans and animals.","Permethrin | (+/-)-3-Phenoxybenzyl 3-(2,2-Dichlorovinyl)-2,2-Dimethylcyclopropanecarboxylate | Cyclopropanecarboxylic Acid, 3-(2,2-Dichloroethenyl)-2,2-Dimethyl-, (3-Phenoxyphenyl)Methyl Ester | Elimite | M-Phenoxybenzyl (+/-)-3-(2,2-Dichlorovinyl)-2,2-Dimethylcyclopropanecarboxylate | Nix | PERMETHRIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700463","Piperacillin Sodium","C749","The sodium salt of piperacillin, a broad-spectrum semisynthetic, ampicillin-derived ureidopenicillin antibiotic with bactericidal activity. Piperacillin binds to and inactivates penicillin-binding proteins (PBPs), enzymes located on the inner membrane of the bacterial cell wall, resulting in the weakening of the bacterial cell wall and cell lysis. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity.","Piperacillin Sodium | CL 227, 193 | PIPERACILLIN SODIUM | Pipracil | Sodium (2S,5R,6R)-6-((R)-2-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate | T-1220",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034283","Pyrimethamine","C788","A synthetic derivative of ethyl-pyrimidine with potent antimalarial properties.  Pyrimethamine is a competitive inhibitor of dihydrofolate reductase (DHFR).  DHFR is a key enzyme in the redox cycle for production of tetrahydrofolate, a cofactor that is required for the synthesis of DNA and proteins.  This agent is often used in combination with other antimalarials for the treatment of uncomplicated falciparum malaria. (NCI04)","Pyrimethamine | Daraprim | PYRIMETHAMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035525","Ribavirin","C807","A synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses. Ribavirin is incorporated into viral RNA, thereby inhibiting viral RNA synthesis, inducing viral genome mutations, and inhibiting normal viral replication.","Ribavirin | 1-.beta.-D-Ribofuranosyl-1H-1,2, 4-triazole-3-carboxamide | 1-Beta-D-ribofuranosyl-1,2,4-triazolo-3-carboxamide | 1-Beta-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide | Copegus | ICN 1229 | ICN-1229 | RIBA | RIBAVIRIN | RTCA | Rebetol | Viramide | Virazid | Virazole | ribavirin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0140575","Rifabutin","C1408","A semisynthetic ansamycin antibiotic with potent antimycobacterial properties.  Rifabutin inhibits bacterial DNA-dependent RNA polymerase, thereby suppressing the initiation of RNA formation and leading to inhibition of RNA synthesis and transcription. (NCI04)","Rifabutin | LM-427 | Mycobutin | RIFABUTIN | rifabutin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035608","Rifampin","C811","A semisynthetic derivative of rifamycin with broad antibacterial activity. Rifampin inhibits DNA-dependent RNA polymerase in susceptible bacteria and is often used in combination with other antibiotics for various infections including tuberculosis.","Rifampin | L-5103 | RIFAMPIN | Rifadin | Rifampicin | Rimactane | rifampin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0292818","Ritonavir","C1609","A peptidomimetic agent that inhibits both HIV-1 and HIV-2 proteases. Ritonavir is highly inhibited by serum proteins but boosts the effect of other HIV proteases by blocking their degradation by cytochrome P450.","Ritonavir | Norvir | RIT | RITONAVIR | ritonavir",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0286738","Saquinavir","C29444","A peptidomimetic inhibitor of human immunodeficiency virus (HIV) protease.","Saquinavir | Fortovase | SAQUINAVIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038670","Sulfacetamide","C62077","A synthetic sulfanylacetamide derivative with bacteriostatic activity. Sulfacetamide inhibits bacterial folic acid synthesis by competing with para amino benzoic acid. With a broad spectrum of action, it is used as an anti-infective topical agent to treat skin infections and as an oral agent for urinary tract infections. (NCI04)","Sulfacetamide | SULFACETAMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038675","Sulfadiazine","C29468","A synthetic pyrimidinyl sulfonamide derivative, short-acting bacteriostatic Sulfadiazine inhibits bacterial folic acid synthesis by competing with para amino benzoic acid. It is used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections. (NCI04)","Sulfadiazine | SULFADIAZINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0384228","Tenofovir","C29490","A nucleoside reverse transcriptase inhibitor analog of adenosine.","Tenofovir | (((1R)-2-(6-Amino-9H-purin-9-yl)-1-methylethoxy)methyl)phosphonic Acid, Monohydrate | (R)-9-(2-Phosphonomethoxypropyl)adenine Hydrate | (R)-9-(Phosphonomethoxypropyl)adenine Hydrate | GS-1275 | GS-1278 | PMPA | Phosphonic Acid, ((2-(6-Amino-9H-purin-9-yl)-1-methylethoxy)methyl)-, Monohydrate, (R)- | TENOFOVIR | Tenofovir Hydrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0076110","Terbinafine","C48019","A synthetic allylamine derivative with antifungal activity. Terbinafine exerts its effect through inhibition of squalene epoxidase, thereby blocking the biosynthesis of ergosterol, an important component of fungal cell membranes. As a result, this agent disrupts fungal cell membrane synthesis and inhibits fungal growth.","Terbinafine | (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene Methanamine | SF 86-327 | TERBINAFINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039644","Tetracycline","C865","A broad-spectrum naphthacene antibiotic produced semisynthetically from chlortetracycline, an antibiotic isolated from the bacterium Streptomyces aureofaciens. In bacteria, tetracycline binds to the 30S ribosomal subunit, interferes with the binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis.","Tetracycline | 4-(Dimethylamino)-1,4,4A,5,5A,6,11,12A-Octahydro-3,6,10,12,12A-Pentahydroxy-6-Methyl-1,11-Dioxo-2-Naphthacenecarboxamide | TCN | TETRACYCLINE | tetracycline",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0546880","Ticarcillin Disodium","C65205","The disodium salt form of ticarcillin, a broad-spectrum, semi-synthetic penicillin antibiotic with bactericidal and beta-lactamase resistant activity. Similar to carbenicillin in action, ticarcillin inactivates the penicillin-sensitive transpeptidase C-terminal domain by opening the lactam ring. This inactivation prevents the cross-linkage of peptidoglycan strands, thereby inhibiting the third and last stage of bacterial cell wall synthesis. This leads to incomplete bacterial cell wall synthesis and eventually causes cell lysis.","Ticarcillin Disodium | TICARCILLIN DISODIUM | Timentin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040341","Tobramycin","C62082","An aminoglycoside antibiotic derived from Streptomyces tenebrarius with bacteriostatic activity. Following active transport into the cell, tobramycin binds irreversibly to a specific aminoglycoside receptor on the bacterial 30S ribosomal subunit and interferes with the initiation complex between messenger RNA and the 30S subunit, thereby inhibiting initiation of protein synthesis, consequently leading to bacterial cell death. In addition, tobramycin induces misreading of the mRNA template causing incorrect amino acids to be incorporated into the growing polypeptide chain, consequently interfering with protein elongation.","Tobramycin | TOBRAMYCIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042313","Vancomycin","C925","A branched tricyclic glycosylated peptide with bactericidal activity against most organisms and bacteriostatic effect on enterococci. At a site different from that of penicillins and cephalosporins, vancomycin binds tightly to the D-alanyl-D-alanine portion of cell wall precursors, thereby interfering with bacterial cell wall synthesis. This leads to activation of bacterial autolysins that destroy the cell wall by lysis. Vancomycin may also alter the permeability of bacterial cytoplasmic membranes and may selectively inhibit RNA synthesis.","Vancomycin | VANCOMYCIN | vancomycin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031834","Physician Office","C16988","A medical facility where a doctor sees and treats patients.","Physician Office | Doctor Office | Doctor's Office | Physician Offices",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014772","Erythrocyte Count","C51946","The determination of the number of erythrocytes in a biospecimen.","Erythrocyte Count | Erythrocytes | RBC | Red Blood Cell Count | Red Blood Cells | Red Cell Count",,,,,,,,,,,,,,,"4030871","Red blood cell count",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1555334","As Needed","C64499","As needed, usually referring to the timing of the administration of a treatment or medication.","As Needed | As Necessary | As Necessary | As Situation Arises | As needed | PRN | Pro Re Nata | pro re nata",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011276","Demeclocycline","C47980","A semi-synthetic, broad-spectrum naphthacene antibiotic produced by the bacterium Streptomyces aureofaciens. Demeclocycline binds to bacterial 30S ribosomal subunit and prevents binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis. Demeclocycline also inhibits the effect of vasopressin on the renal tubules, thereby causing diuresis.","Demeclocycline | 7-Chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamide | DEMECLOCYCLINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022322","Ivermectin","C61796","An orally bioavailable macrocyclic lactone derived from Streptomyces avermitilis, with antiparasitic and potential anti-viral activities. Upon administration, ivermectin exerts its anthelmintic effect through binding and activating glutamate-gated chloride channels (GluCls) expressed on nematode neurons and pharyngeal muscle cells. This causes increased permeability of chloride ions, causing a state of hyperpolarization and results in the paralysis and death of the parasite. Ivermectin may exerts its antiviral effect, including its potential activity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), by binding to the importin (IMP) alpha/beta1 heterodimer, which is responsible for the nuclear import of viral proteins such as the integrase (IN) protein. This inhibits nuclear import of host and viral proteins and may inhibit viral replication.","Ivermectin | Avermectin A1a, 5-O-demethyl-25-de(1-methylpropyl)-22,23-dihydro-25-(1-methylethyl)- | IVERMECTIN | Sklice | Stromectol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0250480","Piperacillin-Tazobactam","C1530","A combination formulation of the antibiotic piperacillin and the beta-lactamase inhibitor tazobactam with antibacterial activity. Piperacillin, a broad-spectrum, semisynthetic penicillin, binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall, thereby interfering with the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. As a result, the cell wall is weakened and the cell lyses. Tazobactam, a penicillanic acid sulfone derivative, irreversibly binds to and inhibits bacterial beta-lactamase at or near its active site, thereby preventing the destruction of the beta-lactamase susceptible piperacillin by this bacterial enzyme.","Piperacillin-Tazobactam | PIPER/TAZO | Piperacillin/Tazobactam | Zosyn | piperacillin-tazobactam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3552763","Pulmonary Embolism","C50713","The obstruction of the pulmonary artery or one of its branches by an embolus, sometimes associated with infarction of the lung.","Pulmonary Embolism | Pulmonary embolism",,,,,,,,,,,,,,,"440417","Pulmonary embolism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014653","Balance","C73497","The maintenance of a stable, upright body position.","Balance | ",,,,,,,,,,,,,,,"4097169","Balance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519598","Transduction Gene","C2178","A gene transferred via a vector to a target tissue for use in Gene Therapy.","Transduction Gene | Vector Mediated Transfer Genes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039902","Thioguanine","C876","A synthetic guanosine analogue antimetabolite. Phosphorylated by hypoxanthine-guanine phosphoribosyltransferase, thioguanine incorporates into DNA and RNA, resulting in inhibition of DNA and RNA syntheses and cell death. This agent also inhibits glutamine-5-phosphoribosylpyrophosphate amidotransferase, thereby inhibiting purine synthesis. (NCI04)","Thioguanine | 2-Amino 6MP | 2-Amino-1,7-dihydro-6H-purine-6-thione | 2-Amino-6-mercaptopurine | 2-Amino-6-purinethiol | 2-Aminopurin-6-thiol | 2-Aminopurine-6(1H)-thione | 2-Aminopurine-6-thiol | 2-Aminopurine-6-thiol Hemihydrate | 2-Mercapto-6-aminopurine | 6 Mercaptoguanine | 6 Thioguanine | 6-Amino-2-mercaptopurine | 6-Mercapto-2-aminopurine | 6-Mercaptoguanine | 6-TG | 6-Thioguanine | 6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI) | BW 5071 | Lanvis | THIOGUANINE | Tabloid | Thioguanine Hemihydrate | Thioguanine Hydrate | Tioguanin | Tioguanine | WR-1141 | Wellcome U3B | X 27 | thioguanine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0886549","Topotecan Hydrochloride","C2828","The hydrochloride salt of a semisynthetic derivative of camptothecin with antineoplastic activity. During the S phase of the cell cycle, topotecan selectively stabilizes topoisomerase I-DNA covalent complexes, inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when complexes are encountered by the DNA replication machinery. Camptothecin is a cytotoxic quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.","Topotecan Hydrochloride | (S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7] indolizino[1,2-b] quinoline-3,14-(4H,12H)-dione Monohydrochloride | Evotopin | Hycamptamine | Hycamtin | Nogitecan Hydrochloride | Potactasol | SKF S 104864 A | SKF S-104864-A | SKF S104864A | TOPOTECAN HYDROCHLORIDE | Topotec | Topotecan HCl | Topotecan hydrochloride | topotecan hydrochloride | topotecan hydrochloride (oral)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0108773","T-Cell Surface Antigen CD2","C15174","T-cell surface antigen CD2 (351 aa, ~39 kDa) is encoded by the human CD2 gene. This protein plays a role in both T-cell activation and T-cell adhesion to other cells.","T-Cell Surface Antigen CD2 | CD2 | CD2 Antigen | CD2 Antigen | CD2R | E-Rosette Receptor | Erythrocyte Receptor | LFA-2 | LFA-3 Receptor | Lymphocyte-Function Antigen-2 | Rosette Receptor | Sheep Erythrocyte Receptor | Sheep Red Blood Cell Receptor | T-Cell Surface Antigen T11/Leu-5 | T-Lymphocyte Surface CD2 Antigen",,,,,,,,,,,,,,,"4077444","Lymphocyte antigen CD2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028081","Night Sweats","C3279","Perspiration experienced nocturnally that is unrelated to environmental temperature.","Night Sweats | NIGHT_SWEATS | Night Sweating",,,,,,,,,,,,,,,"4181178","Night sweats",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028215","Nitrous Oxide","C73617","A naturally occurring gas that is colorless and non flammable. It can be manufactured and used for a variety of things such as a pharmacologic agent to produce anesthesia, a food additive as a propellant, and an additive to fuels to increase available oxygen in combustion.","Nitrous Oxide | Dinitrogen Monoxide | NITROUS OXIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347662","Pre-existing","C73621","Having been present before a specific date or event.","Pre-existing | Pre-exist | Preexist | Preexisting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3809496","Attention Deficit Hyperactivity Disorder, Inattentive Type","C35092","A mental disorder characterized by inattention, easy distraction, careless mistakes and avoidance of tasks that require sustained mental focus. These behaviors can lead to maladaptive consequences in the affected individual's life.","Attention Deficit Hyperactivity Disorder, Inattentive Type | ADD | Attention Deficit Disorder | Attention Deficit Disorder | Attention Deficit Hyperactivity Disorder, Inattentive/Distractible Type | Attention Deficit Hyperactivity Disorder, Predominantly Inattentive Type",,,,,,,,,,,,,,,"4049391|4149353","Undifferentiated attention deficit disorder|Attention deficit hyperactivity disorder, predominantly inattentive type",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0005586","Bipolar Disorder","C34423","A disorder of the brain that causes unusual shifts in mood, energy, activity levels and the ability to carry out day-to-day tasks. Often these moods range and shift from periods of elation and energized behavior to those of hopelessness and depression.","Bipolar Disorder | Bipolar disorder, unspecified | Manic Depressive Disorder | Manic-Depression",,,,,,,,,,,,,,,"436665","Bipolar disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085247","T-Cell Receptor Alpha-Beta","C17433","A heterodimeric complex comprised of the highly variable T-cell receptor (TCR) alpha and beta chain proteins, which are linked by interchain disulfide bonds. This membrane bound complex is expressed on the surface of most T-lymphocytes and is involved in the recognition of peptide antigens that are presented by major histocompatibility (MHC) proteins.  The alpha/beta dimer is non-covalently associated with the CD3 complex, which promotes ligand-dependent signaling.","T-Cell Receptor Alpha-Beta | Alpha-Beta TCR | Alpha-Beta-TCR | Alpha/Beta TCR | T-Cell Receptor Alpha Beta | T-Cell Receptor Alpha/Beta | T-Cell Receptor, Alpha-Beta | T-Cell Receptor, Alpha-Beta | TCR Alpha-Beta | TCR Alpha/Beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085379","Muromonab-CD3","C1321","A murine IgG2a monoclonal antibody with immunosuppressive activity. Muromonab-CD3 binds to and inhibits CD3 on the surface of circulating T-lymphocytes; binding of muromonab-CD3 to CD3-positive T cells results in an early activation of this T cell subset, followed by cytokine release, and subsequently inhibition of T cell functions. This agent may cause the opsonization and elimination of CD3-positive T cells from the circulation by mononuclear phagocytes in the liver and spleen. CD3 is part of the functional T cell receptor (TCR) complex, which is necessary for antigen recognition by T cells, and is required for signal transduction.","Muromonab-CD3 | Anti-CD3 Monoclonal Antibody OKT3 | MUROMONAB-CD3 | MoAb OKT3 | Monoclonal Antibody OKT3 | Orthoclone OKT3 | muromonab-CD3 monoclonal antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
,,"C38935","T-cell antigen CD7 (240 aa, ~25 kDa) is encoded by the human CD7 gene. This protein plays a role in the development and function of lymphoid cells.","T-Cell Antigen CD7 | CD7 | CD7 Antigen | GP40 | Leu-9 | T-Cell Leukemia Antigen | TP41",,,,,,,,,,,,,,,"4285724","Lymphocyte antigen CD7",,,,,,,,,,,,,,,,,,,,,,"--"
"C0031507","Phenytoin","C741","A hydantoin derivative and a non-sedative antiepileptic agent with anticonvulsant activity. Phenytoin potentially acts by promoting sodium efflux from neurons located in the motor cortex reducing post-tetanic potentiation at synapses. The reduction of potentiation prevents cortical seizure foci spreading to adjacent areas, stabilizing the threshold against hyperexcitability. In addition, this agent appears to reduce sensitivity of muscle spindles to stretch causing muscle relaxation.","Phenytoin | 5,5-Diphenyl-2,4-imidazolidinedione | Diphenylhydantoin | PHENYTOIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042291","Valproic Acid","C29536","A synthetic derivative of propylpentanoic acid with antiepileptic properties and potential antineoplastic and antiangiogenesis activities.  In epilepsy, valproic acid appears to act by increasing the concentration of gamma-aminobutyric acid (GABA) in the brain. This agent's antitumor and antiangiogenesis activities may be related to the inhibition of histone deacetylases and nitric oxide synthase, which results in the inhibition of nitric oxide synthesis. (NCI04)","Valproic Acid | 2-Propylpentanoic Acid | 2-Propylvaleric Acid | Depakene | Di-n-propylacetic Acid | Stavzor | VALPROIC ACID | Valproate | valproic acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031412","Phenobarbital","C739","A long-acting barbituric acid derivative with antipsychotic property. Phenobarbital binds to and activates the gamma-aminobutyric acid (GABA)-A receptor, thereby mimicking the inhibitory actions of GABA in the brain.  The activation effects of the phenobarbital-receptor-ionophore complex include increased frequency of chloride channel openings, membrane hyperpolarization and ultimately synaptic inhibition and decreased neuronal excitability. In addition, this agent inhibits glutamate induced depolarization.","Phenobarbital | 5-Ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione | PHENO | PHENOBARBITAL | phenobarbital",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033231","Prochlorperazine Maleate","C775","The maleate salt form of prochlorperazine, a synthetic, piperazine phenothiazine derivative with antiemetic, antipsychotic, antihistaminic, and anticholinergic activities. Prochlorperazine binds to and blocks the postsynaptic dopamine D2-receptor in the chemoreceptor trigger zone (CTZ) of the brain and may prevent chemotherapy-induced emesis. Prochlorperazine maleate also blocks anticholinergic and alpha-adrenergic receptors. Its antagonistic actions on the alpha-1 adrenergic receptors results in sedation, muscle relaxation, and hypotension.","Prochlorperazine Maleate | Compazine | PROCHLORPERAZINE MALEATE | Prochlorperazine Dimaleate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0061863","Granisetron","C62031","An indazole derivative with antiemetic properties. As a selective serotonin receptor antagonist, granisetron competitively blocks the action of serotonin at 5-hydroxytryptamine3 (5-HT3) receptors, resulting in the suppression of chemotherapy- and radiotherapy-induced nausea and vomiting.","Granisetron | 1-Methyl-N-(9-methyl-endo-9-azabicyclo(3.3.1)non-3-yl)-1H-indazole-3-carboxamide | GRANISETRON | granisetron",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0061851","Ondansetron","C1119","A carbazole derivative with antiemetic activity.  As a selective serotonin receptor antagonist, ondansetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting. (NCI04)","Ondansetron | ONDANSETRON | Zofran ODT | Zuplenz | ondansetron",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342579","Electrolyte Imbalance","C50545","Higher or lower than normal values for the serum electrolytes; usually affecting NA, K, CHL, CO2, glucose, bun.","Electrolyte Imbalance | ",,,,,,,,,,,,,,,"4022093","Electrolyte imbalance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4229251","Gastroesophageal Reflux Disease","C26781","A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa.","Gastroesophageal Reflux Disease | GERD | Gastroesophageal reflux disease | Reflux Disease",,,,,,,,,,,,,,,"318800","Gastroesophageal reflux disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018099","Gout","C34650","A condition characterized by painful swelling of the joints, which is caused by deposition of urate crystals.","Gout | gout",,,,,,,,,,,,,,,"440674","Gout",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL473753","Granulocytopenia","C2863","A decrease in the number of mature granulocytes (neutrophils, eosinophils, and basophils) in the peripheral blood.","Granulocytopenia | granulocytopenia",,,,,,,,,,,,,,,"4218497","Granulocytopenic disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706318","Magnet Device","C50040","A device that attracts iron and produces a magnetic field.","Magnet Device | Magnet | Magnet | Magnet Device Component",,,,,,,,,,,,,,,"4195155","Magnet",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021400","Influenza","C53482","An acute viral infection of the respiratory tract, occurring in isolated cases, in epidemics, or in pandemics; it is caused by serologically different strains of viruses (influenzaviruses) designated A, B, and C, has a 3-day incubation period, and usually lasts for 3 to 10 days. It is marked by inflammation of the nasal mucosa, pharynx, and conjunctiva; headache; myalgia; often fever, chills, and prostration; and occasionally involvement of the myocardium or central nervous system.","Influenza | Flu",,,,,,,,,,,,,,,"4266367","Influenza",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0549410","Palmar-Plantar Erythrodysthesia","C27177","A condition characterized by redness, pain, swelling, and tingling in the palms of the hands or the soles of the feet. It may appear as a side effect to chemotherapy agents.","Palmar-Plantar Erythrodysthesia | Hand-Foot Syndrome | Palmar-Plantar Erythodysthesia | Palmar-plantar erythrodysesthesia syndrome | hand-foot syndrome | palmar-plantar erythrodysthesia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0289523","Campath-1G","C72925","A rat IgG2b monoclonal antibody directed against the cell surface glycoprotein CD52. It is used in hematopoietic stem cell transplantation to prevent graft vs host disease by eliminating T cells via antibody dependent cell cytotoxicity in vivo.","Campath-1G | Rat IgG2b Monoclonal Antibody CD52",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705910","Possibly Related to Intervention","C53258","A characteristic indicating that an adverse event may be related to the medical intervention. According to WHO causality assessment criteria of suspected adverse reactions it is applicable to a clinical event, including laboratory test abnormality, with a reasonable time sequence to administration of the drug, but which could also be explained by concurrent disease or other drugs or chemicals. Information on drug withdrawal may be lacking or unclear.","Adverse Event Possibly Related to Intervention | Possible | Possible Attribution | Possibly | Possibly Related | Possibly Related to Intervention | Possibly Related to Intervention",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596973","Monomer","C63845","A chemical subunit that can undergo polymerization by bonding to other subunits.","Monomer | Monomer Liquid | monomer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347862","Continuous Phase","C73479","The substance in an emulsion that usually makes up the largest portion of the emulsion and contains another substance suspended within.","Continuous Phase | Bulk Phase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348302","Dispersed Phase","C73480","The substance in an emulsion that is suspended or dispersed within another substance of greater volume.","Dispersed Phase | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014018","EMULSIFIERS","C73477","A chemical substance that functions to stabilize an emulsion.","Emulsifying Excipient | Emulgent | Emulsifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347445","Parallelogram","C73491","A quadrilateral whose opposite sides are both parallel and equal in length.","Parallelogram | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347622","Polygon","C73492","A closed plane figure bounded by straight sides.","Polygon | Polygonal Shape",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348964","Hexahedron","C73494","Any polyhedron having six plane faces.","Hexahedron | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2336985","Polyhedron","C73493","A solid figure bounded by plane polygons or faces.","Polyhedron | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4082798","Prolate","C73498","A spherical shape that has a polar diameter that is longer than its equatorial diameter.","Prolate | Prolate Spheroid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348972","Meddra High Level Term","C71880","A superordinate descriptor for one or more MedDRA preferred terms (PTs). It is subordinate to high level group term (HLGT).","MedDRA High Level Term | HLT | High Level Term | Meddra High Level Term",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348986","Hoechst Adverse Reaction Terminology System","C71884","A terminology for coding of adverse reactions, developed by Hoechst in 1991.","Hoechst Adverse Reaction Terminology System | HARTS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1137110","International Classification of Diseases, Tenth Revision","C71892","The tenth version of the International Classification of Diseases (ICD), published by the World Health Organization in 1992.","International Classification of Diseases, Tenth Revision | ICD-10 | ICD10 | International Classification of Disease, Tenth Revision | icd 10 | icd_10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1137112","International Classification of Diseases, Ninth Revision, Clinical Modification","C71891","An extension of the ICD-9 created by the U.S. National Center for Health Statistics so that the system could be used to capture more morbidity data. This extension included a section of procedure codes.","International Classification of Diseases, Ninth Revision, Clinical Modification | ICD-9-CM | ICD9-CM | International Classification of Disease, Ninth Revision, Clinical Modification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1137111","International Classification of Diseases, Ninth Revision","C71890","The ninth version of the International Classification of Diseases (ICD), published by the World Health Organization in 1977.","International Classification of Diseases, Ninth Revision | ICD-9 | ICD9 | International Classification of Disease, Ninth Revision",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346598","Japanese Adverse Reaction Terminology","C71885","An adverse reaction terminology created in Japan, based on the World Health Organization's Adverse Reaction Terminology.","Japanese Adverse Reaction Terminology | J-ART | JART",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347090","MedDRA Low Level Term","C71886","Lowest level of the MedDRA terminology, related to a single PT as a synonym, lexical variant, or quasi-synonym.","MedDRA Lowest Level Term | LLT | Low Level Term | Lowest Level Term | MedDRA Low Level Term | Meddra Low Level Term",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347664","Preferred Term","C71887","A descriptive word or phrase selected as an authorized descriptor to represent a discrete concept.","Preferred Term | PT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347091","MedDRA System Organ Class","C71888","Highest level of the MedDRA terminology, and distinguished by anatomical or physiological system, etiology, or purpose.","MedDRA System Organ Class | Meddra System Organ Class | SOC | System Organ Class",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347089","MedDRA High Level Group Term","C71889","A superordinate descriptor for one or more MedDRA high level terms (HLT). It is subordinate to System Organ Class (SOC).","MedDRA High Level Group Term | HLGT | High Level Group Term | Meddra High Level Group Term",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551342","Document Body","C71893","The central message of a communication.","Document Body | Body",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553421","Sender","C71895","Somebody or something that sends or transmits something.","Sender | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348993","Hospitalization or Prolongation of Existing Hospitalization Required","C68605","An indication or description that an extended period of hospitalization is necessary.","Hospitalization or Prolongation of Existing Hospitalization Required | Inpatient Hospitalization or Prolongation of Existing Hospitalization Required | SHOSP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348483","Expedited Report","C68624","A report or observation of one or more adverse events that must be submitted within a specified amount of time due to the severity of one or more of the events.","Expedited Report | Expedited | Expedited Adverse Event Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0560559","Radiation Dose Unit","C18068","A unit of measurement of the dose of radiation received or absorbed.","Radiation Dose Unit | RT_UNIT | Radiation | Radiation Dose Units",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009818","Consultation","C41188","A conference between two or more people to consider a particular question; the act of deliberating together; confering with another researcher, physician, or expert about an issue or a case.","Consultation | Consult",,,,,,,,,,,,,,,"4014829","Consultation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016262","Flowchart","C71897","A diagram that shows step-by-step progression through a procedure or system especially using connecting lines and a set of conventional symbols.","Flowchart | flow chart | flow sheet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0592503","Proprietary Name","C71898","The part of the name or logo associated with a specific product or service identifying and distinguishing it from varieties of the same product or service marketed by competing companies.","Proprietary Name | Brand | Brand Name | Brand Name | TRADENAM | Trade Name | brand name | proprietary name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376658","Catalogs","C71899","A list of goods or services on sale with their description and prices published as a printed document, or as an electronic document.","Catalog | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449497","Type of Device","C53265","Generic category of medical device within the device classification established by FDA. It is used as part of regulatory product submission standard.","Type of Device | DEVTYPE | Device Type | TYPE OF DEVICE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709913","Reprocessor","C53614","Manufacturer of reprocessed single use devices.","Reprocessor | REPROCESSOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL415200","Return","C71900","To give something back, or the getting back thereof.","Return | Returned",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705168","Trapezoid","C48352","A four-sided polygon with only two parallel sides.","Trapezoid | TRAPEZOID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205120","Square Shape","C48350","A plane rectangle with four equal sides and four right angles; a four-sided regular polygon.","Square Shape | SQUARE | Square",,,,,,,,,,,,,,,"4209897","Square",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205142","Rectangle","C48347","A parallelogram with four right angles. A square is a special rectangle with four equal sides.","Rectangle | RECTANGLE",,,,,,,,,,,,,,,"4244423","Rectangular",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706341","Diamond SPL Shape","C48338","The shape has four distinct sides making a parallelogram with two inner obtuse angles and two inner acute angles.","Diamond | DIAMOND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348299","Disc Shape","C73648","A flat circular plate or anything with a similar shape.","Disk Shape | Disc | Disc Shape | Disk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205103","Intermediate","C73705","Lying between two extremes in time or space or degree.","Intermediate | INTERMEDIATE | Intermediate/Normal",,,,,,,,,,,,,,,"4043352","Intermediate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205315","Oblique","C73707","Slanting or inclined in direction or course or position; neither parallel nor perpendicular nor right-angular.","Oblique | ",,,,,,,,,,,,,,,"4052373","Oblique",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0065506","Mafosfamide","C1150","A synthetic oxazaphosphorine derivative with antineoplastic properties.  Mafosfamide alkylates DNA, forming DNA cross-links and inhibiting DNA synthesis.  Although closely related to cyclophosphamide, mafosfamide, unlike cyclophosphamide, does not require hepatic activation to generate its active metabolite 4-hydroxy-cyclophosphamide; accordingly, mafosfamide is potentially useful in the intrathecal treatment of neoplastic meningitis. (NCI04)","Mafosfamide | MAFOSFAMIDE | mafosfamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0163054","Perfosfamide","C1423","The active metabolite of the nitrogen mustard cyclophosphamide with potent antineoplastic and immunosuppressive properties. Perfosfamide alkylates DNA, thereby inhibiting DNA replication and RNA and protein synthesis. (NCI04)","Perfosfamide | 2-[bis(2-chloroethyl)amino]-4-hydroperoxytetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide | 4'-Hydroperoxycyclophosphamide | 4-HC | 4-Hydroperoxycyclophosphamide | 4-Pergamid | Hydroperoxycyclophosphamide | PERFOSFAMIDE | Pergamid | cis-2-[bis(2-chloroethyl)amino]tetrahydro-3H-1,3,2-oxazaphosphorin-4-yl hydroperoxide P-oxide | cis-4-hydroperoxycyclophosphamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448933","Reposition","C73790","The act of placing in a new position.","Reposition | Repositioned | Repositioning",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705946","Coil","C49877","A structure consisting of something wound in a continuous series of loops.","Coil Device | Coil | Coil | Coil Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4230872","Gliosis","C26783","Reactive astrocytic proliferation associated with fibrous tissue formation, secondary to damage (trauma or ischemia) to the central nervous system.","Gliosis | Astrogliosis | GLIOSIS",,,,,,,,,,,,,,,"4217949","Gliosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0225336","Endothelial Cell","C12865","The main type of cell forming the lining of blood and lymph vessels and the inner layer of the endocardium.","Endothelial Cell | Endothelial Cells | Endotheliocyte | endothelial cell",,,,,,,,,,,,,,,"4165055","Endothelial cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3666529","Transmitter","C50231","A device to propagate electromagnetic waves.","Transmitter Device | Transmitter | Transmitter | Transmitter Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515265","Temporal Qualifier","C21514","Terms used to indicate units of time or other terms associated with time.","Temporal Qualifier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348699","Font","C71594","A specific size and style of type within a type family.","Font | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0489654","Style","C71598","A particular kind (as to appearance).","Style | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346608","Justification of text","C71595","The arrangement of text so that it is aligned with either the left or right margin, or both.","Justification | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL415197","Opacity","C71596","The quality of being opaque to a degree; the degree to which something reduces the passage of light.","Opacity | OPACITY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448916","Line","C71604","A mark that is long relative to its width; a length (straight or curved) without breadth or thickness; the trace of a moving point.","Line | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521164","Ring","C61458","Doughnut-shaped object or surface generated by rotating a circle around an axis that does not intersect the circle; any object that resembles a ring.","Ring | Annular",,,,,,,,,,,,,,,"4010091","Annular shape",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2349978","Mathematical Markup Language","C71609","An application of XML for describing mathematical notations and capturing both its structure and content. It aims at integrating mathematical formulae into World Wide Web documents.","Mathematical Markup Language | MathML | MzXML",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551055","Tesla - unit","C42557","A SI unit of magnetic flux density equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.","Tesla | MRI field strength (T) | T | tesla",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3241971","Digit - number character","C73791","A single character in a numbering system.","Numerical Digit | Digit | Digit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348681","Flip Angle","C73792","In magnetic resonance imaging, the rotation of the average axis of the protons, relative to the main magnetic field direction, induced by radiofrequency signals.","Flip Angle | FLIPANGL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0522488","Transverse Plane","C73849","A horizontal surface or plane perpendicular to a vertical axis.","Transverse Plane | Horizontal Plane | Transverse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0311392","Sign","C53458","Objective evidence of disease perceptible to the examining healthcare provider.","Sign | sign",,,,,,,,,,,,,,,"4217210","Sign",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709350","Osseous Component Present","C54171","A morphologic finding indicating the presence of bone elements in a tissue sample.","Osseous Component Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020502","Hyperparathyroidism","C48259","Hyperfunction of the parathyroid glands resulting in the overproduction of parathyroid hormone. It may be primary or secondary; primary hyperparathyroidism is caused by parathyroid adenoma, parathyroid hyperplasia, parathyroid carcinoma, and multiple endocrine neoplasia. It is associated with hypercalcemia and hypophosphatemia. Signs and symptoms include weakness, fatigue, nausea, vomiting, constipation, depression, bone pain, osteoporosis, cystic bone lesions, and kidney stones. Secondary hyperparathyroidism is caused by the chronic stimulation of the parathyroid glands in patients with chronic renal failure, rickets, and malabsorption syndromes.","Hyperparathyroidism | hyperparathyroidism",,,,,,,,,,,,,,,"133729","Hyperparathyroidism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0344106","Sedation","C21097","The process of allaying nervous excitement or the state of being calmed. (Taber's)","Sedation | ",,,,,,,,,,,,,,,"4219502","Sedation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022951","Lactose Intolerance","C3154","Inability to fully digest and absorb lactose due to limited or no lactase activity in the small intestine.  Congenital intolerance is inherited following an autosomal recessive pattern but is rare. It is more often due to a gradual decline of lactase production in adulthood following the ingestion of fewer lactose-containing foods or secondary to an intestinal mucosal brush-border injury. Prevalence is highest among Asians, Native Americans and Africans. Clinical signs include abdominal cramping, bloating, flatulence and diarrhea following the dietary intake of lactose.","Lactose Intolerance | lactose intolerance",,,,,,,,,,,,,,,"36674577|45763650","Intolerance to lactose|Intolerance to milk",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0037763","Muscle Spasm","C50656","A sudden, violent, involuntary contraction of a muscle or group of muscles.","Muscle Spasm | spasm",,,,,,,,,,,,,,,"140821","Spasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030567","Parkinson Disease","C26845","A progressive degenerative disorder of the central nervous system characterized by loss of dopamine producing neurons in the substantia nigra and the presence of Lewy bodies in the substantia nigra and locus coeruleus. Signs and symptoms include tremor which is most pronounced during rest, muscle rigidity, slowing of the voluntary movements, a tendency to fall back, and a mask-like facial expression.","Parkinson Disease | Parkinson Disease | Parkinson's Disease | Parkinson's Disease | Parkinson's disease",,,,,,,,,,,,,,,"381270","Parkinson's disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347947","Reliability (characteristic)","C73622","The extent to which an event or measurement is repeatable, or a process executes as expected.","Reliability | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349101","Validity (characteristic)","C73623","The presence of truth ascribed to a situation or result.","Validity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880174","Contact Information","C60776","Information regarding the means of contacting a person or group.","Contact Information | Contact Info",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698977","Capability","C74979","Having the ability, power or qualities to be able to do something.","Capability | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448924","Share","C73624","Use or hold jointly or in common.","Share | Sharing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0391978","Bone Tissue","C13076","The mineralized osseous tissue that gives rigidity to the bones and forms its honeycomb-like three-dimensional internal structure.","Bone Tissue | Human Bone | Osseous | Osseous Tissue",,,,,,,,,,,,,,,"4151146","Bone (tissue) structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706735","Adverse Event Attribution Category","C53255","A characteristic used to qualify the determination of whether an adverse event is related to medical product or procedure.","Adverse Event Attribution Category | AE_ATTRIBUTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346731","Amended By","C73460","Indicates the person or authoritative body who made an amendment.","Amended By | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517942","Long-term Follow-up","C16032","Follow-up activities that continue beyond the active intervention period.","Long-term Follow-up | LONG-TERM FOLLOW-UP | LTFU | Longterm Follow-up | long term follow-up (clinical study)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003392","Antineoplastic Agent","C274","A substance that inhibits the maturation, growth or spread of tumor cells.","Antineoplastic Agent | ANTINEOPLASTIC_AGENT | Anti-Cancer Agents | Anti-Tumor Agents | Anti-Tumor Drugs | Antineoplastic Drug | Antineoplastic Drugs | Antineoplastics | Antiproliferative Agents | Antiproliferative Drugs | Cancer Drug | Chemotherapeutic Agents, Neoplastic Disease | Tumor-Specific Treatment Agents | antineoplastic | chemotherapeutic agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443211","Established","C71155","Shown to be valid beyond a reasonable doubt.","Established | ",,,,,,,,,,,,,,,"4135515","Established",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2349181","Completed By (qualifier)","C73470","Indicates the person or authoritative body who made completed something.","Completed By | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014537","Epidural Spinal Canal Space","C41449","Space between the dura mater and the walls of the vertebral canal.","Epidural Spinal Canal Space | EPIDURAL SPACE | Epidural | Epidural Space | cavum epidurale | cavum extradurale | epidural | epidural space | extradural space | spatium epidurale | spatium extradurale",,,,,,,,,,,,,"UBERON:0003691","epidural space","4148761","Structure of epidural space",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0929176","Hilum","C73467","A depression or fissure where vessels or nerves or ducts enter a bodily organ.","Hilum | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512910","Intra-abdominal","C12492","Within the abdomen.","Intra-abdominal | Intra-Abdominal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0459892","Waldeyer Ring","C73468","The ring of lymphoid tissue located in the pharynx, consisting of the pharyngeal, tubal, palatine, and lingual tonsils.","Waldeyer Ring | WALDEYER'S TONSILLAR RING | Waldeyer Tonsillar Ring | Waldeyer ring | Waldeyer's Ring | Waldeyer's Tonsillar Ring | Waldeyer's Tonsillar Ring",,,,,,,,,,,,,,,"4076031","Structure of pharyngeal lymphoid ring",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0546861","Doxorubicin Hydrochloride","C1326","The hydrochloride salt of doxorubicin, an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","Doxorubicin Hydrochloride | 14-Hydroxydaunorubicin Hydrochloride | 3-Hydroxyacetyldaunorubicin Hydrochloride | 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI) | 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-,hydrochloride, (8S-cis)-(9CI) | ADM | ADRIAMYCIN, HYDROCHLORIDE | Adriacin | Adriamycin | Adriamycin Hydrochloride | Adriamycin PFS | Adriamycin RDF | Adriamycin hydrochloride | Adriamycine | Adriblastina | Adriblastine | Adrimedac | Chloridrato de Doxorrubicina | DOX | DOXO-CELL | DOXORUBICIN HYDROCHLORIDE | Doxolem | Doxorubicin HCl | Doxorubicin hydrochloride | Doxorubicin.HCl | Doxorubin | FI 106 | FI-106 | FI106 | Farmiblastina | L-Lyxo-hexopyranoside, 3b-glycol-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-alpha-, hydrochloride | Rubex | doxorubicin hydrochloride | hydroxydaunorubicin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010927","Dacarbazine","C411","A triazene derivative with antineoplastic activity. Dacarbazine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. (NCI04)","Dacarbazine | 1H-imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazenyl)- | 4-(Dimethyltriazeno)imidazole-5-carboxamide | 5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide | 5-(3-3-dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide | 5-(Dimethyltriazeno)imidazole-4-carboxamide | 5-(dimethyltriazeno)imidazole-4-carboxamide | Asercit | Biocarbazine | DACARBAZINE | DIC | DTIC | DTIC-Dome | Dacarbazina | Dacarbazina Almirall | Dacarbazine - DTIC | Dacatic | Dakarbazin | Deticene | Detimedac | Dimethyl (triazeno) imidazolecarboxamide | Dimethyl Triazeno Imidazol Carboxamide | Dimethyl Triazeno Imidazole Carboxamide | Dimethyl-triazeno-imidazole-carboximide | Fauldetic | Imidazole Carboxamide | Imidazole Carboxamide Dimethyltriazeno | Imidazole carboxamide | WR-139007 | dacarbazine | dimethyl-triazeno-imidazole carboxamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025033","Mechlorethamine","C62056","A synthetic agent related to sulphur mustard with antineoplastic and immunosuppressive properties. Nitrogen mustard (a member of a family of chemotherapy agents including cyclophosphamide and chlorambucil) is an irritant and carcinogenic agent metabolized to a highly reactive ethylene immonium derivative; the ethylene immonium derivative alkylates DNA and inhibits DNA replication. This agent also exhibits lympholytic properties. (NCI04)","Mechlorethamine | Bis(2-chloroethyl)methylamine | Chlorethazine | Chlormethine | HN 2 | HN2 | MECHLORETHAMINE | Methylbis(beta-chloroethyl)amine | Mustard | Mustine | NITROGEN MUSTARD HN-2 | Nitrogen Mustard | chlorethazine | chloromethine | ethanamine,2-chloro-N-(2-chloroethyl)-N-methyl | methylchlorethamine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033223","Procarbazine","C62072","A methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.","Procarbazine | Benzethyzin | Ibenzmethyzin | N-(1-methylethyl)-4-[(2-methylhydrazino)methyl]benzamide | N-4-isopropylcarbamoylbenzyl-N'-methylhydrazine | N-Methylhydrazine | N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide | PROCARBAZINE | Procarbazin | p-(N'-methylhydrazinomethyl)-N-isopropylbenzamide | procarbazine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042670","Vinblastine","C930","A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","Vinblastine | VINBLASTINE | VLB | Vincaleucoblastine | vinblastine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042679","Vincristine","C933","A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","Vincristine | 22-Oxovincaleukoblastine | LCR | LEUROCRISTINE | Leurocristine | VCR | VINCRISTINE | Vincrystine | vincristine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201850","Alkaline Phosphatase Measurement","C64432","A quantitative measurement of alkaline phosphatase present in a sample.","Alkaline Phosphatase Measurement | ALP | Alkaline Phophatase | Alkaline Phosphatase",,,,,,,,,,,,,,,"4230636","Alkaline phosphatase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0201975","Creatinine Measurement","C64547","A quantitative measurement of the amount of creatinine present in a sample.","Creatinine Measurement | CREAT | Cr | Creatinine | Creatinine Level",,,,,,,,,,,,,,,"4324383","Creatinine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0201682","Chemistry Test","C49237","A laboratory test designed for the quantification of an organic or inorganic chemical within a biological specimen.","Chemistry Test | Chemistry Measurement | Chemistry Procedure | Chemistry Technique",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0200627","Hematology Test","C49286","A laboratory test to measure hematopoietic components and investigate hematologic disorders in a blood sample.","Hematology Test | Blood Test | Hematology Procedure",,,,,,,,,,,,,,,"4141733","Hematology procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348077","Date Fruit","C72063","The sweet edible fruit of the date palm with a single long woody seed.","Date Fruit | DATE | Date | Date",,,,,,,,,,,,,,,"4026205","Date",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0518015","Hemoglobin Measurement","C64848","A quantitative measurement of the amount of hemoglobin present in a biospecimen.","Hemoglobin Measurement | HGB | Hemoglobin | Hemoglobin Monomer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201899","Aspartate Aminotransferase Measurement","C64467","A quantitative measurement of aspartate aminotransferase present in a sample.","Aspartate Aminotransferase Measurement | AST | Aspartate Aminotransferase | SGOT",,,,,,,,,,,,,,,"4263457","Aspartate aminotransferase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0201836","Alanine Aminotransferase Measurement","C64433","A quantitative measurement of alanine aminotransferase present in a sample.","Alanine Aminotransferase Measurement | ALT | Alanine Aminotransferase | Alanine aminotransferase | SGPT",,,,,,,,,,,,,,,"4146380","Alanine aminotransferase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023508","Leukocyte Count","C51948","A test to determine the number of leukocytes in a biospecimen.","Leukocyte Count | Leukocytes | WBC | White Blood Cell Count | White Blood Cells | White Cell Count",,,,,,,,,,,,,,,"4097906|4298431","White blood cell test|White blood cell count",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2349977","On Study","C73469","Actively participating in a study.","On Study | On-Protocol | On-Study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202113","Lactate Dehydrogenase Measurement","C64855","A quantitative measurement of the amount of lactate dehydrogenase present in a sample.","Lactate Dehydrogenase Measurement | LDH | LDH Measurement | Lactate Dehydrogenase",,,,,,,,,,,,,,,"4012918","Lactate dehydrogenase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0240318","Mediastinal Mass","C35295","A mass present in the mediastinal space.","Mediastinal Mass | ",,,,,,,,,,,,,,,"4312034","Mediastinal mass",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1510411","metaplastic cell transformation","C17212","The conversion of a cell from a normal phenotype, which undergoes a limited number of mitotic divisions, into an aberrant phenotype that is immortal and divides indefinitely. Transformed cells no longer retain cell-cycle checkpoints and may ultimately become malignant cancer cells via additional genetic mutations, or damaging environmental events.","Transformation | Cell Transformation | Cellular Transformation | Transformed | Transforming | transformation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773625","Musculoskeletal System","C12754","The system of muscles, tendons, ligaments, bones, joints and associated tissues that move the body and maintain its form.","Musculoskeletal System | MUSCULOSKELETAL SYSTEM | Musculoskeletal",,,,,,,,,,,,,,,"4095277","Structure of musculoskeletal system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348195","Serum HCG Measurement","C73495","A quantitative measurement of the amount of human chorionic gonadotropin present in a sample of serum.","Serum HCG Measurement | Serum Human Chorionic Gonadotropin Measurement | Serum Pregnancy Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348943","Healthcare Payment Method","C70680","Methodology used to compensate a healthcare provider for care provided to a patient.","Healthcare Payment Method | Health Care Payment Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347682","Private Health Insurance","C70696","Financial coverage provided through third party reimbursement, that is designed to minimize monetary loss associated with health care costs.","Private Health Insurance | Health Insurance | Private Insurance Employment Based",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0577559","Mass","C34808","A benign or malignant pathologic structure in any part of the body, resulting from a neoplastic accumulation of cells, inflammatory cells, or cystic changes.","Mass | MASS | mass",,,,,,,,,,,,,,,"4102111|4214641","Mass of body structure|Mass",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0038250","Stem Cell","C12662","An unspecialized cell that has the capacity for reproduction through cell division and can be induced to differentiate into a tissue or organ specific cell.","Stem Cell | Mother Cells | Progenitor Cell | Progenitor Cells | Stem Cells | stem cell",,,,,,,,,,,,,,,"4303257","Stem cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL497334","Angle","C67505","The inclination of one line to another or the plane of one object to another.","Angle | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705738","Statistical Mode","C53320","The value which occurs most often in a set of values. If no value is repeated, there is no mode. If more than one value occurs with the same greatest frequency, each value is a mode.","Mode | Statistical Mode | mode",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031164","Permeability","C71611","A measure of the rate at which a substrate can pass water.","Permeability | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1295726","Perimeter","C71612","The size of something as given by the distance around it.","Perimeter | ",,,,,,,,,,,,,,,"4037740","Perimeter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347775","Circumscribe (action)","C71614","To draw a geometric figure around another figure so that the two are in contact but do not intersect.","Circumscribe | Circumscribed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348974","Histogram","C71615","A bar chart representing a frequency distribution where the heights of the bars represent observed frequencies.","Histogram | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1283195","Mapping","C73942","The creation of a two-dimensional graphic representation of an area or structure, showing the relative position of features or characteristics.","Mapping | ",,,,,,,,,,,,,,,"4236209","Mapping - action",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347509","Physical Shift","C73943","A physical movement from one place to another.","Physical Shift | Displacement | Shift",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205375","Uniform","C73944","The same throughout in structure or composition; lacking variation or diversity in form.","Uniform | ",,,,,,,,,,,,,,,"4100811","Uniform",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205413","Patchy","C73945","Irregular or uneven in quality, texture, or distribution.","Patchy | ",,,,,,,,,,,,,,,"4001776","Patchy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2362314","Temporal -Temporal Qualifier","C73990","Of or relating to time or limited by time.","Temporal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346779","Anatomic Rim","C73991","The border, edge, or margin of an organ or a part.","Anatomic Rim | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515568","de novo","C28354","Anew, afresh, or over again from the beginning.","de novo | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0302592","Cervical Carcinoma","C9039","A carcinoma arising from either the exocervical squamous epithelium or the endocervical glandular epithelium. The major histologic types of cervical carcinoma are squamous cell carcinoma and adenocarcinoma.","Cervical Carcinoma | Cancer of Cervix | Cancer of Uterine Cervix | Cancer of the Cervix | Cancer of the Uterine Cervix | Carcinoma of Cervix | Carcinoma of Cervix Uteri | Carcinoma of Uterine Cervix | Carcinoma of the Cervix | Carcinoma of the Cervix Uteri | Carcinoma of the Uterine Cervix | Cervical Cancer | Cervical Cancer (all types) | Cervical cancer, NOS | Cervix Cancer | Cervix Carcinoma | Cervix Uteri Carcinoma | Uterine Cervix Cancer | Uterine Cervix Carcinoma | cervical cancer",,,,,,,,,,,,,,,"4112314","Carcinoma of cervix",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1513483","Monosomy 7","C36411","A chromosomal abnormality consisting of the absence of one of the copies of chromosome 7 in somatic cells.","Monosomy 7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL374256","Trisomy 4","C36530","A chromosomal abnormality consisting of the presence of a third copy of chromosome 4 in somatic cells.","Trisomy 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0432412","Trisomy 8","C36396","A chromosomal abnormality consisting of the presence of a third copy of chromosome 8 in somatic cells.","Trisomy 8 | tri8",,,,,,,,,,,,,,,"4004640","Trisomy 8",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1096168","Trisomy 17","C37865","A chromosomal abnormality consisting of the presence of a third copy of chromosome 17 in somatic cells.","Trisomy 17 | ",,,,,,,,,,,,,,,"35608062|37111425","Mosaic trisomy 17 syndrome|Partial trisomy of chromosome 17",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3537167","Trisomy 21","C43224","A chromosomal abnormality consisting of the presence of a third copy of chromosome 21 in somatic cells.","Trisomy 21 | Trisomy-21",,,,,,,,,,,,,,,"42539721","Trisomy 21",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1515769","t(4;11)(q21;q23)","C36365","A chromosomal abnormality consisting of the translocation of 4q21 with 11q23.3.","t(4;11)(q21;q23.3) | t(4;11)(q21;q23) | t(4;11)(q21;q23) | t(4;11)(q21;q23.3)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053814","t(5;17)(q35;q21)","C36362","A chromosomal abnormality consisting of the translocation of 5q32 with 17q21.","t(5;17)(q35;q21) | t(5;17)(q32;q12) | t(5;17)(q35;q12)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515702","t(10;14)(q24;q11)","C36352","A chromosomal abnormality consisting of the translocation of 10q24 with 14q11, leading to inappropriate and abundant expression of HOX11 protein in T cells bearing the translocation.","t(10;14)(q24;q11) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516226","Cancer Research and Prevention Foundation","C39347","The Cancer Research and Prevention Foundation is a national, non-profit health foundation whose mission is declared as the prevention and early detection of cancer through scientific research and education. The Foundation's expenses fall into two categories: research and education grants that are awarded to institutions, individuals and organizations, and are selected through a grant-review process approved by the National Institutes of Health.","Cancer Research and Prevention Foundation | CRPF | t(8;14)(q24;q11)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347609","Chemical Probe","C73628","A small molecule that reacts with a known target in a predictable way, thereby showing location, identification, physiological state, etc.","Chemical Probe | Probe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348524","Standard Hit","C73629","An assay independent measure of compound performance in a chemical screen, specifically, a compound with a composite Z score above 8.53 and a reproducibility above 0.99.","Standard Hit | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348563","Study Protocol","C70817","The formal plan of an experiment or research activity, including the objective, rationale, design, materials and methods for the conduct of the study; intervention description, and method of data analysis.","Study Protocol | Protocol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346474","Immune Cell Function Assay","C73490","A set of laboratory assays that examine the responses of lymphoid or myeloid cells after exposure to an experimental material.","Immune Cell Function Assay | Immune Cell Function",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515653","In Vitro Assay","C15958","Assay conducted in an artificial environment, such as in a test tube, under a defined and controlled set of solvent and solute conditions.","In Vitro Assay | in vitro Assay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1567332","Caspase-3, Human","C18031","Caspase-3 (277 aa, ~31 kDa) is encoded by the human CASP3 gene. This protein is involved in the mediation of proteolysis and the activation of apoptosis.","Caspase-3 | Apopain | CASP-3 | CASP3 | CPP-32 | CPP32 | CPP32B | Caspase 3, Apoptosis-Related Cysteine Protease | Cysteine Protease CPP32 | EC 3.4.22.56 | PARP Cleavage Protease | Pro-Caspase 3 | Pro-Caspase-3 | Procaspase 3 | Procaspase-3 | Protein Yama | SCA-1 | SREBP Cleavage Activity 1 | Yama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085416","Oxidative Burst","C63849","A process that consists of the rapid release of reactive oxygen species. The process frequently ocurrs in cells when superoxide radical and hydrogen peroxide species are released.","Oxidative Burst | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0597240","Physical State","C73487","The indication that a chemical form is solid, liquid, or gas.","Physical State | Chemical State | Physical Form | State of Matter",,,,,,,,,,,,,,,"42537231","State of matter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2346862","Aspect Ratio","C73486","The ratio between the longest and shortest dimension of an object.","Aspect Ratio | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348011","Critical Concentration","C73488","The concentration of a solute or dispersion above which spontaneous aggregation or precipitation occurs.","Critical Concentration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881507","Macromolecular Branch","C63925","An oligomeric or polymeric construct that extends from the parent macromolecule.","Macromolecular Branch | Branch",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005554","Biopolymer","C73478","A type of polymer produced by living organisms.","Biopolymer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596306","Chemical Association","C73471","Any process of combining chemical entities that is dependent upon chemical forces.","Chemical Association | Association | Chemical Linkage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348438","Encapsulation","C73476","The process or condition of being enclosed.","Encapsulation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021017","Antibody Isotype","C73483","The genetic or structural type for the constant region of an antibody.","Antibody Isotype | Immunoglobulin Isotype | Isotype",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162404","Bioluminescence","C62655","The production of light by certain living organisms, including fireflies and phytoplankton, by the conversion of chemical to radiant energy.","Bioluminescence | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021431","Infrared Radiation","C16736","Electromagnetic radiation with wavelengths between 750 nanometers and 1 millimeter, between those of visible light and microwaves. This portion of the electromagnetic spectrum can usually be sensed as heat.","Infrared Radiation | Radiation, Infrared",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0563222","Neutron Radiation","C18070","Radiation of neutrons during radioactive decay.","Neutron Radiation | NEUTRON RADIATION | Neutron-Radiation | Radiation, Neutron",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037815","Raman Spectroscopy","C17157","Emission of electromagnetic energy with a shorter frequency (longer wavelength) than that of the incident monochromatic light.  Arises from the low probability absorption of quanta with a higher energy than that required for a transition: the difference in energy is emitted as a lower frequency (energy) photon.  Allows analysis of vibrational and rotational energy levels using visible incident light.","Raman Spectroscopy | Spectroscopy, IR/UV/Raman | Spectroscopy, Raman",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040399","Single Photon Emission Computed Tomography","C17203","A type of tomography in which gamma photon-emitting radionuclides are administered to the patient and then detected by one or more gamma cameras rotated around the patient. From the series of two-dimensional images produced, a three-dimensional image can be created by computer reconstruction.","Single Photon Emission Computed Tomography | Medical Imaging, Single Photon Emission Computed Tomography | SPECT | SPECT SCAN | SPECT imaging | SPET | ST | Single Photon Emission Tomography | Single-Photon Emission Computed | Tomography, Emission-Computed, Single-Photon | single-photon emission computed tomography | tomography, emission computed, single photon",,,,,,,,,,,,,,,"4019823|4125403","Single photon emission computed tomography|Single photon emission computed tomography - action",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1511539","Covalent Interaction","C41573","A physical connection between two atoms or radicals in which a chemical bond is formed by sharing electrons.","Covalent Interaction | Covalent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348396","Electrostatic Attraction","C73472","The attraction between dissimilar exposed charges on two or more molecules.","Electrostatic Attraction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020276","Hydrogen Bonding","C73473","The physical association between an electronegative atom and a hydrogen atom that is directly bound to a second, relatively electronegative atom.","Hydrogen Bonding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596800","Ionic Bonding","C73475","Formation of a chemical bond following a transfer of electrons between two ions with opposite charges.","Ionic Bonding | Electrovalent Bond | Electrovalent Bonding | Ionic Bond",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346563","van der Waals Attraction","C73474","The weak attraction between two or more chemical entities that is caused by the polarization of adjacent atoms or molecules.","van der Waals Attraction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347885","Radioisotopic Labeling (lab procedure)","C73481","A laboratory procedure that results in the incorporation of a radioactive isotope into a molecule of interest.","Radioisotopic Labeling | Radiolabeling | Radiolabelling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596311","Chemical Cleavage","C73482","The breaking of a chemical bond in a molecule resulting in smaller molecules.","Chemical Cleavage | Cleavage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021031","Fab Fragment","C13246","Part of an immunoglobulin antibody that binds a specific antigen and consists of both a light chain and part of a heavy chain.  By comparison, natural antibodies consist of two heavy and two light chains.  An FAB (fragment antibody) offers the advantages of smaller size and lower cross-reactivity compared to the complete antibody. (NCI04)","Fab Fragment | Antigen Binding Fragment | Fab | Immunoglobulin, F(ab) Fragment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883036","Single-Chain Variable Fragment","C63927","A genetically engineered antibody consisting of both the variable heavy chain (VH) and the light chain (VL) of an immunoglobulin. These entities are joined together by a flexible peptide linker.","Single-Chain Variable Fragment | ScFv | Single Chain Fv | Single Chain Variable Fragment | Single-Chain Fv",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348213","Smiles Arbitrary Target Specification","C73484","A language used for describing molecular patterns and properties.","Smiles Arbitrary Target Specification | SMARTS | SMiles ARbitrary Target Specification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001975","Alcohol [Chemical Class]","C218","A class of compounds where a hydroxyl (OH) group is attached to single bonded hydrocarbons.  Alcohols are classified according to the position of the carbon atom with the attached hydroxyl group (i.e. primary alcohols are alcohols with the OH group attached to the primary carbon atom, C1).  Uses include solvents, astringents, and anti-infective activity.","Alcohol [Chemical Class] | Alcohols",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036082","Saline","C821","A solution of salt and water. Saline usually refers to normal or physiological saline, which is an aqueous solution containing 0.9% sodium chloride.","Saline | ISOTONIC SODIUM CHLORIDE SOLUTION | Normal Saline | Normal saline | Sodium Chloride 0.9% | saline",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0991865","Phosphate Buffer","C29321","A chemical reagent containing at least any one of the many phosphoric acid derivatives, usually in salt form.  The phosphoric salt may be one of three types: strongly acid monometallic, neutral or mildly alkaline dimetallic, and strongly alkaline tri-metallic.  Phosphate buffers are typically adjusted to maintain a certain pH or are 'buffered' with other chemical compounds.  Phosphate reagents are used in research laboratories, medicine or industry in various technical procedures. (NCI04)","Phosphate Buffer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023378","LD-50","C16788","The dose of a chemical or biologic preparation (e.g., a bacterial exotoxin or a suspension of bacteria) that is likely to cause death in 50% of the animals being tested; it varies in relation to the type of animal and the route of administration; (the absolute lethal dose is LD100, and minimal lethal dose is LD05).","LD-50 | LC-50 | LC50 | LD50 | Lethal Dose - 50% | Median Lethal Dose",,,,,,,,,,,,,,,"4260190","Lethal dose 50",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882415","Polydispersity Index","C63852","A measure of the distribution of molecular weights in a given polymer sample. The PDI calculated is the weight average molecular weight divided by the number average molecular weight. It indicates the distribution of individual molecular weights in a population of polymers.","Polydispersity Index | PDI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347976","Root Mean Square","C73485","A statistical measure of the magnitude of a set of variable values. The root mean square is the square root of the mean value for the squares of the original values.","Root Mean Square | Quadratic Mean | RMS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883591","Z-Average","C63860","A parameter used for calculations involving mechanical properties. The parameter is measured by using dynamic light scattering to obtain the intensity weighted mean hydrodynamic size of a collection of particles.","Z-Average | Z-Average Value",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0597697","Zeta Potential","C62354","The magnitude of the electrical potential as generated by ion accumulation at the particulate surface. This surface consists of two layers, the Stern layer and the diffuse layer, which comprise an electrical double-layer. The measurement of the electrical potential provides important information regarding the dispersion mechanism, the degree of particle dispersion and the electrostatic potential of the sample.","Zeta Potential | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349183","Colloidal Solution or Suspension Dosage Form","C73489","A colloid that has a continuous liquid phase in which a solid is suspended in a liquid.","Sol | Colloidal Solution | Colloidal Suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3853628","Granule","C61363","Any small grainlike particle.","Granule | Granular",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2350002","Short Value","C73939","A variable that is stored as a signed 16-bit (2-byte) integer.","Short | Short Data Type | Short Value | Short Variable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348746","Genome Assembly Sequence","C73517","An annotated assembly of genome sequences created by the assimilation of data pieces from numerous sources.","Genome Assembly Sequence | Genome Assembly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600680","Untranslated Regions","C73499","A region of a messenger RNA that is not translated into protein.","Untranslated Region | UTR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042460","Vena Cava","C12817","A large vein which returns blood from the head, neck and extremities to the heart.","Vena Cava | VEIN, VENA CAVA | VENA CAVA | Vena caval structure (body structure)",,,,,,,,,,,,,,,"4149003","Vena caval structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882137","Occlusion within Medical Device","C62896","Issue associated with an obstruction or blockage within any of the device components (e.g. tube, opening, pipe) that results in a restriction of flow.","Occlusion within Medical Device | Medical Device Plugged",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033802","Pseudogout","C34955","An acute episode of pain, swelling, and redness, sometimes associated with fever. It is caused by the deposition of calcium pyrophosphate crystals in the joints.","Pseudogout | Chondrocalcinosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1260880","Rhinorrhea","C54282","A discharge of fluid from the nose.","Rhinorrhea | Nasal Discharge | Runny Nose | Runny_nose",,,,,,,,,,,,,,,"4276172","Nasal discharge",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4011649","Sinusitis","C35024","An acute or chronic inflammatory process affecting the mucous membranes of any sinus cavity.","Sinusitis | ",,,,,,,,,,,,,,,"4283893","Sinusitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3279848","Sleep Apnea","C26884","Cessation of breathing for short periods during sleep. It is classified as obstructive, central, or mixed obstructive-central. It can occur at any age but it is more frequent in people over forty. Risk factors include male sex and obesity.","Sleep Apnea | Sleep apnea | sleep apnea",,,,,,,,,,,,,,,"313459","Sleep apnea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0087086","Blood Clot","C27083","An aggregation of blood factors, primarily platelets and fibrin with entrapment of cellular elements, frequently causing vascular obstruction at the point of its formation.","Blood Clot | THROMBUS | Thrombi | Thrombosis | Thrombosis/Thrombus | Thrombus | blood clot | thrombus",,,,,,,,,,,,,,,"4192740","Blood clot",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042890","Vitamin","C944","A group of organic food substances found in animals and plants in small quantities. They must be supplied in diet or dietary supplement and are essential for normal metabolism.","Vitamin | Vitamins | vitamin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0060133","FEC protocol","C9595","A regimen consisting of fluorouracil, epirubicin and intravenous cyclophosphamide, used as a treatment for recurrent and metastatic breast cancer.","FEC Regimen | CTX/EPI/5-FU | Cyclophosphamide/Epirubicin/Fluorouracil | FEC | FEC 100 | FEC regimen | Fluorouracil-Epirubicin-IV Cytoxan Regimen | Fluorouracil/Epirubicin/IV Cyclophosphamide | Fluorouracil/Epirubicin/Intravenous Cyclophosphamide | IV Cyclophosphamide/Epirubicin/Fluorouracil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014582","Epirubicin","C62028","A 4'-epi-isomer of the anthracycline antineoplastic antibiotic doxorubicin.  Epirubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.","Epirubicin | (8S-cis)-10-((3-Amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione | 3-Glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl-3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside | 4'-Epiadriamycin | 4'-Epidoxorubicin | 4'-epi DX | EPIRUBICIN | Epi DX | Epidoxorubicin | Pidorubicin | epirubicin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4014212","Livedo Reticularis","C74524","A recurrent purple discoloration of the skin that does not blanche and is found in a lacy, network pattern, most often in the lower extremities. It may be aggravated by exposure to cold and is classified as idiopathic or secondary. Secondary livedo reticularis may be a cutaneous manifestation of immune system disorders (e.g., lupus erythematosus, rheumatoid arthritis, cryoglobulinemia, lymphoma, etc), and hematologic disorders (polycythemia vera).","Livedo Reticularis | ",,,,,,,,,,,,,,,"4081096","Livedo reticularis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332257","Include","C74521","Add as part of something else; put in as part of a set, group, or category.","Include | Inclusion",,,,,,,,,,,,,,,"4206777","Including",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698562","Brief Fatigue Inventory","C74297","A 9-item questionnaire, developed by Cleeland and Mendoza, designed to assess the severity of fatigue and the impact of fatigue on daily functioning in cancer patients.","Brief Fatigue Inventory | BFI | BFI01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700177","Field of View","C74298","The extent of an area that is visible.","Field of View | FLDVIEW | FOV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043227","Work","C74299","Exertion or effort directed to produce or accomplish something.","Work | Labor | Toil",,,,,,,,,,,,,,,"4126861","Working",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2700446","Self-Report","C74528","An individual's perspective or subjective interpretation of an event or information.","Self-Report | SELF-REPORT | Self Report | Self Reported | Self-Reported | Self-reported",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015027","Ethmoid Bone","C12711","A light and spongy bone that is cubical in shape. This bone is positioned at the anterior part of the cranium, sitting between the two orbits, at the roof of the nose. It consists of four parts: a horizontal or cribriform plate; a perpendicular plate; and two lateral masses or labyrinths.","Ethmoid Bone | ETHMOID BONE | Ethmoid | Ethmoid bone structure (body structure)",,,,,,,,,,,,,,,"4179484","Ethmoid bone structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041213","Trypan Blue","C910","An acid azo dye commonly used as a stain to distinguish viable from non-viable cells. It turns dead cells blue and viable cells unstained. It is a known animal carcinogen and an experimental teratogen.","Trypan Blue | Benzamine Blue | C34H28N6O14S4 | TRYPAN BLUE | Visionblue",,,,,,,,,,,,,,,"4246602","Trypan blue stain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512441","High-Risk Cancer","C28312","Cancer that is likely to recur (come back), or spread.","High-Risk Cancer | high-risk cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0425293","Never Smoker","C65108","A person who has never smoked at the time of the interview or has smoked less than 100 cigarettes in their life.","Never Smoker | 1 | Lifelong Non-Smoker | Never Smoked | Never smoker | Non-Smoker",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448934","Effort","C74530","Physical or mental energy; hard work.","Effort | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3845527","Hopelessness","C74531","The despair you feel when you have abandoned hope of comfort or success.","Hopelessness | Feeling of Hopelessness | Hopeless",,,,,,,,,,,,,,,"4142455","Feeling hopeless",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027769","Nervousness","C74532","An uneasy psychological state; the anxious feeling you have when you have the jitters.","Nervousness | Feeling of Nervousness | Nervous",,,,,,,,,,,,,,,"436817","Feeling nervous",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3887611","Restlessness","C74533","An inability to rest, relax, or be still.","Restlessness | Feeling of Restlessness | Restless",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3536794","Sadness","C74534","Feelings of grief or unhappiness.","Sadness | Feeling of Sadness | Sad | Sad Mood",,,,,,,,,,,,,,,"4169106","Feeling unhappy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3241966","Current Smoker","C67147","An adult who has smoked 100 cigarettes in his or her lifetime and who currently smokes cigarettes. Includes daily smokers and non-daily smokers (also known as occasional smokers).","Current Smoker | 2 | Smoker",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0855235","Worthlessness","C74535","Feelings of being unimportant or useless.","Worthlessness | Feeling of Worthlessness | Worthless",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013221","Drug Toxicity","C27955","An adverse effect of a drug used therapeutically or diagnostically.","Drug Toxicity | toxicity, drug",,,,,,,,,,,,,,,"438028","Poisoning by drug AND/OR medicinal substance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0376325","Hepatitis A Virus","C14325","A single stranded RNA virus.  A member of the picornaviridae family, subfamily hepatovirus.  The causative agent of Hepatitis A.","Hepatitis A Virus | HAV | HEPATITIS A VIRUS | HHVA | Human Hepatitis A Virus | hepatitis A virus",,,,,,,,,,,,,,,"4137138","HAV - Hepatitis A virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1557651","CTCAE Grade 3 Carbon monoxide diffusion capacity (DL(co))","C58096","<50 - 25% of predicted value","Grade 3 Carbon Monoxide Diffusion Capacity, CTCAE | CTCAE Grade 3 Carbon Monoxide Diffusion Capacity | CTCAE Grade 3 Carbon monoxide diffusion capacity (DL(co)) | Grade 3 Carbon monoxide diffusion capacity (DL(co))",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706841","Applicator Tube","C43207","A tube which is provided with a device (the applicator) for administering the dosage form. The applicator may be part of the tube closure or be separate.","Applicator Tube | TUBE, WITH APPLICATOR | Tube, with Applicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001428","Pharyngeal Tonsil","C33318","A fold of lymphatic tissue covered by ciliated epithelium at the very back of the nose, in the roof of the nasopharynx.","Pharyngeal Tonsil | Adenoid | PHARYNGEAL TONSIL | TONSIL, PHARYNGEAL | Tonsil (Pharyngeal) | adenoid | nasopharyngeal tonsil | pharyngeal tonsil | tonsil of Luschka | tonsilla pharyngealis",,,,,,,,,,,,,"UBERON:0001732","pharyngeal tonsil","4184153","Adenoidal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0919449","ETV6/RUNX1 Fusion Gene","C18517","A fusion gene that results from a chromosomal translocation t(12;21)(p13;q22) which fuses intron 5 of the ETV6 gene with intron 2 of the RUNX1 gene. This gene fusion is associated with B-cell lymphoblastic leukemia/lymphoma.","ETV6/RUNX1 Fusion Gene | AML1/TEL Fusion Gene | ETV6-AML1 Fusion Gene | ETV6-RUNX1 Fusion Gene | ETV6/AML1 Fusion Gene | ETV6::RUNX1 Fusion Gene | TEL-AML 1 | TEL-AML1 Oncogene | TEL-AML1 Oncogene | TEL/AML1 Chimeric Gene | TEL/AML1 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708542","International Commission on Radiation Units and Measurements","C43966","The International Commission on Radiation Units and Measurements (ICRU) was established in 1925 by the International Congress of Radiology. Since its inception, it has had as its principal objective the development of internationally acceptable recommendations regarding (1) quantities and units of radiation and radioactivity; (2) procedures suitable for the measurement and application of these quantities in diagnostic radiology, radiation therapy, radiation biology, and industrial operations; and (3) physical data needed in the application of these procedures, the use of which tends to assure uniformity in reporting. The ICRU endeavors to collect and evaluate the latest data and information pertinent to the problems of radiation measurement and dosimetry, and to recommend in its publications the most acceptable values and techniques for current use.","International Commission on Radiation Units and Measurements | ICRU | International Commission of Radiation Units and Measurements",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0722107","Nilutamide","C1173","A synthetic, nonsteroidal agent with antiandrogenic properties. Nilutamide preferentially binds to androgen receptors and blocks androgen receptor activation by testosterone and other androgens; this agent may inhibit androgen-dependent growth of normal and neoplastic prostate cells. (NCI04)","Nilutamide | 1-(3'-Trifluoromethyl-4'-nitrophenyl)-4,4-dimethylimidazoline-3,5-dione | 5,5-Dimethyl-3-[4-nitro-3-(trifluoro-methyl)phenyl]-2,4-imidazolidinedione | Anandron | NILUTAMIDE | Nilandron | RU-23908 | nilutamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520467","Chromosome 12 Short Arm","C13532","Proximal (short) arm of chromosome 12","12p | Chromosome 12 Proximal Arm | Chromosome 12 Short Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515492","Chromosome 9 Short Arm","C13563","Proximal (short) arm of chromosome 9","9p | Chromosome 9 Proximal Arm | Chromosome 9 Short Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521554","6q","C13560","Distal (long) arm of chromosome 6","6q | Chromosome 6 Distal Arm | Chromosome 6 Long Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515980","Ancillary Study","C16041","A study that is secondary to another study.","Ancillary Study | Ancillary Studies | Companion Protocol | ancillary test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1142738","Anidulafungin","C38716","A cyclic lipopeptide echinocandin derivative with antifungal activity.  Anidulafungin inhibits 1,3 beta-D-glucan synthase, an enzyme involved in fungal cell wall synthesis, resulting in cell lysis and death. This agent is active against Candida species and Aspergillus. (NCI04)","Anidulafungin | ANIDULAFUNGIN | Eraxis | LY303366 | anidulafungin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0933845","Parenchyma","C74601","The tissue that constitutes the essential part of an organ as contrasted with e.g., connective tissue and blood vessels.","Parenchyma | parenchyma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698234","Mitotic Figure","C74602","The microscopic appearance of a cell undergoing mitosis.","Mitotic Figure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0824497","Neurovascular Bundle","C74603","A body structure consisting of nerves traveling together with arteries, veins, and/or lymphatics.","Neurovascular Bundle | Vasculo-Nervous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709779","Pushing Tumor Margin","C53991","Describes a tumor border with an expanding and smooth configuration.","Pushing Tumor Margin | Pushing | Pushing Tumor Border | Pushing Tumor Border Configuration | Pushing Tumor Margins Present | Pushing Tumor Margins Present",,,,,,,,,,,,,,,"4240054","Pushing tumor border",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1514211","Exophytic Polypoid Lesion","C40560","A raised, outward growing lesion from the surface epithelium or the lumen of an organ. Representative examples include adenomatous and fibroepithelial polyps.","Exophytic Polypoid Lesion | Polypoid Lesion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054946","FMC-7 antigen, human","C38896","B-lymphocyte antigen CD20 (297 aa, ~33 kDa) is encoded by the human MS4A1 gene. This protein plays a role in both the activation and proliferation of B-cells.","B-Lymphocyte Antigen CD20 | B-Lymphocyte Surface Antigen B1 | B1 | Bp35 | CD20 | CD20 Antigen | CD20 Antigen | CD20 Receptor | Leu-16 | MS4A1 | Membrane-Spanning 4-Domains Subfamily A Member 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0935989","Imatinib","C62035","An antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome.  Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST).  This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins.","Imatinib | 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide | IMATINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333825","Lymphoplasmacytoid Cell","C37000","A mononuclear cell slightly larger than a small lymphocyte with an eccentric dark nucleus. It has basophilic cytoplasm and secretes immunoglobulins.  It may contain intranuclear cytoplasmic inclusions (Dutcher bodies) which are PAS-positive.","Lymphoplasmacytoid Cell | Plasmacytoid Lymphocyte",,,,,,,,,,,,,,,"4245139","Plasmacytoid cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0812425","S-Phase Fraction","C18456","The percentage of cells in a sample currently undergoing mitosis.","S-Phase Fraction | Cell Proliferative Activity | Cellular Proliferation Rate | Labeling Index | Mitotic Index | S-phase fraction | SPF | mitotic index",,,,,,,,,,,,,,,"4099595","Mitotic index",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015176","Europe","C26274","The continent whose boundaries are the Atlantic Ocean in the west, the Arctic Ocean to the north, the Ural Mountains and Ural River in the east, the Caspian Sea, Caucasus mountains and Black Sea in the southeast and the Mediterranean Sea in the south.","Europe | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332183","Frequently","C64649","Coming at short intervals or in great quantities.","Frequently | Frequent",,,,,,,,,,,,,,,"4322298","Frequent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698830","Plasma Cell Labeling Index","C74934","Any of various techniques for determining the s-phase fraction of bone marrow plasma cells. Traditionally, this test has been performed as a two color immunofluorescent microscope technique.","Plasma Cell Labeling Index | Labeling Index | PCLI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0272247","Biclonal Gammopathy","C74936","A primary disturbance in immunoglobulin synthesis characterized by the presence of two distinct monoclonal immunoglobulins in the serum or urine.","Biclonal Gammopathy | ",,,,,,,,,,,,,,,"4180252","Biclonal gammopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1432709","Fluorothymidine F-18","C49093","A radioconjugate consisting of a thymidine analogue radiolabeled with fluorine F 18, a positron emitting isotope.  Phosphorylated by S-phase-specific thymidine kinase 1, 3'-deoxy-3'-[18F]fluorothymidine (18F-FLT) is trapped intracellularly by entering the salvage pathway of DNA synthesis without incorporation into DNA. 18F-FLT serves a marker of tumor cell proliferation for imaging with positron emission tomography (PET); as a marker of proliferation rather than metabolism, it is more specific to tumor tissue than 2-deoxy-2-[18F] fluoro-D-glucose (18F-FDG).  This agent is metabolically stable, accumulates in the normal bone marrow and the liver, and does not cross the blood-brain barrier.","Fluorothymidine F-18 | 18F-FLT | 3'-Deoxy-3'-(18F) Fluorothymidine | 3'-deoxy-3'-(18F) fluorothymidine | 3'-deoxy-3'-[18F]fluorothymidine | 3'-deoxy-3'-[18F]fluorothymidine | ALOVUDINE F-18 | Fluorothymidine F 18 | Thymidine, 3'-deoxy-3'-(18F)fluoro- | fluorothymidine F 18",,,,,,,,,,,,,,,"35622757","Fluorothymidine (18-F)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710834","18F-Fluoromisonidazole","C52180","A radiofluorinated 2-nitroimidazole derivate with hypoxia-specific tracer activity. Misonidazole is reduced under hypoxic conditions and in reduced form covalently binds to macromolecules in hypoxic cells. 18F (fluorine-18) radiofluorination of misonidazole to form 18F-fluoromisonidazole allows radioisotopic imaging of reduced misonidazole bound to macromolecules in hypoxic cells.","18F-Fluoromisonidazole | 18F-MISO | 18F-Misonidazole | 18F-fluoromisonidazole | FLUOROMISONIDAZOLE F-18 | FMISO",,,,,,,,,,,,,,,"4309703","Fluoromisonidazole (18-F)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007608","Cell Motility","C16404","Cell Motility consists of active translocation of a whole cell, or cell body, from one site to another; distinct from cell motion that involves movement of cell processes (e.g., axons, microvilli, etc.). (NCI)","Cell Motility | Motility | Motility, Cellular | cell motility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006277","Bronchitis","C2911","An acute or chronic inflammatory process affecting the bronchi.","Bronchitis | Bronchial infection | bronchitis",,,,,,,,,,,,,,,"256451","Bronchitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1336515","Stromal Invasion","C35954","A term referring to the presence of tumor emboli or tumor masses within the stroma of an organ.","Stromal Invasion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517108","Fahrenheit Scale","C41142","A thermometric scale named after the German physicist Gabriel Fahrenheit, on which under standard atmospheric pressure the boiling point of water is at 212 degrees above the zero of the scale, the freezing point is at 32 degrees above zero, and the zero point approximates the temperature produced by mixing equal quantities by weight of snow and common salt. The scale is used by the general population of USA and Jamaica for non-scientific temperature measurement.","Fahrenheit Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227837","Endocervix","C12309","The portion of the cervix which is lined by single columnar epithelium (mucosa).","Endocervix | ENDOCERVIX | Endocervical | endocervix",,,,,,,,,,,,,,,"4289829","Endocervical structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522644","Uterus - Endometrium (MMHCC)","C22673","The endometrium of the mouse uterus.","Mouse Endometrium | Mouse Uterine Endometrium | Uterus - Endometrium (MMHCC) | Uterus - Endometrium (MMHCC)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016452","Food","C62695","A group of materials of either plant, animal or artificial origin containing essential body nutrients that can be ingested by an organism to produce energy, stimulate growth, and maintain life.","Food | ",,,,,,,,,,,,,,,"4112439","Food",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334227","Malignant Cell","C12917","Cells of, or derived from, a malignant tumor.","Malignant Cell | Cancer Cell | MALIGNANT_CELLS | Tumor cells, malignant","8001/3","Tumor cells, malignant",,,,,,,,,,,,,"4227429","Tumor cells, malignant",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0455288","Corrected Serum Calcium Measurement","C74950","An estimate of serum calcium, corrected for the amount of albumin-bound calcium, used when albumin levels are not within normal ranges. It uses the formula: Corrected calcium (mg/dL) = measured total Ca (mg/dL) + 0.8 (4.0 - serum albumin [g/dL]), where 4.0 represents the average albumin level.","Corrected Serum Calcium Measurement | Corrected Serum Calcium",,,,,,,,,,,,,,,"4042573","Corrected serum calcium measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0234925","Oily Skin","C74591","The pores of the skin are generally large and visible with a coarse or thick texture. The skin has a tendency to look dull and greasy and feels oily to the touch.","Oily Skin | Bleeding on Probing | OILY",,,,,,,,,,,,,,,"4173121","Greasy skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0558145","Normal Skin","C74593","The pores are visible but not large. The skin texture is neither fine or thick and it neither feels dry or oily to the touch.","Normal Skin | Cementoenamel Junction | NORMAL | Normal | Normal skin",,,,,,,,,,,,,,,"4021360","Skin appearance normal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL524168","Barrel Shape","C74937","A bulging cylindrical shape with flat ends.","Barrel | Barrel Shape | Barrel Shaped",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700034","Exophytic","C74938","Growing outward; developing externally.","Exophytic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439656","Voluntary","C74096","Of your own free will or design; not forced or compelled; controlled by individual volition.","Voluntary | ",,,,,,,,,,,,,,,"4114523","Voluntary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1711307","Coordinator","C45284","A person responsible for organizing multiple events or efforts into a smaller number of tasks.","Coordinator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698747","Patient Tracking System","C74928","A computerized system for tracking the status and location of a patient as they move through a medical facility. The system may include specialized software as well as mobile devices.","Patient Tracking System | PTS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0442802","Excessive","C73992","Beyond normal limits; unrestrained.","Excessive | Excessively",,,,,,,,,,,,,,,"4128642","Excessive",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1277691","Pack Year","C73993","A quantification of lifetime tobacco exposure defined as (number of cigarettes smoked per day x number of years smoked)/20. One pack-year is smoking 20 cigarettes a day for one year.","Pack Year | Pack Year: The number of cigarettes smoked per day times the number of years smoked divided by 20 (the number of cigarettes in a pack) | Pack-Year | Smoking Pack Years | pack year | pack years smoked | pack_years_smoked | {Pack Year}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348557","Study Completed","C70756","A clinical study status designating the study has been completed normally, according to the protocol. Subject enrollment stopped. No participants are treated or being followed up.","Study Completed | Completed | Completed Study | Study Completed Status | study completion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987433","Mouse Anatomy Concepts","C22164","Any of the mouse anatomical structures consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function.","Mouse Anatomy Concepts | Mouse Anatomy | Murine Tissue Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882558","Rat Anatomy Concepts","C60538","Body tissues, cavities, fluids, organs, or systems pertaining specifically to rat anatomy.","Rat Anatomy Concepts | Rat Anatomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1719822","Follow","C64950","Adhere to or practice.","Follow | Adhere To | Complies | Complies With | In Accordance | In Accordance With | Per",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205097","Caudal","C73851","Constituting or relating to a tail; situated near the tail.","Caudal | CAUDAL",,,,,,,,,,,,,,,"4262416","Caudal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017452","Georgia","C43477","A state in the southeastern United States. Its capital is Atlanta.","Georgia | GA | Georgia US State of | US: Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016253","Florida (United States)","C43478","A state in the southeastern United States. Its capital is Tallahassee.","Florida | FL | US: Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009399","Colorado","C43501","A state in the Rocky Mountains of western United States. Its capital is Denver.","Colorado | CO | US: Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022557","Kentucky","C43484","A state in the north central United States. Its capital is Frankfort.","Kentucky | KY | US: Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022497","Kansas","C43493","A state in the central midwest United States. Its capital is Topeka.","Kansas | KS | US: Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021206","Indiana","C43483","A state in the north central United States. Its capital is Indianapolis.","Indiana | IN | US: Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020898","Illinois","C43491","A state in the central midwest United States. Its capital is Springfield.","Illinois | IL | US: Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020787","Idaho","C43499","A state in the northern Rocky Mountains of western United States. Its capital is Boise.","Idaho | ID | US: Idaho",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022037","Iowa","C43487","A state in the northern midwest United States. Its capital is Des Moines.","Iowa | IA | US: Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018619","Hawaii","C43510","A pacific island state in the United States. Its capital is Honolulu.","Hawaii | HI | US: Hawaii",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037716","South Carolina","C43475","A state in the mid-atlantic United States. Its capital is Columbia.","South Carolina | SC | US: South Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035487","Rhode Island","C43464","A state in the northeastern United States. Its capital is Providence.","Rhode Island | RI | US: Rhode Island",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030853","Pennsylvania","C43469","A state in the mid-atlantic United States. Its capital is Harrisburg.","Pennsylvania | PA | US: Pennsylvania",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029195","Oregon","C43508","A state in the northwestern United States. Its capital is Salem.","Oregon | OR | US: Oregon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028914","Oklahoma","C43497","A state in the southern midwest United States. Its capital is Oklahoma City.","Oklahoma | OK | US: Oklahoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028905","Ohio","C43482","A state in the north central United States. Its capital is Columbus.","Ohio | OH | US: Ohio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027976","New York","C43468","A state in the northeastern United States. Its capital is Albany.","New York | NY | US: New York",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027951","Nevada","C43503","A state in the western United States. Its capital is Carson City.","Nevada | NV | US: Nevada",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027972","New Mexico","C43504","A state in the southwestern United States. Its capital is Santa Fe.","New Mexico | NM | US: New Mexico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027971","New Jersey","C43467","A state in the mid-atlantic United States. Its capital is Trenton.","New Jersey | NJ | US: New Jersey",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027969","New Hampshire","C43460","A state in the northeastern United States. Its capital is Concord.","New Hampshire | NH | US: New Hampshire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027523","Nebraska","C43494","A state in the central midwest United States. Its capital is Lincoln.","Nebraska | NE | US: Nebraska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028408","North Dakota","C43488","A state in the northern midwest United States. Its capital is Bismarck.","North Dakota | ND | US: North Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028407","North Carolina","C43474","A state in the mid-atlantic United States. Its capital is Raleigh.","North Carolina | NC | US: North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026506","Montana","C43490","A state in the northern midwest United States. Its capital is Helena.","Montana | MT | US: Montana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026221","Mississippi","C43480","A state in the southeastern United States. Its capital is Jackson.","Mississippi | MS | US: Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026183","Minnesota","C43486","A state in the northern midwest United States. Its capital is St. Paul.","Minnesota | MN | US: Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025939","Michigan","C43481","A state in the north central United States. Its capital is Lansing.","Michigan | MI | US: Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024497","Maine","C43457","A state in the northeastern United States. Its capital is Augusta.","Maine | ME | US: Maine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024858","Maryland","C43471","A state in the mid-atlantic United States. Its capital is Annapolis.","Maryland | MD | US: Maryland",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024874","Massachusetts","C43463","A state in the northeast United States. Its capital is Boston.","Massachusetts | MA | US: Massachusetts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024024","Louisiana","C43496","A state in the southern midwest United States. Its capital is Baton Rouge.","Louisiana | LA | US: Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043038","Washington","C43507","A state in the northwest United States. Its capital is Olympia.","Washington | US: Washington | WA | Washington state",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037717","South Dakota","C43489","A state in the northern midwest United States. Its capital is Pierre.","South Dakota | SD | US: South Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812388","Left Ventricular Ejection Time","C74981","The time it take to eject blood from the left ventricle. Measurement begins when the aortic valve opens and ends when the aortic valve closes.","Left Ventricular Ejection Time | Ejection Time | LVET",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0451306","Mini-Mental Status Exam","C74982","A standardized and structured interview originally developed by Marshal Folstein, Susan Folstein and Paul McHugh (Journal of Psychiatric Research, 1975), which is used to evaluate an individual's cognitive function.","Mini-Mental Status Exam | Folstein Mini-Mental Status Exam | MMS1 | MMSE | Mini-Mental State Examination Questionnaire",,,,,,,,,,,,,,,"4169175","Mini-mental state examination",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1257874","Parathyroid Hormone-Related Protein, Human","C20447","Parathyroid hormone-related protein (177 aa, ~20 kDa) is encoded by the human PTHLH gene. This protein plays a role in cell and organ growth, organ development, cell migration, cell differentiation and calcium ion transport.","Parathyroid Hormone-Related Protein | PLP | PTH-Like Protein | PTH-Related Protein | PTH-rP | PTHrP | Parathyroid Hormone Like Tumor Factor | Parathyroid Hormone-Like Hormone | Parathyroid Hormone-Like Hormone | Parathyroid Hormone-Like Hormone Preproprotein | Parathyroid Hormone-Like Protein | Parathyroid Hormone-Like Related Protein | Parathyroid Hormone-Related Peptide | Parathyroid Hormone-Related Protein Preproprotein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1291125","N-Telopeptide","C68563","This polypeptide is comprised of the amino terminal portions of fibrillar collagen, which are not part of the triple helical structure. Bone resorption of type I collagen by osteoclasts results in the release of this peptide. Thus, this polypeptide is utilized as a biomarker for bone loss.","N-Telopeptide | Collagen Cross-Linked N-Telopeptide | N-Terminal Type I Collagen Cross-Linked | NTx | Type I Collagen Cross-Linked N-Telopeptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2362313","Credential letter","C73925","Records that qualify somebody to do something, provides authentication for a claim, or confirms position or status.","Credential | Credential Letter | Credentialed | Credentials",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348091","Delegate Action","C73926","To entrust to another.","Delegate Action | Delegate | Delegated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346557","caXchange","C73927","A configurable hub for exchanging clinical trial information between applications and systems across the caGRID.","caXchange | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880161","Computer Operation","C62617","Data processing in which the result is completely specified by a rule (especially the processing that results from a single instruction).","Computer Operation | Operation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1554961","exception - ResponseLevel","C54420","An instance that does not conform to a rule or generalization.","Exception | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348100","Deserialization","C73933","The process of taking a data object from a transport operation or persisted storage location and converting it back to its original form.","Deserialization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348206","Simple API for XML","C73931","A computer program that divides code up into functional components.","Simple API for XML | SAX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347447","Parser","C73930","A computer program that divides code up into functional components.","Parser | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700108","Unhandled Message","C74935","A message type for which there is no defined routing.","Unhandled Message | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700401","Deny (action)","C74933","Refuse to accept, recognize or acknowledge.","Deny | Denial | Denied | Reject | Rejection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347840","Commit Operation","C73937","The final step in the processing of a business transaction during which a business process is done. Examples of business processes include creation of a study or the registration of a patient into a study.","Commit Operation | Commit | Save",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347972","Rollback Operation","C73938","A command to cancel a business process and return a record to its previous state.","Rollback Operation | Rollback | Undo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3550383","Thromboembolism","C28195","Occlusion of the lumen of a vessel by a thrombus that has migrated from a distal site via the blood stream.","Thromboembolism | Thromboembolic Event | Thromboembolic event",,,,,,,,,,,,,,,"4029321|4159647","Thromboembolus|Thromboembolic disorder",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0038661","Suicide","C3394","The act of ending one's own life.","Suicide | suicide",,,,,,,,,,,,,,,"440925","Suicide",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033740","Protozoal Infection","C34953","An infection that is caused by protozoans.","Protozoal Infection | ",,,,,,,,,,,,,,,"442176","Protozoan infection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4011886","Intracranial Hemorrhage","C50438","Bleeding within the cranium.","Intracranial Hemorrhage | Intracranial hemorrhage",,,,,,,,,,,,,,,"439847","Intracranial hemorrhage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004623","Bacterial Infection","C2890","An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.","Bacterial Infection | Bacterial Disease | Bacterial Disorder | Bacterial infection",,,,,,,,,,,,,,,"432545","Bacterial infectious disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0854751","Stage 0 Colorectal Cancer AJCC v6 and v7","C8932","Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ: intraepithelial or invasion of the lamina propria.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage 0 Colorectal Cancer AJCC v6 and v7 | Colorectal Cancer, Stage 0 | Colorectal Carcinoma Stage 0 | Colorectal Carcinoma in situ | Stage 0 Colorectal (Colon or Rectal) Cancer | Stage 0 Colorectal Cancer | Stage 0 Colorectal Cancer AJCC v6 | Stage 0 Colorectal Cancer AJCC v7 | Stage 0 Colorectal Carcinoma | stage 0 colorectal carcinoma in situ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677947","Stage I Colorectal Cancer AJCC v6 and v7","C8513","Stage I includes: (T1, N0, M0); (T2, N0, M0).  T1: Tumor invades submucosa.  T2: Tumor invades muscularis propria.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage I Colorectal Cancer AJCC v6 and v7 | Colorectal Cancer, Stage I | Dukes A Colorectal Carcinoma | Dukes A colorectal cancer | Stage I Colorectal (Colon or Rectal) Cancer | Stage I Colorectal Cancer | Stage I Colorectal Cancer AJCC v6 | Stage I Colorectal Cancer AJCC v7 | Stage I Colorectal Carcinoma | stage I colorectal cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677948","Stage II Colorectal Cancer AJCC v6","C8514","Stage Group II is subdivided into IIA and IIB on the basis of whether the primary tumor is T3 or T4, respectively.  T3: Tumor invades through the muscularis propria into the subserosa, or into non-peritonealized pericolic or perirectal tissues.  T4: Tumor directly invades other organs or structures, and/or perforates visceral peritoneum. (AJCC 6th ed.)","Stage II Colorectal Cancer AJCC v6 | Colorectal Cancer, Stage II AJCC v6 | Colorectal Carcinoma Stage II AJCC v6 | Dukes B Colorectal Carcinoma | Dukes B colorectal cancer | Stage II Colorectal (Colon or Rectal) Cancer | Stage II Colorectal Cancer | Stage II Colorectal Carcinoma AJCC v6 | stage II colorectal cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677949","Stage III Colorectal Cancer AJCC v6","C8515","Stage Group III is subdivided into IIIA (T1-2, N1, M0), IIIB (T3-4, N1, M0) or IIIC (any T, N2 M0).  T1: Tumor invades the submucosa.  T2: Tumor invades muscularis propria.  T3: Tumor invades through the muscularis propria into the subserosa or into non-peritonealized pericolic or perirectal tissues.  T4: Tumor directly invades other organs or structures, and/or perforates visceral peritoneum.  N1: Metastasis in 1 to 3 regional lymph nodes N2: Metastasis in 4 or more regional lymph nodes.  M0: No distant metastasis.  (AJCC 6th ed.)","Stage III Colorectal Cancer AJCC v6 | Colorectal Cancer, Stage III AJCC v6 | Dukes C Colorectal Carcinoma | Dukes C colorectal cancer | Stage III Colorectal (Colon or Rectal) Cancer | Stage III Colorectal Cancer | Stage III Colorectal Carcinoma AJCC v6 | stage III colorectal cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677950","Stage IV Colorectal Cancer AJCC v6","C8516","Stage IV includes: Any T, any N, M1.  M1: Distant metastasis. (AJCC 6th ed.)","Stage IV Colorectal Cancer AJCC v6 | Astler-Coller D Colorectal Cancer | Colorectal Cancer, Stage IV AJCC v6 | Colorectal Carcinoma Stage IV AJCC v6 | Dukes D Colorectal Carcinoma | Stage IV Colorectal (Colon or Rectal) Cancer | Stage IV Colorectal Cancer | Stage IV Colorectal Carcinoma AJCC v6 | stage IV colorectal cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0750491","Suspected","C71458","Believed likely.","Suspected | ",,,,,,,,,,,,,,,"4217851","Suspected",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0796362","5q31","C13385","A chromosome band present on 5q","5q31 | Chromosome 5q31",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699153","Cell Invasion","C75004","The movement of one cell type into an area normally occupied by a different cell type.","Invasion | Cell Invasion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0176514","Open Lung Biopsy","C51923","Removal of tissue from the lung, for microscopic examination, obtained during an open surgical procedure.","Open Lung Biopsy | Open Biopsy of Lung",,,,,,,,,,,,,,,"4339608","Open biopsy of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348887","Gram per Square Meter per Day","C73722","Dose of drug administered per day expressed as grams per square meter of body surface area (BSA).","Gram per Square Meter per Day | Gram per Square Meter per 24 Hours | g/m2/d | g/m2/day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555767","Medical Oncologist","C17838","A doctor who specializes in treating cancer. Some oncologists specialize in a particular type of cancer treatment. For example, a radiation oncologist specializes in treating cancer with radiation.","Medical Oncologist | medical oncologist | oncologist, medical",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448943","Above","C75329","In a place or position that is higher.","Above | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448942","Below","C75330","In a place or position that is lower.","Below | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0223670","Obturator Foramen","C75332","An opening in the hip bone formed by the public bone and the ischium and closed by the obturator membrane.","Obturator Foramen | Obturator",,,,,,,,,,,,,,,"4078222","Obturator foramen structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0230189","Hypogastric Region","C32755","The lowest central region of the abdomen, below the umbilical region and between the two iliac regions.","Hypogastric Region | Hypogastric | Hypogastrium | Pubic Area | Pubic Region | SUPRAPUBIC REGION | Suprapubic Region",,,,,,,,,,,,,,,"4035235","Hypogastric region structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0741204","ARCH","C61461","A structure with a curved or bowlike outline.","Arch | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348188","Serial Number","C73518","A unique identifier assigned to a member of a series of similar items.","Serial Number | A unique alphanumeric identifier assigned to each of a series of identical manufactured products. | SERIAL | SNO | serialNumberText",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027088","Myometrium","C12314","The smooth muscle lining the uterus.","Myometrium | MYOMETRIUM | myometrium",,,,,,,,,,,,,,,"4099478","Myometrial structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347644","Positive Selection","C71257","The selective retention of a population of desired cells through recognition of cells bearing specific characteristics.","Positive Selection | Positive Cell Enrichment | Positive Cell Selection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022702","Kinetics","C16770","Kinetics is the branch of mechanics concerned with the forces that cause motions of bodies and govern the rates at which molecules and compounds react.","Kinetics | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229807","Iliac Lymph Node","C32761","One of the three lymph nodes of the pelvis: the superior gluteal, interior gluteal or sacral.","Iliac Lymph Node | ILIAC LYMPH NODE | LYMPH NODE, ILIAC | Structure of iliac lymph node (body structure)",,,,,,,,,,,,,,,"4224163","Structure of iliac lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004475","Azacitidine","C288","A pyrimidine nucleoside analogue of cytidine with antineoplastic activity. Azacitidine is incorporated into DNA, where it reversibly inhibits DNA methyltransferase, thereby blocking DNA methylation.  Hypomethylation of DNA by azacitidine may activate tumor suppressor genes silenced by hypermethylation, resulting in an antitumor effect. This agent is also incorporated into RNA, thereby disrupting normal RNA function and impairing tRNA cytosine-5-methyltransferase activity. (NCI04)","Azacitidine | 4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazin-2(1H)-one | 5 AZC | 5-AC | 5-AZC | 5-Aza-cytidine | 5-Azacitidine | 5-Azacytidine | AZACITIDINE | Azacytidine | Azacytidine, 5- | Ladakamycin | Mylosar | Onureg | U-18496 | Vidaza | azacitidine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347695","Property (possession)","C73618","Any tangible or intangible possession that is owned by a person, group, or organization.","Property | Thing Owned",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2355646","Delimiter - data type","C73519","A character or string used to separate, or mark the start and end of, items of data.","Delimiter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347440","Pad Character","C73520","A character used to fill empty space.","Pad Character | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0681509","Electronic Document","C73620","Writing recorded in a format that requires an electronic device to view or modify.","Electronic Document | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282116","Collaboration","C73529","The process by which two or more parties work jointly towards a common goal.","Collaboration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038659","therapeutic suggestion","C48313","A proposal offered for acceptance or rejection.","Suggestion | Suggest",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346841","Application Adapter","C73536","A software layer that converts data from an application into a form that will allow integration with other applications.","Application Adapter | Adapter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348235","Specification","C73537","A detailed description of criteria for a piece of work.","Specification | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0598697","Hazard","C73538","A source of danger or risk.","Hazard | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349155","Worksheet","C73541","A tool used to record data for an activity. It can be a document of events or planned activities or a computer application that calculates different scenarios when the input is modified.","Worksheet | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0392762","Quantitative Concept","C70766","Capable of being estimated or expressed with numeric values.","Quantitative Concept | QUANTITATIVE | Qn | Quantitative | Quantitative",,,,,,,,,,,,,,,"4149267","Quantitative",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026934","Mycoplasma","C73540","A genus of nonmotile facultatively anaerobic bacteria that lack a true cell wall, are gram-negative, and require sterol for growth.","Mycoplasma | MYCOPLASMA",,,,,,,,,,,,,,,"4193931","Genus Mycoplasma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709474","Passage tissue culture technique","C54573","Removal of a cell culture from the culture vessel with a subculture (passage) process, in order to keep the cells at a sufficiently low density to stimulate further growth.","Passage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348519","Feature","C73619","A prominent or identifiable aspect, region, or site of interest.","Feature | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3146295","Triceps","C33812","A skeletal muscle of the limb comprised of three muscular bundles called the heads that originate seperately and join together.","Triceps | Triceps Muscle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0559499","Biceps Brachii","C32200","A muscle in the upper arm. Its action involves the rotation of the arm and the flexing of the elbow.","Biceps Brachii | BICEPS BRACHII MUSCLE | Biceps | Biceps | Biceps Brachii Muscle | MUSCLE, BICEPS BRACHII",,,,,,,,,,,,,,,"4036942","Biceps brachii muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030353","Papilledema","C3307","Swelling around the optic disc, usually due to increased intracranial pressure or pressure on the optic nerve by a tumor.","Papilledema | Papilloedema | papilledema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043237","World Health Organization","C75419","A United Nations agency established to coordinate international health activities and to help governments improve health services.","World Health Organization | WHO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407117","Muscle Layer","C75444","The smooth muscle component of an organ, especially of a hollow organ or tubular structure.","Muscle Layer | Muscularis",,,,,,,,,,,,,,,"4313152","Muscularis propria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016928","Gait","C75445","A pattern or manner of running, walking, or moving on foot.","Gait | ",,,,,,,,,,,,,,,"4272021","Gait",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0489815","Deep Tendon Reflex","C75446","Contraction of a muscle triggered by a signal from a muscle spindle in response to a stimulus applied to a specific trigger point on the body. The strength of the response can provide insight into central and peripheral nerve performance.","Deep Tendon Reflex | DTR | Myostatic Reflex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230463","Plantar Region","C33326","The undersurface of the foot.","Plantar Region | Plantar | SOLE",,,,,,,,,,,,,,,"4238317","Structure of sole of foot",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0386370","Ferumoxtran-10","C38140","A synthetic ultrasmall superparamagnetic iron oxide composed of dextran-coated iron oxide nanoparticles (also known as 'ultrasmall particulate iron oxides' or USPIO). Ferumoxtran-10, which accumulates in non-cancerous lymphatic tissue, is used as a molecular resonance imaging (MRI) contrast agent. (NCI04)","Ferumoxtran-10 | Combidex | USPIO | Ultrasmall Particulate Iron Oxide | ferumoxtran-10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708337","Artificial Heart Valve Leaflet","C50029","A mechanical heart valve where the valve mechanisms consists of two thin blades that hinge from the center and regulate the flow of blood.","Heart Valve Leaflet Device | Artificial Heart Valve Leaflet | Heart Valve Leaflet | Heart Valve Leaflet Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0344413","Heart Block by ECG Finding","C34665","An electrocardiographic finding of blocked cardiac electrical impulses along the fibers normally responsible for impulse conduction.","Heart Block by ECG Finding | Conduction Block | Heart Block | Heart Block | Heart Block by EKG Finding",,,,,,,,,,,,,,,"4064457","EKG: heart block",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0596751","Immunoaffinity Chromatography","C75519","Affinity chromatography using monoclonal or polyclonal antibodies, or (less commonly) antigens, as the immobilized binding phase.","Immunoaffinity Chromatography | Antibody Affinity Chromatography",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1136535","Pegfilgrastim","C1854","A long-acting pegylated form of a recombinant therapeutic agent which is chemically identical to or similar to an endogenous human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. Conjugation of the cytokine with a branched polyethylene glycol molecule (pegylation) significantly increases its therapeutic half-life. (NCI04)","Pegfilgrastim | Dulastin | Filgrastim SD-01 | Fulphila | Fylnetra | G-Lasta | HSP-130 | Jinyouli | Neulasta | Neulastim | Neupopeg | Nyvepria | PEG-filgrastim | PEGFILGRASTIM | PF-06881894 | Pegcyte | Pegfilgrastim Biosimilar HSP-130 | Pegfilgrastim Biosimilar Nyvepria | Pegfilgrastim Biosimilar PF-06881894 | Pegfilgrastim Biosimilar Pegcyte | Pegfilgrastim Biosimilar Udenyca | Pegfilgrastim Biosimilar Ziextenzo | Pegfilgrastim-apgf | Pegfilgrastim-bmez | Pegfilgrastim-cbqv | Pegfilgrastim-fpgk | Pegfilgrastim-jmdb | Pegfilgrastim-pbbk | Pegylated G-CSF | Pegylated GCSF | Pegylated Granulocyte Colony Stimulating Factor | SD-01 | SD-01 sustained duration G-CSF | Stimufend | Tripegfilgrastim | Udenyca | Ziextenzo | filgrastim-SD/01 | pegfilgrastim | pegfilgrastim-apgf | pegfilgrastim-bmez | pegfilgrastim-cbqv",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376541","Recombinant Erythropoietin","C477","A recombinant therapeutic agent which is chemically identical to or similar to the endogenous glycoprotein erythropoietin (Epo).  Epo promotes the differentiation and maturation of hematopoietic progenitors into erythrocytes; is a mitogen and a chemoattractant for endothelial cells; stimulates activated and differentiated B-cells and enhances B-cell immunoglobulin production and proliferation; and is hypoxia-inducible. (NCI04)","Recombinant Erythropoietin | EPOETIN | Erythrocyte Colony Stimulating Factor | Erythropoietin | Hematopoietin | Recombinant EPO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518962","Percent Free Prostate-Specific Antigen Measurement","C20042","PSA circulates in the blood in two forms: free or attached to a protein molecule.  With benign prostate conditions, there is more free PSA, while cancer produces more of the attached form.  A more accurate predictor of cancer than either a patient's age or his total PSA level. (from Cancer Information Service)","Percent Free Prostate-Specific Antigen | free PSA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026597","Motion","C75602","The act or process of changing position or place; the change in position of a body part.","Motion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085089","Artifact","C75603","A structure or appearance that is not naturally present, but has been introduced though manipulation.","Artifact | ARTIFACT",,,,,,,,,,,,,,,"4126705|4167321","Physical object|Artifact",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0008627","Chromosome Banding","C16437","The treatment of chromosomes to reveal characteristic patterns of horizontal bands.  The banding patterns lend each chromosome a distinctive appearance so the 22 pairs of human non-sex chromosomes and the X and Y chromosomes can be identified and distinguished without ambiguity. Banding also permits the recognition of chromosome deletions (lost segments), chromosome duplications (surplus segments) and other types of structural rearrangements of chromosomes.","Chromosome Banding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003463","Anal Neoplasm","C2877","A benign or malignant neoplasm that affects the anal canal or anal margin.  Representative examples of benign neoplasms include squamous papilloma and papillary hidradenoma.  Representative examples of malignant neoplasms include carcinoma, lymphoma, and melanoma.","Anal Neoplasm | Anal Neoplasms, Benign and Malignant | Anal Tumor | Anal Tumors | Anus Neoplasm | Neoplasm of Anus | Neoplasm of the Anus | Tumor of Anus | Tumor of the Anus",,,,,,,,,,,,,,,"4129882","Neoplasm of anus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2699006","Rat Genome Database","C74914","A collaborative effort between research institutions involved in rat genetic and genomic research for the establishment of a database to collect, consolidate, and integrate data generated from ongoing rat genetic and genomic research efforts and to make this data widely available to the scientific community.","Rat Genome Database | RGD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388550","Zebrafish Model Organism Database","C74915","An on-line community database for the development and support of integrated zebrafish genetic, genomic and developmental information, the maintenance of the definitive reference data sets of zebrafish research information, linkage of this information to corresponding data in other model organism and human databases, and the facilitation of the use of zebrafish as a model for human biology in order to serve the needs of the research community.","Zebrafish Model Organism Database | ZFIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2350567","Gene Knockdown","C74927","Any of various techniques to reduce the expression of a gene without eliminating it entirely. The reduced epression may be permanent or via a transient mechanism.","Gene Knockdown | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031916","Pigment","C747","A substance that gives color to tissue. Pigments are responsible for the color of skin, eyes, and hair.","Pigment | pigment",,,,,,,,,,,,,,,"4277923","Pigment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205283","Contiguous","C28019","Adjacent to one another.","Contiguous | contiguous",,,,,,,,,,,,,,,"4277116","Contiguous",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202042","Plasma Glucose Measurement","C41376","Glucose Plasma Concentration (GPC) measurement is an essential diagnostic modality for different types of carbohydrate metabolism derangements including diabetes mellitus. The disordered carbohydrate metabolism that underlies diabetes manifests as hyperglycemia. Plasma glucose concentrations in healthy individuals vary with age. Normal fasting plasma glucose intervals (in the morning after an overnight fast) in children are 3.3 - 5.6 mmol/L (60-100 mg/dL); adult range - 4.1- 5.9 mmol/L (74-106 mg/dL). GPCs are approximately 11% higher than whole blood if the hematocrit is normal. Glucose concentrations in heparinized plasma are reported to be 5% lower than in serum.","Plasma Glucose Measurement | Glucose Plasma Concentration Measurement",,,,,,,,,,,,,,,"4218282","Glucose measurement, plasma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0278962","New York Heart Association Class III/IV","C7922","The two most severe classes of cardiac dysfunction according to a classification system developed by the New York Heart Association to grade cardiovascular function and disability. These classes are defined as follows: Class III - patients with cardiac disease producing marked limitation of activity: comfortable at rest. Less than ordinary physical activity causes symptoms. Class IV - patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms may be present even at rest.","New York Heart Association Class III/IV | NYHA Class III/IV | NYHA III/IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521378","Biliary","C28011","A term that refers to the biliary tract structures.","Biliary | biliary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037657","Insulin-Like Growth Factor","C20442","Bound to IGFBPs in the circulation, Insulin-Like Growth Factors (IGFs, Somatomedins) are a family of extracellular signaling peptides (potential autocrine ligands) involved in mediation of growth hormone action, stimulation of insulin action, and growth and development. The three main somatomedins are Somatomedin C (IGF1), Somatomedin A (IGF2), and Somatomedin B. Single chain IGFs I and II share about 47% amino acid homology with insulin (INS) and 31% with relaxin.","Insulin-Like Growth Factor | IGF | Somatomedin | insulin-like growth factor | somatomedin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0069515","Receptor Tyrosine-Protein Kinase erbB-2, Human","C17319","Receptor tyrosine-protein kinase erbB-2 (1255 aa, ~138 kDa) is encoded by the human ERBB2 gene. This protein is involved in cell proliferation, tyrosine phosphorylation and signal transduction.","Receptor Tyrosine-Protein Kinase erbB-2 | Antigen CD340 | CD340 | CD340 Antigen | EC 2.7.10.1 | ERBB2 | ERBB2 Receptor Protein-Tyrosine Kinase | ERBB2 Receptor Protein-Tyrosine Kinase | HER-2 | HER2 | HER2/neu | MLN 19 | Metastatic Lymph Node Gene 19 Protein | NEU | Proto-Oncogene Neu | Proto-Oncogene c-ErbB-2 | Tyrosine Kinase-Type Cell Surface Receptor HER2 | c-erbB-2 | human EGF receptor 2 | human epidermal growth factor receptor 2 | p185erbB2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085393","Immunocompromised","C14139","A loss of any arm of immune functions, resulting in potential or actual increase in infections. This state may be reached secondary to specific genetic lesions, syndromes with unidentified or polygenic causes, acquired deficits from other disease states, or as result of therapy for other diseases or conditions.","Immunocompromised | Immunocompromised Host | Immunocompromised Patient | Immunosuppressed | Immunosuppressed Host | Immunosuppressed Patient | immunocompromised | immunocompromised host | immunocompromised patient | immunosuppressed host | immunosuppressed patient",,,,,,,,,,,,,,,"4153516|4157007","Patient immunocompromised|Patient immunosuppressed",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1882920","Registration Specialist","C54632","A user who, on behalf of a sponsor, will manage and process the Investigator registrations.","Registration Specialist | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0379955","Indium In-111 Pentetreotide","C1672","An indium 111 radioconjugate of pentetreotide, the diethylenetriaminopentaacetic (DTPA) conjugate of the human hormone somatostatin peptide analogue (octreotide), used for radioimaging neuroendocrine tumor cells. The pentetreotide moiety of indium In 111 pentetreotide binds to somatostatin receptors (SSTRs), especially type 2 receptors, present on the cell membranes of many types of neuroendocrine tumor cells. Upon binding and internalization, this radioconjugate allows for specific imaging of neuroendocrine tumors that overexpress somatostatin using scintigraphic imaging techniques. In addition, high dose indium In 111 pentetreotide may specifically deliver a cytotoxic dose of gamma radiation to SSTR-positive cells thereby killing SSTR-expressing tumor cells.","Indium In-111 Pentetreotide | INDIUM IN-111 PENTETREOTIDE | In 111 Pentetreotide | Indium In 111 Pentetreotide | Indium In 111-Pentetreotide | Indium-111-DTPA-D-Phe-1-octreotide | Indium-In 111 Pentetreotide | Indium-In-111-Pentetreotide | OctreoScan | indium In 111 pentetreotide",,,,,,,,,,,,,,,"40489389","Indium (111-In) pentetreotide",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026766","Multiple Organ Failure","C75568","Complete impairment of two or more organs or organ systems.","Multiple Organ Failure | Multi-Organ Failure | Multi-organ failure | Multiple Organ Dysfunction Syndrome | Multiple System Failure",,,,,,,,,,,,,,,"4212484","Multiple organ failure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018129","Graft Failure","C75570","Failure of transplanted tissue to become functional or operational, often as a result of destruction by the host's immune system.","Graft Failure | Graft Failure | Graft Rejection | Graft failure",,,,,,,,,,,,,,,"4248020","Graft rejection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1167395","Host","C66819","An organism that nourishes and supports another but does not benefit by the association; recipient of transplanted tissue or organ from a donor.","Host | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042784","Viscosity","C75912","The resistance of a liquid to sheer forces and flow.","Viscosity | VISC | VISCOSITY | Visc",,,,,,,,,,,,,,,"4193621","Viscosity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0699829","Renal clearance diagnostic test","C75913","The rate at which a substance is removed from the blood via the kidneys.","Renal Clearance | RENALCL | Renal CL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700395","Smallest","C75908","Least in number, quantity, magnitude or extent of those under consideration.","Smallest | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028783","Obturator Nerve","C75909","A nerve that arises from the second, third, and fourth lumbar nerves and enters the thigh through the obturator canal. It is responsible for the sensory innervation of the skin of the medial aspect of the thigh and also responsible for the motor innervation of the adductor muscles of the lower extremity.","Obturator Nerve | ",,,,,,,,,,,,,,,"4244723","Structure of obturator nerve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698651","Optimum","C75911","The best or most suitable; the greatest degree attainable.","Optimum | Optimal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037296","Skin Test","C17137","A preparation of an antigenic component of an infectious agent that is administered to a patient in order to determine whether previous exposure to the agent has occurred, and/or to assess the integrity of the patient's cellular immune system.  Depending on the clinical situation, the appearance of a delayed (cellular) hypersensitivity response, which manifests as an area of induration and erythema at the injection site, i.e. a positive test result, may indicate previous exposure to a particular infectious agent. (NCI04)","Skin Test | skin test",,,,,,,,,,,,,,,"4205590","Skin test",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347562","Cart Object","C73788","A uniquely identified, typed representation of textual data.","Cart Object | CartObject",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0302891","Native","C73789","Of or related to the original state or source; natural.","Native | ",,,,,,,,,,,,,,,"4135608","Native",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448932","Write","C73994","Communicate or express by means of letters or symbols written or imprinted on a surface to represent the sounds or words of a language; record data on a computer.","Write | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698876","Presacral","C75910","Anterior to or preceding the sacrum.","Presacral | Pre-sacral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1278039","Serum Total Bilirubin Measurement","C61031","A quantitative measurement of the total amount of bilirubin present in a sample of serum.","Serum Total Bilirubin Measurement | ",,,,,,,,,,,,,,,"4195338","Serum total bilirubin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001967","Alcoholic Beverage","C45902","A drink, including beer, wine or liquor, that is made by fermentation of raw materials. An alcoholic beverage contains ethanol (alcohol) as the active ingredient.","Alcoholic Beverage | alcohol type | alcohol_type",,,,,,,,,,,,,,,"4205848","Alcoholic beverage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0443276","Pathological Staging","C28257","An examination that is performed to determine the extent of the spread of cancer based on histopathologic examination of one or more pathology specimens. Pathologic staging uses evidence acquired during the process of clinical staging, supplemented by histopathologic examination of surgical specimens.","Pathological Staging | Pathologic Staging | Surgical Staging | pathological staging",,,,,,,,,,,,,,,"4128939","Pathological staging",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1548788","Inappropriate","C74958","Not in keeping with what is correct or proper.","Inappropriate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009437","Common Bile Duct","C12698","Bile ducts are passageways that carry bile. Two major bile ducts come together into a 'trunk'-the common bile duct which empties into the upper part of the small intestine (the part next to the stomach).","Common Bile Duct | COMMON BILE DUCT | Common Duct | Common Hepatic Duct | Common bile duct structure (body structure) | DUCT, COMMON BILE | Ductus Communis Choledochus | common bile duct | ductus choledochus (biliaris)","C24.0|C24.0","Common bile duct|Common duct",,,,,,,,,,,"UBERON:0001174","common bile duct","4197082","Common bile duct structure",,,,,,,,,,,,,"--","--|--",,,,,,,,"--"
"C0035092","Renal Vein","C33462","The veins which return blood from the kidneys to the vena cava.","Renal Vein | RENAL VEIN | Renal vein | VEIN, RENAL",,,,,,,,,,,,,,,"4208703","Structure of renal vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1947915","crest - location","C61550","A projection or projecting structure, or ridge, especially one surmounting a bone or its border.","Crest | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456786","Square Millimeter","C65104","A unit of area measurement equal to a square measuring one millimeter on each side. One square millimeter is equal to 10(E-2) square centimeter and 10(E-6) square meter.","Square Millimeter | Millimeter Squared | mm2 | mm^2 | sq. mm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334092","Hamartomatous Polyp","C8372","A polyp characterized by an overgrowth of mature cells and tissues that normally occur in the affected area.","Hamartomatous Polyp | ",,,,,,,,,,,,,,,"4099607","Hamartomatous polyp",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710057","Serrated Glandular Architecture","C42599","The common saw-tooth architectural pattern observed within hyperplastic polyps.","Serrated Glandular Architecture | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334307","Tubulovillous Adenoma","C4143","An adenoma arising from the glandular epithelium of the gastrointestinal tract. It is characterized by the presence of a tubular and a villous architectural pattern. Most often it occurs in the large intestine, small intestine, and the stomach. The neoplastic epithelial cells show dysplastic features.","Gastrointestinal Tract Tubulovillous Adenoma | GI Tract Tubulovillous Adenoma | Gastrointestinal Tract Tubulovillous Adenoma | Tubulovillous Adenoma | Tubulovillous adenoma, NOS | tubulovillous adenoma",,,,,,,,,,,,,,,"4267876","Tubulovillous adenoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519984","Villous","C14170","Abounding in, or covered with, fine hairs.","Villous | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334245","Stage 0 Squamous Cell Carcinoma","C27093","A malignant epithelial neoplasm confined to the squamous epithelium, without invasion of the underlying tissues.","Stage 0 Squamous Cell Carcinoma | CARCINOMA, SQUAMOUS CELL, IN SITU, MALIGNANT | Epidermoid Carcinoma In situ | Epidermoid Carcinoma in situ | Epidermoid Cell Carcinoma In situ | Epidermoid Cell Carcinoma in situ | Epidermoid carcinoma in situ, NOS | Grade 3 SIN | Grade 3 Squamous Intraepithelial Neoplasia | Grade III SIN | Grade III Squamous Intraepithelial Neoplasia | Intraepithelial Squamous Cell Carcinoma | Intraepithelial squamous cell carcinoma | SCC in situ | Squamous Carcinoma In situ | Squamous Carcinoma in situ | Squamous Cell Carcinoma In situ | Squamous Cell Carcinoma in situ | Squamous Cell Carcinoma in-situ | Squamous cell carcinoma in situ, NOS | Squamous intraepithelial neoplasia, grade III","8070/2","Squamous cell carcinoma in situ, NOS",,,,,,,,,,,,,"37151870|40390738|4069557|4266203","Squamous cell carcinoma in situ|Squamous cell carcinoma in situ|Squamous intraepithelial neoplasia, high grade|Intraepithelial squamous cell carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--|--|--"
"C0402112","Scientist","C28249","A person who has studied science, especially one who is active in a particular field of investigation.","Scientist | scientist",,,,,,,,,,,,,,,"4145406","Scientist",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347851","Computer Time Stamp","C72669","The date and time at which an event occurs or occurred, computer generated but usually indicated in human-readable form, especially when used to track events.","Computer Time Stamp | Time Stamp | Timestamp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2350001","Population Parameter","C71569","A value, which represents a particular population characteristic. It is a numerical summary of a population as a complete set of data elements.","Population Parameter | PARM | Parameter | Parameter | Population Measure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026510","Montenegro","C64378","A country in southeastern Europe, bordering the Adriatic Sea, between Albania and Bosnia and Herzegovina.","Montenegro | 499 | ME | MNE | MONTENEGRO | People's Republic of Serbia | Republic of Serbia | Socialist Republic of Serbia",,,,,,,,,,,,,,,"40483631","Montenegro",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036708","Serbia","C64377","A republic in southeastern Europe, between Romania and Bosnia and Herzegovina.","Serbia | 688 | People's Republic of Serbia | RS | Republic of Serbia | SERBIA | SRB | Socialist Republic of Serbia",,,,,,,,,,,,,,,"40480046","Republic of Serbia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1335177","Ovarian Serous Adenocarcinoma","C7550","An adenocarcinoma that arises from the ovary and is characterized by the presence of malignant epithelial cells that, in well differentiated tumors, resemble the epithelium of the fallopian tube or, in poorly differentiated tumors, show anaplastic features and marked nuclear atypia.","Ovarian Serous Adenocarcinoma | Ovarian Serous Carcinoma | Serous Adenocarcinoma of Ovary | Serous Adenocarcinoma of the Ovary | Serous Carcinoma of Ovary | Serous Carcinoma of the Ovary | Serous carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015518","Coagulation Factor X","C76142","Coagulation factor X (488 aa, ~55 kDa) is encoded by the human F10 gene. This protein is involved in proteolysis and blood coagulation.","Coagulation Factor X | Blood Coagulation Factor X | EC 3.4.21.6 | F10 | Factor X | Prothrombinase | Stuart Factor | Stuart-Prower Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1559071","CTCAE Grade 3 Rigors/chills","C55317","Severe or prolonged, not responsive to narcotics","Grade 3 Rigors and Chills, CTCAE | CTCAE Grade 3 Rigors and Chills | CTCAE Grade 3 Rigors/chills | Grade 3 Rigors/chills",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1559069","CTCAE Grade 1 Rigors/chills","C55297","Mild","Grade 1 Rigors and Chills, CTCAE | CTCAE Grade 1 Rigors and Chills | CTCAE Grade 1 Rigors/chills | Grade 1 Rigors/chills",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0068722","Nicotine Gum","C15663","A chewing gum containing nicotine used as a substitute for the active ingredient in tobacco. Nicotine chewing gum reduces the withdrawal symptoms associated with smoking cessation.","Nicotine Gum | Nicorette | Nicotine Polacrilex | nicotine gum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037370","Passive Smoke Exposure","C17140","Exposure to tobacco smoke products among individuals who do not smoke. This can result from sharing space with a smoker or from placental transfer from mother to fetus.","Passive Smoke Exposure | Environmental tobacco smoke | Passive Exposure | Passive Smoking | Smoking, Passive | Smoking, Tobacco and Cancer-Passive Smoking | environmental tobacco smoke exposure | environmental_tobacco_smoke_exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706249","Bag Dosing Unit","C48474","A dosing unit equal to the amount of active ingredient(s) contained in a bag.","Bag Dosing Unit | BAG | BG | Bag | {BAG} | {Bag}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017638","Glioma","C3059","A benign or malignant brain and spinal cord tumor that arises from glial cells (astrocytes, oligodendrocytes, ependymal cells). Tumors that arise from astrocytes are called astrocytic tumors or astrocytomas. Tumors that arise from oligodendrocytes are called oligodendroglial tumors. Tumors that arise from ependymal cells are called ependymomas.","Glioma | Glial Neoplasm | Glial Tumor | Glioma, NOS | Neoplasm of Neuroglia | Neoplasm of the Neuroglia | Neuroglial Neoplasm | Neuroglial Tumor | Neuroglial Tumor | Tumor of Neuroglia | Tumor of the Neuroglia | glial tumor | glioma",,,,,,,,,,,,,,,"4019491|40571981","Glioma|Glioma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0149782","Lung Squamous Cell Carcinoma","C3493","A carcinoma arising from squamous bronchial epithelial cells. It may be keratinizing or non-keratinizing. Keratinizing squamous cell carcinoma is characterized by the presence of keratinization, pearl formation, and/or intercellular bridges. Non-keratinizing squamous cell carcinoma is characterized by the absence of keratinization, pearl formation, and intercellular bridges. Cigarette smoking and arsenic exposure are strongly associated with squamous cell lung carcinoma.","Lung Squamous Cell Carcinoma | Epidermoid Cell Carcinoma of Lung | Epidermoid Cell Carcinoma of the Lung | Epidermoid Cell Lung Carcinoma | LSCC | LUSC | Squamous Cell Carcinoma of Lung | Squamous Cell Carcinoma of the Lung | Squamous Cell Lung Cancer | Squamous Cell Lung Carcinoma | Squamous Cell Lung Carcinoma | Squamous cell lung carcinoma",,,,,,,,,,,,,,,"4110705","Squamous cell carcinoma of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0012621","Fluid Discharge","C34548","The pouring forth of a fluid.","Fluid Discharge | Discharge | discharge",,,,,,,,,,,,,,,"4146472|4294698","Discharge - substance|Discharge",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2699893","Targeted Molecular Therapy","C76243","Cancer therapies designed to act upon specific molecules in metabolic pathways or processes involved in carcinogenesis, tumor growth, or tumor spread.","Targeted Molecular Therapy | Molecular Targeted Therapy | molecularly targeted therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0427620","Blood Group A","C76246","A blood group indicating the presence on erythrocytes of only the A form of the H Antigen.","Blood Group A | A | Blood Type A",,,,,,,,,,,,,,,"4008253","Blood group A",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0427623","Blood Group B","C76247","A blood group indicating the presence on erythrocytes of only the B form of the H Antigen.","Blood Group B | B | Blood Type B",,,,,,,,,,,,,,,"4009006","Blood group B",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0427624","Blood Group AB","C76248","A blood group indicating the presence on erythrocytes of both the A and B forms of the H Antigen.","Blood Group AB | AB | Blood Type AB",,,,,,,,,,,,,,,"4013993","Blood group AB",,,,,,,,,,,,,"--",,,,,,,,,"--"
,,"C76249","A blood group indicating the absence on erythrocytes of both the A and B forms of the H Antigen.","Blood Group O | Blood Type O | O",,,,,,,,,,,,,,,"4237761","Blood group O",,,,,,,,,,,,,,,,,,,,,,"--"
"C2699078","Rh Positive Blood Group","C76251","A blood group indicating the presence on erythrocytes of the Rh D form of the Rhesus antigen.","Rh Positive Blood Group | Positive | Rh Positive | Rh+ | Rh+ Blood Group",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699077","Rh Negative Blood Group","C76252","A blood group indicating the absence on erythrocytes of the Rh D form of the Rhesus antigen.","Rh Negative Blood Group | Negative | Rh Negative | Rh- | Rh- Blood Group",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012238","Digestion","C16503","The process or act of converting food into chemical substances that can be absorbed and assimilated.","Digestion | Digestive | digestion",,,,,,,,,,,,,,,"4025208","Digestive system function",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512759","Information Resource","C16048","Sources of information such as libraries, databases, and websites.","Information Resource | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0681495","Movie","C75001","A sequence of images displayed in succession giving the illusion of continuous movement.","Movie | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707478","Conclusion","C54033","A position or opinion or judgment reached after consideration.","Conclusion | conclusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698172","Application Program Interface","C75301","A set of protocols designed to provide communication between a software application and a computer operating system or between applications.","Application Program Interface | API | Application Programming Interface | Interface | Software Interface",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1533691","in vitro","C15263","In the laboratory; literally, 'in glass'.","In Vitro | in vitro | in vitro",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1861851","Adrenal Gland Pheochromocytoma","C3326","A neuroendocrine neoplasm of the sympathetic nervous system that arises from the chromaffin cells of the adrenal medulla and secretes catecholamines. Clinical presentation includes headaches, palpitations, chest and abdominal pain, hypertension, fever, and tremor.  Microscopically, a characteristic nesting (zellballen) growth pattern is usually seen.  Other growth patterns including trabecular pattern may also be present.","Adrenal Gland Pheochromocytoma | Adrenal Gland Chromaffin Paraganglioma | Adrenal Gland Chromaffinoma | Adrenal Gland Paraganglioma | Adrenal Medullary Paraganglioma | Adrenal Medullary Pheochromocytoma | Adrenal Pheochromocytoma | Adrenal medullary paraganglioma | Chromaffin Paraganglioma of the Adrenal Gland | Intraadrenal Paraganglioma | PCC | Pheochromocytoma | Pheochromocytoma (adrenal) | pheochromocytoma",,,,,,,,,,,,,,,"4118993|4311087","Pheochromocytoma|Pheochromocytoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1513540","Mouse Disorder by Site","C26390","An organization of mouse disorders based on the body site affected.","Mouse Disorder by Site | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882644","Rat Proliferative Change by Location","C61111","Disorders of the rat that are characterized by cell proliferation, organized by body location.","Rat Proliferative Change by Location | Rat Disorder by Site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0304604","Topical form corticosteroids","C29505","Any synthetic steroid derivative exhibiting the same function as the naturally occurring corticosteroid hormone, formulated for topical application. Topical corticosteroids are applied to the skin where it exerts its effect, however, corticosteroids can be absorbed systemically after being applied locally. Topical corticosteroids are mainly used for the localized treatment of inflammation of the skin and help relieve symptoms such as itching, swelling and redness.","Topical Corticosteroid | Topical Corticosteroids | Topical Corticosteroids | Topical corticosteroid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443224","Fresh","C75531","Not previously used.","Fresh | ",,,,,,,,,,,,,,,"4126854","Fresh",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698236","Mobilized Peripheral Blood Stem Cell","C75576","Blood stem cells found in the circulation after being stimulated to leave the bone marrow, usually by treatment with a cytokine or other drug.","Mobilized Peripheral Blood Stem Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030393","Parainfluenza virus","C75532","A non-taxanomic group of paramyxoviruses (genus Respirovirus and Rubulavirus) that are a frequent cause of infections of the lower respiratory tract.","Parainfluenza Virus | PIV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040556","Toxoplasma","C75538","A genus of protozoa that is parasitic in humans, other mammals, and some birds.","Toxoplasma | TOXOPLASMA",,,,,,,,,,,,,,,"4264459","Toxoplasma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332189","Episode","C75539","A noteworthy happening that is distinctive in a series of related events.","Episode | EPISODE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0234233","Tenderness","C75540","Discomfort elicited through touch or pressure.","Tenderness | ",,,,,,,,,,,,,,,"4082445","Tenderness",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0333145","Hemorrhagic Cyst","C75548","A cyst containing blood.","Hemorrhagic Cyst | HEMATOCYST",,,,,,,,,,,,,,,"4182060","Hemorrhagic cyst",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3808621","Hemolytic Uremic Syndrome","C75545","Acute kidney injury associated with microangiopathic hemolytic anemia and thrombocytopenia.","Hemolytic Uremic Syndrome | HUS | Hemolytic uremic syndrome | Hemolytic-Uremic Syndrome",,,,,,,,,,,,,,,"197253","Hemolytic uremic syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0679924","professional occupation status","C75558","An occupation requiring special education, especially in the liberal arts or sciences.","Professional Occupation | Professional",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1321772","Clerk","C75552","A person employed in an office who performs various tasks such as keeping records or accounts, filing, letter writing, or transcribing.","Clerk | Clerical Occupation | Office Clerk",,,,,,,,,,,,,,,"4024174","Clerk",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0402546","Salesperson","C75553","A person employed to sell goods or services especially to customers in a store or to customers that are visited within a geographic area.","Salesperson | Sales | Selling Occupation | Shop Salesperson | Shop Salespersons",,,,,,,,,,,,,,,"4011913","Selling occupation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0682209","Skilled Worker","C75554","A worker who has acquired special skills.","Skilled Worker | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0240146","Laborer","C75556","Someone who works with their hands; someone engaged in manual labor.","Laborer | ",,,,,,,,,,,,,,,"4026886","Laborer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221460","Farmer","C75559","A person who produces food by growing plants or tending animals.","Farmer | ",,,,,,,,,,,,,,,"4023490","Farmer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0555052","Homemaker","C75560","A person who manages a home as their main daily activity.","Homemaker | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038492","Student","C75561","A person who is enrolled in an educational institution.","Student | ",,,,,,,,,,,,,,,"4277918","Student",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0682294","Part Time Employment","C75562","Employment involving less than the standard or customary working time.","Part Time Employment | PART-TIME | Part Time | Part-Time | Part-time | Part-time Employment | Working part-time for pay",,,,,,,,,,,,,,,"4059634","Part-time employment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041674","Unemployed","C75563","The state of not having a job.","Unemployed | Does Not Work | Doesn't Work | Don't Work | NOT EMPLOYED | No | UNEMPLOYMENT | Unemployment | Unemployment",,,,,,,,,,,,,,,"4251171","Unemployed",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0596112","Antileukemic Agent","C75574","Any substance that treats, prevents, or inhibits the development of leukemia.","Antileukemic Agent | Anti-leukemic Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005758","Blister","C75564","An intraepidermal/subepidermal cavity filled with clear, serosanguineous or cloudy fluid.","Blister | blister | skin vesicle",,,,,,,,,,,,,,,"4144955","Blister",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0419360","Slit-lamp Examination","C75583","Examination of the anterior segment of the eye using a medical instrument called a slit lamp.","Slit-lamp Examination | SLIT LAMP | Slit Lamp Biomicroscopy | Slit Lamp Examination | slit-lamp biomicroscopy | slit-lamp eye exam",,,,,,,,,,,,,,,"4210011","Ocular slit lamp examination",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4228524","Muscle Contracture","C75585","Permanent contraction of a muscle as a result of spasm or paralysis.","Muscle Contracture | Contraction",,,,,,,,,,,,,,,"4208264","Muscle contracture",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2699154","Cell Wash","C76322","The process of applying a solvent (e.g., water) or a solution (e.g., SSC/SDS) to a biomaterial or an array to remove impurities or unwanted compounds.","Cell Wash | Wash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699518","Absorbable","C75520","Capable of being taken up or taken in.","Absorbable | Absorbable ",,,,,,,,,,,,,,,"3655442","Absorbable",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2699787","Disturbance","C75521","A departure or divergence from that which is considered normal.","Disturbance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698127","Anti-CD25 Monoclonal Antibody","C75525","Any monoclonal antibody directed against the alpha subunit of the human interleukin 2 receptor.","Anti-CD25 Monoclonal Antibody | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420418","SRY Gene","C75527","This gene is involved in testis development and may be involved in transcription.","SRY Gene | SRY | Schirmer Test Wetting | Sex Determining Region Y Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0423791","Maculopapular Lesion","C75579","A skin condition consisting of both macules and papules.","Maculopapular Lesion | Rash maculo-papular",,,,,,,,,,,,,,,"4083795|4168606","Maculopapular eruption|Maculopapular rash",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1515717","t(12;21)(p13.2;q22.1)","C13727","A translocation between chromosomes 12 and 21 involved in TEL-AML1 oncogene formation. The translocation produces a chimeric gene encoding a protein consisting of the N-terminal HLH domain of the TEL ETS-like transcription factor fused with a nearly complete AML1 protein. t(12;21) is the most frequent translocation causing ALL, accounting for 20% of ALL cases.","t(12;21)(p13.2;q22.1) | t(12;21)(p13;q22) | t(12;21)(p13;q22)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513054","Medical Castration","C15743","Refers to the use of drugs to suppress the function of the ovaries or testicles.","Medical Castration | medical castration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698458","New England Census Division","C76338","A census division of the United States consisting of Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, and Connecticut.","New England Census Division | Census Division 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698216","Middle Atlantic Census Division","C76339","A census division of the United States consisting of New Jersey, New York, and Pennsylvania.","Middle Atlantic Census Division | Census Division 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710134","South Mid-Atlantic States","C43441","The area in the United States comprised of the District of Columbia and the following states: Maryland, Virginia, West Virginia, North Carolina and South Carolina.","South Mid-Atlantic States | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699846","East North Central States Census Division","C76340","A census division of the United States consisting of Illinois, Indiana, Michigan, Ohio, and Wisconsin.","East North Central States Census Division | Census Division 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700268","West North Central States Census Division","C76341","A census division of the United States consisting of Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota and South Dakota.","West North Central States Census Division | Census Division 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699495","South Atlantic States Census Division","C76342","A census division of the United States consisting of Delaware, Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, and West Virginia.","South Atlantic States Census Division | Census Division 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699847","East South Central States Census Division","C76343","A census division of the United States consisting of Alabama, Kentucky, Mississippi, and Tennessee.","East South Central States Census Division | Census Division 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700269","West South Central States Census Division","C76344","A census division of the United States consisting of Arkansas, Louisiana, Oklahoma, and Texas.","West South Central States Census Division | Census Division 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698262","Mountain States Census Division","C76345","A census division of the United States consisting of Arizona, Colorado, Idaho, Montana, Nevada, New Mexico, Utah, and Wyoming.","Mountain States Census Division | Census Division 8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698501","Northeastern United States Census Region","C76329","A census region of the United States consisting of Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut, New York, New Jersey, and Pennsylvania.","Northeastern United States Census Region | Census Region 1 | Northeast Census Region | US: Northeast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698219","Midwestern United States Census Region","C76330","A census region of the United States consisting of Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Ohio, Nebraska, North Dakota, South Dakota, and Wisconsin.","Midwestern United States Census Region | Census Region 2 | Midwest Census Region | US: Midwest",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699497","Southern United States Census Region","C76331","A census region of the United States consisting of Florida, Georgia, North Carolina, South Carolina, Virginia, West Virginia, Maryland, Washington, D.C., Delaware, Alabama, Kentucky, Mississippi, Tennessee, Arkansas, Louisiana, Oklahoma, and Texas.","Southern United States Census Region | Census Region 3 | South Census Region | US: South",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700270","Western United States Census Region","C76336","A census region of the United States consisting of Alaska, California, Hawaii, Oregon, Washington, Arizona, Colorado, Idaho, Montana, Nevada, New Mexico, Utah, and Wyoming.","Western United States Census Region | Census Region 4 | US: West | West Census Region",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205392","Some","C65099","At least a small amount or number of, but not a large amount of, or often.","Some | ",,,,,,,,,,,,,,,"4100632","Some",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0050840","Adibendan","C74350","A small amount or duration.","Adibendan | ADIBENDAN | Little",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514815","Refractory Disease","C39752","A disease that resists treatment.","Refractory Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699159","Census Region","C76327","Groupings of states that subdivide the United States for the presentation of census data.","Census Region | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0679201","Inference","C75591","The process by which conclusions are derived from stated facts by the application of logical rules.","Inference | Infer | Inferred",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242456","Policy","C17735","A set of rules adopted by an individual or social group for a specific purpose.","Policy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348662","Concept Unique Identifier","C70818","A unique identifier (code) assigned for each concept that belongs to a particular controlled terminology.","Concept Unique Identifier | CUI | CUI (common unique identifier)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697524","Graph Node","C75907","One of the points that define a graph.","Graph Node | Node | Vertex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699488","Resolution","C75906","A means of finding a solution to a problem, or a means of finding agreement or harmony.","Resolution | Complete | Complete resolution | Resolve | Resolved | Solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706853","Assembly (construction)","C52474","The act of constructing something.","Assembly | Assemble",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698160","Antireflexive Relationship","C75917","A relation in which no element is in relation to itself.","Antireflexive Relationship | Antireflexive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698161","Antisymmetric Relationship","C75920","A binary relation such that if a is related to b and b is related to a, then a equals b.","Antisymmetric Relationship | Antisymmetric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698162","Antitransitive Relationship","C75922","A binary relation such that an element a is related to an element b, and b is in turn related to an element c, but a is not related to c.","Antitransitive Relationship | Antitransitive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700217","Functional Relationship","C75924","An injection (or injective, or one-to-one) such that for every y in Y there is at most one x in X such that f(x) equals y.","Functional Relationship | Functional",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699021","Reflexive Relationship","C75918","A relation in which each element is in relation to itself.","Reflexive Relationship | Reflexive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699074","Reverse-Functional Relationship","C75925","An surjection (or surjective, or onto) such that for every y in Y there is at least one x in X such that f(x) equals y.","Reverse-Functional Relationship | Reverse-Functional",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699744","Symmetric Relationship","C75919","A binary relation such that if a is related to b then b is related to a.","Symmetric Relationship | Symmetric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700062","Transitive Relationship","C75921","A binary relation such that whenever an element a is related to an element b, and b is in turn related to an element c, then a is also related to c.","Transitive Relationship | Transitive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704419","Effective","C49287","Existing in fact and ready for service.","Effective | ",,,,,,,,,,,,,,,"4111919","Effective",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1442820","FLT3LG protein, human","C20492","Fms-related tyrosine kinase 3 ligand (235 aa, ~26 kDa) is encoded by the human FLT3LG gene. This protein is involved in the positive regulation of hematopoietic cell proliferation.","Fms-Related Tyrosine Kinase 3 Ligand | FLT 3 Ligand | FLT3 Ligand | FLT3 Ligand | FLT3-L | FLT3LG | FMS-Related Tyrosine Kinase-3 Ligand | Flt3 Ligand | SL Cytokine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439090","Less Than or Equal To","C61586","A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest is smaller than the other object in one of these ways.","Less Than or Equal To | LE | Less than or equal to | Lesser Than or Equal To | N.M.T. | NMT | NMT (not more than) | Not More Than",,,,,,,,,,,,,,,"4171754","<=",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0146224","Topotecan","C1413","A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Topotecan inhibits topoisomerase I activity by stabilizing the topoisomerase I-DNA covalent complexes during S phase of cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery.","Topotecan | (s)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione | 9-[(dimethylamino)methyl]-10-hydroxy-(20S)-camptothecin | Hycamptamine | TOPOTECAN | Topotecan Lactone | topotecan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0424678","Lean Body Mass","C71258","The mass of the body minus the fat.","Lean Body Mass | LBM",,,,,,,,,,,,,,,"4093982","Lean body mass",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709908","Reported By","C53461","Indicates the person or authoritative body who submitted a report.","Reported By | Reporter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699799","Donor Cellular Infusion","C77273","A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","Donor Cellular Infusion | Donor Cell Infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001138","Acinetobacter","C76200","A genus of bacteria within the phylum Proteobacteria consisting of strictly aerobic nonfermentative gram-negative bacilli.","Acinetobacter | ACINETOBACTER",,,,,,,,,,,,,,,"4300777","Acinetobacter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001250","Actinomyces","C76201","A genus of bacteria within the phylum Actinobacteria consisting of gram-positive bacilli that can be anaerobic or facultatively anaerobic.","Actinomyces | ACTINOMYCES",,,,,,,,,,,,,,,"4236735","Actinomyces",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004587","Bacillus","C76202","A genus of bacteria within the phylum Firmicutes consisting of gram-positive bacilli that are either obligate or facultative aerobes, and test positive for the enzyme catalase.","Bacillus | BACILLUS",,,,,,,,,,,,,,,"4259140","Bacillus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004661","Bacteroides","C76204","A genus of bacteria within the phylum Bacteroidetes consisting of gram-negative bacilli or cocco-bacilli that comprise a major portion of the human normal flora, predominating in the intestinal tract.","Bacteroides | BACTEROIDES",,,,,,,,,,,,,,,"4212359","Bacteroides",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006017","Bordetella pertussis","C76205","A species of bacteria within the phylum Proteobacteria consisting of gram-negative aerobic coccobacillus that are the causative agent of pertussis.","Bordetella pertussis | BORDETELLA PERTUSSIS",,,,,,,,,,,,,,,"4198560","Bordetella pertussis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006034","Borrelia burgdorferi","C76208","A species of bacteria within the phylum Spirochaetes that is the causative agent of Lyme disease.","Borrelia burgdorferi | BORRELIA BURGDORFERI",,,,,,,,,,,,,,,"4295111","Borrelia burgdorferi",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006132","Moraxella catarrhalis","C76210","A species of gram-negative, aerobic, oxidase-positive diplococcus bacteria within the phylum Proteobacteria that causes upper respiratory tract infections, particularly in immunocompromised hosts.","Moraxella catarrhalis | Branhamella catarrhalis | M. catarrhalis | MORAXELLA CATARRHALIS",,,,,,,,,,,,,,,"4087087","Moraxella catarrhalis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006813","Campylobacter","C76211","A genus of gram-negative, microaerophilic, spiral bacteria. They are motile, with either uni- or bi-polar flagella and are oxidase-positive. Several species of Campylobacter have been implicated in human disease.","Campylobacter | CAMPYLOBACTER",,,,,,,,,,,,,,,"4261232","Campylobacter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006916","Capnocytophaga","C76269","A genus of gram-negative, anaerobic bacteria that normally populate the mouth and nasopharynx of dogs and cats.","Capnocytophaga | CAPNOCYTOPHAGA",,,,,,,,,,,,,,,"4329152","Capnocytophaga",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085504","Chlamydia pneumoniae","C76272","A species of chlamydiae bacteria that infects humans and is a major cause of pneumonia.","Chlamydia pneumoniae | CHLAMYDIA PNEUMONIAE | CHLAMYDOPHILA PNEUMONIAE | Chlamydia pneumoniae | Chlamydophila pneumoniae | Chlamydophila pneumoniae",,,,,,,,,,,,,,,"4013868","Chlamydophila pneumoniae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008148","Chlamydia","C76271","A genus of bacteria within the Chlamydiae phylum that contains only the three species Chlamydia trachomatis, Chlamydia suis, and Chlamydia muridarum.","Chlamydia | CHLAMYDIA",,,,,,,,,,,,,,,"4037323","Chlamydia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008862","Citrobacter","C76273","A genus of gram-negative coliform bacteria in the Proteobacteria phylum.","Citrobacter | CITROBACTER",,,,,,,,,,,,,,,"4295448","Citrobacter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009054","Clostridium","C76275","A genus of gram-positive, obligate anaerobic bacteria in the Firmicutes phylum capable of producing endospores.","Clostridium | CLOSTRIDIUM",,,,,,,,,,,,,,,"4218244","Clostridium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0079134","Clostridium difficile","C76276","A species of Clostridium that is the most significant cause of pseudomembranous colitis.","Clostridium difficile | CLOSTRIDIUM DIFFICILE | Clostridioides difficile | Clostridium difficilis",,,,,,,,,,,,,,,"4244400","Clostridioides difficile",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0315194","Corynebacterium jeikeium","C76307","A species of bacteria in the phylum Actinobacteria consisting of lipophilic, non-spore-forming, non-motile, Gram-positive rods that vary from short coccobacilli to long bacillary forms.","Corynebacterium jeikeium | CDC Coryneform Group JK | CDC Group JK | CORYNEBACTERIUM JEIKEIUM | Corynebacterium Group JK",,,,,,,,,,,,,,,"4269491","Corynebacterium jeikeium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010148","Corynebacterium","C76308","A genus of Gram-positive, aerobic or facultatively anaerobic, non-motile, non-sporulated, rod-shaped Actinobacteria. Most are a part of normal skin flora.","Corynebacterium | CORYNEBACTERIUM",,,,,,,,,,,,,,,"4299363","Corynebacterium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010239","Coxiella","C76309","A genus of Gram-negative, acidophilic, rod-shaped, obligate intracellular bacteria in the phylum Proteobacteria.","Coxiella | COXIELLA",,,,,,,,,,,,,,,"4045338","Coxiella",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014344","Enterobacter","C76310","A genus of Gram-negative, motile, facultative anaerobic, rod-shaped bacteria with peritrichous flagella in the phylum Proteobacteria.","Enterobacter | ENTEROBACTER",,,,,,,,,,,,,,,"4242438","Enterobacter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1265175","Vancomycin Resistant Enterococcus","C76312","A non-taxonomic grouping of enterococcus species that are resistant to vancomycin antibiotics through alteration of the peptidoglycan synthesis pathway.","Vancomycin Resistant Enterococcus | ENTEROCOCCUS, VANCOMYCIN-RESISTANT | VANCOMYCIN RESISTANT ENTEROCOCCUS | VRE | Vancomycin-Resistant Enterococcus | Vancomycin-resistant Enterococcus",,,,,,,,,,,,,,,"4034133","Vancomycin resistant Enterococcus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085494","Enterococcus","C76311","A genus of Gram-positive, facultative anaerobic, lactic acid bacteria in the phylum Firmicutes.","Enterococcus | ENTEROCOCCUS | Presumptive enterococcus",,,,,,,,,,,,,,,"4101235","Enterococcus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014833","Escherichia","C77208","A genus of Gram-negative, non-spore forming, facultatively anaerobic, rod-shaped bacteria in the phylum Proteobacteria.","Escherichia | ESCHERICHIA",,,,,,,,,,,,,,,"4277441","Escherichia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0317524","Pseudomonas oryzihabitans","C76319","A species of Gram-negative, rod-shaped, motile bacterium in the phylum Proteobacteria.","Pseudomonas oryzihabitans | Flavimonas oryzihabitans | PSEUDOMONAS ORYZIHABITANS",,,,,,,,,,,,,,,"4034617","Pseudomonas oryzihabitans",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016216","Flavobacterium","C76320","A species of Gram-negative, aerobic, rod-shaped, bacterium in the phylum Bacteroidetes that are motile by gliding.","Flavobacterium | FLAVOBACTERIUM",,,,,,,,,,,,,,,"4077760","Flavobacterium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016878","Fusobacterium","C76323","A genus of filamentous, anaerobic, Gram-negative bacteria in the phylum Fusobacteria.","Fusobacterium | FUSOBACTERIUM",,,,,,,,,,,,,,,"4143777","Fusobacterium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018479","Haemophilus","C76324","A genus of Gram-negative, pleomorphic, coccobacilli bacteria belonging to the Proteobacteria phylum.","Haemophilus | HAEMOPHILUS",,,,,,,,,,,,,,,"4323572","Haemophilus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022938","Lactobacillus","C76352","A genus of Gram-positive facultative anaerobic or microaerophilic bacteria in the phylum Firmicutes.","Lactobacillus | LACTOBACILLUS | lactobacillus",,,,,,,,,,,,,,,"4185121|46272024","Lactobacillus|Lactobacillus",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0023237","Legionella","C76353","A genus of Gram-negative aerobic, motile, nonacid fast, nonencapsulated, gram-negative bacilli that have a nonfermentative metabolism in the phylum Proteobacteria.","Legionella | LEGIONELLA",,,,,,,,,,,,,,,"4326728","Legionella",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023358","Leptospira","C76355","A genus of Gram-negative, aerobic, flexible, spiral-shaped, spirochete with internal flagella in the phylum Spirochaetes.","Leptospira | LEPTOSPIRA",,,,,,,,,,,,,,,"4097667","Leptospira",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0317707","Leptotrichia buccalis","C76356","A species of Gram-negative, anaerobic bacillus in the phylum Fusobacteria.","Leptotrichia buccalis | C76356",,,,,,,,,,,,,,,"4311811","Leptotrichia buccalis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023411","Leuconostoc","C76357","A genus of gram-positive, nonmotile cocci in the phylum Firmicutes.","Leuconostoc | LEUCONOSTOC",,,,,,,,,,,,,,,"4183602","Leuconostoc",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023859","Listeria","C76359","A genus of gram-positive, rod-shaped bacteria in the phylum Firmicutes.","Listeria | LISTERIA",,,,,,,,,,,,,,,"4053183","Listeria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0445813","Methylobacterium","C76361","A genus of non-motile rod-shaped, obligately aerobic, facultative methylotrophs in the phylum Proteobacteria.","Methylobacterium | METHYLOBACTERIUM",,,,,,,,,,,,,,,"4243173","Methylobacterium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025966","Micrococcus","C77086","A genus of spherical, Gram-positive bacteria in the phylum Actinobacteria.","Micrococcus | MICROCOCCUS",,,,,,,,,,,,,,,"4199767","Micrococcus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026914","Mycobacterium avium complex","C76368","A group of very similar Mycobacteria consisting of Mycobacterium avium and M. intracellulare.","Mycobacterium avium complex | MYCOBACTERIUM AVIUM COMPLEX | Mycobacterium avium-intracellulare",,,,,,,,,,,,,,,"4237898","Mycobacterium, avium-intracellulare group",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026926","Mycobacterium tuberculosis","C76370","An obligate anaerobic, weakly Gram-positive species of mycobacterium that is the cause of most cases of tuberculosis.","Mycobacterium tuberculosis | MYCOBACTERIUM TUBERCULOSIS | Mycobacterium tuberculosis ",,,,,,,,,,,,,,,"4034215","Mycobacterium tuberculosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026912","Mycobacterium","C76369","A genus of acid-fast Gram-positive, aerobic and nonmotile bacteria in the phylum Actinobacteria.","Mycobacterium | MYCOBACTERIUM",,,,,,,,,,,,,,,"4348029","Mycobacterium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027571","Neisseria","C76371","A genus of Gram-negative, aerobic, strongly oxidase-positive diplococci bacteria in the phylum Proteobacteria.","Neisseria | NEISSERIA",,,,,,,,,,,,,,,"4244123","Neisseria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028240","Nocardia","C76372","A genus of Gram-positive, catalase-positive, rod-shaped bacteria in the phylum Actinobacteria.","Nocardia | NOCARDIA",,,,,,,,,,,,,,,"4245771","Nocardia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030637","Pasteurella multocida","C76373","A species of Gram-negative, non-motile coccobacillus in the phylum Actinobacteria.","Pasteurella multocida | P. multocida | PASTEURELLA MULTOCIDA | Pasteurella septica",,,,,,,,,,,,,,,"4032583","Pasteurella multocida",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033697","Proteus","C76374","A genus of Gram-negative, oxidase-negative, but catalase- and nitrase-positive bacteria in the phylum Proteobacteria.","Proteus | PROTEUS",,,,,,,,,,,,,,,"4196666","Proteus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033808","Pseudomonas","C76375","A genus of gram-negative, motile, non-spore-forming, rod-shaped bacteria in the phylum Proteobacteria.","Pseudomonas | PSEUDOMONAS",,,,,,,,,,,,,,,"4211547","Pseudomonas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085469","Burkholderia cepacia","C76376","A species of aerobic, gram-negative bacilli in the phylum Proteobacteria.","Burkholderia cepacia | BURKHOLDERIA CEPACIA | CDC Group EO-1 | Pseudomonas cepacia",,,,,,,,,,,,,,,"4034635","Burkholderia cepacia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0318290","Stenotrophomonas maltophilia","C76377","A species of aerobic, nonfermentative, Gram-negative bacterium in the phylum Proteobacteria.","Stenotrophomonas maltophilia | Pseudomonas maltophilia | STENOTROPHOMONAS MALTOPHILIA | Xanthomonas maltophilia",,,,,,,,,,,,,,,"4034125","Stenotrophomonas maltophilia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035496","Rhodococcus","C76378","A genus of aerobic, non-sporulating, non-motile gram-positive bacteria in the phylum Actinobacteria.","Rhodococcus | RHODOCOCCUS",,,,,,,,,,,,,,,"4146043","Rhodococcus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035583","Rickettsia","C76379","A genus of non-motile, Gram-negative, non-spore-forming, obligate intracellular parasitic bacteria in the phylum Proteobacteria.","Rickettsia | RICKETTSIA",,,,,,,,,,,,,,,"4268159","Rickettsia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036111","Salmonella","C76380","A genus of motile, rod-shaped Gram-negative enterobacteria in the phylum Proteobacteria.","Salmonella | SALMONELLA",,,,,,,,,,,,,,,"4099188","Salmonella",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036953","Shigella","C76381","A genus of Gram-negative, non-spore forming rod-shaped bacteria in the phylum Proteobacteria.","Shigella | SHIGELLA",,,,,,,,,,,,,,,"4297755","Shigella",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0318137","Rothia mucilaginosa","C76382","A species of Gram-positive bacteria in the phylum Proteobacteria that is part of the normal flora of the human oral cavity.","Rothia mucilaginosa | ROTHIA MUCILAGINOSA | Stomatococcus mucilaginosus",,,,,,,,,,,,,,,"4211809","Rothia mucilaginosa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038402","Streptococcus","C76383","A genus of Gram-positive bacteria in the phylum Firmicutes and the lactic acid bacteria group.","Streptococcus | STREPTOCOCCUS | Streptococci sp.",,,,,,,,,,,,,,,"4240344","Streptococcus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038410","Streptococcus pneumoniae","C76384","A Gram-positive, alpha-hemolytic diplococcus aerotolerant anaerobe Streptococcus species.","Streptococcus pneumoniae | Diplococcus pneumoniae | STREPTOCOCCUS PNEUMONIAE",,,,,,,,,,,,,,,"4321152","Streptococcus pneumoniae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040837","Treponema","C76385","A genus of Gram-negative, motile, helically coiled bacteria in the phylum Spirochaetes.","Treponema | TREPONEMA",,,,,,,,,,,,,,,"4147389","Treponema",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042628","Vibrio","C76386","A genus of Gram-negative bacteria with a curved rod shape in the phylum Proteobacteria.","Vibrio | VIBRIO",,,,,,,,,,,,,,,"4146528","Vibrio",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006836","Candida","C77163","A genus of yeasts in the phylum Ascomycota. Many species of this genus are endosymbionts of animal hosts.","Candida | CANDIDA",,,,,,,,,,,,,,,"4139129","Candida",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006837","Candida albicans","C77170","A species of diploid fungus in the phylum Ascomycota which is capable of mating but not of meiosis, and is a causal agent of opportunistic oral and genital infections in humans.","Candida albicans | C. albicans | CANDIDA ALBICANS | Candida stellatoidea",,,,,,,,,,,,,,,"4200556","Candida albicans",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319552","Pichia guilliermondii","C77172","A species of yeast in the phylum Ascomycota whose asexual or anamorphic form is known as Candida guilliermondii.","Pichia guilliermondii | C. guilliermondii | Candida guilliermondii | Candida guilliermondii var. carpophila | Endomyces guilliermondii | M. guillliermondii | MEYEROZYMA GUILLIERMONDII | Yamadazyma guilliermondii",,,,,,,,,,,,,,,"4106871","Meyerozyma guilliermondii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319629","Candida krusei","C77173","A species of budding yeast in the phylum Ascomycota.","Candida krusei | C. krusei | I. orientalis | Issatchenkia orientalis | Issatchenkia orientalis | P. kudriavzevii | PICHIA KUDRIAVZEVII",,,,,,,,,,,,,,,"4040298","Pichia kudriavzevii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319596","Clavispora lusitaniae","C77174","A species of yeast in the genus Candida.","Clavispora lusitaniae | C. lusitaniae | CLAVISPORA LUSITANIAE | Candida lusitaniae",,,,,,,,,,,,,,,"4177163","Clavispora lusitaniae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319878","Candida parapsilosis","C77176","A species of yeast in the genus Candida.","Candida parapsilosis | C. parapsilosis | CANDIDA PARAPSILOSIS",,,,,,,,,,,,,,,"4247544","Candida parapsilosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319882","Candida tropicalis","C77177","A species of asexual diploid yeast in the genus Candida.","Candida tropicalis | C. tropicalis | CANDIDA TROPICALIS",,,,,,,,,,,,,,,"4172927","Candida tropicalis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319899","Candida glabrata","C77179","A species of asexual haploid yeast in the genus Candida.","Candida glabrata | C. glabrata | CANDIDA GLABRATA | Torulopsis glabrata",,,,,,,,,,,,,,,"40481156","Candida glabrata",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004034","Aspergillus","C77180","A genus of highly aerobic fungi in the phylum Ascomycota that grow as molds on the surface of a substrate.","Aspergillus | ASPERGILLUS",,,,,,,,,,,,,,,"4085138","Aspergillus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1041068","Aspergillus fumigatus","C77182","A species of mold fungus in the phylum Ascomycota with a stable haploid genome, no known sexual cycle, and that reproduces by forming conidiospores that are released into the environment.","Aspergillus fumigatus | ASPERGILLUS FUMIGATUS | Aspergillus fumigates",,,,,,,,,,,,,,,"4139597","Aspergillus fumigatus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1669942","Aspergillus brasiliensis","C77183","A species of mold fungus in the phylum Ascomycota that is ubiquitous in the environment. They are generally considered asexual, although forms that reproduce sexually have been found.","Aspergillus brasiliensis | ASPERGILLUS BRASILIENSIS | Aspergillus niger | Aspergillus niger",,,,,,,,,,,,,,,"37016281","Aspergillus brasiliensis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010415","Cryptococcus","C77184","A genus of fungi in the phylum Basidiomycota that grows in culture as an encapsulated yeast. Its sexual form is called Filobasidiella and its asexual form is called Cryptococcus.","Cryptococcus | CRYPTOCOCCUS",,,,,,,,,,,,,,,"4069831","Cryptococcus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1008972","Fusarium","C77185","A genus of filamentous fungi in the phylum Ascomycota that is widely distributed in soil and in association with plants.","Fusarium | FUSARIUM",,,,,,,,,,,,,,,"4148080","Fusarium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0677640","Histoplasmosis","C77201","A disease caused by the fungus Histoplasma capsulatum. It primarily affects the lungs but can also occur as a disseminated disease that affects additional organs. The acute respiratory disease has symptoms similar to those of a cold or flu and it usually resolves without treatment in healthy individuals. The disseminated form is generally fatal if untreated.","Histoplasmosis | ",,,,,,,,,,,,,,,"433134","Histoplasmosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
,,,,,,,,,,,,,,,,,,,"4271307","Ajellomyces capsulatus",,,,,,,,,,,,,,,,,,,,,,"--"
"C0043543","Zygomycota","C77194","A phylum of fungi that are characterized by vegetative mycelium that lack septa and sexual reproduction that forms zygospores.","Zygomycota | Zygomycetes",,,,,,,,,,,,,,,"4026934","Phylum Zygomycota",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043541","Zygomycosis","C77212","Any infection due to a fungus of the Zygomycota phylum. The disease typically involves the rhino-facial-cranial area, lungs, gastrointestinal tract, skin, or less commonly other organ systems. The infecting fungi have a predilection for invading vessels of the arterial system, causing embolization and subsequent necrosis of surrounding tissue.","Zygomycosis | Mucormycosis",,,,,,,,,,,,,,,"432830","Zygomycosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035477","Rhizopus","C77196","A genus of filamentous fungi in the phylum Zygomycota.","Rhizopus | RHIZOPUS",,,,,,,,,,,,,,,"4069707","Rhizopus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035924","Rubella Virus","C77198","An enveloped, positive sense single-stranded RNA virus that is the causative agent of Rubella (German Measles).","Rubella Virus | German Measles Virus | RUBELLA VIRUS | Rubivirus Rubella Virus",,,,,,,,,,,,,,,"4178600","Rubella virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035870","Rotavirus","C77199","A genus of double stranded RNA viruses that carry 11 unique double helix molecules of RNA that encode one or two proteins each. The RNA is surrounded by a three-layered icosahedral protein capsid. Viral particles are up to 76.5 nm in diameter and are not enveloped.","Rotavirus | ROTAVIRUS",,,,,,,,,,,,,,,"4214820","Rotavirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035473","Rhinovirus","C77200","A genus of single-stranded positive sense RNA viruses containing a single RNA molecule. The viral particles are not enveloped and are icosahedral in structure.","Rhinovirus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017534","Giardia","C77213","A genus of parasitic protozoa that is the cause of giardiasis.","Giardia | GIARDIA",,,,,,,,,,,,,,,"4263535","Giardia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1744526","Cryptosporidium","C77214","A genus of parasitic protozoa that is the cause of cryptosporidiosis.","Cryptosporidium | CRYPTOSPORIDIUM",,,,,,,,,,,,,,,"4308728","Cryptosporidium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024198","Borrelia Burgdorferi Infection","C45161","An infectious disease caused by the spirochete Borrelia burgdorferi. Early manifestations of infection may include fever, headache, fatigue, depression, and a characteristic skin rash called erythema migrans. Left untreated, late manifestations involving the joints, heart, and nervous system can occur.","Borrelia Burgdorferi Infection | Borrelia | Borrelia burgdorferi Infection | Lyme Disease",,,,,,,,,,,,,,,"440638","Lyme disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033477","Propionibacterium acnes","C14378","A species of relatively slow growing, typically aerotolerant, anaerobic Gram-positive bacteria in the phylum Actinobacteria.","Propionibacterium acnes | Bacillus acnes | C. parvum | CP | CPAR | CPARV | CParv | Corynebacterium acnes | Corynebacterium parvum | Cutibacterium acnes | PROPIONIBACTERIUM ACNES",,,,,,,,,,,,,,,"4214681","Cutibacterium acnes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036766","Serratia marcescens","C14272","A species of motile, Gram-negative enterobacteria in the phylum Proteobacteria, differentiated from other Gram-negative bacteria by its ability to perform casein hydrolysis.","Serratia marcescens | S. marcescens | SERRATIA MARCESCENS",,,,,,,,,,,,,,,"4140691","Serratia marcescens",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023524","Progressive Multifocal Leukoencephalopathy","C26815","A progressive demyelination within the central nervous system associated with reactivation of a latent JC virus infection.","Progressive Multifocal Leukoencephalopathy | PML",,,,,,,,,,,,,,,"433957","Progressive multifocal leukoencephalopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029443","Osteomyelitis","C27577","An acute or chronic inflammation of the bone and its structures due to infection with pyogenic bacteria.","Osteomyelitis | osteomyelitis",,,,,,,,,,,,,,,"141663","Osteomyelitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1535939","Pneumocystis jirovecii Pneumonia","C3334","Pneumonia resulting from infection with Pneumocystis jirovecii, frequently seen in the immunologically compromised, such as persons with AIDS, or steroid-treated individuals, the elderly, or premature or debilitated babies during their first three months.  Patients may be only slightly febrile (or even afebrile), but are likely to be extremely weak, dyspneic, and cyanotic. This is a major cause of morbidity among patients with AIDS.","Pneumocystis Pneumonia | PCP | PJP | Pneumocystis | Pneumocystis carinii Pneumonia | Pneumocystis jirovecii Pneumonia",,,,,,,,,,,,,,,"4190647|438350","Pneumocystosis pneumonia|Pneumocystosis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0444334","Recumbent Position","C77532","Lying down.","Recumbent Position | DECUBITUS | Lying | Recumbent",,,,,,,,,,,,,,,"4009887","Recumbent body position",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041638","Umbilicus","C77533","The depression or scar on the abdomen that marks the former site of attachment of the umbilical cord.","Umbilicus | Belly Button | Navel | UMBILICUS",,,,,,,,,,,,,,,"4300066","Umbilical structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2700613","Span Distance","C77536","The distance or interval between two points.","Span | Span Distance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699309","Skinfold Thickness Analysis","C77537","Techniques for estimating body fat whereby a pinch of skin is precisely measured by calipers at several standardized points on the body to determine the subcutaneous fat layer thickness. These measurements are converted to an estimated body fat percentage by an equation.","Skinfold Thickness Analysis | Skinfold Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0871208","Rating (action)","C77538","The act of ascertaining or fixing the value or worth of something.","Rating | Rate | Rated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0585023","Day of the Week","C77539","Any of the seven named, 24-hour divisions of a calendar week.","Day of the Week | ",,,,,,,,,,,,,,,"4139382","Days of the week",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0585025","Sunday","C64968","The first day of the week.","Sunday | ",,,,,,,,,,,,,,,"4145722","Sunday",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0585024","Monday","C64962","The second day of the week; the first working day.","Monday | ",,,,,,,,,,,,,,,"4139383","Monday",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0585026","Tuesday","C64963","The third day of the week; the second working day.","Tuesday | ",,,,,,,,,,,,,,,"4145723","Tuesday",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0585027","Wednesday","C64964","The fourth day of the week; the third working day.","Wednesday | ",,,,,,,,,,,,,,,"4145724","Wednesday",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0585028","Thursday","C64965","The fifth day of the week; the fourth working day.","Thursday | ",,,,,,,,,,,,,,,"4139384","Thursday",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0585029","Friday","C64966","The sixth day of the week; the fifth working day.","Friday | ",,,,,,,,,,,,,,,"4144785","Friday",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0585030","Saturday","C64967","The seventh and last day of the week.","Saturday | ",,,,,,,,,,,,,,,"4139385","Saturday",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043349","Xerophthalmia","C34503","Dryness of the eye due to inadequate production of tears. Causes include vitamin A deficiency, Sjogren syndrome, rheumatoid arthritis, systemic lupus erythematosus, and scleroderma.","Xerophthalmia | Conjunctival Xerosis",,,,,,,,,,,,,,,"4180937","Xerophthalmia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019156","Sinusoidal Obstruction Syndrome","C26793","A disorder characterized by inflammation and damage of the hepatic sinusoidal endothelial cells of the hepatic venules that leads to venular occlusion and hepatocellular necrosis. It is most often a conditioning-related toxicity that results as a complication of hematopoietic stem cell transplantation (HSCT). It has also been described in populations of individuals who have ingested pyrrolizidine plant alkaloids. The clinical signs and symptoms include hyperbilirubinemia, hepatomegaly, and fluid retention.","Sinusoidal Obstruction Syndrome | Hepatic Veno-Occlusive Disease | Hepatic Veno-Occlusive Disease | Hepatic veno-occlusive disease | Liver Veno-Occlusive Disease | Liver Veno-Occlusive Disease | hepatic veno-occlusive disease",,,,,,,,,,,,,,,"4277276","Veno-occlusive disease of the liver",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030768","Peer Review","C16963","A scholarly process that subjects an author's work or ideas to the scrutiny of one or more others who are experts in the field. These referees each return an evaluation of the work, including suggestions for improvement. Evaluations usually include an explicit recommendation of what to do with the manuscript or proposal. A chief rationale for peer review is that rarely is just one person, or one closely working group, able to spot every mistake or weakness in a complicated piece of work. This is not necessarily because these deficiencies represent needles in a haystack, but because in a new and creative and perhaps eclectic intellectual product, any one of these opportunities for improvement may stand out only to someone with a particular expertise and/or history of experience. Therefore showing a work to various others increases the probability that the weakness will be identified and fixed.","Peer Review | peer review | peer review process",,,,,,,,,,,,,,,"4302266","Peer review",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0736382","Kidney Lobe","C32894","A functional unit of the kidney consisting of a renal pyramid and the renal cortex surrounding it.","Kidney Lobe | Kidney Lower Lobe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699496","South or Central American Indian","C77809","Denotes a person having origins in one of the indigenous people of South or Central America such as Mayans or Incas.","South or Central American Indian | Indigenous South / Central American | Indigenous South or Central American Indian",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698999","Caribbean Indian","C77810","Denotes a person having origins in one of the indigenous people of the Caribbean.","Caribbean Indian | CARIBBEAN INDIAN | Indigenous Caribbean",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0240321","Mediterranean","C77811","Denotes a person having origins in any of the countries abutting the Mediterranean Sea, principally those of Europe.","Mediterranean | MEDITERRANEAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0425358","North American","C77812","Denotes a person of European, Middle Eastern, or North African ancestral origins whose family settled in a North American country such as the United States of America or Canada.","North American | ",,,,,,,,,,,,,,,"4050956","North American origin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698500","North Coast of Africa","C77813","Denotes a person having origins in a northern country of Africa such as Egypt, Sudan, Libya, Algeria, Morocco, or Tunisia.","North Coast of Africa | NORTH AFRICAN | North Coast of Africa Origin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0239310","Northern European","C77814","Denotes a person having origins in any of the countries of northern Europe such as Belgium, Denmark, Austria, Switzerland, Norway, Sweden, or Great Britain.","Northern European | NORTHERN EUROPEAN | Northern European Ancestry | Northern European Descent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698522","Black South or Central American","C77815","Denotes a person having origins in any of the black racial groups of Africa whose family settled in a South or Central American country such as Argentina, Brazil, or Mexico.","Black South or Central American | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700273","White Caribbean","C77816","A person having origins in the Caribbean region who identifies as white.","White Caribbean | WHITE CARIBBEAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0239312","Western European","C77817","Denotes a person having origins in any of the countries of Western Europe such as Spain, Portugal, or France.","Western European | WESTERN EUROPEAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700274","White South or Central American","C77818","A person having origins in the any of the countries of South America or Central America who identifies as white.","White South or Central American | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0239309","Eastern European","C77819","Denotes a person having origins in any of the countries of Eastern Europe such as Czechoslovakia, Poland, Croatia, Hungary, Slovenia, Former Soviet Union, or Finland. It also includes persons who call themselves Gypsies from this region.","Eastern European | EASTERN EUROPEAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698217","Middle Eastern","C77820","Denotes a person having origins in the region of southwest Asia, between the India subcontinent and Europe, including Kuwait, Turkey, Lebanon, Israel, Iraq, Iran, Jordan, Saudi Arabia, lands east of Pakistan or the other countries of the Arabian Peninsula.  Also includes people of Jewish ethnicity including Sephardic and Ashkenazic.","Middle Eastern | MIDDLE EASTERN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029266","Orientation","C77821","A person's awareness of self with regard to time, place, and personal relationships.","Orientation | ",,,,,,,,,,,,,,,"4183166","Orientation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709868","Rectosigmoid Region","C54188","The area where the sigmoid colon joins the rectum.","Rectosigmoid Region | RECTOSIGMOID JUNCTION | Rectosigmoid Junction | Rectosigmoid junction | rectosigmoid junction",,,,,,,,,,,,,"UBERON:0036214","rectosigmoid junction","4177950","Structure of rectosigmoid junction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027567","African","C42331","Denotes a person with ancestral origins are in any of the countries of Africa.","African | AFRICAN | African Ancestry | African Descent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0401640","Needle Biopsy of Prostate","C51694","Removal of tissue from the prostate for microscopic examination, using a needle.","Needle Biopsy of Prostate | Prostate Needle Biopsy",,,,,,,,,,,,,,,"4343108","Needle biopsy of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085162","Whipple Procedure","C15356","Surgical removal of part of the pancreas, duodenum, and distal part of the bile duct.  Sometimes, the lower portion of the stomach and the gallbladder are also removed.  This procedure is performed for pancreatic, ampullary, duodenal and distal bile duct cancers.","Whipple Procedure | Kausch-Whipple Procedure | PANCREATICODUODENECTOMY | Pancreatoduodenectomy | Whipple | Whipple procedure",,,,,,,,,,,,,,,"4020329","Pancreaticoduodenectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033247","Proctocolitis","C77952","Inflammation of the rectum and colon.","Proctocolitis | ",,,,,,,,,,,,,,,"4168036","Proctocolitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0070895","Foscarnet","C71630","A synthetic organic analog of inorganic pyrophosphate with activity against several types of viruses, but primarily used for the treatment of cytomegalovirus retinitis. Foscarnet selectively blocks the pyrophosphate binding site of virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases. Because this agent crosses the blood brain barrier, it may be used in the treatment of viral infections of the central nervous system.","Foscarnet | Carboxyphosphonic Acid | FOSCARNET | Phosphonocarboxylic Acid | Phosphonoformate | Phosphonoformic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021461","Inhaler","C16738","A device by means of which a medicinal product can be administered by inspiration through the nose or the mouth.","Inhaler | INHALER | inhaler",,,,,,,,,,,,,,,"4224211","Inhaler",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0565930","Per Second","C66965","The number of occurrences of something within a second of time.","Per Second | /s | /sec",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439494","Kilometer per Hour","C71203","A unit of both speed (scalar) and velocity (vector), defined as the distance of one thousand meters travelled per unit time equal to one hour.","Kilometer per Hour | Kilometer Per Hour | km/h | km/hr",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439261","Watt","C42549","A SI unit of power equal to the power which in one second produces or transfers the energy of one joule. The unit is used in measurements of power emitted, transferred or received as radiation, sound waves, heat flow rate, and rate of energy transfer.","Watt | W | watt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439390","Milliliter per Second","C69073","A metric unit of volumetric flow rate defined as the rate at which one milliliter of matter crosses a given surface during the period of time equal to one second.","Milliliter per Second | Milliliter/Second | mL/s | mL/sec | ml/s",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1961129","Microvolt","C71175","A SI unit of an electric potential and electromotive force equal to one millionth of a volt.","Microvolt | mcV | uV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348407","Square Micrometer","C73770","A SI unit of area measurement equal to a square whose sides are one micrometer long.","Square Micrometer | MicroSquare Meter | um2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456574","Degree Unit of Plane Angle","C68667","A unit of plane angle measurement equal to the length of the arc cut out by the angle, divided by the circumference of the circle, and multiplied by 360. The symbol for degrees is a small superscript circle. One radian is about 57 degrees and one degree is pi/180 radians.","Degree Unit of Plane Angle | Angular Degree | Deg | Degree | Degrees | deg | degree | degree (angle) | degrees to rotation",,,,,,,,,,,,,,,"4078995","Angular degrees",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1300554","Cubic Meter","C42570","A SI unit of volume or capacity equal to the volume of a cube with edges one meter in length. It is equal to 1,000 liters; 1,000 cubic decimeters; 10(e+6) cubic centimeters; 25.3 cubic feet; 6.29 barrels.","Cubic Meter | Cub. m | Kiloliter | cubic meter | kL | m3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439479","Square Centimeter","C48460","A CGS unit of area measurement equal to a square measuring one centimeter on each side. One square centimeter is equal to 10E-4 square meter.","Square Centimeter | SQUARE CENTIMETER | centimeter squared | cm2 | sq. cm. | square centimeter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711308","Benign Accessory Urethral Gland Neoplasm","C4532","A neoplasm that arises from the accessory urethral glands and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Accessory Urethral Gland Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272684","Accepted","C62559","Generally approved or used.","Accepted | Established",,,,,,,,,,,,,,,"4295935","Accepted",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040395","Tomography","C38093","Imaging by sections or sectioning.","Tomography | ",,,,,,,,,,,,,,,"4160902|4161003|4161190","Tomographic imaging, plain radiologic - action|Tomographic imaging - action|Tomographic imaging",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C0205253","Immediately","C64597","Without delay.","Immediately | Immediate | STAT | statim",,,,,,,,,,,,,,,"4229421","Immediate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085537","Caregiver","C17445","The primary person in charge of the care of a patient, usually a family member or a designated health care professional.","Caregiver | CAREGIVER | Care Provider | Carer | Caretaker | caregiver",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009967","Coping","C78176","The process of successfully managing difficult or challenging situations.","Coping | cope",,,,,,,,,,,,,,,"4225865","Coping behavior",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519427","ASIAN, SOUTHERN","C41263","Denotes a person whose ancestry is in the countries of the Indian sub-continent, including India, Pakistan, Bangladesh, and Sri Lanka.","South Asian | SOUTH ASIAN | South Asians",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002460","American Indian","C43877","Denotes a person having origins in one of the indigenous peoples of North, Central, or South America, who lived in these lands prior to the European colonization.","American Indian | AMERICAN INDIAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085732","Ability","C78209","The quality of being able to perform; a quality that permits or facilitates achievement or accomplishment.","Ability | Able | Able To",,,,,,,,,,,,,,,"4159757","Able",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2700154","Vapor Phase Cooling","C78211","A cryogenic process for the storage and/or shipping of biospecimens. The item to be frozen is placed above a shallow reservoir of cooling liquid in a storage vessel. A vertical temperature gradient is maintained throughout the vapor layer to ensure temperatures sufficiently low to maintain the integrity of the stored material.","Vapor Phase Cooling | Vapor Phase Storage | Vapor-Phase Cooling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709057","MODIFICATION OR ADJUSTMENT","C53606","An indication that a change in treatment or a change to a device will be required following an adverse event.","Adverse Event Modification or Adjustment | AE_TX_MOD | MODIFICATION OR ADJUSTMENT | Modification or Adjustment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201811","Fecal Occult Blood Test","C18014","A noninvasive test that detects the presence of hidden (occult) blood in the stool. This is commonly performed to screen for colon cancer.","Fecal Occult Blood Test | FOBT | Guaiac Smear Test | Hemoccult | Stool guaiac test | fecal occult blood test | stool test",,,,,,,,,,,,,,,"4018619|4213716","Screening for occult blood in feces|Chemical test for occult blood",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0442529","Urban","C77950","Relating to, located in, or characteristic of a city or densely populated area.","Urban | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700616","Workforce - population group","C77921","Total number of a country's population employed in jobs, plus those unemployed people who are seeking work; the entire group of employees in a company.","Workforce | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709497","Percent Foreign Born","C53342","The fraction of a population who's members were born outside of the country.","Percent Foreign Born | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711336","Percent Below Poverty","C53336","The fraction of a population whose income is less than that considered sufficient for survival.","Percent Below Poverty | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709501","Percent non-English Speakers","C53343","The fraction of a population that does not speak English.","Percent non-English Speakers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699029","Relocation of home or business","C77951","The act of changing your residence or place of business.","Relocation | Move | Moved | Relocated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0682213","White Collar Worker","C77922","Refers to workers who perform work that is knowledge intensive and generally non-routine and unstructured.","White Collar Worker | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714552","Weakness","C50809","The property of lacking physical strength.","Weakness | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0237530","Confidence Limit","C53325","Either of the two numbers that specify the endpoints of a confidence interval.","Confidence Limit | Confidence Limits",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010280","Craniotomy","C15214","Surgical creation of an opening of the skull.","Craniotomy | Open Craniotomy | craniotomy | incision of the skull",,,,,,,,,,,,,,,"4101626","Craniotomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1869171","MGMT protein, human","C17315","Methylated-DNA-protein-cysteine methyltransferase (207 aa, ~22 kDa) is encoded by the human MGMT gene. This protein is involved in both repair and dealkylation of DNA.","Methylated-DNA-Protein-Cysteine Methyltransferase | AGT | Alkylguanine DNA Alkyltransferase | DNA-6-O-Methylguanine[protein]-L-Cysteine S-Methyltransferase | EC 2.1.1.63 | MGMT | Methylated-DNA Protein-Cysteine Methyltransferase | Methylated-DNA--Protein-Cysteine Methyltransferase | Methylated-DNA--Protein-Cysteine Methyltransferase | Methylated-DNA—Protein-Cysteine Methyltransferase | Methylguanine-DNA Methyltransferase | O-6-Methylguanine-DNA Alkyltransferase | O-6-Methylguanine-DNA Methyltransferase | O-6-Methylguanine-DNA Methyltransferase | O-6-Methylguanine-DNA-Alkyltransferase | O6-Alkylguanine DNA Alkyltransferase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035345","Retirement","C78237","To stop working at one's occupation; the state of being retired.","Retirement | Retire | Retired",,,,,,,,,,,,,,,"4022069","Retired",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0439834","Slow","C64655","Proceeding at a low speed; taking a comparatively long time.","Slow | Slowly",,,,,,,,,,,,,,,"4116820","Slow",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0222603","Female Breast","C12851","The organ of milk secretion; one of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest of the mature female; it is rudimentary in the male.","Female Breast | Breast, Female",,,,,,,,,,,,,,,"4238935","Female mammary gland structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0278704","Malignant Childhood Neoplasm","C4005","A malignant neoplasm that occurs during childhood. Representative examples include acute leukemias, malignant brain neoplasms, and sarcomas.","Childhood Malignant Neoplasm | Childhood Cancer | Malignant Childhood Neoplasm | Malignant Childhood Neoplasm | Malignant Childhood Tumor | Malignant Neoplasm | Malignant Pediatric Neoplasm | Malignant Pediatric Tumor | Pediatric Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0240919","Rural","C17724","Of or pertaining to the country as opposed to the city. (American Heritage Dictionary)","Rural | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034929","Reflex","C78342","An automatic instinctive unlearned reaction to a stimulus.","Reflex | Reflex Finding | Reflex Observable",,,,,,,,,,,,,,,"4227123","Reflex",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013520","Doppler Echocardiography","C38634","A procedure that uses sound waves to measure characteristics of disturbed bood flow, such as direction, velocity and turbulence. This enables the examiner to differentiate between normal and abnormal flow patterns and, in some cases, to quantitate those characteristics that are helpful in determining the severity of abnormal flow states.","Doppler Echocardiography | DOPPLER ECHOCARDIOGRAPHY | Doppler Study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003322","Cluster of Differentiation","C78347","Cell surface antigens that are differentially expressed on the surface of cells in both a tissue- and differentiation stage-specific manner. Identification of differentiation antigens can be used to characterize, and isolate, the types of cells in a sample and can identify cells that have undergone differentiation or transformation.","Cluster of Differentiation | CD | CD Antigen | Classification Determinant | Cluster of Designation | Cluster of Differentiation Antigens | Differentiation Antigen",,,,,,,,,,,,,,,"4164934","Lymphocyte antigen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028643","Numbness","C34857","A loss of the sensation of feeling in an area of the body.","Numbness | Loss of Sensation",,,,,,,,,,,,,,,"4185563","Numbness",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3275994","Tingling","C50771","A sensation as of repetitive pin pricks, caused by cold or by striking a nerve, or as a result of various diseases of the central or peripheral nervous system.","Tingling | ",,,,,,,,,,,,,,,"4266682","Pins and needles",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698521","Bitmask","C78175","A binary number in which a bit is set to either on or off to store information for bitwise operations.","Bitmask | Bit Mask",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699160","Center for Epidemiologic Studies Depression Scale","C77964","A self-test that measures depressive feelings and behaviors within the general population.","Center for Epidemiologic Studies Depression Scale | CES-D | Center for Epidemiologic Studies Depression Scale (CES-D)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700379","Poor","C77959","Of low value or worth.","Poor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022107","Irritation","C77966","Feelings of annoyance, impatience, and anger.","Irritation | Irritability",,,,,,,,,,,,,,,"4184149","Feeling irritable",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2700116","Unusual","C77967","Out of the ordinary, uncommon, or unexpected.","Unusual | Peculiar",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527305","Feelings","C77965","Emotional sensations.","Feelings | Feeling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449058","Joy","C77961","A feeling of delight.","Joy | Enjoyed | Enjoyment | Feeling of Joy | Joyful",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015726","Fear","C77960","A feeling of apprehension that one may be in danger.","Fear | Fearful | Fearfulness",,,,,,,,,,,,,,,"4029621","Fear",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0392347","Hope (emotion)","C77962","A feeling of optimism that one will attain a desired outcome.","Hope | Hopeful | Hopefulness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023974","Loneliness","C34785","Sadness resulting from being isolated or alone.","Loneliness | ",,,,,,,,,,,,,,,"4147192","Feeling lonely",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0870814","Like","C77969","A feeling of fondness for a person or thing.","Like | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010399","Crying","C77963","The shedding of tears associated with emotions, usually sadness but also joy or frustration.","Crying | Cry",,,,,,,,,,,,,,,"4136768|4152136","Crying|Crying",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2700214","Friendly","C77968","Favorably disposed; not antagonistic or hostile.","Friendly | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026565","Mortality Rate","C16880","The proportion of deaths occurring in a population over a specified time.","Mortality Rate | Death Rate | Mortality | Mortality | mortality | mortality (rate) | mortality rate",,,,,,,,,,,,,,,"4249566","Mortality rate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348526","Standard Population","C71556","A population for a geographic area, such as the U.S. or the world, represented as a table giving the proportions of the population falling into different age groups.","Standard Population | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348525","Standard Million Population","C71557","A standard population for a geographic area consisting of a table giving the number of persons in each age group out of a theoretical cohort of 1,000,000 persons that is distributed by age in the same proportions as the population.","Standard Million Population | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700280","World","C77972","People in general considered as a whole.","World | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030498","Parasite","C28176","Any organism that has a close, symbiotic relationship with a separate, host organism.","Parasite | Parasites | parasite | parasitic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038172","Staphylococcus Aureus","C50921","A common bacterial species found especially on nasal mucous membrane and skin (hair follicles); bacterial species that produces exotoxins including those that cause toxic shock syndrome, with resulting skin rash, and renal, hepatic, and central nervous system disease, and an enterotoxin associated with food poisoning; it causes furunculosis, cellulitis, pyemia, pneumonia, osteomyelitis, endocarditis, suppuration of wounds, other infections; also a cause of infection in burn patients; humans are the chief reservoir.","Staphylococcus Aureus | S. AUREUS | S. aureus | STAPHYLOCOCCUS AUREUS | Staph. aureus | Staphylococcus aureus | Staphylococcus aureus",,,,,,,,,,,,,,,"4149419","Staphylococcus aureus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698848","Polynomial","C78538","A mathematical expression formed by summing multiples of powers of some variable.","Polynomial | Polynomial Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699740","Support Vector Machine","C78542","A classification method that will construct a hyperplane between two sets of data such that it maximizes the margin between the hyperplane and the nearest samples.","Support Vector Machine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697841","Kernel Function","C78544","A function that measures the distance between two expression vectors as the data are projected into higher-dimensional space.","Kernel Function | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0681935","Cross Validation","C78545","A statistical method of partitioning a sample of data into subsets such that the analysis is initially performed on a single subset, while the other subsets are retained for subsequent use in confirming and validating the initial analysis.","Cross Validation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698540","Bootstrapping","C78547","A method for estimating properties of a dataset by measuring those properties when sampling from an approximating distribution.","Bootstrapping | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1698196","Muscle Weakness Upper Limb","C78459","A reduction in the strength of the upper limb muscles.","Muscle Weakness Upper Limb | Muscle weakness upper limb",,,,,,,,,,,,,,,"37017267","Muscle weakness of upper limb",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2699463","Cost Function","C78559","A function or expression that is either maximized or minimized in order to obtain the optimal solution for a mathematical problem.","Cost Function | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698650","Optimization","C78561","An activity that attempts to find the best solution to a problem.","Optimization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001128","Acid","C48057","A substance that yields hydrogen ions or protons in aqueous solutions; a substance capable of accepting a pair of electrons for the formation of a coordinate covalent bond; a substance whose hydrogen can be replaced by metals or basic radicals, or which react with bases to form salts and water.","Acid | Acidic | acid | acidity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0340288","Stable Angina","C66914","Angina pectoris which has not recently changed in frequency, duration or intensity. Stable angina pectoris is relieved by rest or administration or oral, sublingual or transdermal antianginal medications.","Stable Angina | STABLE ANGINA | Stable Angina Pectoris | Stable angina",,,,,,,,,,,,,,,"4119942","Stable angina",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002965","Unstable Angina","C66911","Angina pectoris (or equivalent type of ischemic discomfort) which has recently changed in frequency, duration, intensity, or occurs at rest.","Unstable Angina | UNSTABLE ANGINA | Unstable Angina Pectoris | Unstable angina",,,,,,,,,,,,,,,"315296","Preinfarction syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002963","Variant Angina","C66915","A variant form of angina pectoris caused by coronary artery vasospasm, usually occurring spontaneously and frequently associated with ST segment elevation.","Variant Angina | Prinzmetal Angina | Prinzmetal angina | Prinzmetal's Angina | VARIANT ANGINA | Variant Angina Pectoris",,,,,,,,,,,,,,,"315830","Prinzmetal angina",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698967","Canadian Cardiovascular Society Grading Scale Class I","C77265","Canadian Cardiovascular Society Grading of Angina Pectoris CCSGA101 Standardized Character Result Grade I - Grade I: Ordinary physical activity does not cause angina, such as walking and climbing stairs. Angina with strenuous or rapid or prolonged exertion at work or recreation.","Canadian Cardiovascular Society Grading of Angina Pectoris CCSGA101 Standardized Character Result Grade I | Angina with strenuous exercise | CCS CLASS 1 | CCSGA101-Grade I | Canadian Cardiovascular Society Classification 1 | Canadian Cardiovascular Society Grading Scale Class I | Class I | Class I Angina | Grade I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698968","Canadian Cardiovascular Society Grading of Angina Pectoris CCSGA101 Standardized Character Result Grade II","C77266","Canadian Cardiovascular Society Grading of Angina Pectoris CCSGA101 Standardized Character Result Grade II - Grade II: Slight limitation of ordinary activity. Walking or climbing stairs rapidly, walking uphill, walking or stair climbing after meals, or in cold, or in wind, or under emotional stress, or only during the few hours after awakening. Walking more than two blocks on the level and climbing more than one flight of ordinary stairs at a normal pace and in normal conditions.","Canadian Cardiovascular Society Grading of Angina Pectoris CCSGA101 Standardized Character Result Grade II | Angina with moderate exertion | CCS CLASS 2 | CCSGA101-Grade II | Canadian Cardiovascular Society Classification 2 | Canadian Cardiovascular Society Grading Scale Class II | Class II | Class II Angina | Grade II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698969","Canadian Cardiovascular Society Grading of Angina Pectoris CCSGA101 Standardized Character Result Grade III","C77267","Canadian Cardiovascular Society Grading of Angina Pectoris CCSGA101 Standardized Character Result Grade III - Grade III: Marked limitation of ordinary physical activity. Walking one or two blocks on the level and climbing one flight of stairs in normal conditions and at normal pace.","Canadian Cardiovascular Society Grading of Angina Pectoris CCSGA101 Standardized Character Result Grade III | Angina with mild exertion | CCS CLASS 3 | CCSGA101-Grade III | Canadian Cardiovascular Society Classification 3 | Canadian Cardiovascular Society Grading Scale Class III | Class III | Class III Angina | Grade III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698970","Canadian Cardiovascular Society Grading of Angina Pectoris CCSGA101 Standardized Character Result Grade IV","C77268","Canadian Cardiovascular Society Grading of Angina Pectoris CCSGA101 Standardized Character Result Grade IV - Grade IV: Inability to carry on any physical activity without discomfort, anginal syndrome may be present at rest.","Canadian Cardiovascular Society Grading of Angina Pectoris CCSGA101 Standardized Character Result Grade IV | Angina at any level of physical exertion | CCS CLASS 4 | CCSGA101-Grade IV | Canadian Cardiovascular Society Classification 4 | Canadian Cardiovascular Society Grading Scale Class IV | Class IV | Class IV Angina | Grade IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697844","Killip Class I","C77269","A classification of myocardial infarction characterized by an absence of rales over the lung fields and an absence of S3.","Killip Class I | KILLIP CLASS I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697845","Killip Class II","C77270","A classification of myocardial infarction characterized by rales over 50% or less of the lung fields or the presence of an S3.","Killip Class II | KILLIP CLASS II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697846","Killip Class III","C77271","A classification of myocardial infarction characterized by rales over more than 50% of the lung fields.","Killip Class III | KILLIP CLASS III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697847","Killip Class IV","C77272","A classification of myocardial infarction characterized by cardiogenic shock; an event with systolic BP less than 90 mmHg for greater than 30 minutes, not responsive to fluid resuscitation alone, and felt to be secondary to cardiac dysfunction. Associated signs of hypoperfusion (cool and clammy skin, oliguria, or altered sensorium) or a cardiac index of less than 2.2 L/min/m2 are present. This includes when the systolic BP increases to greater than 90 mmHg in response to inotropic agents in less than 1 hour.)","Killip Class IV | KILLIP CLASS IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1319793","New York Heart Association Class I","C66904","A finding associated with a patient with defined or presumed cardiac disease without limitations of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, or dyspnea. (from The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston, Mass: Little, Brown & Co; 1994:253-256.)","New York Heart Association Class I | NYHA CLASS I | NYHA Class I",,,,,,,,,,,,,,,"4220607","New York Heart Association Classification - Class I",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1319794","New York Heart Association Class II","C66905","A finding associated with a patient with defined or presumed cardiac disease with slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, or dyspnea. (from The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston, Mass: Little, Brown & Co; 1994:253-256.)","New York Heart Association Class II | NYHA CLASS II | NYHA Class II",,,,,,,,,,,,,,,"4226789","New York Heart Association Classification - Class II",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1319795","New York Heart Association Class III","C66907","A finding associated with a patient with defined or presumed cardiac disease with marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea. (from The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston, Mass: Little, Brown & Co; 1994:253-256.)","New York Heart Association Class III | NYHA CLASS III | NYHA Class III",,,,,,,,,,,,,,,"4227345","New York Heart Association Classification - Class III",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1319796","New York Heart Association Class IV","C66908","A finding associated with a patient with defined or presumed cardiac disease with inability to carry on any physical activity without discomfort. Symptoms are present even at rest or minimal exertion. (from The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston, Mass: Little, Brown & Co; 1994:253-256.)","New York Heart Association Class IV | NYHA CLASS IV | NYHA Class IV",,,,,,,,,,,,,,,"4228881","New York Heart Association Classification - Class IV",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1881054","History of Cardiogenic Shock","C66922","An event in the personal medical history of sustained, inadequate tissue perfusion secondary to cardiac dysfunction, generally defined as systolic blood pressure of less than 90 mm Hg of more than 1 hour and not responsive to fluid resuscitation alone. Associated signs of peripheral hypoperfusion (e.g. cool extremities, oliguria, altered sensorium) or a cardiac index of less than 2.2L/min/m^(2) are present. This clinical entity includes instances in which the systolic blood pressure is raised to 90 mmHg or more using inotropic agents, within the first hour. (from NIH Roadmap Cardiovascular Data Standards Working Group)","History of Cardiogenic Shock | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881055","Personal History of Coronary Artery Disease","C66924","An event in the personal medical history of coronary artery disease as evidenced by one of the following: 1) prior coronary artery bypass surgery (CABG), 2) prior percutaneous coronary intervention (PCI), 3) angiographically documented coronary artery stenosis greater than or equal to 50 percent 4) angiographically documented coronary atherosclerosis (not greater than 50 percent), 5) a positive stress test, 6) alternatively documented coronary atherosclerosis using other imaging techniques, 7) prior myocardial infarction, or 8) prior angina pectoris. (from NIH Roadmap Cardiovascular Data Standards Working Group)","Personal History of Coronary Artery Disease | History of Coronary Artery Disease | History of Coronary Artery Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880777","First Ever Onset of Angina Pectoris Event","C67097","The beginning of the first experience of the symptom complex of angina pectoris.","First Ever Onset of Angina Pectoris Event | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880778","First Ever Onset of Heart Failure Event","C67104","The beginning of the first occurrence of heart failure.","First Ever Onset of Heart Failure Event | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0455531","History of Heart Failure","C66926","An event in the personal medical history of heart failure, a condition in which the heart is unable to pump enough blood to meet the body's requirements.","History of Heart Failure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881905","Most Recent Angina Pectoris Event","C67095","The most recent occurrence of angina pectoris.","Most Recent Angina Pectoris Event | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881906","Most Recent Heart Failure Event","C67103","The most recent occurrence of heart failure.","Most Recent Heart Failure Event | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881056","History of Peripheral Vascular Disease","C66923","An event in the personal medical history of peripheral vascular disease as evidenced by: 1. Claudication either with exertion or at rest; 2. Amputation for arterial vascular insufficiency; 3. Aorto-iliac occlusive disease reconstruction, peripheral vascular bypass surgery, angioplasty or stent; or percutaneous intervention to the extremities; 4. Documented abdominal aortic aneurysm (AAA) repair or stent; 5. Positive non-invasive/invasive test. It does not include procedures such as vein stripping, carotid disease, or procedures originating above the diaphragm. (from NIH Roadmap Cardiovascular Data Standards Working Group)","History of Peripheral Vascular Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882942","Resuscitated Cardiac Arrest Event","C67106","Cardiac arrest that is reversed, usually by CPR and/or defibrillation or cardioversion, or cardiac pacing.","Resuscitated Cardiac Arrest Event | Resuscitated Cardiac Arrest",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881057","History of Resuscitated Cardiac Arrest","C66927","An event in the personal medical histroy of cardiac arrest that is reversed, usually by CPR and/or defibrillation or cardioversion, or cardiac pacing.","History of Resuscitated Cardiac Arrest | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881154","In-Hospital Cardiac Arrest","C66928","Cardiac arrest which occurs in the hospital setting.","In-Hospital Cardiac Arrest | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882149","Onset of Angina Pectoris Event","C67096","The beginning of the experience of the symptom complex of angina pectoris.","Onset of Angina Pectoris Event | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879705","Angina Pectoris Prompting Medical Attention Event","C67100","Angina pectoris which leads an individual to seek medical attention.","Angina Pectoris Prompting Medical Attention Event | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879987","Canadian Cardiovascular Society Grading Scale","C66910","Canadian Cardiovascular Society Grading of Angina Pectoris (CCS Grading of Angina Pectoris) Grade.","CCS Grading of Angina Pectoris - Grade | CCS Class | CCSGA1-Canadian CV Society Grade | CCSGA101 | CCSGRDS | Canadian CV Society Grading Scale | Canadian Cardiovascular Society Grading Scale | Canadian Cardiovascular Society Grading Scale Class",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881332","Killip Class","C66916","A finding associated with a patient based on the classification developed by Killip and Kimball, which classifies patients with myocardial infarction based on routine physical examination parameters, such as the presence or absence of rales, or a decreased systolic blood pressure.","Killip Class | KILLIPCL | Killip Classification | Killip Classification Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882083","New York Heart Association Class","C66909","A finding associated with a patient based on the functional classification developed by the New York Heart Association (NYHA), for categorizing patients with defined or presumed cardiac disease. The classification system is based on the ability, or lack thereof, to engage in physical activity. The classification system comprises four classes, though NYHA Class III and Class IV are often aggregated for the purpose of outcomes analysis.","New York Heart Association Class | NYHA Class | NYHACLS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1947978","Encounter","C62143","Each individual, unique interaction between two subjects of interest.","Encounter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346504","International Foot","C71253","A traditional unit of length defined by the U.S. National Bureau of Standards as 30.48 centimeters. It is equal to 0.3048 meter, 12 inches, or to approximately 0.999998 survey foot.","International Foot | Foot | US Foot | [ft_i] | foot | ft",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698752","Pediatric Quality of Life Inventory","C78652","A parent report or patient self report for measuring health-related quality of life (HRQOL) in healthy children and adolescents and those with acute and chronic health conditions. The PedsQL Measurement Model uses a modular approach that integrates both generic core scales and disease-specific modules into one measurement system. (Copyright 1998-2008 James W. Varni, Ph.D.)","Pediatric Quality of Life Inventory | PedsQL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699765","Activities Scale for Kids","C78653","A generic self-report tool developed to measure, describe, and evaluate changes in the level of daily life activities and performance in children aged 5-15 years. (Copyright Dr. Nancy L. Young)","Activities Scale for Kids | ASK | Activity Scale for Kids",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0220843","grasp","C78654","The ability to hold or grasp.","Grip | Grasp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0870731","Internal Consistency","C78687","The extent to which all items in a scale or test measure the same concept.","Internal Consistency | internal consistency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0870740","Inter-rater Reliability","C78688","The extent to which two different researchers obtain the same result when using the same instrument to measure a concept.","Inter-rater Reliability | Interrater Reliability | inter-rater reliability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510592","Content Validity","C78690","The ability of the items in a measuring instrument or test to adequately measure or represent the content of the property that the investigator wishes to measure.","Content Validity | content validity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0681897","Construct Validity","C78691","The extent to which a measurement method accurately represents a construct and is able to produce an observation distinct from that produced by a measure of another construct.","Construct Validity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699472","Criterion Validity","C78692","Extent to which the measurement correlates with an external criterion of the phenomenon under study.","Criterion Validity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880171","Consortium (group)","C61538","A group formed to undertake a venture that is beyond the capabilities of the individual members. Each member of the consortium brings a high level of expertise in a specific area to ensure the successful completion of the project.","Consortium | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226875","Lower Gastrointestinal Tract","C33010","The lower part of the gastrointestinal tract that includes the jejunum and ileum of the small intestine and the large intestine.","Lower Gastrointestinal Tract | GASTROINTESTINAL TRACT, LOWER",,,,,,,,,,,,,,,"4211251","Lower gastrointestinal tract structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3203348","Upper Gastrointestinal Tract","C33837","The upper part of the gastrointestinal tract that includes the esophagus, stomach, and duodenum.","Upper Gastrointestinal Tract | GASTROINTESTINAL TRACT, UPPER",,,,,,,,,,,,,,,"4271189","Upper gastrointestinal tract structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039195","Cytotoxic T-Lymphocyte","C12543","Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. These cells are distinct from natural killer cells and from killer cells mediating antibody-dependent cell cytotoxicity.","Cytotoxic T-Lymphocyte | CTL | Cytolytic T-Cell | Cytotoxic T Cell | Cytotoxic T Cells | Cytotoxic T lymphocyte | Cytotoxic T-Lymphocytes | T-Lymphocyte, Cytotoxic | T-Lymphocytes, Cytotoxic | cytotoxic T cell | cytotoxic T lymphocyte | killer T cell",,,,,,,,,,,,,,,"4024622|4224865","Lymphocyte positive for both CD3 antigen and CD8 antigen|Cytotoxic T lymphocyte",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2981179","Colorectal Cancer pT4a TNM Finding v6","C78695","Colorectal cancer which directly invades other organs or structures.","Colorectal Cancer pT4a TNM Finding v6 | Colorectal Cancer pT4a TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3279475","Nail Pitting","C78496","Depressions on the surface of the nail. This finding may be associated with psoriasis.","Nail Pitting | Colorectal Cancer pT4b TNM Finding",,,,,,,,,,,,,,,"4233101","Pitting of nails",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034629","Radon","C800","An element with atomic symbol Rn, atomic number 86, and 222.0.","Radon | RADON | Rn | radon",,,,,,,,,,,,,,,"4248858","Radon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL378335","Tumor-Targeted Bacterial Therapy","C71728","No Value Exists","Tumor-Targeted Bacterial Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023690","Ligation","C15270","The process of tying off blood vessels so that blood cannot flow to a part of the body or to a tumor.","Ligation | Closure by Ligation | ligation",,,,,,,,,,,,,,,"4321844","Ligation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034014","Pubic Bone","C33423","Either of the two bones (left and right) that form the front of the pelvis.","Pubic Bone | PUBIC BONE | Pubis","C41.4","Pubic bone",,,,,,,,,,,,,"4278089","Bone structure of pubis",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0023036","Laparoscope","C28167","A long, thin tube with a camera lens attached that allows the physician to examine the organs inside the abdominal cavity.","Laparoscope | laparoscope",,,,,,,,,,,,,,,"4313302","Laparoscope",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2697586","Hidden Markov Model","C75940","A statistical model in which the system being modeled has unknown parameters, but the hidden parameters can be determined from the observable parameters. While the state is not directly visible, the variables influenced by the state are visible. Each state has a probability distribution over the possible output tokens. Therefore the sequence of tokens generated by a Hidden Markov Model (HMM) gives some information about the sequence of states.","Hidden Markov Model | HMM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1690986","log10","C75941","The base 10 logarithmic value of argument X.","log10 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439074","Negative Integer","C75942","An integer with a value less than zero.","Negative Integer | Negative Integer Value",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443193","Convergence","C75946","The act of coming together and especially moving toward union or uniformity.","Convergence | Converge | Converging",,,,,,,,,,,,,,,"4137034","Convergence",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2700035","Expectation Maximization Algorithm","C75945","Algorithm used in statistics for finding maximum likelihood estimates of parameters in probabilistic models, where the model depends on unobserved latent (inferred) variables.","Expectation Maximization Algorithm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439780","Forward","C75959","At or near or directed toward the front.","Forward | ",,,,,,,,,,,,,,,"4112419","Forward",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0681916","Statistical Estimation","C53327","A statistical procedure for assigning a plausable value to a parameter based on measured/empirical data.","Statistical Estimation | Estimation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1265875","Decay","C75947","A gradual deterioration or decline to an inferior state.","Decay | ",,,,,,,,,,,,,,,"4053957","Disintegration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2700061","Transition (action)","C75958","A change from one state or stage to another.","Transition | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698774","Ph+/BCR-","C79094","Philadelphia chromosome abnormality; t(9;22)(q34;q11) was found; bcr/abl gene rearrangement was not found.","Ph+/BCR- | Ph Positive/BCR Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206727","Nerve Sheath Neoplasm","C4972","A benign or malignant neoplasm arising from the perineural cells in the sheaths surrounding the nerves. Representative examples include neurofibroma, schwannoma, and malignant peripheral nerve sheath tumor.","Nerve Sheath Neoplasm | Neoplasm of Nerve Sheath | Neoplasm of the Nerve Sheath | Nerve Sheath Tumor | Nerve Sheath Tumors | Tumor of Nerve Sheath",,,,,,,,,,,,,,,"4017276","Nerve sheath tumor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698775","Ph+/BCR+","C79095","Philadelphia chromosome abnormality; t(9;22)(q34;q11) was found; bcr/abl gene rearrangement was found.","Ph+/BCR+ | Ph Positive/BCR Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697662","Illicit Substance","C79097","Something (as drugs or alcoholic beverages) deemed harmful and usually subject to legal restriction.","Illicit Substance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003737","Architecture","C16304","The art or science of building; especially, the art of building houses, churches, bridges, and other structures, for the purposes of civil life","Architecture | Engineering / Architecture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085762","Alcohol Abuse","C20701","The use of alcoholic beverages to excess, either on individual occasions ('binge drinking') or as a regular practice.","Alcohol Abuse | Alcohol Use Disorders",,,,,,,,,,,,,,,"433753","Alcohol abuse",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0687130","Substance of Abuse","C1816","Any substance, including any illegal, prescription, over-the-counter agent or any other compound, used for the purpose other than indicated or used in quantities other than directed. Substances from various drug classes can be abused, such as opioids, amphetamines, analgesics, benzodiazepines, barbiturates, hallucinogens, steroids, tobacco products and alcoholic substances. A substance of abuse may act on the central nervous system (CNS) or can have an effect in other parts of the body and can lead to physical and/or physiological dependence.","Substance of Abuse | Abused Substances",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697883","Laparoscopic Port","C79080","A medical appliance inserted into an incision for laparoscopic examination that provides a pathway for allows other laparoscopy devices to pass through the skin and into the abdominal cavity.","Laparoscopic Port | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038938","Surgical Stapler","C79082","A medical instrument designed for mechanical fastening of soft tissues (e.g., closing of incisions or wounds) by delivering staples into the tissues. These devices usually consist of a mechanism for delivering staples and a disposable cartridge containing the staples.","Surgical Stapler | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0183014","Retractor","C79090","A surgical instrument designed to hold back the edges of a surgical incision or maneuver internal anatomic structures within the operating area, usually to permit an unobstructed view of the area of interest.","Retractor | ",,,,,,,,,,,,,,,"4201724","Retractor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2697884","Laparoscopic Retractor","C79091","A surgical instrument designed to maneuver internal anatomic structures during laparoscopic procedures, usually to permit an unobstructed view of the area of interest.","Laparoscopic Retractor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699315","Smoke Evacuator","C79092","A medical device for the removal of surgical smoke generated by laser or cautery during a medical procedure.","Smoke Evacuator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002688","Amputation","C15179","The surgical removal of all or part of a limb or other appendage.","Amputation | AMPUTATION_TYPE | amputation",,,,,,,,,,,,,,,"4217482","Amputation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026987","Myelofibrosis","C3248","A partial or complete replacement of the bone marrow stroma by fibrous tissue.  It can be a primary bone marrow lesion as part of the chronic myeloproliferative disorders (chronic idiopathic myelofibrosis), a manifestation of acute myeloid leukemia (acute panmyelosis with myelofibrosis), or a secondary phenomenon due to bone marrow involvement by a metastatic tumor (e.g., metastatic breast carcinoma). --2003","Myelofibrosis | Osteomyelofibrosis | myelofibrosis",,,,,,,,,,,,,,,"133169","Myelofibrosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019733","HLA Class I Histocompatibility Antigen, A-2 Alpha Chain","C16691","HLA class I histocompatibility antigen, A-2 alpha chain (365 aa, ~41 kDa) is encoded by the human HLA-A gene. This protein is involved in antigen presentation.","HLA Class I Histocompatibility Antigen, A-2 Alpha Chain | HLA-A | HLA-A Class I Antigen 2 | HLA-A Histocompatibility Type Antigen 2 | HLA-A Histocompatibility Type Antigen*02 | HLA-A*02 | HLA-A2 | HLA-A2 Antigen | HLA-A2 Antigen | MHC Class I Antigen A*02 | MHC Class I Antigen A*2 | Major Histocompatibility Complex, Class I, A2 Antigen",,,,,,,,,,,,,,,"4244712","HLA-A2 antigen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020880","Ileocecal Valve","C13066","The valve between the ileum of the small intestine and the cecum of the large intestine.","Ileocecal Valve | ",,,,,,,,,,,,,,,"4046901","Ileocecal valve structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1881376","Light (qualifier)","C64650","Of comparatively little physical weight or density.","Light | Lightly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700112","Unpaired","C78867","Not matched or mated.","Unpaired | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796563","Localized Malignant Neoplasm","C8576","A malignant neoplasm that is confined to a specific site without evidence of spread to other anatomic sites.","Localized Malignant Neoplasm | Local Cancer | Localized Cancer | Localized Malignancy | local cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700259","Voxel","C79424","The smallest distinguishable 'rectangular-parallel-piped-shaped' part of a three-dimensional space or image.","Voxel | VOXEL | Volume Picture Element | Volume Pixel | {VOXEL}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697493","Gaussian Kernel","C79422","A kernel function described by the equation: ((2PI)^(-0.5))*exp(-u^(2)/2) with u=(x-xi)/h, where h is the window width and xi are the values of the independent variable in the data, and x is the value of the independent variable for which one seeks an estimate.","Gaussian Kernel | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697840","Kernel Bandwidth","C79423","A scalar argument to a kernel function that determines what range of the nearby data points will be heavily weighted in making an estimate.","Kernel Bandwidth | Kernel Window Width | Window Width",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880483","Eigenvalue","C61068","A series of float values each of which represents proportion of variance for each principal component.","Eigenvalue | Eigen Value",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347999","Afimoxifene","C975","A tamoxifen metabolite with both estrogenic and anti-estrogenic effects.  Afimoxifene has a higher affinity for the estrogen receptor than tamoxifen, and functions as an antagonist in breast cancer cells.","Afimoxifene | 4-(1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol | 4-Hydroxy-Tamoxifen | 4-Hydroxytamoxifen | 4-Hydroxytamoxifen | 4-OHT | 4-hydroxytamoxifen | AFIMOXIFENE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL414891","Outer","C38166","Being on or toward the outside of the body or object.","Outer | OUTER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1136216","Diffusion Magnetic Resonance Imaging","C20117","MRI method that measure the diffusion of water in the tissue, rather than the content of water as measured in conventional MRI.","Diffusion MRI | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085406","Anisotropy","C17442","The property of being anisotropic, having a different value when measured in different directions.","Anisotropy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349031","Unit of Diffusion Coefficient","C68743","A unit of factor of proportionality representing the amount of substance diffusing across a unit area through a unit concentration gradient in unit time.","Unit of Diffusion Coefficient | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1947902","Medical Product Labeling","C54694","All written, printed, or graphic matter accompanying an article at any time while such article is in interstate commerce or held for sale after shipment or delivery in interstate commerce.","Labeling | Labeling Materials | Medical Product Label | labeling (content of)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024487","Magnetic Resonance Spectroscopy","C16810","Detection and measurement of the resonant spectra of molecular species in a tissue or sample.","Magnetic Resonance Spectroscopy | NMR Spectroscopy | NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY | Spectroscopy, MR | Spectroscopy, NMR | Spectroscopy, Nuclear Magnetic Resonance",,,,,,,,,,,,,,,"4082847","Magnetic resonance spectroscopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008405","Choline","C61674","Water-soluble vitamin that is a precursor for acetylcholine, phospholipids, and the methyl donor betaine. (DRI)","Choline | (2-Hydroxyethyl)trimethylammonium | 2-hydroxyethyl-trimethyl-ammonium | CHOLINE | Vitamin J | choline",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010286","Creatine","C37937","An endogenous amino acid derivative produced by vertebrate animals and occurring primarily in muscle cells.  Creatine is important for energy storage; it is phosphorylated to creatine phosphate, which serves as a phosphate donor in the conversion of ADP to ATP and supplies energy necessary for muscle contraction.  Dietary supplementation with creatine may improve muscle wasting associated with cancer and other chronic diseases.","Creatine | CREATINE | Glycine, N-(aminoiminomethyl)-N-methyl- | creatine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522706","Magnetic Resonance Spectroscopic Imaging","C29934","Magnetic resonance spectroscopy is a noninvasive imaging technique that acts as a complement to conventional imaging of brain tumors in order to improve the sensitivity and specificity of the diagnostic process. This technique operates by exciting and recording signals from a range of magnetic resonance frequencies, allowing the identification and quantification of several biologically significant molecules containing proton groups that resonate in the appropriate frequency range. The technique facilitates observation of the spatial distribution of metabolic patterns over a region of interest and surrounding tissue at a high spatial resolution.","Magnetic Resonance Spectroscopic Imaging | 1H- Nuclear Magnetic Resonance Spectroscopic Imaging | 1H-nuclear magnetic resonance spectroscopic imaging | MRS | MRS Imaging | MRSI | MS | Magnetic Resonance Spectroscopy | Proton Magnetic Resonance Spectroscopic Imaging | magnetic resonance spectroscopic imaging | proton magnetic resonance spectroscopic imaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448961","Eta","C79085","The symbol for the linear predictor of a generalized linear model, and can also be used to denote the median of a population.","Eta | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698674","Outlier","C79083","An observation in a data set that is numerically distant from the rest of the data.","Outlier | outliers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700224","GISTIC","C79084","A statistical approach for identifying genomic regions of aberration that are more likely to drive cancer pathogenesis. The method identifies those regions of the genome that are aberrant more often than would be expected by chance, with greater weight given to high-amplitude events (high-level copy-number gains or homozygous deletions) that are less likely to represent random aberrations.","GISTIC | Genomic Identification of Significant Targets in Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448771","Dispersion","C53321","The variation between data values in a sample.","Statistical Dispersion | Dispersion | Dispersion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0210657","Pemetrexed","C61614","A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.","Pemetrexed | L-Glutamic Acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl) | MTA | Multitargeted Antifolate | PEMETREXED | Pemfexy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709707","Proportion","C49159","A part, fraction, share, or number considered in relation to the whole amount or number.","Proportion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1552648","F-Distribution","C53221","The distribution of the ratio of two independent quantities each of which is distributed like a variance in a normally distributed sample.","F-Distribution | F Distribution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037508","Sodium Fluoride","C832","An inorganic salt of fluoride used topically or in municipal water fluoridation systems to prevent dental caries.  Fluoride appears to bind to calcium ions in the hydroxyapatite of surface tooth enamel, preventing corrosion of tooth enamel by acids. This agent may also inhibit acid production by commensal oral bacteria. (NCI04)","Sodium Fluoride | Fluoride, sodium | NaF | SODIUM FLUORIDE | Sodium Fluoride (NaF) | Sodium fluoride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0114873","Doxazosin","C61737","A quinazoline with antihypertensive and antineoplastic properties. Doxazosin is an alpha-adrenergic antagonist that selectively inhibits alpha-1 adrenergic receptors. Blockages of the alpha-1 adrenergic action on the vascular smooth muscles lead to a decrease in vascular resistance and antihypertensive activity. This agent also shows high affinity to alpha-1c adrenoceptor, the predominant functional type in the prostate, which may partially attribute to its effect in treatment of benign prostatic hyperplasia. Furthermore, doxazosin induces apoptosis in prostate cancer cells mediated through inhibition of protein kinase B (PKB)/Akt-signaling death receptor regulatory pathway.","Doxazosin | DOXAZOSIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0299792","Aripiprazole","C47403","A quinoline derivate and atypical anti-psychotic agent. Aripiprazole has partial agonistic activity at dopamine D2 receptors and serotonin 5-HT1A receptors, as well as potent antagonistic activity on serotonin 5-HT2A receptors. This drug stabilizes dopamine and serotonin activity in the limbic and cortical system. Aripiprazole is used in managing symptoms of schizophrenia and of acute manic and mixed episodes associated with bipolar I disorders.","Aripiprazole | 2(1H)-Quinolinone, 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro- | ARIPIPRAZOLE | Abilify | Opc 14597",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596092","Animal Colony","C78713","A group of animals of the same species that are living, or being housed together.","Animal Colony | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0850292","Radiofrequency Ablation","C15666","A therapeutic procedure to kill tissue using radiowaves to generate heat. The procedure is performed by the insertion of an electrode into a target tissue. Electrical energy delivered to the electrode heats and destroys the tissue.","Radiofrequency Ablation | Ablation, Radiofrequency | RFA | Radiofrequency Interstitial Ablation | radiofrequency ablation",,,,,,,,,,,,,,,"604322","Radiofrequency ablation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010631","Cystadenocarcinoma","C2971","A malignant cystic epithelial neoplasm arising from the glandular epithelium.  The malignant epithelial cells invade the stroma.  The cystic spaces contain serous or mucinous fluid.  Representative examples include ovarian and pancreatic cystadenocarcinomas.","Cystadenocarcinoma | CYSTADENOCARCINOMA, MALIGNANT | Cystadenocarcinoma, NOS","8440/3","Cystadenocarcinoma, NOS",,,,,,,,,,,,,"4050978","Cystadenocarcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0040739","Allografting","C51673","Grafting or transplanting cells, tissues, or organs between genetically non-identical individuals.","Allografting | allograft",,,,,,,,,,,,,,,"4174368","Allogeneic transplantation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002627","Amniocentesis","C52009","A prenatal diagnostic procedure in which a small sample of amniotic fluid is removed from the uterus by a needle inserted into the abdomen. This procedure is used to detect various genetic abnormalities in the fetus and/or the sex of the fetus.","Amniocentesis | ",,,,,,,,,,,,,,,"4146045","Amniocentesis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002692","Amputation of Leg Through Tibia and Fibula","C51702","The surgical removal of part or all of leg that is below the knee.","Amputation of Leg Through Tibia and Fibula | Below-Knee Amputation",,,,,,,,,,,,,,,"4338257","Amputation of leg through tibia and fibula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003881","Arthrodesis","C52007","Surgical fixation or immobilization of a joint, performed to allow bones to fuse or join together.","Arthrodesis | ",,,,,,,,,,,,,,,"4024267","Arthrodesis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0188602","Amputation of Toe","C51622","The surgical removal of a toe.","Amputation of Toe | ",,,,,,,,,,,,,,,"4159766","Amputation of toe",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516049","Assessment of Gonadal Function","C17869","Testing to determining the function of testes and ovaries, frequently performed as part of a fertility assessment.","Assessment of Gonadal Function | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003893","Arthroplasty","C51691","Surgical reconstruction or replacement of all or part of a malformed, diseased, degenerated, or otherwise damaged joint.","Arthroplasty | ",,,,,,,,,,,,,,,"40481840","Arthroplasty",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0193476","Biopsy of Bile Duct","C51642","Removal of tissue from the bile duct for microscopic examination.","Biopsy of Bile Duct | ",,,,,,,,,,,,,,,"4171831","Biopsy of bile ducts",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0193114","Biopsy of Anus","C51586","Removal of tissue from the anus for microscopic examination.","Biopsy of Anus | Anal Biopsy",,,,,,,,,,,,,,,"4271929","Biopsy of anus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1832008","Balloon-Guided Endoscopic Procedure","C64865","An endoscopic technique that allows deep intubation of the small intestine while using a standard endoscope. An inflatable balloon attached to the endoscope's tip acts as a stabilizer and a second balloon that is advanced ahead of the endoscope acts as a pulling device.","Balloon-Guided Endoscopic Procedure | Balloon-Guided Endoscopy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0398434","Axillary Lymph Node Biopsy","C62658","Surgical removal of tissues from the lymph nodes located in the cavity beneath the junction of the arm and the thorax (armpit) so that a biopsy can be performed.","Axillary Lymph Node Biopsy | Axillary Node Biopsy",,,,,,,,,,,,,,,"4120963","Biopsy of axillary lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005933","Biopsy of Bone","C51927","Removal of bone tissue for microscopic examination.","Biopsy of Bone | Bone Biopsy",,,,,,,,,,,,,,,"4029787","Biopsy of bone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0194379","Biopsy of Bladder","C51700","Removal of tissue from the bladder for microscopic examination.","Biopsy of Bladder | Bladder Biopsy",,,,,,,,,,,,,,,"4267975","Biopsy of bladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0197128","Biopsy of Conjunctiva","C51486","Removal of conjunctival tissue for microscopic examination.","Biopsy of Conjunctiva | Conjunctival Biopsy",,,,,,,,,,,,,,,"4104552|4120666","Excisional biopsy of conjunctiva|Conjunctival biopsy",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0405352","Biopsy of Breast","C51698","Removal of tissue from the breast for microscopic examination.","Biopsy of Breast | Breast Biopsy",,,,,,,,,,,,,,,"4047494","Biopsy of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0191987","Biopsy of Lip","C51653","Removal of tissue from the lip for microscopic examination.","Biopsy of Lip | ",,,,,,,,,,,,,,,"4017700","Biopsy of lip",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0852790","Biopsy of Larynx","C51663","Removal of tissue from the larynx for microscopic examination.","Biopsy of Larynx | Laryngeal Biopsy",,,,,,,,,,,,,,,"4335676","Biopsy of larynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0189784","Biopsy of Heart","C51794","Removal of tissue from the heart for microscopic examination.","Biopsy of Heart | Cardiac Biopsy",,,,,,,,,,,,,,,"4057804","Biopsy of heart",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0185283","Muscle Biopsy","C51895","Removal of tissue from the muscle, for microscopic examination.","Muscle Biopsy | Biopsy of Muscle",,,,,,,,,,,,,,,"4075290","Biopsy of muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0852695","Biopsy of Mucosa","C51922","Removal of mucosal tissue for microscopic examination.","Biopsy of Mucosa | Mucosal Biopsy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0161878","Biopsy of Mouth","C51650","Removal of tissue from the oral cavity for microscopic examination.","Biopsy of Mouth | ",,,,,,,,,,,,,,,"4119815","Biopsy of mouth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0193388","Liver Biopsy","C51677","Removal of tissue from the liver for microscopic examination.","Liver Biopsy | Biopsy of Liver",,,,,,,,,,,,,,,"4314001","Biopsy of liver",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0193606","Biopsy of Pancreas","C51671","Removal of tissue from the pancreas for microscopic examination.","Biopsy of Pancreas | Pancreatic Biopsy",,,,,,,,,,,,,,,"4138981","Biopsy of pancreas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0176358","Biopsy of Nose","C51626","Removal of tissue from the nose for microscopic examination.","Biopsy of Nose | ",,,,,,,,,,,,,,,"4186722","Biopsy of nose",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0396352","Biopsy of Nasopharynx","C51768","Removal of tissue from the nasopharynx for microscopic examination.","Biopsy of Nasopharynx | Nasopharyngeal Biopsy",,,,,,,,,,,,,,,"4339494","Biopsy of nasopharynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0193950","Biopsy of Pharyngeal Tonsil","C51487","Removal of tissue from the pharyngeal tonsil for microscopic examination.","Biopsy of Pharyngeal Tonsil | Biopsy of Adenoids",,,,,,,,,,,,,,,"4252373","Biopsy of adenoids",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0198609","Biopsy of Peritoneum","C51627","Removal of tissue from the peritoneum for microscopic examination.","Biopsy of Peritoneum | Peritoneal Biopsy",,,,,,,,,,,,,,,"4105589","Biopsy of peritoneum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0191244","Biopsy of Pericardium","C51568","Removal of tissue from the pericardium for microscopic examination.","Biopsy of Pericardium | Pericardial Biopsy",,,,,,,,,,,,,,,"4020359","Biopsy of pericardium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0193694","Biopsy of Parathyroid Gland","C51587","Removal of parathyroid tissue for microscopic examination.","Biopsy of Parathyroid Gland | Parathyroid Biopsy",,,,,,,,,,,,,,,"4337807","Biopsy of parathyroid gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0192141","Biopsy of Tongue","C51930","Removal of tissue from the tongue for microscopic examination.","Biopsy of Tongue | Lingual Biopsy",,,,,,,,,,,,,,,"4075158","Biopsy of tongue",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0193781","Biopsy of Thyroid Gland","C51613","Removal of tissue from the thyroid gland for microscopic examination.","Biopsy of Thyroid Gland | ",,,,,,,,,,,,,,,"4085189","Biopsy of thyroid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0403215","Biopsy of Testis","C51894","Removal of testicular tissue for microscopic examination.","Biopsy of Testis | ",,,,,,,,,,,,,,,"4042506","Biopsy of testis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0150866","Skin Biopsy","C51692","Removal of a portion of skin tissue, for microscopic examination.","Skin Biopsy | Biopsy of Skin",,,,,,,,,,,,,,,"4081731","Biopsy of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0193303","Biopsy of Salivary Gland","C51488","Removal of tissue from the salivary gland for microscopic examination.","Biopsy of Salivary Gland | ",,,,,,,,,,,,,,,"4150846","Biopsy of salivary gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0194804","Biopsy of Prostate","C51701","Removal of tissue from the prostate for microscopic examination.","Biopsy of Prostate | Prostate Biopsy | Prostatic Biopsy",,,,,,,,,,,,,,,"4278515","Biopsy of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0189396","Bronchoscopy with Biopsy","C51638","Removal of bronchial tissue for microscopic examination, using an endoscope.","Bronchoscopy with Biopsy | Endobronchial Biopsy",,,,,,,,,,,,,,,"4206027","Bronchoscopy with biopsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0195961","Brain Lobectomy","C52004","Surgical removal of a lobe of the brain.","Brain Lobectomy | ",,,,,,,,,,,,,,,"4200691","Lobectomy of brain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0750294","Vocal Cord Biopsy","C51908","Removal of tissue from the vocal cords for microscopic examination.","Vocal Cord Biopsy | Biopsy of Vocal Cord",,,,,,,,,,,,,,,"4326972","Biopsy of vocal cord",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0194564","Biopsy of Urethra","C51640","Removal of tissue from the urethra for microscopic examination.","Biopsy of Urethra | ",,,,,,,,,,,,,,,"4314771","Biopsy of urethra",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0189353","Biopsy of Trachea","C51631","Removal of tissue from the trachea for microscopic examination.","Biopsy of Trachea | ",,,,,,,,,,,,,,,"4150831","Biopsy of trachea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0740463","Bronchial Biopsy","C51782","Removal of tissue from the bronchus for microscopic examination.","Bronchial Biopsy | Biopsy of Bronchus",,,,,,,,,,,,,,,"4208075","Biopsy of bronchus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0589347","Colonoscopic Polypectomy","C51688","Complete or partial removal of a polypoid lesion from the mucosal surface of the large intestine.","Colonoscopic Polypectomy | Colonic Polypectomy",,,,,,,,,,,,,,,"4209537","Colonoscopic polypectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0870300","Assessment: Cognition","C62736","The examination of the cognitive capacities or deficits of an individual through the application of tests that probe that individual's ability to perform various mental activities such as perception, learning, and reasoning.","Cognitive Assessment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0408197","Cheilectomy","C51596","A surgical procedure used to remove bone spurs or irregularities from a joint.","Cheilectomy | ",,,,,,,,,,,,,,,"4034246","Cheilectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0598836","Checkup","C41383","Checkup is a general examination or inspection, especially one carried out by a doctor or dentist.","Checkup | Check-up",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0195314","Cervical Biopsy","C51628","Removal of tissue from the cervix for microscopic examination.","Cervical Biopsy | ",,,,,,,,,,,,,,,"4175471","Cervical biopsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL493450","Central Venous Cannula Insertion","C40972","A procedure of surgical placement of a catheter, which lumen is usually occupied by a trocar, into the central vein (internal jugular, subclavian, and femoral often used) or veins, to provide vascular access for measurement of hemodynamic variables that cannot be measured accurately by noninvasive means.  It also can be used to deliver medications that were too potent or too toxic to be administered through peripheral access, for parenteral nutrition delivery; and for placing wires and pulmonary artery catheters. Central veins are usually cannulated percutaneously. The procedure is associated with many adverse events and has to be performed or supervised by an experienced physician.","Central Venous Cannula Insertion | Central Venous Catheter Placement | Central venous catheter",,,,,,,,,,,,,,,"4052413","Central venous cannula insertion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1511519","Cordectomy","C28353","An operation on the vocal cords or on the spinal cord.","Cordectomy | cordectomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0678005","Colposcopic Biopsy","C15703","Removal of tissue from the vagina or cervix by the use of a colposcope.","Colposcopic Biopsy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010468","Curettage Procedure","C15216","Removal of tissue with a curette (a spoon-shaped instrument with a sharp edge).","Curettage Procedure | CURETTAGE | Curettage | curettage",,,,,,,,,,,,,,,"4044188|4286052","Curettage - action|Curettage",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0193609","Core Biopsy of Pancreas","C51489","The removal of pancreatic tissue using a needle with a relatively large diameter, for microscopic examination.","Core Biopsy of Pancreas | Core Needle Biopsy of Pancreas",,,,,,,,,,,,,,,"4224650","Core needle biopsy of pancreas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011307","Deafferentation","C21002","Cutting off the afferent nerve supply.  Often performed to relieve pain. (Taber's).","Deafferentation | Denervation",,,,,,,,,,,,,,,"4113616","Denervation - action",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1707881","Ectocervical Biopsy","C51630","Removal of tissue from the ectocervix for microscopic examination.","Ectocervical Biopsy | Exocervical Biopsy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206078","Discectomy","C21009","Surgical excision of an intervertebral disc.  Often performed for pain relief.","Discectomy | ",,,,,,,,,,,,,,,"4145274","Discectomy of spine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0189281","Direct Laryngoscopy with Biopsy","C51659","Removal of laryngeal tissue under direct visualization for microscopic examination.","Direct Laryngoscopy with Biopsy | ",,,,,,,,,,,,,,,"4173589","Direct laryngoscopy with biopsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0189785","Endomyocardial Biopsy","C51674","Removal of myocardial tissue for microscopic examination, usually taken from the right heart using a transvenous approach.","Endomyocardial Biopsy | ",,,,,,,,,,,,,,,"4308808","Endomyocardial biopsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0195343","Endocervical Biopsy","C51629","Removal of tissue from the endocervix for microscopic examination.","Endocervical Biopsy | ",,,,,,,,,,,,,,,"4001516","Endocervical biopsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206058","Elective Surgical Procedure","C51996","Surgery that may be scheduled or undertaken by choice.","Elective Surgical Procedure | ELECTIVE | Elective Surgery",,,,,,,,,,,,,,,"4166767","Optional surgery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0810150","Biopsy of Colon","C51678","Removal of tissue from the colon for microscopic examination, using an endoscope.","Biopsy of Colon | Colonoscopic Biopsy | Colonoscopy and Biopsy",,,,,,,,,,,,,,,"4294513","Biopsy of colon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1510477","Endometrial Biopsy","C51920","Removal of tissue from the endometrial cavity for microscopic examination.","Endometrial Biopsy | endometrial biopsy",,,,,,,,,,,,,,,"4299733","Endometrial biopsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0577780","Biopsy of Pylorus","C51584","Removal of tissue from the pylorus for microscopic examination, using an endoscope.","Biopsy of Pylorus | Pyloric Biopsy",,,,,,,,,,,,,,,"4116631","Biopsy of pylorus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0576452","Biopsy of Jejunum","C51902","Removal of tissue from the jujunum for microscopic examination, using an endoscope.","Biopsy of Jejunum | Jejunal Biopsy",,,,,,,,,,,,,,,"4101674","Biopsy of jejunum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0399805","Biopsy of Duodenum","C51683","Removal of tissue from the duodenum for microscopic examination, using an endoscope.","Biopsy of Duodenum | Duodenal Biopsy | Endoscopic Biopsy of Duodenum",,,,,,,,,,,,,,,"4128717","Biopsy of duodenum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1707921","Enlargement Of Surgical Incision","C50835","A surgical procedure to extend the length of an initial surgical incision.","Enlargement Of Surgical Incision | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880510","Endoscopic Ultrasound-Guided Fine-Needle Aspiration","C67287","The use of endoscopic ultrasound imaging for real-time guidance to identify and approach lesions for fine-needle aspiration.","Endoscopic Ultrasound-Guided Fine-Needle Aspiration | EUS-FNA | endoscopic ultrasound-guided fine needle aspiration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282493","Endoscopic Surgery","C62734","A surgical procedure done with the use or assistance of an endoscopic device.","Endoscopic Surgery | ",,,,,,,,,,,,,,,"4138127","Endoscopic operation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0399943","Biopsy of Small Intestine","C51600","Removal of tissue from the small intestine for microscopic examination, using an endoscope.","Biopsy of Small Intestine | Small Intestinal Biopsy",,,,,,,,,,,,,,,"4000606","Biopsy of small intestine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0192269","Esophageal Biopsy","C51686","Removal of tissue from the esophagus for microscopic examination, using an endoscope.","Esophageal Biopsy | Biopsy of Esophagus",,,,,,,,,,,,,,,"4136205","Biopsy of esophagus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0185032","Epithelial Marsupialization","C50829","A surgical method for curing a cyst. The cyst is opened, its contents removed, and the edges then stitched to the skin incision.","Epithelial Marsupialization | Marsupialization",,,,,,,,,,,,,,,"4040382|4045064|4087433","Marsupialization|Marsupialization - action|Construction of pouch",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C0194890","Epididymectomy","C51493","Surgical removal of the epididymis.","Epididymectomy | ",,,,,,,,,,,,,,,"4289250","Epididymectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0405348","Excisional Biopsy of Breast","C51633","Removal of tissue from the breast for microscopic examination, involving surgical excision of a portion of the breast.","Excisional Biopsy of Breast | ",,,,,,,,,,,,,,,"4028789","Excisional biopsy of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0558588","Examination Under Anesthesia","C40971","A medical inspection, qualified according to the methods employed, as physical examination, radiologic examination, diagnostic imaging examination, etc., performed under conditions of patient's complete or partial local or general insensibility to pain with or without the loss of consciousness, induced by an anesthetic agent or by non-pharmacological anesthesia technique.","Examination Under Anesthesia | Examination under Anesthesia",,,,,,,,,,,,,,,"4164507","Examination under anesthesia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014873","Esophagoscopy","C16560","Endoscopic examination of the esophagus.","Esophagoscopy | esophagoscopy",,,,,,,,,,,,,,,"4171183","Endoscopy of esophagus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0192466","Esophagogastroscopy","C51644","Endoscopic examination of the esophagus and stomach.","Esophagogastroscopy | ",,,,,,,,,,,,,,,"4189724","Esophagogastroscopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0553989","Excisional Biopsy of Lymph Node","C51662","A surgical procedure in which a single or multiple lymph nodes are removed for microscopic examination.","Excisional Biopsy of Lymph Node | Lymph Node Excision",,,,,,,,,,,,,,,"4145401","Excisional biopsy of lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018833","Heart and Lung Transplantation","C15247","The surgical transfer of a heart and one or both lungs from one individual to another.","Heart and Lung Transplantation | Heart Lung Grafting | Heart Lung Transplantation | Heart-Lung Grafting | Heart-Lung Transplantation",,,,,,,,,,,,,,,"4138959","Heart-lung transplant with recipient cardiectomy-pneumonectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0192472","Gastric Biopsy","C51685","Removal of tissue from the stomach for microscopic examination, using an endoscope.","Gastric Biopsy | Biopsy of Stomach | Endoscopic Biopsy of Stomach",,,,,,,,,,,,,,,"4004241","Endoscopic biopsy of stomach",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013804","Fulguration","C15390","A procedure that uses a high-frequency current for the purpose of destroying living tissue, most commonly malignant tumors.","Fulguration | electrofulguration | fulguration",,,,,,,,,,,,,,,"4293744","Fulguration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016641","Orthopedic Stabilization","C52008","An orthopedic procedure for stabilization and maintenance of alignment during the process of healing.","Orthopedic Stabilization | Fracture Fixation | Fracture Fixation | Fracture Procedure | Mechanical Stabilization",,,,,,,,,,,,,,,"4343339","Fixation of fracture",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0200149","Eye Examination","C38060","A test performed by an ophthalmologist or optometrist assessing vision and ability to focus on and discern objects, as well as other tests and examinations pertaining to the eyes.","Eye Examination | Eye Exam | OEEXAM | Ophthalmic Examination",,,,,,,,,,,,,,,"4263508","Ophthalmic examination and evaluation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018823","Heart Transplantation","C15246","A surgical procedure in which a damaged heart is removed and replaced by another heart from a suitable donor.","Heart Transplantation | CARDIAC TRANSPLANT | Cardiac Transplantation | Heart Grafting | Heart Transplant",,,,,,,,,,,,,,,"4137127","Transplantation of heart",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018990","Hemipelvectomy","C51580","Amputation of a lower limb and part of the pelvis through the sacroiliac joint.","Hemipelvectomy | ",,,,,,,,,,,,,,,"36675618","Amputation of entire lower limb and ipsilateral hemipelvis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023072","Laryngoscopy","C16781","Endoscopic examination of the larynx.","Laryngoscopy | laryngoscopy",,,,,,,,,,,,,,,"4103523","Laryngoscopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1455863","Kyphoplasty","C62742","A procedure with the intent of expanding a collapsed vertebra. A surgical instrument is introduced into the spine with a balloon that is inflated to expand the bone. Once this instrument is withdrawn, the space created is then filled with bone cement mixture.","Kyphoplasty | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022671","Kidney Transplantation","C15265","The transfer of a healthy kidney from a donor to a patient for the purpose of replacing one of the failing kidneys of the patient.","Kidney Transplantation | Kidney Grafting | Kidney Transplant | Renal Transplantation",,,,,,,,,,,,,,,"4322471","Transplant of kidney",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0949591","Limb Salvage","C16042","A procedure to avoid amputation of an arm or leg.","Limb Salvage Procedure | Limb Salvage | Limb Salvage Procedures | Limb Sparing Procedure | Limb-Salvage | SURGERY_TYPE_LIMB_SALVAGE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522684","Laser-Induced Fluorescence Endoscopy","C20203","A system for detection of precancerous lesions and early stages of certain types of cancer, consisting of an excimer laser coupled to a dye laser and an endoscopic spectral-image analyzer that are used after the patient has been exposed to tumoriphilic photosensitizers.","Laser-Induced Fluorescence Endoscopy | LIFE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024128","Lung Transplantation","C15274","The surgical transfer of one or both lungs from one individual to another.","Lung Transplantation | Lung Transplant | lung grafting",,,,,,,,,,,,,,,"4337138","Transplant of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023911","Liver Transplantation","C15271","The transfer of a healthy liver allograft from a donor to a patient.","Liver Transplantation | Hepatic Transplantation | Liver Grafting | Liver Transplant | Transplantation of Liver",,,,,,,,,,,,,,,"4076862","Transplantation of liver",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0948550","Mediastinal Biopsy","C51603","Removal of tissue from the mediastinum for microscopic examination, using an endoscope.","Mediastinal Biopsy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518160","Male Gonadal Ridge Implantation","C29899","A technique for transplantation of stem cells, derived from embryonic gonadal ridge (embryonic germ cells), which are pluripotent and capable of self-renewal for long periods. The technique has a wide potential to cure diseases by repairing or replacing damaged cells and tissues as well as in gene therapy.","Male Gonadal Ridge Implantation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0581276","Needle Biopsy of Liver","C51675","Removal of tissue from the liver for microscopic examination, using a needle.","Needle Biopsy of Liver | ",,,,,,,,,,,,,,,"4120661","Needle biopsy of liver",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0558535","Needle Biopsy of Kidney","C51764","Removal of tissue from the kidney, for microscopic examination, using a needle.","Needle Biopsy of Kidney | ",,,,,,,,,,,,,,,"4173506","Needle biopsy of kidney",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0189025","Nasopharyngoscopy","C38075","Endoscopic examination of the nasopharynx.","Nasopharyngoscopy | ",,,,,,,,,,,,,,,"4307682","Nasopharyngoscopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0079850","Mohs Surgery","C28208","A dermatologic procedure used to treat certain forms of skin cancer in which tissue is removed and immediately tested via frozen section; tissue continues to be removed until clear margins are achieved.","Mohs Surgery | MOHS SURGERY | Mohs Micrographic Surgery | Mohs micrographic surgery | Mohs surgery",,,,,,,,,,,,,,,"4167550","Mohs surgery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027732","Nephroureterectomy","C51646","Surgical removal of a kidney and its ureter.","Nephroureterectomy | Ureteronephrectomy | nephroureterectomy | ureteronephrectomy",,,,,,,,,,,,,,,"4022807","Nephroureterectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0194074","Open Biopsy of Kidney","C51732","Removal of tissue from the kidney, for microscopic examination, performed during an open surgical procedure.","Open Biopsy of Kidney | Open Renal Biopsy",,,,,,,,,,,,,,,"4221238","Open biopsy of kidney",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518328","Nipple Discharge Aspiration","C38076","An aspiration of nipple discharge using a fine needle to investigate the presence of disease.","Nipple Discharge Aspiration | Nipple Suction Aspiration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029468","Osteotomy","C51903","Surgical cutting or removal of bone.","Osteotomy | ",,,,,,,,,,,,,,,"4305752","Osteotomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038901","Ophthalmologic Surgical Procedure","C15331","Surgery involving the eyes.","Ophthalmologic Surgical Procedure | Surgery, Ophthalmological | eye surgery | ophthalmological surgical procedure",,,,,,,,,,,,,,,"4189286","Surgical procedure on eye proper",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518717","Ovarian Implantation","C29897","A surgical procedure for infertility related to tubal factors where the ovary is relocated to within the uterine cavity.","Ovarian Implantation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0372299","Percutaneous Biopsy of Kidney","C51901","Removal of tissue from the kidney, for microscopic examination, obtained percutaneously.","Percutaneous Biopsy of Kidney | Percutaneous Renal Biopsy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0187898","Patellectomy","C51641","Surgical removal of part or all of the patella.","Patellectomy | ",,,,,,,,,,,,,,,"4239784","Patellectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0079646","Pancreatic Islet Transplantation","C15352","The surgical transfer of pancreatic islet cells from one individual to another.","Pancreatic Islet Transplantation | islets of Langerhans transplantation",,,,,,,,,,,,,,,"4027241","Islet cell transplant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030275","Pancreas Transplantation","C15293","The surgical transfer of a pancreas from one individual to another.","Pancreas Transplantation | pancreas grafting",,,,,,,,,,,,,,,"4266668","Transplantation of pancreas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL322428","Peritoneoscopy","C38079","Endoscopic examination of peritoneum.","Peritoneoscopy | ",,,,,,,,,,,,,,,"4251314","Laparoscopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0458895","Couinaud Liver Segment","C79730","Any of the eight liver segments that has its own vascular inflow, outflow, and biliary drainage, thus defined as functionally independent.","Couinaud Liver Segment | Couinaud Segment",,,,,,,,,,,,,,,"4092617","Couinaud liver segment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227489","Caudate Lobe","C33000","Couinaud segment I, located on the posterior surface of the liver between the sulcus for the vena cava and the ligamentum venosum.","Caudate Lobe | Caudate | Couinaud Segment I | LIVER, CAUDATE LOBE | Lobus Caudatus | Lobus Spigelii | Spiegel's Lobe | Spigel Lobe",,,,,,,,,,,,,,,"4323544","Structure of caudate lobe of liver",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2697906","Left Posterolateral Segment","C79732","Couinaud segment II, corresponding to the lateral segment of the left lobe of the liver, located to the left of the superior portion of the falciform ligament and the fissure for the ligamentum venosum.","Left Posterolateral Segment | Couinaud Segment II | LIVER, LEFT LOBE POSTEROLATERAL SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697904","Left Anterolateral Segment","C79733","Couinaud segment III, corresponding to the lateral segment of the left lobe of the liver, located to the left of the inferior portion of the falciform ligament, anteriorly overlapping the stomach.","Left Anterolateral Segment | Couinaud Segment III | LIVER, LEFT LOBE ANTEROLATERAL SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697907","Left Superomedial Segment","C79734","Couinaud segment IVa, corresponding to the medial segment of the left lobe of the liver, located superiorly.","Left Superomedial Segment | Couinaud Segment IVa | Couinaud segment IVa | LIVER, LEFT LOBE SUPEROMEDIAL SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697905","Left Inferomedial Segment","C79735","Couinaud segment IVb, corresponding to the medial segment of the left lobe of the liver, located inferiorly.","Left Inferomedial Segment | Couinaud Segment IVb | LIVER, LEFT LOBE INFEROMEDIAL SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0338239","Radioimmunoguided Surgery","C15622","Radioguided surgery is an innovative means by which a radionuclide is used to preoperatively image and intraoperatively visualize a structure of interest to the surgeon for excisional biopsy. This technology has allowed a cost-effective, highly specific means by which to locate a structure (usually a lymph node) and access it for pathologic analysis. The result of radioguided surgery is increased specificity in tissue obtained for biopsy, minimal access incisions, and the reduction of inpatient hospital utilization. (from Medscape)","Radioimmunoguided Surgery | Radioguided Surgery | radioimmunoguided surgery",,,,,,,,,,,,,,,"37111538","Radioimmunoguided surgery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0854573","Prolonged Surgery","C50823","Surgery that is lengthy or that takes longer than anticipated.","Prolonged Surgery | Prolonged surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699084","Right Posteroinferior Segment","C79737","Couinaud segment VI, corresponding to the posterior segment of the right lobe of the liver, located inferiorly.","Right Posteroinferior Segment | Couinaud Segment VI | LIVER, RIGHT LOBE POSTEROINFERIOR SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699085","Right Posterosuperior Segment","C79738","Couinaud segment VII, corresponding to the posterior segment of the right lobe of the liver, located superiorly.","Right Posterosuperior Segment | Couinaud Segment VII | LIVER, RIGHT LOBE POSTEROSUPERIOR SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699083","Right Anterosuperior Segment","C79739","Couinaud segment VIII, corresponding to the anterior segment of the right lobe of the liver, located superiorly.","Right Anterosuperior Segment | Couinaud Segment VIII | LIVER, RIGHT LOBE ANTEROSUPERIOR SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041271","Salpingectomy","C51605","Surgery to remove part or all of the fallopian tube(s).","Salpingectomy | Tubal Excision",,,,,,,,,,,,,,,"4001541","Fallopian tube excision",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1402260","Replacement of Lens","C50836","Surgery to remove a lens and replace it with an artificial lens.","Replacement of Lens | Replacement Of Lens",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0193050","Rectal Biopsy","C51693","Removal of rectal tissue, for microscopic examination.","Rectal Biopsy | Biopsy of Rectum",,,,,,,,,,,,,,,"4184601","Biopsy of rectum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0333641","Atrophy","C79748","Any weakening or degeneration, especially through lack of use.","Atrophy | ATROPHY",,,,,,,,,,,,,,,"4028206","Atrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2700391","Procedure (set of actions)","C79751","Any stepwise set of actions.","Procedure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697585","Hepatocellular","C79753","Pertaining to or affecting liver cells.","Hepatocellular | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448539","Defer","C79754","Hold back to a later time.","Defer | Deferral | Deferred",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698330","Barcelona Criteria","C79760","A method to diagnosis hepatocellular carcinoma based on radiological findings, alfa-fetoprotein level and biopsy.","Barcelona Criteria | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0579037","Stereotactic Biopsy of Brain","C51655","An X-ray procedure using multiple coordinates to precisely determine the location of a tumor or nodule in the brain so as to obtain a tissue sample.","Stereotactic Biopsy of Brain | ",,,,,,,,,,,,,,,"4062876","Stereotactic biopsy of brain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037297","Skin Transplantation","C15325","The grafting of skin from one location to another in an attempt to replace a segment that is lost or damaged beyond repair.","Skin Transplantation | dermatoplasty | skin grafting",,,,,,,,,,,,,,,"4118634|4219240","Grafting to skin|Dermatoplasty",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0192919","Sigmoidoscopy with Biopsy","C51592","Removal of tissue from the sigmoid colon for microscopic examination, using an endoscope.","Sigmoidoscopy with Biopsy | ",,,,,,,,,,,,,,,"4262588","Sigmoidoscopy with biopsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0567344","Shave Excision","C51885","A surgical procedure where thin slices are remove with or as if with a plane.","Shave Excision | SHAVE EXCISION | Shaving Procedure | Shaving Procedure",,,,,,,,,,,,,,,"4129500","Shave excision",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038638","Suction Procedure","C51939","A procedure that makes use of a vacuum for the removal of fluid or tissue.","Suction Procedure | Suction",,,,,,,,,,,,,,,"4164516","Suction drainage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027498","Nausea and Vomiting","C3259","Expelling the contents of the stomach and the sensations associated with it. They are symptoms of an underlying disease or condition and not a specific illness.","Nausea and Vomiting | Nausea_or_vomiting | Vomiting and Nausea",,,,,,,,,,,,,,,"27674","Nausea and vomiting",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0373675","Magnesium Measurement","C64840","A quantitative measurement of the amount of magnesium present in a sample.","Magnesium Measurement | MG | Magnesium",,,,,,,,,,,,,,,"4243005","Magnesium measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0201925","Calcium Measurement","C64488","A quantitative measurement of the amount of calcium present in a sample.","Calcium Measurement | CA | Calcium",,,,,,,,,,,,,,,"4216722","Calcium measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202194","Potassium Measurement","C64853","A quantitative measurement of the amount of potassium present in a sample.","Potassium Measurement | K | Potassium",,,,,,,,,,,,,,,"4245152","Potassium measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0201952","Chloride Measurement","C64495","A quantitative measurement of the amount of chloride present in a sample.","Chloride Measurement | CL | Chloride",,,,,,,,,,,,,,,"4188066","Chloride measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2700121","Uric Acid Crystal Measurement","C74684","The determination of the amount of uric acid crystals present in a sample.","Uric Acid Crystal Measurement | CYURIAC | Uric Acid Crystals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337428","Fibrinogen Measurement","C64606","A quantitative measurement of the amount of fibrinogen present in a sample.","Fibrinogen Measurement | FIBRINO | Fibrinogen | Fibrinogen Antigen",,,,,,,,,,,,,,,"4094436","Fibrinogen measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040165","Thyroxine","C2302","A hormone synthesized and secreted by the thyroid gland containing four iodine atoms and is converted to triiodothyronine (T3) in the body, influencing metabolism and organ function.","Thyroxine | L-3,5,5'-tetraiodothyronine | T4 | thyroxin | thyroxine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040160","Thyroid-Stimulating Hormone","C2280","A peptide hormone secreted by the anterior pituitary. It promotes the growth of the thyroid gland and stimulates the synthesis of thyroid hormones and the release of thyroxine by the thyroid gland.","Thyroid-Stimulating Hormone | TSH | Thyreotrophic Hormone | Thyreotropin | Thyroid Stimulating Hormone | Thyroid Stimulating Hormone | Thyrotropic Hormone | Thyrotropin | thyroid-stimulating hormone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202230","Thyrotropin Measurement","C64813","A quantitative measurement of the amount of thyrotropin present in a sample.","Thyrotropin Measurement | TSH | Thyroid Stimulating Hormone | Thyroid Stimulating Hormone Measurement | Thyrotropin",,,,,,,,,,,,,,,"4246879","Thyroid stimulating hormone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0555903","Total Protein Measurement","C64858","A quantitative measurement of the amount of total protein present in a sample.","Total Protein Measurement | PROT | Protein | Total Protein",,,,,,,,,,,,,,,"4119650","Total protein measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0150887","Synovial Biopsy","C51731","Removal of synovial tissue for microscopic examination.","Synovial Biopsy | ",,,,,,,,,,,,,,,"4046737","Synovial biopsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0751551","Thoracoscopic Surgery","C15726","A minimally invasive thoracic surgical procedure that makes use of a thoracoscope.","Thoracoscopic Surgery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1832004","Ultrasonic Surgical Aspiration","C64863","A procedure in which tissue is broken up into small fragments by ultrasound and then removed by aspiration.","Ultrasonic Surgical Aspiration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040071","Thymectomy","C29894","Surgical removal of part or all of the thymus gland.","Thymectomy | ",,,,,,,,,,,,,,,"4265165","Excision of thymus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0195133","Vaginal Biopsy","C51595","Removal of tissue from the vagina for microscopic examination.","Vaginal Biopsy | ",,,,,,,,,,,,,,,"4006849","Vaginal biopsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0856443","Urostomy","C15759","The creation of a stoma that connects to the urinary tract so that urine drains continuously into an ostomy bag.","Urostomy | Non-Continent Diversion | Non-Continent Urinary Diversion | urostomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0194224","Ureterectomy","C51637","Surgical removal of all or part of the ureter.","Ureterectomy | ",,,,,,,,,,,,,,,"4029570","Ureterectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883418","Ultrasound-Guided Transbronchial Needle Aspiration","C67286","The use of ultrasound imaging to guide needle aspiration through the bronchial wall.","Ultrasound-Guided Transbronchial Needle Aspiration | EBUS-TBNA | Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0193390","Wedge Biopsy of Liver","C51918","Removal of a wedge-shaped portion of theliver, for microscopic examination.","Wedge Biopsy of Liver | ",,,,,,,,,,,,,,,"4308420","Wedge biopsy of liver",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042903","Vitrectomy","C50837","Surgical removal of the vitreous humor from the chamber of the eye.","Vitrectomy | ",,,,,,,,,,,,,,,"4294683","Vitrectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1303192","Vertebroplasty","C62752","A nonsurgical method for the repair of vertebral fractures and compression due to osteoporosis in which a glue-like material is inserted into the center of the collapsed spinal vertebra in order to stabilize and strengthen the crushed bone.","Vertebroplasty | vertebroplasty",,,,,,,,,,,,,,,"4268439","Vertebroplasty",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1881321","Kidney Cancer pT1 TNM Finding v6 and v7","C63562","Kidney cancer with tumor 7 cm or less in greatest dimension, limited to the kidney. (from AJCC 6th and 7th Eds.)","Kidney Cancer pT1 TNM Finding v6 and v7 | Kidney Cancer pT1 TNM Finding | Kidney Cancer pT1 TNM Finding | Kidney Cancer pT1 TNM Finding v6 | Kidney Cancer pT1 TNM Finding v7 | pT1 Kidney Cancer | pT1 Kidney Carcinoma | pT1 Renal Cancer | pT1 Renal Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881320","Kidney Cancer pT0 TNM Finding v6 and v7","C63561","No evidence of primary tumor. (from AJCC 6th and 7th Eds.)","Kidney Cancer pT0 TNM Finding v6 and v7 | Kidney Cancer pT0 TNM Finding | Kidney Cancer pT0 TNM Finding | Kidney Cancer pT0 TNM Finding v6 | Kidney Cancer pT0 TNM Finding v7 | pT0 Kidney Cancer | pT0 Kidney Carcinoma | pT0 Renal Cancer | pT0 Renal Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881330","Kidney Cancer pTX TNM Finding v6 and v7","C63560","Kidney cancer in which the primary tumor cannot be assessed. (from AJCC 6th and 7th Eds.)","Kidney Cancer pTX TNM Finding v6 and v7 | Kidney Cancer pTX TNM Finding | Kidney Cancer pTX TNM Finding | Kidney Cancer pTX TNM Finding v6 | Kidney Cancer pTX TNM Finding v7 | pTX Kidney Cancer | pTX Kidney Carcinoma | pTX Renal Cancer | pTX Renal Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881322","Kidney Cancer pT1a TNM Finding v6 and v7","C63563","Kidney cancer with tumor 4 cm or less in greatest dimension, limited to the kidney. (from AJCC 6th and 7th Eds.)","Kidney Cancer pT1a TNM Finding v6 and v7 | Kidney Cancer pT1a TNM Finding | Kidney Cancer pT1a TNM Finding | Kidney Cancer pT1a TNM Finding v6 | Kidney Cancer pT1a TNM Finding v7 | pT1a Kidney Cancer | pT1a Kidney Carcinoma | pT1a Renal Cancer | pT1a Renal Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881327","Kidney Cancer pT3b TNM Finding v6","C63568","Kidney cancer with tumor grossly extending into the renal vein or its segmental (muscle-containing) branches, or vena cava below the diaphragm. (from AJCC 6th Ed.)","Kidney Cancer pT3b TNM Finding v6 | Kidney Cancer pT3b TNM Finding | pT3b Kidney Cancer v6 | pT3b Kidney Carcinoma v6 | pT3b Renal Cancer v6 | pT3b Renal Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881326","Kidney Cancer pT3a TNM Finding v6","C63567","Kidney cancer with tumor directly invading the adrenal gland or perirenal and/or renal sinus fat, but not beyond Gerota's fascia. (from AJCC 6th Ed.)","Kidney Cancer pT3a TNM Finding v6 | Kidney Cancer pT3a TNM Finding | pT3a Kidney Cancer v6 | pT3a Kidney Carcinoma v6 | pT3a Renal Cancer v6 | pT3a Renal Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881325","Kidney Cancer pT3 TNM Finding v6","C63566","Kidney cancer with tumor extending into major veins or invading the adrenal gland or perinephric tissues, but not extending beyond Gerota's fascia. (from AJCC 6th Ed.)","Kidney Cancer pT3 TNM Finding v6 | Kidney Cancer pT3 TNM Finding | pT3 Kidney Cancer v6 | pT3 Kidney Carcinoma v6 | pT3 Renal Cancer v6 | pT3 Renal Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881324","Kidney Cancer pT2 TNM Finding v6 and v7","C63565","Kidney cancer with tumor more than 7 cm in greatest dimension, limited to the kidney. (from AJCC 6th and 7th Eds.)","Kidney Cancer pT2 TNM Finding v6 and v7 | Kidney Cancer pT2 TNM Finding | Kidney Cancer pT2 TNM Finding | Kidney Cancer pT2 TNM Finding v6 | Kidney Cancer pT2 TNM Finding v7 | pT2 Kidney Cancer | pT2 Kidney Carcinoma | pT2 Renal Cancer | pT2 Renal Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881323","Kidney Cancer pT1b TNM Finding v6 and v7","C63564","Kidney cancer with tumor more than 4 cm but not more than 7 cm in greatest dimension, limited to the kidney. (from AJCC 6th and 7th Eds.)","Kidney Cancer pT1b TNM Finding v6 and v7 | Kidney Cancer pT1b TNM Finding | Kidney Cancer pT1b TNM Finding | Kidney Cancer pT1b TNM Finding v6 | Kidney Cancer pT1b TNM Finding v7 | pT1b Kidney Cancer | pT1b Kidney Carcinoma | pT1b Renal Cancer | pT1b Renal Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880630","Exocrine Pancreatic Cancer pT1 TNM Finding v6","C60944","Exocrine pancreatic cancer with tumor confined to the pancreas and 2 cm or less in greatest dimension. (from AJCC 6th Ed.)","Exocrine Pancreatic Cancer pT1 TNM Finding v6 | Exocrine Pancreatic Cancer pT1 TNM Finding | pT1 Exocrine Cancer of the Pancreas v6 | pT1 Exocrine Carcinoma of the Pancreas v6 | pT1 Exocrine Pancreatic Cancer v6 | pT1 Exocrine Pancreatic Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880635","Exocrine Pancreatic Cancer pTis TNM Finding v6","C60943","Exocrine pancreatic cancer with a finding of carcinoma in situ, also known as grade III pancreatic intraepithelial neoplasia (PanIn III). (from AJCC 6th Ed.)","Exocrine Pancreatic Cancer pTis TNM Finding v6 | Exocrine Pancreatic Cancer pTis TNM Finding | Pancreatic Intraepithelial Neoplasia Grade III v6 | pTis Exocrine Cancer of the Pancreas v6 | pTis Exocrine Carcinoma of the Pancreas v6 | pTis Exocrine Pancreatic Cancer v6 | pTis Exocrine Pancreatic Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881329","Kidney Cancer pT4 TNM Finding v6","C63570","Kidney cancer with tumor extending beyond Gerota's fascia. (from AJCC 6th Ed.)","Kidney Cancer pT4 TNM Finding v6 | Kidney Cancer pT4 TNM Finding | pT4 Kidney Cancer v6 | pT4 Kidney Carcinoma v6 | pT4 Renal Cancer v6 | pT4 Renal Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881328","Kidney Cancer pT3c TNM Finding v6","C63569","Kidney cancer with tumor grossly extending into the vena cava above the diaphragm, or invading the wall of the vena cava. (from AJCC 6th Ed.)","Kidney Cancer pT3c TNM Finding v6 | Kidney Cancer pT3c TNM Finding | pT3c Kidney Cancer v6 | pT3c Kidney Carcinoma v6 | pT3c Renal Cancer v6 | pT3c Renal Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880633","Exocrine Pancreatic Cancer pT4 TNM Finding v6","C60947","Exocrine pancreatic cancer extending beyond the pancreas, involving the celiac axis or superior mesenteric artery and therefore unresectable. (from AJCC 6th Ed.)","Exocrine Pancreatic Cancer pT4 TNM Finding v6 | Exocrine Pancreatic Cancer pT4 TNM Finding | pT4 Exocrine Cancer of the Pancreas v6 | pT4 Exocrine Carcinoma of the Pancreas v6 | pT4 Exocrine Pancreatic Cancer v6 | pT4 Exocrine Pancreatic Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880632","Exocrine Pancreatic Cancer pT3 TNM Finding v6","C60946","Exocrine pancreatic cancer extending beyond the pancreas, but without involvement of the celiac axis or superior mesenteric artery. (from AJCC 6th Ed.)","Exocrine Pancreatic Cancer pT3 TNM Finding v6 | Exocrine Pancreatic Cancer pT3 TNM Finding | pT3 Exocrine Cancer of the Pancreas v6 | pT3 Exocrine Carcinoma of the Pancreas v6 | pT3 Exocrine Pancreatic Cancer v6 | pT3 Exocrine Pancreatic Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880631","Exocrine Pancreatic Cancer pT2 TNM Finding v6","C60945","Exocrine pancreatic cancer with tumor confined to the pancreas but more than 2 cm in greatest dimension. (from AJCC 6th Ed.)","Exocrine Pancreatic Cancer pT2 TNM Finding v6 | Exocrine Pancreatic Cancer pT2 TNM Finding | pT2 Exocrine Cancer of the Pancreas v6 | pT2 Exocrine Carcinoma of the Pancreas v6 | pT2 Exocrine Pancreatic Cancer v6 | pT2 Exocrine Pancreatic Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709726","Prostate Cancer pT2a TNM Finding v6 and v7","C48237","Prostate cancer limited to one-half or less of one lobe of the prostate gland. (from AJCC 6th and 7th Eds.)","Prostate Cancer pT2a TNM Finding v6 and v7 | Prostate Cancer pT2a TNM Finding | Prostate Cancer pT2a TNM Finding | Prostate Cancer pT2a TNM Finding v6 | Prostate Cancer pT2a TNM Finding v7 | pT2a | pT2a Cancer of Prostate | pT2a Cancer of the Prostate | pT2a Carcinoma of Prostate | pT2a Carcinoma of the Prostate | pT2a Prostate Cancer | pT2a Prostate Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709725","Prostate Cancer pT2 TNM Finding v6 and v7","C48236","Prostate cancer confined to the prostate gland. (from AJCC 6th and 7th Eds.)","Prostate Cancer pT2 TNM Finding v6 and v7 | Prostate Cancer pT2 TNM Finding | Prostate Cancer pT2 TNM Finding | Prostate Cancer pT2 TNM Finding v6 | Prostate Cancer pT2 TNM Finding v7 | pT2 Cancer of Prostate | pT2 Cancer of the Prostate | pT2 Carcinoma of Prostate | pT2 Carcinoma of the Prostate | pT2 Prostate Cancer | pT2 Prostate Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709728","Prostate Cancer pT2c TNM Finding v6 and v7","C48239","Prostate cancer involving both lobes of the prostate gland. (from AJCC 6th and 7th Eds.)","Prostate Cancer pT2c TNM Finding v6 and v7 | Prostate Cancer pT2c TNM Finding | Prostate Cancer pT2c TNM Finding | Prostate Cancer pT2c TNM Finding v6 | Prostate Cancer pT2c TNM Finding v7 | pT2c | pT2c Cancer of Prostate | pT2c Cancer of the Prostate | pT2c Carcinoma of Prostate | pT2c Carcinoma of the Prostate | pT2c Prostate Cancer | pT2c Prostate Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709727","Prostate Cancer pT2b TNM Finding v6 and v7","C48238","Prostate cancer involving more than one-half of one lobe, but not both lobes of the prostate gland. (from AJCC 6th and 7th Eds.)","Prostate Cancer pT2b TNM Finding v6 and v7 | Prostate Cancer pT2b TNM Finding | Prostate Cancer pT2b TNM Finding | Prostate Cancer pT2b TNM Finding v6 | Prostate Cancer pT2b TNM Finding v7 | pT2b | pT2b Cancer of Prostate | pT2b Cancer of the Prostate | pT2b Carcinoma of Prostate | pT2b Carcinoma of the Prostate | pT2b Prostate Cancer | pT2b Prostate Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981197","Prostate Cancer pT4 TNM Finding v6","C48243","Prostate cancer extending beyond the capsule of the prostate gland, with involvement of the bladder and/or rectum. (from AJCC 6th Ed.)","Prostate Cancer pT4 TNM Finding v6 | Prostate Cancer pT4 TNM Finding | pT4 Cancer of Prostate v6 | pT4 Cancer of the Prostate v6 | pT4 Carcinoma of Prostate v6 | pT4 Carcinoma of the Prostate v6 | pT4 Prostate Cancer v6 | pT4 Prostate Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709731","Prostate Cancer pT3b TNM Finding v6 and v7","C48242","Prostate cancer with seminal vesicle invasion. (from AJCC 6th and 7th Eds.)","Prostate Cancer pT3b TNM Finding v6 and v7 | Prostate Cancer pT3b TNM Finding | Prostate Cancer pT3b TNM Finding | Prostate Cancer pT3b TNM Finding v6 | Prostate Cancer pT3b TNM Finding v7 | pT3b Cancer of Prostate | pT3b Cancer of the Prostate | pT3b Carcinoma of Prostate | pT3b Carcinoma of the Prostate | pT3b Prostate Cancer | pT3b Prostate Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981196","Prostate Cancer pT3a TNM Finding v6","C48241","Prostate cancer extending beyond the capsule of the prostate gland, without involvement of the seminal vesicles. (from AJCC 6th Ed.)","Prostate Cancer pT3a TNM Finding v6 | Prostate Cancer pT3a TNM Finding | pT3a Cancer of Prostate v6 | pT3a Cancer of the Prostate v6 | pT3a Carcinoma of Prostate v6 | pT3a Carcinoma of the Prostate v6 | pT3a Prostate Cancer v6 | pT3a Prostate Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705907","Breast Cancer pTis Paget's TNM Finding","C48977","Paget disease of the nipple without invasive carcinoma and/or carcinoma in situ in the underlying breast parenchyma. (from AJCC 6th and 7th Ed.)","Breast Cancer pTis Paget TNM Finding v6 and v7 | Breast Cancer pTis Paget TNM Finding | Breast Cancer pTis Paget TNM Finding | Breast Cancer pTis Paget TNM Finding v6 | Breast Cancer pTis Paget TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707040","Breast Cancer pTis (LCIS) TNM Finding v6 and v7","C48976","Breast cancer with a finding of lobular carcinoma in situ. (from AJCC 6th and 7th Ed.)","Breast Cancer pTis (LCIS) TNM Finding v6 and v7 | Breast Cancer pTis (LCIS) TNM Finding | Breast Cancer pTis (LCIS) TNM Finding | Breast Cancer pTis (LCIS) TNM Finding v6 | Breast Cancer pTis (LCIS) TNM Finding v7 | Tis (LCIS) | pTis (LCIS) Breast Cancer v6 | pTis (LCIS) Breast Carcinoma v6 | pTis (LCIS) Cancer of Breast v6 | pTis (LCIS) Cancer of the Breast v6 | pTis (LCIS) Carcinoma of Breast v6 | pTis (LCIS) Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707039","Breast Cancer pTis (DCIS) TNM Finding v6 and v7","C48975","Breast cancer with a finding of ductal carcinoma in situ. (from AJCC 6th and 7th Ed.)","Breast Cancer pTis (DCIS) TNM Finding v6 and v7 | Breast Cancer pTis (DCIS) TNM Finding | Breast Cancer pTis (DCIS) TNM Finding | Breast Cancer pTis (DCIS) TNM Finding v6 | Breast Cancer pTis (DCIS) TNM Finding v7 | pTis (DCIS) Breast Cancer v6 | pTis (DCIS) Breast Carcinoma v6 | pTis (DCIS) Cancer of Breast v6 | pTis (DCIS) Cancer of the Breast v6 | pTis (DCIS) Carcinoma of Breast v6 | pTis (DCIS) Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707027","Breast Cancer pT1a TNM Finding v6 and v7","C48980","Breast cancer with tumor size more than 0.1 cm, but not more than 0.5 cm in greatest dimension. (from AJCC 6th and 7th Eds.)","Breast Cancer pT1a TNM Finding v6 and v7 | Breast Cancer pT1a TNM Finding | Breast Cancer pT1a TNM Finding | Breast Cancer pT1a TNM Finding v6 | Breast Cancer pT1a TNM Finding v7 | pT1a Breast Cancer v6 | pT1a Breast Carcinoma v6 | pT1a Cancer of Breast v6 | pT1a Cancer of the Breast v6 | pT1a Carcinoma of Breast v6 | pT1a Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707030","Breast Cancer pT1mic TNM Finding v6 and v7","C48979","Breast cancer with tumor size 0.1 cm or less in greatest dimension (microinvasion). (from AJCC 6th and 7th Eds.)","Breast Cancer pT1mic TNM Finding v6 and v7 | Breast Cancer pT1mi TNM Finding v6 | Breast Cancer pT1mi TNM Finding v7 | Breast Cancer pT1mic TNM Finding | Breast Cancer pT1mic TNM Finding | pT1mic Breast Cancer v6 | pT1mic Breast Carcinoma v6 | pT1mic Cancer of Breast v6 | pT1mic Cancer of the Breast v6 | pT1mic Carcinoma of Breast v6 | pT1mic Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707029","Breast Cancer pT1c TNM Finding v6 and v7","C48982","Breast cancer with tumor size more than 1.0 cm, but not more than 2.0 cm in greatest dimension. (from AJCC 6th and 7th Eds.)","Breast Cancer pT1c TNM Finding v6 and v7 | Breast Cancer pT1c TNM Finding | Breast Cancer pT1c TNM Finding | Breast Cancer pT1c TNM Finding v6 | Breast Cancer pT1c TNM Finding v7 | pT1c Breast Cancer v6 | pT1c Breast Carcinoma v6 | pT1c Cancer of Breast v6 | pT1c Cancer of the Breast v6 | pT1c Carcinoma of Breast v6 | pT1c Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707028","Breast Cancer pT1b TNM Finding v6 and v7","C48981","Breast cancer with tumor size more than 0.5 cm, but not more than 1.0 cm in greatest dimension. (from AJCC 6th and 7th Eds.)","Breast Cancer pT1b TNM Finding v6 and v7 | Breast Cancer pT1b TNM Finding | Breast Cancer pT1b TNM Finding | Breast Cancer pT1b TNM Finding v6 | Breast Cancer pT1b TNM Finding v7 | pT1b Breast Cancer v6 | pT1b Breast Carcinoma v6 | pT1b Cancer of Breast v6 | pT1b Cancer of the Breast v6 | pT1b Carcinoma of Breast v6 | pT1b Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707032","Breast Cancer pT3 TNM Finding v6 and v7","C48984","Breast cancer with tumor size more than 5.0 cm in greatest dimension. (from AJCC 6th and 7th Eds.)","Breast Cancer pT3 TNM Finding v6 and v7 | Breast Cancer pT3 TNM Finding | Breast Cancer pT3 TNM Finding | Breast Cancer pT3 TNM Finding v6 | Breast Cancer pT3 TNM Finding v7 | pT3 Breast Cancer v6 | pT3 Breast Carcinoma v6 | pT3 Cancer of Breast v6 | pT3 Cancer of the Breast v6 | pT3 Carcinoma of Breast v6 | pT3 Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707031","Breast Cancer pT2 TNM Finding v6 and v7","C48983","Breast cancer with tumor size more than 2.0 cm, but not more than 5.0 cm in greatest dimension. (from AJCC 6th and 7th Eds.)","Breast Cancer pT2 TNM Finding v6 and v7 | Breast Cancer pT2 TNM Finding | Breast Cancer pT2 TNM Finding | Breast Cancer pT2 TNM Finding v6 | Breast Cancer pT2 TNM Finding v7 | pT2 Breast Cancer v6 | pT2 Breast Carcinoma v6 | pT2 Cancer of Breast v6 | pT2 Cancer of the Breast v6 | pT2 Carcinoma of Breast v6 | pT2 Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707035","Breast Cancer pT4b TNM Finding v6 and v7","C48987","Breast cancer with ulceration and/or ipsilateral satellite nodules and/or edema (including peau d'orange) of the skin, which do not meet the criteria for inflammatory carcinoma. (from AJCC 6th and 7th Eds.)","Breast Cancer pT4b TNM Finding v6 and v7 | Breast Cancer pT4b TNM Finding | Breast Cancer pT4b TNM Finding | Breast Cancer pT4b TNM Finding v6 | Breast Cancer pT4b TNM Finding v7 | pT4b Breast Cancer v6 | pT4b Breast Carcinoma v6 | pT4b Cancer of Breast v6 | pT4b Cancer of the Breast v6 | pT4b Carcinoma of Breast v6 | pT4b Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707034","Breast Cancer pT4a TNM Finding v6 and v7","C48986","Breast cancer with extension to the chest wall, not including the pectoralis muscle. (from AJCC 6th and 7th Eds.)","Breast Cancer pT4a TNM Finding v6 and v7 | Breast Cancer pT4a TNM Finding | Breast Cancer pT4a TNM Finding | Breast Cancer pT4a TNM Finding v6 | Breast Cancer pT4a TNM Finding v7 | pT4a Breast Cancer v6 | pT4a Breast Carcinoma v6 | pT4a Cancer of Breast v6 | pT4a Cancer of the Breast v6 | pT4a Carcinoma of Breast v6 | pT4a Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981207","Cutaneous Melanoma pT1 TNM Finding v6","C48842","Cutaneous melanoma 1.0mm or less in thickness, with or without ulceration. (from AJCC 6th Ed.)","Cutaneous Melanoma pT1 TNM Finding v6 | Cutaneous Melanoma pT1 TNM Finding | pT1 Cutaneous Melanoma v6 | pT1 Melanoma of Skin v6 | pT1 Melanoma of the Skin v6 | pT1 Skin Melanoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707587","Cutaneous Melanoma pTis TNM Finding v6 and v7","C48841","Cutaneous melanoma in situ. (from AJCC 6th and 7th Eds.)","Cutaneous Melanoma pTis TNM Finding v6 and v7 | Cutaneous Melanoma pTis TNM Finding | Cutaneous Melanoma pTis TNM Finding | Cutaneous Melanoma pTis TNM Finding v6 | Cutaneous Melanoma pTis TNM Finding v7 | pTis Cutaneous Melanoma | pTis Melanoma of Skin | pTis Melanoma of the Skin | pTis Skin Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707037","Breast Cancer pT4d TNM Finding v6 and v7","C48989","Breast cancer meeting the clinical-pathologic criteria of inflammatory carcinoma. (from AJCC 6th and 7th Eds.)","Breast Cancer pT4d TNM Finding v6 and v7 | Breast Cancer pT4d TNM Finding | Breast Cancer pT4d TNM Finding | Breast Cancer pT4d TNM Finding v6 | Breast Cancer pT4d TNM Finding v7 | pT4d Breast Cancer v6 | pT4d Breast Carcinoma v6 | pT4d Cancer of Breast v6 | pT4d Cancer of the Breast v6 | pT4d Carcinoma of Breast v6 | pT4d Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707036","Breast Cancer pT4c TNM Finding v6 and v7","C48988","Breast cancer with extension to the chest wall, not including the pectoralis muscle, and with edema (including peau d'orange) or ulceration of the skin of the breast or satellite skin nodules confined to the same breast. (from AJCC 6th and 7th Eds.)","Breast Cancer pT4c TNM Finding v6 and v7 | Breast Cancer pT4c TNM Finding | Breast Cancer pT4c TNM Finding | Breast Cancer pT4c TNM Finding v6 | Breast Cancer pT4c TNM Finding v7 | pT4c Breast Cancer v6 | pT4c Breast Carcinoma v6 | pT4c Cancer of Breast v6 | pT4c Cancer of the Breast v6 | pT4c Carcinoma of Breast v6 | pT4c Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981209","Cutaneous Melanoma pT1b TNM Finding v6","C48844","Cutaneous melanoma 1.0mm or less in thickness, with ulceration and/or Clark level IV or V. (from AJCC 6th Ed.)","Cutaneous Melanoma pT1b TNM Finding v6 | Cutaneous Melanoma pT1b TNM Finding | pT1b Cutaneous Melanoma v6 | pT1b Melanoma of Skin v6 | pT1b Melanoma of the Skin v6 | pT1b Skin Melanoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981208","Cutaneous Melanoma pT1a TNM Finding v6","C48843","Cutaneous melanoma 1.0mm or less in thickness and Clark level II or III, with no ulceration. (from AJCC 6th Ed.)","Cutaneous Melanoma pT1a TNM Finding v6 | Cutaneous Melanoma pT1a TNM Finding | pT1a Cutaneous Melanoma v6 | pT1a Melanoma of Skin v6 | pT1a Melanoma of the Skin v6 | pT1a Skin Melanoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707577","Cutaneous Melanoma pT2 TNM Finding v6 and v7","C48845","Cutaneous melanoma 1.01 to 2 mm in thickness, with or without ulceration. (from AJCC 6th and 7th Eds.)","Cutaneous Melanoma pT2 TNM Finding v6 and v7 | Cutaneous Melanoma pT2 TNM Finding | Cutaneous Melanoma pT2 TNM Finding | Cutaneous Melanoma pT2 TNM Finding v6 | Cutaneous Melanoma pT2 TNM Finding v7 | pT2 Cutaneous Melanoma | pT2 Melanoma of Skin | pT2 Melanoma of the Skin | pT2 Skin Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0557529","Oncology Nurse","C18065","A nurse who specializes in treating and caring for people who have cancer.","Oncology Nurse | oncology nurse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010210","Counseling","C61547","The act of receiving professional guidance in resolving personal conflicts and emotional problems.","Counseling | Counseling Intervention | counseling",,,,,,,,,,,,,,,"4254477","Counseling",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0259901","Gastroenterologist","C17818","A doctor who specializes in diagnosing and treating diseases and disorders of the gastrointestinal tract.","Gastroenterologist | gastroenterologist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707581","Cutaneous Melanoma pT3a TNM Finding v6 and v7","C48849","Cutaneous melanoma 2.01 to 4 mm in thickness, with no ulceration. (from AJCC 6th and 7th Eds.)","Cutaneous Melanoma pT3a TNM Finding v6 and v7 | Cutaneous Melanoma pT3a TNM Finding | Cutaneous Melanoma pT3a TNM Finding | Cutaneous Melanoma pT3a TNM Finding v6 | Cutaneous Melanoma pT3a TNM Finding v7 | pT3a Cutaneous Melanoma | pT3a Melanoma of Skin | pT3a Melanoma of the Skin | pT3a Skin Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707580","Cutaneous Melanoma pT3 TNM Finding v6 and v7","C48848","Cutaneous melanoma 2.01 to 4 mm thick, with or without ulceration. (from AJCC 6th and 7th Eds.)","Cutaneous Melanoma pT3 TNM Finding v6 and v7 | Cutaneous Melanoma pT3 TNM Finding | Cutaneous Melanoma pT3 TNM Finding | Cutaneous Melanoma pT3 TNM Finding v6 | Cutaneous Melanoma pT3 TNM Finding v7 | pT3 Cutaneous Melanoma | pT3 Melanoma of Skin | pT3 Melanoma of the Skin | pT3 Skin Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707579","Cutaneous Melanoma pT2b TNM Finding v6 and v7","C48847","Cutaneous melanoma 1.01 to 2 mm thick, with ulceration. (from AJCC 6th and 7th Eds.)","Cutaneous Melanoma pT2b TNM Finding v6 and v7 | Cutaneous Melanoma pT2b TNM Finding | Cutaneous Melanoma pT2b TNM Finding | Cutaneous Melanoma pT2b TNM Finding v6 | Cutaneous Melanoma pT2b TNM Finding v7 | pT2b Cutaneous Melanoma | pT2b Melanoma of Skin | pT2b Melanoma of the Skin | pT2b Skin Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707578","Cutaneous Melanoma pT2a TNM Finding v6 and v7","C48846","Cutaneous melanoma 1.01 to 2 mm in thickness, with no ulceration. (from AJCC 6th and 7th Eds.)","Cutaneous Melanoma pT2a TNM Finding v6 and v7 | Cutaneous Melanoma pT2a TNM Finding | Cutaneous Melanoma pT2a TNM Finding | Cutaneous Melanoma pT2a TNM Finding v6 | Cutaneous Melanoma pT2a TNM Finding v7 | pT2a Cutaneous Melanoma | pT2a Melanoma of Skin | pT2a Melanoma of the Skin | pT2a Skin Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707584","Cutaneous Melanoma pT4a TNM Finding v6 and v7","C48852","Cutaneous melanoma greater than 4.0 mm in thickness, without ulceration. (from AJCC 6th and 7th Eds.)","Cutaneous Melanoma pT4a TNM Finding v6 and v7 | Cutaneous Melanoma pT4a TNM Finding | Cutaneous Melanoma pT4a TNM Finding | Cutaneous Melanoma pT4a TNM Finding v6 | Cutaneous Melanoma pT4a TNM Finding v7 | pT4a Cutaneous Melanoma | pT4a Melanoma of Skin | pT4a Melanoma of the Skin | pT4a Skin Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707583","Cutaneous Melanoma pT4 TNM Finding v6 and v7","C48851","Cutaneous melanoma greater than 4.0 mm in thickness, with or without ulceration. (from AJCC 6th and 7th Eds.)","Cutaneous Melanoma pT4 TNM Finding v6 and v7 | Cutaneous Melanoma pT4 TNM Finding | Cutaneous Melanoma pT4 TNM Finding | Cutaneous Melanoma pT4 TNM Finding v6 | Cutaneous Melanoma pT4 TNM Finding v7 | pT4 Cutaneous Melanoma | pT4 Melanoma of Skin | pT4 Melanoma of the Skin | pT4 Skin Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707582","Cutaneous Melanoma pT3b TNM Finding v6 and v7","C48850","Cutaneous melanoma 2.01 to 4 mm thick, with ulceration. (from AJCC 6th and 7th Eds.)","Cutaneous Melanoma pT3b TNM Finding v6 and v7 | Cutaneous Melanoma pT3b TNM Finding | Cutaneous Melanoma pT3b TNM Finding | Cutaneous Melanoma pT3b TNM Finding v6 | Cutaneous Melanoma pT3b TNM Finding v7 | pT3b Cutaneous Melanoma | pT3b Melanoma of Skin | pT3b Melanoma of the Skin | pT3b Skin Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880143","Colorectal Cancer pTis Intraepithelial TNM Finding","C60842","Colorectal cancer in situ in which cancer cells are confined within the glandular basement membrane (intraepithelial). (from CAP Colorectal Cancer Protocol-January 2005 Revision)","Colorectal Cancer pTis Intraepithelial TNM Finding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707585","Cutaneous Melanoma pT4b TNM Finding v6 and v7","C48853","Cutaneous melanoma greater than 4.0 mm in thickness, with ulceration. (from AJCC 6th and 7th Eds.)","Cutaneous Melanoma pT4b TNM Finding v6 and v7 | Cutaneous Melanoma pT4b TNM Finding | Cutaneous Melanoma pT4b TNM Finding | Cutaneous Melanoma pT4b TNM Finding v6 | Cutaneous Melanoma pT4b TNM Finding v7 | pT4b Cutaneous Melanoma | pT4b Melanoma of Skin | pT4b Melanoma of the Skin | pT4b Skin Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880140","Colorectal Cancer pT3 c/d TNM Finding","C60848","Colorectal cancer with invasion through the muscularis propria into the submucosa, or into non-peritonealized pericolic or perirectal soft tissues, with tumor extension of more than 5 mm beyond the border of the muscularis propria. (from CAP Colorectal Cancer Protocol-January 2005 Revision)","Colorectal Cancer pT3 c/d TNM Finding | pT3 c d Colon Cancer | pT3 c d Colorectal Cancer | pT3 c d Colorectal Carcinoma | pT3 c d Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880139","Colorectal Cancer pT3 a/b TNM Finding","C60847","Colorectal cancer with invasion through the muscularis propria into the submucosa, or into non-peritonealized pericolic or perirectal soft tissues, with tumor extension of 5 mm or less beyond the border of the muscularis propria. (from CAP Colorectal Cancer Protocol-January 2005 Revision)","Colorectal Cancer pT3 a/b TNM Finding | pT3 a b Colon Cancer | pT3 a b Colorectal Cancer | pT3 a b Colorectal Carcinoma | pT3 a b Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880138","Colorectal Cancer pT3 TNM Finding v6","C60846","Colorectal cancer with invasion through the muscularis propria into the submucosa, or into non-peritonealized pericolic or perirectal soft tissues. (from AJCC 6th Ed.)","Colorectal Cancer pT3 TNM Finding v6 | Colorectal Cancer pT3 TNM Finding | pT3 Colon Cancer v6 | pT3 Colorectal Cancer v6 | pT3 Colorectal Carcinoma v6 | pT3 Rectal Cancer v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880137","Colorectal Cancer pT2 TNM Finding v6 and v7","C60845","Colorectal cancer with invasion into the muscularis propria. (from AJCC 6th and 7th Eds.)","Colorectal Cancer pT2 TNM Finding v6 and v7 | Colorectal Cancer pT2 TNM Finding | Colorectal Cancer pT2 TNM Finding | Colorectal Cancer pT2 TNM Finding v6 | Colorectal Cancer pT2 TNM Finding v7 | pT2 Colon Cancer | pT2 Colorectal Cancer | pT2 Colorectal Carcinoma | pT2 Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880136","Colorectal Cancer pT1 TNM Finding v6 and v7","C60844","Colorectal cancer with invasion into the submucosa. (from AJCC 6th and 7th Eds.)","Colorectal Cancer pT1 TNM Finding v6 and v7 | Colorectal Cancer pT1 TNM Finding | Colorectal Cancer pT1 TNM Finding | Colorectal Cancer pT1 TNM Finding v6 | Colorectal Cancer pT1 TNM Finding v7 | pT1 Colon Cancer | pT1 Colorectal Cancer | pT1 Colorectal Carcinoma | pT1 Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880144","Colorectal Cancer pTis Lamina Propria Invasion TNM Finding","C60843","Colorectal cancer in situ involving the lamina propria (intramucosal) without extension through the muscularis mucosa into the submucosa. (from CAP Colorectal Cancer Protocol-January 2005 Revision)","Colorectal Cancer pTis Lamina Propria Invasion TNM Finding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881482","Lung Cancer pTX TNM Finding v6 and v7","C60965","Lung cancer in which the primary tumor cannot be assessed, or in which the diagnosis is confirmed by the presence of malignant cells in sputum or bronchial washings, but not visualized by imaging or bronchoscopy. (from AJCC 6th and 7th Eds.)","Lung Cancer pTX TNM Finding v6 and v7 | Lung Cancer pTX TNM Finding | Lung Cancer pTX TNM Finding | Lung Cancer pTX TNM Finding v6 | Lung Cancer pTX TNM Finding v7 | pTX | pTX Cancer of the Lung | pTX Carcinoma of the Lung | pTX Lung Cancer | pTx Lung Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880141","Colorectal Cancer pT4 TNM Finding v6","C60849","Colorectal cancer with direct invasion of adjacent organs or structures and/or perforation of the visceral peritoneum. Direct invasion in T4 includes invasion of other segments of the colorectum by way of the serosa. Invasion of the sigmoid colon by a carcinoma of the cecum, for example, should be classified as T4. Tumor that is adherent to other organs or structures macroscopically is classified as T4. However, if on microscopic examination, no tumor is present in the adhesion, the classification should be pT3. V and L substaging should be used to indicate the presence or absence of vascular or lymphatic invasion. (from AJCC 6th Ed.)","Colorectal Cancer pT4 TNM Finding v6 | Colorectal Cancer pT4 TNM Finding | pT4 Colon Cancer v6 | pT4 Colorectal Cancer v6 | pT4 Colorectal Carcinoma v6 | pT4 Rectal Cancer v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881480","Lung Cancer pT3 TNM Finding v6","C60970","Lung cancer directly invading the chest wall (including superior sulcus tumors), diaphragm, mediastinal pleura or parietal pericardium, or a tumor of any size extending into the main bronchus less than 2 cm distal to the carina but without involvement of the carina, or a tumor of any size with atelectasis or obstructive pneumonitis involving the entire lung. (from AJCC 6th Ed.)","Lung Cancer pT3 TNM Finding v6 | Lung Cancer pT3 TNM Finding | pT3 Cancer of the Lung v6 | pT3 Carcinoma of the Lung v6 | pT3 Lung Cancer v6 | pT3 Lung Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881479","Lung Cancer pT2 TNM Finding v6","C60969","Lung cancer with a tumor size of greater than 3 cm in greatest dimension, or a tumor of any size extending into the main bronchus (2 cm or more distal to the carina), or a tumor of any size invading the visceral pleura, or a tumor with atelectasis or obstructive pneumonitis extending to the hilar region without involving the entire lung. (from AJCC 6th Ed.)","Lung Cancer pT2 TNM Finding v6 | Lung Cancer pT2 TNM Finding | pT2 Cancer of the Lung v6 | pT2 Carcinoma of the Lung v6 | pT2 Lung Cancer v6 | pT2 Lung Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881478","Lung Cancer pT1 TNM Finding v6","C60968","Lung cancer with a tumor size of 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (not invading the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1. (from AJCC 6th Ed.)","Lung Cancer pT1 TNM Finding v6 | Lung Cancer pT1 TNM Finding | pT1 Cancer of the Lung v6 | pT1 Carcinoma of the Lung v6 | pT1 Lung Cancer v6 | pT1 Lung Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0349680","Acute Bilineal Leukemia","C6923","An acute leukemia of ambiguous lineage in which there is a dual population of blasts with each population expressing markers of a distinct lineage (myeloid and lymphoid or B-and T-lymphocyte).  (WHO, 2001)","Acute Bilineal Leukemia | Acute bilineal leukemia",,,,,,,,,,,,,,,"4028711","Acute biphenotypic leukemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1292776","Myeloid Neoplasm Post Cytotoxic Therapy","C27912","Acute myeloid leukemias, myelodysplastic syndromes, and myelodysplastic/myeloproliferative neoplasms arising as a result of the mutagenic effect of chemotherapy agents and/or radiation that are used for the treatment of neoplastic or non-neoplastic disorders.","Myeloid Neoplasm Post Cytotoxic Therapy | Acute Myeloid Leukaemias and Myelodysplastic Syndromes, Therapy-Related | Therapy related myeloid neoplasm | Therapy-Related AML and MDS | Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome | Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome | Therapy-Related Myeloid Neoplasm | Therapy-Related Myeloid Neoplasm | Therapy-related Myeloid Neoplasms",,,,,,,,,,,,,,,"37158032","Myeloid neoplasm post cytotoxic therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332234","Alkylating Agent-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome","C27913","Acute myeloid leukemias and myelodysplastic syndromes arising as a result of the mutagenic effect of alkylating agents that are used for the treatment of malignant tumors. Patients usually develop a myelodysplastic syndrome which may evolve to a higher grade myelodysplastic syndrome or acute myeloid leukemia. A minority of patients present with an acute myeloid leukemia. Clonal cytogenetic abnormalities are frequently present and usually are unbalanced translocations or deletions of chromosomes 5 and 7. Patients with acute myeloid leukemia usually do not respond to treatment and have an unfavorable clinical outcome.","Alkylating Agent-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome | Alkylating Agent Related Acute Myeloid Leukemia and Myelodysplastic Syndrome | Alkylating Agent-Related AML and MDS",,,,,,,,,,,,,,,"35623630","Acute myeloid leukemia and myelodysplastic syndrome related to alkylating agent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1275661","Acute Myeloid Leukemia with Recurrent Genetic Abnormalities","C7175","A group of acute myeloid leukemias characterized by recurrent genetic abnormalities, mainly balanced translocations.  (WHO, 2001)","Acute Myeloid Leukemia with Recurrent Genetic Abnormalities | AML with Recurrent Genetic Abnormalities | AML-RGA | Acute Myeloid Leukemia with Balanced Translocations/Inversions | Acute Myeloid Leukemia with Defining Genetic Abnormalities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332154","Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11","C9018","Acute myeloid leukemia characterized by the presence of abnormal bone marrow eosinophils and the characteristic cytogenetic abnormality inv(16)(p13.1q22) which results in the expression of the fusion protein CBFB-MYH11.","Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11 | Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11 Fusion | Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB::MYH11 | Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB::MYH11 Fusion | Acute Myeloid Leukemia with inv(16)(p13;q22) | Acute Myeloid Leukemia with inv(16)(p13;q22) | Acute Myeloid Leukemia with inv(16)(p13q22) | Acute Myeloid Leukemia with inv(16)(p13q22)(CBFb/MYH11) | Acute Myeloid Leukemia, inv(16)(p13q22) | Acute myeloid leukemia, inv(16)(p13;q22)",,,,,,,,,,,,,,,"4304355","Acute myeloid leukemia with CBFB::MYH11 fusion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1112486","Aggressive Systemic Mastocytosis","C9285","An aggressive and progressive mast cell neoplasm characterized by systemic infiltration of internal organs by aggregates of neoplastic mast cells. There is no evidence of mast cell leukemia or clonal hematologic malignancy. Clinical symptoms include hepatomegaly, splenomegaly, portal hypertension, malabsorption syndrome, and pathologic fractures.","Aggressive Systemic Mastocytosis | ASM | Advanced Systemic Mastocytosis | Aggressive systemic mastocytosis",,,,,,,,,,,,,,,"37396742|4264453","Aggressive systemic mastocytosis|Aggressive systemic mastocytosis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0400076","Proctocolectomy","C51635","Surgical removal of part or all of the colon, part or all of the anus, and all of the rectum.","Proctocolectomy | ",,,,,,,,,,,,,,,"4017599","Excision of colon and rectum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004114","Astrocytoma","C60781","A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.","Astrocytoma | Astrocytoma, NOS | astrocytoma","9400/3","Astrocytoma, NOS",,,,,,,,,,,,,"608225","Astrocytoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C2750265","Minimally Invasive Lung Adenocarcinoma","C2923","A solitary adenocarcinoma arising from the lung and measuring 3 cm or less in size. It is characterized by a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. It is usually a non-mucinous adenocarcinoma, but rarely may be mucinous.","Minimally Invasive Lung Adenocarcinoma | BAC | Bronchioalveolar Adenocarcinoma of Lung | Bronchioalveolar Adenocarcinoma of the Lung | Bronchioalveolar Lung Carcinoma | Bronchiolo-Alveolar Carcinoma of Lung | Bronchiolo-Alveolar Carcinoma of the Lung | Bronchiolo-Alveolar Lung Carcinoma | Bronchioloalveolar Adenocarcinoma of Lung | Bronchioloalveolar Adenocarcinoma of the Lung | Bronchioloalveolar Carcinoma | Bronchioloalveolar Carcinoma | Bronchioloalveolar Lung Adenocarcinoma | Bronchioloalveolar carcinoma | CARCINOMA, BRONCHIOLOALVEOLAR, MALIGNANT","8251/3","Alveolar adenocarcinoma",,,,,,,,,,,,,"4012173|4263777","Bronchiolo-alveolar adenocarcinoma|Alveolar adenocarcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0334394","Adenocarcinoma with Cartilaginous and Osseous Metaplasia","C7683","An invasive adenocarcinoma characterized by focal or extensive cartilage and/or bone formation.","Adenocarcinoma with Cartilaginous and Osseous Metaplasia | Adenocarcinoma with cartilaginous and osseous metaplasia","8571/3","Adenocarcinoma with cartilaginous and osseous metaplasia",,,,,,,,,,,,,"4209562","Adenocarcinoma with cartilaginous and osseous metaplasia",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1266002","Non-Small Cell Carcinoma","C65151","A malignant epithelial neoplasm characterized by the absence of neoplastic small epithelial cells. A representative example is the lung non-small cell carcinoma.","Non-Small Cell Carcinoma | Non-small cell carcinoma","8046/3","Non-small cell carcinoma",,,,,,,,,,,,,"4028533","Non-small cell carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334393","Adenocarcinoma with Squamous Metaplasia","C4200","An invasive adenocarcinoma characterized by the presence of focal or extensive transformation of malignant glandular cells to squamous epithelial cells.","Adenocarcinoma with Squamous Metaplasia | ADENOACANTHOMA, MALIGNANT | Adenoacanthoma | Adenocarcinoma with squamous metaplasia","8570/3","Adenocarcinoma with squamous metaplasia",,,,,,,,,,,,,"4034839","Adenocarcinoma with squamous metaplasia",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334395","Adenocarcinoma with Spindle Cell Metaplasia","C4201","An invasive adenocarcinoma characterized by focal or extensive transformation of the malignant glandular cells to spindle-shaped cells.","Adenocarcinoma with Spindle Cell Metaplasia | Adenocarcinoma with spindle cell metaplasia","8572/3","Adenocarcinoma with spindle cell metaplasia",,,,,,,,,,,,,"4285284","Adenocarcinoma with spindle cell metaplasia",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1333064","Classic Hodgkin Lymphoma","C7164","A category of Hodgkin lymphomas that includes the following four histologic subtypes: lymphocyte-rich, nodular sclerosis, mixed cellularity, and lymphocyte-depleted classic Hodgkin lymphoma. The vast majority of Hodgkin lymphomas belong to this category.","Classic Hodgkin Lymphoma | CHL | Classical Hodgkin Lymphoma | Classical Hodgkin Lymphoma | Classical Hodgkin's Lymphoma | cHL | classical Hodgkin lymphoma",,,,,,,,,,,,,,,"42538850","Classical Hodgkin lymphoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0431128","Papillary Craniopharyngioma","C4725","A craniopharyngioma composed of sheets of squamous epithelium which separate to form pseudopapillae. This variant typically lacks nuclear palisading, wet keratin, calcification, and cholesterol deposits. Clinically, endocrine deficiencies are more often associated with papillary craniopharyngioma than with the adamantinomatous type. (Adapted from WHO)","Papillary Craniopharyngioma | Craniopharyngioma, papillary | PCP | Papillary Neoplasm of Rathke's Pouch | Papillary Rathke Pouch Neoplasm | Papillary Rathke's Pouch Neoplasm | Papillary Rathke's Pouch Tumor | Papillary Tumor of Rathke's Pouch","9352/1","Craniopharyngioma, papillary",,,,,,,,,,,,,"4028696","Craniopharyngioma, papillary",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1527349","Breast Ductal Carcinoma","C4017","A breast carcinoma arising from the ducts.  While ductal carcinomas can arise at other sites, this term is universally used to refer to carcinomas of the breast. Ductal carcinomas account for about two thirds of all breast cancers. Two types of ductal carcinomas have been described: ductal carcinoma in situ (DCIS) and invasive breast carcinoma of no special type. The latter often spreads to the axillary lymph nodes and other anatomic sites. The two forms of ductal carcinoma often coexist.","Breast Ductal Carcinoma | Duct Adenocarcinoma | Duct Carcinoma | Ductal Adenocarcinoma | Ductal Breast Carcinoma | Ductal Breast Carcinoma | Ductal Carcinoma | Ductal Carcinoma of Breast | Ductal Carcinoma of the Breast | Ductal adenocarcinoma | ductal carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1370500","Tanycytic Ependymoma","C6903","A variant of ependymoma, often found in the spinal cord, with tumor cells arranged in fascicles of variable width and cell density. Ependymal rosettes are generally absent, so this lesion must be distinguished from astrocytic neoplasms, but its EM characteristics are ependymal. (Adapted from WHO.)","Tanycytic Ependymoma | Tanycytic ependymoma",,,,,,,,,,,,,,,"4287480","Ependymoma, tanycytic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043356","Xiphoid Process","C33895","The cartilage just below the sternal body.","Xiphoid Process | XIPHOID PROCESS | Xiphisternum",,,,,,,,,,,,,,,"4069286","Structure of xiphoid process of sternum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710477","Trial Screening","C48262","A process of active consideration of potential subjects for enrollment in a trial.","Trial Screening | SCREENING | screening | screening (of subjects)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018852","Heavy Chain Disease","C3082","A group of rare clonal disorders of immunoglobulin synthesis associated with B-cell proliferative disorders.","Heavy Chain Disease | HCD | Heavy chain disease","9762/3","Heavy chain disease, NOS",,,,,,,,,,,,,"4270220|4288751","Heavy chain disease|Heavy chain disease",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0272203","Indolent Systemic Mastocytosis","C9286","An indolent mast cell neoplasm characterized by systemic infiltration of skin and internal organs by aggregates of neoplastic mast cells. There is no evidence of mast cell leukemia or clonal hematologic malignancy. Clinically, there is no evidence of palpable hepatomegaly and splenomegaly, malabsorption syndrome, or pathologic fractures.","Indolent Systemic Mastocytosis | ISM | Indolent systemic mastocytosis","9741/1","Indolent systemic mastocytosis",,,,,,,,,,,,,"4264452|4324386","Indolent systemic mastocytosis|Indolent systemic mastocytosis",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0206734","Hemangioblastoma","C3801","A rare, highly vascular tumor that is composed of abundant capillaries and stromal cells. It arises from the central nervous system and infrequently other sites. It is a slow growing tumor with a low risk of metastasis, despite its benign histological features.","Hemangioblastoma | Angioblastoma | Capillary Hemangioblastoma | Capillary Hemangioblastoma | Haemangioblastoma","9161/1","Hemangioblastoma",,,,,,,,,,,,,"4215906|607990","Hemangioblastoma|Hemangioblastoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1260326","Interdigitating Dendritic Cell Sarcoma","C9282","A neoplastic proliferation of spindle to ovoid cells which show phenotypic features similar to those of interdigitating dendritic cells.  The clinical course is generally aggressive. (WHO, 2008)","Interdigitating Dendritic Cell Sarcoma | Interdigitating Cell Sarcoma/Tumor | Interdigitating Dendritic Cell Sarcoma/Tumor | Interdigitating Dendritic Cell Sarcoma/Tumor | Interdigitating dendritic cell sarcoma","9757/3","Interdigitating dendritic cell sarcoma",,,,,,,,,,,,,"37396006|4028709","Interdigitating dendritic cell sarcoma|Interdigitating dendritic cell sarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1265996","Large Cell Neuroendocrine Carcinoma","C6875","An aggressive high-grade carcinoma with neuroendocrine differentiation composed of malignant large cells.","Large Cell Neuroendocrine Carcinoma | LCNEC | Large Cell NEC | Large cell neuroendocrine carcinoma | Large-cell neuroendocrine carcinoma","8013/3","Large cell neuroendocrine carcinoma",,,,,,,,,,,,,"4029971","Large cell neuroendocrine carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0474847","Malignant Melanotic Peripheral Nerve Sheath Tumor","C4748","A rare variant of malignant peripheral nerve sheath tumor.  It is characterized by the presence of malignant cells that contain melanin.","Malignant Melanotic Peripheral Nerve Sheath Tumor | MMNST | Malignant Melanocytic Neoplasm of Peripheral Nerve Sheath | Malignant Melanocytic Neoplasm of the Peripheral Nerve Sheath | Malignant Melanocytic Peripheral Nerve Sheath Tumor | Malignant Melanocytic Peripheral Nerve Sheath Tumor | Malignant Melanotic Nerve Sheath Tumor | Malignant Melanotic Schwannian Tumor | Melanocytic MPNST | Melanotic MPNST",,,,,,,,,,,,,,,"4102399|4301643","Melanotic malignant peripheral nerve sheath tumor|Melanotic malignant nerve sheath tumor",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1321427","Epithelioid Malignant Peripheral Nerve Sheath Tumor","C6561","A rare variant of malignant peripheral nerve sheath tumor composed predominantly or exclusively of epithelioid cells.","Epithelioid Malignant Peripheral Nerve Sheath Tumor | Epithelioid MPNST | Epithelioid malignant peripheral nerve sheath tumor | Malignant Epithelioid Neoplasm of Peripheral Nerve Sheath | Malignant Epithelioid Neoplasm of the Peripheral Nerve Sheath | Malignant Epithelioid Peripheral Nerve Sheath Neoplasm | Malignant Epithelioid Peripheral Nerve Sheath Tumor | Malignant Epithelioid Tumor of Peripheral Nerve Sheath | Malignant Epithelioid Tumor of the Peripheral Nerve Sheath",,,,,,,,,,,,,,,"4298153","Epithelioid malignant nerve sheath tumor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036221","Mast Cell Sarcoma","C9348","A rare malignant neoplasm characterized by localized but destructive growth of a tumor consisting of highly atypical, immature mast cells. (WHO, 2001)","Mast Cell Sarcoma | MCS | Mast cell sarcoma","9740/3","Mast cell sarcoma",,,,,,,,,,,,,"4028851|4040379","Mast cell sarcoma|Malignant mast cell tumor (clinical)",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C3279060","Malignant Peripheral Nerve Sheath Tumor","C3798","An uncommon, highly aggressive malignant tumor, arising from the peripheral nerves and affecting mostly adults in their third to sixth decades of life.  It usually occurs in medium-sized and large nerves of the buttock, thigh, upper arm, or the paraspinal region.  It may be associated with neurofibromatosis 1 (NF1).","Malignant Peripheral Nerve Sheath Tumor | MPNST | MPNST, NOS | Malig. periph. nerve sheath tum. | Malignant Neurilemmoma | Malignant Peripheral Nerve Sheath Neoplasm | Malignant Peripheral Nerve Sheath Tumour | Malignant Schwannoma | Malignant peripheral nerve sheath tumor | Neurilemoma, malignant | Neurofibrosarcoma | Neurofibrosarcoma, Malignant | Neurogenic sarcoma | SCHWANNOMA, MALIGNANT | malignant peripheral nerve sheath tumor","9560/3","Neurilemoma, malignant",,,,,,,,,,,,,"4062426|4301642","Malignant peripheral nerve sheath tumor|Malignant peripheral nerve sheath tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0001629","Adrenal Medulla","C12397","The inner region of the adrenal gland. The adrenal medulla produces, stores, and secretes epinephrine and norepinephrine.","Adrenal Medulla | Medulla of Adrenal Gland | Medulla of adrenal gland | Medullary | adrenal medulla",,,,,,,,,,,,,,,"4242540","Adrenal medulla structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1370510","Chordoid Meningioma","C6908","A WHO grade II, usually recurring meningioma characterized by the predominance of tissues that are histologically similar to chordoma.","Chordoid Meningioma | Chordoid meningioma",,,,,,,,,,,,,,,"4266488","Meningioma, chordoid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0431122","Atypical Meningioma","C4723","A WHO grade II meningioma characterized by the presence of brain invasion and an increased mitotic activity, or at least three of the following morphologic features: small cells, high cellularity, prominent nucleoli, lack of architectural pattern, and necrosis.","Atypical Meningioma | Atypical meningioma","9539/1","Atypical meningioma",,,,,,,,,,,,,"4029200","Atypical meningioma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C3163622","Papillary Meningioma","C3904","A WHO grade III meningioma characterized by the predominance of a perivascular pseudopapillary pattern.","Papillary Meningioma | Papillary meningioma","9538/3","Papillary meningioma",,,,,,,,,,,,,"4030268","Papillary meningioma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0431121","Clear Cell Meningioma","C4722","A WHO grade II morphologic variant of meningioma characterized by the presence of clear glycogen-rich polygonal cells.","Clear Cell Meningioma | Clear cell meningioma","9538/1","Clear cell meningioma",,,,,,,,,,,,,"4212098","Clear cell meningioma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0259786","Rhabdoid Meningioma","C6909","A WHO grade III meningioma characterized by the predominant presence of rhabdoid cells forming sheets.","Rhabdoid Meningioma | Rhabdoid meningioma",,,,,,,,,,,,,,,"4164328","Meningioma, rhabdoid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026470","Monoclonal Gammopathy of Undetermined Significance","C3996","A condition in which an abnormal amount of a single immunoglobulin is present in the serum. This category includes IgM monoclonal gammopathy of undetermined significance and non-IgM monoclonal gammopathy of undetermined significance. Up to 25% of cases of monoclonal gammopathy of undetermined significance  progress to a B-cell malignancy or myeloma.","Monoclonal Gammopathy of Undetermined Significance | MGUS | Monoclonal Gammopathy of Undetermined Significance (MGUS) | Monoclonal gammopathy of undetermined significance | Monoclonal gammopathy of undetermined significance (MGUS) | monoclonal gammopathy of undetermined significance",,,,,,,,,,,,,,,"4082463|4149022","Monoclonal gammopathy of uncertain significance|Monoclonal gammopathy of undetermined significance",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1513712","Mucinous","C14163","Containing or resembling mucin.","Mucinous | mucinous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1328061","Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified","C27780","A myelodysplastic/myeloproliferative neoplasm that does not meet the criteria of other myelodysplastic/myeloproliferative neoplasms, myelodysplastic syndromes, and myeloproliferative neoplasms. It is associated with cytopenia, blasts less than 20% in bone marrow and peripheral blood, thrombocytosis, and absence of genetic abnormalities associated with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions.","Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified | MDS/MPD, U | MDS/MPD-U | MDS/MPN, NOS | MDS/MPN, U | MDS/MPN-U | Mixed Myelodysplastic/Myeloproliferative Disease, Unclassifiable | Mixed Myeloproliferative/Myelodysplastic Syndrome, Unclassifiable | Myelodysplastic/Myeloproliferative Disease, Unclassifiable | Myelodysplastic/Myeloproliferative Disease, Unclassifiable | Myelodysplastic/Myeloproliferative Neoplasm, NOS | Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable | Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable | Myelodysplastic/myeloproliferative neoplasm, unclassifiable | Unclassifiable Myelodysplastic/Myeloproliferative Disease | Unclassifiable Myeloproliferative/Myelodysplastic Syndrome",,,,,,,,,,,,,,,"40491844|40493350","Myeloproliferative neoplasm, unclassifiable|Myelodysplastic/myeloproliferative neoplasm, unclassifiable",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3279070","Plexiform Neurofibroma","C3797","An elongated and multinodular neurofibroma, formed when the tumor involves either multiple trunks of a plexus or multiple fascicles of a large nerve, such as the sciatic. Some plexiform neurofibromas resemble a bag of worms, others produce a massive ropy enlargement of the nerve. (Adapted from WHO)","Plexiform Neurofibroma | Plexiform neurofibroma | plexiform neurofibroma","9550/0","Plexiform neurofibroma",,,,,,,,,,,,,"4165560|4295605","Plexiform neurofibroma|Plexiform neurofibroma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0027830","Neurofibroma","C3272","An intraneural or extraneural neoplasm arising from nerve tissues and neural sheaths. It is composed of perineurial-like fibroblasts and Schwann cells. It usually presents as a localized cutaneous lesion and less often as a circumscribed peripheral nerve mass. Patients with neurofibromatosis type 1 present with multiple masses. Neurofibromas which arise from major nerves and plexiform neurofibromas are precursor lesions to malignant peripheral nerve sheath tumors.","Neurofibroma | NEUROFIBROMA, BENIGN | Neurofibroma (WHO Grade I) | Neurofibroma, NOS | neurofibroma","9540/0","Neurofibroma, NOS",,,,,,,,,,,,,"4300676","Neurofibroma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1334968","Nodular Lymphocyte Predominant B-Cell Lymphoma","C7258","A B-cell lymphoma characterized by the presence of scattered clonal cells known as lymphocyte predominant cells (LP cells) in a background of reactive lymphocytes and histiocytes, and formation of a nodular or nodular and diffuse growth pattern.","Nodular Lymphocyte Predominant B-Cell Lymphoma | Hodgkin Lymphoma, Nodular Lymphocyte Predominance | Hodgkin lymphoma nodular LP, NOS | Hodgkin lymphoma nodular lymphocyte predominant type, NOS | Hodgkin lymphoma, lymphocyte predominance, nodular | Hodgkin lymphoma, nodular lymphocyte predominance | NLP-BCL | NLPBL | NLPHL | Nodular Lymphocyte Predominant B-Cell Lymphoma/Nodular Lymphocyte Predominant Hodgkin Lymphoma | Nodular Lymphocyte Predominant Hodgkin Lymphoma | Nodular Lymphocyte Predominant Hodgkin Lymphoma | Nodular Lymphocyte Predominant Hodgkin's Lymphoma | Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site | nodular lymphocyte-predominant Hodgkin lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280793","Oligoastrocytoma","C4050","A WHO grade 2 tumor composed of a conspicuous mixture of two distinct neoplastic cell types morphologically resembling the tumor cells in oligodendroglioma and diffuse astrocytoma. (WHO)","Oligoastrocytoma | GLIOMA, MIXED, BENIGN | Mixed Astrocytic-Oligodendroglial Neoplasm | Mixed Astrocytic-Oligodendroglial Tumor | Mixed Astrocytoma-Oligodendroglioma | Mixed Oligo-Astrocytoma | WHO Grade 2 Mixed Glioma | WHO Grade II Mixed Glioma | oligoastrocytoma",,,,,,,,,,,,,,,"4319257","Mixed glioma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0751396","Oligodendroglioma","C3288","A well-differentiated (WHO grade 2), diffusely infiltrating neuroglial tumor, typically located in the cerebral hemispheres.  It is composed predominantly of cells which morphologically resemble oligodendroglia. The neoplastic cells have rounded homogeneous nuclei and, on paraffin sections, a swollen, clear cytoplasm ('honeycomb' appearance). (Adapted from WHO)","Oligodendroglioma | Oligodendroglioma, NOS | WHO Grade 2 Oligodendroglial Neoplasm | WHO Grade 2 Oligodendroglial Tumor | WHO Grade II Oligodendroglial Neoplasm | WHO Grade II Oligodendroglial Tumor | Well Differentiated Oligodendroglial Tumor | Well Differentiated Oligodendroglioma | oligodendroglioma",,,,,,,,,,,,,,,"40484128","Oligodendroglioma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1367859","Pineal Parenchymal Tumor of Intermediate Differentiation","C6967","A WHO grade 2 or 3 pineal parenchymal neoplasm of intermediate-grade malignancy, affecting all ages.  It is composed of diffuse sheets or large lobules of uniform cells with mild to moderate nuclear atypia and low to moderate level mitotic activity.  (Adapted from WHO)","Pineal Parenchymal Tumor of Intermediate Differentiation | PPTID | Pineal parenchymal tumor of intermediate differentiation",,,,,,,,,,,,,,,"37396187|4264589","Pineal parenchymal tumor of intermediate differentiation|Pineal parenchymal tumor of intermediate differentiation",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1301361","Polymorphic Post-Transplant Lymphoproliferative Disorder","C7183","A clonal B-cell lymphoproliferative disorder arising as a result of post-transplant immunosuppression therapy. It is characterized by destructive infiltration of lymph nodes and extranodal sites by a polymorphic B-cell infiltrate composed of small and medium sized lymphocytes, immunoblasts, and plasma cells. In some cases, reduction of the immunosuppression therapy may lead to regression of the lesions. In other cases the lesions may progress to lymphoma.","Polymorphic Post-Transplant Lymphoproliferative Disorder | Polymorphic B-Cell Lymphoma | Polymorphic B-Cell Post-Transplant Lymphoproliferative Disorder | Polymorphic PTLD",,,,,,,,,,,,,,,"42538580","Polymorphic lymphoproliferative disorder following transplant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206663","Primitive Neuroectodermal Tumor","C3716","A malignant neoplasm that originates in the neuroectoderm. The neuroectoderm constitutes the portion of the ectoderm of the early embryo that gives rise to the central and peripheral nervous systems and includes some glial cell precursors.","Primitive Neuroectodermal Tumor | Neuroectodermal Neoplasm | Neuroectodermal Tumor | Neuroepithelioma | PNET | PNET, NOS | Primitive Neuroectodermal Neoplasm | Primitive Neuroectodermal Tumor (PNET) | Primitive neuroectodermal tumor, NOS | neuroectodermal tumor | primitive neuroectodermal tumor","9503/3","Neuroepithelioma, NOS",,,,,,,,,,,,,"4219855|44782609","Primitive neuroectodermal tumor|Primitive neuroectodermal tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0851140","Stage 0 Cervical Cancer AJCC v6","C4000","Stage 0 includes: (Tis, N0, M0). Tis: Carcinoma in situ. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th ed.)","Stage 0 Cervical Cancer AJCC v6 | CIN 3 AJCC v6 | CIN Grade 3 AJCC v6 | Carcinoma in situ of Cervix AJCC v6 | Carcinoma in situ of Cervix Uteri AJCC v6 | Carcinoma in situ of Uterine Cervix AJCC v6 | Carcinoma in situ of the Cervix AJCC v6 | Carcinoma in situ of the Cervix Uteri AJCC v6 | Carcinoma in situ of the Uterine Cervix AJCC v6 | Cervical Carcinoma in situ AJCC v6 | Cervical Intraepithelial Neoplasia Grade 3 AJCC v6 | Cervical Severe Dysplasia AJCC v6 | Cervical cancer stage 0 AJCC v6 | Cervix Carcinoma in situ AJCC v6 | Cervix Intraepithelial Neoplasia Grade 3 AJCC v6 | Cervix Severe Dysplasia AJCC v6 | Cervix Uteri Carcinoma in situ AJCC v6 | Cervix Uteri Intraepithelial Neoplasia Grade 3 AJCC v6 | Cervix Uteri Severe Dysplasia AJCC v6 | FIGO Stage 0 Carcinoma of Cervix | FIGO Stage 0 Carcinoma of Cervix Uteri | FIGO Stage 0 Carcinoma of Uterine Cervix | FIGO Stage 0 Carcinoma of the Cervix | FIGO Stage 0 Carcinoma of the Cervix Uteri | FIGO Stage 0 Carcinoma of the Uterine Cervix | FIGO Stage 0 Cervical Carcinoma | FIGO Stage 0 Cervix Carcinoma | FIGO Stage 0 Cervix Uteri Carcinoma | FIGO Stage 0 Uterine Cervix Carcinoma | Grade 3 Cervical Intraepithelial Neoplasia AJCC v6 | Intraepithelial Neoplasia of Cervix Grade 3 AJCC v6 | Intraepithelial Neoplasia of Cervix Uteri Grade 3 AJCC v6 | Intraepithelial Neoplasia of Uterine Cervix Grade 3 AJCC v6 | Intraepithelial Neoplasia of the Cervix Grade 3 AJCC v6 | Intraepithelial Neoplasia of the Cervix Uteri Grade 3 AJCC v6 | Intraepithelial Neoplasia of the Uterine Cervix Grade 3 AJCC v6 | Severe Cervical Dysplasia AJCC v6 | Severe Dysplasia of Cervix AJCC v6 | Severe Dysplasia of Cervix Uteri AJCC v6 | Severe Dysplasia of Uterine Cervix AJCC v6 | Severe Dysplasia of the Cervix AJCC v6 | Severe Dysplasia of the Cervix Uteri AJCC v6 | Severe Dysplasia of the Uterine Cervix AJCC v6 | Stage 0 Cervical Cancer | Stage 0 Cervical Cancer | Uterine Cervix Carcinoma in situ AJCC v6 | Uterine Cervix Intraepithelial Neoplasia Grade 3 AJCC v6 | Uterine Cervix Severe Dysplasia AJCC v6",,,,,,,,,,,,,,,"194611","Carcinoma in situ of uterine cervix",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0278576","Stage II Cervical Cancer AJCC v6","C7803","Stage II includes: II (T2, N0, M0); IIA (T2a, N0, M0); IIB (T2b, N0, M0). T2: Cervical carcinoma invades beyond uterus but not to pelvic wall or to lower third of vagina. T2a: Tumor without parametrial invasion. T2b: Tumor with parametrial invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th ed.)","Stage II Cervical Cancer AJCC v6 | AJCC Stage II Cervical Cancer v6 | Cervical Cancer Stage II AJCC v6 | Cervical Carcinoma Stage II AJCC v6 | Cervix Cancer Stage II AJCC v6 | FIGO Stage II Carcinoma of Cervix | FIGO Stage II Carcinoma of Cervix Uteri | FIGO Stage II Carcinoma of Uterine Cervix | FIGO Stage II Carcinoma of the Cervix | FIGO Stage II Carcinoma of the Cervix Uteri | FIGO Stage II Carcinoma of the Uterine Cervix | FIGO Stage II Cervical Carcinoma | FIGO Stage II Cervix Carcinoma | FIGO Stage II Cervix Uteri Carcinoma | FIGO Stage II Uterine Cervix Carcinoma | Stage II Cervical Cancer | Stage II Cervical Cancer | Uterine Cervix Cancer Stage II AJCC v6 | stage II cancer of the cervix",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278575","Stage I Cervical Cancer AJCC v6 and v7","C9204","Stage I includes: I (T1, N0, M0); IA (T1a, N0, M0); IA1 (T1a1, N0, M0); IA2 (T1a2, N0, M0); IB (T1b, N0, M0); IB1(T1b1, N0, M0); IB2 (T1b2, N0, M0). T1: Cervical carcinoma confined to uterus (extension to corpus should be disregarded). T1a: Invasive carcinoma diagnosed only by microscopy. Stromal invasion with a maximum depth of 5.0 mm measured from the base of the epithelium and a horizontal spread of 7.0 mm or less. Vascular space involvement, venous or lymphatic, does not affect classification. T1a1: Measured stromal invasion 3.0 mm or less in depth and 7.0 or less horizontal spread.  T1a2: Measured stromal invasion more than 3.0mm and not more than 5.0 mm with a horizontal spread 7.0mm or less. T1b: Clinically visible lesion confined to the cervix or microscopic lesion greater than T1a/IA2. T1b1: Clinically visible lesion 4.0 cm or less in greatest dimension. T1b2: Clinically visible lesion more than 4.0 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage I Cervical Cancer AJCC v6 and v7 | AJCC Stage I Cervical Cancer | Cervical Cancer Stage I | Cervical Carcinoma Stage I | FIGO Stage I Carcinoma of Cervix | FIGO Stage I Carcinoma of Cervix Uteri | FIGO Stage I Carcinoma of Uterine Cervix | FIGO Stage I Carcinoma of the Cervix | FIGO Stage I Carcinoma of the Cervix Uteri | FIGO Stage I Carcinoma of the Uterine Cervix | FIGO Stage I Cervical Carcinoma | FIGO Stage I Cervix Carcinoma | FIGO Stage I Cervix Uteri Carcinoma | FIGO Stage I Uterine Cervix Carcinoma | Stage I Cervical Cancer | Stage I Cervical Cancer | Stage I Cervical Cancer AJCC v6 | Stage I Cervical Cancer AJCC v7 | Uterine Cervix Cancer Stage I | stage I cancer of the cervix",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278577","Stage III Cervical Cancer AJCC v6 and v7","C9205","Stage III includes: III (T3, N0, M0); IIIA (T3a, N0, M0); IIIB (T1, N1, M0), (T2, N1, M0), (T3a, N1, M0), (T3b, Any N, M0). T3: Tumor extends to pelvic wall and/or involves lower third of vagina, and/or causes hydronephrosis or non-functioning kidney. T3a: Tumor involves lower third of vagina, no extension to pelvic wall.  T3b: Tumor extends to pelvic wall and/or causes hydronephrosis or non functioning kidney.  N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage III Cervical Cancer AJCC v6 and v7 | Cervical Cancer Stage III | Cervical Carcinoma Stage III | FIGO Stage III Carcinoma of Cervix | FIGO Stage III Carcinoma of Cervix Uteri | FIGO Stage III Carcinoma of Uterine Cervix | FIGO Stage III Carcinoma of the Cervix | FIGO Stage III Carcinoma of the Cervix Uteri | FIGO Stage III Carcinoma of the Uterine Cervix | FIGO Stage III Cervical Carcinoma | FIGO Stage III Cervix Carcinoma | FIGO Stage III Cervix Uteri Carcinoma | FIGO Stage III Uterine Cervix Carcinoma | Stage III Cervical Cancer | Stage III Cervical Cancer | Stage III Cervical Cancer AJCC v6 | Stage III Cervical Cancer AJCC v7 | stage III cancer of the cervix",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278578","Stage IV Cervical Cancer AJCC v6 and v7","C9206","Stage IV includes: IVA: (T4, Any N, M0); IVB (Any T, Any N, MI). T4: Tumor invades mucosa of bladder or rectum, and/or extends beyond true pelvis (bullous edema is not sufficient to classify a tumor as T4). M1: Distant metastasis. (AJCC 6th and 7th eds.)","Stage IV Cervical Cancer AJCC v6 and v7 | AJCC Stage IV Cervical Cancer | Cervical Cancer Stage IV | Cervical Carcinoma Stage IV | FIGO Stage IV Carcinoma of Cervix | FIGO Stage IV Carcinoma of Cervix Uteri | FIGO Stage IV Carcinoma of Uterine Cervix | FIGO Stage IV Carcinoma of the Cervix | FIGO Stage IV Carcinoma of the Cervix Uteri | FIGO Stage IV Carcinoma of the Uterine Cervix | FIGO Stage IV Cervical Carcinoma | FIGO Stage IV Cervix Carcinoma | FIGO Stage IV Cervix Uteri Carcinoma | FIGO Stage IV Uterine Cervix Carcinoma | Stage IV Cervical Cancer | Stage IV Cervical Cancer | Stage IV Cervical Cancer AJCC v6 | Stage IV Cervical Cancer AJCC v7 | stage IV cancer of the cervix",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448339","stage IA cervical cancer","C6313","Stage IA includes: IA (T1a, N0, M0); IA1 (T1a1, N0, M0); IA2 (T1a2, N0, M0).  T1a: Invasive carcinoma diagnosed only by microscopy. Stromal invasion with a maximum depth of 5.0 mm measured from the base of the epithelium and a horizontal spread of 7.0 mm or less. Vascular space involvement, venous or lymphatic, does not affect classification. T1a1: Measured stromal invasion 3.0 mm or less in depth and 7.0 or less horizontal spread.  T1a2: Measured stromal invasion more than 3.0 mm and not more than 5.0 mm with a horizontal spread 7.0 mm or less.  N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage IA Cervical Cancer AJCC v6 and v7 | AJCC Stage IA Cervical Cancer | Cervical Cancer Stage IA | FIGO Stage IA Carcinoma of Cervix | FIGO Stage IA Carcinoma of Cervix Uteri | FIGO Stage IA Carcinoma of Uterine Cervix | FIGO Stage IA Carcinoma of the Cervix | FIGO Stage IA Carcinoma of the Cervix Uteri | FIGO Stage IA Carcinoma of the Uterine Cervix | FIGO Stage IA Cervical Carcinoma | FIGO Stage IA Cervix Carcinoma | FIGO Stage IA Cervix Uteri Carcinoma | FIGO Stage IA Uterine Cervix Carcinoma | Stage IA Cervical Cancer | Stage IA Cervical Cancer | Stage IA Cervical Cancer AJCC v6 | Stage IA Cervical Cancer AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336109","Stage IA1 Cervical Cancer","C6314","Stage IA1 includes: T1a1, N0, M0.  T1a1: Measured stromal invasion 3.0 mm or less in depth and 7.0 mm or less in horizontal spread.  N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage IA1 Cervical Cancer AJCC v6 and v7 | AJCC Stage IA1Cervical Cancer | Cervical Cancer Stage IA1 | FIGO Stage IA1 Carcinoma of Cervix | FIGO Stage IA1 Carcinoma of Cervix Uteri | FIGO Stage IA1 Carcinoma of Uterine Cervix | FIGO Stage IA1 Carcinoma of the Cervix | FIGO Stage IA1 Carcinoma of the Cervix Uteri | FIGO Stage IA1 Carcinoma of the Uterine Cervix | FIGO Stage IA1 Cervical Carcinoma | FIGO Stage IA1 Cervix Carcinoma | FIGO Stage IA1 Cervix Uteri Carcinoma | FIGO Stage IA1 Uterine Cervix Carcinoma | Stage IA1 Cervical Cancer | Stage IA1 Cervical Cancer | Stage IA1 Cervical Cancer AJCC v6 | Stage IA1 Cervical Cancer AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336110","Stage IA2 Cervical Cancer","C6315","Stage IA2 includes: T1a2, N0, M0.  T1a2: Measured stromal invasion more than 3.0 mm and not more than 5.0 mm with a horizontal spread 7.0 mm or less.  N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage IA2 Cervical Cancer AJCC v6 and v7 | AJCC Stage IA2 Cervical Cancer | Cervical Cancer Stage IA2 | FIGO Stage IA2 Carcinoma of Cervix | FIGO Stage IA2 Carcinoma of Cervix Uteri | FIGO Stage IA2 Carcinoma of Uterine Cervix | FIGO Stage IA2 Carcinoma of the Cervix | FIGO Stage IA2 Carcinoma of the Cervix Uteri | FIGO Stage IA2 Carcinoma of the Uterine Cervix | FIGO Stage IA2 Cervical Carcinoma | FIGO Stage IA2 Cervix Carcinoma | FIGO Stage IA2 Cervix Uteri Carcinoma | FIGO Stage IA2 Uterine Cervix Carcinoma | Stage IA2 Cervical Cancer | Stage IA2 Cervical Cancer | Stage IA2 Cervical Cancer AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448340","stage IB cervical cancer","C6316","Stage IB includes: IB (T1b, N0, M0); IB1(T1b1, N0, M0); IB2 (T1b2, N0, M0). T1b: Clinically visible lesion confined to the cervix or microscopic lesion greater than T1a/IA2. T1b1: Clinically visible lesion 4.0 cm or less in greatest dimension. T1b2: Clinically visible lesion more than 4.0 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage IB Cervical Cancer AJCC v6 and v7 | AJCC Stage IB Cervical Cancer | Cervical Cancer Stage IB | FIGO Stage IB Carcinoma of Cervix | FIGO Stage IB Carcinoma of Cervix Uteri | FIGO Stage IB Carcinoma of Uterine Cervix | FIGO Stage IB Carcinoma of the Cervix | FIGO Stage IB Carcinoma of the Cervix Uteri | FIGO Stage IB Carcinoma of the Uterine Cervix | FIGO Stage IB Cervical Carcinoma | FIGO Stage IB Cervix Carcinoma | FIGO Stage IB Cervix Uteri Carcinoma | FIGO Stage IB Uterine Cervix Carcinoma | Stage IB Cervical Cancer | Stage IB Cervical Cancer | Stage IB Cervical Cancer AJCC v6 | Stage IB Cervical Cancer AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336128","Stage IB1 Cervical Cancer","C6317","Stage IB1 includes: T1b1, N0, M0.  T1b1: Clinically visible lesion 4.0 cm or less in greatest dimension. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage IB1 Cervical Cancer AJCC v6 and v7 | AJCC Stage IB1 Cervical Cancer | Cervical Cancer Stage IB1 | FIGO Stage IB1 Carcinoma of Cervix | FIGO Stage IB1 Carcinoma of Cervix Uteri | FIGO Stage IB1 Carcinoma of Uterine Cervix | FIGO Stage IB1 Carcinoma of the Cervix | FIGO Stage IB1 Carcinoma of the Cervix Uteri | FIGO Stage IB1 Carcinoma of the Uterine Cervix | FIGO Stage IB1 Cervical Carcinoma | FIGO Stage IB1 Cervix Carcinoma | FIGO Stage IB1 Cervix Uteri Carcinoma | FIGO Stage IB1 Uterine Cervix Carcinoma | Stage IB1 Cervical Cancer | Stage IB1 Cervical Cancer | Stage IB1 Cervical Cancer AJCC v6 | Stage IB1 Cervical Cancer AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336129","Stage IB2 Cervical Cancer","C6318","Stage IB2 includes: T1b2, N0, M0.  T1b2: Clinically visible lesion more than 4.0 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage IB2 Cervical Cancer AJCC v6 and v7 | AJCC Stage IB2 Cervical Cancer | Cervical Cancer Stage IB2 | FIGO Stage IB2 Carcinoma of Cervix | FIGO Stage IB2 Carcinoma of Cervix Uteri | FIGO Stage IB2 Carcinoma of Uterine Cervix | FIGO Stage IB2 Carcinoma of the Cervix | FIGO Stage IB2 Carcinoma of the Cervix Uteri | FIGO Stage IB2 Carcinoma of the Uterine Cervix | FIGO Stage IB2 Cervical Carcinoma | FIGO Stage IB2 Cervix Carcinoma | FIGO Stage IB2 Cervix Uteri Carcinoma | FIGO Stage IB2 Uterine Cervix Carcinoma | Stage IB2 Cervical Cancer | Stage IB2 Cervical Cancer | Stage IB2 Cervical Cancer AJCC v6 | Stage IB2 Cervical Cancer AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278588","Stage IIA Cervical Cancer AJCC v6","C6319","Tumor without parametrial invasion.","Stage IIA Cervical Cancer AJCC v6 | AJCC Stage IIA Cervical Cancer v6 | Cervical Cancer Stage IIA AJCC v6 | FIGO Stage IIA Carcinoma of Cervix | FIGO Stage IIA Carcinoma of Cervix Uteri | FIGO Stage IIA Carcinoma of Uterine Cervix | FIGO Stage IIA Carcinoma of the Cervix | FIGO Stage IIA Carcinoma of the Cervix Uteri | FIGO Stage IIA Carcinoma of the Uterine Cervix | FIGO Stage IIA Cervical Carcinoma | FIGO Stage IIA Cervix Carcinoma | FIGO Stage IIA Cervix Uteri Carcinoma | FIGO Stage IIA Uterine Cervix Carcinoma | Stage IIA Cervical Cancer | Stage IIA Cervical Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278583","Stage IIB Cervical Cancer AJCC v6 and v7","C6320","Stage IIB includes: T2b, N0, M0.  T2b: Tumor with parametrial invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage IIB Cervical Cancer AJCC v6 and v7 | AJCC Stage IIB Cervical Cancer | Cervical Cancer Stage II | FIGO Stage IIB Carcinoma of Cervix | FIGO Stage IIB Carcinoma of Cervix Uteri | FIGO Stage IIB Carcinoma of Uterine Cervix | FIGO Stage IIB Carcinoma of the Cervix | FIGO Stage IIB Carcinoma of the Cervix Uteri | FIGO Stage IIB Carcinoma of the Uterine Cervix | FIGO Stage IIB Cervical Carcinoma | FIGO Stage IIB Cervix Carcinoma | FIGO Stage IIB Cervix Uteri Carcinoma | FIGO Stage IIB Uterine Cervix Carcinoma | Stage IIB Cervical Cancer | Stage IIB Cervical Cancer | Stage IIB Cervical Cancer AJCC v6 | Stage IIB Cervical Cancer AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336204","AJCC Stage IIIA Cervical Cancer","C6322","Stage IIIA includes: T3a, N0, M0.  T3a: Tumor involves lower third of vagina, no extension to pelvic wall.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage IIIA Cervical Cancer AJCC v6 and v7 | AJCC Stage IIIA Cervical Cancer | Cervical Cancer Stage IIIA | FIGO Stage IIIA Carcinoma of Cervix | FIGO Stage IIIA Carcinoma of Cervix Uteri | FIGO Stage IIIA Carcinoma of Uterine Cervix | FIGO Stage IIIA Carcinoma of the Cervix | FIGO Stage IIIA Carcinoma of the Cervix Uteri | FIGO Stage IIIA Carcinoma of the Uterine Cervix | FIGO Stage IIIA Cervical Carcinoma | FIGO Stage IIIA Cervix Carcinoma | FIGO Stage IIIA Cervix Uteri Carcinoma | FIGO Stage IIIA Uterine Cervix Carcinoma | Stage IIIA Cervical Cancer | Stage IIIA Cervical Cancer | Stage IIIA Cervical Cancer AJCC v6 | Stage IIIA Cervical Cancer AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336219","AJCC Stage IIIB Cervical Cancer","C6321","Stage IIIB includes: (T3b, Any N, M0); (T1-3, N1, M0).  T3: Tumor extends to pelvic wall and/or involves lower third of vagina, and/or causes hydronephrosis or non-functioning kidney. T3b: Tumor extends to pelvic wall and/or causes hydronephrosis or non-functioning kidney. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage IIIB Cervical Cancer AJCC v6 and v7 | AJCC Stage IIIB Cervical Cancer | Cervical Cancer Stage IIIB | FIGO Stage IIIB Carcinoma of Cervix | FIGO Stage IIIB Carcinoma of Cervix Uteri | FIGO Stage IIIB Carcinoma of Uterine Cervix | FIGO Stage IIIB Carcinoma of the Cervix | FIGO Stage IIIB Carcinoma of the Cervix Uteri | FIGO Stage IIIB Carcinoma of the Uterine Cervix | FIGO Stage IIIB Cervical Carcinoma | FIGO Stage IIIB Cervix Carcinoma | FIGO Stage IIIB Cervix Uteri Carcinoma | FIGO Stage IIIB Uterine Cervix Carcinoma | Stage IIIB Cervical Cancer | Stage IIIB Cervical Cancer | Stage IIIB Cervical Cancer AJCC v6 | Stage IIIB Cervical Cancer AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278589","Stage IVA Cervical Cancer AJCC v6 and v7","C6323","Stage IVA includes: T4, Any N, M0). T4: Tumor invades mucosa of bladder or rectum, and/or extends beyond true pelvis (bullous edema is not sufficient to classify a tumor as T4). M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage IVA Cervical Cancer AJCC v6 and v7 | AJCC Stage IVA Cervical Cancer | Cervical Cancer Stage IVA | FIGO Stage IVA Carcinoma of Cervix | FIGO Stage IVA Carcinoma of Cervix Uteri | FIGO Stage IVA Carcinoma of Uterine Cervix | FIGO Stage IVA Carcinoma of the Cervix | FIGO Stage IVA Carcinoma of the Cervix Uteri | FIGO Stage IVA Carcinoma of the Uterine Cervix | FIGO Stage IVA Cervical Carcinoma | FIGO Stage IVA Cervix Carcinoma | FIGO Stage IVA Cervix Uteri Carcinoma | FIGO Stage IVA Uterine Cervix Carcinoma | Stage IVA Cervical Cancer | Stage IVA Cervical Cancer | Stage IVA Cervical Cancer AJCC v6 | Stage IVA Cervical Cancer AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527418","Stage IVB Cervical Cancer AJCC v6 and v7","C6324","Stage IVB includes: Any T, Any N, MI. M1: Distant metastasis. (AJCC 6th and 7th eds.)","Stage IVB Cervical Cancer AJCC v6 and v7 | AJCC Stage IVB Cervical Cancer | Cervical Cancer Stage IVB | FIGO Stage IVB Carcinoma of Cervix | FIGO Stage IVB Carcinoma of Cervix Uteri | FIGO Stage IVB Carcinoma of Uterine Cervix | FIGO Stage IVB Carcinoma of the Cervix | FIGO Stage IVB Carcinoma of the Cervix Uteri | FIGO Stage IVB Carcinoma of the Uterine Cervix | FIGO Stage IVB Cervical Carcinoma | FIGO Stage IVB Cervix Carcinoma | FIGO Stage IVB Cervix Uteri Carcinoma | FIGO Stage IVB Uterine Cervix Carcinoma | Stage IVB Cervical Cancer | Stage IVB Cervical Cancer | Stage IVB Cervical Cancer AJCC v6 | Stage IVB Cervical Cancer AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1306247","Melanotic Schwannoma","C6970","A rare circumscribed, non-encapsulated and grossly pigmented nerve sheath tumor. It is composed of cells with the immunophenotypic and electron microscopic features of Schwann cells which contain melanosomes and are positive for melanoma markers. It usually involves spinal nerve roots but may occur in other locations. It may be associated with PRKAR1A gene mutation and Carney complex. Malignant behavior has been reported in a significant number of patients.","Melanotic Schwannoma | Melanocytic Neurilemmoma | Melanocytic Schwannoma | Melanocytic Schwannoma | Melanotic Neurilemmoma | Melanotic Neurinoma | Melanotic schwannoma | Pigmented Neurilemmoma | Pigmented Schwannoma | Pigmented schwannoma",,,,,,,,,,,,,,,"4099824|4300674","Melanotic schwannoma|Melanotic schwannoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0431124","Cellular Schwannoma","C4724","A morphologic variant of schwannoma characterized by hypercellularity, Antoni A pattern, and the absence of well-formed Verocay bodies.","Cellular Schwannoma | Cellular Neurilemmoma | Cellular Neurinoma | Cellular schwannoma",,,,,,,,,,,,,,,"4102397|4297334","Cellular schwannoma|Cellular schwannoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1370659","Plexiform Schwannoma","C6969","A schwannoma characterized by a plexiform or multinodular growth pattern.  It usually arises from the skin or subcutaneous tissues in the extremities, trunk, and head and neck.","Plexiform Schwannoma | Plexiform Neurilemmoma | Plexiform Neurinoma | Plexiform schwannoma",,,,,,,,,,,,,,,"4100555|4297333","Plexiform schwannoma|Plexiform schwannoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0272256","Solitary Plasmacytoma of Bone","C7812","A localized malignant neoplasm that arises in the bone. It is composed of clonal (malignant) plasma cells forming a tumor mass. The most commonly affected bones are the vertebrae, ribs, skull, pelvis, and femur.","Solitary Plasmacytoma of Bone | Bone Solitary Plasmacytoma | SPB | Solitary Osseous Plasmacytoma | Solitary Osseous Plasmacytoma",,,,,,,,,,,,,,,"4145040","Solitary osseous myeloma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1368910","Mature Teratoma","C9015","A teratoma which may be cystic; it is composed entirely of well differentiated, adult-type mature tissues, without evidence of fetal-type immature tissues (grade 0 teratoma).","Mature Teratoma | Grade 0 Teratoma | Mature teratoma | mature teratoma",,,,,,,,,,,,,,,"4175497","Teratoma, benign",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1301365","Systemic Mastocytosis with an Associated Myeloid Neoplasm","C9284","A disorder characterized by systemic infiltration of internal organs by aggregates of clonal mast cells and the presence of a clonal non-mast cell myeloid neoplasm (e.g., myelodysplastic syndrome, myeloproliferative neoplasm, and acute myeloid leukemia).","Systemic Mastocytosis with an Associated Myeloid Neoplasm | SM-AHN | SM-AHNMD | SM-AMN | Systemic Mastocytosis with Associated Clonal Hematological non-Mast-Cell Lineage Disease | Systemic Mastocytosis with Associated Clonal Hematological non-Mast-Cell Lineage Disease | Systemic Mastocytosis with an Associated Hematologic Neoplasm | Systemic Mastocytosis with an Associated Hematological Neoplasm | Systemic Mastocytosis with an Associated Hematological Neoplasm (SM-AHN) | Systemic Mastocytosis with an Associated Hematological Neoplasm (SM-AHN) | Systemic mastocytosis with AHNMD | Systemic mastocytosis with associated hematological clonal non-mast cell disorder",,,,,,,,,,,,,,,"4264694|4288093","Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease|Systemic mastocytosis with associated clonal, hematologic non-mast-cell lineage disease",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0334520","Immature Teratoma","C4286","A teratoma characterized by the presence of an extensive component of immature, fetal-type tissues.","Immature Teratoma | Embryonal teratoma | Grade 2 Teratoma | Immature teratoma, NOS | immature teratoma",,,,,,,,,,,,,,,"37311081|40391775","Malignant immature teratoma|Malignant teratoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0334523","Teratoma with Somatic-Type Malignancy","C4289","A teratoma which is characterized by morphologic transformation to malignancy and an aggressive clinical course. The malignant component most often is sarcomatous or carcinomatous.","Teratoma with Somatic-Type Malignancy | Dermoid Cyst with Malignant Transformation | Dermoid cyst with malignant transformation | Somatic Malignancy | Teratoma with Malignant Transformation | Teratoma with Malignant Transformation | Teratoma with Somatic-type Malignancy | Teratoma with malignant transformation","9084/3","Teratoma with malignant transformation",,,,,,,,,,,,,"4339405","Teratoma with malignant transformation",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1883424","Undifferentiated Carcinoma with Osteoclast-Like Giant Cells","C63622","A usually aggressive carcinoma composed of malignant cells that do not display evidence of glandular or squamous differentiation, and giant cells resembling osteoclasts.","Undifferentiated Carcinoma with Osteoclast-Like Giant Cells | Carcinoma with osteoclast-like giant cells","8035/3","Carcinoma with osteoclast-like giant cells",,,,,,,,,,,,,"4028532","Carcinoma with osteoclast-like giant cells",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1336853","Unclassified Renal Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709717","Prostate Cancer pM1 TNM Finding v6 and v7","C48246","Prostate cancer with distant metastasis. (from AJCC 6th and 7th Eds.)","Prostate Cancer pM1 TNM Finding v6 and v7 | Prostate Cancer pM1 TNM Finding | Prostate Cancer pM1 TNM Finding | Prostate Cancer pM1 TNM Finding v6 | Prostate Cancer pM1 TNM Finding v7 | pM1 Cancer of Prostate | pM1 Cancer of the Prostate | pM1 Carcinoma of Prostate | pM1 Carcinoma of the Prostate | pM1 Prostate Cancer | pM1 Prostate Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981238","Prostate Cancer pMX TNM Finding v6","C52683","Prostate cancer in which the status of distant metastasis cannot be assessed. (from AJCC 6th Ed.)","Prostate Cancer pMX TNM Finding v6 | MX | Prostate Cancer pMX TNM Finding | pMX Cancer of Prostate v6 | pMX Cancer of the Prostate v6 | pMX Carcinoma of Prostate v6 | pMX Carcinoma of the Prostate v6 | pMX Prostate Cancer v6 | pMX Prostate Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881317","Kidney Cancer pN1 TNM Finding v6","C63573","Kidney cancer with metastasis to a single regional lymph node. (from AJCC 6th Ed.)","Kidney Cancer pN1 TNM Finding v6 | Kidney Cancer pN1 TNM Finding | pN1 Kidney Cancer v6 | pN1 Kidney Carcinoma v6 | pN1 Renal Cancer v6 | pN1 Renal Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881316","Kidney Cancer pN0 TNM Finding v6 and v7","C63572","Kidney cancer with no metastasis to regional lymph nodes. (from AJCC 6th and 7th Eds.)","Kidney Cancer pN0 TNM Finding v6 and v7 | Kidney Cancer pN0 TNM Finding | Kidney Cancer pN0 TNM Finding | Kidney Cancer pN0 TNM Finding v6 | Kidney Cancer pN0 TNM Finding v7 | pN0 Kidney Cancer | pN0 Kidney Carcinoma | pN0 Renal Cancer | pN0 Renal Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881319","Kidney Cancer pNX TNM Finding v6 and v7","C63571","Kidney cancer in which the regional lymph nodes cannot be assessed. (from AJCC 6th and 7th Eds.)","Kidney Cancer pNX TNM Finding v6 and v7 | Kidney Cancer pNX TNM Finding | Kidney Cancer pNX TNM Finding | Kidney Cancer pNX TNM Finding v6 | Kidney Cancer pNX TNM Finding v7 | pNX Kidney Cancer | pNX Kidney Carcinoma | pNX Renal Cancer | pNX Renal Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332345","Atypical Adenomatous Lung Hyperplasia","C5665","A preinvasive lesion in the lung. It is characterized by the presence of a small, localized proliferation of mildly to moderately atypical type II pneumocytes and/or Clara cells lining alveolar walls and sometimes respiratory bronchioles.","Atypical Adenomatous Lung Hyperplasia | AAH | Atypical Adenomatous Hyperplasia of Lung | Atypical Adenomatous Hyperplasia of the Lung | Atypical Alveolar Hyperplasia | Bronchioloalveolar Cell Adenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0586362","Pancreatic Intraepithelial Neoplasia","C4845","A pre-cancerous, non-invasive pancreatic epithelial neoplasm that arises from and is confined to the pancreatic ducts.  It is a papillary or flat neoplasm that usually measures less than 5 mm in diameter.","Pancreatic Intraepithelial Neoplasia | PanIN | Pancreatic Dysplasia",,,,,,,,,,,,,,,"4202469","Pancreatic duct dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028377","Normal Distribution","C53215","A family of probability density functions whose mean, median and mode are identical. The function generates a symmetrical curve, whose position and shape is determined by its location and scale parameters, the mean and standard deviation respectively. The standard normal distribution has a location parameter of 0 and a scale parameter of 1.","Normal Distribution | Gaussian | Gaussian Distribution",,,,,,,,,,,,,,,"4106571","Normal distribution",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705957","Pharmaceutical Formulation","C42638","The composition of a dosage form, including the characteristics of its raw materials and the operations required to process it.Formulation factors include chemical nature of the drug (ester, salt, complex, etc), drug solubility in water and organic solvents, particle size and surface area, type of dosage form (solution, suspension, capsule, tablet) and the excipients and processes used in the manufacturing of the drug delivery systems. The design of optimal drug delivery systems is thus an important part of providing an effective therapeutic.Official formulations for approved agents are presented in such books as the National Formulary and US Pharmacopeia. Whereas at one time, these were detailed and almost recipe-like, more recent entries may be limited to specifying the formula and imposing a standard limit for the active agent.","Pharmaceutical Formulation | Drug Formulation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003611","Appendectomy","C51687","Surgical removal of the vermiform appendix.","Appendectomy | appendectomy",,,,,,,,,,,,,,,"4198190","Appendectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1260325","Follicular Dendritic Cell Sarcoma","C9281","A neoplasm composed of spindle to ovoid cells which have morphologic and immunophenotypic characteristics of follicular dendritic cells. It affects lymph nodes and other sites including the tonsils, gastrointestinal tract, spleen, liver, soft tissues, skin, and oral cavity. It usually behaves as a low grade sarcoma. Treatment options include complete surgical removal of the tumor with or without adjuvant chemotherapy or radiotherapy. Recurrences have been reported in up to half of the cases.","Follicular Dendritic Cell Sarcoma | FDCS | Follicular Dendritic Cell Sarcoma/Tumor | Follicular Dendritic Cell Sarcoma/Tumor | Follicular dendritic cell sarcoma | Follicular dendritic cell tumor","9758/3","Follicular dendritic cell sarcoma",,,,,,,,,,,,,"4028710","Follicular dendritic cell sarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C5702659","pN1 TNM Finding","C48746","A pathologic regional lymph node TNM finding. The definition of pN1 finding depends on the particular type of cancer that it refers to; for example, for breast cancer, pN1 finding is defined as follows: cancer with micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). (from AJCC 8th Ed.)","pN1 TNM Finding | Lymph Node Stage pN1 | Node Stage pN1 | pN1 | pN1 Cancer Stage Finding | pN1 Lymph Node Finding | pN1 Lymph Node Stage | pN1 Node Finding | pN1 Node Stage | pN1 Regional Lymph Node Stage Finding | pN1 Regional Lymph Nodes Finding | pN1 Stage | pN1 Stage Finding | pN1 TNM Finding",,,,,,,,,,,,,,,"37164251","pN1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332398","pN2 TNM Finding","C48750","A pathologic regional lymph nodes TNM finding. The definition of pN2 finding depends on the particular type of cancer that it refers to; for example, for breast cancer, pN2 finding is defined as follows: cancer with metastases in 4 to 9 axillary lymph nodes, or metastases in clinically detected internal mammary lymph nodes in the absence of axillary lymph node metastases. 'Clinically detected' is defined as detected by imaging studies (excluding lymphoscintigraphy) or by clinical examination and having characteristics highly suspicious for malignancy or a presumed pathologic macrometastasis based on fine needle aspiration biopsy with cytologic examination; for colorectal cancer, pN2 stage finding is defined as follows: cancer with metastasis in four or more regional lymph nodes. (from AJCC 7th Ed.)","pN2 TNM Finding | Lymph Node Stage pN2 | Node Stage pN2 | pN2 | pN2 Cancer Stage Finding | pN2 Lymph Node Finding | pN2 Lymph Node Stage | pN2 Node Finding | pN2 Node Stage | pN2 Regional Lymph Node Stage Finding | pN2 Regional Lymph Nodes Finding | pN2 Stage | pN2 Stage Finding | pN2 TNM Finding",,,,,,,,,,,,,,,"37164257","pN2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1711119","pN1b Lymph Node Finding","C48748","A pathologic regional lymph node TNM finding. The definition of pN1b finding depends on the particular type of cancer that it refers to; for example, for breast cancer, pN1b finding is defined as follows: cancer with metastasis in internal mammary lymph nodes with microscopic disease detected by sentinel lymph node dissection but not clinically apparent. (from AJCC 6th Ed.)","pN1b TNM Finding | Lymph Node Stage pN1b | Node Stage pN1b | pN1b | pN1b Cancer Stage Finding | pN1b Lymph Node Finding | pN1b Lymph Node Stage | pN1b Node Finding | pN1b Node Stage | pN1b Regional Lymph Node Stage Finding | pN1b Regional Lymph Nodes Finding | pN1b Stage | pN1b Stage Finding | pN1b TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711118","pN1a Lymph Node Finding","C48747","A pathologic regional lymph node TNM finding. The definition of pN1a finding depends on the particular type of cancer that it refers to; for example, for breast cancer, pN1a finding is defined as follows: cancer with metastases in 1-3 axillary lymph nodes, at least one metastasis larger than 2.0 mm. (from AJCC 8th Ed.)","pN1a TNM Finding | Lymph Node Stage pN1a | Node Stage pN1a | pN1a | pN1a Cancer Stage Finding | pN1a Lymph Node Finding | pN1a Lymph Node Stage | pN1a Node Finding | pN1a Node Stage | pN1a Regional Lymph Node Stage Finding | pN1a Regional Lymph Nodes Finding | pN1a Stage | pN1a Stage Finding | pN1a TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700111","United States Military Cancer Institute","C79868","A tri-service program whose goal is to initiate, develop, coordinate and enhance multi-institutional cancer research, education and care within the military system.","United States Military Cancer Institute | USMCI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707007","Breast Cancer pN0 TNM Finding v6","C48991","Breast cancer without histological evidence of regional lymph node involvement (no isolated tumor cell cluster greater than 0.2mm), and in which no examination for isolated tumor cells is performed. (from AJCC 6th Ed.)","Breast Cancer pN0 TNM Finding v6 | Breast Cancer pN0 TNM Finding | pN0 Breast Cancer v6 | pN0 Breast Carcinoma v6 | pN0 Cancer of Breast v6 | pN0 Cancer of the Breast v6 | pN0 Carcinoma of Breast v6 | pN0 Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024884","Radical Mastectomy","C15279","The surgical removal of one or both breasts, including the areola, nipple, axillary lymph nodes, and pectoral muscles.","Radical Mastectomy | Halsted Radical Mastectomy | Halsted radical mastectomy | RADICAL MASTECTOMY | radical mastectomy",,,,,,,,,,,,,,,"4298492","Radical mastectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0184909","Wedge Excision","C51690","Surgical removal of a triangular wedge shaped section of tissue.","Wedge Excision | Wedge Resection | wedge resection",,,,,,,,,,,,,,,"4069074","Wedge resection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2699427","Conjunction","C79874","Something that joins or connects; the state of being joined together.","Conjunction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700580","Package","C79887","A product container with any accompanying materials or components.","Package | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698041","Member Organization","C79888","A grouping of individuals and functions into a single unit that is part of a larger group such as a cooperative group, research network, consortium, etc.","Member Organization | Member",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0680647","Jurisdiction","C79890","The territory within which power can be exercised.","Jurisdiction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699072","Reuse (action)","C79891","To use again.","Reuse | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699424","Concern","C79892","A matter of interest or importance.","Concern | Concerns",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700638","Transference (action)","C79893","The displacement of activities or cognitive content from one area to another.","Transference | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697811","Investigative Subject","C79916","An entity, either biologic or otherwise, of interest in an investigation.","Investigative Subject | Subject",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706092","Cap","C49861","A top (as for a bottle).","Cap Device | Cap | Cap Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0343386","Clostridium difficile Colitis","C35286","A bacterial infection of the colon secondary to infection with Clostridium difficile bacteria. This infection generally results from the loss of normal gut flora secondary to recent antibiotic use, and manifests as copious watery stools, with associated abdominal pain and myalgia. C. difficile is the most common cause of pseudomembranous colitis, and can progress to toxic megacolon if left untreated.","Clostridium difficile Colitis | C. diff Colitis | C.Difficile Colitis | Clostridium Difficile Colitis",,,,,,,,,,,,,,,"4307981","Clostridium difficile colitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021851","Large Intestine","C12379","A muscular tube that extends from the end of the small intestine to the anus.","Large Intestine | LARGE INTESTINE | Large Bowel | Large intestine | Structure of large intestine (body structure) | large intestine",,,,,,,,,,,,,"UBERON:0000059","large intestine","4033554","Structure of large intestine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017196","Gastrostomy","C52006","Creation of an opening between the stomach and the outside of the body.","Gastrostomy | Gastrostomy/fundoplication",,,,,,,,,,,,,,,"4204677","Gastrostomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522195","Drug Administration via Jejunostomy","C38202","Administration of a drug through a surgical opening between the jejunum and the surface of the abdominal wall.","Administration via Jejunostomy | J-Tube | Jejunostomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019270","Hernia","C34685","The protrusion of part of an organ or fibroadipose tissue through an abnormal opening.","Hernia | HERNIA | hernia",,,,,,,,,,,,,,,"4190388","Hernia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1374644","TTR protein, human","C79964","Transthyretin (147 aa, ~16 kDa) is encoded by the human TTR gene. This protein is involved in both the binding and transport of retinol and thyroxine.","Transthyretin | ATTR | Prealbumin | TBPA | TTR | Thyroxine-Binding Prealbumin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022377","Jejunostomy","C79978","Surgical creation of an external opening into the jejunum.","Jejunostomy | ",,,,,,,,,,,,,,,"4144714","Creation of jejunostomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034379","Quality of Health Care","C17046","The degree or grade of excellence with respect to medical services received by patients, administered by providers or programs, in terms of technical competence, need, appropriateness, acceptability, humanity and structure.","Quality of Care | QOC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0535872","IFNA2 protein, human","C26318","Interferon alpha-2 (188 aa, ~22 kDa) is encoded by the human IFNA2 gene. This protein is involved in antiviral defense, cell-cell signaling, and immune activation.","Interferon Alpha-2 | Alpha-2-Interferon | Alpha-2a Interferon | IFN-Alpha-2 | IFN-AlphaA | IFNA2 | IFNA2 Protein | Interferon Alpha 2 | Interferon Alpha 2 | Interferon Alpha 2a | Interferon Alpha 2b | Interferon Alpha A | Interferon Alpha-A | LeIF A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347858","Conservation","C71463","The maintenance of certain characteristics in an unchanged condition.","Conservation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521816","Cellular Morphology","C17768","Cellular morphology is the form and structure of cells, and its relation to cell function, or the scientific study thereof.","Cellular Morphology | CEMORPH | Cell Morphology | Morphology, Cellular",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1302742","Leiomyoma","C3157","A well-circumscribed benign smooth muscle neoplasm characterized by the presence of spindle cells with cigar-shaped nuclei, interlacing fascicles, and a whorled pattern.","Leiomyoma | Fibroid | Fibroid Neoplasm | Fibroid Tumor | LEIOMYOMA, BENIGN | Leiomyoma, NOS | Leiomyomatous Neoplasm | Leiomyomatous Tumor | fibroid | leiomyoma","8890/0","Leiomyoma, NOS",,,,,,,,,,,,,"37016195","Leiomyoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1519522","Tissue Microarray","C19922","A device for use in high-throughput molecular analysis/screening of clinical tissue specimens.  Tissue microarrays spatially arrange 500-1000 tumor biopsies or other tissue onto a microarray block, which is then sliced into sections for probing DNA, RNA or protein targets to provide coincident analysis of all specimens in the array.  Subsequent sections can be analyzed with additional probes.","Tissue Microarray | TMA | Tissue Arrays | Tissue Chip",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042133","Uterine Corpus Leiomyoma","C3434","A benign smooth muscle neoplasm arising from the body of the uterus. It is characterized by the presence of spindle cells with cigar-shaped nuclei, interlacing fascicles, and a whorled pattern.","Uterine Corpus Leiomyoma | Body of Uterus Fibroid | Body of Uterus Leiomyoma | Corpus Uteri Fibroid | Corpus Uteri Leiomyoma | Fibroid of Body of Uterus | Fibroid of Corpus Uteri | Fibroid of Uterine Body | Fibroid of Uterine Corpus | Fibroid of the Body of Uterus | Fibroid of the Corpus Uteri | Fibroid of the Uterine Body | Fibroid of the Uterine Corpus | Fibroid uterus | Fibromyoma | Leiomyofibroma | Leiomyoma of Body of Uterus | Leiomyoma of Corpus Uteri | Leiomyoma of Uterine Body | Leiomyoma of Uterine Corpus | Leiomyoma of the Body of Uterus | Leiomyoma of the Corpus Uteri | Leiomyoma of the Uterine Body | Leiomyoma of the Uterine Corpus | Uterine Body Fibroid | Uterine Body Leiomyoma | Uterine Corpus Fibroid | Uterine Corpus Leiomyomata | Uterine Fibroid | Uterine Fibroids",,,,,,,,,,,,,,,"197236","Uterine leiomyoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0281548","Intraperitoneal chemotherapy","C15581","The administration of pharmaceutical agents directly into the abdominal or peritoneal cavity. This technique is widely utilized for the chemotherapeutic treatment of advanced ovarian cancer.","Intraperitoneal Chemotherapy | Intraperitoneal Therapy | intraperitoneal chemotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0153467","Malignant Peritoneal Neoplasm","C3538","A primary or metastatic malignant neoplasm involving the peritoneum. Representative examples include carcinoma and malignant mesothelioma.","Malignant Peritoneal Neoplasm | Cancer of Peritoneum | Cancer of the Peritoneum | Malignant neoplasm of peritoneum, unspecified | Peritoneal Cancer | Peritoneal Cavity Cancer | peritoneal cancer",,,,,,,,,,,,,,,"443400","Malignant tumor of peritoneum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205699","Carcinomatosis","C3693","Carcinoma that has spread diffusely to an anatomic site or throughout the body.","Carcinomatosis | carcinomatosis | carcinosis","8010/9","Carcinomatosis",,,,,,,,,,,,,"4321558","Carcinomatosis",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C2697568","Health Assessment Questionnaire-II","C80074","A revised, shorter version of the Health Assessment Questionnaire used as a functional status measure for individuals with rheumatic diseases. Copyright 2004 American College of Rheumatology. (Arthritis Rheum. 2004;50:3296-305)","Health Assessment Questionnaire-II | HAQ-II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0200045","Pelvic Examination","C38104","A complete physical examination of a woman's external and internal reproductive organs by a health professional.","Pelvic Examination | Pelvic Exam | internal examination | pelvic examination",,,,,,,,,,,,,,,"4146053","Manual pelvic examination",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005695","Bladder Neoplasm","C2901","A benign or malignant, primary or metastatic neoplasm of the bladder.","Bladder Neoplasm | Bladder Tumor | Bladder Tumors | Neoplasm of Bladder | Neoplasm of Urinary Bladder | Neoplasm of the Bladder | Neoplasm of the Urinary Bladder | Tumor of Bladder | Tumor of Urinary Bladder | Tumor of the Bladder | Tumor of the Urinary Bladder | Urinary Bladder Neoplasm | Urinary Bladder Neoplasms | Urinary Bladder Tumor | Urinary Bladder Tumors",,,,,,,,,,,,,,,"200680","Neoplasm of bladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1881373","Levothyroxine","C62080","A synthetic levoisomer of thyroxine (T4), similar to the endogenous hormone produced by the thyroid gland. Thyroxine is de-iodinated to form triiodothyronine (T3) in the peripheral tissues. T3 enters the cell and binds to nuclear thyroid hormone receptors, and the hormone-receptor complex in turn triggers gene expression and produces proteins required in the regulation of cellular respiration, thermogenesis, cellular growth and differentiation, and metabolism of proteins, carbohydrates and lipids. T4 and T3 also possess cardiac stimulatory effect.","Levothyroxine | (-)-Thyroxine | L-Thyroxine | LEVOTHYROXINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698392","Binet Stage A","C80134","Patients have no anemia or thrombocytopenia and fewer than three areas of lymphoid involvement.","Binet Stage A | Binet Stage A
",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698393","Binet Stage B","C80135","Patients have no anemia or thrombocytopenia and three or more areas of lymphoid involvement.","Binet Stage B | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511118","Binet Staging System","C20114","A staging system for Chronic Lymphocytic Leukemia; it is based upon the presence or absence of anemia and/or thrombocytopenia, and involvement of lymphoid tissues, including splenic lymphoid tissue.","Binet Staging System | Binet Classification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698394","Binet Stage C","C80136","Patients have anemia and/or thrombocytopenia regardless of the number of areas of lymphoid involvement.","Binet Stage C | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697934","LogE","C79966","The log base E value of argument X.","LogE | Natural Logarithm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697616","Homology (attribute)","C79968","The quality of being similar or corresponding in position or value or structure or function.","Homology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201539","Alpha-fetoprotein Measurement","C74732","The determination of the amount of alpha-fetoprotein present in a sample.","Alpha-fetoprotein Measurement | AFP | AFP Level | Alpha Fetoprotein | Alpha-1-Fetoprotein | Alpha-1-Fetoprotein Measurement",,,,,,,,,,,,,,,"4197249","Alpha-1-Fetoprotein measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202035","Gamma Glutamyl Transpeptidase Measurement","C64847","A quantitative measurement of the amount of gamma glutamyl transpeptidase present in a sample.","Gamma Glutamyl Transpeptidase Measurement | GGT | GGTP | Gamma Glutamyl Transferase",,,,,,,,,,,,,,,"4289475","Gamma glutamyl transferase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0441683","Hormone Measurement","C74742","The determination of the amount of hormone present in a sample.","Hormone Measurement | ",,,,,,,,,,,,,,,"4045159","Hormone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4014985","Portal Vein Thrombosis","C78565","The formation of a blood clot (thrombus) in the portal vein.","Portal Vein Thrombosis | Portal vein thrombosis",,,,,,,,,,,,,,,"199837","Portal vein thrombosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039421","Technology","C17187","Technology is the discipline dealing with the art or science of applying scientific knowledge to practical problems.","Technology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697572","Heatmap","C78549","A graphical representation of data where the values taken by a variable in a two-dimensional map are represented as colors.","Heatmap | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699423","Conceptual Parent","C80013","Something from which one or more similar and separate things have developed, or to which they are attached.","Conceptual Parent | Parent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710091","Intergenic SNP","C45384","Single Nucleotide Polymorphism in Intergenic Sequences consists of a variation at an appreciable frequency between individuals of a single interbreeding population of a single nucleotide, due to base substitution, at an equivalent location within a DNA sequence of genetic material that lies between the boundaries of adjacent genes. SNPs occur, on average, once every 1000 bases and can be used in gene mapping and linkage analysis.","Intergenic SNP | Single Nucleotide Polymorphism in Intergenic Sequences",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711332","Splice Site SNP","C45574","An inherited single base substitution in a sequence of eukaryotic DNA located in either an acceptor (3' or downstream) or donor (5' or upstream) splice site of a gene. Functional single nucleotide polymorphisms in these intron-exon junctions can cause incorrect RNA splicing which, in turn, alters gene expression.","Splice Site SNP | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710978","3' Untranslated Region SNP","C45394","A 3' Untranslated Region SNP consists of a variation at an appreciable frequency between individuals of a single interbreeding population of a single nucleotide, due to base substitution, at an equivalent location within the sequence region at the 3' end of a messenger RNA (following the stop codon) that is not translated into protein and may contain transcription and translation regulating sequences.","3' Untranslated Region SNP | 3' UTR SNP | UTR, 3' SNP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711018","5' Untranslated Region SNP","C45393","A 5' Untranslated Region SNP consists of a variation at an appreciable frequency between individuals of a single interbreeding population of a single nucleotide, due to base substitution, at an equivalent location within the sequence region at the 5' end of a messenger RNA (preceding the initiation codon) that is not translated into protein and may contain the ribosome binding site and other transcription and translation regulating sequences.","5' Untranslated Region SNP | 5' UTR SNP | UTR, 5' SNP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206530","Germ-Line Mutation","C17666","Any mutation that appears in the gametes and which will therefore be transmitted to the progeny with some frequency.","Germline Variation | GERMLINE VARIATION | Germline Mutation | Germline Mutation | Germline Mutation Abnormality | Germline Variant | Hereditary Mutation | Simple Germline Variation | germline mutation | hereditary mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511326","Brief Pain Inventory","C18203","A tool for the assessment of pain in both clinical and research settings. The BPI uses simple numeric rating scales from 0 to 10 that are easy to understand and easy to translate into other languages. On the BPI, mild pain is defined as a worst pain score of 1 - 4, moderate pain is defined as a worst pain score of 5 - 6, and severe pain is defined as a worst pain score of 7-10.","Brief Pain Inventory | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042815","Visual Analog Pain Scale","C21120","A pain scale marked off like a ruler from 0 to 10 on which the patient marks the current level of pain experienced.","Visual Analog Pain Scale | Pain VAS | VAS | Visual Analog Scale | Visual Analogue Pain Scale | visual analog scale",,,,,,,,,,,,,,,"4165600","Visual analog pain scale",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0282425","News [Publication Type]","C80148","Recent information about specific and timely events.","News | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699011","Really Simple Syndication","C80149","Various XML file formats suitable for disseminating real-time information via subscription on the Internet.","Really Simple Syndication | RSS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698971","Cancer Data Standards Repository","C80150","A database and a set of APIs and tools used to create, edit, control, deploy and find common data elements (CDEs) for metadata consumers and for UML model development.","Cancer Data Standards Repository | caDSR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881481","Lung Cancer pT4 TNM Finding v6","C60971","Lung cancer with invasion of the mediastinum, heart, great vessels, trachea, esophagus, vertebral body or carina, or presence of separate tumor nodules within a same lobe, or the presence of a malignant pleural effusion. Although most pleural effusions associated with lung cancer are due to tumor, there are a few patients in whom multiple cytopathologic examinations of the pleural fluid are negative for tumor. In these cases, the fluid is non-bloody and is not an exudate. Such patients may be further evaluated with videothoracoscopy and direct pleural biopsy. When these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging element. (from AJCC 6th Ed.)","Lung Cancer pT4 TNM Finding v6 | Lung Cancer pT4 TNM Finding | pT4 Cancer of the Lung v6 | pT4 Carcinoma of the Lung v6 | pT4 Lung Cancer v6 | pT4 Lung Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1276439","Gleason Pattern 1","C28085","A pattern of prostate carcinoma characterized by the presence of a well circumscribed nodule of separate glands which are closely packed. There is no infiltration of the surrounding parenchyma. The epithelial polarity of the malignant cells is preserved and luminal differentiation is present in all glands.","Gleason Pattern 1 | Gleason Grade 1 | Pattern 1",,,,,,,,,,,,,,,"4241069","Gleason Pattern 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1276440","Gleason Pattern 2","C28086","A pattern of prostate carcinoma characterized by the presence of glands that are more loosely arranged and less uniform compared to Gleason pattern 1. Minimal invasion of the surrounding parenchyma may be present. The epithelial polarity of the malignant cells is preserved and luminal differentiation is present in all glands.","Gleason Pattern 2 | Gleason Grade 2 | Pattern 2",,,,,,,,,,,,,,,"4241296","Gleason Pattern 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1276441","Gleason Pattern 3","C28087","A pattern of prostate carcinoma characterized by the presence of glands that are infiltrative and vary in size and shape. The epithelial polarity of the malignant cells is preserved and luminal differentiation is present in all glands.","Gleason Pattern 3 | Gleason Grade 3 | Pattern 3",,,,,,,,,,,,,,,"4240572","Gleason Pattern 3",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332329","Gleason Pattern 4","C28088","A pattern of prostate carcinoma characterized by the presence of fused, cribriform, or poorly defined glands. There is partial loss of normal epithelial polarity.","Gleason Pattern 4 | Gleason Grade 4 | Pattern 4",,,,,,,,,,,,,,,"4240062","Gleason Pattern 4",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1276443","Gleason Pattern 5","C28089","A pattern of prostate carcinoma characterized by almost complete loss of epithelial polarity and luminal differentiation.","Gleason Pattern 5 | Gleason Grade 5 | Pattern 5",,,,,,,,,,,,,,,"4240573","Gleason Pattern 5",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1290407","Great Vessel Neoplasm","C5348","A neoplasm involving a great vessel.","Great Vessel Neoplasm | Great Vessel Tumor | Neoplasm of Great Vessel | Tumor of Great Vessel",,,,,,,,,,,,,,,"4131459","Neoplasm of great vessels",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4229115","Hyperbilirubinemia","C27088","Abnormally high level of bilirubin in the blood. Excess bilirubin is associated with jaundice.","Hyperbilirubinemia | Blood bilirubin increased | Elevated Bilirubin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518577","Surgical Oncologist","C17840","A doctor who specializes in surgical treatment of cancer.","Surgical Oncologist | Oncologic Surgeon | Oncologist, Surgical | surgeon, oncologic | surgical oncologist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278996","Malignant Head and Neck Neoplasm","C4013","A primary or metastatic malignant neoplasm affecting the head and neck.  Representative examples include oral cavity squamous cell carcinoma, laryngeal squamous cell carcinoma, and salivary gland carcinoma.","Malignant Head and Neck Neoplasm | Cancer of Head and Neck | Cancer of the Head and Neck | Head and Neck Cancer | Head and neck cancer, NOS | Malignant Head and Neck Tumor | Malignant Neoplasm of Head and Neck | Malignant Neoplasm of the Head and Neck | Malignant Tumor of Head and Neck | Malignant Tumor of the Head and Neck | Malignant neoplasm of head, face and neck | head and neck cancer",,,,,,,,,,,,,,,"4114222","Malignant tumor of head and neck",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205267","Intermittent","C71325","Periodically stopping and starting.","Intermittent | INTERMITTENT",,,,,,,,,,,,,,,"4321108","Intermittent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519810","Unresectable","C14151","Not capable of being removed by surgery.","Unresectable | No Resection | Non-Resectable | unresectable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518441","Nuclei, Structure/Function","C19401","A branch of cell biology concerned with the working of the nucleus at the microscopic and molecular level.","Nuclei, Structure/Function | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2145472","Urothelial Carcinoma","C4030","A carcinoma arising from the urothelial lining of the urinary tract (bladder, renal pelvis, ureter, or urethra).","Urothelial Carcinoma | Conventional Urothelial Carcinoma | Transitional Cell Carcinoma of the Urinary Tract | Transitional cell car. -uroth. | Transitional cell carcinoma of the urothelial tract | Uroepithelial Carcinoma | Urothelial carcinoma, NOS | Urothelial tract/bladder cancer, NOS | Urothelial/bladder cancer, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0836916","Abdominal Wall","C77608","The tissues that surround the organs that are present within the abdominal cavity. The abdominal wall tissue is composed of layers of fat, parietal peritoneum, fascia, and muscles.","Abdominal Wall | ABDOMINAL WALL | abdominal wall | abdominal wall proper | paries abdominalis | wall of abdomen | wall of abdomen proper",,,,,,,,,,,,,"UBERON:0003697","abdominal wall",,,,,,,,,,,,,,,"--"
"C1334983","Non-Invasive Lesion","C36027","A neoplastic process that is confined to the site of origin without morphologic evidence of cellular infiltration of the surrounding tissues.","Non-Invasive Lesion | Non-invasive Lesion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006625","Cachexia","C2913","A loss of body mass, fatigue, and weakness; it is often associated with chronic disease.","Cachexia | cachexia",,,,,,,,,,,,,,,"134765","Cachexia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039789","Bioequivalence","C71763","The absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study. Where there is an intentional difference in rate (e.g., in certain controlled release dosage forms), certain pharmaceutical equivalents or alternatives may be considered bioequivalent if there is no significant difference in the extent to which the active ingredient or moiety from each product becomes available at the site of drug action. This applies only if the difference in the rate at which the active ingredient or moiety becomes available at the site of drug action is intentional and is reflected in the proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug (21CFR320.1).","Bioequivalence | bioequivalence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013556","Economics","C61331","The branch of social science that deals with the production and distribution and consumption of goods and services and their management.","Economics | Economic | Economically",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0236075","Menopausal Symptom","C3852","Any of the mental or physical manifestations that accompany perimenopause and menopause.","Menopausal Symptom | Menopausal Symptoms",,,,,,,,,,,,,,,"4071683","Menopausal symptom",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0521440","Epigastric","C28026","A locational reference to the mid-upper abdominal area, specifically between the two costal margins and the subcostal plane.","Epigastric | epigastric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031149","Peritoneal Neoplasm","C3322","A benign or malignant neoplasm that affects the peritoneum.  Representative examples of benign neoplasms include adenomatoid tumor and disseminated peritoneal leiomyomatosis.  Representative examples of malignant neoplasms include primary peritoneal carcinoma, metastatic carcinoma to the peritoneum, and malignant mesothelioma.","Peritoneal Neoplasm | ",,,,,,,,,,,,,,,"4129887","Neoplasm of peritoneum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698333","Basic Local Alignment Search Tool","C80132","A sequence search method designed to find regions of similarity between biological sequences.","Basic Local Alignment Search Tool | BLAST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887622","Gap (space)","C80133","An open or empty space in or between things.","Gap | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205309","Known","C80137","Recognized, familiar, or within the scope of knowledge.","Known | Familiar",,,,,,,,,,,,,,,"4279378","Known",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448861","Until","C65136","Up to the point of some specific time or event.","Until | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL415192","Reference Range","C71474","A set of values of particular type of measurement that is used to interpret corresponding observation results.","Reference Range | Norm Range | Normal Ranges | Reference Ranges | normal range | reference interval | reference range | reference values",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012625","Disclosure","C51977","The making known of a fact that had previously been hidden; release of information.","Disclosure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026254","Mitomycins","C663","Any of a class of anti-tumor antibiotics acting as alkylating agents. All mitomycins have the backbone of methyl, aziridine, pyrrolo, indole, and dione moieties. Bioreductively activated mitomycin antibiotics generate oxygen radicals and alkylate DNA, forming inter-strand cross-links and inhibiting DNA synthesis.","Mitomycin Antineoplastic Antibiotic | mitomycin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699638","Statistical Imputation","C80304","The substitution of some value for a missing data point or a missing component of a data point.","Statistical Imputation | Imputation | Impute | Imputed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519805","University of Texas MD Anderson Cancer Center","C39557","The mission areas of the University of Texas MD Anderson Cancer Center include patient care, research, education, and prevention, with an emphasis on cancer control and prevention trials. It strives to rapidly translate scientific knowledge into better cancer therapies and prevention strategies. It was named an NCI-designated comprehensive cancer center in 1971.","University of Texas MD Anderson Cancer Center | MD Anderson Cancer Center | MDACC | University of Texas M D Anderson Cancer Center | University of Texas M D Anderson Cancer Center",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205163","Equality","C61582","The quality of being the same in quantity or measure or value or status.","Equality | EQ | Equal | Equal To | Equals",,,,,,,,,,,,,,,"4319898","Equal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017263","Gene Regulation Process","C21050","Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene expression at the level of transcription or translation.","Gene Regulation Process | Gene Expression Alteration | Gene Expression Regulation | Gene Regulation | Gene Regulation | Regulation of Gene Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698741","Participant Object","C79269","Something that takes part in an activity.","Participant Object | Participant | Participant Thing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700055","Family Collection","C79273","A collection of things sharing a common attribute.","Family Collection | Family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512095","Dynamic Enhanced CT","C19921","A type of computer tomography whereby a contrast medium is administered intravenously or orally prior to X-ray imaging.","Dynamic Enhanced CT | Contrast-Enhanced Spiral CT | Dynamic Contrast Enhanced CT | Dynamic Contrast Enhanced Computed Tomography | Dynamic Contrast Material Enhanced CT | Dynamic Enhanced Computed Tomography | Enhanced Spiral CT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698748","Patlak Plot","C80353","A graphical analysis technique based on a two compartment model that uses linear regression to identify and analyze pharmacokinetics problems involving irreversible uptake in one compartment.","Patlak Plot | Gjedde-Patlak Analysis | Gjedde-Patlak Plot | Patlak Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698452","Network Endpoint","C80357","An individual user device on a data communication network.","Network Endpoint | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699994","Endpoint Reference","C80358","A combination of Web service elements that define the address for a resource in a Simple Object Access Protocol (SOAP) header. It consists of a Uniform Resource Identifier (URI), message reference parameters, and data concerning the interface to be used.","Endpoint Reference | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0391970","Neuroendocrine Tumor G2","C72074","A well-differentiated, intermediate-grade epithelial neoplasm with neuroendocrine differentiation. It usually arises from the digestive system, lung, and head and neck.","Neuroendocrine Tumor G2 | Atypical Carcinoid Tumor | Atypical Carcinoid Tumor | Atypical carcinoid tumor | Carcinoid Tumor, Argentaffin, Malignant | Malignant Argentaffinoma | Malignant Carcinoid Tumor | Malignant carcinoid tumor of unspecified site | NET G2 | Neuroendocrine Tumor Grade 2",,,,,,,,,,,,,,,"4028881|40482859|608265","Atypical carcinoid tumor|Malignant carcinoid tumor|Malignant carcinoid tumor",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C0028165","Nitrogen Mustard Compound","C697","A mustard agent containing nitrogen and chlorine atoms.","Nitrogen Mustard Compound | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1540912","Idiopathic Hypereosinophilic Syndrome","C27038","A syndrome characterized by persistent eosinophilia, for which no underlying cause can be found, and which is associated with signs of organ involvement and dysfunction.  This term has often been applied to cases of chronic eosinophilic leukemia.  (WHO, 2001)","Idiopathic Hypereosinophilic Syndrome | Hyper Eosinophilic Syndrome | Hypereosinophilic Syndrome | Hypereosinophilic Syndrome | Hypereosinophilic syndrome | Hypereosinophilic syndrome [HES], unspecified | Idiopathic hypereosinophilic syndrome [HES] | iHES",,,,,,,,,,,,,,,"40571991|604216","Hypereosinophilic syndrome|Hypereosinophilic syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1882976","Sarcomatous Component Present","C54727","A histopathologic finding characterized by the presence of malignant cells of connective tissue origin in a tumor sample.  Examples of connective tissue cells that can undergo malignant transformation include smooth and skeletal muscle cells, adipose tissue cells, osteocytes, and chondrocytes.","Sarcomatous Component Present | Sarcomatous Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704216","Basaloid Carcinoma","C4121","A malignant epithelial neoplasm characterized by the presence of neoplastic cells with hyperchromatic nuclei, small amount of cytoplasm, and peripheral nuclear palisading.","Basaloid Carcinoma | Basaloid carcinoma","8123/3","Basaloid carcinoma",,,,,,,,,,,,,"4242267","Basaloid carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0184567","Acute Pain","C27003","A sensation of discomfort or distress that has a severe or rapid onset.","Acute Pain | acute pain",,,,,,,,,,,,,,,"433456","Acute pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0150055","Chronic Pain","C26940","Ongoing or recurrent pain that persists beyond that which is expected following acute injury, usually 3 months or more.","Chronic Pain | chronic pain",,,,,,,,,,,,,,,"436096","Chronic pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0278619","Extraosseous Plasmacytoma","C4002","A localized malignant neoplasm arising in an extraosseous site. It is composed of clonal (malignant) plasma cells forming a tumor mass. It most frequently involves the oropharynx, nasopharynx, sinuses, and larynx.","Extraosseous Plasmacytoma | Extramedullary Plasmacytoma | Extraosseous plasmacytoma | Plasmacytoma, extramedullary","9734/3","Plasmacytoma, extramedullary",,,,,,,,,,,,,"4028858|4094548","Plasmacytoma, extramedullary (not occurring in bone)|Extramedullary plasmacytoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1321878","Desmoplastic Infantile Ganglioglioma","C4738","A WHO grade I large cystic tumor that occurs almost exclusively in infants, with a prominent desmoplastic stroma having a neuroepithelial population of neoplastic astrocytes together with a variable neuronal component. It involves the superficial cerebral cortex and leptomeninges, and often attaches to the dura. Although clinically it presents as a large tumor, it generally has a good prognosis following surgical resection. (Adapted from WHO)","Desmoplastic Infantile Ganglioglioma | DIG | Desmoplastic infantile ganglioglioma",,,,,,,,,,,,,,,"4029035","Desmoplastic infantile astrocytoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1793002","Anagrelide Hydrochloride","C28826","The hydrochloride salt of a synthetic quinazoline derivative, Anagrelide Hydrochloride reduces platelet production through a decrease in megakaryocyte maturation. Anagrelide inhibits cyclic AMP phosphodiesterase, as well as ADP- and collagen-induced platelet aggregation. At therapeutic doses, it does not influence white cell counts or coagulation parameters. Anagrelide is used for treatment of essential thrombocythemia to reduce elevated platelet counts and the risk of thrombosis. (NCI04)","Anagrelide Hydrochloride Anhydrous | ANAGRELIDE HYDROCHLORIDE ANHYDROUS | Anagrelide Hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002844","Therapeutic Androgen","C243","A synthetic or animal-derived hormone that is chemically or functionally similar or identical to endogenous androgen with potential use in therapeutic applications.","Therapeutic Androgen | Androgens | androgen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206699","Mucinous Cystadenocarcinoma","C3776","An invasive adenocarcinoma characterized by cystic changes and the presence of malignant glandular cells which contain intracytoplasmic mucin. It may arise from the ovary, pancreas, appendix, and lung.","Mucinous Cystadenocarcinoma | Mucinous cystadenocarcinoma, NOS | Pseudomucinous Adenocarcinoma | Pseudomucinous Cystadenocarcinoma | Pseudomucinous adenocarcinoma","8470/3","Mucinous cystadenocarcinoma, NOS",,,,,,,,,,,,,"4193751","Mucinous cystadenocarcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0238462","Thyroid Gland Medullary Carcinoma","C3879","A neuroendocrine carcinoma arising from the C-cells of the thyroid gland. It is closely associated with multiple endocrine neoplasia syndromes. Approximately 10% to 20% of medullary thyroid carcinomas are familial. Patients usually present with a thyroid nodule that is painless and firm. In the majority of cases nodal involvement is present at diagnosis. Surgery is the preferred treatment for both primary lesions and recurrences. This carcinoma is generally not very sensitive to radiation and almost unresponsive to chemotherapy.","Thyroid Gland Medullary Carcinoma | C Cell Carcinoma | C cell carcinoma | C-Cell Carcinoma | CARCINOMA, C-CELL, MALIGNANT | MTC | Medullary Carcinoma | Medullary Carcinoma of Thyroid | Medullary Carcinoma of Thyroid Gland | Medullary Carcinoma of the Thyroid | Medullary Carcinoma of the Thyroid Gland | Medullary Thyroid Cancer | Medullary Thyroid Carcinoma | Medullary Thyroid Gland Carcinoma | Medullary thyroid carcinoma | Parafollicular Cell Carcinoma | Parafollicular cell carcinoma | Thyroid Gland Medullary Cancer | Thyroid Gland Neuroendocrine Carcinoma | Thyroid Medullary Carcinoma | medullary thyroid cancer",,,,,,,,,,,,,,,"37311897|4111011","Parafollicular cell carcinoma|Medullary thyroid carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0143630","Kit Ligand","C20440","Kit ligand (273 aa, ~31 kDa) is encoded by the human KITLG gene. This protein is involved in melanogenesis, hematopoiesis and mast cell development, migration and function.","Kit Ligand | C-Kit Ligand | KITLG | MGF | MGF Stem Cell Factor | Mast Cell Growth Factor | SCF | Steel Factor | Stem Cell Factor | kit ligand | stem cell factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519221","Secretory Cell","C13055","One of several types of cells that generate and secrete a substance to be used by the organism.","Secretory Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883696","Juvenile Lesion","C62226","A benign or malignant lesion typically arising in the period between infancy and adulthood.","Juvenile Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515963","Anaplastic Carcinoma Cell","C36848","A malignant epithelial cell, usually of large size, characterized by the lack of differentiation. Anaplastic carcinoma cells have large hyperchromatic nuclei and display marked variation in nuclear size and shape, and high mitotic rate. Atypical mitotic figures are often present.","Anaplastic Carcinoma Cell | Anaplastic Malignant Epithelial Cell | Pleomorphic Carcinoma Cell | Pleomorphic Malignant Epithelial Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1619629","Deferasirox","C48384","A synthetic, orally bioavailable, achiral, tridentate triazole derived from salicylic acid with iron-chelating activity. Deferasirox chelates iron at a 2:1 (ligand:iron) ratio. Because of its oral availability and long plasma half-life, this agent may be superior to desferrioxamine (desferal, DFO), which is orally inactive and has a short plasma half-life.","Deferasirox | 4-(3,5-Bis-(hydroxy-phenyl)-1,2,4-triazol-1-yl)-benzoic Acid | DEFERASIROX | Exjade | Jadenu | deferasirox",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011145","Deferoxamine","C416","An iron-chelating agent that binds free iron in a stable complex, preventing it from engaging in chemical reactions. Deferoxamine chelates iron from intra-lysosomal ferritin and siderin forming ferrioxamine, a water-soluble chelate excreted by the kidneys and in the feces via the bile.  This agent does not readily bind iron from transferrin, hemoglobin, myoglobin or cytochrome. (NCI04)","Deferoxamine | 1-Amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(n-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane | DEFEROXAMINE | DFO-B | Desferoxamine B | Desferrioxamine | Desferrioxamine B | N'-[5-[[4-[[5-(Acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxybutanediamide | N-[5-[3-[(5-Aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]propionohydroxamic Acid | deferoxamine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0771055","Melphalan Hydrochloride","C48002","A bifunctional alkylating agent and phenylalanine derivative of nitrogen mustard. Melphalan hydrochloride is converted into highly reactive ethylenimmonium intermediates that induce covalent guanine N7-N7 intra- and inter-crosslinks and alkylation of adenine N3 of DNA. This agent also alkylates RNA and protein structures. As a result RNA transcription and protein synthesis are inhibited, ultimately leading to cell growth arrest and/or death.","Melphalan Hydrochloride | 3-(p-(bis(2-chloroethyl)amino)phenyl)-L-Alanine, Hydrochloride | Alkeran | Alkerana | Evomela | Hepzato | MELPHALAN HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1318558","Congenital Melanocytic Nevus","C3944","A melanocytic nevus that is present at birth. It may present as a small macular, papular, or plaque-like lesion or as a large brown to black hairy skin lesion.","Congenital Melanocytic Nevus | CMN | Congenital Melanocytic Nevi | Congenital Melanocytic Nevus of Skin | Congenital Melanocytic Nevus of the Skin | Congenital Nevus of Skin | Congenital Nevus of the Skin | Congenital Pigmented Melanocytic Nevus | Congenital Pigmented Nevus of Skin | Congenital Pigmented Nevus of the Skin | Congenital Pigmented Skin Nevus | Congenital Skin Nevus",,,,,,,,,,,,,,,"4220346","Congenital pigmented melanocytic nevus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706828","Apocrine Cell","C43374","A glandular secreting cell in which the apical portion of the secreting cell is cast off along with the secretory products that have accumulated therein.","Apocrine Cell | Apocrine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1997894","Clinical Study Subject","C70668","A living person who is observed, analyzed, examined, investigated, experimented upon, and/or treated in the course of a clinical study.  This includes studies where an investigator obtains identifiable private information or data through the intervention or interaction with the individual.","Clinical Study Subject | Clinical Study Participant | Clinical Trial Participant | Clinical Trial Subject | clinical research subject",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0175168","Protein, Organized by Structure","C20028","Organizing term for the Proteins tree","Protein, Organized by Structure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017968","Glycoprotein","C16642","A conjugated protein having a carbohydrate component.","Glycoprotein | glycoprotein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334164","Immunoglobulin Family Protein","C28624","Encoded by Immunoglobulin Family Genes, structurally-related Immunoglobulin Family Proteins contain one, or more, 100-aa Immunoglobulin domain that includes a conserved intradomain disulfide bond and may be involved in protein-protein or protein-ligand interactions. Immunoglobulin Family members include hundreds of functionally diverse proteins, such as Immunoglobulins, the muscle kinase titin, and receptor tyrosine kinases. (NCI)","Immunoglobulin Family Protein | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023820","Lipoprotein","C20029","An important class of serum proteins in which a spherical hydrophobic core of triglycerides or cholesterol esters surrounded by an amphipathic monolayer of phospholipids, cholesterol and apolipoproteins. Classified according to density: chylomicrons, large low density particles, very low density, low density and high density species. Important in lipid transport, especially cholesterol transport in the blood stream. Abnormalities in lipoprotein metabolism have been implicated in certain heart diseases.","Lipoprotein | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025544","Metalloprotein","C16844","Proteins that include a metal ion as part of their structure or they contain a metal cofactor. The metal ion can be an isolated ion or coordinated with a nonprotein organic compound, such as the porphyrin moiety found in hemoproteins. Additionally, the metal can be co-coordinated with both a side chain of the protein and an inorganic nonmetallic ion.","Metalloprotein | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031689","Phosphoprotein","C16982","Proteins that contain phosphate groups esterified to serine, threonine or tyrosine. The phosphate group usually regulates protein function.","Phosphoprotein | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205909","Procarbazine Hydrochloride","C773","The hydrochloride salt of a methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.","Procarbazine Hydrochloride | Benzamide, N-(1-methylethyl)-4-[(2-methylhydrazino) methyl]-, monohydrochloride (9CI) | Ibenzmethyzine hydrochloride | MIH hydrochloride | Matulane | N-(1-methylethyl)-4-[(2-methylhydrazino)methyl]benzamide Hydrochloride | N-4-isopropylcarbamoylbenzyl-N'-methylhydrazine Hydrochloride | N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide Hydrochloride | NCI C01810 | NCI-C01810 | NCIC01810 | Natulan | Natulanar | Natunalar | PCB | PCB Hydrochloride | PCB hydrochloride | PCZ | PROCARBAZINE HYDROCHLORIDE | Ro 4 6467/1 | Ro 4-6467/1 | benzamide, N-(1-methylethyl)-4-[(2-methylhydrazino) methyl]-, monohydrochloride (9CI) | p-(N'-methylhydrazinomethyl)-N-isopropylbenzamide hydrochloride | p-Toluamide, N-isopropyl-.alpha.-(2-methylhydrazino)-, monohydrochloride (8CI) | p-toluamide, N-isopropyl-alpha-(2-methylhydrazino)-, monohydrochloride (8CI) | procarbazine hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0717668","Liposomal Daunorubicin Citrate","C2213","A liposome-encapsulated form of the citrate salt of the anthracycline antineoplastic antibiotic daunorubicin. Daunorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Liposomal delivery of doxorubicin citrate improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects.","Liposomal Daunorubicin Citrate | DaunoXome | Daunorubicin (Liposomal) | Daunorubicin Citrate Liposome Injection | Daunorubicin Liposomal | Daunorubicin liposomal | Liposomal Daunorubicin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0373607","Ferritin Measurement","C74737","The determination of the amount of ferritin present in a sample.","Ferritin Measurement | FERRITIN | Ferritin",,,,,,,,,,,,,,,"4176561","Ferritin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0700476","Goserelin Acetate","C1417","The acetate salt of a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH).  Continuous, prolonged administration of goserelin in males results in inhibition of pituitary gonadotropin secretion, leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. (NCI04)","Goserelin Acetate | D-Ser(bu(t))(6)azgly(10)-LHRH Acetate | GOSERELIN ACETATE | ZDX | Zoladex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0117339","Toremifene Citrate","C1756","The citrate salt of a nonsteroidal triphenylethylene antiestrogen.  Chemically related to tamoxifen, toremifene is a selective estrogen receptor modulator (SERM).  This agent binds competitively to estrogen receptors, thereby interfering with estrogen activity.  Toremifene also has intrinsic estrogenic properties, which is manifested depending on the tissue or species. (NCI04)","Toremifene Citrate | (Z)-2-[4-(4-Chloro-1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine 2-Hydroxy-1,2,3-propanetricarboxylate (1:1) | 2-(p-[(Z)-4-chloro-1,2-diphenyl-1-butenyl]-phenoxy)- N,N-dimethylethylamine citrate (1:1) | Acapodene | FC-1157a | Fareston | GTx-006 | TOREMIFENE CITRATE | Toremifene citrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825157","K3 Rate Constant","C80381","A rate constant used in a three compartment tracer uptake model to represent the transport from a tissue non-metabolized compartment to a metabolized state.","K3 Rate Constant | K3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596497","Elementary Schools","C80410","A school for young children; usually the first 6 or 8 grades.","Grade School | Elementary School",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883684","Gene Feature Physical Location","C54670","The physical location of a gene feature expressed as chromosome and start and end base positions.","Gene Feature Physical Location | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524899","Penetrance","C48667","The degree or probability to which a genotype is expressed as a phenotype.","Penetrance | Genetic Penetrance | penetrance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825164","Study Site","C80403","A facility in which study/protocol activities are conducted.","Study Site | INVESTIGATOR SITE | Investigative Site | Investigator Site | Site | StudySite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825181","Study Coordinating Center","C80431","A consortium, network, or professional organization or group that manages four specific responsibilities in connection with a study (protocol): study protocol concerns, registration of subjects, statistics, and study data.","Study Coordinating Center | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036025","Saccharomyces cerevisiae","C14271","A species of unicellular fungus used as a research subject and in baking and beer brewing.","Saccharomyces cerevisiae | Bakers Yeast | Brewers Yeast | S. capensis | S. cerevisiae | S. italicus | S. oviformis | S. uvarum var. melibiosus | SACCHAROMYCES CEREVISIAE | Saccharomyces capensis | Saccharomyces italicus | Saccharomyces oviformis | Saccharomyces uvarum var. melibiosus",,,,,,,,,,,,,,,"4240960","Saccharomyces cerevisiae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1504917","Lapatinib Ditosylate","C66878","The ditosylate salt of lapatinib, a synthetic, orally-active quinazoline with potential antineoplastic activity. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.","Lapatinib Ditosylate | 4-Quinazolinamine, N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl), bis(4-methylbenzenesulfonate), Monohydrate | LAPATINIB DITOSYLATE | Tykerb | lapatinib ditosylate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1176020","Sunitinib","C71622","An indolinone derivative and tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.  This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.","Sunitinib | 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl- | SUNITINIB | sunitinib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042671","Vinblastine Sulfate","C931","The sulfate salt of vinblastine, a natural alkaloid isolated from the plant Catharanthus roseus (Madagascar periwinkle) with antineoplastic properties.  Vinblastine disrupts microtubule formation and function during mitosis and interferes with glutamic acid metabolism. (NCI04)","Vinblastine Sulfate | 29060 LE | 29060-LE | Exal | VINBLASTINE SULFATE | VINCALEUKOBLASTINE | Velban | Velbe | Velsar | vinblastine sulfate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0377401","Vinorelbine Tartrate","C1395","The ditartrate salt of a semisynthetic vinca alkaloid derived from the leaves of the periwinkle plant (Vinca rosea) with antineoplastic properties.  Vinorelbine binds to tubulin, thereby inhibiting tubulin polymerization into microtubules and spindle formation and resulting in apoptosis of susceptible cancer cells. Inhibition of mitotic microtubules correlates with antitumor activity, whereas inhibition of axonal microtubules seems to correlate with vinorelbine's neurotoxicity. Compared to related vinca alkaloids, vinorelbine is more selective against mitotic than axonal microtubules in vitro, which may account for its decreased neurotoxicity.  This agent is also a radiation-sensitizing agent. (NCI04)","Vinorelbine Tartrate | Biovelbin | Eunades | KW 2307 | KW-2307 | KW2307 | NVB | Navelbine | Navelbine Ditartrate | Navelbine ditartrate | VINORELBINE TARTRATE | Vinorelbine Ditartrate | vinorelbine tartrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035201","Resources","C15321","The funding, research facilities, and materials available for research","Research Resource | Resource | Resources",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018104","Government","C78315","The political organization by which a nation, stateor region is ruled.","Government | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018173","funding grant","C16644","A financial assistance mechanism through which money and/or direct assistance is provided to carry out approved activities.","Grant | Grants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1947943","Supplement (document)","C60763","Textual matter that is added onto a publication or document, usually at the end; a section added to a book or document to give further information or to correct errors.","Supplement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2949735","Recruitment","C78343","The process of enrolling, enlisting, or adding individuals to a group.","Recruitment | recruitment (subjects)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0851285","Regulation","C68821","A rule or order issued by an authority stating what may or may not be done or how something must be done.","Regulation | Regulated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0870077","Rule (guideline)","C78269","A prescribed guide for conduct or action.","Rule | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347650","Potential Study Subject","C70678","A living individual who, due to the possession of one or more characteristics such e.g. as a particular medical condition specific to the study, is pre-qualified as a prospective study subject. A potential subject becomes eligible for the clinical study if he meets the study protocol eligibility criteria and voluntarily gives a legally effective informed consent to participate in the study (except when a waiver for informed consent is granted under FDA and OHRP guidelines).","Potential Study Subject | Potential Clinical Study Participant | Potential Clinical Study Subject | Potential Clinical Trial Participant | Potential Human Clinical Study Subject | Potential Study Participant | Potential Subject",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016617","Foundation","C78335","An institution supported by an endowment.","Foundation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1261210","Reproductive System","C12841","The organs and tissues involved in the production and maturation of gametes and in their union and subsequent development as offspring.","Reproductive System | Genital tract | Reproductive Body System | Reproductive Organ System | Reproductive Tract | reproductive system",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699022","Registration Authority","C74932","An organization authorized to register a registry item.","Registration Authority | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513822","Consortium or Network","C19975","Groups of scientists who link their expertise and resources in collaborative efforts to address important questions of shared interest.","Consortium or Network | Centers, Networks, and Consortia | Consortium | NCI Consortium or Network | Network",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347952","Report Nullification","C68625","Action(s) undertaken to indicate that a previously transmitted report should be considered completely void (nullified).","Report Nullification | Nullification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709630","Preclinical","C48674","Refers to in vitro testing or in vivo animal testing before clinical trials in humans are to be carried out.","Preclinical | Pre-clinical",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0599437","Authority","C79889","A person or group with the power or right to give orders or make decisions for a particular area of activity.","Authority | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0870909","Money","C78415","The official currency issued by a government or national bank.","Money | Currency | Monetary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711371","Reprocess","C51989","To put a material that has been used through a process so that it can be used again.","Reprocess | Reprocessed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707708","Device Labeled for Single Use","C53602","A device that is intended for one use, or on a single patient during a single procedure (Title 21 Chapter 9 Federal Food, Drug and Cosmetic Act).","Device Labeled for Single Use | DEVICE LABELED FOR SINGLE USE | Single-Use Device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448347","Intervention Trial","C16140","A pre-clinical or clinical study in human beings in which individuals are assigned by an investigator based on a protocol to receive specific interventions. The individuals are then followed and biomedical and/or health outcomes are assessed.","Intervention Trial | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697520","Grandfather Clause","C78445","An exemption based on circumstances existing prior to the adoption of some policy.","Grandfather Clause | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1947919","Application (Document)","C60755","A written request for something, such as assistance, employment, or admission to a school.","Application | Application Document | Application Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349109","Variance Reason","C71479","A cause of a difference between what is expected and what actually occurs, or a cause of an activity that varies from a norm or standard.","Variance Reason | Reason for Variance | varianceReason",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699414","Study Related Committee","C78508","A group delegated to consider matters concerning clinical studies or trials.","Study Related Committee | Committee",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036397","Science","C61397","The intellectual and practical activity encompassing the systematic study of the structure and behaviour of the physical and natural world through observation and experiment.","Science | Scientific",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018017","Objective","C49155","A goal or aim to be accomplished or attained.","Objective | ",,,,,,,,,,,,,,,"4253630","Goal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698914","Pseudomonas Exotoxin Immunoconjugate","C78532","An immunotoxin containing epitope of Pseudomonas exotoxin (PE) with immunotherapeutic property. PE, a peptide toxin of 613 amino acids, consists of 3 functional domains: an amino-terminal receptor-binding domain, a middle translocation domain, and a carboxyl-terminal ADP-ribosylation domain. The last 5 carboxyl-terminal amino acids, Arg-Glu-Asp-Leu-Lys, are critical for its cytotoxic action.","Pseudomonas Exotoxin Immunoconjugate | Cosmetic | PE Immunoconjugate | Pseudomonas aeruginosa Exotoxin A Conjugate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003292","Antidiarrheal Agent","C266","A pharmacological agent that may ameliorate the symptoms of diarrhetic illnesses.","Antidiarrheal Agent | Antidiarrhea Agents | Antidiarrhea Drugs | Antidiarrheal Drugs | Antidiarrheals | Antidiarrheas | antidiarrheal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010934","Dactinomycin","C412","A chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces parvulus.  Dactinomycin intercalates between adjacent guanine-cytosine base pairs, blocking the transcription of DNA by RNA polymerase; it also causes single-strand DNA breaks, possibly via a free-radical intermediate or an interaction with topoisomerase II. (NCI04)","Dactinomycin | 2-bis[Cyclo(N-methyl-L-valyl-sarcosyl-L-prolyl-D-valyl-L-threonyl)]-1,9 dimethyl-4,6 3H-phenoxazinone-3 | ACTINOMYCIN D | Actinomycin A IV | Actinomycin C1 | Actinomycin D | Actinomycin I1 | Actinomycin IV | Actinomycin X 1 | Actinomycin-[thr-val-pro-sar-meval] | Cosmegen | DACT | DACTINOMYCIN | Dactinomycine | Lyovac Cosmegen | Lyovac cosmegen | Meractinomycin | dactinomycin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026727","Mucus","C13259","The thick fluid secreted by the mucus glands in the aerodigestive tract and the vagina.","Mucus | MUCUS | mucus",,,,,,,,,,,,,,,"4172465","Mucus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0239043","Chewing Difficulty","C50492","Pain or discomfort with mastication, a symptom of underlying disease. Causes can include problems with the teeth, jaws or temporomandibular joint, mumps, cancer, or a neuromuscular disorder.","Chewing Difficulty | Difficulty Chewing",,,,,,,,,,,,,,,"4012491","Difficulty chewing",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008301","Choking","C50494","Interference with respiration by compression or obstruction of the larynx or trachea.","Choking | ",,,,,,,,,,,,,,,"4096712","Choking",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085624","Burning Sensation","C50476","A sensation of stinging or heat, not necessarily accompanied by redness or physical signs of irritation.","Burning Sensation | ",,,,,,,,,,,,,,,"4235891","Burning sensation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035339","Retinoic Acid Agent","C804","A group of agents that includes retinol (Vitamin A) and related compounds with potential antineoplastic and/or chemopreventive activities.  A retinoic acid agent binds to and/or activates specific nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs), thereby modulating transcription of genes responsible for cell differentiation and proliferation.  A retinoic acid agent may exhibit immunomodulatory and anti-inflammatory properties and may inhibit ornithine decarboxylase, resulting in a decrease in polyamine synthesis and keratinization. (NCI04)","Retinoic Acid Agent | Retinoic Acid and Derivatives | Retinoic Acids | Retinoid | Retinoids | retinoid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0149745","Mouth Sore","C27157","An inflammatory lesion on the mucosal surface of the oral cavity.","Mouth Sore | Mouth Ulcer",,,,,,,,,,,,,,,"4094986","Ulcer of mouth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016343","Floxuridine","C504","A fluorinated pyrimidine monophosphate analogue of 5-fluoro-2'-deoxyuridine-5'-phosphate (FUDR-MP) with antineoplastic activity. As an antimetabolite, floxuridine inhibits thymidylate synthase, resulting in disruption of DNA synthesis and cytotoxicity. This agent is also metabolized to fluorouracil and other metabolites that can be incorporated into RNA and inhibit the utilization of preformed uracil in RNA synthesis. (NCI04)","Floxuridine | 1-(2-Deoxy-beta-D-ribofuranosyl)-5-fluorouracil | 2'-Deoxy-5-fluorouridine | 2-Deoxy-5-fluorouridine | 5-FUDR | 5-FUdR | 5-Fluoro-2'-deoxy-beta-uridine | 5-Fluoro-2'-deoxyuridine | 5-Fluorodeoxyuridine | 5-Fluorouracil Deoxyriboside | 5-Fluorouracil deoxyriboside | 5-Fluorouridine Deoxyribose | FDUR | FLOXURIDINE | FUDR | FUdR | Floxuridin | Fluorodeoxyuridine | Fluorouridine Deoxyribose | Fluoruridine Deoxyribose | Fluoruridine deoxyribose | WR 138720 | WR-138720 | WR138720 | floxuridine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1275732","Subcutaneous Port","C17630","A tube surgically placed into a blood vessel and attached to a disk placed under the skin. It is used for the administration of intravenous fluids and drugs; it can also be used to obtain blood samples.","Subcutaneous Port | subcutaneous port",,,,,,,,,,,,,,,"4134858","Implantable venous access port",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517598","Iron Chelation","C40516","Iron Chelation involves non-covalent coordination bonding between iron and an organic chemical, often as part of an enzyme or protein complex, as in the iron-binding porphyrin group of hemoglobin.","Iron Chelation | Iron Chelating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0216231","Sargramostim","C1492","A recombinant therapeutic agent chemically identical to endogenous human GM-CSF except a leucine substitution in position 23.  Binding to specific cell surface receptors, sargramostim modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production and may reverse treatment-induced neutropenias. This agent also promotes antigen presentation, up-regulates antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function; it may also augment host antitumoral immunity.","Sargramostim | 23-L-Leucinecolony-Stimulating Factor 2 | DRG-0012 | Leukine | Prokine | SARGRAMOSTIM | Sagramostim | Sargramostatin | rhu GM-CFS | sargramostim",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0241157","Pustular Lesion","C78582","A circumscribed and elevated skin lesion filled with purulent material.","Pustular Lesion | PUSTULE | Pustule",,,,,,,,,,,,,,,"4158333|4264772","Pustule|Pustule",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0225778","Pleural Fluid","C77613","The fluid that is ordinarily present in the pleural space. It allows for normal movement of the lungs during respiration.","Pleural Fluid | FLUID, PLEURAL | PLEURAL FLUID | Pleural fluid (thoracentesis fluid)",,,,,,,,,,,,,,,"4100638","Pleural fluid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0178802","Pleural Cavity","C12840","The potential space between parietal and visceral pleurae. There is a separate pleural cavity for each lung.","Pleural Cavity | BODY CAVITY, PLEURAL | PLEURAL CAVITY | Pleural Space | pleural cavity",,,,,,,,,,,,,,,"4237074","Pleural cavity structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025285","Meninges","C12348","Any one of three membranes that surround the brain and spinal cord.","Meninges | MENINGES | Meninges, NOS | meningeal cluster | meninges",,,,,,,,,,,,,,,"4048507","Meninges structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023067","Laryngitis","C26811","An acute or chronic, bacterial or viral inflammatory process affecting the larynx. Signs and symptoms include sore throat, cough, swallowing difficulties, and hoarseness.","Laryngitis | Laryngeal Inflammation | Laryngeal inflammation | laryngitis",,,,,,,,,,,,,,,"24969","Laryngitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205221","Disseminate","C28222","To scatter widely; spread.","Disseminate | Disseminated | Dissemination | disseminate",,,,,,,,,,,,,,,"4277758","Disseminated",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027061","Myocardium","C12371","The striated muscle tissue of the heart enveloped by the epicardium and the endocardium.","Myocardium | CARDIAC MUSCLE TISSUE | Cardiac Muscle | Heart Muscle | MYOCARDIUM | Myocardial Tissue",,,,,,,,,,,,,,,"4253786","Myocardium structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0282399","Ganciclovir Sodium","C1588","The sodium salt form of ganciclovir, a synthetic, antiviral, purine nucleoside analog with antiviral activity, especially against cytomegalovirus (CMV). Ganciclovir sodium is a prodrug that is phosphorylated and subsequently converted into its triphosphate form, the active metabolite ganciclovir-5-triphosphate (ganciclovir-TP), in the infected cells by cellular kinases. Ganciclovir-TP competes as a substrate with nucleotide triphosphates for viral DNA polymerase. Once it gets incorporated into DNA strand, it prevents further polymerization of DNA, thereby interfering with viral DNA replication.","Ganciclovir Sodium | 9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine, Monosodium Salt | BIOLF-62 | BW-759 | BW-759U | Cymevene | Cytovene | Cytovene-IV | DHPG Sodium | DHPG sodium | Denosine | GANCICLOVIR SODIUM | GCV Sodium | GCV sodium | Ganciclovir sodium | RS-21592 Sodium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085297","Immunoglobulins, Intravenous","C2701","A preparation of plasma proteins derived from the pooled plasma of adult donors. Largely comprised of IgG antibodies, therapeutic immune globulin provides passive immunization by increasing the recipient's serum levels of circulating antibodies. IgG antibodies have multiple functions, including binding to and neutralizing bacterial toxins; opsonization of pathogens; activation of complement; and suppression of pathogenic cytokines and phagocytes through binding to CD5, interleukin-1a (IL-1a), interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and T-cell receptors. Therapeutic immune globulin may diminish pathogenic mechanisms in some autoimmune diseases by binding to and inhibiting the activity of autoantibodies. (NCI04)","Therapeutic Immune Globulin | BayGam | Gamimune N | Gamma Globulin | Gammagard S/D | Gammar-P | IgIV | Immune Globulin | Immune Globulin IV | Immune Globulin Intravenous | Iveegam EN | Panglobulin | Panzyga | Polygam S/D | Sandoglobulin | Therapeutic Immunoglobulin | Venoglobulin-I | Venoglobulin-S | WinRho SDF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0587178","Antinuclear Antibody Measurement","C74916","The determination of the amount of antinuclear antibodies present in a sample.","Antinuclear Antibody Measurement | ANA | Antinuclear Antibodies",,,,,,,,,,,,,,,"4234268","ANA measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825310","Mixin","C80695","A class that provides a certain functionality to be inherited by a subclass, but is not meant to stand alone.","Mixin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825311","XML Bound","C80696","Indicates that information in an XML document is represented as an object in computer memory.","XML Bound | Bound",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433119","KIT Oncogene","C18348","Cloned cancer gene for Familial gastrointestinal stromal tumors (GIST), KIT proto-oncogene encodes a putative transmembrane receptor tyrosine kinase for stem cell factor and is critical in the development of pluripotent hematopoietic stem cells, migrating embryonic melanoblasts, and primordial germ cells.  The human proto-oncogene is located at 4q12.","Oncogene KIT | Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog | KIT | PBT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1176468","Erythrocyte Sedimentation Rate Measurement","C74611","A quantitative measurement of the distance that red blood cells travel in one hour in a sample of unclotted blood.","Erythrocyte Sedimentation Rate Measurement | Biernacki Reaction | ESR | Erythrocyte Sedimentation Rate | Erythrocyte sedimentation rate (ESR) | Sed Rate | erythrocyte sedimentation rate | sedimentation rate",,,,,,,,,,,,,,,"4212065","Erythrocyte sedimentation rate measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022457","Oncogene K-Ras","C16766","Human Oncogene K-Ras is a mutated variant of KRAS2 Gene, which encodes two alternative isoforms of monomeric p21 K-RAS protein, a monomeric GTPase involved in transmembrane signal transduction that alternates between inactive GDP-bound and active GTP-bound forms. K-Ras is activated by a guanine nucleotide-exchange factor and inactivated by a GTPase-activating protein. Mitogen-stimulated RAS stabilizes MYC protein and enhances MYC accumulation by the RAS/RAF/MAPK pathway, which appears to inhibit the proteasome-dependent degradation of MYC. Implicated in a variety of human tumors, mutations of specific amino acids activate RAS to transform cells. KRAS is involved in malignancy much more often than is HRAS. Oncogene K-Ras disrupts normal cell function.","Oncogene K-Ras | KRAS | KRAS2 | Ki-RAS | Oncogene, K-Ras | Oncogene, K-Ras-2 | RASK2 | v-Ki-RAS2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4043049","TYMS protein, human","C17199","Thymidylate synthetase protein (312 aa, ~36 kDa) is encoded by the human TYMS gene. The protein is a conserved transferase enzyme that catalyzes methylene tetrahydrofolate (MTHF)/dUMP conversion to dihydrofolate/dTMP in thymidine triphosphate/deoxyribonucleotide biosynthesis. Thymidylate synthetase competes with the methylene tetrahydrofolate receptor for MTHF and maintains the dTMP pool for DNA replication and repair.","Thymidylate Synthase | EC 2.1.1.45 | TMP synthetase | TYMS | Thymidylate Synthetase | dTMP Synthase | thymidylate synthase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035448","Rheumatoid Factor","C805","Antibodies in the serum of individuals with rheumatoid arthritis that react with antigenic determinants or immunoglobulins that enhance agglutination of suspended particles coated with pooled human gamma-globulin. Rheumatoid factors also occur in other autoimmune and certain infectious diseases.","Rheumatoid Factor | RA Factor | RF",,,,,,,,,,,,,,,"4299364","Rheumatoid factor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009375","Colon Neoplasm","C2953","A benign or malignant neoplasm that affects the colon.  Representative examples of benign neoplasms include lipoma and leiomyoma.  Representative examples of malignant neoplasms include carcinoma, lymphoma, and sarcoma.  Colonic adenomas always exhibit epithelial dysplasia and are considered premalignant neoplasms.","Colon Neoplasm | Colon Tumor | Colonic Neoplasm | Colonic Tumor | Neoplasm of Colon | Neoplasm of the Colon | Tumor of Colon | Tumor of the Colon",,,,,,,,,,,,,,,"4130995","Neoplasm of colon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0432516","Ann Arbor Lymphoma Staging System","C54179","The Ann Arbor system classifies lymphoma into four stages based on anatomic lymph nodal group involvement. Disease confined to one nodal group or location defines stage I. Disease limited to one side of the diaphragm, (the muscle separating the chest from the abdomen), defines stage II. Stage III patients have disease on both sides of the diaphragm and stage IV patients once again have disseminated disease. Consideration of involvement of the liver, spleen, and bone marrow are also considered in this system. Finally, the stage is subdivided into categories of A and B depending on the presence of symptoms of itching, weight loss, fever, and night sweats. Those having symptoms receive the designation 'B' and have a worse prognosis.","Ann Arbor Lymphoma Staging System | Ann Arbor | Ann Arbor Staging System",,,,,,,,,,,,,,,"4115000","Ann Arbor lymphoma staging system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0432611","Band Cell","C13117","A late precursor of a granulocyte in which the nucleus is in the form of a curved or coiled band, not having acquired the typical multilobar shape of the mature polymorphonuclear neutrophil.","Band Cell | ",,,,,,,,,,,,,,,"45765692","Band neutrophil",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0229640","Segmented Neutrophil","C36719","A mature neutrophil with a nucleus having distinct lobes connected by filaments.","Segmented Neutrophil | ",,,,,,,,,,,,,,,"4198194","Segmented neutrophil",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0595806","Administration via Gastrostomy","C38199","Drug administration through a gastric fistula or a surgically created artificial opening into the stomach through the abdominal wall with insertion of a tube.","Administration via Gastrostomy | G-TUBE | Gastrostomy",,,,,,,,,,,,,,,"4132254","Gastrostomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0230259","Greater Omentum","C32697","A large fold of peritoneum that hangs down from the stomach, and extends from the stomach to the posterior abdominal wall after associating with the transverse colon.","Greater Omentum | Gastro-Colic Omentum",,,,,,,,,,,,,,,"4149520","Greater omentum structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0230260","Lesser Omentum","C32981","The double layer of peritoneum that extends from the lesser curvature of the stomach and the start of the duodenum to the liver.","Lesser Omentum | Gastro-Hepatic Omentum",,,,,,,,,,,,,,,"4269489","Lesser omentum structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227188","Thoracic Esophagus","C12251","Clinical esophageal segment composed of smooth muscle. It includes the middle third topographic segment, as well as parts of the upper and lower thirds.","Thoracic Esophagus | ESOPHAGUS, THORACIC | Thoracic esophagus | thoracic part of esophagus",,,,,,,,,,,,,,,"4245159","Thoracic esophagus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825406","Quarter","C81008","One of four equal parts; a quantity corresponding to one fourth of the whole.","Quarter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825408","Stair (equipment)","C81011","A support consisting of a place to rest the foot while ascending or descending a stairway.","Stair | Step",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2584300","Climbing","C81002","The act of rising to a higher point.","Climbing | Climb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1830710","Stooping","C81003","The act of bending one's back forward from the waist on down.","Stooping | Leaning Forward | Leaning forward | Stoop",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2584321","Reaching","C81004","The act of stretching out your arm in order to get or touch something.","Reaching | Reach",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206243","Carrying","C81005","The act of moving while supporting something in one's hands or on one's body.","Carrying | Carry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0150768","Shopping","C81006","The act of searching for or buying goods or services.","Shopping | Shop",,,,,,,,,,,,,,,"4043520","Shopping",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2371613","Socializing","C81007","Interactions with one or more individuals, usually with a common purpose or with regards to a common topic of interest.","Socializing | Social Activities | Social Activity | Socialize",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448864","Push","C65061","The act of applying force in order to move something away.","Push | Pushing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230212","Omental Bursa","C81014","A portion of the peritoneal cavity formed by the greater and lesser omentum. It is located posteriorly to the stomach and extends into the greater omentum.","Omental Bursa | ",,,,,,,,,,,,,,,"4034055","Omental bursa structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516366","Cellular Compartment Analysis","C20062","Cell partitioning techniques used to determine the subcellular distribution of molecules of interest.","Cellular Compartment Analysis | Cell Compartment Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1948059","Constant","C64638","Continually recurring or continuing without interruption.","Constant | Constantly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825410","Copy Number Analysis Tool","C81017","A software application that performs copy number and loss of heterozygosity (LOH) analysis on data from Affymetrix mapping genotyping microarrays.","Copy Number Analysis Tool | CNAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825411","Hidden Markov Model Forward Algorithm","C81018","A Hidden Markov Model algorithm that calculates recursively forward along the observation sequence.","Hidden Markov Model Forward Algorithm | HMM Forward-only",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825412","Paired Data","C81019","Data obtained from observations where there is a natural link between an observation in one set of measurements and a particular observation in the other set of measurements.","Paired Data | Paired Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825413","Unpaired Data","C81020","Data obtained from observations where there is a no link between an observation in one set of measurements and a particular observation in the other set of measurements.","Unpaired Data | Unpaired Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825414","CNAT Probe Normalization Method","C81021","A method for performing probe-level normalization of signal intensity to generate summaries file using CNAT method.","CNAT Probe Normalization Method | Probe Normalization Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825415","Negative Number","C81022","A quantity having a value less than zero.","Negative Number | Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825416","Sigma Multiplier","C81023","A tunable Gaussian-smoothing variable for smoothing of copy number data.","Sigma Multiplier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010467","Curcumin","C401","A phytopolylphenol pigment isolated from the plant Curcuma longa, commonly known as turmeric, with a variety of pharmacologic properties.  Curcumin blocks the formation of reactive-oxygen species, possesses anti-inflammatory properties as a result of inhibition of cyclooxygenases (COX) and other enzymes involved in inflammation; and disrupts cell signal transduction by various mechanisms including inhibition of protein kinase C.  These effects may play a role in the agent's observed antineoplastic properties, which include inhibition of tumor cell proliferation and suppression of chemically induced carcinogenesis and tumor growth in animal models of cancer. (NCI04)","Curcumin | (E,E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione | C.I. 75300 | C.I. Natural Yellow 3 | CURCUMIN | Diferuloylmethane | Turmeric Yellow | curcumin",,,,,,,,,,,,,,,"4231130","Curcumin stain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0549183","Midline","C81170","A medial line, especially the medial line or medial plane of the body (or some part of the body).","Midline | MIDLINE | Mesial | Midline (qualifier value) | Midplane",,,,,,,,,,,,,,,"4161551","Midline",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205203","Cross","C81171","Travel across or pass over.","Cross | Across | Traverse",,,,,,,,,,,,,,,"4276954","Crossed",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021270","Infant","C27956","An age group comprised of individuals between one month and two years of age.","Infant | INFANT",,,,,,,,,,,,,,,"4305451","Infant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1336118","Stage IA Lung Cancer AJCC v7","C5642","Stage IA includes: (T1a, N0, M0); (T1b, N0, M0).  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IA Lung Cancer AJCC v7 | Stage IA Carcinoma of Lung | Stage IA Carcinoma of the Lung | Stage IA Lung Cancer | Stage IA Lung Carcinoma | Stage IA Lung Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336138","Stage IB Lung Cancer AJCC v7","C5643","Stage IB includes: T2a, N0, M0.  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IB Lung Cancer AJCC v7 | Stage IB Carcinoma of Lung | Stage IB Carcinoma of the Lung | Stage IB Lung Cancer | Stage IB Lung Carcinoma | Stage IB Lung Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336164","Stage IIA Lung Cancer AJCC v7","C5644","Stage IIA includes: (T2b, N0, M0); (T1a, N1, M0); (T1b, N1, M0); (T2a, N1, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)","Stage IIA Lung Cancer AJCC v7 | Stage IIA Carcinoma of Lung | Stage IIA Carcinoma of the Lung | Stage IIA Lung Cancer | Stage IIA Lung Carcinoma | Stage IIA Lung Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336186","Stage IIB Lung Cancer AJCC v7","C5645","Stage IIB includes: (T2b, N1, M0); (T3, N0, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T3: Lung cancer with a tumor size more than 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus (less than 2 cm distal to the carina but without involvement of the carina); or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe. N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)","Stage IIB Lung Cancer AJCC v7 | Stage IIB Carcinoma of Lung | Stage IIB Carcinoma of the Lung | Stage IIB Lung Cancer | Stage IIB Lung Carcinoma | Stage IIB Lung Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336211","Stage IIIA Lung Cancer AJCC v7","C5646","Stage IIIA includes: (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IIIA Lung Cancer AJCC v7 | Stage IIIA Carcinoma of Lung | Stage IIIA Carcinoma of the Lung | Stage IIIA Lung Cancer | Stage IIIA Lung Carcinoma | Stage IIIA Lung Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336226","Stage IIIB Lung Cancer AJCC v7","C5647","Stage IIIB includes: (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IIIB Lung Cancer AJCC v7 | Stage IIIB Carcinoma of Lung | Stage IIIB Carcinoma of the Lung | Stage IIIB Lung Cancer | Stage IIIB Lung Carcinoma | Stage IIIB Lung Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981352","Stage IV Lung Cancer AJCC v6","C8774","Stage IV includes: Any T, Any N, M1.  M1: Distant metastasis present. (AJCC 6th ed.)","Stage IV Lung Cancer AJCC v6 | Stage IV Carcinoma of Lung AJCC v6 | Stage IV Carcinoma of the Lung AJCC v6 | Stage IV Lung Cancer | Stage IV Lung Cancer | Stage IV Lung Carcinoma AJCC v6 | Unspecified Stage IV Carcinoma of Lung AJCC v6 | Unspecified Stage IV Carcinoma of the Lung AJCC v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0685053","Stage 0 Lung Cancer AJCC v6 and v7","C27467","Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage 0 Lung Cancer AJCC v6 and v7 | Bronchial Carcinoma in situ | Stage 0 Lung Cancer | Stage 0 Lung Cancer | Stage 0 Lung Cancer AJCC v6 | Stage 0 Lung Cancer AJCC v7 | Stage 0 Lung Carcinoma",,,,,,,,,,,,,,,"255507","Carcinoma in situ of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030354","Papilloma","C7440","A benign epithelial neoplasm that projects above the surrounding epithelial surface and consists of villous or arborescent outgrowths of fibrovascular stroma.","Papilloma | PAPILLOMA, BENIGN | Papilloma, NOS","8050/0","Papilloma, NOS",,,,,,,,,,,,,"46273955","Papilloma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0201930","Carbon Dioxide Measurement","C64545","A quantitative measurement of the gas carbon dioxide present in a sample.","Carbon Dioxide Measurement | CO2 | Carbon Dioxide",,,,,,,,,,,,,,,"4135963","Carbon dioxide content measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1707501","Contrast-enhanced Magnetic Resonance Imaging","C46087","A technique that uses radiofrequency waves and a magnet to image the body.  The images are enhanced by the addition of contrast agents which selectively intensify anatomical regions to intensify the clarity of the image for diagnostic purposes. 2005","Contrast-enhanced Magnetic Resonance Imaging | CONTRAST ENHANCED MRI | Contrast-enhanced MRI | MRI With Contrast",,,,,,,,,,,,,,,"4198856","MRI with contrast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL407133","Thick","C81186","Wide in width, extent or cross-section.","Thick | THICK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0442825","Well-defined","C81187","Having a clean and distinct outline as if precisely cut along the edges.","Well-defined | ",,,,,,,,,,,,,,,"4128648","Well defined",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825501","Calvarial","C81190","Of or pertaining to the skullcap.","Calvarial | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205168","Thin","C65127","Narrow in width, extent or cross-section.","Thin | THIN | Thinly",,,,,,,,,,,,,,,"4078812","Thin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825493","Non-Enhancing Lesion","C81175","Visibly abnormal tissue on a magnetic resonance image (MRI) or computed tomography (CT) that does not enhance with contrast and is not edema.","Non-Enhancing Lesion | Non-Contrast Enhancing Lesion | Non-Contrast Enhancing Tissue | Non-Contrast Enhancing Tissue | Noncontrast-Enhancing Tissue | Noncontrast-enhancing Tissue | nCET",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825502","Vasogenic Edema","C81192","Edema that is characterized by increased permeability of capillary endothelial cells.","Vasogenic Edema | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700258","Volume Measurement","C74720","The determination of the volume of a sample.","Volume Measurement | VOL | VOLUME | Volume",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024432","Macrophage","C12558","A cell that arises from stem cells and/or bone marrow-derived monocytes that function in different aspects of host defense and tissue repair; such as phagocytosis, cytotoxic activity, and regulation of the immune response (antigen presentation and T-cell activation).","Macrophage | Macrophages | Monocytes / Macrophages / APC | macrophage",,,,,,,,,,,,,,,"4243353","Macrophage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825743","Third National Health and Nutrition Examination Survey","C81824","A survey conducted between 1988 and 1994 on a nationwide probability sample of approximately 33,994 persons, age 2 months and over. The survey was designed to obtain nationally representative information on the health and nutritional status of the population of the United States through interviews and direct physical examinations.","Third National Health and Nutrition Examination Survey | NHANES III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025465","Mesenteric Artery","C52975","A branch of the abdominal aorta that supplies blood to the intestines.","Mesenteric Artery | ARTERY, MESENTERIC | MESENTERIC ARTERY",,,,,,,,,,,,,,,"4314264","Structure of mesenteric artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348713","Free Text Format","C70764","A format that does not specify any text properties and does not require pre-established arrangement or organization of data.","Free Text Format | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697663","Image Registration","C80145","The process of transforming sets of image data from different times or perspectives into one coordinate system.","Image Registration | REG | Registration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697664","Image Segmentation","C80146","The process of assigning a label to every pixel in an image such that pixels with the same label share certain visual characteristics, allowing the image to be partitioned into multiple segments (e.g., boundaries, lines, curves).","Image Segmentation | SEG | Segmentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449582","Texture","C41144","A measure of the variation of the intensity of a surface, quantifying properties such as smoothness, coarseness, regularity, and resiliency. The term is often used as a descriptor for the structure or organization of a tissue or organ. The three principal approaches used to describe texture are statistical, structural and spectral.","Texture | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2238079","Blood Smear","C79903","A sample of blood applied in a thin film to a microscope slide for study under a microscope.","Blood Smear | peripheral blood smear",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0080048","Privacy","C17385","The quality of being secluded from the presence or view of others; the condition of being concealed or hidden; the ability of a person to control the availability of information about and exposure of him- or herself.","Privacy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009622","Computer","C16464","A machine for performing calculations automatically.","Computer | ",,,,,,,,,,,,,,,"45770976","Computer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706059","Finish","C64943","Use up completely.","Finish | Complete",,,,,,,,,,,,,,,"4223153","Finish",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0596607","Gel Electrophoresis (lab technique)","C18091","Gel electrophoresis is a method of separating large molecules (such as DNA fragments or proteins) from a mixture of similar molecules by electrophoretic filtration through a gelatinous matrix.  Subject to an electric field, each molecule in the sample mixture migrates through the matrix at a different rate, depending mainly on electrical charge and size, resulting in spatial separation within the matrix of each molecular species in the sample mixture.  Agarose and acrylamide in a cylindrical tube or slab gel are commonly used media for electrophoresis of proteins and nucleic acids.","Gel Electrophoresis | GEL ELECTROPHORESIS | Gel Electropheresis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825580","Tranche Distributed Repository","C81327","A distributed repository architecture for storing and sharing large amounts of immutable data. It is a free and open source file storage and dissemination tool that uses distributed replication to ensure the files remain available for a long time.","Tranche Distributed Repository | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0751973","Proteome","C18276","Refers to the total protein-encoding capability of an organism's genome. It is also used to refer to the actual total expressed protein complement of an organism or to the identifiable proteins of a single tissue or cell type or subcellular compartment.","Proteome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825491","Negative Charge","C81173","Having a surplus of electrons; having a lower electric potential.","Negative Charge | Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825492","Neutral Charge","C81174","Having no net electric charge; not electrified.","Neutral Charge | Neutral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027215","N-Cadherins","C60831","Cadherin-2 (906 aa, ~100 kDa) is encoded by the human CDH2 gene. This protein is involved in both neural stem cell anchorage and quiescence.","Cadherin-2 | CD325 Antigen | CDH2 | CDw325 antigen | Cadherin 2 | N-Cadherin | N-Cadherin | N-Cadherin 1 | Neural Cadherin | Neural-Cadherin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1739912","Cadherin-1","C17245","Cadherin-1 (882 aa, ~97 kDa) is encoded by the human CHD1 gene. This protein plays a role in the regulation of cell-cell adhesion, proliferation, and motility of epithelial cells","Cadherin-1 | CAM 120/80 | CD324 | CD324 Antigen | CDH1 | Cadherin 1 | E-Cadherin | E-Cadherin | Epithelial Cadherin | Epithelial Calcium-Dependent Adhesion Protein | Epithelial-Cadherin | Liver Cell Adhesion Molecule | Uvomorulin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335610","RELA Gene","C28646","This gene plays a role in transcriptional regulation and NFKB signal transduction.","RELA Gene | RELA | RELA Proto-Oncogene, NF-KB Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205095","Dorsal","C45874","Pertaining to the back or upper surface of the body; opposite of ventral.","Dorsal | DORSAL",,,,,,,,,,,,,,,"4114675","Dorsal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704448","Ventral","C45875","Pertaining to the underside or lower surface of the body; opposite of dorsal.","Ventral | VENTRAL",,,,,,,,,,,,,,,"4115458","Anterior",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1520141","Whitmore-Jewett Staging System","C18214","A staging system for prostate cancer that uses ABCD.  A and B refer to cancer that is confined to the prostate. C refers to cancer that has grown out of the prostate but has not spread to lymph nodes or other places in the body. D refers to cancer that has spread to lymph nodes or to other places in the body.","Whitmore-Jewett Staging System | ABCD rating | Jewett staging system | Whitmore-Jewett staging system",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519168","Saint Jude Children's Research Hospital","C39510","The St. Jude Children's Research Hospital received its NCI designation in 1977 and was awarded status as a comprehensive cancer center by NCI in 2008. Research is focused specifically on childhood cancers, acquired and inherited immunodeficiencies and genetic disorders.","St. Jude Children's Research Hospital | SJCRH | Saint Jude Children's Research Hospital | Saint Jude Children's Research Hospital | St. Jude | St. Jude Children's Research Hospital | St. Jude Children's Research Hospital | St. Jude's",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039493","Jaw Joint","C32888","The joint between the head of the lower mandible and the temporal bone.","Jaw Joint | TEMPOROMANDIBULAR JOINT | TMJ | Temporomandibular Joint | Temporomandibular joint structure (body structure)",,,,,,,,,,,,,,,"4202366","Temporomandibular joint structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825926","Autologous Stem Cell Rescue","C82054","A type of autologous hematopoietic stem cell transplantation designed to promote recovery if a prior hematopoietic stem cell transplantation fails or is not adequate.","Autologous Stem Cell Rescue | Autologous Rescue | stem cell rescue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553034","Milli","C48437","A prefix indicating a quantity of one one-thousandth, 10E-3.","Milli | [m] | m | milli | milli-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439794","Dense","C61562","Having high relative density or specific gravity; permitting little if any light to pass through.","Dense | Densely",,,,,,,,,,,,,,,"4115469","Dense",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028246","Nociceptor","C13176","A free nerve ending that is a receptor for painful stimuli. (Kanner)","Nociceptor | Nociceptors | Pain Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040996","Trigeminal Nerve","C12806","The fifth set of paired nerves of the face that emerge from the brain steam. These nerves have sensory and motor functions in the face, oral cavity, and nasal cavity.","Trigeminal Nerve | Cranial Nerve V | Fifth Cranial Nerve | NERVE, TRIGEMINAL | Nervus Trigeminus | TRIGEMINAL NERVE | Trigeminal nerve structure (body structure) | fifth cranial nerve | trigeminal nerve",,,,,,,,,,,,,,,"4100485","Trigeminal nerve structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003289","Antidepressant Agent","C265","A pharmacological agent that acts on neurotransmitter signaling pathways to alleviate the symptoms of depression.","Antidepressant Agent | Antidepressant | Antidepressant Drugs | Antidepressants | antidepressant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513765","Muscle Relaxant Preparation","C29891","Synthetic compounds or mixtures with muscle relaxant activity. A muscle relaxant preparation is used to prevent muscle spasms by inhibiting muscle contractions and to relief pain associated with the spasms.","Muscle Relaxant Preparation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1638411","Gently","C64653","In a manner that is soft and mild, having little impact.","Gently | ",,,,,,,,,,,,,,,"4302792","Gently",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018389","Dietary Gum","C68500","A class of water soluble polysaccharides usually isolated from seeds and typically viscous in aqueous solution. (DRI)","Dietary Gum | Gum | Gum",,,,,,,,,,,,,,,"4336222","Gum arabic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0222001","Fingernail","C32609","The nail at the end of a finger.","Fingernail | FINGERNAIL | Finger Nail",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206035","Randomized Controlled Clinical Trial","C46079","A study in which the participants are assigned by chance to separate groups to evaluate treatments.  The study also includes a control group, which is undergoing the same rigors of the study with placebo treatment or standard treatment.  The trial can also be controlled by the addition of a test group to ensure there are no factors present to skew the results and by the inclusion of peer-review analysis by appropriate government officials. 2005","Randomized Controlled Clinical Trial | Randomized | Randomized Controlled Trial | randomized controlled trial | randomized controlled trial (RCT)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009429","Combined Modality Therapy","C15212","Use of two or more simultaneous or consecutive treatment modalities; e.g., surgery + radiation, or radiation + immunotherapy. Does not refer to use of two or more chemotherapeutic agents.","Multimodality Therapy | Combination Therapy | Combined Modality Therapy | Combined Modality Treatment | Combined Treatment | Combined Treatment Modalities | Multimodal Therapy | Multimodal Treatment | Multimodality Treatment | concurrent therapy | multimodality treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085268","Bone Remodeling","C3475","A concomitant process in which old bone is resorbed and new bone is formed. Bone remodeling occurs primarily in bone and involves two types of cells, osteoblasts and osteoclasts. Osteoblasts synthesize bone matrix and form new bone while osteoclasts digest mineral matrix and old bone.","Bone Remodeling | ",,,,,,,,,,,,,,,"4153666","Bone remodeling",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0447454","Mucogingival Junction","C82058","The interface between the more apically located alveolar mucosa and the more coronally located gingiva.","Mucogingival Junction | ",,,,,,,,,,,,,,,"4077269","Mucogingival junction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825929","Root Furcation","C82059","The region of a multirooted tooth at which the root divides.","Root Furcation | Furcation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825931","Furcation Involvement","C82064","Recession of the gum that exposes the furcation of a multirooted tooth.","Furcation Involvement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825933","Rubber Cup","C82066","A cup used for polishing teeth.","Rubber Cup | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017572","Gingival Recession","C82068","A loss of gum tissue resulting in an exposure of the roots of the teeth.","Gingival Recession | Receding Gums",,,,,,,,,,,,,,,"134386","Gingival recession",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0071772","Potassium Nitrate","C82074","A crystalline salt, KNO3; a strong oxidizer used especially in making gunpowder, as a fertilizer, and in medicine.","Potassium Nitrate | POTASSIUM NITRATE | Saltpeter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0684254","Scaler","C82076","A sharpened and shaped dental instrument used to remove soft and hard deposits from tooth surfaces.","Scaler | Dental Scaler",,,,,,,,,,,,,,,"4086022","Dental scaler",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029988","Oxalate","C82078","A salt or ester of oxalic acid.","Oxalate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825943","Interceptive Treatment","C82081","Orthodontic treatment designed to take advantage of the active growth stage of a child's development in order to intercept orthodontic problems early and reduce or eliminate them.","Interceptive Treatment | Early Interceptive Treatment | Phase I Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825944","Miniscrew Temporary Anchorage Device","C82082","A small screw of between 6-14mm in length placed between the roots of a tooth for purposes of anchoring the tooth during orthodontic treatment.","Miniscrew Temporary Anchorage Device | Miniscrew TAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018682","Orthodontic Headgear","C82087","An extraoral orthodontic appliance designed to create traction for growth modification, tooth movement and anchorage.","Orthodontic Headgear | Orthodonic Headgear",,,,,,,,,,,,,,,"4174740","Orthodontic headgear",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825949","Orthodontic Facemask","C82088","A component of a reverse-pull or protraction orthodontic appliance that distributes force across much of the face.","Orthodontic Facemask | Orthodonic Facemask",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017573","Gingivectomy","C82090","A resective periodontal surgical procedure that removes gingival tissue.","Gingivectomy | ",,,,,,,,,,,,,,,"4125944","Gingivectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825951","Adjunctive Orthodontic Procedure","C82091","Any orthodontic procedure that is done as part of another dental procedure.","Adjunctive Orthodontic Procedure | Adjunctive | Adjunctive Orthodonic Procedure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938166","Impaction","C82092","A condition in which a tooth is so crowded in its socket that it cannot erupt normally.","Impaction | Impacted",,,,,,,,,,,,,,,"4043700|4123726","Impacted tooth|Impacted tooth",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2825960","Air Blast","C82101","A short burst of air.","Air Blast | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825961","Anchorage","C82102","Resistance to activation force.","Anchorage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825963","en masse Movement","C82104","Movement of goups of teeth as a unit as opposed to individually.","en masse Movement | en masse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825968","Orthognathous","C82113","Characterized by minimal protrusion of the mandible or minimal prognathism.","Orthognathous | Orthognathic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825969","Intermaxillary Relationship","C82114","Any relationship between the upper and lower jaws.","Intermaxillary Relationship | Intermaxillary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825972","Cant","C82117","Any abnormal inclincation of the occlusal plane.","Cant | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1261286","Opaque","C82125","Impenetrable by light; neither transparent nor translucent.","Opaque | ",,,,,,,,,,,,,,,"4047544","Opaque",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825977","Dental Retraction (procedure)","C82126","A posterior movement of teeth.","Dental Retraction | Retraction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825978","Dental Intrusion","C82127","A translational form of tooth movement directed apically and parallel to the long axis.","Dental Intrusion | Intrusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825979","Dental Protraction","C82128","Anterior displacement of the teeth and/or bones of the face.","Dental Protraction | Dentral Protraction | Protraction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825980","Dental Distalization","C82129","Movement of teeth in a posterior direction.","Dental Distalization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826099","Repetition Time","C82330","The amount of time in milliseconds between successive pulse sequences applied to the same slice.","Repetition Time | REPTIME | TR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826100","Echo Time","C82331","The time in milliseconds between the application of the excitation pulse and the recording of the peak echo signal.","Echo Time | ECHOTIME | TE | Time to Echo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012222","Diffusion","C82333","The movement of chemical species under the influence of a concentration difference and as a result of random thermal agitation. The species will move from the high concentration area to the low concentration area till the concentration is uniform in the whole phase.","Diffusion | ",,,,,,,,,,,,,,,"4263208","Diffusion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205357","Smooth","C82334","Having a surface free from roughness or bumps or ridges or irregularities.","Smooth | ",,,,,,,,,,,,,,,"4305498","Smooth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2826101","PeptideAtlas","C82335","A multi-organism, publicly accessible compendium of peptides identified in a large set of tandem mass spectrometry proteomics experiments. The long term goal of the project is full annotation of eukaryotic genomes through a thorough validation of expressed proteins.","PeptideAtlas | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826102","International Protein Index","C82336","Provides a top level guide to the main databases that describe the proteomes of higher eukaryotic organisms. IPI effectively maintains a database of cross references between the primary data sources, provides minimally redundant yet maximally complete sets of proteins for featured species (one sequence per transcript), and maintains stable identifiers (with incremental versioning) to allow the tracking of sequences in IPI between IPI releases.","International Protein Index | IPI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826103","Sequence Specific Retention Factor","C82337","Predicts the retention time of tryptic peptides during RP-HPLC fractionation based on the hydrophobicity measure algorithm of Krokhin et al. (Mol Cell Proteomics. 2004 Sep;3(9):908-19. Epub 2004 Jul 6)","Sequence Specific Retention Factor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0682708","White Matter","C33892","The nerve tissue forming the bulk of the deep parts of the brain and the superficial parts of the spinal cord. It is composed of nerve cell processes, i.e. extensions (axons), which connect various grey matter areas of the brain to each other and carry nerve impulses to and from the nerve cell bodies within the central nervous system (neurons). Cerebral and spinal white matter does not contain dendrites. White matter is distinguished in that it is composed of axonal nerve fibers covered by a myelin sheath.","White Matter | WHITE MATTER TISSUE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519957","Vasomotor","C28386","Affecting the narrowing and widening of the blood vessels.","Vasomotor | vasomotor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017382","Genetic Counseling","C15240","The process whereby an expert in hereditary disorders provides information about risk and clinical burden of a disorder or disorders to patients or relatives in families with genetic disorders as an aid to making informed and responsible decisions about marriage, children, early diagnosis, and handling disability.","Genetic Counseling | genetic counseling",,,,,,,,,,,,,,,"4196362","Genetic counseling",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2697750","Infusion Site","C77679","The anatomic site through which fluid is introduced into the body.","Infusion Site | SITE, INFUSION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515948","American Society of Clinical Oncology","C39319","The world's leading professional organization representing physicians of all oncology disciplines and subspecialties. ASCO sets the standard for cancer care, supports funding for clinical and translational research, fosters the exchange of information related to cancer, including cancer biology, diagnosis, staging, treatment and psychosocial impact.  ASCO provides training in clinical research and patient care and publishes the Journal of Clinical Oncology.","American Society of Clinical Oncology | ASCO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1267213","Aerodigestive Tract","C82347","Anatomic structures forming the upper respiratory tract and upper part of the digestive tract. They include the oral cavity, sinonasal tract, pharynx, pyriform sinus, larynx, trachea, and esophagus.","Aerodigestive Tract | aerodigestive tract",,,,,,,,,,,,,,,"4000510","Upper aerodigestive tract structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2826145","Fluid Attenuated Inversion Recovery","C82392","A magnetic resonance imaging (MRI) pulse sequence that uses an inversion recovery technique to null fluids present in the imaging area, improving clarity of the object of interest.","Fluid Attenuated Inversion Recovery | FLAIR | FLAIR MRI | FLUID ATTENUATED INVERSION RECOVERY MRI | Fluid Attenuated Inversion Recovery MRI | MRI FLAIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034011","Puberty","C82393","The stage in life when sex glands become functional. It is characterized by the development of secondary sex characteristics, reproductive functions, and growth spurts.","Puberty | puberty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826146","Tanner Scale","C82394","A scale of physical development in children, adolescents and adults based on external primary and secondary sex characteristics, such as the size of the breasts, genitalia, and development of pubic hair.","Tanner Scale | Tanner Stages",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033978","Psychotropic Agent","C82395","A classification of medication that acts on the central nervous system, affecting brain function, level of consciousness, mood, emotions, and behavior.","Psychotropic Agent | Psychotropic | Psychotropic Drug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0935727","Injection Port","C82396","A generic term that describes any implantable venous access device that is inserted into a central vein, and connected to a port that can be palpated and accessed for administration of agents and fluid, or for blood sampling.","Portacath | TIVAS | Totally Implantable Venous Access System | port-a-cath",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704391","Property, LOINC Axis 2","C40566","The type of characteristic that is being evaluated about the component.  For example, some kinds of properties are: mass, concentration, velocity, size, color, shape, duration, volume, count, and time of event.","Property, LOINC Axis 2 | LOINC Axis 2 | Property",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL415073","Nanomaterial","C62371","A bulk material composed of discrete nano-substructures that are engineered, synthesized and characterized for a myriad of applications.","Nanomaterial | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019868","Homeostatic Process","C25989","The body's maintenance of a consistent internal environment within a narrow range of variation. It is important to the continuation of life.","Homeostatic Process | Homeostasis | Homeostasis | Physiological Homeostasis | homeostasis | homeostatic",,,,,,,,,,,,,,,"4317513","Homeostasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017817","Glutathione","C523","A tripeptide comprised of three amino acids (cysteine, glutamic acid, and glycine) present in most mammalian tissue. Glutathione acts as an antioxidant, a free radical scavenger and a detoxifying agent. Glutathione is also important as a cofactor for the enzyme glutathione peroxidase, in the uptake of amino acids, and in the synthesis of leukotrienes. As a substrate for glutathione S-transferase, this agent reacts with a number of harmful chemical species, such as halides, epoxides and free radicals, to form harmless inactive products. In erythrocytes, these reactions prevent oxidative damage through the reduction of methemoglobin and peroxides. Glutathione is also involved in the formation and maintenance of disulfide bonds in proteins and in the transport of amino acids across cell membranes.","Glutathione | GLUTATHIONE | GSH | Glutham | N-(N-L-gamma-glutamyl-L-cysteinyl)glycine | Reduced Glutathione | glutathione",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023775","Lipid Peroxidation","C81870","The degradation of lipids caused by an oxidative attack from free radicals.","Lipid Peroxidation | Lipid Oxidation",,,,,,,,,,,,,,,"4046118","Lipid peroxidation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162772","Reactive Oxygen Species","C1421","Organic or inorganic chemicals that contain an oxygen atom with an unpaired electron. This unstable electron configuration causes these chemicals to be highly reactive with other molecules.","Oxygen Radical | Oxygen Radicals | ROS | Reactive Oxygen Species",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016698","Freeze-Drying","C28150","A dehydration process typically used to preserve a perishable material. The specimen is frozen and then dehydrated at low temperature in a high vacuum.","Freeze-Drying | Drying, Sublimation | Lyophilisation | freeze-dried",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037680","Sonication","C81871","A technique that uses sound energy to agitate or disrupt the components of a sample.","Sonication | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014139","Endocytotic Process","C16544","Cellular uptake of extracellular materials within membrane-limited vacuoles or microvesicles. Endosomes play a central role in endocytosis.","Endocytotic Process | Endocytic Process | Endocytosis | Endocytosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677634","Thrombin Time","C80365","A measurement of the time it takes a plasma sample to clot after adding the active enzyme thrombin.","Thrombin Time | TCT | TT | Thrombin Clotting Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1702300","IL1B protein, human","C20522","Interleukin-1 beta (269 aa, ~31 kDa) is encoded by the human IL1B gene. This protein is involved in the macrophage-dependent inflammatory response.","Interleukin-1 Beta | Catabolin | IL-1 Beta | IL-1-b | IL-1-beta | IL-1B | IL1-Beta | IL1B | IL1B Protein | IL1F2 | Interleukin 1, Beta | Interleukin 1, Beta Proprotein | Interleukin 1-Beta | Interleukin-1-Beta | Interleukin-1-Beta | Preinterleukin 1 Beta | interleukin-1-beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1699802","Interleukin-10, Human","C20512","Interleukin-10 (178 aa, ~21 kDa) is encoded by the human IL10 gene. This protein plays a role in the negative regulation of cytokine expression.","Interleukin-10 | CSIF | CSIF-10 | Cytokine Synthesis Inhibitory Factor | IL-10 | IL10 | IL10A | Interleukin 10 | Interleukin 10 Precursor | T-Cell Growth Inhibitory Factor | TGIF | interleukin-10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1698756","Interleukin-8, Human","C20473","Interleukin-8 (99 aa, ~11 kDa) is encoded by the human CXCL8 gene. This protein is involved in chemotaxis and neutrophil activation.","Interleukin-8 | Alveolar Macrophage Chemotactic Factor I | Anionic Neutrophil Activating Peptide | Anionic Neutrophil-Activating Peptide | Beta Endothelial Cell-Derived Neutrophil Activating Peptide | Beta-Thromboglobulin-Like Protein | C-X-C Motif Chemokine 8 | CXCL8 | GCP-1 | GCP-IL-8 | Granulocyte Chemotactic Peptide Interleukin 8 | Granulocyte Chemotactic Protein 1 | IL-8 | IL8 | Interleukin 8 | Leukocyte Adhesion Inhibitor | Lung Giant Cell Carcinoma-Derived Chemotactic Protein | Lymphocyte Derived Neutrophil Activating Peptide | MDNCF | MONAP | Macrophage-Derived Chemotactic Factor | Monocyte-Derived Neutrophil Chemotactic Factor | Monocyte-Derived Neutrophil-Activating Peptide | NAP-1 | Neutrophil Activation Factor | Neutrophil Activation Peptide | Neutrophil Chemotactic Factor | Neutrophil-Activating Peptide 1 | Neutrophil-Activating Protein 1 | Protein 3-10C | T-Cell Chemotactic Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1448177","Tumor Necrosis Factor, Human","C20535","Tumor necrosis factor (233 aa, ~26 kDa) is encoded by the human TNF gene. This protein is involved in the induction of cytokine expression, the stimulation of cell proliferation and the positive regulation of cell differentiation.","Tumor Necrosis Factor | TNF | TNF Alpha | TNF-A | TNF-Alpha | TNFA | Tumor Necrosis Factor Alpha | Tumor Necrosis Factor Ligand Superfamily Member 2 | Tumor Necrosis Factor-Alpha | Tumor Necrosis Factor-Alpha | Tumor Necrosis Factor-alpha (macrophage-derived)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332583","Green","C48329","The hue of that portion of the visible spectrum lying between yellow and blue, evoked in the human observer by radiant energy with wavelengths of approximately 490 to 570 nanometers; any of a group of colors that may vary in lightness and saturation and whose hue is that of the emerald or somewhat less yellow than that of growing grass.","Green | GREEN",,,,,,,,,,,,,,,"4153954","Green color",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1450275","luminescence","C81012","The emission of light that does not involve the release of heat.","Luminescence | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025251","Membrane Potentials","C82324","The electrical potential difference across a plasma membrane.","Membrane Potential | Transmembrane Potential Difference",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009325","Collagen","C16447","A family of large fibrous proteins that are the main components of connective tissue and are responsible for maintaining tissue structure.","Collagen | collagen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514158","Positive Regulation of Platelet Aggregation Process","C40712","Any platelet aggregation process that increases the rate, frequency or extent of platelet aggregation.","Positive Regulation of Platelet Aggregation Process | Platelet Aggregation Induction | Platelet Aggregation Induction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697937","Longitudinal Relaxation Rate","C80361","The relaxation rate of the net nuclear spin polarization in the direction of the magnetic field of a spectrometer back to its equilibrium value.","Longitudinal Relaxation Rate | 1/T1 | Lattice Relaxation Rate | R1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882924","Relaxivity","C63853","A measure of the ability of magnetic compounds to increase the relaxation rates of the surrounding water proton spins in nuclear magnetic resonance applications.","Relaxivity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700065","Transverse Spin Relaxation Rate","C80362","The relaxation rate of spin polarization in the plane perpendicular to the magnetic field of a spectrometer back to zero as precessing spins loose coherence with each other.","Transverse Spin Relaxation Rate | 1/T2 | R2 | Spin-Spin Relaxation Rate | Transverse Relaxation Rate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700066","Transverse Spin Relaxation Time","C80364","The time it takes for the net nuclear spin in the plane that is perpendicular to the magnetic field of a spectrometer to decay to zero.","Transverse Spin Relaxation Time | 1/R2 | Spin-Spin Relaxation | Spin-Spin Relaxation Time | T2 | T2 Relaxation Time | T2 Time | Transverse Relaxation Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0678538","Potential Energy","C18217","Stored energy.  In biological systems energy is stored in the structure of molecules and is released through metabolism.","Potential Energy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0369241","Mold","C28266","A very large group of microscopic fungi that live on plant or animal matter. Most are filamentous organisms and produce spores that can be air-, water-, or insect-borne.","Mold | Filamentous Fungus | Filamentous fungus | MOLD | Mould | mold",,,,,,,,,,,,,,,"4224654","Mold",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014264","Endotoxin","C50918","The lipopolysaccharide complexes that are part of the outer membrane of the cell wall of Gram-negative bacteria such as E. coli, Salmonella, Shigella, Pseudomonas, Neisseria, Haemophilus, and other leading pathogens. Upon bacterial infections, the lipid component (Lipid A) of endotoxin contributes to its toxicity, while the polysaccharide components contribute to immunogenicity.","Endotoxin | Bacterial Pyrogen | Endotoxins",,,,,,,,,,,,,,,"4112726","Bacterial endotoxin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1881921","Multi-Angle Laser Light Scattering","C62324","A static light scattering technique involving measurement of the amount of light scattered by a suspension at multiple angles relative to the incident laser beam. Masses and the root mean square radius or a measure of geometric size can be determined using this technique on a mega Dalton scale.","Multi-Angle Laser Light Scattering | MALLS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1135847","Field Flow Fractionation","C62321","An analytical technique used to separate a multi-component sample by applying a retarding force or gradient to a sample in a solvent stream, which drives the sample toward a thin channel wall. The velocity at which a component leaves the center solvent stream is dependent on its physical characteristics.","Field Flow Fractionation | AFFF | Asymmetrical Flow Field-Flow Fractionation | Electrical Field-Flow Fractionation | FFF | Field-Flow Fractionation | Flow Field-Flow Fractionation | Sedimentation Field-Flow Fractionation | Thermal Field-Flow Fractionation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242849","Microscopy, Atomic Force","C17754","A technique utilizing a scanning probe to image and analyze the surface of a material with atomic-level resolution.","Atomic Force Microscopy | Scanning Force Microscopy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201699","Capillary Electrophoresis","C17637","An electrophoresis procedure, in which a sample is introduced into a capillary tube and the components are separated by the application of high voltage. Due to the large surface to volume ratio, cooling is more efficient, allowing use of higher voltages.  As a result, separation occurs more quickly and sensitivity is increased. The technique allows for separation of proteins, nucleic acids, and carbohydrates.","Capillary Electrophoresis | CAPILLARY ELECTROPHORESIS | Capillary Electropheresis | Fractionation, Capillary Electrophoresis",,,,,,,,,,,,,,,"4010410","Capillary electrophoresis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242841","Microscopy, Confocal, Laser Scanning","C17753","A system of (usually) epifluorescence light microscopy in which a fine laser beam of light is scanned over the object through the objective lens. The technique is particularly good at rejecting light from outside the plane of focus and so produces higher effective resolution than is normally achieved.","Confocal Microscopy | CONFOCAL MICROSCOPY | Confocal Laser Scanning Microscopy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882368","Photon Correlation Spectroscopy","C62329","A type of spectroscopy that utilizes a laser beam to irradiate a sample containing particles in suspension, resulting in light scattering. Rapid fluctuations in scattering intensity, around a mean value at a certain angle, occur because of particle diffusion and are dependent upon on particle size. The calculated correlation function yields a diffusion coefficient, for a given temperature and viscosity, which can be used to calculate particle size.","Photon Correlation Spectroscopy | DLS | DYNAMIC LIGHT SCATTERING | Dynamic Light Scattering | PCS | Quasi-Elastic Light Scattering | Quasi-elastic Light Scattering",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699863","Electron Microprobe Analysis","C78873","A technique that quantifies the x-rays emitted after ionization by a finely focused beam of electrons directed onto a flat polished specimen.","Electron Microprobe Analysis | EMPA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699864","Electrophoretic Light Scattering","C78868","A technique for determining the zeta potential of a sample through the detection of the motion of dispersed particles relative to a fluid under the influence of an oscillating electric field.","Electrophoretic Light Scattering | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699997","Energy Dispersive Spectroscopy","C78869","A type of spectroscopy that analyzes the X-rays emitted by a sample after exposure to a focused beam of high energy electromagnetic radiation to determine the atomic composition of a region of a sample.","Energy Dispersive Spectroscopy | EDS | EDX | Energy Dispersive X-Ray Spectroscopy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0678118","Transmission Electron Microscopy","C18216","An electron microscopy imaging technique that is utilized to examine structural components of a sample by passing electrons through the specimen.","Transmission Electron Microscopy | Microscopy, Electron, Transmission | TEM | TRANSMISSION ELECTRON MICROSCOPY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0599209","Fast Protein Liquid Chromatography","C80368","A type of liquid chromatography where the solvent flow and composition is controlled by pumps.","Fast Protein Liquid Chromatography | FPLC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026018","Microscopy","C16853","The use of various technologies to resolve the structure or features of objects too small or fine to naturally be seen by eye.","Microscopy | GM | MICROSCOPY",,,,,,,,,,,,,,,"4036697","Microscopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2700202","Focused Ion Beam-Scanning Electron Microscope","C78815","An instrument that combines the use of a focused beam of gallium ions to etch or coat a sample with a scanning electron microscope to image the sample.","Focused Ion Beam-Scanning Electron Microscope | FIB-SEM | FIB/SEM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700238","Gas Sorption","C78875","A technique where a sample is heated and degassed to remove contaminants, followed by exposure to doses of an inert gas. The adsorption of the gas is measured and, subsequently, the gas is withdrawn while the desorption is measured. The profile of adsorption and desorption of the gas at various vacuum pressures can be used to determine the surface area of the sample.","Gas Sorption | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008559","Gel Chromatography","C16433","Gel permeation or sieve chromatography that is performed on porous gels that separate solutes on the basis of size. Smaller solutes are included within the particles of the gel matrix more frequently than larger solutes, thus affecting elution rates.","Gel Filtration Chromatography | Gel Permeation Chromatography | SIZE EXCLUSION CHROMATOGRAPHY | Size Exclusion Chromatography",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1579831","High Performance Liquid Chromatography","C16434","Frequently referred to simply as HPLC, this form of column chromatography is used frequently in biochemistry. The analyte is forced through a column by liquid at high pressure, which decreases the time the separated components remain on the stationary phase. Less time on the column then translates to narrower peaks in the resulting chromatogram and thence to better selectivity and sensitivity.","High Performance Liquid Chromatography | HPLC",,,,,,,,,,,,,,,"4106607|4294814","High pressure liquid chromatography|High performance liquid chromatography measurement",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0262878","Scanning Electron Microscope","C78814","An electron microscope that scans the surface of a sample with a beam of electrons and detects the interaction of the electrons with the atoms on the surface to produce a topographical image of the sample.","Scanning Electron Microscope | SEM",,,,,,,,,,,,,,,"45759516","Scanning electron microscope",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2697588","High Resolution Transmission Electron Microscopy","C78874","A transmission electron microscopy-based imaging technique in which the transmitted and diffracted beams are allowed to interfere, creating phase contrast that allows atomic columns to be documented.","High Resolution Transmission Electron Microscopy | Electron Phase Contrast Imaging | HRTEM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518101","Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry","C19935","In MALDI-TOF, a laser pulse is fired into a protein or peptide sample contained in a light-absorbing matrix. A small explosion vaporizes and ionizes the sample. In the presence of a high electric field, peptide ions are accelerated down an evacuated flight tube. Because large particles travel more slowly than small ones, the masses of the ionized particles are determined by measuring their arrival time at the end of the tube","Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry | MALDI-TOF | MALDI-TOF Mass Spectrometry | Matrix-Assisted Laser Desorption Ionization Time-of-Flight MS | Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1135961","Powder Diffraction","C78872","A technique using X-ray diffraction to characterize the crystallographic structure, size, and orientation in crystallized or powdered solid samples. It can be used to identify unknown substances or to determine the composition of a heterogeneous mixture of solids.","Powder Diffraction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034553","Radioactivity","C17054","The quality of emitting or the emission of corpuscular or electromagnetic radiations consequent to nuclear disintegration, a natural property of all chemical elements of atomic number above 83 and possible of induction in all other known elements.","Radioactivity | Radioactive | radioactive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1608928","Refractometer","C78809","An optical instrument that can be used to determine the refractive index of a sample.","Refractometer | ",,,,,,,,,,,,,,,"45772875","Refractometer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2699274","Scanning Auger Spectrometer (device)","C78816","An instrument that consist of an ultra high vacuum scanning microscope column combined with an electron energy analyzer, which can determine the elemental composition of the outer surface of a sample.","Scanning Auger Spectrometer | AES | Auger Electron Spectrometer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026020","Scanning Electron Microscopy","C16855","Technique of electron microscopy in which the specimen is coated with heavy metal and then scanned by an electron beam. The resolution is not as great as with transmission electron microscopy, but preparation is easier (often by fixation followed by critical point drying), the depth of focus is relatively enormous, the surface of a specimen can be seen (though not the interior unless the specimen is cracked open) and the image is aesthetically pleasing.","Scanning Electron Microscopy | Microscopy, Electron, Scanning | SCANNING ELECTRON MICROSCOPY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677615","Atomic Resolution Microscopy","C20346","Several related technologies for imaging and measuring surfaces on a fine scale, down to the level of molecules and groups of atoms. These technologies share the concept of scanning an extremely sharp tip (3-50 nm radius of curvature) across the object surface. The tip is mounted on a flexible cantilever, allowing the tip to follow the surface profile. When the tip moves in proximity to the investigated object, forces of interaction between the tip and the surface influence the movement of the cantilever. Various interactions can be studied depending on the specific mechanics of the probe. Specialized sensors detect and record the movements of the cantilever, providing an image with resolution at the atomic level.","Atomic Resolution Microscopy | Atomic Scale Microscopy | SPM | Scanning Probe Microscopy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079837","Microscopy, Scanning Tunneling","C76127","An imaging technique that produces a view of the surface of a sample at the atomic level by detecting variations in the current between a conducting tip and the reactive elements within the sample.","Scanning Tunneling Microscopy | Microscopy, Electron Scanning Tunnel | STM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0183400","Spectrophotometer","C62333","A photometer that measures the intensity of light as a function of wavelength.","Spectrophotometer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700282","X-Ray Photoelectron Spectroscopy","C78871","A quantitative spectroscopic technique that both determines the identities and percent composition of elements in a material and measures the elemental chemical and electronic states for a sample. The process, which occurs in a vacuum, involves the irradiation of the material of interest with a beam of aluminum or magnesium X-rays while measuring both the kinetic energy and number of electrons that are released from the outer surface.","X-Ray Photoelectron Spectroscopy | ESCA | Electron Spectroscopy for Chemical Analysis | XPS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040541","Toxicology","C17206","Toxicology is the branch of pharmacology that deals with the nature and effects and treatments of poisons.","Toxicology | Medical Toxicology | TOX | toxicology",,,,,,,,,,,,,,,"4261728","Toxicology",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825784","Molecular Entrapment","C81872","A molecular interaction in which a small molecule or structure becomes trapped, usually in a larger molecule or structure, due to non-covalent interactions.","Molecular Entrapment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2244328","Facilitated Diffusion","C82345","Transport of substances across a biological membrane from an area of higher concentration to an area of lower concentration by means of a carrier molecule.","Facilitated Diffusion | Facilitated Transport",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826108","Restricted Diffusion","C82346","Transport of substances across a biological membrane where the flux rate of the diffusing material is controlled by the permeability of the membrane, which in turn is dictated by the size of the pores.","Restricted Diffusion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022525","Karyometry","C82399","Video-microscopy procedure for the analysis of the nuclear chromatin organization status in neoplastic lesions and the detection of nuclear subpopulations on hematoxylin-eosin stained sections.","Karyometry | Digital Texture Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031330","Pharmacology","C16974","The study of pharmacologic agents. This includes the preparation, compounding, and dispensing of drugs, as well as the characteristics and properties of drugs, their effects on the body, and how they are metabolized and eliminated from the body.","Pharmacology | P | Pharmacologic | Pharmacological | pharmacology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002062","Alkaloid","C221","A family or group of nitrogen-containing base compounds primarily derived from plant and animal sources.  Many alkaloids are used medicinally, including cancer therapy.","Alkaloid | Alkaloids | alkaloid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003376","Antimetabolite","C272","An antineoplastic agent with a structural similarity to a natural substance that can replace that substance in a normal biochemical pathway and interfere with the normal metabolic processes of cells.","Antimetabolite | Antimetabolites | antimetabolite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0598317","Topoisomerase Inhibitor","C1748","Any substance that inhibits topoisomerase, an enzyme that cleaves the DNA backbone to relieve torsional stress in a DNA molecule generated during replication, transcription, and other structural transformations. Inhibition of topoisomerase causes DNA damage, inhibition of DNA replication, and apoptosis.","Topoisomerase Inhibitor | DNA Topoisomerase Inhibitors | Topoisomerase Inhibitors | topoisomerase inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003236","Antineoplastic Antibiotic","C259","An antibiotic, or its derivative, that can kill or inhibit the growth of tumor cells. Antineoplastic antibiotics can interfere with the normal function of cellular nucleic acids and proteins.","Antineoplastic Antibiotic | Anticancer Antibiotic | Anticancer Antibiotics | Antineoplastic Antibiotics | Antitumor Antibiotic | Antitumor Antibiotics | anticancer antibiotic | antineoplastic antibiotics | antitumor antibiotics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005522","Biological Agent","C307","Biotechnology-derived pharmaceutical agents made from living organisms or their products. Includes recombinant proteins, monoclonal antibodies, and nucleic acids.","Biological Agent | BIOLOGIC | Biologic | Biological Drug | Biological Products | Biologicals | Biologics | Biopharmaceuticals | Immunologic, Immunochemical | Immunologics | biologic agent | biological agent | biological drug | biological product",,,,,,,,,,,,,,,"4019381","Biological substance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL034943","Hydration","C28009","The chemical process by which a molecular entity reacts with both the hydroxyl group (-OH) and proton (H+) found in a water molecule.","Hydration | hydration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0457784","Particulate","C1709","The generic term used for a type of air pollution. It consists of complex and varying mixtures of particles suspended in the air such as fine solids such as dirt, soil dust, pollens, molds, ashes, and soot; and aerosols that are formed in the atmosphere from gaseous combustion by-products such as volatile organic compounds, sulfur dioxide and nitrogen oxides. Particles of special concern to the protection of lung health are those known as fine particles, less than 2.5 microns in diameter.","Particulate | Particulates",,,,,,,,,,,,,,,"4132616","Particulate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021441","Parenteral Infusion","C21088","Administration of medications or nutrients directly into the venous system.","Parenteral Infusion Procedure | IV Infusion | Intravenous Infusion | Parenteral Infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1319196","Intravenous Push","C64995","A method of drug delivery in which a usually small volume of drug is administered rapidly into a vein.","Intravenous Push | IV Push | Intravenous Push Route of Administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1458132","Treatment/Psychosocial Effects","C17873","Having to do with the physical, psychological, cognitive, and social consequences of disease, including stigmatization of persons affected.","Psychosocial Effect | Effects, Psychosocial | Psychosocial Effects | Psychosocial Effects/Treatment | Treatment/Psychosocial Effects | psychosocial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028654","Clinical Nurse Specialist","C20832","Clinical Nurse Specialist (CNS) - a licensed registered nurse who has graduate preparation (a master's or a doctorate) in nursing as a CNS.  The CNS is a clinical expert in theory-based and/or research-based nursing practice within a specialty area. (NACNS)","Clinical Nurse Specialist | CNS | Clin Spec",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0599880","Treatment Plan","C60735","A document outlining the essential treatment issues which will be addressed. This may include the problem to be addressed, the proposed treatment, the treatment goal, the time frame to meet goals, and an estimate of the costs.","Treatment Plan | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0151908","Dry Skin","C74592","The pores are generally fine with a papery thin texture that feels dry to the touch. Usually flaky and dull looking.","Dry Skin | DRY | Dry skin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085272","Leuprolide","C62042","A synthetic nonapeptide analogue of gonadotropin-releasing hormone. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.","Leuprolide | 6-D-Leucine-9-(N-ethyl-L-prolinamide)-1-9-luteinizing Hormone-releasing Factor (Pig) | 6-D-Leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig) | LEUPROLIDE | Leuprorelin | leuprolide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023065","Laryngectomy","C15267","Surgery to remove part or all of the larynx.","Laryngectomy | laryngectomy",,,,,,,,,,,,,,,"4217829","Laryngectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4012313","Metabolic Acidosis","C28228","Increased acidity in the blood secondary to acid base imbalance. Causes include diabetes, kidney failure and shock.","Metabolic Acidosis | Acidosis | Acidosis | metabolic acidosis",,,,,,,,,,,,,,,"4245042","Metabolic acidosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005059","Benzocaine","C28923","An ester of paraaminobenzoic acid, lacking the terminal diethylamino group of procaine, with anesthetic activity. Benzocaine binds to the sodium channel and reversibly stabilizes the neuronal membrane which decreases its permeability to sodium ions. Depolarization of the neuronal membrane is inhibited, thereby blocking the initiation and conduction of nerve impulses.","Benzocaine | Anesthesin | BENZOCAINE | Baby Anbesol | Chloraseptic | Ethyl 4-aminobenzoate | Ethyl P-Aminobenzoate | Norcain | Norcaine | Ora-Jel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005684","Malignant Bladder Neoplasm","C9334","A primary or metastatic malignant neoplasm involving the bladder.","Malignant Bladder Neoplasm | Malignant Bladder Tumor | Malignant Neoplasm of Bladder | Malignant Neoplasm of Urinary Bladder | Malignant Neoplasm of the Bladder | Malignant Neoplasm of the Urinary Bladder | Malignant Neoplasm, Bladder | Malignant Neoplasm, Bladder | Malignant Neoplasm, Urinary Bladder | Malignant Tumor of Bladder | Malignant Tumor of Urinary Bladder | Malignant Tumor of the Bladder | Malignant Tumor of the Urinary Bladder | Malignant Tumor, Urinary Bladder | Malignant Urinary Bladder Neoplasm | Malignant Urinary Bladder Tumor | Malignant neoplasm of bladder, unspecified | Urinary Bladder Malignant Neoplasm | Urinary Bladder Malignant Tumor",,,,,,,,,,,,,,,"197508","Malignant tumor of urinary bladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007012","Carbon Dioxide","C65288","A colorless, odorless, incombustible gas resulting from the oxidation of carbon.","Carbon Dioxide | CARBON DIOXIDE | CO2 | Carbonic Acid Gas | carbon dioxide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0949022","Malignant Rectal Neoplasm","C7418","A primary or metastatic malignant neoplasm that affects the rectum.  Representative examples include carcinoma, lymphoma, and sarcoma.","Malignant Rectal Neoplasm | Malignant Neoplasm of Rectum | Malignant Neoplasm of the Rectum | Malignant Rectal Tumor | Malignant Tumor of Rectum | Malignant Tumor of the Rectum | Malignant neoplasm of rectum",,,,,,,,,,,,,,,"443390","Malignant tumor of rectum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007404","Cianidanol","C63654","A flavonol with a hydroxyl group at C-5, -7, -3', and -4'. The (+) enantiomer has the R and S configuration at C-2, and C-3, respectively.","Cianidanol | (+)-Catechin | (2R,3S)-2-(3,4-dihydroxyphenyl)chroman-3,5,7-triol | (2R-trans)-2-(3,4-Dihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3,5,7-triol | (2R-trans)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3,5,7-triol | C | CIANIDANOL | Catechin | Catechin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1962954","Cheilitis, CTCAE","C57901","A disorder characterized by inflammation of the lip.","Cheilitis, CTCAE | Cheilitis | Cheilitis | Cheilitis Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010054","Coronary Atherosclerosis","C35505","Atherosclerosis of the coronary vasculature.","Coronary Atherosclerosis | ",,,,,,,,,,,,,,,"40481919","Coronary atherosclerosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1962975","Face Pain, CTCAE","C56075","Unintended facial pain associated with a medical procedure or administration of a drug.","Face Pain, CTCAE | Face Pain Adverse Event | Face Pain Adverse Event | Face pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018805","Heart Injury","C45430","Trauma to the cardiac muscle or valves.","Heart Injury | ",,,,,,,,,,,,,,,"4311280","Injury of heart",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020672","Decreased Core Body Temperature","C50523","Abnormally low body temperature.","Decreased Core Body Temperature | Hypothermia",,,,,,,,,,,,,,,"435371","Hypothermia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1963162","Lymphocele, CTCAE","C55705","A disorder characterized by a cystic lesion containing lymph.","Lymphocele, CTCAE | Lymphocele | Lymphocele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027363","Occupational Group","C71549","Individuals who have been grouped together in a study based on the similarity of their occupations.","Occupational Group | Occupational Cohort",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030794","Pelvic Pain","C40122","Painful sensation in the pelvis.","Pelvic Pain | Pelvic pain",,,,,,,,,,,,,,,"4147829","Pain in pelvis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033371","Prolactin","C778","Prolactin (227 aa, ~26 kDa) is encoded by the human PRL gene. This protein is involved in the promotion of lactation in the mammary gland.","Prolactin | Decidual Prolactin | Growth Hormone A1 | PRL | prolactin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963234","Serum Sickness, CTCAE_3","C54740","No Value Exists","Serum Sickness, CTCAE 3.0 | Serum Sickness Adverse Event | Serum sickness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040357","Toe","C33788","One of the terminal digits of the foot.","Toe | TOE",,,,,,,,,,,,,,,"4106395","Toe structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1963260","Ureter Obstruction, CTCAE","C57086","No Value Exists","Ureter Obstruction, CTCAE | Ureter Obstruction Adverse Event | Ureter obstruction | Ureteral Obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0057981","Difenoxin","C65381","A phenylpiperidine with antidiarrheal activity and an active metabolite of diphenoxylate. Difenoxin is chemically related to the narcotic opioid meperidine. Difenoxin acts primarily on the gastrointestinal wall by binding to opioid receptors on acetylcholine-containing nerves and inhibiting the release of acetylcholine from presynaptic nerve terminals. This leads to a reduction in intestinal motility. Difenoxin hydrochloride also mimics the action of endogenous opioid peptides at the CNS opioid receptors, (primarily mu-receptors), thereby inducing CNS effects.","Difenoxin | 1-(3-Cyano-3,3-diphenylpropyl)-4-phenylisonipecotic Acid | DIFENOXIN | McN-JR 15,403-11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0151878","Prolonged QT Interval by ECG Finding","C71034","An electrocardiographic finding in which the QT interval not corrected for heart rate is prolonged. Thresholds for different age, gender, and patient populations exist. (CDISC)","Prolonged QT Interval by ECG Finding | PROLONGED QT | Prolonged QT | Prolonged QT Interval | Prolonged QT Interval | Prolonged QT Interval by EKG Finding | Prolonged QT interval | QT Prolongation",,,,,,,,,,,,,,,"4008859","Prolonged QT interval",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4231612","Epiphora","C50552","Excessive tearing of the eyes due to either tear overproduction or impaired drainage of the tear ducts. Causes of tear overproduction include eye irritation (e.g., eye infection, foreign body in the eye), headache, pain reaction, allergies, sinusitis, and injury to the eye.","Epiphora | Excessive Tear Production | Excessive Tearing | Excessive Tearing | Watering Eyes | Watering eyes",,,,,,,,,,,,,,,"435553","Epiphora",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1962962","Hyperpigmentation, CTCAE","C57998","An adverse reaction characterized by darkening of the skin.","Hyperpigmentation, CTCAE | Hyperpigmentation | Hyperpigmentation Adverse Event | Hyperpigmentation Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205042","Coronary Artery","C12843","One of two arteries that arise from the aortic sinuses of the ascending aorta and supply blood to the myocardium","Coronary Artery | ARTERY, CORONARY | CORONARY ARTERY | Coronary artery structure (body structure)",,,,,,,,,,,,,,,"4219982","Coronary artery structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0231800","Expiration","C50391","Expelling modified air from the lungs; breathing out.","Expiration | Exhalation | Exhaling | Expiratory | Expiring",,,,,,,,,,,,,,,"4238519","Expiration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1963233","Seroma, CTCAE","C58401","A finding of tumor-like collection of serum in the tissues.","Seroma, CTCAE | Seroma | Seroma | Seroma Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337704","Ashkenazi Jew","C17950","Ashkenazi Jews, also called Ashkenazim, are Jews who are descendants of Jews from Germany, Poland, Austria and Eastern Europe.","Ashkenazi Jew | ASHKENAZI JEW | Ashkenazim",,,,,,,,,,,,,,,"4218742","Ashkenazi Jew, follower of religion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4230880","Skin Photosensitivity","C38004","Increased sensitivity of the skin to light exposure.","Skin Photosensitivity | Photosensitivity | Photosensitivity",,,,,,,,,,,,,,,"4234104","Photosensitivity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1963240","Bladder Spasms, CTCAE_3","C56757","No Value Exists","Bladder Spasms, CTCAE 3.0 | Bladder Spasm Adverse Event | Bladder spasms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0429097","QRS Complex","C41329","An electrocardiographic finding that represents depolarization of the ventricular myocardium. Normally the ventricles are activated simultaneously.","QRS Complex | EKG QRS Complex",,,,,,,,,,,,,,,"4064625","QRS complex feature",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0447586","Bladder Trigone","C12331","The triangular area in the bladder mucosa that is formed by the two ureteral orifices and the urethral orifice.","Bladder Trigone | BLADDER, TRIGONE | Trigone | Trigone of Bladder | Trigone of bladder | Trigone of the Bladder | Urinary Bladder Trigone | trigone of urinary bladder",,,,,,,,,,,,,,,"4071704","Trigonal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0887732","Azathioprine Sodium","C47961","The sodium salt form of azathioprine, a pro-drug of purine analogue with immunosuppressive activity. Azathioprine is converted in vivo to its active metabolite 6-mercaptopurine (6-MP), which substitutes for the normal nucleoside and mistakenly gets incorporated into DNA sequences. This leads to inhibition of DNA, RNA, and protein synthesis. As a result, cell proliferation may be inhibited, particularly in lymphocytes and leukocytes.","Azathioprine Sodium | AZATHIOPRINE SODIUM | Imuran | Imurel | azathioprine sodium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006114","Cerebral Edema","C4909","Swelling due to an excessive accumulation of fluid in the brain.","Cerebral Edema | Cerebral edema | Edema cerebral | edema, cerebral",,,,,,,,,,,,,,,"376690","Cerebral edema",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0700602","Evening Primrose Oil","C72199","An oil extracted from the seeds of the plant Oenothera biennis, a North American native biennial branching shrub with small yellow flowers. The oil contains the fatty acids linoleic acid and gamma-linolenic acid (GLA), a rare essential fatty acid.","Evening Primrose Oil | Common Evening Primrose | EVENING PRIMROSE OIL | Fever Plant | Great Evening-Primrose | King's-cure-all | Night Willow-herb | Scabish | Scurvish | Tree Primrose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0719064","Choline Magnesium Trisalicylate","C29244","A nonsteroidal anti-inflammatory drug (NSAID) belonging to the salicylate family.  Choline magnesium trisalicylate inhibits inflammation-related prostaglandin synthesis. This agent's analgesic effect is mediated through peripheral and central pathways, resulting in a decrease in pain perception; its antipyretic effect is mediated via the hypothalamic heat regulation center. (NCI04)","Choline Magnesium Trisalicylate | CHOLINE MAGNESIUM TRISALICYLATE | Trilisate | Trisalicylate | choline magnesium trisalicylate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0814896","Significance Level","C41265","The probability of a type I error of a statistical hypothesis test, a fixed probability of wrongly rejecting the null hypothesis H0, if it is in fact true. It is set by the investigator in relation to the consequences of such an error. The often chosen significance level is 5%.","Significance Level | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0950521","cyclophosphamide/fluorouracil/methotrexate protocol","C9874","A regimen consisting of cyclophosphamide, methotrexate and fluorouracil, used as a neoadjuvant or adjuvant treatment for breast cancer; also used for the treatment of recurrent and metastatic breast cancer.","CMF Regimen | CMF | CMF regimen | CTX/5-FU/MTX | Cyclophosphamide/Fluorouracil/Methotrexate | Cyclophosphamide/Fluorouracil/Methotrexate | Cytoxan-Methotrexate-Fluorouracil Regimen | Oral Cyclophosphamide/Methotrexate/Fluorouracil | super-CM regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1186762","Dakins Solution","C28970","A highly diluted solution of sodium hypochlorite (0.5% w/v) with topical anti-infective activity. Dakin's solution is used as an antiseptic to clean infected topical wounds.","Dakins Solution | Aqueous Solution of Sodium Hypochlorite | Dakins Fluid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515975","Anatomic Sites, Other","C13400","An atomic site other than those already listed.","Other Anatomic Site | Anatomic Sites, Other | Anatomic Sites, Other | Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201839","Aldolase Measurement","C74731","The determination of the amount of aldolase present in a sample.","Aldolase Measurement | ALDOLASE | Aldolase",,,,,,,,,,,,,,,"4196218","Aldolase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0853073","PUVA Photochemotherapy","C29973","Phototherapy that combines the use of psoralen with UVA light as a treatment for various skin conditions.","PUVA Photochemotherapy | PUVA | Photochemotherapy | Psoralen + UVA Treatment | Psoralen plus Ultraviolet A Light Therapy | Psoralen/UVA Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1962967","Retinoic Acid Syndrome, CTCAE","C56635","A disorder characterized by weight gain, dyspnea, pleural and pericardial effusions, leukocytosis and/or renal failure originally described in patients treated with all-trans retinoic acid.","Retinoic Acid Syndrome, CTCAE | Retinoic Acid Syndrome | Retinoic Acid Syndrome | Retinoic Acid Syndrome Adverse Event | Retinoic acid syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1550738","Before Meals","C64592","Prior to ingestion of food.","Before Meals | AC | Before Meal | ante cibum",,,,,,,,,,,,,,,"4145729|4208357","Before meal|Before food",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1522058","Coagulative Necrosis","C39608","Ischemic tissue necrosis characterized by the preservation of the architectural pattern and a necrotic ghost appearance of the cells.","Coagulative Necrosis | ",,,,,,,,,,,,,,,"4138252","Coagulative necrosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0585327","Every Twelve Hours","C64502","Every twelve hours.","Every Twelve Hours | Every 12 hours | Q12H",,,,,,,,,,,,,,,"4141101","Every twelve hours",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1275545","Every Sixteen Hours","C64506","Every sixteen hours.","Every Sixteen Hours | Every 16 hours | Q16H",,,,,,,,,,,,,,,"4262455","Every sixteen hours",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1275557","Every Five Days","C71124","Every five days.","Every Five Days | Every 5 days | Q5D",,,,,,,,,,,,,,,"4288396","Every five days",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512328","Hemangioma of the Mouse Nervous System","C22046","No Value Exists","Hemangioma of the Mouse Nervous System | Haemangioma of the Mouse Nervous System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519959","Vasovagal","C38048","Relating to the action of the vagus nerve upon the blood vessels.","Vasovagal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556361","Fatigue, CTCAE_3","C55330","An unfavorable feeling of fatigue temporally associated with the use of a medical treatment or procedure.","Fatigue, CTCAE 3.0 | Fatigue (asthenia, lethargy, malaise) | Fatigue Adverse Event | Fatigue, CTCAE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1557806","Adverse Event Associated with the Kidney and Genitourinary System","C53805","No Value Exists","Adverse Event Associated with the Kidney and Genitourinary System | Adverse Event Associated with Renal and Genitourinary | RENAL/GENITOURINARY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1558153","Adverse Event Associated with Sexual and Reproductive Function","C53797","No Value Exists","Adverse Event Associated with Sexual and Reproductive Function | SEXUAL/REPRODUCTIVE FUNCTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963079","Restrictive Cardiomyopathy, CTCAE","C55069","A disorder characterized by an inability of the ventricles to fill with blood because the myocardium (heart muscle) stiffens and loses its flexibility.","Restrictive Cardiomyopathy, CTCAE | Restrictive Cardiomyopathy | Restrictive cardiomyopathy | Restrictive cardiomyopathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007847","Malignant Cervical Neoplasm","C9311","A primary or metastatic malignant neoplasm involving the cervix.","Malignant Cervical Neoplasm | Malignant Cervical Tumor | Malignant Cervix Neoplasm | Malignant Cervix Tumor | Malignant Cervix Uteri Neoplasm | Malignant Cervix Uteri Tumor | Malignant Neoplasm of Cervix | Malignant Neoplasm of Cervix Uteri | Malignant Neoplasm of Cervix Uteri | Malignant Neoplasm of Uterine Cervix | Malignant Neoplasm of the Cervix | Malignant Neoplasm of the Cervix Uteri | Malignant Neoplasm of the Uterine Cervix | Malignant Tumor of Cervix | Malignant Tumor of Cervix Uteri | Malignant Tumor of Uterine Cervix | Malignant Tumor of the Cervix | Malignant Tumor of the Cervix Uteri | Malignant Tumor of the Uterine Cervix | Malignant Uterine Cervix Neoplasm | Malignant Uterine Cervix Tumor | Malignant neoplasm of cervix uteri, unspecified",,,,,,,,,,,,,,,"198984","Malignant tumor of cervix",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1962974","Chylothorax, CTCAE","C58027","A disorder characterized by milky pleural effusion (abnormal collection of fluid) resulting from accumulation of lymph fluid in the pleural cavity.","Chylothorax, CTCAE | Chylothorax | Chylothorax",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009812","Constitutional Symptom","C38469","A group of symptoms that affect an individual's general well being. Representative examples include fever, chills, fatigue, weakness, and weight loss.","Constitutional Symptom | CONSYMPT | Constitutional Finding | Constitutional Symptoms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009830","Consumption of goods","C66716","The using or using up of goods and services, especially the rate at which they are used.","Consumption of Goods | Consumption",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011127","Pressure Sore","C50706","Death of tissue due to external pressure.","Pressure Sore | Bedsore | Decubiti | Decubitus | Decubitus Ulcer | Pressure Sore Or Ulcer | Pressure Sores | Pressure Ulcer",,,,,,,,,,,,,,,"37151944|37159532","Pressure injury|Pressure injury",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0014485","Epicatechin","C63651","A catechin with the R configuration at C-2 and C-3.","L-Epicatechin | (-)-Epicatechin | (-)-Epicatechol | (2R-cis)-2-(3,4-Dihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3,5,7-triol | EC | Epicatechin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015333","Radiation Exposure","C61398","Exposure to radioactive materials or ionizing radiation, whether by external irradiation, contact or contamination with radioactive material, or incorporation of radioactive materials, as in the case of certain diagnostic procedures.","Radiation Exposure | Radiation",,,,,,,,,,,,,,,"438630","Exposure to radiation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015420","Eyebrow","C32575","The arched strip of hair on the bony ridge above each eye socket.","Eyebrow | EYEBROW | eyebrow",,,,,,,,,,,,,,,"4213292","Eyebrow structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016441","Studies, Follow-Up","C15234","Study in which persons exposed to risk or given a designated preventive or therapeutic regimen are observed over a period or at intervals to determine the outcome of the exposure or regimen.","Follow-Up Study | Follow-up Study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016980","Gallium","C66798","An element with atomic symbol Ga, atomic number 31, and atomic weight 69.7. A rare silvery (usually trivalent) metallic element; brittle at low temperatures but liquid above room temperature; occurs in trace amounts in bauxite and zinc ores.","Gallium | GALLIUM | Ga",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017313","patient care","C15239","Any of the services rendered for the benefit of a patient.","Patient Care | Patient Care Delivery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3278394","Hallucination","C37961","A false sensory perception in the absence of an external stimulus, as distinct from an illusion which is a misperception of an external stimulus.","Hallucination | Hallucinations | hallucination",,,,,,,,,,,,,,,"433031","Hallucinations",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1963123","Valvular Heart Disease, CTCAE","C55071","No Value Exists","Valvular Heart Disease, CTCAE | Valvular Heart Disease Adverse Event | Valvular heart disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018964","Hematoxylin","C75425","No Value Exists","Hematoxylin | Benz(b)indeno(1,2-d)pyran-3,4,6a,9,10(6H)-pentol, 7,11b-dihydro-, cis-(+)- | C.I. 75290 | HEMATOXYLIN | Haematoxylin | Natural Black 1",,,,,,,,,,,,,,,"4131140","Hematoxylin stain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021141","Syndrome of Inappropriate Antidiuretic Hormone Secretion","C3988","A syndrome characterized by abnormal secretion of antidiuretic hormone in conjunction with neoplastic growth occurring anywhere in the body.","Syndrome of Inappropriate Antidiuretic Hormone Secretion | Ectopic ADH Secretion | Ectopic Antidiuretic Hormone Secretion | Inappropriate ADH Secretion | Inappropriate Antidiuretic Hormone Secretion Syndrome | Inappropriate Antidiuretic Hormone Secretion Syndrome | Inappropriate Arginine Vasopressin Secretion | SIADH | Syndrome of Inappropriate Antidiuretic Hormone | Syndrome of Inappropriate Vasopressin Secretion",,,,,,,,,,,,,,,"4207539","Syndrome of inappropriate vasopressin secretion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022568","Keratitis","C26805","Inflammation of the cornea.","Keratitis | ",,,,,,,,,,,,,,,"374035","Keratitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1963156","LARYNGEAL EDEMA","C58189","Laryngeal edema resulting from a known treatment.","Larynx Edema, CTCAE | Edema, larynx | Larynx Edema Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963081","Cerebrospinal Fluid Leak, CTCAE","C55417","No Value Exists","Cerebrospinal Fluid Leak, CTCAE | Cerebrospinal Fluid Leak Adverse Event | Leak, cerebrospinal fluid (CSF)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024523","Malabsorption Syndrome","C3214","A syndrome resulting from the inadequate absorption of nutrients in the small intestine. Symptoms include abdominal pain, bloating, and diarrhea.","Malabsorption Syndrome | Malabsorption | malabsorption syndrome",,,,,,,,,,,,,,,"4138253","Malabsorption syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024894","Mastitis","C53662","Inflammation of breast tissue during lactation or postpartum due to an obstructed duct or infection.","Mastitis | Breast infection | mastitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025381","Mephenytoin","C66091","A heterocyclic organic compound with anticonvulsant property. Although the mechanism of action is not well established, mephenytoin potentially promotes sodium efflux from neurons in motor cortex, and stabilizes the threshold against hyperexcitability caused by excessive stimulation. Thus this agent reduces the membrane sodium gradient and prevents cortical seizure signal spreading. It may cause blood dyscrasias, therefore, this agent was only used after other less toxic anticonvulsants had failed.","Mephenytoin | 2,4-Imidazolidinedione, 5-ethyl-3-methyl-5-phenyl- | 3-Ethylnirvanol | 3-Methyl-5,5-phenylethylhydantoin | MEPHENYTOIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435388","Floor of Mouth","C54187","The horseshoe-shaped part of the oral cavity bounded superiorly by the ventral surface of the tongue, inferiorly by the mylohyoid muscle, anterolaterally by the gingival surfaces of the mandible, and posteriorly by the anterior tonsillar pillar.","Floor of Mouth | FLOOR OF MOUTH | Floor Of Mouth | Floor of mouth | Floor of mouth, NOS | Floor of the Mouth | floor of mouth | floor of oval cavity | floor of the oval cavity | mouth floor",,,,,,,,,,,,,"UBERON:0003679","mouth floor","4267224","Floor of mouth structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL421545","Chiasma","C28351","An anatomical intersection or crossing of two tracts, such as with nerve or ligament fibers.","Chiasma | chiasma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029882","Otitis Media","C34885","Inflammation of the anatomical structures of the middle ear, which is most often caused by an infectious process. Symptoms include erythema and edema of the tympanic membrane, pain, and possibly fever.","Otitis Media | Medial Otitis | Middle Ear Inflammation | Middle ear inflammation",,,,,,,,,,,,,,,"372328","Otitis media",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033971","Group Therapy","C21042","A form of psychiatric treatment in which six to eight patients meet a specific number of times with a therapist.  The value of this type of therapy is the opportunity for gaining insight from others into one's life experience. (Taber's)","Group Therapy | ",,,,,,,,,,,,,,,"4296166","Group psychotherapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1963225","Rectum Pain, CTCAE_3","C56205","No Value Exists","Rectum Pain, CTCAE 3.0 | Rectum Pain Adverse Event | Rectum pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035507","Hind-Brain","C40336","One of three major developmental divisions of the brain, comprising the pons, the medulla oblongata, and the cerebellum.","Hind-Brain | ",,,,,,,,,,,,,,,"4120498","Hindbrain structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038848","Supplies","C60759","Goods for the support and maintenance of some endeavor.","Supplies | Goods",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039866","Thigh","C33763","A part of the lower limb, located between hip and knee.","Thigh | THIGH | hind limb stylopod | hind limb stylopodium | hind propodium | hindlimb propodium | hindlimb stylopod | hindlimb stylopodium | proximal segment of free lower limb | stylopod of hind limb | stylopod of hindlimb | stylopod of lower limb | thigh | upper leg",,,,,,,,,,,,,"UBERON:0000376","hindlimb stylopod","4285289","Thigh structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042237","Malignant Vaginal Neoplasm","C7410","A primary or metastatic malignant neoplasm involving the vagina. Representative examples include carcinomas and sarcomas.","Malignant Vaginal Neoplasm | Malignant Neoplasm of Vagina | Malignant Neoplasm of the Vagina | Malignant Tumor of Vagina | Malignant Tumor of the Vagina | Malignant Vagina Neoplasm | Malignant Vagina Tumor | Malignant Vaginal Tumor | Malignant neoplasm of vagina",,,,,,,,,,,,,,,"4177114","Malignant tumor of vagina",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1963280","Vitreous Hemorrhage, CTCAE_3","C55921","No Value Exists","Vitreous Hemorrhage, CTCAE 3.0 | Vitreous Hemorrhage Adverse Event | Vitreous hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0055711","Ciclopirox","C61677","A synthetic, broad-spectrum antifungal agent with additional antibacterial and anti-inflammatory activities. Ciclopirox exerts its action by binding to and chelating trivalent cations, such as Fe3+ and Al3+, thereby inhibiting the availability of essential co-factors for enzymes. This may lead to a loss of activity of enzymes that are essential for cellular metabolism, organization of cell wall structure and other crucial cell functions. In addition, ciclopirox exerts its anti-inflammatory activity by inhibiting 5-lipoxygenase and cyclooxygenase (COX).","Ciclopirox | CICLOPIROX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0059422","Epicatechin-3-Gallate","C68454","A (-)-epicatechin with a galloyloxy (trihydroxybenzoyloxy) group instead of the hydroxyl group at C-3; (-)-epicatechin esterified with gallic acid (trihydroxybenzoid acid) at C-3.","Epicatechin-3-Gallate | ECG | [(2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chroman-3-yl] 3,4,5-trihydroxybenzoate | cis-3,3',4',5,7-pentahydroxyflavane 3-gallate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0083381","Meloxicam","C61439","An oxicam derivative and a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Unlike traditional nonselective NSAIDs, meloxicam preferentially inhibits the activity of cyclo-oxygenase II (COX-II), resulting in a decreased conversion of arachidonic acid into prostaglandin precursors. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of meloxicam.","Meloxicam | 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide | MELOXICAM | Mobec | Mobic | Mobicox | Movalis | Movatec",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013819","Electroencephalography","C38054","The neurophysiologic exploration of the electrical activity of the brain by the application of electrodes to the scalp. The resulting traces are known as an electroencephalogram (EEG). This test is used to assess brain damage, epilepsy and other problems.","Electroencephalography | EEG | ELECTROENCEPHALOGRAPHY | electroencephalogram",,,,,,,,,,,,,,,"4181917","Electroencephalogram",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0149663","Dehiscence","C50527","A splitting open of an anatomical structure, zone, or organ with the exposure or discharge of its content.","Dehiscence | Organ Dehiscence",,,,,,,,,,,,,,,"4007471","Dehiscence",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0149676","Enzyme Deficiency","C3492","A finding in which there is a subnormal amount of an enzyme. Enzymes are proteins that are necessary in certain catabolic processes.","Enzyme Deficiency | Specific Enzyme Deficiency",,,,,,,,,,,,,,,"434899","Specific enzyme deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152463","Pleurectomy","C51651","The surgical removal of all or part of the pleura.","Pleurectomy | Excision of Pleura | PLEURECTOMY | pleurectomy",,,,,,,,,,,,,,,"4079730","Pleurectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153594","Malignant Testicular Neoplasm","C7251","A primary or metastatic malignant neoplasm that affects the testis. Representative examples include malignant germ cell tumors, sarcomas, leukemias, and lymphomas.","Malignant Testicular Neoplasm | Malignant Neoplasm of Testis | Malignant Neoplasm of the Testis | Malignant Testicular Tumor | Malignant Tumor of Testis | Malignant Tumor of the Testis | Malignant neoplasm of unspecified testis, unspecified whether descended or undescended | Testicular Cancer | Testicular ca. (no germ/tropho.) | Testicular cancer (excluding germ cell or trophoblastic cancer) | testicular cancer",,,,,,,,,,,,,,,"4177115","Malignant tumor of testis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4014826","Irregular Menstruation","C35219","Deviations from the normal process; e.g. delayed, difficult, profuse, scanty, unusual bleeding, etc.","Irregular Menstruation | Irregular menstruation | Menstrual Cycle Irregularities | Menstrual Irregularities",,,,,,,,,,,,,,,"196168","Irregular periods",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704684","Filter Device","C49956","A device designed to remove something from whatever passes through it.","Filter Device | Filter | Filter Device Component",,,,,,,,,,,,,,,"4023557","Filter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0189557","Pleurodesis","C66899","A therapeutic surgical procedure in which the pleural space is surgically eliminated by the adherence of the visceral and parietal pleurae.","Pleurodesis | PLEURODESIS | Pleurodesis, NOS | pleurodesis",,,,,,,,,,,,,,,"4222936","Pleurodesis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0201849","Antidiuretic Hormone Measurement","C74847","The determination of the amount of antidiuretic hormone present in a sample.","Antidiuretic Hormone Measurement | ADH | Antidiuretic Hormone | Vasopressin",,,,,,,,,,,,,,,"4268036","Antidiuretic hormone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0226958","Base of Tongue","C12228","The posterior one third of the tongue behind the terminal sulcus that forms the anterior aspect of the oropharynx responsible for swallowing and modification of the voice in speech.","Base of Tongue | BASE OF THE TONGUE | Base of Tongue | Base of the Tongue | Base of the Tongue | Base of tongue | Base of tongue, NOS | Posterior Tongue | Structure of root of tongue (body structure) | posterior part of tongue",,,,,,,,,,,,,,,"4169910","Structure of root of tongue",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227791","Abnormal Vaginal Discharge","C50795","Abnormal secretions from the vagina.","Abnormal Vaginal Discharge | Vaginal Discharge | Vaginal discharge",,,,,,,,,,,,,,,"4155070","Vaginal discharge",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1963176","Bladder Pain, CTCAE","C56015","No Value Exists","Bladder Pain, CTCAE | Bladder Pain Adverse Event | Bladder pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0267573","Anal Polyp","C3957","A non-neoplastic or neoplastic polypoid lesion that arises from the anus.  Representative examples include the fibroepithelial polyp and squamous papilloma.","Anal Polyp | Polyp of Anus | Polyp of the Anus",,,,,,,,,,,,,,,"4228686","Anal polyp",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0278060","Mental Status, CTCAE","C55432","An adverse event resulting in a change in a patient's intellectual capacity, emotional state, or general mental health.","Mental Status, CTCAE | Mental Status Adverse Event | Mental Status Adverse Event | Mental status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963148","Iron Overload, CTCAE","C55993","A disorder characterized by accumulation of iron in the tissues.","Iron Overload, CTCAE | Iron Overload | Iron Overload | Iron Overload Adverse Event | Iron overload | Iron overload Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337443","Sodium Measurement","C64809","A quantitative measurement of the amount of sodium present in a sample.","Sodium Measurement | SODIUM | Sodium",,,,,,,,,,,,,,,"4097430","Sodium measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL473772","Cognitive Dysfunction","C46083","Interference or disruption of cognitive processes.  This term encompasses a large number of problems and issues associated with intellectual functioning and information processing. 2005","Cognitive Dysfunction | Neurocognitive Dysfunction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2919142","Short Stature, CTCAE","C55745","No Value Exists","Short Stature, CTCAE | Short Stature Adverse Event | Short stature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376358","Malignant Prostate Neoplasm","C7378","A primary or metastatic malignant tumor involving the prostate gland.  The vast majority are carcinomas.","Malignant Prostate Neoplasm | Malignant Neoplasm of Prostate | Malignant Neoplasm of the Prostate | Malignant Prostate Tumor | Malignant Tumor of Prostate | Malignant Tumor of the Prostate | Malignant neoplasm of prostate",,,,,,,,,,,,,,,"200962|4163261","Primary malignant neoplasm of prostate|Malignant tumor of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0439178","Percent of Positive Cells","C70460","A quantitative measurement of the proportion of cells that are positive for a given biomarker.","Percent of Positive Cells | % Positive | PERCENT POSITIVE CELL | Percent Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0518179","Voice Alteration","C61043","Change in the sound and/or speed of the voice. Causes include laryngeal polyp, laryngitis, laryngeal carcinoma, throat carcinoma, Parkinson's disease, multiple sclerosis, stroke, hypothyroidism, oral surgery, tracheostomy, tracheal injury, and laryngeal injury.","Voice Alteration | Change in Voice | Change in Voice | Voice Alternation | Voice alteration",,,,,,,,,,,,,,,"4164647","Change in voice",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0521083","Piper methysticum","C72403","An herb native to islands in the South Pacific. Substances taken from the root have been used in some cultures to relieve stress, anxiety, tension, sleeplessness, and problems of menopause. Kava kava may increase the effect of alcohol and of certain drugs used to treat anxiety and depression. The U.S. Food and Drug Administration advises users that kava kava may cause severe liver damage. The scientific name is Piper methysticum.","Piper methysticum | MACROPIPER METHYSTICUM WHOLE | PIPER METHYSTICUM WHOLE | Piper methysticum G.Forst. | intoxicating pepper | kava | kava kava | rauschpfeffer | tonga | yangona",,,,,,,,,,,,,,,"4230632","Piper methysticum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1963161","Liver Pain, CTCAE","C56115","An adverse event characterized by pain originating in the liver.","Liver Pain, CTCAE | Liver Pain Adverse Event | Liver pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0543450","Carteolol Hydrochloride","C28905","A synthetic quinolinone derivative, antihypertensive Carteolol Hydrochloride is a nonselective beta-adrenoceptor blocking agent for beta-1 and beta-2 receptors with no membrane-stabilizing activity but moderate intrinsic sympathomimetic effects. It is used for treatment of hypertension and certain arrhythmias, and as an anti-angina and antiglaucoma agent. (NCI04)","Carteolol Hydrochloride | CARTEOLOL HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0585361","Twice Daily","C64496","Two times per day, at unspecified times.","Twice Daily | BD | BID | Twice a day | Twice per day | Two Times Daily | Two Times per Day | bis in die",,,,,,,,,,,,,,,"4044571","Twice a day",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0598285","Diagnostic Accuracy","C41440","Tthe proportion of all the observations that have been classified correctly by the diagnostic procedures in given population, or using some diagnostic test, or by some medical institution or professional.","Diagnostic Accuracy | Accuracy of Diagnosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0599819","Peripheral Blood Lymphocyte","C12938","A lymphocyte circulating in the peripheral blood.","Peripheral Blood Lymphocyte | PBL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0749980","Urine Color Change, CTCAE","C57098","No Value Exists","Urine Color Change, CTCAE | Urine Color Change Adverse Event | Urine color change",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0772501","Levalbuterol","C74196","A short-acting sympathomimetic beta-2 adrenergic receptor agonist with bronchodilator activity. Levalbuterol binds to beta-2 adrenergic receptors in bronchial smooth muscle and activates intracellular adenyl cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increased cAMP levels lead to the activation of protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in relaxation of bronchial smooth muscles. The increased cAMP concentrations also inhibit the release of inflammatory mediators, especially from mast cells.","Levalbuterol | LEVALBUTEROL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0805732","Completion Status","C41202","A term used to describe the workflow progression of a document or the state of the project or activity in terms of being finished, concluded, or made whole.","Completion Status | Document Completion Status | STAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0870371","Craving","C41365","The desire to experience the effect(s) of a previously used psycho-active substance. It has to be noted that not all drug craving is based on withdrawal, since craving can often occur in the absence of withdrawal.","Craving | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0907402","Insulin Glargine","C47564","A recombinant human insulin analog with long-acting, blood glucose-lowering activity. Insulin glargine, like regular types of human insulin, regulates glucose metabolism by binding to insulin receptors on muscle and fat cells, thereby facilitating the cellular uptake of glucose. This lowers blood glucose levels. At the same time, insulin glargine inhibits the liver's conversion of stored glycogen into glucose, which also contributes to lower blood glucose levels. Insulin glargine also inhibits lipolysis in adipose tissue, inhibits proteolysis, and enhances protein synthesis. (NCI05)","Insulin Glargine | INSULIN GLARGINE | Insulin Glargine Recombinant | Lantus | insulin glargine | insulin glargine recombinant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698620","CDISC SDTM Anatomical Location Terminology","C74456","Terminology codelist used with Anatomical Locations within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.","CDISC SDTM Anatomical Location Terminology | Anatomical Location | LOC | SDTM-LOC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0701492","Fondaparinux","C73142","A synthetic glucopyranoside with antithrombotic activity. Fondaparinux selectively binds to antithrombin III, thereby potentiating the innate neutralization of activated factor X (Factor Xa) by antithrombin. Neutralization of Factor Xa inhibits its activity and interrupts the blood coagulation cascade, thereby preventing thrombin formation and thrombus development.","Fondaparinux | FONDAPARINUX | Natural Heparin Pentasaccharide | ORG 31540 | PENTA | SR 90107 | fondaparinux",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1141640","Carrot","C72000","No Value Exists","Carrot | CARROT",,,,,,,,,,,,,,,"4106300","Carrot",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1305372","Bronchial Lymph Node","C32232","Lymph node located in the bronchi.","Bronchial Lymph Node | LYMPH NODE, BRONCHIAL",,,,,,,,,,,,,,,"4203158","Structure of hilar lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518542","Ocular Pathology","C18907","Subdiscipline of pathology with a focus on vision and the eye.","Ocular Pathology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333779","Gastric Lymphangioma","C5482","A lymphangioma arising from the stomach.","Gastric Lymphangioma | Lymphangioma of Stomach | Lymphangioma of the Stomach",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517701","Labetuzumab","C2043","A humanized monoclonal antibody that recognizes carcinoembryonic antigen.","Labetuzumab | CEA-Cide | Humanized Anti-CEA Monoclonal Antibody | IMMU-100 | LABETUZUMAB | MAb hMN14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013313","Dura Mater","C32488","The outermost, toughest, and most fibrous of the three membranes (meninges) that surround and protect the brain and spinal cord.","Dura Mater | DURA MATER | Dura",,,,,,,,,,,,,,,"4089184","Dura mater structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519383","Smoking Behavior","C20134","Any of the activities associated with tobacco smoking.","Smoking Behavior | Smoking, Tobacco and Cancer-Behavior",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512287","Gynecologic Oncology Board Certification","C17866","The process by which a person is tested and approved to practice in the specialty field of gynecologic oncology.","Gynecologic Oncology Board Certification | board certification, gynecologic oncology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0520837","Decreased Forced Expiratory Volume","C50524","A decrease in the fraction of the forced vital capacity that is exhaled in a specific number of seconds.","Decreased Forced Expiratory Volume | Forced Expiratory Volume Decreased | Forced expiratory volume decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0853711","Decreased Sperm Count","C61050","A finding indicating the presence of a lower than expected number of spermatozoa in the semen.","Decreased Sperm Count | Reduced Sperm | SPERM, DECREASED | Sperm Count Decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL039490","Tumor Flare, CTCAE","C56637","No Value Exists","Tumor Flare, CTCAE | Tumor Flare Adverse Event | Tumor flare",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1561566","FEV1, CTCAE","C58186","An adverse event marked by a change in FEV1 lung function.","FEV1, CTCAE | FEV(1) | FEV1 Adverse Event | FEV1 Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335151","Other Finding","C36295","An additional finding not previously noted.","Other Finding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963268","Vaginal Dryness, CTCAE_3","C55645","No Value Exists","Vaginal Dryness, CTCAE 3.0 | Vaginal Dryness Adverse Event | Vaginal dryness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205136","Over","C65018","Being above or beyond something.","Over | ",,,,,,,,,,,,,,,"4066802","Over",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1963070","Autoimmune Reaction, CTCAE","C54738","No Value Exists","Autoimmune Reaction, CTCAE | Autoimmune Reaction Adverse Event | Autoimmune reaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0558288","As Required","C64628","No Value Exists","As Required | ",,,,,,,,,,,,,,,"4021818","As required",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0702093","Per Minute","C66967","The number of occurrences of something within a minute of time.","Per Minute | /min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963158","Left Ventricular Diastolic Dysfunction, CTCAE","C55062","An adverse event characterized by impaired functioning of the left ventricle of the heart during the diastole phase of the cardiac cycle.","Left Ventricular Diastolic Dysfunction, CTCAE | Left Ventricular Diastolic Dysfunction Adverse Event | Left ventricular diastolic dysfunction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1275548","Every Twenty-Four Hours","C64515","Every twenty-four hours.","Every Twenty-Four Hours | Every 24 Hours | Every 24 hours | Q24H",,,,,,,,,,,,,,,"4244847","Every twenty four hours",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1275558","Every Five Hours","C64519","Every five hours.","Every Five Hours | Every 5 hours | Q5H",,,,,,,,,,,,,,,"4262458","Every five hours",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1319065","Castrated Male","C54011","A male individual who has had his testicles removed.","Castrated Male | Neutered | Neutered Male",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1319066","Castrated Female","C54014","A female individual who has had her ovaries removed.","Castrated Female | Spayed Female",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510943","Articular Muscle","C32145","A muscle that inserts directly onto the capsule of a joint, acting to retract the capsule in certain movements.","Articular Muscle | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1560185","Adverse Event Associated with Blood and Bone Marrow","C53783","No Value Exists","Adverse Event Associated with Blood and Bone Marrow | BLOOD/BONE MARROW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880932","Gastrointestinal Perforation, CTCAE","C53820","An adverse event marked by rupture in the wall of a structure of the gastrointestinal system.","Gastrointestinal Perforation, CTCAE | Gastrointestinal Perforation Adverse Event | Gastrointestinal Perforation Adverse Event | Perforation, GI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1559995","Adverse Event Associated with the Musculoskeletal System and Soft Tissue","C53807","No Value Exists","Adverse Event Associated with the Musculoskeletal System and Soft Tissue | Adverse Event Associated with Musculoskeletal and Soft Tissue | MUSCULOSKELETAL/SOFT TISSUE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2242975","Urinary Frequency or Urgency, CTCAE","C57095","No Value Exists","Urinary Frequency or Urgency, CTCAE | Urinary Frequency or Urgency Adverse Event | Urinary frequency/urgency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515029","Subsegmental Bronchus of Left Lung","C41267","A part the bronchial tree of the left lung, an air passage arising from any segmental bronchus of the left lung and passing to the naturally delimited part of lung segment (subsegment), where it further subdivides into smaller passages.","Subsegmental Bronchus of Left Lung | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707265","Capsular Invasion","C46128","A microscopic finding indicating the infiltration of the capsule that surrounds an organ by a malignant cellular population.","Capsular Invasion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0192152","Wedge Biopsy","C51916","Removal of a wedge-shaped portion of tissue, for microscopic examinaton.","Wedge Biopsy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1098961","Polyvinylpyrrolidone-Sodium Hyaluronate Gel","C61593","An oral bioadherent gel containing polyvinylpyrrolidone (PVP) and sodium hyaluronate with muco-protective activity. Upon oral application, this gel adheres to the mucosal surface of the mouth and throat, forming a thin layer that acts as a barrier to protect exposed and sensitized nerve endings from the painful stimuli associated with eating, drinking, and talking.","Polyvinylpyrrolidone-Sodium Hyaluronate Gel | Gelclair | polyvinylpyrrolidone-sodium hyaluronate gel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880311","Food Component","C1930","Substances introduced into the body by dietary means.","Food Component | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511814","Devil's Foot/Jambul","C28980","An herbal combination of two plants, devil's claw (Harpagophytum procumbens) and jambul (Eugenia jambolana) that may be administered both orally and topically in various formulations.  Devil's claw has been used as a tonic, as a hypoglycemic, to cleanse the lymph system, and in the treatment of arthritis and rheumatism.  This agent may have anti-inflammatory and analgesic properties, possibly due to the presence of antioxidants, phenols, tannins, triterpenoids and volatile oils.  Jambul seeds and fruits have important carminative and astringent properties and may reduce blood sugar levels. This agent contains glucosides, jamboline and ellagic acid which may check the conversion of starch into sugar. (NCI04)","Devil's Foot/Jambul | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515030","Subsegmental Bronchus of Right Lung","C41268","A part the bronchial tree of the right lung, an air passage arising from any segmental bronchus of the right lung and passing to the naturally delimited part of lung segment (subsegment), where it further subdivides into smaller passages.","Subsegmental Bronchus of Right Lung | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007589","Cell Differentiation Process","C16399","Progressive restriction of the developmental potential and increasing specialization of function which takes place during the development of the embryo and leads to the formation of specialized cells, tissues, and organs.","Cell Differentiation Process | Cell Differentiation | Cell Differentiation | Differentiated | Differentiation | cell differentiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009137","Coal Tar","C44358","A dark brown or black thick liquid obtained by roasting pine wood or formed as a by-product in the production of coke. Coal tar is a complex mixture of organic substances, including benzene, phenols, sulfur, aniline, toluene, xylene, naphthalene, anthracene and phenanthrene. This substance is used to treat certain skin diseases, especially psoriasis, and is used in the synthesis of dyes, drugs, explosives, flavorings, perfumes, preservatives, synthetic resins, paints and stains. Coal tar exposure leads to an increased risk of developing cancer of skin, lung, bladder, kidney and digestive tract as well as leukemia. It is known to be a human carcinogen. (NCI05)","Coal Tar | COAL TAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012125","Dicyclomine","C61720","A carboxylic acid derivative and a selective anticholinergic with antispasmodic activity. Dicyclomine blocks acetylcholine from binding to muscarinic receptors on smooth muscle. This agent has a direct relaxing effect on smooth muscle and therefore prevents spasms in the muscles of the gastrointestinal tract, inhibits gastrointestinal propulsive motility, decreases gastric acid secretion and controls excessive pharyngeal, tracheal and bronchial secretion.","Dicyclomine | DICYCLOMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034603","Radiation Dosimetry","C15312","Any of a number of techniques used to measure radiation exposure.","Radiation Dosimetry | Dosimetry | RADIATION DOSIMETRY | dosimetry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054066","Amoxicillin-Clavulanate Potassium","C1023","A combination of the semisynthetic broad-spectrum antibiotic amoxicillin and the beta-lactamase enzyme inhibitor clavulanate potassium. Clavulanate potassium increases the serum half-life of amoxicillin by inhibiting beta-lactamase-mediated metabolism of amoxicillin.  Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin binding proteins and inhibiting peptidoglycan synthesis, a critical component of bacterial cell walls.","Amoxicillin-Clavulanate Potassium | Augmentin | amoxicillin-clavulanate potassium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0066105","Methenamine Hippurate","C47610","The hippurate salt form of methenamine, a prodrug and inactive weak base that slowly hydrolyzes in acidic urine to ammonia and the effective, urinary tract antiseptic formaldehyde. Formaldehyde probably exerts its antibacterial effect by denaturation of protein. Depending on the urinary concentrations, formaldehyde is either bactericidal or bacteriostatic. Formaldehyde urinary concentrations are dependent on urine pH, volume, and flow rate. Formaldehyde acts as an antibacterial agent against gram-positive and gram-negative organisms.","Methenamine Hippurate | Glycine, N-benzoyl, compound with 1,3,5,7-tetraazatricyclo(3.3.1.1(sup 3,7))decane(1:1) | Hexamethylene Tetramine Hippurate | Hippramine | METHENAMINE HIPPURATE | Urex | Viapta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086908","Repetitive Sequence","C13298","Nucleotide sequences present in multiple copies in the genome. There are several types of repeated sequences. Interspersed (or dispersed) DNA repeats (Interspersed Repetitive Sequences) are copies of transposable elements interspersed throughout the genome.  Flanking (or terminal) repeats (Terminal Repeat Sequences) are sequences that are repeated on both ends of a sequence, for example, the long terminal repeats (LTRs) on retroviruses. Direct terminal repeats are in the same direction and inverted terminal repeats are opposite to each other in direction. Tandem repeats (Tandem Repeat Sequences) are repeated copies which lie adjacent to each other. These can also be direct or inverted. The ribosomal RNA and transfer RNA genes belong to the class of middle repetitive DNA.","Repetitive Sequence | Repeated Sequence | Repeated Sequences | Repetitive Element",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705425","Medical Product Label","C41203","Any display of a written, printed, or graphic matter upon the immediate container of any substance or device to identify something and to indicate the nature, ownership, contents and other characteristic particulars of the object. FDA and the Supreme Court have stated that label is to be interpreted liberally, and includes not only that which accompanies an article but also that which spiritually accompanies an article as well as supplements. Drug label must include: trademark and category of product, description of product chemical and physical characteristics, clinical pharmacology, pharmacokinetics, data on absorption, distribution, metabolism and excretion, special populations, clinical studies, efficacy and safety data, indications, contraindications, adverse events warnings and precautions including lab tests; potential drug interactions, carcinogens statement, pregnancy category.","Medical Product Label | Drug Label | Label | Pharmaceutical Product Label | Product Label | label | package insert | package insert, patient package leaflet | patient package leaflet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278403","Subcutis","C33645","Adipose tissue located under the dermis. It binds underlying structures with the skin. The subcutis is important in the regulation of temperature of the skin itself and the body. The size of this layer varies throughout the body and from person to person.","Subcutis | SUBCUTIS | Subcutaneous Adipose Tissue | Subcutaneous Tissue | hypodermis",,,,,,,,,,,,,,,"4217988","Subcutaneous tissue structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0293359","Insulin Lispro","C29123","A recombinant therapeutic agent which is chemically identical to or similar to endogenous human insulin.  In lispro insulin, the amino acid proline at B-28 and the amino acid lysine at B-29 are reversed, resulting in the rapid dissolution of this insulin to a monomer that is absorbed rapidly after subcutaneous administration.  Lispro insulin is equipotent to human insulin on a molar basis but its effects are faster and of shorter duration.  Endogenous insulin, a pancreatic hormone composed of two polypeptide chains, is important in the normal metabolism of carbohydrates, proteins and fats, promoting glucose utilization and protein synthesis; it has anabolic effects on many types of tissues. (NCI04)","Insulin Lispro | Humalog | INSULIN LISPRO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0357664","Cyclopentolate Hydrochloride","C28948","The hydrochloride salt form of cyclopentolate, an anticholinergic drug. Administered in the eye, cyclopentolate hydrochloride blocks the acetylcholine receptor in the sphincter muscle of the iris and the ciliary muscle, thereby preventing contraction. This dilates the pupil, producing mydriasis, and prevents the eye from accommodating.","Cyclopentolate Hydrochloride | CYCLOPENTOLATE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0520887","ST Segment Depression by ECG Finding","C41330","An electrocardiographic finding of ST segment depression below the baseline, often described as up sloping, down sloping or horizontal.","ST Segment Depression by ECG Finding | EKG ST Segment Depression | ST DEPRESSION | ST Depression | ST Segment Depression | ST Segment Depression by EKG Finding | ST depression",,,,,,,,,,,,,,,"4095285|4180593","ST segment depression|ST Depression",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0524527","Drug Formulation Process","C15653","The act or process of developing or preparing a mixture of ingredients to create a desired end drug product, such as a specific flavor, aroma, or polymer; or the desired final drug product itself; also, a listing of the ingredients and composition of the dosage form.","Drug Formulation Process | Drug Formulation | Formulation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0552449","Equation","C41195","A statement written in symbols that two objects, e.g. mathematical expressions, or arrays of symbols representing a chemical reaction, are equal under certain conditions. Equations are usually and sometimes tacitly accompanied by the requirement to establish these conditions. In the case where mathematical or chemical objects contain arbitrary variables, such a requirement may mean finding those values of the variables that turn the equation into equality. Equations are sometimes called more explicitly as conditional equations.","Equation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0644117","Ibutilide Fumarate","C47561","The fumarate salt form of ibutilide, a class III antiarrhythmic agent. Ibutilide exerts its effect by activating a slow, inward, predominately sodium current rather than by blocking outward potassium currents. This results in prolongation of atrial and ventricular action potential duration and refractory periods. Ibutilide slightly decreases the sinus rate and atrioventricular (AV) conduction and produces a dose-related prolongation of the QT interval. (NCI05)","Ibutilide Fumarate | (+-)-4'-(4-(Ethylheptylamino)-1-hydroxybutyl)methanesulfonanilide Fumarate(2:1)(salt) | Corvert | IBUTILIDE FUMARATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1995620","Biotene Mouthwash, oral solution","C28868","Formulated for oral hygiene, Biotene Mouthwash contains antibacterial enzymes that boost natural salivary antibacterial defenses, protects teeth and gums, and provides relief or prevents dry mouth (xerostomia) induced by some drug therapies, as well as by acute renal failure, bone marrow transplant, hypertension, kidney dialysis, stroke, and radiation therapy. (NCI04)","Bioactive Enzymes-based Mouthwash | Biotactive Enzymes-based Mouthwash | Biotene Mouthwash | Biotene Mouthwash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0680744","Diversion Program","C41190","A type of program designed to assist individuals and families to address diverse issues such as alcohol and drug abuse, child disobedience, behavioral deviations, misdemeanor and felony. Essential components of the program include but are not limited to: information and referral, case management, advocacy, short term support, help in identifying and assessing the services most appropriate to meet the needs of the individual and family. The program helps to guide each individual towards a positive understanding, acceptance and change of the problems at hand whereby the health and safety of the public is maintained.","Diversion Program | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600110","Hydroxyzine Hydrochloride","C47559","The hydrochloride salt form of hydroxyzine, a piperazine histamine H1-receptor antagonist with anti-allergic, antispasmodic, sedative, anti-emetic and anti-anxiety properties. Hydroxyzine hydrochloride blocks the H1 histamine receptor and prevents the symptoms that are caused by histamine activity on capillaries, bronchial smooth muscle, and gastrointestinal smooth muscle, including vasodilatation, increased capillary permeability, bronchoconstriction, and spasmodic contraction of gastrointestinal smooth muscle. In addition, hydroxyzine hydrochloride crosses the blood-brain barrier and acts on the histamine H1-receptors in the central nervous system. (NCI05)","Hydroxyzine Hydrochloride | 1-(p-Chlorobenzhydryl)-4-(2-(2-hydroxyethoxy)ethyl)diethylenediamine Hydrochloride | Anxanil | Atarax | HYDROXYZINE DIHYDROCHLORIDE | Hyzine-50",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700444","Buspirone Hydrochloride","C26641","The hydrochloride salt of an anxiolytic agent chemically and pharmacologically unrelated to benzodiazepines, barbiturates, or other sedative/hypnotic drugs.  Although its exact mechanism of action is unknown, buspirone may exert its anti-anxiety effects via serotonin (5-HT1A) and dopamine receptors (D2) and may indirectly affect other neurotransmitter systems. Unlike typical benzodiazepine anxiolytics, this agent does not exert anticonvulsant or muscle relaxant effects and lacks prominent sedative effects.","Buspirone Hydrochloride | BUSPIRONE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031232","Desipramine Hydrochloride","C28979","The hydrochloride salt form of desipramine, a secondary amine tricyclic antidepressant (TCA). In the central nervous system (CNS), desipramine hydrochloride blocks the re-uptake of neurotransmitters, including norepinephrine and serotonin. This leads to an increase in the amount of these neurotransmitters in the synaptic cleft and prolongs their activities postsynaptically.","Desipramine Hydrochloride | DESIPRAMINE HYDROCHLORIDE | Norpramin | Pertofrane",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1170534","Ethinyl Estradiol/Levonorgestrel","C29034","A combination of two steroid sex hormones, an estrogen and a progestin, used for contraceptive purposes.  Estradiol, the endogenous counterpart of ethinyl estradiol (EE), is the principal, most potent estrogen hormone produced by the ovaries and is vital to the maintenance of fertility and secondary sexual characteristics in females.  Levonorgestrel is a synthetic progestogen.  This drug combination prevents or delays ovulation and causes a variety of hormonal changes.  Ethinyl estradiol inhibits the release of follicle stimulating hormone (FSH), thus suppressing the development of ovarian follicle; levonorgestrel inhibits the release of luteinizing hormone (LH), thus preventing ovulation.  This combination of agents alters the endometrium in such a way as to discourage implantation. (NCI04)","Ethinyl Estradiol/Levonorgestrel | Alesse | Aviane | Enpresse | Lessina | Levlite | Levora | Microgynon | Nordette | Portia | Seasonale | Seasonique | Trivora",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0744295","Gastric Leiomyosarcoma","C27200","An aggressive malignant smooth muscle neoplasm, arising from the stomach.  It is characterized by a proliferation of neoplastic spindle cells.","Gastric Leiomyosarcoma | ",,,,,,,,,,,,,,,"40486566","Leiomyosarcoma of stomach",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0772125","Ginkgo","C29072","A substance derived from the plant Ginkgo biloba.  Ginkgo biloba leaf extract contains potent anti-oxidants and substances believed to improve blood flow to the brain and peripheral tissues.  Ginkgo biloba exocarp polysaccharides (GBEP) can inhibit proliferation and induce apoptosis and differentiation of tumor cells.  As a medicinal herb, ginkgo requires standardization for medicinal use; typically, a 50:1 extract of ginkgo leaf is used in ginkgo supplements. (NCI04)","Ginkgo | GINKGO | Ginkgo Extract | Ginkgo Leaf Extract | Ginkgo biloba",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282125","Demeclocycline Hydrochloride","C28975","The hydrochloride salt of demeclocycline, a broad-spectrum, tetracycline derivative exhibiting antimicrobial, aquaretic and chelating activities. In bacteria, demeclocycline binds reversibly to the 30S ribosomal subunit and blocks the binding of aminoacyl-tRNA to the A-site of the mRNA-ribosome complex, resulting in the inhibition of protein synthesis and bacterial cell death. In mammals, this agent interferes with the action of antidiuretic hormone (ADH) at the level of the renal collecting tubule, resulting in aquaresis. In addition, demeclocycline, which like other tetracyclines chelates calcium in bone and exhibits a yellow fluorescence under ultraviolet (UV) light, may be used as a fluorescent bone-labeling agent in bone histomorphometry.","Demeclocycline Hydrochloride | 7-Chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamide Monohydrochloride | DEMECLOCYCLINE HYDROCHLORIDE | Declomycin | demeclocycline hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0294412","12-Allyldeoxoartemisinin","C41441","A semi-synthetic analogue of Artemisinin - a sesquiterpene lactone extracted from the dry leaves of Artemisia Annua (sweet wormwood) used as anti-malaria agent. Limited data is available on Artemisinin antineoplastic activity.","12-Allyldeoxoartemisinin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0304352","Codeine Sulfate","C53137","The sulfate salt form of codeine, a naturally occurring phenanthrene alkaloid and opioid agonist with analgesic, antidiarrheal and antitussive activity. Codeine sulfate mimics the actions of opioids by binding to the opioid receptors at many sites within the central nervous system (CNS). Stimulation of the mu-subtype opioid receptor stimulates the exchange of GTP for GDP on the G-protein complex and subsequently inhibits adenylate cyclase. This results in a decrease in intracellular cAMP and leads to a reduction in the release of neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline. The analgesic effect of codeine sulfate is likely due to its metabolite morphine, which induces opening of G-protein-coupled inwardly rectifying potassium (GIRK) channels and blocks the opening of N-type voltage-gated calcium channels, thereby resulting in hyperpolarization and reduced neuronal excitability.","Codeine Sulfate | 7,8-Didehydro-4,5-epoxy- 3-methoxy-17-methyl-(5a,6a)-Morphinan-6-ol Sulfate (2:1) | CODEINE SULFATE | Codeine, sulfate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0338106","Colon Adenocarcinoma","C4349","An adenocarcinoma arising from the colon.  It is more frequently seen in populations with a Western type diet and in patients with a history of chronic inflammatory bowel disease.  Signs and symptoms include intestinal bleeding, anemia, and change in bowel habits.  According to the degree of cellular differentiation, colonic adenocarcinomas are divided into well, moderately, and poorly differentiated.  Histologic variants include mucinous adenocarcinoma, signet ring cell carcinoma, medullary carcinoma, serrated adenocarcinoma, cribriform comedo-type adenocarcinoma, and micropapillary adenocarcinoma.","Colon Adenocarcinoma | Adenocarcinoma - colon | Adenocarcinoma of Colon | Adenocarcinoma of the Colon | Adenocarcinoma of the colon | Colonic Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0354648","Colestipol Hydrochloride","C28938","A hydrochloride salt form of colestipol, a positively charged, non-digestible, triamine and epoxypropane copolymer anion-exchange resin that binds to bile acids in the intestine to form an insoluble complex, which is excreted in the feces.","Colestipol Hydrochloride | COLESTIPOL HYDROCHLORIDE | Colestid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001899","Alanine Aminotransferase 1","C38507","Alanine aminotransferase 1 (496 aa, ~55 kDa) is encoded by the human GPT gene. This protein plays a role in both amino acid metabolism and pyruvate synthesis.","Alanine Aminotransferase 1 | AAT1 | ALT1 | Alanine Aminotransferase | EC 2.6.1.2 | GPT | GPT | GPT 1 | GPT1 | Glutamate Pyruvate Transaminase 1 | Glutamic--Alanine Transaminase 1 | Glutamic--Pyruvic Transaminase 1 | Glutamic-Alanine Transaminase | Glutamic-Alanine Transaminase 1 | Glutamic-Pyruvate Transaminase | Glutamic-Pyruvic Transaminase | Glutamic-Pyruvic Transaminase 1 | Glutamic—Pyruvic Transaminase 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0428975","Supraventricular Arrhythmia by ECG Finding","C27158","An electrocardiographic finding of an arrhythmia originating in the atrium, AV node or AV junction.","Supraventricular Arrhythmia by ECG Finding | Supraventricular Arrhythmia | Supraventricular Arrhythmia | Supraventricular Arrhythmia by EKG Finding",,,,,,,,,,,,,,,"4065287","EKG: supraventricular arrhythmia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0429084","P Wave","C41327","An electrocardiographic finding of the current of atrial contraction when they are depolarized. The initial portion of the P wave is largely a reflection of right atrial depolarization and the terminal portion reflects depolarization of the left atrium.","P Wave | EKG P Wave",,,,,,,,,,,,,,,"4140671","P wave feature",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0541154","Colesevelam Hydrochloride","C28937","A hydrochloride salt form of colesevelam, a non-absorbed polymer that binds bile acids in the intestine and lowers serum lipids.","Colesevelam Hydrochloride | 1-Hexaminium, N,N,N-trimethyl-6-(2-propenylamino)-, Chloride, Polymer with (chloromethyl)oxirane, 2-propen-4-amine and N-2-propenyl-1-decanamine, Hydrochloride | COLESEVELAM HYDROCHLORIDE | CholestaGel | GT 31-104HB | Welchol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0053079","Belladonna/Phenobarbital/Ergotamine","C28861","Used to relieve stomach/intestinal symptoms, menopause (hot flashes, sweats, restlessness, and insomnia), headaches, and tachycardia, Belladona Phenobarbital Ergotamine is a combination of an Atropa belladonna alkaloid, a Claviceps purpurea (Ergotamine) alkaloid, and a synthetic barbiturate. Parasympathomimetic Belladona decreases secretion, smooth muscle stimulant Ergotamine blocks alpha-adrenergic activity, and sedative Phenobarbital induces sleep. (NCI04)","Belladonna/Phenobarbital/Ergotamine | Belladonna/Phenobarb/Ergotamine | Bellergal-S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0721010","Hyzaar","C29166","A combination preparation of a synthetic angiotensin II antagonist and a diuretic thiazide, with antihypertensive activity. Losartan, and its metabolite, selectively and competitively block the binding of angiotensin II to the angiotensin II (AT1) receptor. As a result, angiotensin II-AT1 mediated physiological effects such as vasoconstriction and stimulation of aldosterone synthesis and secretion, which regulates extracellular sodium concentration, are blocked. Hydrochlorothiazide inhibits electrolytes reabsorption via binding to Na-Cl cotransporter on the renal distal tubular, thereby increasing excretion of sodium, potassium, chloride, bicarbonate and water. Both agents lead to a reduction in blood pressure.","Losartan/Hydrochlorothiazide | Hyzaar | Losartan Potassium/Hydrochlorothiazide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0719359","Loratadine/Pseudoephedrine","C29163","An oral combination preparation containing the antihistamine loratidine and the indirect-acting sympathicomimetic agent pseudoephedrine, with anti-allergic and decongestant activities. Loratadine, a piperidine, blocks the H1-receptor thereby preventing the symptoms that are caused by histamine activity on capillaries, bronchial smooth muscle, and gastrointestinal smooth muscle, including vasodilatation, increased capillary permeability, bronchoconstriction, and spasmodic contraction of gastrointestinal smooth muscle. Pseudoephedrine displaces norepinephrine from storage vesicles in presynaptic neurons, thereby releasing norepinephrine into the neuronal synapses where it stimulates primarily alpha-adrenergic receptors in the nasal mucosa, thereby producing vasoconstriction, reduces swelling of nasal tissues and decreasing nasal and sinus congestion.","Loratadine/Pseudoephedrine | Claritin D | Pseudoephedrine/Loratadine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0721844","Multivitamins/Minerals","C29270","A dietary supplement containing all or most of the vitamins and some minerals which may not be readily available in the diet.  The vitamin component may be classified according to their solubility either in lipids (vitamins A, D, E, K, F) or in water (vitamins C, B- complex). Present in minute amounts in various foods, vitamins are essential to maintaining normal metabolism and biochemical functions. The mineral component contains essential microelements and metals such as iron, magnesium, chromium and iodine. In addition, these agents may include various anti-oxidant phytochemicals such as flavonoids. (NCI04)","Multivitamins/Minerals | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1095869","Echinacea (plant)","C54160","A genus of nine species of flowering plants in the Family Asteraceae, all native to eastern North America. These are herbaceous, drought-tolerant perennial plants growing to 1 or 2 m in height. The leaves are lanceolate to elliptic, 10-20 cm long and 1.5-10 cm broad. Like all Asteraceae, the flowers are a composite inflorescence, with purple (rarely yellow or white) florets arranged in a prominent, somewhat cone-shaped head; 'cone-shaped' because the petals of the outer ray florets, once the flower head opens, tend to point downward (are decumbent), thus forming a cone. Extracts from the plants, especially Echinacea angustifolia, Echinacea pallida, and Echinacea purpurea, increase the non-specific activity of the immune system.","Echinacea | Coneflower | ECHINACEA, UNSPECIFIED | Echinacea Moench | Purple Coneflower | echinacea | purple coneflower",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1505020","Duloxetine Hydrochloride","C65496","The hydrochloride salt of duloxetine, an orally bioavailable fluoxetine derivative belonging to the class of selective serotonin (5-HT) and norepinephrine (NE) reuptake inhibitors (SNRIs), with central pain inhibitory, anxiolytic and antidepressant activities. Upon oral administration, duloxetine selectively prevents the reuptake of 5-HT and NE via transporter complexes on the pre-synaptic membrane, thereby increasing the level of these neurotransmitters within the synaptic cleft. This potentiates serotonergic and noradrenergic activities in the central nervous system (CNS), and alleviates anxiety, depression, and neuropathy sensations, such as neuropathic pain.","Duloxetine Hydrochloride | Cymbalta | DULOXETINE HYDROCHLORIDE | cymbalta | duloxetine hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511538","Country Code","C20108","An alphanumeric system designed to identify countries. The ISO 3166 standard includes a two letter representation, a three letter representation, and a 3 number representation. The last two are identical to the UN system. The US State Department system maintains a separate two letter representation code set.","Country Code | Country | countryCode",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512986","Mantle Field","C12507","A type of extended radiation field that includes lymph node areas in the neck, chest, and axilla.","Mantle Field | mantle field",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516281","Carcinoma In Pleomorphic Adenoma of the Mouse Salivary Glands","C23129","No Value Exists","Carcinoma In Pleomorphic Adenoma of the Mouse Salivary Glands | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518318","New Approaches to Brain Tumor Therapy Consortium","C37996","The primary objective of the 'New Approaches to Brain Tumor Therapy (NABTT)' CNS Consortium is to improve the therapeutic outcome for adults with primary brain tumors. It is funded by the National Cancer Institute to conduct Phase I and II clinical evaluations of promising new treatment strategies (surgery, radiation, chemotherapy, and biologic therapies), routes of administration, and clinical trial design in the treatment of primary malignancies of the central nervous system. The secondary objective of the NABTT CNS Consortium is to share human brain tumor specimens and clinical and laboratory data to conduct additional research pertaining to 1) the basic biology of primary brain tumors, 2) the neuro-pharmacology of new therapies for primary brain tumors, and 3) improving the care and quality of life of adults with primary brain tumors.","New Approaches to Brain Tumor Therapy Consortium | NABTT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705493","West (direction)","C45852","One of the four primary cardinal directions. West is at 270 degree on a compass card. It is the direction of the sunset.","West | Western",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002103","Atopic Rhinitis","C34987","Allergic rhinitis with a positive skin prick test (SPT equal or greater than 3 mm) to any allergen.","Atopic Rhinitis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002502","Amiloride","C61633","A synthetic pyrazine derivative with antikaliuretic and diuretic properties. Amiloride inhibits sodium channels located in the distal tubules and collecting ducts of the kidney, thereby preventing the absorption of sodium and increasing its excretion along with water, to produce naturesis. In response to the hypernatremic conditions in the kidney, the plasma membrane becomes hyperpolarized and electrochemical forces are reduced, which then prevents the excretion of potassium and hydrogen into the lumen.","Amiloride | AMILORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002525","Essential Amino Acid","C29595","Refer to those amino acids that can not be synthesized in the body and can only be obtained through food supply.","Essential Amino Acid | Indispensable amino acid",,,,,,,,,,,,,,,"4008866","Essential amino acid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004235","Atracurium Besylate","C28839","A synthetic dibenzensulfonate derivative muscle relaxant, Atracurium Besylate acts as a non-depolarizing neuromuscular blocking agent, with short to intermediary duration of action and no significant cardiovascular effects. Not dependent on kidney function for elimination, it provides clinical advantages over other non-depolarizing, neuromuscular blocking agents. (NCI04)","Atracurium Besylate | ATRACURIUM BESYLATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004745","Barbiturate","C67084","A class of drugs characterized as central nervous system (CNS) depressants. Barbiturate compounds bind to the gamma amino butyric acid (GABA)-A receptor, thereby increasing the influx of chloride ions into the neuron and subsequently causing hyperpolarization, which produces a decrease in neuronal transmission. Other barbiturate effects in the CNS may include modulation of sodium and calcium channels as well as inhibition of glutamate-mediated excitation. Although the effects of barbiturates are seen throughout the CNS, the predominant effect occurs in the midbrain region, the part of the brain associated with arousal. CNS depressive effects associated with this drug class include mild sedation, hypnosis, anesthesia, and coma as well as a decrease in seizure activity.","Barbiturate | barbiturate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006456","Buserelin","C320","A synthetic analog of gonadotropin-releasing hormone (GnRH).  Buserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors.  Prolonged administration of buserelin results in sustained inhibition of gonadotropin production, suppression of testicular and ovarian steroidogenesis, and reduced levels of circulating gonadotropin and gonadal steroids. Buserelin is more potent that GnRH. (NCI04)","Buserelin | 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig) | 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig) | BSRL | BUSERELIN | Busereline | Etilamide | HOE 766 | HOE-766 | HOE766 | ICI 123215 | ICI-123215 | ICI123215 | S74 6766 | S74-6766 | S746766 | Tiloryth | buserelin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007144","Gastric Cardia","C12256","The area around the esophagogastric mucosal junction where the esophageal mucosa transitions into the gastric mucosa.","Gastric Cardia | Cardia | Cardia of the Stomach | Cardia, NOS | GASTRIC CARDIA | STOMACH, CARDIA | cardia of stomach | cardial part of stomach | gastric cardia | pars cardiaca (gaster) | pars cardiaca gastricae | stomach cardiac region",,,,,,,,,,,,,"UBERON:0001162","cardia of stomach","4268313","Cardia structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3887632","Human Colostrum","C32348","A thick, protein-rich substance secreted by the breasts during the second half of pregnancy and for a few days after birth before the breast milk comes in. It contains antibodies which serve to give the baby protection from disease and also has a laxative effect on the colon which helps to expel the plug of meconium and facilitate the establishment of normal bowel movements.","Human Colostrum | COLOSTRUM | Colostrum | HUMAN COLOSTRUM",,,,,,,,,,,,,,,"4204986","Colostrum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014963","Ethacrynic Acid","C485","An unsaturated ketone derivative of aryloxyacetic acid without a sulfonamide substituent belonging to the class of loop diuretics. Ethacrynic acid is extensively bound to plasma proteins; both ethacrynic acid in its unchanged form as well as its metabolites are excreted in bile and urine.","Ethacrynic Acid | EA | ETHACRYNIC ACID | Edecrin | Ethacrynic acid | [2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy]acetic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021659","Insulin, Lente","C29122","A long-acting crystalline insulin often used in combination with a short-acting insulin in the treatment of diabetes mellitus.  This type of insulin may be derived from porcine or recombinant sources.  Administered once daily, insulin Lente starts to lower blood glucose within 1 to 3 hours after injection and exerts its peak effect 7 to 15 hours after injection.  Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats; it has anabolic effects on many types of tissues. (NCI04)","Insulin, Lente | Lente Iletin II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022735","Klinefelter Syndrome","C34752","A sex chromosome disorder caused by the presence of an extra X chromosome in the male karyotype. Affected individuals are infertile and have a small penis and testes. They tend to have tall stature and long legs and may have difficulties with speech and language development. Gynecomastia may be present.","Klinefelter Syndrome | 47,XXY Syndrome | Hypogonadotropic Hypogonadism | Klinefelter syndrome | Klinefelter's Syndrome | Klinefelter's Syndrome, XXY | XXY Syndrome | XXY Syndrome (Klinefelter Syndrome)",,,,,,,,,,,,,,,"40420291","Klinefelter syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025462","Mesencephalon","C12510","The uppermost portion of the brainstem located between the pons and the diencephalon. The midbrain contains the cerebral peduncles, oculomotor, trochlear and red nuclei, substantia nigra and various other nuclei and tracts.","Mesencephalon | BRAIN, MIDBRAIN | MIDBRAIN | Mid-brain | Midbrain | midbrain",,,,,,,,,,,,,,,"4268035","Midbrain structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0982118","Dexrazoxane Hydrochloride","C66945","The hydrochloride salt of a bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues.  This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition.","Dexrazoxane Hydrochloride | Cardioxane | DEXRAZOXANE HYDROCHLORIDE | Totect | Zinecard | dexrazoxane hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0813971","Environmental Tobacco Smoke","C2434","Smoke that is emitted from burning tobacco, including cigarette, pipe and cigar, and from tobacco smoke exhaled by smokers. Environmental tobacco smoke consists of a huge variety of chemicals that are produced during the burning of tobacco. Among them are known or suspected toxicants, carcinogens and respiratory irritants, including nicotine, ammonia, formaldehyde, sulfur dioxide, acrolein, hydrogen cyanide, phenol, nitrogen oxide, polycyclic aromatic hydrocarbons, N-Nitrosamines and radionuclides. Environmental tobacco smoke has numerous adverse health effects, is mutagenic and is a known human carcinogen that is associated with an increased risk of developing lung cancer. (NCI05)","Environmental Tobacco Smoke | ETS | Second Hand Smoke | environmental tobacco smoke | secondhand smoke",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0920688","Cancer Diagnosis","C16213","General term for detecting and classifying cancer in patients.","Cancer Diagnosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0055598","CHOP Regimen","C9549","A regimen consisting of cyclophosphamide, doxorubicin, vincristine and prednisone that may be used to treat AIDS-related B-cell lymphomas, blastic plasmacytoid dendritic cell neoplasm (BPDCN), Castleman disease, primary cutaneous CD30+ T-cell lymphoproliferative disorders, post-transplant lymphoproliferative disorders, T-cell lymphomas, Hodgkin lymphoma and other non-Hodgkin lymphoma, including Burkitt lymphoma and diffuse large B-cell lymphoma (DLBCL).","CHOP Regimen | ACOP | CAVP | CHOP | CHOP regimen | COPA | CTX/DOX/PRED/VCR | Cyclophosphamide-Hydroxydaunorubicin-Oncovin-Prednisone Regimen | Cyclophosphamide/Doxorubicin/Prednisone/Vincristine | Cyclophosphamide/Doxorubicin/Prednisone/Vincristine | VACP | VCAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510822","Advisory Committee to the Director, National Cancer Institute","C19226","The Committee advises and makes recommendations to the Director, NCI, for the oversight and integration of various planning and advisory groups serving the broad programmatic and institutional objectives of the Institute. The Committee serves as the official channel through which the findings and recommendations emerging from these groups are submitted to the NCI. The Committee may consider the reports of the various review groups as informational, advisory, or as recommendations, and shall provide the NCI with assistance in identifying opportunities to be pursued within the areas of cancer research that cut across the intramural and extramural programs.","Advisory Committee to the Director, NCI | ACD | Advisory Committee to the Director, National Cancer Institute | Committee to the Director, NCI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0204462","Purdue Pegboard Test","C33899","The Purdue Pegboard test measures finger dexterity and hand-eye coordination by testing an individual's ability to move hands, fingers, and arms (gross motor movement) and to control movements of small objects (fingertip dexterity).  Measurements of the right hand, left hand, and both hands are part of the test.","Purdue Pegboard Test | ",,,,,,,,,,,,,,,"4224278","Purdue pegboard test",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0585322","Every Two Hours","C64516","Every two hours.","Every Two Hours | Every 2 hours | Q2H",,,,,,,,,,,,,,,"4021634","Every two hours",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1275546","Every Eighteen Hours","C64508","Every eighteen hours.","Every Eighteen Hours | Every 18 hours | Q18H",,,,,,,,,,,,,,,"4244846","Every eighteen hours",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4013705","Left Ventricular Systolic Dysfunction","C64251","The degree of impairment of the left cardiac ventricle to contract efficiently. (ACC)","Left Ventricular Systolic Dysfunction | LEFT VENTRICULAR SYSTOLIC DYSFUNCTION | Left Cardiac Ventricular Systolic Dysfunction | Left ventricular systolic dysfunction",,,,,,,,,,,,,,,"4047088","Left ventricular systolic dysfunction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1321164","Gynecologic Oncology","C17829","The branch of oncology that focuses on tumors of the reproductive tract of women.","Gynecologic Oncology | oncology, gynecologic",,,,,,,,,,,,,,,"4247119","Gynecological oncology",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018370","Guernsey","C64375","A British Crown dependency in the English Channel, between England and France.","Guernsey | 831 | Bailiwick of Guernsey | GG | GGY | GUERNSEY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4015675","Cardiac Arrest","C50479","The sudden cessation of cardiac activity in an individual who becomes unresponsive, without normal breathing and no signs of circulation. Cardiac arrest may be reversed by CPR, and/or defibrillation, cardioversion or cardiac pacing.","Cardiac Arrest | Asystole | Cardiac arrest | Heart Arrest",,,,,,,,,,,,,,,"321042","Cardiac arrest",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021658","Insulin, NPH","C29124","An intermediate-acting insulin used in the treatment of diabetes mellitus.  Administered once or twice daily, NPH (neutral protamine hagedorn) insulin lowers blood glucose within 1 to 2 hours after administration and exerts a peak effect at 6 to 10 hours.  Endogenous insulin, a pancreatic hormone composed of two polypeptide chains, is important in the normal metabolism of carbohydrates, proteins and fats, promoting glucose utilization and protein synthesis; it has anabolic effects on many types of tissues. (NCI04)","Insulin, NPH | Humulin N | Novolin N",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022092","Iron-Dextran Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025952","Science of Microbiology","C16851","The science that deals with the study of microorganisms, including algae, archaea, bacteria, fungi, protozoa, and viruses.","Microbiology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026549","Morphine","C62051","An opiate alkaloid isolated from the plant Papaver somniferum and produced synthetically. Morphine binds to and activates specific opiate receptors (delta, mu and kappa), each of which are involved in controlling different brain functions. In the central nervous and gastrointestinal systems, this agent exhibits widespread effects including analgesia, anxiolysis, euphoria, sedation, respiratory depression, and gastrointestinal system smooth muscle contraction. (NCI04)","Morphine | MORPHINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030647","Patella","C33282","A small flat triangular bone in front of the knee that articulates with the femur and protects the knee joint.","Patella | BONE, PATELLA | PATELLA | patella",,,,,,,,,,,,,"UBERON:0002446","patella","4271834","Bone structure of patella",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032788","Postoperative Hemorrhage","C34938","Bleeding occurring after completion of a surgical procedure, which may occur immediately or may be delayed, and which may or may not be wound related.","Postoperative Hemorrhage | Postoperative Bleeding | Postoperative Bleeding | Postoperative hemorrhage",,,,,,,,,,,,,,,"4002836","Postoperative hemorrhage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034561","Radiation-Induced Dermatitis","C3349","A cutaneous inflammatory reaction occurring as a result of exposure to biologically effective levels of ionizing radiation.","Radiation-Induced Dermatitis | Dermatitis radiation | Radiation Dermatitis | Radiodermatitis | radiation dermatitis",,,,,,,,,,,,,,,"137350|4295478","Dermatitis caused by radiation|Radiation-induced dermatosis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0038170","Staphylococcus","C62583","A genus of nonmotile, nonspore-forming, aerobic to facultatively anaerobic bacteria containing Gram-positive, spherical cells, 0.5-1.5 microns in diameter, which divide in more than one plane to form irregular clusters. Coagulase-positive strains produce a variety of toxins and are therefore potentially pathogenic and may cause food poisoning. They are found on the skin, in skin glands, on the nasal and other mucous membranes of warm-blooded animals, and in various food products. The type species is Staphylococcus aureus.","Staphylococcus | STAPHYLOCOCCUS",,,,,,,,,,,,,,,"4278981","Staphylococcus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040428","Tooth Abrasion","C35076","Wearing away of tooth enamel by an outside mechanical force.","Tooth Abrasion | ",,,,,,,,,,,,,,,"436445","Abrasion of tooth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040656","Cutaneous Oximetry","C41375","The noninvasive measurement or determination of the partial pressure of oxygen and carbon dioxide locally in the capillaries of a tissue by the use of sensors applied to the skin. These photoelectric sensors can detect the specific wavelengths of radiation emitted by oxygenated versus reduced hemoglobin.","Cutaneous Oximetry | Transcutaneous Oximetry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042510","Ventricular Fibrillation","C50799","A disorder characterized by an electrocardiographic finding of a rapid grossly irregular ventricular rhythm with marked variability in QRS cycle length, morphology, and amplitude. The rate is typically greater than 300 bpm. (CDISC)","Ventricular Fibrillation | VENTRICULAR FIBRILLATION | VF | VFib | Ventricular fibrillation",,,,,,,,,,,,,,,"437894","Ventricular fibrillation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0055015","Cefuroxime Axetil","C28918","A second generation semi-synthetic cephalosporin and a beta-lactam antibiotic with bactericidal activity. Cefuroxime's effect is dependent on its binding to penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. Binding results in the inhibition of the transpeptidase enzymes, thereby preventing cross-linking of the pentaglycine bridge with the fourth residue of the pentapeptide and interrupting consequent synthesis of peptidoglycan chains. As a result, cefuroxime inhibits bacterial septum and cell wall synthesis formation.","Cefuroxime Axetil | CEFUROXIME AXETIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0061795","Macrogol 3350-Based Iso-Osmotic Laxative","C29080","An isotonic solution containing macrogol 3350 and electrolytes with laxative activity. Macrogol 3350-based oral osmotic laxative promotes the retention of water in the bowel, thereby increasing the water content of stool, which results in increased gastrointestinal motility and stool transit time and evacuation of colonic contents. Macrogol 3350 is also known as polyethylene glycol (PEG) 3350.","Macrogol 3350-Based Iso-Osmotic Laxative | ColonLytely | GoLYTELY | GoLYTELY | Laxabon | Macrogol 3350-Based Iso-Osmotic Oral Laxative | Macrogol 3350/Electrolytes Laxative | Macrogol 3350/Electrolytes Oral Laxative | PEG-Based Laxative | Polyethylene Glycol 3350-Based Laxative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152180","Accessory Nerve Disorder","C26953","A non-neoplastic or neoplastic disorder affecting the accessory nerve (eleventh cranial nerve).","Accessory Nerve Disorder | Accessory nerve disorder | Disorder of 11th Nerve | Disorder of the 11th Nerve | Eleventh Nerve Disorder",,,,,,,,,,,,,,,"437547","Disorder of accessory nerve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0178499","Base","C48056","A substance that dissociates to give hydroxide ions in aqueous solutions; a substance capable of donating a pair of electrons (to an acid) for the formation of a coordinate covalent bond; a substance whose molecule or ion can combine with a proton (hydrogen ion); a substance that combines with acids to form salts.","Base | Basic | alkali | alkalinity | base",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552485","Anorectal Fistula","C60785","A pathologic tract that connects an opening in the anal canal to the perianal skin. In the vast majority of cases there is a history of perianal abscess.","Anorectal Fistula | Anal Fistula | Anal fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0065148","Lodoxamide Tromethamine","C29160","The tromethamide salt form of lodoxamide, a synthetic mast cell stabilizing compound with anti-inflammatory activity. Upon administration to the eye, lodoxamide tromethamide inhibits type I immediate hypersensitivity reaction by preventing the antigen-stimulated calcium influx into mast cells, thereby inhibiting release of histamine. Lodoxamide tromethamide also prevents the release of slow-reacting substances of anaphylaxis (SRS-A) and inhibits eosinophil chemotaxis.","Lodoxamide Tromethamine | Alomide | LODOXAMIDE TROMETHAMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3809256","Glucose Intolerance","C34646","The inability to regulate blood glucose levels resulting in hyperglycemia.","Glucose Intolerance | Glucose intolerance",,,,,,,,,,,,,,,"4150016|4311629","Malabsorption of glucose|Impaired glucose tolerance",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0010192","Cosyntropin","C28941","A synthetically-derived subunit of the endogenous peptide pituitary hormone adrenocorticotropic hormone (ACTH).  Consisting of the first 24 amino acids from the amino terminal of ACTH, Cortrosyn is usually prepared for injection and intended for diagnostic and not therapeutic use.  Similar to endogenous ACTH, this agent stimulates the adrenal secretion of specific adrenal steroids that can be measured in the plasma. (NCI04)","Cosyntropin | COSYNTROPIN | Cortrosyn",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0252287","Bisoprolol Fumarate/Hydrochlorothiazide","C28872","A combination of a synthetic antihypertensive phenoxy-2-propanol derivative and a diuretic thiazide used for hypertension, Bisoprolol Fumarate Hydrochlorothiazide acts as a selective beta-1 (cardio) adrenergic antagonist, without membrane stabilizing activity or intrinsic sympathomimetic activity. Hydrochlorothiazide affects renal tubular electrolyte reabsorption, increasing excretion of sodium and chloride. (NCI04)","Bisoprolol Fumarate/Hydrochlorothiazide | Ziac",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0354872","Cyproheptadine Hydrochloride","C28949","The hydrochloride salt of a synthetic methyl-piperidine derivative with antihistaminic and anti-serotoninergic properties.  Cyproheptadine competes with free histamine (HA) for binding at HA-receptor sites, thereby competitively antagonizing histamine stimulation of HA-receptors in the gastrointestinal tract, large blood vessels, and bronchial smooth muscle. This agent also competes with free serotonin for binding at serotonin receptor sites. Cyproheptadine exhibits anticholinergic and sedative properties and has been shown to stimulate appetite and weight gain. (NCI04)","Cyproheptadine Hydrochloride | 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine Hydrochloride Sesquihydrate | CYPROHEPTADINE HYDROCHLORIDE | Periactin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0723125","Guaifenesin/Codeine","C29082","A combination preparation containing guaifenesin and the opioid agonist codeine with expectorant and antitussive activities, respectively. Guaifenesin works by drawing water into respiratory tracts, by which reducing adhesiveness and surface tension of mucus as well as increasing hydration of mucus, thereby reducing the viscosity of mucus and making cough more productive. Codeine, a naturally occurring phenanthrene alkaloid and opioid agonist mimics the actions of opioids by binding to the opioid receptors at many sites within the central nervous system (CNS), thereby also suppressing the cough reflex by activating receptors in the cough center.","Guaifenesin/Codeine | Brontex | Robitussin AC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029309","Orphenadrine","C61868","A muscarinic antagonist with muscle relaxant activity. Although the mechanism of action has not been determined, orphenadrine appears to block muscarinic acetylcholine receptors as well as N-methyl-D-aspartate (NMDA) receptors in the central nervous system (CNS). This may interfere with the transmission of nerve impulses from the spinal cord to the muscles and may help relax muscles. In addition, orphenadrine exerts antagonistic effects on histamine H1 receptors.","Orphenadrine | ORPHENADRINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0163055","Metaxalone","C47606","An oxazolidinone with centrally-acting skeletal muscle relaxant properties. Although the exact mechanism through which metaxalone exerts its effect is largely unknown, it might be due to general central nervous system (CNS) depression. Metaxalone has no direct effect on the contractile mechanisms of striated muscle, the motor end plate, or the nerve fiber.","Metaxalone | 2-Oxazolidinone, 5-((3,5-dimethylphenoxy)methyl)- | METAXALONE | Skelaxin | Zorane",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831735","Tomotherapy","C62731","A type of external beam radiation therapy in which the radiation is delivered slice-by-slice, providing sequential delivery of radiation to different parts of the tumor. This method differs from other forms of radiation therapy in which the entire tumor volume is irradiated at one time.","Tomotherapy | helical tomotherapy | tomotherapy",,,,,,,,,,,,,,,"3662120","Tomotherapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1707009","Breast Cancer pN0(i+) TNM Finding v6","C48993","Breast cancer without histological evidence of regional lymph node involvement, and positive morphologic findings for isolated tumor cells (ITCs) using any morphologic technique (including hematoxylin-eosin and/or immunohistochemistry), and no ITC cluster greater than 0.2 mm. (from AJCC 6th Ed.)","Breast Cancer pN0(i+) TNM Finding v6 | Breast Cancer pN0(i+) TNM Finding | pN0(i+) Breast Cancer v6 | pN0(i+) Breast Carcinoma v6 | pN0(i+) Cancer of Breast v6 | pN0(i+) Cancer of the Breast v6 | pN0(i+) Carcinoma of Breast v6 | pN0(i+) Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707008","Breast Cancer pN0(i-) TNM Finding v6","C48992","Breast cancer without histological evidence of regional lymph node involvement, and negative morphologic findings for isolated tumor cells using any morphologic technique (including hematoxylin-eosin and/or immunohistochemistry). (from AJCC 6th Ed.)","Breast Cancer pN0(i-) TNM Finding v6 | Breast Cancer pN0(i-) TNM Finding | pN0(i-) Breast Cancer v6 | pN0(i-) Breast Carcinoma v6 | pN0(i-) Cancer of Breast v6 | pN0(i-) Cancer of the Breast v6 | pN0(i-) Carcinoma of Breast v6 | pN0(i-) Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707024","Breast Cancer pNX TNM Finding v6 and v7","C48990","Breast cancer in which regional lymph nodes cannot be assessed (e.g., previously removed, or not removed for pathologic study). (from AJCC 6th and 7th Eds.)","Breast Cancer pNX TNM Finding v6 and v7 | Breast Cancer pNX TNM Finding | Breast Cancer pNX TNM Finding | Breast Cancer pNX TNM Finding v6 | Breast Cancer pNX TNM Finding v7 | pNX Breast Cancer v6 | pNX Breast Carcinoma v6 | pNX Cancer of Breast v6 | pNX Cancer of the Breast v6 | pNX Carcinoma of Breast v6 | pNX Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881318","Kidney Cancer pN2 TNM Finding v6","C63574","Kidney cancer with metastasis to more than one regional lymph node. (from AJCC 6th Ed.)","Kidney Cancer pN2 TNM Finding v6 | Kidney Cancer pN2 TNM Finding | pN2 Kidney Cancer v6 | pN2 Kidney Carcinoma v6 | pN2 Renal Cancer v6 | pN2 Renal Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880625","Exocrine Pancreatic Cancer pN1 TNM Finding v6","C60950","Exocrine pancreatic cancer with regional lymph node metastasis. (from AJCC 6th Ed.)","Exocrine Pancreatic Cancer pN1 TNM Finding v6 | Exocrine Pancreatic Cancer pN1 TNM Finding | pN1 Exocrine Cancer of the Pancreas v6 | pN1 Exocrine Carcinoma of the Pancreas v6 | pN1 Exocrine Pancreatic Cancer v6 | pN1 Exocrine Pancreatic Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880626","Exocrine Pancreatic Cancer pN1a TNM Finding","C60951","Exocrine pancreatic cancer with metastasis to a single regional lymph node. (from CAP Cancer of the Endocrine Pancreas Protocol- January 2005 Revision)","Exocrine Pancreatic Cancer pN1a TNM Finding | pN1a Exocrine Cancer of the Pancreas | pN1a Exocrine Carcinoma of the Pancreas | pN1a Exocrine Pancreatic Cancer | pN1a Exocrine Pancreatic Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880627","Exocrine Pancreatic Cancer pN1b TNM Finding","C60952","Exocrine pancreatic cancer with metastasis to more than one regional lymph node. (from CAP Cancer of the Endocrine Pancreas Protocol- January 2005 Revision)","Exocrine Pancreatic Cancer pN1b TNM Finding | pN1b Exocrine Cancer of the Pancreas | pN1b Exocrine Carcinoma of the Pancreas | pN1b Exocrine Pancreatic Cancer | pN1b Exocrine Pancreatic Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709723","Prostate Cancer pN1 TNM Finding v6 and v7","C48245","Prostate cancer with metastases in regional node(s).  (from AJCC 6th and 7th Eds.)","Prostate Cancer pN1 TNM Finding v6 and v7 | Prostate Cancer pN1 TNM Finding | Prostate Cancer pN1 TNM Finding | Prostate Cancer pN1 TNM Finding v6 | Prostate Cancer pN1 TNM Finding v7 | pN1 Cancer of Prostate | pN1 Cancer of the Prostate | pN1 Carcinoma of Prostate | pN1 Carcinoma of the Prostate | pN1 Prostate Cancer | pN1 Prostate Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707015","Breast Cancer pN1c TNM Finding v6","C49000","Breast cancer with metastasis in 1 to 3 axillary lymph nodes and in internal mammary nodes with microscopic disease detected by sentinel lymph node dissection but not clinically apparent. (from AJCC 6th Ed.)","Breast Cancer pN1c TNM Finding v6 | Breast Cancer pN1c TNM Finding | pN1c Breast Cancer v6 | pN1c Breast Carcinoma v6 | pN1c Cancer of Breast v6 | pN1c Cancer of the Breast v6 | pN1c Carcinoma of Breast v6 | pN1c Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707014","Breast Cancer pN1b TNM Finding v6","C48999","Breast cancer with metastasis in internal mammary lymph nodes with microscopic disease detected by sentinel lymph node dissection but not clinically apparent. (from AJCC 6th Ed.)","Breast Cancer pN1b TNM Finding v6 | Breast Cancer pN1b TNM Finding | pN1b Breast Cancer v6 | pN1b Breast Carcinoma v6 | pN1b Cancer of Breast v6 | pN1b Cancer of the Breast v6 | pN1b Carcinoma of Breast v6 | pN1b Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707013","Breast Cancer pN1a TNM Finding v6 and v7","C48998","Breast cancer with metastasis in 1 to 3 axillary lymph nodes (at least 1 tumor deposit greater than 2.0 mm). (from AJCC 6th and 7th Eds.)","Breast Cancer pN1a TNM Finding v6 and v7 | Breast Cancer pN1a TNM Finding | Breast Cancer pN1a TNM Finding | Breast Cancer pN1a TNM Finding v6 | Breast Cancer pN1a TNM Finding v7 | pN1a Breast Cancer v6 | pN1a Breast Carcinoma v6 | pN1a Cancer of Breast v6 | pN1a Cancer of the Breast v6 | pN1a Carcinoma of Breast v6 | pN1a Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707016","Breast Cancer pN1mi TNM Finding v6","C48997","Breast cancer with micrometastasis (greater than 0.2 mm, none greater than 2.0 mm). (from AJCC 6th Ed.)","Breast Cancer pN1mi TNM Finding v6 | Breast Cancer pN1mi TNM Finding | pN1mi Breast Cancer v6 | pN1mi Breast Carcinoma v6 | pN1mi Cancer of Breast v6 | pN1mi Cancer of the Breast v6 | pN1mi Carcinoma of Breast v6 | pN1mi Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707012","Breast Cancer pN1 TNM Finding v6","C48996","Breast cancer with metastasis to 1 to 3 axillary lymph nodes, and/or internal mammary nodes with microscopic disease detected by sentinel lymph node dissection but not clinically apparent. (from AJCC 6th Ed.)","Breast Cancer pN1 TNM Finding v6 | Breast Cancer pN1 TNM Finding | pN1 Breast Cancer v6 | pN1 Breast Carcinoma v6 | pN1 Cancer of Breast v6 | pN1 Cancer of the Breast v6 | pN1 Carcinoma of Breast v6 | pN1 Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707011","Breast Cancer pN0(mol+) TNM Finding v6 and v7","C48995","Breast cancer with positive molecular findings by RT-PCR, but without histological or immunohistochemical evidence of regional lymph node involvement.  (from AJCC 6th and 7th Ed.)","Breast Cancer pN0(mol+) TNM Finding v6 and v7 | Breast Cancer pN0(mol+) TNM Finding | Breast Cancer pN0(mol+) TNM Finding | Breast Cancer pN0(mol+) TNM Finding V6 | Breast Cancer pN0(mol+) TNM Finding V7 | pN0(mol+) Breast Cancer v6 | pN0(mol+) Breast Carcinoma v6 | pN0(mol+) Cancer of Breast v6 | pN0(mol+) Cancer of the Breast v6 | pN0(mol+) Carcinoma of Breast v6 | pN0(mol+) Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707010","Breast Cancer pN0(mol-) TNM Finding v6 and v7","C48994","Breast cancer without histological evidence of regional lymph node involvement, and with negative molecular findings by RT-PCR. (from AJCC 6th and 7th Ed.)","Breast Cancer pN0(mol-) TNM Finding v6 and v7 | Breast Cancer pN0(mol-) TNM Finding | Breast Cancer pN0(mol-) TNM Finding | Breast Cancer pN0(mol-) TNM Finding v6 | Breast Cancer pN0(mol-) TNM Finding v7 | pN0(mol-) Breast Cancer v6 | pN0(mol-) Breast Carcinoma v6 | pN0(mol-) Cancer of Breast v6 | pN0(mol-) Cancer of the Breast v6 | pN0(mol-) Carcinoma of Breast v6 | pN0(mol-) Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881475","Lung Cancer pN3 TNM Finding v6 and v7","C60976","Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes. (from AJCC 6th and 7th Eds.)","Lung Cancer pN3 TNM Finding v6 and v7 | Lung Cancer pN3 TNM Finding | Lung Cancer pN3 TNM Finding | Lung Cancer pN3 TNM Finding v6 | Lung Cancer pN3 TNM Finding v7 | pN3 | pN3 Cancer of the Lung | pN3 Carcinoma of the Lung | pN3 Lung Cancer | pN3 Lung Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881474","Lung Cancer pN2 TNM Finding v6 and v7","C60975","Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes. (from AJCC 6th and 7th Eds.)","Lung Cancer pN2 TNM Finding v6 and v7 | Lung Cancer pN2 TNM Finding | Lung Cancer pN2 TNM Finding | Lung Cancer pN2 TNM Finding v6 | Lung Cancer pN2 TNM Finding v7 | pN2 | pN2 Cancer of the Lung | pN2 Carcinoma of the Lung | pN2 Lung Cancer | pN2 Lung Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881473","Lung Cancer pN1 TNM Finding","C60974","Lung cancer with metastasis to ipsilateral peribronchial and/or ipsilateral hilar lymph nodes, including intrapulmonary nodes involved by direct extension of the primary tumor. (from CAP Lung Cancer Protocol--January 2005 Revision)","Lung Cancer pN1 TNM Finding | pN1 Cancer of the Lung | pN1 Carcinoma of the Lung | pN1 Lung Cancer | pN1 Lung Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880133","Colorectal Cancer pN2 TNM Finding v6","C60853","Colorectal cancer with metastasis in four or more regional lymph nodes. (from AJCC 6th Ed.)","Colorectal Cancer pN2 TNM Finding v6 | Colorectal Cancer pN2 TNM Finding | pN2 Colon Cancer v6 | pN2 Colorectal Cancer v6 | pN2 Colorectal Carcinoma v6 | pN2 Rectal Cancer v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880132","Colorectal Cancer pN1 TNM Finding v6","C60852","Colorectal cancer with metastasis in 1-3 regional lymph nodes. (from AJCC 6th Ed.)","Colorectal Cancer pN1 TNM Finding v6 | Colorectal Cancer pN1 TNM Finding | pN1 Colon Cancer v6 | pN1 Colorectal Cancer v6 | pN1 Colorectal Carcinoma v6 | pN1 Rectal Cancer v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707571","Cutaneous Melanoma pN3 TNM Finding v6 and v7","C48863","Cutaneous melanoma involving four or more regional lymph nodes, or with a finding of matted metastatic nodes, or with in-transit metastasis or satellite(s) with metastasis in regional lymph node(s). (from AJCC 6th and 7th Eds.)","Cutaneous Melanoma pN3 TNM Finding v6 and v7 | Cutaneous Melanoma pN3 TNM Finding | Cutaneous Melanoma pN3 TNM Finding | Cutaneous Melanoma pN3 TNM Finding v6 | Cutaneous Melanoma pN3 TNM Finding v7 | pN3 Cutaneous Melanoma | pN3 Melanoma of Skin | pN3 Melanoma of the Skin | pN3 Skin Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981217","Cutaneous Melanoma pN2c TNM Finding v6","C48862","Cutaneous melanoma without involvement of regional lymph nodes, with satellite or in-transit metastasis. (from AJCC 6th Ed.)","Cutaneous Melanoma pN2c TNM Finding v6 | Cutaneous Melanoma pN2c TNM Finding | pN2c Cutaneous Melanoma v6 | pN2c Melanoma of Skin v6 | pN2c Melanoma of the Skin v6 | pN2c Skin Melanoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981216","Cutaneous Melanoma pN2b TNM Finding v6","C48861","Cutaneous melanoma with macroscopic, clinically apparent metastasis to two or three regional lymph nodes. (from AJCC 6th Ed.)","Cutaneous Melanoma pN2b TNM Finding v6 | Cutaneous Melanoma pN2b TNM Finding | pN2b Cutaneous Melanoma v6 | pN2b Melanoma of Skin v6 | pN2b Melanoma of the Skin v6 | pN2b Skin Melanoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981215","Cutaneous Melanoma pN2a TNM Finding v6","C48860","Cutaneous melanoma with microscopic, clinically occult metastasis to two or three regional lymph nodes. (from AJCC 6th Ed.)","Cutaneous Melanoma pN2a TNM Finding v6 | Cutaneous Melanoma pN2a TNM Finding | pN2a Cutaneous Melanoma v6 | pN2a Melanoma of Skin v6 | pN2a Melanoma of the Skin v6 | pN2a Skin Melanoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981214","Cutaneous Melanoma pN2 TNM Finding v6","C48859","Cutaneous melanoma involving two to three regional lymph nodes, or involving the regional intra-lymphatic system without nodal involvement. (from AJCC 6th Ed.)","Cutaneous Melanoma pN2 TNM Finding v6 | Cutaneous Melanoma pN2 TNM Finding | pN2 Cutaneous Melanoma v6 | pN2 Melanoma of Skin v6 | pN2 Melanoma of the Skin v6 | pN2 Skin Melanoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981213","Cutaneous Melanoma pN1b TNM Finding v6","C48858","Cutaneous melanoma with macroscopic, clinically apparent metastasis to a single lymph node. (from AJCC 6th Ed.)","Cutaneous Melanoma pN1b TNM Finding v6 | Cutaneous Melanoma pN1b TNM Finding | pN1b Cutaneous Melanoma v6 | pN1b Melanoma of Skin v6 | pN1b Melanoma of the Skin v6 | pN1b Skin Melanoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981212","Cutaneous Melanoma pN1a TNM Finding v6","C48857","Cutaneous melanoma with microscopic, clinically occult metastasis to a single lymph node. (from AJCC 6th Ed.)","Cutaneous Melanoma pN1a TNM Finding v6 | Cutaneous Melanoma pN1a TNM Finding | pN1a Cutaneous Melanoma v6 | pN1a Melanoma of Skin v6 | pN1a Melanoma of the Skin v6 | pN1a Skin Melanoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707023","Breast Cancer pN3c TNM Finding v6 and v7","C49007","Breast cancer with metastasis in ipsilateral supraclavicular lymph nodes. (from AJCC 6th and 7th Eds.)","Breast Cancer pN3c TNM Finding v6 and v7 | Breast Cancer pN3c TNM Finding | Breast Cancer pN3c TNM Finding | Breast Cancer pN3c TNM Finding v6 | Breast Cancer pN3c TNM Finding v7 | pN3c Breast Cancer v6 | pN3c Breast Carcinoma v6 | pN3c Cancer of Breast v6 | pN3c Cancer of the Breast v6 | pN3c Carcinoma of Breast v6 | pN3c Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707022","Breast Cancer pN3b TNM Finding v6","C49006","Breast cancer with metastasis in clinically apparent ipsilateral internal mammary lymph nodes in the presence of 1 or more positive axillary lymph nodes; or in more than 3 axillary lymph nodes and in internal mammary lymph nodes with microscopic disease detected by sentinel lymph node dissection but not clinically apparent. (from AJCC 6th Ed.)","Breast Cancer pN3b TNM Finding v6 | Breast Cancer pN3b TNM Finding | pN3b Breast Cancer v6 | pN3b Breast Carcinoma v6 | pN3b Cancer of Breast v6 | pN3b Cancer of the Breast v6 | pN3b Carcinoma of Breast v6 | pN3b Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707021","Breast Cancer pN3a TNM Finding v6 and v7","C49005","Breast cancer with metastases in 10 or more axillary lymph nodes (at least one tumor deposit greater than 2.0 mm); or metastases to the infraclavicular (level III axillary) lymph nodes. (from AJCC 6th and 7th Eds.)","Breast Cancer pN3a TNM Finding v6 and v7 | Breast Cancer pN3a TNM Finding | Breast Cancer pN3a TNM Finding | Breast Cancer pN3a TNM Finding v6 | Breast Cancer pN3a TNM Finding v7 | pN3a Breast Cancer v6 | pN3a Breast Carcinoma v6 | pN3a Cancer of Breast v6 | pN3a Cancer of the Breast v6 | pN3a Carcinoma of Breast v6 | pN3a Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707019","Breast Cancer pN2b TNM Finding v6","C49003","Breast cancer with metastasis in clinically apparent internal mammary lymph nodes in the absence of axillary lymph node metastases. (from AJCC 6th Ed.)","Breast Cancer pN2b TNM Finding v6 | Breast Cancer pN2b TNM Finding | pN2b Breast Cancer v6 | pN2b Breast Carcinoma v6 | pN2b Cancer of Breast v6 | pN2b Cancer of the Breast v6 | pN2b Carcinoma of Breast v6 | pN2b Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707018","Breast Cancer pN2a TNM Finding v6 and v7","C49002","Breast cancer with metastasis in 4 to 9 axillary lymph nodes (at least 1 tumor deposit greater than 2.0 mm). (from AJCC 6th and 7th Eds.)","Breast Cancer pN2a TNM Finding v6 and v7 | Breast Cancer pN2a TNM Finding | Breast Cancer pN2a TNM Finding | Breast Cancer pN2a TNM Finding v6 | Breast Cancer pN2a TNM Finding v7 | pN2a Breast Cancer v6 | pN2a Breast Carcinoma v6 | pN2a Cancer of Breast v6 | pN2a Cancer of the Breast v6 | pN2a Carcinoma of Breast v6 | pN2a Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709718","Prostate Cancer pM1a TNM Finding v6 and v7","C48256","Prostate cancer with metastasis to non-regional lymph node(s). (from AJCC 6th and 7th Eds.)","Prostate Cancer pM1a TNM Finding v6 and v7 | Prostate Cancer pM1a TNM Finding | Prostate Cancer pM1a TNM Finding | Prostate Cancer pM1a TNM Finding v6 | Prostate Cancer pM1a TNM Finding v7 | pM1a Cancer of Prostate | pM1a Cancer of the Prostate | pM1a Carcinoma of Prostate | pM1a Carcinoma of the Prostate | pM1a Prostate Cancer | pM1a Prostate Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981219","Cutaneous Melanoma pM1a TNM Finding v6","C48867","Cutaneous melanoma with metastasis to skin, subcutaneous tissues or distant lymph nodes. (from AJCC 6th Ed.)","Cutaneous Melanoma pM1a TNM Finding v6 | Cutaneous Melanoma pM1a TNM Finding | pM1a Cutaneous Melanoma v6 | pM1a Melanoma of Skin v6 | pM1a Melanoma of the Skin v6 | pM1a Skin Melanoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709719","Prostate Cancer pM1b TNM Finding v6 and v7","C48248","Prostate cancer with metastasis to bone(s).  (from AJCC 6th and 7th Eds.)","Prostate Cancer pM1b TNM Finding v6 and v7 | Prostate Cancer pM1b TNM Finding | Prostate Cancer pM1b TNM Finding | Prostate Cancer pM1b TNM Finding v6 | Prostate Cancer pM1b TNM Finding v7 | pM1b Cancer of Prostate | pM1b Cancer of the Prostate | pM1b Carcinoma of Prostate | pM1b Carcinoma of the Prostate | pM1b Prostate Cancer | pM1b Prostate Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981220","Cutaneous Melanoma pM1b TNM Finding v6","C48868","Cutaneous melanoma with metastasis to lung. (from AJCC 6th Ed.)","Cutaneous Melanoma pM1b TNM Finding v6 | Cutaneous Melanoma pM1b TNM Finding | pM1b Cutaneous Melanoma v6 | pM1b Melanoma of Skin v6 | pM1b Melanoma of the Skin v6 | pM1b Skin Melanoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709720","Prostate Cancer pM1c TNM Finding v6 and v7","C48249","Prostate cancer with metastasis to other site(s) with or without bone disease.  (from AJCC 6th and 7th Eds.)","Prostate Cancer pM1c TNM Finding v6 and v7 | Prostate Cancer pM1c TNM Finding | Prostate Cancer pM1c TNM Finding | Prostate Cancer pM1c TNM Finding v6 | Prostate Cancer pM1c TNM Finding v7 | pM1c Cancer of Prostate | pM1c Cancer of the Prostate | pM1c Carcinoma of Prostate | pM1c Carcinoma of the Prostate | pM1c Prostate Cancer | pM1c Prostate Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707561","Cutaneous Melanoma pM1c TNM Finding","C48869","Cutaneous melanoma with metastases to all other visceral sites associated with normal serum lactate dehydrogenase (LDH) or distant metastases to any site associated with an elevated serum LDH. (from AJCC 6th and 7th Eds.)","Cutaneous Melanoma pM1c TNM Finding | Cutaneous Melanoma pM1c TNM Finding v6 | Cutaneous Melanoma pM1c TNM Finding v7 | pM1c Cutaneous Melanoma | pM1c Melanoma of Skin | pM1c Melanoma of the Skin | pM1c Skin Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881470","Lung Cancer pM1 TNM Finding v6","C60979","Lung cancer with distant metastasis. (from AJCC 6th Ed.)","Lung Cancer pM1 TNM Finding v6 | Lung Cancer pM1 TNM Finding | pM1 Cancer of the Lung v6 | pM1 Carcinoma of the Lung v6 | pM1 Lung Cancer v6 | pM1 Lung Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448840","Broad","C61485","Very large in expanse or scope; having great extent from one side to the other.","Broad | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826325","Fiducial Marker","C82602","A medical device placed on or inserted in an anatomic site for accurate visualization of a particular area, prior to radiation treatment or surgery. Examples include markers inserted in the prostate gland for visualization of the site affected by cancer, prior to radiation therapy; markers taped to the scalp prior to imaging in frameless stereotactic brain surgery; and femoral and tibial pins used for spatial orientation in total knee replacement.","Fiducial Marker | FID | Fiduciary Marker | Fiduciary Marker | Spatial Fiducials",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040610","Tramadol","C29507","A synthetic codeine analogue, Tramadol has central analgesic properties with effects similar to opioids, such as morphine and codeine, acting on specific opioid receptors. Used as a narcotic analgesic for severe pain, it can be addictive and weakly inhibits norepinephrine and serotonin reuptake. (NCI04)","Tramadol | Ryzolt | TRAMADOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0454199","Planning Target Volume","C82606","A geometrical concept defined to select appropriate beam arrangements, taking into consideration the net effect of all possible geometrical variations, in order to ensure that the prescribed dose is actually absorbed in the clinical target volume.","Planning Target Volume | PTV | Planning target volume (observable entity)",,,,,,,,,,,,,,,"4036402","Planning target volume",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1880496","Empiric","C54726","Derived from experiment and observation rather than theory.","Empiric | Empirical",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020860","IgG4","C78227","Along with the immunoglobulin G3 subclass (IgG3), the IgG4 subtype makes up a minor part of circulating antibodies in healthy individuals. The IgG4 core hinge sequence contains 12 amino acids and two interchain disulfide bonds.This subtype has moderate affinity for binding Fc receptors and does not bind complement component C1q. The production of IgG4 can be stimulated following repeated or long-term exposure to antigen. Elevated levels are found in various diseases and infections and can be indicative of an fibroinflammatory syndrome known as IgG4-related disease.","IgG4 | Immunoglobulin G Subclass 4 | Immunoglobulin G4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698595","CD4 Expressing T Cell Count","C74608","The determination of the number of CD4 expressing T cells present in a sample.","CD4 Expressing T Cell Count | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879847","Biomarker Analysis","C63333","A method of biological assay that looks for the presence of unique molecules or sequences considered indicative for a condition or state.","Biomarker Analysis | Biochemical marker (PSA)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242349","Immunocytochemistry","C17731","A method for the detection of proteins or antigens on samples of cells that are grown in monolayers or in suspension and deposited on slides using antibodies or other biomolecules that bind the target and can be visualized through a chemical process.","Immunocytochemistry | ICC",,,,,,,,,,,,,,,"4132859","Immunocytochemical procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0079278","Gastrointestinal Endoscopy","C78162","Any endoscopic procedure that visualizes a part of the gastrointestinal tract.","Gastrointestinal Endoscopy | Enteroscopy",,,,,,,,,,,,,,,"4039376|4123735","Gastrointestinal tract endoscopy|Enteroscopy",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0079304","Esophagogastroduodenoscopy","C78144","An endoscopic procedure that visualizes the upper part of the gastrointestinal tract up to the duodenum.","Esophagogastroduodenoscopy | EGD | ESOPHAGOGASTRODUODENOSCOPY | Upper Endoscopy",,,,,,,,,,,,,,,"4294382","Esophagogastroduodenoscopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008310","Endoscopic Retrograde Cholangiopancreatography","C16430","A procedure in which the bile ducts, pancreatic duct, and gallbladder are examined using a combination of endoscopy and fluoroscopy.","Endoscopic Retrograde Cholangiopancreatography | ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY | ERCP | endoscopic retrograde cholangiopancreatography",,,,,,,,,,,,,,,"4304943","Endoscopic retrograde cholangiopancreatography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0373483","Drug Test","C78139","A laboratory test of biological material such as blood, urine, hair, saliva or sweat, used to detect the presence of a drug or its metabolites with in the body.","Drug Test | DRUGSCR | Drug Screen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010741","Cytochemistry","C16483","Branch of histochemistry associated with the localization of cellular components by specific staining methods, as for example the localization of acid phosphatases by the Gomori method.","Cytochemistry | Histology, Cytochemistry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0301872","Immune Response Process","C17930","Any immune system response of an organisms to an internal or invasive threat.","Immune Response Process | Immune Response | Immune Response | immune response",,,,,,,,,,,,,,,"4012703|4148055","Host response|Immune response",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2697609","Histamine Challenge Test","C78164","A test to determine if a patient has hyper-responsive airways.","Histamine Challenge Test | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0872187","High Throughput Screening","C18472","Use of robots and other automated techniques to screen large numbers of samples.","High Throughput Screening | High Throughput Assay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034606","Radionuclide Imaging","C62667","An imaging technique that uses a small dose of a radioactive chemical (isotope) called a tracer that can detect sites of cancer growth, trauma, infection or degenerative disorders. The tracer, which is either injected into a vein or swallowed, travels through the bloodstream to the target organ, and emits gamma rays, which are detected by a gamma camera and analyzed by a computer to form an image of the target organ.","Radionuclide Imaging | NM | Nuclear Medicine | Radionuclide Scanning | SCINTIGRAPHY | Scan | Scanning | Scintigraphy | nuclear medicine scan | radioimaging | radionuclide scanning | scintigraphy",,,,,,,,,,,,,,,"4160914","Nuclear medicine imaging procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030604","Partial Pressure","C75755","The pressure exerted by a single component of a mixture of gases.","Partial Pressure | PARTIAL PRESSURE | PPres",,,,,,,,,,,,,,,"4041794","Partial pressure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0805586","Challenge","C78166","The administration of a substance in order to assess for a response.","Challenge | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0231472","Standing","C62166","The act of assuming or maintaining an erect upright position.","Standing | Orthostatic | STANDING",,,,,,,,,,,,,,,"4033753","Orthostatic body position",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034554","Radioallergosorbent Test","C78179","A type of blood test used to test for allergies.","Radioallergosorbent Test | RAST",,,,,,,,,,,,,,,"4216637","Radioallergosorbent test",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242506","Fluorescence Spectroscopy","C17738","Fluorescent spectroscopy or fluorometry is a type of electromagnetic spectroscopy used for analyzing fluorescent spectra. It involves using a beam of light, usually ultraviolet light, that excites the electrons in molecules of certain compounds and causes them to emit light of a lower energy, typically, but not necessarily, visible light.","Fluorescence Spectroscopy | Spectroscopy, Fluorescence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1294075","Sudan IV Staining Method","C78218","The use of Sudan IV, a lysochrome (fat soluble dye) diazo dye, for the staining of lipids, triglycerides and lipoproteins on frozen paraffin sections.","Sudan IV Staining Method | Sudan IV Staining",,,,,,,,,,,,,,,"4035733","Sudan IV stain method",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0430389","Light Microscopy","C17995","Light Microscopy is a technique for producing visible images of structures or details which are too small to be otherwise seen by the human eye. It involves passing light transmitted through or reflected from the subject through a series of lenses to be detected directly by the eye, imaged on a photographic plate, or captured digitally.","Light Microscopy | LIGHT MICROSCOPY | Light microscopy (procedure)",,,,,,,,,,,,,,,"4016247|45771294","Light microscopy|Light microscopy",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL448957","Rh Blood Group","C76250","A blood group system based on recognition of inherited differences in the Rhesus antigen as expressed on erythrocytes.","Rh Blood Group | Rh_Type | Rhesus Blood Group",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448847","Real Number","C62443","Any of the rational or irrational numbers.","Real Number | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697523","Graph Edge","C75923","A connection between nodes in a graph.","Graph Edge | Edge",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825316","Software Service","C80736","A software system providing a public need.","Software Service | Service",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825315","Grid Security Infrastructure","C80712","A mechanism for secure transport that uses public key cryptography as the basis for its functionality.","Grid Security Infrastructure | GSI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3807870","Urinary Urgency","C50792","An acute and compelling urge to urinate.","Urinary Urgency | Micturition Urgency | Urinary urgency",,,,,,,,,,,,,,,"200845","Urgent desire to urinate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1135957","Narration","C80446","A message that tells the particulars of an act or occurrence or course of events.","Narrative | NARRATIVE | Nar | Narration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825190","Digital Signature","C80447","Extra data appended to a message which identifies and authenticates the sender and message data using public-key encryption.","Digital Signature | digital signature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040710","Translating","C80450","The act or process of rendering from one language into another.","Translation | Language Translation | translation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825194","Time Zone","C80453","A geographic region throughout which the same standard time is used.","Time Zone | Timezome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0087130","Uncertainty","C71478","A measure of the inherent variability of repeated observation measurements of a quantity including quantities evaluated by statistical methods and by other means.","Uncertainty | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708563","Invalid Data","C50913","Not valid data.","Invalid Data | INV | INVALID | INVALID DATA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1550695","Negative Infinity","C80215","A number with a value that is less than any other negative number.","Negative Infinity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1550694","Positive Infinity","C80214","A number with a value that is larger than any other positive number.","Positive Infinity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700640","Encode (action)","C80216","To assign a code to represent data.","Encode | Encoded | Encoding | coding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1699029","QS -Quantity Sufficient (potency unit)","C48590","A quantity of an ingredient or product needed to bring up a volume or weight of the preparation to a final amount as it is indicated in the prescription; also refers to a determination of an adequate supply of medicine to fulfill either a prescribed amount or a sufficient quantity to provide treatment over a specified time frame.","Quantity Sufficient | QS | QUANTITY SUFFICIENT | Sufficient Quantity | q.s. | quantity sufficient | quantum sufficiat | {QUANTITY SUFFICIENT}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1548670","Not Asked","C80217","No inquiry was made to gather this information.","Not Asked | NASK | NOT ASKED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0442822","Trace","C80218","A barely detectable amount.","Trace | TRACE",,,,,,,,,,,,,,,"9192","Trace",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1554080","Key - HL7UpdateMode","C46002","A value used to identify a record in a database.","Key | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699575","Deflate Algorithm","C80219","A lossless data compression algorithm that uses a combination of the LZ77 algorithm and Huffman coding.","Deflate Algorithm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697596","gzip File Format","C80220","A file format consisting of a 10-byte header containing a magic number, a version number, and a timestamp, a Deflate-compressed body, and an 8-byte footer containing a checksum and the length of the original uncompressed data.","gzip File Format | GNU zip | GNU zip File Format",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697605","zlib Compression Algorithm","C80221","An abstraction of the Deflate compression algorithm.","zlib Compression | zlib | zlib Compression Algorithm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699422","Compress Algorithm","C80222","A UNIX compression program based on the LZC compression method.","Compress Algorithm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697590","bzip2 Algorithm","C80223","An open source lossless data compression algorithm that compresses most files more effectively than the more traditional gzip or ZIP, but is slower.","bzip2 Algorithm | bzip2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700360","7Z Compression Format","C80224","A compressed archive file format that supports several different data compression, encryption and pre-processing filters.","7Z Compression Format | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555416","Secure Hash Algorithm-1","C80225","An algorithm for computing a condensed representation of a message or a data file that produces a 160-bit message digest.","Secure Hash Algorithm-1 | SHA1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555417","Secure Hash Algorithm-256","C80226","An algorithm for computing a condensed representation of a message or a data file that produces a 256-bit message digest.","Secure Hash Algorithm-256 | SHA-256",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0680199","Vacation","C80227","Leisure time away from work devoted to rest or pleasure.","Vacation | VACATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407115","Bad","C80228","Having undesirable or negative qualities.","Bad | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698122","Answering Machine","C80229","An electronic device that answers a telephone and records messages.","Answering Machine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449911","View","C80271","A specific representation of data, situations, topics, etc.","View | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1999269","Building structure","C80231","A structure that has a roof and walls and stands more or less permanently in one place.","Building | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0442658","Street","C80230","A thoroughfare (usually including sidewalks) that is lined with buildings.","Street | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697794","Geographic Intersection","C80232","A junction where one street or road crosses another.","Intersection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448979","Care Of","C80233","Signifies an intermediary who is responsible for transferring a piece of mail between the postal system and the final addressee.","Care Of | In Care Of",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1550717","post box - building number suffix","C80235","A numbered box in a post office where letters for a patron are kept until called for.","Post Office Box | Post Box",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600182","municipality","C80234","A political unit, such as a city, town, or village, incorporated for local self-government.","Municipality | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1552859","Subsection","C80236","A part of something already divided.","Subsection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0871643","Alphabet","C80238","A character set that includes letters and is used to write a language.","Alphabet | Alphabetic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697660","Ideogram (document)","C80239","A picture or symbol used in a system of writing.","Ideogram | Ideographic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0871464","Syllable","C80240","A unit of spoken language larger than a phoneme.","Syllable | Syllabic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1552605","Soundex","C80241","A phonetic algorithm for indexing words by sound so that similar sounding words are encoded the same.","Soundex | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0871073","Phoneme","C80242","A speech sound that is distinguished by the speakers of a particular language.","Phoneme | Phonetic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698482","Nobility Title","C80272","A part of a name denoting that a person holds a hereditary title.","Nobility Title | Nobility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2598121","Nickname","C80243","A familiar or shortened form of a proper name.","Nickname | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512704","Indigenous","C41152","A person who belongs naturally to a place in the sense of long-term family origins. The term is used specifically to refer to aboriginal populations, e.g. Aborigine in Australia; as well as to identify the majority population, e.g. in the UK it is an alternative to the White.","Indigenous | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033824","Pseudonym","C80244","A fictitious name used when the person performs a particular social role.","Pseudonym | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0402043","Artist","C80245","One who uses imagination and talent or skill to create works of aesthetic value.","Artist | Creative and Performing Artist | Creative and Performing Artists",,,,,,,,,,,,,,,"4011579","Artist",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1275563","At Bedtime","C64593","Beginning hour of sleep.","Hour Of Sleep | At Bedtime | Bedtime | HS | QHS | hora somni",,,,,,,,,,,,,,,"4288399","Once a day, at bedtime",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698559","Breakfast","C80249","The first meal of the day (usually in the morning).","Breakfast | CM | cibus matutinus",,,,,,,,,,,,,,,"35626256","With breakfast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2697949","Lunch","C80250","A midday meal sometimes also called dinner.","Lunch | CD | cibus diurnus",,,,,,,,,,,,,,,"35626255","With lunch",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4048877","Dinner","C80251","The evening meal, usually the main meal of the day.","Supper | CV | Dinner | cibus vespertinus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1550740","Between Meals","C64603","In between meals.","Between Meals | IC | inter cibus",,,,,,,,,,,,,,,"4206720","Between meals",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1879671","After Supper","C64602","After supper or evening meal.","After Supper | After Dinner | PCV | post cibus vespertinus",,,,,,,,,,,,,,,"45757489","After dinner",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1879793","Before Bedtime","C64922","Prior to the hour of sleep.","Before Bedtime | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448863","After Meals","C64594","After the ingestion of food.","After Meals | After a Meal | PC | post cibus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1998546","Environmental Infrastructure","C80260","The basic facilities, equipment, or underlying framework that are necessary for a system or organization to function.","Infrastructure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1999230","Providing (action)","C80514","Supply what is desired or needed.","Provide | Provided | Supplied | Supply",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825235","Object Constraint Language","C80515","An extension to UML that provides constraint and object query expressions on an object-oriented model that cannot otherwise be expressed by diagrammatic notation, providing expressions that have neither the ambiguities of natural language nor the inherent difficulty of using complex mathematics.","Object Constraint Language | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710545","Uniform Distribution","C53214","A continuous statistical distribution whose variable of interest has a single probability of occurrence over all possible values.","Uniform Distribution | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708729","Log Normal Distribution","C53224","The single-tailed probability distribution of any random variable whose logarithm is normally distributed.","Log Normal Distribution | Log-Normal Distribution | Lognormal Distribution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708185","Gamma Distribution","C53223","A two-parameter family of continuous probability distributions, with a scale parameter theta and a shape parameter k.","Gamma Distribution | Gamma-Distribution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711243","Exponential Distribution","C53222","A family of continuous probability distribution functions, whose shape is determined by its rate parameter. It has been described as the continuous analog of the geometric distribution.","Exponential Distribution | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008040","Chi-Square Distribution","C53225","A mathematical distribution whose shape is determined by its one parameter, the degree(s) of freedom (df). This distribution is often used in inferential statistics in tests of significance.","Chi-Square Distribution | Chi Square Distribution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1552647","t-distribution","C53220","A probability distribution that arises in the problem of estimating the mean of a normally distributed population when the sample size is small.","t-Distribution | t Distribution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1552649","Probability Distribution Type - beta","C53227","A unimodal distribution with confined lower and upper bounds.","Beta Distribution | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828371","Border (boundary)","C80507","A boundary line or the area immediately inside the boundary.","Border | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448988","Timing","C80484","The chronological relationship between temporal events.","Timing | Chronology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2718032","Health Level Seven","C80485","A Standards Developing Organization (SDO) operating in the healthcare arena with an emphasis on the domain of clinical and administrative data.","Health Level Seven | HL7 | Health Level 7 (HL7)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699782","Discrete","C75300","Constituting a separate entity or part.","Discrete | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707454","Comparator","C49882","A device for comparing something with a similar thing or with a standard measure.","Comparator Device | Comparator | Comparator Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825217","Union","C80486","A set containing all and only the members of two or more given sets.","Union | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1257972","Data Compression","C64347","The coding of data to save storage space or transmission time.","Data Compression | Compression | Data Compression Algorithm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710028","Scope","C47825","An area in which something acts or operates or has power or control.","Scope | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2911684","Expression","C80488","A combination of symbols that represents a value.","Expression | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825218","Denominator","C80489","The divisor of a fraction.","Denominator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825219","Numerator","C80490","The dividend of a fraction.","Numerator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443220","Flexible","C80495","Able to be adjusted readily to different conditions.","Flexible | ",,,,,,,,,,,,,,,"4126853","Flexible",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825224","HL7 Reference Information Model","C80496","An object oriented information model to harmonize the definition of HL7 messages across different application domains.","Reference Information Model | HL7 Reference Information Model | RIM | Reference information Model (RIM)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825229","Subscript","C80501","A character or symbol set or printed or written below and immediately to one side of another character.","Subscript | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825228","Superscript","C80500","A character or symbol set or printed or written above and immediately to one side of another character.","Superscript | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825230","Line Break","C80502","A code that signifies the end of a line.","Line Break | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0871028","Paragraph","C80504","One of several distinct subdivisions of a text intended to separate ideas.","Paragraph | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376478","Multimedia","C17962","A computer-controlled presentation of some combination of audio, video, animation, graphics, still photo, and/or text where users can control the presentation and often interact with it.","Multimedia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825231","Caption","C80505","A brief description accompanying an illustration.","Caption | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825232","Footnote","C80506","An explanatory note placed below the text on a page.","Footnote | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448982","Frame","C80261","An enclosing border.","Frame | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2003847","House","C80508","A dwelling that serves as living quarters for one or more families.","House | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL415095","Mix (activity)","C64925","To bring or combine together or with something else; add as an additional element or part.","Mix | Mixing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028734","Nocturia","C82673","Frequent episodes of urination during the night.","Nocturia | ",,,,,,,,,,,,,,,"40304526","Nocturia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1537502","KRAS Gene","C25785","This gene is involved in signal transduction and apoptosis.","KRAS Gene | K-ras gene | KRAS | KRas Proto-Oncogene, GTPase Gene | Kras gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448420","Oral Neoplasm","C8989","A benign or malignant neoplasm involving the oral cavity and/or the lips.","Oral Neoplasm | Lip and Oral Cavity Neoplasm | Lip and Oral Cavity Tumor | Lip and Oral Cavity Tumour | Oral Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023448","Lymphoid Leukemia","C7539","A malignant lymphocytic neoplasm of B-cell or T-cell lineage involving primarily the bone marrow and the peripheral blood.  This category includes precursor or acute lymphoblastic leukemias and chronic leukemias.","Lymphoid Leukemia | LEUKEMIA, LYMPHOCYTIC, MALIGNANT | Lymphocytic Leukemia | Lymphogenous Leukemia | Lymphoid leukemia, NOS | lymphocytic leukemia","9820/3","Lymphoid leukemia, NOS",,,,,,,,,,,,,"132853|37156366","Lymphoid leukemia|Lymphoid leukemia",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0747256","Parasitic Infection","C27864","A successful invasion of a host by an organism that uses the host for food and shelter.","Parasitic Infection | Parasitic Disease",,,,,,,,,,,,,,,"432251","Parasitic disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029347","Influenza A Virus","C53454","A negative-strand linear single-strand RNA virus with an 8 segment genome. Virions are enveloped and usually spherical or pleomorphic, 80-120 nm in diameter. Subtyping is based on the antigenic properties of the hemagglutinin and neuraminidase proteins. Influenza type A viruses can infect people, birds, pigs, horses, and other animals, but wild birds are the natural hosts for these viruses.","Influenza A Virus | FLUAV | INFLUENZA A VIRUS | INFLUENZA A VIRUS WHOLE | Influenza A - Not Typed | Influenza Type A | Influenza Virus Type A | influenza A virus",,,,,,,,,,,,,,,"4236145","Influenza A virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029348","Influenza B Virus","C53468","A negative-strand linear single-strand RNA virus with an 8 segment genome. Virions are enveloped and usually spherical or pleomorphic, 50-120 nm in diameter. Influenza B viruses are usually found only in humans. Unlike influenza A viruses, these viruses are not classified according to subtype.","Influenza B Virus | FLUBV | INFLUENZA B VIRUS | INFLUENZA B VIRUS WHOLE | Influenza B | Influenza Type B | Influenza Virus Type B",,,,,,,,,,,,,,,"4231384","Influenza B virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026783","Mumps Virus","C14245","A type of paramyxovirus. It spreads from person to person through coughs, sneezes and saliva, as well as through contact with contaminated items and surfaces. Once the mumps virus enters the body, it passes into the bloodstream and can spread to many different glands and to the brain.","Mumps Virus | MUMPS RUBULAVIRUS | MUMPS VIRUS | Mumps orthorubulavirus | Rubulavirus Mumps",,,,,,,,,,,,,,,"4179054","Mumps virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1268567","Tyrosine Kinase Inhibitor","C1967","Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation.","Tyrosine Kinase Inhibitor | PTK Inhibitors | Protein Tyrosine Kinase Inhibitors | TK Inhibitors | tyrosine kinase inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0044894","15-Hydroxyprostaglandin Dehydrogenase [NAD+]","C78140","15-hydroxyprostaglandin dehydrogenase [NAD+] (266 aa, ~29 kDa) is encoded by the human HPGD gene. This protein is involved in prostaglandin metabolism.","15-Hydroxyprostaglandin Dehydrogenase [NAD+] | 15-Hydroxyprostaglandin Dehydrogenase | 15-PGDH | 15-Prostaglandin Dehydrogenase | EC 1.1.1.141 | HPGD | NAD+-Dependent 15-Hydroxyprostaglandin Dehydrogenase | PGDH | Prostaglandin Dehydrogenase 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229986","Application Site","C77676","The anatomic site at which medical intervention is administered.","Application Site | SITE, APPLICATION | Site, Exposure",,,,,,,,,,,,,,,"4220019","Application site",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698524","Bleeding on Probing","C74951","Bleeding that is induced by gentle manipulation of the gingival tissue at the depth of the gingival sulcus.","Bleeding on Probing | BOP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006736","Stone","C35708","Accumulated material from the secretions of an organ. It is solid and representative examples include gallbladder stones, kidney stones, and salivary gland stones.","Stone | CALCULUS | Calculi | Calculus",,,,,,,,,,,,,,,"4209441|4292565","Calculus|Stone - body material",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0018826","Cardiac Valve","C12729","Any of the four heart valves, including the two atrioventricular valves and the two semilunar valves, which regulate the flow of blood through the chambers of the heart.","Cardiac Valve | CARDIAC VALVE | Cardiac Valves | Cardiac valve structure (body structure) | VALVE, CARDIAC",,,,,,,,,,,,,,,"4068271","Cardiac valve structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3809516","Abdominal Aortic Aneurysm","C27000","Enlargement and ballooning of the vessel that supplies arterial blood to the abdomen, pelvis and legs.","Abdominal Aortic Aneurysm | ",,,,,,,,,,,,,,,"198177","Abdominal aortic aneurysm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035436","Rheumatic Fever","C34984","An inflammatory disorder that follows infection with group A streptococcus. It affects the heart, joints, and subcutaneous tissues. It manifests with pericarditis, heart murmur, congestive heart failure, polyarthritis, subcutaneous nodules, and erythema marginatum. It is characterized by the formation of granulomatous lesions called Aschoff bodies usually in the heart tissue.","Rheumatic Fever | ARF | Acute Rheumatic Fever",,,,,,,,,,,,,,,"442313","Rheumatic fever",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0062941","Omacetaxine Mepesuccinate","C1127","A semisynthetic formulation of the cytotoxic plant alkaloid homoharringtonine isolated from the evergreen tree Cephalotaxus with potential antineoplastic activity. Omacetaxine binds to the 80S ribosome in eukaryotic cells and inhibits protein synthesis by interfering with chain elongation. This agent also induces differentiation and apoptosis in some cancer cell types.","Omacetaxine Mepesuccinate | CGX-635 | Ceflatonin | Cephalotaxine, 4-Methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (Ester) | Cephalotaxine, 4-Methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (Ester), [3(R)]- (9CI) | Cephalotaxine, 4-methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (ester), [3(R)]- (9CI) | HHT | OMACETAXINE MEPESUCCINATE | Omapro | Synribo | homoharringtonine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018939","Hematopoietic and Lymphoid Cell Disorder","C26323","A non-neoplastic or neoplastic disorder that arises from the hematopoietic and lymphoid cells. Representative examples include disorders that affect the synthesis of hemoglobin, coagulation disorders, leukemias, and lymphomas.","Hematopoietic and Lymphoid Cell Disorder | Blood Disease | Blood Disorder | Hematologic Disorder | Hematologic and Lymphocytic Disorder | Hematologic and Lymphocytic Disorder | Hematologic and Lymphoid Cell Disorder | Hematological Disorder | Hematological Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086583","Managed Care","C15364","An arrangement whereby a third-party payer (e.g., insurance company, federal government, or corporation) mediates between physicians and patients, negotiating fees for service and overseeing the types of treatment given.  Managed care has virtually replaced unmanaged indemnity plans, where payment is automatic and oversight procedures are minimal.  Whereas 96% of American workers had unmanaged indemnity in 1984, only 28% did in 1988.  Typically, in managed care, the third-party payer requires second opinions and pre-certification review for patients requiring hospital admission.  They obtain wholesale prices from doctors, and carry out cost-containment measures, including auditing hospitals and reviewing claims.  Managed care has figured heavily in the national debate over health care.","Managed Care | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0557806","College","C61514","An institution of higher education created to educate and grant degrees; often a part of a university.","College | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521528","Chromosome 6 Short Arm","C13559","Proximal (short) arm of chromosome 6","6p | Chromosome 6 Proximal Arm | Chromosome 6 Short Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1291077","Bloating","C78213","Distention of the abdomen associated with a feeling of fullness.","Bloating | bloating",,,,,,,,,,,,,,,"4023572","Abdominal bloating",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031099","Periodontitis","C34918","An acute or chronic inflammatory process that affects the tissues that surround and support the teeth.","Periodontitis | ",,,,,,,,,,,,,,,"141608","Periodontitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1511518","Copy Number Polymorphism","C40207","Variation in the number of copies of a particular sequence within the genetic material of an individual. Large-scale copy number polymorphisms are common and widely distributed in the human genome.","Copy Number Polymorphism | CNA | CNP | CNV | Copy Number Alteration | Copy Number Variant | Copy Number Variation | copy number variant | copy_number_variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516369","Cellular Infiltration","C28491","Normal or pathologic migration and accumulation of cells within tissues.","Cellular Infiltration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1101610","MicroRNAs","C25966","A sequence of single-stranded RNA, that is 20-25 nucleotides in length, which is transcribed from DNA but is not translated into a protein. This nucleic acid may regulate the transcription or translation of other genes.","MicroRNA | MICRO RNA | MIR | MIRN | Micro RNA | Small Temporal RNA | miRNA | micro-RNA | microRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086692","Benign Neoplasm","C3677","A neoplasm characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Neoplasm | Benign Neoplasms | Benign Tumor | Benign Unclassifiable Tumor | NEOPLASM, BENIGN | Neoplasm, benign | Tumor, benign | benign tumor","8000/0","Neoplasm, benign",,,,,,,,,,,,,"4305589","Neoplasm, benign",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C2826174","Cancer Genome Characterization Center","C82428","A multidisciplinary facility using various genomic and/or epigenomic analysis technologies for the systematic, high-resolution, comprehensive characterization of cancer-related genomic alterations in biomolecules obtained from highly-annotated, quality-controlled human cancer biospecimens.","Cancer Genome Characterization Center | CGCC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511696","DNA Sequencing Facility","C16025","A shared facility which provides services for DNA sequencing","DNA Sequencing Facility | Sequencing Core",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0068475","Nebivolol","C66221","A beta-1 adrenergic receptor antagonist with antihypertensive and vasodilatory activity. Nebivolol binds to and blocks the beta-1 adrenergic receptors in the heart, thereby decreasing cardiac contractility and rate. This leads to a reduction in cardiac output and lowers blood pressure. In addition, nebivolol potentiates nitric oxide (NO), thereby relaxing vascular smooth muscle and exerting a vasodilatory effect.","Nebivolol | Bystolic | NEBIVOLOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0057144","Daptomycin","C47470","A semi-synthetic cyclic lipopeptide antibiotic isolated form the bacterium Streptomyces roseosporus with broad-spectrum antibiotic activity against Gram-positive bacteria. Daptomycin has a distinct mechanism of action, in which it binds to bacterial membrane and causes rapid depolarization of the cell membrane due to calcium-dependant potassium efflux; the loss of membrane potential leads to inhibition of DNA, RNA and protein synthesis, resulting in bacterial cell death. This agent does not penetrate the outer membrane of gram-negative bacteria.","Daptomycin | Cubicin | DAPTOMYCIN | LY146032 | N-Decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon1-lactone | daptomycin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1260298","Tigecycline","C72865","A broad-spectrum glycylcycline antibiotic derived from tetracycline. Tigecycline binds to the 30S ribosomal subunit, thereby interfering with the binding of aminoacyl-tRNA to the mRNA-ribosome complex. This prevents the incorporation of amino acid residues into the elongating peptide chain, inhibiting protein synthesis and eventually bacterial cell growth.","Tigecycline | TIGECYCLINE | Tygacil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL375266","Fostamatinib Disodium","C69128","An orally available disodium salt of the Syk kinase inhibitor fostamatinib with potential anti-inflammatory and immunomodulating activities. Fostamatinib inhibits Syk kinase-mediated IgG Fc gamma receptor signaling, resulting in inhibition of the activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage. Syk kinase, widely expressed in hematopoietic cells, is a nonreceptor tyrosine kinase that is involved in coupling activated immunoreceptors to signal downstream events that mediate diverse cellular responses, including proliferation, differentiation, and phagocytosis.","Fostamatinib Disodium | 2H-pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 6-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]- 4-pyrimidinyl]amino]-2,2-dimethyl-4-[(phosphonooxy)methyl]-, Disodium Salt, Hexahydrate | FOSTAMATINIB DISODIUM | Fostamatinib Disodium Hexahydrate | R-935788 Sodium | R788 Sodium | R788 sodium | R935788 Sodium | SYK Kinase Inhibitor R-935788 | Syk kinase inhibitor R-935788 | Tavalisse | Tevalisse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0971579","Vardenafil","C66650","A benzenesulfonamide derivative and phosphodiesterase type 5 (PDE5) inhibitor with vasodilatory activity. Vardenafil selectively inhibits PDE5, thus inhibiting the degradation of cyclic guanosine monophosphate (cGMP) found in the smooth muscle of the corpus cavernosa and corpus spongiosum of the penis. The inhibition of cGMP degradation results in prolonged muscle relaxation, vasodilation, and blood engorgement of the corpus cavernosa, prolonging penile erection.","Vardenafil | VARDENAFIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0346990","Peritoneal Carcinomatosis","C27382","A condition in which a carcinoma has spread extensively throughout the peritoneum.","Peritoneal Carcinomatosis | Abdominal Carcinomatosis | Carcinomatosis of the Peritoneum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347023","Biological Absorption","C71733","The process of penetration of a substance into a living organism. This process could involve specialized and/or non-specialized mechanisms, active transport or passive movement, and carrier system(s). The common routes of absorption in mammals include the organs of the respiratory and gastrointestinal systems, and the skin.","Biological Absorption | Absorption | absorption",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826564","Biological Drug Neutralization","C82903","A physiological process in which body systems act on drugs, neutralizing their chemical effects.","Biological Drug Neutralization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826554","Canada DrugBank","C82881","A public drug database at the University of Alberta which combines detailed drug data with comprehensive drug target information.","Canada DrugBank | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018517","Half Life","C70916","The amount of time needed for a material to lose half of its physical, chemical, or biological activity.","Half Life | Half-Life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826552","International Union of Pure and Applied Chemistry","C82878","An organization of national chemistry societies. It acts as an authority in developing standards for the naming of the chemical elements and their compounds.","International Union of Pure and Applied Chemistry | IUPAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449011","Binding","C82888","The action of attracting something and forming a bond with it.","Binding | Bind | Bound",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707494","Constrain","C49168","The process of keeping something within particular limits or bounds.","Constrain | Constrained | Constrained",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015219","Evolution","C16565","The process by which organism populations change over successive generations that is influenced by gene mutation and natural selection.","Evolution | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1524073","Component, LOINC Axis 1","C40565","The name of the thing (chemical, protein, gene, cell, organ, antigen, event, action) that is being observed, assessed, detected, measured, counted, or evaluated.","Component, LOINC Axis 1 | Component | LOINC Axis 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521746","Protein Info","C41172","Protein; provides access to the encoding gene via its GenBank Accession, the taxon in which this instance of the protein occurs, and references to homologous proteins in other species.","Protein Info | Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040649","Transcription","C17208","A genetic process in which single-stranded RNA with base sequence complementary to a region of plus strand DNA is synthesized by DNA-dependent RNA polymerases. Following the binding of RNA polymerase on DNA promoter regions, the RNA product is synthesized in a 5' to 3' direction, elongating RNA along the DNA strand as the polymerase proceeds, accompanied by unwinding and rewinding of the DNA template.","Transcription | Gene Transcription | Genetic Transcription | RNA Expression | TRNSCPTN | Transcriptional | transcription",,,,,,,,,,,,,,,"4022360","Genetic transcription",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0766234","Technetium Tc-99m Apcitide","C47745","A radioconjugate comprised of the small peptide apcitide labeled with the gamma-emitting technetium TC99m (metastable Tc-99). Apcitide binds to platelet glycoprotein (GP) GPIIb/IIIa receptors on the surface of activated platelets. Labeling apcitide with TC99m allows localization of thrombus formation by gamma-ray imaging equipment and the ability to distinguish between old, inactive thrombi and new, active thrombi.","Technetium Tc-99m Apcitide | (99m)Tc-P280 | A9504 | AcuTect | TECHNETIUM TC-99M APCITIDE | Technetium (99mTc) Apcitide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0303029","Iodine I-131","C1639","A radioactive isotope of iodine with an atomic mass of 131, a half life of eight days, and potential antineoplastic activity. Selectively accumulating in the thyroid gland, iodine I 131 emits beta and gamma particles, thereby killing thyroid cells and decreasing thyroid hormone production.","Iodine I-131 | 131-Iodine | Bound Iodide I-131 | I 131 | I-131 | IODINE I-131 | Iodide I-131 | Iodide, I-131 | Iodine 131 | Iodine I 131 | Iodine-131 | Iodotope | Iodotrope",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024031","Lower Back Pain","C34788","A sensation of discomfort emanating from the lower back.","Lower Back Pain | ",,,,,,,,,,,,,,,"194133","Low back pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827061","Clinical Laboratory Improvement Act","C83475","A Federal law establishing quality standards for all laboratory testing to ensure the accuracy, reliability and timeliness of patient test results regardless of where the test was performed and also to determine if laboratories are achieving those standards.","Clinical Laboratory Improvement Act | CLIA | Clinical Laboratory Improvement Amendments",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827062","Biomarker Imaging Quality of Life Studies Funding Program","C83476","A funding mechanism and prioritization process for essential correlative studies and quality of life studies that are incorporated into the fundamental design of a clinical trial. The objective of this initiative is to ensure that the most important biomarker, imaging, and quality of life studies can be initiated in a timely manner in association with late phase clinical trials.","Biomarker Imaging Quality of Life Studies Funding Program | BIQSFP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827063","Occupancy","C83477","The action or fact of filling a place.","Occupancy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827064","Binary Encoding","C83478","The representation of symbols in a source alphabet by strings of binary digits.","Binary Encoding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205386","Descend","C61573","To travel downward.","Descend | Descending | Descent",,,,,,,,,,,,,,,"4326734","Descending",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0457343","Chronic Phase","C28262","Refers to the early stages of chronic myelogenous leukemia or chronic lymphocytic leukemia. The number of mature and immature abnormal white blood cells in the bone marrow and blood is higher than normal, but lower than in the accelerated or blast phase.","Chronic Phase | chronic phase",,,,,,,,,,,,,,,"4081357","Chronic phase",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1567710","Poly [ADP-Ribose] Polymerase 1, Human","C48215","Poly [ADP-ribose] polymerase 1 (1013aa, ~113 kDa) is encoded by the human PARP1 gene. This protein is involved in poly ADP-ribosylation and in the regulation of various cellular processes such as differentiation, proliferation, tumor transformation, and recovery from DNA damage.","Poly [ADP-Ribose] Polymerase 1 | ADP-Ribosyltransferase | ADP-Ribosyltransferase Diphtheria Toxin-Like 1 | ADP-Ribosyltransferase NAD(+) | ADPRT 1 | ARTD1 | EC 2.4.2.30 | NAD(+) ADP-Ribosyltransferase 1 | PARP | PARP-1 | PARP1 | Poly (ADP Ribose) Polymerase 1 | Poly(ADP Ribose) Polymerase | Poly(ADP Ribose) Polymerase | Poly(ADP Ribose) Polymerase 1 | Poly(ADP-Ribose) Synthetase | Poly(ADP-Ribosyl)Transferase | Poly[ADP-Ribose] Synthase 1 | poly (ADP-ribose) polymerase | poly(ADP-ribose) polymerase-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038179","Starch","C68488","A polysaccharide polymer of alpha-D glucose monomers, either connected by a 1-4 bond (amylose) or a 1-6 bond (amylopectin).","Starch | starch",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376597","Dietary Sucrose","C68477","A disaccharide consisting of glucose and fructose. The linkage is alpha with respect to the glucose and beta with respect to the fructose.","Sucrose | Confectioner's Sugar | SUCROSE | Table sugar",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827065","Non-Cytotoxic Agent","C83487","A pharmacologic substance that does not directly kill cells, but instead affects cellular transport and metabolic functions to ultimately produce cell death.","Non-Cytotoxic Agent | Non-cytotoxic Agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3278087","Thrombocytosis","C35530","A hematology test result that indicates the presence of higher than normal platelet counts in the peripheral blood.","Thrombocytosis | Elevated Platelet Count | Platelet Count Increased",,,,,,,,,,,,,,,"4280071","Thrombocytosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333933","HTR3A Gene","C25908","This gene plays a role in neurotransmitter modulation and in chaperone activity.","HTR3A Gene | 5-Hydroxytryptamine (Serotonin) Receptor 3A Gene | 5-Hydroxytryptamine (Serotonin) Receptor 3A Gene | HTR3A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826594","Computer Job","C82964","A unit of work done by a computer consisting of a single complete task.","Computer Job | Job",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826595","InterProScan","C82965","A computer program developed by the European Bioinformatics Institute that scans an input protein sequence against a range of stored protein signatures.","InterProScan | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887784","Urine Output Decreased","C80522","A finding indicating that the urine production is less than 500 milliliters during a 24 hour period.","Urine Output Decreased | Urine output decreased",,,,,,,,,,,,,,,"37397687","Decreased urine output",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3278910","Neutropenia","C80520","A decrease in the number of neutrophils in the peripheral blood.","Neutropenia | Granulocytopenia | Neutrophil Count Decreased | Neutrophil Count Decreased | Neutrophil count decreased | neutropenia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0435630","Wrist Fracture","C80517","Traumatic injury to the wrist joint in which the continuity of a wrist bone is broken. Symptoms include wrist pain, swelling, and deformity of wrist.","Wrist Fracture | Wrist fracture",,,,,,,,,,,,,,,"4138301","Fracture of distal end of radius and ulna",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4014276","Ejection Fraction Decreased","C83492","A finding indicating a decrease in the volume of blood ejected during ventricular heart contraction.","Ejection Fraction Decreased | Ejection fraction decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0423701","Urinary Tract Pain","C83493","Painful sensation in any part of the urinary tract.","Urinary Tract Pain | Urinary tract pain",,,,,,,,,,,,,,,"4082798","Urinary tract pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0151511","Breast Atrophy","C83494","Involution of the breast parenchyma.","Breast Atrophy | Breast atrophy",,,,,,,,,,,,,,,"81623","Atrophy of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0151685","Accelerated Growth","C83495","A finding indicating a faster than normal rate of development.","Accelerated Growth | Growth accelerated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043144","Wheezing","C78718","A symptom and a finding during physical examination, characterized by a high-pitched, whistling sound during breathing. It results from the narrowing or obstruction of the respiratory airways. The most common causes of wheezing are asthma, chronic obstructive pulmonary disease, tracheobronchitis, and pulmonary edema.","Wheezing | Wheeze",,,,,,,,,,,,,,,"314754","Wheezing",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2749634","Leukopenia","C26816","A laboratory test result indicating a decreased number of white blood cells in the peripheral blood.","Leukopenia | Leukocytopenia | White blood cell decreased | leukopenia",,,,,,,,,,,,,,,"435224","Leukopenia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1096106","Wound Complication","C78719","A medical condition that develops at the site of an existing wound. Examples include swelling, draining, bleeding, formation of hematoma, infection, and necrosis.","Wound Complication | Wound Healing Complication | Wound Healing Disorder | Wound complication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0340770","Venous Injury","C78711","Damage to a vein from traumatic or pathologic processes.","Venous Injury | Venous injury",,,,,,,,,,,,,,,"4275428","Injury of vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4014273","Ventricular Tachycardia","C50802","A disorder characterized by an electrocardiographic finding of three or more consecutive complexes of ventricular origin with a rate greater than a certain threshold (100 or 120 beats per minute are commonly used). The QRS complexes are wide and have an abnormal morphology. (CDISC)","Ventricular Tachycardia | Ventricular tachycardia",,,,,,,,,,,,,,,"4103295","Ventricular tachycardia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042571","Vertigo","C38057","A feeling of movement, a sensation as if the external world were revolving around the patient (objective vertigo) or as if he himself were revolving in space (subjective vertigo). Vertigo is medically distinct from dizziness, lightheadedness, and unsteadiness.","Vertigo | ",,,,,,,,,,,,,,,"439383","Vertigo",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0494559","Inner Ear Disorder","C27166","A non-neoplastic or neoplastic disorder affecting the inner ear. Causes are inner ear infections, head injuries, and neoplasms (e.g., acoustic schwannoma). Symptoms include dizziness, imbalance, nausea, and vision problems.","Inner Ear Disorder | Internal Ear Disorder | Internal Ear Disorder | Vestibular Disorder | Vestibular disorder",,,,,,,,,,,,,,,"4335747","Disorder of inner ear",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042755","Abnormal Virilization","C79859","The abnormal development of male secondary sexual characteristics due to excessive androgens.","Abnormal Virilization | Masculinization | Virilism | Virilization | Virilization",,,,,,,,,,,,,,,"4035817","Virilization",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0853812","Visceral Artery Ischemia","C78712","Decreased blood supply to the small or large intestine due to narrowing or blockage of a visceral (mesenteric) artery. The ischemia results to the damage of the intestinal tissues. It may be chronic, caused by atherosclerosis or acute, secondary to the formation of a thrombus or embolus in the mesenteric arterial lumen. In chronic ischemia, patients present with abdominal pain manifested in a short time after a meal and weight loss. In acute ischemia, patients present with sudden and acute abdominal pain, nausea and vomiting, and blood in the stool.","Visceral Artery Ischemia | Mesenteric Artery Ischemia | Visceral arterial ischemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0853735","Abnormal Vital Capacity","C78715","A pulmonary function test result indicating an abnormal vital capacity as compared to the predicted value.","Abnormal Vital Capacity | Vital capacity abnormal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1867291","Vitreous Hemorrhage","C50469","Blood extravasation in the vitreous humor. Causes include neovascularization, retinal tear, retinal detachment, and rupture of a blood vessel aneurysm in the eye.","Vitreous Hemorrhage | Blood In Vitreous Fluid | Vitreous hemorrhage",,,,,,,,,,,,,,,"315276","Vitreous hemorrhage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1699561","Vulval Infection","C78716","An infectious process affecting the vulva. Causative agents include human papillomavirus, herpes virus, Trichomonas, and Candida. Symptoms include itching and pain in the genital area and discharge.","Vulval Infection | Vulval infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042253","Vaginal Fistula","C79847","An abnormal communication between the vagina and another organ or cavity.","Vaginal Fistula | Fistulous Opening in Vagina | Vaginal fistula",,,,,,,,,,,,,,,"4261630","Fistulous opening in vagina",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2979982","Vaginal Hemorrhage","C26945","Bleeding originating from the vagina.","Vaginal Hemorrhage | Vaginal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1408443","Vaginal Obstruction","C78700","Congenital or acquired blockage of the vagina.","Vaginal Obstruction | Vaginal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0236082","Vaginal Pain","C78701","A painful sensation in the vagina.","Vaginal Pain | Vaginal pain",,,,,,,,,,,,,,,"4244072","Vaginal pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1696155","Vaginal Perforation","C78702","A rupture in the vaginal wall due to traumatic or pathologic processes.","Vaginal Perforation | Vaginal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0269208","Vaginal Stricture","C36064","Narrowing of the vaginal lumen.","Vaginal Stricture | Vaginal stricture",,,,,,,,,,,,,,,"4243763","Stricture of vagina",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2004487","Vaginismus","C78703","Tightness of the vaginal wall during vaginal penetration including sexual intercourse. It is caused by involuntary spasm of the pelvic floor muscles, and results in painful intercourse or failure to have intercourse. It may due to psychological conditions, trauma in the vaginal area, or vaginal infection.","Vaginismus | ",,,,,,,,,,,,,,,"193261|37016663","Vaginospasm|Myalgia of pelvic floor",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0152179","Vagus Nerve Disorder","C27591","A non-neoplastic or neoplastic disorder affecting the vagus nerve (tenth cranial nerve).","Vagus Nerve Disorder | Vagus nerve disorder",,,,,,,,,,,,,,,"432307","Disorder of vagus nerve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1699326","Vas Deferens Anastomotic Leakage","C78704","Leakage due to breakdown of a vas deferens anastomosis.","Vas Deferens Anastomotic Leakage | Vas deferens anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0920165","Vascular Access Complication","C78709","Complications related to damage at the vascular access site. Examples include bleeding, formation of hematoma, aneurysm, pseudoaneurysm, or arteriovenous fistula, development of infection, and catheter thrombosis.","Vascular Access Complication | Vascular access complication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710621","Vasovagal Reaction","C50798","Sudden drop of the blood pressure, bradycardia, and peripheral vasodilation that may lead to loss of consciousness. It results from an increase in the activity of the vagus nerve. It may be triggered by emotions of fear or pain or gastrointestinal upset and may be relieved by lying down while keeping the legs elevated.","Vasovagal Reaction | Vasovagal Response | Vasovagal reaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0567085","Uterine Pain","C78694","A painful sensation in the uterus.","Uterine Pain | Uterine pain",,,,,,,,,,,,,,,"4127066","Pain of uterus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042139","Uterine Perforation","C50793","A rupture in the uterus due to traumatic or pathologic processes.","Uterine Perforation | Uterine perforation | Uterus Perforation | Uterus Wall Perforation",,,,,,,,,,,,,,,"4252406","Perforation of uterus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1698194","Vaginal Anastomotic Leakage","C78698","Leakage due to breakdown of a vaginal anastomosis.","Vaginal Anastomotic Leakage | Vaginal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0241633","Vaginal Dryness","C78699","An uncomfortable feeling of itching and burning in the vaginal opening resulting from inadequate vaginal lubrication. It is commonly seen during and after menopause, childbirth, or stressful conditions. It results in painful intercourse.","Vaginal Dryness | Vaginal dryness",,,,,,,,,,,,,,,"4135950","Vaginal dryness",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL388535","Urinary Tract Obstruction","C79805","Blockage of the normal flow of contents of the urinary tract.","Urinary Tract Obstruction | Urinary tract obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0522153","Urine Discoloration","C78678","Change in the color of the urine. Causes include medications, vitamins, urinary tract infection, liver disease, hemolysis, and kidney cancer.","Urine Discoloration | Urine discoloration",,,,,,,,,,,,,,,"4009586|4055281","Discolored urine|Urine color abnormal",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1698193","Urostomy Leakage","C78679","Leakage of contents from a urostomy.","Urostomy Leakage | Urostomy leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1697984","Urostomy Obstruction","C78680","Blockage of the urostomy.","Urostomy Obstruction | Urostomy obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1698628","Urostomy Site Bleeding","C78682","Hemorrhage from the urostomy site.","Urostomy Site Bleeding | Urostomy site bleeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1698769","Urostomy Stenosis","C78683","Narrowing of the opening of a urostomy.","Urostomy Stenosis | Urostomy stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1699812","Uterine Anastomotic Leakage","C78684","Leakage due to breakdown of a uterine anastomosis.","Uterine Anastomotic Leakage | Uterine anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1696087","Uterine Fistula","C78685","An abnormal communication between the uterus and another organ.","Uterine Fistula | Uterine fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042134","Uterine Hemorrhage","C78686","Bleeding originating from the uterus.","Uterine Hemorrhage | Uterine hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014179","Endometritis","C26764","An acute or chronic, usually bacterial infectious process affecting the endometrium. It may extend to the myometrium and parametrial tissues. Symptoms include lower abdominal pain, vaginal discharge, and vaginal bleeding.","Endometritis | Uterine Infection | Uterine infection",,,,,,,,,,,,,,,"4302765","Endometritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1696113","Uterine Obstruction","C78693","Blockage of the uterine outlet. Causes include uterine tumors and adhesions.","Uterine Obstruction | Uterine obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0080274","Urinary Retention","C50790","Accumulation of urine within the bladder because of the inability to urinate.","Urinary Retention | Bladder Distention | Urinary retention | Urine Retention",,,,,,,,,,,,,,,"192450|4035673","Retention of urine|Bladder retention of urine",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0042029","Urinary Tract Infection","C50791","A bacterial infectious process affecting any part of the urinary tract, most commonly the bladder and the urethra. Symptoms include urinary urgency and frequency, burning sensation during urination, lower abdominal discomfort, and cloudy urine.","Urinary Tract Infection | UTI | Urinary Tract Infectious Disease | Urinary tract infection",,,,,,,,,,,,,,,"81902","Urinary tract infectious disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4230731","Urinary Incontinence","C78497","Involuntary passage of urine outside the body.","Urinary Incontinence | Bladder incontinence | Enuresis | Urinary incontinence | urinary incontinence",,,,,,,,,,,,,,,"197672","Urinary incontinence",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001163","Vestibulocochlear Nerve Disorder","C27207","A non-neoplastic or neoplastic disorder affecting the acoustic nerve.","Vestibulocochlear Nerve Disorder | Acoustic Nerve Disorder | Acoustic nerve disorder NOS",,,,,,,,,,,,,,,"439842","Disorder of acoustic nerve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0000731","Abdominal Distension","C78161","Swelling of the abdomen resulting from excessive food intake, malnutrition, liver disease, primary abdominal tumors, and tumors metastatic to the abdominal cavity.","Abdominal Distension | Abdominal Bloating | Abdominal Distension | Abdominal Distention | Abdominal Distention | Abdominal distension",,,,,,,,,,,,,,,"442597","Swollen abdomen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1112209","Abdominal Infection","C35669","Infection in the abdominal cavity resulting from injury, acute intestinal inflammation (e.g., acute appendicitis), intestinal perforation, or complication of abdominal surgery.","Abdominal Infection | Abdominal infection",,,,,,,,,,,,,,,"4028062","Infectious disease of abdomen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1699695","Abdominal Soft Tissue Necrotic Lesion","C78165","A necrotic process occurring in the soft tissues of the abdominal wall.","Abdominal Soft Tissue Necrotic Lesion | Abdominal soft tissue necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0271355","Abducens Nerve Disorder","C27593","A non-neoplastic or neoplastic disorder affecting the abducens nerve (sixth cranial nerve).","Abducens Nerve Disorder | Abducens Nerve Disease | Abducens nerve disorder | VIth Nerve Disorder",,,,,,,,,,,,,,,"4162701","Abducens nerve disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0392156","Akathisia","C78163","An uncomfortable feeling of inner restlessness and inability to stay still. It can be a side effect of psychotropic medications.","Akathisia | ",,,,,,,,,,,,,,,"4108925","Akathisia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085631","Agitation","C79530","A state of restlessness associated with unpleasant feelings of irritability and tension. Causes include pain, stress, fever, alcohol and nicotine withdrawal, cocaine and hallucinogenic drugs use, depression, bipolar disorders, and schizophrenia.","Agitation | agitation",,,,,,,,,,,,,,,"4086746","Feeling agitated",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022660","Acute Renal Failure","C26808","Sudden and sustained deterioration of the kidney function characterized by decreased glomerular filtration rate, increased serum creatinine or oliguria.","Acute Renal Failure | AKI | ARF | Acute Kidney Injury | Acute kidney injury",,,,,,,,,,,,,,,"197320","Acute kidney injury",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0948089","Acute Coronary Syndrome","C53652","Signs and symptoms related to acute ischemia of the myocardium secondary to coronary artery disease. The clinical presentation covers a spectrum of heart diseases from unstable angina to myocardial infarction.","Acute Coronary Syndrome | Acute coronary syndrome",,,,,,,,,,,,,,,"4215140","Acute coronary syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0240671","Prolonged Partial Thromboplastin Time","C27028","An abnormal laboratory test result in which the partial thromboplastin time is found to be greater than the control value. As a possible indicator of coagulopathy, a prolonged partial thromboplastin time (PTT) may occur in a variety of diseases and disorders, both primary and related to treatment.","Prolonged Partial Thromboplastin Time | Activated partial thromboplastin time prolonged | Prolonged Activated Partial Thromboplastin Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0854391","Aortic Injury","C35623","Damage to the aorta from traumatic or pathologic processes.","Aortic Injury | Aortic injury",,,,,,,,,,,,,,,"40484607","Injury of aorta",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0234022","Anorgasmia","C78177","Inability to achieve orgasm.","Anorgasmia | ",,,,,,,,,,,,,,,"4269918","Orgasm incapacity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2700620","Anorectal Infection","C78174","An infectious process affecting the anal area and the rectum.","Anorectal Infection | Anorectal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0159877","Ankle Fracture","C26989","Traumatic or pathological injury to the ankle joint in which the continuity of an ankle bone is broken. Symptoms include pain, swelling, and difficulty moving the affected leg and foot.","Ankle Fracture | Ankle fracture",,,,,,,,,,,,,,,"4059173","Fracture of ankle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0857035","Anaphylactic Shock","C50460","Progression of anaphylaxis into systemic shock, which is characterized by significant reduction in tissue perfusion which leads to hypoxia and hypotension, and can lead to death if untreated.","Anaphylactic Shock | anaphylactic shock",,,,,,,,,,,,,,,"42536383","Anaphylactic shock",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016167","Anal Ulcer","C79536","A painful tear in the lining of the anal canal, often accompanied by bleeding on defecation. It is usually the result of a traumatic bowel movement or anal sexual penetration.","Anal Ulcer | Anal ulcer",,,,,,,,,,,,,,,"444397","Ulcer of anus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2749156","Anal Stenosis","C78173","Narrowing of the anal canal.","Anal Stenosis | Anal stenosis",,,,,,,,,,,,,,,"4092872|4289616","Acquired anal stenosis|Stricture of anus",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0238637","Anal Pain","C78172","Painful sensation in the anal region.","Anal Pain | Anal pain",,,,,,,,,,,,,,,"442764","Anal pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1697981","Anal Necrotic Lesion","C78171","A necrotic process involving the area of the anus.","Anal Necrotic Lesion | Anal necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1699653","Anal Mucositis","C78170","An inflammatory process affecting the mucous membrane of the anus.","Anal Mucositis | Anal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0426747","Anal Hemorrhage","C78168","Bleeding originating from the anal area.","Anal Hemorrhage | Anal hemorrhage",,,,,,,,,,,,,,,"4245614","Bleeding from anus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3280944","Tricuspid Valve Disorder","C78649","A heart disorder characterized by a defect in tricuspid valve structure or function.","Tricuspid Valve Disorder | Tricuspid valve disease",,,,,,,,,,,,,,,"316993","Tricuspid valve disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152177","Trigeminal Nerve Disorder","C26952","A non-neoplastic or neoplastic disorder affecting the trigeminal nerve (fifth cranial nerve).","Trigeminal Nerve Disorder | Trigeminal nerve disorder",,,,,,,,,,,,,,,"440703","Trigeminal nerve disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0854069","Tumor Pain","C78656","A painful sensation caused by the tumor growth.","Tumor Pain | Tumor pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0494930","Unequal Limb Length","C78657","Discrepancy between the lengths of the lower or upper extremities.","Unequal Limb Length | Unequal limb length",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041747","Unintended Pregnancy","C79801","A pregnancy that was not desired or was timed incorrectly at the time that the conception occurred.","Unintended Pregnancy | Unintended pregnancy",,,,,,,,,,,,,,,"4307820","Unplanned pregnancy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041909","Upper Gastrointestinal Hemorrhage","C78660","Bleeding originating from the upper gastrointestinal tract (oral cavity, pharynx, esophagus, and stomach).","Upper Gastrointestinal Hemorrhage | Upper gastrointestinal hemorrhage",,,,,,,,,,,,,,,"4291649","Upper gastrointestinal bleeding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041912","Upper Respiratory Tract Infection","C35650","An infectious process affecting the upper respiratory tract (nose, paranasal sinuses, pharynx, larynx, or trachea). Symptoms include congestion, sneezing, coughing, fever, and sore throat.","Upper Respiratory Tract Infection | Cold | Respiratory Tract Infection | URI | Upper Respiratory Infection | Upper Respiratory Tract Inflammation | Upper respiratory infection",,,,,,,,,,,,,,,"4181583","Upper respiratory infection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1698675","Ureteric Anastomotic Leakage","C78662","Leakage due to breakdown of a ureteral anastomosis.","Ureteric Anastomotic Leakage | Ureteral Anastomotic Leak | Ureteric anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1699207","Urethral Anastomotic Leakage","C78667","Leakage due to breakdown of a urethral anastomosis.","Urethral Anastomotic Leakage | Urethral anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0948357","Urethral Infection","C78671","A bacterial, viral, or fungal infectious process affecting the urethra.","Urethral Infection | Urethral infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0564755","Acute Perforated Appendicitis","C78178","Acute appendicitis with gangrenous changes resulting in the rupture of the appendiceal wall. The appendiceal wall rupture causes the release of inflammatory and bacterial contents from the appendiceal lumen into the abdominal cavity.","Acute Perforated Appendicitis | Appendicitis perforated",,,,,,,,,,,,,,,"4117866","Acute perforated appendicitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085693","Appendicitis","C35145","Acute inflammation of the vermiform appendix.","Appendicitis | Acute Appendicitis | Acute Appendicitis",,,,,,,,,,,,,,,"4310400","Acute appendicitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003564","Aphonia","C79539","A term referring to the inability to speak. It may result from injuries to the vocal cords or may be functional (psychogenic).","Aphonia | ",,,,,,,,,,,,,,,"40481303","Aphonia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1260873","Aortic Valve Disorder","C78650","A heart disorder characterized by a defect in aortic valve structure or function.","Aortic Valve Disorder | Aortic valve disease",,,,,,,,,,,,,,,"314054","Aortic valve disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003860","Arteritis","C34399","An inflammatory process affecting an artery.","Arteritis | Arteritis, unspecified",,,,,,,,,,,,,,,"314659","Arteritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4229429","AV Block First Degree","C62015","A disorder characterized by an electrocardiographic finding of prolonged PR interval for a specific population. For adults one common threshold is a PR interval greater than 0.20 seconds.","AV Block First Degree | Atrioventricular Block, First Degree | Atrioventricular block first degree | First Degree AV Block | First Degree Atrioventricular Block",,,,,,,,,,,,,,,"314379","First degree atrioventricular block",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0151517","Complete Atrioventricular Block","C50501","A disorder characterized by an electrocardiographic finding of complete failure of atrial electrical impulse conduction to the ventricles. This is manifested on the ECG by disassociation of atrial and ventricular rhythms. The atrial rate must be faster than the ventricular rate. (CDISC)","Complete Atrioventricular Block | AV Block Third Degree | AV Block Third Degree | Atrioventricular Block, Third Degree | Atrioventricular block complete | Complete AV Block | Complete Heart Block | Heart Block | Non-Congenital Complete Atrioventricular Block | Third Degree AV Block | Third Degree Atrioventricular Block",,,,,,,,,,,,,,,"320744","Complete atrioventricular block",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005417","Biliary Fistula","C79540","An abnormal communication between the bile ducts and another organ or cavity.","Biliary Fistula | Biliary fistula",,,,,,,,,,,,,,,"194407","Fistula of bile duct",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0401006","Biliary Anastomotic Leakage","C78183","Leakage of bile due to breakdown of a biliary anastomosis.","Biliary Anastomotic Leakage | Biliary anastomotic leak",,,,,,,,,,,,,,,"4341660","Biliary anastomotic leak",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0267925","Bile Duct Stenosis","C78182","Narrowing or stricture of the bile duct.","Bile Duct Stenosis | Bile duct stenosis",,,,,,,,,,,,,,,"4182588","Stenosis of bile duct",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004509","Azoospermia","C80076","Complete absence of spermatozoa in the semen.","Azoospermia | Aspermia | Azospermia",,,,,,,,,,,,,,,"76744","Azoospermia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0434133","Bladder Perforation","C78208","A rupture in the bladder wall due to traumatic or pathologic processes.","Bladder Perforation | Bladder perforation",,,,,,,,,,,,,,,"4134928","Perforation of bladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1697974","Bladder Anastomotic Leakage","C78206","Leakage of urine due to breakdown of a bladder anastomosis.","Bladder Anastomotic Leakage | Bladder anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3280137","Cholangitis","C26718","An acute or chronic inflammatory process affecting the biliary tract.","Cholangitis | Biliary Tract Infection | Biliary tract infection",,,,,,,,,,,,,,,"195856","Cholangitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0853603","Abnormal Blood Gonadotrophin","C78216","A laboratory test result which indicates abnormal levels of gonadotrophin hormone in the blood.","Abnormal Blood Gonadotrophin | Blood gonadotrophin abnormal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0853122","Blood Corticotrophin Decreased","C78215","A laboratory test result which indicates decreased levels of corticotrophin in the blood.","Blood Corticotrophin Decreased | Blood corticotrophin decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0853592","Abnormal Blood Antidiuretic Hormone","C78214","A laboratory test result which indicates abnormal levels of antidiuretic hormone in the blood.","Abnormal Blood Antidiuretic Hormone | Blood antidiuretic hormone abnormal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006262","Bronchial Fistula","C79543","An abnormal communication between the bronchus and another organ or anatomic site.","Bronchial Fistula | Bronchial fistula",,,,,,,,,,,,,,,"4119938","Bronchial fistula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024902","Breast Pain","C78223","Painful sensation in the breast region.","Breast Pain | Breast Discomfort/Pain | Breast pain",,,,,,,,,,,,,,,"73819","Pain of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3280635","Hypocellular Bone Marrow","C35167","A laboratory finding indicating decreased number of hematopoietic cells in the bone marrow. It may result from decreased proliferation of all or part of the hematopoietic series (erythroid, myeloid, and megakaryocytic). Microscopically, the hematopoietic cells are replaced by adipocytes.","Hypocellular Bone Marrow | Bone Marrow Hypoplasia | Bone marrow hypocellular",,,,,,,,,,,,,,,"4056992","Bone marrow myeloid hypoplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2242472","Bone Infection","C26839","An acute or chronic infectious process affecting the bones.","Bone Infection | Bone infection",,,,,,,,,,,,,,,"72410","Infection of bone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0263472","Body Odor","C79542","Body smell resulting from the growth of bacteria on the body.","Body Odor | Body odor",,,,,,,,,,,,,,,"4178504|4218245","Body odor|Body odor",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0231710","Buttock Pain","C78228","Painful sensation in the buttocks.","Buttock Pain | Buttock pain",,,,,,,,,,,,,,,"4133039","Pain in buttock",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085932","Bullous Dermatitis","C35149","Inflammation of the skin characterized by the presence of bullae which are filled with fluid.","Bullous Dermatitis | Bullous dermatitis",,,,,,,,,,,,,,,"137944","Bullous dermatosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1321133","Bronchial Hemorrhage","C78224","Bleeding from the bronchial wall and/or lung parenchyma.","Bronchial Hemorrhage | Bronchopulmonary Hemorrhage | Bronchopulmonary hemorrhage",,,,,,,,,,,,,,,"4236721","Bronchial hemorrhage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0860239","Catheter-Related Infection","C78232","An infection that arises secondary to catheter use.","Catheter-Related Infection | Catheter Related Infection | Catheter related infection",,,,,,,,,,,,,,,"4258835","Infection associated with catheter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1699694","Cecal Infection","C78235","An infectious process affecting the cecum.","Cecal Infection | Cecal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1699142","Cecal Hemorrhage","C78234","Bleeding originating in the cecum.","Cecal Hemorrhage | Cecal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1392207","Central Nervous System Necrotic Lesion","C78236","A necrotic process affecting the brain and/or spinal cord.","Central Nervous System Necrotic Lesion | Central nervous system necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008035","Chest Wall Pain","C78238","Painful sensation in the chest wall region.","Chest Wall Pain | Chest wall pain | Musculoskeletal Chest Pain | Musculoskeletal chest pain",,,,,,,,,,,,,,,"4010016","Chest wall pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0856203","Infectious Cervicitis","C78360","An infectious process affecting the uterine cervix. Causative agents include Neisseria gonorrhoeae, Chlamydia trachomatis, human papillomavirus, and herpes simplex virus. Physical examination reveals an erythematous, raised lesion in the cervix and mucopurulent discharge.","Infectious Cervicitis | Cervicitis infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0235328","Colonic Obstruction","C78241","Blockage of the normal flow of the intestinal contents in the colon.","Colonic Obstruction | Colonic obstruction",,,,,,,,,,,,,,,"4249110","Obstruction of colon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0151694","Colonic Hemorrhage","C78240","Bleeding originating from the colon.","Colonic Hemorrhage | Colonic hemorrhage",,,,,,,,,,,,,,,"442190","Hemorrhage of colon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0341365","Colonic Fistula","C78239","An abnormal communication between the large intestine and another organ or cavity.","Colonic Fistula | Colonic fistula | Large Bowel Fistula",,,,,,,,,,,,,,,"4059276","Colonic fistula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008733","Chylothorax","C79546","A milky pleural effusion resulting from accumulation of lymph fluid in the pleural cavity. Causes include malignancies (usually lymphoma), trauma to the thoracic duct, tuberculosis, sarcoidosis, and congenital causes.","Chylothorax | Chylous Pleural Effusion",,,,,,,,,,,,,,,"4306136","Chylothorax",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0235198","Concentration Impairment","C80081","Deterioration in the ability to concentrate.","Concentration Impairment | Concentration impairment | Impaired Concentration",,,,,,,,,,,,,,,"4243064|600632","Unable to concentrate|Impaired concentration",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0267491","Colonic Ulcer","C78244","A circumscribed inflammatory and necrotic erosive lesion in the mucosa surface of the colon.","Colonic Ulcer | Colonic ulcer",,,,,,,,,,,,,,,"4261784","Ulceration of colon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0267466","Colonic Stenosis","C78243","Narrowing of the lumen of colon.","Colonic Stenosis | Colonic stenosis",,,,,,,,,,,,,,,"4078069|4309802","Stenosis of colon|Stricture of colon",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3275704","Colonic Perforation","C78242","A rupture in the colonic wall due to traumatic or pathologic processes.","Colonic Perforation | Colonic perforation",,,,,,,,,,,,,,,"4177183","Perforation of colon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011206","Delirium","C2981","A usually reversible condition characterized by the acute and sudden development of confusion, illusions, movement changes, inattentiveness, agitation, and hallucinations. Causes include drug abuse, poisoning, infectious processes, and fluid and electrolyte imbalance.","Delirium | delirium",,,,,,,,,,,,,,,"373995","Delirium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1112573","Delayed Orgasm","C78252","Sexual dysfunction characterized by a delay in climax.","Delayed Orgasm | Delayed orgasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0410916","Neonatal Death","C80082","Death of a live newborn during the first 28 days of life.","Neonatal Death | Death neonatal",,,,,,,,,,,,,,,"4079843","Newborn death",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1697749","Cranial Nerve Infection","C78248","An infectious process affecting a cranial nerve.","Cranial Nerve Infection | Cranial nerve infection",,,,,,,,,,,,,,,"36715546","Infection of cranial nerve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010043","Corneal Ulcer","C50515","Area of epithelial tissue loss from corneal surface; associated with inflammatory cells in the cornea and anterior chamber.","Corneal Ulcer | Corneal ulcer",,,,,,,,,,,,,,,"373202","Corneal ulcer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031048","Constrictive Pericarditis","C78246","A heart disorder in which the pericardial sac becomes thickened and fibrotic, tightening the myocardium and impeding the normal myocardial function.","Constrictive Pericarditis | Constrictive pericarditis",,,,,,,,,,,,,,,"312334","Constrictive pericarditis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1313983","Acute Contagious Conjunctivitis","C35704","Acute inflammation of the conjunctiva characterized by pink or red color in the eyes.","Acute Contagious Conjunctivitis | Conjunctivitis infective | Pinkeye | pinkeye",,,,,,,,,,,,,,,"4163288","Keratoconjunctivitis due to Moraxella bovis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4011764","Cardiac Conduction Disorder","C78245","A disorder affecting the conduction system that sends electrical signals in the myocardium.","Cardiac Conduction Disorder | Conduction Abnormality | Conduction disorder | Disorder of Cardiac Conduction | Heart Conduction Disorder | Heart Conduction Disorder",,,,,,,,,,,,,,,"316999","Conduction disorder of the heart",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085073","Prosthesis-Related Infection","C79705","A bacterial infection related to a device used to replace a missing body part. The infection may occur during the operation from direct contamination or post-operatively through hematogenous spread.","Prosthesis-Related Infection | Device related infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0549249","Depressed Level Of Consciousness","C78253","A neurologic state characterized by decreased ability to perceive and respond.","Depressed Level Of Consciousness | DEPRESSED | Decreased Level  of Consciousness | Decreased Level of Consciousness | Depressed Level of Consciousness | Depressed level of consciousness",,,,,,,,,,,,,,,"40481424","Decreased level of consciousness",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011253","Delusion","C26741","False personal beliefs held contrary to reality, despite contradictory evidence and common sense.","Delusion | Delusions",,,,,,,,,,,,,,,"444401","Delusions",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1698629","Duodenal Infection","C78258","An infectious process affecting the duodenum.","Duodenal Infection | Duodenal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521595","Duodenal Hemorrhage","C78257","Bleeding originating from the duodenum.","Duodenal Hemorrhage | Duodenal hemorrhage",,,,,,,,,,,,,,,"4318535","Duodenal hemorrhage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0267358","Duodenal Fistula","C78256","An abnormal communication between the duodenum and another organ or cavity.","Duodenal Fistula | Duodenal fistula",,,,,,,,,,,,,,,"442551","Duodenal fistula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013292","Duodenal Obstruction","C79548","Blockage of the normal flow of stomach contents through the duodenum.","Duodenal Obstruction | Duodenal obstruction",,,,,,,,,,,,,,,"434085","Obstruction of duodenum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0238093","Duodenal Stenosis","C78260","Narrowing of the lumen of the duodenum.","Duodenal Stenosis | Duodenal stenosis",,,,,,,,,,,,,,,"4218926","Stenosis of duodenum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0740401","Duodenal Perforation","C78259","A rupture in the duodenal wall due to traumatic or pathologic processes.","Duodenal Perforation | Duodenal perforation",,,,,,,,,,,,,,,"4156639","Duodenal perforation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1142644","cytochrome P450 3A4 protein, human","C17573","Cytochrome P450 3A4 (503 aa, ~57 kDa) is encoded by the human CYP3A4 gene. This protein is involved in the oxidation of steroids, fatty acids and xenobiotics.","Cytochrome P450 3A4 | 1,8-Cineole 2-Exo-Monooxygenase | Albendazole Monooxygenase | Albendazole Monooxygenase (Sulfoxide-Forming) | Albendazole Sulfoxidase | CYP3A4 | CYPIIIA3 | CYPIIIA4 | Cytochrome P450 3A3 | Cytochrome P450 HLp | Cytochrome P450 NF-25 | Cytochrome P450 Nifedipine Oxidase | Cytochrome P450, Subfamily IIIA (Niphedipine Oxidase), Polypeptide 3 | Cytochrome P450, Subfamily IIIA (Niphedipine Oxidase), Polypeptide 4 | Cytochrome P450, Subfamily IIIA, Polypeptide 4 | Cytochrome P450-PCN1 | Cytochrome P450PCN1 | EC 1.14.13.- | EC 1.14.13.32 | EC 1.14.13.67 | EC 1.14.13.97 | EC 1.14.14.- | Glucocorticoid-Inducible P450 | Nifedipine Oxidase | P450-3A4 | Quinine 3-Monooxygenase | Steroid-Inducible P450-III | Taurochenodeoxycholate 6-Alpha-Hydroxylase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0856705","Infectious Encephalomyelitis","C79551","An infectious process that affects the brain and spinal cord tissues. It is usually caused by viruses.","Infectious Encephalomyelitis | Encephalomyelitis infection",,,,,,,,,,,,,,,"36715541","Infection causing encephalomyelitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0596773","Infectious Encephalitis","C79550","An acute infectious process that affects the brain tissue. It is usually caused by viruses and less often by bacteria, parasites, and fungi.","Infectious Encephalitis | Encephalitis infection",,,,,,,,,,,,,,,"374020","Infective encephalitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0973461","Dysphasia","C35546","Impairment of verbal communication skills, often resulting from brain damage.","Dysphasia | ",,,,,,,,,,,,,,,"441594","Dysphasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013390","Dysmenorrhea","C34559","Abnormally painful abdominal cramps during menstruation.","Dysmenorrhea | ",,,,,,,,,,,,,,,"194696","Dysmenorrhea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0392699","Dysesthesia","C28246","Distortion of a sense resulting in an abnormal and unpleasant sensation, usually described as burning, tingling, or numbness. Causes include lesions of the nervous system.","Dysesthesia | dysesthesia",,,,,,,,,,,,,,,"4150134","Dysesthesia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0340221","Tracheal Obstruction","C78645","Blockage of the lumen of the trachea. Causes include secretions, foreign bodies, and tumors.","Tracheal Obstruction | Tracheal obstruction",,,,,,,,,,,,,,,"4249742","Obstruction of trachea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040583","Tracheal Stenosis","C78646","Narrowing of the lumen of the trachea.","Tracheal Stenosis | Tracheal stenosis",,,,,,,,,,,,,,,"4010275","Stenosis of trachea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1868703","Bacterial Tracheitis","C78647","Bacterial infectious process with formation of mucopurulent membranes affecting the trachea. Causative agents include Staphylococcus, Streptococcus, Haemophilus influenzae, Pseudomonas, and Klebsiella.","Bacterial Tracheitis | Tracheitis | Tracheitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1699657","Tracheostomy Site Bleeding","C78648","Bleeding from the tracheostomy site.","Tracheostomy Site Bleeding | Tracheostomy site bleeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0852911","Blood Alkaline Phosphatase Increased","C35607","A laboratory test result which indicates an increased level of alkaline phosphatase in a biological specimen.","Blood Alkaline Phosphatase Increased | Alkaline phosphatase increased | Elevated Serum Alkaline Phosphatase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1697788","Decreased Carbon Monoxide Diffusing Capacity","C78229","A lung function test result in which the lung capacity to absorb carbon monoxide is decreased.","Decreased Carbon Monoxide Diffusing Capacity | Carbon monoxide diffusing capacity decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0852680","Blood Cardiac Troponin T Increased","C78231","A laboratory test result which indicates increased levels of cardiac troponin T in a biological specimen.","Blood Cardiac Troponin T Increased | Cardiac troponin T increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0852692","Blood Cardiac Troponin I Increased","C78230","A laboratory test result which indicates increased levels of cardiac troponin I in a biological specimen.","Blood Cardiac Troponin I Increased | Cardiac troponin I increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007971","Cheilitis","C79545","An inflammatory process affecting the lip.","Cheilitis | ",,,,,,,,,,,,,,,"4301764","Cheilitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0403632","Non-Infectious Cystitis","C78250","An inflammation of the bladder which is not caused by an infection of the urinary tract. Representative examples include interstitial cystitis and radiation-induced cystitis.","Non-Infectious Cystitis | Cystitis noninfective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0151578","Increased Creatinine","C78249","A laboratory test result demonstrating an increased concentration of creatinine in a biological specimen.","Increased Creatinine | Creatinine increased | Elevated Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4014882","Creatine Phosphokinase Increased","C78247","A laboratory test result which indicates increased levels of creatine phosphokinase in a biological specimen.","Creatine Phosphokinase Increased | CPK increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3553963","Endophthalmitis","C34586","An infectious process affecting the internal structures of the eye.","Endophthalmitis | ",,,,,,,,,,,,,,,"438411","Endophthalmitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1541923","Infective Endocarditis","C78265","An infectious process involving the endocardial layer of the heart.","Infective Endocarditis | Endocarditis infective",,,,,,,,,,,,,,,"4119460","Infective endocarditis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2919133","Ejaculation Disorder","C78264","A disorder referring to problems related to ejaculation. This category includes premature, delayed, retrograde, and painful ejaculation.","Ejaculation Disorder | Ejaculation Dysfunction | Ejaculation disorder | Ejaculatory Dysfunction",,,,,,,,,,,,,,,"4305075","Disorder of ejaculation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0578541","Edema Trunk","C78263","Swelling due to an excessive accumulation of fluid in trunk area.","Edema Trunk | Edema trunk",,,,,,,,,,,,,,,"4199409","Edema of trunk",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085649","Edema Limbs","C78262","Swelling due to an excessive accumulation of fluid in the upper or lower extremities.","Edema Limbs | Edema limbs | Limb Edema | Limb edema | Limbs Edema | PERIPHERAL EDEMA | Peripheral Edema",,,,,,,,,,,,,,,"4158343|4220064","Peripheral edema|Peripheral edema",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0542571","Face Edema","C78289","Swelling due to an excessive accumulation of fluid in facial tissues.","Face Edema | Edema face",,,,,,,,,,,,,,,"40482052","Edema of face",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0151474","Alcohol Intolerance","C78167","Increased sensitivity to the adverse effects of alcohol, which can include nasal congestion, skin flushes, heart dysrhythmias, nausea, vomiting, indigestion and headaches.","Alcohol Intolerance | Alcohol intolerance",,,,,,,,,,,,,,,"4010023","Alcohol intolerance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040460","Toothache","C78640","A painful sensation originating from a tooth.","Toothache | ",,,,,,,,,,,,,,,"4099176","Toothache",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014518","Toxic Epidermal Necrolysis","C79777","A systemic, serious, and life-threatening disorder characterized by erythematous and necrotic lesions in the skin and mucous membranes that are associated with bullous detachment of the epidermis. The epidermal and mucous membranes detachment leads to sepsis and may be fatal. The lesions appear throughout the body and occupy more than 30% of the body surfaces. It is a hypersensitivity reaction usually caused by drugs (e.g., sulfonamides, nonsteroidal anti-inflammatory drugs, anticonvulsants, and antiretroviral drugs).","Toxic Epidermal Necrolysis | Lyell Syndrome | Lyell's Syndrome | TEN | Toxic epidermal necrolysis",,,,,,,,,,,,,,,"35625873","Lyell syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0340214","Tracheal Fistula","C78641","An abnormal communication between the trachea and another organ or anatomic site.","Tracheal Fistula | Tracheal fistula",,,,,,,,,,,,,,,"4121300","Tracheal fistula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0340220","Tracheal Hemorrhage","C78642","Bleeding originating from the trachea.","Tracheal Hemorrhage | Tracheal hemorrhage",,,,,,,,,,,,,,,"4121303","Tracheal hemorrhage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1699329","Tracheal Mucositis","C78644","An inflammatory process affecting the mucous membrane of the trachea.","Tracheal Mucositis | Tracheal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034155","Thrombotic Thrombocytopenic Purpura","C78797","A coagulation disorder characterized by extensive formation of thrombi in small blood vessels throughout the body due to low levels of ADAMTS13 protein, and resulting in consumption of circulating platelets, which is characterized by thrombocytopenia, anemia, neurologic changes, and sometimes fever and renal dysfunction.","Thrombotic Thrombocytopenic Purpura | Moschowitz Disease | TTP | Thrombotic thrombocytopenic purpura",,,,,,,,,,,,,,,"4301602","Thrombotic thrombocytopenic purpura",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0494698","Dental Developmental Disorder","C35596","A disorder of the teeth arising during odontogenesis.","Dental Developmental Disorder | Tooth Development Disorder | Tooth development disorder",,,,,,,,,,,,,,,"4159157","Disorder of tooth development",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040434","Tooth Discoloration","C80112","A change in tooth color. Causes may be local or systemic and include tobacco use, foods, dental plaques, caries, restorative filling materials, trauma, medications, infections, hereditary diseases, and nutritional deficiencies.","Tooth Discoloration | Tooth discoloration",,,,,,,,,,,,,,,"4126781|4133221","Staining of tooth|Tooth discolored",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0877046","Tooth Infection","C78639","An infectious process affecting a tooth.","Tooth Infection | Dental Infection | Tooth infection",,,,,,,,,,,,,,,"4322737","Infection of tooth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038833","Superior Vena Cava Syndrome","C3396","Obstruction of the blood flow in the superior vena cava caused by a malignant neoplasm, thrombosis, or aneurysm. It is a medical emergency requiring immediate treatment. Signs and symptoms include swelling and cyanosis of the face, neck, and upper arms, cough, orthopnea, and headache.","Superior Vena Cava Syndrome | Superior vena cava syndrome | superior vena cava syndrome",,,,,,,,,,,,,,,"4272799","Superior vena cava syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4229989","Supraventricular Tachycardia","C35061","A disorder characterized by an electrocardiographic finding of a tachycardia which does not originate in the ventricles or His Purkinje system. There is an abnormally high heart rate and QRS complexes are typically narrow, but aberration or preexcitation may be present. (CDISC)","Supraventricular Tachycardia | SVT | Supraventricular tachycardia",,,,,,,,,,,,,,,"4275423","Supraventricular tachycardia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039584","Testicular Disorder","C26890","A non-neoplastic or neoplastic disorder affecting the testis. Representative examples include torsion, infarction, germ cell tumor, sex cord-stromal tumor, lymphoma, and leukemia.","Testicular Disorder | Testicular Disease | Testicular disorder",,,,,,,,,,,,,,,"4276801","Disorder of testis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268969","Testicular Hemorrhage","C78635","Bleeding originating from the testis.","Testicular Hemorrhage | Testicular hemorrhage",,,,,,,,,,,,,,,"4299088","Hemorrhage of testis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039591","Testicular Pain","C78636","A painful sensation in the testis.","Testicular Pain | Testicular pain",,,,,,,,,,,,,,,"4270932","Pain in testicle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1699328","Spermatic Cord Anastomotic Leakage","C78622","Leakage due to breakdown of a spermatic cord anastomosis.","Spermatic Cord Anastomotic Leakage | Spermatic cord anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268940","Spermatic Cord Hemorrhage","C78623","Bleeding originating from the spermatic cord.","Spermatic Cord Hemorrhage | Spermatic cord hemorrhage",,,,,,,,,,,,,,,"4144374","Hemorrhage of spermatic cord",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1557933","Spermatic Cord Obstruction","C78624","Blockage of the normal flow of the contents of the spermatic cord.","Spermatic Cord Obstruction | Spermatic cord obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0080179","Vertebral Fracture","C80516","Traumatic or pathological injury to the spine in which the continuity of a vertebral bone is broken. Symptoms include back pain and difficulty bending and twisting.","Vertebral Fracture | Spinal Fracture | Spinal fracture",,,,,,,,,,,,,,,"4174520","Fracture of vertebral column",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037997","Splenic Disorder","C35823","A non-neoplastic or neoplastic disorder affecting the spleen. Examples include infection, hemangioma, lymphoma, leukemia and angiosarcoma.","Splenic Disorder | Spleen Disorder | Spleen disorder",,,,,,,,,,,,,,,"201265","Disorder of spleen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0948149","Splenic Infection","C78627","An infectious process affecting the spleen. Predisposing factors include immunosuppression, diabetes mellitus, and sickle cell anemia. Infectious agents include bacteria (e.g., staphylococcus and streptococcus) and fungi.","Splenic Infection | Splenic infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1699177","Gastrointestinal Stoma Stenosis","C78628","Narrowing of the lumen of a gastrointestinal stoma.","Gastrointestinal Stoma Stenosis | Stenosis of gastrointestinal stoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038325","Stevens-Johnson Syndrome","C79484","A systemic, serious, and life-threatening disorder characterized by lesions in the skin and mucous membranes that may lead to necrosis. The lesions may appear anywhere in the body but they occur more commonly in the palms, soles, dorsum of the hands, and extensor surfaces. The lesions are vesicular or necrotic in the center, surrounded by an erythematous zone and occupy less than 10% of the body surfaces. The appearance of the mucocutaneous lesions is preceded by an upper respiratory tract infection. It is an immune complex hypersensitivity reaction usually caused by drugs (e.g., sulfa, phenytoin, penicillin), viruses (e.g., herpes simplex, influenza, hepatitis), and malignancies (e.g., carcinoma and lymphoma).","Stevens-Johnson Syndrome | Erythema Multiforme Major | Stevens Johnson Syndrome | Stevens-Johnson syndrome",,,,,,,,,,,,,,,"141651","Stevens-Johnson syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1610624","Stoma Site Infection","C78629","An infectious process affecting a surgically created opening in the surface of the body.","Stoma Site Infection | Stoma site infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221512","Stomach Pain","C78630","A painful sensation in the stomach.","Stomach Pain | Gastric Pain | Stomach pain",,,,,,,,,,,,,,,"4152197","Stomach ache",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024799","Stomal Ulcer","C79766","An ulcer that develops in the jejunal mucosa close to the anastomosis site following a gastroenterostomy procedure.","Stomal Ulcer | Marginal Ulcer | Stomal ulcer",,,,,,,,,,,,,,,"4059178","Gastrojejunal ulcer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038450","Stridor","C78632","A symptom resulting from laryngeal obstruction. It is characterized by a high pitched breathing sound.","Stridor | ",,,,,,,,,,,,,,,"253321","Stridor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3152142","Sudden Cardiac Death","C50911","An unexpected natural death from a cardiac cause within a short time period from the onset of symptoms.","Sudden Cardiac Death | SCD",,,,,,,,,,,,,,,"4317150","Sudden cardiac death",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0424000","Suicidal Ideation","C80102","Thoughts of taking one's own life.","Suicidal Ideation | Suicidal ideation",,,,,,,,,,,,,,,"4273391","Suicidal thoughts",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038663","Suicide Attempt","C80111","Self-inflicted harm in an attempt to end one's own life.","Suicide Attempt | Suicide attempt",,,,,,,,,,,,,,,"4219484","Suicide attempt",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1698669","Superficial Soft Tissue Fibrosis","C78633","Fibrotic degeneration of the superficial soft tissues.","Superficial Soft Tissue Fibrosis | Superficial soft tissue fibrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0235511","Superficial Thrombophlebitis","C78634","Thrombosis and inflammation of a superficial vein of the extremities. Symptoms include red discoloration and warmth of the skin and pain along the affected vein.","Superficial Thrombophlebitis | Superficial thrombophlebitis",,,,,,,,,,,,,,,"4085025","Superficial thrombophlebitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0151977","Small Intestinal Ulcer","C78619","A circumscribed inflammatory and necrotic erosive lesion in the mucosa surface of the small intestine.","Small Intestinal Ulcer | Small intestine ulcer",,,,,,,,,,,,,,,"4342655","Ulceration of small intestine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037383","Sneezing","C50746","A symptom consisting of the involuntary expulsion of air from the nose.","Sneezing | ",,,,,,,,,,,,,,,"4328356","Sneezing",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0149778","Soft Tissue Infection","C79745","A bacterial infectious process affecting the soft tissues. A severe form caused by anaerobic or aerobic bacteria is associated with soft tissues necrosis and affects the subcutaneous adipose tissue, muscles, fascia, and the skin.","Soft Tissue Infection | Soft tissue infection",,,,,,,,,,,,,,,"4320030","Soft tissue infection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1698668","Lower Limb Soft Tissue Necrotic Lesion","C78620","A necrotic process affecting the soft tissues of the lower extremity.","Lower Limb Soft Tissue Necrotic Lesion | Soft tissue necrosis lower limb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1698634","Upper Limb Soft Tissue Necrotic Lesion","C78621","A necrotic process affecting the soft tissues of the upper extremity.","Upper Limb Soft Tissue Necrotic Lesion | Soft tissue necrosis upper limb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3854544","Sore Throat","C50747","Any kind of inflammatory process of the tonsils, pharynx, or/and larynx characterized by pain in swallowing.","Sore Throat | Sore throat | Sore_throat",,,,,,,,,,,,,,,"259153","Pain in throat",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2750633","Spasticity","C79750","Increased involuntary muscle tone caused by central nervous system disorders that affect the regions interfering with voluntary movement. It results in gait, movement, and speech disturbances. Representative examples of disorders causing spasticity include brain or spinal cord injury, and multiple sclerosis.","Spasticity | Spastic",,,,,,,,,,,,,,,"4287788|4329728","Spasticity|Spasticity",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1698036","Small Intestinal Infection","C78618","An infectious process affecting the small intestine.","Small Intestinal Infection | Small intestine infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0151924","Small Intestinal Stenosis","C78617","Narrowing of the lumen of small intestine.","Small Intestinal Stenosis | Small intestinal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0151739","Small Intestinal Perforation","C78616","A rupture in the wall of the small intestine due to traumatic or pathologic processes.","Small Intestinal Perforation | Small intestinal perforation",,,,,,,,,,,,,,,"4341631","Perforation of small intestine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0235329","Small Intestinal Obstruction","C78615","Blockage of the normal flow of the small intestinal contents.","Small Intestinal Obstruction | Small intestinal obstruction",,,,,,,,,,,,,,,"4090129","Small bowel obstruction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1698626","Small Intestinal Mucositis","C78613","An inflammatory process affecting the mucous membrane of the small intestine.","Small Intestinal Mucositis | Small intestinal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0241075","Skin Induration","C78611","An area of hardness in the skin. Causes include inflammatory process and infiltration of the skin by malignant neoplasms.","Skin Induration | Skin induration",,,,,,,,,,,,,,,"4145436","Induration of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037278","Skin Infection","C35025","An inflammatory process affecting the skin, caused by bacteria, viruses, parasites, or fungi. Examples of bacterial infection include carbuncles, furuncles, impetigo, erysipelas, and abscesses. Examples of viral infection include shingles, warts, molluscum contagiosum, and pityriasis rosea. Examples of parasitic infection include scabies and lice. Examples of fungal infection include athlete's foot, yeast infection, and ringworm.","Skin Infection | Skin infection",,,,,,,,,,,,,,,"201093","Infection of skin and/or subcutaneous tissue",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4227329","Skin Ulcer","C54247","A circumscribed and often suppurating skin crater which usually includes loss of skin integrity of the superficial skin or the mucous membranes.","Skin Ulcer | Skin Ulceration | Skin ulceration",,,,,,,,,,,,,,,"4262920","Skin ulcer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1698195","Small Intestinal Anastomotic Leakage","C78612","Leakage due to breakdown of a small intestinal anastomosis.","Small Intestinal Anastomotic Leakage | Small intestinal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3806871","Skin Hyperpigmentation","C79731","Darkening of the skin due to excessive melanin deposition. Causes include skin injuries, pregnancy, eczema, and Addison disease.","Skin Hyperpigmentation | Hyperpigmentation | Skin hyperpigmentation",,,,,,,,,,,,,,,"4172432|4174813","Hyperpigmentation of skin|Hyperpigmentation",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C4228718","Skin Hypopigmentation","C78610","Abnormal lightening of skin due to decreased melanin production or deposition. Vitiligo, albinism, and leukoderma are among the disorders that are associated with skin hypopigmentation.","Skin Hypopigmentation | Hypopigmentation | Pigment Dilution | Skin hypopigmentation",,,,,,,,,,,,,,,"4041510|4088375|4230341","Skin hypopigmented|Depigmentation|Hypopigmentation",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C0036830","Serum Sickness","C79718","Delayed-type hypersensitivity reaction to foreign proteins derived from an animal serum. It occurs approximately six to twenty one days following the administration of the foreign antigen. Symptoms include fever, arthralgias, myalgias, skin eruptions, lymphadenopathy, chest pain, and dyspnea. Certain drugs (e.g., antibiotics, anticancer agents, and anti-inflammatory medications) and infectious disorders (e.g., hepatitis B) may also cause serum sickness-like reaction.","Serum Sickness | Serum sickness",,,,,,,,,,,,,,,"4308547|4309477|432522","Serum rash|Urticaria due to serum|Transfusion reaction due to serum protein reaction",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C0030469","Paranasal Sinus Disorder","C26843","A non-neoplastic or neoplastic disorder affecting the paranasal sinuses. Examples include inflammation, polyps, and cancer.","Paranasal Sinus Disorder | Paranasal Sinus Disease | Sinus disorder",,,,,,,,,,,,,,,"256440","Disorder of nasal sinus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0522251","Sinus Pain","C78609","Painful sensation in the face, between the eyes, or upper teeth originating from the sinuses. It is usually caused by sinus infections.","Sinus Pain | Sinus pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2750812","Scoliosis","C78603","A congenital or acquired spinal deformity characterized by lateral curvature of the spine.","Scoliosis | SCOLIOSIS",,,,,,,,,,,,,,,"72418","Scoliosis deformity of spine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1299539","Scrotal Infection","C78606","A bacterial, fungal or viral infectious process affecting the scrotum.","Scrotal Infection | Scrotal infection",,,,,,,,,,,,,,,"4154121","Infection of scrotum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0236078","Scrotal Pain","C78607","Painful sensation in the scrotal area.","Scrotal Pain | Scrotal pain",,,,,,,,,,,,,,,"4071874","Pain in scrotum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0476327","Serum Amylase Increased","C78608","A laboratory test indicating increased levels of amylase in the serum.","Serum Amylase Increased | Serum amylase increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036094","Salivary Gland Fistula","C79715","An abnormal communication between a salivary gland and another organ or anatomic site.","Salivary Gland Fistula | Salivary gland fistula",,,,,,,,,,,,,,,"28462","Fistula of salivary gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0392318","Salivary Gland Infection","C78601","A viral (such as mumps) or bacterial infectious process affecting the salivary gland. The salivary gland becomes enlarged and is often painful.","Salivary Gland Infection | Salivary gland infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0240940","Scalp Pain","C79716","Painful sensation in the skin covering the top and the back of the head.","Scalp Pain | Scalp pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036412","Sclera Disorder","C79717","A disorder affecting the sclera. Examples include inflammatory processes (e.g., scleritis and episcleritis), and degenerative processes. Primary tumors of the sclera are extremely rare.","Sclera Disorder | Scleral Disorder | Scleral disorder",,,,,,,,,,,,,,,"436134","Disorder of sclera",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0151705","Retroperitoneal Hemorrhage","C26944","Bleeding originating in the retroperitoneal area.","Retroperitoneal Hemorrhage | Retroperitoneal hemorrhage",,,,,,,,,,,,,,,"4318539","Retroperitoneal hemorrhage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3160858","Reversible Posterior Leukoencephalopathy Syndrome","C78598","An acute or subacute reversible condition characterized by headaches, mental status changes, visual disturbances, and seizures associated with imaging findings of posterior leukoencephalopathy. It has been observed in association with hypertensive encephalopathy, eclampsia, and immunosuppressive and cytotoxic drug treatment.","Reversible Posterior Leukoencephalopathy Syndrome | PRES | Posterior Reversible Encephalopathy Syndrome | RPLE | Reversible Occipital Parietal Encephalopathy | Reversible Posterior Cerebral Edema Syndrome | Reversible posterior leukoencephalopathy syndrome",,,,,,,,,,,,,,,"42872891","Posterior reversible encephalopathy syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL387475","Infectious Rhinitis","C78599","An inflammatory process affecting the nasal mucosa, usually caused by viruses (e.g., rhinovirus, adenovirus, parainfluenza virus, and coronavirus). It is characterized by chills, headaches, mucopurulent nasal discharge, coughing, and facial pain.","Infectious Rhinitis | Non-Allergic Rhinitis | Rhinitis infective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242707","Right Ventricular Dysfunction","C50733","Impairment of the right ventricular function associated with low ejection fraction and decreased motility of the right ventricular wall.","Right Ventricular Dysfunction | Right ventricular dysfunction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0266989","Salivary Duct Inflammation","C78600","An inflammatory process affecting the salivary duct.","Salivary Duct Inflammation | Salivary duct inflammation",,,,,,,,,,,,,,,"4025346|4218650","Sialoangiitis|Sialodochitis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C4230812","Retinal Tear","C50732","A usually small tearing of the retina occurring when the vitreous separates from the retina. It may lead to retinal detachment. Symptoms include flashes and floaters.","Retinal Tear | Retinal Tears | Retinal tear",,,,,,,,,,,,,,,"4317972","Retinal tear",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0860564","APL Differentiation Syndrome","C78597","A syndrome observed in patients with acute promyelocytic leukemia treated with all-trans retinoic acid. It is characterized by weight gain, dyspnea, pleural and pericardial effusions, leukocytosis, and renal failure.","APL Differentiation Syndrome | Differentiation Syndrome | Retinoic Acid Syndrome | Retinoic Acid Syndrome | Retinoic acid syndrome",,,,,,,,,,,,,,,"36676614","Differentiation syndrome due to and following chemotherapy co-occurrent with acute promyelocytic leukemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0341563","Esophageal Anastomotic Leakage","C78270","Leakage due to breakdown of an esophageal anastomosis.","Esophageal Anastomotic Leakage | Esophageal anastomotic leak",,,,,,,,,,,,,,,"4340523","Esophageal anastomotic leak",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3551697","Erythroderma","C39646","A generalized inflammatory cutaneous disorder characterized by erythema and desquamation.","Erythroderma | Exfoliative Dermatitis",,,,,,,,,,,,,,,"4270887","Erythroderma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0156272","Enterovesical Fistula","C78266","An abnormal communication between the urinary bladder and the intestine.","Enterovesical Fistula | Enterovesical fistula",,,,,,,,,,,,,,,"201344","Intestinovesical fistula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1142115","Infectious Enterocolitis","C80513","An infectious process affecting the small and large intestines. Symptoms include diarrhea, cramping abdominal pain, and fever.","Infectious Enterocolitis | Enterocolitis infectious",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0267075","Esophageal Ulcer","C26950","An ulcerated lesion in the esophageal wall.","Esophageal Ulcer | Esophageal ulcer",,,,,,,,,,,,,,,"25844","Ulcer of esophagus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4229315","Esophageal Stricture","C34595","Narrowing of the lumen of the esophagus.","Esophageal Stricture | Esophageal Stenosis | Esophageal stenosis | Stenosis of the esophagus",,,,,,,,,,,,,,,"4268622","Stricture of esophagus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014860","Esophageal Perforation","C50693","The presence of a hole or other type of opening in the esophageal wall through which the contents of the esophagus can pass into the mediastinum. The most common cause of esophageal perforation is injury during a medical procedure such as esophagoscopy or placement of a naso-gastric tube; and pathologic process such as neoplasm or gastric reflux with ulceration. Less common causes include injuries from penetrating or blunt trauma or injury to the esophagus during an operation on another organ, mechanical problem such as violent retching or vomiting; ingestion of a foreign body or caustic agents. The condition often results in infection of the mediastinum and mediastinitis.","Esophageal Perforation | Esophageal perforation | Perforation Of Esophagus | Perforation Of Esophagus | Perforation of Esophagus",,,,,,,,,,,,,,,"22955","Perforation of esophagus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221727","Esophageal Pain","C78280","Painful sensation in the esophageal region.","Esophageal Pain | Esophageal pain",,,,,,,,,,,,,,,"4009391","Pain in esophagus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0239296","Esophageal Obstruction","C78279","Blockage of the normal flow of the contents in the esophagus.","Esophageal Obstruction | Esophageal obstruction",,,,,,,,,,,,,,,"4224926","Obstruction of esophagus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1697884","Esophageal Necrotic Lesion","C78278","A necrotic process involving the esophageal wall.","Esophageal Necrotic Lesion | Esophageal necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0851979","Esophageal Infection","C78277","An infectious process affecting the esophagus.","Esophageal Infection | Esophageal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0239293","Esophageal Hemorrhage","C78271","Bleeding originating from the esophagus.","Esophageal Hemorrhage | Esophageal hemorrhage",,,,,,,,,,,,,,,"23245","Esophageal bleeding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014856","Esophageal Fistula","C79574","An abnormal communication between the esophagus and another organ or anatomic site.","Esophageal Fistula | Esophageal fistula",,,,,,,,,,,,,,,"4149721","Esophageal fistula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0155789","Esophageal Varices Hemorrhage","C78282","Bleeding from esophageal varices.","Esophageal Varices Hemorrhage | Esophageal varices hemorrhage | Esophageal varices with bleeding",,,,,,,,,,,,,,,"28779","Bleeding esophageal varices",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL388509","Euphoria","C34598","An exaggerated feeling of well-being which is disproportionate to events and stimuli. It may result from psychological causes, organic brain syndromes, or toxic states.","Euphoria | euphoria",,,,,,,,,,,,,,,"4312216","Euphoria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0154833","Retinal Vascular Disorder","C35170","Retinal damage resulting from diminished blood flow/oxygenation due to abnormalities of the retinal vessels.  Causes include hypertension, diabetes, thrombosis, embolism, and hemorrhage.","Retinal Vascular Disorder | Retinal vascular disorder",,,,,,,,,,,,,,,"434337","Retinal vascular disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029878","Otitis Externa","C79601","Inflammation of the anatomical structures of the outer ear and ear canal, which is most often caused by an infectious process. Symptoms include erythema, edema, and pain.","Otitis Externa | External Ear Inflammation | External Ear Inflammation | External Otitis | External ear inflammation | Inflammation of External Auditory Canal | Inflammation of the External Auditory Canal",,,,,,,,,,,,,,,"380731","Otitis externa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4228004","Facial Muscle Weakness","C78290","A reduction in the strength of the facial muscles.","Facial Muscle Weakness | Facial muscle weakness",,,,,,,,,,,,,,,"434657","Weakness of face muscles",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0854286","Eyelid Function Disorder","C78288","A disorder characterized by impaired eyelid function.","Eyelid Function Disorder | Eyelid function disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0151827","Eye Pain","C78287","Painful sensation in the eye.","Eye Pain | Eye pain",,,,,,,,,,,,,,,"379031","Pain in eye",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015403","Eye Infection","C45372","An infectious process affecting any part of the eye. Causes include viruses and bacteria. Symptoms include itching and discomfort in the eye, watery eyes, eye pain and discharge, and blurring vision. Representative examples include pink eye, blepharitis, and trachoma.","Eye Infection | Eye Infections | Eye infection",,,,,,,,,,,,,,,"4134613","Eye infection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015371","Extrapyramidal Disorder","C79593","A movement disorder caused by defects in the basal ganglia. The clinical manifestations include changes in the muscle tone, dyskinesia, and akinesia. Causes include vascular disorders, degenerative disorders, and antipsychotic drugs.","Extrapyramidal Disorder | Extrapyramidal and movement disorder, unspecified | Extrapyramidal disorder",,,,,,,,,,,,,,,"373747","Extrapyramidal disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4012905","Extraocular Muscle Paresis","C78286","A slight or incomplete paralysis of an extraocular muscle.","Extraocular Muscle Paresis | Extraocular muscle paresis",,,,,,,,,,,,,,,"4148062","Paresis of extraocular muscles",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0012173","Dietary Fiber","C68492","In food, fiber is the part of fruits, vegetables, legumes, and whole grains that cannot be digested. The fiber in food may help prevent cancer. In the body, fiber refers to tissue made of long threadlike cells, such as muscle fiber or nerve fiber.","Dietary Fiber | Fiber | fiber",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015927","Intrauterine Fetal Death","C50620","Death of a fetus after 10 weeks gestation.","Intrauterine Fetal Death | Fetal Death | Fetal Demise | Fetal death | INTRAUTERINE DEATH | IUD",,,,,,,,,,,,,,,"4079844","Fetal death",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0877195","Acquired Feminization","C78299","The development of secondary female sex characteristics in males due to extrinsic factors.","Acquired Feminization | Feminization acquired",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0269131","Female Genital Tract Fistula","C78298","An abnormal communication between a female reproductive system organ and another organ or cavity.","Female Genital Tract Fistula | Female genital tract fistula",,,,,,,,,,,,,,,"199879","Fistula of the female genital organs",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0333650","Adipose Tissue Atrophy","C78297","Shrinking of adipose tissue.","Adipose Tissue Atrophy | Fat Atrophy | Fat atrophy",,,,,,,,,,,,,,,"4174254","Fatty atrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0459524","Fallopian Tube Stenosis","C78295","Narrowing of the lumen of the fallopian tube.","Fallopian Tube Stenosis | Fallopian tube stenosis",,,,,,,,,,,,,,,"4088628","Fallopian tube stenosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1557983","Fallopian Tube Perforation","C78294","A rupture of the fallopian tube wall due to tubal pregnancy, or other traumatic or pathologic processes.","Fallopian Tube Perforation | Fallopian tube perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041274","Fallopian Tube Obstruction","C78293","Blockage of the normal flow of the contents in the fallopian tube.","Fallopian Tube Obstruction | Fallopian tube obstruction",,,,,,,,,,,,,,,"4129549","Blocked fallopian tube",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1698039","Fallopian Tube Anastomotic Leakage","C78292","Leakage due to breakdown of a fallopian tube anastomosis.","Fallopian Tube Anastomotic Leakage | Fallopian tube anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085639","Fall","C50558","A sudden movement downward, usually resulting in injury.","Fall | ",,,,,,,,,,,,,,,"436583","Fall",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015468","Facial Pain","C79594","Painful sensation in the face.","Facial Pain | Facial pain",,,,,,,,,,,,,,,"4317968","Pain in face",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015464","Facial Nerve Disorder","C27594","A non-neoplastic or neoplastic disorder affecting the facial nerve (seventh cranial nerve).","Facial Nerve Disorder | Facial nerve disorder",,,,,,,,,,,,,,,"378135","Facial nerve disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1167767","Gallbladder Necrotic Lesion","C78307","A necrotic process occurring in the gallbladder.","Gallbladder Necrotic Lesion | Gallbladder necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0744254","Gallbladder Infection","C78306","An acute or chronic infectious process affecting the gallbladder.","Gallbladder Infection | Gallbladder infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0156216","Gallbladder Fistula","C78305","An abnormal communication between the gallbladder and another organ or cavity.","Gallbladder Fistula | Gallbladder fistula",,,,,,,,,,,,,,,"200154","Fistula of gallbladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3809740","Gait Disturbance","C78303","A finding referring to walking difficulties.","Gait Disturbance | Gait disturbance",,,,,,,,,,,,,,,"437643","Abnormal gait",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085635","Flasher","C50568","The perception of sudden or brief bursts (flashes) of light.","Flasher | Flashers | Flashing lights | Photopsia",,,,,,,,,,,,,,,"4206763","Photopsia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016199","Flank Pain","C34615","Painful sensation in the region below the ribs and above the hip.","Flank Pain | Flank pain",,,,,,,,,,,,,,,"4090433","Flank pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3554553","Fibrinogen Decreased","C78300","A laboratory test result which indicates decreased levels of fibrinogen in a biological specimen.","Fibrinogen Decreased | Fibrinogen decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0585012","Gastric Stenosis","C78317","Narrowing of the lumen of the stomach.","Gastric Stenosis | Gastric stenosis",,,,,,,,,,,,,,,"442253","Stenosis of stomach",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0235884","Gastric Perforation","C78316","A rupture in the gastric wall caused by traumatic or pathologic processes.","Gastric Perforation | Gastric perforation",,,,,,,,,,,,,,,"4340781","Perforation of stomach",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0341221","Gastric Necrotic Lesion","C78314","A necrotic process affecting the gastric wall.","Gastric Necrotic Lesion | Gastric necrosis",,,,,,,,,,,,,,,"4342645","Gastric necrosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0235325","Gastric Hemorrhage","C54582","Bleeding from the gastric wall.","Gastric Hemorrhage | Gastric hemorrhage",,,,,,,,,,,,,,,"193250","Gastric hemorrhage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017128","Gastric Fistula","C79595","An abnormal communication between the stomach and another organ or anatomic site.","Gastric Fistula | Gastric fistula",,,,,,,,,,,,,,,"192669","Gastric fistula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0341564","Gastric Anastomotic Leakage","C78310","Leakage due to breakdown of a gastric anastomosis.","Gastric Anastomotic Leakage | Gastric anastomotic leak",,,,,,,,,,,,,,,"4341250","Gastric anastomotic leak",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0156215","Gallbladder Perforation","C78309","A rupture in the gallbladder wall caused by traumatic or pathologic processes.","Gallbladder Perforation | Gallbladder perforation",,,,,,,,,,,,,,,"196469","Perforation of gallbladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL386687","Gallbladder Pain","C78304","Painful sensation in the gallbladder region.","Gallbladder Pain | Gallbladder pain",,,,,,,,,,,,,,,"4010981","Gallbladder pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0156214","Gallbladder Obstruction","C78308","Blockage of the normal flow of the contents of the gallbladder.","Gallbladder Obstruction | Gallbladder obstruction",,,,,,,,,,,,,,,"192363|4058818","Obstruction of gallbladder|Occlusion of gallbladder",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0392171","Flu-Like Symptoms","C78302","Complaints describing a pattern similar to influenza, which may include one or more of the following symptoms: fever, chills, muscle or body aches, cough, sore throat, rhinitis, or fatigue.","Flu-Like Symptoms | Flu like symptoms | ILI | Influenza-Like Illness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1836462","Generalized Muscle Weakness","C78323","A reduction in the strength of muscles in multiple anatomic sites.","Generalized Muscle Weakness | Generalized muscle weakness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1843863","Gastroparesis","C80512","Paralysis of the muscles of the stomach wall resulting in delayed emptying of the gastric contents into the small intestine.","Gastroparesis | ",,,,,,,,,,,,,,,"195847","Gastroparesis syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1698678","Gastrointestinal Stoma Necrotic Lesion","C78321","A necrotic process affecting the post-operative stoma area in the gastrointestinal tract.","Gastrointestinal Stoma Necrotic Lesion | Gastrointestinal stoma necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0687713","Gastrointestinal Pain","C78320","Painful sensation in the gastrointestinal region.","Gastrointestinal Pain | Gastrointestinal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079238","Digestive System Fistula","C78319","An abnormal communication between any part of the digestive system and another organ or cavity.","Digestive System Fistula | Gastrointestinal Fistula | Gastrointestinal Fistula | Gastrointestinal fistula",,,,,,,,,,,,,,,"42536508|4295370","Fistula of digestive system|Gastrointestinal fistula",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0341562","Digestive System Anastomotic Leakage","C78318","Leakage due to breakdown of a gastrointestinal anastomosis.","Digestive System Anastomotic Leakage | Gastrointestinal System Anastomotic Leakage | Gastrointestinal System Anastomotic Leakage | Gastrointestinal anastomotic leak",,,,,,,,,,,,,,,"4341249","Gastrointestinal anastomotic leak",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0236062","Haptoglobin Decreased","C78330","A laboratory test result which indicates decreased levels of haptoglobin in a biological specimen.","Haptoglobin Decreased | Haptoglobin decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0744403","Gum Infection","C78329","An acute or chronic infectious process affecting the gums.","Gum Infection | Gum infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4229445","Growth Retardation","C78328","Stature that is smaller than normal as expected for age.","Growth Retardation | Growth suppression",,,,,,,,,,,,,,,"40481177|4245750","Growth retardation|Growth retardation",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0860787","Abnormal Growth Hormone","C78327","A laboratory test result which indicates abnormal levels of growth hormone in a biologic specimen.","Abnormal Growth Hormone | Growth hormone abnormal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0751941","Glossopharyngeal Nerve Disorder","C27211","A non-neoplastic or neoplastic disorder affecting the glossopharyngeal nerve (ninth cranial nerve).","Glossopharyngeal Nerve Disorder | Glossopharyngeal nerve disorder | IX Nerve Disorder | Ninth Nerve Disorder",,,,,,,,,,,,,,,"435803","Disorder of glossopharyngeal nerve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0877743","Gingival Pain","C78325","Painful sensation in the gingival region.","Gingival Pain | Gingival pain",,,,,,,,,,,,,,,"4009488","Sore gums",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0151604","Genital Edema","C78324","Swelling due to an excessive accumulation of fluid in the genitals.","Genital Edema | Genital edema",,,,,,,,,,,,,,,"4102122","Genital edema",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3151386","Hearing Impairment","C50576","Partial or complete loss of the ability to detect or understand sounds resulting from damage to the outer, middle, or inner ear structures. Causes include exposure to loud noise, ear infections, injuries to the ear, genetic, and congenital disorders.","Hearing Impairment | Hearing difficulty | Hearing impaired",,,,,,,,,,,,,,,"4038030","Hearing difficulty",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1561246","Head Soft Tissue Necrotic Lesion","C78331","A necrotic process affecting the soft tissues of the head.","Head Soft Tissue Necrotic Lesion | Head soft tissue necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3280569","Hoarseness","C47813","Harsh and raspy voice secondary to laryngeal infection, voice overuse, irritants inhalation, vocal cord paralysis, vocal cord polyps, and malignant neoplasms arising from or spreading to the larynx.","Hoarseness | Dysphonia",,,,,,,,,,,,,,,"4177176","Hoarse",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019557","Hip Fracture","C26794","Traumatic or pathological injury to the hip in which the continuity of either the femoral head, femoral neck, intertrochanteric or subtrochanteric regions is broken. Symptoms include pain in the hip or groin, bruising and swelling in and around the hip area. The injured hip is turned outward and the leg appears shorter on that side.","Hip Fracture | Hip fracture",,,,,,,,,,,,,,,"4138412","Fracture of proximal end of femur",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0522067","Hepatic Pain","C78341","A painful sensation in the liver.","Hepatic Pain | Hepatic pain",,,,,,,,,,,,,,,"4009394","Liver pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0151798","Hepatic Necrotic Lesion","C78340","A necrotic process affecting the hepatic parenchyma.","Hepatic Necrotic Lesion | Hepatic necrosis",,,,,,,,,,,,,,,"4337543","Hepatic necrosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1112211","Hepatic Infection","C78339","An acute or chronic infectious process affecting the liver.","Hepatic Infection | Hepatic infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0235912","Hepatic Hemorrhage","C78338","Bleeding originating from the liver.","Hepatic Hemorrhage | Hepatic hemorrhage",,,,,,,,,,,,,,,"4043254","Hemorrhage of liver",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265031","Hemorrhoidal Hemorrhage","C78337","Bleeding from the hemorrhoids.","Hemorrhoidal Hemorrhage | Hemorrhoidal hemorrhage",,,,,,,,,,,,,,,"4198840","Bleeding hemorrhoids",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0549448","Hemoglobin Increased","C78333","A laboratory test result which indicates increased levels of hemoglobin in a biological specimen.","Hemoglobin Increased | Hemoglobin increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018962","Hematosalpinx","C78332","The presence of blood in a fallopian tube.","Hematosalpinx | ",,,,,,,,,,,,,,,"4301594","Hematosalpinx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0520564","Ileal Ulcer","C78357","A circumscribed inflammatory and necrotic erosive lesion in the mucosa surface of the ileum.","Ileal Ulcer | Ileal ulcer",,,,,,,,,,,,,,,"4196699","Ileal ulcer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0400847","Ileal Stenosis","C78356","Narrowing of the lumen of ileum.","Ileal Stenosis | Ileal stenosis",,,,,,,,,,,,,,,"36717315","Stenosis of ileum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0559938","Ileal Perforation","C78355","A rupture in the ileal wall due to traumatic or a pathologic processes.","Ileal Perforation | Ileal perforation | Perforation of Ileum",,,,,,,,,,,,,,,"4083971","Perforation of ileum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1699648","Ileal Obstruction","C78354","Blockage of the normal flow of the small intestinal contents in the ileum.","Ileal Obstruction | Ileal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1699655","Ileal Fistula","C78352","An abnormal communication between the ileum and another organ or cavity.","Ileal Fistula | Ileal fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0347703","Injury to Jugular Vein","C78364","Damage to the jugular vein from traumatic or pathologic processes.","Injury to Jugular Vein | Injury to jugular vein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0160705","Injury to Inferior Vena Cava","C78363","Damage to the inferior vena cava from traumatic or pathologic processes.","Injury to Inferior Vena Cava | Injury to inferior vena cava",,,,,,,,,,,,,,,"194807","Injury of inferior vena cava",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0160680","Injury to Carotid Artery","C79599","Damage to the carotid artery. Causes include blunt injuries (e.g., motor vehicle accidents and sports-related injuries) and penetrating traumas (e.g., gunshot and knife injuries).","Injury to Carotid Artery | Injury to carotid artery",,,,,,,,,,,,,,,"315116","Injury of carotid artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1608954","Infusion Site Extravasation","C78362","Leakage of a pharmacologic or a biological substance from the infusion site into the surrounding tissue. Signs and symptoms include induration, erythema, swelling, burning sensation, and pain at the infusion site.","Infusion Site Extravasation | Infusion site extravasation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0948715","Infusion-Related Reaction","C78361","A reaction to the infusion of pharmacological or biological substances. Symptoms may appear within minutes to hours following the infusion and may include pruritus, flushing, swelling, dyspnea, bronchospasm, and hypotension.","Infusion-Related Reaction | Infusion Related Reaction | Infusion related reaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825140","Not High School Graduate","C76123","Indicates a person has attended high school but did not complete high school and did not receive a high school diploma.","Not High School Graduate | Some High School Completion | Started high school but didn't graduate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1699208","Intraoperative Hepatobiliary Injury","C78382","Damage to the hepatic parenchyma and biliary tract during a surgical procedure.","Intraoperative Hepatobiliary Injury | Intraoperative hepatobiliary injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079027","Intraoperative Hemorrhage","C35135","Uncontrolled bleeding during a surgical procedure.","Intraoperative Hemorrhage | Intraoperative hemorrhage | Operative Hemorrhage",,,,,,,,,,,,,,,"4308716","Intraoperative hemorrhage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1699741","Intraoperative Head and Neck Injury","C78381","Damage to head and neck during a surgical procedure.","Intraoperative Head and Neck Injury | Intraoperative head and neck injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1698097","Intraoperative Digestive System Injury","C78380","Damage to any part of the digestive system during a surgical procedure.","Intraoperative Digestive System Injury | Intraoperative Gastrointestinal Injury | Intraoperative Gastrointestinal Injury | Intraoperative gastrointestinal injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1699738","Intraoperative Endocrine Injury","C78379","Damage to an endocrine gland during a surgical procedure.","Intraoperative Endocrine Injury | Intraoperative endocrine injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1699211","Intraoperative Ear Injury","C78378","Damage to the ear during a surgical procedure.","Intraoperative Ear Injury | Intraoperative ear injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1699742","Intraoperative Cardiac Injury","C78377","Damage to the heart during a surgical procedure.","Intraoperative Cardiac Injury | Intraoperative cardiac injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1558321","Intraoperative Breast Injury","C78376","Damage to the breast parenchyma during a surgical procedure.","Intraoperative Breast Injury | Intraoperative breast injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1698098","Intraoperative Arterial Injury","C78375","Damage to an artery during a surgical procedure.","Intraoperative Arterial Injury | Intraoperative arterial injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0236178","Intra-Abdominal Hemorrhage","C78372","Bleeding within the abdominal cavity.","Intra-Abdominal Hemorrhage | Intra-abdominal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0877223","Intestinal Stoma Site Hemorrhage","C78371","A finding of blood leakage from the intestinal stoma.","Intestinal Stoma Site Hemorrhage | Intestinal Stoma Site Bleeding | Intestinal stoma site bleeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1142487","Intestinal Stoma Obstruction","C78370","A blockage of the intestinal stoma.","Intestinal Stoma Obstruction | Intestinal stoma obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1142488","Intestinal Stoma Leakage","C78369","Leakage of contents from the intestinal stoma.","Intestinal Stoma Leakage | Intestinal stoma leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0160692","Injury to Superior Vena Cava","C78365","Damage to the superior vena cava from traumatic or pathologic processes.","Injury to Superior Vena Cava | Injury to superior vena cava",,,,,,,,,,,,,,,"441443","Injury of superior vena cava",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1699739","Intraoperative Reproductive System Injury","C78387","Damage to the reproductive organs during a surgical procedure.","Intraoperative Reproductive System Injury | Intraoperative reproductive tract injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1699743","Intraoperative Renal Injury","C78386","Damage to the kidney during a surgical procedure.","Intraoperative Renal Injury | Intraoperative renal injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1699740","Intraoperative Ocular Injury","C78385","Damage to the eye during a surgical procedure.","Intraoperative Ocular Injury | Intraoperative ocular injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1699210","Intraoperative Neurological Injury","C78384","Damage to any part of the nervous system during a surgical procedure.","Intraoperative Neurological Injury | Intraoperative neurological injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1699209","Intraoperative Musculoskeletal Injury","C78383","Damage to any part of the musculoskeletal system during a surgical procedure.","Intraoperative Musculoskeletal Injury | Intraoperative musculoskeletal injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521596","Jejunal Hemorrhage","C78397","Bleeding originating from the jejunal wall.","Jejunal Hemorrhage | Jejunal hemorrhage",,,,,,,,,,,,,,,"46273182","Hemorrhage of jejunum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0582253","Jejunal Fistula","C78396","An abnormal communication between the jejunum and another organ or cavity.","Jejunal Fistula | Jejunal fistula",,,,,,,,,,,,,,,"4119648","Jejunal fistula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4048184","Trochlear Nerve Disorder","C78395","A non-neoplastic or neoplastic disorder affecting the trochlear nerve (IVth cranial nerve).","Trochlear Nerve Disorder | IVth Cranial Nerve Disorder | IVth nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0917798","Cerebrovascular Ischemia","C78394","Diminished or absent blood supply to the brain caused by obstruction (thrombosis or embolism) of an artery resulting in neurologic damage.","Cerebrovascular Ischemia | Ischemia cerebrovascular",,,,,,,,,,,,,,,"374384","Cerebral ischemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3806118","Iron Overload","C78393","Accumulation of iron in the tissues. It may be a manifestation of an inherited disorder (e.g., hemochromatosis) or acquired (in patients with repeated blood transfusions). Symptoms include hepatomegaly, arthritis, diabetes mellitus, and bronzed skin. If untreated it has a progressive course and may lead to death.","Iron Overload | Iron overload | iron overload",,,,,,,,,,,,,,,"4246084","Iron overload",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1698100","Intraoperative Venous Injury","C78392","Damage to a vein during a surgical procedure.","Intraoperative Venous Injury | Intraoperative venous injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1698677","Intraoperative Urinary System Injury","C78391","Damage to any part of the urinary system during a surgical procedure.","Intraoperative Urinary System Injury | Intraoperative urinary injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1698099","Intraoperative Splenic Injury","C78390","Damage to the spleen during a surgical procedure.","Intraoperative Splenic Injury | Intraoperative splenic injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1558746","Intraoperative Skin Injury","C78389","Damage to the skin during a surgical procedure.","Intraoperative Skin Injury | Intraoperative skin injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1699737","Intraoperative Respiratory Injury","C78388","Damage to the respiratory system during a surgical procedure.","Intraoperative Respiratory Injury | Intraoperative respiratory injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1699588","Laryngeal Fistula","C78410","An abnormal communication between the larynx and another organ or cavity.","Laryngeal Fistula | Laryngeal fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023052","Laryngeal Edema","C79607","Swelling due to an excessive accumulation of fluid in the larynx.","Laryngeal Edema | Laryngeal edema",,,,,,,,,,,,,,,"22350","Edema of larynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1699327","Large Intestinal Anastomotic Leakage","C78408","Leakage due to breakdown of a large intestinal anastomosis.","Large Intestinal Anastomotic Leakage | Large intestinal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022927","Lactation Disorder","C79606","A disorder not necessarily related to pregnancy that is observed in females and males. It is characterized by disturbances of milk secretion. Causes include damage to the breast parenchyma due to inflammation, medications, pituitary tumors, and hypothyroidism.","Lactation Disorder | Lactation disorder",,,,,,,,,,,,,,,"80471","Disorder of lactation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3805943","Pyelonephritis","C34965","An inflammatory process affecting the kidney. The cause is most often bacterial, but may also be fungal in nature. Signs and symptoms may include fever, chills, flank pain, painful and frequent urination, cloudy or bloody urine, and confusion.","Pyelonephritis | Kidney Infection | Kidney infection | PYELONEPHRITIS",,,,,,,,,,,,,,,"198199","Pyelonephritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1699736","Kidney Anastomotic Leakage","C78406","Leakage of urine due to breakdown of a kidney anastomosis.","Kidney Anastomotic Leakage | Kidney anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1699182","Lumbar Spine Joint Range of Motion Decreased","C78405","Decreased flexibility of a lumbar spine joint.","Lumbar Spine Joint Range of Motion Decreased | Joint range of motion decreased lumbar spine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1698040","Cervical Spine Joint Range of Motion Decreased","C78404","Decreased flexibility of a cervical spine joint.","Cervical Spine Joint Range of Motion Decreased | Joint range of motion decreased cervical spine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0877027","Joint Range of Motion Decreased","C78403","Decreased joint flexibility.","Joint Range of Motion Decreased | Joint range of motion decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0157749","Joint Infection","C78402","An infectious process affecting a joint. Causative agents include bacteria, viruses, fungi, and parasites.","Joint Infection | Joint infection",,,,,,,,,,,,,,,"4180167","Infectious disorder of joint",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1253936","Joint Effusion","C49052","Abnormally increased amount of fluid in a joint cavity, usually as a result of joint inflammation.","Joint Effusion | Joint effusion",,,,,,,,,,,,,,,"79903","Effusion of joint",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0267489","Jejunal Ulcer","C78401","A circumscribed inflammatory and necrotic erosive lesion in the mucosa surface of the jejunum.","Jejunal Ulcer | Jejunal ulcer",,,,,,,,,,,,,,,"4183009","Jejunal ulcer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0151923","Jejunal Stenosis","C78400","Narrowing of the lumen of jejunum.","Jejunal Stenosis | Jejunal stenosis",,,,,,,,,,,,,,,"36716989","Stenosis of jejunum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0542147","Jejunal Perforation","C78399","A rupture in the jejunal wall due to traumatic or pathologic processes.","Jejunal Perforation | Jejunal perforation",,,,,,,,,,,,,,,"4106869","Perforation of jejunum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1699656","Jejunal Obstruction","C78398","Blockage of the normal flow of the small intestinal contents in the jejunum.","Jejunal Obstruction | Jejunal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013609","Localized Edema","C78437","Swelling due to an excessive accumulation of fluid at a specific anatomic site.","Localized Edema | Localized edema",,,,,,,,,,,,,,,"4171917|4195595","Localized edema|Localized edema",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1262113","Lipohypertrophy","C78436","Hypertrophy of the subcutaneous adipose tissue at the site of multiple subcutaneous injections of insulin.","Lipohypertrophy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0549475","Hyperlipasemia (finding)","C78435","A laboratory test result which indicates increased levels of lipase in a biologic specimen.","Hyperlipasemia | Elevated Lipase | Lipase Increased | Lipase Increased | Lipase increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0267028","Lip Pain","C79684","Painful sensation in the lip.","Lip Pain | Lip pain",,,,,,,,,,,,,,,"4264585","Cheilodynia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1698666","Lip Infection","C78434","An acute or chronic infectious process affecting the lips.","Lip Infection | Lip infection",,,,,,,,,,,,,,,"42537660","Infection of lip",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021177","Increased Libido","C78433","Increased sexual desire.","Increased Libido | Libido increased",,,,,,,,,,,,,,,"4237753","Increased libido",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011124","Decreased Libido","C78432","Decreased sexual desire.","Decreased Libido | Libido decreased",,,,,,,,,,,,,,,"4087317|436246","Lack of libido|Reduced libido",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0023518","Leukocytosis","C35524","A laboratory test result indicating an increased number of white blood cells in the peripheral blood.","Leukocytosis | Elevated White Blood Cell Count | High White Blood Cell Count | WBC Increased | White Blood Cell Count Increased",,,,,,,,,,,,,,,"438398","Leukocytosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023380","Lethargy","C78416","Decreased consciousness characterized by mental and physical inertness.","Lethargy | Listless | lethargy",,,,,,,,,,,,,,,"4061577","Lethargy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4015502","Laryngospasm","C79609","Paroxysmal spasmodic muscular contraction of the vocal cords. It is brief, usually lasting for less than one minute, interrupting the speech and breathing and may produce a high-pitched breathing sound. It may occur under anesthesia or may be associated with gastroesophageal reflex disease.","Laryngospasm | ",,,,,,,,,,,,,,,"437904","Laryngeal spasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1328466","Laryngopharyngeal Dysesthesia","C78414","A disorder characterized by an uncomfortable persistent sensation in the area of the laryngopharynx.","Laryngopharyngeal Dysesthesia | Laryngopharyngeal dysesthesia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3805714","Laryngeal Stenosis","C79608","Narrowing of the laryngeal airway.","Laryngeal Stenosis | Laryngeal stenosis",,,,,,,,,,,,,,,"24974","Stenosis of larynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0264306","Laryngeal Obstruction","C78413","Blockage of the laryngeal airway passage.","Laryngeal Obstruction | Laryngeal obstruction",,,,,,,,,,,,,,,"30124","Obstruction of larynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1698768","Laryngeal Mucositis","C78412","An inflammatory process affecting the mucous membrane of the larynx.","Laryngeal Mucositis | Laryngeal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1697747","Laryngeal Hemorrhage","C78411","Bleeding originating from the larynx.","Laryngeal Hemorrhage | Laryngeal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024248","Lymphocele","C78442","A cystic lesion containing lymph. It usually results from injury, gynecologic surgery, or urologic surgery.","Lymphocele | ",,,,,,,,,,,,,,,"4119772","Lymphocele",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0578050","Lymph Node Pain","C78440","A painful sensation in a lymph node.","Lymph Node Pain | Lymph node pain",,,,,,,,,,,,,,,"4103478","Pain of lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0398372","Lymph Leakage","C78439","The loss of lymph into the surrounding tissue or body cavity.","Lymph Leakage | Chyle Leakage | Lymph leakage",,,,,,,,,,,,,,,"4120797|4194414","Escape of lymph|Leakage of chyle",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0024205","Lymphadenitis","C26821","Acute or chronic inflammation of one or more lymph nodes. It is usually caused by an infectious process.","Lymphadenitis | Adenitis | Lymph gland infection",,,,,,,,,,,,,,,"316084","Lymphadenitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0876973","Infectious Lung Disorder","C26873","An acute or chronic infectious process affecting the lungs.","Infectious Lung Disorder | Infectious Lung Disease | Infectious Lung Diseases | Infectious Lung Disorders | Lung Infection | Lung infection",,,,,,,,,,,,,,,"4028389","Infectious disease of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026265","Mitral Valve Disorder","C78446","A heart disorder characterized by a defect in mitral valve structure or function.","Mitral Valve Disorder | Mitral valve disease",,,,,,,,,,,,,,,"319843","Mitral valve disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3809922","Menorrhagia","C26829","Heavy bleeding during regular menstruation.","Menorrhagia | menorrhagia",,,,,,,,,,,,,,,"4302555","Menorrhagia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0233794","Memory Impairment","C78444","Deterioration in memory function.","Memory Impairment | Memory Deficits | Memory impairment",,,,,,,,,,,,,,,"4304008","Memory impairment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025064","Mediastinitis","C26827","An inflammatory process affecting the mediastinum.","Mediastinitis | ",,,,,,,,,,,,,,,"4189294","Inflammatory disorder of mediastinum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1112480","Mediastinal Hemorrhage","C78443","Bleeding originating from the mediastinum.","Mediastinal Hemorrhage | Mediastinal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0338831","Mania","C61374","Excitement of psychotic proportions manifested by mental and physical hyperactivity, disorganisation of behaviour and elevation of mood.","Mania | Manic | Manic State",,,,,,,,,,,,,,,"4333677","Mania",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0853698","Lymphocytosis","C34791","A finding indicating the presence of a non-neoplastic or neoplastic proliferation of lymphocytes in the peripheral blood, effusions, or bone marrow.","Lymphocytosis | Lymphocyte count increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342102","Nipple Deformity","C78503","A congenital or acquired deformity of the nipple.","Nipple Deformity | Nipple deformity",,,,,,,,,,,,,,,"4034231","Nipple deformity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4230087","Night Blindness","C34850","Inability to see clearly in dim light.","Night Blindness | Night blindness | Nyctalopia",,,,,,,,,,,,,,,"374037","Night blindness",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027796","Neuralgia","C79695","Intense painful sensation along a nerve or group of nerves. It is caused by irritation or trauma to a nerve or inflammation of a nerve.","Neuralgia | ",,,,,,,,,,,,,,,"373852","Neuralgia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1561251","Neck Soft Tissue Necrotic Lesion","C78502","A necrotic process affecting the soft tissues of the neck.","Neck Soft Tissue Necrotic Lesion | Neck soft tissue necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007859","Neck Pain","C50663","Painful sensation in the neck area.","Neck Pain | Neck pain | Pain In Neck",,,,,,,,,,,,,,,"24134","Neck pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0240464","Neck Edema","C78501","Swelling due to an accumulation of excessive fluid in the neck.","Neck Edema | Neck edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027424","Nasal Congestion","C78500","The blockage of the nasal passage due to mucosal edema. It is usually the result of a viral infection or an allergic reaction.","Nasal Congestion | Nasal Stuffiness | Nasal congestion | Stuffiness | Stuffy nose",,,,,,,,,,,,,,,"4195085","Nasal congestion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3279476","Nail Ridging","C78499","Straight elevated lines on the nail surface. Ridges may be vertical (running from the cuticle to the nail tip) or horizontal (running from one side of the nail to the other). Vertical ridges are usually not associated with underlying disorders and tend to become more pronounced with age. Horizontal ridges may be associated with metabolic disorders and malnutrition.","Nail Ridging | Nail ridging",,,,,,,,,,,,,,,"4154925","Ridged nails",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0263540","Nail Loss","C78494","Loss of all or a portion of a nail.","Nail Loss | Nail loss",,,,,,,,,,,,,,,"4331594","Onychomadesis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0343026","Nail Infection","C78493","An infectious process affecting the nail.","Nail Infection | Nail infection",,,,,,,,,,,,,,,"4080305","Infection of nail",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221345","Nail Discoloration","C78492","A change in the color of the nail.","Nail Discoloration | Chromonychia | Nail discoloration | Pigmentary Change of Nails",,,,,,,,,,,,,,,"4230815","Nail discoloration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0281914","Musculoskeletal Deformity","C78488","Congenital or acquired deformity of the musculoskeletal system.","Musculoskeletal Deformity | Musculoskeletal deformity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0241492","Muscle Weakness Trunk","C78458","A reduction in the strength of the trunk muscles.","Muscle Weakness Trunk | Muscle weakness trunk",,,,,,,,,,,,,,,"4092726","Truncal muscle weakness",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4228442","Muscle Weakness Lower Limb","C78456","A reduction in the strength of the lower limb muscles.","Muscle Weakness Lower Limb | Muscle weakness lower limb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1698038","Muscle Weakness Left-Sided","C78455","A reduction in the strength of the muscles in the left side of the body.","Muscle Weakness Left-Sided | Muscle weakness left-sided",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1698484","Mucosal Infection","C78454","An acute or chronic infectious process affecting a mucosal surface.","Mucosal Infection | Mucosal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4230040","Involuntary Movements","C78453","Uncontrolled and purposeless movements.","Involuntary Movements | Movements involuntary",,,,,,,,,,,,,,,"4143065","Involuntary movement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0264907","AV Block Second Degree Mobitz Type I","C62017","A disorder characterized by an electrocardiographic finding of intermittent failure of atrial electrical impulse conduction to the ventricles, characterized by a progressively lengthening PR interval prior to the block of an atrial impulse. (CDISC)","AV Block Second Degree Mobitz Type I | AV Block Second Degree Möbitz Type I | Mobitz I | Mobitz Type I Second Degree AV Block | Mobitz type I | Möbitz I | Möbitz Type I Second Degree AV Block | Second Degree Atrioventricular Block Mobitz Type I | Second Degree Atrioventricular Block Möbitz Type I | Type 1 2nd degree AV Block | Type 1 Second Degree AV Block | Type 1 Second Degree Atrioventricular Block | Wenckebach Block",,,,,,,,,,,,,,,"4205137","Mobitz type I incomplete atrioventricular block",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0155700","AV Block Second Degree Mobitz Type II","C62018","A disorder characterized by an electrocardiographic finding of intermittent failure of atrial electrical impulse conduction to the ventricles, characterized by a relatively constant PR interval prior to the block of an atrial impulse. (CDISC)","AV Block Second Degree Mobitz Type II | AV Block Second Degree Möbitz Type II | Mobitz (type) II atrioventricular block | Mobitz II | Mobitz Type II Second Degree AV Block | Möbitz II | Möbitz Type II Second Degree AV Block | Second Degree Atrioventricular Block Mobitz Type II | Second Degree Atrioventricular Block Möbitz Type II | Type 2 2nd degree AV Block | Type 2 Second Degree AV Block | Type II Second Degree AV Block | Type II Second Degree Atrioventricular Block",,,,,,,,,,,,,,,"313780","Mobitz type II atrioventricular block",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152149","Ovulatory Pain","C78514","Painful sensation in one side of the abdomen between menstrual cycles, around the time of the discharge of the ovum from the ovarian follicle.","Ovulatory Pain | Ovulation Pain | Ovulation pain",,,,,,,,,,,,,,,"201626","Mittelschmerz",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0269164","Ovarian Rupture","C78513","Tearing or disruption of the ovarian tissue.","Ovarian Rupture | Ovarian rupture",,,,,,,,,,,,,,,"4339536","Rupture of ovary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0349735","Ovarian Infection","C78512","An infectious process affecting the ovary.","Ovarian Infection | Ovarian infection",,,,,,,,,,,,,,,"4090469","Infection of ovary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1696704","Ovarian Hemorrhage","C78511","Bleeding originating from the ovary.","Ovarian Hemorrhage | Ovarian hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221776","Oral Pain","C78509","Painful sensation in the mouth, tongue, or lips.","Oral Pain | Oral pain",,,,,,,,,,,,,,,"4010025","Painful mouth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029163","Oral Hemorrhage","C79699","Bleeding originating from the mouth.","Oral Hemorrhage | Oral hemorrhage",,,,,,,,,,,,,,,"4330466","Bleeding of mouth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1696083","Oral Cavity Fistula","C78506","An abnormal communication between the oral cavity and the adjacent tissues.","Oral Cavity Fistula | Oral cavity fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1533675","Optic Nerve Disorder","C79698","A non-neoplastic or neoplastic disorder affecting the optic nerve (second cranial nerve).","Optic Nerve Disorder | Optic nerve disorder | Second Cranial Nerve Disorder",,,,,,,,,,,,,,,"257293","Disorder of visual pathways",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3810502","Oligospermia","C34860","Decreased number of spermatozoa in the semen.","Oligospermia | Low Sperm Count",,,,,,,,,,,,,,,"4339289","Oligozoospermia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0751937","Olfactory Nerve Disorder","C27210","A non-neoplastic or neoplastic disorder affecting the olfactory nerve (first cranial nerve).","Olfactory Nerve Disorder | Disorder of 1st Nerve | Disorder of the 1st Nerve | Olfactory nerve disorder",,,,,,,,,,,,,,,"435253","Disorder of olfactory nerve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0271353","Oculomotor Nerve Disorder","C27598","A non-neoplastic or neoplastic disorder affecting the oculomotor nerve (third cranial nerve).","Oculomotor Nerve Disorder | Oculomotor nerve disorder",,,,,,,,,,,,,,,"4264613","Third cranial nerve disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0149700","Gastric Obstruction","C78505","Blockage of the normal flow of the contents in the stomach.","Gastric Obstruction | Obstruction gastric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0476281","Non-Cardiac Chest Pain","C78504","Pain in the chest unrelated to a heart disorder.","Non-Cardiac Chest Pain | NON-CARDIAC CHEST PAIN | Non-cardiac chest pain | Noncardiac chest pain",,,,,,,,,,,,,,,"4164649","Non-cardiac chest pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0581395","Penile Infection","C78526","An infectious process affecting the penis.","Penile Infection | Penile infection",,,,,,,,,,,,,,,"4205814","Infection of penis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1561256","Pelvic Soft Tissue Necrotic Lesion","C78525","A necrotic process affecting the soft tissues of the pelvis.","Pelvic Soft Tissue Necrotic Lesion | Pelvic soft tissue necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242172","Pelvic Inflammatory Disease","C3889","Pelvic inflammatory disease (PID) is an acute or chronic inflammation in the pelvic cavity. It is most commonly caused by sexually transmitted diseases, including chlamydia and gonorrhea that have ascended into the uterus, fallopian tubes, or ovaries as a result of intercourse or childbirth, or of surgical procedures, including insertion of IUDs or abortion. PID may be either symptomatic or asymptomatic. It may cause infertility and it may raise the risk of ectopic pregnancy. PID is a disease associated with HIV infection.","Pelvic Inflammatory Disease | PID | Pelvic Infection | Pelvic infection | pelvic inflammatory disease",,,,,,,,,,,,,,,"199067","Female pelvic inflammatory disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1535916","Pelvic Floor Muscle Weakness","C78524","A reduction in the strength of the muscles of the pelvic floor.","Pelvic Floor Muscle Weakness | Pelvic floor muscle weakness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030587","Paroxysmal Atrial Tachycardia","C34900","A disorder characterized by an electrocardiographic finding of episodic atrial tachycardia with abrupt onset and termination.","Paroxysmal Atrial Tachycardia | PAT | Paroxysmal atrial tachycardia | True Paroxysmal Atrial Tachycardia",,,,,,,,,,,,,,,"4108830","Atrial paroxysmal tachycardia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030578","Paronychia","C79702","An acute or chronic infection of the soft tissues around the nail. Symptoms include pain, tenderness, erythema, and swelling around the nail. Acute infection results from minor trauma to the fingertip and Staphylococcus aureus is usually the causative agent. Chronic infection is usually caused by Candida albicans.","Paronychia | ",,,,,,,,,,,,,,,"137057","Paronychia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030554","Paresthesia","C28177","Abnormal cutaneous sensations of tingling, numbness, pressure, cold, and warmth that an individual experiences without the presence of a stimulus. It results from functional disturbances of sensory neurons. Causes include peripheral vascular disease, peripheral neuropathy, and nerve damage.","Paresthesia | Pins and Needles | paresthesia",,,,,,,,,,,,,,,"4236484","Paresthesia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2609319","Papulopustular Rash","C80119","Skin eruption consisting of papules and pustules, most often appearing in the face, scalp, and upper trunk.  It is usually caused by corticosteroids or epidermal growth factor receptor inhibitors.","Papulopustular Rash | Papulopustular Eruption | Papulopustular rash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0267953","Pancreatic Necrotic Lesion","C78522","A necrotic process affecting the pancreas.","Pancreatic Necrotic Lesion | Pancreatic necrosis",,,,,,,,,,,,,,,"4080069","Necrosis of pancreas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0521613","Pancreatic Hemorrhage","C78521","Bleeding originating from the pancreas.","Pancreatic Hemorrhage | Pancreatic hemorrhage",,,,,,,,,,,,,,,"4319445","Hemorrhage of pancreas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030290","Pancreatic Fistula","C79701","An abnormal communication between the pancreas and another organ or cavity.","Pancreatic Fistula | Pancreatic fistula",,,,,,,,,,,,,,,"4093273","Pancreatic fistula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0549370","Pancreatic Enzymes Decreased","C78520","A laboratory test result which indicates decreased levels of pancreatic enzymes in a biologic specimen.","Pancreatic Enzymes Decreased | Pancreatic enzymes decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0940747","Pancreatic Duct Stenosis","C78519","Narrowing of the lumen of the pancreatic duct.","Pancreatic Duct Stenosis | Pancreatic duct stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0341498","Pancreatic Anastomotic Leakage","C78518","Leakage due to breakdown of a pancreatic anastomosis.","Pancreatic Anastomotic Leakage | Pancreatic anastomotic leak",,,,,,,,,,,,,,,"4341772","Pancreatic anastomotic leak",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0948160","Pancreatic Infection","C78517","An infectious process affecting the pancreas.","Pancreatic Infection | Pancreas infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0240717","Perineal Pain","C78529","Painful sensation in the perineal area.","Perineal Pain | Perineal pain",,,,,,,,,,,,,,,"4021670","Perineal pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007177","Cardiac Tamponade","C50481","Acute compression of the heart caused by increased intrapericardial pressure due to the collection of blood or fluid in the pericardium from rupture of the heart, penetrating trauma, or progressive effusion.","Cardiac Tamponade | Pericardial Tamponade | Pericardial tamponade",,,,,,,,,,,,,,,"318450","Cardiac tamponade",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0156218","Bile Duct Perforation","C78528","A rupture in the wall of the extrahepatic or intrahepatic bile duct due to traumatic or pathologic processes.","Bile Duct Perforation | Perforation bile duct",,,,,,,,,,,,,,,"192957","Perforation of bile duct",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0497481","Penile Pain","C78527","Painful sensation in the penis.","Penile Pain | Penile pain",,,,,,,,,,,,,,,"4109081","Pain in penis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0151205","Periorbital Edema","C78530","Swelling due to an excessive accumulation of fluid around the orbits of the face.","Periorbital Edema | Periorbital edema",,,,,,,,,,,,,,,"4177665","Periorbital edema",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0235490","Peripheral Ischemia","C78535","Deficient blood distribution to the limbs caused by narrowing or obstruction of the lumen of the peripheral arteries.","Peripheral Ischemia | Peripheral ischemia",,,,,,,,,,,,,,,"4124836","Peripheral ischemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0948065","Periorbital Infection","C78531","An infectious process affecting the tissues around the orbit.","Periorbital Infection | Periorbital infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1696082","Peritoneal Necrotic Lesion","C78543","A necrotic process affecting the peritoneum.","Peritoneal Necrotic Lesion | Peritoneal necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0851980","Peritoneal Infection","C78540","An infectious process affecting the peritoneum.","Peritoneal Infection | Peritoneal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1278821","Peripheral Nervous System Infectious Disorder","C27589","An infectious process affecting the peripheral nerves.","Peripheral Nervous System Infectious Disorder | Peripheral nerve infection",,,,,,,,,,,,,,,"4107729","Infectious disorder of the peripheral nervous system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347530","Plaque Forming Unit Equivalent 1000 Mouse LD50","C73575","An amount of toxin that would kill 50% of 1000 mice, expressed as an equivalent amount of plaque-forming units.","Plaque Forming Unit Equivalent 1000 Mouse LD50 | PFU Equivalent 1000 Mouse LD50 | PFU e.1000 mouse LD50 | plaque forming unit equiv 1000 mouse LD50",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032781","Post-Nasal Drip","C78566","Excessive mucous secretion in the back of the nasal cavity or throat, causing sore throat and/or coughing. It is usually due to allergic rhinitis or a cold.","Post-Nasal Drip | Postnasal Drip | Postnasal drip",,,,,,,,,,,,,,,"257683","Posterior rhinorrhea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008033","Pleuritic Pain","C78564","Painful sensation in the pleura.","Pleuritic Pain | Pleuritic pain",,,,,,,,,,,,,,,"4330445","Pleuritic pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0919907","Pleural Infection","C78563","An infectious process affecting the pleura.","Pleural Infection | Pleural infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019123","Hemothorax","C50582","A collection of blood in the pleural cavity.","Hemothorax | Pleural Hemorrhage | Pleural hemorrhage",,,,,,,,,,,,,,,"4135466","Hemothorax",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1112243","Infective Phlebitis","C78558","Infection at the site of needle puncture or intravenous catheter placement due to poor aseptic techniques. It is characterized by erythema, pain, swelling, and induration at the catheter insertion site.","Infective Phlebitis | Phlebitis infective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0858635","Pharyngolaryngeal Pain","C78556","Painful sensation in the pharyngolaryngeal region.","Pharyngolaryngeal Pain | Pharyngolaryngeal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031350","Pharyngitis","C26851","Inflammation of the throat most often caused by viral and bacterial infections. Other causes include allergens, chemical substances, and trauma.","Pharyngitis | Sore Throat",,,,,,,,,,,,,,,"4226263","Pharyngitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0396006","Pharyngeal Stenosis","C78555","Narrowing of the pharyngeal airway.","Pharyngeal Stenosis | Pharyngeal stenosis",,,,,,,,,,,,,,,"4049234","Pharyngeal stenosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1696156","Pharyngeal Necrotic Lesion","C78554","A necrotic process affecting the pharynx.","Pharyngeal Necrotic Lesion | Pharyngeal necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1699324","Pharyngeal Mucositis","C78553","An inflammatory process affecting the mucous membrane of the pharynx.","Pharyngeal Mucositis | Pharyngeal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0576995","Pharyngeal Hemorrhage","C26986","Bleeding originating from the pharynx.","Pharyngeal Hemorrhage | Pharyngeal hemorrhage",,,,,,,,,,,,,,,"4208719","Pharyngeal hemorrhage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0396009","Pharyngeal Fistula","C78551","An abnormal communication between the pharynx and another organ or anatomic site.","Pharyngeal Fistula | Pharyngeal fistula",,,,,,,,,,,,,,,"4051495","Pharyngocutaneous fistula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1696702","Pharyngeal Anastomotic Leakage","C78550","Leakage due to breakdown of a pharyngeal anastomosis.","Pharyngeal Anastomotic Leakage | Pharyngeal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3495442","Phantom Pain","C79703","Painful sensation related to a limb or an organ that is removed from or is not physically part of the body.","Phantom Pain | Phantom pain",,,,,,,,,,,,,,,"46271848","Phantom pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0240735","Personality Change","C78548","A noticeable change in a person's behavior and thinking. Causes include depression, drug or alcohol abuse, brain injuries, brain tumors, and Alzheimer's disease.","Personality Change | Personality change",,,,,,,,,,,,,,,"444092","Personality change",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034063","Pulmonary Edema","C26868","Accumulation of fluid in the lung tissues causing disturbance of the gas exchange that may lead to respiratory failure. It is caused by direct injury to the lung parenchyma or congestive heart failure. The symptoms may appear suddenly or gradually. Suddenly appearing symptoms include difficulty breathing, feeling of suffocation, and coughing associated with frothy sputum. Gradually appearing symptoms include difficulty breathing while lying in bed, shortness of breath during activity, and weight gain (in patients with congestive heart failure).","Pulmonary Edema | Pulmonary edema | pulmonary edema",,,,,,,,,,,,,,,"4078925","Pulmonary edema",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4012112","Psychosis","C78576","A mental disorder characterized by personality change, impaired functioning, and loss of touch with reality.","Psychosis | psychosis",,,,,,,,,,,,,,,"436073","Psychotic disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0240812","Prostatic Pain","C78574","Pain in the prostate gland.","Prostatic Pain | Prostatic pain",,,,,,,,,,,,,,,"4280580","Pain of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268889","Prostatic Obstruction","C78573","Squeezing of the urethra secondary to enlargement of the prostate gland, resulting in voiding symptoms (straining to void, slow urine stream, and incomplete emptying of the bladder).","Prostatic Obstruction | Prostatic obstruction",,,,,,,,,,,,,,,"4188305","Prostatic obstruction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268891","Prostatic Hemorrhage","C78572","Bleeding originating from the prostate gland.","Prostatic Hemorrhage | Prostatic hemorrhage",,,,,,,,,,,,,,,"4261336","Hemorrhage of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0240811","Prostatic Infection","C27615","An acute or chronic infectious process affecting the prostate gland.","Prostatic Infection | Prostate infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1698096","Urostomy Prolapse","C78571","Displacement of the urostomy.","Urostomy Prolapse | Prolapse of urostomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1699141","Intestinal Stoma Prolapse","C78570","An intestinal stoma complication characterized by protrusion of the intestine above the abdominal surface.","Intestinal Stoma Prolapse | Enterostomy Prolapse | Prolapse of intestinal stoma",,,,,,,,,,,,,,,"37172176","Enterostomy prolapse",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0700200","Presyncope","C80100","An episode of lightheadedness and dizziness which may precede an episode of syncope.","Presyncope | ",,,,,,,,,,,,,,,"4142895","Near syncope",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1834852","Premature Menopause","C80099","Cessation of menstruation before the age of 40. Symptoms include hot flashes, night sweats, mood swings, and decreased sex drive.","Premature Menopause | POF | Premature Ovarian Failure | Premature menopause | early menopause | premature menopause | premature ovarian failure",,,,,,,,,,,,,,,"198715","Premature menopause",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022876","Premature Labor","C50917","Regular uterine activity with associated cervical change prior to 37 weeks gestation.","Premature Labor | Preterm Labor",,,,,,,,,,,,,,,"4273560","Premature labor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4229369","Precocious Puberty","C79704","Unusually early sexual maturity.","Precocious Puberty | Precocious puberty | Sexual Precocity",,,,,,,,,,,,,,,"4267558","Precocious puberty",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1112276","Thoracic Procedure Postoperative Complication","C78567","Any disorder occurring postoperatively as a consequence of a thoracic procedure.","Thoracic Procedure Postoperative Complication | Postoperative thoracic procedure complication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1792980","Restrictive Cardiomyopathy","C62798","A type of heart disorder referring to the inability of the ventricles to fill with blood because the myocardium (heart muscle) stiffens and looses its flexibility. Causes include replacement of the myocardium with scar tissue, abnormal cellular infiltration of the myocardium, or deposition of a substance (e.g., amyloid) in the myocardium.","Restrictive Cardiomyopathy | Restrictive cardiomyopathy",,,,,,,,,,,,,,,"4190773","Restrictive cardiomyopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3549784","Respiratory Failure","C26872","The significant impairment of gas exchange within the lungs resulting in hypoxia, hypercarbia, or both, to the extent that organ tissue perfusion is severely compromised. Causes include chronic obstructive pulmonary disease, asthma, emphysema, acute respiratory distress syndrome, pneumonia, pulmonary edema, pneumothorax, and congestive heart failure. Treatment requires intubation and mechanical ventilation until the time the lungs recover sufficient function.","Respiratory Failure | Respiratory failure",,,,,,,,,,,,,,,"4256228","Respiratory failure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0392175","Renal Hemorrhage","C78594","Bleeding originating from the kidney.","Renal Hemorrhage | Renal hemorrhage",,,,,,,,,,,,,,,"4316366","Hemorrhage of kidney",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3554467","Renal Colic","C78593","Paroxysmal and severe flank pain radiating to the inguinal area. It is caused by the passage of a kidney stone through the ureter.","Renal Colic | Renal colic",,,,,,,,,,,,,,,"201690","Renal colic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0542142","Recurrent Laryngeal Nerve Paralysis","C78592","Paralysis of the recurrent laryngeal nerve. Causes include surgical and non-surgical traumas, neoplasms (e.g., lung carcinoma), and inflammatory neuritis.","Recurrent Laryngeal Nerve Paralysis | Recurrent Laryngeal Nerve Palsy | Recurrent laryngeal nerve palsy | Vagus Nerve Laryngeal Paralysis",,,,,,,,,,,,,,,"4181181","Vagus nerve laryngeal paralysis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0400839","Rectal Ulcer","C78590","A circumscribed inflammatory and necrotic erosive lesion in the mucosa surface of the rectum.","Rectal Ulcer | Rectal ulcer",,,,,,,,,,,,,,,"76150","Ulcer of rectum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0267581","Rectal Stenosis","C78589","Narrowing of the rectal lumen.","Rectal Stenosis | Rectal stenosis",,,,,,,,,,,,,,,"4264479","Stenosis of rectum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0341402","Rectal Perforation","C78588","An rupture in the rectal wall due to traumatic or pathologic processes.","Rectal Perforation | Rectal perforation",,,,,,,,,,,,,,,"4028907","Perforation of rectum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034886","Rectal Pain","C78587","Pain in the rectal area.","Rectal Pain | Rectal pain",,,,,,,,,,,,,,,"76458","Rectal pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1697746","Rectal Obstruction","C78586","Blockage of the normal flow of the intestinal contents in the rectum.","Rectal Obstruction | Rectal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1697980","Rectal Necrotic Lesion","C78585","A necrotic process involving the rectal wall.","Rectal Necrotic Lesion | Rectal necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1328588","Rectal Mucositis","C78584","An inflammatory process affecting the mucous membrane of the rectum.","Rectal Mucositis | Rectal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0267596","Rectal Hemorrhage","C27054","Bleeding originating from the rectal wall and discharged from the anus.","Rectal Hemorrhage | Rectal hemorrhage",,,,,,,,,,,,,,,"4026112","Rectal hemorrhage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034884","Rectal Fistula","C79713","An abnormal communication between the rectum and another organ or cavity.","Rectal Fistula | Rectal fistula",,,,,,,,,,,,,,,"4213865","Rectal fistula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1698511","Rectal Anastomotic Leakage","C78583","Leakage due to breakdown of a rectal anastomosis.","Rectal Anastomotic Leakage | Rectal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0175167","Acneiform Dermatitis","C35277","Cutaneous eruptions resembling acne, characterized by the presence of papulonodules, pustules, comedones, or cysts in the face, trunk, and extremities. Causes include infections and the use of certain medications (e.g., antibiotics and steroids).","Acneiform Dermatitis | Rash acneiform",,,,,,,,,,,,,,,"4299558","Acneiform eruption",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034544","Radiculitis","C78581","An inflammatory process affecting a nerve root. Patients experience pain radiating along a nerve path because of spinal pressure on the nerve root that connects to the nerve path.","Radiculitis | ",,,,,,,,,,,,,,,"444263","Radiculitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1720798","Radiation-Recall Dermatitis","C78580","Acute skin inflammatory reaction caused by drugs, especially chemotherapeutic agents, weeks or months following radiotherapy. The inflammatory reaction is confined to the previously irradiated skin and the symptoms disappear after the removal of the pharmacologic agent.","Radiation-Recall Dermatitis | Radiation Recall Dermatitis | Radiation recall reaction (dermatologic)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034150","Purpura","C78787","A small blood vessel hemorrhage into the skin and/or mucous membranes. Newer lesions appear reddish in color. Older lesions are usually a darker purple color and eventually become a brownish-yellow color.","Purpura | ",,,,,,,,,,,,,,,"4047773|4307580","Purpura|Purpuric disorder",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3280945","Pulmonary Valve Disorder","C78579","A heart disorder characterized by a defect in pulmonary valve structure or function.","Pulmonary Valve Disorder | Pulmonary valve disease",,,,,,,,,,,,,,,"319845","Pulmonary valve disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL505182","Hypothermia","C78351","Abnormally low body temperature.","Hypothermia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020626","Hypoparathyroidism","C78350","An endocrine disorder characterized by decreased production of parathyroid hormone by the parathyroid glands. It is usually caused by damage of the parathyroid glands during head and neck surgery. Signs and symptoms include muscle cramps, abdominal pain, dry skin, brittle nails, cataracts, tetany, and convulsions.","Hypoparathyroidism | ",,,,,,,,,,,,,,,"140362","Hypoparathyroidism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4012065","Hypohidrosis","C34718","Reduced sweating. Causes include burns, dehydration, radiation, and leprosy.","Hypohidrosis | ",,,,,,,,,,,,,,,"4264520","Hypohidrosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152181","Hypoglossal Nerve Disorder","C26954","A non-neoplastic or neoplastic disorder affecting the hypoglossal nerve (twelfth cranial nerve).","Hypoglossal Nerve Disorder | Disorder of XII Nerve | Disorder of the XII Nerve | Hypoglossal nerve disorder | Twelfth Nerve Disorder",,,,,,,,,,,,,,,"435537","Disorder of hypoglossal nerve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4228958","Hypertrichosis","C79597","Excessive hair growth anywhere on the body.","Hypertrichosis | ",,,,,,,,,,,,,,,"443793","Hypertrichosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0917799","Hypersomnia","C78346","A sleep disorder characterized by excessive sleepiness.","Hypersomnia | Hypersomnia | Primary Hypersomnia",,,,,,,,,,,,,,,"438134","Hypersomnia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3281276","Hyperhidrosis","C78345","Excessive perspiration.","Hyperhidrosis | Hyperhydrosis",,,,,,,,,,,,,,,"138565","Hyperhidrosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0451597","Productive Cough","C78569","A cough accompanied by expectorated secretions.","Productive Cough | Loose Cough | Productive cough | Wet Cough",,,,,,,,,,,,,,,"4102774","Productive cough",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4014829","Hirsutism","C61444","Male-pattern hair growth on a female.","Hirsutism | ",,,,,,,,,,,,,,,"134718","Hirsutism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0426390","Bladder Spasm","C78210","A sudden and involuntary contraction of the bladder wall.","Bladder Spasm | Bladder spasm",,,,,,,,,,,,,,,"4090870","Spasm of bladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3809444","Cognitive Disturbance","C27101","A notable change in cognitive function.","Cognitive Disturbance | Cognitive disturbance | Neurocognitive Disturbance",,,,,,,,,,,,,,,"443432","Impaired cognition",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2607914","Allergic Rhinitis","C79532","Inflammation of the nasal mucous membranes caused by an IgE-mediated response to external allergens. The inflammation may also involve the mucous membranes of the sinuses, eyes, middle ear, and pharynx. Symptoms include sneezing, nasal congestion, rhinorrhea, and itching. It may lead to fatigue, drowsiness, and malaise thus causing impairment of the quality of life.","Allergic Rhinitis | Allergic rhinitis",,,,,,,,,,,,,,,"257007","Allergic rhinitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221725","Bronchial Obstruction","C78225","Blockage of a bronchus passage most often by bronchial secretions and exudates.","Bronchial Obstruction | Bronchial obstruction",,,,,,,,,,,,,,,"4279071","Obstruction of bronchus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1504507","Bronchial Stricture","C78226","Narrowing of a bronchial tube.","Bronchial Stricture | Bronchial stricture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0238132","Bronchopleural Fistula","C80694","An abnormal communication between a bronchus and the pleural cavity.","Bronchopleural Fistula | Bronchopleural fistula",,,,,,,,,,,,,,,"4119939","Bronchopleural fistula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0853142","CD4 Lymphocytes Decreased","C78233","A laboratory test result which indicates decreased levels of CD4 lymphocytes in a biospecimen.","CD4 Lymphocytes Decreased | CD4 lymphocytes decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023182","Cerebrospinal Fluid Leakage","C50487","The loss of cerebrospinal fluid.","Cerebrospinal Fluid Leakage | Cerebrospinal fluid leakage",,,,,,,,,,,,,,,"4251618","Cerebrospinal fluid leakage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0948245","Cytokine Release Syndrome","C78251","A syndrome that occurs after therapeutic infusion of antibodies into the blood and is characterized by nausea, headache, tachycardia, hypotension, rash, and shortness of breath. It is caused by the release of cytokines from the cells that are targeted by the antibodies. Most patients experience a mild to moderate reaction; however, the reaction may be severe and life-threatening.","Cytokine Release Syndrome | Cytokine release syndrome",,,,,,,,,,,,,,,"46271778","Cytokine release syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4227706","Dysarthria","C79549","Slow and slurred speech resulting from inability to coordinate the muscles that are used in speech. Causes include brain damage, Parkinson disease, and developmental causes.","Dysarthria | ",,,,,,,,,,,,,,,"4196636","Dysarthria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0239223","External Ear Pain","C78285","Painful sensation in the external ear region.","External Ear Pain | External ear pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3808650","Fecal Incontinence","C78498","Involuntary passage of stool from the rectum.","Fecal Incontinence | Bowel incontinence | Fecal incontinence | fecal incontinence",,,,,,,,,,,,,,,"197675","Incontinence of feces",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0158353","Infectious Myositis","C26984","An infectious process affecting the skeletal muscles. It can be caused by viruses (including HIV), bacteria, fungi, and parasites. Symptoms include muscle weakness and muscle pain.","Infectious Myositis | Infective Myositis | Infective myositis",,,,,,,,,,,,,,,"76508","Infective myositis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0853225","INR Increased","C78366","A laboratory test result demonstrating an increased ratio of the patient's prothrombin time to a control sample.","INR Increased | Elevated Prothrombin Time International Normalized Ratio | INR increased | International Normalized Ratio Increased | Supratherapeutic International Normalized Ratio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025287","Meningismus","C79694","The symptoms of neck stiffness, headache, and photophobia resulting from meningeal irritation. Causes include subarachnoid hemorrhage and acute febrile diseases.","Meningismus | meningeal syndrome",,,,,,,,,,,,,,,"441130","Meningeal irritation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1699181","Muscle Weakness Right-Sided","C78457","A reduction in the strength of the muscles in the right side of the body.","Muscle Weakness Right-Sided | Muscle weakness right-sided",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1397452","Pulmonary Fistula","C78577","An abnormal communication between the lung and another organ or anatomic site.","Pulmonary Fistula | Pulmonary fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042021","Urinary Tract Fistula","C79850","An abnormal communication between any part of the urinary system and another organ or cavity.","Urinary Tract Fistula | Urinary fistula",,,,,,,,,,,,,,,"4238036","Urinary fistula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4012463","Alopecia","C50575","Hair loss usually from the scalp. It may result in bald spots or spread to the entire scalp or the entire epidermis. It may be androgenetic or caused by chemotherapeutic agents, compulsive hair pulling, autoimmune disorders or congenital conditions.","Alopecia | Alopecia Areata | Hair Loss | alopecia",,,,,,,,,,,,,,,"133280","Alopecia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242209","Sugar","C71939","A white crystalline carbohydrate, typically sucrose, used as a sweetener and preservative.","Sugar | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016767","Fruit","C71972","A structure consisting of the fertilized and mature ovules ('seeds') and the ovary wall, which may be fleshy (as in the apple) or dry and hard (as in a maple fruit.","Fruit | Fructus",,,,,,,,,,,,,,,"4217045","Fruit",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0012171","Dietary Fats","C2317","A class of food constituents, also known as fats and oils, that serve as a source of energy and essential fatty acids in animals. The major components of lipids are fatty acids, triglycerides, phospholipids, glycolipids, sphingolipids, steroids (cholesterol), and lipoproteins.","Dietary Lipid | Dietary Fat | Total Dietary Fat | Total Dietary Lipid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0915224","Aliskiren","C65222","An orally active nonpeptide renin inhibitor with antihypertensive activity. Aliskiren selectively binds to the S3 sub-pocket of renin, an enzyme in the renin-angiotensin-aldosterone system (RAAS) that is responsible for converting angiotensinogen to angiotensin I (AT I). By inhibiting the activity of renin, the conversion to AT I is prevented, which in turn prevents the conversion of AT I to AT II. This prevents arterial vasoconstriction by AT II and inhibits the production of aldosterone by AT II. As aldosterone causes re-uptake of sodium and water and eventually an increase in extracellular volume, aliskiren is able to prevent the effects that contribute to an increase in blood pressure.","Aliskiren | (2S,4S,5S,7S)-5-Amino-N-(2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnonamide | ALISKIREN | CGP 60536 | SPP100 | Tekturna",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334036","Apocrine Metaplasia","C8359","A morphologic finding indicating the alteration of the glandular acinar epithelial cells to apocrine sweat gland cells.","Apocrine Metaplasia | ",,,,,,,,,,,,,,,"4217928","Apocrine metaplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010947","Dairy Product","C413","Food made from the milk of some mammals, most commonly cows, goats and sheep.","Dairy Product | Dairy Food | Dairy Food Product | Dairy Products",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0429028","QT Interval","C83501","The time interval between the start of the Q wave and the end of the T wave in the cardiac cycle.","QT Interval | ",,,,,,,,,,,,,,,"4216826","QT interval feature",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0429087","PR Interval","C83502","The time interval between the start of the P wave and the beginning of the QRS complex in the cardiac cycle.","PR Interval | PR interval",,,,,,,,,,,,,,,"4274406","PR interval - finding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0081408","Zileuton","C26667","A synthetic derivative of hydroxyurea with antiasthmatic properties. The leukotriene inhibitor zileuton blocks 5-lipoxygenase, which catalyzes the formation of leukotrienes from arachidonic acid; causes bronchodilation; decreases bronchial mucous secretion and edema; and may prevent or decrease the symptoms of asthma. (NCI04)","Zileuton | (+-)-N-Hydroxy-N-(1-benzo[b]thien-2-ylethyl)-urea | N-(1-Benzo[b]thien-2-ylethyl)-N-hydroxyurea | ZILEUTON | Zyflo | zileuton",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1565830","PTGS1 protein, human","C19705","Prostaglandin G/H synthase 1 (599 aa, ~69 kDa) is encoded by the human PTGS1 gene. This protein plays a role in vasoconstriction, blood pressure homeostasis and prostaglandin metabolism.","Prostaglandin G/H Synthase 1 | COX | COX-1 | COX1 | COX3 | Cyclo-Oxygenase-1 | Cyclooxygenase | Cyclooxygenase 3 | Cyclooxygenase-1 | EC 1.14.99.1 | Fatty Acid Cyclooxygenase | PGH Synthase | PGH Synthase 1 | PGHS-1 | PHS 1 | PHS1 | PTGS | PTGS1 | Prostaglandin G/H Synthase and Cyclooxygenase | Prostaglandin H2 Synthase | Prostaglandin H2 Synthase 1 | Prostaglandin-Endoperoxide Synthase | Prostaglandin-Endoperoxide Synthase 1 | Prostaglandin-Endoperoxide Synthase 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023545","Leukotriene","C608","Any eicosanoid produced by the oxidation of either eicosapentaenoic acid (EPA) or arachidonic acid (AA) by arachidonate 5-lipoxygenase in leukocytes. Leukotrienes act locally as autocrine or paracrine hormones to modulate immune responses and inflammation.","Leukotriene | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347179","Active Study","C70747","A clinical study status designating the study open to accrual.","Active Study | Active | Active Study Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280630","Uterine Carcinosarcoma","C42700","A usually aggressive malignant neoplasm arising from the uterine corpus and less often the cervix.  It is characterized by the presence of two components: a malignant epithelial component and a sarcomatous component.  In the uterine corpus the epithelial component is usually glandular whereas in the cervix is usually non-glandular.  Carcinosarcoma of the cervix, although it is aggressive, it may have a better prognosis compared to the uterine corpus carcinosarcoma.","Uterine Carcinosarcoma | Carcinosarcoma of the Uterus | Carcinosarcoma of the uterus | Malignant Mixed Mesodermal (Mullerian) Tumor of the Uterus | Malignant Mixed Mesodermal (Müllerian) Tumor of the Uterus | Uterine Malignant Mixed Mesodermal (Mullerian) Tumor | Uterine Malignant Mixed Mesodermal (Müllerian) Tumor",,,,,,,,,,,,,,,"45773362","Carcinosarcoma of uterus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017289","Immunoglobulin Gene Rearrangement Process","C20045","Any process of gene rearrangement that creates a novel junction among the immunoglobuling-coding variable, diversity, joining or constant segments. This process involves sequence recognition, cleavage, excision and ligation by recombinases to create a contiguous protein-coding gene. Immunoglobulin gene rearrangement is involved in generation of antibody diversity.","Immunoglobulin Gene Rearrangement Process | Immunoglobulin Gene Rearrangement | Immunoglobulin Gene Rearrangement",,,,,,,,,,,,,,,"4227758","Gene re-arrangement, B lymphocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827355","Linguistic Form","C84268","A unit of speech such as, a word, suffix, phrase, or sentence.","Linguistic Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826580","MAGE-TAB","C82937","A tab-delimited, spreadsheet-based format that can be used for annotating and communicating microarray data with experimental details in a MIAME (Minimum Information About a Microarray Experiment) compliant fashion.","MAGE-TAB | MAGETAB | MicroArray Gene Expression Tabular | MicroArray Gene Expression Tabular Format",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710036","Search Criteria","C42871","An object that exists for defining the search parameters for a domain.","Search Criteria | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449010","Exclusion","C82931","The deliberate act of omission.","Exclusion | Exclude | Excluded",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828366","BioSample Type - extract","C82948","A solution of essential constituents of a complex material; a substance removed from another substance.","Extract | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708571","Invoker","C52265","A person who calls for, activates, or starts a process, procedure, or program.","Invoker | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881007","Grid Service Fault","C64695","The result of execution of a Grid Service Operation when an unexpected or illegal event occurs during processing, generally indicating through a message and/or additional details, the cause of abnormal execution.","Grid Service Fault | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205279","Contamination","C68768","The presence of any substance or organism that makes a preparation impure.","Contamination | CONTAMINATED | Contaminated | Contaminated Specimen",,,,,,,,,,,,,,,"4269056","Contaminated",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014417","Environmental Pollutants","C1751","Any chemical compound, biological object, physical factor in a concentration or amount that adversely alters the physical, chemical, or biological properties of the environment. The term includes pathogens, toxic metals, carcinogens, oxygen-demanding materials, radiation, natural substances, synthetic industrial chemicals, biocides and all other harmful substances and factors. (NCI)","Pollutant | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699517","Absent Adverse Event","C75533","The absence of adverse events or within normal limits or values.","Absent Adverse Event | CTCAE Grade 0 | Common Terminology Criteria for Adverse Events Grade 0 | Grade 0 | Toxicity Value 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412750","CTCAE v4 Grade 1","C84263","An adverse event that is asymptomatic; or involves mild or minor symptoms; or is of marginal clinical relevance; or consists of clinical or diagnostic observations alone; or for which intervention is not indicated; or for which only non-prescription intervention is indicated.","CTCAE v4 Grade 1 | Mild Adverse Event | Mild Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412751","2","C84264","An adverse event for which only minimal, local, or noninvasive intervention (e.g. packing, cautery) is indicated; or that limits instrumental activities of daily living (ADLs, e.g., shopping, laundry, transportation, or ability to conduct finances).","CTCAE v4 Grade 2 | 2 | Grade 2 | MODERATE | Moderate Adverse Event | Moderate Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2919019","Severe Adverse Event - CTCAE v4 Grade 3","C84265","An adverse event that is medically significant but not life-threatening; or for which inpatient care or prolongation of hospitalization are indicated; or that is an important medical event that does not result in hospitalization, but may jeopardize the patient or may require intervention either to prevent hospitalization, to prevent the AE from becoming life-threatening or causing death; or that is disabling; or that results in persistent or significant disability, incapacity, or limitation of self care activities of daily living (ADLs, e.g., getting in and out of bed, dressing, eating, getting around inside, bathing, or using the toilet).","CTCAE v4 Grade 3 | Severe Adverse Event | Severe Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517874","Life Threatening Adverse Event","C84266","An adverse event that has life-threatening consequences; for which urgent intervention is indicated; that puts the patient at risk of death at the time of the event if immediate intervention is not undertaken.","Life Threatening Adverse Event | 5 | AESLIFE | Grade 4 | Life-threatening adverse experience | life-threatening adverse event/ experience",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827363","Daycare","C84278","Daytime supervision, which may include recreational or medical facilities, for children, seniors, or people needing special assistance.","Daycare | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827364","Attendance","C84279","The act of being present (at a meeting or event etc.)","Attendance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827365","Contaminant","C84280","A substance that makes a material impure.","Contaminant | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0178639","Food Preparation","C17604","The process of taking raw food and producing a finished meal.  Investigations into the link between food preparation methods and human disease","Food Preparation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827352","Serum Free Immunoglobulin Light Chain","C84260","Human immunoglobulin kappa and/or lambda light chains detected in their free form in serum as a result of overproduction by plasma cells in excess over heavy chains due to neoplastic plasma cell proliferations.","Serum Free Immunoglobulin Light Chain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0444467","Thoracoabdominal","C84285","Relating to, involving, or affecting the thorax and abdomen.","Thoracoabdominal | ",,,,,,,,,,,,,,,"4124605","Thoracoabdominal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1513478","Monosomy 13","C36383","A chromosomal abnormality consisting of the absence of a copy (homolog) of chromosome 13.","Monosomy 13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0432411","Trisomy 9","C84282","A chromosomal abnormality consisting of the presence of a third copy of chromosome 9 in somatic cells.","Trisomy 9 | ",,,,,,,,,,,,,,,"4007085","Trisomy 9",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0795856","Trisomy 15","C84283","A chromosomal abnormality consisting of the presence of a third copy of chromosome 15 in somatic cells.","Trisomy 15 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827366","Trisomy 19","C84284","A chromosomal abnormality consisting of the presence of a third copy of chromosome 19 in somatic cells.","Trisomy 19 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0178417","Anhedonia","C3673","An inability to experience pleasure.","Anhedonia | ",,,,,,,,,,,,,,,"4102935","Anhedonia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827384","BLAST Bit Score","C84318","A numeric result derived from the BLAST raw score which is normalized to the statistical parameters of the scoring system in use. The BLAST bit score allows for alignment comparisons between independent searches.","BLAST Bit Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827385","BLAST Raw Score","C84319","The numeric result derived from a BLAST sequence alignment assessment, calculated from the sum of substitution and gap scores.","BLAST Raw Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827386","BLAST E-Value","C84320","The statistical probability of the number of alignments that are expected to occur by chance, in a database of a given size, with a score greater than or equal to the BLAST raw score. A low BLAST E-value is indicative of high statistical significance.","BLAST E-Value | BLAST E Value | BLAST Expectation Value",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456388","Blood Product","C81304","Any natural or synthetic composition that replicates the structure or function of a native component of blood.","Blood Product | ",,,,,,,,,,,,,,,"4132660","Blood product",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0267963","Pancreatic Insufficiency","C84316","Inability of the exocrine pancreas to produce and secrete an adequate amount of digestive enzymes into the small intestine.  Patients present with symptoms of malabsorption syndrome, abdominal discomfort, and bloating.  Causes include chronic pancreatitis, cystic fibrosis, and autoimmune disorders.","Pancreatic Insufficiency | Exocrine Pancreas Insufficiency | Exocrine Pancreatic Insufficiency",,,,,,,,,,,,,,,"4186463","Exocrine pancreatic insufficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0175738","Freezer","C84327","A refrigerated cabinet or room for preserving materials at or below 32F (0C).","Freezer | ",,,,,,,,,,,,,,,"4290529","Freezer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2826097","Sonic Hedgehog/Patch Pathway Inactivated","C82328","A genetic finding indicating that the sonic hedgehog/patch pathway is inactivated.","Sonic Hedgehog/Patch Pathway Inactivated | Rack | SHH/PTCH Pathway Inactivated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041361","Tumor Antigen","C912","1. antigens that may be frequently associated with tumors or may be specifically found on tumor cells of the same origin (tumor specific); 2. tumor antigens may also be associated with replication and transformation by certain DNA tumor viruses, including adenoviruses and papovaviruses. Neoantigens. Any immunologically detectable marker whose presence or amount indicates the presence of a tumor.","Tumor Antigen | TAA | Tumor-Associated Antigen | tumor-specific antigen",,,,,,,,,,,,,,,"4248853","Tumor-associated antigen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013330","Dust","C84281","A fine powdery material such as dry earth or pollen that can be blown about in the air.","Dust | ",,,,,,,,,,,,,,,"4140824","Dust",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0279557","Lung Adenosquamous Carcinoma","C9133","An aggressive carcinoma with a poor prognosis characterized by a presence of both malignant squamous cells and glandular cells.","Lung Adenosquamous Carcinoma | Adenosquamous Cell Lung Carcinoma | Adenosquamous Lung Cancer | Adenosquamous Lung Carcinoma | Adenosquamous Lung Carcinoma",,,,,,,,,,,,,,,"37166745","Adenosquamous carcinoma of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152013","Lung Adenocarcinoma","C3512","A carcinoma that arises from the lung and is characterized by the presence of malignant glandular epithelial cells.  There is a male predilection with a male to female ratio of 2:1.  Usually lung adenocarcinoma is asymptomatic and is identified through screening studies or as an incidental radiologic finding.  If clinical symptoms are present they include shortness of breath, cough, hemoptysis, chest pain, and fever.  Tobacco smoke is a known risk factor.","Lung Adenocarcinoma | Adenocarcinoma | Adenocarcinoma of Lung | Adenocarcinoma of the Lung | LUAD | Lung adenocarcinoma",,,,,,,,,,,,,,,"4112738","Adenocarcinoma of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1335325","Lung Papillary Adenocarcinoma","C5650","A morphologic variant of lung adenocarcinoma characterized by the presence of papillary structures.","Lung Papillary Adenocarcinoma | Papillary Adenocarcinoma of Lung | Papillary Adenocarcinoma of the Lung | Papillary Lung Adenocarcinoma | Papillary Lung Adenocarcinoma",,,,,,,,,,,,,,,"37166771","Papillary adenocarcinoma of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332137","Lung Acinar Adenocarcinoma","C5649","A morphologic variant of lung adenocarcinoma characterized by the presence of acinar structures composed of columnar or cuboidal cells. (NCI05)","Lung Acinar Adenocarcinoma | Acinar Adenocarcinoma of Lung | Acinar Adenocarcinoma of the Lung | Acinar Lung Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206692","Breast Lobular Carcinoma","C3771","An adenocarcinoma of the breast arising from the lobules.  This is a relatively uncommon carcinoma, represents approximately 10% of the breast adenocarcinomas and is often bilateral or multifocal.","Breast Lobular Carcinoma | Lobular Adenocarcinoma | Lobular Breast Carcinoma | Lobular Breast Carcinoma | Lobular Carcinoma | Lobular Carcinoma of Breast | Lobular Carcinoma of the Breast | Lobular adenocarcinoma | lobular carcinoma","8520/3","Lobular carcinoma, NOS",,,,,,,,,,,,,"4080865|4232456","Infiltrating lobular carcinoma of breast|Lobular carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1511228","Blood Vessel Tissue","C32213","The tissue component of a blood vessel. Large vessels contain three layers of tissue, the tunica intima, tunica media, and tunica adventitia. Capillary tissue is composed of a single layer of endothelium and connective tissue.","Blood Vessel Tissue | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025584","Metatarsal Bone","C12752","A bone belonging to the middle part of the foot located between toes and ankle. There are 5 metatarsal bones and they are numbered from the medial side.","Metatarsal Bone | BONE, METATARSAL | METATARSAL BONE | Metatarsal Bones | Metatarsals | Metatarsus",,,,,,,,,,,,,,,"4202658","Metatarsal bone structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025526","Metacarpal Bone","C12751","Any of the five bones between the wrist and the fingers that form the skeleton of the palm.","Metacarpal Bone | BONE, METACARPAL | METACARPAL BONE | Metacarpal | Metacarpal Bones | Metacarpals | Metacarpus | Os Metacarpale",,,,,,,,,,,,,,,"4265712","Metacarpal bone structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016505","Foot Bone","C13068","One of the seven tarsal, five metatarsal, or 14 phalangeal bones in the foot.","Foot Bone | Bone Foot | Foot Bones",,,,,,,,,,,,,,,"4222767","Bone structure of foot",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042779","Viscera","C28287","Two or more internal organs.","Viscera | viscera",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006030","Boron","C61481","An element with atomic symbol B, atomic number 5, and atomic weight 11.","Boron | B | BORON",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827401","MammaPrint","C84345","An in vitro molecular diagnostic test that uses gene expression profiling to analyze gene activity within a breast cancer tumor sample. It looks at the activity of 70 genes and is useful in assessing the likelihood of metastasis and recurrence.","MammaPrint | Breast Cancer 70-gene Profile Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0559189","Autograft","C75339","A graft transferred from one location to another within the same individual.","Autograft | Autologous Graft",,,,,,,,,,,,,,,"4049326","Autograft",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1955970","National Heart, Lung, and Blood Institute","C82613","An institute within the National Institutes of Health that provides global leadership for a research, training, and education program to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives.","National Heart, Lung, and Blood Institute | NHLBI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0234173","Moro Reflex","C81311","An involuntary, primal response in the neonate to loud noise or the feeling of falling. The response is characterized by the infant's arms symmetrically spreading out to the side and then back to the midline, and involuntarily flexing the fingers and toes.","Moro Reflex | MORORFX | Startle Reflex",,,,,,,,,,,,,,,"4033385","Moro reflex",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0234174","Sucking Reflex","C81323","An involuntary, primal response in the neonate when a nipple is placed on an infant's lips.","Sucking Reflex | SUCKRFX | Suck Swallow Reflex",,,,,,,,,,,,,,,"4163675","Sucking reflex",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0278129","Step Reflex","C81322","An involuntary, primal response in the neonate to take brisk steps when the feet are placed on a surface whilst in a supported standing position.","Step Reflex | STEPRFX | Stepping Reflex",,,,,,,,,,,,,,,"4041992","Stepping reflex",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0457224","Tonic Neck Reflex","C81324","An involuntary, primal response in the neonate in which the arm extends to follow the infant's gaze, while the opposing arm and leg flex inward.","Tonic Neck Reflex | ATNR | ATNRFX | Asymmetric Tonic Neck Reflex | Asymmetrical Tonic Neck Reflex",,,,,,,,,,,,,,,"4290614","Tonic neck reflex",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0234175","Grasp Reflex","C81254","An involuntary, primal response in the neonate to grasp the fingers when their palm is touched. This reflex is present until six months of age.","Grasp Reflex | PLMGRRFX | Palmar Grasp Reflex",,,,,,,,,,,,,,,"4100337","Palmar reflex",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0278133","Rooting Reflex","C81320","An involuntary, primal response in the neonate to search for the nipple when the cheek is touched.","Rooting Reflex | ROOTRFX",,,,,,,,,,,,,,,"4085486","Rooting reflex",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825532","Apgar Test","C81230","A test devised by Dr. Virginia Apgar to assess the overall health of a newborn upon birth. The test is administered at one and five minutes after birth and allows for the assignation of numerical values between zero and two for specific observations regarding skin color, pulse rate, reflex irritability, muscle tone and breathing.","Apgar Test | APGAR Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825565","Point in Time Test Given","C81297","The hour, minute, and/or second that an examination was administered.","Point in Time Test Given | assessment timepoint | assessment_timepoint",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825569","Breathing Effort Score","C81306","A component of the Apgar score, it is the numerical value assigned to the assessment of breathing effort by a neonate. 0 = no spontaneous respirations; 1 = slow or irregular respirations or a weak cry; 2 = strong, consistent respirations with a robust cry.","Breathing Effort Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825571","Heart Rate Score","C81309","A component of the Apgar score, it is the numerical value assigned to an assessment of the circulatory status of a neonate. 0 = no pulse; 1 = rate less than 100 beats per minute; 2 = rate greater than 100 beats per minute.","Heart Rate Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825573","Muscle Tone Score","C81312","A component of the Apgar score, it is the numerical value assigned to an assessment of the residual muscle tension of a neonate. 0 = flaccid; 1 = flexion of extremities; 2 = active motion.","Muscle Tone Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825576","Reflex Irritability Score","C81319","A component of the Apgar score, it is the numerical value assigned to the neonate's response to stimuli, such as a mild pinch. 0 = no reaction; 1 = grimace; 2 = grimace with a cough, sneeze, or vigorous cry.","Reflex Irritability Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825577","Skin Color Score","C81321","A component of the Apgar score, it is the numerical value assigned to an assessment of the color of the skin of a neonate. 0 = pale blue; 1 = pink body and pale blue extremities; 2 = pink body and extremities.","Skin Color Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0552479","history of alcohol use","C81229","A description of an individual's current and past experience with alcoholic beverage consumption.","Alcohol Use History | Alcohol History | Alcohol Use | alcohol history | alcohol_history",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2239127","Drug use history","C81246","A description of an individual's current and past use and/or abuse of drugs and chemicals. This includes prescription medication, illicit drugs and recreational substances.","Drug Use History | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825558","Red Reflex Test","C81283","An optic examination in which an ophthalmoscope or retinoscope is placed approximately 30cm from the eye to visualize whether a reddish hue is reflected from the retina.","Red Reflex Test | Red Reflex Vision Test | Red Reflex Vision Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086912","Research Methodology","C81265","A description of the technique for the appraisal of a subject or object.","Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825533","Attending Health Care Provider","C81231","The individual assigned to be the primary care manager overseeing a patient's medical care during an episode of hospitalization.","Attending Health Care Provider | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019247","Genetic Disorder","C3101","Genetic diseases are diseases in which inherited genes predispose to increased risk. The genetic disorders associated with cancer often result from an alteration or mutation in a single gene. The diseases range from rare dominant cancer family syndrome to familial tendencies in which low-penetrance genes may interact with other genes or environmental factors to induce cancer. Research may involve clinical, epidemiologic, and laboratory studies of persons, families, and populations at high risk of these disorders.","Genetic Disorder | Genetic Condition | Genetic Syndrome | Hereditary Disease | Hereditary Diseases | Inherited Disease | Molecular Disease",,,,,,,,,,,,,,,"37204336|443916","Genetic disease|Hereditary disease",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2825560","S-Beta Thalassemia","C81288","A disorder characterized by the body's inability to synthesize beta-globin chains, leading to the formation of abnormal hemoglobin and anemia. This inherited autosomal recessive blood disorder is caused by germline mutation of the HBB gene.","S-Beta Thalassemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019021","Hemoglobin C Disease","C34675","An autosomal recessive hemoglobinopathy with a mild clinical course. Most patients are asymptomatic. When symptoms appear, they include mild hemolytic anemia and occasionally jaundice.","Hemoglobin C Disease | ",,,,,,,,,,,,,,,"4176425","Hemoglobin C disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825546","Imaging Information","C81256","A collection of data pertinent to a radiographic study.","Imaging Information | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825561","Image Identifier","C81289","A sequence of letters, numbers, or other characters that specifically identifies a particular image.","Image Identifier | imageIdentifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1317250","Collection Date","C81286","The date on which the sample or data was collected.","Collection Date | date of sample collection | date_of_sample_collection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0552379","Collection Time","C81287","The hour, minute, and/or second at which the sample or data was collected.","Collection Time | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0442816","Normal Reference Range","C78727","Reported values within the typical or expected range.","Normal Reference Range | NORMAL | Normal",,,,,,,,,,,,,,,"37159741|4124457|4128647","Reference range|Normal range|Normal limits",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C0005612","Birth Weight","C76325","The first weight of a newborn obtained after birth.","Birth Weight | BRTHWT",,,,,,,,,,,,,,,"4264825","Birth weight",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221097","Total Body Length","C81298","The total linear extent of the body.","Total Body Length | BODLNGTH | Body Length",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825540","Crown to Rump Length Measurement","C81242","A measurement from the high prominence of the head to the low prominence of the buttocks of a fetus or embryo during ultrasound. This measurement is useful in determining gestational age.","Crown to Rump Length Measurement | CRL | CRWNRMPL | Crown Rump length | Crown to Rump Length",,,,,,,,,,,,,,,"4172711","Crown rump length of fetus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0262499","Head Circumference","C81255","A circumferential measurement of the head at the widest point, which is traditionally above the eyebrows.","Head Circumference | HDCIRC | Occipital-Frontal Circumference",,,,,,,,,,,,,,,"4181669","Head circumference",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825545","Gestational Weeks Assessment","C81253","Gestational age (written with both weeks and days, e.g. 39 weeks and 0 days) is calculated using the best obstetrical estimated due date (EDD) based on the following formula: Gestational Age = (280 - (EDD - Reference Date))/ 7. Note: Reference Date is the date on which you are trying to determine gestational age. (reVITALize)","Gestational Weeks Assessment | Gestational Age | Gestational Weeks | Gestational Weeks",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825570","Estimation Method","C81307","A description of the technique for the approximate calculation of a value.","Estimation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2015861","Multiple Birth","C81271","Multiple fetuses birthed live or dead in a single pregnancy regardless of gestational age, and regardless of whether the fetuses were birthed on different dates.","Multiple Birth | Multiple Births | Multiple birth | Mutiple birth | Plurality",,,,,,,,,,,,,,,"4163851","Multiple birth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0150589","Infant Formula","C81249","A nutritional substitute for breast milk, usually with a foundation of cow or soy milk.","Infant Formula | ",,,,,,,,,,,,,,,"4132339","Infant formula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825575","Physical Symmetry","C81316","A physical attribute of visual balance and proportion between opposing structures.","Physical Symmetry | Symmetry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825496","Delivery Procedure","C81179","Description of the method by which a fetus is delivered.","Delivery Procedure | Birth Method of Delivery | Birth Method of Delivery | DLVRMODE | Mode of Delivery",,,,,,,,,,,,,,,"4128030","Delivery procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1541822","Vaginal Delivery","C81303","Birth of the fetus through the vagina.","Vaginal Delivery | VAGINAL DELIVERY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825568","Vaginal Assisted Delivery","C81301","Birth of the fetus through the vagina with the application of vacuum or forceps or any other instrument.","Vaginal Assisted Delivery | Assisted Vaginal Delivery | Operative Vaginal Delivery | VAGINAL ASSISTED DELIVERY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2911686","First Feeding","C81272","The first time that a neonate is provided nutrition.","First Feeding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0237433","Pediatrician","C83190","A medical doctor with specialized training in the care of children.","Pediatrician | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3553252","Congenital Hypothyroidism","C26734","A deficiency of thyroid hormone present at birth. The etiology can be genetic or environmental, or a combination of both; treatment is based on severity and causality.","Congenital Hypothyroidism | ",,,,,,,,,,,,,,,"133728","Congenital hypothyroidism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268151","Transferase Deficiency Galactosemia","C81325","A disorder characterized by the body's inability to metabolize galactose. This type of galactosemia is caused by germline mutations in the GALT gene which leads to the inhibition in the activity of the enzyme galactose-1-phosphate uridyl transferase.","Transferase Deficiency Galactosemia | Transferase Deficient Galactosemia | Transferase Deficient Galactosemia | Transferase-deficient Galactosemia",,,,,,,,,,,,,,,"4051523","Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031485","Phenylketonuria","C81315","An autonomic recessive genetic disorder characterized by the body's inability to metabolize and utilize the amino acid phenylalanine, resulting in mental retardation, behavioral and movement problems, seizures, and developmental delays.","Phenylketonuria | PKU | phenylketonuria",,,,,,,,,,,,,,,"40388130","Phenylketonuria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825562","Sick Newborn","C81291","A neonate that is unwell.","Sick Newborn | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825541","Deceased Sibling","C81244","The historical fact that a legal or consanguineous brother or sister has died.","Deceased Sibling | ",,,,,,,,,,,,,,,"42538168","Sibling deceased",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007465","Cause of Death","C81239","The circumstance or condition that results in the death of a living being.","Cause of Death | CAUSE_OF_DEATH | COD | DEATHD | Death Diagnosis | cause of death | cause_of_death",,,,,,,,,,,,,,,"4083743","Cause of death",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015746","Feeding Method","C81267","A description of the technique for the manner in which a subject is administered food.","Feeding Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006042","Bottle Feeding","C81305","Provision of liquid nutrition via a closed container system with a rubber like mouthpiece resembling a nipple.","Bottle Feeding | ",,,,,,,,,,,,,,,"4220481","Bottle feeding of patient",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1301894","Medical Record Number","C81262","An identifying number within an institution that is used to reference a subject's medical information.","Medical Record Number | MR | MR Number | Medical record number | Patient MRN",,,,,,,,,,,,,,,"4161822","Medical record number",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825537","Birth Facility","C81237","The facility which provides a setting with provisions for monitoring and delivering babies.","Birth Facility | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879733","Area Code","C62138","A three-digit Numbering Plan Areas (NPAs) assigned to small divisions of the 19 North American countries included in the North American Numbering Plan.","Area Code | Telephone Area Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1160858","Behavioral Assessment","C81234","Assessment of individual responses to age appropriate stimuli.","Behavioral Assessment | ",,,,,,,,,,,,,,,"4023020","Behavioral assessment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0451021","Bayley Scale of Infant Development I","C81232","The first edition of a standardized series of measurements that assesses the cognitive, motor, and behavioral development in infants and babies from one to twenty-four months of age.","Bayley Scale of Infant Development I | Bayley Scale of Infant Development | Bayley Scale of Infant Development | Bayley Scales of Infant Development | Bayley Scales of Infant Development",,,,,,,,,,,,,,,"4164673","Bayley scale of infant development",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825547","Last Screening","C81258","The most recent screening.","Last Screening | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229298","Right Ear","C81285","The organ of hearing located on the right side of the head.","Right Ear | ",,,,,,,,,,,,,,,"4103458","Right ear structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0229299","Left Ear","C81259","The organ of hearing located on the left side of the head.","Left Ear | ",,,,,,,,,,,,,,,"4233086","Left ear structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3467798","Robatumumab","C71527","A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Anti-IGF-1R fully human monoclonal antibody SCH 717454 binds to membrane-bound IGF-1R, preventing binding of the ligand IGF-1 and the subsequent triggering of the PI3K/Akt signaling pathway; downregulation of this survival pathway may result in the induction of apoptosis and decreased cellular proliferation. The activation of IGF-1R, a tyrosine kinase and a member of the insulin receptor family, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been highly implicated in tumorigenesis and metastasis.","Robatumumab | Anti-IGF-1R Recombinant Monoclonal Antibody SCH 717454 | Anti-IGF-1R Recombinant Monoclonal Antibody SCH 717454 | Immunoglobulin G1, Anti-(Human Insulin-Like Growth Factor I Receptor) (Human Monoclonal SCH 717454 Heavy Chain), Disulfide with Human Monoclonal SCH 717454 Light Chain, Dimer | ROBATUMUMAB | Sch717454",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008651","Human Chromosome 1","C13204","The designation for each member of the largest human autosomal chromosome pair. Chromosome 1 spans about 247 million nucleotide base pairs and represents about 8% of the total DNA in normal diploid cells.","Human Chromosome 1 | Chromosome 1 | Chromosome 1 | chr1",,,,,,,,,,,,,,,"4186765","Chromosome pair 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008652","Human Chromosome 10","C13205","The designation for each member of the tenth largest human autosomal chromosome pair. Chromosome 10 spans about 135 million base pairs and represents between 4 and 4.5% of the total DNA in normal diploid cells.","Human Chromosome 10 | Chromosome 10 | Chromosome 10 | chr10",,,,,,,,,,,,,,,"4208684","Chromosome pair 10",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008653","Human Chromosome 11","C13206","The designation for each member of the eleventh largest human autosomal chromosome pair. Chromosome 11 spans about 134.5 million base pairs and represents between 4 and 4.5% of the total DNA in normal diploid cells.","Human Chromosome 11 | Chromosome 11 | Chromosome 11 | chr11",,,,,,,,,,,,,,,"4037698","Chromosome pair 11",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008654","Human Chromosome 12","C13207","The designation for each member of the twelfth largest human autosomal chromosome pair. Chromosome 12 spans about 143 million base pairs and represents between 4 and 4.5% of the total DNA in normal diploid cells.","Human Chromosome 12 | Chromosome 12 | Chromosome 12 | chr12",,,,,,,,,,,,,,,"4074272","Chromosome pair 12",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008655","Human Chromosome 13","C13208","The designation for each member of the thirteenth largest human autosomal chromosome pair. Chromosome 13 spans about 113 million base pairs and represents between 3.5 and 4% of the total DNA in normal diploid cells.","Human Chromosome 13 | Chromosome 13 | Chromosome 13 | chr13",,,,,,,,,,,,,,,"4208553","Chromosome pair 13",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008656","Human Chromosome 14","C13209","The designation for each member of the fourteenth largest human autosomal chromosome pair. Chromosome 14 spans about 105 million base pairs and represents between 3 and 3.5% of the total DNA in normal diploid cells.","Human Chromosome 14 | Chromosome 14 | Chromosome 14 | chr14",,,,,,,,,,,,,,,"4281107","Chromosome pair 14",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008657","Human Chromosome 15","C13210","The designation for each member of the fifteenth largest human autosomal chromosome pair. Chromosome 15 spans about 106 million base pairs and represents between 3 and 3.5% of the total DNA in normal diploid cells.","Human Chromosome 15 | Chromosome 15 | Chromosome 15 | chr15",,,,,,,,,,,,,,,"4325610","Chromosome pair 15",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008658","Human Chromosome 16","C13211","The designation for each member of the sixteenth largest human autosomal chromosome pair. Chromosome 16 spans about 90 million base pairs and represents just under 3% of the total DNA in normal diploid cells.","Human Chromosome 16 | Chromosome 16 | Chromosome 16 | chr16",,,,,,,,,,,,,,,"4214108","Chromosome pair 16",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008660","Human Chromosome 18","C13213","The designation for each member of the eighteenth largest human autosomal chromosome pair. Chromosome 18 spans about 76 million base pairs and represents about 2.5% of the total DNA in normal diploid cells.","Human Chromosome 18 | Chromosome 18 | Chromosome 18 | chr18",,,,,,,,,,,,,,,"4024413","Chromosome pair 18",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008661","Human Chromosome 19","C13214","The designation for each member of the nineteenth largest human autosomal chromosome pair. Chromosome 19 spans more than 63 million base pairs and represents between 2 and 2.5% of the total DNA in normal diploid cells.","Human Chromosome 19 | Chromosome 19 | chr19",,,,,,,,,,,,,,,"4233351","Chromosome pair 19",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008662","Human Chromosome 2","C13215","The designation for each member of the second largest human autosomal chromosome pair. Chromosome 2 spans more than 237 million base pairs and represents almost 8% of the total DNA in normal diploid cells.","Human Chromosome 2 | Chromosome 2 | Chromosome 2 | chr2",,,,,,,,,,,,,,,"4034512","Chromosome pair 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008663","Human Chromosome 20","C13216","The designation for each member of the third smallest human autosomal chromosome pair. Chromosome 20 spans around 63 million base pairs and represents between 2 and 2.5% of the total DNA in normal diploid cells.","Human Chromosome 20 | Chromosome 20 | Chromosome 20 | chr20",,,,,,,,,,,,,,,"4104611","Chromosome pair 20",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008664","Human Chromosome 21","C13217","The designation for each member of the second smallest human autosomal chromosome pair. Chromosome 21 spans around 47 million nucleotides and represents about 1.5% of the total DNA in normal diploid cells.","Human Chromosome 21 | Chromosome 21 | Chromosome 21 | chr21",,,,,,,,,,,,,,,"4181633","Chromosome pair 21",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008665","Human Chromosome 22","C13218","The designation for each member of the smallest human autosomal chromosome pair. Chromosome 22 spans about 49 million base pairs and represents between 1.5 and 2% of the total DNA in normal diploid cells.","Human Chromosome 22 | Chromosome 22 | Chromosome 22 | chr22",,,,,,,,,,,,,,,"4193490","Chromosome pair 22",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008666","Human Chromosome 3","C13219","The designation for each member of the third largest human autosomal chromosome pair. Chromosome 3 spans almost 200 million base pairs and represents about 6.5% of the total DNA in normal diploid cells.","Human Chromosome 3 | Chromosome 3 | Chromosome 3 | chr3",,,,,,,,,,,,,,,"4034417","Chromosome pair 3",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008667","Human Chromosome 4","C13220","The designation for each member of the fourth largest human autosomal chromosome pair. Chromosome 4 spans more than 186 million base pairs and represents between 6 and 6.5% of the total DNA in normal diploid cells.","Human Chromosome 4 | Chromosome 4 | Chromosome 4 | chr4",,,,,,,,,,,,,,,"4193511","Chromosome pair 4",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008668","Human Chromosome 5","C13221","The designation for each member of the fifth largest human autosomal chromosome pair. Chromosome 5 spans about 181 million base pairs and represents almost 6% of the total DNA in normal diploid cells.","Human Chromosome 5 | Chromosome 5 | Chromosome 5 | chr5",,,,,,,,,,,,,,,"4050471","Chromosome pair 5",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008669","Human Chromosome 6","C13222","The designation for each member of the sixth largest human autosomal chromosome pair. Chromosome 6 spans more than 170 million base pairs and represents between 5.5 and 6% of the total DNA in normal diploid cells.","Human Chromosome 6 | Chromosome 6 | Chromosome 6 | chr6",,,,,,,,,,,,,,,"4164274","Chromosome pair 6",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008670","Human Chromosome 7","C13223","The designation for each member of the seventh largest human autosomal chromosome pair. Chromosome 7 spans more than 158 million base pairs and represents between 5 and 5.5% of the total DNA in normal diploid cells.","Human Chromosome 7 | Chromosome 7 | Chromosome 7 | chr7",,,,,,,,,,,,,,,"4322462","Chromosome pair 7",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008671","Human Chromosome 8","C13224","The designation for each member of the eighth largest human autosomal chromosome pair. Chromosome 8 spans about 145 million base pairs and represents between 4.5 and 5.0% of the total DNA in normal diploid cells.","Human Chromosome 8 | Chromosome 8 | Chromosome 8 | chr8",,,,,,,,,,,,,,,"4299764","Chromosome pair 8",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008672","Human Chromosome 9","C13225","The designation for each member of the ninth largest human autosomal chromosome pair. Chromosome 9 spans about 145 million base pairs of nucleic acids and represents between 4 and 4.5% of the total DNA in normal diploid cells.","Human Chromosome 9 | Chromosome 9 | Chromosome 9 | chr9",,,,,,,,,,,,,,,"4030085","Chromosome pair 9",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827405","International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes","C84350","A system for scoring myelodysplasia syndrome progression risk, based on a combination of: percentage of blast cells in the bone marrow, the presence and severity of specific cytogenetic abnormalities, and the number of cytopenias in the peripheral blood.","International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes | IPSS | International Prognostic Scoring System (IPSS) for MDS | International Prognostic Scoring System for MDS | International Prognostic Scoring System for Myelodysplastic Syndromes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043832","Deferiprone","C73030","An orally bioavailable bidentate ligand with iron chelating activity. Deferiprone binds to iron in a 3:1 (ligand:iron) molar ratio. By binding to iron, deferiprone is able to remove excess iron from the body.","Deferiprone | 4(1H)-Pyridinone, 3-hydroxy-1,2-dimethyl- | APO-066 | CP20 | DEFERIPRONE | DN-180-01-AF | Ferriprox",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881237","Interstitial Radiation Therapy","C66891","A type of internal radiation therapy in which radioactive material sealed in needles, seeds, wires, or catheters is placed directly into a tumor or body tissue. (Cancer.gov)","Interstitial Radiation Therapy | BRACHYTHERAPY, INTERSTITIAL | INSTIT | Implant Radiation | Interstitial brachytherapy (procedure) | Radiation, Implants | implant radiation | interstitial radiation therapy",,,,,,,,,,,,,,,"4012485","Interstitial brachytherapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0228482","Vermis","C33866","A medial narrow structure connecting the two hemispheres of the cerebellum.","Vermis | CEREBELLAR VERMIS | Vermis of Cerebelli",,,,,,,,,,,,,,,"4237897","Cerebellar vermis structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265316","Phakomatosis","C84348","One of the hereditary syndromes that are associated with lesions of the nervous system, skin, and retina. This group includes neurofibromatosis, tuberous sclerosis, von Hippel-Lindau syndrome, and Sturge-Weber syndrome.","Phakomatosis | Neuro-Oculo-Cutaneous Syndrome | Neurocutaneous Syndrome | Phacomatosis",,,,,,,,,,,,,,,"4302754","Neurocutaneous syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827403","Anaplastic Astroblastoma, MN1-Altered","C84347","An astroblastoma, MN1-altered, characterized by the presence of high mitotic activity, cytologic atypia, and architectural distortion.","Anaplastic Astroblastoma, MN1-Altered | Anaplastic Astroblastoma | Anaplastic Astroblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524466","Intracranial","C84351","Situated or occurring within the cranium; affecting or involving intracranial structures.","Intracranial | ",,,,,,,,,,,,,,,"4123444","Intracranial",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009170","Cocaine","C80153","A tropane alkaloid with central nervous systems (CNS) stimulating and local anesthetic activity. Cocaine binds to the dopamine, serotonin, and norepinephrine transport proteins and inhibits the re-uptake of dopamine, serotonin, and norepinephrine into pre-synaptic neurons. This leads to an accumulation of the respective neurotransmitters in the synaptic cleft and may result in increased postsynaptic receptor activation. The mechanism of action through which cocaine exerts its local anesthetic effects is by binding to and blocking the voltage-gated sodium channels in the neuronal cell membrane. By stabilizing neuronal membranes, cocaine inhibits the initiation and conduction of nerve impulses and produces a reversible loss of sensation.","Cocaine | (1R,2R,3S,5S)-2-Methoxycarbonyltropan-3-yl Benzoate | COCAINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456904","Intraoperative","C84355","Occurring during the course of a surgical procedure.","Intraoperative | Intra-operative",,,,,,,,,,,,,,,"4080004","Intraoperative",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348482","Exemption","C73530","Immunity from an obligation or duty.","Exemption | Exempt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346570","Investigational Medical Device","C72968","A device that is the subject of clinical investigation or research to determine the safety or effectiveness of the device. Investigational devices include transitional devices (21 CFR 812.3(r)) that are objects of investigations. An investigational device may be an approved device that is being studied for an unapproved use or efficacy.","Investigational Medical Device | Investigational Device | investigational device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348572","Study on Hold","C70755","A clinical study status designating that an order has been issued to a study sponsor to delay a proposed investigation or to suspend an ongoing one. When a proposed study is placed on clinical hold, subjects may not be given the investigational product as part of the study. When an ongoing study is placed on clinical hold, no new subjects may be recruited to the study and placed on the investigational product. Subjects already in the study have to stop receiving therapy involving the investigational agent unless the FDA specifically permits it.","Study on Hold | Clinical Hold | Study Suspended | Study on Hold Status | Study on-Hold | clinical hold (of a clinical trial)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516732","Community Clinical Oncology Program","C16097","The Community Clinical Oncology Program (CCOP) was established by the National Cancer Institute (NCI) in 1983. Through this program, community physicians work with scientists conducting NCI-supported clinical trials.","Community Clinical Oncology Program | CCOP | Community Oncology | Oncology Programs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347782","NIH Clinical Center","C62563","The research hospital for the NIH, the Federal Government's principal agency for biomedical research. The NIH Clinical Center is actually made up of two centers: the Warren Grant Magnuson Clinical Center and the Mark O. Hatfield Clinical Research Center. The Clinical Center as a whole promotes translational research, that is, the transformation of scientific laboratory research into applications that benefit patient health and medical care. At the Center, patient care units are in close proximity to cutting-edge technologies and laboratories doing related research. This 'bench-to-bedside' approach facilitates interaction and collaboration among clinicians and researchers. The Clinical Center supports clinical trials conducted by the 27 Institutes and Centers of the NIH, including the National Cancer Institute (NCI).","NIH Clinical Center | Clinical Center | Clinical Center",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513887","National Cancer Program","C18893","Plans and coordinates the national cancer research program, encompassing the programs of the National Cancer Institute, related programs of the other research institutes, and other Federal and non-Federal programs.","National Cancer Program | NCP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004933","Behavioral Intervention","C15184","The use of operant conditioning, including rewards and punishments, in helping a person create an atmosphere where he or she does not contribute to painful stimuli.","Behavioral Intervention | BEHAVIORAL THERAPY | Behavior Conditioning Therapy | Behavior Modification | Behavior Therapy | Behavior or Life Style Modifications | Behavioral Interventions | Behavioral Modification | Behavioral Therapy | Behavioral Treatment | Behavioral Treatments | behavior modification",,,,,,,,,,,,,,,"4040976","Behavioral therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2346846","Approved Protocol - clinical study status","C70745","Protocol is approved by the review board.","Approved Protocol | Approved | Approved Clinical Study Protocol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348555","Study Closed to Accrual","C70751","A clinical study status designating the study that stopped patient accrual; other study activities specified by the study protocol might continue.","Study Closed to Accrual | Closed to Accrual | Closed to Accrual Study Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348556","Study Closed to Accrual and Treatment","C70752","A clinical study status designating the study that stopped further patient accrual as well as the treatment of the subjects already enrolled in the trial.","Study Closed to Accrual and Treatment | Closed to Accrual and Treatment | Closed to Accrual and Treatment Study Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347711","Protocol Disapproved","C70748","A clinical study protocol review status designating the protocol that was denied the approval.","Protocol Disapproved | Disapproved | Study Protocol Disapproved",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005508","Biological Availability","C70913","The rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of action (21CFR320.1).","Bioavailability | Drug Bioavailability | bioavailability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448486","Pharmacodynamics","C15720","The study of the biochemical and physiological effects of drugs and the mechanisms of their actions, including the correlation of actions and effects of drugs with their chemical structure, also, such effects on the actions of a particular drug or drugs.","Pharmacodynamics | PD | pharmacodynamics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0222604","Male Breast","C33048","One of the two, usually rudimentary, mammary glands in the male.","Male Breast | ",,,,,,,,,,,,,,,"4238523","Male mammary gland structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227813","Corpus Uteri","C12316","The Corpus uteri, or body of uterus, is the part of the uterus above the isthmus, comprising about two thirds of the non-pregnant organ.","Corpus Uteri | CORPUS UTERI | Corpus | Corpus uteri | Uterine Body | Uterus, Corpus | body of uterus | corpus",,,,,,,,,,,,,,,"4034303","Body of uterus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023470","Myeloid Leukemia","C3172","A clonal proliferation of myeloid cells and their precursors in the bone marrow, peripheral blood, and spleen. When the proliferating cells are immature myeloid cells and myeloblasts, it is called acute myeloid leukemia. When the proliferating myeloid cells are neutrophils, it is called chronic myelogenous leukemia.","Myeloid Leukemia | LEUKEMIA, GRANULOCYTIC, MALIGNANT | Leukemia Granulocytic | Leukemia Myeloid | Myelocytic Leukemia | Myelogenous Leukemia | Myeloid leukemia, NOS | Non-Lymphoblastic Leukemia | Non-Lymphocytic Leukemia | Non-lymphoblastic Leukemia | Non-lymphocytic Leukemia","9860/3","Myeloid leukemia, NOS",,,,,,,,,,,,,"140666|37156272","Myeloid leukemia|Myeloid leukemia",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0017421","Female Genitalia","C61600","The external female sexual organs.","Female Genitalia | FEMALE GENITALIA",,,,,,,,,,,,,,,"4132420|4137062|4203155","Female genital organ structure|Female genital tract structure|Female genital structure",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C1512394","Hematopoietic and Lymphatic System","C41165","The bodily system of organs and tissues, primarily the bone marrow, spleen, tonsils, and lymph nodes, involved in the production of blood considered together with the interconnected system of spaces and vessels between body tissues and organs by which lymph circulates throughout the body.","Hematopoietic and Lymphatic System | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017422","Male Genitalia","C61599","The external male sexual organs.","Male Genitalia | MALE GENITALIA | Male Genital Organ | Male Genital Organs",,,,,,,,,,,,,,,"4133451|4232009","Male genital organ structure|Male genital structure",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1955975","National Institute on Alcohol Abuse and Alcoholism","C82603","An institute within the National Institutes of Health that provides leadership in the national effort to reduce alcohol-related problems.","National Institute on Alcohol Abuse and Alcoholism | NIAAA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1955974","National Institute on Aging (U.S.)","C82604","An institute within the National Institutes of Health that leads a broad scientific effort to understand the nature of aging and to extend the healthy, active years of life.","National Institute on Aging | NIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513895","National Institute of Allergy and Infectious Disease","C19753","An institute within the National Institutes of Health that conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases.","National Institute of Allergy and Infectious Disease | NIAID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035176","Research Support","C17090","This includes all types of grants, cooperative agreements, and research contracts that support research directly and for which individuals and/or projects have been peer-reviewed.","Research Funding | Research Support | Research Support",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1955976","National Institute of Arthritis and Musculoskeletal and Skin Diseases","C82605","An institute within the National Institutes of Health that supports research into the causes, treatment, and prevention of arthritis and musculoskeletal and skin diseases, the training of basic and clinical scientists to carry out this research, and the dissemination of information on research progress in these diseases.","National Institute of Arthritis and Musculoskeletal and Skin Diseases | NIAMS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513888","National Center for Complementary and Alternative Medicine","C19897","A center within the National Institutes of Health that acts as the Federal Government's lead agency for scientific research on the diverse medical and health care systems, practices, and products that are not generally considered part of conventional medicine.","National Center for Complementary and Alternative Medicine | NCCAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511999","Division of Basic Sciences","C19215","This division (1) plans, directs, coordinates and evaluates the Institute's intramural programs in basic science relating to cellular, molecular, genetic, biochemical and immunological mechanisms relevant to the understanding, diagnosis and treatment of cancer; (2) establishes program priorities, allocates resources, integrates the projects of the various laboratories, evaluates program effectiveness and represents the division in management and scientific decision-making meetings within the Institute; (3) identifies the need for and establishes new intramural research activities; (4) supports training and research opportunities in the basic sciences for young investigators; (5) supports the translational research by integrating and coordinating divisional research activities with other NCI divisions, with the institutes, centers and divisions within the NIH as well as with the private sector and the academic research community. (NCI)","Division of Basic Sciences | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512000","Division of Cancer Biology","C18748","The Division of Cancer Biology (DCB) was created by the reorganization of NCI in 1995, and has the principal Federal responsibility for managing a grant- and contract-supported program of basic and applied research on cancer cell biology, including research on carcinogenesis and cancer immunology. In addition to investigating basic cellular mechanisms, this research includes examination of the role of biological, chemical, and physical agents in the initiation, promotion or inhibition of cancer and the biological and health effects of exposures to ionizing and non-ionizing radiation.","Division of Cancer Biology | DCB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512004","Division of Cancer Treatment and Diagnosis","C18751","Improves the lives of the American public by discovering and conducting better ways to diagnose, assess, treat, and cure cancer through stimulating, coordinating, and funding a national program of cancer research.","Division of Cancer Treatment and Diagnosis | DCTD | Division of Cancer Treatment, Diagnosis and Center",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518562","Office of the Director","C19203","Office of the NCI Director serves as the focal point for the National Cancer Program; develops a National Cancer Plan and monitors implementation of the plan; directs and coordinates the Institute's programs and activities; and develops and provides policy guidance and staff direction to the Institute's programs in areas such as program coordination, program planning, clinical care and administrative management.","Office of the Director | NCI Director | NCI Office of the Director",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826326","Center for Information Technology","C82607","A center within the National Institutes of Health that provides, coordinates, and manages information technology, and advances computational science within NIH.","Center for Information Technology | CIT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1955978","National Institute on Deafness and Other Communication Disorders","C82608","An institute within the National Institutes of Health that is mandated to conduct and support biomedical and behavioral research and research training in the normal and disordered processes of hearing, balance, smell, taste, voice, speech, and language.","National Institute on Deafness and Other Communication Disorders | NIDCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513898","National Institute of Diabetes and Digestive and Kidney Diseases","C19756","An institute within the National Institutes of Health that conducts and supports much of the clinical research on the diseases of internal medicine and related subspecialty fields, as well as many basic science disciplines.","National Institute of Diabetes and Digestive and Kidney Diseases | NIDDK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1955977","National Institute of Biomedical Imaging and Bioengineering","C82609","An institute within the National Institutes of Health with the mission to improve health by leading the development and accelerating the application of biomedical technologies. The Institute is committed to integrating the physical and engineering sciences with the life sciences, to advance basic research and medical care.","National Institute of Biomedical Imaging and Bioengineering | NIBIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1955979","National Institute of Environmental Health Sciences","C82610","An institute within the National Institutes of Health with the mission to reduce the burden of human illness and disability by understanding how the environment influences the development and progression of human disease.","National Institute of Environmental Health Sciences | NIEHS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1955969","National Eye Institute","C82611","An institute within the National Institutes of Health with the mission to conduct and support research, training, health information dissemination, and other programs with respect to blinding eye diseases, visual disorders, mechanisms of visual function, preservation of sight, and the special health problems and requirements of the blind.","National Eye Institute | NEI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513900","National Institute of General Medical Sciences","C20131","The National Institute of General Medical Sciences (NIGMS) primarily supports basic biomedical research that is not targeted to specific diseases or disorders.","National Institute of General Medical Sciences | NIGMS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826328","Division of Blood Diseases and Resources","C82614","A division of the National Heart, Lung, and Blood Institute that supports research on the causes, prevention, and treatment of nonmalignant blood diseases, including anemias, sickle cell disease, and thalassemia; premalignant processes such as myelodysplasia and myeloproliferative disorders; hemophilia and other abnormalities of hemostasis and thrombosis; and immune dysfunction.","Division of Blood Diseases and Resources | DBDR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826329","Division of Epidemiology and Clinical Applications","C82615","A division of the National Eye Institute that has the mission to plan, develop, and conduct human population studies concerned with the cause, prevention, and treatment of eye disease and vision disorders, with emphasis on the major causes of blindness and visual impairment. They also carry out programs of education in biometric and epidemiologic principles and methods for the vision research community as well as providing biometric and epidemiologic assistance to National Eye Institute intramural and extramural staff and to vision research workers elsewhere.","Division of Epidemiology and Clinical Applications | DECA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513896","National Institute of Child Health and Human Development (U.S.)","C19754","An institute within the National Institutes of Health that conducts and supports research on all stages of human development from preconception to adulthood, to better understand the health of children, adults, families, and communities.","National Institute of Child Health and Human Development | NICHD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1955973","National Human Genome Research Institute","C82617","An institute within the National Institutes of Health (NIH) that led NIH's contribution to the International Human Genome Project. Since the completion of this project its mission has expanded to encompass a broad range of studies aimed at understanding the structure and function of the human genome and its role in health and disease. To that end it supports the development of resources and technology that will accelerate genome research and its application to human health. A critical part of its mission continues to be the study of the ethical, legal and social implications (ELSI) of genome research.","National Human Genome Research Institute | NHGRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512959","Intramural Research","C16103","Research that takes place on the NCI campus.","Intramural Research | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826331","Division of Lung Diseases","C82618","A division of the National Heart, Lung, and Blood Institute that leads a national program in the causes, diagnosis, treatment, and prevention of diseases of the heart, blood vessels, lungs, and blood; in sleep disorders; and in the uses of blood and blood resources.","Division of Lung Diseases | DLD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826332","Division of Cardiovascular Diseases","C82619","A division of the National Heart, Lung, and Blood Institute that provides leadership for a national and international extramural program in cardiovascular diseases that integrates basic science and clinical research, including translational research, networks, and multicenter clinical trials.","Division of Cardiovascular Diseases | Division of Heart and Vascular Diseases",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027470","National Library of Medicine (U.S.)","C82620","A division of the National Institutes of Health, it is the world's largest biomedical library. The Library is involved in development of electronic sevices.  Its mission is to enable biomedical research, support health care and public health, and promote healthy behavior.","National Library of Medicine | NLM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826334","NCMHD","C82622","An institute within the National Institutes of Health with the mission to promote minority health and to lead, coordinate, support, and assess the NIH effort to reduce and ultimately eliminate health disparities.","National Institute on Minority Health and Health Disparities | NCMHD | NIMHD | National Center on Minority Health and Health Disparities | National Center on Minority Health and Health Disparities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027466","National Institute of Mental Health","C16894","An institute within the National Institutes of Health with the mission to transform the understanding and treatment of mental illnesses through basic and clinical research, paving the way for prevention, recovery and cure.","National Institute of Mental Health | NIMH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826336","Blueprint for Neuroscience","C82626","A framework to enhance cooperative activities among the National Institutes of Health (NIH) Office of the Director and the NIH institutes and centers that support research on the nervous system. By pooling resources and expertise, the Blueprint takes advantage of economies of scale, confronts challenges too large for any single institute or center, and develops research tools and infrastructure that serve the entire neuroscience community.","Blueprint for Neuroscience | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513901","National Institute of Nursing Research","C19758","An institute within the National Institutes of Health with the mission to promote and improve the health of individuals, families, communities, and populations. It supports and conducts clinical and basic research and research training on health and illness across the lifespan.","National Institute of Nursing Research | NINR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2350584","National Institute of Neurological Disorders and Stroke","C82627","An institute within the National Institutes of Health with the mission to reduce the burden of neurological disease by conducting and funding research on brain and nervous system disorders.","National Institute of Neurological Disorders and Stroke | NINDS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826337","Offices of Research Facilities Development and Operations","C82628","An office within the National Institutes of Health that supports the organization's mission by providing, maintaining, and operating safe, healthy, and attractive facilities.","Offices of Research Facilities Development and Operations | Office of Research Facilities Development and Operations",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826338","Office of Logistics and Acquisition Operations","C82629","An office of the National Institutes of Health that acts as a central services organization for personal property, logistics and acquisition services.","Office of Logistics and Acquisition Operations | OLAO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826339","Office of Research Services","C82630","An office of the National Institutes of Health (NIH) that plans and directs service programs for public safety and security operations, scientific and regulatory support programs, and a wide variety of other program and employee services. It advises the NIH Deputy Director for Management and delivery of technical and administrative services in support of the NIH research mission.","Office of Research Services | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512001","Division of Cancer Control and Population Sciences","C19217","Conducts and supports an integrated program of the highest quality genetic, epidemiological, behavioral, social, applied, and surveillance cancer research.","Division of Cancer Control and Population Sciences | DCCPS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826340","NIH Roadmap for Medical Research","C82632","A program created to address roadblocks to research and to transform the way biomedical research is conducted by overcoming specific hurdles or filling defined knowledge gaps. These programs span all areas of health and disease research and boundaries of the National Institutes of Health (NIH) Institutes and Centers (ICs). These are programs that might not otherwise be supported by the NIH ICs because of their scope or because they are inherentlly risky.","NIH Roadmap for Medical Research | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513889","National Center for Research Resources","C20016","A center within the National Institutes of Health that provides laboratory scientists and clinical researchers with the tools and training they need to understand, detect, treat, and prevent a wide range of diseases.","National Center for Research Resources | NCRR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512005","Division of Clinical Sciences","C18752","Merged with the Division of Basic Sciences in January, 2001 to form the Center for Cancer Research","Division of Clinical Sciences | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826341","Superfund Basic Research Program","C82633","A program of the National Institute of Environmental Health Sciences to create a network of university grants that are designed to seek solutions to the complex health and environmental issues associated with the nations hazardous waste sites.","Superfund Basic Research Program | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826342","Fogarty International Center","C82634","The international component of the National Institutes of Health (NIH) dedicated to advancing the mission of NIH by supporting and facilitating global health research conducted by U.S. and international investigators, building partnerships between health research institutions in the U.S. and abroad, and training the next generation of scientists to address global health needs.","Fogarty International Center | FIC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2737276","Women's Health Initiative (WHI)","C82635","A major 15-year research program launched in 1991 to address the most common causes of death, disability and poor quality of life in postmenopausal women, focusing on cardiovascular disease, cancer, and osteoporosis.","Women's Health Initiative | WHI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826343","Worker Education Training Program","C82636","In conjunction with 20 awardees, this program supports the development of curricula and initiation of training programs throughout the country to help employers meet Occupational Safety and Health Administration (OSHA) requirements under CFR 1910.120, Hazardous Waste Operations & Emergency Response.","Worker Education Training Program | WETP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553389","Suspension","C49134","To stop a process by imposing a freeze on it.","Suspension | Suspended",,,,,,,,,,,,,,,"4295936","Suspended",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0150097","Crossover Study","C82637","A type of clinical study in which each study subject receives the same series of treatments but in a random order that differs across arms of the study. Each subject serves as their own control in this type of study.","Crossover Study | CROSS-OVER | CROSSOVER | crossover trial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826344","Factorial Study","C82638","A type of clinical study in which two or more treatments are given alone and in combination, such that all possible combinations are represented across the treatment arms, and are compared in parallel against the study control group.","Factorial Study | FACTORIAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826345","Parallel Study","C82639","A type of clinical study in which subjects are assigned to one of two treatment arms at the beginning of the trial and continue in that arm throughout the length of the trial. Study subjects are only exposed to the treatment that is assigned to the particular study arm they are enrolled in.","Parallel Study | PARALLEL | Parallel Trial | parallel design trial | parallel group trial | parallel trial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826346","Single Group Study","C82640","A type of clinical study in which there is only one treatment arm available to all study participants.","Single Group Study | SINGLE GROUP | Single Arm Study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826348","Invitation","C82643","A request (spoken or written) to participate, be present, or take part in something","Invitation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348570","Study Terminated","C70757","A clinical study status designating the study has been stopped prematurely and will not resume. Subject enrollment stopped. No participants are treated or being followed up.","Study Terminated | Study Terminated Status | Terminated | Terminated Study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348571","Study Withdrawn","C70758","A clinical study status designating the study that has been stopped prematurely: Subject enrollment never started.  Study will not resume.","Study Withdrawn | Study Withdrawn Status | Withdrawn | Withdrawn Study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347177","Active Comparator","C68609","A therapeutically active agent, treatment regimen or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","Active Comparator | Active Control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449009","Reject","C82650","Dismiss from consideration.","Reject | Rejected | Rejection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015744","Feedback - system communication","C82652","An evaluative response to an inquiry, process, event, or activity.","Feedback | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0681833","Basic Research","C15714","Fundamental research designed to obtain or increase general scientific knowledge.","Basic Research | BASIC SCIENCE | Basic Science | Basic Science Research | Basic Science Research",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348368","Early Detection Study","C71484","Clinical studies testing the efficacy of devices, techniques, procedures, or tests for earlier diagnosis of disease.","Early Detection Study | Early Detection Trial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0699910","Study of epidemiology","C15721","The study of human populations to identify causes of disease and factors determining and influencing the frequency and distribution of disease, injury, and other health related events.","Epidemiology Research | Epidemiologic Research | Epidemiologic Study | Epidemiologic Trial | Epidemiological Research | Epidemiological Study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018757","Health Services Research","C15245","A multidisciplinary field of inquiry that examines the costs, quality, accessibility, delivery, organization, and financing of health care services.","Health Services Research | HEALTH SERVICES RESEARCH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518527","Observational Study","C16084","Studies among cancer patients and healthy populations that involve no intervention or alteration in the status of the participants.","Observational Study | OBSERVATIONAL | Observational Trial | observational study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086750","Outcomes Research","C15365","The study of the end results of health services, with the intention of providing scientific evidence relating to the value of the decisions made by all who participate in the health care process.","Outcomes Research | Health Outcomes Research | outcomes research",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348164","Screening Study","C71485","Clinical studies testing the efficacy of devices, techniques, procedures, or tests for the purpose of detecting the presence of disease, usually before there are any symptoms.","Screening Study | SCREENING | Screening Trial | screening trials",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348611","Supportive Care Study","C71486","Clinical studies intended to improve the comfort and quality of life for the patient using drugs, nutritional, dietary, behavioral or other interventions.","Supportive Care Study | SUPPORTIVE CARE | Supportive Care Trial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883202","Subinvestigator","C54622","Any individual member of the clinical trial team designated and supervised by the investigator at a trial site to perform critical trial-related procedures and/or to make important trial-related decisions (e.g., associates, residents, research fellows).","Subinvestigator | SUBINVESTIGATOR | sub-investigator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2911692","Response (communication)","C82658","A statement (either spoken or written) that is made in reply to a question, request, criticism, or accusation.","Communication Response | Response | Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517317","French Southern and Antarctic Lands","C20105","A group of islands in the southern Indian Ocean, southeast of Africa, about equidistant between Africa, Antarctica, and Australia.","French Southern and Antarctic Lands | 260 | ATF | FRENCH SOUTHERN AND ANTARCTIC LANDS | FRENCH SOUTHERN TERRITORIES | French Southern Territories | French Southern Territories | TF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709013","Metropolitan France","C47871","The part of France situated in Western Europe, including Corsica, as opposed to the overseas departments and territories of the French Republic. Metropolitan France extends from the Mediterranean Sea to the North Sea and from the Rhine River to the Atlantic Ocean.","Metropolitan France | FX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023034","Lao People's Democratic Republic","C16780","A country in southeastern Asia, north and east of Thailand, west of Vietnam.","Lao People's Democratic Republic | 418 | LA | LAO | LAO PEOPLE'S DEMOCRATIC REPUBLIC | LAOS | Laos",,,,,,,,,,,,,,,"4329583","Laos",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031995","Pitcairn","C16993","A country in the Pacific, comprised of islands in the South Pacific Ocean, about midway between Peru and New Zealand, southeast of French Polynesia.","Pitcairn | 612 | PCN | PITCAIRN | PITCAIRN ISLANDS | PN | Pitcairn Island",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519796","United States Minor Outlying Islands","C20112","The U.S. Minor Outlying Islands consist of Baker Island, Howland Island, Jarvis Island, Johnston Atoll, Kingman Reef, Midway Island, Navassa Island, Palmyra Atoll, and Wake Island (Wake Atoll).","United States Minor Outlying Islands | UMI | UNITED STATES MINOR OUTLYING ISLANDS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043444","Congo, the Democratic Republic of the","C17266","A country in central Africa, northeast of Angola.","Congo, the Democratic Republic of the | 180 | CD | COD | CONGO (KINSHASA) | CONGO, THE DEMOCRATIC REPUBLIC OF | DEMOCRATIC REPUBLIC OF THE CONGO | Democratic Republic of the Congo | Zaire",,,,,,,,,,,,,,,"4073742","Democratic Republic of the Congo",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1513841","NIH Center for Scientific Review","C19764","Provides staff support to the Office of the Director, NIH, in the formulation of grant application review policies and procedures. In addition, CSR provides central receipt of all PHS applications for research and review.","NIH Center for Scientific Review | CSR | Center for Scientific Review | Division of Research Grants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010362","Cross-Sectional Study","C53310","A study in which participants are examined once for a characteristic, such as disease, at a single point in time.","Cross-Sectional Study | CROSS SECTIONAL | cross-sectional study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023981","Longitudinal Study","C15273","A study in which participants are followed and repeatedly evaluated over a period of time.","Longitudinal Study | PROSPECTIVE | longitudinal study | prospective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035363","Retrospective Studies","C53312","A study in which participants with known outcomes are assessed based on data collected before the study.","Retrospective Study | RETROSPECTIVE | retrospective study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026376","Molecular Biology","C16872","The study of biology at a molecular level. It chiefly concerns itself with understanding the interactions between the various systems of a cell, including the interrelationship of DNA, RNA and protein synthesis and learning how these interactions are regulated. The field overlaps with other areas of biology, particularly genetics and biochemistry.","Molecular Biology | DNA Molecular Biology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448487","Cell Biology","C17992","The study of the internal workings of cells at the microscopic and molecular level.","Cell Biology | Cellular Biology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516188","Cancer Control","C15971","Integrated program having an objective of reducing risk, incidence, and mortality from cancer and to enhancing the quality of life for cancer survivors. Realized through an orderly sequence of measures from genetic, epidemiologic, behavioral, social, applied, and surveillance cancer research to the development and implementation of effective interventions, and monitor and analysis of cancer trends in all segments of the population.","Cancer Control | Cancer Control Science",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281206","Cancer Prevention","C15669","All methods of preventing cancer including limit of exposure to carcinogens and infectious agents, diet, education, etc","Cancer Prevention | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014507","Epidemiology","C16556","The study of the causes, incidence and distribution of disease in the population and its application for prevention or control.","Epidemiology | Epidemiologic | Epidemiological | epidemiology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522647","Developmental Therapeutics Program","C16009","As the drug discovery and development arm of the National Cancer Institute, the Developmental Therapeutics Program (DTP) plans, conducts, and facilitates development of therapeutic agents for cancer and AIDS.  They are a resource for research materials, including Web-accessible data and tools, vialed and plated compounds, tumor cells, animals, and Investigational New Drug (IND)-directed studies.  (DTP web site)","Developmental Therapeutics Program | DTP | Developmental Therapeutics | Developmental Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0080339","Women's health occupation","C17399","Many diseases and disorders affect men and women differently.  Some predominantly effect one or the other while others take different clinical courses, with differing prognoses and outcomes.  Women's health takes a specific focus on the health and wellbeing of women.","Women's Health | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1155872","Cell Cycle Regulation Process","C19598","Control of the rate or manner of the periodic biochemical and structural events occurring during proliferation of cells; the cycle is divided into periods called: G0, Gap1 (G1), synthesis (S1), Gap2 (G2), and mitosis (M). The period runs from one division to the next.","Cell Cycle Regulation Process | Cell Cycle Control | Cell Cycle Regulation | Cell Cycle Regulation | Cell Cycle Regulation, Including Apoptosis | cell-cycle regulation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596286","Cell Growth Regulation","C18080","Cell growth regulation controls the rate, or the mechanism, of complex coordinated cellular phenomena that promote cell metabolism, cell growth, and cell division.","Cell Growth Regulation | Cellular Regulation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826361","Cancer Diagnosis Program","C82662","A program within the National Cancer Institute that stimulates and supports diagnostics research, resources and improved technologies to guide the choice of treatment for cancer patients.","Cancer Diagnosis Program | CDP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512006","Division of Extramural Activities","C18753","A division within the National Cancer Institute that coordinates the scientific review of extramural research for consideration of funding, and provides systematic surveillance after awards are made.","Division of Extramural Activities | DEA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826364","Radiation Research Program","C82665","A program within the National Cancer Institute (NCI) that is responsible for the clinically-related extramural radiation research program. It establishes priorities, allocates resources, and evaluates the effectiveness of such radiation research being conducted by NCI grantees.","Radiation Research Program | RRP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826365","Translational Research Program","C82666","A program within the National Cancer Institute designed to integrate scientific advancements in the understanding of the biology of human cancer, with the development of new interventions for the prevention, diagnosis, and treatment of cancer, or populations at risk for cancer. This is accomplished by fostering broad interdisciplinary investigations that focus on bringing discoveries from the laboratory to the clinic, and coordinating resources of the National Cancer Institute with those of academia, industry, and non-profit organizations/foundations.","Translational Research Program | TRP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826366","Investigational Device Exemption","C82667","Allows an investigational device to be used in a clinical study in order to collect safety and effectiveness data required to support a Premarket Approval application or a Premarket Notification submission to the Food and Drug Administration.","Investigational Device Exemption | IDE | Investigational Device Exemption (IDE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826367","Center for Biologics Evaluation and Research","C82668","The center within the Food and Drug Administration that regulates biological products for human use under applicable federal laws. It protects and advances the public health by ensuring that biological products are safe and effective and available to those who need them. It also provides the public with information to promote the safe and appropriate use of biological products.","Center for Biologics Evaluation and Research | CBER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826368","Center for Drug Evaluation and Research","C82669","The center within the Food and Drug Administration that assures the safety and effectiveness of drugs that are made available to improve the health of people in the United States. It regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs.","Center for Drug Evaluation and Research | CDER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826369","Center for Devices and Radiological Health","C82670","The Center within the Food and Drug Administration that is responsible for regulating firms who manufacture, repackage, relabel, and/or import medical devices sold in the United States. In addition, it regulates radiation-emitting electronic products (medical and non-medical) such as lasers, x-ray systems, ultrasound equipment, microwave ovens and color televisions.","Center for Devices and Radiological Health | CDRH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0681876","Population Study (research activity)","C15716","Multidisciplinary study done at the population level or among the population groups, generally to find the cause, incidence or spread of the disease or to see the response to the treatment, nutrition or environment.","Population Study | Population Based Study | ecologic study | ecological study | population study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0199236","Family Study","C15407","Research conducted on related or non-related members of families, examining the affects of genetics, the environment, or twin offspring.","Family Study | FAMILY BASED | Familial Study | Family Based Study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031928","Pilot Study","C15303","The initial study examining a new method or treatment.","Pilot Study | Pilot | pilot study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347366","Nonrandom Sampling","C71502","Any method of selecting a sample in which cases are not chosen by random sampling.","Nonrandom Sampling | Nonprobability Sampling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0150105","Random Sampling","C53194","A method of selecting a sample from a population in such a way that every sample that could be selected has an equal chance of being selected.","Random Sampling | Probabilty Sampling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514878","Research Facilities Construction Grants","C20018","Support to expand, remodel, renovate, or alter biomedical or behavioral research facilities.","Research Facilities Construction Grants | C06 Mechanism | C06 Program",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514387","Predoctoral Individual National Research Service Award","C20002","Provides support for promising doctoral candidates who will be performing dissertation research and training in scientific health-related fields relevant to the missions of the participating NIH Institutes during the tenure of the award. It is also used to improve the diversity of the health-related research workforce by supporting the training of predoctoral students from groups that have been shown to be underrepresented.","Predoctoral Individual National Research Service Award | F31 Award | Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514255","Postdoctoral Individual National Research Service Award","C20001","To provide support to promising Fellowship Applicants with the potential to become productive, independent investigators in scientific health-related research fields relevant to the missions of participating NIH Institutes and Centers.","Postdoctoral Individual National Research Service Award | F32 Award | NRSA Individual Postdoctoral Fellowships (F32)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513903","National Research Service Award for Senior Fellows","C19497","To provide senior fellowship support to established scientists who wish to make major changes in the direction of their research careers or who wish to broaden their scientific background by acquiring new research capabilities as independent research investigators in scientific health-related fields relevant to the missions of the NCI. This award is designed for sabbatical periods.","National Research Service Award for Senior Fellows | F33 Award | Senior Fellowships (F33) | Senior Scholarship Award | Senior Scholarship Award (F33)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513132","Mentored Research Scientist Development Award","C20005","To provide support for a transition period between postdoctoral training and an independent research career.","Mentored Research Scientist Development Award | K01 Award | K01 Mechanism | K01 Program | Mentored Training Award | Research Scientist Development Award",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512700","Independent Scientist Award","C19270","The Independent Scientist Award (ISA) (K02) provides support for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers.  This award is intended to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research.","Independent Scientist Award | ISA | K02 Award",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514883","Senior Scientist Research and Mentorship Award","C20006","Intended to provide protected time for outstanding senior scientists who have demonstrated a sustained high level of productivity conducting biomedical research relevant to the scientific mission of the appropriate institute to focus on their research and to provide mentoring of new investigators.","Senior Scientist Research and Mentorship Award | K05 Mechanism | K05 Program | Research Scientist Award",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510752","Academic/Teacher Award","C20009","To create and encourage a stimulating approach to disease curricula that will attract high quality students, foster academic career development of promising young teacher-investigators, develop and implement excellent multidisciplinary curricula through interchange of ideas and enable grantee institution to strengthen its existing teaching program.","Academic/Teacher Award | K07 Mechanism | K07 Program",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516614","Clinical Investigator Award (CIA)","C20010","Provides support and time for an intensive, supervised research career development experience to individuals with a clinical doctoral degree who are committed to a career in laboratory or clinically-based research.","Clinical Investigator Award (CIA) | Clinical Investigator Award | K08 Mechanism | K08 Program",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519074","Physician Scientist Award (Program) (PSA)","C20007","Designed to take individuals with clinical degrees and give them experience in clinical research.","Physician Scientist Award (Program) (PSA) | K12 Mechanism | K12 Program | Mentored Clinical Scientist Development Program",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516298","Career Transition Award","C20008","The purpose of the NCI Transition Career Development Award (K22) is to provide 'protected time' for newly independent investigators to develop and receive support for their initial cancer research programs.  This award is intended to facilitate the transition of investigators from the mentored to the independent stage of their careers in cancer research.  It applies to clinicians who are pursuing basic science careers; clinicians who are pursuing careers in patient-oriented research; and to individuals pursuing careers in the prevention, control and population sciences.","Career Transition Award | K22 Mechanism | K22 Program",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513131","Mentored Patient-Oriented Research Career Development Award","C19763","To support the career development of investigators who have made a commitment to focus their research endeavors on patient-oriented research.  This mechanism provides support for supervised study and research for clinically trained professionals who have the potential to develop into productive, clinical investigators focusing on patient-oriented research.","Mentored Patient-Oriented Research Career Development Award | K23 Award | K23 Mechanism | K23 Program | Mentored Patient-Oriented Research Career Development Award (K23)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513289","Midcareer Investigator Award in Patient-Oriented Research","C19769","To provide support to mid-career health-professional doctorates or equivalent who are typically at the Associate Professor level or the equivalent for protected time to devote to patient-oriented research and to act as research mentors primarily for clinical residents, clinical fellows and/or junior clinical faculty.","Midcareer Investigator Award in Patient-Oriented Research | K24 Mechanism | K24 Program | Midcareer Investigator Award in Patient-Oriented Research (K24)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516628","Clinical Research Curriculum Award (CRCA)","C19704","An institutional-level award designed to improve the quality of training in clinical research, attract talented individuals to the challenges of clinical research, and to provide them with the critical skills that are needed to translate basic discoveries into clinical treatments.","Clinical Research Curriculum Award (CRCA) | K30 Mechanism | K30 Program",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514476","Program Research Project Grants","C18922","The program project grant is an institutional award made in the name of a program director for the support of a broadly based, long-term, multidisciplinary research program that has a well-defined central theme, research focus, or objective. The grant funds at least three interrelated projects and, often, core resources that support at least three projects at all times. Interrelationships and synergism among component research projects should result in greater scientific contributions than if each project were supported through a separate mechanism. The grant is based on the concept that projects closely related to a central theme can be conducted more effectively and efficiently through a coordinated, collaborative, multidisciplinary approach.","Program Research Project Grants | P01 Mechanism | P01 Program | Program Project Grant | Research Program Projects",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519441","Specialized Center Grant","C20019","Support all aspects of R&D from basic to clinical and may involve ancillary support activities such as patient care. They differ from program project grants in that they are usually developed in response to an institute initiative and subsequently receive continuous attention from its staff. Centers also may serve as regional or national resources for special research.","Specialized Center Grant | P50 Mechanism | P50 Program | Specialized Center",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0260206","Research Projects, R-Series","C19289","A financial assistance mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.","Research Projects, R-Series | R01 Mechanism | R01 Program | RPG | Research Grants | Research Project Grants | Research Project Grants | Research Projects",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510751","Academic Research Enhancement Awards","C18635","The three goals of the AREA program are: to support meritorious research, to strengthen the research environment of the institution, and to expose students to research. The focus is not on course work but on hands-on meritorious research.","Academic Research Enhancement Awards (Area) | AREA | Academic Research Enhancement Awards | R15 Mechanism | R15 Program",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517019","Exploratory/Developmental Grant","C20012","The objective of this Exploratory/Developmental Grant (R21) mechanism is to encourage applications for one-time grants to support: 1) innovative research directions requiring preliminary testing or development; 2) exploration of the use of approaches and concepts new to a particular substantive area; 3) research and development of new technologies, techniques or methods; or 4) initial research and development of a body of data upon which significant future research may be built, i.e., the data should have a high level of impact on the field.","Exploratory/Developmental Grant | R21 Mechanism | R21 Program",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512169","Education Projects","C20015","Used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.","Education Projects | R25 Mechanism | R25 Program",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517020","Exploratory/Developmental Grants Phase II","C20013","The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism.","Exploratory/Developmental Grants Phase II | R33 Mechanism | R33 Program",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519365","Small Business Innovation Research Grant","C19022","R43/44. grant type for Small Business Innovation Research","Small Business Innovation Research Grant | SBIR | SBIRS (R43/44) | Small Business Innovation Research",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517618","James A. Shannon Director's Award","C19616","An award to provide limited support to scientists whose research applications fall short of the institute/center funding cutoff but are at the margin of funding in which high quality grants are not awarded due to lack of funds.","James A. Shannon Director's Award | R55 Mechanism | R55 Program | Shannon Awards",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512801","Institutional National Research Service Award","C18854","National Research Service Award (NRSA) institutional training grants (T32) enable eligible institutions to develop or enhance predoctoral and postdoctoral research training opportunities for individuals, selected by the institution, who are training for careers in specified shortage areas of biomedical and behavioral research. The purpose of the NRSA program is to help ensure that highly trained scientists are available in adequate numbers and in the appropriate research areas and fields to carry out the nation's biomedical and behavioral research agenda. (National Research Service Award Institutional Research Training Grants, NIH Guide, Volume 23, Number 21, June 3, 1994)","Institutional National Research Service Award | Institutional Award | T32 Mechanism | T32 Program",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1548793","Specimen Condition -frozen","C70717","A specimen that has been subjected to and immobilized by severe cold.","Frozen Specimen | FROZEN | Frozen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0200966","Gram Staining Method","C23014","This is a method (named after the Danish bacteriologist, Hans Christian Gram) for staining and identifying bacteria. It is based on the differential retention of a crystal violet-iodine complex within the cell membrane. Gram-positive organisms will appear blue-black or purple while Gram-negative organisms will appear red.","Gram Staining Method | GRAM STAIN | Gram Staining",,,,,,,,,,,,,,,"4266852|45769414","Gram stain method|Gram stain",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1332607","Brain Sarcoma","C5154","A sarcoma arising from the brain.","Brain Sarcoma | Intracranial Sarcoma | Primary Brain Sarcoma | Primary Intracranial Sarcoma | Sarcoma of Brain | Sarcoma of the Brain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827414","Extraneural","C84369","Situated or occurring outside the nerve or nerves.","Extraneural | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827415","Radioactive Instillation","C84370","Implantation of radioactive material in an internal anatomic site.","Radioactive Instillation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019421","Heterosexuality","C84362","A sexual attraction to members of the opposite sex.","Heterosexuality | Hetero | Heterosexual | STRAIGHT OR HETEROSEXUAL | Straight",,,,,,,,,,,,,,,"4069091","Heterosexual",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827413","Men who have Sex with Men","C84365","Men who engage in sexual activity with other men, regardless of how they identify themselves.","Men who have Sex with Men | MSM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242566","Intravenous Drug User","C84367","A person who injects recreational drugs.","Intravenous Drug User | IDU",,,,,,,,,,,,,,,"4042893","Intravenous drug user",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022526","Karyotyping","C16768","The preparation, analysis, and interpretation of a karyotype, the representation of the chromosome set of a cell.","Karyotyping | Genetics, Karyotyping | KARYOTYPING | Karotype Analysis | Karyotype",,,,,,,,,,,,,,,"4196111","Karyotype determination",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029965","Ovulation","C66849","The discharge of a secondary oocyte from a vesicular follicle of the ovary.","Ovulation | Release of Egg | ovulation",,,,,,,,,,,,,,,"4144404","Ovulation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007117","Skin Basal Cell Carcinoma","C2921","The most frequently seen skin cancer. It arises from basal cells of the epidermis and pilosebaceous units. Clinically it is divided into the following types: nodular, ulcerative, superficial, multicentric, erythematous, and sclerosing or morphea-like. More than 95% of these carcinomas occur in patients over 40. They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck and the remaining 15% on the trunk and extremities. Basal cell carcinoma usually grows in a slow and indolent fashion. However, if untreated, the tumor may invade the subcutaneous fat, skeletal muscle and bone. Distant metastases are rare. Excision, curettage and irradiation cure most basal cell carcinomas.","Skin Basal Cell Carcinoma | BCC | Basal Cell Cancer | Basal Cell Carcinoma | Basal Cell Carcinoma of Skin | Basal Cell Carcinoma of the Skin | Basal Cell Epithelioma | Basal Cell Skin Carcinoma | Basal cell carcinoma | Basal cell epithelioma | Skin Basal Cell Cancer | basal cell cancer | basal cell carcinoma",,,,,,,,,,,,,,,"4028320|4112752","Basal cell carcinoma|Basal cell carcinoma of skin",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0034052","Pulmonary Artery","C12774","Either one of two arteries arising from the pulmonary trunk that carry deoxygenated blood to the lungs.","Pulmonary Artery | ARTERY, PULMONARY | PULMONARY ARTERY BRANCH | Pulmonary artery structure (body structure)",,,,,,,,,,,,,,,"4215757","Pulmonary artery structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034090","Pulmonary Vein","C12776","One of four veins that carries oxygen-rich blood from the lungs to the cardiac left atrium.","Pulmonary Vein | PULMONARY VEIN | VEIN, PULMONARY",,,,,,,,,,,,,,,"4046592","Structure of vein of pulmonary circulation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332256","Contain","C79873","Include or hold; have within or as a component.","Contain | Comprise | Contained | Containing | Contains",,,,,,,,,,,,,,,"4175355","Containing",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206677","Adenomatous Polyp","C3764","A polypoid neoplasm that arises from the glandular epithelium of the gastrointestinal tract. There is a proliferation of glandular cells that may display dysplastic cytologic features. Representative examples include the adenomatous polyps of the colon and rectum.","Adenomatous Polyp | Adenomatous polyp, NOS | GI Tract Adenomatous Polyp | Gastrointestinal Tract Adenomatous Polyp | Polypoid Adenoma | Polypoid adenoma","8210/0","Adenomatous polyp, NOS",,,,,,,,,,,,,"4219051","Adenomatous polyp",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C2827441","Exemplary Quality","C84422","Indicates a biomedical image that is of best quality, most adequate for diagnostic purposes or for publication.","Exemplary Quality | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827442","Diagnostic Quality","C84423","Indicates a biomedical image that is of acceptable quality, with no technical defect likely to impair using the image for diagnosis.","Diagnostic Quality | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827444","Limited Quality","C84425","Indicates a biomedical image that is of acceptable quality, with some technical defect but still adequate for diagnostic purposes.","Limited Quality | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827445","Non-diagnostic Quality","C84426","Indicates a biomedical image that is unacceptable for diagnostic purposes.","Non-diagnostic Quality | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041341","Tuberous Sclerosis","C3424","Hereditary disease characterized by seizures, mental retardation, developmental delay, and skin and ocular lesions. First signs usually occur during infancy or childhood but in rare cases may not occur until 2nd or 3rd decade.","Tuberous Sclerosis | Bourneville's Disease | TSC | Tuberous Sclerosis Complex | Tuberous Sclerosis Syndrome | Tuberous sclerosis | tuberous sclerosis",,,,,,,,,,,,,,,"380839","Tuberous sclerosis syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027832","Neurofibromatosis Type 2","C3274","An autosomal dominant disorder caused by mutations in the NF2 tumor suppressor gene.  It is characterized by the development of peripheral and central nervous system tumors including acoustic schwannomas, neurofibromas, gliomas, and meningiomas.","Neurofibromatosis Type 2 | Acoustic Neurofibromatosis | Bilateral Acoustic Neurofibromatosis | Central Neurofibromatosis | NF2 | Neurofibromatosis 2 | acoustic neurofibromatosis | neurofibromatosis type 2",,,,,,,,,,,,,,,"380975","Neurofibromatosis type 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027831","Neurofibromatosis Type 1","C3273","The most common type of neurofibromatosis.  It is characterized clinically by cutaneous and subcutaneous tumors with patches of hyperpigmentation. The hyperpigmented skin areas, are present from birth and found anywhere on the body surface.  They can vary markedly in size and color.  The dark brown areas are called cafe-au-lait spots. The multiple cutaneous and subcutaneous tumors are nerve sheath tumors, called neurofibromas.  They can develop anywhere along the peripheral nerve fibers. Neurofibromas can become quite large, causing a major disfigurement, eroding bone, and compressing various peripheral nerve structures.  Type 1 neurofibromatosis has dominant inheritance, with a gene locus on the proximal long arm of chromosome 17.","Neurofibromatosis Type 1 | NF1 | Neurofibromatosis | Neurofibromatosis 1 | Neurofibromatosis Type 1 Microdeletion Syndrome | Peripheral Neurofibromatosis | Recklinghausen disease | Von Recklinghausen Disease | Von Recklinghausen disease | neurofibromatosis type 1",,,,,,,,,,,,,,,"377252","Neurofibromatosis type 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038505","Sturge-Weber Syndrome","C3391","A congenital disorder caused by mutation in the GNAQ gene. It is characterized by the presence of a port-wine nevus birthmark on one or both sides of the face. Additional clinical manifestations may include seizures, leptomeningeal angiomas, glaucoma, progressive hemiparesis, and cognitive deficits.","Sturge-Weber Syndrome | Encephalotrigeminal Syndrome | SWS | Sturge-Weber Disease | Sturge-Weber syndrome",,,,,,,,,,,,,,,"4057962","Sturge-Weber syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019562","Von Hippel Lindau Syndrome","C3105","An inherited familial cancer syndrome which is characterized by development of capillary hemangioblastomas of the central nervous system and retina; clear cell renal carcinoma; pheochromocytoma; pancreatic tumors; and inner ear tumors. The syndrome is associated with germline mutations of the VHL tumor suppressor gene, located on chromosome 3p25-26. Symptoms of VHL syndrome may not be apparent until the third decade of life. CNS hemangioblastoma is the most common cause of death, followed by clear cell renal cell carcinoma. --2004","Von Hippel Lindau Syndrome | Cerebroretinal Angiomatosis | VHL syndrome | Von Hippel-Lindau Disease | Von Hippel-Lindau Syndrome | Von Hippel-Lindau Syndrome | Von Hippel-Lindau Syndrome (VHL) | von Hippel-Lindau syndrome",,,,,,,,,,,,,,,"4263213","Von Hippel-Lindau syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1514475","Prognostic Marker","C20069","Genes and proteins for which the expression or presence of can help predict the course and outcome of a disease.","Prognostic Marker | Molecular Marker of Prognosis | Prognosis Marker",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206743","Rhabdoid Tumor","C3808","An aggressive malignant embryonal neoplasm usually occurring during childhood.  It is characterized by the presence of large cells with abundant cytoplasm, large eccentric nucleus, and a prominent nucleolus and it is associated with abnormalities of chromosome 22.  It can arise from the central nervous system, kidney, and the soft tissues.  The prognosis is poor.","Rhabdoid Tumor | Rhabdoid Sarcoma | Rhabdoid sarcoma | Rhabdoid tumor, NOS | rhabdoid tumor",,,,,,,,,,,,,,,"4307938","Malignant rhabdoid tumor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0559458","Central Nervous System Neuroblastoma",,,,,,,,,,,,,,,,,,"37118768|4083496","Neuroblastoma of central nervous system|Neuroblastoma of brain",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1384403","Cellular Ependymoma","C4713","An ependymoma which shows conspicuous cellularity without a significant increase in mitotic rate. (Adapted from WHO)","Cellular Ependymoma | Cellular ependymoma",,,,,,,,,,,,,,,"40455015","Cellular ependymoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0677866","Brain Stem Neoplasm","C4869","A benign or malignant neoplasm that affects the brain stem.","Brain Stem Neoplasm | Brain Stem Tumor | Brainstem Neoplasm | Brainstem Tumor | Neoplasm of Brain Stem | Neoplasm of Brainstem | Neoplasm of the Brain Stem | Neoplasm of the Brainstem | Tumor of Brain Stem | Tumor of Brainstem | Tumor of the Brain Stem | Tumor of the Brainstem | brain stem tumor",,,,,,,,,,,,,,,"4131104","Neoplasm of brain stem",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0580822","Aggressive","C14138","Describes a tumor or condition that develops, grows, or spreads rapidly.","Aggressive | Aggression | aggressive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034789","Surface Immunoglobulin","C573","Immunoglobulin containing a transmembrane region and expressed on the plasma membrane of a B cell.  Contrast with secreted Ig which has no transmembrane region but which can still be bound to the cell surface via Fc receptors.","Surface Immunoglobulin | Immunoglobulin, Surface | Surface Ig | sIg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881181","Incorrect Interpretation of Signal","C63086","Problem with the device inappropriately analyzing a signal.","Incorrect Interpretation of Signal | Incorrect Interpretation of Rhythm Medical Device Problem | Radiolucency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881180","Inadequate Instructions for Healthcare Professional","C63087","Problem associated with inaccuracies in any written, printed, or graphic matter that is affixed to the device or its packaging with any matter that accompanies the device including verbal instructions related to identification, technical description and use of the device provided by the device manufacturers that is intended for healthcare professionals.","Inadequate Instructions for Healthcare Professional | Incorrect Instruction for Medical Device Use | Pulp Chamber",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334953","Neuroblastic Tumor","C6963","A group of nervous system tumors which display neuronal differentiation.  It includes tumors that are composed of immature round cells and tumors that display advanced differentiation and the formation of ganglion cells.","Neuroblastic Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017075","Ganglioneuroma","C3049","A benign neuroblastic tumor of the sympathetic nervous system that occurs in childhood. Ganglioneuroma typically arises from the sympathetic trunk in the mediastinum. Histologic features include spindle cell proliferation (resembling a neurofibroma) and the presence of large ganglion cells. Common presenting features include a palpable abdominal mass, hepatomegaly, and a thoracic mass detected on routine chest X-ray.","Ganglioneuroma | GANGLIONEUROMA, BENIGN | Ganglioneuroma (Schwannian Stroma-Dominant) | Neural Crest Tumor, Benign","9490/0","Ganglioneuroma",,,,,,,,,,,,,"37016148|4207199","Ganglioneuroma|Ganglioneuroma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1333355","ERCC1 Gene","C20554","This gene is involved in nucleotide excision repair.","ERCC1 Gene | ERCC Excision Repair 1, Endonuclease Non-Catalytic Subunit Gene | ERCC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1817756","Immune System Process","C17937","Any multicellular process of immune cells effecting or involved with the immune response or immune maintenance. (NCI)","Immune System Process | Immune Function | Immune Function | Immune Function, Multicellular | Multicellular Immune Function | immune function",,,,,,,,,,,,,,,"4025357","Immunologic function",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014609","Epithelium","C12710","The avascular cellular layers that cover body surfaces and cavities and may form glands.","Epithelium | epithelium",,,,,,,,,,,,,,,"4135211","Epithelium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031765","Phototherapy","C15301","The treatment of a disorder by exposure to light, including ultraviolet and infrared radiation. (Bartleby.com)","Phototherapy | Actinotherapy | Bright Light Therapy | PHOTOTHERAPY | light therapy | phototherapy",,,,,,,,,,,,,,,"4151902","Light therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1880266","Defense","C61556","Protection from harm.","Defense | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827466","Central Site","C84471","An organizational unit or facility responsible for the coordination and/or management oversight of activities that occur at secondary or contributing organizational units engaged in the same research activities.","Central Site | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827569","Lung Squamous Dysplasia","C84971","A morphologic finding indicating the presence of dysplasia in the bronchial squamous epithelium. It is precursor of lung squamous cell carcinoma.","Lung Squamous Dysplasia | Angiogenic Squamous Dysplasia | Angiogenic Squamous Dysplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205242","Cleft","C61510","A split or indentation in something.","Cleft | CLEFT",,,,,,,,,,,,,,,"4236899","Cleaved",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033105","Statistical Prevalence","C17010","The ratio (for a given time period) of the number of occurrences of a disease or event to the number of units at risk in the population.","Prevalence | PREVALENCE | prevalence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449072","Dry","C80399","The act of removing moisture from something.","Dry | Desiccate | Desiccation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887638","Infant Failure to Thrive","C85038","A clinical finding indicating less than normal growth in infancy.","Infant Failure to Thrive | Failure to Thrive | Failure to Thrive | Failure to Thrive in Infant",,,,,,,,,,,,,,,"4200326","Failure to thrive in infant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1562630","Ectopia","C65199","Abnormal position of a part or organ.","Ectopia | Ectopic",,,,,,,,,,,,,,,"4166114","Congenital ectopia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202071","Homovanillic Acid Measurement","C74863","The determination of the amount of homovanillic acid metabolite present in a sample.","Homovanillic Acid Measurement | HVA | Homovanillic Acid",,,,,,,,,,,,,,,"4281996","Homovanillic acid measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2343585","Methylnaltrexone Bromide","C80569","The bromide salt form of methylnaltrexone, a methyl derivative of noroxymorphone with selective, peripherally-acting mu-opioid receptor antagonistic activity. Methylnaltrexone displaces opioids from peripheral opioid receptors in the gastrointestinal tract, the bladder, and the skin, thereby reversing the opioid-related peripheral side-effects, such as constipation, urinary retention, and pruritis, respectively. Unlike naltrexone and due to the presence of a positively charged nitrogen atom in methylnaltrexone, this agent does not cross the blood-brain barrier and does not affect the centrally-mediated analgesic effect of opioids.","Methylnaltrexone Bromide | METHYLNALTREXONE BROMIDE | Relistor | methylnaltrexone bromide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700151","Vanillyl Mandelic Acid Measurement","C74875","The determination of the amount of vanillyl mandelic acid metabolite present in a sample.","Vanillyl Mandelic Acid Measurement | VMA | Vanillyl Mandelic Acid | Vanillylmandelate | Vanilmandelic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537048","Trisomy 18","C36626","A chromosomal abnormality consisting of the presence of a third copy of chromosome 18 in somatic cells.","Trisomy 18 | Trisomy-18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027773","Nesidioblastosis","C4375","A sporadic or inherited disorder characterized by the focal or diffuse proliferation of the cells of the islets of Langerhans in the pancreas. It results in hyperinsulinemia and hypoglycemia.","Nesidioblastosis | Islet Cell Adenomatosis | Islet cell adenomatosis",,,,,,,,,,,,,,,"4175014","Islet cell hyperplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004903","Beckwith-Wiedemann Syndrome","C34415","A genetic syndrome caused by abnormalities in chromosome 11. It is characterized by large birth weight, macroglossia, umbilical hernia, ear abnormalities, and hypoglycemia. Patients with this syndrome have an increased risk of developing embryonal tumors (gonadoblastoma, hepatoblastoma, Wilms tumor, rhabdomyosarcoma) and adrenal cortex carcinomas.","Beckwith-Wiedemann Syndrome | Beckwith-Wiedemann | Beckwith-Wiedemann Syndrome/Isolated Hemihyperplasia | Beckwith-Wiedemann syndrome",,,,,,,,,,,,,,,"4305179","Beckwith-Wiedemann syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825781","Email Attachment","C81866","A file that is linked to an e-mail message.","Email Attachment | Attachment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553857","MIME - CodeSystem","C74930","A standard file format for transferring non-textual data over the internet.","Multipurpose Internet Mail Extensions | MIME",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697791","International Registration Data Identifier","C74929","An internationally unique identifier for a data element.","International Registration Data Identifier | IRDI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697592","caGrid Global Model Exchange","C74931","A grid service that provides a repository responsible for storing and linking data models as defined within namespaces in a distributed environment. It enables other services to publish, retrieve, discover, remove, and version metadata definitions.","caGrid Global Model Exchange | GME | Global Model Exchange",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705249","Administered Component Concept","C42642","The concept for an administered component.","Administered Component Concept | Concept",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825800","ISO 11404","C81892","A standard that specifies the nomenclature and shared semantics for a collection of data types commonly occurring in programming languages and software interfaces.","ISO 11404 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825802","ISO 21090","C81895","An international standard developed and maintained by the International Organization for Standards (ISO) that provides a set of data type definitions for representing and exchanging basic concepts that are commonly encountered in healthcare environments in support of information exchange in the healthcare environment and establishes the semantics and representations for their use.","ISO 21090 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825804","World Wide Web Consortium","C81897","An organization that develops interoperable technologies (specifications, guidelines, software, and tools) to lead the Web to its full potential. W3C is a forum for information, commerce, communication, and collective understanding.","World Wide Web Consortium | W3C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514575","Protocol Forms Template","C41114","The description and the values of the components comprising Case Report forms.","Protocol Forms Template | Template",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879841","Binary Object","C60708","An object that includes binary encoding of a picture, photo, image, graphic, sound, or video.","Binary Object | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1552662","Parametric Probability Distribution - ParameterizedDataType","C82844","A generic data type to specify an uncertain value of an ordered data type using a parametric method (i.e., a distribution function and its parameters are specified). In addition to the specific parameters of the distribution, a mean and standard deviation are always specified.","Parametric Probability Distribution | PPD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707461","Component Concept","C42640","The concept component(s) used for a concept derivation.","Component Concept | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825812","Deploy","C81906","To distribute systematically or strategically.","Deploy | Deployment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825824","State Machine","C81926","A model of computation consisting of a set of states, a set of input events, a set of output events, and a state transition function.","State Machine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825826","Technical Guide","C81929","A document that provides basic information or instruction related to performing a specialized skill or task.","Technical Guide | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825827","Use Case","C81930","A document that describes the interaction between a user (or other initiator of the interaction) and a system, represented as a sequence of simple steps leading to a particular goal.","Use Case | use case",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1140093","CRISP Thesaurus","C39368","The Computer Retrieval of Information on Scientific Projects Database (CRISP) is a searchable database of federally funded biomedical research projects maintained by the Office of Extramural Research at NIH. It includes projects funded by NIH, Substance Abuse and Mental Health Services Administration, Health Resources and Services Administration, Food and Drug Administration, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Office of Assistant Secretary of Health.","Computer Retrieval of Information on Scientific Projects Database | CRISP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1135584","Medical Subject Headings","C82845","The National Library of Medicine's controlled vocabulary thesaurus. It consists of sets of terms naming descriptors in a hierarchical structure that permits searching at various levels of specificity.","Medical Subject Headings | MSH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826024","North American Association of Central Cancer Registries","C82178","A professional organization that develops and promotes uniform data standards for cancer registration; provides education and training; certifies population-based registries; aggregates and publishes data from central cancer registries; and promotes the use of cancer surveillance data and systems for cancer control and epidemiologic research, public health programs, and patient care to reduce the burden of cancer in North America.","North American Association of Central Cancer Registries | NAACCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0681470","Glossary","C18232","An alphabetical list of technical terms in some specialized field of knowledge; usually published as an appendix to a text on that field.","Glossary | Glossaries | glossary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826098","NCI Center for Bioinformatics","C82329","Helps speed scientific discovery and facilitates translational research by building many types of tools and resources that enable information to be shared along the continuum from the scientific bench to the clinical bedside and back.","NCI Center for Bioinformatics | NCICB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826537","has_a Relationship","C82846","A relationship of specialization that states that a concept is a superset of another concept. The inverse of the isa relationship.","has_a Relationship | Parent-Child Relationship | has_a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL386646","English Language","C82847","An Indo-European language belonging to the West Germanic branch; the official language of Britain and the United States, and most of the Commonwealth countries.","English Language | ENG | English",,,,,,,,,,,,,,,"4180186","English language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020751","Icelandic Language","C82848","An Indo-European language belonging to the North Germanic (Scandinavian) branch; the official language of Iceland.","Icelandic Language | ISL | Icelandic",,,,,,,,,,,,,,,"4175776","Icelandic language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2826008","C3D Format","C82159","A public domain, binary file format that is used to record synchronized 3D and analog motion capture data.","C3D Format | C3D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007670","Centers for Disease Control and Prevention","C16408","An agency of the US Public Health Service that serves as the national focus for developing and applying disease prevention and control, environmental health and health promotion and health education activities designed to improve the health of the people of the United States. The CDC is responsible for controlling the induction and spread of infectious diseases, and provides consultation and assistance to other nations and international agencies to assist in improving their disease prevention and control, environmental health, and health promotion activities.","Centers for Disease Control and Prevention | CDC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348045","DICOM Terminology","C69186","A set of standard terms for communications regarding medical imaging.","DICOM Terminology | DICOM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826012","Healthcare Information Technology Standards Panel","C82164","A cooperative partnership between the public and private sectors for the purpose of achieving a widely accepted and useful set of standards specifically to enable and support widespread interoperability among healthcare software applications, as they will interact in a local, regional and national health information network for the United States.","Healthcare Information Technology Standards Panel | HITSP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825556","Hemoglobin C to Total Hemoglobin Ratio Measurement","C81278","The determination of the ratio of Hemoglobin C compared to total Hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.","Hemoglobin C to Total Hemoglobin Ratio Measurement | HGBCHGB | Hemoglobin C/Total Hemoglobin | North American Association of Central Cancer Registries | Percent Hemoglobin C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041740","University","C48647","A large and diverse institution of higher learning created to educate for life and for a profession and to grant degrees; an establishment where a seat of higher learning is housed, including administrative and living quarters as well as facilities for research and teaching; the body of faculty and students at a university.","University | UNIV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1371271","National Drug File - Reference Terminology","C43815","Published by the US Veterans' Administration. National Drug File Reference Terminology covers clinical drugs used at the VA.","US Department of Veterans Affairs National Drug Formulary Reference Terminology | NDFRT | US Veterans' Administration National Drug Formulary Reference Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0347983","Cells per Liter","C67241","A unit of cell concentration expressed as a number of cells per unit volume equal to one liter.","Cells per Liter | Cells/L | cells per liter | {Cells}/L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553036","Nano","C54713","A unit prefix indicating a quantity of 10E-9 or one one-billionth.","Nano | [n] | n | nano | nano-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0560268","Volume Fraction","C67469","Quotient of the volume of a component and the total volume of the system containing the component. For clinical chemistry the term component is recommended, IS0 uses substance. For clinical chemistry the term system is recommended, IS0 uses mixture.","Volume Fraction | VFr | VOLUME FRACTION | volume fraction | {Volume Fraction} | {v/v}",,,,,,,,,,,,,,,"4041094","Volume fraction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL480949","Multiply","C65000","To combine or increase by multiplication.","Multiply | Multiplication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1565860","Prostaglandin G/H Synthase 2, Human","C17984","Prostaglandin G/H synthase 2 (604 aa, ~69 kDa) is encoded by the human PTGS2 gene. This protein plays a role in prostaglandin metabolism.","Prostaglandin G/H Synthase 2 | COX-2 | COX2 | Cyclo-Oxygenase-2 | Cyclooxygenase | Cyclooxygenase 2 | Cyclooxygenase-2 | EC 1.14.99.1 | Glucocorticoid-Regulated Inflammatory Prostaglandin G/H Synthase | PGH Synthase 2 | PGHS-2 | PGHS2 | PHS II | PTGS | PTGS2 | Prostaglandin G/H Synthase and Cyclooxygenase | Prostaglandin H2 Synthase 2 | Prostaglandin-Endoperoxide Synthase | Prostaglandin-Endoperoxide Synthase 2 | Prostaglandin-Endoperoxide Synthase 2 | cyclooxygenase-2 | prostaglandin-endoperoxide synthase 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0166417","PPAR gamma","C34077","Peroxisome proliferator-activated receptor gamma (505 aa, ~58 kDa) is encoded by the human PPARG gene. This protein plays a role in transcriptional regulation, lipid metabolism, cell differentiation, glucose homeostasis and apoptosis.","Peroxisome Proliferator-Activated Receptor Gamma | NR1C3 | Nuclear Receptor Subfamily 1 Group C Member 3 | PPAR Gamma | PPAR-gamma | PPARG | PPARG1 | PPARG2 | Peroxisome Proliferative Activated Receptor Gamma | Peroxisome Proliferative Activated Receptor Gamma | Peroxisome Proliferator-Activated Receptor-Gamma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079904","NF-kappa B","C17380","NF-kB is a heterodimer complex of two DNA-binding subunits from two families of ubiquitous, inducible, nuclear transcription activators involved in cytokine-induced activation of gene expression.  NFKB1 or NFKB2 is bound to REL, RELA, or RELB to form the NF-kB complex. NF-kB is inhibited by IkB proteins (NFKBIA or NFKBIB), which inactivate NF-kB by trapping it in the cytoplasm.  Phosphorylation of IkB by kinases (IKBKA or IKBKB) marks them for ubiquitination, allowing NF-kB translocation to the nucleus and DNA binding at kappa-B transcription enhancer motifs.  In B-lymphocytes, NF-kB binds to the immunoglobulin kappa light chain enhancer and in T-lymphocytes it binds to enhancers in virally infected cells, including HIV.  (from OMIM 164011, 164012, 164910, 164014, 604758, and NCI)","NF-kB | NF-Kappa B | NF-Kappa-B | NF-KappaB | NFKB | Nuclear Factor Kappa B | Nuclear Factor Kappa-B | Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells | Nuclear Factor NF-Kappa-B | Nuclear Factor of Kappa Light Chain Gene Enhancer in B Cells | Nuclear Factor of Kappa Light Polypeptide Gene Enhancer in B-Cells | Nuclear Transcription Factor NF-kB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202616","Skeletal Survey X-Ray","C38092","A procedure used to detect fractures, tumors, or degenerative conditions of the bone.","Skeletal Survey X-Ray | Skeletal Survey",,,,,,,,,,,,,,,"4167021","Radiologic examination, osseous survey, complete",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0200898","DNA Analysis","C17632","Any DNA based laboratory tests.","DNA Analysis | ",,,,,,,,,,,,,,,"4266507","DNA analysis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1301128","Biopsy Site","C77677","The anatomic site targeted for a biopsy procedure.","Biopsy Site | SITE, BIOPSY",,,,,,,,,,,,,,,"4287190","Biopsy site",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0599554","endotracheal","C84984","Within the trachea.","Endotracheal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881822","Microkatal per Liter","C67397","Unit of catalytic activity concentration defined as activity equal to one millionth of katal per one liter of the system volume.","Microkatal per Liter | Attokatal per Picoliter | Femtokatal per Nanoliter | Microkatal/Liter | Nanokatal per Milliliter | Picokatal per Microliter | Yoctokatal per Attoliter | Zeptokatal per Femtoliter | akat/pL | fkat/nL | mckat/L | microkatal per liter | nkat/mL | pkat/uL | ukat/L | ukat/l | ykat/aL | zkat/fL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0392760","Affected","C64917","To be influenced by or changed.","Affected | affected",,,,,,,,,,,,,,,"4084411","Affecting",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007682","Central Nervous System Disorder","C2934","A non-neoplastic or neoplastic disorder which affects the brain and/or spinal cord.","Central Nervous System Disorder | Central Nervous System Disease | Disorder of Central Nervous System",,,,,,,,,,,,,,,"376106","Disorder of the central nervous system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006280","Bronchodilator","C319","Agents that cause an increase in the expansion of a bronchus or bronchial tubes.","Bronchodilator | bronchodilator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524880","Squash","C72013","No Value Exists","Squash | WINTER SQUASH",,,,,,,,,,,,,,,"4134229","Squash",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033713","Proto-Oncogene","C17023","Oncogenes are altered forms of normal cellular genes called proto-oncogene. Many proto-oncogenes are homologous to viral oncogenes and involved in the control of cell proliferation or differentiation. Mutations, amplifications or rearrangements of proto-oncogenes lead to upregulated or deregulated cell growth and allow them to function as oncogenes.","Proto-Oncogene | Cellular Oncogene | Cellular Oncogenes | c-ONC | proto-oncogene",,,,,,,,,,,,,,,"4032947","Proto-oncogene",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522020","NMYC Gene Amplification","C36673","A molecular genetic abnormality indicating the presence of multiple copies of the MYCN gene.","NMYC Gene Amplification | MYCN Amplification | MYCN Gene Amplification | N-myc Gene Amplification | NMYC (amp) | Neuroblastoma-Derived V-Myc Avian Myelocytomatosis Viral Related Oncogene Amplification | V-Myc Avian Myelocytomatosis Viral Oncogene Neuroblastoma Derived Homolog Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001701","Aerobic Exercise","C39774","Sustained exercise that places an increased oxygen demand on the cardiovascular system and promotes an increased efficiency of the body's use of oxygen.","Aerobic Exercise | Aerobic Activity | aerobic exercise",,,,,,,,,,,,,,,"4038196","Aerobic exercises",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006684","Calcium Channel Blocker","C333","A pharmaceutical agent that inhibits the movement of calcium across through calcium channels in the cell membrane, preventing or decreasing the amount of calcium able to enter the cell. These drugs are used for their chronotropic, antihypertensive and vasodilatory effects.","Calcium Channel Blocker | CCB | Calcium Channel Blockers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512814","Oncogene TRK","C18457","Human Oncogene TRK is a mutated variant of NTRK1 Gene (INSR family), which encodes two alternative type I membrane protein Neurotrophic Tyrosine Kinase Receptor Type 1 with similar biological properties. TRKA-II is primarily expressed in neurons; TRKA-I is non-neuronal. NTRK1 exists as low affinity monomeric and high affinity dimeric structures, with TRKA, TRKB, or TRKC, that bind neurotrophins. TRKA, TRKB, and TRKC partners are preferred by NGF, NTF5 and BDNF, and NTF3, respectively. Ligands stimulate autophosphorylation of TRK. NTRK1 defects cause CIPA. Oncogene TRK disrupts normal cell function.","Oncogene TRK | Oncogene, NTRK1 | Oncogene, Neurotrophic Tyrosine Kinase, Receptor, Type 1 Gene | Oncogene, TRKA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810329","Seizure Disorder","C3020","A brain disorder characterized by episodes of abnormally increased neuronal discharge resulting in transient episodes of sensory or motor neurological dysfunction, or psychic dysfunction. These episodes may or may not be associated with loss of consciousness or convulsions.","Seizure Disorder | Epilepsy | Epilepsy | epilepsy",,,,,,,,,,,,,,,"4029498","Seizure disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1514819","Regional Disease","C41844","A disease or condition that extends beyond the site of origin and spreads into adjacent tissues and regional lymph nodes.","Regional Disease | Regional",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710038","Second-Line Therapy","C54350","The second preferred therapy for a particular condition, used after first-line treatment fails or if a person cannot tolerate first-line drugs.","Second-Line Therapy | SECOND LINE TREATMENT | Second Line Therapy | Second Line Treatment | Second Line Treatment | Second line of therapy | second-line therapy",,,,,,,,,,,,,,,"45769571","Second line treatment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0807727","Imaging Region of Interest","C85402","A specific area of interest defined by a sequence of image overlays or a sequence of contours described as a single point (for a point ROI) or more than one point (representing and open or closed polygon).","Imaging Region of Interest | ROI | Region of Interest",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005329","Beverage","C85058","A liquid that is suitable for human consumption.","Beverage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205296","Natural","C85060","A description for something that exists in or is produced by nature, and is not artificial or man-made.","Natural | ",,,,,,,,,,,,,,,"4176413","Natural",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3552413","Malocclusion","C85055","An inherited or acquired dental abnormality characterized by improper alignment of the teeth.","Malocclusion | ",,,,,,,,,,,,,,,"260759","Malocclusion of teeth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827582","Orofacial","C85054","Of, or relating to the mouth and face.","Orofacial | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827624","Disabilities of the Arm Shoulder and Hand Outcome Measure","C85391","A 30-item, self-report questionnaire designed to measure physical and social function along with symptom impact associated with musculoskeletal disorders of the upper limb.","Disabilities of the Arm Shoulder and Hand Outcome Measure | DASH | DASH Outcome Measure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0451005","Assessment of Motor and Process Skills","C85392","An observational assessment that is used to measure the quality of a person's activities of daily living (ADL). The quality of the person's ADL performance is assessed by rating the effort, efficiency, safety, and independence of 16 ADL motor and 20 ADL process skill items.","Assessment of Motor and Process Skills | AMPS",,,,,,,,,,,,,,,"4159539","Assessment of motor and process skills",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827625","Jebsen-Taylor Hand Function Test","C85393","A seven part test that evaluates a broad range of hand functions used in daily activities using common items such as cans, paper clips, and pencils.","Jebsen-Taylor Hand Function Test | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827626","Grooved Pegboard Test","C85394","A manipulative dexterity test using a pegboard device with five rows of five holes. It features 25 key-style pegs with holes in various positions in space, and is especially good for testing lateralized brain damage.","Grooved Pegboard Test | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827627","Manual Ability Measure-36","C85395","A rating scale of 36 everyday tasks that measures self-reported manual ability.","Manual Ability Measure-36 | MAM-36 | Manual Ability Measure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0430561","Skin Prick Test","C85396","A test for sensitivity to allergens. A solution containing a suspected allergy-causing substance is placed on the skin and then the skin is pricked or scratched to allow the allergen to enter the skin. If the skin develops a red, raised wheal it usually means that the person is allergic to that allergen.","Skin Prick Test | Allergy Skin Prick Test | SPT",,,,,,,,,,,,,,,"4242723","Prick test",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037981","Spirometry","C85397","Measurement of the breathing capacity of the lung by means of a spirometer.","Spirometry | SPIROMETRY",,,,,,,,,,,,,,,"4133840","Spirometry",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022400","Jogging","C85398","Running at a trot as a form of cardiopulmonary exercise.","Jogging | Jog",,,,,,,,,,,,,,,"4025002","Jogging",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034512","Racquet Sport","C85400","Any sport where players use racquets to hit a ball or other object.","Racquet Sport | Racket Sport",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005377","Bicycling","C85401","Riding a bicycle for transportation or recreation.","Bicycling | Bike",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827424","Spectrum","C84383","An array of entities, such as light waves or particles, ordered in accordance with the magnitudes of a common physical property, such as wavelength or mass.","Spectrum | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827423","Spectral Unmixing","C84381","The procedure by which the measured spectrum of a mixed pixel is decomposed into a collection of constituent spectra.","Spectral Unmixing | Unmixing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026618","Dental Fluorosis","C85059","A condition that results from excessive fluoride ingestion during tooth development, resulting in tooth discoloration ranging from white streaks to brown stains and cracks or pits in the tooth enamel.","Dental Fluorosis | Fluorosis",,,,,,,,,,,,,,,"4147380","Dental fluorosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827410","Intracranial Leptomeningeal Lesion","C84358","A non-neoplastic or neoplastic pathologic process affecting the leptomeninges of the brain.","Intracranial Leptomeningeal Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827411","Spinal Leptomeningeal Lesion","C84359","A non-neoplastic or neoplastic pathologic process affecting the leptomeninges of the spinal cord.","Spinal Leptomeningeal Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827412","Distant Intracranial Metastasis","C84360","The presence of brain metastasis that originates from a cancer growth in a distant anatomic site.","Distant Intracranial Metastasis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522279","Iron Staining Method","C23016","Iron stain is the classic method for demonstrating iron in tissues. Hemosiderin (storage iron granules) may be present in areas of old hemorrhage or be deposited in tissues with iron overload. Prussian blue stain is used for the demonstration of ferric iron in the tissue sections. This stain can aid in identifying hemochromatosis and hemosederosis where abnormal large deposits of iron may be seen. In the prussian blue staining, the sections are treated with an acidic solution of potassium ferrocyanide and any ferric iron present reacts to form an insoluble bright blue pigment called Prussian blue.","Iron Staining Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0522534","Saturation","C61427","Impregnation of one substance by another to the greatest possible extent; that concentration of a dissolved substance that cannot be exceeded.","Saturation | Saturated",,,,,,,,,,,,,,,"4013734","Saturated",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827631","School Age Child","C85405","An age group comprised of individuals between 5 and 12 years of age.","School Age Child | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827632","Gross Income","C85406","A person's total income before taxes, exclusions, and deductions.","Gross Income | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827633","Evans Staging System","C85407","A staging system for neuroblastoma proposed by Evans, based on both the site of origin and the clinical behavior of the tumor.","Evans Staging System | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827639","Shimada Classification System","C85413","A classification system defining a neuroblastoma as having a favorable or unfavorable prognosis, based on histopathologic criteria.","Shimada Classification System | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0432510","International Neuroblastoma Staging System","C85416","A surgicopathological staging system for neuroblastoma, based on the Evans staging system.","International Neuroblastoma Staging System | INSS | inss stage | inss_stage",,,,,,,,,,,,,,,"4110410","International neuroblastoma staging system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827648","Pediatric Oncology Group Neuroblastoma Staging System","C85423","A clinicopathological staging system for neuroblastoma, which places emphasis on the presence or absence of regional lymph node involvement by tumor.","Pediatric Oncology Group Neuroblastoma Staging System | POG Neuroblastoma Staging System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0451267","Likert Scale","C85429","A psychometric scale commonly used in questionnaires where a respondent is asked to evaluate an opinion according to subjective or objective criteria, by rating their level of agreement or disagreement with a statement.","Likert Scale | ",,,,,,,,,,,,,,,"4165276","Likert scale",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827654","Dichotomous Response Format","C85430","A response format that has two possible responses (e.g.,Yes/No, True/False, Agree/Disagree).","Dichotomous Response Format | Dichotomous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827655","Open-ended Response Format","C85431","A response format that allows a respondent to answer using their own knowledge and/or feelings, without specified response categories.","Open-ended Response Format | Open-ended",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827656","Close-ended Response Format","C85432","A response format where specified response categories are provided for the respondent to chose in order to answer the question.","Close-ended Response Format | Close-ended",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527117","Personnel","C60758","Persons employed in any field.","Personnel | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1368354","Mixed Neoplasm","C6930","A neoplasm composed of at least two distinct cellular populations.","Mixed Neoplasm | Mixed Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332883","Central Nervous System Immature Teratoma","C7014","A teratoma involving the central nervous system and characterized by the presence of an extensive component of immature, fetal-type tissues.","Central Nervous System Immature Teratoma | CNS Immature Teratoma | Immature Teratoma of CNS | Immature Teratoma of Central Nervous System | Immature Teratoma of the CNS | Immature Teratoma of the Central Nervous System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332886","Central Nervous System Mature Teratoma","C7013","A mature teratoma arising in the central nervous system.","Central Nervous System Mature Teratoma | CNS Mature Teratoma | Mature Teratoma of CNS | Mature Teratoma of Central Nervous System | Mature Teratoma of the CNS | Mature Teratoma of the Central Nervous System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038039","Sport","C85399","An active diversion requiring physical exertion and competition.","Sport | Sports",,,,,,,,,,,,,,,"4212586","Sport",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018553","Cowden Syndrome","C3076","An autosomal dominant hereditary syndrome characterized by a variety of hamartomas and neoplasms including verrucous skin lesions, fibromas of the oral cavity, facial trichilemmomas, hamartomatous colonic polyps, thyroid neoplasms, breast cancer, and dysplastic gangliocytomas of the cerebellum.","Cowden Syndrome | Cowden Disease | Cowden disease | Cowden syndrome | Cowden's Disease | Ruvalcaba-Myhre-Smith Syndrome | multiple hamartoma syndrome",,,,,,,,,,,,,,,"4240212","Cowden syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023798","Lipoma","C3192","A benign, usually painless, well-circumscribed lipomatous tumor composed of adipose tissue.","Lipoma | LIPOMA, BENIGN | Lipoma, NOS | lipoma","8850/0","Lipoma, NOS",,,,,,,,,,,,,"440358","Lipoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1527375","Breast Fibrocystic Change","C3039","Fibrosis associated with cyst formation in the breast parenchyma.","Breast Fibrocystic Change | Breast Fibrocystic Disease | Cystic Disease of Breast | Cystic Disease of the Breast | Diffuse Cystic Mastopathy | Fibrocystic Breast | Fibrocystic Breast Disease | Fibrocystic Change of Breast | Fibrocystic Change of the Breast | Fibrocystic Disease | Fibrocystic Disease of Breast | Fibrocystic Disease of the Breast | Fibrocystic Mastopathy | benign breast disease | fibrocystic breast changes | fibrocystic breast disease | mammary dysplasia",,,,,,,,,,,,,,,"78804","Fibrocystic disease of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0476089","Endometrial Carcinoma","C7558","A malignant tumor arising from the epithelium that lines the cavity of the uterine body.  The vast majority of endometrial carcinomas are adenocarcinomas; squamous cell and adenosquamous carcinomas represent a minority of the cases.  Endometrioid adenocarcinoma is the most frequently seen variant of endometrial adenocarcinoma.  Uterine bleeding is an initial clinical sign.  The prognosis depends on the stage of the tumor, the depth of myometrial wall invasion, and the degree of differentiation.","Endometrial Carcinoma | CARCINOMA, ENDOMETRIAL, MALIGNANT | Carcinoma of Endometrium | Carcinoma of the Endometrium | Endometrial Cancer | UCEC | Uterine Corpus Endomential Carcinoma | endometrial cancer",,,,,,,,,,,,,,,"4110871","Endometrial carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1322271","Wrist Joint","C33894","A joint between the distal end of the radius and the proximal row of carpal bones.","Wrist Joint | Carpal | Radiocarpal Joint | WRIST JOINT | Wrist | carpal region joint | joint of carpal region | joint of wrist | wrist joint",,,,,,,,,,,,,"UBERON:0001491","wrist joint","4254083","Wrist joint structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827657","Data Conversion","C85434","The translation of computer data from one format to another.","Data Conversion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827658","Scalable Vector Graphics","C85435","A specification for describing vector graphics using extensible markup language.","Scalable Vector Graphics | SVG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827659","Kaplan Meier Survival Plot","C85436","A visual depiction of a survival function for survival data consisting of a series of horizontal steps of declining magnitude plotted against time.","Kaplan Meier Survival Plot | Kaplan-Meier Estimator | Kaplan-Meier Survival Plot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827660","Portable Network Graphics","C85437","An extensible file format for lossless data compression of images.","Portable Network Graphics | PNG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827661","Spreadsheet","C85438","A document that organizes data into rows and columns.","Spreadsheet | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827662","Graphics Visualization","C85439","Computer methods for creating images, diagrams or animations.","Graphics Visualization | Visualization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827663","Codec","C85440","An electronic device or component capable of converting digital signals to and from analog form.","Codec | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2003903","Profiling (action)","C84385","An analysis (often in graphical form) representing the extent to which something exhibits various characteristics.","Profile | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827422","Mathematical Factor","C84380","Any of the numbers (or symbols) that form a product when multiplied together.","Mathematical Factor | Factor | Multiplicative Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0682001","Performing Arts","C85433","Forms of creative activity that involve performance before an audience (e.g., drama, dance, music).","Performing Arts | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4227551","Sarcoidosis","C34995","An idiopathic inflammatory disorder characterized by the formation of non-necrotizing epithelioid granulomas which contain giant cells. It usually affects the lungs, lymph nodes, liver, and skin. Cardiac involvement is also possible.","Sarcoidosis | Sarcoid | sarcoid | sarcoidosis",,,,,,,,,,,,,,,"438688","Sarcoidosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2826285","Flow Rate","C82554","The speed of movement of a liquid.","Flow Rate | FLRT | flowRate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1301880","Start Time","C78441","The time at which something is to start or did start.","Start Time | STTIM | start time | start_time",,,,,,,,,,,,,,,"4160040","Start time",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206131","Adipocyte","C12556","A connective tissue cell that is specialized to synthesize and store fat.","Adipocyte | Adipose Cell | Fat Cell | Lipocyte",,,,,,,,,,,,,,,"4087477","Adipocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011860","Type 2 Diabetes Mellitus","C26747","A type of diabetes mellitus that is characterized by insulin resistance or desensitization and increased blood glucose levels. This is a chronic disease that can develop gradually over the life of a patient and can be linked to both environmental factors and heredity.","Type 2 Diabetes Mellitus | Adult Onset Diabetes | Adult-Onset Diabetes | Diabetes, Type 2 | Diabetes, Type II | NIDDM | Non-Insulin Dependent Diabetes | Non-Insulin Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes | T2DM - Type 2 Diabetes mellitus | Type 2 Diabetes | Type 2 Diabetes Mellitus Non-Insulin Dependent | Type II Diabetes | Type II Diabetes Mellitus | Type II Diabetes mellitus | Type II diabetes",,,,,,,,,,,,,,,"201826","Type 2 diabetes mellitus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3551314","Digital Clubbing","C85489","An enlargement of the tips of the fingers or toes and a change in the angle where the nails emerge. It occurs when the amount of soft tissue beneath the nail beds increases. It may be idiopathic, hereditary, or associated with a wide range of diseases, including cardiopulmonary disorders and malignant neoplasms.","Digital Clubbing | Clubbing | Finger Clubbing",,,,,,,,,,,,,,,"4279382","Clubbing",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009742","Congo Red","C81102","The sodium salt of benzidinediazo-bis-1-naphthylamine-4-sulfonic acid; a diazo dye that is red in alkaline solution and blue in acid solution and used especially as an indicator and as a biological stain.","Congo Red | CONGO RED",,,,,,,,,,,,,,,"4264539","Congo red stain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706803","Amyloidogenesis","C44955","Amyloidogenesis is the formation or growth of amyloid structures, implicated in many human diseases including Alzheimer s disease (AD), Parkinson s disease (PD), type II diabetes, and spongiform encephalopathies. In these disease states, normally soluble proteins aggregate as amyloidogenic insoluble fibrils that accumulate in affected tissues or organs.","Amyloidogenesis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008909","Claustrophobia","C85490","An irrational fear of being in a confined space.","Claustrophobia | ",,,,,,,,,,,,,,,"4058397","Claustrophobia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202041","Serum Glucose Measurement","C61027","A quantitative measurement of the amount of glucose present in a sample of serum.","Serum Glucose Measurement | ",,,,,,,,,,,,,,,"4331286","Glucose measurement, serum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0077404","Troponin T","C38041","Troponin I, troponin T, and troponin C are the three closely associated subunits of the troponin complex of thin filaments in muscle. The complex serves as a calcium-sensitive switch that regulates muscle contraction. Troponin T binds tropomyosin to the troponin complex and inhibits F-actin-myosin interactions. The troponin T gene family comprises three isoforms: slow skeletal (TNNT1), cardiac (TNNT2) and fast skeletal (TNNT3). Because it is not normally found in blood, cardiac troponin-T in serum is a sensitive indicator of myocardial cell injury.","Troponin T | TNNT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0077401","Troponin I","C17343","Troponin I, troponin T, and troponin C are the three closely associated subunits of the troponin complex of thin filaments in muscle.  The complex serves as a calcium-sensitive switch that regulates muscle contraction.  In the absence of calcium, Troponin I binds actin, inhibits actomyosin ATPase activity, and inhibits F-actin-myosin interactions.  The troponin I gene family comprises three isoforms: skeletal TNI-fast, skeletal TNI-slow, and TNI-cardiac.  (from OMIM 191044, 191043, 191042 and NCI)","Troponin I | TNNI | TnI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519247","Sentinel Lymph Node Mapping","C20206","A technique that uses dyes and/or radioactive agents to map the lymphatic drainage of an area in which a tumor is located, thereby identifying the sentinel node.","Sentinel Lymph Node Mapping | Sentinel Lymph Node Imaging | sentinel lymph node mapping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3853888","Oncogene ErbB2","C16239","Human Oncogene ErbB2 is a mutated variant of ERBB2 Gene, which encodes ERRB2 Receptor Protein Tyrosine Kinase, a 185-kDa type I membrane glycoprotein similar to EGFR that controls cell growth. Ligand binding increases ERBB2 tyrosine phosphorylation. A heterodimer with ERBB3 and ERBB4, p185ERBB2 is an essential component of the heregulin/neuregulin receptor. ERBB2 forms an IL6-dependent complex with IL6R gp130, resulting in ERBB2 tyrosine phosphorylation and MAPK activation. Oncogene ERBB2 disrupts normal cell function.","Oncogene ErbB2 | HER -2 | HER-2/NEU | Oncogene, C-Erb -2 | Oncogene, C-ErbB-2 | Oncogene, ERBB2 | Oncogene, NEU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514489","Proliferative Index","C28042","The percentage of cells in a biological specimen that are dividing.","Proliferative Index | Cell Proliferation Index | PI | PROLIFERATIVE INDEX | Proliferation Index | proliferative index",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031119","Peripheral Nerve","C12768","Any nerve outside the brain or spinal cord that connects with peripheral receptors or effectors.","Peripheral Nerve | NERVE, PERIPHERAL | PERIPHERAL NERVE | Peripheral Nerves | Peripheral nerve structure (body structure) | nerve | nerves | peripheral nerve",,,,,,,,,,,,,"UBERON:0001021","nerve","4225241","Peripheral nerve structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0598391","Protein Replacement Therapy","C16221","Administration of a protein to compensate for the loss, as from disease or surgery, of a gland or tissue that would normally produce the protein.","Protein Replacement Therapy | Enzyme Replacement Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1136201","Orthopedic Surgical Procedures","C16186","A surgical procedure to treat and correct deformities, diseases, and injuries to the skeletal system, its articulations, and associated structures.","Orthopedic Surgical Procedure | Orthopedic Surgical Procedures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0402735","Service Occupation","C85488","An occupation which provides a service to others rather than creating a product.","Service Occupation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827712","Equipment Operator","C85487","One who is in control of the functioning of a piece of machinery. Usually, this individual has received instruction as to the proper operation of the machinery and is knowledgeable about the performance and hazards associated with the activity.","Equipment Operator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448990","Any","C81168","One, some, every, or all without specification.","Any | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698021","Mathematical Graph","C75914","A set of objects called points, nodes, or vertices connected by a binary relation between vertices called lines or edges. It is a mathematical structure used to model pairwise relations between objects from a certain collection.","Mathematical Graph | Graph",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0589500","Retrograde","C50406","Moving in a direction contrary to the usual one.","Retrograde | Backward",,,,,,,,,,,,,,,"4013725","Retrograde",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827562","Navigation","C84954","The act or task of directed movement from one location to another.","Navigation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0699788","Import","C73599","An activity concerned with bringing any good, commodity, or service from a foreign source.","Import | IMPORT | Importation | Imported",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426948","CHFR Gene","C77209","This gene is involved in the mitotic checkpoint.","CHFR Gene | CHFR | Checkpoint with Forkhead and Ring Finger Domains Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827421","Construct","C84378","An abstract or general idea inferred or derived from specific instances.","Construct | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0871935","Theory","C84379","A well-substantiated explanation of some aspect of the natural world.","Theory | Theoretical",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008508","Chorionic Villus","C34125","Tiny vascular tissue projections from the membranous sac that surrounds the embryo.","Chorionic Villus | ",,,,,,,,,,,,,,,"4069427","Chorionic villi structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034627","Radius Bone","C12777","The long bone of the forearm that extends from the lateral aspect of the elbow to the thumb-side of the wrist.","Radius Bone | BONE, RADIUS | Bone structure of radius (body structure) | RADIUS | Radial Bone | Radius | radius bone",,,,,,,,,,,,,,,"4266067","Bone structure of radius",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040067","Hand Digit 1","C52834","The thick and short hand digit which is next to the index finger in humans.","Hand Digit 1 | HAND DIGIT 1 | Thumb | digit 1 of fore-paw | digit 1 of manus | finger 1 | first digit of hand | fore digit I | fore limb digit 1 | hand digit 1 | manual digit 1 | manual digit I | pollex",,,,,,,,,,,,,"UBERON:0001463","manual digit 1","4297767","Thumb structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0553695","Exocrine Pancreas","C32546","An enzyme producing region of the pancreatic tissue containing the pancreatic acini and exocrine intralobular ducts which collectively secrete the digestive enzymes into the main pancreatic duct to drain into the duodenal part of the small intestine.","Exocrine Pancreas | PANCREAS, EXOCRINE",,,,,,,,,,,,,,,"4066128","Structure of exocrine pancreas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0598170","Melanoblast","C85503","An immature precursor cell that gives rise to a melanocyte.","Melanoblast | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043425","Yolk Sac","C14128","Membranous sac on the ventral aspect of the developing embryo that acts as a primitive circulatory system as well as providing nourishment.","Yolk Sac | SAC, YOLK",,,,,,,,,,,,,,,"4094642","Yolk sac structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036631","Seminoma","C9309","A radiosensitive malignant germ cell tumor found in the testis (especially undescended), and extragonadal sites (anterior mediastinum and pineal gland).  It is characterized by the presence of uniform cells with clear or dense cytoplasm which contains glycogen, and by a large nucleus which contains one or more nucleoli.  The neoplastic germ cells form aggregates separated by fibrous septa.  The fibrous septa contain chronic inflammatory cells, mainly lymphocytes.","Seminoma | SEMINOMA, MALIGNANT | Seminoma, NOS | Seminoma, Pure | seminoma","9061/3","Seminoma, NOS",,,,,,,,,,,,,"40482780","Seminoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1336724","Testicular Non-Seminomatous Germ Cell Tumor","C9313","A testicular germ cell tumor characterized by the absence of a seminomatous component. It includes embryonal carcinoma, yolk sac tumor, choriocarcinoma, teratoma, and mixed forms.","Testicular Non-Seminomatous Germ Cell Tumor | Testicular Germ Cell Tumor Non-Seminomatous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033325","Prognosis","C17013","Prediction of the probable course and outcome of a disease.","Prognosis | Prediction of Outcome | prognosis",,,,,,,,,,,,,,,"4069425","Determination of prognosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1429990","Mesothelin, Human","C20887","Mesothelin (630 aa, ~69 kDa) is encoded by the human MSLN gene. This protein may play a role in cellular adhesion.","Mesothelin | CAK1 Antigen | MSLN | Pre-Pro-Megakaryocyte-Potentiating Factor | mesothelin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041107","Trisomy","C3421","A chromosomal abnormality consisting of the presence of one chromosome in addition to the normal diploid number.","Trisomy | trisomy",,,,,,,,,,,,,,,"4193626","Trisomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043381","Human Chromosome Y","C13286","The smaller of the two human sex chromosome. Its presence usually determines the development of a fetus as male, while its absence usually determines the development of a fetus as female.","Human Chromosome Y | Chromosome Y | Chromosome Y | Human Y Chromosome | Y Chromosome | chrY",,,,,,,,,,,,,,,"4183858","Sex chromosome Y",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0796361","Chromosome 7q","C13384","Distal (long) arm of chromosome 7","7q | Chromosome 7 Distal Arm | Chromosome 7 Long Arm | Chromosome 7q",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515510","9q","C13564","Distal (long) arm of chromosome 9","9q | Chromosome 9 Distal Arm | Chromosome 9 Long Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521048","20q","C13549","Distal (long) arm of chromosome 20","20q | Chromosome 20 Distal Arm | Chromosome 20 Long Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511041","Balanced Translocation","C6822","Interchanges of genetic material among different chromosomes following the breaking off of pieces of chromosomes such that the total chromosome composition may still contain all of the genetic material.Balanced Chromosomal Rearrangement.","Balanced Translocation | Balanced | Balanced Chromosomal Aberration/Rearrangement | Balanced Chromosomal Alteration | Balanced Chromosomal Rearrangement | Balanced Chromosomal Translocation | Balanced Chromosomal Translocation | Translocation, Balanced",,,,,,,,,,,,,,,"37019048","Balanced translocation of chromosome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0796367","11q23","C13390","A chromosome band present on 11q","11q23 | Chromosome 11q23",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333532","FANCG Gene","C24385","This gene is involved in the maintenance of genomic integrity and nuclear signal transduction. Allelic variants of the gene are involved in Fanconi syndrome.","FANCG Gene | FA Complementation Group G Gene | FANCG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796349","Chromosome 17 Short Arm","C13382","Proximal (short) arm of chromosome 17","17p | Chromosome 17 Proximal Arm | Chromosome 17 Short Arm | Chromosome 17p",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333875","High Grade Squamous Intraepithelial Neoplasia","C8336","A precancerous neoplastic process characterized by the presence of moderate or severe dysplastic cytological changes which extend to the upper part of the squamous epithelium.  Maturation at the surface of the squamous epithelium may or may not be present.  Representative examples include the high grade esophageal squamous intraepithelial neoplasia, high grade cervical squamous intraepithelial neoplasia, high grade vaginal intraepithelial neoplasia, and high grade vulvar intraepithelial neoplasia.","High Grade Squamous Intraepithelial Neoplasia | HSIL | High-Grade Squamous Intraepithelial Lesion | Squamous intraepithelial neoplasia, high grade | high-grade squamous intraepithelial lesion","8077/2","Squamous intraepithelial neoplasia, high grade",,,,,,,,,,,,,"4331440","High-grade squamous intraepithelial lesion",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0036471","Scrotum","C12785","The musculocutaneous pouch that encloses the testicles.","Scrotum | SCROTUM | Scrotal structure (body structure) | Scrotum, NOS | scrotum",,,,,,,,,,,,,"UBERON:0001300","scrotum","4066714","Scrotal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708636","Laboratory or Pathology Department","C53551","A facility responsible for various analyses on tissue samples.","Laboratory or Pathology Department | LABORATORY OR PATHOLOGY DEPARTMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827508","Grace Period","C84817","A length of time beyond a specified date during which rules or penalties are withheld.","Grace Period | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827513","Summary 3 Report","C84831","A report that documents which cancer anatomic sites are being treated at the cancer center and whether the center is placing these patients onto therapeutic protocols.","Summary 3 Report | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0588162","Breast Tissue Expander","C85840","An inflatable reservoir that is used to expand the remaining breast skin after a mastectomy and prior to surgical reconstruction.","Breast Tissue Expander | Breast Expander | Tissue Expander",,,,,,,,,,,,,,,"4149480","Breast tissue expander",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL414356","MYCN Gene","C18405","This gene is involved in transcriptional regulation and amplification of this gene is associated with a variety of tumors, most notably neuroblastomas.","MYCN Gene | MYCN | MYCN Proto-Oncogene, bHLH Transcription Factor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017256","Gene Amplification","C16605","Any DNA sequence rearrangement that results in the gain of one or more copies of a DNA segment that contains at least one gene.","Gene Amplification | Amplification | Transcript Amplification | gene amplification",,,,,,,,,,,,,,,"4054400","Gene amplification",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827988","Color Mapping Function","C85844","A function that transforms the colors of one (source) image to the colors of another (target) image.","Color Mapping Function | Color Map",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827989","Grayscale Image","C85845","An image composed of pixels with varying intensities of a single color.","Grayscale Image | Monochrome Image",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827990","Grayscale Color Map","C85846","A color map composed of shades of gray, varying from black at the weakest intensity to white at the strongest.","Grayscale Color Map | Grayscale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827991","Hot-cold Color Map","C85847","A color map composed of warm and cool colors, varying from blue at the weakest intensity to red at the strongest and with a neutral color at the midpoint. It is useful for data where the sign is important.","Hot-cold Color Map | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827992","Warm Color Map","C85848","A color map that varies from red at one extreme to yellow at the other extreme.","Warm Color Map | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827993","Cool Color Map","C85849","A color map that varies from cyan at one extreme to magenta at the other extreme.","Cool Color Map | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827994","Undirected Graph","C85850","A graph in which the edges are not ordered, and therefore, are symmetric.","Undirected Graph | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827995","Graph Layout","C85851","A pictorial representation of a graph on plane, for visualization of certain properties of the graph or of the data modeled by the graph.","Graph Layout | Graph Drawing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827996","Graph Radial Layout","C85852","A type of graph that uses a focus node with other nodes arranged in concentric circles around the focus to illustrate the central node's degree of connectivity to the other nodes.","Graph Radial Layout | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827997","Graph Circular Layout","C85853","A type of graph where all nodes are placed on the perimeter of a circle and are joined by lines passing within the circle. It is especially useful for illustrating networks.","Graph Circular Layout | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827998","Graph Combinatorial Layout","C85854","A type of graph similar to a radial layout, but compressed to fit rapidly-branching networks.","Graph Combinatorial Layout | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827999","Rounded Rectangle","C85855","A shape similar to a rectangle but with corners that resemble an arc of a circle.","Rounded Rectangle | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828002","Proprietary Data Format","C85871","A file format that is controlled by a private person or organization where the mode of presentation of its data is opaque and its specification is not publicly available.","Proprietary Data Format | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828003","Open Specification Data Format","C85872","A published specification for storing digital data that is freely distributed and available to be used and implemented by anyone.","Open Specification Data Format | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828004","Plain Text Data Format","C85873","A data format consisting of readable textual material maintained as a sequential file.","Plain Text Data Format | TXT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1563385","Fanconi Anemia Complementation Group Protein","C85881","A protein that is a member of a structurally diverse group that forms a protein complex which may regulate both DNA repair and the cell cycle. Mutation of any member of this group may inhibit the formation of the complex and is associated with Fanconi anemia.","Fanconi Anemia Complementation Group Protein | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0531299","FANCA protein, human","C85882","Fanconi anemia group A protein (1455 aa, ~163 kDa) is encoded by the human FANCA gene. This protein may be involved in both DNA damage repair and cell cycle checkpoint regulation.","Fanconi Anemia Group A Protein | FANCA | Protein FACA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828009","Fanconi Anemia Group B Protein","C85884","Fanconi anemia group B protein (859 aa, ~98 kDa) is encoded by the human FANCB gene. This protein may play a role in both ubiquitination and DNA repair.","Fanconi Anemia Group B Protein | FAAP95 | FANCB | Fanconi Anemia-Associated Polypeptide of 95 kDa | Protein FACB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1528329","FANCC protein, human","C85885","Fanconi anemia group C protein (558 aa, ~63 kDa) is encoded by the human FANCC gene. This protein may be involved in DNA cross-link repair and cell cycle checkpoint regulation.","Fanconi Anemia Group C Protein | FANCC | Protein FACC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1568210","FANCD2 protein, human","C85886","Fanconi anemia group D2 protein (1471 aa, ~166 kDa) is encoded by the human FANCD2 gene. This protein plays a role in chromosome pairing during meiosis, repair of DNA double-strand breaks and cell cycle checkpoint regulation.","Fanconi Anemia Group D2 Protein | FANCD2 | Protein FACD2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447811","FANCE protein, human","C85888","Fanconi anemia group E protein (536 aa, ~59 kDa) is encoded by the human FANCE gene. This protein is involved in the localization of the Fanconi anemia complementation group protein complex.","Fanconi Anemia Group E Protein | FANCE | Protein FACE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0911827","FANCF protein, human","C85891","Fanconi anemia group F protein (374 aa, ~42 kDa) is encoded by the human FANCF gene. This protein may play a role in both cell cycle checkpoint regulation and DNA damage repair.","Fanconi Anemia Group F Protein | FANCF | Protein FACF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333238","Fanconi Anemia Group G Protein, Human","C26135","Fanconi anemia group G protein (622 aa, ~69 kDa) is encoded by the human FANCG gene. This protein may be involved in DNA damage repair and cell cycle checkpoint regulation.","Fanconi Anemia Group G Protein | DNA Repair Protein XRCC9 | FANCG | Fanconi Anemia Complementation Group G | Protein FACG | X-Ray Repair Complementing Defective Repair In Chinese Hamster Cells 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004290","Evoked Response Audiometry","C85857","An auditory test utilizing the electrical activity of neural impulses to localize the exact site of a pathologic process that causes the hearing loss.","Evoked Response Audiometry | ",,,,,,,,,,,,,,,"4099247","Electric response audiometry",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0200269","Conditioning Play Audiometry","C85858","An auditory test performed in children with hearing impairment.  The child is asked to wait and listen for a specific stimulus.  Subsequently, the child responds by performing a motor activity in response to the specific stimulus.","Conditioning Play Audiometry | ",,,,,,,,,,,,,,,"4272008","Conditioning play audiometry",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268281","Neuronal Ceroid Lipofuscinosis Type 1","C85861","A condition associated with mutation(s) in the PPT1 gene, encoding palmitoyl-protein thioesterase 1. The condition is one of a group of genetically heterogeneous neurodegenerative disorders, characterized by accumulation of intracellular lipopigments.","Neuronal Ceroid Lipofuscinosis Type 1 | CLN1 | Infantile Neuronal Ceroid Lipofuscinosis | Infantile Neuronal Ceroid Lipofuscinosis | Santavuori Disease",,,,,,,,,,,,,,,"4241463","Infantile neuronal ceroid lipofuscinosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022340","Neuronal Ceroid Lipofuscinosis Type 2","C85864","A condition associated with mutation(s) in the TPP1 gene, encoding tripeptidyl-peptidase- 1. The condition is one of a group of genetically heterogeneous neurodegenerative disorders, characterized by accumulation of intracellular lipopigments.","Neuronal Ceroid Lipofuscinosis Type 2 | CLN2 | Late Infantile Neuronal Ceroid Lipofuscinosis | Late Infantile Neuronal Ceroid Lipofuscinosis",,,,,,,,,,,,,,,"4033084","Late-infantile neuronal ceroid lipofuscinosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0086647","Mucopolysaccharidosis Type IIIA","C84897","A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme heparan sulfate sulfatase. It is characterized by behavioral changes, sleep disturbances, mental developmental delays and seizures.","Mucopolysaccharidosis Type IIIA | MPS III A | Sanfilippo A",,,,,,,,,,,,,,,"4215209","Mucopolysaccharidosis, MPS-III-A",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0086648","Mucopolysaccharidosis Type IIIB","C84898","A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme N-acetyl-alpha-D-glucosaminidase. It is characterized by behavioral changes, sleep disturbances, and mental developmental delays.","Mucopolysaccharidosis Type IIIB | MPS III B | Sanfilippo B",,,,,,,,,,,,,,,"4243053","Mucopolysaccharidosis, MPS-III-B",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0086649","Mucopolysaccharidosis Type IIIC","C84899","A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme acetyl-CoA:alpha-glucosaminide acetyltransferase. It is characterized by behavioral changes, sleep disturbances, and mental developmental delays.","Mucopolysaccharidosis Type IIIC | MPS III C | Sanfilippo C",,,,,,,,,,,,,,,"4326882","Mucopolysaccharidosis, MPS-III-C",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0086650","Mucopolysaccharidosis Type IIID","C84900","A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme N-acetylglucosamine-6-sulfatase. It is characterized by behavioral changes, sleep disturbances and mental developmental delays.","Mucopolysaccharidosis Type IIID | MPS III D | Sanfilippo D",,,,,,,,,,,,,,,"4049596","Mucopolysaccharidosis, MPS-III-D",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0086651","Mucopolysaccharidosis Type IVA","C84901","A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme galactosamine-6-sulfatase. It is characterized by skeletal and central nervous system deficits.","Mucopolysaccharidosis Type IVA | MPS IV A",,,,,,,,,,,,,,,"4219277","Mucopolysaccharidosis, MPS-IV-A",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0086652","Mucopolysaccharidosis Type IVB","C84902","A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme beta galactosidase. It is characterized by skeletal dysplasia and short stature.","Mucopolysaccharidosis Type IVB | MPS IV B",,,,,,,,,,,,,,,"4031815","Mucopolysaccharidosis, MPS-IV-B",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2828000","X-Linked Inherited Disorder","C85865","An inherited disorder affecting mostly males. It results from defective genes that are present on the X chromosome.","X-Linked Inherited Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0277564","Acquired","C85869","Of or relating to a medical condition or characteristic that is not present at birth but develops subsequently.","Acquired | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376628","Chromosome Breakage","C85870","A structural chromosomal abnormality caused by the spontaneous or induced breakage of a chromosome. It may result in DNA sequence deletions, chromosomal translocations, or chromosomal inversions.","Chromosome Breakage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3552471","Microcephaly","C85874","A congenital or acquired developmental disorder in which the circumference of the head is smaller than normal for the person's age and sex.","Microcephaly | Microcephalus",,,,,,,,,,,,,,,"606878","Microcephaly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2828005","Aspergillus Galactomannan Antigen Test","C85875","An enzyme-linked serum immunoassay used for the detection of aspergillosis.","Aspergillus Galactomannan Antigen Test | Aspergillus Spp Galactomannan Antigen Test | Platelia (R) Aspergillus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3808931","Cafe Au Lait Spot","C40460","A light brown, sharply demarcated skin patch. It is a manifestation of neurofibromatosis type 1 and McCune-Albright syndrome.","Cafe Au Lait Spot | Cafe Au Lait Patch | Cafe Au Lait Patch | Café Au Lait Patch | Café Au Lait Spot",,,,,,,,,,,,,,,"4066941","Café au lait spots",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2828006","Substrate Deprivation Therapy","C85876","A therapeutic procedure based on the inhibition or reduction of the biosynthesis of compounds that cannot break down in the cells.","Substrate Deprivation Therapy | Substrate Reduction Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828007","3H-Thymidine Labeling Index","C85879","A labeling index evaluating the percentage of cells present in the S-phase fraction. It is used to determine the proliferative activity of tumor cells in a tissue sample.","3H-Thymidine Labeling Index | 3H-dT-LI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828388","Calcofluor White Stain (reagent)","C85880","A fluorescent stain that binds to the cell wall. It is used for the detection of fungi, parasites, and yeasts, using fluorescent microscopy.","Calcofluor White Stain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827597","Computer Configuration","C85235","Refers to 1) the way a computer's operating system is set up, 2) the total combination of hardware components that make up the computer system, or 3) the specific software settings that have been established for the system.","Computer Configuration | Config | Configuration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827600","Lower Case Letter","C85241","Any of the small, non-capital alphabetic letters.","Lower Case Letter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827599","Upper Case Letter","C85240","One of the large alphabetic characters used as the first letter in writing or printing proper names and sometimes for emphasis.","Upper Case Letter | Capital Letter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883682","Token","C67478","A physical device or abstract concept, such as a PIN, that will enable authorized access to a computer system or network.","Token | token",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0454271","Low-Dose Rate Brachytherapy","C85254","Internal radiation treatment that targets a cancerous tissue with low doses of radiation through the use of inserted temporary or permanent implants.","Low-Dose Rate Brachytherapy | Brachytherapy, Low Dose | LOW-DOSE RATE BRACHYTHERAPY",,,,,,,,,,,,,,,"4040610|604265","Low dose rate brachytherapy|Low dose rate brachytherapy",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0436226","Proton Beam Radiation Therapy","C66897","A type of external beam radiation therapy using a beam of protons. It has the advantage of precisely localizing the radiation dose on the targeted tissue and avoiding damage to the healthy surrounding tissues.","Proton Beam Radiation Therapy | External Beam Radiotherapy (protons) | External beam radiation therapy protons (procedure) | PBRT | PROTON Therapy | Proton | Proton EBRT | Proton External Beam Radiotherapy | Proton Radiation Therapy | Radiation, Proton Beam | proton beam radiation therapy",,,,,,,,,,,,,,,"4024005|4058600","External beam radiation therapy protons|Proton therapy",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1710571","Unlikely Related to Intervention","C53257","A characteristic used to qualify the adverse event as unlikely related to the medical intervention. According to WHO causality assessment criteria of suspected adverse reactions it is applicable to a clinical event, including laboratory test abnormality, with a temporal relationship to the medical intervention which makes a causal relationship improbable, and in which other interventions or underlying disease provide plausible explanations.","Adverse Event Unlikely Related to Intervention | Doubtful Attribution | Unlikely | Unlikely Adverse Event Attribution to Product or Procedure | Unlikely Attribution | Unlikely Related | Unlikely Related to Intervention | Unlikely Related to Intervention | Unlikley Adverse Event Attribution to Product or Procedure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704623","Unrelated to Intervention","C53256","A characteristic used to qualify the adverse event as clearly not related to the medical intervention.","Adverse Event Unrelated to Intervention | Unrelated | Unrelated Attribution | Unrelated to Intervention | Unrelated to Intervention",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709683","Probable Attribution","C53259","A characteristic used to qualify the adverse event as likely related to the medical intervention. According to WHO causality assessment criteria of suspected adverse reactions it is applicable to a clinical event, including laboratory test abnormality, with a reasonable time sequence to the medical intervention, unlikely to be attributed to concurrent disease or other medical interventions, and which follows a clinically reasonable response on withdrawal (dechallenge). Rechallenge information is not required to fulfill this definition.","Adverse Event Probably Related to Intervention | Likely Related | Probable | Probable Attribution | Probably | Probably Related | Probably Related to Intervention | Probably Related to Intervention",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1547277","Draft","C85255","A preliminary version of a written work, design, or picture.","Draft | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827605","Central Office","C85256","The administrative office designated by a study coordinating center to receive expedited adverse event reports from the participating sites and then process, review, and submit those expedited reports to the sponsor.","Central Office | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826664","Adverse Event associated with Hospitalization","C83052","An indication or description that an adverse event is associated with or prolongs hospitalization.","Adverse Event associated with Hospitalization | AESHOSP | AE_HOSPITALIZATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827606","Recovered from Adverse Event without Sequelae","C85257","One of the possible results of an adverse event outcome where the subject recuperated and is free of any pathological conditions resulting from the prior disease or injury.","Recovered from Adverse Event without Sequelae | Recovered | Recovered or Resolved without Sequelae",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880147","Commercial Organization","C54620","A for-profit business, including individuals operating commercial enterprises as sole proprietorships, limited and general partnerships, and corporations; or a not-for-profit organization, including private educational and health services institutions, cooperatives, and corporations.","Commercial Organization | For Profit Organization",,,,,,,,,,,,,,,"762744","For profit organization",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347788","Clinical Study Lead Organization","C70790","An organization responsible for the overall scientific and administrative coordination, study monitoring, and data management activities of a particular clinical trial.","Clinical Study Lead Organization | Lead Organization | Lead Study Site | Study Lead Organization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825553","Numeric Value","C81274","Information in the form of a numeral contained in a data field.","Numeric Value | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826303","Elapsed Time","C82572","The interval between two reference points in time.","Elapsed Time | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0303979","Plastic","C86968","Various high-molecular-weight thermoplastic or thermosetting polymers that are capable of being molded, extruded, drawn, or otherwise shaped and then hardened into a form. It is solid in its finished state.","Plastic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699275","Schirmer test wetting","C75526","A test used to determine the amount of tears collected on a filter paper strip in 5 minutes.","Schirmer Test Wetting | SCHIRMER METHOD | Schirmer Test | Wetting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828081","NINCDS-ADRDA Criteria for Alzheimer's Disease","C86983","Criteria for the diagnosis of Alzheimer's disease (AD), proposed in 1984 by the National Institute of Neurological and Communicative Disorders (NINCDS) and the Stroke-Alzheimer's Disease and Related Disorders Association (ADRDA, now the Alzheimer's Association). The criteria state that existing cognitive impairment may be considered possible or probable AD by neuropsychological testing but definitive diagnosis requires histopathologic confirmation. They specify eight cognitive domains that may be impaired in AD: memory, language, perceptual skills, attention, constructive abilities, orientation, problem solving, and functional abilities.","NINCDS-ADRDA Criteria for Alzheimer's Disease | National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association Criteria for Alzheimer's Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022408","Arthropathy","C35760","Any disorder of the joints.","Arthropathy | Joint Disorder",,,,,,,,,,,,,,,"73553","Arthropathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2828146","Conclusive","C87050","Putting an end to doubt or question; leading to final results or an outcome.","Conclusive | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456984","Clinical Test Result","C77140","The result of a laboratory, radiologic, or other clinical test performed to determine the presence, absence, or degree of a condition.","Clinical Test Result | Clinical Measurement | Diagnostic Test Result | Test Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043345","Xeroderma","C35134","A non-neoplastic disorder characterized by abnormally dry skin.  Causes include vitamin A deficiency, sunlight exposure, medications, metabolic disorders, autoimmune disorders, and hereditary genetic disorders.","Xeroderma | ",,,,,,,,,,,,,,,"4198562","Xeroderma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2828152","International Classification of Diseases for Oncology, Third Edition","C87061","The third edition of the International Classification of Diseases for Oncology, published in 2000, used principally in tumor and cancer registries for coding the site (topography) and the histology (morphology) of neoplasms.","International Classification of Diseases for Oncology, Third Edition | ICD-O-3 | ICD-O-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828074","Wechsler Preschool and Primary Scale of Intelligence","C86974","An intelligence test published by Harcourt Assessment and designed for children ages 2 years 6 months to 7 years 3 months. It provides subtest and composite scores that represent intellectual functioning in verbal and performance cognitive domains, and provides a composite score that represents a child's general intellectual ability.","Wechsler Preschool and Primary Scale of Intelligence | WPPSI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0728820","Stanford Binet Intelligence Test","C86973","A standardized test to evaluate intelligence and cognitive abilities, suitable for both children and adults. It assesses five factors: Fluid Reasoning, Knowledge, Quantitative Reasoning, Visual-Spatial Processing, and Working Memory. In order to accurately assess individuals with deafness, limited English, or communication disorders, each factor is assessed in both verbal and nonverbal domains.","Stanford Binet Intelligence Test | Stanford Binet Intelligence Scale",,,,,,,,,,,,,,,"4158763","Stanford Binet intelligence scale",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2919020","DNA Index","C86972","The ratio of the DNA content or chromosome number in a tumor sample compared to that in a normal sample.","DNA Index | DNA_INDEX_NUMERIC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828073","Modal Chromosome Number","C86971","The most common chromosome number within a population or sample.","Modal Chromosome Number | Modal Number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527148","Development","C84377","The act of improving by expanding or enlarging or refining.","Development | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2750984","Strabismus","C35040","Strabismus is the intermittent or constant misalignment of an eye so that its line of vision is not pointed at the same object as the other eye. Strabismus is caused by an imbalance in the extraocular muscles which control the positioning of the eyes. Strabismus is normal in newborns but should resolve by the time the baby is 6 months old. In older children with strabismus, the brain may learn to ignore the input from one eye, and this may lead to amblyopia, a potentially permanent decrease in vision in that eye if not corrected.","Strabismus | Squint | Squinting",,,,,,,,,,,,,,,"4329707","Strabismus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710524","UV Radiation Exposure","C44462","The exposure to uv radiation via incident light from the sun.","UV Radiation Exposure | Ultraviolet Radiation Related Exposures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707519","Corrective Action Number","C53619","Number assigned to an action reported to FDA under 21 USC 260(f).","Corrective Action Number | CORRECTIVE ACTION NUMBER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035331","Retinal","C68300","Retinoid with an aldehyde group.","Retinal | RETINAL, ALL-TRANS | Retinaldehyde | Retinyl Aldehyde | Vitamin A Aldehyde",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511958","Digital Photography","C19342","Photographic images captured electronically.","Digital Photography | digital photography",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443221","Forced","C87139","Compelled by force or necessity.","Forced | ",,,,,,,,,,,,,,,"4137042","Forced",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0233888","Prepuberty","C87136","The period of development immediately prior to the onset of puberty when changes occur that lead to sexual maturity.","Prepuberty | Prepubertal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828180","Contact Biometry Measurement","C87141","Techniques to determine intraocular axial length that require contact with the eye.","Contact Biometry Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0776981","Eyepatch","C87142","A covering worn over one eye.","Eyepatch | ",,,,,,,,,,,,,,,"45762846","Eye patch",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0595921","Intraocular Pressure","C87143","The fluid pressure within the eye.","Intraocular Pressure | IOP",,,,,,,,,,,,,,,"4158245","Disorder of intraocular pressure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0183969","Tonometer","C87146","A handheld instrument that provides a measurement of intraocular pressure.","Tonometer | Tono-Pen",,,,,,,,,,,,,,,"4309296","Tonometer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034951","Refractive Error","C87145","A defect in the focusing of light on the retina as in astigmatism, myopia, or hyperopia.","Refractive Error | ",,,,,,,,,,,,,,,"4191597","Disorder of refraction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015421","Glasses","C87148","Frames with lenses worn in front of the eye for vision correction, eye protection, or protection from UV rays.","Glasses | Eyeglasses",,,,,,,,,,,,,,,"4173573","Eyeglasses",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042812","Visual Acuity","C87149","Sharpness of vision, the ability to discern fine detail.","Visual Acuity | VA",,,,,,,,,,,,,,,"4239582","Visual acuity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1299003","Ocular","C87163","Of or relating to the eye.","Ocular | ",,,,,,,,,,,,,,,"42538089","Ocular",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL449053","Retinal","C87176","Of, relating to, or involving the retina.","Retinal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL791262","TOP2A protein, human","C17801","DNA topoisomerase 2-alpha (1531 aa, ~174 kDa) is encoded by the human TOP2A gene. This protein is involved in the modulation of DNA topology.","DNA Topoisomerase 2-Alpha | DNA Topoisomerase II, 170 kD | DNA Topoisomerase II, Alpha | DNA Topoisomerase II, Alpha Isozyme | DNA Topoisomerase II-Alpha | EC 5.6.2.2 | TOP2A | Topo II Alpha | Topoisomerase (DNA) II Alpha (170kD) | Topoisomerase (DNA) II Alpha 170kDa | Topoisomerase II Alpha | Topoisomerase II Alpha | Topoisomerase, DNA, II, Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040078","Thymidine Kinase","C17198","Human Thymidine Kinases (Thymidine Kinase Family) catalyze thymidine phosphorylation via ATP to deoxythymidine monophosphate. (NCI)","Thymidine Kinase | EC 2.7.1.21",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1529821","CDKN1A protein, human","C17783","Cyclin-dependent kinase inhibitor 1 (164 aa, ~18 kDa) is encoded by the human CDKN1A gene. This protein is involved in cell cycle arrest.","Cyclin-Dependent Kinase Inhibitor 1 | CDK-Interacting Protein 1 | CDKN1A | CDKN1A Protein | CIP-1 Protein | Cyclin-Dependent Kinase Inhibitor 1A | MDA 6 | MDA-6 | Melanoma Differentiation-Associated Protein 6 | WAF-1 Protein | Waf1p21 | p21 | p21CIP1 | p21Cip1/Waf1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1741716","G1/S-Specific Cyclin-D1, Human","C17988","G1/S-specific cyclin-D1 (295 aa, ~34 kDa) is encoded by the human CCND1 gene. This protein is involved in the regulation of the G1/S transition of the cell cycle.","G1/S-Specific Cyclin-D1 | BCL-1 Oncogene | BCL1 | CCND1 | CCND1a | Cyclin D | Cyclin D1 | Cyclin D1a | Cyclin-D1 | Cyclin-D1a | D11S287E | G1/S-Specific Cyclin D1 | G1/S-Specific Cyclin D1a | G1/S-Specific Cyclin-D1a | G2/S-Specific Cyclin-D1 | PRAD1 | PRAD1 Oncogene | U21B31",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919418","Cyclin-Dependent Kinase Inhibitor Proteins","C18492","A protein that plays a role in the inhibition of cyclin-dependent kinases.","Cyclin-Dependent Kinase Inhibitor Protein | CDK Inhibitor Protein | CDKI Protein | Cyclin Kinase Inhibitor | Cyclin-Dependent Kinase Inhibitor | Cyclin-Dependent Kinase Inhibitor | Cyclin-Dependent Kinase Inhibitors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002395","Alzheimer's Disease","C2866","A progressive, neurodegenerative disease characterized by loss of function and death of nerve cells in several areas of the brain leading to loss of cognitive function such as memory and language.","Alzheimer's Disease | Alzheimer Disease | Alzheimer dementia | Alzheimer disease | Alzheimer's Dementia | Alzheimer's disease | Alzheimer's disease, unspecified | Alzheimer’s disease",,,,,,,,,,,,,,,"378419","Alzheimer's disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0079150","Electronic Medical Record","C45259","An automated, on-line medical record containing clinical and demographic information about a patient that is available to providers, ancillary service departments, pharmacies, and others involved in patient treatment or care.","Electronic Medical Record | Computer Based Patient Record | EMR | EMR (electronic medical record) | electronic medical record",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973049","Stress Electrocardiography","C80406","A recording of cardiac electrical activity during stress or exercise.","Stress Electrocardiography | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202054","Glycosylated Hemoglobin Measurement","C64849","A quantitative measurement of the amount of glycosylated hemoglobin present in a sample of blood.","Glycosylated Hemoglobin Measurement | Glycated Hemoglobin | Glycosylated Hemoglobin A1C | HBA1C | HbA1c | Hemoglobin A1C | Hemoglobin A1C Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0344420","Left Bundle Branch Block by ECG Finding","C62269","An electrocardiographic finding of a wide QRS complex with evidence of delayed conduction to the left ventricle, manifested as a widened initial portion of the QRS complex in leads V5, V6, I and aVL and with QRS duration greater than or equal to 120 ms. (CDISC)","Left Bundle Branch Block by ECG Finding | Complete LBBB | LBBB | LEFT BUNDLE BRANCH BLOCK | Left Bundle Branch Block | Left Bundle Branch Block | Left Bundle Branch Block by EKG Finding | Left bundle branch block | Left bundle-branch block",,,,,,,,,,,,,,,"4064614","EKG: left bundle branch block",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3278726","Right Bundle Branch Block by ECG Finding","C62270","An electrocardiographic finding of a wide QRS complex with evidence of delayed conduction to the right ventricle, manifested by a widened initial portion of the QRS in V1 and V2, a widened S wave in V5, V6, I and aVL, and with QRS duration greater than or equal to 120 ms.  An RsR' complex is typically present in leads V1 and V2. (CDISC)","Right Bundle Branch Block by ECG Finding | Complete RBBB | RBBB | RIGHT BUNDLE BRANCH BLOCK | Right Bundle Branch Block | Right Bundle Branch Block | Right Bundle Branch Block by EKG Finding | Right bundle branch block | Right bundle-branch block",,,,,,,,,,,,,,,"314059|4064460","Right bundle branch block|EKG: right bundle branch block",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3278719","Left Ventricular Hypertrophy","C50631","Enlargement or overgrowth of the myocardium of the left ventricle, due to chronic pressure overload.","Left Ventricular Hypertrophy | ",,,,,,,,,,,,,,,"4184746","Left ventricular hypertrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2749773","Right Ventricular Hypertrophy","C50734","Enlargement or overgrowth of the myocardium of the right ventricle, due chronic pressure overload.","Right Ventricular Hypertrophy | ",,,,,,,,,,,,,,,"4231591","Right ventricular hypertrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037492","Sodium Channel","C17145","An ion channel with selective permeability for sodium.","Sodium Channel | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332206","Block","C61286","Interrupt the normal function of; hinder or prevent the progress or accomplishment of; stop from happening or developing; interfere with or prevent the reception of signals; impede the movement of.","Block | Blockade | Blocked | Blocking",,,,,,,,,,,,,,,"4008386","Blocking",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265388","Autosomal Recessive Disorder","C85866","An inherited disorder manifested only when two copies of a mutated gene are present.","Autosomal Recessive Disorder | Autosomal Recessive Inherited Disorder",,,,,,,,,,,,,,,"4312226","Autosomal recessive hereditary disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043210","Woman","C14284","An adult, female human.","Woman | Human, Female",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1552743","State","C87194","A constituent administrative district of a nation.","State | Territory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828209","Mailstop Code","C87190","A unique routing code used by a company or organization for internal mail delivery.","Mailstop Code | MSC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828208","Locality","C87189","A location known by a local name (e.g., neighborhood, place, or district).","Locality | Geographic Locality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001567","Administrative District","C87191","A location defined for administrative purposes.","Administrative District | Adminstrative District",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016249","floor (object)","C87192","A location comprising a single level of a multilevel building.","Story | Floor | Level",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449056","Subdivision","C87193","An area of real estate divided into multiple lots.","Subdivision | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337652","Living Quarters","C86029","Housing in which people can reside.","Living Quarters | DWELLTYP | Dwelling Type | Housing",,,,,,,,,,,,,,,"4251773","Living quarters",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0745696","Corrective Lens","C87188","A lens generally worn in front of the eye, mainly used to treat myopia, hyperopia, astigmatism, and presbyopia. This includes glasses, contact lenses, and intraocular implanted lenses.","Corrective Lens | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086032","Color Vision","C87177","The ability to perceive differences in color.","Color Vision | ",,,,,,,,,,,,,,,"4155901","Color vision",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010031","Cornea","C12342","A dome-shaped, transparent, avascular tissue covering the front of the eye. It is composed of five layers: squamous epithelium, Bowman's membrane, stroma, Descemet's membrane, and endothelium. Refraction of light contributing to eye's focusing ability is its characteristic function. It contains unmyelinated nerve endings which are responsible for the high sensitivity of the tissue.","Cornea | CORNEA | Cornea, NOS | Corneal structure (body structure) | EYE, CORNEA | Human Cornea | cornea",,,,,,,,,,,,,,,"4102766","Corneal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0220952","Diagnostic and Statistical Manual of Mental Disorders, 4th Edition","C86966","Published by the American Psychiatric Association, the DSM is a listing of currently recognized mental health disorders and their diagnostic criteria, for children and adults. It includes statistical information on etiology, incidence, prevalence, age of onset and prognosis. The 4th edition was published in 1994. As new information becomes available subsequent editions are published.","Diagnostic and Statistical Manual of Mental Disorders, 4th Edition | DSM-4 | DSM-IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0679229","Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition","C86967","Published by the American Psychiatric Association, the DSM is a listing of currently recognized mental health disorders and their diagnostic criteria, for children and adults. It includes statistical information on etiology, incidence, prevalence, age of onset and prognosis. The 3rd edition was published in 1980. As new information becomes available subsequent editions are published.","Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition | DSM-3 | DSM-III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1328319","Ankle-Brachial Index","C87304","The ratio of ankle systolic pressure to brachial systolic pressure, used to assess arterial insufficiency in the lower extremities.","Ankle-Brachial Index | ABI | Ankle-Arm Index | Ankle-Arm Pressure Index | Ankle-Brachial Pressure Index",,,,,,,,,,,,,,,"40489833","Ankle brachial pressure index",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2828255","Quartile","C87306","Any of four equal-sized sets of observations in a ranked sample.","Quartile | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828256","Cognitive Abilities Screening Instrument","C87307","A 25-item screening test for dementia that provides quantitative assessment on attention, concentration, orientation, short-term memory, long-term memory, language abilities, visual construction, list-generating fluency, abstraction, and judgment.","Cognitive Abilities Screening Instrument | CASI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085132","Sly Syndrome","C84903","A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme beta-glucuronidase. It is characterized by hepatosplenomegaly, skeletal deformities, enlarged head, and mental retardation.","Sly Syndrome | Beta-Glucuronidase Deficiency | Mucopolysaccharidosis Type VII",,,,,,,,,,,,,,,"4184782","Mucopolysaccharidosis, MPS-VII",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2828254","Snellen Fraction","C87305","A representation of visual acuity in the form of a fraction that relates a subject's visual acuity to that of a standardized norm. The numerator is the testing distance and the denominator is the relative distance at which a specific line can be read.","Snellen Fraction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1140095","Current Procedural Terminology","C87308","A proprietary medical nomenclature of the American Medical Association widely used to report medical procedures and services under public and private health insurance programs.","Current Procedural Terminology | CPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0071810","Pramocaine","C61903","A morpholine derivative with local anesthetic property. Pramocaine decreases the permeability of the neuronal membrane to sodium ions by reversibly binding to and inhibiting voltage-gated sodium channels. This results in stabilization of the membrane and, thereby inhibiting the ionic fluxes required for membrane depolarization, hence resulting in the failure to initiate a propagated action potential and subsequent conduction blockade.","Pramocaine | 4-(3-(p-Butoxyphenoxy)propyl)morpholine | PRAMOXINE | Pramoxine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1523982","TRIad of COstimulatory Molecules (B7-1, ICAM-1, LFA-3)","C2192","TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3).  An immunostimulant.","TRICOM | B7-1, ICAM-1, LFA-3 | B7-1, intercellular adhesion molecule-1, and leukocyte function-associated antigen-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0297960","Patupilone","C1623","A compound isolated from the myxobacterium Sorangium cellulosum.  Similar to paclitaxel, patupilone induces microtubule polymerization and stabilizes microtubules against depolymerization conditions.  In addition to promoting tubulin polymerization and stabilization of microtubules, this agent is cytotoxic for cells overexpressing P-glycoprotein, a characteristic that distinguishes it from the taxanes.  Patupilone may cause complete cell-cycle arrest.","Patupilone | (-)-Epothilone B | (1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione | EPO-906A | EPO906 | Epothilone B | Epothilone B | PATUPILONE | epothilone B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828257","International Classification of Diseases for Oncology, Second Edition","C87309","The second edition of the International Classification of Diseases for Oncology, published by the World Health Organization in 1992, and used for coding neoplasms between 1992 and 2000.","International Classification of Diseases for Oncology, Second Edition | ICD-O-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1552910","Mile","C71183","A traditional unit of distance equal to 5280 international feet, 1760 international yards, or 1609.344 meters.","Mile | International Mile | Statute Mile | [mi_i] | statute mile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828033","Pipe","C86044","A tube with a small bowl at one end, especially one used for smoking tobacco.","Pipe | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0232305","Right Ventricular Hypertrophy by ECG Finding","C71077","An electrocardiographic finding suggestive of a hypertrophied right ventricle, characterized by large R wave amplitudes in the right precordial leads and secondary findings of right atrial enlargement, right axis deviation, and typical pattern of ST depression and T wave inversion in the right precordial leads. (CDISC)","Right Ventricular Hypertrophy by ECG Finding | RIGHT VENTRICULAR HYPERTROPHY | Right Ventricular Hypertrophy | Right Ventricular Hypertrophy by EKG Finding | Right ventricular Hypertrophy",,,,,,,,,,,,,,,"4065283","EKG: right ventricle hypertrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0232306","Left Ventricular Hypertrophy by ECG Finding","C71076","An electrocardiographic finding suggestive of a hypertrophied left ventricle, characterized by large QRS amplitudes and secondary findings of left atrial enlargement, left axis deviation, or typical pattern of ST depression and T wave inversion. (CDISC)","Left Ventricular Hypertrophy by ECG Finding | LEFT VENTRICULAR HYPERTROPHY | Left Ventricular Hypertrophy | Left Ventricular Hypertrophy | Left Ventricular Hypertrophy by EKG Finding",,,,,,,,,,,,,,,"4065282|4102533","EKG:left ventricle hypertrophy|Left ventricular hypertrophy by electrocardiogram",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0556640","Megabecquerel","C70512","A unit of radioactivity equal to 10E6 nuclear disintegrations or other nuclear transformations per second, or to 10E6 becquerels.","Megabecquerel | MBq | megabecquerel(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032850","Fowls, Domestic","C53475","Domesticated fowl grown for their meat and eggs.","Poultry | POULTRY, UNSPECIFIED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0452867","Pork","C71958","The meat of the domestic pig.","Pork | PORK",,,,,,,,,,,,,,,"4037243","Pork",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005639","Bisexuality","C84364","A sexual attraction to members of both sexes, genders, or gender identities.","Bisexuality | BISEXUAL | Bi | Bisexual",,,,,,,,,,,,,,,"4170582","Bisexual",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019900","Homosexuality","C84363","A sexual attraction to members of the same sex.","Homosexuality | GAY | Gay | Homosexual",,,,,,,,,,,,,,,"444056","Gay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016053","Fibromyalgia","C87497","A chronic disorder of unknown etiology characterized by pain, stiffness, and tenderness in the muscles of neck, shoulders, back, hips, arms, and legs. Other signs and symptoms include headaches, fatigue, sleep disturbances, and painful menstruation.","Fibromyalgia | Fibromyalgia Syndrome",,,,,,,,,,,,,,,"40405599","Fibromyalgia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1846439","Odontoid Hypoplasia","C86969","An often asymptomatic developmental abnormality of the cervical spine. It is characterized by the hypoplasia of the odontoid which appears as a stubby peg of an odontoid process. Symptoms may develop after minor trauma and include localized neck pain, atlantoaxial instability, and transient or permanent neurologic manifestations.","Odontoid Hypoplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040479","Torsades De Pointes by ECG Finding","C50779","An electrocardiographic finding of an atypical rapid polymorphic ventricular tachycardia with a characteristic rotation of the QRS complex around the isoelectric baseline, occurring in the setting of a prolonged QT interval. In addition, the QRS complex displays a periodic waxing and waning of amplitude on the electrocardiogram.","Torsades De Pointes by ECG Finding | TORSADES DE POINTES | Torsades De Pointes | Torsades De Pointes | Torsades De Pointes by EKG Finding | Torsades de Pointes | Torsades de pointes | Ventricular tachycardia, torsades de pointes",,,,,,,,,,,,,,,"4135823|4141527","Torsades de pointes|EKG: torsades de pointes",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1881010","Grouping Factor","C61039","A factor whose levels separate the sampling units into groups whereby no subject is exposed to more than one level of the factor.","Grouping Factor | Between-Subjects Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1550543","Fulfill","C87531","Satisfy the requirements or expectations of.","Fulfill | Meet | Met",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0807984","Sample Weight","C87555","A positive numeric adjustment for a value based on its relative representation in a population. It is used to adjust sample data to correct for design features such as oversampling and design deficiencies such as nonresponse.","Sample Weight | ",,,,,,,,,,,,,,,"4013575|4160351","Specimen mass measurement|Specimen weight",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2981279","Decade","C87556","A period of 10 years.","Decade | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0771967","Black Cohosh","C26647","A triterpene-containing herb isolated from the roots and rhizomes of the plant Cimicifuga racemosa (also known as Actaea racemosa). While the mechanism of action of black cohosh is not completely understood, it appears to act as a selective estrogen receptor modulator.  In vitro, this preparation has been shown to induce cell cycle arrest and caspase-dependent apoptosis of estrogen-sensitive breast cancer cells. (NCI04)","Black Cohosh | Actaea racemosa Root | BLACK COHOSH | Cimicifuga racemosa Root | Cimicifugae racemosae Rhizoma | Fariy Candle Root | Remifemin | black cohosh | black snakeroot | bugbane | bugwort | rattlesnake root",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0993630","Garlic","C38706","A bulbous herb isolated from the plant Allium sativum with potential antineoplastic activity. Garlic contains a number of different organosulfur compounds, some of which have displayed antineoplastic activity. (NCI04)","Garlic | Ajo | Allium Sativum | Allium sativum | GARLIC | garlic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0813171","St. John's Wort","C2589","An herbal extract prepared from the plant Hypericum perforatum (St. John's wort) with photodynamic, antineoplastic, and antidepressant activities. Hypericin, one of the active compounds found in Hypericum perforatum, is a photosensitizer that, when exposed to a particular wavelength and intensity of light, may induce tumor cell apoptosis. Another compound, hyperforin, induces caspase-dependent apoptosis in certain tumor cell lines. Hypericum perforatum preparations may also stimulate the activity of cytochrome P450 enzymes and P-glycoprotein drug transporters, resulting in increased metabolism and decreased efficacy of various chemotherapeutic agents and other drugs.","St. John's Wort | Hypericum Perforatum Extract | ST. JOHN'S WORT | St John's Wort | St. John's wort | hypericum perforatum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281563","Shark Cartilage","C2318","A nutritional supplement gleaned from the exoskeleton of the shark. Shark cartilage inhibits metalloproteinases (MMPs) and possesses antiangiogenic and antimetastatic properties. (NCI04)","Shark Cartilage | BeneFin (Lane Shark Cartilage Powder) | Cartilade | SHARK CARTILAGE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019234","Herbalism","C15250","Therapy based on plant-derived preparations which include the following: Individual herbs - Ginkgo biloba, Hypericum, Garlic, Ginseng, Echinacea, Saw palmetto, Urtica diocia (nettle), Kava kava, Hawthorne, Witch Hazel, Bilberry, Ginger, Aloe vera, Capsicum, Feverfew, Green tea, Tee Tree oil, Licorice root, Yohimbe, Valerian, Bee Pollen, Cat's Claw, Evening Primrose, Dong Quai, Fenugreek, Marshmallow, Psyllium, Turmeric. Combinations include: Padma 28, Hoxey, Essiac, Saw palmetto, Pygeum africanum.","Botanical Therapy | Herbal Medicine / Botanical Therapy | Herbal Therapy | Phytotherapy or Herbalism | herbal medicine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0795585","Bee Pollen","C87557","A supplement containing granules composed of pollen gathered by bees for food and honey. Although the exact composition of nutrients in bee pollen differs depending on various factors, in general it contains important nutrients including vitamins, minerals, amino acids, carotenes, antioxidants, trace elements, carbohydrates as well as other unidentified substances.","Bee Pollen | BEE POLLEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0872889","CHASTEBERRY","C87559","The round, black berries of the flowering shrub Vitex agnus-castus, native to Mediterranean countries and Asia. Chaste berries contain glycosides, flavonoids, alkaloids, monoterpenes, and sesquiterpenes. Chaste berries are considered as a reproductive tonic herb.","Chaste Berry | Chasteberry | Monk's Pepper | chaste tree berry | monk's pepper",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981281","Chickweed Tincture","C87560","A tincture made from the dried parts of Stellaria media, a widespread annual plant. Chickweed tincture contains mucilage, saponins, silica, minerals, vitamins A, B, C and fatty acids. It may have expectorant and anti-septic actions.","Chickweed Tincture | Starweed | Stitchwort",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3486602","Chamaelirium luteum root extract","C87561","An herbal remedy made from the dried root of Chamaelirium luteum, a lily native to the eastern and southern parts of North America. The root contains steroidal saponins and glycosides such as chamaelirin, helonin and diosgenin, and the fatty acids oleic, linoleic, and stearic acid. This product is mostly used as a tonic.","Chamaelirium luteum Root | Blazing Star | CHAMAELIRIUM LUTEUM ROOT | Devil's Bit | False Unicorn Root | False Unicorn Root | Helonias Root",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019233","Herbal Tea","C87562","An aqueous extract derived from parts of various plants, but excluding that made from the leaves of the real tea bush Camellia sinensis. The parts used can be fresh or dried leaves, roots, seeds and flowers.","Herbal Tea | ",,,,,,,,,,,,,,,"4023861","Herbal tea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0125173","Lachesis Venom","C87563","A homeopathic remedy derived from the venom of the bushmaster snake, Lachesis Muta, found in Central and South America. Fresh lachesis is diluted in alcohol to obtain the mother tincture.","Lachesis Venom | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642442","Glycyrrhiza lepidota Root","C87564","The dried root of Glycyrrhiza glabra, a legume native to southern Europe and parts of Asia. Licorice root contains glycyrrhizin that is hydrolyzed to the main sweet component glycyrrhetic acid.","Glycyrrhiza lepidota Root | American Licorice Root | GLYCYRRHIZA LEPIDOTA ROOT | Glycyrrhiza glutinosa Root | Licorice Root",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981283","Nux Vomica Seed","C87566","An herbal remedy derived from the seeds of the evergreen tree Strychnos nux-vomica, a native to southeast Asia and northern Australia. The seeds, found inside the green to orange-colored fruit, contain the alkaloids strychnine and brucine that can act as a CNS stimulant at therapeutic doses.","Nux Vomica Seed | Strychnine Tree Seed | Strychnos nux-vomixa Seed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0073603","Royal Jelly","C87569","A honey bee secretion that is used in the nutrition of larvae and to stimulate development of adult queens. It contains B-complex vitamins such as pantothenic acid (vitamin B5) and vitamin B6 (pyridoxine), amino acids, minerals, enzymes, monosaccharides and 10-hydroxy-2-decenoic acid (10-HDA). Royal jelly has been shown to have antibacterial and immunomodulatory activities.","Royal Jelly | ROYAL JELLY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981284","Sage Tea","C87570","An herbal tea made from the dried leaves of Salvia officinalis, a small perennial evergreen. Sage leaves contain tannic acid, oleic acid, ursonic acid, ursolic acid, cornsole, cornsolic acid, fumaric acid, chlorogenic acid, caffeic acid, niacin, nicotinamide, flavones, flavonoid glycosides, and estrogenic substances. Extract of Sage exhibits antioxidant and radical-scavenging activities.","Sage Tea | Salvia officinalis Tea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0771635","Sarsaparilla","C87571","An herbal product made from the dried root of the several perennial trailing vines of the genus Smilax, native to Central America. Sarsaparilla, used commonly as a flavoring, contains steroidal saponins, numerous phytosterols and flavonoids.","Sarsaparilla | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981285","Sepia Ink","C87572","The dark ink ejected from cuttlefish of the order Sepiida. The ink, containing melanin, can be dried and mixed with lactose to produce a mother tincture.","Sepia Ink | Cuttlefish Ink | Sepia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0770599","Pulsatilla preparation","C71828","An herbal remedy derived from perennial plants of the genus Pulsatilla, a native to central and northern Europe and southern England. The plant contains lactones, saponins, anemone camphor, tannins, and a volatile oil. This remedy has been used traditionally to induce abortions and childbirth.","Pulsatilla Extract | Meadow Anemone | Pasque Flower | Wind Flower",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448750","Migration","C50651","Non-random movement of an object(s) from one location to another.","Migration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981367","Institutional Biosafety Committee","C87779","An institutional-level board mandated by federal law for oversight of recombinant DNA research and work involving biohazardous agents taking place at that institution. They are charged with assessing the risk of research to the environment and to public health. The board must have at least five members, with at least one with recombinant DNA expertise; at least two members must be unaffiliated with the institution.","Institutional Biosafety Committee | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0795675","Valeriana officinalis homeopathic preparation","C38725","An herbal extract isolated from the root of the plant Valeriana officinalis with sedative and anxiolytic activities.  Valeriana officinalis extract contains four distinct classes of phytochemical constituents: volatile oils; sesquiterpenoids, including valerenic acid and its hydroxyl and acetoxyl derivative; valepotriates; and volatile pyridine alkaloids. Although the exact mechanism of action has not been established, the sesquiterpenoids in Valeriana officinalis extract, particularly valerenic acid, appear to account for its sedative and anxiolytic effects.  Valerenic acid is both a subtype-selective GABA-A receptor agonist and a 5HT-5A receptor partial agonist. The sedative-hypnotic benzodiazepines are GABA-A receptor agonists.","Valerian | VALERIAN | Valeriana Officinalis Extract",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706308","Jaw","C54020","A device designed to use opposing parts to close on and hold an object.","Jaw Device | Jaw | Jaw Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981382","Pincers","C87796","A tool consisting of a pair of handled jaws designed for holding and pulling.","Pincers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024748","Alpha-Mannosidosis","C84548","An autosomal recessive lysosomal storage disease characterized by deficient activity of the enzyme alpha-D-mannosidase. There is a wide range of signs and symptoms including hepatomegaly, splenomegaly, hearing loss, respiratory infections, mental retardation, skeletal abnormalities, leveled nasal bridge and protruding forehead.","Alpha-Mannosidosis | ",,,,,,,,,,,,,,,"4051046","Deficiency of alpha-mannosidase",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0237897","Physical Strength","C87802","Degree of intensity or force in regard to a physical activity.","Physical Strength | Strength",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0396568","Wedge Resection of Lung","C51625","Surgical removal of a wedge-shaped section of lung.","Wedge Resection of Lung | Wedge Excision of Lung",,,,,,,,,,,,,,,"4337034","Wedge excision of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516294","Cardiac Muscle Contraction","C30095","Driven primarily by voltage-gated Ca+2 action potentials originating in sinoatrial pace-maker cells, Cardiac Muscle Contraction involves shortening of the gap junction-linked nonsyncytial striated heart myocytes in the atrial and ventricular chambers that forces movement of the blood through the circulatory system.","Cardiac Muscle Contraction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1289960","Desvenlafaxine","C61703","A synthetic phenethylamine bicyclic derivative with antidepressant activity. Desvenlafaxine is a selective reuptake inhibitor of serotonin and norepinephrine due to its high binding affinities to the pre-synaptic serotonin and norepinephrine transporters. By blocking both transporters, this agent prolongs neurotransmitter activities of both serotonin and norepinephrine, thereby alleviating depressive state.","Desvenlafaxine | DESVENLAFAXINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043443","Ketotifen Fumarate","C47579","The fumarate salt of ketotifen, a cycloheptathiophene derivative with anti-allergic activity. Ketotifen selectively blocks histamine (H1) receptors and prevents the typical symptoms caused by histamine release. This agent also interferes with the release of inflammatory mediators from mast cells involved in hypersensitivity reactions, thereby decreasing chemotaxis and activation of eosinophils.","Ketotifen Fumarate | 10H-Benzo(4,5)cyclohepta(1,2-b)thiophen-10-one, 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-,(E)-2-butenedioate(1:1) | 4-(1-Methyl-4-piperidylidene)-4H-benzo[4,5]cyclohepta[1,2-b] thiophen-10(9H)-one hydrogen fumarate | KETOTIFEN FUMARATE | Zaditen | Zaditor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3277040","Valvular Insufficiency","C50796","Dysfunction of one of the cardiac valves characterized by incomplete valve closure.","Valvular Insufficiency | Valvular Insufficiency/ Regurgitation",,,,,,,,,,,,,,,"45769385","Valvular insufficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040960","Tricuspid Valve","C12805","A three-cusp valve of the heart that regulates the flow of blood between the right atrium and the right ventricle of the heart.","Tricuspid Valve | Right Atrioventricular Valve | TRICUSPID VALVE | Tricuspid valve structure (body structure) | VALVE, RIGHT ATRIOVENTRICULAR",,,,,,,,,,,,,,,"4263592","Tricuspid valve structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034086","Pulmonary Valve","C12775","A valve that is located between and controls the flow of blood from the right ventricle of the heart and the pulmonary artery.","Pulmonary Valve | PULMONARY VALVE | Pulmonary valve structure (body structure) | Pulmonic Valve | VALVE, PULMONARY",,,,,,,,,,,,,,,"4191610","Pulmonary valve structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026264","Mitral Valve","C12753","A dual-flap valve of the heart that regulates the flow of blood between the left atrium and the left ventricle of the heart.","Mitral Valve | Left Atrioventricular Valve | MITRAL VALVE | Mitral valve structure (body structure) | VALVE, LEFT ATRIOVENTRICULAR",,,,,,,,,,,,,,,"4237831","Mitral valve structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003501","Aortic Valve","C12670","A valve that is located between and controls the flow of blood from the left ventricle of the heart and the aorta.","Aortic Valve | AORTIC VALVE | Aortic valve structure (body structure) | VALVE, AORTIC",,,,,,,,,,,,,,,"4145283","Aortic valve structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1520755","17q","C13543","Distal (long) arm of chromosome 17","17q | Chromosome 17 Distal Arm | Chromosome 17 Long Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1327813","chromosome 14q","C13538","Distal (long) arm of chromosome 14","14q | Chromosome 14 Distal Arm | Chromosome 14 Long Arm | Chromosome 14q",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520839","Chromosome 19 Short Arm","C13545","Proximal (short) arm of chromosome 19","19p | Chromosome 19 Proximal Arm | Chromosome 19 Short Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516518","Chromosomal Insertion","C6828","A chromosomal rearrangement in which a segment a segment of DNA is added internally to a chromosome.","Chromosomal Insertion | ins",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021943","Chromosomal Inversion","C6827","A type of chromosome rearrangement in which a segment has been turned through 180 degrees (inverted), and inserted back into its original location on the chromosome.","Chromosomal Inversion | Inversion | Inversion, Chromosomal | Inverted Chromosome | inv",,,,,,,,,,,,,,,"4219494|4246618","Chromosome inversion|Genetic inversion",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1327810","Chromosome 1 Short Arm","C13526","Proximal (short) arm of chromosome 1","1p | Chromosome 1 Proximal Arm | Chromosome 1 Short Arm | Chromosome 1p",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520690","16q","C13542","Distal (long) arm of chromosome 16","16q | Chromosome 16 Distal Arm | Chromosome 16 Long Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520537","13q","C13534","Distal (long) arm of chromosome 13","13q | Chromosome 13 Distal Arm | Chromosome 13 Long Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812225","Kit device","C42793","Gear consisting of a set of articles or tools for a specified purpose","Kit | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512348","Health Information National Trends Survey","C20093","A survey designed to collect nationally representative data routinely about the American public's use of cancer-related information. The survey provides updates on changing patterns, needs, and information opportunities in health, identifies changing communications trends and practices, assesses cancer information access and usage, provides information about how cancer risks are perceived, and offers a testbed to researchers to test new theories in health communication.","Health Information National Trends Survey | HINTS | NCI Health Information National Trends Survey | Use of Technology for Health",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473812","Little","C76350","A small amount or duration.","Little | Scant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334276","Adenocarcinoma In Situ","C4123","A lesion in which the normally situated glands are partially or completely replaced by atypical cells with malignant characteristics.","Adenocarcinoma In Situ | AIS | Adenocarcinoma in situ | Adenocarcinoma in situ, NOS","8140/2","Adenocarcinoma in situ, NOS",,,,,,,,,,,,,"4198862","Adenocarcinoma in situ",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0699791","Gastric Carcinoma","C4911","A malignant epithelial tumor of the stomach mucosa. The vast majority of gastric carcinomas are adenocarcinomas, arising from the gastric glandular epithelium.","Gastric Carcinoma | Cancer of Stomach | Cancer of the Stomach | Carcinoma of Stomach | Carcinoma of the Stomach | Gastric (Stomach) Cancer | Gastric Cancer | Gastric cancer, NOS | Stomach Cancer | Stomach Carcinoma | gastric cancer | stomach cancer",,,,,,,,,,,,,,,"4155299","Carcinoma of stomach",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1305143","Hyperdiploidy","C80336","A chromosomal abnormality in which the chromosomal number is greater than the normal diploid number.","Hyperdiploidy | Hyperdiploid",,,,,,,,,,,,,,,"4208087","Hyperploidy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0333691","Hypodiploidy","C80337","A chromosomal abnormality in which the chromosomal number is less than the normal diploid number.","Hypodiploidy | Hypodiploid",,,,,,,,,,,,,,,"4048414","Hypoploidy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0582680","Vineland Adaptive Behavior Scales","C88048","An instrument for evaluation of social functioning in individuals from preschool to 18 years old. Focusing on adaptive behaviors, the results are meant to support the diagnosis of intellectual and developmental disabilities.","Vineland Adaptive Behavior Scales | VABS",,,,,,,,,,,,,,,"4126647","Vineland adaptive behavior scales",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1663627","ALK Tyrosine Kinase Receptor, Human","C27032","ALK tyrosine kinase receptor (1620 aa, ~176 kDa) is encoded by the human ALK gene. This protein is involved in ligand binding, tyrosine phosphorylation and signal transduction.","ALK Tyrosine Kinase Receptor | ALK | Anaplastic Lymphoma Kinase | Anaplastic Lymphoma Kinase | CD246 Antigen | EC 2.7.10.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417123","MET Gene","C18325","This gene plays a regulatory role in the modulation of cell-surface receptors and hepatocyte growth factor interactions.","MET Gene | MET | MET Proto-Oncogene, Receptor Tyrosine Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705785","BIRC5 wt Allele","C49359","Human BIRC5 wild-type allele is located in the vicinity of 17q25 and is approximately 10 kb in length. This allele, which encodes baculoviral IAP repeat-containing protein 5, is involved in the prevention of apoptotic cell death.","BIRC5 wt Allele | API4 | Baculoviral IAP Repeat-Containing 5 wt Allele | EPR-1 | IAP4 | Survivin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007594","Cell Fusion","C16401","A technique to form a single hybrid cell, by fusion of two or more dissimilar cells, either spontaneously or by induced fusion. The cells fuse and coalesce, but their nuclei may remain separated.  The cell fusion technique can be used as a method of assigning genes to specific chromosomes.","Cell Fusion | Cell Biology, Cell Fusion",,,,,,,,,,,,,,,"4202070","Cell fusion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242508","Recreational Drug","C84368","A drug used for personal enjoyment rather than for medicinal purposes.","Recreational Drug | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0115471","3,4-Methylenedioxymethamphetamine","C61081","A ring-substituted amphetamine derivative, structurally related to the hallucinogen mescaline, with entactogenic, neurotoxic, and motor-stimulatory activities. 3,4-methylenedioxymethamphetamine (MDMA) produces an acute, rapid enhancement in both the release of serotonin from and the inhibition of serotonin reuptake by serotonergic nerve endings in the brain. Once within the cell, MDMA depletes stores of tryptophan hydroxylase (TPH) via acute oxidative inactivation; in turn, depleted stores of TPH leave cell terminals open to damage from oxidative stress, possibly a source of MDMA neurotoxicity. This agent also induces norepinephrine, dopamine, and acetylcholine release and can act directly on a number of receptors, including alpha 2-adrenergic and 5-hydroxytryptamine (5-HT) 2A receptors. MDMA may suppress the dyskinesia associated with long-term use of L-dopamine (L-DOPA) without affecting the efficacy of L-DOPA treatment.","3,4-Methylenedioxymethamphetamine | Ecstasy | MDMA | MIDOMAFETAMINE | N-Methyl-3,4-methylenedioxyamphetamine | XTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025611","Methamphetamine","C61840","An amphetamine with central nervous system (CNS) stimulating activity. Methamphetamine acts by both facilitating the release of catecholamines, particularly noradrenaline, dopamine and serotonin, from nerve terminals in the brain and by inhibiting their uptake. This leads to an increase in synaptic concentration of these neurotransmitters and results in increased stimulation of postsynaptic receptors.","Methamphetamine | METHAMPHETAMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008320","Cholecystectomy","C51676","Surgical removal of the gallbladder.","Cholecystectomy | CHOLECYSTECTOMY",,,,,,,,,,,,,,,"4242997","Cholecystectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705192","Seeding","C54575","To inoculate with microorganisms.","Seed | Seeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL414471","Natural History","C16147","A study that monitors the development and progression of a disease or condition with no emphasis on diagnosis or treatment.","Natural History Study | NATURAL HISTORY | Natural History | Natural History | natural history study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0520863","Diastolic Dysfunction","C79547","Impairment in the filling of the ventricles during diastole. Causes include hypertrophic and restrictive cardiomyopathies, coronary artery disease, chronic high blood pressure, aortic stenosis, and aging.","Diastolic Dysfunction | ",,,,,,,,,,,,,,,"141038","Diastolic dysfunction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038879","Sural Nerve","C77675","A peripheral nerve that runs close to the small saphenous vein. It supplies innervation to the skin of the lower back of the leg and sends a branch to the lateral side of the foot and little toe.","Sural Nerve | NERVE, SURAL | SURAL NERVE",,,,,,,,,,,,,,,"4218411","Structure of sural nerve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1095989","Brain Natriuretic Peptide Measurement","C74735","The determination of the amount of brain natriuretic peptide present in a sample.","Brain Natriuretic Peptide Measurement | B-Type Natriuretic Peptide | B-Type Natriuretic Peptide Measurement | BNP | BNP Measurement | Brain Natriuretic Peptide",,,,,,,,,,,,,,,"4307029","Brain natriuretic peptide measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053874","Verbal Rating Scale for Pain","C21133","A pain rating scale that includes specific pain criteria and self-reported ratings based upon patient verbalizations.","Verbal Rating Scale for Pain | Pain VRS | Verbal Rating Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0445107","Not Used","C69062","Not employed or utilized.","Not Used | Unused",,,,,,,,,,,,,,,"4135256","Not used",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227900","Right Fallopian Tube","C33475","The fallopian tube that extends from the uterus to the ovary in the right side of the pelvic cavity.","Right Fallopian Tube | Fallopian Tube, Right",,,,,,,,,,,,,,,"4067406","Structure of right fallopian tube",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827353","Urine Free Immunoglobulin Light Chain","C84261","Human immunoglobulin kappa and/or lambda light chains detected in their free form in urine as a result of overproduction by plasma cells in excess over heavy chains due to neoplastic plasma cell proliferations.","Urine Free Immunoglobulin Light Chain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332241","Equivocal","C86071","Open to question.","Equivocal | EQUIVOCAL | Questionable",,,,,,,,,,,,,,,"4172976","Equivocal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0086805","Photon","C88112","A single unit of electromagnetic radiation, generally considered to be a discrete particle having no mass or charge.","Photon | ",,,,,,,,,,,,,,,"4126234","Photon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024419","Waldenstrom Macroglobulinemia","C80307","Lymphoplasmacytic lymphoma associated with bone marrow involvement and IgM monoclonal gammopathy.","Waldenstrom Macroglobulinemia | Waldenstrom macroglobulinemia | Waldenstrom's Macroglobulinemia | Waldenstrom's macroglobulinemia | Waldenström Macroglobulinemia","9761/3","Waldenstrom macroglobulinemia",,,,,,,,,,,,,"4149011","Waldenstrom's macroglobulinemia",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0039416","Technetium Tc-99m Medronate","C67060","A radiopharmaceutical containing methylene diphosphonate (medronate; MDP) complexed with the gamma-emitting radionuclide technetium Tc 99m with radioisotopic activity and hydroxyapatite affinity. Upon intravenous administration, skeletal uptake of technetium Tc 99m methylene diphosphonate occurs as a function of skeletal blood flow and osteogenic activity. The MDP moiety of this agent has affinity for hydroxyapatite crystals in bone with abnormal accumulation at sites with increased osteoid mineralization; labeling of MDP with Tc 99m allows scintigraphic imaging of areas of abnormal osteogenesis associated with malignant bone lesions.","Technetium Tc-99m Medronate | (99m)Tc-Medronate | 99mTc-MDP | TECHNETIUM TC-99M MEDRONATE | TechneScan MDP | Technetium Tc 99m Medronate | Technetium Tc 99m Methylene Diphosphonate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335110","Oligodendroglial Tumor","C6960","A neoplasm of the central nervous system composed predominantly of cells morphologically resembling oligodendroglia.  Oligodendroglial tumors histologically comprise a continuous spectrum ranging from well-differentiated neoplasms to frankly malignant tumors. WHO grading system recognizes two malignancy grades: WHO grade 2 for well-differentiated tumors (oligodendroglioma) and WHO grade 3 for anaplastic oligodendroglioma. (Adapted from WHO)","Oligodendroglial Tumor | Oligodendroglial Neoplasm | oligodendroglial tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0270994","Steroid Myopathy","C88134","A non-neoplastic disorder affecting the skeletal muscles. It is caused by damage to muscle fibers either by excessive intake of corticosteroids (steroid treatment) or high levels of endogenous corticosteroids due to hormonal abnormalities. Patients usually present with weakness mainly in the proximal muscles of the upper and lower extremities and the neck flexors.","Steroid Myopathy | ",,,,,,,,,,,,,,,"4097390","Steroid-induced myopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1578545","Unprotected Sexual Intercourse","C88146","Sexual intercourse without the use of precautions to prevent conception or the transmission of sexually transmitted diseases.","Unprotected Sexual Intercourse | ",,,,,,,,,,,,,,,"4046817","Unprotected sexual intercourse",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2981713","Milligram per Square Meter per Week","C88148","A dose calculation unit expressed in milligram(s) per square meter per period of time equal to seven days.","Milligram per Square Meter per Week | Milligram/meter2/week | mg/m2/week | mg/m2/wk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887873","Hearing Loss","C35731","A partial or complete loss of hearing in one or both ears. It is classified as conductive, sensory, or central.","Hearing Loss | ",,,,,,,,,,,,,,,"377889","Hearing loss",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018827","Cardiac Ventricle","C12730","One of the two lower chambers of the heart that receives blood from an atrium and pumps blood to the arteries.","Cardiac Ventricle | Cardiac Ventricles | Cardiac ventricular structure (body structure) | HEART, VENTRICLE | Heart Ventricle | Ventricle | Ventricles, Heart",,,,,,,,,,,,,,,"4070760","Cardiac ventricular structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0012963","Dobutamine","C61733","A synthetic catecholamine with sympathomimetic activity. Dobutamine is a direct-acting inotropic agent and an adrenergic agonist that stimulates primarily the beta-1 adrenoceptor, with lesser effect on beta-2 or alpha receptors. Via beta-1 adrenoceptor of the heart, this agent induces positive inotropic effect with minimal changes in chronotropic activities or systemic vascular resistance. Dobutamine also causes vasodilation by stimulating beta-2 adrenergic receptors in blood vessels, augmented by reflex vasoconstriction resulting in increased cardiac output.","Dobutamine | DOBUTAMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1532575","Milligram per Square Meter per Day","C66974","A dose calculation unit expressed in milligram(s) per square meter per period of time equal to twenty-four hours.","Milligram per Square Meter per Day | Milligram per Square Meter per 24 Hours | Milligram/meter2/day | mg/m2/24.h | mg/m2/d | mg/m2/day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1532561","Microgram per Kilogram per Day","C73729","A dose calculation unit expressed in microgram(s) per kilogram per period of time equal to twenty-four hours.","Microgram per Kilogram per Day | Microgram per Kilogram per 24 Hours | Microgram/Kilogram/Day | mcg/kg/d | ug/kg/24.h | ug/kg/d | ug/kg/day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021587","Artificial Insemination","C16739","Introduction of sperm into the female reproductive tract by artificial means in order to achieve fertilization.","Artificial Insemination | ",,,,,,,,,,,,,,,"4239302","Artificial insemination",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0184069","Treadmill","C88163","A piece of exercise equipment used to walk or run on, for the purposes of cardiovascular training or testing.","Treadmill | ",,,,,,,,,,,,,,,"4004884","Treadmill",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2981722","Cardiorespiratory Fitness","C88164","The ability of the heart and lungs to deliver blood and oxygen to the tissues during aerobic activity. It is a general measure of the relative conditioning of the heart and respiratory system.","Cardiorespiratory Fitness | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2709220","Pedometer","C88165","An instrument for counting the number of steps taken while walking. This information can be used to estimate the distance traveled or calories used.","Pedometer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0178951","Accelerometer","C88166","An instrument used for measuring a change in velocity.","Accelerometer | Acceleration Sensor | Accelerometer Sensor",,,,,,,,,,,,,,,"601833","Accelerometer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0700329","Morphologic Finding","C35867","A light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample.","Morphologic Finding | Morphology | Morphology (A/O/U)",,,,,,,,,,,,,,,"4218474","Morphologic finding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0449681","Incision Site","C77683","The anatomic site of a cut made during surgery. The term may also refer to the resultant scar from the surgical procedure.","Incision Site | SITE, SURGICAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205249","Healed","C41133","Recovered, restored to healthy condition by natural processes, e.g. by scar formation; freed from illness or injury.","Healed | ",,,,,,,,,,,,,,,"4235270","Healed",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1571702","Objective","C88181","Based on fact or observable phenomena and not on personal feeling or bias.","Objective | ",,,,,,,,,,,,,,,"4128618","Objective",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0439655","Subjective","C88182","Modified by personal feeling or bias.","Subjective | ",,,,,,,,,,,,,,,"4114518","Subjective",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0600564","Self-Efficacy","C88184","A person's subjective assessment of their ability to succeed at a task or challenge.","Self-Efficacy | ",,,,,,,,,,,,,,,"603106","Self efficacy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2981729","Integrated Fitness Assessment","C88185","An assessment used to indicate a person's overall level of fitness, including tests used to assess a person's muscle strength, endurance, and flexibility.","Integrated Fitness Assessment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1550321","Vaginal Cuff","C88207","The part of the apical portion of the vagina which is closed with sutures following total hysterectomy.","Vaginal Cuff | Vaginal cuff (morphologic abnormality)",,,,,,,,,,,,,,,"4229665","Vaginal cuff",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010442","Culdoscope","C88208","An endoscope for examination of a woman's pelvic organs through the vagina.","Culdoscope | ",,,,,,,,,,,,,,,"4242135","Culdoscope",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010443","Culdoscopy","C88209","Endoscopic examination of a woman's pelvic organs using a culdoscope inserted through the vagina.","Culdoscopy | ",,,,,,,,,,,,,,,"4195717","Endoscopy of cul-de-sac",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1134528","NY-ESO-1 peptide vaccine","C2657","A cancer vaccine consisting of an immunogenic peptide derived from the cancer-testis antigen (NY-ESO-1), an antigen found in normal testis and various tumors. Vaccination with NY-ESO-1 peptide vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response to cells expressing NY-ESO-1 antigen, resulting in tumor cell lysis.","NY-ESO-1 Peptide Vaccine | ESO-1 Peptide Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1318963","Readiness","C86583","The state of having been made ready or prepared for use or action.","Readiness | ",,,,,,,,,,,,,,,"4247390","Readiness",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3871452","Dinutuximab","C1570","A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Dinutuximab binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells.  GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung.","Dinutuximab | Ch 14.18UTC | Ch14.18 | DINUTUXIMAB | Dinutuximab Beta | MOAB Ch14.18 | Monoclonal Antibody Ch14.18 | Qarziba | Unituxin | monoclonal antibody Ch14.18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2607234","Ganetespib","C77872","A synthetic small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Ganetespib binds to and inhibits Hsp90, resulting in the proteasomal degradation of oncogenic client proteins, the inhibition of cell proliferation and the elevation of heat shock protein 72 (Hsp72); it may inhibit the activity of multiple kinases, such as c-Kit, EGFR, and Bcr-Abl, which as client proteins depend on functional HsP90 for maintenance. Hsp90, a 90 kDa molecular chaperone upregulated in a variety of tumor cells, plays a key role in the conformational maturation, stability and function of 'client' proteins within the cell, many of which are involved in signal transduction, cell cycle regulation and apoptosis, including kinases, transcription factors and hormone receptors.  Hsp72 exhibits anti-apoptotic functions; its up-regulation may be used as a surrogate marker for Hsp90 inhibition.","Ganetespib | 3-(2,4-dihydroxy-5-isopropylphenyl)-4-(1-methylindol-5-yl)-5-hydroxy-4h-1,2,4-triazole 3h-1,2,4-triazol-3-one | 5-(2,4-dihydroxy-5-(1-methylethyl)phenyl)-2,4-dihydro-4-(1-methyl-1h-indol-5-yl)- | GANETESPIB | Hsp90 Inhibitor STA-9090 | Hsp90 Inhibitor STA-9090 | STA 9090 | STA-9090 | STA9090",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009315","Colistimethate","C72729","A broad-spectrum polymyxin antibiotic against most aerobic Gram-negative bacteria except Proteus bacteria. Colistimethate is a mixture of methanesulfonate derivatives of cyclic polypeptides colistin A and B from Bacillus colistinus or B. polymyxa. Colistin functions as a surfactant which penetrates into and disrupts the bacterial cell membrane, thereby resulting in bactericidal effect.","Colistimethate | COLISTIMETHATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881534","Make - Instruction Imperative","C64661","Form from constituents.","Make | fiat | ft. | let it be made",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705171","Trocar Device","C50327","A sharp, pointed rod designed to pierce the wall of a body cavity to withdraw fluid or allow placement of a catheter or other device.","Trocar Device | Trocar | Trocar Device Component",,,,,,,,,,,,,,,"4038673","Trocar",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021941","Equipment and supply inventories","C86559","A list of goods and materials, or those goods and materials themselves, held available for use by a business.","Inventory | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011882","Diabetic Neuropathy","C26748","A chronic, pathological complication associated with diabetes mellitus, where nerve damages are incurred due to diabetic microvascular injury involving small blood vessels that supply these nerves, resulting in peripheral and/or autonomic nerve dysfunction.","Diabetic Neuropathy | ",,,,,,,,,,,,,,,"4044391","Neuropathy due to diabetes mellitus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011884","Diabetic Retinopathy","C34538","A chronic, pathological complication associated with diabetes mellitus, where retinal damages are incurred due to microaneurysms in the vasculature of the retina, progressively leading to abnormal blood vessel growth, and swelling and leaking of fluid from blood vessels, resulting in vision loss or blindness.","Diabetic Retinopathy | ",,,,,,,,,,,,,,,"4174977","Retinopathy due to diabetes mellitus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017741","Glucose Tolerance Test","C45946","A test that involves administration of a know quantity of glucose as a means of screening for glucose intolerance or diabetes mellitus. Typically a baseline (fasting plasma or serum glucose) is drawn prior to the administration of the glucose bolus.  Serial plasma glucose levels are obtained (e.g. 30min, 1hr, 2hr, 3hr) and a plot of plasma glucose versus time is created.  Comparison of these values against standardized results can be used in establishing the diagnosis of glucose intolerance or diabetes mellitus.","Glucose Tolerance Test | ",,,,,,,,,,,,,,,"4012477","Glucose tolerance test",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0373715","Proinsulin Measurement","C81967","The determination of the amount of proinsulin present in a sample.","Proinsulin Measurement | PROINSUL | Proinsulin",,,,,,,,,,,,,,,"4017228","Proinsulin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202100","C-peptide Measurement","C74736","The determination of the amount of C-peptide present in a sample.","C-peptide Measurement | C-peptide | C-peptide suppression test | CPEPTIDE",,,,,,,,,,,,,,,"4229110","Insulin C-peptide measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0486293","Albumin To Creatinine Protein Ratio Measurement","C74761","The determination of the ratio of albumin compared to creatinine protein present in a urine sample. The measurement may be expressed as a ratio or percentage.","Albumin To Creatinine Protein Ratio Measurement | ALBCREAT | Albumin/Creatinine | Microalbumin/Creatinine Ratio",,,,,,,,,,,,,,,"4108431","Albumin/creatinine ratio measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0534343","Cystatin-M, Human","C25800","Cystatin-M (149 aa, ~17 kDa) is encoded by the human CST6 gene. This protein plays a role in the modulation of cathepsin B activity.","Cystatin-M | CST6 | Cystatin 6 | Cystatin 6 | Cystatin E | Cystatin M | Cystatin-6 | Cystatin-E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520364","11p15","C13616","A chromosome band present on 11p","11p15 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881824","Microsatellite Instability Analysis","C63331","A laboratory procedure to detect microsatellite instability.","Microsatellite Instability Analysis | MSI Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332289","Anaplastic Kidney Wilms Tumor","C6952","Wilms tumor of the kidney characterized by the presence of nuclear anaplasia.  Anaplasia is defined by the presence of all of the following: multipolar polyploid mitotic figures, marked nuclear enlargement, and hyperchromasia.  When anaplasia is diffuse, it is associated with an unfavorable clinical outcome.","Anaplastic Kidney Wilms Tumor | Anaplastic Renal Wilm's Tumor | Anaplastic Renal Wilms Tumor | Anaplastic Renal Wilms Tumor | Anaplastic Renal Wilms' Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1453113","CST3 protein, human","C88359","Cystatin-C (146 aa, ~16 kDa) is encoded by the human CST3 gene. This protein is involved in the inhibition of cysteine proteinases.","Cystatin-C | Cystatin C | Cystatin-3 | Gamma-Trace | Neuroendocrine Basic Polypeptide | Post-Gamma-Globulin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981884","Facility Oncology Registry Data Standards","C88367","A coding manual produced by the Commission on Cancer of the American College of Surgeons that provides definitions and detailed instructions for coding patient diagnosis, treatment, and outcome.","Facility Oncology Registry Data Standards | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003469","Anxiety Disorder","C2878","A category of psychiatric disorders which are characterized by anxious feelings or fear often accompanied by physical symptoms associated with anxiety.","Anxiety Disorder | Anxiety",,,,,,,,,,,,,,,"442077","Anxiety disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0241934","Hypomania","C78349","A less severe form of mania characterized by elevated mood, hyperactivity, and grandiosity. In contrast to mania, these symptoms do not cause significant impairment of the individual's productivity at work, or social and family relationships.","Hypomania | Hypomanic Mood",,,,,,,,,,,,,,,"4333678","Hypomania",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3553161","Schizophrenia","C3362","A major psychotic disorder characterized by abnormalities in the perception or expression of reality. It affects the cognitive and psychomotor functions. Common clinical signs and symptoms include delusions, hallucinations, disorganized thinking, and retreat from reality.","Schizophrenia | Schizophrenia, unspecified | schizophrenia",,,,,,,,,,,,,,,"435783","Schizophrenia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4227790","Hyperactivity","C34706","Increased motor activity that is not goal directed.","Hyperactivity | hyperactivity",,,,,,,,,,,,,,,"4195305","Hyperactive behavior",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3554311","Personality Disorder","C34922","A diverse category of psychiatric disorders characterized by behavior that deviates markedly from the expectations of the individual's culture; this pattern of deviation is pervasive and inflexible and is stable over time. The behavioral pattern negatively interferes with relationships and work.","Personality Disorder | ",,,,,,,,,,,,,,,"441838","Personality disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038436","Post-Traumatic Stress Disorder","C3389","An anxiety disorder precipitated by an experience of intense fear or horror while exposed to a traumatic (especially life-threatening) event. The disorder is characterized by intrusive recurring thoughts or images of the traumatic event; avoidance of anything associated with the event; a state of hyperarousal and diminished emotional responsiveness. These symptoms are present for at least one month and the disorder is usually long-term.","Post-Traumatic Stress Disorder | Combat Neurosis | PTSD | post-traumatic stress disorder",,,,,,,,,,,,,,,"436676","Posttraumatic stress disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028768","Obsessive Compulsive Disorder","C88411","A disorder characterized by the presence of persistent and recurrent irrational thoughts (obsessions), resulting in marked anxiety and repetitive excessive behaviors (compulsions) as a way to try to decrease that anxiety.","Obsessive Compulsive Disorder | OCD | Obsessive-Compulsive Disorder | obsessive-compulsive disorder",,,,,,,,,,,,,,,"440374","Obsessive-compulsive disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4229368","Autism Spectrum Disorder","C88412","A spectrum of developmental disorders that includes autism, Asperger syndrome, and Rett syndrome. Signs and symptoms include poor communication skills, defective social interactions, and repetitive behaviors.","Autism Spectrum Disorder | Pervasive Developmental Disorders",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003431","Antisocial Personality Disorder","C88413","A disorder characterized by a pervasive pattern of disregard for and violation of the rights of others that is manifested in childhood or early adolescence. (adapted from DSM-IV)","Antisocial Personality Disorder | Psychopathy | Sociopathy",,,,,,,,,,,,,,,"440988","Antisocial personality disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035258","Restless Leg Syndrome","C84501","A condition that occurs while resting or lying in bed; it is characterized by an irresistible urgency to move the legs to obtain relief from a strange and uncomfortable sensation in the legs.","Restless Leg Syndrome | RLS | Restless Legs Syndrome | Restless legs syndrome | restless legs syndrome",,,,,,,,,,,,,,,"73754","Restless legs",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027235","Ipratropium","C61794","A synthetic derivative of the alkaloid atropine with anticholinergic properties. Ipratropium antagonizes the actions of acetylcholine at parasympathetic postganglionic effector cell junctions. When inhaled, ipratropium binds competitively to cholinergic receptors in the bronchial smooth muscle thereby blocking the bronchoconstrictor actions of the acetylcholine (Ach) mediated vagal impulses. Inhibition of the vagal tone leads to dilation of the large central airways resulting in bronchodilation.","Ipratropium | (3-endo,8-syn)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane | IPRATROPIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0905678","Tiotropium Bromide Monohydrate","C61974","The monohydrate bromide salt form of tiotropium, a quaternary ammonium derivative of atropine and a long-acting muscarinic receptor antagonist, with bronchodilating activity. Upon inhalation, tiotropium binds to and blocks mainly muscarinic M3 receptors located on smooth muscle cells, thereby preventing smooth muscle contraction.","Tiotropium Bromide Monohydrate | 1,4-Dihydro-3,5-Diiodo-1-Methyl-4-Oxopyridine-2,6-Dicarboxylic Acid | 6Beta,7Beta-Epoxy-3Beta-Hydroxy-8-Methyl-1Alpha-H,5Alpha-H-Tropanium Bromide, Di-2-Thienylglycolate Monohydrate | Spiriva | TIOTROPIUM BROMIDE MONOHYDRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0082607","Fluticasone","C61767","A synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, antiinflammatory and antipruritic effects. Fluticasone binds and activates glucocorticoid receptor, resulting in the activation of lipocortin. Lipocortin, in turn, inhibits cytosolic phospholipase A2, which triggers a cascade of reactions involved in the synthesis of inflammatory mediators, such as prostaglandins and leukotrienes. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.","Fluticasone | FLUTICASONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029995","Oxandrolone","C29306","A synthetic, anabolic steroid hormone analog of testosterone. Similar to testosterone, oxandrolone binds to and activates specific nuclear receptors. This agent may be used for testosterone replacement therapy in hypogonadal men, in HIV-wasting syndrome, and in other conditions in order to increase nitrogen retention and fat-free muscle mass. (NCI04)","Oxandrolone | OXANDROLONE | Oxandrin | oxandrolone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279610","Stromal Predominant Kidney Wilms Tumor","C9148","Wilms tumor of the kidney characterized by the predominance of the mesenchymal component.","Stromal Predominant Kidney Wilms Tumor | Stromal Predominant Kidney Adenosarcoma | Stromal Predominant Nephroblastoma | Stromal Predominant Renal Adenosarcoma | Stromal Predominant Renal Wilm's Tumor | Stromal Predominant Renal Wilms Tumor | Stromal Predominant Renal Wilms Tumor | Stromal Predominant Renal Wilms' Tumor | Stromal Predominant Wilms Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279611","Mixed Cell Type Kidney Wilms Tumor","C9149","Wilms tumor of the kidney characterized by the presence of blastema, epithelial, and mesenchymal components (triphasic pattern) or a combination of two of them (biphasic pattern).","Mixed Cell Type Kidney Wilms Tumor | Mixed Cell Type Kidney Adenosarcoma | Mixed Cell Type Kidney Nephroblastoma | Mixed Cell Type Renal Adenosarcoma | Mixed Cell Type Renal Wilm's Tumor | Mixed Cell Type Renal Wilms Tumor | Mixed Cell Type Renal Wilms Tumor | Mixed Cell Type Renal Wilms' Tumor | Mixed Cell Type Wilms Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007959","Charcot-Marie-Tooth Disease","C75467","An inherited degenerative disorder involving the peripheral nerves. It is caused by mutations in the genes that are responsible for the production of proteins necessary for the function and structure of the peripheral nerves. It is characterized by muscle atrophy and weakness in the feet, legs, hands, and arms and loss of sensation in the limbs.","Charcot-Marie-Tooth Disease | Charcot Marie Tooth Disease | Hereditary Motor and Sensory Neuropathy | Hereditary Sensorimotor Neuropathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0561770","Verbal Memory","C88416","The ability to store and recall linguistic information.","Verbal Memory | ",,,,,,,,,,,,,,,"4155505","Verbal memory observable",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0542316","Visual Memory","C88417","The ability to store and recall visual information.","Visual Memory | ",,,,,,,,,,,,,,,"4153993","Visual memory",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025265","Working Memory","C88418","Short term memory related to the storage, processing and recall of information required for the accomplishment of immediate cognitive tasks.","Working Memory | ",,,,,,,,,,,,,,,"4239348","Immediate memory",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0935584","Executive Function","C88419","A set of mental processes that controls and manages the cognitive functions.","Executive Function | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0678858","Gross Motor Skill","C88420","The ability to use large muscle groups for gross body movements. This developmental skill begins in infancy and early childhood.","Gross Motor Skill | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3550800","Nephrogenic Rest","C88537","Remnants of nephrogenic blastema cells in the kidney following embryonic development.","Nephrogenic Rest | ",,,,,,,,,,,,,,,"4237049","Nephrogenic rest",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1319017","Perilobar Nephrogenic Rest","C88538","A nephrogenic rest found at the periphery of the renal lobe.","Perilobar Nephrogenic Rest | Perilobar Nephrongenic Rest",,,,,,,,,,,,,,,"4237164","Nephrogenic rest, perilobar",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1319016","Intralobar Nephrogenic Rest","C88540","A nephrogenic rest found within the renal lobe.","Intralobar Nephrogenic Rest | ",,,,,,,,,,,,,,,"4226400","Nephrogenic rest, intralobar",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332890","Hemihypertrophy","C88541","A finding indicating the presence of greater than normal asymmetry between the right and left sides of the body. The asymmetry may be manifested in the entire side or part of it.","Hemihypertrophy | Hemi-hypertrophy | Hemihyperplasia | hemihypertrophy",,,,,,,,,,,,,,,"40402869","Congenital hemihypertrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0950121","Denys-Drash Syndrome","C84668","A rare congenital syndrome caused by mutations in the WT1 gene. It is characterized by the presence of congenital nephropathy (diffuse mesangial sclerosis), Wilms tumor, and intersex disorders.","Denys-Drash Syndrome | DDS | Denys Drash Syndrome | Denys-Drash syndrome | Nephrotic Syndrome Type 4",,,,,,,,,,,,,,,"4125955","Drash syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2982003","Nerve Conduction Velocity Test","C88502","A test that measures the speed of nerve activity along the length of a nerve. It is used to detect nerve damage or dysfunction.","Nerve Conduction Velocity Test | NCV | Nerve Conduction Velocity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982007","Flat Tympanometry Result","C88507","A tympanometry test result indicating the lack of movement of the tympanic membrane due to middle ear pathology.","Flat Tympanometry Result | Flat Typanometry Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085853","Tympanometry","C88505","The study of the mobility of the tympanic membrane and conduction bones through air pressure changes. It is used to detect middle ear abnormalities.","Tympanometry | TYMPANOMETRY | Tympanometry Test",,,,,,,,,,,,,,,"4237233","Tympanometry testing",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2982008","Retracted Tympanometry Result","C88508","A tympanometry test result indicating the retraction of the tympanic membrane resulting from negative ear pressure.","Retracted Tympanometry Result | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449083","Hypoproteinemia","C88511","A laboratory test result indicating abnormally low levels of total protein in the serum.","Hypoproteinemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037447","Socialization","C88512","The process of learning and adopting behavioral patterns that conform with the surrounding culture.","Socialization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012546","Diphtheria","C34541","A Gram-positive bacterial infection caused by Corynebacterium diphtheriae. It usually involves the oral cavity, pharynx, and nasal cavity. Patients develop pseudomembranes in the affected areas and manifest signs and symptoms of an upper respiratory infection. The diphtheria toxin may cause myocarditis, polyneuritis, and other systemic effects.","Diphtheria | ",,,,,,,,,,,,,,,"4077816","Infection due to Corynebacterium diphtheriae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1826402","NHEJ1 Gene","C88513","This gene is involved in DNA repair and V(D)J recombination.","NHEJ1 Gene | NHEJ1 | Nonhomologous End-Joining Factor 1Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1722208","Calcium Release-Activated Calcium Channel Protein 1, Human","C88519","Calcium release-activated calcium channel protein 1 (301 aa, ~33 kDa) is encoded by the human ORAI1 gene. This protein plays a role in both the regulation of cellular calcium concentration and the transcription of pathogen responsive genes.","Calcium Release-Activated Calcium Channel Protein 1 | Calcium Released-Activated Calcium Channel Protein 1 | ORAI1 | Protein Orai-1 | Transmembrane Protein 142A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0754710","N-Terminal Fragment Brain Natriuretic Protein","C88524","N-terminal fragment brain natriuretic protein (76 aa, ~9 kDa) is encoded by the human NPPB gene. This protein is a marker for cardiac failure.","N-Terminal Fragment Brain Natriuretic Protein | N Terminal Brain Natriuretic Protein | N-Terminal Fragment of Brain Natriuretic Protein | N-Terminal Fragment of Prohormone Brain Natriuretic Peptide | NT-pro-BNP | NT-proBNP | NT-proBNP(1-76)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007412","Catecholamine","C88516","A group of sympathetic amines containing a catechol group derived from the amino acid tyrosine. Catecholamines are hormones and neuromodulators synthesized in the chromaffin cells of the adrenal glands and the postganglionic fibers of the sympathetic nervous system in response to stress. Examples of catecholamines are epinephrine (adrenaline), norepinephrine (noradrenaline) and dopamine, all of which participate in a wide variety of functions throughout the body.","Catecholamine | catecholamine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706124","Terminology Kind","C43642","Kinds are types. By definition, kinds are all pairwise disjoint from one another. In other words the sets of individuals of a given kind have no overlap with any other kind. A namespace can contain multiple kinds, and often will. (Apelon)","Kind | Terminology Kind",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0876919","Meaning","C88149","The idea or message that is intended, expressed, or signified.","Meaning | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982197","United States Immunodeficiency Network","C88717","A research consortium established to advance scientific research in the primary immune deficiency diseases (PIDD).","United States Immunodeficiency Network | USIDNET",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009630","Concanavalin A","C88774","A mannose-binding lectin originally isolated from jack-bean, Canavalia ensiformis. Concanavalin A is a potent lymphocyte mitogen and a stimulator of matrix metalloproteinases, thereby exhibiting immunostimulatory effects. It is used in the characterization and purification of glycoproteins.","Concanavalin A | Con-A | ConA",,,,,,,,,,,,,,,"4183311","Concanavalin A",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031858","Phytohemagglutinins","C88791","A class of lectins, found in beans, with hemagglutination properties. Phytohemagglutinin binds to complex oligosaccharides containing galactose, N-acetylglucosamine and mannose, causing agglutination of most mammalian red blood cell types. It induces mitosis and affects cell membrane permeability, thereby facilitating protein transport.","Phytohemagglutinin | PHA | PHYTOHEMAGGLUTININ | phytohemagglutinin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032350","Pokeweed Mitogen","C88789","A group of proteins isolated from the roots of pokeweed, Phytolacca americana, with hemagglutinating and mitogenic properties. Pokeweed mitogen is particularly mitogenic for lymphocytes and also agglutinates erythrocytes.","Pokeweed Mitogen | PWM",,,,,,,,,,,,,,,"4099781","Pokeweed mitogen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024103","Breast Lump","C3197","A mass in the mammary gland, either mobile or immobile. Once the mass has reached the size of a small garden pea, it can be detected by palpation. With mammography a larger number of early breast cancers are being detected since this techniques allows detection prior to the point at which the mass can be felt. Breast masses are not always malignant. Benign fibrocystic breast disease is not uncommon. A fine needle biopsy aspiration can distinguish a cystic mass from a solid one.","Breast Lump | Breast Mass | Breast Nodule | Lump in Breast | Mass in Breast",,,,,,,,,,,,,,,"80767","Breast lump",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0149741","Nipple Discharge","C35161","The flow of fluid from the nipple of the breast.","Nipple Discharge | nipple discharge",,,,,,,,,,,,,,,"4012345|4181744","Nipple discharge symptom|Discharge from nipple",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0017416","Female Reproductive System Neoplasm","C3053","A benign, precancerous, or malignant neoplasm that affects the female reproductive system. Representative examples include uterine corpus leiomyoma, endocervical polyp, ovarian carcinoma, cervical carcinoma, and endometrial carcinoma.","Female Reproductive System Neoplasm | Female Reproductive System Tumor | Gynecologic Neoplasm | Gynecologic Tumor | Neoplasm of Female Reproductive System | Neoplasm of the Female Reproductive System | Tumor of Female Reproductive System | Tumor of the Female Reproductive System",,,,,,,,,,,,,,,"4131756","Neoplasm of female genital organ",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1513894","National Health Interview Survey","C19752","Since its inception in 1957, the NHIS has been a continuing nationwide sample survey in which data are collected through personal interviews with household members by U.S. Bureau of the Census interviewers. Data are used to provide national estimates on the incidence of acute conditions, the prevalence of chronic conditions and impairments, the extent of disability, the utilization of health care services (physician visits and hospital episodes), and other health-related topics. All conditions are coded according to the International Classification of Diseases. The survey is periodically redesigned to emphasize data collection on current health issues. (Alcohol Epidemiologic Data Directory, June 2000)","National Health Interview Survey | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018687","Health behavior","C16663","The actions taken by an individual to maintain, attain, and protect their good health. Health behavior reflects a person's health beliefs.","Health Behavior | Health and Behavior",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553338","Dominican","C43824","Denotes the inhabitants of Dominica, a person from there, or their descendants elsewhere.","Dominica Islander | DOMINICA ISLANDER | Dominican",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037713","South America","C26277","South America is a continent of the western hemisphere with most of its area in the southern hemisphere.  It is situated between the Pacific Ocean and the Atlantic Ocean and is attached at the north to North America by the Isthmus of Panama.","South America | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706210","Cassette","C49865","A container designed to hold film or magnetic tape.","Cassette Device | Cassette | Cassette Device Component | Cassette Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883674","Digital","C62251","A form of representation in which distinct objects (or digits) are used to express or represent something in the real world.","Digital | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982364","Primary Care Evaluation of Mental Disorders Patient Health Questionnaire","C88892","A self-administered diagnostic instrument developed for use in Primary Care settings to screen for common mental disorders, including alcohol abuse and dependence. (Copyright Pfizer)","Primary Care Evaluation of Mental Disorders Patient Health Questionnaire | PRIME-MD PHQ-9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982365","Generalized Anxiety Disorder Questionnaire","C88893","A self-administered diagnostic instrument developed to screen for generalized anxiety disorder. (Copyright Pfizer)","Generalized Anxiety Disorder Questionnaire | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449943","Serotype","C88894","A characterization of a cell or microorganism based on the antigenic properties of the molecules on its surface.","Serotype | ",,,,,,,,,,,,,,,"4171266","Serotype",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005088","Benzoyl Peroxide","C47411","A peroxide with antibacterial, irritant, keratolytic, comedolytic, and anti-inflammatory activity. Upon topical application, benzoyl peroxide decomposes to release oxygen which is lethal to the bacteria Proprionibacterium acnes. Due to its irritant effect, benzoyl peroxide increases turnover rate of epithelial cells, thereby peeling the skin and promoting the resolution of comedones. Benzoyl peroxide is used in the treatment of acne vulgaris.","Benzoyl Peroxide | Acnegel | BENZOYL PEROXIDE | Benoxyl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0991855","Omega-3 Fatty Acid","C493","Any fatty acid that contains an unsaturated bond originating from the 3rd carbon from the methyl end. Omega-3 fatty acids do not occur naturally with chain lengths shorter than 16 carbon units.","Omega-3 Fatty Acid | OMEGA-3 FATTY ACIDS | Omega 3 Fatty Acid | Omega-3 Fatty Acids | Omega-3 PUFA | Omega-3 Polyunsaturated Fatty Acid | n-3 Fatty Acid | omega-3 fatty acid | omega-3-Fatty Acids",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0133860","Omega-6 Fatty Acid","C2563","Essential fatty acids obtained from food sources that are necessary for normal biological functions, as well as growth and development.","Omega-6 Fatty Acid | OMEGA-6 FATTY ACIDS | Omega 6 Fatty Acid | Omega-6 PUFAs | n-6 Fatty Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596611","Gene Mutation","C18093","The result of any gain, loss or alteration of the sequences comprising a gene, including all sequences transcribed into RNA.","Gene Mutation | DNA Alteration | DNA Sequence Alteration | Gene Alteration | Gene Mutation Type | Sequence Alteration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024660","Mammalia","C14234","A class of warm-blooded vertebrate animals having the skin more or less covered with hair; young are born alive except for the small subclass of monotremes and nourished with milk.","Mammalia | Mammal | Mammalian | Mammals, General",,,,,,,,,,,,,,,"4300606","Class Mammalia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0301569","Soft Diet","C28238","A diet consisting of bland foods that are softened by cooking, mashing, pureeing, or blending.","Soft Diet | soft diet",,,,,,,,,,,,,,,"4301609","Soft diet",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162327","RNA Sequence","C89252","The sequence of nucleotide residues along an RNA chain.","RNA Sequence | Sequence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015965","Fetus","C13235","An unborn or unhatched vertebrate in the later stages of development showing the main recognizable features of the mature being.","Fetus | FETUS | Fetal | fetus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279652","Rectal Mucinous Adenocarcinoma","C7973","An invasive adenocarcinoma of the rectum characterized by the presence of pools of extracellular mucin.  Malignant glandular epithelial cells are present in the mucin collections.  Mucin constitutes more than 50% of the lesion.","Rectal Mucinous Adenocarcinoma | Colloid Adenocarcinoma of Rectum | Colloid Adenocarcinoma of the Rectum | Colloidal Adenocarcinoma of Rectum | Colloidal Adenocarcinoma of the Rectum | Mucinous Adenocarcinoma of Rectum | Mucinous Adenocarcinoma of the Rectum | Rectal Colloid Adenocarcinoma | Rectal Colloidal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0149978","Rectal Adenocarcinoma","C9383","An adenocarcinoma arising from the rectum.  It is more frequently seen in populations with a Western type diet and in patients with a history of chronic inflammatory bowel disease.  Signs and symptoms include intestinal bleeding, anemia, and change in bowel habits.  According to the degree of cellular differentiation, rectal adenocarcinomas are divided into well, moderately, and poorly differentiated.  Histologic variants include mucinous adenocarcinoma, signet ring cell carcinoma, medullary carcinoma, serrated adenocarcinoma, cribriform comedo-type adenocarcinoma, and micropapillary adenocarcinoma.","Rectal Adenocarcinoma | Adenocarcinoma - rectum | Adenocarcinoma of Rectum | Adenocarcinoma of the Rectum | Adenocarcinoma of the rectum",,,,,,,,,,,,,,,"4110575","Adenocarcinoma of rectum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0279639","Colon Mucinous Adenocarcinoma","C7966","An invasive adenocarcinoma of the colon characterized by the presence of pools of extracellular mucin.  Malignant glandular epithelial cells are present in the mucin collections.  Mucin constitutes more than 50% of the lesion.","Colon Mucinous Adenocarcinoma | Colloid Adenocarcinoma of Colon | Colloid Adenocarcinoma of the Colon | Colloid Colon Adenocarcinoma | Colloidal Adenocarcinoma of Colon | Colloidal Adenocarcinoma of the Colon | Colloidal Colon Adenocarcinoma | Colon Colloid Adenocarcinoma | Colon Colloidal Adenocarcinoma | Colonic Colloid Adenocarcinoma | Colonic Colloidal Adenocarcinoma | Colonic Mucinous Adenocarcinoma | Mucinous Adenocarcinoma of Colon | Mucinous Adenocarcinoma of the Colon | Mucinous Colon Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1168401","Head and Neck Squamous Cell Carcinoma","C34447","A squamous cell carcinoma that arises from any of the following anatomic sites: lip and oral cavity, nasal cavity, paranasal sinuses, pharynx, larynx, and salivary glands.","Head and Neck Squamous Cell Carcinoma | HNSCC | Head and neck squamous cell carcinoma, NOS | SCCHN | Squamous Cell Carcinoma of Head and Neck | Squamous Cell Carcinoma of the Head and Neck | squamous cell carcinoma of the head and neck",,,,,,,,,,,,,,,"37396745","Squamous cell carcinoma of head and neck",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710176","Lung Squamous Cell Carcinoma, Small Cell Variant","C45504","A poorly differentiated morphologic variant of squamous cell lung carcinoma characterized by the presence of small tumor cells with focal squamous differentiation.","Lung Squamous Cell Carcinoma, Small Cell Variant | Squamous Cell Lung Carcinoma, Small Cell Variant | Squamous Cell Lung Carcinoma, Small Cell Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266006","Squamous Cell Carcinoma, Clear Cell Type","C65180","A squamous cell carcinoma characterized by the presence of malignant cells with clear cytoplasm.","Squamous Cell Carcinoma, Clear Cell Type | Squamous cell carcinoma, clear cell type","8084/3","Squamous cell carcinoma, clear cell type",,,,,,,,,,,,,"4028879","Squamous cell carcinoma, clear cell type",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334244","Papillary Squamous Cell Carcinoma","C4102","A well differentiated squamous cell carcinoma characterized by a papillary, exophytic growth pattern and hyperkeratosis. The most commonly affected anatomic sites are the larynx, penis, cervix, vagina, and vulva.","Papillary Squamous Cell Carcinoma | Papillary Epidermoid Carcinoma | Papillary Epidermoid Cell Carcinoma | Papillary Squamous Carcinoma | Papillary epidermoid carcinoma | Papillary squamous cell carcinoma","8052/3","Papillary squamous cell carcinoma",,,,,,,,,,,,,"4191609","Papillary squamous cell carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C2982689","Ontology Concept","C89273","A unique entry or term in a specific ontology.","Ontology Concept | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982690","Data Context","C89274","Attributes from a data source that provide meaning that is relevant for annotation.","Data Context | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079466","Guanfacine","C61779","A centrally acting adrenergic agonist with non-stimulant and antihypertensive property. Guanfacine selectively stimulates alpha-2 adrenergic receptors in the central nervous system, thereby resulting in inhibition of sympathetic nervous system outflow. Used alone or in combination with other drugs, this agent causes reduction of peripheral and renal vascular resistance, and lowers both systolic and diastolic blood pressure and heart rate.","Guanfacine | GUANFACINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272241","Written Documentation","C86042","Printed or written information for future reference.","Written Documentation | Documentation | WRITTEN DOCUMENTATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512376","Hematogenous","C14152","Originating in the blood, or disseminated by the circulation or through the bloodstream.","Hematogenous | hematogenous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981730","Financial Account","C88186","A formal relationship established to provide for regular banking and business services.","Financial Account | Account",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981731","Service Item","C88187","A distinct item or unit of work available by fee for service purchase.","Service Item | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987583","Inquiry","C88188","A request for information.","Inquiry | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987582","Billing","C88189","The process of requesting payment of a debt for goods or services.","Billing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981733","Invoice","C88191","A document containing an itemized list of debts owed for goods or services.","Invoice | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981734","Customer","C88192","An individual or group that has purchased goods or services.","Customer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346844","Approval Date","C71476","A date of an official approbation, recognition, or acceptance as satisfactory.","Approval Date | Date of Approval",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981735","Quotation","C88193","A statement of the current price for goods or services.","Quotation | Quote",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880641","Telephone Extension Number","C62139","The number assigned within an organization to an individual telephone that extends the external telephone number.","Telephone Extension Number | Extension | Extension Number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1260875","Mating","C88194","The act of pairing individuals for sexual reproduction.","Mating | Mate | Mated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038280","Sterilization for infection control","C84382","A process for killing microorganisms.","Sterilization | STERILIZE | Sterilization Method | Sterilize | disinfectant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987508","Feeding","C88198","To supply with nourishment; give food to.","Feeding | Feed",,,,,,,,,,,,,,,"4043372","Feeding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1764827","Isolate","C53471","A specific individual microbe and its genetically identical progeny separated on a single occasion from a sample taken from a host or culture system.","Isolate | ISOLATE | Microbial Isolate",,,,,,,,,,,,,,,"4303145","Microbial isolate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1520147","Whole Organism","C13413","Considering the organism as a whole","Whole Organism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079411","Generations","C88214","A single step in the line of descent from a common ancestor.","Generation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708005","FDA National Drug Code","C54185","A unique numeric code assigned by the U.S. Food and Drug Administration to prescription drugs and insulin products manufactured, prepared, processed, or propagated by registered establishments for commercial distribution. U.S. prescription drugs must use an NDC; most non-prescription drugs are also primarily referenced by NDC. NDC codes change often as companies merge, new products are introduced, and drugs are retired.  Each code is a unique 10-digit, 3-segment number in one of the following configurations: 4-4-2, 5-3-2, or 5-4-1. The first, labeler code segment is assigned by the FDA to identify the establishment. The second, product code segment identifies a specific strength, dosage form, and formulation for a particular firm. The third, package code segment identifies package sizes and types. Both the product and package codes are assigned by the establishment. An asterisk may appear as a placeholder in the second or third segments.","FDA National Drug Code | FDA NDC | Food and Drug Administration National Drug Code | NDC | NDC Code | NDC Number | U.S. Food and Drug Administration National Drug Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448536","Artificial","C61464","Not naturally arising.","Artificial | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034760","Reagent","C802","Any natural or synthetic substance used in a chemical or biological reaction in order to produce, identify, or measure another substance.","Reagent | reagent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987482","Animal Coat","C88212","The covering of hair, wool, or fur on the body of an animal.","Coat | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2750981","Hearing Disorder","C3078","A disorder characterized by the partial or complete loss of the ability to detect sounds due to damage to the ear structures or inability of the brain to properly interpret or process the auditory signals it receives from the anatomic structures of the ear.","Hearing Disorder | ",,,,,,,,,,,,,,,"378444","Hearing disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2981738","delta-x Nomenclature","C88199","A convention for representing the molecular structure of fatty acids where each double bond is represented by the symbol delta with an exponent of x that indicates the xth carbon-carbon bond as counted from the carboxylic end. Each double bond is also preceded by an indication of the conformation as either cis or trans.","delta-x Nomenclature | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981739","n-x Nomenclature","C88200","A convention for categorizing the physiological properties of a fatty acid by indicating the location of its double bond as counted from the terminal methyl carbon (designated as x or omega) (e.g., omega-6 fatty acid).","n-x Nomenclature | omega-x Nomenclature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007004","Carbohydrate","C344","A class of hydrocarbons with an empirical formula of Cm(H20)n (where m and n may be equal) and includes monomers, polymers and derivatives of aldoses, ketoses, saccharides, and alditols.","Carbohydrate | Carbohydrates | carbohydrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439962","Mixture","C45305","A substance consisting of two or more substances mixed together (not in fixed proportions and not with chemical bonding).","Mixture | MIXTURE SUBSTANCE",,,,,,,,,,,,,,,"4159724","Mixture",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0681818","Social survey","C88201","To take or register the number of votes or opinions.","Poll | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827398","Primary Data","C84339","The fundamental representation of collected data (what is considered fundamental is defined by community consensus and may be ambiguous or mutable).","Primary Data | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3241922","Operation Activity","C88213","Performance of a practical work or of something involving the practical application of principles or processes.","Operation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825141","Experimental Finding","C76124","An interpretation of results of an experiment.","Experimental Finding | Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825142","Experimental Result","C76125","The outcome of an experiment or set of experiments, including observations and primary, processed, and analyzed data.","Experimental Result | Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449037","Processed Data","C84340","Data derived from other data.","Processed Data | Derived Data",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242377","Visible Light","C17732","Electromagnetic radiation in the portion of the spectrum from about 380 nm (violet) to 800 nm (red).","Visible Light | Radiation, Visible Light",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016107","Filtration","C16583","The process of passing a liquid or gas through a filter.","Filtration | Fractionation, Filtration",,,,,,,,,,,,,,,"4231018","Filtration - action",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042491","Ventilation","C88203","The act of moving air into and out of a space.","Ventilation | Ventilate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020167","Humidity","C88206","A measure of the water vapor content of air.","Humidity | HUMID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1821461","Close Relationship","C89291","A relationship bound by mutual interests or loyalties.","Close Relationship | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029408","Osteoarthritis","C3293","A noninflammatory degenerative joint disease occurring chiefly in older persons, characterised by degeneration of the articular cartilage, hypertrophy of bone at the margins and changes in the synovial membrane. It is accompanied by pain and stiffness, particularly after prolonged activity.","Osteoarthritis | DEGENERATIVE JOINT DISEASE",,,,,,,,,,,,,,,"80180","Osteoarthritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2982591","Congenital Amegakaryocytosis","C89161","A rare disorder of infancy characterized by marked reduction or absence of megakaryocytes and thrombocytopenia.","Congenital Amegakaryocytosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0855124","High Grade Burkitt-Like Lymphoma","C5005","A high grade B-cell lymphoma showing greater pleomorphism in nuclear size and shape than the classical Burkitt lymphoma.","High Grade Burkitt-Like Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443089","Buffy Coat","C84507","The middle layer of an anticoagulated blood specimen following separation by centrifugation. It contains most of the white blood cells and platelets.","Buffy Coat | BUFFY COAT",,,,,,,,,,,,,,,"4122286","Buffy coat",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005423","Biliary Tract","C12678","The system that transports bile from the hepatocytes in the liver to the small intestine. It is comprised of the intrahepatic bile ducts, hepatic ducts, common bile duct, cystic duct, and the gallbladder.","Biliary Tract | BILIARY TRACT | Bile Tract | Biliary System | Biliary tract, NOS | Tract, Biliary | biliary system | biliary tract",,,,,,,,,,,,,,,"4146820","Biliary tract structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003483","Aorta","C12669","The major arterial trunk that carries oxygenated blood from the left ventricle into the ascending aorta behind the heart, the aortic arch, through the thorax as the descending aorta and through the abdomen as the abdominal aorta; it bifurcates into the left and right common iliac arteries.","Aorta | AORTA | ARTERY, AORTA | Aortic | Aortic structure (body structure) | aorta | trunk of aortic tree | trunk of systemic arterial tree",,,,,,,,,,,,,"UBERON:0000947","aorta","4049896","Aortic structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014170","Endometrial Neoplasm","C3012","A benign, borderline, or malignant neoplasm that affects the endometrium.","Endometrial Neoplasm | Endometrial Tumor | Endometrium Neoplasm | Endometrium Tumor | Neoplasm of Endometrium | Neoplasm of the Endometrium | Tumor of Endometrium | Tumor of the Endometrium",,,,,,,,,,,,,,,"4048225","Neoplasm of endometrium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0192871","Total Colectomy","C51924","Surgical removal of the entire colon.","Total Colectomy | Complete Excisioin of Colon | TOTAL COLECTOMY",,,,,,,,,,,,,,,"4096461","Total colectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009274","Colectomy","C15209","Surgical removal of part or all of the colon.","Colectomy | colectomy",,,,,,,,,,,,,,,"4079713","Excision of colon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0192863","Transverse Colectomy","C51612","Surgical removal of the transverse colon.","Transverse Colectomy | Colon Resection, Transverse Extended | TRANSVERSE COLECTOMY",,,,,,,,,,,,,,,"4097958","Transverse colectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0192861","Right Colectomy","C51623","Surgical removal of the right part of the colon.","Right Colectomy | RIGHT COLECTOMY | Right Hemicolectomy",,,,,,,,,,,,,,,"4233412","Right colectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708726","Locus","C45822","The position of a gene or a chromosomal marker on a chromosome; also, a stretch of DNA at a particular place on a particular chromosome. The use of locus is sometimes restricted to mean regions of DNA that are expressed.","Locus | Gene Locus | locus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812241","BRAF Gene","C18363","This gene is involved in cell organization/biogenesis and the inhibition of apoptosis.","BRAF Gene | B-Raf Proto-Oncogene, Serine/Threonine Kinase Gene | BRAF | BRAF gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205224","Essential","C71578","Absolutely or vitally necessary; indispensable.","Essential | ",,,,,,,,,,,,,,,"4142180","Essential",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0546535","Hemicolectomy","C86074","Surgical removal of approximately half of the colon.","Hemicolectomy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517068","Extranodal Disease","C39695","A clinical finding that refers to the spread of lymphoid cancer in anatomic sites or systems other than the original lymph node site of growth.","Extranodal Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3853647","In Situ Hybridization Staining Method","C23022","A staining procedure which detects and indicates the location of specific nucleic acid sequences in a tissue or cellular sample. The DNA or RNA sequence of interest in the host cell is detected by hybridization with a labeled cDNA, RNA or modified nucleic acid-containing probe.","In Situ Hybridization Staining Method | ISH | ISH Staining Method | in situ Hybridization Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982953","Fixed-Point Number","C89579","A real number with a fixed number of digits following the decimal or radix point.","Fixed-Point Number | Fixed Point | Fixed-point | Fixed-point Value | Fixed-point Value | Invariant Point | Invariant-point Number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347120","Microgram per Square Meter per Hour","C73727","A dose calculation unit expressed in microgram(s) per square meter per period of time equal to sixty minutes.","Microgram per Square Meter per Hour | Microgram/Square Meter/Hour | mcg/m2/h | ug/m2/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3665414","Milligram per Kilogram per Day","C66976","A dose calculation unit expressed in milligram(s) per kilogram per period of time equal to twenty-four hours.","Milligram per Kilogram per Day | Milligram per Kilogram per 24 Hours | Milligram/Kilogram/Day | mg/kg/d | mg/kg/day | milligram/kilogram/day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983134","Federation of Gynecology and Obstetrics","C89808","An international organization with a mission to promote the wellbeing of women and to raise the standards of practice in obstetrics and gynecology. They are the creator of staging criteria to describe the extent and spread of gynecologic malignancies.","Federation of Gynecology and Obstetrics | FIGO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0556978","Gram per Week","C89829","A dose administration rate unit equal to the rate at which a gram of a product is delivered or administered over the time period of one week. This is also a unit of mass flow rate equivalent to the rate at which a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to one week.","Gram per Week | Gram/Week | g/wk | gram per week",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019144","Hepatectomy","C15249","Surgical removal of all or part of the liver.","Hepatectomy | Liver Resection | hepatectomy",,,,,,,,,,,,,,,"4030150","Excision of liver",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010137","Cortisone","C2291","A steroid hormone synthesized and secreted by the adrenal gland and necessary for life. It is involved with maintaining cardiovascular function, blood glucose balance, regulating the inflammatory response and metabolism of proteins, carbohydrates, and fat.","Cortisone | 17,21-Dihydroxypregn-4-ene-3,11,20-trione | cortisone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018808","Heart Murmur","C84480","A periodic humming or blowing sound heard on auscultation of the heart that can indicate the presence of cardiac disease; murmurs are the result of vibrations caused by the turbulent flow of blood in the heart or great vessels. Murmurs are characterized according to the area of generation (mitral, aortic, tricuspid, or pulmonary) and according to the period of the cycle (systolic or diastolic).","Heart Murmur | Cardiac Murmur | Heart murmur | Murmur",,,,,,,,,,,,,,,"316822|4225205","Heart murmur|Heart murmur",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2825127","UGT1A1*28 Allele","C72564","Human UGT1A1*28 allele is located in the vicinity of 2q37 and is approximately 13 kb in length. This allele, which encodes UDP-glucuronosyltransferase 1-1 protein, plays a role in the transformation of small lipophilic molecules into water-soluble metabolites. UGT1A1*28 allele has a polymorphism in the promoter region that is associated with decreased transferase activity and decreases in both tolerance and effectiveness of cancer therapeutics and antiviral drugs.","UGT1A1*28 Allele | NM_000463.2:c.-55_-54dupAT | NM_000463.2:c.-55_-54insAT | UDP Glucuronosyltransferase Family 1 Member A1*28 Allele | UDP Glycosyltransferase 1 Family, Polypeptide A1*28 Allele | UGT1A1 (TA)7 Allele | UGT1A1 A(TA)7TAA Allele | UGT1A1 NM_000463.2:c.-55_-54dupAT | UGT1A1 NM_000463.2:c.-55_-54insAT | UGT1A1 TATA Element ins TA Allele | UGT1A1 Variant (TA)7 Allele | UGT1A1 Variant Allele (TA)7 | UGT1A1 c.-55_-54dupAT | UGT1A1 c.-55_-54insAT | UGT1A1*28 | UGT1A1, 2-BP ins, TA, TATAA Element Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983217","Annotation Type","C89919","Defines the type of annotation (e.g., direct, mapped, transitive closure).","Annotation Type | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009462","Community","C16453","A set of individuals with some shared element. The substance of shared element varies widely, from geography to a situation to interest to lives and values. The term is widely used to evoke sense of collectivity.","Community | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376218","Warfarin Sodium","C1658","The sodium salt form of warfarin, a coumarin and a vitamin K antagonist, with anticoagulant activity. Warfarin sodium inhibits both vitamin K and vitamin K epoxide reductases, thereby interfering with the cyclic interconversion of vitamin K epoxide to its reduced form, vitamin KH2. Vitamin KH2 is a cofactor for the carboxylation of glutamate residues on the N-terminal regions of vitamin K-dependent proteins.  As a result, maturation of vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S is inhibited. Without these coagulation factors, thrombogenesis and blood clot formation are prevented.","Warfarin Sodium | Coumadin | Marevan | Panwarfin | Prothromadin | Tintorane | WARFARIN SODIUM | Waran | Warfilone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708973","Medullary Bone","C53466","The central and spongy portion of the bone.","Medullary Bone | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019376","Saimiriine Herpesvirus 2","C90038","A virus in the family herpesviridae and the type species of rhadinovirus. It is an enveloped virus with a genome consisting of a single segment of double-stranded DNA that is approximately 112kb in length. It normally infects squirrel monkeys, where it creates a persistent infection.","Saimiriine Herpesvirus 2 | Herpesvirus saimiri 2 | Saimirine herpesvirus 2 | Squirrel Monkey Herpesvirus",,,,,,,,,,,,,,,"4052682","Saimiriine herpesvirus 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1425020","DCLRE1C Gene","C90040","This gene is involved in both DNA repair and V(D)J recombination.","DCLRE1C Gene | DCLRE1C | DNA Cross-Link Repair 1C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983312","DCLRE1C wt Allele","C90041","Human DCLRE1C wild-type allele is located in the vicinity of 10p13 and is approximately 97 kb in length. This allele, which encodes protein artemis, plays a role in the mediation of both V(D)J recombination and DNA repair via nonhomologous end joining. Mutation of the gene is associated with severe combined immunodeficiency Athabaskan type and Omenn syndrome.","DCLRE1C wt Allele | A-SCID | ARTEMIS | ASCID | DCLREC1C | DNA Cross-Link Repair 1C (PSO2 Homolog, S. cerevisiae) Gene | DNA Cross-Link Repair 1C wt Allele | FLJ11360 | FLJ36438 | OTTHUMP00000019166 | OTTHUMP00000019167 | OTTHUMP00000019168 | OTTHUMP00000019170 | OTTHUMP00000019171 | OTTHUMP00000019172 | PSO2 Homolog Gene | RS-SCID | SCIDA | SNM1C | Severe Combined Immunodeficiency, Type a (Athabascan) Gene | hSNM1C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698931","RAG1 wt Allele","C80070","Human RAG1 wild-type allele is located in the vicinity of 11p13 and is approximately 12 kb in length. This allele, which encodes V(D)J recombination-activating protein 1, plays a role in the mediation of immunoglobulin recombination. Mutation of the gene is associated with several hereditary immunodeficiencies. Genetic variation may be associated with the relapse of acute lymphoblastic leukemia.","RAG1 wt Allele | MGC43321 | RAG-1 | RING Finger Protein 74 Gene | RNF74 | Recombination Activating 1 wt Allele | Recombination Activating Gene 1 Gene | Recombination Activating Gene 1 wt Allele | Recombination Activating Protein 1 Gene | Recombination-Activating Gene 1 Gene | V(D)J Recombination-Activating Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698932","RAG2 wt Allele","C80071","Human RAG2 wild-type allele is located in the vicinity of 11p13 and is approximately 6 kb in length. This allele, which encodes V(D)J recombination-activating protein 2, is involved in the regulation of immunoglobulin recombination. Mutation of the gene is associated with several hereditary immunodeficiencies. Genetic variation may be associated with the relapse of acute lymphoblastic leukemia.","RAG2 wt Allele | RAG-2 | Recombination Activating 2 wt Allele | Recombination Activating Gene 2 Gene | Recombination Activating Gene 2 wt Allele | Recombination-Activating Gene 2 Gene | V(D)J Recombination-Activating Protein 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0589414","Homework","C89269","School work assigned for completion outside of school.","Homework | ",,,,,,,,,,,,,,,"4209554","Homework",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0086542","Leisure Time","C86566","Time used for ease and relaxation.","Leisure Time | Leisure | Leisure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449082","Assistance","C89271","The act of contributing to the fulfillment of a need or furtherance of an effort.","Assistance | Aid | Assist | Assisted | Help",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0871683","Classmate","C89270","A member of the same class at school.","Classmate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439064","Many","C78728","An indefinite large quantity that is considered to be greater than several.","Many | ",,,,,,,,,,,,,,,"4127778","Numerous",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2987476","Exist","C89327","The state or fact of existing at a place and time.","Be | Being | Exist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880391","Domestic","C62264","Of, involving, or concerning a specific, local region such as a home or country.","Domestic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1331418","Comfort","C89275","A feeling of freedom from constraint or embarrassment; feeling relaxed and natural.","Comfort | Ease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0699756","Intimacy","C89292","A condition of close feelings shared between two people. Intimacy includes emotional intimacy and physical intimacy.","Intimacy | Intimate",,,,,,,,,,,,,,,"4224001","Intimate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0518031","Endurance","C89276","The ability to sustain an activity over a period of time.","Endurance | ",,,,,,,,,,,,,,,"4247389","Endurance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0678226","Due to","C89272","Caused by or resulting from.","Due To | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3154893","Possess","C89277","Have as an attribute, quality, or characteristic.","Possess | Have",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449055","Worry","C86941","Mental distress resulting from concern for something impending or anticipated.","Worry | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003988","Asian American","C16310","Denotes a person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent, and who was either born in the United States or who was naturalized as a citizen of the United States.","Asian American | ASIAN AMERICAN | Asian Americans",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0595998","Reside","C89279","To live in a certain place.","Reside | Live",,,,,,,,,,,,,,,"4076103","Household composition",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0521320","Girlfriend","C89282","A girl or woman who is the lover of a boy or man.","Girlfriend | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521319","Boyfriend","C89281","A boy or man who is the lover of a girl or woman.","Boyfriend | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205388","Few","C64942","An indefinite but relatively small number.","Few | A few",,,,,,,,,,,,,,,"4211692","Few",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2983415","Persistent Disease","C90169","A disease that does not go to remission despite treatment.","Persistent Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983141","Microgram per Kilogram per Week","C89830","A dose administration rate unit where the amount of product to be delivered or administered is calculated in micrograms as a function of the subject's weight in kilograms and is delivered or administered over the time period of one week.","Microgram per Kilogram per Week | Microgram/Kilogram/Week | microgram per kilogram per week | ug/kg/wk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206634","Myxoid Liposarcoma","C27781","A liposarcoma characterized by the presence of round non-lipogenic primitive mesenchymal cells and small signet ring lipoblasts within a myxoid stoma with a branching vascular pattern.  This category includes hypercellular lesions with round cell morphology, formerly known as round cell liposarcoma.","Myxoid Liposarcoma | MLPS | Myxoid liposarcoma | Myxoid/Round Cell Liposarcoma | Myxoid/Round Cell Liposarcoma | Myxoliposarcoma","8852/3","Myxoid liposarcoma",,,,,,,,,,,,,"4101123|4300686","Myxoid liposarcoma|Myxoid liposarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0334471","Round Cell Liposarcoma","C4252","A poorly differentiated liposarcoma, characterized by the presence of solid sheets of primitive round mesenchymal cells and the absence of myxoid stroma.","Round Cell Liposarcoma | Cellular Myxoid Liposarcoma | Round cell liposarcoma","8853/3","Round cell liposarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C0034542","Radical Neck Dissection","C51759","A surgical procedure in which all the ipsilateral cervical lymph node groups of the neck, internal jugular vein, sternocleidomastoid muscle, spinal accessory nerve, and submandibular gland are removed.","Radical Neck Dissection | ",,,,,,,,,,,,,,,"4164300","Radical neck dissection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0193864","Modified Radical Neck Dissection","C51904","A surgical procedure in which all the ipsilateral cervical lymph node groups of the neck are removed but the internal jugular vein, sternocleidomastoid muscle, and/or spinal accessory nerve are preserved.","Modified Radical Neck Dissection | ",,,,,,,,,,,,,,,"4012004","Modified radical neck dissection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705982","KRAS wt Allele","C52546","Human KRAS wild-type allele is located in the vicinity of 12p12.1 and is approximately 45 kb in length. This allele, which encodes GTPase KRas protein, plays a role in the modulation of both cellular proliferation and differentiation. Mutations in the gene are associated with juvenile myelomonocytic leukemia, Noonan syndrome 3 and cardiofaciocutaneous syndrome.","KRAS wt Allele | C-K-RAS | C-K-Ras Oncogene | CFC2 | Cellular c-Ki-Ras2 Proto-Oncogene | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | K-Ras 2A | KI-RAS | KRAS1 | KRAS2 | KRas Proto-Oncogene, GTPase wt Allele | Kirsten Rat Sarcoma Viral Oncogene Homolog Gene | NS | NS3 | PR310 | RALD | RASK2 | v-Ki-RAS2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog Gene | v-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0582653","Perceived Stress Scale","C89993","A 10-item self-report questionnaire that measures a person's evaluation of the stressfulness of life situations in the past month. Each item is rated 0-4 on a 5-point Likert scale. (Cohen, et al, J Health Soc Behav, 24 (1983))","Perceived Stress Scale | PSS",,,,,,,,,,,,,,,"4136939","Perceived stress scale",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0678341","Responsibility","C90023","A duty, obligation, or burden; something for which one is responsible.","Responsibility | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1998882","Sometimes","C90025","From time to time, but not continually or always.","Sometimes | From Time to Time | From time to time but not too often | From time to time, occasionally | Occasionally | Only occasionally | Sometimes | Sometimes (About Half the Time)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983310","Overcome","C90036","Deal with successfully.","Overcome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983311","Going Well","C90037","Proceeding in a satisfactory manner; proceeding as expected or planned.","Going Well | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3146297","Study of behavior during childhood","C90346","Observed actions from individuals between 2 and 18 years of age.","Behavior during Childhood | Child Behavior | Prostate Bed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229722","Submandibular Lymph Node","C77650","A lymph node located beneath the floor of the oral cavity.","Submandibular Lymph Node | LYMPH NODE, MANDIBULAR | Lymph Node(s) Submandibular | Lymph Node, Submandibular | SUBMANDIBULAR LYMPH NODE | Submandibular lymph nodes | submandibular lymph node | submandibular node",,,,,,,,,,,,,"UBERON:0002520","submandibular lymph node","4241334","Structure of submandibular lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0553668","Labored Breathing","C90501","Breathing that requires observed effort or an increased amount of energy.","Labored Breathing | ",,,,,,,,,,,,,,,"4087166","Labored breathing",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2983702","Unlabored","C90502","An action that occurs with a normal amount of effort or energy (as in unlabored breathing).","Unlabored | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0871489","Team","C86041","Two or more people working together.","Team | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1961136","Excellent","C82488","Conforming to the highest quality or standard.","Excellent | ",,,,,,,,,,,,,,,"4137085","Excellent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2911689","Fair","C82489","Having no exceptional quality or ability.","Fair | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018482","Hemophilus Infection","C34654","An infection that is caused by the organism Hemophilus.","Hemophilus Infection | ",,,,,,,,,,,,,,,"4211821","Haemophilus infection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022005","Iohexol","C65939","An X-ray contrast medium containing iohexol in various concentrations, from 140 to 350 milligrams of iodine per milliliter.","Iohexol | IOHEXOL | IOHEXOL | Omnipaque",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0452703","Pastry","C86577","Any of various baked foods made of dough or batter.","Pastry | ",,,,,,,,,,,,,,,"4028472","Pastry",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0682134","Citizen","C90516","A native or naturalized member of a state or country, especially one entitled to vote and enjoy other privileges there.","Citizen | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983714","US Citizen","C90517","A native or legal naturalized citizen of the United States.","US Citizen | U.S. Citizen | United States Citizen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983715","Non-US Citizen","C90518","A person who is not a legal citizen of the United States.","Non-US Citizen | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021080","Immunosuppressive Effect","C40913","An Immunosuppressive Effect involves interference with, or restraint of, the function of biologic molecules and complexes, or cellular, cell, or tissue components of a normal immune response.","Immunosuppressive Effect | Immunosuppression Effect",,,,,,,,,,,,,,,"4242843","Immunosuppression",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2828393","Exact (qualifier)","C86021","Marked by strict and particular and complete accordance with fact.","Exact | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704740","Aland Islands","C44481","An archipelago in the Baltic Sea at the entrance to the Gulf of Bothnia between Sweden and Finland.","Aland Islands | ALA | ALAND ISLANDS | Ahvenanmaa | Ahvenanmaa Islands | Åland Islands",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0454673","Jersey","C64374","A British Crown dependency in the English Channel southeast of Guernsey.","Jersey | 832 | Bailiwick of Jersey | JE | JERSEY | JEY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518860","Palestinian Territory, Occupied","C20110","A sovereign state in western Africa consisting of the West Bank and the Gaza Strip. Its capital is Jerusalem.","State of Palestine | 275 | PALESTINIAN TERRITORY, OCCUPIED | PS | PSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0454682","Saint Barthelemy","C83609","An island in the Caribbean sea, southeast of Anguilla and north of Saint Kitts and Nevis.","Saint Barthelemy | 652 | BL | BLM | SAINT BARTHELEMY | Saint Barthélemy | Saint-Barthélemy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0454685","Saint Martin (French Part)","C83610","A country comprising the northern portion of an island in the Caribbean sea, between Anguilla and Saint Barthelemy.","Saint Martin (French Part) | 663 | MAF | MF | SAINT MARTIN | SAINT MARTIN (FRENCH PART) | SAINT MARTIN, FRENCH | Saint Martin, French",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016242","Vitreous Floater","C50808","Spots before the eyes caused by opaque cell fragments in the vitreous humor or lens.","Vitreous Floater | Floaters | Myodesopsia | Myodesopsias | Vitreous Floaters",,,,,,,,,,,,,,,"4034681|4036946","Vitreous floaters|Floaters in visual field",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1708333","Health Care Organization","C43960","An organization that provides healthcare services or that is involved in the provision of health care activities. Groupings or subdivisions of an organization, such as departments, may also be considered as organizations where there is a need to identify them.","Health Care Organization | HCO | Healthcare Organization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036950","Shellfish","C71915","Any aquatic invertebrate animal having a shell and belonging to the phylum Mollusca, the class Crustacea (phylum Arthropoda), or the phylum Echinodermata. The term is often used for the edible species of the groups, especially those that are fished or raised commercially.","Shellfish | SHELLFISH, UNSPECIFIED",,,,,,,,,,,,,,,"42536288","Shellfish",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518237","Malignant Ovarian Brenner Tumor","C4270","A malignant neoplasm that arises from the ovary. It is characterized by the presence of an invasive malignant urothelial-type cellular component and nests of benign urothelial-type cells in a fibrotic stroma. When the neoplasm is confined to the ovary, the prognosis is good.","Malignant Ovarian Brenner Tumor | Brenner tumor, malignant | Malignant Brenner Tumor of Ovary | Malignant Brenner Tumor of the Ovary | Malignant Ovarian Transitional Cell Neoplasm | Malignant Ovarian Transitional Cell Tumor","9000/3","Brenner tumor, malignant",,,,,,,,,,,,,"4173156","Brenner tumor, malignant",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C2983794","Abutment Screw","C90601","The screw that secures an abutment onto a dental implant.","Abutment Screw | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983793","Root Eminence","C90600","The convex bulge in the gum below a tooth caused by the underlying structure of the tooth root.","Root Eminence | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043369","Xylitol","C76517","A natural sweetener, with protective, saliva producing and moisturizing activities. Upon administration, xylitol produces saliva and may protect against cavities. This relieves persistent dry mouth and hydrates the mouth.","Xylitol | XYLITOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1268568","Juice","C65141","The liquid produced by squeezing or crushing a fruit or vegetable.","Juice | ",,,,,,,,,,,,,,,"4030422","Juice",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0587906","Clinics and Hospitals","C19326","Institutions with an organized medical staff for the medical care, treatment, and cure of the sick and wounded, for the study of disease, and for the training of physicians, nurses, and allied health personnel.","Clinics and Hospitals | Clinics or Hospitals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0277786","Chief Complaint","C85497","The primary reason for a patient visit.","Chief Complaint | CC | Main Complain | Presenting Complaint | Primary Complaint",,,,,,,,,,,,,,,"37158808","Chief complaint",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0678227","Causing","C86056","Existing in such a way that some specific thing happens as a result.","Causing | Causation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005036","Benzene","C302","A clear, colorless, highly flammable and volatile, liquid aromatic hydrocarbon with a gasoline-like odor. Benzene is found in crude oils and as a by-product of oil-refining processes. In industry benzene is used as a solvent, as a chemical intermediate, and is used in the synthesis of numerous chemicals. Exposure to this substance causes neurological symptoms and affects the bone marrow causing aplastic anemia, excessive bleeding and damage to the immune system. Benzene is a known human carcinogen and is linked to an increased risk of developing lymphatic and hematopoietic cancers, acute myelogenous leukemia, as well as chronic lymphocytic leukemia. (NCI05)","Benzene | BENZENE | benzene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0452428","Drink","C86036","A single serving of a beverage; any liquid suitable for drinking.","Drink | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1365948","Coffee Flavor","C73380","A characteristic of a medicinal product, specifying that its most predominant agreeable savor detected by the unified sensation of taste and olfactory receptors resembles coffee.","Coffee Flavor | COFFEE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0349374","Cow Milk","C66153","A body substance containing proteins, fats, lactose, and various vitamins and minerals produced by the mammary glands of mature female bovines.","Cow Milk | COW MILK | Milk",,,,,,,,,,,,,,,"4290627","Cow's milk",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2983796","Leukemogenic","C90605","Leading to or causing leukemia.","Leukemogenic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005862","Southern Blotting","C16356","A technique for the detection of specific DNA fragments that have been separated by polyacrylamide-gel electrophoresis, transferred to a nitrocellulose or other type of paper or nylon membrane, and detected by hybridization and visualization with a labeled probe.","Southern Blotting | Blotting, Southern | Southern | Southern Blot | Southern Blot Hybridization | Southern blot",,,,,,,,,,,,,,,"4267885","Southern blot assay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2712334","Respiratory Tract Aspiration","C83507","Accidental inhalation of a foreign material into the lungs.","Respiratory Tract Aspiration | Aspiration | Unintentional Material Aspiration | Unintentional Material Aspiration",,,,,,,,,,,,,,,"4187777","Aspiration into respiratory tract",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0525032","International Normalized Ratio of Prothrombin Time","C64805","A measure of the extrinsic pathway of coagulation. The International Normalized Ratio of Prothrombin Time (INR) is the ratio of a patient prothrombin time to a normal (control) sample raised to the power of the International Sensitivity Index (ISI) with a range of 0.8 to 1.2 seconds.","International Normalized Ratio of Prothrombin Time | INR | Prothrombin Intl. Normalized Ratio",,,,,,,,,,,,,,,"4306239","International normalized ratio",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448869","Wedge","C65202","Any shape that is triangular in cross section.","Wedge | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0336537","Robot","C20678","A mechanical device that sometimes resembles a living animal and is capable of performing a variety of often complex human tasks on command or by being programmed in advance.","Robot | Robots",,,,,,,,,,,,,,,"4307520","Robot",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0728939","Subtotal","C60760","The total of part of a series of numbers.","Subtotal | ",,,,,,,,,,,,,,,"4115477","Subtotal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032639","Pons Varolii","C12511","The middle portion of the brainstem located between the midbrain and the medulla oblongata. The fourth ventricle lies dorsal to the pons which also contains the motor trigeminal nuclei and the abducens nuclei. The cerebellum contributes a large number of afferent fibers to the pons.","Pons Varolii | BRAIN, PONS | PONS VAROLII | Pons | Pons Cerebelli | Pontine structure (body structure) | pons",,,,,,,,,,,,,,,"4170881","Pontine structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025148","Medulla Oblongata","C12442","The lower portion of the brainstem located between the pons and the spinal cord. This structure contains several descending and ascending tracts, lower cranial nerve nuclei, a significant proportion of the reticular system of the brainstem and other structures.","Medulla Oblongata | BRAIN, MEDULLA OBLONGATA | MEDULLA OBLONGATA | Medulla | Medullary | Myelencephalon | medulla oblongata",,,,,,,,,,,,,,,"4132145","Medulla oblongata structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029126","Optic Chiasm","C90609","An anatomic structure formed by the crossing of the two optic nerves under the hypothalamus.","Optic Chiasm | OPTIC CHIASM | Structure of optic chiasma (body structure) | optic chiasm | optic chiasma",,,,,,,,,,,,,,,"4349938","Structure of optic chiasma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027946","Neutron","C40432","An elementary particle with 0 charge and a mass about equal to that of a proton.","Neutron | ",,,,,,,,,,,,,,,"4240229","Neutron",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033727","Proton","C17024","A fundamental particle with a positive charge.","Proton | proton",,,,,,,,,,,,,,,"4230486","Proton",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022122","Ischium","C32884","The most posterior and ventral bone making up the pelvis.","Ischium | Bone structure of ischium (body structure) | Hip | ISCHIUM | ischial bone | ischium | ischium bone","C41.4","Ischium",,,,,,,,,,,"UBERON:0001274","ischium","4312458","Bone structure of ischium",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0039277","Talus","C52799","The bone of the foot that connects with the tibia and fibula to form the ankle joint.","Talus | Astragalus | TALUS",,,,,,,,,,,,,,,"4284385","Bone structure of talus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021708","Intensive Care Unit","C53511","A health care facility unit that provides intensive care to critically ill patients and patients with complex medical problems who require constant monitoring or special therapy.","Intensive Care Unit | CRITICAL CARE UNIT | Critical Care Unit | ICU | INTENSIVE CARE UNIT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1300563","Gram per Kilogram","C69104","A unit of a mass fraction expressed as a number of grams of substance per kilogram of mixture. Gram per kilogram is also used as a dose calculation unit to express a quantity of substance in grams per one kilogram of body mass.","Gram per Kilogram | Gram/Kilogram | Microgram per Milligram | Milligram per Gram | g/kg | mcg/mg | mg/g | milligram(s)/gram | ug/mg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1552983","Units Of Measure - mesh","C71222","A traditional unit of length defined as the number of opening per inch of a screen, e.g. the number of strands or particles per inch.","Mesh | [mesh_i] | mesh",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008984","Clitoris","C12308","The erectile tissue in the vulva. It is composed of the corpora cavernosa and the glans clitoris.","Clitoris | CLITORIS | clitoris",,,,,,,,,,,,,"UBERON:0002411","clitoris","4276496","Clitoral structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1304517","Extrarenal Rhabdoid Tumor","C6586","A rhabdoid tumor which arises in the soft tissues.  It occurs in infants and children and may be associated with loss of chromosome 22.  It is characterized by the presence of cells with a large eccentric nucleus, prominent nucleolus, and abundant cytoplasm.","Extrarenal Rhabdoid Tumor | Malignant Extrarenal Rhabdoid Neoplasm | Rhabdoid Tumor of Soft Tissue",,,,,,,,,,,,,,,"4299132","Extrarenal rhabdoid tumor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1304513","Composite Hemangioendothelioma","C45475","An intermediate, locally aggressive and rarely metastasizing blood vessel neoplasm that predominantly involves the skin and superficial soft tissues, with rare cases reported in the kidney, lymph nodes, and spleen. It is characterized by the presence of spindle, plump, and epithelioid endothelial cells and cellular atypia.","Composite Hemangioendothelioma | CHE",,,,,,,,,,,,,,,"4300581|45766494","Composite hemangioendothelioma|Composite hemangioendothelioma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0334556","Adamantinoma","C7644","A low grade malignant neoplasm arising from the long bones. The tibia is the most frequently affected bone site. Patients present with swelling which may or may not be associated with pain. Morphologically, it is characterized by a biphasic pattern consisting of an epithelial and an osteofibrous component. The vast majority of cases recur if they are not treated with radical surgery. In a minority of cases the tumor may metastasize to other anatomic sites including lymph nodes, lungs, liver, brain, and skeleton.","Adamantinoma | ADAMANTINOMA, MALIGNANT | Adamantinoma of Long Bones | Adamantinoma of long bones | Adamantinoma, malignant | Extragnathic Adamantinoma","9261/3","Adamantinoma of long bones",,,,,,,,,,,,,"4144194|4211371","Adamantinoma of long bone|Adamantinoma of long bones",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1710042","Secondary Osteosarcoma","C53704","An osteosarcoma arising from a pre-existing lesion of the bone, usually Paget disease, or due to radiation therapy.","Secondary Osteosarcoma | Secondary Bone Osteosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710026","Sclerosing Epithelioid Fibrosarcoma","C49027","A well-circumscribed malignant fibroblastic neoplasm that usually arises from the soft tissue. It is characterized by the presence of nests of malignant epithelioid fibroblasts and sclerotic collagen stroma formation.","Sclerosing Epithelioid Fibrosarcoma | SEF | Sclerosing epithelioid fibrosarcoma",,,,,,,,,,,,,,,"45766456","Sclerosing epithelioid fibrosarcoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1304512","Retiform Hemangioendothelioma","C27511","A rare, intermediate, locally aggressive and rarely metastasizing blood vessel neoplasm of the skin and subcutaneous tissue that usually affects the distal extremities, most often the leg.  It manifests as a slow-growing red/bluish nodule or plaque and is characterized by the presence of hobnail endothelial cells and formation of arborizing vascular channels.","Retiform Hemangioendothelioma | Hobnail Hemangioendothelioma | RHE",,,,,,,,,,,,,,,"4300579|45766493","Retiform hemangioendothelioma|Retiform hemangioendothelioma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1335661","Radiation-Related Angiosarcoma","C27513","A malignant vascular neoplasm arising in an anatomic site exposed to radiation therapy.","Radiation-Related Angiosarcoma | Radiation-Induced Angiosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0346087","Papillary Intralymphatic Angioendothelioma","C7526","A rare, intermediate and rarely metastasizing blood vessel neoplasm that most often affects the skin and soft tissue of the extremities and manifests as a slow-growing induration, nodule, or plaque. Rare cases have been described in the spleen, tongue, and testis as well. It is characterized by the presence of lymphatic-like vascular channels and papillary endothelial proliferation.","Papillary Intralymphatic Angioendothelioma | Dabska Tumor | Dabska tumor | Endovascular papillary angioendothelioma | Malignant Endothelial Papillary Angioendothelioma | PILA | Papillary Endovascular Angioendothelioma",,,,,,,,,,,,,,,"37164469|4030138","Papillary intralymphatic angioendothelioma|Papillary intralymphatic angioendothelioma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1266128","Ossifying Fibromyxoid Tumor","C6582","A rare soft tissue tumor of uncertain lineage characterized by the presence of neoplastic spindle to round cells forming cords in a fibromyxoid stroma.  The lesions are associated with the formation of metaplastic bone.  Most patients present with painless subcutaneous masses.  Recurrences have been reported in a minority of patients.","Ossifying Fibromyxoid Tumor | OFMT | Ossifying Fibromyxoid Neoplasm | Ossifying Fibromyxoid Neoplasm | Ossifying Fibromyxoma | Ossifying fibromyxoid tumor",,,,,,,,,,,,,,,"4028565|4298239","Ossifying fibromyxoid tumor|Ossifying fibromyxoid tumor",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1709103","Myxoinflammatory Fibroblastic Sarcoma","C49025","A low grade, locally aggressive, fibroblastic neoplasm that occurs primarily in the distal extremities.  It is characterized by the presence of spindle-shaped fibroblasts, multivacuolated lipoblast-like cells, bizarre ganglion-like cells with inclusion-like nuclei, myxoid stroma formation, and a mixture of acute and chronic inflammatory cells.  Distant metastases are very rare.","Myxoinflammatory Fibroblastic Sarcoma | Acral Myxoinflammatory Fibroblastic Sarcoma | Inflammatory Myxohyaline Tumor of the Distal Extremities with Virocyte/Reed-Sternberg-Like Cells | Inflammatory Myxoid Tumor of the Soft Parts with Bizarre Giant Cells | MIFS | Myxoinflammatory fibroblastic sarcoma (MIFS)",,,,,,,,,,,,,,,"45766450","Myxoinflammatory fibroblastic sarcoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334472","Mixed Liposarcoma","C4253","A malignant neoplasm characterized by the presence of a combination of liposarcomatous morphologic subtypes: myxoid/round cell and well differentiated/dedifferentiated liposarcoma or myxoid/round cell and pleomorphic liposarcoma.","Mixed Liposarcoma | Mixed liposarcoma","8855/3","Mixed liposarcoma",,,,,,,,,,,,,"4007138","Mixed liposarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1266120","Malignant Solitary Fibrous Tumor","C6894","A malignant neoplasm of probable fibroblastic derivation. It is characterized by the presence of atypical round to spindle-shaped cells, increased cellularity, necrotic change and high mitotic activity.","Malignant Solitary Fibrous Tumor | Malignant Hemangiopericytoma | Solitary fibrous tumor, malignant","8815/3","Solitary fibrous tumor, malignant",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C1266111","Malignant Glomus Tumor","C4221","A very rare morphologic variant of glomus tumor with a size greater than 2 cm.  The tumor arises in subfascial or visceral tissues. It is characterized by the presence of atypical mitotic figures, or marked nuclear atypia, or the combination of both.  It has an aggressive clinical course.","Malignant Glomus Tumor | Glomangiosarcoma | Glomus tumor, malignant | Malignant Glomus Neoplasm","8710/3|8711/3","Glomangiosarcoma|Glomus tumor, malignant",,,,,,,,,,,,,"4028856|4029477","Glomus tumor, malignant|Glomangiosarcoma",,,,,,,,,,,,,"--","--|--",,,,,,,,"--|--"
"C0205766","Fibromyxoid Tumor","C66760","A soft tissue tumor of uncertain lineage characterized by the presence of neoplastic spindle-shaped to round cells in a fibromyxoid stroma. Metaplastic bone formation may or may not be present.","Fibromyxoid Tumor | FIBROMYXOMA, BENIGN | Fibromyxoid Neoplasm | Fibromyxoid Neoplasm | Fibromyxoma",,,,,,,,,,,,,,,"4314278","Fibromyxoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1367420","Kaposiform Hemangioendothelioma","C27510","An intermediate, locally aggressive blood vessel neoplasm characterized by the presence of spindle endothelial cells, and formation of capillary-sized and slit-like vascular channels.  It is often associated with hemorrhage and hemosiderin deposition.","Kaposiform Hemangioendothelioma | KHE | Kaposiform hemangioendothelioma",,,,,,,,,,,,,,,"4281384|4300580","Hemangioendothelioma|Kaposiform hemangioendothelioma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1708550","Intimal Sarcoma","C53677","A malignant neoplasm arising from the large blood vessels.  It is characterized by the presence of tumor cells that grow within the lumen of the blood vessels.  The intraluminal tumor growth may result in vascular obstruction and spread of tumor emboli to peripheral organs.  The prognosis is usually poor.","Intimal Sarcoma | Intimal sarcoma",,,,,,,,,,,,,,,"45766495","Intimal sarcoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3853704","Abate (action)","C86045","Become less in amount or intensity.","Abate | Abated | Abating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0680230","Accomplishment","C86038","Something that has been achieved or completed successfully.","Accomplishment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0234238","Ache","C86024","A dull persistent (usually moderately intense) pain.","Ache | ",,,,,,,,,,,,,,,"4100071|4253769","Aching pain|Aching sensation quality",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0376649","Address","C86945","A formal speech or report.","Address | ",,,,,,,,,,,,,,,"37116950","Address (property)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0680730","Adjudication","C86039","The final judgment in a legal proceeding.","Adjudication | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001830","Agrobacterium","C86011","Small motile rod bacteria that can reduce nitrates and cause galls on plant stems.","Agrobacterium | AGROBACTERIUM",,,,,,,,,,,,,,,"4140675","Agrobacterium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0439095","Alpha","C86942","The 1st letter of the Greek alphabet.","Alpha | ",,,,,,,,,,,,,,,"4137015","Alpha",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002607","Ammonia","C76698","An inorganic compound composed of a single nitrogen atom covalently bonded to three hydrogen atoms that is an amidase inhibitor and neurotoxin. It is both manufactured and produced naturally from bacterial processes and the breakdown of organic matter. Ammonia is used in many industrial processes, and as a fertilizer and refrigerant. It is characterized as a colorless gas or compressed liquid with a pungent odor and exposure occurs by inhalation, ingestion, or contact.","Ammonia | AMMONIA | Ammonia Solution, Strong",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0194412","Radical Cystoprostatectomy","C51899","The simultaneous surgical resection of the urinary bladder and prostate gland with pelvic lymphadenectomy.","Radical Cystoprostatectomy | Cystoprostatectomy | cystoprostatectomy",,,,,,,,,,,,,,,"4216658","Radical cystoprostatectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2987624","Segmentectomy","C91061","Resection of a segment of an organ or partial resection of a gland.","Segmentectomy | SEGMENTECTOMY | Segmental Resection | segmental resection | segmentectomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042650","Video Recording","C91063","The storing or preserving of video images to be displayed later.","Video Recording | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984009","Suboptimal","C91065","Being below an optimal level or standard.","Suboptimal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984010","Macro","C91066","A prefix meaning very large or big in scale or scope or capability.","Macro | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225897","Left Ventricle","C12871","The left lower chamber of the heart that receives blood from the left atrium and pumps it through the aorta to the body.","Left Ventricle | HEART, LEFT VENTRICLE",,,,,,,,,,,,,,,"4339094","Left cardiac ventricular structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2984008","Image Quantification","C91062","The process of measuring attributes of an image, by human sense or machine observations and experiences, and mapping them into members of some set of numbers or coded concepts.","Image Quantification | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984012","Non-Parameningeal Head and Neck Area","C91069","The superficial areas of head and neck including the oral cavity, buccal mucosa, and the parotid region.","Non-Parameningeal Head and Neck Area | Non-parameningeal Head and Neck Area",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439476","Centimeters of Water","C91060","A unit of pressure defined by a column of water with a height of one centimeter, frequently used to measure central venous pressure, intracranial pressure, and for pressures during mechanical ventilation.","Centimeters of Water | Centimeters of Water Column | Centimeters of water | cm H2O | cmH2O | cm[H2O]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002930","Anesthesiology","C86047","The medical specialty concerned with patient comfort before, during, and after surgery and other medical procedures, including administration of anesthesia.","Anesthesiology | ",,,,,,,,,,,,,,,"4192655","Anesthetics",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0232766","Asterixis","C86048","A tremor of the wrist that is observed when the wrist is extended.","Asterixis | ",,,,,,,,,,,,,,,"4138992","Asterixis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1999228","Document Attachment","C86943","A file or document affixed to another file or document.","Attachment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0741453","Bedridden","C86052","Confined to bed (by illness).","Bedridden | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282072","Betaine Hydrochloride","C82301","The hydrochloride form of betaine, a crystalline alkaloid occurring in sugar beets and other plants. Betaine, acting as a transmethylating metabolic intermediate, is the oxidation product of choline. Betaine hydrochloride is used as a gastric acidifier supplement.","Betaine Hydrochloride | (Carboxymethyl)trimethylammonium Chloride | Achylin | BETAINE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554684","Block (unit of measure)","C86947","A number, quantity, or group of things considered as a unit.","Block | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006086","Brace","C86054","An orthopedic device used to support a moveable body part.","Brace | Orthosis",,,,,,,,,,,,,,,"4235639","Brace",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0054151","Brotizolam","C87057","A triazolo-benzodiazepine derivative with sedative, hypnotic, anxiolytic and anticonvulsant activities. Brotizolam binds to the benzodiazepine binding site on the gamma aminobutyric acid (GABA)-A receptor in the central nervous system (CNS). This leads to an increase in the opening of chloride channels, membrane hyperpolarization and increases the inhibitory effect of GABA on the CNS.","Brotizolam | 2-Bromo-4-(O-Chlorophenyl)-9-Methyl-6H-Thieno(3,2-F)-S-Triazolo(4,3-A)(1,4)Diazepine | 6H-Thieno(3,2-F)(1,2,4)Triazolo(4,3-A)(1,4)Diazepine,2-Bromo-4-(2-Chlorophenyl)-9-Methyl- | BROTIZOLAM | WE-941",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054900","Cavitec","C86057","A proprietary eugenol and zinc oxide dental liner. It can be used as a base under composite or amalgam fillings.","Cavitec | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1283174","Check","C86058","The act of inspecting or verifying.","Check | Checked | Checking",,,,,,,,,,,,,,,"4232679","Checking - action",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1873633","Lisdexamfetamine","C75114","A prodrug of the d-isomer of amphetamine, a non-catecholamine sympathomimetic amine with central nervous system (CNS) stimulating activity. Upon administration, lisdexamphetamine is converted to dextroamphetamine through cleavage of the lysine group. Dextroamphetamine acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from its storage sites in nerve terminals in the CNS, and inhibits their uptake within the mesocorticolimbic system, a major component of the brain reward system, resulting in measurable behavioral changes such as euphoria, mental alertness and excitement and appetite suppression. As a CNS stimulant, this agent may increase blood pressure.","Lisdexamfetamine | LISDEXAMFETAMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882931","wild-type reovirus","C60774","An isolate of the oncolytic, human wild-type serotype 3 Dearing (T3D) strain of the double-stranded RNA virus reovirus (Respiratory Enteric Orphan virus), with potential oncolytic activity. Upon administration, pelareorep is able to replicate specifically in cancer cells bearing an activated Ras pathway. This induces apoptosis in Ras-activated tumor cells and subsequently frees progeny viral particles to infect, replicate in and induce cell death of surrounding cancer cells. In addition, viral replication causes the activation of innate and adaptive immune responses, causing a natural killer (NK)-cell-mediated and a cytotoxic T-cell (CTL)-mediated killing of tumor cells, respectively. Ras-activated tumor cells are deficient in their ability to trigger the antiviral response mediated by the host cellular protein, double-stranded RNA-dependent protein kinase (PKR).","Pelareorep | PELAREOREP | PO BB0209 | PO-BB0209 | Reolysin | Reolysin | Reovirus Serotype 3 | Wild-type Reovirus | Wild-type Reovirus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698272","Foretinib","C80058","An orally bioavailable small molecule with potential antineoplastic activity. Foretinib binds to and selectively inhibits hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), which may result in the inhibition of tumor angiogenesis, tumor cell proliferation and metastasis. The proto-oncogene c-MET has been found to be over-expressed in a variety of cancers. VEGFR2 is found on endothelial and hematopoietic cells and mediates the development of the vasculature and hematopoietic cells through VEGF signaling.","Foretinib | FORETINIB | GSK1363089 | MET/VEGFR-2 inhibitor GSK1363089 | Multitargeted Tyrosine Kinase Inhibitor GSK1363089 | Multitargeted Tyrosine Kinase Inhibitor GSK1363089 | N-(3-Fluoro-4-((6-methoxy-7-(3-(morpholin-4-yl)propoxy)quinolin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | XL880 | foretinib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0754011","Abiraterone","C77333","A steroidal compound with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.","Abiraterone | 17-(3-Pyridyl)androsta-5,16-dien-3beta-ol | ABIRATERONE | CB 7598",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984084","French-American-British Classification","C91220","A classification system for acute myeloid leukemias, acute lymphoblastic leukemias, and myelodysplastic syndromes.  It is based on the morphologic and cytochemical evaluation of bone marrow and peripheral blood smears.","French-American-British Classification | FAB | FAB Classification for Bone Marrow | FAB_TYPE | French-American-British Classification System | fab morphology code | fab_morphology_code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021156","Incisor","C32769","One of the teeth in front of the canines in either jaw designed for cutting or gnawing.","Incisor | INCISOR | TOOTH, INCISOR",,,,,,,,,,,,,,,"4301249","Structure of incisor tooth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2983704","Subordinate","C90504","Lower in rank or importance, or dependent on something else.","Subordinate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984051","Able to Enjoy Life","C91116","A question about whether an individual enjoys or has enjoyed life.","Able to Enjoy Life Question | Able to Enjoy Life | Able to Enjoy Life | I Enjoy Life | I am able to enjoy life | I enjoyed life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984044","Able to Work","C91109","A question about whether an individual is or was able to work.","Able to Work Question | Able to Work | Able to Work | I am able to work",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984045","Accepted Illness","C91110","A question about whether an individual accepts or has accepted their illness.","Accepted Illness | I have accepted my illness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984047","Bothered By Side Effects of Treatment","C91112","A question about whether an individual is or has been bothered by the side effects of their treatment.","Bothered By Side Effects of Treatment | Bothered By Side Effects | Bothered By Side Effects | Bothered by Side Effects of Treatment | I am bothered by the side effects of treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984049","Content with Quality of Life","C91114","A question about whether an individual is or was content with the quality of their life.","Content with Quality of Life | I am content with the quality of my life right now",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984050","Emotional Support from Family","C91115","A question about whether an individual has or had emotional support from their family.","Emotional Support from Family | I get emotional support from my family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984052","Enjoy Things for Fun","C91117","A question about whether an individual enjoys or has enjoyed the things they do for fun.","Enjoy Things for Fun | I am enjoying the things I usually do for fun",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984053","Family Accepts Illness","C91118","A question about whether an individual's family accepts or has accepted their illness.","Family Accepts Illness | My family has accepted my illness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984048","Feel Close to Friends","C91113","A question about whether a person feels or felt close to their friends.","Feel Close to Friends | I feel close to my friends",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984059","Feel Close to Partner","C91127","A question about whether a person feels or felt close with their partner or main support person.","Feel Close to Partner | I feel close to my partner (or the person who is my main support)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987492","Feel Ill Survey Question","C91121","A question about whether an individual feels or felt ill.","Feel Ill | Feel Ill or Unwell | I feel ill",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0849963","Feeling nervous","C91125","A question about whether an individual feels or felt nervous.","Feel Nervous | Feeling nervous | Felt Nervous | Have you felt agitated/nervous | I feel nervous | I felt nervous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987511","Feel Sad Question","C91129","A question about whether an individual feels or felt sad.","Feel Sad | Feeling sad | Felt Sad | I feel sad | I felt sad",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984055","Forced to be in Bed","C91120","A question about whether an individual is or has been forced to spend time in bed.","Forced to be in Bed | I am forced to spend time in bed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984057","Have Nausea","C91124","A question about whether a person has or had nausea.","Have Nausea | Had Nausea | Have you felt nauseated | I have nausea | Nausea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984058","Have Pain","C91126","A question about whether an individual has or had pain.","Have Pain | Did you have any pain yesterday or today | Had Pain | Have Any Pain | Have you had pain | I have pain | Pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4048330","Lacks Energy","C91122","A question about whether an individual has or had a lack of energy.","Lacks Energy | Feeling a Lack of Energy | Had a Lack of Energy | I have a lack of energy | Lack Energy | Lack Energy | Lack of energy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984056","Losing Hope Against Illness","C91123","A question about whether an individual is or was losing hope in the fight against their illness.","Losing Hope Against Illness | I am losing hope in the fight against my illness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984061","Satisfied with Coping with Illness","C91130","A question about an individual's satisfaction with their ability to cope with their illness.","Satisfied with Coping with Illness | I am satisfied with how I am coping with my illness | Satisfied With Coping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984054","Satisfied with Family Communication","C91119","A question about an individual's satisfaction with their family's communication about their illness.","Satisfied with Family Communication | I am satisfied with family communication about my illness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984060","Satisfied with Sex Life","C91128","A question about an individual's satisfaction with their sex life.","Satisfied with Sex Life | I am satisfied with my sex life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984071","Sleeping Well","C91206","A question about whether an individual sleeps or slept well.","Sleeping Well | I am sleeping well",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984072","Receive Support from Friends","C91207","A question about whether an individual recieves or received support from their friends.","Receive Support from Friends | I get support from my friends | Support from Friends | Support from Friends",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984046","Trouble Meeting Family Needs Because of Physical Condition","C91111","A question about whether an individual has or had trouble meeting the needs of their family because of their physical condition.","Trouble Meeting Family Needs Because of Physical Condition | Because of my physical condition, I have trouble meeting the needs of my family | Trouble Meeting Family Needs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984074","Work is Fulfilling","C91209","A question about whether an individual finds or found their work fulfilling.","Work is Fulfilling | My work is fulfilling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984076","Worry About Dying","C91212","A question about whether an individual worries or worried about dying.","Worry About Dying | I worry about dying | Worry Dying | Worry Dying",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984075","Worry About Worsening Condition","C91211","A question about whether an individual worries or worried about their condition worsening.","Worry About Worsening Condition | I worry that my condition will get worse | Worry Worsening Condition | Worry Worsening Condition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984077","Not at All","C91213","A subjective answer of no agreement or ability.","Not at All | Not at all | Not at all",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984078","A little bit","C91214","A subjective answer of weak agreement.","A little bit | A Little | A little bit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984079","Somewhat","C91215","A subjective answer of partial agreement.","Somewhat | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984080","Quite a Bit","C91216","A subjective answer describing a fairly large amount or extent.","Quite a Bit | A Great Deal | A lot | Quite a bit | Quite a bit | Quite a lot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984081","Very Much","C91217","A subjective answer describing a great amount or extent.","Very Much | A Lot | A whole lot | Very | Very much | Very much | Very much indeed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0231242","Complicated","C86059","Difficult to analyze or understand.","Complicated | ",,,,,,,,,,,,,,,"4114501","Complicated",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162340","Comprehension","C86022","An ability to understand the meaning or importance of something (or the knowledge acquired as a result).","Comprehension | Understanding",,,,,,,,,,,,,,,"4282173","Understanding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2363152","Cortisporin","C87058","A combination preparation containing the polypeptide antibiotic polymyxin b, the aminoglycoside antibiotic neomycin, the glucocorticoid hydrocortisone and, in some formulations, the antibiotic bacitracin zinc with antibacterial and anti-inflammatory activities.  Polymyxin B, neomycin and bacitracin zinc exert antibacterial effects through a cationic detergent-like action on cell membranes, inhibition of protein synthesis, and inhibition of peptidoglycan synthesis, respectively. Hydrocortisone initially binds to the cytoplasmic glucocorticoid receptor; then the receptor-ligand complex is translocated to the nucleus where it initiates the transcription of genes encoding for anti-inflammatory mediators, such as cytokines and lipocortins.","Neomycin/Bacitracin Zinc/Polymyxin B/Hydrocortisone | Cortisporin | Cortisporin Formulation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010397","Crutch","C86060","A wooden or metal staff that fits under the armpit and reaches to the ground, used as an aid while walking.","Crutch | ",,,,,,,,,,,,,,,"4251933","Crutch",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010404","Cryoglobulin","C86062","An abnormal plasma protein that precipitates within the microvasculature on exposure to cold; microvasculature effects of cryoglobulinemia may result in restricted tissue blood flow, tissue hypoxia, and tissue necrosis.","Cryoglobulin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0320130","Dactylaria","C86061","A genus of soil-dwelling fungi.","Dactylaria | ",,,,,,,,,,,,,,,"4298232","Dactylaria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348308","doconexent","C68346","A polyunsaturated very long-chain fatty acid with a 22-carbon backbone and 6 double bonds, originating from the 3rd, 6th, 9th, 12th, 15th and 18th positions from the methyl end.","Doconexent | (All-Z)-4,7,10,13,16,19-Docosahexaenoic Acid | All-cis-4, 7, 10, 13, 16, 19-Docosahexaenoic Acid | All-cis-docosa-4,7,10,13,16,19-hexaenoic acid | Cervonic Acid | Cis-4,7,10,13,16,19-Docosahexaenoic Acid | DHA | DOCONEXENT | Docosahexaenoic Acid n-3 | Fatty Acid 22:6 n-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0058830","Dycal","C86067","A proprietary, rigid, self-setting restorative material.","Dycal | Radiopaque Calcium Hydroxide Composition",,,,,,,,,,,,,,,"4080147","Calcium hydroxide cement - setting",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1527344","Dysphonia","C86950","A speech disorder resulting in impaired utterance of sounds by the vocal folds.","Dysphonia | dysphonia",,,,,,,,,,,,,,,"40326053","Dysphonia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332219","Easy","C86068","Posing no difficulty; requiring little effort.","Easy | Not at all | Not at all a problem | Not difficult at all",,,,,,,,,,,,,,,"4264231","Easy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013470","Eat","C86069","To take food into the body by mouth.","Eat | ",,,,,,,,,,,,,,,"4025561|4170223","Food intake|Eating",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0014149","Endodontics","C86070","The branch of dentistry dealing with diseases of the dental pulp.","Endodontics | ",,,,,,,,,,,,,,,"4247117","Endodontics - specialty",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0180759","Esthesiometer","C86072","An instrument to measure the degree of sensation, by determining at how short a distance two impressions upon the skin can be distinguished, and thus to determine whether the condition of tactile sensibility is normal or altered.","Esthesiometer | ",,,,,,,,,,,,,,,"45767900","Esthesiometer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0747130","Pacemaker Placement","C80434","A surgical procedure in which a small, battery-powered device is placed in the chest wall to transmit electrical impulses to the heart muscles to stimulate contraction.","Pacemaker Placement | Insertion of a permanent pacemaker",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4014613","Lymphadenopathy","C50764","An enlarged lymph node. Causes include viral and bacterial infections and cancers that affect the lymph nodes.","Lymphadenopathy | Adenopathy | Swollen Gland | Swollen Gland | adenopathy | lymphadenopathy",,,,,,,,,,,,,,,"315085","Lymphadenopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015827","Fenfluramine","C81418","An amphetamine derivative and a sympathomimetic stimulant with appetite-suppressant property. Fenfluramine, which was part of the Fen-Phen anti-obesity medication, stimulates the release of serotonin from vesicular storage, and modulates serotonin transporter function. Since serotonin regulates mood and appetite, among other functions, increased serotonin level results in a feeling of fullness and loss of appetite.","Fenfluramine | 1-(meta-Trifluoromethyl-phenyl)-2 Ethylaminopropane | 2-Ethylamino-1-(3-trifluoromethylphenyl)propane | 3-(Trifluoromethyl)-N-ethyl-alpha-methylphenethylamine | FENFLURAMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031447","Phentermine","C61890","A natural monoamine alkaloid derivative and a sympathomimetic stimulant with appetite suppressant property. Phentermine, which was part of the Fen-Phen anti-obesity medication, stimulates hypothalamic release of norepinephrine, a neurotransmitter involved in stress responses (fight-or-flight reactions), and reduces hunger sensation. Phentermine also causes the release of epinephrine or adrenaline outside of the brain, resulting in breakdown of stored fat.","Phentermine | 1,1-Dimethyl-2-phenylethylamine | 2-Amino-2-methyl-1-phenylpropane | 2-Phenyl-tert-butylamine | PHENTERMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023660","Lidocaine","C614","A synthetic aminoethylamide with local anesthetic and antiarrhythmic properties. Lidocaine stabilizes the neuronal membrane by binding to and inhibiting voltage-gated sodium channels, thereby inhibiting the ionic fluxes required for the initiation and conduction of impulses and effecting local anesthesia.","Lidocaine | .omega.-Diethylamino-2,6-dimethylacetanilide | 2-(Diethylamino)-2',6'-acetoxylidide | 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide | 2-Diethylamino-2',6'-acetoxylidide | Cuivasil | Duncaine | LIDOCAINE | Leostesin | Lidothesin | Lignocaine | Omega-diethylamino-2,6-dimethylacetanilide | Rucaina | lidocaine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449057","Explanation","C86073","A set of statements describing a group of facts that clarifies the cause, context and/or consequence of those facts.","Explanation | Explanatory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017954","Glycophorin","C86976","A family of sialoglycoproteins that are found in erythrocytes. Members of this family are transmembrane proteins and are able to interact with both oligosaccharides on the extracellular surface and the cytoplasmic contractile proteins spectrin and actin.","Glycophorin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0311608","Glyoxylate Dehydrogenase (Acylating)","C86977","An oxidoreductase that catalyzes the conversion of Coenzyme A to oxalyl-Coenzyme A and the reduction of NADP+ to form NADPH through the cleavage of a glyoxylate molecule. This enzyme is involved in the biosynthesis of carbohydrate from fatty acids or other precursors.","Glyoxylate Dehydrogenase (Acylating) | EC 1.2.1.17 | Glyoxylate:NADP+ Oxidoreductase (CoA-Oxalylating)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018880","Helium","C85242","A gaseous element with atomic symbol He, atomic number 2, and atomic weight 4.00.","Helium | HELIUM | He",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019653","Histoplasma","C86075","A genus of microscopic fungus that causes the disease histoplasmosis.","Histoplasma | ",,,,,,,,,,,,,,,"4217628","Histoplasma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0521057","Hypha","C86076","Any of the threadlike filaments forming the mycelium of a fungus.","Hypha | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711190","Southeast","C45855","The ordinal direction halfway between south and east.","Southeast | Southeastern",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020899","Illiterate","C86556","Not able to read or write.","Illiterate | ",,,,,,,,,,,,,,,"4059164","Illiteracy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0949860","Isoprostane","C87059","A group of compounds similar to prostaglandins with immunomodulating activity. Isoprostanes are formed through free radical catalyzing non-enzymatic reactions involving peroxidation of essential fatty acids, mainly arachidonic acid or any other fatty acid with 3 or more double bonds. Isoprostanes are abundant in tissues and fluids and their concentration is dependent on the amount of oxidative stress and may be upregulated in certain diseases such as cancer, cardiovascular and neurological disorders.","Isoprostane | Isoprostanes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1061245","Jamesdicksonia","C86560","A genus of fungi of the Exobasidiomycetes class. It contains no medically significant pathogens.","Jamesdicksonia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022422","Judaism","C86561","The monotheistic religion of the Jews having its spiritual and ethical principles embodied chiefly in the Torah and in the Talmud.","Judaism | Jewish",,,,,,,,,,,,,,,"4171751","Judaism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0557653","Kitchen","C86562","A room or part of a room used for cooking and food preparation.","Kitchen | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1260920","Kneeling","C86563","In a position where one or both knees are on the ground.","Kneeling | Kneel",,,,,,,,,,,,,,,"4185532","Kneeling",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0926407","Lambda Sutural Junction","C86944","The point of junction of the sagittal and lambdoid sutures of the skull.","Lambda Sutural Junction | Lambda",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663199","Sodium Hypochlorite","C80658","A chlorine compound often used as a disinfectant or a bleaching agent. Sodium hypochlorite in 0.5% w/v solution is called Dakin's solution, and is used as an antiseptic to clean infected topical wounds.","Sodium Hypochlorite | Hypochlorite Sodium | Hypochlorous Acid, Sodium Salt | SODIUM HYPOCHLORITE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524904","Lamiaceae","C86564","A plant family of aromatic herbs and shrubs having flowers resembling the lips of a mouth and four-lobed ovaries yielding four one-seeded nutlets which includes the mints, thyme, sage, and rosemary.","Lamiaceae | ",,,,,,,,,,,,,,,"4027301","Family Lamiaceae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0441054","Lawnmower","C86565","A machine to cut grass to an even length.","Lawnmower | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023368","Leptotrichia","C86014","A genus of long filamentous gram-negative anaerobic rod bacteria in the Fusobacteriaceae family; sometimes associated with oral or urogenital infections.","Leptotrichia | ",,,,,,,,,,,,,,,"4199151","Leptotrichia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0064956","Librax","C87060","A combination formulation containing the hydrochloride salt form of the benzodiazepine chlordiazepoxide and the bromide salt form of the quaternary ammonium antimuscarinic clidinium with anxiolytic, sedative and antispasmodic activities. Chlordiazepoxide binds to a specific benzodiazepine-binding site on the gamma-aminobutyric acid (GABA)-A receptor in the central nervous system (CNS). This leads to an increase in the opening of chloride channels, membrane hyperpolarization and increases the inhibitory effect of GABA on the CNS. Clidinium binds to and blocks muscarinic receptors in the gastrointestinal (GI) tract. This leads to a decrease in stomach secretions, GI motility and GI spasms.","Chlordiazepoxide Hydrochloride/Clidinium Bromide | Librax",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827491","Radiolucency","C84557","The quality of being almost completely transparent to X-rays or other forms of radiation; the amount of radiation that is permitted to pass through a structure.","Radiolucency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206244","Lifting","C86567","The act of raising something.","Lifting | Lift | Lifted",,,,,,,,,,,,,,,"4106638","Lifting",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007018","Carbon Monoxide","C76742","An odorless, tasteless, poisonous gas, CO, that results from the incomplete combustion of carbon. Inhalation causes central nervous system damage and asphyxiation.","Carbon Monoxide | CARBON MONOXIDE | CO | carbon monoxide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0718861","Belladonna/Phenobarbital","C87056","A combination preparation containing the belladonna alkaloids atropine sulfate, hyoscyamine sulfate, and scopolamine hydrobromide, and the barbiturate phenobarbital with antispasmodic, anxiolytic and sedative activities. The belladonna alkaloids bind to and block muscarinic receptors in the gastrointestinal (GI) tract. This leads to a decrease in stomach secretions, GI motility and GI spasms. Phenobarbital binds to a distinct site on the gamma-aminobutyric acid (GABA)-A subtype receptor in the central nervous system (CNS), thereby increasing the influx of chloride ions into the neuron and potentiating GABA-induced increases in chloride conductance. This enhances postsynaptic responses to the inhibitory actions of GABA and causes CNS depression.","Belladonna/Phenobarbital | Belladonna Alkaloids/Phenobarbital",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229665","Arterial Blood","C78729","Blood found in arteries, generally oxygenated blood which is transported with nutrients to body tissues through the arterial system. The exception is blood within the pulmonary artery which carries deoxygenated blood to the lungs.","Arterial Blood | ARTERIAL BLOOD | Blood arterial",,,,,,,,,,,,,,,"4187930","Arterial blood",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001930","Alcaligenes","C86012","A genus of Gram-negative, aerobic, rod-shaped bacteria in the family Alcaligenaceae.","Alcaligenes | ALCALIGENES",,,,,,,,,,,,,,,"4288470","Alcaligenes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0432470","XY Female","C86031","A person who has a chromosome composition of 46 XY and who is phenotypically female.","XY Female | ",,,,,,,,,,,,,,,"4219609","XY females",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0262659","Vaginal Carcinoma","C3917","A carcinoma arising from the vaginal epithelium. The majority of vaginal carcinomas are squamous cell carcinomas.","Vaginal Carcinoma | Cancer of Vagina | Cancer of the Vagina | Carcinoma of Vagina | Carcinoma of the Vagina | Vagina Cancer | Vagina Carcinoma | Vaginal Cancer | Vaginal cancer, NOS | vaginal cancer",,,,,,,,,,,,,,,"4110873","Carcinoma of vagina",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0679210","Literal","C86569","Limited to the explicit meaning of a word or text.","Literal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2003888","Lower (action)","C86568","To become lower, grow less, or diminish, as in amount, intensity, degree, or value.","Lower | Lowered | Lowering",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028884","Odor","C86573","The sensation that results when olfactory receptors in the nose are stimulated by particular chemicals in gaseous form.","Odor | odor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4012195","Macroglossia","C84832","A finding indicating enlargement of the tongue.","Macroglossia | ",,,,,,,,,,,,,,,"437979","Enlargement of tongue",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024726","Manitoba","C86002","A province of central Canada, lying between the provinces of Saskatchewan and Ontario. Its capital is Winnipeg.","Manitoba | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0599773","Homologous Recombination","C18144","The process of exchange of genetic material between autonomous replicons, which depends on regions of extensive sequence homology between the participating DNA strands. This process involves double-strand breakage of one participant, resection of the break, and strand invasion, followed by formation, displacement and resolution of the Holliday junction. This process is involved in repairing broken DNA and creating combinations of genes that may be unique from the parent duplexes. Disruptions in this process can result in inviability, premature aging and predisposition to cancers and degenerative diseases.","Homologous Recombination | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024861","Mask","C86570","A protective covering worn over the face, or an apparatus for administering anesthesia or oxygen through the nose or mouth.","Mask | ",,,,,,,,,,,,,,,"4130245","Mask",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3277167","Melena","C86571","Abnormally dark tarry feces containing blood, usually from gastrointestinal bleeding.","Melena | Melaena",,,,,,,,,,,,,,,"4103703","Melena",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0233660","Mental Blocking","C86946","Difficulty in recollection, or interruption of a train of thought or speech, due to emotional factors.","Mental Blocking | Blocking | Mental Block",,,,,,,,,,,,,,,"4103874","Thought block",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026536","Moraxella","C86009","A genus of Gram-negative bacteria in the Moraxellaceae family ocurring as short rods, coccobacilli or diplococci.","Moraxella | Branhamella | Branhamella Species | MORAXELLA",,,,,,,,,,,,,,,"4263926","Moraxella",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2984127","Dynamic Extension","C91271","A computer program that enables an application to define classes dynamically.","Dynamic Extension | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984128","Dynamic Extension Class","C91272","A class created by the Dynamic Extension computer program.","Dynamic Extension Class | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984129","Metaphone","C91275","A phonetic algorithm for indexing words based on the way they sound.","Metaphone | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1856100","Behavioral Disorder","C35470","A specific behavioral problem that occurs in persistent patterns and characteristic clusters and that causes clinically significant impairment.","Behavioral Disorder | Behavior-Related Disorder | Behavior-Related Disorder | Behavior-Related Problem | Behaviour-Related Disorder | Lifestyle-Related Condition | Lifestyle-Related Disorder | Lifestyle-Related Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011350","Enamel","C32505","A hard, thin, translucent layer of calcified substance that envelops and protects the dentin of the crown of the tooth. It is the hardest substance in the body and is almost entirely composed of calcium salts.","Enamel | ",,,,,,,,,,,,,,,"4297440","Enamel structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0430262","Indirect Antiglobulin Test","C91372","A test that uses Coombs' reagent to detect the presence of anti-erythrocyte antibodies in serum.","Indirect Antiglobulin Test | ANGLBIND | Antiglobulin Test, Indirect | Indirect Anti-human Globulin Test | Indirect Coombs Test",,,,,,,,,,,,,,,"4055434","Indirect Coombs test",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0349631","Richter Syndrome","C35424","Transformation of chronic lymphocytic leukemia into aggressive non-Hodgkin lymphoma, usually diffuse large B-cell lymphoma (immunoblastic or centroblastic variant).  Occasional cases of transformation to Hodgkin lymphoma have also been described, particularly in patients treated with purine nucleotide analogues.  Molecular genetic studies suggest that in approximately half of the cases, the lymphoma is clonally related to the underlying chronic lymphocytic leukemia, whereas in the remaining cases the lymphoma probably represents a secondary, unrelated neoplasm.","Richter Syndrome | Richter syndrome | Richter transformation | Richter's Syndrome | Richter's Syndrome | Richter's Transformation",,,,,,,,,,,,,,,"4173956","Richter's syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2984099","Subjective Numeracy Scale","C91235","A self-report measure of perceived ability to perform various mathematical tasks and preference for the use of numerical versus prose information. The 8-item scale contains no mathematics questions and has no correct or incorrect answers. Instead, it consists of 4 questions asking respondents to assess their numerical ability in different contexts and 4 questions asking them to state their preferences for the presentation of numerical and probabilistic information. (Fagerlin, et al., Medical Decision Making, 2007: 27: 672-680)","Subjective Numeracy Scale | SNS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984100","Words or Numbers for Chance Events","C91236","A question about whether a person prefers words or numbers for describing the chance of an event happening.","Words or Numbers for Chance Events | When people tell you the chance of something happening, do you prefer that they use words ('it rarely happens') or numbers ('there's a 1% chance')",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984101","How Good Calculating 15 Percent Tip","C91237","A question about how proficient an individual is with calculating a 15 percent tip.","How Good Calculating 15 Percent Tip | How Good Calculating Tip | How good are you at calculating a 15% tip",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984102","How Good Calculating 25 Percent Off","C91238","A question about how proficient an individual is with calculating a 25 percent reduction.","How Good Calculating 25 Percent Off | How Good Calculating Percent Off | How good are you at figuring out how much an item will cost if it is 25% off",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984103","How Good at Fractions","C91239","A question about how proficient an individual is at working with fractions.","How Good at Fractions | How Good At Fractions | How Good At Fractions | How good are you at working with fractions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984104","How Good at Percentages","C91240","A question about how proficient an individual is at working with percentages.","How Good at Percentages | How Good At Percentages | How Good At Percentages | How good are you at working with percentages",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984105","How Useful Tables and Graphs Accompanying Newspaper or Other Text","C91241","A question about how useful an individual finds or found tables and graphs that accompany a newspaper story or other text.","How Useful Tables and Graphs Accompanying Newspaper or Other Text | How Useful Tables and Graphs | When reading the newspaper, how helpful do you find tables and graphs that are parts of a story",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984106","How Useful Numerical Information","C91242","A question about how useful an individual finds or found numerical information.","How Useful Numerical Information | How often do you find numerical information to be useful",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984107","Words or Percentages for Weather Forecast","C91243","A question about whether a person prefers words or percentages for describing the chance of a weather event.","Words or Percentages for Weather Forecast | When you hear a weather forecast, do you prefer predictions using percentages (e.g., 'there will be a 20% chance of rain today') or predictions using only words (e.g., 'there is a small chance of rain today') | Words or Numbers for Weather Forecast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984111","Not at All Good","C91249","A subjective answer indicating the opinion of not being skilled.","Not at All Good | Not at all good",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984112","Extremely Good","C91250","A subjective answer indicating the opinion of being well skilled.","Extremely Good | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984115","Always Prefer Words","C91253","A subjective answer indicating a strong preference for word explanations over number explanations.","Always Prefer Words | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984116","Always Prefer Numbers or Percentages","C91254","A subjective answer indicating a strong preference for number explanations over word explanations.","Always Prefer Numbers or Percentages | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984136","Likert Score 2","C91291","A subjective score of 2 on a Likert scale.","Likert Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984137","Likert Score 3","C91292","A subjective score of 3 on a Likert scale.","Likert Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984138","Likert Score 4","C91293","A subjective score of 4 on a Likert scale.","Likert Score 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984139","Likert Score 5","C91294","A subjective score of 5 on a Likert scale.","Likert Score 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007189","Cardiology","C86055","The branch of medicine dealing with the heart and its diseases.","Cardiology | ",,,,,,,,,,,,,,,"4215120","Cardiology",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0000857","Abstracting","C86046","The process of creating a summary of the main points of an article, argument, or theory.","Abstracting | Abstract | Abstracted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040713","Translator","C86928","A person or program involved in revealing the meaning of a text or spoken language into a form recognized by the target audience.","Translator | ",,,,,,,,,,,,,,,"4214604","Translator",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3266812","Methodology","C86572","The system of methods followed in a particular discipline.","Methodology | methodology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0150646","Interpreter","C86557","Someone who mediates between speakers of different languages.","Interpreter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043327","Xanthomonas","C86018","A genus of bacteria in the family Xanthomonadaceae, similar to Pseudomonas but producing a yellow pigment that is not soluble in water.","Xanthomonas | XANTHOMONAS",,,,,,,,,,,,,,,"4070158","Xanthomonas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0432475","XX Male","C86032","A person who has a chromosome composition of 46 XX and who is phenotypically male.","XX Male | ",,,,,,,,,,,,,,,"4251774","XX males",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521323","Trisomy X","C86948","A form of chromosomal variation characterized by the presence of an extra X chromosome in each cell of a human female.","Trisomy X | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0233931","Wet Dream","C86938","An involuntary ejaculation of semen accompanying an erotic dream.","Wet Dream | Nocturnal Emission",,,,,,,,,,,,,,,"4095774|4319125","Wet dreams|Nocturnal emission",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0680189","Weekday","C86936","Any day other than Saturday and Sunday.","Weekday | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0681211","Wedding","C86935","The social event at which the ceremony of marriage is performed.","Wedding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0148537","Vitrebond","C86934","A proprietary glass ionomer restorative material.","Vitrebond | Vitrabond",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041928","Uranium","C86020","A radioactive element with atomic symbol U, atomic number 92, and atomic weight 238.","Uranium | URANIUM | Uranium U-238 | Uranium, Natural",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0237284","Unresponsive","C86933","Failing to produce an effect from some foregoing stimulus or agent.","Unresponsive | Not Responsive",,,,,,,,,,,,,,,"4309389","Unresponsive",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0453880","Undergarment","C86932","A garment worn under other garments, usually next to the skin.","Undergarment | Underclothing | Underwear",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1550585","Entity Handling - upright","C86043","In a vertical position or posture.","Upright | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0522497","Transmural","C86929","Passing through the wall of an organ or other bodily structure.","Transmural | ",,,,,,,,,,,,,,,"4013721","Transmural",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039988","Thoracoplasty","C86923","Surgical removal of a rib to gain access during surgery or to collapse the chest wall and a diseased lung.","Thoracoplasty | ",,,,,,,,,,,,,,,"4301336","Thoracoplasty procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039227","taboo (idea)","C86920","A cultural ban on behaviors or actions that are seen as unacceptable or improper.","Taboo | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038238","Steatorrhea","C86917","A finding of an excessive amount of fat in the stool.","Steatorrhea | ",,,,,,,,,,,,,,,"4279305","Fatty stool",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0234856","Speak","C86914","To communicate using verbal language.","Speak | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0149779","Somatization","C86911","The conversion of mental experiences or states into physical symptoms.","Somatization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828368","Shave (action)","C86037","To cut thin slices from; cut or remove with or as if with a plane.","Shave | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036765","Serratia","C86010","A genus of small motile peritrichous bacteria in the Enterobacteriacaea family consisting of Gram-negative rods.","Serratia | SERRATIA",,,,,,,,,,,,,,,"4170580","Serratia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1532253","Sedentary Lifestyle","C86589","A type of lifestyle that lacks physical exercise, characterized by sitting, reading, watching television or using a computer for much of the day without vigorous physical exertion.","Sedentary Lifestyle | Sedentary Behavior",,,,,,,,,,,,,,,"4188316","Sedentary lifestyle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036234","Saskatchewan","C86004","A province of west cental Canada, lying between the provinces of Alberta and Manitoba. Its capital is Regina.","Saskatchewan | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0260217","Rhodotorula mucilaginosa","C86027","A pigmented yeast from the Basidiomycota phylum, characterized by salmon-pink to coral-red colonies. It is a common saprophytic airborne contaminant of skin, lungs, urine and feces and can colonize moist surfaces in humans, including the skin, respiratory, genitourinary and gastrointestinal tracts. It has recently been identified in nosocomial infections, especially with immunocompromised patients. It has also been reported as causing fungemia, endocarditis and meningitis.","Rhodotorula mucilaginosa | R. mucilaginosa | R. pilimanae | R. rubra | RHODOTORULA MUCILAGINOSA | Rhodotorula pilimanae | Rhodotorula rubra | S. albo-rubescens | Sporobolomyces albo-rubescens",,,,,,,,,,,,,,,"4315395","Rhodotorula rubra",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1009803","Resultor","C86588","A genus of very small, flagellated green algae.","Resultor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034872","Recreation","C86586","Any activity that is intended for refreshment or diversion.","Recreation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524637","Recognition","C86585","The act of seeing something as familiar.","Recognition | ",,,,,,,,,,,,,,,"4209828","Recognition",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0684328","Reasoning","C86584","Thinking that is coherent and logical.","Reasoning | ",,,,,,,,,,,,,,,"4230784","Thinking",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034390","Quebec","C86003","A province of eastern Canada. Its capital is Quebec.","Quebec | Québec",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033701","Proteus mirabilis","C86019","A Gram-negative, facultatively anaerobic bacterium with swarming motility, and urease activity.","Proteus mirabilis | P. mirabilis | PROTEUS MIRABILIS",,,,,,,,,,,,,,,"4248426","Proteus mirabilis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033476","Propionibacterium","C86013","A genus of gram-positive, anaerobic, rod-shaped bacteria in the Propionibacteriaceae family that is a normal skin saprophyte but that can cause chronic infections and abscesses.","Propionibacterium | PROPIONIBACTERIUM",,,,,,,,,,,,,,,"4144074","Propionibacterium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033269","Productivity","C86582","The ratio of the quantity and quality of units produced to the labor per unit of time.","Productivity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0138406","Prisma VLC Dycal","C86581","A proprietary light-cured, calcium hydroxide and resin cavity liner.","Prisma VLC Dycal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0679105","pleasurable emotion","C86580","An emotion associated with feeling good.","Pleasure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032064","Plague","C85015","A Gram-negative bacterial infection caused by Yersinia pestis. It is usually transmitted to humans from bites of infected rodent fleas. It is manifested as a bubonic, septicemic, or pneumonic plague. In bubonic plague, the lymph nodes adjacent to the site of the skin bite are infected and enlarged. In septicemic plague, the infection spreads directly through the bloodstream. In pneumonic plague, the infection spreads to the lungs either following bubonic plague, or by inhalation of infective droplets. If untreated, it may lead to death.","Plague | ",,,,,,,,,,,,,,,"434271","Plague",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032058","Placentation","C86579","The formation of the placenta in the uterus.","Placentation | ",,,,,,,,,,,,,,,"4008237","Placentation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0441468","Photograph","C86035","An image recorded by a camera.","Photograph | ",,,,,,,,,,,,,,,"4119691","Photograph",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1510410","Parosmia","C86949","An olfactory disturbance where the sense of smell inaccurately conveys disagreeable sensations.","Parosmia | ",,,,,,,,,,,,,,,"46270715","Parosmia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221166","Paraparesis","C86576","A slight paralysis or weakness of both legs.","Paraparesis | ",,,,,,,,,,,,,,,"4081615","Paraparesis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029335","Orthodontics","C86575","The branch of dentistry dealing with the prevention or correction of irregularities of the teeth.","Orthodontics | ",,,,,,,,,,,,,,,"4214574","Orthodontics",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029040","Ontario","C86001","A province in east-central Canada bordered by Quebec to the east and Manitoba to the west.","Ontario | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0752343","Nunavut","C86016","An Arctic territory in northern Canada created in 1999 and governed solely by the Inuit; includes the eastern part of what was the Northwest Territories and most of the islands of the Arctic Archipelago. Its captal is Iqaluit.","Nunavut | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1956182","Newfoundland and Labrador","C86005","A province in the east of Canada, composed of Newfoundland Island and Labrador. Its capital is St. John's","Newfoundland and Labrador | Newfoundland | Newfoundland",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2135828","Navy","C86040","An organization of military naval forces.","Navy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0315276","Morganella morganii","C86015","A species of oxidase-negative Gram-negative bacillus bacteria in the Enterobacteriaceae family with anaerobic respiration.","Morganella morganii | Bacillus morgani | MORGANELLA MORGANII | Organism N1 | PROTEUS MORGANII | Proteus morganii | Salmonella morgani",,,,,,,,,,,,,,,"4348164","Morganella morganii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025635","Methemoglobin","C86008","A product of hemoglobin produced by oxidation of the iron atom from the ferrous to the ferric state.","Methemoglobin | methemoglobin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0346028","Apocrine Neoplasm","C6798","A benign or malignant sweat gland neoplasm with apocrine differentiation. Representative examples include apocrine adenoma, ceruminous adenocarcinoma, and apocrine breast carcinoma.","Apocrine Neoplasm | Apocrine Neoplasm of Skin | Apocrine Neoplasm of the Skin | Apocrine Skin Neoplasm | Apocrine Skin Tumor | Apocrine Tumor | Apocrine Tumor of Skin | Apocrine Tumor of the Skin",,,,,,,,,,,,,,,"4112755","Tumor of skin with apocrine differentiation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026196","Minoxidil","C47623","An orally administered vasodilator with hair growth stimulatory and antihypertensive effects. Minoxidil is converted into its active metabolite minoxidil sulphate by sulphotransferase enzymes. Minoxidil sulphate exerts its antihypertensive effect by opening of plasma membrane adenosine triphosphate (ATP)-sensitive potassium channels (KATP channels), thereby directly and rapidly relaxing arteriolar smooth muscle and subsequent reduction of elevated systolic and diastolic blood pressure by decreasing peripheral vascular resistance. This agent's hair growth stimulatory effect may be mediated through its vasodilatory activity, thereby increasing cutaneous blood flow, or due to its direct stimulatory effect on hair follicle cells and forcing them from their resting phase into their active growth phase.","Minoxidil | 2,3-Dihydro-3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine | 2,4-Pyrimidinediamine, 6-(1-Piperidinyl)-, 3-Oxide | Alostil | Loniten | MINOXIDIL | Rogaine | U 10858",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0051522","Aluminum Sulfate","C75770","An aluminum salt of sulfuric acid, an industrial chemical used in many industrial applications. In purification of drinking water, aluminum sulfate acts as a flocculating agent which causes impurities to coagulate and sediment, so that they are easily removed by filtration. It is also used as a mordant in textile dyeing and paper manufacture.","Aluminum Sulfate | ALUMINUM SULFATE | Aluminum Sulfate (2:3) Hydrate | Aluminum Sulphate | Dialuminum Trisulfate Hydrate | Sulfuric Acid, Aluminum Salt (3:2), Hydrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0291772","Alosetron","C73100","A potent and selective 5-HT3 receptor antagonist. Alosetron blocks the actions of serotonin at 5-HT3 sites in the peripheral nervous system, particularly on enteric and nociceptive sensory neurons, thereby affecting the regulation of visceral pain, decreasing gastrointestinal contraction and motility, and decreasing gastrointestinal secretions. This agent is used to treat diarrhea-predominant irritable bowel syndrome in women.","Alosetron | ALOSETRON | GR 68755",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0051150","Alfuzosin","C61627","A synthetic quinazoline compound with smooth muscle relaxing activity. Alfuzosin selectively binds to and antagonizes alpha-1-adrenergic receptors in smooth muscle of the bladder neck and prostate, thereby relaxing the smooth muscle and decreasing the obstruction and urethral resistance seen with benign prostate hyperplasia (BPH) and prostate cancer. This agent also blocks alpha-1-adrenergic receptors in peripheral vascular smooth muscle, which leads to vasodilatation and a subsequent decrease in peripheral vascular resistance.","Alfuzosin | (+/-)-N-(3-((4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino)propyl)tetrahydrofuran-2-carboxamide | ALFUZOSIN | N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001047","Acetylcysteine","C200","A synthetic N-acetyl derivative and prodrug of the endogenous amino acid L-cysteine, a precursor of the antioxidant glutathione (GSH), with mucolytic, antioxidant, and potential cytoprotective, cancer-preventive, and anti-inflammatory activities.  Upon administration, acetylcysteine exerts its mucolytic activity by reducing disulfide bonds in mucoproteins, resulting in liquification of mucus and reducing its viscosity. It is also used for the treatment of acetaminophen overdose as it can restore the depleted GSH reserves in the hepatocytes during the process of detoxification.  The antioxidant activity is attributed to the ability of GSH to scavenge reactive oxygen species (ROS), thereby preventing ROS-mediated cell damage, decreasing oxidative stress, protecting cells against the damaging effects of free radicals and preventing apoptosis in these cells. In addition, this may inhibit tumor cell proliferation, progression and survival, in susceptible tumor cells that rely on ROS-mediated signaling for their proliferation and malignant behavior. Under certain circumstances, acetylcysteine is able to induce apoptosis in susceptible cells, including certain tumor cells, via the intrinsic mitochondria-dependent pathway but not involving endoplasmic reticulum stress. Also, acetylcysteine may also be able to degrade Notch2, thereby preventing proliferation, migration, and invasion in Notch2-overexpressing glioblastoma cells. In addition, acetylcysteine may inhibit viral stimulation by reactive oxygen intermediates, thereby producing antiviral activity in HIV patients. Acetylcysteine also possesses anti-inflammatory activity through modulation of the nuclear factor-kappa B (NF-kB) pathway and the modulation of cytokine synthesis.","Acetylcysteine | ACETYLCYSTEINE | Acetadote | Airbron | Broncholysin | Brunac | Fabrol | Fluatox | Fluimucetin | Fluimucil | Fluprowit | L-Alpha-acetamido-beta-mercaptopropionic Acid | Muco Sanigen | Mucocedyl | Mucolator | Mucolyticum | Mucomyst | Mucosolvin | Mucret | N-Acetyl Cysteine | N-Acetyl-L-cysteine | N-Acetylcysteine | N-acetyl-3-mercaptoalanine | N-acetyl-L-cysteine | N-acetylcysteine | NAC | Neo-Fluimucil | Parvolex | Respaire | Tixair | acetylcysteine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0000959","Acepromazine","C77568","A phenothiazine derivative with depressant effect on the central nervous system. Acepromazine acts as a dopamine receptor antagonist in the CNS, thereby causing sedation, muscular relaxation and a reduction in spontaneous activity. Its fast-acting neuroleptic effect with low toxicity is of particular value in veterinary medicine.","Acepromazine | 10-(3-Dimethylaminopropyl)phenothiazine-3-ethylone | ACEPROMAZINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0078569","Venlafaxine","C1278","A synthetic phenethylamine bicyclic derivative with antidepressant activity. Venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV), are potent inhibitors of neuronal serotonin and norepinephrine reuptake and weak dopamine reuptake inhibitors.  This agent may reduce hormone-related vasomotor symptoms. (NCI04)","Venlafaxine | VENLAFAXINE | venlafaxine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1098706","AVP protein, human","C2285","Arginine-vasopressin (9 aa, ~1 kDa) is encoded by the human AVP gene. This protein is involved in peripheral blood vessel vasoconstriction and antidiuretic action in the kidney.","Arginine-Vasopressin | ADH | AVP | Antidiuretic Hormone | Arg-Vasopressin | Arginine Vasopressin | Vasopressin | Vasopressin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042523","Verapamil","C928","A phenylalkylamine calcium channel blocking agent. Verapamil inhibits the transmembrane influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility.  This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04)","Verapamil | VERAPAMIL | alpha-[3-[[2-(3,4-Dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042849","Vitamin B Complex","C940","A compound containing several or all of the B-vitamins, including thiamine, riboflavin, niacin (nicotinic acid), niacinamide (nicotinamide), the vitamin B6 group (including pyridoxine, pyridoxal, pyridoxamine), biotin, pantothenic acid, folic acid, possibly para-aminobenzoic.","Vitamin B Complex | Becotin | Neurobion | vitamin B complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0251504","Zaleplon","C29551","A nonbenzodiazepine from the pyrazolopyrimidine class with hypnotic, sedative, anxiolytic, and muscle relaxant properties. Zaleplon interacts with the gamma-aminobutyric acid (GABA) -A receptor, thereby affecting the chloride channel ionophore complex and potentiating the inhibitory effects of GABA. In addition, zaleplon binds selectively to the brain omega-1 receptor situated on the alpha subunit of the GABA-A/chloride ion channel receptor complex and potentiates t-butyl-bicyclophosphorothionate (TBPS) binding.","Zaleplon | Sonata | ZALEPLON",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043474","Zidovudine","C947","A synthetic dideoxynucleoside. After intracellular phosphorylation to its active metabolite, zidovudine inhibits DNA polymerase, resulting in the inhibition of DNA replication and cell death. This agent also decreases levels of available pyrimidines. (NCI04)","Zidovudine | 1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)-5-methylpyrimidine-2,4-(1H,3H)-dione | 3'-Azido-3'-deoxythymidine | AZT | Azidothymidine | Aztec | BW A509U | BW-A 509U | BW-A509U | Compound S | DRG-0004 | Retrovir | ZDV | ZIDOVUDINE | zidovudine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043481","Zinc","C948","An element with atomic symbol Zn, atomic number 30, and atomic weight 65.39.","Zinc | ZINC | Zn",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043491","Zinc Oxide","C949","A mild astringent and topical protectant with some antiseptic action. It is also used in bandages, pastes, ointments, dental cements, and as a sunblock.","Zinc Oxide | C.I. Pigment White 4 | ZINC OXIDE | zinc oxide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0301331","Zinc Undecylenate","C29552","A natural or synthetic fungistatic fatty acid, antifungal Zinc Undecylenate is used topically in creams against fungal infections, eczemas, ringworm, and other cutaneous conditions. The zinc provides an astringent action, reducing rawness and irritation. (NCI04)","Zinc Undecylenate | ZINC UNDECYLENATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0078794","Zinc Sulfate","C1280","A salt of the essential trace metal zinc. Zinc is involved in tissue repair and is an important constituent of some proteins, including those involved in taste and smell. Zinc sulfate supplementation may prevent radiation-induced aguesia. (NCI04)","Zinc Sulfate | ZINC SULFATE, UNSPECIFIED FORM | Zinc sulfate | zinc sulfate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0000608","Aminocaproic Acid","C47391","A synthetic lysine derivative with antifibrinolytic activity. Aminocaproic acid competitively inhibits activation of plasminogen, thereby reducing conversion of plasminogen to plasmin (fibrinolysin), an enzyme that degrades fibrin clots as well as fibrinogen and other plasma proteins including the procoagulant factors V and VIII. Aminocaproic acid competitively reduces the conversion of plasminogen to plasmin by plasminogen activators. It directly inhibits proteolytic activity of plasmin, but higher doses are required than are needed to reduce plasmin formation. Aminocaproic acid is used in the treatment of hemorrhage and prophylactically against hemorrhage, including hyperfibrinolysis-induced hemorrhage and postsurgical hemorrhage.","Aminocaproic Acid | 6-Aminocaproic Acid | 6-Aminohexanoic Acid | AMINOCAPROIC ACID | Amicar | Aminocaproic acid | Epsilon S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0528166","Zolmitriptan","C47789","A member of the triptan class of agents with anti-migraine properties. Zolmitriptan selectively binds to and activates serotonin (5-HT) 1B receptors expressed in intracranial arteries and 5-HT 1D receptors located on peripheral trigeminal sensory nerve terminals in the meninges and central terminals in brainstem sensory nuclei. Receptor binding results in constriction of cranial vessels, reduction of vessel pulsation and inhibition of nociceptive transmission, thereby providing relief of migraine headaches. Zolmitriptan may also relieve migraine headaches by inhibition of pro-inflammatory neuropeptide release.","Zolmitriptan | 2-Oxazolidinone, 4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)-,(S)- | 311C90 | ZOLMITRIPTAN | Zomig",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0724725","Zolpidem Tartrate","C29553","The tartrate salt of an imidazopyridine with non-benzodiazepine benzodiazepine-receptor agonist and sedative-hypnotic activities. Zolpidem binds selectively to the alpha 1 subunit of the omega-1 (BZ1) receptor of the gamma-aminobutyric acid type A (GABA-A) receptor-chloride ionophore complex, thereby opening neuronal chloride channels, hyperpolarizing neuronal cell membranes, and inhibiting neuronal firing. In contrast, benzodiazepines non-selectively bind to and activate all omega receptor subtypes, exhibiting anticonvulsant and myorelaxant activities in addition to a sedative-hypnotic activity.","Zolpidem Tartrate | Ambien | Intermezzo | ZOLPIDEM TARTRATE | zolpidem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879601","Candida Albicans Skin Test Reagent","C2595","A culture filtrate of cells of Candida Albicans propagated in a chemically defined medium and used as a recall antigen to evaluate cellular immunity in infection, cancer, and other disease states. (NCI)","Candida Albicans Skin Test Reagent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0379135","Becaplermin","C1668","The recombinant analog of endogenous beta (B) chain of the cytokine platelet-derived growth factor (PDGF).  Synthesized primarily by megakaryocytes, endogenous PDGF consists of two related peptide chains, PDGF-A and PDGF-B.  PDGF functions as a local autocrine and paracrine growth factor in many cellular processes.  Recombinant PDGF, alone and in combination with other agents, may be useful in promoting bone formation and soft tissue repair. (NCI04)","Becaplermin | BECAPLERMIN | PDGF Beta Chain | Platelet-Derived Growth Factor Beta Chain | Platlet-Derived Growth Factor Beta Chain | Recombinant Platelet Derived Growth Factor Beta Chain | Regranex | rhPDGF-BB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0937917","Bimatoprost","C47414","A synthetic prostamide and structural prostaglandin analogue with ocular hypotensive activity. Bimatoprost mimics the effects of the endogenous prostamides and reduces intraocular pressure by increasing outflow of aqueous humor through both the pressure-sensitive outflow pathway (the trabecular meshwork), and the pressure-insensitive outflow pathway (the uveoscleral routes).  It is not clear whether bimatoprost lowers intraocular pressure by stimulating F-Prostanoid receptors or by acting on specific prostamide receptors.","Bimatoprost | 5-Heptenamide, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-,(5Z)- | AGN 192024 | BIMATOPROST | Latisse | Lumigan | bimatoprost",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515928","Alternative Medicine, Direct","C19936","Any medical substance or procedure not generally accepted by orthodox western medicine or an unorthodox application of an otherwise accepted substance or procedure.","Alternative Medicine, Direct | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0272286","Thrombocytopenia Due to Immune Destruction","C3991","Thrombocytopenia that results from immune destruction of platelets.","Thrombocytopenia Due to Immune Destruction | Immune Thrombocytopenia",,,,,,,,,,,,,,,"4103532","Immune thrombocytopenia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0376405","Patient Noncompliance","C91752","Failure of a patient to follow medical advice, take medication as directed, or adhere to a prescribed course of treatment.","Patient Noncompliance | PATIENT NONCOMPLIANCE | Subject Non-Compliance | non-compliance",,,,,,,,,,,,,,,"4322482","Noncompliance with treatment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0200555","Direct Antiglobulin Test","C81974","A measurement of the antibody or complement-coated erythrocytes in a blood specimen in vivo.","Direct Antiglobulin Test | ANGLOBDR | Antiglobulin Test Polyspecific, Direct | Antiglobulin Test, Direct | DAT | Direct Anti-human Globulin Test | Direct Coombs Test",,,,,,,,,,,,,,,"4299254","Direct Coombs test",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348232","Spatial Qualifier","C73706","A term used to indicate an object's position in space or it's relationship in space to another object.","Spatial Qualifier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0458421","Bladder Wall","C48941","The tissue layers that form the urinary bladder. They include the mucosa, submucosa, smooth muscle, and serosa.","Bladder Wall | BLADDER WALL | Structure of wall of urinary bladder (body structure) | Urinary Bladder Wall | Wall, NOS | wall of urinary bladder",,,,,,,,,,,,,,,"4190181","Structure of wall of urinary bladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0699885","Bladder Carcinoma","C4912","A carcinoma arising from the bladder epithelium.  Approximately 90% of the bladder carcinomas are transitional cell carcinomas.  The remainder are squamous cell carcinomas, adenocarcinomas and small cell neuroendocrine carcinomas.","Bladder Carcinoma | Bladder Cancer | Cancer of Bladder | Cancer of Urinary Bladder | Cancer of the Bladder | Cancer of the Urinary Bladder | Carcinoma of Bladder | Carcinoma of Urinary Bladder | Carcinoma of the Bladder | Carcinoma of the Urinary Bladder | Urinary Bladder Cancer | Urinary Bladder Carcinoma | bladder cancer",,,,,,,,,,,,,,,"4113110","Carcinoma of bladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242297","Nutritional Supplementation","C15425","The addition of one or more elements and/or chemical compounds that are either absent or deficient in an individual's daily diet.","Nutritional Supplementation | Supplementation | supplementation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4076257","Soy Isoflavones","C65152","A dietary supplement isolated from soybeans containing phytoestrogen isoflavones. Although the mechanism of action is unclear, soy isoflavones mimic estrogen action mediated through estrogen receptors. In addition, this agent also modulates estrogen metabolism. As a result, soy isoflavones have been shown to reduce tumor cell proliferation and induce tumor cell apoptosis, as well as to be able to regulate hormone balance and reduce the risks of breast cancer, heart disease, and osteoporosis.","Soy Isoflavones | NovaSoy | SOY ISOFLAVONES | Solgen 40 | Soy Isoflavone | Soybean Isoflavone Mixture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4231129","Autoimmune Hemolytic Anemia","C34378","An acquired anemia caused by destruction of the red blood cells by autoantibodies. Causes include autoimmune disorders, lymphoproliferative disorders, and infections.","Autoimmune Hemolytic Anemia | autoimmune hemolytic anemia",,,,,,,,,,,,,,,"441269","Autoimmune hemolytic anemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1305188","Right Colon","C12383","The proximal segment of the large intestine that is located in the right side of the abdominal cavity. It includes the cecum (with the attached appendix) and the ascending colon.","Right Colon | COLON, RIGHT",,,,,,,,,,,,,,,"4201145","Right colon structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227388","Left Colon","C33929","The portion of the large intestine that includes the descending and sigmoid colon.","Left Colon | COLON, LEFT",,,,,,,,,,,,,,,"4207989","Left colon structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017118","Gastrectomy","C15236","Surgical removal of part or all of the stomach.","Gastrectomy | Gastric Resection | gastrectomy",,,,,,,,,,,,,,,"4203442","Gastrectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031349","Pharyngectomy","C51608","Surgery involving the complete or partial excision of the pharynx.","Pharyngectomy | ",,,,,,,,,,,,,,,"4197112","Pharyngectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0189231","Total Laryngectomy","C51771","Surgery to completely remove the larynx.","Total Laryngectomy | total laryngectomy",,,,,,,,,,,,,,,"4280225","Total laryngectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026051","Microwave Radiation","C16862","Electromagnetic radiation between the ultrahigh frequency radio and infrared (in the 10e-3 (micro) to about 0.5 X 10e-1 meter) region of the spectrum.","Microwave Radiation | Electromagnetic, Microwave | Radiation, Microwave",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520021","Virtual Endoscopy","C20097","The use of 3D CT or MRI scans to construct a simulated visualization of patient specific organs similar or equivalent to those produced by standard endoscopic procedures.  Virtual endoscopic visualization avoids the risks associated with real endoscopy.  Additionally, there are many body regions not accessible to or compatible with real endoscopy that can be explored with virtual endoscopy. (from R. Robb presentation at Visible Human Project Conference)","Virtual Endoscopy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0193788","Total Thyroidectomy","C51762","Surgery involving the complete excision of the thyroid gland.","Total Thyroidectomy | ",,,,,,,,,,,,,,,"4073199","Total thyroidectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017673","Glossectomy","C51604","Surgery involving partial or complete excision of the tongue.","Glossectomy | Excision of Tongue | Resection of Tongue | glossectomy",,,,,,,,,,,,,,,"4178608","Glossectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0404079","Total Abdominal Hysterectomy","C51695","Surgical removal of all of the uterus, via an abdominal approach.","Total Abdominal Hysterectomy | ",,,,,,,,,,,,,,,"4021531","Total abdominal hysterectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002804","Roux-en-Y Anastomosis","C51756","Gastric bypass procedure in which part of the stomach is closed off with staples, and part of the small intestine is bypassed.  This procedure is performed in severely obese patients, for permanent weight loss.","Roux-en-Y Anastomosis | Roux-en-Y",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014871","Gastroesophageal Junction","C32668","The anatomical location where the esophagus joins to the stomach.","Gastroesophageal Junction | GASTROESOPHAGEAL JUNCTION | cardioesophageal junction | esophagogastric junction | gastroesophageal junction",,,,,,,,,,,,,"UBERON:0007650","esophagogastric junction","4098665","Cardioesophageal junction structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698887","Promonocyte Count","C74621","The determination of the number of promonocytes in a blood sample.","Promonocyte Count | PROMONO | Promonocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2363628","Vernier Caliper","C81184","A medical device that is a combination of ruler and caliper that can measure the distance between two points. The configuration of this device permits the measurement of internal dimensions.","Vernier Caliper | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229656","Promonocyte","C13121","An immature cell of the mononuclear phagocytic system. It is the representation of one stage of monocyte development.","Promonocyte | Premonocyte",,,,,,,,,,,,,,,"4027272","Promonocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085581","Restrictive Lung Disease","C91762","Decreased lung volume and inadequate ventilation due to parenchymal lung disorders (e.g., interstitial pulmonary fibrosis) or extrapulmonary disorders (e.g., scoliosis).  Patients present with shortness of breath and cough.","Restrictive Lung Disease | ",,,,,,,,,,,,,,,"4266931","Restrictive lung disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0230143","Costal Arch","C52715","The medial margin of the thorax created by the seventh to tenth rib.","Costal Arch | ",,,,,,,,,,,,,,,"4084812","Structure of costal arch",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2984543","Extremely Helpful","C91761","A subjective answer of extreme agreement regarding the helpfulness of something.","Extremely Helpful | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984554","Emotional Well-being","C91778","The status of one's general temperament and outlook on life.","Emotional Well-being | Emotional Health | Emotional State",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0517226","Physical Well-being","C91779","The general condition of one's body.","Physical Well-being | Physical Health",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984555","Functional Well-being","C91780","The status of one's ability to perform activities of daily living and participate socially and occupationally.","Functional Well-being | Functional Health",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984556","How True","C91781","A question about an individual's agreement with a statement.","How True | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707348","Brain Gray Matter","C49333","The areas of the brain composed of neurons and (in contrast to the white matter) unmyelinated nerve fibers.","Brain Gray Matter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007776","Cerebral Cortex","C12443","The outer layer of the cerebrum composed of neurons and unmyelinated nerve fibers. It is responsible for memory, attention, consciousness and other higher levels of mental function.","Cerebral Cortex | CEREBRAL CORTEX | Cortex | Cortical | cerebral cortex | cortex of cerebral hemisphere","C71.0","Cerebral cortex",,,,,,,,,,,"UBERON:0000956","cerebral cortex","4222448","Structure of cerebral cortex",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0237088","Mental and Behavioral Signs and Symptoms","C3858","Clinical evidence of disease resulting from mental and/or behavioral dysfunction.","Mental and Behavioral Signs and Symptoms | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415876","IDH1 Gene","C77215","This gene plays a role in carbohydrate metabolism.","IDH1 Gene | IDH1 | Isocitrate Dehydrogenase 1 (NADP+), Soluble Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984557","Tyrer-Cuzick Model","C91783","A breast cancer risk model that incorporates both genetic and nongenetic factors. It uses a combination of extensive family history, endogenous estrogen exposure, and benign breast disease (atypical hyperplasia) in order to predict a 10-year risk of breast cancer development. (Amir, Evans, Shenton, et al., www.jmedgenet.com)","Tyrer-Cuzick Model | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984558","Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm","C91784","A risk model for familial breast and ovarian cancer. It can be used to compute BRCA1 and BRCA2 mutation carrier probabilities and age specific risks for breast and ovarian cancer. (University of Cambridge, 2009 Genetic Epidemiology Unit)","Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm | BOADICEA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014964","Ethambutol","C61755","An antibiotic with bacteriostatic, antimicrobial and antitubercular properties. Ethambutol interferes with the biosynthesis of arabinogalactan, a major polysaccharide of the mycobacterial cell wall. It inhibits the polymerization of cell wall arabinan of arabinogalactan and lipoarabinomannan by blocking arabinosyl transferases and induces the accumulation of D-arabinofuranosyl-P-decaprenol, an intermediate in arabinan biosynthesis. This results in halting bacterial growth.","Ethambutol | ETHAMBUTOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0076115","Terconazole","C29493","A synthetic triazole derivative structurally related to fluconazole, antifungal Terconazole seems to disrupt cell wall synthesis by inhibiting biosynthesis of ergosterol or other sterols, damaging the fungal cell membrane, altering its permeability, and promoting loss of essential intracellular elements.  Terconazole is active against Candida sp.. (NCI04)","Terconazole | TERCONAZOLE | Terazol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0291771","Alosetron Hydrochloride","C47386","The hydrochloride salt form of alosetron, a potent and selective 5-HT3 receptor antagonist. Alosetron blocks the actions of serotonin at 5-HT3 sites in the peripheral nervous system, particularly on enteric and nociceptive sensory neurons, thereby affecting the regulation of visceral pain, decreasing gastrointestinal contraction and motility, and decreasing gastrointestinal secretions. This agent is used to treat diarrhea-predominant irritable bowel syndrome in women.","Alosetron Hydrochloride | 1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2((5-methyl-1H-imidazol-4-yl)methyl)-, Monohydrochloride | 2,3,4,5-Tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one Monohydrochloride | ALOSETRON HYDROCHLORIDE | GR 68755c | Lotronex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1257653","Acepromazine Maleate","C76652","The maleate salt of acepromazine, a phenothiazine derivative with depressant effect on the central nervous system. Acepromazine acts as a dopamine receptor antagonist in the CNS, thereby causing sedation, muscular relaxation and a reduction in spontaneous activity. Its fast-acting neuroleptic effect with low toxicity is of particular value in veterinary medicine.","Acepromazine Maleate | 10-(3-(Dimethylamino)propyl)phenothiazin-2-yl methyl Ketone Maleate (1:1) | ACEPROMAZINE MALEATE | Plegicil | Sedalin | Soprontin | Vetranquil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987632","Thumbnail Image","C91820","A small image that is representative of a larger image file.","Thumbnail | Thumbnail Image",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3181682","Cabozantinib","C52200","An orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.","Cabozantinib | 1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- fluorophenyl)- | CABOZANTINIB | N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide | XL184",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827501","Operator (symbol)","C84752","A symbol used to perform an arithmetic or logical operation.","Operator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242503","Inequality","C91406","The condition of not being equal.","Inequality | Not Equal | Not Equal To | Unequal | Unequal To",,,,,,,,,,,,,,,"4215113","Unequal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709043","Missed Dose","C50429","A dose of medicine that was not taken at the prescribed dosing interval.","Missed Dose | missed dose amount | missed_dose_amount",,,,,,,,,,,,,,,"37154568","Missed dose",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010265","Posterior Cranial Fossa","C33361","The infratentorial compartment of the cranial cavity. Its boundaries are formed by the sphenoid bone, temporal bone, and parietal bone, and it contains the cerebellum and brain stem.","Posterior Cranial Fossa | Structure of posterior fossa of cranial cavity (body structure) | posterior cranial fossa",,,,,,,,,,,,,,,"4261980","Structure of posterior fossa of cranial cavity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2004459","Abdominoperineal Resection","C91826","A therapeutic surgical procedure in which the anus, rectum, part of the sigmoid colon, and the regional lymph nodes are removed through abdominal and perineal incisions.","Abdominoperineal Resection | APR | Abdominal Perineal Resection | Abdomino-perineal Resection of Rectum | abdominoperineal resection",,,,,,,,,,,,,,,"4144721","Abdominoperineal resection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2984584","Ampullectomy","C91827","A therapeutic endoscopic procedure performed to remove adenomas from the ampulla of Vater. It involves the excision of the ampulla of Vater and the implantation of the common bile duct and pancreatic main duct into the wall of duodenum.","Ampullectomy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0371451","Bilobectomy","C91828","A therapeutic surgical procedure involving the removal of two lobes of the right lung.","Bilobectomy | BILOBECTOMY | Right Lung Bilobectomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984585","Bland Embolization","C91829","Non-chemotherapeutic embolization involving the injection of small particles through a catheter in the hepatic artery. It is performed to block the blood supply to liver cancer.","Bland Embolization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984586","Central Hepatectomy","C91830","A therapeutic surgical procedure to remove liver cancers located at the central segment of the liver. It involves the resection of the central hepatic segment with the left and right segments remaining intact.","Central Hepatectomy | Central Liver Resection | Mesohepatectomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009558","Completion Pneumonectomy","C91831","A surgical procedure involving the removal of the entire remaining lung tissue following partial lung resection.","Completion Pneumonectomy | ",,,,,,,,,,,,,,,"4337607","Completion pneumonectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2984587","Wire-Guided Localization","C91832","A procedure involving the use of a wire for the localization of a usually non-palpable breast lesion that needs to be surgically removed.","Wire-Guided Localization | Wire Localization | Wire-guided Localization | needle localization | needle-localized biopsy | needle/wire localization | wire localization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086337","Feeding Tube","C91833","A tube directed into the stomach, duodenum or jejunum from the nose, mouth or through the skin, for the purposes of delivering nutrition.","Feeding Tube | Enteral Tube",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0192499","Fundoplication","C91834","A therapeutic surgical procedure to treat gastroesophageal reflux disease and hiatus hernia. It involves the wrapping of the fundus of the stomach around the lower esophagus to strengthen the lower esophageal sphincter.","Fundoplication | ",,,,,,,,,,,,,,,"4231904","Fundoplication",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1868801","Hyperthermic Intraperitoneal Chemotherapy","C91835","A procedure performed in combination with abdominal surgery for cancer that has spread to the abdomen. It involves the infusion of a heated chemotherapy solution that circulates into the abdominal cavity.","Hyperthermic Intraperitoneal Chemotherapy | HIPEC",,,,,,,,,,,,,,,"3654354","Administration of hyperthermic antineoplastic agent into peritoneal cavity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0204819","Nasogastric Intubation","C91836","A procedure involving the insertion of a plastic tube into the stomach through the nose.","Nasogastric Intubation | ",,,,,,,,,,,,,,,"4227418","Insertion of nasogastric tube",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030788","Pelvic Exenteration","C91837","A major surgical procedure involving the removal of all the contents of the pelvic cavity, including reproductive organs, bladder, rectum, and anus. It is performed for cancers of the pelvic cavity organs that have not responded to other treatment options.","Pelvic Exenteration | pelvic exenteration",,,,,,,,,,,,,,,"4178736","Pelvic exenteration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0810152","Sigmoidectomy","C91838","A surgical procedure involving the partial or complete resection of the sigmoid colon.","Sigmoidectomy | Colon Resection, Sigmoid Extended | Colorectal Resection | SIGMOIDECTOMY | Sigmoid Colectomy",,,,,,,,,,,,,,,"4225427","Sigmoid colectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2984588","Supracricoid Laryngectomy","C91839","A conservation laryngeal surgery involving the resection of the true and false vocal cords, both paraglottic spaces, and the thyroid cartilage. In some cases the preepiglottic space and the epiglottis are also removed.","Supracricoid Laryngectomy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984592","Transoral Laser Surgery (Glottis)","C91851","An endoscopic laser microsurgical laryngeal procedure for patients with early glottis tumors.","Transoral Laser Surgery (Glottis) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042020","Urinary Diversion","C91841","Surgical diversion of the urine flow following cystectomy or in patients with a non-functioning bladder.","Urinary Diversion | urinary diversion",,,,,,,,,,,,,,,"4002243","Urinary diversion procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827667","Tivozanib","C85444","An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities.  Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death. VEGFR tyrosine kinases, frequently overexpressed by a variety of tumor cell types, play a key role in angiogenesis.","Tivozanib | AV 951 | AV-951 | AV951 | TIVOZANIB | Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828109","Noise Artifact","C87013","An artifact that appears as a point to point signal fluctuation in a uniform material.","Noise Artifact | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828141","Protocol Error Artifact","C87045","An image of reduced quality resulting from the use of incorrect or incomplete instructions.","Protocol Error Artifact | Protocol Error",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828134","Patient Motion Artifact","C87038","An artifact resulting from movement of the patient during image capture.","Patient Motion Artifact | Patient Motion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828087","Motion Related Artifact","C86989","An artifact resulting from movement of the object being imaged during the imaging sequence.","Motion Related Artifact | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0852336","Immune Hemolytic Anemia","C91782","An acquired anemia resulting from immune-mediated destruction of the red blood cells. Causes include autoimmune disorders, blood transfusions, and drugs.","Immune Hemolytic Anemia | immune complex hemolytic anemia | immunohemolytic anemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227598","Urothelium","C12884","Transitional epithelium lining the renal pelvis, bladder, ureter, and part of the urethra.","Urothelium | Transitional Epithelium of the Urinary Tract | urothelium",,,,,,,,,,,,,,,"4239969","Urothelium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1375004","SHBG protein, human","C17128","Sex hormone-binding globulin (402 aa, ~44 kDa) is encoded by the human SHBG gene. This protein is involved in steroid transport.","Sex Hormone-Binding Globulin | ABP | Androgen Binding Protein | Androgen-Binding Protein | SBP | SHBG | Sex Steroid-Binding Protein | TeBG | Testis-Specific Androgen-Binding Protein | Testosterone Estradiol Binding Globulin | Testosterone-Binding Beta-Globulin | Testosterone-Estradiol-Binding Globulin | Testosterone-Estrogen-Binding Globulin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1568102","serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 5 protein, human","C17790","Serpin B5 (375 aa, ~42 kDa) is encoded by the human SERPINB5 gene. This protein plays a role in the regulation of cell movement and in tumor suppression.","Serpin B5 | Maspin | PI-5 | PI5 | Protease Inhibitor 5 | SERPINB5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523113","Blast Count","C74605","The determination of the number of blast cells present in a biospecimen.","Blast Count | BLAST | Blasts",,,,,,,,,,,,,,,"4016230","Blast count, blood",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1456587","Bariatric Surgery","C84399","Surgery performed in morbidly obese patients to help promote weight loss. The procedure aims at the reduction of the stomach size and it is usually achieved either with the implantation of a medical device or the removal of part of the stomach.","Bariatric Surgery | Gastrointestinal Bariatric Surgery | Weight Loss Surgery",,,,,,,,,,,,,,,"4326683","Bariatric operative procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0458827","Airway","C89842","The part of the respiratory system between the nose or mouth and the lungs.","Airway | Airway structure (body structure)",,,,,,,,,,,,,,,"4230487","Airway structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024887","Subcutaneous Mastectomy","C89773","A surgical procedure that removes the breast tissue while leaving the skin, nipple, areola, and chest wall muscles intact.","Subcutaneous Mastectomy | Nipple-Sparing Mastectomy",,,,,,,,,,,,,,,"4322169","Subcutaneous mastectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0189240","Supraglottic Laryngectomy","C51889","Surgical removal of the portion of the larynx superior to the true vocal cords.","Supraglottic Laryngectomy | supraglottic laryngectomy",,,,,,,,,,,,,,,"4308648","Partial supraglottic laryngectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL387726","anti-myeloma monoclonal antibody-DM4 immunoconjugate BT-062","C78840","An immunoconjugate consisting of a monoclonal antibody directed against syndecan-1 (CD138) covalently attached to the maytansinoid DM4, a derivative of the cytotoxic agent maytansine (DM1), with potential antineoplastic activity. Upon administration, indatuximab ravtansine binds to syndecan-1-expressing tumor cells; upon internalization the DM4 moiety is released, binding to tubulin and disrupting microtubule assembly/disassembly dynamics, which may result in the inhibition of cell division and cell growth of syndecan-1-expressing tumor cells. Syndecan-1, a type 1 transmembrane proteoglycan and tumor-associated antigen (TAA), is overexpressed in a variety of cancer cells and plays a key role in the regulation of cell growth, differentiation, and adhesion.","Indatuximab Ravtansine | Anti-Myeloma Monoclonal Antibody-DM4 Immunoconjugate BT-062 | Anti-Myeloma Monoclonal Antibody-DM4 Immunoconjugate BT-062 | BT-062 | BT062 | INDATUXIMAB RAVTANSINE | Maytansinoid-Conjugated Anti-Myeloma Monoclonal Antibody BT062",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229789","Paraaortic Lymph Node","C77643","A lymph node located adjacent to the lumbar region of the spine.","Paraaortic Lymph Node | Aortic Lymph Node | LYMPH NODE, LUMBAR | Lymph Node(s) Paraaortic | Lymph Node, Para-Aortic | PARA-AORTIC LYMPH NODE | Para-Aortic Nodes | Paraaortic lymph nodes | Structure of aortic lymph node (body structure) | lateral aortic lymph node | lateral aortic node | para-aortic lymph node | paraaortic lymph node",,,,,,,,,,,,,"UBERON:0016386","paraaortic lymph node","4262286","Structure of aortic lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0279024","Radiosensitization","C15464","The use of a drug that makes tumor cells more sensitive to radiation therapy.","Radiosensitization | RADIOSENSITIZATION | radiosensitization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826274","Treatment Name","C82542","The literal identifier of a therapy.","Treatment Name | TRT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796679","Chemoembolization","C15752","A procedure that introduces chemotherapy to blood vessels adjacent to a tumor, for the purpose of both treating the tumor and interrupt blood flow to the tumor, which serves both to trap the chemotherapeutic agent at the tumor and to decrease the amount of nutrients flowing to the tumor.","Chemoembolization | Chemotherapy Embolization | chemoembolization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038506","Stutter","C35043","A speech disorder characterized by frequent sound or syllable repetitions, sound prolongations, or other dysfluencies that are inappropriate for the individual's age.","Stutter | ",,,,,,,,,,,,,,,"436667","Stuttering",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0699744","Ear Infection","C27193","A viral or bacterial infection that affects the external, middle, or inner ear.  It may follow an upper respiratory infection.  Signs and symptoms include pain, ear discharge, ear fullness, hearing loss, vertigo, nausea, and vomiting.","Ear Infection | Ear infection | Otitis",,,,,,,,,,,,,,,"4044878","Infection of ear",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1280519","Efficacy","C88183","The capacity to bring about a desired effect.","Efficacy | Effectiveness | efficacy",,,,,,,,,,,,,,,"4116832","Effectiveness",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710174","Lung Squamous Cell Carcinoma, Clear Cell Variant","C45503","A morphologic variant of squamous cell lung carcinoma characterized by the presence of clear cells.","Lung Squamous Cell Carcinoma, Clear Cell Variant | Squamous Cell Lung Carcinoma, Clear Cell Variant | Squamous Cell Lung Carcinoma, Clear Cell Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710175","Lung Squamous Cell Carcinoma, Papillary Variant","C45502","A morphologic variant of squamous cell lung carcinoma characterized by the presence of papillary structures.","Lung Squamous Cell Carcinoma, Papillary Variant | Squamous Cell Lung Carcinoma, Papillary Variant | Squamous Cell Lung Carcinoma, Papillary Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229473","Clear Cell","C12478","A cell with empty-appearing cytoplasm when viewed with a light microscope.","Clear Cell | Clear Cells | clear cell",,,,,,,,,,,,,,,"4232731","Cell of Claudius",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334756","Micropapillary Growth Pattern","C36181","A morphologic finding indicating the presence of a growth pattern dominated by the presence of small papillary structures.","Micropapillary Growth Pattern | Micropapillary | Micropapillary Pattern | Micropapillary Pattern",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596030","Acinar Cell","C13077","A secreting cell that lines an acinus (i.e. a small sac or sac-like structure).  A representative example is the acinar cell located in the pancreas that produces pancreatic enzymes and juices.","Acinar Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412993","EML4 Gene","C71003","This gene may play a role in cytoskeletal assembly.","EML4 Gene | EML4 | Echinoderm Microtubule Associated Protein Like 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332080","ALK Gene","C38184","This gene is involved in brain development and neuronal specificity.","ALK Gene | ALK | ALK Receptor Tyrosine Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987521","Translocation of object","C89777","The movement of a physical object from one place to another. (NCI)","Translocation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1261077","Lower Lobe of the Left Lung","C33020","The larger lobe of the left lung, situated below and behind the oblique fissure.","Lower Lobe of the Left Lung | Inferior Lobe of the Left Lung | LLL | LUNG, LEFT LOWER LOBE | Lower Lobe of Left Lung-LLL | Lower Lobe of the Left Lung-LLL | Lung Left Lower Lobe | lower lobe of left lung",,,,,,,,,,,,,,,"4165555","Structure of lower lobe of left lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1261076","Upper Lobe of the Left Lung","C33021","The smaller lobe of the left lung, situated above and in front the oblique fissure, which includes the apex.","Upper Lobe of the Left Lung | LUL | LUNG, LEFT UPPER LOBE | Lung Left Upper Lobe | Superior Lobe of the Left Lung | Upper Lobe of Left Lung-LUL | Upper Lobe of the Left Lung-LUL",,,,,,,,,,,,,,,"4259129","Structure of upper lobe of left lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1261075","Lower Lobe of the Right Lung","C33022","The lobe of the right lung situated below the oblique fissure.","Lower Lobe of the Right Lung | Inferior Lobe of the Right Lung | LUNG, RIGHT LOWER LOBE | Lower Lobe of Right Lung -RLL | Lower Lobe of the Right Lung -RLL | Lung Right Lower Lobe | RLL",,,,,,,,,,,,,,,"4131818","Structure of lower lobe of right lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1261074","Upper Lobe of the Right Lung","C33023","The lobe of the right lung, situated above the horizontal fissure, which includes the apex.","Upper Lobe of the Right Lung | LUNG, RIGHT UPPER LOBE | Lung Right Upper Lobe | RUL | Superior Lobe of the Right Lung | Upper Lobe of Right Lung -RUL | Upper Lobe of the Right Lung -RUL",,,,,,,,,,,,,,,"4174862","Structure of upper lobe of right lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040604","Trail Making Test","C92205","A neuropsychological test of visual attention and task switching that requires a subject to connect a sequence of 25 consecutive targets. It provides an easy to administer and reliable assessment of attention, sequencing, cognition, visual search, and motor function.","Trail Making Test | TMT | TMT01",,,,,,,,,,,,,,,"4165596","Trail making test",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2984905","E-Z Notation","C92192","A system for naming the stereoisomers of a molecule. The configuration at each double bond is determined by the priority of the side groups and whether the highest priority groups are on the same or opposite side. A Z indicates that the highest-priority side groups are on the same side and an E indicates that the highest-priority side groups are on opposite sides. Priority is given to the bonded atom with the higher atomic number.","E-Z Notation | E/Z Isomer Conformation | E/Z Isomer Conformation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984906","E Isomer","C92193","A double bond with its highest priority side groups on opposite sides.","E Isomer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984907","Z Isomer","C92194","A double bond with its highest priority side groups on the same sides.","Z Isomer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1739687","Belagenpumatucel-L","C73438","A transforming growth factor beta2 (TGF-beta2) antisense gene-modified allogeneic tumor cell vaccine with potential immunostimulatory and antineoplastic activities. Belagenpumatucel-L is prepared by transfecting allogeneic non-small cell lung cancer (NSCLC) cells with a plasmid containing a TGF-beta2 antisense transgene, expanding the cells, and then irradiating and freezing them. Upon administration, this agent may elicit a cytotoxic T lymphocyte (CTL) response against host NSCLC cells, resulting in decreased tumor cell proliferation; vaccine immunogenicity may be potentiated by suppression of tumor TGF-beta2 production by antisense RNA expressed by the vaccine plasmid TGF-beta2 antisense transgene. Elevated levels of TGF-beta2 are frequently linked to immunosuppression in cancer patients and may be inversely correlated with prognosis in patients with NSCLC.","Belagenpumatucel-L | Lucanix",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706226","Endoscope Device","C49940","A device consisting of a tube containing flexible optic fibers that may be inserted into a body opening to allow a doctor to examine hollow organs inside the body. The result may be viewed on a video screen. It has diagnostic (e.g., biopsy) and therapeutic capabilities.","Endoscope Device | Endoscope | Endoscope | Endoscope Device Component | endoscope",,,,,,,,,,,,,,,"4290594","Endoscope",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3146232","Point of Interception","C92209","The point at which a line or curve crosses an axis.","Intercept | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984910","Rescale","C92210","To establish something relative to a new reference scale.","Rescale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3809746","Orthostatic Hypotension","C84970","Sudden fall of the blood pressure of at least 20/10 mm Hg when a person stands up.","Orthostatic Hypotension | Postural Hypotension",,,,,,,,,,,,,,,"319041","Orthostatic hypotension",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0750558","Unlikely","C85549","Having little chance of being the case or of coming about.","Unlikely | Doubtful",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511666","DNA Crosslinking Agent","C25760","An agent able to covalently bind to DNA causing inter- or intra-stranded cross-linking of DNA.  The cross-linking results in misreading of the DNA code and inhibition of DNA synthesis. (NCI)","DNA Crosslinking Agent | DNA Crosslinker",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037287","Skin Nodule","C3373","A benign or malignant round or oval and elevated solid lesion that arises from the skin or subcutaneous tissue.","Skin Nodule | Cutaneous Nodule | Nodule of Skin | Nodule of the Skin",,,,,,,,,,,,,,,"4319300","Skin nodule",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2985104","Receptive Vocabulary","C92443","The body of words that a person recognizes and understands when read or heard.","Receptive Vocabulary | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0175681","Pitch","C92445","The subjective property of a tone, determined by the frequency of the wave that produces it, that is perceived as highness or lowness.","Pitch | Sound Pitch | Tone Pitch",,,,,,,,,,,,,,,"4198104","Pitch",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2985106","Voice Handicap Index","C92446","A self-assessment to evaluate the perceived psychosocial consequences of a patient's voice disorder in terms of emotional, physical, and functional factors.","Voice Handicap Index | VHI | VHI01",,,,,,,,,,,,,,,"42872764","Voice handicap index",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031577","Phonation","C92447","The process of producing vocal sounds by vibration of the vocal cords during an expiration of air.","Phonation | ",,,,,,,,,,,,,,,"4184650","Laryngeal voice function",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018786","Audiogram","C92448","A graphic record of the softest sounds that a person can hear at various frequencies, used to measure hearing loss.","Audiogram | ",,,,,,,,,,,,,,,"4139936","Audiogram",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2987623","Discrimination","C92450","The unfair treatment of a person or group based on class or category bias.","Discrimination | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985108","Conflicts Tactics Scale, Parent-Child","C92451","A standard survey tool for assessing the parental resolution of conflict between parents and children, including nonviolent discipline and physical aggression. It consists of a 35-item self-administered questionnaire.","Conflicts Tactics Scale, Parent-Child | CTS PC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985109","Conflicts Tactics Scale 2","C92452","A standard survey tool for assessing the resolution of conflict between intimate partners. It consists of a 78-item self-administered questionnaire.","Conflicts Tactics Scale 2 | CTS-2 | Conflict Tactics Scale for Partner and Spouse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1300196","Organization","C92453","The activity or result of distributing or disposing of things properly or methodically.","Organization | ",,,,,,,,,,,,,,,"4300364","Organized",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021797","Interpersonal Relations","C92454","A short or long-term association between two or more people, including kinship relations, romantic, business, and social interactions.","Interpersonal Relationship | Relations with Others | Relations with other people",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985111","Healthy Food Environment","C92456","A neighborhood or locale that provides access to healthy foods and healthy eating alternatives.","Healthy Food Environment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985112","Job Decision Latitude","C92457","The extent to which one can make decisions and exercise control over their work.","Job Decision Latitude | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985113","Concentrated Disadvantage","C92458","The recognition that low neighborhood socioeconomic conditions have an impact on the services and opportunities available to its residents and have a wide and long-lasting effect on their economic, social and educational development. U.S. Census data can be used to determine the concentration of poverty at the neighborhood level.","Concentrated Disadvantage | Concentrated Neighborhood Disadvantage | Neighborhood Concentrated Disadvantage | Neighborhood Disadvantage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985114","Psychological Demand","C92459","The mental arousal or stimulation necessary to accomplish a task.","Psychological Demand | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985115","Race/Ethnic Residential Segregation","C92460","A social environmental measure of neighborhood race and/or ethnic residential segregation based on data from the U.S. Census Bureau.","Race/Ethnic Residential Segregation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985116","Non-word Repetition","C92461","A measure of linguistic development based on a person's ability to accurately repeat nonsense words.","Non-word Repetition | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985117","Grammatical Impairment","C92462","A test that assesses a respondent's knowledge of grammar. It identifies respondents with specific language impairment (SLI) or other categories of language impairment.","Grammatical Impairment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985118","Receptive Vocabulary Assessment","C92463","A test that assesses an individual's understanding of spoken English language.","Receptive Vocabulary Assessment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985119","Word Decoding","C92464","A test that assesses a respondent's ability to pronounce words accurately. It tests a respondent's word reading accuracy and fluency.","Word Decoding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0525079","Bendamustine","C73261","A bifunctional mechlorethamine derivative with alkylating and antimetabolite activities. Although the exact mechanism of action of bendamustine is unknown, this agent appears to alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and eventually the induction of apoptosis.","Bendamustine | 5-(Bis(2-chloroethyl)amino)-1-methyl-2-benzimidazolebutyric Acid | BENDAMUSTINE | SDX 105 | SDX-105 | SDX105 | bendamustine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049082","PF-477736","C68820","A proprietary compound targeting cell cycle checkpoint kinase 1 (chk1) with potential chemopotentiation activity. Chk1 inhibitor PF-477736 inhibits chk1, an ATP-dependent serine-threonine kinase that is a key component in the DNA replication-monitoring S/G2 checkpoint system. By overriding the last checkpoint defense against DNA damaging agent-induced lethal damage, chk1 inhibitor PF-477736 may potentiate the antitumor efficacy of various chemotherapeutic agents against tumor cells with intrinsic checkpoint defects.","CHK1 Inhibitor PF-477736 | PF-00477736 | PF-477736",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1099777","Frovatriptan Succinate","C47544","The succinate salt form of frovatriptan, a synthetic triptan with serotonin (5-HT) receptor agonist activity. Frovatriptan succinate binds selectively and with high affinity to 5-HT 1B and presynaptic 5-HT 1D receptors in the extracerebral and intracranial arteries. This leads to an inhibition of serotonin activity and results in vasoconstriction of the painfully dilated blood vessels during migraine attack. Frovatriptan succinate is indicated for the acute treatment of migraine. (NCI05)","Frovatriptan Succinate | 1H-Carbazole-6-carboxamide, 2,3,4,9-tetrahydro-3-(methylamino)-,(3R)-, Butanedioate(1:1) | FROVATRIPTAN SUCCINATE | Frova",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448753","Soreness","C50748","A dull achy pain.","Soreness | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985123","Matched Tissues","C92469","Tissues samples from a single source that differ minimally (e.g., normal and cancerous tissues, treated and untreated tissues).","Matched Tissues | Matched Normal | Matched_Normal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982902","Cervical Cancer pT1 TNM Finding v7","C89525","Cervical cancer confined to uterus (extension to corpus should be disregarded). (from AJCC 7th Ed.)","Cervical Cancer pT1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016374","Flurandrenolide","C47537","A synthetic glucocorticoid with anti-inflammatory and anti-allergic properties. Flurandrenolide exerts its effects by interacting with specific cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. The synthesis of certain anti-inflammatory proteins is induced while the synthesis of certain inflammatory mediators is inhibited. As a result, there is an overall reduction in chronic inflammation and autoimmune reactions.","Flurandrenolide | 6alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregn-4-ene-3,20-dione, cyclic 16,17-acetal with Acetone | Cordran | FLURANDRENOLIDE | Fludroxycortide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0045093","Gemcitabine","C66876","A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in 'masked termination' during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","Gemcitabine | 1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose | 2'Deoxy-2',2'-Difluorocytidine | Difluorodeoxycytidine | GEMCITABINE | dFdC | dFdCyd | gemcitabine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1135132","Ixabepilone","C37452","An orally bioavailable semisynthetic analogue of epothilone B with antineoplastic activity. Ixabepilone binds to tubulin and promotes tubulin polymerization and microtubule stabilization, thereby arresting cells in the G2-M phase of the cell cycle and inducing tumor cell apoptosis. This agent demonstrates antineoplastic activity against taxane-resistant cell lines.","Ixabepilone | (1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione | Azaepothilone B | BMS 247550 | BMS-247550 | BMS247550 | Epothilone | Epothilone-B BMS 247550 | IXABEPILONE | Ixempra | ixabepilone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527127","Recombinant Interleukin-18","C1680","A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin-18 (IL-18). Produced primarily by macrophages, IL-18 induces the production of interferon-gamma (IFN-gamma), and enhances the activity of natural killer (NK) and cytotoxic T lymphocytes (CTL).  As a potential immunotherapeutic agent, iboctadekin displays antitumor effects in vitro and in animal models. (NCI04)","Iboctadekin | Human Interleukin-18 (Recombinant, Expressed in Escherichia coli) | Human Recombinant Interleukin-18 | IBOCTADEKIN | IFN-Gamma-Inducing Factor | IL-18 | Interferon-Gamma-Inducing Factor | Interleukin-18 | Recombinant Interleukin-18 | Recombinant Interleukin-18 | SB 485232 | SB-485232",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014520","Epidermis","C12708","The epithelial portion of the skin (cutis). It consists of the following layers: stratum corneum (horny layer), stratum granulosum (granular layer), stratum spinosum (prickle cell layer), and stratum basale (basal cell layer).","Epidermis | EPIDERMAL TISSUE | Epidermal | epidermis",,,,,,,,,,,,,,,"4206782","Epidermis structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL420231","Maternal","C89336","A designation that has some relationship to motherhood.","Maternal | maternal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1313606","prostate cancer antigen 3, human","C92559","Prostate cancer antigen 3 (~4 kb) is encoded by the human PCA3 gene. This non-coding RNA may be involved in prostate carcinoma.","Prostate Cancer Antigen 3 | Non-Protein Coding RNA 19 | PCA3 | PRUNE2 Antisense RNA 1 | PRUNE2-AS1 | Prostate Cancer Associated 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1261155","Serum Aspartate Aminotransferase Measurement","C61018","A quantitative measurement of the amount of aspartate aminotransferase present in a sample of serum.","Serum Aspartate Aminotransferase Measurement | Serum Aspartate Transaminase Measurement | Serum SGOT Measurement",,,,,,,,,,,,,,,"4094595","AST serum measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2985206","8-iso-PGF2a","C92599","A lipid peroxidation disease marker detected in the serum, biological fluids, and cell cultures using ELISA immunoassay kits.  It is increased in patients with non-insulin dependent diabetes mellitus, coronary heart disease, and hypertension.","8-iso Prostaglandin F2alpha | 8-Iso-Prostaglandin F2 Alpha | 8-Isoprostane | 8-epi-PGF2a | 8-epi-Prostaglandin F2 Alpha | 8-epi-Prostaglandin F2a | 8-iso Prostaglandin F2alpha (8-iso-PGF2a) | 8-iso Prostaglandin F2alpha (8-iso-PGF2a) | 8-iso-PGF2a | 8-iso-Prostaglandin F2a | 8-iso-Prostaglandin F2alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985217","Job Strain","C92619","Negative physical or emotional health outcomes resulting from high job demands with low job decision latitude.","Job Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL331369","Therapeutic Allogeneic Lymphocytes","C28676","A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species. (NCI04)","Therapeutic Allogeneic Lymphocytes | Allogeneic Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020971","Immunization","C15258","Inoculating an individual with either killed or live agents to prevent contraction of a disease.","Immunization | immunization",,,,,,,,,,,,,,,"4144375","Active immunization",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008151","Chlamydia trachomatis","C86253","A species of facultatively aerobic, Gram-negative, coccobacilli assigned to the phylum Chlamydiae. This species cannot be grown on an artificial medium, lacks peptidoglycan within the cell wall, forms elementary and reticulate bodies and can be identified using monoclonal antibodies (mAbs) to epitopes in the VS 4 region of MOMP along with DNA sequencing. C. trachomatis is an obligate intracellular parasite that can be transmitted through sexual contact causing infections of the genital tract and rectum and infertility in women, as well as cause eye infections.","Chlamydia trachomatis | CHLAMYDIA TRACHOMATIS",,,,,,,,,,,,,,,"4274488","Chlamydia trachomatis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2982883","Cervical Cancer Pathologic TNM Finding v7","C89503","A pathologic finding about one or more characteristics of cervical cancer, following the rules of the TNM AJCC v7 classification system. TNM pathologic findings are based on clinical findings supplemented by histopathologic examination of one or more tissue specimens acquired during surgery.","Cervical Cancer Pathologic TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982884","Cervical Cancer Pathologic Primary Tumor TNM Finding v7","C89504","A pathologic finding about one or more characteristics of cervical cancer, following the rules of the TNM AJCC v7 classification system as they pertain to staging of the primary tumor.","Cervical Cancer Pathologic Primary Tumor TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982900","Cervical Cancer pT0 TNM Finding v7","C89523","Cervical cancer with no evidence of primary tumor. (from AJCC 7th Ed.)","Cervical Cancer pT0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982903","Cervical Cancer pT1a TNM Finding v7","C89526","Invasive cervical cancer diagnosed only by microscopy.  Stromal invasion with a maximum depth of 5.0 mm measured from the base of the epithelium and a horizontal spread of 7.0 mm or less.  Vascular space involvement, venous or lymphatic, does not affect classification. (from AJCC 7th Ed.)","Cervical Cancer pT1a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982904","Cervical Cancer pT1a1 TNM Finding v7","C89527","Invasive cervical cancer with measured stromal invasion 3.0 mm or less in depth and 7.0 mm or less in horizontal spread. (from AJCC 7th Ed.)","Cervical Cancer pT1a1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982906","Cervical Cancer pT1a2 TNM Finding v7","C89529","Invasive cervical cancer with measured stromal invasion more than 3.0 mm and not more than 5.0 mm with a horizontal spread 7.0 mm or less. (from AJCC 7th Ed.)","Cervical Cancer pT1a2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982907","Cervical Cancer pT1b TNM Finding v7","C89530","Cervical cancer with microscopic lesion greater than T1a/IA2. (from AJCC 7th Ed.)","Cervical Cancer pT1b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982909","Cervical Cancer pT1b1 TNM Finding v7","C89533","Cervical cancer with clinically visible lesion 4.0 cm or less in greatest dimension confined to the cervix. (from AJCC 7th Ed.)","Cervical Cancer pT1b1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982910","Cervical Cancer pT1b2 TNM Finding v7","C89534","Invasive cervical cancer with clinically visible lesion more than 4.0 cm in greatest dimension confined to the cervix. (from AJCC 7th Ed.)","Cervical Cancer pT1b2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982911","Cervical Cancer pT2 TNM Finding v7","C89535","Cervical cancer invades beyond uterus but not to pelvic wall or to lower third of vagina. (from AJCC 7th Ed.)","Cervical Cancer pT2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982912","Cervical Cancer pT2a TNM Finding v7","C89536","Cervical cancer invades beyond uterus but not to pelvic wall or to lower third of vagina.  There is no parametrial invasion. (from AJCC 7th Ed.)","Cervical Cancer pT2a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982913","Cervical Cancer pT2a1 TNM Finding v7","C89537","Cervical cancer invades beyond uterus but not to pelvic wall or to lower third of vagina.  There is no parametrial invasion.  Clinically visible lesions 4.0 cm or less in greatest dimension are present.  (from AJCC 7th Ed.)","Cervical Cancer pT2a1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982914","Cervical Cancer pT2a2 TNM Finding v7","C89538","Cervical cancer invades beyond uterus but not to pelvic wall or to lower third of vagina.  There is no parametrial invasion.  Clinically visible lesions more than 4.0 cm in greatest dimension are present.  (from AJCC 7th Ed.)","Cervical Cancer pT2a2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982915","Cervical Cancer pT2b TNM Finding v7","C89539","Cervical cancer invades beyond uterus but not to pelvic wall or to lower third of vagina.  Parametrial invasion is present.  (from AJCC 7th Ed.)","Cervical Cancer pT2b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982917","Cervical Cancer pT3 TNM Finding v7","C89540","Cervical cancer extends to pelvic wall and/or involves lower third of vagina, and/or causes hydronephrosis or nonfunctioning kidney. (from AJCC 7th Ed.)","Cervical Cancer pT3 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982918","Cervical Cancer pT3a TNM Finding v7","C89541","Cervical cancer involves lower third of vagina, without extension to pelvic wall. (from AJCC 7th Ed.)","Cervical Cancer pT3a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982919","Cervical Cancer pT3b TNM Finding v7","C89542","Cervical cancer extends to pelvic wall and/or causes hydronephrosis or nonfunctioning kidney. (from AJCC 7th Ed.)","Cervical Cancer pT3b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982920","Cervical Cancer pT4 TNM Finding v7","C89543","Cervical cancer invades mucosa of bladder or rectum, and/or extends beyond true pelvis (bullous edema is not sufficient to classify a tumor as T4). (from AJCC 7th Ed.)","Cervical Cancer pT4 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982901","Cervical Cancer pTis TNM Finding v7","C89524","Cervical cancer with a finding of carcinoma in situ (preinvasive carcinoma).  Note: FIGO no longer includes Stage 0 (Tis) (from AJCC 7th Ed.)","Cervical Cancer pTis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982899","Cervical Cancer pTX TNM Finding v7","C89522","Cervical cancer in which primary tumor cannot be assessed. (from AJCC 7th Ed.)","Cervical Cancer pTX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982921","Cervical Cancer Pathologic Regional Lymph Nodes TNM Finding v7","C89544","A pathologic finding about one or more characteristics of cervical cancer, following the rules of the TNM AJCC v7 classification system as they pertain to staging of regional lymph nodes.","Cervical Cancer Pathologic Regional Lymph Nodes TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982923","Cervical Cancer pN0 TNM Finding v7","C89546","Cervical cancer with no regional lymph node metastasis. (from AJCC 7th Ed.)","Cervical Cancer pN0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982924","Cervical Cancer pN1 TNM Finding v7","C89547","Cervical cancer with regional lymph node metastasis. (from AJCC 7th Ed.)","Cervical Cancer pN1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982922","Cervical Cancer pNX TNM Finding v7","C89545","Cervical cancer in which regional lymph nodes cannot be assessed. (from AJCC 7th Ed.)","Cervical Cancer pNX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982925","Cervical Cancer Pathologic Distant Metastasis TNM Finding v7","C89548","A pathologic finding about one or more characteristics of cervical cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  There is no pathologic M0 for cervical cancer. (from AJCC 7th Ed.)","Cervical Cancer Pathologic Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982926","Cervical Cancer pM1 TNM Finding v7","C89549","Cervical cancer with distant metastasis (including peritoneal spread, involvement of supraclavicular, mediastinal, or paraaortic lymph nodes, lung, liver, or bone). (from AJCC 7th Ed.)","Cervical Cancer pM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553165","Strand Displacement Amplification","C92626","An isothermal, in vitro nucleic acid amplification method that allows primer-directed amplification of a target sequence. It utilizes a primer that can be nicked to create a polymerase start site and a DNA polymerase that will displace a downstream strand as it tracks along the template.","Strand Displacement Amplification | SDA | Strand Displacement Amplification Assay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985221","Cytokine Panel 12","C92627","An assay to detect the presence and level of 12 cytokines in a blood sample (IFN gamma, IL1 beta, IL10, IL12, IL13, IL2, IL2R, IL4, IL5, IL6, IL8, TNF alpha).","Cytokine Panel 12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985222","Multi-Analyte Fluorescent Detection","C92628","A method for simultaneous detection of multiple target molecules. It utilizes specific antibodies for the analytes of interest coupled to fluorescent polystyrol beads. After conjugation of the captured analyte to the bead, the beads are differentiated by their size and their spectral signature, allowing quantitation of analyte concentration in the sample.","Multi-Analyte Fluorescent Detection | MAFD | Multi-Analyte Fluorescent Detection (MAFD)Assay | Multi-Analyte Fluorescent Detection Assay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334247","Keratinizing Squamous Cell Carcinoma","C4105","Squamous cell carcinomas with morphologically prominent production of keratin.","Keratinizing Squamous Cell Carcinoma | Squamous cell carcinoma, keratinizing, NOS","8071/3","Squamous cell carcinoma, keratinizing, NOS",,,,,,,,,,,,,"4078953","Squamous cell carcinoma, keratinizing",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1881297","Keratin Present","C65174","A morphologic finding indicating the presence of keratin in a tissue sample.","Keratin Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3710770","Wilms Tumor Protein, Human","C17549","Wilms tumor protein (449 aa, ~49 kDa) is encoded by the human WT1 gene. This protein is involved in transcriptional regulation, embryonic morphogenesis and in both tumor suppression and tumorigenesis.","Wilms Tumor Protein | WT1 | WT1 Gene Product | WT1 Protein | WT1 Protein | WT33",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0993600","Valeriana officinalis","C38680","A plant, the root of which is used to derive an herbal medicinal preparation with antianxiety and hypnotic activities.  Valerian root contains volatile oils (sesquiterpenes and monoterpenes), valepotriates, alkaloids and lignans.  This agent may inhibit the uptake and stimulate the release of [3H]GABA (gamma-aminobutyric acid), resulting in decreased central nervous system activity. (NCI04)","Valeriana officinalis | Common Valerian | Indian valerian | Mexican valerian | Pacific valerian | VALERIANA OFFICINALIS WHOLE | Valerian | Valerianae radix | garden valerian | valerian",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985235","Other Experiencer","C92653","A reference to someone other than the subject as being the one who has had an episode of the condition of interest, such as a disease.","Other Experiencer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982881","Cervical Cancer cM0 TNM Finding v7","C89501","Cervical cancer in which there is no evidence of distant metastasis. (from AJCC 7th Ed.)","Cervical Cancer cM0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515672","mTOR Inhibitor","C2201","Any substance that inhibits mammalian target of rapamycin (mTOR or FK506 binding protein 12-rapamycin associated protein 1 (FRAP1)), a serine/threonine protein kinase that is active in the control of cell growth, cell proliferation, and cell motility. Inhibition of mTOR can inhibit cell proliferation.","mTOR Inhibitor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2744440","Niraparib","C80059","An orally bioavailable inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2 (PARP-1 and -2), with antineoplastic activity. Upon administration, niraparib binds to and inhibits the activity of PARP-1 and -2, thereby inhibiting PARP-1 and -2-mediated DNA repair, enhancing the accumulation of DNA strand breaks, promoting genomic instability and resulting in apoptosis. The PARP family of proteins catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks.","Niraparib | MK 4827 | MK-4827 | MK4827 | NIRAPARIB | PARP Inhibitor MK4827",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707080","Temsirolimus","C1844","An ester analog of rapamycin. Temsirolimus binds to and inhibits the mammalian target of rapamycin (mTOR), resulting in decreased expression of mRNAs necessary for cell cycle progression and arresting cells in the G1 phase of the cell cycle. mTOR is a serine/threonine kinase which plays a role in the PI3K/AKT pathway that is upregulated in some tumors.","Temsirolimus | 42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin | CCI 779 | CCI-779 | CCI-779 Rapamycin Analog | CCI779 | Cell Cycle Inhibitor 779 | Rapamycin Analog | Rapamycin Analog CCI-779 | TEMSIROLIMUS | Torisel | temsirolimus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0071097","Pioglitazone","C71633","An orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity. Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis. This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation.","Pioglitazone | PIOGLITAZONE | pioglitazone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018081","Gonorrhea","C92950","A common sexually transmitted bacterial infection caused by Neisseria gonorrhoeae. It is transmitted through vaginal, oral, or anal intercourse. Infected individuals may be asymptomatic. Symptoms in males include burning sensation during urination, discharge from the penis, and painful swelling of the testes. Symptoms in females include painful urination, vaginal discharge, and vaginal bleeding between periods. If untreated, the infection may lead to pelvic inflammatory disease.","Gonorrhea | GC",,,,,,,,,,,,,,,"433417","Gonorrhea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0858195","Mycobacterium Avium Complex Lymphadenitis","C27314","Lymph node infection by Mycobacterium avium or Mycobacterium intracellulare. It most often affects children and usually presents with cervical lymph node enlargement. It generally follows a benign clinical course.","Mycobacterium Avium Complex Lymphadenitis | MAC Lymphadenitis | MAI Lymphadenitis | Mycobacterium Avium Intracellulare Lymphadenitis | Mycobacterium tuberculosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981591","Unplanned Subject Visit Description","C88009","An account or record of an unexpected subject visit.","Unplanned Subject Visit Description | SVUPDES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006497","Buttock","C89806","Either of the fleshy mounds in the rear pelvic area of the human body formed by the gluteal muscles.","Buttock | BUTTOCK | buttock | clunis | gluteal part of pelvic girdle | gluteal region | regio glutealis",,,,,,,,,,,,,"UBERON:0013691","buttock","4263335","Buttock structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1880450","Mean QRS Axis","C62132","The mean (average) direction (range -180 degrees to 180 degrees) of the electrical potential generated by ventricular depolarization in a particular plane (usually the frontal plane).","Mean QRS Axis | Summary (Mean) QRS Axis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006655","Calcaneum","C32250","The irregular and largest tarsal bone that forms the heel.","Calcaneum | CALCANEUS | Calcaneus | Calcaneus Bone | calcaneal bone | calcaneum | calcaneus | calcaneus bone | os calcis",,,,,,,,,,,,,"UBERON:0001450","calcaneus","4196052","Bone structure of calcaneum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0222682","Phalanx","C33317","A bone in the fingers or toes.","Phalanx | BONE, PHALANGE | Phalanges | Phalanx",,,,,,,,,,,,,,,"4103215","Phalanx structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0230445","Calf","C93027","The posterior aspect of the lower extremity that extends from the knee to the foot.","Calf | CALF",,,,,,,,,,,,,,,"4201893","Structure of calf of leg",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0230171","Flank","C93028","The region on either side of the body that extends from the last rib to the hip.","Flank | FLANK",,,,,,,,,,,,,,,"4242421","Flank structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021445","Inguinal Canal","C93029","The oblique anatomic tunnel in the anterior lower abdomen. In males it conveys the spermatic cord structures and is the passage through which the testes descend into the scrotum; in females it conveys the round ligament.","Inguinal Canal | ",,,,,,,,,,,,,,,"4236019","Inguinal canal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2985401","Parameningeal","C93030","Of, or related to, the structures proximal to meninges.","Parameningeal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985402","Paratesticular Soft Tissue","C93031","The soft tissues in close proximity to the testis.","Paratesticular Soft Tissue | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0886883","Divalproex Sodium","C28996","A stable coordination compound comprised of sodium valproate and valproic acid with anticonvulsant and antiepileptic activities. Divalproex dissociates to the valproate ion in the gastrointestinal tract. This agent binds to and inhibits gamma-aminobutyric acid (GABA) transaminase and its anticonvulsant activity may be exerted by increasing brain concentration of GABA and by inhibiting enzymes that catabolize GABA or block the reuptake of GABA into glia and nerve endings. Divalproex may also work by suppressing repetitive neuronal firing through inhibition of voltage-sensitive sodium channels.","Divalproex Sodium | Abbott 50711 | DIVALPROEX SODIUM | Depakote | Depakote ER | Epilex | Epival | Sodium Divalproex | Sodium Hydrogen Bis(2-propylpentanoate) | Valparin | Valproate Semisodium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266012","Micropapillary Transitional Cell Carcinoma","C65182","A transitional cell carcinoma characterized by a micropapillary growth pattern. Typical example is the micropapillary variant of infiltrating bladder urothelial carcinoma.","Micropapillary Transitional Cell Carcinoma | ",,,,,,,,,,,,,,,"4029975","Micropapillary urothelial carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0599921","Mucosa-Associated Lymphoid Tissue","C12910","Lymphoid tissue located beneath the mucosal epithelia of those mucosal surfaces that have contact with the external environment, such as the respiratory, digestive, and urinary systems. MALT consists of a collection of predominantly small lymphocytes, fewer larger, transformed lymphocytes, and plasma cells. It protects the body from pathogens that enter via the mucosa. MALT gives rise to a distinctive type of B-cell lymphoma that usually follows an indolent clinical course.","Mucosa-Associated Lymphoid Tissue | Lymphoid Tissue, Mucosa-associated | MALT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376674","Postprandial","C65056","After a meal.","Postprandial | postprandial",,,,,,,,,,,,,,,"4088117","Postprandial",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1773650","Internal Iliac Lymph Node","C88142","A lymph node located along the internal iliac artery.","Internal Iliac Lymph Node | INTERNAL ILIAC LYMPH NODE | Internal iliac lymph node group (body structure) | Structure of internal iliac lymph node (body structure)",,,,,,,,,,,,,,,"4074827|4239688","Internal iliac lymph node group|Structure of hypogastric lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0229815","External Iliac Lymph Node","C88143","A lymph node located along the external iliac artery.","External Iliac Lymph Node | EXTERNAL ILIAC LYMPH NODE | Lymph Node(s) Iliac-External | Structure of external iliac lymph node (body structure) | external iliac lymph node | external iliac node",,,,,,,,,,,,,"UBERON:0015880","external iliac lymph node","4279135","Structure of external iliac lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0229822","Obturator Lymph Node","C88141","A pelvic lymph node located along the obturator artery.","Obturator Lymph Node | OBTURATOR LYMPH NODE | Structure of obturator lymph node (body structure)",,,,,,,,,,,,,,,"4261844","Structure of obturator lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0796357","Genetic Variation Analysis","C18302","The identification of genetic variation in a biological sample.","Genetic Variation Analysis | Genetic Variation Analysis  | Mutation Analysis | Mutation Analysis | mutation analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826900","Laboratory Test Group Identifier","C83310","A character or string that represents a laboratory test group.","Laboratory Test Group Identifier | LBGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0184906","Bifurcation","C90367","A division of a main body into two parts.","Bifurcation | ",,,,,,,,,,,,,,,"4286053","Bifurcation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1719274","Biventricular Pacemaker","C80460","A implantable cardiac pacemaker with an additional third lead placed in the left ventricle that is designed to keep the contractions of the ventricles synchronized with each other.","Biventricular Pacemaker | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038013","Ankylosing Spondylitis","C84564","An autoimmune chronic inflammatory disorder characterized by inflammation in the vertebral joints of the spine and sacroiliac joints. It predominantly affects young males. Patients present with stiffness and pain in the spine.","Ankylosing Spondylitis | Ankylosing spondylitis of unspecified sites in spine",,,,,,,,,,,,,,,"437082","Ankylosing spondylitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0337434","Estradiol Measurement","C74782","The determination of the amount of estradiol present in a sample.","Estradiol Measurement | ESTRDIOL | Estradiol | Oestradiol",,,,,,,,,,,,,,,"4292703","Estradiol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206655","Alveolar Rhabdomyosarcoma","C3749","A rapidly growing malignant mesenchymal neoplasm. It is characterized by the presence of round cells with myoblastic differentiation and a fibrovascular stroma resembling an alveolar growth pattern. The tumor usually presents in the extremities.","Alveolar Rhabdomyosarcoma | ARMS | Alveolar rhabdomyosarcoma | Monomorphous Round Cell Rhabdomyosarcoma | alveolar rhabdomyosarcoma","8920/3","Alveolar rhabdomyosarcoma",,,,,,,,,,,,,"4272931|4298235","Alveolar rhabdomyosarcoma|Alveolar rhabdomyosarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0206657","Alveolar Soft Part Sarcoma","C3750","A rare malignant neoplasm characterized by the presence of large epithelioid cells with abundant cytoplasm forming nests and pseudoalveolar structures. The groups of the epithelioid cells are separated by thin-walled sinusoidal spaces. It occurs most often in adolescents and young adults. In adults the most common sites of involvement are the extremities, and in infants and children, the head and neck. It usually presents as a slowly growing mass and it frequently metastasizes to other anatomic sites. The most common sites of metastasis are the lungs, bone, and brain.","Alveolar Soft Part Sarcoma | ASPS | Alveolar soft part sarcoma | Alveolar soft-part sarcoma | alveolar soft part sarcoma","9581/3","Alveolar soft part sarcoma",,,,,,,,,,,,,"4301648|4339208","Alveolar soft part sarcoma|Alveolar soft part sarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1306573","Botryoid-Type Embryonal Rhabdomyosarcoma","C9150","A morphologic variant of embryonal rhabdomyosarcoma arising from organs with a mucosal epithelial surface.  It is characterized by the formation of a cambium layer in the affected tissue and polypoid nodules within an abundant myxoid stroma.","Botryoid-Type Embryonal Rhabdomyosarcoma | Botryoid Sarcoma | Botryoid sarcoma | Sarcoma Botryoides | Sarcoma botryoides",,,,,,,,,,,,,,,"4228783","Botryoid sarcoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008479","Chondrosarcoma","C2946","A malignant cartilaginous matrix-producing mesenchymal neoplasm arising from the bone and soft tissue.  It usually affects middle-aged to elderly adults.  The pelvic bones, ribs, shoulder girdle, and long bones are the most common sites of involvement.  Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion.","Chondrosarcoma | CHONDROSARCOMA, MALIGNANT | Chondrosarcoma, NOS | chondrosarcoma","9220/3","Chondrosarcoma, NOS",,,,,,,,,,,,,"40481938","Chondrosarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0008487","Chordoma","C2947","A malignant bone tumor arising from the remnants of the fetal notochord. Although it can occur at all ages, it is more frequently seen in middle-aged adults. The most frequent sites of involvement are the sacrococcygeal area, spheno-occipital area, and cervico-thoraco-lumbar spine. Chordomas tend to recur and may metastasize. The most common sites of metastasis are lung, bone, lymph nodes, and subcutaneous tissue.","Chordoma | CHORDOMA, MALIGNANT | Chordoma, NOS | chordoma","9370/3","Chordoma, NOS",,,,,,,,,,,,,"4178109|607974","Chordoma|Chordoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1266167","Clear Cell Chondrosarcoma","C6475","A rare, usually low grade chondrosarcoma characterized by the presence of tumor cells with clear cytoplasm. It usually arises in the epiphyseal ends of long bones.","Clear Cell Chondrosarcoma | Clear cell chondrosarcoma","9242/3","Clear cell chondrosarcoma",,,,,,,,,,,,,"4028692","Clear cell chondrosarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0206651","Clear Cell Sarcoma of Soft Tissue","C3745","A rare malignant neoplasm with melanocytic differentiation characterized by the presence of polygonal or spindle shaped clear cells. This sarcoma usually affects the tendons and aponeuroses and is associated with a poor prognosis due to recurrences and metastases.","Clear Cell Sarcoma of Soft Tissue | Clear Cell Sarcoma of Soft Parts | Clear Cell Sarcoma of Tendons and Aponeuroses | Clear cell sarcoma - not kidney | Clear cell sarcoma of soft tissue | Clear cell sarcoma/Malignant melanoma of soft parts (excluding Clear cell sarcoma of the kidney) | Melanoma of Soft Parts | Melanoma of the Soft Parts | Melanoma, malignant, of soft parts | clear cell sarcoma of soft tissue | malignant melanoma of soft parts","9044/3","Clear cell sarcoma, NOS",,,,,,,,,,,,,"4155072|4299430","Clear cell sarcoma|Malignant melanoma of soft tissues",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1266166","Conventional Osteosarcoma","C35870","A high grade malignant bone-forming mesenchymal neoplasm producing osteoid. The tumor arises from the medullary portion of the bone. It affects the long bones and most commonly, the distal femur, proximal tibia, and proximal humerus. Pain with or without a palpable mass is the most common clinical presentation. It usually has an aggressive growth and may metastasize through the hematogenous route. The lung is the most frequent site of metastasis.","Conventional Osteosarcoma | COS | Central | Central Osteosarcoma | Central osteosarcoma | Conventional Central Osteosarcoma | Conventional central osteosarcoma | Intracortical Osteogenic Sarcoma | Intracortical Osteosarcoma | Intracortical osteosarcoma | Medullary Osteosarcoma | Medullary osteosarcoma","9195/3","Intracortical osteosarcoma",,,,,,,,,,,,,"4029653|4029654","Central osteosarcoma|Intracortical osteosarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0862878","Dedifferentiated Chondrosarcoma","C6476","An aggressive morphologic variant of chondrosarcoma. It is composed of a low grade chondrosarcoma and a high grade non-cartilagenous sarcomatous component. Due to the aggressive nature of the disease, its prognosis is poor.","Dedifferentiated Chondrosarcoma | Dedifferentiated chondrosarcoma","9243/3","Dedifferentiated chondrosarcoma",,,,,,,,,,,,,"4029031","Dedifferentiated chondrosarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0205824","Dedifferentiated Liposarcoma","C3704","An atypical lipomatous tumor/well differentiated liposarcoma that shows progression to a usually non-lipomatous, high grade sarcoma.  The non-lipomatous sarcoma component may be present in the primary lesion or at the site of recurrence.","Dedifferentiated Liposarcoma | DDLPS | Dedifferentiated liposarcoma","8858/3","Dedifferentiated liposarcoma",,,,,,,,,,,,,"4284833|4301652","Dedifferentiated liposarcoma|Dedifferentiated liposarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0392784","Dermatofibrosarcoma Protuberans","C4683","A low grade fibroblastic neoplasm presenting as a nodular cutaneous mass, most often on the trunk and the proximal extremities.  The tumor diffusely infiltrates the dermis and the subcutaneous tissues.  It is considered a locally aggressive neoplasm, which often recurs but rarely metastasizes.","Dermatofibrosarcoma Protuberans | DFSP | Dermatofibrosarcoma | Dermatofibrosarcoma protuberans, NOS | dermatofibrosarcoma protuberans","8832/1","Dermatofibrosarcoma protuberans, NOS",,,,,,,,,,,,,"4174440|4295283","Dermatofibrosarcoma protuberans|Dermatofibrosarcoma protuberans",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0281508","Desmoplastic Small Round Cell Tumor","C8300","An aggressive malignant soft tissue neoplasm of uncertain differentiation.  It is characterized by a recurrent chromosomal translocation t(11;22)(p13;q12) and the presence of small round cells in a desmoplastic stroma.  It usually affects children and young adults.  The most common site of involvement is the abdomen.  Patients usually present with abdominal distention, pain, ascites, and a palpable abdominal mass.  The prognosis is usually poor.","Desmoplastic Small Round Cell Tumor | DSRCT | Desmoplas. small round cell tumor | Desmoplastic Small Round-Cell Neoplasm | Desmoplastic Small Round-Cell Tumor | Desmoplastic small round cell tumor | Polyphenotypic Small Round Cell Tumor | desmoplastic small round cell tumor","8806/3","Desmoplastic small round cell tumor",,,,,,,,,,,,,"4029522","Desmoplastic small round cell tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0206656","Embryonal Rhabdomyosarcoma","C8971","A poorly circumscribed morphologic variant of rhabdomyosarcoma.  It is characterized by the presence of primitive skeletal muscle differentiation in any stage of myogenesis.","Embryonal Rhabdomyosarcoma | ERMS | Embryonal rhabdomyosarcoma | embryonal rhabdomyosarcoma","8910/3","Embryonal rhabdomyosarcoma, NOS",,,,,,,,,,,,,"4031038|4300682","Embryonal rhabdomyosarcoma|Embryonal rhabdomyosarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0334486","Low Grade Endometrioid Stromal Sarcoma","C4263","An infiltrating mesenchymal tumor arising from the uterine corpus, cervix, vagina, and the ovary. It is characterized by the presence of oval to spindle-shape cells that resemble the cells of the endometrial stroma, without evidence of significant atypia and pleomorphism. Numerous small vessels are also present. It is usually characterized by indolent growth and late recurrences.","Low Grade Endometrioid Stromal Sarcoma | Endolymphatic Stromal Myosis | Endolymphatic stromal myosis | Low Grade Endometrial Stromal Sarcoma",,,,,,,,,,,,,,,"4028557|44783286","Endometrial stromal sarcoma, low grade|Low grade endometrial stromal sarcoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1710535","Undifferentiated Stromal Sarcoma","C53994","An infiltrating high-grade malignant mesenchymal tumor arising from the uterine corpus, cervix, vagina, and ovary.","Undifferentiated Stromal Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206732","Epithelioid Hemangioendothelioma","C3800","A low-grade malignant blood vessel neoplasm.  It is characterized by the presence of epithelioid endothelial cells.  The neoplastic cells are arranged in cords and nests, which are embedded in a myxoid to hyalinized stroma.","Epithelioid Hemangioendothelioma | Epithelioid Angioendothelioma | Epithelioid Angiosarcoma | Epithelioid hemangioendothelioma, NOS | Epithelioid hemangioendothelioma, malignant","9133/3","Epithelioid hemangioendothelioma, NOS",,,,,,,,,,,,,"4298140","Epithelioid hemangioendothelioma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0205944","Epithelioid Sarcoma","C3714","An aggressive malignant neoplasm of uncertain differentiation, characterized by the presence of epithelioid cells forming nodular patterns.  The nodules often undergo central necrosis, resulting in a pseudogranulomatous growth pattern.  It usually occurs in young adults.  The most common sites of involvement are the extremities (distal-type epithelioid sarcoma), and less frequently the pelvis, perineum, and genital organs (proximal-type epithelioid sarcoma).","Epithelioid Sarcoma | ES | Epithelioid Cell Sarcoma | Epithelioid cell sarcoma | Epithelioid sarcoma","8804/3","Epithelioid sarcoma",,,,,,,,,,,,,"4244886","Epithelioid sarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0684337","Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor","C27291","A spectrum of malignant tumors, affecting mostly males under age 20, characterized morphologically by the presence of small round cells.  Ewing sarcoma and peripheral primitive neuroectodermal tumor represent the ends of a spectrum, with Ewing sarcoma lacking evidence of neural differentiation and the markers that characterize the peripheral primitive neuroectodermal tumor.  Ewing sarcoma and peripheral primitive neuroectodermal tumor may share cytogenetic abnormalities, proto-oncogene expression, cell culture and immunohistochemical abnormalities.  These tumors may occur in the soft tissues or the bones.  Pain and the presence of a mass are the most common clinical symptoms.","Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | EFTs | Ewing Family of Tumors | Ewing sarcoma family of tumors | Ewing sarcoma/Peripheral PNET | Ewing sarcoma/Peripheral primitive neuroectodermal tumor | Ewing's Family of Tumors | Ewing's Family of Tumours | Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Tumors of Ewing's Family | Tumors of the Ewing's Family",,,,,,,,,,,,,,,"45766528","Ewing sarcoma / peripheral neuroectodermal tumor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333514","Extraskeletal Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor","C27293","A spectrum of malignant tumors arising from the soft tissues, characterized morphologically by the presence of small round cells.  Ewing sarcoma and peripheral primitive neuroectodermal tumor represent the ends of a spectrum, with Ewing sarcoma lacking evidence of neural differentiation and the markers that characterize the peripheral primitive neuroectodermal tumor.  Ewing sarcoma and peripheral primitive neuroectodermal tumor may share cytogenetic abnormalities, proto-oncogene expression, cell culture and immunohistochemical abnormalities.  Pain and the presence of a mass are the most common clinical symptoms.","Extraskeletal Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Extraosseous Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Extraosseous Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Extraosseous Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1275279","Mesenchymal Extraskeletal Chondrosarcoma","C27481","A rare malignant tumor of soft tissue characterized by a bimorphic pattern composed of undifferentiated small round cells and islands of well differentiated hyaline cartilage.","Mesenchymal Extraskeletal Chondrosarcoma | ",,,,,,,,,,,,,,,"4297346","Extraskeletal mesenchymal chondrosarcoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334551","Extraskeletal Myxoid Chondrosarcoma","C27502","A rare malignant soft tissue neoplasm of uncertain differentiation, characterized by the presence of chondroblast-like cells in a myxoid stroma and a multinodular growth pattern.  The most common sites of involvement are the deep soft tissues of the extremities, particularly the thigh.  It usually presents as an enlarging soft tissue mass.  Patients may have long survivals, but local recurrences and metastases occur in approximately half of the cases.  The most common site of metastasis is the lungs.","Extraskeletal Myxoid Chondrosarcoma | EMC | Extraosseous Chondrosarcoma | Extraskeletal Chondrosarcoma | Myxoid Chondrosarcoma | Myxoid Extraosseous Chondrosarcoma | Myxoid Extraskeletal Chondrosarcoma | Myxoid chondrosarcoma | NR4A3-Rearranged Myxoid Sarcoma","9231/3","Myxoid chondrosarcoma",,,,,,,,,,,,,"4297345","Extraskeletal myxoid chondrosarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0855052","Extraskeletal Osteosarcoma","C8810","An osteosarcoma arising from the soft tissue.","Extraskeletal Osteosarcoma | Extraosseous Osteosarcoma | Extraskeletal Osteogenic Sarcoma | OSTEOSARCOMA, EXTRASKELETAL, MALIGNANT | Soft Tissue Osteosarcoma",,,,,,,,,,,,,,,"4298240","Extraskeletal osteosarcoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334459","Infantile Fibrosarcoma","C4244","A fibrosarcoma that occurs in infants.  It shares identical morphologic features with adult fibrosarcoma but carries the t(12;15)(p13;q25) translocation that results in ETV6-NTRK3 gene fusion.  It usually affects the superficial and deep soft tissues of the extremities.  The prognosis is generally much more favorable than for adult fibrosarcoma, and it rarely metastasizes.","Infantile Fibrosarcoma | Congenital Fibrosarcoma | Congenital fibrosarcoma | IFS | Infantile fibrosarcoma | Infantile fibrosarcoma (congenital fibrosarcoma)","8814/3","Infantile fibrosarcoma",,,,,,,,,,,,,"4300585","Infantile fibrosarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1275282","Low Grade Fibromyxoid Sarcoma","C45202","A low-grade, late-metastasizing variant of fibrosarcoma characterized by alternating fibrous and myxoid areas and a whorling growth pattern.  The neoplastic cells have a spindle morphology, and lack hyperchromasia or significant nuclear atypia.  Approximately 40% of cases show the focal presence of collagen rosettes.  A t(7;16)(q33;p11) translocation has been identified in the majority of cases, associated with the presence of FUS-CREB3L2 fusion protein.  Rare cases carry the t(11;16)(p11;p11) translocation which is associated with the presence of the FUS-CREB3L1 fusion protein.","Low Grade Fibromyxoid Sarcoma | Low-grade fibromyxoid sarcoma",,,,,,,,,,,,,,,"45771361","Low grade fibromyxoid sarcoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708751","Low Grade Myofibroblastic Sarcoma","C49024","A low-grade malignant neoplasm arising from the soft tissue and rarely bone. It is characterized by the presence of spindle-shaped myofibroblasts and collagenous stroma formation in a storiform growth pattern. Metastasis is very rare.","Low Grade Myofibroblastic Sarcoma | Low Grade Myofibroblastic Sarcoma | Low-Grade Myofibroblastic Sarcoma | Low-grade myofibroblastic sarcoma | Myofibroblastic Sarcoma | Myofibroblastic Sarcoma | Myofibroblastic sarcoma | Myofibrosarcoma",,,,,,,,,,,,,,,"45766454","Low grade myofibroblastic sarcoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266168","Malignant Tenosynovial Giant Cell Tumor","C6535","An uncommon malignant tumor arising from the tendon sheath. Morphologically, it is characterized by the presence of a cellular infiltrate reminiscent of a giant cell tumor with prominent malignant characteristics. Recurrent giant cell tumors with a sarcomatous dedifferentiation are included in this category as well.","Malignant Tenosynovial Giant Cell Tumor | Giant cell tumor of tendon sheath, malignant | Malignant Giant Cell Neoplasm of Tendon Sheath | Malignant Giant Cell Neoplasm of the Tendon Sheath | Malignant Giant Cell Tumor of Tendon Sheath | Malignant Giant Cell Tumor of Tendon Sheath | Malignant Giant Cell Tumor of the Tendon Sheath | Malignant Tendon Sheath Giant Cell Neoplasm | Malignant Tendon Sheath Giant Cell Tumor | Malignant tenosynovial giant cell tumor","9252/3","Malignant tenosynovial giant cell tumor",,,,,,,,,,,,,"4029655","Malignant tenosynovial giant cell tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0206637","Mesenchymal Chondrosarcoma","C3737","A morphologic variant of chondrosarcoma arising from bone and soft tissue. It is characterized by the presence of malignant small round cells, biphasic growth pattern, and well differentiated hyaline cartilage. Clinical presentation includes pain and swelling. The clinical course is aggressive, with local recurrences and distant metastases.","Mesenchymal Chondrosarcoma | Mesenchymal chondrosarcoma","9240/3","Mesenchymal chondrosarcoma",,,,,,,,,,,,,"4209580","Mesenchymal chondrosarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334454","Myxofibrosarcoma","C6496","A malignant fibroblastic neoplasm arising from the soft tissue. It is characterized by the presence of spindle-shaped cells, cellular pleomorphism, thin-walled blood vessels, fibrous septa, and myxoid stroma.","Myxofibrosarcoma | Fibromyxosarcoma | Myxoid MFH | Myxoid Malignant Fibrous Histiocytoma",,,,,,,,,,,,,,,"45771359","Myxofibrosarcoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029463","Osteosarcoma","C9145","A usually aggressive malignant bone-forming mesenchymal neoplasm, predominantly affecting adolescents and young adults. It usually involves bones and less frequently extraosseous sites. It often involves the long bones (particularly distal femur, proximal tibia, and proximal humerus). Pain with or without a palpable mass is the most frequent clinical symptom. It may spread to other anatomic sites, particularly the lungs.","Osteosarcoma | OSTEOSARCOMA, MALIGNANT | Osteogenic Sarcoma | Osteosarcoma, NOS | osteogenic sarcoma | osteosarcoma","9180/3","Osteosarcoma, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C0206642","Parosteal Osteosarcoma","C8969","A low grade malignant bone-forming mesenchymal neoplasm arising from the surface of the bone. It usually affects the distal posterior femur, the proximal tibia, and proximal humerus. Painless swelling is the usual clinical sign. Most patients are young adults and the prognosis is usually excellent.","Parosteal Osteosarcoma | Juxtacortical Osteogenic Sarcoma | Juxtacortical Osteosarcoma | Juxtacortical osteosarcoma | Parosteal | Parosteal Osteogenic Sarcoma | Parosteal osteosarcoma","9192/3","Parosteal osteosarcoma",,,,,,,,,,,,,"4028857","Parosteal osteosarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1377843","Periosteal Osteosarcoma","C8970","An intermediate grade malignant bone-forming mesenchymal neoplasm with chondroblastic differentiation.  It arises from the surface of the bone and affects the diaphysis or diaphyseal- metaphyseal portion of the long bones.  A painless mass or swelling is the most common clinical sign.  It is associated with a better prognosis than conventional osteosarcoma.","Periosteal Osteosarcoma | Juxtacortical Chondroblastic Osteosarcoma | Periosteal osteosarcoma | Surface Periosteal","9193/3","Periosteal osteosarcoma",,,,,,,,,,,,,"4029029","Periosteal osteosarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0205825","Pleomorphic Liposarcoma","C3705","A rare, aggressive liposarcoma characterized by the presence of varying proportions of pleomorphic lipoblasts in a background that resembles undifferentiated pleomorphic sarcoma.","Pleomorphic Liposarcoma | Pleomorphic liposarcoma","8854/3","Pleomorphic liposarcoma",,,,,,,,,,,,,"4010104|4300687","Pleomorphic liposarcoma|Pleomorphic liposarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0334480","Pleomorphic Rhabdomyosarcoma","C4258","An aggressive malignant mesenchymal neoplasm with skeletal muscle differentiation, occurring in adults and rarely in children.  The tumor is characterized by the presence of bizarre round, spindle, and polygonal cells.  Clinical presentation includes a rapidly enlarging painful mass usually of the lower extremities.","Pleomorphic Rhabdomyosarcoma | Pleomorphic rhabdomyosarcoma, NOS",,,,,,,,,,,,,,,"4298312|4301647","Pleomorphic rhabdomyosarcoma|Pleomorphic rhabdomyosarcoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2985448","Radiation-Related Sarcoma","C93125","A sarcoma that arises in the bones or soft tissues following exposure to ionizing or non-ionizing radiation.","Radiation-Related Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279622","Small Cell Osteosarcoma","C4023","An osteosarcoma usually arising from the metaphysis of long bones. It is characterized by the presence of small cells and osteoid production. The prognosis is usually unfavorable.","Small Cell Osteosarcoma | Small Cell Osteogenic Sarcoma | Small cell osteosarcoma","9185/3","Small cell osteosarcoma",,,,,,,,,,,,,"4049129","Small cell osteosarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1266134","Spindle Cell Rhabdomyosarcoma","C6519","An uncommon variant of rhabdomyosarcoma characterized by the presence of whorls of spindle cells forming a storiform pattern. In children it usually arises in the paratesticular region. In adults it usually arises from the deep soft tissues in the head and neck.","Spindle Cell Rhabdomyosarcoma | Spindle cell rhabdomyosarcoma","8912/3","Spindle cell rhabdomyosarcoma",,,,,,,,,,,,,"4029528|4297338","Spindle cell rhabdomyosarcoma|Spindle cell rhabdomyosarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1266165","High Grade Surface Osteosarcoma","C53958","A usually aggressive high grade malignant bone-forming mesenchymal neoplasm arising from the surface of the bone.","High Grade Surface Osteosarcoma | High grade surface osteosarcoma | High-Grade Surface Osteosarcoma","9194/3","High grade surface osteosarcoma",,,,,,,,,,,,,"4029030","High grade surface osteosarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0259782","Telangiectatic Osteosarcoma","C3902","An osteosarcoma usually arising from the metaphysis of long bones. It is characterized by the presence of a cystic architecture with blood-filled spaces. The prognosis is similar to that of conventional osteosarcoma.","Telangiectatic Osteosarcoma | Malignant Bone Aneurysm | Telangiectatic Osteogenic Sarcoma | Telangiectatic osteosarcoma","9183/3","Telangiectatic osteosarcoma",,,,,,,,,,,,,"4302615","Telangiectatic osteosarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1266163","Low Grade Central Osteosarcoma","C6474","A low grade osteosarcoma arising from the medullary portion of the bone. It affects the long bones and is characterized by the presence of fibroblastic stroma and osteoid production. Pain and swelling are the usual sign and symptom. The prognosis is more favorable than conventional osteosarcoma.","Low Grade Central Osteosarcoma | Intraosseous Well Differentiated Osteosarcoma | Intraosseous Well-Differentiated Osteogenic Sarcoma | Intraosseous Well-Differentiated Osteosarcoma | Intraosseous well differentiated osteosarcoma | LGCOS | Low Grade Intramedullary Osteosarcoma | Low-Grade Intramedullary Osteosarcoma | Low-grade central osteosarcoma | Low-grade intramedullary osteosarcoma",,,,,,,,,,,,,,,"45766519","Low grade central osteosarcoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334552","Malignancy in Giant Cell Tumor of Bone","C4304","A malignant tumor that arises from the bone.  It is characterized by the presence of an area of high grade sarcoma in an otherwise typical giant cell tumor (primary malignancy in giant cell tumor), or the presence of sarcoma in which the pre-existing giant cell tumor may or may not be apparent (secondary malignancy in giant cell tumor).","Malignancy in Giant Cell Tumor of Bone | Dedifferentiated Giant Cell Tumor | Giant Cell Bone Sarcoma | Giant Cell Sarcoma of Bone | Giant Cell Sarcoma of the Bone | Giant cell sarcoma of bone | Giant cell tumor of bone, malignant | Malignancy in Giant Cell Tumor of the Bone | Malignant Giant Cell Tumor of Bone | Malignant Giant Cell Tumor of Bone | OSTEOCLASTOMA, MALIGNANT","9250/3","Giant cell tumor of bone, malignant",,,,,,,,,,,,,"4003785","Giant cell tumor of bone, malignant",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0085096","Peripheral Vascular Disorder","C35136","Any disorder affecting blood flow through the veins or arteries outside of the heart.","Peripheral Vascular Disorder | Peripheral Vascular Disease | Peripheral vascular disease, unspecified",,,,,,,,,,,,,,,"321052","Peripheral vascular disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1257974","Regenerative Medicine","C93254","The branch of medicine that involves the laboratory growth of functional tissues and organs and their use to regenerate or replace tissues and organs in the body that are damaged by diseases or cannot be healed. Examples include the transplantation of in vitro developed tissues, cell therapies, and stimulation of regeneration by biological substances.","Regenerative Medicine | regenerative medicine",,,,,,,,,,,,,,,"37397656","Regenerative medicine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2826646","Concomitant Medication Dose Unit","C83034","The unit of measure for the concomitant medication dose.","Concomitant Medication Dose Unit | CMDOSU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826654","Concomitant Medication Dose Frequency","C83042","The rate of concomitant medication usage.","Concomitant Medication Dose Frequency | CMDOSFRQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517457","Gastrointestinal Absorption Inhibition","C41491","Gastrointestinal Absorption Inhibition involves interference with, or restraint of, activities of uptake from the intestinal lumen of fluids, solutes, proteins, fats, and other nutrients into the intestinal epithelial cells, blood, lymph, or interstitial fluids.","Gastrointestinal Absorption Inhibition | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538577","PARP1 Gene","C48684","This gene is involved in cellular repair and apoptosis.","PARP1 Gene | PARP1 | Poly(ADP-Ribose) Polymerase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0000962","Acetabulum","C32042","Two cup shaped areas, one each on the lateral side of the lower pelvis that house the head of the femur to form the ball and socket joint of the hip.","Acetabulum | ACETABULUM | Bone structure of acetabulum (body structure) | acetabular part of hip bone | acetabular region | acetabulum","C41.4","Acetabulum",,,,,,,,,,,"UBERON:0001269","acetabular part of hip bone","4292088","Bone structure of acetabulum",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1290884","Inflammatory Disorder","C93210","An infectious or non infectious disorder characterized by signs and symptoms derived from focal or extensive tissue infiltration by acute (e.g., polymorphonuclear) or chronic (e.g., lymphocytic-plasmacytic) inflammatory cells. Representative examples of infectious disorders include viral infections, bacterial infections, and parasitic infections. Representative examples of non-infectious inflammatory disorders include inflammatory bowel disease and inflammatory polyps.","Inflammatory Disorder | Inflammatory Disease | Inflammatory_Disease",,,,,,,,,,,,,,,"4027384","Inflammatory disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016977","Gallbladder Disorder","C34631","A non-neoplastic or neoplastic disorder that affects the gallbladder. Representative examples of non-neoplastic disorders include acute and chronic cholecystitis, often associated with the presence of gallstones. Representative examples of neoplastic disorders include adenoma, carcinoma, lymphoma, and sarcoma.","Gallbladder Disorder | Gall Bladder Disease | Gall Bladder Disorder | Gallbladder Disease",,,,,,,,,,,,,,,"192353","Disorder of gallbladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007570","Celiac Disease","C26714","An autoimmune genetic disorder with an unknown pattern of inheritance that primarily affects the digestive tract. It is caused by intolerance to dietary gluten. Consumption of gluten protein triggers an immune response which damages small intestinal villi and prevents adequate absorption of nutrients. Clinical signs include abdominal cramping, diarrhea or constipation and weight loss. If untreated, the clinical course may progress to malnutrition, anemia, osteoporosis and an increased risk of intestinal malignancies. However, the prognosis is favorable with successful avoidance of gluten in the diet.","Celiac Disease | Celiac Sprue | Gluten-Induced Enteropathy | Non Tropical Sprue | celiac disease",,,,,,,,,,,,,,,"194992","Celiac disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036597","Self-esteem","C93085","A feeling of self-worth, self-confidence, and self-respect.","Self-esteem | self-esteem",,,,,,,,,,,,,,,"4084725","Self-esteem",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1510639","Social Capital","C93209","The value derived from social networking that fosters a fellowship with trustworthy relationships and reciprocal interconnectedness among people, businesses or institutions that as intangible assets are both valuable and mutually beneficial to individuals and the society.","Social Capital | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021125","Impulsive Behavior","C93213","Initiation of actions without forethought as to the cost, results or consequences.","Impulsive Behavior | Impulsivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042693","Violence","C93214","An act of aggression between individuals.","Violence | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010325","Crime","C93215","An act that is punishable by law; illegal activities in general.","Crime | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0522174","Delinquency","C93216","An act by a minor that is punishable by law.","Delinquency | ",,,,,,,,,,,,,,,"4009710","Delinquent behavior",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2985497","Perceived Social Support/Conflict","C93218","An individuals' perception of the amount of positive support (e.g., love, care, concern) and negative support (e.g., demand, critique) that they experience.","Perceived Social Support/Conflict | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039474","Temperament","C93212","An individual's habitual frame of mind or natural emotional disposition.","Temperament | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0000943","Acculturation","C93211","The process of adopting the traits or social patterns of a different population group.","Acculturation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985498","Intraesophageal Impedance pH Monitoring","C93219","A method for monitoring the pH in the distal esophagus for the detection of acid reflux and the diagnosis of gastroesophageal reflux disease.","Intraesophageal Impedance pH Monitoring | Impedance-pH monitoring | pH Impedance Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019186","Hepatitis Viruses","C14216","A non-taxonomic classification of unrelated viruses that cause liver inflammation and dysfunction.","Hepatitis Virus | Infectious Agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985853","Repetition Number","C93651","An integer that identifies the particular occurrence of a repeating activity or entity.","Repetition Number | Repetition Ordinal | repetitionNumber",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512628","Imaging Agent","C1966","A compound that enables or improves the visualization of body structures or functions for medical imaging.","Imaging Agent | Image Enhancement Agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020522","Type IV Hypersensitivity","C3115","Delayed hypersensitivity reaction (DTH) - type IV reaction, an inflammatory response that develops 24 to 72 hours after exposure to an antigen that the immune system recognizes as foreign. DTH is mediated by T cells rather than by antibodies. Th1 cells produce interferon gamma, interleukin (IL)-2, and tumor necrosis factor-beta and promote a cell-mediated immune response.","Type IV Hypersensitivity | DTH | Delayed Hypersensitivity Reaction | Delayed-Type Hypersensitivity | Delayed-Type Hypersensitivity | Delayed-Type Hypersensitivity Response | Type 4 Hypersensitivity Reaction | Type IV Hypersensitivity Reaction | delayed-type hypersensitivity response",,,,,,,,,,,,,,,"4101555","Cell-mediated immune reaction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706969","Blood Chemistry Measurement","C47868","The determination of the measured concentrations of chemical constituents of the blood by assay in a clinical laboratory.","Blood Chemistry Measurement | Blood Chemistry Evaluation | Blood Chemistry Study | Blood Chemistry Test | blood chemistry study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0556984","Three Times Daily","C64527","Three times per day.","Three Times Daily | 3 times daily | 3 times per day | TID | Three Times Per Day | Three times a day | ter in die",,,,,,,,,,,,,,,"4041301","Three times daily",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1443048","Trichophyton antigen","C94662","A sterile solution containing culture filtrate of various Trichophyton species. It is used to test for delayed hypersensitivity to the fungus.","Trichophyton Antigen | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1620287","Prasugrel","C81566","An orally bioavailable thienopyridine, with antiplatelet activity. Upon oral administration, the active metabolite of prasugrel targets and irreversibly binds to the platelet receptor for adenosine diphosphate (ADP), thereby blocking the binding of ADP to its receptor. This inhibits ADP-mediated activation of the glycoprotein complex GPIIb/IIIa, fibrinogen binding to platelets and platelet adhesion and aggregation. This results in increased bleeding time.","Prasugrel | PRASUGREL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0599196","Early Childhood","C89346","A human life stage that begins at two years of age and continues until five complete years of age.","Early Childhood | ",,,,,,,,,,,,,,,"37016982","Early childhood",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037421","Social Isolation","C21100","A condition in which an individual feels or is made to feel as though he or she has no place within society.  This is often the case with persons who have inadequate support systems or who suffer from stigmatized disease, such as AIDS and mental illness.","Social Isolation | ",,,,,,,,,,,,,,,"4309238","Social isolation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023901","Liver Function Test","C74954","The quantitative measurement of liver enzymes in the blood, which is useful in assessing the functional state of a patient's liver. Liver function tests include the measurement of albumin, alanine transaminase, aspartate transaminase, alkaline phosphatase, bilirubin, and gamma glutamyl transferase.","Liver Function Test | LFT | liver function test",,,,,,,,,,,,,,,"4098135","Hepatic function panel",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227130","Tooth Socket","C94543","Any of the bone cavities of the mandible or maxilla in which the roots of the teeth are anchored.","Tooth Socket | Alveolus | Dental Alveolus",,,,,,,,,,,,,,,"4263721","Structure of alveolus dentalis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011327","Dental Assistant","C53428","A person trained and qualified to provide chairside assistance to a dentist, along with performance of other supportive duties such as to receive and prepare patients for dental treatment; to prepare materials and equipment for use by the dentist; to perform reversible intra-oral procedures under the supervision of the dentist; to perform dental radiography work; to maintain dental equipment and treatment area and to keep records of appointments, examinations, treatments and supplies.","Dental Assistant | Assistant | DENTAL ASSISTANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004277","Dental Attrition","C94544","The loss of tooth structure by mechanical forces from opposing teeth.","Dental Attrition | Attrition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986566","Bioactive Glass Product","C94548","A surface-reactive glass-ceramic biomaterial that is capable of ion exchange and hydrolysis. It is useful for bone repair and bone regeneration.","Bioactive Glass Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986567","Bottom of Gingival Sulcus","C94549","The point at which the gingival sulcus terminates because the tissue attaches directly to the tooth.","Bottom of Gingival Sulcus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221819","Orthodontic braces","C94550","An orthodontic appliance designed to correct misaligned teeth.","Orthodontic Braces | Braces",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221839","Elastics","C94567","Elastic bands used in orthodontics to move teeth in a desired direction.","Elastics | Elastic Band | Rubber Band",,,,,,,,,,,,,,,"4104873|45758860","Orthodontic elastic|Orthodontic band, elastic",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2986578","Decayed, Missing, and Filled Teeth Index","C94566","A system used to quantitate and illustrate the current state of a person's dentition. It is a sum of the total number of teeth that are decayed, missing, or filled. It is calculated either for 32 permanent teeth, or for 28 teeth (excluding the third molars).","Decayed, Missing, and Filled Teeth Index | DMFT Index",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449150","Scrape","C94576","To draw one thing roughly across another.","Scrape | Scraping | Scraping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987480","Scratch -action","C94577","To wear away a surface with a sharp object.","Scratch | Scratching",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986582","Stained Appearance","C94578","Marked or discolored by foreign material.","Stained Appearance | Stained",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710579","Upper Jaw Incisor","C49794","Either of the incisors found in the upper jaw.","Upper Jaw Incisor | Maxillary Central Incisor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986584","Dental Whitening","C94591","A process that employs special bleaching agents for restoring the color of teeth.","Dental Whitening | Whitening",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040597","Traction","C21119","The application of pulling forces to improve functional alignment.","Traction | ",,,,,,,,,,,,,,,"4280205","Traction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0225386","Breath","C94552","The air that is inhaled and exhaled during respiration.","Breath | ",,,,,,,,,,,,,,,"4042494","Breath",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2986569","Buildup","C94553","Material that has accumulated gradually.","Buildup | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986570","Business Personnel","C94554","Persons employed by an organization, business, or service.","Business Personnel | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986571","Caries into Dentin","C94555","Tooth decay that extends through the enamel into the dentin layer.","Caries into Dentin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986572","Caries Restricted to Enamel","C94556","Tooth decay that is restricted to the enamel layer.","Caries Restricted to Enamel | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986573","Caries, Region Unknown","C94557","Tooth decay of an unspecified location.","Caries, Region Unknown | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435391","Cementoenamel Junction","C74953","The area of a tooth where the enamel of the crown and the cementum of the root(s) are joined.","Cementoenamel Junction | ",,,,,,,,,,,,,,,"4242418","Structure of cementoenamel junction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007789","Cerebral Palsy","C34460","A group of disorders affecting the development of movement and posture, often accompanied by disturbances of sensation, perception, cognition, and behavior. It results from damage to the fetal or infant brain.","Cerebral Palsy | Cerebral palsy, unspecified",,,,,,,,,,,,,,,"4134120","Cerebral palsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0266924","Chronic Pericoronitis","C94558","Long-term inflammation of the gingiva surrounding the crown of a tooth, usually of an incompletely erupted tooth.","Chronic Pericoronitis | ",,,,,,,,,,,,,,,"4175002","Chronic pericoronitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2057703","Jaw Clicking or Popping","C94559","Noise in the temporomandibular joint, with or without pain, when fully opening the jaw.","Jaw Clicking or Popping | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986575","Connect","C94560","To become joined or linked.","Connect | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242385","Crossbite","C94561","An abnormal occlusion where some of the mandibular teeth are buccal to the maxillary teeth.","Crossbite | ",,,,,,,,,,,,,,,"4033469","Crossbite",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0259825","Dental Drilling","C94562","Use of a cutting burr in a handheld instrument to remove diseased tooth structure and/or shape a tooth for retention of a replacement material.","Dental Drilling | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986576","Distobuccal","C94563","Describes a location in the mouth that is toward the back and to the cheek side.","Distobuccal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986577","Distolingual","C94564","Describes a location in the mouth that is toward the back and to the tongue side.","Distolingual | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1533692","Tooth Eruption","C94569","The act of a tooth breaking through the gum.","Tooth Eruption | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986579","Force-sensitive Electronic Probe","C94570","A periodontal probe that uses a standardized pressure to measure the depth of periodontal pockets, recession, or attachment levels.","Force-sensitive Electronic Probe | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017814","Glutaral","C80930","A water-soluble oily liquid, C5H8O2, containing two aldehyde groups, used as a disinfectant and as a fixative for biological tissues.","Glutaral | GLUTARAL | Glutaraldehyde | Glutaraldehyde",,,,,,,,,,,,,,,"4319262","Glutaraldehyde",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018464","Habit","C94571","A pattern of repeat behavior requiring little conscious thought.","Habit | ",,,,,,,,,,,,,,,"4233389","Habit",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2986583","Incisal edge of tooth","C94587","The cutting edge of an incisor tooth.","Incisal Edge | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349948","Lingual","C94565","Describes a location in the mouth that is toward or near the tongue.","Lingual | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0458583","Lower Lip","C94572","The lip that covers the anterior portion of the mandible.","Lower Lip | ",,,,,,,,,,,,,,,"4135698","Lower lip structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2986580","Overeruption","C94573","Projection of a tooth beyond its normal position.","Overeruption | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986581","Panoramic","C94574","A wide angle view.","Panoramic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986585","Zygomatic Buttress","C94592","The portion of the maxillary jaw bone and other facial bones that form the most lateral mid face skeletal structure known as the cheekbone.","Zygomatic Buttress | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3146293","Uprighting","C94590","Straightening a tooth to its proper vertical position.","Uprighting | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0522503","Transparent","C94589","Allowing the passage of light such that images can be seen through with clarity.","Transparent | Clear",,,,,,,,,,,,,,,"4115096","Translucent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0457750","Tooth Angulation","C94588","The relationship of the tooth in the jaw bone compared to the vertical position of zero degrees when viewed in an x-ray.","Tooth Angulation | ",,,,,,,,,,,,,,,"4150443","Tooth angulation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227075","Tooth 32","C94586","The lower right 3rd molar, as defined by the Universal tooth numbering system.","Tooth 32 | ",,,,,,,,,,,,,,,"4305593","Structure of permanent mandibular right third molar tooth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227074","Tooth 31","C94585","The lower right 2nd molar, as defined by the Universal tooth numbering system.","Tooth 31 | ",,,,,,,,,,,,,,,"3667161","Structure of permanent mandibular right second molar tooth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1491311","Tooth 2","C94584","The upper right 2nd molar, as defined by the Universal tooth numbering system.","Tooth 2 | ",,,,,,,,,,,,,,,"3667163","Structure of permanent maxillary right second molar tooth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227055","Tooth 18","C94583","The lower left 2nd molar, as defined by the Universal tooth numbering system.","Tooth 18 | ",,,,,,,,,,,,,,,"3667160","Structure of permanent mandibular left second molar tooth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227054","Tooth 17","C94582","The lower left 3rd molar, as defined by the Universal tooth numbering system.","Tooth 17 | ",,,,,,,,,,,,,,,"4251170","Structure of permanent mandibular left third molar tooth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227053","Tooth 16","C94581","The upper left 3rd molar, as defined by the Universal tooth numbering system.","Tooth 16 | ",,,,,,,,,,,,,,,"4227293","Structure of permanent maxillary left third molar tooth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227052","Tooth 15","C94580","The upper left 2nd molar, as defined by the Universal tooth numbering system.","Tooth 15 | ",,,,,,,,,,,,,,,"3667162","Structure of permanent maxillary left second molar tooth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227032","Tooth 1","C94579","The upper right 3rd molar, as defined by the Universal tooth numbering system.","Tooth 1 | ",,,,,,,,,,,,,,,"4239046","Structure of permanent maxillary right third molar tooth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036285","Scarlet Fever","C94575","A streptococcal infection, mainly occurring among children, that is characterized by a red skin rash, sore throat, and fever.","Scarlet Fever | ",,,,,,,,,,,,,,,"141213","Scarlet fever",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2985494","Resorption","C93204","A process in which a substance, such as tissue, is lost by being destroyed and then absorbed by the body.","Resorption | RESORPTION | resorption",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826279","Abnormal Finding","C82547","A decision that an observation or result is outside the parameters considered normal.","Abnormal Finding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707968","Extended Release Dosage Form","C42713","A solid, semi-solid, solution or suspension designed to release active and/or inert ingredient(s) at a controlled, prolonged rate so as to reduce dosing frequency.","Extended Release Dosage Form | ER | Extended Release | Extended Release Dose Form | Extended-Release Profile | XR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041660","Undecylenic Acid","C29530","A natural or synthetic fungistatic fatty acid, antifungal Undecylenic Acid is used topically as a zinc salt in various creams against fungal infections, eczemas, ringworm, and other cutaneous conditions. The zinc provides an astringent action, reducing rawness and irritation.","Undecylenic Acid | Cruex | Desinex | UNDECYLENIC ACID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986712","Study Position","C94847","An assignment to a portion of a study based on a set of criteria that ensures a desired distribution of subjects across all portions of a study.","Study Position | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982754","Bladder Cancer cM0 TNM Finding v7","C89364","Bladder cancer without evidence of distant metastasis. (from AJCC 7th Ed.)","Bladder Cancer cM0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206698","Cholangiocarcinoma","C4436","A carcinoma that arises from the intrahepatic bile ducts, the hepatic ducts, or the common bile duct distal to the insertion of the cystic duct. The vast majority of tumors are adenocarcinomas.","Cholangiocarcinoma | CC | CHOLANGIOCARCINOMA, MALIGNANT | Cholangiocar.- intra/extrahepatic | Cholangiocarcinoma, intrahepatic and extrahepatic bile ducts (adenocarcinoma) | Cholangiocellular Carcinoma | Intrahepatic Bile Duct Cancer (Cholangiocarcinoma) | cholangiocarcinoma | cholangiosarcoma","8160/3","Cholangiocarcinoma",,,,,,,,,,,,,"4321680","Cholangiocarcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334287","Fibrolamellar Carcinoma","C4131","A distinctive type of liver cell carcinoma that arises in non-cirrhotic livers and is seen predominantly in young patients.  The tumor cells are polygonal and deeply eosinophilic, and are embedded in a fibrous stroma.  The prognosis is similar to classical hepatocellular carcinoma that arises in non-cirrhotic livers, and better than hepatocellular carcinoma that arises in cirrhotic livers.","Fibrolamellar Carcinoma | FLC | Fibrolamellar Cancer | Fibrolamellar Carcinoma of Liver Cells | Fibrolamellar Carcinoma of the Liver Cells | Fibrolamellar Hepatocellular Carcinoma | Fibrolamellar Hepatocellular Carcinoma | Hepatocellular Fibrolamellar Carcinoma | Hepatocellular carcinoma, fibrolamellar | Liver Cell Fibrolamellar Carcinoma | Oncocytic Hepatocellular Tumor | Polygonal Cell Type Hepatocellular Carcinoma with Fibrous Stroma","8171/3","Hepatocellular carcinoma, fibrolamellar",,,,,,,,,,,,,"4048870|4099699","Hepatocellular carcinoma, fibrolamellar|Fibrolamellar hepatocellular carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0184930","Loop Electrosurgical Excision","C51760","Uses a thin, low-voltage electrified wire loop to cut out a thin layer of abnormal tissue; generally used to remove abnormal cells on the surface of the cervix.","Loop Electrosurgical Excision | LEEP | Loop Electrosurgical Excision Procedure | loop electrosurgical excision procedure | loop excision",,,,,,,,,,,,,,,"4285815","Loop electrosurgical excision procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1862361","Dystonia","C34563","A movement disorder characterized by sustained or intermittent muscle contractions, resulting in abnormal movements and/or postures.","Dystonia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002736","Amyotrophic Lateral Sclerosis","C34373","A neurodegenerative disorder characterized by progressive degeneration of the motor neurons of the central nervous system. It results in weakness and atrophy of the muscles which leads to an inability to initiate and control voluntary movements.","Amyotrophic Lateral Sclerosis | ALS | Amyotrophic lateral sclerosis | Lou Gehrig Disease",,,,,,,,,,,,,,,"373182","Amyotrophic lateral sclerosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0919377","Homocysteine Acid Measurement","C74741","The determination of the amount of homocysteine amino acid present in a sample.","Homocysteine Acid Measurement | HOMOCY | Homocysteine",,,,,,,,,,,,,,,"4017770|4018331","Homocysteine measurement|Homocystine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2984109","Very Often","C91245","On most occasions, or in most situations.","Very Often | Very often | Very often indeed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3149311","Thyroid Gland Papillary Carcinoma","C4035","A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland.  Radiation exposure is a risk factor and it is the most common malignant thyroid lesion, comprising 75% to 80% of all thyroid cancers in iodine sufficient countries.  Diagnostic procedures include thyroid ultrasound and fine needle biopsy.  Microscopically, the diagnosis is based on the distinct characteristics of the malignant cells, which include enlargement, oval shape, elongation, and overlapping of the nuclei.  The nuclei also display clearing or have a ground glass appearance.","Thyroid Gland Papillary Carcinoma | PTC | Papillary Cancer of Thyroid | Papillary Cancer of Thyroid Gland | Papillary Cancer of the Thyroid | Papillary Cancer of the Thyroid Gland | Papillary Carcinoma of Thyroid | Papillary Carcinoma of Thyroid Gland | Papillary Carcinoma of the Thyroid | Papillary Carcinoma of the Thyroid Gland | Papillary Thyroid Cancer | Papillary Thyroid Carcinoma | Papillary Thyroid Carcinoma, NOS | Papillary Thyroid Gland Carcinoma | Papillary carcinoma of thyroid | Papillary thyroid carcinoma | Thyroid Gland Papillary Cancer | Thyroid Papillary Carcinoma | papillary thyroid cancer",,,,,,,,,,,,,,,"4116228","Papillary thyroid carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1336695","Tall Cell Variant Thyroid Gland Papillary Carcinoma","C35558","A morphologic variant of papillary carcinoma of the thyroid gland characterized by the presence of tall malignant follicular cells, arranged in papillary and trabecular patterns.  Necrotic changes and high mitotic activity are present.","Tall Cell Variant Thyroid Gland Papillary Carcinoma | Tall Cell Variant Papillary Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505075","Invasive Follicular Variant Thyroid Gland Papillary Carcinoma","C7381","A nonencapsulated, infiltrating papillary carcinoma of the thyroid gland characterized by the predominance of follicular structures. The malignant follicular cells display the nuclear features that characterize the papillary adenocarcinomas of the thyroid gland.","Invasive Follicular Variant Thyroid Gland Papillary Carcinoma | Follicular Variant Thyroid Gland Papillary Carcinoma | Follicular Variant Thyroid Gland Papillary Carcinoma, Infiltrative Subtype",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0392197","Warmth","C85500","Having a moderate degree of heat.","Warmth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021005","Immunogenetics","C16715","A sub-field of genetics that uses both genetic and immunological analyses to study the genetics behind antibody formation and the immune response. (Biotech Life Science Dictionary)","Immunogenetics | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003316","Epitope","C13189","The simplest form of an antigenic determinant, on a complex antigenic molecule, which can combine with antibody or T cell receptor.","Epitope | Antigenic Determinant | Antigenic Determinants | Binding Determinants | epitope",,,,,,,,,,,,,,,"4178594","Epitope",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031715","Phosphorylation Process","C16983","The creation of a phosphate derivative of an organic molecule. This is usually achieved by transferring a phosphate group from ATP via the action of a kinase.","Phosphorylation Process | Phosphorylation | phosphorylation",,,,,,,,,,,,,,,"4181210","Phosphorylation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028959","Oligosaccharide","C714","A carbohydrate comprised of three to ten monosaccharides joined by ether bridges (covalent bonds centered by an oxygen).","Oligosaccharide | Oligosaccharides",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522225","Knock-out","C22491","Inactivation of specific genes by homologous recombination. Knockouts are often created in laboratory organisms such as yeast or mice so that scientists can study the knockout organism as a model for a particular disease.","Knock-out | Knockout",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278626","Thoracic Surgeon","C17836","A surgeon who specializes in treatment of diseases and disorders of the chest, heart and lungs.","Thoracic Surgeon | Chest Surgeon | surgeon, chest | surgeon, thoracic | thoracic surgeon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3161472","Cellular Membrane","C14070","Any of the lipid bilayer membranes within a cell.","Cellular Membrane | Cell Membrane",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439505","Per Day","C66968","A frequency rate of occurrences of something within a period of time equal to twenty-four hours.","Per Day | Per 24 Hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1948033","Proposal (document)","C60762","A suggestion, intention or plan, especially one put forward formally or officially.","Proposal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710234","Subsite","C45966","A position within another named site.","Subsite | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828392","Standard (document)","C81893","A document, established by consensus and approved by a recognized body, that provides, for common and repeated use, rules, guidelines or characteristics for activities or their results.","Standard | standard | technical standard",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699007","Rationale","C80263","An explanation of the fundamental reasons.","Rationale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677898","Invasive Malignant Neoplasm","C8505","Cancer that has spread beyond the layer of tissue in which it developed and is growing into surrounding, healthy tissues.","Invasive Malignant Neoplasm | Infiltrating Malignant Neoplasm | infiltrating cancer | invasive cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1457900","Each","C64933","Used to refer to every member of a group of people or things, considered individually.","Each | EA",,,,,,,,,,,,,,,"4304901","Each",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1956962","Xeloda-Oxaliplatin Regimen","C63597","A regimen consisting of capecitabine and oxaliplatin used for the treatment of advanced stage colorectal cancer. This regimen differs from a similar regimen, CAPOX, with regards to the dosing schedule for oxaliplatin.","XELOX Regimen | CapeOx | Capecitabine/Oxaliplatin | XELOX | XELOX regimen | Xeloda-Oxaliplatin Regimen | Xeloda/Oxaliplatin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018528","Hallucinogen Dependence","C34657","A drug dependence for a hallucinogenic substance.","Hallucinogen Dependence | ",,,,,,,,,,,,,,,"433180","Hallucinogen dependence",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002658","Amphetamine","C62006","A synthetic substance related to natural sympathomimetic amines. Amphetamine appears to exert its central nervous system (CNS) and peripheral effects indirectly by inducing the release of biogenic amines from their storage sites in nerve terminals. This agent is a commonly abused psychostimulant drug, which may be snorted, taken orally, smoked, or injected.  Amphetamine induces psychologic dependence which is manifested by elevated mood, increased wakefulness, concentration, physical performance and a feeling of well-being. With sustained use, the effects of tachycardia and enhanced alertness diminish while psychotoxic effects such as hallucinations and delusions may occur. (NCI04)","Amphetamine | AMPHETAMINE | Amfetamine | Benzedrine | Desoxynorephedrine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221757","Alpha-1 Antitrypsin Deficiency","C84397","A genetic disorder characterized by decreased alpha-1 antitrypsin activity in the lungs and blood and deposition of alpha-1 antitrypsin protein in the hepatocytes. These abnormalities result from defective production of alpha-1 antitrypsin and lead to the development of emphysema, cirrhosis, and liver failure.","Alpha-1 Antitrypsin Deficiency | A-1ATD | A1AD | Alpha 1-Antitrypsin Disease | Alpha-1 Antitrypsin | Alpha-1-Antitrypsin Deficiency",,,,,,,,,,,,,,,"192275","Alpha-1-antitrypsin deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0400966","Nonalcoholic Fatty Liver Disease","C84444","A term referring to fatty replacement of the hepatic parenchyma which is not related to alcohol use.","Nonalcoholic Fatty Liver Disease | NAFLD - Nonalcoholic Fatty Liver Disease | Non-Alcoholic Fatty Liver Disease",,,,,,,,,,,,,,,"37164766","Non-alcoholic fatty liver disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018995","Hereditary Hemochromatosis","C84481","An inherited metabolic disorder characterized by iron accumulation in the tissues.","Hereditary Hemochromatosis | Hemochromatosis | Primary Hemochromatosis",,,,,,,,,,,,,,,"4148231","Hereditary hemochromatosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2986928","Interlaboratory","C95130","Involving cooperation between labs.","Interlaboratory | Inter-laboratory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986929","Intralaboratory","C95131","Occurring within a single lab.","Intralaboratory | Intra-laboratory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021067","Immunoperoxidase Procedure","C95132","An immunological procedure in which antibodies are coupled with a peroxidase molecule. Following localization via the antibody, the peroxidase is reacted with a corresponding substrate to produce a product which can be seen with a light microscope.","Immunoperoxidase Procedure | Immunoperoxidase | Immunoperoxidase Staining",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831905","Eltrombopag","C71634","An orally active thrombopoietin receptor agonist with megakaryopoiesis stimulating activity. Eltrombopag binds to and stimulates the platelet thrombopoietin receptor (TPO-R or CD110), a member of the hematopoietin receptor superfamily. Activation of TPO-R leads to the proliferation and differentiation of megakaryocytes, thereby increasing the production of blood platelets.","Eltrombopag | ELTROMBOPAG | eltrombopag",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0937932","Rasburicase","C2404","A recombinant urate oxidase enzyme isolated from a genetically-modified strain of Saccharomyces cerevisiae.  Urate oxidase catalyzes the oxidation of uric acid to the excretable metabolite allantoin, a molecule that is 5-10 times more water-soluble than uric acid.  An enzyme that occurs endogenously in most mammals, urate oxidase is not found in humans. (NCI04)","Rasburicase | Elitek | RASBURICASE | Recombinant Urate Oxidase | SR 29142 | SR-29142 | Urate Oxidase | rasburicase | recombinant urate oxidase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020987","Immunocompetence","C28159","The ability of lymphoid cells to mount a humoral or cellular immune response when challenged by antigen.","Immunocompetence | immunocompetence",,,,,,,,,,,,,,,"4148698","Immunologic competence",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021069","Immunoprecipitation","C16724","Antigen aggregation with antibody, in the right ratios, to cause precipitation.","Immunoprecipitation | IMMUNOPRECIPITATION | IP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0736268","Hepatic Tissue","C32735","The tissue of the liver. It includes the hepatic lobules, hepatic sinusoids, perisinusoidal spaces, and portal triad. The hepatic lobules are composed of hepatocytes.","Hepatic Tissue | Hepatic Parenchyma | Liver Tissue",,,,,,,,,,,,,,,"4027893|4120372","Structure of parenchyma of liver|Liver tissue",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL408815","Causality","C82552","The principle that a relationship exists between a primary entity A, or cause, and the occurrence of a secondary entity B, or effect.","Causality | CausalAssessment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985233","Processor","C92651","A person, enterprise, or entity that prepares products for marketing or distribution.","Processor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1372955","Active ingredient","C82533","The pharmaceutically active components of a preparation.","Active Ingredient | INGRD | active ingredient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348552","Study Activity","C71473","An action, undertaking, or event, which is anticipated to be performed or was performed according to the study protocol during the execution of the study.","Study Activity | StudyActivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698909","Protocol Milestone","C74588","Occurrences within some epochs that are initiated by a protocol-specified event. The most common protocol milestone is 'Informed Consent Obtained' which usually documents the start of the study.","Protocol Milestone | PROTOCOL MILESTONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1273803","Regulatory Authority","C88081","A geopolitical organization responsible for regulating products used in health care.","Regulatory Authority | REGULATORY AUTHORITY | RegulatoryAuthority | health authority | regulatory authorities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983136","Territory","C89811","A geographical area under the jurisdiction of a sovereign state and marked off for administrative or other purposes.","Territory | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0870992","Observer","C92650","A person, organization, or device that makes an observation.","Observer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0920350","Lymphocytic Thyroiditis","C38766","An inflammatory disorder that affects the thyroid gland.  It is characterized by the infiltration of the thyroid parenchyma by lymphocytes.  It includes Hashimoto thyroiditis and subacute lymphocytic thyroiditis.","Lymphocytic Thyroiditis | ",,,,,,,,,,,,,,,"4281109","Autoimmune thyroiditis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2703171","Olaratumab","C79825","A fully human IgG1 monoclonal antibody directed against the platelet-derived growth factor receptor alpha (PDGFR alpha) with potential antineoplastic activity. Anti-PDGFR alpha monoclonal antibody IMC-3G3 selectively binds to PDGFR alpha, .blocking the binding of its ligand, PDGF; signal transduction downstream of PDGFR through the MAPK and PI3K pathways is inhibited, which may result in inhibition of angiogenesis and tumor cell proliferation. Overexpressed by various cancer cell types, PDGFR is a transmembrane protein tyrosine kinase receptor, consisting of isoforms A and B that is important in regulating cellular growth and differentiation and angiogenesis.","Olaratumab | Anti-PDGFR alpha Monoclonal Antibody IMC-3G3 | Anti-PDGFR alpha Monoclonal Antibody IMC-3G3 | Anti-Platelet-Derived Growth Factor Receptor alpha Monoclonal Antibody IMC-3G3 | IMC-3G3 | LY 3012207 | LY-3012207 | LY3012207 | Lartruvo | OLARATUMAB | anti-PDGFR alpha monoclonal antibody IMC-3G3 | anti-platelet-derived growth factor receptor alpha monoclonal antibody IMC-3G3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883337","Thyroid Cancer pTX TNM Finding v6 and v7","C60860","Thyroid cancer in which the primary tumor cannot be assessed. (from AJCC 6th and 7th Eds.)","Thyroid Cancer pTX TNM Finding v6 and v7 | Thyroid Cancer pTX TNM Finding | Thyroid Cancer pTX TNM Finding | Thyroid Cancer pTX TNM Finding v6 | Thyroid Cancer pTX TNM Finding v7 | pTX Cancer of the Thyroid | pTX Thyroid Cancer TNM Finding | pTX Thyroid Carcinoma TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2315881","I-131 Uptake Test","C38088","A type of nuclear test of the thyroid that measures how much radioactive iodine is taken up by the thyroid gland in a given time period. This test is performed to evaluate thyroid function, particularly when blood tests of thyroid function (for example, T3 or T4 levels) have abnormal results. (from Medline Plus Medical Encyclopedia)","I-131 Uptake Test | I 131 Uptake | I-131 Uptake and Scan | Radioactive Iodine Uptake",,,,,,,,,,,,,,,"35622415","Radionuclide imaging of thyroid using iodine radioisotope",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003256","Avidity","C16297","Strength of binding, usually of a small molecule with multiple binding sites by a larger, particularly the binding of a complex antigen by an antibody.","Avidity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826759","Electrocardiogram Time","C83151","The time at which the electrocardiogram assessment took place.","Electrocardiogram Time | EGTIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0262923","Urine Protein Measurement","C74760","The determination of the amount of protein present in a urine sample.","Urine Protein Measurement | ",,,,,,,,,,,,,,,"4211845","Urine protein measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1880451","Mean QRS Duration","C62087","The average (mean) duration (time) of the QRS interval, obtained from a set of measurements of the QRS interval. The QRS interval is defined as the time from the beginning of the QRS complex to the end of the QRS complex, representing the time it takes for the ventricles to depolarize.","Mean QRS Duration | EKG Mean QRS Duration | Mean QRS duration, ms | Summary (Mean) QRS Duration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347724","QTcB Prolongation Greater Than 500 msec","C71096","Corrected QT interval longer than 500 msec, in accordance with Bazett's correction formula.","QTcB Prolongation Greater Than 500 msec | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335597","RAS Family Gene","C25784","A family of genes that encode structurally similar small GTPases involved in a variety of signal transduction pathways. Mutation of genes in this family is associated with cancer.","RAS Family Gene | RAS, NOS | ras gene family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709815","RET/PTC Rearrangement","C46005","A gene rearrangement involving the RET proto-oncogene. RET gene rearrangements are associated with several different neoplastic conditions.","RET/PTC Rearrangement | Positive | RET Gene Rearrangement | RET Rearrangement | Rearrangement identified | Ret Proto-Oncogene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831796","Pazopanib","C74547","A small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.","Pazopanib | Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl- | GW786034 | PAZOPANIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003486","Aortic Aneurysm","C26697","A sac formation resulting from the localized dilatation of the wall of the aorta.","Aortic Aneurysm | Aortic aneurysm",,,,,,,,,,,,,,,"317585","Aortic aneurysm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0340643","Aortic Dissection","C50461","A progressive tear in the tissue lining the aorta, characterized by the passage of blood from the tunica intima into, and partially through, the tunica media.","Aortic Dissection | Aortic dissection | Dissection of unspecified site of aorta",,,,,,,,,,,,,,,"320739","Dissection of aorta",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3549860","Uterine Corpus Leiomyosarcoma","C6340","An aggressive malignant smooth muscle neoplasm, arising from the uterine corpus.  It is characterized by a proliferation of neoplastic spindle cells.","Uterine Corpus Leiomyosarcoma | Body of Uterus Leiomyosarcoma | Corpus Uteri Leiomyosarcoma | Leiomyosarcoma - uterus | Leiomyosarcoma of Body of Uterus | Leiomyosarcoma of Corpus Uteri | Leiomyosarcoma of Uterine Body | Leiomyosarcoma of Uterine Corpus | Leiomyosarcoma of Uterus | Leiomyosarcoma of the Body of Uterus | Leiomyosarcoma of the Corpus Uteri | Leiomyosarcoma of the Uterine Body | Leiomyosarcoma of the Uterine Corpus | Leiomyosarcoma of the Uterus | Leiomyosarcoma of the uterus | Uterine Body Leiomyosarcoma",,,,,,,,,,,,,,,"36674730|40492385","Leiomyosarcoma of corpus uteri|Leiomyosarcoma of uterus",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0038257","Stent Device","C50190","A device designed to support a tubular structure, especially the small stainless steel expandable mesh tube inserted within an artery.","Stent Device | Stent | Stent | Stent Device Component | Stent used | stent",,,,,,,,,,,,,,,"4280677","Stent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1881855","Minimal Invasion Present","C65201","A morphologic finding indicating the infiltration of the stroma immediately adjacent to a carcinoma in situ by isolated malignant cells or small groups of malignant cells.","Minimal Invasion Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826293","Clinical Significance","C82562","A finding that has treatment or management implications for a patient's condition.","Clinical Significance | clinical significance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986961","FIGO Stage IIA1 Cervical Carcinoma","C95172","Stage IIA1 includes: T2a1, N0, M0.  Tumor invades beyond uterus but no to pelvic wall or to lower third of vagina. No parametrial invasion.  T2a1: Clinically visible lesion 4.0 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IIA1 Cervical Cancer AJCC v7 | FIGO Stage IIA1 Cervical Carcinoma | Stage IIA1 Cervical Cancer | Stage IIA1 Cervical Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986962","FIGO Stage IIA2 Cervical Carcinoma","C95173","Stage IIA2 includes: T2a2, N0, M0.  Tumor invades beyond uterus but no to pelvic wall or to lower third of vagina. No parametrial invasion.  T2a2: Clinically visible lesion more than 4.0 cm in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IIA2 Cervical Cancer AJCC v7 | FIGO Stage IIA2 Cervical Carcinoma | Stage IIA2 Cervical Cancer | Stage IIA2 Cervical Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986963","Stage IIIC1 Uterine Corpus Cancer AJCC v7","C95174","Stage IIIC1 includes: T1-T3, N1, M0.  T1: Tumor confined to corpus uteri.  T2: Tumor invades stromal connective tissue of the cervix but does not extend beyond uterus.  T3: Tumor involves serosa and/or adnexa, vagina, or parametrial tissue. N1: Regional lymph node metastasis to pelvic lymph nodes. M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","Stage IIIC1 Uterine Corpus Cancer AJCC v7 | Stage IIIC1 Uterine (including Endometrial) Cancer | Stage IIIC1 Uterine Corpus Cancer | Stage IIIC1 Uterine Corpus Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986965","Stage IIIC2 Uterine Corpus Cancer AJCC v7","C95176","Stage IIIC2 includes: T1-T3, N2, M0. T1: Tumor confined to corpus uteri.  T2: Tumor invades stromal connective tissue of the cervix but does not extend beyond uterus.  T3: Tumor involves serosa and/or adnexa, vagina, or parametrial tissue.  N2: Regional lymph node metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes.  M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","Stage IIIC2 Uterine Corpus Cancer AJCC v7 | Stage IIIC2 Uterine (including Endometrial) Cancer | Stage IIIC2 Uterine Corpus Cancer | Stage IIIC2 Uterine Corpus Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0191342","Debridement of Wound of Skin","C51905","A procedure to remove dead tissue or foreign material from a skin wound to expose underlying healthy tissue and to promote healing.","Debridement of Wound of Skin | Debridement of Wound",,,,,,,,,,,,,,,"4311933","Debridement of wound of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2713339","Alpha-Lipoic Acid","C61595","A naturally occurring micronutrient, synthesized in small amounts by plants and animals (including humans), with antioxidant and potential chemopreventive activities. Alpha-lipoic acid acts as a free radical scavenger and assists in repairing oxidative damage and regenerates endogenous antioxidants, including vitamins C and E and glutathione. This agent also promotes glutathione synthesis. In addition, alpha-lipoic acid exerts metal chelating capacities and functions as a cofactor in various mitochondrial enzyme complexes involved in the decarboxylation of alpha-keto acids.","Alpha-Lipoic Acid | 5-(1,2-Dithiolan-3-yl)pentanoic Acid | 6,8-Thioctic Acid | ALPHA LIPOIC ACID | Lipoic Acid | Thioctate | Thioctic Acid | alpha-lipoic acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279000","Liver Carcinoma","C7927","A carcinoma that arises from the hepatocytes or intrahepatic bile ducts.  The main subtypes are hepatocellular carcinoma (hepatoma) and cholangiocarcinoma.","Liver Carcinoma | Biliary Tract Cancer | Cancer of Liver | Cancer of Liver and Intrahepatic Bile Duct | Cancer of Liver and Intrahepatic Biliary Tract | Cancer of the Liver | Cancer of the Liver and Intrahepatic Biliary Tract | Liver Cancer | Liver Carcinoma | Liver and Intrahepatic Bile Duct Cancer | Liver and Intrahepatic Bile Duct Carcinoma | Liver and Intrahepatic Bile Duct Carcinoma | Liver and Intrahepatic Biliary Tract Cancer | Liver and Intrahepatic Biliary Tract Carcinoma | Liver and Intrahepatic Biliary Tract Carcinoma | Liver and hepatobiliary cancer, NOS | Liver/hepatobiliary cancer | Primary Liver Carcinoma | liver cancer",,,,,,,,,,,,,,,"37162059","Primary liver cell carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1881430","Liver Cancer pT3 TNM Finding v6","C61173","Liver cancer with multiple tumors at least one of which is more than 5 cm in size, or a tumor involving a major branch of the portal or hepatic vein. (from AJCC 6th Ed.)","Liver Cancer pT3 TNM Finding v6 | pT3 Cancer of the Liver TNM Finding v6 | pT3 Carcinoma of the Liver TNM Finding v6 | pT3 Liver Carcinoma TNM Finding v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983409","Liver Cancer pT4 TNM Finding v7","C90163","Liver cancer with tumor(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of visceral peritoneum. (from AJCC 7th Ed.)","Liver Cancer pT4 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983408","Liver Cancer pT3b TNM Finding v7","C90162","Liver cancer with single tumor or multiple tumors of any size involving a major branch of the portal vein or hepatic vein. (from AJCC 7th Ed.)","Liver Cancer pT3b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983407","Liver Cancer pT3a TNM Finding v7","C90161","Liver cancer with multiple tumors more than 5 cm in greatest dimension. (from AJCC 7th Ed.)","Liver Cancer pT3a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983406","Liver Cancer pT2 TNM Finding v7","C90160","Liver cancer with solitary tumor with vascular invasion or multiple tumors none more than 5 cm in greatest dimension. (from AJCC 7th Ed.)","Liver Cancer pT2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983405","Liver Cancer pT1 TNM Finding v7","C90159","Liver cancer with solitary tumor without vascular invasion. (from AJCC 7th Ed.)","Liver Cancer pT1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983404","Liver Cancer pT0 TNM Finding v7","C90158","Liver cancer with no evidence of a primary tumor. (from AJCC 7th Ed.)","Liver Cancer pT0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983403","Liver Cancer pTX TNM Finding v7","C90156","Liver cancer in which the primary tumor cannot be assessed. (from AJCC 7th Ed.)","Liver Cancer pTX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983413","Liver Cancer pN1 TNM Finding v7","C90167","Liver cancer with regional lymph node metastasis. (from AJCC 7th Ed.)","Liver Cancer pN1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983412","Liver Cancer pN0 TNM Finding v7","C90166","Liver cancer with no regional lymph node metastasis. (from AJCC 7th Ed.)","Liver Cancer pN0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983411","Liver Cancer pNX TNM Finding v7","C90165","Liver cancer in which regional lymph nodes cannot be assessed. (from AJCC 7th Ed.)","Liver Cancer pNX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983416","Liver Cancer pM1 TNM Finding v7","C90170","Liver cancer with distant metastasis. (from AJCC 7th Ed.)","Liver Cancer pM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881423","Liver Cancer pMX TNM Finding v6","C61178","Liver cancer in which distant metastasis cannot be assessed. (from AJCC 6th Ed.)","Liver Cancer pMX TNM Finding v6 | pMX Cancer of the Liver TNM Finding v6 | pMX Carcinoma of the Liver TNM Finding v6 | pMX Liver Carcinoma TNM Finding v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881421","Liver Cancer pM0 TNM Finding","C61179","Liver cancer with no evidence of distant metastasis. (from AJCC 6th Ed.)","Liver Cancer pM0 TNM Finding | pM0 Cancer of the Liver TNM Finding | pM0 Carcinoma of the Liver TNM Finding | pM0 Liver Carcinoma TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336369","Stage IVB Hepatocellular Carcinoma AJCC v7","C5765","Stage IVB includes: Any T, Any N, M1.  M1: Distant metastasis. (AJCC 7th ed.)","Stage IVB Hepatocellular Carcinoma AJCC v7 | Stage IVB Carcinoma of Liver Cells | Stage IVB Carcinoma of the Liver Cells | Stage IVB Hepatocellular Cancer | Stage IVB Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage IVB Liver Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336339","Stage IVA Hepatocellular Carcinoma AJCC v7","C5764","Stage IVA includes: Any T, N1, M0.  N1: Regional lymph node metastasis. M0: No distant metastasis.  (AJCC 7th ed.)","Stage IVA Hepatocellular Carcinoma AJCC v7 | Stage IVA Hepatocellular Cancer | Stage IVA Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVA Liver Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983424","Stage IV Hepatocellular Carcinoma AJCC v7","C90181","Stage IV includes: IVA: (Any T, N1, M0); IVB: (Any T, Any N, M1). N1: Regional lymph node metastasis. M0: No distant metastasis.  M1: Distant metastasis. (AJCC 7th ed.)","Stage IV Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Cancer | Stage IV Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981620","Stage IIIC Hepatocellular Carcinoma AJCC v7","C88044","Stage IIIC includes: T4, N0, M0.  T4: Tumors(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of visceral peritoneum. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)","Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Cancer | Stage IIIC Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | stage IIIC adult primary liver cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336223","Stage IIIB Hepatocellular Carcinoma AJCC v7","C5762","Stage IIIB includes: T3b, N0, M0. T3b: Single tumor or multiple tumors of any size involving a major branch of the portal vein or hepatic vein.  N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)","Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIB Carcinoma of Liver Cells | Stage IIIB Carcinoma of the Liver Cells | Stage IIIB Hepatocellular Cancer | Stage IIIB Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIB Liver Cancer | Stage IIIB Liver Carcinoma | Stage IIIB Liver Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336208","Stage IIIA Hepatocellular Carcinoma AJCC v7","C5761","Stage IIIA includes: T3a, N0, M0.  T3a: Multiple tumors more than 5 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)","Stage IIIA Hepatocellular Carcinoma AJCC v7 | Stage IIIA Carcinoma of Liver Cells | Stage IIIA Carcinoma of the Liver Cells | Stage IIIA Hepatocellular Cancer | Stage IIIA Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIA Liver Cancer | Stage IIIA Liver Carcinoma | Stage IIIA Liver Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336296","Stage II Liver Cancer","C7117","Stage II carcinoma of the liver according to the American Joint Committee on Cancer, 6th, 7th, and 8th editions.","Stage II Liver Cancer | Stage II Liver Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336462","Stage I Liver Carcinoma","C7116","Stage I carcinoma of the liver according to the American Joint Committee on Cancer, 6th, 7th, and 8th editions.","Stage I Liver Cancer | Stage I Liver Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982582","Thyroid Cancer pT4b TNM Finding v7","C89152","Thyroid cancer with very advanced disease.  Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels.  (from AJCC 7th Ed.)","Thyroid Cancer pT4b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982580","Thyroid Cancer pT4a TNM Finding v7","C89150","Thyroid cancer with moderately advanced local disease.  Tumor of any size extending beyond the thyroid gland capsule to invade subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve. (from AJCC 7th Ed.)","Thyroid Cancer pT4a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883332","Thyroid Cancer pT4 TNM Finding v6","C60865","Thyroid cancer with any size tumor extending beyond the thyroid gland capsule to invade subcutaneous soft tissues, larynx, trachea, esophagus, recurrent laryngeal nerve, prevertebral fascia, or encasing the carotid artery or mediastinal vessels. All anaplastic carcinomas are also classified as pT4, with separate subclassification. (from AJCC 6th Ed.)","Thyroid Cancer pT4 TNM Finding v6 | pT4 Cancer of the Thyroid v6 | pT4 Carcinoma of the Thyroid TNM Finding v6 | pT4 Thyroid Cancer TNM Finding v6 | pT4 Thyroid Carcinoma TNM Finding v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883331","Thyroid Cancer pT3 TNM Finding v6 and v7","C60864","Thyroid cancer with a tumor size greater than 4 cm in greatest dimension and limited to the thyroid gland, or a tumor of any size with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues).  (from AJCC 6th and 7th Eds.)","Thyroid Cancer pT3 TNM Finding v6 and v7 | Thyroid Cancer pT3 TNM Finding | Thyroid Cancer pT3 TNM Finding | Thyroid Cancer pT3 TNM Finding v6 | Thyroid Cancer pT3 TNM Finding v7 | pT3 Cancer of the Thyroid | pT3 Carcinoma of the Thyroid TNM Finding | pT3 Thyroid Cancer TNM Finding | pT3 Thyroid Carcinoma TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883330","Thyroid Cancer pT2 TNM Finding v6 and v7","C60863","Thyroid cancer with a tumor size greater than 2 cm but not more than 4 cm in greatest dimension, and limited to the thyroid gland. (from AJCC 6th and 7th Eds.)","Thyroid Cancer pT2 TNM Finding v6 and v7 | Thyroid Cancer pT2 TNM Finding | Thyroid Cancer pT2 TNM Finding | Thyroid Cancer pT2 TNM Finding v6 | Thyroid Cancer pT2 TNM Finding v7 | pT2 Cancer of the Thyroid | pT2 Carcinoma of the Thyroid TNM Finding | pT2 Thyroid Cancer TNM Finding | pT2 Thyroid Carcinoma TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982578","Thyroid Cancer pT1a TNM Finding v7","C89148","Thyroid cancer with a tumor size of 1 cm or less in greatest dimension, limited to the thyroid gland. (from AJCC 7th Ed.)","Thyroid Cancer pT1a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883329","Thyroid Cancer pT1 TNM Finding v6 and v7","C60862","Thyroid cancer with a tumor size of 2 cm or less in greatest dimension, and limited to the thyroid gland. (from AJCC 6th and 7th Eds.)","Thyroid Cancer pT1 TNM Finding v6 and v7 | Thyroid Cancer pT1 TNM Finding | Thyroid Cancer pT1 TNM Finding | Thyroid Cancer pT1 TNM Finding v6 | Thyroid Cancer pT1 TNM Finding v7 | pT1 Cancer of the Thyroid | pT1 Carcinoma of the Thyroid TNM Finding | pT1 Thyroid Cancer TNM Finding | pT1 Thyroid Carcinoma TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883328","Thyroid Cancer pT0 TNM Finding v6 and v7","C60861","Thyroid cancer with no evidence of primary tumor. (from AJCC 6th and 7th Eds.).","Thyroid Cancer pT0 TNM Finding v6 and v7 | Thyroid Cancer pT0 TNM Finding | Thyroid Cancer pT0 TNM Finding | Thyroid Cancer pT0 TNM Finding v6 | Thyroid Cancer pT0 TNM Finding v7 | pT0 Cancer of the Thyroid | pT0 Carcinoma of the Thyroid TNM Finding | pT0 Thyroid Cancer TNM Finding | pT0 Thyroid Carcinoma TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982585","Thyroid Cancer pN1b TNM Finding v7","C89155","Thyroid cancer with metastasis to unilateral, bilateral or contralateral cervical (Levels I, II, III, IV, or V) or retropharyngeal or superior mediastinal lymph nodes (Level VII). (from AJCC 7th Ed.)","Thyroid Cancer pN1b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883325","Thyroid Cancer pN1a TNM Finding v6 and v7","C60874","Thyroid cancer with metastasis to pretracheal, paratracheal or prelaryngeal/Delphian lymph nodes (Level VI lymph nodes). (from AJCC 6th and 7th Eds.)","Thyroid Cancer pN1a TNM Finding v6 and v7 | Thyroid Cancer pN1a TNM Finding | Thyroid Cancer pN1a TNM Finding | Thyroid Cancer pN1a TNM Finding v6 | Thyroid Cancer pN1a TNM Finding v7 | pN1a Cancer of Thyroid | pN1a Carcinoma of Thyroid | pN1a Carcinoma of the Thyroid TNM Finding | pN1a Thyroid Cancer | pN1a Thyroid Cancer TNM Finding | pN1a Thyroid Carcinoma | pN1a Thyroid Carcinoma TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883324","Thyroid Cancer pN1 TNM Finding v6 and v7","C60873","Thyroid cancer with metastasis to regional lymph nodes. (from AJCC 6th and 7th Eds.)","Thyroid Cancer pN1 TNM Finding v6 and v7 | Thyroid Cancer pN1 TNM Finding | Thyroid Cancer pN1 TNM Finding | Thyroid Cancer pN1 TNM Finding v6 | Thyroid Cancer pN1 TNM Finding v7 | pN1 Cancer of Thyroid | pN1 Carcinoma of Thyroid | pN1 Carcinoma of the Thyroid TNM Finding | pN1 Thyroid Cancer | pN1 Thyroid Cancer TNM Finding | pN1 Thyroid Carcinoma | pN1 Thyroid Carcinoma TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883323","Thyroid Cancer pN0 TNM Finding v6 and v7","C60871","Thyroid cancer with no regional lymph node metastasis. (from AJCC 6th and 7th Eds.)","Thyroid Cancer pN0 TNM Finding v6 and v7 | Thyroid Cancer pN0 TNM Finding | Thyroid Cancer pN0 TNM Finding | Thyroid Cancer pN0 TNM Finding v6 | Thyroid Cancer pN0 TNM Finding v7 | pN0 Thyroid Cancer | pN0 Thyroid Carcinoma | pTX Carcinoma of the Thyroid TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883327","Thyroid Cancer pNX TNM Finding v6 and v7","C60872","Thyroid cancer in which regional lymph nodes cannot be assessed. (from AJCC 6th and 7th Eds.)","Thyroid Cancer pNX TNM Finding v6 and v7 | Thyroid Cancer pNX TNM Finding | Thyroid Cancer pNX TNM Finding | Thyroid Cancer pNX TNM Finding v6 | Thyroid Cancer pNX TNM Finding v7 | pNX Cancer of Thyroid | pNX Carcinoma of Thyroid | pNX Carcinoma of the Thyroid TNM Finding | pNX Thyroid Cancer | pNX Thyroid Cancer TNM Finding | pNX Thyroid Carcinoma | pNX Thyroid Carcinoma TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883321","Thyroid Cancer pM1 TNM Finding v6 and v7","C60798","Thyroid cancer with distant metastasis. (from AJCC 6th and 7th Eds.)","Thyroid Cancer pM1 TNM Finding v6 and v7 | Thyroid Cancer pM1 TNM Finding | Thyroid Cancer pM1 TNM Finding | Thyroid Cancer pM1 TNM Finding v6 | Thyroid Cancer pM1 TNM Finding v7 | pM1 Cancer of the Thyroid | pM1 Carcinoma of the Thyroid | pM1 Thyroid Cancer | pM1 Thyroid Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883320","Thyroid Cancer pM0 TNM Finding","C60797","Thyroid cancer with no evidence of distant metastasis. (from AJCC 6th Ed.)","Thyroid Cancer pM0 TNM Finding | pM0 Cancer of the Thyroid | pM0 Carcinoma of the Thyroid | pM0 Thyroid Cancer | pM0 Thyroid Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883322","Thyroid Cancer pMX TNM Finding v6","C60799","Thyroid cancer in which the status of distant metastasis cannot be assessed. (from AJCC 6th Ed.)","Thyroid Cancer pMX TNM Finding v6 | pMX Cancer of the Thyroid v6 | pMX Carcinoma of the Thyroid v6 | pMX Thyroid Cancer v6 | pMX Thyroid Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986945","Ishak Score","C95149","A scoring system described by Dr. Ishak and colleagues that assesses the histopathologic degree of liver damage.","Ishak Score | ISHAK FIBROSIS SCORE | ISHAK Fibrosis Score | Ishak Classification | Ishak Fibrosis Score | Ishtak Classification | ishak fibrosis score | ishak_fibrosis_score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986946","Ishak Score 0","C95150","No evidence of fibrosis.","Ishak Score 0 | 0 (No Fibrosis) | 0 - No Fibrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986947","Ishak Score 1","C95151","Minimal fibrosis in some portal areas.","Ishak Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986949","Ishak Score 3","C95153","Fibrosis extends beyond the portal areas. Occasional portal to portal bridging fibrosis is present.","Ishak Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986948","Ishak Score 2","C95152","Minimal fibrosis in most portal areas.","Ishak Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986950","Ishak Score 4","C95154","Marked bridging fibrosis (portal to portal and porto-central) is present.","Ishak Score 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986951","Ishak Score 5","C95155","Marked bridging fibrosis with formation of occasional hepatic nodules is present.","Ishak Score 5 | 5 (Nodular Formation and Incomplete Cirrhosis) | 5 - Nodular Formation and Incomplete Cirrhosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986952","Ishak Score 6","C95156","Marked fibrosis with cirrhosis is present.","Ishak Score 6 | 6 (Established Cirrhosis) | 6 - Established Cirrhosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3551790","Migraine","C89715","A common, severe type of vascular headache often associated with increased sympathetic activity, resulting in nausea, vomiting, and light sensitivity.","Migraine | Migraine Headache",,,,,,,,,,,,,,,"318736","Migraine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019558","Hip Joint","C32742","A ball-and-socket joint between the head of the femur and the acetabulum.","Hip Joint | Coxofemoral Joint | HIP JOINT | Hip (proximal femur) | Hip joint structure (body structure) | JOINT, HIP","C41.4","Hip joint",,,,,,,,,,,,,"4082516","Hip joint structure",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C2981278","Undifferentiated (Anaplastic) Stage IVC Thyroid Gland Cancer","C87554","Stage IVC includes: Any T, Any N, M1.  M1: Distant metastasis.  (AJCC 7th ed.)","Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v7 | Stage IVC Thyroid Gland Undifferentiated (Anaplastic) Carcinoma | Stage IVC Thyroid Gland Undifferentiated (Anaplastic) Carcinoma AJCC v7 | Undifferentiated (Anaplastic) Stage IVC Thyroid Gland Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981275","Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7","C87551","Stage IVC includes: Any T, Any N, M1.  M1: Distant metastasis.  (AJCC 7th ed.)","Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7 | Stage IVC Thyroid Gland Medullary Cancer | Stage IVC Thyroid Gland Medullary Carcinoma | Stage IVC Thyroid Gland Medullary Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981277","Undifferentiated (Anaplastic) Stage IVB Thyroid Gland Cancer","C87553","Stage IVB includes: T4b, Any N, M0.  T4b: Anaplastic carcinoma with gross extrathyroid extension.  M0: No distant metastasis.  (AJCC 7th ed.)","Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v7 | Stage IVB Thyroid Gland Undifferentiated (Anaplastic) Carcinoma | Stage IVB Thyroid Gland Undifferentiated (Anaplastic) Carcinoma AJCC v7 | Undifferentiated (Anaplastic) Stage IVB Thyroid Gland Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981274","Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7","C87550","Stage IVB includes: T4b, Any N, M0.  T4b: Very advanced disease.  Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels.  M0: No distant metastasis.  (AJCC 7th ed.)","Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7 | Stage IVB Thyroid Gland Medullary Cancer | Stage IVB Thyroid Gland Medullary Carcinoma | Stage IVB Thyroid Gland Medullary Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981276","Undifferentiated (Anaplastic) Stage IVA Thyroid Gland Cancer","C87552","Stage IVA includes: T4a, Any N, M0.  T4a: Intrathyroidal anaplastic carcinoma. M0: No distant metastasis.  (AJCC 7th ed.)","Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v7 | Stage IVA Thyroid Gland Undifferentiated (Anaplastic) Carcinoma | Stage IVA Thyroid Gland Undifferentiated (Anaplastic) Carcinoma AJCC v7 | Undifferentiated (Anaplastic) Stage IVA Thyroid Gland Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981273","Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7","C87549","Stage IVA includes: (T4a, N0, M0); (T4a, N1a, M0); (T1, N1b, M0); (T2, N1b, M0); (T3, N1b, M0); (T4a, N1b, M0).  T4a: Moderately advanced local disease.  Tumor of any size extending beyond the thyroid gland capsule to invade subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve.  T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  T3: Tumor more than 4 cm in greatest dimension and limited to the thyroid gland, or tumor of any size with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues).  T4b: Very advanced disease.  Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels.  N0: No regional lymph node metastasis.  N1a: Metastasis to pretracheal, paratracheal or prelaryngeal/Delphian lymph nodes (Level VI lymph nodes).  N1b: Metastasis to unilateral, bilateral or contralateral cervical (Levels I, II, III, IV, or V) or retropharyngeal or superior mediastinal lymph nodes (Level VII). M0: No distant metastasis.  (AJCC 7th ed.)","Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Medullary Cancer | Stage IVA Thyroid Gland Medullary Carcinoma | Stage IVA Thyroid Gland Medullary Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336442","Stage IV Medullary Carcinoma of the Thyroid Gland","C6136","Stage IV includes: IVA (T4a, N0, M0); (T4a, N1a, M0); (T1, N1b, M0); (T2, N1b, M0); (T3, N1b, M0); (T4a, N1b, M0); IVB (T4b, Any N, M0); IVC (Any T, Any N, M1). T4a: Moderately advanced local disease.  Tumor of any size extending beyond the thyroid gland capsule to invade subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve.  T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  T3: Tumor more than 4 cm in greatest dimension and limited to the thyroid gland, or tumor of any size with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues).  T4b: Very advanced disease.  Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels.  N0: No regional lymph node metastasis.  N1a: Metastasis to pretracheal, paratracheal or prelaryngeal/Delphian lymph nodes (Level VI lymph nodes).  N1b: Metastasis to unilateral, bilateral or contralateral cervical (Levels I, II, III, IV, or V) or retropharyngeal or superior mediastinal lymph nodes (Level VII). M0: No distant metastasis.  M1: Distant metastasis.  (AJCC 7th ed.)","Stage IV Thyroid Gland Medullary Carcinoma AJCC v7 | Stage IV Medullary Carcinoma of Thyroid | Stage IV Medullary Carcinoma of Thyroid Gland | Stage IV Medullary Carcinoma of the Thyroid | Stage IV Medullary Carcinoma of the Thyroid Gland | Stage IV Medullary Thyroid Gland Carcinoma | Stage IV Thyroid Gland Medullary Cancer | Stage IV Thyroid Gland Medullary Carcinoma | Stage IV Thyroid Gland Medullary Carcinoma | Stage IV Thyroid Medullary Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278851","Stage IV Thyroid Gland Papillary Carcinoma AJCC v7","C9083","Stage IV includes: IVA (T4a, N0, M0); (T4a, N1a, M0); (T1, N1b, M0); (T2, N1b, M0); (T3, N1b, M0); (T4a, N1b, M0); IVB (T4b, Any N, M0); IVC (Any T, Any N, M1). T4a: Moderately advanced local disease.  Tumor of any size extending beyond the thyroid gland capsule to invade subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve.  T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  T3: Tumor more than 4 cm in greatest dimension and limited to the thyroid gland, or tumor of any size with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues).  T4b: Very advanced disease.  Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels.  N0: No regional lymph node metastasis.  N1a: Metastasis to pretracheal, paratracheal or prelaryngeal/Delphian lymph nodes (Level VI lymph nodes).  N1b: Metastasis to unilateral, bilateral or contralateral cervical (Levels I, II, III, IV, or V) or retropharyngeal or superior mediastinal lymph nodes (Level VII).  M0: No distant metastasis.  M1: Distant metastasis. (AJCC 7th ed.)","Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IV Papillary Carcinoma of Thyroid | Stage IV Papillary Carcinoma of Thyroid Gland | Stage IV Papillary Carcinoma of the Thyroid | Stage IV Papillary Carcinoma of the Thyroid Gland | Stage IV Papillary Thyroid Cancer | Stage IV Papillary Thyroid Gland Carcinoma | Stage IV Thyroid Gland Papillary Cancer | Stage IV Thyroid Gland Papillary Carcinoma | Stage IV Thyroid Gland Papillary Carcinoma | Stage IV Thyroid Papillary Carcinoma",,,,,,,,,,,,,,,"46271139","Metastatic papillary thyroid carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0278854","stage IV follicular thyroid cancer","C9086","Stage IV includes: IVA (T4a, N0, M0); (T4a, N1a, M0); (T1, N1b, M0); (T2, N1b, M0); (T3, N1b, M0); (T4a, N1b, M0); IVB (T4b, Any N, M0); IVC (Any T, Any N, M1). T4a: Moderately advanced local disease.  Tumor of any size extending beyond the thyroid gland capsule to invade subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve. T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  T3: Tumor more than 4 cm in greatest dimension and limited to the thyroid gland, or tumor of any size with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues).  T4b: Very advanced disease.  Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels.  N0: No regional lymph node metastasis.  N1a: Metastasis to pretracheal, paratracheal or prelaryngeal/Delphian lymph nodes (Level VI lymph nodes).  N1b: Metastasis to unilateral, bilateral or contralateral cervical (Levels I, II, III, IV, or V) or retropharyngeal or superior mediastinal lymph nodes (Level VII).  M0: No distant metastasis.  M1: Distant metastasis. (AJCC 7th ed.)","Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Follicular Cancer | Stage IV Thyroid Gland Follicular Carcinoma | Stage IV Thyroid Gland Follicular Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336274","Stage III Medullary Carcinoma of the Thyroid Gland","C6135","Stage III includes: (T1, N1a, M0); (T2, N1a, M0); (T3, N1a, M0). T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  T3: Tumor more than 4 cm in greatest dimension and limited to the thyroid gland, or tumor of any size with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues).  N1a: Metastasis to pretracheal, paratracheal or prelaryngeal/Delphian lymph nodes (Level VI lymph nodes).  M0: No distant metastasis. (AJCC 7th ed.)","Stage III Thyroid Gland Medullary Carcinoma AJCC v7 | Stage III Medullary Carcinoma of Thyroid | Stage III Medullary Carcinoma of Thyroid Gland | Stage III Medullary Carcinoma of the Thyroid | Stage III Medullary Carcinoma of the Thyroid Gland | Stage III Medullary Thyroid Gland Carcinoma | Stage III Thyroid Gland Medullary Cancer | Stage III Thyroid Gland Medullary Carcinoma | Stage III Thyroid Gland Medullary Carcinoma | Stage III Thyroid Medullary Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336275","Stage III Papillary Carcinoma of the Thyroid Gland","C9122","Stage III includes: (T3, N0, M0); (T1, N1a, M0); (T2, N1a, M0); (T3, N1a, M0). T3: Tumor greater than 4 cm in greatest dimension and limited to the thyroid gland, or tumor of any size with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues).  T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  N0: No regional lymph node metastasis.  N1a: Metastasis to pretracheal, paratracheal or prelaryngeal/Delphian lymph nodes (Level VI lymph nodes).  M0: No distant metastasis. (AJCC 7th ed.)","Stage III Thyroid Gland Papillary Carcinoma AJCC v7 | Stage III Papillary Carcinoma of Thyroid | Stage III Papillary Carcinoma of Thyroid Gland | Stage III Papillary Carcinoma of the Thyroid | Stage III Papillary Carcinoma of the Thyroid Gland | Stage III Papillary Thyroid Gland Carcinoma | Stage III Thyroid Gland Papillary Cancer | Stage III Thyroid Gland Papillary Carcinoma | Stage III Thyroid Gland Papillary Carcinoma | Stage III Thyroid Papillary Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279178","Stage III Follicular Carcinoma of the Thyroid Gland","C9121","Stage III includes: (T3, N0, M0); (T1, N1a, M0); (T2, N1a, M0); (T3, N1a, M0). T3: Tumor greater than 4 cm in greatest dimension and limited to the thyroid gland, or tumor of any size with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues).  T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  N0: No regional lymph node metastasis.  N1a: Metastasis to pretracheal, paratracheal or prelaryngeal/Delphian lymph nodes (Level VI lymph nodes).  M0: No distant metastasis. (AJCC 7th ed.)","Stage III Thyroid Gland Follicular Carcinoma AJCC v7 | Stage III Follicular Carcinoma of Thyroid | Stage III Follicular Carcinoma of Thyroid Gland | Stage III Follicular Carcinoma of the Thyroid | Stage III Follicular Carcinoma of the Thyroid Gland | Stage III Follicular Thyroid Gland Carcinoma | Stage III Thyroid Follicular Carcinoma | Stage III Thyroid Gland Follicular Cancer | Stage III Thyroid Gland Follicular Carcinoma | Stage III Thyroid Gland Follicular Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336327","Stage II Medullary Carcinoma of the Thyroid Gland","C6134","Stage II includes: (T2, N0, M0); (T3, N0, M0).  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  T3: Tumor more than 4 cm in greatest dimension and limited to the thyroid gland, or tumor of any size with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues).  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage II Thyroid Gland Medullary Carcinoma AJCC v7 | Stage II Medullary Carcinoma of Thyroid | Stage II Medullary Carcinoma of Thyroid Gland | Stage II Medullary Carcinoma of the Thyroid | Stage II Medullary Carcinoma of the Thyroid Gland | Stage II Medullary Thyroid Gland Carcinoma | Stage II Thyroid Gland Medullary Cancer | Stage II Thyroid Gland Medullary Carcinoma | Stage II Thyroid Gland Medullary Carcinoma | Stage II Thyroid Medullary Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278850","Stage II Papillary Carcinoma of the Thyroid Gland","C9082","Stage II includes: Under 45 years: Any T, Any N, M1.  45 years and older: T2, N0, M0.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  N0: No regional lymph node metastasis.  M1: Distant metastasis.  M0: No evidence of distant metastasis.  (from AJCC 7th Ed.)","Stage II Thyroid Gland Papillary Carcinoma AJCC v7 | Stage II Papillary Carcinoma of Thyroid | Stage II Papillary Carcinoma of Thyroid Gland | Stage II Papillary Carcinoma of the Thyroid | Stage II Papillary Carcinoma of the Thyroid Gland | Stage II Papillary Thyroid Cancer | Stage II Papillary Thyroid Gland Carcinoma | Stage II Thyroid Gland Papillary Cancer | Stage II Thyroid Gland Papillary Carcinoma | Stage II Thyroid Gland Papillary Carcinoma | Stage II Thyroid Papillary Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278853","Stage II Follicular Carcinoma of the Thyroid Gland","C9085","Stage II includes: Under 45 years: Any T, Any N, M1.  45 years and older: T2, N0, M0.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  N0: No regional lymph node metastasis.  M1: Distant metastasis.  M0: No evidence of distant metastasis.  (from AJCC 7th Ed.)","Stage II Thyroid Gland Follicular Carcinoma AJCC v7 | Stage II Follicular Carcinoma of Thyroid | Stage II Follicular Carcinoma of Thyroid Gland | Stage II Follicular Carcinoma of the Thyroid | Stage II Follicular Carcinoma of the Thyroid Gland | Stage II Follicular Thyroid Gland Carcinoma | Stage II Thyroid Follicular Cancer | Stage II Thyroid Follicular Carcinoma | Stage II Thyroid Gland Follicular Cancer | Stage II Thyroid Gland Follicular Carcinoma | Stage II Thyroid Gland Follicular Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336491","Stage I Medullary Carcinoma of the Thyroid Gland","C6133","Stage I includes: T1, N0, M0.  T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage I Thyroid Gland Medullary Carcinoma AJCC v7 | Stage I Medullary Carcinoma of Thyroid | Stage I Medullary Carcinoma of Thyroid Gland | Stage I Medullary Carcinoma of the Thyroid | Stage I Medullary Carcinoma of the Thyroid Gland | Stage I Medullary Thyroid Gland Carcinoma | Stage I Thyroid Gland Medullary Cancer | Stage I Thyroid Gland Medullary Carcinoma | Stage I Thyroid Gland Medullary Carcinoma | Stage I Thyroid Medullary Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278849","Stage I Papillary Carcinoma of the Thyroid Gland","C9081","Stage I includes: Under 45 years: Any T, Any N, M0.  45 years and older: T1, N0, M0.  T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland.  N0: No regional lymph node metastasis.  M0: No evidence of distant metastasis. (from AJCC 7th Ed.)","Stage I Thyroid Gland Papillary Carcinoma AJCC v7 | Stage I Papillary Carcinoma of Thyroid | Stage I Papillary Carcinoma of Thyroid Gland | Stage I Papillary Carcinoma of the Thyroid | Stage I Papillary Carcinoma of the Thyroid Gland | Stage I Papillary Thyroid Cancer | Stage I Papillary Thyroid Gland Carcinoma | Stage I Thyroid Gland Papillary Cancer | Stage I Thyroid Gland Papillary Carcinoma | Stage I Thyroid Gland Papillary Carcinoma | Stage I Thyroid Papillary Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278852","Stage I Follicular Carcinoma of the Thyroid Gland","C9084","Stage I includes: Under 45 years: Any T, Any N, M0.  45 years and older: T1, N0, M0.  T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland.  N0: No regional lymph node metastasis.  M0: No evidence of distant metastasis. (from AJCC 7th Ed.)","Stage I Thyroid Gland Follicular Carcinoma AJCC v7 | Stage I Follicular Carcinoma of Thyroid | Stage I Follicular Carcinoma of Thyroid Gland | Stage I Follicular Carcinoma of the Thyroid | Stage I Follicular Carcinoma of the Thyroid Gland | Stage I Follicular Thyroid Gland Carcinoma | Stage I Thyroid Follicular Cancer | Stage I Thyroid Follicular Carcinoma | Stage I Thyroid Gland Follicular Cancer | Stage I Thyroid Gland Follicular Carcinoma | Stage I Thyroid Gland Follicular Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513061","Medical Research Council Dyspnea Scale","C21157","A scale grading dyspnea from 0 (not troubled with breathlessness except with strenuous exercise) to 4 (too breathless to leave the house or breathless when dressing or undressing). (Brooks 1982)","Medical Research Council Dyspnea Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL054945","Anaplastic","C14144","A term used to describe cancer cells that divide rapidly and have little or no resemblance to normal cells.","Anaplastic | Undifferentiated | anaplastic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986985","MedActive Oral Product","C95197","Proprietary, over-the-counter products containing stannous fluoride and Spilanthes extract for the relief of dry mouth symptoms.","MedActive Oral Product | MedActive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011079","Debridement","C51682","A procedure to remove dead tissue or foreign material from a wound to expose underlying healthy tissue and to promote healing.","Debridement | ",,,,,,,,,,,,,,,"4272410","Debridement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705185","Robot","C50152","A mechanical device designed to perform an automated action.","Robot Device | Robot | Robot Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0409974","Lupus Erythematosus","C27153","An autoimmune, connective tissue chronic inflammatory disorder affecting the skin, joints, kidneys, lungs, heart, and the peripheral blood cells. It is more commonly seen in women than men. Variants include discoid and systemic lupus erythematosus.","Lupus Erythematosus | Lupus | lupus",,,,,,,,,,,,,,,"255891","Lupus erythematosus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1773643","Postnatal","C81317","The time period after birth.","Postnatal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281318","antiangiogenesis therapy","C15568","A therapeutic regimen that uses synthetic compounds or natural substances to prevent the development of new blood vessels.","Antiangiogenesis Therapy | Angiogenesis Inhibition | Anti-Angiogenesis | Antiangiogenesis | antiangiogenesis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827741","Excretion Rate","C85534","The speed relative to time that an exogenous compound is removed from a body system.","Excretion Rate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0444330","Slide Device","C50178","A flat rectangular piece of glass on which specimens can be mounted for microscopic study.","Slide Device | Microscope Slide | Slide | Slide | Slide Device Component | Slide Device Component",,,,,,,,,,,,,,,"4197344","Microscope slide",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0525037","CDKN2A Gene","C18022","This gene functions as a tumor suppressor and transcriptional regulator.","CDKN2A Gene | CDKN2A | Cyclin-Dependent Kinase Inhibitor 2A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280274","Antiviral Therapy","C16119","Treatment of viral infections with agents that prevent viral replication in infected cells without impairing the host cell function.","Antiviral Therapy | Infectious Diseases / Treatment, Viral | Treatment of Infectious Diseases, Viral | treatment of viral infectious disease",,,,,,,,,,,,,,,"4140762","Antiviral therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2985499","Coping Style Assessment Tool","C93220","A self-report inventory that measures how a person copes with problems and stress. The protocol includes 8 scales within 2 categories. (Copyright Psychological Assessment Resources)","Coping Style Assessment Tool | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004627","Bacterial Protein","C16319","Proteins that originated from bacteria sources.","Bacterial Protein | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513448","Panitumumab","C1857","A human IgG2kappa monoclonal antibody specific for the epidermal growth factor receptor (EGFR). Monoclonal antibody E7.6.3 binds to the EGFR, blocking the binding of epidermal growth factor and transforming growth factor alpha to EGFR-expressing cancer cells and ultimately inhibiting EGFR-dependent cell activation and proliferation. (NCI)","Panitumumab | ABX-EGF | ABX-EGF Monoclonal Antibody | ABX-EGF, Clone E7.6.3 | E7.6.3 | Human IgG2K Monoclonal Antibody | MoAb ABX-EGF | MoAb E7.6.3 | Monoclonal Antibody ABX-EGF | Monoclonal Antibody E7.6.3 | PANITUMUMAB | Vectibix | panitumumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987124","Patient Reported Outcome","C95401","Information collected directly from a patient that typically includes subjective feelings regarding symptoms, functions in daily life, physical, mental, emotional, spiritual, and social well being, and satisfaction with his/her health care.","Patient Reported Outcome | PRO | Patient Reported Outcomes (PROs) | Patient-Reported Outcome | Symptom Endpoint | patient-reported outcome (PRO)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987125","Past Week","C95402","The most recent week. May include the present day.","Past Week | In the last week | Last 7 Days | Last Seven Days | Last Week | Past 7 Days | Past Seven Days | Preceding Week",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1367202","Ipilimumab","C2654","A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.","Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody | BMS 734016 | BMS-734016 | BMS734016 | IPILIMUMAB | Ipilimumab Biosimilar CS1002 | MDX 010 | MDX-010 | MDX-CTLA4 | MDX010 | Yervoy | ipilimumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2351038","Tremelimumab","C49085","A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.","Tremelimumab | Anti-CTLA4 Human Monoclonal Antibody CP-675,206 | CP 675 | CP 675206 | CP-675 | CP-675,206 | CP-675206 | CP675 | CP675206 | Imjudo | Immunoglobulin G2, Anti-(Human CTLA-4 (Antigen)) (Human Monoclonal CP-675206 Clone 11.2.1 Heavy Chain) Disulfide with Human Monoclonal CP-675206 Clone 11.2.1 Light Chain, Dimer | TREMELIMUMAB | Ticilimumab | Tremelimumab-actl | ticilimumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3467876","Dabrafenib","C82386","An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.","Dabrafenib | BRAF Inhibitor GSK2118436 | BRAF Inhibitor GSK2118436 | Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro- | DABRAFENIB | GSK 2118436 | GSK 2118436A | GSK-2118436 | GSK-2118436A | GSK2118436 | GSK2118436A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333295","Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","C36080","A biologic subset of diffuse large B-cell lymphomas with a unique molecular signature or expression profile.  It represents approximately 50% of diffuse large B-cell lymphomas, and is characterized by the expression of CD10, BCL-6, A-myb, and LMO2 genes, BCL-2 translocation, and c-REL amplification.  Morphologically, the vast majority of these lymphomas are centroblastic and a small minority are immunoblastic (ratio20:1).  Patients with this type of diffuse large B-cell lymphoma have a more favorable outcome, with a 5-year survival rate of 60% and a median survival of 10 years.","Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | DLBCL Germinal Center B-Cell Type | Diffuse Large B-Cell Lymphoma with a Germinal Center B-Cell Expression Profile | GCB-DLBCL | Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma | Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162596","Anticardiolipin Antibody","C95408","An autoantibody that reacts with cardiolipin. Different immunoglobulin subclasses and isotypes are associated with different diseases and conditions. Some anticardiolipin antibodies prolong phospholipid dependent clotting while others are associated with spontaneous abortion.","Anticardiolipin Antibody | ACA | aCL",,,,,,,,,,,,,,,"4166679","Cardiolipin antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0342257","Diabetes Complication","C84415","Organ or tissue damage due to diabetes mellitus. It includes heart disease and stroke, renal disease and renal failure, retinopathy, neuropathies, and erectile dysfunction.","Diabetes Complication | ",,,,,,,,,,,,,,,"442793","Complication due to diabetes mellitus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825873","Thyroid Antithyroglobulin Antibody Measurement","C81992","The determination of the amount of thyroid antithyroglobulin antibodies present in a sample.","Thyroid Antithyroglobulin Antibody Measurement | Anti Thyroglobulin Antibody Measurement | THYATAB | Thyroid Antithyroglobulin Antibodies | anti-thyroglobulin",,,,,,,,,,,,,,,"4065904","Thyroglobulin antibody measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1429427","TPO protein, human","C16752","Thyroid peroxidase (933 aa, ~103 kDa) is encoded by the human TPO gene. This protein plays a role in thyroid hormone synthesis.","Thyroid Peroxidase | EC 1.11.1.8 | Iodide Peroxidase | Iodinase | Iodoperoxidase (Heme Type) | Iodotyrosine Deiodase | Iodotyrosine Deiodinase | Monoiodotyrosine Deiodinase | THYROID PEROXIDASE | TPO | Thyroperoxidase | Tyrosine Iodinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040135","Thyroid Hormone","C886","Any of several closely related compounds that are produced by the thyroid gland and are active metabolically.","Thyroid Hormone | Thyroid Gland Hormone | thyroid hormone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023861","Listeria monocytogenes","C86502","A species of facultatively anaerobic, Gram positive, rod shaped bacteria in the phylum Firmicutes. This species is motile by up to four peritrichous flagella, catalase positive, hemolytic, produces acid from glucose, trehalose, levulose and salacin, indole negative and does not reduce nitrate. L. monocytogenes is a food borne pathogen, being the causative agent of listeriosis in humans and animals.","Listeria monocytogenes | Bacterium monocytogenes hominis | Corynebacterium infantisepticum | Corynebacterium parvulum | LISTERIA MONOCYTOGENES | Listerella hepatolytica",,,,,,,,,,,,,,,"4261846","Listeria monocytogenes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2987126","Developmental Neuropsychological Assessment","C95403","A series of neurocognitive tests for children from 3 to 16 years of age. NEPSY can be used for general, diagnostic, selective, or full assessment of neuropsychological development. (Copyright: Pearson Education, Inc; Marit Korkman, Ph.D., Ursula Kirk, Ph.D., and Sally Kemp, Ph.D., authors)","Developmental Neuropsychological Assessment | Developmental Neuropsycological Assessment | NEPSY | NEPSY | Neuropsychological Assessment  | Neuropsycological Assessment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229584","Pyramidal Lobe","C33437","A conical thyroid gland lobe.  When it is present, it usually arises from the isthmus.","Pyramidal Lobe | Pyramidal Lobe of the Thyroid",,,,,,,,,,,,,,,"4251154","Structure of pyramidal lobe of thyroid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0229583","Thyroid Gland Isthmus","C32887","The narrow, central portion of the thyroid gland that crosses the trachea anteriorly and connects the lateral lobes of the gland. When present, the normal variant pyramidal lobe may extend from the isthmus.","Thyroid Gland Isthmus | Isthmus | THYROID GLAND ISTHMUS",,,,,,,,,,,,,,,"4237182","Structure of isthmus of thyroid gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0229582","Left Thyroid Gland Lobe","C32973","The cone-like lobe of the thyroid gland that is located in the left side of the trachea.","Left Thyroid Gland Lobe | Left Lobe | THYROID GLAND, LEFT LOBE",,,,,,,,,,,,,,,"4194655","Structure of left lobe of thyroid gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0229581","Right Thyroid Gland Lobe","C33491","The cone-like lobe of the thyroid gland that is located in the right side of the trachea.","Right Thyroid Gland Lobe | Right Lobe | THYROID GLAND, RIGHT LOBE",,,,,,,,,,,,,,,"4105759","Structure of right lobe of thyroid gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2983414","Liver Cancer Pathologic Distant Metastasis TNM Finding v7","C90168","A pathologic finding about one or more characteristics of liver cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  There is no pathologic M0 for liver cancer. (from AJCC 7th Ed.)","Liver Cancer Pathologic Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983419","Liver Cancer cM0 TNM Finding v7","C90173","Liver cancer without evidence of distant metastasis. (from AJCC 7th Ed.)","Liver Cancer cM0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983410","Liver Cancer Pathologic Regional Lymph Nodes TNM Finding v7","C90164","A pathologic finding about one or more characteristics of liver cancer, following the rules of the TNM AJCC v7 classification system as they pertain to staging of regional lymph nodes.","Liver Cancer Pathologic Regional Lymph Nodes TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983401","Liver Cancer Pathologic Primary Tumor TNM Finding v7","C90153","A pathologic finding about one or more characteristics of liver cancer, following the rules of the TNM AJCC v7 classification system as they pertain to staging of the primary tumor.","Liver Cancer Pathologic Primary Tumor TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0222724","Clivus","C12494","A sloped depression between the dorsum sellae and foramen magnum at the base of the skull.","Clivus | CLIVUS",,,,,,,,,,,,,,,"4288019","Clivus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL973068","Meal","C80248","Any of the occasions for eating food that occur by custom or habit at more or less fixed times.","Meal | cibus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705541","Telephone Device Component","C50212","Electronic equipment that converts sound into electrical signals that can be transmitted over distances and then converts received signals back into sounds.","Telephone Device | Phone | Telephone | Telephone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881417","Liver Cancer Pathologic Primary Tumor TNM Finding v6","C61166","A pathologic finding about one or more characteristics of liver cancer, following the rules of the TNM AJCC v6 classification system as they pertain to staging of the primary tumor. TNM pathologic primary tumor findings are based on clinical findings supplemented by histopathologic examination of one or more tissue specimens acquired during surgery.","Liver Cancer Pathologic Primary Tumor TNM Finding v6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881432","Liver Cancer pTX TNM Finding v6","C61169","Liver cancer in which the primary tumor cannot be assessed. (from AJCC 6th Ed.)","Liver Cancer pTX TNM Finding v6 | pTX Cancer of the Liver TNM Finding v6 | pTX Carcinoma of the Liver TNM Finding v6 | pTX Liver Carcinoma TNM Finding v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881431","Liver Cancer pT4 TNM Finding v6","C61174","Liver cancer with tumor(s) invading adjacent organs other than the gallbladder or with tumor perforating the visceral peritoneum. (from AJCC 6th Ed.)","Liver Cancer pT4 TNM Finding v6 | pT4 Cancer of the Liver TNM Finding v6 | pT4 Carcinoma of the Liver TNM Finding v6 | pT4 Liver Carcinoma TNM Finding v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881429","Liver Cancer pT2 TNM Finding v6","C61172","Liver cancer with a solitary tumor of any size with vascular invasion, or with multiple tumors none of which are more than 5 cm in size. (from AJCC 6th Ed.)","Liver Cancer pT2 TNM Finding v6 | pT2 Cancer of the Liver TNM Finding v6 | pT2 Carcinoma of the Liver TNM Finding v6 | pT2 Liver Carcinoma TNM Finding v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881428","Liver Cancer pT1 TNM Finding v6","C61171","Liver cancer with a solitary tumor of any size without vascular invasion. (from AJCC 6th Ed.)","Liver Cancer pT1 TNM Finding v6 | pT1 Cancer of the Liver TNM Finding v6 | pT1 Carcinoma of the Liver TNM Finding v6 | pT1 Liver Carcinoma TNM Finding v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881427","Liver Cancer pT0 TNM Finding v6","C61170","Liver cancer with no evidence of a primary tumor. (from AJCC 6th Ed.)","Liver Cancer pT0 TNM Finding v6 | pT0 Cancer of the Liver TNM Finding v6 | pT0 Carcinoma of the Liver TNM Finding v6 | pT0 Liver Carcinoma TNM Finding v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881418","Liver Cancer Pathologic Regional Lymph Nodes TNM Finding v6","C61167","A pathologic finding about one or more characteristics of liver cancer, following the rules of the TNM AJCC v6 classification system as they pertain to staging of regional lymph nodes. TNM pathologic regional lymph nodes findings are based on clinical findings supplemented by histopathologic examination of one or more tissue specimens acquired during surgery.","Liver Cancer Pathologic Regional Lymph Nodes TNM Finding v6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881426","Liver Cancer pNX TNM Finding v6","C61175","Liver cancer in which the regional lymph nodes cannot be assessed. (from AJCC 6th Ed.)","Liver Cancer pNX TNM Finding v6 | pNX Cancer of the Liver TNM Finding v6 | pNX Carcinoma of the Liver TNM Finding v6 | pNX Liver Carcinoma TNM Finding v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881425","Liver Cancer pN1 TNM Finding v6","C61177","Liver cancer with regional lymph node metastasis. (from AJCC 6th Ed.)","Liver Cancer pN1 TNM Finding v6 | pN1 Cancer of the Liver TNM Finding v6 | pN1 Carcinoma of the Liver TNM Finding v6 | pN1 Liver Carcinoma TNM Finding v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881424","Liver Cancer pN0 TNM Finding v6","C61176","Liver cancer with no regional lymph node metastasis. (from AJCC 6th Ed.)","Liver Cancer pN0 TNM Finding v6 | pN0 Cancer of the Liver TNM Finding v6 | pN0 Carcinoma of the Liver TNM Finding v6 | pN0 Liver Carcinoma TNM Finding v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881416","Liver Cancer Pathologic Distant Metastasis TNM Finding v6","C61168","A pathologic finding about one or more characteristics of liver cancer, following the rules of the TNM AJCC v6 classification system as they pertain to distant metastases. TNM pathologic distant metastasis findings are based on clinical findings supplemented by histopathologic examination of one or more tissue specimens acquired during surgery.","Liver Cancer Pathologic Distant Metastasis TNM Finding v6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881422","Liver Cancer pM1 TNM Finding v6","C61180","Liver cancer with distant metastasis. (from AJCC 6th Ed.)","Liver Cancer pM1 TNM Finding v6 | pM1 Cancer of the Liver TNM Finding v6 | pM1 Carcinoma of the Liver TNM Finding v6 | pM1 Liver Carcinoma TNM Finding v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336456","Stage I Hepatocellular Carcinoma AJCC v6 and v7","C5758","Stage I includes: T1, N0, M0.  T1: Solitary tumor without vascular invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage I Hepatocellular Carcinoma AJCC v6 and v7 | Hepatocellular Cancer Stage I | Liver Cell Cancer Stage I | Stage I Hepatocellular Cancer | Stage I Hepatocellular Carcinoma | Stage I Hepatocellular Carcinoma AJCC v6 | Stage I Hepatocellular Carcinoma AJCC v7 | Stage I Liver Cell Cancer | Stage I Liver Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336290","Stage II Hepatocellular Carcinoma AJCC v6 and v7","C5759","Stage II includes: T2, N0, M0.  T2: Solitary tumor with vascular invasion or multiple tumors none more than 5 cm.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage II Hepatocellular Carcinoma AJCC v6 and v7 | Hepatocullular Cancer Stage II | Liver Cell Cancer Stage II | Stage II Hepatocellular Cancer | Stage II Hepatocellular Carcinoma | Stage II Hepatocellular Carcinoma AJCC v6 | Stage II Hepatocellular Carcinoma AJCC v7 | Stage II Liver Cell Cancer | Stage II Liver Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346620","Knowledge Field","C70772","A branch of knowledge.","Knowledge Field | Content Area | Field",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025353","mental health","C93187","The overall state of an individual's psychologic constitution.","Mental Health | Mental Well-being | mental health",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028707","Science of nutrition","C16927","The science of food, the nutrients and other substances contained therein, their action, interaction, and balance in relation to health and disease.","Nutritional Science | Nutrition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079920","Occupational Health","C17381","The identification and control of risks and hazards in the workplace to establish and maintain a safe and healthy work environment.","Occupational Health | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0237104","spirituality","C90526","Having to do with deep, often religious, feelings and beliefs, including a person's sense of peace, purpose, connection to others, and beliefs about the meaning of life.","Spirituality | spirituality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1700874","Axitinib","C38718","An orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect.","Axitinib | AG 013736 | AG-013736 | AG013736 | AXITINIB | Inlyta | N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide | axitinib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0438673","Microwave Thermotherapy","C93351","Any procedure in which microwave irradiation is used for the purpose of heating and destroying the surrounding tissue.","Microwave Thermotherapy | MICROWAVE THERAPY | microwave therapy | microwave thermotherapy",,,,,,,,,,,,,,,"4167178","Microwave diathermy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705366","Driver","C49931","A computer interface designed to control the interaction between a CPU and a peripheral device.","Driver Device | Driver | Driver Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449164","CyberKnife","C95484","A proprietary, robotic radiosurgery system designed to deliver precise beams of high dose radiation to tumors with extreme accuracy.","CyberKnife | Radiation, Cyberknife",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0683457","State-Trait Anxiety Inventory","C95491","An instrument for measuring anxiety. It is designed to differentiate between temporary 'state anxiety' and general, long-standing 'trait anxiety'. (Copyright Mind Garden, Inc.)","State-Trait Anxiety Inventory | ",,,,,,,,,,,,,,,"4121658","State-trait anger expression inventory",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL449160","Calm","C95492","A feeling of freedom from agitation or excitement.","Calm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0423896","Content","C95494","A feeling of satisfaction with things as they are.","Content | Contentment",,,,,,,,,,,,,,,"4154768","Feeling content",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL449162","Indecision","C95495","A feeling of doubt concerning two or more possible alternatives or courses of action.","Indecision | Indecisive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987186","Jittery","C95496","A feeling of nervous unease.","Jittery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987187","Pleasant","C95497","Feeling friendly, kind, or good-natured.","Pleasant | Pleasant Feeling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3146231","Secure feeling","C95498","Feeling untroubled by fear, doubt, or vulnerability.","Secure | Secure Feeling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0237529","Self-confidence","C95499","A feeling of trust in yourself and your abilities.","Self-confidence | ",,,,,,,,,,,,,,,"4023041","Self-confidence",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205361","Steady","C95500","Not subject to change, especially in behavior.","Steady | ",,,,,,,,,,,,,,,"4204522","Steady",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2987481","Emotional Strain","C95501","A feeling of difficulty that causes worry or emotional tension.","Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0235108","Tension","C95502","A feeling of mental or emotional strain or suspense.","Tension | Tense | Tense Feeling",,,,,,,,,,,,,,,"4136244","Feeling tense",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3887804","Upset","C95503","A feeling of worry and unhappiness.","Upset | ",,,,,,,,,,,,,,,"4076636","Feeling upset",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2987183","Misfortune","C95489","Unforseen trouble.","Misfortune | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439671","Gestation","C92804","The period of fetal development in the uterus from the start of conception until its birth.","Gestation | Gestational | Gestational",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982577","Thyroid Cancer Pathologic Primary Tumor TNM Finding v7","C89147","A pathologic finding about one or more characteristics of thyroid cancer, following the rules of the TNM AJCC v7 classification system as they pertain to staging of the primary tumor.  Note: All categories may be subdivided: (s) solitary tumors and (m) multifocal tumor (the largest determines the classification) (from AJCC 7th Ed.)","Thyroid Cancer Pathologic Primary Tumor TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982584","Thyroid Cancer Pathologic Regional Lymph Nodes TNM Finding v7","C89154","A pathologic finding about one or more characteristics of thyroid cancer, following the rules of the TNM AJCC v7 classification system as they pertain to staging of regional lymph nodes.","Thyroid Cancer Pathologic Regional Lymph Nodes TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982586","Thyroid Cancer Pathologic Distant Metastasis TNM Finding v7","C89156","A pathologic finding about one or more characteristics of thyroid cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  There is no pathologic M0 for thyroid cancer.","Thyroid Cancer Pathologic Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982589","Thyroid Cancer cM0 TNM Finding v7","C89159","Thyroid cancer without evidence of distant metastasis. (from AJCC 7th Ed.)","Thyroid Cancer cM0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1441129","Radioactive Iodine","C2462","A radioactive form of iodine, often used for imaging tests or to treat an overactive thyroid, thyroid cancer, and certain other cancers. For imaging tests, the patient takes a small dose of radioactive iodine that collects in thyroid cells and certain kinds of tumors and can be detected by a scanner. To treat thyroid cancer, the patient takes a large dose of radioactive iodine, which kills thyroid cells. Radioactive iodine is also used in internal radiation therapy for prostate cancer, intraocular (eye) melanoma, and carcinoid tumors. Radioactive iodine is given by mouth as a liquid or in capsules, by infusion, or sealed in seeds, which are placed in or near the tumor to kill cancer cells.","Radioactive Iodine | radioactive iodine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0260087","Otolaryngologist","C17823","A doctor who specializes in treating diseases of the ear, nose, and throat.","Otolaryngologist | ENT Doctor | ENT Specialist | ENT doctor | Ear, Nose, and Throat Doctor | OTOLARYNGOLOGIST | Otorhinolaryngologist | otolaryngologist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987198","Bone Marrow Donors Worldwide","C95515","An organization based in Leiden, Netherlands that coordinates the collection of HLA phenotypes from volunteer stem cell donors and cord blood donors, and is responsible for coordination of their distribution worldwide.","Bone Marrow Donors Worldwide | BMDW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987199","ISBT-128 Donation Identification Number","C95517","A globally unique identifier that is assigned to each collection and each pooled product. The identifier is composed of four parts: a Facility Identification Number (FIN), a year of assignment, a serial number, and flag characters.","ISBT-128 Donation Identification Number | DIN | Donation Identification Number | ISBT DIN | ISBT-128 DIN | ISBT-128 Donor Identification Number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987201","AXP AutoXpress Platform","C95519","A proprietary system for recovery of stem-cell rich fractions from human umbilical cord blood and volume reduction of blood components.","AXP AutoXpress Platform | AutoXpress | AutoXpress Platform",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987202","Sepax Cell Separation Device","C95520","A proprietary system for the automated processing of whole blood into plasma, buffy coat, and erythrocyte fractions.","Sepax Cell Separation Device | Sepax",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041718","Centers for Medicare and Medicaid Services","C95516","An agency within the US Department of Health and Human Services responsible for administration of several key federal health care programs. In addition to Medicare and Medicaid, the Centers for Medicare and Medicaid Services oversee the Children's Health Insurance Program (CHIP), the Health Insurance Portability and Accountability Act (HIPAA), the Clinical Laboratory Improvement Amendments (CLIA), and other services.","Centers for Medicare and Medicaid Services | CMS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2030664","Hepatitis B Surface Antigen Neutralization","C95522","An assay used to confirm the presence of Hepatitis B virus in a blood sample. Following repeated positive results by a virus-specific enzyme immunosorbant assay, free antibodies specific for Hepatitis B surface antigens (HBsAg) are added to the assay and should react with the virus and block a subsequent enzyme immunosorbant assay.","Hepatitis B Surface Antigen Neutralization | HBsAg Neutralization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987205","Hepatitis C Virus Recombinant Immunoblot Assay","C95525","An assay used to verify the presence of anti-HCV antibodies in a blood sample. Serum is incubated with a membrane strip on which four recombinant viral proteins are attached. The immunoblot is considered positive if two or more proteins react and indeterminate if only one positive band is detected.","Hepatitis C Virus Recombinant Immunoblot Assay | HCV RIBA | HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY | Hepatitis C Virus Recombinant Immonoblot Assay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987204","HIV1 p24 Antigen Neutralization","C95523","An assay used to confirm the presence of HIV1 p24 antigen in a blood sample. Following repeated positive results by a virus-specific enzyme immunosorbant assay, free antibodies specific for HIV1 p24 are added to the assay and should react with the viral protein and block a subsequent enzyme immunosorbant assay.","HIV1 p24 Antigen Neutralization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0860963","HIV Western Blot","C95524","An assay used to confirm the presence of anti-HIV1 antibodies in a blood samples. Serum is incubated with vital protein that have been gel separated and affixed to a membrane. The test is considered positive if two or more proteins react and indeterminate if only one positive band is detected.","HIV Western Blot | Anti-HIV Western Blot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987206","Anti-HIV2 Enzyme Immunoassay","C95526","An enzyme immunoassay for the qualitative detection of antibodies to human immunodeficiency viruses in human serum or plasma.","Anti-HIV2 Enzyme Immunoassay | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987207","Fluorescent Treponemal Antibody Absorption","C95527","An enzyme immunoassay for the detection of the bacteria Treponema pallidum, which causes syphilis. Serum is prereacted (absorbed) with protein from a non-pathogenic treponeme.","Fluorescent Treponemal Antibody Absorption | FTA-Abs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041234","Chagas Disease","C84629","A parasitic infection caused by Trypanosoma cruzi. It is transmitted by insect bites. It is characterized by an acute and chronic phase; in the acute phase patients may have fever, malaise, and swelling at the site of the insect bite. In the chronic phase patients develop hepatosplenomegaly, lymphadenopathy, cardiomyopathy and arrhythmias.","Chagas Disease | American Trypanosomiasis",,,,,,,,,,,,,,,"436334","Infection by Trypanosoma cruzi",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2987203","BioArchive System","C95521","A proprietary computerized system for liquid nitrogen cryopreservation, tracking, and retrieval for stem cell samples.","BioArchive System | BioArchive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987208","Forma (company)","C95528","A manufacturer of laboratory freezers and other appliances designed for medical and scientific applications.","Forma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987209","MVE Freezer","C95529","A brand of cryofreezers designed to store samples in liquid nitrogen or vapor phase liquid nitrogen.","MVE Freezer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987210","Taylor-Wharton Freezer","C95530","A brand of cryofreezers, dewars, and shippers for samples preserved in liquid nitrogen or vapor phase liquid nitrogen.","Taylor-Wharton Freezer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987211","Dry Shipper","C95531","A container used to ship products frozen in liquid nitrogen. It is designed so that the liquid nitrogen is absorbed into retention medium that surrounds the samples and maintains them at liquid nitrogen temperatures.","Dry Shipper | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710368","Temperature Sensor","C50304","A sensor designed to respond to the temperature of a space, surface, or environment.","Temperature Sensor Device | Temperature Sensor | Temperature Sensor Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987212","Cryoguard Thermal Exposure Indicator","C95532","A proprietary temperature monitor device designed to irreversibly change color to indicate that it has been exposed to temperatures above its signal temperature.","Cryoguard Thermal Exposure Indicator | Cryoguard Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987668","Neutralization","C95533","The act of rendering something ineffective or inactive.","Neutralization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987213","Hemoglobin Trait","C95534","A condition in which a person is heterozygous for a globin gene, with a one normal allele and one defective allele.","Hemoglobin Trait | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0472762","Alpha Thalassemia Trait","C95535","A condition in which a person has reduced protein production from two of the four alpha-globin alleles.","Alpha Thalassemia Trait | ",,,,,,,,,,,,,,,"4098749","Alpha trait thalassemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2062366","Alpha Thalassemia Silent Carrier","C95536","A condition in which a person has reduced protein production from one of the four alpha-globin alleles.","Alpha Thalassemia Silent Carrier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3161174","Hemoglobin H Disease","C95504","A form of alpha thalassemia that results from reduced protein production from three of the four alpha-globin genes. Clinically it is characterized by chronic hemolytic anemia.","Hemoglobin H Disease | Alpha Thalassemia, Severe Disease",,,,,,,,,,,,,,,"4168911","Hemoglobin H disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2987217","Rapid Screening Method for Alpha Thalassemia","C95541","Screening techniques for alpha thalassemia that use melting curve analysis of PCR products generated from the alpha globin alleles.","Rapid Screening Method for Alpha Thalassemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987215","Beta Thalassemia Plus Structural Variants","C95538","A heterozygous state in which a person has a mutation in a beta globin allele causing beta thalassemia, together with other structural variants in the other allele.","Beta Thalassemia Plus Structural Variants | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221019","Sickle Beta Thalassemia","C95539","A heterozygous state in which a person has a hemoglobin S allele along with a beta-thalassemia allele. The severity of the condition is determined to a large extent by the quantity of normal hemoglobin produced by the beta-thalassemia gene.","Sickle Beta Thalassemia | Hb S-Beta Thalassemia | S-Beta Thalassemia | Sickle Cell-Beta Thalassemia | Sickle Cell-Beta-Thalassemia",,,,,,,,,,,,,,,"4130067","Sickle cell-beta-thalassemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2987214","Homozygous Hemoglobin C or E, Non-Disease","C95537","A state in which both beta-globin alleles code for a C or E variant but which leads to such minor changes to the hemoglobin that it does not cause disease.","Homozygous Hemoglobin C or E, Non-Disease | Homozygous Hemoglobin C or E, Non-disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987216","Monomeric Cyanine Dye","C95540","A green-fluorescent dye that has the ability to penetrate apoptotic cells because of permeability changes associated with the loss in asymmetry of the plasma membrane. Once inside the cell, the dye binds to DNA.","Monomeric Cyanine Dye | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019873","Homidium Bromide","C65857","A dark red, crystalline, non-volatile solid which fluoresces readily when exposed to ultraviolet light. It is a DNA intercalating agent and is commonly used as a marker for visualizing nucleic acids in electrophoresis and other methods of DNA separation and purification.","Homidium Bromide | 2,7-diamino-9-phenyl-10-ethylphenanthridinium Bromide | 3,8-Diamino-5-ethyl-6-phenylphenanthridinium Bromide | Ethidium Bromide | Ethidium Bromide | HOMIDIUM BROMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205950","Skullcap","C81188","The roof or dome of the skull.","Skullcap | BONE, CALVARIUM | Calvarium",,,,,,,,,,,,,,,"4033834","Structure of vault of skull",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL426295","Deficiency","C94372","In medicine, a shortage of a substance (such as a vitamin or mineral) needed by the body.","Deficiency | deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0151706","Vaginal Bleeding","C95557","Vaginal bleeding unrelated to normal menstruation.","Vaginal Bleeding | ",,,,,,,,,,,,,,,"4129155","Vaginal bleeding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027877","Neuronal Ceroid Lipofuscinosis","C61257","A group of mostly autosomal recessive inherited neurodegenerative disorders characterized by accumulation of lipofuscin in the neuronal cells and in other tissues including liver, spleen, kidneys, and myocardium. Signs and symptoms include motor disturbances and cognitive decline.","Neuronal Ceroid Lipofuscinosis | Neuronal ceroid lipofuscinosis",,,,,,,,,,,,,,,"4170931","Neuronal ceroid lipofuscinosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2826283","Planned Dose","C82551","The proposed dosage of the treatment.","Planned Dose | PDOSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016519","Foramen Magnum","C12495","A large orifice in the occipital bone through which the spinal cord enters the cranial cavity.","Foramen Magnum | ",,,,,,,,,,,,,,,"4081789","Structure of foramen magnum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882351","Petroclival Region","C62644","The area between the clivus and the petrous portion of the temporal bone.","Petroclival Region | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987150","Falcine","C95441","Of or related to the falx cerebri.","Falcine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987151","Petrous","C95442","Pertaining to the petrous or hard, stony portion of the temporal bone.","Petrous | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0222711","Internal Auditory Canal","C95443","A canal in the petrous region of the temporal bone that serves as the passage for cranial nerves (mainly the VII and VIII cranial nerves) towards the middle and inner ear.","Internal Auditory Canal | Internal Acoustic Meatus | internal acoustic meatus",,,,,,,,,,,,,,,"4267855","Structure of internal acoustic meatus of temporal bone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2987152","Supraorbital","C95444","Located above the eye socket.","Supraorbital | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987153","Suprasellar","C95445","Located above the sella turcica.","Suprasellar | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020352","Hetastarch","C559","A synthetic, nonionic hydroxyethyl derivative of starch used as a plasma expander when prepared in an isotonic solution. Upon intravenous administration, hydroxyethyl starch colloid increases blood volume and thus improves circulation. This agent is almost exclusively excreted by the kidneys and is potentially nephrotoxic.","Hetastarch | 2-Hydroxyethyl Starch Ether | HES | HETASTARCH | Hespan | Hextend | Hydroxyethyl Starch | Venofundin | Volulyte | Voluven",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1305205","Acridine Orange Staining Method","C85554","A microscopy staining method that utilizes acridine orange, a fluorescent cationic dye that is selective for nucleic acids, to determine the presence of viable cells or microorganisms in a sample. Acridine orange interacts with RNA and DNA and the lysosomal compartment of cells.","Acridine Orange Staining Method | ACRIDINE ORANGE STAIN",,,,,,,,,,,,,,,"4024949","Acridine orange stain method",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0232187","Heart Rhythm","C87081","The recurrent, measured movements (rhythm) of a beating heart.","Heart Rhythm | Cardiac Rhythm | Rhythm",,,,,,,,,,,,,,,"4091457","Cardiac rhythm type",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205556","Qualitative Concept","C92722","A measurement expressed in words rather than numbers.","Qualitative Concept | Qualitative | Qualitative",,,,,,,,,,,,,,,"4097969","Qualitative",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085611","Atrial Arrhythmia by ECG Finding","C80503","An electrocardiographic finding of an atypical cardiac rhythm resulting from a pathologic process in the cardiac atria.","Atrial Arrhythmia by ECG Finding | Atrial Arrhythmia | Atrial Arrhythmia | Atrial Arrhythmia by EKG Finding",,,,,,,,,,,,,,,"4068155","Atrial arrhythmia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025598","Metformin","C61612","An agent belonging to the biguanide class of antidiabetics with antihyperglycemic activity. Metformin is associated with a very low incidence of lactic acidosis. This agent helps reduce LDL cholesterol and triglyceride levels, and is not associated with weight gain, and prevents the cardiovascular complications of diabetes. Metformin is not metabolized and is excreted unchanged by the kidneys.","Metformin | 1,1-Dimethylbiguanide | METFORMIN | N,N-Dimethylimidodicarbonimidic Diamide | N,N-dimethylbiguanide | metformin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL964107","LEP protein, human","C46081","Leptin (167 aa, ~16 kDa) is encoded by the human LEP gene.  This protein is secreted by adipocytes and plays a role in the regulation of both appetite and body fat stores.","Leptin | LEP | Obese Protein | Obesity Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1438411","Adiponectin, Human","C94786","Adiponectin (244 aa, ~26 kDa) is encoded by the human ADIPOQ gene. This protein is involved in the modulation of both glucose metabolism and lipid homeostasis.","Adiponectin | 30 kDa Adipocyte Complement-Related Protein | ACRP30 | Adipocyte Complement-Related 30 kDa Protein | Adipocyte, C1q and Collagen Domain-Containing Protein | Adipocyte-Specific Secretory Protein | Adipose Most Abundant Gene Transcript 1 Protein | Gelatin-Binding Protein | Gelatin-Binding Protein, 28-kD | apM-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0232326","ST Segment Abnormality by ECG Finding","C71026","An electrocardiographic finding of ST segment elevation or depression.","ST Segment Abnormality by ECG Finding | ST Segment Abnormality | ST Segment Abnormality | ST Segment Abnormality by EKG Finding | ST segment changes",,,,,,,,,,,,,,,"4184762","EKG ST segment changes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4025245","T Wave Abnormality by ECG Finding","C71083","An electrocardiographic finding of a T wave which appears peaked, inverted, flattened or biphasic.","T Wave Abnormality by ECG Finding | T Wave Abnormality | T Wave Abnormality | T Wave Abnormality by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL455355","Bundle Branch Block by ECG Finding","C84603","An electrocardiographic finding of a prolongation of the QRS complex. It is caused by damage to one of the bundle branches, resulting in impaired transmission of cardiac electrical impulses.","Bundle Branch Block by ECG Finding | Bundle Branch Block | Bundle Branch Block | Bundle Branch Block by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2673438","Tourette Syndrome","C35078","A neurologic disorder caused by defective metabolism of the neurotransmitters in the brain. It is characterized by repeated involuntary movements (motor tics) and uncontrollable vocal sounds (vocal tics). The symptoms are usually manifested before the age of eighteen.","Tourette Syndrome | Gilles de la Tourette syndrome | Tourette's Syndrome",,,,,,,,,,,,,,,"379782","Gilles de la Tourette's syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0200695","Hemoglobin F Measurement","C92262","The determination of the amount of hemoglobin F present in a sample.","Hemoglobin F Measurement | Fetal Hemoglobin | HGBF | Hemoglobin F",,,,,,,,,,,,,,,"4049246","Fetal hemoglobin determination",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1281911","Hemoglobin A Measurement","C92258","The determination of the amount of hemoglobin A present in a sample.","Hemoglobin A Measurement | HGBA | Hemoglobin A",,,,,,,,,,,,,,,"4199033","Hemoglobin A measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2987219","Stay Out of Bed","C95543","The ability to maintain the energy required to be out of bed.","Stay Out of Bed | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1305428","Dressing","C95544","The act of putting on clothes.","Dressing | ",,,,,,,,,,,,,,,"4044710","Dressing",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2987220","Light Work","C95545","Work tasks that require little physical or mental effort.","Light Work | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987222","Hard Work","C95547","Work tasks that require a great amount of physical or mental effort.","Hard Work | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2199604","Easy Bleeding","C95552","Bleeding that is disproportionate to the offending trauma.","Easy Bleeding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004379","Driving","C95548","Operating a motor vehicle.","Driving | ",,,,,,,,,,,,,,,"4044725","Driving",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL449181","People","C95553","Human beings in general.","People | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987225","Better Off","C95554","Being in more desirable circumstances.","Better Off | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018379","Guilt","C95555","A feeling of shame and sorrow based on the belief of having done something wrong or failing an obligation.","Guilt | Feeling Guilty | Guilty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0234909","Nail Changes","C95556","Alteration of the normal characteristics of the fingernails or toenails. Examples include thickening, thinning, deformity, and separation from the nail bed.","Nail Changes | Nail Change | Nail disorder",,,,,,,,,,,,,,,"4211923","Nail changes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2987223","Run Errand","C95549","To make a short trip for a particular purpose, especially to buy or deliver something.","Run Errand | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449185","Cooking","C95550","The act of preparing something to eat by the application of heat.","Cooking | Cook | Cooked",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987224","Attend Paid Job","C95551","The ability to maintain gainful employment.","Attend Paid Job | Work for Pay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986537","Five-year Survival Rate","C94503","The percentage of people in a study or treatment group who are alive five years after they were diagnosed with or treated for a disease, such as cancer. The disease may or may not have come back.","Five-year Survival Rate | five-year survival rate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0057223","Cytochrome P450 2D6","C17287","Cytochrome P450 2D6 (497 aa, ~56 kDa) is encoded by the human CYP2D6 gene. This protein plays a role in flavoprotein metabolism.","Cytochrome P450 2D6 | CYP2D6 | CYPIID6 | Cytochrome P450 Subfamily IID Polypeptide 6 | Cytochrome P450, Subfamily IID | Cytochrome P450, Subfamily IID-Like 1 | Cytochrome P450-DB1 | Debrisoquine 4-Hydroxylase | EC 1.14.14.1 | Flavoprotein-Linked Monooxygenase | LIVER KIDNEY MICROSOMAL TYPE 1 ANTIGEN | Liver Kidney Microsomal 1 Antigen | Microsomal Monooxygenase | P450-2D6 | P450-DB1 | P450DB1 | Xenobiotic Monooxygenase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016365","Fluoxetine","C506","A diphenhydramine derivative and selective serotonin reuptake inhibitor with antidepressant, anti-anxiety, antiobsessional and antibulimic activity and with potential immunomodulating activity. Upon administration, fluoxetine binds to the presynaptic serotonin (5-HT) receptor resulting in negative allosteric modulation of the receptor complex, thereby blocking recycling of serotonin by the presynaptic receptor. Inhibition of serotonin reuptake by fluoxetine enhances serotonergic function through serotonin accumulation in the synaptic space, resulting in long-term desensitization and downregulation of 5-HT receptors, preventing 5-HT-mediated signaling and leading to antidepressant, anti-anxiety, antiobsessional and antibulimic effects. In addition, fluoxetine may inhibit the expression of pro-inflammatory cytokines, including interleukin-6 (IL-6). This may prevent IL-6-mediated inflammation and cytokine storm.","Fluoxetine | FLUOXETINE | N-methyl-gamma-(4-(trifluoromethyl) -phenoxy)-benzenepropanamine | fluoxetine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0070122","Paroxetine","C61879","No Value Exists","Paroxetine | (-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine | (-)-trans-4-(p-fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine | BRL 29060 | PAROXETINE | Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3s-trans)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0074393","Sertraline","C61939","A drug used to treat depression. It is a type of selective serotonin reuptake inhibitor (SSRI).","Sertraline | SERTRALINE | sertraline",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085208","Bupropion","C62012","An aminoketone with antidepressant activity. The molecular mechanism of the antidepressant effect of bupropion is unknown.  This agent does not inhibit monoamine oxidase and, compared to classical tricyclic antidepressants, is a weak blocker of the neuronal uptake of serotonin and norepinephrine. Buproprion also weakly inhibits the neuronal re-uptake of dopamine.","Bupropion | 1-Propanone, 1-(3-Chlorophenyl)-2-((1,1-dimethylethyl)amino)- | Amfebutamon | BUPROPION | bupropion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013085","Doxepin","C65475","A dibenzoxepin derivative and tricyclic antidepressant (TCA) with antipruritic, antidepressive and anxiolytic activities. Doxepin blocks the reuptake of norepinephrine and serotonin (5-HT) into presynaptic terminals thereby prolonging the availability of the monoaminergic neurotransmitters within the synaptic cleft and enhancing their neurotransmission. Doxepin also has antagonistic effects on histamine H1, 5-HT2, alpha-1 adrenergic, and muscarinic receptors. The antipruritic effect of this agent is mediated through inhibition of histamine receptors.","Doxepin | DOXEPIN | Silenor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040207","Ticlopidine","C61972","A thienopyridine derivative with anticoagulant activity. Ticlopidine inhibits adenosine-diphosphate (ADP) binding to its platelet receptor. This prevents ADP activation and inhibits platelet expression of the glycoprotein (GP) IIb/IIIA receptors, binding of fibrinogen to platelet glycoprotein GP IIb-IIIa and platelet-platelet interaction. This results in increased bleeding time.","Ticlopidine | TICLOPIDINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008845","Citalopram","C61680","A bicyclic phthalene derivative and selective serotonin reuptake inhibitor (SSRI), with antidepressant and anxiolytic activities. Citalopram selectively inhibits the neuronal reuptake of the neurotransmitter serotonin (5-HT) in presynaptic cells in the central nervous system, thereby increasing levels of 5-HT within the synaptic cleft and enhancing the actions of serotonin on its receptors. Increased serotonergic neurotransmission results in antidepressive and anxiolytic effects.","Citalopram | 1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile | CITALOPRAM | Cipram | Lu 10-171 | Nitalapram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1278444","Nicotine Replacement","C15710","Therapy to help control nicotine withdrawal symptoms during tobacco cessation","Nicotine Replacement | NRT | Nicotine Replacement Therapy | nicotine replacement therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1524026","Metabolic Process","C19536","Organic processes in a cell or organism that are necessary to sustain life. Cellular metabolism can be divided into two categories. Anabolism entails the construction of complex organic molecules from simpler precursors, while catabolism involves the breakdown of complex substances into simpler molecules.","Metabolic Process | Metabolic | Metabolic Process, Cellular | Metabolism | Metabolized | cellular metabolism | metabolism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040044","Thrombolytic Therapy","C15338","Any pharmacologic intervention used to destroy or dissolve a clot in a blood vessel or graft.","Thrombolytic Therapy | fibrinolytic therapy",,,,,,,,,,,,,,,"4145042","Thrombolytic therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1285521","Half","C81009","One of two equal parts; a quantity corresponding to one half of the whole.","Half | HEMI",,,,,,,,,,,,,,,"4180934","Hemi",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0694634","Intra-arterial","C94248","Within an artery (blood vessel that carries blood from the heart to tissues and organs in the body).","Intra-arterial | intra-arterial",,,,,,,,,,,,,,,"4041303","Intra-arterial",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706376","Mechanism Component of Device","C50285","A device consisting of moving parts designed to perform a function.","Mechanism Device | Mechanism | Mechanism Component of Device | Mechanism Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0070166","Clopidogrel","C61686","A thienopyridine, with antiplatelet activity. Clopidogrel targets, irreversibly binds to and alters the platelet receptor for adenosine diphosphate (ADP), thereby blocking the binding of ADP to its receptor, inhibiting ADP-mediated activation of the glycoprotein complex GPIIb/IIIa, and inhibiting fibrinogen binding to platelets and platelet adhesion and aggregation. This results in increased bleeding time.","Clopidogrel | CLOPIDOGREL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0935929","Anti-diabetic Agent","C29711","Any substance used to reduce hyperglycemia or treat disorders associated with diabetes. Based on their mechanism of action, this class of agents can be classified to the following groups: directly acting insulomimetics, which activates insulin receptors; indirectly acting insulinomimetics, which increase insulin release such as sulfonylureas or which potentiate the effect of insulin such as metformin; those act directly on the metabolism of glucose such as inhibitors of glucosidases and inhibitors of aldose reductase.","Anti-diabetic Agent | Anti-diabetics | Antidiabetic Agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831786","Hypofractionated Radiation Therapy","C62726","Radiation treatment in which the total dose of radiation is divided into large doses and treatments are given less than once a day.","Hypofractionated Radiation Therapy | Hypofractionated | Hypofractionated Radiotherapy | Radiation, Hypofractionated | hypofractionated radiation therapy | hypofractionation",,,,,,,,,,,,,,,"3655895","Hypofractionated radiation therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2985417","Primary Care Provider","C93060","A medical professional who provides, coordinates, or helps a patient access a range of health care services. This is usually a medical doctor (MD), but may also be a Doctor of Osteopathic Medicine, nurse practitioner, clinical nurse specialist, or physician assistant, as allowed under state law.","Primary Care Provider | PCP | Primary Care Doctor | Primary Care Doctor | Primary Care Physician | Primary Health Care Provider | primary care doctor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985450","Rehabilitation Specialist","C93127","A healthcare professional who helps people recover from an illness or injury and return to daily life. Examples of rehabilitation specialists are physical therapists and occupational therapists.","Rehabilitation Specialist | Rehabilitation Practitioner | rehabilitation specialist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0088688","Ropidoxuridine","C48813","An orally available 5-substituted 2-pyrimidinone-2'-deoxyribonucleoside analogue and prodrug of 5-iododeoxyuridine (IUdR), an iodinated analogue of deoxyuridine, with radiosensitizing activity. Upon oral administration, ropidoxuridine (IPdR) is efficiently converted to idoxuridine (IUdR) by a hepatic aldehyde oxidase. In turn, IUdR is incorporated into DNA during replication, thereby sensitizing cells to ionizing radiation by increasing DNA strand breaks. Compared to IUdR, ropidoxuridine is associated with a lower toxicity profile and improved anti-tumor activity.","Ropidoxuridine | 2(1H)-Pyrimidinone, 1-(2-deoxy-beta-D-erythro-pentofuranosyl)-5-iodo- | 5-Iodo-2-pyrimidinone 2' deoxyribonucleoside | 5-Iodo-2-pyrimidinone-2'-deoxyribose | 5-Iodo-2-pyrimidinone-2'-deoxyribose | IPdR | ROPIDOXURIDINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042256","Vaginal Itching","C35112","Itching of the skin of the vagina, vulva, and surrounding area.","Vaginal Itching | ",,,,,,,,,,,,,,,"4145769","Pruritus of vagina",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035953","Running","C94737","The act of traveling on foot at a fast pace.","Running | Run",,,,,,,,,,,,,,,"4168648","Running",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032043","Placenta","C13272","An organ present in some vertebrates during embryonic gestation that surrounds the fetus and provides it with nutrients and oxygen, facilitates gas and waste exchange between the fetus and mother, and provides parasitic cloaking from the mother's immune system by excretion of neurokinin B.","Placenta | PLACENTA | Placental | allantoic placenta | eutherian placenta | placenta",,,,,,,,,,,,,"UBERON:0001987","placenta","4299940","Placental structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0445623","Microorganism","C14329","A microscopic organism. The term microorganism may refer to a prokaryote or eukaryote, and may be a unicellular or multicellular organism. All taxonomic kingdoms contain microorganisms.","Microorganism | Micro-organism | Microbe | Microbial | Microorganisms | Microorganisms, General | Single-Celled Organism | microorganism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1550235","Cord - Body Parts","C61540","A long slender flexible material usually consisting of several strands woven or twisted together; a part of the body resembling a cord.","Cord | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827157","Fosbretabulin Tromethamine","C83721","The tromethamine salt form of prodrug fosbretabulin, a water-soluble phosphate derivative of a stilbenoid phenol derived from the African bush willow (Combretum caffrum) with antineoplastic activities. Upon administration, fosbretabulin is dephosphorylated to its active metabolite, combretastatin A4, which targets and binds to tubulin dimers and prevents microtubule polymerization, thereby resulting in mitotic arrest and apoptosis in endothelial cells. As apoptotic endothelial cells detach from their substrata, tumor blood vessels collapse; the acute disruption of tumor blood flow may result in tumor necrosis.","Fosbretabulin Tromethamine | 1,3-Dihydroxy-2-(Hydroxymethyl)Propan-2-Aminium 2-Methoxy-5-((1z)-2-(3,4,5-Trimethoxyphenyl)Ethenyl)Phenyl Hydrogen Phosphate | 1,3-Propanediol, 2-Amino-2-(Hydroxymethyl)-, Compd. With 2-Methoxy-5-((1z)-2-(3,4,5-Trimethoxyphenyl)Ethenyl)Phenyl Dihydrogen Phosphate (1:1) | CA4P | FOSBRETABULIN TROMETHAMINE | Zybrestat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985521","VEGFR Tyrosine Kinase Inhibitor","C93259","Any substance that inhibits vascular endothelial growth factor receptor, a family of tyrosine kinase receptors involved in the formation of blood vessels.","VEGFR Tyrosine Kinase Inhibitor | VEGFR Inhibitor | VEGFR tyrosine kinase inhibitor | vascular endothelial growth factor receptor tyrosine kinase inhibitor",,,,,,,,,,,,,,,"37206743","Vascular endothelial growth factor receptor antagonist",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827641","Unfavorable Shimada Classification","C85415","Patients of any age with stroma-poor tumors, undifferentiated or differentiated neuroblasts, and a mitosis-karyorrhexis index of more than 200; or patients older than 18 months with stroma-poor tumors, undifferentiated neuroblasts, and a mitosis-karyorrhexis index of 100-200; or patients older than 60 months with stroma-poor tumors, differentiated neuroblasts, and a mitosis-karyorrhexis index of less than 100.","Unfavorable Shimada Classification | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827640","Favorable Shimada Classification","C85414","Patients of any age with stroma-rich tumors and no nodular pattern; or patients younger than 18 months with stroma-poor tumors, a mitosis-karyorrhexis index of less than 200, and differentiated or undifferentiated neuroblasts; or patients younger than 60 months with stroma-poor tumors, a mitosis-karyorrhexis index of less than 100, and well-differentiated neuroblasts.","Favorable Shimada Classification | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205486","Psychological","C94316","Having to do with how the mind works and how thoughts and feelings affect behavior.","Psychological | psychological",,,,,,,,,,,,,,,"4246513","Psychologic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0489633","Review of Systems","C95618","A comprehensive assessment of a patient, which includes a subjective history taking component as well as an objective based structured interview and physical examination of all the body systems.","Review of Systems | ROS",,,,,,,,,,,,,,,"4187458","Review of systems",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1561595","Specimen Condition - Clotted","C78724","A specimen that has become coagulated.","Clotted Specimen | CLOTTED | Coagulated Specimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027853","Neurologic Examination","C81313","The assessment of the functionality of the brain, spinal column, and nerves.","Neurologic Examination | NVEXAM | Nervous System Examination | Neurological Assessment | Neurological Examination | neurological exam",,,,,,,,,,,,,,,"4021179|4225119","Neurological assessment|Neurological examination",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2827649","POG Neuroblastoma Stage A","C85424","The primary tumor is grossly completely resected; microscopic residual disease may be present or absent; lymph nodes adherent to the primary tumor may be positive; intracavitary lymph nodes not adherent to the primary tumor are negative; if the primary tumor is located in the abdomen or pelvis, the liver is not involved microscopically.","POG Neuroblastoma Stage A | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827650","POG Neuroblastoma Stage B","C85425","The primary tumor is grossly incompletely resected; lymph nodes and liver are not involved by tumor.","POG Neuroblastoma Stage B | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827651","POG Neuroblastoma Stage C","C85426","The primary tumor is grossly completely or incompletely resected; intracavitary lymph nodes not adherent to the primary tumor are positive microscopically; the liver is not involved microscopically.","POG Neuroblastoma Stage C | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827652","POG Neuroblastoma Stage D","C85427","Tumor has spread beyond the intracavitary lymph nodes.","POG Neuroblastoma Stage D | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827634","Evans Stage I","C85408","Tumor confined to the original site of growth.","Evans Stage I | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827635","Evans Stage II","C85409","Tumor spread in continuity beyond the original site of growth without crossing the midline. The lymph nodes on the homolateral site may or may not be affected.","Evans Stage II | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827636","Evans Stage III","C85410","Tumor spread in continuity beyond the midline or tumor spread to lymph nodes bilaterally.","Evans Stage III | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827637","Evans Stage IV","C85411","Tumor spread to distant anatomic sites.","Evans Stage IV | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827638","Evans Stage V","C85412","Tumor spread defined as stage I or II and distant metastasis confined to the liver, skin, and bone marrow.","Evans Stage V | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827642","INSS Stage 1","C85417","The tumor is confined to the original site of growth; no metastasis.","INSS Stage 1 | Stage 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827643","INSS Stage 2A","C85418","The tumor is unilateral and the resection is grossly incomplete; no evidence of lymph node involvement.","INSS Stage 2A | Stage 2A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827644","INSS Stage 2B","C85419","The tumor is unilateral and the resection is complete or incomplete; ipsilateral lymph nodes are involved by tumor.","INSS Stage 2B | Stage 2B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827645","INSS Stage 3","C85420","The tumor extends across the midline and the regional lymph nodes may or may not be involved by tumor; or the tumor is unilateral and the contralateral lymph nodes are involved by tumor; or the tumor is in midline and there is bilateral lymph node involvement by tumor.","INSS Stage 3 | Stage 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827646","INSS Stage 4","C85421","Tumor spread to distant lymph nodes, bone marrow, bones, and liver.","INSS Stage 4 | Stage 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827647","INSS Stage 4S","C85422","Patients are less than one year old with localized primary tumor and dissemination limited to the following specific anatomic sites: liver, skin, or bone marrow.","INSS Stage 4S | Stage 4S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332239","Alterations in Smell or Taste","C5038","A change to taste and/or olfactory perception resulting from disease processes or treatment.","Alterations in Smell or Taste | New_Olfactory_and_Taste_Disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826959","Questionnaire Data Collection Date Time","C83370","The date and time questionnaire data was collected.","Questionnaire Data Collection Date Time | QSDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0150063","Feeling powerless","C95745","A feeling of being unable to control yourself or your circumstances.","Helplessness | Helpessness | Helpless | Helplessness",,,,,,,,,,,,,,,"4140981","Feeling powerless",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013144","Sleepiness","C95746","The sensation of struggling to remain awake.","Sleepiness | Sleepy",,,,,,,,,,,,,,,"4152347","Drowsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0238196","Small Intestinal Carcinoma","C7724","A carcinoma arising from the small intestine. The vast majority are adenocarcinomas. The remaining cases are adenosquamous, squamous, or undifferentiated carcinomas.","Small Intestinal Carcinoma | Cancer of Small Bowel | Cancer of the Small Bowel | Carcinoma of Small Bowel | Carcinoma of Small Intestine | Carcinoma of the Small Bowel | Carcinoma of the Small Intestine | Small Bowel Cancer | Small Bowel Carcinoma | Small Intestinal Cancer | Small Intestine Cancer | Small intestine cancer, NOS | small intestine cancer",,,,,,,,,,,,,,,"40490989","Carcinoma of small intestine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036915","Sexuality","C92984","The feeling an individual has about their own sexual preferences and how those views are acted upon.","Sexuality | sexuality",,,,,,,,,,,,,,,"4040734","Finding related to sexual state",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4014210","Ischemic Stroke","C95802","An acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction of brain tissue.","Ischemic Stroke | Acute ischemic stroke | Arterial Ischemic Stroke | ISCHEMIC STROKE | Ischemia Stroke | Ischemic Cerebrovascular Accident | Ischemic Cerebrovascular Accident | Ischemic Stroke | Ischemic stroke",,,,,,,,,,,,,,,"4310996","Ischemic stroke",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4228092","Hemorrhagic Stroke","C95803","An acute episode of focal or global cerebral or spinal dysfunction caused by intraparenchymal, intraventricular, or subarachnoid hemorrhage.","Hemorrhagic Stroke | HEMORRHAGIC STROKE | Hemorrhagic Cerebrovascular Accident | Hemorrhagic Cerebrovascular Accident | Hemorrhagic Stroke | Hemorrhagic stroke",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007282","Carotid Artery Stenosis","C95804","A narrowing of the carotid artery lumen. It is usually caused by the formation of an atherosclerotic plaque. Symptoms are usually present when there is severe narrowing or obstruction of the arterial lumen and manifest as ischemic cerebrovascular accidents.","Carotid Artery Stenosis | ",,,,,,,,,,,,,,,"442615","Carotid artery stenosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035439","Rheumatic Heart Disease","C34882","An autoinflammatory condition following an infection with Group A Beta Hemolytic Streptococcus (GABHS), in which the heart is attacked by antibodies formed in reaction to a recent GABHS infection. Chief anatomic changes of the valve include leaflet thickening, commissural fusion, and shortening and thickening of the tendinous cords, all of which can result in valvular dysfunction.","Rheumatic Heart Disease | RHD",,,,,,,,,,,,,,,"319825","Rheumatic heart disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704436","Peripheral Artery Disease","C84496","A disorder of the arteries supplying the upper and lower extremity and the visceral organs. This includes the mesenteric arteries, the renal arteries and the aorta and excludes cerebrovascular arterial disease. Patients experience cramping and pain usually in the calves and thighs while walking. The symptoms subside with rest.","Peripheral Artery Disease | PAD | Peripheral Arterial Disease | Peripheral Arterial Disorder | Peripheral Arterial Disorder",,,,,,,,,,,,,,,"3654996","Peripheral arterial disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518681","Outcome of Therapy","C18919","The result of therapy for a given disease or condition in a patient or group of patients.","Outcome of Therapy | Therapy Effect | Therapy Outcome | Treatment Effect | Treatment Outcome | effect | treatment effect | treatment outcome | treatment_outcome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3279182","Congenital Heart Disease","C95834","A heart disease that is present at birth. Representative examples include atrial septal defect, ventricular septal defect, tetralogy of Fallot, and patent foramen ovale.","Congenital Heart Disease | ",,,,,,,,,,,,,,,"312723","Congenital heart disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015668","Fat Necrosis","C26772","Destruction of adipose tissue caused by the activity of lipase on damaged fat cells.","Fat Necrosis | fat necrosis",,,,,,,,,,,,,,,"4081236|4195121","Fat necrosis|Fat necrosis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0009072","Clothing","C86930","A covering designed to be worn on the body.","Clothing | Clothes | Garment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4014726","Joint Stiffness","C79603","A sensation of discomfort and tightness while moving a joint. Typically there is decreased joint range of motion. Causes include arthritis, joint overuse, joint injury, and the aging process.","Joint Stiffness | ",,,,,,,,,,,,,,,"72404","Joint stiffness",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0050380","ABVD","C9509","A regimen consisting of doxorubicin, bleomycin, vinblastine and dacarbazine that can be used in the treatment of Hodgkin lymphoma (HL).","ABVD Regimen | ABVD | ABVD regimen | Adriamycin-Bleomycin-Vinblastine-Dacarbazine Regimen | BLEO/DOX/DTIC/VBL | Bleomycin/Dacarbazine/Doxorubicin/Vinblastine | Doxorubicin/Bleomycin/Vinblastine/Dacarbazine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986411","Improvement","C94226","A condition superior to an earlier condition.","Improvement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0238598","Young Adult","C91107","An age group comprised of individuals who have reached sexual maturity but whose character and personality are still developing. In psychology this generally covers the age range of 20-40.","Young Adult | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033611","Protective Clothing","C95904","Clothing designed to protect the wearer from injury or exposure to hazardous conditions or substances.","Protective Clothing | Protective Garment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4231481","Facial Nerve Paralysis","C26769","Partial or complete paralysis of the facial muscles of one side of a person's face. It is caused by damage to the seventh cranial nerve. It is usually temporary but it may recur.","Facial Nerve Paralysis | Bell's Palsy | Cranial Nerve VII Palsy | Cranial Nerve VII Palsy | Cranial nerve palsy VII | Facial Nerve Palsy | Facial Nerve Palsy | Facial Nerve Paralysis | Facial Palsy | Facial Paralysis | Facial nerve palsy",,,,,,,,,,,,,,,"374923","Bell's palsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0442111","Intracerebral","C43302","Of, ocurring in, or situated within the cerebrum.","Intracerebral | ",,,,,,,,,,,,,,,"4112420","Intracerebral",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0475383","T1a TNM Finding","C48721","A general term that refers to a TNM finding of a primary tumor limited to the site of growth.  The definition of T1a TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to a primary tumor that is more than 0.1cm, but not more than 0.5 cm in greatest dimension; for kidney cancer it refers to a primary tumor that is 4 cm or less in greatest dimension; and for thyroid cancer it refers to a primary tumor that is 1 cm or less in greatest dimension.","T1a TNM Finding | T1a | T1a Cancer Stage Finding | T1a Primary Tumor Finding | T1a Primary Tumor Stage Finding | T1a Stage | T1a Stage Finding | T1a Stage Finding | T1a TNM Finding | T1a Tumor Finding | T1a Tumor Stage | Tumor Stage T1a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475385","T1b TNM Finding","C48722","A general term that refers to a TNM finding of a primary tumor limited to the site of growth.  The definition of T1b TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to a primary tumor that is more than 0.5 cm, but not more than 1.0 cm in greatest dimension; for kidney cancer it refers to a primary tumor that is more than 4 cm, but not more than 7 cm in greatest dimension; and for thyroid cancer it refers to a primary tumor that is more than 1 cm but not more than 2 cm in greatest dimension.","T1b TNM Finding | T1b | T1b Cancer Stage Finding | T1b Primary Tumor Finding | T1b Primary Tumor Stage Finding | T1b Stage | T1b Stage Finding | T1b Stage Finding | T1b TNM Finding | T1b Tumor Finding | T1b Tumor Stage | Tumor Stage T1b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3834244","T1c TNM Finding","C48723","A general term that refers to a TNM finding of a primary tumor limited to the site of growth.  The definition of T1c TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to a primary tumor that is more than 1.0 cm, but not more than 2.0 cm in greatest dimension; for uterine corpus cancer it refers to a primary tumor that invades one-half or more of the myometrium; and for melanoma of the iris it refers to a primary tumor limited to the iris with secondary glaucoma.","T1c TNM Finding | T1c | T1c Cancer Stage Finding | T1c Primary Tumor Finding | T1c Primary Tumor Stage Finding | T1c Stage | T1c Stage Finding | T1c Stage Finding | T1c TNM Finding | T1c Tumor Finding | T1c Tumor Stage | Tumor Stage T1c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3869913","T1mi TNM Finding","C95805","A term that refers to a TNM finding of a primary tumor limited to the site of growth and indicates microinvasion only.","T1mi TNM Finding | T1mi | T1mi Stage Finding | T1mi Stage Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475387","T2a TNM Finding","C48725","A general term that refers to a TNM finding of a primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2a TNM finding depends on the specific type of cancer that it refers to; for example, for kidney cancer it refers to a primary tumor that measures more than 7 cm but less than or equal to 10 cm in greatest dimension, and is limited to the kidney; for bladder cancer it refers to a primary tumor that invades the superficial muscularis propria (inner half); for cervical cancer it refers to a primary tumor that invades beyond the uterus but not to the pelvic wall or to the lower third of vagina and there is no parametrial invasion.","T2a TNM Finding | T2a | T2a Cancer Stage Finding | T2a Primary Tumor Finding | T2a Primary Tumor Stage Finding | T2a Stage | T2a Stage Finding | T2a Stage Finding | T2a TNM Finding | T2a Tumor Finding | T2a Tumor Stage | Tumor Stage T2a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3833471","T2b TNM Finding","C48726","A general term that refers to a TNM finding of a primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2b TNM finding depends on the specific type of cancer that it refers to; for example, for kidney cancer it refers to a primary tumor that measures more than 10 cm in greatest dimension, and is limited to the kidney; for bladder cancer it refers to a primary tumor that invades the deep muscularis propria (outer half); for cervical cancer it refers to a primary tumor that invades beyond the uterus but not to the pelvic wall or to the lower third of vagina and there is parametrial invasion.","T2b TNM Finding | T2b | T2b Cancer Stage Finding | T2b Primary Tumor Finding | T2b Primary Tumor Stage Finding | T2b Stage | T2b Stage Finding | T2b Stage Finding | T2b TNM Finding | T2b Tumor Finding | T2b Tumor Stage | Tumor Stage T2b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475389","T2c TNM Finding","C48727","A general term that refers to a TNM finding of a primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2c TNM finding depends on the specific type of cancer that it refers to; for example, for prostate cancer it refers to a primary tumor that involves both lobes of the prostate gland; for ovarian cancer it refers to a primary tumor that involves one or both ovaries with extension or implants on the uterus and/or fallopian tubes, or other pelvic tissues, with malignant cells in either ascites or peritoneal washings; for fallopian tube cancer it refers to a primary tumor with pelvic extension and malignant cells in ascites or peritoneal washings.","T2c TNM Finding | T2c | T2c Cancer Stage Finding | T2c Primary Tumor Finding | T2c Primary Tumor Stage Finding | T2c Stage | T2c Stage Finding | T2c Stage Finding | T2c TNM Finding | T2c Tumor Finding | T2c Tumor Stage | Tumor Stage T2c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475390","T3a TNM Finding","C48729","A general term that refers to a TNM finding of a primary tumor usually indicating that the cancer is locally invasive. The definition of T3a TNM finding depends on the specific type of cancer that it refers to; for example, for kidney cancer it refers to a primary tumor that grossly extends into the renal vein or its segmental (muscle containing) branches or the tumor invades perirenal and/or renal sinus fat but does not extends beyond Gerota's fascia; for cervical cancer it refers to a primary tumor that involves the lower third of vagina, without extension to pelvic wall; for liver cancer it refers to the presence of multiple tumors measuring more than 5 cm in greatest dimension.","T3a TNM Finding | T3a | T3a Cancer Stage Finding | T3a Primary Tumor Finding | T3a Primary Tumor Stage Finding | T3a Stage | T3a Stage Finding | T3a Stage Finding | T3a TNM Finding | T3a Tumor Finding | T3a Tumor Stage | Tumor Stage T3a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475391","T3b TNM Finding","C48730","A general term that refers to a TNM finding of a primary tumor usually indicating that the cancer is locally invasive. The definition of T3b TNM finding depends on the specific type of cancer that it refers to; for example, for kidney cancer it refers to a primary tumor that grossly extends into the vena cava below the diaphragm; for cervical cancer it refers to a primary tumor that extends to the pelvic wall and/or causes hydronephrosis or nonfunctioning kidney; for liver cancer it refers to a single tumor or multiple tumors of any size involving a major branch of the portal vein or hepatic vein.","T3b TNM Finding | T3b | T3b Cancer Stage Finding | T3b Primary Tumor Finding | T3b Primary Tumor Stage Finding | T3b Stage | T3b Stage Finding | T3b Stage Finding | T3b TNM Finding | T3b Tumor Finding | T3b Tumor Stage | Tumor Stage T3b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475394","T3c TNM Finding","C48731","A general term that refers to a TNM finding of a primary tumor usually indicating that the cancer is locally invasive. The definition of T3c TNM finding depends on the specific type of cancer that it refers to; for example, for kidney cancer it refers to a primary tumor that grossly extends into the vena cava above the diaphragm, or invades the wall of the vena cava; for fallopian tube cancer it refers to a primary tumor with peritoneal metastasis outside the pelvis measuring more than 2 cm in diameter; for melanoma of the conjunctiva it refers to a primary tumor invading the orbit.","T3c TNM Finding | T3c | T3c Cancer Stage Finding | T3c Primary Tumor Finding | T3c Primary Tumor Stage Finding | T3c Stage | T3c Stage Finding | T3c Stage Finding | T3c TNM Finding | T3c Tumor Finding | T3c Tumor Stage | Tumor Stage T3c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475395","T4a TNM Finding","C48733","A general term that refers to a TNM finding of a primary tumor with direct invasion of adjacent structures. The definition of T4a TNM finding depends on the specific type of cancer that it refers to; for example, for bladder cancer it refers to a primary tumor that invades the prostatic stroma, uterus, and vagina; for gastric cancer it refers to a primary tumor that invades the serosa (visceral peritoneum); for colorectal cancer it refers to a primary tumor that penetrates to the surface of the visceral peritoneum.","T4a TNM Finding | T4a | T4a Cancer Stage Finding | T4a Primary Tumor Finding | T4a Primary Tumor Stage Finding | T4a Stage | T4a Stage Finding | T4a Stage Finding | T4a TNM Finding | T4a Tumor Finding | T4a Tumor Stage | Tumor Stage T4a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475396","T4b TNM Finding","C48734","A general term that refers to a TNM finding of a primary tumor with direct invasion of adjacent structures. The definition of T4b TNM finding depends on the specific type of cancer that it refers to; for example, for bladder cancer it refers to a primary tumor that invades the pelvic wall and abdominal wall; for gastric cancer it refers to a primary tumor that invades adjacent structures; for colorectal cancer it refers to a primary tumor with direct invasion or adherence to other organs or structures.","T4b TNM Finding | T4b | T4b Cancer Stage Finding | T4b Primary Tumor Finding | T4b Primary Tumor Stage Finding | T4b Stage | T4b Stage Finding | T4b Stage Finding | T4b TNM Finding | T4b Tumor Finding | T4b Tumor Stage | Tumor Stage T4b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475397","T4c TNM Finding","C48735","A general term that refers to a TNM finding of a primary tumor with direct invasion of adjacent structures. The definition of T4c TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to a primary tumor that extends to the chest wall, not including the pectoralis muscle, and with edema (including peau d'orange) or ulceration of the skin of the breast or satellite skin nodules confined to the same breast; for ocular adnexal lymphoma it refers to a primary tumor that Involves the maxillofacial, ethmoidal, and/or frontal sinuses; for carcinoma of the conjunctiva it refers to a primary tumor that invades adjacent paranasal sinuses.","T4c TNM Finding | T4c | T4c Cancer Stage Finding | T4c Primary Tumor Finding | T4c Primary Tumor Stage Finding | T4c Stage | T4c Stage Finding | T4c Stage Finding | T4c TNM Finding | T4c Tumor Finding | T4c Tumor Stage | Tumor Stage T4c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3833423","T4d TNM Finding","C48736","A general term that refers to a TNM finding of a primary tumor with direct invasion of adjacent structures. The definition of T4d TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to a primary tumor that meets the clinical-pathologic criteria of inflammatory carcinoma; for ocular adnexal lymphoma it refers to a primary tumor with intracranial spread; for carcinoma of the conjunctiva it refers to a primary tumor that invades the brain.","T4d TNM Finding | T4d | T4d Cancer Stage Finding | T4d Primary Tumor Finding | T4d Primary Tumor Stage Finding | T4d Stage | T4d Stage Finding | T4d Stage Finding | T4d TNM Finding | T4d Tumor Finding | T4d Tumor Stage | Tumor Stage T4d",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272445","Phosphatidylinositol N-Acetylglucosaminyltransferase Subunit A","C95927","Phosphatidylinositol N-acetylglucosaminyltransferase subunit A (484 aa, ~54 kDa) is encoded by the human PIGA gene. This protein is involved in the mediation of glycophosphoinositol anchor synthesis.","Phosphatidylinositol N-Acetylglucosaminyltransferase Subunit A | EC 2.4.1.198 | GlcNAc-PI Synthesis Protein | PIG-A | PIGA | Phosphatidylinositol Glycan Anchor Biosynthesis, Class A | Phosphatidylinositol-Glycan Biosynthesis Class A Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0108793","Complement Decay-Accelerating Factor","C95931","Complement decay-accelerating factor (381 aa, ~41 kDa) is encoded by the human CD55 gene. This protein plays a role in the negative regulation of the complement cascade.","Complement Decay-Accelerating Factor | CD Antigen CD55 | CD55 | CD55 Antigen | CD55 Protein | DAF | Decay Accelerating Factor | Decay-Accelerating Factor | Decay-Accelerating Factor for Complement",,,,,,,,,,,,,,,"4311401","Decay accelerating factor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0054966","CD59 Glycoprotein","C95934","CD59 glycoprotein (128 aa, ~14 kDa) is encoded by the human CD59 gene. This protein is involved in the inhibition of the assembly of the membrane attack complex in the complement cascade.","CD59 Glycoprotein | 1F5 Antigen | 20 kDa Homologous Restriction Factor | CD Antigen CD59 | CD59 | CD59 Antigen | CD59 Protein | HRF-20 | HRF20 | Human Leukocyte Antigen MIC11 | MAC-IP | MAC-Inhibitory Protein | MACIF | MEM43 Antigen | MIRL | Membrane Attack Complex Inhibition Factor | Membrane Inhibitor of Reactive Lysis | Protectin",,,,,,,,,,,,,,,"4226977","Lymphocyte antigen CD59",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL426355","Delivery of Placenta","C92766","The natural process whereby the placenta detaches from the uterus. It occurs during the third stage of childbirth and shortly after delivery of the fetus.","Delivery of Placenta | Placenta Delivery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0445036","M1a Stage Finding","C48701","A TNM finding indicating the spread of cancer to distant anatomic sites.  The definition of M1a TNM finding depends on the specific type of cancer that it refers to; for example, for colorectal cancer it refers to metastasis confined to one organ or site (e.g., liver, lung, ovary, nonregional node); for prostate cancer it refers to metastasis to non-regional lymph node(s); for bone cancer it refers to metastasis to the lung.","M1a TNM Finding | M1a | M1a Cancer Stage Finding | M1a Distant Metastasis Finding | M1a Distant Metastasis Stage Finding | M1a Metastasis Finding | M1a Metastasis Stage | M1a Stage | M1a Stage Finding | M1a Stage Finding | M1a TNM Finding | Metastasis Stage M1a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0445064","M1b Stage Finding","C48702","A TNM finding indicating the spread of cancer to distant anatomic sites.  The definition of M1b TNM finding depends on the specific type of cancer that it refers to; for example, for colorectal cancer it refers to metastases in more than one organ/site or the peritoneum; for prostate cancer it refers to metastasis to bone(s); for bone cancer it refers to metastasis to distant sites other than lung.","M1b TNM Finding | M1b | M1b Cancer Stage Finding | M1b Distant Metastasis Finding | M1b Distant Metastasis Stage Finding | M1b Metastasis Finding | M1b Metastasis Stage | M1b Stage | M1b Stage Finding | M1b Stage Finding | M1b TNM Finding | Metastasis Stage M1b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0445037","M1c Stage Finding","C48703","A TNM finding indicating the spread of cancer to distant anatomic sites.  The definition of M1c TNM finding depends on the specific type of cancer that it refers to; for example, for prostate cancer it refers to metastasis to anatomic site(s) other than bone, with or without bone disease; for retinoblastoma it refers to central nervous system metastasis; for melanoma of the uvea it refers to distant metastasis, with the largest diameter of the largest metastasis measuring 8.0 cm or more.","M1c TNM Finding | M1c | M1c Cancer Stage Finding | M1c Distant Metastasis Finding | M1c Distant Metastasis Stage Finding | M1c Metastasis Finding | M1c Metastasis Stage | M1c Stage | M1c Stage Finding | M1c Stage Finding | M1c TNM Finding | Metastasis Stage M1c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272458","cM0 (i+)","C95956","A distant metastasis TNM finding indicating that there is no evidence of distant metastasis clinically or by radiologic studies, but there are small numbers of cells detected by special studies in the blood and bone marrow, or there is tiny metastasis (no larger than 0.2 mm) detected in nonregional lymph nodes.","cM0 (i+) TNM Finding | cM0 (i+) | cM0 (i+) Finding | cM0 (i+) Stage Finding | cM0 (i+) Stage Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456906","N1a TNM Finding","C48707","A general term that refers to a TNM finding of cancer metastases usually in a limited number of regional lymph nodes. The definition of N1a TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastasis in 1 to 3 axillary lymph nodes (at least 1 tumor deposit greater than 2.0 mm); for cutaneous melanoma it refers to micrometastasis in one regional lymph node; for colorectal cancer it refers to metastasis in one regional lymph node.","N1a TNM Finding | Lymph Node Stage N1a | N1a | N1a Cancer Stage Finding | N1a Lymph Node Finding | N1a Lymph Node Stage | N1a Node Finding | N1a Node Stage | N1a Regional Lymph Node Stage Finding | N1a Regional Lymph Nodes Finding | N1a Stage | N1a Stage Finding | N1a Stage Finding | N1a TNM Finding | Node Stage N1a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456908","N1b TNM Finding","C48708","A general term that refers to a TNM finding of cancer metastases usually in a limited number of regional lymph nodes. The definition of N1b TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected; for cutaneous melanoma it refers to macrometastasis in one regional lymph node; for colorectal cancer it refers to metastasis in 2-3 regional lymph nodes.","N1b TNM Finding | Lymph Node Stage N1b | N1b | N1b Cancer Stage Finding | N1b Lymph Node Finding | N1b Lymph Node Stage | N1b Node Finding | N1b Node Stage | N1b Regional Lymph Node Stage Finding | N1b Regional Lymph Nodes Finding | N1b Stage | N1b Stage Finding | N1b Stage Finding | N1b TNM Finding | Node Stage N1b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709107","N1c TNM Finding","C48709","A general term that refers to a TNM finding of cancer metastases usually in a limited number of regional lymph nodes. The definition of N1c TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in 1 to 3 axillary lymph nodes and in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected; for colorectal cancer it refers to tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional lymph node metastasis.","N1c TNM Finding | Lymph Node Stage N1c | N1c | N1c Cancer Stage Finding | N1c Lymph Node Finding | N1c Lymph Node Stage | N1c Node Finding | N1c Node Stage | N1c Regional Lymph Node Stage Finding | N1c Regional Lymph Nodes Finding | N1c Stage | N1c Stage Finding | N1c Stage Finding | N1c TNM Finding | Node Stage N1c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0445079","N2a TNM Finding","C48711","A general term that refers to a TNM finding of cancer metastases in several regional lymph nodes.  The definition of N2a TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in 4 to 9 axillary lymph nodes (at least 1 tumor deposit greater than 2.0 mm); for cutaneous melanoma it refers to micrometastases in 2-3 regional lymph nodes; for colorectal cancer it refers to metastases in 4-6 regional lymph nodes.","N2a TNM Finding | Lymph Node Stage N2a | N2a | N2a Cancer Stage Finding | N2a Lymph Node Finding | N2a Lymph Node Stage | N2a Node Finding | N2a Node Stage | N2a Regional Lymph Node Stage Finding | N2a Regional Lymph Nodes Finding | N2a Stage | N2a Stage Finding | N2a Stage Finding | N2a TNM Finding | Node Stage N2a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0445080","N2b TNM Finding","C48712","A general term that refers to a TNM finding of cancer metastases in several regional lymph nodes.  The definition of N2b TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases only in clinically detected ipsilateral internal mammary nodes and in the absence of clinically evident level I, II axillary lymph node metastases; for cutaneous melanoma it refers to macrometastases in 2-3 regional lymph nodes; for colorectal cancer it refers to metastases in seven or more regional lymph nodes.","N2b TNM Finding | Lymph Node Stage N2b | N2b | N2b Cancer Stage Finding | N2b Lymph Node Finding | N2b Lymph Node Stage | N2b Node Finding | N2b Node Stage | N2b Regional Lymph Node Stage Finding | N2b Regional Lymph Nodes Finding | N2b Stage | N2b Stage Finding | N2b Stage Finding | N2b TNM Finding | Node Stage N2b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3833426","N2c TNM Finding","C48713","A general term that refers to a TNM finding of cancer metastases in several regional lymph nodes.  The definition of N2c TNM finding depends on the specific type of cancer that it refers to; for example, for cutaneous melanoma it refers to intralymphatic metastases (in transit or satellite metastases) without metastatic nodes; for lip and oral cavity cancer it refers to metastases in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension.","N2c TNM Finding | Lymph Node Stage N2c | N2c | N2c Cancer Stage Finding | N2c Lymph Node Finding | N2c Lymph Node Stage | N2c Node Finding | N2c Node Stage | N2c Regional Lymph Node Stage Finding | N2c Regional Lymph Nodes Finding | N2c Stage | N2c Stage Finding | N2c Stage Finding | N2c TNM Finding | Node Stage N2c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831805","N3a TNM Finding","C48715","A general term that refers to a TNM finding of cancer metastases in multiple lymph nodes.  The definition of N3a TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in 10 or more axillary lymph nodes (at least one tumor deposit greater than 2.0 mm) or metastases to the infraclavicular (level III axillary) lymph nodes; for gastric cancer it refers to metastases in 7-15 regional lymph nodes; for nasopharyngeal cancer it refers to metastases to one or more lymph nodes greater than 6 cm in greatest dimension.","N3a TNM Finding | Lymph Node Stage N3a | N3a | N3a Cancer Stage Finding | N3a Lymph Node Finding | N3a Lymph Node Stage | N3a Node Finding | N3a Node Stage | N3a Regional Lymph Node Stage Finding | N3a Regional Lymph Nodes Finding | N3a Stage | N3a Stage Finding | N3a Stage Finding | N3a TNM Finding | Node Stage N3a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3833393","N3b TNM Finding","C48716","A general term that refers to a TNM finding of cancer metastases in multiple lymph nodes.  The definition of N3b TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in clinically detected ipsilateral internal mammary lymph nodes in the presence of one or more positive axillary lymph nodes, or in more than 3 axillary lymph nodes and in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected; for gastric cancer it refers to metastases in sixteen or more regional lymph nodes; for nasopharyngeal cancer it refers to extension to the supraclavicular fossa.","N3b TNM Finding | Lymph Node Stage N3b | N3b | N3b Cancer Stage Finding | N3b Lymph Node Finding | N3b Lymph Node Stage | N3b Node Finding | N3b Node Stage | N3b Regional Lymph Node Stage Finding | N3b Regional Lymph Nodes Finding | N3b Stage | N3b Stage Finding | N3b Stage Finding | N3b TNM Finding | Node Stage N3b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709110","N3c TNM Finding","C48717","A general term that refers to a TNM finding of cancer metastases in multiple lymph nodes.  The definition of N3c TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in ipsilateral supraclavicular lymph nodes.","N3c TNM Finding | Lymph Node Stage N3c | N3c | N3c Cancer Stage Finding | N3c Lymph Node Finding | N3c Lymph Node Stage | N3c Node Finding | N3c Node Stage | N3c Regional Lymph Node Stage Finding | N3c Regional Lymph Nodes Finding | N3c Stage | N3c Stage Finding | N3c Stage Finding | N3c TNM Finding | Node Stage N3c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272440","N0 (i-)","C95921","A regional lymph node TNM finding indicating that there is no evidence of regional lymph node metastasis histologically, and immunohistochemistry is negative.","pN0 (i-) TNM Finding | N0 (i-) | N0 (i-) Stage Finding | N0 (i-) Stage Finding | N0 (i-) TNM Finding | N0 (i-) TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272441","N0 (i+)","C95922","A regional lymph node TNM finding indicating that there are malignant cells in regional lymph node(s) no greater than 0.2 mm and are detected by hematoxylin and eosin stain or immunohistochemistry.","pN0 (i+) TNM Finding | N0 (i+) | N0 (i+) Stage Finding | N0 (i+) Stage Finding | N0 (i+) TNM Finding | N0 (i+) TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272442","N0 (mol-)","C95923","A regional lymph node TNM finding indicating that there is no evidence of regional lymph node metastasis histologically and molecular analysis (RT-PCR) is negative.","pN0 (mol-) TNM Finding | N0 (mol-) | N0 (mol-) Stage Finding | N0 (mol-) Stage Finding | N0 (mol-) TNM Finding | N0 (mol-) TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272443","N0 (mol+)","C95925","A regional lymph node TNM finding indicating that there is no evidence of regional lymph node metastasis histologically and by immunohistochemistry, but the molecular analysis (RT-PCR) is positive.","pN0 (mol+) TNM Finding | N0 (mol+) | N0 (mol+) Stage Finding | N0 (mol+) Stage Finding | N0 (mol+) TNM Finding | N0 (mol+) TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272446","N1bI Stage Finding","C95929","A regional lymph node TNM finding indicating that there is metastasis to 1-3 nodes.  The metastasis is greater than 2 mm and all are less than 20 mm.","N1bI Stage Finding | N1bI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272449","N1bII Stage Finding","C95935","A regional lymph node TNM finding indicating that there is metastasis to four or more nodes.  The metastasis is greater than 2 mm and all are less than 20 mm.","N1bII Stage Finding | N1bII",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272450","N1bIII Stage Finding","C95936","A regional lymph node TNM finding indicating that the tumor extends beyond the lymph node capsule and is less than 20 mm.","N1bIII Stage Finding | N1bIII",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272451","N1bIV Stage Finding","C95937","A regional lymph node TNM finding indicating that the metastases to the lymph nodes are more than 20 mm.","N1bIV Stage Finding | N1bIV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3869928","N1mi TNM Finding","C95955","A regional lymph node TNM finding indicating the presence of micrometastases (greater than 0.2 mm and/or more than 200 cells, but none greater than 2.0 mm).","N1mi TNM Finding | N1mi | N1mi Stage Finding | N1mi Stage Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202236","Triglyceride Measurement","C64812","A quantitative measurement of the amount of triglyceride present in a sample.","Triglyceride Measurement | TRIG | Triglycerides",,,,,,,,,,,,,,,"4032789","Triglycerides measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1445957","Serum Total Cholesterol Measurement","C61032","A quantitative measurement of the total amount of cholesterol present in a sample of serum.","Serum Total Cholesterol Measurement | Total Cholesterol",,,,,,,,,,,,,,,"4260765","Serum total cholesterol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2985545","Healthcare Proxy","C93314","A type of advance directive that gives a person (such as a relative, lawyer, or friend) the authority to make healthcare decisions for another person. It becomes active when that person loses the ability to make decisions for himself or herself.","Healthcare Proxy | HCP | healthcare proxy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002475","Mitomycin","C1820","A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species.  Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.  Preferentially toxic to hypoxic cells, mitomycin C also inhibits RNA and protein synthesis at high concentrations. (NCI04)","Mitomycin | (1aS,8S,8aR,8bS)-6-Amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione | Ametycine | Jelmyto | MITO | MITO-C | MITOMYCIN | MITOMYCIN C | Mito-C | Mito-Medac | Mitocin | Mitocin-C | Mitolem | Mitomycin C | Mitomycin C | Mitomycin pyelocalyceal | Mitomycin-C | Mitomycin-X | Mitomycine C | Mitosol | Mitozytrex | Mutamycin | Mutamycine | NCI-C04706 | [1aS-(1a alpha,8beta,8a alpha,8b alpha)]-6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0059541","erythritol anhydride","C44373","A colorless, highly flammable, liquid cyclic ether. Diepoxybutane is primarily used for research purposes, but is also used as a curing agent for polymer resins and as a cross-linking agent for making synthetic textile fibers. Exposure to this substance can severely irritate and burn the eyes and skin and can cause liver damage. Diepoxybutane is reasonably anticipated to be a human carcinogen based on evidence of carcinogenicity in experimental animals. (NCI05)","Diepoxybutane | 1,1'-Bi(ethylene Oxide) | 1,2,3,4- Diepoxybutane | 2,2'-Bioxirane | Butadiene Dioxide | DEB | DIEPOXYBUTANE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003138","Antacid Preparation","C29633","Natural or synthetic compounds or mixtures, Antiacid Preparations such as sodium bicarbonate, sodium citrate, and phosphate salts act as proton acceptors, neutralizing the acidity of a biologic environment (skin, gastric content, urine, etc.) and raising the pH. These agents are used topically or systemically for management of metabolic acidosis, improved muscle contraction, and hyper-acidic conditions (preventing, counteracting, or neutralizing stomach acidity). (NCI04)","Antacid Preparation | Antacids",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019593","Histamine-2 Receptor Antagonist","C29702","Any agent that competitively binds to and blocks the histamine H2 receptors found in the stomach, heart, uterus, on vascular smooth muscle and in the central nervous system (CNS). Of particular clinical relevance is the blockage of H2 receptors found on the parietal cells of the stomach, which prevents gastric acid secretion.","Histamine-2 Receptor Antagonist | H2 Antagonist | H2 Blocker | H2 Blockers | H2 Receptor Antagonist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0358591","Proton Pump Inhibitor","C29723","Any one of the substituted benzimidazole compounds with anti-ulcer activity. A proton pump inhibitor is orally administered in the neutrally charged, inactive form and, upon entering the acidic environment of the parietal cell, gets protonated and converted into its active form. The active form will covalently and irreversibly bind to the proton pump, the H+/K+-ATPase, located on the surface of parietal cells. This leads to an inhibition of the transport of hydrogen ions, in exchange for potassium ions, into the gastric lumen and results in an inhibition of gastric acid secretion.","Proton Pump Inhibitor | PPI | Proton Pump Inhibitors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0850666","Helicobacter Pylori Infection","C39293","A bacterial infection of the stomach, caused by Helicobacter pylori.  It is associated with the development of peptic ulcer and mucosa-associated lymphoid tissue lymphoma.","Helicobacter Pylori Infection | H. Pylori Infection | H. pylori Infection",,,,,,,,,,,,,,,"36717498","Infection caused by Helicobacter pylori",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3272459","Stage X","C95957","A stage term that is applied to patients who have not been evaluated, but are presumed to have cancer.","Stage X | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3536806","Home Health Nursing","C20883","Professional nursing care provided within the home of the individual under care.","Home Health Nursing | HOME, NURSING CARE | Visiting Nursing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085555","Hospice Care","C15252","The active total care of patients whose disease is not responsive to curative treatment. The goal of palliative care is achievement of the best possible quality of life for patients and their families. Control of pain, of other symptoms, and of psychological, social, and spiritual problems is paramount. Palliative care affirms life and regards dying as a normal process, neither hastens nor postpones death, provides relief from pain and other distressing symptoms, integrates the psychological and spiritual aspects of patient care, offers a support system to help patients live as actively as possible until death, and offers a support system to help the family cope during the patient's illness and in their own bereavement. (World Health Organization)","Hospice Care | End of Life Care | Hospice | hospice",,,,,,,,,,,,,,,"4301458","Hospice care",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040987","Trifluridine","C905","A fluorinated thymidine analog with potential antineoplastic activity. Trifluridine is incorporated into DNA and inhibits thymidylate synthase, resulting in inhibition of DNA synthesis, inhibition of protein synthesis, and apoptosis. This agent also exhibits antiviral activity. (NCI04)","Trifluridine | 2'-Deoxy-5-trifluoromethyluridine | F3TdR | TRIFLURIDINE | Triflorothymidine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL421635","Adenoviral Vector Ad5-CEA(6D) Vaccine","C91373","A replication-defective, E1- and E2b-deleted oncolytic adenoviral serotype 5 (Ad5) encoding an epitope of human carcinoembryonic antigen (CEA) with potential antineoplastic activity. Adenoviral vector Ad5-CEA(6D) vaccine expresses a highly immunogenic analogue of CEA [CAP1-(6D)]. Upon administration, this vaccine may induce both humoral and cellular immune responses against tumor cells expressing the CEA antigen, thereby resulting in the immune-mediated inhibition of tumor cell proliferation and tumor cell death. CEA, a tumor-associated antigen, is overexpressed in various tumor cell types. Deletion of early genes E1 and E2b in Ad5 potentially circumvent pre-existing anti-adenovirus immunity and is capable of inducing strong immune responses.","Adenoviral Vector Ad5-CEA(6D) Vaccine | Ad5 CEA Vaccine | ETBX-011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2975147","Onalespib","C85454","A synthetic, orally bioavailable, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Onalespib selectively binds to Hsp90, thereby inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability and degradation of many oncogenic signaling proteins.","Onalespib | (2,4-Dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone | AT 13387 | AT-13387 | AT13387 | Hsp90 Inhibitor AT13387 | ONALESPIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0344441","Histologic Test","C49131","A diagnostic test used to examine and define microscopic tissue structure, composition, or etiology. The test results are often used by a clinician to diagnose disease or disordered function.","Histologic Test | ",,,,,,,,,,,,,,,"37018329","Histologic test",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0439199","Decimeter","C64698","The metric unit of length equal to one tenth of a meter.","Decimeter | decimeter | dm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517294","foreign","C25512","Not belonging to that in which it is contained; introduced from an outside source.","Foreign | FOREIGN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827485","Dried Specimen","C84516","Tissue which has been kept dry.","Dried Specimen | DRIED | Dried",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827484","Fixed Slide","C84515","A slide on which a fixed specimen has been mounted.","Fixed Slide | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827483","Fixed Specimen","C84514","Tissue which is preserved in a fixative solution, usually formalin.","Fixed Specimen | Fixed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827486","Fresh Specimen","C84517","Tissue which has not been exposed to a fixative solution.","Fresh Specimen | FRESH | Fresh | Fresh frozen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827487","Touch Prep Slide","C84518","A glass slide with attached tissue prepared by direct touching of the tissue to the slide.","Touch Prep Slide | Touch Preparation | Touch Preparation Slide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827488","Zinc-Based Fixative","C84519","A fixative solution which contains zinc salts.","Zinc-Based Fixative | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3163821","Appendix Carcinoma","C9330","A malignant epithelial neoplasm arising from the appendix.  The vast majority of the cases are adenocarcinomas.","Appendix Carcinoma | Appendiceal Cancer | Appendix Cancer | Carcinoma of Appendix | Carcinoma of the Appendix",,,,,,,,,,,,,,,"40492937","Carcinoma of appendix",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2750266","Bronchogenic Carcinoma","C35875","A lung carcinoma arising from the bronchial epithelium.","Bronchogenic Carcinoma | Bronchial Carcinoma | Bronchiogenic Carcinoma | Bronchogenic Lung Cancer | Bronchogenic Lung Carcinoma | Bronchus Cancer | CARCINOMA, BRONCHIAL, MALIGNANT | bronchogenic carcinoma",,,,,,,,,,,,,,,"4111805","Squamous cell carcinoma of bronchus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023452","Childhood Acute Lymphoblastic Leukemia","C3168","An acute lymphoblastic leukemia occurring during childhood.  The majority of cases are B-acute lymphoblastic leukemias. Approximately 15% of the cases are T-acute lymphoblastic leukemias.","Childhood Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia (ALL) | Childhood ALL | Childhood Acute Lymphocytic Leukemia | Childhood Acute Lymphogenous Leukemia | Childhood Acute Lymphoid Leukemia | Childhood Precursor Lymphoblastic Leukemia | Pediatric ALL | Pediatric Acute Lymphoblastic Leukemia | Pediatric Acute Lymphocytic Leukemia | Pediatric Acute Lymphocytic Leukemia (ALL) | Pediatric Acute Lymphogenous Leukemia | Pediatric Acute Lymphoid Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332948","Childhood Brain Germinoma","C6207","A germinoma arising from the brain during childhood.","Childhood Brain Germinoma | Germinoma of Childhood Brain | Germinoma of Pediatric Brain | Germinoma of the Childhood Brain | Germinoma of the Pediatric Brain | Pediatric Brain Germ Cell Cancer | Pediatric Brain Germinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0220603","Childhood Brain Neoplasm","C7703","A benign or malignant, primary or metastatic neoplasm of the brain occurring in children.","Childhood Brain Neoplasm | Brain Neoplasm | Brain Neoplasms, Childhood | Childhood Brain Tumor | Childhood Neoplasm of Brain | Childhood Neoplasm of the Brain | Childhood Tumor of Brain | Childhood Tumor of the Brain | Pediatric Brain Neoplasm | Pediatric Brain Tumor | Pediatric Neoplasm of Brain | Pediatric Neoplasm of the Brain | Pediatric Tumor of Brain | Pediatric Tumor of the Brain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448993","Functional Assessment","C81250","An appraisal of the operation and performance of an object of interest.","Functional Assessment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0220611","Childhood Rhabdomyosarcoma","C7705","An aggressive malignant mesenchymal neoplasm arising from skeletal muscle in children.  Only a small percentage of tumors arise in the skeletal muscle of the extremities. The majority arise in other anatomic sites.","Childhood Rhabdomyosarcoma | Pediatric Rhabdomyosarcoma | Rhabdomyosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334488","Clear Cell Sarcoma of the Kidney","C4264","A rare pediatric sarcoma affecting the kidney. It is characterized by the presence of epithelioid or spindle cells forming cords or nests, separated by fibrovascular septa. It metastasizes to lung, bone, brain and soft tissue.","Clear Cell Sarcoma of the Kidney | CCSK | Childhood Clear Cell Sarcoma of the Kidney | Childhood Kidney Clear Cell Sarcoma | Childhood Renal Clear Cell Sarcoma | Clear Cell Sarcoma of Kidney | Clear cell sarcoma - kidney | Clear cell sarcoma of kidney | Clear cell sarcoma of the kidney | Clear cell sarcoma of the kidney (CCSK) | Kidney Clear Cell Sarcoma | Pediatric Kidney Clear Cell Sarcoma | Pediatric Renal Clear Cell Sarcoma | Renal Clear Cell Sarcoma | clear cell sarcoma of the kidney","8964/3","Clear cell sarcoma of kidney",,,,,,,,,,,,,"4084645","Clear cell sarcoma of kidney",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0238122","Fallopian Tube Carcinoma","C3867","A carcinoma arising from the fallopian tube. Most patients are postmenopausal, and postmenopausal bleeding is the most frequently seen symptom. Morphologically, the majority of fallopian tube carcinomas are serous or endometrioid adenocarcinomas.","Fallopian Tube Carcinoma | Cancer of Fallopian Tube | Cancer of the Fallopian Tube | Carcinoma of Fallopian Tube | Carcinoma of the Fallopian Tube | Fallopian Tube Cancer | Fallopian tube carcinoma",,,,,,,,,,,,,,,"4174891","Carcinoma of fallopian tube",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0235782","Gallbladder Carcinoma","C3844","A malignant tumor arising from the epithelium of the gallbladder. It is usually associated with the presence of gallstones. Clinical symptoms are not specific and usually present late in the course. Morphologically, most gallbladder carcinomas are adenocarcinomas; squamous cell carcinomas, adenosquamous carcinomas, signet ring carcinomas, and undifferentiated carcinomas can also occur.","Gallbladder Carcinoma | Cancer of Gallbladder | Cancer of the Gallbladder | Carcinoma of Gallbladder | Carcinoma of the Gallbladder | Gall bladder carcinoma (adeno) | Gall bladder carcinoma (adenocarcinoma) | Gallbladder Cancer | gallbladder cancer",,,,,,,,,,,,,,,"4162998","Carcinoma of gallbladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3887461","Head and Neck Carcinoma","C35850","A carcinoma that arises from the head and neck region.  Representative examples include oral cavity squamous cell carcinoma, laryngeal squamous cell carcinoma, and salivary gland carcinoma.","Head and Neck Carcinoma | Carcinoma of Head and Neck | Carcinoma of the Head and Neck",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206624","Hepatoblastoma","C3728","A malignant embryonal neoplasm that arises from the liver. It occurs almost exclusively in infants, although isolated cases in older children and adults have been reported. Microscopically,  it consists of either epithelial or epithelial and mesenchymal components.","Hepatoblastoma | HBL | HEPATOBLASTOMA, MALIGNANT | Pediatric Embryonal Hepatoma | Pediatric Hepatoblastoma | hepatoblastoma",,,,,,,,,,,,,,,"4001172|4261495","Hepatoblastoma|Hepatoblastoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1512433","High Grade Cervical Squamous Intraepithelial Neoplasia","C40197","A precancerous neoplastic process that affects the cervical squamous epithelium. It is usually associated with human papillomavirus infection. It is classified as cervical squamous intraepithelial neoplasia 2 when there is nuclear atypia in both the upper and lower epithelial layers, mitotic figures are confined to the basal two-thirds of the epithelium, and maturation is present in the upper half of the epithelium. It is classified as cervical squamous intraepithelial neoplasia 3 when there is nuclear atypia and mitotic figures throughout the entire thickness of the epithelium, and maturation is absent or confined to the upper third of the epithelium.","High Grade Cervical Squamous Intraepithelial Neoplasia | HSIL of Cervix | High Grade Cervical Squamous Intraepithelial Lesion | High-Grade CIN | High-Grade Cervical SIL | High-Grade Cervical Squamous Intraepithelial Lesion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279530","Malignant Bone Neoplasm","C4016","A primary or metastatic malignant neoplasm affecting the bone or articular cartilage.","Malignant Bone Neoplasm | Bone Cancer | Bone cancer, NOS | Cancer of Bone | Cancer of the Bone | Malignant Bone Tumor | Malignant Neoplasm of Bone | Malignant Neoplasm of the Bone | Malignant Osseous Neoplasm | Malignant Osseous Tumor | Malignant Tumor of Bone | Malignant Tumor of the Bone | Osseous Cancer | bone cancer",,,,,,,,,,,,,,,"443564","Malignant neoplasm of bone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153633","Malignant Brain Neoplasm","C3568","A primary or metastatic malignant neoplasm affecting the brain.","Malignant Brain Neoplasm | Brain Cancer | Brain Neoplasms, Malignant | Cancer of Brain | Cancer of the Brain | Malignant Brain Tumor | Malignant Neoplasm of Brain | Malignant Neoplasm of the Brain | Malignant Tumor of Brain | Malignant Tumor of the Brain | Malignant neoplasm of brain, unspecified",,,,,,,,,,,,,,,"443588","Malignant neoplasm of brain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0496836","Malignant Eye Neoplasm","C4767","A primary or metastatic malignant neoplasm involving the structures of the eye (conjunctiva, cornea, uvea, retina), the lacrimal system, and the eyelid. Representative examples include melanoma, carcinoma, lymphoma, and retinoblastoma.","Malignant Eye Neoplasm | Cancer of Eye | Cancer of the Eye | Eye Cancer | Eye Neoplasm, Malignant | Malignant Eye Tumor | Malignant Neoplasm of Eye | Malignant Neoplasm of the Eye | Malignant Ocular Neoplasm | Malignant Ocular Tumor | Malignant Tumor of Eye | Malignant Tumor of the Eye | Malignant eye cancer, NOS | Malignant neoplasm of unspecified site of unspecified eye | eye cancer",,,,,,,,,,,,,,,"4181477","Malignant neoplasm of eye",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153655","Malignant Pineal Region Neoplasm","C3573","A malignant neoplasm that affects the pineal region.","Malignant Pineal Region Neoplasm | Malignant Neoplasm of Pineal Gland | Malignant Neoplasm of the Pineal Gland | Malignant Pineal Area Neoplasm | Malignant Pineal Area Tumor | Malignant Pineal Gland Neoplasm | Malignant Pineal Gland Tumor | Malignant Pineal Region Tumor | Malignant Tumor of Pineal Gland | Malignant Tumor of the Pineal Gland | Malignant neoplasm of pineal gland",,,,,,,,,,,,,,,"4178977","Malignant tumor of pineal gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153470","Malignant Splenic Neoplasm","C3539","A malignant neoplasm affecting the spleen. Representative examples include leukemias, lymphomas, and sarcomas.","Malignant Splenic Neoplasm | Cancer of the Spleen | Malignant Neoplasm of Spleen | Malignant Neoplasm of the Spleen | Malignant Splenic Tumor | Malignant Tumor of Spleen | Malignant Tumor of the Spleen | Malignant neoplasm of spleen | Spleen Cancer | Splenic Cancer",,,,,,,,,,,,,,,"4180913","Malignant tumor of spleen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153567","Malignant Uterine Neoplasm","C3552","Primary or metastatic malignant neoplasm involving the uterine corpus and/or the cervix.","Malignant Uterine Neoplasm | Cancer of Uterus | Cancer of the Uterus | Malignant Neoplasm of Uterus | Malignant Neoplasm of the Uterus | Malignant Tumor of Uterus | Malignant Tumor of the Uterus | Malignant Uterine Tumor | Malignant neoplasm of uterus, part unspecified | Uterine Cancer | Uterine cancer, NOS | uterine cancer",,,,,,,,,,,,,,,"197230","Malignant neoplasm of uterus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007129","Merkel Cell Carcinoma","C9231","A rare aggressive neuroendocrine carcinoma that usually arises from the skin. Rarely, it arises from extracutaneous sites, including the oral cavity, salivary glands, breast, vulva, and vaginal wall. The tumor is composed of small round cells with scanty cytoplasm. Merkel cell polyomavirus is implicated in the majority of cases.","Merkel Cell Carcinoma | Cutaneous Apudoma | Cutaneous Neuroendocrine Carcinoma | MCC | Merkel Cell Cancer | Merkel cell cancer | Merkel cell carcinoma | Merkel cell carcinoma, unspecified | Merkel cell tumor | Neuroendocrine Carcinoma of Skin | Neuroendocrine Carcinoma of the Skin | Neuroendocrine Skin Carcinoma | Trabecular Skin Carcinoma | neuroendocrine carcinoma of the skin | trabecular cancer","8247/3","Merkel cell carcinoma",,,,,,,,,,,,,"4100425|4197286","Merkel cell carcinoma|Merkel cell carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0687150","Parathyroid Gland Carcinoma","C4906","A malignant tumor arising from the parenchymal cells of the parathyroid gland. It is associated with the symptoms of primary hyperparathyroidism, resulting from the excessive production of parathyroid hormone. Morphologically, the differential diagnosis from parathyroid gland adenoma may be difficult. A definitive diagnosis of carcinoma is made only in the presence of capsular invasion, vascular invasion, and/or perineural invasion.","Parathyroid Gland Carcinoma | Adenocarcinoma of Parathyroid | Adenocarcinoma of Parathyroid Gland | Adenocarcinoma of the Parathyroid | Adenocarcinoma of the Parathyroid Gland | CARCINOMA, PARATHYROID GLAND, MALIGNANT | Cancer of Parathyroid Gland | Cancer of the Parathyroid Gland | Carcinoma of Parathyroid | Carcinoma of Parathyroid Gland | Carcinoma of the Parathyroid | Carcinoma of the Parathyroid Gland | Parathyroid Adenocarcinoma | Parathyroid Cancer | Parathyroid Carcinoma | Parathyroid Gland Adenocarcinoma | Parathyroid Gland Cancer | Parathyroid cancer, NOS | parathyroid cancer",,,,,,,,,,,,,,,"37161444|4116231","Adenocarcinoma of parathyroid gland|Parathyroid carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0031118","Peripheral Nervous System Neoplasm","C3321","A benign or malignant neoplasm arising from a peripheral nerve or the perineural sheaths.","Peripheral Nervous System Neoplasm | CNS-excluded nervous sys. cancer | CNS-excluded nervous system cancer, NOS | Neoplasm of PNS | Neoplasm of Peripheral Nerve | Neoplasm of Peripheral Nervous System | Neoplasm of the PNS | Neoplasm of the Peripheral Nerve | Neoplasm of the Peripheral Nervous System | Neoplasms, PNS | Neoplasms, Peripheral Nervous System | PNS Neoplasm | PNS Neoplasms | PNS Tumor | Peripheral Nerve Neoplasm | Peripheral Nerve Tumor | Peripheral Nervous System Tumor | Tumor of PNS | Tumor of Peripheral Nerve | Tumor of Peripheral Nervous System | Tumor of the PNS | Tumor of the Peripheral Nerve | Tumor of the Peripheral Nervous System",,,,,,,,,,,,,,,"4130045","Neoplasm of peripheral nerve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032019","Pituitary Gland Neoplasm","C3330","A benign or malignant neoplasm affecting the pituitary gland. The vast majority are pituitary neuroendocrine tumors (formerly pituitary adenomas).","Pituitary Gland Neoplasm | Neoplasm of Pituitary | Neoplasm of Pituitary Gland | Neoplasm of the Pituitary | Neoplasm of the Pituitary Gland | Neoplasm of uncertain behavior of pituitary gland | Pituitary Gland Tumor | Pituitary Neoplasm | Pituitary Tumor | Tumor of Pituitary | Tumor of Pituitary Gland | Tumor of the Pituitary | Tumor of the Pituitary Gland | pituitary tumor",,,,,,,,,,,,,,,"4130061","Neoplasm of pituitary gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023484","Plasma Cell Leukemia","C3180","An aggressive plasma cell neoplasm characterized by the presence of neoplastic plasma cells in the peripheral blood. It is characterized by the presence of a circulating clonal plasma cell count that exceeds 2x10^9/L or is 20% of the leukocyte differential count.","Plasma Cell Leukemia | Leukemia Plasmacytic | PCL | Plasma cell leukemia | Plasmacytic Leukemia | Plasmacytic leukemia","9733/3","Plasma cell leukemia",,,,,,,,,,,,,"133154|4028859","Plasma cell leukemia|Plasma cell leukemia",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0079748","Lymphoblastic Lymphoma","C9360","A lymphoma composed of immature small to medium-sized precursor lymphoid cells (lymphoblasts). It includes the B- and T-cell lymphoblastic lymphoma.","Lymphoblastic Lymphoma | LBL | LYMPHOMA, LYMPHOBLASTIC, MALIGNANT | Lymphoblastic (diffuse) lymphoma, unspecified site | Precursor Cell Lymphoblastic Lymphoma | Precursor Lymphoblastic Lymphoma | lymphoblastic lymphoma | precursor lymphoblastic lymphoma","9727/3","Precursor cell lymphoblastic lymphoma, NOS",,,,,,,,,,,,,"4029659","Precursor cell lymphoblastic lymphoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0854917","Rhabdoid Tumor of the Kidney","C8715","A rhabdoid tumor that arises from the kidney.  It occurs in children and it is associated with abnormalities of chromosome 22. It is characterized by the presence of cells with a large eccentric nucleus, prominent nucleolus, and abundant cytoplasm.  The prognosis is poor.","Rhabdoid Tumor of the Kidney | Kidney Rhabdoid Tumor | MRTK | Malignant Rhabdoid Tumor of Kidney | Malignant Rhabdoid Tumor of the Kidney | Renal Rhabdoid Neoplasm | Renal Rhabdoid Tumor | Rhabdoid Neoplasm of Kidney | Rhabdoid Neoplasm of the Kidney | Rhabdoid Tumor of the Kidney (RTK) | Rhabdoid Tumour of Kidney | Rhabdoid Tumour of the Kidney | Rhabdoid tumor (kidney) (RT) | Rhabdoid tumor of the kidney",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1531608","Smoldering Multiple Myeloma","C7149","Multiple myeloma lacking clinical manifestations and organ impairment.","Smoldering Multiple Myeloma | Asymptomatic Myeloma | Asymptomatic Plasma Cell Myeloma | Indolent Multiple Myeloma | Smoldering Multiple Myeloma | Smoldering Multiple Myeloma/Plasma Cell Myeloma | Smoldering Myeloma | Smoldering Myeloma | Smoldering Plasma Cell Myeloma | Smoldering Plasma Cell Myeloma | smoldering myeloma",,,,,,,,,,,,,,,"4184985","Smoldering myeloma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0879615","Stromal Neoplasm","C6781","A benign or malignant mesenchymal neoplasm composed of stromal cells.  Representative examples include gastrointestinal stromal tumor, endometrial stromal sarcoma, and prostate stromal sarcoma.","Stromal Neoplasm | Stromal Tumor | stromal tumor","8935/1","Stromal tumor, NOS",,,,,,,,,,,,,"4029529","Stromal tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1883486","Uterine Corpus Cancer","C61574","A malignant neoplasm arising from the uterine corpus. This category includes endometrial carcinoma and carcinosarcoma.","Uterine Corpus Cancer | Cancer of the Corpus Uteri | Corpus Uteri Cancer | Uterine (Including Endometrial) Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677055","Vulvar Carcinoma","C4866","A carcinoma arising from the vulva.  It usually affects elderly women but has been observed in premenopausal women as well.  The most frequently seen histologic type is squamous cell carcinoma. The most common site of involvement is the labia majora.  In many cases, the development of vulvar cancer is preceded by condyloma or squamous dysplasia.","Vulvar Carcinoma | Cancer of Vulva | Cancer of the Vulva | Carcinoma of Vulva | Carcinoma of the Vulva | Vulva Cancer | Vulva Carcinoma | Vulvar Cancer | Vulvar cancer, NOS | vulvar cancer",,,,,,,,,,,,,,,"40487046","Carcinoma of vulva",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002940","Aneurysm","C26693","Bulging or ballooning in an area of an artery secondary to arterial wall weakening.","Aneurysm | ANEURYSM | Aneurysm of unspecified site",,,,,,,,,,,,,,,"4311963|4332246","Aneurysm|Aneurysm",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2827467","Asbestos-Related Lung Disorder","C84472","A disorder affecting the lungs due to asbestos exposure. Examples include asbestosis and lung carcinoma.","Asbestos-Related Lung Disorder | Asbestos-Related Lung Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004153","Atherosclerosis","C35768","Build-up of fatty material and calcium deposition in the arterial wall resulting in partial or complete occlusion of the arterial lumen.","Atherosclerosis | Unspecified atherosclerosis",,,,,,,,,,,,,,,"4306703","Atherosclerosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3275505","Atrial Septal Defect","C84473","The presence of a defect (opening) in the septum that separates the two atria of the heart. It can be congenital or acquired.","Atrial Septal Defect | ASD | Atrial Septum Defect",,,,,,,,,,,,,,,"4289309","Atrial septal defect",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4231142","Bronchiectasis","C84475","Segmental, irreversible dilation of the bronchial tree resulting in the accumulation of secretions which leads to obstruction. The most common cause is bacterial infection.","Bronchiectasis | BRONCHIECTASIS",,,,,,,,,,,,,,,"256449","Bronchiectasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036980","Cardiogenic Shock","C50482","Shock resulting from primary failure of the heart in its pumping function, as in myocardial infarction, severe cardiomyopathy, or mechanical obstruction or compression of the heart.","Cardiogenic Shock | Cardiogenic shock",,,,,,,,,,,,,,,"198571","Cardiogenic shock",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007273","Carotid Artery Disorder","C84476","A non-neoplastic or neoplastic disorder affecting the carotid artery.","Carotid Artery Disorder | ",,,,,,,,,,,,,,,"4153380","Disorder of carotid artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827468","Congenital Coronary Artery Abnormality","C84477","A congenital condition referring to defects of the course and structure of the coronary arteries.","Congenital Coronary Artery Abnormality | Congenital Artery Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4230034","Congenital Septal Defect","C84482","A congenital disorder characterized by the presence of an abnormal communication between the atria or the ventricles of the heart due to defects in the cardiac septum.","Congenital Septal Defect | Cardiac Septal Defects | Holes in the Heart",,,,,,,,,,,,,,,"4262613","Congenital septal defect",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827469","Coronary Microvascular Disease","C84478","A disorder affecting the smallest coronary arteries. Causes include atherosclerosis and arterial spasm. Chest pain is a frequently observed symptom.","Coronary Microvascular Disease | CMD | Cardiac Syndrome X | Microvascular Angina | Microvascular angina | Syndrome X",,,,,,,,,,,,,,,"4119952","Cardiac syndrome X",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010674","Cystic Fibrosis","C2975","A congenital, autosomal, metabolic disorder affecting the exocrine glands. The secretions of exocrine glands are abnormal, resulting in excessively viscid mucus production that causes obstruction of passageways, including pancreatic and bile ducts, intestines, and bronchi. Symptoms usually appear in childhood, and include meconium ileus, poor growth despite good appetite, malabsorption and foul bulky stools, chronic bronchitis with cough, recurrent pneumonia, bronchiectasis, emphysema, clubbing of the fingers, and salt depletion in hot weather secondary to increased sodium and chloride concentration in sweat.","Cystic Fibrosis | cystic fibrosis",,,,,,,,,,,,,,,"441267","Cystic fibrosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014118","Endocarditis","C34582","Inflammation of the endocardium.","Endocarditis | endocarditis",,,,,,,,,,,,,,,"441589","Endocarditis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0398623","Thrombophilia","C84479","A condition characterized by an abnormally high level of thrombi. Causes include thrombotic thrombocytopenic purpura, disseminated intravascular coagulation, bone marrow disorders, and antiphospholipid antibody syndrome.","Thrombophilia | Excessive Blood Clotting | Excessive Blood Clotting | Hypercoagulability | Hypercoagulability State | Hypercoagulable",,,,,,,,,,,,,,,"4125650","Thrombophilia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1800706","Idiopathic Pulmonary Fibrosis","C35716","Chronic and progressive fibrosis of the lung parenchyma of unknown cause.","Idiopathic Pulmonary Fibrosis | IPF | idiopathic pulmonary fibrosis",,,,,,,,,,,,,,,"45763750","Idiopathic pulmonary fibrosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3806657","Iron-Deficiency Anemia","C84484","Anemia caused by low iron intake, inefficient iron absorption in the gastrointestinal tract, or chronic blood loss.","Iron-Deficiency Anemia | Iron deficiency anemia, unspecified",,,,,,,,,,,,,,,"436659","Iron deficiency anemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026691","Kawasaki Disease","C34825","A vasculitis characterized by inflammation of the arteries, particularly the coronary arteries. The vasculitis may lead to aneurysm formation and possibly, heart attacks. It affects young children who usually present with persistent high fever, redness of the mucous membranes of the mouth, redness of the palms and soles, skin rashes, lymphadenitis, and joint pain and swelling.","Kawasaki Disease | Infantile Polyarteritis Nodosa | Mucocutaneous Lymph Node Syndrome | Mucocutaneous lymph node syndrome [Kawasaki]",,,,,,,,,,,,,,,"314381","Acute febrile mucocutaneous lymph node syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3809224","Long QT Syndrome","C34786","A ventricular arrhythmia characterized by a long QT interval, and accompanied by syncopal episodes sometimes leading to sudden death due to paroxysmal ventricular arrhythmia. This arrhythmia is associated with a prolongation of repolarization following depolarization of the cardiac ventricles. The prolongation of the Q-T interval combined with torsades de pointes manifests as several different forms; some may be acquired or congenital; some may lead to serious arrhythmia and sudden cardiac death.","Long QT Syndrome | LONG QT SYNDROME | Ventricular arrhythmia associated with long QT syndrome",,,,,,,,,,,,,,,"314664","Long QT syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024796","Marfan Syndrome","C34807","A genetic syndrome inherited as an autosomal dominant trait. It is caused by mutations in the FBN1 gene. It is characterized by tall stature, elongated extremities, mitral valve prolapse, aortic dilatation, aortic dissection, and subluxation of the lens.","Marfan Syndrome | Marfan syndrome | Marfan's Syndrome",,,,,,,,,,,,,,,"258540","Marfan's syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524620","Metabolic Syndrome","C84442","A combination of medical conditions that when present, increase the risk of heart attack, stroke, and diabetes mellitus. It includes the following medical conditions: increased blood pressure, central obesity, dyslipidemia, impaired glucose tolerance, and insulin resistance.","Metabolic Syndrome | Cardiometabolic Syndrome | Metabolic Syndrome X | metabolic syndrome | metabolic syndrome X",,,,,,,,,,,,,,,"436940","Metabolic syndrome X",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4230703","Mitral Valve Prolapse","C50655","A fairly common and often benign valvular heart disorder characterized by redundancy or hooding of mitral valve leaflets so that they prolapse into the left atrium, often causing mitral regurgitation. It is often a symptomless condition but may be marked by varied symptoms (e.g. chest pain, fatigue, dizziness, dyspnea, or palpitations) leading in some cases to endocarditis or ventricular tachycardia.","Mitral Valve Prolapse | Floppy Mitral Valve | Mitral Valve Prolapse Syndrome",,,,,,,,,,,,,,,"4252872","Mitral valve prolapse",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027404","Narcolepsy","C84489","A sleep disorder characterized by a tendency for excessive sleepiness during the day which occurs even after adequate sleep in the nighttime. The persons who suffer from this condition experience fatigue and may fall asleep at inappropriate times during the day.","Narcolepsy | ",,,,,,,,,,,,,,,"436100","Narcolepsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002892","Pernicious Anemia","C2871","Megaloblastic anemia caused by vitamin B-12 deficiency due to impaired absorption. The impaired absorption of vitamin B-12 is secondary to atrophic gastritis and loss of gastric parietal cells.","Pernicious Anemia | Intrinsic Factor Deficiency | Vitamin B12 deficiency anemia due to intrinsic factor deficiency | pernicious anemia",,,,,,,,,,,,,,,"432295","Pernicious anemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1504421","Rh Incompatibility","C84504","A complication during pregnancy; it occurs when the mother is Rh-negative and the infant is Rh-positive. This complication generally does not affect first-born Rh-positive babies. Rh-positive newborn babies from subsequent pregnancies develop complications of Rh incompatibility which include hemolysis, jaundice, enlarged liver and spleen, petechiae, hypotonia, neurologic damage, and heart problems.","Rh Incompatibility | Rh Incompatibility | Rhesus Incompatibility | Rhesus Incompatibility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336084","Squamous Lung Dysplasia","C7436","A term referring to neoplastic changes in the bronchial epithelium manifested as dysplasia.","Bronchial Intraepithelial Neoplasia | Lung Squamous Dysplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4231089","Tetralogy of Fallot","C84505","A congenital heart disorder characterized by the presence of the following four abnormalities: ventricular septal defect, pulmonary stenosis, overriding aorta, and right ventricular hypertrophy.","Tetralogy of Fallot | TETRALOGY OF FALLOT",,,,,,,,,,,,,,,"320835","Tetralogy of Fallot",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1969953","Varicose Vein","C35114","A vascular abnormality characterized by the presence of enlarged and tortuous veins, particularly in the legs.","Varicose Vein | Varices | Varicosity | Varix | varicose vein",,,,,,,,,,,,,,,"4029830","Varix",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2748688","Ventricular Septal Defect","C84506","The presence of a defect (opening) in the septum that separates the two ventricles of the heart. It can be congenital or acquired.","Ventricular Septal Defect | VSD",,,,,,,,,,,,,,,"434462","Ventricular septal defect",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042974","von Willebrand Disease","C68677","Hereditary or acquired coagulation disorder characterized by a qualitative or quantitative deficiency of the von Willebrand factor. The latter plays an important role in platelet adhesion. Signs and symptoms include bruises, nose bleeding, gum bleeding following a dental procedure, heavy menstrual bleeding, and gastrointestinal bleeding.","von Willebrand Disease | Von Willebrand's disease | von Willebrand Disorder | von Willebrand's Disease",,,,,,,,,,,,,,,"434316","von Willebrand disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3277352","Acute Liver Failure","C84396","Rapid deterioration of liver function causing encephalopathy and coagulopathy. It results from damage to the liver parenchyma usually secondary to acetaminophen overdose or viral infections.","Acute Liver Failure | Acute Hepatic Failure",,,,,,,,,,,,,,,"4026032","Acute hepatic failure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085280","Alagille Syndrome","C35139","An autosomal dominant genetic syndrome caused by mutations in the JAG1 gene. It is characterized by cholestatic jaundice in infancy, hepatosplenomegaly, distinctive facial features (prominent forehead, elongated nose, and pointed chin), cardiac murmurs, bone malformations, and sometimes mild mental retardation.","Alagille Syndrome | Arteriohepatic Dysplasia",,,,,,,,,,,,,,,"4136964","Arteriohepatic dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023896","Alcoholic Liver Disease","C34783","A disorder caused by damage to the liver parenchyma due to alcohol consumption. It may present with an acute onset or follow a chronic course, leading to cirrhosis.","Alcoholic Liver Disease | Alcoholic liver disease, unspecified",,,,,,,,,,,,,,,"201612","Alcoholic liver damage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0149841","Benign Recurrent Intrahepatic Cholestasis","C84402","Reappearance of cholestasis caused by obstruction within the liver by non-cancerous conditions.","Benign Recurrent Intrahepatic Cholestasis | ",,,,,,,,,,,,,,,"4150383","Benign recurrent intrahepatic cholestasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827432","Bile Acid Synthesis Defect","C84403","A congenital or acquired defect in the bile acid biosynthesis, resulting in progressive liver disease.","Bile Acid Synthesis Defect | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005411","Biliary Atresia","C34421","A congenital disorder characterized by blockage or absence of the intrahepatic or extrahepatic bile ducts.","Biliary Atresia | Congenital Biliary Atresia",,,,,,,,,,,,,,,"196796","Congenital biliary atresia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3275124","Biliary System Disorder","C2899","A non-neoplastic or neoplastic disorder that affects the intrahepatic or extrahepatic bile ducts or the gallbladder. Representative examples of non-neoplastic disorders include cholangitis and cholecystitis. Representative examples of neoplastic disorders include extrahepatic bile duct adenoma, intrahepatic and extrahepatic cholangiocarcinoma, and gallbladder carcinoma.","Biliary System Disorder | Biliary Disease | Biliary Disorder | Biliary Tract Disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005686","Bladder Disorder","C2900","A non-neoplastic or neoplastic disorder affecting the urinary bladder. A representative example of non-neoplastic bladder disorder is bacterial bladder infection. A representative example of neoplastic bladder disorder is bladder carcinoma.","Bladder Disorder | Bladder Disease | Urinary Bladder Disorder",,,,,,,,,,,,,,,"201337","Disorder of bladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827448","Childhood Diabetes Mellitus","C84433","Diabetes mellitus that develops during childhood.","Childhood Diabetes Mellitus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827454","Childhood Kidney Disorder","C84448","A kidney disorder that appears during childhood.","Childhood Kidney Disorder | Childhood Renal Disorder | Childhood Renal Disorder | Pediatric Kidney Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810486","Chronic Renal Failure","C9438","Impairment of the renal function due to chronic kidney damage.","Chronic Renal Failure | CRF - Chronic Renal Failure | Chronic Renal Disease",,,,,,,,,,,,,,,"198185","Chronic renal failure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0267809","Cryptogenic Cirrhosis","C84411","Cirrhosis in which no causative agent can be identified.","Cryptogenic Cirrhosis | ",,,,,,,,,,,,,,,"4232955","Cryptogenic cirrhosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0342245","Diabetic Eye Disease","C84420","A group of disorders affecting the eye in patients with diabetes mellitus. It includes cataract, glaucoma, retinopathy, and blindness.","Diabetic Eye Disease | ",,,,,,,,,,,,,,,"443767","Disorder of eye due to diabetes mellitus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011881","Diabetic Nephropathy","C84417","Progressive kidney disorder caused by vascular damage to the glomerular capillaries, in patients with diabetes mellitus. It is usually manifested with nephritic syndrome and glomerulosclerosis.","Diabetic Nephropathy | Diabetic Kidney Disease",,,,,,,,,,,,,,,"192279","Disorder of kidney due to diabetes mellitus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0860207","Drug Induced Liver Injury","C84427","Damage to the liver tissue due to drug overdose.","Drug Induced Liver Injury | ",,,,,,,,,,,,,,,"4144765","Drug-induced disorder of liver",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0745744","End Stage Liver Disease","C84428","A disorder characterized by irreversible damage to the liver tissue, leading to complete liver failure. Causes include cirrhosis, viral hepatitis, metastases to the liver, genetic disorders, toxins, and drugs.","End Stage Liver Disease | Chronic Liver Failure | End Stage Liver Disease (Decompensated Liver Disease) | End-Stage Liver Disease",,,,,,,,,,,,,,,"45769564","End stage liver disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3151569","Focal Segmental Glomerulosclerosis","C37308","A renal disorder characterized by sclerotic lesions in the glomeruli. Causes include drugs, viruses, and malignancies (lymphomas), or it may be idiopathic. It presents with asymptomatic proteinuria or nephritic syndrome and it may lead to renal failure.","Focal Segmental Glomerulosclerosis | FSGS | FSGS - Focal Segmental Glomerulosclerosis",,,,,,,,,,,,,,,"4030513","Focal segmental glomerulosclerosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017658","Glomerulonephritis","C26784","A renal disorder characterized by damage in the glomeruli. It may be acute or chronic, focal or diffuse, and it may lead to renal failure. Causes include autoimmune disorders, infections, diabetes, and malignancies.","Glomerulonephritis | GLOMERULONEPHRITIS | Glomerular Nephritis",,,,,,,,,,,,,,,"4263367","Glomerulonephritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0282488","Interstitial Cystitis","C27189","Inflammation of the urinary bladder wall leading to urinary frequency, urgency, and discomfort, pelvic pain, and pain during intercourse. Morphologically it is characterized by a transmural bladder inflammatory infiltrate containing mast cells.","Interstitial Cystitis | ",,,,,,,,,,,,,,,"75863","Chronic interstitial cystitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3553282","Irritable Bowel Syndrome","C82343","Gastrointestinal symptoms characterized by chronic abdominal pain and altered bowel habits in the absence of any organic cause.","Irritable Bowel Syndrome | IBS | irritable bowel syndrome | irritable colon | mucus colitis | spastic colon",,,,,,,,,,,,,,,"75576","Irritable bowel syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827436","Liver Disease Associated with Cystic Fibrosis","C84412","A spectrum of liver disorders that develop in patients with cystic fibrosis. It includes asymptomatic elevation of the liver function tests, steatosis, cholecystitis with cholelithiasis, sclerosing cholangitis, biliary cirrhosis, and cholangiocarcinoma.","Liver Disease Associated with Cystic Fibrosis | Cystic Fibrosis Liver Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1328348","Mitochondrial Hepatopathy","C84443","A liver disorder caused by primary or secondary defects in the function of the mitochondria in the hepatocytes.","Mitochondrial Hepatopathy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027613","Neonatal Hepatitis","C84446","Hepatitis developing during the neonatal period.","Neonatal Hepatitis | ",,,,,,,,,,,,,,,"4320490","Neonatal hepatitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL449062","Nephropathy","C34843","A term referring to any disease affecting the kidneys.","Nephropathy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3241937","Nonalcoholic Steatohepatitis","C84445","Fatty replacement and damage to the hepatocytes not related to alcohol use. It may lead to cirrhosis and liver failure.","Nonalcoholic Steatohepatitis | NASH - Nonalcoholic Steatohepatitis | Nonalcoholic Steatohepatitis (NASH) | Nonalcoholic steatohepatitis (NASH)",,,,,,,,,,,,,,,"40484532","Nonalcoholic steatohepatitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2362324","Childhood Obesity","C84449","A condition in which a child's body mass index (BMI) falls at or above the 95th percentile based on the normative values for the age and sex of the reference population.","Childhood Obesity | Pediatric Obesity | Pediatric Obesity",,,,,,,,,,,,,,,"40481140","Childhood obesity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022680","Polycystic Kidney Disease","C75464","A usually autosomal dominant and less frequently autosomal recessive genetic disorder characterized by the presence of numerous cysts in the kidneys leading to end-stage renal failure. The autosomal dominant trait is associated with abnormalities on the short arm of chromosome 16. Symptoms in patients with the autosomal dominant trait usually appear at middle age and include abdominal pain, hematuria, and high blood pressure. Patients may develop brain aneurysms and liver cysts. Patients with the autosomal recessive trait present with progressive renal failure early in life and symptoms resulting from hepatic fibrosis. The autosomal recessive trait is associated with abnormalities of chromosome 6. Polycystic kidney disease may also result as a side effect in patients on renal dialysis.","Polycystic Kidney Disease | Fibrocystic Renal Disease | PKD - Polycystic Kidney Disease",,,,,,,,,,,,,,,"4220238","Multiple congenital cysts of kidney",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008312","Primary Biliary Cirrhosis","C27167","An autoimmune inflammatory disorder characterized by destruction of the small intrahepatic bile ducts. It affects predominantly females and it may lead to cirrhosis and liver failure. Patients have antimitochondrial and antinuclear antibodies in the peripheral blood.","Primary Biliary Cirrhosis | Chronic Non-Suppurative Destructive Cholangitis | Primary Biliary Cholangitis | Primary Biliary Cirrhosis (PBC) | Primary biliary cirrhosis",,,,,,,,,,,,,,,"4135822","Primary biliary cholangitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0566602","Primary Sclerosing Cholangitis","C4828","A chronic, autoimmune inflammatory liver disorder characterized by narrowing and scarring of the lumen of the bile ducts. It is often seen in patients with ulcerative colitis. Signs and symptoms include jaundice, fatigue, and malabsorption. It may lead to cirrhosis and liver failure.","Primary Sclerosing Cholangitis | PSC | Sclerosing Cholangitis",,,,,,,,,,,,,,,"4058821","Primary sclerosing cholangitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268312","Progressive Familial Intrahepatic Cholestasis","C84453","A genetic syndrome affecting infants and children. It is characterized by chronic intrahepatic cholestasis usually progressing to cirrhosis within the first ten years of life.","Progressive Familial Intrahepatic Cholestasis | ",,,,,,,,,,,,,,,"4253211","Progressive intrahepatic cholestasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0154830","Proliferative Diabetic Retinopathy","C84457","Advanced retinopathy due to diabetes mellitus characterized by the formation of new vessels in the retina. The new vessels are abnormal and fragile. If hemorrhage occurs due to the vascular fragility, there is increased risk of vision loss or blindness.","Proliferative Diabetic Retinopathy | ",,,,,,,,,,,,,,,"380096","Proliferative retinopathy due to diabetes mellitus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033575","Prostate Disorder","C26865","A non-neoplastic or neoplastic disorder that affects the prostate gland.  Representative examples include prostatitis, prostatic intraepithelial neoplasia, and carcinoma.","Prostate Disorder | Prostate Disease",,,,,,,,,,,,,,,"196734","Disorder of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827460","Vascular Access Graft Failure","C84459","Failure to achieve vascular access due to damage of the graft that was created for this purpose.","Vascular Access Graft Failure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3275515","Vesicoureteral Reflux","C84467","Abnormal flow of urine from the urinary bladder back into the ureters.","Vesicoureteral Reflux | VUR - Vesicoureteral Reflux | Vesicoureteric Reflux",,,,,,,,,,,,,,,"197036","Vesicoureteric reflux",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003850","Arteriosclerosis","C34398","A vascular disorder characterized by thickening and hardening of the walls of the arteries.","Arteriosclerosis | Arterial Sclerosis | Arteriosclerosis/ Atherosclerosis | Vascular Sclerosis",,,,,,,,,,,,,,,"4103842","Arteriosclerosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030805","Bullous Pemphigoid","C84389","An autoimmune chronic skin disorder characterized by the presence of large blisters. It usually affects elderly people and tends to subside spontaneously.","Bullous Pemphigoid | ",,,,,,,,,,,,,,,"4298692","Bullous pemphigoid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010481","Cushing Syndrome","C2969","A syndrome caused by high levels of cortisol in the blood either due to excessive production and secretion of corticosteroids secondary to pituitary or adrenocortical neoplasms, or intake of glucocorticoid drugs. Signs and symptoms include a round face, upper body obesity, fragile and thin skin, purple stretch marks in the skin, fatigue, muscle weakness, hypertension, diabetes mellitus, hypertrichosis and amenorrhea in women, impotence in men, and osteoporosis.","Cushing Syndrome | Cortisol Excess | Cushing syndrome | Cushing's Syndrome | Hypercortisolism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4013837","Dermatitis","C2983","An inflammatory process affecting the skin. Signs include red rash, itching, and blister formation. Representative examples are contact dermatitis, atopic dermatitis, and seborrheic dermatitis.","Dermatitis | Inflammation of Skin | Inflammation of the Skin | Skin Inflammation | Skin Inflammation/ Irritation | dermatitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0877121","AIDS-Related Disorder","C4991","A non-neoplastic or neoplastic disorder arising as a result of the immunologic defects caused by Autoimmune Deficiency Syndrome.","AIDS-Related Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013743","Eisenmenger Syndrome","C84390","A syndrome characterized by the reversal of a septal defect-associated left-to-right shunt due to the resulting secondary pulmonary hypertension. The presence of the pulmonary hypertension causes increased pressure in the right heart chambers resulting in the reversal of the shunt into a right-to-left shunt. Signs and symptoms include cyanosis, pulmonary hypertension, heart failure, and high red blood cell count.","Eisenmenger Syndrome | Eisenmenger's Syndrome | Eisenmenger's syndrome",,,,,,,,,,,,,,,"40493243","Eisenmenger's syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014175","Endometriosis","C3014","The growth of functional endometrial tissue in anatomic sites outside the uterine body. It most often occurs in the pelvic organs.","Endometriosis | ENDOMETRIOSIS | endometriosis",,,,,,,,,,,,,,,"4244991|433527","Endometriosis|Endometriosis (clinical)",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C4231190","Goiter","C26785","Enlargement of the thyroid gland usually caused by lack of iodine in the diet, hyperthyroidism, or thyroid nodules. Symptoms include difficulty in breathing and swallowing.","Goiter | Thyromegaly | goiter",,,,,,,,,,,,,,,"135772","Goiter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4230251","Age-Related Macular Degeneration","C84391","Age-related loss of vision in the central portion of the retina (macula), secondary to retinal degeneration.","Age-Related Macular Degeneration | AMD | ARMD | Macular Degeneration | age-related macular degeneration",,,,,,,,,,,,,,,"374028","Age related macular degeneration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2750632","Mental Retardation","C84392","A developmental disorder characterized by less than average intelligence and significant limitations in adaptive behavior with onset before the age of 18.","Mental Retardation | ",,,,,,,,,,,,,,,"4041136","Intellectual functioning disability",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026471","Monoclonal Gammopathy","C35548","An abnormal laboratory test result indicating the presence of monoclonal immunoglobulins in the blood or urine.","Monoclonal Gammopathy | Monoclonal Paraproteinemia",,,,,,,,,,,,,,,"4002359|4149022","Monoclonal gammopathy (clinical)|Monoclonal gammopathy of undetermined significance",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2827429","Simultanagnosia","C84395","A symptom describing the inability to comprehend more than one element of a visual picture at a given moment, or to integrate the whole visual picture.","Simultanagnosia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0000744","Abetalipoproteinemia","C84525","An autosomal recessive disorder characterized by defective absorption of dietary fat, cholesterol and fat-soluble vitamins. It results in multiple vitamin deficiencies. Signs and symptoms include failure to thrive, diarrhea, steatorrhea, acanthocytosis and ataxia.","Abetalipoproteinemia | ",,,,,,,,,,,,,,,"4098595","Abetalipoproteinemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0846967","Acanthoma","C7419","A benign skin neoplasm composed of epithelial cells.","Acanthoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3553389","Acanthosis Nigricans","C26687","A melanotic cutaneous lesion that develops in the axilla and other body folds. It may be idiopathic, drug-induced, or it may be associated with the presence of an endocrine disorder or malignancy.","Acanthosis Nigricans | ",,,,,,,,,,,,,,,"4299544","Acanthosis nigricans",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268419","Acatalasemia","C84526","A rare autosomal recessive disorder characterized by deficiency of catalase in the peripheral blood. It is usually manifested with periodontal infections.","Acatalasemia | Acatalasia",,,,,,,,,,,,,,,"4147488","Acatalasemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001079","Achondrogenesis","C84527","A rare group of disorders characterized by defective development of bones and cartilage.","Achondrogenesis | ",,,,,,,,,,,,,,,"4082503","Achondrogenesis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001080","Achondroplasia","C34345","An autosomal dominant disorder caused by mutation(s) in the FGFR3 gene, encoding fibroblast growth factor receptor 3. The condition is characterized by inappropriate cartilage growth plate differentiation and deficient endochondral growth, manifest clinically with severe rhizomelic short stature, short limbs, characteristic facies with frontal bossing and midface hypoplasia.","Achondroplasia | ",,,,,,,,,,,,,,,"4311402","Achondroplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152200","Achromatopsia","C84528","An autosomal recessive genetic disorder affecting the cone cells of the eye. It may be complete, in which the individual can only perceive black, white, or shades or gray, or incomplete, in which the individual has a residual amount of color vision.","Achromatopsia | ",,,,,,,,,,,,,,,"374936","Achromatopsia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0263859","Acquired Hyperostosis Syndrome","C84530","A chronic inflammatory disorder characterized by hyperostosis, osteitis, synovitis and palmoplantar pustulosis. The most common site of involvement is the anterior chest wall.","Acquired Hyperostosis Syndrome | ",,,,,,,,,,,,,,,"4245526","SAPHO syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0796147","Acrocallosal Syndrome","C84531","A rare genetic syndrome characterized by agenesis of the corpus callosum, polydactyly, mental and motor retardation.","Acrocallosal Syndrome | ",,,,,,,,,,,,,,,"37396220","Acrocallosal syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3806012","Kurczynski Casperson Syndrome","C34348","A genetic disorder characterized by craniosynostosis and fusion of the fingers and toes.","Acrocephalosyndactyly | ",,,,,,,,,,,,,,,"439134","Acrocephalosyndactyly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001197","Acrodermatitis","C84532","An inflammatory skin condition affecting children. It is often associated with Epstein-Barr virus infection, hepatitis B infection or cytomegalovirus infection. It is characterized by the presence of cutaneous rashes and patches on the palms and soles. The trunk is not affected.","Acrodermatitis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001206","Acromegaly","C84533","A syndrome characterized by enlargement of the hands, feet, ears, nose, lips, and tongue, skin thickening and swelling of internal organs. It is caused by overproduction of growth hormone in the pituitary gland, usually by a pituitary adenoma.","Acromegaly | acromegaly",,,,,,,,,,,,,,,"4253197","Acromegaly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001255","Actinomycetales Infection","C84534","An infectious process caused by actinomycetales which is an order of Actinobacteria.","Actinomycetales Infection | ",,,,,,,,,,,,,,,"36715956","Infection caused by Actinomycetales",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001261","Actinomycosis","C34350","An infectious process caused by bacteria of the Actinomyces species. It is characterized by the formation of purulent and painful abscesses in the mouth, lungs and gastrointestinal tract.","Actinomycosis | ",,,,,,,,,,,,,,,"436020","Actinomycotic infection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014059","Acute Disseminated Encephalomyelitis","C34578","An inflammatory process affecting the central nervous system. It is characterized by perivascular demyelination. Symptoms usually follow an acute viral infection or immunization and include fever, confusion, somnolence and involuntary movements. It may lead to coma and death.","Acute Disseminated Encephalomyelitis | ADEM",,,,,,,,,,,,,,,"374021","Acute disseminated encephalomyelitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014077","Acute Hemorrhagic Leukoencephalitis","C84535","A degenerative brain disorder presenting with acute neurological manifestations. It usually associated with an acute infection or vaccination. It is characterized by brain hemorrhage, vascular necrosis and demyelination. Signs and symptoms include fever, headache, vomiting, convulsions and loss of consciousness.","Acute Hemorrhagic Leukoencephalitis | ",,,,,,,,,,,,,,,"4249574","Acute hemorrhagic leukoencephalitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1963929","Acute Infective Polyneuritis","C26790","An acute inflammatory process affecting the peripheral nervous system and nerve roots. It results in demyelination. It is often caused by an acute viral or bacterial infection.","Acute Infective Polyneuritis | ",,,,,,,,,,,,,,,"374925","Acute infective polyneuritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162565","Acute Intermittent Porphyria","C84536","A genetic metabolic disorder inherited in an autosomal dominant pattern. It is caused by a deficiency of the enzyme porphobilinogen deaminase, which is involved in heme biosynthesis. Signs and symptoms include nausea, vomiting, severe abdominal pain and distension, urinary retention, port-wine urine discoloration, hypertension, tachycardia, muscle weakness, loss of sensation, anxiety, depression, and arm, leg and back pain.","Acute Intermittent Porphyria | Porphyria, Acute Intermittent",,,,,,,,,,,,,,,"4120604","Acute intermittent porphyria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0220711","Long-Chain Acyl-CoA Dehydrogenase Deficiency","C84537","A genetic disorder characterized by deficiency of the enzyme long-chain acyl-coenzyme A dehydrogenase that metabolizes long-chain fatty acids. Signs and symptoms appear in infancy or childhood and may be triggered during fasting, illness or exercise. They include hypoglycemia, muscle weakness and lethargy.","Long-Chain Acyl-CoA Dehydrogenase Deficiency | Acyl-CoA Dehydrogenase, Long-Chain Deficiency | Acyl-CoA Dehydrogenase, Long-Chain Deficiency | LCAD | Long-Chain Acyl-Coenzyme A Dehydrogenase Deficiency",,,,,,,,,,,,,,,"4029741","Long chain acyl-CoA dehydrogenase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0220710","Medium-Chain Acyl-CoA Dehydrogenase Deficiency","C84538","A genetic disorder characterized by deficiency of the enzyme medium-chain acyl-coenzyme A dehydrogenase that metabolizes medium-chain fatty acids. Signs and symptoms appear in infancy or childhood and may be triggered during fasting or illness. They include vomiting, hypoglycemia and lethargy.","Medium-Chain Acyl-CoA Dehydrogenase Deficiency | Acyl-CoA Dehydrogenase, Medium-Chain Deficiency | Acyl-CoA Dehydrogenase, Medium-Chain Deficiency | MCAD | Medium-Chain Acyl-Coenzyme A Dehydrogenase Deficiency",,,,,,,,,,,,,,,"4029371","Medium-chain acyl-coenzyme A dehydrogenase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0342783","Acyl-CoA Dehydrogenase, Short-Chain Deficiency","C84539","A genetic disorder characterized by deficiency of the enzyme short-chain acyl-coenzyme A dehydrogenase that metabolizes short-chain fatty acids. Signs and symptoms appear in infancy or childhood and may be triggered during fasting or illness. They include vomiting, hypoglycemia, lethargy, hypotonia and failure to thrive.","Acyl-CoA Dehydrogenase, Short-Chain Deficiency | SCAD | Short-Chain Acyl-CoA Dehydrogenase Deficiency (SCAD) | Short-Chain Acyl-Coenzyme A Dehydrogenase Deficiency (SCAD)",,,,,,,,,,,,,,,"37204063|4050147","Short chain acyl-coenzyme A dehydrogenase deficiency|Deficiency of butyryl-CoA dehydrogenase",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0001403","Addison's Disease","C26689","A long-standing and persistent diminished production of adrenocortical hormones due to a disorder originating within the adrenal glands.","Addison's Disease | Addison Disease | Addison's Disease | Addisons Disease | Chronic Primary Adrenal Insufficiency | Primary Hypoadrenalism",,,,,,,,,,,,,,,"443394","Addison's disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001529","Adiposis Dolorosa","C84540","A rare genetic disorder characterized by the development of painful lipomas during adulthood, especially in menopausal women. Associated symptoms include fatigue, obesity, confusion and depression.","Adiposis Dolorosa | Dercum Disease | Dercum's Disease",,,,,,,,,,,,,,,"4324974","Lipomatosis dolorosa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0342492","Adrenal hypertrophy or hyperplasia","C35408","A congenital or acquired hyperplasia of the cells of the adrenal cortex or medulla.","Adrenal Hyperplasia | Adrenal Gland Hyperplasia | Adrenal Gland Hyperplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001624","Adrenal Gland Neoplasm","C2859","A benign or malignant (primary or metastatic) neoplasm affecting the adrenal glands.","Adrenal Gland Neoplasm | Adrenal Gland Tumor | Adrenal Neoplasm | Adrenal Neoplasms | Adrenal Tumor | Neoplasm of Adrenal Gland | Neoplasm of the Adrenal Gland | Tumor of Adrenal Gland | Tumor of the Adrenal Gland",,,,,,,,,,,,,,,"4130675","Neoplasm of adrenal gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041228","African Trypanosomiasis","C84541","A parasitic disorder caused by protozoa of the Trypanosoma brucei species. It is transmitted by flies and is endemic in various regions of Sub-Saharan Africa. Signs and symptoms include fever, joint pain, headache, and significant swelling of the lymph nodes. If left untreated, the parasitic infection causes anemia, heart, kidney, and endocrine failure, and neurologic damage. Subsequently patients develop confusion, disruption of the sleep cycle, and mental deterioration. The infection may lead to coma and death.","African Trypanosomiasis | Sleeping Sickness",,,,,,,,,,,,,,,"438344","African trypanosomiasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4013279","Hirschsprung Disease","C34700","A congenital disorder characterized by the absence of myenteric ganglion cells in the distal colon. It results in a functional stenosis of the distal colon and a massive distention of the proximal colon.","Hirschsprung Disease | Aganglionic Megacolon | Aganglionic Megacolon | Hirschsprung's Disease",,,,,,,,,,,,,,,"194149","Congenital aganglionic megacolon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001816","Agnosia","C84542","A rare disorder characterized by the lack of ability to recognize individuals, objects, shapes, sounds, or smells. There is no loss of memory. It is caused by neurological damage in the brain, specifically in the occipital or parietal lobes.","Agnosia | ",,,,,,,,,,,,,,,"4173136","Agnosia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085090","AIDS-Related Lymphoma","C3471","An aggressive lymphoma that develops in HIV-positive patients.  There is a significant increase in the incidence of lymphomas associated with the AIDS epidemic.  These lymphomas are usually extranodal, most often express a B-cell phenotype and morphologically are classified as Burkitt, diffuse large B-cell, and Hodgkin lymphomas.  The prognosis is closely related to the severity of immunodeficiency.","AIDS-Related Lymphoma | AIDS Lymphoma | AIDS Related Lymphoma | HIV Associated Lymphoma | Lymphoma AIDS Related | Lymphoma, AIDS-Related",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001860","Ainhum","C84544","Spontaneous autoamputation of a digit, usually the fifth toe. It results from the formation of a fibrotic band which constricts the full radius of the digit and eventually causes the spontaneous autoamputation.","Ainhum | Dactylolysis",,,,,,,,,,,,,,,"136912","Ainhum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001916","Albinism","C84543","A congenital disorder characterized by partial or complete absence of melanin pigment in the eyes, hair and skin.","Albinism | albinism",,,,,,,,,,,,,,,"4049014","Albinism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0270726","Alexander Disease","C84545","A rare genetic neurodegenerative disorder which belongs to the group of leukodystrophies. It has a slow and progressive clinical course and is characterized by developmental delay, macrocephaly, seizures, dementia and spasticity.","Alexander Disease | ",,,,,,,,,,,,,,,"4218753","Alexander's disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002066","Alkaptonuria","C84546","A rare autosomal recessive disorder characterized by abnormalities in the metabolism of phenylalanine and tyrosine. It results in the accumulation in the blood of homogentisic acid which is excreted in the urine. The presence of homogentisic acid in the urine causes its color to turn black. The excessive amount of homogentisic acid in the blood may cause damage to cartilage and heart valves, and may result in the formation of kidney stones.","Alkaptonuria | ",,,,,,,,,,,,,,,"4232841","Homogentisate 1,2-dioxygenase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004031","Allergic Bronchopulmonary Aspergillosis","C84547","An immune reaction to aspergillus in patients usually suffering from asthma or cystic fibrosis.","Allergic Bronchopulmonary Aspergillosis | ABPA",,,,,,,,,,,,,,,"257583","Allergic bronchopulmonary aspergillosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002312","Alpha Thalassemia","C34368","A genetic hematologic disorder characterized by partial or complete absence of the alpha globin chains of the heme molecule.","Alpha Thalassemia | ",,,,,,,,,,,,,,,"4287844","Alpha thalassemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1567741","Alport Syndrome","C34842","A genetic syndrome usually inherited as an X-link trait. It is caused by abnormalities in the COL4A5 gene. It affects males more often than females and is characterized by hematuria, progressive renal insufficiency, hearing loss, and ocular abnormalities.","Alport Syndrome | Alport's Syndrome | Hereditary Nephritis",,,,,,,,,,,,,,,"36674698","Alport syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268425","Alstrom Syndrome","C84549","A rare autosomal recessive syndrome caused by mutations in the gene ALMS1. Signs and symptoms include blindness, obesity, hearing loss, endocrine abnormalities, cardiomyopathy and congestive heart failure, hepatic and renal failure.","Alstrom Syndrome | Alström Syndrome",,,,,,,,,,,,,,,"4270189","Alstrom syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0149793","Amaurosis Fugax","C84550","Transient, monocular loss of vision.","Amaurosis Fugax | Amaurosis fugax",,,,,,,,,,,,,,,"4338523","Amaurosis fugax",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002438","Amebiasis","C84551","A parasitic infectious disorder caused by amoebas. The parasite may cause colitis which is manifested with bloody diarrhea, abdominal pain, nausea and fever. In rare cases it may spread to the liver, brain and lungs.","Amebiasis | ",,,,,,,,,,,,,,,"438959","Amebic infection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002448","Ameloblastoma","C4313","The most common odontogenic tumor, arising from the epithelial component of the embryonic tooth and usually affecting the molar-ramus region of the mandible or maxilla.  Although most ameloblastomas are morphologically and clinically benign, they may cause extensive local destruction, recur, or metastasize.","Ameloblastoma | Ameloblastoma, NOS","9310/0","Ameloblastoma, NOS",,,,,,,,,,,,,"4069420","Ameloblastoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0002636","Amniotic Band Syndrome","C84552","A rare congenital disorder which is caused by entrapment of anatomic parts of the fetus in fibrous amniotic bands during pregnancy. It may result in the formation of constriction rings around the digits and upper and lower extremities, swelling of the extremities and congenital amputations.","Amniotic Band Syndrome | Amniotic Band Constriction | Deformity due to Amniotic Band",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206247","Amyloid Neuropathy","C84553","Neuropathy caused by amyloid deposition in the peripheral nerves.","Amyloid Neuropathy | ",,,,,,,,,,,,,,,"4102494","Polyneuropathy due to amyloidosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1563715","Long QT Syndrome 7","C84559","A subtype of long QT syndrome caused by mutation(s) in the KCNJ2 gene, encoding inward rectifier potassium channel 2. It is characterized by ventricular arrhythmia, muscle weakness, and developmental abnormalities which include micrognathia, low-set ears and deformities of the fingers.","Long QT Syndrome 7 | ATS | Andersen Syndrome | Andersen Syndrome | Andersen-Tawil syndrome | LQT7",,,,,,,,,,,,,,,"4224848","Andersen Tawil syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003810","Ovarian Sertoli-Leydig Cell Tumor","C2880","A benign or malignant sex cord-stromal tumor arising from the ovary. It is characterized by the presence of neoplastic Leydig cells. Signs and symptoms include hirsutism, menorrhagia and metrorrhagia. It may be associated with trisomy 8.","Ovarian Sertoli-Leydig Cell Tumor | Androblastoma | Arrhenoblastoma | Ovarian Sertoli-Leydig Cell Neoplasm | Sertoli-Leydig Cell Tumor | Sertoli-Leydig Cell Tumor of Ovary | Sertoli-Leydig Cell Tumor of the Ovary | Sertoli-Leydig Neoplasm of Ovary | Sertoli-Leydig Neoplasm of the Ovary | Sertoli-Leydig cell tumor of the ovary | androblastoma | arrhenoblastoma","8630/1","Androblastoma, NOS",,,,,,,,,,,,,"4112079","Sertoli-Leydig cell tumor of ovary",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0162635","Angelman Syndrome","C75462","A genetic syndrome characterized by mental retardation, speech impairment, microcephaly, ataxia, and seizures. The majority of cases result from deletions on the long arm of chromosome 15. A minority of cases result from mutations in the UBE3A gene.","Angelman Syndrome | ",,,,,,,,,,,,,,,"4296631","Angelman syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017531","Castleman Disease","C3056","A disorder characterized by lymphoid hyperplasia in the lymph nodes. There are two histologic variants recognized: the hyaline-vascular type and the plasma cell type. In the hyaline vascular type there are hyalinized vessels present in the lymphoid follicles. In the plasma cell type there is pronounced plasma cell proliferation. Clinically, the disease may be localized; manifested with localized lymphadenopathy, or multicentric; manifested with generalized lymphadenopathy, fever, organomegaly, and sometimes POEMS syndrome. In contrast to patients with localized disease who are usually cured following resection of the lesion, patients with the multicentric form of the disease may follow a progressive clinical course, complicated by infection, Kaposi sarcoma or lymphoma.","Castleman Disease | AFLH | Angiofollicular Lymphoid Hyperplasia | Angiofollicular Lymphoid Hyperplasia | Castleman's Disease | Castleman's Tumor | Castleman's disease | GLNH | Giant Lymph Node Hyperplasia",,,,,,,,,,,,,,,"4118225","Castleman disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162359","Anhidrotic Ectodermal Dysplasia 1","C84562","A rare genetic disorder characterized by mutations in the gene encoding ectodysplasin A. It results in abnormalities in the morphogenesis of the structures originating from the ectoderm.","Anhidrotic Ectodermal Dysplasia 1 | ",,,,,,,,,,,,,,,"4082355","Hypohidrotic X-linked ectodermal dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4017049","Aniridia","C84563","A rare genetic inherited abnormality characterized by the partial or complete absence of the iris of the eye.","Aniridia | ",,,,,,,,,,,,,,,"440195","Congenital aniridia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003175","Anthrax","C84565","An infection caused by Bacillus anthracis bacteria. It may affect the lungs, gastrointestinal tract, or skin. Patients with lung infection present with fever, headaches, cough, chest pain and shortness of breath. Patients with gastrointestinal infection present with nausea, vomiting and bloody diarrhea. Patients with skin infection develop blisters and ulcers.","Anthrax | ",,,,,,,,,,,,,,,"438960","Anthrax",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0403529","Anti-Glomerular Basement Membrane Disease","C84566","An autoimmune disorder characterized by the production of autoantibodies against type IV collagen of the glomerular basement membrane of the kidney. In the majority of patients the immune reaction also extends to the alveolar capillary membrane of the lungs. The latter cases are referred to as Goodpasture Syndrome.","Anti-Glomerular Basement Membrane Disease | ",,,,,,,,,,,,,,,"37312293","Anti-glomerular basement membrane disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035615","Aortic Arch Syndrome","C34391","A syndrome resulting from structural defects of the arteries that arise from the aortic arch. Signs and symptoms include weakness, dizziness, arm numbness, blurred vision and transient ischemic attacks.","Aortic Arch Syndrome | Aortic arch syndrome [Takayasu]",,,,,,,,,,,,,,,"4009628|4351864","Right aortic arch|Right aortic arch",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0003492","Aortic Coarctation","C84567","Congenital narrowing of a segment of the aorta. Signs and symptoms include hypertension, muscle weakness, shortness of breath, headaches and leg cramps.","Aortic Coarctation | Coarctation of Aorta",,,,,,,,,,,,,,,"321119","Coarctation of aorta",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3806863","Arachnoid Cyst","C3455","An intracranial or spinal cyst which contains fluid and is composed of arachnoid cells. Intracranial arachnoid cysts may present with headaches, seizures and hydrocephalus. Spinal arachnoid cysts may present with symptoms of radiculopathy.","Arachnoid Cyst | Leptomeningeal Cyst",,,,,,,,,,,,,,,"37205767|4143302","Arachnoid cyst|Arachnoid cyst",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0268548","Argininemia","C84568","A rare autosomal recessive metabolic disorder characterized by a deficiency of the enzyme arginase resulting in accumulation of arginine and urea in the blood and cerebrospinal fluid. Signs and symptoms include developmental delays, spasticity, ataxia, seizures and mental retardation.","Argininemia | Hyperargininemia",,,,,,,,,,,,,,,"4053156","Arginase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268547","Argininosuccinic Aciduria","C84569","A genetic inherited disorder caused by mutations in the ASL gene. It is characterized by accumulation of ammonia in the blood. It presents with lethargy in the first few days of life, accompanied by developmental delay and mental retardation.","Argininosuccinic Aciduria | Argininosuccinate Lyase Deficiency",,,,,,,,,,,,,,,"4164940","Argininosuccinate lyase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1836638","Arnold-Chiari Malformation","C84570","A rare genetic brain malformation characterized by displacement of the brain stem and cerebellum through the foramen magnum. It may result in hydrocephalus.","Arnold-Chiari Malformation | (Arnold) Chiari Malformation | Chiari Malformation",,,,,,,,,,,,,,,"4099094","Chiari malformation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0349788","Arrhythmogenic Right Ventricular Dysplasia","C84571","A rare genetic disorder characterized by cardiomyopathy affecting the right ventricle. The heart tissue is replaced by fibrous and adipose tissues. It is characterized by ventricular arrhythmia and right ventricular dysfunction. It is a cause of sudden death.","Arrhythmogenic Right Ventricular Dysplasia | ARVD | Arrhythmogenic RVD | Arrhythmogenic Right Ventricular Cardiomyopathy | Right Ventricular Dysplasia",,,,,,,,,,,,,,,"4101624","Arrhythmogenic right ventricular dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3550642","Arthrogryposis","C84572","A rare, non-progressive congenital disorder characterized by multiple joint contractures which are present at birth.","Arthrogryposis | ",,,,,,,,,,,,,,,"4009040","Arthrogryposis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003949","Asbestosis","C84573","A lung disorder caused by inhalation of asbestos fibers. It results in fibrosis of the lung parenchyma. Signs and symptoms include coughing, shortness of breath and chest pain.","Asbestosis | Pneumoconiosis due to asbestos and Other mineral fibers | asbestosis",,,,,,,,,,,,,,,"256450","Asbestosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0752352","Atrophic Muscular Disorder","C84574","A group of primary or secondary disorders affecting the muscles. It is characterized by an abnormal reduction in the muscle volume and atrophy. The atrophy may be caused by diseases of the muscle tissues or diseases of the peripheral nerves.","Atrophic Muscular Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004310","Auditory Perceptual Disorder","C84575","A disorder characterized by the inability of the brain to properly interpret or process the auditory signals it receives from the anatomic structures of the ear.","Auditory Perceptual Disorder | ",,,,,,,,,,,,,,,"4041828","Auditory processing disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4231138","Autoimmune Hepatitis","C27029","Hepatitis caused by autoantibodies. Drugs, infections, and toxins may trigger the production of the autoantibodies against the liver parenchyma.","Autoimmune Hepatitis | Autoimmune hepatitis",,,,,,,,,,,,,,,"200762","Autoimmune hepatitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1328840","Autoimmune Lymphoproliferative Syndrome","C37864","An autoimmune hematologic disorder characterized by autoimmune hemolytic anemia, thrombocytopenia, lymphadenopathy, hepatomegaly and splenomegaly. Patients are at an increased risk of developing Hodgkin and non-Hodgkin lymphomas.","Autoimmune Lymphoproliferative Syndrome | ALPS | Autoimmune Lymphoproliferative Syndrome (ALPS) | Canale-Smith Syndrome",,,,,,,,,,,,,,,"45765493","Autoimmune lymphoproliferative syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085409","Autoimmune Polyendocrinopathy Syndrome","C84576","A rare genetic syndrome characterized by autoantibodies production against more than one endocrine organ. The range of endocrinopathies includes hypoparathyroidism, adrenal insufficiency, hypogonadism, type 1 diabetes mellitus and hypothyroidism.","Autoimmune Polyendocrinopathy Syndrome | Autoimmune Polyendocrinopathy",,,,,,,,,,,,,,,"4223448","Autoimmune polyendocrinopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0338508","Autosomal Dominant Optic Atrophy","C84577","An autosomal dominant hereditary condition characterized by optic atrophy and progressive visual loss.","Autosomal Dominant Optic Atrophy | ",,,,,,,,,,,,,,,"4048740","Dominant hereditary optic atrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085413","Autosomal Dominant Polycystic Kidney Disease","C84578","Polycystic kidney disease inherited in an autosomal dominant pattern. Symptoms usually appear at middle age and include abdominal pain, hematuria and high blood pressure. Patients may develop brain aneurysms and liver cysts.","Autosomal Dominant Polycystic Kidney Disease | ",,,,,,,,,,,,,,,"35623051","Autosomal dominant polycystic kidney disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0406702","Autosomal Recessive Hypohidrotic Ectodermal Dysplasia","C84580","A rare autosomal recessive disorder characterized by developmental abnormalities of the skin, sweat glands, hair and nails. Patients have a reduced ability to sweat. Other signs and symptoms include hypotrichosis and teeth malformations.","Autosomal Recessive Hypohidrotic Ectodermal Dysplasia | ",,,,,,,,,,,,,,,"4098884","Autosomal recessive hypohidrotic ectodermal dysplasia syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085548","Autosomal Recessive Polycystic Kidney Disease","C84579","Polycystic kidney disease inherited in an autosomal recessive pattern. Patients present with progressive renal failure early in life. The autosomal recessive trait is associated with abnormalities of chromosome 6.","Autosomal Recessive Polycystic Kidney Disease | Autosomal Recessive Polycystic Kidney | Polycystic Kidney Disease, Infantile Type",,,,,,,,,,,,,,,"201675","Polycystic kidney disease, infantile type",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004576","Babesiosis","C84581","A parasitic infection caused by Babesia. It is transmitted by ticks and infects the red blood cells. Signs and symptoms include fever, fatigue and hemolytic anemia.","Babesiosis | ",,,,,,,,,,,,,,,"439730","Babesiosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004692","Balantidiasis","C84583","A parasitic protozoal infection caused by Balantidium coli that involves the large intestinal mucosa. Signs and symptoms include nausea, vomiting, diarrhea, abdominal pain, fever, headache and weight loss.","Balantidiasis | ",,,,,,,,,,,,,,,"197206","Balantidiasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574083","Barth Syndrome","C84585","A rare X-linked syndrome caused by mutations in TAZ1 gene. Signs and symptoms include cardiomyopathy, neutropenia, muscle weakness and atrophy, growth delay, cardiolipin deficiency and 3-methylglutaconic aciduria.","Barth Syndrome | 3-Methylglutaconic Aciduria Type 2",,,,,,,,,,,,,,,"4175583","3-Methylglutaconic aciduria type 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004771","Bartonella Infection","C84586","A gram-negative bacterial infection caused by bacteria of the genus Bartonella. It is transmitted by ticks, flies and mosquitoes. Signs and symptoms include fever, headache, muscle pain, enlargement of the lymph nodes and anemia.","Bartonella Infection | Bartonellosis",,,,,,,,,,,,,,,"440330","Bartonellosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0341700","Bartter Syndrome","C34412","A rare inherited syndrome characterized by juxtaglomerular cell hyperplasia, hyperaldosteronism, hypokalemia, and alkalosis. Patients have high levels of plasma renin concentration which is not associated with hypertension.","Bartter Syndrome | Bartter's Syndrome | Hypokalemic Alkalosis",,,,,,,,,,,,,,,"45769152","Bartter syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004779","Nevoid Basal Cell Carcinoma Syndrome","C2892","An autosomal dominant genetic syndrome caused by abnormalities in the PTCH and SUFU gene. It is characterized by multiple basal cell carcinomas at a young age, odontogenic keratocysts, and skeletal defects (bifurcated and splayed ribs, fusion of vertebrae, spinal bifida). Patients with this syndrome may also develop medulloblastomas and ovarian fibromas.","Nevoid Basal Cell Carcinoma Syndrome | Basal Cell Nevus Syndrome | Gorlin Syndrome | Gorlin syndrome | Gorlin-Goltz Syndrome | Multiple Basal Cell Carcinomas | Nevoid Basal Cell Cancer Syndrome | basal cell nevus syndrome | nevoid basal cell carcinoma syndrome",,,,,,,,,,,,,,,"4287999","Gorlin syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0917713","Becker's Muscular Dystrophy","C84587","An X-linked inherited disorder characterized by slowly progressing weakness in the muscles of the legs and pelvis.","Becker's Muscular Dystrophy | Becker",,,,,,,,,,,,,,,"4308668","Becker muscular dystrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206644","Fibrous Histiocytoma","C3739","A benign neoplasm composed of fibroblastic spindle cells in a whorled storiform pattern.  It is characterized by the presence of foam cells, inflammatory cells, hemosiderin deposition and stromal hemorrhage.","Fibrous Histiocytoma | Benign Fibrous Histiocytoma | Benign Fibrous Histiocytoma | Benign fibrous histiocytoma | Fibrous histiocytoma, NOS | Fibroxanthoma, NOS | HISTIOCYTOMA, FIBROUS, BENIGN",,,,,,,,,,,,,,,"4093908","Benign fibrous histiocytoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3280140","Benign Migratory Glossitis","C84588","A benign condition characterized by the development of irregular patches in the surface of the tongue resulting in a map-like appearance. The patches migrate from day to day and usually resolve without treatment.","Benign Migratory Glossitis | Geographic Tongue",,,,,,,,,,,,,,,"441333","Geographic tongue",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030804","Benign Mucous Membrane Pemphigoid","C34907","A chronic autoimmune disorder characterized by the development of blisters and ulcers in mucous membranes. It affects most often the gums, eyelids and genital mucosa sites.","Benign Mucous Membrane Pemphigoid | ",,,,,,,,,,,,,,,"4142060","Benign mucous membrane pemphigoid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0270851","Benign Neonatal Epilepsy","C84593","An inherited or sporadic disorder characterized by epileptic seizures in the first four to six weeks of life. The seizures tend to subside after the fifteenth week of life.","Benign Neonatal Epilepsy | ",,,,,,,,,,,,,,,"4244383","Benign neonatal convulsions",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221032","Berardinelli-Seip Congenital Lipodystrophy","C84594","A genetic disorder caused by mutations in the AGPAT2 and BSCL2 genes. It is characterized by lipoatrophy in the trunk, face, and extremities, hypertriglyceridemia, muscle hypertrophy, cardiomyopathy and hepatomegaly. Patients develop insulin resistance, leading to diabetes mellitus.","Berardinelli-Seip Congenital Lipodystrophy | Berardinelli Lipodystrophy Syndrome | Berardinelli Seip Syndrome | Congenital Generalized Lipodystrophy | Lawrence-Seip Syndrome | Seip-Bernardinelli Syndrome | Total Lipodystrophy",,,,,,,,,,,,,,,"4111658","Congenital generalized lipodystrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005129","Bernard-Soulier Syndrome","C84595","A rare, autosomal recessive bleeding disorder characterized by deficiency or absence of the Ib/IX/V complex on the surface of platelets. It results in thrombocytopenia, prolonged bleeding time and the presence of giant platelets.","Bernard-Soulier Syndrome | Platelet Glycoprotein Ib Deficiency",,,,,,,,,,,,,,,"4185078","Bernard Soulier syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2931893","Beta-Mannosidosis","C84596","An autosomal recessive lysosomal storage disease characterized by a deficient activity of the enzyme beta-mannosidase. It is caused by mutations in the MANBA gene. Common features of this disorder are mental retardation, developmental delays and recurrent respiratory infections.","Beta-Mannosidosis | ",,,,,,,,,,,,,,,"4031942","Beta-D-mannosidosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827494","Beta-Methylcrotonylglycinuria","C84597","A very rare metabolic disorder characterized by an inborn error in the leucine degradation pathway. Patients excrete large amounts of beta-methyl-crotonylglycine in the urine.","Beta-Methylcrotonylglycinuria | Beta-methylcrotonyglycinuria (Types I or II)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023892","Biliary Cirrhosis","C51225","Cirrhosis of the liver caused either by destruction of the intrahepatic bile ducts (primary biliary cirrhosis) or blockage of the extrahepatic bile ducts (secondary biliary cirrhosis).","Biliary Cirrhosis | Biliary Liver Cirrhosis | Biliary cirrhosis, unspecified",,,,,,,,,,,,,,,"192675","Biliary cirrhosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0220754","Biotinidase Deficiency","C84598","A genetic disorder caused by mutations in the BTD gene. It is characterized by reduced or absent activity of the enzyme biotinidase which is responsible for the recycling of the vitamin biotin. Signs and symptoms appear in childhood and include seizures, hypotonia and developmental delays. If left untreated, it leads to vision and hearing loss, infections, alopecia and ataxia.","Biotinidase Deficiency | ",,,,,,,,,,,,,,,"4338534","Biotinidase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005716","Blastomycosis","C34428","A fungal infection caused by inhalation of spores of Blastomyces dermatitidis. It presents with flu-like symptoms including fever, chills, cough, pleuritic chest pain and myalgias. It may lead to a chronic granulomatous pulmonary infection and disseminate to other anatomic sites including skin, nervous system and bones.","Blastomycosis | ",,,,,,,,,,,,,,,"433146","Blastomycosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006057","Botulism","C84599","A serious bacterial infection caused by botulinum toxin which is produced by Clostridium botulinum. Patients are infected usually by ingestion of contaminated food or wound contamination. It leads to muscle paralysis which may result in respiratory failure.","Botulism | ",,,,,,,,,,,,,,,"4135020","Infection caused by Clostridium botulinum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221759","Brachial Plexus Neuritis","C84600","An inflammatory process affecting the brachial plexus. It results in severe pain in the upper extremity and shoulder, upper arm weakness and loss of sensation in the upper arm.","Brachial Plexus Neuritis | ",,,,,,,,,,,,,,,"375631","Brachial neuritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018523","Brain Iron Accumulation Type I Syndrome","C8967","A rare neuroaxonal dystrophy, histologically characterized by axonal spheroids, iron deposition, Lewy body (LB)-like intraneuronal inclusions and neurofibrillary tangles.","Brain Iron Accumulation Type I Syndrome | Hallervorden-Spatz Syndrome | Hallervorden-Spatz disease | NBIA 1",,,,,,,,,,,,,,,"4106888","Pigmentary pallidal degeneration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242644","Brown-Sequard Syndrome","C84601","A disorder caused by a spinal injury leading to an incomplete spinal lesion. Patients develop paralysis, ataxia and loss of sensation. Causes include spinal cord tumors, spinal traumas, ischemia, and inflammatory processes affecting the spine.","Brown-Sequard Syndrome | Brown-Sequard syndrome",,,,,,,,,,,,,,,"4101563","Brown-Séquard syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006309","Brucellosis","C84602","A gram negative bacterial infection caused by bacteria of the genus Brucella. Humans are infected by ingesting unpasteurized milk or meat from infected animals. Signs and symptoms include fevers, sweating, weakness, headache, muscle pain, arthritis and anemia.","Brucellosis | Undulant Fever",,,,,,,,,,,,,,,"441497","Brucellosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1142166","Brugada Syndrome Ventricular Arrhythmia by ECG Finding","C71059","An electrocardiographic finding of a pattern of right bundle branch block and ST-segment elevation within electrocardiogram leads V1-V3. This pattern emerges as a result of a defect in ion channel genes, resulting in atypical electrophysiological activity in the right ventricle and a propensity for malignant tachyarrhythmias.","Brugada Syndrome Ventricular Arrhythmia by ECG Finding | BRUGADA SYNDROME | Brugada Syndrome | Brugada Syndrome Ventricular Arrhythmia | Brugada Syndrome Ventricular Arrhythmia by EKG Finding | Ventricular arrhythmia associated with Brugada syndrome",,,,,,,,,,,,,,,"4303408","Brugada syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085568","Buruli Ulcer","C84604","A cutaneous infection caused by Mycobacterium ulcerans. It presents with painless nodular swelling of the skin, leading to the formation of necrotizing ulcers.","Buruli Ulcer | ",,,,,,,,,,,,,,,"4048718","Buruli ulcer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006542","Byssinosis","C84605","An occupational lung disorder caused by exposure to cotton dust. It occurs more commonly in workers in the textile industry. Signs and symptoms include chest tightness, cough and wheezing. The symptoms tend to get worse at the beginning of the week and subside by the end of the week.","Byssinosis | ",,,,,,,,,,,,,,,"4311814","Byssinosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0751587","CADASIL Syndrome","C84606","A hereditary cerebrovascular disorder caused by mutations in the Notch 3 gene. It is characterized by alterations of the muscular wall of the small vessels in the brain, resulting in transient ischemic attacks. It may lead to cognitive problems and dementia.","CADASIL Syndrome | CADASIL",,,,,,,,,,,,,,,"4190891","Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006666","Calciphylaxis","C84607","A rare syndrome characterized by vascular calcification and skin necrosis. It seen in patients with end stage renal disease.","Calciphylaxis | ",,,,,,,,,,,,,,,"4028960","Calciphylaxis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1861922","Campomelic Dysplasia","C84609","A genetic congenital disorder characterized by bowing and angulation of the long bones. It may be associated with other skeletal and extraskeletal defects.","Campomelic Dysplasia | CMD",,,,,,,,,,,,,,,"4326424","Camptomelic dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011989","Camurati-Engelmann Syndrome","C84610","An autosomal dominant skeletal disorder caused by mutations in the TGFB1 gene. It is characterized by thickening of the bones, particularly the long bones of the extremities. It is associated with muscle weakness and tiredness.","Camurati-Engelmann Syndrome | Camurati-Englemann Disease | Progressive Diaphyseal Dysplasia",,,,,,,,,,,,,,,"4142627","Diaphyseal dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206307","Canavan Disease","C84611","A disorder that belongs in the group of leukodystrophies. It is caused by mutations in the ASPA gene which is responsible for the production of the enzyme aspartoacylase. It is characterized by spongy degeneration of the white matter of the brain. Signs and symptoms appear in infancy and include mental retardation, loss of motor skills, abnormal muscle tone, feeding difficulties and a very large head.","Canavan Disease | Spongy Degeneration of Central Nervous System",,,,,,,,,,,,,,,"4214740","Spongy degeneration of central nervous system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0751753","Carbamoyl-Phosphate Synthetase I Deficiency","C84612","A congenital disorder caused by mutations in the CPS1 gene. It is characterized by accumulation of ammonia in the blood. Signs and symptoms appear in infancy and include lethargy, seizures, developmental delay and mental disability.","Carbamoyl-Phosphate Synthetase I Deficiency | Carbamoyl Phosphate Synthetase Deficiency",,,,,,,,,,,,,,,"35623050","Carbamoyl-phosphate synthetase 1 deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0282577","Carbohydrate-Deficient Glycoprotein Syndrome","C84615","An genetically heterogeneous group of autosomal recessive disorders of carbohydrate metabolism characterized by psychomotor retardation, growth retardation, ataxia, seizures, hepatomegaly with steatosis and hypothyroidism.","Carbohydrate-Deficient Glycoprotein Syndrome | Congenital Disorder of Glycosylation | Congenital Disorders of Glycosylation",,,,,,,,,,,,,,,"4079878","Carbohydrate-deficient glycoprotein syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1275081","Cardiofaciocutaneous Syndrome","C84617","A rare genetic syndrome most often caused by BRAF gene mutations. It is characterized by a distinctive facial appearance (high forehead, short nose, and widely spaced eyes), sparse and brittle hair, skin disorders, heart malformations, mental retardation and developmental delay.","Cardiofaciocutaneous Syndrome | CFC | CFC Syndrome | Cardiofaciocutaneous (CFC) Syndrome",,,,,,,,,,,,,,,"4300448","Cardio-facio-cutaneous syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162510","Caroli Disease","C84619","A rare congenital disorder characterized by cystic dilatation of the intrahepatic bile ducts. It is associated with cholangitis and the formation of stones.","Caroli Disease | ",,,,,,,,,,,,,,,"37397179","Caroli disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007384","Cataplexy","C84618","A rare disorder characterized by sudden and transient episodes of loss of muscle tone. It often follows an experience of intense emotions. It is seen in patients with narcolepsy.","Cataplexy | ",,,,,,,,,,,,,,,"4263753","Cataplexy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007361","Cat-Scratch Disease","C84620","A bacterial infection caused by Bartonella henselae. It is transmitted to humans from a scratch, bite, or lick from a cat. A blister or a bump appears on the skin following the scratch or bite. Subsequently, there is lymph node enlargement around the scratch or bite site. The lymph node enlargement most often occurs under the arm or the neck. Some patients experience fever, fatigue, headaches or sore throat as well.","Cat-Scratch Disease | Cat-Scratch Fever",,,,,,,,,,,,,,,"440642","Cat scratch disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018920","Cavernous Hemangioma","C3086","A hemangioma characterized by the presence of cavernous vascular spaces.","Cavernous Hemangioma | Cavernoma | Cavernous Angioma | Cavernous hemangioma","9121/0","Cavernous hemangioma",,,,,,,,,,,,,"4142343|4218030","Cavernous hemangioma|Cavernous hemangioma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0751951","Central Core Disease","C83010","An autosomal dominant congenital disorder affecting the skeletal muscles. Microscopically, it is characterized by disorganized areas, which are called cores, seen usually in the center of the muscle fibers. Clinically it presents as mild to severe muscle weakness. It may be associated with skeletal abnormalities including scoliosis, joint deformities, and hip dislocation.","Central Core Disease | Central Core Myopathy",,,,,,,,,,,,,,,"4182404","Central core disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0752160","Central Nervous System Cavernous Hemangioma","C84621","A cavernous hemangioma arising from the central nervous system.","Central Nervous System Cavernous Hemangioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0751878","Central Nervous System Vasculitis","C84622","Vasculitis affecting the blood vessels of the brain and/or spinal cord.","Central Nervous System Vasculitis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206083","Central Pontine Myelinolysis","C84623","A central nervous system disorder caused by demyelination within the central basis pontis of the brain. It is characterized by spastic quadriplegia, pseudobulbar palsy and encephalopathy. It is observed in patients with severe hyponatremia, particularly when the hyponatremia is corrected too rapidly.","Central Pontine Myelinolysis | Central pontine myelinolysis",,,,,,,,,,,,,,,"4238559","Central pontine myelinolysis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0262404","Cerebellar Degeneration","C84624","Degeneration of the cerebellum. It may be an inherited condition, a paraneoplastic syndrome, or secondary to autoimmune disorders.","Cerebellar Degeneration | ",,,,,,,,,,,,,,,"4318864","Cerebellar degeneration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085220","Cerebral Amyloid Angiopathy","C84625","A disorder characterized by the deposition of amyloid in the wall of the vessels in the brain.","Cerebral Amyloid Angiopathy | ",,,,,,,,,,,,,,,"4045749","Cerebral amyloid angiopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2919945","Familial Cerebral Cavernous Malformation","C84626","A disorder characterized by malformations in the structure of the capillaries in the brain. It is caused by mutations in the CCM2, KRIT1 and PDCD10 genes. The capillaries fill with blood and stretch, thereby creating cavernous spaces. Some patients experience headaches, seizures, or visual and hearing disturbances. Cerebral hemorrhage may also occur.","Cerebral Cavernous Malformation | ",,,,,,,,,,,,,,,"37396995","Hereditary cavernous hemangioma of brain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007814","Cerebrospinal Fluid Otorrhea","C34461","Discharge of cerebrospinal fluid through the ear structures.","Cerebrospinal Fluid Otorrhea | ",,,,,,,,,,,,,,,"437578","Cerebrospinal fluid otorrhea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007815","Cerebrospinal Fluid Rhinorrhea","C84627","Discharge of cerebrospinal fluid through the nose.","Cerebrospinal Fluid Rhinorrhea | ",,,,,,,,,,,,,,,"435805","Cerebrospinal fluid rhinorrhea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0238052","Cerebrotendinous Xanthomatosis","C84628","A rare inherited lipid-storage disorder caused by defects in the CYP27A1 gene. It is characterized by progressive neurologic dysfunction, premature atherosclerosis and development of cataracts.","Cerebrotendinous Xanthomatosis | ",,,,,,,,,,,,,,,"4268608","Cholestanol storage disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024445","LIPOMATOSIS, FAMILIAL BENIGN CERVICAL","C4392","A neoplastic process characterized by a symmetric poorly circumscribed overgrowth of adipose tissue in the neck.  It predominantly affects middle age men of Mediterranean origin.","Cervical Symmetrical Lipomatosis | Multiple Symmetrical Lipomatosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376378","Cervicocranial Syndrome","C34411","A neurologic syndrome following injury of the spinal sympathetic nerves of the neck. The injury usually results from arthritis or pinching by the adjacent vertebrae. Symptoms include facial pain, chronic allergies, dizziness, neck pain, ear pain and vertigo.","Cervicocranial Syndrome | Barre-Lieou Syndrome | Posterior Cervical Sympathetic Syndrome",,,,,,,,,,,,,,,"81660","Cervicocranial syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008029","Cherubism","C84630","A rare autosomal dominant inherited disorder usually caused by mutations in the SH3BP2 gene. It is characterized by a prominent lower part of the face due to bilateral replacement of the mandibular or maxillary bones by lesions. The lesions contain osteoclast-like cells admixed with spindle-shaped mononuclear stromal cells.  With time, the lesions become more fibrotic and less osteoclast-rich.","Cherubism | Familial Fibrous Dysplasia of the Jaws | Familial Multilocular Cystic Disease of the Jaws",,,,,,,,,,,,,,,"4294407","Fibrous dysplasia of jaw",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4024224","Chilblains","C84631","A rare condition characterized by skin inflammation, blister formation, swelling and ulcerations in the extremities. It occurs in persons exposed to cold temperatures.","Chilblains | ",,,,,,,,,,,,,,,"141456","Chilblains",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036346","Childhood Schizophrenia","C35004","Schizophrenia occurring in childhood.","Childhood Schizophrenia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1997732","Chlamydophila psittaci Infection","C44959","A bacterial infection caused by Chlamydophila psittaci. Humans are infected by handling sick birds. The Chlamydiae cause respiratory infection manifests with fever, malaise, cough, dyspnea, sore throat, photophobia and headaches.","Chlamydophila psittaci Infection | Chlamydia Psittaci Infection | Chlamydia psittaci | Chlamydia psittaci Infection | Psittacosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008340","Choledochal Cyst","C2943","Cystic dilatation of the hepatic duct or bile duct.","Choledochal Cyst | ",,,,,,,,,,,,,,,"37163116","Choledochal cyst",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008445","Chondrodysplasia Punctata","C84632","A rare congenital developmental disorder characterized by the presence of stippled foci of calcification in the hyaline cartilage, joint contractions, mental retardation and ichthyosis.","Chondrodysplasia Punctata | Chondrodysplasia Punctata (Stippled Epiphyses) Group",,,,,,,,,,,,,,,"4150458","Chondrodysplasia punctata",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4228128","Chorea","C84633","A neurological condition affecting the involuntary movements. It is characterized by brief, non-repetitive irregular muscle contractions. It is seen in patients with Huntington's disease.","Chorea | ",,,,,,,,,,,,,,,"440990","Chorea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008525","Choroideremia","C34469","A rare, X-linked inherited disorder characterized by choroid atrophy and retinal degeneration. It leads to progressive loss of vision.","Choroideremia | Progressive Choroidal Atrophy",,,,,,,,,,,,,,,"433465","Choroideremia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008626","Chromosome Disorder","C34470","A disorder that results from a chromosomal abnormality.","Chromosome Disorder | Chromosome Abnormality Disorder",,,,,,,,,,,,,,,"4257441|434153","Chromosomal disorder|Congenital chromosomal disease",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0677504","Chromosome Fragile Site","C13375","Heritable sensitive regions of chromosomes which show up in vitro as non-staining bands. They are associated with chromosome breakage and other aberrations. No abnormal phenotype has been definitely identified with autosomal fragile sites, but some rare autosomal recessive disorders may be due to homozygosity for fragile sites. A fragile site on the X chromosome is associated with Fragile X Syndrome. Fragile sites are designated by the letters 'fra' followed by the designation for the specific chromosome and locus.","Chromosome Fragile Site | FRAGILE SITE | Fragile Site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0393819","Chronic Inflammatory Demyelinating Polyneuropathy","C84636","An immunologic inflammatory disorder characterized by loss of myelin in the peripheral nerves. Patients present with progressive weakness and loss of sensory function in the legs and arms.","Chronic Inflammatory Demyelinating Polyneuropathy | CIDP | Chronic Inflammatory Demyelinating Polyneuritis | Chronic Inflammatory Demyelinating Polyradiculoneuropathy",,,,,,,,,,,,,,,"381009","Chronic inflammatory demyelinating polyradiculoneuropathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4014770","Chronic Pancreatitis","C84637","A chronic inflammatory process causing damage and fibrosis of the pancreatic parenchyma. Signs and symptoms include abdominal pain, malabsorption and diabetes mellitus.","Chronic Pancreatitis | Chronic pancreatitis",,,,,,,,,,,,,,,"195596","Chronic pancreatitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008732","Chylous Peritoneal Effusion","C34482","Accumulation of chyle (milky fluid) in the peritoneal cavity. It results from the disruption of the lymphatic vessels in the abdominal cavity.","Chylous Peritoneal Effusion | Chylous Ascites | Chylous Ascites",,,,,,,,,,,,,,,"4204072","Chylous ascites",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008780","Ciliary Motility Defect","C84638","Defective movements of the cilia. It includes abnormal movements of the cilia in the nose and paranasal sinuses, the respiratory tract and spermatozoa.","Ciliary Motility Defect | Ciliary Motility Disorders | Dysmotility Syndrome | Immotile Cilia Syndrome",,,,,,,,,,,,,,,"4313982","Immotile cilia syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3844613","Citrullinemia","C84639","A rare autosomal recessive inherited disorder caused by mutations in the ASS1 and SLC25A13 genes. It is characterized by a defective urea cycle, resulting in the accumulation of ammonia and other toxic substances in the blood.","Citrullinemia | ",,,,,,,,,,,,,,,"4162980","Citrullinemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0431375","Classical Lissencephaly","C84640","A genetic disorder caused by mutations in the LIS1, XLIS, or TUBA1A genes. It results in brain malformation characterized by the underdevelopment or absence of gyri or ridges in the cerebral cortex. Signs and symptoms include epilepsy and mental retardation.","Classical Lissencephaly | Lissencephaly Type I",,,,,,,,,,,,,,,"4100574","Type 1 lissencephaly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008928","Cleidocranial Dysplasia","C75020","A rare autosomal dominant disorder caused by mutations in the RUNX2 gene.  It is characterized by developmental abnormalities in the bones and teeth, including the complete or partial absence of the clavicles, delayed closure of the fontanels, protruding mandible, hypertelorism, scoliosis, and short stature.","Cleidocranial Dysplasia | Cleidocranial Dysostosis",,,,,,,,,,,,,,,"4281998","Cleidocranial dysostosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024899","Mastocytosis","C84269","A clonal myeloproliferative neoplasm characterized by the proliferation and accumulation of neoplastic mast cells in one or multiple organs or organ systems. It is a heterogeneous group of neoplasms, ranging from cutaneous proliferations which may regress spontaneously, to aggressive neoplasms associated with organ failure and short survival.","Mastocytosis | Mast Cell Disease",,,,,,,,,,,,,,,"37309640|4054320|439412","Mast cell activation syndrome|Mast cell hyperplasia|Mast cell disorder",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C3808276","Clubfoot","C84641","The most common congenital deformation of the foot, occurring in 1 of 1,000 live births. The most common form is talipes equinovarus, where the deformed foot is turned downward and inward sharply.","Clubfoot | Club Foot | Clubbed Foot | Talipes | Talipes Equinovarus",,,,,,,,,,,,,,,"438242","Talipes equinovarus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003165","Anthracosis","C34390","A chronic lung disorder characterized by deposition of coal dust in the lung parenchyma leading to the formation of black nodules and emphysema. It occurs in coal miners.","Anthracosis | Coal Miner's Pneumoconiosis | Coalworker's pneumoconiosis",,,,,,,,,,,,,,,"252946","Coal workers' pneumoconiosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009186","Coccidioidomycosis","C84642","A fungal infection caused by Coccidioides immitis. Affected individuals usually have mild flu-like symptoms. However, pneumonia and systemic involvement with the formation of abscesses may develop as complications of the disease.","Coccidioidomycosis | Valley Fever",,,,,,,,,,,,,,,"437217","Coccidioidomycosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009187","Coccidiosis","C34493","A parasitic infection caused by Coccidia. It affects livestock, birds and humans. In humans the parasite infests the intestinal tract and may cause watery diarrhea, abdominal pain, fever, nausea and vomiting.","Coccidiosis | ",,,,,,,,,,,,,,,"433401","Coccidiosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009207","Cockayne Syndrome","C9460","An autosomal recessive syndrome caused by mutations in the ERCC8 and ERCC6 genes. It is characterized by growth and developmental delay, vision and hearing impairment, and impairment of the peripheral nervous system function.","Cockayne Syndrome | Cockayne syndrome",,,,,,,,,,,,,,,"4052211","Cockayne syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265252","Coffin-Lowry Syndrome","C84643","An inherited syndrome caused by mutations in the RPS6KA3 gene. It is characterized by mental retardation, developmental delay, microcephaly, short stature and kyphoscoliosis.","Coffin-Lowry Syndrome | ",,,,,,,,,,,,,,,"4035173","Coffin-Lowry syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001627","Congenital Adrenal Hyperplasia","C34360","A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.","Congenital Adrenal Hyperplasia | Adrenal Hyperplasia | Adrenal Hyperplasia, Congenital | Adrenogenital Disorder | Adrenogenital Syndrome | Congenital Adrenal Gland Hyperplasia | Congenital Adrenal Gland Hyperplasia",,,,,,,,,,,,,,,"4029573","Congenital adrenal hyperplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020497","Congenital Cortical Hyperostosis","C84645","A rare congenital disorder characterized by thickening or expansion of the bones.","Congenital Cortical Hyperostosis | ",,,,,,,,,,,,,,,"4083321","Infantile cortical hyperostosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002876","Congenital Dyserythropoietic Anemia","C84646","A rare group of disorders that result in anemia that is caused by ineffective erythropoiesis, which is associated with multinuclear erythroblasts, and which may present in childhood. The most common mutations are in the CDAN1 and SEC23B genes.","Congenital Dyserythropoietic Anemia | ",,,,,,,,,,,,,,,"4204062","Congenital dyserythropoietic anemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2750426","Congenital Myasthenic Syndrome","C84647","A group of rare genetic neuromuscular disorders characterized by neuromuscular junction defects. The defects are classified as presynaptic, synaptic, or postsynaptic. Signs and symptoms include muscle weakness, easy fatigability, feeding and respiratory difficulties, and scoliosis.","Congenital Myasthenic Syndrome | ",,,,,,,,,,,,,,,"4046356","Congenital myasthenic syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0752282","Congenital Structural Myopathy","C84648","A group of rare genetic muscle disorders characterized by hypotonia, muscle weakness, and delayed development of motor skills.","Congenital Structural Myopathy | Centronuclear Myopathy",,,,,,,,,,,,,,,"4218407","Myotubular myopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039131","Congenital Syphilis","C84649","A life-threatening bacterial infection of the newborn caused by Treponema pallidum. It is transmitted to the infant from a mother with syphilis through the placenta during pregnancy. Signs and symptoms include irritability, fever, failure to thrive, saddle nose, cutaneous rash, and pneumonia.","Congenital Syphilis | ",,,,,,,,,,,,,,,"434279","Congenital syphilis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827496","Deafness due to Connexin 26 Gene Anomaly","C84650","Congenital deafness caused by mutations in the gene GJB2 (deafness gene).","Deafness due to Connexin 26 Gene Anomaly | Connexin 26 Gene Anomaly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4023708","Cor Triatriatum","C84651","A rare congenital abnormality of the heart characterized by the presence of three atria. The right or left atrium is divided into two parts by fibromuscular tissue or a membrane. It may be associated with other heart congenital abnormalities.","Cor Triatriatum | ",,,,,,,,,,,,,,,"441108","Cor triatriatum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0270972","Cornelia De Lange Syndrome","C75016","A rare syndrome characterized by low birth weight, delayed growth, mental retardation, behavioral problems, and a distinctive facial appearance (thin, arched eyebrows, low set ears, small teeth, and small nose). The majority of cases are caused by mutations in the NIPBL gene. Less severe forms of the syndrome are caused by mutations in the SMC1A and SMC3 genes.","Cornelia De Lange Syndrome | ",,,,,,,,,,,,,,,"4227105","De Lange syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0587248","Costello Syndrome","C84652","A genetic syndrome caused by mutations in the HRAS gene. It is characterized by developmental delay, mental retardation, loose skin folds, cardiomyopathy, tachycardia, and structural heart defects. Patients are at an increased risk of developing benign or malignant neoplasms.","Costello Syndrome | ",,,,,,,,,,,,,,,"4149919","Costello syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010273","Craniofacial Dysostosis","C84653","A syndrome inherited in an autosomal dominant pattern. It is characterized by early fusion of the bones of the skull and face. Patients have a distinctive facial appearance which includes low-set ears, brachycephaly, hypertelorism, exophthalmos, and mandibular prognathism.","Craniofacial Dysostosis | Crouzon Syndrome",,,,,,,,,,,,,,,"4103387","Crouzon syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0079173","Craniomandibular Disorders","C84654","A disorder that affects the muscles of head and neck and temporomandibular joint.","Craniomandibular Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2750811","Craniosynostosis","C84655","A congenital disorder characterized by earlier than normal closure of some or all sutures of the infant skull.","Craniosynostosis | CRANIOSYNOSTOSIS | Craniosynostosis Syndrome",,,,,,,,,,,,,,,"4210998","Craniosynostosis syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022336","Creutzfeldt-Jakob Disease","C26802","A rare transmittable degenerative disorder of the brain caused by prions. Morphologically it is characterized by spongiform degeneration of the cerebral and cerebellar cortex. Signs and symptoms include sleep disturbances, personality changes, aphasia, ataxia, muscle atrophy and weakness, visual loss, and myoclonus. It usually leads to death within a year from the onset of the disease.","Creutzfeldt-Jakob Disease | CJD | Classic Creutzfeldt-Jakob Disease | Creutzfeldt-Jacob Disease | Creutzfeldt-Jacob Disease",,,,,,,,,,,,,,,"372241","Creutzfeldt-Jakob disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010314","Cri du Chat Syndrome","C34518","A genetic syndrome resulting from a partial deletion on the short arm of chromosome 5. It is characterized by a cat-like cry in infancy, microcephaly, mental retardation, growth failure, round face, hypertelorism, and cardiac failure.","Cri du Chat Syndrome | 5p Deletion Syndrome | 5p Partial Monosomy Syndrome | Cat-Cry Syndrome | Cri-du-Chat Syndrome",,,,,,,,,,,,,,,"440518","5p partial monosomy syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010324","Crigler-Najjar Syndrome","C84656","A rare autosomal recessive inherited syndrome characterized by abnormalities in the metabolism of bilirubin. It results in the development of jaundice. It may cause brain damage in infancy.","Crigler-Najjar Syndrome | ",,,,,,,,,,,,,,,"4151846","Crigler-Najjar syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2316212","Cryopyrin-Associated Periodic Syndrome","C84657","A group of autoinflammatory syndromes caused by mutations in the NLRP3 gene. Signs and symptoms include rash, fever, headache, joint pain, conjunctivitis, and weakness. The symptoms may exacerbate with exposure to cold weather.","Cryopyrin-Associated Periodic Syndrome | CAPS | Cryopyrinopathy",,,,,,,,,,,,,,,"4328432","Cryopyrin associated periodic syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023283","Cutaneous Leishmaniasis","C34768","Leishmaniasis affecting the skin. It is the most common form of leishmaniasis. It presents with erythematous macules and papules, and nodules which may eventually ulcerate. The lesions appear in the bite site in the exposed skin areas.","Cutaneous Leishmaniasis | ",,,,,,,,,,,,,,,"4080607","Cutaneous leishmaniasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2930812","Cutis Laxa","C84663","A congenital or acquired disorder affecting the elastic fibers of the skin. It is characterized by loss of elasticity resulting in loosening and folding of the skin.","Cutis Laxa | Elastolysis",,,,,,,,,,,,,,,"4242416","Cutis laxa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010678","Cysticercosis","C34520","A parasitic infection caused by the larval form of Taenia solium. It is a disseminated infection affecting the central nervous system, subcutaneous tissues, lungs, heart and liver. The most serious complications result from infection of the brain parenchyma. Patients may develop seizures, hydrocephalus, encephalopathy and meningoencephalitis.","Cysticercosis | ",,,,,,,,,,,,,,,"440953","Cysticercosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010690","Cystinosis","C2976","An autosomal recessive hereditary disorder characterized by defective transportation of cystine across the lysosomal membranes and systemic deposition of cystine crystals in the body. It is associated with slight increase of the plasma cystine, cystinuria, aminoaciduria, glycosuria, polyuria, hypophosphatemia, rickets, and renal tubular dysfunction.","Cystinosis | ",,,,,,,,,,,,,,,"4100827","Cystinosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010691","Cystinuria","C84664","An autosomal recessive inherited metabolic disorder caused by mutations in the SLC3A1 and SLC7A9 genes. It is characterized by deficient re-absorption of cystine in the proximal tubules of the kidney. It results in the formation of stones in the kidney, ureter, and urinary bladder.","Cystinuria | ",,,,,,,,,,,,,,,"4225406","Cystinuria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010823","Cytomegaloviral Infection","C53649","A herpesvirus infection caused by Cytomegalovirus. Healthy individuals generally do not produce symptoms. However, the infection may be life-threatening in affected immunocompromised patients. The virus may cause retinitis, esophagitis, gastritis, and colitis. Morphologically, it is characterized by the presence of intranuclear inclusion bodies.","Cytomegaloviral Infection | CMV Infection | Cytomegalovirus | Cytomegalovirus (CMV) | Cytomegalovirus Infection | HCMV Infection",,,,,,,,,,,,,,,"440032","Cytomegalovirus infection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3280907","Dandy-Walker Malformation","C75012","A rare congenital brain malformation disorder characterized by agenesis or hypoplasia of the cerebellar vermis, cystic dilatation of the fourth ventricle, and enlargement of the posterior fossa.","Dandy-Walker Malformation | Dandy-Walker Syndrome",,,,,,,,,,,,,,,"4031189","Dandy-Walker syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022595","Darier Disease","C84665","An autosomal dominant inherited chronic skin disorder caused by mutations in the ATP2A2 gene. It is characterized by the development of yellow-brown keratotic skin papules in the neck, ears, forehead, chest, back and groin. It is associated with fragility of the free margins of the nails.","Darier Disease | Keratosis Follicularis",,,,,,,,,,,,,,,"4174992","Darier disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265201","De Sanctis-Cacchione syndrome","C84666","A rare autosomal recessive inherited syndrome. It is characterized by xeroderma pigmentosum, mental retardation, dwarfism, hypogonadism, and neurologic abnormalities.","De Sanctis-Cacchione Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3549665","Deafness","C27644","An inherited or acquired condition characterized by the inability to hear in one or both ears.","Deafness | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0432442","Deletion 18p Syndrome","C84521","A rare genetic syndrome characterized by the deletion of the short arm of chromosome 18. It is associated with mental and growth retardation, prominent ears and ptosis.","Deletion 18p Syndrome | 18P Syndrome",,,,,,,,,,,,,,,"4155536","Deletion of short arm of chromosome 18",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0432443","Deletion 18q Syndrome","C84522","A condition in which some or all of the cells of the body contain extra genetic material from chromosome 18. Clinical features of this condition may include the following: spina bifida, hearing loss, cleft lip, cleft palate, undescended testes, rocker bottom feet, micrognathia, low set ears, cardiac anomalies (ventricular septal defect, atrial septal defect, patent ductus arteriosus, tetralogy of Fallot), intellectual disability, holoprosencephaly, pituitary dysplasia, seizures, autoimmune disorders, hip dysplasia, and/or congenital cataracts.","Deletion 18q Syndrome | 18Q Syndrome | 18q Deletion Syndrome | 18q-Syndrome | Chromosome 18q Deletion Syndrome",,,,,,,,,,,,,,,"4152969","Deletion of long arm of chromosome 18",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011311","Dengue Fever","C34528","An acute infection caused by Dengue virus. Signs and symptoms include sudden onset of fever, headache, rash, arthralgia, and myalgia. It is transmitted through mosquitoes.","Dengue Fever | Break Bone Fever | Dengue",,,,,,,,,,,,,,,"440022","Dengue",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019100","Dengue Hemorrhagic Fever","C34683","A serious condition caused by Dengue virus infection. Patients present with an acute febrile illness followed by restlessness, irritability, and bleeding. It may lead to hemorrhagic shock and death.","Dengue Hemorrhagic Fever | ",,,,,,,,,,,,,,,"4049502","Dengue hemorrhagic fever",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3552372","Dentinogenesis Imperfecta","C84667","A congenital tooth development disorder caused by mutations in the DSPP gene. The teeth are weak, discolored, and translucent.","Dentinogenesis Imperfecta | ",,,,,,,,,,,,,,,"4024669","Dentinogenesis imperfecta",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011608","Dermatitis Herpetiformis","C26742","A chronic autoimmune skin disorder characterized by the development of pruritic papulovesicular and bullous lesions in the elbows, knees, buttocks, and back. It is associated with an increased expression of HLA-A1, HLA-B8, and HLA-DR3 antibodies.","Dermatitis Herpetiformis | ",,,,,,,,,,,,,,,"140487","Dermatitis herpetiformis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4229692","Dextrocardia","C84669","A rare congenital abnormality in which the heart is located in the right side of the chest. It is associated with other congenital heart defects.","Dextrocardia | DEXTROCARDIA",,,,,,,,,,,,,,,"4100815","Dextrocardia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4014484","Diabetes Insipidus","C43263","A disorder characterized by excretion of large amounts of urine, accompanied by excessive thirst. Causes include deficiency of antidiuretic hormone or failure of the kidneys to respond to antidiuretic hormone. It may also be drug-related.","Diabetes Insipidus | ",,,,,,,,,,,,,,,"30968","Diabetes insipidus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007795","Diffuse Cerebral Sclerosis of Schilder","C84670","A rare congenital demyelinating disorder affecting the central nervous system. It is characterized by a demyelinating destructive lesion affecting an entire brain lobe or hemisphere. Signs and symptoms include dementia, cortical deafness and blindness, pseudobulbar palsy, and hemiplegia.","Diffuse Cerebral Sclerosis of Schilder | Diffuse sclerosis of central nervous system",,,,,,,,,,,,,,,"376970","Schilder's disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020498","Diffuse Idiopathic Skeletal Hyperostosis","C84671","A rare degenerative disorder that affects the spine. It is characterized by ossification of ligaments resulting in calcifications along the sides of the spinal vertebrae.","Diffuse Idiopathic Skeletal Hyperostosis | DISH | Forestier's Disease",,,,,,,,,,,,,,,"77961","Disseminated idiopathic skeletal hyperostosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4017803","Tylosis","C3147","An inherited disorder characterized by the development of keratotic lesions on the palms and soles. It appears in childhood as redness on the palms and soles which progresses to well demarcated, thickened, yellowish and waxy lesions.","Tylosis | Diffuse Palmoplantar Keratoderma | Keratosis Palmaris et Plantaris",,,,,,,,,,,,,,,"37396336|4271018","Autosomal dominant diffuse palmoplantar keratoderma Norrbotten type|Hereditary diffuse palmoplantar keratoderma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1959620","Dihydropyrimidine Dehydrogenase Deficiency","C84672","A rare disorder characterized by an inborn error in pyrimidine metabolism. It results in the deficiency or complete absence of the enzyme dihydropyrimidine dehydrogenase. Individuals with this disorder may develop a severe toxicity reaction if they are exposed to the chemotherapeutic agent 5-fluorouracil.","Dihydropyrimidine Dehydrogenase Deficiency | DPD Deficiency | DPYD Deficiency | Dihydrouracil Dehydrogenase Deficiency | Thymine-Uracilurea | Thymine-Uraciluria",,,,,,,,,,,,,,,"4299531","Dihydropyrimidine dehydrogenase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3554475","Dilated Cardiomyopathy","C84673","Cardiomyopathy which is characterized by dilation and contractile dysfunction of the left and right ventricles. It may be idiopathic, or it may result from a myocardial infarction, myocardial infection, or alcohol abuse. It is a cause of congestive heart failure.","Dilated Cardiomyopathy | Congestive Cardiomyopathy",,,,,,,,,,,,,,,"4163710","Dilated cardiomyopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0012517","Dipetalonemiasis","C34540","A parasitic infection caused by genus of filarial worms called Dipetalonema. It produces microfilariae in the blood and body fluids.","Dipetalonemiasis | Dipetalonema Infection | Dipetalonema Infections",,,,,,,,,,,,,,,"436343","Infection by Dipetalonema",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3552386","Distal Muscular Dystrophy","C84675","A group of genetic degenerative muscle disorders affecting the muscles of the lower arms, hands, lower legs, and feet.","Distal Muscular Dystrophy | Distal Myopathy",,,,,,,,,,,,,,,"4243215","Distal muscular dystrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265344","Donohue Syndrome","C84676","A rare autosomal recessive genetic disorder caused by mutations in the insulin receptor gene. Signs and symptoms include a characteristic facial appearance (protuberant and low-set ears, thick lips, and flaring nostrils), intrauterine growth retardation, insulin resistance, and enlarged genitalia.","Donohue Syndrome | Leprechaunism",,,,,,,,,,,,,,,"4006979","Leprechaunism syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013100","Dracunculiasis","C84677","A parasitic infection caused by Dracunculus medinensis. It is caused by drinking water contaminated with water fleas. The larvae enter the body through the intestine. Signs and symptoms include pain, edema, blisters, and ulcers.","Dracunculiasis | Guinea Worm Disease",,,,,,,,,,,,,,,"193708","Infection by Dracunculus medinensis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3151695","Duane Syndrome","C84678","A rare disorder affecting the muscles of the eye. It is characterized by an abnormal contraction of some eye muscles and failure of contraction of other eye muscles. It leads to limited abduction and adduction of the affected eye.","Duane Syndrome | Duane Retraction Syndrome",,,,,,,,,,,,,,,"376989","Duane's syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022350","Dubin-Johnson Syndrome","C34741","An inherited autosomal recessive disorder characterized by the presence of mild jaundice due to abnormalities in the bilirubin transportation from the liver parenchyma to the biliary system.","Dubin-Johnson Syndrome | Chronic Idiopathic Jaundice",,,,,,,,,,,,,,,"4195953","Dubin-Johnson syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013264","Duchenne Muscular Dystrophy","C75482","An X-linked inherited disorder caused by mutations in the DMD gene found on the X chromosome. It is characterized by rapidly progressing muscle weakness and muscle atrophy initially involving the lower extremities and eventually affecting the whole body. It affects males whereas females can be carriers. The symptoms start before the age of six and may appear at infancy.","Duchenne Muscular Dystrophy | Duchenne",,,,,,,,,,,,,,,"4296473","Duchenne muscular dystrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3250443","MYOTONIC DYSTROPHY 1","C84679","A rare autosomal dominant disorder caused by mutations in the DMPK gene. It is characterized by myotonia, muscular dystrophy, hypogonadism, heart conduction defects and cataracts.","Dystrophia Myotonica 1 | Myotonic Dystrophy 1 | Steinert Disease | Steinert Myotonic Dystrophy Syndrome | Steinert Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2931689","Dystrophia Myotonica 2","C84680","A rare autosomal dominant disorder caused by mutations in the CNBP gene. It is characterized by muscle pain, fatigue, and weakness of the proximal muscles of the lower extremities.","Dystrophia Myotonica 2 | DM2 | Myotonic Dystrophy 2 | PROMM | Proximal Myotonic Myopathy | Ricker Syndrome",,,,,,,,,,,,,,,"37395761","Proximal myotonic myopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3808336","Ebstein Anomaly","C84681","A rare congenital heart malformation characterized by apical displacement of the opening of the tricuspid valve. The defect involves both the right ventricle and the tricuspid valve, and can lead to cardiomyopathy and tachyarrhythmias.","Ebstein Anomaly | Ebstein's Anomaly | Ebstein's Anomaly of Tricuspid Valve | Ebstein's anomaly",,,,,,,,,,,,,,,"4069182","Ebstein's anomaly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266065","Porocarcinoma","C5560","A carcinoma with eccrine differentiation arising from the sweat glands. It may arise de novo or as a malignant transformation of a pre-existing poroma. It usually grows in the legs, buttocks, feet, and trunk and usually presents as an ulcerative plaque. It is characterized by the presence of intraepidermal and dermal nests of malignant epithelial cells. It may recur after excision and metastasize to the lymph nodes and less frequently to distal anatomic sites.","Porocarcinoma | Eccrine Porocarcinoma | Eccrine Porocarcinoma | Epidermotropic Eccrine Carcinoma | Malignant Eccrine Poroma",,,,,,,,,,,,,,,"4029994","Eccrine porocarcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013502","Echinococcosis","C84682","A parasitic infection caused by tapeworm larvae of Echinococcus. It affects livestock and humans. It is characterized by the formation of hydatid cysts mainly in the liver, lungs, spleen, and kidneys. Rupture of the cysts may lead to shock.","Echinococcosis | ",,,,,,,,,,,,,,,"440043","Echinococcosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013575","Ectodermal Dysplasia","C84683","A group of inherited disorders characterized by malformations of the structures that derive from the ectoderm, such as hair, teeth, nails and sweat glands.","Ectodermal Dysplasia | ",,,,,,,,,,,,,,,"134757","Ectodermal dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013589","Ectromelia","C34567","A congenital defect characterized by the absence or hypoplasia of one or more extremities.","Ectromelia | ",,,,,,,,,,,,,,,"4182590","Ectromelia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013720","Ehlers-Danlos Syndrome","C34568","An inherited connective tissue disorder characterized by loose and fragile skin and joint hypermobility.","Ehlers-Danlos Syndrome | Ehlers-Danlos syndrome",,,,,,,,,,,,,,,"79145","Ehlers-Danlos syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013903","Ellis-Van Creveld Syndrome","C84684","A rare autosomal recessive syndrome caused by mutations in the EVC gene. It is characterized by dwarfism, small chest, ectodermal dysplasia, and postaxial polydactyly. There is an increased frequency of congenital heart malformations.","Ellis-Van Creveld Syndrome | Chondroectodermal Dysplasia",,,,,,,,,,,,,,,"80838","Chondroectodermal dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0410189","Emery-Dreifuss Muscular Dystrophy","C84685","An X-linked or autosomal dominant inherited muscular dystrophy. It is characterized by slowly progressive muscle weakness, atrial conduction defects, cardiomyopathy, and early contractures of the elbow, ankle and neck.","Emery-Dreifuss Muscular Dystrophy | EDMD",,,,,,,,,,,,,,,"4009185","Emery-Dreifuss muscular dystrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014008","Empty Sella Syndrome","C84686","A syndrome characterized by flattening or regression of the pituitary gland within the sella turcica cavity, resulting in an MRI image of an empty sella turcica. Signs and symptoms are secondary to pituitary gland hypofunction.","Empty Sella Syndrome | Empty Sella",,,,,,,,,,,,,,,"4029448","Empty sella syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1850870","Encephalocele","C84687","A congenital neural tube closure defect resulting in the protrusion of the brain through a skull opening. When the protrusion includes the meninges, the term encephalomeningocele is used.","Encephalocele | Cranium Bifidum",,,,,,,,,,,,,,,"432419","Encephalocele",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014084","Enchondromatosis","C3008","A rare benign disorder characterized by lack of normal endochondral ossification, and the growth of multiple enchondromas.  It primarily affects the bones of the hand, in children and young adults.  Extent of the disease varies; in some cases, neoplastic involvement may be widespread causing considerable deformity.","Enchondromatosis | Dyschondroplasia | Ollier Disease | Ollier's Disease",,,,,,,,,,,,,,,"4145177","Enchondromatosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041472","Endemic Typhus Fever","C84688","A bacterial infection caused by Rickettsia typhi or Rickettsia felis. It is transmitted to humans from infected rat fleas. Symptoms include fever, headache, joint and muscle pain, and weakness.","Endemic Typhus Fever | Endemic Flea-Borne Typhus | Endemic Typhus",,,,,,,,,,,,,,,"433961","Murine typhus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014461","Eosinophilic Granuloma","C3016","A clinical variant of Langerhans cell histiocytosis characterized by unifocal involvement of a bone (most often), skin, or lung.  Patients are usually older children or adults usually presenting with a lytic bone lesion.  The etiology is unknown.  Morphologically, eosinophilic granuloma is characterized by the presence of Langerhans cells in a characteristic milieu which includes histiocytes, eosinophils, neutrophils, and small, mature lymphocytes.","Eosinophilic Granuloma | Chronic Unifocal Langerhans Cell Histiocytosis | Eosinophilic Xanthomatous Granuloma | Eosinophilic granuloma | Monostotic Langerhans Cell Histiocytosis | Unifocal Langerhans Cell Histiocytosis | Unifocal Langerhans-cell histiocytosis",,,,,,,,,,,,,,,"4028706|4044708","Eosinophilic granuloma|Eosinophilic granuloma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0041473","Epidemic Louse-Borne Typhus","C84689","A gram-negative bacterial infection caused by Rickettsia prowazekii. It is spread by lice infected with the bacteria. Signs and symptoms include sudden headache, generalized muscle pain, malaise, and macular skin lesions. The infection may affect the central nervous system causing encephalitis.","Epidemic Louse-Borne Typhus | Epidemic Typhus | Epidemic Typhus Fever",,,,,,,,,,,,,,,"440636","Louse-borne typhus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014527","Epidermolysis Bullosa","C67383","An autosomal recessive inherited skin disorder caused by mutations in the genes encoding keratins 5 and 14, collagen VII or laminin 5. It is characterized by skin fragility and the formation of blisters. The blisters may become large and ulcerated, resulting in skin infections and loss of body fluids.","Epidermolysis Bullosa | epidermolysis bullosa",,,,,,,,,,,,,,,"4246290","Epidermolysis bullosa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0079293","Epidermolysis Bullosa Acquisita","C84690","A chronic autoimmune inflammatory disorder characterized by the formation of subepidermal blisters in the skin and the mucous membranes.","Epidermolysis Bullosa Acquisita | EBA | Epidermolysis Bullosa Aquisita",,,,,,,,,,,,,,,"4100661","Acquired epidermolysis bullosa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0079294","Epidermolysis Bullosa Dystrophica","C84691","A genetic skin disorder caused by mutations in the type VII collagen gene (COL7A1). It is characterized by the formation of blisters and scarring in the skin and mucous membranes.","Epidermolysis Bullosa Dystrophica | ",,,,,,,,,,,,,,,"4110130","Dystrophic epidermolysis bullosa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0079298","Epidermolysis Bullosa Simplex","C84692","A genetic skin disorder caused by mutations in the KRT5 and KRT14 genes. It is characterized by the formation of blisters and increased fragility of the skin.","Epidermolysis Bullosa Simplex | ",,,,,,,,,,,,,,,"4284702","Epidermolysis bullosa simplex",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0079153","Epidermolytic Ichthyosis","C62569","An autosomal dominant inherited skin disorder caused by mutations in the KRT1 and KRT10 genes. It is manifested at birth and is characterized by generalized erythema, skin blisters and skin fragility.","Epidermolytic Ichthyosis | BCIE | Bullous Congenital Ichthyosiform Erythroderma | Epidermolytic Hyperkeratosis | Epidermolytic Hyperkeratosis",,,,,,,,,,,,,,,"4110127","Bullous ichthyosiform erythroderma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1721006","Epidermolytic Palmoplantar Keratoderma","C84693","A genetic skin disorder caused by mutations in the KRT9 gene. It is characterized by hyperkeratosis in the palms and soles resulting in abnormal thickening of the skin in these areas.","Epidermolytic Palmoplantar Keratoderma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1368797","Epithelioid Hemangioma","C4298","A hemangioma characterized by the presence of epithelioid endothelial cells.","Epithelioid Hemangioma | Angiolymphoid Hyperplasia with Eosinophilia | Epithelioid hemangioma | Histiocytoid Hemangioma | Histiocytoid hemangioma","9125/0","Epithelioid hemangioma",,,,,,,,,,,,,"4144388","Epithelioid hemangioma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0085273","Erythema Infectiosum","C84695","A self-limited viral infectious disorder caused by the human parvovirus B19. It affects predominantly children and is characterized by the development of a bright red skin eruption in the cheeks. It is followed by a maculopapular skin eruption in the extremities which eventually fades into a lacey pattern.","Erythema Infectiosum | Fifth Disease",,,,,,,,,,,,,,,"134569","Primate erythroparvovirus 1 infection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265961","Erythrokeratodermia Variabilis","C84696","A rare genetic chronic skin disorder characterized by hyperkeratosis and transient erythema. Mutations in GJB3 and GJB4 genes have been identified as causative agents.","Erythrokeratodermia Variabilis | Erythrokeratodermia Variabilis et Progressiva",,,,,,,,,,,,,,,"4289750","Erythrokeratodermia variabilis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4229647","Erythromelalgia","C34593","A rare disorder characterized by periodic inflammation and blockage of the vessels of the extremities, resulting in skin redness, swelling, and burning pain in the affected sites. It may manifest as a primary disorder caused by mutations of the SCN9A gene or as a secondary disorder due to hematologic disorders or medication side effects.","Erythromelalgia | ",,,,,,,,,,,,,,,"134380","Erythromelalgia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162530","Erythropoietic Porphyria","C84697","A rare congenital metabolic disorder characterized by an inborn error of porphyrin-heme biosynthesis. It is caused by deficiency of the enzyme uroporphyrinogen III cosynthetase. It results in cutaneous photosensitivity leading to blistering and scarring of the exposed skin areas.","Erythropoietic Porphyria | CEP",,,,,,,,,,,,,,,"4282625","Erythropoietic porphyria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162568","Erythropoietic Protoporphyria","C84698","A rare congenital metabolic disorder characterized by an inborn error of porphyrin-heme biosynthesis. It is caused by deficiency of the enzyme ferrochelatase. Signs and symptoms include painful cutaneous photosensitivity leading to blistering and scarring of the exposed skin areas, erythrodontia, red discoloration of urine, hemolytic anemia, and splenomegaly.","Erythropoietic Protoporphyria | EPP | Protoporphyria, Erythropoietic",,,,,,,,,,,,,,,"4177022","Erythropoietic protoporphyria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014848","Esophageal Achalasia","C84699","A finding indicating the lack of adequate relaxation of the lower esophageal sphincter resulting in difficulty swallowing food.","Esophageal Achalasia | Achalasia Cardia | Achalasia of Cardia",,,,,,,,,,,,,,,"318186|37399429","Achalasia of esophagus|Idiopathic achalasia of esophagus",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0030186","Extramammary Paget Disease","C3302","A malignant neoplasm in which there is infiltration of the skin by neoplastic large cells with abundant pale cytoplasm and large nuclei with prominent nucleoli (Paget cells). It may affect the anus, penis, scrotum, and vulva.","Extramammary Paget Disease | Cutaneous Paget's Disease | EMPD | Extramammary Paget's Disease | Paget Disease Extramammary | Paget Disease, Extramammary | Paget disease, extramammary | Paget's Disease of Skin | Paget's Disease of the Skin | Paget's Skin Disease","8542/3","Paget disease, extramammary",,,,,,,,,,,,,"4048474|4323699","Paget's disease of skin|Paget's disease, extramammary (except Paget's disease of bone)",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"CL412926","Fabry Disease","C84701","A rare X-linked inherited lysosomal storage disorder characterized by deficiency of the enzyme alpha-galactosidase A. It results in the accumulation of glycolipids in the blood vessels and tissues. Signs and symptoms include hypertension, cardiomyopathy, angiokeratomas, neuropathy, hypohidrosis, keratopathy, proteinuria, and renal failure.","Fabry Disease | Alpha-Galactosidase A Deficiency | Angiokeratoma Corporis Diffusum | Fabry's Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4230159","Facial Asymmetry","C84702","A finding indicating the absence of balanced proportions between parts of the face.","Facial Asymmetry | ",,,,,,,,,,,,,,,"4035630","Facial asymmetry",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL475596","Facial Hemiatrophy","C84703","Progressive atrophy of the tissues that comprise half of the face.","Facial Hemiatrophy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0238288","Facioscapulohumeral Muscular Dystrophy","C84704","An autosomal dominant disorder affecting the skeletal muscles of the face, scapula, and upper arm. Patients present with muscle weakness in these anatomic areas. The muscle weakness eventually spreads to other skeletal muscles as well.","Facioscapulohumeral Muscular Dystrophy | ",,,,,,,,,,,,,,,"4163266","Facioscapulohumeral muscular dystrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL480897","Factor I Deficiency","C26692","A usually inherited blood coagulation disorder characterized by the partial or complete absence of fibrinogen in the blood, resulting in bleeding.","Factor I Deficiency | Fibrinogen Deficiency | Hypofibrinogenemia",,,,,,,,,,,,,,,"4120779","Factor I deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015523","Hereditary Factor XI Deficiency","C84705","A rare inherited bleeding disorder caused by deficiency of coagulation factor XI. It may be asymptomatic or manifest with bleeding.","Hereditary Factor XI Deficiency | Factor XI Deficiency | Hemophilia C | Hereditary Factor XI Deficiency | Hereditary Factor XI Deficiency Disease | Hereditary Factor XI Deficiency Disease | Hereditary factor XI deficiency",,,,,,,,,,,,,,,"437256","Hereditary factor XI deficiency disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0272334","Hereditary Factor XII Deficiency","C26770","A rare autosomal recessive inherited bleeding disorder caused by deficiency of coagulation factor XII. It may be asymptomatic or manifest with bleeding.","Hereditary Factor XII Deficiency | Factor XII Deficiency | Hereditary Factor XII Deficiency | Hereditary Factor XII Deficiency Disease | Hereditary Factor XII Deficiency Disease | Hereditary Hageman Factor Deficiency",,,,,,,,,,,,,,,"4183313","Hereditary factor XII deficiency disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015558","Fallopian Tube Neoplasm","C3032","A benign or malignant neoplasm affecting the fallopian tube. Representative examples of benign neoplasms include papilloma, adenofibroma, and leiomyoma. Representative examples of malignant neoplasms include carcinoma, carcinosarcoma, and adenosarcoma.","Fallopian Tube Neoplasm | Fallopian Tube Tumor | Neoplasm of Fallopian Tube | Neoplasm of the Fallopian Tube | Tumor of Fallopian Tube | Tumor of the Fallopian Tube",,,,,,,,,,,,,,,"4130533","Neoplasm of fallopian tube",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206245","Familial Amyloid Neuropathy","C84554","A rare inherited neuropathy characterized by deposition of amyloid in the peripheral nerves.","Familial Amyloid Neuropathy | Amyloid Neuropathies, Familial | Familial Amyloid Polyneuropathy",,,,,,,,,,,,,,,"4173311","Familial amyloid polyneuropathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0740340","Hereditary Amyloidosis","C84555","An autosomal dominant inherited form of amyloidosis.","Hereditary Amyloidosis | AF | Amyloidosis, Familial | Familial Amyloidosis | Familial Amyloidosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085106","Familial Benign Pemphigus","C82865","An autosomal dominant disorder characterized by a history of multiple relapses and remissions of pemphigus lesions.","Familial Benign Pemphigus | Benign Familial Pemphigus | Hailey-Hailey Disease",,,,,,,,,,,,,,,"4194945","Familial benign pemphigus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013364","Familial Dysautonomia","C84706","A congenital disorder caused by mutations in the IKBKAP gene. It is characterized by damage of the sympathetic and parasympathetic and sensory nervous system.","Familial Dysautonomia | Familial dysautonomia | HSAN 3 | HSAN III | Hereditary Sensory and Autonomic Neuropathy Type III | Neuropathy, Hereditary Sensory and Autonomic, Type III | Riley- Day | Riley-Day Syndrome | hereditary sensory and autonomic neuropathy type III",,,,,,,,,,,,,,,"4104196","Familial dysautonomia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0949658","Familial Hypertrophic Cardiomyopathy","C84773","Hypertrophic cardiomyopathy caused by mutations in the genes encoding components of the sarcomere, in the absence of predisposing conditions.","Familial Hypertrophic Cardiomyopathy | Hypertrophic Familial Cardiomyopathy",,,,,,,,,,,,,,,"4222765","Primary familial hypertrophic cardiomyopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4227883","Familial Mediterranean Fever","C84707","A usually autosomal recessive inherited inflammatory disorder caused by mutations in the MEFV gene. It is characterized by recurrent painful inflammatory attacks in the abdomen, joints, and chest. The inflammatory attacks are associated with fever.","Familial Mediterranean Fever | FMF",,,,,,,,,,,,,,,"193445","Familial Mediterranean fever",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0271694","Familial Partial Lipodystrophy","C84708","An autosomal dominant inherited disorder that appears in childhood or adolescence. It is characterized by loss of adipose tissue in the extremities and accumulation of adipose tissue in the face and neck.","Familial Partial Lipodystrophy | Congenital Partial Lipodystrophy",,,,,,,,,,,,,,,"4174059","Familial partial lipodystrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030443","Familial Periodic Paralysis","C84709","A group of genetic neurological disorders caused by mutations in genes involved in the sodium and calcium channels in nerve cells. It is characterized by episodes of muscle paralysis in which the affected muscles become flaccid and the deep tendon reflexes disappear. Between the episodes the affected muscles usually work normally.","Familial Periodic Paralysis | ",,,,,,,,,,,,,,,"73184","Familial periodic paralysis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015624","Fanconi Syndrome","C3034","A genetic or acquired disorder characterized by impairment of the function of the proximal tubules of the kidney. It results in decreased reabsorption of electrolytes, glucose, amino acids, and other nutrients.","Fanconi Syndrome | De Toni-Debre-Fanconi Syndrome | Fanconi's syndrome | Lignac-Fanconi Syndrome",,,,,,,,,,,,,,,"4229557","Fanconi syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268255","Farber Lipogranulomatosis","C84710","A very rare autosomal recessive metabolic disorder affecting lipid metabolism. It is caused by mutations in the ASAH1 gene and is characterized by fatty accumulation in the body tissues. Patients develop lipogranulomas in the skin and internal organs, edema and pain in the joints and a hoarse voice. It may be associated with intellectual disability.","Farber Lipogranulomatosis | ",,,,,,,,,,,,,,,"4196512","Farber's lipogranulomatosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206042","Fatal Familial Insomnia","C84711","A very rare autosomal dominant inherited sleep disorder caused by a mutation in the gene responsible for the prion protein. It affects individuals usually in their fourth decade. Its initial manifestation is difficulty in falling asleep. It is followed by complete inability to sleep. Patients develop deterioration of their mental and motor functions and die soon after the first symptoms appear, because of the total absence of sleep.","Fatal Familial Insomnia | ",,,,,,,,,,,,,,,"444300","Fatal familial insomnia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015773","Felty Syndrome","C84712","A syndrome characterized by the presence of rheumatoid arthritis, splenomegaly, and granulocytopenia. Patients are at an increased risk of infection because of the low white cell counts.","Felty Syndrome | Felty's Syndrome | Felty's syndrome, unspecified site",,,,,,,,,,,,,,,"81097","Felty's syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015923","Fetal Alcohol Syndrome","C84713","A teratogenic disorder observed in a newborn or child of a mother who consumed alcohol during pregnancy. Manifestations of the syndrome include low birth weight, atypical facies, microcephaly, failure to thrive, developmental defects, organ dysfunction, mental deficiencies, poor motor coordination and behavioral problems.","Fetal Alcohol Syndrome | FAS | Fetal alcohol syndrome",,,,,,,,,,,,,,,"4004785","Fetal alcohol syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016052","Fibromuscular Dysplasia","C84714","A disorder characterized by fibrous thickening of the arterial wall resulting in narrowing of the arterial lumen. It most often affects the renal artery and less often the carotid artery and abdominal arteries. It can cause hypertension and aneurysm formation.","Fibromuscular Dysplasia | Arterial fibromuscular dysplasia",,,,,,,,,,,,,,,"4135811","Fibromuscular dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016632","Fox-Fordyce Disease","C84716","A chronic inflammatory skin disorder characterized by pruritic papular eruptions in areas with apocrine glands. It usually affects the axillae bilaterally. There is rupture of the apocrine ducts resulting in inflammation and formation of the papular skin lesions.","Fox-Fordyce Disease | ",,,,,,,,,,,,,,,"136186","Apocrine miliaria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016667","Fragile X Syndrome","C84717","A genetic syndrome caused by mutations in the FMR1 gene which is responsible for the expression of the fragile X mental retardation 1 protein. This protein participates in neural development. This syndrome is manifested with mental, emotional, behavioral, physical, and learning disabilities.","Fragile X Syndrome | ",,,,,,,,,,,,,,,"436803","Fragile X syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016719","Friedreich Ataxia","C84718","An autosomal recessive inherited disorder caused by mutations in the FXN gene. It is characterized by progressive degeneration of the nerve tissues of the spinal cord. The main symptoms include gait and balance disturbances, lack of limb coordination, and speech disturbances.","Friedreich Ataxia | Friedreich ataxia | Friedreich's Ataxia",,,,,,,,,,,,,,,"441554","Friedreich ataxia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4229268","Frontotemporal Dementia","C84719","A syndrome caused by progressive degeneration of the frontal or temporal lobes of the brain. It is manifested with personality changes and deterioration of the language skills.","Frontotemporal Dementia | ",,,,,,,,,,,,,,,"4043378","Frontotemporal dementia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016781","Fuchs Endothelial Dystrophy","C84721","An autosomal dominant, bilateral, slowly progressive degeneration of corneal endothelial cells with thickening of Descemet's membrane and accumulation of excrescences. It results in corneal edema and loss of vision.","Fuchs Endothelial Dystrophy | Fuchs' Endothelial Dystrophy",,,,,,,,,,,,,,,"4109696","Fuchs' corneal dystrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016879","Fusobacterium Infection","C84722","Infection with anaerobic gram-negative bacteria of the genus Fusobacterium. It results in abscess formation and tissue damage.","Fusobacterium Infection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016952","Galactosemia","C84723","An autosomal recessive inherited metabolic disorder caused by mutations in the GALE, GALK1, and GALT genes. It is characterized by deficiency of the enzymes responsible for the metabolism of galactose. Signs and symptoms include intellectual disability, hepatomegaly, hepatic failure, and renal failure.","Galactosemia | ",,,,,,,,,,,,,,,"439788","Galactosemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016978","Gallbladder Neoplasm","C3048","A benign or malignant neoplasm affecting the gallbladder. Representative examples of benign neoplasms include lipoma, leiomyoma, and neurofibroma. Representative examples of malignant neoplasms include carcinoma, lymphoma, and sarcoma.","Gallbladder Neoplasm | Gallbladder Tumor | Neoplasm of Gallbladder | Neoplasm of the Gallbladder | Tumor of Gallbladder | Tumor of the Gallbladder",,,,,,,,,,,,,,,"4130520","Neoplasm of gallbladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0267211","Gastric Antral Vascular Ectasia","C84724","Dilatation of the vessels in the antrum of the stomach. It is associated with portal hypertension, scleroderma, and chronic renal failure. It may cause gastric bleeding.","Gastric Antral Vascular Ectasia | ",,,,,,,,,,,,,,,"4184809","Vascular ectasia of gastric antrum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265706","Gastroschisis","C84725","A congenital birth defect characterized by the exposure of the fetal intestines outside the abdominal wall through an abdominal wall opening.","Gastroschisis | Eventration | GASTROSCHISIS",,,,,,,,,,,,,,,"4218764","Gastroschisis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0544755","Genu Varum","C84726","A deformity of the legs characterized by medial angulation, resulting in a bow appearance.","Genu Varum | Bowed Legs",,,,,,,,,,,,,,,"4101367","Bandy legged",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017495","Gerstmann-Straussler-Scheinker Disease","C84727","A very rare and fatal disorder of spongiform encephalopathy usually caused by mutations of the prion protein (PRNP) gene. It is characterized by the accumulation of amyloid in the brain. Signs and symptoms include lack of motor coordination, unsteady gait, and difficulty walking. As the disease progresses, patients develop speech difficulties and dementia.","Gerstmann-Straussler-Scheinker Disease | ",,,,,,,,,,,,,,,"442759","Gerstmann-Straussler-Scheinker syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1850386","Giant Axonal Neuropathy","C84728","A rare inherited disorder affecting the neurofilaments. It is caused by mutations in the GAN gene. It is characterized by the presence of abnormally large nerve cell axons. Signs and symptoms include difficulty walking, sensory disturbances, lack of motor coordination and abnormal reflexes in the limbs.","Giant Axonal Neuropathy | ",,,,,,,,,,,,,,,"4134579","Giant axonal neuropathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017155","Giant Hypertrophic Gastritis","C67277","Gastritis characterized by hypertrophy of the gastric mucosa with creation of giant gastric folds. It is associated with hypoalbuminemia due to albumin loss from the stomach. Signs and symptoms include nausea, vomiting, abdominal pain, edema, and weight loss.","Giant Hypertrophic Gastritis | Hypertrophic Gastritis | Menetrier Disease | Menetrier disease | Menetrier's Disease | Ménétrier Disease | gastric mucosal hypertrophy | giant hypertrophic gastritis",,,,,,,,,,,,,,,"201059","Hypertrophic gastritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017551","Gilbert Syndrome","C84729","An autosomal recessive inherited disorder characterized by unconjugated hyperbilirubinemia, resulting in harmless intermittent jaundice.","Gilbert Syndrome | Gilbert Disease | Gilbert's Syndrome",,,,,,,,,,,,,,,"4099740","Gilbert's syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268450","Gitelman Syndrome","C84730","An inherited disorder caused by mutations in the SLC12A3 gene. It is characterized by deficient reabsorption of electrolytes in the distal convoluted tubules of the kidneys. It results in hypochloremic metabolic alkalosis, hypokalemia, hypocalciuria, and hypomagnesemia.","Gitelman Syndrome | ",,,,,,,,,,,,,,,"45769163","Gitelman syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017653","Glomus Tumor","C3060","A rare benign or malignant mesenchymal neoplasm arising from cells that resemble the modified smooth muscle cells of the glomus body. The majority of glomus tumors occur in the distal extremities.","Glomus Tumor | Glomus Neoplasm","8711/0","Glomus tumor, NOS",,,,,,,,,,,,,"4014760|4298135","Glomus tumor|Glomus tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0751748","Glycine Encephalopathy","C84937","An autosomal recessive metabolic disorder caused by mutations in the AMT and GLDC genes. It is characterized by abnormal accumulation of glycine in the brain and other tissues. Signs and symptoms include lethargy, feeding difficulties, hypotonia, intellectual deformities, and seizures.","Glycine Encephalopathy | Non-Ketotic Hyperglycinemia | Nonketotic Hyperglycinemia",,,,,,,,,,,,,,,"4035269","Non-ketotic hyperglycinemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017920","Glycogen Storage Disease Type I","C84733","An autosomal recessive inherited type of glycogen storage disease. It is characterized by a deficiency of the enzyme glucose-6-phosphatase, resulting in the inability of the liver to produce free glucose causing severe hypoglycemia. There is abnormal accumulation of glycogen in the liver and kidneys.","Glycogen Storage Disease Type I | ",,,,,,,,,,,,,,,"4053065|4219504","Deficiency of glucose-6-phosphatase|Glycogen storage disease, type I",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0017921","Glycogen Storage Disease Type II","C84734","An autosomal recessive inherited type of glycogen storage disease caused by deficiency of the enzyme acid alpha-glucosidase. It results in the abnormal accumulation of glycogen in the heart, skeletal muscles, liver, and nervous system.","Glycogen Storage Disease Type II | ",,,,,,,,,,,,,,,"4049724|4051044|4143341|4166143","Deficiency of glucan 1,4-alpha-glucosidase|Deficiency of alpha-glucosidase|Generalized glycogenosis|Glycogen storage disease due to acid maltase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--|--"
"C0878677","Glycogen Storage Disease Type IIb","C84735","A genetic metabolic disorder causing hypertrophic cardiomyopathy. Mutations of the LAMP2 gene have been reported in association with this disease.","Glycogen Storage Disease Type IIb | Danon Disease",,,,,,,,,,,,,,,"4167868","Danon disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017922","Glycogen Storage Disease Type III","C84736","An autosomal recessive inherited type of glycogen storage disease caused by deficiency of the glycogen debranching enzyme. It results in the accumulation of structurally abnormal glycogen in the heart, skeletal muscles, and/or liver.","Glycogen Storage Disease Type III | ",,,,,,,,,,,,,,,"4284550","Glycogen storage disease type III",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017923","Glycogen Storage Disease Type IV","C84737","A rare inherited type of glycogen storage disease caused by deficiency of amylo-1,4-1,6 transglucosidase.","Glycogen Storage Disease Type IV | ",,,,,,,,,,,,,,,"4009322","Glycogen storage disease, type IV",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017924","Glycogen Storage Disease Type V","C84738","An autosomal recessive inherited type of glycogen storage disease caused by deficiency of myophosphorylase. It results in myalgias, muscle cramping and stiffness, and exercise intolerance.","Glycogen Storage Disease Type V | ",,,,,,,,,,,,,,,"4185544","Glycogen storage disease, type V",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085131","GM1 Gangliosidosis","C84739","An autosomal recessive lysosomal storage disease characterized by deficiency of the enzyme acid beta-galactosidase, resulting in the accumulation of acid lipids in the nervous system. Signs and symptoms include neurologic disturbances, muscle atrophy, dystonia, eye abnormalities, and formation of angiokeratomas.","GM1 Gangliosidosis | ",,,,,,,,,,,,,,,"4079873","GM1 gangliosidosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265240","Goldenhar Syndrome","C84740","A congenital birth defect characterized by incomplete development or absence of face structures, usually affecting one side of the face. The defects include partially formed or absent ear, nose, lip, mandible, and/or soft palate.","Goldenhar Syndrome | ",,,,,,,,,,,,,,,"4003957","Goldenhar syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL480921","Goodpasture Syndrome","C34649","An autoimmune disorder characterized by pulmonary hemorrhage and glomerulonephritis. It is a hypersensitivity reaction resulting in the formation of antibodies against the pulmonary alveoli and the basement membrane of the glomeruli.","Goodpasture Syndrome | Goodpasture's Syndrome | Lung Purpura with Glomerulonephritis",,,,,,,,,,,,,,,"195289","Goodpasture's syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085074","Granuloma Annulare","C3470","A localized or generalized inflammatory skin disorder characterized by the formation of papules and ring-shaped plaques in the skin. Morphologically these lesions are granulomatous inflammatory processes with central necrosis surrounded by palisading histiocytes.","Granuloma Annulare | ",,,,,,,,,,,,,,,"4277253","Granuloma annulare",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018213","Graves Disease","C3071","Hyperthyroidism associated with diffuse hyperplasia of the thyroid gland (goiter), resulting from production of antibodies that are directed against the thyrotropin receptor complex of the follicular epithelial cells. As a result, the thyroid gland enlarges and secretes increased amounts of thyroid hormones.","Graves Disease | Basedow Disease | Graves' Disease | Graves' Disease",,,,,,,,,,,,,,,"4232076","Graves' disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0272302","Gray Platelet Syndrome","C84741","A rare inherited bleeding disorder characterized by the decrease or absence of the platelet alpha-granules and their proteins in the peripheral blood platelets.","Gray Platelet Syndrome | Grey Platelet Syndrome",,,,,,,,,,,,,,,"4197685","Gray platelet syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040761","Transposition of Great Vessels","C84742","A congenital cardiac defect in which two heart vessels are reversed (transposed).","Transposition of Great Vessels | Great Vessels Transposition | Great Vessels Transposition",,,,,,,,,,,,,,,"432431","Discordant ventriculoarterial connection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018414","Gynatresia","C84743","A congenital or acquired occlusion of an opening in any part of the female genital tract.","Gynatresia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018425","Gyrate Atrophy","C84744","A rare autosomal recessive inherited disorder caused by mutations in the OAT gene. It is characterized by progressive atrophy of the retina and choroid, leading to loss of vision and blindness.","Gyrate Atrophy | ",,,,,,,,,,,,,,,"4199780","Gyrate atrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040414","Hairy Tongue","C35075","A benign condition affecting the dorsum of the tongue. It is characterized by defective desquamation resulting in elongation of the filiform papillae. The dorsum of the tongue has a furry appearance and is usually stained black.","Hairy Tongue | ",,,,,,,,,,,,,,,"4217621","Black hairy tongue",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0917715","Hajdu-Cheney Syndrome","C84745","A very rare inherited connective tissue disorder characterized by osteoporosis, skull deformities, short stature, and bone flexibility.","Hajdu-Cheney Syndrome | ",,,,,,,,,,,,,,,"4270610","Hajdu-Cheney syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018522","Hallermann Syndrome","C84746","A very rare syndrome characterized by multiple congenital abnormalities including abnormally shaped head, mandibular hypoplasia, parrot nose, bilateral congenital cataracts, microphthalmia, dwarfism and hypotrichosis.","Hallermann Syndrome | Hallermann's Syndrome | Hallermann-Streiff Syndrome",,,,,,,,,,,,,,,"4194517","Hallermann-Streiff syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0243025","Hantavirus Pulmonary Syndrome","C84747","An infection caused by Hantaviruses. It manifests with flu-like symptoms but it rapidly progresses to life-threatening respiratory problems.","Hantavirus Pulmonary Syndrome | ",,,,,,,,,,,,,,,"4026113","Hantavirus pulmonary syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018609","Hartnup Disease","C84748","An autosomal recessive inherited metabolic disorder caused by mutations in the SLC6A19 gene. It is characterized by defective absorption of neutral amino acids. Signs and symptoms include skin eruptions reminiscent of pellagra, aminoaciduria, and cerebellar ataxia.","Hartnup Disease | ",,,,,,,,,,,,,,,"4216498","Neutral 1 amino acid transport defect",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0677607","Hashimoto Thyroiditis","C27191","An autoimmune disorder caused by the production of autoantibodies against thyroid tissue. There is progressive destruction of the thyroid follicles leading to hypothyroidism.","Hashimoto Thyroiditis | Autoimmune Thyroiditis | Autoimmune thyroiditis | Chronic Lymphocytic Thyroiditis | Hashimoto Disease | Hashimoto disease | Hashimoto thyroiditis | Hashimoto's Disease | Hashimoto's Thyroiditis | Lymphocytic Thyroiditis | autoimmune thyroiditis",,,,,,,,,,,,,,,"135215","Hashimoto thyroiditis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162739","HELLP Syndrome","C84750","Severe preeclampsia associated with any of the following findings: thrombocytopenia (platelets less than 100,000 per microliter), impaired liver function (twice normal elevation of hepatic transaminases; severe, persistent right upper quadrant or epigastric pain), progressive renal insufficiency (serum creatinine greater than 1.1 mg/dL or doubling of baseline in the absence of other renal disease), pulmonary edema, or new-onset cerebral or visual disturbances.","HELLP Syndrome | Hemolysis-Elevated Liver Enzymes-Low Platelet Count Syndrome",,,,,,,,,,,,,,,"4316372","HELLP syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018889","Helminthiasis","C84751","A parasitic infection characterized by the infestation with worms, mainly in the intestine.","Helminthiasis | ",,,,,,,,,,,,,,,"441793","Helminth infection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018922","Hemangiopericytoma","C3087","An antiquated term that refers to benign or malignant mesenchymal neoplasms characterized by the presence of neoplastic spindle-shaped to round cells arranged around thin-walled branching vascular spaces.","Hemangiopericytoma | Hemangiopericytoma, NOS | hemangiopericytoma",,,,,,,,,,,,,,,"4046649","Hemangiopericytoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3554542","Hemophagocytic Lymphohistiocytosis","C34792","A rare, but potentially life-threatening disorder, characterized by the proliferation of histiocytes and macrophages, and phagocytosis of red blood cells, white blood cells, and platelets. It may be inherited or secondary due to infections, autoimmune disorders, or underlying malignancies. Signs and symptoms include fever, lymphadenopathy, hepatomegaly, splenomegaly, and pancytopenia.","Hemophagocytic Lymphohistiocytosis | HLH | Hemophagocytic Disorder | hemophagocytic lymphohistiocytosis",,,,,,,,,,,,,,,"4121123","Hemophagocytic lymphohistiocytosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019069","Hemophilia A","C27146","An inherited deficiency of coagulation factor VIII characterized by the tendency to spontaneous or exaggerated post-traumatic hemorrhage. Inherited as an X-linked recessive disease, hemophilia A is the most common hemophilia, occurring in approximately 1 in 10,000 male births.","Hemophilia A | Factor VIII Deficiency | Hereditary Factor VIII Deficiency | Hereditary Factor VIII Deficiency Disease | Hereditary factor VIII deficiency",,,,,,,,,,,,,,,"434007","Hereditary factor VIII deficiency disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008533","Hemophilia B","C26721","An X-linked inherited bleeding disorder caused by deficiency of the coagulation factor IX.","Hemophilia B | Christmas Disease | Factor IX Deficiency | Hereditary Factor IX Deficiency | Hereditary Factor IX Deficiency Disease | Hereditary factor IX deficiency",,,,,,,,,,,,,,,"436678","Hereditary factor IX deficiency disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019101","Hemorrhagic Fever with Renal Syndrome","C84753","A disorder caused by hantaviruses of the family Bunyaviridae. It is transmitted by rodents and is manifested with fever, hemorrhage, and renal failure. Other symptoms include headaches, abdominal and back pain, and blurred vision.","Hemorrhagic Fever with Renal Syndrome | ",,,,,,,,,,,,,,,"37399017","Hemorrhagic fever with renal syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034152","Henoch-Schönlein Purpura","C34963","A systemic, usually self-limited immune complex vasculitis, characterized by immunoglobulin A deposition in the small vessels and kidneys. It is manifested with small hemorrhages in the skin, gastrointestinal symptoms, arthritis, and nephropathy.","Henoch-Schönlein Purpura | HSP | Henoch-Schonlein Purpura | Schoenlein-Henoch Purpura",,,,,,,,,,,,,,,"4101602","Immunoglobulin A vasculitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162569","Hepatoerythropoietic Porphyria","C84754","A very rare form of porphyria cutanea tarda. It is characterized by deficiency of the enzyme uroporphyrinogen decarboxylase. Signs and symptoms appear early in childhood and include extreme photosensitivity in the sun exposed areas of the skin with blistering and scar formation.","Hepatoerythropoietic Porphyria | ",,,,,,,,,,,,,,,"4006312","Homozygous porphyria cutanea tarda",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019202","Hepatolenticular Degeneration","C84756","A rare autosomal recessive inherited disorder caused by mutations in the ATP7B gene. It is characterized by copper accumulation in the tissues, particularly brain and liver. It results in liver failure, neurologic, and psychotic manifestations.","Hepatolenticular Degeneration | Wilson Disease | Wilson's Disease",,,,,,,,,,,,,,,"4229262","Wilson's disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019243","Hereditary Angioedema","C84758","Autosomal dominant inherited disorder characterized by abnormalities of C1 inhibitor. Patients present with swelling of the skin, subcutaneous tissues, and mucosa sites.","Hereditary Angioedema | ",,,,,,,,,,,,,,,"4307793","Hereditary angioedema",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2717905","Hereditary Angioedema Types I and II","C84757","Autosomal dominant inherited disorders characterized by abnormalities of C1 inhibitor. Patients present with swelling of the skin, subcutaneous tissues, and mucosa sites. In type I hereditary angioedema, the plasma levels of C1 inhibitor are decreased. In type II hereditary angioedema, the C1 inhibitor is dysfunctional and its plasma levels may be normal or elevated.","Hereditary Angioedema Types I and II | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162531","Hereditary Coproporphyria","C84759","An autosomal dominant inherited disorder of porphyrin metabolism caused by deficiency of the enzyme coproporphyrinogen oxidase. It results in neurologic damage and can include abdominal pain, constipation and psychiatric manifestations.","Hereditary Coproporphyria | ",,,,,,,,,,,,,,,"4251631","Hereditary coproporphyria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016751","Hereditary Fructose Intolerance","C84720","A genetic disorder characterized by the absence of the enzyme aldolase-B from the liver. This enzyme is essential for the metabolism of fructose. Signs and symptoms from fructose ingestion are evident in infancy and include vomiting, abdominal pain and hypoglycemia. Long term complications include hepatic and renal failure.","Hereditary Fructose Intolerance | Fructose Intolerance | Fructose-1,6-Bisphosphate Aldolase B Deficiency",,,,,,,,,,,,,,,"432873","Hereditary fructosuria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002881","Hereditary Hemolytic Anemia","C34379","A congenital hemolytic anemia caused by defects of the erythrocyte membrane, enzyme deficiencies, or hemoglobinopathies.","Hereditary Hemolytic Anemia | Congenital Hemolytic Anemia",,,,,,,,,,,,,,,"28396","Hereditary hemolytic anemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039445","Hereditary Hemorrhagic Telangiectasia","C35064","An autosomal dominant hereditary disorder caused by mutations in the ACVRL1, ENG, and SMAD4 genes. It is characterized by the presence of telangiectasias in the skin, mucous membranes, lungs, brain, liver, and gastrointestinal tract. It results in hemorrhages from the affected areas.","Hereditary Hemorrhagic Telangiectasia | Hereditary hemorrhagic telangiectasia | Osler-Weber-Rendu Disease | Telangiectasia, Hereditary Hemorrahagic, of Rendu, Osler",,,,,,,,,,,,,,,"313504","Osler hemorrhagic telangiectasia syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512419","Hereditary Melanoma","C8498","A melanoma defined by the presence of multiple cases of cutaneous melanoma among blood-relatives on the same side of the family.  It is caused by germline mutations in the CDKN2A or CDK4 genes.  It is associated with an increased risk of pancreatic cancer in a subset of CDKN2A families (WHO, 2006).","Hereditary Melanoma | Familial Cutaneous Melanoma | Familial Melanoma | Hereditary Cutaneous (Skin) Melanoma | Hereditary Cutaneous Melanoma | Melanoma, Familial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1721005","Hereditary Leukokeratosis","C84760","An autosomal dominant inherited disorder characterized by thickened and spongy oral mucosa with a white tint. It may affect other anatomic sites as well.","Hereditary Leukokeratosis | Cannon Disease | Hereditary Mucosal Leukokeratosis | Hereditary Mucosal Leukokeratosis | White Sponge Nevus | White Sponge Nevus of Cannon",,,,,,,,,,,,,,,"4308059","White sponge nevus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020435","Hereditary Hyperbilirubinemia","C84761","An inherited disorder affecting the metabolism of bilirubin. It results in increased levels of bilirubin in the blood. Representative examples of this condition include Gilbert syndrome and Crigler-Najjar syndrome.","Hereditary Hyperbilirubinemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079504","Hermansky-Pudlak Syndrome","C37261","A group of autosomal recessive inherited disorders characterized by albinism, bleeding tendency, and lung disorders such as pulmonary fibrosis.","Hermansky-Pudlak Syndrome | ",,,,,,,,,,,,,,,"4245912","Hermansky-Pudlak syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0276226","Herpes Simplex Encephalitis","C84762","A serious viral disorder characterized by infection of the brain by herpes simplex virus type 1 or 2. Herpes simplex virus type 1 affects adults, whereas herpes simplex virus type 2 affects newborns. Signs and symptoms include fever, headaches, vomiting, seizures and psychiatric manifestations.","Herpes Simplex Encephalitis | ",,,,,,,,,,,,,,,"376026","Encephalitis due to Herpesviridae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017409","Herpes Zoster Oticus","C84763","A viral ear infection caused by the spread of varicella-zoster virus to the facial nerves. It is characterized by intense otalgia and a cutaneous vesicular eruption.","Herpes Zoster Oticus | ",,,,,,,,,,,,,,,"138682","Herpes zoster auricularis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827503","HFE-Associated Hereditary Hemochromatosis","C84764","A hereditary disorder of iron metabolism caused by mutations in the HFE gene. It is characterized by increased absorption of iron in the gastrointestinal mucosa. It results in abnormal iron accumulation in the liver, pancreas, skin, joints, heart, and testes. It may lead to skin pigmentation, liver failure, heart failure, and hypogonadism.","HFE-Associated Hereditary Hemochromatosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206671","Hidradenoma","C7563","A benign epithelial neoplasm arising from the sweat glands. Variants include the clear cell, nodular, and solid cystic hidradenoma.","Hidradenoma | Acrospiroma | Eccrine Acrospiroma | Eccrine acrospiroma | Hidradenoma, NOS",,,,,,,,,,,,,,,"4102382|4217948","Hidradenoma|Sweat gland adenoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0206702","Hilar Cholangiocarcinoma","C36077","A carcinoma that arises from the junction, or adjacent to the junction, of the right and left hepatic ducts.","Hilar Cholangiocarcinoma | Hilar CC | Hilar CCA | Klatskin Tumor | Klatskin tumor | Perihilar CC | Perihilar CCA | Perihilar Cholangiocarcinoma | hCC | hCCA | pCC | pCCA",,,,,,,,,,,,,,,"4098954","Klatskin's tumor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0398367","Kikuchi-Fujimoto Disease","C71719","A benign and self-limited localized disorder characterized by histiocytic proliferation and necrotic changes in the lymph nodes. It is rarely associated with lupus erythematosus. Signs and symptoms include localized lymphadenitis, fever, and leucopenia.","Kikuchi-Fujimoto Disease | Histiocytic Necrotizing Lymphadenitis | Histiocytic Necrotizing Lymphadenitis | Kikuchi Lymphadenitis | Kikuchi-Fujimoto Disease",,,,,,,,,,,,,,,"4130834","Histiocytic necrotizing lymphadenitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268601","HMG-CoA Lyase Deficiency","C84523","A rare genetic inherited disorder characterized by inability of the body to process the amino acid leucine. Signs and symptoms include vomiting, dehydration, lethargy, convulsions, and coma.","HMG-CoA Lyase Deficiency | 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency | 3-OH 3-Methyl Glutaric Aciduria | Deficiency of Hydroxymethylglutaryl-CoA Lyase | Hydroxymethylglutaric Aciduria | Hydroxymethylglutaryl-CoA Lyase Deficiency",,,,,,,,,,,,,,,"4052123","Deficiency of hydroxymethylglutaryl-CoA lyase",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001519","Holmes-Adie Syndrome","C34357","A rare syndrome characterized by an abnormally dilated pupil, hypoflexia, and diaphoresis. The syndrome is usually caused by a viral or bacterial infection. The abnormally dilated pupil is caused by damage to postganglionic parasympathetic fibers innervating the eye.","Holmes-Adie Syndrome | Adie Pupil | Adie Syndrome | Tonic Pupil",,,,,,,,,,,,,,,"435279","Tonic pupillary reaction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4011586","Holoprosencephaly","C74988","A rare disorder characterized by the failure of the forebrain to divide into distinct hemispheres. It is associated with craniofacial abnormalities, developmental abnormalities, and seizures.","Holoprosencephaly | Holoprosencephaly Sequence",,,,,,,,,,,,,,,"4149584","Holoprosencephaly sequence",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3806789","Homocystinuria","C84765","An autosomal recessive inherited metabolic disorder caused by mutations in the CBS, MTHFR, MTR, and MTRR genes. It is characterized by abnormalities in the methionine metabolism and is associated with deficiency of cystathionine synthase. It results in the accumulation of homocysteine in the serum. It may affect the cardiovascular, musculoskeletal and the central nervous systems.","Homocystinuria | ",,,,,,,,,,,,,,,"4012934","Homocystinuria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020179","Huntington's Disease","C82342","A progressive hereditary neurodegenerative disorder inherited in an autosomal dominant fashion. Symptoms may appear at any age and include uncontrolled movements, clumsiness, balance problems, difficulty walking, talking, or swallowing. The disease has a progressive course with a decline in mental abilities, and the development of psychiatric problems.","Huntington's Disease | HD | Huntington Disease | Huntington's Chorea | Huntington's disease",,,,,,,,,,,,,,,"374341","Huntington's chorea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020192","Hyaline Membrane Syndrome","C27562","A serious disorder affecting newborns, particularly premature infants. It is caused by deficiency of surfactant, resulting in the formation of a membrane in the alveoli lining. This membrane contains fibrin and cellular debris and interferes with respiration. Infants with this disorder develop breathing problems immediately or in a few hours after delivery. It may lead to respiratory failure.","Hyaline Membrane Syndrome | ",,,,,,,,,,,,,,,"258866","Respiratory distress syndrome in the newborn",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020217","Hydatidiform Mole","C3110","A gestational trophoblastic disorder characterized by marked enlargement of the chorionic villi, hyperplasia of the villous trophoblastic cells and hydropic changes.","Hydatidiform Mole | Hydatid Mole | Hydatid mole | Molar Pregnancy | hydatidiform mole | molar pregnancy","9100/0","Hydatidiform mole, NOS",,,,,,,,,,,,,"439083","Hydatidiform mole, benign",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0020241","Hydroa Vacciniforme","C84766","A rare skin disorder of unknown etiology affecting children. It is a photodermatitis, characterized by the formation of vesicles and scarring on sun exposed areas.","Hydroa Vacciniforme | ",,,,,,,,,,,,,,,"4308081","Hydroa vacciniforme",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4228386","Hydrops Fetalis","C84767","A condition characterized by fluid accumulation in two or more anatomic compartments in the fetus.","Hydrops Fetalis | ",,,,,,,,,,,,,,,"4173169","Hydrops fetalis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020413","Hymenolepiasis","C84768","A parasitic infection caused by tapeworms. Most infected individuals do not have symptoms. When symptoms appear, they include diarrhea, abdominal pain, restlessness, and irritability.","Hymenolepiasis | ",,,,,,,,,,,,,,,"193707","Hymenolepiasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0598608","Hyperhomocysteinemia","C84770","A serious metabolic condition caused by mutations in the MTHFR gene, medications, or nutritional deficiency. It results in increased levels of homocysteine in the blood. Patients with this condition are at an increased risk for recurrent blood clots formation and cardiovascular accidents.","Hyperhomocysteinemia | ",,,,,,,,,,,,,,,"4304907","Hyperhomocysteinemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023817","Hyperlipoproteinemia, Type I","C84771","A genetic disorder of lipoprotein metabolism caused by mutations in the LPL and apolipoprotein (apo) C-II genes. It is characterized by increased levels of chylomicrons and triglycerides in the blood.","Hyperlipoproteinemia, Type I | Familial Essential Hyperlipemia | Familial Hyperchylomicronemia | Hyperlipoproteinemia Type 1A | Hyperlipoproteinemia Type I | Lipoprotein Lipase Deficiency",,,,,,,,,,,,,,,"4077382","Hyperlipoproteinemia, type I",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020494","Hyperostosis Frontalis Interna","C84772","A condition of unknown etiology characterized by thickening of the inner table of the frontal bone of the skull. It is seen more often in females and is usually bilateral.","Hyperostosis Frontalis Interna | ",,,,,,,,,,,,,,,"36684082|4219370","Stewart-Morel-Morgagni syndrome|Hyperostosis interna frontalis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3278959","Hypertrophic Cardiomyopathy","C34449","A condition in which the myocardium is hypertrophied without an obvious cause. The hypertrophy is generally asymmetric and may be associated with obstruction of the ventricular outflow tract.","Hypertrophic Cardiomyopathy | ",,,,,,,,,,,,,,,"4124693","Hypertrophic cardiomyopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0473527","Hypoalphalipoproteinemia","C84774","A metabolic disorder characterized by deficiency of high density (alpha) lipoprotein in the blood.","Hypoalphalipoproteinemia | ",,,,,,,,,,,,,,,"4098594","Hypoalphalipoproteinemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002884","Hypochromic Anemia","C34380","Anemia caused by the reduction of hemoglobin in relation to the red cell volume. As a result, the red cells have an area of central pallor which is increased in size. The leading cause is iron deficiency.","Hypochromic Anemia | ",,,,,,,,,,,,,,,"4195171","Normocytic hypochromic anemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0238358","Hypokalemic Periodic Paralysis","C84775","A rare, autosomal dominant inherited disorder characterized by irregular episodes of muscle weakness or paralysis which are always accompanied by low levels of potassium in the blood.","Hypokalemic Periodic Paralysis | ",,,,,,,,,,,,,,,"4221408","Familial hypokalemic periodic paralysis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020630","Hypophosphatasia","C26798","A rare, serious metabolic disorder caused by mutations in the gene encoding tissue non-specific alkaline phosphatase (TNSALP) activity. It is characterized by low activity of TNSALP in the serum. The signs and symptoms vary significantly and include death in utero, failure to thrive, premature loss of deciduous teeth, early loss of the adult dentition, hypercalcemia, osteomalacia, skeletal defects, renal stones, and movement disorders.","Hypophosphatasia | ",,,,,,,,,,,,,,,"4096352","Hypophosphatasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4012361","Ichthyosis","C84776","A group of inherited or acquired skin disorders characterized by a dry, thickened, and scaly skin. The skin changes range from mild to severe.","Ichthyosis | ",,,,,,,,,,,,,,,"37204332","Ichthyosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0432306","Ichthyosis Bullosa of Siemens","C84777","A rare autosomal dominant inherited form of ichthyosis. It is characterized by the presence of an erythematous skin with blisters at birth. The skin subsequently becomes dry, flaky and hyperkeratotic.","Ichthyosis Bullosa of Siemens | ",,,,,,,,,,,,,,,"4111337","Ichthyosis bullosa of Siemens",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0079584","Ichthyosis Vulgaris","C84778","The most common form of ichthyosis. It is an autosomal dominant inherited or acquired disorder characterized by scaling and desquamation of the skin.","Ichthyosis Vulgaris | ",,,,,,,,,,,,,,,"4109197","Ichthyosis vulgaris",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4016870","Idiopathic CD4-Positive T-Lymphocytopenia","C84780","A rare immunodeficiency syndrome characterized by the decrease of the CD4-positive lymphocytes below 300 per cubic millimeter in the absence of identifiable immunodeficiency causes. Patients with this syndrome are at an increased risk of opportunistic infections.","Idiopathic CD4-Positive T-Lymphocytopenia | ",,,,,,,,,,,,,,,"35622306","Idiopathic CD4 lymphocytopenia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0751757","Idiopathic Hypersomnolence","C84781","A rare sleep disorder characterized by prolonged sleep at night and extreme sleepiness during the day. There are no apparent causes. This disorder affects the ability to function.","Idiopathic Hypersomnolence | ",,,,,,,,,,,,,,,"43531627","Idiopathic hypersomnia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017661","Immunoglobulin A Nephropathy","C34643","A chronic autoimmune glomerulonephritis characterized by the deposition of immunoglobulin A in the mesangium of the glomeruli. It is manifested with hematuria and mild proteinuria.","IgA Nephropathy | Berger's Disease | IGA Glomerulonephritis",,,,,,,,,,,,,,,"4128061","IgA nephropathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020877","Ileitis","C84782","Inflammation of the ileum.","Ileitis | ",,,,,,,,,,,,,,,"4203614","Ileitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL449043","Immunodeficiency with Hyper-IgM","C84783","A genetically heterogenous group of conditions characterized by decreased levels of IgG, IgA, and IgE, and normal or increased levels of IgM. Patients are at an increased risk of infections and development of malignancies.","Immunodeficiency with Hyper-IgM | Immunodeficiency With Hyper-IgM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003466","Imperforate Anus","C84784","A congenital birth defect characterized by the absence of a normal anal opening. It may be associated with other congenital abnormalities.","Imperforate Anus | Anal Atresia",,,,,,,,,,,,,,,"4004155","Anal atresia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0154246","Urea Cycle Metabolism Disorder","C84785","A genetic inborn error of metabolism characterized by the deficiency of one of the enzymes necessary for the urea cycle. It results in accumulation of ammonia in the body.","Urea Cycle Metabolism Disorder | Disorder of Urea Cycle Metabolism | Inborn Urea Cycle Disorder | Inborn Urea Cycle Disorder",,,,,,,,,,,,,,,"434311","Disorder of the urea cycle metabolism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0238190","Inclusion Body Myositis","C84786","An acquired or hereditary chronic inflammatory disorder of the muscles characterized by the morphologic finding of vacuoles and filamentous inclusions in the muscle tissues.","Inclusion Body Myositis | ",,,,,,,,,,,,,,,"4216406","Inclusion body myositis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4225596","Incontinentia Pigmenti","C84787","A rare disorder caused by mutations in the IKBKG gene. It is characterized by skin abnormalities, alopecia, dystrophic nails, and abnormal tooth shape. The skin changes evolve from an initial blistering rash, to wart-like lesions, and eventually to hypopigmentation.","Incontinentia Pigmenti | Incontinentia Pigmenti Syndrome",,,,,,,,,,,,,,,"4279548","Incontinentia pigmenti syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0270724","Infantile Neuroaxonal Dystrophy","C84927","A rare autosomal recessive neurodegenerative disorder caused by mutations in the PLA2G6 gene. It is characterized by the development of swellings called spehroids along the axons of the central nervous system. Signs and symptoms appear early in life and include movement difficulties, muscle hypotonia and spasticity, and dementia.","Infantile Neuroaxonal Dystrophy | ",,,,,,,,,,,,,,,"4199308","Infantile neuroaxonal dystrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0282527","Infantile Refsum Disease","C84789","A genetic disorder characterized by abnormalities in the breakdown of phytanic acid. It results in accumulation of phytanic acid in the blood, brain and other tissues. Signs and symptoms include retinitis pigmentosa which may lead to blindness, hearing problems and deafness, hypotonia, ataxia, nystagmus, facial deformities, and mental and growth retardation.","Infantile Refsum Disease | ",,,,,,,,,,,,,,,"435813","Infantile Refsum's disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3277735","Intestinal Atresia","C84790","A congenital malformation characterized by the absence of a normal opening in a part of the intestine. It can occur either in the small or the large intestine.","Intestinal Atresia | Atresia of the Intestine | Congenital Intestinal Atresia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3553260","Intracranial Hypertension","C84791","A finding characterized by increased cerebrospinal fluid pressure within the skull.","Intracranial Hypertension | ",,,,,,,,,,,,,,,"4154803","Raised intracranial pressure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022134","Islet Cell Adenoma","C65184","A benign endocrine neoplasm arising from the pancreas. It is separated from the normal pancreatic tissues by a thin collagenous capsule. It may secrete a hormone (e.g. insulin, gastrin) or it may be non-functional.","Islet Cell Adenoma | ",,,,,,,,,,,,,,,"4295115","Pancreatic endocrine tumor, benign",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0795841","Jacobsen Syndrome","C75457","A very rare genetic syndrome caused by deletion of the terminal band of chromosome 11. It is characterized by the presence of growth and psychomotor retardation, broad nasal bridge, low set ears, strabismus, trigonocephaly, and thrombocytopenia.","Jacobsen Syndrome | 11q Terminal Deletion Disorder",,,,,,,,,,,,,,,"37395854","Jacobsen syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014057","Japanese B Encephalitis","C34577","Viral encephalitis caused by the mosquito-born Japanese encephalitis virus. Signs and symptoms include an initial period of fever, headaches, and malaise, followed by neck rigidity, hemiparesis, and convulsions. It may lead to coma.","Japanese B Encephalitis | Japanese Encephalitis",,,,,,,,,,,,,,,"381789","Japanese encephalitis virus disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022387","Jervell and Lange Nielsen Syndrome","C84793","An autosomal recessive inherited syndrome caused by mutations in the KCNE1 and KCNQ1 genes. It is characterized by congenital hearing loss and arrhythmia. It is a form of long QT syndrome.","Jervell and Lange Nielsen Syndrome | JLNS1",,,,,,,,,,,,,,,"4161597","Jervell and Lange-Nielsen syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265275","Jeune Syndrome","C84794","A rare autosomal recessive inherited syndrome characterized by a narrow thorax, micromelia, and respiratory disturbances which may lead to asphyxiation. It may be associated with bilateral microcystic renal disease which may lead to renal failure.","Jeune Syndrome | Asphyxiating Thoracic Dystrophy",,,,,,,,,,,,,,,"4327478","Jeune thoracic dystrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0431399","Joubert Syndrome","C74996","A rare genetic syndrome characterized by the hypoplasia or absence of the cerebellar vermis. Signs and symptoms include rapid breathing (hyperpnea), sleep apnea, abnormal eye movements, mental retardation, and ataxia.","Joubert Syndrome | ",,,,,,,,,,,,,,,"37396990","Joubert syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0270853","Juvenile Myoclonic Epilepsy","C84796","An epilepsy characterized by myoclonic jerks, generalized tonic-clonic seizures, and sometimes absence seizures. It appears during adolescence.","Juvenile Myoclonic Epilepsy | ",,,,,,,,,,,,,,,"4267274","Juvenile myoclonic epilepsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036310","Juvenile Osteochondrosis of Spine","C34999","A disorder characterized by osteochondrosis of the vertebral epiphyses in childhood.","Juvenile Osteochondrosis of Spine | Calve's Disease | Scheuermann's Disease",,,,,,,,,,,,,,,"433565","Juvenile osteochondrosis of spine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023290","Kala-Azar","C34771","A chronic parasitic infection affecting the viscera and caused by Leishmania donovani. Signs and symptoms include fever, anorexia, fatigue, lymphadenopathy, anemia, and hepatosplenomegaly. If left untreated it may lead to death.","Kala-Azar | Visceral Leishmaniasis",,,,,,,,,,,,,,,"200652","Visceral leishmaniasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162809","Hypogonadotropic Hypogonadism with Anosmia","C75479","An X-linked or autosomal dominant genetic syndrome characterized by hypogonadotropic hypogonadism and anosmia.","Hypogonadotropic Hypogonadism with Anosmia | Kallmann Syndrome | Kallmann Syndrome",,,,,,,,,,,,,,,"4244350","Hypogonadism with anosmia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022521","Kartagener Syndrome","C84797","A rare autosomal recessive inherited syndrome characterized by situs inversus, bronchiectasis, and chronic sinusitis. There is a defect in the function of the cilia that line the respiratory tract.","Kartagener Syndrome | ",,,,,,,,,,,,,,,"4173466","Kartagener syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022541","Kearns-Sayre Syndrome","C84798","A rare mitochondrial myopathy characterized by a progressive limitation of eye movements, leading to immobility and eye drop. It may be associated with muscle weakness, heart block, hearing loss, ataxia and short stature.","Kearns-Sayre Syndrome | ",,,,,,,,,,,,,,,"4093427","Kearns-Sayre syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022572","Keratoacanthoma","C3146","A dome-shaped, rapidly growing skin lesion composed of well differentiated squamous cells. It usually occurs on sun-exposed areas of the body, most often the head, neck, and limbs. It is considered a variant of well-differentiated squamous cell carcinoma with distinct clinical behavior. Keratoacanthomas affect males more frequently than females and the majority tend to regress spontaneously.","Keratoacanthoma | Cutaneous Keratoacanthoma | Skin Keratoacanthoma | keratoacanthoma",,,,,,,,,,,,,,,"4112746","Keratoacanthoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3551636","Keratoconus","C26806","A degenerative, structural disorder of the eye, characterized by a cone-shaped protrusion of the cornea. It may lead to visual disturbances.","Keratoconus | ",,,,,,,,,,,,,,,"374362","Keratoconus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022610","Kernicterus","C84799","A rare neurologic disorder occurring in infants with jaundice. It results from brain damage by existing high levels of unconjugated-indirect bilirubin.","Kernicterus | Bilirubin Encephalopathy",,,,,,,,,,,,,,,"4326231","Kernicterus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206085","Kleine-Levin Syndrome","C84800","A rare disorder characterized by episodes of excessive sleep and behavioral alterations while awake. It affects predominantly males. The individuals exhibit normal behavior between episodes.","Kleine-Levin Syndrome | ",,,,,,,,,,,,,,,"4008567","Kleine-Levin syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022739","Klippel-Trenaunay-Weber Syndrome","C84801","A rare syndrome characterized by the presence of port-wine stain (a vascular malformation), varicose veins, and hypertrophy of the soft tissues and bones in an extremity. It usually affects one extremity, most commonly a leg.","Klippel-Trenaunay-Weber Syndrome | ",,,,,,,,,,,,,,,"36715431","Klippel Trenaunay syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0270707","Kluver-Bucy Syndrome","C84802","A rare syndrome resulting from damage to both temporal lobes of the brain. Signs and symptoms include oral exploratory behavior, docility, altered sexuality, dietary changes, and visual agnosia.","Kluver-Bucy Syndrome | ",,,,,,,,,,,,,,,"4024419","Temporal lobectomy behavior syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1622892","Korsakoff Syndrome","C84803","A psychotic syndrome caused by damage to the brain by lack of thiamine (vitamin B1). Signs and symptoms include anterograde and retrograde amnesia, confabulation, apathy, ataxia, and coma.","Korsakoff Syndrome | ",,,,,,,,,,,,,,,"4288013","Korsakoff's psychosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022790","Krukenberg Tumor","C3153","Metastatic signet-ring cell carcinoma in the ovary. The primary site is the gastrointestinal tract or breast.","Krukenberg Tumor | Krukenberg Neoplasm | Krukenberg tumor",,,,,,,,,,,,,,,"4181016","Metastatic signet ring cell carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0751783","Lafora Disease","C84804","A rare, fatal autosomal recessive inherited disorder caused by mutations in the genes EPM2A and EPM2b. It is characterized by the presence of cytoplasmic inclusion bodies called Lafora bodies in many cells of the body including neurons, muscle cells, and liver cells. The Lafora bodies contain mucopolysaccharides. Signs and symptoms include seizures, myoclonus, ataxia, and dementia.","Lafora Disease | ",,,,,,,,,,,,,,,"4046214","Lafora disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022972","Lambert Eaton Myasthenic Syndrome","C3155","A rare autoimmune presynaptic disorder characterized by impairment of the impulse transmission at the neuromuscular junction. It affects predominantly the proximal muscles of the lower extremities, resulting in muscle weakness and fatigability. It has been associated with small cell lung carcinoma.","Lambert Eaton Myasthenic Syndrome | ",,,,,,,,,,,,,,,"4237155","Eaton-Lambert syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0079154","Lamellar Ichthyosis","C84805","A very rare, autosomal recessive inherited skin disorder present at birth. It is characterized by the presence of a transparent membrane encasing the newborn. This membrane sheds in about two weeks after birth to reveal generalized scaling and skin erythema.","Lamellar Ichthyosis | ",,,,,,,,,,,,,,,"4003980","Lamellar ichthyosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0282512","Landau-Kleffner Syndrome","C84806","A rare childhood syndrome characterized by the progressive or sudden inability to understand and use spoken language (aphasia) and paroxysmal electrical brain waves. Patients develop epileptic seizures and behavioral changes.","Landau-Kleffner Syndrome | Acquired Epileptic Aphasia",,,,,,,,,,,,,,,"4046219","Acquired epileptic aphasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039133","Latent Syphilis","C35056","A stage of syphilis characterized by the serologic evidence of infection by Treponema pallidum without evidence of accompanying signs or symptoms related to the disease.","Latent Syphilis | ",,,,,,,,,,,,,,,"40485064","Latent syphilis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043019","Lateral Medullary Syndrome","C84807","A syndrome caused by an infarct in the vertebral or posterior inferior cerebellar artery. It is characterized by sensory defects affecting the same side of the face as the infarct and the opposite side of the trunk as the infarct. Patients experience difficulty swallowing and/or speaking.","Lateral Medullary Syndrome | Wallenberg Syndrome | Wallenberg's Syndrome",,,,,,,,,,,,,,,"4301259","Posterior inferior cerebellar artery syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0917796","Leber Hereditary Optic Atrophy","C84808","A hereditary disorder caused by mitochondrial mutations, resulting in the degeneration of the retinal ganglion cells and optic atrophy. It is characterized by an acute or subacute loss of central vision. It may initially affect one eye only, but eventually the central loss of vision becomes bilateral.","Leber Hereditary Optic Atrophy | ",,,,,,,,,,,,,,,"4240232","Leber's optic atrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023195","Lecithin Acyltransferase Deficiency","C84813","A disorder of lipoprotein metabolism caused by mutations in the LCAT gene. It is characterized by deficiency of the enzyme lecithin cholesterol acyltransferase. It is manifested with corneal opacity, hemolytic anemia, and proteinuria.","Lecithin Acyltransferase Deficiency | ",,,,,,,,,,,,,,,"37167480|4029265","Familial lecithin cholesterol acyltransferase deficiency|Lecithin cholesterol acyltransferase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C4229116","Leigh Disease","C84814","An inherited disorder affecting the nervous system, caused by genetic mutations in the mitochondrial DNA or deficiency of pyruvate dehydrogenase. Signs and symptoms appear in infancy and include loss of the motor abilities, poor sucking abilities, irritability, lack of muscle tone, and seizures.","Leigh Disease | Leigh Syndrome | Leigh's Disease | Leigh's disease",,,,,,,,,,,,,,,"4106216","Leigh's disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023281","Leishmaniasis","C34767","A parasitic infection caused by protozoa of the genus Leishmania. It is transmitted to humans via the bite of sandflies. There are three main forms of the disease: cutaneous, mucocutaneous, and visceral leishmaniasis. Cutaneous leishmaniasis causes skin ulcers; mucocutaneous leishmaniasis causes destructive lesions of the mucous membranes of the nose, mouth, and throat; visceral leishmaniasis is the most severe form of the disease and is manifested with anemia, weight loss, hepatomegaly and splenomegaly.","Leishmaniasis | ",,,,,,,,,,,,,,,"433407","Leishmaniasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0238111","Lennox-Gastaut Syndrome","C84816","A syndrome characterized by frequent episodes of epilepsy during childhood. The epileptic episodes may be tonic, atonic, myoclonic, or absence seizures. It may be accompanied by mental retardation and behavioral problems.","Lennox-Gastaut Syndrome | LGS",,,,,,,,,,,,,,,"4046213","Lennox-Gastaut syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0175704","LEOPARD Syndrome","C84820","A genetic syndrome caused by mutations in the PTPN11 and RAF1 genes. It is characterized by the following abnormalities: multiple lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonary stenosis, abnormalities in genitalia, growth retardation, and deafness.","LEOPARD Syndrome | Lentigines, Electrocardiographic Conduction Defects, Ocular Hypertelorism, Pulmonary Stenosis, Abnormalities of the Genitals, Retarded Growth, Deafness | Multiple Lentigines Syndrome",,,,,,,,,,,,,,,"4009625","Multiple lentigines syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023343","Leprosy","C84824","A bacterial granulomatous infection caused by Mycobacterium leprae. It is a progressive disease affecting the skin, peripheral nerves, and limbs. If untreated, it causes permanent tissue damage leading to autoamputations.","Leprosy | Hansen Disease | Hansen's Disease",,,,,,,,,,,,,,,"432821","Leprosy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023364","Leptospirosis","C84825","A contagious bacterial infection caused by spirochetes of the genus Leptospira. Humans are infected by contact with water and soil which have been contaminated with animal waste products. The signs and symptoms include an initial flu-like phase, followed by a second phase in which patients may develop meningitis, liver failure and renal failure.","Leptospirosis | Weil Disease",,,,,,,,,,,,,,,"432246","Leptospirosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0752347","Lewy Body Dementia","C84826","A progressive form of dementia characterized by the presence of protein deposits called Lewy bodies in the midbrain and cerebral cortex, and loss of cholinergic and dopaminergic neurons. The signs and symptoms overlap with Alzheimer and Parkinson disease.","Lewy Body Dementia | Dementia with Lewy bodies | Lewy Body Disease",,,,,,,,,,,,,,,"380701|4196433","Diffuse Lewy body disease|Senile dementia of the Lewy body type",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0023652","Lichen Sclerosus et Atrophicus","C26817","A chronic inflammatory process affecting the skin. It is characterized by the presence of white, indurated plaques, epidermal atrophy, and fibrosis of the upper dermis. It usually appears in the vulva and penis.","Lichen Sclerosus et Atrophicus | Lichen sclerosus et atrophicus",,,,,,,,,,,,,,,"619347|619430","Lichen sclerosus|Lichen sclerosus",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0221043","Liddle Syndrome","C84827","An autosomal dominant inherited syndrome caused by dysregulation of the amiloride-sensitive sodium channel. It is characterized by early onset hypertension, hypokalemia, metabolic alkalosis, low plasma renin and hypoaldosteronism.","Liddle Syndrome | ",,,,,,,,,,,,,,,"45769156","Pseudoprimary hyperaldosteronism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0686353","Limb-Girdle Muscular Dystrophy","C84828","A group of autosomal recessive and less frequently autosomal dominant muscular dystrophies affecting the muscles of the hips and shoulders.","Limb-Girdle Muscular Dystrophy | Limb girdle dystrophy",,,,,,,,,,,,,,,"4344042","Muscular dystrophy with predominantly proximal limb girdle distribution",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0338430","Limbic Encephalitis","C4350","A rare disorder characterized by degenerative changes in the limbic area of the brain. Causes include infections and autoimmune conditions; it may also manifest as a paraneoplastic syndrome, most often caused by small cell lung carcinoma. Signs and symptoms include behavioral changes, hallucinations and dementia.","Limbic Encephalitis | ",,,,,,,,,,,,,,,"4041673","Limbic encephalitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023795","Lipoid Proteinosis of Urbach and Wiethe","C84829","A rare, autosomal recessive metabolic disorder characterized by hoarseness of voice, eyelid beading, skin lesions, and seizures.","Lipoid Proteinosis of Urbach and Wiethe | LIPOPROTEINOSIS",,,,,,,,,,,,,,,"4299851","Lipid proteinosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036420","Localized Scleroderma","C72069","A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. Localized scleroderma typically affects the skin, with formation of patches or lines of thick and unyielding tissue; there can be muscle and underlying tissue involvement as well as occasional joint complications. The affected areas of skin can be restrictive and disfiguring. The shape, depth and location of the affected area is used to classify one of the four types of local scleroderma. An individual can have a combination of localized scleroderma types.","Localized Scleroderma | Localized scleroderma [morphea] | Morphea",,,,,,,,,,,,,,,"441928","Localized scleroderma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517991","Chromosome 8 deletion","C36535","A cytogenetic abnormality that refers to loss of all or part of chromosome 8.","Loss of Chromosome 8 | Chromosome 8 Deletion | del(8)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024221","Lymphangioma","C8965","A benign lesion composed of dilated lymphatic channels. Painless swelling is the usual clinical manifestation.","Lymphangioma | Capillary lymphangioma | LYMPHANGIOMA, BENIGN | Lymphangioma, NOS","9170/0|9171/0","Lymphangioma, NOS|Capillary lymphangioma",,,,,,,,,,,,,"433997","Lymphangioma",,,,,,,,,,,,,"--","--|--",,,,,,,,"--"
"C0751674","Lymphangioleiomyomatosis","C3725","A multifocal neoplasm with perivascular epithelioid cell differentiation affecting almost exclusively females of child-bearing age. It is characterized by the presence of smooth muscle and epithelioid cells and by the proliferation of lymphatic vessels. Sites of involvement include the lungs, mediastinum, and the retroperitoneum. It usually presents with chylous pleural effusion or ascites.","Lymphangioleiomyomatosis | LAM | Lymphangiomyomatosis",,,,,,,,,,,,,,,"4247665","Lymphangiomyomatosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024408","Spinocerebellar Ataxia Type 3","C84830","A very rare, autosomal dominant inherited neurodegenerative disorder. Signs and symptoms include ataxia, spasticity, and abnormalities in the ocular movements.","Spinocerebellar Ataxia Type 3 | Machado-Joseph Disease | Machado-Joseph Disease | SCA3",,,,,,,,,,,,,,,"4240649","Azorean disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024525","Malakoplakia","C84833","An inflammatory reaction characterized by the presence of papules or nodules usually in the genitourinary tract. It is usually a reaction to an infection. Morphologically, it consists of foamy histiocytes and characteristic basophilic inclusion bodies called Michaelis-Gutmann bodies.","Malakoplakia | ",,,,,,,,,,,,,,,"37396819|4130713|4178261","Malakoplakia|Malakoplakia|Malakoplakia",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C0024530","Malaria","C34797","A protozoan infection caused by the genus Plasmodium. There are four species of Plasmodium that can infect humans: Plasmodium falciparum, vivax, ovale, and malariae. It is transmitted to humans by infected mosquitoes. Signs and symptoms include paroxysmal high fever, sweating, chills, and anemia.","Malaria | ",,,,,,,,,,,,,,,"438067","Malaria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1955869","Malformations of Cortical Development","C84834","A group of neural cortical developmental malformations of diverse genetic causes. Clinical manifestations include epilepsy and developmental delays.","Malformations of Cortical Development | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221011","Malignant Atrophic Papulosis","C84835","A rare disorder of unknown etiology. It may present as a cutaneous disorder with a benign clinical course or a systemic disorder with a grim prognosis. Both the cutaneous and systemic variants are characterized by the presence of papular skin lesions. The systemic variant, in addition to the skin papules, is characterized by gastrointestinal manifestations including abdominal pain and distention, nausea, vomiting, diarrhea, intestinal infarction, and intestinal perforation. The central and peripheral nervous systems may also be involved in the systemic variant.","Malignant Atrophic Papulosis | Degos Disease",,,,,,,,,,,,,,,"4271031","Malignant atrophic papulosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3549501","Undifferentiated Pleomorphic Sarcoma","C4247","An undifferentiated soft tissue sarcoma characterized by the presence of a pleomorphic malignant cellular infiltrate.  It is also known as malignant fibrous histiocytoma.","Undifferentiated Pleomorphic Sarcoma | FIBROSARCOMA, PLEOMORPHIC, MALIGNANT | Fibroxanthosarcoma | Histiocytoma, Fibrous, Malignant | MFH | Malignant Fibrous Histiocytoma | Malignant Fibrous Histiocytoma | Malignant Fibrous Histiocytoma of Soft Tissue and Bone | Malignant Fibrous Histiocytoma of the Soft Tissue and Bone | Malignant Fibroxanthoma | Malignant fibrous histiocytoma | Storiform-Pleomorphic Fibrous Histiocytoma | Storiform-Pleomorphic MFH | Storiform-Pleomorphic Malignant Fibrous Histiocytoma | UPS | Unclassified Pleomorphic Sarcoma | Unclassified Pleomorphic Sarcoma | Unclassified Pleomorphic Sarcoma (Formerly 'MFH') | Unclassified Pleomorphic Sarcoma (Formerly 'Malignant Fibrous Histiocytoma') | Undifferentiated Pleomorphic Soft Tissue Sarcoma | Undifferentiated pleomorphic sarcoma | malignant fibrous cytoma | malignant fibrous histiocytoma","8830/3","Malignant fibrous histiocytoma",,,,,,,,,,,,,"40481499|4145768","Malignant fibrous histiocytoma|Fibrous histiocytoma, malignant",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0024591","Malignant Hyperthermia Syndrome","C84869","A rare disorder characterized by rapid rise of the body temperature, accompanied by rhabdomyolysis and, if untreated, by collapse and death. It occurs in susceptible individuals who receive certain drugs for general anesthesia, gas anesthetics, or succinylcholine. It may be inherited in an autosomal dominant pattern.","Malignant Hyperthermia Syndrome | Malignant Hyperpyrexia | Malignant Hyperthermia",,,,,,,,,,,,,,,"4020879|440285","Malignant hyperpyrexia due to anesthetic|Malignant hyperthermia",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0024633","Mallory-Weiss Syndrome","C84881","A disorder characterized by upper gastrointestinal tract bleeding caused by longitudinal mucosal tears in the gastroesophageal junction. The tears result from retching or forceful coughing. It was initially described in alcoholics.","Mallory-Weiss Syndrome | ",,,,,,,,,,,,,,,"316457","Mallory-Weiss syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024759","Mansonelliasis","C84882","A parasitic infection caused by the nematode Mansonella. Signs and symptoms include pruritus, headache, fever, arthralgias, and eosinophilia.","Mansonelliasis | ",,,,,,,,,,,,,,,"4347656","Mansonelliasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024776","Maple Syrup Urine Disease","C34806","An autosomal recessive inherited disorder caused by mutations in the BCKDHA, BCKDHB, DBT, and DLD genes. It is characterized by a deficiency of branched-chain alpha-keto acid dehydrogenase complex, leading to accumulation of metabolites in the body fluids. The name of the disease derives from the sweet odor of the urine in infants, reminiscent of maple syrup. Signs and symptoms usually appear in infancy and include lethargy and developmental delays. If untreated, it may lead to seizures, coma, and death.","Maple Syrup Urine Disease | ",,,,,,,,,,,,,,,"4100475","Maple syrup urine disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024788","Marburg Virus Disease","C84883","A viral infectious disorder caused by Marburg virus. Signs and symptoms include fever, headache, myalgias, chest and abdominal pain, jaundice, liver failure, massive hemorrhaging, and multiple organ failure.","Marburg Virus Disease | Marburg Hemorrhagic Fever",,,,,,,,,,,,,,,"4300760","Marburg virus disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3549606","Medullary Sponge Kidney","C34751","A developmental disorder of the kidney characterized by cystic dilatation of the medullary collecting ducts, resulting in a spongy gross appearance of the kidney. It may be asymptomatic or complicated by hematuria, infections, or renal stones.","Medullary Sponge Kidney | ",,,,,,,,,,,,,,,"195072","Medullary sponge kidney",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0339277","Meesmann Corneal Dystrophy","C84795","An autosomal dominant inherited corneal disorder caused by mutations in the KRT3 and KRT12 genes. It is characterized by the formation of multiple tiny cysts in the epithelial layer of the cornea. The cysts may rupture, causing pain, redness and light sensitivity. Vision usually is not affected.","Meesmann Corneal Dystrophy | Juvenile Epithelial of Meesmann Corneal Dystrophy",,,,,,,,,,,,,,,"440408","Meesman's corneal dystrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002888","Megaloblastic Anemia","C34382","Anemia characterized by the presence of unusually large erythroblasts in the bone marrow called megaloblasts. It is usually caused by vitamin B12 or folic acid deficiency. Other causes include toxins and drugs.","Megaloblastic Anemia | ",,,,,,,,,,,,,,,"435789","Megaloblastic anemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162671","MELAS Syndrome","C84885","A rare progressive neurodegenerative disorder characterized by mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes.","MELAS Syndrome | MELAS | Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke",,,,,,,,,,,,,,,"4219010","Juvenile myopathy, encephalopathy, lactic acidosis, stroke",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025235","Melkersson-Rosenthal Syndrome","C84886","A rare syndrome characterized by recurrent facial nerve paralysis, edema of the lips and face, and furrowed tongue.","Melkersson-Rosenthal Syndrome | ",,,,,,,,,,,,,,,"4295340","Melkersson's syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025239","Melorheostosis","C84887","A very rare bone disorder characterized by thickening of the cortex in a linear pattern. Signs and symptoms include joint pain, joint swelling, limb deformity, and changes in the skin covering the bone lesion.","Melorheostosis | ",,,,,,,,,,,,,,,"4260835","Melorheostosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041318","Meningeal Tuberculosis","C84888","A bacterial infection of the membranes covering the brain and the spinal cord caused by Mycobacterium tuberculosis.","Meningeal Tuberculosis | ",,,,,,,,,,,,,,,"441775","Tuberculosis of meninges",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022716","Menkes Disease","C75486","An X-linked disorder caused by mutations in the ATP7A gene resulting in the abnormal transport and metabolism of copper. It affects primarily male infants. It is characterized by hypotonia, seizures, failure to thrive, and peculiar colorless or steel-colored brittle hair.","Menkes Disease | Kinky Hair Syndrome | Menkes Kinky Hair Syndrome | Menkes Kinky-Hair Syndrome",,,,,,,,,,,,,,,"4241728","Menkes kinky-hair syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162672","Myoclonic Epilepsy Associated with Ragged-Red Fibers","C84889","A condition that can be caused by mutation(s) in more than one mitochondrial gene. It is characterized by myoclonic epilepsy and ragged-red fibers present on muscle biopsy.","Myoclonic Epilepsy Associated with Ragged-Red Fibers | MERRF Syndrome | MERRF Syndrome",,,,,,,,,,,,,,,"4044227","Myoclonic epilepsy with ragged red fibers",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268615","5' 10' Methylenetetrahydrofolate Reductase Deficiency","C84524","A rare disorder associated with mental retardation, spasticity, and early death.","5' 10' Methylenetetrahydrofolate Reductase Deficiency | 5' 10' Methylenetetrahydrofolate Reductase Deficiency (MTHFR) | 5,10-Methylenetetrahydrofolate Reductase Deficiency | MTHFR",,,,,,,,,,,,,,,"4216432","5,10-Methylenetetrahydrofolate reductase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1959626","Mevalonate Kinase Deficiency","C84890","A very rare autosomal recessive disorder of cholesterol biosynthesis. It is caused by a deficiency of the enzyme mevalonate kinase, resulting in the accumulation of mevalonic acid in the urine. Signs and symptoms include psychomotor retardation, ataxia, recurrent fevers, skin rash, hepatosplenomegaly, and lymphadenopathy.","Mevalonate Kinase Deficiency | HIDS | Hyperimmunoglobulin D with Periodic Fever Syndrome | MKD | Mevalonic Aciduria",,,,,,,,,,,,,,,"4051518","Deficiency of mevalonate kinase",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085407","Microsporidiosis","C84891","A fungal infection caused by Microsporidia. It occurs in immunocompromised patients, causing diarrhea and wasting.","Microsporidiosis | Microsporidia Infection",,,,,,,,,,,,,,,"44783575","Infection by Microsporidia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704320","Minimal Change Glomerulonephritis","C34844","A glomerular disorder characterized by the electron microscopic finding of loss of podocyte foot processes. Light microscopic examination does not show glomerular changes. Patients present with proteinuria and nephrotic syndrome.","Minimal Change Glomerulonephritis | Lipoid Nephrosis | Minimal Change Disease | Minimal Change Nephropathy | Nil Disease",,,,,,,,,,,,,,,"4260398","Minimal change disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026272","Mixed Connective Tissue Disease","C84892","An autoimmune overlap syndrome characterized by the presence of symptoms of systemic lupus erythematosus, systemic scleroderma, and polymyositis.","Mixed Connective Tissue Disease | MCTD",,,,,,,,,,,,,,,"4134867","Mixed collagen vascular disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221060","Mobius Syndrome","C84893","A very rare congenital syndrome affecting the sixth and seventh cranial nerves. It is characterized by facial paralysis leading to lack of facial expression and the inability to move the eyes laterally.","Mobius Syndrome | Moebius Syndrome | Möbius Syndrome | Oromandibular-Limb Hypogenesis Spectrum",,,,,,,,,,,,,,,"4231449","Oromandibular-limb hypogenesis spectrum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0546966","Monilethrix","C84894","A rare autosomal dominant inherited hair shaft disorder caused by mutations in certain cuticular type II keratin genes. It is characterized by the presence of thin, fragile hairs that appear beaded.","Monilethrix | ",,,,,,,,,,,,,,,"4289476","Beaded hair",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026654","Moyamoya Disease","C84895","A rare inherited vascular disorder characterized by constriction of arteries at the base of the brain, resulting in the formation of collateral circulation in order to compensate for the constriction. The name 'moyamoya' in Japanese means 'puff of smoke' and derives from the characteristic radiographic appearance of the collateral vessels.","Moyamoya Disease | ",,,,,,,,,,,,,,,"378774","Moyamoya disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0238286","Mucolipidosis Type IV","C84896","An autosomal recessive lysosomal storage disease caused by mutations in the MCOLN1 gene. It is characterized by psychomotor developmental delays and ophthalmologic abnormalities.","Mucolipidosis Type IV | Mucolipidosis IV",,,,,,,,,,,,,,,"37110837","Mucolipidosis type IV",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023786","Mucopolysaccharidosis Type I","C85053","The most common type of mucopolysaccharidosis. It is inherited in an autosomal recessive pattern. It comprises a group of lysosomal storage diseases which includes the most severe form (Hurler syndrome) and the mildest form (Scheie syndrome).","Mucopolysaccharidosis Type I | MPS I | Mucopolysaccharidosis I",,,,,,,,,,,,,,,"4294142","Mucopolysaccharidosis, MPS-I",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1864436","Muenke Syndrome","C84904","A rare autosomal dominant inherited disorder caused by mutations in the FGFR3 gene. It is characterized by premature fusion of cranial bones, resulting in head shape abnormalities, flattened cheekbones, and wide-set eyes.","Muenke Syndrome | FGFR3-Related Craniosynostosis",,,,,,,,,,,,,,,"37204059","Muenke syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1321489","Muir-Torre Syndrome","C84905","A usually autosomal dominant inherited neoplastic syndrome caused by mutations in the hMSH-2 and hMLH-1 genes. It is characterized by the presence of sebaceous skin tumors (adenoma or carcinoma), and internal organ malignant tumors, usually of the gastrointestinal or genitourinary tract.","Muir-Torre Syndrome | ",,,,,,,,,,,,,,,"4301407","Muir-Torré syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524582","Mulibrey Nanism","C84906","An autosomal recessive inherited disorder caused by mutations in the TRIM37 gene. It is characterized by marked growth retardation and abnormalities in multiple organs including heart, liver, muscle, eyes, and brain.","Mulibrey Nanism | Perheentupa Syndrome",,,,,,,,,,,,,,,"4304396","Mulibrey nanism syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011263","Multi-Infarct Dementia","C34522","A common form of dementia caused by multiple cortical or subcortical cerebral infarctions.","Multi-Infarct Dementia | Multi Infarct Dementia",,,,,,,,,,,,,,,"379778","Multi-infarct dementia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268596","Multiple Acyl-CoA Dehydrogenase Deficiency","C84907","A rare autosomal recessive inherited metabolic disorder caused by mutations in the ETFA, ETFB, or ETFDH genes. It is characterized by deficiency of either electron transfer flavoprotein (ETF) or electron transfer flavoprotein dehydrogenase (ETFDH). Clinical presentations include congenital abnormalities (brain and facial malformations), hypotonia, dilated cardiomyopathy, hepatomegaly, metabolic acidosis, hypoglycemia, and behavioral changes.","Multiple Acyl-CoA Dehydrogenase Deficiency | Glutaric Acidemia Type 2 | Glutaric Aciduria, Type 2 | Multiple Acyl Coenzyme A Dehydrogenase Deficiency",,,,,,,,,,,,,,,"4119295","Glutaric aciduria, type 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1955745","Multiple Endocrine Neoplasia","C6432","An autosomal dominant inherited neoplastic syndrome characterized by the development of various endocrine neoplasms and abnormalities in various anatomic sites. There are four types recognized: type 1 (MEN 1), caused by inactivation of the tumor suppressor gene MEN-1, type 2A (MEN 2A), caused by mutation of the RET gene, type 2B (MEN 2B) also caused by mutation of the RET gene, and type 4 (MEN 4) caused by mutation of the CDKN1B gene. Patients with MEN 1 may develop hyperparathyroidism and parathyroid gland adenomas, pituitary gland adenomas, pancreatic islet cell neoplasms, and carcinoid tumors. Patients with MEN 2A develop medullary thyroid carcinomas and may also develop pheochromocytomas and parathyroid gland hyperplasia. Patients with MEN 2B develop medullary thyroid carcinomas and numerous neural defects including neuromas. Patients with MEN 4 develop endocrine neoplasms, particularly in the parathyroid glands, pituitary, and pancreas.","Multiple Endocrine Neoplasia | Endocrine adenomatosis | MEN | MEN Syndromes | MEN syndrome | Multiple Endocrine Adenomatosis | Multiple Endocrine Neoplasia Syndrome | Multiple Endocrine Neoplasia Syndrome(s) | Multiple endocrine adenomas | multiple endocrine adenomatosis | multiple endocrine neoplasia syndrome","8360/1","Multiple endocrine adenomas",,,,,,,,,,,,,"30678","Polyglandular activity in multiple endocrine adenomatosis",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0025267","Multiple Endocrine Neoplasia Type 1","C3225","Multiple endocrine neoplasia caused by inactivation of the tumor suppressor gene MEN-1. Patients may develop hyperparathyroidism and parathyroid gland adenomas, pituitary gland adenomas, pancreatic islet cell neoplasms, and carcinoid tumors.","Multiple Endocrine Neoplasia Type 1 | MEA Type 1 | MEA Type I | MEN 1 | MEN Type 1 | MEN Type I | MEN1 syndrome | Multiple Endocrine Adenomatosis | Multiple Endocrine Adenomatosis Type 1 | Multiple Endocrine Adenomatosis Type I | Multiple Endocrine Adenomatosis, Type I | Multiple Endocrine Neoplasia Type I | Multiple Endocrine Neoplasia, Type I | Multiple endocrine neoplasia [MEN] type I | Wermer Syndrome | Wermer syndrome | Wermer's Syndrome | multiple endocrine neoplasia type 1 syndrome",,,,,,,,,,,,,,,"28127","Multiple endocrine neoplasia, type 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025268","Multiple Endocrine Neoplasia Type 2A","C3226","Multiple endocrine neoplasia caused by mutation of the RET gene. Patients develop medullary thyroid carcinomas, and may also develop pheochromocytomas and parathyroid gland hyperplasia.","Multiple Endocrine Neoplasia Type 2A | MEA Type 2a | MEA Type II | MEN 2A | MEN Type 2a | MEN Type II | Multiple Endocrine Adenomatosis Type 2A | Multiple Endocrine Adenomatosis Type 2a | Multiple Endocrine Adenomatosis Type II | Multiple Endocrine Adenomatosis, Type II | Multiple Endocrine Neoplasia Type 2a | Multiple Endocrine Neoplasia Type II | Multiple Endocrine Neoplasia, Type II | Multiple endocrine neoplasia [MEN] type IIA",,,,,,,,,,,,,,,"36717452","Multiple endocrine neoplasia type 2A",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025269","Multiple Endocrine Neoplasia Type 2B","C3227","Multiple endocrine neoplasia caused by mutation of the RET gene. Patients develop medullary thyroid carcinomas and numerous neural defects including neuromas.","Multiple Endocrine Neoplasia Type 2B | MEN 2B | MEN IIB | MEN Type 2B | MEN Type IIB | Multiple Endocrine Adenomatosis Type IIB | Multiple Endocrine Neoplasia Type 2b | Multiple Endocrine Neoplasia Type 3 | Multiple Endocrine Neoplasia Type IIB | Multiple Endocrine Neoplasia Type III | Multiple Endocrine Neoplasia, Type III | Multiple endocrine neoplasia [MEN] type IIB",,,,,,,,,,,,,,,"199775","Multiple endocrine neoplasia, type 3",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206641","Multiple Osteochondromas","C53457","An autosomal dominant neoplastic chondrogenic process affecting multiple sites. It is caused by mutations in the EXT1 or EXT2 genes.  Grossly and microscopically, the lesions resemble an osteochondroma.","Multiple Osteochondromas | Osteochondromatosis","9210/1","Osteochondromatosis, NOS",,,,,,,,,,,,,"4279615","Osteochondromatosis",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0268263","Multiple Sulfatase Deficiency Disease","C84908","A rare autosomal recessive lysosomal storage disease caused by mutations in SUMF1 gene. It is characterized by deficiency of all sulfatase enzymes. Signs and symptoms include neurologic damage, mental retardation, skeletal abnormalities, hepatosplenomegaly, and ichthyosis.","Multiple Sulfatase Deficiency Disease | ",,,,,,,,,,,,,,,"4183021","Multiple sulfatase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037019","Multiple System Atrophy","C84909","A rare neurodegenerative disorder characterized by loss of autonomic nervous system functions and disturbances of motor, balance and muscle coordination.","Multiple System Atrophy | Shy-Drager Syndrome | Shy-Drager syndrome | multiple system atrophy",,,,,,,,,,,,,,,"4044053","Multiple system atrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4014877","Muscular Dystrophy","C84910","A group of inherited progressive muscle disorders characterized by muscle weakness and eventual death of the muscle tissues. Examples include Duchenne muscular dystrophy, Becker's muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, and limb-girdle muscular dystrophy.","Muscular Dystrophy | ",,,,,,,,,,,,,,,"4247802","Muscular dystrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4015111","Myokymia","C84911","A disorder characterized by involuntary and irregular muscle contractions not associated with muscle weakness or atrophy. It most often affects facial muscles. It may be localized or generalized.","Myokymia | ",,,,,,,,,,,,,,,"4100643","Myokymia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027122","Myositis Ossificans","C3253","A self-limited benign neoplasm characterized by a zonal architecture. It is composed of spindle cells oriented randomly or in short intersecting fascicles. Peripherally, the spindle cells merge with osteoblasts that rim and populate ill-defined trabeculae and sheets of unmineralized woven bone, which is surrounded by well-formed trabecular and cortical-type bone that remodels into lamellar bone. Treatment is usually simple excision. Prognosis is excellent; recurrence is uncommon. (WHO 2020)","Myositis Ossificans | ",,,,,,,,,,,,,,,"4196401","Muscular ossification",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027127","Myotonia Congenita","C84912","A genetic congenital neuromuscular disorder affecting the skeletal muscles. It is caused by mutations in the chloride channel gene (CLCN1 gene). It is characterized by muscle stiffness, hypertrophy, pain, and cramping.","Myotonia Congenita | ",,,,,,,,,,,,,,,"37117999","Myotonia congenita",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0553604","Myotonic Disorder","C84913","An inherited or acquired, localized or generalized disorder affecting the muscles. It may be associated with abnormalities in the chloride or sodium channels of the muscles. It is characterized by delayed muscle relaxation following stimulation or contraction. Representative examples include myotonia congenita and myotonic dystrophy.","Myotonic Disorder | ",,,,,,,,,,,,,,,"73183","Myotonic disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027126","Myotonic Dystrophy","C84914","An inherited progressive disorder affecting the muscles. It is characterized by muscle wasting and hypotonia, cataracts, heart conduction defects and endocrinopathies.","Myotonic Dystrophy | Myotonic dystrophy",,,,,,,,,,,,,,,"79804","Steinert myotonic dystrophy syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027341","Nail-Patella Syndrome","C75120","A rare autosomal dominant syndrome caused by mutations in the LMX1B gene. It is characterized by fingernail deformities, absence or hypoplasia of the patellae, iliac horns, deformities of the radial heads, nephropathy, and glaucoma.","Nail-Patella Syndrome | Hereditary Osteo-Onychodysplasia",,,,,,,,,,,,,,,"4318821","Nail-patella syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018197","Nasal Cavity and Paranasal Sinus Lethal Midline Granuloma","C8196","An aggressive, progressive, and destructive lesion affecting the nasal cavities, paranasal sinuses, and the palate.  The vast majority of cases are malignant lymphoproliferations affecting the midline of the face in patients with nasal type extranodal NK/T-cell lymphoma.","Nasal Cavity and Paranasal Sinus Lethal Midline Granuloma | Lethal midline granuloma | Midfacial Necrotising Lesion | Midline Lethal Granuloma of Nasal Cavity and Paranasal Sinus | Midline Lethal Granuloma of the Nasal Cavity and Paranasal Sinus",,,,,,,,,,,,,,,"133511","Lethal midline granuloma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027439","Nasopharyngeal Neoplasm","C3257","A benign or malignant neoplasm affecting the nasopharynx. Representative examples of benign neoplasms include angiofibroma and squamous papilloma. Representative examples of malignant neoplasms include keratinizing squamous cell carcinoma and nonkeratinizing carcinoma.","Nasopharyngeal Neoplasm | Nasopharyngeal Neoplasms | Nasopharyngeal Tumor | Neoplasm of Nasopharynx | Neoplasm of the Nasopharynx | Tumor of Nasopharynx | Tumor of the Nasopharynx",,,,,,,,,,,,,,,"4054514","Neoplasm of nasopharynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4082937","Necrotizing Enterocolitis","C84915","A fulminating disease of neonates in which there is extensive mucosal ulceration, pseudomembrane formation, submucosal hemorrhage, and necrosis usually of the right colon, cecum, terminal ileum, and appendix, possibly due to perinatal intestinal ischemia and bacterial invasion. Progression can lead to necrosis, perforation and/or scarring of the intestinal tract.","Necrotizing Enterocolitis | NEC | Necrotizing Enterocolitis | Necrotizing Enterocolitis in Fetus or Newborn | Perinatal Necrotizing Enterocolitis",,,,,,,,,,,,,,,"201957","Necrotizing enterocolitis in fetus OR newborn",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0238124","Necrotizing Fasciitis","C84916","Infection of the deep skin and subcutaneous tissues and necrosis of the fascia. It is caused by bacteria including group A streptococcus, Staphylococcus aureus and Clostridium perfringens. It may develop following trauma and invasive procedures.","Necrotizing Fasciitis | ",,,,,,,,,,,,,,,"133566","Necrotizing fasciitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017575","Necrotizing Ulcerative Gingivitis","C34637","A bacterial infectious process affecting the gums. It is characterized by the development of necrotic, ulcerated, and painful lesions with creation of pseudomembranes extending along the gingival margins.","Necrotizing Ulcerative Gingivitis | Vincent Angina | Vincent's Angina",,,,,,,,,,,,,,,"45769192","Necrotizing ulcerative gingivitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027577","Nelson Syndrome","C84917","A syndrome that develops following bilateral adrenalectomy for Cushing syndrome. The signs and symptoms result from the presence of an adenocorticotropin-secreting pituitary gland adenoma, and include enlargement of the sella turcica and pressure on the adjacent structures, and skin hyperpigmentation.","Nelson Syndrome | ",,,,,,,,,,,,,,,"4182585","Nelson syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3275341","Nephrocalcinosis","C84918","Deposition of calcium in the renal parenchyma, resulting from high levels of calcium in the blood and/or urine.","Nephrocalcinosis | ",,,,,,,,,,,,,,,"4171974","Nephrocalcinosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2749763","Nephrogenic Diabetes Insipidus","C84919","Diabetes insipidus caused by insensitivity of the kidneys to antidiuretic hormone.","Nephrogenic Diabetes Insipidus | ",,,,,,,,,,,,,,,"438476","Nephrogenic diabetes insipidus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1619692","Nephrogenic Fibrosing Dermopathy","C84920","A rare disorder characterized by fibrosis of the skin and internal organs. It occurs in patients with renal failure who had imaging studies performed using gadolinium.","Nephrogenic Fibrosing Dermopathy | ",,,,,,,,,,,,,,,"4173471","Nephrogenic systemic fibrosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265962","Netherton Syndrome","C84922","A rare autosomal recessive form of ichthyosis caused by mutations in the SPINK5 gene. Patients have spiky and fragile hair.","Netherton Syndrome | ",,,,,,,,,,,,,,,"4209834","Netherton's syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3277540","Neural Tube Defect","C84923","A congenital defect characterized by failure of the neural tube to close completely; this results in the presence of openings in the brain or spinal cord. Examples of neural tube defects include encephalocele and spina bifida.","Neural Tube Defect | NTD | Spinal Dysraphism",,,,,,,,,,,,,,,"4102400","Neural tube defect",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0393576","Neuroacanthocytosis","C84926","A group of neurologic disorders associated with acanthocytosis on the peripheral blood smear. The neurologic disorders include movement disorders, ataxia, cognitive disturbances, personality changes, and seizures.","Neuroacanthocytosis | ",,,,,,,,,,,,,,,"4097680|4284540","Chorea acanthocytosis syndrome|Choreoacanthocytosis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0338437","Neurocysticercosis","C84932","A parasitic infection with tapeworms of the genus Taenia affecting the brain. It is manifested with seizures and headaches.","Neurocysticercosis | ",,,,,,,,,,,,,,,"4092992","Cysticercosis of central nervous system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206754","Neuroendocrine Neoplasm","C3809","An epithelial neoplasm with neuroendocrine differentiation. This category includes neuroendocrine tumors, neuroendocrine carcinomas, and paragangliomas.","Neuroendocrine Neoplasm | NEN | Neuroendocrine Tumor | neuroendocrine tumor",,,,,,,,,,,,,,,"4028860","Neuroendocrine neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0687720","Neurogenic Diabetes Insipidus","C84933","Diabetes insipidus caused by decreased secretion of antidiuretic hormone from the pituitary gland.","Neurogenic Diabetes Insipidus | ADH Deficiency | AVP deficiency | Antidiuretic Hormone Deficiency | Arginine Vasopressin Deficiency | Central Diabetes Insipidus | Vasopressin Deficiency",,,,,,,,,,,,,,,"4164730","Neurohypophyseal diabetes insipidus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027873","Neuromyelitis Optica","C84934","An autoimmune inflammatory syndrome characterized by optic neuritis and myelitis. Signs and symptoms include loss of vision, weakness and paralysis of the extremities, and loss of sensation.","Neuromyelitis Optica | Devic Syndrome | Neuromyelitis optica [Devic]",,,,,,,,,,,,,,,"380995","Neuromyelitis optica",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027927","Neurosyphilis","C84935","Infection of the brain or spinal cord by Treponema pallidum. It occurs many years following the original infection which remained untreated. Signs and symptoms include abnormal gait, blindness, depression, paralysis, seizures and dementia.","Neurosyphilis | ",,,,,,,,,,,,,,,"375738","Neurosyphilis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0220756","Niemann-Pick Disease, Type C","C85214","An autosomal recessive inherited lysosomal storage disease caused by mutations in the NPC1 and NPC2 genes. It is characterized by progressive neurologic deterioration manifested with ataxia, dementia, seizures, and dystonia. Other signs and symptoms include hepatosplenomegaly, jaundice, and respiratory failure.","Niemann-Pick Disease, Type C | Type C Niemann-Pick Disease",,,,,,,,,,,,,,,"4283682","Niemann-Pick disease, type C",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0398791","Nijmegen Breakage Syndrome","C4692","A disorder, wherein unstable chromosomes have a tendency to break and become rearranged, characterized by microcephaly, stunted growth, subnormal mental development, cafe-au-lait spots, and immunodeficiency. The syndrome is named after the University of Nijmegen in the Netherlands. (JABL99)","Nijmegen Breakage Syndrome | ",,,,,,,,,,,,,,,"4120785","Microcephaly, normal intelligence and immunodeficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028271","Gangrenous Stomatitis","C34852","Gangrene of the mucous membranes of the mouth leading to ulcers and destruction of the soft tissues of the face and bones. It usually occurs in malnourished children in areas of poor sanitation and immunocompromised patients.","Gangrenous Stomatitis | Noma",,,,,,,,,,,,,,,"141055","Cancrum oris",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827493","Non-Trisomic Autosomal Aneuploidy","C84561","Autosomal aneuploidy not associated with trisomy. It results in developmental malformations.","Non-Trisomic Autosomal Aneuploidy | Aneuploid Chromosome Number - Non-Trisomic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028326","Noonan Syndrome","C34854","A genetic syndrome caused by mutations in the PTPN11 gene (over 50% of the cases) or less frequently mutations in the SOS1, RAF1, or KRAS genes. It is characterized by short stature, webbed neck, hypertelorism, low-set ears, deafness, and thrombocytopenia or abnormal platelet function.","Noonan Syndrome | Noonan syndrome | Noonan's Syndrome",,,,,,,,,,,,,,,"4118400","Noonan's syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028817","Ochronosis","C84938","A disorder characterized by bluish-black discoloration of the cartilaginous tissues due to accumulation of homogentisic acid. It is associated with alkaptonuria. Signs and symptoms include dark urine, skin pigmentation, and arthritis.","Ochronosis | ",,,,,,,,,,,,,,,"4254774","Alcaptonuric ochronosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1282359","Ocular Cicatricial Pemphigoid","C84939","A chronic autoimmune disorder that belongs to the mucous membrane pemphigoid disorders. It is characterized by bilateral scarring and opacification of the conjunctivae. It presents with pain and burning sensation in the eyes and photophobia. It leads to blindness.","Ocular Cicatricial Pemphigoid | ",,,,,,,,,,,,,,,"4152707","Ocular cicatricial pemphigoid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028860","Oculocerebrorenal Syndrome","C84940","An X-linked inherited multisystem metabolic disorder caused by mutations in the OCRL1 gene. The main manifestations of this disorder result from involvement of the eyes, nervous system and kidneys. Signs and symptoms include congenital cataracts, infantile glaucoma, intellectual disability, hypotonia, aminoaciduria and renal tubular dysfunction.","Oculocerebrorenal Syndrome | Lowe Syndrome",,,,,,,,,,,,,,,"4194065","Lowe syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0078918","Oculocutaneous Albinism","C84941","An autosomal recessive inherited disorder caused by mutations of the OCA2, SLC45A2, TYR and TYRP1 genes. It is characterized by hypopigmentation of the skin, hair, and eyes, resulting in very fair skin, white colored hair, and reduced pigmentation in the iris and retina. Individuals may have vision disturbances and photophobia.","Oculocutaneous Albinism | ",,,,,,,,,,,,,,,"4273682","Oculocutaneous albinism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0244252","Oculopharyngeal Muscular Dystrophy","C84942","An autosomal dominant disorder caused by mutations in the PABPN1 gene, encoding polyadenylate-binding protein 2. The condition is characterized by progressive ptosis, dysphagia and weakness of the muscles of the face, neck, and extraocular muscles.","Oculopharyngeal Muscular Dystrophy | OPMD",,,,,,,,,,,,,,,"4297463","Oculopharyngeal muscular dystrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028968","Olivopontocerebellar Atrophy","C84947","A group of sporadic and inherited neurodegenerative disorders affecting the cerebellum, pons, and inferior olives.","Olivopontocerebellar Atrophy | ",,,,,,,,,,,,,,,"4283390","Olivopontocerebellar degeneration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0393626","Opsoclonus Myoclonus Syndrome","C4686","A combination of opsoclonus (involuntary conjugate eye movements of large amplitude) and myoclonic jerks. This can be a paraneoplastic syndrome (a result of brain metastasis) or post-infectious (viral encephalitis).","Opsoclonus Myoclonus Syndrome | Opsoclonus-Myoclonus Syndrome",,,,,,,,,,,,,,,"4043399","Opsoclonus-myoclonus syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3278618","Optic Atrophy","C34863","A disorder characterized by loss of optic nerve fibers. It may be inherited or acquired. Acquired causes include ischemia, optic nerve neuropathy, glaucoma, trauma, radiation, brain tumors, and multiple sclerosis. It leads to vision disturbances.","Optic Atrophy | ",,,,,,,,,,,,,,,"372914","Optic atrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029134","Optic Neuritis","C84950","A disorder characterized by inflammation of the optic nerve. Causes include autoimmune disorders, infections, toxins, drugs, and multiple sclerosis. It may manifest with acute loss of vision and pain.","Optic Neuritis | Optic Neuritis | Optic Neuropathy",,,,,,,,,,,,,,,"374954","Optic neuritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3854181","Organoid Nevus","C4678","A hamartomatous skin lesion containing sebaceous glands. It is usually located in the scalp.","Organoid Nevus | Linear Sebaceous Nevus | Nevus Sebaceous of Jadassohn",,,,,,,,,,,,,,,"45772903","Sebaceous nevus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268542","Ornithine Carbamoyltransferase Deficiency Disease","C84957","An X-linked urea cycle metabolic disorder characterized by deficiency of ornithine carbamoyltransferase, resulting in the accumulation of amino acids and ammonia in the serum. Signs and symptoms include seizures, delayed growth, behavioral changes, ataxia, lethargy, and coma.","Ornithine Carbamoyltransferase Deficiency Disease | Ornithine Carbamoyltransferase Deficiency | Ornithine Transcarbamylase Deficiency",,,,,,,,,,,,,,,"4214885","Ornithine carbamoyltransferase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554670","Orofaciodigital Syndrome Type 1","C75481","An X-linked inherited syndrome caused by mutations in the OFD1 gene mapped to chromosome Xp22.2.  It is characterized by malformations of the face, oral cavity, and fingers.","Orofaciodigital Syndrome Type 1 | ",,,,,,,,,,,,,,,"35622373","Oro-facial digital syndrome type 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1535893","Orthostatic Intolerance","C84973","A condition characterized by development of symptoms while standing. It is an autonomic nervous system disorder and the symptoms are relieved once the person sits back down. Symptoms include heart palpitations, sweating, anxiety, lightheadedness, hyperpnea, anxiety, and blurred vision.","Orthostatic Intolerance | Orthostasis | Orthostatic intolerance",,,,,,,,,,,,,,,"3655887","Orthostatic intolerance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206366","Ossification of Posterior Longitudinal Ligament","C84975","A disorder characterized by benign depositions of calcium in the posterior longitudinal ligament. Signs and symptoms result from the compression of nerve roots and include motor and sensory disturbances in the lower and upper extremities, and pain in the neck and arms.","Ossification of Posterior Longitudinal Ligament | ",,,,,,,,,,,,,,,"4236035","Ossification of posterior longitudinal ligament",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029422","Osteochondrodysplasia","C84978","A term referring to disorders characterized by abnormalities in the development of bones and cartilage.","Osteochondrodysplasia | Congenital Skeletal Dysplasia | Skeletal Dysplasia",,,,,,,,,,,,,,,"4025195","Osteochondrodysplasia syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029434","Osteogenesis Imperfecta","C26837","A group of usually autosomal dominant inherited disorders characterized by defective synthesis of collagen type I resulting in defective collagen formation. It is characterized by brittle and easily fractured bones.","Osteogenesis Imperfecta | Osteogenesis imperfecta",,,,,,,,,,,,,,,"78257","Osteogenesis imperfecta",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029442","Osteomalacia","C26838","A metabolic bone disease that results from either a deficiency in vitamin D, or an abnormality in the metabolism of vitamin D, or a deficiency of calcium in the diet.  The most common symptoms are bone pain and muscle weakness.  When it occurs in children it is commonly referred to as rickets. (Diagnostic Surgical Pathology, 3rd ed.) --2003","Osteomalacia | osteomalacia",,,,,,,,,,,,,,,"432594","Osteomalacia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029455","Osteopoikilosis","C84985","A rare autosomal dominant inherited disorder characterized by the presence of small areas of increased density throughout the bones.","Osteopoikilosis | ",,,,,,,,,,,,,,,"78854","Osteopoikilosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265334","Pachyonychia Congenita","C84986","A rare genetic disorder caused by mutations in the KRT6A, KRT6B, KRT16, and KRT17 genes. It is characterized by hypertrophy and abnormalities in the shape of the fingernails and toe nails.","Pachyonychia Congenita | ",,,,,,,,,,,,,,,"4215114","Pachyonychia congenita syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030185","Breast Paget Disease","C47857","A malignant neoplasm in which there is infiltration of the skin overlying the breast by neoplastic large cells with abundant pale cytoplasm and large nuclei with prominent nucleoli (Paget cells). It is almost always associated with an intraductal or invasive ductal carcinoma of the breast. The clinical features include focal skin reddening, and eczema. Retraction of the nipple may sometimes occur.","Breast Paget Disease | Mammary Paget Disease | Mammary Paget's Disease | Paget Disease of the Breast | Paget Disease of the Breast | Paget disease of breast | Paget disease, mammary | Paget's Disease of Breast | Paget's Disease of the Breast","8540/3","Paget disease, mammary",,,,,,,,,,,,,"4106557","Paget's disease, mammary",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1367970","Pagetoid Reticulosis","C35794","A variant of mycosis fungoides, characterized by an exclusively intraepidermal atypical (cerebriform) lymphocytic infiltrate.  Patients present with a localized psoriasiform or hyperkeratotic patch or plaque, usually in the extremities.  Extracutaneous dissemination of the disease has never been reported.","Pagetoid Reticulosis | Pagetoid reticulosis",,,,,,,,,,,,,,,"4299142|4302511","Pagetoid reticulosis|Pagetoid reticulosis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0265220","Pallister-Hall Syndrome","C84987","A very rare autosomal dominant inherited disorder caused by mutations in the GLI3 gene. It is characterized by a spectrum of abnormalities which include polydactyly, cutaneous syndactyly, bifid epiglottis, hypothalamic hamartoma, and laryngotracheal cleft.","Pallister-Hall Syndrome | Ano-cerebro-digital Syndrome | Hypothalamic Hamartoblastoma Syndrome",,,,,,,,,,,,,,,"4209716","Pallister-Hall syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3549781","Palmar Fibromatosis","C3469","A superficial fibromatosis arising from the soft tissue of the palm. It is characterized by the presence of spindle-shaped fibroblasts, and an infiltrative growth pattern. It predominantly affects adult males.","Palmar Fibromatosis | Dupuyten Disease | Dupuyten Disease/Contracture | Dupuytren Contracture | Dupuytren's Contracture",,,,,,,,,,,,,,,"4308093","Dupuytren's disease of palm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4229552","Palmoplantar Keratoderma","C34748","A group of autosomal dominant, autosomal recessive, X-linked inherited or acquired disorders characterized by the thickening of the palms and soles due to hyperkeratosis.","Palmoplantar Keratoderma | ",,,,,,,,,,,,,,,"45768452","Palmoplantar keratoderma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL480898","Pancreatic Insulin-Producing Neuroendocrine Tumor","C3140","An insulin-producing neuroendocrine tumor arising from the beta cells of the pancreas.  It may or may not be associated with inappropriate secretion of insulin and an associated clinical syndrome.","Pancreatic Insulin-Producing Neuroendocrine Tumor | Beta Cell Tumor | Beta Cell Tumor of Pancreas | Beta Cell Tumor of the Pancreas | Insulin-Producing Islet Cell Tumor | Insulin-Producing Tumor of Islet Cells | Insulin-Producing Tumor of the Islet Cells | Pancreatic Beta Cell Tumor | Pancreatic Insulin Producing NET | Pancreatic Insulin Producing Neoplasm | Pancreatic Insulin Producing Neuroendocrine Tumor | Pancreatic Insulin Producing Tumor | beta cell neoplasm | beta cell tumor of the pancreas | pancreatic insulin-producing tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272505","FACIT Fatigue Scale","C96033","A 13-item, symptom-specific subscale of the FACIT scales that uses a 5-point Likert scale to measure a person's self-reported fatigue while performing normal daily activities.","FACIT Fatigue Scale | FACIT-F | Functional Assessment of Chronic Illness Therapy-Fatigue Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272501","pTa TNM Finding","C96025","A term that refers to a TNM finding of a primary, non-invasive papillary carcinoma.","pTa TNM Finding | Ta | Ta Stage Finding | Ta Stage Finding | Ta TNM Finding | Ta TNM Finding | pTa | pTa Primary Tumor Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332382","N4 TNM Finding","C96026","A general term that refers to a TNM finding of cancer metastases in multiple lymph nodes. The definition of N4 TNM finding depends on the specific type of cancer that it refers to; for example, for ocular adnexal lymphoma it refers to metastases to central lymph nodes.","N4 TNM Finding | N4 | N4 Stage Finding | N4 Stage Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1328479","Pancreatic Neuroendocrine Carcinoma","C3770","An aggressive high-grade carcinoma with neuroendocrine differentiation that arises from the islet cells of the pancreas. It is composed of malignant small or large cells. The mitotic count is more than 20 per 2 mm2 and/or the Ki-67 index is more than 20%.","Pancreatic Neuroendocrine Carcinoma | CARCINOMA, ISLET CELL, MALIGNANT | High Grade Pancreatic Neuroendocrine Carcinoma | High-Grade Pancreatic Neuroendocrine Carcinoma | Islet Cell Cancer | Islet Cell Carcinoma | Islet cell carcinoma | Malignant Islet Cell Tumor | Malignant Pancreatic Endocrine Tumor | PanNEC | Pancreatic Endocrine Carcinoma | Pancreatic NEC | Pancreatic NEC G3 | Pancreatic Neuroendocrine Cancer | Poorly Differentiated Neuroendocrine Neoplasm | Poorly Differentiated Pancreatic Endocrine Carcinoma | islet cell cancer | pancreatic endocrine cancer",,,,,,,,,,,,,,,"4095437|4110585|4244742","Malignant tumor of Islets of Langerhans|Carcinoma of endocrine pancreas|Pancreatic endocrine tumor, malignant",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"CL449044","Pantothenate Kinase-Associated Neurodegeneration","C84988","A rare autosomal recessive inherited disorder caused by mutations in the PANK2 gene. It is characterized by abnormal accumulation of iron in the basal ganglia. Signs and symptoms include progressive motor disturbances, muscle spasm and rigidity, dysarthria, mental deterioration, and behavioral changes.","Pantothenate Kinase-Associated Neurodegeneration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1843278","Panuveitis","C84989","A disorder characterized by inflammation of the entire uvea which includes the iris, ciliary body, and choroid. Causes include systemic infections, sarcoidosis, and cancers.","Panuveitis | ",,,,,,,,,,,,,,,"439014","Panuveitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206700","Papillary Cystadenocarcinoma","C3777","A malignant cystic serous or mucinous epithelial neoplasm characterized by the presence of malignant glandular epithelial cells forming papillary structures. Stromal invasion is present.","Papillary Cystadenocarcinoma | CYSTADENOCARCINOMA, PAPILLARY, MALIGNANT | Papillary cystadenocarcinoma, NOS | Papillocystic adenocarcinoma","8450/3","Papillary cystadenocarcinoma, NOS",,,,,,,,,,,,,"4099473","Papillary cystadenocarcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0030360","Papillon-Lefevre Syndrome","C84992","A rare autosomal recessive inherited disorder caused by mutations in the cathepsin C gene. It is manifested with periodontitis resulting in the premature loss of teeth and palmoplantar keratoderma.","Papillon-Lefevre Syndrome | Papillon-Lefevre Disease",,,,,,,,,,,,,,,"4220949","Papillon-Lefèvre syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030409","Paracoccidioidomycosis","C34891","A systemic fungal infection caused by Paracoccidioides brasiliensis that is most often seen in immunocompromised patients. It affects the mucous membranes, lymph nodes, lungs and bones.","Paracoccidioidomycosis | ",,,,,,,,,,,,,,,"439733","Paracoccidioidomycosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030421","Paraganglioma","C3308","A neoplasm arising from paraganglia located along the sympathetic or parasympathetic nerves.  Infrequently, it may arise outside the usual distribution of the sympathetic and parasympathetic paraganglia.  Tumors arising from the adrenal gland medulla are called pheochromocytomas.  Morphologically, paragangliomas usually display a nesting (Zellballen) growth pattern.  There are no reliable morphologic criteria to distinguish between benign and malignant paragangliomas.  The only definitive indicator of malignancy is the presence of regional or distant metastases.","Paraganglioma | Neoplasm of Paraganglion | Neoplasm of the Paraganglion | Paraganglioma, NOS | Paraganglion Neoplasm | Paraganglion Tumor | Paraganglionic Neoplasm | Paraganglionic Tumor | Tumor of Paraganglion | Tumor of the Paraganglion | paraganglioma",,,,,,,,,,,,,,,"4120306|4196794","Paraganglioma|Paraganglioma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0030424","Paragonimiasis","C84995","A parasitic infection caused by trematodes of the Paragonimus genus. Humans are infected from ingestion of raw or undercooked food. It results in chronic lung infection and eosinophilia.","Paragonimiasis | ",,,,,,,,,,,,,,,"436039","Infection by Paragonimus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0393534","Paraneoplastic Cerebellar Degeneration","C4685","A rare, immune-mediated disorder characterized by cerebellar degeneration due to the presence of an often undetected malignancy (usually carcinoma or lymphoma) in an anatomic site other than the cerebellum. Signs and symptoms include progressive ataxia, dysarthria, and nystagmus.","Paraneoplastic Cerebellar Degeneration | ",,,,,,,,,,,,,,,"4102330","Paraneoplastic cerebellar degeneration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030491","Parapsoriasis","C3312","An inflammatory skin disorder of unknown etiology characterized by papules and plaques or scaly patches resembling psoriasis.","Parapsoriasis | ",,,,,,,,,,,,,,,"320798","Parapsoriasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030593","Pars Planitis","C34903","An inflammatory disorder of the cilliary body in the uvea that affects healthy, younger individuals who are often asymptomatic. It has a long clinical course with relapses and remissions. Symptoms include mildly decreased vision and floaters. It may be associated with autoimmune disorders.","Pars Planitis | ",,,,,,,,,,,,,,,"434026","Pars planitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030779","Pelger-Huet Anomaly","C85002","An autosomal dominant inherited condition caused by mutations in the lamin B receptor gene. It is characterized by defects in the neutrophil lobulation, resulting in the presence of dumbbell-shaped neutrophils with bilobed nuclei in the peripheral blood smear.","Pelger-Huet Anomaly | ",,,,,,,,,,,,,,,"4311674","Pelger-Huët anomaly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205711","Pelizaeus-Merzbacher Disease","C75487","An X-linked inherited disorder caused by mutations in the PLP1 gene on chromosome X.  The signs and symptoms are the result of defective myelination of the central nervous system and include nystagmus, hypotonia, tremor, ataxia, spastic quadriparesis, and diffuse leukoencephalopathy.","Pelizaeus-Merzbacher Disease | ",,,,,,,,,,,,,,,"4275445","Pelizaeus-Merzbacher disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019343","Pemphigoid Gestationis","C85003","An autoimmune bullous dermatitis that develops during pregnancy, most often during the second and third trimesters.","Pemphigoid Gestationis | Gestational Pemphigoid | Herpes Gestationis",,,,,,,,,,,,,,,"4311256","Herpes gestationis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030807","Pemphigus","C34909","A blistering skin disorder. Morphologically it is characterized by acantholysis and intraepidermal blister formation.","Pemphigus | ",,,,,,,,,,,,,,,"135338","Pemphigus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030848","Penile Fibromatosis","C3316","Fibromatosis arising from the soft tissues of the penis. It is characterized by the presence of spindle-shaped fibroblasts, and an infiltrative growth pattern.  It causes the penis to bend when it becomes erect.","Penile Fibromatosis | Penile Induration | Peyronie Disease | Peyronie's Disease | Peyronie's Fibromatosis",,,,,,,,,,,,,,,"196157","Induratio penis plastica",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0520720","Perineural Cyst","C4797","Cyst of the nerve roots filled with cerebrospinal fluid, usually located in the sacral area of the spine.","Perineural Cyst | Cyst of Nerve Root | Cyst of the Nerve Root | Nerve Root Cyst | Perineurial Cyst | Tarlov Cyst",,,,,,,,,,,,,,,"4218724","Perineural cyst",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030330","Peritoneal Panniculitis","C85004","A disorder characterized by chronic inflammation and fibrosis of the adipose tissues in the peritoneal cavity.","Peritoneal Panniculitis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282528","Peroxisomal Disorder","C85005","A group of congenital disorders of lipid metabolism, caused by loss of the normal peroxisomes. Signs and symptoms include developmental delays, mental retardation, facial abnormalities, hepatomegaly, and hypotonia.","Peroxisomal Disorder | Disorder of Peroxisomal Function | Peroxisomal Function Disorder",,,,,,,,,,,,,,,"441268","Disorder of peroxisomal function",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031190","Persistent Fetal Circulation","C85006","A cardiopulmonary disorder characterized by systemic arterial hypoxemia secondary to pulmonary hypertension and extrapulmonary right to left shunting across the foramen ovale and ductus arteriosus.","Persistent Fetal Circulation | PPHN | Persistent Fetal Circulation Syndrome | Persistent Pulmonary Hypertension of the Newborn",,,,,,,,,,,,,,,"4121462","Persistent pulmonary hypertension of the newborn",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023234","Perthes Disease","C34766","A very rare disorder of unknown etiology affecting children. It is characterized by avascular necrosis of the femoral head.","Perthes Disease | Legg-Calve-Perthes Disease | Legg-Perthes Disease",,,,,,,,,,,,,,,"4006963","Avascular necrosis of the capital femoral epiphysis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014553","Absence Epilepsy","C3023","Epilepsy characterized by very brief episodes of sudden cessation of activity, usually associated with eye blinking. There is no loss of the muscle tone.","Absence Epilepsy | Absence Epilepsy | Petit Mal Epilepsy | Petit Mal Epilepsy",,,,,,,,,,,,,,,"4046210|4179936|4194232","Juvenile absence epilepsy|Childhood absence epilepsy|Absence seizure",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C0031269","Peutz-Jeghers Syndrome","C3324","An inherited condition characterized by generalized hamartomatous multiple polyposis of the intestinal tract. Transmitted in an autosomal dominant fashion, Peutz-Jeghers syndrome consistently involves the jejunum and is associated with melanin spots of the lips, buccal mucosa, and fingers. This syndrome is associated with abnormalities of chromosome 19. Also known as Jeghers-Peutz syndrome and Peutz's syndrome.","Peutz-Jeghers Syndrome | Jeghers-Peutz Syndrome | PJS | Peutz's Syndrome | Peutz-Jeghers Disease | Peutz-Jeghers syndrome",,,,,,,,,,,,,,,"4182399","Peutz-Jeghers syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521532","Pick's Disease","C85008","A rare neurodegenerative disorder leading to dementia. It is characterized by frontotemporal lobar degeneration with accumulation of tau proteins which form Pick bodies.","Pick's Disease | Pick Disease | Pick's disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0080024","Piebaldism","C85009","A rare, autosomal dominant disorder caused usually by mutations in the KIT gene. It is characterized by abnormalities in the development of melanocytes. It presents with multiple symmetrical hypopigmented or depigmented patches of skin and a midline patch of white hair.","Piebaldism | ",,,,,,,,,,,,,,,"37397476","Piebaldism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031900","Pierre Robin Syndrome","C85010","A rare congenital malformation characterized by micrognathia, posterior retraction of the tongue, and cleft palate.","Pierre Robin Syndrome | Pierre Robin Sequence | Robin Sequence",,,,,,,,,,,,,,,"4263588","Robin sequence",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206711","Pilomatricoma","C7368","A benign adnexal neoplasm arising from hair-bearing skin surfaces, usually the head and neck and upper extremities. It usually presents as a solitary, slow-growing nodular mass. Morphologically, it displays differentiation towards the matrix and inner sheath of the normal hair follicle and the hair cortex. Complete surgical excision is usually curative. Occasionally, it may recur.","Pilomatricoma | Benign Hair Follicle Neoplasm | Benign Pilomatricoma | Benign Pilomatrixoma | Calcifying Epithelioma of Malherbe | Calcifying Epitherlioma of Malherbe | Calcifying epithelioma of Malherbe | PILOMATRIXOMA, BENIGN | Pilomatricoma, NOS | Pilomatrixoma",,,,,,,,,,,,,,,"4166153|4185707","Pilomatrixoma|Pilomatrixoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1412004","Pineal Region Neoplasm","C3328","A benign or malignant neoplasm that affects the pineal region.","Pineal Region Neoplasm | Neoplasm of Pineal Area | Neoplasm of Pineal Region | Neoplasm of the Pineal Area | Neoplasm of the Pineal Region | Neoplasm of uncertain behavior of pineal gland | Pineal Area Neoplasm | Pineal Area Tumor | Pineal Body Neoplasm | Pineal Body Tumor | Pineal Neoplasm | Pineal Region Tumor | Pineal Tumor | Pinealoma | Tumor of Pineal Area | Tumor of Pineal Region | Tumor of the Pineal Area | Tumor of the Pineal Region | pineal region tumor","9360/1","Pinealoma",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C0031946","Pinta","C85011","An endemic bacterial infection caused by Treponema carateum. It is manifested with chronic cutaneous lesions. The early lesions consist of papules and erythematous plaques. The late lesions consist of hypochromic, achromic, hyperpigmented and atrophic lesions. The late skin lesions may cause destruction of bones and cartilage and produce disfiguring changes.","Pinta | ",,,,,,,,,,,,,,,"433966","Pinta",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0458224","Piriformis Muscle Syndrome","C85012","A condition referring to irritation or compression of the proximal sciatic nerve, secondary to contraction of the piriformis muscle. It results in pain in the hip or the back of the leg mimicking disk-related sciatica.","Piriformis Muscle Syndrome | Piriformis Syndrome",,,,,,,,,,,,,,,"4044021","Piriformis syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162853","Pityriasis Lichenoides","C85013","A rare cutaneous disorder of unknown etiology that can present either as an acute condition, with multiple papular lesions which become vesicular and necrotic (pityriasis lichenoides et varioliformis acuta) or chronic, with small, scaling papules (pityriasis lichenoides chronica).","Pityriasis Lichenoides | ",,,,,,,,,,,,,,,"4066834","Pityriasis lichenoides",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032027","Pityriasis Rubra Pilaris","C85014","A rare cutaneous disorder of unknown etiology characterized by the presence of reddish-orange scaly plaques, palmoplantar keratoderma, keratotic follicular papules, and confluent erythematous areas with areas of normal skin between the lesions.","Pityriasis Rubra Pilaris | ",,,,,,,,,,,,,,,"136774","Pityriasis rubra pilaris",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032249","Plummer-Vinson Syndrome","C85016","A syndrome characterized by dysphagia, upper esophageal webs, iron deficiency anemia, and glossitis.","Plummer-Vinson Syndrome | Paterson-Kelly syndrome | Plummer-Vinson syndrome | Sideropenic dysphagia | sideropenic dysphagia",,,,,,,,,,,,,,,"4198185","Plummer-Vinson syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085404","POEMS Syndrome","C80303","A syndrome characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes. It is associated with plasma cell dyscrasia.","POEMS Syndrome | Crow-Fukase syndrome",,,,,,,,,,,,,,,"4193776","POEMS syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032357","Poland Syndrome","C85017","A rare developmental disorder characterized by underdevelopment or absence of the pectoralis muscle in one side of the chest, usually associated with ipsilateral cutaneous syndactyly, and ipsilateral breast and nipple hypoplasia.","Poland Syndrome | Poland Anomaly",,,,,,,,,,,,,,,"4244512","Poland anomaly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032533","Polymyalgia Rheumatica","C85018","A syndrome characterized by pain, stiffness, and tenderness of the proximal muscle groups including the shoulder, pelvic girdle and the neck. There is no muscle atrophy and muscle biopsies do not reveal pathologic changes. Additional signs and symptoms include low grade fever, fatigue and depression.","Polymyalgia Rheumatica | Polymyalgia rheumatica",,,,,,,,,,,,,,,"255348","Polymyalgia rheumatica",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016065","Polyostotic Fibrous Dysplasia","C34610","Fibrous dysplasia affecting more than one bone. When it is associated with café-au-lait skin pigmentation and endocrine disorders, it is known as McCune-Albright syndrome.","Polyostotic Fibrous Dysplasia | Polyostotic Fibrous Dysplasia of Bone",,,,,,,,,,,,,,,"76801","Polyostotic fibrous dysplasia of bone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162839","Porokeratosis","C85019","A clonal proliferation of abnormal keratinocytes characterized by the development of localized or multiple atrophic skin patches surrounded by an annular keratotic ring called cornoid lamella.","Porokeratosis | ",,,,,,,,,,,,,,,"4266206","Porokeratosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1299624","Postural Orthostatic Tachycardia Syndrome","C85020","A syndrome characterized by orthostatic intolerance resulting in tachycardia, often accompanied by a decrease in the blood pressure. It occurs when individuals change from the supine position to an upright position. Other signs and symptoms include lightheadedness, fainting, fatigue and muscle weakness.","Postural Orthostatic Tachycardia Syndrome | POTS | Postural orthostatic tachycardia syndrome",,,,,,,,,,,,,,,"4159659","Postural orthostatic tachycardia syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032897","Prader-Willi Syndrome","C75463","A genetic syndrome caused by deletions or disruptions of chromosome 15. It is characterized by reduced fetal activity, mental retardation, hypotonia, short stature, and hypogonadism.","Prader-Willi Syndrome | Prader-Labhart-Willi Syndrome | Prader-Willi-Labhart Syndrome",,,,,,,,,,,,,,,"441963","Prader-Willi syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0495181","Preeclampsia","C85021","A systolic blood pressure of 140 mmHg or higher, or a diastolic blood pressure of 90 mmHg or higher on two occasions at least 4 hours apart (or greater than or equal to 160/110 mmHg within a short interval) after 20 weeks of gestation in a woman with previously normal blood pressure. It may present with proteinuria but if not, it may be associated with thrombocytopenia, impaired liver function, progressive renal insufficiency, pulmonary edema, or new-onset cerebral or visual disturbances.","Preeclampsia | ",,,,,,,,,,,,,,,"439393","Pre-eclampsia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032915","Pre-Excitation Syndrome","C34940","An electrocardiographic finding characterized by a premature activation of the whole or some part of the ventricle. The PR interval is usually shortened and delta waves are frequently present. (CDISC)","Pre-Excitation Syndrome | PRE-EXCITATION | Pre-excitation | Ventricular preexcitation",,,,,,,,,,,,,,,"4108828","Ventricular pre-excitation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1314753","Gestational Hypertension","C4371","A blood pressure elevation after 20 weeks of gestation in the absence of either proteinuria or systemic findings like thrombocytopenia, impaired liver function, progressive renal insufficiency, pulmonary edema or the new-onset of cerebral or visual disturbances.","Gestational Hypertension | Pregnancy Associated Hypertension | Pregnancy Associated Hypertension | Pregnancy Induced Hypertension | Pregnancy-Induced Hypertension",,,,,,,,,,,,,,,"4167493","Pregnancy-induced hypertension",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033117","Priapism","C85022","Persistent and usually painful erection that lasts for at least four hours in the absence of physical or psychological stimulation, which can be caused by hematologic disorders, including sickle cell disease and leukemia, spinal cord injuries, and medications.","Priapism | ",,,,,,,,,,,,,,,"315586","Priapism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221002","Primary Hyperparathyroidism","C48280","Hyperfunction of the parathyroid glands resulting in the overproduction of parathyroid hormone. It is caused by parathyroid adenoma, parathyroid hyperplasia, parathyroid carcinoma, and multiple endocrine neoplasia. It is associated with hypercalcemia and hypophosphatemia. Signs and symptoms include weakness, fatigue, nausea, vomiting, constipation, depression, bone pain, osteoporosis, cystic bone lesions, and kidney stones.","Primary Hyperparathyroidism | ",,,,,,,,,,,,,,,"136934","Primary hyperparathyroidism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029411","Primary Hypertrophic Osteoarthropathy","C85023","A rare disorder characterized by hypertrophy of the bones of the distal extremities, periostosis of the tubular bones, digital clubbing, and skin changes including coarse facial features, acne, and hyperhydrosis.","Primary Hypertrophic Osteoarthropathy | ",,,,,,,,,,,,,,,"4338236","Pachydermoperiostosis syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0282513","Primary Progressive Aphasia","C85024","A rare neurologic progressive disorder characterized by impairment of the language and speech abilities.","Primary Progressive Aphasia | ",,,,,,,,,,,,,,,"36716896","Primary progressive apraxia of speech",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0751706","Primary Progressive Nonfluent Aphasia","C85025","A rare neurologic progressive disorder characterized by impairment of the production of speech.","Primary Progressive Nonfluent Aphasia | ",,,,,,,,,,,,,,,"37396465","Primary progressive non fluent aphasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033300","Progeria","C34951","A very rare genetic disorder caused by mutations in the LMNA gene. It is characterized by premature aging. Signs and symptoms include failure to thrive, limited growth, alopecia, wrinkled skin, small face, development of atherosclerosis, and heart disease. There is no cure for this condition. Individuals do not usually survive beyond their early twenties. Death usually occurs as a result of complications from atherosclerosis.","Progeria | Hutchinson-Gilford Disease | Hutchinson-Gilford Progeria Syndrome | Premature Senility Syndrome",,,,,,,,,,,,,,,"4033479","Hutchinson-Gilford syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030442","Progressive Bulbar Palsy","C85026","A progressive motor neuron disorder affecting the muscles which are innervated by cranial nerves of the lower brain stem. Signs and symptoms include difficulties in chewing and swallowing, dysarthria, and weakness of the facial muscles and tongue.","Progressive Bulbar Palsy | Progressive bulbar palsy",,,,,,,,,,,,,,,"436684","Progressive bulbar palsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0917981","Progressive Muscular Atrophy","C85027","A rare, milder form of amyotrophic lateral sclerosis. It is characterized by a slowly progressive clinical course. Signs and symptoms include muscle weakness, atrophy, and fasciculation.","Progressive Muscular Atrophy | ",,,,,,,,,,,,,,,"376679","Progressive muscular atrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0751778","Progressive Myoclonus Epilepsy","C7636","A rare group of disorders characterized by the development of myoclonic and tonic-clonic epileptic seizures associated with progressive degeneration of the nervous system.","Progressive Myoclonus Epilepsy | ",,,,,,,,,,,,,,,"4147501","Progressive myoclonic epilepsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038868","Progressive Supranuclear Palsy","C85028","A rare neurodegenerative disorder characterized by gait and balance difficulties and loss of coordination of eye movements.","Progressive Supranuclear Palsy | Progressive supranuclear ophthalmoplegia | Steele-Richardson-Olszewski Syndrome",,,,,,,,,,,,,,,"40391011","Progressive supranuclear palsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268532","Prolidase Deficiency","C85029","A rare autosomal recessive inherited inborn error of metabolism caused by mutations in the PEPD gene. Signs and symptoms include facial abnormalities, mental retardation, skin ulcers, susceptibility to infections, and skeletal abnormalities.","Prolidase Deficiency | ",,,,,,,,,,,,,,,"4233876|4236676|4237410|4251577","Deficiency of proline dipeptidase|Deficiency of imidodipeptidase|Deficiency of prolidase|Hyperimidodipeptiduria",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--|--"
"C0268579","Propionic Acidemia","C85030","A rare autosomal inherited organic acid disorder caused by mutations in the PCCA and PCCB genes. It results in the accumulation of harmful organic acids in the blood and urine. Signs and symptoms appear in infancy and include vomiting, poor feeding, loss of appetite, hypotonia, and lethargy.","Propionic Acidemia | ",,,,,,,,,,,,,,,"4289321","Propionic acidemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0234512","Prosopagnosia","C85031","Impaired ability to recognize other human faces in the absence of a vision disorder. It may be a congenital disorder or the result of brain injury.","Prosopagnosia | Face Blindness",,,,,,,,,,,,,,,"4081623","Prosopagnosia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085261","Proteus Syndrome","C85032","A very rare congenital disorder characterized by the development of multiple cutaneous and subcutaneous lesions including lipomas, nevi, and vascular malformations, associated with partial gigantism or digital overgrowth.","Proteus Syndrome | ",,,,,,,,,,,,,,,"4047612","Proteus syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4225641","Prune Belly Syndrome","C85033","A rare congenital syndrome occurring almost exclusively in males. It is characterized by partial or complete lack of the abdominal wall muscles, enlarged bladder, dilated ureters, hydronephrosis, and undescended testes.","Prune Belly Syndrome | Eagle-Barrett Syndrome | Syndrome of Agenesis of Abdominal Muscles | Triad Syndrome",,,,,,,,,,,,,,,"201397","Prune belly syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033805","Pseudohypoaldosteronism","C85034","An inherited or acquired disorder of electrolyte metabolism, characterized by the inability of the renal tubules to respond to aldosterone. It is manifested by hyperkalemic metabolic acidosis, urinary salt wasting, normal or increased aldosterone secretion and normal glomerular filtration rate.","Pseudohypoaldosteronism | ",,,,,,,,,,,,,,,"4297464","Pseudohypoaldosteronism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033822","Pseudomyxoma Peritonei","C3345","A usually well differentiated mucinous adenocarcinoma of the peritoneum.  The majority of cases represent tumor spread from a primary low grade mucinous neoplasm of the appendix.  Cases of pseudomyxoma peritonei associated with mucinous adenocarcinomas of the gallbladder, stomach, colon, rectum, pancreas, lung, breast, and fallopian tubes have also been reported.  In the past, the ovary has been considered as a common primary site associated with pseudomyxoma peritonei.  However, there is recent evidence based on immunohistochemistry and molecular genetic analysis suggesting that most cases of pseudomyxoma peritonei probably represent metastasis from an appendiceal and not ovarian primary.","Pseudomyxoma Peritonei | Gelatinous Ascites | Mucinous Ascites | Mucinous Carcinoma Peritonei | Myxoma Peritonei | Peritoneal Cavity Pseudomyxoma Peritonei | Pseudomyxoma peritonei | Well Differentiated Peritoneal Mucinous Adenocarcinoma | pseudomyxoma peritonei","8480/6","Pseudomyxoma peritonei",,,,,,,,,,,,,"4012801","Pseudomyxoma peritonei",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0033845","Pseudotumor Cerebri","C85035","An idiopathic disorder characterized by chronic increase in the intracranial pressure. It occurs predominantly in obese females of childbearing age. It is associated with papilledema.","Pseudotumor Cerebri | Idiopathic Intracranial Hypertension",,,,,,,,,,,,,,,"312902","Benign intracranial hypertension",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033847","Pseudoxanthoma Elasticum","C85036","A rare, progressive, autosomal recessive inherited disorder caused by mutations in the ABCC6 gene. It is characterized by calcification and fragmentation of the elastic fibers of the skin, retina, and cardiovascular system. Signs and symptoms include skin plaques and bumps, thickened skin, retinal hemorrhage and obstruction of the blood vessels.","Pseudoxanthoma Elasticum | ",,,,,,,,,,,,,,,"4090976","Pseudoxanthoma elasticum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3808435","Pulmonary Alveolar Proteinosis","C85037","A rare lung disorder characterized by the filling of the pulmonary alveoli with proteinaceous material which stains positive with periodic acid-Schiff stain. It may be idiopathic or secondary due to hematologic malignancies or the inhalation of mineral dusts. Signs and symptoms include dyspnea, cough and low grade fever.","Pulmonary Alveolar Proteinosis | ",,,,,,,,,,,,,,,"435853","Pulmonary alveolar proteinosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206629","Pulmonary Blastoma","C3732","A biphasic tumor that consists of fetal adenocarcinoma (typically low-grade) and primitive mesenchymal stroma. Foci of specific mesenchymal differentiation (osteosarcoma, chondrosarcoma, or rhabdomyosarcoma) may also be present, but are not required for the diagnosis. Most patients are smokers.  The prognosis is very poor. (WHO 2015)","Pulmonary Blastoma | Blastoma of Lung | Blastoma of the Lung | Lung Blastoma | Pneumoblastoma | Pulmonary blastoma","8972/3","Pulmonary blastoma",,,,,,,,,,,,,"40391740|4183159","Pulmonary blastoma|Pulmonary blastoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0036205","Pulmonary Sarcoidosis","C34997","Sarcoidosis affecting the lung parenchyma. It is characterized by the presence of non-necrotizing granulomas in the lung tissues. It is manifested with dyspnea, cough, fever, night sweats, fatigue, and weight loss.","Pulmonary Sarcoidosis | Lung Sarcoidosis",,,,,,,,,,,,,,,"4086243","Pulmonary sarcoidosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034091","Pulmonary Veno-Occlusive Disease","C85039","A disorder characterized by pulmonary venous constriction or occlusion, resulting in pulmonary hypertension.","Pulmonary Veno-Occlusive Disease | ",,,,,,,,,,,,,,,"4232485","Pulmonary veno-occlusive disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034341","Pyruvate Carboxylase Deficiency","C85040","A rare autosomal recessive inherited metabolic disorder caused by mutations in the PC gene. It results in the accumulation of lactic acid and other toxic substances in the blood. Signs and symptoms appear early in life and include failure to thrive, mental and growth retardation, motor disturbances, seizures, and lactic acidosis.","Pyruvate Carboxylase Deficiency | Pyruvate Carboxylase Deficiency Disease",,,,,,,,,,,,,,,"4227732","Pyruvate carboxylase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034362","Q Fever","C34970","A bacterial infection caused by Coxiella burnetii. It is transmitted to humans by the inhalation of infected air particles or contact with fluids and feces of infected animals. Signs and symptoms include the abrupt onset of fever, headache, myalgias, and weakness.","Q Fever | ",,,,,,,,,,,,,,,"434567","Q fever",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034494","Rabies","C28182","A life-threatening viral infection caused by the neurotropic Rabies virus. It is transmitted to humans usually from a bite by an infected dog. The initial signs and symptoms include malaise, fever, and headache, followed by the central nervous system manifestations which include abrupt behavioral changes. Paralysis, lethargy, and coma follow the behavioral changes.","Rabies | rabies",,,,,,,,,,,,,,,"377793","Rabies",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0270857","Reflex Epilepsy","C85041","Epilepsy triggered by an external stimulus or an internal mental process. Photosensitive epilepsy is the most common form of reflex epilepsy.","Reflex Epilepsy | ",,,,,,,,,,,,,,,"4194366","Reflex epilepsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034931","Complex Regional Pain Syndrome I","C85042","A neurologic condition characterized by burning pain, tenderness, swelling, and changes in the skin color and temperature of a body part or extremity that has no identifiable nerve injury; most pediatric patients present with this form.","Complex Regional Pain Syndrome I | CRPS I | RND | RSDS | Reflex Neurovascular Dystrophy | Reflex Sympathetic Dystrophy Syndrome | Reflex Sympathetic Dystrophy Syndrome",,,,,,,,,,,,,,,"42536233|46273207","Complex regional pain syndrome type I|Complex regional pain syndrome of upper limb",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0034960","Refsum Disease","C85043","A rare autosomal recessive condition caused by mutation(s) in the PHYH gene, encoding phytanoyl-CoA dioxygenase, peroxisomal. It is characterized by abnormalities in the breakdown of phytanic acid and impaired growth of myelin sheaths. Signs and symptoms include neurologic damage, cerebellar degeneration, and neuropathy.","Refsum Disease | ",,,,,,,,,,,,,,,"4101333","HSMN IV",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3809597","Renal Tubular Acidosis","C28129","The inability of the kidneys to maintain acid-base homeostasis.","Renal Tubular Acidosis | renal tubular acidosis",,,,,,,,,,,,,,,"4070448","Renal tubular acidosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1849620","Renovascular Hypertension","C85044","High blood pressure secondary to renal artery stenosis.","Renovascular Hypertension | Renovascular hypertension",,,,,,,,,,,,,,,"317895","Renovascular hypertension",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524801","Retinal Neoplasm","C4800","A benign or malignant neoplasm affecting the retina. Representative examples of benign neoplasms include retinocytoma and hemangioma. Representative examples of malignant neoplasms include retinoblastoma, lymphoma and melanoma.","Retinal Neoplasm | Neoplasm of Retina | Neoplasm of the Retina | Retina Neoplasm | Retina Tumor | Retinal Tumor | Tumor of Retina | Tumor of the Retina",,,,,,,,,,,,,,,"4131904","Neoplasm of retina",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4013933","Retinitis Pigmentosa","C85045","A rare inherited retinal dystrophy disorder characterized by spots of black bone-spicule pigmentation of the retinal pigment epithelium. It is manifested with decreased vision in low light or in the night, followed by decreased peripheral vision, and, eventual decreased central vision. It may lead to blindness.","Retinitis Pigmentosa | ",,,,,,,,,,,,,,,"4103381","Retinitis pigmentosa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152439","Retinoschisis","C85046","An inherited or acquired disorder characterized by splitting of the retina into two layers. It results in loss of vision.","Retinoschisis | ",,,,,,,,,,,,,,,"381282","Retinoschisis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035344","Retinopathy of Prematurity","C34982","A bilateral retinopathy characterized by neovascularization, scarring, retinal detachment, and eventually blindness. It may be mild or severe. It occurs in babies born prematurely. Causes include oxygen toxicity and hypoxia.","Retinopathy of Prematurity | Retrolental Fibroplasia | Retrolental Fibroplasia | Terry Syndrome",,,,,,,,,,,,,,,"373766","Retinopathy of prematurity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3276077","Retroperitoneal Fibrosis","C26876","A rare, serious disorder characterized by extensive fibrosis in the retroperitoneum. In most cases its etiology is unknown. In some cases it is related to autoimmunity or metastatic cancer. It leads to the entrapment and obstruction of vital retroperitoneal structures including the ureters.","Retroperitoneal Fibrosis | ",,,,,,,,,,,,,,,"4176725","Retroperitoneal fibrosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035372","Rett Syndrome","C75488","A progressive neurologic disorder caused by mutations in the MECP2 gene on chromosome X. It almost exclusively affects girls. It is characterized by language and learning difficulties, poor communication skills, and repetitive hand motions. Other signs and symptoms include microcephaly, scoliosis, breathing abnormalities, and sleep disturbances.","Rett Syndrome | Rett's syndrome",,,,,,,,,,,,,,,"4288480","Rett's disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035400","Reye Syndrome","C34983","An acute and potentially fatal metabolic disorder characterized by cerebral edema, fatty liver and hypoglycemia. It occurs primarily in children and has been associated with the use of aspirin for the treatment of viral infections. However, it can also occur in the absence of aspirin use.","Reye Syndrome | Reye syndrome | Reye's Syndrome | Reye's syndrome",,,,,,,,,,,,,,,"375241","Reye's syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0282529","Rhizomelic Chondrodysplasia Punctata","C85047","An autosomal recessive inherited peroxisomal disorder caused by mutations in the PEX7, DHAPAT, and AGP genes. It is characterized by short limbs, bones and cartilage abnormalities, congenital cataracts, and severe mental retardation.","Rhizomelic Chondrodysplasia Punctata | Rhizomelic Chondrodysplasia Punctata Syndrome | Rhizomelic Dwarfism",,,,,,,,,,,,,,,"4209722","Rhizomelic chondrodysplasia punctata syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265205","Robinow Syndrome","C85048","A rare autosomal recessive or dominant inherited disorder. The autosomal recessive form is caused by mutations in the ROR2 gene. There is no causative mutation identified for the autosomal dominant form. It is manifested with short limbs, abnormal facial features, underdeveloped genitalia, and wedge-shaped vertebrae.","Robinow Syndrome | ",,,,,,,,,,,,,,,"4297776","Robinow syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035828","Long QT Syndrome 1","C85049","An autosomal dominant condition caused by mutation(s) in the KCNQ1 gene, encoding potassium voltage-gated channel subfamily KQT member 1. It is characterized by a prolonged QT interval that may result in torsade de pointes, ventricular fibrillation and/or sudden cardiac death.","Long QT Syndrome 1 | LQT1 | Romano-Ward Syndrome | Romano-Ward Syndrome",,,,,,,,,,,,,,,"4049219","Romano-Ward syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019625","Rosai-Dorfman-Destombes Disease","C36075","A rare histiocytic disorder of unknown etiology, characterized by distention of the lymph node sinuses and sinusoidal histiocytic infiltration. The histiocytes characteristically contain ingested lymphocytes and are S100 and CD68 positive, and CD1a negative. Patients present with cervical lymphadenopathy, fever, leukocytosis, and hypergammaglobulinemia. It can affect extranodal sites, including skin, bones, and the respiratory tract. It occurs in isolation or may be associated with autoimmune disorders or malignancies. Mutations in NRAS, KRAS, MAP2K1, and ARAF genes have been identified in affected tissues, suggesting a clonal origin in some cases. It is a self-limited disorder, although some patients may have a poor prognosis.","Rosai-Dorfman-Destombes Disease | Destombes-Rosai-Dorfman Disease | RDD | Rosai-Dorfman Disease | Rosai-Dorfman Disease | SHML | Sinus Histiocytosis with Massive Lymphadenopathy | Sinus Histiocytosis with Massive Lymphadenopathy",,,,,,,,,,,,,,,"4046208|4142173|46272742","Sinus histiocytosis|Sinus histiocytosis with massive lymphadenopathy|Histiocytosis-lymphadenopathy plus syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C0032339","Rothmund-Thomson Syndrome","C3335","An autosomal recessive inherited syndrome usually caused by mutations in the RECQL4 gene. It is characterized by poikilodermatous skin changes, sparse hair, cataracts, small stature, skeletal abnormalities, and an increased predisposition to cancer, particularly osteosarcoma.","Rothmund-Thomson Syndrome | RTS | Rothmund Thomson Syndrome | Rothmund-Thompson Syndrome | Rothmund-Thomson syndrome",,,,,,,,,,,,,,,"4286355","Rothmund-Thomson syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035920","Rubella Infection","C85051","A viral infection caused by the rubella virus. It is initially manifested with flu-like symptoms that last one or two days, followed by the development of a characteristic red rash which lasts from one to five days. The rash first appears in the neck and face. It subsequently spreads to the rest of the body.","Rubella Infection | German Measles | Rubella | Three-Day Measles",,,,,,,,,,,,,,,"4273323","Rubella",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2346875","Alisertib","C71717","A second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Alisertib binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation. Aurora A kinase localizes to the spindle poles and to spindle microtubules during mitosis, and is thought to regulate spindle assembly. Aberrant expression of Aurora kinases occurs in a wide variety of cancers, including colon and breast cancers.","Alisertib | ALISERTIB | Aurora A Kinase Inhibitor MLN8237 | Aurora A Kinase Inhibitor MLN8237 | Benzoic Acid, 4-((9-Chloro-7-(2-Fluoro-6-Methoxyphenyl)-5H-Pyrimido(5,4-d)(2)Benzazepin-2-yl)Amino)-2-Methoxy- | MLN 8237 | MLN-8237 | MLN8237",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1541521","AMG 386","C91711","An angiopoietin (Ang) 1 and 2 neutralizing peptibody, with potential antiangiogenic activity. AMG 386 targets and binds to Ang1 and Ang2, thereby preventing the interaction of the angiopoietins with their target tie2 receptors. This may inhibit angiogenesis and may eventually lead to an inhibition of tumor cell proliferation.","Trebananib | AMG 386 | AMG-386 | AMG386 | Angiopoietin 1/2-Neutralizing Peptibody AMG 386 | Angiopoietin 1/2-Neutralizing Peptibody AMG 386 | TREBANANIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035934","Rubinstein-Taybi Syndrome","C75466","A rare genetic syndrome mapped to chromosome 16p13.3 and associated with mutations in the CREBBP gene. It is characterized by mental and growth retardation, distinctive facial features (prominent nose, low-set ears, microcephaly, and small mouth), and broad thumbs and great toes. Patients are at an increased risk of developing benign and malignant neoplasms, including nervous system neoplasms and malignant lymphoproliferative disorders.","Rubinstein-Taybi Syndrome | ",,,,,,,,,,,,,,,"4166857","Rubinstein-Taybi syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036161","Sandhoff Disease","C85052","An autosomal recessive inherited lysosomal storage disorder caused by mutations in the HEXB gene. It is characterized by deficiency of the enzyme hexosaminidase, resulting in the accumulation of gangliosides in the central nervous system and other body tissues. Signs and symptoms include progressive motor and mental deterioration, early blindness, macrocephaly, seizures, and hepatosplenomegaly.","Sandhoff Disease | Sandhoff disease",,,,,,,,,,,,,,,"4031489","Sandhoff disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036323","Schistosomiasis","C35000","A parasitic infection caused by flukes of the genus Schistosoma. Signs and symptoms include fever, abdominal pain, eosinophilia and hepatosplenomegaly. If left untreated it may eventually cause liver damage leading to cirrhosis, bladder cancer and kidney failure.","Schistosomiasis | Bilharzia | Liver Fluke Infestation | Snail Fever",,,,,,,,,,,,,,,"436038","Infection by Schistosoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL935576","Scimitar Syndrome","C85056","A rare congenital cardiopulmonary defect characterized by abnormal right-sided pulmonary venous drainage and right lung malformations.","Scimitar Syndrome | ",,,,,,,,,,,,,,,"4218874","Scimitar syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036413","Scleredema Adultorum","C85057","A usually benign and self-limited skin disorder of unknown etiology, characterized by induration of the skin. It may be associated with infection, diabetes mellitus, and hematologic malignancies. Morphologically, there is deposition of mucin in the dermis.","Scleredema Adultorum | ",,,,,,,,,,,,,,,"4319301","Scleredema",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0263390","Scleromyxedema","C85061","A rare chronic and progressive skin disorder characterized by mucin deposition in the skin, resulting in the thickening and hardening of the skin, predominantly in the face, fingers, and extremities.","Scleromyxedema | ",,,,,,,,,,,,,,,"4297661","Scleromyxedema",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036489","Sea-Blue Histiocyte Syndrome","C85062","A rare, inherited or acquired syndrome characterized by the presence of histiocytes in the bone marrow which contain granules stained blue with hematoxylin-eosin stain, mild thrombocytopenia and purpura, and splenomegaly.","Sea-Blue Histiocyte Syndrome | ",,,,,,,,,,,,,,,"4292862","Sea-blue histiocyte syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022603","Seborrheic Keratosis","C9006","A common benign neoplasm usually affecting older individuals. The lesions usually arise in the trunk, head and neck, but they can occur on any skin surface other than the palms, soles, and mucosal surfaces. They appear as flat-based papules or plaques. Histologically, there is intraepidermal proliferation of basaloid keratinocytes, acanthosis, hyperkeratosis, and cysts formation.","Seborrheic Keratosis | Basal Cell Papilloma | Keratosis Seborrheica",,,,,,,,,,,,,,,"40568467|4104248","Seborrheic keratosis|Seborrheic keratosis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2827583","Selective Antibody Deficiency with Normal Immunoglobulins","C85073","A rare syndrome characterized by deficiency of specific antibodies to polysaccharide antigens while the specific antibodies to protein antigens are normal.","Selective Antibody Deficiency with Normal Immunoglobulins | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0338503","Septo-Optic Dysplasia","C85063","A very rare congenital syndrome characterized by hypoplasia of the optic nerve, impaired vision, absence of the septum pellucidum and hypopituitarism.","Septo-Optic Dysplasia | De Morsier Syndrome | De Morsier syndrome | Septo-Optic Dysplasia Sequence",,,,,,,,,,,,,,,"4328365","Septo-optic dysplasia sequence",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1175175","Severe Acute Respiratory Syndrome","C85064","A viral respiratory infection caused by the SARS coronavirus. It is transmitted through close person-to-person contact. It is manifested with high fever, headache, dry cough and myalgias. It may progress to pneumonia and cause death.","Severe Acute Respiratory Syndrome | SARS",,,,,,,,,,,,,,,"320651","Severe acute respiratory syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206724","Sex Cord-Stromal Tumor","C3794","A neoplasm arising in the ovary or testis. It is composed of granulosa cells, Leydig cells, Sertoli cells, and fibroblasts. Each of these cell types may constitute the only cellular component that is present in the neoplasm or it may be mixed with other cell types in various combinations. The prognosis can not always be predicted on histologic grounds alone. Approximately, 10% of these tumors may metastasize. Representative examples include granulosa cell tumor, Leydig cell tumor, Sertoli cell tumor, and tumors of the thecoma-fibroma group.","Sex Cord-Stromal Tumor | Gonadal stromal tumor, NOS | Sex Cord-Stromal Neoplasm | sex cord tumor | sex cord-gonadal stromal tumor | sex cord-stromal tumor","8590/1","Sex cord-gonadal stromal tumor, NOS",,,,,,,,,,,,,"4019485","Specialized gonadal neoplasm",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0036996","Short Rib-Polydactyly Syndrome","C85065","A rare congenital lethal syndrome characterized by the presence of extra fingers and toes and short ribs, the latter resulting in inability of the lungs to expand. The newborn dies shortly after birth.","Short Rib-Polydactyly Syndrome | ",,,,,,,,,,,,,,,"4006937","Short rib polydactyly syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0342853","Sialic Acid Storage Disease","C85067","A rare, autosomal recessive lysosomal storage disease caused by mutations in the SLC17A5 gene. It primarily affects the nervous system. Signs and symptoms include developmental delay, intellectual disability, hypotonia, failure to thrive, seizures, and ataxia.","Sialic Acid Storage Disease | Salla Disease",,,,,,,,,,,,,,,"4031943","Sialuria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037023","Sialadenitis","C26882","An acute or chronic inflammatory process affecting a salivary gland. Signs and symptoms include pain and tenderness in the affected area.","Sialadenitis | Sialoadenitis",,,,,,,,,,,,,,,"29056","Sialoadenitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0175693","Russell-Silver Syndrome","C85068","A rare inherited growth disorder characterized by growth retardation, feeding difficulties, failure to thrive, facial abnormalities and asymmetry of limbs. Camptodactyly or clinodactyly may be present.","Russell-Silver Syndrome | Russell-Silver Dwarfism | Silver-Russell Dwarfism | Silver-Russell Syndrome | Silver-Russell Syndrome",,,,,,,,,,,,,,,"4034695","Russell-Silver syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL449045","Sinus Histiocytosis","C85069","A morphologic finding indicating the presence of histiocytic infiltrates within distended lymph node sinuses.","Sinus Histiocytosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037231","Sjogren-Larsson Syndrome","C85070","An autosomal recessive condition caused by mutation(s) in the ALDH3A2 gene, encoding fatty aldehyde dehydrogenase. It is a characterized by dry and scaly skin, neurological dysfunction and mild to moderate intellectual disability.","Sjogren-Larsson Syndrome | Fatty Aldehyde Dehydrogenase Deficiency",,,,,,,,,,,,,,,"4006297","Sjögren-Larsson syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0549567","Skin Pigmentation Disorder","C34557","A disorder of the skin characterized by loss or reduction of the skin color. It is caused by loss of melanocytes or abnormalities in melanin production.","Skin Pigmentation Disorder | Pigmentation Disorders",,,,,,,,,,,,,,,"4188191","Disorder of skin pigmentation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0175694","Smith-Lemli-Opitz Syndrome","C85071","A rare, autosomal recessive syndrome caused by mutations in the DHCR7 gene. It is characterized by deficiency of the enzyme 3 beta-hydroxysterol-delta 7-reductase resulting in defects in the cholesterol synthesis. It is manifested with multiple congenital malformations, including facial abnormalities, microcephaly, and syndactyly. Behavioral abnormalities may also be present.","Smith-Lemli-Opitz Syndrome | ",,,,,,,,,,,,,,,"4185410","Smith-Lemli-Opitz syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152116","Spasmodic Torticollis","C85072","A rare movement disorder of unknown etiology, characterized by painful, involuntary turns of the head to the right, left, upwards, or downwards.","Spasmodic Torticollis | Cervical Dystonia",,,,,,,,,,,,,,,"376387","Spasmodic torticollis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2751038","Speech Disorder","C5041","A term referring to disorders characterized by the disruption of normal speech. It includes stuttering, lisps, dysarthria and voice disorders.","Speech Disorder | Speech And Language Deficits | Speech Manifestations | Speech impediment or impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0553720","Spherocytosis","C85074","A hereditary or acquired blood disorder characterized by the presence of smaller than normal, sphere-shaped erythrocytes. It results in hemolytic anemia and splenomegaly.","Spherocytosis | ",,,,,,,,,,,,,,,"4066047","Spherocytosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026847","Spinal Muscular Atrophy","C85075","An inherited disorder characterized by degeneration of the spinal cord and the cerebellum. Symptoms may appear at any age and include progressive loss of coordination of gait, hands, speech, and eye movements.","Spinal Muscular Atrophy | Spinal muscular atrophy, unspecified",,,,,,,,,,,,,,,"372605","Spinal muscular atrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0700595","Spinal Muscular Atrophy of Childhood","C85076","A group of congenital neurodegenerative disorders affecting motor neurons, resulting in muscle weakness and atrophy in childhood. Signs and symptoms include hypotonia, difficulty breathing, poor feeding, and flaccid quadriplegia.","Spinal Muscular Atrophy of Childhood | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3806753","Spinocerebellar Ataxia","C82341","An inherited disorder characterized by degeneration of the spinal cord and the cerebellum.  Symptoms may appear at any age and include progressive loss of coordination of gait, hands, speech, and eye movements.","Spinocerebellar Ataxia | Spinocerebellar Degeneration",,,,,,,,,,,,,,,"4305294","Spinocerebellar ataxia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038165","Staphylococcal Scalded Skin Syndrome","C85077","A blistering skin disorder caused by exfoliative toxins produced by Staphylococcus aureus infection. The toxins cause the formation of bullae and diffuse skin desquamation. The lesions may be localized or generalized, far away from the initial site of infection.","Staphylococcal Scalded Skin Syndrome | ",,,,,,,,,,,,,,,"132392","Staphylococcal scalded skin syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0271093","Stargardt Disease","C85078","An autosomal recessive and rarely autosomal dominant inherited disorder caused by mutations in the ABCA4 or ELOVL4 genes respectively. It is characterized by macular degeneration that begins in late childhood resulting in progressive loss of vision.","Stargardt Disease | ",,,,,,,,,,,,,,,"4289290","Stargardt's disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4228131","Status Epilepticus","C85079","A life-threatening situation in which the brain is in a continuous state of seizure.","Status Epilepticus | ",,,,,,,,,,,,,,,"4332304","Status epilepticus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085292","Stiff Person Syndrome","C85170","A rare neurologic disorder characterized by muscle rigidity. It usually affects the axial muscles and eventually extends to the proximal limb muscles. It is associated with muscle spasms which may lead to muscle damage and fractures.","Stiff Person Syndrome | Stiff-Person Syndrome | Stiff-man syndrome",,,,,,,,,,,,,,,"379008","Stiff-person syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038522","Subacute Sclerosing Panencephalitis","C85171","A rare, slowly progressive post-infectious neurological disorder affecting the central nervous system. It is characterized by seizures, ataxia, myoclonus, personality changes, spasticity, and coma. The symptoms appear several years following measles infection at an early age.","Subacute Sclerosing Panencephalitis | SSPE",,,,,,,,,,,,,,,"373408","Subacute sclerosing panencephalitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3276100","Subvalvular Aortic Stenosis","C85172","An aortic stenosis caused by fibromuscular stenosis or hypertrophic cardiomyopathy. It may be associated with congenital heart defects.","Subvalvular Aortic Stenosis | ",,,,,,,,,,,,,,,"4069183","Subaortic stenosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038644","Sudden Infant Death Syndrome","C85173","Unexpected death in infancy which remains unexplained following autopsy, review of the medical history, and investigation of the death circumstances and death scene.","Sudden Infant Death Syndrome | SIDS | crib death | sudden infant death syndrome",,,,,,,,,,,,,,,"435937","Sudden infant death syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1262087","SUNCT Syndrome","C85174","A rare disorder characterized by episodes of short-lasting pain in one eye or one side of the head. The pain attacks are associated with watery eyes, swelling of the eyelids, sweaty forehead, and nasal congestion.","SUNCT Syndrome | Short-lasting Unilateral Neuralgiform Headache with Conjunctival Injection and Tearing Syndrome",,,,,,,,,,,,,,,"37110728","Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038828","Superior Mesenteric Artery Syndrome","C85175","A very rare syndrome characterized by compression of the third portion of the duodenum against the aorta. The compression is caused by the superior mesenteric artery. It results in complete or partial duodenal obstruction. Signs and symptoms include nausea, vomiting, abdominal pain and distention, failure to gain weight, and weight loss.","Superior Mesenteric Artery Syndrome | ",,,,,,,,,,,,,,,"4057687","Superior mesenteric artery syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003499","Supravalvular Aortic Stenosis","C85176","A rare, congenital or acquired aortic stenosis characterized by localized or diffuse narrowing of the ascending aorta.","Supravalvular Aortic Stenosis | ",,,,,,,,,,,,,,,"4147787","Supravalvar aortic stenosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085077","Sweet Syndrome","C85177","A rare syndrome characterized by fever, skin papules and plaques, and leukocytosis. Morphologically, the skin lesions show neutrophilic infiltrates and dermal edema. It may occur in the absence of underlying conditions. It may also be associated with the presence of cancer or may be a side effect of medications.","Sweet Syndrome | ",,,,,,,,,,,,,,,"4225434","Acute febrile neutrophilic dermatosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0264395","Swyer James Syndrome","C85178","A rare syndrome characterized by the presence of a small lung as a result of unilateral post-infectious bronchiolitis obliterans.","Swyer James Syndrome | Swyer-James-MacLeod Syndrome | Unilateral Hyperlucent Lung | Unilateral pulmonary emphysema [MacLeod's syndrome]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4228165","Syringomyelia","C85179","A rare disorder characterized by the formation of a cyst in the spinal cord. It results in weakness, pain, and stiffness in the shoulders, arms, legs, or back. It may be associated with Chiari malformation. Other causes include spinal cord injury, inflammation, or tumor.","Syringomyelia | SYRINGOMYELIA",,,,,,,,,,,,,,,"4009653","Syringomyelia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221013","Systemic Mastocytosis","C9235","Systemic infiltration of extracutaneous sites by clonal mast cells, with or without evidence of skin involvement.","Systemic Mastocytosis | Systemic Tissue Mast Cell Disease | Systemic mastocytosis | Systemic mastocytosis, NOS | Systemic tissue mast cell disease | systemic mastocytosis",,,,,,,,,,,,,,,"37153959|4246284","Systemic mastocytosis|Systemic mast cell disease",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0039223","Tabes Dorsalis","C35057","A form of neurosyphilis characterized by slowly progressive degeneration of the spinal cord. Signs and symptoms include pain, ataxia, loss of coordination, personality changes, blindness, urinary incontinence, dementia, and degeneration of the joints.","Tabes Dorsalis | ",,,,,,,,,,,,,,,"4201172","Tabetic neurosyphilis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039254","Taeniasis","C85180","A parasitic infection caused by tapeworms of the genus Taenia. Humans are infected by eating undercooked or raw meat of infected animals. It is usually an asymptomatic infection and patients may become aware of the infection by noticing segments of the tapeworm in their feces. If symptoms are present, they include nausea, abdominal pain, indigestion, constipation, or diarrhea.","Taeniasis | ",,,,,,,,,,,,,,,"433135","Infection by Taenia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1739395","Takotsubo Cardiomyopathy","C85181","A rare disorder characterized by transient left ventricular wall systolic dysfunction, resulting in apical ballooning appearance, chest pain, and ST segment elevation.","Takotsubo Cardiomyopathy | Broken-heart Syndrome | TTS | Tako-Tsubo Cardiomyopathy | Takotsubo Syndrome | Takotsubo syndrome",,,,,,,,,,,,,,,"40479589","Takotsubo cardiomyopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039292","Tangier Disease","C85182","A rare, autosomal recessive inherited disorder of cholesterol transport, resulting in severe reduction of the amount of high density lipoprotein in the plasma and accumulation of cholesterol esters in the tissues. Signs and symptoms include large tonsils, hepatosplenomegaly, lymphadenopathy, and hypocholesterolemia.","Tangier Disease | ",,,,,,,,,,,,,,,"37118965","Tangier disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039319","Tarsal Tunnel Syndrome","C85183","A syndrome resulting from the entrapment and compression of the tibial nerve. Signs and symptoms include burning sensation, tingling, and pain in the foot sole.","Tarsal Tunnel Syndrome | ",,,,,,,,,,,,,,,"192885","Tarsal tunnel syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039373","Tay-Sachs Disease","C85184","A rare, fatal, autosomal recessive lipid storage disorder caused by mutations in the HEXA gene. It is characterized by deficiency of beta-hexosaminidase A, resulting in accumulation of gangliosides in the neurons of the brain and spinal cord. Signs and symptoms include progressive deterioration of the mental and physical abilities early in life, accompanied by blindness, deafness, muscle atrophy, and paralysis.","Tay-Sachs Disease | Tay Sachs Disease | Tay-Sachs disease",,,,,,,,,,,,,,,"4009170","Tay-Sachs disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039585","Androgen Insensitivity Syndrome","C27226","A disorder of sexual development in persons with 46XY karyotype, characterized by an abnormality of the genes encoding androgen receptors. It results in a female sex appearance or the development of both male and female characteristics.","Androgen Insensitivity Syndrome | Androgen Resistance Syndrome | Testicular Feminization Syndrome",,,,,,,,,,,,,,,"440359","Androgen resistance syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039614","Tetanus","C85185","A serious infectious disorder that follows wound contamination by the Gram-positive bacterium Clostridium tetani. The bacteria produce a neurotoxin called tetanospasmin, which causes muscle spasm in the jaw and other anatomic sites.","Tetanus | ",,,,,,,,,,,,,,,"435740","Tetanus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039726","Thalamic Disease","C85186","A disorder of the thalamus. Causes include brain neoplasms, cerebrovascular disorders, brain trauma, brain hypoxia, infections, and brain hemorrhage. Signs and symptoms include movement and sensory abnormalities, visual abnormalities, ataxia, and coma.","Thalamic Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002875","Thalassemia Major","C34375","An autosomal recessive disorder that affects the production of beta polypeptide chains which are necessary for the hemoglobin synthesis. Anemia and failure to thrive are characteristic features.","Beta Thalassemia | Thalassemia Major | Thalassemia Major",,,,,,,,,,,,,,,"4327045","Thalassemia major",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039743","Thanatophoric Dysplasia","C85187","A severe autosomal dominant inherited disorder caused by mutations in the FGFR3 gene. It is characterized by multiple skeletal abnormalities, including extremely short limbs. It results in the death of the neonate.","Thanatophoric Dysplasia | ",,,,,,,,,,,,,,,"4164551","Thanatophoric dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039984","Thoracic Outlet Syndrome","C85188","A syndrome resulting from the compression of the blood vessels or nerves in the space between the clavicle and first rib (thoracic outlet). It is caused by car accident injuries or repetitive job or sport-related injuries. Signs and symptoms include pain in the shoulders and neck, numbness in the fingers, and weakening grip.","Thoracic Outlet Syndrome | ",,,,,,,,,,,,,,,"4027534","Thoracic outlet syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040124","Thyroglossal Duct Cyst","C85189","A congenital benign cyst arising from the remnants of the thyroglossal duct. It is usually located in the midline of the neck.","Thyroglossal Duct Cyst | Thyroglossal Cyst | Thyrolingual Cyst",,,,,,,,,,,,,,,"4215136","Thyroglossal duct cyst",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1563716","Thyroid Dysgenesis","C85190","A congenital condition characterized by hypoplasia, absence, or ectopic position of the thyroid gland. It is manifested with congenital hypoparathyroidism.","Thyroid Dysgenesis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2937288","Thyroid Hormone Resistance Syndrome","C85191","A rare, autosomal recessive inherited disorder usually caused by mutations in the THRB gene. It is characterized by a defective physiological resistance to thyroid hormones, resulting in the elevation of thyroxin and triiodothyronine in the serum.","Thyroid Hormone Resistance Syndrome | Thyroid Hormone Resistance",,,,,,,,,,,,,,,"4030054","Thyroid hormone resistance syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040361","Togaviridae Infection","C85192","A viral infection caused by any of the arboviruses of the Togaviridae family. It is transmitted by arthropods. Signs and symptoms include fever, headache, nausea, vomiting, rash, confusion, and seizures.","Togaviridae Infection | ",,,,,,,,,,,,,,,"4141878","Disease due to Togaviridae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040381","Tolosa-Hunt Syndrome","C85193","A disorder characterized by unilateral acute orbital pain associated with muscle weakness or paralysis of the orbital muscles. It is caused by non-specific inflammation of the cavernous sinus or superior orbital fissure.","Tolosa-Hunt Syndrome | ",,,,,,,,,,,,,,,"4317989","Tolosa-Hunt syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0542241","Bacterial Toxemia","C50780","The condition resulting from the spread of bacterial products (toxins) by the bloodstream.","Bacterial Toxemia | Toxemia | toxemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040553","Toxocariasis","C85194","A parasitic infection caused by Toxocara. Humans are infected by the larvae of Toxocara canis and Toxocara cati from dogs and cats respectively. Most cases remain asymptomatic. The parasites may affect the eye, causing diminished vision, or other major organs, causing hepatomegaly, eosinophilia, wheezing, and coughing.","Toxocariasis | ",,,,,,,,,,,,,,,"432249","Infection due to Toxocara",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0340231","Tracheobronchomalacia","C85195","A rare congenital or acquired disorder characterized by excessive collapsibility of the trachea and major bronchi resulting in breathing problems. It is caused by damage to the tracheobronchial cartilage.","Tracheobronchomalacia | ",,,,,,,,,,,,,,,"4124675","Tracheobronchomalacia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040587","Tracheobronchomegaly","C85196","A rare syndrome of unknown etiology, characterized by marked dilatation of the lumen of the trachea and the main bronchi. It results in bronchiectasis and recurrent lung infections.","Tracheobronchomegaly | Mounier-Kuhn Syndrome",,,,,,,,,,,,,,,"4239007","Congenital tracheobronchomegaly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0338591","Transient Global Amnesia","C85198","A condition characterized by sudden, temporary, usually short-lived memory loss, not associated with a neurologic disorder. Affected individuals lose memory function for recent events and have a decreased ability to retain new information. It is usually a solitary event.","Transient Global Amnesia | Transient global amnesia",,,,,,,,,,,,,,,"437306","Transient global amnesia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4229856","Treacher Collins Syndrome","C75018","A rare autosomal dominant syndrome caused by mutations in the TCOF1 gene. Its characteristics include underdevelopment of the facial bones, small jaw and chin, absent or small ears, defects in the middle ear resulting in hearing loss, and downward sloping palpebral fissures.","Treacher Collins Syndrome | Mandibulofacial Dysostosis",,,,,,,,,,,,,,,"4304838","Treacher Collins syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040843","Treponemal Infection","C85197","A sexually transmitted infection caused by the Gram-negative spirochete Treponema pallidum. It is manifested as syphilis.","Treponemal Infection | Treponema pallidum",,,,,,,,,,,,,,,"436033","Syphilis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040896","Trichinosis","C85199","A parasitic infection caused by larvae of worms of the genus Trichinella. It is transmitted to humans by ingesting raw or undercooked meat from infected animals. Signs and symptoms include abdominal discomfort, nausea, vomiting, fever, diarrhea, headache, coughing, myalgias, arthralgias, and eye swelling.","Trichinosis | Trichinellosis",,,,,,,,,,,,,,,"46271001","Infection by larvae of Trichinella",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023003","Trichorhinophalangeal Syndrome Type II","C75118","A rare, usually sporadic and less frequently familiar syndrome caused by deletions on the long arm of chromosome 8. It is characterized by distinctive facial appearance (sparse hair, pear-shaped nose, and large ears), multiple exostoses, redundant skin, and mental retardation.","Trichorhinophalangeal Syndrome Type II | Langer-Giedion Syndrome",,,,,,,,,,,,,,,"4165567","Langer-Giedion syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1955934","Trichothiodystrophy","C4924","A rare, autosomal recessive inherited syndrome characterized by brittle hair, mental and physical retardation, and decreased fertility.","Trichothiodystrophy | Trichothiodystrophy Syndrome | trichothiodystrophy",,,,,,,,,,,,,,,"37109718","Trichothiodystrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0243002","Tricuspid Valve Atresia","C85202","A congenital heart defect characterized by the complete lack of formation of the tricuspid valve. Cyanosis is the predominant clinical symptom.","Tricuspid Valve Atresia | Congenital Atresia of Tricuspid Valve | Tricuspid Atresia | Tricuspid Atresia",,,,,,,,,,,,,,,"4101606|4269199","Right atrioventricular valve atresia|Congenital atresia of tricuspid valve",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0158328","Trigger Finger Disorder","C85203","A painful hand deformity affecting the fingers. It is due to damage of the finger flexor tendons, causing the finger to remain in a locked position.","Trigger Finger Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333693","Triploidy Syndrome","C85204","A very rare congenital syndrome characterized by the presence of three haploid sets of chromosomes. The surviving infants have multiple severe birth defects.","Triploidy Syndrome | Triploid Syndrome",,,,,,,,,,,,,,,"4282915","Triploidy syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0432408","Trisomy 12","C36420","A chromosomal abnormality consisting of the presence of a third copy of chromosome 12 in somatic cells.","Trisomy 12 | ",,,,,,,,,,,,,,,"4004641","Trisomy 12",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041182","Trophoblastic Tumor","C3422","A gestational or non-gestational neoplasm characterized by excessive proliferation of trophoblastic cells.","Trophoblastic Tumor | Trophoblastic Neoplasm | Trophoblastic Neoplasms | Trophoblastic neoplasms",,,,,,,,,,,,,,,"4019490","Trophoblastic neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4230993","True Hermaphroditism","C85207","A rare condition characterized by the unequivocal presence of both testicular and ovarian tissues in an individual. It is usually manifested with ambiguous external genitalia.","True Hermaphroditism | HERMAPHRODITISM | OVOTESTIS",,,,,,,,,,,,,,,"605298","Ovotestis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041351","Tularemia","C85208","A serious Gram-negative bacterial infection caused by Francisella tularensis. It is transmitted to humans through bites from infected insects, inhaling airborne bacteria, handling infected animals, or consuming contaminated food or water. Signs and symptoms include skin ulcers, mouth sores, lymphadenopathy, sore throat, fever and pneumonia.","Tularemia | ",,,,,,,,,,,,,,,"441781","Tularemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041408","Turner Syndrome","C26900","A gonadal dysgenesis syndrome occurring in phenotypic females, characterized by the absence of a part or all of one of the sex chromosomes. Signs and symptoms include short stature, webbing of neck, low-set ears, hypogonadism, and sterility.","Turner Syndrome | 45,X Gonadal Dysgenesis | 45,X0 Syndrome | 45X Syndrome | Bonnevie-Ullrich Syndrome | Gonadal Dysgenesis | Monosomy X | Turner syndrome | Ullrich-Turner Syndrome",,,,,,,,,,,,,,,"4307885","Turner syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0949628","Uniparental Disomy","C85215","A condition characterized by the inheritance of a chromosome pair from one parent and no chromosomal copies from the other parent. It results in developmental abnormalities or rare recessive disorders. Examples of uniparental disomy include the Prader-Willi syndrome and Angelman syndrome.","Uniparental Disomy | ",,,,,,,,,,,,,,,"37111459","Uniparental disomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042111","Urticaria Pigmentosa/Maculopapular Cutaneous Mastocytosis","C3433","The most frequent form of cutaneous mastocytosis.  In children, the lesions tend to be papular, and are characterized by aggregates of elongated or spindle-shaped mast cells which fill the papillary dermis and extend into the reticular dermis.  In adults, the lesions tend to have fewer mast cells compared to those in children.  The lesions are located most commonly on the trunk, but they can be seen on the extremities, head and neck. (WHO, 2001)","Urticaria Pigmentosa/Maculopapular Cutaneous Mastocytosis | UP/MPCM | Urticaria Pigmentosa | Urticaria pigmentosa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0271097","Usher Syndrome","C85217","A rare, autosomal recessive inherited syndrome caused by mutations in the CDH23, CLRN1, GPR98, MYO7A, PCDH15, USH1C, USH1G, and USH2A genes. It is characterized by hearing loss or deafness and progressive loss of vision. The loss of vision is the result of retinitis pigmentosa.","Usher Syndrome | ",,,,,,,,,,,,,,,"4240613","Retinitis pigmentosa-deafness syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042170","Uveomeningoencephalitic Syndrome","C85218","A systemic inflammatory process affecting the inner ear, eyes, skin, and meninges. It is manifested with hearing disorders, panuveitis, alopecia, poliosis, vitiligo, neck stiffness, headaches, and focal neurologic signs.","Uveomeningoencephalitic Syndrome | Vogt-Koyanagi-Harada Syndrome",,,,,,,,,,,,,,,"4108968","Vogt-Koyanagi-Harada disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162532","Variegate Porphyria","C85219","An autosomal dominant disorder of porphyria-heme metabolism. It is manifested with acute attacks including abdominal pain, vomiting, diarrhea, constipation, seizures, anxiety, and confusion. Patients may experience skin sensitivity to sunlight.","Variegate Porphyria | ",,,,,,,,,,,,,,,"4238505","Variegate porphyria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011269","Vascular Dementia","C34525","A degenerative vascular disorder affecting the brain. It is caused by the blockage of the blood supply to the brain. It is manifested with decline of memory and cognitive functions.","Vascular Dementia | ",,,,,,,,,,,,,,,"443605","Vascular dementia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011993","VIP-Producing Neuroendocrine Tumor","C26749","An often clinically aggressive neuroendocrine tumor located in the pancreas or small intestine.  It is composed of cells containing vasoactive intestinal peptide.  It may cause intractable diarrhea and metabolic disturbances.","VIP-Producing Neuroendocrine Tumor | VIP Producing Neoplasm | VIP Producing Tumor | VIP- Secreting Neoplasm | VIP- Secreting Tumor | VIP-Producing NET | VIPoma | Vasoactive Intestinal Peptide Producing Neoplasm | Vasoactive Intestinal Peptide Producing Tumor | Vasoactive Intestinal Peptide Secreting Neoplasm | Vipoma, NOS",,,,,,,,,,,,,,,"4098951","Vasoactive intestinal peptide-secreting tumor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023049","Visceral Larva Migrans","C34758","A parasitic infection caused by worms found in domestic animals. In humans nematode larvae enter the portal system from the small intestine and disseminate in visceral organs causing inflammatory reactions. Signs and symptoms include eosinophilia, hepatomegaly, splenomegaly, and lung infections.","Visceral Larva Migrans | ",,,,,,,,,,,,,,,"4314427","Visceral larva migrans syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042842","Vitamin A Deficiency","C85220","Deficiency of vitamin A due to malnutrition, malabsorption, or dietary lack. It is manifested with reduced night vision, night blindness, and xerophthalmia.","Vitamin A Deficiency | ",,,,,,,,,,,,,,,"438114","Vitamin A deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0936215","Vitamin B6 Deficiency","C85221","Deficiency of vitamin B6. It is usually caused by alcoholism, malabsorption, or as a side effect of medications. Signs and symptoms include stomatitis, glossitis, dermatitis, peripheral neuropathy, irritability, seizures, and anemia.","Vitamin B6 Deficiency | Pyridoxine Deficiency | Pyridoxine Deficincy",,,,,,,,,,,,,,,"435787","Vitamin B6 deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1264041","von Willebrand Disease, Type 3","C85213","The most severe form of von Willebrand disease, inherited in an autosomal recessive pattern. It is characterized by marked deficiency or absence of von Willebrand factor in the plasma and platelets, and low plasma levels of factor VIII. It may cause severe bleeding.","von Willebrand Disease, Type 3 | ",,,,,,,,,,,,,,,"4133986","Hereditary von Willebrand disease type 3",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3266898","Waardenburg Syndrome","C85222","A rare, autosomal dominant inherited syndrome caused by mutations in the PAX3, MITF, and SNAI2 genes. Signs and symptoms include hearing loss, dystopia canthorum (widely spaced inner corners of the eyes), and changes in the color of the skin, hair, and eyes.","Waardenburg Syndrome | Waardenburg's Syndrome",,,,,,,,,,,,,,,"4170892","Waardenburg syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043020","Wallerian Degeneration","C85223","A condition caused by degeneration, atrophy, and destruction of the distal part of a nerve fiber's axon and myelin, when continuity with the neural cell nucleus has been severed due to injury. Signs and symptoms include muscle weakness, altered sensation, and limb numbness.","Wallerian Degeneration | ",,,,,,,,,,,,,,,"4263767","Wallerian degeneration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0272414","Wandering Spleen","C85224","A condition characterized by an abnormal spleen position due to loss, weakness, or malformation of one or more of the ligaments that hold the spleen in its normal position in the left upper abdomen. It may present as a birth defect or follow injuries or pregnancy. Signs and symptoms include abdominal discomfort and splenomegaly.","Wandering Spleen | ",,,,,,,,,,,,,,,"4100245","Wandering spleen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043068","Waterhouse-Friderichsen Syndrome","C85225","A serious disorder characterized by massive adrenal gland hemorrhage secondary to a bacterial infection, most often Neisseria meningitidis infection. It is manifested with decreased blood pressure, shock, disseminated intravascular coagulation, and adrenocortical insufficiency.","Waterhouse-Friderichsen Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0265313","Weill-Marchesani Syndrome","C85226","A rare, autosomal recessive or dominant inherited connective tissue disorder. The autosomal recessive variant is caused by mutations in the ADAMTS10 gene. It is characterized by abnormalities in the lens of the eye, short stature, brachydactyly, and joint stiffness.","Weill-Marchesani Syndrome | ",,,,,,,,,,,,,,,"4103383","Weill-Marchesani syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0349464","Wernicke-Korsakoff Syndrome","C35764","A syndrome caused by thiamine deficiency. It usually occurs in alcoholics and is characterized by confusion, ataxia, and ophthalmoplegia.","Wernicke-Korsakoff Syndrome | Wernicke Encephalopathy",,,,,,,,,,,,,,,"4288013","Korsakoff's psychosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037769","West Syndrome","C84788","A rare autosomal recessive inherited neurodegenerative disorder caused by mutations in the PLA2G6 gene. It is characterized by the development of swellings called spheroids along the axons of the central nervous system. Signs and symptoms appear early in life and include movement difficulties, muscle hypotonia and spasticity, and cognitive dysfunction.","West Syndrome | ",,,,,,,,,,,,,,,"376105","West syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153064","Western Equine Encephalomyelitis","C85227","A mosquito-born viral infection caused by the Western equine encephalitis virus. The signs and symptoms range from flu-like illness to permanent central nervous system damage, coma, and death.","Western Equine Encephalomyelitis | ",,,,,,,,,,,,,,,"380942","Western equine encephalitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023788","Whipple Disease","C85228","A systemic infection caused by the Gram-positive bacterium Tropheryma whipplei. It affects the small intestine resulting in malabsorption. Other sites or systems affected by the infection are the joints, central nervous system, and the cardiovascular system.","Whipple Disease | Whipple's Disease",,,,,,,,,,,,,,,"197782","Whipple's disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043167","Whooping Cough","C85231","A contagious bacterial respiratory infection caused by Bordetella pertussis. It is characterized by severe and uncontrollable cough, resulting in a whooping sound during breathing following the cough.","Whooping Cough | Pertussis | pertussis | whooping cough",,,,,,,,,,,,,,,"257778","Pertussis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0175702","Williams Syndrome","C85232","A rare syndrome caused by multiple gene deletions from a region of chromosome 7, including the deletion of CLIP2, ELN, GTF2I, GTF2IRD1 and LIMK1 genes. It is characterized by distinctive facial appearance (elfin facies), mild-to-moderate mental retardation, cheerfulness, cardiovascular abnormalities and infantile hypercalcemia.","Williams Syndrome | Williams syndrome | Williams-Beuren Syndrome | Williams-Beuren Syndrome (WBS)",,,,,,,,,,,,,,,"4268609","Williams syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206115","WAGR Syndrome","C3718","A syndrome characterized by a predisposition for Wilms tumor, aniridia, genitourinary anomalies, and developmental delay. This is a contiguous gene syndrome due to deletion in the vicinity of chromosome 11p13 in a region containing the WT1 and PAX6 genes.","WAGR Syndrome | 11p Partial Monosomy Syndrome | WAGR Syndrome | WAGR syndrome | Wagr Syndrome | Wilms Tumor, Aniridia, Genitourinary Anomalies and Developmental Delay Syndrome | Wilms Tumor-Aniridia-Genitourinary Anomalies-Mental Retardation Syndrome | Wilms Tumor-Aniridia-Genitourinary Anomalies-Mental Retardation Syndrome | Wilms tumor-aniridia-genitourinary anomalies-mental retardation syndrome",,,,,,,,,,,,,,,"37399431","WAGR syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1956097","Wolf-Hirschhorn Syndrome","C35528","A genetic syndrome resulting from a partial deletion on the short arm of chromosome 4 (4p deletion syndrome). It is characterized by mental retardation, microcephaly, seizures, muscle hypotonia, a distinctive facial appearance with prominent forehead and wide set eyes, growth failure with malformations of the spine, hands, and feet, congenital heart defects, and genitourinary malformations.","Wolf-Hirschhorn Syndrome | 4p Deletion Syndrome",,,,,,,,,,,,,,,"37397559|4062498","Wolf Hirschhorn syndrome|4p partial monosomy syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0043207","Wolfram Syndrome","C35133","A rare inherited syndrome caused by mutations in the WFS1 and CISD2 genes. It is characterized by diabetes insipidus, diabetes mellitus, optic atrophy, and deafness.","Wolfram Syndrome | DIDMOAD | Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy, and Deafness Syndrome",,,,,,,,,,,,,,,"4322638","Wolfram syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043346","Xeroderma Pigmentosum","C3452","An inherited skin disorder characterized by photosensitivity with severe sunburn in infancy, the development of numerous pigmented spots resembling freckles, larger atrophic lesions associated with telangiectasis, and multiple solar keratoses. Transmitted in an autosomal recessive manner, xeroderma pigmentosa involves a defect in nucleotide excision repair (NER), leading to deficient repair of DNA damaged by UV radiation and chromosome breakage. Individuals with this disease develop multiple malignant cutaneous neoplasms at an early age and may suffer from severe ophthalmic and neurologic abnormalities.","Xeroderma Pigmentosum | Angioma Pigmentosum Atrophicum | Atrophoderma Pigmentosum | Kaposi Dermatosis | Kaposi Disease | Melanosis Lenticularis Progressiva | Pigmented Epitheliomatosis | Xeroderma Pigmentosum Syndrome | Xeroderma of Kaposi | xeroderma pigmentosum",,,,,,,,,,,,,,,"4195318","Xeroderma pigmentosum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1839259","Spinal and Bulbar Muscular Atrophy, X-linked 1","C85233","A rare, slowly progressive degenerative disorder affecting males. It is caused by mutations in the androgen receptor (AR) gene. It is characterized by bulbar and limb muscle weakness and atrophy, and gynecomastia.","Spinal and Bulbar Muscular Atrophy, X-linked 1 | Kennedy Disease | SBMA | SMAX1 | Spinal and Bulbar Muscular Atrophy | X-Linked Bulbar-Muscular Atrophy",,,,,,,,,,,,,,,"4047740","Bulbospinal neuronopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0733682","Hypophosphatemic Rickets, X-Linked Dominant","C85234","An X-linked dominant disorder caused by mutations in the PHEX gene. It is characterized by growth retardation, osteomalacia, hypophosphatemia, and defects in the renal reabsorption of phosphorus.","X-Linked Dominant Hypophosphatemic Rickets | Hereditary 1,25(OH)2D-resistant Rickets | Hypophosphatemic Vitamin D-resistant Rickets | Vitamin D-resistant Rickets | X-Linked Hypophosphatemia | X-linked Dominant Hypophosphatemic Rickets | X-linked Hypophosphatemic Rickets",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079588","X-Linked Ichthyosis","C84779","The second most common form of ichthyosis. It is an X-linked inherited disorder with mild skin manifestations. The skin changes appear at birth and include keratinization and scaling.","X-Linked Ichthyosis | Ichthyosis, X-linked",,,,,,,,,,,,,,,"4219258","X-linked ichthyosis with steryl-sulfatase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242526","XO Syndrome","C85210","A gonadal dysgenesis syndrome occurring in phenotypic females, characterized by the complete absence of one of the sex chromosomes. Signs and symptoms include short stature and hypogonadism.","XO Syndrome | Turner Syndrome (XO Syndrome)",,,,,,,,,,,,,,,"46271763","Monosomy X",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827598","XXXY and XXXXY Syndrome","C85236","Rare syndromes caused by chromosomal defects and characterized by the presence of multiple X chromosomes and one Y chromosome. Signs and symptoms include short stature, mental retardation, hypogonadism, undescended testes, gynecomastia, and hypotonia.","XXXY and XXXXY Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL358892","47,XYY Syndrome","C85237","A condition caused by the presence of an extra Y chromosome resulting in 47,XYY karyotype in an individual with male phenotype. The condition is characterized by tall stature, increased risk of learning disabilities, and delayed development of speech and language. Testicular function and size are normal.","47,XYY Syndrome | 47,XYY | XYY Syndrome | XYY Syndrome",,,,,,,,,,,,,,,"4176135","Double Y syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043388","Yaws","C41353","An endemic, infectious, nonvenereal disease in humans that presents mainly in children younger than 15 years. The disease occurs primarily in warm, humid, tropical areas of Africa, Asia, South America, and Oceania, among poor rural populations where conditions of overcrowding and poor sanitation prevail. Infection with Treponema pertenue, a subspecies of Treponema pallidum, causes the disease.","Yaws | ",,,,,,,,,,,,,,,"432829","Yaws",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043395","Yellow Fever Virus Infection","C35547","A viral infection caused by a flavivirus called yellow fever virus. It is transmitted to humans from infected mosquitoes. The signs and symptoms range from a mild febrile illness to liver damage with jaundice and hemorrhages.","Yellow Fever Virus Infection | Yellow Fever | yellow fever",,,,,,,,,,,,,,,"441210","Yellow fever",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221348","Yellow Nail Syndrome","C85238","A rare syndrome characterized by the presence of thickened yellow nails, lymphedema, and respiratory abnormalities, including pleural effusion, bronchiectasis, chronic sinusitis, and persistent cough. Some cases are associated with mutations in the FOXC2 gene.","Yellow Nail Syndrome | ",,,,,,,,,,,,,,,"4271140","Hereditary lymphedema and yellow nails",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043459","Zellweger Syndrome","C85239","A rare group of autosomal recessive inherited disorders characterized by the reduction or absence of peroxisomes in the tissues. Signs and symptoms include increased levels of iron and copper in the blood and tissues, hepatomegaly, facial abnormalities, mental retardation, seizures, and hypotonia.","Zellweger Syndrome | ",,,,,,,,,,,,,,,"4228533","Zellweger syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043515","Zollinger Ellison Syndrome","C3453","A syndrome characterized by the presence of a gastrin-secreting tumor, usually in the pancreas or duodenum, resulting in increased gastric acidity and formation of gastric ulcers. Signs and symptoms include abdominal pain and diarrhea. It may be sporadic or a manifestation of multiple endocrine neoplasia type 1.","Zollinger Ellison Syndrome | Zollinger-Ellison Syndrome | Zollinger-Ellison syndrome",,,,,,,,,,,,,,,"4200399","Zollinger-Ellison syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006279","Bronchoalveolar Lavage Fluid","C13195","Fluid introduced into, and collected from, the lungs by a bronchoalveolar lavage procedure.","Bronchoalveolar Lavage Fluid | Bronchial Lavage | Bronchial Lavage Fluid | FLUID, BRONCHOALVEOLAR LAVAGE | Fluid, Bronchial Lavage",,,,,,,,,,,,,,,"4121345","Bronchoalveolar lavage fluid specimen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827481","Cytoplasmic RNA","C84512","RNA present in the cytoplasm. It is involved in the protein export process from the cells.","Cytoplasmic RNA | RNA, Cytoplasmic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038352","Gastric Content","C77614","The contents of the stomach that may include undigested food mixed with juices secreted by the gastric mucosal glands.","Gastric Content | GASTRIC CONTENTS | Stomach Contents",,,,,,,,,,,,,,,"4265063","Gastric contents",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027342","Nail","C33156","The cutaneous plate on the dorsal surface of the distal end of a finger or toe.","Nail | NAIL | Nail Apparatus | Nails | nail | nail/claw",,,,,,,,,,,,,"UBERON:0001705","nail","4200277","Nail plate structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518867","Pancreatic Exocrine Secretion","C33256","Secretion from the pancreas that contains digestive enzymes.","Pancreatic Exocrine Secretion | Exocrine Pancreas Secretion | Pancreatic Fluid | Pancreatic Juices | Pancreatic fluid | pancreatic juice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0137714","Poly A RNA","C80376","An RNA transcript that contains a tail of poly A residues at its 3' end.","Poly A RNA | Poly-A RNA | Polyadenylated RNA | RNA, Poly-A enriched",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1306459","Primary Malignant Neoplasm","C84509","A malignant tumor at the original site of growth.","Primary Malignant Neoplasm | Malignant (primary) neoplasm, unspecified",,,,,,,,,,,,,,,"439392","Primary malignant neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035709","Small Nuclear RNA","C815","A small RNA molecule (100-300 nucleotides) located in the cell nucleus. This nucleic acid plays a role in RNA splicing, transcriptional regulation, telomere maintenance and rRNA modification.","Small Nuclear RNA | SMALL NUCLEAR RNA | Small Nuclear Ribonucleic Acid | U-RNA | snRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827482","Whole Bone Marrow","C84513","Bone marrow sample containing a mixture of different types of stem cells, including hematopoietic stem cells, mesenchymal stem cells, and multipotent progenitor cells.","Whole Bone Marrow | WBM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0935624","Capillary vessel","C12685","A tiny vessel that can be either a blood capillary or a lymphatic capillary.","Capillary | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007301","Cartilage","C12373","A type of connective tissue composed of chondrocytes and an extracellular matrix, composed of collagen, elastin, and ground substance. There are three types of cartilage; namely elastic, hyaline, and fibrocartilage.","Cartilage | CARTILAGE | Cartilagenous | cartilage",,,,,,,,,,,,,,,"4206445","Cartilage tissue",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017070","Dorsal Root Ganglion","C12462","Ganglion with sensory function within the vertebral column.","Dorsal Root Ganglion | GANGLION, DORSAL ROOT | Spinal Ganglion",,,,,,,,,,,,,,,"4324710","Structure of spinal nerve ganglion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014533","Epididymis","C12328","A crescent-like structure located in the upper and posterior surfaces of the testis. It consists of the efferent ductules and the duct of the epididymis. It facilitates the maturation of sperm that is produced in the testis.","Epididymis | EPIDIDYMIS | Epididymal | epididymis",,,,,,,,,,,,,"UBERON:0001301","epididymis","4227148","Epididymis structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522529","Islet Cell","C32885","A pancreatic cell that produces and secretes hormones such as insulin and glucagon.","Islet Cell | Islet Cells | endocrine pancreas cell | islet cell | islets of Langerhans cell",,,,,,,,,,,,,,,"4235795","Endocrine pancreas cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206207","Joint Capsule","C84388","Dense fibrous connective tissue sealing the joint. It is attached to the bones and provides stability.","Joint Capsule | Articular Capsule",,,,,,,,,,,,,,,"4137606","Structure of articular capsule",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022907","Lacrimal Gland","C12346","Paired, almond-shaped exocrine glands situated superior and posterior to each orbit of the eye that produce and secrete the watery serous component of tears.","Lacrimal Gland | GLAND, LACRIMAL | LACRIMAL GLAND | Lacrimal gland | Lacrimal gland structure (body structure) | glandula lacrimalis | lacrimal gland | lacrimal-preorbital gland","C69.5","Lacrimal gland",,,,,,,,,,,"UBERON:0001817","lacrimal gland","4028662","Lacrimal gland structure",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0023685","Ligament","C13046","Band of fibrous tissue connecting bone to bone or cartilage to bone thereby supporting or strengthening a joint.","Ligament | Human Ligament | LIGAMENT | Ligaments | ligament | ligament organ",,,,,,,,,,,,,"UBERON:0000211","ligament","4178597","Structure of ligament",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227952","Male Prepuce","C33049","A fold of skin covering the tip of the penis.","Male Prepuce | FORESKIN | Foreskin | Preputium Penis | foreskin | penile prepuce | prepuce of male | prepuce of penis | preputium penis",,,,,,,,,,,,,"UBERON:0001332","prepuce of penis","4076570","Preputial structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224498","Meniscus","C33096","A crescent-shaped wedge of cartilaginous material that serves as a cushion in the knee, between the tuberosities of the femur and the tibia. There are two locations, the medial meniscus located on the inner aspect of the knee and the lateral which is located on the outer aspect.","Meniscus | MENISCUS",,,,,,,,,,,,,,,"4253205","Meniscus structure of joint",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242602","Peripheral Blood Stem Cell Transplantation","C15430","A method of hematopoietic reconstitution utilizing stem cells harvested from the circulating blood of a patient or donor. Peripheral blood stem cell transplantation (PBSCT) is used for the treatment of certain blood disorders, following partial or complete bone marrow ablation, or following high dose chemotherapy or radiation treatment for cancer. Immature circulating blood cells, similar to stem cells in the bone marrow, are removed before treatment. The cells are then given to the patient after treatment to help the bone marrow recover and continue producing healthy blood cells. Transplantation may be autologous (the patient's own blood cells are used), allogeneic (blood cells are donated by someone else), or syngeneic (blood cells are donated by an identical twin).","Peripheral Blood Stem Cell Transplantation | PBPC transplantation | PBSCT | PERIPHERAL BLOOD STEM CELL TRANSPLANT | Peripheral Blood | Peripheral Blood Progenitor Cell Transplantation | Peripheral Stem Cell Support | Peripheral Stem Cell Transplant | Peripheral Stem Cell Transplantation | peripheral stem cell support | peripheral stem cell transplantation",,,,,,,,,,,,,,,"4081380","Peripheral blood stem cell graft",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0278701","Gastric Adenocarcinoma","C4004","An adenocarcinoma arising from the stomach glandular epithelium. Gastric adenocarcinoma is primarily a disease of older individuals.  It most commonly develops after a long period of atrophic gastritis and is strongly associated with Helicobacter pylori infection. The lack of early symptoms often delays the diagnosis of gastric cancer. The majority of patients present with advanced tumors which have poor rates of curability. Microscopically, two important histologic types of gastric adenocarcinoma are recognized: the intestinal and diffuse type. The overall prognosis of gastric adenocarcinomas is poor, even in patients who receive a 'curative' resection (adapted from Sternberg's Surgical Pathology, 3rd ed., 1999).","Gastric Adenocarcinoma | Adenocarcinoma | Adenocarcinoma - stomach | Adenocarcinoma of Stomach | Adenocarcinoma of the Stomach | Adenocarcinoma of the stomach | Gastric (Stomach) Adenocarcinoma | Gastric Adenocarcinoma, NOS | STAD | Stomach Adenocarcinoma",,,,,,,,,,,,,,,"4248802","Adenocarcinoma of stomach",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0279635","Diffuse Gastric Adenocarcinoma","C9159","An adenocarcinoma arising from the stomach.  Microscopically, it is characterized by the presence of a diffuse infiltrate, composed of individual adenocarcinoma cells or groups of adenocarcinoma cells in a fibrous or mucoid stroma.  Many cells contain mucin droplets, producing a signet-ring configuration.","Gastric Diffuse Adenocarcinoma | Adenocarcinoma of Linitis Plastica Type | Adenocarcinoma of the Linitis Plastica Type | Diffuse | Diffuse Adenocarcinoma of Stomach | Diffuse Adenocarcinoma of the Stomach | Diffuse Gastric Adenocarcinoma | Diffuse Gastric Adenocarcinoma | Diffuse Stomach Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279633","Gastric Intestinal Type Adenocarcinoma","C9157","An adenocarcinoma of the stomach arising on a background of intestinal metaplasia.  Microscopically, it is characterized by a glandular pattern and it closely resembles a colonic adenocarcinoma.","Gastric Intestinal-Type Adenocarcinoma | Gastric Intestinal Type Adenocarcinoma | Gastric Intestinal Type Adenocarcinoma | Intestinal | Intestinal Adenocarcinoma of Stomach | Intestinal Adenocarcinoma of the Stomach | Intestinal Gastric Adenocarcinoma | Intestinal Stomach Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334809","Gastric Mucinous Adenocarcinoma","C5248","A variant of gastric adenocarcinoma with more than half of the tumor containing extracellular mucinous pools.","Gastric Mucinous Adenocarcinoma | Mucinous (Colloid) adenocarcinoma | Mucinous Adenocarcinoma of Stomach | Mucinous Adenocarcinoma of the Stomach | Mucinous Gastric Adenocarcinoma | Mucinous Gastric Adenocarcinoma | Mucinous Stomach Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333785","Gastric Papillary Adenocarcinoma","C5472","A variant of gastric adenocarcinoma with exophytic growth and elongated finger-like processes lined by cylindrical or cuboidal cells supported by fibrovascular connective tissue cores.","Gastric Papillary Adenocarcinoma | Papillary Adenocarcinoma of Stomach | Papillary Adenocarcinoma of the Stomach | Papillary adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333791","Gastric Tubular Adenocarcinoma","C5473","A variant of gastric adenocarcinoma characterized by prominent dilated or slit-like tubules.","Gastric Tubular Adenocarcinoma | Tubular Adenocarcinoma of Stomach | Tubular Adenocarcinoma of the Stomach | Tubular adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987682","Radical Hysterectomy","C94470","The surgical removal of the uterus and surrounding structures, including bilateral pelvic lymph nodes, the parametrium, and the upper one-third to one-half of the vagina.","Radical Hysterectomy | radical hysterectomy",,,,,,,,,,,,,,,"4021530","Radical hysterectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0995150","Grapefruit","C71974","The sour to semi-sweet fruit of Citrus x paradisi. Grapefruit can have interactions with drugs, often increasing the effective potency of compounds.","Grapefruit | GRAPEFRUIT",,,,,,,,,,,,,,,"4103594","Grapefruit",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0541315","Everolimus","C48387","A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)","Everolimus | (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone | 42-O-(2-Hydroxy)ethyl Rapamycin | Afinitor | Certican | EVEROLIMUS | RAD 001 | RAD-001 | RAD001 | Votubia | Zortress | everolimus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034193","Antrum Pylori","C12259","The initial part of the pyloric canal of the stomach. This site contains endocrine cells that produce gastrin and somatostatin.","Antrum Pylori | ANTRUM PYLORI | Antrum | Gastric Antrum | Gastric antrum | pyloric antrum",,,,,,,,,,,,,,,"4281229","Pyloric antrum structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0447070","Gastroepiploic Artery","C52857","One of two (right and left) arteries along the greater curvature of the stomach that supply blood to the greater omentum and stomach.","Gastroepiploic Artery | ",,,,,,,,,,,,,,,"4126223","Gastroepiploic artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0226299","Gastric Artery","C32654","Either of two arteries (left gastric and right gastric) that supply blood to the stomach and lesser curvature.","Gastric Artery | ",,,,,,,,,,,,,,,"4279682","Structure of gastric artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037996","Splenic Artery","C33597","An artery arising from the celiac trunk with four main branches that supply the spleen, stomach and pancreas.","Splenic Artery | Lienal Artery | SPLENIC ARTERY",,,,,,,,,,,,,,,"4328894","Structure of splenic artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL426234","Bowel Function","C94609","The way the intestines work in terms of how often there are bowel movements, the ability to control when to have a bowel movement, and whether the stools are hard and dry as in constipation or watery as in diarrhea.","Bowel Function | bowel function",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030518","Parathyroid Gland","C12765","One of two small paired endocrine glands, superior and inferior, usually found embedded in the connective tissue capsule on the posterior surface of the thyroid gland; these glands secrete parathyroid hormone that regulates the metabolism of calcium and phosphorus. The parenchyma is composed of chief and oxyphilic cells arranged in anastomosing cords.","Parathyroid Gland | GLAND, PARATHYROID | Head and Neck, Parathyroid | PARATHYROID GLAND | Parathyroid | Parathyroid gland | Parathyroid structure (body structure) | parathyroid | parathyroid gland",,,,,,,,,,,,,"UBERON:0001132","parathyroid gland","4006785","Parathyroid structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039099","Synovial Membrane","C12473","The inner layer of the connective tissue that seals the joint.","Synovial Membrane | SYNOVIAL MEMBRANE | SYNOVIUM | Synovial Stratum | Synovium | membrana synovialis (capsula articularis) | membrana synovialis capsulae articularis | stratum synoviale | stratum synoviale (capsula articularis) | synovial membrane | synovial membrane of synovial joint",,,,,,,,,,,,,"UBERON:0002018","synovial membrane of synovial joint","4275262","Synovial membrane",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039508","Tendon","C13045","A band of fibrous connective tissue that joins bone to muscle.","Tendon | Human Tendon | TENDON | Tendon structure (body structure) | Tendons | tendon",,,,,,,,,,,,,"UBERON:0000043","tendon","4045430","Tendon structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042360","Vas Deferens","C12813","Duct carrying spermatozoa.","Vas Deferens | Ductus Deferens | VAS DEFERENS | deferent duct | ductus deferens | vas deferen | vas deferens",,,,,,,,,,,,,"UBERON:0001000","vas deferens","4212492","Vas deferens structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002424","Ambulatory Care Facility","C16281","A medical care center that provides healthcare services on an outpatient basis.","Ambulatory Care Facility | ACF | AMB | AMBULATORY CARE FACILITY | Ambulatory | Ambulatory Care | Ambulatory Care Facilities | Clinic | OUTPATIENT CLINIC | Outpatient Care Facility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0180416","Diaper","C96167","A barrier garment or padding used to absorb urine and stool, thereby helping to protect the skin and keep clothing and bedding clean.","Diaper | ",,,,,,,,,,,,,,,"4178590","Diaper",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3272624","Arterial Access Port Removal","C96175","Removal of a medical device implanted in an artery for the delivery of medication, fluids, nutrition, or other ordered treatment.","Arterial Access Port Removal | Arterial Access Port Removed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515978","Anatomy Qualifier","C13442","An adjectival term used to specify a region of the body or other concepts associated with the body.","Anatomy Qualifier | Anatomic Qualifier | Anatomy Qualifiers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085590","Catheter Device","C50344","A flexible tube designed to transfer fluids into or out of the body.","Catheter Device | Catheter | Catheter | Catheter Device Component | catheter",,,,,,,,,,,,,,,"4060422","Catheter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015376","Extravasation","C48198","The leakage of body fluid or cells from the vascular system to the surrounding tissues. This process occurs either by force or as a result of a pathologic reaction (e.g., inflammation). This process may sometimes allow cancer cells to migrate from capillaries to adjacent tissues, initiating micro-metastases.","Extravasation | extravasation",,,,,,,,,,,,,,,"4295895","Extravasation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004799","Basement Membrane","C13191","Ubiquitous supportive tissue adjacent to epithelium and around smooth and striated muscle cells. This tissue contains intrinsic macromolecular components such as collagen, laminin, and sulfated proteoglycans. As seen by light microscopy one of its subdivisions is the basal (basement) lamina.","Basement Membrane | ",,,,,,,,,,,,,,,"4288753","Basement membrane",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1439173","BLCA-4","C18594","A bladder cancer-associated antigen (BLCA) isolated from the nuclear matrix of bladder cancer cells and not detected in normal bladder cells. Detection of BLCA-4 in the urine may be a marker for bladder cancer.","BLCA-4 | Bladder Cancer Specific Antigen-4 | Bladder Cancer Specific Nuclear Matrix Protein BLCA-4 | Bladder Cancer-Associated Antigen-4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005810","Blood Group","C76244","A classification of blood based on the presence or absence of inherited antigenic substances on the surface of erythrocytes.","Blood Group | Blood Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0055966","Clusterin","C84432","Clusterin (449 aa, ~52 kDa) is encoded by the human CLU gene. This protein may be involved in lipid metabolism, complement regulation and the initiation of apoptosis.","Clusterin | Aging-Associated Gene 4 Protein | Apo-J | Apolipoprotein J | CLI | Complement Cytolysis Inhibitor | Complement Lysis Inhibitor | Complement-Associated Protein SP-40,40 | Ku70-Binding Protein 1 | NA1/NA2 | Sulfated Glycoprotein 2 | TRPM-2 | Testosterone-Repressed Prostate Message 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0805077","Dispensed Amount","C78721","The quantity of a product that has been dispensed.","Dispensed Amount | DISPAMT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919457","FHIT Gene","C18524","This gene is involved in nucleotide metabolism and cell cycle control.","FHIT Gene | FHIT | Fragile Histidine Triad Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376180","Gastrin","C94668","Gastrin (101 aa, ~11 kDa) is encoded by the human GAST gene. This protein plays a role in the modulation of gastric acid and pancreatic digestive enzyme secretion.","Gastrin | (Prepro)Gastrin | GAST | Preprogastrin | gastrin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017687","Glucagon","C2268","Glucagon (29 aa, ~3 kDa) is encoded by the human GCG gene. This protein plays a role in the regulation of blood sugar levels through the stimulation of hepatic glycogenolysis and gluconeogenesis.","Glucagon | Antidiabetic Hormone | GCG | HG Factor | HG-Factor | Hyperglycemic Glycogenolytic Factor | Hyperglycemic-Glycogenolytic Factor | glucagon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704838","HIF1A wt Allele","C52040","Human HIF1A wild-type allele is located within 14q21-q24 and is approximately 53 kb in length. This allele, which encodes hypoxia-inducible factor 1 alpha protein, is involved in angiogenesis and transcriptional regulation during the cellular adaptive response to hypoxia. Overexpression of the HIF1A gene is associated with several types of cancer such as hepatocellular carcinoma and renal cell carcinoma.","HIF1A wt Allele | BHLHE78 | HIF-1A | HIF-1alpha | HIF1 | HIF1-ALPHA | HIF1-Alpha | Hypoxia-Inducible Factor 1, Alpha Subunit (Basic Helix-Loop-Helix Transcription Factor) wt Allele | MOP1 | PASD8 | bHLHe78",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0074825","Insulin-Like Growth Factor-Binding Protein","C17332","A family of soluble proteins that bind insulin-like growth factors and modulate their biological actions at the cellular level.  Serum IGFBP levels have been found to be negatively correlated to the risk of cancer.","Insulin-Like Growth Factor-Binding Protein | IGFBP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1872103","IGFBP3 protein, human","C17509","Insulin-like growth factor-binding protein 3 (291 aa, ~32 kDa) is encoded by the human IGFBP3 gene. This protein plays a role in insulin-like growth factor signaling, apoptosis promotion, and cell proliferation inhibition.","Insulin-Like Growth Factor-Binding Protein 3 | Acid Stable Subunit of The 140 k IGF Complex | Binding Protein 29 | Binding Protein 53 | Growth Hormone-Dependent Binding Protein | IBP-3 | IGF Binding Protein 3 | IGF-Binding Protein 3 | IGFBP-3 | IGFBP3 | Insulin-Like Growth Factor Binding Protein 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699071","Returned Amount","C78722","The quantity of a product that has been returned.","Returned Amount | RETAMT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0763464","KRAS protein, human","C17383","GTPase KRas (189 aa, ~21 kDa) is encoded by the human KRAS gene. This protein is involved in the regulation of GTP metabolism and in signaling.","GTPase KRas | K-Ras 2 | K-Ras 2A | K-Ras p21 Protein | K-Ras-2 Protein | K-Ras-2 p21 | KRAS | KRAS2 | Ki-Ras | c-K-Ras | c-K-Ras Protein | c-Ki-ras | p21 K-Ras Protein | p21 K-Ras Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0752312","Mitogen-Activated Protein Kinases","C16376","Mitogen-activated protein kinases (MAPKs) are serine-threonine protein kinases activated in response to a variety of extracellular stimuli and encoded by a multigene family. The MAPKs are part of complex protein kinase cascades. One of the several classes of MAPKs includes (among other ERKs) the extracellular signal-regulated kinases ERK1 (p44MAPK) and ERK2 (p42MAPK), activated by the RAF/MEK/ERK signaling pathway. ERK1/2 are widely involved in eukaryotic signal transduction. Upon activation, ERKs translocate to the nucleus and phosphorylate nuclear targets. Phosphorylated ERKs form essential dimers with phosphorylated and unphosphorylated ERK partners. Dimerization is part of the mechanism of MAP kinase family action. Mitogen-activated protein kinases (MAPKs) promote entry in the cell cycle.  (from OMIM 601795, 176948, Swiss-Prot P27361, P28482 and NCI)","Mitogen-Activated Protein Kinase | EC 2.7.2- | ERK | Extracellular Signal-Regulated Kinases | MAPK | Map Kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2713871","MAPK1 protein, human","C17589","Mitogen-activated protein kinase 1 (390 aa, ~41 kDa) is encoded by the human MAPK1 gene. This protein plays a role in cell cycle regulation, signal transduction, transcriptional regulation and serine/threonine phosphorylation.","Mitogen-Activated Protein Kinase 1 | EC 2.7.11.24 | ERK-2 | ERT1 | Extracellular Signal-Regulated Kinase 2 | MAP Kinase 1 | MAP Kinase 2 | MAP Kinase Isoform p42 | MAPK 1 | MAPK 2 | MAPK1 | Mitogen-Activated Protein Kinase 2 | PRKM1 | p42-MAPK | p42MAPK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0082529","Mitogen-Activated Protein Kinase 3","C17408","Mitogen-activated protein kinase 3 (379 aa, ~43 kDa) is encoded by the human MAPK3 gene. This protein plays a role in transcriptional regulation, serine/threonine phosphorylation and both cytokine-dependent and stress-activated signaling.","Mitogen-Activated Protein Kinase 3 | EC 2.7.11.24 | ERK-1 | ERT2 | Extracellular Signal-Regulated Kinase 1 | Insulin-Stimulated MAP2 Kinase | MAP Kinase 3 | MAP Kinase 3 | MAP Kinase Isoform p44 | MAPK 3 | MAPK3 | Microtubule-Associated Protein 2 Kinase | p44 | p44 (MAPK) | p44-ERK1 | p44-MAPK | p44ERK1 | p44MAPK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334489","MCM2 Gene","C20373","This gene plays a role in the initiation of DNA replication. It is also involved in cell cycle control and cell proliferation.","MCM2 Gene | MCM2 | MCM2 Minichromosome Maintenance Deficient 2, Mitotin (S. Cerevisiae) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522558","Recombinant Monocyte Chemoattractant Protein-1","C1393","A recombinant therapeutic agent which is chemically identical to or similar to endogenous human monocyte chemoattractant protein-1, a member of the CC chemokine family which is chemotactic for monocytes. (NCI04)","Recombinant Monocyte Chemoattractant Protein-1 | CCL2 | HC11 | Human Macrophage Chemoattractant Protein-1 | MCAF | MCP-1 | Monocyte Chemoattractant Protein 1 | Monocyte Chemotactic Protein-1 | Monocyte Chemotactic and Activating Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347168","Mitogen-Activated Protein Kinase Kinase Inhibitor","C69145","Any substance that inhibits mitogen-activated protein kinase kinase (MEK), an enzyme that catalyzes the addition of a phosphate group to a mitogen-activated protein kinase. Inhibition of mitogen-activated protein kinase kinase results in the inhibition of cell proliferation.","Mitogen-Activated Protein Kinase Kinase Inhibitor | MAP2K Inhibitor | MAPK/ERK Kinase Inhibitor | MAPKK Inhibitor | MEK Inhibitor | MKK Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3711265","ALOX5 protein, human","C68729","Arachidonate 5-lipoxygenase protein (674 aa, ~78 kDa) is encoded by the human ALOX5 gene. This protein plays a role in the synthesis of leukotrienes from arachidonic acid; thus, it mediates both inflammation and allergen responses.","Arachidonate 5-Lipoxygenase | 5-LO | 5-Lipoxygenase | 5LOX | ALOX5 | EC 1.13.11.34",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812228","AKT1 Gene","C18350","This gene is involved in signal transduction and negative regulation of apoptosis. It also plays a role in glucose transport, glycogen synthesis, protein synthesis and neuronal survival.","AKT1 Gene | AKT Serine/Threonine Kinase 1 Gene | AKT1 | v-akt Murine Thymoma Viral Oncogene Homolog 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4042483","Apoptosis Regulator Bcl-2, Human","C18115","Apoptosis regulator Bcl-2 (239 aa, ~26 kDa) is encoded by the human BCL2 gene. This protein plays a role in cellular survival.","Apoptosis Regulator Bcl-2 | B-Cell CLL/lymphoma 2 | B-cell leukemia/lymphoma 2 protein | BCL-2 Protein | BCL2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334630","Malignant Vascular Neoplasm","C7390","A malignant neoplasm arising from the vascular tissue.  It is characterized by vascular channel formation and malignant endothelial cells.","Malignant Vascular Neoplasm | Cancerous Tumor of Blood Vessel | Malignant Tumor of Blood Vessel | Malignant Vascular Tissue Neoplasm | Malignant Vascular Tissue Tumor | Malignant Vascular Tumor | Vascular Neoplasms, Malignant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1257954","COX-2 Inhibitor","C80509","A subgroup of non-steroidal anti-inflammatory drugs (NSAID) that specifically targets at cyclooxygenase 2, an enzyme involved in pain and inflammation.","COX-2 Inhibitor | COX-2 inhibitor | Cyclooxygenase II Inhibitor | PTGS2 Inhibitor | Prostaglandin-Endoperoxide Synthase 2 Inhibitor | cyclooxygenase-2 inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812265","ERBB3 Gene","C18386","This gene is involved in signal transduction pathways that result in cellular proliferation or differentiation. The gene has also been associated with numerous cancers.","ERBB3 Gene | ERBB3 | Erb-B2 Receptor Tyrosine Kinase 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0618743","Human Glandular Kallikrein 2","C18163","Kallikrein-2 (261 aa, ~29 kDa) is encoded by the human KLK2 gene. This protein plays a role in proteolysis and vasodilation.","Kallikrein-2 | EC 3.4.21.35 | Glandular Kallikrein 2 | Glandular Kallikrein 2 Precursor | Glandular Kallikrein 2 Precursor | Glandular Kallikrein-1 | KLK2 | Kallikrein 2 | Kallikrein 2, Prostatic | Kallikrein, Glandular | Kallikrein, Prostatic | Prostatic Kallikrein 2 | Tissue Kallikrein-2 | hGK-1 | hK2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2975999","Hydroxymethylglutaryl Coenzyme A Reductase, Human","C54701","3-hydroxy-3-methylglutaryl-coenzyme A reductase (888 aa, ~97 kDa) is encoded by the human HMGCR gene. This protein is involved in cholesterol synthesis.","3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase | EC 1.1.1.34 | HMG CoA Reductase | HMG-CoA Reductase | HMGCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0674299","CCL22 protein, human","C28735","C-C motif chemokine 22 (93 aa, ~11 kDa) is encoded by the human CCL22 gene. This protein is involved in the chemotaxis of monocytes, dendritic cells, natural killer cells and activated T-lymphocytes.","C-C Motif Chemokine 22 | CC Chemokine STCP-1 | CCL22 | Chemokine (C-C Motif) Ligand 22 | MDC(1-69) | Macrophage-Derived Chemokine | Small Inducible Cytokine A22 | Small Inducible Cytokine A22 | Small Inducible Cytokine Subfamily A (Cys-Cys), Member 22 | Small-Inducible Cytokine A22 | Stimulated T Cell Chemotactic Protein 1 | Stimulated T-Cell Chemotactic Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417497","MUC5AC Gene","C90332","This gene plays a role in the protection of the respiratory and gastrointestinal tracts.","MUC5AC Gene | MUC5AC | Mucin 5AC, Oligomeric Mucus/Gel-Forming Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1770516","Nuclear Factor of Kappa Light Chain Gene Enhancer in B-Cells 2","C18550","Nuclear factor NF-kappa-B p100 subunit (900 aa, ~97 kDa) is encoded by the human NFKB2 gene. This protein plays a role in both transcriptional regulation and signal transduction.","Nuclear Factor NF-kappa-B p100 Subunit | DNA-Binding Factor KBF2 | H2TF1 | LYT10 Protein | Lymphocyte Translocation Chromosome 10 Protein | Lyt10 | NF-Kappa B p49/p100 | NF-kB Subunit 2 | NF-kappa-B2 | NF-kappaB(p50) | NFKB p49/p100 Subunit | NFKB2 | NFKB2 Protein | Nuclear Factor Kappa B Subunit 2 | Nuclear Factor Kappa-B Subunit 2 | Nuclear Factor NF-Kappa-B P100 Subunit | Nuclear Factor of Kappa Light Chain Gene Enhancer in B-Cells 2 | Nuclear Factor of Kappa Light Polypeptide Gene Enhancer in B-Cells 2 | Oncogene Lyt-10 | Transcription Factor NFKB2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1504812","CDKN1B protein, human","C17901","Cyclin-dependent kinase inhibitor 1B (198 aa, ~22 kDa) is encoded by the human CDKN1B gene. This protein plays a role in cell cycle arrest.","Cyclin-Dependent Kinase Inhibitor 1B | CDKN1B | Cyclin-Dependent Kinase Inhibitor p27 | p27(KIP1) | p27-Kip1 | p27Kip1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL964499","PCNA protein, human","C17323","Proliferating cell nuclear antigen (261 aa, ~29 kDa) is encoded by the human PCNA gene. This protein is involved in the regulation of both DNA replication and DNA mismatch repair.","Proliferating Cell Nuclear Antigen | Cyclin | DNA Polymerase Delta Auxiliary Protein | PCNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412404","16,16-Dimethylprostaglandin E2","C84850","A stable derivative of prostaglandin E2 (PGE2) with potential hematopoietic activity. Administration of 16,16 dimethyl-prostaglandin E2 (dmPGE2) appears to lead to increased formation of hematopoietic stem and progenitor cells. Even though the exact mechanism of action has yet to be fully elucidated, this agent may stimulate hematopoiesis by activating the Wnt signaling pathway, which increases cellular levels of beta-catenin, a subunit of the cadherin protein complex.","16,16-Dimethyl Prostaglandin E2 | 16,16-DIMETHYLPROSTAGLANDIN E2 | 16,16-Dimethylprostaglandin E2 | dmPGE2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796359","DNA ploidy analysis","C18303","A test used to measure nuclear deoxyribonucleic acid content (ploidy or multiplicity of the basic number of chromosomes) in a cell.","DNA Ploidy Analysis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812215","RAF1 Gene","C18338","This gene is involved in cell growth, proliferation, differentiation and migration. It also plays a role in apoptosis.","RAF1 Gene | RAF1 | v-RAF-1 Murine Leukemia Viral Oncogene Homolog 1Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3275167","Garden Snail","C71941","A species of land snail in the family Helicidae native to the Mediterranean area and western Europe but widely distributed throughout temperate regions worldwide.","Garden Snail | Cornu aspersum | GARDEN SNAIL | Snail",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037659","SST protein, human","C28418","Somatostatin (116 aa, ~13 kDa) is encoded by the human SST gene. This protein plays a role in the downregulation of somatotropin release.","Somatostatin | Growth Hormone Release Inhibiting Factor | Growth Hormone Release-Inhibiting Factor | Growth Hormone-Inhibiting Hormone | Panhibin | Prepro-Somatostatin | SST | Somatotropin Release Inhibiting Factors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0087071","Telomerase","C17470","A reverse transcriptase responsible for maintaining the telomere length of replicating cells. Telomerase recognizes a telomere-specific GC rich sequence and adds telomeric repeats by using and RNA template.","Telomerase | telomerase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040690","Transforming Growth Factor-Beta Superfamily","C20455","A family of structurally-related cytokines that bind to their cognate serine/threonine kinase receptors as homodimers or heterodimers linked by a single disulfide bond. These proteins play a role in embryonic development, hematopoiesis, tissue repair and extracellular matrix remodeling.","Transforming Growth Factor-Beta Superfamily | Bone-Derived Transforming Growth Factor | Milk Growth Factor | TGF B | TGF Beta | TGF-B | TGF-Beta | Transforming Growth Factor Beta | Transforming Growth Factor-Beta | Transforming Growth Factor-Beta | Tumor Growth Factor B | Tumor Growth Factor Beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515232","TdT-Mediated dUTP Nick End Labeling Assay","C19815","A method to detect apoptosis.","TdT-Mediated dUTP Nick End Labeling Assay | TUNEL Assay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006611","MUC-1 Antigen","C2407","MUC-1 antigen is a mammary-type apomucin, a high molecular weight transmembrane glycoprotein, of which the extracellular domain is formed by a repeating 20 amino acid sequence (in tandem) with a high content of serine and threonine on which are O-linked carbohydrate chains. MUC-1 synthesis and secretion are features of glandular epithelial tissues; MUC-1 is overexpressed in lactating breast and in breast, ovary, lung, and prostate malignancies.","MUC-1 Antigen | CA15-3 Antigen | Cancer Antigen 15-3 | DF3 Antigen | Episialin | ImMucin | MAM-6 | MUC-1 | Mucin Antigen | Mucin Peptide MUC-1 | Polymorphic Epithelial Mucin | Sialylated MUC-1 | mucin/peptide",,,,,,,,,,,,,,,"4012706","Cancer antigen 15-3",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1414529","FANCC Gene","C86025","This gene may play a role in DNA cross-link repair.","FANCC Gene | FA Complementation Group C Gene | FANCC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008545","Chromatid","C13200","One of the two side by side replicas produced by chromosome replication in mitosis or meiosis. Subunit of a chromosome after replication and prior to anaphase of meiosis II or mitosis. At anaphase of meiosis II or mitosis when the centromeres divide and the sister chromatids separate each chromatid becomes a chromosome. (Biology-Text.com)","Chromatid | ",,,,,,,,,,,,,,,"4307364","Chromatid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1414530","FANCD2 Gene","C86549","This gene is involved in the regulation of meiosis, DNA repair and the cell cycle.","FANCD2 Gene | FA Complementation Group D2 Gene | FANCD2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414531","FANCE Gene","C86551","This gene plays a role in the regulation of both DNA repair and protein localization.","FANCE Gene | FA Complementation Group E Gene | FANCE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414527","FANCA Gene","C85995","This gene may be involved in the mediation of DNA repair.","FANCA Gene | FA Complementation Group A Gene | FANCA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414528","FANCB Gene","C86017","This gene may play a role in DNA repair.","FANCB Gene | FA Complementation Group B Gene | FANCB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414532","FANCF Gene","C86553","This gene may be involved in the regulation of DNA repair.","FANCF Gene | FA Complementation Group F Gene | FANCF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3179062","Image Guided Radiation Therapy","C62727","A procedure that uses a computer to create a picture of a tumor to help guide the radiation beam during radiation therapy. The pictures are made using CT, ultrasound, X-ray, or other imaging techniques. Image-guided radiation therapy makes radiation therapy more accurate and causes less damage to healthy tissue.","Image Guided Radiation Therapy | IGRT | Image-Guided Radiotherapy | image-guided radiation therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415877","IDH2 Gene","C84948","This gene plays a role in intermediary metabolism.","IDH2 Gene | IDH2 | Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517170","Fibrillary Neoplastic Astrocyte","C37129","A neoplastic astrocyte characterized by the presence of an atypical nucleus (large, irregular, or hyperchromatic), scant amount of cytoplasm, and cell processes that contribute to the formation of a fibrillary matrix.","Fibrillary Neoplastic Astrocyte | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514085","Neoplastic Small Cell","C37103","A benign or malignant cell that is characterized by the presence of a small nucleus and scant amount of cytoplasm.  It may be epithelial, lymphoid, neuroepithelial, or mesenchymal in origin.","Neoplastic Small Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004112","Astrocyte","C12477","A heterogeneous group of specialized neuroglial cells with many diverse supporting roles in the structure, function, and homeostasis of the central nervous system.","Astrocyte | Astrocytes | Astroglia | astrocyte",,,,,,,,,,,,,,,"4301136","Astrocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0458828","Stage IA1","C27983","A stage term referring to invasive cervical and lung cancer.  For cervical cancer, it includes: T1a1, N0, M0.  T1a1: Tumor with stromal invasion 3.0 mm or less in depth and 7.0 mm or less in horizontal spread.  N0: No regional lymph node metastasis. M0: No distant metastasis. For lung cancer, it includes: (T1mi, N0, M0); (T1a, N0, M0). T1mi: Minimally invasive adenocarcinoma: adenocarcinoma (3 cm or less in greatest dimension) with a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. N0: No regional lymph node metastasis. M0: No distant metastasis. (adapted from AJCC)","Stage IA1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0458829","Stage IA2","C27984","A stage term referring to invasive cervical cancer and invasive lung cancer. For cervical cancer, it includes: T1a2, N0, M0.  T1a2: Tumor with stromal invasion more than 3.0 mm and not more than 5.0 mm with a horizontal spread 7.0 mm or less.  N0: No regional lymph node metastasis. M0: No distant metastasis. For lung cancer, it includes: T1b, N0, M0. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (adapted from AJCC)","Stage IA2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272667","Stage IB Cervix","C96240","A stage term referring to invasive cervical cancer that is confined to the cervix without lymph node involvement.  It includes: IB (T1b, N0, M0); IB1 (T1b1, N0, M0); IB2 (T1b2, N0, M0). (partially adapted from AJCC)","Stage IB Cervix | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519505","Stage IB1","C28052","A stage term referring to invasive cervical cancer that is confined to the cervix without lymph node involvement.  It includes: T1b1, N0, M0. (partially adapted from AJCC)","Stage IB1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519506","Stage IB2","C28053","A stage term referring to invasive cervical cancer that is confined to the cervix without lymph node involvement.  It includes: T1b2, N0, M0.  (partially adapted from AJCC)","Stage IB2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272668","Stage II Cervix","C96241","A stage term referring to cervical cancer invading beyond uterus but not to pelvic wall or to lower third of vagina, without lymph node involvement or distant metastasis. Parametrial invasion may or may not be present.  It includes: IIA (T2a, N0, M0); IIA1 (T2a1, N0, M0); IIA2 (T2a2, N0, M0); IIB (T2b, N0, M0); T2: Cervical carcinoma invades beyond uterus but not to pelvic wall or to lower third of vagina. T2a: Tumor without parametrial invasion.  T2a1: Clinically visible lesion 4.0 cm or less in greatest dimension.  T2a2: Clinically visible lesion more than 4.0 cm in greatest dimension.  T2b: Tumor with parametrial invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (partially adapted from AJCC)","Stage II Cervix | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272669","Stage IIA Cervix","C96242","A stage term referring to cervical cancer invading beyond uterus but not to pelvic wall or to lower third of vagina, without lymph node involvement or distant metastasis.  There is no parametrial invasion. It includes: IIA1 (T2a1, N0, M0); IIA2 (T2a2, N0, M0).  T2a1: Clinically visible lesion 4.0 cm or less in greatest dimension.  T2a2: Clinically visible lesion more than 4.0 cm in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (partially adapted from AJCC)","Stage IIA Cervix | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272670","FIGO Stage 0","C96243","A FIGO stage term that applies to gynecologic cancers and refers to carcinoma in situ.  For cervical cancer, it used to refer to cancer that is confined to the cervical epithelium without stromal invasion; for endometrial cancer, it used to refer to cancer that is confined to the endometrium without myometrial invasion.  FIGO no longer includes stage 0 cervical or endometrial cancer.","FIGO Stage 0 | Stage 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272671","FIGO Stage I","C96244","A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to invasive cancer that is confined to the cervix; for endometrial cancer, it refers to cancer confined to the corpus uteri with no or less than one-half myometrial invasion (IA) or invasion of one-half or more of the myometrium (IB).","FIGO Stage I | FIGO Stage 1 | FIGO grade 1 | Stage I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272672","FIGO Stage IA","C96245","A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to invasive cancer that is diagnosed microscopically only.  The stromal invasion has a maximum depth of 5.00 mm and a horizontal spread of 7.00 mm or less; for endometrial cancer, it refers to cancer limited to endometrium or invades less than one-half of the myometrium.","FIGO Stage IA | Stage IA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272673","FIGO Stage IA1","C96246","A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to invasive cancer that is diagnosed microscopically only.  The stromal invasion has a maximum depth of 3.00 mm and a horizontal spread of 7.00 mm or less; there is no FIGO stage IA1 for endometrial cancer.","FIGO Stage IA1 | Stage IA1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272674","FIGO Stage IA2","C96247","A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to invasive cancer that is diagnosed microscopically only.  The stromal invasion is more than 3.00 mm but no more than 5.00 mm with a horizontal spread of 7.00 mm or less; there is no FIGO stage A2 for endometrial cancer.","FIGO Stage IA2 | Stage IA2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272675","FIGO Stage IB","C96248","A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to invasive cancer that is clinically visible and is confined to the cervix or it is diagnosed microscopically and the stromal invasion is more than 5.00 mm and the horizontal spread is more than 7.00 mm; for endometrial cancer, it refers to cancer that is confined to the uterine body and invades one-half or more of the myometrium.","FIGO Stage IB | Stage IB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272676","FIGO Stage IB1","C96249","A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to clinically visible lesions that measure 4.0 cm or less in diameter; there is no FIGO stage IB1 for endometrial cancer.","FIGO Stage IB1 | Stage IB1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272677","FIGO Stage IB2","C96250","A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to clinically visible lesions that measure more than 4.0 cm in diameter; there is no FIGO stage IB2 for endometrial cancer.","FIGO Stage IB2 | Stage IB2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272678","FIGO Stage IC","C96251","A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, there is no FIGO stage IC; for endometrial cancer, in the older FIGO classification stage scheme, it referred to invasion of more than a half of the myometrium.  Stage IC for endometrial cancer has been eliminated in the most recent (2010) FIGO classification stage scheme.","FIGO Stage IC | Stage IC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272679","FIGO Stage II","C96252","A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer that invades beyond the cervix, but not to the pelvic wall or lower third of the vagina; for endometrial cancer, it refers to cancer that invades the stromal connective tissue of the cervix, but it does not extend beyond the uterus.","FIGO Stage II | FIGO Stage 2 | FIGO grade 2 | Stage II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272680","FIGO Stage IIA","C96253","A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer that invades beyond the cervix, but not to the pelvic wall or lower third of the vagina and there is no parametrial invasion; for endometrial cancer, in the older FIGO classification stage scheme, it referred to endocervical glandular involvement only.  Stage IIA for endometrial cancer has been eliminated in the most recent (2010) FIGO classification stage scheme.","FIGO Stage IIA | Stage IIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272681","FIGO Stage IIB","C96254","A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer that invades beyond the cervix, but not to the pelvic wall or lower third of the vagina and there is parametrial invasion; for endometrial cancer, in the older FIGO classification stage scheme, it referred to cervical stromal invasion.  Stage IIB for endometrial cancer has been eliminated in the most recent (2010) FIGO classification stage scheme.","FIGO Stage IIB | Stage IIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272682","FIGO Stage III","C96255","A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer that extends to the pelvic wall, and/or involves the lower third of vagina, and/or causes hydronephrosis or non-functioning kidney; for endometrial cancer, FIGO stage III is subdivided into stages IIIA and IIIB; in FIGO stage IIIA, there is involvement of the serosa and/or the adnexa; for FIGO stage IIIB, there is vaginal or parametrial involvement.","FIGO Stage III | FIGO Stage 3 | FIGO grade 3 | Stage III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272683","FIGO Stage IIIA","C96256","A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer that involves the lower third of vagina and there is no extension to the pelvic wall; for endometrial cancer, it refers to cancer with involvement of the serosa and/or the adnexa.","FIGO Stage IIIA | Stage IIIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272684","FIGO Stage IIIB","C96257","A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer that extends to the pelvic wall, and/or causes hydronephrosis or non-functioning kidney; for endometrial cancer, it refers to cancer with vaginal or parametrial involvement.","FIGO Stage IIIB | Stage IIIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272685","FIGO Stage IIIC","C96258","A FIGO stage term that applies to gynecologic cancers. For endometrial cancer, it refers to cancer with metastasis to the pelvic or para-aortic lymph nodes or both.","FIGO Stage IIIC | Stage IIIC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272686","FIGO Stage IIIC1","C96259","A FIGO stage term that applies to gynecologic cancers. For endometrial cancer, it refers to cancer with regional metastasis to pelvic lymph nodes.","FIGO Stage IIIC1 | Stage IIIC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272687","FIGO Stage IIIC2","C96260","A FIGO stage term that applies to gynecologic cancers. For endometrial cancer, it refers to it refers to cancer with regional metastasis to para-aortic lymph nodes with or without metastasis to pelvic lymph nodes.","FIGO Stage IIIC2 | Stage IIIC2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272688","FIGO Stage IV","C96261","A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer that invades the mucosa of bladder or rectum, and/or extends beyond the true pelvis (FIGO stage IVA), or to cancer with distant metastases (FIGO stage IVB); for endometrial cancer, it refers to cancer that invades the bladder mucosa and/or the bowel mucosa (FIGO stage IVA), or to cancer with distant metastases (FIGO stage IVB).","FIGO Stage IV | FIGO Stage 4 | Stage IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272689","FIGO Stage IVA","C96262","A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer that invades the mucosa of bladder or rectum, and/or extends beyond the true pelvis; for endometrial cancer, it refers to cancer that invades the bladder mucosa and/or the bowel mucosa.","FIGO Stage IVA | Stage IVA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272690","FIGO Stage IVB","C96263","A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer with distant metastases, including peritoneal involvement, involvement of the supraclavicular or mediastinal lymph nodes, and metastases to the lung, bone, or liver; for endometrial cancer, it refers to cancer with distant metastases, including metastases to the inguinal lymph nodes, intraperitoneal involvement, or metastases to the lung, bone, or liver.  Endometrial cancer metastases to the para-aortic lymph nodes, vagina, adnexa, or pelvic serosa are excluded from this stage.","FIGO Stage IVB | Stage IVB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826175","NPM1 Gene Mutation","C82429","Mutation of the nucleophosmin gene. It is seen in acute myeloid leukemias usually associated with a normal karyotype.","NPM1 Gene Mutation | Mutation of the Nucleophosmin Gene | NPM1 Mutation | Nucleophosmin Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511473","CEBPA Gene Mutation","C38372","Mutation of the CEBPA gene encoding CCAAT/enhancer binding protein alpha. It is seen in acute myeloid leukemias usually associated with a normal karyotype.","CEBPA Gene Mutation | C/EBP-Alpha Gene Mutation | C/EBPalpha Mutation | CCAAT Enhancer Binding Protein Alpha Gene Mutation | CCAAT/Enhancer Binding Protein, Alpha Gene Mutation | CEBP Gene Mutation | CEBPA | CEBPA Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880568","Ethanol Ablation Therapy","C67444","An injection of ethanol (alcohol) through the skin directly into a tumor to kill cancer cells. Ultrasound or a CT scan is used to guide the needle into the tumor.","Ethanol Ablation Therapy | Ablation, Ethanol Injection | Ethanol Injection Ablation | PEI | alcohol ablation | ethanol ablation | percutaneous ethanol injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985560","Radioembolization","C93340","A combination therapy for cancer treatment that couples radiation therapy and embolization through the introduction of radioactive microspheres directly into vessels supplying the tumor, allowing for the delivery of high dose radiation without irradiating healthy tissue.","Radioembolization | intra-arterial brachytherapy | radioembolization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272701","Mononucleotide Marker Panel","C96288","A set of genetic loci where each locus contains a mononucleotide (single base pair) repeat sequence. Changes in the length of the repeat indicate mutations in mismatch repair genes resulting in microsatellite instability.","Mononucleotide Marker Panel | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272702","Mononucleotide and Dinucleotide Marker Panel","C96289","A set of genetic loci where each locus contains either a mononucleotide (single base pair) repeat or a dinucleotide (two nucleotide subunits) repeat sequence. Changes in the length of the repeat indicate mutations in mismatch repair genes resulting in microsatellite instability. Dinucleotide repeats are less sensitive than mononucleotide repeats, but provide internal sample control.","Mononucleotide and Dinucleotide Marker Panel | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL413528","Doxorubicin-Eluting Beads","C82419","A drug-device combination product consisting of small polymeric beads impregnated with the anthracycline antibiotic doxorubicin with potential antineoplastic activity. The beads consist of polyvinyl alcohol (PVA) microspheres modified with sulfonic acid groups and loaded with doxorubicin. During transarterial chemoembolization (TACE), doxorubicin-eluting beads embolize to the tumor vasculature and release cytotoxic doxorubicin, which may result in both ischemic necrosis of tumor tissue due to mechanical blockage of the tumor vasculature and doxorubicin-mediated inhibition of tumor cell proliferation.","Doxorubicin-Eluting Beads | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520853","19q","C13546","Distal (long) arm of chromosome 19","19q | Chromosome 19 Distal Arm | Chromosome 19 Long Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517971","Loss of Chromosome 19q","C36507","A cytogenetic abnormality that refers to the loss of all or part of the long arm of chromosome 19 (19q). It has been described in gliomas and hemangiopericytomas.","Loss of Chromosome 19q | 19q only deleted | del(19q)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0265392","Loss of Chromosome 1p","C36501","A cytogenetic abnormality that refers to the loss of all or part of the short arm of chromosome 1 (1p). It has been described in gliomas, meningiomas, neuroblastomas, hepatocellular carcinomas, breast carcinomas, acinar prostate adenocarcinomas, pancreatic carcinomas, and adrenal gland adenomas.","Loss of Chromosome 1p | 1p Deletion | 1p only deleted | Loss of Chromosome 1p (Deletion) | del(1p)",,,,,,,,,,,,,,,"4268568","1p partial monosomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1515766","t(3;5)(q25;q34)","C36415","A cytogenetic abnormality that refers to the translocation of the long arm (q25) of chromosome 3 and the long arm (q34) of chromosome 5. It is associated with the development of acute myeloid leukemia arising from myelodysplastic syndrome, acute myeloid leukemia with multilineage dysplasia, and acute myeloid leukemia with myelodysplasia-related changes.","t(3;5)(q25;q34) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515779","t(6;11)(q27;q23)","C36610","A cytogenetic abnormality that refers to the translocation of the long arm (q27) of chromosome 6 and the long arm (q23) of chromosome 11. It is associated with the development of de novo acute myeloid leukemia.","t(6;11)(q27;q23) | t(6;11)(q27;q23.3)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513481","Monosomy 5","C36523","A cytogenetic aneuploidy abnormality that refers to the presence of one chromosome 5 only. It is associated with the development of refractory anemia with excess blasts, refractory anemia with multilineage dysplasia, and refractory anemia with multilineage dysplasia and ringed sideroblasts.","Monosomy 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0694898","WT1 Gene","C18262","This gene plays a role in regulation of transcription. It is involved in the control of both cell differentiation and proliferation.","WT1 Gene | WT1 | WT1 Transcription Factor Gene | Wilms Tumor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3266990","KIT Gene Mutation","C39712","A molecular genetic abnormality that refers to mutation of the c-kit (CD117) proto-oncogene. It is associated with the development of gastrointestinal stromal tumor and gastrointestinal autonomic nerve tumor. It has also been described in acute myeloid leukemias, dysgerminomas, and seminomas.","KIT Gene Mutation | C-KIT Mutation | C-KIT Mutation | CD117 Gene Mutation | CD117 Mutation | CKIT Mutation - Unspecified | KIT Mutation | KIT Proto-Oncogene Tyrosine Protein Kinase Gene Mutation | V-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Gene Mutation | c-KIT Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881788","Mesenchymal Metaplasia","C54710","A morphologic finding that refers to the transformation or replacement of a group of non-mesenchymal cells into osseous, cartilagenous, or lipomatous cells.","Mesenchymal Metaplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448801","Lymphocytic Infiltrate","C35983","A morphologic finding referring to the presence of a cellular infiltrate that is composed of non-neoplastic or neoplastic lymphocytes in a tissue sample.","Lymphocytic Infiltrate | Lymphocytic infiltration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347359","Non-Fasting Specimen","C70702","A specimen obtained from a subject who has not abstained from food or water.","Non-Fasting Specimen | Non-Fasting Biospecimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879741","As Directed","C64619","Indicates that a drug or therapy should be used as specified by the prescribing physician.","As Directed | Ut Dictum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512200","Glomeruloid Vessels Present","C35926","A morphologic finding that refers to microvascular proliferation that resembles glomeruloid structures.  It is seen in gliomas.","Glomeruloid Vessels Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334962","Polymorphonuclear Cell Infiltrate","C35982","A morphologic finding referring to an acute inflammatory infiltrate that is composed of polymorphonuclear cells.","Polymorphonuclear Cell Infiltrate | Neutrophilic Infiltrate | Neutrophilic Infiltrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272724","Perinuclear Halo Present","C96344","A morphologic finding referring to the presence of a vacuolated area that surrounds the nucleus.  It results from nuclear shrinking.","Perinuclear Halo Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272725","Mini-Gemistocyte","C96345","A neoplastic gemistocytic astrocyte characterized by a diminutive size, a single, eccentric nucleus, and a cytoplasmic droplet of eosinophilic material.","Mini-Gemistocyte | Minigemistocyte",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272726","Circumferential Endothelial Hyperplasia","C96346","Intraluminal hyperplasia of endothelial cells, encircling the entire lumen.","Circumferential Endothelial Hyperplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272727","Chicken-Wire Vasculature","C96347","A morphologic finding that refers to delicate vascular channel formations.  It is characterized by the formation of arborizing and curving capillaries.","Chicken-Wire Vasculature | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272728","Multiple Serpentine Pseudopalisading Pattern","C96348","A morphologic finding referring to the presence of multiple foci of serpentine necrosis and glial cell perivascular pseudopalisading in a glioma.","Multiple Serpentine Pseudopalisading Pattern | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333514","Zonal Necrosis","C96350","A morphologic finding referring to the presence of necrosis that is confined to a specific anatomic zone. Representative example is the hepatic zonal necrosis that affects the hepatic parenchyma either in the portal areas or around the hepatic veins.","Zonal Necrosis | ",,,,,,,,,,,,,,,"4238867","Zonal necrosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3272729","Perineuronal and/or Perivascular Satellitosis","C96351","A morphologic finding that refers to the accumulation of glial cells encircling neurons and/or vessels in a tissue specimen.","Perineuronal and/or Perivascular Satellitosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272730","Entrapped Gray Matter Present","C96352","A morphologic finding that refers to the presence of ectopic gray matter in a tissue sample.","Entrapped Gray Matter Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272731","Entrapped White Matter Present","C96353","A morphologic finding that refers to the presence of ectopic white matter in a tissue sample.","Entrapped White Matter Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449215","Microcyst","C96357","A tiny cyst that is usually identified by microscopic examination in a tissue specimen.","Microcyst | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272735","Small Cell Component Present","C96361","A morphologic finding that refers to the presence of a small cell component in a cellular infiltrate.","Small Cell Component Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272736","Oligodendroglioma-Like Component with Perinuclear Cytoplasmic Halos Present","C96362","A morphologic finding referring to the presence of a cellular infiltrate that is composed of cells with perinuclear cytoplasmic halos, resembling oligodendrocytes.","Oligodendroglioma-Like Component with Perinuclear Cytoplasmic Halos Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1317977","Epithelial Metaplasia","C96363","A morphologic finding that refers to the replacement of a group of one type of epithelial cells (e.g., glandular epithelial cells) to another type of epithelial cells (e.g., squamous epithelial cells).","Epithelial Metaplasia | ",,,,,,,,,,,,,,,"4184611","Epithelial metaplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3272737","Micro-Mineralization","C96365","A term that refers to the microarchitectural environment and mineralization.","Micro-Mineralization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032976","Pregnancy Test","C92949","Any examination performed to assess if a female is gravid.","Pregnancy Test | ",,,,,,,,,,,,,,,"4250175","Pregnancy detection examination",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332469","Fissure","C66793","A long narrow slit or groove that divides an organ into lobes.","Fissure | ",,,,,,,,,,,,,,,"4046645","Fissured",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1515800","t(9;11)(p22;q23)","C36370","A cytogenetic abnormality that refers to the translocation of the short arm (p21.3) of chromosome 9 and the long arm (q23.3) of chromosome 11. It is associated with the development of acute myeloid leukemia with the MLLT3-MLL fusion gene transcript.","t(9;11)(p21.3;q23.3) | t(9;11)(p22.3;q23.3) | t(9;11)(p22;q23) | t(9;11)(p22;q23)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521461","Loss of Chromosome 5q","C27712","A cytogenetic abnormality that refers to loss of all or part of the long arm of chromosome 5 (5q). It is associated with the development of myelodysplastic syndrome with isolated deletion (5q), acute myeloid leukemia with multilineage dysplasia, and acute myeloid leukemia with myelodysplasia-related changes.","Loss of Chromosome 5q | 5q Deletion | 5q- | del(5q)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0265415","Loss of Chromosome 7q","C36408","A cytogenetic abnormality that refers to loss of all or part of the long arm of chromosome 7 (7q). It is associated with the development of chronic myelomonocytic leukemia with eosinophilia, refractory anemia with excess blasts, refractory anemia with multilineage dysplasia, and refractory anemia with multilineage dysplasia and ringed sideroblasts.","Loss of Chromosome 7q | 7q Deletion | 7q- | del(7q)",,,,,,,,,,,,,,,"4216042","7q partial monosomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517995","Loss of Chromosome 9q","C39875","A cytogenetic abnormality that refers to the loss of all or part of the long arm of chromosome 9 (9q).  It is associated with the development of acute myeloid leukemia and various types of carcinomas.","Loss of Chromosome 9q | del(9q)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517997","Loss of Chromosome Y","C36599","A cytogenetic abnormality that refers to the loss of all or part of the sex-determining chromosome Y. It is associated with the development of the accelerated and blast phases of chronic myelogenous leukemia, BCR-ABL1 positive, and various types of carcinomas.","Loss of Chromosome Y | del(Y)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515701","t(10;11)(p11;q23)","C36611","A cytogenetic abnormality that refers to the translocation of the short arm (p11) of chromosome 10 and the long arm (q23) of chromosome 11. It is associated with the development of acute myeloid leukemia with variant MLL translocations.","t(10;11)(p11;q23) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515710","t(11;19)(q23;p13.1)","C36371","A cytogenetic abnormality that refers to the translocation of the long arm (q23.3) of chromosome 11 and the short arm (p13.1) of chromosome 19. It is associated with the development of acute myeloid leukemia with variant MLL translocations and topoisomerase II inhibitor-related acute myeloid leukemia.","t(11;19)(q23.3;p13.1) | t(11;19)(q23;p13.1) | t(11;19)(q23;p13.1)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897145","inv(16)(p13.1;q22)","C36373","A chromosomal inversion that involves chromosome 16. It is associated with the development of acute myeloid leukemia CBFB-MYH11, acute myelomonocytic leukemia with abnormal eosinophils, and granulocytic sarcoma.","inv(16)(p13.1;q22) | inv(16)(p13.1;q22.1) | inv(16)(p13.1q22) | inv(16)(p13.1q22) | inv(16)(p13.1q22.1) | inv(16)(p13;q22) | inv(16)(p13q22)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938165","Parathyroid Hormone","C41027","Parathyroid hormone (115 aa, ~13 kDa) is encoded by the human PTH gene. This protein is involved in the modulation of calcium ion and phosphate concentration in the blood.","Parathyroid Hormone | PTH | Parathormone | Parathyrin | Parathyroid Hormone 1 | Prepro-PTH | Preproparathyroid Hormone | parathormone | parathyrin | parathyroid hormone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987134","DKK1 protein, human","C95418","Dickkopf-related protein 1 (266 aa, ~29 kDa) is encoded by the human DKK1 gene. This protein is involved in both receptor binding and cell communication.","Dickkopf-Related Protein 1 | Dickkopf Related Protein-1 | Dickkopf-1 | Dkk-1 | SK | hDkk-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825912","Type I Collagen C-Telopeptide Measurement","C82038","The determination of the amount of the type I collagen C-telopeptide present in a sample.","Type I Collagen C-Telopeptide Measurement | C-Terminal Telopeptide of Type I Collagen | CTXI | Type I Collagen C-Telopeptides | Type I Collagen X-linked C-telopeptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826670","Site Unblinding Occurrence","C83058","An indication or description that the trial site has been unblinded in a blinded clinical trial.","Site Unblinding Occurrence | DSUNBLND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826259","Subject Unblinding","C82524","An indication or description that a previously masked component of a study is revealed to the individual taking part in the study.","Subject Unblinding | UNBLND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2364481","Romiplostim","C52183","A recombinant protein with megakaryopoiesis stimulating activity. Romiplostim mimics endogenous thrombopoietin (TPO), directly binding to and activating the platelet thrombopoietin receptor (TpoR, Mpl, or CD110 antigen), a cytokine receptor belonging to the hematopoietin receptor superfamily. Activation of TpoR stimulates the proliferation and differentiation of megakaryocytes, resulting in an increase in the production of blood platelets.","Romiplostim | AMG 531 | Amgen Megakaryopoiesis Protein 2 | Nplate | ROMIPLOSTIM | romiplostim",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0718327","Imiquimod","C1431","A synthetic agent with immune response modifying activity. As an immune response modifier (IRM), imiquimod stimulates cytokine production, especially interferon production, and exhibits antitumor activity, particularly against cutaneous cancers. Imiquimod's proapoptotic activity appears to be related to Bcl-2 overexpression in susceptible tumor cells. (NCI04)","Imiquimod | 1H-Imidazo(4,5-c)quinolin-4-amine, 1-(2-methylpropyl)- | 4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline | Aldara | IMIQUIMOD | R 837 | S 26308 | Zyclara | imiquimod",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1721288","Sevelamer Carbonate","C78122","No Value Exists","Sevelamer Carbonate | Renagel | SEVELAMER CARBONATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986936","How Often Able to Control Irritations in the Last Month","C95139","A question about the frequency an individual feels or felt able to control the irritations in their life during the last month.","How Often Able to Control Irritations in the Last Month Question | How Often Able to Control Irritations | How Often Able to Control Irritations | How Often Able to Control Irritations in the Last Month | How Often Able to Control Irritations in the Last Month | In the last month, how often have you been able to control irritations in your life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0063242","Hypromelloses","C80902","A semisynthetic, inert, viscoelastic polymer. It is used as an ophthalmic lubricant and as an excipient in oral medications.","Hypromelloses | HPMC | HYPROMELLOSE, UNSPECIFIED | Hydroxypropyl Methylcellulose | Hypromellose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040613","Tranexamic Acid","C47765","A synthetic derivative of the amino acid lysine with antifibrinolytic activity. With strong affinity for the five lysine-binding sites of plasminogen, tranexamic acid competitively inhibits the activation of plasminogen to plasmin, resulting in inhibition of fibrinolysis; at higher concentrations, this agent noncompetitively inhibits plasmin. This agent has a longer half-life, is approximately ten times more potent, and is less toxic than aminocaproic acid, which possesses similar mechanisms of action.","Tranexamic Acid | Amixam | Cyclohexanecarboxylic Acid, 4-(aminomethyl)-, trans- | Cyclokapron | Cyklokapron | Hemostan | Lysteda | Prexam | TRANEXAMIC ACID | Tranexamic acid | Tranhexamic Acid | Tranofast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2932409","Brentuximab Vedotin","C66944","An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.","Brentuximab Vedotin | ADC SGN-35 | Adcetris | Anti-CD30 Antibody-Drug Conjugate SGN-35 | Anti-CD30 Monoclonal Antibody-MMAE SGN-35 | Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35 | BRENTUXIMAB VEDOTIN | Brentuximab vedotin | SGN 35 | SGN-35 | SGN35 | cAC10-vcMMAE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449214","Event-Free Survival","C96340","The length of time after treatment during which a patient survives with no sign of a particular complication of disease.","Event-Free Survival | EFS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515091","Surgically-Created Resection Cavity","C20051","The space that is left after the surgical removal of a body part or tumor.","Surgically-Created Resection Cavity | Intrasurgical Resection Cavity | Resection Cavity | SCRC | Surgically-Created Cystic Resection Cavity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0580586","Extracranial","C94424","Outside of the cranium (bones that surround the brain).","Extracranial | extracranial",,,,,,,,,,,,,,,"4119321","Extracranial",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2911690","Disease Controlled","C82500","An indication or description that a particular disorder is being managed successfully.","Disease Controlled | CTRL | Controlled | Under Control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513384","Molecular Genetic Technique","C19235","The methods and tools used for DNA analysis and manipulation.","Molecular Genetic Technique | Molecular Biology Technique | Molecular Technique",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919528","KMT2A Gene","C18585","This gene is involved in transcriptional regulation and alterations in the gene are associated with acute lymphoblastic leukemia.","KMT2A Gene | KMT2A | Lysine Methyltransferase 2A Gene | MLL | MLL Gene | MLL Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282451","Clinical Practice Guidelines","C28237","Guidelines developed to help health care professionals and patients make decisions about screening, prevention, or treatment of a specific health condition.","Clinical Practice Guidelines | clinical practice guidelines",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0872139","cross reactivity immunity","C96482","A molecular interaction between a ligand molecule and a receptor molecule, where the ligand and receptor are not conventional partners. This interaction can occur because the ligand molecule shares structural features with the archetypal ligand.","Cross Reaction | Cross Reactivity | Cross-reaction | Cross-reactive | Crosstalk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272807","Simultaneous Trisomies of Chromosomes 4 and 10","C96481","The concurrent presence of three copies each of chromosomes 4 and 10.","Simultaneous Trisomies of Chromosomes 4 and 10 | Double Trisomy 4, 10 | Trisomy 4 and 10 | Trisomy of Both Chromosomes 4 and 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986930","How Often Upset by Something Unexpected in the Last Month","C95133","A question about the frequency an individual is or was upset about something unexpected during the last month.","How Often Upset by Something Unexpected in the Last Month | How Often Upset By Something Unexpected Last Month | How Often Upset By Something Unexpected Last Month | How Often Upset By Something Unexpected in the Last Month | In the last month, how often have you been upset because of something that happened unexpectedly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986931","How Often Unable to Control Important Things in the Last Month","C95134","A question about the frequency an individual feels or felt unable to control the important things in their life during the last month.","How Often Unable to Control Important Things in the Last Month Question | How Often Unable to Control Important Things | How Often Unable to Control Important Things | How Often Unable to Control Important Things in the Last Month | How Often Unable to Control Important Things in the Last Month | In the last month, how often have you felt that you were unable to control the important things in your life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986932","How Often Felt Nervous and Stressed in the Last Month","C95135","A question about the frequency an individual feels or felt nervous and stressed during the last month.","How Often Felt Nervous and Stressed in the Last Month | How Often Felt Nervous and Stressed | How Often Felt Nervous and Stressed | In the last month, how often have you felt nervous and 'stressed'",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986933","How Often Felt Confident About Ability to Handle Problems in the Last Month","C95136","A question about the frequency an individual feels or felt confident about their ability to handle personal problems during the last month.","How Often Felt Confident About Ability to Handle Problems in the Last Month | How Often Felt Confident About Ability to Handle Problems | How Often Felt Confident About Ability to Handle Problems | In the last month, how often have you felt confident about your ability to handle your personal problems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986934","How Often Felt Things Going Your Way in the Last Month","C95137","A question about the frequency an individual feels or felt that things were going their way during the last month.","How Often Felt Things Going Your Way in the Last Month | How Often Felt Things Going Your Way | How Often Felt Things Going Your Way | In the last month, how often have you felt that things were going your way",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986935","How Often Could not Cope with Things that Needed Doing in the Last Month","C95138","A question about the frequency an individual feels or felt they could not cope with all the things they need to do during the last month.","How Often Could not Cope with Things that Needed Doing in the Last Month | How Often Could Not Cope With Things That Needed Doing | How Often Could Not Cope With Things That Needed Doing | In the last month, how often have you found that you could not cope with all the things that you had to do",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986937","How Often Felt on Top of Things in the Last Month","C95140","A question about the frequency an individual feels or felt on top of things during the last month.","How Often Felt on Top of Things in the Last Month | How Often Felt On Top Of Things | How Often Felt On Top Of Things | In the last month, how often have you felt that you were on top of things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986938","How Often Angered by Things Outside Your Control in the Last Month","C95141","A question about the frequency an individual feels or felt angered by things outside their control during the last month.","How Often Angered by Things Outside Your Control in the Last Month | How Often Angered By Things Outside Your Control | How Often Angered By Things Outside Your Control | In the last month, how often have you been angered because of things that happened that were outside of your control | In the last month, how often have you been angered because of things that were outside of your control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986939","How Often Felt Difficulties too High to Overcome in the Last Month","C95142","A question about the frequency an individual feels or felt that difficulties were too many to overcome during the last month.","How Often Felt Difficulties too High to Overcome in the Last Month | How Often Felt Difficulties Too High To Overcome | How Often Felt Difficulties Too High To Overcome | In the last month, how often have you felt difficulties were piling up so high that you could not overcome them",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986940","Almost Never","C95143","A subjective answer that something rarely happens.","Almost Never | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986941","Fairly Often","C95144","A subjective answer that something occurs relatively frequently.","Fairly Often | Rather Often | rather often",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1311230","Lacosamide","C83859","A functionalized amino acid compound specifically synthesized as an anticonvulsive drug to use as add-on therapy for partial-onset seizures with antinociceptive and neuroprotective activities. Lacosamide selectively enhances slow inactivation of voltage-gated sodium channels without affecting fast inactivation, thereby stabilizing hyperexcitabe neuronal membranes. Furthermore, this agent binds to collapsin response mediator protein 2 (CRMP2; DPYSL2), a cytosolic phosphoprotein expressed in most tissues. In the nervous system, CRMP2 acts as a mediator of growth cone collapse as well as modifies axon number, length, and neuronal polarity.","Lacosamide | (2R)-2-(Acetylamino)-N-benzyl-3-methoxypropanamide | ADD 234037 | Erlosamide | Harkoseride | LACOSAMIDE | SPM 927 | Vimpat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0074719","Sodium Metaarsenite","C91098","A highly soluble, orally available trivalent arsenic-containing telomerase inhibitor with potential antitumor activity. Although the exact mechanism through which sodium metaarsenite exerts its effect has yet to be fully elucidated, this agent appears to target and bind to telomeric sequences, specifically TTAGGG repeats, leading to a shortening of telomeres, and subsequent induction of apoptosis and inhibition of tumor cell growth. In addition, sodium metaarsenite also leads to the translocation of the catalytic subunit of telomerase into the cytoplasm and inhibition of the activity of telomerase. Telomerase is active in most tumors cells and is responsible for the maintenance of telomere length and plays a key role in cellular proliferation, but is quiescent in normal, healthy cells. The susceptibility to sodium metaarsenite seems to be inversely correlated with initial length of telomeres.","Sodium Metaarsenite | KML-001 | SODIUM ARSENITE | Sodium Arsenite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2744646","Ganitumab","C71531","A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Ganitumab binds to membrane-bound IGF-1R, preventing binding of the ligand IGF-1 and the subsequent triggering of the PI3K/Akt signaling pathway; inhibition of this survival signaling pathway may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. IGF-1R is a tyrosine kinase and a member of the insulin receptor family. IGF-1R activation stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been highly implicated in tumorigenesis and metastasis.","Ganitumab | AMG 479 | AMG-479 | AMG479 | Anti-IGF-1R Human Monoclonal Antibody AMG-479 | GANITUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2934615","CDK2/TRKA inhibitor PHA-848125 AC","C88312","The maleate salt form of milciclib, an orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and tropomyosin receptor kinase A (TRKA), with potential antineoplastic activity. CDK2/TRKA inhibitor PHA-848125 AC potently inhibits cyclin-dependent kinase 2 (CDK2) and exhibits activity against other CDKs including CDK1 and CDK4, in addition to TRKA. Inhibition of these kinases may result in cell cycle arrest and apoptosis of tumor cells that express these kinases. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some cancer cell types. The neurotrophin receptor TRKA is mutated in a variety of cancer cell types.","Milciclib Maleate | 1H-Pyrazolo(4,3-H)quinazoline-3-carboxamide, 4,5-dihydro-N,1,4,4-tetramethyl-8-((4-(4-methyl-1-piperazinyl)phenyl)amino)-, (2Z)-2-Butenedioate (1:1) | CDK2/TRKA Inhibitor PHA-848125 AC | MILCICLIB MALEATE | N,1,4,4-Tetramethyl-8-[[4-(4-methylpiperazin-1-yl)phenyl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide | PHA-848125 AC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2002939","Sepantronium Bromide","C61091","A small-molecule proapoptotic agent with potential antineoplastic activity. Sepantronium bromide selectively inhibits survivin expression in tumor cells, resulting in inhibition of survivin antiapoptotic activity (via the extrinsic or intrinsic apoptotic pathways) and tumor cell apoptosis. Survivin, a member of the inhibitor of apoptosis (IAP) gene family, is expressed during embryonal development and is absent in most normal, terminally differentiated tissues; upregulated in a variety of human cancers, its expression in tumors is associated with a more aggressive phenotype, shorter survival times, and a decreased response to chemotherapy.","Sepantronium Bromide | 1H-Naphth(2,3-d)imidazolium, 4,9-dihydro-1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazinylmethyl)-, Bromide | SEPANTRONIUM BROMIDE | Survivin Inhibitor YM155 | Survivin Inhibitor YM155 | YM-155",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346611","KSP inhibitor ARRY-520","C68937","A synthetic, small molecule targeting the kinesin spindle protein (KSP) with potential antineoplastic activity. Filanesib specifically inhibits KSP (kinesin-5 or Eg5), resulting in activation of the spindle assembly checkpoint, induction of cell cycle arrest during the mitotic phase, and consequently cell death in tumor cells that are actively dividing. Because KSP is not involved in postmitotic processes, such as neuronal transport, this agent does not cause the peripheral neuropathy that is often associated with tubulin-targeting agents. KSP is an ATP-dependent microtubule motor protein that is essential for the formation of bipolar spindles and the proper segregation of sister chromatids during mitosis.","Filanesib | 1,3,4-Thiadiazole-3(2H)-carboxamide, 2-(3-Aminopropyl)-5-(2,5-difluorophenyl)-N-methoxy-N-methyl-2-phenyl-, (2S)- | ARRY 520 | ARRY-520 | ARRY520 | FILANESIB | KSP Inhibitor ARRY-520",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347623","Polymeric Camptothecin Prodrug XMT-1001","C69079","A polymeric prodrug of camptothecin (CPT) with potential antineoplastic activity. Polymeric camptothecin prodrug XMT-1001 consists of CPT conjugated to the 60-70 kDa, inert, bio-degradable, hydrophilic copolymer poly[1-hydroxymethylene hydroxymethyl formal] (PHF). Through a dual-phase, non-enzymatic release mechanism, CPT is first released in plasma from XMT-1001 as the lipophilic prodrugs CPT-SI (a succinimidoglycinate derivative) and CPT-SA (a succinamidoyl glycinate derivative), which are then hydrolyzed within tissues to release the lactone form of CPT. CPT inhibits the catalytic activity of DNA topoisomerase I, thereby inhibiting DNA replication and inducing apoptosis. This agent may exhibit a more favorable pharmacokinetic profile than other agents in the same class.","Polymeric Camptothecin Prodrug XMT-1001 | MER-1001 | XMT-1001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1832037","Checkpoint Kinase Inhibitor AZD7762","C66961","A synthetic small molecule inhibitor of checkpoint kinases (Chks) with potential chemosensitizing activity. AZD7762 binds to and inhibits Chks, which may prevent cell cycle arrest and subsequent nucleotide excision repair in DNA-damaged tumor cells, resulting in tumor cell apoptosis. This agent may enhance the cytotoxicity of DNA-damaging agents. Chks are protein kinases that regulate either G1/S or G2/M transitions in the cell cycle. In the presence of DNA damage or incomplete DNA replication, Chks become activated and initiate cell cycle arrest to allow DNA repair or the completion of DNA replication.","Checkpoint Kinase Inhibitor AZD7762 | AZD-7762 | AZD7762",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347621","Firtecan Pegol","C70651","A polyethylene glycol (PEG) conjugate of 7-ethyl-10-hydroxycamptothecin with potential antineoplastic activity. After hydrolysis in vivo, 7-ethyl-10-hydroxycamptothecin (SN38), an active metabolite of irinotecan, is released from firtecan pegol; 7-ethyl-10-hydroxycamptothecin selectively stabilizes topoisomerase I-DNA covalent complexes, resulting in single-stranded and double-stranded DNA breaks, the inhibition of DNA replication, and the induction of apoptosis. This agent is designed to deliver the active metabolite to tumor cells without the need for conversion as is the case with irinotecan. Compared to unPEGylated 7-ethyl-10-hydroxycamptothecin, PEGylation improves solubility and allows for parental delivery, and may result in a longer half-life and higher exposure for tumor cells.","Firtecan Pegol | EZN-2208 | FIRTECAN PEGOL | PEG-SN38 | Poly(oxy-1,2-ethanediyl), alpha,alpha',alpha'',alpha'''-(oxydi-3,1,2-propanetriyl)tetrakis(omega-(2-((2-(((4S)- 4,11-diethyl-9-hydroxy-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano(3',4':6,7) indolizino(1,2-b)quinolin-4-yl)oxy)-2-oxoethyl)amino)-2-oxoethoxy)- | Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449098","Often","C91247","On many occasions, or in many situations.","Often | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002615","Ammonium Chloride","C47396","A systemic and urinary acidifying salt. Ammonium chloride helps maintain pH and exerts a mild diuretic effect. This acid forming salt also exerts an expectorant effect by irritating the mucous membranes and is used for alleviation of cough.","Ammonium Chloride | AMMONIUM CHLORIDE | Amchlor | Ammonium Muriate | Sal Ammoniac | Salammonite | Salmiac",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514892","Resistance Process","C41546","A Resistance Process consists of activities of biologic molecules or complexes involved in processes that maintain immunity to, or counteract, defeat, or withstand the effects of, an antagonistic agent.","Resistance Process | Resistance | Resistant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1535531","Recombinant Thyroid-Stimulating Hormone","C887","A recombinant form of the heterodimeric human anterior pituitary glycoprotein thyroid-stimulating hormone (TSH) with potential use in hormone replacement therapy. Recombinant TSH binds to TSH receptors on thyroid epithelial cells and stimulates TSH-dependent signaling pathways. This stimulates iodine uptake and organification, and induces synthesis and secretion of thyroglobulin (Tg), triiodothyronine (T3), and thyroxine (T4).","Recombinant Thyroid-Stimulating Hormone | Recombinant TSH | THYROTROPIN | Thyroid Stimulating Hormone | Thyrotropin | Thytropar | rhTSH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0060520","Fluorescein","C61766","An organic compound that has wide use as a synthetic coloring agent. It is prepared by heating phthalic anhydride and resorcinol over a zinc catalyst, and it crystallizes as a deep red powder. This agent emits an intense green fluorescence in the presence of alkaline solutions and therefore is used as a label when conjugated to antibodies or as a contrast agent for ophthalmic angiography.","Fluorescein | FLUORESCEIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206359","Isothiocyanates","C45711","A chemical group containing the monovalent -N=C=S group. Isothiocyanate is the fundamental structure in many synthetic and biological active compounds.","Isothiocyanate | Isothiocyanates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032962","Pregnancy Complication","C34941","The co-occurrence of pregnancy and a disease. The disease may precede or follow conception and it may or may not have a deleterious effect on the pregnant woman or fetus.","Pregnancy Complication | Complication Related to Pregnancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1337615","Bulk (conceptual)","C69010","Large size, volume, or amount.","Bulk | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827500","Newborn Examination","C84749","A general assessment of the overall health of a newborn.","Newborn Examination | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3662195","Labor and Delivery Complication","C87091","The occurrence of a pregnancy complication during childbirth, which includes both labor (the process of childbirth) and delivery (the birth itself).","Labor and Delivery Complication | ",,,,,,,,,,,,,,,"440795","Complication occurring during labor and delivery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2985264","Fetal Examination","C92714","A test or diagnostic examination to assess the health status and well being of the fetus.","Fetal Examination | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521124","Against","C64937","In opposition to or in competition with someone or something.","Against | ",,,,,,,,,,,,,,,"4279930","Against",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1366332","Immunoglobulin Kappa Locus","C26425","This region represents the germline organization of the kappa light chain locus. The locus includes V (variable), J (joining), and C (constant) segments. During B cell development, a recombination event at the DNA level joins a single V segment with a J segment; the C segment is later joined by splicing at the RNA level. Recombination of many different V segments with several J segments provides a wide range of antigen recognition. Additional diversity is attained by junctional diversity, resulting from the random additional of nucleotides by terminal deoxynucleotidyltransferase, and by somatic hypermutation, which occurs during B cell maturation in the spleen and lymph nodes. (from LocusLink)","Immunoglobulin Kappa Locus | IGK | Immunoglobulin Kappa Gene | Kappa Light Chain Gene",,,,,,,,,,,,,,,"4006732","Immunoglobulin kappa light chain gene",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017351","Immunoglobulin Heavy Locus","C26422","This region represents the germline organization of the immunoglobulin heavy chain locus. The locus includes V (variable), J (joining), diversity (D), and C (constant) segments. During B cell development, a recombination event at the DNA level joins a D segment with a J segment; a V segment is then joined to the D-J gene. The C segment is later joined by splicing at the RNA level. Recombination of many different V segments with several D and J segments provides a wide range of antigen recognition. Additional diversity is attained by junctional diversity, resulting from the random additional of nucleotides by terminal deoxynucleotidyltransferase, and by somatic hypermutation, which occurs during B cell maturation in the spleen and lymph nodes. (from LocusLink)","Immunoglobulin Heavy Locus | IGH | Immunoglobulin Heavy Chain Gene | Immunoglobulin Heavy Chain Locus | Immunoglobulin Heavy Gene",,,,,,,,,,,,,,,"4194511","Immunoglobulin gene GM allotype",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0072402","Serine/Threonine Protein Kinase","C17325","A class of enzymes that transfer phosphate groups to serine or threonine residues in peptides or proteins. These proteins are involved in the progression of signal transduction pathways.","Serine/Threonine Protein Kinase | EC 2.7.11 | STK | Serine-Threonine Protein Kinase | Serine/Threonine-Protein Kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1449702","Protein Kinase Inhibitor","C1404","Any substance that inhibits protein kinase, an enzyme that catalyzes the addition of a phosphate group to a protein and is active in many diverse signaling pathways.","Protein Kinase Inhibitor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0220903","Purine","C786","A series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases. They include ADENINE and GUANINE, constituents of nucleic acids, as well as many alkaloids such as CAFFEINE and THEOPHYLLINE. Uric acid is the metabolic end product of purine metabolism.","Purine | 1H-Purine | PURINE | beta-Purine | purine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028621","Nucleoside","C707","Any of the glycosylamines consisting of either a purine or pyrimidine nucleobase, to a ribose or deoxyribose ring. Examples of these include cytidine, uridine, adenosine, guanosine, thymidine, inosine and others.","Nucleoside | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516672","Clonal Immunoglobulin Gene Rearrangement","C36443","A DNA sequence rearrangement that results in the creation of a novel immunoglobulin. This process occurs during the differentiation of B-lymphocytes, such that individual B-cell progenitors, and their descendents, express an identical antibody molecule.","Clonal Immunoglobulin Gene Rearrangement | Monoclonal Immunoglobulin Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272928","Alexa Fluor","C96647","Any of series of proprietary fluorescent dyes that span the visible spectrum. They are typically used as cell and tissue labels in fluorescence microscopy and cell biology.","Alexa Fluor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272897","Stack","C96607","An ordered collection of data items arranged so as to be accessed in last-in first-out order.","Stack | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281481","Anti-Tumor Necrosis Factor Therapy","C15577","Drug treatment to reduce the activity of tumor necrosis factor, particulary to control inflammation in disease modalities.","Anti-Tumor Necrosis Factor Therapy | Anti-TNF Therapy | anti-TNF therapy | anti-TNF-alpha therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334346","Latent Membrane Protein 1","C18863","Latent membrane protein 1 (386 aa, ~42 kDa) is encoded by the Epstein-Barr virus LMP1 gene. This protein is involved in both the activation of nuclear factor-kappa-B family signaling pathways and the inhibition of apoptosis of infected B-lymphocytes.","Latent Membrane Protein 1 | EBV LMP-1 | EBV LMP1 | EBV Latent Membrane Protein 1 | LMP-1 | LMP1 | LMP1 | Latent Membrane Protein-1 | Protein p63 | Protein p63; ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711339","Nominal Scale","C47798","A scale that uses only categories, with no inherent order. (www.reference-wordsmith.com)","Nominal Scale | NOMINAL | Nom",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709336","Ordinal Scale","C47797","A scale that uses ordered numbers where the difference between successive designations may not be constant.","Ordinal Scale | ORDINAL | Ord | Ordinal Sequence | Ordinal Series",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709842","Ratio Scale","C47800","A scale that uses ordered numbers with a constant difference and which has a natural zero.","Ratio Scale | Ratio Sequence | Ratio Series",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335580","RAD51C Gene","C20814","This gene plays a role in DNA repair and meiotic recombination.","RAD51C Gene | RAD51 Paralog C Gene | RAD51C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1172465","H2AX protein, human","C19432","Histone H2AX (143 aa, ~15 kDa) is encoded by the human H2AX gene. This protein plays a role in nucleosome formation and V(D)J recombination.","Histone H2AX | H2A Histone Family, Member X | H2A.X | H2A/X | H2AFX | H2AX | H2AX Histone | Histone H2A.X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005910","Body Weight","C81328","The weight of a subject.","Body Weight | BW | Vital Signs – Weight | Weight | Weight at encounter | patient weight | patient_weight | subjectWeight | weight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521114","Infrequent","C64954","Not occurring regularly or at short intervals.","Infrequent | Infrequently | OCCASIONAL | Occasional | Rare",,,,,,,,,,,,,,,"4100948","Infrequent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL413610","LMP-400","C90594","An indenoisoquinoline and non-camptothecin inhibitor of topoisomerase I (Top I) with potential antineoplastic activity. Topoisomerase I inhibitor LMP400 binds to the topoisomerase I-DNA covalent cleavage complexes, and inhibits repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations. Compared to camptothecins, indenoisoquinolines are chemically stable, produce stable Top I-DNA cleavage complexes, induce unique DNA cleavage sites and appear more resistant to multidrug efflux pumps.","Topoisomerase I Inhibitor LMP400 | LMP400",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL413611","Topoisomerase I Inhibitor LMP776","C90595","An indenoisoquinoline and non-camptothecin inhibitor of topoisomerase I (Top I) with potential antineoplastic activity. Topoisomerase I inhibitor LMP776 binds to the topoisomerase I-DNA covalent cleavage complexes, and inhibits repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations. Compared to camptothecins, indenoisoquinolines are chemically stable, produce stable Top I-DNA cleavage complexes, induce unique DNA cleavage sites and appear more resistant to multidrug efflux pumps.","Topoisomerase I Inhibitor LMP776 | LMP776",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336711","Testicular Leukemia","C9277","An acute or chronic leukemia that affects the testis. Microscopically, there is interstitial infiltration of the testis by leukemic cells.","Testicular Leukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054950","CD30 Antigen","C38906","Tumor necrosis factor receptor superfamily member 8 (595 aa, ~ 64 kDa) is encoded by the human TNFRSF8 gene. This protein is involved in ligand-mediated signal transduction, the positive regulation of apoptosis and the inhibition of cell proliferation.","Tumor Necrosis Factor Receptor Superfamily Member 8 | Antigen CD30 | CD30 | CD30 Antigen | CD30L Receptor | Cytokine Receptor CD30 | Ki-1 Antigen | Lymphocyte Activation Antigen CD30 | Lymphoid Activation Antigen CD30 | TNF Receptor 8 | TNFRSF8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376526","Human Herpesvirus 8","C14327","A gammaherpesvirus that contributes to the development of Kaposi sarcoma.","Human Herpesvirus 8 | HHV-8 | HHV8 | HUMAN HERPESVIRUS 8 | Herpes Virus 8 | Human Gammaherpesvirus 8 | KSHV | Kaposi Sarcoma Herpes Virus | Kaposi Sarcoma-Associated Herpes Virus | Kaposi sarcoma-associated herpesvirus | Kaposi's Sarcoma-associated Herpesvirus | Kaposi's sarcoma-associated herpesvirus | Virus-HHV8 | human herpesvirus 8",,,,,,,,,,,,,,,"4146444","Human herpesvirus 8",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0167636","PAX5 protein, human","C30124","Paired box protein Pax-5 (391 aa, ~42 kDa) is encoded by the human PAX5 gene. This protein plays a role in B-cell differentiation, neural development, spermatogenesis and gene transcription.","Paired Box Protein Pax-5 | B-Cell Lineage Specific Activator Protein | B-Cell Specific Transcription Factor | B-Cell-Specific Transcription Factor | BSAP | PAX5 | Paired Box 5 | Paired Box Homeotic Gene 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334162","Immunoglobulin-Binding Protein 1, Human","C26637","Immunoglobulin-binding protein 1 (339 aa, ~39 kDa) is encoded by the human IGBP1 gene. This protein plays a role in the modulation of both protein phosphatase activity and B-cell receptor-mediated signaling.","Immunoglobulin-Binding Protein 1 | Alpha 4 | Alpha 4 Protein | B Cell Signal Transduction Molecule Alpha 4 | B-Cell Signal Transduction Molecule Alpha 4 | CD79A-Binding Protein 1 | CD79a-Binding Protein 1 | IGBP1 | Immunoglobulin (CD79A) Binding Protein 1 | Immunoglobulin Binding Protein 1 | Immunoglobulin Binding Protein 1 | Protein Alpha-4 | Protein Phosphatase 2/4/6 Regulatory Subunit | Renal Carcinoma Antigen NY-REN-16",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1448774","BCL6 protein, human","C26149","B-cell lymphoma 6 protein (706 aa, ~79 kDa) is encoded by the human BCL6 gene. This protein is involved in transcriptional repression, apoptosis regulation and cell cycle progression.","B-Cell Lymphoma 6 Protein | B-Cell Lymphoma 5 Protein | B-cell CLL/Lymphoma-6 | BCL-5 | BCL-6 | BCL5 | BCL6 | BCL6 Protein | Cys-His2 Zinc Finger Transcription Factor | LAZ-3 Protein | LAZ3 | Protein LAZ-3 | ZNF51 | Zinc Finger Protein 51 | Zinc Finger and BTB Domain-Containing Protein 27",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1505685","B-Cell Receptor CD22, Human","C17279","B-cell receptor CD22 (847 aa, ~95 kDa) is encoded by the human CD22 gene. This protein is involved in B-cell/B-cell interactions and downstream signaling.","B-Cell Receptor CD22 | B-Cell Antigen CD22 | B-Lymphocyte Cell Adhesion Molecule | BL-CAM | CD22 | CD22 Antigen | Lyb8 | Sialic Acid-Binding Ig-Like Lectin 2 | Sialic Acid-Binding Immunoglobulin-Like Lectin 2 | Siglec-2 | T-Cell Surface Antigen Leu-14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705283","IRF4 wt Allele","C52132","Human IRF4 wild-type allele is located within 6p25-p23 and is approximately 20 kb in length. This allele, which encodes interferon regulatory factor 4 protein, plays a role in lymphocyte proliferation and maturation.","IRF4 wt Allele | Interferon Regulatory Factor 4 wt Allele | LSIRF Gene | MUM1 Gene | Multiple Myeloma Oncogene 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376515","BCL2 Gene","C17963","This gene is involved in apoptotic regulation. Overexpression of this gene promotes the pathogenesis of B-Cell lymphomas, due to anti-apoptotic activity.","BCL2 Gene | B-Cell CLL/Lymphoma 2 Gene | BCL2 | BCL2, Apoptosis Regulator Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025250","Neprilysin","C16836","Neprilysin (750 aa, ~86 kDa) is encoded by the human MME gene. This protein is involved in the metabolism of biologically active peptides.","Neprilysin | Antigen CD10 | Atriopeptidase | CALLA | CD10 | CD10 Antigen | Common ALL Antigen | Common Acute Lymphoblastic Leukemia Antigen | EC 3.4.24.11 | Enkephalinase | MME | Membrane Metalloendopeptidase | Membrane Metalloendopeptidase | NEP | Neutral Endopeptidase | SFE | Skin Fibroblast Elastase | cALLa",,,,,,,,,,,,,,,"4180068","Lymphocyte antigen CD10",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1416991","MALT1 Gene","C60671","This gene plays a role in signal transduction and in the pathology of mucosa-associated lymphoid tissue lymphomas.","MALT1 Gene | MALT1 | MALT1 Paracaspase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413172","CCND1 Gene","C18021","This gene plays a role in the regulation of mitotic events.","CCND1 Gene | CCND1 | Cyclin D1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515498","9p21","C13489","A chromosome band present on 9p","9p21 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919436","REL Protein","C18508","Proto-oncogene c-Rel (619 aa, ~69 kDa) is encoded by the human REL gene. This protein plays a role in both transcriptional regulation and signal transduction.","Proto-Oncogene c-Rel | REL | REL Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332399","BCL6 Gene","C24260","This gene is involved in transcriptional repression and plays a role in the modulation of B-cell responses.","BCL6 Gene | B-Cell CLL/Lymphoma 6 Gene | BCL6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708843","MYC wt Allele","C53086","Human MYC wild-type allele is located in the vicinity of 8q24.21 and is approximately 5 kb in length. This allele, which encodes myc proto-oncogene protein, plays a role in the regulation of transcription by RNA polymerase II. Burkitt's lymphoma is associated with at least three translocations, t(2;8)(p12;q24), t(8;14)(q24;q32) and t(8;22)(q24;q11) which fuse the gene to the promoter site for either the immunoglobin heavy or light chain genes. In a variety of other tumors the gene is expressed aberrantly.","MYC wt Allele | C-MYC | MRTL | MYCC | bHLHe39 | v-MYC Myelocytomatosis Viral Oncogene Homolog (Avian) Gene | v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337924","Melanesian","C43409","Denotes a person from any of the islands in the region extending from the west Pacific to the Arafura Sea, north and north-east of Australia. or of that ancestry.","Melanesian | MELANESIAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0240790","Polynesian","C43405","Denotes a person from any of the over 1,000 islands in the central and southern Pacific Ocean bounded by a triangle with its three corners at Hawaii, New Zealand, and Easter Island or a person of that ancestry.","Polynesian | POLYNESIAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556099","Micronesian","C43402","Denotes a person from any of the islands in the western pacific encompassing the area from the Philippines in the west, Indonesia to the south west, Papua New Guinea and Melanesia to the south, and Polynesia to the south-east and east.","Micronesian | MICRONESIAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334779","Mitotic Activity","C35959","Having to do with the presence of dividing (proliferating) cells. Cancerous tissue generally has more mitotic activity than normal tissues.","Mitotic Activity | Mitosis (Y/N) | Mitotic Rate | mitotic activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162541","Bacteriophage P1","C14301","A double-stranded DNA virus that infects E. coli and other enteric bacteria. Additionally, this phage is used in molecular biotechnology as a cloning vector for eukaryotic DNA.","Bacteriophage P1 | Enterobacteria Phage P1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1524027","Haemophilus Influenzae B Vaccine","C1126","A vaccine against serotype b of the Gram-negative bacterium H. influenzae (Hib). Hib vaccines contain polysaccharide-protein conjugate antigens that produce greater host immune responses than first-generation purified polysaccharide vaccine. These vaccines may differ with regard to use of protein carriers, polysaccharides, diluents, and preservatives.","Haemophilus Influenzae B Vaccine | ActHIB | Haemophilus b conjugate vaccine | Haemophilus b oligosaccharide conjugate vacccine | Haemophilus influenzae B Polysaccharide Conjugate Vaccine (PRP-OMP) | Haemophilus influenzae B Polysaccharide Conjugate Vaccine (PRP-T) | Hib TITER vaccine | Hib Vaccine | HibTITER | PRP vaccine | PedvaxHIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0305065","Polyvalent pneumococcal vaccine","C1643","An polyvalent vaccine used to prevent infection by the bacterium Streptococcus pneumoniae. Pneumococcal polyvalent vaccine contains highly purified capsular antigens from the 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae to ensure cross-protection. Following vaccination, protective capsular type-specific antibody levels typically develop by the third week; serotype-specific antibody levels generally decline after 5-10 years.","Pneumococcal Polyvalent Vaccine | PCV 23 | PPSV | PPSV23 | PPSV23 Vaccine | Pneumococcal 23-valent Polysaccharide Vaccine | Pneumococcal Polysaccharide Vaccine | Pneumococcal Vaccine Polyvalent | Pneumovax 23 | Pnu-Imune 23",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518062","Lymphocyte Function","C19633","Cell biology studies concerned with understanding the functioning of lymphocytes.","Lymphocyte Function | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086661","MYC Gene","C16887","This gene plays a role in cell cycle progression and apoptosis. Cytogenetic aberrations in the gene are involved in cellular transformation and are associated with a variety of hematopoietic tumors, leukemias and lymphomas.","MYC Gene | MYC | v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1135135","Erlotinib","C65530","A quinazoline derivative with antineoplastic properties.  Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.","Erlotinib | ERLOTINIB | erlotinib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1122962","Gefitinib","C1855","An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis. (NCI04)","Gefitinib | 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline | GEFITINIB | Iressa | N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) propoxy]-4-quinazolinamine | Tykessa | ZD 1839 | ZD-1839 | ZD1839 | gefitinib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831875","Urelumab","C62449","A fully human agonistic monoclonal antibody targeting the CD137 receptor with potential immunostimulatory and antineoplastic activities. Anti-CD137 monoclonal antibody specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells. CD137 is a member of the tumor necrosis factor (TNF)/nerve growth factor (NGF) family of receptors and is expressed by activated T- and B-lymphocytes and monocytes; its ligand has been found to play an important role in the regulation of immune responses.","Urelumab | BMS-663513 | Immunoglobulin G4, Anti-(Human Receptor 4-1BB) (Human Gamma-Chain), Disulfide with Human Kappa-Chain, Dimer | URELUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008318","Cholecalciferol","C48194","A steroid hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role in maintaining blood calcium and phosphorus levels and mineralization of bone. The activated form of cholecalciferol binds to vitamin D receptors and modulates gene expression. This leads to an increase in serum calcium concentrations by increasing intestinal absorption of phosphorus and calcium, promoting distal renal tubular reabsorption of calcium and increasing osteoclastic resorption.","Cholecalciferol | (3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol | 9,10-Secocholesta-5,7,10(19)-trien-3-beta-ol | 9,10-Secocholesta-5,7,10(19)-trien-3-ol | CHOLECALCIFEROL | Calciol | Delsterol | Vitamin D3 | cholecalciferol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1550615","Venous Blood","C78730","Blood carried in veins, generally deoxygenated blood containing urea and other waste products which is transported through the venous system to the heart and lungs. The exception is blood within the pulmonary vein which is oxygenated and travels from the lungs to the left atrium of the heart.","Venous Blood | Blood venous | VENOUS BLOOD",,,,,,,,,,,,,,,"4203287","Venous blood",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2986425","Unresected","C94255","Describes an organ, tissue, or cancer that has not been either partly or completely removed by surgery.","Unresected | unresected",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0080188","CD15 Antigen","C96898","A carbohydrate molecule found on the surface of neutrophils, eosinophils and monocytes. It is involved in neutrophil chemotaxis and phagocytosis. Expression of this antigen is associated with Hodgkin disease, chronic lymphocytic leukemia, and acute lymphoblastic leukemia.","CD15 Antigen | 3-Fucosyl-N-Acetyl-Lactosamine | C15 | CD15 | LeX | Lewis X | LewisX Antigen | SSEA-1 | Stage-Specific Embryonic Antigen 1",,,,,,,,,,,,,,,"4174192","Lymphocyte antigen CD15",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2744538","FCER2 protein, human","C96902","Low affinity immunoglobulin epsilon Fc receptor (321 aa, ~36 kDa) is encoded by the human FCER2 gene. This protein is involved in B cell differentiation and IgE production.","Low Affinity Immunoglobulin Epsilon Fc Receptor | Antigen CD23 | BLAST-2 | C-Type Lectin Domain Family 4 Member J | CD23 | CD23 Antigen | Fc-Epsilon-RII | Immunoglobulin E-Binding Factor | Lymphocyte IgE Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0081938","Itgb1 protein, human","C96911","Integrin beta-1 (798 aa, ~88 kDa) is encoded by the human ITGB1 gene. This protein plays a role in leukocyte migration, signal transduction, ligand binding and cell adhesion.","Integrin Beta-1 | Antigen CD29 | CD29 | CD29 Antigen | Fibronectin Receptor Subunit Beta | GPIIA | Glycoprotein IIa | ITGB1 | VLA-4 Subunit Beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0753253","SDC1 protein, human","C96914","Syndecan-1 (310 aa, ~32 kDa) is encoded by the human SDC1 gene. This protein is involved in the mediation of cell adhesion, signaling and cytoskeletal organization.","Syndecan-1 | Antigen CD138 | CD138 | CD138 Antigen | SDC1 | SYND1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0149707","Hematospermia","C96935","A finding indicating the presence of blood in the semen.","Hematospermia | ",,,,,,,,,,,,,,,"439871","Hemospermia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1832054","Selumetinib","C66939","An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2. MEK 1 and 2 are dual specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various cancer cells, and are drivers of diverse cellular responses, including proliferation. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers.","Selumetinib | ARRY-142886 | AZD 6244 | AZD-6244 | AZD6244 | MEK Inhibitor AZD6244 | MEK inhibitor AZD6244 | SELUMETINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0762659","Amrubicin Hydrochloride","C47948","The hydrochloride salt of a third-generation synthetic 9-amino-anthracycline with antineoplastic activity. Amrubicin intercalates into DNA and inhibits the activity of topoisomerase II, resulting in inhibition of DNA replication, and RNA and protein synthesis, followed by cell growth inhibition and cell death. This agent has demonstrated a higher level of anti-tumor activity than conventional anthracycline drugs without exhibiting any indication of the cumulative cardiac toxicity common to this class of compounds.","Amrubicin Hydrochloride | (+)-(7S,9S)-9-Acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)- 6,11-dihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride | AMRUBICIN HYDROCHLORIDE | Amrubicin HCl | Calsed | SM 5887 | SM-5887 | SM5887 | SMP-5887",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1121854","Symbicort","C71534","An inhalation aerosol formulation containing budesonide and the fumarate dihydrate salt of formoterol with anti-inflammatory and bronchial smooth muscle-relaxing activities. The synthetic corticosteroid steroid budesonide binds to intracellular glucocorticosteroid receptors (GRs), exhibiting inhibitory activities against multiple cell types and mediators associated with allergic inflammation. The long-acting beta-adrenergic receptor agonist formoterol selectively binds to beta-2 adrenergic receptors in bronchial smooth muscle, activating intracellular adenyl cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP); increased intracellular cAMP result in the relaxation of bronchial smooth muscle and inhibition of the cellular release of mediators of immediate hypersensitivity, especially from mast cells.","Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol | Symbicort Turbuhaler",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418289","PCA3 Gene","C92557","This gene may be involved in prostate cancer.","PCA3 Gene | PCA3 | Prostate Cancer Associated 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0971731","Degarelix","C48385","A long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial (Leydig) cells in the testes.","Degarelix | ASP 3550 | ASP-3550 | ASP3550 | DEGARELIX | FE 200486 | FE-200486 | FE200486 | Firmagon | N-acetyl-3-(naphtalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-4-((((4S)-2,6-dioxohexahydropyrimidin-4-yl)carbonyl)amino)-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide | degarelix",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085228","Fluvoxamine","C61769","A 2-aminoethyl oxime ether of aralkylketones, with antidepressant, antiobsessive-compulsive, and anxiolytic properties. Fluvoxamine, chemically unrelated to other selective serotonin reuptake inhibitors, selectively blocks serotonin reuptake by inhibiting the serotonin reuptake pump at the presynaptic neuronal membrane. This increases serotonin levels within the synaptic cleft, prolongs serotonergic transmission and decreased serotonin turnover, thereby leading to antidepressant, anxiolytic and antiobsessive-compulsive effects. Fluvoxamine shows no significant affinity for histaminergic, alpha or beta adrenergic, muscarinic, or dopaminergic receptors in vitro.","Fluvoxamine | FLUVOXAMINE | fluvoxamine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332826","CYP1A2 Gene","C26519","This gene plays a role in the oxidation/activation of procarcinogens. It is also involved in the metabolism of drugs and other xenobiotics.","CYP1A2 Gene | CYP1A2 | Cytochrome P450, Family 1, Subfamily A, Polypeptide 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332829","CYP2C9 Gene","C21597","This gene is involved in the oxidation of drugs, xenobiotics, fatty acids and steroids.","CYP2C9 Gene | CYP2C9 | Cytochrome P450, Family 2, Subfamily C, Polypeptide 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2608038","Eribulin Mesylate","C26644","The mesylate salt of a synthetic analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression.","Eribulin Mesylate | 2-(3-Amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopentacosin-5-(4H)-one | B1939 Mesylate | E7389 | ER-086526 | ER-086526 Mesylate | ERIBULIN MESYLATE | Halaven | Halichondrin B Analog | eribulin mesylate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1690432","Denosumab","C61313","A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity. Denosumab specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces, resulting in inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation.","Denosumab | AMG 162 | AMG-162 | DENOSUMAB | Denosumab Biosimilar MW032 | Denosumab Biosimilar QL1206 | Denosumab Biosimilar TK-006 | Prolia | Ranmark | TK-006 | Xgeva | denosumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273143","Clonal Subgroup","C96960","A population of cells or organisms that are identifiable by specific, shared characteristics and presumed to have originated from a single progenitor.","Clonal Subgroup | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014027","Enalaprilat","C47510","The active metabolite of the pro-drug enalapril, a dicarboxylate-containing angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. Enalaprilat prevents the conversion of angiotensin I into angiotensin II by inhibiting ACE, thereby leading to decreased vasopressor activity and resulting in vasodilation. This agent also decreases aldosterone secretion by the adrenal cortex, which leads to an increase in natriuresis.","Enalaprilat | ENALAPRILAT | ENALAPRILAT DIHYDRATE | Enalaprilat Dihydrate | N-(1(S)-Carboxy-3-phenylpropyl)-L-alanyl-L-proline",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007277","Carotid Body","C66852","A cluster of cells that function as chemo-receptors, located at the bifurcation of the carotid artery. Its main purpose is to detect changes in the composition of arterial blood.","Carotid Body | CAROTID BODY | Carotid body | carotid body | carotid glomus | glomus caroticum",,,,,,,,,,,,,"UBERON:0001629","carotid body","4197418","Carotid body structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042425","Ampulla of Vater","C13011","The junction of the common bile and main pancreatic ducts, which protrudes into the medial aspect of the descending duodenum at the major duodenal papilla. The flow of bile and pancreatic juices into the duodenum through the Ampulla of Vater is controlled by the sphincter of Oddi.","Ampulla of Vater | AMPULLA OF VATER | Ampulla | Ampulla Of Vater | Hepatopancreatic Ampulla | Vater's Ampulla | Vater's ampulla | ampulla biliaropancreatica | ampulla of Vater | ampulla of bile duct | biliaropancreatic ampulla | hepatopancreatic ampulla | papilla Vateri",,,,,,,,,,,,,"UBERON:0004913","hepatopancreatic ampulla","4283974","Structure of ampulla of Vater",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017067","Ganglion","C12719","A cluster of nervous tissue principally composed of neuronal cell bodies external to the central nervous system (CNS).","Ganglion | GANGLION | Ganglia | Ganglionic | Neural Ganglion | ganglion",,,,,,,,,,,,,"UBERON:0000045","ganglion","4271846","Structure of nervous system ganglion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0086610","Mesothelium","C33105","A simple layer of cells, derived from the mesoderm that lines the coelom or body cavity of the embryo. In the adult, it covers all true serous membranes (peritoneum, pericardium, pleura).","Mesothelium | MESOTHELIUM | mesothelium",,,,,,,,,,,,,"UBERON:0001136","mesothelium","4323589","Mesothelium structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242692","Skeletal Muscle Tissue","C13050","Striated muscles that are under voluntary control of the organism.  They are connected at either or both ends to a bone and are utilized for locomotion and other movements.","Skeletal Muscle Tissue | MUSCLE, SKELETAL | SKELETAL MUSCLE TISSUE | Skeletal Muscle | skeletal muscle tissue",,,,,,,,,,,,,"UBERON:0001134","skeletal muscle tissue","4133963","Skeletal muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004247","Atrioventricular Node","C32161","A small mass of specialized cardiac muscle fibers, located near the ostium of the coronary sinus and giving rise to the atrioventricular bundle of the conduction system of the heart.","Atrioventricular Node | A-V Node",,,,,,,,,,,,,,,"4093760","Structure of atrioventricular node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017068","Autonomic Ganglion","C12720","A cluster of nerve cell bodies in the peripheral nervous system, which consists of large, multipolar, motor neurons. There are two types of autonomic ganglia: sympathetic ganglia lie close to the CNS in sympathetic chain, or in clusters called prevertebral ganglia, and parasympathetic ganglia occur farther from CNS, often in target organs.","Autonomic Ganglion | Autonomic Ganglia",,,,,,,,,,,,,,,"4211554","Autonomic plexus ganglia structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018792","Cardiac Atrium","C12728","The paired upper chambers of the heart. The left atrium receives oxygenated blood from the pulmonary vein and pumps blood into the left ventricle. The right atrium receives venous deoxygenated blood from the entire body via the superior and inferior vena cavae and pumps blood into the right ventricle.","Cardiac Atrium | Atria of Heart | Atria, Cardiac | Atrial structure (body structure) | Atrium | Atrium of Heart | Auricle of Heart | Cardiac Atria | HEART, ATRIUM | Heart Atria | Heart Atrium",,,,,,,,,,,,,,,"4242112","Atrial structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0225836","Interatrial Septum","C32818","The tissue that separates the right atrium from the left atrium in the heart.","Interatrial Septum | Atrial Septum | Heart, Atrial Septum | INTERATRIAL SEPTUM",,,,,,,,,,,,,,,"4241346","Interatrial septum structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0230976","Amniotic Cavity","C34102","The fluid-filled space within the amnion that contains the developing fetus.","Amniotic Cavity | ",,,,,,,,,,,,,,,"4274953","Structure of amniotic cavity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010672","Cystic Duct","C32421","A short duct attached to the gallbladder through which the bile from the gallbladder is secreted in the common bile duct.","Cystic Duct | DUCT, CYSTIC | cystic duct","C24.0|C24.0","Cystic bile duct|Cystic duct",,,,,,,,,,,,,"4299647","Cystic duct structure",,,,,,,,,,,,,"--","--|--",,,,,,,,"--"
"C0010092","Corpus Luteum","C26465","A group of cells that remain of the Graafian follicle following ovulation. This structure is composed of endocrine tissue and produces progesterone. This is needed to prepare the uterine lining for implantation by the fertilized egg.","Corpus Luteum | CORPUS LUTEUM",,,,,,,,,,,,,,,"4062794","Structure of corpus luteum of ovary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008524","Choroid Plexus","C12694","Blood vessels forming villous structures in the third, fourth, and lateral ventricles of the brain.","Choroid Plexus | BRAIN, CHOROID PLEXUS | CHOROID PLEXUS",,,,,,,,,,,,,,,"4216205","Structure of choroid plexus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008484","Chordae Tendineae","C32307","Tendons that connect the papillary muscles to the tricuspid valve and mitral valve.","Chordae Tendineae | CHORDAE TENDINEAE | Chorda Tendinea",,,,,,,,,,,,,,,"4010666","Structure of chordae tendineae cordis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006298","Brown Adipose Tissue","C32235","Brown-colored adipose tissue that is present in higher concentrations in newborns and hibernating animals. It contains numerous small droplets of lipids and high numbers of mitochondria as its primary function is to generate body heat.","Brown Adipose Tissue | ADIPOSE TISSUE, BROWN | BAT | Brown Fat",,,,,,,,,,,,,,,"4051715","Brown fat",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1511308","Breast Fat Pad","C12369","A mass of adipose tissue in the breast that is surrounded by fibrous tissue.","Breast Fat Pad | Mammary Gland Fat Pad",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517187","Fimbriated End of the Fallopian Tube","C32607","The fringed end of the fallopian tube.","Fimbriated End of the Fallopian Tube | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0684077","Fibrocartilage","C32599","Connective tissue with fibrous and cartilaginous components.","Fibrocartilage | ",,,,,,,,,,,,,,,"4241162","Fibrocartilage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015813","Head of the Femur","C32718","The highest portion of the femoral bone that articulates with the acetabulum.","Head of the Femur | FEMORAL HEAD | Femur Head | Structure of head of femur (body structure)",,,,,,,,,,,,,,,"4102173","Structure of head of femur",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014540","Epiglottis","C12709","A small cartilagenous flap-like valve that closes over the larynx during swallowing to prevent food entering the lungs.","Epiglottis | EPIGLOTTIS | Epiglottic | epiglottis",,,,,,,,,,,,,,,"4189377","Epiglottis structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227829","Ectocervix","C12310","The portion of the cervix that extends into the vaginal vault, and is lined with stratified squamous epithelium.","Ectocervix | Exocervix | ectocervical | ectocervix",,,,,,,,,,,,,,,"4151672","Exocervical structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1328067","Breast Duct Lavage","C51969","A minimally-invasive procedure that permits sampling of breast ductal fluids for cytopathologic analysis.","Breast Duct Lavage | ductal lavage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020412","Hymen","C32750","Thin membranous tissue that surrounds the vaginal opening.","Hymen | ",,,,,,,,,,,,,,,"4101271","Structure of hymen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554606","Hippocampus","C12444","A curved gray matter structure of the temporal lobe lying on the floor of the lateral ventricle of the brain.","Hippocampus | BRAIN, HIPPOCAMPUS | HIPPOCAMPUS | Hippocampal | Hippocampal structure (body structure)",,,,,,,,,,,,,,,"4205874","Hippocampal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227948","Glans Penis","C12324","The most distal portion of the penis covered by the foreskin.","Glans Penis | Glans penis | PENIS, GLANS | glans penis",,,,,,,,,,,,,,,"4247281","Glans penis structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023317","Lens","C12743","A biconvex transparent structure of the eye through which light is focused on the retina. The lens sits behind the iris and is supported by the zonule, which connects it to the ciliary body. The lens is an avascular structure.","Lens | Crystalline Lens | EYE, LENS | LENS | Lens of Eye | Ocular Lens | Structure of lens of eye (body structure) | lens",,,,,,,,,,,,,,,"4301506","Lens clear",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227766","Labium Minus","C12307","One of the two longitudinal folds of skin located between the labia majora.","Labium Minus | LABIUM MINUS | Labia Minora | Labia Minus | Labium minus",,,,,,,,,,,,,,,"4137758","Labium minus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227760","Labium Majus","C12306","One of the two longitudinal folds of skin that form the lateral boundary of the vulva. It extends from the mons pubis to the perineum.","Labium Majus | LABIUM MAJUS | Labia Majora | Labia Majus | Labium majus",,,,,,,,,,,,,,,"4219641","Labium majus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2985476","Isthmus","C93172","A narrow part inside the body that connects two larger structures.","Isthmus | isthmus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042458","Inferior Vena Cava","C12815","A large vein that returns blood from the lower half of the body to the heart.","Inferior Vena Cava | Caudal Vena Cava | INFERIOR VENA CAVA | Posterior Vena Cava | inferior vena cava",,,,,,,,,,,,,,,"4271699","Inferior vena cava structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031272","Peyer Patch","C12771","Lymphoid cell tissue in the small intestinal mucosa.","Peyer Patch | PEYER'S PATCH | Peyer's Patch | Peyer's Patches",,,,,,,,,,,,,,,"4143073","Structure of aggregated lymphoid follicle of small intestine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036099","Minor Salivary Gland","C33129","A small salivary gland located within the aerodigestive tract.","Minor Salivary Gland | ",,,,,,,,,,,,,,,"4227271","Minor salivary gland structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035298","Retina","C12343","A light-sensitive membrane that lines the back wall of the eyeball. The retina is continuous with the optic nerve and this way transmits optical images to the brain.","Retina | RETINA | Retinal structure (body structure) | inner layer of eyeball | retina | retina of camera-type eye | tunica interna of eyeball",,,,,,,,,,,,,"UBERON:0000966","retina","4208981","Retinal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034196","Pylorus","C12260","The lower part of the stomach that connects to the duodenum.","Pylorus | PYLORUS | STOMACH, PYLORUS | pars pylorica | pars pylorica gastricae | pyloric part of stomach | pyloric region | pylorus | stomach pyloric region",,,,,,,,,,,,,"UBERON:0001166","pylorus","4090133","Pyloric structure of stomach",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227238","Pyloric Sphincter","C33433","The muscular structure at the distal portion of the stomach, opening into the duodenum.","Pyloric Sphincter | PYLORIC SPHINCTER",,,,,,,,,,,,,,,"4236761","Pyloric sphincter structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227824","Perimetrium","C33298","The serosal surface of the uterus.","Perimetrium | Uterine Body Serosal Surface",,,,,,,,,,,,,,,"4294518","Structure of uterine serosa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030288","Pancreatic Duct","C12272","A duct joining the pancreas to the common bile duct to supply pancreatic juices.","Pancreatic Duct | Canal of Wirsung | Main Pancreatic Duct | PANCREATIC DUCT | Pancreatic duct | pancreatic duct",,,,,,,,,,,,,,,"4289618","Pancreatic duct structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0222007","Toenail","C33790","A thin, horny translucent plate covering the end of each toe.","Toenail | TOENAIL | Toe Nail",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039259","Tail","C77663","The flexible prolongated structure of the posterior part of an animal's body.","Tail | TAIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042459","Superior Vena Cava","C12816","The large vein that terminates in the right atrium and transports deoxygenated blood from the head, neck, arms, and chest to the heart.","Superior Vena Cava | Anterior Vena Cava | Cranial Vena Cava | SUPERIOR VENA CAVA | superior vena cava","C49.3","Superior vena cava",,,,,,,,,,,,,"4167648","Superior vena cava structure",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0038553","Sublingual Salivary Gland","C12234","A salivary gland located under the tongue in the floor of the oral cavity.","Sublingual Salivary Gland | GLAND, SALIVARY, SUBLINGUAL | Rivinus' gland | SALIVARY GLAND, SUBLINGUAL | Sublingual Gland | Sublingual gland | Sublingual gland structure (body structure) | ductus sublingualis | sublingual gland",,,,,,,,,,,,,"UBERON:0001832","sublingual gland","4229131","Sublingual gland structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1267092","Smooth Muscle Tissue","C12437","Involuntary muscle tissue of the internal organs. It is composed of elongated muscle cells or fibers that are not arranged in a striated pattern and form layers of muscle tissue. The smooth muscle cells contain a contractile apparatus composed of thin and thick filaments and a cytoskeleton composed of intermediate filaments.","Smooth Muscle Tissue | MUSCLE, SMOOTH | SMOOTH MUSCLE TISSUE | Smooth Muscle",,,,,,,,,,,,,,,"4220025","Smooth muscle (organ) structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037189","Sinoatrial Node","C33555","A cluster of specialized cells located in the upper area of the right atrium. These cells generate the electrical impulses that result in the normal sinus rhythm.","Sinoatrial Node | S-A Node",,,,,,,,,,,,,,,"4339406","Structure of sinoatrial node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036760","Serosa","C13169","A membrane lining the external walls of the body cavities and reflected over the surfaces of protruding organs. It consists of mesothelium lying on a connective tissue layer, and secretes a watery exudate.","Serosa | Serous Membrane | serosa | serous membrane",,,,,,,,,,,,,,,"4295423","Serous membrane structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036505","Sebaceous Gland","C33519","Small glands located within the epidermis, and associated with the hair follicle, that produce and secrete an oily substance that lubricates the skin and hair.","Sebaceous Gland | GLAND, SEBACEOUS | SEBACEOUS GLAND",,,,,,,,,,,,,,,"4009566","Sebaceous gland structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036270","Scalp","C89807","The skin which covers the top of the head and which is usually covered by hair.","Scalp | SCALP | Scalp structure (body structure) | scalp",,,,,,,,,,,,,"UBERON:0000403","scalp","4213244","Scalp structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020885","Ileum","C12387","The final section of the small intestine.","Ileum | ILEUM | Ileal structure (body structure) | SMALL INTESTINE, ILEUM | ileum",,,,,,,,,,,,,"UBERON:0002116","ileum","4144672","Ileal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1513778","Mutation Detection","C18890","The detection by physical, chemical, or biological means of an altered DNA sequence. Includes SSCP, DNA sequencing, hybridization, and reporter gene expression.","Mutation Detection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226246","Cerebellar Artery","C52845","An artery that originates from the basilar artery and distributes blood to the cerebellum.","Cerebellar Artery | ",,,,,,,,,,,,,,,"4301712","Structure of cerebellar artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0226601","Cerebellar Vein","C53032","A superficial vein that is located on the cerebellum and that drains the cerebellum.","Cerebellar Vein | ",,,,,,,,,,,,,,,"4289233","Structure of cerebellar vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007770","Cerebral Artery","C12691","An artery which directly supplies the cerebral cortex and which has deeper branches that supply the underlying white matter.","Cerebral Artery | CEREBRAL ARTERY | Cerebral Arteries",,,,,,,,,,,,,,,"4227577","Structure of cerebral artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007797","Cerebral Vein","C53037","Any of the external or internal veins that drain the cerebral hemispheres.","Cerebral Vein | CEREBRAL VEIN",,,,,,,,,,,,,,,"4286503","Structure of cerebral vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015801","Femoral Artery","C12715","An artery that starts within the inguinal region and extends to the lower extremities.","Femoral Artery | ARTERY, FEMORAL | FEMORAL ARTERY | Femoral | Femoral artery | Structure of femoral artery (body structure) | femoral artery",,,,,,,,,,,,,"UBERON:0002060","femoral artery","4297788","Structure of femoral artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015808","Femoral Nerve","C52816","A nerve that originates from the lumbar nerves and innervates the anterior region of the thigh.","Femoral Nerve | NERVE, FEMORAL",,,,,,,,,,,,,,,"4034284","Structure of femoral nerve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152442","Mammary Duct Ectasia","C3522","Dilatation of the lumen of the mammary ducts without evidence of epithelial atypia.","Mammary Duct Ectasia | Comedomastitis | Ectasia of Mammary Duct | Ectasia of the Mammary Duct",,,,,,,,,,,,,,,"438808","Mammary duct ectasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022427","Jugular Vein","C12738","Veins in the neck which drain the brain, face, and neck into the brachiocephalic or subclavian veins.","Jugular Vein | JUGULAR VEIN | Structure of jugular vein (body structure) | VEIN, JUGULAR | Vena Jugularis",,,,,,,,,,,,,,,"4269235","Structure of jugular vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519013","Periurethral Zone of the Prostatic Parenchyma","C33311","The inner most portion of the prostatic parenchyma surrounding the mid and proximal portions of the prostatic urethra where the ejaculatory ducts enter the urethra.","Periurethral Zone of the Prostatic Parenchyma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036037","Sacral Bone","C33504","One of the five bones of the spine that fuse to create the sacrum.","Sacral Bone | ","C41.4","Sacrum",,,,,,,,,,,,,"4185240","Bone structure of sacrum",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1519612","Transitional Zone of the Prostatic Parenchyma","C33803","The zone of the prostatic parenchyma that surrounds the proximal urethra.","Transitional Zone of the Prostatic Parenchyma | TZ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378602","Contusion","C50441","A bruise due to trauma.","Contusion | ",,,,,,,,,,,,,,,"4203279|441737","Contusion - lesion|Contusion",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1418424","PDE5A Gene","C95467","This gene plays a role in signaling.","PDE5A Gene | PDE5A | Phosphodiesterase 5A, cGMP-Specific Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272796","Colorectal Sporadic Serrated Polyp","C96469","A term that refers to a group of polypoid lesions in the colon and rectum that are characterized by the presence of serrated architecture of the epithelial component.  This group includes hyperplastic polyps, traditional serrated adenomas, and sessile serrated adenomas/polyps.","Colorectal Sporadic Serrated Polyp | cGMP-Specific 3',5'-Cyclic Phosphodiesterase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020888","Iliac Vein","C12734","Any of the three veins including the common, external and internal iliac veins.","Iliac Vein | ILIAC VEIN",,,,,,,,,,,,,,,"4088187","Iliac vein structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0226812","Brachial Vein","C12883","Deep vein of the upper arm that forms at the junction of the radial and ulnar veins and ends at the inferior border of the teres major.","Brachial Vein | BRACHIAL VEIN | VEIN, BRACHIAL",,,,,,,,,,,,,,,"4067169","Structure of brachial vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004456","Axillary Vein","C32171","A large blood vessel which returns blood to the heart from the lateral thorax, axilla, and upper limb. Each side of the body contains one axillary vein.","Axillary Vein | AXILLARY VEIN",,,,,,,,,,,,,,,"4288602","Structure of axillary vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038530","Subclavian Artery","C33643","An artery located below the clavicle that supplies blood to the head and the arms. The right subclavian artery originates from the brachiocephalic artery and the left subclavian artery originates from the aortic arch.","Subclavian Artery | ARTERY, SUBCLAVIAN | SUBCLAVIAN ARTERY | Structure of subclavian artery (body structure)","C49.3","Subclavian artery",,,,,,,,,,,,,"4272388","Structure of subclavian artery",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1510461","Aortic Body","C97112","A small mass that is located in the inferior surface of the aortic arch. It functions as a peripheral chemoreceptor and is composed of glomus cells.","Aortic Body | AORTIC BODY | aortic body",,,,,,,,,,,,,"UBERON:0034971","aortic body","4327482","Aortic body",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1120106","Ertapenem","C61752","A 1-beta-methyl carbapenem and broad-spectrum beta-lactam antibiotic with bactericidal property. Ertapenem binds to penicillin binding proteins (PBPs) located on the bacterial cell wall, in particular PBPs 2 and 3, thereby inhibiting the final transpeptidation step in the synthesis of peptidoglycan, an essential component of the bacterial cell wall. Inhibition results in a weakening and subsequent lysis of the cell wall leading to cell death of Gram-positive and Gram-negative aerobic and anaerobic pathogens. This agent is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, cephalosporinases and extended-spectrum beta-lactamases.","Ertapenem | ERTAPENEM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1832027","Ofatumumab","C66952","A fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. Ofatumumab binds specifically to CD20 on the surfaces of B cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B cells overexpressing CD20. The CD20 antigen, found on over 90% of B cells, B cell lymphomas, and other B cells of lymphoid tumors of B cell origin, is a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel; it is exclusively expressed on B cells during most stages of B cell development.","Ofatumumab | Arzerra | GSK1841157 | HuMax-CD20 | HuMax-CD20, 2F2 | Kesimpta | OFATUMUMAB | ofatumumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334376","Breast Intracystic Papillary Carcinoma","C7645","An intraductal breast carcinoma characterized by a papillary growth within a large cystic duct. There is no evidence of invasion of the breast parenchyma.","Breast Intracystic Papillary Carcinoma | Intracystic Breast Carcinoma | Intracystic Papillary Adenocarcinoma | Intracystic Papillary Breast Carcinoma | Intracystic Papillary Breast Carcinoma | Intracystic papillary adenocarcinoma | Noninfiltrating Intracystic Breast Carcinoma",,,,,,,,,,,,,,,"45766397","Encapsulated papillary carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332315","Apocrine Carcinoma In Situ of Breast","C5140","A ductal breast carcinoma in situ, characterized by the presence of neoplastic epithelial cells with apocrine differentiation.","Breast Apocrine Carcinoma In Situ | Apocrine Breast Carcinoma In Situ | Apocrine Breast Carcinoma In Situ | Apocrine Carcinoma In Situ of Breast | Apocrine Carcinoma In Situ of the Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334296","Solid Carcinoma","C4137","A carcinoma morphologically characterized by the presence of solid sheets of malignant epithelial cells in tissues.","Solid Carcinoma | Solid carcinoma, NOS","8230/3","Solid carcinoma, NOS",,,,,,,,,,,,,"4219923","Solid carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1335326","Papillary Growth Pattern","C35911","A morphologic finding indicating the presence of a cellular infiltrate with papillary growth in a tissue sample.","Papillary Growth Pattern | Papillary Pattern | Papillary Pattern | Papillary, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0393023","R-CHOP Regimen","C9760","A regimen consisting of cyclophosphamide, doxorubicin, prednisone, rituximab and vincristine that may be used for the treatment of AIDS-related B-cell lymphomas, Castleman disease, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, gastric and nongastric MALT lymphomas, nodular lymphocyte-predominant Hodgkin lymphoma, mantle cell Lymphoma, nodal marginal zone lymphoma (NMZL), splenic marginal zone lymphoma (SMZL), Waldenström macroglobulinemia and lymphoplasmacytic lymphoma, and post-transplant lymphoproliferative disorders.","R-CHOP Regimen | CHOP-Rituximab | CTX/DOX/MOAB IDEC-C2B8/PRED/VCR | Cyclophosphamide/Doxorubicin/Prednisone/Rituximab/Vincristine | R-CHOP | R-CHOP (SC Rituximab) | R-CHOP (rituximab-abbs) | R-CHOP (rituximab-arrx) | R-CHOP (rituximab-blit) | R-CHOP (rituximab-pvvr) | R-CHOP (rituximab-rite) | R-CHOP (rituximab-rixa) | R-CHOP (rituximab-rixi) | R-CHOP regimen | Rituxan/CHOP | Rituximab-Cyclophosphamide-Hydroxydaunorubicin-Oncovin-Prednisone Regimen | Rituximab/Cyclophosphamide/Doxorubicin/Prednisone/Vincristine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677922","Ovarian Ablation","C15691","Surgery, radiation therapy, or a drug treatment to stop the functioning of the ovaries.","Ovarian Ablation | ovarian ablation | ovarian suppression",,,,,,,,,,,,,,,"4161586","Ovarian ablation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332514","Asymmetry","C28025","Lack or absence of balanced proportions between parts of a thing.","Asymmetry | asymmetry",,,,,,,,,,,,,,,"4186570","Asymmetry",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026192","Minority Group","C16863","A minority is a group that is outnumbered by persons who do not belong to it, often people with different nationality, religion, culture or lifestyle from that of the mainstream in the society; racial or ethnic groups officially recognized by the U.S. government as minority populations.","Minority Group | Ethnic and Racial Minorities | Minorities | Minority",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337493","Paternal","C94324","Having to do with the father, coming from the father, or related through the father.","Paternal | paternal",,,,,,,,,,,,,,,"4075823","Paternal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3273256","Squamocolumnar Junction","C97148","The border between the squamous epithelium that lines the ectocervix and the columnar epithelium that lines the endocervix.","Squamocolumnar Junction | Ecto/Endocervical Junction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0683604","Payment-based participation","C17752","The payment mechanism that is used to compensate a healthcare provider for the care provided to a patient in form of a fee for each specific service performed as it is rendered and identified by a claim for payment.","Fee for Service Payment Method | FFS | Fee for Service | Fee-for-Service",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513793","Myelosuppressive Therapy","C15690","Any treatment that decreases the rate of blood cell production in the bone marrow.","Myelosuppressive Therapy | myelosuppressive therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882265","Practice-Based Research Collaborative in Evidence-Based Dentistry","C62551","A network of dental practices that will establish the infrastructure to perform a wide variety of oral health research studies in Idaho, Montana, Oregon, Utah and Washington.","Practice-Based Research Collaborative in Evidence-Based Dentistry | PRECEDENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549092","Antrum","C97102","A chamber formation in an organ.","Antrum | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0149614","Adnexal Mass","C35155","An abnormal growth in the ovary, fallopian tube, or surrounding connective tissue.","Adnexal Mass | adnexal mass",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826030","MIR335 wt Allele","C82185","The human MIR335 wild-type allele is located in the vicinity of 7q32.2 and is approximately 93 bases in length. This allele, which encodes MIR335 pre-miRNA, plays a role in the regulation of gene expression. Alteration in the expression of this gene is associated with development of breast cancer.","MIR335 wt Allele | MIRN335 | MicroRNA 335 wt Allele | hsa-mir-335",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL479739","Glomerular Filtration Rate Measurement","C90505","A kidney function test that measures the fluid volume that is filtered from the kidney glomeruli to the Bowman's capsule per unit of time.","Glomerular Filtration Rate | GFR",,,,,,,,,,,,,,,"4213477","Glomerular filtration rate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1511939","Differentiation Inducer","C1934","An agent that induces the differentiation or maturation of cells, specifically neoplastic cells, resulting in decreases in tumor growth and metastasis. (NCI04)","Differentiation Inducer | Differentiating Agents | Differentiation Agents",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515032","Substrate Interaction Domain","C14073","A Substrate Domain is a protein region that physically interacts stereospecifically, and usually at high affinity, with a specific target substrate. In enzymes, the substrate domain is often, though not necessarily, coincident with the catalytic domain. Typically, substrate interaction results in some protein conformational alteration and functional modification. (NCI)","Substrate Interaction Domain | Substrate Domain | Substrate Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278321","Bilateral Oophorectomy","C51590","Surgery to remove both ovaries.","Bilateral Oophorectomy | ",,,,,,,,,,,,,,,"4297990","Excision of bilateral ovaries",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2697943","1p/19q Codeletion","C79099","A chromosomal aberration where there is a loss of both the short arm of chromosome 1 and the long arm of chromosome 19. This chromosomal aberration is associated with oligodendroglial tumors.","1p/19q Codeletion | 1p/19q Co-deletion | 1p/19q co-deletion | Loss of Chromosomes 1p/19q | Loss of Chromosomes 1p/19q | Positive | del(1p/19q)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273280","Dental-Enamel Junction","C97212","The area of a tooth where the enamel and the underlying dentin are joined.","Dental-Enamel Junction | DEJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273281","Antral Follicle Count","C97213","The number of small ovarian follicles (approximately 2-8 mm in diameter) that can be detected and counted with transvaginal ultrasonography, to determine the remaining fertility potential in a woman.","Antral Follicle Count | AFC | Graafian Follicle Count | Tertiary Follicle Count",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3163695","Arterial Embolization","C15917","Therapeutic blockage of an artery by a clot of foreign material.","Arterial Embolization | TAE | Transarterial Embolization | arterial embolization",,,,,,,,,,,,,,,"40489494","Transarterial embolization",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1134675","Yttrium Y 90 Glass Microspheres","C38679","An injectable formulation of yttrium Y 90 consisting of glass microspheres containing the radioisotope yttrium Y 90.  When injected into the tumor vascular bed, yttrium Y 90 glass microspheres occlude tumor blood vessels and deliver a cytotoxic dose of beta radiation to the tumor site, thereby reducing the tumor burden. (NCI04)","Yttrium Y 90 Glass Microspheres | TheraSphere | Y-90 Therasphere",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017238","Absorbable Gelatin Sponge","C38705","A sterile hemostatic agent composed of purified porcine-derived gelatin.  In regional chemotherapy, absorbable gelatin sponge may be used to embolize arteries in the region of a tumor in order to block or retard blood flow; this blockage results in a locally increased concentration of chemotherapeutic agents delivered to the tumor when chemotherapeutic agents are infused into the embolized arterial circulation upstream of the blockage.","Absorbable Gelatin Sponge | Gelatin Sponge, Absorbable | Gelfoam",,,,,,,,,,,,,,,"4209894","Absorbable gelatin sponge",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332149","Possible","C82490","Capable of happening or occurring.","Possible | ",,,,,,,,,,,,,,,"4162850","Possible",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020349","5-Hydroxyeicosatetraenoic Acid","C558","A lipoxygenase metabolite of arachidonic acid and an intermediate in the pathway of leukotriene synthesis. 5-hydroxyeicosatetraenoic acid (5-HETE) is also a modulator of tubuloglomerular feedback, one of the mechanism the kidney uses to regulate glomerular filtration rate. Along with leukotriene B4, 5-HETE is often used as biomarker in evaluating eicosanoid metabolism and disease state.","5-Hydroxyeicosatetraenoic Acid | 5-HETE | 5-Hydroxy-6,8,11,14-eicosatetraenoic Acid | HETE | Hydroxyeicosatetraenoic Acid | Hydroxyeicosatetraenoic Acid",,,,,,,,,,,,,,,"4094963","Hydroxyeicosatetraenoic acid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0050078","8-Hydroxy-2'-deoxyguanosine","C1297","A major spontaneous oxidized derivative of 2'-deoxyguanosine and a biomarker of oxidative DNA damage. 8-hydroxy-2'-deoxyguanosine (8-oxo-dG) is formed through the reaction of guanine with reactive oxygen species. Although normally repaired and removed by the base excision repair mechanism, 8-oxo-dG can potentially mispair with deoxyadenine leading to G-to-T transversion mutations, which cause frequent recombinations and single nucleotide polymorphisms (SNPs) in the human genome. The concentration of 8-oxo-dG within a cell is a measurement of oxidative stress and may thus be used to assess the extent of physiological and environmental damage to DNA.","8-Hydroxy-2'-deoxyguanosine | 2-Amino-9-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3,7-dihydropurine-6,8-dione | 8-HYDROXY-2'-DEOXYGUANOSINE | 8-Hydroxy-2-deoxyguanosine | 8-OHdG | 8-Oxo-2'-Deoxyguanosine | 8-Oxo-2'-Deoxyguanosine | 8-Oxo-2'-deoxyguanosine | 8-Oxo-7,8-dihydro-2'-deoxyguanosine | 8-Oxo-dG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527130","Recombinant Interleukin-3","C588","A recombinant form of interleukin-3, a cytokine produced by activated T-cells and mast cells involved in intercellular communication, hematopoiesis, and inflammation. IL-3 binds and activates specific receptors on hematopoietic cells and in the nervous system, triggering expression of specific genes via the Ras signaling pathway and through Jak2 activation. This agent stimulates the proliferation of pluripotent hematopoietic progenitor cells.","Recombinant Interleukin-3 | Colony-Stimulating Factor 2 Alpha | Eosinophil-Mast Cell Growth-Factor | Erythrocyte Burst-Promoting Factor | IL-3 | ILE-964 | Interleukin-3 | MCGF | Mast-Cell Colony-Stimulating Factor | Multipotential Colony-Stimulating Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162765","Isoprenylation Process","C17560","The covalent addition of prenyl and multiprenyl residues to a macromolecule.","Isoprenylation Process | Isoprenylation | Prenylation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0057628","Mucin-1, Human","C38967","Mucin-1 (1255 aa, ~122 kDa) is encoded by the human MUC1 gene. This protein plays a role in both signaling and cell adhesion.","Mucin-1 | Breast Carcinoma-Associated Antigen DF3 | CA 15-3 | CA 27-29 | CA 27.29 | CD227 | CD227 Antigen | Cancer Antigen 15-3 | Cancer Antigen 27.29 | Carcinoma-Associated Mucin | DF3 Antigen | EMA | Episialin | Epithelial Membrane Antigen | H23 Antigen | H23AG | KL-6 | Krebs von den Lungen-6 | MUC-1 | MUC1 | Mucin | Mucin 1 | PEM | PEMT | PUM | Peanut-Reactive Urinary Mucin | Polymorphic Epithelial Mucin | Transmembrane Mucin 1 | Tumor-Associated Epithelial Membrane Antigen | Tumor-Associated Mucin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333106","Colorectal Adenoma with Mild Dysplasia","C27458","An adenoma that arises from the colon or rectum.  It is characterized by the presence of mild epithelial dysplasia.","Colorectal Adenoma with Mild Dysplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333108","Colorectal Adenoma with Severe Dysplasia","C5685","An adenoma that arises from the colon or rectum.  It is characterized by the presence of severe epithelial dysplasia.","Colorectal Adenoma with Severe Dysplasia | Colorectal Adenoma with Marked Dysplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206674","Villous Adenoma","C7399","An adenoma arising from the glandular epithelium of the gastrointestinal tract. It is characterized by the presence of a villous architectural pattern. Most often it occurs in the large intestine, small intestine, and the stomach. The neoplastic epithelial cells show dysplastic features.","Gastrointestinal Tract Villous Adenoma | GI Tract Villous Adenoma | Gastrointestinal Tract Villous Adenoma | Villous Adenoma | Villous adenoma, NOS | villous adenoma",,,,,,,,,,,,,,,"4030273","Villous adenoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334292","Tubular Adenoma","C4133","An adenoma arising from the glandular epithelium of the gastrointestinal tract. It is characterized by the presence of a tubular architectural pattern. Most often it occurs in the large intestine, small intestine, and the stomach. The neoplastic epithelial cells show dysplastic features.","Gastrointestinal Tract Tubular Adenoma | ADENOMA, TUBULAR CELL, BENIGN | GI Tract Tubular Adenoma | Gastrointestinal Tract Tubular Adenoma | Tubular Adenoma | Tubular adenoma, NOS",,,,,,,,,,,,,,,"40479386","Tubular adenoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266025","Traditional Serrated Adenoma","C38458","An adenoma that arises from the large intestine and the appendix.  It is characterized by prominent serration of the glands.","Traditional Serrated Adenoma | Serrated Adenoma | Serrated Adenoma Type II | Serrated adenoma | TSA | Traditional serrated adenoma",,,,,,,,,,,,,,,"40483192","Traditional serrated adenoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2732618","Serrated Lesions and Polyps","C96414","Polyps that arises from the large intestine and the appendix. They are characterized by the presence of serrated glands and the absence of generalized dysplasia.","Serrated Lesions and Polyps | SSA | SSA/P | SSP | Serrated Adenoma Type I | Serrated Polyp with Abnormal Proliferation | Sessile Serrated Adenoma | Sessile Serrated Adenoma/Polyp | Sessile Serrated Adenoma/Polyp | Sessile Serrated Polyp | Sessile Serrated Polyp/Adenoma | Sessile serrated adenoma | Sessile serrated polyp",,,,,,,,,,,,,,,"40480151","Sessile serrated adenoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0854486","Functioning Pituitary Neuroendocrine Tumor","C8388","A hormone producing pituitary neuroendocrine tumor associated with a hormonal syndrome.","Functioning Pituitary Neuroendocrine Tumor | Functioning Adenoma of Pituitary | Functioning Adenoma of Pituitary Gland | Functioning Adenoma of the Pituitary | Functioning Adenoma of the Pituitary Gland | Functioning PitNET/Adenoma | Functioning Pituitary Adenoma | Functioning Pituitary Gland Adenoma | Functioning Pituitary Gland Adenoma | Functioning Pituitary Gland Adenoma (Benign) | Functioning Pituitary Neuroendocrine Tumor/Adenoma | Secretory Adenoma of Pituitary | Secretory Adenoma of Pituitary Gland | Secretory Adenoma of the Pituitary | Secretory Adenoma of the Pituitary Gland | Secretory Pituitary Adenoma | Secretory Pituitary Gland Adenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335909","Salivary Gland Sebaceous Lymphadenoma","C35555","A rare, benign epithelial neoplasm composed of irregular proliferating nests and islands of epithelium, including solid and gland-like sebaceous elements, surrounded by lymphoid stroma. Most occur in the parotid gland. Symptoms include a progressively enlarging, painless mass.  Sebaceous lymphadenocarcinoma is the malignant counterpart.","Salivary Gland Sebaceous Lymphadenoma | Sebaceous Lymphadenoma of Salivary Gland | Sebaceous Lymphadenoma of the Salivary Gland","8563/0","Lymphadenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C1368816","Sebaceous Adenoma","C4174","A benign, well circumscribed neoplasm arising from the sebaceous glands. It usually presents as a small yellowish tumor in the sun exposed skin of head and neck. It is characterized by the presence of sebaceous cells aggregates with a peripheral rim of basaloid cells.","Sebaceous Adenoma | ADENOMA, SEBACEOUS, BENIGN | Adenoma of Sebaceous Gland | Adenoma of the Sebaceous Gland | Adenoma, Sebaceous Cell | Sebaceous Gland Adenoma | Sebaceous adenoma | Skin Appendage Sebaceous Adenoma",,,,,,,,,,,,,,,"4301753","Sebaceous adenoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519176","Salivary Gland Pleomorphic Adenoma","C40409","A benign, slow-growing tumor composed of cells that demonstrate both epithelial and mesenchymal differentiation. It is the most common neoplasm of salivary gland origin, and mostly occurs in the parotid gland. The average age of patients has been reported to be 43 years; women are more often affected than men. The malignant change rate has been estimated to be 6%. The malignant counterpart is carcinoma ex pleomorphic adenoma.","Salivary Gland Pleomorphic Adenoma | Benign Mixed Salivary Gland Neoplasm | Benign Mixed Salivary Gland Tumor | Benign Mixed Salivary Neoplasm | Benign Mixed Salivary Tumor",,,,,,,,,,,,,,,"40487052","Pleomorphic adenoma of salivary gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0346026","Benign Mixed Tumor of the Skin","C4474","A rare, benign, slow-growing and painless neoplasm of sweat glands. It usually arises in the head and neck. It is characterized by the presence of a mesenchymal chondroid stroma, fibrosis, and epithelial structures.","Benign Mixed Tumor of the Skin | Benign Mixed Tumor of Skin | Benign Mixed Tumor of Skin (Chondroid Syringoma) | Benign Mixed Tumor of the Skin | Benign Mixed Tumor of the Skin | Benign Mixed Tumor of the Skin (Chondroid Syringoma) | Chondroid Syringoma | Chondroid Syringoma | Chondroid syringoma | Mixed Tumor of the Skin (Chondroid Syringoma) | Mixed Tumor of the Skin (Chondroid Syringoma)",,,,,,,,,,,,,,,"4112754|4271022","Eccrine mixed tumor|Eccrine mixed tumor",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0026277","Pleomorphic Adenoma","C8602","A neoplasm characterized by the presence of benign epithelial and myoepithelial cells and a mesenchymal component that may contain mucoid, myxoid, cartilaginous, or osseous areas. It may be completely or partially encapsulated. It occurs in the parotid gland, submandibular gland, minor salivary glands in the oral cavity, upper respiratory tract, and nasal cavity and paranasal sinuses. It usually presents as a slow growing painless mass. Infrequently, patients may present with pain and facial palsy. It may recur after excision or transform to a malignant neoplasm (carcinoma ex pleomorphic adenoma).","Pleomorphic Adenoma | Pleomorphic adenoma | TUMOR, MIXED, BENIGN","8940/0","Pleomorphic adenoma",,,,,,,,,,,,,"4307654","Pleomorphic adenoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"CL388631","Papillary Adenoma","C79951","An adenoma characterized by the presence of papillary epithelial patterns.","Papillary Adenoma | ADENOMA, PAPILLARY, BENIGN","8260/0","Papillary adenoma, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C1709240","Adrenal Cortical Incidentaloma","C48458","An adenoma of the adrenal cortex characterized by the absence of a hormonal syndrome or symptoms suggestive of adrenal disease.","Non-Functioning Adrenal Cortical Adenoma | Adrenal Cortical Incidentaloma | Non-Functioning Adrenal Cortex Adenoma | Non-Functioning Adrenal Cortex Adenoma | Non-Functioning Adrenal Cortical Adenoma | Non-Functioning Adrenal Gland Adenoma | Nonfunctional Adrenal Cortex Adenoma | Nonfunctional Adrenal Cortex Adenoma | Nonfunctioning Adrenal Cortex Adenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332640","Lung Mucous Gland Adenoma","C5664","A benign adenomatous neoplasm that arises from the mucous glands in the bronchus.","Lung Mucous Gland Adenoma | Adenoma of Bronchial Mucous Gland | Adenoma of the Bronchial Mucous Gland | Bronchial Cystadenoma | Lung Mucus Gland Adenoma | Lung Polyadenoma",,,,,,,,,,,,,,,"3654607","Adenoma of bronchial mucous gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266045","Metanephric Adenoma","C27253","A benign, well-circumscribed renal cortical neoplasm affecting females more often than males.  Polycythemia has been reported in twelve-percent of patients.","Metanephric Adenoma | Embryonal adenoma | Kidney Embryonal Adenoma | Metanephric adenoma","8191/0|8325/0","Embryonal adenoma|Metanephric adenoma",,,,,,,,,,,,,"4028884","Metanephric adenoma",,,,,,,,,,,,,"--","--|--",,,,,,,,"--"
"C0334325","Lipoadenoma","C4159","An adenoma in which the neoplastic epithelial cells are admixed with adipose tissue cells.","Lipoadenoma | ADENOLIPOMA, BENIGN | Adenolipoma","8324/0","Lipoadenoma",,,,,,,,,,,,,"4328878","Lipoadenoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1336750","Thyroid Gland Oncocytic Adenoma","C6042","A thyroid gland adenoma composed of large cells with abundant granular eosinophilic cytoplasm and large nuclei with prominent nucleoli.","Thyroid Gland Oncocytic Adenoma | Benign Oncocytoma of Thyroid | Benign Oncocytoma of Thyroid Gland | Benign Oncocytoma of the Thyroid | Benign Oncocytoma of the Thyroid Gland | Benign Thyroid Gland Oncocytoma | Benign Thyroid Oncocytoma | Follicular Adenoma of Thyroid Gland of Oxyphilic Cell Type | Follicular Adenoma of Thyroid of Oxyphilic Cell Type | Follicular Adenoma of the Thyroid Gland of the Oxyphilic Cell Type | Follicular Adenoma of the Thyroid of the Oxyphilic Cell Type | Hurthle Cell Adenoma | Hurthle Cell Adenoma of Thyroid | Hurthle Cell Adenoma of Thyroid Gland | Hurthle Cell Adenoma of the Thyroid | Hurthle Cell Adenoma of the Thyroid Gland | Hurthle cell adenoma | Oncocytic Adenoma of Thyroid | Oncocytic Adenoma of Thyroid Gland | Oncocytic Adenoma of the Thyroid | Oncocytic Adenoma of the Thyroid Gland | Thyroid Follicular Adenoma of Oxyphilic Cell Type | Thyroid Follicular Adenoma of the Oxyphilic Cell Type | Thyroid Gland Follicular Adenoma of Oxyphilic Cell Type | Thyroid Gland Follicular Adenoma of the Oxyphilic Cell Type | Thyroid Gland Hurthle Cell Adenoma | Thyroid Gland Hurthle Cell Adenoma | Thyroid Gland Oncocytic Adenoma | Thyroid Gland Oncocytic Adenoma | Thyroid Hurthle Cell Adenoma | Thyroid Oncocytic Adenoma",,,,,,,,,,,,,,,"4232172","Oxyphilic adenoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0151468","Thyroid Gland Follicular Adenoma","C3502","A benign, encapsulated neoplasm arising from the follicular cells of the thyroid gland. It may be associated with thyroid hormone secretion but it does not have malignant characteristics.","Thyroid Gland Follicular Adenoma | ADENOMA, FOLLICULAR CELL, BENIGN | Adenoma of Thyroid | Adenoma of Thyroid Gland | Adenoma of the Thyroid | Adenoma of the Thyroid Gland | Follicular Adenoma | Follicular Adenoma of Thyroid | Follicular Adenoma of Thyroid Gland | Follicular Adenoma of the Thyroid | Follicular Adenoma of the Thyroid Gland | Follicular adenoma | Thyroid Adenoma | Thyroid Follicular Adenoma | Thyroid Gland Adenoma","8330/0","Follicular adenoma, NOS",,,,,,,,,,,,,"4112986|4114219","Thyroid follicular adenoma|Thyroid adenoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1384514","Conn Syndrome","C34510","An endocrine disorder characterized by excessive production of aldosterone by the adrenal glands. Causes include adrenal gland adenoma and adrenal gland hyperplasia. The overproduction of aldosterone results in sodium and water retention and hypokalemia. Patients present with high blood pressure, muscle weakness, and headache.","Conn Syndrome | Conn's Syndrome | Primary Hyperaldosteronism",,,,,,,,,,,,,,,"434000","Primary aldosteronism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266014","Salivary Gland Canalicular Adenoma","C5979","A benign epithelial neoplasm primarily composed of branching and interconnecting cords of single and double-cell thick rows of columnar epithelium in a very loose stroma. It often occurs in the upper lip, where only pleomorphic adenoma is more frequent. Asymptomatic swelling of the upper lip is the most common clinical finding. It may present clinically and histologically as a multifocal lesion, a feature not generally seen with other intraoral salivary gland tumors.","Salivary Gland Canalicular Adenoma | Canalicular Adenoma of Salivary Gland | Canalicular Adenoma of the Salivary Gland | Canalicular adenoma","8149/0","Canalicular adenoma",,,,,,,,,,,,,"4029977","Canalicular adenoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0205646","Basal Cell Adenoma","C5950","A salivary gland benign epithelial neoplasm with a uniform, monomorphic appearance that is dominated by basal cells forming trabecular structures. It is rare and occurs mostly on the parotid gland. The average age of patients has been reported to be 58 years. Swelling is the most constant clinical finding.","Basal Cell Adenoma | BCA | Basal Cell Adenoma | Basal Cell Adenoma of Salivary Gland | Basal Cell Adenoma of the Salivary Gland | Basal cell adenoma | Salivary Gland Basal Cell Adenoma | Salivary Gland Basal Cell Adenoma","8147/0","Basal cell adenoma",,,,,,,,,,,,,"4098712","Basal cell adenoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334303","Alveolar Adenoma","C4140","A benign, well circumscribed lung neoplasm morphologically characterized by the presence of cystic spaces resembling alveoli, lined by a simple cuboidal epithelium. The cystic spaces are surrounded by a spindle cell stroma which may show myxoid changes. It is a solitary, usually peripheral lung lesion. Patients are usually asymptomatic and its discovery is an incidental finding during chest X-ray examination. Surgical excision is curative.","Alveolar Adenoma | ADENOMA, BRONCHIOLOALVEOLAR, BENIGN | Adenoma of Alveoli | Adenoma of the Alveoli | Alveolar adenoma","8251/0","Alveolar adenoma",,,,,,,,,,,,,"4217161","Alveolar adenoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1266141","Metanephric Adenofibroma","C39812","A benign, solitary, and partially cystic neoplasm arising from the kidney. It occurs in children and adults. Presenting symptoms include hematuria and polycythemia. It is characterized by the presence of epithelial nodules embedded in a stroma containing spindle cells.","Metanephric Adenofibroma | Nephrogenic Adenofibroma | Nephrogenic adenofibroma",,,,,,,,,,,,,,,"4028566","Nephrogenic adenofibroma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0346005","Pilar Sheath Acanthoma","C4468","A benign, small, papular or nodular skin neoplasm that usually arises above the upper lip. It is characterized by an epithelial proliferation with a central cavity. The cavity wall is lined with keratinocytes.","Pilar Sheath Acanthoma | Acanthoma of Pilar Sheath | Acanthoma of the Pilar Sheath | Infundibular Adenoma | Infundibuloisthmicoma",,,,,,,,,,,,,,,"4111929","Pilar sheath acanthoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333414","Epidermolytic Acanthoma","C27516","A benign epithelial verrucous lesion of the skin. Morphologically, it is characterized by the presence of epidermolytic hyperkeratosis and papillomatosis.","Epidermolytic Acanthoma | ",,,,,,,,,,,,,,,"37116872","Epidermolytic acanthoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1301270","Acantholytic Acanthoma","C27517","A benign epithelial neoplasm of the skin. It presents as a papular or nodular lesion. Morphologically, it is characterized by the presence of hyperkeratosis, acanthosis, papillomatosis, and prominent acantholysis.","Acantholytic Acanthoma | ",,,,,,,,,,,,,,,"4264284","Acantholytic acanthoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0151241","Atrial Myxoma","C3499","A cardiac myxoma arising from the atrium.","Atrial Myxoma | Myxoma of Atrium | Myxoma of the Atrium",,,,,,,,,,,,,,,"4124689","Atrial myxoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206633","Angiomyolipoma","C3734","A neoplasm with perivascular epithelioid cell differentiation often associated with tuberous sclerosis.  It is characterized by a mixture of epithelioid cells, smooth muscle, vessels, and mature adipose tissue.  The kidney is the most common site of involvement.  Other sites of involvement include the liver, lung, lymph nodes, and retroperitoneum.  The vast majority of cases follow a benign clinical course.  However, cases of metastatic angiomyolipomas with sarcomatoid features have been described.","Angiomyolipoma | angiomyolipoma","8860/0","Angiomyolipoma",,,,,,,,,,,,,"4063049","Angiomyolipoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0206731","Angiofibroma","C3799","A morphologic variant of fibroma characterized by the presence of numerous dilated vascular channels.","Angiofibroma | ANGIOFIBROMA, BENIGN | Angiofibroma, NOS | Angiofibromatous Hyperplasia | Fibroangioma, Benign | Fibrous Papule | Telangiectatic Fibroma","9160/0","Angiofibroma, NOS",,,,,,,,,,,,,"4116203","Angiofibroma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0018915","Hemangioendothelioma","C3084","A vascular proliferation characterized by the presence of prominent endothelial cells and the formation of vascular channels. Hemangioendotheliomas may display borderline or low grade characteristics.","Hemangioendothelioma | Angioendothelioma | Hemangioendothelioma, NOS","9130/1","Hemangioendothelioma, NOS",,,,,,,,,,,,,"4281384|4298139","Hemangioendothelioma|Hemangioendothelioma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0175633","Process of adhesion","C17597","The property of remaining in close proximity, as that resulting from the physical attraction of molecules to a substance or the molecular attraction existing between the surfaces of contacting bodies.","Adhesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0341858","Uterine Corpus Adenomyosis","C6996","The growth of endometrial tissue inside the muscular wall of the uterine corpus. Clinical manifestations include pain, dysmenorrhea, and menorrhagia.","Uterine Corpus Adenomyosis | ADENOMYOSIS | Adenomyosis | Adenomyosis of Uterus | Adenomyosis of the Uterus | Uterine Adenomyosis | Uterine Adenomyosis | Uterus Corpus Adenomyosis",,,,,,,,,,,,,,,"200461|37205049|4058381|4127413","Endometriosis of uterus|Uterine adenomyosis|Endometriosis interna|Endometriosis of myometrium",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--|--"
"C1266146","Breast Adenomyoepithelioma","C6899","A usually benign tumor arising from the breast. It is characterized by the proliferation of cells with myoepithelial differentiation around spaces which are lined by epithelial cells. Rarely, the epithelial and/or myoepithelial cells may undergo malignant transformation. Cases with malignant transformation may follow an aggressive clinical course, including recurrences and local and distant metastases.","Breast Adenomyoepithelioma | Adenomyoepithelioma | Adenomyoepithelioma of the Breast",,,,,,,,,,,,,,,"4029652","Adenomyoepithelioma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698277","AUTOLYZED","C78725","A specimen that has undergone autolysis, or self-digestion by the specimen's own digestive enzymes.","Autolyzed Specimen | AUTOLYZED | Autolized Specimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024138","Discoid Lupus Erythematosus","C26820","A chronic, autoimmune skin condition that manifests with a red, scaling rash, most often found on the face, ears, and scalp; these lesions often lead to permanent scarring and dyspigmentation. Patients may have lesions with or without other symptoms or antibodies suggestive of systemic lupus erythematosus (SLE).","Discoid Lupus Erythematosus | DLE",,,,,,,,,,,,,,,"4066824","Discoid lupus erythematosus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334494","Borderline Ovarian Brenner Tumor","C9459","A neoplasm of low malignant potential arising from the ovary. It is characterized by the presence of neoplastic atypical urothelial-type cells in a fibrotic stroma without evidence of invasion.","Borderline Ovarian Brenner Tumor | Borderline Brenner Neoplasm of Ovary | Borderline Brenner Neoplasm of the Ovary | Borderline Brenner Tumor of Ovary | Borderline Brenner Tumor of the Ovary | Borderline Ovarian Brenner Neoplasm | Borderline Ovarian Brenner Tumor | Borderline Ovarian Brenner Tumor/Atypical Proliferative Ovarian Brenner Tumor | Borderline Ovarian Brenner Tumor/Atypical Proliferative Ovarian Brenner Tumor | Borderline Ovarian Transitional Cell Neoplasm | Borderline Ovarian Transitional Cell Tumor | Low Malignancy Potential Brenner Neoplasm of Ovary | Low Malignancy Potential Brenner Neoplasm of the Ovary | Low Malignancy Potential Brenner Tumor of Ovary | Low Malignancy Potential Brenner Tumor of the Ovary | Low Malignancy Potential Ovarian Brenner Neoplasm | Low Malignancy Potential Ovarian Brenner Tumor | Proliferating Brenner Neoplasm of Ovary | Proliferating Brenner Neoplasm of the Ovary | Proliferating Brenner Tumor of Ovary | Proliferating Brenner Tumor of the Ovary | Proliferating Ovarian Brenner Neoplasm | Proliferating Ovarian Brenner Tumor","9000/1","Brenner tumor, borderline malignancy",,,,,,,,,,,,,"4234377","Brenner tumor, borderline malignancy",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1332598","Borderline Ovarian Serous Tumor","C5226","A low grade serous epithelial neoplasm arising from the ovary.  It is characterized by an atypical proliferation of serous-type epithelial cells without evidence of stromal invasion.  It is often asymptomatic but rarely it may present with abdominal pain or abdominal enlargement due to rupture or torsion.","Borderline Ovarian Serous Tumor | Borderline Ovarian Serous Neoplasm | Borderline Serous Neoplasm of Ovary | Borderline Serous Neoplasm of the Ovary | Borderline Serous Tumor of Ovary | Borderline Serous Tumor of the Ovary | Ovarian Serous Neoplasm of Low Malignant Potential | Ovarian Serous Tumor of Low Malignant Potential | Proliferating Ovarian Serous Neoplasm | Proliferating Ovarian Serous Tumor | Proliferating Serous Neoplasm of Ovary | Proliferating Serous Neoplasm of the Ovary | Proliferating Serous Tumor of Ovary | Proliferating Serous Tumor of the Ovary | Serous Neoplasm of Ovary with Low Malignant Potential | Serous Neoplasm of the Ovary with Low Malignant Potential | Serous Ovarian Neoplasm of Low Malignant Potential | Serous Ovarian Tumor of Low Malignant Potential | Serous Tumor of Ovary with Low Malignant Potential | Serous Tumor of the Ovary with Low Malignant Potential",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279664","Borderline Ovarian Mucinous Tumor","C40036","A low grade mucinous epithelial neoplasm arising from the ovary.  It is characterized by an atypical proliferation of mucinous-type epithelial cells without evidence of stromal invasion.  The mucinous epithelial cells may be of intestinal or endocervical type.","Borderline Ovarian Mucinous Tumor | Borderline Ovarian Mucinous Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332596","Borderline Ovarian Seromucinous Tumor/Atypical Proliferative Ovarian Seromucinous Tumor","C7281","A low grade, non-invasive ovarian epithelial neoplasm characterized by the presence of atypical neoplastic serous and mucinous cells.","Borderline Ovarian Seromucinous Tumor/Atypical Proliferative Ovarian Seromucinous Tumor | Borderline Ovarian Mixed Epithelial Tumor | Borderline Ovarian Seromucinous Tumor/Atypical Proliferative Ovarian Seromucinous Tumor ","8474/1","Seromucinous borderline tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C1511270","Borderline Ovarian Serous Neoplasm with Microinvasion","C40027","A low grade ovarian epithelial neoplasm characterized by the presence of neoplastic serous epithelial cells, atypia, and microinvasion of the ovarian stroma.","Borderline Ovarian Serous Tumor/Atypical Proliferative Ovarian Serous Tumor with Microinvasion | Borderline Ovarian Serous Neoplasm with Microinvasion | Borderline Ovarian Serous Tumor with Microinvasion | Borderline Ovarian Serous Tumor with Microinvasion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334338","Borderline Ovarian Endometrioid Tumor/Atypical Proliferative Ovarian Endometrioid Tumor","C7983","An epithelial neoplasm that arises from the ovary characterized by the presence of glandular or cystic spaces which contain atypical glandular epithelial cells resembling endometrial cells. The surrounding ovarian stroma is often fibrotic. There is no evidence of stromal invasion.","Borderline Ovarian Endometrioid Tumor/Atypical Proliferative Ovarian Endometrioid Tumor | Borderline Endometrioid Neoplasm of Ovary | Borderline Endometrioid Neoplasm of the Ovary | Borderline Endometrioid Tumor of Ovary | Borderline Endometrioid Tumor of the Ovary | Borderline Ovarian Endometrioid Neoplasm | Borderline Ovarian Endometrioid Tumor | Borderline Ovarian Endometrioid Tumor | EBT/APET | Endometrioid Neoplasm of Low Malignant Potential | Endometrioid Neoplasm with Proliferating Activity, Ovarian | Endometrioid Tumor of Low Malignant Potential | Endometrioid Tumor with Proliferating Activity, Ovarian | Endometrioid tumor of low malignant potential | Low Malignant Potential Endometrioid Neoplasm of Ovary | Low Malignant Potential Endometrioid Neoplasm of the Ovary | Low Malignant Potential Endometrioid Tumor of Ovary | Low Malignant Potential Endometrioid Tumor of the Ovary | Low Malignant Potential Ovarian Endometrioid Neoplasm | Low Malignant Potential Ovarian Endometrioid Tumor | Ovarian Endometrioid Borderline Neoplasm | Ovarian Endometrioid Borderline Tumor | Ovarian Endometrioid Neoplasm of Low Malignant Potential | Ovarian Endometrioid Neoplasm with Proliferating Activity | Ovarian Endometrioid Tumor of Low Malignant Potential | Ovarian Endometrioid Tumor with Proliferating Activity | Proliferating Endometrioid Neoplasm of Ovary | Proliferating Endometrioid Neoplasm of the Ovary | Proliferating Endometrioid Tumor of Ovary | Proliferating Endometrioid Tumor of the Ovary | Proliferating Ovarian Endometrioid Neoplasm | Proliferating Ovarian Endometrioid Tumor","8380/1","Endometrioid adenoma, borderline malignancy",,,,,,,,,,,,,"4093624|4294274","Endometrioid adenofibroma, borderline malignancy|Endometrioid adenoma, borderline malignancy",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0279676","Borderline Ovarian Clear Cell Tumor","C40080","An epithelial neoplasm with low malignant potential affecting the ovary.  It is characterized by the presence of clear or hobnail cells.  In some cases, the cells may display nuclear atypia and prominent nucleoli.  When such cells are present, they remain confined to the glands.  There is no evidence of stromal invasion.","Borderline Ovarian Clear Cell Tumor | Borderline Ovarian Clear Cell Neoplasm | Clear cell cystic tumor of borderline malignancy",,,,,,,,,,,,,,,"4030113","Clear cell cystic tumor of borderline malignancy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0154129","Neoplasm of Uncertain Malignant Potential","C3646","A neoplasm displaying morphologic, phenotypic, or genotypic characteristics that are clearly not benign but do not permit the establishment of a definitive diagnosis of malignancy.  Such neoplasms may or may not eventually have a more aggressive clinical course.  Representative examples include lymphoproliferations of uncertain malignant potential (e.g., lymphomatoid granulomatosis and lymphomatoid papulosis), borderline ovarian epithelial neoplasms (e.g., borderline ovarian endometrioid tumor and borderline ovarian mucinous tumor), borderline exocrine pancreatic neoplasm (e.g., pancreatic borderline intraductal papillary-mucinous neoplasm), and primary borderline peritoneal epithelial neoplasm.","Neoplasm of Uncertain Malignant Potential | ",,,,,,,,,,,,,,,"432582","Neoplastic disease of uncertain behavior",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0877326","Bone Infarction","C27220","Ischemic necrosis of the bone tissue and the marrow.","Bone Infarction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511535","Cost Effective Management","C19248","Managed care that is based on cost/benefit analysis.","Cost Effective Management | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1302864","Eccrine Carcinoma","C27255","An adenocarcinoma with eccrine differentiation arising from the sweat glands. It includes the following subtypes: ductal eccrine adenocarcinoma, papillary eccrine carcinoma, and eccrine porocarcinoma.","Eccrine Carcinoma | CARCINOMA, ECCRINE GLAND, MALIGNANT | Eccrine Adenocarcinoma | Eccrine Gland Adenocarcinoma | Eccrine Gland Carcinoma | Eccrine adenocarcinoma","8413/3","Eccrine adenocarcinoma",,,,,,,,,,,,,"4028545|4290984","Eccrine adenocarcinoma|Eccrine carcinoma of skin",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0206686","Adrenal Cortical Carcinoma","C9325","A rare, usually large (greater than 5cm), malignant epithelial tumor arising from the adrenal cortical cells.  Symptoms are usually related to the excessive production of hormones, and include Cushing's syndrome and virilism in women.  Common sites of metastasis include liver, lung, bone, and retroperitoneal lymph nodes.  Advanced radiologic procedures have enabled the detection of small tumors, resulting in the improvement of the 5-year survival.","Adrenal Cortical Carcinoma | Adenocarcinoma, Adrenocortical, Malignant | Adrenal Cortex Adenocarcinoma | Adrenal Cortex Cancer | Adrenal Cortex Carcinoma | Adrenal Cortex Carcinoma | Adrenal Cortical Adenocarcinoma | Adrenal Cortical Carcinoma | Adrenal cortical adenocarcinoma | Adrenal cortical carcinoma | Adrenocortical Carcinoma | Adrenocortical carcinoma | Adrenocortical carcinoma, NOS | CARCINOMA, ADRENOCORTICAL, MALIGNANT | Carcinoma of Adrenal Cortex | Carcinoma of the Adrenal Cortex | Cortical Cell Carcinoma | adrenocortical cancer | adrenocortical carcinoma | cancer of the adrenal cortex","8370/3","Adrenal cortical carcinoma",,,,,,,,,,,,,"4318952","Adrenal cortical carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334240","Combined Lung Small Cell Carcinoma","C9137","A morphologic variant of small cell lung carcinoma in combination with a non-small cell carcinoma.","Combined Lung Small Cell Carcinoma | Combined Small Cell Carcinoma | Combined Small Cell Carcinoma of Lung | Combined Small Cell Carcinoma of the Lung | Combined Small Cell Lung Cancer | Combined Small Cell Lung Carcinoma | Combined Small Cell Lung Carcinoma | Combined Small Cell and Large Cell Lung Carcinoma | Combined Small Cell-Adenocarcinoma | Combined Small Cell-Large Carcinoma | Combined Small and Large Cell Lung Cancer | Combined Small and Large Cell Lung Carcinoma | Combined Type Small Cell Carcinoma of Lung | Combined Type Small Cell Carcinoma of the Lung | Combined Type Small Cell Lung Carcinoma | Mixed Small Cell and Large Cell Carcinoma of Lung | Mixed Small Cell and Large Cell Carcinoma of the Lung | Mixed Small Cell and Large Cell Lung Carcinoma | Small Cell and Large Cell Carcinoma of Lung | Small Cell and Large Cell Carcinoma of the Lung | Small Cell and Large Cell Lung Carcinoma","8045/3","Combined small cell carcinoma",,,,,,,,,,,,,"4065083","Combined small cell carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1332557","Bladder Clear Cell Adenocarcinoma","C6179","A bladder adenocarcinoma characterized by the presence of malignant glandular epithelial cells and clear cells distributed in a tubulo-cystic, papillary, or diffuse pattern. There is a female predilection. Clinical presentation includes hematuria and dysuria.","Bladder Clear Cell Adenocarcinoma | Bladder Mesonephric Adenocarcinoma | Bladder Mesonephric Carcinoma | Clear Cell Adenocarcinoma of Bladder | Clear Cell Adenocarcinoma of Urinary Bladder | Clear Cell Adenocarcinoma of the Bladder | Clear Cell Adenocarcinoma of the Urinary Bladder | Urinary Bladder Clear Cell Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706827","Apocrine Carcinoma","C4169","A carcinoma with apocrine differentiation arising from the sweat glands. It presents as single or multiple nodular lesions which may be ulcerated or hemorrhagic and is usually in the axilla and less often in the anogenital region. It grows in the dermis and infiltrates subcutaneous tissues. It is characterized by the presence of large cells with abundant eosinophilic cytoplasm and large often vesicular nuclei. Most cases are slow growing tumors and have a prolonged course.","Apocrine Carcinoma | Apocrine Adenocarcinoma | Apocrine Gland Carcinoma | Apocrine Gland Carcinoma | Apocrine adenocarcinoma | Carcinoma of Apocrine Gland","8401/3","Apocrine adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C0206697","Adnexal Carcinoma","C3775","A carcinoma arising from the sebaceous glands, sweat glands, or the hair follicles. Representative examples include sebaceous carcinoma, apocrine carcinoma, eccrine carcinoma, and pilomatrical carcinoma.","Adnexal Carcinoma | Adnexal carcinoma | CARCINOMA, ADNEXAL, MALIGNANT | Carcinoma of Adnexa | Carcinoma of Skin Appendage | Skin Appendage Carcinoma | Skin appendage carcinoma",,,,,,,,,,,,,,,"4271597","Skin appendage carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1321861","Adenocarcinoma in Adenomatous Polyp","C7676","An adenocarcinoma that arises from an adenomatous polyp.","Adenocarcinoma in Adenomatous Polyp | Adenocarcinoma in Gastrointestinal Adenomatous Polyp | Adenocarcinoma in adenomatous polyp","8210/3","Adenocarcinoma in adenomatous polyp",,,,,,,,,,,,,"37016272|4183317","Adenocarcinoma in adenomatous polyp|Adenocarcinoma in adenomatous polyp",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"CL323981","Brenner Tumor","C39954","A tumor composed of solid and cystic nests of neoplastic urothelial-type cells in an abundant stromal component that is dense and fibroblastic in nature. It arises from the ovary and very rarely the paratesticular structures. It includes benign Brenner tumor, borderline Brenner tumor, and malignant Brenner tumor.","Brenner Tumor | Brenner tumor, NOS","9000/0","Brenner tumor, NOS",,,,,,,,,,,,,"35625720","Brenner tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0006079","Bowen Disease of the Skin","C62571","A form of squamous cell carcinoma in situ. It is a distinct clinicopathological entity and arises from the skin or the mucocutaneous junction. It affects predominantly white males in their 6-8th decades of life. Exposed and non-exposed skin sites are equally affected. UV damage and ingestion of inorganic arsenic may play a role in the development of the disease. On the skin surface, it presents as a single or multiple erythematous, scaly, keratotic patches or plaques. The clinical entity of erythroplasia of Queyrat is regarded as Bowen disease of the penis and it presents as an asymptomatic, red, circumscribed plaque. Morphologically, Bowen disease is characterized by the presence of hyperkeratosis, parakeratosis, dyskeratosis, and acanthosis. The keratotic squamous cells are atypical and display hyperchromatism and abnormal mitotic figures. The dermoepidermal basement membrane is intact. Complete surgical removal of the lesion may be curative.","Bowen Disease of the Skin | Bowen Disease | Bowen disease | Bowen's Disease of the Skin | Intraepidermal Squamous Cell Carcinoma, Bowen Type | Intraepidermal squamous cell carcinoma, Bowen type","8081/2","Bowen disease",,,,,,,,,,,,,"4224505","Bowen's disease",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C2828361","Do (activity)","C86066","Perform or execute.","Do | Did | Does",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273291","Embolic Agent","C97229","A substance used to block an artery, thereby eliminating the blood flow to a specific part of an organ. An embolic agent may cause permanent or temporary blockage depending on the nature of the material used.","Embolic Agent | Embolization Agent | embolic agent | embolic_agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273295","Plastic Embolic Bead","C97233","An embolic bead that is made from a plastic-like resin or polymer.","Plastic Embolic Bead | Plastic Beads | Plastic Embolization Bead",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449155","Use","C95018","To put into action or service.","Use | Employ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831993","Yttrium Y 90 Resin Microspheres","C64539","An injectable formulation of the radioisotope yttrium Y 90 encapsulated in resin microspheres with potential antineoplastic activity. When injected into arterial vasculature supplying the tumor, yttrium Y 90 resin microspheres occlude tumor blood vessels and selectively deliver a cytotoxic dose of beta emitting yttrium Y 90 to the tumor site, which may result in tumor cell death and tumor regression.","Yttrium Y 90 Resin Microspheres | SIR-Spheres | Y-90 Sirsphere",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441774","Stage IVC","C28055","Cancer that has spread to distant anatomic sites beyond its original site of growth. The definition of stage IVC depends on the particular type of cancer that it refers to; for example, for head and neck carcinomas (lip and oral cavity carcinoma, laryngeal carcinoma, nasal cavity and paranasal sinus carcinoma, pharynx carcinoma, thyroid gland carcinoma, and major salivary gland carcinoma) and head and neck mucosal melanoma, stage IVC is defined as follows: any T, any N, M1; for appendix carcinoma, stage IVC is defined as follows: any T, any N, M1b, any G. M1: Distant metastasis.  M1b: Nonperitoneal metastasis.  G: Grade (cellular differentiation).","Stage IVC | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206682","Thyroid Gland Follicular Carcinoma","C8054","A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland.  The nuclear features which characterize the thyroid gland papillary carcinoma are absent.  Radiation exposure is a risk factor and it comprises approximately 10% to 15% of thyroid cancers.  Clinically, it usually presents as a solitary mass in the thyroid gland.  It is generally unifocal and thickly encapsulated and shows invasion of the capsule or the vessels.  Diagnostic procedures include thyroid ultrasound and fine needle biopsy.","Thyroid Gland Follicular Carcinoma | CARCINOMA, FOLLICULAR CELL, MALIGNANT | FTC | Follicular Adenocarcinoma | Follicular Cancer of Thyroid | Follicular Cancer of Thyroid Gland | Follicular Cancer of the Thyroid | Follicular Cancer of the Thyroid Gland | Follicular Carcinoma | Follicular Carcinoma of Thyroid | Follicular Carcinoma of Thyroid Gland | Follicular Carcinoma of the Thyroid | Follicular Carcinoma of the Thyroid Gland | Follicular Thyroid Cancer | Follicular Thyroid Carcinoma | Follicular Thyroid Gland Carcinoma | Follicular adenocarcinoma, well differentiated | Follicular carcinoma, NOS | Follicular carcinoma, well differentiated | Follicular thyroid carcinoma | Thyroid Follicular Carcinoma | Thyroid Gland Follicular Cancer | Well-Differentiated Follicular Adenocarcinoma | Well-Differentiated Follicular Carcinoma | Well-differentiated Follicular Adenocarcinoma | Well-differentiated Follicular Carcinoma | follicular thyroid cancer","8331/3","Follicular adenocarcinoma, well differentiated",,,,,,,,,,,,,"4102290|4111010|4199584","Follicular adenocarcinoma, well differentiated|Follicular thyroid carcinoma|Follicular adenocarcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--|--"
"C0344460","Carcinoma ex Pleomorphic Adenoma","C4397","A carcinoma arising in a pre-existing pleomorphic adenoma. It most often occurs in the parotid gland and less often in the submandibular gland and minor salivary gland. Patients usually present with a history of a long-standing mass which recently had undergone rapid growth. The prognosis depends on the invasiveness of the malignant component. Patients with non-invasive or minimally invasive tumors usually have a good prognosis following surgical resection. Invasive tumors are usually aggressive and are associated with recurrences and metastases.","Carcinoma ex Pleomorphic Adenoma | CXPA | Carcinoma in Pleomorphic Adenoma | Carcinoma in pleomorphic adenoma",,,,,,,,,,,,,,,"4066512","Carcinoma ex pleomorphic adenoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0749424","Thyroid Gland Oncocytic Carcinoma","C4946","A follicular carcinoma of the thyroid gland, characterized by the presence of large cells with eosinophilic granular cytoplasm and pleomorphic nuclei with prominent, eosinophilic nucleoli.  The nuclear features that characterize the papillary carcinomas of the thyroid gland are absent.","Thyroid Gland Oncocytic Carcinoma | Hurthle Cell Carcinoma of Thyroid | Hurthle Cell Carcinoma of Thyroid Gland | Hurthle Cell Carcinoma of the Thyroid | Hurthle Cell Carcinoma of the Thyroid Gland | Hurthle Cell Thyroid Gland Carcinoma | Oncocytic Carcinoma of Thyroid | Oncocytic Carcinoma of the Thyroid | Thyroid Gland Hurthle Cell Carcinoma | Thyroid Gland Hurthle Cell Carcinoma | Thyroid Gland Oncocytic Follicular Carcinoma | Thyroid Gland Oncocytic Follicular Carcinoma | Thyroid Hurthle Cell Carcinoma | Thyroid Oncocytic Carcinoma",,,,,,,,,,,,,,,"4307263","Hurthle cell carcinoma of thyroid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266089","Metaplastic Carcinoma","C27949","A general term used to describe carcinomas arising from epithelial cells that have been transformed into another cells type (metaplastic epithelial cells). A representative example is the adenocarcinoma arising in Barrett esophagus. This term is also used to describe carcinomas in which the malignant epithelial cells show differentiation towards another cell type. A representative example of the latter is the metaplastic breast carcinoma in which the malignant glandular cells show squamous, spindle cell, or chondroid/osseous differentiation.","Metaplastic Carcinoma | metaplastic carcinoma","8575/3","Metaplastic carcinoma, NOS",,,,,,,,,,,,,"4030123","Metaplastic carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0206693","Medullary Carcinoma, Not Otherwise Specified","C66718","A term referring to medullary carcinomas which can develop in various anatomic sites such as the thyroid gland, breast, colon, rectum, and small intestine.","Medullary Carcinoma, Not Otherwise Specified | ","8510/3","Medullary carcinoma, NOS",,,,,,,,,,,,,"4140205","Medullary carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0345958","Lung Large Cell Carcinoma","C4450","An undifferentiated non-small cell lung carcinoma composed of large polygonal cells without evidence of glandular, squamous, or neuroendocrine differentiation.","Lung Large Cell Carcinoma | Anaplastic Lung Carcinoma | Large Cell Carcinoma of Lung | Large Cell Carcinoma of the Lung | Large Cell Lung Cancer | Large Cell Lung Carcinoma | Large Cell Lung Carcinoma | Large Cell Undifferentiated Lung Carcinoma | Lung Large Cell Undifferentiated Carcinoma | large cell carcinoma",,,,,,,,,,,,,,,"4110589","Large cell carcinoma of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334358","Lacrimal Gland Carcinoma","C6129","A carcinoma that arises from the lacrimal glands. Representative examples include adenocarcinoma, carcinoma ex pleomorphic adenoma, squamous cell carcinoma, adenoid cystic carcinoma, and mucoepidermoid carcinoma.","Lacrimal Gland Carcinoma | Carcinoma of Lacrimal Gland | Carcinoma of the Lacrimal Gland",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334364","Papillary Mucinous Cystadenocarcinoma","C65204","An invasive adenocarcinoma characterized by cystic changes, papillary growth pattern, and the presence of malignant glandular cells which contain intracytoplasmic mucin.","Papillary Mucinous Cystadenocarcinoma | Papillary mucinous cystadenocarcinoma",,,,,,,,,,,,,,,"4287716","Papillary mucinous cystadenocarcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3838947","Invasive Breast Micropapillary Carcinoma","C36084","An invasive breast carcinoma characterized by the presence of clusters of malignant cells located within artifactual clear stromal spaces that resemble vascular spaces.","Invasive Breast Micropapillary Carcinoma | Infiltrating Micropapillary Breast Carcinoma | Invasive Micropapillary Breast Carcinoma | Invasive Micropapillary Breast Carcinoma",,,,,,,,,,,,,,,"45766427","Invasive micropapillary carcinoma of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266037","Lung Adenocarcinoma with Mixed Bronchioloalveolar and Invasive Components","C65197","A lung adenocarcinoma consisting of a bronchioloalveolar component and an invasive adenocarcinomatous component.","Lung Adenocarcinoma with Mixed Bronchioloalveolar and Invasive Components | Lung adenocar. w/ bronch. feat. | Lung adenocarcinoma with bronchioloalveolar features",,,,,,,,,,,,,,,"4028540","Adenocarcinoma with mixed subtypes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206684","Sebaceous Carcinoma","C40310","An adenocarcinoma with sebaceous differentiation. It presents as a painless mass and it may be multifocal. It grows in the ocular adnexae and in the skin of head and neck, trunk, genitals, and extremities. It is characterized by the presence of malignant cells with multivesicular and clear cytoplasm. It may recur and metastasize.","Sebaceous Carcinoma | ADENOCARCINOMA, SEBACEOUS, MALIGNANT | Carcinoma of Sebaceous Gland | Carcinoma of the Sebaceous Gland | Carcinoma, Sebaceous Cell | Sebaceous Adenocarcinoma | Sebaceous Cancer | Sebaceous Gland Carcinoma | Sebaceous carcinoma",,,,,,,,,,,,,,,"4141248|4182993","Sebaceous adenocarcinoma|Sebaceous adenocarcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0948750","Salivary Gland Carcinoma","C9272","A carcinoma that arises from the major or minor salivary glands.  Representative examples include carcinoma ex pleomorphic adenoma, adenocarcinoma, adenoid cystic carcinoma, and mucoepidermoid carcinoma.","Salivary Gland Carcinoma | Carcinoma of Salivary Gland | Carcinoma of the Salivary Gland | Salivary Gland Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879257","Hereditary Papillary Renal Cell Carcinoma","C9222","A familial carcinoma inherited in an autosomal dominant trait.  It is characterized by the development of multiple, bilateral papillary renal cell carcinomas.  The carcinomas range from microscopic lesions to clinically symptomatic tumors.  It is associated with activating mutations of the MET oncogene.","Hereditary Papillary Renal Cell Carcinoma | Familial Renal Papillary Carcinoma | Hereditary Kidney Papillary Carcinoma | Hereditary Papillary Carcinoma of Kidney | Hereditary Papillary Carcinoma of the Kidney | Hereditary Papillary Renal Carcinoma | Hereditary Papillary Renal Cell Cancer",,,,,,,,,,,,,,,"37399456","Hereditary papillary renal cell carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1514428","Primary Peritoneal Carcinoma","C40022","A rare carcinoma that arises from the peritoneum and resembles the malignant surface epithelial-stromal tumors that arise from the ovary.  Serous adenocarcinoma is the most common histologic variant. It affects women almost exclusively.  The diagnosis of primary peritoneal carcinoma can be made only if both ovaries are not involved by tumor, or, if the ovaries are involved, the tumor is confined to the ovarian surface without invasion of the ovarian stroma and the peritoneal involvement is greater than the ovarian surface involvement.","Primary Peritoneal Carcinoma | PPC | Primary Peritoneal Cancer | Primary peritoneal carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335907","Salivary Gland Polymorphous Adenocarcinoma","C35702","A low grade malignant epithelial neoplasm arising from the salivary gland. It usually arises from the oral cavity, with approximately 60% of the cases involving the palate. The most common presenting sign is a painless mass in the palate. It is characterized by the presence of uniform, small to medium size malignant epithelial cells and an infiltrating pattern. There is a variety of morphologic patterns which may be present within an individual tumor, including lobular, papillary, papillary-cystic, cribriform, and trabecular pattern. It usually has a favorable clinical outcome and a low metastatic potential.","Salivary Gland Polymorphous Adenocarcinoma | Polymorphous adenocarcinoma, classic | Polymorphous low grade adenocarcinoma | Salivary Gland PmA | Salivary Gland Polymorphous Adenocarcinoma, Classical Variant | Salivary Gland Polymorphous Low Grade Adenocarcinoma | Salivary Gland Polymorphous Low Grade Adenocarcinoma | Salivary Gland Terminal Duct Adenocarcinoma","8525/3","Polymorphous adenocarcinoma",,,,,,,,,,,,,"4312929","Polymorphous low grade adenocarcinoma of salivary gland",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334359","Papillary Serous Cystadenocarcinoma","C8377","A malignant cystic serous epithelial neoplasm characterized by the presence of malignant glandular epithelial cells forming papillary structures. Stromal invasion is present.","Papillary Serous Cystadenocarcinoma | Papillary Serous Adenocarcinoma | Papillary Serous Carcinoma | Papillary serous adenocarcinoma | Papillary serous cystadenocarcinoma | papillary serous carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205642","Oncocytic Adenocarcinoma","C3679","An adenocarcinoma characterized by the presence of large malignant epithelial cells with abundant granular eosinophilic cytoplasm (oncocytes). Representative examples include thyroid gland oncocytic follicular carcinoma, oncocytic breast carcinoma, and salivary gland oncocytic carcinoma.","Oncocytic Adenocarcinoma | Hurthle Cell Adenocarcinoma | Hurthle Cell Carcinoma | Hurthle cell adenocarcinoma | Hurthle cell carcinoma | ONCOCYTOMA, MALIGNANT | Oncocytic Carcinoma | Oncocytic adenocarcinoma | Oncocytic carcinoma | Oxyphilic Adenocarcinoma | Oxyphilic Adenocarcinoma | Oxyphilic adenocarcinoma","8290/3","Oxyphilic adenocarcinoma",,,,,,,,,,,,,"4212379","Oxyphilic adenocarcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334699","Malignant Myoepithelioma","C7596","An infiltrating malignant tumor characterized by the presence of atypical cells with myoepithelial differentiation. Representative examples include malignant breast myoepithelioma and salivary gland myoepithelial carcinoma.","Malignant Myoepithelioma | MYOEPITHELIOMA, MALIGNANT | Malignant myoepithelioma | Myoepithelial Carcinoma | Myoepithelial carcinoma",,,,,,,,,,,,,,,"4029680","Malignant myoepithelioma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205969","Thymic Carcinoma","C7569","A diverse group of carcinomas of the thymus gland, previously known as thymoma type C.  It includes morphologic variants derived from purely epithelial cells, as well as from cells with neuroendocrine differentiation.","Thymus Carcinoma | Thymic Carcinoma | Thymic Carcinoma | Thymic Carcinoma (Excluding Well Differentiated Thymic Carcinoma) | Thymic Carcinoma Excluding Well Differentiated Thymic Carcinoma | Thymoma Type C | thymic carcinoma | type C thymoma","8586/3","Thymic carcinoma, NOS",,,,,,,,,,,,,"4029017","Thymic carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1412016","Sweat Gland Carcinoma","C6938","A carcinoma that arises from the sweat glands. Representative examples include porocarcinoma, hidradenocarcinoma, microcystic adnexal carcinoma, skin adenoid cystic carcinoma, apocrine carcinoma, and digital papillary adenocarcinoma.","Sweat Gland Carcinoma | CARCINOMA, SWEAT GLAND, MALIGNANT | Carcinoma of Sweat Gland | Carcinoma of the Sweat Gland | Sweat Gland Adenocarcinoma | Sweat gland carcinoma","8400/3","Sweat gland adenocarcinoma",,,,,,,,,,,,,"4115295|4136528","Malignant skin tumor with eccrine differentiation|Sweat gland adenocarcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1266005","Basaloid Squamous Cell Carcinoma","C54244","A squamous cell carcinoma characterized by the presence of cells with hyperchromatic nuclei, scant amount of cytoplasm, and peripheral nuclear palisading.","Basaloid Squamous Cell Carcinoma | Basaloid squamous cell carcinoma","8083/3","Basaloid squamous cell carcinoma",,,,,,,,,,,,,"4029973","Basaloid squamous cell carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1332842","Carcinosarcoma of Salivary Gland","C35831","An aggressive, high grade malignant tumor that arises from the salivary gland. It is characterized by the presence of a malignant epithelial and a sarcomatous component.","Salivary Gland Carcinosarcoma | Carcinosarcoma of Salivary Gland | Carcinosarcoma of the Salivary Gland | Carcinosarcoma of the Salivary Gland | True Malignant Mixed Tumor of the Salivary Gland",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2314897","Skin Squamous Cell Carcinoma In Situ","C2906","Intraepidermal squamous cell carcinoma, confined to the epidermis. There is no evidence of invasion.","Skin Squamous Cell Carcinoma In Situ | Intraepidermal Squamous Cell Carcinoma | Skin Squamous Cell Cancer In Situ | Squamous Cell Carcinoma in situ of Skin | Squamous Cell Carcinoma in situ of the Skin",,,,,,,,,,,,,,,"4112745","Squamous cell carcinoma in situ of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0345905","Intrahepatic Cholangiocarcinoma","C35417","A carcinoma that arises from the intrahepatic bile duct epithelium in any site of the intrahepatic biliary tree.  Grossly, the malignant lesions are solid, nodular, and grayish.  Morphologically, the vast majority of cases are adenocarcinomas.  Signs and symptoms include malaise, weight loss, right upper quadrant abdominal pain, and night sweats.  Early detection is difficult and the prognosis is generally poor.","Intrahepatic Cholangiocarcinoma | CHOLANGIOCARCINOMA, INTRAHEPATIC, MALIGNANT | ICC | ICCA | Intrahepatic Bile Duct Cancer (Cholangiocarcinoma) | Intrahepatic Bile Duct Carcinoma | Intrahepatic Carcinoma of Bile Duct | Intrahepatic Carcinoma of the Bile Duct | Intrahepatic Cholangiocellular Carcinoma | Intrahepatic bile duct carcinoma | iCC | iCCA",,,,,,,,,,,,,,,"37166753","Cholangiocarcinoma of intrahepatic biliary tract",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1866553","Carotid Body Paraganglioma","C2932","A parasympathetic paraganglioma arising from paraganglia adjacent to or in the bifurcation of the common carotid artery.  Most patients present with a slow growing, painless mass in the neck.","Carotid Body Paraganglioma | Carotid Body Chemodectoma | Carotid Body Tumor | Carotid body paraganglioma | Carotid body tumor | Chemodectoma | Paraganglioma of Carotid Body | Paraganglioma of the Carotid Body | Tumor of Carotid Body | Tumor of the Carotid Body",,,,,,,,,,,,,,,"4148626","Carotid body tumor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334011","High Grade Cervical Intraepithelial Neoplasia","C7670","Squamous or glandular cervical intraepithelial neoplasia characterized by the presence of moderate or severe dysplastic changes.","High Grade Cervical Intraepithelial Neoplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986622","Cervical Intraepithelial Neoplasia Grade 2/3","C94676","A neoplastic process in the cervix characterized by morphologic features of both moderate and severe intraepithelial neoplasia.","Cervical Intraepithelial Neoplasia Grade 2/3 | CIN 2/3 | cervical intraepithelial neoplasia grade 2/3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0349458","Low Grade Cervical Intraepithelial Neoplasia","C4630","Squamous or glandular cervical intraepithelial neoplasia characterized by the presence of mild dysplastic changes.","Low Grade Cervical Intraepithelial Neoplasia | Cervical intraepithelial neoplasia, low grade | Low-Grade Cervix Intraepithelial Neoplasia | Low-Grade Cervix Uteri Intraepithelial Neoplasia | Low-Grade Intraepithelial Neoplasia of Cervix | Low-Grade Intraepithelial Neoplasia of Cervix Uteri | Low-Grade Intraepithelial Neoplasia of Uterine Cervix | Low-Grade Intraepithelial Neoplasia of the Cervix | Low-Grade Intraepithelial Neoplasia of the Cervix Uteri | Low-Grade Intraepithelial Neoplasia of the Uterine Cervix | Low-Grade Uterine Cervix Intraepithelial Neoplasia",,,,,,,,,,,,,,,"192676","Cervical intraepithelial neoplasia grade 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206708","Cervical Intraepithelial Neoplasia","C3782","Squamous or glandular intraepithelial neoplasia that affects the cervical mucosal epithelium. There is no evidence of stromal invasion. According to the degree of cellular atypia and the associated architectural changes, it is classified as low or high grade.","Cervical Intraepithelial Neoplasia | CIN | Cervical Dysplasia | Cervical intraepith. neoplasia | Cervical intraepithelial neoplasia (CIN) | Cervix Intraepithelial Neoplasia | Cervix Uteri Intraepithelial Neoplasia | Intraepithelial Neoplasia of Cervix | Intraepithelial Neoplasia of Cervix Uteri | Intraepithelial Neoplasia of Uterine Cervix | Intraepithelial Neoplasia of the Cervix | Intraepithelial Neoplasia of the Cervix Uteri | Intraepithelial Neoplasia of the Uterine Cervix | Uterine Cervix Intraepithelial Neoplasia | cervical intraepithelial neoplasia",,,,,,,,,,,,,,,"198572","Cervical intraepithelial neoplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0342190","C-Cell Hyperplasia","C46100","Neoplastic or reactive proliferation of the C-cells in the thyroid gland. The neoplastic C-cell hyperplasia is associated with familial medullary thyroid gland carcinoma and multiple endocrine neoplasia type II and IIB. Morphologically, it is characterized by the presence of clusters of intrafollicular C-cells with atypical cytologic features. The reactive C-cell hyperplasia is also known as physiological or secondary C-cell hyperplasia and it is associated with conditions that cause hypercalcemia (e.g., hyperparathyroidism).","C-Cell Hyperplasia | ",,,,,,,,,,,,,,,"4130021","C-cell hyperplasia of thyroid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033141","Idiopathic Cardiomyopathy","C53654","A disease of the heart muscle or myocardium proper whose cause is unknown.","Idiopathic Cardiomyopathy | ",,,,,,,,,,,,,,,"4232495","Primary cardiomyopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014122","Subacute Bacterial Endocarditis","C34583","Subacute inflammation of the endocardium. Streptococcus viridans is the usual etiologic agent of subacute bacterial endocarditis. The distinction between 'acute' and 'subacute' endocarditis has traditionally been made based on the pathogenic organism and clinical presentation.","Subacute Bacterial Endocarditis | SBE",,,,,,,,,,,,,,,"4249899","Subacute bacterial endocarditis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516475","Classic Congenital Mesoblastic Nephroma","C39814","A congenital mesoblastic nephroma characterized by the presence of interlacing fascicles of fibroblastic cells, low mitotic activity, and collagen formation.","Classic Congenital Mesoblastic Nephroma | Classic Congenital Mesoblastic Nephroma | Classic Congenital Mesoblastic Nephroma | Classic Mesoblastic Nephroma | Classic Mesoblastic Nephroma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516474","Cellular Congenital Mesoblastic Nephroma","C39815","A congenital mesoblastic nephroma characterized by increased cellularity, sheet-like proliferation of fibroblastic cells, and increased mitotic activity.  Necrotic changes are commonly present.","Cellular Congenital Mesoblastic Nephroma | Cellular Congenital Mesoblastic Nephroma | Cellular Congenital Mesoblastic Nephroma | Cellular Mesoblastic Nephroma | Cellular Mesoblastic Nephroma | Infantile Renal Fibrosarcoma",,,,,,,,,,,,,,,"4233783","Mesoblastic nephroma, cellular",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221287","Combined Hepatocellular Carcinoma and Cholangiocarcinoma","C3828","A rare tumor containing unequivocal elements of both hepatocellular and cholangiocarcinoma that are intimately admixed.  This tumor should be distinguished from separate hepatocellular carcinoma and cholangiocarcinoma arising in the same liver.  The prognosis of this tumor is poor.","Combined Hepatocellular Carcinoma and Cholangiocarcinoma | Carcinoma of Liver and Intrahepatic Biliary Tract | Carcinoma of the Liver and Intrahepatic Biliary Tract | Cholangiohepatoma | Combined Hepatocellular Cancer and Intrahepatic Bile Duct Cancer (Cholangiocarcinoma) | Combined hepatocellular carcinoma and cholangiocarcinoma | Hepatocholangiocarcinoma | Liver and Intrahepatic Biliary Tract Carcinoma | Mixed Hepatocellular Cholangiocarcinoma | cHCC-CCA","8180/3","Combined hepatocellular carcinoma and cholangiocarcinoma",,,,,,,,,,,,,"4166154|4180407","Combined hepatocellular carcinoma and cholangiocarcinoma|Combined hepatocellular carcinoma and cholangiocarcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"CL448546","Clear Cell Adenofibroma","C8987","A benign or borderline neoplasm characterized by the presence of glandular structures which contain clear cells and a fibrotic stroma.","Clear Cell Adenofibroma | Clear cell adenofibroma","8313/0","Clear cell adenofibroma",,,,,,,,,,,,,"4240840","Clear cell adenofibroma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1333162","Cranial Nodular Fasciitis","C27248","A rare, self-limiting, rapidly growing, non-encapsulated benign osteolytic neoplasm that arises from the cranium. It is characterized by the presence of plump spindle-shaped fibroblasts, multinucleated osteoclast-like giant cells, chronic inflammatory infiltrate, red blood cell extravasation, and high mitotic activity.","Cranial Nodular Fasciitis | Cranial Pseudosarcomatous Fasciitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001618","Adrenal Cortical Neoplasm","C2858","A benign or malignant (primary or metastatic) neoplasm affecting the adrenal cortex.","Adrenal Cortical Neoplasm | Adrenal Cortex Neoplasm | Adrenal Cortex Neoplasm | Adrenal Cortex Tumor | Adrenocortical Neoplasm | Adrenocortical Tumor",,,,,,,,,,,,,,,"4131119","Neoplasm of adrenal cortex",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002991","Skin Fibrous Histiocytoma","C6801","A solitary, slowly growing, nodular tumor most often affecting the extremities. It is composed of fibrous and histiocytic cells which infiltrate the dermis and occasionally the underlying subcutaneous tissue.  Usually local excision is curative. Recurrences are reported only in a small minority of cases.","Skin Fibrous Histiocytoma | Benign Cutaneous Fibrous Histiocytoma | Benign Fibrous Cutaneous Histiocytoma | Benign Fibrous Histiocytoma of Skin | Benign Fibrous Histiocytoma of the Skin | Benign Skin Fibrous Histiocytoma | Cutaneous Fibrous Histiocytoma | Cutaneous Fibrous Histiocytoma | Dermatofibroma | Fibrous Histiocytoma of Skin | Fibrous Histiocytoma of the Skin","8832/0","Dermatofibroma, NOS",,,,,,,,,,,,,"4047077|4111938|4144608|4300587","Sclerosing angioma|Fibrous histiocytoma of skin|Dermatofibroma|Sclerosing angioma of skin",,,,,,,,,,,,,"--","--",,,,,,,,"--|--|--|--"
"C0268837","Cystitis Glandularis","C39860","A reactive inflammatory disorder affecting the bladder.  It is characterized by the development of small cysts in the bladder wall.  The cysts are lined by metaplastic glandular cells.","Cystitis Glandularis | ",,,,,,,,,,,,,,,"4248714","Cystitis glandularis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152262","Cystitis Cystica","C96230","A reactive inflammatory disorder affecting the bladder. It is characterized by the development of small cysts in the bladder wall. The cysts are lined by urothelial cells.","Cystitis Cystica | ",,,,,,,,,,,,,,,"201633","Cystitis cystica",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0149523","Acute Cystitis","C26934","An acute infection of the bladder. It is usually caused by bacteria. Signs and symptoms include increased frequency of urination, pain or burning during urination, fever, cloudy or bloody urine, and suprapubic pain.","Acute Cystitis | ",,,,,,,,,,,,,,,"194081","Acute cystitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334285","Bile Duct Mucinous Cystic Neoplasm","C4129","An epithelial, usually multiloculated neoplasm arising from the intrahepatic or extrahepatic bile ducts. It occurs predominantly in females. Signs and symptoms include abdominal mass, abdominal pain, and jaundice. Morphologically, the cystic spaces are lined by columnar epithelium and contain mucinous or serous fluid.","Bile Duct Mucinous Cystic Neoplasm | Bile Duct Cystadenoma | Bile Duct Cystadenoma | Bile Duct MCN | Bile duct cystadenoma | Cystadenoma of Bile Duct | Cystadenoma of the Bile Duct","8161/0","Bile duct cystadenoma",,,,,,,,,,,,,"4307811","Bile duct cystadenoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0206709","Serous Cystadenoma","C3783","A serous neoplasm in which the cysts and papillae are lined by a single layer of cells without atypia, architectural complexity or invasion.","Serous Cystadenoma | Serous Cystoma | Serous cystadenoma, NOS | Serous cystoma","8441/0","Serous cystadenoma, NOS",,,,,,,,,,,,,"4197571","Serous cystadenoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0010635","Mucinous Cystadenoma","C2973","A benign or low malignant potential cystic epithelial neoplasm composed of cells which contain intracytoplasmic mucin. It may arise from the ovary, pancreas, appendix, and lung.","Mucinous Cystadenoma | ADENOMA, MUCINOUS, BENIGN | Mucinous Adenoma | Mucinous Cystoma | Mucinous adenoma | Mucinous cystoma | Pseudomucinous Cystadenoma","8470/0|8480/0","Mucinous cystadenoma, NOS|Mucinous adenoma",,,,,,,,,,,,,"4281855","Mucinous cystadenoma",,,,,,,,,,,,,"--","--|--",,,,,,,,"--"
"C0010633","Cystadenoma","C2972","A benign or borderline cystic epithelial neoplasm arising from the glandular epithelium.  The epithelial cells line the cystic spaces which contain serous or mucinous fluid.  Representative examples include ovarian and pancreatic cystadenomas.","Cystadenoma | CYSTADENOMA, BENIGN | Cystadenoma, NOS | Cystoma","8440/0","Cystadenoma, NOS",,,,,,,,,,,,,"4166210","Cystadenoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334317","Cystadenofibroma","C8985","A benign or borderline neoplasm that arises from the ovaries and the fallopian tubes. It is characterized by the presence of cystic glandular structures and fibrous tissue.","Cystadenofibroma | Cystadenofibroma, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334286","Bile Duct Mucinous Cystic Neoplasm with an Associated Invasive Carcinoma","C4130","A mucinous cystic neoplasm that arises from the intrahepatic or extrahepatic bile ducts and it is associated with an invasive carcinomatous component.","Bile Duct Mucinous Cystic Neoplasm with an Associated Invasive Carcinoma | Bile Duct Cystadenocarcinoma | Bile Duct Cystadenocarcinoma | Bile Duct MCN with an Associated Invasive Carcinoma | Bile duct cystadenocarcinoma | Biliary Cystadenocarcinoma | Cystadenocarcinoma of Bile Duct | Cystadenocarcinoma of the Bile Duct","8161/3","Bile duct cystadenocarcinoma",,,,,,,,,,,,,"4174515","Bile duct cystadenocarcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0037619","Solitary Breast Cyst","C3378","A single, fluid-filled cyst in the breast parenchyma.","Solitary Breast Cyst | Solitary Cyst of Breast | Solitary Cyst of the Breast",,,,,,,,,,,,,,,"78473","Solitary cyst of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0237021","Complex Ovarian Cyst","C5215","A cystic lesion that arises from the ovary. It is characterized by the presence of cystic spaces that contain fluid and a solid tissue component.","Complex Ovarian Cyst | Complex Cyst of Ovary | Complex Cyst of the Ovary | Complex Cystic Neoplasm of Ovary | Complex Cystic Neoplasm of the Ovary | Complex Cystic Ovarian Neoplasm | Complex Cystic Ovarian Tumor | Complex Cystic Tumor of Ovary | Complex Cystic Tumor of the Ovary",,,,,,,,,,,,,,,"762484","Complex ovarian cyst",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152244","Aneurysmal Bone Cyst","C3516","A locally aggressive and destructive benign cystic neoplasm of the bone. It is characterized by the formation of multiloculated hemorrhagic cystic spaces which are separated by fibrous septa. It can arise from any bone, but usually affects the metaphysis of long bones.  It manifests with pain and swelling and may recur following curettage.","Aneurysmal Bone Cyst | ABC | Aneurysmal Cyst of Bone | Aneurysmal Cyst of the Bone",,,,,,,,,,,,,,,"4294380|74737","Aneurysmal bone cyst|Aneurysmal bone cyst",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1275859","Urothelial Dysplasia","C39856","A morphologic finding indicating the presence of dysplastic changes in the transitional cell epithelium of the urinary tract.","Urothelial Dysplasia | Transitional Cell Dysplasia of the Urinary Tract",,,,,,,,,,,,,,,"4164326","Transitional cell dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334058","Low Grade Intraepithelial Neoplasia","C8367","A precancerous neoplastic process that affects the squamous, glandular, or transitional cell epithelium without evidence of invasion. It is characterized by the presence of mild epithelial dysplasia.","Low Grade Intraepithelial Neoplasia | Grade 1 Intraepithelial Neoplasia | Grade I Intraepithelial Neoplasia | Mild Epithelial Dysplasia",,,,,,,,,,,,,,,"4141593","Mild epithelial dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334015","High Grade Intraepithelial Neoplasia","C7348","A precancerous neoplastic process that affects the squamous, glandular, or transitional cell epithelium without evidence of invasion. According to the degree of nuclear atypia, number of mitotic figures, and presence of architectural distortion, it is classified as grade II (moderate dysplasia) or grade III (severe dysplasia).","High Grade Intraepithelial Neoplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880424","Breast Ductal Carcinoma In Situ, Solid Type","C66933","Breast ductal carcinoma in situ in which the tumor cells fill the ductal spaces as solid sheets.","Breast Ductal Carcinoma In Situ, Solid Type | Ductal Breast Carcinoma In Situ, Solid Type | Ductal Breast Carcinoma In Situ, Solid Type | Ductal Breast Carcinoma in Situ, Solid Type | Ductal carcinoma in situ, solid type","8230/2","Ductal carcinoma in situ, solid type",,,,,,,,,,,,,"4029189","Ductal carcinoma in situ, solid type",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334383","Breast Ductal Carcinoma In Situ and Lobular Carcinoma In Situ","C4195","The co-existence of ductal and lobular carcinoma in situ in the breast, without evidence of stromal invasion.","Breast Ductal Carcinoma In Situ and Lobular Carcinoma In Situ | DCIS and LCIS of Breast | DCIS and LCIS of the Breast | Ductal Breast Carcinoma In Situ and Lobular Carcinoma In Situ | Ductal Breast Carcinoma In Situ and Lobular Carcinoma In Situ | Ductal Carcinoma in situ with Lobular Carcinoma in situ of Breast | Ductal Carcinoma in situ with Lobular Carcinoma in situ of the Breast | Ductal and Lobular Breast Carcinoma in situ | Ductal and Lobular Carcinoma in situ of Breast | Ductal and Lobular Carcinoma in situ of the Breast | Intraductal Carcinoma and Lobular Carcinoma in situ | Intraductal and Lobular Breast Carcinoma in situ | Intraductal and Lobular Carcinoma in situ of Breast | Intraductal and Lobular Carcinoma in situ of the Breast | Intraductal carcinoma and lobular carcinoma in situ | Non-Infiltrating Ductal and Non-Infiltrating Lobular Breast Carcinoma | Non-Infiltrating Ductal with Non-Infiltrating Lobular Carcinoma of Breast | Non-Infiltrating Ductal with Non-Infiltrating Lobular Carcinoma of the Breast | Non-Invasive Ductal Breast Carcinoma with Non-Invasive Lobular Breast Carcinoma | Non-Invasive Ductal Carcinoma with Non-Invasive Lobular Carcinoma of Breast | Non-Invasive Ductal Carcinoma with Non-Invasive Lobular Carcinoma of the Breast | Non-Invasive Ductal and Non-Invasive Lobular Breast Carcinoma | Non-Invasive Ductal and Non-Invasive Lobular Carcinoma | Non-Invasive Ductal with Non-Invasive Lobular Breast Carcinoma","8522/2","Intraductal carcinoma and lobular carcinoma in situ",,,,,,,,,,,,,"4093306","Intraductal carcinoma and lobular carcinoma in situ",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1334249","Breast Micropapillary Ductal Carcinoma In Situ","C5139","Breast ductal carcinoma in situ characterized by the presence of neoplastic epithelial cells arranged in micropapillary patterns.","Breast Micropapillary Ductal Carcinoma In Situ | Breast Intraductal Micropapillary Carcinoma | Breast Micropapillary DCIS | Intraductal Micropapillary Breast Carcinoma | Intraductal Micropapillary Breast Carcinoma | Intraductal micropapillary carcinoma | Micropapillary DCIS of Breast | Micropapillary DCIS of the Breast | Micropapillary Ductal Breast Carcinoma in situ | Micropapillary Ductal Carcinoma In Situ | Micropapillary Ductal Carcinoma in situ of Breast | Micropapillary Ductal Carcinoma in situ of the Breast | Non-Infiltrating Micropapillary Breast Carcinoma | Non-Infiltrating Micropapillary Carcinoma of Breast | Non-Infiltrating Micropapillary Carcinoma of the Breast | Non-Infiltrating Micropapillary Ductal Breast Carcinoma | Non-Infiltrating Micropapillary Ductal Carcinoma of Breast | Non-Infiltrating Micropapillary Ductal Carcinoma of the Breast | Non-Invasive Micropapillary Breast Carcinoma | Non-Invasive Micropapillary Carcinoma of Breast | Non-Invasive Micropapillary Carcinoma of the Breast | Non-Invasive Micropapillary Ductal Breast Carcinoma | Non-Invasive Micropapillary Ductal Carcinoma of Breast | Non-Invasive Micropapillary Ductal Carcinoma of the Breast","8507/2","Intraductal micropapillary carcinoma",,,,,,,,,,,,,"4029513","Intraductal micropapillary carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1334413","Low-Grade Ductal Carcinoma In Situ of Breast","C9457","Breast ductal carcinoma in situ characterized by the presence of small, monomorphic neoplastic cells that form cribriform, micropapillary, or solid patterns. The nuclei are uniform and mitotic figures are rare.","Breast Ductal Carcinoma In Situ, Low Grade | DCIS Grade 1 | DIN 1C | Ductal Intraepithelial Neoplasia, Grade 1C | Low Grade Ductal Breast Carcinoma In Situ | Low Grade Ductal Breast Carcinoma In Situ | Low-Grade DCIS | Low-Grade Ductal Carcinoma In Situ of Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334206","Intermediate-Grade Ductal Carcinoma In Situ of Breast","C9456","Breast ductal carcinoma in situ characterized by the presence of monomorphic neoplastic cells that form cribriform, micropapillary, or solid patterns. Intraluminal necrosis is present in some ducts. Ducts that contain neoplastic cells with occasional nucleoli and coarse chromatin may also be present.","Breast Ductal Carcinoma In Situ, Intermediate Grade | DCIS Grade 2 | DIN 2 | Ductal Intraepithelial Neoplasia, Grade 2 | Intermediate Grade Ductal Breast Carcinoma In Situ | Intermediate Grade Ductal Breast Carcinoma In Situ | Intermediate-Grade DCIS | Intermediate-Grade Ductal Carcinoma In Situ of Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334002","Breast Ductal Carcinoma In Situ, High Grade","C7949","Breast ductal carcinoma in situ characterized by the presence of neoplastic cells with severe dysplasia and the formation of micropapillary, cribriform, or solid patterns. The nuclei show marked pleomorphism and have prominent nucleoli. Mitotic activity is usually present. There is comedo-type of necrosis present in the ducts. The necrotic debris is surrounded by pleomorphic malignant cells.","Breast Ductal Carcinoma In Situ, High Grade | DCIS Grade 3 | DIN 3 | Ductal Intraepithelial Neoplasia, Grade 3 | High Grade Ductal Breast Carcinoma In Situ | High Grade Ductal Breast Carcinoma In Situ | High-Grade DCIS of Breast | High-Grade DCIS of the Breast | High-Grade Ductal Carcinoma In Situ of Breast | grade III ductal carcinoma in situ",,,,,,,,,,,,,,,"37156152","Non-infiltrating intraductal carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334248","Breast Ductal Carcinoma In Situ, Cribriform Pattern","C5138","Breast ductal carcinoma in situ characterized by the presence of a cribriform architectural pattern.","Breast Ductal Carcinoma In Situ, Cribriform Pattern | Breast Ductal Carcinoma In Situ with Cribriform Pattern | Breast Ductal Carcinoma In Situ, Cribriform Type | Breast Intraductal Cribriform Adenocarcinoma | Cribriform DCIS of Breast | Cribriform DCIS of the Breast | Cribriform Ductal Breast Carcinoma in situ | Cribriform Ductal Carcinoma in situ of Breast | Cribriform Ductal Carcinoma in situ of the Breast | DCIS of Breast with Cribriform Pattern | DCIS of the Breast with Cribriform Pattern | Ductal Carcinoma in situ of Breast with Cribriform Pattern | Ductal Carcinoma in situ of the Breast with Cribriform Pattern | Intraductal Cribriform Breast Adenocarcinoma | Intraductal Cribriform Breast Adenocarcinoma | Non-Infiltrating Cribriform Ductal Breast Carcinoma | Non-Invasive Cribriform Ductal Breast Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376319","Congenital Granular Cell Epulis","C4675","A congenital gingival tumor that occurs along the alveolar ridge of the maxilla. It usually affects female infants. The histogenesis is unknown. Morphologically, it is characterized by the presence of large cells with eosinophilic granular cytoplasm. Complete surgical resection is curative.","Congenital Granular Cell Epulis | Congenital Epulis | Congenital Epulis | Congenital Granular Cell Tumor | Gingival Granular Cell Tumor",,,,,,,,,,,,,,,"4233560","Congenital gingival granular cell tumor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334578","Papillary Ependymoma","C4319","A rare variant of ependymoma characterized by well formed papillae. Tumor cell processes abutting capillaries are usually GFAP-positive. Differential diagnoses include choroid plexus papilloma, papillary meningioma and metastatic papillary carcinoma. (Adapted from WHO)","Papillary Ependymoma | Papillary ependymoma","9393/3","Papillary ependymoma",,,,,,,,,,,,,"4028715","Papillary ependymoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C3642437","Endometrioid Stromal and Related Neoplasms","C8384","A category of mesenchymal gynecologic neoplasms. It includes endometrial stromal nodule, endometrioid stromal sarcoma, and undifferentiated sarcoma. Endometrial stromal nodule has been described in the uterine corpus only. Histologically, it is characterized by the lack of infiltration of the surrounding tissues. Endometrioid stromal sarcoma affects the uterine corpus, and rarely, the ovaries, cervix, vagina, peritoneum, and retroperitoneum. In the uterine corpus it is classified as low grade or high grade endometrial stromal sarcoma. In the remainder of the anatomic sites it is classified as low grade endometrioid stromal sarcoma. Undifferentiated sarcoma was previously also known as high grade endometrial stromal sarcoma. In 2014, high grade endometrial stromal sarcoma was reclassified and is currently considered a distinct and rare neoplasm that affects the uterine corpus only. It appears to have a prognosis that falls between low grade endometrial stromal sarcoma and undifferentiated sarcoma. The latter affects the uterine corpus and rarely the remainder of the anatomic sites.","Endometrioid Stromal and Related Neoplasms | Endometrial Stromal Neoplasm | Endometrioid Stromal Neoplasm | Endometrioid Stromal and Related Tumors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1368041","Pancreatic Somatostatinoma","C95595","A neuroendocrine tumor arising from the delta cells of the pancreas.  It is characterized by inappropriate secretion of somatostatin and associated with diabetes mellitus, hypochlorhydria, gallbladder disease, diarrhea, steatorrhea, anemia, and weight loss.","Pancreatic Somatostatinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882278","Pancreatic Polypeptide Tumor","C67453","A benign or malignant neuroendocrine tumor that arises from the pancreas and secretes pancreatic polypeptide.","Pancreatic Polypeptide Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014132","Endocrine Neoplasm","C3010","A benign or malignant neoplasm arising from the epithelial cells of an endocrine organ. Representative examples include pituitary gland adenoma, pituitary gland carcinoma, thyroid gland carcinoma, carcinoid tumor, and neuroendocrine carcinoma.","Endocrine Neoplasm | Endocrine System Neoplasm | Endocrine System Tumor | Endocrine Tumor",,,,,,,,,,,,,,,"4300595|4302836","Neoplasm of endocrine system|Neoplasm of endocrine gland",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0021670","Pancreatic Insulinoma","C95598","An insulin-producing neuroendocrine tumor arising from the beta cells of the pancreas. Patients exhibit symptoms related to hypoglycemia due to inappropriate secretion of insulin.","Pancreatic Insulinoma | Insulinoma | insulinoma",,,,,,,,,,,,,,,"4121326","Insulinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL428078","Pancreatic Glucagonoma","C95597","A usually malignant, glucagon-producing neuroendocrine tumor arising from the pancreatic alpha cells. It may be associated with necrolytic erythema migrans, diarrhea, diabetes, glossitis, weight loss, malabsorption, and anemia. Almost 25% of patients experience thromboembolic complications, and 50% have liver metastases at the time of diagnosis.","Pancreatic Glucagonoma | Glucagonoma | glucagonoma","8152/3","Glucagonoma",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C0017150","Gastrin-Producing Neuroendocrine Tumor","C3050","A gastrin-producing neuroendocrine tumor. It is usually located in the pancreas but it is also found at other anatomic sites, including the stomach and small intestine.","Gastrin-Producing Neuroendocrine Tumor | G Cell Tumor | G-Cell Gastrin Producing Tumor | G-Cell Tumor | Gastrin Secreting Tumor | Gastrin-Producing NET | Gastrinoma | gastrinoma",,,,,,,,,,,,,,,"4037498|4121327","Gastrinoma|Gastrinoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0040147","Thyroiditis","C26894","Inflammation of the thyroid gland. This category includes Hashimoto thyroiditis, Riedel thyroiditis, acute thyroiditis, subacute thyroiditis, and radiation-induced thyroiditis.","Thyroiditis | Thyroiditis, unspecified | thyroiditis",,,,,,,,,,,,,,,"133444","Thyroiditis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0154162","Riedel Fibrosing Thyroiditis","C35827","An inflammatory disorder of unknown etiology that affects the thyroid gland. It is characterized by extensive fibrosis of the thyroid parenchyma. The fibrosis extends beyond the thyroid gland capsule to the adjacent structures.","Riedel Fibrosing Thyroiditis | Riedel Thyroiditis | Riedel's Fibrosing Thyroiditis",,,,,,,,,,,,,,,"4228334","Riedel's thyroiditis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0342176","Subacute Granulomatous Thyroiditis","C35828","Self-limited inflammation of the thyroid gland characterized by the presence of multinucleated giant cells. Patients present with neck pain, often associated with fever and dysphagia. The clinical course includes an initial phase of hyperthyroidism, followed by a phase of hypothyroidism, and eventually a return to normal thyroid function.","Subacute Granulomatous Thyroiditis | De Quervain Thyroiditis | De Quervain's Thyroiditis | DeQuervain Thyroiditis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0346021","Benign Eccrine Neoplasm","C6797","An epithelial neoplasm that arises from the eccrine glands and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential. Representative examples include hidrocystoma, syringoma, and syringofibroadenoma.","Benign Eccrine Neoplasm | Benign Eccrine Neoplasm of Skin | Benign Eccrine Neoplasm of the Skin | Benign Eccrine Skin Neoplasm | Benign Eccrine Skin Tumor | Benign Eccrine Tumor | Benign Eccrine Tumor of Skin | Benign Eccrine Tumor of the Skin",,,,,,,,,,,,,,,"4111934","Benign skin tumor with eccrine differentiation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022752","Knowledge Base","C47846","A database or other collection of knowledge expressed in a formal knowledge representation language.","Knowledge Base | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334121","Inflammatory Myofibroblastic Tumor","C6481","A multinodular intermediate fibroblastic neoplasm that arises from soft tissue or viscera, in children and young adults.  It is characterized by the presence of spindle-shaped fibroblasts and myofibroblasts, and a chronic inflammatory infiltrate composed of eosinophils, lymphocytes, and plasma cells.","Inflammatory Myofibroblastic Tumor | IMT | Inflammatory Fibrosarcoma | Inflammatory Myofibroblastic Neoplasm | Inflammatory Pseudotumor | Inflammatory myofibroblastic tumor","8825/1","Myofibroblastic tumor, NOS",,,,,,,,,,,,,"36674274|4021373","Inflammatory myofibroblastic tumor|Myofibroblastic tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0079218","Desmoid Fibromatosis","C9182","An insidious, locally aggressive, poorly circumscribed neoplasm arising from the deep soft tissues. It is characterized by the presence of elongated spindle-shaped fibroblasts, collagenous stroma formation, and an infiltrative growth pattern. It lacks metastatic potential.","Desmoid Fibromatosis | Aggressive Fibromatosis | Aggressive fibromatosis | Deep Fibromatosis | Deep Fibromatosis/Desmoid Tumor | Deep Fibromatosis/Desmoid Tumor | Desmoid Tumor | Desmoid-Type Fibromatosis | Desmoid-Type Fibromatosis | desmoid tumor","8821/1","Aggressive fibromatosis",,,,,,,,,,,,,"37110721","Aggressive fibromatosis",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0221290","Chondromyxoid Fibroma","C3830","An uncommon benign cartilaginous neoplasm arising from the bone. It is characterized by the presence of spindle-shaped or stellate chondrocytes, a lobulated growth pattern, myxoid stroma formation, and sometimes multinucleated giant cells. It has been associated with chromosomal rearrangement of 6q13 and 6q25 bands. The most common clinical symptom is mild, localized pain.","Chondromyxoid Fibroma | Chondromyxoid fibroma","9241/0","Chondromyxoid fibroma",,,,,,,,,,,,,"4216782","Chondromyxoid fibroma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1335931","Breast Sclerosing Adenosis","C5205","Breast adenosis characterized by the proliferation of acini, a lobulated architectural pattern, and stromal sclerosis.  The luminal epithelial and myopepithelial cells are preserved.  Microcalcifications and foci of apocrine metaplasia may be present.","Breast Sclerosing Adenosis | Sclerosing Adenosis of Breast | Sclerosing Adenosis of the Breast | Sclerosing Breast Adenosis | sclerosing adenosis",,,,,,,,,,,,,,,"45757076","Sclerosing adenosis of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0269252","Apocrine Metaplasia of Breast","C7759","A morphologic finding indicating the transformation of the epithelial cells in a breast tissue sample to cells with abundant eosinophilic cytoplasm.","Apocrine Metaplasia of Breast | ",,,,,,,,,,,,,,,"4285205","Apocrine metaplasia of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1707597","Cyst Formation","C50520","A morphologic finding indicating the presence of cystic structures in a tissue sample.","Cyst Formation | Cyst(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085750","Adenosis of Breast","C3484","A non-neoplastic disorder characterized by epithelial and/or myoepithelial tissue growth in the breast lobules.  It may be associated with apocrine changes or sclerosis.","Breast Adenosis | Adenosis of Breast | Adenosis of the Breast | adenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0406579","Giant Cell Fibroblastoma","C4700","A morphologic variant of dermatofibrosarcoma protuberans that is most often seen in childhood and is characterized by the presence of spindle-shaped fibroblastic cells, a storiform growth pattern, numerous multinucleated giant cells, wide vessel-like spaces, and extensive myxoid change.","Giant Cell Fibroblastoma | GCF | Giant cell fibroblastoma | giant cell fibroblastoma","8834/1","Giant cell fibroblastoma",,,,,,,,,,,,,"4030132|4032908","Giant cell fibroblastoma|Giant cell fibroblastoma of skin",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1520159","Wolffian Tumor","C40141","An adnexal epithelial neoplasm of Wolffian (mesonephric) origin. It predominantly affects the broad ligament and presents as a unilateral adnexal mass. Most tumors behave in a benign fashion.","Wolffian Tumor | FATWO | Female Adnexal Tumor of Probable Wolffian Origin | Mesonephric Adenoma | Mesonephric adenoma | Mesonephroma | Mesonephroma, NOS | Mesonephroma, benign | Mesonephromas | Retiform Wolffian Adenoma | WAT | Wolffian Adenoma | Wolffian Adnexal Neoplasm | Wolffian Adnexal Tumor | Wolffian Adnexal Tumor | Wolffian Duct Adenoma | Wolffian Duct Neoplasm | Wolffian Duct Tumor | Wolffian duct adenoma | Wolffian duct tumor | mesonephroma",,,,,,,,,,,,,,,"4217973","Mesonephroma, benign",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018952","Extramedullary Hematopoiesis","C41235","Hematopoiesis that occurs outside of the bone marrow. It occurs during fetal development or it may result from pathologic processes that affect the bone marrow.","Extramedullary Hematopoiesis | EXTRAMEDULLARY HEMATOPOIESIS",,,,,,,,,,,,,,,"4180460","Extramedullary hematopoiesis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0341110","Viral Esophagitis","C27108","Viral infection of the esophagus. It often occurs in immunocompromised patients and it is caused by cytomegalovirus or herpes simplex virus. Symptoms include pain on swallowing, fever, and retrosternal burning.","Viral Esophagitis | ",,,,,,,,,,,,,,,"4340113","Viral esophagitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0341109","Fungal Esophagitis","C27107","Infection of the esophagus caused by fungi, most often candida albicans and candida tropicalis. It usually affects patients with immunodeficiency disorders or diabetes mellitus. Symptoms include dysphagia and pain on swallowing.","Fungal Esophagitis | ",,,,,,,,,,,,,,,"4342627","Fungal esophagitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3809720","Eosinophilic Esophagitis","C27105","Allergic inflammation of the esophagus. Morphologically, it is characterized by the presence of eosinophils infiltrating the esophageal epithelium. Patients present with swallowing difficulty and heartburn.","Eosinophilic Esophagitis | EoE",,,,,,,,,,,,,,,"27918","Eosinophilic esophagitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0341108","Bacterial Esophagitis","C27106","An acute bacterial infection that affects the esophagus. Symptoms include severe pain on swallowing and retrosternal pain. Endoscopic examination reveals esophageal mucosal ulcerations and pseudomembranous formations.","Bacterial Esophagitis | ",,,,,,,,,,,,,,,"4341224","Bacterial esophagitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021684","Health Insurance Reimbursement","C16746","Money paid out by an insurance company to an individual, or their designated recipient, for covered medical expenses.","Health Insurance Reimbursement | Insurance, Health, Reimbursement | Insurance, Health, Reimbursement | Third Party Payment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004030","Aspergillosis","C2886","An infection that is caused by Aspergillus.","Aspergillosis | aspergillosis",,,,,,,,,,,,,,,"434281","Aspergillosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0859920","Hair Follicle Neoplasm","C7367","A benign or malignant neoplasm that arises from the hair follicle of the skin.","Hair Follicle Neoplasm | Hair Follicle Tumor | Hair Matrix Neoplasm | Hair Matrix Tumor | Neoplasm of Hair Follicle | Neoplasm of the Hair Follicle | Neoplasm with Follicular Differentiation | Tumor with Follicular Differentiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1275236","Tendon Sheath Fibroma","C6485","A small, slow growing, benign neoplasm arising from the tendon sheaths. The tumor is characterized by the presence of spindle-shaped fibroblasts and collagenous stroma formation.","Tendon Sheath Fibroma | Fibroma of Tendon Sheath | Fibroma of the Tendon Sheath",,,,,,,,,,,,,,,"4301526|45766451","Fibroma of tendon sheath|Fibroma of tendon sheath",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1266119","Solitary Fibrous Tumor","C7634","A localized neoplasm of probable fibroblastic derivation. It is characterized by the presence of round to spindle-shaped cells, hylanized stroma formation, thin-walled branching blood vessels, and thin bands of collagen.","Solitary Fibrous Tumor | Hemangiopericytoma | Localized Fibrous Mesothelioma | Localized Fibrous Tumor | Localized fibrous tumor | SFT | Solitary Fibrous Tumor, NOS | Solitary Fibrous Tumor, Not Otherwise Specified | Solitary fibrous tumor | Submesothelial Fibroma",,,,,,,,,,,,,,,"4030130","Solitary fibrous tumor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0432528","Proliferative Fasciitis","C4728","A rapidly growing, poorly circumscribed, mass-forming proliferation that arises from the subcutaneous tissues. It is characterized by the presence of spindle-shaped fibroblasts, round ganglion-like cells, myxoid to collagenous stroma formation, and high mitotic activity. It recurs only rarely following local excision and does not metastasize.","Proliferative Fasciitis | ",,,,,,,,,,,,,,,"4110729","Proliferative fasciitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0410005","Nodular Fasciitis","C3827","A self-limiting, rapidly growing, non-encapsulated benign neoplasm that arises from the soft tissues. It is characterized by the presence of plump spindle-shaped fibroblasts, multinucleated osteoclast-like giant cells, chronic inflammatory infiltrate, red blood cell extravasation, and high mitotic activity.","Nodular Fasciitis | Pseudosarcomatous Fasciitis",,,,,,,,,,,,,,,"4266330|45766455","Nodular fasciitis|Nodular fasciitis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0206648","Myofibromatosis","C3742","A benign, multifocal, nodular and well-circumscribed neoplasm usually seen as a congenital neoplasm or in the first year of life. It is characterized by a biphasic growth pattern and is composed of small, undifferentiated mesenchymal cells associated with branching thin-walled vessels and more mature neoplastic spindle cells with abundant eosinophilic cytoplasm in a collagenous stroma.","Myofibromatosis | Infantile Hemangiopericytoma | Infantile Myofibromatosis | Infantile myofibromatosis | Multicentric Myofibromatosis","8824/1","Myofibromatosis",,,,,,,,,,,,,"40443058|4249896","Myofibromatosis|Myofibromatosis",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C4228279","Myofibroma","C7052","A benign, localized, nodular and well-circumscribed neoplasm usually seen as a congenital neoplasm or in the first year of life. It is characterized by a biphasic growth pattern and is composed of small, undifferentiated mesenchymal cells associated with branching thin-walled vessels and more mature neoplastic spindle cells with abundant eosinophilic cytoplasm in a collagenous stroma.","Myofibroma | Solitary Myofibroma","8824/0","Myofibroma",,,,,,,,,,,,,"4029201","Myofibroma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334460","Elastofibroma","C4245","A benign, slow-growing tumor arising from the soft tissues usually in the mid-thoracic region of the elderly. It is characterized by the presence of paucicellular collagenous tissue, adipocytes and a predominance of large coarse elastic fibers arranged in globules.","Elastofibroma | Elastofibroma Dorsi","8820/0","Elastofibroma",,,,,,,,,,,,,"4321725","Elastofibroma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334399","Ovarian Luteinized Thecoma","C4203","A variant of ovarian thecoma characterized by the presence of lutein cells. It is associated with a lower frequency of estrogenic manifestations compared to typical thecomas. In a minority of cases androgenic manifestations are present.","Ovarian Luteinized Thecoma | Luteinized Ovarian Thecoma | Luteinized Thecoma of Ovary | Luteinized Thecoma of the Ovary | Thecoma, luteinized","8601/0","Thecoma, luteinized",,,,,,,,,,,,,"4184449","Thecoma, luteinized",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1519696","Tumor of the Thecoma/Fibroma Group","C39950","A sex cord-stromal tumor that arises from the ovary or the testis. Representative examples include fibroma, fibrosarcoma, and thecoma.","Tumor of the Thecoma/Fibroma Group | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0158360","Plantar Fibromatosis","C4680","A superficial fibromatosis arising from soft tissue of the plantar regions. It is characterized by the presence of spindle-shaped fibroblasts, hypercellularity, and an infiltrative growth pattern.","Plantar Fibromatosis | Ledderhose Disease | Ledderhose's Disease",,,,,,,,,,,,,,,"134460","Plantar fascial fibromatosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0238067","Collagenous Colitis","C27021","A type of microscopic colitis of unknown etiology. It is characterized by the presence of collagen deposits in the lamina propria of the colonic mucosa. Patients present with chronic watery diarrhea. Colonoscopy reveals normal-appearing mucosa. The diagnosis is made with the microscopic examination of the colonic biopsy samples.","Collagenous Colitis | ",,,,,,,,,,,,,,,"4000167","Collagenous colitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023891","Alcoholic Cirrhosis","C34782","A disorder of the liver characterized by the presence of fibrotic scar tissue instead of healthy liver tissue. This condition is attributed to excessive consumption of alcoholic beverages.","Alcoholic Cirrhosis | Cirrhosis of the Liver Secondary to Alcohol Use",,,,,,,,,,,,,,,"196463","Alcoholic cirrhosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0333577","Cholesterol Deposit","C54097","Deposition of cholesterol in the skin. It appears as a slightly elevated and yellow bump usually in the skin around the eyes.","Cholesterol Deposit | Cholesterosis",,,,,,,,,,,,,,,"4174818","Cholesterolosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0267853","Cholecystitis with Cholelithiasis","C35332","An acute or chronic inflammation of the gallbladder associated with the presence of gallstones.","Cholecystitis with Cholelithiasis | ",,,,,,,,,,,,,,,"443785","Calculus of gallbladder with cholecystitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017154","Chronic Atrophic Gastritis","C7405","Atrophic gastritis that is persistent and long-standing.","Chronic Atrophic Gastritis | Gastric Atrophy | gastric atrophy",,,,,,,,,,,,,,,"192667","Atrophic gastritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1321756","Achalasia","C50451","Failure of the smooth muscle fibers of the gastrointestinal tract to relax at any one point of junction of one part with another.","Achalasia | ",,,,,,,,,,,,,,,"4174974","Achalasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704399","Gastrointestinal Stromal Tumor of Uncertain Malignant Potential","C54000","A gastrointestinal stromal tumor that is characterized by a maximum diameter greater than 5 cm and equal or less than 10 cm (gastric localization), or greater than 2 cm and equal or less than 5 cm (intestinal localization) and no more than 5 mitotic figures per 50 high power fields.","Gastrointestinal Stromal Tumor of Uncertain Malignant Potential | Gastrointestinal stromal tumor, uncertain malignant potential",,,,,,,,,,,,,,,"4029026","Gastrointestinal stromal tumor, uncertain malignant potential",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1849982","Steatosis","C36185","Acumulation of adipose tissue in intracytoplasmic or extracellular spaces.","Steatosis | FATTY CHANGE | Fatty Change",,,,,,,,,,,,,,,"37162002|4104542","Steatosis|Fatty degeneration",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0158683","Polycystic Liver Disease","C82833","A usually asymptomatic hereditary disorder which is often associated with polycystic kidney disease. It is characterized by the presence of fluid-filled biliary cysts throughout the liver.","Polycystic Liver Disease | ",,,,,,,,,,,,,,,"197654","Congenital cystic disease of liver",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001339","Acute Pancreatitis","C95437","An acute inflammatory process that leads to necrosis of the pancreatic parenchyma. Signs and symptoms include severe abdominal pain, nausea, vomiting, diarrhea, fever, and shock. Causes include alcohol consumption, presence of gallstones, trauma, and drugs.","Acute Pancreatitis | Acute pancreatitis",,,,,,,,,,,,,,,"199074","Acute pancreatitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0400822","Lymphocytic Colitis","C27147","Microscopic colitis characterized by the accumulation of lymphocytes in the colonic epithelium and lamina propria. Patients present with chronic watery diarrhea. Colonoscopy reveals normal colonic mucosa. The diagnosis is made with the microscopic examination of the colonic biopsy samples.","Lymphocytic Colitis | ",,,,,,,,,,,,,,,"37162240","Lymphocytic colitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0267111","Gastric Dysplasia","C95754","A morphologic finding indicating the presence of dysplastic changes within the gastric mucosal epithelial cells.","Gastric Dysplasia | ",,,,,,,,,,,,,,,"4050252","Gastric dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036130","Salpingitis","C26880","Acute or chronic inflammation of the fallopian tube. It is most often caused by Neisseria gonorrhoeae and Chlamydia trachomatis infections. The infections usually originate in the vagina and ascend to the fallopian tube. Symptoms include abdominal, pelvic, and lower back pain, pain during ovulation and sexual intercourse, fever, nausea, and vomiting. Complications include infertility and ectopic pregnancy.","Salpingitis | ",,,,,,,,,,,,,,,"4338958","Salpingitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0000832","Placental Abruption","C26685","Placental separation from the uterus with bleeding (concealed or vaginal) before fetal birth, with or without maternal/fetal compromise. (reVITALize)","Placental Abruption | Abruptio Placentae | Abruptio Placentae, Premature Separation of Placenta | Premature Separation of Placenta | Premature Separation of Placenta",,,,,,,,,,,,,,,"198488","Placental abruption",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008495","Chorioamnionitis","C26720","A morphologic finding indicating inflammation of the fetal sac membranes. It is characterized by neutrophilic infiltration of the amnion and chorion.","Chorioamnionitis | ",,,,,,,,,,,,,,,"4021397","Chorioamnionitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007860","Cervicitis","C26716","An acute or chronic inflammatory process that affects the cervix. Causes include sexually transmitted diseases and bacterial infections. Clinical manifestations include abnormal vaginal bleeding and vaginal discharge.","Cervicitis | ",,,,,,,,,,,,,,,"444078","Inflammation of cervix",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018413","Ovarian Gynandroblastoma","C3072","A rare neoplasm arising from the ovary. Although it may occur at any age, it is more often seen in young females. Morphologically, it is characterized by a mixture of two cellular populations: well differentiated Sertoli cells and granulosa cells, with the latter constituting at least ten percent of the neoplasm. The vast majority of cases are stage I lesions at presentation and produce either estrogenic or androgenic manifestations. Although it may present as a massive ovarian tumor, it usually follows a benign clinical course. Very rare case reports of testicular lesions morphologically resembling gynandroblastomas are in fact variants of juvenile granulose cell tumor, or Sertoli cell tumor, or a combination of both.","Ovarian Gynandroblastoma | Gynandroblastoma | Gynandroblastoma of Ovary | Gynandroblastoma of the Ovary","8632/1","Gynandroblastoma",,,,,,,,,,,,,"4097238|4110866","Gynandroblastoma|Gynandroblastoma of ovary",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0206661","Gonadoblastoma","C3754","A mixed germ cell/sex cord-stromal tumor characterized by the presence of large germ cells which resemble seminoma cells and small cells which resemble Sertoli or granulosa cells. It occurs in the testis and the ovary and is identified in children and adults. It is often associated with gonadal dysgenesis and abnormal karyotype.","Gonadoblastoma | ","9073/1","Gonadoblastoma",,,,,,,,,,,,,"37160610|4253033","Gonadoblastoma|Gonadoblastoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0588125","Tenosynovial Giant Cell Tumor, Localized Type","C6532","A well-circumscribed, lobulated tumor, completely or partially covered by a fibrous capsule. It usually arises in the fingers.  It is characterized by the presence of mononuclear cells, multinucleated osteoclast-like giant cells, hemosiderin-laden macrophages, foam cells, and an inflammatory infiltrate. The tumor is slow-growing, usually developing over several years. Clinical presentation includes painless edema of the affected site.","Tenosynovial Giant Cell Tumor, Localized Type | Localized Giant Cell Neoplasm of Tendon Sheath | Localized Giant Cell Neoplasm of Tenosynovium | Localized Giant Cell Neoplasm of the Tenosynovium | Localized Giant Cell Tumor of Tendon Sheath | Localized Giant Cell Tumor of Tendon Sheath | Localized Giant Cell Tumor of Tenosynovium | Localized Giant Cell Tumor of the Tenosynovium | Localized Tenosynovial Giant Cell Neoplasm | Localized Tenosynovial Giant Cell Tumor | Nodular Tenosynovitis",,,,,,,,,,,,,,,"436200|45766524","Nodular tenosynovitis|Tenosynovial giant cell tumor, localized",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0017525","Giant Cell Tumor","C3055","A benign, intermediate, or malignant tumor that arises from the bone or soft tissue. It is characterized by the presence of multinucleated osteoclast-like giant cells.","Giant Cell Tumor | ",,,,,,,,,,,,,,,"4019912|40483254","Giant cell tumor|Giant cell tumor",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1321220","Mixed Germ Cell-Sex Cord-Stromal Tumor","C5241","A biphasic neoplasm that arises from the ovary or the testis. It is characterized by the presence of neoplastic germ cells and neoplastic sex cord-stromal cells. It includes the gonadoblastoma and mixed germ cell-sex cord stromal tumor, unclassifiable.","Mixed Germ Cell-Sex Cord-Stromal Tumor | Mixed Germ Cell-Sex Cord Neoplasm | Mixed Germ Cell-Sex Cord Tumor | Mixed Germ Cell-Sex Cord-Stromal Neoplasm",,,,,,,,,,,,,,,"4247366","Mixed germ cell-sex cord-stromal tumor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0598589","Inherited Neuropathy","C27187","A hereditary disorder that affects the sensory and/or motor nerves or the autonomic nerves.","Inherited Neuropathy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1849984","Hemochromatosis","C82892","Accumulation of iron in internal organs.","Hemochromatosis | Hemosiderosis | Hemosiderosis | hemochromatosis",,,,,,,,,,,,,,,"4305596","Hemosiderosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018552","Hamartoma","C3075","A benign and excessive tumor-like growth of mature cells and normal tissues which grow in a disorganized pattern.","Hamartoma | HAMARTOMA | hamartoma",,,,,,,,,,,,,,,"4198703|4266653","Hamartoma|Hamartoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0206622","Adenomyoma","C3726","A benign neoplasm characterized by the presence of a glandular and a mesenchymal (fibromyomatous) component. It occurs in the uterine corpus, cervix, and uterine ligaments. A variant of adenomyoma associated with glandular architectural complexity is called atypical polypoid adenomyoma. Simple polypectomy is usually curative. Atypical polypoid adenomyoma may recur following polypectomy.","Adenomyoma | ADENOMYOMA, BENIGN",,,,,,,,,,,,,,,"4224139","Adenomyoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0346049","Fibrohistiocytic Neoplasm","C8402","A benign, intermediate, or malignant mesenchymal neoplasm composed of fibrohistiocytic cells, spindle fibroblastic cells, and histiocytes, in a storiform pattern.","Fibrohistiocytic Neoplasm | Fibrohistiocytic Tumor",,,,,,,,,,,,,,,"37152448","Fibrohistiocytic neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023381","Letterer-Siwe Disease","C3160","A multifocal, multisystem form of Langerhans-cell histiocytosis. There is involvement of multiple organ systems including the bones, skin, liver, spleen, and lymph nodes. Patients are usually infants presenting with fever, hepatosplenomegaly, lymphadenopathy, bone and skin lesions, and pancytopenia.","Letterer-Siwe Disease | Acute Disseminated Langerhans Cell Histiocytosis | Letterer-Siwe disease | Multifocal Multisystem Langerhans Cell Histiocytosis | Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis",,,,,,,,,,,,,,,"4028708","Langerhans cell histiocytosis, disseminated",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002390","Extrinsic Allergic Alveolitis","C34369","An inflammatory interstitial lung disease caused by hypersensitivity reaction to inhalation or ingestion of antigens.  The antigens are usually related to the patient's occupation.  It can present as an acute illness with flu-like symptoms, subacute with repeated episodes of pneumonia, or chronic with dyspnea and productive cough.  The majority of patients recover following the cessation of the exposure to the antigen that causes the disease.  Chronic exposure may eventually progress to interstitial lung fibrosis.","Extrinsic Allergic Alveolitis | Allergic Pneumonitis | Hypersensitivity Pneumonitis",,,,,,,,,,,,,,,"444084","Extrinsic allergic alveolitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1335966","Simple Endometrial Hyperplasia with Atypia","C6991","A proliferation of endometrial cells resulting in glandular enlargement and budding without changes in the basic structure of the endometrium. Epithelial atypia is present.","Simple Endometrial Hyperplasia with Atypia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0442835","Breast Atypical Lobular Hyperplasia","C4730","Lobular neoplasia characterized by lobular epithelial proliferation that does not completely fill the lobular unit of the breast.","Breast Atypical Lobular Hyperplasia | ALH | Atypical Breast Lobular Hyperplasia | Atypical Lobular Breast Hyperplasia | Atypical Lobular Breast Hyperplasia | Atypical Lobular Hyperplasia of Breast | Atypical Lobular Hyperplasia of the Breast | atypical lobular breast hyperplasia | atypical lobular hyperplasia",,,,,,,,,,,,,,,"4144952|42872705","Atypical lobular hyperplasia|Atypical lobular hyperplasia of breast",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1332347","Breast Atypical Ductal Hyperplasia","C8436","A neoplastic process that arises from the terminal ductal lobular unit of the breast parenchyma.  It is usually solitary and confined to a single lobular unit.  It is characterized by the presence of a monomorphic epithelial proliferation in a cribriform, micropapillary, or solid growth pattern.  Focal architectural features of low grade ductal carcinoma in situ are present.  There is an increased risk for development of invasive breast carcinoma.","Breast Atypical Ductal Hyperplasia | ADH | Atypical Breast Ductal Hyperplasia | Atypical Ductal Breast Hyperplasia | Atypical Ductal Breast Hyperplasia | Atypical Ductal Hyperplasia of Breast | Atypical Ductal Hyperplasia of the Breast | DIN 1B | Ductal Intraepithelial Neoplasia, Grade 1B | atypical ductal breast hyperplasia | atypical ductal hyperplasia",,,,,,,,,,,,,,,"4322553","Atypical ductal hyperplasia of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333138","Complex Endometrial Hyperplasia with Atypia","C35560","A hyperplasia characterized by excessive proliferation of endometrial cells, resulting in the formation of complex epithelial structures.  It is associated with cytologic atypia and an increased risk of endometrial adenocarcinoma.","Complex Endometrial Hyperplasia with Atypia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456483","Simple Endometrial Hyperplasia","C35463","A proliferation of endometrial cells resulting in glandular enlargement and budding without changes in the basic structure of the endometrium. Epithelial atypia may be present or absent.","Simple Endometrial Hyperplasia | Simple",,,,,,,,,,,,,,,"199886","Simple endometrial hyperplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334969","Nodular Lymphoid Hyperplasia of Lung","C35713","A rare, reactive lesion in the lung parenchyma. It is characterized by the formation of a single or several nodules that are composed of lymphocytic infiltrates with reactive germinal centers.","Nodular Lymphoid Hyperplasia of Lung | ",,,,,,,,,,,,,,,"37397455","Pulmonary nodular lymphoid hyperplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332918","Cervical Microglandular Polyp","C6856","A benign endocervical polypoid epithelial hyperplasia characterized by the presence of tightly packed glandular structures. It is usually seen in women on oral contraceptive therapy and during pregnancy.","Cervical Microglandular Polyp | Microglandular Polyp of Cervix | Microglandular Polyp of Uterine Cervix | Microglandular Polyp of the Cervix | Microglandular Polyp of the Uterine Cervix | Uterine Cervix Microglandular Polyp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333980","Focal Nodular Hyperplasia of the Liver","C4916","A non-neoplastic, regenerating hepatocellular hyperplasia, secondary to the presence of focal vascular abnormalities in the liver.","Focal Nodular Hyperplasia of the Liver | FNH | Focal Nodular Hyperplasia of Liver",,,,,,,,,,,,,,,"4047301|4133325","Focal nodular hyperplasia|Focal nodular hyperplasia of liver",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0741698","Ductal Hyperplasia of Breast","C9492","Hyperplasia of the epithelial cells in the breast ducts. It includes the atypical ductal hyperplasia, papillary intraductal hyperplasia, intraductal myoepitheliosis, and ductal hyperplasia of the usual type.","Breast Ductal Hyperplasia | Breast Epithelial Hyperplasia | Ductal Breast Hyperplasia | Ductal Breast Hyperplasia | Ductal Hyperplasia of Breast | Ductal Hyperplasia of the Breast | Epithelial Hyperplasia of Breast | Epithelial Hyperplasia of the Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022548","Keloid","C3145","An irregularly shaped, elevated mark on the skin caused by deposits of excessive amounts of collagen during wound healing. It extends beyond the original boundaries of the wound and may enlarge progressively.","Keloid | Keloid Process | keloid",,,,,,,,,,,,,,,"132982|4241582","Keloid scar|Keloid",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1368066","Pancreatic Gastrinoma","C95596","A neuroendocrine tumor arising from the pancreas.  It is characterized by inappropriate secretion of gastrin and associated with Zollinger Ellison syndrome. The latter is characterized by the presence of peptic ulcer, gastroesophageal reflux disease, abdominal pain, diarrhea, and malabsorption.","Pancreatic Gastrinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL480914","Pancreatic Neuroendocrine Tumor","C27720","A well-differentiated, low-, intermediate-, or high-grade neoplasm with neuroendocrine differentiation that arises from the islet cells of the pancreas. According to the presence or absence of clinical syndromes that result from hormone hypersecretion, pancreatic neuroendocrine tumors are classified either as functional or nonfunctional.","Pancreatic Neuroendocrine Tumor | Islet Cell Tumor | Islet cell tumors - pancreas | Islet cell tumors of the pancreas | PanNET | Pancreatic NET | Pancreatic Well Differentiated Neuroendocrine Neoplasm | Pancreatic Well-Differentiated Neuroendocrine Neoplasm | Well Differentiated Pancreatic Endocrine Neoplasm | Well Differentiated Pancreatic Endocrine Tumor | Well Differentiated Pancreatic Neuroendocrine Neoplasm | Well-Differentiated Pancreatic Endocrine Neoplasm | Well-Differentiated Pancreatic Neuroendocrine Neoplasm | islet cell tumor",,,,,,,,,,,,,,,"4030276|4161034","Pancreatic endocrine tumor|Islet cell neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0878500","Intraepithelial Neoplasia","C8366","A precancerous neoplastic process that affects the squamous, glandular, or transitional cell epithelium without evidence of invasion. According to the degree of nuclear atypia, number of mitotic figures, and presence of architectural distortion, it is classified as low grade (mild dysplasia) or high grade (moderate or severe dysplasia).","Intraepithelial Neoplasia | Epithelial Dysplasia | Epithelial dysplasia | Intraepithelial Neoplasm",,,,,,,,,,,,,,,"4247011","Epithelial dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0282612","Prostatic Intraepithelial Neoplasia","C4064","A neoplastic proliferation of the epithelial cells that line the acini and the ducts of the prostate gland.  The neoplastic epithelial cells are confined within the acini and the ducts and they do not invade the surrounding prostatic stroma.  Morphologically, it is classified as low or high grade.","Prostatic Intraepithelial Neoplasia | PIN | PIN - Prostatic Intraepithelial Neoplasia | Prostate intraepithelial neopl. | Prostate intraepithelial neoplasia (PIN) | prostatic intraepithelial neoplasia",,,,,,,,,,,,,,,"192681","Prostatic intraepithelial neoplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333324","Dysplasia in Barrett Esophagus","C27833","Epithelial dysplasia that develops in Barrett esophagus. It is classified as low or high grade. When technical reasons make the interpretation of atypia difficult, atypia is present but it is not quite to the level of dysplasia, or atypia is present at the bases of the crypts but does not reach the surface of the crypts, then the diagnosis of Barrett esophagus-indefinite for dysplasia is made.","Dysplasia in Barrett Esophagus | Dysplasia in Barrett's Esophagus",,,,,,,,,,,,,,,"46269823","Barretts esophagus with dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334037","Intestinal Metaplasia","C8360","A morphologic finding indicating the replacement of epithelial tissue outside the intestines by intestinal-type epithelium.","Intestinal Metaplasia | Intestinal metaplasia",,,,,,,,,,,,,,,"4239525","Intestinal metaplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018188","Granuloma","C3064","An inflammatory reaction usually caused by infectious organisms, foreign bodies, or cholesterol deposits. It is characterized by the presence of epithelioid histiocytes and chronic inflammation.","Granuloma | GRANULOMA | Granulomatous Lesion",,,,,,,,,,,,,,,"4163983","Granuloma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333404","Eosinophilic Infiltrate","C35981","An inflammatory infiltrate composed exclusively or predominantly of eosinophils.","Eosinophilic Infiltrate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333036","Chronic Inflammatory Infiltrate","C35980","A morphologic finding indicating the presence of reactive lymphocytes, lymphoplasmacytic cells, and/or reactive plasma cells in a tissue sample.","Chronic Inflammatory Infiltrate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333361","Acute Inflammatory Infiltrate","C35979","A morphologic finding indicating the presence of neutrophils and/or eosinophils in a tissue sample.","Acute Inflammatory Infiltrate | ",,,,,,,,,,,,,,,"4163835","Acute inflammation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026918","Mycobacterial Infection","C26831","Infection due to organisms from the genus Mycobacteria.","Mycobacterial Infection | Mycobacterium Infection | Mycobacterium, NOS",,,,,,,,,,,,,,,"440631","Mycobacteriosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334062","Hyalinized Stroma Formation","C36000","Replacement of tissue stromal elements by hyaline material.","Hyalinized Stroma Formation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3529384","ACOX2 protein, human","C96443","Peroxisomal acyl-coenzyme A oxidase 2 (681 aa, ~77 kDa) is encoded by the human ACOX2 gene. This protein is involved in the mediation of fatty acid oxidation and the synthesis of bile acid.","Peroxisomal Acyl-Coenzyme A Oxidase 2 | 3-Alpha,7-Alpha,12-Alpha-Trihydroxy-5-Beta-Cholestanoyl-CoA 24-Hydroxylase | 3-Alpha,7-Alpha,12-Alpha-Trihydroxy-5-Beta-Cholestanoyl-CoA Oxidase | ACOX2 | EC 1.17.99.3 | THCA-CoA Oxidase | THCCox | Trihydroxycoprostanoyl-CoA Oxidase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0672250","keratin 7","C96446","Keratin, type II cytoskeletal 7 (469 aa, ~51 kDa) is encoded by the human KRT7 gene. This protein plays a role in DNA replication and cytoskeleton modeling.","Keratin, Type II Cytoskeletal 7 | CK-7 | Cytokeratin-7 | K7 | KRT7 | Keratin-7 | Sarcolectin | Type-II Keratin Kb7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663104","Desmin","C96450","Desmin (470 aa, ~54 kDa) is encoded by the human DES gene. This protein is involved in the regulation of cytoskeletal dynamics in muscle cells.","Desmin | DES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812267","ERBB4 Gene","C18388","This gene is involved in neuronal development and plays a role in receptor tyrosine kinase signal transduction that regulates cellular proliferation and differentiation.","ERBB4 Gene | ERBB4 | Erb-B2 Receptor Tyrosine Kinase 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0138837","protein farnesyltransferase","C17526","A heterodimeric enzyme (alpha and beta subunits) that catalyzes the addition of farnesyl groups, as farnesyl diphosphate, to the C termini of proteins.","Farnesyl Protein Transferase | Farnesyl Transferase | Farnesyltransferase | Protein Farnesyltransferase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1504631","SLC2A1 protein, human","C17585","Solute carrier family 2, facilitated glucose transporter member 1 (492 aa, ~54 kDa) is encoded by the human SLC2A1 gene. This protein plays a role in glucose transport.","Solute Carrier Family 2, Facilitated Glucose Transporter Member 1 | GLUT1 Protein | Glucose Transporter Type 1, Erythrocyte/Brain | Glut-1 | HepG2 Glucose Transporter | SLC2A1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0063740","involucrin","C96453","Involucrin (585 aa, ~68 kDa) is encoded by the human IVL gene. This protein plays a role in the keratinization of stratified squamous epithelia.","Involucrin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1504921","KRT1 protein, human","C96456","Keratin, type II cytoskeletal 1 (644 aa, ~66 kDa) is encoded by the human KRT1 gene. This protein is involved in the development of the epidermis.","Keratin, Type II Cytoskeletal 1 | 67 kDa Cytokeratin | CK-1 | Cytokeratin-1 | Hair Alpha Protein | K1 | KRT1 | Keratin-1 | Type-II Keratin Kb1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1433368","KRT20 protein, human","C96459","Keratin, type I cytoskeletal 20 (424 aa, ~48 kDa) is encoded by the human KRT20 gene. This protein plays a role in the organization of keratins in the intestinal epithelium.","Keratin, Type I Cytoskeletal 20 | CK-20 | Cytokeratin-20 | K20 | KRT20 | Keratin-20 | Protein IT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335591","RARB Gene","C24724","This gene is involved in the regulation of embryonic morphogenesis and related processes.","RARB Gene | RARB | Retinoic Acid Receptor, Beta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419285","RASSF1 Gene","C60665","This gene plays a role in the maintenance of genomic integrity and possibly tumor suppression.","RASSF1 Gene | RASSF1 | Ras Association Domain Family Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2001898","MMP2 protein, human","C17592","72 kDa type IV collagenase (660 aa, ~74 kDa) is encoded by the human MMP2 gene. This protein is involved in both proteolysis and angiogenesis.","72 kDa Type IV Collagenase | 72 kDa Gelatinase | 72kDa Gelatinase | 72kDa Type IV Collagenase | 72kDa Type IV Collagenase | EC 3.4.24.24 | Gelatinase A | MMP-2 | MMP2 | Matrix Metalloprotease 2 | Matrix Metalloprotease-2 | Matrix Metalloproteinase 2 | Matrix Metalloproteinase-2 | TBE-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3657771","MMP9 protein, human","C17575","Matrix metalloproteinase-9 (707 aa, ~78 kDa) is encoded by the human MMP9 gene. This protein plays a role in collagen degradation, macrophage differentiation and cell migration.","Matrix Metalloproteinase-9 | 92 kDa Gelatinase | 92 kDa Type IV Collagenase | EC 3.4.24.35 | GELB | Gelatinase B | MMP-9 | MMP9 | Macrophage Gelatinase | Matrix Metalloprotease 9 | Matrix Metalloprotease-9 | Matrix Metalloproteinase 9 | Type V Collagenase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026902","MYC Family Genes","C18537","MYC Family Genes encode MYC Family Proteins, class III bHLH leucine zipper transcription factors having cellular proliferative and apoptotic roles. Dimerization via leucine zippers of MYC proteins with bHLH/lz proteins, such as MAX, is required for efficient DNA binding. Leucine zippers are present in many gene regulatory proteins, including CREB proteins, Jun/AP1 transcription factors, and FOS-type proteins, as well as MYC proteins. The periodically repeated leucine side chains extending from one alpha helix interdigitate with leucine residues of another alpha helix, facilitating coiled-coil dimerization; like charge repulsion in this region perturbs homodimer formation; heterodimers are promoted by opposing charge attractions. c-MYC transcription factor binds to CAC(GA)TG DNA sites. MYC sequences have been highly conserved throughout evolution, from Drosophila to vertebrates. (NCI)","MYC Family Gene | MYC Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0536940","CTAG1 protein, human","C39286","Cancer/testis antigen 1 (180 aa, ~18 kDa) is encoded by both the human CTAG1A gene and the human CTAG1B gene. This protein may be involved in both testis development and spermatogenesis.","Cancer/Testis Antigen 1 | Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 | CT6.1 | CTAG | CTAG1 | CTAG1A | CTAG1B | Cancer Antigen 3 | Cancer/Testis Antigen 1-B | Cancer/Testis Antigen 6.1 | ESO1 | L Antigen Family Member 2 | LAGE-2 | LAGE2B | NY-ESO-1 | New York Esophageal Squamous Cell Carcinoma 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL425147","Pro-oxidant","C93260","A substance that can produce oxygen byproducts of metabolism that can cause damage to cells.","Pro-oxidant | pro-oxidant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514557","Protein Kinase Protein Phosphorylation","C18970","Protein Kinase Protein Phosphorylation involves covalent linkage of a phosphate group (from a donor compound such as ATP) with a serine, threonine, or tyrosine residue of a Protein Kinase acceptor, often as a mechanism of kinase activity regulation.","Protein Kinase Protein Phosphorylation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0668624","AKT1 protein, human","C17579","RAC-alpha serine/threonine-protein kinase (480 aa, ~56 kDa) is encoded by the human AKT1 gene. This protein is involved in signal transduction, serine/threonine phosphorylation, apoptosis regulation and neurogenesis.","RAC-Alpha Serine/Threonine Kinase | AKT1 | C-AKT | EC 2.7.11.1 | PKB | PKB Alpha | PKB Protein | PRKBA | Protein Kinase B | Protein Kinase B Alpha | Protein Kinase B-Alpha | Proto-Oncogene c-Akt | RAC | RAC-Alpha Protein Kinase | RAC-PK-Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2350345","AMP-Activated Protein Kinases","C94701","5'-AMP-activated protein kinase is a protein complex that is a heterotrimer of an alpha, a beta and a gamma subunit. This complex is involved in the regulation of glucose uptake, the oxidation of fatty acids and mitochondria biogenesis.","5'-AMP-Activated Protein Kinase | 5' AMP-Activated Protein Kinase | 5' Adenosine Monophosphate-Activated Protein Kinase | 5-AMP-Activated Protein Kinase | AMP-Activated Protein Kinase | AMPK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4044495","Insulin-Like Growth Factor 1 Receptor, Human","C17531","Insulin-like growth factor 1 receptor (1367 aa, ~155 kDa) is encoded by the human IGF1R gene. This protein is involved in cell proliferation and apoptosis inhibition.","Insulin-Like Growth Factor 1 Receptor | Antigen CD221 | CD221 | CD221 Antigen | EC 2.7.10.1 | IGF-1R | IGF-I Receptor | IGF1R | Insulin-Like Growth Factor I Receptor | Insulin-Like-Growth Factor I Receptor | Receptors, Insulin-Like-Growth Factor I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1448132","INSR protein, human","C17072","Insulin receptor (1382 aa, ~156 kDa) is encoded by the human INSR gene. This protein plays a role in both signal transduction and glucose homeostasis.","Insulin Receptor | Antigen CD220 | CD220 | CD220 Antigen | EC 2.7.10.1 | INSR | IR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1307407","FRAP1 protein, human","C38929","Serine/threonine-protein kinase mTOR (2549 aa, ~289 kDa) is encoded by the human MTOR gene. This protein is involved in protein phosphorylation, signaling and cell growth.","Serine/Threonine-Protein Kinase mTOR | EC 2.7.11.1 | FK506 Binding Protein 12-Rapamycin Associated Protein 1 | FK506 Binding Protein 12-Rapamycin Associated Protein 2 | FK506-Binding Protein 12-Rapamycin Complex-Associated Protein 1 | FKBP-Rapamycin Associated Protein | FKBP12 Rapamycin Complex Associated Protein 1 | FKBP12-Rapamycin Complex-Associated Protein | FRAP | FRAP1 | FRAP2 | Mammalian Target of Rapamycin | Mechanistic Target of Rapamycin | RAFT1 | RAPT1 | Rapamycin Target Protein | Rapamycin Target Protein 1 | mTOR | mammalian target of rapamycin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0379275","PPAR delta","C96462","Peroxisome proliferator-activated receptor delta (441 aa, ~50 kDa) is encoded by the human PPARD gene. This protein is involved in the regulation of ligand-activated transcription.","Peroxisome Proliferator-Activated Receptor Delta | NR1C2 | NUC1 | NUCI | Nuclear Hormone Receptor 1 | Nuclear Receptor Subfamily 1 Group C Member 2 | PPAR-Beta | PPAR-Delta | PPARD | Peroxisome Proliferator-Activated Receptor Beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984184","40S Ribosomal Protein S6","C91352","40S ribosomal protein S6 (249 aa, ~29 kDa) is encoded by the human RPS6 gene. This protein plays a role in the selection of genes for translation into mRNA.","40S Ribosomal Protein S6 | Phosphoprotein NP33 | RPS6 | S6RP | Small Ribosomal Subunit Protein eS6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0072259","PTGIS protein, human","C96440","Prostacyclin synthase (500 aa, ~57 kDa) is encoded by the human PTGIS gene. This protein plays a role in the mediation of prostaglandin biosynthesis.","Prostacyclin Synthase | EC 5.3.99.4 | PTGIS | Prostaglandin I2 Synthase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1278052","Serum Lactate Dehydrogenase Measurement","C61026","A quantitative measurement of the amount of lactate dehydrogenase present in a sample of serum.","Serum Lactate Dehydrogenase Measurement | ",,,,,,,,,,,,,,,"4210717","Serum lactate dehydrogenase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1571495","BIRC5 protein, human","C18179","Baculoviral IAP repeat-containing protein 5 (142 aa, ~16 kDa) is encoded by the human BIRC5 gene. This protein plays a role in the regulation of both apoptosis and the cell cycle.","Baculoviral IAP Repeat-Containing Protein 5 | API4 | Apoptosis Inhibitor 4 | Apoptosis Inhibitor Survivin | BIRC5 | Baculoviral IAP Repeat-Containing 5 (Survivin) | EPR-1 | IAP4 | Survivin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336633","TK Gene","C20224","The TK Gene encodes thymidine kinase, a transferase class pyrimidine salvage enzyme that catalyzes ATP-dependent phosphorylation of thymine deoxyribonucleoside. The TK gene and promoter are used widely in genetic research because of the easily selectable phenotype.","TK Gene | Thymidine Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033679","Transglutaminase","C96437","A family of enzymes that catalyze the formation of a covalent bond between the epsilon-amino group of a protein- or peptide-bound lysine and the gamma-carboxyamide group of a protein- or peptide-bound glutamine. These proteins are involved in the crosslinking of proteins in blood coagulation, skin formation and hair development.","Transglutaminase | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002766","Pain Therapy","C15180","(i) the systematic study of clinical and basic science and its application for the reduction of pain and suffering; (ii) the blending of tools, techniques and principles taken from the discrete healing art disciplines and reformulated as a holistic application for the reduction of pain and suffering; and (iii) a newly emerging discipline emphasizing an interdisciplinary approach with a goal of reduction of pain and suffering. (AAPM)","Pain Therapy | Analgesia | Pain Control | Pain Management | Pain, Pain Management | analgesia",,,,,,,,,,,,,,,"4083171","Pain management",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334678","Myelodysplastic Syndrome, Not Otherwise Specified with Single Lineage Dysplasia","C82591","A myelodysplastic syndrome characterized by dysplastic changes involving only one myeloid cell lineage in the bone marrow.","Myelodysplastic Syndrome, Not Otherwise Specified with Single Lineage Dysplasia | MDS with Low Blasts and Single Lineage Dysplasia | MDS-LB-SLD | MDS-SLD | Myelodysplastic Syndrome with Low Blasts and Single Lineage Dysplasia | Myelodysplastic Syndrome with Single Lineage Dysplasia | Myelodysplastic Syndrome with Single Lineage Dysplasia | RCUD | Refractory Cytopenia with Unilineage Dysplasia | Refractory Cytopenia with Unilineage Dysplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1367654","Marginal Zone Lymphoma","C4341","A usually indolent mature B-cell lymphoma, arising from the marginal zone of lymphoid tissues.  It is characterized by the presence of small to medium sized atypical lymphocytes.  It comprises three entities, according to the anatomic sites involved: extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, which affects extranodal sites (most often stomach, lung, skin, and ocular adnexa); nodal marginal zone B-cell lymphoma, which affects lymph nodes without evidence of extranodal disease; and splenic marginal zone B-cell lymphoma, which affects the spleen and splenic hilar lymph nodes, bone marrow, and often the peripheral blood.","Marginal Zone Lymphoma | MZBCL | MZL | Marginal Zone B-Cell Lymphoma | Marginal zone lymphoma, NOS | marginal zone B-cell lymphoma | marginal zone lymphoma","9699/3","Marginal zone B-cell lymphoma, NOS",,,,,,,,,,,,,"4028704|40490918","Marginal zone B-cell lymphoma|Marginal zone lymphoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1334634","Mature B-Cell Non-Hodgkin Lymphoma","C7056","A non-Hodgkin lymphoma that originates from mature B lymphocytes. Representative examples include diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, and small lymphocytic lymphoma.","Mature B-Cell Non-Hodgkin Lymphoma | Mature B-Cell Lymphoma | Mature B-Cell Lymphomas | Mature B-Cell Non-Hodgkin's Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1292758","T Lymphoblastic Lymphoma","C6919","The most frequent type of lymphoblastic lymphoma.  It comprises approximately 85-90% of cases.  It is more frequently seen in adolescent males.  It frequently presents with a mass lesion in the mediastinum.  Pleural effusions are common.  (WHO, 2001)","T Lymphoblastic Lymphoma | Precur. T-lymphoblastic lymphoma | Precursor T Lymphoblastic Lymphoma | Precursor T-Cell Lymphoblastic Lymphoma | Precursor T-Lymphoblastic Lymphoma | Precursor T-cell lymphoblastic lymphoma | Precursor T-lymphoblastic lymphoma | T-Lymphoblastic Lymphoma | T-lymphoblastic lymphoma | precursor T-lymphoblastic lymphoma",,,,,,,,,,,,,,,"4029660|4227963","Precursor T-cell lymphoblastic lymphoma|Precursor T-cell lymphoblastic lymphoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0024167","Ovarian Stromal Luteoma","C3202","A benign ovarian stromal tumor in which more than 90% of the tumor cells resemble steroid hormone-secreting cells. Crystals of Reinke are not present. It occurs in post-menopausal women and it is usually associated with estrogenic effects.","Ovarian Stromal Luteoma | LUTEOMA, BENIGN | Luteal Cell Neoplasm | Luteal Cell Tumor | Luteinoma | Luteoma | Ovarian Stroma Luteoma","8610/0","Luteoma, NOS",,,,,,,,,,,,,"4097073","Luteoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C2987179","Pancreatic Mucinous Cystic Neoplasm with Low Grade Dysplasia","C95483","A non-invasive mucinous cystic neoplasm that arises from the pancreas and is characterized by the presence of mild dysplasia and absence of mitotic figures.","Pancreatic Mucinous-Cystic Neoplasm, Low Grade | Pancreatic Mucinous Cystic Neoplasm with Low Grade Dysplasia | Pancreatic Mucinous Cystic Neoplasm with Low-Grade Dysplasia | Pancreatic Mucinous-Cystic Neoplasm with Low Grade Dysplasia | Pancreatic Mucinous-Cystic Neoplasm with Low Grade Dysplasia | Pancreatic Mucinous-Cystic Neoplasm, Low-Grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334412","Ovarian Steroid Cell Tumor","C4215","An ovarian tumor in which the vast majority of the cells (more than 90% of the tumor cells) resemble steroid hormone-secreting cells. It usually presents with androgenic manifestations. Approximately one-third of the cases follow a malignant clinical course.","Ovarian Steroid Cell Tumor | Lipid Cell Neoplasm of Ovary | Lipid Cell Neoplasm of the Ovary | Lipid Cell Tumor of Ovary | Lipid Cell Tumor of the Ovary | Lipid cell tumor of ovary | Ovarian Lipid Cell Neoplasm | Ovarian Lipid Cell Tumor | Ovarian Lipoid Cell Neoplasm | Ovarian Steroid Cell Neoplasm | Steroid Cell Tumor of Ovary | Steroid Cell Tumor of the Ovary","8670/0","Lipid cell tumor of ovary",,,,,,,,,,,,,"4250007","Lipid cell tumor of ovary",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0023601","Leydig Cell Tumor","C3188","A sex cord-stromal tumor occurring in the testis and rarely in the ovary. It is predominantly or completely composed of Leydig cells which may contain crystals of Reinke. In males it usually presents as a painless testicular enlargement and it may be associated with gynecomastia and decreased libido. The majority of the cases have a benign clinical course. Approximately 10% of the cases have a malignant clinical course and metastasize. In females it may be associated with androgenic manifestations and it follows a benign clinical course.","Leydig Cell Tumor | Interstitial Cell Neoplasm | Interstitial Cell Tumor | Leydig Cell Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0948976","Leukemia Cutis","C88156","Cutaneous involvement by an acute or chronic leukemia.","Leukemia Cutis | ",,,,,,,,,,,,,,,"4301780","Leukemic infiltration of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334608","Angiomatous Meningioma","C4332","A WHO grade I meningioma characterized by the presence of small and medium sized vessels that predominate over the meningioma cells.","Angiomatous Meningioma | Angiomatous meningioma","9534/0","Angiomatous meningioma",,,,,,,,,,,,,"4250780","Angiomatous meningioma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0220633","Uveal Melanoma","C7712","A melanoma derived from melanocytes of the uveal tract.  It is the most common primary intraocular tumor in the United States and Western Europe.  Similar to melanoma of the skin, it is rare in Africa and Asia.  Diagnostic procedures include ophthalmoscopic exam, fluorescein angiography and ultrasound.  Treatment includes: surgical excision of the eye, iridocyclectomy and tumor resection.  Recent treatments also include radiotherapy or photo coagulation.  Classification of uveal melanomas recognizes four cell types within these tumors: epithelioid, intermediate, mixed cell, and spindle cell types.  The spindle cell type uveal melanomas are further sub-classified as spindle cell type A and spindle cell type B.","Uveal Melanoma | Intraocular Melanoma | MELANOMA, UVEAL, MALIGNANT | Melanoma of Uvea | Melanoma of the Uvea | UVM | Uveal Tract Melanoma | intraocular melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206735","Amelanotic Melanoma","C3802","A melanoma characterized by the complete absence of melanin pigment in the melanoma cells. It occurs more frequently on the face and it is often associated with desmoplastic reaction.","Amelanotic Melanoma | Amelanotic melanoma | MELANOMA, AMELANOTIC, MALIGNANT | amelanotic melanoma","8730/3","Amelanotic melanoma",,,,,,,,,,,,,"4290935","Amelanotic melanoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334596","Central Nervous System Medulloepithelioma","C4327","A rare, usually aggressive malignant embryonal neoplasm of the central nervous system occurring in children. It is characterized by the presence of neuroepithelial cells which form papillary, trabecular, or tubular structures and absence of C19MC amplification. Symptoms include headache, nausea, and vomiting.","Central Nervous System Medulloepithelioma | Medulloepithelioma | Medulloepithelioma | Medulloepithelioma, Central Nervous System",,,,,,,,,,,,,,,"37311758|37396186|4308216","Medulloepithelioma of central nervous system|Medulloepithelioma|Medulloepithelioma",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C2985220","Anaplastic Medulloblastoma","C92625","A medulloblastoma characterized by marked nuclear pleomorphism, and high mitotic activity.","Anaplastic Medulloblastoma | Anaplastic medulloblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334035","Glandular Metaplasia","C8358","A morphologic finding indicating the alteration of the squamous or transitional epithelial cells to glandular cells.","Glandular Metaplasia | ",,,,,,,,,,,,,,,"4189207","Glandular metaplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332965","Congenital Mesoblastic Nephroma","C6569","A low grade childhood congenital malignant neoplasm arising from the kidney. It is characterized by the presence of fibroblastic cells. The majority of cases occur in the first year of life. Complete excision is usually associated with an excellent prognosis.","Congenital Mesoblastic Nephroma | CMN | Congenital Mesoblastic Nephroma | Congenital Mesoblastic Nephroma | Mesoblastic Nephroma | Mesoblastic Nephroma | Mesoblastic nephroma | STROMAL NEPHROMA, MALIGNANT | congenital mesoblastic nephroma","8960/1","Mesoblastic nephroma",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C0334611","Transitional Meningioma","C4333","A WHO grade I meningioma characterized by the coexistence of meningothelial cells and fibrous architectural patterns.","Transitional Meningioma | Mixed Meningioma | Mixed meningioma | Transitional (Mixed) Meningioma | Transitional meningioma","9537/0","Transitional meningioma",,,,,,,,,,,,,"4277603","Transitional meningioma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334607","Psammomatous Meningioma","C4331","A WHO grade I meningioma characterized by the presence of psammoma bodies that predominate over the meningeal cells.","Psammomatous Meningioma | Psammomatous meningioma","9533/0","Psammomatous meningioma",,,,,,,,,,,,,"4243303","Psammomatous meningioma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334606","Fibrous Meningioma","C4330","A WHO grade I meningioma characterized by the presence of spindle cells that form bundles in a collagen matrix.","Fibrous Meningioma | Fibroblastic Meningioma | Fibroblastic meningioma | Fibrous meningioma","9532/0","Fibrous meningioma",,,,,,,,,,,,,"4176436","Fibrous meningioma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1384406","Secretory Meningioma","C4718","A WHO grade I meningioma characterized by the presence of epithelial differentiation and numerous intracellular PAS positive bodies that are rich in glycogen.","Secretory Meningioma | Secretory meningioma",,,,,,,,,,,,,,,"4100554","Secretory meningioma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206627","Mixed Mesodermal (Mullerian) Tumor","C3730","A group of tumors affecting the female reproductive system, characterized by the presence of epithelial and stromal elements. It includes the following clinicopathological entities: adenofibroma, adenomyoma, Mullerian adenosarcoma, and malignant mixed mesodermal (Mullerian) tumor.","Mixed Mesodermal (Mullerian) Tumor | Mesodermal Mixed Tumor | Mesodermal mixed tumor | Mixed Mesodermal (Mullerian) Neoplasm | Mixed Mesodermal (Müllerian) Neoplasm | Mixed Mesodermal (Müllerian) Tumor | Mixed Mullerian Tumor | Mixed Müllerian Tumor | Mullerian mixed tumor | Mullerian tumor","8950/3|8951/3","Mullerian mixed tumor|Mesodermal mixed tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--|--"
"CL448522","MEST","C37263","A rare, usually benign tumor that arises from the kidney. It belongs to the spectrum of mixed epithelial and stromal tumor family. It usually affects females. It is characterized by the presence of a biphasic pattern with tubular and cystic structures in a spindle cell stroma. Patients usually present with flank pain and hematuria.","Kidney Mixed Epithelial and Stromal Tumor | MEST | Mixed Epithelial Stromal Tumor of the Kidney | Mixed Epithelial Stromal Tumor of the Kidney | Renal Epithelial Stromal Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266138","Adult Cystic Nephroma","C7504","A localized, well-circumscribed multilocular tumor lined by hobnail epithelium. It was previously classified along with pediatric cystic nephroma, as a separate entity from mixed epithelial and stromal tumors. Now it is classified within the spectrum of the mixed epithelial and stromal tumor family. Most of these tumors are benign. (WHO 2016).","Adult Cystic Nephroma | Benign cystic nephroma | Cystic Nephroma | Cystic Nephroma","8959/0","Benign cystic nephroma",,,,,,,,,,,,,"4030135","Benign cystic nephroma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0346166","Ovarian Seromucinous Tumor","C4508","A benign, borderline, or malignant mixed epithelial tumor of the ovary. It is characterized by the presence of more than one epithelial cell type, most often serous and endocervical-type mucinous.","Ovarian Seromucinous Tumor | Ovarian Mixed Epithelial Tumor",,,,,,,,,,,,,,,"4112859","Mixed epithelial tumor of ovary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512511","Appendix Goblet Cell Carcinoid","C3689","An invasive mixed adenoneuroendocrine carcinoma of the appendix characterized by a submucosal growth and the presence of neoplastic signet-ring cells resembling goblet cells of the intestine.","Appendix Goblet Cell Adenocarcinoma | Appendix Adenocarcinoid Tumor | Appendix Goblet Cell Carcinoid | Appendix Goblet Cell Carcinoid | Appendix Goblet Cell Carcinoid Tumor | Appendix Mixed Carcinoid-Adenocarcinoma | Appendix Mucinous Carcinoid Tumor | Goblet Cell Carcinoid Tumor | Mucinous Carcinoid Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883077","Spindle Cell Metaplasia","C54709","A morphologic finding indicating the transformation of non-spindle cells to spindle-shaped cells.","Spindle Cell Metaplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334803","Morular Metaplasia of the Endometrium","C37269","A morphologic finding indicating the replacement of part of the glandular endometrial epithelium by nodular structures that contain non-keratinizing squamous cells.","Morular Metaplasia of the Endometrium | MM | Morular Metaplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1621583","Administer","C64912","To dispense, apply, or tender something to another, such as administering a medicine.","Administer | ",,,,,,,,,,,,,,,"4302651","Administer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033137","Primary Health Care","C94340","Health services that meet most basic health care needs over time. Primary care includes physical exams, treatment of common medical conditions, and preventive care such as immunizations and screenings. Primary care doctors are usually the first health professionals patients see for basic medical care. They may refer a patient to a specialist if needed.","Primary Care | primary care",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011268","Senile Dementia","C34524","Loss of intellectual abilities in an elderly person, interfering with this person's activities.","Senile Dementia | ",,,,,,,,,,,,,,,"4048875","Senile dementia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3272759","Brain Development Abnormality","C96412","A group of congenital or acquired disorders that affect the normal development of the brain.","Brain Development Abnormality | Brain Developmental Abnormality | Brain Developmental Abnormality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206635","Adrenal Gland Myelolipoma","C3736","A benign soft tissue lesion arising from the adrenal gland.  It is composed of mature adipose and hematopoietic/lymphoid tissues.","Adrenal Gland Myelolipoma | MYELOLIPOMA, BENIGN | Myelolipoma","8870/0","Myelolipoma",,,,,,,,,,,,,"4048432","Myelolipoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0346210","Vulvar Intraepithelial Neoplasia","C4756","Intraepithelial neoplasia of the vulvar squamous epithelium. There is no evidence of invasion. It includes vulvar squamous intraepithelial lesion, HPV-associated and vulvar intraepithelial neoplasia, HPV-independent.","Vulvar Intraepithelial Neoplasia | Intraepithelial Neoplasia of Vulva | Intraepithelial Neoplasia of the Vulva | Squamous Vulvar Intraepithelial Neoplasia | VIN | Vulva Intraepithelial Neoplasia | Vulval Intraepithelial Neoplasia",,,,,,,,,,,,,,,"4161430|4221231","Dysplasia of vulva|Vulval intraepithelial neoplasia (VIN)",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0333873","Squamous Cell Intraepithelial Neoplasia","C8334","A precancerous neoplastic intraepithelial process involving the squamous epithelium.","Squamous Cell Intraepithelial Neoplasia | SIL | SIN | Squamous Intraepithelial Lesion | squamous intraepithelial lesion",,,,,,,,,,,,,,,"4087092","Squamous intraepithelial lesion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518872","Pancreatic Mucinous-Cystic Neoplasm","C41247","A non-invasive or invasive cystic epithelial neoplasm that affects almost exclusively females.  It is characterized by the presence of columnar mucin-producing epithelial cells and ovarian-type stroma formation.","Pancreatic Mucinous-Cystic Neoplasm | Pancreatic Mucinous Cystic Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1456781","Benign Skin Melanocytic Nevus","C7571","A circumscribed proliferation of melanocytes in the skin. It is characterized by the absence of atypical or malignant cytological features, and absence of invasive features or metastatic potential. Variants include the Spitz nevus, halo nevus, blue nevus, and balloon cell nevus.","Benign Skin Melanocytic Nevus | Benign Melanocytic Nevus | Benign Melanocytic Nevus | Benign Melanocytic Nevus of Skin | Benign Melanocytic Nevus of the Skin | Benign Melanocytic Skin Nevus | Benign Mole | Benign Nevus of Skin | Benign Nevus of the Skin | Benign Skin Nevus",,,,,,,,,,,,,,,"4221679","Melanocytic nevus of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0259781","Compound Nevus","C3901","A nevus composed of neoplastic melanocytes that infiltrate both the epidermis and the dermis.","Compound Nevus | Compound Nevus of Skin | Compound Nevus of the Skin | Compound nevus | compound nevus","8760/0","Compound nevus",,,,,,,,,,,,,"4171355","Compound nevus",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0161823","Traumatic Neuroma","C3666","A non-neoplastic proliferation of a nerve caused by injury to the nerve due to trauma or surgery. It presents as a firm nodule that may be associated with pain or tenderness. It most often occurs in the lower extremity following amputation, or in the head and neck region.","Traumatic Neuroma | ",,,,,,,,,,,,,,,"4044412|4270062","Traumatic neuroma|Traumatic neuroma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3273355","Laser Cryo Enrichment","C97316","A technology that allows for high-throughput laser dissection of frozen specimens. Reference slides are cut and are used to determine regions that should be retained. After review of the reference slide by a pathologist, tissues are robotically dissected in large groups. The main tissue block remains unchanged and is not chemically treated or thawed, which allows for extraction and analysis of high quality DNA, RNA, or protein.","Laser Cryo Enrichment | LCE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1378050","Oncocytic Neoplasm","C7072","A usually benign neoplasm composed of large cells with abundant eosinophilic granular cytoplasm.","Oncocytic Neoplasm | ONCOCYTOMA, BENIGN | Oncocytic Tumor | Oncocytoma | Papillary Thyroid Carcinoma, Oncocytic Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028882","Odontoma","C3287","A benign, slow growing, and painless hamartomatous tumor occurring in tooth-bearing areas of the jaws. According to the presence or absence of tooth-like structures, it is classified as complex type or compound type. Odontoma of complex type is characterized by the presence of enamel and dentin and the absence of tooth-like structures. It is treated with local excision. If it is incompletely removed, it may recur. Odontoma of compound type is characterized by the presence of tooth-like structures. It is treated by local excision. Recurrences have not been reported.","Odontoma | Fibro-Odontoma | Fibroodontoma | ODONTOMA, BENIGN | Odontoma, NOS","9280/0","Odontoma, NOS",,,,,,,,,,,,,"608016","Benign odontoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0028439","Notochord","C12463","A rod-shaped embryonic midline structure that is found in all chordates. Notochords, comprised of stiff cartilage-like material, are oriented from head to tail and are the basis for axial skeleton development.","Notochord | ",,,,,,,,,,,,,,,"4289998","Structure of notochord",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334242","Papillary Carcinoma In Situ","C65163","An epithelial neoplasm with a papillary growth pattern in which the malignant cells are confined to the epithelium, without evidence of invasion.","Papillary Carcinoma In Situ | Papillary carcinoma in situ","8509/2","Solid papillary carcinoma in situ",,,,,,,,,,,,,"4016393","Papillary carcinoma in situ",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334357","Papillary Cystic Neoplasm","C4179","A benign, malignant, or borderline epithelial neoplasm characterized by the presence of papillary mucinous, serous, or clear cell structures and cystic structures.","Papillary Cystic Neoplasm | Papillary Cystic Tumor | Papillary cystic tumor",,,,,,,,,,,,,,,"37157148|4097828","Solid pseudopapillary neoplasm|Papillary cystic tumor",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0001429","Warthin Tumor","C2854","A benign tumor that arises from the salivary gland and is characterized by the presence of an oncocytic, often papillary epithelial component, dense lymphoid stroma, and cystic spaces. It occurs primarily in the parotid gland and is the second most common benign parotid gland tumor (after pleomorphic adenoma). A strong association with smoking has been reported. It typically presents as a painless swelling in the lower portion of the parotid gland.","Warthin Tumor | Adenolymphoma | Papillary Cystadenoma Lymphomatosum | Papillary cystadenoma lymphomatosum | Salivary Gland Warthin Tumor | Warthin tumor | Warthin's Tumor","8561/0","Adenolymphoma",,,,,,,,,,,,,"4048446|4307552","Adenolymphoma|Adenolymphoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0001420","Papillary Adenocarcinoma","C2853","A morphologic variant of adenocarcinoma. It is characterized by the presence of a papillary growth pattern. Representative examples include thyroid gland papillary carcinoma, invasive papillary breast carcinoma, and ovarian serous surface papillary adenocarcinoma.","Papillary Adenocarcinoma | ADENOCARCINOMA, PAPILLARY, MALIGNANT | Papillary adenocarcinoma","8260/3","Papillary adenocarcinoma, NOS",,,,,,,,,,,,,"4172953","Papillary adenocarcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334489","Pancreatoblastoma","C4265","A rare malignant epithelial neoplasm arising from the pancreas. The vast majority of cases occur during childhood. It is characterized by acinar differentiation, the formation of squamoid corpuscles, and the formation of stromal bands. Patients may present with an abdominal mass. Symptoms include pain, weight loss, and diarrhea. It may metastasize to lymph nodes, liver, and distant anatomic sites. Children who do not have metastatic disease at the time of diagnosis usually have a favorable clinical outcome when treated with a combination of surgery and chemotherapy. However, children with metastatic disease at presentation or adult patients usually have a poor prognosis.","Pancreatoblastoma | ","8971/3","Pancreatoblastoma",,,,,,,,,,,,,"40391739|4205868","Pancreatoblastoma|Pancreatoblastoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0029441","Osteoid Osteoma","C3297","A small, benign bone-forming neoplasm that can arise from any bone but more frequently affects the long bones. The central portion of the neoplasm (nidus) contains differentiated osteoblasts that produce osteoid and sometimes bone. The lesion is usually surrounded by hypervascular sclerotic bone and has limited growth potential. Clinical signs and symptoms include pain and localized tenderness, at the site of the lesion. The pain may be intense but in the majority of cases it is completely alleviated by non-steroidal anti-inflammatory drugs. Prognosis is excellent and recurrences are rare.","Osteoid Osteoma | Osteoid osteoma, NOS","9191/0","Osteoid osteoma, NOS",,,,,,,,,,,,,"4121333|4325607","Osteoid osteoma|Osteoid osteoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0029423","Osteochondroma","C3295","A common, benign cartiliginous neoplasm arising from the metaphysis of bone. The tumor grows on the surface of the bone; it may be pedunculated or sessile. It is characterized by the presence of chondrocytes, a cartilage cap, and a fibrous perichondrium that extends to the periosteum of the bone. In some cases, there is deletion of 8q24.1 chromosome locus.","Osteochondroma | OSTEOCHONDROMA, BENIGN | Osteocartilaginous Exostosis | Osteocartilaginous exostosis","9210/0","Osteochondroma",,,,,,,,,,,,,"40480080|4181934","Osteochondroma|Osteochondroma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0029417","Osteoblastoma","C3294","A rare benign bone-forming neoplasm usually arising from the spine. It is a well-circumscribed lytic tumor that varies in size. The tumor is composed of woven bone trabeculae and shares similar histologic characteristics with the osteoid osteoma. Surgical curettage is the treatment of choice. The prognosis is excellent.","Osteoblastoma | Giant Osteoid Osteoma | Giant osteoid osteoma | OSTEOBLASTOMA, BENIGN | Ossifying Giant Cell Tumor | Osteoblastoma, NOS","9200/0","Osteoblastoma, NOS",,,,,,,,,,,,,"4205414","Osteoblastoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1335906","Salivary Gland Oncocytoma","C5932","A rare benign epithelial neoplasm composed of oncocytes, which are large cells with a large amount of granular eosinophilic cytoplasm containing numerous tightly-packed mitochondria.  Approximately 85% to 90% occur in the parotid gland; most of the remainder occur in the submandibular gland. The peak incidence is in the seventh through ninth decades of life. In almost all cases, swelling is the only complaint of the patient.","Salivary Gland Oncocytoma | Oncocytoma of Salivary Gland | Oncocytoma of the Salivary Gland | Oxyphilic Adenoma of Salivary Gland | Oxyphilic Adenoma of the Salivary Gland | Salivary Gland Oxyphilic Adenoma",,,,,,,,,,,,,,,"4311572","Benign oncocytoma of salivary gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0600066","Malignant Phyllodes Tumor","C4275","A phyllodes tumor with sarcomatous stroma. The sarcomatous component is usually of the fibrosarcomatous type. Liposarcomatous, chondrosarcomatous, osteosarcomatous, or rhabdomyosarcomatous differentiation may also occur in the stroma. It may recur and metastasize following surgical resection. The lung and skeleton are the anatomic sites most frequently involved by metastases.","Malignant Phyllodes Tumor | Cystosarcoma phyllodes, malignant | Malignant Cystosarcoma Phyllodes | Malignant Phyllodes Neoplasm | Phyllodes tumor, malignant","9020/3","Phyllodes tumor, malignant",,,,,,,,,,,,,"4337106","Malignant phyllodes tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1708353","SDHx-Related Syndromes","C48300","An autosomal dominant hereditary neoplastic syndrome caused by mutations in the SDHA,SDHB, SDHC, SDHD, and SDHAF2 genes. It is characterized by the development of paragangliomas and pheochromocytomas, gastrointestinal stromal tumors, and SDH-deficient renal cell carcinomas.","Succinate Dehydrogenase-Deficient Tumor Syndrome | Familial Paraganglioma Syndrome | Familial Paraganglioma-Pheochromocytoma Syndrome | Familial Paraganglioma-Pheochromocytoma Syndrome | Hereditary Paraganglioma-Pheochromocytoma Syndrome | Hereditary Paraganglioma-Pheochromocytoma Syndrome | SDH Deficient Tumor Syndrome | SDH Deficient Tumor Syndrome | SDH-Deficient Tumor Syndrome | SDH-Deficient Tumor Syndrome | SDHx-Related Syndromes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031154","Peritonitis","C26849","Inflammation of the peritoneum due to infection by bacteria or fungi. Causes include liver disease, perforation of the gastrointestinal tract or biliary tract, and peritoneal dialysis. Patients usually present with abdominal pain and tenderness, fever, chills, and nausea and vomiting. It is an emergency medical condition that requires prompt medical attention and treatment.","Peritonitis | peritonitis",,,,,,,,,,,,,,,"196152","Peritonitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1335334","Paraganglioma-Like Dermal Melanocytic Tumor","C37258","A benign primary melanocytic tumor of the skin that presents as a dermal nodule. Morphologically, it is characterized by the presence of paraganglioma-like features that include a nested growth pattern of the tumor cells. The nests are composed of epithelioid cells and are separated by delicate fibrous strands. Cytoplasmic melanin is not present; however immunohistochemical studies have confirmed the melanocytic lineage of the tumor cells.","Paraganglioma-Like Dermal Melanocytic Tumor | Dermal Melanocytic Tumor Resembling Paraganglioma | PDMT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205874","Squamous Papilloma","C3712","A benign epithelial neoplasm characterized by a papillary growth pattern and a proliferation of neoplastic squamous cells without morphologic evidence of malignancy. Most frequently it arises in the oral cavity, nasopharynx, larynx, esophagus, vagina, and vulva.","Squamous Papilloma | Epidermoid Cell Papilloma | Epidermoid Papilloma | Keratotic Papilloma | Keratotoc papilloma | PAPILLOMA, SQUAMOUS CELL, BENIGN | Squamous Cell Papilloma | Squamous Cell Papilloma | Squamous Cell Papilloma  | Squamous Papilloma | Squamous Papilloma | Squamous cell papilloma, NOS | Squamous papilloma","8052/0","Squamous cell papilloma, NOS",,,,,,,,,,,,,"4272024","Squamous cell papilloma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1335910","Salivary Gland Sialadenoma Papilliferum","C35836","An uncommon exophytic papillary proliferation that involves mucosal surface epithelium and salivary duct epithelium. It is exceptional among salivary gland neoplasms because it manifests as an exophytic papillary excrescence of the mucosa, rather than as a submucosal or intraglandular mass. It most often affects the hard or soft palate.  It is generally asymptomatic.","Salivary Gland Sialadenoma Papilliferum | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206721","Inverted Papilloma","C3793","An endophytic benign papillary epithelial neoplasm that results from the invagination and proliferation of epithelial cells in the underlying stroma.  Representative examples are the inverted urothelial papilloma that arises from the urinary tract and inverted Schneiderian papilloma that arises from the nasal cavity or paranasal sinuses.","Inverted Papilloma | inverted papilloma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0150270","Pharmacologic Management","C21090","A health/illness/pain management principle specifically directed at the management of pharmacologic agents in maximizing beneficial outcomes and minimizing unfavorable effects.","Pharmacologic Management | Analgesic Management | Medication Management",,,,,,,,,,,,,,,"4082382","Management of drug regimen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0333983","Hyperplastic Polyp","C4083","A polyp found mainly in the stomach and colon.  Microscopically, it is characterized by elongated, serrated crypts lined by proliferative epithelium.  Hyperplastic polyps are traditionally considered non-neoplastic, but ras mutation is common, clonality has been demonstrated and biochemical abnormalities and epidemiological associations that occur in colorectal adenomas and carcinomas have been found (WHO Tumors of the Digestive System, 2000).","Hyperplastic Polyp | HP | MP | Metaplastic Polyp",,,,,,,,,,,,,,,"4265059","Hyperplastic polyp",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0920184","Fundic Gland Polyp","C8961","The most common gastric polyp in the Western hemisphere.  The lesion consists of a localized hyperplasia of the deep epithelial compartment of the oxyntic mucosa, with variable degrees of cystic dilatation.  Malignant transformation is the exception.  (WHO, 2000)","Fundic Gland Polyp | ",,,,,,,,,,,,,,,"40492420","Fundic gland polyp",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1880996","Gonadal Polyembryoma","C66776","A rare malignant germ cell tumor arising from the testis and less often from the ovary. It is characterized by the presence of embryoid bodies which resemble early embryos.","Gonadal Polyembryoma | Polyembryoma","9072/3","Polyembryoma",,,,,,,,,,,,,"4152945|607957","Polyembryoma|Polyembryoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0032231","Pleuritis","C26860","Inflammation of the pleura. It is usually caused by infections. Chest pain while breathing or coughing is the presenting symptom.","Pleuritis | Pleurisy",,,,,,,,,,,,,,,"78786","Pleurisy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206666","Placental Site Trophoblastic Tumor","C3757","A rare gestational trophoblastic tumor characterized by the presence of a diffuse cellular infiltrate composed of intermediate trophoblasts and cytotrophoblasts and by the absense of a significant population of syncytiotrophoblasts.","Placental Site Trophoblastic Tumor | PSTT | Placental Site Gestational Trophoblastic Tumor | Placental-Site GTT | Placental-Site Gestational Trophoblastic Neoplasm | Placental-Site Gestational Trophoblastic Tumor | Placental-Site Gestational Trophoblastic Tumor","9104/1","Placental site trophoblastic tumor",,,,,,,,,,,,,"4028645|4328506","Placental site trophoblastic tumor|Placental site trophoblastic tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1533161","Poroma","C27273","A benign, well circumscribed adnexal neoplasm arising from the intraepidermal portion of the sweat gland duct. It usually presents as a solitary, dome-shaped papule, nodule, or plaque on acral sites. It is characterized by a proliferation of uniform basaloid cells in the dermis and is associated with the presence of focal ductal and cystic structures. Complete excision is curative.","Poroma | Eccrine Poroma | Eccrine poroma | Poroid Tumor","8409/0","Poroma, NOS",,,,,,,,,,,,,"4030285|4266187","Eccrine poroma|Eccrine poroma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0396053","Vocal Cord Nodule","C3370","A non-neoplastic growth in the vocal cord. It is characterized by tissue swelling in both vocal cords in a symmetrical manner. It is caused by vocal abuse behavior. Hoarseness is the presenting symptom.","Vocal Cord Nodule | Nodule of Vocal Cord | Nodule of the Vocal Cord | Singers' Node | Singers' Nodule",,,,,,,,,,,,,,,"4034633","Singers' nodes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0264231","Paranasal Sinus Polyp","C7486","A polyp that arises from the paranasal sinus mucosa. Causes include allergic rhinitis, chronic sinusitis, and cystic fibrosis. It is characterized by the presence of edematous tissue infiltrated by inflammatory cells, including eosinophils.","Paranasal Sinus Polyp | Accessory Sinus Polyp | Polyp of Accessory Sinus | Polyp of Paranasal Sinus | Polyp of the Accessory Sinus | Polyp of the Paranasal Sinus",,,,,,,,,,,,,,,"4138403","Polyp of nasal sinus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221273","Juvenile Polyp","C3826","A non-neoplastic hamartomatous polyp that arises from the stomach and intestinal tract.  It is characterized by the presence of tortuous and cystically dilated glands, edematous changes, and inflammation.","Juvenile Polyp | Retention Polyp",,,,,,,,,,,,,,,"4005169","Juvenile polyp",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333111","Colorectal Inflammatory Polyp","C5680","A non-neoplastic polypoid lesion in the colon and rectum.  It may arise in a background of inflammatory bowel disease or colitis.  It is characterized by the presence of a distorted epithelium, inflammation, and fibrosis.","Colorectal Inflammatory Polyp | Inflammatory Polyp of Large Bowel | Inflammatory Polyp of the Large Bowel | Large Bowel Inflammatory Polyp | Large Intestinal Inflammatory Polyp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0855073","Liver Embryonal Sarcoma","C27096","An aggressive malignant mesenchymal neoplasm that arises from the liver and usually occurs in older children.  It is composed of immature spindle, stellate, polymorphous, and giant cells.","Liver Embryonal Sarcoma | ESL | Embryonal Sarcoma | Embryonal Sarcoma (Undifferentiated Sarcoma) | Embryonal Sarcoma of the Liver | Embryonal sarcoma | UES | Undifferentiated (Embryonal) Sarcoma | Undifferentiated (Embryonal) Sarcoma | Undifferentiated (Embryonal) Sarcoma of the Liver | Undifferentiated Sarcoma | Undifferentiated sarcoma","8991/3","Embryonal sarcoma",,,,,,,,,,,,,"37396736|4241991","Embryonal sarcoma of liver|Embryonal sarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0431111","Ectomesenchymoma","C4716","An exceedingly rare, aggressive malignant mesenchymal neoplasm characterized by the presence of a sarcomatous component and a ganglionic or a neuroectodermal component.","Ectomesenchymoma | Malignant Ectomesenchymoma | Sarcoma with Ganglionic or Neuroectodermal Differentiation | Sarcoma with Ganglionic or Neuroectodermal Differentiation | ectomesenchymoma | malignant ectomesenchymoma",,,,,,,,,,,,,,,"4029024","Rhabdomyosarcoma with ganglionic differentiation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035411","Rhabdomyoma","C3358","A benign mesenchymal tumor arising from skeletal or cardiac muscle.","Rhabdomyoma | RHABDOMYOMA, BENIGN | Rhabdomyoma, NOS | Rhabdomyomatous Neoplasm","8900/0","Rhabdomyoma, NOS",,,,,,,,,,,,,"4120309|608189","Rhabdomyoma|Rhabdomyoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0752244","Rathke Pouch Cyst","C4977","Rathke's pouch cysts are rarely symptomatic in the first two decades of life though they may produce symptoms in the third and fourth decades of life.  When the cysts do present in the first decades of life, the symptoms are generally associated with diabetes insipidus or other conditions related to hypopituitarism.","Rathke Pouch Cyst | Cyst of Rathke's Pouch | Rathke Cleft Cyst | Rathke's Pouch Cyst | Suprasellar Cyst",,,,,,,,,,,,,,,"4203940","Rathke's pouch cyst",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1524022","Radiation-Induced Change","C22493","Techniques used for altering the genetic material of an organism by exposure to ionizing radiation.","Radiation-Induced Change | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273360","Explanted Organ","C97326","Donor tissue that is removed due to rejection.","Explanted Organ | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273361","Nickel Metabolic Disorder","C97327","A storage disorder that results from impaired metabolism of nickel.","Nickel Metabolic Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273362","Polycystic","C97328","The presence of multiple cysts in one or several organs.","Polycystic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0654019","Tumor-associated Antigen 43-9F","C96507","A novel tumor-associated carbohydrate epitope identified by the 43-9F monoclonal antibody and associated with the growth pattern of squamous cell lung carcinomas. Tumor-associated antigen 43-9F is used to differentiate between normal cells and cancer cells in tumor biopsy specimens.","Tumor-associated Antigen 43-9F | Tumor-associated Antigen 43-9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054541","Calponin","C96483","A family of actin and calcium binding proteins found mostly in smooth muscle-containing tissues. These proteins play a role in the regulation of actin/myosin interactions and the subsequent mediation of smooth muscle contraction.","Calponin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0751980","Comet Assay","C96515","A rapid, simple, visual and sensitive technique for measuring DNA breakage in individual mammalian cells in response to a test agent. A cell is immobilized in agarose and made permeable and the broken DNA migrates out under the influence of the electric field. A damaged cell has the appearance of a comet with a brightly fluorescent cell body and a tail whose length and fluorescence intensity are related to the number of DNA-strand breaks induced by the test agent.","Single Cell Gel Electrophoresis | COMET | Comet Assay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272839","Microvessel Density","C96517","The density of newly formed blood vessels in a tissue. Microvascular density can be used to describe the proliferation speed of a tissue, with higher density indicating faster tissue growth.","Microvascular Density | MVD | Microvessel Density | Microvessel Density",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272808","Serum Interleukin-2 Receptor Subunit Alpha Measurement","C96484","An immunoassay that is used to determine the amount of soluble interleukin-2 receptor subunit alpha in a patient serum sample. High levels of the soluble form of the receptor can be indicative of hematological malignancies and other neoplastic disorders.","Serum Soluble Interleukin-2 Receptor Subunit Alpha Measurement | Serum Interleukin-2 Receptor Subunit Alpha Measurement | Serum Interleukin-2 Receptor Subunit Alpha Measurement | Serum sIL2RA Measurement | Serum sIL2Ra Measurement | Soluble IL-2 Receptor Alpha Measurement | Soluble Interleukin-2 Receptor | Soluble Interleukin-2 Receptor Alpha Assay | Soluble Interleukin-2 Receptor Alpha Measurement | Soluble Interleukin-2 Receptor Assay | Soluble Interleukin-2 Receptor Subunit Alpha Assay | Soluble Serum IL-2 Receptor Alpha Measurement | Soluble Serum IL2Ra Measurement | sIL-2R Alpha Assay | sIL-2R Assay | sIL-2RA Assay | sIL2RA Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1370723","Stromal Sarcoma","C6926","A malignant neoplasm characterized by the presence of atypical mesenchymal-stromal cells. Representative examples include endometrial stromal sarcoma and prostate stromal sarcoma.","Stromal Sarcoma | STROMAL SARCOMA, MALIGNANT | Stromal Tumor, Malignant","8935/3","Stromal sarcoma, NOS",,,,,,,,,,,,,"4029530","Stromal sarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0343083","Intravascular Papillary Endothelial Hyperplasia","C4391","A reactive, well-circumscribed vascular lesion. It is characterized by the formation of thin papillae projecting within the lumen of blood vessels. The papillae are lined by plump endothelial cells. Blood clots are also present.","Intravascular Papillary Endothelial Hyperplasia | Masson Hemangioma | Masson Lesion | Masson Pseudotumor | Masson lesion | Masson's Pseudosarcoma | Masson's Pseudotumor | Masson's Vegetant Hemangioma | Papillary Endothelial Hyperplasia | Papillary Endothelial Hyperplasia",,,,,,,,,,,,,,,"4032883","Intravascular papillary endothelial hyperplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025464","Mesenchymoma","C3233","A term describing a soft tissue tumor which consists of two or more mesenchymal lines of differentiation, excluding a fibroblastic line of differentiation.","Mesenchymoma | ","8990/1","Mesenchymoma, NOS",,,,,,,,,,,,,"4195947","Mesenchymoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0450172","Milliampere","C97343","A unit of electric current equal to one thousandth of an ampere.","Milliampere | mA | mAmp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334403","Juvenile Granulosa Cell Tumor","C4207","A sex cord-stromal tumor occurring in the ovary and testis. In females it occurs predominantly in the first three decades of life and presents unilaterally as stage I disease in the vast majority of cases. It is characterized by the presence of granulosa cells forming macrofollicular structures. The majority of cases have a good prognosis. In males it represents the most frequent congenital testicular neoplasm, and the vast majority of cases occur in the perinatal period. It presents as a scrotal or abdominal mass, and it more often affects the left testis. Approximately 20% of the patients have ambiguous external genitalia. It is characterized by the presence of cystic spaces lined by granulosa cells and cells resembling theca cells. Metastases have not been reported.","Juvenile Granulosa Cell Tumor | Granulosa cell tumor, juvenile | Juvenile Type Granulosa Cell Neoplasm | Juvenile Type Granulosa Cell Tumor | Juvenile Type Granulosa Cell Tumor","8622/1","Granulosa cell tumor, juvenile",,,,,,,,,,,,,"4297451","Juvenile granulosa cell tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1879643","Adult Granulosa Cell Tumor","C66750","A low-grade malignant sex cord-stromal tumor occurring in the ovary and rarely in the testis. It is composed of granulosa cells in an often fibrothecomatous stroma. The neoplastic cells may form various patterns including the microfollicular, which is characterized by the presence of Call-Exner bodies, macrofollicular, insular, trabecular, and diffuse pattern. In females, it affects middle aged to post-menopausal women. Signs and symptoms include abdominal mass, hemoperitoneum, and ascites. Estrogenic and rarely androgenic manifestations may be present. The vast majority of cases present as stage I tumors; however, all tumors have a potential for aggressive clinical course. In males, it is reported in the age range of 16-76 years and the average age at presentation is 44 years. A minority of patients have gynecomastia. Metastases have been reported in a minority of patients.","Adult Granulosa Cell Tumor | Adult Type Granulosa Cell Tumor | Adult Type Granulosa Cell Tumor | Adult granulosa cell tumor | Granulosa cell tumor, adult type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036769","Sertoli Cell Tumor","C39976","A sex cord-stromal tumor of the testis or the ovary. It is characterized by the presence of Sertoli cells forming tubules. Leydig cells are rare or absent. It may be associated with Peutz-Jeghers syndrome. In males, the presenting symptom is a slow growing testicular mass. Most cases follow a benign clinical course. In females it may present with estrogenic or androgenic manifestations. The vast majority of cases have a benign clinical course.","Sertoli Cell Tumor | Sertoli cell adenoma | Sertoli cell tumor, NOS","8640/1","Sertoli cell tumor, NOS",,,,,,,,,,,,,"40637066","Sertoli cell tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1518875","Pancreatic Serous Neoplasm","C41248","A benign or malignant epithelial neoplasm that is usually cystic and arises from the exocrine pancreas.  It is characterized by the presence of neoplastic epithelial cells that produce fluid similar to serum.  Representative examples include serous cystadenoma and serous cystadenocarcinoma.","Pancreatic Serous Neoplasm | Pancreatic Serous Cystic Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511605","Cystic Change","C41454","A microscopic finding indicating the formation of cystic structures in a tissue sample.","Cystic Change | CYSTIC DEGENERATION | Cystic Changes | Cystic Structures Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1321683","Melanoacanthoma","C27548","A benign, darkly pigmented skin lesion characterized by proliferation of keratinocytes and melanocytes.","Melanoacanthoma | ",,,,,,,,,,,,,,,"4214680","Melanoacanthoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334019","Inverted Follicular Keratosis","C9007","Seborrheic keratosis that arises from follicular structures in the skin. It presents as a solitary nodule in the skin and is characterized by the presence of prominent squamous eddies.","Inverted Follicular Keratosis | ",,,,,,,,,,,,,,,"4035473|4190451","Inverted keratosis|Inverted follicular keratosis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0036503","Sebaceous Gland Neoplasm","C3363","A benign or malignant neoplasm that arises from the sebaceous glands. Representative examples include sebaceous adenoma and sebaceous carcinoma.","Sebaceous Gland Neoplasm | Neoplasm with Sebaceous Differentiation | Sebaceous Gland Tumor | Sebaceous Neoplasm | Sebaceous Tumor | Tumor with Sebaceous Differentiation",,,,,,,,,,,,,,,"4129077|4266640","Tumor of skin with sebaceous differentiation|Neoplasm with sebaceous differentiation",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0346208","Vaginal Intraepithelial Neoplasia","C4521","A superficial neoplastic process involving exclusively the vaginal squamous epithelium without extension to underlying tissue.  It is classified as low- or high-grade intraepithelial neoplasia.","Vaginal Intraepithelial Neoplasia | Intraepithelial Neoplasia of Vagina | Intraepithelial Neoplasia of the Vagina | Intraepithelial Neoplasm of Vagina | Intraepithelial Neoplasm of the Vagina | Intraepithelial Tumor of Vagina | Intraepithelial Tumor of the Vagina | VAIN | Vaginal Intraepithelial Neoplasm | Vaginal Intraepithelial Tumor | Vaginal SIL | Vaginal Squamous Intraepithelial Lesion | Vaginal intraepithelial neoplasia",,,,,,,,,,,,,,,"4110874","Vaginal intraepithelial neoplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1336030","Solid Pseudopapillary Neoplasm of the Pancreas","C37212","A low-grade malignant neoplasm that arises from the exocrine pancreas. It is characterized by the presence of uniform cells that form solid and pseudopapillary patterns, cystic changes, and hemorrhage. Perineural invasion, vascular invasion, and invasion into surrounding tissues may be present. It usually presents as an encapsulated, solitary, and lobulated pancreatic mass. It is usually found incidentally during physical examination or it may present with abdominal discomfort and pain. It occurs predominantly in young women. Complete removal of the tumor is curative in the majority of cases.","Solid Pseudopapillary Neoplasm of the Pancreas | Frantz Tumor | Solid Pseudopapillary Tumor of the Pancreas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030809","Pemphigus Vulgaris","C34910","An autoimmune blistering disorder. It is characterized by the presence of painful blisters and erosions in the skin and mucous membranes.","Pemphigus Vulgaris | ",,,,,,,,,,,,,,,"4170723","Pemphigus vulgaris",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023646","Lichen Planus","C3189","A chronic, recurrent, pruritic inflammatory disorder of unknown etiology that affects the skin and mucus membranes. It presents with rashes and papules that tend to resolve spontaneously. It may be associated with hepatitis C. Certain drugs that contain arsenic or bismuth are associated with reactions mimicking lichen planus.","Lichen Planus | ",,,,,,,,,,,,,,,"132703","Lichen planus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022593","Keratosis","C34747","Excessive growth of keratin on the skin.","Keratosis | ",,,,,,,,,,,,,,,"4112748","Keratosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162820","Allergic Contact Dermatitis","C26998","An inflammatory skin condition caused by an immune response to direct contact between the skin and an allergen. It consists of a delayed type of allergic reaction at the affected site with resulting red, swollen, and blistered skin that may itch or leak.","Allergic Contact Dermatitis | ",,,,,,,,,,,,,,,"4031019","Allergic contact dermatitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0149516","Chronic Sinusitis","C35151","Inflammation of the paranasal sinuses that typically lasts beyond eight weeks. It is caused by infections, allergies, and the presence of sinus polyps or deviated septum. Signs and symptoms include headache, nasal discharge, swelling in the face, dizziness, and breathing difficulties.","Chronic Sinusitis | ",,,,,,,,,,,,,,,"257012","Chronic sinusitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2826557","Chronic Sclerosing Sialadenitis","C82887","A chronic fibrotic inflammatory process affecting the salivary gland. Signs and symptoms include firm and painful swelling of the salivary gland, often associated with the presence of salivary gland stones.","Chronic Sclerosing Sialadenitis | Kuttner Tumor | Kuttner's Tumor",,,,,,,,,,,,,,,"40488411","Chronic sclerosing sialadenitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332540","Benign Testicular Sertoli Cell Tumor","C6522","A non-metastasizing sex cord-stromal tumor that arises from the testis. Morphologically, it is characterized by the presence of Sertoli cells forming tubules. Leydig cells are rare or absent.","Benign Testicular Sertoli Cell Tumor | Benign Sertoli Cell Neoplasm of Testis | Benign Sertoli Cell Neoplasm of the Testis | Benign Sertoli Cell Tumor of Testis | Benign Sertoli Cell Tumor of the Testis | Benign Testicular Sertoli Cell Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0346179","Ovarian Hilus Cell Tumor","C4214","A benign Leydig cell tumor which arises in the hilar area of the ovary.","Ovarian Hilus Cell Tumor | Hilar Cell Neoplasm | Hilar Cell Tumor of Ovary | Hilar Cell Tumor of the Ovary | Hilar cell tumor | Hilus Cell Neoplasm | Hilus Cell Tumor | Hilus cell tumor | Ovarian Hilar Cell Tumor","8660/0","Hilus cell tumor",,,,,,,,,,,,,"4015923|4110867","Hilus cell tumor|Hilus cell tumor of ovary",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0038987","Sweat Gland Neoplasm","C3398","A benign or malignant neoplasm arising from the sweat glands.","Sweat Gland Neoplasm | Neoplasm of Sweat Gland | Neoplasm of the Sweat Gland | Sweat Gland Neoplasms | Sweat Gland Tumor | Sweat gland tumor, NOS | Tumor of Sweat Gland | Tumor of the Sweat Gland","8400/1","Sweat gland tumor, NOS",,,,,,,,,,,,,"4044192|4054402","Sweat gland tumor|Neoplasm of sweat gland",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0038478","Struma Ovarii","C7468","An ovarian mature teratoma characterized by the presence of aberrant thyroid tissue.","Struma Ovarii | ","9090/0","Struma ovarii, NOS",,,,,,,,,,,,,"4087722","Struma ovarii",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334400","Ovarian Sclerosing Stromal Tumor","C4204","A benign ovarian stromal tumor characterized by the presence of cellular areas which contain fibroblasts and round cells. The cellular areas are separated by sclerotic or edematous hypocellular tissue. Symptoms include abdominal discomfort and menstrual abnormalities.","Ovarian Sclerosing Stromal Tumor | Ovarian Sclerosing Stromal Neoplasm | Sclerosing Stromal Neoplasm of Ovary | Sclerosing Stromal Neoplasm of the Ovary | Sclerosing Stromal Tumor | Sclerosing Stromal Tumor of Ovary | Sclerosing Stromal Tumor of the Ovary","8602/0","Sclerosing stromal tumor",,,,,,,,,,,,,"4273235","Sclerosing stromal tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1516693","Collagenous Stroma Formation","C41472","A morphologic finding indicating the presence of dense stromal fibrosis in a tissue sample.","Collagenous Stroma Formation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516838","Endocervical Mucosa","C33989","The mucous lining of the canal of the cervix uteri. It is composed of epithelium, basement membrane, lamina propria mucosae, and lamina muscularis mucosae.","Endocervical Mucosa | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512164","Ectocervical Mucosa","C33990","The mucous covering of the vaginal portion of the cervix. It is composed of epithelium, basement membrane, lamina propria mucosae, and lamina muscularis mucosae.","Ectocervical Mucosa | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0343641","Human Papillomavirus Infection","C27851","An infectious process caused by a human papillomavirus. This infection can cause abnormal tissue growth.","Human Papillomavirus Infection | HPV | HPV Infection | Human Papilloma Virus Infection",,,,,,,,,,,,,,,"441788","Human papilloma virus infection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883714","Parotid Gland Warthin Tumor","C66865","An adenoma that arises from the parotid gland. It is characterized by an oncocytic, often papillary, epithelial component, dense lymphoid stroma, and cystic spaces. A strong association with smoking has been reported. It typically presents as a painless swelling in the lower portion of the parotid gland.","Parotid Gland Warthin Tumor | Parotid Gland Adenolymphoma | Parotid Gland Papillary Cystadenoma Lymphomatosum | Parotid Gland Warthin's Tumor",,,,,,,,,,,,,,,"40488895","Warthin's tumor of parotid gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043037","Verruca Vulgaris","C27087","A benign squamoproliferative skin lesion caused by human papillomavirus. It is characterized by hyperkeratosis, acanthosis, papillomatosis, parakeratosis, and prominent rete ridges. It usually affects the hands and fingers. Other sites of involvement include the elbows, knees, face, and genitalia.","Verruca Vulgaris | Common Viral Wart | Common Wart",,,,,,,,,,,,,,,"140641","Verruca vulgaris",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042548","Verruca Plantaris","C26913","A wart on the plantar surface of the foot. It is caused by human papillomavirus.","Verruca Plantaris | Plantar Wart",,,,,,,,,,,,,,,"137785","Verruca plantaris",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018916","Hemangioma","C3085","A benign vascular lesion characterized by the formation of capillary-sized or cavernous vascular channels.","Hemangioma | Angioma | Benign Angioma | Benign Hemangioma | HEMANGIOMA, BENIGN | Hemangioma, NOS","9120/0","Hemangioma, NOS",,,,,,,,,,,,,"441818","Hemangioma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0003857","Arteriovenous Malformation","C2882","A benign vascular lesion characterized by the presence of a complex network of communicating arterial and venous vascular structures.","Arteriovenous Malformation | AVM | AVM/H | Arteriovenous Angioma | Arteriovenous Hemangioma | Arteriovenous Hemangioma/Malformation | Arteriovenous Malformation | Arteriovenous Malformation | Arteriovenous Malformation/Hemangioma | Arteriovenous Malformation/Hemangioma | Arteriovenous hemangioma | Racemose Angioma | Racemose Hemangioma | Racemose hemangioma",,,,,,,,,,,,,,,"4119780","Congenital arteriovenous malformation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027707","Interstitial Nephritis","C26834","Inflammation of the renal tubules and supporting tissues of the kidney.","Interstitial Nephritis | INTERSTITIAL NEPHRITIS | Tubulointerstitial Nephritis",,,,,,,,,,,,,,,"4131045","Interstitial nephritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4015547","Chronic Kidney Disease, Stage 5","C9439","Long-standing and persistent renal disease with glomerular filtration rate (GFR) less than 15 ml/min.","Chronic Kidney Disease, Stage 5 | Chronic kidney disease, stage 5 | ESRD | End Stage Kidney Disease | End Stage Kidney Failure | End Stage Renal Disease | End Stage Renal Failure | End stage renal disease | End-stage Renal Disease",,,,,,,,,,,,,,,"193782|443611","End-stage renal disease|Chronic kidney disease stage 5",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0436545","Non-Specific Granulomatous Orchitis","C27162","Granulomatous inflammation of the testis. It is characterized by the formation of granulomas around the seminiferous tubules. History of trauma may be present. It is assumed to be a reactive process due to autoimmune phenomena.","Non-Specific Granulomatous Orchitis | ",,,,,,,,,,,,,,,"4179055","Non-specific granulomatous orchitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004690","Balanitis","C26705","An infectious or non-infectious inflammatory process that affects the glans penis.  Symptoms include redness and pain of the glans penis and foreskin and discharge.","Balanitis | ",,,,,,,,,,,,,,,"4260520","Balanitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448344","Invasive Thymoma","C6453","A thymoma of any morphologic type that extends beyond the capsule and infiltrates the surrounding tissues.","Invasive Thymoma | Infiltrating Thymoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039747","Thecoma","C3405","An ovarian or testicular stromal tumor characterized by the presence of lipid-rich neoplastic spindle cells. In females, uterine bleeding is the most common symptom. A minority of post-menopausal women with thecoma have an associated endometrial adenocarcinoma or rarely a malignant mixed mullerian tumor or endometrial stromal sarcoma. Rare cases with nuclear atypia and mitotic activity may metastasize. In males, thecomas are rare and they usually present as slow growing, sometimes painful masses. Metastases have not been reported.","Thecoma | Thecoma, NOS","8600/0","Thecoma, NOS",,,,,,,,,,,,,"35622944","Fibrothecoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1266090","Hepatoid Adenocarcinoma","C66950","An adenocarcinoma with morphologic characteristics similar to hepatocellular carcinoma, arising from an anatomic site other than the liver.","Hepatoid Adenocarcinoma | Hepatoid Carcinoma | Hepatoid adenocarcinoma | Hepatoid carcinoma","8576/3","Hepatoid adenocarcinoma",,,,,,,,,,,,,"4030124","Hepatoid adenocarcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0206675","Adenomatoid Tumor","C3762","A benign, well-circumscribed neoplasm arising from mesothelial cells. It is characterized by the formation of glandular and tubular patterns. It usually involves the paratesticular region, uterus, and fallopian tube. Rare cases involving the pleura, peritoneum, adrenal gland, and liver have also been reported.","Adenomatoid Tumor | Adenomatoid Tumor, Benign | Adenomatoid tumor, NOS | Benign Localized Epithelial Mesothelioma | Benign Mesothelial Neoplasm | Benign Mesothelial Tumor | Benign Mesothelioma | Benign Neoplasm of Mesothelium | Benign Neoplasm of the Mesothelium | Benign Tumor of Mesothelium | Benign Tumor of the Mesothelium | MESOTHELIOMA, BENIGN | Mesothelioma, Benign | Mesothelioma, benign","9050/0|9052/0|9054/0","Mesothelioma, benign|Epithelioid mesothelioma, benign|Adenomatoid tumor, NOS",,,,,,,,,,,,,"4053032","Adenomatoid tumor",,,,,,,,,,,,,"--","--|--|--",,,,,,,,"--"
"C3273369","Isohemagglutinin Anti-A","C97347","An antibody that is reactive towards the A antigen present on the surface of some red blood cells. They are usually IgM antibodies and are isoantibodies, antibodies produced by an individual against antigens produced by members of the same species (isoantigens).","Isohemagglutinin Anti-A | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273370","Isohemagglutinin Anti-B","C97348","An antibody that is reactive towards the B antigen present on the surface of some red blood cells. They are usually IgM antibodies and are isoantibodies, antibodies produced by an individual against antigens produced by members of the same species (isoantigens).","Isohemagglutinin Anti-B | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3281249","Hepatosplenomegaly","C97345","An abnormal enlargement of both the liver and spleen.","Hepatosplenomegaly | ",,,,,,,,,,,,,,,"4279681","Hepatosplenomegaly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3273371","CD4 Positive Memory T-Lymphocyte","C97349","A mature T lymphocyte that has encountered antigen at a previous time and is primed to react strongly during its next encounter with that antigen. These cells can be identified by the presence of both the CD4 and CD45RO molecules on their surface.","CD4 Positive Memory T-Lymphocyte | CD4 Positive Memory T-Cell | CD4+ Memory T Cell | CD4+ Memory T Lymphocyte | CD4+ Memory T-Cell | CD4+ Memory T-Lymphocyte | CD4+/CD45RO+ T Cell | CD4-Positive Memory T-Lymphocyte",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273372","CD4 Positive Naive T-Lymphocyte","C97350","A T lymphocyte that has differentiated in the bone marrow, undergone central selection in the thymus, but has not encountered its cognate antigen in the peripheral circulation. These cells can be identified by presence of both the CD4 and CD45RA molecules on their surface.","CD4 Positive Naive T-Lymphocyte | CD4+ Naive T Cell | CD4+ Naive T-Lymphocyte | CD4+/CD45RA+ T Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031303","Bacteriophage Phi X 174","C97346","A bacteriophage that infects E. coli. Its genome is a circular DNA of 5386 bases.","Bacteriophage Phi X 174 | Enterobacteria Phage PhiX174 | Phi X 174 | Phi X174 | PhiX174",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334257","Intrahepatic Bile Duct Mucinous Cystic Neoplasm","C96835","A mucinous cystic neoplasm that arises from the intrahepatic bile ducts.","Intrahepatic Bile Duct Mucinous Cystic Neoplasm | Intrahepatic Bile Duct Cystadenoma | Intrahepatic Bile Duct MCN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273131","Intrahepatic Bile Duct Biliary Intraepithelial Neoplasia","C96943","A neoplastic, non-invasive lesion that affects the intrahepatic bile duct epithelium.  It is characterized by the presence of atypical epithelial cells with an increased nuclear/cytoplasmic ratio, nuclear hyperchromasia, and loss of nuclear polarity.","Intrahepatic Bile Duct Biliary Intraepithelial Neoplasia | Intrahepatic Bile Duct BilIN | Intrahepatic Bile Duct Dysplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333992","Clear Cell Acanthoma","C97041","An acanthoma characterized by the presence of psoriasiform epidermal acanthosis and basal cells with pale cytoplasm.","Clear Cell Acanthoma | Degos Acanthoma | Pale (Clear Cell) Acanthoma",,,,,,,,,,,,,,,"4115280|4277257","Clear cell acanthoma|Clear cell acanthoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3273210","Alcoholic Brain Atrophy","C97043","Atrophy of the cerebral cortex and/or cerebellum due to chronic ethanol consumption.","Alcoholic Brain Atrophy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273211","Age-Related Atrophy","C97044","Atrophy of the nervous system tissues and/or muscle tissues that is related to aging.","Age-Related Atrophy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005944","Metabolic Bone Disorder","C97045","A group of disorders that affect the bones secondary to increased levels of minerals or deficient levels of minerals such as calcium, magnesium, phosphorus, and vitamin D. Representative examples are osteomalacia, osteoporosis, and Paget disease.","Metabolic Bone Disorder | MBD | Metabolic Bone Disease",,,,,,,,,,,,,,,"4174382","Metabolic bone disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3273212","Human Papillomavirus-Related Adenosquamous Carcinoma","C97046","An adenosquamous carcinoma associated with the presence of human papillomavirus infection.","Human Papillomavirus-Related Adenosquamous Carcinoma | HPV-Related Adenosquamous Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273215","Invasive Breast Lobular Carcinoma, Alveolar Variant","C97049","A grade I invasive lobular carcinoma of the breast, characterized by the presence of round groups of neoplastic cells.","Invasive Breast Lobular Carcinoma, Alveolar Variant | Invasive Lobular Breast Carcinoma, Alveolar Variant | Invasive Lobular Breast Carcinoma, Alveolar Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273216","Invasive Breast Lobular Carcinoma, Pleomorphic Variant","C97051","A grade II invasive lobular carcinoma of the breast, characterized by the presence of neoplastic cells with large and atypical nuclei.","Invasive Breast Lobular Carcinoma, Pleomorphic Variant | Invasive Lobular Breast Carcinoma, Pleomorphic Variant | Invasive Lobular Breast Carcinoma, Pleomorphic Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273217","Invasive Breast Lobular Carcinoma, Solid Variant","C97052","A grade I invasive lobular carcinoma of the breast, characterized by the presence of neoplastic cells that form trabeculae and groups infiltrating collagen bundles.","Invasive Breast Lobular Carcinoma, Solid Variant | Invasive Lobular Breast Carcinoma, Solid Variant | Invasive Lobular Breast Carcinoma, Solid Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273218","Invasive Lobular Breast Carcinoma, Tubulolobular Variant","C97053","An invasive lobular carcinoma of the breast, characterized by the presence of neoplastic cells forming small tubular structures.","Invasive Breast Lobular Carcinoma, Tubulolobular Variant | Invasive Lobular Breast Carcinoma, Tubulolobular Variant | Invasive Lobular Breast Carcinoma, Tubulolobular Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0264856","Giant Cell Myocarditis","C97055","An often fatal inflammatory disorder that affects the myocardium. Morphologically, it is characterized by the presence of an inflammatory infiltrate in the myocardial tissue that includes multinucleated giant cells. It is often associated with the presence of an autoimmune disorder. Patients present with arrhythmias and/or heart failure. Heart transplantation is the only treatment option available.","Giant Cell Myocarditis | ",,,,,,,,,,,,,,,"4246167","Giant cell myocarditis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0342117","Colloid Nodule","C97056","A non-cancerous thyroid gland nodule that contains colloid material.","Colloid Nodule | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273219","Condyloma Acuminatum with Dysplasia","C97057","Condyloma acuminatum that is associated with the presence of dysplastic epithelial changes.","Condyloma Acuminatum with Dysplasia | Condyloma Acuminatum with Dysplasia | Condyloma with Dysplasia | Condyloma with Dysplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273220","Mixed Congenital Mesoblastic Nephroma","C97058","A congenital mesoblastic nephroma characterized by the presence of classic and cellular areas.","Mixed Congenital Mesoblastic Nephroma | Mixed Congenital Mesoblastic Nephroma | Mixed Congenital Mesoblastic Nephroma | Mixed Mesoblastic Nephroma | Mixed Mesoblastic Nephroma",,,,,,,,,,,,,,,"4237165","Mesoblastic nephroma, mixed",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0400990","Biliary Cyst","C97060","A cystic dilatation that occurs in any part of the biliary tree.","Biliary Cyst | ",,,,,,,,,,,,,,,"4340397","Cyst of biliary tract",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3273222","Metaplastic Synovial Cyst","C97061","A cyst lined by tissue that resembles synovial villi.","Metaplastic Synovial Cyst | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0265761","Laryngocele","C97062","A rare congenital malformation in the larynx. It is characterized by the presence of an air-filled sac within the laryngeal wall which may bulge on the neck.","Laryngocele | ",,,,,,,,,,,,,,,"4197544","Congenital laryngocele",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0345319","Paratubal Cyst","C97063","A cystic structure located between the ovary and fallopian tube.","Paratubal Cyst | Hydatid Cyst | Hydatid Cyst | Hydatid Cyst of Morgagni | Hydatid Cyst of Morgagni | Hydatid of Morgagni",,,,,,,,,,,,,,,"4005596","Cyst of hydatid of Morgagni",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0392775","Cystic Medial Necrosis","C97064","An idiopathic disorder characterized by the degeneration of the aortic media tissue and formation of cyst-like spaces. It may lead to aortic dissection.","Cystic Medial Necrosis | Familiar Thoracic Aortic Aneurysm",,,,,,,,,,,,,,,"4124849|4171209","Cystic adventitial disease|Cystic medial necrosis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3273223","Periosteal Desmoid Tumor","C97065","A reactive, benign fibrous lesion that develops in the periosteum of the femur.  It usually affects boys and there is a history of trauma.  It is characterized by the formation of dense collagen tissue and reactive bone.","Periosteal Desmoid Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0149882","Acute Esophagitis","C97066","An acute inflammatory process affecting the esophageal wall.","Acute Esophagitis | ",,,,,,,,,,,,,,,"26459","Acute esophagitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1443971","Chronic Esophagitis","C97067","A chronic inflammatory process affecting the esophageal wall.","Chronic Esophagitis | ",,,,,,,,,,,,,,,"4249567","Chronic esophagitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3273224","Adult Extramedullary Hematopoiesis","C97068","Extramedullary hematopoiesis occurring during adulthood.","Adult Extramedullary Hematopoiesis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1701938","Associated Pulmonary Arterial Hypertension","C97147","Pulmonary hypertension that results from another disorder (e.g., connective tissue disorder).","Associated Pulmonary Arterial Hypertension | APAH",,,,,,,,,,,,,,,"44783621","Associated pulmonary arterial hypertension",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029191","Orchitis","C97145","Inflammation of one or both testes due to viral or bacterial infections. Signs and symptoms include enlargement or tenderness of the affected testis, inguinal lymphadenopathy, blood in the semen, and pain during urination, intercourse, or ejaculation.","Orchitis | ",,,,,,,,,,,,,,,"4171915","Orchitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0238306","Arterionephrosclerosis","C97144","Scarring and atrophy of the renal cortex that occurs in hypertensive patients and in old age.","Arterionephrosclerosis | Benign Nephrosclerosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0259777","Ureteritis Cystica","C97143","A non-neoplastic lesion of the ureter characterized by the presence of multiple submucosal small cysts in the ureteral wall.  It is caused by inflammation due to urinary tract stones or infection.","Ureteritis Cystica | ",,,,,,,,,,,,,,,"199869","Pyeloureteritis cystica",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001361","Acute Tonsillitis","C97142","An acute inflammation of the tonsils caused by viruses or bacteria. Signs and symptoms include fever, enlargement of the tonsils, difficulty swallowing, and enlargement of the regional lymph nodes.","Acute Tonsillitis | ",,,,,,,,,,,,,,,"24660","Acute tonsillitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4012476","Extrahepatic Biliary Atresia","C97069","A congenital disorder characterized by blockage or absence of the extrahepatic bile ducts.","Extrahepatic Biliary Atresia | Congenital Extrahepatic Biliary Atresia",,,,,,,,,,,,,,,"4220532","Congenital atresia of extrahepatic bile duct",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1855284","Intrahepatic Biliary Atresia","C97070","A congenital disorder characterized by blockage or absence of the intrahepatic bile ducts.","Intrahepatic Biliary Atresia | Congenital Intrahepatic Biliary Atresia",,,,,,,,,,,,,,,"4109620","Intrahepatic biliary atresia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2673892","Ductal Plate Malformation","C97072","A congenital disorder of the intrahepatic bile ducts characterized by abnormal embryonal development of the ductal plates.","Ductal Plate Malformation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273225","Hereditary Neurodegenerative Disorder","C97073","An inherited disorder characterized by progressive degeneration and atrophy of the nervous system.","Hereditary Neurodegenerative Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037889","Hereditary Spherocytosis","C97074","An autosomal dominant inherited disorder characterized by the presence of smaller than normal, sphere-shaped erythrocytes. It results in hemolytic anemia and splenomegaly.","Hereditary Spherocytosis | ",,,,,,,,,,,,,,,"24909","Hereditary spherocytosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0410787","Hereditary Connective Tissue Disorder","C97075","An inherited genetic disorder that affects the connective tissues. Representative examples include Ehlers-Danlos syndrome and Marfan syndrome.","Hereditary Connective Tissue Disorder | Connective Tissue Hereditary Disorder",,,,,,,,,,,,,,,"4176799","Connective tissue hereditary disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3273226","Giant Cell Angioblastoma","C97076","A rare, slow-growing, locally aggressive soft tissue tumor characterized by the presence of oval to spindle cells forming concentric aggregates around small vessels.  Giant multinucleated cells are also present.","Giant Cell Angioblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1275592","Funisitis","C97077","An acute inflammation of the umbilical cord. It is characterized by the presence of polymorphonuclear cells migrating from the fetal umbilical cord vessels through the umbilical cord towards the bacteria containing amniotic fluid.","Funisitis | ",,,,,,,,,,,,,,,"4262612","Funisitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL449221","Benign Lymphoid Hyperplasia","C97078","A non-neoplastic proliferation of lymphocytes in lymph nodes and/or extranodal sites.","Reactive Lymphoid Hyperplasia | Benign Lymphoid Hyperplasia | Benign Lymphoid Hyperplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273227","Bronchial Epithelial Hyperplasia","C97079","Hyperplasia of the bronchial epithelial cells.  It is often associated with squamous metaplasia.","Bronchial Epithelial Hyperplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0399495","Denture-Induced Fibrous Hyperplasia","C97080","A benign fibrous hyperplasia in the oral mucosa caused by the prolonged wear of ill-fitting denture.","Denture-Induced Fibrous Hyperplasia | Epulis Fissuratum",,,,,,,,,,,,,,,"605699","Inflammatory fibroepithelial hyperplasia of oral mucous membrane caused by denture",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1265933","Diffuse Hyperplasia","C97081","Hyperplasia characterized by the presence of a diffuse cellular infiltrate.","Diffuse Hyperplasia | ",,,,,,,,,,,,,,,"4053536","Diffuse hyperplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0399439","Drug Induced Gingival Hyperplasia","C97082","Overgrowth of the gingival tissue caused by phenytoin, cyclosporine A, and calcium channel blockers.","Drug Induced Gingival Hyperplasia | ",,,,,,,,,,,,,,,"4244340","Drug-induced gingival hyperplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206067","Focal Epithelial Hyperplasia","C97083","Hyperplasia characterized by the presence of a focal proliferation of epithelial cells.","Focal Epithelial Hyperplasia | ",,,,,,,,,,,,,,,"4289100","Focal epithelial hyperplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3273228","Lymph Node Follicular Hyperplasia","C97084","Hyperplasia of the germinal centers resulting in the enlargement of the lymph node.","Lymph Node Follicular Hyperplasia | Follicular Hyperplasia | Follicular Lymph Node Hyperplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023869","Lithiasis","C97086","The formation of stones (calculi) in the body.","Lithiasis | ",,,,,,,,,,,,,,,"4278093","Lithiasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024214","Lymphangiectasia","C97087","Dilatation of the lymphatic vessels.","Lymphangiectasia | LYMPHANGIECTASIS",,,,,,,,,,,,,,,"4167819","Lymphangiectasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0149670","Carbohydrate Metabolism Disorder","C97089","An inherited or acquired disorder that affects the metabolism of the carbohydrates. Representative examples include diabetes mellitus, glycogen storage disease, mucopolysaccharidoses, and lactose intolerance.","Carbohydrate Metabolism Disorder | ",,,,,,,,,,,,,,,"437515","Disorder of carbohydrate metabolism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002514","Amino Acid Metabolism Disorder","C97090","An inherited disorder that affects the metabolism of the amino acids. Representative examples include alkaptonuria, homocystinuria, tyrosinemia, and phenylketonuria.","Amino Acid Metabolism Disorder | Disorder of Amino Acid Metabolism",,,,,,,,,,,,,,,"4096204|4178632|435774","Disorders of amino acid transport and metabolism|Inborn error of amino acid metabolism|Disorder of amino acid metabolism",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C3273230","Intermediary Metabolism Disorder","C97091","An inborn metabolic disorder affecting the intermediary metabolism process. It results in accumulation of substances in the body that can cause acute or chronic intoxication.","Intermediary Metabolism Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0154251","Lipid Metabolism Disorder","C97092","An inherited metabolic disorder caused by an enzyme deficiency, resulting in an inability to oxidize fatty acids for energy production.","Lipid Metabolism Disorder | ",,,,,,,,,,,,,,,"437530","Disorder of lipid metabolism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3149917","Lipodystrophy","C97093","A congenital or acquired disorder characterized by abnormal loss or redistribution of the adipose tissue in the body.","Lipodystrophy | Lipodsystrophic Syndromes",,,,,,,,,,,,,,,"134324","Lipodystrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3273231","Calcium Oxalate Crystal Deposition","C97094","A finding indicating the formation of calcium oxalate crystal deposits in an organ.","Calcium Oxalate Crystal Deposition | ",,,,,,,,,,,,,,,"762915","Deposition of calcium oxalate crystals",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032708","Porphyria","C97096","A group of genetic or acquired metabolic disorders characterized by defects in the enzymes that are involved in the heme synthesis.","Porphyria | ",,,,,,,,,,,,,,,"4305376","Porphyria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334039","Nephrogenic Metaplasia","C97097","A reactive metaplastic change in the urinary tract epithelium.  The metaplastic changes in the epithelium resemble renal tubular structures.  It can occur following surgical procedures, inflammation, stone formation, or trauma.","Nephrogenic Metaplasia | ",,,,,,,,,,,,,,,"4300071","Nephrogenic metaplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3273232","Cadmium Deposition","C97098","A finding indicating the presence of cadmium mineral deposits in an organ.","Cadmium Deposition | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0235950","Zinc Deficiency Disorder","C97099","A genetic or acquired metabolic disorder that is associated with zinc deficiency in the tissues.","Zinc Deficiency Disorder | ",,,,,,,,,,,,,,,"4029274","Zinc deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3273233","Muscle Cell Hypertrophy","C97100","A morphologic finding indicating the presence of enlarged muscle cells in a muscle tissue sample.","Muscle Cell Hypertrophy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3553854","Blindness","C97109","The lack of vision. It is caused by neurological or physiological factors.","Blindness | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037928","Spinal Cord Disorder","C97110","A non neoplastic or neoplastic disorder that affects the spinal cord.","Spinal Cord Disorder | ",,,,,,,,,,,,,,,"135526","Spinal cord disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0266493","Ecchordosis Physaliphora","C97111","A very rare, slow growing, usually asymptomatic hamartomatous lesion that arises from ectopic notochordal tissue.  Morphologically it is characterized by the presence of typical physaliphorous cells in a myxoid background.","Ecchordosis Physaliphora | ",,,,,,,,,,,,,,,"4288881","Ecchordosis physaliphora",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1959622","Passive Congestion","C97113","Tissue congestion due to the obstruction of venous blood flow return.","Passive Congestion | ",,,,,,,,,,,,,,,"4337139","Passive congestion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3273239","Proliferative Inflammatory Atrophy","C97114","A lesion in the prostate gland characterized by glandular atrophy, chronic inflammation, and epithelial hyperplasia. It has been suggested that it is a precancerous lesion and it may lead to the development of prostatic intraepithelial neoplasia and prostatic carcinoma.","Proliferative Inflammatory Atrophy | PIA | Prostate Proliferative Inflammatory Atrophy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333988","Pseudoepitheliomatous Hyperplasia","C97115","A benign lesion characterized by epidermal and adnexal epithelial hyperplasia.  It is caused by chronic inflammation and infection.  It may be associated with cutaneous neoplasms as well.","Pseudoepitheliomatous Hyperplasia | Pseudoepitheliomatous_Hyperplasia",,,,,,,,,,,,,,,"4012800|4112747","Pseudoepitheliomatous hyperplasia|Pseudoepitheliomatous hyperplasia",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0333161","Pseudocyst","C97117","A cyst-like structure that lacks an epithelial lining.","Pseudocyst | PSEUDOCYST",,,,,,,,,,,,,,,"4028351","Pseudocyst",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3273240","Pseudomonas-Related Vasculitis","C97118","A necrotizing vasculitis caused by Pseudomonas aeruginosa.","Pseudomonas-Related Vasculitis | Pseudomonas-Related_Vasculitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152171","Idiopathic Pulmonary Hypertension","C97119","Increased blood pressure in the arteries of the lungs; the etiology is unknown.","Idiopathic Pulmonary Hypertension | IPAH | Idiopathic Pulmonary Arterial Hypertension",,,,,,,,,,,,,,,"44782560","Idiopathic pulmonary arterial hypertension",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006288","Bronchopulmonary Sequestration","C97124","A rare congenital abnormality of the lungs. It consists of a mass of lung parenchyma that does not communicate with the bronchial tree and receives its blood supply from the systemic circulation instead of the pulmonary circulation.","Bronchopulmonary Sequestration | Congenital Sequestration of Lung | Pulmonary Sequestration | Sequestered Lobe (Pulmonary Sequestration)",,,,,,,,,,,,,,,"4088076","Congenital sequestration of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3273245","Acute Rejection","C97128","Rejection of a transplanted organ that usually occurs after the first week of the transplantation.  The risk of acute rejection is highest in the first three months following transplantation.  Morphologically, there is an inflammatory infiltrate composed of lymphocytes and neutrophils and vascular damage in the rejected tissue.","Acute Rejection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273251","Sclerosing Polycystic Adenosis","C97135","A rare, benign, well-circumscribed salivary gland neoplasm that predominantly affects females.  It is characterized by the presence of microcysts, ducts, and acini in a sclerotic stroma.  Focal lymphocytic infiltrates may also be present.","Sclerosing Polycystic Adenoma | Salivary Gland Sclerosing Polycystic Adenosis | Sclerosing Polycystic Adenosis | Sclerosing Polycystic Adenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035854","Rosacea","C97136","A chronic erythematous skin disorder that affects the face. It is characterized by the development of redness in the cheeks, nose, and/or forehead and telangiectasia. Sometimes, the erythematous changes may involve the eyelids.","Rosacea | Acne Rosacea",,,,,,,,,,,,,,,"136773","Rosacea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3273252","Squamous Metaplasia Without Atypia","C97137","A morphologic finding indicating the transformation of glandular or transitional epithelial cells to squamous epithelial cells that lack atypical features.","Squamous Metaplasia Without Atypia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1739148","Acute Synovitis","C97140","An acute inflammation of a synovial membrane. It is associated with swelling and pain in the affected area.","Acute Synovitis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039503","Tendonitis","C97141","Inflammation of a tendon, usually resulting from an overuse injury.  It is characterized by swelling of the tendon, tenderness around the inflamed tendon, and pain while moving the affected area of the body.","Tendonitis | ",,,,,,,,,,,,,,,"4147145","Tendinitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2830052","Ibrutinib","C81934","An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration, ibrutinib binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is required for B cell receptor signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies. The expression of BTK in tumor cells is also associated with increased proliferation and survival.","Ibrutinib | 2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)- | BTK Inhibitor PCI-32765 | BTK Inhibitor PCI-32765 | CRA 032765 | CRA-032765 | CRA032765 | IBRUTINIB | Imbruvica | PCI 32765 | PCI-32765 | PCI32765",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0358430","Muscle Relaxant","C29696","Any agent that relaxes skeletal muscles and reduces muscle contraction.","Muscle Relaxant | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230120","Anal Region","C32069","The area that includes the anus and the perianal skin.","Anal Region | ANAL REGION",,,,,,,,,,,,,,,"4219928","Anal region structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0278488","Stage IV Breast Cancer AJCC v6 and v7","C3995","Stage IV includes: Any T, Any N, M1.  M1: Distant metastasis. (AJCC 6th and 7th Eds.)","Stage IV Breast Cancer AJCC v6 and v7 | Breast Cancer Stage IV | Breast Carcinoma Stage IV | Stage IV Breast Cancer | Stage IV Breast Cancer | Stage IV Breast Cancer AJCC v6 | Stage IV Breast Cancer AJCC v7 | Stage IV Breast Carcinoma | stage IV breast cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512656","Immunocompetent","C28363","Having the ability to produce a normal immune response.","Immunocompetent | immunocompetent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030548","Total Parenteral Nutrition","C29484","Total parenteral nutrition formulated for intravenous administration in patients who cannot eat or cannot get enough nutrients from the foods they eat.  It is a liquid mixture of proteins, carbohydrates, fats, vitamins, minerals and other nutrients.","Total Parenteral Nutrition | TPN | hyperalimentation | parenteral nutrition | total parenteral nutrition",,,,,,,,,,,,,,,"4021169","Total parenteral nutrition",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023694","Infrared Photocoagulation Therapy","C62730","The use of an intense beam of light, such as a laser, to seal off blood vessels or destroy tissue.","Infrared Photocoagulation Therapy | INFRARED PHOTO COAGULATION | Infrared Coagulation | infrared coagulation | photocoagulation",,,,,,,,,,,,,,,"4045082|4274801","Photocoagulation - action|Photocoagulation",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0038587","Substance Withdrawal Syndrome","C35046","A substance-specific organic brain syndrome that follows the discontinuation of administration or use, or reduction in intake of an addictive substance, e.g. opioids, barbiturates and alcohol; amphetamines or similarly acting sympathomimetics; cocaine; nicotine; sedatives, hypnotics, or anxiolytics. Syndrome manifests with diverse, often painful physical and psychological symptoms, which include but not limited to intense drug craving, anxiety, depression, insomnia, nausea, perspiration, body aches, tremors, hallucinations, and convulsions.","Substance Withdrawal Syndrome | Drug Withdrawal | Withdrawal Syndrome",,,,,,,,,,,,,,,"37165425","Substance withdrawal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0558302","Sublingual","C89785","Beneath the tongue.","Sublingual | ",,,,,,,,,,,,,,,"4021639","Sublingual",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1515102","Swish and Spit Route of Administration","C38302","Administration of a liquid substance to the oral mucosa by swishing the drug inside the mouth for a certain amount of time then spiting it out. The drug action is mostly topical/local.","Swish and Spit Route of Administration | SWSP | Swish and Spit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515103","Swish and Swallow Route of Administration","C38303","Administration of a liquid substance to the oral mucosa by swishing the drug inside the mouth for a certain amount of time then allowed to be swallowed. The drug action is both topical and systemic","Swish and Swallow Route of Administration | SWSW | Swish and Swallow",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0179031","Ampule","C43165","A container capable of being hermetically sealed, intended to hold sterile materials.","Ampule | AMPULE | Ampoule",,,,,,,,,,,,,,,"45762934","Ampule",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL449030","Gallon","C48495","A traditional unit of volume used for measuring liquids and dry matter. Gallons of various sizes (predominantly in the range of 3.5 - 4.75 liters) have been used in different countries since Roman times.","Gallon | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347093","Medical Drop","C69442","A unit of volume equal to approximately 0.08333 milliliter (1 mL = 12 medical drops).","Medical Drop | Drop | [drp] | drops | gtt | {drop}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1631160","Microgram per Square Centimeter","C67311","A metric unit of areal density equal to approximately 2.94935E-4 ounce per square yard. Also used as a dose calculation unit.","Microgram per Square Centimeter | Microgram per Centimeter Squared | Microgram/Square Centimeter | mcg/cm2 | microgram per centimeter squared | ug/cm2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0560135","Electronvolt","C67278","A unit of energy defined as the kinetic energy acquired by an electron in passing through a potential difference of one volt in a vacuum. Its value is experimentally determined as 1,602 177 x 10E-19 joule (approximately). The unit is accepted for use with SI units.","Electronvolt | Electron Volt | eV | electronvolt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1371294","Carbohydrate Metabolism Alteration","C40630","A finding indicating a deficiency or excess in carbohydrate metabolism .","Carbohydrate Metabolism Alteration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003765","Arginine","C62008","An essential amino acid in juvenile humans, Arginine is a complex amino acid, often found at active site in proteins and enzymes due to its amine-containing side chain. Arginine may prevent or treat heart and circulatory diseases, combat fatigue, and stimulate the immune system. It also boosts production of nitric oxide, relaxing blood vessels, and treating angina and other cardiovascular problems. Arginine is also an important intermediate in the urea cycle and in detoxification of nitrogenous wastes. (NCI04)","Arginine | ARGININE | Amino-5-guanidino-pentanoic acid | Arg | L-Arginine | L-arginine | arginine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL432980","Erythroleukemia","C7152","Acute erythroid leukemia characterised by the presence of at least 50% erythroid precursors and at least 20% myeloblasts in the bone marrow.","Erythroleukemia | Erythroleukemia (Erythroid/Myeloid) | Erythroleukemia, Erythroid/Myeloid | M6A | M6a | erythroleukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826178","Acute Myeloid Leukemia with CEBPA Mutation","C82433","An acute myeloid leukemia with non-germline mutations of the CEBPA gene.","Acute Myeloid Leukemia with CEBPA Mutation | AML with Mutated CEBPA | AML with mutated CEBPA | Acute Myeloid Leukemia with Mutated CEBPA | Acute Myeloid Leukemia with Mutated CEBPA | Acute Myeloid Leukemia with Non-Germline Mutated CEBPA | Acute myeloid leukemia with mutated CEBPA | Non-Familial Acute Myeloid Leukemia with Mutated CEBPA",,,,,,,,,,,,,,,"35622696","Acute myeloid leukemia with CEBPA somatic mutations",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2826177","Acute Myeloid Leukemia with NPM1 Mutation","C82431","An acute myeloid leukemia with mutation of the nucleophosmin gene. It is usually associated with normal karyotype and frequently has myelomonocytic or monocytic features. It usually responds to induction therapy.","Acute Myeloid Leukemia with NPM1 Mutation | AML with Mutated NPM1 | AML with mutated NPM1 | Acute Myeloid Leukemia with Cytoplasmic Nucleophosmin | Acute Myeloid Leukemia with Mutated NPM1 | Acute Myeloid Leukemia with Mutated NPM1 | Acute myeloid leukemia with mutated NPM1 | NPMc+ AML",,,,,,,,,,,,,,,"45766616","Acute myeloid leukemia with mutated NPM1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2826173","Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15-MKL1","C82427","An acute myeloid leukemia associated with t(1;22)(p13.3;q13.1) resulting in the expression of RBM15-MKL1 fusion protein. It affects infants and children and usually shows megakaryocytic maturation.","Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15-MKL1 | AML (Megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 | AML (megakaryoblastic) with t(1;22) (p13;q13); RBM15-MKL1 | AML (megakaryoblastic) with t(1;22)(p13.3;q13.3); RBM15-MKL1 | Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15- MRTFA | Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15-MKL1 Fusion | Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15::MLK1 Fusion | Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15::MRTFA | Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.3); RBM15-MKL1 | Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 | Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 | Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1","9911/3","Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1",,,,,,,,,,,,,"42872942","Acute myeloid leukemia with RBM15::MKL1 fusion",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C2826172","Acute Myeloid Leukemia with inv(3) (q21.3;q26.2) or t(3;3) (q21.3;q26.2); GATA2, MECOM","C82426","An acute myeloid leukemia associated with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2) resulting in the reposition of a distal GATA2 enhancer to activate MECOM expression. It may present de novo or follow a myelodysplastic syndrome. The clinical course is aggressive.","Acute Myeloid Leukemia with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM | AML with MECOM Rearrangements | AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM | AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 | Acute Myeloid Leukemia with MECOM Rearrangements | Acute Myeloid Leukemia with inv(3) (q21.3;q26.2) or t(3;3) (q21.3;q26.2); GATA2, EVI1 | Acute Myeloid Leukemia with inv(3) (q21.3;q26.2) or t(3;3) (q21.3;q26.2); GATA2, MECOM | Acute Myeloid Leukemia with inv(3) (q21.3;q26.2) or t(3;3) (q21.3;q26.2); GATA2, MECOM | Acute Myeloid Leukemia with inv(3) (q21.3;q26.2) or t(3;3) (q21.3;q26.2); GATA2, MECOM(EVI1) | Acute Myeloid Leukemia with inv(3) (q21.3;q26.2) or t(3;3) (q21.3;q26.2); GATA2::MECOM | Acute Myeloid Leukemia with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2, EVI1 | Acute Myeloid Leukemia with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM(EVI1) | Acute Myeloid Leukemia with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2::MECOM | Acute Myeloid Leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 | Acute Myeloid Leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 | Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1","9869/3","Acute myeloid leukemia with inv(3)(q21;q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C2826169","Acute Myeloid Leukemia with t(6;9)(p22.3;q34.1); DEK-NUP214","C82423","An acute myeloid leukemia associated with t(6;9)(p22.3;q34.1) resulting in DEK-NUP214(CAN) fusion protein expression. It is often associated with multilineage dysplasia and basophilia. It affects both children and adults and it usually has an unfavorable clinical outcome.","Acute Myeloid Leukemia with t(6;9)(p22.3;q34.1); DEK-NUP214 | AML with t(6;9)(p23;q34); DEK-NUP214 | AML with t(6;9)(p23;q34);DEK-NUP214 | AML with t(6;9)(p23;q34.1);DEK-NUP214 | Acute Myeloid Leukemia with t(6;9) | Acute Myeloid Leukemia with t(6;9) (p22.3;q34.1); DEK-NUP214 | Acute Myeloid Leukemia with t(6;9) (p22.3;q34.1); DEK-NUP214 Fusion | Acute Myeloid Leukemia with t(6;9) (p22.3;q34.1); DEK::NUP214 Fusion | Acute Myeloid Leukemia with t(6;9) (p23;q34.1); DEK-NUP214 | Acute Myeloid Leukemia with t(6;9)(p22.3;q34); DEK-NUP214 | Acute Myeloid Leukemia with t(6;9)(p22.3;q34.1); DEK::NUP214 | Acute Myeloid Leukemia with t(6;9)(p23;q34); DEK-NUP214 | Acute Myeloid Leukemia with t(6;9)(p23;q34); DEK-NUP214 | Acute Myeloid Leukemia with t(6;9)(p23;q34.1); DEK::NUP214 | Acute myeloid leukemia with t(6;9)(p23;q34); DEK-NUP214","9865/3","Acute myeloid leukemia with t(6;9)(p23;q34); DEK-NUP214",,,,,,,,,,,,,"42872933","Acute myeloid leukemia with DEK::NUP214 fusion",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1541334","adult acute myeloid leukemia with 11q23 (MLL) abnormalities","C68696","An acute myeloid leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A occurring in adults.","Adult Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A | Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); MLLT3-KMT2A | Adult Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3 (AF9)-KMT2A | Adult Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A | Adult Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A Fusion | Adult Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-MLL | Adult Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3::KMT2A | Adult Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3::KMT2A Fusion | Adult Acute Myeloid Leukemia with t(9;11)(p21;q23); MLLT3-MLL | Adult Acute Myeloid Leukemia with t(9;11)(p21;q23); MLLT3::MLL | Adult Acute Myeloid Leukemia with t(9;11)(p22.3;q23.3); MLLT3-KMT2A | Adult Acute Myeloid Leukemia with t(9;11)(p22.3;q23.3); MLLT3::KMT2A | Adult Acute Myeloid Leukemia with t(9;11)(p22;q23); MLLT3-MLL | Adult Acute Myeloid Leukemia with t(9;11)(p22;q23); MLLT3-MLL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825114","Adult Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11","C68697","An acute myeloid leukemia with inv(16)(p13.1q22); CBFB-MYH11 occurring in adults.","Adult Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11 | Acute Myeloid Leukemia (AML) with inv(16)(p13.1q22); CBFB-MYH11 | Adult Acute Myeloid Leukemia with inv(16)(p13.1q22) | Adult Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11 Fusion | Adult Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB::MYH11 | Adult Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB::MYH11 Fusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0053523","Betamethasone Dipropionate","C47963","The 17,21-dipropionate ester of betamethasone, a synthetic glucocorticoid with metabolic, immunosuppressive and anti-inflammatory actions. Betamethasone dipropionate binds to specific intracellular glucocorticoid receptors and subsequently binds to DNA to modify gene expression. The synthesis of certain anti-inflammatory proteins is induced while the synthesis of certain inflammatory mediators is inhibited.  As a result, there is an overall reduction in chronic inflammation and autoimmune reactions.","Betamethasone Dipropionate | BETAMETHASONE DIPROPIONATE | Diprolene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0750848","Betamethasone Valerate","C47962","The 17-valerate ester of betamethasone, a synthetic glucocorticoid with metabolic, immunosuppressive and anti-inflammatory actions. Betamethasone valerate binds to specific intracellular glucocorticoid receptors and subsequently binds to DNA to modify gene expression. The synthesis of certain anti-inflammatory proteins is induced while the synthesis of certain inflammatory mediators is inhibited. As a result, there is an overall reduction in chronic inflammation and autoimmune reactions.","Betamethasone Valerate | BETAMETHASONE VALERATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011705","Desonide","C61702","A synthetic glucocorticosteroid for topical use, with anti-inflammatory activity. Desonide binds to glucocorticoid receptors in the cytoplasm, and the ligand-receptor complex is translocated as a homodimer into the nucleus, where transcription activation via glucocorticoid response elements within glucocorticoid-responsive genes occur. This agent induces transcription of genes coding for anti-inflammatory proteins, including lipocortin-1, interleukin-10, interleukin-1 receptor antagonist and neutral endopeptidase. Increased synthesis of lipocortin-1 has an inhibitory effect on phospholipase A2, which in turn inhibits the release arachidonic acid, thereby controlling the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.","Desonide | DESONIDE | Desonate | Verdeso",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011707","Desoximetasone","C47477","A synthetic glucocorticoid receptor agonist with metabolic, anti-inflammatory and immunosuppressive activity. Desoximetasone activates specific intracellular receptors, which bind to distinct sites on DNA to modify gene transcription. This results in an induction of the synthesis of anti-inflammatory proteins and suppression of the synthesis of inflammatory mediators. This leads to an overall reduction in chronic inflammation and autoimmune reactions. Desoximetasone is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.","Desoximetasone | 9-Fluoro-11-beta,21-dihydroxy-16-alpha-methylpregna-1,4-diene-3,20-dione | DESOXIMETASONE | Topicort | Topicort LP | Topsilon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0720464","Diflorasone Diacetate","C47488","The acetate salt form of diflorasone, a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties. Like other glucocorticoids, diflorasone enters the cell by diffusion across the cell membrane and binds to the glucocorticoid receptor (GR) in the cytoplasm. The receptor complex subsequently translocates to the nucleus and activates or represses genes by interacting with short, palindromic DNA sequences called glucocorticoid response element (GRE). Gene activation leads to the exertion of anti-inflammatory effects, e.g. upregulation of IkappaB, while gene repression inhibits production of pro-inflammatory cytokines such as interleukin-1 (IL-1), IL-2 and IL-6, thereby preventing activation of cytotoxic T-lymphocytes.","Diflorasone Diacetate | 6alpha,9-Difluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17,21-Diacetate | 6alpha-Fluorobetamethasone-17,21 Diacetate | DIFLORASONE DIACETATE | Florone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0098735","Halobetasol Propionate","C47553","The propionate salt form of halobetasol, a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictor activities. Halobetasol, a topical steroid, diffuses across cell membranes to interact with cytoplasmic corticosteroid receptors located in both the dermal and intradermal cells, thereby activating gene expression of anti-inflammatory proteins mediated via corticosteroid receptor response element. Specifically, this agent induces phospholipase A2 inhibitory proteins, which inhibit the release of arachidonic acid, thereby inhibiting the biosynthesis of potent mediators of inflammation, such as prostaglandins and leukotrienes. As a result, halobetasol reduces edema, erythema, and pruritus through its cutaneous effects on vascular dilation and permeability.","Halobetasol Propionate | 21-Chloro-6alpha,9-difluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate | HALOBETASOL PROPIONATE | Ultravate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0051556","Amcinonide","C47389","A synthetic glucocorticoid receptor agonist that mimics the metabolic, anti-inflammatory, and immunosuppressive activity of the natural glucocorticoids. Amcinonide interacts with specific corticosteroid receptors and was internalized, which leads to binding of DNA and modification of gene expression. This results in synthesis of anti-inflammatory mediators while inhibiting synthesis of inflammatory mediators. Consequently, an overall reduction in chronic inflammation and autoimmune reactions are achieved.","Amcinonide | 1,4-Pregnadiene-2,20-dione-16,17-cyclopentylidenedioxy-9-fluoro-11,21-dihydroxy-21-acetate | AMCINONIDE | CL 34699 | Cyclocort | Triamcinolonacetatcyclopentanonid | Visderm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0733757","Halcinonide","C47552","A topical, synthetic glucocorticoid with anti-inflammatory and anti-allergic properties. Halcinonide exerts its effect by interacting with specific intracellular receptors, and the ligand-receptor complex subsequently modulates gene expressions via the typical glucocorticoid signalling pathway. This results in the synthesis of certain anti-inflammatory proteins as well as in synthesis inhibition of certain inflammatory mediators. Consequently, an overall reduction in chronic inflammation and autoimmune reactions are accomplished. (NCI05)","Halcinonide | 21-Chloro-9-fluoro-11beta,16alpha,17-trihydroxypregn-4-ene-3,20-dione Cyclic 16,17-Acetal with Acetone | HALCINONIDE | Halciderm | Halcort | Halog | Pregn-4-ene-3,20-dione, 21-chloro-9-fluoro-11-hydroxy-16,17-((1-methylethylidene)bis(oxy))-,(11beta,16alpha)- | Volog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040866","Triamcinolone Acetonide","C48027","The acetonide salt form of triamcinolone, a synthetic glucocorticosteroid with immunosuppressive and anti-inflammatory activity. Triamcinolone acetonide binds to specific cytosolic glucocorticoid receptors and subsequently interacts with glucocorticoid receptor response element on DNA and alters gene expression. This results in an induction of the synthesis of certain anti-inflammatory proteins while inhibiting the synthesis of certain inflammatory mediators. Consequently, an overall reduction in chronic inflammation and autoimmune reactions are accomplished.","Triamcinolone Acetonide | 9-alpha-Fluoro-11-beta,21-dihydroxy-16-alpha-isopropylidenedioxy-1,4-pregnadiene,3,20-dione | AllerNaze | Aristocort A | Kenalog | Nasacort | ReadySharp Triamcinolone | TRIAMCINOLONE ACETONIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0051113","Alclometasone Dipropionate","C47385","The dipropionate salt form of alclometasone, a synthetic corticosteroid with low to medium potency. Alclometasone dipropionate is a glucocorticoid receptor agonist that mimics the metabolic, anti-inflammatory, immunosuppressive, antipruritic, and vasoconstrictive effects of natural glucocorticoids. This drug interacts with specific intracellular receptors and binds to DNA to modify gene expression. This results in an induction of synthesis of certain proteins while inhibiting the synthesis of others. Alclometasone dipropionate is used for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. (NCI05)","Alclometasone Dipropionate | (7alpha,11beta,16alpha)-7-Chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)pregna-1,4-diene-3,20-dione | 7a-Chloro-11b,17,21-trihydroxy-16a-methylpregna-1,4-diene-3,20-dione-17,21-dipropionate | ALCLOMETASONE DIPROPIONATE | Aclovate | BRN 2317658 | Delonal | Vaderm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0736448","Wall of Body of Uterus","C41270","Wall of body of uterus is composed of three layers: endometrium, myometrium, and perimetrium. Endometrium is the inner mucosal layer lining and is covered with columnar epithelium and tubular glands. Myometrium is a thick, muscular layer, consisting largely of bundles of smooth muscle fibers arranged in longitudinal, circular, and spiral patterns, and interlaced with connective tissue. Perimetrium is the outer layer composed of the peritoneal layer of the broad ligament that covers the body of the uterus and part of the cervix.","Wall of Body of Uterus | UTERINE WALL | Uterus Wall",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0352536","Hydrocortisone Butyrate","C48022","The butyrate salt form of hydrocortisone, a synthetic glucocorticoid receptor agonist with antiinflammatory, antipruritic and vasoconstrictive effects. Binding and activation of the glucocorticoid receptor results in the activation of lipocortin that in turn inhibits cytosolic phospholipase A2. Lack of phospholipase A2 prevents the release of arachidonic acid, precursor for inflammatory mediator prostaglandins and leukotrienes, from the cell membrane. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leading to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.","Hydrocortisone Butyrate | 11-beta,17-alpha,21-Trihydroxy-4-pregnene-3,20-dione 17-alpha-butyrate | HYDROCORTISONE BUTYRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0063079","Hydrocortisone Valerate","C48024","The valerate salt form of hydrocortisone, a synthetic glucocorticoid receptor agonist with antiinflammatory, antipruritic and vasoconstrictive effects. Binding and activation of the glucocorticoid receptor results in the activation of lipocortin that in turn inhibits cytosolic phospholipase A2. Lack of phospholipase A2 prevents the release of arachidonic acid, precursor for inflammatory mediator prostaglandins and leukotrienes, from the cell membrane. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.","Hydrocortisone Valerate | 11beta,17,21-Trihydroxypregn-4-ene-3,20-dione 17-Valerate | HYDROCORTISONE VALERATE | Westcort",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0063077","Hydrocortisone Acetate","C61785","The synthetic acetate ester form of hydrocortisone, a corticosteroid with anti-inflammatory and immunosuppressive properties. Hydrocortisone acetate initially binds to the cytoplasmic glucocorticoid receptor; then the receptor-ligand complex is translocated to the nucleus where it initiates the transcription of genes encoding for anti-inflammatory mediators, such as cytokines and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes.","Hydrocortisone Acetate | HYDROCORTISONE ACETATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1099414","Pimecrolimus","C47671","A 33-epi-chloro-derivative of the ascomycin macrolactam with immunosuppressant property. Pimecrolimus binds to the receptor macrophilin-12 (FKBP-12) forming a complex that blocks the calcium-dependent signal transduction cascade mediated by calcineurin. Via dephosphorylation, calcineurin is the enzyme responsible for activating nuclear factor of activated T-cells (NF-AT), a T cell transcriptional regulatory factor. As a consequence, the synthesis and release of Th1- (T helper 1) and Th2- (T helper 2) type cytokines, and other inflammatory mediators from T-cells and mast cells are blocked and the expression of signals essential for the activation of inflammatory T-lymphocytes is inhibited. However, pimecrolimus mode of action is cell-selective and does not affect Langerhans' cells/dendritic cells and primary fibroblasts.","Pimecrolimus | 15,19-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone, 3-((1E)-2-((1R,3R,4S)-4-chloro-3-methoxycyclohexyl)-1-methylethenyl)-8-ethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-14,16-dimethoxy-4,10,12,18-tetramethyl-,(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)- | 33-epi-Chloro-33-desoxyascomycin | Elidel | PIMECROLIMUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1273024","Flumethasone Pivalate","C65718","No Value Exists","Flumethasone Pivalate | FLUMETHASONE PIVALATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983781","Orteronel","C90582","An orally bioavailable non-steroidal androgen synthesis inhibitor of steroid 17alpha-monooxygenase (17,20 lyase) with potential antiandrogen activity. TAK-700 binds to and inhibits the steroid 17alpha-monooxygenase in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells. The cytochrome P450 enzyme CYP17A1 (P450C17), localized to the endoplasmic reticulum (ER), exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces steroidal hormones, such as progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens.","Orteronel | 6-((7S)-7-hydroxy-6,7-dihydro-5h-pyrrolo(1,2-c)imidazol-7-yl)-N-methyl-2-naphthalenecarboxamide | Androgen Synthesis Inhibitor TAK-700 | CYP17A1 Lyase Inhibitor TAK-700 | ORTERONEL | Steroid 17alpha-monooxygenase TAK-700 | TAK 700 | TAK-700 | TAK700",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1702299","Interleukin-1 Alpha, Human","C20521","Interleukin-1 alpha (271 aa, ~31 kDa) is encoded by the human IL1A gene. This protein is involved in B-cell maturation and proliferation, thymocyte proliferation and the stimulation of inflammation.","Interleukin-1 Alpha | Hematopoietin-1 | IL-1 Alpha | IL-1-a | IL-1-alpha | IL-1A | IL-1alpha | IL1 | IL1-Alpha | IL1A | IL1A Protein | IL1F1 | Interleukin 1, Alpha | Interleukin 1-Alpha | Interleukin-1-Alpha | Interleukin-1-Alpha | Preinterleukin 1 Alpha | Pro-Interleukin-1-Alpha | interleukin-1-alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334102","IL12B Gene","C24495","This gene is involved in immunity/defense via the stimulation of both T cells and natural killer cells. It also plays a role in cell differentiation.","IL12B Gene | IL12B | Interleukin 12B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1701815","IL12A protein, human","C28508","Interleukin-12 subunit alpha (219 aa, ~25 kDa) is encoded by the human IL12A gene. This protein plays a role in cytokine signaling in both T-cells and natural killer cells.","Interleukin-12 Subunit Alpha | CLMF | CLMF p35 | Cytotoxic Lymphocyte Maturation Factor | Cytotoxic Lymphocyte Maturation Factor 1, p35 | Cytotoxic Lymphocyte Maturation Factor 35 kDa Subunit | IL-12, subunit p35 | IL-12A | IL12 Subunit P35 | IL12, Subunit P35 | IL12A | IL12A Protein | IL35 Subunit | IL35 Subunit A | Interleukin 12A | Interleukin 12A (Natural Killer Cell Stimulatory Factor 1, Cytotoxic Lymphocyte Maturation Factor 1, p35) | Interleukin 12A Precursor | Interleukin-12 Alpha Chain | Interleukin-12 Alpha Chain Precursor | Interleukin-12A | Interleukin-12A | NF Cell Stimulatory Factor Chain 1 | NFSK | NKSF1 | Natural Killer Cell Stimulatory Factor 1, 35 kD Subunit | Natural Killer Cell Stimulatory Factor, 35 kD Subunit | Natural Killer Cell Stimulatory Factor, 35-kD Subunit | interleukin 12, p35",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1530116","STAT3 protein, human","C28664","Signal transducer and activator of transcription 3 (770 aa, ~88 kDa) is encoded by the human STAT3 gene. This protein plays a role in cytokine signaling and gene expression.","Signal Transducer and Activator of Transcription 3 | APRF | Acute-Phase Response Factor | STAT3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332710","CD34 Gene","C21003","This gene is involved in hematopoiesis; however, a specific physiological function has yet to be identified.","CD34 Gene | CD34 | CD34 Antigen Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273494","Fill Out Form","C97566","Enter requested information onto a form.","Fill Out Form | Fill In | Fill In Form | Fill Out",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008803","Cinnarizine","C76060","No Value Exists","Cinnarizine | 1-(Diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine | 1-Benzhydryl-4-cinnamylpiperazin | 1-Cinnamyl-4-(diphenylmethyl)piperazine | Aplactan | CINNARIZINE | Cinnageron | MD516 | Votegol | Zepamol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417199","MMP1 Gene","C41043","This gene plays a role in cell migration, inflammation and the regulation of extracellular matrix remodeling.","MMP1 Gene | MMP1 | Matrix Metalloproteinase 1 (Interstitial Collagenase) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0718050","Sevelamer","C84172","A non-absorbable polymeric amine and phosphate binding agent that can be used to prevent hyperphosphatemia. Upon oral administration, the amine groups in sevelamer become protonated in the intestines and bind to the dietary phosphate groups in the gastrointestinal (GI) tract, thereby preventing the absorption of phosphate and controlling phosphate plasma levels. In addition, sevelamer, as a phosphate binder, can be used to prevent the absorption of the radionuclide phosphorus P 32 (P-32).","Sevelamer | 2-Propen-1-amine, Polymer with (Chloromethyl)oxirane | Allylamine Polymer with 1-Chloro-2,3-epoxypropane | Allylamine-epichlorohydrin Copolymer | SEVELAMER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025242","Memantine","C73269","A low-affinity, voltage-dependent, noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. Memantine binds to and inhibits cation channels of glutamanergic NMDA receptors located in the central nervous system (CNS), preventing the prolonged influx of calcium ions and the associated neuronal excitotoxicity, and thereby potentially enhancing cognitive function. Memantine is also a 5-hydroxytryptamine type 3 (5HT3) receptor and nicotinic receptor antagonist.","Memantine | MEMANTINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0051336","Alpha-carotene","C68304","Carotenoid consisting of a cyclic structure on each end with additional double bonds at the number 5 and 4' carbon atoms of the cyclic structures.","Alpha-carotene | (6'R)-beta, epsilon-carotene | .ALPHA.-CAROTENE | 3,7,12,16-tetramethyl-1-(2,6,6-trimethyl-1-cyclohexenyl)-18-(2,6,6-trimethyl-1-cyclohex-2-enyl)-octadeca-1,3,5,7,9,11,13,15,17-nonaene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007271","Carotenoid","C351","A class of hydrocarbons (carotenes) and their oxygenated derivatives which exhibit chemopreventive properties.  Carotenoids are pigments found in green, yellow, and leafy vegetables, and yellow fruits. The pigments are fat-soluble, unsaturated aliphatic hydrocarbons functioning as provitamins and are converted to vitamin A through enzymatic processes in the intestinal wall.","Carotenoid | Carotenoids | Carotenoids (NOS) | carotenoid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0896117","Beta-cryptoxanthin","C68306","Carotenoid having a chemical structure similar to beta-carotene with addition of a hydroxyl group at the number 3 carbon atom.","Beta-cryptoxanthin | 3,5,5-trimethyl-4-[3,7,12,16-tetramethyl-18-(2,6,6-trimethyl-1-cyclohexenyl) octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-cyclohex-3-en-1-ol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273525","Architecture and Engineering Occupations","C97624","A class of professional or vocational positions of employment that involve architecture or engineering.","Architecture and Engineering Occupations | Architecture and Engineering",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273526","Arts, Design, Entertainment, Sports and Media Occupations","C97625","A class of professional or vocational positions of employment that involve arts, design, entertainment, sports or media.","Arts, Design, Entertainment, Sports and Media Occupations | Arts, Design, Entertainment, Sports and Media",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL783625","Building and Grounds Cleaning and Maintenance Occupations","C97626","A class of professional or vocational positions of employment that involve building and grounds clearing or maintenance.","Building and Grounds Cleaning and Maintenance Occupations | Building and Grounds Cleaning and Maintenance | Building and Grounds Clearing and Maintenance | Building and Grounds Clearing and Maintenance Occupations",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273529","Community and Social Services Occupations","C97628","A class of professional or vocational positions of employment that involve community or social services.","Community and Social Services Occupations | Community and Social Services",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273530","Computer and Mathematical Occupations","C97629","A class of professional or vocational positions of employment that involve computers or math.","Computer and Mathematical Occupations | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273531","Construction and Extraction Occupations","C97630","A class of professional or vocational positions of employment that involve construction or extraction.","Construction and Extraction Occupations | Construction and Extraction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273532","Education, Training and Library Occupations","C97631","A class of professional or vocational positions of employment that involve education, training or libraries.","Education, Training and Library Occupations | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273533","Farming, Fishing, and Forestry Occupations","C97632","A class of professional or vocational positions of employment that involve farming, fishing or forestry.","Farming, Fishing, and Forestry Occupations | Agricultural, Forestry and Fishery Laborer | Agricultural, Forestry and Fishery Labourers | Farming, Fishing, and Forestry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273534","Food Preparation and Serving, Related Occupations","C97633","A class of professional or vocational positions of employment that involve food preparation or serving.","Food Preparation and Serving, Related Occupations | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273535","Healthcare Practitioners and Technical Occupations","C97634","A class of professional or vocational positions of employment that involve healthcare practice or technical operations.","Healthcare Practitioners and Technical Occupations | Specialist/Technologist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273536","Healthcare Support Occupations","C97635","A class of professional or vocational positions of employment that involve healthcare support.","Healthcare Support Occupations | Healthcare Support",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273537","Installation, Maintenance and Repair Occupations","C97636","A class of professional or vocational positions of employment that involve installation, maintenance or repair.","Installation, Maintenance and Repair Occupations | Installation, Maintenance and Repair",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1277117","Legal Occupations","C97637","A class of professional or vocational positions of employment that involve legal activities.","Legal Occupations | Legal Professional | Legal Professionals",,,,,,,,,,,,,,,"4153434","Law occupation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3273538","Life, Physical, and Social Science Occupations","C97638","A class of professional or vocational positions of employment that involve life, physical or social sciences.","Life, Physical, and Social Science Occupations | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273539","Management Occupations","C97639","A class of professional or vocational positions of employment that involve management.","Management Occupations | Management",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273540","Office and Administrative Support Occupations","C97640","A class of professional or vocational positions of employment that involve office or administrative support.","Office and Administrative Support Occupations | Office and Administrative Support",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273541","Personal Care and Service Occupations","C97641","A class of professional or vocational positions of employment that involve personal care or service.","Personal Care and Service Occupations | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273542","Production Occupations","C97642","A class of professional or vocational positions of employment that involve production.","Production Occupations | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600092","Protective Service Occupations","C97643","A class of professional or vocational positions of employment that involve protective services.","Protective Service Occupations | Protective Services | Protective Services Worker | Protective Services Workers",,,,,,,,,,,,,,,"4023489|4203585","Protective service worker|Protective services occupation",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3273543","Sales and Related Occupations","C97644","A class of professional or vocational positions of employment that involve sales or related activities.","Sales and Related Occupations | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273544","Transportation and Material Moving Occupations","C97645","A class of professional or vocational positions of employment that involve transportation or material moving.","Transportation and Material Moving Occupations | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026126","Military Occupation","C97647","An employment class consisting of all persons employed in the military.","Military Occupation | ",,,,,,,,,,,,,,,"4118810","Military personnel",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL421480","CXCR4 inhibitor POL6326","C91094","An orally bioavailable inhibitor of CXC chemokine receptor 4 (CXCR4) with receptor binding and hematopoietic stem cell-mobilization activities. Balixafortide binds to the chemokine receptor CXCR4, thereby preventing the binding of stromal derived factor-1 (SDF-1 or CXCL12) to the CXCR4 receptor and subsequent receptor activation. This may induce the mobilization of hematopoietic stem and progenitor cells from the bone marrow into blood. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types; CXCL12/CXCR4 interaction induces retention of hematopoietic cells in the bone marrow.","Balixafortide | Ala-cys-ser-ala-pro-arg-tyr-cys-tyr-gln-lys-pro-pro-tyr-his Cyclic (2->9)-disulfide | BALIXAFORTIDE | CXCR4 Inhibitor POL6326 | POL6326",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0380056","anti-Mullerian hormone type II receptor","C21334","Anti-Muellerian hormone type-2 receptor (573 aa, ~63 kDa) is encoded by the human AMHR2 gene. This protein plays a role in signaling, serine/threonine phosphorylation and ligand binding.","Anti-Muellerian Hormone Type-2 Receptor | AMH Type II Receptor | AMHR | AMHR2 | Anti-Mullerian Hormone Receptor | Anti-Mullerian Hormone Receptor Type II | Anti-Mullerian Hormone Receptor Type II | Anti-Mullerian Hormone Type II Receptor | EC 2.7.11.30 | MIS Type II Receptor | MISRII | MRII",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3849882","EC 2.7.1.112","C28496","Vascular endothelial growth factor receptor 2 (1356 aa, ~152 kDa) is encoded by the human KDR gene. This protein is involved in ligand-dependent signaling, vasculogenesis and tyrosine phosphorylation.","Vascular Endothelial Growth Factor Receptor 2 | Antigen CD309 | CD309 | CD309 Antigen | EC 2.7.1.112 | EC 2.7.10.1 | FLK-1 | Fetal Liver Kinase 1 | KDR | Kinase Insert Domain Receptor | Kinase Insert Domain Receptor (A Type III Receptor Tyrosine Kinase) | Protein-Tyrosine Kinase Receptor Flk-1 | VEGFR-2 | VEGFR2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1568520","Vascular Endothelial Growth Factor Receptor 1, Human","C17975","Vascular endothelial growth factor receptor 1 (1338 aa, ~151 kDa) is encoded by the human FLT1 gene. This protein is involved in angiogenesis, tyrosine phosphorylation, ligand binding and signal transduction.","Vascular Endothelial Growth Factor Receptor 1 | EC 2.7.10.1 | FLT | FLT-1 | FLT1 | Flt-1 | Fms-Like Tyrosine Kinase 1 | Receptor Tyrosine Kinase,Class V | Tyrosine Protein Kinase FRT | Tyrosine Protein Kinase Receptor FLT | Tyrosine-Protein Kinase FRT | Tyrosine-Protein Kinase Receptor FLT | VEGFR | VEGFR-1 | VEGFR1 | Vascular Endothelial Growth Factor Receptor | Vascular Permeability Factor Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL964236","KIT protein, human","C17328","Mast/stem cell growth factor receptor Kit (976 aa, ~110 kDa) is encoded by the human KIT gene. This protein is involved in cell survival, tyrosine phosphorylation and ligand-mediated signaling.","Mast/Stem Cell Growth Factor Receptor Kit | Antigen CD117 | C-KIT | CD117 | CD117 Antigen | EC 2.7.10.1 | KIT | KIT (CD117) | Mast Cell Growth Factor Receptor | PBT | Piebald Trait Protein | Proto-Oncogene Tyrosine-Protein Kinase Kit | Proto-Oncogene c-Kit | SCF Receptor | SCFR | Stem Cell Factor Receptor | Stem Cell Factor Receptor | Tyrosine-Protein Kinase Kit | c-kit receptor | p145 c-kit | stem cell factor receptor | v-kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2919031","Division (action)","C86065","The process of separation into parts. The term may be used to indicate rather specific separation into equal parts, or division along boundaries that are considered attractive for some reason.","Division | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079717","Integrin AlphaL/Beta2","C97746","Integrin alphaL/beta2 is a protein complex comprised of a heterodimer of integrin alphaL and integrin beta2. This complex is involved in leukocyte adhesion, cytolysis, helper T-cell interactions, and antibody-dependent killing by natural killer cells and granulocytes.","Integrin AlphaL/Beta2 | Alpha-L/Beta-2 | AlphaL/Beta2 | CD11a/CD18 | Integrin Alpha-L/Beta-2 | Integrin AlphaLBeta2 | LFA 1 | LFA-1 | LFA1 | Lymphocyte Function-Associated Antigen 1 | Lymphocyte Function-Associated Antigen-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0209606","Integrin Alpha4/Beta1","C97745","Integrin alpha4/beta1 is a protein complex comprised of a heterodimer of integrin alpha4 and integrin beta1. This complex plays a role in cell-cell adhesion, cell-matrix adhesion, inflammation, hematopoietic cell homing and immune system function.","Integrin Alpha4/Beta1 | Alpha-4/Beta-1 | Alpha4/Beta1 | Alpha4Beta1 Integrin | CD49d-CD29 | CD49d/CD29 | Integrin Alpha-4/Beta-1 | Integrin alpha4beta1 | VLA-4 | VLA-4 Receptor | VLA4 | Very Late Activation Antigen-4 | Very Late Antigen-4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441765","Stage 0is","C27965","Cancer confined to the epithelium with formation of a flat surface without invasion of the basement membrane.","Stage 0is | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441764","Stage 0a","C27964","Cancer confined to the epithelium with formation of papillary structures without invasion of the basement membrane or noninvasive localized squamous cell carcinoma.","Stage 0a | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221205","Yellow","C48330","The hue of that portion of the visible spectrum lying between orange and green, evoked in the human observer by radiant energy with wavelengths of approximately 570 to 590 nanometers; any of a group of colors of a hue resembling that of ripe lemons and varying in lightness and saturation.","Yellow | YELLOW",,,,,,,,,,,,,,,"4153953","Yellow color",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085105","Breast Self-Examination","C70551","Procedure where the individual examines their own breasts for lumps and other changes.","Breast Self-Examination | BSE | Breast Self-Surveillance | breast self-exam",,,,,,,,,,,,,,,"4257684","Breast self-examination",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037114","Silicone","C28189","A synthetic gel that is used as an outer coating on breast implants and as the inside filling of some implants.","Silicone | silicone",,,,,,,,,,,,,,,"4030112","Silicone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516834","Employment Opportunities","C19463","Jobs available at NCI","Employment Opportunities | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828242","Saracatinib","C48378","An orally available 5-, 7-substituted anilinoquinazoline with anti-invasive and anti-tumor activities. Saracatinib is a dual-specific inhibitor of Src and Abl, protein tyrosine kinases that are overexpressed in chronic myeloid leukemia cells. This agent binds to and inhibits these tyrosine kinases and affects cell motility, cell migration, adhesion, invasion, proliferation, differentiation, and survival. Specifically, Saracatinib inhibits Src kinase-mediated osteoclast bone resorption.","Saracatinib | 4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- | AZD0530 | N-(5-Chloro-1,3-Benzodioxol-4-Yl)-7-(2-(4-Methylpiperazin-1-yl)Ethoxy)-5-((Oxan-4-yl)Oxy)Quinazolin-4-Amine | SARACATINIB | SRC Kinase Inhibitor AZD0530",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040507","Total Hepatectomy","C51781","Surgical removal of the entire liver.","Total Hepatectomy | ",,,,,,,,,,,,,,,"4066035","Total hepatectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1156200","Histone Acetylation","C20740","Histone Acetylation involves covalent linkage of acetyl groups to highly basic histone proteins associated with DNA, particularly in active chromatin, and may be involved in regulation of gene expression.","Histone Acetylation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349075","Unit per Milligram of Creatinine","C73781","An arbitrary unit of substance concentration expressed in unit(s) per milligram of creatinine.","Unit per Milligram of Creatinine | U/mg creat | Unit/Milligram of Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0854924","Endometrial Serous Adenocarcinoma","C27838","A high-grade, aggressive adenocarcinoma arising from the endometrium. It is characterized by the presence of complex papillary patterns with cellular budding. Atypical mitoses, necrosis, and psammoma bodies may be present. It is classified as type II endometrial carcinoma and it is not associated with endometrial hyperplasia. It tends to invade deeply into the myometrium and spreads into the lymphatic vessels. Patients frequently present with spread of the tumor beyond the uterus at the time of diagnosis. The prognosis is usually poor.","Endometrial Serous Adenocarcinoma | Serous endometrial adenocarcinoma | Uterine Corpus Serous Adenocarcinoma | Uterine Papillary Serous Carcinoma | Uterine Serous Adenocarcinoma | Uterine Serous Carcinoma | Uterine Serous Papillary Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027753","Nerve Growth Factor beta Subunit","C20444","Beta-nerve growth factor (241 aa, ~27 kDa) is encoded by the human NGF gene. This protein plays a role in both the maintenance and differentiation of sympathetic and sensory neurons.","Beta-Nerve Growth Factor | Beta-NGF | NGF | Nerve Growth Factor | Nerve Growth Factor | Nerve Growth Factor 1 | Nerve Growth Factor, Beta Subunit | nerve growth factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0064332","Keyhole Limpet Hemocyanin","C1139","A natural protein isolated from the marine mollusc keyhole limpet.  Keyhole limpet hemocyanin is an immunogenic carrier protein that, in vivo, increases antigenic immune responses to haptens and other weak antigens such as idiotype proteins. (NCI04)","Keyhole Limpet Hemocyanin | KEYHOLE LIMPET HEMOCYANIN | KLH | keyhole limpet hemocyanin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512317","HPV 16 E6 (18-26) Peptide","C38117","A peptide derived from the oncogenic human papillomavirus (HPV) early gene product E6.  The HPV 16 transforming protein E6 is expressed in precancerous and malignant cervical lesions and has a high affinity for the most common human lymphocyte antigen (HLA), HLA-A2.  Immunogenic peptides from the HPV 16 E6 may be used to trigger a T-cell-mediated immune response to HPV. (NCI04)","HPV 16 E6 (18-26) Peptide | HPV 16 E6:18-26",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0133938","E6 protein, Human papillomavirus type 16","C1397","Protein E6 (158 aa, ~19 kDa) is encoded by the human papillomavirus type 16 E6 gene. This protein is involved in both transcriptional activation and degradation of cellular tumor antigen p53.","Protein E6, Human Papillomavirus Type 16 | HPV 16 E6 Peptide | HPV-16 E6 | HPV-16 E6 Peptide | HPV16 E6 | Human Papillomavirus 16 E6 Peptide | Human Papillomavirus Type 16 E6 Protein | Protein E6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009886","Contraceptive Device","C42734","A device designed to prevent conception through local or systemic effect, such as a barrier contraceptive, an intrauterine device, or a means of preventing ovulation (e.g., birth control pill).","Contraceptive Device | Contraceptive",,,,,,,,,,,,,,,"4225628","Contraceptive device",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0419518","Contraceptive Coil","C92758","A medical device that is inserted into the uterus to prevent pregnancy.","Contraceptive Coil | ",,,,,,,,,,,,,,,"4208658","Contraceptive coil",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0493327","Contraceptive Cap","C92757","A medical device with a small rubber cap that fits over the cervix to block sperm from entering the cervical os.","Contraceptive Cap | ",,,,,,,,,,,,,,,"4221157|4283456","Vaginal contraceptive cap|Cervical contraceptive cap",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL449143","Contraceptive Implant","C92759","A drug implant that acts as a birth control device and which is inserted under the skin for drug delivery into the body.","Contraceptive Implant | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985284","Contraceptive Patch","C92760","A dermal patch that contains estrogen and progestin hormones for release and absorption through the skin and into the body to prevent pregnancy.","Contraceptive Patch | ",,,,,,,,,,,,,,,"765426","Contraceptive patch",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2985296","Hormonal Contraception","C92808","The birth control method that utilizes external source of sex hormones to prevent pregnancy by interfering with the ovulation, fertilization or implantation of the fertilized egg in the uterus.","Hormonal Contraception | Hormonal Birth Control | hormonal contraceptive type | hormonal_contraceptive_type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985328","Spermicidal Cream","C92883","A vaginal cream that is deleterious to sperm.","Spermicidal Cream | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985330","Spermicidal Jelly","C92885","A vaginal jelly that is deleterious to sperm.","Spermicidal Jelly | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1136199","Vaginal Suppository","C68990","A suppository intended for administration within the vagina.","Vaginal Suppository Dosage Form | Vag Supp | Vaginal Suppository | Vaginal Suppository Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985329","Spermicidal Foam","C92884","A vaginal foam that is deleterious to sperm.","Spermicidal Foam | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005551","Biological Rhythm","C16348","A biologically inherent cyclic variation or recurrence of an event or state, such as the sleep cycle, circadian rhythms, or periodic diseases.","Biological Rhythm | Biological Rhythm and Oscillation",,,,,,,,,,,,,,,"4168130","Biorhythm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0183461","Contraceptive Sponge","C69055","A sponge impregnated with an antispermicidal agent; it is designed to be placed into the vaginal canal to prevent live sperm from entering the uterus.","Contraceptive Sponge | Contraceptive Sponges",,,,,,,,,,,,,,,"45761294","Contraceptive sponge",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009254","Withdrawal Contraception","C92919","A birth control method adopted during sexual intercourse by withdrawing the penis from the vagina before ejaculation.","Withdrawal Contraception | ",,,,,,,,,,,,,,,"4059972|4232340","Uses withdrawal method of contraception|Onanism",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0036899","Sexual Abstinence","C92877","Prevention of conception by not engaging in sexual intercourse.","Sexual Abstinence | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985333","Surgical Contraception","C92892","A method of achieving contraception with the aid of a surgical procedure that prevents fertilization of an egg by a sperm.","Surgical Contraception | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0520483","Tubal Ligation","C92901","A method of female sterilization where the fallopian tubes are surgically ligated to prevent conception.","Tubal Ligation | Ligation of Fallopian Tubes | tubal ligation",,,,,,,,,,,,,,,"4298948","Ligation of fallopian tube",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0230065","Retro-Orbital Region","C54155","The area of the body behind the orbit of the eye.","Retro-Orbital Region | RETRO-ORBITAL REGION | Retro-Orbital Area",,,,,,,,,,,,,,,"4140674","Structure of retroorbital region",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1413207","CD1A Gene","C97921","This gene is involved in antigen presentation.","CD1A Gene | CD1A | CD1a Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0963782","T-Cell Surface Glycoprotein CD1a","C97923","T-cell surface glycoprotein CD1a (327 aa, ~37 kDa) is encoded by the human CD1A gene. This protein is involved in the mediation of lipid and glycolipid antigen presentation.","T-Cell Surface Glycoprotein CD1a | Antigen CD1a | CD1a | CD1a Antigen | Cluster of Differentiation 1 A | Cortical Thymocyte Antigen CD1A | Differentiation Antigen CD1-Alpha-3 | Epidermal Dendritic Cell Marker CD1a | T-Cell Surface Antigen T6/Leu-6 | Thymocyte Antigen CD1A | hTa1 Thymocyte Antigen",,,,,,,,,,,,,,,"4175324","Lymphocyte antigen CD1a",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0064582","Lactic Acid","C76926","A substance made from sugars in milk, by the action of certain enzymes. It is used in skin care products to reduce wrinkles and soften the skin. It is also being studied in the treatment of hand-foot syndrome (a condition marked by pain, swelling, numbness, tingling, or redness of the hands or feet) in patients receiving chemotherapy. Lactic acid is also made in muscles in the body and is used in many chemical processes in the body. It is a type of alpha hydroxyl acid.","Lactic Acid | LACTIC ACID, UNSPECIFIED FORM | Lactate | lactic acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0047506","Iobenguane","C87757","A synthetic, aralkylguanidine analogue of the adrenergic neurotransmitter norepinephrine (NE) and adrenergic neuron blocking agent with potential diagnostic imaging or antineoplastic activity when radiolabeled. Iobenguane, also known as metaiodobenzylguanidine (MIBG), is taken up and accumulates in the granules of adrenal medullary chromaffin cells and in the pre-synaptic granules of adrenergic neurons in a manner almost identical with that of NE. In radiolabeled forms, iobenguane may be used to image or eradicate neuroendocrine tissues and tumor cells.","Iobenguane | ((3-Iodophenyl)Methyl)Guanidine | 3-Iodobenzylguanidine | IOBENGUANE | M-Iodobenzylguanidine | MIBG | Metaiodobenzylguanidine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0254260","Eukaryotic Translation Initiation Factor 4E-Binding Protein 1, Human","C91349","Eukaryotic translation initiation factor 4E-binding protein 1 (118 aa, ~13 kDa) is encoded by the human EIF4EBP1 gene. This protein is involved in the modulation of translation and the sequestration of eukaryotic translation initiation factor 4E.","Eukaryotic Translation Initiation Factor 4E-Binding Protein 1 | 4E-BP1 | 4EBP1 | EIF4EBP1 | PHAS-I | Phosphorylated Heat- and Acid-Stable Protein Regulated by Insulin 1 | eIF4E-Binding Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016904","Gamma-Aminobutyric Acid","C80523","A naturally occurring neurotransmitter with central nervous system (CNS) inhibitory activity. Gamma-aminobutyric acid (GABA), converted from the principal excitatory neurotransmitter glutamate in the brain, plays a role in regulating neuronal excitability by binding to its receptors, GABA-A and GABA-B, and thereby causing ion channel opening, hyperpolarization and eventually inhibition of neurotransmission.","Gamma-Aminobutyric Acid | .GAMMA.-AMINOBUTYRIC ACID | 4-Aminobutanoic Acid | GABA | Piperidic Acid",,,,,,,,,,,,,,,"4123523","Gamma-aminobutyric acid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523665","Glutamate Measurement","C74739","The determination of the amount of glutamate present in a sample.","Glutamate Measurement | GLUTAM | Glutamate | Glutamic Acid",,,,,,,,,,,,,,,"4020980","Glutamate measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825891","Fibroblast Growth Factor Basic Form Measurement","C82014","The determination of the amount of fibroblast growth factor basic form present in a sample.","Fibroblast Growth Factor Basic Form Measurement | FGF2 | FGFBF | Fibroblast Growth Factor Basic Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0207096","Erythromycin Oxime","C87758","No value exists.","Erythromycin Oxime | 9-Hydroxyiminoerythromycin | ERYTHROMYCIN OXIME | Erythromycin A Oxime | Erythromycin Oxime
 | Erythromycin, 9-Oxime | Erythromycin-9-oxime | RU-28111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0228973","Para-Spinal Ganglion","C97925","A sympathetic ganglion located adjacent to the spinal column.","Para-Spinal Ganglion | Bilaterally Symmetric Sympathetic Chain Ganglion | PARAVERTEBRAL GANGLIA | Paraspinal Ganglion | Paravertebral Ganglion | Spinal Ganglion",,,,,,,,,,,,,,,"4238337","Structure of sympathetic trunk ganglia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448516","Accelerated Phase of Disease","C36155","The phase of a disease characterized by laboratory and clinical findings that indicate rapid progression.","Accelerated Phase of Disease | Accelerated Phase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0081939","(AA).PECAM1.0","C17402","Platelet endothelial cell adhesion molecule (738 aa, ~83 kDa) is encoded by the human PECAM1 gene. This protein is involved in leukocyte transendothelial migration and angiogenesis.","Platelet Endothelial Cell Adhesion Molecule | CD31 | CD31 Antigen | CD31 Antigen | EndoCAM | GPIIA' | PECA1 | PECAM | PECAM-1 | PECAM1 | Platelet Endothelial Cell Adhesion Molecule-1 | Platelet and Endothelial Cell Adhesion Molecule 1 | Platelet/Endothelial Cell Adhesion Molecule 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0199230","Cancer Screening","C15406","The use of any device, marker, or other means for the purpose of detecting the presence of a tumor, usually before there are any symptoms.","Cancer Screening | Cancer Screening for Patients | Early Cancer Detection | Screening | Screening of Cancer | cancer screening",,,,,,,,,,,,,,,"4048727","Screening for cancer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0201544","Prostate Specific Antigen Measurement","C17634","The determination of the prostate specific antigen present in a sample.","Prostate Specific Antigen Measurement | PSA | PSA Assay | PSA Level | PSA Measurement | PSA test | Prostate Specific Antigen | Prostate Specific Antigen Assay | Prostatic Specific Antigen Measurement | prostate-specific antigen test",,,,,,,,,,,,,,,"4272032","Prostate specific antigen measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002763","CNS Stimulant","C47795","Any agent capable of having a stimulating effect on the central nervous system (CNS).","CNS Stimulant | Analeptic Agent | Analeptics | psychostimulant | stimulant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020592","Hypnotics and Sedatives","C29756","Any agent that depresses the central nervous system (CNS) and is used to induce calm and sleep.","Sedative and Hypnotic | Minor Tranquilizer | sedative | tranquilizer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0236969","Substance-Related Disorder","C92203","A category of psychiatric disorders which include disorders related to the taking of a drug of abuse (including alcohol, prescribed medications and recreational drugs).","Substance-Related Disorder | Substance-related disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827774","Current Therapy","C85582","The name of the therapy that is currently being administered.","Current Therapy | Background Treatment | CURTRT | Current Therapy or Treatment | Current Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0771004","Azelastine Hydrochloride","C47408","The hydrochloride salt form of azelastine, a phthalazinone derivative with antihistaminergic activity. Azelastine hydrochloride competes with histamine for the H1 receptor, thereby diminishing the actions of histamine on effector cells and decreasing the histamine-mediated symptoms of allergic reaction, such as bronchoconstriction, vasodilation, increased capillary permeability and spasmodic contractions of gastrointestinal smooth muscle.","Azelastine Hydrochloride | 1(2H)-Phthalazinone, 4-((4-Chlorophenyl)methyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-, Monohydrochloride | AZELASTINE HYDROCHLORIDE | Astelin | Optivar | W-2979M",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054827","Carprofen","C65290","A propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic activities, used exclusively in veterinary medicine. Carprofen inhibits the activity of the enzymes cyclo-oxygenase (COX) I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. This inhibits the formation of prostaglandins, by prostaglandin synthase, that are involved in pain, inflammation and fever. Ibuprofen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation.","Carprofen | (RS)-2-(6-Chloro-9H-carbazol-2-yl)propanoic acid | CARPROFEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0108342","Carbamide Peroxide","C77033","An agent composed of urea and hydrogen peroxide. As an earwax removal agent, carbamide peroxide releases, upon administration into the ear, oxygen and causes foaming which helps soften, loosen and remove excessive earwax. It is also used as a disinfectant and in dentistry for its teeth whitening effects.","Carbamide Peroxide | CARBAMIDE PEROXIDE | Urea Peroxide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038119","Butorphanol Tartrate","C61658","No Value Exists","Butorphanol Tartrate | (-)-17-(Cyclobutylmethyl)morphinan-3,14-diol D-(-)-tartrate (1:1) (salt) | BUTORPHANOL TARTRATE | Stadol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333964","Liver Dysplastic Nodule","C7656","A premalignant neoplastic nodular lesion of the liver that usually measures less than 15 mm.  It is found during microscopic examination of liver tissues, usually in cirrhotic livers.  Based on the degree of atypia, it is classified as low or high grade.","Liver Dysplastic Nodule | DN | Dysplastic Nodule of Liver | Dysplastic Nodule of the Liver | Hepatic DN | Hepatic Dysplastic Nodule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0061105","Ganglioside GD3","C39782","A cell surface antigen expressed on all tumors of neuroectodermal origin, including melanoma, neuroblastomas, sarcoma, astrocytomas, and small cell lung cancer. GD3, an O-acetylated disialoganglioside, belongs to the group of glycosphingolipids that are widely expressed in many tissues and organs in vertebrates and have been suggested to be involved in the regulation of development and differentiation as recognition molecules or signal modulators. GD3 and GD2 gangliosides represent distinct and relevant immunotherapeutic target structures on melanoma, thereby both have the potential to be used as components of anti-melanoma vaccines.","Ganglioside GD3 | Disialosyllactosylceramide | GANGLIOSIDE GD3 | GD3 ganglioside | N-Acetylneuraminyl N-acetylneuraminylgalactosylglucosylceramide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0061104","Ganglioside GD2","C1110","A cell surface antigen expressed on all tumors of neuroectodermal origin, including melanoma, neuroblastomas, sarcoma, astrocytomas, and small cell lung cancer. GD2, an O-acetylated disialoganglioside, belongs to the group of glycosphingolipids that are widely expressed in many tissues and organs in vertebrates and have been suggested to be involved in the regulation of development and differentiation as recognition molecules or signal modulators. Due to its high level of expression in neuroblastoma, GD2 has the potential to be used as a component of anti-neuroblastoma vaccines, in addition to being used in polyvalent anti-melanoma vaccines.","Ganglioside GD2 | DISIALOGANGLIOSIDE GD-2 | Disialoganglioside GD-2 | GANGLIOSIDE GD2 | GD2 | GD2 Ganglioside | GalNAc(beta 1->4)-[NeuAc(alpha 2->8)NeuAc(alpha 2->3)]Gal(beta 1->4)GlcCer | Ganglioside, GD2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336620","TGFA Gene","C24855","This gene is involved in angiogenesis and mitogenesis.","TGFA Gene | TGFA | Transforming Growth Factor Alpha Gene | Transforming Growth Factor, Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0110462","Colistimethate Sodium","C65349","The sodium salt of colistimethate, a broad-spectrum polymyxin antibiotic against most aerobic Gram-negative bacteria except Proteus bacteria. Colistimethate sodium contains the pentasodium salt of the penta(methanesulfonic acid) derivative of colistin A as the major component and a small proportion of the petasodium salt of the pentamethanesulfonate derivative of colistin B. Colistins are cyclic polypeptides produced from Bacillus colistinus or B. polymyxa and function as a surfactant which penetrates into and disrupts the bacterial cell membrane, thereby resulting in bactericidal effect.","Colistimethate Sodium | COLISTIMETHATE SODIUM | Colimyscine | Colistin Sodium Methanesulfonate | Coly-Mycin | Pentasodium Colistinmethanesulfonate | W-1929",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983912","Coagulation Factor VIIa Human","C90854","A recombinant form of activated human blood coagulation factor VII that promotes hemostasis by activating the extrinsic pathway of the coagulation cascade.","Coagulation Factor VIIa Human | COAGULATION FACTOR VIIA HUMAN | Factor Viia Human | Human Factor VII (Activated)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0055729","Cilostazol","C1051","A quinolinone derivative and cellular phosphodiesterase inhibitor, more specific for phosphodiesterase III (PDE III). Although the exact mechanism of action of is unknown, cilostazol and its metabolites appears to inhibit PDE III activity, thereby suppressing cyclic adenosine monophosphate (cAMP) degradation. This results in an increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation.","Cilostazol | 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone | CILOSTAZOL | Pletal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0752310","Dexmedetomidine Hydrochloride","C72738","The hydrochloride salt form of dexmedetomidine, an imidazole derivate and active d-isomer of medetomidine with analgesic, anxiolytic and sedative activities. Dexmedetomidine selectively binds to and activates presynaptic alpha-2 adrenoceptors located in the brain, thereby inhibiting the release of norepinephrine from synaptic vesicles. This leads to an inhibition of postsynaptic activation of adrenoceptors, which inhibits sympathetic activity, thereby leading to analgesia, sedation and anxiolysis.","Dexmedetomidine Hydrochloride | DEXMEDETOMIDINE HYDROCHLORIDE | Precedex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010977","Dantrolene Sodium","C61698","The sodium salt form of dantrolene, a hydantoin derivative and direct-acting skeletal muscle relaxant. Dantrolene depresses excitation-contraction coupling in skeletal muscle by binding to the ryanodine receptor 1, and decreasing intracellular calcium concentration. Ryanodine receptors mediate the release of calcium from the sarcoplasmic reticulum, an essential step in muscle contraction.","Dantrolene Sodium | DANTROLENE SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1435444","Darunavir","C65364","A human immunodeficiency virus type 1 (HIV-1) protease nonpeptidic inhibitor, with activity against HIV. Upon oral administration, darunavir selectively targets and binds to the active site of HIV-1 protease, and inhibits the dimerization and catalytic activity of HIV-1 protease. This inhibits the proteolytic cleavage of viral Gag and Gag-Pol polyproteins in HIV-infected cells. This inhibition leads to the production of immature, non-infectious viral proteins that are unable to form mature virions, and prevents HIV replication.","Darunavir | (3R,3aS,6aR)-Hexahydrofuro(2,3-b)furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N1-isobutylsulfanilamido)propyl)carbamate | DARUNAVIR | TMC114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279151","DHEA Mustard","C2707","A steroidal alkylating agent with potential antineoplastic activity.  Alkylating agents exert cytotoxic and, in some cases, chemotherapeutic effects by transferring alkyl groups to DNA, thereby damaging DNA and interfering with DNA replication and cell division. (NCI04)","DHEA Mustard | Dehydroepiandrosterone mustard | dehydroepiandrosterone mustard",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1170000","Drotrecogin Alfa (Activated)","C80267","A recombinant form of human protein C with anti-thrombotic, anti-inflammatory, and profibrinolytic properties.","Drotrecogin Alfa (Activated) | Blood Coagulation Factor XIV (Human) | DROTRECOGIN ALFA (ACTIVATED) | Drotrecogin Alfa, Activated | Recombinant Human Activated Protein C (Rh-APC) | Revombinant Human Autoprothrombin IIA, Activated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0771848","Donepezil Hydrochloride","C2603","The hydrochloride salt of a piperidine derivative with neurocognitive-enhancing activity. Donepezil reversibly inhibits acetylcholinesterase, thereby blocking the hydrolysis of the neurotransmitter acetylcholine and, consequently, increasing its activity.  This agent may improve neurocognitive function in Alzheimer's disease, reduce sedation associated with opioid treatment of cancer pain, and improve neurocognitive function in patients who have received radiation therapy for primary brain tumors or brain metastases.","Donepezil Hydrochloride | 1-Benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine Hydrochloride | Aricept | DONEPEZIL HYDROCHLORIDE | E-2020",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0075770","Docosanol","C47498","A saturated 22-carbon aliphatic alcohol with antiviral activity. Docosanol has a distinct mechanism of action and inhibits fusion between the plasma membrane and the herpes simplex virus envelope, thereby preventing viral entry into cells and subsequent viral activity and replication. Docosanol is used topically in the treatment of recurrent herpes simplex labialis episodes and relieves associated pain and may help heal sores faster.","Docosanol | Abreva | Behenyl Alcohol | DOCOSANOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273740","American College of Rheumatology Criteria for Improvement in Rheumatoid Arthritis","C97983","Standard criteria to compare the effectiveness of various arthritis medications or treatments. The American College of Rheumatology criteria consists of a variety of measures such as, the number of tender joints, number of swollen joints, patient's assessment of pain, patient's and physician's global assessments of disease activity, patient's assessment of physical function, and laboratory evaluation of an acute-phase reactant.","American College of Rheumatology Criteria for Improvement in Rheumatoid Arthritis | ACR Criteria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0451528","Systemic Lupus Erythematosus Disease Activity Index","C97984","A clinical index for the measurement of disease activity in systemic lupus erythematosus. The index utilizes 24 weighted variables that measure disease activity, damage from disease, and health status.","Systemic Lupus Erythematosus Disease Activity Index | SLEDAI",,,,,,,,,,,,,,,"4158768","Systemic lupus erythematosus disease activity index",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0046200","2-Hydroxyestrone","C63947","A metabolite formed during the catabolism of estrone by the liver through the hydroxylation of the carbon at position 2 by cytochrome P450 (CYP) enzymes, including CYP1A1 and 1A2, with potential anticarcinogenic activity. The mechanism of action for the antitumor activity of 2-hydroxyestrone is not known but this metabolic product has minimal estrogenic activity compared to the parent compound and other estrone metabolites. Additionally, O-methylation of this compound produces 2-methoxyestradiol (2-MeOE2), which is a potent inhibitor of both cell proliferation and angiogenesis.","2-Hydroxyestrone | 1,3,5(10)-Estratrien-2,3-diol-17-one | 2-HYDROXYESTRONE | 2-OHE(1) | 2-OHE1 | Catecholestrone | Estra-1,3,5(1)-Trien-17-One, 2,3-Dihydroxy-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985765","Enhancement Description","C93562","The textual representation for how an entity is enhanced, either physically or electronically.","Enhancement Description | Enhancement | Enhancement morphology | enhancementDescription",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334230","Malignant Spindle Cell Neoplasm","C27091","A neoplasm characterized by the presence of malignant spindle cells.","Malignant Spindle Cell Neoplasm | Malignant Spindle Cell Tumor | Malignant tumor, spindle cell type | Spindle Cell Cancer | spindle cell cancer","8004/3","Malignant tumor, spindle cell type",,,,,,,,,,,,,"4228203","Malignant tumor, fusiform cell type",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C2985971","Defined Imaging Enhancement Description","C93771","The textual representation for how an image is enhanced either physically or electronically.","Defined Imaging Enhancement Description | DefinedImaging.enhancementDescription",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826609","Architectural Distortion","C82986","A morphologic finding indicating alteration of the shape/pattern of tissue components.","Architectural Distortion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273747","American College of Rheumatology Improvement Criteria","C97995","Standard criteria to compare the effectiveness of medications or treatments for rheumatoid diseases. The American College of Rheumatology criteria consists of a variety of physical assessments, laboratory evaluation, and patient assessments.","American College of Rheumatology Improvement Criteria | ACR Improvement Criteria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1402294","Primary Lesion","C40558","A term that refers to a pathologic process in its original anatomic site of growth.","Primary Lesion | PRIMARY | Primary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0222611","Axillary Tail of the Breast","C12305","The superolateral extension of the mammary gland into the axilla that consists of fibroadipose tissue, lymph nodes, and lymphatics.","Axillary Tail of the Breast | Axillary Process of Breast | Axillary Tail of Breast | Axillary tail of breast | Tail of Spence | axillary tail of breast",,,,,,,,,,,,,,,"4244524","Structure of axillary tail of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030747","Pectoralis Muscle","C33286","Muscles of the upper chest. The term may refer to one of two muscles, the pectoralis major and pectoralis minor. The former is a thick muscle in the anterior portion of the chest. Its action involves flexion, medial rotation, and adduction of the humerus. The latter is a thin muscle located beneath the pectoralis major. Its action involves lowering the scapula and raising the ribs.","Pectoralis Muscle | MUSCLE, PECTORALIS",,,,,,,,,,,,,,,"4304695","Pectoral muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242114","Suspicion","C85902","An impression that something is possible or probable.","Suspicion | ",,,,,,,,,,,,,,,"45768444","Suspicion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039461","Television","C96983","Television (CTV/PTV)","Television | TV",,,,,,,,,,,,,,,"4114817","Television",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825165","Nuclear Stress Test","C80408","A study using radioisotope tagged blood components and a nuclear scanning machine to monitor the blood flow to the myocardium during or immediately following exercise.","Nuclear Stress Test | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711887","Varenicline Tartrate","C61998","A drug used to help people stop smoking by acting the same way nicotine acts in the brain. It is a type of nicotine receptor partial agonist.","Varenicline Tartrate | Chantix | VARENICLINE TARTRATE | varenicline tartrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085934","Bupropion Hydrochloride","C1317","The hydrochloride salt of the aminoketone bupropion, with antidepressant activity and for potential use in promoting smoking cessation and improving sexual desire. Bupropion is a weak blocker of the neuronal uptake of serotonin, dopamine and norepinephrine and is a central nicotinic acetylcholine receptor antagonist.","Bupropion Hydrochloride | (+-)-1-(3-Chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone Hydrochloride | Amfebutamone | BUPROPION HYDROCHLORIDE | BW 323U66 | Wellbutrin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1171947","Commit Lozenge","C90531","A lozenge preparation containing the alkaloid nicotine with nicotine replacement activity. Upon administration of the lozenge, nicotine is released and, although nicotine binds to nicotinic cholinergic receptors at the autonomic ganglia, adrenal medulla and at neuromuscular junctions as well, the binding of nicotine to the receptors in the central nervous system (CNS) appears to be responsible for the addictive nature of nicotine. Binding to CNS nicotinic acetylcholine receptors causes the release of the neurotransmitter dopamine which appears to be responsible for the addiction of nicotine. Administration of nicotine may prevent nicotine craving and may help with the withdrawal symptoms associated with smoking cessation.","Nicotine Lozenge | Commit | nicotine lozenge",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0939401","Nicotine Nasal Spray","C16162","A nasal spray composed of an aqueous solution containing the alkaloid nicotine with nicotine replacement activity. Upon administration of the spray into the nostrils, nicotine is taken up from the nasal mucosa into the bloodstream. Although nicotine binds to nicotinic cholinergic receptors at the autonomic ganglia, adrenal medulla and at neuromuscular junctions as well, the binding of nicotine to the receptors in the central nervous system (CNS) appears to be responsible for the addictive nature of nicotine. Binding to CNS nicotinic acetylcholine receptors causes the release of the neurotransmitter dopamine which appears to be responsible for the addiction of nicotine. Administration of nicotine may prevent nicotine craving and may help with the withdrawal symptoms associated with smoking cessation.","Nicotine Nasal Spray | Nicotrol NS | nicotine nasal spray",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0814019","Nicotine inhaler","C19977","A device consisting of a mouthpiece and a thin, plastic cartridge that contains nicotine plug and delivers nicotine in a vapor that is absorbed in the mouth.","Nicotine Inhaler | Nicotrol Inhaler | Puffer | Smokeless Nicotine Inhaler | nicotine inhaler",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020587","Hypnotherapy","C15420","Therapeutic use of hypnotism by a clinical professional.","Hypnotherapy | Clinical Hypnosis | Hypnosis",,,,,,,,,,,,,,,"4064580","Hypnotherapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0394664","Acupuncture Therapy","C15176","The practice of piercing specific points on the body with very thin sterile needles in order to relieve pain or induce regional anesthesia.","Acupuncture Therapy | Acupuncture | acupuncture",,,,,,,,,,,,,,,"4260518","Acupuncture",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030258","Booklet","C94823","A small book, often having a paper cover.","Booklet | Pamphlet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273800","Chore","C98073","A household activity that must be done regularly as a duty.","Chore | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1571726","Housework","C98072","Activities performed to maintain a living space, such as cleaning.","Housework | ",,,,,,,,,,,,,,,"4043521","Doing housework",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3273801","Watch Television","C98074","The act of spending time viewing a television.","Watch Television | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273806","Cigarillo","C98082","A small cigar similar in size to a cigarette. Unlike a cigarette, a cigarillo is wrapped in whole-leaf tobacco.","Cigarillo | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0061817","Tumstatin","C90606","Tumstatin (245 aa, ~27 kDa) is encoded by the human COL4A3 gene. This protein is involved in the modulation of angiogenesis.","Tumstatin | COL4A3 Monomeric NC1 Domain | Collagen IV (Alpha 3) Monomeric NC1 Domain | TUMSTATIN | Tumstatin (Human Placenta Collagen Type IV alpha3 Chain NC1 Domain)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229715","Parotid Gland Lymph Node","C33278","A lymph node located close to, on, or within the parotid gland.","Parotid Gland Lymph Node | LYMPH NODE, PAROTID | Lymph Node(s) Parotid | Lymph node level VIII (qualifier value) | PAROTID GLAND LYMPH NODE | parotid lymph node | parotid node",,,,,,,,,,,,,"UBERON:0015857","parotid lymph node","4009134","Structure of parotid lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0750492","Likely","C85550","Having a good chance of being the case or of coming about.","Likely | Likeliness | Probably",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705209","Film","C49955","A photographic material designed to capture an image upon exposure to electromagnetic radiation.","Film Device | Film | Film | Film Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014892","Estazolam","C47520","A triazolo-benzodiazepine with anxiolytic, anticonvulsant, hypnotic, and muscle relaxant properties. Estazolam binds to the gamma-aminobutyric acid (GABA) receptor at a site distinct from the inhibitory neurotransmitter GABA binding site in the limbic system of the central nervous system (CNS). This binding leads to an opening of the chloride channels, which allows the flow of chloride ions into the neuron, hyperpolarizes the neuronal membrane, inhibits neuronal firing, and leads to a decrease in neuronal excitability.","Estazolam | 8-Chloro-6-phenyl-4H-(1,2,4)triazolo-(4,3-a)(1,4)benzodiazepine | ESTAZOLAM | Esilgan | ProSom",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700606","Esmolol Hydrochloride","C47519","The hydrochloride salt form of esmolol, a short and rapid-acting beta adrenergic antagonist belonging to the class II anti-arrhythmic drugs and devoid of intrinsic sympathomimetic activity. Esmolol hydrochloride competitively blocks beta-1 adrenergic receptors in cardiac muscle and reduces the contractility and cardiac rate of heart muscle, thereby decreasing cardiac output and myocardial oxygen demands. This agent also decreases sympathetic output centrally and blocks renin secretion. At higher doses, esmolol hydrochloride also blocks beta-2 receptors located in bronchial and vascular smooth muscle, thereby leading to smooth muscle relaxation.","Esmolol Hydrochloride | (+-)-Methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate Hydrochloride | 4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzenepropanoic Acid Methyl Ester HCl | ASL 8052 | Brevibloc | ESMOLOL HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0772203","Eprosartan Mesylate","C47515","The mesylate salt form of eprosartan, a non-biphenyl, non-tetrazole, nonpeptide angiotensin II antagonist with antihypertensive activity. Eprosartan mesylate antagonizes angiotensin II type I receptors in tissues such as vascular smooth muscle and the adrenal gland. This prevents angiotensin II-induced vasoconstriction and prevents angiotensin II-mediated stimulation of aldosterone secretion by the adrenal cortex, which decreases the excretion of sodium and water and increases the excretion of potassium.","Eprosartan Mesylate | (E)-2-Butyl-1-(p-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic Acid, Monomethanesulfonate | 2-Thiophenepropanoic Acid, alpha-((2-butyl-1-((4-carboxyphenyl)methyl)-1H-imidazol-5-yl)methylene)-,(E)-, Monomethanesulfonate | EPROSARTAN MESYLATE | Teveten",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0971023","Entecavir","C65513","A synthetic analog of 2-deoxyguanosine with antiviral activity against hepatitis B virus (HBV).  Entecavir is activated in vivo to a 5-triphosphate metabolite. In turn, the triphosphate form competes with the natural substrate deoxyguanosine triphosphate (dGTP) for incorporation into viral DNA. The incorporation of the activated triphosphate metabolite of entecavir inhibits the reverse transcriptase (RT) viral RNA-dependent HBV DNA polymerase and, so, the replication of viral DNA and transcription.","Entecavir | 6H-Purin-6-One, 2-Amino-1,9-Dihydro-9-((1S,3R,4S)-4-Hydroxy-3-(Hydroxymethyl)-2-Methylenecyclopentyl)- Monohydrate | 9-((1S,3R,4S)-4-Hydroxy-3-(Hydroxymethyl)-2-Methylenecyclopentyl)Guanine Monohydrate | BMS-200475-01 | Baraclude | ENTECAVIR | ETV | SQ-34676 | SQ34676",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0059374","Enrofloxacin","C72660","No Value Exists","Enrofloxacin | 1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolonecarboxylic acid | Bay-Vp-2674 | Baytril | ENROFLOXACIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0909839","Emtricitabine","C47509","A synthetic fluoro derivative of thiacytidine with potent antiviral activity. Emtricitabine is phosphorylated to form emtricitabine 5'-triphosphate within the cell. This metabolite inhibits the activity of human immunodeficiency virus (HIV) reverse transcriptase both by competing with the natural substrate deoxycytidine 5'-triphosphate and by incorporation into viral DNA causing a termination of DNA chain elongation (due to the lack of the essential 3'-OH group).","Emtricitabine | (-)-2'-Deoxy-5-fluoro-3'-thiacytidine | 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-,(2R-cis)- | BW-524W91 | Coviracil | EMTRICITABINE | Emtriva | FTC | dOTFC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229792","Mesenteric Lymph Node","C77641","A lymph node located in the mesentery.","Mesenteric Lymph Node | LYMPH NODE, MESENTERIC | Lymph Node(s) Mesenteric | MESENTERIC LYMPH NODE | Mesenteric Nodes | Mesenteric lymph nodes | mesenteric lymph node | mesenteric node",,,,,,,,,,,,,"UBERON:0002509","mesenteric lymph node","4087351","Structure of lymph node of mesentery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3282905","Intraocular","C96904","Within the eyeball.","Intraocular | intraocular",,,,,,,,,,,,,,,"42538482","Intraocular",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018549","Halothane","C47554","A nonflammable, halogenated, hydrocarbon and general inhalation anesthetic. Although the exact mechanism of action is unknown, halothane provides relatively rapid induction of anesthesia by depressing the central nervous system, thereby producing a reversible loss of consciousness and sensation. (NCI05)","Halothane | 1,1,1-Trifluoro-2-bromo-2-chloroethane | HALOTHANE | Narcotan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0284906","Fosphenytoin Sodium","C47543","The sodium salt form of fosphenytoin, a prodrug that is hydrolyzed to the anticonvulsant phenytoin upon parental administration. Phenytoin exerts its effect most likely through an enhancement of sodium efflux from neurons in the motor cortex. This leads to a suppression of excessive neuronal firing and spread of seizure activity. Other physiologic effects from actions of phenytoin include modulation of the voltage-dependent calcium channels of neurons, inhibition of calcium flux across neuronal membranes and enhancement of sodium-potassium ATPase activity of neurons and glial cells. (NCI05)","Fosphenytoin Sodium | 2,4-Imidazolidinedione, 5,5-diphenyl-3-((phosphonooxy)methyl)-, Disodium Salt | Cerebyx | FOSPHENYTOIN SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1320129","Fosamprenavir Calcium","C61771","The calcium salt form of fosamprenavir, prodrug of amprenavir, and a human immunodeficiency virus (HIV) protease inhibitor with antiviral property. Fosamprenavir is converted to amprenavir by cellular phosphatases in the epithelial cells of the intestine. Then amprenavir binds to the active site of HIV-1 protease, thereby preventing the proteolytic cleavage of viral Gag-Pol polypeptide into individual functional proteins, thereby leading to the formation of immature non-infectious viral particles.","Fosamprenavir Calcium | 908 | FOSAMPRENAVIR CALCIUM | GW433908 | Lexiva",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0720479","Fluorescein Sodium Injection","C82405","An injectable form of the sodium salt of the fluorophore fluorescein. Fluorescein responds to electromagnetic radiation between the wavelengths of 465-490 nm and fluoresces, emitting light at wavelengths of 520-530 nm that can be detected visually.","Fluorescein Sodium Injection | AK-Fluor | Fluorescite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016267","Flucloxacillin","C80591","A narrow-spectrum, semisynthetic isoxazolyl penicillin with antibacterial activity. Floxacillin binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall, eventually causing cell lysis.","Flucloxacillin | 3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolylpenicillin | 6-(3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid | BRL 2039 | FLUCLOXACILLIN | Floxacillin | Floxacillin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0060276","Ferrous Fumarate","C61763","The fumarate salt form of the mineral iron. Administration of ferrous fumarate results in elevation of serum iron concentration, which is then assimilated into hemoglobin, required for the transport of oxygen, or trapped in the reticuloendothelial cells for storage. This agent is used as a dietary supplement, and to prevent or treat iron deficiency related syndromes.","Ferrous Fumarate | FERROUS FUMARATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0167117","Exenatide","C65611","A 39 amino acid peptide and synthetic version of exendin-4, a hormone found in the saliva of the venomous lizard Gila monster, with insulin secretagogue and antihyperglycemic activity. Exenatide is administered subcutaneously and mimics human glucagon-like peptide-1 (GLP-1). Compared to GLP-1, exenatide has a longer half-life of 2.4 hours.","Exenatide | AC-2993 | Byetta | EXENATIDE | LY2148568 | PT302",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0537270","Insulin Detemir","C65920","A long-lasting, recombinant version of human insulin. It is an insulin analogue with myristic acid bound to the lysine at position B29 and a deletion of B30.","Insulin Detemir | INSULIN DETEMIR | Levemir",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279261","Immune Globulin/Zidovudine","C15479","A combination of agents containing immune globulin and zidovudine.","Immune Globulin/Zidovudine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020196","Hyaluronic Acid","C549","A glucosaminoglycan consisting of D-glucuronic acid and N-acetyl-D-glucosamine disaccharide units that is a component of connective tissue, skin, vitreous humour, umbilical cord, synovial fluid and the capsule of certain microorganisms contributing to adhesion, elasticity, and viscosity of extracellular substances.","Hyaluronic Acid | HYALURONIC ACID | Hyaluronan | Hyaluronate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019435","Hexachlorophene","C47556","A chlorinated bisphenol antiseptic agent with bacteriostatic activity. Hexachlorophene is used topically in soaps, creams and dermatological preparations and is active against gram-positive organisms, but much less effective against gram-negative organisms. (NCI05)","Hexachlorophene | 2,2'-Methylenebis(3,4,6-trichlorophenol) | Bis(3,5,6-trichloro-2-hydroxyphenyl)-methane | Dermadex | Gamophen | HEXACHLOROPHENE | Hexa-Germ | Hexascrub | Phisohex | Septisol | Turgex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL425124","Herbal Supplement","C93221","Any supplement that contains plant and/or plant parts.","Herbal Supplement | herbal supplement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0588057","Popliteal Lymph Node","C53146","Lymph node located within the fat layer of the knee joint.","Popliteal Lymph Node | LYMPH NODE, POPLITEAL | Lymph Node(s) Popliteal | POPLITEAL LYMPH NODE | Popliteal Nodes | popliteal lymph node",,,,,,,,,,,,,"UBERON:0001543","popliteal lymph node","4165367","Popliteal lymph node structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025545","Metallothionein","C16845","A family of cysteine-rich proteins that bind to and transport heavy metal ions.","Metallothionein | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1684405","Lubiprostone","C66040","A bicyclic fatty acid derived from prostaglandin E1 and a chloride channel activator with laxative activity. Upon intake, lubiprostone specifically binds to and activates the type 2 chloride channel (ClC-2) in the apical membrane of the gastrointestinal epithelium. This produces an efflux of chloride ions, thereby drawing water into the gastrointestinal lumen. The resulting increased amounts of intestinal fluid soften the stool, increase motility, and improve bowel movements.","Lubiprostone | Amitiza | LUBIPROSTONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0126177","Loteprednol Etabonate","C47589","The etabonate salt form of loteprednol, an ophthalmic analog of the corticosteroid prednisolone with anti-inflammatory activity. Loteprednol etabonate exerts its effect by interacting with specific intracellular receptors and subsequently binds to DNA to modify gene expression. This results in an induction of the synthesis of certain anti-inflammatory proteins while inhibiting the synthesis of certain inflammatory mediators. Loteprednol etabonate specifically induces phospholipase A2 inhibitory proteins (collectively called lipocortins), which inhibit the release of arachidonic acid, thereby inhibiting the biosynthesis of potent mediators of inflammation, such as prostaglandins and leukotrienes.","Loteprednol Etabonate | Alrex | Androsta-1,4-diene-17-carboxylic Acid, 17-((ethoxycarbonyl)oxy)-11-hydroxy-3-oxo-, chloromethyl Ester,(11beta,17alpha)- | LOTEPREDNOL ETABONATE | Lotemax",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0721422","Loracarbef","C47588","A semi-synthetic, broad-spectrum, beta-lactamase resistant, second-generation cephalosporin antibiotic derived from cephasporium. The bactericidal activity of loracarbef results from the inhibition of bacterial cell wall synthesis through interference with the cross-linking of peptidoglycan units. This results in a reduction of cell wall stability and causes cell lysis. Loracarbef is more active against a variety of gram-negative organisms but less active against gram-positive pathogens compared to first-generation agents.","Loracarbef | (6R, 7S)-7-[(R)-2-Amino-2-phenylacetamido]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid, Monohydrate | LORACARBEF | Lorabid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007258","Carnitine","C82599","An amino acid derivative.  Carnitine facilitates long-chain fatty acid entry into mitochondria, delivering substrate for oxidation and subsequent energy production. Fatty acids are utilized as an energy substrate in all tissues except the brain.","Carnitine | (3-Carboxy-2-hydroxypropyl)trimethylammonium Hydroxide Inner Salt | CARNITINE | DL-CARNITINE | DL-Carnitine | carnitine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0722072","Potassium Phosphate/Sodium Phosphate","C29288","A combination preparation containing potassium phosphate and sodium phosphate used for electrolyte-replacement purposes, dietary supplementation and to acidify urine. Phosphate, a predominant intracellular anion, plays an important role in energy storage, osteoblastic and osteoclastic activities, regulating serum calcium concentrations and numerous cellular phosphate-transfer reactions. Potassium phosphate and sodium phosphate are used to acidify the urine and lower the urinary calcium concentration. This may reduce rash and odor caused by ammonium in the urine.","Potassium Phosphate/Sodium Phosphate | Neutra-Phos | PHOS-NaK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0064079","Isosorbide Mononitrate","C47575","The mononitrate salt form of isosorbide, an organic nitrate with vasodilator activity. Isosorbide mononitrate relaxes vascular smooth muscle by formation of the free radical nitric oxide (NO), which is identical to the endothelium-derived relaxing factor (EDRF). NO activates guanylyl cyclase, thereby increasing the synthesis of cGMP within smooth muscle, resulting in dephosphorylation of light chain myosin and relaxation of peripheral arteries and veins. In addition, isosorbide mononitrate relaxes coronary arteries, thereby increasing the blood circulation through the ischemic area. (NCI05)","Isosorbide Mononitrate | 1,4:3,6-Dianhydro-D-glucitol 5-nitrate | ISMO | ISOSORBIDE MONONITRATE | Imdur | Monoket | Monosordil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022180","Isoflurane","C65978","A fluorinated ether with general anesthetic and muscle relaxant activities. Although the exact mechanism of action has not been established, inhaled isoflurane, appears to act on the lipid matrix of the neuronal cell membrane, which results in disruption of neuronal transmission. This agent enhances the release of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), thereby increasing the activity of the inhibitory neurotransmitter on synaptic transmission. Isoflurane may also both inhibit glutamatergic excitatory transmission by increasing glutamate re-uptake, and potentiate glycine receptor activity, which decreases motor function. In addition, isoflurane may alter certain pro- and anti-inflammatory cytokines, including interleukin-6 and -10 (IL-6, IL-10), possibly through the activation of the nuclear factor kappa B (NF-KB) pathway, which may affect immune responses during surgery.","Isoflurane | 1-Chloro-2,2,2-trifluoroethyl Difluoromethyl Ether | 2-Chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane | Aerrane | Forane | ISOFLURANE | Isoflo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0060241","Iron Sucrose","C65963","A sterile aqueous complex of polynuclear iron (III)-hydroxide in sucrose for intravenous use. Following intravenous administration, iron sucrose is dissociated by the reticuloendothelial system into iron and sucrose; the sucrose component is eliminated mainly by urinary excretion. Iron sucrose can be administered with or without erythropoietin to raise hemoglobin levels and may be used in cases of oral iron therapy intolerance or ineffectiveness. Hypersensitivity reactions are less common with iron sucrose compared to other parenteral iron products, such as iron dextran.","Iron Sucrose | Ferric Hydroxide Saccharate Injection | Ferric Hydroxide Sucrose Complex | IRON SUCROSE | Intravenous Ferric Hydroxide Saccharate | Iron Saccharate | Iron Saccharate Injection | Iron Sucrose Injection | Iron Sucrose for Injection | Iron sucrose | Saccharated Ferric Oxide | Saccharated Iron Oxide | Venofer | iron (III) Oxide, Saccharate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2351029","Maropitant Citrate","C78028","A neurokinin receptor antagonist with antiemetic activity. This agent is approved for veterinary use only.","Maropitant Citrate | (2S,3S)-N-(5-(1,1-Dimethylethyl)-2-methoxybenzyl)-2-(diphenylmethyl)-1-azabicyclo(2.2.2)octan-3-amine 2-hydroxy-1,2,3-propanetricarboxylate (1:1), Monohydrate | CJ-11,972 | Cerenia | MAROPITANT CITRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1445693","MSM/Glucosamine","C29234","A combination preparation of glucosamine, a hexosamine sugar polymer, and methyl sulfonyl methane (MSM), a derivative of dimethyl sulphoxide, with anti-arthritic and anti-inflammatory activities. The mechanism of action has not yet been fully elucidated but addition of glucosamine to chondrocytes results in inhibition of proteoglycan catabolism. Glucosamine inhibits interleukin-1-induced production of inflammatory mediators (nitric oxide, prostaglandin E2), and inhibit aggrecanase activity, which results in preservation of proteoglycan and chondrocytes. Other studies have also shown glucosamine to reduce the generation of reactive oxygen species by macrophages, and inhibit lysosomal enzymes. MSM has been suggested to exert its analgesic effect by inhibiting pain impulses along type C nerve fibers, reducing inflammation and muscle spasms, as well as promoting blood flow, thereby promoting the healing of cartilage lesions.","MSM/Glucosamine | MSM w/Glucosamine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412993","Morphine Sulfate Sustained-Release Tablet","C84853","A sustained-release tablet formulation containing the sulfate salt of the opiate alkaloid morphine with analgesic activity. Morphine binds to and activates the mu-opioid receptors in the central nervous system (CNS), thereby mimicking the effects of the endogenous opioids. Binding of morphine to opioid receptors stimulates exchange of GTP for GDP, inhibits adenylate cyclase, and decreases intracellular cAMP. This inhibits the release of various nociceptive neurotransmitters, such as substance P, gamma-aminobutyric acid (GABA), dopamine, acetylcholine, noradrenaline, vasopressin, and somatostatin. In addition, morphine closes N-type voltage-gated calcium channels and opens calcium-dependent inwardly rectifying potassium channels, which results in hyperpolarization of neuronal membranes and a reduction in neuronal excitability, and subsequently, analgesia and sedation.","Morphine Sulfate Sustained-Release Tablet | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1871526","Raltegravir","C72837","A small molecule with activity against human immunodeficiency virus (HIV). Raltegravir is an integrase inhibitor that blocks the integration of the viral genome into the host DNA, a critical step in the pathogenesis of HIV.","Raltegravir | MK-0518 | N-(2-(4-(4-Fluorobenzylcarbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl)-5-methyl-1,3,4-oxadiazole-2-carboxamide | RALTEGRAVIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1436328","Eszopiclone","C65545","A nonbenzodiazepine, cyclopyrrolone and active stereoisomer of zopiclone with hypnotic and sedative activity and without significant anxiolytic activity. Although the exact mechanism of action remains to be fully elucidated, eszopiclone is able to bind to and activate the omega-1 subtype of the alpha subunit of the gamma-aminobutyric acid-benzodiazepine GABA receptor complex (GABA-A), a chloride ionophore complex in the central nervous system (CNS). This leads to the opening of chloride channels, causing hyperpolarization, inhibition of neuronal firing, and enhancement of the inhibitory effect of GABA. This eventually leads to a hypnotic effect and allows for an induction of sleep.","Eszopiclone | (+)-(5S)-6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methylpiperazine-1-carboxylate | (S)-Zopiclone | ESZOPICLONE | Lunesta | SEP-190",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518408","Nonmelanomatous","C14147","Having to do with skin cancer that forms in the lower part of the epidermis (the outer layer of the skin) or in squamous cells, but not in melanocytes (skin cells that make pigment).","Nonmelanomatous | nonmelanomatous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881019","HLA Class I Histocompatibility Antigen, A-1 Alpha Chain","C62772","HLA class I histocompatibility antigen, A-1 alpha chain protein (365 aa, ~41 kDa) is encoded by the human HLA-A gene. This protein plays a role in the presentation of foreign antigens to the immune system. It is associated with a number of diseases including graft-versus-host disease, hemochromatosis and certain types of cancer.","HLA Class I Histocompatibility Antigen, A-1 Alpha Chain | HLA-A*01 | HLA-A*1 | HLA-A1 | HLA-A1 Antigen | MHC Class I Antigen A*1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229847","Epitrochlear Lymph Node","C98182","A lymph node located above and adjacent to the elbow.","Epitrochlear Lymph Node | EPITROCHLEAR LYMPH NODE | Epitrochlear | Lymph Node(s) Epitrochlear",,,,,,,,,,,,,,,"4103514","Structure of epitrochlear lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0877794","Femoral Lymph Node","C98183","A lymph node located in the upper inner portion of the thigh.","Femoral Lymph Node | FEMORAL LYMPH NODE | Femoral | Lymph Node(s) Femoral",,,,,,,,,,,,,,,"4087354","Femoral lymph node group",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0733936","Pulmonary Hilar Lymph Node","C98187","A lymph node located in the hilum of the lung.","Pulmonary Hilar Lymph Node | Bronchopulmonary lymph node group (body structure) | HILAR LYMPH NODE | Hilar Lymph Node | Hilar Lymph Node",,,,,,,,,,,,,,,"4136267","Hilar lymph node group",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0229711","Occipital Lymph Node","C98188","A lymph node located in the back of the head adjacent to the trapezius muscle.","Occipital Lymph Node | Lymph Node(s) Occipital | Lymph node level XB (qualifier value) | OCCIPITAL LYMPH NODE | occipital lymph node | occipital node",,,,,,,,,,,,,"UBERON:0035204","occipital lymph node","4189397","Structure of occipital lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0229802","Retroperitoneal Lymph Node","C98189","A lymph node located in the retroperitoneal space.","Retroperitoneal Lymph Node | Lymph Node(s) Retroperitoneal | RETROPERITONEAL LYMPH NODE | Retroperitoneal lymph nodes | retroperitoneal lymph node | retroperitoneal node",,,,,,,,,,,,,"UBERON:0035371","retroperitoneal lymph node","4239385","Structure of retroperitoneal lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0229782","Splenic Hilar Lymph Node","C33600","A lymph node located in the hilar region of the spleen.","Splenic Hilar Lymph Node | SPLENIC HILAR LYMPH NODE | Splenic Hilar Nodes | Splenic Lymph Node",,,,,,,,,,,,,,,"4093871","Structure of splenic lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0230064","Periorbital","C98190","Occurring in, or located in the area around the orbit of the eye.","Periorbital | ",,,,,,,,,,,,,,,"4139981","Periorbital",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0248719","Telmisartan","C47746","A benzimidazole derivative and a non-peptide angiotensin II receptor antagonist with antihypertensive property. Telmisartan selectively antagonizes angiotensin II binding to the AT1 subtype receptor, located in vascular smooth muscle and adrenal gland. The antagonism results in vasodilation and inhibits the angiotensin II-mediated aldosterone production, which in turn leading to a decrease in sodium and water as well as an increase in potassium excretion leading to a subsequent reduction in blood pressure.","Telmisartan | (1,1'-Biphenyl)-2-carboxylic Acid, 4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)- | 4'-((4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic Acid | BIBR 277 | Micardis | TELMISARTAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4229742","Frontal Bossing","C98242","A skeletal deformity characterized by an unusually prominent forehead. Causes include acromegaly, Hurler syndrome, Silver-Russell syndrome, and thalassemia major.","Frontal Bossing | ",,,,,,,,,,,,,,,"4234412","Frontal bossing",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2674899","Hypertelorism","C34715","A condition in which there is an abnormally increased distance between two organs or bodily parts; most often, this term is referring to an increased distance between the orbits (orbital hypertelorism).","Hypertelorism | Hypertelorism of Orbit",,,,,,,,,,,,,,,"4318653","Hypertelorism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698596","CD4 T Cell to CD8 T Cell Ratio Measurement","C74637","The determination of the ratio of CD4 T cells compared to CD8 T cells present in a sample. The measurement may be expressed as a ratio or percentage.","CD4 T Cell to CD8 T Cell Ratio Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987316","Physical Quantity Time Data Type","C95675","A data type comprised of the amount or total number of a measured entity with units that describe a period of time.","Physical Quantity Time Data Type | PQ.TIME",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337494","Biological Father","C96572","A male who contributes to the genetic makeup of his offspring through the fertilization of an ovum by his sperm.","Biological Father | FATHER, BIOLOGICAL | Father | Natural Father",,,,,,,,,,,,,,,"4321888","Natural father",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2986513","Heritage","C94432","Something handed down from the past, such as a tradition, birthright, or inherited traits.","Heritage | heritage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705685","Initial Usage","C53612","An indication of the first time a device was employed.","Initial Usage | INITIAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1298613","Intracavitary","C28364","Within a cavity or space, such as the abdomen, pelvis, or chest.","Intracavitary | intracavitary",,,,,,,,,,,,,,,"4161589","Intracavitary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1313386","Insulin Glulisine","C65921","A drug used to control the amount of sugar in the blood of patients with diabetes mellitus. It is a form of the hormone insulin that is made in the laboratory. Insulin glulisine gets into the blood faster than insulin when it is injected under the skin before or shortly after a meal. It is a type of therapeutic insulin.","Insulin Glulisine | Apidra | INSULIN GLULISINE | insulin glulisine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0253456","Tyrosine-Protein Kinase JAK3","C28492","Tyrosine-protein kinase JAK3 (1124 aa, ~125 kDa) is encoded by the human JAK3 gene. This protein is involved in T-cell development, immunity, signaling and tyrosine phosphorylation.","Tyrosine-Protein Kinase JAK3 | EC 2.7.10.2 | JAK-3 | JAK3 | Janus Kinase 3 | Janus Kinase 3 | L-JAK | Leukocyte Janus Kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273919","Growth Chart Percentile","C98260","A commonly used clinical indicator to assess the size and growth pattern of an individual child. Percentiles indicate a rank of what percent of the reference population the individual would equal or exceed.","Growth Chart Percentile | Growth Percentile | Percentile Rank",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273920","5th Growth Percentile","C98261","An indication that an individual ranks the same or more than 5 percent of the reference population for a given attribute.","5th Growth Percentile | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273921","10th Growth Percentile","C98262","An indication that an individual ranks the same or more than 10 percent of the reference population for a given attribute.","10th Growth Percentile | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273922","25th Growth Percentile","C98263","An indication that an individual ranks the same or more than 25 percent of the reference population for a given attribute.","25th Growth Percentile | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273923","50th Growth Percentile","C98264","An indication that an individual ranks in the middle of the reference population for a given attribute.","50th Growth Percentile | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273924","75th Growth Percentile","C98265","An indication that an individual ranks the same or more than 75 percent (top 25 percent) of the reference population for a given attribute.","75th Growth Percentile | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273925","90th Growth Percentile","C98266","An indication that an individual ranks the same or more than 90 percent (top 10 percent) of the reference population for a given attribute.","90th Growth Percentile | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273926","95th Growth Percentile","C98267","An indication that an individual ranks the same or more than 95 percent (top 5 percent) of the reference population for a given attribute.","95th Growth Percentile | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388460","BCG Solution","C83496","A solution containing an attenuated, live culture preparation of the Bacillus Calmette Guerin (BCG) strain of Mycobacterium bovis with potential immunostimulating activity. Although the precise mechanism of action is unknown, upon intravesical administration, attenuated, live BCG bacteria in the solution come into direct contact with the bladder wall, inciting an antitumor granulomatous inflammatory reaction.","BCG Solution | BCG solution | Bacillus Calmette Guerin Solution | Bacillus Calmette-Guerin Solution | TICE BCG Solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273927","The Cancer Genome Atlas","C98269","A comprehensive and coordinated effort to accelerate understanding of the molecular basis of cancer through the application of genome analysis technologies, including large-scale genome sequencing. This project is a joint effort of the National Cancer Institute and the National Human Genome Research Institute. (http://cancergenome.nih.gov/abouttcga)","The Cancer Genome Atlas | TCGA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511022","BRCA1 Gene Mutation","C19635","A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA1 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA1 gene. Approximately 75% of these alterations result in a truncated form of the breast cancer type 1 susceptibility protein. Mutations in the BRCA1 gene predispose individuals to breast and ovarian cancers.","BRCA1 Gene Mutation | BRCA1 | BRCA1 Mutation | BRCA1 Mutation | BROVCA1 Gene Mutation | Breast Cancer 1 Gene Mutation | Breast Cancer 1, Early Onset Gene Mutation | Breast Cancer Type 1 Susceptibility Gene Mutation | Mutation of the BRCA1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511024","BRCA2 Gene Mutation","C19636","A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA2 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA2 gene. Most of these alterations result in a truncated form of the breast cancer type 2 susceptibility protein. Mutations in the BRCA2 gene predispose males to breast cancer.","BRCA2 Gene Mutation | BRCA2 | BRCA2 Mutation | BRCA2 Mutation | BRCC2 Gene Mutation | BROVCA2 Gene Mutation | Breast Cancer 2 Gene Mutation | Breast Cancer 2, Early Onset Gene Mutation | Breast Cancer Type 2 Susceptibility Gene Mutation | FANCD1 Gene Mutation | Mutation of the BRCA2 Gene | XRCC11 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273928","Bone-in-Bone Sign","C98271","A radiologic finding that is seen in osteopetrosis. It is characterized by an increased sclerosis in the superior and inferior aspects of the midbody of the vertebra, resulting in the image of a duplicate vertebral body inside the normal one.","Bone-in-Bone Sign | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2749337","Cerebral Atrophy","C98273","Atrophy of the cerebrum caused by focal or generalized neuronal loss.","Cerebral Atrophy | Cortical Atrophy",,,,,,,,,,,,,,,"4150603","Cerebral atrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1866954","Metaphyseal Widening","C98274","A radiologic finding characterized by an increased width of the metaphyseal regions. It is seen in rickets.","Metaphyseal Widening | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273929","Bat Wing Pulmonary Opacities","C98272","A radiologic finding that is detected with frontal chest X-ray or chest CT scan. It is characterized by bilateral perihilar pulmonary shadowing. It is seen in pulmonary edema, pulmonary hemorrhage, pneumonia, carcinoma, and lymphoid malignancies.","Bat Wing Pulmonary Opacities | Bat Wing Sign | Batman Sign",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0445202","Prophylactic","C95560","Any intervention to prevent disease or infection.","Prophylactic | Prophylactic Treatment | prophylactic",,,,,,,,,,,,,,,"4118659","Prophylactic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516640","Cancer Treatment Trial","C16096","A clinical study designed to evaluate biomedical or behavioral cancer interventions, generating safety data and efficacy information.","Cancer Treatment Trial | Cancer Treatment Trial | Clinical Trials: Cancer Treatment | Clinical Trials: Cancer Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010701","Phyllodes Tumor","C2977","A benign, borderline, or malignant fibroepithelial neoplasm arising from the breast and rarely the prostate gland.  It may recur following resection.  The recurrence rates are higher for borderline and malignant phyllodes tumors.  In borderline and malignant phyllodes tumors metastases to distant anatomic sites can occur.  The incidence of metastases is higher in malignant phyllodes tumors.","Phyllodes Tumor | CSP | Cystosarcoma Phyllodes | Phyllodes Neoplasm | cystosarcoma phyllodes | phyllodes tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516170","Cancer Cell Growth","C19387","The unregulated growth of cancer cells insofar as growth control and contact inhibition.","Cancer Cell Growth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202123","Luteinizing Hormone Measurement","C74790","The determination of the amount of luteinizing hormone present in a sample.","Luteinizing Hormone Measurement | LH | Luteinizing Hormone | Lutropin",,,,,,,,,,,,,,,"4287388","Luteinizing hormone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202022","Follicle Stimulating Hormone Measurement","C74783","The determination of the amount of follicle stimulating hormone present in a sample.","Follicle Stimulating Hormone Measurement | FSH | Follicle Stimulating Hormone",,,,,,,,,,,,,,,"4149280","Follicle stimulating hormone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517919","Lobular Carcinoma Cell","C36879","A carcinoma cell that originates from the breast lobules. Lobular carcinoma cells are usually smaller than those of ductal breast carcinoma, are less pleomorphic, and have fewer mitotic figures.","Lobular Carcinoma Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007135","Scirrhous Adenocarcinoma","C2928","An infiltrating adenocarcinoma characterized by the presence of desmoplastic stromal reaction.","Scirrhous Adenocarcinoma | Adenocarcinoma With Productive Fibrosis | Adenocarcinoma with Productive Fibrosis | FIBROADENOCARCINOMA, MALIGNANT | Fibrocarcinoma | Scirrhous Carcinoma | Scirrhous adenocarcinoma | Scirrhous carcinoma","8141/3","Scirrhous adenocarcinoma",,,,,,,,,,,,,"4167165","Scirrhous adenocarcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0009333","Collagen IV","C16448","The major structural component of basement membranes, Collagen-IV consists of six subunits encoded by genes COL4A1, COL4A2, COL4A3, COL4A4, COL4A5 and COL4A6.","Collagen IV | Collagen Type IV | Type IV Collagen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986836","Visual Interpretation","C95000","Perusal of an image for information that can be gleaned from the relative intensities that display tracer uptake.","Visual Interpretation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032831","Potassium Iodide","C47680","A metal halide composed of potassium and iodide with thyroid protecting and expectorant properties. Potassium iodide can block absorption of radioactive iodine by the thyroid gland through flooding the thyroid with non-radioactive iodine and preventing intake of radioactive molecules, thereby protecting the thyroid from cancer causing radiation. In addition, this agent acts as an expectorant by increasing secretion of respiratory fluids resulting in decreased mucus viscosity.","Potassium Iodide | POTASSIUM IODIDE | Pima | Potassium Iodide Oral Solution | Potassium Iodide Solution | Potassium Salt of Hydriodic Acid | SSKI | Thyro-Block",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028426","Noscapine","C80589","A phthalide isoquinoline non-narcotic alkaloid derived from the opium poppy Papaver somniferum, with mild analgesic, antitussive, and potential antineoplastic activities. Noscapine exerts its antitussive effects through the activation of sigma opioid receptors. This agent appears to exert its antimitotic effect by binding to tubulin, resulting in a disruption of microtubule assembly dynamics and subsequently, the inhibition of mitosis and tumor cell death.","Noscapine | NOSCAPINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515131","T-Cell Receptor Excision Circle","C2561","The reciprocal product of T-cell receptor (TCR) gene rearrangement. Following TCR gene rearrangement the T-cell receptor excision circle (TREC) is maintained in the cell as a non-replicating episome. With each cell division the TREC is segregated to a single daughter cell and becomes diluted in the population. Recent TCR rearrangement can be detected by a spike in the number of TREC and can be used to quantify thymic T-cell output.","T-Cell Receptor Excision Circle | T-Cell Receptor-Rearrangement Excision DNA Circle | T-cell Receptor Excision Circle | TREC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0733394","Midodrine Hydrochloride","C47620","The hydrochloride salt form of midodrine, a direct-acting prodrug and sympathomimetic agent with antihypotensive properties. Midodrine is converted to its active metabolite, desglymidodrine by deglycination reaction. Desglymidodrine selectively binds to and activates alpha-1-adrenergic receptors of the arteriolar and venous vasculature. This causes smooth muscle contraction and leads to an elevation of blood pressure. Desglymidodrine diffuses poorly across the blood-brain barrier, and is therefore not associated with effects on the central nervous system.","Midodrine Hydrochloride | (+-)-2-Amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)acetamide Monohydrochloride | 1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol Hydrochloride | Amatine | Gutron | MIDODRINE HYDROCHLORIDE | Midamine | ProAmantine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026056","Midazolam","C62049","A short-acting benzodiazepine derivative with an imidazole structure and with anxiolytic, amnestic, hypnotic, anticonvulsant and sedative properties. Midazolam exerts its effect by binding to the benzodiazepine receptor at the gamma-aminobutyric acid (GABA) receptor-chloride ionophore complex in the central nervous system (CNS). This leads to an increase in the opening of chloride channels, membrane hyperpolarization and increases the inhibitory effect of GABA in the CNS. Midazolam may also interfere with the reuptake of GABA, thereby causing accumulation of GABA in the synaptic cleft.","Midazolam | MIDAZOLAM | midazolam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1576821","Micafungin Sodium","C66145","The sodium salt form of micafungin, a semi-synthetic echinocandin derived from a natural product of the fungus Coleophoma empetri with antifungal activity. Micafungin, like other cyclic lipopeptides, noncompetitively inhibits the fungal specific enzyme 1,3-beta-D-glucan synthase, an enzyme essential for the synthesis of the important fungal cell wall component 1,3-beta-D-glucan. By preventing the synthesis of 1,3-beta-D-glucan, the cell wall is weakened which leads to osmotic lysis and eventually fungal cell death.","Micafungin Sodium | MICAFUNGIN SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026186","Minocycline Hydrochloride","C47622","The hydrochloride salt of minocycline, a broad spectrum long-acting derivative of the antibiotic tetracycline, with antibacterial and anti-inflammatory activities. Minocycline binds to the bacterial 30S ribosomal subunit and interferes with the binding of tRNA to the ribosomal complex, thereby inhibiting protein translation in bacteria. In addition, minocycline inhibits the inflammatory enzyme 5-lipoxygenase (5LOX) and may impede T cell-microglia interactions; both activities may contribute to minocycline's neuroprotective effects. 5LOX catalyzes the synthesis of inflammatory mediators such as prostaglandins and leukotrienes.","Minocycline Hydrochloride | 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide Monohydrochloride | Dynacin | MINOCYCLINE HYDROCHLORIDE | Minocin | Minomax | Minomycin | Tri-minocycline | Vectrin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0057831","Dichloralphenazone","C87204","No Value Exists","Dichloralphenazone | 1,2-Dihydro-1,5-Dimethyl-2-Phenyl-3H-Pyrazol-3-One, Compd. with 2,2,2-Trichloro-1,1-Ethanediol (1:2) | Antipyrine, Compound with Chloral Hydrate (1:2) | DICHLORALPHENAZONE | Dichloralantipyrine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0064007","Isometheptene","C75929","No Value Exists","Isometheptene | 4-Hexenylamine, N,1,5-trimethyl- | 5-Hepten-2-amine, N,6-dimethyl- | 6-Methylamino-2-methylheptene | ISOMETHEPTENE | Methyloctenylamine | N,6-Dimethyl-5-hepten-2-amine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0754517","Moxifloxacin Hydrochloride","C38696","The hydrochloride salt of a fluoroquinolone antibacterial antibiotic. Moxifloxacin binds to and inhibits the bacterial enzymes DNA gyrase (topoisomerase II) and topoisomerase IV, resulting in inhibition of DNA replication and repair and cell death in sensitive bacterial species.","Moxifloxacin Hydrochloride | Avelox | BAY 128039 | MOXIFLOXACIN HYDROCHLORIDE | Moxeza | Vigamox",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0771294","Moexipril Hydrochloride","C29267","The hydrochloride salt form of moexipril, a prodrug and non-sulfhydryl angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Moexipril hydrochloride is hydrolized into its active form moexiprilat, which competitively inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the actions of the potent vasoconstrictor angiotensin II and leads to vasodilatation. It also prevents angiotensin II-induced aldosterone secretion by the adrenal cortex, thereby promoting diuresis and natriuresis. Moexipril hydrochloride also directly suppresses renin release.","Moexipril Hydrochloride | MOEXIPRIL HYDROCHLORIDE | Moexipril HCl | Univasc",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027348","Nalbuphine","C61854","A synthetic mixed opioid agonist-antagonist with analgesic properties. Although its exact mechanism has not been fully delineated, it is hypothesized that upon administration, nalbuphine binds to kappa receptors in the central nervous system (CNS), thereby inhibiting the release of neurotransmitters that mediate pain, such as substance P. Additionally, nalbuphine exerts post-synaptic inhibitory effects on interneurons and output neurons of the spinothalamic tract, responsible for transporting nociceptive information. Compared to other opioid agents that stimulate mu receptors, nalbuphine antagonizes mu receptors, thereby potentially producing less intense respiratory depression.","Nalbuphine | NALBUPHINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007569","Celiac Artery","C52846","A major abdominal artery that arises from the abdominal aorta below the diaphragm.  It supplies blood to the digestive organs. It has three major branches, left gastric artery, common hepatic artery, and splenic artery.","Celiac Artery | CELIAC ARTERY | Celiac Axis | Celiac Trunk | Coeliac Artery | Coeliac Axis | Coeliac Trunk | Structure of celiac artery (body structure)",,,,,,,,,,,,,,,"4239981","Structure of celiac artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3273948","Pseudoprogression","C98298","A radiologic finding observed during magnetic resonance imaging of brain glioblastoma, following concurrent radiotherapy and temozolomide treatment or vaccine therapy. It refers to the false positive finding of progression and enhancement of the lesion. It is considered a treatment effect due to tumor cell necrosis and subsequent edema formation and increased vascular permeability.","Pseudoprogression | PPD-Pseudoprogression | PSEUDOPROGRESSION | PsP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0451246","Expanded Disability Status Scale","C98302","A system for quantifying disability in multiple sclerosis (MS). Based on a standard neurological examination, the Expanded Disability Status Scale quantifies disability in seven Functional Systems (plus 'Other') and assigns a Functional System Score in each. Results are ranked as steps from 0 to 10, with steps 1 through 4.5 describing MS patients who are fully ambulatory and steps 5 through 9.5 describing increasing impairment to ambulation. Step 10 refers to death due to MS.","Expanded Disability Status Scale | EDSS | Kurtzke Expanded Disability Status Scale",,,,,,,,,,,,,,,"4169156","Kurtzke multiple sclerosis rating scale",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4229687","Leukodystrophy","C61253","A group of rare genetic neurodegenerative disorders that affect infants and children. These disorders are characterized by metabolic abnormalities in the development of the myelin sheaths in the white matter. Clinical signs and symptoms include developmental delays, mental retardation, dementia, seizures, loss of motor skills, and muscle weakness. Representative examples include metachromatic leukodystrophy, Krabbe disease, Canavan disease, and Alexander disease.","Leukodystrophy | ",,,,,,,,,,,,,,,"374912","Leukodystrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517532","Germinal Center B-Lymphocyte","C38335","A mature B-lymphocyte that is present in the geminal center of a lymphoid follicle.","Germinal Center B-Lymphocyte | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL428178","Z-endoxifen hydrochloride","C95713","The hydrochloride salt and the z (cis-) stereoisomer of endoxifen with potential antineoplastic activity. Endoxifen, the active metabolite of tamoxifen, competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA and thus reducing DNA synthesis. Unlike tamoxifen, however, which relies on CYP2D6 activity for its conversion to the active metabolite endoxifen, the direct administration of endoxifen bypasses the CYP2D6 route. As CYP2D6 activity can vary widely among individuals due to genetic CYP2D6 polymorphisms, endoxifen is therefore theoretically more potent and more uniform in its bioavailability across patient populations.","Endoxifen Hydrochloride | 4-Hydroxy-N-Desmethyltamoxifen Hydrochloride | ENDOXIFEN HYDROCHLORIDE | Z-Endoxifen HCl | Z-Endoxifen Hydrochloride | Z-Endoxifen Hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001480","Adenosine Triphosphate","C209","An adenine nucleotide comprised of three phosphate groups esterified to the sugar moiety, found in all living cells. Adenosine triphosphate is involved in energy production for metabolic processes and RNA synthesis.  In addition, this substance acts as a neurotransmitter.  In cancer studies, adenosine triphosphate is synthesized to examine its use to decrease weight loss and improve muscle strength.","Adenosine Triphosphate | ADENOSINE TRIPHOSPHATE | ATP | Adenosine 5'-(Tetrahydrogen Triphosphate) | Adenosine 5'-Triphosphoric Acid | adenosine triphosphate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274014","Brief Ataxia Rating Scale","C98367","A validated instrument to assess ataxia using five criteria for evaluation: Gait, Knee-tibia test, Finger-to-nose test, Dysarthria, and Occulomotor abnormalities.","Brief Ataxia Rating Scale | BARS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986560","Best Overall Response","C94536","The most clinically favorable response recorded from the start of the study treatment until the end of treatment.","Best Overall Response | BESTRESP | Best Response | best overall response | best response | best_overall_response | best_response | treatment outcome | treatment_outcome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229633","Myeloblast","C13015","An immature cell that represents the first stage in the granulocytic series of hematopoiesis. It is found in bone marrow and differentiates into a promyelocyte. Its nucleus is composed of very fine, evenly distributed chromatin with 2-5 nucleoli. The cytoplasm is basophilic and non-granular.","Myeloblast | myeloblastic",,,,,,,,,,,,,,,"4048558","Myeloblast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3274029","Perineuronal Satellitosis","C98382","A morphologic finding that refers to the accumulation of glial cells encircling neurons in a tissue specimen.","Perineuronal Satellitosis | SATELLITOSIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274041","KRAS NP_004976.2:p.G12W","C98394","A change in the amino acid residue at position 12 in the GTPase KRas protein where glycine has been replaced by tryptophan.","KRAS NP_004976.2:p.G12W | GTPase KRas G12W | K-Ras 2 G12W | KRAS G12W | KRAS Gly12Trp | KRAS NP_004976.2:p.Gly12Trp | KRAS p.G12W | KRAS p.Gly12Trp | Ki-Ras G12W | NP_004976.2:p.Gly12Trp | Perivascular Satellitosis | c-K-ras G12W",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1148846","RNA Binding","C20737","RNA Binding is the molecular interaction between an RNA molecule and a macromolecule (usually protein or nucleic acid) for transport, catalysis, localization, or modification of function.","RNA Binding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162401","Differential Leukocyte Count","C98493","A hematologic procedure for the evaluation of the qualitative and quantitative characteristics of the white cells in peripheral blood smears and bone marrow aspirates.","Differential Leukocyte Count | Leukocyte Cell Differential | Leukocyte Cell Fraction | Leukocyte Diff | WBCDIFF",,,,,,,,,,,,,,,"4013251","Differential white blood cell count procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0545131","Blood Cell Count with Differential","C98494","A hematologic procedure to determine the number of red blood cells, white blood cells, and platelets, including the white cell differential count and red cell morphology, in a blood sample.","Blood Cell Count with Differential | CBC with Diff",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826693","Study Identifier","C83082","A sequence of characters used to identify, name, or characterize the study.","Study Identifier | STUDYID | STUDY_ID | Study ID | clinical study id | clinical_study_id",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019034","Sickle Cell-Hemoglobin C Disease","C34676","A hemoglobinopathy that is considered a hybrid of sickle cell disease and hemoglobin C disease. Patients present with the symptoms of sickle cell disease but the latter are less frequent and severe compared to sickle cell disease.","Sickle Cell-Hemoglobin C Disease | HbSC | Hemoglobin SC Disease | Hemoglobin SC Disease",,,,,,,,,,,,,,,"24006","Sickle cell-hemoglobin C disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3274465","Sickle Beta Plus Thalassemia","C98837","A mild form of sickle cell thalassemia characterized by the presence of hemoglobin S and a small amount of hemoglobin A in the red blood cells. It is characterized by the presence of small red blood cells and mild anemia.","Sickle Beta Plus Thalassemia | Sickle B+ Thalassemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274463","Sickle Beta 0 Thalassemia","C98835","A form of sickle cell thalassemia characterized by the absence of hemoglobin A. Patients usually have severe anemia identical to that seen in sickle cell disease.","Sickle Beta 0 Thalassemia | Hb S Beta 0 Thalassemia | Hemoglobin S Beta 0 Thalassemia | S Beta 0 Thalassemia | Sickle Beta Zero Thalassemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274466","Endometrioid Tissue Present","C98839","A microscopic finding indicating the presence in a sample of tissue that resembles endometrial tissue.","Endometrioid Tissue Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418401","PDCD1 Gene","C94695","This gene plays a role in apoptosis.","PDCD1 Gene | PDCD1 | Programmed Cell Death 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366777","TRAF2 Gene","C28653","This gene is involved in signal transduction and inhibition of apoptosis.","TRAF2 Gene | TNF Receptor Associated Factor 2 Gene | TRAF2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334487","MCAM Gene","C21261","This gene plays a role in cell adhesion and receptor signaling.","MCAM Gene | MCAM | Melanoma Cell Adhesion Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272886","Circulating Endothelial Cell Count","C96592","The determination of the amount of circulating endothelial cells present in a sample.","Circulating Endothelial Cell Count | CEC | Circulating Endothelial Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1948052","Now (temporal qualifier)","C65002","At the present time.","Now | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0972255","Collagen Alpha-1(I) Chain","C30013","Collagen alpha-1(I) chain (1464 aa, ~139 kDa) is encoded by the human COL1A1 gene. This protein is involved in the formation of fibrillar collagen.","Collagen Alpha-1(I) Chain | Alpha 1 Type I Collagen | Alpha-1 Type I Collagen | Alpha1(I) Procollagen | COL1A1 | Collagen Alpha 1 Chain Type I | Collagen Alpha 1(I) Chain | Collagen Alpha-1(I) Chain Preproprotein | Collagen I (Alpha 1) | Collagen I (Alpha 1) | Collagen I, Alpha-1 Polypeptide | Collagen of Skin, Tendon and Bone, Alpha-1 Chain | Collagen of Skin, Tendon, and Bone, Alpha-1 Chain | Collagen, Type I, Alpha 1 | Pro-Alpha-1 Collagen Type 1 | Type I Proalpha 1 | Type I Procollagen Alpha 1 Chain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035018","REL Gene","C17084","This gene is involved in transcriptional regulation and signal transduction through the nuclear factor kappa B NFKB signal transduction pathway.","REL Gene | REL | v-REL Avian Reticuloendotheliosis Viral Oncogene Homolog Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008586","Chromogranin","C16436","Chromogranins are acidic secretory glycoproteins with a widespread but specific distribution in neuroendocrine tissues. The chromogranin family is heterogenous, consisting of propeptides such as chromogranin-A, chromogranin-B and secretogranin II, which can either elicit an effect themselves, or serve as precursors to a large number of peptides, which are biologically more active.","Chromogranin | CHG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1456796","TNFRSF8 Gene","C38905","This gene is involved in pro-apoptotic regulation via the NF-kappaB signal transduction pathway.","TNFRSF8 Gene | CD30 | TNFRSF8 | Tumor Necrosis Factor Receptor Superfamily, Member 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162508","JUN Gene","C19531","This gene plays a critical role in transcriptional regulation and cellular growth.","JUN Gene | JUN | Jun Proto-oncogene, AP-1 Transcription Factor Subunit Gene | v-JUN Sarcoma Virus 17 Oncogene Homolog (Avian) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0694897","VHL Gene","C18261","This gene is involved in transcriptional repression and protein degradation.","VHL Gene | VHL | Von Hippel-Lindau Tumor Suppressor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0440743","Serous","C14168","Of or producing or containing serum.","Serous | serous",,,,,,,,,,,,,,,"4105064","Serous",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205188","Operable","C94254","Describes a condition that can be treated by surgery.","Operable | operable",,,,,,,,,,,,,,,"4294980","Operable",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0439824","Verbal","C94846","Expressed in spoken words.","Verbal | ",,,,,,,,,,,,,,,"4112257","Verbal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0694883","STK11 Gene","C18253","This gene plays a role in cell cycle regulation. It is also putatively involved in glucose production.","STK11 Gene | LKB1 | STK11 | Serine/Threonine Kinase 11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL414509","Cortisol","C2290","A hormone made by the adrenal cortex (the outer layer of the adrenal gland). It helps the body use glucose (a sugar), protein, and fats. Cortisol made in the laboratory is called hydrocortisone. It is used to treat many conditions, including inflammation, allergies, and some cancers. Cortisol is a type of glucocorticoid hormone.","Cortisol | (11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione | Hydrocortisone | cortisol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334899","NR3C1 Gene","C28571","This gene is involved in ligand-activated transcriptional regulation and mutations in the gene are associated with glucocorticoid resistance.","NR3C1 Gene | NR3C1 | Nuclear Receptor Subfamily 3, Group C, Member 1 (Glucocorticoid Receptor) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333257","DUSP1 Gene","C24355","This gene is a transcriptional target of TP53 protein and plays a role in cell cycle regulation.","DUSP1 Gene | DUSP1 | Dual Specificity Phosphatase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514470","Progenitor Cell Engraftment","C16034","Establishment of a self replicating population of stem cells with subsequent repopulation of differentiated cell types.","Progenitor Cell Engraftment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418898","PRKAA2 Gene","C94745","This gene plays a role in the cellular stress response.","PRKAA2 Gene | PRKAA2 | Protein Kinase, AMP-Activated, Alpha 2 Catalytic Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1367441","FASN Gene","C26564","This gene is involved in the production of both lung surfactant and the fatty components of milk. It also plays a role in the conversion and storage of energy in liver and adipose tissues.","FASN Gene | FASN | Fatty Acid Synthase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1337092","CCL2 Gene","C20907","This gene is involved in inflammatory processes and disease development.","CCL2 Gene | CCL2 | Chemokine (C-C Motif) Ligand 2 Gene | MCP-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1337114","SELE Gene","C21043","This gene plays a role in inflammation by mediating cellular adhesion to vasculature.","SELE Gene | SELE | Selectin E Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006558","C Peptide","C94608","C peptide (31 aa, ~3 kDa) is encoded by the human INS gene. This protein is involved in both signal transduction and the modulation of blood flow.","C Peptide | C-Peptide | C-peptide | Human Proinsulin C-Peptide | Proinsulin C-Peptide | connecting peptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515187","Take","C65105","As pertains to a medication: ingest, inhale, instill, or inject.","Take | ",,,,,,,,,,,,,,,"4305543","Take",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003216","Anti-Ulcer Agent","C29701","Natural or synthetic Anti-ulcer Agents relieve and reduce the symptoms of ulcers in the stomach and upper small intestine, systemically and locally, by reducing gastric secretion (proton pump inhibitors), neutralizing hyperacidity (alkalinizing agents), or improving healing and protecting the mucosa (sucralfate). Recurrent gastric and duodenal ulcers caused by Helicobacter pylori infections are treated with antibiotic therapy.","Anti-ulcer Agent | Antacid | Antacid medication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539082","CD40LG Gene","C21132","This gene plays a role in the stimulation of B cells in immune responses.","CD40LG Gene | CD154 Gene | CD40 Ligand Gene | CD40LG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335808","SELL Gene","C21046","This gene plays a role in leukocyte-endothelial cell interactions.","SELL Gene | SELL | Selectin L Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420708","TFRC Gene","C38517","This gene plays a regulatory role in receptor-mediated endocytosis and iron metabolism.","TFRC Gene | TFRC | Transferrin Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334091","IGF2 Gene","C24486","This gene plays a role in cell growth and proliferation. It is also involved in the regulation of prenatal skeletal and muscular development.","IGF2 Gene | IGF2 | Insulin-Like Growth Factor 2 (Somatomedin A) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274505","Content Identifier","C99023","The unique identifier for a piece of content such as a document, image, or other media in a specified context.","Content Identifier | Content ID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0171023","Olanzapine","C47639","A synthetic derivative of thienobenzodiazepine with antipsychotic, antinausea, and antiemetic activities. As a selective monoaminergic antagonist, olanzapine binds with high affinity binding to the following receptors: serotoninergic, dopaminergic, muscarinic M1-5, histamine H1, and alpha-1-adrenergic receptors; it binds weakly to gamma-aminobutyric acid type A, benzodiazepine, and beta-adrenergic receptors. The antinausea and antiemetic effects of this agent appear to be due to the blockade of 5-HT2 and 5-HT3 receptors for serotonin. Although its exact mechanism of action in schizophrenia is unknown, it has been proposed that olanzapine's antipsychotic activity is mediated through antagonism to dopamine D2 receptors with rapid ligand-receptor dissociation kinetics that help to minimize extrapyramidal symptoms (EPS). Olanzapine may also stimulate appetite.","Olanzapine | 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine | LY 170053 | OLANZAPINE | Zyprexa | Zyprexa Zydis | olanzapine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346821","Pidilizumab","C71014","A humanized monoclonal antibody directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities. Pidilizumab blocks interaction between the receptor PD-1 with its ligands, PD-1 ligand 1 (PD-1L1) and PD-1 ligand 2 (PD-1L2), resulting in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells, and the augmentation of the anti-tumor activities of NK cells. PD-1 is an inhibitory receptor belonging to the B7-receptor family that is expressed on lymphocytes and myeloid cells; its ligands, PD-1L1 and PD-1L2, are expressed not only by hematopoietic cells but also by cells in non-lymphoid tissues.","Pidilizumab | Anti-PD-1 Monoclonal Antibody CT-011 | CT 011 | CT-011 | CT011 | Immunoglobulin G1, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal CT-011 Gamma1 Heavy Chain (220-213')-disulfide with Humanized Mouse Monoclonal CT-011 Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide, Glycosylated (CT-011 is Expressed in NSO Cells) | MDV9300 | PIDILIZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349976","Gamma - unit of measure","C68914","A unit of magnetic flux density equal to 10(E-9) tesla (one nanotesla) or 10(E-5) oersted, traditionally used in geophysics for measurement of changes in the Earth's magnetic field.","Gamma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336637","TLR5 Gene","C24866","This gene plays a role in the mediation of cytokine production and immunity.","TLR5 Gene | TLR5 | Toll-Like Receptor 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1267822","CD4+ CD25+ Regulatory T Cells","C78829","Regulatory T cells that express CD4 and CD25 (interleukin 2 receptor) antigens, with immunomodulating activity. CD4+CD25+ T regulatory cells (Tregs), a subset of CD4+ T cells expressing high levels of CD25 and the transcription factor Foxp3, are essential in maintaining immunologic homeostasis, preventing autoimmunity by suppressing self-reactive T cells; CD4+CD25+ Tregs may induce tolerance to allogeneic organ transplants such as hematopoetic stem cell transplants (HSCTs).","CD4+ CD25+ Regulatory T Cells | CD4+ CD25+ FOXP3+ Regulatory T Cells | T reg | T-regulatory cell | regulatory T cell | suppressor T cell",,,,,,,,,,,,,,,"4019606","T lymphocyte positive for both CD4 antigen and CD25 antigen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0312740","Effector Immune Cell","C28241","An immune cell, usually a T- or B- lymphocyte, that is responding to an antigen exposure.","Effector Immune Cell | Effector Cell | Effector Cell | Effector Immune Cell | effector cell",,,,,,,,,,,,,,,"4313580","Immune effector cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1336642","TNC Gene","C21091","This gene is involved in cell adhesion, differentiation and proliferation.","TNC Gene | TNC | Tenascin C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539630","HBEGF Gene","C24353","This gene plays a role in macrophage-mediated cellular proliferation and growth regulation in fibroblasts and smooth muscle cells.","HBEGF Gene | HBEGF | Heparin-Binding EGF-Like Growth Factor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3884279","Epiregulin, Human","C26171","Epiregulin (49 aa, ~6 kDa) is encoded by the human EREG gene. This protein is involved in the positive regulation of cell proliferation.","Epiregulin | EREG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3884533","Betacellulin, Human","C20432","Betacellulin (80 aa, ~9 kDa) is encoded by the human BTC gene. This protein is involved in epidermal growth factor receptor family signaling pathways.","Betacellulin | BTC | Beta Cellulin | Beta-Cellulin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333570","FOLH1 Gene","C38315","This gene plays a role in folate metabolism. It is also involved in neuronal transmission.","FOLH1 Gene | FOLH1 | Folate Hydrolase 1 Gene | PSMA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348919","HLA-A*0201 Positive Cells Present","C69178","A laboratory test result indicating the presence of HLA-A*0201 positive cells in a tissue sample.","HLA-A*0201 Positive Cells Present | HLA-A*0201 Positive | HLA-A*02:01 Positive | HLA-A*02:01 Positive Cells Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL426012","Fertile","C94191","Able to produce children.","Fertile | Fertility | fertile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366765","MAPK3 Gene","C21226","This gene is involved in signal transduction and positive regulation of the cell cycle.","MAPK3 Gene | MAPK3 | Mitogen-Activated Protein Kinase 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032950","Prednisolone","C769","A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisolone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)","Prednisolone | (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione | .delta.1-Hydrocortisone | 1,2-Dehydrohydrocortisone | Adnisolone | Aprednislon | Capsoid | Cortalone | Cortisolone | Dacortin H | Decaprednil | Decortin H | Delta(1)Hydrocortisone | Delta- Cortef | Delta-Cortef | Delta-Diona | Delta-F | Delta-Phoricol | Delta1-dehydro-hydrocortisone | Deltacortril | Deltahydrocortisone | Deltasolone | Deltidrosol | Dhasolone | Di-Adreson-F | Dontisolon D | Estilsona | Fisopred | Frisolona | Gupisone | Hostacortin H | Hydeltra | Hydeltrasol | Klismacort | Kuhlprednon | Lenisolone | Lepi-Cortinolo | Linola-H N | Linola-H-Fett N | Longiprednil | Metacortandralone | Meti Derm | Meticortelone | Opredsone | PREDNISOLONE | Panafcortelone | Precortisyl | Pred-Clysma | Predeltilone | Predni-Coelin | Predni-Helvacort | Prednicortelone | Prednisolonum | Prelone | Prenilone | Sterane | prednisolone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016280","Fludrocortisone","C71629","A synthetic corticosteroid with antiinflammatory and antiallergic properties. Fludrocortisone is a mineralocorticoid receptor and glucocorticoid receptor agonist that binds to cytoplasmic receptors, translocates to the nucleus and subsequently initiates the transcription of glucocorticoid-responsive genes such as lipocortins to inhibit phospholipase A2. This prevents the release of arachidonic acid, a precursor to prostaglandins and leukotrienes, both important mediators in the pro-inflammatory response mechanism. In addition, this agent exerts its mineralocorticoid effect on the distal tubules and collecting ducts of the kidney by inducing permease, an enzyme that regulates Na+ permeability in cells, thereby enhancing Na+ reabsorption and water retention as well as increasing K+, H+ excretion.","Fludrocortisone | FLUDROCORTISONE | Florinef | fludrocortisone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040864","Triamcinolone","C901","A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. Upon cell entry, triamcinolone binds to and activates the glucocorticoid receptor, which leads to translocation of the ligand-receptor complex to the nucleus and induces expression of glucocorticoid-responsive genes such as lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both mediators of inflammation. In addition, pro-inflammatory cytokine production, including interleukin (IL)-1and IL-6, and the activation of cytotoxic T-lymphocytes is also inhibited. T-cells are prevented from making IL-2 and proliferating. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis through increasing Ikappa-B expression and curtailing activation of nuclear factor (NF)kappa-B.","Triamcinolone | (11beta,16alpha)-9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione | Aristocort | TRIAMCINOLONE | triamcinolone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366882","MAPK1 Gene","C21227","This gene plays a role in signal transduction and positive regulation of the cell cycle.","MAPK1 Gene | MAPK1 | Mitogen-Activated Protein Kinase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3849701","Interleukin-18, Human","C20520","Interleukin-18 (193 aa, ~22 kDa) is encoded by the human IL18 gene. This protein is involved in the regulation of both natural killer cell activity and the production of interferon gamma.","Interleukin-18 | IFN-gamma-Inducing Factor | IGIF | IL-1 Gamma | IL-18 | IL-1g | IL18 | IL18 Protein | IL1F4 | Interferon Gamma-Inducing Factor | Interferon-Gamma Inducing Factor | Interferon-Gamma-Inducing Factor | Interleukin 18 | Interleukin 18 Proprotein | Interleukin-1 Gamma | Interleukin-18 Precursor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041014","Liothyronine","C907","A therapeutic formulation of the primary physiologically active form of endogenous thyroid hormone. In vivo, triiodothyronine enters the nucleus and binds to nuclear thyroid hormone receptors that subsequently bind to thyroid response elements (TREs) located in target genes. Receptor binding by triiodothyronine in combination with recruited coactivators results in maximal transcriptional activation after binding to TREs; in general, binding of thyroid hormone receptor alone to TREs leads to repression of gene transcription (NCI04)","Liothyronine | L-Triiodothyronine | LIOTHYRONINE | Therapeutic T3 | Triiodothyronine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0936106","liotrix","C87251","No Value Exists","Liotrix | Euthroid | LIOTRIX | Levothyroxine Sodium mixture with Liothyronine Sodium | Thyrolar",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202225","Free Thyroxine Measurement","C74786","The determination of the amount of free thyroxine present in a sample.","Free Thyroxine Measurement | Free T4 | T4-Free | T4FR | Thyroxine, Free",,,,,,,,,,,,,,,"4196969","T4 free measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705808","SLC5A5 wt Allele","C52303","Human SLC5A5 wild-type allele is located within 19p13.2-p12 and is approximately 22 kb in length. This allele, which encodes sodium/iodide cotransporter protein, plays a role in the mediation of iodide transport into the thyroid. Mutations in the gene are linked to hypothyroidism due to an iodide transport defect.","SLC5A5 wt Allele | NIS Gene | SLC5A5 | Sodium-Iodide Symporter Gene | Solute Carrier Family 5 (Sodium Iodide Symporter), Member 5 Gene | Solute Carrier Family 5 (Sodium/Iodide Cotransporter), Member 5 wt Allele | TDH1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332709","CD28 Gene","C21291","This gene plays several roles in cellular functions specific to the T-cell.","CD28 Gene | CD28 | CD28 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334306","KDR Gene","C24532","This gene plays a role in angiogenesis and vascular regulation.","KDR Gene | KDR | Kinase Insert Domain Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414603","FGF19 Gene","C96328","This gene is involved in growth factor signaling.","FGF19 Gene | FGF19 | Fibroblast Growth Factor 19 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040123","TG protein, human","C2304","Thyroglobulin (2768 aa, ~305 kDa) is encoded by the human TG gene. This protein is involved in thyroid hormone synthesis.","Thyroglobulin | TG | THYROGLOBULIN | Tg | Thyroid Thyroglobulin | thyroglobulin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242301","Furuncle","C99087","Bacterial infection of the hair follicle and the surrounding skin. It is caused by Staphylococcus aureus. It presents as a painful, erythematous and swollen skin lesion.","Furuncle | Boil",,,,,,,,,,,,,,,"4220002|4245878","Furuncle|Furuncle",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0021099","Impetigo","C99088","A contagious bacterial cutaneous infection that affects children and is usually caused by Staphylococcus aureus. It usually presents in the face with honey colored scabs.","Impetigo | ",,,,,,,,,,,,,,,"140480","Impetigo",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2749205","Pyloric Stenosis","C34966","Narrowing of the pyloric lumen caused either by hypertrophy of the surrounding muscles or tissue scarring due to a chronic peptic ulcer.","Pyloric Stenosis | Gastric Outlet Obstruction",,,,,,,,,,,,,,,"4273754","Pyloric stenosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005694","Bladder Obstruction","C79541","Blockage of the opening between the bladder and the urethra resulting in the reduction or prevention of the urine flow from the bladder into the urethra.","Bladder Obstruction | Bladder Outlet Obstruction | Urinary Outlet Obstruction",,,,,,,,,,,,,,,"4220439|433813","Bladder outlet obstruction|Bladder neck obstruction",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3274533","Content Item","C99095","A single digital file in the Electronic Content material.","Content Item | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274532","Electronic Content","C99094","Material recorded in a format that requires an electronic device to view or modify, encompassing documents, images, multimedia, web pages, and other digital media.","Electronic Content | Digital Content",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553268","Georgetown","C44633","A person having origins in the original Georgetown Yupik people.","Georgetown Yupik | Georgetown | Georgetown | Georgetown (Yupik-Eskimo) | Native Village of Georgetown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812298","FLT1 Gene","C18414","This gene is involved in cellular proliferation, differentiation and tyrosine kinase signal transduction.","FLT1 Gene | FLT1 | FMS Related Tyrosine Kinase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0442158","Perianal Region","C99148","The skin area around the anus.","Perianal Region | PERIANAL REGION | Perianal",,,,,,,,,,,,,,,"4287469","Perianal region structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0379710","caveolin 1","C17971","Caveolin-1 (178 aa, ~20 kDa) is encoded by the human CAV1 gene. This protein plays a role in caveolae formation and function.","Caveolin-1 | CAV | CAV1 | Caveolae Protein, 22kD | Caveolin 1 | Caveolin 1 | Caveolin 1, Caveolae Protein, 22kD | Cell Growth-Inhibiting Protein 32 | VIP21",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3530142","SPARC protein, human","C92668","SPARC (303 aa, ~35 kDa) is encoded by the human SPARC gene. This protein is involved in calcium binding and deposition, cell cycle progression, extracellular matrix synthesis and cell morphology.","SPARC | BM-40 | Basement-Membrane Protein 40 | ON | Osteonectin | Secreted Protein Acidic and Rich in Cysteine 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0694889","RB1 Gene","C17360","This gene is involved in the regulation of cell differentiation, growth and proliferation.","RB1 Gene | RB | RB Transcriptional Corepressor 1 Gene | RB transcriptional corepressor 1 | RB1 | RB1; RB transcriptional corepressor 1; RB Transcriptional Corepressor 1 Gene | Retinoblastoma 1 (Including Osteosarcoma) Gene | Retinoblastoma protein 1 gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0303212","Chromium Cr-51","C80652","No Value Exists","Chromium Cr-51 | CHROMIUM CR-51 | Chromium Cr 51",,,,,,,,,,,,,,,"4199745","Chromium-51",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1413173","CCND2 Gene","C39596","This gene is involved in the regulation of the G1/S phase of the cell cycle.","CCND2 Gene | CCND2 | Cyclin D2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1337106","TBP Gene","C20460","This gene plays an essential role in RNA polymerase II transcription and initiation.","TBP Gene | TATA Sequence-Binding Protein Gene | TBP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3252356","Interleukin-15, Human","C20517","Interleukin-15 (162 aa, ~18 kDa) is encoded by the human IL15 gene. This protein plays a role in the regulation of both proliferation and activation of both T-cells and natural killer cells.","Interleukin-15 | IL-15 | IL15 | IL15 Protein | Interleukin 15 | Interleukin-15 Precursor | MGC9721",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3657270","Nivolumab","C68814","A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","Nivolumab | ABP 206 | Anti-PD-1 Human Monoclonal Antibody MDX-1106 | BCD-263 | BMS 936558 | BMS-936558 | BMS936558 | CMAB819 | MDX 1106 | MDX-1106 | MDX1106 | NIVO | NIVOLUMAB | Nivolumab Biosimilar ABP 206 | Nivolumab Biosimilar BCD-263 | Nivolumab Biosimilar CMAB819 | ONO 4538 | ONO-4538 | ONO4538 | Opdivo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL007210","Breast Mixed Ductal and Lobular Carcinoma","C5160","A breast carcinoma characterized by the presence of a lobular and a ductal component. The ductal component comprises less than 50 percent of the tumor.","Breast Mixed Ductal and Lobular Carcinoma | Ductal and Lobular Carcinoma | Mixed Ductal and Lobular Breast Carcinoma | Mixed Ductal and Lobular Carcinoma | Mixed Ductal and Lobular Carcinoma of Breast | Mixed Ductal and Lobular Carcinoma of the Breast | Mixed Lobular and Ductal Breast Carcinoma | Mixed Lobular and Ductal Breast Carcinoma | Mixed Lobular and Ductal Carcinoma | Mixed Lobular and Ductal Carcinoma of Breast | Mixed Lobular and Ductal Carcinoma of the Breast",,,,,,,,,,,,,,,"40480215","Mixed ductal and lobular carcinoma of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1416655","KIT Gene","C18609","This gene plays a role in cellular hematopoiesis and differentiations. Mutations in the gene are associated with several diseases, including acute myelogenous leukemia, gastrointestinal tumors, and mast cell disease.","KIT Gene | KIT | V-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333685","GNAQ Gene","C38316","This gene plays a role in signal transduction and is involved in calcium signaling.","GNAQ Gene | G Protein Subunit Alpha q Gene | GNAQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448326","SRC Gene","C19917","This gene is involved in apoptosis, hormonogenesis, focal adhesion and the formation of intercellular junctions.","SRC Gene | SRC | SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883670","Apocrine Differentiation","C62493","A morphologic finding that indicates the presence of cells with abundant eosinophilic and granular cytoplasm in a tumor sample.","Apocrine Differentiation | Apocrine Features | Apocrine Features Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229889","Lymphatic Vessel","C33038","A tubule that carries lymph throughout the body.","Lymphatic Vessel | VESSEL, LYMPHATIC | lymph vessel | lymphatic vessel",,,,,,,,,,,,,,,"4308890","Structure of lymphatic vessel",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333615","Fibrotic Stroma Formation","C36178","A morphologic finding that indicates the presence of reactive fibrotic stroma in a tissue sample.","Fibrotic Stroma Formation | Stromal Central Fibrotic Focus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1160421","Pattern Formation","C19970","Pattern Formation is a developmental morphogenetic process that establishes basic configurations of cellular organization necessary for further and accurate development of the spatial arrangements of embryonic tissue.","Pattern Formation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709101","Myofibroblastic Differentiation","C49101","A morphologic finding that indicates the presence of myofibroblastic differentiation in a cellular infiltrate of a tissue sample.","Myofibroblastic Differentiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334857","Myxoid Stroma Formation","C35998","A morphologic finding that indicates the presence of myxoid changes in the stroma of a tissue sample.","Myxoid Stroma Formation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL413952","None or Not Applicable","C18902","A term used to indicate that information on a specific question or subject can not be provided because there is no relevance.","None or Not Applicable | N/A | Not Applicable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1455888","Atypical Glandular Cell","C36912","An abnormal endocervical or endometrial cell found in a cervical smear, not further characterized as neoplastic or non-neoplastic. It is often associated with clinically significant uterine lesions.","Atypical Glandular Cell | AGC | Atypical Glandular Cell, NOS | Atypical Glandular Cell, Not Otherwise Specified | atypical glandular cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0195324","Conization","C15402","Surgical removal of a cone-shaped portion of tissue from the uterine cervix.","Conization | Cone Biopsy of Cervix | Conization of Cervix | Conization of Uterine Cervix | cone biopsy | conization",,,,,,,,,,,,,,,"4005173|4181912","Cone biopsy|Cone biopsy of cervix",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0242277","Proerythroblast","C13129","The earliest of four stages in development of the normoblast.","Proerythroblast | ",,,,,,,,,,,,,,,"4041901","Pronormoblast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1378511","Acute Undifferentiated Leukemia","C9298","A rare acute leukemia of ambiguous lineage in which the blasts do not express markers specific to myeloid or lymphoid lineage.","Acute Undifferentiated Leukemia | Acute Leukemia Not Otherwise Specified | Acute Leukemia, NOS | Acute leukemia, NOS | Leukemia Stem Cell | Stem Cell Acute Leukemia | Stem Cell Leukemia | Stem cell leukemia | Undifferentiated Acute Leukemia",,,,,,,,,,,,,,,"37167452","Acute undifferentiated leukemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1005556","Human Papillomavirus-6","C14319","Genital warts caused by HPV 6 and 11 are the most common STD in the United States. Over a million cases are seen per year.","Human Papillomavirus-6 | HPV 6 | HPV-6 | HUMAN PAPILLOMAVIRUS TYPE 6 | Human Papillomavirus Type 6",,,,,,,,,,,,,,,"4070759","Human papillomavirus type 6",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0694890","RET Gene","C18257","This gene plays an essential role in neural crest development, cellular growth and differentiation. Mutations in the gene are associated with a variety of neoplasias and carcinomas.","RET Gene | RET | RET Proto-Oncogene (Multiple Endocrine Neoplasia and Medullary Thyroid Carcinoma 1, Hirschsprung Disease) Gene",,,,,,,,,,,,,,,"4233628","RET proto-oncogene",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1421224","TTR Gene","C79961","This gene is involved in both the binding and transport of retinol and the thyroid hormone thyroxine.","TTR Gene | TTR | Transthyretin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413322","CEBPA Gene","C39598","This gene plays a role in body weight homeostasis and cellular proliferation. Mutations in the gene are associated with acute myeloid leukemia.","CEBPA Gene | CCAAT Enhancer Binding Protein Alpha Gene | CEBPA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034392","Quercetin","C792","A polyphenolic flavonoid with potential chemopreventive activity. Quercetin, ubiquitous in plant food sources and a major bioflavonoid in the human diet, may produce antiproliferative effects resulting from the modulation of either EGFR or estrogen-receptor mediated signal transduction pathways. Although the mechanism of action of action is not fully known, the following effects have been described with this agent in vitro: decreased expression of mutant p53 protein and p21-ras oncogene, induction of cell cycle arrest at the G1 phase and inhibition of heat shock protein synthesis. This compound also demonstrates synergy and reversal of the multidrug resistance phenotype, when combined with chemotherapeutic drugs, in vitro. Quercetin also produces anti-inflammatory and anti-allergy effects mediated through the inhibition of the lipoxygenase and cyclooxygenase pathways, thereby preventing the production of pro-inflammatory mediators.","Quercetin | 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one | 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-chromen-4-one | 3,3',4',5,7-Pentahydroxyflavone | C.I. Natural Yellow 10 | QUERCETIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013900","Ellagic Acid","C63641","No Value Exists","Ellagic Acid | 2,3,7,8-Tetrahydroxy[1]benzopyrano[5,4,3-cde][1]-benzopyran-5,10-dione | Benzoaric Acid | ELLAGIC ACID | Eleagic acid | Gallogen | Lagistase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL414666","Kinase","C28597","Encoded by Kinase Family Genes, Kinase enzymes covalently transfer the terminal, gamma phosphate group from ATP to a variety of substrates and typically play key regulatory roles in diverse cellular functions. (NCI)","Kinase | Kinase Family | kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963262","Urethra Obstruction, CTCAE","C57091","Blockage of the normal flow of urine in the urethra occurring following a procedure or pharmaceutical intervention.","Urethra Obstruction, CTCAE | Urethra Obstruction Adverse Event | Urethra obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705206","Counter Device","C49894","A device designed to keep track of the number of times something happens.","Counter Device | Counter | Counter Device Component",,,,,,,,,,,,,,,"4122664","Counter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333368","EZH2 Gene","C21327","This gene plays a role in chromatin remodeling and transcriptional regulation.","EZH2 Gene | EZH2 | Enhancer of Zeste 2 Polycomb Repressive Complex 2 Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1093046","Human Papillomavirus-11","C99178","A human papillomavirus that is a common causative agent of genital warts. Human papillomavirus-11 is considered low-risk for causing malignancies.","Human Papillomavirus-11 | HPV 11 | HPV-11 | HUMAN PAPILLOMAVIRUS TYPE 11 | Human Papillomavirus Type 11 | Human papillomavirus 11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274595","Tartrate-Resistant Acid Phosphatase Type 5b, human","C99185","Tartrate-resistant acid phosphatase type 5b (325 aa, ~37 kDa) is encoded by the human ACP5 gene. This protein is involved in acid phosphatase activity and is comprised of two disulfide linked polypeptides which are the result of proteolytic cleavage of the tartrate-resistant acid phosphatase type 5 protein.","Tartrate-Resistant Acid Phosphatase Type 5b | EC 3.1.3.2 | TRACP-5b | Tartrate-Resistant Acid Phosphatase-5b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1566918","Tartrate-Resistant Acid Phosphatase Type 5, Human","C99184","Tartrate-resistant acid phosphatase type 5 (325 aa, ~37 kDa) is encoded by the human ACP5 gene. This protein plays a role in the mediation of phosphate group removal from sialoproteins.","Tartrate-Resistant Acid Phosphatase Type 5 | ACP5 | EC 3.1.3.2 | TR-AP | TRACP-5a | Tartrate-Resistant Acid ATPase | Tartrate-Resistant Acid Phosphatase Type 5a | Tartrate-Resistant Acid Phosphatase-5a | TrATPase | Type 5 Acid Phosphatase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001973","Alcohol Dependence","C93040","Physical and psychological dependence on alcohol.","Alcohol Dependence | alcohol dependence | alcoholism",,,,,,,,,,,,,,,"435243","Alcohol dependence",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1880156","Comprehensive","C61528","Broad in scope; including all or everything.","Comprehensive | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0686907","Consequence","C74555","The result of an action.","Consequence | ",,,,,,,,,,,,,,,"4013717","Consequence of",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0585323","Every Three Hours","C64517","Every three hours.","Every Three Hours | Every 3 hours | Q3H",,,,,,,,,,,,,,,"4023339","Every three hours",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0585324","Every Four Hours","C64518","Every four hours.","Every Four Hours | Every 4 hours | Q4H",,,,,,,,,,,,,,,"4021636","Every four hours",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0585325","Every Six Hours","C64520","Every six hours.","Every Six Hours | Every 6 hours | Q6H",,,,,,,,,,,,,,,"4144047","Every six hours",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0585326","Every Eight Hours","C64523","Every eight hours.","Every Eight Hours | Every 8 hours | Q8H",,,,,,,,,,,,,,,"4145087","Every eight hours",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0585329","Every Morning","C64595","Every morning, before 12:00pm.","Every Morning | QAM | quaque ante meridiem",,,,,,,,,,,,,,,"4141102","Every morning",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0558287","Every Other Day","C64525","Every other day.","Every Other Day | Every Second Day | Every Two Days | Every other day | Q2D | QOD | Quoque Alternis Die | q.a.d.",,,,,,,,,,,,,,,"4021817","Alternate days",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0179415","Breath Alcohol Test Device","C99266","A device that approximates a blood alcohol level from the components of an expired breath.","Breath Alcohol Test Device | Breath Alcohol Tester | Breathalyzer",,,,,,,,,,,,,,,"4079331","Breath analyzer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3274646","Participant Case or Control Status","C99268","An indication of a subject's status as a case or a control for a given study.","Participant Case or Control Status | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274647","True Case Status","C99269","The participant is a true case for the phenotype under consideration.","True Case Status |  Case | Case",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274648","True Control Status","C99270","The participant is a true control for the phenotype under consideration.","True Control Status | Control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274649","Probable Case Status","C99271","The participant is a probable case for the phenotype under consideration.","Probable Case Status | Probable Case",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274650","Probable Control Status","C99272","The participant is a probable control for the phenotype under consideration.","Probable Control Status | Probable Control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274651","Neither Case or Control Status","C99273","The participant is neither a true case or true control for the phenotype under consideration.","Neither Case or Control Status | Neither | Neither Case nor Control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274652","Unable to Assess Case or Control Status","C99274","The participant's case/control status could not be assessed.","Unable to Assess Case or Control Status | Control Status not Assessed | Unassessed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812214","PIM1 Gene","C18337","This gene is involved in apoptosis, cell cycle regulation and signal transduction.","PIM1 Gene | PIM1 | Pim-1 Proto-Oncogene, Serine/Threonine Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332721","CDK1 Gene","C28559","This gene is involved in the cellular transition from the G1/S phase and from the G2/M phase of the cell cycle.","CDK1 Gene | CDC2 | CDC2 Gene | CDK1 | Cyclin-Dependent Kinase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332738","CDKN2C Gene","C24288","This gene is involved in cell cycle inhibition and regulation.","CDKN2C Gene | CDKN2C | Cyclin-Dependent Kinase Inhibitor 2C (p18, Inhibits CDK4) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413865","CYP27B1 Gene","C40073","This gene is involved in vitamin D metabolism and calcium homeostasis.","CYP27B1 Gene | CYP27B1 | Cytochrome P450 Family 27 Subfamily B Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0771310","Nefazodone Hydrochloride","C29283","A synthetic derivative of phenylpiperazine and chemically unrelated to selective serotonin reuptake inhibitors, tricyclics, tetracyclics, or monoamine oxidase inhibitors (MAOI), antidepressant Nefazadone Hydrochloride antagonizes central 5-HT2 receptors and inhibits reuptake of serotonin and norepinephrine. (NCI04)","Nefazodone Hydrochloride | NEFAZODONE HYDROCHLORIDE | Nefazadone HCl | Serzone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0540623","Naratriptan","C61857","No Value Exists","Naratriptan | NARATRIPTAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0721921","Naphazoline Hydrochloride","C47632","The hydrochloride salt form of naphazoline, an imidazole derivative and a direct-acting sympathomimetic amine with vasoconstrictive properties. Upon ocular administration, naphazoline hydrochloride exerts its effect by acting on alpha-adrenergic receptors in the arterioles of the conjunctiva to produce vasoconstriction, resulting in decreased conjunctival congestion and diminished itching, irritation and redness.","Naphazoline Hydrochloride | 1H-Imidazole, 4,5-dihydro-2-(1-naphthalenylmethyl)-, Monohydrochloride | 2-(1-Naphthylmethyl)-2-imidazoline Hydrochloride | Albalon | NAPHAZOLINE HYDROCHLORIDE | Nafazair | Opcon | Vasocon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0355800","Naltrexone Hydrochloride","C679","The hydrochloride salt of naltrexone, a noroxymorphone derivative with competitive opioid antagonistic activity. Naltrexone and its metabolite 6-beta-naltrexol reverse the effects of opioids by binding to various opioid receptors in the central nervous system CNS), including the mu-, kappa- and gamma-opioid receptors; opioid effects of analgesia, euphoria, sedation, respiratory depression, miosis, bradycardia, and physical dependence are inhibited. Naltrexone is longer-acting and more potent compared to naloxone.","Naltrexone Hydrochloride | (5alpha)-17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one Hydrochloride | Depade | NALTREXONE HYDROCHLORIDE | Naltrexone.HCl | ReVia | Revia | naltrexone hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027358","Naloxone","C62054","A thebaine derivate with competitive opioid antagonistic properties. Naloxone reverses the effects of opioid analgesics by binding to the opioid receptors in the CNS, and inhibiting the typical actions of opioid analgesics, including analgesia, euphoria, sedation, respiratory depression, miosis, bradycardia, and physical dependence. Naloxone binds to mu-opioid receptors with a high affinity, and a lesser degree to kappa- and gamma-opioid receptors in the CNS.","Naloxone | (-)-Naloxone | NALOXONE | naloxone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL414199","Nadide","C87339","A dinucleotide of adenine and nicotinamide. It has coenzyme activity in redox reactions and also acts as a donor of ADP-ribose moieties.","Nadide | 3-Carbamoyl-1-Beta-D-Ribofuranosylpyridinium Hydroxide 5'-5'-Ester with Adenosine 5'-(Trihydrogen Pyrophosphate) Inner Salt | 3-Carbamoyl-1-Beta-D-Ribofuranosylpyridinium Hydroxide, 5'-Ester with Adenosine 5'-Pyrophosphate, Inner Salt | Adenosine 5'-(Trihydrogen Diphosphate), 5'-5'-Ester with 3-(Aminocarbonyl)-1-Beta-D-Ribofuranosylpyridinium, Hydroxide, Inner Salt | Beta-NAD | Co-I | Codehydrogenase I | Coenzyme I | Cozymase | DPN | Diphosphopyridine Nucleotide | NAD | NADIDE | Nicotinamide Adenine Dinucleotide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0770150","Nicardipine Hydrochloride","C29840","The hydrochloride salt form of nicardipine, a synthetic derivative of nitrophenyl-pyridine and potent calcium channel blocker, Nicardipine (Nifedipine Family) blocks calcium ions from certain cell walls and inhibits contraction of coronary and peripheral arteries, resulting in lowered oxygen requirements for heart muscle and decreased arterial contraction and spasm. It is used clinically as a cerebral and coronary vasodilator. (NCI04)","Nicardipine Hydrochloride | NICARDIPINE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054015","Nesiritide","C47636","A recombinant version of the cardiac neurohormone, human B-type natriuretic peptide (hBNP) produced by the ventricular myocardium. Nesiritide binds to natriuretic peptide receptors on vascular smooth muscle and endothelial cells, through which it triggers guanylate cyclase dependent signal transduction resulting in increase of intracellular concentrations of cGMP. This leads to smooth muscle cell relaxation causing arterial and venous dilatation.","Nesiritide | 1,2-Dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecaazacyclotripentacontane, Cyclic Peptide Derivative | Human Brain Natriuretic Factor-32 | L-Histidine, L-seryl-L-prolyl-L-lysyl-L-methionyl-L-valyl-L-glutaminylglycyl-L-serylglycyl-L-cysteinyl-L-phenylalanylglycyl-L-arginyl-L-lysyl-L-methionyl-L-alpha-aspartyl-L-arginyl-L-isoleucyl-L-seryl-L-seryl-L-seryl-L-serylglycyl-L-leucylglycyl-L-cysteinyl-L-lysyl-L-valyl-L-leucyl-L-arginyl-L-arginyl-, Cyclic (10-26)-disulfide | NESIRITIDE | Natriuretic Peptide Type-B | Natriuretic factor-32",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027679","Neostigmine","C75024","A parasympathomimetic agent that acts as a reversible acetylcholinesterase inhibitor.","Neostigmine | NEOSTIGMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032539","Polymyxin Antibiotic","C78160","Any of the polymyxin antibiotics, cyclic peptides with long hydrophobic ends, obtained from Bacillus polymyxa strains. Polymyxin antibiotics exert their antimicrobial effect through their cationic detergent actions on cell membranes. Specifically, they bind to the negatively charged site in the lipopolysaccharide (LPS) layer of the bacterial cell membrane via electrostatic affinity with the positively charged amino groups in the cyclic peptide portion of the polymyxin antibiotic. Subsequently, the fatty acid portion of the polymyxin antibiotic dissolves in the hydrophobic region of the bacterial cell membrane. This results in an alteration in cell membrane structure, an increase in permeability for water and other molecules and disruption of cell wall integrity. This leads to bacterial cell death.","Polymyxin Antibiotic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0069177","Nyquil","C29296","A commercial combination preparation, by Vicks, containing acetaminophen, dextromethorphan hydrobromide and doxylamine succinate used to relieve symptoms of cold and flu. Acetaminophen exerts analgesic and antipyretic actions by inhibiting prostaglandin synthesis. Dextromethorphan exerts antitussive activity by raising the threshold for coughing in the cough center. Doxylamine succinate, an antihistamine, blocks the effects of histamine, thereby treating symptoms such as sneezing, itchy, watery eyes, runny nose, itchy throat and causes drowsiness.","Nyquil | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700459","Nortriptyline Hydrochloride","C704","The hydrochloride salt form of nortriptyline, a tricyclic antidepressant agent used for short-term treatment of various forms of depression. Nortriptyline blocks the norepinephrine presynaptic receptors, thereby blocking the reuptake of this neurotransmitter and raising the concentration in the synaptic cleft in the CNS. Nortriptyline also binds to alpha-adrenergic, histaminergic and cholinergic receptors. Long-term treatment with nortriptyline produces a downregulation of adrenergic receptors due to the increased stimulation of these receptors.","Nortriptyline Hydrochloride | 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N-methyl-, Hydrochloride | Allegron | NORTRIPTYLINE HYDROCHLORIDE | Norpress | Pamelor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028351","Norepinephrine, DL-","C62098","A synthetic phenylethylamine that mimics the sympathomimetic actions of the endogenous norepinephrine. Norepinephrine acts directly on the alpha- and beta-adrenergic receptors. Clinically, norepinephrine is used as a peripheral vasoconstrictor that causes constriction of arterial and venous beds via its alpha-adrenergic action. It is also used as a potent inotropic and chronotropic stimulator of the heart mediated through its beta-1 adrenergic action.","Norepinephrine, DL- | (+/-)-Noradrenaline | (.+-.)-Noradrenaline | (.+-.)-Norepinephrine | 1,2-benzenediol, 4-(2-amino-1-hydroxyethyl)-, (+/-)- | Arterenol | NORADRENALINE, (+/-)- | Noradrenaline | Norepinephrine | Norepinephrine | noradrenaline | norepinephrine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085154","Nizatidine","C29295","A competitive and reversible histamine H2-receptor antagonist with antacid activity. Nizatidine inhibits the histamine H2-receptors located on the basolateral membrane of the gastric parietal cell, thereby reducing basal and nocturnal gastric acid secretion, resulting in a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli.","Nizatidine | Axid | NIZATIDINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017887","Nitroglycerin","C29294","An organic nitrate with vasodilator activity. Nitroglycerin is converted into nitric oxide (NO) in smooth muscle and activates guanylyl cyclase, thereby increasing cGMP concentration, and resulting in smooth muscle relaxation. Dilatation of the veins results in decreased venous return to the heart, thereby decreasing left ventricular volume (reduced preload) and decreasing myocardial oxygen requirements. Arteriolar relaxation reduces arteriolar resistance (reduced afterload), thereby decreasing myocardial oxygen demands. In addition, nitroglycerine causes coronary artery dilatation, thereby improving myocardial blood distribution.","Nitroglycerin | NITROGLYCERIN | Rectiv | nitroglycerin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710261","Sustained Release Dosage Form","C42672","A dosage form designed to release active and/or inert ingredient(s) slowly so as to achieve a constant circulating concentration of the ingredient over a period of time.","Sustained Release Dosage Form | SR | Sustained Release | Sustained Release Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028116","Nisoldipine","C29291","A dihydropyridine calcium channel blocking agent. Nisoldipine inhibits the transmembrane influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility. This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04)","Nisoldipine | NISOLDIPINE | Nisoldipine SR | Sular",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1794621","Core","C99275","A cylindrical piece of tissue, such as that resulting from a core biopsy.","Core Specimen | Core | Tissue Core",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274654","Tissue Scroll","C99276","A piece of tissue cut on a microtome so that it rolls up on itself, giving it an appearance similar to a paper scroll.","Tissue Scroll | Scroll | Scroll Specimen | Scroll Specimen | Tissue Scroll",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1134659","Ziv-Aflibercept","C2682","A recombinant protein comprised of epitopes of the extracellular domains of human vascular endothelial growth factor receptors (VEGFR) fused to the constant region (Fc) of human IgG1 with potential antiangiogenic activity. Afilbercept, functioning as a soluble decoy receptor, binds to pro-angiogenic vascular endothelial growth factors (VEGFs), thereby preventing VEGFs from binding to their endogenous receptors. Disruption of the binding of VEGFs to their cellular receptors may result in the inhibition of tumor angiogenesis, metastasis, and ultimately tumor regression.","Ziv-Aflibercept | AFLIBERCEPT | AVE0005 | Aflibercept | Aflibercept | Aflibercept beta | Eylea | VEGF Trap | VEGF Trap R1R2 | VEGF-Trap | Vascular Endothelial Growth Factor Trap | Zaltrap | Ziv-aflibercept | aflibercept | vascular endothelial growth factor trap",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420175","SLC2A4 Gene","C89034","This gene plays a role in glucose transport regulation.","SLC2A4 Gene | SLC2A4 | Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 4 Gene | Solute Carrier Family 2 Member 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512508","HHV8 Infection","C39291","An infectious process caused by the human herpesvirus 8. This infection is associated with Kaposi sarcoma.","HHV8 Infection | Human Herpes Virus 8 Infection | Human Herpes Virus 8 Infection | Human Herpesvirus 8 Infection | Human Herpesvirus-8 (HHV-8)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513019","Mature B-Lymphocyte","C33058","A descendant of a lymphoid stem cell that differentiates into either a plasma cell or a memory B cell in response to a specific antigen. The mature B lymphocyte develops and differentiates in the bone marrow.","Mature B-Lymphocyte | Mature B-Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332729","CDH5 Gene","C20722","This gene plays a role in cellular adhesion and endothelial cell cohesion.","CDH5 Gene | CDH5 | Cadherin 5, Type 2 (Vascular Epithelium) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366563","TFF1 Gene","C20872","This gene is involved in maintenance of gastric mucosal integrity and regulates gastric cell proliferation.","TFF1 Gene | TFF1 | Trefoil Factor 1 (Breast Cancer, Estrogen-Inducible Sequence Expressed In) Gene | Trefoil Factor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366519","MMP11 Gene","C24608","This gene plays a role in embryogenesis.","MMP11 Gene | MMP11 | Matrix Metalloproteinase 11 (Stromelysin 3) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539083","CD52 Gene","C38907","This gene is postulated to play a role in the regulation of carbohydrate trafficking; however this role has not been substantiated.","CD52 Gene | CD52 | CD52 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3252639","Cytochrome P450 1A1, Human","C17296","Cytochrome P450 1A1 (512 aa, ~58 kDa) is encoded by the human CYP1A1 gene. This protein is involved in the metabolism of fatty acids and xenobiotics.","Cytochrome P450 1A1 | Aryl Hydrocarbon Hydroxylase | CYP1A1 | CYP1A1 Product | CYPIA1 | Cytochrome P1-450, Dioxin-Inducible | Cytochrome P450 Form 6 | Cytochrome P450, Subfamily I (Aromatic Compound-Inducible), Polypeptide 1 | Cytochrome P450-C | Cytochrome P450-P1 | EC 1.14.14.1 | Flavoprotein-Linked Monooxygenase | Microsomal Monooxygenase | P450 Form 6 | P450-1A1 | P450-C | P450-P1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919521","PTTG1 Gene","C18580","This gene plays a role in cell cycle regulation.","PTTG1 Gene | PTTG1 | Pituitary Tumor-Transforming 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418677","PMP22 Gene","C75900","This protein plays a role in the maintenance of myelin.","PMP22 Gene | PMP22 | Peripheral Myelin Protein 22 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414994","GATA3 Gene","C75492","This gene plays a role in the modulation of transcription.","GATA3 Gene | GATA Binding Protein 3 Gene | GATA3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421527","XBP1 Gene","C71425","This gene is involved in the transcription of major histocompatibility complex class II genes and the response to endoplasmic reticulum stress.","XBP1 Gene | X-Box Binding Protein 1 Gene | XBP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334032","HDAC1 protein, human","C19671","Histone deacetylase 1 (482 aa, ~55 kDa) is encoded by the human HDAC1 gene. This protein is involved in chromatin remodeling and the negative regulation of apoptosis.","Histone Deacetylase 1 | EC 3.5.1.98 | HD1 | HDAC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0671924","HAT1 protein, human","C18184","Histone acetyltransferase type B catalytic subunit (419 aa, ~50 kDa) is encoded by the human HAT1 gene. This protein plays a role in both histone acetylation and chromatin silencing.","Histone Acetyltransferase Type B Catalytic Subunit | EC 2.3.1.48 | HAT1 | HAT1 Acetyltransferase | Histone Acetyltransferase 1 | Histone Acetyltransferase 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511897","Dideoxy Chain Termination DNA Sequencing","C19641","A DNA sequencing technique in which a mixture of deoxynucleosidetriphosphates (dNTPs) and chain-terminating dNTPs, which are radioactively or fluorescently labeled, are combined within the reaction mixture. Once the reaction is complete, the DNA strands are separated by size, and the labeled chain terminating dNTPs can be read in sequence by the investigator or by a machine.","Dideoxy Chain Termination DNA Sequencing | SANGER SEQUENCING | Sanger Sequencing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1294197","Nucleic Acid Sequencing","C18881","The process of determining the sequence of purines and pyrimidines in nucleic acids and polynucleotides.","Nucleic Acid Sequencing | Molecular Biology, Nucleic Acid Sequencing | NUCLEIC ACID SEQUENCING | Sequencing | sequencing assay | sequencing_assay",,,,,,,,,,,,,,,"4035735","Nucleic acid sequencing",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516719","Commercial Sources","C19287","A category used for classifying sources of research reagents not obtained through academic institutions.","Commercial Sources | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274677","Histologic Progression","C99318","The evolution of a low-grade neoplastic pathologic process to a high grade malignancy.","Histologic Progression | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0969119","HDAC6 protein, human","C19679","Histone deacetylase 6 (1215 aa, ~131 kDa) is encoded by the human HDAC6 gene. This protein plays a role in the unfolded protein response, cell motility and the deacetylation of both histones and tubulin.","Histone Deacetylase 6 | EC 3.5.1.98 | HD6 | HDAC6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334033","HDAC5 protein, human","C19678","Histone deacetylase 5 (1122 aa, ~122 kDa) is encoded by the human HDAC5 gene. This protein is involved in chromatin silencing, transcriptional regulation and histone deacetylation.","Histone Deacetylase 5 | Antigen NY-CO-9 | EC 3.5.1.98 | HD5 | HDAC5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0910119","HDAC4 protein, human","C19673","Histone deacetylase 4 (1084 aa, ~119 kDa) is encoded by the human HDAC4 gene. This protein plays a role in the regulation of cell differentiation and histone deacetylation.","Histone Deacetylase 4 | EC 3.5.1.98 | HD4 | HDAC-A | HDAC4 | Histone Deacetylase A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1098658","histone deacetylase 3, human","C19672","Histone deacetylase 3 (428 aa, ~49 kDa) is encoded by the human HDAC3 gene. This protein is involved in the negative regulation of apoptosis, histone deacetylation and signal regulation.","Histone Deacetylase 3 | EC 3.5.1.98 | HD3 | HDAC3 | RPD3-2 | SMAP45",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0768528","HDAC2 protein, human","C18294","Histone deacetylase 2 (488 aa, ~55 kDa) is encoded by the human HDAC2 gene. This protein plays a role in histone deacetylation, chromatin remodeling and embryonic structure development.","Histone Deacetylase 2 | EC 3.5.1.98 | HD2 | HDAC2 | Transcriptional Regulator Homolog RPD3 | YY1-Associated Factor 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413858","CYP17A1 Gene","C40067","This gene plays a role in the metabolism of estrogen and glucocorticoids. It is also involved in sexual maturation.","CYP17A1 Gene | CYP17A1 | Cytochrome P450, Family 17, Subfamily A, Polypeptide 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038792","Sulindac","C850","A sulfinylindene derivative prodrug with potential antineoplastic activity. Converted in vivo to an active metabolite, sulindac, a nonsteroidal anti-inflammatory drug (NSAID), blocks cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway; this inhibition permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death. (NCI04)","Sulindac | (Z)-5-fluoro-2-methyl-1-[[4-(methylsulfinyl)phenyl]methylene]-1H-indene-3-acetic acid | Aflodac | Algocetil | Apo-Sulin | Arthrocine | Artribid | Citireuma | Clinoril | Clisundac | Imbaral | MK-231 | Novo-Sundac | Reumofil | Reumyl | SULINDAC | Sudac | Sulindac Sulfoxide | Sulinol | Sulreuma | cis-5-fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid | sulindac",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023438","CALLA Positive Lymphoblastic Leukemia","C3165","Acute lymphoblastic leukemia which is positive for the common acute lymphoblastic leukemia antigen.","cALLa Positive Lymphoblastic Leukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514294","Pre-Pre-B Acute Lymphoblastic Leukemia","C27799","Acute lymphoblastic leukemia of early B-lineage.","Pre-Pre-B Acute Lymphoblastic Leukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274706","Autoimmune Cytopenia","C99382","Cytopenia caused by autoantibodies against the red blood cells, neutrophils, and/or platelets.","Autoimmune Cytopenia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0751871","Autoimmune Nervous System Disorder","C99383","A disorder characterized by the degeneration of the nervous system due to autoimmunity.  Representative examples include multiple sclerosis, Guillain-Barre syndrome, and myasthenia gravis.","Autoimmune Nervous System Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274708","Polysaccharide Hydrolase","C99387","An enzyme that hydrolyzes the breakdown of a polysaccharide to simple sugars.","Polysaccharide Hydrolase | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0678941","Gene Mutant","C97927","A variation in the nucleic acid sequence of a specific gene.","Gene Variant | GENETIC_SEQ | Gene Mutant | Gene Mutant | Gene Mutation | Gene Variation | alternative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3266859","Follicle Stimulating Hormone Beta Polypeptide","C65746","A pharmacologic form of follicle-stimulating hormone used in the treatment of infertility.","Follicle Stimulating Hormone Beta Polypeptide | FOLLICLE STIMULATING HORMONE BETA POLYPEPTIDE | FSH Beta Polypeptide | Follitropin Beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2608320","Low-Dose Aspirin","C94758","Aspirin containing a lower dose than a standard adult tablet, usually between 81 and 100mg.","Low-Dose Aspirin | Baby Aspirin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226300","Common Hepatic Artery","C32729","An artery arising from the celiac trunk that supplies portions of the stomach, small intestines, liver and gallbladder. It branches off to form the right gastric artery and the gastroduodenal artery and continues distally as the proper hepatic artery, whose branches give rise to the cystic artery, and the left and right hepatic arteries.","Common Hepatic Artery | HEPATIC ARTERY | Hepatic Artery | hepatic artery",,,,,,,,,,,,,,,"4280344","Structure of common hepatic artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4230171","Attention Deficit Hyperactivity Disorder","C97160","A disorder characterized by a marked pattern of inattention and/or hyperactivity-impulsivity that is inconsistent with developmental level and clearly interferes with functioning in at least two settings (e.g. at home and at school). When present, the symptoms of hyperactivity are most often present before the age of 7 years. There are three recognized presentations or subtypes from most to least common: combined type, inattentive/distractible type, hyperactive/impulsive type.","Attention Deficit Hyperactivity Disorder | ADHD | Attention Deficit-Hyperactivity Disorder | Attention Deficit/Hyperactivity Disorder",,,,,,,,,,,,,,,"438409","Attention deficit hyperactivity disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516390","Central Zone of the Prostatic Parenchyma","C32282","Part of the functional area of the prostate that is above and in front of the transitional zone. The central zone comprises about 20-25% of the gland and is the location of about 10% of the prostate cancers found in the gland.","Central Zone of the Prostatic Parenchyma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986478","Neurobehavioral","C94325","Having to do with the way the brain affects emotion, behavior, and learning. Some cancers or their treatment may cause neurobehavioral problems.","Neurobehavioral | neurobehavioral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0971174","Inhibin B","C2278","Inhibin B, consisting of an alpha subunit and a beta B subunit linked by disulphide bonds, is a heterodimer hormone produced by the follicle cells of the ovary and by the Sertoli and Ledig cells of testis.  Although other forms of inhibin also exist in men, inhibin B is the predominant form in the circulation in men.","Inhibin B | Inhibin Beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987514","Anatomical base","C92955","The underlying or supportive part of an anatomic structure.","Base | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2370892","Cognitive Flexibility","C99493","The ability to restructure knowledge and change behavioral responses depending on the context of a situation.","Cognitive Flexibility | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274767","Delayed Reward Discounting","C99494","A form of impulsivity related to the increased perceived value of immediate gratification as compared to a larger future reward. The more remote the future reward, the lower its perceived present value (the more it is discounted) and the less likely it is to be chosen.","Delayed Reward Discounting | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274768","Inhibitory Nerve Control","C99495","Nerve impulses that act to inhibit or stop a particular physiological activity or response.","Inhibitory Nerve Control | Inhibitory Control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985654","Study Site Personnel","C93442","A person who performs a particular role within the context of a specific study site.","Study Site Personnel | StudySitePersonnel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982635","Prostate Cancer cT1 TNM Finding v7","C89210","Clinically inapparent tumor neither palpable nor visible by imaging. (from AJCC 7th Ed.)","Prostate Cancer cT1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982639","Prostate Cancer cT2 TNM Finding v7","C89214","Prostate cancer confined within the prostate.  Tumor found in one or both lobes by needle biopsy, but not palpable or reliably visible by imaging, is classified as T1c. (from AJCC 7th Ed.)","Prostate Cancer cT2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982643","Prostate Cancer cT3 TNM Finding v7","C89218","Prostate cancer extending through the prostatic capsule.  Invasion into the prostatic apex or into (but not beyond) the prostatic capsule is classified not as T3 but as T2. (from AJCC 7th Ed.)","Prostate Cancer cT3 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982646","Prostate Cancer cT4 TNM Finding v7","C89221","Prostate cancer with fixed tumor or tumor invading adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall. (from AJCC 7th Ed.)","Prostate Cancer cT4 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982651","Prostate Cancer Clinical Distant Metastasis TNM Finding v7","C89226","A clinical finding about one or more characteristics of prostate cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.","Prostate Cancer Clinical Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826333","D-Dimer Measurement","C82621","The determination of the amount of d-dimers present in a sample.","D-Dimer Measurement | D-Dimer | DDIMER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0052128","Thrombin-Antithrombin Complex","C17272","A protease involved in clotting","Thrombin-Antithrombin Complex | ",,,,,,,,,,,,,,,"4182199","Thrombin-antithrombin complex",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709729","Prostate Cancer pT3 TNM Finding v6 and v7","C48240","Prostate cancer with extraprostatic extension. (from AJCC 6th and 7th Eds.)","Prostate Cancer pT3 TNM Finding v6 and v7 | Prostate Cancer pT3 TNM Finding | Prostate Cancer pT3 TNM Finding | Prostate Cancer pT3 TNM Finding v6 | Prostate Cancer pT3 TNM Finding v7 | pT3 Cancer of Prostate | pT3 Cancer of the Prostate | pT3 Carcinoma of Prostate | pT3 Carcinoma of the Prostate | pT3 Prostate Cancer | pT3 Prostate Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982628","Prostate Cancer pT4 TNM Finding v7","C89203","Prostate cancer with tumor invading the rectum, levator muscles, and/or pelvic wall. (from AJCC 7th Ed.)","Prostate Cancer pT4 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335809","SELP Gene","C21041","This gene plays a role in cellular adhesion and mediates immune and endothelial cell interactions.","SELP Gene | SELP | Selectin P Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448735","Proteasome","C13314","Proteolytic complexes, proteolytic core of the proteasome system, that degrade cytosolic and nuclear proteins are implicated in ATP dependent ubiquitin protein complex degradation and in antigen processing in antigen presenting cells. The 20S proteasome (700 kD), essential in ATP ubiquitin degradation pathway, has 13-15 subunits each of which has three or four different peptidase activities. The 20S proteasome interacts with additional subunits, PA700 and PA28, to form an ATP-dependent multicatalytic proteinase complex (MPC) involved in the degradation of ubiquitinated cellular proteins and certain non-ubiquitinated proteins. 26S proteasomes may be formed in an ATP dependent fashion from a 20S proteasome and additional components, CF1 (660 kD), CF2 (250 kD) and CF3 (600 kD).","Proteasome | Proteosome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826732","PTCH1 Gene","C18255","This gene is involved in tumor suppression and mutations in this gene have been associated with several cancers and cancer related diseases.","PTCH1 Gene | PTCH1 | Patched 1 Gene | Patched Homolog 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982629","Prostate Cancer Pathologic Regional Lymph Nodes TNM Finding v7","C89204","A pathologic finding about one or more characteristics of prostate cancer, following the rules of the TNM AJCC v7 classification system as they pertain to staging of regional lymph nodes.  (from AJCC 7th Ed.)","Prostate Cancer Pathologic Regional Lymph Nodes TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982638","Prostate Cancer cT1c TNM Finding v7","C89213","Tumor identified by needle biopsy (e.g., because of elevated PSA). (from AJCC 7th Ed.)","Prostate Cancer cT1c TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982637","Prostate Cancer cT1b TNM Finding v7","C89212","Tumor incidental histologic finding in more than 5% of tissue resected. (from AJCC 7th Ed.)","Prostate Cancer cT1b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982636","Prostate Cancer cT1a TNM Finding v7","C89211","Tumor incidental histologic finding in 5% or less of tissue resected. (from AJCC 7th Ed.)","Prostate Cancer cT1a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982633","Prostate Cancer cTX TNM Finding v7","C89208","Primary tumor cannot be assessed. (from AJCC 7th Ed.)","Prostate Cancer cTX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982642","Prostate Cancer cT2c TNM Finding v7","C89217","Prostate cancer with tumor involving both lobes. (from AJCC 7th Ed.)","Prostate Cancer cT2c TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982641","Prostate Cancer cT2b TNM Finding v7","C89216","Prostate cancer with tumor involving more than one-half of one lobe, but not both lobes. (from AJCC 7th Ed.)","Prostate Cancer cT2b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982640","Prostate Cancer cT2a TNM Finding v7","C89215","Prostate cancer with tumor involving one-half of one lobe or less. (from AJCC 7th Ed.)","Prostate Cancer cT2a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982645","Prostate Cancer cT3b TNM Finding v7","C89220","Prostate cancer invading seminal vesicle(s). (from AJCC 7th Ed.)","Prostate Cancer cT3b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982644","Prostate Cancer cT3a TNM Finding v7","C89219","Prostate cancer with extracapsular extension (unilateral or bilateral). (from AJCC 7th Ed.)","Prostate Cancer cT3a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982655","Prostate Cancer cM1b TNM Finding v7","C89230","Prostate cancer with metastasis to bone(s). (from AJCC 7th Ed.)","Prostate Cancer cM1b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982652","Prostate Cancer cM0 TNM Finding v7","C89227","Prostate cancer without evidence of distant metastasis. (from AJCC 7th Ed.)","Prostate Cancer cM0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982653","Prostate Cancer cM1 TNM Finding v7","C89228","Prostate cancer with distant metastasis. (from AJCC 7th Ed.)","Prostate Cancer cM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982650","Prostate Cancer cN1 TNM Finding v7","C89225","Prostate cancer with metastasis in regional lymph node(s). (from AJCC 7th Ed.)","Prostate Cancer cN1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982654","Prostate Cancer cM1a TNM Finding v7","C89229","Prostate cancer with metastasis to non-regional lymph node(s). (from AJCC 7th Ed.)","Prostate Cancer cM1a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982627","Prostate Cancer pT3a TNM Finding v7","C89202","Prostate cancer with extraprostatic extension or microscopic invasion of bladder neck.  Positive surgical margin should be indicated by an R1 descriptor (residual microscopic disease). (from AJCC 7th Ed.)","Prostate Cancer pT3a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709722","Prostate Cancer pN0 TNM Finding v6 and v7","C48244","Prostate cancer with no positive regional nodes. (from AJCC 6th and 7th Eds.)","Prostate Cancer pN0 TNM Finding v6 and v7 | Prostate Cancer pN0 TNM Finding | Prostate Cancer pN0 TNM Finding | Prostate Cancer pN0 TNM Finding v6 | Prostate Cancer pN0 TNM Finding v7 | pN0 Cancer of Prostate | pN0 Cancer of the Prostate | pN0 Carcinoma of Prostate | pN0 Carcinoma of the Prostate | pN0 Prostate Cancer | pN0 Prostate Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512118","EGFRvIII Peptide","C29017","A synthetic peptide sequence derived from the tumor specific mutant variant of epidermal growth factor receptor EGFRvIII originally found in glioblastoma multiforme, caused by the deletion of exons 2-7. Unlike wild-type EGFR, EGFRvIII is a dominant oncogene that can directly lead to cancer. EGFRvIII is expressed in multiple cancer types including breast, ovarian, and metastatic prostate cancers, and other types of solid tumors due to alternative splicing; has not been observed in normal human tissues. Vaccination with EGFRvIII peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte response against tumor cells positive for EGFRvIII, resulting in decreased tumor growth. (NCI04)","EGFRvIII Peptide | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332819","CXCL5 Gene","C24792","This gene plays a role in chemotaxis and neutrophil activation.","CXCL5 Gene | CXCL5 | Chemokine (C-X-C Motif) Ligand 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332770","CNTNAP1 Gene","C24304","This gene plays a role in brain signal transduction, and may be involved in cellular adhesion.","CNTNAP1 Gene | CNTNAP1 | Contactin Associated Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274784","Commence","C99525","To cause to start.","Commence | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1305671","Cytological Procedure","C16490","Technique or procedure for manipulation of cells and analysis of cell properties and subcellular features.","Cytological Procedure | Cytologic Procedure | Cytologic Technique | Cytological Techniques | Cytology",,,,,,,,,,,,,,,"45771295","Cytology",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2985506","PSA Failure","C93229","An increase in serum prostate-specific antigen (PSA) levels following treatment for prostate cancer.","PSA Failure | Biochemical Recurrence | PSA failure | PSA-Only Recurrence | biochemical recurrence | biochemical relapse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334703","Metachronous Malignant Neoplasm","C38156","A malignant tumor that arises at a site separate from another, primary malignant tumor in the same anatomic system.  It is not clear if metachronous malignant neoplasms represent new primary tumors or metastatic disease.  Examples include metachronous osteosarcoma of the bones that develops in patients with known primary bone osteosarcoma, and metachronous Wilms' tumor that affects the opposite kidney in patients with a history of Wilms' tumor.","Metachronous Malignant Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2737269","Pyrosequencing","C99481","A DNA sequencing method that uses a 'sequencing by synthesis' strategy. The strand complementary to a template is synthesized a single base at a time through the sequential addition of individual solutions of each base. Incorporation of a base into the growing strand generates free pyrophosphate that is detected as light, as generated by a luciferase-catalyzed reaction.","Pyrosequencing | PYROSEQUENCING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274762","COLD-PCR","C99486","A modification of the standard polymerase chain reaction that increases the ability to preferentially amplify minority alleles and somatic mutations in the presence of an excess of wild-type molecules. Sequence-variant molecules are preferentially selected by the lower melting temperature of their mismatched heteroduplex after they've annealed to a wild-type molecule that is present in excess. By carefully selecting the denaturing temperature below the Tm for the wild-type molecule, only the mismatch heteroduplexes will melt and act as efficient templates for strand synthesis.","COLD-PCR | Co-amplification at Lower Denaturation Temperature-PCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274763","Peptide Nucleic Acid Clamping","C99487","A modification of the standard polymerase chain reaction that increases the ability to preferentially amplify mutant alleles in the presence of an excess of wild-type molecules. Wild-type molecules are rendered inactive for amplification by binding of a peptide nucleic acid (PNA) probe that hybridizes to wild-type sequence with greater affinity and under less stringent conditions.","Peptide Nucleic Acid Clamping | PCR Clamp | PCR Clamping | PNA-clamping | Peptide Nucleic Acid Clamp | Peptide Nucleic Acid-mediated Competitive-PCR Clamping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2936630","Laboratory Proficiency Testing","C99489","A program for the determination of laboratory performance where individual labs perform the same test on the same or similar items or materials, with the results from each lab compared and evaluated.","Proficiency Testing | Laboratory Proficiency Testing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274764","Proficiency Testing Challenge","C99490","Any individual test given to a laboratory as part of a proficiency test.","Proficiency Testing Challenge | Challenge",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274765","Next-Generation Technology","C99491","The next improvement of a device, procedure, technique, or service that provides a significant improvement in the state of the art.","Next-Generation Technology | Next Generation Procedure | Second Generation Procedure | Second Generation Technique",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518409","Nonmetastatic","C14148","Cancer that has not spread from the primary site (place where it started) to other places in the body.","Nonmetastatic | nonmetastatic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983279","Colorectal Cancer Clinical TNM Finding v7","C89983","A clinical finding about one or more characteristics of colorectal cancer, following the rules of the TNM AJCC v7 classification system.  Clinical assessment is based on medical history, physical examination, sigmoidoscopy, and colonoscopy with biopsy.  Examinations designed to demonstrate the presence of extrarectal or extracolonic metastasis may include chest radiographic films, computed tomography (CT; abdomen, pelvis, chest), magnetic resonance imaging (MRI), and positron emission tomography (PET) or fused PET/CT scans. (from AJCC 7th Ed.)","Colorectal Cancer Clinical TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983245","Colorectal Cancer pT4b TNM Finding v7","C89947","Colorectal cancer with direct invasion or adherence to other organs or structures. (from AJCC 7th Ed.)","Colorectal Cancer pT4b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983244","Colorectal Cancer pT4a TNM Finding v7","C89946","Colorectal cancer with penetration to the surface of the visceral peritoneum. (from AJCC 7th Ed.)","Colorectal Cancer pT4a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983243","Colorectal Cancer pT3 TNM Finding v7","C89945","Colorectal cancer with invasion through the muscularis propria into pericolorectal tissues. (from AJCC 7th Ed.)","Colorectal Cancer pT3 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983242","Colorectal Cancer pTis TNM Finding v7","C89944","Colorectal cancer with a finding of carcinoma in situ: intraepithelial or invasion of lamina propria.  Note: Tis includes cancer cells confined within the glandular basement membrane (intraepithelial) or mucosal lamina propria (intramucosal) with no extension through the muscularis mucosae into the submucosa. (from AJCC 7th Ed.)","Colorectal Cancer pTis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880135","Colorectal Cancer pT0 TNM Finding v6 and v7","C60840","Colorectal cancer with no evidence of primary tumor. (from AJCC 6th and 7th Eds.)","Colorectal Cancer pT0 TNM Finding v6 and v7 | Colorectal Cancer pT0 TNM Finding | Colorectal Cancer pT0 TNM Finding | Colorectal Cancer pT0 TNM Finding v6 | Colorectal Cancer pT0 TNM Finding v7 | pT0 Colon Cancer | pT0 Colorectal Cancer | pT0 Colorectal Carcinoma | pT0 Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880142","Colorectal Cancer pTX TNM Finding v6 and v7","C60839","Colorectal cancer in which the primary tumor cannot be assessed. (from AJCC 6th and 7th Eds.)","Colorectal Cancer pTX TNM Finding v6 and v7 | Colorectal Cancer pTX TNM Finding | Colorectal Cancer pTX TNM Finding | Colorectal Cancer pTX TNM Finding v6 | Colorectal Cancer pTX TNM Finding v7 | pTX Colon Cancer | pTX Colorectal Cancer | pTX Colorectal Carcinoma | pTX Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983253","Colorectal Cancer pN2b TNM Finding v7","C89955","Colorectal cancer with metastasis in seven or more regional lymph nodes. (from AJCC 7th Ed.)","Colorectal Cancer pN2b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983252","Colorectal Cancer pN2a TNM Finding v7","C89954","Colorectal cancer with metastasis in 4-6 regional lymph nodes. (from AJCC 7th Ed.)","Colorectal Cancer pN2a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983251","Colorectal Cancer pN2 TNM Finding v7","C89953","Colorectal cancer with metastasis in four or more regional lymph nodes. (from AJCC 7th Ed.)","Colorectal Cancer pN2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983250","Colorectal Cancer pN1c TNM Finding v7","C89952","Colorectal cancer with tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional lymph node metastasis. (from AJCC 7th Ed.)","Colorectal Cancer pN1c TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983249","Colorectal Cancer pN1b TNM Finding v7","C89951","Colorectal cancer with metastasis in 2-3 regional lymph nodes. (from AJCC 7th Ed.)","Colorectal Cancer pN1b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983248","Colorectal Cancer pN1a TNM Finding v7","C89950","Colorectal cancer with metastasis in one regional lymph node. (from AJCC 7th Ed.)","Colorectal Cancer pN1a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983247","Colorectal Cancer pN1 TNM Finding v7","C89949","Colorectal cancer with metastasis in 1-3 regional lymph nodes. (from AJCC 7th Ed.)","Colorectal Cancer pN1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880131","Colorectal Cancer pN0 TNM Finding v6 and v7","C60851","Colorectal cancer without regional lymph node metastasis. (from AJCC 6th and 7th Eds.)","Colorectal Cancer pN0 TNM Finding v6 and v7 | Colorectal Cancer pN0 TNM Finding | Colorectal Cancer pN0 TNM Finding | Colorectal Cancer pN0 TNM Finding v6 | Colorectal Cancer pN0 TNM Finding v7 | pN0 Colon Cancer | pN0 Colorectal Cancer | pN0 Colorectal Carcinoma | pN0 Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880134","Colorectal Cancer pNX TNM Finding v6 and v7","C60850","Colorectal cancer in which the regional lymph nodes cannot be assessed. (from AJCC 6th and 7th Eds.)","Colorectal Cancer pNX TNM Finding v6 and v7 | Colorectal Cancer pNX TNM Finding | Colorectal Cancer pNX TNM Finding | Colorectal Cancer pNX TNM Finding v6 | Colorectal Cancer pNX TNM Finding v7 | pNX Colon Cancer | pNX Colorectal Cancer | pNX Colorectal Carcinoma | pNX Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983280","Colorectal Cancer Clinical Distant Metastasis TNM Finding v7","C89984","A clinical finding about one or more characteristics of colorectal cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.","Colorectal Cancer Clinical Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983284","Colorectal Cancer cM1b TNM Finding v7","C89988","Colorectal cancer with metastases in more than one organ/site or the peritoneum. (from AJCC 7th Ed.)","Colorectal Cancer cM1b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983283","Colorectal Cancer cM1a TNM Finding v7","C89987","Colorectal cancer with metastasis confined to one organ or site (e.g., liver, lung, ovary, nonregional node). (from AJCC 7th Ed.)","Colorectal Cancer cM1a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983282","Colorectal Cancer cM1 TNM Finding v7","C89986","Colorectal cancer with distant metastasis. (from AJCC 7th Ed.)","Colorectal Cancer cM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983281","Colorectal Cancer cM0 TNM Finding v7","C89985","Colorectal cancer without evidence of distant metastasis. (from AJCC 7th Ed.)","Colorectal Cancer cM0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983254","Colorectal Cancer Pathologic Distant Metastasis TNM Finding v7","C89956","A pathologic finding about one or more characteristics of colorectal cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  There is no pathologic M0 for colorectal cancer. (from AJCC 7th Ed.)","Colorectal Cancer Pathologic Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983256","Colorectal Cancer pM1b TNM Finding v7","C89958","Colorectal cancer with metastases in more than one organ/site or the peritoneum. (from AJCC 7th Ed.)","Colorectal Cancer pM1b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880129","Colorectal Cancer pM1 TNM Finding v6 and v7","C60856","Colorectal cancer with distant metastasis. (from AJCC 6th and 7th Eds.)","Colorectal Cancer pM1 TNM Finding v6 and v7 | Colorectal Cancer pM1 TNM Finding | Colorectal Cancer pM1 TNM Finding | Colorectal Cancer pM1 TNM Finding v6 | Colorectal Cancer pM1 TNM Finding v7 | pM1 Colon Cancer | pM1 Colorectal Cancer | pM1 Colorectal Carcinoma | pM1 Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984087","Colorectal Cancer by AJCC v7 Stage","C91223","A term that refers to the staging of colorectal carcinoma according to the American Joint Committee on Cancer, 7th edition.","Colorectal Cancer by AJCC v7 Stage | Colorectal Carcinoma by AJCC v7 Stage | Colorectal Carcinoma by AJCC v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984909","Stage Unknown","C92207","The extent of organ/tissue involvement by a malignant neoplasm is not reported or not assessed.","Stage Unknown | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981405","Stage IVB Colorectal Cancer AJCC v7","C87820","Stage IVB includes: Any T, Any N, M1b.  M1b: Metastases in more than one organ/site or the peritoneum. (AJCC 7th ed.)","Stage IVB Colorectal Cancer AJCC v7 | Stage IVB Colorectal (Colon or Rectal) Cancer | Stage IVB Colorectal Cancer | Stage IVB Colorectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981404","Stage IVA Colorectal Cancer AJCC v7","C87819","Stage IVA includes: Any T, Any N, M1a.  M1a: Metastasis confined to one organ or site (e.g., liver, lung, ovary, nonregional node).  (AJCC 7th ed.)","Stage IVA Colorectal Cancer AJCC v7 | Stage IVA Colorectal (Colon or Rectal) Cancer | Stage IVA Colorectal Cancer | Stage IVA Colorectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981403","Stage IIIC Colorectal Cancer AJCC v7","C87818","Stage IIIC includes: (T4a, N2a, M0); (T3-T4a, N2b, M0); (T4b, N1-N2, M0).  T3: Tumor invades through the muscularis propria into pericolorectal tissues.  T4a: Tumor penetrates to the surface of the visceral peritoneum.  T4b: Tumor directly invades or is adherent to other organs or structures. N1: Metastasis in 1-3 regional lymph nodes.  N2: Metastasis in four or more regional lymph nodes.  N2a: Metastasis in 4-6 regional lymph nodes.  N2b: Metastasis in seven or more regional lymph nodes.  M0: No distant metastasis.  (AJCC 7th ed.)","Stage IIIC Colorectal Cancer AJCC v7 | Stage IIIC Colorectal (Colon or Rectal) Cancer | Stage IIIC Colorectal Cancer | Stage IIIC Colorectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981402","Stage IIIB Colorectal Cancer AJCC v7","C87817","Stage IIIB includes: (T3-T4a, N1/N1c, M0); (T2-T3, N2a, M0); (T1-T2, N2b, M0). T1: Tumor invades submucosa.  T2: Tumor invades muscularis propria.  T3: Tumor invades through the muscularis propria into pericolorectal tissues.  T4a: Tumor penetrates to the surface of the visceral peritoneum.  N1: Metastasis in 1-3 regional lymph nodes.  N1c: Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional lymph node metastasis.  N2a: Metastasis in 4-6 regional lymph nodes.  N2b: Metastasis in seven or more regional lymph nodes.  M0: No distant metastasis.  (AJCC 7th ed.)","Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIB Colorectal (Colon or Rectal) Cancer | Stage IIIB Colorectal Cancer | Stage IIIB Colorectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981401","Stage IIIA Colorectal Cancer AJCC v7","C87816","Stage IIIA includes: (T1-T2, N1/N1c, M0); (T1, N2a, M0). T1: Tumor invades submucosa.  T2: Tumor invades muscularis propria.  N1: Metastasis in 1-3 regional lymph nodes.  N1c: Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional lymph node metastasis. N2a: Metastasis in 4-6 regional lymph nodes.  M0: No distant metastasis.  (AJCC 7th ed.)","Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIA Colorectal (Colon or Rectal) Cancer | Stage IIIA Colorectal Cancer | Stage IIIA Colorectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981400","Stage IIC Colorectal Cancer AJCC v7","C87815","Stage IIC includes: T4b, N0, M0. T4b: Tumor directly invades or is adherent to other organs or structures. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IIC Colorectal Cancer AJCC v7 | Stage IIC Colorectal (Colon or Rectal) Cancer | Stage IIC Colorectal Cancer | Stage IIC Colorectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981399","Stage IIB Colorectal Cancer AJCC v7","C87814","Stage IIB includes: T4a, N0, M0.  T4a: Tumor penetrates to the surface of the visceral peritoneum.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IIB Colorectal Cancer AJCC v7 | Stage IIB Colorectal (Colon or Rectal) Cancer | Stage IIB Colorectal Cancer | Stage IIB Colorectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981398","Stage IIA Colorectal Cancer AJCC v7","C87813","Stage IIA includes: T3, N0, M0. T3: Tumor invades through the muscularis propria into pericolorectal tissues.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IIA Colorectal Cancer AJCC v7 | Stage IIA Colorectal (Colon or Rectal) Cancer | Stage IIA Colorectal Cancer | Stage IIA Colorectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981892","Cutaneous Melanoma TNM Finding v7","C88378","A finding about one or more characteristics of cutaneous melanoma, following the rules of the TNM AJCC v7 classification system.  The TNM clinical and pathologic regional lymph nodes tumor classifications of cutaneous melanoma are not the same. (from AJCC 7th Ed.)","Cutaneous Melanoma TNM Finding v7 | Skin Melanoma TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981898","Cutaneous Melanoma pT1b TNM Finding v7","C88384","Cutaneous melanoma with a tumor measuring 1.0 mm or less in thickness, with ulceration or mitoses equal to or more than 1/mm2. (from AJCC 7th Ed.)","Cutaneous Melanoma pT1b TNM Finding v7 | Skin Melanoma pT1b TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981897","Cutaneous Melanoma pT1a TNM Finding v7","C88383","Cutaneous melanoma with a tumor measuring 1.0 mm or less in thickness, without ulceration and with mitosis less than 1/mm2. (from AJCC 7th Ed.)","Cutaneous Melanoma pT1a TNM Finding v7 | Skin Melanoma pT1a TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981896","Cutaneous Melanoma pT1 TNM Finding v7","C88382","Cutaneous melanoma with a tumor measuring 1.0 mm or less in thickness. (from AJCC 7th Ed.)","Cutaneous Melanoma pT1 TNM Finding v7 | Skin Melanoma pT1 TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707573","Cutaneous Melanoma pT0 TNM Finding v6 and v7","C48840","Cutaneous melanoma with no evidence of primary tumor. (from AJCC 6th and 7th Eds.)","Cutaneous Melanoma pT0 TNM Finding v6 and v7 | Cutaneous Melanoma pT0 TNM Finding | Cutaneous Melanoma pT0 TNM Finding | Cutaneous Melanoma pT0 TNM Finding v6 | Cutaneous Melanoma pT0 TNM Finding v7 | pT0 Cutaneous Melanoma | pT0 Melanoma of Skin | pT0 Melanoma of the Skin | pT0 Skin Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981895","Cutaneous Melanoma pTX TNM Finding v7","C88381","Cutaneous melanoma in which the primary tumor cannot be assessed (e.g., curettaged or severely regressed melanoma). (from AJCC 7th Ed.)","Cutaneous Melanoma pTX TNM Finding v7 | Skin Melanoma pTX TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981918","Cutaneous Melanoma cN3 TNM Finding v7","C88404","Cutaneous melanoma with 1 or more metastatic nodes with in transit met(s)/satellite(s). (from AJCC 7th Ed.)","Cutaneous Melanoma cN3 TNM Finding v7 | Skin Melanoma cN3 TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981917","Cutaneous Melanoma cN2c TNM Finding v7","C88403","Cutaneous melanoma with intralymphatic metastases (in transit or satellite metastases) without metastatic nodes. (from AJCC 7th Ed.)","Cutaneous Melanoma cN2c TNM Finding v7 | Skin Melanoma cN2c TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981916","Cutaneous Melanoma cN1 TNM Finding v7","C88402","Cutaneous melanoma with macrometastasis in one regional lymph node.  Macrometastases are defined as clinically detectable nodal metastases confirmed by therapeutic lymphadenectomy or when nodal metastasis exhibits gross extracapsular extension. (from AJCC 7th Ed.)","Cutaneous Melanoma cN1 TNM Finding v7 | Skin Melanoma cN1 TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981915","Cutaneous Melanoma cN0 TNM Finding v7","C88401","Cutaneous melanoma in which no regional metastases are detected. (from AJCC 7th Ed.)","Cutaneous Melanoma cN0 TNM Finding v7 | Skin Melanoma cN0 TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981914","Cutaneous Melanoma cNX TNM Finding v7","C88400","Cutaneous melanoma in which the regional lymph nodes cannot be assessed (e.g., previously removed for another reason).  (from AJCC 7th Ed.)","Cutaneous Melanoma cNX TNM Finding v7 | Skin Melanoma cNX TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981924","Cutaneous Melanoma cM1c TNM Finding v7","C88410","Cutaneous melanoma with metastases to all other visceral sites associated with normal serum lactate dehydrogenase (LDH) or distant metastases to any site associated with an elevated serum LDH. (from AJCC 7th Ed.)","Cutaneous Melanoma cM1c TNM Finding v7 | Skin Melanoma cM1c TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981923","Cutaneous Melanoma cM1b TNM Finding v7","C88409","Cutaneous melanoma with metastases to lung associated with normal serum lactate dehydrogenase (LDH). (from AJCC 7th Ed.)","Cutaneous Melanoma cM1b TNM Finding v7 | Skin Melanoma cM1b TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981922","Cutaneous Melanoma cM1a TNM Finding v7","C88408","Cutaneous melanoma with metastases to skin, subcutaneous tissues, or distant lymph nodes associated with normal serum lactate dehydrogenase (LDH). (from AJCC 7th Ed.)","Cutaneous Melanoma cM1a TNM Finding v7 | Skin Melanoma cM1a TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981920","Cutaneous Melanoma cM0 TNM Finding v7","C88406","Cutaneous melanoma with no detectable evidence of distant metastases. (from AJCC 7th Ed.)","Cutaneous Melanoma cM0 TNM Finding v7 | Skin Melanoma cM0 TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981910","Cutaneous Melanoma pM1a TNM Finding v7","C88396","Cutaneous melanoma with metastases to skin, subcutaneous tissues, or distant lymph nodes associated with normal serum lactate dehydrogenase (LDH). (from AJCC 7th Ed.)","Cutaneous Melanoma pM1a TNM Finding v7 | Skin Melanoma pM1a TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981911","Cutaneous Melanoma pM1b TNM Finding v7","C88397","Cutaneous melanoma with metastases to lung associated with normal serum lactate dehydrogenase (LDH). (from AJCC 7th Ed.)","Cutaneous Melanoma pM1b TNM Finding v7 | Skin Melanoma pM1b TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981906","Cutaneous Melanoma pN2b TNM Finding v7","C88392","Cutaneous melanoma with macrometastases in 2-3 regional lymph nodes.  Macrometastases are defined as clinically detectable nodal metastases confirmed by therapeutic lymphadenectomy or when nodal metastasis exhibits gross extracapsular extension. (from AJCC 7th Ed.)","Cutaneous Melanoma pN2b TNM Finding v7 | Skin Melanoma pN2b TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981905","Cutaneous Melanoma pN2a TNM Finding v7","C88391","Cutaneous melanoma with micrometastases in 2-3 regional lymph nodes.  Micrometastases are diagnosed after sentinel lymph node biopsy and completion of lymphadenectomy (if performed). (from AJCC 7th Ed.)","Cutaneous Melanoma pN2a TNM Finding v7 | Skin Melanoma pN2a TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981904","Cutaneous Melanoma pN2 TNM Finding v7","C88390","Cutaneous melanoma with metastases in 2-3 regional lymph nodes or in transit met(s)/satellite(s) without metastatic nodes. (from AJCC 7th Ed.)","Cutaneous Melanoma pN2 TNM Finding v7 | Skin Melanoma pN2 TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981903","Cutaneous Melanoma pN1b TNM Finding v7","C88389","Cutaneous melanoma with macrometastasis in one regional lymph node.  Macrometastases are defined as clinically detectable nodal metastases confirmed by therapeutic lymphadenectomy or when nodal metastasis exhibits gross extracapsular extension. (from AJCC 7th Ed.)","Cutaneous Melanoma pN1b TNM Finding v7 | Skin Melanoma pN1b TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981902","Cutaneous Melanoma pN1a TNM Finding v7","C88388","Cutaneous melanoma with micrometastasis in one regional lymph node.  Micrometastases are diagnosed after sentinel lymph node biopsy and completion of lymphadenectomy (if performed). (from AJCC 7th Ed.)","Cutaneous Melanoma pN1a TNM Finding v7 | Skin Melanoma pN1a TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707563","Cutaneous Melanoma pN0 TNM Finding v6 and v7","C48855","Cutaneous melanoma without involvement of regional lymph nodes. (from AJCC 6th and 7th Eds.)","Cutaneous Melanoma pN0 TNM Finding v6 and v7 | Cutaneous Melanoma pN0 TNM Finding | Cutaneous Melanoma pN0 TNM Finding | Cutaneous Melanoma pN0 TNM Finding v6 | Cutaneous Melanoma pN0 TNM Finding v7 | pN0 Cutaneous Melanoma | pN0 Melanoma of Skin | pN0 Melanoma of the Skin | pN0 Skin Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981901","Cutaneous Melanoma pN1 TNM Finding v7","C88387","Cutaneous melanoma with metastasis in one regional lymph node. (from AJCC 7th Ed.)","Cutaneous Melanoma pN1 TNM Finding v7 | Skin Melanoma pN1 TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981907","Cutaneous Melanoma pN2c TNM Finding v7","C88393","Cutaneous melanoma with intralymphatic metastases (in transit or satellite metastases) without metastatic nodes. (from AJCC 7th Ed.)","Cutaneous Melanoma pN2c TNM Finding v7 | Skin Melanoma pN2c TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981900","Cutaneous Melanoma pNX TNM Finding v7","C88386","Cutaneous melanoma in which the regional lymph nodes cannot be assessed (e.g., previously removed for another reason).  (from AJCC 7th Ed.)","Cutaneous Melanoma pNX TNM Finding v7 | Skin Melanoma pNX TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0854698","Stage IV Cutaneous Melanoma AJCC v6 and v7","C9096","Stage IV includes: (Any T, Any N, M1).  M1: Distant metastasis. (from AJCC 6th and 7th Eds.)","Stage IV Cutaneous Melanoma AJCC v6 and v7 | Malignant Melanoma (of Skin), Stage IV | Stage IV Cutaneous (Skin) Melanoma | Stage IV Cutaneous Malignant Melanoma | Stage IV Cutaneous Melanoma | Stage IV Malignant Melanoma of Skin | Stage IV Malignant Melanoma of the Skin | Stage IV Malignant Skin Melanoma | Stage IV Melanoma of Skin | Stage IV Melanoma of the Skin | Stage IV Skin Melanoma | Stage IV Skin Melanoma AJCC v6 | Stage IV Skin Melanoma AJCC v7 | stage IV melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981926","Stage III Cutaneous Melanoma AJCC v7","C88415","Stage III includes: Any T, N1-3, M0.  Stage III is divided into three pathologic subgroups: IIIA, IIIB, and IIIC.  There are no clinical subgroups for stage III.  N1: Cutaneous melanoma with metastasis in one regional lymph node.  N2: Cutaneous melanoma with metastases in 2-3 regional lymph nodes or in transit met(s)/satellite(s) without metastatic nodes.  N3: Cutaneous melanoma with 4 or more metastatic nodes, or matted nodes, or in transit met(s)/satellite(s) with metastatic node(s).  M0: No detectable evidence of distant metastases. (from AJCC 7th Ed.)","Stage III Cutaneous Melanoma AJCC v7 | Stage III Cutaneous (Skin) Melanoma | Stage III Skin Melanoma | Stage III Skin Melanoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL413973","stage IIC skin melanoma","C86034","Stage IIC includes: T4b, N0, M0.  T4b: Cutaneous melanoma with a tumor measuring more than 4.0 mm in thickness, with ulceration.  N0: No regional lymph node metastases.  M0: No detectable evidence of distant metastases. (from AJCC 6th and 7th Eds.)","Stage IIC Cutaneous Melanoma AJCC v6 and v7 | Stage IIC Cutaneous (Skin) Melanoma | Stage IIC Skin Melanoma | Stage IIC Skin Melanoma | Stage IIC Skin Melanoma AJCC v6 | Stage IIC Skin Melanoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336187","stage IIB melanoma of skin","C27742","Stage IIB includes: (T3b, N0, M0); (T4a, N0, M0).  T3b: Cutaneous melanoma with a tumor measuring 2.01-4.0 mm in thickness, with ulceration.  T4a: Cutaneous melanoma with a tumor measuring more than 4.0 mm in thickness, without ulceration.  N0: No regional lymph node metastases.  M0: No detectable evidence of distant metastases. (from AJCC 6th and 7th Eds.)","Stage IIB Cutaneous Melanoma AJCC v6 and v7 | Stage IIB Cutaneous (Skin) Melanoma | Stage IIB Melanoma | Stage IIB Melanoma of Skin | Stage IIB Melanoma of the Skin | Stage IIB Skin Melanoma | Stage IIB Skin Melanoma AJCC v6 | Stage IIB Skin Melanoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL413972","stage IIA skin melanoma","C86033","Stage IIA includes: (T2b, N0, M0); (T3a, N0, M0).  T2b: Cutaneous melanoma with a tumor measuring 1.01-2.0 mm in thickness, with ulceration.  T3a: Cutaneous melanoma with a tumor measuring 2.01-4.0 mm in thickness, without ulceration.  N0: No regional lymph node metastases.  M0: No detectable evidence of distant metastases. (from AJCC 6th and 7th Eds.)","Stage IIA Cutaneous Melanoma AJCC v6 and v7 | Stage IIA Cutaneous (Skin) Melanoma | Stage IIA Skin Melanoma | Stage IIA Skin Melanoma | Stage IIA Skin Melanoma AJCC v6 | Stage IIA Skin Melanoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL413971","stage IB skin melanoma","C86030","Stage IB includes: (T1b, N0, M0); (T2a, N0, M0).  T1b: Cutaneous melanoma with a tumor measuring 1.0 mm or less in thickness, with ulceration or mitoses equal or more than 1/mm2. T2a: Cutaneous melanoma with a tumor measuring 1.01-2.0 mm in thickness, without ulceration.  N0: No regional lymph node metastases.  M0: No detectable evidence of distant metastases. (from AJCC 7th Ed.)","Stage IB Cutaneous Melanoma AJCC v7 | Stage IB Cutaneous (Skin) Melanoma | Stage IB Skin Melanoma | Stage IB Skin Melanoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL413970","stage IA skin melanoma","C86026","Stage IA includes: T1a, N0, M0.  T1a: Cutaneous melanoma with a tumor measuring 1.0 mm or less in thickness, without ulceration and with mitosis less than 1/mm2.  N0: No regional lymph node metastases.  M0: No detectable evidence of distant metastases. (from AJCC 7th Ed.)","Stage IA Cutaneous Melanoma AJCC v7 | Stage IA Cutaneous (Skin) Melanoma | Stage IA Skin Melanoma | Stage IA Skin Melanoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537719","MIR21 Gene","C80740","This gene is involved in the regulation of gene expression and plays an oncogenic role in hepatocellular, breast, esophageal, gastric, pancreatic, prostatic and squamous cell carcinomas, glioblastoma and glioma.","MIR21 Gene | MIR21 | MicroRNA 21 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537709","MIR15A Gene","C81884","This gene is involved in the regulation of gene expression and plays a potential tumor suppressor role in prostate carcinomas, various leukemias, pituitary adenoma, polycystic kidney disease and polycystic liver disease.","MIR15A Gene | MIR15A | MicroRNA 151 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826003","MIR146B Gene","C81779","This gene is involved in the regulation of gene expression and plays a role in the development of carcinoma of the breast and glioma.","MIR146B Gene | MIR146B | MicroRNA 146b Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537715","MIR19A Gene","C80717","This gene is involved in the regulation of gene expression and plays a role in the development of hepatocellular, lung and thyroid carcinomas, plasma cell myeloma, medulloblastoma, Cowden's syndrome and spinocerebellar ataxia.","MIR19A Gene | MIR19A | MicroRNA 19a Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826005","MIR181A2 Gene","C81746","This gene is involved in the regulation of gene expression and plays a role in the development of plasma cell myeloma and glioma.","MIR181A2 Gene | MIR181A2 | MicroRNA 181a-2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537860","MIR222 Gene","C80726","and acts as an oncogene in breast, lung, thyroid and prostate carcinomas as well as metastatic melanoma and glioblastoma multiforme.","MIR222 Gene | MIR222 | MicroRNA 222 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537811","MIR155 Gene","C81744","This gene is involved in the regulation of gene expression and plays a potential tumor suppressor role in breast and pancreatic carcinomas, acute lymphoblastic leukemia and diffuse large B-cell lymphoma.","MIR155 Gene | MIR155 | MicroRNA 155 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332794","CSK Gene","C20123","This gene is involved in signal transduction and intercellular adhesion.","CSK Gene | CSK | c-SRC Tyrosine Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3644178","Human Papilloma Virus Vaccine","C1951","A recombinant vaccine of different types of HPV proteins which are well-conserved within types with a significant inter-type variation.","Human Papilloma Virus Vaccine | HPV | HPV Vaccine | HPV vaccine | Recombinant Human Papilloma Virus Vaccine | human papillomavirus vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0587117","Evening","C64936","The time period between late afternoon and bedtime.","Evening | ",,,,,,,,,,,,,,,"4136346","Evening",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334466","Lymphomatous Adult T-Cell Leukemia/Lymphoma","C36266","An adult T-cell leukemia/lymphoma characterized by generalized lymphadenopathy without peripheral blood involvement.  Most patients have advanced disease, however hypercalcemia is not frequently present.","Lymphomatous Adult T-Cell Leukemia/Lymphoma | Lymphomatous Adult T-Cell Lymphoma/Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982739","Bladder Cancer TNM Finding v7","C89349","A finding about one or more characteristics of bladder cancer, following the rules of the TNM AJCC v7 classification system.","Bladder Cancer TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879867","Bladder Cancer pT0 TNM Finding v6 and v7","C61206","Bladder cancer in which there is no evidence of a primary tumor. (from AJCC 6th and 7th Eds.)","Bladder Cancer pT0 TNM Finding v6 and v7 | Bladder Cancer pT0 TNM Finding | Bladder Cancer pT0 TNM Finding | Bladder Cancer pT0 TNM Finding v6 | Bladder Cancer pT0 TNM Finding v7 | pT0 Bladder Carcinoma TNM Finding | pT0 Cancer of the Bladder TNM Finding | pT0 Carcinoma of the Bladder TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879868","Bladder Cancer pT1 TNM Finding v6 and v7","C61209","Bladder cancer with tumor invading subepithelial connective tissue. (from AJCC 6th and 7th Eds.)","Bladder Cancer pT1 TNM Finding v6 and v7 | Bladder Cancer pT1 TNM Finding | Bladder Cancer pT1 TNM Finding | Bladder Cancer pT1 TNM Finding v6 | Bladder Cancer pT1 TNM Finding v7 | pT1 Bladder Carcinoma TNM Finding | pT1 Cancer of the Bladder TNM Finding | pT1 Carcinoma of the Bladder TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982742","Bladder Cancer pT2 TNM Finding v7","C89352","Bladder cancer with tumor invading the muscularis propria. (from AJCC 7th Ed.)","Bladder Cancer pT2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982743","Bladder Cancer pT2a TNM Finding v7","C89353","Bladder cancer with tumor invading the superficial muscularis propria (inner half).  (from AJCC 7th Ed.)","Bladder Cancer pT2a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982744","Bladder Cancer pT2b TNM Finding v7","C89354","Bladder cancer with tumor invading the deep muscularis propria (outer half).  (from AJCC 7th Ed.)","Bladder Cancer pT2b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879872","Bladder Cancer pT3 TNM Finding v6 and v7","C61213","Bladder cancer with tumor invading the perivesical tissue. (from AJCC 6th and 7th Eds.)","Bladder Cancer pT3 TNM Finding v6 and v7 | Bladder Cancer pT3 TNM Finding | Bladder Cancer pT3 TNM Finding | Bladder Cancer pT3 TNM Finding v6 | Bladder Cancer pT3 TNM Finding v7 | pT3 Bladder Carcinoma TNM Finding | pT3 Cancer of the Bladder TNM Finding | pT3 Carcinoma of the Bladder TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879873","Bladder Cancer pT3a TNM Finding v6 and v7","C61214","Bladder cancer with microscopic invasion into the perivesical tissue. (from AJCC 6th and 7th Eds.)","Bladder Cancer pT3a TNM Finding v6 and v7 | Bladder Cancer pT3a TNM Finding | Bladder Cancer pT3a TNM Finding | Bladder Cancer pT3a TNM Finding v6 | Bladder Cancer pT3a TNM Finding v7 | pT3a Bladder Carcinoma TNM Finding | pT3a Cancer of the Bladder TNM Finding | pT3a Carcinoma of the Bladder TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879874","Bladder Cancer pT3b TNM Finding v6 and v7","C61215","Bladder cancer with tumor macroscopically invading the perivesical tissue (extravesical mass).  (from AJCC 6th and 7th Eds.)","Bladder Cancer pT3b TNM Finding v6 and v7 | Bladder Cancer pT3b TNM Finding | Bladder Cancer pT3b TNM Finding | Bladder Cancer pT3b TNM Finding v6 | Bladder Cancer pT3b TNM Finding v7 | pT3b Bladder Carcinoma TNM Finding | pT3b Cancer of the Bladder TNM Finding | pT3b Carcinoma of the Bladder TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982745","Bladder Cancer pT4 TNM Finding v7","C89355","Bladder cancer with tumor invading any of the following: prostatic stroma, seminal vesicles, uterus, vagina, pelvic wall, abdominal wall. (from AJCC 7th Ed.)","Bladder Cancer pT4 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982746","Bladder Cancer pT4a TNM Finding v7","C89356","Bladder cancer with tumor invading prostatic stroma, uterus, vagina.  (from AJCC 7th Ed.)","Bladder Cancer pT4a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879879","Bladder Cancer pTa TNM Finding v6 and v7","C61207","Bladder cancer with a finding of noninvasive papillary carcinoma. (from AJCC 6th and 7th Eds.)","Bladder Cancer pTa TNM Finding v6 and v7 | Bladder Cancer pTa TNM Finding | Bladder Cancer pTa TNM Finding | Bladder Cancer pTa TNM Finding v6 | Bladder Cancer pTa TNM Finding v7 | pTa Bladder Carcinoma TNM Finding | pTa Cancer of the Bladder TNM Finding | pTa Carcinoma of the Bladder TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879880","Bladder Cancer pTis TNM Finding v6 and v7","C61208","Bladder cancer with a finding of carcinoma in situ: 'flat tumor'. (from AJCC 6th and 7th Eds.)","Bladder Cancer pTis TNM Finding v6 and v7 | Bladder Cancer pTis TNM Finding | Bladder Cancer pTis TNM Finding | Bladder Cancer pTis TNM Finding v6 | Bladder Cancer pTis TNM Finding v7 | pTis Bladder Carcinoma TNM Finding | pTis Cancer of the Bladder TNM Finding | pTis Carcinoma of the Bladder TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879878","Bladder Cancer pTX TNM Finding v6 and v7","C61205","Bladder cancer in which the primary tumor cannot be assessed. (from AJCC 6th and 7th Eds.)","Bladder Cancer pTX TNM Finding v6 and v7 | Bladder Cancer pTX TNM Finding | Bladder Cancer pTX TNM Finding | Bladder Cancer pTX TNM Finding v6 | Bladder Cancer pTX TNM Finding v7 | pTX Bladder Carcinoma TNM Finding | pTX Cancer of the Bladder TNM Finding | pTX Carcinoma of the Bladder TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879877","Bladder Cancer pT4b TNM Finding v6 and v7","C61218","Bladder cancer with tumor invading pelvic wall, abdominal wall. (from AJCC 6th and 7th Eds.)","Bladder Cancer pT4b TNM Finding v6 and v7 | Bladder Cancer pT4b TNM Finding | Bladder Cancer pT4b TNM Finding | Bladder Cancer pT4b TNM Finding v6 | Bladder Cancer pT4b TNM Finding v7 | pT4b Bladder Carcinoma TNM Finding | pT4b Cancer of the Bladder TNM Finding | pT4b Carcinoma of the Bladder TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879862","Bladder Cancer pN0 TNM Finding v6 and v7","C61220","Bladder cancer in which there is no regional lymph node metastasis. (from AJCC 6th and 7th Eds.)","Bladder Cancer pN0 TNM Finding v6 and v7 | Bladder Cancer pN0 TNM Finding | Bladder Cancer pN0 TNM Finding | Bladder Cancer pN0 TNM Finding v6 | Bladder Cancer pN0 TNM Finding v7 | pN0 Bladder Carcinoma TNM Finding | pN0 Cancer of the Bladder TNM Finding | pN0 Carcinoma of the Bladder TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982748","Bladder Cancer pN1 TNM Finding v7","C89358","Bladder cancer with single regional lymph node metastasis in the true pelvis (hypogastric, obturator, external iliac, or presacral lymph node). (from AJCC 7th Ed.)","Bladder Cancer pN1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982749","Bladder Cancer pN2 TNM Finding v7","C89359","Bladder cancer with multiple regional lymph node metastases in the true pelvis (hypogastric, obturator, external iliac, or presacral lymph node metastasis).  (from AJCC 7th Ed.)","Bladder Cancer pN2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982750","Bladder Cancer pN3 TNM Finding v7","C89360","Bladder cancer with metastasis to the common iliac lymph nodes. (from AJCC 7th Ed.)","Bladder Cancer pN3 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879866","Bladder Cancer pNX TNM Finding v6 and v7","C61219","Bladder cancer in which the regional lymph nodes cannot be assessed. (from AJCC 6th and 7th Eds.)","Bladder Cancer pNX TNM Finding v6 and v7 | Bladder Cancer pNX TNM Finding | Bladder Cancer pNX TNM Finding | Bladder Cancer pNX TNM Finding v6 | Bladder Cancer pNX TNM Finding v7 | pNX Bladder Carcinoma TNM Finding | pNX Cancer of the Bladder TNM Finding | pNX Carcinoma of the Bladder TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982753","Bladder Cancer Clinical Distant Metastasis TNM Finding v7","C89363","A clinical finding about one or more characteristics of bladder cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.","Bladder Cancer Clinical Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982755","Bladder Cancer cM1 TNM Finding v7","C89365","Bladder cancer with distant metastasis. (from AJCC 7th Ed.)","Bladder Cancer cM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982751","Bladder Cancer Pathologic Distant Metastasis TNM Finding v7","C89361","A pathologic finding about one or more characteristics of bladder cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  There is no pathologic M0 for bladder cancer. (from AJCC 7th Ed.)","Bladder Cancer Pathologic Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879860","Bladder Cancer pM1 TNM Finding v6 and v7","C61226","Bladder cancer with distant metastasis. (from AJCC 6th and 7th Eds.)","Bladder Cancer pM1 TNM Finding v6 and v7 | Bladder Cancer pM1 TNM Finding | Bladder Cancer pM1 TNM Finding | Bladder Cancer pM1 TNM Finding v6 | Bladder Cancer pM1 TNM Finding v7 | pM1 Bladder Carcinoma TNM Finding | pM1 Cancer of the Bladder TNM Finding | pM1 Carcinoma of the Bladder TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984068","Bladder Cancer by AJCC v7 Stage","C91202","A term that refers to the staging of bladder cancer according to the American Joint Committee on Cancer, 7th edition.","Bladder Cancer by AJCC v7 Stage | Bladder Carcinoma by AJCC v7 Stage | Bladder Carcinoma by AJCC v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987497","Stage IV Bladder Cancer AJCC v7","C89366","Stage IV includes: (T4b, N0, M0); (Any T, N1-3, M0); (Any T, Any N, M1).  T4b: Tumor invades pelvic wall, abdominal wall.  N0: No regional lymph node metastasis.  N1: Single regional lymph node metastasis in the true pelvis (hypogastric, obturator, external iliac, or presacral lymph node).  N2: Multiple regional lymph node metastases in the true pelvis (hypogastric, obturator, external iliac, or presacral lymph node metastasis).  N3: Metastasis to the common iliac lymph nodes.  M0: No distant metastasis.  M1: Distant metastasis.  (AJCC 7th ed.)","Stage IV Bladder Cancer AJCC v7 | Stage IV Bladder Cancer | Stage IV Bladder Cancer | Stage IV Bladder Carcinoma | Stage IV Bladder Carcinoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278824","Stage III Bladder Cancer AJCC v6 and v7","C7898","Stage III includes: (T3a, N0, M0); (T3b, N0, M0); (T4a, N0, M0).  T3a: Tumor microscopically invades perivesical tissue.  T3b: Tumor macroscopically invades perivesical tissue (extravesical mass).  T4a: Tumor invades prostatic stroma, uterus, vagina.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)","Stage III Bladder Cancer AJCC v6 and v7 | Cancer of Bladder Stage III | Cancer of the Bladder Stage III | Jewett-Marshall Stage C Bladder Cancer | Jewett-Marshall Stage C Urinary Bladder Cancer | Jewett-Marshall Stage C Urinary Bladder Carcinoma | Stage III Bladder Cancer | Stage III Bladder Cancer | Stage III Bladder Cancer AJCC v6 | Stage III Bladder Cancer AJCC v7 | Stage III Bladder Carcinoma | Stage III Bladder Carcinoma AJCC v6 | Stage III Bladder Carcinoma AJCC v7 | Stage III Carcinoma of Bladder | Stage III Carcinoma of Urinary Bladder | Stage III Carcinoma of the Bladder | Stage III Carcinoma of the Urinary Bladder | Stage III Urinary Bladder Carcinoma | stage III bladder cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278823","Stage II Bladder Cancer AJCC v6 and v7","C7897","Stage II includes: (T2a, N0, M0); (T2b, N0, M0).  T2a: Tumor invades superficial muscle (inner half).  T2b: Tumor invades deep muscle (outer half).  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th Eds.)","Stage II Bladder Cancer AJCC v6 and v7 | Cancer of Bladder Stage II | Cancer of the Bladder Stage II | Jewett-Marshall Stage B Bladder Cancer | Jewett-Marshall Stage B Bladder Carcinoma | Jewett-Marshall Stage B Urinary Bladder Cancer | Jewett-Marshall Stage B Urinary Bladder Carcinoma | Stage II Bladder Cancer | Stage II Bladder Cancer | Stage II Bladder Cancer AJCC v6 | Stage II Bladder Cancer AJCC v7 | Stage II Bladder Carcinoma | Stage II Bladder Carcinoma AJCC v6 | Stage II Bladder Carcinoma AJCC v7 | Stage II Carcinoma of Bladder | Stage II Carcinoma of Urinary Bladder | Stage II Carcinoma of the Bladder | Stage II Carcinoma of the Urinary Bladder | Stage II Urinary Bladder Carcinoma | stage II bladder cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0154091","Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7","C3644","Stage 0is includes: Tis, N0, M0.  Tis: Carcinoma in situ: 'flat tumor'.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7 | Bladder Flat CIS | Bladder Flat Carcinoma in Situ | Carcinoma in situ of Urinary Bladder | Carcinoma in situ of the Urinary Bladder | Flat CIS of the Bladder | Flat CIS of the Urinary Bladder | Flat Carcinoma in Situ of the Bladder | Flat Carcinoma in Situ of the Urinary Bladder | High Grade Bladder Intraurothelial Neoplasia | Stage 0is Bladder Cancer | Stage 0is Bladder Carcinoma | Stage 0is Bladder Urothelial Cancer | Stage 0is Bladder Urothelial Carcinoma | Stage 0is Bladder Urothelial Carcinoma | Stage 0is Bladder Urothelial Carcinoma AJCC v6 | Stage 0is Bladder Urothelial Carcinoma AJCC v7 | Stage 0is Carcinoma of Bladder | Stage 0is Carcinoma of Urinary Bladder | Stage 0is Carcinoma of the Bladder | Stage 0is Carcinoma of the Urinary Bladder | Stage 0is Urinary Bladder Carcinoma | Urinary Bladder Flat CIS | Urinary Bladder Flat Carcinoma in Situ",,,,,,,,,,,,,,,"192855","Cancer in situ of urinary bladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266011","Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7","C9267","Stage 0a includes: Ta, N0, M0. Ta: Papillary noninvasive carcinoma.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7 | Non-Invasive Papillary Carcinoma of Bladder | Non-Invasive Papillary Carcinoma of Urinary Bladder | Non-Invasive Papillary Carcinoma of the Bladder | Non-Invasive Papillary Carcinoma of the Urinary Bladder | Non-Invasive Papillary Urothelial Carcinoma | Stage 0a Bladder Cancer | Stage 0a Bladder Carcinoma | Stage 0a Bladder Urothelial Cancer | Stage 0a Bladder Urothelial Carcinoma | Stage 0a Bladder Urothelial Carcinoma | Stage 0a Bladder Urothelial Carcinoma AJCC v6 | Stage 0a Bladder Urothelial Carcinoma AJCC v7 | Stage 0a Carcinoma of Bladder | Stage 0a Carcinoma of Urinary Bladder | Stage 0a Carcinoma of the Bladder | Stage 0a Carcinoma of the Urinary Bladder | Stage 0a Urinary Bladder Carcinoma",,,,,,,,,,,,,,,"4028727","Papillary transitional cell carcinoma, non-invasive",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0278822","Stage I Carcinoma of Bladder","C7896","Stage I includes: T1, N0, M0.  T1: Tumor invades subepithelial connective tissue. N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)","Stage I Bladder Cancer AJCC v6 and v7 | Bladder Cancer Stage I | Jewett-Marshall Stage A Bladder Cancer | Jewett-Marshall Stage A Bladder Carcinoma | Jewett-Marshall Stage A Urinary Bladder Cancer | Jewett-Marshall Stage A Urinary Bladder Carcinoma | Stage I Bladder Cancer | Stage I Bladder Cancer | Stage I Bladder Cancer AJCC v6 | Stage I Bladder Cancer AJCC v7 | Stage I Bladder Carcinoma | Stage I Bladder Carcinoma AJCC v6 | Stage I Bladder Carcinoma AJCC v7 | Stage I Carcinoma of Bladder | Stage I Carcinoma of Urinary Bladder | Stage I Carcinoma of the Bladder | Stage I Carcinoma of the Urinary Bladder | Stage I Urinary Bladder Carcinoma | stage I bladder cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0401783","Adjudicator","C96561","An individual that presides over and arbitrates disputes between individuals or organizations.","Adjudicator | ADJUDICATOR",,,,,,,,,,,,,,,"4143814","Adjudicator",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2986556","Reader 1","C94532","The first in a series of readers that are performing an assessment.","Reader 1 | READER 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986557","Reader 2","C94533","The second in a series of readers that are performing an assessment.","Reader 2 | READER 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700166","Fecal Immunochemical Test","C74538","A fecal occult blood test that uses an immunological assay to detect hemoglobin in stool.","Fecal Immunochemical Test | FIT | Immunochemical FOBT | iFOBT | immunoassay fecal occult blood test | immunochemical fecal occult blood test | immunologic fecal occult blood test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420369","SPP1 Gene","C95570","This gene is involved in signaling and tissue mineralization.","SPP1 Gene | SPP1 | Secreted Phosphoprotein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086035","Competency","C99568","The quality of being qualified for some purpose; having suitable or sufficient skill.","Competency | Competence | Competent",,,,,,,,,,,,,,,"4135707","Competence",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0333118","Retain","C99569","To maintain possession of something.","Retain | Keep",,,,,,,,,,,,,,,"4266485","Retained",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0935912","Computed Tomography Colonography","C28395","An imaging technique of the colon involving helical computed tomography and computer software to generate high-resolution 2-dimensional and 3-dimensional images of the inner surface of the colon. These images are then interpreted by a radiologist to determine the presence of several types of abnormalities of the colon.","Computed Tomography Colonography | CT colonography | CTC | Virtual Colonoscopy | computed tomographic colonography | computed tomography colography | virtual colonoscopy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085246","T-Cell Receptor Gamma-Delta","C17432","A heterodimeric complex comprised of the T-cell receptor gamma and delta chain proteins, which are linked by interchain disulfide bonds. This membrane bound complex is expressed on the surface of a small percentage of T-lymphocytes and is involved in the recognition of antigenic lipids, peptide antigens, and peptides presented by major histocompatibility (MHC) proteins. The gamma/delta dimer associates with the CD3 protein complex, which promotes ligand-dependent signaling.","T-Cell Receptor Gamma-Delta | T-Cell Receptor Gamma Delta | T-Cell Receptor Gamma/Delta | T-Cell Receptor, Gamma-Delta | T-Cell Receptor, Gamma-Delta | TCR Gamma-Delta | TCR Gamma/Delta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0069141","nucleophosmin","C17570","Nucleophosmin (294 aa, ~33 kDa) is encoded by the human NPM1 gene. This protein is involved in ribosomal function.","Nucleophosmin | B23 Nuclear Matrix Protein | NPM1 | Nucleolar Phosphoprotein B23 | Numatrin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335959","STAT5B protein, human","C28669","Signal transducer and activator of transcription 5B (787 aa, ~90 kDa) is encoded by the human STAT5B gene. This protein plays a role in the metabolism of small molecules, transcriptional regulation and signal transduction.","Signal Transducer and Activator of Transcription 5B | STAT5B | Transcription Factor STAT5B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0123257","IBP-2 protein, human","C17506","Insulin-like growth factor-binding protein 2 (325 aa, ~35 kDa) is encoded by the human IGFBP2 gene. This protein is involved in the modulation of plasma half-life for and signaling by insulin-like growth factors.","Insulin-Like Growth Factor-Binding Protein 2 | IBP-2 | IBP2 | IGF Binding Protein 2 | IGF-BP53 | IGF-Binding Protein 2 | IGFBP-2 | IGFBP2 | Insulin-Like Growth Factor Binding Protein 2 | Insulin-Like Growth Factor Binding Protein 2 (36kD) | Insulin-Like Growth Factor Binding Protein 2, 36kDa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0971207","TLR7 protein, human","C30108","Toll-like receptor 7 (1049 aa, ~121 kDa) is encoded by the human TLR7 gene. This protein plays a role in the response to single-stranded RNA.","Toll-Like Receptor 7 | TLR7 | Toll-Like Receptor 7-Like",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1540293","CD276 Gene","C93063","This gene is involved in the regulation of T cell immune responses.","CD276 Gene | CD276 | CD276 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424930","APOBEC3G Gene","C68588","This gene may play a role in cell growth and the cell cycle.","APOBEC3G Gene | APOBEC3G | Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3G Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517561","Intrathoracal","C12491","Within the thorax.","Intrathoracal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812306","GLI2 Gene","C18422","This gene is involved in transcriptional regulation and plays a role in sonic hedgehog signal transduction.","GLI2 Gene | GLI Family Zinc Finger 2 Gene | GLI-Kruppel Family Member GLI2 Gene | GLI2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335270","PTCH2 Gene","C24697","This gene plays a role in intercellular communication, embryonic structure development, and in tumorigenesis.","PTCH2 Gene | PTCH2 | Patched 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1364142","SMO Gene","C24817","This gene plays a role in G protein-coupled receptor signal transduction and sonic hedgehog pathway activation.","SMO Gene | SMO | Smoothened, Frizzled Class Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032200","Platelet-Derived Growth Factor","C20448","A family of growth factors that act as potent mitogens and are involved in the stimulation of angiogenesis. There are four members of this family (platelet-derived growth factor A, B, C and D) that are characterized by a core motif of eight cysteines. They bind to their cognate receptor tyrosine kinases (platelet-derived growth factor receptor family) as homodimers or heterodimers to stimulate signaling.","Platelet-Derived Growth Factor | PDGF | PDGF Family | Platelet-Derived Growth Factor Family | platelet-derived growth factor",,,,,,,,,,,,,,,"4001178","Platelet-derived growth factor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0071253","Platelet-Derived Growth Factor Receptor","C17322","A cell surface protein that has tyrosine-kinase activity. This receptor specifically binds to platelet derived growth factor, and its analogs and antagonists. Ligand binding causes homodimerization or heterodimerization, resulting in receptor activation.","Platelet-Derived Growth Factor Receptor | PDGF Receptor | PDGFR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510924","Anti-CEA Antibody","C2456","Any antibody against the tumor associated antigen carcinoembryonic antigen (CEA; CEACAM5), with potential antineoplastic activity. The CEA antigen is overexpressed in certain types of cancer cells.","Anti-CEA Antibody | Anti-CEACAM5 Antibody | Anti-Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 Antibody | anti-CEA antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708225","Gene Signature","C48182","A form of gene expression profiling that is indicative of the biological behavior of a tumor or cancer. This pattern of expression is comprised of unique clusters of genes that display differential levels of expression. The technology is based on microarray analysis and allows for accurate prognostication based upon these criteria.","Gene Signature | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1313494","TLR3 protein, human","C30104","Toll-like receptor 3 (904 aa, ~104 kDa) is encoded by the human TLR3 gene. This protein plays a role in binding to viral double-stranded RNA and modulation of antiviral responses.","Toll-Like Receptor 3 | CD283 Antigen | TLR3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439508","Per Year","C74924","A frequency rate of occurrences of something within a period of time equal to three hundred sixty-five days.","Per Year | /Year | /a | Every Year | PA | Per Annum | Yearly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274817","Index Colonoscopy","C99594","A colonoscopy performed for screening or diagnostic purposes that is used as a baseline procedure to compare with future follow-up colonoscopies.","Index Colonoscopy | Baseline Colonoscopy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0055599","bleomycin/cyclophosphamide/doxorubicin/prednisone/vincristine protocol","C9550","A chemotherapy combination consisting of bleomycin, cyclophosphamide, doxorubicin, prednisone, and vincristine.","Bleomycin/Cyclophosphamide/Doxorubicin/Prednisone/Vincristine | BACOP | BLEO/CTX/DOX/PRED/VCR | CA-BOP  | CAVPB | CHOP-B  | CHOP-Bleo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280697","carboplatin/etoposide/ifosfamide","C10345","A regimen consisting of carboplatin, etoposide and ifosfamide that can be used in the treatment of non-Hodgkin and Hodgkin lymphomas, including diffuse large B-cell lymphoma and T-cell lymphoma, mycosis fungoides/Sezary syndrome, and gestational trophoblastic neoplasia (GTN).","ICE Regimen | CBDCA/IFF/VP-16 | Carboplatin/Etoposide/Ifosfamide | ICE | ICE regimen | Ifosfamide-Carboplatin-Etoposide Regimen | Ifosfamide/Carboplatin/Etoposide | fosfamide/Carboplatin/Etoposide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879552","leucovorin calcium/methotrexate","C11823","A regimen consisting of leucovorin and methotrexate that can be used for the treatment of osteosarcoma.","Leucovorin Calcium/Methotrexate Regimen | Leucovorin Calcium-Methotrexate | Leucovorin Calcium/Methotrexate | Leucovorin Calcium/Methotrexate | MTX-CF | Methotrexate w/Leucovorin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0056633","cyclophosphamide/prednisone/vincristine protocol","C9573","A regimen consisting of cyclophosphamide, vincristine and prednisone that may be used to treat Castleman disease, post-transplant lymphoproliferative disorders, indolent forms of non-Hodgkin lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.","CVP Regimen | COP Regimen | CTX/PRED/VCR | CVP | CVP regimen | Cyclophosphamide-Vincristine-Prednisone Regimen | Cyclophosphamide/Prednisone/Vincristine | VCP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0107744","Cyclophosphamide/Mechlorethamine/Prednisone/Procarbazine/Vincristine protocol","C28890","A chemotherapy combination consisting of cyclophosphamide, mechlorethamine, prednisone, procarbazine, and vincristine.","Cyclophosphamide/Mechlorethamine/Prednisone/Procarbazine/Vincristine | C-MOPP | CMOPP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280276","Cyclophosphamide/Mitoxantrone/Prednisone/Vincristine","C10211","A combination of agents containing cyclophosphamide, mitoxantrone, prednisone and vincristine.","Cyclophosphamide/Mitoxantrone/Prednisone/Vincristine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879966","CNOP Regimen","C63453","A regimen consisting of cyclophosphamide, mitoxantrone, vincristine and prednisone used to treat both indolent and aggressive forms of non-Hodgkin lymphoma.","CNOP Regimen | CNOP | Cytoxan-Novantrone-Oncovin-Prednisone Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0065477","MACOP-B Regimen","C63457","A regimen consisting of methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine and prednisone, used to treat aggressive forms of non-Hodgkin lymphoma.","MACOP-B Regimen | B-CHOP-M | MACOP-B | Methotrexate-Adriamycin-Cytoxan-Oncovin-Prednisone-Bleomycin Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882461","Prednisone-Methotrexate-Adriamycin-Cytoxan-Etoposide-Cytarabine-Bleomycin-Oncovin-Methotrexate Regimen","C63460","A non-cross resistant regimen consisting of prednisone, methotrexate, doxorubicin, cyclophosphamide and etoposide (ProMACE) alternating with cytarabine, bleomycin, vincristine and methotrexate (CytaBOM), used to treat aggressive forms of non-Hodgkin lymphoma.","ProMACE Alternating with CytaBOM Regimen | Prednisone-Methotrexate-Adriamycin-Cytoxan-Etoposide-Cytarabine-Bleomycin-Oncovin-Methotrexate Regimen | ProMACE-CytaBOM | ProMACE-CytaBOM Regimen | ProMACE-CytaBOM Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0056286","cyclophosphamide/prednisone/procarbazine/vincristine protocol","C9567","A regimen that is a derivative of the original MOPP regimen consisting of cyclophosphamide, vincristine, procarbazine and prednisone used as an initial treatment for Hodgkin lymphoma. Also used for the treatment of non-Hodgkin lymphoma.","COPP Regimen | C-MOPP | COPP | COPP regimen | CTX/PCB/PRED/VCR | Cyclophosphamide/Prednisone/Procarbazine/Vincristine | Cytoxan-Oncovin-Procarbazine-Prednisone Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1112748","Colon Tubulovillous Adenoma","C5496","A neoplasm that arises from the glandular epithelium of the colonic mucosa. It is characterized by tubular and villous architectural patterns. The neoplastic glandular cells have dysplastic features.","Colon Tubulovillous Adenoma | Colonic Tubulovillous Adenoma | Tubulovillous Adenoma of Colon | Tubulovillous Adenoma of the Colon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0267392","Colon Inflammatory Polyp","C5517","A non-neoplastic polypoid lesion in the colon.  It may arise in a background of inflammatory bowel disease or colitis.  It is characterized by the presence of a distorted epithelium, inflammation, and fibrosis.","Colon Inflammatory Polyp | Colonic Inflammatory Polyp | Inflammatory Polyp of Colon | Inflammatory Polyp of the Colon",,,,,,,,,,,,,,,"81064","Pseudopolyposis of colon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3274192","EGFR NP_005219.2:p.T790M","C98503","A change in the amino acid residue at position 790 in the epidermal growth factor receptor protein where threonine has been replaced by methionine.","EGFR NP_005219.2:p.T790M | EGFR NP_005219.2:p.Thr790Met | EGFR T790 Resistant Mutation | EGFR T790M | EGFR T790M Resistant Mutation | EGFR T790M TKI Resistant Mutation | EGFR Thr790Met | EGFR p.T790M | EGFR p.Thr790Met | Epidermal Growth Factor Receptor T790M | Exon 20 Thr790Met | NP_005219.2:p.Thr790Met | Proto-Oncogene c-ErbB-1 T790M | Receptor Tyrosine-Protein Kinase erbB-1 T790M | T790M",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3266992","EGFR Gene Mutation","C98357","A change in the nucleotide sequence of the EGFR gene.","EGFR Gene Mutation | EGFR Mutation | ERBB Gene Mutation | ERBB1 Gene Mutation | Epidermal Growth Factor Receptor Gene Mutation | HER1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0694891","SMAD4 Gene","C18258","This gene plays a role in signal transduction and transcriptional activation. It is also involved in suppression of angiogenesis.","SMAD4 Gene | SMAD Family Member 4 Gene | SMAD4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366550","GNAS Gene","C38317","This gene plays a role in signal transduction and is associated with pituitary tumors.","GNAS Gene | GNAS | GNAS Complex Locus Gene | GNAS1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1835898","PALB2 Gene","C84945","This gene may play a role in the repair of DNA damage that is resolved by recombination.","PALB2 Gene | PALB2 | Partner and Localizer of BRCA2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0669365","NOS3 protein, human","C38571","Nitric oxide synthase, endothelial (1203 aa, ~133 kDa) is encoded by the human NOS3 gene. This protein plays a role in the modulation of vascular smooth muscle relaxation, VEGF-induced angiogenesis and blood coagulation.","Nitric Oxide Synthase, Endothelial | CNOS | Constitutive NOS | EC 1.14.13.39 | EC-NOS | ECNOS | ENOS | Endothelial NOS | Endothelial Nitric Oxide Synthase | Endothelial Nitric Oxide Synthase 3 | NOS Type III | NOS3 | NOSIII | Nitric Oxide Synthase 3 | Nitric Oxide Synthase 3 | cNOS | eNOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201478","Hepatitis B Surface Antibody Measurement","C74711","The determination of the surface antibody reaction of a sample to the Hepatitis B virus.","Hepatitis B Surface Antibody Measurement | Anti-HBs | HBSAB | HBV Surface Antibody | HBV Surface Antibody Measurement | HBsAb | Hepatitis B Virus Surface Antibody",,,,,,,,,,,,,,,"4278658","Hepatitis B surface antibody measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1414121","DNMT1 Gene","C73654","This gene is involved in epigenetic modification of DNA.","DNMT1 Gene | DNA (Cytosine-5)-Methyltransferase 1 Gene | DNMT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417574","MYOD1 Gene","C93113","This gene plays a role in DNA binding and myogenesis.","MYOD1 Gene | MYOD1 | Myogenic Differentiation 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274902","Fecal DNA Test","C99751","A non-invasive test that uses DNA analysis to detect long DNA in stool.","Fecal DNA Test | Stool DNA Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986280","Stratum Group Number","C94082","An integer that identifies the stratum group to study personnel, such as the statistician and registrars. This index is used to cross-reference the stratum group and set of arms during registration. It is provided to perform a lookup in the randomization book or statistical algorithm when performing randomization.","Stratum Group Number | StratumGroup.groupNumber",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514832","Remission Induction Therapy","C15746","Initial treatment with anticancer drugs to decrease the signs or symptoms of cancer or make them disappear.","Remission Induction Therapy | remission induction therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334276","Infiltrating Ductal and Infiltrating Lobular Breast Carcinoma","C6393","An invasive ductal breast carcinoma associated with an invasive lobular carcinomatous component.","Invasive Breast Ductal Carcinoma and Invasive Lobular Carcinoma | Infiltrating Ductal and Infiltrating Lobular Breast Carcinoma | Invasive Ductal and Invasive Lobular Breast Carcinoma | Invasive Ductal and Invasive Lobular Breast Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982575","Thyroid Cancer TNM Finding v7","C89145","A finding about one or more characteristics of thyroid cancer, following the rules of the TNM AJCC v7 classification system.  Both the histologic diagnosis and the age of the patient are of such importance in the behavior and prognosis of thyroid cancer that these factors are included in this staging system. (from AJCC 7th Ed.)","Thyroid Cancer TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982583","Thyroid Cancer pT4b Anaplastic Carcinoma TNM Finding v7","C89153","Anaplastic carcinoma with gross extrathyroid extension. (from AJCC 7th Ed.)","Thyroid Cancer pT4b Anaplastic Carcinoma TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982581","Thyroid Cancer pT4a Anaplastic Carcinoma TNM Finding v7","C89151","Intrathyroidal anaplastic carcinoma. (from AJCC 7th Ed.)","Thyroid Cancer pT4a Anaplastic Carcinoma TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982588","Thyroid Cancer Clinical Distant Metastasis TNM Finding v7","C89158","A clinical finding about one or more characteristics of thyroid cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.","Thyroid Cancer Clinical Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982590","Thyroid Cancer cM1 TNM Finding v7","C89160","Thyroid cancer with distant metastasis. (from AJCC 7th Ed.)","Thyroid Cancer cM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0056273","COP-BLAM protocol","C9564","A regimen consisting of bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone that can be used for the treatment of Hodgkin lymphoma (HL).","BACOPP Regimen | BACOPP | BLEO/CTX/DOX/PCB/PRED/VCR | BLEO/CTX/DOX/PCB/PRED/VCR  | Bleomycin/Cyclophosphamide/Doxorubicin/Prednisone/Procarbazine/Vincristine | Bleomycin/Cyclophosphamide/Doxorubicin/Prednisone/Procarbazine/Vincristine | Bleomycin/Cyclophosphamide/Doxorubicin/Prednisone/Procarbazine/Vincristine Regimen | CAOPP  | CAP-BOP | CAP-BOP  | COP-BLAM III | COP-BLAM III ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281465","bleomycin/cyclophosphamide/doxorubicin/prednisolone/vindesine","C10783","A regimen consisting of bleomycin, cyclophosphamide, doxorubicin, prednisolone, and vindesine that can be used for the treatment of lymphoma.","Bleomycin/Cyclophosphamide/Doxorubicin/Prednisolone/Vindesine Regimen | BLEO/CTX/DAVA/DOX/PRDL | BLEO/CTX/DAVA/DOX/PRDL  | Bleomycin/Cyclophosphamide/Doxorubicin/Prednisolone/Vindesine | Bleomycin/Cyclophosphamide/Doxorubicin/Prednisolone/Vindesine | CHEP Bleo | CHEP Bleo  | CHEP-Bleomycin | LNH 84 | LNH-84 | LNH-84 Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0385706","ACVBP Regimen","C63446","A regimen consisting of doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone used to treat aggressive forms of non-Hodgkin lymphoma.","ACVBP Regimen | ACVBP | Adriamycin-Cytoxan-Vindesine-Bleomycin-Prednisone Regimen | Adriamycin-Cytoxan-Vindesine-Bleomycin-Prednisone Regimen  | Adriamycin/Cyclophosphamide/Vindesine/Bleomycin/Prednisone | Bleomycin/Cyclophosphamide/Doxorubicin/Prednisone/Vindesine | Doxorubicin-Cyclophosphamide-Vindesine-Bleomycin-Prednisone | Doxorubicin/Cyclophosphamide/Vindesine/Bleomycin/Prednisone | Doxorubicin/Cyclophosphamide/Vindesine/Bleomycin/Prednisone Regimen | LNH-87 | LNH-87 ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0961694","M-BACOP Regimen","C99696","A regimen consisting of methotrexate with leucovorin rescue, bleomycin, doxorubicin, cyclophosphamide, vincristine, and prednisolone.","M-BACOP Regimen | ACOMP-B (D) Regimen | Methotrexate-Leucovorin-Doxorubicin-Cyclophosphamide-Vincristine-Prednisolone-Bleomycin Regimen | Methotrexate-Leucovorin-Doxorubicin-Cyclophosphamide-Vincristine-Prednisolone-Bleomycin Regimen ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0246511","bleomycin/cyclophosphamide/doxorubicin/etoposide/prednisone/vincristine","C11343","A regimen consisting of bleomycin, cyclophosphamide, doxorubicin, etoposide, prednisone and vincristine that can be used for the treatment of non-Hodgkin lymphoma (NHL).","VACOP-B Regimen | BLEO/CTX/DOX/PRED/VCR/VP-16 | BLEO/CTX/DOX/PRED/VCR/VP-16 | Bleomycin/Cyclophosphamide/Doxorubicin/Etoposide/Prednisone/Vincristine | Bleomycin/Cyclophosphamide/Doxorubicin/Etoposide/Prednisone/Vincristine | Bleomycin/Cyclophosphamide/Doxorubicin/Etoposide/Prednisone/Vincristine Regimen | P-VABEC | P-VABEC | VACOP-B | VACOP-B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887850","EPOCH protocol","C63779","A regimen consisting of etoposide, prednisone, vincristine (Oncovin), cyclophosphamide and doxorubicin hydrochloride (hydroxydaunorubicin hydrochloride), which may be used in combination with rituximab (R-EPOCH) for the treatment of various aggressive B cell and T cell non-Hodgkin lymphomas.","EPOCH Regimen | DA-EPOCH | DA-EPOCH Regimen | Dose-adjusted Etoposide/Vincristine/Doxorubicin/Cyclophosphamide/Prednisone Regimen | EPOCH | EPOCH regimen | Etoposide-Prednisone-Oncovin-Cyclophosphamide-Hydroxydaunorubicin Regimen | Etoposide/Prednisone/Oncovin/Cyclophosphamide/Hydroxydaunorubicin Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274868","F-MACHOP Regimen","C99697","A regimen consisting of 5-fluorouracil, methotrexate with leucovorin rescue, cytarabine, cyclophosphamide, doxorubicin, vincristine, and prednisone.","F-MACHOP Regimen | 5-Fluorouracil-Methotrexate-Leucovorin-Cytarabine-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone Regimen | F-MACHOP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0084185","cyclophosphamide/doxorubicin/etoposide/mechlorethamine/methotrexate/prednisone/procarbazine/vincristine","C9679","A regimen consisting of prednisone, methotrexate, doxorubicin, cyclophosphamide, etoposide (ProMACE) followed by mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) that may be used in the treatment of non-Hodgkin lymphoma (NHL).","ProMACE-MOPP Regimen | CTX/DOX/MTX/NM/PCB/PRED/VCR/VP-16 | CTX/DOX/MTX/NM/PCB/PRED/VCR/VP-16 | Cyclophosphamide/Doxorubicin/Etoposide/Mechlorethamine/Methotrexate/Prednisone/Procarbazine/Vincristine | Cyclophosphamide/Doxorubicin/Etoposide/Mechlorethamine/Methotrexate/Prednisone/Procarbazine/Vincristine | Cyclophosphamide/Doxorubicin/Etoposide/Mechlorethamine/Methotrexate/Prednisone/Procarbazine/Vincristine Regimen | Prednisone-Methotrexate-Doxorubicin-Cyclophosphamide-Etoposide-Mechlorethamine-Vincristine-Prednisone-Procarbazine | Prednisone/Methotrexate/Adriamycin/Cyclophosphamide/Etoposide-Mechlorethamine/Oncovin/Prednisone/Procarbazine | Prednisone/Methotrexate/Doxorubicin/Cyclophosphamide/Etoposide Followed by Mechlorethamine/Vincristine/Prednisone/Procarbazine | Prednisone/Methotrexate/Doxorubicin/Cyclophosphamide/Etoposide-Mechlorethamine/Vincristine/Prednisone/Procarbazine | ProMACE-MOPP | ProMACE/MOPP | ProMace-MOPP | ProMace/MOPP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706050","Guide Device","C49974","A device designed to help direct the passage of another object.","Guide Device | Guide | Guide Device Component",,,,,,,,,,,,,,,"4123765","Guide",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3274883","London Deauville Criteria Point Scale 1","C99728","The results of the positron emission tomography are negative; there is no detectable abnormal tracer uptake.","London Deauville Criteria Point Scale 1 | 1 | London Deauville Criteria PET Point 1 | PET Score 1 | Score 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274898","London Deauville Criteria Point Scale 2","C99747","The results of the positron emission tomography are negative; the tracer uptake is less than or equal to the mediastinum.","London Deauville Criteria Point Scale 2 | 2 | London Deauville Criteria PET Point 2 | PET Score 2 | Score 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274899","London Deauville Criteria Point Scale 3","C99748","The results of the positron emission tomography are negative; the tracer uptake is greater than the mediastinum but less than or equal to the liver.","London Deauville Criteria Point Scale 3 | 3 | London Deauville Criteria PET Point 3 | PET Score 3 | Score 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274900","London Deauville Criteria Point Scale 4","C99749","The results of the positron emission tomography are positive; the tracer uptake is moderately more than the liver uptake, at any disease site.","London Deauville Criteria Point Scale 4 | 4 | London Deauville Criteria PET Point 4 | PET Score 4 | Score 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274901","London Deauville Criteria Point Scale 5","C99750","The results of the positron emission tomography are positive; the tracer uptake is markedly increased at any disease site.","London Deauville Criteria Point Scale 5 | 5 | London Deauville Criteria PET Point 5 | PET Score 5 | Score 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012734","Disruptive Behavior Disorder","C99753","A classification of disorders in the Diagnostic and Statistical Manual of Mental Disorders (DSM) that are usually diagnosed in infancy, childhood or adolescence and are characterized by an individual's inability to behave in a cooperative manner.","Disruptive Behavior Disorder | Disruptive Behavior Disorders | Disruptive Behavior Disorders",,,,,,,,,,,,,,,"437259","Disruptive behavior disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3274905","Retail Environment","C99758","The milieu in which a product or service is promoted for sale.","Retail Environment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274904","Unmet","C99757","A need or request was not fulfilled.","Unmet | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274903","Disapproval","C99756","An action that is deemed unsatisfactory or unacceptable.","Disapproval | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035397","Rewards","C99754","Positive reinforcement for a desired action, behavior or response.","Reward | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034119","Punishment","C99755","Punitive action for an unwanted behavior or response.","Punishment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2933427","Akt Inhibitor MK2206","C90581","An orally bioavailable allosteric inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor MK2206 binds to and inhibits the activity of Akt in a non-ATP competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","Akt Inhibitor MK2206 | 1,2,4-Triazolo(3,4-f)(1,6)naphthyridin-3(2H)-one, 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl- | Akt inhibitor MK2206 | MK 2206 | MK-2206 | MK-2206 FREE BASE | MK2206",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274204","EGFR NP_005219.2:p.L858R","C98515","A change in the amino acid residue at position 858 in the epidermal growth factor receptor protein where leucine has been replaced by arginine.","EGFR NP_005219.2:p.L858R | EGFR Activating Mutation L858R | EGFR Exon 21 L858R Mutation | EGFR Exon 21 Substitution Mutation L858R | EGFR L858R | EGFR Leu858Arg | EGFR NP_005219.2:p.Leu858Arg | EGFR p.L858R | EGFR p.Leu858Arg | Epidermal Growth Factor Receptor L858R | Exon 21 Leu858Arg | NP_005219.2:p.Leu858Arg | Proto-Oncogene c-ErbB-1 L858R | Receptor Tyrosine-Protein Kinase erbB-1 L858R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335613","RET Oncoprotein","C19954","Human RET Oncoprotein is a product of mutated variants (Oncogene RET) of RET Gene, which encodes Tyrosine-Protein Kinase Receptor RET, a type I membrane protein receptor for Glial Cell Line-Derived with an extracellular cadherin-like domain and important in neural crest development. Some oncogenic RET point mutations cause constitutive kinase activation.  PTC1 oncogene involves fusion of RET kinase to the H4 dimerization leucine zipper.  In PTC6, RET is fused to the N-terminal part of Transcriptional Intermediary Factor-1-Alpha. In PTC7, RET is fused to a C-terminal part of TIF1-Gamma. Oncogenic RET mutations are associated with Hirschsprung's disease, Multiple Endocrine Neoplasia, pheochromocytoma, hyperparathyroidism and medullary thyroid cancer. RET Oncoprotein disrupts normal cell function.","RET Oncoprotein | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333410","EC 2.7.1.112","C26156","Ephrin type-A receptor 2 (976 aa, ~108 kDa) is encoded by the human EPHA2 gene. This protein plays a role in ephrin-A binding, cell-cell signaling and signaling pathway regulation.","Ephrin Type-A Receptor 2 | EC 2.7.1.112 | EC 2.7.10.1 | EPHA2 | Ephrin Receptor Epha2 | Ephrin Receptor Epha2 | Epithelial Cell Kinase | Epithelial Cell Receptor Protein Tyrosine Kinase | Epithelial Cell Receptor Protein-Tyrosine Kinase | Tyrosine-Protein Kinase Receptor ECK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412097","ABL1 Gene","C17346","This gene is involved in cell adhesion, differentiation, division and stress response.","ABL1 Gene | ABL | ABL Proto-Oncogene 1, Non-Receptor Tyrosine Kinase Gene | ABL1 | v-Abl Abelson Murine Leukemia Viral Oncogene Homolog 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983398","Liver Cancer TNM Finding v7","C90149","A finding about one or more characteristics of liver cancer, following the rules of the TNM AJCC v7 classification system.  Intrahepatic bile duct cancers are no longer included in this classification.  The staging of liver cancer now includes only hepatocellular carcinoma. (from AJCC 7th Ed.)","Liver Cancer TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2974289","Crizotinib","C74061","An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","Crizotinib | (R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine | 2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)- | Alkixen | CRIZOTINIB | Crizocent | MET Tyrosine Kinase Inhibitor PF-02341066 | MET tyrosine kinase inhibitor PF-02341066 | PF 02341066 | PF-02341066 | PF-2341066 | PF02341066 | Xalkori",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983418","Liver Cancer Clinical Distant Metastasis TNM Finding v7","C90172","A clinical finding about one or more characteristics of liver cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.","Liver Cancer Clinical Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983420","Liver Cancer cM1 TNM Finding v7","C90174","Liver cancer with distant metastasis. (from AJCC 7th Ed.)","Liver Cancer cM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042517","Ventriculostomy","C99771","A therapeutic procedure that involves the creation of an opening in a cerebral ventricle for drainage purposes.","Ventriculostomy | ",,,,,,,,,,,,,,,"4271587","Ventriculostomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0376695","Victimization","C99770","A process that results in an individual experiencing psychological and/or physical pain and suffering.","Victimization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0373598","Dehydroepiandrosterone Measurement","C74852","The determination of the amount of dehydroepiandrosterone hormone present in a sample.","Dehydroepiandrosterone Measurement | DHEA | DHEA Measurement | Dehydroepiandrosterone | Dehydroisoandrosterone",,,,,,,,,,,,,,,"4017061","Dehydroepiandrosterone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1336737","TPMT protein, human","C21594","Thiopurine S-methyltransferase (245 aa, ~28 kDa) is encoded by the human TPMT gene. This protein is involved in the metabolism of xenobiotics.","Thiopurine S-Methyltransferase | EC 2.1.1.67 | TPMT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388707","Sperm Banking","C15326","Freezing sperm for use in the future. This procedure can allow men to father children after loss of fertility.","Sperm Banking | sperm banking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700396","Injection site","C77680","The anatomic site at which a medication or a vaccine is injected.","Injection Site | SITE, INJECTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274920","Have Shortness of Breath question","C99773","A question about whether an individual has or had shortness of breath.","Have Shortness of Breath | Have Been Short of Breath | Have Been Short of Breath | I have been short of breath | Shortness of breath | Were you short of breath",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274921","Bothered by Change in Weight","C99774","A question about whether an individual is or has been bothered by a change in weight.","Bothered by Change in Weight | I am bothered by a change in weight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274922","Get Tired Easily","C99775","A question about whether an individual tires or has tired easily.","Get Tired Easily | I get tired easily | I got tired easily | I tire easily | Tire Easily",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3463815","Feel Fatigue","C99776","A question about whether an individual feels or felt fatigued.","Feel Fatigue | Fatigue | Fatigue Distress | Fatigue Intensity | Feel Fatigued | Frequency of Fatigue | I feel fatigued",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274923","Feel Weak All Over","C99777","A question about whether an individual feels or felt weak all over.","Feel Weak All Over | I feel weak all over",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274924","Have Been Coughing","C99778","A question about whether an individual is or has been coughing.","Have Been Coughing | Cough | I have been coughing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274925","Unhappy With Appearance","C99779","A question about whether an individual is or was unhappy with their appearance.","Unhappy With Appearance | I am unhappy with my appearance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274926","Hard to Tell Other People About Infection","C99780","A question about whether an individual has or had a hard time telling other people about their infection.","Hard to Tell Other People About Infection | It is hard to tell other people about my infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274927","Worry About Spreading Infection","C99781","A question about whether an individual worries or worried about spreading their infection.","Worry About Spreading Infection | I worry about spreading my infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274928","Concern About Future","C99782","A question about whether an individual has or had concerns about what the future holds for them.","Concern About Future | I am concerned about what the future holds for me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274929","Worry About Effect of Stress on Illness","C99783","A question about whether an individual worries or worried about the effect of stress on their illness.","Worry About Effect of Stress on Illness | I worry about the effect of stress on my illness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274930","Embarrassed by Illness","C99784","A question about whether an individual is or was embarrassed about their illness.","Embarrassed by Illness | I am embarrassed by my illness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274931","Pain Has Interfered with Normal Work or Activities","C99785","A question about whether a person has or had pain that interfered with normal work or activities.","Pain Has Interfered with Normal Work or Activities | Did pain interfere with your daily activities | Pain Has Interfered With Normal Work or Activities | Pain Has Interfered With Normal Work or Activities | Pain Interference with Work | Pain Interferes with Normal Work or Activity | Pain has interfered with my normal work or activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274932","Satisfied with Physical Appearance","C99786","A question about an individual's satisfaction with their physical appearance.","Satisfied with Physical Appearance | I am satisfied with my physical appearance | Satisfied With Physical Appearance | Satisfied With Physical Appearance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274933","Have Swelling in Face Arms or Legs","C99787","A question about whether an individual has or had swelling in their face, arms or legs.","Have Swelling in Face Arms or Legs | I have had swelling in my face, arms or legs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274934","Feel Sexually Attractive","C99788","A question about whether an individual feels or felt sexually attractive.","Feel Sexually Attractive | I feel sexually attractive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274935","Have Good Appetite","C99789","A question about whether an individual has or had a good appetite.","Have Good Appetite | I have a good appetite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274936","Feel Motivated to do Things","C99790","A question about whether a person feels or felt motivated to do things.","Feel Motivated to do Things | I feel motivated to do things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274937","Hopeful About Future","C99791","A question about whether an individual feels or felt hopeful about the future.","Hopeful About Future | Feel Hopeful About the Future | I am hopeful about the future | I felt hopeful about the future",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274938","Have People to Help if Needed","C99792","A question about whether an individual has or had people to help them if they need it.","Have People to Help if Needed | I have people to help me if I need it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274939","Thinking Clear","C99793","A question about whether an individual is or was thinking clearly.","Thinking Clear | My thinking is clear | Thinking Clearly | Thinking is Clear",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274940","Have Trouble Concentrating","C99794","A question about whether an individual has or had trouble concentrating.","Have Trouble Concentrating | I had trouble concentrating | I have had trouble concentrating | I have trouble concentrating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274941","Have Trouble Remembering Things","C99795","A question about whether an individual has or had trouble remembering things.","Have Trouble Remembering Things | Have you had trouble remembering things | I have trouble remembering things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0073992","Salmeterol","C29443","A highly selective, long-acting beta-2 adrenergic agonist with bronchodilatory activity. Salmeterol's benzene moiety resembles the structure of catecholamines, and occupies the active site of beta-2 adrenergic receptor, while the long, lipophilic side chain of salmeterol, binds to the so called 'exosite' near the beta-2 adrenergic receptors. The binding at the exosite allows the active portion of the molecule to remain at the receptor site and continually engage and disengage with the receptor, therefore providing a long duration of action. This agent stimulates intracellular adenyl cyclase to catalyze the conversion of adenosine triphosphate to cyclic-3',5'-adenosine monophosphate (cAMP). Increased cAMP levels result in relaxation of bronchiolar smooth muscle, bronchodilation and increased bronchial airflow.","Salmeterol | SALMETEROL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2703143","mTOR Kinase Inhibitor AZD8055","C78856","An inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor AZD8055 inhibits the serine/threonine kinase activity of mTOR, resulting in decreased expression of mRNAs necessary for cell cycle progression, which may induce cell cycle arrest and tumor cell apoptosis. mTOR phosphorylates transcription factors, such as S6K1 and 4E-BP1, which stimulate protein synthesis and regulate cell growth, proliferation, motility, and survival.","mTOR Kinase Inhibitor AZD8055 | AZD-8055 | AZD8055",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0050560","Acivicin","C986","A modified amino acid and structural analog of glutamine.  Acivicin inhibits glutamine amidotransferases in the purine and pyrimidine biosynthetic pathways, thereby inhibiting tumor growth in cell lines dependent on glutamine metabolism. (NCI04)","Acivicin | (S-(R*,R*))-4,5-Dihydro-alpha-amino-3-chloro-5-isoxazoleacetic Acid | ACIVICIN | AT-125 | U-42126",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0935675","Lutetium Lu 177 Monoclonal Antibody CC49","C2598","A radioimmunoconjugate of the humanized monoclonal antibody (MoAb) CC49 labeled with lutetium 131 (Lu-177). MoAb CC49 binds to the pancarcinoma tumor-associated glycoprotein (TAG)-72 with high affinity. Lu-177 MoAb CC49 delivers gamma radiation emitting Lu-177 nuclide directly to tumor cells that express TAG-72, and so may be used in radioimmunotherapeutic treatment of cancers.","Lutetium Lu 177 Monoclonal Antibody CC49 | 177 Lu-CC49",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527262","Alvespimycin","C38142","An analogue of the antineoplastic benzoquinone antibiotic geldanamycin. Alvespimycin binds to HSP90, a chaperone protein that aids in the assembly, maturation and folding of proteins. Subsequently, the function of Hsp90 is inhibited, leading to the degradation and depletion of its client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction.","Alvespimycin | 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin | 17-DMAG | 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin | 17-dimethylaminoethylamino-17-demethoxygeldanamycin | ALVESPIMYCIN | Geldanamycin,17-demethoxy-17-((2-(dimethylamino)ethyl)amino)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0768182","Iodine I 131 Tositumomab","C2444","A monoclonal antibody directed against the CD20 protein expressed on the surface of B-lymphocytes and radiolabeled with the radioisotope iodine I 131 with potential antineoplastic activity. Iodine I 131 tositumomab binds to and selectively delivers cyctotoxic radiation to CD20-expressing B-lymphocytes, thereby minimizing systemic radiotoxicity.","Iodine I 131 Tositumomab | 131-I-Anti-B1 Monoclonal Antibody | Bexxar | I 131 Monoclonal Antibody Anti-B1 | I 131 Tositumomab | I131-MOAB-B1 | Iodine I 131 MOAB Anti-B1 | Iodine I 131 Monoclonal Antibody Anti-B1 | Iodine-131 Anti-B1 Antibody | Iodine-131 Anti-CD20 Monoclonal Antibody | Iodine-131 Tositumomab | TOSITUMOMAB I-131 | Tositumomab and I-131 | Tositumomab and I-131 (Bexxar) | iodine I 131 tositumomab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0935762","In 111 Monoclonal Antibody B3","C2615","A radioimmunoconjugate of monoclonal antibody (MoAb) B3 labeled with Indium 111 (In-111). MoAb B3 is a murine MoAb that recognizes a Lewis Y carbohydrate antigen present on the surface of many carcinomas. This radioimmunoconjugate emits gamma radiation and X-Ray photons that can be captured by gamma camera, allowing imaging of Lewis Y expressing tissues.","In 111 Monoclonal Antibody B3 | 111 In-B3 | Indium In 111 Monoclonal Antibody B3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831873","Tivantinib","C62437","An orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity. c-Met inhibitor ARQ 197 binds to the c-Met protein and disrupts c-Met signal transduction pathways, which may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein, the product of the proto-oncogene c-Met, is a receptor tyrosine kinase also known as hepatocyte growth factor receptor (HGFR); this protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis.","Tivantinib | (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione | ARQ 197 | ARQ-197 | ARQ197 | TIVANTINIB | c-Met Inhibitor ARQ 197",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2316164","Olaparib","C71721","A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.","Olaparib | AZD 2281 | AZD-2281 | AZD2281 | KU 0059436 | KU-0059436 | KU0059436 | Lynparza | OLAPARIB | Olanib | Olaparix | PARP Inhibitor AZD2281 | PARP inhibitor AZD2281 | olaparib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0171337","bleomycin/cyclophosphamide/dexamethasone/doxorubicin/vincristine","C9698","A regimen consisting of bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone for treating patients with non-Hodgkin lymphoma (NHL).","BACOD Regimen | BACOD | BLEO/CTX/DM/DOX/VCR | Bleomycin-Doxorubicin-Cyclophosphamide-Vincristine-Dexamethasone Bleomycin/Doxorubicin/Cyclophosphamide/Vincristine/Dexamethasone Regimen | Bleomycin/Adriamycin/Cyclophosphamide/Oncovin/Dexamethasone | Bleomycin/Cyclophosphamide/Dexamethasone/Doxorubicin/Vincristine | Bleomycin/Doxorubicin/Cyclophosphamide/Vincristine/Dexamethasone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521896","Monoclonal Antibody B3","C2726","A murine IgG1 monoclonal antibody directed against Lewis Y antigen and related carbohydrate antigens of cell surface glycoproteins found in many tumor cells.  Monoclonal antibody B3 can be conjugated with various toxins in order to target their cytotoxic activity to tumor cells expressing these carbohydrate antigens. (NCI04)","Monoclonal Antibody B3 | B3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516025","Antineoplaston Agent","C2500","A peptide, amino acid derivative, and/or organic acid extracted from blood serum, urine, or synthesized chemically, that inhibits the methylation of nucleic acids and the incorporation of L-glutamine into tumor-cell proteins. These agents also intercalate into DNA, leading to cell cycle arrest in the G1 phase and inhibition of mitosis and terminal cell differentiation. In addition, antineoplastons may inhibit RAS oncogene expression and activate the tumor suppressor gene p53, resulting in cell differentiation and apoptosis. (NCI04)","Antineoplaston Agent | Antineoplastons | antineoplaston",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515929","Alternative Medicine, Indirect","C19937","Medical substance or procedure in the process of becoming accepted by orthodox western medicine.","Alternative Medicine, Indirect | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003993","Asparaginase","C286","An enzyme isolated from the bacterium Escherichia coli or the bacterium Erwinia carotovora with antileukemic activity. Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia in leukemic cells, resulting in the depletion of asparagine, inhibition of protein synthesis, cell cycle arrest in the G1 phase, and apoptosis in susceptible leukemic cell populations. Asparagine is critical to protein synthesis in leukemic cells; some leukemic cells cannot synthesize this amino acid de novo due to the absent or deficient expression of the enzyme asparagine synthase. The E. carotovora-derived form of asparaginase is typically reserved for cases of asparaginase hypersensitivity.","Asparaginase | ASP-1 | ASPARAGINASE | Asparaginase II | Asparaginase-E.Coli | Colaspase | Elspar | Kidrolase | L-ASP | L-Asnase | L-Asparaginase | L-Asparagine Amidohydrolase | L-Asparagine amidohydrolase | L-asparaginase | Laspar | Lcf-ASP | Leucogen | Leunase | MK-965 | Paronal | Re-82-TAD-15 | Serasa | Spectrila | asparaginase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0771311","Alendronic Acid","C61625","A second generation bisphosphonate and synthetic analog of pyrophosphate with anti-bone-resorption activity. Alendronic acid binds to and inhibits the activity of farnesyl pyrophosphate synthetase, an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids, donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which are important in the process of osteoclast turnover. As a result, bone resorption and turnover are reduced.","Alendronic Acid | (4-Amino-1-hydroxybutylidene)bisphosphonic Acid | ALENDRONIC ACID | Alendronate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881944","NHL-BFM-90 Regimen","C67197","A regimen used for the treatment of localized aggressive forms of childhood B-cell non-Hodgkin lymphoma, including lymphoblastic lymphoma.","NHL-BFM-90 Regimen | BFM-90 Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0338248","carmustine/cytarabine/etoposide/melphalan regimen","C11103","No Value Exists","Carmustine/Cytarabine/Etoposide/Melphalan | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879265","BEACOPP Regimen","C11638","A regimen consisting of bleomycin, etoposide, doxorubicin hydrochloride (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine and prednisone, used for the treatment of advanced-stage Hodgkin lymphoma.","BEACOPP Regimen | BEACOPP | BEACOPP regimen | Bleomycin-Etoposide-Adriamycin-Cyclophosphamide-Oncovin-Procarbazine-Prednisone Regimen | Bleomycin/Cyclophosphamide/Doxorubicin/Etoposide/Prednisone/Procarbazine/Vincristine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510931","Anti-MUC-1 Monoclonal Antibody","C29983","A monoclonal antibody recognizing human mucin, a cell surface antigen encoded by the MUC-1 gene. In normal tissue, mucin exists as heavily glycosylated form, while tumor-associated mucin molecules are hypo-glycosylated. Hypo-glycosylation exposes the normally cryptic tandem peptide repeats in cancer-associated mucin, thereby allows antigen-antibody interaction with MUC-1 antibody. As a result, the MUC-1 antibody inhibits the initiation of the immunosuppressive cascade triggered by mucin, including production and secretion of prostaglandin E2 (PGE2), followed by VEGF induction and suppression of natural killer cell, lymphokine-activated killer cell and cytotoxic T cell activity.","Anti-MUC-1 Monoclonal Antibody | Anti-MUC-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0763109","Anti-B4 Blocked Ricin Immunotoxin","C2380","An immunotoxin comprised of an anti-B4 (anti-CD19) murine monoclonal antibody linked to the modified plant-derived toxin blocked ricin. The antibody moiety of anti-B4 blocked ricin immunotoxin binds to B lymphocytes that express B4; after internalization of the immunotoxin by the B4-expressing B cell, the ricin moiety cleaves the N-glycosidic bond between the ribose and adenine base at position 4324 in the B lymphocyte 28S ribosomal RNA, resulting in ribosome inactivation, inhibition of protein synthesis, and cell death. Blocked ricin is ricin which has been chemically modified such that the lectin binding sites of the B chain (galactose-binding sites) have been blocked by covalent attachment of affinity ligands, leaving the ribosome-inactivating activity of the ricin A chain intact.","Anti-B4 Blocked Ricin Immunotoxin | Anti B4-BR | Anti B4bR | Anti-B4 Blocked Ricin | Anti-B4-bR | Monoclonal Antibody Anti-B4 Blocked Ricin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812303","FYN Gene","C18419","This gene plays a role in the regulation of cell growth and proliferation.","FYN Gene | FYN | FYN Proto-Oncogene, Src Family Tyrosine Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0065344","Lymphocyte Specific Protein Tyrosine Kinase p56(lck)","C17309","Tyrosine-protein kinase Lck (509 aa, ~58 kDa) is encoded by the human LCK gene. This protein is involved in tyrosine phosphorylation, T-cell maturation and ligand-dependent signaling.","Tyrosine-Protein Kinase Lck | EC 2.7.1.112 | EC 2.7.10.2 | LCK | LSK | Leukocyte C-Terminal Src Kinase | Lymphocyte Cell-Specific Protein-Tyrosine Kinase | Lymphocyte-Specific Protein Tyrosine Kinase | Lymphocyte-Specific Protein-Tyrosine Kinase | Lymphocyte-Specific p56LCK Tyrosine Protein Kinase | P56-LCK | Protein YT16 | Proto-Oncogene Lck | Proto-Oncogene Tyrosine-Protein Kinase LCK | T Cell-Specific Protein-Tyrosine Kinase | T-Cell Specific Protein Tyrosine Kinase | p56-LCK | p56-LCK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033681","Protein Tyrosine Kinase","C17020","Kinases that phosphorylate protein tyrosine residues. These kinases play major roles in mitogenic signalling, and can be divided into two subfamilies: receptor tyrosine kinases, that have an extracellular ligand-binding domain, a single transmembrane domain, and an intracellular tyrosine kinase domain; and nonreceptor tyrosine kinases, which are soluble, cytoplasmic kinases. (Dictionary of Cell and Molecular Biology Online)","Protein Tyrosine Kinase | EC 2.7.10 | PTK | Protein-Tyrosine Kinase | Tyrosine Kinase | Tyrosine Protein Kinase | Tyrosine-Protein Kinase | Tyrosine-Specific Protein Kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1456380","Mitogen-Activated Protein Kinase 14, Human","C26369","Mitogen-activated protein kinase 14 (360 aa, ~42 kDa) is encoded by the human MAPK14 gene. This protein is involved in MAP kinase signaling pathways, serine/threonine phosphorylation and the regulation of gene expression.","Mitogen-Activated Protein Kinase 14 | CSAID-Binding Protein | CSAIDS Binding Protein | CSBP | Cytokine Suppressive Anti-Inflammatory Drug Binding Protein | EC 2.7.11.24 | MAP Kinase 14 | MAP Kinase 14 | MAP Kinase Mxi2 | MAP Kinase p38 Alpha | MAPK 14 | MAPK14 | MAX-Interacting Protein 2 | Mitogen-Activated Protein Kinase p38 Alpha | SAPK2A | Stress-Activated Protein Kinase 2A | p38 MAP Kinase | p38 MAPK | p38 Mitogen Activated Protein Kinase | p38Alpha EXIP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0050668","Activin","C20456","Disulfide-linked homo- and heterodimeric growth factors (Activin A, Activin B, Activin AB) of the TGF Family with effects on a range of cell types in addition to promoting FSH release in gonadal sites, depending on subunit composition. Composed of Beta-A and Beta-B subunits.","Activin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1686883","Growth/Differentiation Factor 9, Human","C26375","Growth/differentiation factor 9 (454 aa, ~51 kDa) is encoded by the human GDF9 gene. This protein plays a role in folliculogenesis.","Growth/Differentiation Factor 9 | GDF-9 | GDF-9 Protein | GDF9 | GDF9 Protein | Growth Differentiation Factor 9 | Growth Differentiation Factor 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0104998","T-Lymphocyte Activation Antigen CD80","C15173","T-lymphocyte activation antigen CD80 (288 aa, ~33 kDa) is encoded by the human CD80 gene. This protein is involved in the regulation of T-cell activation.","T-Lymphocyte Activation Antigen CD80 | Activation B7-1 Antigen | B-lymphocyte Activation Antigen B7-1 | B7 | B7-1 | B71 Antigen | BB1 | CD28 Antigen Ligand 1 | CD28LG | CD28LG1 | CD80 | CD80 Antigen | CD80 Antigen | CTLA-4 Counter-Receptor B7.1 | LAB7",,,,,,,,,,,,,,,"4012718","Lymphocyte antigen CD80",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0965245","CD274 protein, human","C96024","Programmed cell death 1 ligand 1 (290 aa, ~33 kDa) is encoded by the human CD274 gene. This protein is involved in the mediation of both the activation and proliferation of T cells.","Programmed Cell Death 1 Ligand 1 | B7 Homolog 1 | B7-H1 | CD Antigen CD274 | CD274 | CD274 Antigen | PD-L1 | PDL1 | Pdcd1 Ligand 1 | Programmed Death Ligand 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2742904","TYMP protein, human","C26148","Thymidine phosphorylase (482 aa, ~50 kDa) is encoded by the human TYMP gene. This protein plays a role in pyrimidine metabolism, DNA replication and endothelial cell migration and tube formation.","Thymidine Phosphorylase | EC 2.4.2.4 | ECGF1 | Endothelial Cell Growth Factor 1 (Platelet-Derived) | Gliostatin | PD-ECGF | Platelet-Derived Endothelial Cell Growth Factor 1 | Platelet-Derived Endothelial Cell Growth Factor 1 | TP | TYMP | TdRPase | Thymidylate Phosphorylase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448407","Oncogene FGR","C18333","Human Oncogene FGR is a mutated variant of FGR Gene (SRC Family), which encodes 529-aa 60-kDa p55-FGR, a protein tyrosine kinase that may bind PTPNS1 and contains 1 SH2 and 1 SH3 domain. Oncogene FGR disrupts normal cell function.","Oncogene FGR | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042666","VIM protein, human","C48797","Vimentin (466 aa, ~54 kDa) is encoded by the human VIM gene. This protein plays a role in the localization of organelles and other cellular components.","Vimentin | Epididymis Luminal Protein 113 | VIM | Vimentin Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041484","Tyrosinase","C17226","Tyrosinase (529 aa, ~60 kDa) is encoded by the human TYR gene. This protein is involved in pigment biosynthesis, eye development and the metabolism of both tyrosine and L-dopa.","Tyrosinase | EC 1.14.18.1 | LB24-AB | Monophenol Monooxygenase | SK29-AB | TYR | Tumor Rejection Antigen AB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201983","Sulfated DHEA Measurement","C96629","The determination of the amount of sulfated dehydroepiandrosterone (DHEA) present in a sample.","Sulfated DHEA Measurement | DHEA Sulfate | DHEA Sulfate Measurement | DHEA-S | DHEA-S Measurement | DHEAS | Dehydroepiandrosterone Sulfate | Dehydroepiandrosterone Sulfate Measurement | sDHEA",,,,,,,,,,,,,,,"4216461","Dehydroepiandrosterone sulfate level",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019623","Malignant Histiocytosis","C7202","An antiquated term referring to cases of systemic non-Hodgkin lymphomas which are composed of large, atypical neoplastic lymphoid cells and cases of hemophagocytic syndromes. In the past, cases of anaplastic large cells lymphoma were called malignant histiocytosis.","Malignant Histiocytosis | ","9750/3","Malignant histiocytosis",,,,,,,,,,,,,"4029203|4041104","Malignant histiocytosis|Malignant histiocytosis (clinical)",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0049174","5-Fluoro-2-Deoxycytidine","C62785","An antimetabolite consisting of a fluorinated pyrimidine analog with potential antineoplastic activity. As a prodrug, 5-fluoro-2-deoxycytidine is converted by intracellular deaminases to the cytotoxic agent 5-Fluorouracil (5-FU). 5-FU is subsequently metabolized to active metabolites including 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP binds to and inhibits thymidylate synthase, thereby reducing the production of thymidine monophosphate, which leads to depletion of thymidine triphosphate. This inhibits DNA synthesis and cell division. FUTP competes with uridine triphosphate for incorporation into the RNA strand thus leading to an inhibition of RNA and protein synthesis. Other fluorouracil metabolites also get incorporated into both DNA and RNA, thereby further hampering cellular growth.","5-Fluoro-2-Deoxycytidine | 5-FLUORO-2'-DEOXYCYTIDINE | 5-fluoro-2-deoxycytidine | Cytidine, 2'-deoxy-5-fluoro- | FdCyd | Ro 5-1090",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281534","Fluorouracil/Irinotecan/Leucovorin Calcium regimen (IFL)","C10836","A combination of agents containing fluorouracil, irinotecan and leucovorin calcium.","Fluorouracil/Irinotecan/Leucovorin Calcium | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278901","Fluorouracil/Leucovorin Calcium/Levamisole","C9813","A combination of agents containing fluorouracil, leucovorin calcium, levamisole.","Fluorouracil/Leucovorin Calcium/Levamisole | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279296","fluorouracil/levamisole","C9981","A regimen consisting of fluorouracil and levamisole that may be used in the treatment of colon cancer.","Fluorouracil/Levamisole Regimen | 5-FU/LEV | 5FU/Levamisole | Fluorouracil and Levamisole | Fluorouracil-Levamisole | Fluorouracil/Levamisole | Fluorouracil/Levamisole | LEV | Levamisole-Fluorouracil | Levamisole/Fluorouracil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0338085","Fluorouracil/Interferon Alfa","C10987","No Value Exists","Fluorouracil/Interferon Alfa | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880666","FU-LV Regimen","C63388","A regimen consisting of fluorouracil and leucovorin, used in both the adjuvant and metastatic disease setting, for the treatment of colorectal cancer. This regimen is also combined with radiation for the treatment of gastric and esophageal cancer.","FU-LV Regimen | 5FU/LV | FU-LV | FU-LV regimen | FULV (L-Leucovorin) | Fluorouracil-Leucovorin Regimen | Machover regimen | Mayo Clinic Regimen | Mayo Clinic regimen | Roswell Park Regimen | Roswell Park regimen | de Gramont Regimen | de Gramont regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677790","Fluorouracil/Gemcitabine/Leucovorin Calcium","C11313","No Value Exists","Fluorouracil/Gemcitabine/Leucovorin Calcium | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0907349","Nelarabine","C1704","An arabinonucleoside antimetabolite with antineoplastic activity. Nelarabine is demethoxylated by adenosine deaminase to become biologically active 9-beta-D-arabinosylguanine (ara-G); ara-G incorporates into DNA, thereby inhibiting DNA synthesis and inducing an S phase-dependent apoptosis of tumor cells. (NCI04)","Nelarabine | 2-Amino, 6-Methoxypurine Arabinoside | 2-Amino-6-methoxypurine arabinoside | 2-Amino-9-beta-D-arabinofuranosyl-6-methoxy-9H-purine | 506U78 | Arranon | Compound 506U78 | GW506U78 | NELARABINE | nelarabine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1454487","Myc Proto-Oncogene Protein, Human","C17391","Myc proto-oncogene protein (439 aa, ~49 kDa) is encoded by the human MYC gene. This protein plays a role in the regulation of transcription and cell proliferation.","Myc Proto-Oncogene Protein | Class E Basic Helix-Loop-Helix Protein 39 | MYC | MYC Transcription Factor | Proto-Oncogene c-Myc | Transcription Factor p64 | bHLHe39 | c-MYC Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0299316","Banoxantrone","C79528","A bioreductive, alkylaminoanthraquinone prodrug with antineoplastic activity. Under hypoxic conditions, often seen in solid tumors, banoxantrone (AQ4N) is converted and activated by cytochrome P450 enzymes, which are upregulated in certain tumors, to the cytotoxic DNA-binding agent AQ4. Banoxantrone intercalates into and crosslinks DNA, and inhibits topoisomerase II. This results in an inhibition of DNA replication and repair in tumor cells. Combined with conventional therapeutic agents, both oxygenic and hypoxic regions of tumors can be targeted.","Banoxantrone | 9,10-Anthracenedione, 1,4-bis((2-(dimethylamino)ethyl)amino)-5,8-dihydroxy-, N,N'-dioxide | AQ 4N | Aq4N | BANOXANTRONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2713007","Ridaforolimus","C49061","A small molecule and non-prodrug analogue of the lipophilic macrolide antibiotic rapamycin with potential antitumor activity. Ridaforolimus binds to and inhibits the mammalian target of rapamycin (mTOR), which may result in cell cycle arrest and, consequently, the inhibition of tumor cell growth and proliferation. Upregulated in some tumors, mTOR is a serine/threonine kinase involved in regulating cellular proliferation, motility, and survival that is located downstream of the PI3K/Akt signaling pathway.","Ridaforolimus | AP23573 | Deforolimus | MK-8669 | RIDAFOROLIMUS | Rapamycin, 42-(dimethylphosphinate) | ridaforolimus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2743963","Rilotumumab","C67079","A fully human IgG2 monoclonal antibody directed against the human hepatocyte growth factor (HGF) with potential antineoplastic activity. Anti-HGF monoclonal antibody AMG 102 binds to and neutralizes HGF, preventing the binding of HGF to its receptor c-Met and so c-Met activation; inhibition of c-Met-mediated signal transduction may result in the induction of apoptosis in cells expressing c-Met. c-Met (HGF receptor or HGFR), a receptor tyrosine kinase overexpressed or mutated in a variety of epithelial cancer cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.","Rilotumumab | AMG 102 | AMG-102 | AMG102 | Anti-HGF Monoclonal Antibody AMG 102 | Fully Human Anti-HGF Monoclonal Antibody AMG 102 | RILOTUMUMAB | anti-HGF monoclonal antibody AMG 102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1506057","AEE788","C48369","An orally bioavailable multiple-receptor tyrosine kinase inhibitor. AEE788 inhibits phosphorylation of the tyrosine kinases of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and vascular endothelial growth factor receptor 2 (VEGF2), resulting in receptor inhibition, the inhibition of cellular proliferation, and induction of tumor cell and tumor-associated endothelial cell apoptosis. (NCI05)","Multikinase Inhibitor AEE788 | AEE 788 | AEE-788 | AEE788 | AEE788",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1958300","veliparib","C60768","A poly(ADP-ribose) polymerase (PARP) -1 and -2 inhibitor with chemosensitizing and antitumor activities. With no antiproliferative effects as a single agent at therapeutic concentrations, ABT-888 inhibits PARPs, thereby inhibiting DNA repair and potentiating the cytotoxicity of DNA-damaging agents. PARP nuclear enzymes are activated by DNA single or double strand breaks, resulting in the poly(ADP-ribosyl)ation of other nuclear DNA binding proteins involved in DNA repair; poly(ADP-ribosyl)ation contributes to efficient DNA repair and to survival of proliferating cells exposed to mild genotoxic stresses as induced by as oxidants, alkylating agents or ionizing radiation.","Veliparib | 2-((R)-2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide | ABT 888 | ABT-888 | ABT888 | PARP-1 inhibitor ABT-888 | VELIPARIB | veliparib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2975395","Navitoclax","C64776","An orally active, synthetic small molecule and an antagonist of a subset of the B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. Navitoclax selectively binds to apoptosis suppressor proteins Bcl-2, Bcl-XL, and Bcl-w, which are frequently overexpressed in a wide variety of cancers, including those of the lymph, breast, lung, prostate, and colon, and are linked to tumor drug resistance. Inhibition of these apoptosis suppressors prevents their binding to the apoptotic effectors Bax and Bak proteins, thereby triggering apoptotic processes in cells overexpressing Bcl-2, Bcl-XL, and Bcl-w. This eventually reduces tumor cell proliferation.","Navitoclax | A-855071.0 | ABT-263 | BcI-2 Family Protein Inhibitor ABT-263 | NAVITOCLAX | navitoclax",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0935761","Yttrium Y 90 Monoclonal Antibody B3","C2614","A radioimmunoconjugate of monoclonal antibody (MoAb) B3 conjugated with isotope yttrium 90. MoAb B3 is a murine MoAb that recognizes a Lewis Y carbohydrate antigen present on the surface of many carcinomas. This radioimmunoconjugate emits beta particles that causes cytotoxicity in tumor cells and has both diagnostic and therapeutic uses.","Yttrium Y 90 Monoclonal Antibody B3 | 90 Y-B3 | MOAB B3, Yttrium Y 90 | Y 90 Monoclonal Antibody B3 | Y90-B3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796473","BL22 immunotoxin","C1842","A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody RFB4 fused to a fragment of Pseudomonas exotoxin-A with potential antineoplastic activity.  BL22 immunotoxin binds to CD22, an antigen expressed in B-cell malignancies, thereby delivering its toxin directly to tumor cells.  The toxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also blocks translational elongation via binding to elongation factor-2 in eukaryotic cells.","BL22 Immunotoxin | Anti-CD22 Recombinant Immunotoxin BL22 | BL22 | BL22 Immunotoxin [RFB4(dsFv)-PE38] | BL22 immunotoxin | CAT 3888 | CAT-3888 | CAT3888 | GCR 3888 | GCR-3888 | GCR3888 | Immunotoxin BL22 | RFB4(dsFv)-PE38 Immunotoxin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1948068","Belinostat","C48812","A novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase.","Belinostat | BELINOSTAT | Beleodaq | PXD 101 | PXD-101 | PXD101 | belinostat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0525227","Brimonidine","C65269","An imidazole derivative and a selective alpha-2 adrenergic receptor agonist. Upon ocular administration, brimonidine acts on the blood vessels causing them to constrict which leads to a decrease in the production of aqueous humor. Brimonidine also enhances the uveoscleral outflow of aqueous humor. This reduces intraocular pressure.","Brimonidine | BRIMONIDINE | Brimodine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1701190","Brivanib Alaninate","C53397","The alaninate salt of a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. Brivanib strongly binds to and inhibits VEGFR2, a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells; inhibition of VEGFR2 may result in inhibition of tumor angiogenesis, inhibition of tumor cell growth, and tumor regression.","Brivanib Alaninate | BMS 582664 | BMS-582664 | BRIVANIB ALANINATE | brivanib alaninate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2717021","Moxetumomab Pasudotox","C68819","A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38) with potential antineoplastic activity. The Fv portion of anti-CD22 immunotoxin CAT-8015 binds to CD22, a cell surface receptor expressed on a variety of malignant B-cells, thereby delivering the toxin moiety PE38 directly to tumor cells. Once internalized, PE38 induces caspase-mediated apoptosis via a mechanism involving mitochondrial damage and blocks translational elongation by binding to elongation factor 2 (EF-2). Anti-CD22 immunotoxin CAT-8015 exhibits a greater affinity for CD22 than its predecessor, anti-CD22 immunotoxin CAT-3888 (BL22 immunotoxin), and hence may be more effective against tumor cells expressing lower levels of CD22.","Moxetumomab Pasudotox | Anti-CD22 Immunotoxin CAT-8015 | CAT 8015 | CAT-8015 | CAT8015 | GCR-8015 | HA22 | Immunotoxin CAT-8015 | Lumoxiti | MOXETUMOMAB PASUDOTOX | Moxetumomab Pasudotox-TDFK | Moxetumomab pasudotox | anti-CD22 immunotoxin CAT-8015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279519","Conjugated Estrogens/Cyclophosphamide/Doxorubicin/Fluorouracil/Methotrexate/Tamoxifen","C10113","A combination of agents containing conjugated estrogens, cyclophosphamide, doxorubicin, fluorouracil, methotrexate and tamoxifen.","Conjugated Estrogens/Cyclophosphamide/Doxorubicin/Fluorouracil/Methotrexate/Tamoxifen | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281656","Carboxyamidotriazole/Paclitaxel","C10924","A combination of agents containing carboxyamidotriazole and paclitaxel.","Carboxyamidotriazole/Paclitaxel | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0064494","Carboxyamidotriazole","C1141","An orally-active agent with potential antineoplastic activity.  Carboxyamidotriazole binds to and inhibits non-voltage-operated Ca2+ channels, blocking both Ca2+ influx into cells and Ca2+ release from intracellular stores and resulting in the disruption of calcium channel-mediated signal transduction and inhibition of vascular endothelial growth factor (VEGF) signaling, endothelial proliferation, and angiogenesis.  This agent may also inhibit tumor cell growth, invasion and metastasis. (NCI04)","Carboxyamidotriazole | 1H-1,2,3-Triazole-4-carboxamide, 5-amino-1-((3,5-dichloro-4(4-chlorobenzoyl)phenyl)methyl) | 5-Amino-1-((3,5-dichloro-4-(4-chlorobenzoyl)phenyl)methyl)-1H-1,2,3-triazole-4-carboxamide | CAI | CARBOXYAMIDOTRIAZOLE | Carboxyamido-triazole | Carboxyaminoimidazole | L651582 | carboxyamidotriazole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054427","CTX/DOX/5-FU","C9533","A regimen consisting of oral cyclophosphamide, doxorubicin and fluorouracil, used as a treatment for recurrent and metastatic breast cancer.","CAF Regimen | CAF | CAF regimen | CAFFI | CDF | Oral CTX/DOX/5-FU | Oral Cyclophosphamide-Adriamycin-Fluorouracil Regimen | Oral Cyclophosphamide/Doxorubicin/Fluorouracil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281475","Busulfan/Melphalan/Thiotepa","C10791","No Value Exists","Busulfan/Melphalan/Thiotepa | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0772139","Bendamustine Hydrochloride","C61565","The hydrochloride salt of bendamustine, a bifunctional mechlorethamine derivative with alkylator and antimetabolite activities. Bendamustine possesses three active moieties: an alkylating group; a benzimidazole ring, which may act as a purine analogue; and a butyric acid side chain. Although its exact mechanism of action is unknown this agent appears to act primarily as an alkylator. Bendamustine metabolites alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and, subsequently, apoptosis. Bendamustine may differ from other alkylators in that it may be more potent in activating p53-dependent stress pathways and inducing apoptosis; it may induce mitotic catastrophe; and it may activate a base excision DNA repair pathway rather than an alkyltransferase DNA repair mechanism. Accordingly, this agent may be more efficacious and less susceptible to drug resistance than other alkylators.","Bendamustine Hydrochloride | 2-Benzimidazolinebutryric acid, 1-methyl-5-bis(2-chloroethyl)amino-, hydrochloride | BENDAMUSTINE HYDROCHLORIDE | Belrapzo | Bendamustin Hydrochloride | Bendeka | CEP 18083 | CEP-18083 | CEP18083 | Cytostasan Hydrochloride | Levact | Ribomustin | SyB L-0501 | Treakisym | Treanda | VIVIMUSTA | bendamustine hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698319","Bacillus Calmette-Guerin Antigen","C77178","An antigen preparation derived from Bacillus Calmette-Guerin, used as a component of BCG vaccine.","Bacillus Calmette-Guerin Antigen | BACILLUS CALMETTE-GUERIN LIVE ANTIGEN, UNSPECIFIED SUBSTRAIN | BCG",,,,,,,,,,,,,,,"37397599","Bacillus Calmette-Guerin antigen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0194037","Autologous Bone Marrow Transplantation","C15395","Bone marrow transfer in which the patient is his own donor.  Bone marrow is removed prior to bone marrow ablation treatment and then returned to reconstitute the hematopoietic system. Prior to reinfusion the bone marrow is often treated to purge it of residual tumor cells.","Autologous Bone Marrow Transplantation | ABMT | Autologous Blood and Marrow Transplantation | Autologous Bone Marrow Transplant | Autologous Marrow Transplantation | autologous bone marrow transplantation",,,,,,,,,,,,,,,"4240337","Autologous bone marrow transplant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0281527","Carboplatin/Interleukin-6/Sargramostim","C10829","No Value Exists","Carboplatin/Interleukin-6/Sargramostim | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1676709","Sorafenib Tosylate","C2194","The tosylate salt of sorafenib, a synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","Sorafenib Tosylate | 4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic Acid Methyamide-4-methylbenzenesulfonate Tosylate | BAY 43-9006 Tosylate | BAY 54 9085 | BAY 54-9085 | BAY 549085 | BAY-54-9085 | BAY549085 | Nexavar | SORAFENIB TOSYLATE | sorafenib | sorafenib tosylate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0053006","Daniquidone","C66984","A water-insoluble heterocyclic amide with potential antineoplastic activity. Daniquidone inhibits topoisomerases I and II, thereby inhibiting DNA replication and repair, and RNA and protein synthesis. The acetylated form of daniquidone is highly toxic and is capable of inducing unscheduled DNA synthesis; rapid acetylators are more likely to experience toxicity with this agent.","Daniquidone | 8-Aminoisoindolo(1,2-b)quinazolin-12(10H)-one | Batracylin | Bay H 2049 | DANIQUIDONE | batracylin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054326","carmustine/cyclophosphamide/prednisone/procarbazine/vinblastine","C9530","A regimen consisting of carmustine, cyclophosphamide, vinblastine, procarbazine and prednisone for the treatment of Hodgkin Lymphoma (HL).","BCVPP Regimen | BCNU/CTX/PCB/PRED/VBL | BCNU/Cyclophosphamide/Vinblastine/Procarbazine/Prednisone | BCVPP | BVCPP | Carmustine-Cyclophosphamide-Vinblastine-Procarbazine-Prednisone | Carmustine/Cyclophosphamide/Prednisone/Procarbazine/Vinblastine | Carmustine/Cyclophosphamide/Prednisone/Procarbazine/Vinblastine | Carmustine/Cyclophosphamide/Vinblastine/Procarbazine/Prednisone | Carmustine/Cyclophosphamide/Vinblastine/Procarbazine/Prednisone Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042680","Vincristine Sulfate","C1739","The sulfate salt of a natural alkaloid isolated from the plant Catharanthus roseus (Vinca rosea L.) with antimitotic and antineoplastic activities. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca(2+)-activated ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.","Vincristine Sulfate | Kyocristine | Leurocristine Sulfate | Leurocristine sulfate | Leurocristine, sulfate | Oncovin | VINCRISTINE SULFATE | Vincasar | Vincasar PFS | Vincosid | Vincrex | Vincristine, sulfate | vincristine sulfate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0763138","Incyclinide","C2454","A chemically-modified tetracycline with potential antineoplastic activity. Incyclinide inhibits matrix metalloproteinases (MMPs), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. This agent also causes mitochondrial depolarization in tumor cells and induces both cellular apoptosis and tissue necrosis.","Incyclinide | 4-Dimethlyamino Sancycline | 4-Dimethlyaminosancycline | 4-dedimethylamino sancycline | 6-deoxy, 6-demethyl, 4-de-dimethylamino tetracycline | 6-deoxy-6-demethyl-4-dedimethylaminotetracycline | CMT-3 | COL 3 | COL-3 | INCYCLINIDE | Metastat | Tetracycline CMT-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513446","Monoclonal Antibody COL-1","C28893","A recombinant immunoglobulin antibody directed against the tumor-associated antigen carcinoembryonic antigen (CEA). CEA is a cell surface glycoprotein expressed at high levels in embryonic and fetal digestive epithelial tissue, breast carcinoma, and squamous cell carcinoma of the head and neck. Except for some reactivity to skin and gastric and colon mucosa, monoclonal antibody COL-1COL-1 does not appear to react with normal tissues. (NCI04)","Monoclonal Antibody COL-1 | COL 1 | COL-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879969","Cyclophosphamide-Oncovin-Doxorubicin-Methotrexate/Ifosfamide, VePesid, AraC Regimen","C63448","A regimen that alternates cyclophosphamide, vincristine, doxorubicin and high-dose methotrexate (CODOX-M) with ifosfamide, etoposide and high-dose cytarabine (IVAC), and can be used in the treatment of Burkitt lymphoma and Burkitt-like lymphoma.","CODOX-M Alternating with IVAC Regimen | CODOX-M Alternating with IVAC | CODOX-M/IVAC | CODOX-M/IVAC Regimen | CODOX-M/IVAC Regimen | Cyclophosphamide-Oncovin-Doxorubicin-Methotrexate/Ifosfamide, VePesid, AraC Regimen | Cyclophosphamide/Oncovin/DOXorubicin/Methotrexate Alternating with Ifosfamide/Vepesid/Ara-C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0055987","cyclophosphamide/fluorouracil/methotrexate/prednisone/vincristine","C9557","A regimen consisting of cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone that may be used in the treatment of breast cancer.","CMFVP Regimen | CFPMV | CMFVP | CTX/5-FU/MTX/PRED/VCR | Cyclophosphamide-Methotrexate-Fluorouracil-Vincristine-Prednisone | Cyclophosphamide/Fluorouracil/Methotrexate/Prednisone/Vincristine | Cyclophosphamide/Fluorouracil/Methotrexate/Prednisone/Vincristine | Cyclophosphamide/Methotrexate/Fluorouracil/Vincristine/Prednisone | Cyclophosphamide/Methotrexate/Fluorouracil/Vincristine/Prednisone Regimen | SWOG CMFVP | VPCMF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0055985","cyclophosphamide/fluorouracil/methotrexate/prednisone protocol","C9555","No Value Exists","Cyclophosphamide/Fluorouracil/Methotrexate/Prednisone | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL381677","Carmustine Implant","C2487","A synthetic, biodegradable wafer containing the agent carmustine with antineoplastic activity. Used to deliver drug directly into a brain tumor site and typically implanted post-surgically, the wafer is made of a biodegradable poly-anhydride copolymer and contains the nitrosourea carmustine.  As an antineoplastic nitrosourea, carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  Carmustine also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)","Carmustine Implant | BCNU Wafer | Carmustine Copolymer | Carmustine Wafer | Carmustine Wafers | Carmustine wafer polifeprosan 20 | Gliadel | Gliadel Wafer | Gliadel Wafers | NPC 08 | NPC08 | Polifeprosan 20 with Carmustine Implant | Polifeprosan 20 with Carmustine Implant | polifeprosan 20 carmustine implant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279842","Cyclophosphamide/Dexamethasone/Doxorubicin/Verapamil/Vincristine","C10131","No Value Exists","Cyclophosphamide/Dexamethasone/Doxorubicin/Verapamil/Vincristine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831965","Pegdinetanib","C62791","A pegylated form of a thermostable and protease resistant peptide targeting human vascular endothelial growth factor receptor-2 (VEGFR-2) with potential antiangiogenic activity. Derived from the 10th type III domain of human fibronectin and one of the natural ligands, pegdinetanib binds to VEGFR-2 and prevents activation of VEGFR-2 by other activating ligands. This may inhibit the growth of new tumor blood vessels.","Pegdinetanib | Angiocept | BMS-844203 | CT-322 | PEGDINETANIB | VEGFR-2 inhibitor CT-322",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0111606","Cyclopentenyl Cytosine","C1359","A pro-drug carbocyclic analogue of cytidine with antineoplastic and antiviral activities. Cyclopentenyl cytosine (CPEC) is converted to the active metabolite cyclopentenyl cytosine 5'-triphosphate (CPEC-TP); CPEC-TP competitively inhibits cytidine triphosphate (CTP) synthase, thereby depleting intracellular cytidine pools and inhibiting DNA and RNA synthesis. This agent may also induce differentiation of some tumor cell types. The antiviral activity of this agent is broad-spectrum.","Cyclopentenyl Cytosine | 2(1H)-Pyrimidinone, 4-amino-1-[4, 5-dihydroxy- 3-(hydroxymethyl)-2-cyclopenten-1-yl]- | CPE-C | CYCLOPENTENYL CYTOSINE | Cyclopentenylcytosine | Cyclopentenylcytosine Triphosphate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0169964","Somatropin","C837","A recombinant form of endogenous human growth hormone (GH), a polypeptide produced by the anterior lobe of the human pituitary gland. GH exhibits growth-promoting effects and metabolic effects on carbohydrate, fat, protein and bone metabolism. GH stimulates protein synthesis and the uptake of amino acids into cells, and induces lipolysis in adipose tissues. The secretion of GH increases with sexual maturation and then declines steadily.","Somatropin | Asellacrin | Crescormon | Genotropin | Growth Hormone, Human | Omnitrope | Recombinant GH | Recombinant Human Growth Hormone | Recombinant Somatotropin | SOMATROPIN | Somatotropic Hormone | rhGH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0107994","Cabergoline","C47428","A synthetic ergoline derivative and a long-acting dopamine receptor agonist with high affinity for the dopamine D2 receptor. Cabergoline exerts an inhibitory effect on prolactin secretion by acting on dopamine receptors present in pituitary lactotrophs. This drug also binds to dopamine D2 receptors in the corpus striatum, thereby mimicking the actions of dopamine on motor control. Cabergoline also possesses antioxidant and neuroprotective properties due to its free radical scavenging activity. Cabergoline is used in the treatment of Parkinson's disease and in the treatment of hyperprolactinemia.","Cabergoline | 1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea | CABERGOLINE | Dostinex | FCE 21336",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709429","Carfilzomib","C52196","An epoxomicin derivate with potential antineoplastic activity. Carfilzomib irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S catalytic core subunit of the proteasome, a protease complex responsible for degrading a large variety of cellular proteins. Inhibition of proteasome-mediated proteolysis results in an accumulation of polyubiquinated proteins, which may lead to cell cycle arrest, induction of apoptosis, and inhibition of tumor growth.","Carfilzomib | (2S)-N-((1S)-1-Benzyl-2-(((1S)-3-methyl-1-(((2R)-2-methyloxiran-2-yl)carbonyl)butyl)amino)-2-oxoethyl)-4-methyl-2-(((2S)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)amino)pentanamide | CARFILZOMIB | CFZ | Carfilnat | Kyprolis | PR 171 | PR-171 | PR171",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0971473","Cilengitide","C1834","A cyclic Arg-Gly-Asp peptide with potential antineoplastic activity.  Cilengitide binds to and inhibits the activities of the alpha(v)beta(3) and alpha(v)beta(5) integrins, thereby inhibiting endothelial cell-cell interactions, endothelial cell-matrix interactions, and angiogenesis. (NCI04)","Cilengitide | CILENGITIDE | EMD 121974 | EMD-121974 | cilengitide | cyclo(L-arginylglycyl-L-a-aspartyl-D-phenylalanyl-N-methyl-L-valyl)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831854","Catumaxomab","C62445","A trifunctional bispecific monoclonal antibody with potential antineoplastic activity. Catumaxomab has two antigen-recognition sites: one for human CD3, a T cell surface antigen; and one for human epithelial cell adhesion molecule (EpCAM), a cell surface antigen expressed by a variety of epithelial tumor cells. In addition, the modified Fc portion of this antibody binds Fc receptors on antigen presenting cells (APCs) such as macrophages and dendritic cells (DCs). Catumaxomab brings T cells, EpCAM-expressing epithelial tumor cells and APCs together into tricellular complexes, which may result in a potent cytotoxic T-lymphocyte (CTL) response against EpCAM-expressing epithelial tumor cells. Fc-mediated binding of APCs in the tricellular complex potentiates EpCAM antigen presentation to T cells and the activation of anti-tumor cytotoxic T cell functions.","Catumaxomab | CATUMAXOMAB | Removab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1698364","Cediranib","C80867","An orally bioavailable indole ether quinazoline derivative and vascular endothelial growth factor receptor (VEGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, cediranib binds to and inhibits the three VEGFR subtypes 1 (VEGFR-1), 2 (VEGFR-2) and 3 (VEGFR-3), thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth. Expression of VEGFRs may be upregulated in a variety of tumor cell types.","Cediranib | 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline | AZ-D2171 | AZD 2171 | AZD2171 | CEDIRANIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334088","IGF1R Gene","C20135","This gene is involved in the regulation of apoptosis and cell proliferation and plays a role in cellular transformation and malignancy.","IGF1R Gene | IGF1R | Insulin Like Growth Factor 1 Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279074","recombinant soluble human CD4 protein","C2342","A recombinant human soluble CD4 with antiviral activity. Recombinant human soluble CD4 has the amino terminus but not the T-cell binding domain of the endogenous CD4 antigen. This soluble CD4 protein competitively binds to envelope glycoprotein (gp120) of human immunodeficiency virus (HIV) resulting in inhibition of interaction between gp120 and the endogenous CD4 antigen, thereby blocking viral recognition of CD4 and subsequent entry of HIV into CD4 bearing cells.","Recombinant Soluble Human CD4 Protein | rCD4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2713559","Laromustine","C2653","A sulfonyl hydrazine prodrug with antineoplastic activity. Laromustine releases the DNA chloroethylating agent 90CE after entering the blood stream; 90CE chloroethylates alkylates the O6 position of guanine, resulting in DNA crosslinking, strand breaks, chromosomal aberrations, and disruption of DNA synthesis. Intracellular metabolism of this agent also releases methyl isocyanate which inhibits O6-alkyl-guanine transferase, an enzyme involved with DNA repair.","Laromustine | 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylaminocarbonyl)hydrazine | 101M | Cloretazine | LAROMUSTINE | Onrigin | VNP40101M | laromustine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825895","Granulocyte Colony Stimulating Factor Measurement","C82018","The determination of the amount of granulocyte colony stimulating factor present in a sample.","Granulocyte Colony Stimulating Factor Measurement | GCSF | Granulocyte Colony Stimulating Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281167","Cisplatin/Cyclophosphamide/Paclitaxel","C10604","No Value Exists","Cisplatin/Cyclophosphamide/Paclitaxel | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280544","CDDP/VBL","C10263","No Value Exists","Cisplatin/Vinblastine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281284","Cisplatin/Topotecan","C10653","A combination of agents containing cisplatin and topotecan.","Cisplatin/Topotecan | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0672257","Cisplatin/Paclitaxel","C10228","A combination of agents containing cisplatin and paclitaxel.","Cisplatin/Paclitaxel | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1328025","Pertuzumab","C38692","A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. (NCI04)","Pertuzumab | 2C4 | 2C4 Antibody | BCD-178 | EG1206A | HLX11 | HS627 | Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide with Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer | MoAb 2C4 | Monoclonal Antibody 2C4 | Omnitarg | PERTUZUMAB | Perjeta | Pertuzumab Biosimilar BCD-178 | Pertuzumab Biosimilar EG1206A | Pertuzumab Biosimilar HLX11 | Pertuzumab Biosimilar HS627 | Pertuzumab Biosimilar TQB2440 | RO4368451 | Rhumab 2C4 | TQB 2440 | TQB-2440 | TQB2440 | pertuzumab | rhuMAb2C4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0092777","Clofarabine","C26638","A second generation purine nucleoside analog with antineoplastic activity. Clofarabine is phosphorylated intracellularly to the cytotoxic active 5'-triphosphate metabolite, which inhibits the enzymatic activities of ribonucleotide reductase and DNA polymerase, resulting in inhibition of DNA repair and synthesis of DNA and RNA. This nucleoside analog also disrupts mitochondrial function and membrane integrity, resulting in the release of pre-apoptotic factors, including cytochrome C and apoptotic-inducing factors, which activate apoptosis.","Clofarabine | 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine | 2-Chloro-9-(2-deoxy-2-fluoroarabinofuranosyl)adenine | CLOFARABINE | Clofarex | Clolar | clofarabine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280497","cytarabine/etoposide","C10239","A regimen consisting of cytarabine and etoposide that may be used in the treatment of central nervous system (CNS) lymphomas, Burkitt lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia.","CYVE Regimen | ARA-C/VP-16 | Ara-C/Etoposide | CYVE | Cyclophosphamide and Etoposide (CYVE) | Cytarabine and Etoposide | Cytarabine and Etoposide (CYVE) | Cytarabine-Etoposide | Cytarabine/Etoposide | Cytarabine/Etoposide | Cytarabine/Etoposide Regimen | Cytarabine/VP-16 | Cytarabine/VePesid | Etoposide/Cytarabine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0935954","Oblimersen Sodium","C66722","The sodium salt of a phosphorothioate antisense oligonucleotide targeted to the initiation codon region of mRNA for the anti-apoptotic gene Bcl-2. Oblimersen inhibits Bcl-2 mRNA translation, which may result in decreased expression of the Bcl-2 protein and tumor cell apoptosis. This agent may enhance the efficacy of standard cytotoxic chemotherapy. The anti-apoptotic bcl-2 protein is an integral outer mitochondrial membrane protein (OMMP) that is overexpressed in some cancer cell types and is linked to tumor drug resistance.","Oblimersen Sodium | Anticode G3139 | Augmerosen | BCL-2 Antisense Oligodeoxynucleotide G3139 | BCL-2 Antisense/G3139 | G 3139 | G-3139 | G3139 | G3139 Antisense Oligonucleotide | G3139 BCL-2 Antisense Oligo | G3139 BCL-2 Antisense Oligodeoxynucleotide | G3139 BCL-2 Antisense Oligonucleotide | Genasense | OBLIMERSEN SODIUM | augmerosen | bcl-2 antisense oligodeoxynucleotide G3139 | oblimersen sodium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522575","Recombinant Vascular Endothelial Growth Factor","C1272","A recombinant therapeutic agent which is chemically identical to or similar to endogenous vascular endothelial growth factor (VEGF).  Produced by a wide variety of cell types, endogenous VEGF is a homodimeric, glycosylated protein that is a highly specific mitogen for vascular endothelial cells; significantly influences vascular permeability; appears to play a role in neovascularisation under physiological conditions; is a potent chemoattractant; has pro-coagulatory activities; and is hypoxia-inducible.  Therapeutic VEGF may be used to induce angiogenesis in the treatment of ischemic conditions and may have a role in stimulating nerve regeneration. (NCI04)","Recombinant Vascular Endothelial Growth Factor | VEGF | VPF | Vascular Endothelial Growth Factor | Vascular Permeability Factor | rhuVEGF | vascular endothelial growth factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512580","IDEC-Y2B8 Monoclonal Antibody/Rituximab","C12167","No Value Exists","IDEC-Y2B8 Monoclonal Antibody/Rituximab | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280658","Cyclophosphamide/Vincristine","C10313","No Value Exists","Cyclophosphamide/Vincristine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280003","cyclophosphamide/prednisone","C10163","No Value Exists","Cyclophosphamide/Prednisone | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280920","Cyclophosphamide/Fludarabine","C10489","No Value Exists","Cyclophosphamide/Fludarabine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086444","Dexrazoxane","C1333","A bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition.","Dexrazoxane | (+)-(S)-4,4'-(1-Methyl-1,2-ethanediyl)di(2,6-piperazinedione) | 2, 6-Piperazinedione, 4,4'-propylenedi-, (P)- (8CI) | 2,6-Piperazinedione, 4, 4'-(1-methyl-1,2-ethanediyl)bis-, (S)- (9CI) | 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-,(S)-(9CI) | 2,6-Piperazinedione, 4,4'propylenedi-,(P)-(8CI) | ADR 529 | ADR-529 | ADR529 | DEXRAZOXANE | ICRF 187 | ICRF-187 | ICRF187 | Razoxane (+)-form | Soluble ICRF (L-isomer) | dexrazoxane",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0113600","Diaziquone","C1363","A water-soluble, synthetic aziridinylbenzoquinone with potential antineoplastic activity. Bioactivation of aziridinylbenzoquinone RH1 occurs through the two-electron reduction of the quinone to the hydroquinone by the two-electron quinone reductase DT-diaphorase (DTD). The resultant hydroquinone selectively alkylates and cross-links DNA at the 5'-GNC-3' sequence, inihibiting DNA replication, inducing apoptosis, and inhibiting tumor cell proliferation. DTD is over-expressed in many tumors relative to normal tissue, including lung, colon, breast and liver tumors.","Diaziquone | 1,4-Cyclohexadiene-1,4-dicarbamic acid, 2, 5-bis(1-aziridinyl)-3,6-dioxo-, diethyl ester | 1,4-cyclohexadiene-1,4-dicarbamic acid, 2, 5-bis(1-aziridinyl)-3,6-dioxo-, diethyl ester | 1,4-cyclohexadiene-1,4-dicarbamic acid,2,5-bis(1-aziridinyl)-3,6-dioxo,-diethyl ester | 2,5-bis(1-aciridinyl)-3,6-bis(ethoxycarbonylamino)-1,4-benzoquinone | 2,5-bis(1-aziridinyl)-3,6-bis(ethoxycarbonylamino)-1,4-benzoquinone | 2,5-bis(1-aziridinyl)-3,6-dioxo-1,4-cyclohexadiene-1,4-dicarbamic acid diethyl ester | 2,5-diaziridinyl-3,6-bis(ethoxycarbonyl-amino)-1,4-benzoquinone | AZQ | Aziridinyl Benzoquinone | Aziridinylbenzoquinone | Aziridinylbenzoquinone carbamic acid | CI-904 | Carbamic acid, [2,5-bis(1-aziridinyl)-3,6-dioxo-1, 4-cyclohexadiene-1,4-diyl]bis-, diethyl ester (9CI) | DIAZIQUONE | [2,5-bis(1-aziridinyl)-3,6-dioxo-1,4-cyclohexadiene-1,4-diyl]biscarbamic acid diethyl ester | carbamic acid, [2,5-bis(1-aziridinyl)-3,6-dioxo-1, 4-cyclohexadiene-1,4-diyl]bis-, diethyl ester (9CI) | diaziquone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0057634","Cisplatin/Cytarabine/Dexamethasone","C9583","A combination of agents containing cisplatin, cytarabine and dexamethasone.","Cisplatin/Cytarabine/Dexamethasone | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0164662","Stavudine","C1428","A nucleoside reverse transcriptase inhibitor analog of thymidine. Stavudine has been recommended to undergo phase-out management due to its long-term, irreversible side-effects.","Stavudine | 1-(2,3-Dideoxy-beta-glycero-pent-2-enofuranosyl)thymine | 2',3'-Didehydro-3'-deoxythymidine | 3'-Deoxy-2'-thymidinene | BMY-27857 | Didehydrodeoxythymidine | Dideoxydidehydrothymidine | STAVUDINE | Zerit | d4T | stavudine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677667","Raltitrexed","C1804","A quinazoline folate analogue with antineoplastic activity.  After transport into cells via the reduced folate carrier, raltitrexed undergoes intracellular polyglutamation and blocks the folate-binding site of thymidylate synthase, thereby inhibiting tetrahydrofolate activity and DNA replication and repair and resulting in cytotoxicity. (NCI04)","Raltitrexed | D1694 | ICI D1694 | N-(5-[N-(3,4-Dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic Acid | N-[[5-[[(1,4-Dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyl]carbonyl]-L-glutamic Acid | RALTITREXED | Tomudex | ZD 1694 | ZD-1694 | ZD1694 | raltitrexed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0392970","docetaxel/doxorubicin","C11218","A regimen consisting of doxorubicin and docetaxel that may be used in the treatment of breast cancer and anaplastic carcinoma.","Docetaxel/Doxorubicin Regimen | AT | AT Regimen | AT Regimen | Adriamycin-Taxotere Regimen | Adriamycin/Taxotere | DOX/TXT | Docetaxel and Doxorubicin (AT) | Docetaxel-Doxorubicin | Docetaxel/Doxorubicin | Docetaxel/Doxorubicin | Doxorubicin-Docetaxel | Doxorubicin/Docetaxel | Doxorubicin/Docetaxel Regimen | Doxorubicin/Docetaxel Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0654036","Terameprocol","C61441","A synthetic tetra-methylated derivative of nordihydroguaiaretic acid (NDGA) and transcriptional inhibitor with potential antiviral, antiangiogenic, and antineoplastic activities. Terameprocol competes with the transcription factor Sp1 for specific Sp1 DNA binding domains within gene promoter regions during DNA synthesis. In virally-infected cells, blocking of the Sp1 binding site suppresses Sp1-regulated viral promoter activity and gene expression, thereby inhibiting viral transcription and replication. In tumor cells, blockage of Sp1 binding sites by this agent interferes with the transcription of the Sp1-dependant genes cyclin-dependant kinase (Cdc2), survivin, and vascular endothelial growth factor (VEGF), which are overexpressed in a variety of cancers. By suppressing Sp1-regulated transcription of these genes, terameprocol may reduce tumor angiogenesis and tumor cell proliferation and induce tumor cell apoptosis.","Terameprocol | 1,1'-(2,3-Dimethyl-1,4-butanediyl)bis(3,4-dimethoxybenzene) | EM-1421 | M4N | TERAMEPROCOL | TMNDGA | Tetra-O-methyl Nordihydroguaiaretic Acid | Tetra-O-methyl-NDGA | Tetramethoxynordihydroguaiaretic Acid | tetra-O-methyl NDGA | tetra-O-methyl nordihydroguaiaretic acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0914674","carmustine/cisplatin/dacarbazine/tamoxifen protocol","C63781","A regimen consisting of tamoxifen, cisplatin, dacarbazine and carmustine used for the treatment of advanced-stage or metastatic melanoma.","Dartmouth Regimen | DTIC-Cisplatin-BCNU-Tamoxifen Regimen | Dacarbazine-Cisplatin-Carmustine-Tamoxifen Regimen | Dartmouth regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512081","Cisplatin/Cyclophosphamide/Dexamethasone/Doxorubicin/Etoposide/Thalidomide","C28969","A combination of agents containing cisplatin, cyclophosphamide, dexamethasone, doxorubicin, etoposide and thalidomide.","Cisplatin/Cyclophosphamide/Dexamethasone/Doxorubicin/Etoposide/Thalidomide | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511713","Dacarbazine/Mesna","C28967","A combination of agents containing dacarbazine and mesna.","Dacarbazine/Mesna | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510925","Anti-Dopamine-b-Hydroxylase Monoclonal Antibody-Saporin","C28966","An immunoconjugate of the anti-dopamine-b-hydroxylase monoclonal antibody covalently linked to the ribosome-inactivating protein (RIP) saporin derived from Saponaria officinalis. The monoclonal antibody component recognizes and attaches to the membrane-associated antigen, dopamine-b-hydroxylase, resulting in the conjugate being internalized by receptor-mediated endocytosis. The saporin toxin is then released from the complex, and binds to ribosomal subunits, thereby halts protein synthesis, and results in cell death. This immunoconjugate targets the dopamine-beta-hydroxylase enzyme localized on adrenergic nerves in the brainstem particular medulla and pons, thereby could be used to study neurodegenerative disorders and/or address fundamental neurobiological questions.","Anti-Dopamine-b-Hydroxylase Monoclonal Antibody-Saporin | DSAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0053376","beta-2'-deoxythioguanosine","C1350","A thiopurine nucleoside derivative with antineoplastic activity. After conversion to the triphosphate, beta-thioguanine deoxyriboside is incorporated into DNA, resulting in inhibition of DNA replication.  This agent is cytotoxic against leukemia cell lines and has demonstrated some activity against leukemia cells in vivo.  Beta-thioguanine deoxyriboside demonstrates antineoplastic activity against 6-thioguanine-resistant tumor cells. (NCI04)","Beta-Thioguanine Deoxyriboside | .beta.-2'-Deoxy-6-thioguanosine | .beta.-2'-Deoxythioguanosine | .beta.-2'-Deoxythiol guanosine | .beta.-Thioguanine deoxyriboside | 1,9-dihydro-6H-purine-6-thione, 2-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl) | 2'-DEOXYTHIOGUANOSINE | 2'-Deoxythioguanosine | 2'-Desoxy-6-thioguanosine | 2'-deoxythioguanosine | 2'-desoxy-6-thioguanosine | 6-Mercaptoguaninedeoxyriboside | 6H-Purine-6-thione, 2-amino-9-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-1,9-dihydro- | 9H-Purine-6-thiol, 2-amino-9-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-, monohydrate | 9H-purine-6-thiol, 2-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl) monohydrate | ATEGANOSINE | Ateganosine | B-TGDR | BTG | Beta Thioguanine Deoxyriboside | Thioguanine 9.beta.D-2'-deoxyriboside | beta-2'-deoxy-6-thioguanosine | beta-2'-deoxythioguanosine | beta-2'-deoxythiol guanosine | thioguanine 9-beta-D-2'-deoxyriboside",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796678","Depsipeptides","C1976","A bicyclic peptide antibiotic with one or more amide bonds replaced by ester bonds. Depsipeptide antibiotics act as histone deacetylase inhibitors and regulate chromatin structure and transcription by increasing histone acetylation, thereby resulting in alterations in gene expression and inducing cell differentiation, cell cycle arrest, and apoptosis.","Depsipeptide Antineoplastic Antibiotic | Depsipeptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677768","Di-dgA-RFB4 Immunotoxin","C2334","An immunotoxin of monoclonal antibody (MoAb) RFB4 covalently linked to two deglycosylated ricin toxin A-chain (Di-dgA). This agent can be extracted from castor beans. MoAb RFB4 recognizes CD22 antigen, a B-cell adhesion protein expressed on malignant cells in about 70 percent of non-Hodgkin lymphoma and chronic lymphocytic leukemia. Ricin toxin A-chain, a potent protein synthesis inhibitor, was deglycosylated and was used in this immunoconjugate to avoid hepatic entrapment. This Di-dgA conjugated MoAb RFB4 delivers 7 fold more cytotoxicity than the single dgA immunotoxin against CD22-positive malignant cells.","Di-dgA-RFB4 Immunotoxin | Di-dgA-RFB4 Monoclonal Antibody | Monoclonal Antibody Di-dgA-RFB4 | di-dgA-RFB4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0165590","Dorzolamide","C62026","An inhibitor of carbonic anhydrase, a zinc-containing enzyme that catalyzes the rapid conversion of carbon dioxide and water into carbonic acid, protons and bicarbonate ions.  Distributed throughout many cells and tissues, various carbonic anhydrases play important roles in mineral and metabolic homeostasis. (NCI04)","Dorzolamide | DORZOLAMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677788","doxorubicin/gemcitabine","C11312","A regimen consisting of doxorubicin and gemcitabine that may be used in the treatment of certain types of renal cell carcinoma.","Doxorubicin/Gemcitabine Regimen | Adriamycin/Gemzar | Doxorubicin and Gemcitabine | Doxorubicin-Gemcitabine | Doxorubicin/Gemcitabine | Doxorubicin/Gemcitabine | dFdC/DOX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879589","Doxorubicin Hcl Liposome/Gemcitabine","C11851","No Value Exists","Doxorubicin Hcl Liposome/Gemcitabine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879444","Tariquidar","C2246","An anthranilamide derivative with multidrug resistance properties.  Tariquidar non-competitively binds to the p-glycoprotein transporter, thereby inhibiting transmembrane transport of anticancer drugs.  Inhibition of transmembrane transport may result in increased intracellular concentrations of an anticancer drug, thereby augmenting its cytotoxicity. (NCI04)","Tariquidar | TARIQUIDAR | XR9576 | tariquidar",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879507","Docetaxel/Trastuzumab","C11800","No Value Exists","Docetaxel/Trastuzumab | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0285858","Cisplatin/Cytarabine/Etoposide/Methylprednisolone","C9720","No Value Exists","Cisplatin/Cytarabine/Etoposide/Methylprednisolone | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1327830","Enzastaurin","C77392","A substance being studied in the treatment of certain types of cancer, including non-Hodgkin lymphoma, breast, colon, lung, ovarian, and prostate. Enzastaurin blocks certain cell signaling pathways, and may prevent the growth of new blood vessels that tumors need to grow. It is a type of serine threonine kinase inhibitor and a type of antiangiogenesis agent.","Enzastaurin | ENZASTAURIN | enzastaurin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014921","Estramustine","C479","A synthetic molecule combining estradiol and nornitrogen mustard through a carbamate link. Estramustine and its major metabolite estramustine bind to microtubule-associated proteins (MAPs) and tubulin, thereby inhibiting microtubule dynamics and leading to anaphase arrest in a dose-dependent fashion. This agent also exhibits anti-androgenic effects. (NCI04)","Estramustine | 17beta-(estra-1,3,5(10)-triene-3,17-diol 3-(bis(2-chloroethyl)carbamate)) | ESTRAMUSTINE | Estradiol 3-[bis(2-chloroethyl)carbamate] | Leo 275 | RO 21-8837 | estra-1,3,5(10)triene-317beta-diol 3-[N,N-bis-(2-chloroethyl)carbamate] | estradiol 3-bis(2-chloroethyl)carbamate | estramustine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1439263","Epothilone D","C2672","A natural polyketide compound isolated from the myxobacterium Sorangium cellulosum. Also known as desoxyepothilone B, epothilone D binds to tubulin and inhibits the disassembly of microtubules, resulting in the inhibition of mitosis, cellular proliferation, and cell motility. (NCI04)","Epothilone D | (4S-(4R*,7S,8R*,9R*,13Z,16R*(E)))-4,8-Dihydroxy-5,5,7,9,13-pentamethyl-16-(1-methyl-2-(2-methyl-4-thiazolyl)ethenyl)oxacyclohexadec-13-ene-2,6-dione | 12,13-Deoxyepothilone B | Desoxyepothilone B | EPOTHILONE D | KOS 862 | KOS-862 | epothilone D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242275","Epidermal Growth Factor","C20425","Epidermal growth factor (53 aa, ~6 kDa) is encoded by the human EGF gene. This protein is involved in mitogenesis and magnesium reabsorption.","Epidermal Growth Factor | Anthelone U | EGF | Human Urinary Gastric Inhibitor | Urogastrone | epidermal growth factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0537439","Enfuvirtide","C2105","A short polypeptide with activity against human immunodeficiency virus (HIV). Enfuvirtide binds to the first heptad-repeat (HR1) in the gp41 viral envelope glycoprotein, thereby preventing conformational changes required for fusion of viral and cellular membranes and preventing the virus from entering a host cell.","Enfuvirtide | DP178 | ENFUVIRTIDE | Fuzeon | T-20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796658","Fowlpox Virus Vaccine/Interleukin-2/Vaccinia-Tyrosinase Vaccine","C11610","No Value Exists","Fowlpox Virus Vaccine/Interleukin-2/Vaccinia-Tyrosinase Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880658","FOLFIRI Regimen","C63593","A regimen consisting of leucovorin calcium (calcium folinate), 5-fluorouracil, and irinotecan that can be used in the treatment of ampullary, appendiceal, small bowel, pancreatic and occult primary adenocarcinoma; colorectal, esophageal and esophagogastric junction, gastric, and hepatobiliary cancers; well-differentiated grade 3 neuroendocrine tumors (NETs), and extrapulmonary poorly differentiated neuroendocrine carcinoma, large or small cell carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm.","FOLFIRI Regimen | FOLFIRI | FOLFIRI (L-Leucovorin) | FOLFIRI regimen | Fluorouracil Continuous Infusion/Leucovorin/Irinotecan | Fluorouracil-Folinic Acid-Irinotecan | Fluorouracil/Folinic Acid/Irinotecan | Fluorouracil/Leucovorin/Irinotecan | Folinic Acid-Fluorouracil-Irinotecan Regimen | Folinic Acid/Fluorouracil/Irinotecan Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280447","cyclophosphamide/doxorubicin/fluorouracil/leucovorin calcium","C10223","A regimen consisting of fluorouracil, leucovorin, doxorubicin, and cyclophosphamide for the treatment of breast cancer.","FLAC Regimen | CALF | CF/CTX/DOX/5-FU | Cyclophosphamide/Doxorubicin/Fluorouracil/Leucovorin | Cyclophosphamide/Doxorubicin/Fluorouracil/Leucovorin Calcium | FLAC | Fluorouracil-Leucovorin-Doxorubicin-Cyclophosphamide | Fluorouracil/Leucovorin/Adriamycin/Cyclophosphamide | Fluorouracil/Leucovorin/Doxorubicin/Cyclophosphamide | Fluorouracil/Leucovorin/Doxorubicin/Cyclophosphamide Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1721684","Lexatumumab","C64621","A fully human monoclonal agonistic antibody directed against tumor necrosis factor-alpha (TNF-alpha)-related apoptosis-inducing ligand receptor-2 (TRAIL-R2) with potential antitumor activity. Mimicking the natural ligand TRAIL, lexatumumab binds to and activates TRAIL-R2, which may trigger apoptosis in and inhibit the growth of TRAIL-R2-expressing tumor cells. TRAIL-R2, also known as death receptor 5 (DR5), is a member of the TNF receptor family and is expressed on many malignant cell types.","Lexatumumab | Anti-TRAIL Receptor 2 Monoclonal Antibody HGS-ETR2 | HGS-ETR2 | HGS1018 | LEXATUMUMAB | Monoclonal Antibody HGS-ETR2 | anti-TRAIL R2 mAb HGS-ETR2 | lexatumumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796480","Monoclonal Antibody HeFi-1","C2505","A murine monoclonal antibody with potential antineoplastic activity. Monoclonal antibody HeFi-1 binds to CD30, a cell surface antigen found on mitogen-activated B-cells and T-cells, and Reed-Sternberg cells.  Monoclonal antibody HeFi-1 has been shown to arrest tumor growth and prevent metastasis in animal models. (NCI04)","Monoclonal Antibody HeFi-1 | HeFi-1 | MoAb HeFi-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0061008","Gallium Nitrate","C1109","A hydrated nitrate salt of the group IIIa element gallium with potential use in the treatment of malignancy-associated hypercalcemia.  Gallium nitrate localizes preferentially to areas of bone resorption and remodeling and inhibits osteoclast-mediated resorption by enhancing hydroxyapatite crystallization and reduction of bone mineral solubility.  This agent also increases calcium and phosphorous deposition into bone and may increase collagen synthesis. (NCI04)","Gallium Nitrate | GALLIUM NITRATE | GaN | Gallium nitrate | Ganite | WR-135675 | gallium nitrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987643","Fresolimumab","C63546","A pan-specific, recombinant, fully human monoclonal antibody directed against human transforming growth factor (TGF) -beta 1, 2 and 3 with potential antineoplastic activity. Fresolimumab binds to and inhibits the activity of all isoforms of TGF-beta, which may result in the inhibition of tumor cell growth, angiogenesis, and migration. TGF-beta, a cytokine often over-expressed in various malignancies, may play an important role in promoting the growth, progression, and migration of tumor cells.","Fresolimumab | Anti-TGF-Beta Monoclonal Antibody GC1008 | FRESOLIMUMAB | GC1008 | Human Anti-TGF-Beta Monoclonal Antibody GC1008 | Immunoglobulin G4, anti-(transforming growth factor beta) (human monoclonal GC-1008 heavy chain), disulfide with human monoclonal GC-1008 light chain, Dimer | anti-TGF-beta monoclonal antibody GC1008",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512304","HIV Peptide Vaccine","C29085","A vaccine containing one or more peptides derived from the human immunodeficiency virus (HIV). As a vaccine antigen, an HIV peptide may stimulate the host immune response against HIV, thereby preventing or treating HIV infection. (NCI04)","HIV Peptide Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3658037","Interleukin-13, Human","C20515","Interleukin-13 (146 aa, ~16 kDa) is encoded by the human IL13 gene. This protein plays a role in the negative regulation of cytokine production and the positive regulation of B-cell proliferation.","Interleukin-13 | IL-13 | IL13 | Interleukin 13 | interleukin-13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512579","I131-COL1","C29106","A radioimmunoconjugate of a murine monoclonal antibody (MoAb) COL1, labeled with iodine 131 (I-131). COL1 recognizes an epitope of carcinoembryonic antigen (CEA), which is over-expressed in many tumor cell types. I-131 MoAb COL1 delivers beta and gamma radiation emitting I-131 nuclide directly to tumor cells that express CEA, thereby allowing imaging and/or treatment of cancers.","I131-COL1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020231","Hydrazine","C29097","A highly reactive base and reducing agent used in many industrial and medical applications.  In biological applications, hydrazine and its derivatives exhibit antidepressant properties by inhibiting monoamine oxidase (MAO), an enzyme that catalyzes the deamination and inactivation of certain stimulatory neurotransmitters such as norepinephrine and dopamine.  In psychiatry, the use of hydrazine derivatives is limited due to the emergence of the tricyclic antidepressants. (NCI04)","Hydrazine | HYDRAZINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0655013","LMB-2 Immunotoxin","C2513","A fusion protein consisting of the Fv portion of a monoclonal antibody attached to a 38-kDa fragment of the Pseudomonas exotoxin A (with amino acids 365-380 deleted).  LMB-2 immunotoxin targets the interleukin 2 receptor (also known as IL-2R or CD25) which is expressed on activated normal T and B cells and macrophages and on the cells of various hematologic malignancies.  The antibody attaches to the IL-2R on the cell membrane, facilitating the entry of the exotoxin. The exotoxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis. (NCI04)","LMB-2 Immunotoxin | Anti-Tac(Fv)-PE38 | Humanized AntiTac Toxin | Immunotoxin LMB-2 | LMB-2 | LMB-2 (Anti-TAC(FV)-PE-38) | LMB-2 immunotoxin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1699239","IL7 protein, human","C20510","Interleukin-7 (177 aa, ~20 kDa) is encoded by the human IL7 gene. This protein plays a role in lymphocyte proliferation.","Interleukin-7 | IL-7 | IL7 | IL7 Protein | Interleukin 7 Precursor | Lymphopoietin-1 | interleukin-7 | lymphopoietin-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1134607","Monoclonal Antibody Mik-Beta-1","C2669","A murine monoclonal antibody directed against of the beta subunit of interleukin-2 receptor (IL-2R), expressed on resting T-lymphocytes, natural killer (NK) cells, and some leukemic cell types.  Monoclonal antibody Mik-Beta-1 prevents the binding of IL-2 to IL-2R beta, thereby inhibiting the IL-2-mediated proliferation and activation of T-cells.","Monoclonal Antibody Mik-Beta-1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2746063","Imetelstat","C49084","A synthetic lipid-conjugated, 13-mer oligonucleotide N3'-P5'-thio-phosphoramidate with potential antineoplastic activity. Complementary to the template region of telomerase (hTR) RNA, imetelstat acts as a competitive enzyme inhibitor that binds and blocks the active site of the enzyme (a telomerase template antagonist), a mechanism of action which differs from that for the antisense oligonucleotide-mediated inhibition of telomerase activity through telomerase mRNA binding. Inhibition of telomerase activity in tumor cells by imetelstat results in telomere shortening, which leads to cell cycle arrest or apoptosis.","Imetelstat | DNA, d(3'-amino-3'-deoxy-P-thio)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-[O-[2-hydroxy-3- [(1-oxohexadecyl)amino]propyl] hydrogen phosphorothioate] | GRN 163L | GRN-163L | IMETELSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0532362","Irofulven","C1717","A semisynthetic sesquiterpene derivative of illudin S, a natural toxin isolated from the fungus Omphalotus illudens.  Irofulven alkylates DNA and protein macromolecules, forms adducts, and arrests cells in the S-phase of the cell cycle.  This agent requires NADPH-dependent metabolism by alkenal/one oxidoreductase for activity. Irofulven is more active in vitro against tumor cells of epithelial origin and is more resistant to deactivation by p53 loss and MDR1 than other alkylating agents. (NCI04)","Irofulven | (R)-6'-Hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethylspiro(cyclopropane-1,5'(5H)-inden)-7'(6'H)-one | 6-Hydroxymethylacylfulvene | 6-hydroxymethylacylfulvene | HMAF | Hydroxymethylacylfulvene | IROFULVEN | MGI 114 | MGI-114 | irofulven",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527260","Ispinesib","C38131","A synthetic small molecule, derived from quinazolinone, with antineoplastic properties. Ispinesib selectively inhibits the mitotic motor protein, kinesin spindle protein (KSP), resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest during the mitotic phase, and cell death in tumor cells that are actively dividing. Because KSP is not involved in nonmitotic processes, such as neuronal transport, ispinesib may be less likely to cause the peripheral neuropathy often associated with the tubulin-targeting agents.","Ispinesib | CK0238273 | ISPINESIB | SB-715992 | ispinesib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0174543","KNI-272","C29140","A synthetic peptide-based antiviral agent.  As a peptidomimetic substrate containing an unnatural amino acid, allophenylnorstatine, KNI-272 selectively binds to and inhibits the human immunodeficiency virus (HIV) 1 and 2 proteases, thereby preventing cleavage of the gag-pol viral polyprotein and resulting in the release of immature, noninfectious virions. (NCI04)","KNI-272 | 4-Thiazolidinecarboxamide, N-(1,1-dimethylethyl)-3- [2-hydroxy-3-[[2-[[(5-isoquinolinyloxy)acetyl]amino]-3- (methylthio)-1-oxopropyl]amino]-1-oxo-4-phenylbutyl]-,[4R-[3[2S*, 3S*(R*)],4R*]]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796420","LMB-1 Immunotoxin","C2499","A chimeric protein consisting of the Fv portion of a monoclonal antibody attached to a fragment of Pseudomonas exotoxin A without its cell-binding region.  LMB-1 immunotoxin targets B3, a Lewis Y-related carbohydrate epitope found on some solid tumors.  The antibody attaches to the tumor cell and the exotoxin stops protein synthesis by inactivating elongation factor 2. (NCI04)","LMB-1 Immunotoxin | B3-NLysPE38 | Immunotoxin LMB-1 | LMB-1 | LMB-1 immunotoxin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280508","Interleukin-2/Lymphokine-Activated Killer Cells","C10246","No Value Exists","Interleukin-2/Lymphokine-Activated Killer Cells | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020811","Idoxuridine","C563","An iodinated analogue of deoxyuridine, with antiviral activity against herpes simplex virus (HSV) and potential radiosensitizing activities. Upon ocular administration, idoxuridine (IUdR) is converted to its mono-, di-, and triphosphate forms, is incorporated into DNA and disrupts viral replication. Upon oral administration of the idoxuridine prodrug ropidoxuridine and hepatic conversion by aldehyde oxidase into idoxuridine, this agent incorporates into DNA and sensitizes cells to ionizing radiation by increasing DNA strand breaks.","Idoxuridine | 1-(2-Deoxy-beta-D-ribofuranosyl)-5-iodouracil | 1-beta-D-2'-Deoxyribofuranosyl-5-iodouracil | 1beta-D-2'-Deoxyribofuranosyl-5-iodouracil | 2'-Deoxy-5-iodouridine | 5-IUdR | 5-Iodo-2'-deoxyuridine | 5-Iododeoxyuridine | 5-iodo-2'-deoxyuridine | Dendrid | Herplex | IDOXURIDINE | IDU | IDUR | IUDR | IUdR | IdURD | Idexur | Idoxene | Idulea | Iduridin | Iododeoxyuridine | Kerecid | SKF 14287 | Stoxil | Uracil, 5-iodo-1-(2-deoxy-beta-D-ribofuranosyl)- | Uridine, 2'-deoxy-5-iodo- | Virudox | idoxuridine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1504945","INO-1001","C61315","A isoindolinone derivative and potent inhibitor of the nuclear enzyme poly (ADP-ribose) polymerase (PARP) with chemosensitization and radiosensitization properties. INO-1001 inhibits PARP, which may result in inhibition of tumor cell DNA repair mechanisms and, so, tumor cell resistance to chemotherapy and radiation therapy. PARP enzymes are activated by DNA breaks and have been implicated in the repair of DNA single-strand breaks (SSB).","INO-1001 | INO 1001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2703174","Cixutumumab","C79828","A fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.","Cixutumumab | Anti-IGF-1R Recombinant Monoclonal Antibody IMC-A12 | CIXUTUMUMAB | IMC A12 | IMC-A12 | IMCA12 | cixutumumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022687","Lymphokine-Activated Killer Cells","C13008","Killer cell lymphocytes activated in the presence of interleukin-2 (IL-2).  Lymphokine-activated killer cells (LAKs) are cytotoxic effector cells with an exceptionally wide target cell spectrum including normal and malignant cells of different origins.  LAK cells exhibit a profound heterogeneity with regard to phenotype surface marker expression; it remains to be determined if they represent a unique cell lineage.","Lymphokine-Activated Killer Cells | Cells, LAK | LAK Cells | LAK cell | Lymphokine Activated Killer Cell | Therapeutic Lymphokine-Activated Killer Cells | lymphokine-activated killer cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831958","Tasisulam","C62794","An acyl-sulfonamide with potential antineoplastic activity. Selectively toxic towards tumor cells, tasisulam appears to induce tumor cell apoptosis by a mitochondrial-targeted mechanism involving the loss of mitochondrial membrane potential and induction of reactive oxygen species (ROS). In combination with an angiogenesis inhibitor, this agent may exhibit synergistic antiangiogenic activity.","Tasisulam | LY-573636 | LY573636 | N-(2,4-Dichlorobenzoyl)-5-bromothiophene-2-sulfonamide | TASISULAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1615613","Enzastaurin Hydrochloride","C26658","The hydrochloride salt of enzastaurin, a synthetic macrocyclic bisindolemaleimide with potential antineoplastic activity.  Binding to the ATP-binding site, enzastaurin selectively inhibits protein kinase C beta, an enzyme involved in the induction of vascular endothelial growth factor (VEGF)-stimulated neo-angiogenesis. This agent may decrease tumor blood supply and so tumor burden.","Enzastaurin Hydrochloride | 1H-Pyrrole-2,5-dione, 3-(1-Methyl-1H-indol-3-yl)-4-(1-(1-(2-pyridinylmethyl)-4-piperidinyl)-1H-indol-3-yl)-, Monohydrochloride | 3-(1-Methyl-1H-indol-3-yl)-4-[1-[1-(2-pyridinylmethyl)-4-piperidinyl]-1H-indol-3-yl]-1H-pyrrole-2,5-dione Dihydrochloride | ENZASTAURIN HYDROCHLORIDE | Enzastaurin Monohydrochloride | LY317615 | enzastaurin hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0296314","LMB-7 Immunotoxin","C1619","A single chain chimeric protein consisting of a monoclonal antibody fragment attached to a portion of the Pseudomonas exotoxin A. LMB-7 immunotoxin attaches to B3, a Lewis Y-related carbohydrate epitope on some solid tumor cells.  The antibody attaches to the cell and the exotoxin inhibits protein synthesis by inactivating elongation factor 2. (NCI04)","LMB-7 Immunotoxin | B3(Fv)-PE38 | B3(Fv)-PE38 Immunotoxin | HB21(Fv)PE40 | Immunotoxin LMB-7 | LMB-7 (Single-Chain Immunotoxin) | LMB-7 immunotoxin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0678023","LMB-9 Immunotoxin","C2472","A recombinant disulfide stabilized anti-Lewis Y IgG immunotoxin containing a 38 KD toxic element derived from the Pseudomonas aeruginosa exotoxin A and a monoclonal antibody fragment, designed to target adenocarcinomas expressing Lewis Y. LMB-9 immunotoxin attaches to tumor cells, facilitating he entry of the exotoxin. The exotoxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis.","LMB-9 Immunotoxin | B3 (dsFv)-PE38 | Immunotoxin LMB-9 | LMB-9 | LMB-9 immunotoxin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0935985","Cositecan","C1877","A synthetic silicon-containing agent related to camptothecin with antineoplastic properties.  Cositecan stabilizes the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks and consequently triggering apoptosis.  Because it is lipophilic, cositecan exhibits enhanced tissue penetration and bio-availability compared to water-soluble camptothecins.","Cositecan | (4S)-4-Ethyl-4-hydroxy-11-(2-(trimethylsilyl)ethyl)-1,12-dihydro-14H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H)-dione | BNP1350 | COSITECAN | DB 172 | Karenitecin | karenitecin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513451","Monoclonal Antibody HD37-SMPT-dgA Immunotoxin","C29222","An immunotoxin consisting of the murine anti-CD19 monoclonal antibody HD37 conjugated to a deglycosylated ricin A chain (dgA) via the linking molecule N-succinimidyl-oxycarbonyl-alpha-methyl-alpha-(2-pyridyldithio) toluene (SMPT).  The HD37 component binds to CD19, a B-cell restricted antigen, thereby targeting the delivery of the cytotoxic ricin A chain to B-cells. The ricin A chain component binds to B-cells and disrupts ribosomal activity and protein synthesis and induces cell cycle arrest. (NCI04)","Monoclonal Antibody HD37-SMPT-dgA Immunotoxin | IgG-HD37-SMPT-dgA | MoAb HD37-SMPT-dgA Immunotoxin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0123931","Irinotecan","C62040","A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.  Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme.  One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death.  Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.","Irinotecan | (+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione | (+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate | 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin | IRINOTECAN | [1,4'-bipiperidine]-1'-carboxylic acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester | irinotecan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0939353","Idarubicin Hydrochloride","C1587","The hydrochloride salt of the anthracycline antineoplastic antibiotic idarubicin.  Idarubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.  Due to its high lipophilicity, idarubicin penetrates cell membranes more efficiently than other anthracycline antibiotic compounds","Idarubicin Hydrochloride | IDARUBICIN HYDROCHLORIDE | IMI-30 | Idamycin | Idamycin PFS | Idarubicin HCl | Idarubicin hydrochloride | SC-33428 | Zavedos",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006388","Levobunolol","C62043","A naphthalenone and non-cardioselective adrenergic beta-receptor antagonist with anti-glaucoma activity. Upon administration in the eye, levobunolol blocks beta-adrenergic receptors, thereby causing vasoconstriction. Levobunolol also decreases ciliary's body production of aqueous humor, leading to a decrease in aqueous humor.","Levobunolol | LEVOBUNOLOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0165479","Liarozole","C1433","An orally-active benzimidazole derivative with potential antineoplastic activity. As a retinoic acid metabolism blocking agent, liarozole inhibits cytochrome P450-dependent all-trans-retinoic acid (ATRA)-4-hydroxylase, resulting in an increase in endogenous ATRA production, inhibition of cell proliferation, and induction of cell differentiation. This agent also inhibits aromatase, the enzyme that catalyzes the final, rate-limiting step in estrogen biosynthesis.","Liarozole | 1H-Benzimidazole, 5-((3-chlorophenyl)-1H-imidazol-1-ylmethyl)- | LIAROZOLE | Liazal | R 75251 | R-61405 | liarozole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0066789","MOPP Regimen","C9619","A regimen consisting of mechlorethamine, vincristine (Oncovin), procarbazine and prednisone, used alone or in combination with radiation therapy for the treatment of stage I-IV Hodgkin lymphoma. Due to the increased risk of gonadal toxicity, this regimen has been widely replaced by the ABVD regimen.","MOPP Regimen | MOPP | MOPP regimen | Mechlorethamine/Prednisone/Procarbazine/Vincristine Regimen | Mustargen-Oncovin-Procarbazine-Prednisone Regimen | NM/PCB/PRED/VCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0338297","Etoposide/Ifosfamide/Mesna/Mitoxantrone","C11137","No Value Exists","Etoposide/Ifosfamide/Mesna/Mitoxantrone | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0066554","etoposide/ifosfamide/methotrexate/mitoguazone protocol","C9615","A combination of agents containing etoposide, ifosfamide, methotrexate and mitoguazone.","Etoposide/Ifosfamide/Methotrexate/Mitoguazone | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2002471","mocetinostat","C62521","A rationally designed, orally available, Class 1-selective, small molecule, 2-aminobenzamide HDAC inhibitor with potential antineoplastic activity. Mocetinostat binds to and inhibits Class 1 isoforms of HDAC, specifically HDAC 1, 2 and 3, which may result in epigenetic changes in tumor cells and so tumor cell death; although the exact mechanism has yet to be defined, tumor cell death may occur through the induction of apoptosis, differentiation, cell cycle arrest, inhibition of DNA repair, upregulation of tumor suppressors, down regulation of growth factors, oxidative stress, and autophagy, among others. Overexpression of Class I HDACs 1, 2 and 3 has been found in many tumors and has been correlated with a poor prognosis.","Mocetinostat | Benzamide, N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]- | MG-0103 | MGCD 0103 | MGCD-0103 | MGCD0103 | MOCETINOSTAT | N-(2-aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide | mocetinostat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2703178","Anti-EphA2 Monoclonal Antibody-MMAF Immunoconjugate MEDI-547","C79836","An auristatin analogue immunoconjugate directed against Eph receptor A2 (EphA2)-positive cancer cells with potential antineoplastic activity. Anti-EphA2 monoclonal antibody-MMAF immunoconjugate MEDI-547 is generated by conjugating the fully human IgG1 anti-EphA2 monoclonal antibody (1C1) to the small-molecule microtubule inhibitor monomethyl auristatin phenylalanine (MMAF) via the stable linker maleimidocaproyl (mc) (1C1-mcMMAF). The monoclonal antibody moiety of this agent selectively binds to cells expressing the EphA2 receptor. After internalization and enzymatic cleavage of the immunoconjugate within the tumor cell cytosol, free MMAF binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. The cell-surface receptor EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) involved in mammalian development, is overexpressed by a variety of different cancer cell types.","Anti-EphA2 Monoclonal Antibody-MMAF Immunoconjugate MEDI-547 | 1C1-mcMMAF | MEDI-547 | Medi-547",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1328709","Siplizumab","C38685","A humanized monoclonal immunoglobulin G1 antibody with potential antineoplastic activity. Siplizumab binds to CD2, a specific receptor found in T cells and NK cells, thereby triggering a host immune response that results in lysis of CD2+ cells, selective suppression of the immune system, and control of activated T cell growth.","Siplizumab | Immunoglobulin G1, Anti-(human CD2 (Antigen))(Human-rat Monoclonal MEDI-507 G1-chain), Disulfide with Human-rat Monoclonal MEDI-507 Light Chain, Dimer | MEDI-507 | SIPLIZUMAB | siplizumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281736","Bispecific Antibody MDX-H210","C1578","A humanized bivalent antibody directed against both cytotoxic effector cells expressing Fc gamma receptor type I (Fc gammaRI, or CD64) and HER2/neu-overexpressing tumor cells with potential antineoplastic activity. Bispecific antibody MDX-H210 was constructed by chemically linking Fab' fragments of the anti-HER2/neu-specific monoclonal antibody 520C9 and the Fab' fragments of the anti-Fc gammaRI-specific monoclonal antibody H22. This agent selectively binds to both HER2/neu-expressing tumor cells and Fc gammaRI-expressing cytotoxic effector cells, which may trigger antibody-dependent cell-mediated cytotoxicity (ADCC) and cell lysis of HER2/neu-expressing tumor cells. While HER2/neu is overexpressed in a variety of epithelial malignancies, expression of Fc gammaRI is primarily found in cytotoxic immune cells, including monocytes, macrophages, and cytokine-activated polymorphonuclear (PMN) cells.","Bispecific Antibody MDX-H210 | 520C9x22 Bispecific Antibody | 520C9xH22 Bispecific Antibody | Antibody, Bispecific 520C9xH22 | Bispecific Antibody 520C9 x H22 | Bispecific Antibody MDXH210 | BsAb 520C9x22 | BsAb 520C9xH22 | MDX-210 | MDX-H210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796331","At 211 Monoclonal Antibody 81C6","C2490","A radioimmunoconjugate of a human-murine chimeric IgG2 monoclonal antibody (MoAb) 81C6 labeled with an alpha-emitting radionuclide Astatine 211 (At-211), with imaging and radioimmunotherapeutic properties. MoAb 81C6 recognizes the extracellular matrix antigen tenascin (hexabrachion), which is up-regulated in gliomas and other cancers. Using MoAb 81C6 as a carrier for At-211 results in the targeted imaging and/or destruction of cells expressing tenascin.","At 211 Monoclonal Antibody 81C6 | Astatine 211 Conjugated 81C6 Anti-Tenascin Monoclonal Antibody | Astatine At 211 MOAB 81C6 | Astatine At 211 Monoclonal Antibody 81C6 | Astatine-211 Labelled Anti-Tenascin Monoclonal Antibody 81C6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796329","iodine I 131 monoclonal antibody 81C6","C2488","A radioimmunoconjugate consisting of 81C6, a murine IgG2 anti-tenascin monoclonal antibody labeled with iodine 131 (I-131), with radioimaging and radioimmunotherapeutic activities. Using monoclonal antibody 81C6 as a carrier for I-131 results in the targeted imaging and/or destruction of cells expressing tenascin. Tenascin is an extracellular matrix protein which is overexpressed in gliomas and other cancers.","Iodine I 131 Monoclonal Antibody 81C6 | 81C6-I-131 | I 131 Monoclonal Antibody 81C6 | IODINE I-131 MONOCLONAL ANTIBODY 81C6 | Neuradiab | iodine I 131 MOAB 81C6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281490","Doxorubicin/Etoposide/Mitotane/Vincristine","C10800","No Value Exists","Doxorubicin/Etoposide/Mitotane/Vincristine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0338361","dacarbazine/doxorubicin/ifosfamide/mesna protocol","C11179","No Value Exists","Dacarbazine/Doxorubicin/Ifosfamide/Mesna | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1257385","Lonafarnib","C1829","A synthetic tricyclic derivative of carboxamide with antineoplastic properties.  Lonarfanib binds to and inhibits farnesyl transferase, an enzyme involved in the post-translational modification and activation of Ras proteins.  Ras proteins participate in numerous signalling pathways (proliferation, cytoskeletal organization), and play an important role in oncogenesis.  Mutated ras proteins have been found in a wide range of human cancers. (NCI04)","Lonafarnib | 4-[2-[4-(3,10-Dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide | 4-[2-[4-[(11R)-3,10-Dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide | LONAFARNIB | SCH 66336 | SCH-66336 | SCH66336 | Sarasar | lonafarnib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1530795","BID protein, human","C21199","BH3-interacting domain death agonist (195 aa, ~22 kDa) is encoded by the human BID gene. This protein plays a role in the promotion of apoptosis.","BH3-Interacting Domain Death Agonist | BH3 Interacting Domain Death Agonist | BID | p22 BID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1531411","BIRC2 protein, human","C20931","Baculoviral IAP repeat-containing protein 2 (618 aa, ~70 kDa) is encoded by the human BIRC2 gene. This protein plays a role in the regulation of apoptosis.","Baculoviral IAP Repeat-Containing Protein 2 | Apoptosis Inhibitor 1 | BIRC2 | C-IAP1 | Cellular Inhibitor of Apoptosis-1 | HIAP-2 | HIAP2 | Human Inhibitor of Apoptosis Protein-2 | IAP Homolog B | Inhibitor Of Apoptosis Protein 2 | Mammalian IAP Homolog B | RING Finger Protein 48 | TNFR2-TRAF-Signaling Complex Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0766164","BCL10 protein, human","C26153","B-cell lymphoma/leukemia 10 (233 aa, ~26 kDa) is encoded by the human BCL10 gene. This protein is involved in both the promotion of apoptosis and the activation of nuclear factor-kappa-B signaling.","B-Cell Lymphoma/Leukemia 10 | B-Cell CLL/Lymphoma 10 | BCL10 | Bcl-10 | CARD-Containing Molecule Enhancing NF-Kappa-B | CARD-Containing Proapoptotic Protein | CARD-Like Apoptotic Protein | CED-3/ICH-1 Prodomain Homologous E10-Like Regulator | CIPER | Caspase-Recruiting Domain-Containing Protein | Cellular Homolog of vCARMEN | Cellular-E10 | Mammalian CARD-Containing Adapter Molecule E10 | c-E10 | cCARMEN | hCLAP | mE10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242853","RAS Superfamily Protein","C18549","Small cellular monomeric proteins with GTPase activity, RAS Superfamily Proteins are involved in signal transduction in normal cellular growth, differentiation, and development.","RAS Superfamily Protein | Ras-Related Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3710914","Interferon-Induced, Double-Stranded RNA-Activated Protein Kinase, Human","C34095","Interferon-induced, double-stranded RNA-activated protein kinase (551 aa, ~62 kDa) is encoded by the human EIF2AK2 gene. This protein is involved in both serine/threonine phosphorylation and the inhibition of protein synthesis.","Interferon-Induced, Double-Stranded RNA-Activated Protein Kinase | EC 2.7.11.1 | EIF2AK2 | Eukaryotic Translation Initiation Factor 2-Alpha Kinase 2 | Interferon-Induced Double-Stranded RNA-Activated Protein Kinase | Interferon-Inducible Double Stranded RNA Dependent Protein Kinase | Interferon-Inducible RNA-Dependent Protein Kinase | Interferon-Inducible elF2Alpha Kinase | P1/eIF2A Protein Kinase | PKR | PRKR | Protein Kinase RNA-Activated | eIF-2A protein kinase 2 | p68 Kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826002","MIR146A Gene","C81741","This gene is involved in the regulation of gene expression and plays a role in the development of hepatocellular, breast, thyroid, ovarian and prostatic carcinomas.","MIR146A Gene | MIR146A | MicroRNA 146A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039667","Dihydrofolate Reductase","C17191","Dihydrofolate reductase (187 aa, ~21 kDa) is encoded by the human DHFR gene. This protein is involved in folate metabolism and the synthesis of nucleotides and glycine.","Dihydrofolate Reductase | DHFR | EC 1.5.1.3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3493232","Methylenetetrahydrofolate Reductase, Human","C17311","Methylenetetrahydrofolate reductase (656 aa, ~75 kDa) is encoded by the human MTHFR gene. This protein plays a role in folate metabolism.","Methylenetetrahydrofolate Reductase | 5-methyltetrahydrofolate:NADP oxidoreductase | EC 1.5.1.20 | MTHFR | Methylenetetrahydrofolate Reductase (NADPH)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700602","Farletuzumab","C61503","A humanized, immunoglobulin G1 monoclonal antibody with potential antitumor activity. Farletuzumab specifically targets at glycoprotein 3 (GP-3), a cell surface antigen that is overexpressed on many epithelial-derived cancer cells. Upon binding to the GP-3 antigen, farletuzumab triggers a host immune response against GP-3 expressing cells resulting in cell lysis.","Farletuzumab | FARLETUZUMAB | MORAb-003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4048552","SNDX-275","C1863","A synthetic benzamide derivative with potential antineoplastic activity. Entinostat binds to and inhibits histone deacetylase, an enzyme that regulates chromatin structure and gene transcription. This agent appears to exert dose-dependent effects in human leukemia cells including cyclin-dependent kinase inhibitor 1A (p21/CIP1/WAF1)-dependent growth arrest and differentiation at low drug concentrations; a marked induction of reactive oxygen species (ROS); mitochondrial damage; caspase activation; and, at higher concentrations, apoptosis. In normal cells, cyclin-dependent kinase inhibitor 1A expression has been associated with cell-cycle exit and differentiation.","Entinostat | Carbamic Acid, N-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-, 3- pyridinylmethyl Ester | Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester (9CI) | ENTINOSTAT | HDAC inhibitor SNDX-275 | MS 27-275 | MS 275 | MS-275 | MS275 | N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]b enzamide | SNDX 275 | SNDX-275 | SNDX275 | entinostat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0065452","Cisplatin/Doxorubicin/Methotrexate/Vinblastine","C9604","No Value Exists","Cisplatin/Doxorubicin/Methotrexate/Vinblastine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030073","Oxymorphone","C29314","A semisynthetic narcotic analgesic related to hydromorphone and other opiates, Oxymorphone, hydroxy-dihydromorphinone, affects the central nervous system and smooth muscles by activation of specific opiate receptors. Similar to morphine, but more potent and without cough suppressant activity, it is used in treatment of moderate to severe pain, including obstetrical pain, or as an adjunct to anaesthesia. (NCI04)","Oxymorphone | 4,5Alpha-Epoxy-3,14-Dihydroxy-17-Methylmorphinan-6-One | Morphinan-6-One, 4,5-Epoxy-3,14-Dihydroxy-17-Methyl- | OXYMORPHONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796561","Melanoma vaccine","C2517","A cancer vaccine prepared from human melanoma cancer cells. It can be used alone or with other therapy in treating melanoma.","Melanoma Vaccine | melanoma vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513261","Micellar Paclitaxel","C29256","A systemic administered polymeric micelle containing paclitaxel that may be used for chronic inflammatory diseases, such as rheumatoid arthritis and psoriasis. Paclitaxel, a toxoid, binds to and stabilizes tubulin and inhibits the disassembly of microtubules, thereby inhibiting cell division. Paclitaxel also inhibits metalloproteinase, thereby blocking the activities of matrix metalloproteinases (MMPs) and preventing collagen degradation in cartilage and bone.","Micellar Paclitaxel | Paxceed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0083812","O(6)-benzylguanine","C1306","A guanine analogue with antineoplastic activity. O6-benzylguanine binds the DNA repair enzyme O(6)-alkylguanine DNA alkyltransferase (AGT), transferring the benzyl moiety to the active-site cysteine and resulting in inhibition of AGT-mediated DNA repair. Co-administration of this agent potentiates the effects of other chemotherapeutic agents that damage DNA. (NCI04)","O6-Benzylguanine | 2-amino-6-(benzyloxy)purine | 2-amino-6-(phenylmethoxy)-9h-purine | 6-O-BENZYLGUANINE | 6-O-Benzylguanine | O(6)-Benzylguanine | O(6)-benzylguanine | O-6-Benzylguanine | O6-BG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3467794","Rigosertib Sodium","C71355","The sodium salt form of rigosertib, a synthetic benzyl styryl sulfone analogue and Ras mimetic, with potential antineoplastic activity. Upon administration, rigosertib targets and binds to Ras-binding domain (RBD) found in many Ras effector proteins, including Raf kinase and phosphatidylinositol 3-kinase (PI3K). This prevents Ras from binding to its targets and inhibits Ras-mediated signaling pathways, including Ras/Raf/Erk, Ras/CRAF/polo-like kinase1 (Plk1), and Ras/ PI3K/Akt signaling pathways. This induces cell cycle arrest and apoptosis and inhibits proliferation in a variety of susceptible tumor cells.","Rigosertib Sodium | ON 01910.Na | Polo-like kinase 1 Inhibitor ON 01910.Na | Polo-like kinase 1 Inhibitor ON 01910.Na | RIGOSERTIB SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3181262","Rindopepimut","C69076","A cancer vaccine consisting of a human epidermal growth factor receptor variant III (EGFRvIIi)-specific peptide conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH) with potential antineoplastic activity. Vaccination with rindopepimut may elicit a cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing EGFRvIII. EGFRvIII, a functional variant of EGFR that is not expressed in normal tissues, was originally discovered in glioblastoma multiforme (GBM) and has also been found in various other cancers such as breast, ovarian, metastatic prostate, colorectal, and head and neck cancers. EGFRvIII contains an 83 amino acid deletion in its extracellular domain and has been shown to transform NIH/3T3 mouse embryonic fibroblast cells in vitro.","Rindopepimut | Anti-EGFRvIII Vaccine CDX-110 | CDX-110 | L-Cysteine, L-leucyl-L-alpha-glutamyl-L-alpha-glutamyl-L-lysyl-L-lysylglycyl-L-asparaginyl-L-tyrosyl-L-valyl-L-valyl-L-threonyl-L-alpha-aspartyl-L-histidyl-S-(1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)-, complex with hemocyanin (Megathura crenulata) | PF-04948568 | RINDOPEPIMUT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1134503","Pentostatin/Rituximab","C12074","No Value Exists","Pentostatin/Rituximab | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524684","Pentosan Polysulfate Sodium","C946","The sodium salt of a semisynthetic heparin-like glucosaminoglycan.  Although its mechanism of action is unknown, pentosan polysulfate may act as a buffer to control cell permeability by preventing irritating solutes from reaching cells coated with it. Administered orally, excreted pentosan polysulfate adheres to the urinary bladder wall, preventing irritants from entering bladder cells and the development or progression of interstitial cystitis (IC), a complication of some chemotherapies. This agent also exhibits anticoagulant and fibrinolytic properties. In addition, pentosan polysulfate may block endothelial P-selectin and increase microvascular blood flow in sickle cell disease.","Pentosan Polysulfate Sodium | Cartrophen | Elmiron | Fibrase | Fibrezym | Fibrocid | HOE-BAY 946 | Hemoclar | PENTOSAN POLYSULFATE SODIUM | Pentosan | Sodium Pentosan Polysulfate | Sodium Xylan Polysulfate | TRF 1101 | TRF-1101 | TRF1101 | Tavan SP-54 | Thrombocid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0391001","Peginterferon Alfa-2a","C33987","A covalent conjugate of recombinant interferon alfa, subtype 2a, and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha-2a protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha-2a, thereby extending the duration of its therapeutic effects, but may also reduce interferon-mediated stimulation of an immune response. (NCI04)","Peginterferon Alfa-2a | PEG-Interferon Alfa-2a | PEG-interferon alfa-2a | PEGINTERFERON ALFA-2A | Pegasys | Peginterferon alfa-2a | Pegylated Interferon Alfa-2a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796545","Peginterferon Alfa-2b","C1845","A covalent conjugate of recombinant interferon alpha, subtype 2b, and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha-2b protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha-2b, thereby extending the duration of its therapeutic effects, but may also reduce the interferon-mediated stimulation of an immune response. (NCI04)","Peginterferon Alfa-2b | PEG Interferon Alpha-2b | PEG Intron | PEG-IFN Alfa-2b | PEG-IFN-a 2b | PEG-Interferon Alfa-2b | PEG-Intron | PEG-interferon alfa-2b | PEGINTERFERON ALFA-2B | PegIntron | Peginterferon alfa-2b | Pegylated Interferon Alpha-2b | Pegylated Interferon alfa-2b | Polyethylene Glycol IFN-A2b | Polyethylene Glycol Interferon Alfa-2b | SCH 54031 | SCH-54031 | SCH54031 | Sylatron",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1134696","Nab-paclitaxel","C2688","A Cremophor EL-free, albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. This formulation solubilizes paclitaxel without the use of the solvent Cremophor, thereby permitting the administration of larger doses of paclitaxel while avoiding the toxic effects associated with Cremophor.","Nab-paclitaxel | ABI 007 | ABI-007 | ABI007 | Abraxane | Albumin-Stabilized Nanoparticle Paclitaxel | Albumin-bound Paclitaxel | Nanoparticle Albumin-bound Paclitaxel | Nanoparticle Paclitaxel | Naveruclif | Paclitaxel Albumin | Paclitaxel Albumin-Stabilized Nanoparticle Formulation | Paclitaxel Nanoparticle Albumin-bound | Paclitaxel Protein-Bound | Paclitaxel nanoparticle albumin-bound | Protein-bound Paclitaxel | nanoparticle paclitaxel | paclitaxel albumin-stabilized nanoparticle formulation | protein-bound paclitaxel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0912586","Vatalanib","C1868","An orally bioavailable anilinophthalazine with potential antineoplastic activity.  Vatalanib binds to and inhibits the protein kinase domain of vascular endothelial growth factor receptors 1 and 2; both receptor tyrosine kinases are involved in angiogenesis.  This agent also binds to and inhibits related receptor tyrosine kinases, including platelet-derived growth factor (PDGF) receptor, c-Kit, and c-Fms.","Vatalanib | CGP 79787 | CGP-79787 | N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine | PTK787 | PTK787/ZK 222584 | VATALANIB | ZK-232934 | vatalanib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281338","PSC 833/Vinblastine","C10691","No Value Exists","PSC 833/Vinblastine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281559","Paclitaxel/PSC 833","C10855","No Value Exists","Paclitaxel/PSC 833 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0753474","Valspodar","C1405","An analogue of cyclosporin-A. Valspodar inhibits p-glycoprotein, the multidrug resistance efflux pump, thereby restoring the retention and activity of some drugs in some drug-resistant tumor cells. This agent also induces caspase-mediated apoptosis. (NCI04)","Valspodar | 6-[(2S,4R,6E)-4-Methyl-2-(methylamino)-3-oxo-6-octenoic Acid]cyclosporin D | Amdray | Cyclo((2S,4R,6E)-4-methyl-2-(methylamino)-3-oxo-6-octenoyl)-L-valyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-me | PSC 833 | PSC-833 | PSC833 | SZD PSC 833 | VALSPODAR | VP16",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879395","PSA RNA-Pulsed Dendritic Cell Vaccine","C2236","An autologous dendritic cell vaccine with potential immunostimulatory activity. Dendritic cells harvested from a prostate cancer patient are transfected with the mRNA encoding for prostate specific antigen (PSA), a tumor marker secreted by prostatic epithelial and ductal cells. When reintroduced back to the patient, these PSA RNA pulsed autologous dendritic cells may elicit a cytotoxic T-cell (CTL) response against PSA-positive prostate cancer cells.","PSA RNA-Pulsed Dendritic Cell Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0211169","Milodistim","C1477","A recombinant fusion protein derived from the coding sequences of two growth factors, interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF).  Milodistim exhibits greater receptor binding affinity and colony stimulating activity than its parent cytokines.  This agent stimulates proliferation of immature hematopoietic cells and allows the stimulation and expansion of multi-lineage hematopoiesis from immature bone marrow progenitor cells. (NCI04)","Milodistim | 23-L-Leucine-27-L-aspartic acid-39-L-glutamic acid-colony-stimulating factor 2 (Human Clone pHG25 Protein Moiety Reduced), (127-9')-protein with 9-Glycine-10-glycine-11-glycine-12-glycine-13-L-serine-14-glycine-15-glycine-16-glycine-18-glycine-19-L-serine-34-L-aspartic acid-89-L-aspartic acid-9-152-interleukin 3 (human clone D11 Precursor Protein Moiety Reduced) | GM-CSF/IL-3 Fusion Protein | GM-CSF/IL3 Fusion Protein | Granulocyte-Macrophage Colony Stimulating Factor/Interleukin-3 Fusion Protein | MILODISTIM | PIXY321 | Pixykine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709400","Dacomitinib","C53398","A highly selective, orally bioavailable small-molecule inhibitor of the HER family of tyrosine kinases with potential antineoplastic activity. Dacomitinib specifically and irreversibly binds to and inhibits human Her-1, Her-2, and Her-4, resulting in the proliferation inhibition and apoptosis of tumor cells that overexpress these receptors.","Dacomitinib | (2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide | DACOMITINIB | EGFR Inhibitor PF-00299804 | PF 00299804 | PF-00299804 | PF-00299804-03 | PF-299804 | PF00299804 | Vizimpro",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0071568","Pegaspargase","C1200","A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)","Pegaspargase | (Monomethoxypolyethylene Glycol Succinimidyl)74-L-Asparaginase | L-Asparaginase with Polyethylene Glycol | Oncaspar | Oncaspar-IV | PEG-Asparaginase | PEG-L-Asparaginase | PEG-L-Asparaginase (Enzon - Kyowa Hakko) | PEG-asparaginase | PEGASPARGASE | PEGLA | Polyethylene Glycol L-Asparaginase | Polyethylene Glycol-L-Asparaginase | pegaspargase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518780","PCLUS 6.1-18MN","C2787","A synthetic HIV-1 envelope peptide that was developed for use as a vaccine.  Vaccination with PCLUS 6.1-18MN may stimulate the host immune system to mount cytotoxic T lymphocyte (CTL) and T helper cell responses, and induce the production of neutralizing antibodies. (NCI04)","PCLUS 6.1-18MN | AIDs Peptide Vaccine (Peninsula) Construct 6.1-18 MN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518779","PCLUS 3-18MN","C2786","A synthetic HIV-1 envelope peptide that was developed for use as a vaccine.  Vaccination with PCLUS 3-18MN may stimulate the host immune system to mount cytotoxic T lymphocyte (CTL) and T helper cell responses, and induce the production of neutralizing antibodies. (NCI04)","PCLUS 3-18MN | AIDs Peptide Vaccine (Peninsula) Construct 3-18 MN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1670100","Tigapotide","C78474","A synthetic 15-mer peptide corresponding to amino acids 31-45 of the 94-amino acid isoform of human prostate secretory protein (PSP-94) with potential anti-metastasis and anti-angiogenesis activities. PSP-94-derived peptide PCK3145 may inhibit the secretion of the metastasis-related protein matrix metalloproteinase-9 (MMP-9) and its potential binding to its cell surface receptor CD44; may interfere with the vascular endothelial growth factor (VEGF) signaling pathway, resulting in an anti-angiogenesis effect; and may reduce the levels of parathyroid hormone-related protein (PTHrP), decreasing plasma calcium levels. PSP-94, one of three predominant proteins found in seminal fluid, may be down-regulated in prostate cancer, representing a potential survival mechanism for prostate cancer cells. MMP-9 is implicated in the invasion and metastasis of cancer. PTHrP may be expressed by various tumor cell types, resulting in the hypercalcemia of malignancy.","Tigapotide | PCK3145 | PSP-94-Derived Peptide PCK3145 | Prostate-Secretory Protein-94-Derived Peptide PCK3145 | TIGAPOTIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0756934","PC-SPES","C1828","An herbal mixture with potential antineoplastic effects. PC-SPES, an herbal supplement containing extracts from 8 herbs including Chrysanthemum morifolium, Ganoderma lucidum (a root fungus), Glycyrrhiza glabra (Spanish liquorice), Isatis indigotica, Panax pseudoginseng, Rabdosia rubescens, Scutellaria baicalensis, and Serona repens (saw palmetto), with potential antineoplastic and antiproliferative effects, specifically in prostate cancer cells. Its exact pharmacology is not fully understood due to the complexity of the herbal mixture and may involve multiple metabolic pathways. Exposure to PC-SPES in vitro has resulted in a decreased expression of genes encoding cell cycle regulatory proteins as well as an upregulation of genes that modulate apoptosis in both androgen-dependent and androgen-independent cells. The PC in the acronym PC-SPES stands for Prostate Cancer, while SPES is the Latin word for hope.","Chrysanthemum morifolium/Ganoderma lucidum/Glycyrrhiza glabra/Isatis indigotica/Panax pseudoginseng/Rabdosia rubescens/Scutellaria baicalensis/Serona repens Supplement | PC-SPES | PC-SPES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0070167","lomustine/procarbazine/vincristine","C9627","A combination of agents containing lomustine, procarbazine and vincristine.","Lomustine/Procarbazine/Vincristine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1541350","Falimarev","C29316","A cancer vaccine comprised of a recombinant fowlpox viral vector encoding the carcinoembryonic antigen (CEA), MUC-1, a transmembrane glycoprotein secreted by glandular epithelial tissues, and TRICOM, comprised of three co-stimulatory molecule transgenes (B7-1, ICAM-1 and LFA-3). This agent may enhance CEA and MUC-1 presentation to antigen-presenting cells (APC) and may activate a cytotoxic T-cell response against CEA- and MUC-1-expressing tumor cells.","Falimarev | Fowlpox-CEA(D609)-MUC1(L93)-TRICOM Vaccine | Fowlpox-CEA-MUC-1-TRICOM | PANVAC-F | fCEA-MUC-1-TRI | falimarev | rFowlpox-CEA(D609)/MUC1(L93)/TRICOM Vaccine | recombinant fowlpox-CEA-MUC-1-TRICOM vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1541349","Inalimarev","C29317","A cancer vaccine comprised of a recombinant vaccinia viral vector encoding the carcinoembryonic antigen (CEA), MUC-1 (mucin-1), a transmembrane glycoprotein secreted by glandular tissues, and TRICOM, comprised of the three co-stimulatory molecule transgenes B7-1, ICAM-1 and LFA-3. Upon administration, inalimarev may enhance CEA and MUC-1 presentation to antigen presenting cells (APC) and may activate a cytotoxic T lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells.","Inalimarev | PANVAC-V | Vaccinia-CEA-MUC1-TRICOM Vaccine | inalimarev | rVaccinia-CEA(D609)/MUC1(L93)/TRICOM Vaccine | recombinant vaccinia-CEA-MUC-1-TRICOM vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0135096","N-Phosphonacetyl-L-aspartate","C1398","A stable transition state analogue for an aspartate transcarbamylase-catalyzed reaction with antineoplastic activity. Sparfosic acid is a stable transition analogue of the activated complex for the reaction catalyzed by aspartate transcarbamylase, the first step in the pyrimidine biosynthetic pathway. This agent inhibits de novo pyrimidine biosynthesis and increases the extent to which fluorouracil metabolites are incorporated into RNA.","Sparfosic Acid | L-Aspartic acid, N-(phosphonoacetyl)- | N-Phosphonacetyl-L-aspartate | N-phosphonacetyl-L-aspartate | PALA | Phosphonacetyl-L-aspartic Acid | SPARFOSIC ACID | Sparfosate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0851287","Phosphorus P-32","C1698","A radioactive isotope of phosphorus with beta particle-emitting radiocytotoxic activity. Emitted by phosphorus P32, beta particles directly damage cellular DNA and, by ionizing intracellular water to produce several types of cytotoxic free radicals and superoxides, indirectly damage intracellular biological macromolecules, resulting in tumor cell death.","Phosphorus P-32 | P-32 | P32 | PHOSPHORUS P-32 | Phosphorus P 32 | phosphorus-32",,,,,,,,,,,,,,,"4138967","Phosphorus-32",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0213800","Rubitecan","C1485","A semisynthetic agent related to camptothecin with potent antitumor and antiviral properties.  Rubitecan binds to and inhibits the enzyme topoisomerase I and induces protein-linked DNA single-strand breaks, thereby blocking DNA and RNA synthesis in dividing cells; this agent also prevents repair of reversible single-strand DNA breaks. (NCI04)","Rubitecan | 9-NC | 9-Nitro-20(S)-camptothecin | 9-nitrocamptothecin | Camptogen | Nitrocamptothecin | Orathecin | RFS 2000 | RUBITECAN | nitrocamptothecin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1998098","Panobinostat","C66948","A cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. HDAC is an enzyme that deacetylates chromatin histone proteins.","Panobinostat | (2E)-N-hydroxy-3-(4-(((2-(2-methyl-1h-indol-3-yl)ethyl)amino)methyl)phenyl)prop-2-enamide | Faridak | LBH 589 | LBH-589 | LBH589 | PANOBINOSTAT | panobinostat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518802","PNU-214565","C29328","A recombinant fusion protein of the bacterial superantigen Staphylococcal enterotoxin A (SEA) and the variable Fab fragment of the C242 monoclonal antibody. Upon administering nacolomab tafenatox, the Fab fragment binds to Lewis antigen, a glycoprotein overexpressed in human colon and pancreatic carcinoma cell surfaces, thereby directing PNU-214565 to the tumor target area and providing tumor specificity. Superantigen staphylococcal enterotoxin A (SEA) promotes the crosslinking of T-cell receptor (TCR) Vb regions with major histocompatibility complex (MHC) class II molecules on antigen presenting cells, thereby enhancing cytotoxic T-lymphocyte activation, cytokine production and tumor cell lysis.","Nacolomab Tafenatox | C242Fab-SEA Immunotoxin | NACOLOMAB TAFENATOX | PNU-214565 | PNU-214565",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030899","Pentoxifylline","C733","A methylxanthine derivative with hemorrheologic and immunomodulating properties. Pentoxifylline inhibits phosphodiesterase, resulting in increased levels of cyclic adenosine monophosphate (cAMP) in erythrocytes, endothelium, and the surrounding tissues. This leads to vasodilation, improves erythrocyte flexibility, and enhances blood flow. In addition, the increased level of cAMP in platelets inhibits platelet aggregation, which may contribute to a reduction in blood viscosity. This agent also inhibits production of tumor necrosis factor-alpha and interferon-gamma, while it induces Th2-like (T-helper 2) cytokine production, thereby inhibiting Th1-mediated (T-helper 1) inflammatory and autoimmune responses.","Pentoxifylline | 3,7-Dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione | Oxpentifylline | PENTOXIFYLLINE | PTX | Pentoxyphylline | Trental | pentoxifylline",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280905","Doxorubicin/Paclitaxel","C10476","No Value Exists","Doxorubicin/Paclitaxel | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281286","Cyclophosphamide/Paclitaxel","C10655","A combination of agents containing cyclophosphamide and paclitaxel.","Cyclophosphamide/Paclitaxel | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0338263","Paclitaxel/Vinorelbine","C11115","A combination of agents containing paclitaxel and vinorelbine.","Paclitaxel/Vinorelbine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0754570","Perifosine","C1727","An orally active alkyl-phosphocholine compound with potential antineoplastic activity.  Targeting cellular membranes, perifosine modulates membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth.  This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis.  Perifosine has a lower gastrointestinal toxicity profile than the related agent miltefosine. (NCI04)","Perifosine | 4-[[Hydroxy(octadecyloxy)phosphinyl]oxy]-1,1-dimethylpiperidinium, Inner Salt | D21266 | KRX 0401 | KRX-0401 | KRX0401 | Octadecyl-(N,N-dimethylpiperidino-4-yl)phosphate | Octadecylphosphopiperidine | PERIFOSINE | perifosine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282297","Petrolatum Hydrophilic","C29356","A non-polar semi-solid mixture of hydrocarbons that is derived from petroleum. This agent has application as a lubricant, emollient, and a carrier for other agents.","Petrolatum Hydrophilic | Hydrophilic Petrolatum | Petrolatum, Hydrophilic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0887016","Pheniramine Maleate","C29358","The maleate salt form of pheniramine, an alkylamine derivative with antihistaminic and vasodilatory properties. Pheniramine maleate binds to histamine H1 receptors, thereby inhibiting phospholipase A2 and production of endothelium-derived relaxing factor, nitric oxide. Subsequent lack of activation of guanylyl cyclase through nitric oxide results in decreased cyclic GMP (cGMP) levels, thereby inhibiting constriction of smooth muscle tissue, and decreased capillary permeability and histamine-activated allergic reactions.","Pheniramine Maleate | PHENIRAMINE MALEATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1134444","Idronoxil","C2642","A synthetic flavonoid derivative. Idronoxil activates the mitochondrial caspase system, inhibits X-linked inhibitor of apoptosis (XIAP), and disrupts FLICE inhibitory protein (FLIP) expression, resulting in tumor cell apoptosis. This agent also inhibits DNA topoisomerase II by stabilizing the cleavable complex, thereby preventing DNA replication and resulting in tumor cell death.","Idronoxil | 3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol | IDRONOXIL | NOX66 | NV-06 | Phenoxodiol | phenoxodiol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0220893","Phenyl Acetate","C1501","An aromatic fatty acid metabolite of phenylalanine with potential antineoplastic activity.  Naturally occurring in mammals, phenylacetate induces differentiation, growth inhibition, and apoptosis in tumor cells.  Implicated mechanisms of action include decreased protein prenylation, activation of the peroxisome proliferation-activated receptors, inhibition of DNA methylation, and depletion of glutamine. (NCI04)","Phenyl Acetate | Acetic Acid Phenyl Ester | Acetylphenol | PHENYL ACETATE | Phenyl acetate | Phenylacetate | phenylacetate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0718066","Sodium Phenylbutyrate","C1440","The sodium salt of phenylbutyrate, a derivative of the short-chain fatty acid butyrate, with potential antineoplastic activity. Phenylbutyrate reversibly inhibits class I and II histone deacetylases (HDACs), which may result in a global increase in gene expression, decreased cellular proliferation, increased cell differentiation, and the induction of apoptosis in susceptible tumor cell populations.","Sodium Phenylbutyrate | 4-Phenylbutyric Acid, Sodium Salt | Buphenyl | Phenylbutyrate Sodium | SODIUM PHENYLBUTYRATE | SPB11 | Sodium 4-Phenylbutyrate | Sodium 4-phenylbutyrate | phenylbutyrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0298067","Pirfenidone","C2635","An orally active synthetic antifibrotic agent structurally similar to pyridine 2,4-dicarboxylate. Pirfenidone inhibits fibroblast, epidermal, platelet-derived, and transforming beta-1 growth factors, thereby slowing tumor cell proliferation. This agent also inhibits DNA synthesis and the production of mRNA for collagen types I and III, resulting in a reduction in radiation-induced fibrosis. (NCI04)","Pirfenidone | PIRFENIDONE | pirfenidone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054332","Piritrexim","C1031","A synthetic antifolate agent with antiparasitic, antipsoriatic and antitumor properties. Piritrexim inhibits the enzyme dihydrofolate reductase enzyme, thereby disrupting folate metabolism and DNA synthesis and cell division. (NCI04)","Piritrexim | 2,4-Diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine | 6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine | 6-[(2,5-Dimethoxyphenyl)methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine | BW 301U | BW-301U | PIRITREXIM | piritrexim",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031990","Piroxicam","C751","A nonsteroidal oxicam derivative with anti-inflammatory, antipyretic and analgesic properties. As a non-selective, nonsteroidal anti-inflammatory drug (NSAID), piroxicam binds and chelates both isoforms of cyclooxygenases (COX1 and COX2), thereby stalling phospholipase A2 activity and conversion of arachidonic acid into prostaglandin precursors at the rate limiting cyclooxygenase enzyme step. This results in inhibition of prostaglandin biosynthesis. As a second, independent effect, piroxicam inhibits the activation of neutrophils thereby contributing to its overall anti-inflammatory effects.","Piroxicam | 4-Hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboximide-1,1-dioxide | Feldene | PIROXICAM | PXM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026234","Plicamycin","C658","An antibiotic isolated from the bacterium Streptomyces plicatus with antineoplastic activity. Plicamycin, also known as mithramycin, binds to the minor groove of DNA at GC-rich sites, resulting in inhibition of RNA synthesis; this agent also inhibits mRNA expression, resulting in a reduction in protein synthesis. In addition, plicamycin may inhibit bone resorption by down regulating transcription of c-src, an oncogene involved in bone metabolism and resorption. (NCI04)","Plicamycin | A-2371 | Aureolic acid | MTH | Mithracin | Mithracine | Mithramycin | PA-144 | PLICAMYCIN | mithramycin | plicamycin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0071359","Poly ICLC","C1198","A synthetic complex of carboxymethylcellulose, polyinosinic-polycytidylic acid, and poly-L-lysine double-stranded RNA. Poly ICLC may stimulate the release of cytotoxic cytokines and, by inducing interferon-gamma production, may increase the tumoricidal activities of various immunohematopoietic cells. (NCI04)","Poly ICLC | HILTONOL | Hiltonol | Poly I:Poly C with Poly-L-Lysine Stabilizer | PolyI:PolyC with Poly-L-Lysine Stabilizer | Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose | Polyriboinosinic-Polyribocytidylic Acid-Polylysine Carboxymethylcellulose | Stabilized Polyriboinosinic/Polyribocytidylic Acid | poly-ICLC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085542","Pravastatin","C62070","A synthetic lipid-lowering agent. Pravastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. Pravastatin lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. (NCI04)","Pravastatin | PRAVASTATIN | [1S-[1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha]]-1,2,6,7,8,8a-Hexahydro-beta,!d,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-1-naphthaleneheptanoic Acid | pravastatin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281567","cyclophosphamide/doxorubicin/etoposide/prednisone","C10861","A combination of agents containing cyclophosphamide, doxorubicin, etoposide and prednisone.","Cyclophosphamide/Doxorubicin/Etoposide/Prednisone | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516983","Etoposide/Prednisone","C29376","No Value Exists","Etoposide/Prednisone | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278531","CTX/DOX/MTX/PRED/VP-16","C9771","A regimen consisting of prednisone, methotrexate, doxorubicin, cyclophosphamide and etoposide that may be used in the treatment of non-Hodgkin lymphoma (NHL).","ProMACE Regimen | CTX/DOX/MTX/PRED/VP-16 | Cyclophosphamide/Doxorubicin/Etoposide/Methotrexate/Prednisone | Cyclophosphamide/Doxorubicin/Etoposide/Methotrexate/Prednisone | Prednisone-Methotrexate-Adriamycin-Cyclophosphamide-Etoposide | Prednisone/Methotrexate/Adriamycin/Cyclophosphamide/Etoposide | Prednisone/Methotrexate/Doxorubicin/Cyclophosphamide/Etoposide | Prednisone/Methotrexate/Doxorubicin/Cyclophosphamide/Etoposide Regimen | ProMACE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034239","Pyrazinamide","C29395","A synthetic pyrazinoic acid amide derivative with bactericidal property. Pyrazinamide is particularly active against slowly multiplying intracellular bacilli (unaffected by other drugs) by an unknown mechanism of action. Its bactericidal action is dependent upon the presence of bacterial pyrazinamidase, which removes the amide group to produce active pyrazinoic acid. Pyrazinamide is an important component of multidrug therapy for tuberculosis. (NCI04)","Pyrazinamide | PYRAZINAMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2267033","Retinoid","C68299","Class of compounds consisting of four isoprenoid units joined in a head-to-tail manner and customarily containing five conjugated double bonds.","Retinoid | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514916","Retinoic Acid Binding","C26052","Retinoic Acid Binding consists of a biophysical interaction between retinoic acid (ligand) and a biological molecule, such as specific steroid receptor-like transcriptional regulator proteins containing an N-terminal modulating domain, a DNA-binding domain, and a C-terminal ligand-binding domain. The ligand-activated receptor complexes selectively bind as homodimers or heterodimers (with other steroid family receptors) to DNA response elements in target gene promoters, enhance transcriptional activity with coactivators, and mediate tissue growth and differentiation in embryogenesis, organogenesis, limb development, bone growth, and maintenance of normal epithelia.","Retinoic Acid Binding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0935789","Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine","C2619","A vaccine consisting of recombinant vaccinia virus encoding the tumor-associated antigen carcinoembryonic antigen (CEA) and a TRIad of COstimulatory Molecules (B7-1, ICAM-1, and LFA-3; also called TRICOM). Vaccination with recombinant vaccinia-CEA(6D)-TRICOM vaccine stimulates the host immune system to mount a T-cell response against tumor cells expressing the CEA antigen. The use of TRICOM in the vaccine may elicit a greater antitumor cytotoxic T lymphocyte (CTL) immune response compared to the use of vaccinia-CEA alone.","Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine | Vaccinia-CEA-TRICOM Vaccine | rV-CEA(6D)-TRICOM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0393081","Vaccinia Prostate Specific Antigen Vaccine","C2433","A vaccine consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA). Vaccination with recombinant vaccinia prostate-specific antigen vaccine stimulates the host immune system to mount a cytotoxic T-cell response against tumor cells expressing PSA.","Recombinant Vaccinia PSA Vaccine | PSA Vaccinia (CV1-produced), THERION | PSA Vaccinia (chick embryo dermo cell-produced) THERION | Prostate Specific Antigen Expressing Vaccinia Virus Vaccine | RV-PSA (RECOMB VACCINIA/PSA-CV-1) | Vaccinia PSA Vaccine | Vaccinia-PSA Vaccine | Vaccinia-Prostate-Specific Antigen Vaccine | rV-PSA | rV-PSA Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879372","Recombinant Vaccinia-B7.1 Vaccine","C2237","A recombinant vaccinia virus encoding the T-cell co-stimulatory molecule B7-1. Co-administration of recombinant vaccinia-B7.1 and a tumor-associated antigen vaccine may enhance tumor-associated antigen-specific T-cell responses. (NCI04)","Recombinant Vaccinia-B7.1 Vaccine | Recombinant Vaccinia-B7.1 | rV-B7 (Recomb Vaccinia/B7) | rV-B7.1 | rV-B7.1 Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0618111","Raloxifene Hydrochloride","C1762","The hydrochloride salt form of raloxifene, a selective benzothiophene estrogen receptor modulator (SERM) with lipid lowering effects and activity against osteoporosis. Raloxifene hydrochloride specifically binds to estrogen receptors in responsive tissue, including liver, bone, breast, and endometrium. The resulting ligand-receptor complex is translocated to the nucleus where, depending on the tissue type, it promotes or suppresses the transcription of estrogen-regulated genes, thereby exerting its agonistic or antagonistic effects. This agent functions as an estrogen agonist in lipid metabolism, thereby decreasing total and LDL cholesterol levels. In tissue like bone, it decreases bone resorption and bone turnover and increases bone mineral density. Raloxifene hydrochloride acts as an estrogen antagonist in uterine and breast tissue. This agent also exerts an anti-proliferative effect on estrogen-sensitive breast cancer.","Raloxifene Hydrochloride | (6-Hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)methanone Hydrochloride | Evista | Keoxifene Hydrochloride | LY-156758 | Optruma | RALOXIFENE HYDROCHLORIDE | Raloxifene HCl | Raloxifene hydrochloride | Raloxifene.HCl | raloxifene hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034678","ras Oncogene","C17061","A family of oncogenes that are highly homologous with the retrovirus-associated DNA sequences (ras) originally isolated from Harvey and Kirsten murine sarcoma viruses. Mutated or overexpressed forms of the human ras genes are associated with constitutive ras GTPase activity, increased cellular proliferation, and cell transformation.","RAS Family Oncogene | Oncogene RAS | RAS | RAS Oncogene | Retrovirus Associated Sequence Oncogene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1176289","Tipifarnib","C1703","A nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits the enzyme farnesyl protein transferase, an enzyme involved in protein processing (farnesylation) for signal transduction.  By inhibiting the farnesylation of proteins, this agent prevents the activation of Ras oncogenes, inhibits cell growth, induces apoptosis, and inhibits angiogenesis. (NCI04)","Tipifarnib | (+)-6-[Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone | R115777 | TIPIFARNIB | Zarnestra | tipifarnib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279338","bleomycin/cytarabine/methotrexate/vincristine","C10007","A regimen consisting of cytarabine, bleomycin, methotrexate, and vincristine for the treatment of non-Hodgkin lymphoma (NHL).","CytaBOM Regimen | ARA-C/BLEO/MTX/VCR | Bleomycin/Cytarabine/Methotrexate/Vincristine | Bleomycin/Cytarabine/Methotrexate/Vincristine | CytaBOM | Cytarabine-Bleomycin-Vincristine-Methotrexate | Cytarabine-Bleomycin-Vincristine-Methotrexate Regimen | Cytarabine/Bleomycin/Oncovin/Methotrexate | Cytarabine/Bleomycin/Vincristine/Methotrexate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0073012","Rebeccamycin","C1213","An indolocarbazole glycoside antineoplastic antibiotic isolated from the bacterium Saccharothrix aerocolonigenes.  Rebeccamycin intercalates into DNA and stabilizes the DNA-topoisomerase I complex, thereby interfering with the topoisomerase I-catalyzed DNA breakage-reunion reaction and initiating DNA cleavage and apoptosis. (NCI04)","Rebeccamycin | 5H-Indolo[2, 3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione, 1,11-dichloro-12, 13-dihydro-12-(4-O-methyl-.beta.-D-glucopyranosyl)- | 5H-indolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7(6H)-dione,1,11-dichloro-12,13-dihydro-12-(4-O-methyl-beta-D-glucopyranosyl) | BRN 4732638 | REBECCAMYCIN | rebeccamycin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1134640","Recombinant Fowlpox-Prostate Specific Antigen Vaccine","C2675","A cancer vaccine consisting of a recombinant fowlpox virus encoding human prostate-specific antigen (PSA). Administration of this agent may stimulate a cytotoxic T cell response against PSA-expressing tumor cells. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells. (NCI04)","Recombinant Fowlpox-Prostate Specific Antigen Vaccine | Fowlpox-PSA Vaccine | Recombinant Fowlpox-PSA | Recombinant Fowlpox-PSA Vaccine | Recombinant Fowlpox-Prostate Specific Antigen | rF-PSA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1134686","Fowlpox-Sargramostim Vaccine","C2686","A cancer vaccine adjuvant consisting of a recombinant fowlpox virus encoding human granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF binds to specific cell surface receptors on various immuno-hematopoietic cell types, enhancing their proliferation and differentiation and stimulating macrophage and dendritic cell functions in antigen presentation and antitumor cell-mediated immunity. Administration of recombinant fowlpox GM-CSF vaccine adjuvant may induce an immune response against tumor cells. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells.","Recombinant Fowlpox GM-CSF Vaccine Adjuvant | Fowlpox-Sargramostim | rF-GM-CSF | rF-Sargramostim",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0935790","Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine","C2620","A cancer vaccine comprised of a recombinant fowlpox virus vector encoding the carcinoembryonic antigen (CEA) and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM). This agent may enhance CEA presentation to antigen presenting cells (APC) and activate cytotoxic T-cells against CEA-expressing tumors. (NCI04)","Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine | Recombinant Fowlpox-CEA-TRICOM Vaccine | fowlpox-CEA-B7.1/ICAM-1/LFA-3 | rF-CEA(6D)TRICOM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL372122","beta all trans Retinoic Acid","C68301","Retinoid with a carboxylic acid group.","Retinoic Acid | 3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1142934","Satraplatin","C1493","An orally administered third generation platinum compound with potential antineoplastic activity. Satraplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in cell growth inhibition and apoptosis.","Satraplatin | (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum | (OC-6-43)-bis(acetato-O)amminedichloro(cyclohexanamine)platinum | BMS-182751 | BMY-45594 | JM 216 | JM-216 | Orplatna | SATRAPLATIN | platinum,bis(acetato-O)amminedichloro(cyclohexanamine)-,(OC-6-43) | satraplatin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831731","Bosutinib","C60809","A synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype.","Bosutinib | 4-Anilino-3-quinolinecarbonitrile | 4-Anilinobenzo(g)quinoline-3-carbonitrile | 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile | BOSUTINIB | Bosulif | SKI 606 | SKI-606 | SKI606",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0074125","bleomycin/doxorubicin/lomustine/streptozocin protocol","C9637","A regimen consisting of streptozocin, lomustine, doxorubicin, and bleomycin that may be used in the treatment of Hodgkin lymphoma (HL).","SCAB Regimen | BLEO/CCNU/DOX/SZC | Bleomycin/Doxorubicin/Lomustine/Streptozocin | Bleomycin/Doxorubicin/Lomustine/Streptozocin | Bleomycin/Doxorubicin/Lomustine/Streptozocin Regimen | CABS | SCAB | Streptozocin-Lomustine-Doxorubicin-Bleomycin | Streptozocin/CCNU/Adriamycin/Bleomycin | Streptozocin/Lomustine/Doxorubicin/Bleomycin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513757","Murine MCA Ricin Conjugate","C29415","An immunotoxin consisting of a murine monoclonal antibody (MCA) conjugated to the toxin ricin. The monoclonal antibody component binds to cell surface antigens, thereby targeting delivery of cytotoxic ricin to a specific cell type. The ricin component binds to cells and disrupts ribosomal activity and protein synthesis and induces cell cycle arrest. (NCI04)","Murine MCA Ricin Conjugate | Ricin Conjug. Murine MCA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0209211","Lanreotide","C1523","A synthetic cyclic octapeptide analogue of somatostatin. Lanreotide binds to somatostatin receptors (SSTR), specifically SSTR-2 and also to SSTR-5 with a lesser affinity. However, compare with octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Furthermore, lanreotide has an acute effect on decreasing circulating total and free insulin-like growth factor 1 (IGF-I).  This agent is usually given as a prolonged-release microparticle or Autogel formulation for the treatment of acromegaly and to relieve the symptoms of neuroendocrine tumors.","Lanreotide | Angiopeptin | BIM-23014 | DC 13116 | Dermopeptin | Ipstyl | L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7)-disulfide | LANREOTIDE | Nal-cyclo(cys-tyr-trp-lys-val-cys)-thr-NH2 | Somatulina | Somatuline",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278671","carmustine/cisplatin/cyclophosphamide","C9783","A regimen consisting of carmustine, cyclophosphamide, and cisplatin that may be used in the treatment of breast cancer.","CBP Regimen | BCNU/CDDP/CTX | CBP | CPB | Carmustine/Cisplatin/Cyclophosphamide | Carmustine/Cisplatin/Cyclophosphamide | Cyclophosphamide-Carmustine-Cisplatin | Cyclophosphamide/BCNU/Platinol | Cyclophosphamide/Carmustine/Cisplatin | Cyclophosphamide/Carmustine/Cisplatin Regimen | STAMP I | STAMP-I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038467","Strontium","C846","An element with atomic symbol Sr, atomic number 38, and atomic weight 87.62.","Strontium | STRONTIUM | Sr | strontium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038432","Streptozocin","C845","A methylnitrosourea antineoplastic antibiotic isolated from the bacterium Streptomyces achromogenes.  Streptozocin alkylates DNA, forming inter-strand DNA cross-links and inhibiting DNA synthesis.  Due to its glucose moiety, this agent is readily taken up by pancreatic beta cells, inducing diabetes mellitus at high concentrations.  Unlike other nitrosoureas, streptozocin causes little myelosuppression. (NCI04)","Streptozocin | 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose | 2-deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose | 2-deoxy-2-[[(methylnitrosamino)-carbonyl]amino]-D-glucopyranose | STREPTOZOCIN | STZ | Streptozotocin | U 9889 | U-9889 | Zanosar | streptozocin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1258770","SS1(dsFv)-PE38 Immunotoxin","C2609","A recombinant immunotoxin consisting of the single chain anti-mesothelin monoclonal antibody SS1(dsFv) linked to Pseudomonas exotoxin PE-38. The monoclonal antibody moiety of the agent binds to cells that express mesothelin, a cell surface glycoprotein which may be overexpressed in ovarian cancer, mesotheliomas, and some squamous cell carcinomas; after internalization, the exotoxin moiety inactivates eukaryotic translation elongation factor 2, thereby disrupting tumor cell protein synthesis. (NCI04)","SS1(dsFv)-PE38 Immunotoxin | Immunotoxin, SS1(dsFv)-PE38 | SS1(dsFv) PE38 | SS1P",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3253587","Hsp90 Inhibitor SNX-5422 Mesylate","C91068","The orally bioavailable mesylate salt of a synthetic prodrug targeting the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Although the mechanism of action remains to be fully elucidated, Hsp90 inhibitor SNX-5422 is rapidly converted to SNX-2112, which accumulates more readily in tumors relative to normal tissues. SNX-2112 inhibits Hsp90, which may result in the proteasomal degradation of oncogenic client proteins, including HER2/ERBB2, and the inhibition of tumor cell proliferation. Hsp90 is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, such as HER2/ERBB2, AKT, RAF1, BCR-ABL, and mutated p53, as well as many other molecules that are important in cell cycle regulation or immune responses.","Hsp90 Inhibitor SNX-5422 Mesylate | SNX-5422 | SNX-5422 MESYLATE | SNX-5422 Mesylate | SNX-5422 mesylate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036078","Sulfasalazine","C29469","A synthetic salicylic acid derivative with affinity for connective tissues containing elastin and formulated as a prodrug, antiinflammatory Sulfasalazine acts locally in the intestine through its active metabolites, sulfamide 5-aminosalicylic acid and salicylic acid, by a mechanism that is not clear. It appears inhibit cyclooxygenase and prostaglandin production and is used in the management of inflammatory bowel diseases. (NCI04)","Sulfasalazine | 2-Hydroxy-5-[[4-[(2-pyridinylamino)sulfonyl]phenyl]azo]benzoic Acid | Azulfidine | SULFASALAZINE | Salazosulfapyridine | Sulphasalazine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038880","Suramin","C853","A polysulphonated naphthylurea with potential antineoplastic activity.  Suramin blocks the binding of various growth factors, including insulin-like growth factor I (IGF-I), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and tumor growth factor-beta (TGF-beta), to their receptors, thereby inhibiting endothelial cell proliferation and migration.  This agent also inhibits vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis; retroviral reverse transcriptase; uncoupling of G-proteins from receptors; topoisomerases; cellular folate transport; and steroidogenesis. (NCI04)","Suramin | SURAMIN | suramin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279945","Hydrocortisone/Suramin","C10154","No Value Exists","Hydrocortisone/Suramin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510871","Aminoglutethimide/Hydrocortisone/Suramin","C29471","No Value Exists","Aminoglutethimide/Hydrocortisone/Suramin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279936","Tumor Necrosis Factor Therapy","C15507","A biological therapy that involves the use of anti-tumor necrosis factor antagonists. It results in the inhibition of tumor necrosis factor and the decrease of the inflammatory response in autoimmune disorders.","Tumor Necrosis Factor Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1456409","Etravirine","C73195","A diarylpyrimidine non-nucleoside reverse transcriptase inhibitor. Etravirine is designed to be active against HIV isolates with mutations that confer resistance to the two most commonly prescribed first-generation NNRTIs. It can bind the enzyme reverse transcriptase (RT) in multiple conformations, both for native and mutant RT, thereby blocking the enzymatic activity of RT.","Etravirine | 4-(6-Amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yloxy)-3,5-dimethylbenzonitrile | ETRAVIRINE | ETV | Intelence | TMC-125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242633","Type 2 Helper Cell","C12540","Type 2 Helper Cells are a subset of helper-inducer T-lymphocytes which synthesize and secrete the interleukins IL-4, IL-5, IL-6, and IL-10. These cytokines influence B-cell development and antibody production as well as augmenting humoral responses.","Type 2 Helper Cell | Th-2 Cell | Th2 Cell | Th2 Cells",,,,,,,,,,,,,,,"4169283","T helper subset 2 cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0533115","3'-C-ethynylcytidine","C29475","A synthetic cytidine nucleoside containing a covalently bound ethynyl group with potential antineoplastic and radiosensitizing activities. 3'-C-ethynylcytidine is metabolized in tumor cells to ethynylcytidine triphosphate (ECTP), which inhibits RNA synthesis by competitive inhibition of RNA polymerases I, II and III; subsequently, RNase L is activated, resulting in apoptosis. RNase L is a potent antiviral and antiproliferative endoribonuclease that cleaves singled stranded RNA, causes 28s rRNA fragmentation, and activates Janus Kinase (JAK), a mitochondrial-dependent apoptosis signaling molecule.","3'-C-ethynylcytidine | 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine | 3'-C-Ethynylcytidine | ECdy | ECyd | TAS-106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517268","Flutamide/Hydrocortisone/Suramin","C29472","No Value Exists","Flutamide/Hydrocortisone/Suramin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0081489","O-Chloroacetylcarbamoylfumagillol","C1298","A synthetic analog of fumagillin, an antibiotic isolated from the fungus Aspergillus fumigatus fresenius with antineoplastic activity.  TNP-470 binds to and irreversibly inactivates methionine aminopeptidase-2 (MetAP2), resulting in endothelial cell cycle arrest late in the G1 phase and inhibition of tumor angiogenesis.  This agent may also induce the p53 pathway, thereby stimulating the production of cyclin-dependent kinase inhibitor p21 and inhibiting angiogenesis. (NCI04)","O-Chloroacetylcarbamoylfumagillol | (3R,4S,5S,6R)-5-Methoxy-4- [(2R,3R)-2-methyl-3-(3-methyl-2-butenyl) -oxiranyl]-1-oxaspiro [2,5] oct-6-yl(chloroacetyl) Carbamate | 5-methoxy-4-(2-methyl-3-(3-methyl-2-butenyl)oxiranyl)-1-oxaspiro(2,5)oct-6-yl(chloroacetyl) carbamate | AGM-1470 | TNP-470 | [3R-[3alpha,4alpha(2R*,3R*),5beta,6beta]]-5-Methoxy-4-[2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2.5]oct-6-yl (chloroacetyl)carbamate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0288792","Tazarotene","C29487","A synthetic, topical retinoid.  Tazarotene induces the expression of tazarotene-induced gene 3 (TIG3), a tumor suppressor gene.  In psoriasis, tazarotene normalizes abnormal keratinocyte differentiation and reduces their hyperproliferation. (NCI04)","Tazarotene | 6-[(3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]- 3-Pyridinecarboxylic Acid, Ethyl Ester | AGN-190168 | Avage | Ethyl 6-(2-(4,4-Dimethylthiochroman-6-yl)ethynyl)nicotinate | TAZAROTENE | Tazorac | tazarotene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1143028","Tandutinib","C48404","A piperazinyl quinazoline receptor tyrosine kinase inhibitor with antineoplastic activity. Tandutinib inhibits the autophosphorylation of FLT3 (FMS-Like Tyrosine kinase-3), c-KIT and PDGF (platelet-derived growth factor) receptor tyrosine kinases, thereby inhibiting cellular proliferation and inducing apoptosis.","Tandutinib | 1-Piperazinecarboxamide, 4-(6-Methoxy-7-(3-(1-piperidinyl)propoxy)-4-quinazolinyl)-N-(4-(1-methylethoxy)phenyl)- | CT53518 | MLN 518 | MLN518 | TANDUTINIB | tandutinib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0771774","Tamsulosin Hydrochloride","C29486","The hydrochloride salt of tamsulosin, a sulfonamide derivative with adrenergic antagonist activity. Tamsulosin selectivity binds to and blocks the activity of alpha1 adrenoreceptors in the human prostate and bladder neck; blockade of these adrenoceptors can cause smooth muscle in the prostate and bladder neck to relax, resulting in an improvement in urinary flow rate.","Tamsulosin Hydrochloride | Flomax | TAMSULOSIN HYDROCHLORIDE | tamsulosin hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0250723","Talampanel","C38139","A synthetic derivative of dioxolo-benzodiazepine with anti-seizure activity.  Talampanel antagonizes the AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) subtype of glutamate excitatory amino acid receptors and may inhibit the growth of gliomas by interfering with neurotransmitters involved in brain tumor growth. This agent may also protect against traumatic brain injury.","Talampanel | (R)-(-)-1-(4-Aminophenyl)-3-acetyl-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine | GYKI-53773 | LY-300164 | TALAMPANEL | talampanel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1872514","talactoferrin alfa","C78460","An orally bioavailable recombinant human lactoferrin produced in the fungus Aspergillus niger with potential antineoplastic and immunomodulating activities. Upon oral administration, talactoferrin is transported into small intestinal Peyer's patches of the gut-associated lymphoreticular tissues (GALT), where it recruits circulating immature dendritic cells (DCs) bearing tumor antigens and induces their maturation. In the GALT, DC maturation in the presence of tumor antigens and lymphoid effector cells may induce systemic innate and adaptive immune responses mediated by anti-tumor natural killer (NK) cells, cytotoxic T lymphocytes, and natural killer T (NKT) cells; activation of tumor-draining lymph nodes, cellular infiltration of distant tumors, and tumor-cell death may follow. Raising the initial immune response in the GALT, distant from the primary tumor, may counter local tumor-mediated immunosuppression.","Talactoferrin Alfa | Oral Recombinant Human Lactoferrin | Oral rhLF | TALACTOFERRIN ALFA | TLF | Talactoferrin | talactoferrin | talactoferrin alfa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1099776","Tenofovir Disoproxil Fumarate","C47747","A pro-drug, fumaric acid salt form of tenofovir, a nucleoside reverse transcriptase inhibitor analog of adenosine. Tenofovir disoproxil fumarate is prescribed to treat HIV and chronic hepatitis B virus (HBV) in adults.","Tenofovir Disoproxil Fumarate | 9-((R)-2-((Bis(((isopropoxycarbonyl)oxy)methoxy)phosphinyl)methoxy)propyl)adenine, Fumarate | PMPA Prodrug | TDF | TENOFOVIR DISOPROXIL FUMARATE | Tenofovir DF | Viread",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039677","Tetrahydrouridine","C868","A synthetic pyrimidine nucleoside analogue with biomodulating activity. Tetrahydrouridine increases the efficacy of the radiosensitizer cytochlor (5-chloro-2'-deoxycytidine) by inhibiting the enzyme deoxycytidine monophosphate (dCMP) deaminase and preventing the premature deamination of the cytochlor metabolite 5-chloro-2'-deoxycytidine monophosphate (CldCMP) to 5-chloro-2'-deoxyuridine monophosphate (CldUMP); in turn, this increases tumor concentrations of CldUMP which is then further anabolized and incorporated selectively into tumor DNA as CldU (5-chloro-2'-deoxyuridine). (NCI04)","Tetrahydrouridine | 2(1H)-pyrimidinone, tetrahydro-4-hydroxy-1-beta-D-ribofuranosyl- | TETRAHYDROURIDINE | THU | tetrahydrouridine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0663733","Tipranavir","C66603","A non-peptidomimetic agent that inhibits both wild type and drug resistant forms of human immunodeficiency virus (HIV) protease.","Tipranavir | TIPRANAVIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2587204","Recombinant Thyrotropin Alfa","C61322","A recombinant form of the human anterior pituitary glycoprotein thyroid stimulating hormone (TSH) with use in the diagnostic setting. With an amino acid sequence identical to that of human TSH, thyrotropin alfa binds to TSH receptors on normal thyroid epithelial cells or well-differentiated thyroid cancer cells, stimulating iodine uptake and organification, synthesis and secretion of thyroglobulin (Tg), triiodothyronine (T3), and thyroxine (T4).","Recombinant Thyrotropin Alfa | Recombinant TSH Alpha | Recombinant Thyrotropin Alpha | THYROTROPIN ALFA | TSH-alpha | Thyrogen | Thyroid Stimulating Hormone Alpha | Thyrotropin Alfa | thyrotropin alfa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0388828","Sialyl Tn-KLH Vaccine","C1690","A vaccine containing a pancarcinoma carbohydrate antigen conjugated with keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Sialylated Tn antigen (sTn) is a monosaccharide glycan usually O-linked to serine or threonine residues of mucins found on most epithelial cancers. Conjugation with KLH, a hapten carrier and an immunostimulant, improves host immune responses. Vaccination with sTn-KLH vaccine may produce antibodies and elicit a cytotoxic T lymphocyte (CTL) response against those tumor cells expressing sTn, resulting in decreased tumor growth.","Sialyl Tn-KLH Vaccine | STn-KLH Vaccine | Sialyl Tn-KLH | Theratope | Theratope STn-KLH Vaccine | Theratope Vaccine | Theratope siayl-Tn-KLH vaccine | sialyl Tn-KLH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0076339","Tiomolibdate Diammonium","C74001","An ammonium salt with potential antiangiogenic and antitumor activities. Tetrathiomolybdate has been found to deplete systemic copper reserves through an unknown mechanism. This agent has been shown to inhibit the activities of cuproenzymes, including superoxide dismutase 1 (SOD1) and cytochrome c oxidase (COX), which may contribute to its antiangiogenic and antitumor effects.","Tiomolibdate Diammonium | ATTM | Ammonium Molybdenum Sulfide | Ammonium Tetrathiomolybdate | Ammonium Tetrathiomolybdate | Coprexa | Diammonium Tetrathiomolybdate | Molybdate(2-), Tetrathioxo-, Ammonium (1:2), (T-4)- | Molybdate(2-), Tetrathioxo-, Diammonium, (T-4)- | TIOMOLIBDATE DIAMMONIUM | ammonium tetrathiomolybdate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0077681","7-Hydroxystaurosporine","C1271","A synthetic derivative of staurosporine with antineoplastic activity. 7-hydroxystaurosporine inhibits many phosphokinases, including the serine/threonine kinase AKT, calcium-dependent protein kinase C, and cyclin-dependent kinases. This agent arrests tumor cells in the G1/S of the cell cycle and prevents nucleotide excision repair by inhibiting the G2 checkpoint kinase chk1, resulting in apoptosis. (NCI04)","7-Hydroxystaurosporine | (+)-UCN-01 | 2,3,9,10,11,12-Hexahydro-3-hydroxy-9-methoxy-8-methyl-10-(methylamino)-8,12-epoxy-1H,8H-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)triinden-1-one | 7-HYDROXYSTAUROSPORINE | 7-Hydroxy-staurosporine | 8,12-Epoxy-1H,8H-2,7b,12a-triazadibenzo[a, g]cyclonona[cde] Trinden-1-one, 2,3,9,10,11, 12-hexahydro-3-hydroxy-9-methoxy-8-methyl-10-(methylamino) | UCN-01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0077209","Trimetrexate Glucuronate","C1265","A lipid soluble methotrexate derivative with potential antineoplastic activity.  Trimetrexate glucuronate inhibits the enzyme dihydrofolate reductase, thereby preventing the synthesis of purine nucleotides and thymidylate, with subsequent inhibition of DNA and RNA synthesis.  Trimetrexate glucuronate also exhibits antiviral activity. (NCI04)","Trimetrexate Glucuronate | 2,4-Diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline mono-D-glucuronate | Neutrexin | TMTX | TRIMETREXATE GLUCURONATE | trimetrexate glucuronate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796529","Trastuzumab/Gemcitabine","C37808","A regimen consisting of gemcitabine and trastuzumab that may be used in the treatment of human epidermal growth factor receptor 2 (HER2)-positive recurrent or metastatic breast cancer.","Gemcitabine/Trastuzumab Regimen | Gemcitabine and Trastuzumab | Gemcitabine and Trastuzumab-anns | Gemcitabine and Trastuzumab-dkst | Gemcitabine and Trastuzumab-dttb | Gemcitabine and Trastuzumab-herw | Gemcitabine and Trastuzumab-pkrb | Gemcitabine and Trastuzumab-qyyp | Gemcitabine and Trastuzumab-strf | Gemcitabine and Trastuzumab-zerc | Gemcitabine-Trastuzumab | Gemcitabine-Trastuzumab Regimen | Gemcitabine/Trastuzumab | Gemzar/Herceptin | Trastuzumab/Gemcitabine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0935819","Trastuzumab/Vinorelbine","C11959","No Value Exists","Trastuzumab/Vinorelbine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1311070","Trabectedin","C1691","A tetrahydroisoquinoline alkaloid isolated from the marine tunicate Ecteinascidia turbinata with potential antineoplastic activity. Binding to the minor groove of DNA, trabectedin interferes with the transcription-coupled nucleotide excision repair machinery to induce lethal DNA strand breaks and blocks the cell cycle in the G2 phase.","Trabectedin | ET 743 | ET-743 | ET743 | Ecteinascidin | Ecteinascidin 743 | Spiro(6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo(7,8)isoquino(3,2,-b)(3)benzazocine-20,1'(2'H)-isoquinolin)-19-one, 3',4',6,6a,7,13,14,16-Octahydro-5-(acetyloxy)-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-, (6R-(6-alpha,6a-beta,7-beta,13-beta,14-beta,16-alpha,20R*))- | TRABECTEDIN | Yondelis | ecteinascidin 743 | trabectedin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516984","Etoposide/Prednisone/Vinblastine","C29542","A combination of agents containing etoposide, prednisone and vinblastine.","Etoposide/Prednisone/Vinblastine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054889","cyclophosphamide/doxorubicin/vincristine protocol","C9540","A chemotherapy combination consisting of cyclophosphamide, doxorubicin, and vincristine.","Cyclophosphamide/Doxorubicin/Vincristine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0564461","Ultraviolet B Radiation","C27987","Ultraviolet B Radiation is the 290 to 320 nanometers portion of the sun's radiant electromagnetic energy spectrum, partially absorbed by the Earth's protective stratospheric ozone layer. Recent ozone depletion has permitted more UVB to reach the Earth's surface with a wide range of potentially damaging health effects related to skin, eyes, and immune system. Evidence shows a dose-response relationship between nonmelanoma skin cancer and cumulative exposure to UVB radiation. (NCI04)","Ultraviolet B Radiation | UVB | UVB Radiation | UVB radiation | Ultraviolet-B Radiation | ultraviolet B radiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3665674","Warburg Therapy","C29545","The cornerstone of oxygenation therapy is the presumption that human disease, including cancer, is caused by a deficit of tissue oxygen. According to proponents, hypoxia results in anaerobic fermentation, a loss of capacity for oxidative detoxification of toxins and metabolic products, and failure of immune killing of invading bacteria and viruses. To restore ability to carry out these functions, oxygenation promoters propose using chemicals they claim will release oxygen in tissue or act as germicides in vivo.","Warburg Therapy | Oxygen Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0672708","Vorinostat","C1796","A synthetic hydroxamic acid derivative with antineoplastic activity. Vorinostat, a second generation polar-planar compound, binds to the catalytic domain of the histone deacetylases (HDACs). This allows the hydroxamic moiety to chelate zinc ion located in the catalytic pockets of HDAC, thereby inhibiting deacetylation and leading to an accumulation of both hyperacetylated histones and transcription factors. Hyperacetylation of histone proteins results in the upregulation of the cyclin-dependant kinase p21, followed by G1 arrest. Hyperacetylation of non-histone proteins such as tumor suppressor p53, alpha tubulin, and heat-shock protein 90 produces additional anti-proliferative effects. This agent also induces apoptosis and sensitizes tumor cells to cell death processes. Vorinostat crosses the blood-brain barrier.","Vorinostat | L-001079038 | MSK-390 | N-Hydroxy-N'-phenyloctanediamide | SAHA | Suberanilohydroxamic Acid | Suberoylanilide Hydroxamic Acid | VORINOSTAT | Zolinza | suberoylanilide hydroxamic acid | vorinostat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879622","Salmonella VNP20009","C2556","A genetically stable Salmonella typhimurium strain, attenuated by chromosomal deletion of the purI and msbB genes, with tumor-targeting activity. In rodent models, salmonella VNP20009 has been shown to selectively accumulate and grow in a variety of tumor types, inhibiting the growth of primary and metastatic tumors. This agent may be genetically engineered to contain transgenes that express therapeutic agents or cell surface tumor-associated antigen-specific antibodies, such as CEA-specific antibodies, which may improve its tumor targeting and therapeutic potential.","Salmonella VNP20009 | Auxotrophic Lipid A S. Typhimurium mutant | Live, Attenuated Salmonella Typhimurium | VNP 20009 | VNP20009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1872226","Pazopanib Hydrochloride","C60779","The hydrochloride salt of a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.","Pazopanib Hydrochloride | 5-((4-((2,3-Dimethyl-2h-Indazol-6-Yl)Methylamino)Pyrimidin-2-yl)Amino)-2-Methylbenzenesulfonamide Monohydrochloride | GW 786034B | GW-786034B | GW786034B | PAZOPANIB HYDROCHLORIDE | Pazopater | Votrient | pazopanib hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0077975","VAD regimen (Cytarabine, Dexamethasone and Vincristine)","C63498","A regimen consisting of vincristine, doxorubicin and dexamethasone used as induction treatment for plasma cell myeloma and Wilms tumor.","VAD Regimen | VAD | Vincristine-Adriamycin-Dexamethasone Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0075860","doxorubicin/fluoxymesterone/thiotepa/vinblastine","C9638","A regimen consisting of fluoxymesterone, thiotepa, doxorubicin, and vinblastine that may be used in the treatment of advanced breast cancer.","VATH Regimen | DOX/FXM/TSPA/VBL | Doxorubicin/Fluoxymesterone/Thiotepa/Vinblastine | Doxorubicin/Fluoxymesterone/Thiotepa/Vinblastine | Doxorubicin/Fluoxymesterone/Thiotepa/Vinblastine Regimen | TsAVbH | VATH | Vinblastine-Doxorubicin-Thiotepa-Fluoxymesterone | Vinblastine/Adriamycin/Thiotepa/Halotestin | Vinblastine/Doxorubicin/Thiotepa/Fluoxymesterone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0303596","Yttrium Y-90","C1641","Radioactive isotope of yttrium.  A beta/gamma-emitter with a half life of 2.7 days.","Yttrium Y-90 | Y-90 | YTTRIUM Y-90 | Yttrium 90 | Yttrium 90 | yttrium Y 90",,,,,,,,,,,,,,,"4033097","Yttrium-90",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2830054","Folate Receptor-Targeted Vinca Alkaloid EC0489","C81935","A folate receptor-targeting cytotoxic drug conjugate consisting of a folate vitamin analogue linked to a vinca alkaloid microtubule destabilizing agent with potential antineoplastic activity. Mediated through its folate moiety, folate receptor-targeted vinca alkaloid EC0489 delivers the cytotoxic vinca alkaloid moiety directly to cells expressing folic acid receptors, frequently upregulated in many types of tumor cells. After ligand-receptor internalization, the vinca alkaloid moiety binds to tubulin and disrupts microtubule assembly-disassembly dynamics, resulting in cell cycle arrest and apoptosis. The relative tumor cell specificity of this agent reduces the toxicity profile of its vinca alkaloid moiety.","Folate Receptor-Targeted Vinca Alkaloid EC0489 | EC0489",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0771309","Valacyclovir Hydrochloride","C29535","The hydrochloride salt of valacyclovir. Valacyclovir is an acyclovir prodrug that, after metabolization, inhibits viral DNA replication. It is used in the management of herpes simplex and varicella zoster infections, as well as prophylactically for human cytomegalovirus infections.","Valacyclovir Hydrochloride | 256U87 Hydrochloride | BW 256U | BW-256U87 | BW256U | L-Valine ester with 9-((2-hydroxyethoxy)methyl)guanine Hydrochloride | VALACYCLOVIR HYDROCHLORIDE | Valaciclovir HCl | Valtrex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042216","Vaccinia Virus","C14281","DNA viruses used in several biotechnology applications, including expression vector systems.","Vaccinia Virus | VACCINIA VIRUS | VV | Vaccinia",,,,,,,,,,,,,,,"4027500","Vaccinia virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1515621","gp-120 Antigen","C29554","A recombinant HIV gp120 envelope protein with potential use in HIV vaccine therapy. Gp-120 antigen is used to elicit a gp120-specific T-cell response. (NCI04)","gp-120 Antigen | gp-120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677808","ERB-38 Immunotoxin","C2453","A bivalent fusion protein consisting of disulfide-stabilized Fv fragments of an anti-HER2 (erbB2) monoclonal antibody (e23) and a truncated version of the M(r) 38 fragment of Pseudomonas exotoxin that lacks the toxin's cell binding domain. ERB-38 immunotoxin binds specifically to cells that overexpress HER2, the antigenic target of the monoclonal antibody; the exotoxin portion of the immunotoxin then lyses the cells bound by the antibody portion. (NCI04)","ERB-38 Immunotoxin | Erb-38 | erb-38 immunotoxin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1384659","Vandetanib","C2737","An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis.","Vandetanib | AZD 6474 | AZD-6474 | AZD6474 | Caprelsa | Lucivand | VANDETANIB | ZD-6474 | ZD6474 | Zactima | vandetanib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3275017","Problem with Teeth, Denture or Mouth","C99880","A question about whether an individual has or had problems with their teeth, denture or mouth.","Problem with Teeth, Denture or Mouth | Have you had a problem with teeth denture or mouth | Problem with Teeth Denture or Mouth | Problem with Teeth Denture or Mouth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3275018","Trouble Pronouncing Words due to Problem with Teeth, Denture or Mouth","C99881","A question about whether an individual has or had trouble pronouncing words due to problems with their teeth, denture or mouth.","Trouble Pronouncing Words due to Problem with Teeth, Denture or Mouth | Because of problems with your teeth, denture or mouth have you had trouble pronouncing words | Had Trouble Pronouncing Words | Had Trouble Pronouncing Words",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3275019","Feel Sense of Taste has Worsened","C99882","A question about whether an individual feels or felt their sense of taste has worsened.","Feel Sense of Taste has Worsened | Because of problems with your teeth, denture or mouth have you felt sense of taste has worsened | Felt Sense of Taste has Worsened | Felt Sense of Taste has Worsened",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3275020","Painful Ache in Mouth due Problem with Teeth, Denture or Mouth","C99883","A question about whether an individual has or had a painful ache in their mouth due to problems with teeth, denture or mouth.","Painful Ache in Mouth due Problem with Teeth, Denture or Mouth | Because of problems with your teeth, denture or mouth have you had painful aching in the mouth | Had Painful Aching in the Mouth | Had Painful Aching in the Mouth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3275021","Uncomfortable Eating Food due to Problem with Teeth, Denture or Mouth","C99884","A question about whether a person finds or has found it uncomfortable to eat any foods because of problems with their teeth, denture or mouth.","Uncomfortable Eating Food due to Problem with Teeth, Denture or Mouth | Because of problems with your teeth, denture or mouth have you found it uncomfortable to eat any foods | Found it Uncomfortable to Eat Any Foods | Found it Uncomfortable to Eat Any Foods",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3275022","Self-Conscious due to Problems with Teeth, Dentures or Mouth","C99885","A question about whether an individual is or has been self-conscious of problems with their teeth, dentures or mouth.","Self-Conscious due to Problems with Teeth, Dentures or Mouth | Because of problems with your teeth, denture or mouth have you have been self-conscious | Have Been Self-Conscious | Have Been Self-Conscious",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3463816","Feel Tense due to Mouth Problems","C99886","A question about whether an individual feels or felt tense.","Feel Tense due to Mouth Problems | Because of problems with your teeth, denture or mouth have you felt tense | Felt Tense | Felt Tense",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3275023","Unsatisfactory Diet due to Problem with Teeth, Denture or Mouth","C99887","A question about whether an individual has or had an unsatisfactory diet due to problems with teeth, denture or mouth.","Unsatisfactory Diet due to Problem with Teeth, Denture or Mouth | Because of problems with your teeth, denture or mouth have you had an unsatisfactory diet | Had an Unsatisfactory Diet | Had an Unsatisfactory Diet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3275024","Meal Interruptions due to Problems with Teeth, Denture or Mouth","C99888","A question about whether an individual has or had meal interruptions due to problems with their teeth, denture or mouth.","Meal Interruptions due to Problems with Teeth, Denture or Mouth | Because of problems with your teeth, denture or mouth have you had to interrupt meals | Had to Interrupt Meals | Had to Interrupt Meals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3275025","Difficulty Relaxing due to Problem with Teeth, Denture or Mouth","C99889","A question about whether an individual finds or has found it difficult to relax because of problems with their teeth, denture or mouth.","Difficulty Relaxing due to Problem with Teeth, Denture or Mouth | Because of problems with your teeth, denture or mouth have you found it difficult to relax | Found it Difficult to Relax | Found it Difficult to Relax",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3275026","Have Embarrassment due to Problem with Teeth, Denture or Mouth","C99890","A question about whether an individual has or had embarrassment due to problems with their teeth, denture or mouth.","Have Embarrassment due to Problem with Teeth, Denture or Mouth | Because of problems with your teeth, denture or mouth have you been a bit embarrassed | Have Been a Bit Embarrassed | Have Been a Bit Embarrassed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3275027","Irritable with Other People due to Problems with Teeth, Dentures or Mouth","C99891","A question about whether an individual is or has been irritable with other people due to problems with their teeth, dentures or mouth.","Irritable with Other People due to Problems with Teeth, Dentures or Mouth | Because of problems with your teeth, denture or mouth have you been irritable with other people | Have Been Irritable with Other People | Have Been Irritable with Other People",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3275028","Difficulty Doing Usual Jobs due to Problem with Teeth, Denture or Mouth","C99892","A question whether an individual has or had difficulty doing their usual jobs due to problem with their teeth, denture or mouth.","Difficulty Doing Usual Jobs due to Problem with Teeth, Denture or Mouth | Because of problems with your teeth, denture or mouth have you had difficulty doing usual jobs | Had Difficulty Doing Usual Jobs | Had Difficulty Doing Usual Jobs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3275029","Feel Life in General was Less Satisfying","C99893","A question about whether an individual feels or felt that life in general is less satisfying.","Feel Life in General was Less Satisfying | Because of problems with your teeth, denture or mouth have you felt life in general was less satisfying | Felt Life in General was Less Satisfying | Felt Life in General was Less Satisfying",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3275030","Unable to Function due to Problems with Teeth, Dentures or Mouth","C99894","A question about whether an individual is or has been unable to function due to problems with teeth, dentures or mouth.","Unable to Function due to Problems with Teeth, Dentures or Mouth Question | Because of problems with your teeth, denture or mouth have you been totally unable to function | Have Been Totally Unable to Function | Have Been Totally Unable to Function | Unable to Function due to Problems with Teeth, Dentures or Mouth | Unable to Function due to Problems with Teeth, Dentures or Mouth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3275031","Hardly Ever","C99895","Seldom; rarely; almost never.","Hardly Ever | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079885","MYCN protein, human","C17379","N-myc proto-oncogene protein (464 aa, ~50 kDa) is encoded by the human MYCN gene. This protein plays a role in the regulation of transcription and DNA binding.","N-Myc Proto-Oncogene Protein | Class E Basic Helix-Loop-Helix Protein 37 | MYCN | MYCN Protein | N-Myc Protein | NMYC | NMYC Gene Product | Neuroblastoma MYC | bHLHe37",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1530798","BAD protein, human","C21191","Bcl2 antagonist of cell death (168 aa, ~18 kDa) is encoded by the human BAD gene. This protein is involved in the mediation of apoptosis.","Bcl2 Antagonist of Cell Death | BAD | BAD Protein | BCL-X/BCL-2 Binding Protein | BCL2-Antagonist of Cell Death | BCL2-Binding Component 6 | BCL2-Binding Protein | Bcl-2-Like Protein 8 | Bcl-XL/Bcl-2-Associated Death Promoter | Bcl2-L-8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882417","Polymorphism","C61384","The quality or state of being able to assume different forms.","Polymorphism | Polymorphic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3486709","brain-derived neurotrophic factor, human","C20445","Brain-derived neurotrophic factor (247 aa, ~28 kDa) is encoded by the human BDNF gene. This protein plays a role in both the development of the nervous system and neuronal survival.","Brain-Derived Neurotrophic Factor | Abrineurin | BDNF | Brain Derived Neurotrophic Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985164","Serine/Threonine-Protein Phosphatase 2A 65 kDa Regulatory Subunit A Alpha Isoform","C92538","Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform (589 aa, ~65 kDa) is encoded by the human PPP2R1A gene. This protein is involved in the regulation of protein phosphatase 2A complex assembly.","Serine/Threonine-Protein Phosphatase 2A 65 kDa Regulatory Subunit A Alpha Isoform | Medium Tumor Antigen-Associated 61 kDa Protein | PP2A Subunit A Isoform PR65-Alpha | PP2A Subunit A Isoform R1-Alpha | PPP2R1A | Testicular Secretory Protein Li 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0059249","Annexin A5","C21333","Annexin A5 (320 aa, ~36 kDa) is encoded by the human ANXA5 gene. This protein plays a role in the inhibition of blood coagulation and the transmembrane transport of calcium.","Annexin A5 | ANNEXIN A5 | ANXA5 | Anchorin CII | Annexin A5 Protein | Annexin V | Annexin-5 | CBP-I | Calphobindin I | Endonexin II | Lipocortin V | PAP-I | PP4 | Placental Anticoagulant Protein 4 | Placental Anticoagulant Protein I | Placental Protein 4 | Thromboplastin Inhibitor | VAC-Alpha | Vascular Anticoagulant-Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1437911","TRAF3 protein, human","C96379","TNF receptor-associated factor 3 (568 aa, ~64 kDa) is encoded by the human TRAF3 gene. This protein is involved in the induction of apoptosis and signaling.","TNF Receptor-Associated Factor 3 | CAP-1 | CD40 Associated Protein 1 | CD40 Binding Protein | CD40 Receptor Associated Factor 1 | CD40 Receptor-Associated Factor 1 | CD40-Associated Protein 1 | CD40-Binding Protein | CD40BP | CRAF1 | EC 2.3.2.27 | LAP1 | LMP1-Associated Protein 1 | LMP1-associated protein 1 | RING-Type E3 Ubiquitin Transferase TRAF3 | TRAF3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2933084","ADA protein, human","C16261","Adenosine deaminase (363 aa, ~41 kDa) is encoded by the human ADA gene. This protein plays a role in purine metabolism.","Adenosine Deaminase | ADA | Adenine Deaminase | Adenosine Aminohydrolase | EC 3.5.4.4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005064","Benzodiazepine","C1012","Drugs from this chemical class are used for their central nervous system depressant properties including sedation, facilitation of sleep, seizure control, general anesthesia, anxiolytic, amnestic, and for detoxification from similar (cross tolerant) drugs","Benzodiazepine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985400","Serum Tumor Marker Test","C93025","A laboratory test in which a monoclonal antibody is used to detect a tumor-specific marker in a blood sample.","Serum Tumor Marker Test | serum tumor marker test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279738","Salivary Gland Acinic Cell Carcinoma","C8013","A carcinoma of the salivary gland characterized by serous acinar cell differentiation.  The vast majority of cases occur in the parotid gland.  It usually presents as a slowly enlarging mass.  A minority of patients experience pain.  It may recur or metastasize.  Multiple recurrences and metastasis to cervical lymph nodes are usually associated with a poor prognosis.","Salivary Gland Acinic Cell Carcinoma | Acinic Cell Carcinoma of Salivary Gland | Acinic Cell Carcinoma of the Salivary Gland | Acinic Cell Neoplasm of Salivary Gland | Acinic Cell Neoplasm of the Salivary Gland | Acinic Cell Tumor of Salivary Gland | Acinic Cell Tumor of the Salivary Gland | Salivary Gland Acinic Cell Cancer | Salivary Gland Acinic Cell Neoplasm | Salivary Gland Acinic Cell Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042874","Vitamin E","C942","A natural fat-soluble antioxidant with potential chemopreventive activity. Also known as tocopherol, vitamin E ameliorates free-radical damage to biological membranes, protecting polyunsaturated fatty acids (PUFA) within membrane phospholipids and within circulating lipoproteins. Peroxyl radicals react 1000-fold faster with vitamin E than with PUFA.  In the case of oxygen free radical-mediated tumorigenesis, vitamin E may be chemopreventive. (NCI04)","Vitamin E Compound | 2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)chroman-6-ol | 3,4-Dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-ol | 5,7,8-Trimethyltocol | E Vitamin | Vitamin E | vitamin E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417664","NEDD9 Gene","C71006","This gene is involved in the modulation of signal pathways induced by cellular adhesion.","NEDD9 Gene | NEDD9 | Neural Precursor Cell Expressed, Developmentally Down-Regulated 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332379","BAK1 Gene","C20413","This gene is involved in the regulation of apoptosis by inhibiting cell death.","BAK1 Gene | BAK1 | BCL2-Antagonist/Killer 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0057338","Fatty Acid Desaturase 1","C82861","Fatty acid desaturase 1 (444 aa, ~52 kDa) is encoded by the human FADS1 gene. This protein plays a role in catalyzing saturation and desaturation of fatty acids.","Fatty Acid Desaturase 1 | D5D | Delta(5) Desaturase | Delta(5) Fatty Acid Desaturase | EC 1.14.19.- | EC1.14.19.- | FADS1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0134982","SYK protein, human","C18169","Tyrosine-protein kinase SYK (635 aa, ~72 kDa) is encoded by the human SYK gene. This protein plays a role in tyrosine phosphorylation, receptor signaling and B- and T-cell differentiation.","Tyrosine-Protein Kinase SYK | 2.7.1.112 | EC 2.7.10.2 | PTK72 | PTK72 Protein | Protein-Tyrosine Kinase SYK | SYK | Spleen Tyrosine Kinase | Spleen Tyrosine Kinase | p72-Syk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0380051","stress-activated protein kinase 1","C17780","Mitogen-activated protein kinase 8 (427 aa, ~48 kDa) is encoded by the human MAPK8 gene. This protein plays a role in serine/threonine phosphorylation, apoptosis and toll-like receptor signaling.","Mitogen-Activated Protein Kinase 8 | EC 2.7.11.24 | JN Kinase | JNK1 Protein | MAP Kinase 8 | MAP Kinase 8 | MAPK 8 | MAPK8 | SAPK/JNK | SAPK1 | SAPK1/JNK | SAPK1c | Stress-Activated Protein Kinase 1 | Stress-Activated Protein Kinase 1c | Stress-Activated Protein Kinase JNK1 | c-JUN N-Terminal Kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0518895","Neurocognitive","C94321","Having to do with the ability to think and reason. This includes the ability to concentrate, remember things, process information, learn, speak, and understand.","Neurocognitive | neurocognitive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032207","Platinum","C756","An element with atomic symbol Pt, atomic number 78, and atomic weight 195.09.","Platinum | C.I. 77795 | PLATINUM | Platinum Metallicum | Pt | platinum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540007","Bifocal","C100090","Arising from, pertaining to, or having two locations.","Bifocal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272292","Secure File Transfer Protocol","C100048","A network protocol designed to move files securely between a computer and a host over a TCP network, such as the Internet.","Secure File Transfer Protocol | sFTP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272293","Transfer Of Images And Data","C100049","Application software written to allow the submission and download of images and data.","Transfer Of Images And Data | TRIAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037943","Lumbar Puncture","C15327","An invasive procedure in which a hollow needle is introduced through an intervertebral space in the lower back to access the subarachnoid space in order to sample cerebrospinal fluid or to administer medication.","Lumbar Puncture | LP | Spinal Tap | lumbar puncture | spinal tap",,,,,,,,,,,,,,,"4080549","Lumbar puncture",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3805686","Ridge","C61549","Any long raised border or margin of a bone or tooth or membrane.","Ridge | ",,,,,,,,,,,,,,,"4097382","Ridging",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003662","Aqueous Humor","C13190","The watery fluid which is present in the anterior and posterior chambers of the eye.","Aqueous Humor | AQUEOUS HUMOR | Aqueous Fluid | Aqueous Humour | EYE, AQUEOUS HUMOR | aqueous humor | aqueous humor of eyeball | aqueous humour | humor aquosus",,,,,,,,,,,,,"UBERON:0001796","aqueous humor of eyeball","4143091|4337386","Aqueous humor|Structure of aqueous humor",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0006205","Broad Ligament","C12318","A wide fold of peritoneum that connects the uterus to the lateral walls and floor of the pelvis, and contains the ovaries, fallopian tubes, ovarian ligaments, round ligament of the uterus, and ovarian and uterine arteries.","Broad Ligament | BROAD LIGAMENT | Broad ligament | Lateral Ligament | broad ligament of uterus | broad uterine ligament",,,,,,,,,,,,,"UBERON:0012332","broad ligament of uterus","4142361","Broad ligament structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008114","Mentum","C81169","The part of the face below the lower lip and including the protruding part of the lower jaw.","Mentum | CHIN | Chin | chin | mental part of face | mental region | mental region of face | regio mentalis",,,,,,,,,,,,,"UBERON:0008199","chin","4147228","Chin structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0917710","Hepatic Duct","C32730","Any of the three ducts associated with the liver including the right hepatic duct, left hepatic duct and common hepatic duct.","Hepatic Duct | hepatic duct","C24.0|C24.0","Hepatic bile duct|Hepatic duct",,,,,,,,,,,"UBERON:0005171","hepatic duct","4209734","Structure of hepatic duct",,,,,,,,,,,,,"--","--|--",,,,,,,,"--"
"C0687028","Duct","C12948","A tube that carries various secretions from one part of the body to another.","Duct | DUCT | duct",,,,,,,,,,,,,,,"4222517","Duct (organ) structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002260","Eflornithine","C226","A difluoromethylated ornithine compound with antineoplastic activity.  Eflornithine irreversibly inhibits ornithine decarboxylase, an enzyme required for polyamine biosynthesis, thereby inhibiting the formation and proliferation of tumor cells. Polyamines are involved in nucleosome oligomerization and DNA conformation, creating a chromatin environment that stimulates neoplastic transformation of cells. This agent has been shown to induce apoptosis in leiomyoma cells. (NCI04)","Eflornithine | 2-(Difluoromethyl)-DL-ornithine | 2-Difluoromethylornithine | Alpha-Difluoromethylornithine | D,L-alpha-Difluoromethylornithine | DFMO | Difluoromethylornithine | Difluromethylornithine | EFLORNITHINE | difluoromethylornithine | eflornithine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229744","Scalene Lymph Node","C89780","A lymph node located in proximity to any of the scalene muscles.","Scalene Lymph Node | Inferior Deep Cervical Lymph Node | Lymph Node(s) Scalene | SCALENE LYMPH NODE",,,,,,,,,,,,,,,"4217305","Structure of scalene lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2987379","Merestinib","C95729","An orally available, small molecule inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Merestinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. This agent has potent anti-tumor efficacy in mono and combination therapy in a broad range of cancers. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","Merestinib | 3-Pyridinecarboxamide, N-(3-fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-1,2-dihydro-6-methyl-2-oxo- | LY-2801653 | LY2801653 | MERESTINIB | c-Met Inhibitor LY2801653",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3241921","Round Ligament","C12319","Any of the round ligaments including the round ligament of the liver and the round ligament of the uterus.","Round Ligament | ROUND LIGAMENT | Round ligament",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1682317","Tumor Necrosis Factor Ligand Superfamily Member 13B, Human","C94789","Tumor necrosis factor ligand superfamily member 13B (285 aa, ~31 kDa) is encoded by the human TNFSF13B gene. This protein is involved in signal transduction and the modulation of B- and T-cell proliferation.","Tumor Necrosis Factor Ligand Superfamily Member 13B | Antigen CD257 | B Lymphocyte Stimulator | B-Cell-Activating Factor | B-Lymphocyte Stimulator | BAFF | BLyS | CD257 | CD257 Antigen | Dendritic Cell-Derived TNF-Like Molecule | TALL-1 | TNF Homolog That Activates Apoptosis, NKFB, and JNK | TNF- and APOL-Related Leukocyte Expressed Ligand 1 | TNFSF13B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521598","Dietary Intervention","C15447","Any alteration or treatment in an individual's diet with a planned goal, usually designed to improve the individual's overall health.","Dietary Intervention | Dietary Modification | Nutrition Intervention | Nutrition Interventions | Nutritional Interventions | intervention, dietary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443248","Lichenoid","C100095","Having the characteristics of a chronic, recurrent, pruritic inflammatory disorder of unknown etiology that affects the skin and mucus membranes. It presents with rashes and papules that tend to resolve spontaneously. It may be associated with hepatitis C. Certain drugs that contain arsenic or bismuth are associated with reactions mimicking lichen planus.","Lichenoid | ",,,,,,,,,,,,,,,"4137815","Lichenoid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3639090","Oral Mucositis Rating Scale","C100096","A research tool used to assess inflammation in the mouth and classification of oral changes after bone marrow transplant and chronic graft versus host disease.","Oral Mucositis Rating Scale | OMRS | ORMS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3809745","Hyperkeratosis","C35541","Hypertrophy of the outermost layer of the epidermis. It may be caused by physical or chemical irritants, irradiation, infection, or neoplastic processes.","Hyperkeratosis | HYPERKERATOSIS | Increased Keratinization | hyperkeratosis",,,,,,,,,,,,,,,"4098436","Hyperkeratosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0344353","Vegan Diet","C15630","A type of vegetarian diet that excludes all animal products, including dairy, eggs, meat, poultry, fish, and animal fats.","Vegan Diet | ",,,,,,,,,,,,,,,"37153968","Vegan diet",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2986820","Scanner Patient Bed Position","C94978","A designated location of the bed as it is moved through the scanner for purposes of positioning a desired part of the subject in the field of view.","Scanner Patient Bed Position | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026639","Oral Mucosa","C77637","Moist tissue lining the oral cavity, containing mucous secreting glands.","Oral Mucosa | MUCOSA, ORAL | ORAL MUCOSA | mouth mucosa | mouth mucous membrane | mouth organ mucosa | mucosa of mouth | mucous membrane of mouth | oral mucous membrane | oral part of viscerocranial mucosa | tunica mucosa oris",,,,,,,,,,,,,"UBERON:0003729","mouth mucosa","4034271","Oral mucous membrane structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL505186","Perfusion Magnetic Resonance Imaging","C93243","A diagnostic procedure to assess the circulatory perfusion of an anatomical location using a magnetic resonance imaging machine.","Perfusion Magnetic Resonance Imaging | PERFUSION MRI | Perfusion Sequence | magnetic resonance perfusion imaging | perfusion magnetic resonance imaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281361","Pancreatic Adenocarcinoma","C8294","An adenocarcinoma which arises from the exocrine pancreas.  Ductal adenocarcinoma and its variants are the most common types of pancreatic adenocarcinoma.","Pancreatic Adenocarcinoma | Adenocarcinoma - pancreas | Adenocarcinoma of Pancreas | Adenocarcinoma of the Pancreas | Adenocarcinoma of the pancreas | Pancreas Adenocarcinoma",,,,,,,,,,,,,,,"45763891","Adenocarcinoma of pancreas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1336861","Undifferentiated Carcinoma of the Pancreas","C5722","A carcinoma that arises from the pancreas and is characterized by the presence of malignant cells that do not show differentiation. The prognosis is poor.","Pancreatic Undifferentiated Carcinoma | Pancreatic Carcinosarcoma | Pleomorphic Large Cell Pancreatic Carcinoma | Sarcomatoid Pancreatic Carcinoma | Spindle Cell Pancreatic Carcinoma | Undifferentiated (Anaplastic) Pancreatic Carcinoma | Undifferentiated Carcinoma of Pancreas | Undifferentiated Carcinoma of the Pancreas | Undifferentiated Pancreatic Carcinoma | Undifferentiated Pancreatic Carcinoma | Undifferentiated carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335317","Pancreatic Signet Ring Cell Carcinoma","C5720","A rare pancreatic ductal adenocarcinoma with poor prognosis.  It is characterized by the presence of malignant signet ring cells infiltrating the pancreatic parenchyma in an individual cell pattern.","Pancreatic Signet Ring Cell Adenocarcinoma | Pancreatic Signet Ring Cell Carcinoma | Pancreatic Signet Ring Cell Carcinoma | Pancreatic Signet-Ring Cell Carcinoma | Signet Ring Cell Carcinoma of Pancreas | Signet Ring Cell Carcinoma of the Pancreas | Signet ring cell carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987166","Pancreatic Medullary Carcinoma","C95466","A pancreatic ductal adenocarcinoma characterized by poor differentiation and a prominent syncytial growth pattern.  The prognosis is more favorable compared to conventional pancreatic ductal adenocarcinoma.","Pancreatic Medullary Carcinoma | Medullary carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987165","Pancreatic Hepatoid Adenocarcinoma","C95465","A rare adenocarcinoma that arises from the pancreas.  It is characterized by marked hepatocellular differentiation.","Pancreatic Hepatoid Adenocarcinoma | Hepatoid carcinoma | Pancreatic Hepatoid Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0771211","Tropisetron Hydrochloride","C95284","The hydrochloride salt form of tropisetron, a selective, competitive serotonin 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist, with antinauseant and antiemetic activities. Tropisetron competitively binds to and blocks the action of serotonin at 5HT3 receptors peripherally on vagus nerve terminals located in the gastrointestinal (GI) tract as well as centrally in the chemoreceptor trigger zone (CTZ) of the area postrema of the central nervous system (CNS). This results in the suppression of chemotherapy- and radiotherapy-induced nausea and vomiting.","Tropisetron Hydrochloride | 1H-Indole-3-Carboxylic Acid, (3-endo)-8-Methyl-8-Azabicyclo(3.2.1)Oct-3-yl Ester, Monohydrochloride | 1alpha-H,5alpha-H-tropan-3alpha-yl Indole-3-Carboxylate Hydrochloride | Novaban | SDZ-ICS 930 | TROPISETRON HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3711557","AURKA protein, human","C30006","Aurora kinase A (403 aa, ~46 kDa) is encoded by the human AURKA gene. This protein is involved in mediating microtubular structure and facilitating chromosome segregation during mitosis and meiosis.","Aurora Kinase A | ARK-1 | AURKA | Aurora 2 | Aurora A | Aurora A Kinase | Aurora Kinase A Protein | Aurora-A | Aurora-Related Kinase 1 | Aurora/IPL1-Like Kinase | Aurora/IPL1-Related Kinase 1 | Breast Tumor-Amplified Kinase | Breast-Tumor-Amplified Kinase | IPL1-Related Kinase | Protein Phosphatase 1, Regulatory Subunit 47 | STK15 | STK6 | Serine/Threonine Kinase 15 | Serine/Threonine Kinase 6 | Serine/Threonine Protein Kinase 15 | Serine/Threonine-Protein Kinase 15 | Serine/Threonine-Protein Kinase 6 | Serine/Threonine-Protein Kinase Aurora-A | hARK1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1564138","IDO1 protein, human","C79782","Indoleamine 2,3-dioxygenase (403 aa, ~45 kDa) is encoded by the human IDO1 gene. This protein is involved in the degradation of tryptophan.","Indoleamine 2,3-Dioxygenase 1 | EC 1.13.11.52 | IDO | IDO-1 | IDO1 | Indole 2,3-Dioxygenase | Indoleamine 2,3 Dioxygenase | Indoleamine 2,3-Dioxygenase | Indoleamine 2,3-Dioxygenase | Indoleamine-Pyrrole 2,3 Dioxygenase | Indoleamine-Pyrrole 2,3-Dioxygenase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0623362","Matrix Metalloproteinases","C18164","Matrix metalloproteinases are Zn(2+)-binding endopeptidases that degrade components of the extracellular matrix. These enzymes are implicated in tissue remodeling processes, wound healing, angiogenesis, and tumor invasion. Matrix metalloproteinases have been associated with the development of advanced-stage cancer via their role in tumor progression, invasion, and metastasis.","Matrix Metalloproteinase | MMP | Matrix Metalloprotease | matrix metalloproteinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516559","Circulatory Process","C41510","A Circulatory Process consists of functions of cellular, cell, or tissue components of the heart and vessels by which blood and lymph is circulated through the body.","Circulatory Process | Circulation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282554","chemokine","C20466","Chemokines constitute a superfamily of small (8-10 kDa), inducible, secreted, pro-inflammatory cytokines that are involved in a variety of immune and inflammatory responses as well as in viral infection.  Chemokines act primarily as chemoattractants and activators of specific types of leukocytes.  Some members of this family were initially identified on the basis of their biological activities (e.g., IL-8, GRO), others were discovered using subtractive hybridization (e.g., RANTES) or signal sequence trap (e.g., PBSF/SDF-1)11 cloning strategies.  They attract and activate leukocytes and regulate diverse cellular systems and organs ranging from blood vessels to the central nervous system.","Chemokine | Chemokines | Chemotactic Cytokine | Chemotactic Cytokines | Homologous Chemotactic Cytokines | Intercrine | Intercrines | SIS cytokines",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027758","S100 Calcium Binding Protein","C29924","A family of low molecular weight proteins that are characterized by the presence of two EF-hand calcium binding domains. These proteins form homodimers that localize either in the cytoplasm or nucleus of neural crest-derived cells and are involved in the regulation of many cellular processes such as cell cycle progression and differentiation.","S100 Calcium Binding Protein | S-100 Protein | S100 | S100 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1411929","TIF2 factor, human","C19888","Nuclear receptor coactivator 2 (1464 aa, ~159 kDa) is encoded by the human NCOA2 gene. This protein plays a role in the regulation of steroid-mediated gene transcription.","Nuclear Receptor Coactivator 2 | Class E Basic Helix-Loop-Helix Protein 75 | Glucocorticoid Receptor Interacting Protein 1 | Glucocorticoid Receptor-Interacting Protein 1 | Glucocorticoid Receptor-Interacting Protein-1 | NCOA2 | NCoA-2 | Nuclear Receptor Coactivator-2 | TIF2 | TIF2/GRIP-1 | Transcriptional Intermediary Factor 2 | bHLHe75 | hTIF2 | p160 Steroid Receptor Coactivator 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0145946","Tissue Inhibitor of Metalloproteinase-2","C17542","Metalloproteinase inhibitor 2 (220aa, ~24 kDa) is encoded by the human TIMP2 gene. This protein plays a role in metalloproteinase inhibition.","Metalloproteinase Inhibitor 2 | CSC-21K | TIMP-2 | Tissue Inhibitor of Metalloproteinases 2 | Tissue Inhibitor-of Metalloproteinase-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825911","Tissue Inhibitor of Metalloproteinase 1 Measurement","C82036","The determination of the amount of tissue inhibitor of metalloproteinase 1 present in a sample.","Tissue Inhibitor of Metalloproteinase 1 Measurement | EPA | Erythroid Potentiating Activity | Fibroblast Collagenase Inhibitor | Metalloproteinase Inhibitor 1 | TIMP1 | Tissue Inhibitor of Metalloproteinase 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333851","Sezary Cell","C36722","A large, neoplastic T-lymphocyte with an irregularly shaped nuclei and scant cytoplasm that is associated with Sezary Syndrome.","Sezary Cell | Cerebriform Lymphocyte | Sézary Cell",,,,,,,,,,,,,,,"4164910","Sézary cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1259929","BRAF protein, human","C17476","Serine/threonine-protein kinase B-raf (766 aa, ~84 kDa) is encoded by the human BRAF gene. This protein plays a role in protein phosphorylation, mitogenesis and neuronal signal transduction.","Serine/Threonine-Protein Kinase B-Raf | 94 kDa B-raf Protein | B-RAF Protein Kinase | B-RAF Serine/Threonine Protein Kinase | BRAF | BRAF Protein | BRAF1 Protein | EC 2.7.11.1 | KRAB Protein | Proto-Oncogene B-Raf | RAFB1 Protein | p94 | v-Raf Murine Sarcoma Viral Oncogene Homolog B1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812230","AKT2 Gene","C18352","This gene plays a role in glucose homeostasis and the inhibition of apoptosis.","AKT2 Gene | AKT Serine/Threonine Kinase 2 Gene | AKT2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0044602","Phosphatidylinositol-4,5-Bisphosphate 3-Kinase","C17270","An enzyme that catalyzes the conversion of phosphatidylinositol to phosphatidylinositol 3-phosphate. This is the first committed step in the biosynthesis of phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate. This pathway is thought to play a critical role in DNA repair, V(D)J recombination and cell cycle checkpoints. (from LocusLink)","Phosphatidylinositol-4,5-Bisphosphate 3-Kinase | 1-Phosphatidylinositol 3-Kinase | EC 2.7.1.153 | PI 3 Kinase | PI3 Kinase | PI3 kinase | PI3-Kinase | PI3K | Phosphatidylinositide 3-Kinase | Phosphatidylinositol 3 Kinase | Phosphatidylinositol 3 Kinase | Phosphatidylinositol 3-Kinase | Phosphatidylinositol-3-Kinase | Type I Phosphatidylinositol Kinase | Type III Phosphoinositide 3-Kinase | phosphatidylinositol-3 kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014563","Therapeutic Epinephrine","C473","The synthetic form of the naturally occurring sympathomimetic amine with vasoconstricting, intraocular pressure-reducing, and bronchodilating activities. By stimulating vascular alpha-adrenergic receptors, epinephrine causes vasoconstriction, thereby increasing vascular resistance and blood pressure. When administered in the conjunctiva, this agent binds to alpha-adrenergic receptors in the iris sphincter muscle, resulting in vasoconstriction, a decrease in the production of aqueous humor, and a lowering of intraocular pressure. Through its beta1 receptor-stimulating actions, epinephrine increases the force and rate of myocardial contraction and relaxes bronchial smooth muscle, resulting in bronchodilation.","Therapeutic Epinephrine | Adrenal | Adrenaline | EPINEPHRINE | Epi | Epinephrine | Epinephrine autoinjector | Epipen | adrenaline",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024094","Lumbosacral Region","C48824","The part of the spine in the lower back that consists of the lumbar region and the sacrum.","Lumbosacral Region | LUMBOSACRAL SPINE | Lumbosacral Region of the Spine",,,,,,,,,,,,,,,"4063784","Lumbosacral region structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002455","American Cancer Society","C16282","A nationwide, community-based voluntary health organization, the largest private source of cancer research funds in the U.S. Headquartered in Atlanta, Georgia, the ACS has state divisions and more than 3,400 local offices. ACS provides information on cancer incidence, mortality, causes, manifestations, treatment, and prevention, as well as on cancer research and clinical trials, and promotes beneficial policies, laws, and regulations for patients and families affected by cancer.","American Cancer Society | ACS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985652","Qualified Person","C93440","A person that has been recognized as having certain training/experience or other characteristics that would make that person an appropriate performer for a certain activity.","Qualified Person | QualifiedPerson",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024643","Malondialdehyde","C94711","An organic compound with the formula CH2(CHO)2, and a byproduct of lipid metabolism in the body. Malondialdehyde, a highly reactive compound, is one of the many reactive electrophile species that cause toxic stress in cells and form covalent protein adducts, called advanced lipoxidation end products (ALE). This compound also forms mutagenic DNA adducts when it reacts with deoxyadenosine and deoxyguanosine in DNA. Malondialdehyde is also found in many foods and is present in high levels in rancid foods.","Malondialdehyde | 1,3-Propanedial | 1,3-Propanedialdehyde | 1,3-Propanedione | MALONDIALDEHYDE | Malonaldehyde | Malonic Aldehyde | Malonicdialdehyde | Malonodialdehyde | malondialdehyde",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0534137","CYP2B6 protein, human","C40050","Cytochrome P450 2B6 (491 aa, ~56 kDa) is encoded by the human CYP2B6 gene. This protein plays a role in the metabolism of steroids and pharmaceuticals.","Cytochrome P450 2B6 | CPB6 | CYP2B | CYP2B6 | CYPIIB6 | Cytochrome P450 CYP2B6 | Cytochrome P450 Family 2 Subfamily B Polypeptide 6 | Cytochrome P450 IIB1 | EC 1.14.14.1 | IIB1 | P450 | P450 IIB1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0960580","Cytochrome P450 2C19, Human","C25948","Cytochrome P450 2C19 (490 aa, ~56 kDa) is encoded by the human CYP2C19 gene. This protein is involved in steroid, terpenoid and drug metabolism.","Cytochrome P450 2C19 | (R)- Limonene 6-Monooxygenase | (S)- Limonene 6-Monooxygenase | (S)- Limonene 7-Monooxygenase | CYP2C19 | CYPIIC17 | CYPIIC19 | Cytochrome P450, Family 2, Subfamily C, Polypeptide 19 | Cytochrome P450, Family 2, Subfamily C, Polypeptide 19 | Cytochrome P450, Subfamily IIC (Mephenytoin 4-Hydroxylase), Polypeptide 19 | Cytochrome P450-11A | Cytochrome P450-254C | EC 1.14.13.- | EC 1.14.13.48 | EC 1.14.13.49 | EC 1.14.13.80 | Flavoprotein-Linked Monooxygenase | Mephenytoin 4'-Hydroxylase | Mephenytoin 4-Hydroxylase | Mephenytoin 4-Prime-Hydroxylase | Microsomal Monooxygenase | P450-11A | P450-254C | Xenobiotic Monooxygenase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019648","Histone H4","C16686","Histone H4 (103 aa, ~11 kDa) is encoded by the human H4C1, H4C2, H4C3, H4C4, H4C5, H4C6, H4C6, H4C8, H4C9, H4C11, H4C12, H4C13, H4C14, H4C15, H4-16 genes. This protein plays a role in nucleating the formation of high order chromatin structures as a part of nucleosomes.","Histone H4 | H4 | HIST1H4 | HISTONE H4 | Histone 1, H4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019647","Histone H3","C16685","Histone H3 is a core subunit of the eukaryotic nucleosome complex. Histones are basic nuclear proteins responsible for the nucleosome structure of chromatin. Repeating nucleosome units contain two molecules each of Histones H2A, H2B, H3, and H4 that form an octamer complex around which approximately 146 base pairs of DNA is wrapped. Linker Histone H1 interacts with DNA between nucleosome units in mediating chromatin compaction into higher order structures. (NCI)","Histone H3 | H3 | HISTONE H3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001038","Acetylation","C16255","Acetylation involves the covalent linkage of an acetyl group into an organic molecule.","Acetylation | acetylation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0883157","Inhibin A","C2277","Gonadal glycoprotein hormone, Inhibin A, consists of an alpha subunit covalently linked to a beta-A subunit and strongly inhibits pituitary FSH secretion.  Serum concentrations transit during the menstrual cycle.  Dimers of the beta subunit (a TGF-beta superfamily member), termed activin, are potent stimulators of FSH secretion.  (from OMIM 147380 and NCI)","Inhibin A | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1307126","Coagulation Factor VIII, Human","C16571","Coagulation factor VIII (2351 aa, ~267 kDa) is encoded by the human F8 gene. This protein plays a role in the modulation of coagulation factor IX activity and blood coagulation.","Coagulation Factor VIII | AHF | Antihaemophilic Factor | Antihemophilic Factor | COAGULATION FACTOR VIII | Coagulation Factor VIIIc | F8 | FVIII | Factor VIII | Factor VIII F8B | Procoagulant Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043233","Workers Compensation Plan","C70692","An insurance program designed to financially compensate an employee in the event of an injury sustained while working.","Workers Compensation Plan | Workers Compensation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1439079","Ras Association Domain-Containing Protein 1, Human","C60667","Ras association domain-containing protein 1 (344 aa, ~39 kDa) is encoded by the human RASSF1 gene. This protein is involved in death receptor-dependent apoptosis and cell cycle regulation.","Ras Association Domain-Containing Protein 1 | Cardiac-Specific Ras Association Domain Family 1 Protein | Pancreas-Specific Ras Association Domain Family 1 Protein | RASSF1 | Ras Association Domain Family 1 Protein | Ras Association Domain Family Protein 1 | Tumor Suppressor Protein RDA32",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332098","APAF1 Gene","C20358","This gene is involved in pro-apoptotic regulation through caspase interaction.","APAF1 Gene | APAF1 | Apoptotic Protease Activating Factor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1672855","APAF1 protein, human","C20930","Apoptotic protease-activating factor 1 (1248 aa, ~142 kDa) is encoded by the human APAF1 gene. This protein plays a role in protein-protein interactions, protein modification and apoptosis induction.","Apoptotic Protease-Activating Factor 1 | APAF1 | APAF1 Protein | Apaf-1 | Apoptotic Protease Activating Factor | Apoptotic Protease Activating Factor 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698024","Matrix Metalloproteinase 2 measurement","C80193","The determination of the amount of matrix metalloproteinase 2 present in a sample.","Matrix Metalloproteinase 2 Measurement | Gelatinase A | MMP2 | Matrix Metalloproteinase 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0752253","Neuregulins","C20433","Neuregulin (heregulin) polypeptides have been shown to interact with and activate the ErbB2, ErbB3 and ErbB4 receptor proteins, and have been found to be essential for the normal development of the cardiovascular, pancreatic and nervous systems. Neuregulins are involved in the normal development of mammary gland, are secreted by breast cancer cells, and can alternatively promote or inhibit breast cancer cell division.","Neuregulin | ARIA | GGF | Glial Growth Factor | Heregulin | NDF | Neu-Differentiation Factor | Sensory-and-motor-derived factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447107","Hepatocyte Growth Factor, Human","C20428","Hepatocyte growth factor (728 aa, ~83 kDa) is encoded by the human HGF gene. This protein is involved in both the modulation of hepatocyte proliferation and growth factor receptor signaling in hepatocytes and many other cell types.","Hepatocyte Growth Factor | Fibroblast-Derived Tumor Cytotoxic Factor | HGF | HGF/SF | Hepatopoietin A | Lung Fibroblast-Derived Mitogen | SF | Scatter Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334189","IGF2R protein, human","C26253","Cation-independent mannose-6-phosphate receptor (2491 aa, ~274 kDa) is encoded by the human IGF2R gene. This protein is involved in receptor-mediated endocytosis.","Cation-Independent Mannose-6 Phosphate Receptor | 300 kDa Mannose 6-Phosphate Receptor | Antigen CD222 | CD222 | CD222 Antigen | CI Man-6-P Receptor | CI-MPR | IGF-II Receptor | IGF2R | Insulin-Like Growth Factor 2 Receptor | Insulin-Like Growth Factor 2 Receptor | Insulin-Like Growth Factor II Receptor | M6P/IGF2 Receptor | M6P/IGF2R | M6PR | MPR 300",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981781","Breast Cancer TNM Finding v7","C88257","A finding about one or more characteristics of breast cancer, following the rules of the TNM AJCC v7 classification system.","Breast Cancer TNM Finding v7 | Breast Carcinoma TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707026","Breast Cancer pT1 TNM Finding v6 and v7","C48978","Breast cancer with tumor size 2.0 cm or less in greatest dimension. (from AJCC 6th and 7th Ed.)","Breast Cancer pT1 TNM Finding v6 and v7 | Breast Cancer pT1 TNM Finding | Breast Cancer pT1 TNM Finding | Breast Cancer pT1 TNM Finding v6 | Breast Cancer pT1 TNM Finding v7 | pT1 Breast Cancer v6 | pT1 Breast Carcinoma v6 | pT1 Cancer of Breast v6 | pT1 Cancer of the Breast v6 | pT1 Carcinoma of Breast v6 | pT1 Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707041","Breast Cancer pTis TNM Finding v6 and v7","C48974","Breast cancer with a finding of carcinoma in situ. (from AJCC 6th and 7th Eds.)","Breast Cancer pTis TNM Finding v6 and v7 | Breast Cancer pTis TNM Finding | Breast Cancer pTis TNM Finding | Breast Cancer pTis TNM Finding v6 | Breast Cancer pTis TNM Finding v7 | Breast Carcinoma pTis TNM Finding v7 | pTis Breast Cancer v6 | pTis Breast Carcinoma v6 | pTis Cancer of Breast v6 | pTis Cancer of the Breast v6 | pTis Carcinoma of Breast v6 | pTis Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707025","Breast Cancer pT0 TNM Finding v6 and v7","C48973","Breast cancer with no evidence of primary tumor. (from AJCC 6th and 7th Eds.)","Breast Cancer pT0 TNM Finding v6 and v7 | Breast Cancer pT0 TNM Finding | Breast Cancer pT0 TNM Finding | Breast Cancer pT0 TNM Finding v6 | Breast Cancer pT0 TNM Finding v7 | Breast Carcinoma pT0 TNM Finding v7 | pT0 Breast Cancer v6 | pT0 Breast Carcinoma v6 | pT0 Cancer of Breast v6 | pT0 Cancer of the Breast v6 | pT0 Carcinoma of Breast v6 | pT0 Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707038","Breast Cancer pTX TNM Finding v6 and v7","C48972","Breast cancer in which the primary tumor cannot be assessed. (from AJCC 6th and 7th Eds.)","Breast Cancer pTX TNM Finding v6 and v7 | Breast Cancer pTX TNM Finding | Breast Cancer pTX TNM Finding | Breast Cancer pTX TNM Finding v6 | Breast Cancer pTX TNM Finding v7 | Breast Carcinoma pTX TNM Finding v7 | pTX Breast Cancer v6 | pTX Breast Carcinoma v6 | pTX Cancer of Breast v6 | pTX Cancer of the Breast v6 | pTX Carcinoma of Breast v6 | pTX Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347197","Breast Cancer cN3c TNM Finding v6 and v7","C73355","Breast cancer with metastasis in ipsilateral supraclavicular lymph node(s). (from AJCC 6th and 7th Eds.)","Breast Cancer cN3c TNM Finding v6 and v7 | Breast Cancer cN3c TNM Finding | Breast Cancer cN3c TNM Finding | Breast Cancer cN3c TNM Finding v6 | Breast Cancer cN3c TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347196","Breast Cancer cN3b TNM Finding v6 and v7","C73354","Breast cancer with metastasis in ipsilateral internal mammary lymph node(s) and axillary lymph node(s). (from AJCC 6th and 7th Eds.)","Breast Cancer cN3b TNM Finding v6 and v7 | Breast Cancer cN3b TNM Finding | Breast Cancer cN3b TNM Finding | Breast Cancer cN3b TNM Finding v6 | Breast Cancer cN3b TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347195","Breast Cancer cN3a TNM Finding v6 and v7","C73353","Breast cancer with metastasis in ipsilateral infraclavicular lymph node(s). (from AJCC 6th and 7th Eds.)","Breast Cancer cN3a TNM Finding v6 and v7 | Breast Cancer cN3a TNM Finding | Breast Cancer cN3a TNM Finding | Breast Cancer cN3a TNM Finding v6 | Breast Cancer cN3a TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981887","Breast Cancer cN3 TNM Finding v7","C88370","Breast cancer with metastases in ipsilateral infraclavicular (level III) axillary lymph node(s) with or without level I, II axillary lymph node involvement; or in clinically detected ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement. (from AJCC 7th Ed.)","Breast Cancer cN3 TNM Finding v7 | Breast Carcinoma cN3 TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981886","Breast Cancer cN2b TNM Finding v7","C88369","Breast cancer with metastases only in clinically detected ipsilateral internal mammary nodes and in the absence of clinically evident level I, II axillary lymph node metastases.  'Clinically detected' is defined as detected by imaging studies (excluding lymphoscintigraphy) or by clinical examination and having characteristics highly suspicious for malignancy or a presumed pathologic macrometastasis based on fine needle aspiration biopsy with cytologic examination. (from AJCC 7th Ed.)","Breast Cancer cN2b TNM Finding v7 | Breast Carcinoma cN2b TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347192","Breast Cancer cN2a TNM Finding v6 and v7","C73350","Breast cancer with metastases in ipsilateral level I, II axillary lymph nodes fixed to one another (matted) or to other structures. (from AJCC 6th and 7th Eds.)","Breast Cancer cN2a TNM Finding v6 and v7 | Breast Cancer cN2a TNM Finding | Breast Cancer cN2a TNM Finding | Breast Cancer cN2a TNM Finding v6 | Breast Cancer cN2a TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981885","Breast Cancer cN2 TNM Finding v7","C88368","Breast cancer with metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases.  'Clinically detected' is defined as detected by imaging studies (excluding lymphoscintigraphy) or by clinical examination and having characteristics highly suspicious for malignancy or a presumed pathologic macrometastasis based on fine needle aspiration biopsy with cytologic examination. (from AJCC 7th Ed.)","Breast Cancer cN2 TNM Finding v7 | Breast Carcinoma cN2 TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347190","Breast Cancer cN1 TNM Finding v6 and v7","C73348","Breast cancer with metastasis to movable ipsilateral level I, II axillary lymph node(s).  (from AJCC 6th and 7th Eds.)","Breast Cancer cN1 TNM Finding v6 and v7 | Breast Cancer cN1 TNM Finding | Breast Cancer cN1 TNM Finding | Breast Cancer cN1 TNM Finding v6 | Breast Cancer cN1 TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347189","Breast Cancer cN0 TNM Finding v6 and v7","C73347","Breast cancer with no regional lymph node metastasis. (from AJCC 6th and 7th Eds.)","Breast Cancer cN0 TNM Finding v6 and v7 | Breast Cancer cN0 TNM Finding | Breast Cancer cN0 TNM Finding | Breast Cancer cN0 TNM Finding v6 | Breast Cancer cN0 TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347198","Breast Cancer cNX TNM Finding v6 and v7","C73346","Breast cancer in which regional lymph nodes cannot be assessed. (from AJCC 6th and 7th Eds.)","Breast Cancer cNX TNM Finding v6 and v7 | Breast Cancer cNX TNM Finding | Breast Cancer cNX TNM Finding | Breast Cancer cNX TNM Finding v6 | Breast Cancer cNX TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981888","Breast Cancer Clinical Distant Metastasis TNM Finding v7","C88371","A clinical finding about one or more characteristics of breast cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.","Breast Cancer Clinical Distant Metastasis TNM Finding v7 | Breast Carcinoma Clinical Distant Metastasis TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981891","Breast Cancer cM1 TNM Finding v7","C88374","Breast cancer with distant detectable metastases as determined by classic clinical and radiographic means and/or histologically proven larger than 0.2 mm. (from AJCC 7th Ed.)","Breast Cancer cM1 TNM Finding v7 | Breast Carcinoma cM1 TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981889","Breast Cancer cM0(i+) TNM Finding v7","C88372","Breast cancer in which there is no clinical or radiographic evidence of distant metastases, but deposits of molecularly or microscopically detected tumor cells in circulating blood, bone marrow, or other nonregional nodal tissue that are no larger than 0.2 mm in a patient without symptoms or signs of metastases. (from AJCC 7th Ed.)","Breast Cancer cM0(i+) TNM Finding v7 | Breast Carcinoma cM0(i+) TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981890","Breast Cancer cM0 TNM Finding v7","C88373","Breast cancer in which there is no clinical or radiographic evidence of distant metastases. (from AJCC 7th Ed.)","Breast Cancer cM0 TNM Finding v7 | Breast Carcinoma cM0 TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981866","Breast Cancer Pathologic Primary Tumor TNM Finding v7","C88347","A pathologic finding about one or more characteristics of breast cancer, following the rules of the TNM AJCC v7 classification system as they pertain to staging of the primary tumor.  The TNM pathologic and clinical primary tumor classifications of breast cancer are the same, regardless of whether they are based on pathologic and/or clinical criteria.","Breast Cancer Pathologic Primary Tumor TNM Finding v7 | Breast Carcinoma Pathologic Primary Tumor TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707005","Breast Cancer pM1 TNM Finding v6 and v7","C49009","Breast cancer with distant metastasis. (from AJCC 6th and 7th Eds.)","Breast Cancer pM1 TNM Finding v6 and v7 | Breast Cancer pM1 TNM Finding | Breast Cancer pM1 TNM Finding | Breast Cancer pM1 TNM Finding v6 | Breast Cancer pM1 TNM Finding v7 | pM1 Breast Cancer v6 | pM1 Breast Carcinoma v6 | pM1 Cancer of Breast v6 | pM1 Cancer of the Breast v6 | pM1 Carcinoma of Breast v6 | pM1 Carcinoma of the Breast v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981880","Breast Cancer Pathologic Distant Metastasis TNM Finding v7","C88363","A pathologic finding about one or more characteristics of breast cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases. TNM pathologic distant metastasis findings are based on clinical findings supplemented by histopathologic examination of one or more tissue specimens acquired during surgery.","Breast Cancer Pathologic Distant Metastasis TNM Finding v7 | Breast Carcinoma Pathologic Distant Metastasis TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332290","Consistent","C85901","Marked by a reasonable or logical relation of parts and holding together as a harmonious or credible whole.","Consistent | Consistent With",,,,,,,,,,,,,,,"4299436","Consistent with",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042926","Vocabulary","C92442","The collection of words used by, understood by, or available for use by a person or group.","Vocabulary | vocabulary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1956259","Acronym","C93495","The non-unique initials or abbreviated name used for identification.","Acronym | acronym | program acronym | program_acronym",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2980042","Stage IIIC Breast Cancer AJCC v7","C88377","Stage IIIC includes: Any T, N3, M0.  N3: Metastases in ipsilateral infraclavicular (level III) axillary lymph nodes(s) with or without level I, II axillary lymph node involvement; or in clinically detected ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)","Stage IIIC Breast Cancer AJCC v7 | Stage IIIC Breast Cancer | Stage IIIC Breast Cancer | stage IIIC breast cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278513","Stage IIIB Breast Carcinoma","C7782","Stage IIIB includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0).  T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules).  N0: No regional lymph node metastasis.  N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s).  N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)","Stage IIIB Breast Cancer AJCC v7 | Breast Cancer Stage IIIB | Breast Carcinoma Stage IIIB | Stage IIIB Breast Cancer | Stage IIIB Breast Cancer | Stage IIIB Breast Carcinoma | stage IIIB breast cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278489","Stage IIIA Breast Carcinoma","C7770","Stage IIIA includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0).  T0: No evidence of primary tumor.  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension.  T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension.  T3: Tumor more than 50 mm in greatest dimension.  N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s).  N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)","Stage IIIA Breast Cancer AJCC v7 | Breast Cancer Stage IIIA | Breast Carcinoma Stage IIIA | Stage IIIA Breast Cancer | Stage IIIA Breast Cancer | Stage IIIA Breast Carcinoma | stage IIIA breast cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336178","Stage IIB Breast Carcinoma","C5455","Stage IIB includes: (T2, N1, M0); (T3, N0, M0).  T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension.  T3: Tumor more than 50 mm in greatest dimension.  N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s).  N0: No regional lymph node metastasis.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 6th and 7th Eds.)","Stage IIB Breast Cancer AJCC v6 and v7 | Breast Cancer Stage IIB | Breast Carcinoma Stage IIB | Stage IIB Breast Cancer | Stage IIB Breast Cancer | Stage IIB Breast Cancer AJCC v6 | Stage IIB Breast Cancer AJCC v7 | Stage IIB Breast Carcinoma | stage IIB breast cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336156","Stage IIA Breast Carcinoma","C5454","Stage IIA includes: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0).  T0: No evidence of primary tumor.  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension.  N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s).  N0: No regional lymph node metastasis.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 6th and 7th Eds.)","Stage IIA Breast Cancer AJCC v6 and v7 | Breast Cancer Stage IIA | Breast Carcinoma Stage IIA | Stage IIA Breast Cancer | Stage IIA Breast Cancer | Stage IIA Breast Cancer AJCC v6 | Stage IIA Breast Cancer AJCC v7 | Stage IIA Breast Carcinoma | stage IIA breast cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL413892","breast cancer, stage IB","C85836","Stage IB includes: (T0, N1mi, M0); (T1, N1mi, M0).  T0: No evidence of primary tumor.  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension.  N1mi: Nodal micrometastases.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)","Stage IB Breast Cancer AJCC v7 | Stage IB Breast Cancer | Stage IB Breast Cancer | stage IB breast cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL413891","breast cancer, stage IA","C85835","Stage IA includes: T1, N0, M0.  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)","Stage IA Breast Cancer AJCC v7 | Stage IA Breast Cancer | Stage IA Breast Cancer | stage IA breast cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711357","Administration via Implantation","C38201","Drug administration via imbedded implants used as depot formulations to limit high drug concentrations to the area surrounding the pathology or to provide sustained drug release for systemic therapy. Implant systems are used when chronic therapy is indicated and may take the form of highly viscous liquids, semi-solid formulations, rod impregnated with drug substances, or a liquid which gels in situ. Release kinetics may be controlled by varying polymer composition, different types of stimuli, such as electrical, and varying of implant structure, e.g. as coating.","Administration via Implantation | Implant | Implantation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706421","Pump Device","C50128","A device designed to facilitate the movement of a fluid.","Pump Device | Pump | Pump Device Component | pump",,,,,,,,,,,,,,,"4260370","Pump",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640002","Image Annotation Statement","C101135","A statement used to describe something found and to be addressed on an image or series of images. It describes a thing found, measured and graphically annotated on an image or images from the same series. It consists of a subject, predicate and object.","Image Annotation Statement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639991","Geometric Shape","C101119","The spatial outline of an object as described by the configuration of straight or curved lines.","Geometric Shape | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639992","Annotation Collection","C101123","A set of annotations, or comments about an idea, subject or item.","Annotation Collection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639993","Worklist","C101124","A collection of activities or pieces of work that are generally assigned to an individual or machine to perform.","Worklist | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540678","Task","C101129","An assigned piece of work, usually with a time allotment.","Task | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640001","Entity Statement","C101134","A declaration of a relationship between entities, consisting of a subject, predicate and object.","Entity Statement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539882","Milliampere second","C101136","A measure of the electric charge and the time in which the charge is dispersed. This is used as a setting on a radiography machine to determine the density of the radiographic image.","Milliampere second | mAs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518275","Neuroendocrine Cell","C12485","An endocrine cell that produces and releases hormones and regulatory proteins such as neurotransmitters and neuropeptide hormones. This type of cell enables autocrine communication with paracrine and endocrine cells throughout the body.","Neuroendocrine Cell | Neuroendocrine Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0106701","BMI1 protein, human","C17480","Polycomb complex protein BMI-1 (326 aa, ~37 kDa) is encoded by the human BMI1 gene. This protein is involved in transcriptional repression during embryonic development.","Polycomb Complex Protein BMI-1 | BMI1 | BMI1 Protein | DNA Binding Protein BMI-1 | Leukemia Viral BMI-1 Oncogene Homolog | Polycomb Group RING Finger Protein 4 | RING Finger Protein 51",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527598","Tyrosine-Protein Kinase JAK1, Human","C28493","Tyrosine-protein kinase JAK1 (1154 aa, ~133 kDa) is encoded by the human JAK1 gene. This protein plays a role in both tyrosine phosphorylation and interferon-mediated signaling.","Tyrosine-Protein Kinase JAK1 | EC 2.7.1.112 | EC 2.7.10.2 | JAK1 | Janus Kinase 1 | Janus Kinase 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705183","Retainer Device","C50144","A physical device designed to hold something in place.","Retainer Device | Retainer | Retainer Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0971008","MDM2 protein, human","C17515","E3 ubiquitin-protein ligase Mdm2 (491 aa, ~55 kDa) is encoded by the human MDM2 gene. This protein is involved in the mediation of the ubiquitination and degradation of protein substrates, and the inhibition of apoptosis induction that is mediated by cellular tumor antigen p53.","E3 Ubiquitin-Protein Ligase MDM2 | Double Minute 2 Protein | EC 2.3.2.27 | HDM2 | MDM 2 Protein | MDM2 | MDM2 Protein | Oncoprotein Mdm2 | RING-Type E3 Ubiquitin Transferase Mdm2 | Ubiquitin-Protein Ligase E3 MDM2 | p53 Binding Protein | p53-Binding Protein MDM2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448405","Oncogene MET","C18248","The MET oncogene is derived from a chromosomal rearrangement involving the MET and TPR (translocated promoter region) loci and is a cloned gene for Hereditary Papillary Renal Carcinoma.  The MET proto-oncogene encodes hepatocyte growth factor receptor, a disulfide-linked two subunit receptor protein tyrosine kinase.  The human gene is located at 7q31.","Oncogene MET | Activated Hepatocyte Growth Factor Receptor Gene | Hepatocyte Growth Factor Receptor Gene | MET | Oncogene HGFR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1610382","G2/Mitotic-Specific Cyclin-B1, Human","C17981","G2/mitotic-specific cyclin-B1 (433 aa, ~48 kDa) is encoded by the human CCNB1 gene. This protein plays a role in mediating the progression of the cell cycle from G2 to mitosis.","G2/Mitotic-Specific Cyclin-B1 | CCNB | CCNB1 | CGB1 | Cyclin B | Cyclin B1 | Cyclin-B1 | G2/Mitotic-Specific Cyclin B1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984945","25-Hydroxyvitamin D Measurement","C92268","The determination of the amount of 25-Hydroxyvitamin D present in a sample.","25-Hydroxyvitamin D Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1318460","Thyroid peroxidase antibody procedure","C96638","The determination of the amount of thyroperoxidase antibody present in a sample.","Thyroperoxidase Antibody Measurement | Anti-TPO | Anti-TPO Antibody Measurement | Anti-TPO Measurement | Anti-Thyroid Peroxidase Antibody Measurement | Anti-Thyroperoxidase Antibody Measurement | THYPXDAB | TPO Antibody Measurement | Thyroid Antimicrosomal Antibody | Thyroid Peroxidase Antibody Measurement | Thyroperoxidase Antibody",,,,,,,,,,,,,,,"4304801","Measurement of thyroperoxidase antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0111208","CTLA4 protein, human","C17489","Cytotoxic T-lymphocyte protein 4 (223 aa, ~25 kDa) is encoded by the human CTLA4 gene. This protein is involved in the inhibition of T-cell mediated immune responses.","Cytotoxic T-Lymphocyte Protein 4 | CD152 | CD152 Antigen | CTLA-4 | CTLA4 | CTLA4 Protein | CTLA4-TM | Cytotoxic T Lymphocyte-Associated Protein 4 | Cytotoxic T-Lymphocyte-Associated Antigen 4 | Cytotoxic T-Lymphocyte-Associated Protein 4 | Cytotoxic T-Lymphocyte-Associated Protein 4 | Cytotoxic T-Lymphocyte-Associated Serine Esterase-4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705105","Wire Device","C50269","A metal strand designed for signal or power transmission or for structural or other purpose.","Wire Device | Device Wire | Wire | Wire Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1872956","C-C Chemokine Receptor Type 9, Human","C37457","C-C chemokine receptor type 9 (369 aa, ~42 kDa) is encoded by the human CCR9 gene. This protein is involved in chemokine-dependent G protein-coupled receptor signaling.","C-C Chemokine Receptor Type 9 | C-C CKR-9 | CC-CKR-9 | CCR-9 | CCR9 | CDw199 Antigen | Chemokine (C-C Motif) Receptor 9 | Chemokine Binding Protein 2 | G-Protein Coupled Receptor 28 | GPR-9-6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1448238","FCGR2A protein, human","C38553","Low affinity immunoglobulin gamma Fc region receptor II-a (317 aa, ~35 kDa) is encoded by the human FCGR2A gene. This protein plays a role in the endocytosis of opsonized antigens.","Low Affinity Immunoglobulin Gamma Fc Region Receptor II-A | CD32 | CD32 Antigen | CD32A | CD32A Antigen | FCG2 | FCGR2 | FCGR2A | FCGR2A1 | Fc-Gamma RII-A | Fc-Gamma RIIA | Fc-Gamma-RIIA | FcGR | FcRII-a | FcRIIA | IGFR2 | IgG Fc Receptor II-a | IgG Fc Receptor IIA | IgG Fc Receptor IIA | Immunoglobulin G Fc Receptor IIA | Low Affinity IgG Fc Fragment Receptor IIA | Low Affinity Immunoglobulin Gamma Fc Region Receptor IIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040648","TRANSCRIPTION FACTOR","C17207","Transcription factors are a diverse group of proteins that bind to DNA at specific promoter or enhancer regions. They also bind to DNA-associated proteins to initiate, stimulate, inhibit or terminate transcription. The proteins are often physically associated in a preinitiation complex and contain structural motifs.","Transcription Factor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827383","Ribosomal Protein S6 Kinase Beta-1","C84317","Ribosomal protein S6 kinase beta-1 (525 aa, ~59 kDa) is encoded by the human RPS6KB1 gene. This protein is involved in phosphorylation of ribosomal protein S6.","Ribosomal Protein S6 Kinase Beta-1 | 70 kDa Ribosomal Protein S6 Kinase 1 | EC 2.7.11.1 | EC2.7.11.1 | Ribosomal Protein S6 Kinase I | S6 Kinase-Related Kinase | S6K | S6K1 | p70 Ribosomal S6 Kinase Alpha | p70 S6 Kinase Alpha | p70 S6K Alpha | p70(S6K)-Alpha | p70-Alpha | p70-S6K | p70S6K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333633","FOXO3A protein, human","C28520","Forkhead box protein O3 (673 aa, ~71 kDa) is encoded by the human FOXO3 gene. This protein is involved in the modulation of transcription, apoptosis and embryonic pattern formation.","Forkhead Box Protein O3 | AF6q21 Protein | FOXO3 | FOXO3A | Forkhead Box O3A | Forkhead Box Protein O3A | Forkhead in Rhabdomyosarcoma-Like 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273510","HSP90AB1 protein, human","C97591","Heat shock protein HSP 90-beta (724 aa, ~83 kDa) is encoded by the human HSP90AB1 gene. This protein plays a role in the modulation of both interferon signaling and protein folding.","Heat Shock Protein HSP 90-Beta | HSP 84 | HSP 90 | HSP84 | HSP90AB1 | HSPCB | Heat Shock 84 kDa | Heat Shock Protein 90kDa Alpha Family Class B Member 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0527057","Fibroblast Growth Factor Receptor 3, Human","C26129","Fibroblast growth factor receptor 3 (806 aa, ~88 kDa) is encoded by the human FGFR3 gene. This protein is involved in fibroblast growth factor signaling and skeletal development.","Fibroblast Growth Factor Receptor 3 | CD333 Antigen | EC 2.7.1.112 | EC 2.7.10.1 | FGFR-3 | FGFR3 | Hydroxyaryl-Protein Kinase | Tyrosine Kinase JTK4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0218227","MPL protein, human","C17695","Thrombopoietin receptor (635 aa, ~71 kDa) is encoded by the human MPL gene. This protein plays a role in thrombopoietin signaling and the regulation of both megakaryocytopoiesis and platelet formation.","Thrombopoietin Receptor | CD110 | CD110 Antigen | MPL | Myeloproliferative Leukemia Protein | Proto-Oncogene c-Mpl | TPO-R | TPOR | c-MPL Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600673","Statistic","C83503","A datum that can be represented numerically.","Statistic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1384494","Metastatic Carcinoma","C3482","Carcinoma that has spread from its original site of growth to other anatomic sites.","Metastatic Carcinoma | Carcinoma, metastatic, NOS","8010/6","Carcinoma, metastatic, NOS",,,,,,,,,,,,,"4194691","Carcinoma, metastatic",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1963737","Radiation Necrosis","C94479","Tissue necrosis due to radiation exposure.","Radiation Necrosis | radiation necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2607869","Anti-HIF-1alpha LNA Antisense Oligonucleotide EZN-2968","C68930","A synthetic antisense oligodeoxynucleotide (AS ODN) targeting hypoxia-inducible factor-1alpha (HIF-1alpha) with potential antineoplastic activity. Anti-HIF-1alpha LNA antisense oligonucleotide EZN-2968 hybridizes with HIF-1alpha mRNA and blocks t HIF-1 alpha protein expression, which may result in the inhibition of angiogenesis, the inhibition of tumor cell proliferation, and apoptosis. HIF-1alpha, normally activated in response to hypoxia-induced stress, is a key transcription regulator of a large number of genes important in cellular adaptation to low-oxygen conditions, including angiogenesis, cell proliferation, apoptosis, and cell invasion.","Anti-HIF-1alpha LNA Antisense Oligonucleotide EZN-2968 | EZN-2968 | RO7070179 | anti-HIF-1alpha LNA AS-ODN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831982","Crenolanib","C64639","An orally bioavailable benzimidazole targeting the platelet-derived growth factor receptor (PDGFR) subtypes alpha and beta and FMS-related tyrosine kinase 3 (Flt3), with potential antineoplastic activity. Upon oral administration, crenolanib binds to and inhibits both wild-type and mutated forms of PDGFR and Flt3, which may result in the inhibition of PDGFR- and Flt3-related signal transduction pathways. This results in inhibition of tumor angiogenesis and tumor cell proliferation in PDGFR and/or Flt3 overexpressing tumor cells. PDGFR and Flt3, class III receptor tyrosine kinases, are upregulated or mutated in many tumor cell types.","Crenolanib | 4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]- | CP 868 596 | CP-868,596 | CP-868596 | CP868596 | CRENOLANIB | PDGFR Inhibitor CP-868596 | [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1832009","Vemurafenib","C64768","An orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Approximately 90% of BRAF gene mutations involve a valine-to-glutamic acid mutation at residue 600 (V600E); the oncogene protein product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) gene mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors, including melanoma, colorectal, thyroid and other cancers.","Vemurafenib | 1-propanesulfonamide, n-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)- | BRAF (V600E) kinase inhibitor RO5185426 | BRAF(V600E) Kinase Inhibitor RO5185426 | PLX 4032 | PLX-4032 | PLX4032 | RG 7204 | RG-7204 | RG7204 | RO 5185426 | RO-5185426 | VEMURAFENIB | Zelboraf",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987313","Periodic Interval Data Type","C95672","A data type comprised of an interval of time that occurs intermittently.","Periodic Interval Data Type | PIVL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1310111","CRLF2 protein, human","C97432","Cytokine receptor-like factor 2 (371 aa, ~42 kDa) is encoded by the human CRLF2 gene. This protein is involved in the mediation of both cytokine binding and signaling.","Cytokine Receptor-Like Factor 2 | CRLF2 | Cytokine Receptor CRL2 | Cytokine Receptor-Like 2 | IL-XR | TSLP Receptor | Thymic Stromal Lymphopoietin Protein Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825588","IKZF1 Gene","C68730","This gene is involved in B-cell and T-cell maturation.","IKZF1 Gene | IKAROS Family Zinc Finger 1 Gene | IKZF1 | Ikaros",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1367374","CBL Protein, Human","C18547","E3 ubiquitin-protein ligase CBL (906 aa, ~100 kDa) is encoded by the human CBL gene. This protein is involved in the ubiquitination of tyrosine-protein kinases.","E3 Ubiquitin-Protein Ligase CBL | CBL | CBL Gene Product | CBL Protein | CBL2 Gene Product | Casitas B-Lineage Lymphoma Proto-Oncogene | EC 2.3.2.27 | Proto-Oncogene c-Cbl | RING Finger Protein 55 | RING-Type E3 Ubiquitin Transferase CBL | Signal Transduction Protein CBL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640008","Agonizing Pain","C101161","A sensation of great anguish and suffering.","Agonizing Pain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640009","Annoying Pain","C101162","A sensation of discomfort or distress that is bothersome and irritating.","Annoying Pain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640010","Killing Pain","C101163","A sensation of extreme discomfort and anguish that is perceived as severe enough to cause one's death.","Killing Pain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640011","Miserable Pain","C101164","A sensation of discomfort or distress that renders an individual unable to find any happiness.","Miserable Pain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0559222","Nagging Pain","C101165","A sensation of discomfort or distress that is persistent and continuous.","Nagging Pain | ",,,,,,,,,,,,,,,"4116812","Gnawing pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0578064","Sickening Pain","C101166","A sensation of discomfort or distress that makes the individual queasy or nauseated.","Sickening Pain | ",,,,,,,,,,,,,,,"4103481","Sickening with pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640012","Terrifying Pain","C101167","A sensation of discomfort or distress that is frightening or scary.","Terrifying Pain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0578063","Tiring Pain","C101168","A sensation of discomfort or distress that renders an individual weary and without energy.","Tiring Pain | ",,,,,,,,,,,,,,,"4103480","Tiring with pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640013","Torturing Pain","C101169","A sensation of having discomfort or distress inflicted upon an individual.","Torturing Pain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642475","Troublesome Pain","C101170","A sensation of discomfort or distress that worries an individual or interrupts their ability to complete desired activities.","Troublesome Pain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640014","Unbearable Pain","C101171","A sensation of extreme discomfort and anguish that is overwhelming and unendurable.","Unbearable Pain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0234230","Burning Pain","C101172","A sensation of intensely hot or searing discomfort.","Burning Pain | ",,,,,,,,,,,,,,,"4264107","Burning pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0458254","Cramping Pain","C101173","A sense of discomfort or distress that is spasmodic or clenching.","Cramping Pain | ",,,,,,,,,,,,,,,"4133046","Cramping pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0458259","Crushing Pain","C101174","A sense of discomfort or distress that is squeezing or excessively compressing.","Crushing Pain | ",,,,,,,,,,,,,,,"4133049","Crushing pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008628","Chromosomal Deletion","C9484","Loss of a portion of a chromosome arm.","Chromosomal Deletion | Deletion, Chromosomal | Partial Monosomy | del",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1566685","Tyrosine-Protein Phosphatase Non-Receptor Type 11, Human","C18030","Tyrosine-protein phosphatase non-receptor type 11 (597 aa, ~68 kDa) is encoded by the human PTPN11 gene. This protein is involved in hormone-mediated signaling, cell adhesion and dephosphorylation of proteins.","Tyrosine-Protein Phosphatase Non-Receptor Type 11 | EC 3.1.3.48 | PTP-1D | PTP-2C | PTPN11 | Protein Tyrosine Phosphatase 2C | Protein Tyrosine Phosphatase, Non-Receptor Type 11 | Protein Tyrosine Phosphatase, Non-Receptor Type 11 | Protein-Tyrosine Phosphatase 1D | SH-PTP2 | SH-PTP3 | SHP-2 | SHP2 Phosphatase | Shp2 | Tyrosine Phosphatase SHP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085113","NF1 Gene","C17424","This gene plays a role in signal transduction and cytoskeletal remodeling.","NF1 Gene | NF1 | Neurofibromin 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0252194","Integrin Alpha-4","C97749","Integrin alpha-4 (1032 aa, ~115 kDa) is encoded by the human ITGA4 gene. This protein is involved in the mediation of both cell-cell and cell-matrix interactions in leukocytes.","Integrin Alpha-4 | Antigen CD49d | CD49 Antigen-Like Family Member D | CD49d | CD49d Antigen | ITGA4 | Integrin Alpha-IV | VLA-4 Subunit Alpha",,,,,,,,,,,,,,,"4012716","Lymphocyte antigen CD49D",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0278144","Dull Pain","C101175","A sensation of discomfort or distress that is non-specific or without clear boundaries.","Dull Pain | ",,,,,,,,,,,,,,,"4309024","Dull pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640015","Hurting Pain","C101176","A sensation of discomfort or distress that is very unpleasant.","Hurting Pain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640016","Pressing Pain","C101177","A sensation of discomfort or distress from excess weight or pressure on a specific anatomical location.","Pressing Pain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0234254","Radiating Pain","C101178","A sensation of discomfort or distress that spreads from one anatomic location to another.","Radiating Pain | ",,,,,,,,,,,,,,,"4322871","Radiating pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0455270","Sharp Pain","C101179","A sensation of discomfort or distress that is distinct and intensely focused.","Sharp Pain | ",,,,,,,,,,,,,,,"4336371","Sharp pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0278146","Shooting Pain","C101180","An intense sensation of discomfort or distress that radiates from one location to another sharply.","Shooting Pain | ",,,,,,,,,,,,,,,"4171519","Shooting pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0458257","Splitting Pain","C101181","An intense sensation of discomfort or distress that feels like being cut apart.","Splitting Pain | ",,,,,,,,,,,,,,,"4133048","Splitting pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0278145","Stabbing Pain","C101182","An intense sensation of discomfort or distress that is sharp and feels as though a knife has penetrated an anatomical location.","Stabbing Pain | ",,,,,,,,,,,,,,,"4207678","Stabbing pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640017","Tearing Pain","C101183","An intense sensation of discomfort or distress that feels like being torn or ripped apart.","Tearing Pain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640018","Painometer","C101184","A self-administered pain assessment tool the Pain-O-Meter (POM) was developed in 1996 by F. Gaston-Johansson to improve the assessment and management of acute and chronic pain.","Painometer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0183210","Sensor","C28220","A device that responds to a stimulus, such as heat, light, or pressure, and generates a signal that can be measured or interpreted.","Sensor | sensor",,,,,,,,,,,,,,,"4254068","Sensor device",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2985381","Systemic Radiation Therapy","C92991","Radiation therapy in which radioactive drugs are administered orally or through an injection then circulate through the blood and collect in tumor sites where they kill cancer cells.","Systemic Radiation Therapy | Radiation, Systemic | systemic radiation therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640032","Indefinite","C101204","Without end.","Indefinite | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640033","Debond Procedure","C101205","A procedure in orthodontics in which brackets are removed from the teeth.","Debond Procedure | Debond",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333735","GPRK2L protein, human","C26232","G protein-coupled receptor kinase 4 (578 aa, ~67 kDa) is encoded by the human GRK4 gene. This protein is involved in the phosphorylation of G protein-coupled receptors.","G Protein-Coupled Receptor Kinase 4 | EC 2.7.1.- | EC 2.7.11.16 | G Protein-Coupled Receptor Kinase 2 (Drosophila)-Like | G Protein-Coupled Receptor Kinase 2-Like | G Protein-Coupled Receptor Kinase 2-Like | G Protein-Coupled Receptor Kinase GRK4 | G Protein-Dependent Receptor Kinase 4 | GPRK2L | ITI1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0051844","angiogenin, ribonuclease, RNase A family, 5, human","C20430","Angiogenin (147 aa, ~17 kDa) is encoded by the human ANG gene. This protein plays a role in the modulation of both vascular development and transcription.","Angiogenin | ANG | Angiogenin, ribonuclease, RNase A family, 5 | EC 3.1.27.- | EC3.1.27.- | RNase 5 | Ribonuclease 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540512","Circumferential Supracrestal Fiberotomy","C101206","A surgical procedure to prevent rotational relapse of teeth after an orthodontic treatment; the epithelial attachment surrounding the involved teeth is severed.","Circumferential Supracrestal Fiberotomy | CSF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006840","Candidiasis","C26711","Infection with the organism Candida.","Candidiasis | Candida Infection | Candidosis | thrush",,,,,,,,,,,,,,,"433968","Candidiasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035322","Retinal Pigment Epithelium","C33470","A continuous, insulating monolayer of cuboidal/columnar epithelium which extends from the margins of the optic nerve head to the ora serrata where it is continuous with the pigment epithelium of the pars plana. This cell layer has many physical, optical, metabolic/biochemical and transport functions which play a critical role in the normal visual process, including acting as a selective filter to determine what nutrients reach the retina from the choroid.","Retinal Pigment Epithelium | RETINAL PIGMENTED EPITHELIAL LAYER | RPE",,,,,,,,,,,,,,,"4186569","Structure of retinal pigment epithelium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0180022","Colonoscope","C17613","A fiber-optic device used to performed colonoscopy. A colonoscope is a 75-inch long flexible tube, with camera and a special attachment to snip off or cauterize polyps, and to perform biopsies on the colon and rectum.","Colonoscope | colonoscope",,,,,,,,,,,,,,,"4233512","Colonoscope",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1416681","KLKB1 Gene","C95565","This gene plays a role in proteolytic processing.","KLKB1 Gene | KLKB1 | Kallikrein B, Plasma (Fletcher Factor) 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0060369","Fibroblast Growth Factor Receptors","C17297","Family of receptor tyrosine kinases for fibroblast growth factor. Amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution.","Fibroblast Growth Factor Receptor Family | FGF Receptor | FGF Receptor Family | FGF-R | FGFR | FGFR Family | FGFR Family Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0061516","Oxiglutatione","C62624","The oxidized disulfide form of glutathione (GSH) with potential protective activity. Glutathione disulfide (GSSG) is reduced by glutathione reductase to GSH. GSSG and GSH together play important roles in numerous redox reactions, such as those involved in the detoxification of harmful substances and free radicals, and in reactions preventing oxidative damage in erythrocytes. Upon ocular administration in irrigation solution, glutathione disulfide may exert a beneficial effect on the intracellular redox state of glutathione, thereby protecting the integrity and barrier function of the corneal endothelial cells.","Oxiglutatione | Bis(gamma-Glutamyl-L-cysteinylglycine) Disulfide | GSSG | Glutathione Disulfide | Glutathione Disulfide | L-Oxidized Glutathione | N,N'-(Dithiobis((R)-1-((carboxymethyl)carbamoyl)ethylene))di-L-glutamine | N-(N-gamma-glutamyl-cysteinyl)glycine-(2,2)-disulfide | OXIGLUTATIONE | Oxigluthione",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705286","MYB wt Allele","C53082","Human MYB wild-type allele is located within 6q22-q23 and is approximately 38 kb in length. This allele, which encodes Myb proto-oncogene protein, plays a role in both the modulation of transcription by RNA polymerase II and differentiation of hematopoietic progenitor cells.","MYB wt Allele | Avian Myeloblastosis Viral Oncogene Homolog Gene | Cmyb | MYB | MYB Proto-Oncogene, Transcription Factor wt Allele | MYB Protooncogene, Transcription Factor Gene | V-Myb Myeloblastosis Viral Oncogene Homolog Gene | c-MYB | efg | v-MYB Myeloblastosis Viral Oncogene Homolog (Avian) Gene | v-Myb Avian Myeloblastosis Viral Oncogene Homolog Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1134651","Beta-Glucan","C2678","A polysaccharide isolated from the cell walls of bacteria, plants, and fungi with immunostimulant and antineoplastic activities. In a solubilized form, beta-glucan binds to a lectin site within complement receptor 3 (CR3) on leukocytes, priming the receptor to trigger cytotoxic degranulation of leukocytes when leukocyte CR3 binds to complement 3 (iC3b)-coated tumors. Thus, the attachment of beta-glucan to CR3 of circulating leukocytes simulates leukocytes to kill iC3b-coated tumor cells in the same way as they kill iC3b-coated yeast. (NCI04)","Beta-Glucan | beta-glucan",,,,,,,,,,,,,,,"763418","Beta glucan",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2982859","Cervical Cancer Clinical Primary Tumor TNM Finding v7","C89479","A clinical finding about one or more characteristics of cervical cancer, following the rules of the TNM AJCC v7 classification system as they pertain to staging of the primary tumor.","Cervical Cancer Clinical Primary Tumor TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982874","Cervical Cancer cT3b TNM Finding v7","C89494","Cervical cancer extends to pelvic wall and/or causes hydronephrosis or nonfunctioning kidney. (from AJCC 7th Ed.)","Cervical Cancer cT3b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982873","Cervical Cancer cT3a TNM Finding v7","C89493","Cervical cancer involves lower third of vagina, without extension to pelvic wall. (from AJCC 7th Ed.)","Cervical Cancer cT3a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982872","Cervical Cancer cT3 TNM Finding v7","C89492","Cervical cancer extends to pelvic wall and/or involves lower third of vagina, and/or causes hydronephrosis or nonfunctioning kidney. (from AJCC 7th Ed.)","Cervical Cancer cT3 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982871","Cervical Cancer cT2b TNM Finding v7","C89491","Cervical cancer invades beyond uterus but not to pelvic wall or to lower third of vagina.  Parametrial invasion is present.  (from AJCC 7th Ed.)","Cervical Cancer cT2b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982870","Cervical Cancer cT2a2 TNM Finding v7","C89490","Cervical cancer invades beyond uterus but not to pelvic wall or to lower third of vagina.  There is no parametrial invasion.  Clinically visible lesions more than 4.0 cm in greatest dimension are present.  (from AJCC 7th Ed.)","Cervical Cancer cT2a2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982869","Cervical Cancer cT2a1 TNM Finding v7","C89489","Cervical cancer invades beyond uterus but not to pelvic wall or to lower third of vagina.  There is no parametrial invasion.  Clinically visible lesions 4.0 cm or less in greatest dimension are present.  (from AJCC 7th Ed.)","Cervical Cancer cT2a1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982868","Cervical Cancer cT2a TNM Finding v7","C89488","Cervical cancer invades beyond uterus but not to pelvic wall or to lower third of vagina.  There is no parametrial invasion. (from AJCC 7th Ed.)","Cervical Cancer cT2a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982867","Cervical Cancer cT2 TNM Finding v7","C89487","Cervical cancer invades beyond uterus but not to pelvic wall or to lower third of vagina. (from AJCC 7th Ed.)","Cervical Cancer cT2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982866","Cervical Cancer cT1b2 TNM Finding v7","C89486","Invasive cervical cancer with clinically visible lesion more than 4.0 cm in greatest dimension confined to the cervix. (from AJCC 7th Ed.)","Cervical Cancer cT1b2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982865","Cervical Cancer cT1b1 TNM Finding v7","C89485","Cervical cancer with clinically visible lesion 4.0 cm or less in greatest dimension confined to the cervix. (from AJCC 7th Ed.)","Cervical Cancer cT1b1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982864","Cervical Cancer cT1b TNM Finding v7","C89484","Cervical cancer with clinically visible lesion confined to the cervix. (from AJCC 7th Ed.)","Cervical Cancer cT1b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982863","Cervical Cancer cT1 TNM Finding v7","C89483","Cervical cancer confined to uterus (extension to corpus should be disregarded). (from AJCC 7th Ed.)","Cervical Cancer cT1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982861","Cervical Cancer cT0 TNM Finding v7","C89481","Cervical cancer with no evidence of primary tumor. (from AJCC 7th Ed.)","Cervical Cancer cT0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982862","Cervical Cancer cTis TNM Finding v7","C89482","Cervical cancer with a finding of carcinoma in situ. (from AJCC 7th Ed.)","Cervical Cancer cTis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982860","Cervical Cancer cTX TNM Finding v7","C89480","Cervical cancer in which primary tumor cannot be assessed. (from AJCC 7th Ed.)","Cervical Cancer cTX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982876","Cervical Cancer Clinical Regional Lymph Nodes TNM Finding v7","C89496","A clinical finding about one or more characteristics of cervical cancer, following the rules of the TNM AJCC v7 classification system as they pertain to staging of regional lymph nodes.","Cervical Cancer Clinical Regional Lymph Nodes TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982879","Cervical Cancer cN1 TNM Finding v7","C89499","Cervical cancer with regional lymph node metastasis. (from AJCC 7th Ed.)","Cervical Cancer cN1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982878","Cervical Cancer cN0 TNM Finding v7","C89498","Cervical cancer with no regional lymph node metastasis. (from AJCC 7th Ed.)","Cervical Cancer cN0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982877","Cervical Cancer cNX TNM Finding v7","C89497","Cervical cancer in which regional lymph nodes cannot be assessed. (from AJCC 7th Ed.)","Cervical Cancer cNX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982880","Cervical Cancer Clinical Distant Metastasis TNM Finding v7","C89500","A clinical finding about one or more characteristics of cervical cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.","Cervical Cancer Clinical Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982882","Cervical Cancer cM1 TNM Finding v7","C89502","Cervical cancer with distant metastasis (including peritoneal spread, involvement of supraclavicular, mediastinal, or paraaortic lymph nodes, lung, liver, or bone). (from AJCC 7th Ed.)","Cervical Cancer cM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982857","Cervical Cancer TNM Finding v7","C89477","A finding about one or more characteristics of cervical cancer, following the rules of the TNM AJCC v7 classification system.","Cervical Cancer TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981950","Soft Tissue Sarcoma TNM Finding v7","C88449","A finding about one or more characteristics of soft tissue sarcoma, following the rules of the TNM AJCC v7 classification system.  Kaposi sarcoma, fibromatosis (desmoid tumor), and sarcoma arising from the dura mater, brain, parenchymatous organs, or hollow viscera are not included in this classification. (from AJCC 7th Ed.)","Soft Tissue Sarcoma TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981954","Soft Tissue Sarcoma pT0 TNM Finding v7","C88453","Soft tissue sarcoma with no evidence of primary tumor. (from AJCC 7th Ed.)","Soft Tissue Sarcoma pT0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981955","Soft Tissue Sarcoma pT1 TNM Finding v7","C88454","Soft tissue sarcoma with tumor measuring 5 cm or less in greatest dimension. (from AJCC 7th Ed.)","Soft Tissue Sarcoma pT1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981956","Soft Tissue Sarcoma pT1a TNM Finding v7","C88455","Soft tissue sarcoma with superficial tumor measuring 5 cm or less in greatest dimension. (from AJCC 7th Ed.)","Soft Tissue Sarcoma pT1a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981957","Soft Tissue Sarcoma pT1b TNM Finding v7","C88456","Soft tissue sarcoma with deep tumor measuring 5 cm or less in greatest dimension. (from AJCC 7th Ed.)","Soft Tissue Sarcoma pT1b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981958","Soft Tissue Sarcoma pT2 TNM Finding v7","C88457","Soft tissue sarcoma with tumor measuring more than 5 cm in greatest dimension. (from AJCC 7th Ed.)","Soft Tissue Sarcoma pT2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981959","Soft Tissue Sarcoma pT2a TNM Finding v7","C88458","Soft tissue sarcoma with superficial tumor measuring more than 5 cm in greatest dimension. (from AJCC 7th Ed.)","Soft Tissue Sarcoma pT2a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981960","Soft Tissue Sarcoma pT2b TNM Finding v7","C88459","Soft tissue sarcoma with deep tumor measuring more than 5 cm in greatest dimension. (from AJCC 7th Ed.)","Soft Tissue Sarcoma pT2b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981953","Soft Tissue Sarcoma pTX TNM Finding v7","C88452","Soft tissue sarcoma in which the primary tumor cannot be assessed. (from AJCC 7th Ed.)","Soft Tissue Sarcoma pTX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981963","Soft Tissue Sarcoma pN0 TNM Finding v7","C88462","Soft tissue sarcoma without regional lymph node metastasis. (from AJCC 7th Ed.)","Soft Tissue Sarcoma pN0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981964","Soft Tissue Sarcoma pN1 TNM Finding v7","C88463","Soft tissue sarcoma with regional lymph node metastasis.  Note: Presence of positive nodes (N1) in M0 tumors is considered Stage III. (from AJCC 7th Ed.)","Soft Tissue Sarcoma pN1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981962","Soft Tissue Sarcoma pNX TNM Finding v7","C88461","Soft tissue sarcoma in which regional lymph nodes cannot be assessed.  (from AJCC 7th Ed.)","Soft Tissue Sarcoma pNX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032145","Plasminogen Activator Inhibitor","C16997","A member of the serpin family of serine protease inhibitor proteins that inhibits plasminogen activator type proteases.","Plasminogen Activator Inhibitor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1612225","Bone Morphogenetic Protein 6, Human","C21356","Bone morphogenetic protein 6 (513 aa, ~57 kDa) is encoded by the human BMP6 gene. This protein is involved in bone development.","Bone Morphogenetic Protein 6 | BMP-6 | BMP6 | VG-1-R | VG-1-Related Protein | VGR-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1567772","Bone Morphogenetic Protein 2, Human","C21350","Bone morphogenetic protein 2 (396 aa, ~45 kDa) is encoded by the human BMP2 gene. This protein plays a role in cartilage and bone formation.","Bone Morphogenetic Protein 2 | BMP-2 | BMP-2A | BMP2 | Bone Morphogenetic Protein 2A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981968","Soft Tissue Sarcoma Clinical Distant Metastasis TNM Finding v7","C88467","A clinical finding about one or more characteristics of soft tissue sarcoma, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.","Soft Tissue Sarcoma Clinical Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981969","Soft Tissue Sarcoma cM0 TNM Finding v7","C88468","Soft tissue sarcoma without evidence of distant metastasis. (from AJCC 7th Ed.)","Soft Tissue Sarcoma cM0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981970","Soft Tissue Sarcoma cM1 TNM Finding v7","C88469","Soft tissue sarcoma with distant metastasis. (from AJCC 7th Ed.)","Soft Tissue Sarcoma cM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981965","Soft Tissue Sarcoma Pathologic Distant Metastasis TNM Finding v7","C88464","A pathologic finding about one or more characteristics of soft tissue sarcoma, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  There is no pathologic M0 for soft tissue sarcoma.","Soft Tissue Sarcoma Pathologic Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981966","Soft Tissue Sarcoma pM1 TNM Finding v7","C88465","Soft tissue sarcoma with distant metastasis. (from AJCC 7th Ed.)","Soft Tissue Sarcoma pM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796624","stage IV soft tissue sarcoma","C8586","Stage IV includes: Any T, Any N, M1, Any G.  M1: Distant metastasis. (AJCC 7th ed.)","Stage IV Soft Tissue Sarcoma AJCC v7 | Stage IV Sarcoma of Soft Tissue | Stage IV Sarcoma of the Soft Tissue | Stage IV Soft Tissue Sarcoma | Stage IV Soft Tissue Sarcoma | stage IV soft tissue sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796623","stage III soft tissue sarcoma","C8585","Stage III includes: (T2a, T2b, N0, M0, G3); (Any T, N1, M0, Any G).  T2a: Superficial tumor more than 5 cm in greatest dimension.  T2b: Deep tumor more than 5 cm in greatest dimension.  N0: No regional lymph node metastasis.  N1: Regional lymph node metastasis.  M0: No distant metastasis.  G3: Grade 3.  There is no T2a for the pathologic group. (AJCC 7th ed.)","Stage III Soft Tissue Sarcoma AJCC v7 | Stage III Sarcoma of Soft Tissue | Stage III Sarcoma of the Soft Tissue | Stage III Soft Tissue Sarcoma | Stage III Soft Tissue Sarcoma | stage III soft tissue sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796620","Stage IIB Soft Tissue Sarcoma","C8582","Stage IIB includes: (T2a, N0, M0, G2); (T2b, N0, M0, G2).  T2a: Superficial tumor more than 5 cm in greatest dimension.  T2b: Deep tumor more than 5 cm in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  G2: Grade 2.  (AJCC 7th ed.)","Stage IIB Soft Tissue Sarcoma AJCC v7 | Stage IIB Sarcoma of Soft Tissue | Stage IIB Sarcoma of the Soft Tissue | Stage IIB Soft Tissue Sarcoma | Stage IIB Soft Tissue Sarcoma | stage IIB soft tissue sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796619","Stage IIA Soft Tissue Sarcoma","C8581","Stage IIA includes: (T1a, N0, M0, G2, G3); (T1b, N0, M0, G2, G3).  T1a: Superficial tumor 5 cm or less in greatest dimension.  T1b: Deep tumor 5 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  G2: Grade 2.  G3: Grade 3. (AJCC 7th ed.)","Stage IIA Soft Tissue Sarcoma AJCC v7 | Stage IIA Sarcoma of Soft Tissue | Stage IIA Sarcoma of the Soft Tissue | Stage IIA Soft Tissue Sarcoma | Stage IIA Soft Tissue Sarcoma | stage IIA soft tissue sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796618","Stage IB Soft Tissue Sarcoma","C8580","Stage IB includes: (T2a, N0, M0, G1, GX); (T2b, N0, M0, G1, GX).  T2a: Superficial tumor more than 5 cm in greatest dimension.  T2b: Deep tumor more than 5 cm in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  G1: Grade 1.  GX: Grade cannot be assessed. (AJCC 7th ed.)","Stage IB Soft Tissue Sarcoma AJCC v7 | Stage IB Sarcoma of Soft Tissue | Stage IB Sarcoma of the Soft Tissue | Stage IB Soft Tissue Sarcoma | Stage IB Soft Tissue Sarcoma | stage IB soft tissue sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796621","Stage IA Soft Tissue Sarcoma","C8583","Stage IA includes: (T1a, N0, M0, G1, GX); (T1b, N0, M0, G1, GX).  T1a: Superficial tumor 5 cm or less in greatest dimension.  T1b: Deep tumor 5 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  G1: Grade 1.  GX: Grade cannot be assessed. (AJCC 7th ed.)","Stage IA Soft Tissue Sarcoma AJCC v7 | Stage IA Sarcoma of Soft Tissue | Stage IA Sarcoma of the Soft Tissue | Stage IA Soft Tissue Sarcoma | Stage IA Soft Tissue Sarcoma | stage IA soft tissue sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448509","Reactive Lymphocyte","C12847","A type of white blood cell that enlarges in response to antigenic stimulation.","Reactive Lymphocyte | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1956422","Cancer Stem Cell","C68706","A malignant cell which may derive from mutations in normal stem cells. Cancer stem cells proliferate and give rise to other malignant cells. They may be present in very small numbers in the tumor and may not be present in all tumors. Many investigators believe that cancer stem cells cause relapse of the tumor and that novel cancer therapies should specifically target those cells.","Cancer Stem Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022634","Ketone","C94716","Organic compounds with a carbonyl group (C=O) bonded to two other carbon atoms as the skeleton structure. Acetone is the simplest ketone compound.","Ketone | Ketones | ketone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0967777","MOK protein, human","C29759","MAPK/MAK/MRK overlapping kinase (419 aa, ~48 kDa) is encoded by the human MOK gene. This protein plays a role in serine/threonine phosphorylation.","MAPK/MAK/MRK Overlapping Kinase | EC 2.7.11.22 | MOK Protein Kinase | RAGE | RAGE1 | Renal Tumor Antigen | Renal Tumor Antigen | Renal Tumor Antigen 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3502086","HSP90 inhibitor PU-H71","C101227","A purine-based heat shock protein 90 (Hsp90) inhibitor with potential antineoplastic activity. Zelavespib specifically inhibits active Hsp90, thereby inhibiting its chaperone function and promoting the proteasomal degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. This may result in the inhibition of cellular proliferation in susceptible tumor cell populations. Hsp90, a molecular chaperone protein, is upregulated in a variety of tumor cell types.","Zelavespib | 9H-Purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)- | Hsp90 Inhibitor PU-H71 | Hsp90 Inhibitor PU-H71 | PU-H-71 | PU-H71 | PUH71 | ZELAVESPIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0436307","Chemoradiotherapy","C94626","Treatment that combines chemotherapy with radiation therapy. Chemoradiation can be concurrent or sequential. ","Chemoradiotherapy | CRT | CRTx | Chemoradiation | RCTx | RT-CT | Radiochemotherapy | chemoradiation | chemoradiotherapy",,,,,,,,,,,,,,,"45766298","Combined chemotherapy and radiation therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2987516","Cervix Intraepithelial Neoplasia Grade 3 AJCC v7","C89550","Stage 0 includes: (Tis, N0, M0). Tis: Carcinoma in situ. N0: No regional lymph node metastasis.  M0: No distant metastasis. FIGO no longer includes stage 0. (AJCC 7th ed.)","Stage 0 Cervical Cancer AJCC v7 | CIN 3 | CIN 3 AJCC v7 | CIN Grade 3 | CIN Grade 3 AJCC v7 | Carcinoma in situ of cervix, unspecified | Carcinoma in situ of the Cervix | Carcinoma in situ of the Cervix AJCC v7 | Cervical Carcinoma in situ | Cervical Carcinoma in situ AJCC v7 | Cervix Intraepithelial Neoplasia Grade 3 | Cervix Intraepithelial Neoplasia Grade 3 AJCC v7 | Severe Cervical Dysplasia | Severe Cervical Dysplasia AJCC v7 | Severe Dysplasia of Uterine Cervix | Severe Dysplasia of Uterine Cervix AJCC v7 | Stage 0 Cervical Cancer | Stage 0 Cervical Cancer | Stage 0 Cervical Cancer  | stage 0 cervical carcinoma in situ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987519","Cervical carcinoma stage II AJCC v7","C89551","Stage II includes: II (T2, N0, M0); IIA (T2a, N0, M0); IIA1 (T2a1, N0, M0); IIA2 (T2a2, N0, M0); IIB (T2b, N0, M0); T2: Cervical carcinoma invades beyond uterus but not to pelvic wall or to lower third of vagina. T2a: Tumor without parametrial invasion.  T2a1: Clinically visible lesion 4.0 cm or less in greatest dimension.  T2a2: Clinically visible lesion more than 4.0 cm in greatest dimension.  T2b: Tumor with parametrial invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage II Cervical Cancer AJCC v7 | Stage II Cervical Cancer | Stage II Cervical Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2216727","malignant neoplasm of cervix stage IIa","C89552","Stage IIA includes: IIA (T2a, N0, M0); IIA1 (T2a1, N0, M0); IIA2 (T2a2, N0, M0).  T2a: Tumor without parametrial invasion.  T2a1: Clinically visible lesion 4.0 cm or less in greatest dimension.  T2a2: Clinically visible lesion more than 4.0 cm in greatest dimension.  N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)","Stage IIA Cervical Cancer AJCC v7 | Stage IIA Cervical Cancer | Stage IIA Cervical Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0886584","Metyrosine","C998","A methylated tyrosine, a catecholamine synthesis antagonist with antihypertensive property. Metyrosine competitively inhibits tyrosine 3-monooxygenase, an enzyme that activates molecular oxygen to catalyze the hydroxylation of tyrosine to dihydroxyphenylalanine (Dopa), an intermediate to catecholamine (dopamine, norepinephrine, and epinephrine) production. This agent reduces the elevated levels of catecholamines associated with pheochromocytoma, thereby preventing hypertension.","Metyrosine | Alpha-methyl-p-tyrosine | Demser | L-588357-0 | METYROSINE | MK-781 | Metirosine | methyl-tyrosine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL383618","Glesatinib","C77876","An orally bioavailable, small-molecule, multitargeted tyrosine kinase inhibitor with potential antineoplastic activity. Glesatinib binds to and inhibits the phosphorylation of several receptor tyrosine kinases (RTKs), including the c-Met receptor (hepatocyte growth factor receptor); the Tek/Tie-2 receptor; vascular endothelial growth factor receptor (VEGFR) types 1, 2, and 3; and the macrophage-stimulating 1 receptor (MST1R or RON). Inhibition of these RTKs and their downstream signaling pathways may result in the inhibition of tumor angiogenesis and tumor cell proliferation in tumors overexpressing these RTKs.","Glesatinib | GLESATINIB | MG90265 | MG90265X | MGCD265 | Multitargeted Tyrosine Kinase Inhibitor MGCD265 | TKI MGCD265",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0947703","Fibrin Sealant","C2664","A plasma-derived fibrin biomatrix preparation consisting of two separate solutions that are combined on application. The sealer protein solution contains clottable human fibrinogen and bovine aprotinin, a fibrinolysis inhibitor; the thrombin solution contains human thrombin and calcium chloride. When the solutions are combined, a clot is formed, reproducing the final stages of the coagulation cascade.","Fibrin Sealant | Artiss | Beriplast P | TISSEEL | TISSEEL VH Kit | fibrin sealant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640066","Random Periareolar Fine-Needle Aspiration","C101266","A procedure in which a fine needle is inserted around the area of the areola to aspirate cells from the breast parenchyma and is used to evaluate the short-term risk of developing breast cancer in women with a family history of breast cancer.","Random Periareolar Fine-Needle Aspiration | RPFNA | Random Periareolar Fine Needle Aspiration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0751623","Second Primary Malignant Neoplasm","C95606","A primary malignant neoplasm in a patient who has been already diagnosed with a primary malignant neoplasm in another anatomic site.","Second Primary Malignant Neoplasm | Second Malignant Neoplasm | Second Primary Cancer | Second primary tumor | second cancer",,,,,,,,,,,,,,,"609278","Second primary cancer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2982631","Prostate Cancer Clinical TNM Finding v7","C89206","A clinical finding about one or more characteristics of prostate cancer, following the rules of the TNM AJCC v7 classification system.","Prostate Cancer Clinical TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982634","Prostate Cancer cT0 TNM Finding v7","C89209","No evidence of primary tumor. (from AJCC 7th Ed.)","Prostate Cancer cT0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982649","Prostate Cancer cN0 TNM Finding v7","C89224","Prostate cancer with no regional lymph node metastasis. (from AJCC 7th Ed.)","Prostate Cancer cN0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982648","Prostate Cancer cNX TNM Finding v7","C89223","Prostate cancer in which the regional lymph nodes cannot be assessed.  (from AJCC 7th Ed.)","Prostate Cancer cNX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982656","Prostate Cancer cM1c TNM Finding v7","C89231","Prostate cancer with metastasis to other site(s) with or without bone disease. (from AJCC 7th Ed.)","Prostate Cancer cM1c TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982625","Prostate Cancer Pathologic TNM Finding v7","C89200","A pathologic finding about one or more characteristics of prostate cancer, following the rules of the TNM AJCC v7 classification system.  (from AJCC 7th Ed.)","Prostate Cancer Pathologic TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709724","Prostate Cancer pNX TNM Finding v6 and v7","C52682","Prostate cancer in which the regional lymph nodes were not sampled. (from AJCC 6th and 7th Eds.)","Prostate Cancer pNX TNM Finding v6 and v7 | Prostate Cancer pNX TNM Finding | Prostate Cancer pNX TNM Finding | Prostate Cancer pNX TNM Finding v6 | Prostate Cancer pNX TNM Finding v7 | pNX Cancer of Prostate | pNX Cancer of the Prostate | pNX Carcinoma of Prostate | pNX Carcinoma of the Prostate | pNX Prostate Cancer | pNX Prostate Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984097","Prostate Cancer by AJCC v7 Stage","C91233","A term that refers to the staging of prostate carcinoma according to the American Joint Committee on Cancer, 7th edition.","Prostate Cancer by AJCC v7 Stage | Prostate Carcinoma by AJCC v7 Stage | Prostate Carcinoma by AJCC v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3146264","Stage IV Prostate Cancer AJCC v7","C89235","Stage IV includes: (T4, N0, M0, Any PSA, Any Gleason); (Any T, N1, M0, Any PSA, Any Gleason); (Any T, Any N, M1, Any PSA, Any Gleason). cT4: Tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall.  pT4: Invasion of rectum, levator muscles, and/or pelvic wall.  N1: Metastasis in regional lymph node(s).  M1: Distant metastasis.  (AJCC 7th ed.)","Stage IV Prostate Cancer AJCC v7 | Stage IV Prostate Cancer | Stage IV Prostate Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3146262","Stage III Prostate Cancer AJCC v7","C89234","Stage III includes: T3a-b, N0, M0, Any PSA, Any Gleason.  cT3a: Tumor with extracapsular extension (unilateral or bilateral).  pT3a: Tumor with extraprostatic extension or microscopic invasion of bladder neck.  T3b: Tumor invades seminal vesicle(s).  cN0: No regional lymph node metastasis.  pN0: No positive regional nodes.  M0: No distant metastasis.  (AJCC 7th ed.)","Stage III Prostate Cancer AJCC v7 | Stage III Prostate Cancer | Stage III Prostate Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL415847","stage IIB prostate cancer","C88107","Stage IIB includes: (T2c, N0, M0, Any PSA, Any Gleason); (T1-2, N0, M0, PSA equal or more than 20, Any Gleason); (T1-2, N0, M0, Any PSA, Gleason equal or more than 8).  T2c: Tumor involves both lobes.  T1a: Tumor incidental histologic finding in 5% or less of tissue resected.  T1b: Tumor incidental histologic finding in more than 5% of tissue resected.  T1c: Tumor identified by needle biopsy (e.g., because of elevated PSA).  T2a: Tumor involves one-half of one lobe or less.  T2b: Tumor involves more than one-half of one lobe, but not both lobes.  cN0: No regional lymph node metastasis.  pN0: No positive regional nodes.  M0: No distant metastasis.  Gleason equal or more than 8: Poorly differentiated/undifferentiated (marked anaplasia).  (AJCC 7th ed.)","Stage IIB Prostate Cancer AJCC v7 | Stage IIB Prostate Cancer | Stage IIB Prostate Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL415846","stage IIA prostate cancer","C88106","Stage IIA includes: (T1a-c, N0, M0, PSA less than 20, Gleason 7); (T1a-c, N0, M0, PSA equal or more than 10 and less than 20, Gleason equal or less than 6); (T2a, N0, M0, PSA less than 20, Gleason equal or less than 7); (T2b, N0, M0, PSA less than 20, Gleason equal or less than 7); (T2b, N0, M0, PSA X, Gleason X). T1a: Tumor incidental histologic finding in 5% or less of tissue resected.  T1b: Tumor incidental histologic finding in more than 5% of tissue resected.  T1c: Tumor identified by needle biopsy (e.g., because of elevated PSA).  T2a: Tumor involves one-half of one lobe or less.  T2b: Tumor involves more than one-half of one lobe, but not both lobes.  cN0: No regional lymph node metastasis.  pN0: No positive regional nodes.  M0: No distant metastasis.  Gleason 7: Moderately differentiated (moderate anaplasia).  Gleason Equal or Less than 6: Well differentiated (slight anaplasia).  (AJCC 7th ed.)","Stage IIA Prostate Cancer AJCC v7 | Stage IIA Prostate Cancer | Stage IIA Prostate Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3146263","Stage I Prostate Cancer AJCC v7","C89232","Stage I includes: (T1a-c, N0, M0, PSA less than 10, Gleason equal or less than 6); (T2a, N0, M0, PSA less than 10, Gleason equal or less than 6); (T1-2a, N0, M0, PSA X, Gleason X).  T1a: Tumor incidental histologic finding in 5% or less of tissue resected.  T1b: Tumor incidental histologic finding in more than 5% of tissue resected.  T1c: Tumor identified by needle biopsy (e.g., because of elevated PSA).  T2a: Tumor involves one-half of one lobe or less. cN0: No regional lymph node metastasis.  pN0: No positive regional nodes.  M0: No distant metastasis.  Gleason Equal or Less than 6: Well differentiated (slight anaplasia).  Gleason X: Gleason score cannot be processed.  (AJCC 7th ed.)","Stage I Prostate Cancer AJCC v7 | Stage I Prostate Cancer | Stage I Prostate Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1379609","Fibronectin","C16581","Fibronectin (2386 aa, ~263 kDa) is encoded by the human FN1 gene. This protein is involved in cell adhesion- and migration-dependent processes including embryogenesis, wound healing, blood coagulation, host defense, and metastasis.","Fibronectin | CIG | Cold-Insoluble Globulin | FN | FN1 | FNZ | Fibronectin 1 | Fibronectin Isoform 1 | Isoform 1 Fibronectin | LETS | LETS Protein | Large External Transformation-Sensitive Protein | Large, External, Transformation-Sensitive Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL360009","Aromatase","C16307","Aromatase (503 aa, ~58 kDa) is encoded by the human CYP19A1 gene. This protein is involved in the conversion of androgens to estrogens.","Aromatase | Aromatase Cytochrome P450 | CYP19A1 | CYPXIX | Cytochrome P-450AROM | Cytochrome P450 19A1 | Cytochrome P450, Family 19, Subfamily A, Polypeptide 1 | EC 1.14.14.1 | EC 1.14.14.14 | EC:1.14.14.14 | Estrogen Synthetase | Flavoprotein-Linked Monooxygenase | Microsomal Monooxygenase | p450arom",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202115","Lactic Acid Measurement","C79450","The determination of the amount of lactic acid present in a sample.","Lactic Acid Measurement | 2-hydroxypropanoic acid | LACTICAC | Lactate | Lactic Acid",,,,,,,,,,,,,,,"4213582","Lactic acid measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001122","Acidosis","C83504","An abnormally high acidity of the blood and other body tissues. Acidosis can be either respiratory or metabolic.","Acidosis | ",,,,,,,,,,,,,,,"435517","Acidosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2983012","Ovarian Cancer and Primary Peritoneal Carcinoma TNM Finding v7","C89637","A finding about one or more characteristics of ovarian cancer or primary peritoneal carcinoma, following the rules of the TNM AJCC v7 classification system.  Ovarian cancer and primary peritoneal carcinoma are surgically/pathologically staged malignancies. (from AJCC 7th Ed.)","Ovarian Cancer and Primary Peritoneal Carcinoma TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983017","Ovarian Cancer and Primary Peritoneal Carcinoma pT1 TNM Finding v7","C89642","Ovarian cancer limited to ovaries (one or both). (from AJCC 7th Ed.)","Ovarian Cancer and Primary Peritoneal Carcinoma pT1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983018","Ovarian Cancer and Primary Peritoneal Carcinoma pT1a TNM Finding v7","C89643","Ovarian cancer limited to one ovary; capsule intact, no tumor on ovarian surface.  No malignant cells in ascites or peritoneal washings.  (from AJCC 7th Ed.)","Ovarian Cancer and Primary Peritoneal Carcinoma pT1a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983019","Ovarian Cancer and Primary Peritoneal Carcinoma pT1b TNM Finding v7","C89644","Ovarian cancer limited to both ovaries; capsule intact, no tumor on ovarian surface.  No malignant cells in ascites or peritoneal washings. (from AJCC 7th Ed.)","Ovarian Cancer and Primary Peritoneal Carcinoma pT1b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983020","Ovarian Cancer and Primary Peritoneal Carcinoma pT1c TNM Finding v7","C89645","Ovarian cancer or primary peritoneal carcinoma limited to one or both ovaries with any of the following: capsule ruptured, tumor on ovarian surface, malignant cells in ascites or peritoneal washings. (from AJCC 7th Ed.)","Ovarian Cancer and Primary Peritoneal Carcinoma pT1c TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983021","Ovarian Cancer and Primary Peritoneal Carcinoma pT2 TNM Finding v7","C89646","Ovarian cancer or primary peritoneal carcinoma involving one or both ovaries with pelvic extension. (from AJCC 7th Ed.)","Ovarian Cancer and Primary Peritoneal Carcinoma pT2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983022","Ovarian Cancer and Primary Peritoneal Carcinoma pT2a TNM Finding v7","C89647","Ovarian cancer or primary peritoneal carcinoma with extension and/or implants on uterus and/or tube(s).  No malignant cells in ascites or peritoneal washings. (from AJCC 7th Ed.)","Ovarian Cancer and Primary Peritoneal Carcinoma pT2a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983023","Ovarian Cancer and Primary Peritoneal Carcinoma pT2b TNM Finding v7","C89648","Ovarian cancer or primary peritoneal carcinoma with extension to and/or implants on other pelvic tissues.  No malignant cells in ascites or peritoneal washings. (from AJCC 7th Ed.)","Ovarian Cancer and Primary Peritoneal Carcinoma pT2b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983024","Ovarian Cancer and Primary Peritoneal Carcinoma pT2c TNM Finding v7","C89649","Ovarian cancer or primary peritoneal carcinoma with pelvic extension and/or implants (T2a or T2b) with malignant cells in ascites or peritoneal washings. (from AJCC 7th Ed.)","Ovarian Cancer and Primary Peritoneal Carcinoma pT2c TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983025","Ovarian Cancer and Primary Peritoneal Carcinoma pT3 TNM Finding v7","C89650","Ovarian cancer or primary peritoneal carcinoma involving one or both ovaries with microscopically confirmed peritoneal metastasis outside the pelvis. (from AJCC 7th Ed.)","Ovarian Cancer and Primary Peritoneal Carcinoma pT3 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983026","Ovarian Cancer and Primary Peritoneal Carcinoma pT3a TNM Finding v7","C89651","Ovarian cancer or primary peritoneal carcinoma with microscopic peritoneal metastasis beyond pelvis (no macroscopic tumor). (from AJCC 7th Ed.)","Ovarian Cancer and Primary Peritoneal Carcinoma pT3a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983027","Ovarian Cancer and Primary Peritoneal Carcinoma pT3b TNM Finding v7","C89652","Ovarian cancer or primary peritoneal carcinoma with macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension. (from AJCC 7th Ed.)","Ovarian Cancer and Primary Peritoneal Carcinoma pT3b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983028","Ovarian Cancer and Primary Peritoneal Carcinoma pT3c TNM Finding v7","C89653","Ovarian cancer or primary peritoneal carcinoma with peritoneal metastasis beyond pelvis more than 2 cm in greatest dimension and/or regional lymph node metastasis. (from AJCC 7th Ed.)","Ovarian Cancer and Primary Peritoneal Carcinoma pT3c TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983015","Ovarian Cancer and Primary Peritoneal Carcinoma pTX TNM Finding v7","C89640","Ovarian cancer or primary peritoneal carcinoma in which the primary tumor cannot be assessed. (from AJCC 7th Ed.)","Ovarian Cancer and Primary Peritoneal Carcinoma pTX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983016","Ovarian Cancer and Primary Peritoneal Carcinoma pT0 TNM Finding v7","C89641","Ovarian cancer or primary peritoneal carcinoma with no evidence of primary tumor. (from AJCC 7th Ed.)","Ovarian Cancer and Primary Peritoneal Carcinoma pT0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983031","Ovarian Cancer and Primary Peritoneal Carcinoma pN0 TNM Finding v7","C89656","Ovarian cancer or primary peritoneal carcinoma without regional lymph node metastasis. (from AJCC 7th Ed.)","Ovarian Cancer and Primary Peritoneal Carcinoma pN0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983032","Ovarian Cancer and Primary Peritoneal Carcinoma pN1 TNM Finding v7","C89657","Ovarian cancer or primary peritoneal carcinoma with regional lymph node metastasis. (from AJCC 7th Ed.)","Ovarian Cancer and Primary Peritoneal Carcinoma pN1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983030","Ovarian Cancer and Primary Peritoneal Carcinoma pNX TNM Finding v7","C89655","Ovarian cancer or primary peritoneal carcinoma in which regional lymph nodes cannot be assessed. (from AJCC 7th Ed.)","Ovarian Cancer and Primary Peritoneal Carcinoma pNX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983036","Ovarian Cancer and Primary Peritoneal Carcinoma Clinical Distant Metastasis TNM Finding v7","C89661","A clinical finding about one or more characteristics of ovarian cancer or primary peritoneal carcinoma, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.","Ovarian Cancer and Primary Peritoneal Carcinoma Clinical Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983037","Ovarian Cancer and Primary Peritoneal Carcinoma cM0 TNM Finding v7","C89662","Ovarian cancer or primary peritoneal carcinoma without evidence of distant metastasis. (from AJCC 7th Ed.)","Ovarian Cancer and Primary Peritoneal Carcinoma cM0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983038","Ovarian Cancer and Primary Peritoneal Carcinoma cM1 TNM Finding v7","C89663","Ovarian cancer or primary peritoneal carcinoma with distant metastasis (excludes peritoneal metastasis). (from AJCC 7th Ed.)","Ovarian Cancer and Primary Peritoneal Carcinoma cM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983033","Ovarian Cancer and Primary Peritoneal Carcinoma Pathologic Distant Metastasis TNM Finding v7","C89658","A pathologic finding about one or more characteristics of ovarian cancer or primary peritoneal carcinoma, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  There is no pathologic M0 for ovarian cancer or primary peritoneal carcinoma.","Ovarian Cancer and Primary Peritoneal Carcinoma Pathologic Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983034","Ovarian Cancer and Primary Peritoneal Carcinoma pM1 TNM Finding v7","C89659","Ovarian cancer or primary peritoneal carcinoma with distant metastasis (excludes peritoneal metastasis). (from AJCC 7th Ed.)","Ovarian Cancer and Primary Peritoneal Carcinoma pM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0392220","Scalpel","C28218","A small, thin knife used for surgery.","Scalpel | scalpel",,,,,,,,,,,,,,,"4010669","Scalpel",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036186","Saphenous Vein","C33511","One of two (Greater, Small) superficial veins of the leg and thigh.","Saphenous Vein | SAPHENOUS VEIN | VEIN, SAPHENA",,,,,,,,,,,,,,,"4235177","Saphenous vein structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1318439","Urine Creatinine Measurement","C61048","A quantitative measurement of the total amount of creatinine present in a sample of urine.","Urine Creatinine Measurement | ",,,,,,,,,,,,,,,"4150621","Creatinine measurement, urine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1314305","Compression Pump","C93147","A system comprised of a programmable pneumatic compressor controller and appendage-specific air-chambered garments designed to stimulate the lymphatic system and treat lymphedema.","Compression Pump | Pneumatic Compression Device | Pneumatic Compression Pump | compression pump",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985539","Compression Garment","C93298","A tight-fitting, elastic garment, such as a sleeve or stocking. Compression garments are used in the treatment of lymphedema (swelling caused by a buildup of lymph fluid in tissue). They are also used to improve blood flow.","Compression Garment | compression garment",,,,,,,,,,,,,,,"4234435","Pressure garments",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640003","Computed Tomography Dose Index Volume","C101138","The International Electrotechnical Commission preferred expression of radiation dose in computed tomography (CT) dosimetry. It is calculated by averaging the radiation dose delivered over x,y and z directions and expressed in the SI unit of Gray (Gy).","Computed Tomography Dose Index Volume | COMPUTED_VOLUME | CTDIvol | ctdiVol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539930","Dose Length Product","C101137","The product of the number of computed tomography (CT) scans multiplied by the scan width (i.e., total scan length). This value is an indicator of the integrated radiation dose of a specific CT scan. This is expressed in the SI units milligray x centimeters (mGy x cm). DLP is CTDIvol x slice thickness x # of slices.","Dose Length Product | DLP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0422392","Screening Method","C67056","Any method of detecting the presence of disease.","Screening Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0541653","Medical Chart Review","C64254","A procedure of review of the quality of a chart's documentation and coding by a certified professional medical auditor.","Medical Chart Review | Chart Review",,,,,,,,,,,,,,,"4029547","Chart evaluation by healthcare professional",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3539897","Have","C101282","Used to describe the possession, relationships, or the state of something or someone.","Have | Had | Has",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515135","T-Cell Surface Glycoprotein CD3 Zeta Chain","C38903","T-cell surface glycoprotein CD3 zeta chain (164 aa, ~18 kDa) is encoded by the human CD247 gene. This protein is involved in T-cell intracellular signaling.","T-Cell Surface Glycoprotein CD3 Zeta Chain | CD-3-Zeta | CD247 | CD3-Zeta | CD3z | T-Cell Receptor T3 Zeta Chain | T-Cell Receptor T3 Zeta Chain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1175384","FZD3 protein, human","C26165","Frizzled-3 (666 aa, ~76 kDa) is encoded by the human FZD3 gene. This protein plays a role in Wnt-dependent G protein-coupled receptor signaling","Frizzled-3 | FZD3 | FZD3 Protein | Frizzled 3 | Frizzled 3 | Frizzled 3 Protein | Frizzled Family Receptor 3 | Frizzled Homolog 3 | Fz-3 | hFz3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007427","CTSD protein, human","C16388","Cathepsin D (412 aa, ~45 kDa) is encoded by the human CTSD gene. This protein is involved in proteolysis.","Cathepsin D | CTSD | Cathepsin D (Lysosomal Aspartyl Protease) | EC 3.4.23.5 | Epididymis Secretory Sperm Binding Protein Li 130P",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986592","Definitive Treatment","C94601","The treatment plan for a disease or disorder that has been chosen as the best one for a patient after all other choices have been considered.","Definitive Treatment | Definitive Therapy | definitive treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039316","Tarsal Bone","C12796","Any one of the seven bones forming the instep of the foot.","Tarsal Bone | BONE, TARSUS | Bone, Tarsal | TARSUS BONE | Tarsal Bones | Tarsals | Tarsus Bone",,,,,,,,,,,,,,,"4029838|4142814","Bone structure of tarsus|Bone structure of ankle joint region",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0024091","Lumbar Vertebra","C12744","One of the five bones situated between the thoracic vertebrae and the sacrum in the lower part of the spine.","Lumbar Vertebra | Bone structure of lumbar vertebra (body structure) | LUMBAR VERTEBRA | Lumbar Vertebrae",,,,,,,,,,,,,,,"4250034","Bone structure of lumbar vertebra",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348949","Vismodegib","C74038","An orally bioavailable, small molecule inhibitor of SMO and the Hedgehog (Hh) pathway, with potential antineoplastic activity. Upon oral administration, vismodegib targets, binds to and inhibits the cell membrane-spanning G-protein coupled receptor SMO, which may result in the suppression of Hh pathway signaling and a decrease in tumor cell proliferation and survival. SMO is activated upon binding of Hh ligand to the cell surface receptor Patched (PTCH); inappropriate activation of Hh signaling and uncontrolled cellular proliferation may be associated with SMO mutations.","Vismodegib | 2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide | Erivedge | GDC 0449 | GDC-0449 | GDC0449 | Hedgehog Antagonist GDC-0449 | VISMODEGIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1328236","monoclonal antibody SGN-30","C2007","A genetically-engineered, chimeric mouse-human, anti-CD30 monoclonal antibody with potential antineoplastic activity. Brentuximab specifically binds to the receptor CD-30, a member of the tumor necrosis factor receptor super-family, which may be overexpressed on the surfaces of Hodgkin lymphoma cells and anaplastic-large cell lymphoma cells. After binding to CD30, this agent interferes with the G1 phase of the cell cycle, thereby inducing growth arrest and apoptosis in susceptible tumor cell populations.","Brentuximab | Anti-CD30 Monoclonal Antibody | BRENTUXIMAB | CAC-10 | CAC10 | Monoclonal Antibody SGN-30 | Monoclonal Antibody SGN-30 | SGN-30 | SGN30",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1120776","Epratuzumab","C1887","A recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells.  After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC).","Epratuzumab | AMG 412 | EPRATUZUMAB | Humanized Anti-CD22 Monoclonal Antibody IgG1 | IMMU-HLL2 | LymphoCide | epratuzumab | hLL2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025589","Metatarsophalangeal Joint","C33108","A spheroid joint located between the heads of the metatarsal bone and the base of the proximal phalanx of the toe.","Metatarsophalangeal Joint | METATARSOPHALANGEAL JOINT",,,,,,,,,,,,,,,"4186923","Metatarsophalangeal joint structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0064906","Nafarelin","C61613","No Value Exists","Nafarelin | 6-D-(2-naphthyl)alanyl-GnRH | NAFARELIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0121902","Histrelin","C74270","A long-acting, synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH) with potential anti-tumor activity. Upon administration, histrelin binds to and activates GnRH receptors; prolonged administration results in pituitary GnRH receptor desensitization and inhibition of follicle stimulating hormone (FSH) and luteinizing hormone (LH) secretion, leading to a significant decline in testosterone production in males and may inhibit androgen receptor-positive tumor progression; in females, prolonged administration results in decreased estradiol production.","Histrelin | HISTRELIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0209366","Cetrorelix","C2481","Cetrorelix is a synthetic decapeptide which is structurally related to gonadotrophin-releasing hormone (luteinising-hormone releasing hormone).  It acts as an LHRH antagonist. (from ASTA Medica)","Cetrorelix | CETRORELIX | D-20761 | SB-75",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0073629","Ganirelix","C77423","No Value Exists","Ganirelix | GANIRELIX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0209904","Epristeride","C81621","No Value Exists","Epristeride | EPRISTERIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1308614","Tumor Necrosis Factor Receptor Superfamily Member 11B, Human","C30111","Tumor necrosis factor receptor superfamily member 11B (401 aa, ~46 kDa) is encoded by the human TNFRSF11B gene. This protein plays a role in the negative regulation of both osteoblast differentiation and bone resorption.","Tumor Necrosis Factor Receptor Superfamily Member 11B | Osteoclastogenesis Inhibitory Factor | Osteoprotegerin | TNFRSF11B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0961340","Receptor Activator of Nuclear Factor-kappa B","C84994","Tumor necrosis factor receptor superfamily member 11A (616 aa, ~66 kDa) is encoded by the human TNFRSF11A gene. This protein plays a role in the regulation of bone density and calcium metabolism.","Tumor Necrosis Factor Receptor Superfamily Member 11A | CD265 | CD265 Antigen | ODFR | Osteoclast Differentiation Factor Receptor | RANK | Receptor Activator of NF-KB | Receptor Activator of NF-Kappa-B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038975","SV40","C14279","A small (40 to 45 nm) DNA virus of the genus Polyomavirus, family Papovaviridae; the cause of seemingly inapparent infections in monkeys, especially rhesus, and a common contaminant of monkey cell cultures; the virus may cause inapparent infection in humans and may be excreted in stools of children for several weeks; it can produce fibrosarcoma in suckling hamsters, and transformation may occur in human diploid cells; it may also form 'hybrid' virus in cells also infected with certain adenoviruses.","SV40 | Simian Vacuolating Virus 40 | Simian Virus 40 | Virus-SV40 | simian virus 40",,,,,,,,,,,,,,,"4242538","Simian virus 40",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3887672","Macrophage Colony-Stimulating Factor 1","C20437","Macrophage colony-stimulating factor 1 (554 aa, ~60 kDa) is encoded by the human CSF1 gene. This protein is involved in in the regulation of survival, proliferation and differentiation of mononuclear phagocytes.","Macrophage Colony-Stimulating Factor 1 | CSF-1 | CSF1 | Colony Stimulating Factor 1 | Colony Stimulating Factor 1 | Colony-Stimulating Factor 1 | M-CSF | MCSF | Macrophage Colony Stimulating Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0065337","Interleukin-16","C20518","Interleukin-16 (121 aa, ~12 kDa) is encoded by the human IL16 gene. This protein plays a role in leukocyte chemotaxis.","Interleukin-16 | IL-16 | IL16 | IL16 Protein | Interleukin 16 | LCF | Lymphocyte Chemoattractant Factor | Neuronal Interleukin 16 | prIL-16",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0506994","Goblet Cell","C12586","A mucin-producing and -secreting epithelial cell found mainly in the intestinal and respiratory tracts.","Goblet Cell | Goblet Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333121","Columnar Metaplasia","C35846","A morphologic finding indicating the transformation of non-columnar epithelial cells into columnar cells.","Columnar Metaplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225338","Columnar Cell","C13158","An epithelial cell that is taller than it is wide. The nucleus is oval, usually situated at the base of the cell. These cells line large glands and ducts.","Columnar Cell | Columnar Cells",,,,,,,,,,,,,,,"4245382","Columnar epithelial cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1261084","Common Iliac Artery","C32357","An artery arising from the bifurcation of the abdominal aorta which then bifurcates forming the internal and external iliac arteries.","Common Iliac Artery | COMMON ILIAC ARTERY | Common iliac artery structure (body structure)",,,,,,,,,,,,,,,"4249294","Common iliac artery structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1268855","Gonadotropin Releasing Hormone Antagonist","C2092","Any agent that binds to the gonadotropin releasing hormone receptors and causes both the inhibition of gonadotropin releasing hormone activities and a decrease in the pituitary output of follicle stimulating hormone and luteinizing hormone.","Gonadotropin Releasing Hormone Antagonist | GnRH Antagonist | Gonadotropin Releasing Hormone Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1744706","intolerance to substance","C71437","An inability to absorb or metabolize certain substances in the normal way.","Intolerance | INTOLERANCE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348174","Enzalutamide","C71744","An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance.","Enzalutamide | ASP9785 | Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl- | ENZALUTAMIDE | MDV 3100 | MDV-3100 | MDV3100 | Selective Androgen Receptor Modulator MDV3100 | Xtandi | enzalutamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1699342","Transforming Growth Factor Beta-2, Human","C20458","Transforming growth factor beta-2 (414 aa, ~48 kDa) is encoded by the human TGFB2 gene. This protein plays a role in cell proliferation, cell death and a large number of signal transduction pathways.","Transforming Growth Factor Beta-2 | BSC-1 Cell Growth Inhibitor | CETERMIN | Cartilage-Inducing Factor-B | Cetermin | G-TSF | Glioblastoma-Derived T-Cell Suppressor Factor | Polyergin | TGF-Beta 2 | TGF-Beta2 | TGF-b2 | TGF-beta-2 | TGFB2 | Transforming Growth Factor Beta 2 | Transforming Growth Factor-Beta 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1700887","Interleukin-2 Receptor Subunit Alpha, Human","C17073","Interleukin-2 receptor subunit alpha (272 aa, ~31 kDa) is encoded by the human IL2RA gene. This protein plays a role in interleukin-2-dependent signaling.","Interleukin-2 Receptor Subunit Alpha | CD25 | IL-2 Receptor | IL-2 Receptor Subunit Alpha | IL-2-RA | IL-2R | IL-2R Subunit Alpha | IL2 Receptor | IL2-RA | IL2R | IL2RA | Interleukin 2 Receptor | Interleukin 2 Receptor, Alpha | Interleukin-2 Receptor Alpha Chain | Interleukin-2 Receptor Alpha Chain | Low Affinity Interleukin 2 Receptor | T-Cell Growth Factor Receptor | TAC Antigen | p55",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0429863","Pulsatility Index","C101388","A diagnostic indicator of vascular resistance that is calculated by dividing the difference between the peak systolic and minimum diastolic blood velocities by the mean velocity.","Pulsatility Index | PI",,,,,,,,,,,,,,,"4090817","Pulsatility index, arterial velocity waveform",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017054","Gamma-Tocopherol","C68317","The orally bioavailable gamma form of the naturally-occurring fat-soluble vitamin E, found in certain nuts and seeds, with potential antioxidant activity. Although the exact mechanism of action of this tocopherol has yet to be fully identified, gamma-tocopherol appears to have the ability to scavenge free radicals, thereby protecting against oxidative damage.","Gamma-Tocopherol | .GAMMA.-TOCOPHEROL | 2,7,8-trimethyl-2-(4,8,12-trimethyltridecyl)chroman-6-ol | Gamma-tocopherol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938214","Alpha-Tocopherol","C74960","The orally bioavailable alpha form of the naturally-occurring fat-soluble vitamin E, with potent antioxidant and cytoprotective activities.  Upon administration, alpha-tocopherol neutralizes free radicals, thereby protecting tissues and organs from oxidative damage. Alpha-tocopherol gets incorporated into biological membranes, prevents protein oxidation and inhibits lipid peroxidation, thereby maintaining cell membrane integrity and protecting the cell against damage. In addition, alpha-tocopherol inhibits the activity of protein kinase C (PKC) and PKC-mediated pathways. Alpha-tocopherol also modulates the expression of various genes, plays a key role in neurological function, inhibits platelet aggregation and enhances vasodilation. Compared with other forms of tocopherol, alpha-tocopherol is the most biologically active form and is the form that is preferentially absorbed and retained in the body.","Alpha-Tocopherol | .ALPHA.-TOCOPHEROL | 2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)chroman-6-ol | 3,4-Dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-ol | Alpha-tocopherol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085495","Enterococcus faecium","C86369","A species of facultatively anaerobic, Gram positive, cocci shaped bacteria in the phylum Firmicutes. This species is catalase negative, requires folic acid for growth in culture, ferments arabinose and melibiose, does not ferment citrate, does not reduce tetrazolium and is a lactic acid bacteria. E. faecium is a leading agent of nosocomial infections in humans.","Enterococcus faecium | ENTEROCOCCUS FAECIUM | Streptococcus faecium",,,,,,,,,,,,,,,"4234555","Enterococcus faecium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085274","Parvovirus B19","C89772","A parvovirus that is the causative agent of Fifth disease. It is a non-enveloped, icosahedral virus that contains a single-stranded linear DNA genome; approximately equal proportions of DNA of positive and negative sense are found in separate particles.","Parvovirus B19 | B19 Virus | Erythrovirus B19 | HUMAN PARVOVIRUS B19 | Human Erythrovirus B19 | Human Parvovirus B19",,,,,,,,,,,,,,,"4270772","Primate erythroparvovirus 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0597298","Isoform","C47803","Refers to variants of the same protein which can be separated on special conducting media using electrophoresis. The differences may arise from genetically determined differences in primary structure or by modification of the same primary sequence.","Isoform | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0535210","metabotropic glutamate receptor type 1","C26239","Metabotropic glutamate receptor 1 (1194 aa, ~132 kDa) is encoded by the human GRM1 gene. This protein plays a role in in G protein-coupled receptor signal transduction and synaptic transmission.","Metabotropic Glutamate Receptor 1 | GRM1 | GRM1-Alpha | Glutamate Receptor, Metabotropic 1 | MGLUR1-Alpha | mGluR1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0072480","Proto-Oncogene Proteins c-sis","C20449","Platelet-derived growth factor subunit B (241 aa, ~27 kDa) is encoded by the human PDGFB gene. This protein is involved in the regulation of embryonic development, cell proliferation, cell migration, cell survival and chemotaxis.","Platelet-Derived Growth Factor Subunit B | PDGF B-Chain | PDGF Subunit B | PDGF, B Chain | PDGF-2 | PDGFB | Platelet Derived Growth Factor Beta Chain | Platelet Derived Growth Factor Beta Chain | Platelet-Derived Growth Factor 2 | Platelet-Derived Growth Factor B Chain | Platelet-Derived Growth Factor Beta | Platelet-Derived Growth Factor Beta Polypeptide | Platelet-Derived Growth Factor, B Chain | Platelet-Derived Growth Factor, Beta Polypeptide | Proto-Oncogene c-Sis | SIS Gene Product",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0258846","SHH protein, human","C29962","Sonic hedgehog protein (462 aa, ~50 kDa) is encoded by the human SHH gene. This protein plays a role in embryonic pattern formation.","Sonic Hedgehog Protein | HHG-1 | HHG1 | SHH | Sonic Hedgehog Homolog | Sonic Hedgehog Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647986","Cytidine Deaminase","C48963","Cytidine deaminase (146 aa, ~16 kDa) is encoded by the human CDA gene. This protein is involved in the deamination of cytidine and deoxycytidine to uridine and deoxyuridine, respectively.","Cytidine Deaminase | CDA | Cytidine Aminohydrolase | EC 3.5.4.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514577","Proton Radiation","C40431","Radiation of protons during radioactive decay.","Proton Radiation | PROTON RADIATION | Radiation, Charged Particles-Protons",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1742865","Transmembrane Protease Serine 2, Human","C30110","Transmembrane protease serine 2 (492 aa, ~54 kDa) is encoded by the human TMPRSS2 gene. This protein plays a role in proteolysis.","Transmembrane Protease Serine 2 | EC 3.4.21.- | Epitheliasin | Serine Protease 10 | TMPRSS2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0599295","ERG Gene","C18139","This gene plays a regulatory role in transcription, cellular maintenance and hematopoiesis.","ERG Gene | ERG | ETS Transcription Factor ERG Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162768","Fusion Protein","C17561","A protein in which the coding region of two genes have become in-frame and co-continuous.  Fusion proteins can be formed by chromosomal breakage and/or recombination and also can be experimentally created using recombinant DNA techniques.","Fusion Protein | Chimera Protein | Chimeric Protein | fusion protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0533325","Twist-Related Protein 1, Human","C39918","Twist-related protein 1 (202 aa, ~21 kDa) is encoded by the human TWIST1 gene. This protein plays a role in the negative regulation of both transcription and myogenesis.","Twist-Related Protein 1 | Acrocephalosyndactyly 3 Protein | Class A Basic Helix-Loop-Helix Protein 38 | H-Twist | TWIST | TWIST1 | TWIST1 Protein | Twist Homolog | Twist Homolog 1 | Twist Related Protein 1 | bHLHa38",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1451297","Multidrug Resistance-Associated Protein 1, Human","C17682","Multidrug resistance-associated protein 1 (1531 aa, ~172 kDa) is encoded by the human ABCC1 gene. This protein plays a role in the cellular export of both organic anions and xenobiotics.","Multidrug Resistance-Associated Protein 1 | ABCC1 | ATP-Binding Cassette Sub-Family C Member 1 | ATP-Binding Cassette, Sub-Family C, Member 1 | ATP-Binding Cassette, Sub-Family C, Member 1 | LTC4 Transporter | Leukotriene C(4) Tansporter | MRP1 Protein | Multiple Drug Resistance-Associated Protein | Multiple Drug Resistance-Associated Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1317964","Intercellular Adhesion Molecule 2, Human","C17503","Intercellular adhesion molecule 2 (275 aa, ~31 kDa) is encoded by the human ICAM2 gene. This protein is involved in both integrin binding and the modulation of leukocyte adhesion.","Intercellular Adhesion Molecule 2 | CD102 | CD102 Antigen | ICAM-2 | ICAM2",,,,,,,,,,,,,,,"4012723","Lymphocyte antigen CD102",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2983138","Gastric Cancer TNM Finding v7","C89822","A finding about one or more characteristics of gastric cancer, following the rules of the TNM AJCC v7 classification system.  Tumors arising at the esophagogastric junction, or arising in the stomach in a distance equal or less than 5 cm from the esophagogastric junction and crossing the esophagogastric junction are staged using the TNM system for esophageal adenocarcinoma.  Lymphomas, sarcomas, and carcinoid tumors (low-grade neuroendocrine tumors) are not included in this classification. (from AJCC 7th Ed.)","Gastric Cancer TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880928","Gastric Cancer pTX TNM Finding v6 and v7","C61181","Gastric cancer in which the primary tumor cannot be assessed. (from AJCC 6th and 7th Eds.)","Gastric Cancer pTX TNM Finding v6 and v7 | Gastric Cancer pTX TNM Finding | Gastric Cancer pTX TNM Finding | Gastric Cancer pTX TNM Finding v6 | Gastric Cancer pTX TNM Finding v7 | pTX Cancer of the Stomach | pTX Carcinoma of the Stomach | pTX Gastric Cancer | pTX Gastric Carcinoma | pTX Stomach Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983150","Gastric Cancer pT4b TNM Finding v7","C89841","Gastric cancer with tumor invading adjacent structures. (from AJCC 7th Ed.)","Gastric Cancer pT4b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983149","Gastric Cancer pT4a TNM Finding v7","C89840","Gastric cancer with tumor invading serosa (visceral peritoneum). (from AJCC 7th Ed.)","Gastric Cancer pT4a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983148","Gastric Cancer pT4 TNM Finding v7","C89839","Gastric cancer with tumor invading serosa (visceral peritoneum) or adjacent structures.  The adjacent structures of the stomach include the spleen, transverse colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small intestine, and retroperitoneum.  Intramural extension to the duodenum or esophagus is classified by the depth of the greatest invasion in any of these sites, including the stomach. (from AJCC 7th Ed.)","Gastric Cancer pT4 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983147","Gastric Cancer pT3 TNM Finding v7","C89838","Gastric cancer with tumor penetrating subserosal connective tissue without invasion of visceral peritoneum or adjacent structures.  The adjacent structures of the stomach include the spleen, transverse colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small intestine, and retroperitoneum.  Intramural extension to the duodenum or esophagus is classified by the depth of the greatest invasion in any of these sites, including the stomach. (from AJCC 7th Ed.)","Gastric Cancer pT3 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983145","Gastric Cancer pT2 TNM Finding v7","C89834","Gastric cancer with tumor invading the muscularis propria.  A tumor may penetrate the muscularis propria with extension into the gastrocolic or gastrohepatic ligaments, or into the greater or lesser omentum, without perforation of the visceral peritoneum covering these structures. In this case, the tumor is classified T3. If there is perforation of the visceral peritoneum covering the gastric ligaments or the omentum, the tumor should be classified T4. (from AJCC 7th Ed.)","Gastric Cancer pT2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983144","Gastric Cancer pT1b TNM Finding v7","C89833","Gastric cancer invading the submucosa. (from AJCC 7th Ed.)","Gastric Cancer pT1b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983143","Gastric Cancer pT1a TNM Finding v7","C89832","Gastric cancer with tumor invading lamina propria or muscularis mucosae.  (from AJCC 7th Ed.)","Gastric Cancer pT1a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983142","Gastric Cancer pT1 TNM Finding v7","C89831","Gastric cancer invading lamina propria, muscularis mucosae, or submucosa. (from AJCC 7th Ed.)","Gastric Cancer pT1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880929","Gastric Cancer pTis TNM Finding v6 and v7","C61183","Gastric cancer in situ with cancer cells confined within the glandular basement membrane (intraepithelial) and without invasion into the lamina propria. (from AJCC 6th and 7th Eds.)","Gastric Cancer pTis TNM Finding v6 and v7 | Gastric Cancer pTis TNM Finding | Gastric Cancer pTis TNM Finding | Gastric Cancer pTis TNM Finding v6 | Gastric Cancer pTis TNM Finding v7 | pTis Cancer of the Stomach | pTis Carcinoma of the Stomach | pTis Gastric Cancer | pTis Gastric Carcinoma | pTis Stomach Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880921","Gastric Cancer pT0 TNM Finding v6 and v7","C61182","Gastric cancer with no evidence of a primary tumor. (from AJCC 6th and 7th Eds.)","Gastric Cancer pT0 TNM Finding v6 and v7 | Gastric Cancer pT0 TNM Finding | Gastric Cancer pT0 TNM Finding | Gastric Cancer pT0 TNM Finding v6 | Gastric Cancer pT0 TNM Finding v7 | pT0 Cancer of the Stomach | pT0 Carcinoma of the Stomach | pT0 Gastric Cancer | pT0 Gastric Carcinoma | pT0 Stomach Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983155","Gastric Cancer pN3 TNM Finding v7","C89847","Gastric cancer with metastasis in seven or more regional lymph nodes. (from AJCC 7th Ed.)","Gastric Cancer pN3 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983157","Gastric Cancer pN3b TNM Finding v7","C89849","Gastric cancer with metastasis in sixteen or more regional lymph nodes. (from AJCC 7th Ed.)","Gastric Cancer pN3b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983156","Gastric Cancer pN3a TNM Finding v7","C89848","Gastric cancer with metastasis in 7-15 regional lymph nodes. (from AJCC 7th Ed.)","Gastric Cancer pN3a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983153","Gastric Cancer pN1 TNM Finding v7","C89845","Gastric cancer with metastasis in 1-2 regional lymph nodes. (from AJCC 7th Ed.)","Gastric Cancer pN1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880920","Gastric Cancer pNX TNM Finding v6 and v7","C61191","Gastric cancer in which the regional lymph nodes cannot be assessed. (from AJCC 6th and 7th Eds.)","Gastric Cancer pNX TNM Finding v6 and v7 | Gastric Cancer pNX TNM Finding | Gastric Cancer pNX TNM Finding | Gastric Cancer pNX TNM Finding v6 | Gastric Cancer pNX TNM Finding v7 | pNX Cancer of the Stomach | pNX Carcinoma of the Stomach | pNX Gastric Cancer | pNX Gastric Carcinoma | pNX Stomach Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983152","Gastric Cancer pN0 TNM Finding v7","C89844","Gastric cancer without regional lymph node metastasis.  Note: A designation of pN0 should be used if all examined lymph nodes are negative, regardless of the total number removed and examined. (from AJCC 7th Ed.)","Gastric Cancer pN0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983154","Gastric Cancer pN2 TNM Finding v7","C89846","Gastric cancer with metastasis in 3-6 regional lymph nodes. (from AJCC 7th Ed.)","Gastric Cancer pN2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983160","Gastric Cancer Clinical Distant Metastasis TNM Finding v7","C89852","A clinical finding about one or more characteristics of gastric cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.","Gastric Cancer Clinical Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983161","Gastric Cancer cM0 TNM Finding v7","C89853","Gastric cancer without evidence of distant metastasis. (from AJCC 7th Ed.)","Gastric Cancer cM0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983162","Gastric Cancer cM1 TNM Finding v7","C89854","Gastric cancer with distant metastasis. (from AJCC 7th Ed.)","Gastric Cancer cM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983158","Gastric Cancer Pathologic Distant Metastasis TNM Finding v7","C89850","A pathologic finding about one or more characteristics of gastric cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  There is no pathologic M0 for gastric cancer. (from AJCC 7th Ed.)","Gastric Cancer Pathologic Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880914","Gastric Cancer pM1 TNM Finding v6 and v7","C61198","Gastric cancer with distant metastasis. (from AJCC 6th and 7th Eds.)","Gastric Cancer pM1 TNM Finding v6 and v7 | Gastric Cancer pM1 TNM Finding | Gastric Cancer pM1 TNM Finding | Gastric Cancer pM1 TNM Finding v6 | Gastric Cancer pM1 TNM Finding v7 | pM1 Cancer of the Stomach | pM1 Carcinoma of the Stomach | pM1 Gastric Cancer | pM1 Gastric Carcinoma | pM1 Stomach Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879262","Tegafur-gimeracil-oteracil Potassium","C1833","An orally bioavailable fluoropyrimidine antagonist composed of tegafur combined with two modulators of 5-fluorouracil (5-FU) activity, gimeracil and potassium oxonate, in a molar ratio of 1:0.4:1. Tegafur is a prodrug of 5-fluorouracil, an antimetabolite that inhibits thymidylate synthase, DNA synthesis and cell division, and competes with uridine triphosphate, thus inhibiting RNA and protein synthesis. Gimeracil is a reversible inhibitor of dihydropyrimidine dehydrogenase (DPD), the liver enzyme responsible for rapid catabolism of 5-FU into inactive metabolites. Potassium oxonate preferentially localizes in the gut and inhibits the enzyme orotate phosphoribosyl-transferase (OPRT), thereby decreasing activation of 5-FU in the gut and activated 5-FU-related gastrointestinal toxicity.","Tegafur-gimeracil-oteracil Potassium | BMS 247616 | BMS-247616 | S-1 | TS-1 | TS-One | Tegafur gimeracil oteracil | Tegafur, mixture with Gimeracil and Potassium Oxonate | Tegafur/Gimeracil/Oteracil | Teysuno",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518826","PS IL-10/Placebo","C29336","No Value Exists","PS IL-10/Placebo | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346839","Teglarinad Chloride","C68931","A water-soluble prodrug of a cyanoguanidine compound with potential antineoplastic activity. In vivo, teglarinad chloride is rapidly converted into active drug through hydrolytic cleavage of a carbonate ester bond. Although the exact mechanism of action has yet to be fully elucidated, the active drug appears to antagonize nuclear factor-kappa B (NF-kB) transcription, resulting in the induction of tumor cell apoptosis.","Teglarinad Chloride | CHS828 Prodrug | EB1627 | GMX1777 | Pyridinium, 4-[[[[6-(4-chlorophenoxy)hexyl]amino](cyanoamino) methylene]amino]-1-(3-oxo-2,4,7,10,13,16-hexaoxaheptadec-1-yl)-, chloride | TEGLARINAD CHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796403","Carboplatin/Gemcitabine","C11469","No Value Exists","Carboplatin/Gemcitabine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1541473","pan-HER Kinase Inhibitor AC480","C48380","An orally bioavailable pan-HER tyrosine kinase inhibitor with potential antineoplastic activity. BMS-599626 inhibits human epidermal growth factor receptors (HER) HER1, HER2 and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors. (NCI05)","pan-HER Kinase Inhibitor AC480 | AC480 | BMS-599626",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984086","Gastric Cancer by AJCC v7 Stage","C91222","A term that refers to the staging of gastric carcinoma according to the American Joint Committee on Cancer, 7th edition.","Gastric Cancer by AJCC v7 Stage | Gastric Carcinoma by AJCC v7 Stage | Gastric Carcinoma by AJCC v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0154060","Stage 0 Gastric Cancer AJCC v6 and v7","C7788","Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ: intraepithelial tumor without invasion of the lamina propria.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage 0 Gastric Cancer AJCC v6 and v7 | Carcinoma in situ of Stomach | Carcinoma in situ of stomach | Carcinoma in situ of the Stomach | Carcinoma of Stomach Stage 0 | Carcinoma of the Stomach Stage 0 | Gastric Carcinoma Stage 0 | Gastric Carcinoma in situ | Gastric Carcinoma, Stage 0 | Stage 0 Carcinoma of Stomach | Stage 0 Carcinoma of the Stomach | Stage 0 Gastric (Stomach) Cancer | Stage 0 Gastric Cancer | Stage 0 Gastric Cancer | Stage 0 Gastric Cancer AJCC v6 | Stage 0 Gastric Cancer AJCC v7 | Stage 0 Gastric Carcinoma | Stage 0 Stomach Cancer | Stage 0 Stomach Carcinoma | Stomach Carcinoma Stage 0 | Stomach Carcinoma in situ | stage 0 gastric carcinoma in situ",,,,,,,,,,,,,,,"200974","Carcinoma in situ of stomach",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1336115","Stage IA Gastric Carcinoma","C5468","Stage IA includes: T1, N0, M0.  T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IA Gastric Cancer AJCC v7 | Carcinoma of Stomach Stage IA | Carcinoma of the Stomach Stage IA | Gastric Cancer Stage IA | Gastric Carcinoma Stage IA | Stage IA Carcinoma of Stomach | Stage IA Carcinoma of the Stomach | Stage IA Gastric (Stomach) Cancer | Stage IA Gastric Cancer | Stage IA Gastric Cancer | Stage IA Gastric Carcinoma | Stage IA Stomach Carcinoma | Stomach Carcinoma Stage IA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336134","Stage IB Gastric Carcinoma","C5469","Stage IB includes: (T2, N0, M0); (T1, N1, M0).  T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis.  N1: Metastasis in 1-2 regional lymph nodes. M0: No distant metastasis. (AJCC 7th ed.)","Stage IB Gastric Cancer AJCC v7 | Carcinoma of Stomach Stage IB | Carcinoma of the Stomach Stage IB | Gastric Cancer Stage IB | Gastric Carcinoma Stage IB | Stage IB Carcinoma of Stomach | Stage IB Carcinoma of the Stomach | Stage IB Gastric (Stomach) Cancer | Stage IB Gastric Cancer | Stage IB Gastric Cancer | Stage IB Gastric Carcinoma | Stage IB Stomach Carcinoma | Stomach Carcinoma Stage IB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL415534","Stage IIA Gastric Cancer AJCC v7","C87775","Stage IIA includes: (T3, N0, M0); (T2, N1, M0); (T1, N2, M0). T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  T2: Tumor invades the muscularis propria. T3: Tumor penetrates subserosal connective tissue without invasion of visceral peritoneum or adjacent structures.  N0: No regional lymph node metastasis.  N1: Metastasis in 1-2 regional lymph nodes.  N2: Metastasis in 3-6 regional lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IIA Gastric Cancer AJCC v7 | Stage IIA Gastric (Stomach) Cancer | Stage IIA Gastric Cancer | Stage IIA Gastric Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL415535","Stage IIB Gastric Cancer AJCC v7","C87776","Stage IIB includes: (T4a, N0, M0); (T3, N1, M0); (T2, N2, M0); (T1, N3, M0).  T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  T2: Tumor invades the muscularis propria. T3: Tumor penetrates subserosal connective tissue without invasion of visceral peritoneum or adjacent structures.  T4a: Tumor invades serosa (visceral peritoneum).  N0: No regional lymph node metastasis.  N1: Metastasis in 1-2 regional lymph nodes.  N2: Metastasis in 3-6 regional lymph nodes.  N3: Metastasis in seven or more regional lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IIB Gastric Cancer AJCC v7 | Stage IIB Gastric (Stomach) Cancer | Stage IIB Gastric Cancer | Stage IIB Gastric Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336207","Stage IIIA Gastric Carcinoma","C5471","Stage IIIA includes: (T4a, N1, M0); (T3, N2, M0); (T2, N3, M0).  T2: Tumor invades the muscularis propria. T3: Tumor penetrates subserosal connective tissue without invasion of visceral peritoneum or adjacent structures.  T4a: Tumor invades serosa (visceral peritoneum).  N1: Metastasis in 1-2 regional lymph nodes.  N2: Metastasis in 3-6 regional lymph nodes.  N3: Metastasis in seven or more regional lymph nodes. M0: No distant metastasis.  (AJCC 7th ed.)","Stage IIIA Gastric Cancer AJCC v7 | Carcinoma of Stomach Stage IIIA | Carcinoma of the Stomach Stage IIIA | Gastric Cancer Stage IIIA | Gastric Carcinoma Stage IIIA | Stage IIIA Carcinoma of Stomach | Stage IIIA Carcinoma of the Stomach | Stage IIIA Gastric (Stomach) Cancer | Stage IIIA Gastric Cancer | Stage IIIA Gastric Cancer | Stage IIIA Gastric Carcinoma | Stage IIIA Stomach Carcinoma | Stomach Carcinoma Stage IIIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336222","Stage IIIB Gastric Carcinoma","C5470","Stage IIIB includes: (T4b, N0, M0); (T4b, N1, M0); (T4a, N2, M0); (T3, N3, M0).  T3: Tumor penetrates subserosal connective tissue without invasion of visceral peritoneum or adjacent structures.  T4a: Tumor invades serosa (visceral peritoneum).  T4b: Tumor invades adjacent structures. N0: No regional lymph node metastasis.  N1: Metastasis in 1-2 regional lymph nodes.  N2: Metastasis in 3-6 regional lymph nodes.  N3: Metastasis in seven or more regional lymph nodes. M0: No distant metastasis.  (AJCC 7th ed.)","Stage IIIB Gastric Cancer AJCC v7 | Carcinoma of Stomach Stage IIIB | Carcinoma of the Stomach Stage IIIB | Gastric Cancer Stage IIIB | Gastric Carcinoma Stage IIIB | Stage IIIB Carcinoma of Stomach | Stage IIIB Carcinoma of the Stomach | Stage IIIB Gastric (Stomach) Cancer | Stage IIIB Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIB Gastric Carcinoma | Stage IIIB Stomach Carcinoma | Stomach Carcinoma Stage IIIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL415536","Stage IIIC Gastric Cancer AJCC v7","C87777","Stage IIIC includes: (T4b, N2, M0); (T4b, N3, M0); (T4a, N3, M0).  T4a: Tumor invades serosa (visceral peritoneum).  T4b: Tumor invades adjacent structures. N2: Metastasis in 3-6 regional lymph nodes.  N3: Metastasis in seven or more regional lymph nodes. M0: No distant metastasis.  (AJCC 7th ed.)","Stage IIIC Gastric Cancer AJCC v7 | Stage IIIC Gastric (Stomach) Cancer | Stage IIIC Gastric Cancer | Stage IIIC Gastric Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449088","Stage IV Gastric Cancer AJCC v7","C89861","Stage IV includes: (Any T, Any N, M1).  M1: Distant metastasis. (AJCC 7th ed.)","Stage IV Gastric Cancer AJCC v7 | Stage IV Gastric (Stomach) Cancer | Stage IV Gastric Cancer | Stage IV Gastric Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273294","Drug-eluting Embolic Bead","C97232","An embolic bead that, in addition to blocking blood flow, also releases a chemotherapeutic drug.","Drug-eluting Embolic Bead | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1870115","Silodosin","C81372","An orally available, alpha-1 adrenoreceptor (alpha-1a) selective antagonist that can be used to relieve symptoms of benign prostate hyperplasia (BPH). Upon administration, silodosin selectively binds alpha-1a receptors located in the human prostate and bladder with high affinity and blocks signaling pathways mediated by alpha-1a. Blockade of these receptors causes smooth muscle relaxation, lowers intraurethral pressure, and results in improved urine flow and a reduction in the symptoms of BPH, such as difficulty with urinating, painful urination, urinary frequency and incomplete bladder emptying. In addition, silodosin may be used to improve lower urinary tract symptoms, which can occur after receiving radiation therapy for prostate cancer.","Silodosin | Rapaflo | Rapilif | SILODOSIN | Silodyx | Urief | Urorec",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982928","Uterine Corpus Carcinoma TNM Finding v7","C89554","A finding about one or more characteristics of uterine corpus carcinoma, following the rules of the TNM AJCC v7 classification system.  Carcinosarcomas should be staged as carcinoma. (from AJCC 7th Ed.)","Uterine Corpus Carcinoma TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982932","Uterine Corpus Carcinoma pT0 TNM Finding v7","C89558","Uterine corpus carcinoma in which there is no evidence of a primary tumor. (from AJCC 7th Ed.)","Uterine Corpus Carcinoma pT0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982934","Uterine Corpus Carcinoma pT1 TNM Finding v7","C89560","Uterine corpus carcinoma with tumor confined to uterine corpus. (from AJCC 7th Ed.)","Uterine Corpus Carcinoma pT1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982935","Uterine Corpus Carcinoma pT1a TNM Finding v7","C89561","Uterine corpus carcinoma with tumor limited to endometrium or invading less than one-half of the myometrium. (from AJCC 7th Ed.)","Uterine Corpus Carcinoma pT1a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982936","Uterine Corpus Carcinoma pT1b TNM Finding v7","C89562","Uterine corpus carcinoma with tumor invading one-half or more of the myometrium. (from AJCC 7th Ed.)","Uterine Corpus Carcinoma pT1b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982937","Uterine Corpus Carcinoma pT2 TNM Finding v7","C89563","Uterine corpus carcinoma that invades stromal connective tissue of the cervix but does not extend beyond uterus.  Endocervical glandular involvement only should be considered as Stage I and not as Stage II. (from AJCC 7th Ed.)","Uterine Corpus Carcinoma pT2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982938","Uterine Corpus Carcinoma pT3 TNM Finding v7","C89564","Uterine corpus carcinoma that involves serosa and/or adnexa, vagina, or parametrial tissue. (from AJCC 7th Ed.)","Uterine Corpus Carcinoma pT3 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982939","Uterine Corpus Carcinoma pT3a TNM Finding v7","C89565","Uterine corpus carcinoma that involves serosa and/or adnexa (direct extension or metastasis). (from AJCC 7th Ed.)","Uterine Corpus Carcinoma pT3a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982940","Uterine Corpus Carcinoma pT3b TNM Finding v7","C89566","Uterine corpus carcinoma that involves vagina or parametrial tissue.  (from AJCC 7th Ed.)","Uterine Corpus Carcinoma pT3b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982941","Uterine Corpus Carcinoma pT4 TNM Finding v7","C89567","Uterine corpus carcinoma that invades bladder mucosa and/or bowel mucosa (bullous edema is not sufficient to classify a tumor as T4). (from AJCC 7th Ed.)","Uterine Corpus Carcinoma pT4 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982933","Uterine Corpus Carcinoma pTis TNM Finding v7","C89559","Uterine corpus carcinoma with a finding of carcinoma in situ (preinvasive carcinoma).  FIGO no longer includes Stage 0 (Tis). (from AJCC 7th Ed.)","Uterine Corpus Carcinoma pTis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982931","Uterine Corpus Carcinoma pTX TNM Finding v7","C89557","Uterine corpus carcinoma in which primary tumor cannot be assessed. (from AJCC 7th Ed.)","Uterine Corpus Carcinoma pTX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983239","Colorectal Cancer TNM Finding v7","C89941","A finding about one or more characteristics of colorectal cancer, following the rules of the TNM AJCC v7 classification system.  Sarcomas, lymphomas, and carcinoid tumors of the large intestine are not included in this classification. (from AJCC 7th Ed.)","Colorectal Cancer TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982944","Uterine Corpus Carcinoma pN0 TNM Finding v7","C89570","Uterine corpus carcinoma with no evidence of regional lymph node metastasis. (from AJCC 7th Ed.)","Uterine Corpus Carcinoma pN0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982945","Uterine Corpus Carcinoma pN1 TNM Finding v7","C89571","Uterine corpus carcinoma with regional lymph node metastasis to pelvic lymph nodes. (from AJCC 7th Ed.)","Uterine Corpus Carcinoma pN1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982946","Uterine Corpus Carcinoma pN2 TNM Finding v7","C89572","Uterine corpus carcinoma with regional lymph node metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes. (from AJCC 7th Ed.)","Uterine Corpus Carcinoma pN2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982943","Uterine Corpus Carcinoma pNX TNM Finding v7","C89569","Uterine corpus carcinoma in which regional lymph nodes cannot be assessed. (from AJCC 7th Ed.)","Uterine Corpus Carcinoma pNX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982950","Uterine Corpus Carcinoma Clinical Distant Metastasis TNM Finding v7","C89576","A clinical finding about one or more characteristics of uterine corpus carcinoma, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases. (from AJCC 7th Ed.)","Uterine Corpus Carcinoma Clinical Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982951","Uterine Corpus Carcinoma cM0 TNM Finding v7","C89577","Uterine corpus carcinoma with no distant metastasis. (from AJCC 7th Ed.)","Uterine Corpus Carcinoma cM0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982952","Uterine Corpus Carcinoma cM1 TNM Finding v7","C89578","Uterine corpus carcinoma with distant metastasis (includes metastasis to inguinal lymph nodes intraperitoneal disease, or lung, liver, or bone.  It excludes metastasis to para-aortic lymph nodes, vagina, pelvic serosa, or adnexa). (from AJCC 7th Ed.)","Uterine Corpus Carcinoma cM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982947","Uterine Corpus Carcinoma Pathologic Distant Metastasis TNM Finding v7","C89573","A pathologic finding about one or more characteristics of uterine corpus carcinoma, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases. There is no pathologic M0 for uterine corpus carcinoma.  (from AJCC 7th Ed.)","Uterine Corpus Carcinoma Pathologic Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982948","Uterine Corpus Carcinoma pM1 TNM Finding v7","C89574","Uterine corpus carcinoma with distant metastasis (includes metastasis to inguinal lymph nodes intraperitoneal disease, or lung, liver, or bone.  It excludes metastasis to para-aortic lymph nodes, vagina, pelvic serosa, or adnexa). (from AJCC 7th Ed.)","Uterine Corpus Carcinoma pM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984082","Uterine Corpus Cancer by AJCC v7 Stage","C91218","A term that refers to the staging of uterine corpus cancer (carcinoma or carcinosarcoma) according to the American Joint Committee on Cancer, 7th edition.","Uterine Corpus Cancer by AJCC v7 Stage | Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983007","Stage 0 Uterine Corpus Cancer AJCC v7","C89632","Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis.  This staging applies to carcinomas and carcinosarcomas.  FIGO no longer includes Stage 0 (Tis). (AJCC 7th ed.)","Stage 0 Uterine Corpus Cancer AJCC v7 | Stage 0 Uterine (including Endometrial) Cancer | Stage 0 Uterine Corpus Cancer | Stage 0 Uterine Corpus Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983008","Stage I Uterine Corpus Cancer AJCC v7","C89633","Stage I includes: I (T1, N0, M0); IA: (T1a, N0, M0); IB (T1b, N0, M0). T1: Tumor confined to corpus uteri. T1a: Tumor limited to the endometrium or invades less than one-half of the myometrium. T1b: Tumor invades one-half or more of the myometrium. N0: No regional lymph node metastasis. M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","Stage I Uterine Corpus Cancer AJCC v7 | Stage I Uterine (including Endometrial) Cancer | Stage I Uterine Corpus Cancer | Stage I Uterine Corpus Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336113","stage IA uterine corpus cancer","C6301","Stage IA includes: T1a, N0, M0.  T1a: Tumor limited to the endometrium or invades less than one-half of the myometrium. N0: No regional lymph node metastasis. M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","Stage IA Uterine Corpus Cancer AJCC v7 | Stage IA Uterine (including Endometrial) Cancer | Stage IA Uterine Corpus Cancer | Stage IA Uterine Corpus Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336132","stage IB uterine corpus cancer","C6302","Stage IB includes: T1b, N0, M0.  T1b: Tumor invades one-half or more of the myometrium. N0: No regional lymph node metastasis. M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","Stage IB Uterine Corpus Cancer AJCC v7 | Stage IB Uterine (including Endometrial) Cancer | Stage IB Uterine Corpus Cancer | Stage IB Uterine Corpus Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983009","Stage II Uterine Corpus Cancer AJCC v7","C89634","Stage II includes: T2, N0, M0.  T2: Tumor invades stromal connective tissue of the cervix but does not extend beyond uterus.  Endocervical glandular involvement only should be considered as Stage I and not as Stage II.  N0: No regional lymph node metastasis. M0: No distant metastasis.  This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","Stage II Uterine Corpus Cancer AJCC v7 | Stage II Uterine (including Endometrial) Cancer | Stage II Uterine Corpus Cancer | Stage II Uterine Corpus Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983010","Stage III Uterine Corpus Cancer AJCC v7","C89635","Stage III includes: III (T3, N0, M0); IIIA (T3a, N0, M0); IIIB (T3b, N0, M0); IIIC (T1-T3, N1/N2, M0); IIIC1 (T1-T3, N1, M0); IIIC2 (T1-T3, N2, M0). T3: Tumor involves serosa and/or adnexa, vagina, or parametrial tissue. T3a: Tumor involves serosa and/or adnexa (direct extension or metastasis). T3b: Tumor involves vagina (direct extension or metastasis) or parametrial tissue. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis to pelvic lymph nodes. N2: Regional lymph node metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes.  M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","Stage III Uterine Corpus Cancer AJCC v7 | Stage III Uterine (including Endometrial) Cancer | Stage III Uterine Corpus Cancer | Stage III Uterine Corpus Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336205","stage IIIA uterine corpus cancer","C6306","Stage IIIA includes: T3a, N0, M0.  T3a: Tumor involves serosa and/or adnexa (direct extension or metastasis). N0: No regional lymph node metastasis. M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","Stage IIIA Uterine Corpus Cancer AJCC v7 | Stage IIIA Uterine (including Endometrial) Cancer | Stage IIIA Uterine Corpus Cancer | Stage IIIA Uterine Corpus Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336220","stage IIIB uterine corpus cancer","C6307","Stage IIIB includes: T3b, N0, M0.  T3b: Tumor involves vagina (direct extension or metastasis) or parametrial tissue. N0: No regional lymph node metastasis. M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","Stage IIIB Uterine Corpus Cancer AJCC v7 | Stage IIIB Uterine (including Endometrial) Cancer | Stage IIIB Uterine Corpus Cancer | Stage IIIB Uterine Corpus Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336334","stage IVA uterine corpus cancer","C6309","Stage IVA includes: T4, Any N, M0. T4: Tumor invades bladder mucosa and/or bowel mucosa (bullous edema is not sufficient to classify a tumor as T4).  M0: No distant metastasis.  This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","Stage IVA Uterine Corpus Cancer AJCC v7 | Stage IVA Uterine (including Endometrial) Cancer | Stage IVA Uterine Corpus Cancer | Stage IVA Uterine Corpus Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336364","stage IVB uterine corpus cancer","C6310","Stage IVB includes: Any T, Any N, M1.  M1: Distant metastasis (includes metastasis to inguinal lymph nodes, intraperitoneal disease, or lung, liver, or bone.  It excludes metastasis to para-aortic lymph nodes, vagina, pelvic serosa, or adnexa). This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","Stage IVB Uterine Corpus Cancer AJCC v7 | Stage IVB Uterine (including Endometrial) Cancer | Stage IVB Uterine Corpus Cancer | Stage IVB Uterine Corpus Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346449","Linsitinib","C70982","An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Linsitinib selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. Overexpressed in a variety of human cancers, IGF-1R stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis.","Linsitinib | Cyclobutanol, 3-[8-amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methyl, cis- | IGF-1R inhibitor OSI-906 | LINSITINIB | OSI-906 | OSI-906AA | OSI906 | cis-3-(8-Amino-1-(2-Phenylquinolin-7-yl)Imidazo(1,5-A)Pyrazin-3-yl)-1-Methylcyclobutanol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274575","AZD7451","C99161","A tropomyosin receptor kinase (TRK) inhibitor with potential antineoplastic activity. Upon administration, utatrectinib binds to TRK, thereby preventing the neurotrophin-TRK interaction and subsequent TRK activation. This may eventually result in an inhibition of tumor cell proliferation in TRK-expressing tumor cells. TRK, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth, invasion and survival.","Utatrectinib | AZD7451 | TRK Inhibitor AZD7451 | Tropomyosin Receptor Kinase Inhibitor AZD7451 | Tropomyosin Receptor Kinase Inhibitor AZD7451 | UTATRECTINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0338113","Uterine Corpus Sarcoma","C6339","A malignant mesenchymal neoplasm arising from the wall of the uterine corpus (uterine body).  The most representative examples are leiomyosarcoma and endometrial stromal sarcoma.","Uterine Corpus Sarcoma | Body of Uterus Sarcoma | Corpus Uteri Sarcoma | Sarcoma of Body of Uterus | Sarcoma of Corpus Uteri | Sarcoma of Uterine Body | Sarcoma of Uterine Corpus | Sarcoma of Uterus | Sarcoma of the Body of Uterus | Sarcoma of the Corpus Uteri | Sarcoma of the Uterine Body | Sarcoma of the Uterine Corpus | Sarcoma of the Uterus | Uterine Body Sarcoma | Uterine Sarcoma | Uterus Sarcoma | uterine sarcoma",,,,,,,,,,,,,,,"4112867","Sarcoma of uterus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2982955","Leiomyosarcoma and Endometrial Stromal Sarcoma TNM Finding v7","C89581","A finding about one or more characteristics of leiomyosarcoma and endometrial stromal sarcoma, following the rules of the TNM AJCC v7 classification system.","Leiomyosarcoma and Endometrial Stromal Sarcoma TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982959","Leiomyosarcoma and Endometrial Stromal Sarcoma pT0 TNM Finding v7","C89585","No evidence of primary tumor. (from AJCC 7th Ed.)","Leiomyosarcoma and Endometrial Stromal Sarcoma pT0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982960","Leiomyosarcoma and Endometrial Stromal Sarcoma pT1 TNM Finding v7","C89586","Tumor limited to the uterus. (from AJCC 7th Ed.)","Leiomyosarcoma and Endometrial Stromal Sarcoma pT1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982961","Leiomyosarcoma and Endometrial Stromal Sarcoma pT1a TNM Finding v7","C89587","Tumor 5 cm or less in greatest dimension. (from AJCC 7th Ed.)","Leiomyosarcoma and Endometrial Stromal Sarcoma pT1a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982962","Leiomyosarcoma and Endometrial Stromal Sarcoma pT1b TNM Finding v7","C89588","Tumor more than 5 cm in greatest dimension. (from AJCC 7th Ed.)","Leiomyosarcoma and Endometrial Stromal Sarcoma pT1b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982963","Leiomyosarcoma and Endometrial Stromal Sarcoma pT2 TNM Finding v7","C89589","Tumor extends beyond the uterus, within the pelvis. (from AJCC 7th Ed.)","Leiomyosarcoma and Endometrial Stromal Sarcoma pT2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982965","Leiomyosarcoma and Endometrial Stromal Sarcoma pT2a TNM Finding v7","C89590","Tumor involves adnexa. (from AJCC 7th Ed.)","Leiomyosarcoma and Endometrial Stromal Sarcoma pT2a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982966","Leiomyosarcoma and Endometrial Stromal Sarcoma pT2b TNM Finding v7","C89591","Tumor involves other pelvic tissues. (from AJCC 7th Ed.)","Leiomyosarcoma and Endometrial Stromal Sarcoma pT2b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982967","Leiomyosarcoma and Endometrial Stromal Sarcoma pT3 TNM Finding v7","C89592","Tumor infiltrates abdominal tissues. (from AJCC 7th Ed.)","Leiomyosarcoma and Endometrial Stromal Sarcoma pT3 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982968","Leiomyosarcoma and Endometrial Stromal Sarcoma pT3a TNM Finding v7","C89593","Tumor infiltrates abdominal tissues, one site. (from AJCC 7th Ed.)","Leiomyosarcoma and Endometrial Stromal Sarcoma pT3a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982969","Leiomyosarcoma and Endometrial Stromal Sarcoma pT3b TNM Finding v7","C89594","Tumor infiltrates abdominal tissues, more than one site. (from AJCC 7th Ed.)","Leiomyosarcoma and Endometrial Stromal Sarcoma pT3b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982970","Leiomyosarcoma and Endometrial Stromal Sarcoma pT4 TNM Finding v7","C89595","Tumor invades bladder or rectum. (from AJCC 7th Ed.)","Leiomyosarcoma and Endometrial Stromal Sarcoma pT4 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982958","Leiomyosarcoma and Endometrial Stromal Sarcoma pTX TNM Finding v7","C89584","Primary tumor cannot be assessed. (from AJCC 7th Ed.)","Leiomyosarcoma and Endometrial Stromal Sarcoma pTX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982973","Leiomyosarcoma and Endometrial Stromal Sarcoma pN0 TNM Finding v7","C89598","No regional lymph node metastasis. (from AJCC 7th Ed.)","Leiomyosarcoma and Endometrial Stromal Sarcoma pN0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982974","Leiomyosarcoma and Endometrial Stromal Sarcoma pN1 TNM Finding v7","C89599","Regional lymph node metastasis. (from AJCC 7th Ed.)","Leiomyosarcoma and Endometrial Stromal Sarcoma pN1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982972","Leiomyosarcoma and Endometrial Stromal Sarcoma pNX TNM Finding v7","C89597","Regional lymph nodes cannot be assessed. (from AJCC 7th Ed.)","Leiomyosarcoma and Endometrial Stromal Sarcoma pNX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982978","Leiomyosarcoma and Endometrial Stromal Sarcoma Clinical Distant Metastasis TNM Finding v7","C89603","A clinical finding about one or more characteristics of leiomyosarcoma and endometrial stromal sarcoma, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  (from AJCC 7th Ed.)","Leiomyosarcoma and Endometrial Stromal Sarcoma Clinical Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982979","Leiomyosarcoma and Endometrial Stromal Sarcoma cM0 TNM Finding v7","C89604","No distant metastasis. (from AJCC 7th Ed.)","Leiomyosarcoma and Endometrial Stromal Sarcoma cM0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982980","Leiomyosarcoma and Endometrial Stromal Sarcoma cM1 TNM Finding v7","C89605","Distant metastasis (excluding adnexa, pelvic and abdominal tissues). (from AJCC 7th Ed.)","Leiomyosarcoma and Endometrial Stromal Sarcoma cM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982975","Leiomyosarcoma and Endometrial Stromal Sarcoma Pathologic Distant Metastasis TNM Finding v7","C89600","A pathologic finding about one or more characteristics of leiomyosarcoma and endometrial stromal sarcoma, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  There is no pathologic M0.  (from AJCC 7th Ed.)","Leiomyosarcoma and Endometrial Stromal Sarcoma Pathologic Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982976","Leiomyosarcoma and Endometrial Stromal Sarcoma pM1 TNM Finding v7","C89601","Distant metastasis (excluding adnexa, pelvic and abdominal tissues). (from AJCC 7th Ed.)","Leiomyosarcoma and Endometrial Stromal Sarcoma pM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280624","stage I uterine sarcoma","C8258","Stage I includes: T1, N0, M0.  T1: Tumor limited to the uterus.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","Stage I Uterine Sarcoma AJCC v7 | Stage I Uterine Sarcoma | Stage I Uterine Sarcoma | stage I uterine sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2219531","stage IA uterine sarcoma","C87132","Stage IA includes: T1a, N0, M0.  T1a: For leiomyosarcoma and endometrial stromal sarcoma: tumor 5 cm or less in greatest dimension.  For adenosarcoma: tumor limited to endometrium/endocervix.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)","Stage IA Uterine Sarcoma AJCC v7 | Stage IA Uterine Sarcoma | Stage IA Uterine Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2219532","stage IB uterine sarcoma","C87133","Stage IB includes: T1b, N0, M0.  T1b: For leiomyosarcoma and endometrial stromal sarcoma: tumor more than 5 cm in greatest dimension.  For adenosarcoma: tumor invades to less than half of the myometrium.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)","Stage IB Uterine Sarcoma AJCC v7 | Stage IB Uterine Sarcoma | Stage IB Uterine Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280625","stage II uterine sarcoma","C8259","Stage II includes: T2, N0, M0.  T2: Tumor extends beyond the uterus, within the pelvis.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","Stage II Uterine Sarcoma AJCC v7 | Stage II Uterine Sarcoma | Stage II Uterine Sarcoma | stage II uterine sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2219536","stage IIIA uterine sarcoma","C87135","Stage IIIA includes: T3a, N0, M0.  T3a: Tumor infiltrates abdominal tissues, one side. N0: No regional lymph node metastasis. M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","Stage IIIA Uterine Sarcoma AJCC v7 | Stage IIIA Uterine Sarcoma | Stage IIIA Uterine Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2219537","stage IIIB uterine sarcoma","C87137","Stage IIIB includes: T3b, N0, M0. T3b: Tumor infiltrates abdominal tissues, more than one side.  N0: No regional lymph node metastasis. M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","Stage IIIB Uterine Sarcoma AJCC v7 | Stage IIIB Uterine Sarcoma | Stage IIIB Uterine Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828179","stage IIIC uterine sarcoma","C87138","Stage IIIC includes: T1-T3, N1, M0.  T1: Tumor limited to the uterus. T2: Tumor extends beyond the uterus, within the pelvis.  T3: Tumor infiltrates abdominal tissues.  N1: Regional lymph node metastasis.  M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","Stage IIIC Uterine Sarcoma AJCC v7 | Stage IIIC Uterine Sarcoma | Stage IIIC Uterine Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2219538","stage IVA uterine sarcoma","C87140","Stage IVA includes: T4, Any N, M0. T4: Tumor involves bladder or rectum.  M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","Stage IVA Uterine Sarcoma AJCC v7 | Stage IVA Uterine Sarcoma | Stage IVA Uterine Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2219539","stage IVB uterine sarcoma","C87144","Stage IVB includes: Any T, Any N, M1.  M1: Distal metastasis (excluding adnexa, pelvic and abdominal tissues).  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","Stage IVB Uterine Sarcoma AJCC v7 | Stage IVB Uterine Sarcoma | Stage IVB Uterine Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982981","Adenosarcoma TNM Finding v7","C89606","A finding about one or more characteristics of adenosarcoma, following the rules of the TNM AJCC v7 classification system.","Adenosarcoma TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982985","Adenosarcoma pT0 TNM Finding v7","C89610","No evidence of primary tumor. (from AJCC 7th Ed.)","Adenosarcoma pT0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982986","Adenosarcoma pT1 TNM Finding v7","C89611","Tumor limited to the uterus. (from AJCC 7th Ed.)","Adenosarcoma pT1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982987","Adenosarcoma pT1a TNM Finding v7","C89612","Tumor limited to endometrium/endocervix. (from AJCC 7th Ed.)","Adenosarcoma pT1a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982988","Adenosarcoma pT1b TNM Finding v7","C89613","Tumor invades to less than half of the myometrium. (from AJCC 7th Ed.)","Adenosarcoma pT1b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982989","Adenosarcoma pT1c TNM Finding v7","C89614","Tumor invades more than half of the myometrium. (from AJCC 7th Ed.)","Adenosarcoma pT1c TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982990","Adenosarcoma pT2 TNM Finding v7","C89615","Tumor extends beyond the uterus, within the pelvis. (from AJCC 7th Ed.)","Adenosarcoma pT2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982991","Adenosarcoma pT2a TNM Finding v7","C89616","Tumor involves adnexa. (from AJCC 7th Ed.)","Adenosarcoma pT2a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982992","Adenosarcoma pT2b TNM Finding v7","C89617","Tumor involves other pelvic tissues. (from AJCC 7th Ed.)","Adenosarcoma pT2b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982993","Adenosarcoma pT3 TNM Finding v7","C89618","Tumor involves abdominal tissues. (from AJCC 7th Ed.)","Adenosarcoma pT3 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982994","Adenosarcoma pT3a TNM Finding v7","C89619","Tumor involves abdominal tissues, one site. (from AJCC 7th Ed.)","Adenosarcoma pT3a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982995","Adenosarcoma pT3b TNM Finding v7","C89620","Tumor invades abdominal tissues, more than one site. (from AJCC 7th Ed.)","Adenosarcoma pT3b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982996","Adenosarcoma pT4 TNM Finding v7","C89621","Tumor invades bladder or rectum. (from AJCC 7th Ed.)","Adenosarcoma pT4 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982984","Adenosarcoma pTX TNM Finding v7","C89609","Primary tumor cannot be assessed. (from AJCC 7th Ed.)","Adenosarcoma pTX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982999","Adenosarcoma pN0 TNM Finding v7","C89624","No regional lymph node metastasis. (from AJCC 7th Ed.)","Adenosarcoma pN0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983000","Adenosarcoma pN1 TNM Finding v7","C89625","Regional lymph node metastasis. (from AJCC 7th Ed.)","Adenosarcoma pN1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982998","Adenosarcoma pNX TNM Finding v7","C89623","Regional lymph nodes cannot be assessed. (from AJCC 7th Ed.)","Adenosarcoma pNX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983004","Adenosarcoma Clinical Distant Metastasis TNM Finding v7","C89629","A clinical finding about one or more characteristics of adenosarcoma, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  (from AJCC 7th Ed.)","Adenosarcoma Clinical Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983005","Adenosarcoma cM0 TNM Finding v7","C89630","No distant metastasis. (from AJCC 7th Ed.)","Adenosarcoma cM0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983006","Adenosarcoma cM1 TNM Finding v7","C89631","Distant metastasis (excluding adnexa, pelvic and abdominal tissues). (from AJCC 7th Ed.)","Adenosarcoma cM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983001","Adenosarcoma Pathologic Distant Metastasis TNM Finding v7","C89626","A pathologic finding about one or more characteristics of adenosarcoma, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  There is no pathologic M0.  (from AJCC 7th Ed.)","Adenosarcoma Pathologic Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983002","Adenosarcoma pM1 TNM Finding v7","C89627","Distant metastasis (excluding adnexa, pelvic and abdominal tissues). (from AJCC 7th Ed.)","Adenosarcoma pM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2219533","stage IC uterine sarcoma","C87134","Stage IC includes: T1c, N0, M0.  T1c: For adenosarcoma: tumor invades more than half of the myometrium.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  Stage IC does not apply for leiomyosarcoma and endometrial stromal sarcoma.  (AJCC 7th ed.)","Stage IC Uterine Sarcoma AJCC v7 | Stage IC Uterine Sarcoma | Stage IC Uterine Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272961","Liver Kidney Microsomal Type 1 Antibody Measurement","C96683","The determination of the amount of liver kidney microsomal type 1 antibody present in a sample.","Liver Kidney Microsomal Type 1 Antibody Measurement | LKM-1 | LKM1AB | Liver Kidney Microsomal Type 1 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983039","Fallopian Tube Cancer TNM Finding v7","C89664","A finding about one or more characteristics of fallopian tube cancer, following the rules of the TNM AJCC v7 classification system.  Histologic confirmation of primary disease with complete evaluation of the abdomen and pelvis is required. (from AJCC 7th Ed.)","Fallopian Tube Cancer TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983043","Fallopian Tube Cancer pT0 TNM Finding v7","C89668","Fallopian tube cancer with no evidence of primary tumor. (from AJCC 7th Ed.)","Fallopian Tube Cancer pT0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983045","Fallopian Tube Cancer pT1 TNM Finding v7","C89670","Fallopian tube cancer limited to fallopian tube(s). (from AJCC 7th Ed.)","Fallopian Tube Cancer pT1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983046","Fallopian Tube Cancer pT1a TNM Finding v7","C89671","Fallopian tube cancer with tumor limited to one tube, without penetrating the serosal surface; no ascites.  (from AJCC 7th Ed.)","Fallopian Tube Cancer pT1a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983047","Fallopian Tube Cancer pT1b TNM Finding v7","C89672","Fallopian tube cancer with tumor limited to both tubes, without penetrating the serosal surface; no ascites. (from AJCC 7th Ed.)","Fallopian Tube Cancer pT1b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983048","Fallopian Tube Cancer pT1c TNM Finding v7","C89673","Fallopian tube cancer with tumor limited to one or both tubes with extension onto or through the tubal serosa, or with malignant cells in ascites or peritoneal washings. (from AJCC 7th Ed.)","Fallopian Tube Cancer pT1c TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983049","Fallopian Tube Cancer pT2 TNM Finding v7","C89674","Fallopian tube cancer with tumor involving one or both fallopian tubes with pelvic extension. (from AJCC 7th Ed.)","Fallopian Tube Cancer pT2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983050","Fallopian Tube Cancer pT2a TNM Finding v7","C89675","Fallopian tube cancer with extension and/or metastasis to the uterus and/or ovaries. (from AJCC 7th Ed.)","Fallopian Tube Cancer pT2a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983051","Fallopian Tube Cancer pT2b TNM Finding v7","C89676","Fallopian tube cancer with extension to other pelvic structures. (from AJCC 7th Ed.)","Fallopian Tube Cancer pT2b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983052","Fallopian Tube Cancer pT2c TNM Finding v7","C89677","Fallopian tube cancer with pelvic extension and malignant cells in ascites or peritoneal washings. (from AJCC 7th Ed.)","Fallopian Tube Cancer pT2c TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983053","Fallopian Tube Cancer pT3 TNM Finding v7","C89678","Fallopian tube cancer with tumor involving one or both fallopian tubes, with peritoneal implants outside the pelvis. (from AJCC 7th Ed.)","Fallopian Tube Cancer pT3 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983054","Fallopian Tube Cancer pT3a TNM Finding v7","C89679","Fallopian tube cancer with microscopic peritoneal metastasis outside the pelvis. (from AJCC 7th Ed.)","Fallopian Tube Cancer pT3a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983055","Fallopian Tube Cancer pT3b TNM Finding v7","C89680","Fallopian tube cancer with macroscopic peritoneal metastasis outside the pelvis 2 cm or less in greatest dimension. (from AJCC 7th Ed.)","Fallopian Tube Cancer pT3b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983056","Fallopian Tube Cancer pT3c TNM Finding v7","C89681","Fallopian tube cancer with peritoneal metastasis outside the pelvis and more than 2 cm in diameter. (from AJCC 7th Ed.)","Fallopian Tube Cancer pT3c TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983044","Fallopian Tube Cancer pTis TNM Finding v7","C89669","Fallopian tube cancer with a finding of carcinoma in situ (limited to tubal mucosa). (from AJCC 7th Ed.)","Fallopian Tube Cancer pTis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983042","Fallopian Tube Cancer pTX TNM Finding v7","C89667","Fallopian tube cancer in which the primary tumor cannot be assessed. (from AJCC 7th Ed.)","Fallopian Tube Cancer pTX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983059","Fallopian Tube Cancer pN0 TNM Finding v7","C89684","Fallopian tube cancer without regional lymph node metastasis. (from AJCC 7th Ed.)","Fallopian Tube Cancer pN0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983060","Fallopian Tube Cancer pN1 TNM Finding v7","C89685","Fallopian tube cancer with regional lymph node metastasis. (from AJCC 7th Ed.)","Fallopian Tube Cancer pN1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983058","Fallopian Tube Cancer pNX TNM Finding v7","C89683","Fallopian tube cancer in which regional lymph nodes cannot be assessed. (from AJCC 7th Ed.)","Fallopian Tube Cancer pNX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983064","Fallopian Tube Cancer Clinical Distant Metastasis TNM Finding v7","C89689","A clinical finding about one or more characteristics of fallopian tube cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.","Fallopian Tube Cancer Clinical Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983065","Fallopian Tube Cancer cM0 TNM Finding v7","C89690","Fallopian tube cancer without evidence of distant metastasis. (from AJCC 7th Ed.)","Fallopian Tube Cancer cM0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983066","Fallopian Tube Cancer cM1 TNM Finding v7","C89691","Fallopian tube cancer with distant metastasis (excluding metastasis within the peritoneal cavity). (from AJCC 7th Ed.)","Fallopian Tube Cancer cM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983061","Fallopian Tube Cancer Pathologic Distant Metastasis TNM Finding v7","C89686","A pathologic finding about one or more characteristics of fallopian tube cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  There is no pathologic M0 for fallopian tube cancer.","Fallopian Tube Cancer Pathologic Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983062","Fallopian Tube Cancer pM1 TNM Finding v7","C89687","Fallopian tube cancer with distant metastasis (excluding metastasis within the peritoneal cavity). (from AJCC 7th Ed.)","Fallopian Tube Cancer pM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984083","Fallopian Tube Cancer by AJCC v7 Stage","C91219","A term that refers to the staging of fallopian tube carcinoma according to the American Joint Committee on Cancer, 7th edition.","Fallopian Tube Cancer by AJCC v7 Stage | Fallopian Tube Carcinoma by AJCC v7 Stage | Fallopian Tube Carcinoma by AJCC v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0347176","Stage 0 Fallopian Tube Cancer AJCC v7","C40105","Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ (limited to tubal mucosa). N0: No regional lymph node metastasis.  M0: No distant metastasis. FIGO no longer includes stage 0. (AJCC 7th ed.)","Stage 0 Fallopian Tube Cancer AJCC v7 | Fallopian Tube Carcinoma in Situ | Stage 0 Fallopian Tube Cancer | Stage 0 Fallopian Tube Cancer | Tubal Intraepithelial Carcinoma",,,,,,,,,,,,,,,"4243876","Carcinoma in situ of fallopian tube",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0854926","Stage I Fallopian Tube Cancer AJCC v6 and v7","C8720","Stage I includes: (T1, N0, M0); IA (T1a, N0, M0); IB (T1b, N0, M0); IC (T1c, N0, M0).  T1: Tumor limited to the fallopian tube(s).  T1a: Tumor limited to one tube, without penetrating the serosal surface; no ascites.  T1b: Tumor limited to both tubes, without penetrating the serosal surface; no ascites.  T1c: Tumor limited to one or both tubes with extension onto or through the tubal serosa, or with malignant cells in ascites or peritoneal washings.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage I Fallopian Tube Cancer AJCC v6 and v7 | AJCC Stage I Fallopian Tube Cancer | FIGO Stage I Carcinoma of Fallopian Tube | FIGO Stage I Carcinoma of the Fallopian Tube | FIGO Stage I Fallopian Tube Carcinoma | Fallopian Tube Cancer Stage I | Stage I Fallopian Tube Cancer | Stage I Fallopian Tube Cancer | Stage I Fallopian Tube Cancer AJCC v6 | Stage I Fallopian Tube Cancer AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336114","Fallopian Tube Cancer Stage IA","C6269","Stage IA includes: T1a, N0, M0. T1a: Tumor limited to one tube, without penetrating the serosal surface; no ascites.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage IA Fallopian Tube Cancer AJCC v6 and v7 | AJCC Stage IA Fallopian Tube Cancer | FIGO Stage IA Carcinoma of Fallopian Tube | FIGO Stage IA Carcinoma of the Fallopian Tube | FIGO Stage IA Fallopian Tube Carcinoma | Fallopian Tube Cancer Stage IA | Stage IA Fallopian Tube Cancer | Stage IA Fallopian Tube Cancer | Stage IA Fallopian Tube Cancer AJCC v6 | Stage IA Fallopian Tube Cancer AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336133","Fallopian Tube Cancer Stage IB","C6270","Stage IB includes: T1b, N0, M0.  T1b: Tumor limited to both tubes, without penetrating the serosal surface; no ascites.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage IB Fallopian Tube Cancer AJCC v6 and v7 | AJCC Stage IB Fallopian Tube Cancer | FIGO Stage IB Carcinoma of Fallopian Tube | FIGO Stage IB Carcinoma of the Fallopian Tube | FIGO Stage IB Fallopian Tube Carcinoma | Fallopian Tube Cancer Stage IB | Stage IB Fallopian Tube Cancer | Stage IB Fallopian Tube Cancer | Stage IB Fallopian Tube Cancer AJCC v6 | Stage IB Fallopian Tube Cancer AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336149","Fallopian Tube Cancer Stage IC","C6271","Stage IC includes: T1c, N0, M0.  T1c: Tumor limited to one or both tubes with extension onto or through the tubal serosa, or with malignant cells in ascites or peritoneal washings.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)","Stage IC Fallopian Tube Cancer AJCC v6 and v7 | AJCC Stage IC Fallopian Tube Cancer | FIGO Stage IC Carcinoma of Fallopian Tube | FIGO Stage IC Carcinoma of the Fallopian Tube | FIGO Stage IC Fallopian Tube Carcinoma | Fallopian Tube Cancer Stage IC | Stage IC Fallopian Tube Cancer | Stage IC Fallopian Tube Cancer | Stage IC Fallopian Tube Cancer AJCC v6 | Stage IC Fallopian Tube Cancer AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0854927","Stage II Fallopian Tube Cancer AJCC v6 and v7","C8721","Stage II includes: (T2, N0, M0); IIA: (T2a, N0, M0); IIB (T2b, N0, M0); IIC (T2c, N0, M0).  T2: Tumor involves one or both fallopian tubes with pelvic extension.  T2a: Extension and/or metastasis to the uterus and/or ovaries.  T2b: Extension to other pelvic structures.  T2c: Pelvic extension with malignant cells in ascites or peritoneal washings.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage II Fallopian Tube Cancer AJCC v6 and v7 | AJCC Stage II Fallopian Tube Cancer | FIGO Stage II Carcinoma of Fallopian Tube | FIGO Stage II Carcinoma of the Fallopian Tube | FIGO Stage II Fallopian Tube Carcinoma | Fallopian Tube Cancer Stage II | Stage II Fallopian Tube Cancer | Stage II Fallopian Tube Cancer | Stage II Fallopian Tube Cancer AJCC v6 | Stage II Fallopian Tube Cancer AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336161","Fallopian Tube Cancer Stage IIA","C6272","Stage IIA includes: T2a, N0, M0.  T2a: Extension and/or metastasis to the uterus and/or ovaries.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)","Stage IIA Fallopian Tube Cancer AJCC v6 and v7 | AJCC Stage IIA Fallopian Tube Cancer | FIGO Stage IIA Carcinoma of Fallopian Tube | FIGO Stage IIA Carcinoma of the Fallopian Tube | FIGO Stage IIA Fallopian Tube Carcinoma | Fallopian Tube Cancer Stage IIA | Stage IIA Fallopian Tube Cancer | Stage IIA Fallopian Tube Cancer | Stage IIA Fallopian Tube Cancer AJCC v6 | Stage IIA Fallopian Tube Cancer AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336183","Fallopian Tube Cancer Stage IIB","C6277","Stage IIB includes: T2b, N0, M0.  T2b: Extension to other pelvic structures.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)","Stage IIB Fallopian Tube Cancer AJCC v6 and v7 | AJCC Stage IIB Fallopian Tube Cancer | FIGO Stage IIB Carcinoma of Fallopian Tube | FIGO Stage IIB Carcinoma of the Fallopian Tube | FIGO Stage IIB Fallopian Tube Carcinoma | Fallopian Tube Cancer Stage IIB | Stage IIB Fallopian Tube Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Fallopian Tube Cancer AJCC v6 | Stage IIB Fallopian Tube Cancer AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336198","Fallopian Tube Cancer Stage IIC","C6276","Stage IIC includes: T2c, N0, M0.  T2c: Pelvic extension with malignant cells in ascites or peritoneal washings.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)","Stage IIC Fallopian Tube Cancer AJCC v6 and v7 | AJCC Stage IIC Fallopian Tube Cancer | FIGO Stage IIC Carcinoma of Fallopian Tube | FIGO Stage IIC Carcinoma of the Fallopian Tube | FIGO Stage IIC Fallopian Tube Carcinoma | Fallopian Tube Cancer Stage IIC | Stage IIC Fallopian Tube Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Fallopian Tube Cancer AJCC v6 | Stage IIC Fallopian Tube Cancer AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0854928","Stage III Fallopian Tube Cancer AJCC v7","C89692","Stage III includes: (T3, N0, M0); IIIA (T3a, N0, M0); IIIB (T3b, N0, M0); IIIC (T3c, N0, M0); (Any T, N1, M0).  T3: Tumor involves one or both fallopian tubes, with peritoneal implants outside the pelvis.  T3a: Microscopic peritoneal metastasis outside the pelvis.  T3b: Macroscopic peritoneal metastasis outside the pelvis 2 cm or less in greatest dimension.  T3c: Peritoneal metastasis outside the pelvis and more than 2 cm in diameter.  N0: No regional lymph node metastasis.  N1: Regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)","Stage III Fallopian Tube Cancer AJCC v7 | Stage III Fallopian Tube Cancer | Stage III Fallopian Tube Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336206","Fallopian Tube Cancer Stage IIIA","C6273","Stage IIIA includes: T3a, N0, M0.  T3a: Microscopic peritoneal metastasis outside the pelvis.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)","Stage IIIA Fallopian Tube Cancer AJCC v7 | AJCC Stage IIIA Fallopian Tube Cancer | FIGO Stage IIIA Carcinoma of Fallopian Tube | FIGO Stage IIIA Carcinoma of the Fallopian Tube | FIGO Stage IIIA Fallopian Tube Carcinoma | Fallopian Tube Cancer Stage IIIA | Stage IIIA Fallopian Tube Cancer | Stage IIIA Fallopian Tube Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336221","Fallopian Tube Cancer Stage IIIB","C6274","Stage IIIB includes: T3b, N0, M0.  T3b: Macroscopic peritoneal metastasis outside the pelvis 2 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)","Stage IIIB Fallopian Tube Cancer AJCC v7 | AJCC Stage IIIB Fallopian Tube Cancer | FIGO Stage IIIB Carcinoma of Fallopian Tube | FIGO Stage IIIB Carcinoma of the Fallopian Tube | FIGO Stage IIIB Fallopian Tube Carcinoma | Fallopian Tube Cancer Stage IIIB | Stage IIIB Fallopian Tube Cancer | Stage IIIB Fallopian Tube Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336236","Fallopian Tube Cancer Stage IIIC","C6275","Stage IIIC includes: (T3c, N0, M0); (Any T, N1, M0).  T3c: Peritoneal metastasis outside the pelvis and more than 2 cm in diameter.  N0: No regional lymph node metastasis.  N1: Regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)","Stage IIIC Fallopian Tube Cancer AJCC v7 | AJCC Stage IIIC Fallopian Tube Cancer | FIGO Stage IIIC Carcinoma of Fallopian Tube | FIGO Stage IIIC Carcinoma of the Fallopian Tube | FIGO Stage IIIC Fallopian Tube Carcinoma | Fallopian Tube Cancer Stage IIIC | Stage IIIC Fallopian Tube Cancer | Stage IIIC Fallopian Tube Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0920280","Stage IV Fallopian Tube Cancer AJCC v6 and v7","C8963","Stage IV includes: (Any T, Any N, M1).  M1: Distant metastasis (excludes metastasis within the peritoneal cavity). (AJCC 6th and 7th eds.)","Stage IV Fallopian Tube Cancer AJCC v6 and v7 | AJCC Stage IV Fallopian Tube Cancer | FIGO Stage IV Carcinoma of Fallopian Tube | FIGO Stage IV Carcinoma of the Fallopian Tube | FIGO Stage IV Fallopian Tube Carcinoma | Fallopian Tube Cancer Stage IV | Stage IV Fallopian Tube Cancer | Stage IV Fallopian Tube Cancer | Stage IV Fallopian Tube Cancer AJCC v6 | Stage IV Fallopian Tube Cancer AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983067","Gestational Trophoblastic Tumor TNM Finding v7","C89693","A finding about one or more characteristics of gestational trophoblastic tumor, following the rules of the TNM AJCC v7 classification system.","Gestational Trophoblastic Tumor TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983071","Gestational Trophoblastic Tumor pT0 TNM Finding v7","C89697","Gestational trophoblastic tumor with no evidence of primary tumor. (from AJCC 7th Ed.)","Gestational Trophoblastic Tumor pT0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983072","Gestational Trophoblastic Tumor pT1 TNM Finding v7","C89698","Gestational trophoblastic tumor confined to uterus. (from AJCC 7th Ed.)","Gestational Trophoblastic Tumor pT1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983073","Gestational Trophoblastic Tumor pT2 TNM Finding v7","C89699","Gestational trophoblastic tumor extending to other genital structures (ovary, tube, vagina, broad ligaments) by metastasis or direct extension. (from AJCC 7th Ed.)","Gestational Trophoblastic Tumor pT2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983070","Gestational Trophoblastic Tumor pTX TNM Finding v7","C89696","Gestational trophoblastic tumor in which the primary tumor cannot be assessed. (from AJCC 7th Ed.)","Gestational Trophoblastic Tumor pTX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983079","Gestational Trophoblastic Tumor Clinical Distant Metastasis TNM Finding v7","C89705","A clinical finding about one or more characteristics of gestational trophoblastic tumor, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.","Gestational Trophoblastic Tumor Clinical Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983080","Gestational Trophoblastic Tumor cM0 TNM Finding v7","C89706","Gestational trophoblastic tumor without evidence of distant metastasis. (from AJCC 7th Ed.)","Gestational Trophoblastic Tumor cM0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983081","Gestational Trophoblastic Tumor cM1 TNM Finding v7","C89707","Gestational trophoblastic tumor with distant metastasis. (from AJCC 7th Ed.)","Gestational Trophoblastic Tumor cM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983082","Gestational Trophoblastic Tumor cM1a TNM Finding v7","C89708","Gestational trophoblastic tumor with lung metastasis. (from AJCC 7th Ed.)","Gestational Trophoblastic Tumor cM1a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983083","Gestational Trophoblastic Tumor cM1b TNM Finding v7","C89709","Gestational trophoblastic tumor with all other distant metastasis. (from AJCC 7th Ed.)","Gestational Trophoblastic Tumor cM1b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983074","Gestational Trophoblastic Tumor Pathologic Distant Metastasis TNM Finding v7","C89700","A pathologic finding about one or more characteristics of gestational trophoblastic tumor, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  There is no pathologic M0 for gestational trophoblastic tumor.","Gestational Trophoblastic Tumor Pathologic Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983075","Gestational Trophoblastic Tumor pM1 TNM Finding v7","C89701","Gestational trophoblastic tumor with distant metastasis. (from AJCC 7th Ed.)","Gestational Trophoblastic Tumor pM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983076","Gestational Trophoblastic Tumor pM1a TNM Finding v7","C89702","Gestational trophoblastic tumor with lung metastasis. (from AJCC 7th Ed.)","Gestational Trophoblastic Tumor pM1a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983077","Gestational Trophoblastic Tumor pM1b TNM Finding v7","C89703","Gestational trophoblastic tumor with all other distant metastasis. (from AJCC 7th Ed.)","Gestational Trophoblastic Tumor pM1b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828182","stage I gestational trophoblastic tumor","C87150","Stage I includes: (T1, M0, Risk factors: unknown); IA (T1, M0, Risk factors: low risk); IB (T1, M0, Risk factors: high risk).  T1: Tumor confined to uterus.  M0: No distant metastasis.  (AJCC 7th ed.)","Stage I Gestational Trophoblastic Tumor AJCC v7 | Stage I Gestational Trophoblastic Tumor | Stage I Gestational Trophoblastic Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828183","Stage IA Gestational Trophoblastic Tumor AJCC v7","C87151","Stage IA includes: T1, M0, Risk factors: low risk.  T1: Tumor confined to uterus.  M0: No distant metastasis.  (AJCC 7th ed.)","Stage IA Gestational Trophoblastic Tumor AJCC v7 | Stage IA Gestational Trophoblastic Tumor | Stage IA Gestational Trophoblastic Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828184","Stage IB Gestational Trophoblastic Tumor AJCC v7","C87152","Stage IB includes: T1, M0, Risk factors: high risk.  T1: Tumor confined to uterus.  M0: No distant metastasis.  (AJCC 7th ed.)","Stage IB Gestational Trophoblastic Tumor AJCC v7 | Stage IB Gestational Trophoblastic Tumor | Stage IB Gestational Trophoblastic Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828185","stage II gestational trophoblastic tumor","C87153","Stage II includes: (T2, M0, Risk factors: unknown); IIA (T2, M0, Risk factors: low risk); IIB (T2, M0, Risk factors: high risk).  T2: Tumor extends to other genital structures (ovary, tube, vagina, broad ligaments) by metastasis or direct extension.  M0: No distant metastasis.  (AJCC 7th ed.)","Stage II Gestational Trophoblastic Tumor AJCC v7 | Stage II Gestational Trophoblastic Tumor | Stage II Gestational Trophoblastic Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828186","Stage IIA Gestational Trophoblastic Tumor AJCC v7","C87154","Stage IIA includes: T2, M0, Risk factors: low risk.  T2: Tumor extends to other genital structures (ovary, tube, vagina, broad ligaments) by metastasis or direct extension.  M0: No distant metastasis.  (AJCC 7th ed.)","Stage IIA Gestational Trophoblastic Tumor AJCC v7 | Stage IIA Gestational Trophoblastic Tumor | Stage IIA Gestational Trophoblastic Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828187","Stage IIB Gestational Trophoblastic Tumor AJCC v7","C87155","Stage IIB includes: T2, M0, Risk factors: high risk.  T2: Tumor extends to other genital structures (ovary, tube, vagina, broad ligaments) by metastasis or direct extension.  M0: No distant metastasis.  (AJCC 7th ed.)","Stage IIB Gestational Trophoblastic Tumor AJCC v7 | Stage IIB Gestational Trophoblastic Tumor | Stage IIB Gestational Trophoblastic Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828188","stage III gestational trophoblastic tumor","C87156","Stage III includes: (Any T, M1a, Risk factors: unknown); IIIA (Any T, M1a, Risk factors: low risk); IIIB (Any T, M1a, Risk factors: high risk).  M1a: Lung metastasis.  (AJCC 7th ed.)","Stage III Gestational Trophoblastic Tumor AJCC v7 | Stage III Gestational Trophoblastic Tumor | Stage III Gestational Trophoblastic Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828189","Stage IIIA Gestational Trophoblastic Tumor AJCC v7","C87157","Stage IIIA includes: Any T, M1a, Risk factors: low risk.  M1a: Lung metastasis.  (AJCC 7th ed.)","Stage IIIA Gestational Trophoblastic Tumor AJCC v7 | Stage IIIA Gestational Trophoblastic Tumor | Stage IIIA Gestational Trophoblastic Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828190","Stage IIIB Gestational Trophoblastic Tumor AJCC v7","C87158","Stage IIIB includes: Any T, M1a, Risk factors: high risk.  M1a: Lung metastasis.  (AJCC 7th ed.)","Stage IIIB Gestational Trophoblastic Tumor AJCC v7 | Stage IIIB Gestational Trophoblastic Tumor | Stage IIIB Gestational Trophoblastic Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828191","stage IV gestational trophoblastic tumor","C87159","Stage IV includes: (Any T, M1b, Risk factors: unknown); IVA (Any T, M1b, Risk factors: low risk); IVB (Any T, M1b, Risk factors: high risk).  M1b: All other distant metastasis.  (AJCC 7th ed.)","Stage IV Gestational Trophoblastic Tumor AJCC v7 | Stage IV Gestational Trophoblastic Tumor | Stage IV Gestational Trophoblastic Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828192","Stage IVA Gestational Trophoblastic Tumor AJCC v7","C87160","Stage IVA includes: Any T, M1b, Risk factors: low risk.  M1b: All other distant metastasis.  (AJCC 7th ed.)","Stage IVA Gestational Trophoblastic Tumor AJCC v7 | Stage IVA Gestational Trophoblastic Tumor | Stage IVA Gestational Trophoblastic Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828193","Stage IVB Gestational Trophoblastic Tumor AJCC v7","C87161","Stage IVB includes: Any T, M1b, Risk factors: high risk.  M1b: All other distant metastasis.  (AJCC 7th ed.)","Stage IVB Gestational Trophoblastic Tumor AJCC v7 | Stage IVB Gestational Trophoblastic Tumor | Stage IVB Gestational Trophoblastic Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336632","HTATIP protein, human","C19887","Histone acetyltransferase KAT5 (513 aa, ~59 kDa) is encoded by the human KAT5 gene. This protein is involved in DNA damage response, histone acetylation and transcriptional activation.","Histone Acetyltransferase KAT5 | 60 kDa Tat-Interactive Protein | EC 2.3.1.48 | HIV-1 Tat Interactive Protein | HIV-1 Tat Interactive Protein, 60kDa | HTATIP | Histone Acetyltransferase HTATIP | Lysine Acetyltransferase 5 | TAT Interacting Protein 60 | TIP60 | TIP60 | Tip60 | cPLA(2)-Interacting Protein | cPLA2 Interacting Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0377897","Ku autoantigen, 80 kDa","C17969","X-ray repair cross-complementing protein 5 (732 aa, ~83 kDa) is encoded by the human XRCC5 gene. This protein is involved in both V(D)J recombination and DNA repair.","X-Ray Repair Cross-Complementing Protein 5 | 86 kDa Subunit of Ku Antigen | ATP-Dependent DNA Helicase 2 Subunit 2 | ATP-Dependent DNA Helicase II 80 kDa Subunit | ATP-Dependent DNA Helicase II, 86 kD Subunit | CTC Box-Binding Factor 85 kDa Subunit | CTC85 | DNA Repair Protein XRCC5 | EC 3.6.4.- | Ku Antigen, 80-KD Subunit | Ku Autoantigen, 80kDa | Ku80 Protein | Ku80 Protein | Ku86 | Ku86 Autoantigen Related Protein 1 | Lupus Ku Autoantigen Protein p86 | Nuclear Factor IV | TLAA | Thyroid-Lupus Autoantigen | X-Ray Repair Complementing Defective Repair In Chinese Hamster Cells 5 | X-Ray Repair Complementing Defective Repair In Chinese Hamster Cells 5 (Double-Strand-Break Rejoining) | XRCC5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708734","Epiphysis of the Bone","C32529","The round end of the long bones.","Epiphysis of the Bone | EPIPHYSIS | Epiphysis | Long Bone Epiphysis",,,,,,,,,,,,,,,"4183710","Structure of epiphysis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0522522","Transarterial","C101514","Through an artery.","Transarterial | ",,,,,,,,,,,,,,,"4011473","Transarterial approach",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2983573","Prostate Bed","C90348","The cavity just below the bladder where the prostate gland is located.","Prostate Bed | PROSTATE BED | Prostate Fossa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982808","Vulvar Cancer TNM Finding v7","C89417","A finding about one or more characteristics of vulvar cancer, following the rules of the TNM AJCC v7 classification system.  Vulvar cancer is a surgically staged malignancy. (from AJCC 7th Ed.)","Vulvar Cancer TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982811","Vulvar Cancer pT0 TNM Finding v7","C89420","Vulvar cancer with no evidence of primary tumor. (from AJCC 7th Ed.)","Vulvar Cancer pT0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982814","Vulvar Cancer pT1a TNM Finding v7","C89423","Vulvar cancer with tumor size 2 cm or less, confined to the vulva or perineum and with stromal invasion 1.0 mm or less.  The depth of invasion is defined as the measurement of the tumor from the epithelial-stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion.  (from AJCC 7th Ed.)","Vulvar Cancer pT1a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982815","Vulvar Cancer pT1b TNM Finding v7","C89424","Vulvar cancer with tumor size greater than 2 cm, or any size with stromal invasion more than 1.0 mm, confined to the vulva or perineum. (from AJCC 7th Ed.)","Vulvar Cancer pT1b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982816","Vulvar Cancer pT2 TNM Finding v7","C89425","Vulvar cancer with tumor of any size with extension to adjacent perineal structures (lower/distal 1/3 urethra, lower/distal 1/3 vagina, anal involvement). (from AJCC 7th Ed.)","Vulvar Cancer pT2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982817","Vulvar Cancer pT3 TNM Finding v7","C89426","Vulvar cancer with tumor of any size with extension to any of the following: upper/proximal 2/3 urethra, upper/proximal 2/3 vagina, bladder mucosa, rectal mucosa, or fixed to pelvic bone. (from AJCC 7th Ed.)","Vulvar Cancer pT3 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982812","Vulvar Cancer pTis TNM Finding v7","C89421","Vulvar cancer with a finding of carcinoma in situ. (from AJCC 7th Ed.)","Vulvar Cancer pTis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982810","Vulvar Cancer pTX TNM Finding v7","C89419","Vulvar cancer in which the primary tumor cannot be assessed. (from AJCC 7th Ed.)","Vulvar Cancer pTX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982820","Vulvar Cancer pN0 TNM Finding v7","C89429","Vulvar cancer without regional lymph node metastasis. (from AJCC 7th Ed.)","Vulvar Cancer pN0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982821","Vulvar Cancer pN1 TNM Finding v7","C89430","Vulvar cancer with one or two lymph node metastasis each measuring 5 mm or less, or one lymph node metastasis measuring 5 mm or greater. (from AJCC 7th Ed.)","Vulvar Cancer pN1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982822","Vulvar Cancer pN1a TNM Finding v7","C89431","Vulvar cancer with one or two lymph node metastasis each measuring 5 mm or less. (from AJCC 7th Ed.)","Vulvar Cancer pN1a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982823","Vulvar Cancer pN1b TNM Finding v7","C89432","Vulvar cancer with one lymph node metastasis measuring 5 mm or greater. (from AJCC 7th Ed.)","Vulvar Cancer pN1b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982824","Vulvar Cancer pN2 TNM Finding v7","C89433","Vulvar cancer with three or more lymph node metastases each measuring 5 mm or less, or two or more lymph node metastases measuring 5 mm or greater, or lymph node metastasis with extracapsular spread. (from AJCC 7th Ed.)","Vulvar Cancer pN2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982825","Vulvar Cancer pN2a TNM Finding v7","C89434","Vulvar cancer with three or more lymph node metastases each measuring 5 mm or less. (from AJCC 7th Ed.)","Vulvar Cancer pN2a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982826","Vulvar Cancer pN2b TNM Finding v7","C89435","Vulvar cancer with two or more lymph node metastases measuring 5 mm or greater. (from AJCC 7th Ed.)","Vulvar Cancer pN2b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982827","Vulvar Cancer pN2c TNM Finding v7","C89436","Vulvar cancer with lymph node metastasis with extracapsular spread. (from AJCC 7th Ed.)","Vulvar Cancer pN2c TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982828","Vulvar Cancer pN3 TNM Finding v7","C89437","Vulvar cancer with fixed or ulcerated regional lymph node metastasis. (from AJCC 7th Ed.)","Vulvar Cancer pN3 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982819","Vulvar Cancer pNX TNM Finding v7","C89428","Vulvar cancer in which regional lymph nodes cannot be assessed. (from AJCC 7th Ed.)","Vulvar Cancer pNX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982833","Vulvar Cancer Clinical Distant Metastasis TNM Finding v7","C89442","A clinical finding about one or more characteristics of vulvar cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.","Vulvar Cancer Clinical Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982834","Vulvar Cancer cM0 TNM Finding v7","C89443","Vulvar cancer without evidence of distant metastasis. (from AJCC 7th Ed.)","Vulvar Cancer cM0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982835","Vulvar Cancer cM1 TNM Finding v7","C89444","Vulvar cancer with distant metastasis (including pelvic lymph node metastasis). (from AJCC 7th Ed.)","Vulvar Cancer cM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982830","Vulvar Cancer Pathologic Distant Metastasis TNM Finding v7","C89439","A pathologic finding about one or more characteristics of vulvar cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  There is no pathologic M0 for vulvar cancer.","Vulvar Cancer Pathologic Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982831","Vulvar Cancer pM1 TNM Finding v7","C89440","Vulvar cancer with distant metastasis (including pelvic lymph node metastasis). (from AJCC 7th Ed.)","Vulvar Cancer pM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984069","Vulvar Cancer by AJCC v7 Stage","C91203","A term that refers to the staging of vulvar carcinoma according to the American Joint Committee on Cancer, 7th edition.","Vulvar Cancer by AJCC v7 Stage | Vulvar Carcinoma by AJCC v7 Stage | Vulvar Carcinoma by AJCC v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987483","Stage 0 Vulvar Cancer","C89445","Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ (preinvasive carcinoma). N0: No regional lymph node metastasis.  M0: No distant metastasis. FIGO no longer includes stage 0. (AJCC 7th ed.)","Stage 0 Vulvar Cancer AJCC v7 | Carcinoma in situ of vulva | Stage 0 Vulvar Cancer | Stage 0 Vulvar Cancer | Stage 0 Vulvar Carcinoma | Stage 0 Vulvar Carcinoma AJCC v7 | stage 0 vulvar carcinoma in situ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987498","Stage I Vulvar Cancer","C89447","Stage I includes: T1, N0, M0. T1: Invasive vulvar cancer confined to the vulva or perineum. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage I Vulvar Cancer AJCC v7 | Stage I Vulvar Cancer | Stage I Vulvar Cancer | Stage I Vulvar Carcinoma | Stage I Vulvar Carcinoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2217807","stage IA vulvar cancer","C89448","Stage IA includes: T1a, N0, M0. T1a: Tumor confined to the vulva and perineum, 2 cm or less in greatest dimension, and with stromal invasion no greater than 1 mm.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IA Vulvar Cancer AJCC v7 | Stage IA Vulvar Cancer | Stage IA Vulvar Cancer | Stage IA Vulvar Carcinoma | Stage IA Vulvar Carcinoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2217808","stage IB vulvar cancer","C89449","Stage IB includes: T1b, N0, M0.  T1b: Vulvar cancer with tumor size greater than 2 cm, or any size with stromal invasion more than 1.0 mm, confined to the vulva or perineum.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IB Vulvar Cancer AJCC v7 | Stage IB Vulvar Cancer | Stage IB Vulvar Cancer | Stage IB Vulvar Carcinoma | Stage IB Vulvar Carcinoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987477","Stage II Vulvar Cancer AJCC v7","C89451","Stage II includes: T2, N0, M0.  T2: Vulvar cancer with tumor of any size with extension to adjacent perineal structures (lower/distal 1/3 urethra, lower/distal 1/3 vagina, anal involvement).  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)","Stage II Vulvar Cancer AJCC v7 | Stage II Vulvar Cancer | Stage II Vulvar Cancer | Stage II Vulvar Carcinoma | Stage II Vulvar Carcinoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828099","stage IIIA vulvar cancer","C87003","Stage IIIA includes: (T1/T2, N1a/N1b, M0). T1: Invasive vulvar cancer confined to the vulva or perineum.  T2: Vulvar cancer with tumor of any size with extension to adjacent perineal structures (lower/distal 1/3 urethra, lower/distal 1/3 vagina, anal involvement).  N1a: Vulvar cancer with one or two lymph node metastasis each measuring 5 mm or less.  N1b: Vulvar cancer with one lymph node metastasis measuring 5 mm or greater.  M0: No distant metastasis.  (AJCC 7th ed.)","Stage IIIA Vulvar Cancer AJCC v7 | Stage IIIA Vulvar Cancer | Stage IIIA Vulvar Cancer | Stage IIIA Vulvar Carcinoma | Stage IIIA Vulvar Carcinoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828100","stage IIIB vulvar cancer","C87004","Stage IIIB includes: (T1/T2, N2a/N2b, M0).  T1: Invasive vulvar cancer confined to the vulva or perineum.  T2: Vulvar cancer with tumor of any size with extension to adjacent perineal structures (lower/distal 1/3 urethra, lower/distal 1/3 vagina, anal involvement).  N2a: Vulvar cancer with three or more lymph node metastases each measuring 5 mm or less.  N2b: Vulvar cancer with two or more lymph node metastases measuring 5 mm or greater.  M0: No distant metastasis.  (AJCC 7th ed.)","Stage IIIB Vulvar Cancer AJCC v7 | Stage IIIB Vulvar Cancer | Stage IIIB Vulvar Cancer | Stage IIIB Vulvar Carcinoma | Stage IIIB Vulvar Carcinoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828101","stage IIIC vulvar cancer","C87005","Stage IIIC includes: (T1/T2, N2c, M0).  T1: Invasive vulvar cancer confined to the vulva or perineum.  T2: Vulvar cancer with tumor of any size with extension to adjacent perineal structures (lower/distal 1/3 urethra, lower/distal 1/3 vagina, anal involvement).  N2c: Vulvar cancer with lymph node metastasis with extracapsular spread.  M0: No distant metastasis.  (AJCC 7th ed.)","Stage IIIC Vulvar Cancer AJCC v7 | Stage IIIC Vulvar Cancer | Stage IIIC Vulvar Cancer | Stage IIIC Vulvar Carcinoma | Stage IIIC Vulvar Carcinoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2217809","stage IVA vulvar cancer","C89454","Stage IVA includes: (T1/T2, N3, M0); (T3, Any N, M0).  T1: Invasive vulvar cancer confined to the vulva or perineum.  T2: Vulvar cancer with tumor of any size with extension to adjacent perineal structures (lower/distal 1/3 urethra, lower/distal 1/3 vagina, anal involvement).  T3: Vulvar cancer with tumor of any size with extension to any of the following: upper/proximal 2/3 urethra, upper/proximal 2/3 vagina, bladder mucosa, rectal mucosa, or fixed to pelvic bone.  N3: Vulvar cancer with fixed or ulcerated regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)","Stage IVA Vulvar Cancer AJCC v7 | Stage IVA Vulvar Cancer | Stage IVA Vulvar Cancer | Stage IVA Vulvar Carcinoma | Stage IVA Vulvar Carcinoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0852667","Stage IVB Vulvar Cancer AJCC v6 and v7","C27247","Stage IVB includes: Any T, Any N, M1.  M1: distant metastasis (including pelvic lymph node metastasis).  (AJCC 6th and 7th eds.)","Stage IVB Vulvar Cancer AJCC v6 and v7 | Stage IVB Carcinoma of Vulva | Stage IVB Carcinoma of the Vulva | Stage IVB Vulva Carcinoma | Stage IVB Vulval Cancer | Stage IVB Vulval Carcinoma | Stage IVB Vulvar Cancer | Stage IVB Vulvar Cancer | Stage IVB Vulvar Cancer AJCC v6 | Stage IVB Vulvar Cancer AJCC v7 | Stage IVB Vulvar Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1285530","Palliative","C101516","Any action or response, without curative intent, that mitigates some or all of the unpleasant effects of a disease or condition.","Palliative | PALLIATIVE | PB-Palliative Benefit | Palliative - procedure intent",,,,,,,,,,,,,,,"4179711","Palliative intent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0251006","Receptor-Type Tyrosine-Protein Kinase FLT3, Human","C26202","Receptor-type tyrosine-protein kinase FLT3 (993 aa, ~113 kDa) is encoded by the human FLT3 gene. This protein plays a role in tyrosine phosphorylation and the proliferation and survival of hematopoietic stem cells and dendritic cells.","Receptor-Type Tyrosine-Protein Kinase FLT3 | CD135 Antigen | FL Cytokine Receptor | FLK-2 | FLT-3 | FLT3 | Fetal Liver Kinase-2 | Flt-3 Receptor | Fms-Related Tyrosine Kinase 3 | Fms-Related Tyrosine Kinase 3 | STK-1 | Stem Cell Tyrosine Kinase 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL964054","G6PD protein, human","C16640","Glucose-6-phosphate 1-dehydrogenase (515 aa, ~59 kDa) is encoded by the human G6PD gene. This protein plays a role in pentose metabolism to produce NADPH.","Glucose-6-Phosphate 1-Dehydrogenase | EC 1.1.1.49 | G6PD | Glucose-6-Phosphate Dehydrogenase | Glucose-6-Phosphate Dehydrogenase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433120","NUP98/NSD1 Fusion Gene","C99434","A fusion gene that results from a chromosomal translocation t(5;11)(q35;p15.5) which fuses the first half of the NUP98 gene to the 3' portion of the NSD1 gene. This fusion is associated with myelodysplastic syndrome.","NUP98/NSD1 Fusion Gene | NUP98-NSD1 Fusion Gene | NUP98::NSD1 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1505151","Afadin, Human","C33946","Afadin (1824 aa, ~207 kDa) is encoded by the human AFDN gene. This protein is involved in the formation of adherens junctions.","Afadin | AF-6 | AF-6 Protein | AF-6 Protein | AF6 | AFDN | ALL1-Fused Gene From Chromosome 6 Protein | Afadin Adherens Junction Formation Factor | MLLT4 | Protein AF-6 | Trithorax Homolog 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982837","Vaginal Cancer TNM Finding v7","C89455","A finding about one or more characteristics of vaginal cancer, following the rules of the TNM AJCC v7 classification system.","Vaginal Cancer TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982841","Vaginal Cancer pT0 TNM Finding v7","C89459","Vaginal cancer with no evidence of primary tumor. (from AJCC 7th Ed.)","Vaginal Cancer pT0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982843","Vaginal Cancer pT1 TNM Finding v7","C89462","Vaginal cancer with a tumor confined to vagina. (from AJCC 7th Ed.)","Vaginal Cancer pT1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982844","Vaginal Cancer pT2 TNM Finding v7","C89463","Vaginal cancer invading the paravaginal tissues but not the pelvic wall. (from AJCC 7th Ed.)","Vaginal Cancer pT2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982845","Vaginal Cancer pT3 TNM Finding v7","C89464","Vaginal cancer extending to the pelvic wall.  Pelvic wall is defined as muscle, fascia, neurovascular structures, or skeletal portions of the bony pelvis.  (from AJCC 7th Ed.)","Vaginal Cancer pT3 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982846","Vaginal Cancer pT4 TNM Finding v7","C89465","Vaginal cancer invading the mucosa of the bladder or rectum and/or extending beyond the true pelvis (bullous edema is not sufficient evidence to classify a tumor as T4).  (from AJCC 7th Ed.)","Vaginal Cancer pT4 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982842","Vaginal Cancer pTis TNM Finding v7","C89461","Vaginal cancer with a finding of carcinoma in situ. (from AJCC 7th Ed.)","Vaginal Cancer pTis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982840","Vaginal Cancer pTX TNM Finding v7","C89458","Vaginal cancer in which the primary tumor cannot be assessed. (from AJCC 7th Ed.)","Vaginal Cancer pTX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982849","Vaginal Cancer pN0 TNM Finding v7","C89468","Vaginal cancer without regional lymph node metastasis. (from AJCC 7th Ed.)","Vaginal Cancer pN0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982850","Vaginal Cancer pN1 TNM Finding v7","C89469","Vaginal cancer with pelvic or inguinal lymph node metastasis. (from AJCC 7th Ed.)","Vaginal Cancer pN1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982848","Vaginal Cancer pNX TNM Finding v7","C89467","Vaginal cancer in which regional lymph nodes cannot be assessed. (from AJCC 7th Ed.)","Vaginal Cancer pNX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982854","Vaginal Cancer Clinical Distant Metastasis TNM Finding v7","C89473","A clinical finding about one or more characteristics of vaginal cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.","Vaginal Cancer Clinical Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982855","Vaginal Cancer cM0 TNM Finding v7","C89474","Vaginal cancer without evidence of distant metastasis. (from AJCC 7th Ed.)","Vaginal Cancer cM0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982856","Vaginal Cancer cM1 TNM Finding v7","C89475","Vaginal cancer with distant metastasis. (from AJCC 7th Ed.)","Vaginal Cancer cM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982851","Vaginal Cancer Pathologic Distant Metastasis TNM Finding v7","C89470","A pathologic finding about one or more characteristics of vaginal cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  There is no pathologic M0 for vaginal cancer.","Vaginal Cancer Pathologic Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982852","Vaginal Cancer pM1 TNM Finding v7","C89471","Vaginal cancer with distant metastasis.  (from AJCC 7th Ed.)","Vaginal Cancer pM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984070","Vaginal Cancer by AJCC v7 Stage","C91204","A term that refers to the staging of vaginal cancer according to the American Joint Committee on Cancer, 7th edition.","Vaginal Cancer by AJCC v7 Stage | Vaginal Carcinoma by AJCC v7 Stage | Vaginal Carcinoma by AJCC v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3146269","Stage 0 Vaginal Cancer AJCC v7","C89476","Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ (preinvasive carcinoma). N0: No regional lymph node metastasis.  M0: No distant metastasis.  FIGO no longer includes stage 0. (AJCC 7th ed.)","Stage 0 Vaginal Cancer AJCC v7 | Carcinoma in situ of vagina | Grade III Vaginal Intraepithelial Neoplasia | Grade III Vaginal Intraepithelial Neoplasia AJCC v7 | Stage 0 Vaginal Cancer | Stage 0 Vaginal Cancer | VAIN 3 | VAIN 3 AJCC v7 | VAIN III | VAIN III AJCC v7 | Vaginal Intraepithelial Neoplasia Grade 3 | Vaginal Intraepithelial Neoplasia Grade 3 AJCC v7 | stage 0 vaginal carcinoma in situ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278741","Stage I Vaginal Cancer AJCC v6 and v7","C7856","Stage I includes: (T1, N0, M0).  T1: Tumor confined to vagina.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage I Vaginal Cancer AJCC v6 and v7 | AJCC Stage I Vaginal Cancer | FIGO Stage I Carcinoma of Vagina | FIGO Stage I Carcinoma of the Vagina | FIGO Stage I Vagina Carcinoma | FIGO Stage I Vaginal Carcinoma | Stage I Vaginal Cancer | Stage I Vaginal Cancer | Stage I Vaginal Cancer AJCC v6 | Stage I Vaginal Cancer AJCC v7 | Stage I Vaginal Carcinoma AJCC v6 | Stage I Vaginal Carcinoma AJCC v7 | Vaginal Cancer Stage I | stage I vaginal cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278742","Stage II Vaginal Cancer AJCC v6 and v7","C7857","Stage II includes: T2, N0, M0. T2: Tumor invades paravaginal tissues but not to pelvic wall.  N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage II Vaginal Cancer AJCC v6 and v7 | AJCC Stage II Vaginal Cancer | FIGO Stage II Carcinoma of Vagina | FIGO Stage II Carcinoma of the Vagina | FIGO Stage II Vagina Carcinoma | FIGO Stage II Vaginal Carcinoma | Stage II Vaginal Cancer | Stage II Vaginal Cancer | Stage II Vaginal Cancer AJCC v6 | Stage II Vaginal Cancer AJCC v7 | Stage II Vaginal Carcinoma AJCC v6 | Stage II Vaginal Carcinoma AJCC v7 | Vaginal Cancer Stage II | stage II vaginal cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278743","Stage III Vaginal Cancer AJCC v6 and v7","C7858","Stage III includes: (T1-3, N1, M0) and (T3, N0, M0). T1: Tumor confined to vagina.  T2: Tumor invades paravaginal tissues but not to pelvic wall.  T3: Tumor extends to pelvic wall.  N0: No regional lymph node metastasis.  N1: Pelvic or inguinal lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage III Vaginal Cancer AJCC v6 and v7 | AJCC Stage III Vaginal Cancer | FIGO Stage III Carcinoma of Vagina | FIGO Stage III Carcinoma of the Vagina | FIGO Stage III Vagina Carcinoma | FIGO Stage III Vaginal Carcinoma | Stage III Vaginal Cancer | Stage III Vaginal Cancer | Stage III Vaginal Cancer AJCC v6 | Stage III Vaginal Cancer AJCC v7 | Stage III Vaginal Carcinoma AJCC v6 | Stage III Vaginal Carcinoma AJCC v7 | Vaginal Cancer Stage III | stage III vaginal cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278744","Stage IVA Vaginal Cancer AJCC v6 and v7","C7859","Stage IVA includes: T4, Any N, M0. T4: Tumor invades mucosa of the bladder or rectum and/or extends beyond the true pelvis (bullous edema is not sufficient evidence to classify a tumor as T4).  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage IVA Vaginal Cancer AJCC v6 and v7 | AJCC Stage IVA Vaginal Cancer | FIGO Stage IVA Carcinoma of Vagina | FIGO Stage IVA Carcinoma of the Vagina | FIGO Stage IVA Vagina Carcinoma | FIGO Stage IVA Vaginal Carcinoma | Stage IVA Vaginal Cancer | Stage IVA Vaginal Cancer | Stage IVA Vaginal Cancer AJCC v6 | Stage IVA Vaginal Cancer AJCC v7 | Stage IVA Vaginal Carcinoma AJCC v6 | Stage IVA Vaginal Carcinoma AJCC v7 | Vaginal Cancer Stage IVA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1377787","Stage IVB Vaginal Cancer AJCC v6 and v7","C9355","Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 6th and 7th eds.)","Stage IVB Vaginal Cancer AJCC v6 and v7 | AJCC Stage IVB Vaginal Cancer | FIGO Stage IVB Carcinoma of Vagina | FIGO Stage IVB Carcinoma of the Vagina | FIGO Stage IVB Vagina Carcinoma | FIGO Stage IVB Vaginal Carcinoma | Stage IVB Vaginal Cancer | Stage IVB Vaginal Cancer | Stage IVB Vaginal Cancer AJCC v6 | Stage IVB Vaginal Cancer AJCC v7 | Stage IVB Vaginal Carcinoma AJCC v6 | Stage IVB Vaginal Carcinoma AJCC v7 | Vaginal Cancer Stage IVB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983523","Exocrine and Endocrine Pancreatic Cancer TNM Finding v7","C90284","A finding about one or more characteristics of exocrine or endocrine pancreatic cancer, following the rules of the TNM AJCC v7 classification system.  Pancreatic neuroendocrine tumors (including carcinoid tumors) are now staged by a single pancreatic staging system. (from AJCC 7th Ed.)","Exocrine and Endocrine Pancreatic Cancer TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983527","Exocrine and Endocrine Pancreatic Cancer pT0 TNM Finding v7","C90288","Exocrine or endocrine pancreatic cancer with no evidence of primary tumor. (from AJCC 7th Ed.)","Exocrine and Endocrine Pancreatic Cancer pT0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983529","Exocrine and Endocrine Pancreatic Cancer pT1 TNM Finding v7","C90290","Exocrine or endocrine pancreatic cancer with tumor limited to the pancreas, measuring 2 cm or less in greatest dimension.. (from AJCC 7th Ed.)","Exocrine and Endocrine Pancreatic Cancer pT1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983531","Exocrine and Endocrine Pancreatic Cancer pT2 TNM Finding v7","C90292","Exocrine or endocrine pancreatic cancer with tumor limited to the pancreas, measuring more than 2 cm in greatest dimension. (from AJCC 7th Ed.)","Exocrine and Endocrine Pancreatic Cancer pT2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983532","Exocrine and Endocrine Pancreatic Cancer pT3 TNM Finding v7","C90293","Exocrine or endocrine pancreatic cancer with tumor extending beyond the pancreas but without involvement of the celiac axis or the superior mesenteric artery. (from AJCC 7th Ed.)","Exocrine and Endocrine Pancreatic Cancer pT3 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983533","Exocrine and Endocrine Pancreatic Cancer pT4 TNM Finding v7","C90294","Exocrine or endocrine pancreatic cancer with tumor involving the celiac axis or the superior mesenteric artery (unresectable primary tumor). (from AJCC 7th Ed.)","Exocrine and Endocrine Pancreatic Cancer pT4 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983528","Exocrine and Endocrine Pancreatic Cancer pTis TNM Finding v7","C90289","Exocrine or endocrine pancreatic cancer with a finding of carcinoma in situ.  This also includes the PanIn III classification.  (from AJCC 7th Ed.)","Exocrine and Endocrine Pancreatic Cancer pTis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983526","Exocrine and Endocrine Pancreatic Cancer pTX TNM Finding v7","C90287","Exocrine or endocrine pancreatic cancer in which the primary tumor cannot be assessed. (from AJCC 7th Ed.)","Exocrine and Endocrine Pancreatic Cancer pTX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983536","Exocrine and Endocrine Pancreatic Cancer pN0 TNM Finding v7","C90297","Exocrine or endocrine pancreatic cancer with no regional lymph node metastasis. (from AJCC 7th Ed.)","Exocrine and Endocrine Pancreatic Cancer pN0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983537","Exocrine and Endocrine Pancreatic Cancer pN1 TNM Finding v7","C90298","Exocrine or endocrine pancreatic cancer with regional lymph node metastasis. (from AJCC 7th Ed.)","Exocrine and Endocrine Pancreatic Cancer pN1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983535","Exocrine and Endocrine Pancreatic Cancer pNX TNM Finding v7","C90296","Exocrine or endocrine pancreatic cancer in which the regional lymph nodes cannot be assessed. (from AJCC 7th Ed.)","Exocrine and Endocrine Pancreatic Cancer pNX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983541","Exocrine and Endocrine Pancreatic Cancer Clinical Distant Metastasis TNM Finding v7","C90302","A clinical finding about one or more characteristics of exocrine or endocrine pancreatic cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.","Exocrine and Endocrine Pancreatic Cancer Clinical Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983542","Exocrine and Endocrine Pancreatic Cancer cM0 TNM Finding v7","C90303","Exocrine or endocrine pancreatic cancer without evidence of distant metastasis. (from AJCC 7th Ed.)","Exocrine and Endocrine Pancreatic Cancer cM0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983543","Exocrine and Endocrine Pancreatic Cancer cM1 TNM Finding v7","C90304","Exocrine or endocrine pancreatic cancer with distant metastasis. (from AJCC 7th Ed.)","Exocrine and Endocrine Pancreatic Cancer cM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983538","Exocrine and Endocrine Pancreatic Cancer Pathologic Distant Metastasis TNM Finding v7","C90299","A pathologic finding about one or more characteristics of exocrine or endocrine pancreatic cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  There is no pathologic M0 for exocrine or endocrine pancreatic cancer. (from AJCC 7th Ed.)","Exocrine and Endocrine Pancreatic Cancer Pathologic Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983539","Exocrine and Endocrine Pancreatic Cancer pM1 TNM Finding v7","C90300","Exocrine or endocrine pancreatic cancer with distant metastasis. (from AJCC 7th Ed.)","Exocrine and Endocrine Pancreatic Cancer pM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0586365","Stage 0 Pancreatic Cancer AJCC v6 and v7","C5729","Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th Eds.)","Stage 0 Pancreatic Cancer AJCC v6 and v7 | Pancreatic Cancer Stage 0 | Pancreatic Carcinoma in Situ | Stage 0 Carcinoma of Pancreas | Stage 0 Carcinoma of the Pancreas | Stage 0 Exocrine and Endocrine Pancreatic Cancer AJCC v6 and v7 | Stage 0 Pancreatic Cancer | Stage 0 Pancreatic Cancer | Stage 0 Pancreatic Cancer AJCC v6 | Stage 0 Pancreatic Cancer AJCC v7 | Stage 0 Pancreatic Carcinoma | stage 0 pancreatic carcinoma in situ",,,,,,,,,,,,,,,"4205668","Severe pancreatic duct dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL415840","Stage IA Pancreatic Cancer AJCC v6 and v7","C88100","Stage IA includes: T1, N0, M0. T1: Tumor limited to the pancreas, 2 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (from AJCC 7th Ed.)","Stage IA Pancreatic Cancer AJCC v6 and v7 | Stage IA Exocrine and Endocrine Pancreatic Cancer AJCC v6 and v7 | Stage IA Pancreatic Cancer | Stage IA Pancreatic Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL415841","Stage IB Pancreatic Cancer AJCC v6 and v7","C88101","Stage IB includes: T2, N0, M0. T2: Tumor limited to the pancreas, more than 2 cm in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (from AJCC 7th Ed.)","Stage IB Pancreatic Cancer AJCC v6 and v7 | Stage IB Exocrine and Endocrine Pancreatic Cancer AJCC v6 and v7 | Stage IB Pancreatic Cancer | Stage IB Pancreatic Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL415842","Stage IIA Pancreatic Cancer AJCC v6 and v7","C88102","Stage IIA includes: T3, N0, M0.  T3: Tumor extends beyond the pancreas but without involvement of the celiac axis or the superior mesenteric artery.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (from AJCC 7th Ed.)","Stage IIA Pancreatic Cancer AJCC v6 and v7 | Stage IIA Exocrine and Endocrine Pancreatic Cancer AJCC v6 and v7 | Stage IIA Pancreatic Cancer | Stage IIA Pancreatic Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL415843","Stage IIB Pancreatic Cancer AJCC v6 and v7","C88103","Stage IIB includes: (T1, N1, M0); (T2, N1, M0); (T3, N1, M0).  T1: Tumor limited to the pancreas, 2 cm or less in greatest dimension.  T2: Tumor limited to the pancreas, more than 2 cm in greatest dimension. T3: Tumor extends beyond the pancreas but without involvement of the celiac axis or the superior mesenteric artery.  N1: Regional lymph node metastasis.  M0: No distant metastasis. (from AJCC 7th Ed.)","Stage IIB Pancreatic Cancer AJCC v6 and v7 | Stage IIB Exocrine and Endocrine Pancreatic Cancer AJCC v6 and v7 | Stage IIB Pancreatic Cancer | Stage IIB Pancreatic Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1167722","Stage III Pancreatic Cancer AJCC v6 and v7","C7787","Stage III includes: T4, Any N, M0. T4: Tumor involves the celiac axis or the superior mesenteric artery.  M0: No distant metastasis.  (AJCC 6th and 7th Eds.)","Stage III Pancreatic Cancer AJCC v6 and v7 | Pancreatic Cancer Stage III | Stage III Carcinoma of Pancreas | Stage III Carcinoma of the Pancreas | Stage III Exocrine and Endocrine Pancreatic Cancer AJCC v6 and v7 | Stage III Pancreatic Cancer | Stage III Pancreatic Cancer | Stage III Pancreatic Cancer AJCC v6 | Stage III Pancreatic Cancer AJCC v7 | Stage III Pancreatic Carcinoma | stage III pancreatic cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1167725","Stage IV Pancreatic Cancer AJCC v6 and v7","C5711","Stage IV includes: Any T, Any N, M1.  M1: Distant metastasis. (AJCC 6th and 7th Eds.)","Stage IV Pancreatic Cancer AJCC v6 and v7 | Pancreatic Cancer Stage IV | Stage IV Carcinoma of Pancreas | Stage IV Carcinoma of the Pancreas | Stage IV Exocrine and Endocrine Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IV Pancreatic Cancer AJCC v6 | Stage IV Pancreatic Cancer AJCC v7 | Stage IV Pancreatic Carcinoma | stage IV pancreatic cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640144","Tumor Bed","C101558","The tissue that envelopes a tumor site, following the surgical removal of the tumor.","Tumor Bed | Tumor bed (morphologic abnormality)",,,,,,,,,,,,,,,"37156113","Tumor bed",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1175432","MLL/ELL Fusion Protein, Human","C101058","A fusion protein encoded by the MLL/ELL gene. This protein is comprised of the N-terminal AT hook and DNA methyltransferase domains of histone-lysine N-methyltransferase MLL fused to all but the first 46 amino acids of the RNA polymerase II elongation factor ELL.","MLL/ELL Fusion Protein | Histone-Lysine N-Methyltransferase 2A/RNA Polymerase II Elongation Factor ELL Fusion Protein | Histone-Lysine N-Methyltransferase MLL/RNA Polymerase II Elongation Factor ELL Fusion Protein | KMT2A::ELL Fusion Protein | MLL-ELL Fusion Protein | MLL::ELL Fusion Protein | Myeloid/Lymphoid or Mixed-Lineage Leukemia Protein 1/RNA Polymerase II Elongation Factor ELL Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518132","MLL-ENL Fusion Protein Expression","C38391","Expression of a fusion protein that results from a t(11;19)(q23;p13.3) translocation which fuses the 5' half of the KMT2A gene to most of the MLLT1 gene and is associated with acute lymphoblastic leukemia and other leukemia types.","KMT2A-MLLT1 Fusion Protein Expression | KMT2A-ENL Fusion Protein Expression | KMT2A-ENL Fusion Protein Expression | KMT2A-MLLT1 Fusion Protein Expression | KMT2A/MLLT1 Fusion Protein Expression | MLL-ENL Fusion Protein Expression | MLL-ENL Fusion Protein Expression | MLL-MLLT1 Fusion Protein Expression | MLL/ENL Fusion Protein Expression | MLL/MLLT1 Fusion Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0530678","TSP2 protein, human","C18038","Thrombospondin-2 (1172 aa, ~130 kDa) is encoded by the human THBS2 gene. This protein plays a role in both cell-cell and cell-matrix interactions.","Thrombospondin-2 | THBS2 | TSP-2 | TSP2 | Thrombospondin 2 | Thrombospondin II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0971015","glutathione S-transferase T1","C26244","Glutathione S-transferase theta-1 (240 aa, ~27 kDa) is encoded by the human GSTT1 gene. This protein is involved in glutathione metabolism.","Glutathione S-Transferase Theta-1 | EC 2.5.1.18 | GST Class-Theta-1 | GSTT1 | Glutathione S-Transferase Theta 1 | Glutathione S-Transferase Theta 1 | Glutathione-S-Transferase T1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0075632","Sumatriptan","C1240","A sulfonamide triptan with vasoconstrictor activity. Sumatriptan selectively binds to and activates serotonin 5-HT1D receptors in the central nervous system (CNS), thereby constricting cerebral blood vessels. This may lead to a relief in pain from vascular headaches. Sumatriptan may also relieve vascular headaches by decreasing the release of vasoactive neuropeptides from perivascular trigeminal axons in the dura mater during a migraine, by reducing extravasation of plasma proteins, and by decreasing the release of other mediators of inflammation from the trigeminal nerve.","Sumatriptan | SUMATRIPTAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640140","Stage I Thyroid Gland Papillary or Follicular Carcinoma Under 45 Years","C101539","Stage I includes: Any T, Any N, M0.  M0: No evidence of distant metastasis.  (from AJCC 7th Ed.)","Stage I Differentiated Thyroid Gland Carcinoma Under 45 Years AJCC v7 | Stage I Differentiated Thyroid Gland Cancer Under 45 Years | Stage I Differentiated Thyroid Gland Carcinoma Under 45 Years | Stage I Differentiated Thyroid Gland Carcinoma Under 45 Years | Stage I Differentiated Thyroid Gland Carcinoma Under 45 Years AJCC v7 | Stage I Differentiated Thyroid Gland Carcinoma Under 45 Years NCIT | Stage I Thyroid Gland Papillary or Follicular Carcinoma Under 45 Years",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640141","Stage I Thyroid Gland Papillary or Follicular Carcinoma 45 Years and Older","C101540","Stage I includes: T1, N0, M0.  T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland.  N0: No regional lymph node metastasis.  M0: No evidence of distant metastasis. (from AJCC 7th Ed.)","Stage I Differentiated Thyroid Gland Carcinoma 45 Years and Older AJCC v7 | Stage I Differentiated Thyroid Gland Cancer 45 Years and Older | Stage I Differentiated Thyroid Gland Carcinoma 45 Years and Older | Stage I Differentiated Thyroid Gland Carcinoma 45 Years and Older | Stage I Differentiated Thyroid Gland Carcinoma 45 Years and Older AJCC v7 | Stage I Thyroid Gland Papillary or Follicular Carcinoma 45 Years and Older",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640142","Stage II Thyroid Gland Papillary or Follicular Carcinoma Under 45 Years","C101541","Stage II includes: Any T, Any N, M1.  M1: Distant metastasis.  (from AJCC 7th Ed.)","Stage II Differentiated Thyroid Gland Carcinoma Under 45 Years AJCC v7 | Stage II Differentiated Thyroid Gland Cancer Under 45 Years | Stage II Differentiated Thyroid Gland Carcinoma Under 45 Years | Stage II Differentiated Thyroid Gland Carcinoma Under 45 Years | Stage II Differentiated Thyroid Gland Carcinoma Under 45 Years AJCC v7 | Stage II Thyroid Gland Papillary or Follicular Carcinoma Under 45 Years",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640143","Stage II Thyroid Gland Papillary or Follicular Carcinoma 45 Years and Older","C101542","Stage II includes: T2, N0, M0.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  N0: No regional lymph node metastasis.  M0: No evidence of distant metastasis.  (from AJCC 7th Ed.)","Stage II Differentiated Thyroid Gland Carcinoma 45 Years and Older AJCC v7 | Stage II Differentiated Thyroid Gland Cancer 45 Years and Older | Stage II Differentiated Thyroid Gland Carcinoma 45 Years and Older | Stage II Differentiated Thyroid Gland Carcinoma 45 Years and Older | Stage II Differentiated Thyroid Gland Carcinoma 45 Years and Older AJCC v7 | Stage II Thyroid Gland Papillary or Follicular Carcinoma 45 Years and Older",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512220","Glycinamide Ribonucleotide Formyltransferase Inhibitor","C2692","Any substance that inhibits glycinamide ribonucleotide formyltransferase, the first folate dependent enzyme in de novo purine synthesis. Inhibition of glycinamide ribonucleotide formyltransferase causes purine depletion and results in inhibition of DNA synthesis and cell cycle arrest.","Glycinamide Ribonucleotide Formyltransferase Inhibitor | glycinamide ribonucleotide formyltransferase inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0176940","Distal Pancreatectomy","C51647","Surgical removal of the distal part of the pancreas.","Distal Pancreatectomy | distal pancreatectomy",,,,,,,,,,,,,,,"4222733","Distal subtotal pancreatectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2349941","Fosaprepitant","C72787","A water-soluble, N-phosphorylated prodrug of the substance P (SP; neurokinin 1 (NK1)) antagonist aprepitant, with antiemetic activity. Upon intravenous administration and rapid conversion to aprepitant, this agent selectively binds to and blocks the human substance P receptors in the central nervous system (CNS). This inhibits receptor binding of the endogenous substance P and prevents substance P-induced emesis.","Fosaprepitant | FOSAPREPITANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0525033","Probiotic","C93144","A live microorganism used as a dietary supplement to help with digestion and normal bowel function. It may also help keep the gastrointestinal (GI) tract healthy. A bacterium found in yogurt called Lactobacillus acidophilus, is the most common probiotic.","Probiotic | Probiotic Supplement | Probiotic supplements (pills, liquid, powder; or other probiotics) | probiotic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335430","PDGFA protein, human","C30162","Platelet-derived growth factor subunit A (211 aa, ~24 kDa) is encoded by the human PDGFA gene. This protein plays a role in the regulation of chemotaxis, cell migration, cell survival, cell proliferation, and embryonic development.","Platelet-Derived Growth Factor Subunit A | PDGF A-Chain | PDGF Subunit A | PDGF-1 | PDGFA | Platelet-Derived Growth Factor A Chain | Platelet-Derived Growth Factor Alpha | Platelet-Derived Growth Factor Alpha | Platelet-Derived Growth Factor Alpha Chain | Platelet-Derived Growth Factor Alpha Polypeptide | Platelet-Derived Growth Factor, A Chain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336625","TGFBR3 Gene","C24860","This gene plays a role in the TGF-beta signaling pathway.","TGFBR3 Gene | TGFBR3 | Transforming Growth Factor Beta Receptor 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL414355","ROS1 Gene","C18399","This gene plays a role in receptor tyrosine phosphorylation signal transduction, and is thought to play a role in cellular growth or differentiation, but an exact function has not been substantiated.","ROS1 Gene | ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene | ROS1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042395","Vasoactive Intestinal Peptide","C21442","Vasoactive intestinal peptide (28 aa, ~3 kDa) is encoded by the human VIP gene. This protein is involved in vasodilation, arterial blood pressure, glycogenolysis, stimulation of myocardial contractility, and relaxation of the smooth muscles of the trachea, stomach and gall bladder.","Vasoactive Intestinal Peptide | VIP | Vasoactive Intestinal Polypeptide | vasoactive intestinal peptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030298","Pancreatic Polypeptide","C725","A 36-amino acid polypeptide with physiological regulatory functions. It is secreted by pancreatic tissue. Plasma pancreatic polypeptide increases after ingestion of food, with age, and in disease states. A lack of pancreatic polypeptide in the islets of Langerhans has been associated with the obese syndrome in rats and mice.","Pancreatic Polypeptide | Interacinar Cell Pancreatic Polypeptide | PANCREATIC POLYPEPTIDE | PP | pancreatic polypeptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0250455","FOXO1A protein, human","C26207","Forkhead box protein O1 (655 aa, ~70 kDa) is encoded by the human FOXO1 gene. This protein plays a role in the regulation of embryonic development, transcription and apoptosis.","Forkhead Box Protein O1 | FOXO1 | FOXO1A | Forkhead Box O1A | Forkhead Box Protein O1A | Forkhead in Rhabdomyosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1337013","Differentiated Thyroid Gland Carcinoma","C7153","An adenocarcinoma that arises from the thyroid gland and shows extensive evidence of follicular cell differentiation.  According to the nuclear features of the malignant follicular cells, it is classified either as papillary or follicular carcinoma.","Differentiated Thyroid Gland Carcinoma | Differentiated Thyroid Cancer | Differentiated Thyroid Carcinoma | Differentiated Thyroid Gland Cancer | Follicular/Papillary Thyroid Gland Carcinoma | Thyroid Gland Differentiated Carcinoma | Thyroid Gland Well Differentiated Carcinoma | Well Differentiated Thyroid Carcinoma | Well Differentiated Thyroid Gland Carcinoma | Well-Differentiated Thyroid Cancer",,,,,,,,,,,,,,,"36676291","Primary differentiated carcinoma of thyroid gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0662972","BCL2/Adenovirus E1B 19 kDa Protein-Interacting Protein 3-Like, Human","C21374","BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like (219 aa, ~24 kDa) is encoded by the human BNIP3L gene. This protein is involved in the induction of apoptosis.","BCL2/Adenovirus E1B 19 kDa Protein-Interacting Protein 3-Like | Adenovirus E1b19k-Binding Protein B5 | BCL2/Adenovirus E1B 19 kDa Protein-Interacting Protein 3A | BCL2/Adenovirus E1B 19-Kd Protein-Interacting Protein 3a | BCL2/Adenovirus E1B 19kd Interacting Protein 3-Like | BNIP3L | BNIP3a | NIP3-Like Protein X | NIP3L | NIX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1860707","TUBEROUS SCLEROSIS 2 (disorder)","C75331","Tuberous sclerosis mapped to chromosome 16p13.3 (TSC2 gene).","Tuberous Sclerosis 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1854465","Tuberous Sclerosis 1","C75122","Tuberous sclerosis mapped to chromosome 9q34 (TSC1 gene).","Tuberous Sclerosis 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3275275","Angiopoietin-Related Protein 4","C96325","Angiopoietin-related protein 4 (406 aa, ~45 kDa) is encoded by the human ANGPTL4 gene. This protein plays a role in the modulation of signaling during hypoxic stress and angiogenesis.","Angiopoietin-Related Protein 4 | ANGPTL4 | Angiopoietin-Like Protein 4 | HFARP | Hepatic Fibrinogen/Angiopoietin-Related Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL416238","Mipsagargin","C90554","A soluble, thapsigargin prodrug containing the cytotoxic analog of thapsigargin, 8-O-(12Aminododecanoyl)-8-O debutanoylthapsigargin (12-ADT) linked, via a carboxyl group, to the targeting peptide containing aspartic acid with potential antineoplastic activity. Upon intravenous administration, mipsagargin targets prostate specific membrane antigen (PSMA), a type II membrane carboxypeptidase, which is overexpressed in prostate cancer cells and in the neovasculature of most solid tumors but not in normal blood vessels. Mipsagargin is subsequently converted, through hydrolysis, into the active cytotoxic analog of thapsigargin 12-ADT-Asp. 12-ADT binds to and blocks the Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase (SERCA) pump, thereby increasing the concentration of cytosolic calcium which leads to an induction of apoptosis. By preventing nutrient supply to tumor cells, G-202 may be able to inhibit tumor growth. Compared to thapsigargin alone, thapsigargin prodrug G-202 is able to achieve higher concentrations of the active agents at the tumor site while avoiding systemic toxicity.","Mipsagargin | G-202 | MIPSAGARGIN | Thapsigargin Prodrug G-202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL383482","Live-Attenuated Listeria Encoding Human Mesothelin Vaccine CRS-207","C74055","A recombinant Listeria-based cancer vaccine containing a live-attenuated strain of the facultative intracellular bacterium Listeria monocytogenes (Lm) expressing human mesothelin with potential immunostimulatory and antineoplastic activities. Upon administration of this vaccine, Listeria invade professional phagocytes within the immune system and express mesothelin, which may activate a cytotoxic T-lymphocyte (CTL) response against mesothelin-expressing tumor cells, resulting in tumor cell lysis. In addition, the Listeria vector itself may induce a potent innate and adaptive immunity unrelated to mesothelin expression. Mesothelin is a cell surface glycoprotein involved in cell adhesion and is overexpressed in many epithelial-derived cancers, including pancreatic, ovarian and lung cancers, and malignant mesotheliomas.","Live-Attenuated Listeria Encoding Human Mesothelin Vaccine CRS-207 | CRS-207 | LADD Listeria monocytogenes CRS-207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1611934","Saxagliptin","C75983","A potent, selective and competitive, cyanopyrrolidine-based, orally bioavailable inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. Saxagliptin is metabolized into an, although less potent, active mono-hydroxy metabolite.","Saxagliptin | BMS-477118-11 | SAXAGLIPTIN | Saxagliptin Hydrate | Saxagliptin Monohydrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0238461","Thyroid Gland Anaplastic Carcinoma","C3878","A primary carcinoma of the thyroid gland composed of undifferentiated cells.  The malignant cells demonstrate evidence of epithelial differentiation, either by immunohistochemistry or electron microscopic studies. Microscopically, in the majority of cases there is a mixture of spindle, epithelioid, and giant cells. The vast majority of the patients present with a rapidly enlarging neck mass. The clinical course is usually aggressive.","Thyroid Gland Anaplastic Carcinoma | ATC | Anaplastic Carcinoma of Thyroid | Anaplastic Carcinoma of Thyroid Gland | Anaplastic Carcinoma of the Thyroid | Anaplastic Carcinoma of the Thyroid Gland | Anaplastic Follicular Cell Derived Thyroid Carcinoma | Anaplastic Follicular Cell Derived Thyroid Gland Carcinoma | Anaplastic Thyroid Cancer | Anaplastic Thyroid Carcinoma | Anaplastic Thyroid Gland Carcinoma | Anaplastic thyroid carcinoma | Dedifferentiated Thyroid Gland Carcinoma | Metaplastic Thyroid Gland Carcinoma | Pleomorphic Thyroid Gland Carcinoma | Sarcomatoid Thyroid Gland Carcinoma | Thyroid Gland Carcinosarcoma | Thyroid Gland Giant Cell Carcinoma | Thyroid Gland Metaplastic Carcinoma | Thyroid Gland Pleomorphic Carcinoma | Thyroid Gland Sarcomatoid Carcinoma | Thyroid Gland Spindle Cell Carcinoma | Thyroid Gland Undifferentiated (Anaplastic) Carcinoma | Thyroid Gland Undifferentiated (Anaplastic) Carcinoma | Undifferentiated (Anaplastic) Thyroid Gland Cancer | Undifferentiated (Anaplastic) Thyroid Gland Carcinoma | Undifferentiated Carcinoma of Thyroid | Undifferentiated Carcinoma of Thyroid Gland | Undifferentiated Carcinoma of the Thyroid | Undifferentiated Carcinoma of the Thyroid Gland | Undifferentiated Thyroid Carcinoma | Undifferentiated Thyroid Gland Carcinoma | Undifferentiated Thyroid Tumor | anaplastic thyroid cancer",,,,,,,,,,,,,,,"4112985","Anaplastic thyroid carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2981272","Stage IVC Thyroid Gland Papillary or Follicular Carcinoma","C87548","Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 7th ed.)","Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage IVC Differentiated Thyroid Gland Cancer | Stage IVC Differentiated Thyroid Gland Carcinoma | Stage IVC Differentiated Thyroid Gland Carcinoma | Stage IVC Thyroid Gland Papillary or Follicular Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981271","Stage IVB Thyroid Gland Papillary or Follicular Carcinoma","C87547","Stage IVB includes: T4b, Any N, M0. T4b: Very advanced disease.  Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage IVB Differentiated Thyroid Gland Cancer | Stage IVB Differentiated Thyroid Gland Carcinoma | Stage IVB Differentiated Thyroid Gland Carcinoma | Stage IVB Thyroid Gland Papillary or Follicular Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981270","Stage IVA Thyroid Gland Papillary or Follicular Carcinoma","C87546","Stage IVA includes: (T4a, N0, M0); (T4a, N1a, M0); (T1, N1b, M0); (T2, N1b, M0); (T3, N1b, M0); (T4a, N1b, M0). T4a: Moderately advanced local disease.  Tumor of any size extending beyond the thyroid gland capsule to invade subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve.  T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  T3: Tumor more than 4 cm in greatest dimension and limited to the thyroid gland, or tumor of any size with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues).  N0: No regional lymph node metastasis.  N1a: Metastasis to pretracheal, paratracheal or prelaryngeal/Delphian lymph nodes (Level VI lymph nodes).  N1b: Metastasis to unilateral, bilateral or contralateral cervical (Levels I, II, III, IV, or V) or retropharyngeal or superior mediastinal lymph nodes (Level VII).  M0: No distant metastasis. (AJCC 7th ed.)","Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage IVA Differentiated Thyroid Gland Cancer | Stage IVA Differentiated Thyroid Gland Carcinoma | Stage IVA Differentiated Thyroid Gland Carcinoma | Stage IVA Thyroid Gland Papillary or Follicular Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981269","Stage III Thyroid Gland Papillary or Follicular Carcinoma","C87545","Stage III includes: (T3, N0, M0); (T1, N1a, M0); (T2, N1a, M0); (T3, N1a, M0). T3: Tumor greater than 4 cm in greatest dimension and limited to the thyroid gland, or tumor of any size with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues).  T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  N0: No regional lymph node metastasis.  N1a: Metastasis to pretracheal, paratracheal or prelaryngeal/Delphian lymph nodes (Level VI lymph nodes).  M0: No distant metastasis. (AJCC 7th ed.)","Stage III Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage III Differentiated Thyroid Gland Cancer | Stage III Differentiated Thyroid Gland Carcinoma | Stage III Differentiated Thyroid Gland Carcinoma | Stage III Thyroid Gland Papillary or Follicular Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879464","Folfirinox Regimen","C11764","A regimen consisting of fluorouracil, irinotecan, leucovorin and oxaliplatin that can be used for the treatment of pancreatic and colorectal cancers; occult primary, ampullary, appendiceal and small bowel adenocarcinomas; well-differentiated grade 3 neuroendocrine tumors (NETs), and extrapulmonary poorly differentiated neuroendocrine carcinoma, large or small cell carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm.","Folfirinox Regimen | FOLFIRINOX | Fluorouracil with Irinotecan Hydrochloride, Leucovorin Calcium and Oxaliplatin | Fluorouracil/Irinotecan/Leucovorin Calcium/Oxaliplatin | Folinic Acid/Fluorouracil/Irinotecan/Oxaliplatin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987648","Afatinib","C66940","An orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity. Upon administration, afatinib selectively and irreversibly binds to and inhibits the epidermal growth factor receptors 1 (ErbB1; EGFR), 2 (ErbB2; HER2), and 4 (ErbB4; HER4), and certain EGFR mutants, including those caused by EGFR exon 19 deletion mutations or exon 21 (L858R) mutations. This may result in the inhibition of tumor growth and angiogenesis in tumor cells overexpressing these RTKs. Additionally, afatinib inhibits the EGFR T790M gatekeeper mutation which is resistant to treatment with first-generation EGFR inhibitors. EGFR, HER2 and HER4 are RTKs that belong to the EGFR superfamily; they play major roles in both tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types.","Afatinib | (2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide | AFATINIB | BIBW 2992 | BIBW-2992 | BIBW2992",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511766","Dendritic Cell Tumor Peptide Vaccine","C1987","A vaccine composed of dendritic cells pulsed with peptide epitopes that stimulate cytotoxic T lymphocyte anti-tumor activity. (NCI)","Dendritic Cell Tumor Peptide Vaccine | DC tumor peptide vaccine | dendritic cells pulsed with tumor peptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987138","Methylcytosine Dioxygenase TET1, Human","C95425","Methylcytosine dioxygenase TET1 (2136 aa, ~235 kDa) is encoded by the human TET1 gene. This protein is involved in the mediation of DNA methylation.","Methylcytosine Dioxygenase TET1 | CXXC-Type Zinc Finger Protein 6 | EC 1.14.11.80 | EC 1.14.11.n2 | LCX | Leukemia-Associated Protein with a CXXC Domain | TET1 | Ten-Eleven Translocation 1 Gene Protein | Tet Oncogene Family Member 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333435","Epstein-Barr Nuclear Antigen 3","C18758","Viral nuclear antigen expressed in latency","Epstein-Barr Nuclear Antigen 3 | EBNA3 | Epstein Barr Nuclear Antigen 3 | Epstein Barr Nuclear Antigen 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1437533","78 kDa glucose-regulated protein, Human","C48836","78 kDa glucose-regulated protein (654 aa, ~72kDa) is encoded by the human HSPA5 gene. The protein is intracellularly localized in the endoplasmic reticulum lumen, and plays a role in the assembly of multimeric protein complexes inside the organelle. In addition, the protein is thought to function as a pro-survival protein, or an inhibitor of apoptosis.","78 kDa Glucose-Regulated Protein | BiP | BiP Protein | Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein grp78 | GRP 78 Protein | GRP78 | HSPA5 | Heat Shock 70 kDa Protein 5 | Immunoglobulin Heavy Chain Binding Protein | Immunoglobulin Heavy Chain-Binding Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1743053","DNA (Cytosine-5)-Methyltransferase 3A, Human","C73691","DNA (cytosine-5)-methyltransferase 3A protein (909 aa, ~102 kDa) is encoded by the human DNMT3A gene. This soluble, nuclear protein is involved in epigenetic modification of chromatin, catalyzing the methylation of C5 in CpG dinucleotides within DNA.","DNA (Cytosine-5)-Methyltransferase 3A | DNA MTase HsaIIIA | DNA Methyltransferase 3A | DNA Methyltransferase HsaIIIA | DNMT3A | DNMT3a | EC 2.1.1.37 | M.HsaIIIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019643","Histone Deacetylase","C16682","Histone acetylation and deacetylation alternately exposes and occludes DNA to transcription factors. Histone deacetylation is catalyzed by the histone deacetylases.  There are at least 2 classes of HDACs, class I consisting of proteins homologous to yeast Rpd3 (e.g., HDAC1, HDAC2, and HDAC3) and class II consisting of proteins homologous to yeast Hda1 (e.g., HDAC4 and HDAC6). (from OMIM)","Histone Deacetylase | HDAC | histone deacetylase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015684","Fatty Acid","C492","Monobasic, aliphatic acids with varying chain lengths between 6 and 30.  Fatty acids are a major constituent in all fats and can be either saturated, monounsaturated, or polyunsaturated.  Saturated and monounsaturated fatty acids are synthesized by the body, whereas polyunsaturated fatty acids are not and must be obtained in the diet. (NCI)","Fatty Acid | Fatty Acids | fatty acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985836","Probability Code","C93634","A coded value specifying the likelihood of the entity or event.","Probability Code | probabilityCode",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272864","Alpha Fetoprotein L3 Measurement","C96564","The determination of the amount of alpha fetoprotein L3 present in a sample.","Alpha Fetoprotein L3 Measurement | AFP L3 Measurement | AFP-L3 Measurement | AFPL3 | Alpha Fetoprotein L3 | Alpha-Fetoprotein L3 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1171362","protein expression","C18966","The biosynthesis of new (often sets of distinct, functionally related) protein products, usually involving new mRNA transcripts, typically in response to an activating stimulus.","Protein Expression | Expressed | protein expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640076","Whole Genome Sequencing","C101294","A procedure that can determine the DNA sequence for nearly the entire genome of an individual.","Whole Genome Sequencing | WGS | WGS (whole genome sequencing) | WHOLE GENOME SEQUENCING | Whole-Genome Sequencing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL026907","Androstenedione","C2300","A steroid hormone synthesized by the adrenal glands and the gonads from either 17-alpha-hydroxyprogesterone or dehydroepiandrosterone and is a precursor of testosterone.","Androstenedione | 4-Androstene-3,17-dione | Androst-4-ene-3,17-dione | Delta-4-Androstenedione | delta4-Androstene-3,17-dione",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1313279","E3 Ubiquitin-Protein Ligase FANCL, Human","C92483","E3 ubiquitin-protein ligase FANCL (375 aa, ~43 kDa) is encoded by the human FANCL gene. This protein is involved in the regulation of both protein ubiquitination and DNA repair.","E3 Ubiquitin-Protein Ligase FANCL | EC 2.3.2.27 | EC 6.3.2.-, Formerly | FAAP43 | FANCL | Fanconi Anemia Group L Protein | Fanconi Anemia-Associated Polypeptide of 43 kDa | Fanconi Anemia-Associated Polypeptide, 43 kD | PHD Finger Protein 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025118","Medicine","C16833","The branches of medical science that deal with nonsurgical techniques.","Medicine | medicine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0683956","Disease Predictive Factor","C28282","Characteristics and conditions that have a bearing on the likelihood of a person developing a disease or disorder.","Disease Predictive Factor | predictive factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274718","ERCC1 Protein Expression","C99406","An immunohistochemical diagnostic test to evaluate the expression of ERCC1 protein at the cellular level.","ERCC1 Protein Expression | Excision Repair Cross-Complementing Group 1 Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415275","GPX1 Gene","C55288","This gene plays a role in the inhibition of oxidative stress and increases cellular resistance to toxic challenges.","GPX1 Gene | GPX1 | Glutathione Peroxidase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420222","SLC7A11 Gene","C61131","This gene plays a role in amino acid transport.","SLC7A11 Gene | SLC7A11 | Solute Carrier Family 7, (Cationic Amino Acid Transporter, Y+ System) Member 11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0753910","Receptor, Melanocortin, Type 1","C48827","Melanocyte-stimulating hormone receptor (317 aa, ~35 kDa) is encoded by the human MC1R gene. This protein plays a role in both hormone binding and melanogenesis.","Melanocyte-Stimulating Hormone Receptor | MC1-R | MC1R | MC1R Protein | MSH-R | Melanocortin 1 Receptor | Melanocortin Receptor 1 | Melanotropin Receptor | melanocortin 1 receptor | melanotropin receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1738886","Glutathione S-Transferase Mu 1, Human","C18290","Glutathione S-transferase Mu 1 (218 aa, ~26 kDa) is encoded by the human GSTM1 gene. This protein is involved in the metabolism of small molecules and xenobiotics.","Glutathione S-Transferase Mu 1 | EC 2.5.1.18 | GST Class-Mu-1 | GST HB Subunit 4 | GSTM1 | GSTM1 Protein | GSTM1-1 | GSTM1-2 | GSTM1a-1a | GSTM1b-1b | GTH4 | Glutathione S-Transferase M1 | Glutathione S-Transferase M1 | Glutathione S-Transferase Mu-1 | HB Subunit 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035547","Ribonucleotide Reductase","C17101","Ribonucleotide Reductase is a heterodimeric cytoplasmic enzyme essential in dividing cells that reduces ribonucleotides to deoxyribonucleotide precursors for DNA synthesis in S phase. It consists of two subunits, M1 Chain and M2 Chain. Complex allosteric control, mediated by deoxynucleoside triphosphates, and by ATP bound to the M1 subunit prevents DNA replication and cell proliferation. A substrate specificity site and a catalytic activity site regulate enzyme activity. A substrate-binding catalytic site on M1 is only formed in the presence of M2. Enzyme activity closely correlates with the cellular rate of growth and appears to vary with the cell cycle. (NCI)","Ribonucleotide Reductase | EC 1.17.4.-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0243044","HSP90 Heat-Shock Proteins","C17766","A family of structurally related proteins that play a role in cell signalling, protein folding and cellular stress responses. The members of this family are approximately 90 kDa.","Heat Shock Protein 90 | HSP-90 | HSP90",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0243043","Heat-Shock Proteins 70","C17765","A family of structurally related proteins that are involved in both protein folding and cellular stress responses. The members of this family are approximately 70 kDa.","Heat Shock Protein 70 | 70-kD Heat Shock Protein | 70-kD Heat-Shock Protein | 70-kDa Heat Shock Protein | HSP 70 | HSP-70 | HSP70 | HSPA | Heat Shock Protein Family A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826663","Adverse Event Ongoing","C83051","An indication or description that an adverse event is continuing.","Adverse Event Ongoing | AEONGO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333564","FIGO Stage I Gestational Trophoblastic Tumor","C6391","Lesion is confined to the uterus.","FIGO Stage I Gestational Trophoblastic Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333559","FIGO Stage II Gestational Trophoblastic Tumor","C6396","Lesion invades outside of the uterus, but it is limited to the genital structures.","FIGO Stage II Gestational Trophoblastic Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333558","FIGO Stage III Gestational Trophoblastic Tumor","C6400","Lesion affects the lungs, with or without known genital structures invasion.","FIGO Stage III Gestational Trophoblastic Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333563","FIGO Stage IV Gestational Trophoblastic Tumor","C6404","Gestational trophoblastic tumor in all other metastatic sites.","FIGO Stage IV Gestational Trophoblastic Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812201","ETS1 Gene","C18327","This gene is involved in transcriptional activation and may play a role in the suppression of tumorigenicity.","ETS1 Gene | ETS Proto-Oncogene 1, Transcription Factor Gene | ETS1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036751","Serotonin","C828","A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, hemostasis, and cardiovascular integrity. Multiple receptor families (RECEPTORS, SEROTONIN) explain the broad physiological actions and distribution of this biochemical mediator.","Serotonin | 5-HT | 5-Hydroxytryptamine | 5-hydroxytryptamine | SEROTONIN | serotonin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366449","F2R Gene","C24383","This gene is involved in coagulation and proteolytic cleavage regulation.","F2R Gene | Coagulation Factor II (Thrombin) Receptor Gene | F2R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336905","Endometrial Endometrioid Adenocarcinoma","C6287","A primary endometrial adenocarcinoma composed of neoplastic cells that form complex glandular patterns associated with budding and branching of the neoplastic glands.  The neoplastic glands resemble those of the normal endometrium and may or may not be associated with sheet-like proliferation of malignant cells.  Endometrioid adenocarcinoma is the most commonly seen morphologic variant of endometrial adenocarcinoma.","Endometrial Endometrioid Adenocarcinoma | EEC | Endometrial Endometrioid Carcinoma | Endometrioid Adenocarcinoma of Endometrium | Endometrioid Adenocarcinoma of the Endometrium | Endometrioid Carcinoma of Endometrium | Endometrioid Carcinoma of the Endometrium | Endometrioid endomet. adenocar. | Endometrioid endometrial adenocarcinoma | Uterine Corpus Endometrioid Adenocarcinoma | Uterine Corpus Endometrioid Carcinoma",,,,,,,,,,,,,,,"37166788","Endometrioid carcinoma of endometrium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041538","Ubiquitin","C17227","Conserved nuclear and cytoplasmic Ubiquitins are synthesized as either a polyubiquitin precursor with head to tail repeats or as a single ubiquitin fused to an unrelated tail protein and are typically involved in selective ATP-dependent nonlysosomal degradation of cellular proteins, histone modification, maintenance of chromatin structure, regulation of gene expression, stress response, and ribosome biogenesis. Ubiquitins often appear to be covalently bound to proteins as a marker for degradation. Ubiquitin-dependent proteolysis by the 26S proteasome plays a pivotal role in cell cycle progression. (NCI)","Ubiquitin | Ubiquitinated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985121","BRAF V600K Mutation Present","C92466","A molecular finding indicating the presence of a BRAF V600K mutation in a tissue sample.","BRAF V600K Mutation Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0082708","GLI3 protein, human","C17410","Zinc finger protein GLI3 (1580 aa, ~170 kDa) is encoded by the human GLI3 gene. This protein is involved in transcriptional regulation, limb development and signal transduction.","Zinc Finger Protein GLI3 | GLI-Kruppel Family Member 3 Protein | GLI3 | GLI3 Protein | Glioma-Associated Oncogene Homolog 3 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0539211","NOTCH4 protein, human","C18054","Neurogenic locus notch homolog protein 4 (2003 aa, ~210 kDa) is encoded by the human NOTCH4 gene. This protein plays a role in both cell-fate determination and cell-cell signaling.","Neurogenic Locus Notch Homolog Protein 4 | Human Homolog 4 of Drosophila Notch4 Protein | NOTCH4 | Neurogenic Locus Notch Homolog Protein 4 Notch Homolog 4 | Notch 4 | Notch4 / Int3 Gene Product | Notch4 Protein | hNotch4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0256371","Protein Kinase C Alpha","C17805","Protein kinase C alpha type (672 aa, ~77 kDa) is encoded by the human PRKCA gene. This protein is involved in lipid-dependent signaling, cell proliferation, apoptosis, cell differentiation, cell migration, cell adhesion, and platelet function.","Protein Kinase C Alpha Type | EC 2.7.11.13 | PKC-A | PKC-Alpha | PKCA | PRKCA | Protein Kinase C-Alpha | Protein Kinase C-Alpha | Protein Kinase Calpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0100804","Neuropilin-1","C33981","Neuropilin-1 (923 aa, ~103 kDa) is encoded by the human NRP1 gene. This protein is involved in growth factor-mediated signaling.","Neuropilin-1 | Blood Dendritic Cell Antigen 4 | CD304 Antigen | NRP | NRP1 | Neuropilin 1 | VEGF165R | Vascular Endothelial Cell Growth Factor 165 Receptor | Vascular Endothelial Cell Growth Factor-165 Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540506","Des-Gamma Carboxyprothrombin","C101804","Des-gamma carboxyprothrombin (622 aa, ~70 kDa) is encoded by the human F2 gene. This protein is involved in blood coagulation. This form of prothrombin is not efficiently converted to the active enzyme thrombin because it lacks gamma-carboxyglutamyl residues. These modified glutamyl residues are absent because of either vitamin K deficiency or inhibition of vitamin K activity that, in turn, inhibits the enzyme that carboxylates these residues, vitamin K-dependent gamma-carboxylase.","Des-Gamma Carboxyprothrombin | DCP | Des-Gamma-Carboxy Prothrombin | PIVKA-II | Protein Induced by Vitamin K Absence or Antagonist II | Protein Induced by Vitamin K Absence-II | Protein Induced by Vitamin K Absence/Antagonist-II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640796","Image Plane","C102516","The position and orientation of the image slice relative to the patient-based coordinate system.","Image Plane | ANTPLANE | Anatomical Plane",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987022","Probable Methylcytosine Dioxygenase TET2","C95254","Methylcytosine dioxygenase TET2 (2002 aa, ~224 kDa) is encoded by the human TET2 gene. This protein is involved in methylcytosine oxidation.","Methylcytosine Dioxygenase TET2 | EC 1.14.11.80 | EC 1.14.11.n2 | TET2 | Tet Oncogene Family Member 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039155","Systole","C62110","The contraction of the chambers of the heart (especially the ventricles) to drive blood into the aorta and pulmonary artery.","Systole | Systolic",,,,,,,,,,,,,,,"36716960|4008099","Systolic phase|Systole",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0004339","Auscultation","C85573","Listening with a device, such as a stethoscope, to anatomical locations that produce audible sounds like the heart, lungs and abdomen.","Auscultation | AUSCULTATION",,,,,,,,,,,,,,,"4243768","Auscultation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030318","Panic","C94438","A sudden and overwhelming sense of fear characterized by the inability to function as normal.","Panic | panic",,,,,,,,,,,,,,,"4196358","Panic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2930490","Vadimezan","C2504","A fused tricyclic analogue of flavone acetic acid with potential antineoplastic activity. Vadimezan induces the cytokines tumor necrosis alpha (TNF-alpha), serotonin and nitric oxide, resulting in hemorrhagic necrosis and a decrease in angiogenesis.  This agent also stimulates the anti-tumor activity of tumor-associated macrophages.","Vadimezan | 5,6-Dimethylxanthenone-4-Acetic Acid | 5,6-MexXAA | AS 1404 | AS A404 | AS-1404 | AS-A404 | AS1404 | ASA404 | DMXAA | Dimethyloxoxanthene Acetic Acid | Dimethylxanthenone Acetic Acid | VADIMEZAN | dimethylxanthenone acetic acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3711103","C-C Chemokine Receptor Type 5, Human","C25777","C-C chemokine receptor type 5 (352 aa, ~41 kDa) is encoded by the human CCR5 gene. This protein is involved in the modulation of inflammatory responses and cellular signaling.","C-C Chemokine Receptor Type 5 | C-C CKR-5 | C-C Motif Chemokine Receptor 5 | CC Chemokine Receptor 5 | CC-CKR-5 | CCCKR5 | CCR-5 | CCR5 | CCR5 Protein | CD195 Antigen | CHEMR13 | CKR-5 | CKR5 | CMKBR5 | Chemokine (C-C Motif) Receptor 5 | Chemokine (C-C) Receptor 5 | Chemokine Receptor CCR5 | HIV-1 Fusion Co-Receptor | HIV-1 Fusion Coreceptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699023","Regulator of G-Protein Signaling 5, Human","C74519","Regulator of G-protein signaling 5 (5181 aa, ~21 kDa) is encoded by the human RGS5 gene. This protein plays a role in the signaling of heterotrimeric G-proteins.","Regulator of G-Protein Signaling 5 | RGS5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3529617","calreticulin, human","C95315","Calreticulin (417 aa, ~48 kDa) is encoded by the human CALR gene. This protein plays a role in protein folding.","Calreticulin | Autoantigen Ro | CALR | CRP55 | Calregulin | Complement Component C1q Receptor | ERp60 | Endoplasmic Reticulum Resident Protein 60 | HACBP | grp60",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1309709","Toll-Like Receptor 9, human","C96048","Toll-like receptor 9 (1032 aa, ~116 kDa) is encoded by the human TLR9 gene. This protein plays a role in the mediation of inflammatory signaling.","Toll-Like Receptor 9 | Antigen CD289 | CD289 | CD289 Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0754727","TLR2 protein, human","C30102","Toll-like receptor 2 (784 aa, ~90 kDa) is encoded by the human TLR2 gene. This protein is involved in signal transduction that modulates innate immunity.","Toll-Like Receptor 2 | CD282 Antigen | TIL4 | TLR2 | Toll/Interleukin 1 Receptor-Like 4 | Toll/Interleukin 1 Receptor-Like Protein 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0971363","Toll-Like Receptor 1","C30101","Toll-like receptor 1 (786 aa, ~90 kDa) is encoded by the human TLR1 gene. This protein plays a role in antimicrobial immune responses.","Toll-Like Receptor 1 | CD281 Antigen | TIL | TLR1 | Toll/Interleukin-1 Receptor-Like | Toll/Interleukin-1 Receptor-Like Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1530270","IRF1 protein, human","C26627","Interferon regulatory factor 1 (325 aa, ~37 kDa) is encoded by the human IRF1 gene. This protein plays a role in the regulation of interferon gene expression.","Interferon Regulatory Factor 1 | IRF-1 | IRF1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514967","Stereotaxis","C20642","Use of a computer and scanning devices to create three-dimensional pictures.","Stereotaxis | Stereotactic | stereotaxis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3853603","Unit - NCI Thesaurus Property","C68553","The property used in conjunction with a nutrient or food component, typically expressed in gram (g), milligram (mg), microgram (mcg), joule, or kilojoule.","Unit | Units",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522314","End Time","C82573","The time when an event has ceased.","End Time | ENTIM | stop time | stop_time",,,,,,,,,,,,,,,"4262328","Stop time",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0086047","Conferences","C17453","A prearranged meeting for consultation or exchange of information or discussion, especially one with a formal agenda.","Conference | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042655","Video","C96985","Video (CVT/PVT)","Video | ",,,,,,,,,,,,,,,"4120684","Video",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1144173","KL protein, human","C98116","Klotho (1012 aa, ~116 kDa) is encoded by the human KL gene. This protein is involved in signal transduction.","Klotho | EC 3.2.1.31 | KL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537841","MIR203A Gene","C81788","This gene is involved in the regulation of gene expression and plays a role in the development of acute lymphoblastic leukemia and chronic myeloid leukemia.","MIR203A Gene | MIR203 | MIR203 Gene | MIR203A | MicroRNA 203a Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0972212","SFN protein, human","C26474","14-3-3 protein sigma (248 aa, ~28 kDa) is encoded by the human SFN gene. This protein plays a role in adaptor signal protein functions.","14-3-3 Protein Sigma | 14-3-3 Sigma | Epithelial Cell Marker Protein 1 | SFN | Stratifin | Stratifin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0447411","Alveolar Ridge","C89749","The thickened bony structures in the mandible and maxilla that contain the sockets of the teeth.","Alveolar Ridge | ALVEOLAR PROCESS | Alveolar Margin | Alveolar Process | Alveolar ridge | alveolar body | alveolar bone | alveolar margin | alveolar process | alveolar ridge | margo alveolaris",,,,,,,,,,,,,"UBERON:0004103","alveolar ridge","37157592","Structure of alveolar arch",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0808901","EWSR1 Gene","C18322","This gene may play a role in post-transcriptional regulation; however the function remains to be elucidated. Mutations in the gene result in Ewing sarcoma and other tumors.","EWSR1 Gene | EWS RNA-Binding Protein 1 Gene | EWSR1 | Ewing Sarcoma Breakpoint Region 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348945","Heat Shock Factor Protein 1","C71446","Heat shock factor protein 1 (529 aa, ~57 kDa) is encoded by the human HSF1 gene. This protein plays a role in activating the transcription of heat shock protein genes.","Heat Shock Factor Protein 1 | HSF 1 | HSTF 1 | Heat Shock Transcription Factor 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036394","Sciatic Nerve","C52810","The long nerve that is formed by the merging of the ventral rami of the L4, L5, and S1 in the pelvis and passes down the lower limb where it divides into the common peroneal and tibial nerves.","Sciatic Nerve | NERVE, SCIATIC | SCIATIC NERVE | sciatic nerve",,,,,,,,,,,,,"UBERON:0001322","sciatic nerve","4190750","Structure of sciatic nerve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019155","Hepatic Vein","C32736","The blood vessels that drain blood from the central veins of the liver into the inferior vena cava.","Hepatic Vein | HEPATIC VEIN | hepatic vein | liver vein | vein of liver | vena hepatica",,,,,,,,,,,,,"UBERON:0001143","hepatic vein","4233953","Structure of hepatic vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1336843","Typical Acute Promyelocytic Leukemia","C27756","Acute Promyelocytic leukemia characterized by the presence of hypergranular promyelocytes and characteristic cells that contain bundles of Auer rods.","Typical Acute Promyelocytic Leukemia | Hypergranular Acute Promyelocytic Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706122","CYP3A5*3 Allele","C46021","Human CYP3A5*3 allele is located in the vicinity of 7q21.1 and is approximately 32 kb in length. This allele, a variant form of the human CYP3A5 wild-type allele, encodes cytochrome P450 3A5*3 protein. The CYP3A5*3 allele exhibits a clinically-relevant SNP (g.6986A>G) in intron 3 that results in a splicing defect and premature stop at 102 amino acids. This alteration severely decreases the enzymatic activity of the cytochrome P450 3A5*3 protein.","CYP3A5*3 Allele | CYP3A5*3 | CYP3A5, g.6986A>G | Cytochrome P450, Family 3, Subfamily A, Polypeptide 5*3 Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710304","TNF wt Allele","C51526","Human TNF wild-type allele is located in the vicinity of 6p21.3 and is approximately 3 kb in length. This allele, which encodes tumor necrosis factor protein, is involved in a wide spectrum of biological processes including cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation. Aberrant alleles have been associated with a variety of diseases, including autoimmune diseases, insulin resistance, and cancer.","TNF wt Allele | DIF | TNF A | TNF, Macrophage-Derived Gene | TNF, Monocyte-Derived Gene | TNF-alpha | TNFA | TNFSF2 | Tumor Necrosis Factor (TNF Superfamily, Member 2) wt Allele | Tumor Necrosis Factor Gene | Tumor Necrosis Factor, Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700093","Tumor Necrosis Factor Measurement","C74751","The determination of the amount of tumor necrosis factor present in a sample.","Tumor Necrosis Factor Measurement | TNF | TNF Alpha Measurement | TNF Measurement | Tumor Necrosis Factor | Tumor Necrosis Factor Alpha Measurement | Tumor Necrosis Factor alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640816","International Neuroblastoma Risk Group Classification System","C102563","A classification system developed to establish a consensus approach for pretreatment risk stratification of neuroblastomas.","International Neuroblastoma Risk Group Classification System | INRG Classification System | Neuroblastoma Risk Group",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437071","International Neuroblastoma Pathology Classification","C102562","A classification system established by adopting the original system proposed by Shimada with subsequent revisions. The INPC distinguishes favorable and unfavorable histology groups.","International Neuroblastoma Pathology Classification | INPC | inpc grade | inpc_grade",,,,,,,,,,,,,,,"4252877","International neuroblastoma pathology classification",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640814","Favorable","C102560","Expressing something as positive, advantageous or desired.","Favorable | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640815","Unfavorable","C102561","Expressing something as negative, undesired or adverse.","Unfavorable | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0170521","DDIT3 protein, human","C92545","DNA damage-inducible transcript 3 protein (169 aa, ~19 kDa) is encoded by the human DDIT3 gene. This protein plays a role in the sequestration of transcription factors.","DNA Damage-Inducible Transcript 3 Protein | C/EBP-Homologous Protein | C/EBP-Homologous Protein 10 | CHOP | CHOP-10 | DDIT-3 | DDIT3 | Growth Arrest and DNA Damage-Inducible Protein GADD153",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1741914","C-X-C Chemokine Receptor Type 3, Human","C26227","C-X-C chemokine receptor type 3 (368 aa, ~41 kDa) is encoded by the human CXCR3 gene. This protein plays a role in cell proliferation, cell survival and angiogenesis.","C-X-C Chemokine Receptor Type 3 | CD183 | CD183 Antigen | CKR-L2 | CXC-R3 | CXCR-3 | CXCR3 | Chemokine (C-X-C Motif) Receptor 3 | G Protein-Coupled Receptor 9 | G-Protein Coupled Receptor 9 | IP10 Receptor | Interferon-Inducible Protein 10 Receptor | Mig Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0666364","TNFSF11 protein, human","C30113","Tumor necrosis factor ligand superfamily member 11 (317 aa, ~35 kDa) is encoded by the human TNFSF11 gene. This protein is involved in osteoclast differentiation and activation and the regulation of the interactions between T-cells and dendritic cells.","Tumor Necrosis Factor Ligand Superfamily Member 11 | CD254 | CD254 Antigen | ODF | OPGL | Osteoclast Differentiation Factor | Osteoprotegerin Ligand | RANKL | Receptor Activator of NF-Kappa-B Ligand | Receptor Activator of Nuclear Factor Kappa B Ligand | Receptor Activator of Nuclear Factor Kappa-B Ligand | TNF-Related Activation-Induced Cytokine | TNFSF11 | TRANCE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0071795","ribonuclease L, human","C101337","2-5A-dependent ribonuclease (741 aa, ~84 kDa) is encoded by the human RNASEL gene. This protein plays a role in both RNA processing and the antiviral response.","2-5A-Dependent Ribonuclease | 2-5A-Dependent RNase | EC 3.1.26.- | Interferon-Induced 2-5A-Dependent RNase | RNASEL | RNase L | Ribonuclease 4 | Ribonuclease L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1436587","SH2 Domain-Containing Protein 1A, Human","C75395","SH2 domain-containing protein 1A (128 aa, ~14 kDa) is a cell division protein that is encoded by the human SH2D1A gene and has roles in activation, proliferation, differentiation and function of T- and B-cells.","SH2 Domain-Containing Protein 1A | Duncan Disease SH2-Protein | SH2D1A | SLAM-Associated Protein | Signaling Lymphocytic Activation Molecule-Associated Protein | T-Cell Signal Transduction Molecule SAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3536861","Thiazide Diuretic","C49185","Any benzothiadiazide derivative or other thiazide-like agent with diuretic and anti-hypertensive activity. Thiazide diuretics inhibit the sodium-chloride transporter in the distal tubule in the kidneys, thereby suppressing sodium and chloride reabsorption from the distal convoluted tubules (DCT) and increasing the excretion of sodium, chloride, potassium and water. In addition, thiazide diuretics decrease excretion of calcium and uric acid. These agents cause vasodilation possibly by activating calcium-activated potassium channels in vascular smooth muscle and inhibiting various carbonic anhydrases in vascular tissue.","Thiazide Diuretic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1569730","Insulin-Like Growth Factor II, Human","C16744","Insulin-like growth factor II (180 aa, ~20 kDa) is encoded by the human IGF2 gene. This protein plays a role in cellular growth, development, and mitogenesis.","Insulin-Like Growth Factor II | IGF-2 | IGF-II | IGF2 | Insulin-Like Growth Factor 2 | Insulin-Like Growth Factor 2 | Somatomedin A | Somatomedin-A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516213","Cancer Patient","C19700","A person who receives medical care for the purpose of treating, diagnosing or preventing cancer.","Cancer Patient | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707492","Consent Withdrawn","C48271","When the permission to do something is rescinded or withdrawn.","Consent Withdrawn | Withdrawal of Consent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516232","Cancer Survivorship Research","C18674","Research on cancer survivors, covers the full spectrum of biomedical and psycho-social issues that arise at the point of discontinuation of cancer-specific therapy to the point of terminal diagnosis (6 months or less to live).","Cancer Survivorship Research | Cancer Survivorship | Survivorship, Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511934","Differentiating Neuroblastoma","C42048","A neuroblastoma in which the differentiating neuroblasts constitute more than five-percent of the tumor cells.","Differentiating Neuroblastoma | Differentiating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333732","Karyorrhexis","C39616","Degeneration of the cell nucleus marked by contraction of the chromatin into small pieces and loss of the nuclear boundary.","Karyorrhexis | ",,,,,,,,,,,,,,,"4145118","Karyorrhexis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517445","Ganglioneuroblastoma, Nodular","C42058","A ganglioneuroblastoma characterized by the presence of neuroblastic cells in a Schwannian stroma, and the formation of hemorrhagic neuroblastic nodules.","Ganglioneuroblastoma, Nodular | GNBn",,,,,,,,,,,,,,,"37311700","Nodular ganglioneuroblastoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517444","Ganglioneuroblastoma, Intermixed","C42057","A ganglioneuroblastoma characterized by the presence of neuroblastic cells in a Schwannian stroma, without the presence of hemorrhagic neuroblastic nodules.","Ganglioneuroblastoma, Intermixed | GNB-i | Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich)",,,,,,,,,,,,,,,"37311699","Intermixed ganglioneuroblastoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205815","Epithelioid Leiomyosarcoma","C3700","A morphologic variant of leiomyosarcoma characterized by the presence of epithelioid round cells with eosinophilic to clear cytoplasm.","Epithelioid Leiomyosarcoma | Epithelioid leiomyosarcoma","8891/3","Epithelioid leiomyosarcoma",,,,,,,,,,,,,"4173148","Epithelioid leiomyosarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1333157","Conventional Leiomyosarcoma","C9428","An uncommon, aggressive malignant smooth muscle neoplasm.  It is characterized by the presence of atypical large spindle or round cells, nuclear palisading, tumor cell necrosis, mitotic figures and may be associated with vascular invasion.","Conventional Leiomyosarcoma | Classic Leiomyosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279671","Cervical Squamous Cell Carcinoma","C4028","A squamous cell carcinoma arising from the cervical epithelium. It usually evolves from a precancerous cervical lesion. Increased numbers of sexual partners and human papillomavirus (HPV) infection are risk factors for cervical squamous cell carcinoma. Survival is most closely related to the stage of disease at the time of diagnosis.","Cervical Squamous Cell Carcinoma | Cervical Squamous Cell Cancer | Cervical Squamous Cell Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Cervix Squamous Cell Carcinoma | Cervix Uteri Squamous Cell Carcinoma | Squamous Cell Carcinoma of Cervix | Squamous Cell Carcinoma of Cervix Uteri | Squamous Cell Carcinoma of Uterine Cervix | Squamous Cell Carcinoma of the Cervix | Squamous Cell Carcinoma of the Cervix Uteri | Squamous Cell Carcinoma of the Uterine Cervix | Squamous cervical cancer | Uterine Cervix Squamous Cell Carcinoma",,,,,,,,,,,,,,,"4116080","Squamous cell carcinoma of cervix",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2826603","Mucin Depletion","C82974","A morphologic and histochemical finding indicating depletion of mucin in the glands.","Mucin Depletion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986966","Stage IIA1","C95177","A stage term that applies to cervical cancer and indicates that the tumor invades beyond the uterus but not to the pelvic wall or to the lower third of vagina. There is no parametrial invasion.  The lesion is clinically visible and measures 4.0 cm or less in greatest dimension.","Stage IIA1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986967","Stage IIA2","C95178","A stage term that applies to cervical cancer and indicates that the tumor invades beyond the uterus but not to the pelvic wall or to the lower third of vagina. There is no parametrial invasion.  The lesion is clinically visible and measures more than 4.0 cm in greatest dimension.","Stage IIA2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079091","Integrin Alpha-L","C17372","Integrin alpha-L (1170 aa, ~129 kDa) is encoded by the human ITGAL gene. This protein plays a role in cell motility and cell-cell adhesion.","Integrin Alpha-L | Alpha L Integrin Chain | CD11 Antigen-Like Family Member A | CD11A | ITGAL | LFA-1 Alpha | LFA-1A | Leukocyte Adhesion Glycoprotein LFA-1 Alpha Chain | Leukocyte Function-Associated Molecule 1 Alpha Chain | Lymphocyte Function-Associated Antigen-1 Alpha Chain | Lymphocyte Function-Associated Antigen-1, Alpha Subunit",,,,,,,,,,,,,,,"4287247","Lymphocyte antigen CD11a",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348996","Hsp90 inhibitor AUY922","C71467","A derivative of 4,5-diarylisoxazole and a third-generation heat shock protein 90 (Hsp90) inhibitor with potential antineoplastic activity. Luminespib has been shown to bind with high affinity to and inhibit Hsp90, resulting in the proteasomal degradation of oncogenic client proteins; the inhibition of cell proliferation; and the elevation of heat shock protein 72 (Hsp72) in a wide range of human tumor cell lines. Hsp90, a 90 kDa molecular chaperone, plays a key role in the conformational maturation, stability and function of other substrate or 'client' proteins within the cell, many of which are involved in signal transduction, cell cycle regulation and apoptosis, including kinases, transcription factors and hormone receptors.  Hsp72 exhibits anti-apoptotic functions; its up-regulation may be used as a surrogate marker for Hsp90 inhibition.","Luminespib | AUY922 | Hsp90 Inhibitor AUY922 | Hsp90 Inhibitor AUY922 | LUMINESPIB | NVP AUY 922 | NVP-AUY 922",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697961","Trametinib","C77908","An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration, trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity serine/threonine and tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.","Trametinib | GSK 1120212 | GSK 212 | GSK-1120212 | GSK-212 | GSK1120212 | GSK212 | JTP 74057 | JTP-74057 | JTP74057 | MEK Inhibitor GSK1120212 | N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide | TRAMETINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0338237","Antibiotic Therapy","C15620","Treatment of bacterial infections with antibiotics.","Antibiotic Therapy | Treatment of Bacterial Infectious Disease",,,,,,,,,,,,,,,"4085730","Antibiotic therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4067681","Dilation and Curettage","C15226","A surgical scraping and removal of the inner lining of the uterus through direct dilation of the uterine cervix.","Dilation and Curettage | D and C | D&C | Dilation and Curettage Procedure | Dilation and Curettage of the Uterus | dilatation and curettage | dilation and curettage",,,,,,,,,,,,,,,"4047258","Dilation and curettage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3274072","KRAS NP_004976.2:p.Q61E","C98424","A change in the amino acid residue at position 61 in the GTPase KRas protein where glutamine has been replaced by glutamic acid.","KRAS NP_004976.2:p.Q61E | GTPase KRas Q61E | K-Ras 2 Q61E | KRAS Gln61Glu | KRAS NP_004976.2:p.Gln61Glu | KRAS Q61E | KRAS p.Gln61Glu | KRAS p.Q61E | Ki-Ras Q61E | NP_004976.2:p.Gln61Glu | NP_004976.2:p.Q61E | c-K-ras Q61E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274085","KRAS NP_004976.2:p.Q61R","C98437","A change in the amino acid residue at position 61 in the GTPase KRas protein where glutamine has been replaced by arginine.","KRAS NP_004976.2:p.Q61R | GTPase KRas Gln61Arg | GTPase KRas Q61R | K-Ras 2 Q61R | KRAS Gln61Arg | KRAS NP_004976.2:p.Gln61Arg | KRAS Q61R | KRAS p.Gln61Arg | KRAS p.Q61R | Ki-Ras Q61R | NP_004976.2:p.Gln61Arg | NP_004976.2:p.Q61R | c-K-ras Q61R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274081","KRAS NP_004976.2:p.Q61L","C98433","A change in the amino acid residue at position 61 in the GTPase KRas protein where glutamine has been replaced by leucine.","KRAS NP_004976.2:p.Q61L | GTPase KRas Gln61Leu | GTPase KRas Q61L | K-Ras 2 Q61L | KRAS Gln61Leu | KRAS NP_004976.2:p.Gln61Leu | KRAS Q61L | KRAS p.Gln61Leu | KRAS p.Q61L | Ki-Ras Q61L | NP_004976.2:p.Gln61Leu | NP_004976.2:p.Q61L | c-K-ras Q61L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274074","KRAS NP_004976.2:p.Q61H","C98426","A change in the amino acid residue at position 61 in the GTPase KRas protein where glutamine has been replaced by histidine.","KRAS NP_004976.2:p.Q61H | GTPase KRas Gln61His | GTPase KRas Q61H | K-Ras 2 Q61H | KRAS Gln61His | KRAS NP_004976.2:p.Gln61His | KRAS Q61H | KRAS p.Gln61His | KRAS p.Q61H | Ki-Ras Q61H | NP_004976.2:p.Gln61His | NP_004976.2:p.Q61H | c-K-ras Q61H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274051","KRAS NP_004976.2:p.G13D","C98403","A change in the amino acid residue at position 13 in the GTPase KRas protein where glycine has been replaced by aspartic acid.","KRAS NP_004976.2:p.G13D | GTPase KRas G13D | GTPase KRas Gly13Asp | K-Ras 2 G13D | KRAS G13D | KRAS Gly13Asp | KRAS NP_004976.2:p.Gly13Asp | KRAS p.G13D | KRAS p.Gly13Asp | Ki-Ras G13D | NP_004976.2:p.Gly13Asp | c-K-ras G13D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274012","KRAS NP_004976.2:p.G12C","C98365","A change in the amino acid residue at position 12 in the GTPase KRas protein where glycine has been replaced by cysteine.","KRAS NP_004976.2:p.G12C | GTPase KRas G12C | GTPase KRas Gly12Cys | K-Ras 2 G12C | KRAS G12C | KRAS G12C Mutation | KRAS Gly12Cys | KRAS NP_004976.2:p.Gly12Cys | KRAS p.G12C | KRAS p.Gly12Cys | Ki-Ras G12C | NP_004976.2:p.G12C | NP_004976.2:p.Gly12Cys | c-K-ras G12C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274033","KRAS NP_004976.2:p.G12R","C98386","A change in the amino acid residue at position 12 in the GTPase KRas protein where glycine has been replaced by arginine.","KRAS NP_004976.2:p.G12R | GTPase KRas G12R | K-Ras 2 G12R | KRAS G12R | KRAS G12R Mutation | KRAS Gly12Arg | KRAS NP_004976.2:p.Gly12Arg | KRAS p.G12R | KRAS p.Gly12Arg | Ki-Ras G12R | NP_004976.2:p.Gly12Arg | c-K-ras G12R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274036","KRAS NP_004976.2:p.G12S","C98389","A change in the amino acid residue at position 12 in the GTPase KRas protein where glycine has been replaced by serine.","KRAS NP_004976.2:p.G12S | GTPase KRas G12S | K-Ras 2 G12S | KRAS G12S | KRAS Gly12Ser | KRAS NP_004976.2:p.Gly12Ser | KRAS p.G12S | KRAS p.Gly12Ser | Ki-Ras G12S | NP_004976.2:p.Gly12Ser | c-K-ras G12S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274038","KRAS NP_004976.2:p.G12V","C98391","A change in the amino acid residue at position 12 in the GTPase KRas protein where glycine has been replaced by valine.","KRAS NP_004976.2:p.G12V | GTPase KRas G12V | GTPase KRas Gly12Val | K-Ras 2 G12V | K-Ras 2 Gly12Val | KRAS G12V | KRAS Gly12Val | KRAS NP_004976.2:p.Gly12Val | KRAS p.G12V | KRAS p.Gly12Val | Ki-Ras G12V | Ki-Ras Gly12Val | NP_004976.2:p.G12V | NP_004976.2:p.Gly12Val | c-K-ras G12V | c-K-ras Gly12Val",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274010","KRAS NP_004976.2:p.G12A","C98363","A change in the amino acid residue at position 12 in the GTPase KRas protein where glycine has been replaced by alanine.","KRAS NP_004976.2:p.G12A | GTPase KRas G12A | GTPase KRas Gly12Ala | K-Ras 2 G12A | KRAS G12A | KRAS Gly12Ala | KRAS NP_004976.2:p.Gly12Ala | KRAS p.G12A | KRAS p.Gly12Ala | Ki-Ras G12A | NP_004976.2:p.G12A | NP_004976.2:p.Gly12Ala | c-K-ras G12A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274016","KRAS NP_004976.2:p.G12D","C98369","A change in the amino acid residue at position 12 in the GTPase KRas protein where glycine has been replaced by aspartic acid.","KRAS NP_004976.2:p.G12D | G12D Mutated KRAS | GTPase KRas G12D | GTPase KRas Gly12Asp | K-Ras 2 G12D | K-Ras 2 Gly12Asp | KRAS G12D | KRAS Gly12Asp | KRAS NP_004976.2:p.Gly12Asp | KRAS p.G12D | KRAS p.Gly12Asp | Ki-Ras G12D | Ki-Ras Gly12Asp | NP_004976.2:p.G12D | NP_004976.2:p.Gly12Asp | c-K-ras G12D | c-K-ras Gly12Asp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513883","National Cancer Institute Cancer Centers Program","C39466","The NCI Cancer Centers Program comprises more than 50 NCI-designated cancer centers engaged in multidisciplinary research to reduce cancer incidence, morbidity and mortality. Through Cancer Center Support grants, this program supports three types of centers: Comprehensive Cancer Centers, Clinical Cancer Centers, and Cancer Centers. It was the National Cancer Act of 1971 that strengthened the program by authorizing the establishment of 15 new cancer centers and the continued support for existing ones.","National Cancer Institute Cancer Centers Program | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1948070","Board (committee)","C61480","A committee having supervisory powers.","Board | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL426423","Multidisciplinary","C94845","Bringing together multiple scientific disciplines to address specific issues.","Multidisciplinary | Interdisciplinary | multidisciplinary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0805443","Cancer Registry","C15753","Cancer registries gather a wide variety of specific information on cancer patients that can be analyzed to identify health disparity trends in cancer incidence, mortality and patient survival.","Cancer Registry | CancerRegistry | Registry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278598","Hematologist","C17831","A doctor who specializes in diagnosing and treating diseases and disorders of the blood and blood-forming organs.","Hematologist | HEMATOLOGIST | hematologist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511246","Bone Marrow Stem Cell","C13456","A hematopoietic stem cell found in the bone marrow.","Bone Marrow Stem Cell | Bone Marrow Blood-Forming Cell | Bone Marrow Blood-Forming Cells | Bone Marrow Stem Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1701118","C-C Motif Chemokine 19, Human","C28733","C-C motif chemokine 19 (98 aa, ~11 kDa) is encoded by the human CCL19 gene. This protein is involved in lymphocyte recirculation and homing.","C-C Motif Chemokine 19 | Beta Chemokine Exodus 3 | Beta Chemokine Exodus-3 | Beta-Chemokine Exodus-3 | CC Chemokine Ligand 19 | CCL19 | CK Beta-11 | Chemokine (C-C Motif) Ligand 19 | EBI1 Ligand Chemokine | EBI1-Ligand Chemokine | ELC | Epstein-Barr Virus-Induced Molecule 1 Ligand Chemokine | Exodus 3 | Exodus-3 | MIP-3-Beta | Macrophage Inflammatory Protein 3 Beta | Macrophage Inflammatory Protein 3-Beta | Small Inducible Cytokine A19 | Small Inducible Cytokine A19 | Small Inducible Cytokine Subfamily A (Cys-Cys), Member 19 | Small-Inducible Cytokine A19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332074","AKT3 Gene","C20937","This gene is involved in signal transduction and the inhibition of apoptosis.","AKT3 Gene | AKT Serine/Threonine Kinase 3 Gene | AKT3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419244","RAD54L Gene","C20809","This gene plays a role in the homologous recombination of double-strand DNA breaks.","RAD54L Gene | RAD54-like (S. cerevisiae) Gene | RAD54L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1506962","RECQL protein, human","C17914","ATP-dependent DNA helicase Q1 (649 aa, ~73 kDa) is encoded by the human RECQL gene. This protein plays a role in DNA renaturation.","ATP-Dependent DNA Helicase Q1 | DNA Helicase, RecQ-Like Type 1 | DNA-Dependent ATPase Q1 | EC 3.6.4.12 | RECQL | RecQ Protein-Like 1 | RecQ1 | RecQL Helicase | RecQL Helicase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085187","Telomere","C13295","A stretch of repetitive nucleotide sequences (TTAGGG repeats in humans) found at both ends of each chromatid arm that plays a role in chromosome stability during replication.","Telomere | Telomeres | telomere",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366903","PML Gene","C24686","This gene plays a role in tumor suppression and is involved in the regulation of p53 in response to oncogenic signal transduction.","PML Gene | PML | PML Nuclear Body Scaffold Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366536","RARA Gene","C21571","This gene plays a role in transcription and retinoic acid receptor signal transduction.","RARA Gene | RARA | Retinoic Acid Receptor Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0228121","Tentorium Cerebelli","C33749","A dural partition that separates the occipital lobes of the cerebrum from the cerebellum and divides the cranial cavity into supratentorial and infratentorial compartments; it helps to stabilize the brain within the cranial cavity.","Tentorium Cerebelli | TENTORIUM CEREBELLI",,,,,,,,,,,,,,,"4164293","Structure of tentorium cerebelli",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0908506","Receptors, Eph Family","C18606","Eph receptor tyrosine kinases and their ligands, the ephrins, appear to lie functionally at the interface between pattern formation and morphogenesis.  They play a major role in axonal pathfinding and target recognition during central nervous system (CNS) development.  (from Development 1999;126:2033-2044 and Exp Neurol 1999;156:218-22)","Ephrin Receptor | EPH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024320","Lymphotoxin-Alpha","C20536","Lymphotoxin-alpha (205 aa, ~22 kDa) is encoded by the human LTA gene. This protein plays a role in cell-cell signaling and the positive regulation of apoptosis.","Lymphotoxin-Alpha | LT | LT-Alpha | LTA | Lymphotoxin A | Lymphotoxin Alpha | Lymphotoxin-A | TNF Beta | TNF Superfamily Member 1 | TNF-Beta | TNF-b | TNFSF1 | Tumor Necrosis Factor Beta | Tumor Necrosis Factor Ligand Superfamily Member 1 | Tumor Necrosis Factor-Beta | Tumor Necrosis Factor-Beta",,,,,,,,,,,,,,,"4166507","Tumor necrosis factor beta",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332816","CXCL11 Gene","C24789","This gene is involvd in the regulation of immune responses and cellular responses.","CXCL11 Gene | CXCL11 | Chemokine (C-X-C Motif) Ligand 11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332684","CCL21 Gene","C24775","This gene is involved in the regulation of leukocyte migration.","CCL21 Gene | CCL21 | Chemokine (C-C Motif) Ligand 21 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514388","Preemptive Analgesia","C21093","Treatment with analgesics on a schedule or in advance of the return of pain in an attempt to minimize peaks in the pain cycle.","Preemptive Analgesia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0379149","Temoporfin","C1669","A synthetic light-activated chlorin with photodynamic activity. Upon systemic administration, temoporfin distributes throughout the body and is taken up by tumor cells. Upon stimulation of temoporfin by non-thermal laser light (at 652 nm), and in the presence of oxygen, this agent produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to tumor cells. This may kill tumor cells and may reduce the tumor size.","Temoporfin | 5,10,15,20-Tetra-(m-hydroxyphenyl)chlorin | Foscan | TEMOPORFIN | m-Tetrahydroxyphenyl-chlorin | mTHPC | meta-Tetrahydroxyphenyl Chlorin | meta-Tetrahydroxyphenylchlorin | temoporfin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388406","Fentanyl Matrix Transdermal Patch","C80067","A transdermal formulation containing the synthetic phenylpiperidine opioid agonist fentanyl, with analgesic activity. Upon topical administration, fentanyl diffuses from the transdermal patch through the skin, is transported via the systemic circulation, and selectively binds to the mu-receptor in the central nervous system (CNS), mimicking the effects of endogenous opiates. Stimulation of the mu-receptor inhibits adenyl cyclase activity, induces opening of G-protein-coupled inwardly rectifying potassium (GIRK) channels, and blocks the opening of N-type voltage-gated calcium channels, resulting in hyperpolarization and reduced neuronal excitability; in addition, neuronal release of neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline may decrease.","Fentanyl Matrix Transdermal Patch | Durogesic DTrans | Fentanyl Matrix Transdermal Delivery System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0877373","Advanced Malignant Neoplasm","C9270","A malignant neoplasm that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Malignant Neoplasm | Advanced Cancer | advanced cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642488","Interstitial Photodynamic Therapy","C102743","Photodynamic therapy that uses light-emitting fibers to treat deep-seated solid tumors.","Interstitial Photodynamic Therapy | I-PDT | Interstitial Illumination Photodynamic Therapy | Interstitial Illumination Photodynamic Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015237","Pharmaceutical Excipient","C42637","Any intentionally added component of a finished pharmaceutical product other than the claimed therapeutic or diagnostic ingredient(s). The excipients are added to facilitate administration or manufacture, improve product delivery, promote the consistent release and bioavailability of the drug, enhance stability, assist in product identification, or enhance other product characteristics. Pharmaceutical excipients do not affect therapeutic effects of the preparation or suitable tests or assays. The term does not apply to macromolecular compounds like albumin, or compounds like amino acids and sugars that are used in biological products, nor does it apply to process or product-related impurities (e.g. degradation products, residual solvents), or extraneous contaminants.","Pharmaceutical Excipient | Drug Excipient | Excipient | Inactive Ingredient | Inert Ingredient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032712","Porphyrin","C764","A group of organic heterocyclic compounds that are comprised of four modified pyrrole subunits connected via methine bridges and form an aromatic macrocyclic structure, which has one or more side chains attached. Many porphyrins are naturally occurring pigments. Porphyrins with metal ions bound to the porphin ring can be cofactors for biological processes, such as oxygen transport by hemes and photosynthesis by chlorophyll.","Porphyrin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4011994","Preterm Birth","C92861","Birth when a fetus is less than 37 weeks and 0 days gestational age.","Preterm Birth | Pre-Term | Premature delivery | Preterm | Preterm Delivery",,,,,,,,,,,,,,,"4086393","Premature delivery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162713","Photosensitizing Agent","C1420","Any pharmaceutical that is administered as an inactive precursor that can be converted to its pharmacologically active form through exposure to ultraviolet radiation or sunlight.","Photosensitizing Agent | Photosensitizer | Photosensitizers | photosensitizer | photosensitizing agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031740","Photodynamic Therapy","C15300","Use of light activated drugs (photosensitizing agents) to treat cancer and other conditions.","Photodynamic Therapy | PDT | PHOTODYNAMIC THERAPY | Photoradiation Therapy | photodynamic therapy",,,,,,,,,,,,,,,"4117979","Photodynamic therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2983187","Full Term Neonatal Stage","C89887","A human life stage that begins at full term birth and continues until twenty-seven complete days of age.","Full Term Neonatal Stage | Full-term Birth | Neonatal Stage | Term Neonatal Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511549","Cryopreserved Tissue","C19313","Tissues which are indefinitely maintained in a viable state at extremely low temperatures.","Cryopreserved Tissue | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0195681","Cervical Cerclage","C102763","A surgical procedure performed to prevent a miscarriage by stitching the opening of the cervix closed.","Cervical Cerclage | Cervical Stitch | Tracheloplasty",,,,,,,,,,,,,,,"4142512","Cerclage of uterine cervix",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0677798","Thermal Ablation Therapy","C15670","A procedure using heat to remove tissue or a part of the body, or destroy its function.  For example, to remove the lining of the uterus, a catheter is inserted through the cervix into the uterus, a balloon at the end of the catheter is inflated, and fluid inside the balloon is heated to destroy the lining of the uterus.","Thermal Ablation Therapy | thermal ablation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041249","Tryptophan","C29603","The least plentiful of all 22 amino acids and an essential amino acid in humans (provided by food), Tryptophan is found in most proteins and a precursor of serotonin. Tryptophan is converted to 5-hydroxy-tryptophan (5-HTP), converted in turn to serotonin, a neurotransmitter essential in regulating appetite, sleep, mood, and pain. Tryptophan is a natural sedative and present in dairy products, meats, brown rice, fish, and soybeans. (NCI04)","Tryptophan | (S)-2-Amino-3-(1H-indol-3-yl)-propanoic acid | TRYPTOPHAN | Trp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085828","Transcription Factor AP-1","C17450","A dimeric complex of related bZIP JUN, FOS, MAF and ATF transcription factors that must dimerize in order to bind to AP1 recognition sites (TPA-Responsive Element, TRE) or cAMP response elements in DNA, AP-1 controls basal and inducible transcription of several genes.","AP-1 Complex | AP-1 | AP-1 | AP1 | Activator Protein 1 | Activator Protein 1 Complex | Enhancer-Binding Protein AP1 | Transcription Factor AP-1 Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017710","Glucocorticoid","C2323","A corticosteroid that supports a variety of cardiovascular, metabolic, immunologic, and homeostatic functions, and which binds specifically to the glucocorticoid receptor (GR; NR3C1). Glucocorticoid binding to GR leads to the transportation of the activated receptor-glucocorticoid complex to the nucleus, after which it binds to glucocorticoid response elements (GRE) and regulates the expression of GR-responsive genes.","Glucocorticoid | glucocorticoid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0083344","ASCL1 protein, human","C21321","Achaete-scute homolog 1 (236 aa, ~25 kDa) is encoded by the human ASCL1 gene. This protein plays a role in both transcriptional regulation and signal transduction.","Achaete-Scute Homolog 1 | ASCL1 | ASH-1 | ASH1 | Achaete Scute Protein | Achaete-Scute Complex Homolog-Like 1 Protein | Achaete-Scute Complex-Like 1 Protein | Achaete-Scute Homolog 1 Protein | Class A Basic Helix-Loop-Helix Protein 46 | Human Achaete-Scute Homolog 1 Protein | MASH1 | Mammalian Achaete-Scute Homolog 1 | bHLHa46 | hASH1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415725","HES1 Gene","C84292","This gene is involved in the modulation of transcription.","HES1 Gene | HES1 | Hairy and Enhancer of Split 1, (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919428","NQO1 Gene","C18501","This gene is involved in drug/xenobiotic metabolism, biosynthetic processes and the prevention of cellular oxidative stress.","NQO1 Gene | NAD(P)H Dehydrogenase, Quinone 1 Gene | NQO1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773661","Tocopherol","C68313","A class of vitamin E compounds naturally found in many different sources, such as oils, nuts, and vegetables. Tocopherols have antioxidant activity.","Tocopherol | 2,7,8-trimethyl-2-(4,8,12-trimethyltridecyl)chroman-6-ol | TOCOPHEROL | Tocopherols",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020306","Hydroquinone","C29823","Produced as an inhibitor, an antioxidant, and an intermediate in the synthesis of dyes, motor fuels, and oils; in photographic processing; and naturally in certain plant species, Hydroquinone is a phenol derivative with antioxidant properties that can cause toxicity in several organs, notably the kidney. Used as a topical treatment for skin hyperpigmentation and in various cosmetic products, it is metabolized mainly to glutathione conjugates and forms mutagenic DNA adducts in in-vitro systems. (NCI04)","Hydroquinone | 1,4-Benzenediol | Benzoquinol | HYDROQUINONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1142098","Vitamin E Measurement","C74906","The determination of the amount of Vitamin E present in a sample.","Vitamin E Measurement | VITE | Vitamin E",,,,,,,,,,,,,,,"4327956","Vitamin E measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0290022","Melanoma-Derived Growth Regulatory Protein, Human","C98126","Melanoma-derived growth regulatory protein (131 aa, ~15 kDa) is encoded by the human MIA gene. This protein plays a role in the repression of melanoma cell proliferation.","Melanoma-Derived Growth Regulatory Protein | Melanoma Inhibitory Activity Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1528383","Stromal Cell-Derived Factor 1, Human","C28774","Stromal cell-derived factor 1 (93 aa, ~11 kDa) is encoded by the human CXCL12 gene. This protein is involved in signal transduction and chemotaxis of T-lymphocytes, and monocytes.","Stromal Cell-Derived Factor 1 | C-X-C Motif Chemokine 12 | CXCL12 | Chemokine (C-X-C Motif) Ligand 12 | IRH | Intercrine Reduced In Hepatomas | PBSF | Pre-B Cell Growth Stimulating Factor | Pre-B Cell Growth-Stimulating Factor | SDF-1 | SDF-1-Beta(1-72) | SDF1 | hIRH | hSDF-1 | hSDF-1beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0549379","Recurrent Malignant Neoplasm","C4813","The reemergence of a malignant neoplasm after a period of remission.","Recurrent Malignant Neoplasm | Recurrence | Recurrent Cancer | Recurrent Malignant Tumor | recurrence | recurrent cancer",,,,,,,,,,,,,,,"37166154","Recurrent malignant neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0677932","Progressive Neoplastic Disease","C8510","Cancer that is growing, spreading, or getting worse.","Progressive Neoplastic Disease | progressive disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1317554","Natriuretic Peptides B","C88522","Natriuretic peptides B (134 aa, ~15 kDa) is encoded by the human NPPB gene. This protein is involved in the maintenance of cardiac homeostasis.","Natriuretic Peptides B | Gamma-Brain Natriuretic Peptide | Iso-ANP | ProB-Type Natriuretic Peptide | proBNP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273995","BRAF NP_004324.2:p.V600K","C98347","A change in the amino acid residue at position 600 in the serine/threonine protein kinase B-raf protein where valine has been replaced by lysine.","BRAF NP_004324.2:p.V600K | BRAF NP_004324.2:p.Val600Lys | BRAF V600K | BRAF Val600Lys | BRAF p.V600K | BRAF p.Val600Lys | NP_004324.2:p.Val600Lys | Serine/Threonine-Protein Kinase B-raf V600K | Serine/Threonine-Protein Kinase B-raf Val600Lys",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273990","BRAF NP_004324.2:p.V600E","C98342","A change in the amino acid residue at position 600 in the serine/threonine protein kinase B-raf protein where valine has been replaced by glutamic acid.","BRAF NP_004324.2:p.V600E | Activating BRAF V600E Mutation | BRAF NP_004324.2:p.Val600Glu | BRAF V600E | BRAF V600E Activating Mutation | BRAF V600E Driver Mutation | BRAF V600E Mutation | BRAF Val600Glu | BRAF p.V600E | BRAF p.Val600Glu | BRAFv600E | Deleterious BRAF V600E Mutation | NP_004324.2:p.V600E | NP_004324.2:p.Val600Glu | Serine/Threonine-Protein Kinase B-raf V600E | Serine/Threonine-Protein Kinase B-raf Val600Glu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0555198","Malignant Glioma","C4822","A grade 3 or grade 4 glioma arising from the central nervous system. This category includes glioblastoma, anaplastic astrocytoma, anaplastic ependymoma, anaplastic oligodendroglioma, and anaplastic oligoastrocytoma.","Malignant Glioma | GLIOMA, MALIGNANT | Glioma, malignant | High Grade Glioma | High-Grade Glioma | Malignant Glial Neoplasm | Malignant Glial Tumor | Malignant Neuroglial Neoplasm | Malignant Neuroglial Tumor","9380/3","Glioma, malignant",,,,,,,,,,,,,"4253951","Malignant glioma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1518369","Non-Keratinizing Malignant Squamous Cell","C36792","A malignant squamous cell that does not produce keratin.","Non-Keratinizing Malignant Squamous Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516433","Cervical Squamotransitional Carcinoma","C40194","A human papillomavirus-related cervical squamous cell carcinoma characterized by the presence of papillary structures with fibrovascular cores. It is covered with multiple layers of atypical cells that resemble cervical intraepithelial neoplasia 3.","Cervical Squamotransitional Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516418","Cervical Lymphoepithelioma-Like Carcinoma","C40193","A variant of cervical squamous cell carcinoma characterized by the presence of islands of cells with uniform, vesicular nuclei and prominent nucleoli and a dense lymphocytic infiltrate.","Cervical Lymphoepithelioma-Like Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522040","Signet Ring Adenocarcinoma Cell","C36777","A malignant glandular cell containing cytoplasmic mucin. The presence of mucin pushes the nucleus of the cell to the periphery, assuming a configuration resembling a signet ring.","Signet Ring Adenocarcinoma Cell | Signet Ring Malignant Glandular Cell | Signet-Ring Adenocarcinoma Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516403","Cervical Adenoid Basal Carcinoma","C40213","A rare low grade carcinoma that arises from the cervix. It is characterized by the presence of nests of basaloid cells with focal glandular formations.","Cervical Adenoid Basal Carcinoma | Cervical Adenoid Basal Cancer",,,,,,,,,,,,,,,"35621807","Adenoid basal carcinoma of cervix uteri",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1265998","Glassy Cell Carcinoma","C65159","A malignant epithelial neoplasm composed of atypical cells with glassy cytoplasm.","Glassy Cell Carcinoma | ","8015/3","Glassy cell carcinoma",,,,,,,,,,,,,"4028531","Glassy cell carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1335060","Non-Small Cell Adenocarcinoma","C27745","A carcinoma characterized by the presence of large adenocarcinoma cells.","Non-Small Cell Adenocarcinoma | Nonsmall Cell Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1453955","Leukemia Inhibitory Factor, Human","C20524","Leukemia inhibitory factor (202 aa, ~22 kDa) is encoded by the human LIF gene. This protein plays a role in the positive regulation of neuronal cell differentiation and the induction of hematopoietic differentiation in normal and myeloid leukemia cells.","Leukemia Inhibitory Factor | Cholinergic Differentiation Factor | D Factor | D-Factor | Differentiation Inhibitory Activity | Differentiation Stimulating Factor | Differentiation-Stimulating Factor | Hepatocyte-Stimulating Factor III | Human Interleukin in DA Cells | LIF | Leukemia-Inhibitory Factor | MLPLI | Melanoma-Derived LPL Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0768285","CCL27 protein, human","C28740","C-C motif chemokine 27 (112 aa, ~13 kDa) is encoded by the human CCL27 gene. This protein is involved in the modulation of chemotaxis of memory T-cells.","C-C Motif Chemokine 27 | CC Chemokine ILC | CCL27 | CTACK | Chemokine (C-C Motif) Ligand 27 | Cutaneous T Cell-Attracting Chemokine | Cutaneous T-Cell-Attracting Chemokine | Cuteaneous T-Cell Attracting Chemokine | Eskine | IL-11 R-Alpha-Locus Chemokine | IL-11 Ralpha-Locus Chemokine | IL-11R Alpha-Locus Chemokine | IL11RA-Locus Chemokine | Skinkine | Small Inducible Cytokine A27 | Small Inducible Cytokine A27 | Small Inducible Cytokine Subfamily A (Cys-Cys), Member 27 | Small-Inducible Cytokine A27",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0963811","CXCL13 protein, human","C29030","C-X-C motif chemokine 13 (109 aa, ~13 kDa) is encoded by the human CXCL13 gene. This protein is involved in chemotaxis of B-cells.","C-X-C Motif Chemokine 13 | ANGIE | B Cell-Attracting Chemokine 1 | B Lymphocyte Chemoattractant | B-Cell Chemoattractant | B-Cell-Attracting Chemokine 1 | B-Cell-Homing Chemokine | B-Lymphocyte Chemoattractant | BCA-1 | Burkitt's Lymphoma Receptor-1 Ligand | CXC Chemokine BLC | CXCL13 | Chemokine (C-X-C Motif) Ligand 13 | Small Inducible Cytokine B Subfamily (Cys-X-Cys Motif), Member 13 | Small Inducible Cytokine B13 | Small Inducible Cytokine B13 | Small-Inducible Cytokine B13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0390071","C-C Motif Chemokine 13, Human","C28726","C-C motif chemokine 13 (98 aa, ~11 kDa) is encoded by the human CCL13 gene. This protein is involved in leukocyte chemotaxis and inflammation.","C-C Motif Chemokine 13 | CCL13 | CK-Beta-10 | Chemokine (C-C Motif) Ligand 13 | MCP-4 | Monocyte Chemoattractant Protein 4 | Monocyte Chemotactic Protein 4 | NCC-1 | New CC Chemokine 1 | Small Inducible Cytokine A13 | Small Inducible Cytokine A13 | Small Inducible Cytokine Subfamily A (Cys-Cys), Member 13 | Small-Inducible Cytokine A13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1363878","XCL1 Gene","C24794","This gene is involved in cellular migration and inflammatory processes.","XCL1 Gene | Chemokine (C Motif) Ligand 1 Gene | XCL1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0535298","Fractalkine","C20489","Fractalkine (397 aa, ~42 kDa) is encoded by the human CX3CL1 gene. This protein is involved in chemotaxis of T-cells and monocytes.","Fractalkine | C-X3-C Motif Chemokine 1 | CX3C Membrane-Anchored Chemokine | CX3CL1 | Chemokine (C-X3-C Motif) Ligand 1 | Neurotactin | Small Inducible Cytokine D1 | Small Inducible Cytokine D1 | Small-Inducible Cytokine D1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1620077","Interleukin-4 Receptor Subunit Alpha, Human","C26268","Interleukin-4 receptor subunit alpha (825 aa, ~90 kDa) is encoded by the human IL4R gene. This protein plays a role in both interleukin-4 signaling and immunoglobulin E production.","Interleukin-4 Receptor Subunit Alpha | CD124 | IL-4 Receptor Subunit Alpha | IL-4R Subunit Alpha | IL-4R-Alpha | IL-4RA | IL4R | IL4RA | Interleukin 4 Receptor | Interleukin 4 Receptor | Interleukin 4 Receptor Alpha | Interleukin-4 Receptor | Interleukin-4 Receptor Alpha | Interleukin-4 Receptor Alpha Chain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0214733","C-C Motif Chemokine 7, Human","C28731","C-C motif chemokine 7 (99 aa, ~11 kDa) is encoded by the human CCL7 gene. This protein is involved in chemotaxis of monocytes and eosinophils.","C-C Motif Chemokine 7 | CCL7 | FIC | MARC | MCP-3 | MCP3 | Monocyte Chemoattractant Protein 3 | Monocyte Chemotactic Protein 3 | NC28 | SCYA7 | Small Inducible Cytokine A7 | Small Inducible Cytokine A7 | Small-Inducible Cytokine A7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1138418","ribosomal protein S6 kinase, 70kD, polypeptide 2","C29911","Ribosomal protein S6 kinase beta-2 (482 aa, ~53 kDa) is encoded by the human RPS6KB2 gene. This protein is involved in serine/threonine protein phosphorylation.","Ribosomal Protein S6 Kinase Beta-2 | 70 kDa Ribosomal Protein S6 Kinase 2 | RPS6KB2 | Ribosomal Protein S6 Kinase Beta 2 | Ribosomal Protein S6 Kinase, 70kDa, Polypeptide 2 | S6 Kinase-Related Kinase | S6K-Beta | S6K-Beta 2 | S6K-Beta-2 | S6K2 | SRK | Serine/Threonine-Protein Kinase 14 B | Serine/Threonine-Protein Kinase 14 Beta | p70 Ribosomal S6 Kinase Beta | p70 S6 Kinase Beta | p70 S6K Beta | p70 S6K-Beta | p70 S6KB | p70-Beta | p70-S6K 2 | p70-S6KB | p70S6KB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1870328","C-X-C Motif Chemokine 6, Human","C29339","C-X-C motif chemokine 6 (114 aa, ~12 kDa) is encoded by the human CXCL6 gene. This protein is involved in neutrophil chemotaxis, angiogenesis and anti-bacterial activity.","C-X-C Motif Chemokine 6 | CKA-3 | CXCL6 | Chemokine (C-X-C Motif) Ligand 6 | Chemokine Alpha 3 | GCP-2 | Granulocyte Chemotactic Protein 2 | Small Inducible Cytokine B6 | Small Inducible Cytokine B6 | Small Inducible Cytokine Subfamily B (Cys-X-Cys), Member 6 | Small Inducible Cytokine Subfamily B (Cys-X-Cys), Member B | Small-Inducible Cytokine B6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1308247","CCL20 protein, human","C28734","C-C motif chemokine 20 (98 aa, ~11 kDa) is encoded by the human CCL20 gene. This protein is involved in chemotaxis of lymphocytes and dendritic cells.","C-C Motif Chemokine 20 | Beta Chemokine Exodus-1 | Beta-Chemokine Exodus-1 | CC Chemokine LARC | CCL20 | Chemokine (C-C Motif) Ligand 20 | Exodus 1 | Exodus-1 | Liver and Activation-Regulated Chemokine | MIP-3-Alpha | Macrophage Inflammatory Protein 3 Alpha | Macrophage Inflammatory Protein 3-Alpha | Small Inducible Cytokine A20 | Small Inducible Cytokine A20 | Small Inducible Cytokine Subfamily A (Cys-Cys), Member 20 | Small-Inducible Cytokine A20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538928","Usual","C102843","That which is considered customary.","Usual | Customary | Typical | Usually",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205403","Extreme","C102844","The highest degree of severity.","Extreme | Extremely",,,,,,,,,,,,,,,"4053601","Extreme",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0164209","Substance P Receptor","C41023","Substance-P receptor (407 aa, ~46 kDa) is encoded by the human TACR1 gene. This protein is involved in tachykinin-dependent G protein-coupled receptor signaling.","Substance-P Receptor | NK-1 Receptor | NK-1R | NK1R | NKIR | Neurokinin 1 Receptor | SPR | Substance P Receptor | TAC1R | TACR1 | Tachykinin 1 Receptor | Tachykinin Receptor 1 | Tachykinin Receptor 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0754115","5-Hydroxytryptamine Receptor 3A","C25906","5-hydroxytryptamine receptor 3A (478 aa, ~ 55 kDa) is encoded by the human HTR3A gene. This protein plays a role in serotonin-dependent depolarization in neurons.","5-Hydroxytryptamine Receptor 3A | 5-HT-3 | 5-HT3R | 5-Hydroxytryptamine (Serotonin) Receptor-3 | 5-Hydroxytryptamine 3 Receptor | 5-Hydroxytryptamine Receptor 3 | 5-hydroxytryptamine (Serotonin) Receptor 3A | 5HT3R | HTR3 | HTR3 Protein | HTR3A | Serotonin 5-HT-3 Receptor | Serotonin 5-HT-3 Receptor | Serotonin Receptor 3A | Serotonin-Gated Ion Channel Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417250","MRE11 Gene","C98167","This gene plays a role in DNA recombination and repair.","MRE11 Gene | MRE11 | MRE11 Homolog, Double Strand Break Repair Nuclease Gene | MRE11A | MRE11A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1529634","Runx3 protein, human","C91790","Runt-related transcription factor 3 (415 aa, ~44 kDa) is encoded by the human RUNX3 gene. This protein is involved in the modulation of transcription.","Runt-Related Transcription Factor 3 | Acute Myeloid Leukemia 2 Protein | CBF-Alpha-3 | Core-Binding Factor Subunit Alpha-3 | Oncogene AML-2 | PEA2-Alpha C | PEBP2-Alpha C | Polyomavirus Enhancer-Binding Protein 2 Alpha C Subunit | SL3-3 Enhancer Factor 1 Alpha C Subunit | SL3/AKV Core-Binding Factor Alpha C Subunit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417102","MEF2C Gene","C92161","This gene plays a role in muscular and vascular development.","MEF2C Gene | MEF2C | Myocyte Enhancer Factor 2C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412615","ATF1 Gene","C92177","This gene is involved in the modulation of transcription of genes with promoters containing a cAMP response element.","ATF1 Gene | ATF1 | Activating Transcription Factor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273988","BRAF NP_004324.2:p.V600D","C98340","A change in the amino acid residue at position 600 in the serine/threonine protein kinase B-raf protein where valine has been replaced by aspartic acid.","BRAF NP_004324.2:p.V600D | BRAF NP_004324.2:p.Val600Asp | BRAF V600D | BRAF Val600Asp | BRAF p.V600D | BRAF p.Val600Asp | NP_004324.2:p.Val600Asp | Serine/Threonine-Protein Kinase B-raf V600D | Serine/Threonine-Protein Kinase B-raf Val600Asp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412072","ABCB5 Gene","C73555","This gene plays a role in both membrane transport and drug resistance.","ABCB5 Gene | ABCB5 | ATP-Binding Cassette, Sub-Family B (MDR/TAP), Member 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413238","CD79A Gene","C97421","This gene is involved in B-cell signaling and proliferation.","CD79A Gene | CD79A | CD79a Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332739","CDKN3 Gene","C24289","This gene plays a role in cell cycle regulation.","CDKN3 Gene | CDKN3 | Cyclin-Dependent Kinase Inhibitor 3 (CDK2-Associated Dual Specificity Phosphatase) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640517","European Quality of Life Five Dimension Five Level Scale Questionnaire","C102117","A standardized rating scale which is used as a measure of health outcome. This instrument is a descriptive system consisting of 5 dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. Each dimension has 5 levels ranging from no problem to extreme problem or incapable, which are assessed by the patient.","European Quality of Life Five Dimension Five Level Scale Questionnaire | EQ-5D-5L | EQ5D02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0995611","Atopobium","C85972","A genus of anaerobic, Gram positive, cocci shaped bacterium in the phylum Actinobacteria and the family Coriobacteriaceae.","Atopobium | ",,,,,,,,,,,,,,,"4018412","Atopobium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1036500","Eggerthella","C86348","A genus of aerobic, Gram positive, rod shaped bacterium in the phylum Actinobacteria and the family Coriobacteriaceae.","Eggerthella | EGGERTHELLA",,,,,,,,,,,,,,,"4187181","Eggerthella",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011731","Desulfovibrio","C86339","A genus of anaerobic, Gram negative, rod shaped bacterium assigned to the phylum Proteobacteria and the family Desulfovibrionaceae.","Desulfovibrio | DESULFOVIBRIO | Desulfomonas | Desulfomonas species",,,,,,,,,,,,,,,"4352645","Desulfovibrio",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242946","Prevotella","C86660","A genus of anaerobic, Gram negative, rod shaped bacterium assigned to the phylum Bacteroidetes and the family Prevotellaceae.","Prevotella | PREVOTELLA",,,,,,,,,,,,,,,"4015682","Prevotella",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0297890","STAT6 protein, human","C28670","Signal transducer and activator of transcription 6 (847 aa, ~94 kDa) is encoded by the human STAT6 gene. This protein is involved in the modulation of both gene expression and signal transduction.","Signal Transducer and Activator of Transcription 6 | IL-4 Stat | STAT6 | Transcription Factor IL-4 STAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0539535","C-C Motif Chemokine 17","C28730","C-C motif chemokine 17 (94 aa, ~11 kDa) is encoded by the human CCL17 gene. This protein plays a role in both T-cell chemotaxis and function.","C-C Motif Chemokine 17 | CC Chemokine TARC | CCL17 | Chemokine (C-C Motif) Ligand 17 | Small Inducible Cytokine A17 | Small Inducible Cytokine A17 | Small Inducible Cytokine Subfamily A (Cys-Cys), Member 17 | Small-Inducible Cytokine A17 | T Cell-Directed CC Chemokine | Thymus and Activation-Regulated Chemokine",,,,,,,,,,,,,,,"37110841","C-C motif chemokine 17",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332830","CYP2D6 Gene","C26517","This gene plays a role in the metabolism of numerous clinically-relevant drugs. It is also involved in the oxidation of xenobiotics.","CYP2D6 Gene | CYP2D6 | Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415846","ICOS Gene","C94801","This gene is involved in the immune response.","ICOS Gene | ICOS | Inducible T-Cell Co-Stimulator Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0064971","Lignans","C1145","Two (hydr)oxylated phenyl-propane (C6C3) monomers connected by the beta carbons of the C3 chains to form a) diarylbutanes, and sometimes by additional other bonds to form b) dihydronaphtalenes, c) tetrahydrofuranes, d) dioxabicyclooctanes. The building blocks for lignin. (Boker, et al)","Lignan | lignan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1210566","Eubacteriaceae","C85935","A taxonomic family of bacterium in the phylum Firmicutes that includes the genera Acetobacterium, Eubacterium and Garciella among others.","Eubacteriaceae | ",,,,,,,,,,,,,,,"4306351","Eubacteriaceae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042446","Veillonella","C86837","A genus of anaerobic, Gram negative, cocci shaped bacterium assigned to the phylum Firmicutes and the family Veillonellaceae.","Veillonella | VEILLONELLA",,,,,,,,,,,,,,,"4107221","Veillonella",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL383599","Alpha-Gal Glycosphingolipids","C78200","A preparation of glycosphingolipids (GSL), containing the disaccharide epitope galactose-alpha-1,3-galactose (alpha-Gal), with potential antineoplastic activity. Upon intratumoral injection, alpha-Gal glycosphingolipids may stimulate the immune system to mount complement-mediated cytotoxicity (CMC) and antibody-dependent cell-mediated cytotoxicity (ADCC) responses against alpha-Gal GSL, which may result in tumor cell death; these responses involve natural anti-alpha-Gal immunoglobulins (Igs).  As antibodies that occur naturally due to sensitization to alpha-Gal present on symbiotic bacterial flora, anti-alpha-Gal Igs are present in unusually high amounts in human sera.  GSL represent a glycolipid subtype containing the amino alcohol sphingosine; tumor-associated GSL antigens contain various oligosaccharide residues.","Alpha-Gal Glycosphingolipids | GSL alpha-GAL | Galactose(alpha1,3,)galactose Glycosphingolipids",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984255","Natural Killer Cell-Mediated Cytotoxicity Pathway","C91442","Natural killer (NK) cells are lymphocytes of the innate immune system that are involved in early defenses against both allogeneic (nonself) cells and autologous cells undergoing various forms of stress, such as infection with viruses, bacteria, or parasites or malignant transformation. Although NK cells do not express classical antigen receptors of the immunoglobulin gene family, such as the antibodies produced by B cells or the T cell receptor expressed by T cells, they are equipped with various receptors whose engagement allows them to discriminate between target and nontarget cells. Activating receptors bind ligands on the target cell surface and trigger NK cell activation and target cell lysis. However Inhibitory receptors recognize MHC class I molecules (HLA) and inhibit killing by NK cells by overruling the actions of the activating receptors. This inhibitory signal is lost when the target cells do not express MHC class I and perhaps also in cells infected with virus, which might inhibit MHC class I expression or alter its conformation. The mechanism of NK cell killing is the same as that used by the cytotoxic T cells generated in an adaptive immune response; cytotoxic granules are released onto the surface of the bound target cell, and the effector proteins they contain penetrate the cell membrane and induce programmed cell death.","Natural Killer Cell-Mediated Cytotoxicity Pathway | NK Cell Cytotoxicity | Natural killer cell mediated cytotoxicity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826257","Prior Medication Usage","C82522","An indication or description that medications were taken previously.","Prior Medication Usage | PRIOR | prior drugs | prior_drugs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1559309","Grade 2 Diarrhea, CTCAE","C57293","Increase of 4-6 stools per day over baseline; moderate increase in ostomy output compared to baseline; limiting instrumental ADL","Grade 2 Diarrhea, CTCAE | CTCAE Grade 2 Diarrhea | Grade 2 Diarrhea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034597","Radiologic Health","C17058","The study of the health effects of radiation, with an emphasis on protecting the public, radiation workers, and the environment, and on establishing standards for radiation exposure.","Radiologic Health | Radiological Health",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2742502","Ramucirumab","C70792","A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells.","Ramucirumab | Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B | Cyramza | IMC 1121B | IMC-1121B | IMC1121B | LY 3009806 | LY-3009806 | LY3009806 | Monoclonal Antibody HGS-ETR2 | RAMUCIRUMAB | anti-VEGFR-2 fully human monoclonal antibody IMC-1121B | ramucirumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336467","Stage 1 Neuroblastoma","C6638","Localized tumor with complete gross excision, with or without microscopic residual disease; representative ipsilateral lymph nodes negative for tumor microscopically. (cancer.gov)","Stage 1 Neuroblastoma | Stage I Neuroblastoma | stage 1 neuroblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336301","Stage 2 Neuroblastoma","C6639","Stage 2 includes stage 2A and stage 2B.  Stage 2A: Localized tumor with incomplete gross excision; representative ipsilateral nonadherent lymph nodes negative for tumor microscopically. Stage 2B: Localized tumor with or without complete gross excision, with ipsilateral nonadherent lymph nodes positive for tumor. Enlarged contralateral lymph nodes must be negative microscopically. (cancer.gov)","Stage 2 Neuroblastoma | Stage II Neuroblastoma | stage 2 neuroblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640961","Stage 2A Neuroblastoma","C102845","Localized tumor with incomplete gross excision; representative ipsilateral nonadherent lymph nodes negative for tumor microscopically. (cancer.gov)","Stage 2A Neuroblastoma | Stage IIA Neuroblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640962","Stage 2B Neuroblastoma","C102846","Localized tumor with or without complete gross excision, with ipsilateral nonadherent lymph nodes positive for tumor. Enlarged contralateral lymph nodes must be negative microscopically. (cancer.gov)","Stage 2B Neuroblastoma | Stage IIB Neuroblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336257","Stage 3 Neuroblastoma","C6640","Unresectable unilateral tumor infiltrating across the midline, with or without regional lymph node involvement; or localized unilateral tumor with contralateral regional lymph node involvement; or midline tumor with bilateral extension by infiltration (unresectable) or by lymph node involvement. The midline is defined as the vertebral column. Tumors originating on one side and crossing the midline must infiltrate to or beyond the opposite side of the vertebral column. (cancer.gov)","Stage 3 Neuroblastoma | Stage III Neuroblastoma | stage 3 neuroblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278694","Stage 4 Neuroblastoma","C6641","Any primary tumor with dissemination to distant lymph nodes, bone, bone marrow, liver, skin, and/or other organs, except as defined for stage 4S. (cancer.gov)","Stage 4 Neuroblastoma | Disseminated Neuroblastoma | Stage IV Neuroblastoma | stage 4 neuroblastoma",,,,,,,,,,,,,,,"45772700","Metastatic neuroblastoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1135161","Stage 4S neuroblastoma","C9504","Localized primary tumor, as defined for stage 1, 2A, or 2B, with dissemination limited to skin, liver, and/or bone marrow (limited to infants younger than 1 year). Marrow involvement should be minimal (i.e., <10% of total nucleated cells identified as malignant by bone biopsy or by bone marrow aspirate). More extensive bone marrow involvement would be considered stage 4 disease. The results of the MIBG scan, if performed, should be negative for disease in the bone marrow. (cancer.gov)","Stage 4S Neuroblastoma | Neuroblastoma Stage IVS | Pepper's Syndrome | Stage IVS Neuroblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201924","Calcitonin Measurement","C74848","The determination of the amount of calcitonin hormone present in a sample.","Calcitonin Measurement | CLCTONN | Calcitonin",,,,,,,,,,,,,,,"4147378","Calcitonin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1826567","PELP1 Gene","C92151","This gene is involved in the regulation of steroid receptor-mediated transcription.","PELP1 Gene | PELP1 | Proline, Glutamate and Leucine Rich Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418776","PPARA Gene","C91749","This gene is involved in ligand-mediated transcriptional regulation.","PPARA Gene | PPARA | Peroxisome Proliferator-Activated Receptor Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202025","Fructosamine Measurement","C74678","The determination of the amount of fructosamine present in a sample.","Fructosamine Measurement | FRUCT | Fructosamine | Glycated Serum Protein",,,,,,,,,,,,,,,"4300166","Fructosamine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698488","Nonesterified Fatty Acids Measurement","C80200","The determination of the amount of free non-esterified fatty acids present in a sample.","Non-esterified Fatty Acids Measurement | FATACFR | Free Fatty Acid | Free Non-esterified Fatty Acids Measurement | Non-Esterified Fatty Acid, Free",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1442821","Fos-Related Antigen 1, human","C18530","Fos-related antigen 1 (271 aa, ~29 kDa) is encoded by the human FOSL1 gene. This protein is involved in the regulation of gene expression.","Fos-Related Antigen 1 | FOS-Like Antigen 1 Protein | FOS-Related Antigen 1 Protein | FOSL1 | FOSL1 Protein | FOSL1 Protein | FRA-1 | FRA1 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0542495","Serum Triglyceride Measurement","C61037","A quantitative measurement of the amount of triglycerides present in a sample of serum.","Serum Triglyceride Measurement | ",,,,,,,,,,,,,,,"4156816","Measurement of serum triglyceride level",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2986558","Response in Target Lesion","C94534","A qualitative or quantitative measurement of the response of a target lesion(s) to the therapy.","Response in Target Lesion | LESION_RESPONSE | TRGRESP | Target Lesions | Target Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512089","Duke Cancer Institute","C39393","The Duke Cancer Institute is dedicated to a broad spectrum of cancer research and the translation of that research into the latest in patient care. The Center serves as the focus for all of Duke University's activities in cancer, a single entity that integrates and aligns patient care and research with the goals of improving patient outcomes, decreasing the burden of cancer and accelerating scientific progress. It became an NCI-designated comprehensive cancer center in 1972.","Duke Cancer Institute | Duke Comprehensive Cancer Center | Duke Comprehensive Cancer Center",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0902566","Aloxistatin","C76907","An inhibitor of cysteine protease with blood platelet aggregation inhibiting activity. Aloxistatin is an irreversible, membrane-permeable inhibitor of lysosomal and cytosolic cysteine proteases with the ability to inhibit calpain activity in intact platelets.","Aloxistatin | ALOXISTATIN | E 64c Ethyl Ester | E 64d",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881814","Metronomic Chemotherapy","C62453","A chemotherapy regimen consisting of repetitive, low doses of chemotherapy drugs that are designed to minimize toxicity. This therapeutic treatment targets the endothelium or stroma as opposed to targeting the tumor or cancerous region.","Metronomic Chemotherapy | metronomic therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879772","Afatinib Dimaleate","C97273","The dimaleate salt form of afatinib, an orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity. Upon administration, afatinib selectively and irreversibly binds to and inhibits the epidermal growth factor receptors 1 (ErbB1; EGFR), 2 (ErbB2; HER2), and 4 (ErbB4; HER4), and certain EGFR mutants, including those caused by EGFR exon 19 deletion mutations or exon 21 (L858R) mutations. This may result in the inhibition of tumor growth and angiogenesis in tumor cells overexpressing these RTKs. Additionally, afatinib inhibits the EGFR T790M gatekeeper mutation which is resistant to treatment with first-generation EGFR inhibitors. EGFR, HER2 and HER4 are RTKs that belong to the EGFR superfamily; they play major roles in both tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types.","Afatinib Dimaleate | (2E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydrofuran-3-yl)oxy)quinazolin- 6-yl)-4-(dimethylamino)but-2-enamide bis(hydrogen (2Z)-but-2-enedioate) | 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-,(2E)-, (2Z)-2-Butenedioate (1:2) | AFATINIB DIMALEATE | BIBW 2992MA2 | BIBW2992 MA2 | Gilotrif",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0585332","Every Two Weeks","C71127","Every two weeks.","Every Two Weeks | EVERY 2 WEEKS | Every 2 weeks | Every other week | Q2S",,,,,,,,,,,,,,,"4061709","Biweekly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1423021","ZEB2 Gene","C75441","This gene is involved in regulation of transcription.","ZEB2 Gene | ZEB2 | Zinc Finger E-Box Binding Homeobox 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541326","Recursive Partitioning Assessment","C102857","A set of pretreatment prognostic factors used to predict potential outcomes for neurooncology patients.","Recursive Partitioning Assessment | RPA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242792","Progression-free Survival","C28234","The length of time during and after treatment in which a patient is living with a disease that does not get worse. Progression-free survival may be used in a clinical study or trial to help find out how well a new treatment works.","Progression-free Survival | PFS | progression-free survival",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1328690","Monoclonal Antibody GD2 Anti-Idiotype Vaccine","C26450","A class of vaccines that consist of anti-idiotype monoclonal antibodies against the tumor-associated antigen disialoganglioside GD2 with potential antineoplastic activity.  Vaccination with a monoclonal antibody GD2 anti-idiotype vaccine produces an immunoglobulin response against GD2 with subsequent destruction of GD2 positive tumor cells via antibody-dependent cellular cytotoxicity (ADCC).  GD2 is overexpressed in melanoma, neuroblastoma, soft tissue sarcoma, and small cell carcinoma of the lung. (NCI04)","Monoclonal Antibody GD2 Anti-Idiotype Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1560131","CTCAE Grade 4 Allergic reaction/hypersensitivity (including drug fever)","C54757","Anaphylaxis","Grade 4 Allergic Reaction and Hypersensitivity Including Drug Fever, CTCAE | CTCAE Grade 4 Allergic Reaction and Hypersensitivity Including Drug Fever | CTCAE Grade 4 Allergic reaction/hypersensitivity (including drug fever) | Grade 4 Allergic reaction/hypersensitivity (including drug fever)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL026905","Androgen","C2298","A type of hormone that promotes the development and maintenance of male sex characteristics.","Androgen | androgen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879393","MSH6 Gene","C19195","This gene is involved in mismatch repair and plays a role in several cancers.","MSH6 Gene | MSH6 | MutS Homolog 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418449","PEA15 Gene","C79783","This gene may play a role in signal transduction, sugar transport and protein localization.","PEA15 Gene | PEA15 | Phosphoprotein Enriched In Astrocytes 15 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0101583","Early E1A Protein","C17473","Early E1A protein is encoded by the adenovirus E1A gene. This protein is involved in inducing infected cells to enter the cell cycle and promoting replication of the viral genome.","Early E1A Protein | Adenovirus E1A Protein | Control Protein E1A | E1A Protein | E1A Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1308290","CCL15 protein, human","C28729","C-C motif chemokine 15 (113 aa, ~12 kDa) is encoded by the human CCL15 gene. This protein is involved in the chemotaxis of T-cells and monocytes.","C-C Motif Chemokine 15 | CCL15 | Chemokine (C-C Motif) Ligand 15 | Chemokine CC-2 | HCC-2 | LKN-1 | Leukotactin 1 | Leukotactin-1 | MIP-1 Delta | MIP-5 | MRP-2B | Macrophage Inflammatory Protein 5 | Mrp-2b | NCC-3 | New CC Chemokine 3 | Small Inducible Cytokine A15 | Small Inducible Cytokine A15 | Small-Inducible Cytokine A15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882310","Cisplatin-Pemetrexed Regimen","C63788","A regimen consisting of pemetrexed and cisplatin that may be used for the treatment of head and neck cancers, malignant peritoneal and pleural mesothelioma, and non-small cell lung cancer (NSCLC).","Cisplatin/Pemetrexed Regimen | Cisplatin and Pemetrexed | Cisplatin-Pemetrexed Regimen | Cisplatin/Pemetrexed | Pemetrexed-Cisplatin Regimen | Pemetrexed-Cisplatin Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517352","GD2 Binding","C40954","GD2 Binding Interaction involves non-covalent attachment of a molecule through intermolecular physical forces of attraction to a widely expressed cell surface ganglioside antigen, GD2.","GD2 Binding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640977","Significant Intercurrent Illness","C102864","Any disease or disorder of relevance that occurs before, during or after another illness.","Significant Intercurrent Illness | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640976","Short Acting Myeloid Growth Factor","C102863","Any of the synthetic, short-acting hematopoietic growth factors that stimulate the growth of myeloid cells.","Short Acting Myeloid Growth Factor | Short-Acting Myeloid Growth Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640975","Long Acting Myeloid Growth Factor","C102862","Any of the synthetic, long-acting hematopoietic growth factors that stimulate the growth of myeloid cells.","Long Acting Myeloid Growth Factor | Long-Acting Myeloid Growth Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3493229","ICAM1 protein, human","C17304","Intercellular adhesion molecule 1 (532 aa, ~58 kDa) is encoded by the human ICAM1 gene. This protein plays a role in integrin binding, immune signaling and leukocyte transendothelial migration.","Intercellular Adhesion Molecule 1 | CD54 | CD54 Antigen | Human Rhinovirus Receptor | ICAM-1 | ICAM1 | Intercellular Adhesion Molecule-1 | Major Group Rhinovirus Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1565716","FGFR4 protein, human","C25859","Fibroblast growth factor receptor 4 (802 aa, ~88 kDa) is encoded by the human FGFR4 gene. This protein plays a role in the regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis.","Fibroblast Growth Factor Receptor 4 | CD334 Antigen | EC 2.7.10.1 | FGFR-4 | FGFR4 | Tyrosine Kinase Related To Fibroblast Growth Factor Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3849511","ANGPT2 protein, human","C18056","Angiopoietin-2 (496 aa, ~57 kDa) is encoded by the human ANGPT2 gene. This protein plays a role in the regulation of endothelial cell apoptosis.","Angiopoietin-2 | ANGPT2 | Ang-2 | Ang2 | Angiopoietin 2 | Tie2-Ligand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0231335","Childhood","C89345","A time period that begins at the beginning of the human embryonic stage and continues until the end of adolescence.","Childhood | Child Life Stage",,,,,,,,,,,,,,,"4116829|4286638","Childhood|Childhood",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C4082587","HLA Class II Histocompatibility Antigen Gamma Chain","C97420","HLA class II histocompatibility antigen gamma chain (296 aa, ~34 kDa) is encoded by the human CD74 gene. This protein plays a role in MHC class II-dependent immunity.","HLA Class II Histocompatibility Antigen Gamma Chain | CD Antigen CD74 | CD74 | CD74 Antigen | HLA-DR Antigens-Associated Invariant Chain | Ia Antigen-Associated Invariant Chain | Ii | p33",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0533668","Angiopoietin-1, Human","C18042","Angiopoietin-1 (498 aa, ~58 kDa) is encoded by the human ANGPT1 gene. This protein is involved in both signal transduction and angiogenesis.","Angiopoietin-1 | ANG-1 | ANG1 | ANGPT1 | Angiopoietin 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825916","Vascular Cell Adhesion Molecule 1 Measurement","C82042","The determination of the amount of vascular cell adhesion molecule 1 present in a sample.","Vascular Cell Adhesion Molecule 1 Measurement | VCAM1 | Vascular Cell Adhesion Molecule 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0558176","Gastroesophageal Reflux","C92560","The backward flow of stomach acid contents into the esophagus (the tube that connects the mouth to the stomach).","Gastroesophageal Reflux | Gastrointestinal Regurgitation | esophageal reflux | gastric reflux | gastroesophageal reflux | reflux",,,,,,,,,,,,,,,"4023183","Gastric reflux",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708385","Hospitalization Required","C50414","A patient condition where evaluation and/or treatment in a hospital is considered mandatory.","Hospitalization Required | Patient_was_hospitalised | Patient_was_hospitalized | Required hospitalization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1620185","Cytochrome P450 1A2, Human","C17673","Cytochrome P450 1A2 (515 aa, ~58 kDa) is encoded by the human CYP1A2 gene. This protein is involved in the hydroxylation of fatty acids, steroids and xenobiotics.","Cytochrome P450 1A2 | Aryl Hydrocarbon Hydroxylase | CYP1A2 | CYPIA2 | Cytochrome P(3)450 | Cytochrome P-450, Aromatic Compound-Inducible | Cytochrome P450 4 | Cytochrome P450, Family 1, Subfamily A, Polypeptide 2 | Cytochrome P450, Family 1, Subfamily A, Polypeptide 2 | Cytochrome P450, Subfamily I (Aromatic Compound-Inducible), Polypeptide 2 | Cytochrome P450-P3 | Dioxin-Inducible P3-450 | EC 1.14.14.1 | Flavoprotein-Linked Monooxygenase | Microsomal Monooxygenase | P(3)450 | P450 4 | P450 Form 4 | P450-P3 | Xenobiotic Monooxygenase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1738970","ABCB1 protein, human","C17746","Multidrug resistance protein 1 (1280 aa, ~141 kDa) is encoded by the human ABCB1 gene. This protein plays a role in both ATP-dependent transport of xenobiotics and resistance to chemotherapeutics.","Multidrug Resistance Protein 1 | ABCB1 | ATP-Binding Cassette Sub-Family B Member 1 | ATP-Binding Cassette, Sub-Family B, Member 1 | CD243 Antigen | EC 3.6.3.44, Formerly | EC 7.6.2.2 | MDR1 Protein | Multidrug Resistance 1 | P-Glycoprotein 1 | P-Glycoprotein Transporter | p-glycoprotein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL421608","Targeted Therapy","C93352","A type of cancer treatment that uses testing and medication to more precisely identify and treat cancer. These treatments target and disable genes or proteins necessary to the proliferation of cancer cells.","Targeted Therapy | Target/Mechanism | targeted therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3853822","Palbociclib","C49176","An orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.","Palbociclib | 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one | Ibrance | PALBOCICLIB | PD 0332991 | PD 332991 | PD 991 | PD-0332991 | PD-0332991 | PD0332991 | Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1814684","Arformoterol Tartrate","C65240","The tartrate salt of arformoterol, the (R,R)-enantiomer of formoterol and a long-acting beta-2 adrenergic agonist with bronchodilator activity. Arformoterol selectively binds to and activates beta-2 adrenergic receptors in bronchiolar smooth muscle, thereby causing stimulation of adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increased intracellular cAMP levels cause relaxation of bronchial smooth muscle and lead to an inhibition of release of inflammatory mediators from mast cells. This may eventually lead to an improvement of airway function.","Arformoterol Tartrate | ARFORMOTEROL TARTRATE | Brovana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0679547","Panendoscopy","C94528","An endoscopic examination of the pharynx, larynx, trachea and esophagus.","Panendoscopy | PANENDOSCOPY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1170584","Cyclosporine Ophthalmic Emulsion","C80051","An topical ophthalmic formulation containing cyclosporine, an undecapeptide produced by the fungus Beauveria nivea, with immunosuppressant and anti-inflammatory activities. The exact therapeutic mechanism of action of cyclosporine is not known but may involve binding to the cellular protein cytophilin, resulting in inhibition of the enzyme calcineurin. This agent appears to specifically and reversibly inhibit immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited with T-helper cells as the primary target. Cyclosporine also inhibits lymphokine production and release.","Cyclosporine Ophthalmic Emulsion | Restasis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677856","autologous lymphocytes","C12939","In transplantation, refers to a person's own white blood cells. Lymphocytes have a number of roles in the immune system, including the production of antibodies and other substances that fight infections and other diseases.","Autologous Lymphocyte | Autologous Lymphocytes | autologous lymphocyte",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL421478","Carboxyamidotriazole Orotate","C91090","The orotate salt form of carboxyamidotriazole (CAI), an orally bioavailable small molecule with potential antiangiogenic and antiproliferative activities. Carboxyamidotriazole binds to and inhibits non-voltage-operated calcium channels, blocking both Ca2+ influx into cells and Ca2+ release from intracellular stores, resulting in the disruption of calcium channel-mediated signal transduction. CAI inhibits PI3 activity and vascular endothelial growth factor (VEGF) signaling. This may inhibit endothelial proliferation, tumor cell growth, invasion and metastasis.","Carboxyamidotriazole Orotate | 1,2,3-Carboxyamido-triazole Orotate | CARBOXYAMIDOTRIAZOLE OROTATE | CTO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019644","Histone H1","C16683","Linker Histone H1 interacts with DNA between nucleosome units in mediating chromatin compaction into higher order structures. Histones are basic nuclear proteins responsible for the nucleosome structure of eukaryotic chromatin. Repeating nucleosome units contain two molecules each of core Histones H2A, H2B, H3, and H4 that form an octamer complex around which approximately 146 base pairs of DNA is wrapped. (NCI)","Histone H1 | H1 | HISTONE H1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202218","Sex Hormone Binding Protein Measurement","C74745","The determination of the amount of sex hormone binding protein present in a sample.","Sex Hormone Binding Protein Measurement | SHBG | SHBG Measurement | Sex Hormone Binding Globulin | Sex Hormone Binding Globulin Measurement | Sex Hormone Binding Protein | Sex Hormone-Binding Globulin Measurement",,,,,,,,,,,,,,,"4082602","Sex hormone binding globulin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0428461","Serum VLDL Cholesterol Measurement","C64806","A quantitative measurement of the amount of very-low-density-lipid (VLDL) cholesterol present in a sample of serum.","Serum VLDL Cholesterol Measurement | ",,,,,,,,,,,,,,,"4042060","Serum VLDL cholesterol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030011","Oxidation","C16944","The process of oxidizing; the addition of oxygen to a compound accompanied by a loss of electrons.","Oxidation | oxidation | oxidize",,,,,,,,,,,,,,,"4132287","Oxidation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1310668","Proto-Oncogene Tyrosine-Protein Kinase ROS, Human","C17691","Proto-oncogene tyrosine-protein kinase ROS (2347 aa, ~264 kDa) is encoded by the human ROS1 gene. This protein is involved in cell growth, tyrosine phosphorylation and receptor-mediated signaling.","Proto-Oncogene Tyrosine-Protein Kinase ROS | EC 2.7.10.1 | Proto-Oncogene c-Ros | Proto-Oncogene c-Ros-1 | ROS1 | ROS1 Protein | Receptor Tyrosine Kinase c-Ros Oncogene 1 | c-Ros Receptor Tyrosine Kinase | c-Ros Tyrosine Kinase | c-Ros Tyrosine Kinase | gp280",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640640","YMRS - Disruptive-Aggressive Behaviour","C102241","Young Mania Rating Scale (YMRS) Disruptive-aggressive behaviour.","YMRS - Disruptive-Aggressive Behaviour | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206435","Poliovirus","C14259","An enterovirus comprised of an single-stranded positive sense RNA genome and a protein capsid. This virus is the human pathogen that causes poliomyelitis.","Poliovirus | ENC | Enterovirus C | Human enterovirus C | POLIOVIRUS | Polio Virus",,,,,,,,,,,,,,,"4196091","Human poliovirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL413562","Anti-EGFRvIII Immunotoxin MR1-1","C88307","A recombinant immunotoxin consisting of single-chain variable domain fragment antibody directed against the tumor-specific antigen EGFRvIII (MR1scFv) fused to domains II and III of the Pseudomonas exotoxin (PE38KDEL), with potential antineoplastic activity. Upon administration, the antibody moiety of anti-EGFRvIII immunotoxin MR1-1 binds to EGFRvIII; upon internalization, the exotoxin portion inhibits protein synthesis, resulting in a reduction in tumor cell proliferation of EGFRvIII- expressing tumor cells. EGFRvIII, a type III in-frame deletion mutation of the epidermal growth factor receptor (EGFR) gene, is expressed by a variety of cancers, including glioblastoma multiforme, non-small lung carcinoma, and breast carcinoma. Compared to intact IgG antibodies, single-chain antibodies such as MR1scFv are smaller and may penetrate tumors better. Pseudomonas exotoxin PE38KDEL was modified to remove the natural cell binding domain.","Anti-EGFRvIII Immunotoxin MR1-1 | MR1-1 | MR1-1KDEL | MR1scFvPE38KDEL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826110","Onartuzumab","C82348","A humanized monovalent monoclonal antibody directed against the hepatocyte growth factor receptor (c-Met) with potential antineoplastic activity. Anti-MET monoclonal antibody MetMAb binds to the extracellular domain of c-Met, preventing the binding of its ligand, hepatocyte growth factor (HGF); the activation of the c-Met signaling pathway is thus inhibited, which may result in cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase, is overexpressed on the cell surfaces of a variety of cancer cell types and may play a key role in their proliferation, invasion and survival.","Onartuzumab | Anti-MET Monoclonal Antibody MetMAb | MetMAb | OA-5D5 | ONARTUZUMAB | PRO 143966 | RO5490258",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035691","RNA Virus","C14269","A virus whose genome consists of RNA.","RNA Virus | Virus-RNA | Viruses, RNA",,,,,,,,,,,,,,,"4036212","RNA virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1872203","Pasireotide","C69131","A synthetic long-acting cyclic peptide with somatostatin-like activity. Pasireotide activates a broad spectrum of somatostatin receptors, exhibiting a much higher binding affinity for somatostatin receptors 1, 3, and 5 than octreotide in vitro, as well as a comparable binding affinity for somatostatin receptor 2. This agent is more potent than somatostatin in inhibiting the release of human growth hormone (HGH), glucagon, and insulin.","Pasireotide | Cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L-phenylalanyl-) | PASIREOTIDE | SOM230",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4048794","TLN 4601","C62508","A potent inhibitor of the RAS/RAF/MAPK signaling pathway with potential antineoplastic activity. Diazepinomicin binds to and inhibits Ras kinase, thereby preventing the phosphorylation and activation of proteins downstream of the Ras signal transduction pathway, including serine/threonine kinase RAF (BRAF) and extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK-2), that play a crucial role in regulating cell growth and survival. Diazepinomicin also selectively binds to the peripheral benzodiazepine receptor (BZRP), a receptor highly expressed in certain cancer cells, thus inducing cell cycle arrest and apoptosis in BZRP-expressing cells. In addition, diazepinomicin is able to cross the blood-brain barrier, thereby reaching therapeutic concentrations in the brain.","Diazepinomicin | 11h-dibenzo(B,E)(1,4)diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl)- | BU-4664L | DIAZEPINOMICIN | ECO-4601 | TLN-4601",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1541477","PEP-3-KLH Conjugate Vaccine","C74070","A cancer vaccine consisting of PEP-3, a synthetic peptide encompassing a tumor-specific mutated segment of the epidermal growth factor receptor type vIII (EGFRvIII), conjugated to the naturally-occurring immunoadjuvant keyhole limpet hemocyanin (KLH) with potential immunostimulating and antineoplastic activities. Upon administration, PEP-3-KLH conjugate vaccine may induce a cytotoxic immune response against tumor cells that overexpress EGFRvIII; this antitumoral immune response may involve antibody-dependent cellular cytotoxicity (ADCC).","PEP-3-KLH Conjugate Vaccine | PEP-3-KLH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640978","Hopkins Verbal Learning Test Revised","C102866","An assessment tool to ascertain verbal learning and memory skills that is well tolerated by those with moderate to severe dementia.","Hopkins Verbal Learning Test Revised | HVLT-R | HVLT-R NCI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986546","Target Lesion Identification","C94520","The identification of a lesion that is present at baseline, is measurable and is the primary target of the therapeutic intervention.","Target Lesion Identification | Index | TARGET | target lesion | target_lesion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0588058","Intra-Abdominal Lymph Node","C12360","Any lymph node within the abdomen.","Intra-Abdominal Lymph Node | ABDOMINAL LYMPH NODE | Intra-Abdominal Lymph Nodes | Intra-abdominal lymph nodes",,,,,,,,,,,,,,,"4075247","Abdominal lymph node group",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517562","Intrathoracic Lymph Node","C12359","Any lymph node within the thoracic cavity.","Intrathoracic Lymph Node | INTRATHORACIC LYMPH NODE | Intra-Thoracic Lymph Node | Intrathoracic Lymph Nodes | Intrathoracic lymph nodes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1565805","Fibroblast Growth Factor 9, Human","C26146","Fibroblast growth factor 9 (208 aa, ~23 kDa) is encoded by the human FGF9 gene. This protein is involved in embryonic development, cell proliferation, cell differentiation and cell migration.","Fibroblast Growth Factor 9 | FGF-9 | FGF9 | GAF | Glia-Activating Factor | HBGF-9 | Heparin-Binding Growth Factor 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773618","Ornithine Decarboxylase","C38931","Ornithine decarboxylase (461 aa, ~51 kDa) is encoded by the human ODC1 gene. This protein plays a role in the biosynthesis of polyamines.","Ornithine Decarboxylase | EC 4.1.1.17 | ODC | ODC1 | Ornithine Decarboxylase 1 | Ornithine Decarboxylase 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0907797","CCL26 protein, human","C28739","C-C motif chemokine 26 (94 aa, ~11 kDa) is encoded by the human CCL26 gene. This protein plays a role in eosinophil and basophil chemotaxis.","C-C Motif Chemokine 26 | CC Chemokine IMAC | CCL26 | Chemokine (C-C Motif) Ligand 26 | Chemokine N1 | Eotaxin 3 | Eotaxin-3 | MIP-4-Alpha | Macrophage Inflammatory Protein 4-Alpha | Small Inducible Cytokine A26 | Small Inducible Cytokine A26 | Small Inducible Cytokine Subfamily A (Cys-Cys), Member 26 | Small-Inducible Cytokine A26 | TSC-1 | Thymic Stroma Chemokine-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0538075","Chemokine CCL24","C28736","C-C motif chemokine 24 (119 aa, ~13 kDa) is encoded by the human CCL24 gene. This protein plays a role in chemotaxis of eosinophils and resting T-lymphocytes.","C-C Motif Chemokine 24 | CCL24 | CK-Beta-6 | Eosinophil Chemotactic Protein 2 | Eotaxin 2 | Eotaxin-2 | MPIF-2 | Myeloid Progenitor Inhibitory Factor 2 | Myeloid Progenitor Inhibitory Factor-2 | Small Inducible Cytokine A24 | Small Inducible Cytokine A24 | Small Inducible Cytokine Subfamily A (Cys-Cys), Member 24 | Small-Inducible Cytokine A24",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521898","FCGR3A protein, human","C38559","Low affinity immunoglobulin gamma Fc region receptor III-A (254 aa, ~29 kDa) is encoded by the human FCGR3A gene. This protein is involved in antibody-mediated immunity.","Low Affinity Immunoglobulin Gamma Fc Region Receptor III-A | CD16 | CD16A | CD16A Antigen | FCG3 | FCGR3 | FCGR3A | FCRIII-2 | Fc Gamma Receptor III-A | Fc-Gamma RIII | Fc-Gamma RIII-Alpha | Fc-Gamma RIIIA | FcR-10 | FcRIII | FcRIIIA | FcgammaRIIIA | IGFR3 | IgG Fc Receptor III-2 | IgG Fc Receptor IIIA | IgG Fc Receptor IIIA | Immunoglobulin G Fc Receptor III-2 | Low Affinity IgG Fc Receptor IIIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0556993","Teacher","C102873","One who instructs or educates others.","Teacher | EDUCATOR | Educator | Instructor",,,,,,,,,,,,,,,"4072012","Instructor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL437148","Autologous Pluripotent ALDHbr Stem Cells ALD-451","C78466","A specific population of autologous, pluripotent bone marrow derived cells that express high levels of the cytosolic enzyme aldehyde dehydrogenase (ALDH) with potential protective and neuro-cognition improving activity. Expression of high levels of ALDH is an indicator of the biological activity in heterogenous early stage stem cells. Upon intravenous administration, these ALDH bright cells may protect normal cells and may repair damaged cells. These cells may also protect brain cells from damage and may improve neurocognition.","Autologous Pluripotent ALDHbr Stem Cells ALD-451 | ALD-451 | ALD-451 Bright Cells | Aldehyde Dehydrogenase-Bright Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938167","Liothyronine","C2303","A thyroid hormone containing 3 iodine atoms generally synthesized from levothyroxine, and has greater biological activity.","Triiodothyronine | 3,3',5-triiodo-L-thyronine | Liothyronine | T-3 | T3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522668","Recombinant Tumor Necrosis Factor Family Protein","C1941","A recombinant therapeutic agent which is chemically identical to or similar to one of a number of endogenous tumor necrosis factor (TNF) proteins. TNF family cytokines bind to and activate specific cell-surface receptors, thereby mediating inflammatory processes, cell proliferation, immunity, angiogenesis, and tumor cell cytotoxicity. One primary antitumor effect of TNFs involves stimulation of T cell-mediated antitumor cytotoxicity.","Recombinant Tumor Necrosis Factor Family Protein | TNF | Tumor Necrosis Factor Family Protein | Tumor Necrosis Factors | tumor necrosis factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022179","Isoflavone","C599","A class of polyphenolic compounds derived from the Fabaceae family with potential phytoestrogenic, cholesterol-reducing, chemotherapeutic and antioxidant activity. In isoflavones the phenyl group on the benzopyran ring is in position 3 relative to the oxygen of the ring. Most isoflavones for human consumption and that are currently studied are derived from soy beans.","Isoflavone | 3-phenylchromone | ISOFLAVONE | Isoflavones | Soy Isoflavones | isoflavone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424448","CHEK2 Gene","C40965","This gene plays a role in cell survival and the negative regulation of cell growth.","CHEK2 Gene | CHEK2 | Checkpoint Kinase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010531","Cyclic AMP-Dependent Protein Kinases","C16479","Most cellular effects of cAMP are mediated through PKA by serine or threonine phosphorylation of target proteins. Human Protein Kinase A (cAMP Ser/Thr Protein Kinase Family) is an inactive tetrameric cytoplasmic holoenzyme composed of homo- or heterodimeric regulatory subunits associated with two catalytic subunits. cAMP causes dissociation of inactive holoenzyme into a cAMP-bound dimer of regulatory subunits and two free monomeric catalytic subunits that phosphorylate many cytoplasmic and nuclear substrates. In human, regulatory PRKAR1A, PRKAR1B, PRKAR2A, and PRKAR2B subunits and catalytic PRKACA, PRKACB, and PRKACG subunits have been identified. (NCI)","Protein Kinase A | PKA | cAMP-Dependent Protein Kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0541106","NPM1/ALK Fusion Protein","C99362","A fusion protein (680 aa, ~75 kDa) that is encoded by the NPM1/ALK fusion gene. This protein contains the N-terminal domain from the nucleophosmin protein and the cytoplasmic domain of the ALK tyrosine kinase receptor protein.","NPM1/ALK Fusion Protein | NPM-ALK Fusion Protein | NPM/ALK Fusion Protein | NPM1-ALK Fusion Protein | NPM1::ALK Fusion Protein | Nucleophosmin/ALK Tyrosine Kinase Receptor Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0249989","Recombinant Flt3 Ligand","C1714","A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine Flt3. Flt3 ligand binds to the Flt3 tyrosine kinase receptor and, synergistically with other growth factors, stimulates the proliferation and mobilization of bone marrow precursor cells, including CD34+ cells, and dendritic cells. When proteolytically cleaved, the transmembrane isoform of Flt3 ligand generates the soluble form soluble Flt3 ligand, which is also biologically active.","Recombinant Flt3 Ligand | CDX-301 | FLT 3 Ligand | FLT3 Ligand | Flt3-Ligand | Flt3L | Mobist | Mobista | flt3L | rhuFlt3L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640982","International Neuroblastoma Response Criteria","C102869","A standard approach to aid in the stratification of neuroblastoma risk and disease evaluation.","International Neuroblastoma Response Criteria | INRC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017011","Gamma Radiation","C44386","High-energy, short wavelength, ionizing electromagnetic radiation emitted from the nucleus. Gamma radiation frequently accompanies alpha and beta emissions and always accompanies fission. Gamma rays are very penetrating and are best stopped or shielded by dense materials, such as lead or depleted uranium. Gamma rays are identical to x-rays and are only differentiated by their origin. (from NRC Glossary)","Gamma Radiation | GAMMA RAY | Gamma | Gamma Ray | gamma ray",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272929","Fat Measurement","C96648","The determination of the amount of fat present in a sample.","Fat Measurement | FAT | Fat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0300061","centromere protein F, 350-400 kDa (mitosin), human","C17928","Centromere protein F (3210 aa, ~368 kDa) is encoded by the human CENPF gene. This protein plays a role in cell cycle progression and is required for both kinetochore formation and chromosome segregation during mitosis.","Centromere Protein F | AH Antigen | CENP-F Kinetochore Protein | CENPF | Cell-Cycle-Dependent 350K Nuclear Protein | Kinetochore Protein CENP-F | Mitosin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812291","MYBL2 Gene","C18409","This gene plays a regulatory role in cell cycle progression.","MYBL2 Gene | MYBL2 | v-MYB Myeloblastosis Viral Oncogene Homolog (Avian)-Like 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0373748","Zinc Measurement","C80210","The determination of the amount of zinc present in a sample.","Zinc Measurement | ZINC | Zinc",,,,,,,,,,,,,,,"4324843","Zinc measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0178638","Folate","C1444","A cofactor for 1-carbon transfer involved with DNA synthesis.","Folate | 2-[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]aminopentanedioic acid | Vitamin B-11 | folate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0087162","Vitamin B6","C1334","A group of water-soluble vitamins essential for metabolism and normal physiological functions. B6 vitamins, including pyridoxine, pyridoxal, and pyridoxamine, are converted in vivo to pyridoxal phosphate, a cofactor necessary for the synthesis of amino acids, neurotransmitters, and sphingolipids.  More than 100 enzymes involved in protein metabolism require vitamin B6 as a cofactor. Vitamin B6 is essential to red blood cell, nervous system, and immune systems functions and helps maintain normal blood glucose levels. Vitamin B6 is found in a wide variety of foods including cereals, beans, meat, poultry, fish, and some fruits and vegetables. (NCI04)","Vitamin B6 | VIT B6 | Vitamin B 6 | Vitamin B-6 | vitamin B6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036002","S-Adenosylmethionine","C63661","A nutritional supplement that is synthesized from adenosine triphosphate (ATP) and the amino acid methionine by the endogenous essential enzyme methionine adenosyltransferase (MAT), with potential antineoplastic activity.  Upon administration, S-adenosylmethionine acts as a methyl donor for various transmethylation reactions. In cancer cells, this agent induces the methylation of tumor promoting genes, reverses DNA hypomethylation, and leads to the suppression of oncogene transcription. This induces apoptosis in and inhibits proliferation of susceptible tumor cells.","S-Adenosylmethionine | 5'-[(3-Amino-3-carboxypropyl)methylsulfonio]-5'-deoxyadenosine Hydroxide, Inner Salt | Active Methionine | S-Adenosyl-l-methionine | S-Adenosyl-l-methionine 1,4-Butanedisulfonate | S-Adenosyl-methionine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1384573","folate receptor 1 (adult), human","C39284","Folate receptor alpha (257 aa, ~30 kDa) is encoded by the human FOLR1 gene. This protein is involved in cellular import of folate, 5-methyltetrahydrofolate, and folic acid derivatives.","Folate Receptor Alpha | Adult Folate Receptor | Adult Folate-Binding Protein | FBP | FOLR | FOLR1 | FR-Alpha | FolRa | Folate Receptor 1 | Folate Receptor 1 | Folate Receptor, Alpha | Folate-Binding Protein, Adult | KB Cells FBP | MOv18 | Ovarian Tumor-Associated Antigen MOv18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2584446","Iobenguane I-123","C80094","An iodine (I) 123 labeled aralkylguanidine norepinephrine analogue used as a diagnostic imaging tracer. Iobenguane, structurally related to norepinephrine, functioning as a false substrate of norepinephrine, and is taken up and localized in the granules of pre-synaptic adrenergic neurons. When labeled with I-123, this agent is useful for the imaging of neuroendocrine tissues and tumors.","Iobenguane I-123 | AdreView | IOBENGUANE I-123 | iobenguane I 123",,,,,,,,,,,,,,,"4193805","Iobenguane (123-I)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1447061","HSPB1 protein, human","C16671","Heat shock protein beta-1 (205 aa, ~23 kDa) is encoded by the human HSPB1 gene. This protein is involved in protein denaturation and the cellular response to oxidative stress.","Heat Shock Protein Beta-1 | 28 kDa Heat Shock Protein | Estrogen-regulated 24 kDa Protein | HSP 27 | HSPB1 | Heat Shock 27 kD Protein 1 | Heat Shock 27 kDa Protein | Heat Shock Protein 27 | Hsp27 | HspB1 | SRP27 | Stress-responsive Protein 27",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521184","Atypical Squamous Cell of Undetermined Significance","C8434","Abnormal cells from the outer walls of the cervix (the lower, narrow end of the uterus). Abnormal squamous cells (thin, flat cells that look like fish scales) are found in a low number of Pap smears (a procedure used to detect cervical cancer) and may indicate infection with the human papillomavirus (HPV) or another infectious agent. The risk of developing cervical cancer is very low for patients with ASCUS without HPV infection.","Atypical Squamous Cell of Undetermined Significance | ASC-US | ASCUS | Atypical Squamous Cell of Uncertain Significance | atypical squamous cells of undetermined significance",,,,,,,,,,,,,,,"4191603","Atypical squamous cells of undetermined significance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1320453","Cervical Squamous Cell Carcinoma In Situ","C7347","Stage 0 includes: (Tis, N0, M0). Tis: Carcinoma in situ. N0: No regional lymph node metastasis.  M0: No distant metastasis. FIGO no longer includes stage 0. (AJCC 7th ed.)","Cervical Squamous Cell Carcinoma In Situ | CIN 3 | Cervical Squamous Cell Carcinoma In Situ AJCC v7 | Cervical Squamous Intraepithelial Neoplasia 3 | Cervix Squamous Cell Carcinoma In Situ | Cervix Uteri Squamous Cell Carcinoma In Situ | Severe Squamous Dysplasia of the Cervix | Squamous Cell Carcinoma In Situ of Cervix | Squamous Cell Carcinoma In Situ of Cervix Uteri | Squamous Cell Carcinoma In Situ of Uterine Cervix | Squamous Cell Carcinoma In Situ of the Cervix | Squamous Cell Carcinoma In Situ of the Cervix Uteri | Squamous Cell Carcinoma In Situ of the Uterine Cervix | Uterine Cervix Squamous Cell Carcinoma In Situ | cervical squamous intraepithelial neoplasia 3",,,,,,,,,,,,,,,"4247367","Squamous cell carcinoma in situ of uterine cervix",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0349459","Cervical Squamous Intraepithelial Neoplasia 2","C40198","Cervical squamous intraepithelial neoplasia characterized by the presence of maturation in the upper half of the squamous epithelium and conspicuous nuclear atypia which is present in all epithelial layers.  Mitotic figures are present in the basal two thirds of the epithelium.","Cervical Squamous Intraepithelial Neoplasia 2 | CIN 2 | Moderate Squamous Dysplasia of the Cervix | cervical squamous intraepithelial neoplasia 2",,,,,,,,,,,,,,,"196165","Cervical intraepithelial neoplasia grade 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1527424","Cervical Squamous Intraepithelial Neoplasia 1","C40199","Cervical squamous intraepithelial neoplasia characterized by the presence of maturation in the upper two-thirds of the squamous epithelium and mild nuclear atypia which is present in all epithelial layers.  Mitotic figures are present in the basal third of the epithelium.","Cervical Squamous Intraepithelial Neoplasia 1 | CIN 1 | cervical squamous intraepithelial neoplasia 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1302773","Low Grade Squamous Intraepithelial Neoplasia","C8335","A precancerous neoplastic process characterized by the presence of mild dysplastic cytological changes which are usually present in the lower part of the squamous epithelium.  Representative examples include the low grade esophageal squamous intraepithelial neoplasia, low grade cervical squamous intraepithelial neoplasia, low grade vaginal intraepithelial neoplasia, and low grade vulvar intraepithelial neoplasia.","Low Grade Squamous Intraepithelial Neoplasia | Grade 1 Squamous Intraepithelial Neoplasia | Grade I Squamous Intraepithelial Neoplasia | LSIL | Low-Grade Squamous Intraepithelial Lesion | Squamous intraepithelial neoplasia, grade I | Squamous intraepithelial neoplasia, low grade | low-grade squamous intraepithelial lesion","8077/0","Squamous intraepithelial neoplasia, low grade",,,,,,,,,,,,,"4013220|4270888|42872604","Low-grade squamous intraepithelial lesion|Squamous intraepithelial neoplasia grade 1|Squamous intraepithelial neoplasia, low grade",,,,,,,,,,,,,"--","--",,,,,,,,"--|--|--"
"C1519433","Special Diet Therapy","C15383","A form of therapy which includes dietary approaches and special diets that are applied as alternative therapies for risk factors or chronic disease in general.","Special Diet Therapy | DIET",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825234","Non-insulin Hypoglycemic","C80511","Any substance, other than insulin, used to treat hyperglycemia.","Non-insulin Hypoglycemic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0664123","Receptors, Tumor Necrosis Factor, Member 10b","C18178","Tumor necrosis factor receptor superfamily member 10B (440 aa, ~48 kDa) is encoded by the human TNFRSF10B gene. This protein is involved in the modulation of the caspase cascade.","Tumor Necrosis Factor Receptor Superfamily Member 10B | Apoptosis Inducing Protein TRICK2A/2B | Apoptosis Inducing Receptor TRAIL-R2 | CD262 Antigen | Cytotoxic TRAIL Receptor-2 | DR5 | Death Domain Containing Receptor For TRAIL/Apo-2L | Death Receptor 5 | Fas-Like Protein | Fas-Like Protein Precursor | P53-Regulated DNA Damage-Inducible Cell Death Receptor (Killer) | TNF Receptor Superfamily Member 10b | TNF-Related Apoptosis-Inducing Ligand Receptor 2 | TNFRSF10B | TRAIL Receptor 2 | TRAIL receptor 2 | TRAIL-R2 | TRAILR-2 | TRAILR2 | Tumor Necrosis Factor Receptor-Like Protein ZTNFR9 | death receptor 5 | tumor necrosis factor receptor superfamily member 10B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416660","KLF4 Gene","C73449","This gene plays a role in gene transcription.","KLF4 Gene | KLF4 | Kruppel Like Factor 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1567673","DNA Repair Protein Complementing XP-G Cells, Human","C21460","DNA repair protein complementing XP-G cells (1186 aa, ~133 kDa) is encoded by the human ERCC5 gene. This protein plays a role in the repair of UV-induced DNA damage.","DNA Repair Protein Complementing XP-G Cells | DNA Excision Repair Protein ERCC-5 | DNA Excision Repair Protein ERCC-5 | EC 3.1.-.- | ERCC5 | ERCM2 | UVDR | XPG | XPG-Complementing Protein | XPGC | Xeroderma Pigmentosum Group G Complementing Protein | Xeroderma Pigmentosum Group G-Complementing Protein | Xeroderma Pigmentosum, Complementation Group G | Xeroderma Pigmentosum, Group G Correcting Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825564","Submitting Facility","C81294","The hospital or medical institution that is submitting data or information.","Submitting Facility | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347676","Primary Healthcare Payer","C70688","A health plan or payer obligated to pay a healthcare service claim first.","Primary Healthcare Payer | Primary Payer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826835","Disposition Category","C83245","A classification of disposition data.","Disposition Category | DSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2608036","CDISC SDTM Race Terminology","C74457","Terminology codelist used to identify the race of an individual within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.","CDISC SDTM Race Terminology | RACE | Race | SDTM-RACE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825883","Calprotectin Measurement","C82005","The determination of the amount of calprotectin present in a sample.","Calprotectin Measurement | CALPRO | Calprotectin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641008","PROMIS Adult Sleep-Related Impairment Item Bank","C102989","A set of questions designed to evaluate patient-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours, and assess functional impairments during wakefulness associated with sleep problems or impaired alertness.","PROMIS Adult Sleep-Related Impairment Item Bank | Patient Reported Outcomes Measurement Information System Adult Sleep-Related Impairment Item Bank",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641009","List of Threatening Experiences Questionnaire","C102991","A 12 category life events questionnaire designed to assess the quality of life of a patient before, during and following stressful life events.","List of Threatening Experiences Questionnaire | Brief Life Event Questionnaire | LTE Questionnaire | LTE-Q | List of Threatening Experiences",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2714104","Mitochondrial Isocitrate Dehydrogenase [NADP], Human","C84990","Isocitrate dehydrogenase [NADP], mitochondrial protein (452 aa, ~51 kDa) is encoded by the human IDH2 gene. This protein plays a role in intermediary metabolism.","Isocitrate Dehydrogenase [NADP], Mitochondrial | EC 1.1.1.42 | ICD-M | IDH2 | IDP | Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial | Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial | NADP (+)-Specific ICDH | Oxalosuccinate Decarboxylase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796520","ETV6 Gene","C18312","This gene plays a regulatory role in transcription and in matrix metalloproteinase activity.","ETV6 Gene | ETS Variant Transcription Factor 6 Gene | ETV6 | TEL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0063948","IDH1 protein, human","C77217","Isocitrate dehydrogenase [NADP] cytoplasmic (414 aa, 47 kDa) is encoded by the human IDH1 gene. This protein plays a role the oxidation of isocitrate and oxalosuccinate.","Isocitrate Dehydrogenase [NADP] Cytoplasmic | Cytosolic NADP-Isocitrate Dehydrogenase | EC 1.1.1.42 | IDH | IDH1 | IDP | NADP (+)-specific ICDH | Oxalosuccinate Decarboxylase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425445","ASXL1 Gene","C97320","This gene may be involved in both transcriptional regulation and chromatin remodeling.","ASXL1 Gene | ASXL Transcriptional Regulator 1 Gene | ASXL1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538927","Exome (Molecular Biology Term)","C101296","The portion of the genome that is characterized by exon sequences, which represent the genetic template for the synthesis of proteins and other functional gene products.","Exome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425343","PHF6 Gene","C101449","This gene plays a role in transcriptional regulation.","PHF6 Gene | PHD Finger Protein 6 Gene | PHF6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826302","Reported Term","C82571","The collected name for an event observation.","Reported Event Term | Reported Term | TERM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL322751","Hypoxanthine-Guanine Phosphoribosyltransferase","C38496","Hypoxanthine-guanine phosphoribosyltransferase (218 aa, ~25 kDa) is encoded by the human HPRT1 gene. This protein plays a role in nucleoside metabolism.","Hypoxanthine-Guanine Phosphoribosyltransferase | EC 2.4.2.8 | HGPRT | HGPRTase | HPRT1 | Hypoxanthine Phosphoribosyltransferase 1 | Hypoxanthine Phosphoribosyltransferase 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539795","Cohesin Subunit SA-2, Human","C101348","Cohesin subunit SA-2 (1231 aa, ~141 kDa) is encoded by the human STAG2 gene. This protein is involved in chromosomal localization.","Cohesin Subunit SA-2 | Cohesin Subunit SA2 | SCC3 Homolog 2 | STAG2 | Stromal Antigen 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0535219","Structural Maintenance of Chromosomes Protein 3, Human","C26084","Structural maintenance of chromosomes protein 3 (1217 aa, ~142 kDa) is encoded by the human SMC3 gene. This protein plays a role in chromosome cohesion and may be expressed as an extracellular glycoprotein that plays a role in cell-matrix adhesion.","Structural Maintenance of Chromosomes Protein 3 | Bamacan | Bamacan Proteoglycan | Basement Membrane-Associated Chondroitin Proteoglycan | CSPG6 | Chondroitin Sulfate Proteoglycan 6 | Chromosome-Asociated Polypeptide | Human Chromosome-Associated Polypeptide | SMC Protein 3 | SMC-3 | SMC3 | hCAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699700","Structural Maintenance of Chromosomes Protein 1A","C75512","Structural maintenance of chromosomes protein 1A (1233 aa, ~143 kDa) is a cell cycle protein that is encoded by the human SMC1A gene and plays a role in mitotic chromatid cohesion.","Structural Maintenance of Chromosomes Protein 1A | SMC1 Alpha Protein | Sb1.8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1435548","RUNX1 protein, human","C18319","Runt-related transcription factor 1 (453 aa, ~49 kDa) is encoded by the human RUNX1 gene. This protein is involved in the promotion of gene transcription and hematopoiesis.","Runt-Related Transcription Factor 1 | AML-1 | AML-1 Protein | AML1 | AML1 Protein | Acute Myeloid Leukemia 1 Protein | Acute Myeloid Leukemia-1 Protein | CBF-Alpha | CBF-Alpha B | CBF-Alpha-2 | CBFA2 | Core-Binding Factor Alpha | Core-Binding Factor Alpha B Subunit | Core-Binding Factor Subunit Alpha-2 | Core-Binding Factor, Runt Domain, Alpha Subunit 2 | Oncogene AML-1 | PEA2-Alpha B | PEBP2-Alpha B | Polyomavirus Enhancer Binding Protein 2 Alpha B Subunit | Polyomavirus Enhancer-Binding Protein 2 Alpha B Subunit | RUNX1 | SL3-3 Enhancer Factor 1 Alpha B Subunit | SL3/AKV Core-Binding Factor Alpha B Subunit | Sl3/AKV Core-Binding Factor Alpha B Subunit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0069508","oncogene protein E7, Human papillomavirus type 16","C1179","Protein E7 (98 aa, ~11 kDa) is encoded by the human papillomavirus type 16 E7 gene. This protein is involved in the modulation of the activity of both retinoblastoma protein and histone deacetylases in the infected host cell, which is associated with viral genome replication and host cell transformation.","Protein E7, Human Papillomavirus Type 16 | HPV-16 E7 | HPV-16 E7 peptide | HPV16 E7 | Human Papillomavirus Type 16, E7 Protein | Papillomavirus Type 16 Protein E7 | Protein E7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273993","BRAF NP_004324.2:p.V600G","C98345","A change in the amino acid residue at position 600 in the serine/threonine protein kinase B-raf protein where valine has been replaced by glycine.","BRAF NP_004324.2:p.V600G | BRAF NP_004324.2:p.Val600Gly | BRAF V600G | BRAF p.V600G | BRAF p.Val600Gly | NP_004324.2:p.Val600Gly | Serine/Threonine-Protein Kinase B-raf V600G | Serine/Threonine-Protein Kinase B-raf Val600Gly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274001","BRAF NP_004324.2:p.V600R","C98353","A change in the amino acid residue at position 600 in the serine/threonine protein kinase B-raf protein where valine has been replaced by arginine.","BRAF NP_004324.2:p.V600R | BRAF NP_004324.2:p.Val600Arg | BRAF V600R | BRAF Val600Arg | BRAF p.V600R | BRAF p.Val600Arg | NP_004324.2:p.Val600Arg | Serine/Threonine-Protein Kinase B-raf V600R | Serine/Threonine-Protein Kinase B-raf Val600Arg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1307220","MAP3K8 protein, human","C20585","Mitogen-activated protein kinase kinase kinase 8 (467 aa, ~58 kDa) is encoded by the human MAP3K8 gene. This protein plays a role in T cell activation and serine/threonine phosphorylation.","Mitogen-Activated Protein Kinase Kinase Kinase 8 | C-COT | COT Gene Product | COT Proto-Oncogene Serine/Threonine-Protein Kinase | Cancer Osaka Thyroid Oncogene Protein | EC 2.7.11.25 | Ewing Sarcoma Transformant | MAP Kinase Kinase Kinase 8 | MAP3K8 | MAP3K8 Kinase | Proto-Oncogene c-Cot | Serine/Threonine-Protein Kinase Cot | TPL-2 | Tpl2 | Tumor Progression Locus 2 | p38 MAPK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007745","Ceramide","C359","One of a number of a class of sphingolipids, N-acyl derivatives with long chains. Ceramide is the core molecule for the synthesis of sphingomyelin, an essential lipid for myelination and neurotransmission; it may function as a second messenger to stimulate differentiation, inhibit proliferation, and induce apoptosis. (NCI04)","Ceramide | Ceramide (lipids) | N-Acyl Sphingosine | ceramide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004610","Bacteremia","C102993","A laboratory test result that indicates the presence of bacteria in the blood.","Bacteremia | ",,,,,,,,,,,,,,,"132736","Bacteremia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085082","Fungemia","C102992","A laboratory test result indicating the presence of fungi or yeasts in the blood.","Fungemia | ",,,,,,,,,,,,,,,"4202922","Fungemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641010","Immunohematological","C102994","Pertaining to antigen and antibody reactions that involve hematopoietic cells.","Immunohematological | Immunohematologic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881081","Hyperfractionated Cyclophosphamide-Vincristine-Adriamycin-Dexamethasone/High-dose Methotrexate-Cytarabine Regimen","C63472","A regimen consisting of cyclophosphamide, vincristine, doxorubicin and dexamethasone, administered on a hyperfractionated schedule, alternating with high-dose cytarabine and methotrexate, that can be used in the treatment of acute lymphoblastic leukemia (ALL) and certain types of non-Hodgkin lymphoma (NHL), including Burkitt lymphoma, and blastic plasmacytoid dendritic cell neoplasm (BPDCN).","HyperCVAD Alternating with High-dose MTX AraC Regimen | Cyclophosphamide/Vincristine/Doxorubicin/Dexamethasone Alternating with High-Dose Methotrexate/Cytarabine | Hyper-CVAD/MA | HyperCVAD Alternating with High Dose Methotrexate and Cytarabine | HyperCVAD Alternating with Methotrexate/Cytarabine | HyperCVAD-HD MTX AraC Regimen | HyperCVAD/HD MTX AraC Regimen | HyperCVAD/HD MTX AraC Regimen | HyperCVAD/MTX-Ara-C | HyperCVAD/MTX/AraC | Hyperfractionated Cyclophosphamide-Vincristine-Adriamycin-Dexamethasone Alternating with Cytarabine/Methotrexate Regimen | Hyperfractionated Cyclophosphamide-Vincristine-Adriamycin-Dexamethasone/High-dose Methotrexate-Cytarabine Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510824","Aerobic","C28341","In biochemistry, reactions that need oxygen to happen or happen when oxygen is present.","Aerobic | aerobic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641082","NIH Consensus Response Criteria for Chronic GVHD","C103138","A tool used to assess response to therapy for chronic Graft versus Host Disease (cGVHD) based on clinical trial findings and recommended by the NIH Chronic Graft-versus-Host Disease Consensus Response Criteria Working Group. The criteria were established in 2005 (Biol Blood Marrow Transplant, 12 (2006), pp. 252-266) and revised in 2014 (Biol Blood Marrow Transplant, 21 (2015), pp. 984-999).","NIH Consensus Response Criteria for Chronic GVHD | NIH Chronic GVHD Consensus Project Response Criteria | NIH Consensus Response Criteria for cGVHD | NIH Consensus Response Criteria for cGVHD | NIH Consensus Response Criteria for chronic Graft vs Host Disease | NIH cGVHD Consensus Project Response Criteria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641083","Complete Response in cGVHD","C103139","Complete resolution of all signs and symptoms in all affected organs or tissues in chronic Graft versus Host Disease (cGVHD).","Complete Response in cGVHD | Complete Response | Complete Response in chronic Graft vs Host Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641084","Partial Response in cGVHD","C103140","Improvement in one or more organ or tissue without progression in other affected organs or tissue in chronic Graft versus Host Disease (cGVHD).","Partial Response in cGVHD | Partial Response | Partial Response in chronic Graft vs Host Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641085","Less Than Partial Response in cGVHD","C103141","Change towards improvement from the pretreatment baseline, but not meeting the criteria for Complete Response or Partial Response in chronic Graft versus Host Disease (cGVHD).","Less Than Partial Response in cGVHD | Less Than Partial Response in chronic Graft vs Host Disease | Response is Less Than Partial Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538874","Stable chronic Graft vs Host Disease","C103142","No change in chronic Graft versus Host Disease (cGVHD) progression during the preceding 3 months.","Stable cGVHD | Stable Disease | Stable chronic Graft vs Host Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540542","Exacerbation of cGVHD","C103143","A worsening of chronic Graft versus Host Disease (cGVHD) manifestations during withdrawal of immunosuppressive therapy which does not exceed those at the beginning of the trial and improves after reinstatement of previous treatment.","Exacerbation of cGVHD |  Flare | Exacerbation of cGVHD | Exacerbation of chronic Graft vs Host Disease | Flare",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539781","Progressive cGVHD","C103145","Failure of therapy to control chronic Graft versus Host Disease (cGVHD).","Progressive cGVHD | Progressive Disease | Progressive chronic Graft vs Host Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641086","Mixed Response in cGVHD","C103146","Improvement in some organs, but worsening in others in chronic Graft versus Host Disease (cGVHD); this is categorized as progressive disease.","Mixed Response in cGVHD | Mixed Response | Mixed Response in chronic Graft vs Host Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022864","Birthing Labor","C92743","Uterine contractions resulting in cervical change (dilation and/or effacement). (reVITALize)","Birthing Labor | Labor",,,,,,,,,,,,,,,"4124667","Labor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2984677","Device Impedance Testing Evaluation Method","C91944","Testing the resistance to current flow in a device's circuit or component.","Device Impedance Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984652","Device Electrical Evaluation Method","C91919","A test that evaluates the functioning of a device's electrical systems.","Device Electrical Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706360","Oximeter Device","C50065","A device designed to measure oxygen saturation in arterial blood.","Oximeter Device | Oximeter Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700590","Diaphoresis","C35051","Profuse sweating.","Diaphoresis | ",,,,,,,,,,,,,,,"4203638","Excessive sweating",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0231835","Tachypnea","C50767","Abnormal increase of rate of breathing.","Tachypnea | Fast Breathing | Increased Respiratory Rate | tachypnea",,,,,,,,,,,,,,,"317376","Tachypnea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641081","Anaerobic","C103137","A chemical process that does not require oxygen or occurs in the absence of oxygen.","Anaerobic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825125","Caulophyllum thalictroides Root","C72494","A herbal remedy derived from the root of the perennial flowering plant Caulophyllum thalictroides grown in the eastern North America. Blue cohosh root contains a variety of compounds, including the alkaloid N-methylcytisine and the saponin caulosaponin. Blue Cohosh is typically in the form of a tincture or a decoction.","Caulophyllum thalictroides Root | Beech Drops | Blue Cohosh Root | Blue Ginseng | Blueberry Root | CAULOPHYLLUM THALICTROIDES ROOT | Papoose Root | Yellow Ginseng",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537343","Sphingosine 1-Phosphate Receptor 1, Human","C102500","Sphingosine 1-phosphate receptor 1 (382 aa, ~43 kDa) is encoded by the human S1PR1 gene. This protein plays a role in phospholipid binding.","Sphingosine 1-Phosphate Receptor 1 | Antigen CD363 | CD363 | CD363 Antigen | Endothelial Differentiation G-Protein Coupled Receptor 1 | S1P Receptor 1 | S1P Receptor Edg-1 | S1P1 | Sphingosine 1-Phosphate Receptor Edg-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273725","Immunocytokine NHS-IL12","C97961","A fusion protein consisting of the heavy-chains of the human antibody NHS76, raised against DNA released by necrotic tumor cells, and fused to two molecules of a genetically modified human interleukin-12 (IL-12) with potential immunostimulating and antineoplastic activities. Upon administration, the antibody moiety of immunocytokine NHS-IL12 binds to DNA released from necrotic tumor cells located primarily at the core of necrotic solid tumors, thereby delivering the IL-12 moiety. In turn, the IL-12 moiety of this agent stimulates the host immune system to mount an immune response against tumor cells, thereby inhibiting tumor growth. IL-12 is a proinflammatory cytokine with numerous immunoregulatory functions and may augment host immune responses to tumor cells. By targeting tumor cells, NHS-IL-12 may reduce the toxicity associated with systemic administration of recombinant human IL-12.","Immunocytokine NHS-IL12 | IMMUNOCYTOKINE NHS-IL12 | M-9241 | M9241 | NHS-IL-12 | NHS-IL12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4045305","Anetumab Ravtansine","C98293","A fully human IgG1 monoclonal antibody directed against the cell surface glycoprotein mesothelin and conjugated to the maytansinoid DM4 with potential antineoplastic activity. The monoclonal antibody moiety of anetumab ravtansine targets and binds to the tumor associated antigen mesothelin; upon internalization, the DM4 moiety binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of mesothelin-expressing tumor cells. Mesothelin is overexpressed on all mesotheliomas as well as many ovarian and pancreatic cancers while minimally expressed on normal tissue.","Anetumab Ravtansine | ANETUMAB RAVTANSINE | Anti-mesothelin Antibody-Drug Conjugate BAY 94-9343 | BAY 94-9343",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1269175","Staphylococcus capitis","C86752","A species of facultatively anaerobic, Gram positive, cocci shaped bacteria in the phylum Firmicutes. This species is catalase positive, and negative for alkaline phosphatase, urease, oxidase and coagulase. It is able to ferment glucose, fructose, lactose, trehalose, glycerol, and mannitol, but not arabinose, sucrose, xylose, turanose, xylitol, rhamnose, or maltose. S. capitis is part of the human skin flora but is a pathogen that can cause pneumonia, urinary tract infection, catheter related bacteremia, cellulitis, and endocarditis.","Staphylococcus capitis | STAPHYLOCOCCUS CAPITIS",,,,,,,,,,,,,,,"4222739","Staphylococcus capitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2936597","Human Papillomavirus-31","C102904","A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-31 is associated with a high risk for cervical intraepithelial neoplasia.","Human Papillomavirus-31 | 31 | HPV 31 | HPV-31 | HPV31 | HUMAN PAPILLOMAVIRUS TYPE 31 | Human Papillomavirus 31 | Human Papillomavirus Type 31 | Human papillomavirus 31",,,,,,,,,,,,,,,"37158814","Human papillomavirus type 31",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1645198","Human Papillomavirus-26","C102995","A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-26 may be associated with a high risk for cervical intraepithelial neoplasia.","Human Papillomavirus-26 | 26 | Alphapapillomavirus 5 | HPV-26 | HPV26 | Human Papillomavirus Type 26",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641011","Human Papillomavirus-33","C102996","A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-33 is associated with a high risk for cervical intraepithelial neoplasia.","Human Papillomavirus-33 | 33 | HPV 33 | HPV-33 | HPV33 | HUMAN PAPILLOMAVIRUS TYPE 33 | Human Papillomavirus 33 | Human Papillomavirus Type 33 | Human papillomavirus 33",,,,,,,,,,,,,,,"37158815","Human papillomavirus type 33",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641012","Human Papillomavirus-35","C102997","A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-35 is associated with a high risk for cervical intraepithelial neoplasia.","Human Papillomavirus-35 | 35 | HPV 35 | HPV-35 | HPV35 | HUMAN PAPILLOMAVIRUS TYPE 35 | Human Papillomavirus Type 35 | Human papillomavirus 35",,,,,,,,,,,,,,,"37158816","Human papillomavirus type 35",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641013","Human Papillomavirus-39","C102998","A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-39 is associated with a high risk for cervical intraepithelial neoplasia.","Human Papillomavirus-39 | 39 | HPV 39 | HPV-39 | HPV39 | HUMAN PAPILLOMAVIRUS TYPE 39 | Human Papillomavirus Type 39 | Human papillomavirus 39",,,,,,,,,,,,,,,"37158817","Human papillomavirus type 39",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641014","Human Papillomavirus-45","C102999","A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-45 is associated with a high risk for cervical intraepithelial neoplasia.","Human Papillomavirus-45 | 45 | HPV 45 | HPV-45 | HPV45 | HUMAN PAPILLOMAVIRUS TYPE 45 | Human Papillomavirus Type 45 | Human papillomavirus 45",,,,,,,,,,,,,,,"37158818","Human papillomavirus type 45",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641015","Human Papillomavirus-51","C103000","A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-51 is associated with a high risk for cervical intraepithelial neoplasia.","Human Papillomavirus-51 | 51 | HPV 51 | HPV-51 | HPV51 | HUMAN PAPILLOMAVIRUS TYPE 51 | Human Papillomavirus Type 51 | Human papillomavirus 51",,,,,,,,,,,,,,,"37158819","Human papillomavirus type 51",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641016","Human Papillomavirus-52","C103001","A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-52 is associated with a high risk for cervical intraepithelial neoplasia.","Human Papillomavirus-52 | 52 | HPV 52 | HPV-52 | HPV52 | HUMAN PAPILLOMAVIRUS TYPE 52 | Human Papillomavirus Type 52 | Human papillomavirus 52",,,,,,,,,,,,,,,"37158820","Human papillomavirus type 52",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1629153","Human Papillomavirus-53","C103002","A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-53 may be associated with a high risk for cervical intraepithelial neoplasia.","Human Papillomavirus-53 | 53 | Alphapapillomavirus 6 | HPV 53 | HPV-53 | HPV53 | HUMAN PAPILLOMAVIRUS TYPE 53 | Human Papillomavirus Type 53",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641017","Human Papillomavirus-56","C103003","A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-56 is associated with a high risk for cervical intraepithelial neoplasia.","Human Papillomavirus-56 | 56 | HPV 56 | HPV-56 | HPV56 | HUMAN PAPILLOMAVIRUS TYPE 56 | Human Papillomavirus Type 56 | Human papillomavirus 56",,,,,,,,,,,,,,,"37158821","Human papillomavirus type 56",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641018","Human Papillomavirus-58","C103004","A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-58 is associated with a high risk for cervical intraepithelial neoplasia.","Human Papillomavirus-58 | 58 | HPV 58 | HPV-58 | HPV58 | HUMAN PAPILLOMAVIRUS TYPE 58 | Human Papillomavirus Type 58 | Human papillomavirus 58",,,,,,,,,,,,,,,"37158822","Human papillomavirus type 58",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641019","Human Papillomavirus-59","C103005","A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-59 is associated with a high risk for cervical intraepithelial neoplasia.","Human Papillomavirus-59 | 59 | HPV 59 | HPV-59 | HPV59 | HUMAN PAPILLOMAVIRUS TYPE 59 | Human Papillomavirus Type 59 | Human papillomavirus 59",,,,,,,,,,,,,,,"37158823","Human papillomavirus type 59",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641020","Human Papillomavirus-66","C103006","A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-66 is associated with a high risk for cervical intraepithelial neoplasia.","Human Papillomavirus-66 | 66 | HPV 66 | HPV-66 | HPV66 | HUMAN PAPILLOMAVIRUS TYPE 66 | Human Papillomavirus Type 66 | Human papillomavirus 66",,,,,,,,,,,,,,,"37154569","Human papillomavirus type 66",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641021","Human Papillomavirus-68","C103007","A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-68 may be associated with a high risk for cervical intraepithelial neoplasia.","Human Papillomavirus-68 | 68 | HPV 68 | HPV-68 | HPV68 | HUMAN PAPILLOMAVIRUS TYPE 68 | Human Papillomavirus Type 68 | Human papillomavirus 68",,,,,,,,,,,,,,,"37154570","Human papillomavirus type 68",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641022","Human Papillomavirus-73","C103008","A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-73 may be associated with a high risk for cervical intraepithelial neoplasia.","Human Papillomavirus-73 | 73 | HPV-73 | HPV73 | Human Papillomavirus Type 73",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641023","Human Papillomavirus-82","C103009","A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-82 may be associated with a high risk for cervical intraepithelial neoplasia.","Human Papillomavirus-82 |  HPV-82 |  HPV82 | 82 | HPV-82 | HPV82 | Human Papillomavirus Type 82",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937291","Chemo/immuno/hormone Therapy Regimen","C62634","Any regimen that can be used for the treatment of cancer and non-neoplastic disease.","Chemo/immuno/hormone Therapy Regimen | Chemotherapy Regimen | Chemotherapy/Chemoimmunotherapy Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449006","Prothrombin","C82854","Prothrombin (622 aa, ~70 kDa) is encoded by the human F2 gene. This protein plays a role in both coagulation and proteolysis of fibrinogen.","Prothrombin | Coagulation Factor II | EC 3.4.21.5 | F2 | Factor II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0254781","3-chlorotyrosine","C103150","A specific biomarker of hypochlorous acid (HClO), the oxidation product of myeloperoxidase (MPO). Under oxidative stress, 3-chlorotyrosine is produced in proteins with tyrosine residues by the strong oxidant HClO. HClO which is formed at sites of inflammation is also the anti-bacterial molecule produced by neutrophils through MPO-catalyzed oxidation. MPO is a heme-containing enzyme secreted by activated neutrophils and monocytes; it is the only enzyme that produces HClO. Therefore, 3-chlorotyrosine can potentially be used to help determine the extent of neutrophilic inflammation.","3-Chlorotyrosine | 3-CHLOROTYROSINE | 3-Chloro-L-Tyrosine | Chlorotyrosine | Cl-Tyr | L-(8CI)-3-Chloro-Tyrosine | Monochlorotyrosine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036001","S-Adenosylhomocysteine","C103149","An amino acid derivative and an intermediate in the synthesis of cysteine and adenosine. S-adenosylhomocysteine (SAH) is formed upon S-adenosylmethionine (SAM)-dependent methylation (homocysteine methionine cycle) of biological molecules, such as DNA, RNA, and proteins. It is then hydrolyzed by S-adenosylhomocysteine hydrolase to form adenosine and homocysteine. As SAH modulates methylation dependent reactions, SAH levels and the ratio of SAH:SAM may be used to assess methylation status of macrocolecules.","S-Adenosylhomocysteine | (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine | AdoHCy | S-ADENOSYL-L-HOMOCYSTEINE | S-Adenosyl-L-homocysteine | SAH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641090","Hematopoietic Cell Transplant Relapse Low Risk Rate","C103153","Risk of hematopoietic cell transplant relapse rates per patient year with p value between 0.00 and 0.24.","Hematopoietic Cell Transplant Relapse Low Risk Rate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641091","Hematopoietic Cell Transplant Relapse Standard Risk Rate","C103154","Risk of hematopoietic cell transplant relapse rates per patient year with p value between 0.26 and 0.37.","Hematopoietic Cell Transplant Relapse Standard Risk Rate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641092","Hematopoietic Cell Transplant Relapse High Risk Rate","C103155","Risk of hematopoietic cell transplant relapse rates per patient year with p value higher than 0.52.","Hematopoietic Cell Transplant Relapse High Risk Rate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641089","Hematopoietic Cell Transplant Relapse","C103152","Recurrence of malignancy following hematopoietic cell transplantation, based on one or more of the following parameters: marrow morphology, flow cytometry, cytogenetic studies, including fluorescence in situ hybridization, electrophoresis, immunofixation assays, and polymerase chain reaction-based assays for disease markers, or imaging results.","Hematopoietic Cell Transplant Relapse | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522555","TK1 protein, human","C38512","Thymidine kinase, cytosolic (234 aa, ~25 kDa) is encoded by the human TK1 gene. This protein plays a role in pyrimidine metabolism.","Thymidine Kinase, Cytosolic | Cytosolic Thymidine Kinase | EC 2.7.1.21 | Soluble Thymidine Kinase 1 | TK1 | Thymidine Kinase 1 | Thymidine Kinase 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0897751","sphingosine kinase-1","C92513","Sphingosine kinase 1 (384 aa, ~43 kDa) is encoded by the human SPHK1 gene. This protein plays a role in the phosphorylation of sphingosine.","Sphingosine Kinase 1 | EC 2.7.1.91 | SK 1 | SPHK1 | SPK 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985736","Change Reason","C93529","The rationale for why an entity or event is changed.","Change Reason | MOD_REASON | changeReason",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985898","Type Code","C93698","A coded value specifying an identifiable class of an entity or activity based on common qualities.","Type Code | typeCode",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825517","Interpolation Imputation Technique","C81208","The substitution of missing data with an estimated value that falls between known data points.","Interpolation Imputation Technique | INTERP | Interpolation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639994","Discordance","C101125","A lack of agreement of findings.","Discordance | Discordant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985867","Role Code","C93666","A coded value specifying the type of responsibility of an entity.","Role Code | roleCode",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705858","Frame","C49963","A structure designed to support or contain an object.","Frame Device | Frame | Frame Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1540291","CD248 Gene","C78157","This gene may play a role in angiogenesis.","CD248 Gene | CD248 | CD248 Molecule, Endosialin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413933","DCT Gene","C82885","This gene is involved in melanin biosynthesis.","DCT Gene | DCT | Dopachrome Tautomerase (Dopachrome Delta-Isomerase, Tyrosine-Related Protein 2) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697963","MGMT Methylation Assay","C79101","An assay to determine the pattern of methylation in the promoter of the MGMT gene. Aberrant methylation of the MGMT promoter is associated with squamous cell carcinoma.","MGMT Methylation Assay | MGMT Methylation Status | MGMT Promoter Methylation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0132638","Killer Cell Lectin-Like Receptor Subfamily B Member 1, Human","C26477","Killer cell lectin-like receptor subfamily B member 1 (225 aa, ~25 kDa) is encoded by the human KLRB1 gene. This protein plays a role in the modulation of natural killer cell cytotoxicity.","Killer Cell Lectin-Like Receptor Subfamily B Member 1 | C-Type Lectin Domain Family 5 Member B | CD161 | CD161 Antigen | KLRB1 | Killer Cell Lectin-Like Receptor Subfamily B, Member 1 | Killer Cell Lectin-Like Receptor Subfamily B, Member 1 Protein | NKR | NKR-P1 | NKR-P1A | NKRP1A Protein | Natural Killer Cell Surface Protein P1A | hNKR-P1A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1259013","Interleukin-2 Receptor Subunit Beta, Human","C26267","Interleukin-2 receptor subunit beta (551 aa, ~61 kDa) is encoded by the human IL2RB gene. This protein is involved in signal transduction-mediated by and receptor mediated endocytosis of interleukin-2.","Interleukin-2 Receptor Subunit Beta | CD122 | CD122 Antigen | High Affinity IL-2 Receptor Beta Subunit | High Affinity IL-2 Receptor Subunit Beta | IL-2 Receptor Subunit Beta | IL-2R Subunit Beta | IL-2RB | IL2 Receptor Beta | IL2 Receptor Beta | IL2RB | Interleukin 2 Receptor Beta | Interleukin-2 Receptor Beta Chain | Intermediate Affinity Interleukin 2 Receptor Beta Subunit | Intermediate Affinity Interleukin 2 Receptor Subunit Beta | Medium Affinity Interleukin 2 Receptor Beta Subunit | Medium Affinity Interleukin 2 Receptor Subunit Beta | P70-75 | p75",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0534157","CDKL2 protein, human","C25874","Cyclin-dependent kinase-like 2 (493 aa, ~56 kDa) is encoded by the human CDKL2 gene. This protein is involved in protein phosphorylation and signal transduction.","Cyclin-Dependent Kinase-Like 2 | CDC2-Related Kinase | CDKL2 | Cyclin-Dependent Kinase-Like 2 (CDC2-Related Kinase) | EC 2.7.11.22 | KKIAMRE | Protein Kinase p56 KKIAMRE | Serine/Threonine Protein Kinase KKIAMRE | p56 KKIAMRE Protein Kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413288","CDK7 Gene","C89764","This gene is involved in the regulation of the cell cycle and RNA polymerase II-mediated transcription.","CDK7 Gene | CDK7 | Cyclin-Dependent Kinase 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0757505","CDKL5 protein, human","C75306","Cyclin-dependent kinase-like 5 (1030 aa, ~116 kDa) is encoded by the human CDKL5 gene. This protein plays a role in protein phosphorylation.","Cyclin-Dependent Kinase-Like 5 | EC 2.7.11.22 | Serine/Threonine-Protein Kinase 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413697","CRABP1 Gene","C97195","This gene is involved in retinoic acid signaling.","CRABP1 Gene | CRABP1 | Cellular Retinoic Acid Binding Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513908","Natural History and Cofactors","C16136","Elucidation and description of disease progress","Natural History and Cofactors | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600228","Cardiopulmonary Arrest","C50483","Cessation of breathing and/or cardiac function.","Cardiopulmonary Arrest | ",,,,,,,,,,,,,,,"4256374","Cardiorespiratory arrest",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032290","Aspiration Pneumonitis","C34932","Inflammation of the lungs due to the inhalation of solid or liquid material.","Aspiration Pneumonitis | Aspiration Pneumonia | Aspiration Pneumonia",,,,,,,,,,,,,,,"4306082","Aspiration pneumonitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032183","Platelet Factor 4","C20811","Platelet factor 4 (101 aa, ~11 kDa) is encoded by the human PF4 gene. This protein is involved in the negative regulation of endothelial cell proliferation, the chemotaxis of neutrophils and monocytes and the positive regulation of blood coagulation.","Platelet Factor 4 | C-X-C Motif Chemokine 4 | CXCL4 | Chemokine (C-X-C motif) Ligand 4 | Iroplact | Oncostatin-A | PF4 | Platelet Factor-4 | Small Inducible Cytokine B4 | Small Inducible Cytokine Subfamily B, Member 4 | Small-Inducible Cytokine B4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2606206","CTSB protein, human","C18267","Cathepsin B (339 aa, ~38 kDa) is encoded by the human CTSB gene. This protein plays a role in proteolysis, immunity and the regulation of apoptosis.","Cathepsin B | APP Secretase | APPS | Amyloid Precursor Protein Secretase | CTSB | Cathepsin B1 | EC 3.4.22.1 | Preprocathepsin B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035679","RNA Polymerase II","C95948","An enzyme complex that catalyzes the transcription of DNA to produce the precursor of messenger RNA and most small nuclear RNA and microRNA transcripts.","RNA Polymerase II | POLR2 | Pol II | RNA Pol II | RNAP II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332588","Bone Morphogenetic Protein 10","C21346","Bone morphogenetic protein 10 (424 aa, ~48 kDa) is encoded by the human BMP10 gene. This protein plays a role in both signal transduction and cardiac muscle cell proliferation.","Bone Morphogenetic Protein 10 | BMP-10 | BMP10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1868219","FIP1L1/PDGFRA FUSION GENE","C99743","A fusion gene (~2.6 kb) that results from a chromosomal deletion del(4)(q12q12) which fuses the 5' half of the FIP1L1 gene to the 3' part of the PDGFRA gene. This rearrangement is associated with myeloproliferative disorders.","FIP1L1/PDGFRA Fusion Gene | FIP1L1-PDGFRA Fusion Gene | FIP1L1::PDGFRA Fusion Gene | PDGFRA/FIP1L1 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515705","t(11;14)(q13;q32)","C27490","A cytogenetic abnormality that refers to the translocation of the long arm (q13) of chromosome 11 and the long arm (q32) of chromosome 14. It results in up-regulation of cyclin D1 and is the most common translocation detected in multiple myeloma.","t(11;14)(q13;q32) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1833640","PAX8/PPARG Fusion Gene","C99365","A fusion gene that results from a chromosomal translocation t(2;3)(q13;p25) which fuses exon 7, 8 or 9 of the PAX8 gene with exons 1-6 of the PPARG gene. This rearrangement is associated with both thyroid follicular adenoma and thyroid follicular carcinoma.","PAX8/PPARG Fusion Gene | PAX8-PPARG Fusion Gene | PAX8/PPARgamma1 Fusion Gene | PAX8::PPARG Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512554","Hypermethylation","C20102","Hypermethylation appears to be a controlled, epigenetic, heritable, and aberrant DNA methylation reaction on gene promoter regions and CpG islands associated with loss of (e.g., tumor-suppressor) gene function in diverse cellular pathways through transcriptional silencing by the formation of transcriptionally repressive chromatin.","Hypermethylation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205444","Tenth","C81010","One of ten equal parts; a quantity corresponding to one tenth of the whole.","Tenth | One Tenth",,,,,,,,,,,,,,,"4151372","Tenth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085207","Gestational Diabetes","C34942","Carbohydrate intolerance first diagnosed during pregnancy.","Gestational Diabetes | Diabetes in Pregnancy | Gestational Diabetes Mellitus | Gestational Diabetes Mellitus",,,,,,,,,,,,,,,"4024659","Gestational diabetes mellitus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3273238","Regulatory Report","C97107","A type of report required by a regulatory agency.","Regulatory Report | Reg Rept | Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415481","HBB Gene","C84951","This gene plays a role in the transport of oxygen to tissues of the adult body.","HBB Gene | HBB | Hemoglobin Beta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0438215","Abnormal Laboratory Test Result","C26683","A laboratory test result that falls outside of the normal, acceptable range.","Abnormal Laboratory Test Result | Abnormal Lab Test Result | Abnormal Laboratory Test | Abnormal, NOS",,,,,,,,,,,,,,,"4012972","Laboratory test result abnormal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202143","Neopterin Measurement","C80199","The determination of the amount of neopterin present in a sample.","Neopterin Measurement | NEOPTERN | Neopterin",,,,,,,,,,,,,,,"4301896","Neopterin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516592","Classic Burkitt Lymphoma of the Mouse Hematologic System","C21917","Mature B cell, lymphoblastic, starry sky effect","Classic Burkitt Lymphoma of the Mouse Hematologic System | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709219","Neurological Deficit or Dysfunction","C50672","A finding of pathologic function within the central or peripheral nervous system, secondary to developmental abnormalities, infections, neurologic damage, or tumors.","Neurological Deficit or Dysfunction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418697","PHOX2B Gene","C97724","This gene plays a role in the regulation of transcription.","PHOX2B Gene | PHOX2B | Paired-Like Homeobox 2b Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1835417","BCR-ABL Fusion Gene","C94600","A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of the ABL1 gene. There are 3 potential products that are formed depending on which BCR exon has the breakpoint. All of the protein products have constitutively active tyrosine kinase activity. This fusion is associated with both chronic myeloid leukemia and acute lymphoblastic leukemia.","BCR/ABL1 Fusion Gene | BCR-ABL | BCR-ABL Fusion Gene | BCR-ABL Oncogene | BCR-ABL Rearrangement | BCR-ABL Translocation Mutation | BCR-ABL fusion gene | BCR-ABL1 Fusion Gene | BCR-ABL1 Translocation | BCR/ABL Translocation | BCR::ABL1 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023005","Langerhans Cell","C12584","Dendritic clear cells in the epidermis, containing distinctive granules that appear rod- or racket-shaped in section, but lacking tonofilaments, melanosomes, and desmosomes; they carry surface receptors for immunoglobulin (Fc) and complement (C3), and are believed to be antigen fixing and processing cells of monocytic origin; active participants in cutaneous delayed hypersensitivity.","Langerhans Cell | Langerhans Cells",,,,,,,,,,,,,,,"4295003","Langerhans' cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0230436","Popliteal Fossa","C103222","A diamond-shaped depression located in the back of the knee joint.","Popliteal Fossa | POPLITEAL FOSSA | Popliteal Fossa Structure | popliteal area | popliteal fossa",,,,,,,,,,,,,"UBERON:0013069","popliteal area","4138531","Popliteal fossa structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0747055","Organic","C63848","A substance relating to or containing elemental carbon or carbon compounds.","Organic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3177416","IAP inhibitor AT-406","C90574","An orally available mimetic of the natural second mitochondrial-derived activator of caspases (Smac) and inhibitor of Inhibitor of Apoptosis Proteins (IAPs), with potential immunomodulating, apoptotic-inducing, chemo-radio-sensitizing and antineoplastic activities. Upon oral administration,xevinapant targets and binds to the Smac binding groove on IAPs, including the direct caspase inhibitor X chromosome-linked IAP (XIAP), and the cellular IAPs 1 (c-IAP1) and 2 (c-IAP2). This inhibits the activities of these IAPs and promotes the induction of apoptosis. Additionally, as xevinapant inhibits the activity of IAPs, it may work synergistically with cytotoxic drugs and/or radiation to overcome tumor cell resistance to apoptosis. As IAPs regulate nuclear factor-kappa B (NFkB) signaling pathways, which drives the expression of genes involved in immune and inflammatory responses, xevinapant may enhance anti-tumor immune responses when administered with certain immunomodulating agents, such as immune checkpoint inhibitors. IAPs are overexpressed by many cancer cell types and suppress both intrinsic and extrinsic apoptosis by binding to and inhibiting active caspases via their baculoviral lAP repeat (BIR) domains. They contribute to chemo-radio-resistance of cancer cells to certain cytotoxic agents and radiation, promote tumor cell survival and are associated with poor prognosis in certain types of cancer. SMAC, a pro-apoptotic mitochondrial protein, is an endogenous inhibitor of the IAPs family of cellular proteins.","Xevinapant | AT-406 | D1143 | Debio 1143 | Debio-1143 | Debio1143 | IAP Inhibitor AT-406 | IAPs Antagonist Debio 1143 | IAPs Inhibitor Debio 1143 | Pyrrolo(1,2-a)(1,5)diazocine-8-carboxamide, n-((1,1'-biphenyl)-2-ylmethyl)decahydro-5-(((2s)-2-(methylamino)-1-oxopropyl)amino)-3-(3-methyl-1-oxobutyl)-6-oxo-, (5s,8s,10ar) | SM-406 | SMAC Mimetic Debio 1143 | SMAC Mimetic Debio 1143 | Second Mitochondrial-derived Activator of Caspases Mimetic Debio 1143 | XEVINAPANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826153","MORAb-004","C82406","A humanized IgG1 monoclonal antibody directed against human endosialin/TEM1 (tumor endothelial marker;CD248) with potential anti-angiogenic and antineoplastic activities. Ontuxizumab binds to and inhibits the activity of cell surface protein endosialin/TEM1, which may result in the inhibition of angiogenesis, tumor cell proliferation and metastasis. Endosialin/TEM1 plays a key role in angiogenesis and may be overexpressed on tumor stromal cells and endothelial cells.","Ontuxizumab | Anti-Endosialin Monoclonal Antibody MORAb-004 | Immunoglobulin G1, Anti-(Human Protein TEM1 (Tumor Endothelial Marker 1)) (Human-Mouse Monoclonal MORAb-004 Heavy Chain), Disulfide with Human-Mouse Monoclonal MORAb-004 kappa-chain, Dimer | MORAb-004 | ONTUXIZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279407","Cisplatin/Cyclophosphamide/Fluorouracil/Vincristine","C10043","No Value Exists","Cisplatin/Cyclophosphamide/Fluorouracil/Vincristine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537681","250 (qualifier value)","C69123","A natural number greater than 249 and less than 251 and the quantity that it denotes.","Two Hundred Fifty | 250",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008073","Developmental Disorder","C89330","A disorder diagnosed in childhood that is marked by either physical or mental impairment or both, which in turn affects the child from achieving age related developmental milestones.","Developmental Disorder | ",,,,,,,,,,,,,,,"435244","Developmental disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334804","Motor Manifestations","C5039","The presence of an alteration in the ability to move one's body or any body parts in accordance with one's intent.","Motor Manifestations | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641146","Photoacoustic Spectroscopy","C103229","The technique of measuring the effect of absorbed electromagnetic energy on solids, liquids and gases through detection of the acoustic waves released from the absorbing material.","Photoacoustic Spectroscopy | Photoacoustic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1310906","interleukin-8 converting enzyme, human","C17277","Cathepsin L1 (333 aa, ~38 kDa) is encoded by the human CTSL gene. This protein is involved in both proteolysis and immunity.","Cathepsin L1 | CATL | CTSL | CTSL Protein | Cathepsin L | EC 3.4.22.15 | MEP | Major Excreted Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0284930","CTSK protein, human","C90322","Cathepsin K (329 aa, ~37 kDa) is encoded by the human CTSK gene. This protein is involved in proteolysis.","Cathepsin K | CTSK | Cathepsin O | Cathepsin O2 | Cathepsin X | EC 3.4.22.38",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515670","mRNA Expression","C18888","The synthesis or transcription of messenger RNA.","mRNA Expression | Expressed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007428","Cathepsin","C16389","Lysosomal proteinases or endopeptidases that function optimally at an acidic pH to catalyze the hydrolysis of peptidic bonds. Elevated cathepsin enzyme activity in either serum or extracellular matrix is often indicative of pathological conditions such as Alzheimer's disease, several types of cancer, arthritis, and osteoporosis.","Cathepsin | CATHEPSIN | Cathepsins",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2605495","Cathepsin S, Human","C103232","Cathepsin S (331 aa, ~37 kDa) is encoded by the human CTSS gene. This protein is involved in both proteolysis and immunity.","Cathepsin S | CTSS | CTSS EC 3.4.22.27 | Cathepsin S Precursor | EC 3.4.22.27",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272892","Epstein-Barr Capsid IgM Antibody Measurement","C96601","The determination of the amount of Epstein-Barr capsid IgM antibody present in a sample.","Epstein-Barr Capsid IgM Antibody Measurement | EBCIGMAB | Epstein-Barr Capsid IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272891","Epstein-Barr Capsid IgG Antibody Measurement","C96600","The determination of the amount of Epstein-Barr capsid IgG antibody present in a sample.","Epstein-Barr Capsid IgG Antibody Measurement | EBCIGGAB | Epstein-Barr Capsid IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272893","Epstein-Barr Early Antigen Measurement","C96602","The determination of the amount of Epstein-Barr early antigen present in a sample.","Epstein-Barr Early Antigen Measurement | EBEAG | EBER | Epstein-Barr Early Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0373901","Antibody test; Epstein-Barr (EB) virus, nuclear antigen (EBNA)","C96604","The determination of the amount of Epstein-Barr nuclear antigen present in a sample.","Epstein-Barr Nuclear Antigen Measurement | EBNAG | Epstein-Barr Nuclear Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201374","Epstein-Barr Nuclear Antibody Measurement","C96603","The determination of the amount of Epstein-Barr nuclear antibody present in a sample.","Epstein-Barr Nuclear Antibody Measurement | EBNAB | Epstein-Barr Nuclear Antibody | Epstein-Barr Nuclear Antigen Antibody",,,,,,,,,,,,,,,"4279552","Epstein-Barr nuclear antibody measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL376143","Cytomegalovirus pp65-Specific Cytotoxic T Lymphocytes","C71747","Cytotoxic T lymphocytes (CTLs) specifically reactive to the cytomegalovirus (CMV) phosphoprotein pp65 with potential antiviral activity. To prepare CMV pp65-specific cytotoxic T lymphocytes in vitro, dendritic cells (DCs) are pulsed with CMV pp65 epitopes and then used to stimulate and propagate CMV pp65-specific cytotoxic T lymphocytes from peripheral blood mononuclear cells (PBMNCs); the CMV pp65-specific cytotoxic T lymphocyte population is then expanded so as to be sufficient for use in adoptive T lymphocyte therapy. When administered into a patient post-allogeneic hematopoietic stem cell transplantation, this agent may elicit a specific CTL response against CMV-infected host cells, which may result in the resolution of CMV infection. The CMV pp65 protein (65 kDa lower matrix phosphoprotein), the primary component of the enveloped subviral particle, is an immunodominant target for helper and cytotoxic T lymphocyte responses to CMV.","Cytomegalovirus pp65-Specific Cytotoxic T Lymphocytes | CMV pp65-Specific CTL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1568975","Interleukin 2 Receptor, Gamma Chain","C26266","Cytokine receptor common subunit gamma (369 aa, ~42 kDa) is encoded by the human IL2RG gene. This protein plays a role in both immune responses and interleukin signaling.","Cytokine Receptor Common Subunit Gamma | CD132 | CD132 Antigen | Common Cytokine Receptor Gamma Chain | Common Gamma Chain | GammaC | IL-2 Receptor Subunit Gamma | IL-2R Subunit Gamma | IL-2RG | IL2RG | Interleukin 2 Receptor Gamma | Interleukin 2 Receptor Gamma | Interleukin 2 Receptor, Gamma | Interleukin 2 Receptor, Gamma Chain | Interleukin-2 Receptor Subunit Gamma | p64",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002006","Aldosterone","C219","A mineralocorticoid hormone produced by aldosterone synthase (CYP11B2) in the zona glomerulosa of the adrenal cortex. Aldosterone binds to mineralocorticoid receptors (MR; NR3C2) and MR-aldosterone complexes regulate the expression of genes involved in the retention of sodium, the secretion of potassium, and water reabsorption, all of which may result increased blood pressure.","Aldosterone | (+)-Aldosterone | ALDOSTERONE | aldosterone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010124","Corticosterone","C393","A corticosteroid intermediate in the steroidogenic pathway that converts pregnenolone to aldosterone. In humans, corticosterone has limited glucocorticoid or mineralocorticoid activity.","Corticosterone | (11beta)-11,21-Dihydroxypregn-4-ene-3,20-dione | CORTICOSTERONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0933402","Lymph Node Cortex","C33029","The portion of the lymph node that contains nodules with germinal centers where B lymphocyte mature into plasma cells after activation. The nodules are separated by diffuse lymphatic tissue, lymph sinuses and trabeculae.","Lymph Node Cortex | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229703","Lymph Node Hilum","C33031","The concave side of the lymph node.","Lymph Node Hilum | LYMPH NODE HILUM",,,,,,,,,,,,,,,"4242375","Structure of hilum of lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0556150","Docosahexaenoic Acid","C68345","A polyunsaturated very long-chain fatty acid with a 22-carbon backbone and 6 double bonds. Four separate isomers can be called by this name.","Docosahexaenoic Acid | Fatty Acid 22:6",,,,,,,,,,,,,,,"4022871","Docosahexaenoic acid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0000545","Eicosapentaenoic Acid","C67080","An essential, polyunsaturated, 20-carbon omega-3 fatty acid with anti-inflammatory and potential antineoplastic and chemopreventive activities. Eicosapentaenoic acid (EPA) may activate caspase 3, resulting in apoptosis in susceptible tumor cell populations. In addition, this agent may inhibit cyclooxygenase-2 (COX-2), resulting in inhibition of prostaglandin synthesis and prostaglandin-mediated inflammatory processes.","Eicosapentaenoic Acid | All cis-5,8,11,14,17-Eicosapentaenoic Acid | EPA | Fatty Acid 20:5 | IPA | Icosapentaenoic Acid | Timnodonic Acid",,,,,,,,,,,,,,,"4028146","Eicosapentaenoic acid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641148","Decant","C103237","To transfer liquid from one container to another.","Decant | Decanted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL414840","Inner","C37980","Inside or closer to the inside of the body or object.","Inner | INNER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986524","Open Resection","C94462","Surgery to remove part or all of an organ or a tumor and nearby lymph nodes. The incision is large enough to let the surgeon see into the body.","Open Resection | open resection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0121811","HIP1 protein, human","C97539","Huntingtin-interacting protein 1 (1037 aa, ~116 kDa) is encoded by the human HIP1 gene. This protein plays a role in both clathrin-coat assembly and endocytosis.","Huntingtin-Interacting Protein 1 | HIP-1 | HIP-I | HIP1 | Huntingtin-Interacting Protein I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417054","MBL2 Gene","C68578","This gene is involved in the complement immune response pathway.","MBL2 Gene | MBL2 | Mannose-Binding Lectin (Protein C) 2, Soluble (Opsonic Defect) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011491","Deoxycytidylate Deaminase","C53621","Deoxycytidylate deaminase (178 aa, ~20 kDa) is encoded by the human DCTD gene. This protein plays a role in the conversion of deoxycytidine to deoxyuridine.","Deoxycytidylate Deaminase | DCTD Protein | Deoxycytidine Monophosphate Deaminase | dCMP Deaminase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034834","Prolactin Receptor","C17076","Prolactin receptor (622 aa, ~70 kDa) is encoded by the human PRLR gene. This protein is involved in prolactin signaling.","Prolactin Receptor | PRL-R | PRLR",,,,,,,,,,,,,,,"4085430","Prolactin receptor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1740167","Prostatic Acid Phosphatase, Human","C18015","Prostatic acid phosphatase (386 aa, ~45 kDa) is encoded by the human ACP3 gene. This protein is involved in the dephosphorylation of both lipids and tyrosine and has ecto-5'-nucleotidase activity.","Prostatic Acid Phosphatase | 5'-NT | 5'-Nucleotidase | ACP3 | ACPP | Acid Phosphatase 3 | EC 3.1.3.2 | EC 3.1.3.48 | EC 3.1.3.5 | Ecto-5'-Nucleotidase | PAP | Protein Tyrosine Phosphatase ACP3 | TMPase | Thiamine Monophosphatase | prostatic acid phosphatase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517577","Infiltrating Mixed Breast Carcinoma","C40347","An invasive breast carcinoma characterized by the presence of more than one malignant epithelial histologic pattern.","Breast Mixed Carcinoma | Infiltrating Mixed Breast Carcinoma | Invasive Breast Mixed Carcinoma | Invasive Breast Mixed Carcinoma | Invasive Mixed Breast Carcinoma | Invasive Mixed Breast Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3532429","Breast Usual Ductal Hyperplasia","C27941","A neoplastic ductal proliferative lesion of the breast characterized by the formation of secondary lumens and prominent intraductal proliferation of a heterogeneous cellular population that may include epithelial cells, myoepithelial cells, or metaplastic apocrine cells.","Breast Usual Ductal Hyperplasia | Breast Hyperplasia without Atypia | Ductal Breast Hyperplasia of Usual Type | Ordinary Intraductal Breast Hyperplasia | UDH | Usual Ductal Breast Hyperplasia | Usual Ductal Breast Hyperplasia",,,,,,,,,,,,,,,"43021121","Usual ductal hyperplasia of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882327","Percent of Predicted Value","C67217","A unit of percentage measurement for quantitative evaluation of a forecasted or presumed value against the actual observation value.","Percent of Predicted Value | % of Predicted | %{Predicted} | Percent of Predicted | percent of predicted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704300","Induced Abortion Finding","C50613","Abortion brought on intentionally.","Induced Abortion Finding | Induced Abortion",,,,,,,,,,,,,,,"4240605","Termination of pregnancy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708045","Lung Fetal Adenocarcinoma","C45509","A rare morphologic variant of lung adenocarcinoma characterized by the presence of glandular structures containing glycogen-rich cells forming tubules that resemble fetal lung tubules.","Lung Fetal Adenocarcinoma | Fetal Adenocarcinoma | Fetal Lung Adenocarcinoma | Fetal Lung Adenocarcinoma | Fetal adenocarcinoma | Pulmonary Adenocarcinoma of Fetal Type | Pulmonary Endodermal Tumor Resembling Fetal Lung | Well-Differentiated Fetal Lung Adenocarcinoma","8333/3","Fetal adenocarcinoma",,,,,,,,,,,,,"45768879","Primary fetal adenocarcinoma of lung",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C2825579","Elevated Test Result","C81326","A result of a test that is higher than a previous value or a normal range of values.","Elevated Test Result | Elevated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524447","Endorectal","C103269","Pertaining to the lumen or inner part of the rectum.","Endorectal | Transrectal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2936499","Hand Assisted Laparoscopy","C103268","A type of laparoscopic surgery where the surgeon uses both a laparoscope and his or her hand to help with dissection, retraction, and removal of tissue through a hand port incision.","Hand Assisted Laparoscopy | Hand Assisted Laparoscopic Surgery | Hand-Assisted Laparoscopy | Hand-Assisted Laparoscopy; Hand Assisted Laparoscopic Surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641165","Narrow Surgical Margin","C103267","An indication that a surgical margin is in close proximity to the excised tumor.","Narrow Surgical Margin | Close Surgical Margin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413882","CYP3A5 Gene","C46074","This gene is involved in the metabolism of fatty acids, steroids, drugs and xenobiotics. It also plays a role in the metabolism of sex hormones.","CYP3A5 Gene | CYP3A5 | Cytochrome P450 Family 3 Subfamily A Member 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0761993","ABCG2 protein, human","C21253","Broad substrate specificity ATP-binding cassette transporter ABCG2 (655 aa, ~72 kDa) is encoded by the human ABCG2 gene. This protein is involved in the transport of urate, heme, porphyrin and xenobiotics.","Broad Substrate Specificity ATP-Binding Cassette Transporter ABCG2 | ABCG2 | ATP Binding Cassette Transporter G2 | ATP-Binding Cassette Sub-Family G Member 2 | ATP-Binding Cassette Sub-Family G Member 2 | ATP-Binding Cassette, Sub-Family G, Member 2 | BCRP1 Protein | BRCP | Breast Cancer Resistance Protein | Breast Cancer Resistance Protein 1 | CD338 | CD338 Antigen | CDw338 | Mitoxantrone Resistance Protein | Mitoxantrone Resistance-Associated Protein | Mitoxantrone-Resistance Protein | Placenta Specific MDR Protein | Placenta-Specific ATP-Binding Cassette Transporter | Urate Exporter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1566695","Neurogenic Locus Notch Homolog Protein 2, Human","C97679","Neurogenic locus notch homolog protein 2 (2471 aa, ~265 kDa) is encoded by the human NOTCH2 gene. This protein plays a role in intercellular communication.","Neurogenic Locus Notch Homolog Protein 2 | NOTCH2 | Notch 2 | Notch Homolog 2 | hN2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335068","NOTCH1 protein, human","C33976","Neurogenic locus notch homolog protein 1 (2555 aa, ~273 kDa) is encoded by the human NOTCH1 gene. This protein is involved in both cell-cell signaling and cell-fate determination.","Neurogenic Locus Notch Homolog Protein 1 | NOTCH1 | Notch Homolog 1 | Notch Homolog 1 | Notch1 Preproprotein | TAN-1 | TAN1 | Translocation-Associated Notch Protein TAN-1 | hN1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0911126","Hairy, HRT1 protein","C101109","Hairy/enhancer-of-split related with YRPW motif protein 1 (304 aa, ~33 kDa) is encoded by the human HEY1 gene. This protein is involved in dimerization with transcription factors to suppress transcription.","Hairy/Enhancer-of-Split Related with YRPW Motif Protein 1 | Basic Helix-Loop-Helix Protein OAF1 | CHF-2 | Cardiovascular Helix-Loop-Helix Factor 2 | Class B Basic Helix-Loop-Helix Protein 31 | HES-Related Repressor Protein 1 | HESR-1 | HEY1 | HRT-1 | Hairy and Enhancer of Split-Related Protein 1 | Hairy-Related Transcription Factor 1 | bHLHb31 | hHRT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1504871","Placenta Growth Factor, Human","C28666","Placenta growth factor (221 aa, ~25 kDa) is encoded by the human PGF gene. This protein is involved in both angiogenesis and the positive regulation of endothelial cell growth.","Placenta Growth Factor | Isoform PlGF-3 | PGF | PLGF-2 | PlGF | PlGF-203 | Placental Growth Factor | Placental Growth Factor | Placental Growth Factor-Like",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004905","Beclomethasone","C62009","A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, beclomethasone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.","Beclomethasone | (11beta,16beta)-9-Chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)pregna-1,4-diene-3,20-dione | BECLOMETHASONE | beclomethasone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007068","Carboxymethylcellulose","C83594","A polymer and cellulose derivative that can be used as a viscosity modifier and thickener to stabilize emulsions. In medical products, carboxymethylcellulose is used as a lubricating agent in artificial tears and in wound dressings to improve wound healing.","Carboxymethylcellulose | CARBOXYMETHYLCELLULOSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008992","Clobetasol","C65339","A topical synthetic corticosteroid with anti-inflammatory, anti-pruritic, and vasoconstrictive properties. Upon topical administration, clobetasol binds to cytoplasmic glucocorticoid receptors (GRs) and activates GR-mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators. Specifically, clobetasol induces phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from membrane phospholipids by phospholipase A2. This inhibits skin inflammation, and reduces swelling, redness, itching and rashes.","Clobetasol | CLOBETASOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986953","Exponential Function","C95157","A function of the form f(x) = ab^x, characterized by the fact that the growth rate of such a function is directly proportional to the value of the function.","Exponential Function | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040338","Smokeless Tobacco","C892","Tobacco that is not smoked but used in another form such as chewing tobacco or snuff.","Smokeless Tobacco | Smoking, Tobacco and Cancer - Smokeless Tobacco",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205716","Seventh Day Adventist","C103289","A religious group of Protestant Christians whose beliefs are distinguished by the observance of Saturday as the Sabbath and by its emphasis on the imminent end of the world and second coming of Jesus Christ.","Seventh Day Adventist | ",,,,,,,,,,,,,,,"4177539","Seventh Day Adventist, follower of religion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0337757","Mormon","C103290","A religious group that identifies with the beliefs and culture of the Latter-Day Saint movement.","Mormon | LDS",,,,,,,,,,,,,,,"4028345","Church of Jesus Christ of Latter Day Saints",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0425335","Hindu","C103291","A religious group that encompasses a diverse set of beliefs and traditions that originated in the Indian subcontinent.","Hindu | ",,,,,,,,,,,,,,,"4052018","Hindu, follower of religion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1998233","Eastern Orthodox Christian","C103288","A religious group whose beliefs are based on the practices defined by the first seven ecumenical councils and whose members are located in or descended from the people of Eastern or Southeastern Europe.","Eastern Orthodox Christian | Byzantine | Eastern Orthodox | Greek Orthodox",,,,,,,,,,,,,,,"4179372","Greek Orthodox",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242220","Protestant Christian","C103287","A religious group encompassing numerous Christian denominations and a wide theological spectrum that have a common origin stemming from the Reformation which resulted in separation from the Catholic Church and its practices.","Protestant Christian | Protestant",,,,,,,,,,,,,,,"4149940","Protestant, follower of religion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242211","Roman Catholic","C103286","A religious group that has beliefs derived from the first practicing Christians and is led by the pope, or bishop of Rome.","Roman Catholic | Catholic",,,,,,,,,,,,,,,"4058123","Roman Catholic, follower of religion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026870","Muslim","C103285","A religious group that follows the words and belief system founded by the prophet Muhammad and are written in the Koran.","Muslim | Islamic",,,,,,,,,,,,,,,"4147079","Muslim, follower of religion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0587175","Buddhist","C103284","A religious group that follows the teachings of Siddhartha Gautama, who taught that the end of suffering can be achieved by eliminating the desire for material comforts.","Buddhist | ",,,,,,,,,,,,,,,"4203579","Buddhist, follower of religion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574825","Sephardic Jew","C103283","A member of the Jewish faith whose ancestors lived in North Africa, the Middle East, Portugal or Spain.","Sephardic Jew | SEPHARDIC JEW | Sephardi",,,,,,,,,,,,,,,"4201430","Sephardic Jew, follower of religion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1439273","ADRB1 Gene","C39778","This gene plays a role in neuronal G protein-coupled receptor signal transduction that modulates the physiological effects of epinephrine and norepinephrine.","ADRB1 Gene | ADRB1 | Adrenoceptor Beta 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447703","CREB1 protein, human","C38537","Cyclic AMP-responsive element-binding protein 1 (341 aa, ~37 kDa) is encoded by the human CREB1 gene. This protein plays a role in transcriptional regulation.","Cyclic AMP-Responsive Element-Binding Protein 1 | Active Transcription Factor CREB | CREB-1 | CREB1 | Transactivator Protein | cAMP Responsive Element Binding Protein 1 | cAMP-Responsive Element Binding Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1609393","SDC4 protein, human","C101433","Syndecan-4 (198 aa, ~22 kDa) is encoded by the human SDC4 gene. This protein is involved in cell surface localization of heparan sulfate.","Syndecan-4 | Amphiglycan | Ryudocan | Ryudocan Core Protein | SYND4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418596","PITX2 Gene","C75891","This gene is involved in both the development of the pancreas and transcriptional regulation.","PITX2 Gene | PITX2 | Paired-Like Homeodomain 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831985","Recombinant Human Mannose-binding Lectin","C1151","A recombinant protein similar or identical to human mannan-binding lectin (MBL) with opsonin activity. MBL, a soluble pattern recognition receptor (PRR) collectin in the C-type lectin superfamily, is a plasma protein that plays an important role in innate immunity; MBL contains a carbohydrate recognition domain at one end and a collagen-like stalk domain at the other. Upon MBL binding to mannose residues on mannose-containing polysaccharides (mannans) on the surfaces of microorganisms, activation of the complement system results in the deposition of complement components (opsonization) and the clearance of the opsonized microorganisms by phagocytic cells. MBL is part of the mannan-binding lectin pathway (also known as the Ali/Krueger pathway), which has similarities to the classical complement pathway in that activation of C4 and C2 produce activated complement proteins further down the complement cascade. However, unlike the classical complement pathway, activation of this pathway is not antibody dependent.","Mannose-Binding Lectin | MBL | MBP | Mannan-Binding Lectin | Mannose Binding Protein | Recombinant Human Mannose-binding Lectin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641166","Consent Waiver","C103270","The release from the requirement to obtain informed consent during a study that is granted by Human Subject Protection committee for a research institution for a protocol that is being reviewed by the Institutional Review Board.","Consent Waiver | Waiver Of Informed Consent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414509","F5 Gene","C91332","This gene plays a role in coagulation.","F5 Gene | Coagulation Factor V (Proaccelerin, Labile Factor) Gene | Coagulation Factor V Gene | F5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414504","F2 Gene","C82852","This gene plays a role in the coagulation cascade.","F2 Gene | Coagulation Factor II (Thrombin) Gene | F2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013765","elastin, human","C75335","Elastin (786 aa, ~68 kDa) is encoded by the human ELN gene. This protein is involved in the elasticity of the extracellular matrix.","Elastin | ELN | Tropoelastin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3850446","COMT protein, human","C16387","Catechol O-methyltransferase (271 aa, ~30 kDa) is encoded by the human COMT gene. This protein is involved in the metabolism of neurotransmitters.","Catechol O-Methyltransferase | COMT | EC 2.1.1.6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523511","Apolipoprotein E Measurement","C82002","The determination of the amount of apolipoprotein E present in a sample.","Apolipoprotein E Measurement | APOE | APOE Measurement | Apolipoprotein E",,,,,,,,,,,,,,,"4019453","Apolipoproteins E measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332773","COL1A2 Gene","C29950","This gene plays a role in the compositional regulation of several connective tissues.","COL1A2 Gene | COL1A2 | Collagen Type I Alpha 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2976741","ADRB2 protein, human","C21297","Beta-2 adrenergic receptor (413 aa, ~47 kDa) is encoded by the human ADRB2 gene. This protein is involved in both catecholamine binding and G protein-coupled receptor signaling.","Beta-2 Adrenergic Receptor | ADRB2 | ADRB2R | ADRBR | Adrenergic, Beta-2-, Receptor, Surface | B2AR | BAR | Beta-2 Adrenoceptor | Beta-2-Adrenergic Receptor | Beta-2-Adrenergic Receptor | Beta-Adrenergic Receptor | Catecholamine Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881472","Lung Cancer pN0 TNM Finding v6 and v7","C60973","Lung cancer with no evidence of metastasis to regional lymph nodes. (from AJCC 6th and 7th Eds.)","Lung Cancer pN0 TNM Finding v6 and v7 | Lung Cancer pN0 TNM Finding | Lung Cancer pN0 TNM Finding | Lung Cancer pN0 TNM Finding v6 | Lung Cancer pN0 TNM Finding v7 | pN0 | pN0 Cancer of the Lung | pN0 Carcinoma of the Lung | pN0 Lung Cancer | pN0 Lung Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881476","Lung Cancer pNX TNM Finding v6 and v7","C60972","Lung cancer in which regional lymph nodes cannot be assessed. (from AJCC 6th and 7th Eds.)","Lung Cancer pNX TNM Finding v6 and v7 | Lung Cancer pNX TNM Finding | Lung Cancer pNX TNM Finding | Lung Cancer pNX TNM Finding v6 | Lung Cancer pNX TNM Finding v7 | pNX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034821","Low-Density Lipoprotein Receptor","C17074","Low-density lipoprotein receptor (860 aa, ~95 kDa) is encoded by the human LDLR gene. This protein is involved in the endocytosis of cholesterol.","Low-Density Lipoprotein Receptor | LDL Receptor | LDLR | Low Density Lipoprotein Receptor | Low Density Lipoprotein Receptor | Low-Density Lipoprotein Receptor Class A Domain-Containing Protein 3",,,,,,,,,,,,,,,"4242218","LDL receptor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1429429","RAP1GDS1 protein, human","C97760","Rap1 GTPase-GDP dissociation stimulator 1 (607 aa, ~66 kDa) is encoded by the human RAP1GDS1 gene. This protein is involved in the mediation of guanine nucleotide exchange.","Rap1 GTPase-GDP Dissociation Stimulator 1 | Exchange Factor smgGDS | RAP1GDS1 | SMG GDS Protein | SMG P21 Stimulatory GDP/GTP Exchange Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881477","Lung Cancer pT0 TNM Finding v6 and v7","C60966","Lung cancer without any evidence of a primary tumor. (from AJCC 6th and 7th Eds.)","Lung Cancer pT0 TNM Finding v6 and v7 | Lung Cancer pT0 TNM Finding | Lung Cancer pT0 TNM Finding | Lung Cancer pT0 TNM Finding v6 | Lung Cancer pT0 TNM Finding v7 | pT0 | pT0 Cancer of the Lung | pT0 Carcinoma of the Lung | pT0 Lung Cancer | pT0 Lung Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539025","Assessment of Survivor Concerns","C103247","A brief questionnaire designed to measure fears about recurrence and health in cancer survivors.","Assessment of Survivor Concerns | ASC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641153","Worry About Future Diagnostic Tests","C103248","A question about how much an individual worries or worried about the need to have future diagnostic tests.","Worry About Future Diagnostic Tests | I Worry About Future Diagnostic Tests | I Worry About Future Diagnostic Tests",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641154","Worry About Another Type of Cancer","C103249","A question about how much an individual worries or worried about having another type of cancer.","Worry About Another Type of Cancer | I Worry About Another Type Of Cancer | I Worry About Another Type Of Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641155","Worry About My Cancer Coming Back","C103250","A question about how much an individual worries or worried about their cancer coming back.","Worry About My Cancer Coming Back | I Worry About My Cancer Coming Back | I Worry About My Cancer Coming Back",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641156","Worry About My Health","C103251","A question about how much an individual worries or worried about their health.","Worry About My Health | I Worry About My Health | I Worry About My Health | Worried About Health",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641157","Worry About My Children's Health","C103252","A question about how much an individual worries or worried about the health of their children.","Worry About My Children's Health | I Worry About My Children's Health | I Worry About My Children's Health",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2964120","In General Would You Say Your Health Is","C103254","A question about an individual's assessment of their general health.","In General Would You Say Your Health Is | In general, how would you describe your health | In general, would you say your health is",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2964121","In General Would You Say Your Quality Of Life Is","C103255","A question about an individual's assessment of their quality of life.","In General Would You Say Your Quality Of Life Is | In general, would you say your quality of life is",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2964117","In General How Would You Rate Your Physical Health","C103256","A question about an individual's rating of their physical health.","In General How Would You Rate Your Physical Health | In general, how would you rate your physical health",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2964116","In General How Would You Rate Your Mental Health Including Your Mood And Ability To Think","C103257","A question about an individual's rating of their mental health, including emotions and ability to think.","In General How Would You Rate Your Mental Health Including Your Mood And Ability To Think | In General How Would You Rate Your Mental Health | In general, how would you rate your mental health, including your mood and your ability to think",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641159","In General How Would You Rate Your Satisfaction With Your Social Activities And Relationships","C103258","A question about an individual's rating of their satisfaction with social activities and relationships.","In General How Would You Rate Your Satisfaction With Your Social Activities And Relationships | In general, how would you rate your satisfaction with your social activities and relationships",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641160","In General Please Rate How Well You Carry Out Your Usual Social Activities And Roles","C103259","A question about an individual's rating of how well they carry out their usual social activities and roles.","In General Please Rate How Well You Carry Out Your Usual Social Activities And Roles | In General Please Rate How Well You Rate You Carry Out Your Usual Social Activities And Roles | In general, please rate how well you carry out your usual social activities and roles. (This includes activities at home, at work and in your community, and responsibilities as a parent, child, spouse, employee, friend, etc)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2964546","To What Extent Are You Able To Carry Out Your Everyday Physical Activities Such As Walking Climbing Stairs Carrying Groceries Or Moving A Chair","C103260","A person's assessment of the extent to which they can carry out everyday physical activities.","To What Extent Are You Able To Carry Out Your Everyday Physical Activities Such As Walking Climbing Stairs Carrying Groceries Or Moving A Chair | To What Extent Are You Able To Carry Out Everyday Physical Activities | To what extent are you able to carry out your everyday physical activities such as walking, climbing stairs, carrying groceries, or moving a chair",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641161","In The Past 7 Days How Often Have You Been Bothered By Emotional Problems Such As Feeling Anxious Depressed Or Irritable","C103261","A question about an individual's assessment of how often they have been bothered by emotional problems in the past seven days.","In The Past 7 Days How Often Have You Been Bothered By Emotional Problems Such As Feeling Anxious Depressed Or Irritable | In The Past 7 Days How Often Have You Been Bothered By Emotional Problems | In the past 7 days, how often have you been bothered by emotional problems such as feeling anxious, depressed or irritable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641162","In The Past 7 Days How Would You Rate Your Fatigue On Average","C103262","A question about an individual's rating of the average amount of fatigue they have felt in the past seven days.","In The Past 7 Days How Would You Rate Your Fatigue On Average | In the past 7 days, how would you rate your fatigue on average",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641163","In The Past 7 Days How Would You Rate Your Pain On Average","C103263","A question about an individual's rating of the average amount of pain they have felt in the past seven days.","In The Past 7 Days How Would You Rate Your Pain On Average | In the past 7 days how bad was your pain on average | In the past 7 days, how would you rate your pain on average",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0446523","Antecubital Fossa","C103238","A triangular space on the anterior side of the elbow joint. Three main veins of the arm, the brachial artery, the medial nerve and the tendon of the biceps pass through this space.","Antecubital Fossa | ANTECUBITAL FOSSA | Antecubital Region | Cubital Fossa | Elbow Pit",,,,,,,,,,,,,,,"4348994","Surface region of antecubital fossa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3642464","Cryovial","C103245","A vial used to store specimens in a cryopreservative at very low temperatures.","Cryovial | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1700928","Endoscopic Mucosal Resection","C103242","An endoscopic procedure that visualizes a part of the gastrointestinal tract to first identify and demarcate superficial mucosal lesions, then to guide a submucosal injection to the site to lift the lesion and finally to aid in the removal of the lesion.","Endoscopic Mucosal Resection | EMR | Endoscopic Mucosal Resection (EMR)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641164","Macrodissection","C103265","A laboratory procedure where manual dissection of a frozen or fixed biospecimen block is performed to isolate a specific tissue type or cell population of interest.","Macrodissection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332860","Cauda Equina Paraganglioma","C5324","A slow-growing, well-differentiated neuroendocrine neoplasm arising from the cauda equina.","Cauda Equina Neuroendocrine Tumor | Cauda Equina Neuroendocrine Tumor (Previously Paraganglioma) | Cauda Equina Neuroendocrine Tumor/Paraganglioma | Cauda Equina Paraganglioma | Paraganglioma of Cauda Equina | Paraganglioma of Filum Terminale | Paraganglioma of the Cauda Equina | Paraganglioma of the Filum Terminale | Spinal Paraganglioma | Spinal Paraganglioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539058","Tissue Source Site","C103264","A clinical site that collects and provides patient samples and clinical metadata for research use.","Tissue Source Site | TSS | Tissue Source | Tissue Source Site (TSS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0842176","Total Proctocolectomy","C103239","Surgical removal of the entire colon, anus, and rectum.","Total Proctocolectomy | Pan-Procto Colectomy | Pan-Proctocolectomy | Panproctocolectomy",,,,,,,,,,,,,,,"37204027","Excision of entire colon and entire rectum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641151","Cryomold","C103244","A small shaped container used to create blocks of frozen specimens in a cryopreservative solution for future sectioning and microscopic analysis.","Cryomold | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449219","Brochure","C96987","A pamphlet or booklet, especially one containing summarized, descriptive, or introductory information or advertising.","Brochure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641158","PROMIS Global Health Questionnaire","C103253","A 10 question instrument designed to provide an efficient way of gathering general perceptions of health.","PROMIS Global Health Questionnaire | 10 PROMIS Global Health | PROMIS Global | PROMIS Global-10 | Ten PROMIS Global Health Questionnaire | Ten PROMIS Global Health Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475208","Titer","C67454","Concentration of a substance in a solution as determined by the quantitative reaction with added measured volume(s) of a solution of the precisely known concentration(s) of a standard reagent.","Titer | TITER | Titr | Titre | titer | titre | {Titer} | {titer}",,,,,,,,,,,,,,,"4038832","Titer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3540495","Body Image Scale","C103280","A brief questionnaire for assessing body image changes in patients with cancer.","Body Image Scale | BIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641178","Feel Self-Conscious About Appearance","C103292","A question about whether an individual feels or felt self conscious about their appearance.","Feel Self-Conscious About Appearance | Feeling Self-Conscious About Appearance | Feeling Self-Conscious About Appearance | Have you been feeling self-conscious about your appearance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438131","Feel Physically Less Attractive as Result of Disease or Treatment","C103293","A question about whether an individual feels or has felt less physically attractive as a result of their disease or treatment.","Feel Physically Less Attractive as Result of Disease or Treatment | Assessment of Physical Attractiveness of Self | Feel Less Physically Attractive Due to Disease or Treatment | Feel Physically Less Attractive as Result of Disease or Treatment | Feel Physically Less Attractive as a Result of Illness or Treatment | Have you felt less physically attractive as a result of your disease or treatment | Have you felt less physically attractive as a result of your disease or treatment? | Have you felt physically less attractive as a result of your disease and treatment | Have you felt physically less attractive as a result of your illness or treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641188","Dissatisfaction with Appearance When Dressed","C103303","A question about whether an individual is or was diissatisfied with their appearance when dressed.","Dissatisfaction with Appearance When Dressed | Have you been dissatisfied with your appearance when dressed | Have you been dissatisfied with your appearance when dressed?",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641189","Feel Less Feminine Due to Disease or Treatment","C103304","A question about whether an individual feels or felt less feminine as a result of their disease or treatment.","Feel Less Feminine Due to Disease or Treatment | Feeling Less Feminine Due to Disease or Treatment | Feeling Less Feminine Due to Disease or Treatment | Have you been feeling less feminine as a result of your disease or treatment | Have you been feeling less feminine as a result of your disease or treatment?",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641190","Difficult to Look at Self Naked","C103305","A question about whether an individual finds or found it difficult looking at themselves naked.","Difficult to Look at Self Naked | Did you find it difficult to look at yourself naked | Did you find it difficult to look at yourself naked?",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641191","Feel Less Sexually Attractive Due to Disease or Treatment","C103306","A question about whether an individual feels or felt less sexually attractive as a result of their disease or treatment.","Feel Less Sexually Attractive Due to Disease or Treatment | Feeling less sexually attractive | Have you been feeling less sexually attractive as a result of your disease or treatment | Have you been feeling less sexually attractive as a result of your disease or treatment?",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641192","Avoid People Due to Physical Appearance","C103307","A question about whether an individual avoids or has avoided people because of the way they feel about their physical appearance.","Avoid People Due to Physical Appearance | Did you avoid people because of the way you felt about your physical appearance | Did you avoid people because of the way you felt about your physical appearance?",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641194","Feel Dissatisfied with Body","C103309","A question about whether an individual is or was dissatisfied with their body.","Feel Dissatisfied with Body | Dissatisfied with Body | Have Been Dissatisfied with Body | Have you been dissatisfied with your body | Have you been feeling dissatisfied with your body | Have you been feeling dissatisfied with your body?",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641195","Dissatisfied with Appearance of Scar","C103310","A question about whether an individual is or was dissatisfied with the appearance of their scar.","Dissatisfied with Appearance of Scar | Have you been dissatisfied with the appearance of your scar | Have you been dissatisfied with the appearance of your scar?",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641201","Multidimensional Body-Self Relations Questionnaire Appearance Orientation","C103316","A well-validated, self-report inventory for the assessment of body image.","Multidimensional Body-Self Relations Questionnaire Appearance Orientation | MBSRQ | Multidimensional Body-Self Relations Questionnaire (MBSRQ) - Appearance Orientation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641202","Before Going Out in Public I Notice My Looks","C103317","A question about whether an individual notices or has noticed how they look before going out in public.","Before Going Out in Public I Notice My Looks | Before going out in public, I always notice how I look | Before going out in public, I always notice how I look.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641203","Careful to Buy Clothes that Make Me Look Good","C103318","A question about whether an individual is or was careful to buy clothes that make them look good.","Careful to Buy Clothes that Make Me Look Good | I am careful to buy clothes that will make me look my best | I am careful to buy clothes that will make me look my best.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641204","Check My Appearance in Mirror Whenever","C103319","A question about whether an individual checks or has checked their appearance using a mirror whenever they can.","Check My Appearance in Mirror Whenever | I check my appearance in a mirror whenever I can | I check my appearance in a mirror whenever I can.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641205","Before Going Out I Spend Time Preparing","C103320","A question about whether an individual spends or has spent much time getting ready before going out.","Before Going Out I Spend Time Preparing | Before going out I usually spend a lot of time getting ready | Before going out I usually spend a lot of time getting ready.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641206","Important that I Look Good","C103321","A question about whether an individual feels or felt it is important they look good.","Important that I Look Good | It is important that I always look good | It is important that I always look good.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641207","Use Very Few Grooming Products","C103322","A question about an individual's use of very few grooming products.","Use Very Few Grooming Products | I use very few grooming products | I use very few grooming products.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641208","Self-Conscious if Grooming is Wrong","C103323","A question about whether an individual is or was self-conscious if their grooming is wrong.","Self-Conscious if Grooming is Wrong | I am self-conscious if my grooming isn't right | I am self-conscious if my grooming isn't right.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641209","Wear Whatever is Handy Without Care","C103324","A question about whether an individual wears or wore whatever is handy without caring how it looked.","Wear Whatever is Handy Without Care | I usually wear whatever is handy without caring how it looks | I usually wear whatever is handy without caring how it looks.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641210","Do Not Care What Others Think of My Appearance","C103325","A question about whether an individual cares or has cared about what people think about their appearance.","Do Not Care What Others Think of My Appearance | I don't care what people think about my appearance | I don't care what people think about my appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641211","Special Care with Hair Grooming","C103326","A question about whether an individual takes or took special care with their hair grooming.","Special Care with Hair Grooming | I take special care with my hair grooming | I take special care with my hair grooming.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641212","Never Think About Appearance","C103327","A question about whether an individual never thinks or has never thought about their appearance.","Never Think About Appearance | I never think about my appearance | I never think about my appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641213","Always Trying to Improve Physical Appearance","C103328","A question about whether an individual is or was always trying to improve their physical appearance.","Always Trying to Improve Physical Appearance | I am always trying to improve my physical appearance | I am always trying to improve my physical appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641215","Breast Cancer Treatment Outcomes Scale-Cosmetic Status","C103331","A measure of perceived aesthetics after breast-conserving surgical treatment and radiotherapy.","Breast Cancer Treatment Outcomes Scale-Cosmetic Status | BCTOS | Breast Cancer Treatment Outcomes Scale (BCTOS) - Cosmetic Status | Breast Cancer Treatment Outcomes Scale - Cosmetic Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539027","Breast Size Difference Since Cancer Treatment question","C103332","A question about the difference in an individual's breast size between the treated and untreated breast since treatment for breast cancer.","Breast Size Difference Since Cancer Treatment | Breast size",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641216","Breast Texture Difference Since Cancer Treatment","C103333","A question about the difference in an individual's breast texture or hardening between the treated and untreated breast since treatment for breast cancer.","Breast Texture Difference Since Cancer Treatment | Breast texture (hardening)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539031","Nipple Appearance Difference Since Breast Cancer Treatment question","C103334","A question about whether an individual feels or felt there is a difference in nipple appearance between the treated and untreated breast since treatment for breast cancer.","Nipple Appearance Difference Since Breast Cancer Treatment | Nipple Appearance Difference Since Cancer Treatment | Nipple Appearance Difference Since Cancer Treatment | Nipple appearance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641217","Breast Shape Difference Since Cancer Treatment","C103335","A question about the difference in an individual's breast shape between the treated and untreated breast since treatment for breast cancer.","Breast Shape Difference Since Cancer Treatment | Breast shape",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641218","Breast Elevation Difference Since Cancer Treatment","C103336","A question about the difference in an individual's breast elevation between the treated and untreated breast since treatment for breast cancer.","Breast Elevation Difference Since Cancer Treatment | Breast elevation (how high the breast is)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641219","Fit of Bra Difference Since Breast Cancer Treatment","C103337","A question about whether an individual's bra fits differently between the treated and untreated breast since treatment for breast cancer.","Fit of Bra Difference Since Breast Cancer Treatment | Fit of Bra | Fit of Bra Difference Since Cancer Treatment | Fit of bra",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641220","Fit of Clothing Difference Since Breast Cancer Treatment","C103338","A question about whether an individual's clothing fits differently between the treated and untreated breast since treatment for breast cancer.","Fit of Clothing Difference Since Breast Cancer Treatment | Fit of Clothing Difference Since Cancer Treatment | Fit of clothing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539075","Pretreatment Period","C103341","The time prior to the treatment of interest.","Pretreatment Period | Pretreatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641222","Very Good","C103342","An indication that something has a high degree of quality, value or worth.","Very Good | Very good",,,,,,,,,,,,,,,"763695","Very good",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0074554","Simvastatin","C29454","A lipid-lowering agent derived synthetically from a fermentation product of the fungus Aspergillus terreus.  Hydrolyzed in vivo to an active metabolite, simvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis.  This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. (NCI04)","Simvastatin | MK 733 | SIMVASTATIN | Synvinolin | Zocor | [1S-[1alpha,3alpha,7beta,8beta(2S*,4S*),8abeta]]-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl 2,2-dimethylbutanoate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641272","Very Severe","C103457","Exceedingly intense or unpleasant in degree, quality or extent.","Very Severe | Very severe",,,,,,,,,,,,,,,"763690","Very severe",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206710","Basal Cell Neoplasm","C3784","A neoplastic proliferation of basal cells in the epidermis (part of the skin) or other anatomic sites (most frequently the salivary glands).  The basal cell neoplastic proliferation in the epidermis results in basal cell carcinomas.  The basal cell neoplastic proliferation in the salivary glands can be benign, resulting in basal cell adenomas or malignant, resulting in basal cell adenocarcinomas.","Basal Cell Neoplasm | Basal Cell Neoplasms | Basal Cell Tumor | Basal cell tumor","8090/1","Basal cell tumor",,,,,,,,,,,,,"4133295","Basal cell neoplasm (morphology)",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1529457","DRD4 protein, human","C26121","D(4) dopamine receptor (467 aa, ~48 kDa) is encoded by the human DRD4 gene. This protein is involved in G protein-coupled receptor signaling and neurotransmitter binding.","D(4) Dopamine Receptor | D(2C) Dopamine Receptor | D4DR | DRD4 | DRD4 Protein | Dopamine D4 Receptor | Dopamine Receptor D4 | Dopamine Receptor D4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333252","DRD2 2 Allele","C19810","Human DRD2 Gene at 11q23 encodes Dopamine Receptor D2, a G-protein coupled receptor that inhibits adenylyl cyclase activity. Missense mutation in DRD2 causes myoclonus dystonia; other mutations have been associated with schizophrenia. Alternative splicing results in two different isoforms. A third variant has been described, but it has not been determined whether this form is normal or due to aberrant splicing. Different alleles are associated with increased incidence of substance abuse. (NCI)","DRD2 2 Allele | DRD2 A2 Allele | Dopamine Receptor D2 A2 Allele | TaqI A2 Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333251","DRD2 1 Allele","C19799","Human DRD2 Gene at 11q23 encodes Dopamine Receptor D2, a G-protein coupled receptor that inhibits adenylyl cyclase activity. Missense mutation in DRD2 causes myoclonus dystonia; other mutations have been associated with schizophrenia. Alternative splicing results in two different isoforms. A third variant has been described, but it has not been determined whether this form is normal or due to aberrant splicing. Different alleles are associated with increased incidence of substance abuse. The A1 allele has been associated with alcoholism. (NCI)","DRD2 1 Allele | DRD2 A1 Allele | Dopamine Receptor D2 A1 Allele | TaqI A1 Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349052","Unit of Magnetic Field Strength","C68795","A unit of magnetic field strength.","Unit of Magnetic Field Strength | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512952","Intrahepatic Route of Drug Administration","C38248","Intrahepatic route of drug administration is a method of drug delivery within the liver, predominantly via hepatic vein or artery. Regimen might be more beneficial then systemic one by delivering a higher dose of drug to the liver and reducing overall systemic exposure.","Intrahepatic Route of Administration | IH | INTRAHEPATIC | Intrahepatic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710471","Tremolite Asbestos","C45530","A naturally occurring, grayish, fibrous amphibole asbestos mineral and occurs as a contaminant in chrysotile asbestos. Chronic inhalation of its dust may cause asbestosis and increases the risk of respiratory tract cancer, mesothelioma and other lung cancers. Tremolite Asbestos is a known human carcinogen. (NCI05)","Tremolite Asbestos | TREMOLITE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706702","Actinolite Asbestos","C45526","A naturally occurring, bright green, fibrous amphibole asbestos mineral found in metamorphic rocks and as a contaminant in amosite asbestos. Chronic inhalation of its dust may cause asbestosis and increases the risk of respiratory tract cancer, mesothelioma and other lung cancers. Actinolite asbestos is a known human carcinogen. (NCI05)","Actinolite Asbestos | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0056502","Crocidolite Asbestos","C29816","A naturally occurring, blue, fibrous amphibole asbestos mineral. Crocidolite is used extensively in industry for various purposes. Chronic inhalation of its dust may cause asbestosis and increases the risk of respiratory tract cancer, mesothelioma and other lung cancers. Crocidolite asbestos is a known human carcinogen. (NCI05)","Crocidolite Asbestos | CROCIDOLITE | Crocidolite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0116466","Erionite","C44382","A naturally occurring, fibrous mineral consisting of white, prismatic crystals. Erionite is one of the more common types of zeolites that are found in the earth's crust. This mineral is used as a metal-impregnated catalyst, as a fertilizer, to control odors in livestock production and is used in animal feed, pet litter and horticultural applications. Excessive inhalation of its dust can cause pulmonary fibrosis or silicatosis and prolonged exposure to erionite causes mesothelioma in humans. It is known to be a human carcinogen. (NCI05)","Erionite | Zeolite",,,,,,,,,,,,,,,"4150725","Erionite",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0051740","Amosite Asbestos","C45527","A naturally occurring, fibrous amphibole asbestos mineral with a color ranging from gray to greenish-brown. Amosite is used extensively in industry for various purposes. Chronic inhalation of its dust may cause asbestosis and increases the risk of respiratory tract cancer, mesothelioma and other lung cancers. Amosite asbestos is a known human carcinogen. (NCI05)","Amosite Asbestos | AMOSITE | Amosite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706820","Anthophyllite Asbestos","C45528","A naturally occurring, rare, fibrous amphibole asbestos mineral with a color ranging from grayish-white to green. Chronic inhalation of its dust may cause asbestosis and increases the risk of respiratory tract cancer, mesothelioma and other lung cancers. Anthophyllite asbestos is a known human carcinogen. (NCI05)","Anthophyllite Asbestos | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0055667","Chrysotile Asbestos","C45529","A naturally occurring, fibrous and silky, serpentine asbestos mineral with a color ranging from gray-white to yellow-green and is the most abundant and widely-used form of asbestos. Chrysotile is widely used in industry for various purposes. Chronic inhalation of its dust may cause asbestosis and increases the risk of digestive tract cancer, laryngeal cancer, mesothelioma and other lung cancers. Chrysotile asbestos is a known human carcinogen. (NCI05)","Chrysotile Asbestos | CHRYSOTILE | Chrysotile | White Asbestos",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0073096","Resveratrol","C1215","A phytoalexin derived from grapes and other food products with antioxidant and potential chemopreventive activities. Resveratrol induces phase II drug-metabolizing enzymes (anti-initiation activity); mediates anti-inflammatory effects and inhibits cyclooxygenase and hydroperoxidase functions (anti-promotion activity); and induces promyelocytic leukemia cell differentiation (anti-progression activity), thereby exhibiting activities in three major steps of carcinogenesis. This agent may inhibit TNF-induced activation of NF-kappaB in a dose- and time-dependent manner. (NCI05)","Resveratrol | (E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol | 3,4',5-Stilbenetriol | RESVERATROL | resveratrol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3146288","Herbal","C94319","Having to do with plants.","Herbal | herbal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335253","PRDM1 Gene","C24692","This gene is involved in repression of transcription. It plays a role in the formation of pre-plasma memory B cells and immunoglobulin-secreting plasma cells.","PRDM1 Gene | PR/SET Domain 1 Gene | PRDM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334314","KRT19 Gene","C38195","This gene plays a role in cytoskeletal regulation and the corresponding cellular morphology.","KRT19 Gene | KRT19 | Keratin 19, Type I Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414250","ECT2 Gene","C101783","This gene plays a role in both GTPase-mediated signaling and cellular stress responses.","ECT2 Gene | ECT2 | Epithelial Cell Transforming Sequence 2 Oncogene Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641319","Likert Score 1","C103506","A subjective score of 1 on a Likert scale.","Likert Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641320","Likert Score 6","C103507","A subjective score of 6 on a Likert scale.","Likert Score 6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641321","Likert Score 7","C103508","A subjective score of 7 on a Likert scale.","Likert Score 7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641322","Likert Score 8","C103509","A subjective score of 8 on a Likert scale.","Likert Score 8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641323","Likert Score 9","C103510","A subjective score of 9 on a Likert scale.","Likert Score 9 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641324","Worst Imaginable Pain","C103511","The most severe pain an individual can conceive of experiencing.","Worst Imaginable Pain | Pain as bad as you can imagine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366767","ACVRL1 Gene","C21269","This gene is involved in the mediation of cell-surface receptor interactions for the TGF-beta superfamily of ligands.","ACVRL1 Gene | ACVRL1 | Activin A Receptor, Type II-Like Kinase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2745793","Retinal Dehydrogenase 2, Human","C21330","Retinal dehydrogenase 2 (518 aa, ~57 kDa) is encoded by the human ALDH1A2 gene. This protein plays a role in retinol metabolism.","Retinal Dehydrogenase 2 | ALDH1A2 | Aldehyde Dehydrogenase 1 Family, Member A2 | Aldehyde Dehydrogenase 1A2 | Aldehyde Dehydrogenase Family 1 Member A2 | EC 1.2.1.36 | RALDH 2 | RALDH(II) | RALDH-2 | RALDH2 | RalDH2 | Retinaldehyde-Specific Dehydrogenase Type 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520649","15q26","C26386","A chromosome band present on 15q","15q26 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538917","ARAF Gene","C18354","This gene plays a role in signal transduction and the cellular response to mitogens.","ARAF Gene | A-Raf Proto-Oncogene, Serine/Threonine Kinase Gene | ARAF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1337098","BLM Gene","C20805","This gene plays a role in DNA unwinding and recombination-mediated telomere lengthening.","BLM Gene | BLM | Bloom Syndrome Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515459","8q22","C13589","A chromosome band present on 8q","8q22 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827901","Minute Times Nanomole per Milliliter","C85733","Minutes times nanomoles per milliliter.","Minute Times Nanomole per Milliliter | (umol/L).min | min*nmol/mL | min*umol/L | min.umol/L | min.umol/l | nmol*min/mL | umol*min/L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709312","Oncocytic Variant Thyroid Gland Papillary Carcinoma","C46093","A morphologic variant of papillary carcinoma of the thyroid gland characterized by the presence of papillary or follicular structures, containing malignant follicular cells with abundant granular eosinophilic cytoplasm. These cells have the nuclear features that characterize the papillary carcinomas of the thyroid gland.","Oncocytic Variant Thyroid Gland Papillary Carcinoma | Oncocytic Variant Thyroid Gland Papillary Cancer | Oxyphilic Variant Thyroid Gland Papillary Carcinoma | Papillary carcinoma, oxyphilic cell",,,,,,,,,,,,,,,"4029990","Papillary carcinoma, oxyphilic cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641608","Definitely Disagree","C103802","An unequivocal feeling of opposition.","Definitely Disagree | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641609","Mostly Disagree","C103803","A predominant feeling of opposition.","Mostly Disagree | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641610","Neither Agree or Disagree","C103804","Without concurrence or opposition.","Neither Agree or Disagree | Neutral | No Opinion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641611","Mostly Agree","C103805","A predominant feeling of concurrence.","Mostly Agree | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641612","Definitely Agree","C103806","An unequivocal feeling of concurrence.","Definitely Agree | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3282906","Intrapleural","C96907","Within the pleural cavity.","Intrapleural | intrapleural",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984520","dual PI3 kinase/mTOR inhibitor GDC-0980","C91731","An orally available agent targeting phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinase in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Apitolisib inhibits both PI3K kinase and mTOR kinase, which may result in tumor cell apoptosis and growth inhibition of cancer cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated in a PI3K-independent fashion.","Apitolisib | APITOLISIB | Dual PI3 Kinase/mTOR Inhibitor GDC-0980 | GDC 0980 | GDC-0980 | GNE 390 | RG 7422",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040061","Thromboxane","C879","Any eicosanoid with a 6-membered ether-containing ring with potential prothrombotic activity. Thromboxanes are synthesized from prostaglandin H2 by thromboxane-A synthase in activated platelets.","Thromboxane | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515445","8q","C13562","Distal (long) arm of chromosome 8","8q | Chromosome 8 Distal Arm | Chromosome 8 Long Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0312359","Macrophage Migration Inhibitory Factor","C28467","Macrophage migration inhibitory factor (115 aa, ~12 kDa) is encoded by the human MIF gene. This protein is involved in the regulation of the innate immune response.","Macrophage Migration Inhibitory Factor | EC 5.3.2.1 | EC 5.3.3.12 | Glycosylation-Inhibiting Factor | L-Dopachrome Isomerase | L-Dopachrome Tautomerase | MIF | Phenylpyruvate Tautomerase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421564","YWHAZ Gene","C88202","This gene is involved in both interactions with phosphoproteins and signal transduction.","YWHAZ Gene | Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein, Zeta Polypeptide Gene | YWHAZ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0373704","Pregnenolone","C82315","An endogenous steroid hormone synthesized from cholesterol, which can act either as a neuroactive steroid or as a prohormone for progestogens, mineralocorticoids, glucocorticoids, androgens, estrogens, and the neuroactive steroids.","Pregnenolone | 3beta-Hydroxypregn-5-en-20-one | 5-Pregnen-3-beta-ol-20-one | Arthenolone | Bina-Skin | Enelone | Natolon | Natolone | PREGNENOLONE | Regnosone | Skinostelon | delta5-Pregnenolone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2937276","Slight","C103807","Small or little in size, quantity, or degree.","Slight | Slightly",,,,,,,,,,,,,,,"4115447","Slight",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0212320","Core-Binding Factor","C17683","CBF is an alpha/beta heterodimeric transcription factor involved in the transcriptional regulation of several genes important in hematopoiesis.  The CBFalpha subunit binds directly to the enhancer core DNA sequence on target genes, whereas the beta subunit does not bind the DNA directly but increases the affinity and stabilizes the binding of the alpha subunit to the DNA.","Core-Binding Factor | CBF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708127","GM-K562 Cell Vaccine","C52190","A cell-based vaccine comprised of K562 cells transfected with the granulocyte macrophage-colony stimulating factor (GM-CSF) gene with potential immunopotentiating properties. Vaccination with GM-K562 cells may stimulate the host immune system to produce an antitumoral T-lymphocyte response, thereby inhibiting tumor growth. K562 cells are derived from the human erythroleukemia cell line K562. GM-CSF (also known as sagramostim) expressed by vaccine cells binds to specific cell surface receptors, modulating the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production. GM-CSF also promotes antigen presentation, up-regulates antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function; it may also augment host antitumoral immunity.","GM-K562 Cell Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0257001","Plerixafor","C1777","A bicyclam with hematopoietic stem cell-mobilizing activity. Plerixafor blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation.","Plerixafor | 1,1'-[1,4-Phenylenebis(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane | AMD 3100 | AMD-3100 | AMD3100 | JM-3100 | Mozobil | PLERIXAFOR | SDZ SID 791 | plerixafor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0073633","Ranolazine","C66507","An orally available, piperazine derivative with anti-anginal and potential antineoplastic activities. Ranolazine's mechanism of action for its anti-ischemic effects has yet to be fully elucidated but may involve the alteration of the trans-cellular late sodium current in the ischemic myocyte. By preventing the rise of intracellular sodium levels, ranolazine may affect the transport activity of sodium-dependent calcium channels and prevent the calcium overload during myocardial ischemia, thereby preventing cellular injury. Ranolazine's potential antineoplastic effect may depend on its inhibitory effect on fatty acid oxidation, which may sensitize tumor cells to apoptosis and decrease tumor cell proliferation; fatty acid oxidation provides energy and promotes tumor cell proliferation and survival.","Ranolazine | 1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-(2-hydroxy- 3-(2-methoxyphenoxy)propyl)- | RANOLAZINE | Ranexa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1566537","Ranibizumab","C67562","A second-generation, recombinant humanized IgG1 kappa monoclonal antibody fragment directed against human vascular endothelial growth factor (VEGF) alpha. Ranibizumab binds to VEGF alpha and inhibits VEGF alpha binding to its receptors, VEGFR1 and VEGFR2, thereby preventing the growth and maintenance of tumor blood vessels. The molecular weight of this agent (48 kD) is much smaller than the molecular weight of bevacizumab (MW ~149 kD), allowing complete penetration of the retina and the subretinal space following intravitreal injection. In contrast to other anti-VEGF aptamers such as pegaptanib, ranibizumab has a high specificity and affinity for all soluble human isoforms of VEGF.","Ranibizumab | Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor) Fab Fragment (Human-Mouse Monoclonal rhuFab V2 Gamma1 Chain), Disulfide With Human-Mouse Monoclonal rhuFab V2 Light Chain | Lucentis | RANIBIZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706409","Implanted Port Access Device","C50111","A device designed for the introduction of fluid to or removal of fluid from a system; also an electronic circuit that acts as a connection to an outside device.","Implanted Port Access Device | Port | Port Device | Port Device Component | port",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0165949","Antigen Peptide Transporter 2, Human","C21579","Antigen peptide transporter 2 (686 aa, ~76 kDa) is encoded by the human TAP2 gene. This protein is involved in MHC class I protein folding and antigen presentation.","Antigen Peptide Transporter 2 | ABC Transporter, MHC 2 | APT2 | ATP-Binding Cassette Sub-Family B Member 3 | ATP-Binding Cassette, Sub-Family B, Member 3 | PSF-2 | Peptide Supply Factor 2 | Peptide Transporter Involved In Antigen Processing 2 | Peptide Transporter PSF2 | Peptide Transporter TAP2 | Really Interesting New Gene 11 Protein | TAP2 | Transporter 2, ABC (ATP Binding Cassette) | Transporter 2, ATP-Binding Cassette, Sub-Family B | Transporter 2, ATP-Binding Cassette, Sub-Family B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0140599","Antigen Peptide Transporter 1, Human","C21574","Antigen peptide transporter 1 (808 aa, ~87 kDa) is encoded by the human TAP1 gene. This protein plays a role in cytoplasmic antigen transport and subsequent presentation by MHC class I molecules.","Antigen Peptide Transporter 1 | ABC Transporter, MHC 1 | APT1 | ATP-Binding Cassette Sub-Family B Member 2 | ATP-Binding Cassette, Sub-Family B, Member 2 | PSF-1 | Peptide Supply Factor 1 | Peptide Transporter Involved In Antigen Processing 1 | Peptide Transporter PSF1 | Peptide Transporter TAP1 | Really Interesting New Gene 4 Protein | TAP1 | Transporter 1, ATP-Binding Cassette, Sub-Family B | Transporter 1, ATP-Binding Cassette, Sub-Family B | Transporter Associated With Antigen Processing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054869","CTSH protein, human","C17276","Pro-cathepsin H (335 aa, ~37 kDa) is encoded by the human CTSH gene. This protein plays a role in both degradation of proteins in the lysosome and antigen processing.","Cathepsin H | Aleurain | CPSB | CTSH | CTSH Protein | Cathepsin B3 | Cathepsin BA | EC 3.4.22.16 | MGC1519 | N-Benzoylarginine-Beta-Naphthylamide Hydrolase | Pro-Cathepsin H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0763658","BIRC3 protein, human","C20946","Baculoviral IAP repeat-containing protein 3 (604 aa, ~68 kDa) is encoded by the human BIRC3 gene. This protein is involved in the inhibition of apoptosis.","Baculoviral IAP Repeat-Containing Protein 3 | API2 | Apoptosis Inhibitor 2 | BIRC3 | C-IAP2 | Cellular Inhibitor of Apoptosis-2 | EC 2.3.2.27 | HIAP-1 | HIAP1 | Human Inhibitor of Apoptosis Protein-1 | IAP Homolog C | Inhibitor Of Apoptosis Protein 1 | Inhibitor ff Apoptosis Protein 1 | Mammalian IAP Homolog C | RING Finger Protein 49 | RING-Type E3 Ubiquitin Transferase BIRC3 | TNFR2-TRAF Signaling Complex Protein | TNFR2-TRAF-Signaling Complex Protein 1 | hIAP-1 | hIAP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1134655","NA17-A Antigen","C37450","A specific melanoma antigen protein derived from a patient (NA17) with cutaneous melanoma metastases. When administered in a vaccine formulation, NA17-A antigen may stimulate a cytotoxic T lymphocyte (CTL) response against tumors that express this antigen, which may result in a reduction in tumor size. The NA17-A antigen is part of the enzyme N-acetyl glucosaminyltransferase V (GnT-V). Approximately half of melanomas have been found to express significant levels of this atypical protein, which is not expressed by normal tissues.","NA17-A Antigen | NA17-A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0067113","Nitrosonornicotine","C44414","A yellow, oily liquid nitrosamine that solidifies at cold temperatures and emits toxic fumes of nitrogen oxides when heated to decomposition. Nitrosonornicotine is found in tobacco products and is likely produced by the nitrosation of nicotine during the making and smoking of tobacco products. This substance is only used in research to induce tumors in experimental animals. Exposure to nitrosonornicotine affects the liver and nitrosonornicotine is reasonably anticipated to be a human carcinogen. (NCI05)","Nitrosonornicotine | (S)-N'-nitrosonornicotine | 1'-Demethyl-1'-nitroso-nicotine | 1'-Nitrosonornicotine | 3-(1-Nitroso-2-pyrrolidinyl)pyridine | N-NITROSONORNICOTINE | N-nitrosonornicotine | NNN | anti-N'-nitrosonornicotine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079349","fibroblast growth factor-1","C20548","Fibroblast growth factor 1 (17 aa, ~155 kDa) is encoded by the human FGF1 gene. This protein plays a role in cell proliferation, angiogenesis, cell differentiation, and cell migration.","Fibroblast Growth Factor 1 | Acidic Fibroblast Growth Factor | Alpha Fibroblast Growth Factor | Beta-Endothelial Cell Growth Factor | ECGF | Endothelial Cell Growth Factor | Endothelial Cell Growth Factor, Alpha | Endothelial Cell Growth Factor, Beta | FGF-1 | FGF1 | HBGF-1 | Heparin Binding Growth Factor 1 | Heparin Binding Growth Factor-1 | Prostatropin | aFGF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017837","Glutathione S-Transferase","C16641","A class of enzymes that catalyze the reaction of glutathione with an acceptor molecule (an arene oxide) to form an S-substituted glutathione; a key step in detoxification of many substances; start of the mercapturic acid pathway.","Glutathione S-Transferase | EC 2.5.1.18 | GST | Glutathione S-Alkyltransferase | Glutathione S-Aralkyltransferase | Glutathione S-Aryltransferase | S-(Hydroxyalkyl)Glutathione Lyase | glutathione S-transferase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413132","CASP3 Gene","C26574","This gene plays a role in the execution phase of apoptosis and is involved in DNA repair.","CASP3 Gene | CASP3 | Caspase 3, Apoptosis-Related Cysteine Peptidase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812235","RHOB Gene","C18357","This gene plays a role in signal transduction. It is involved in several cellular functions including cell adhesion, differentiation and motility.","RHOB Gene | RAS Homolog Family Member B Gene | RHOB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332167","High Risk","C102401","The potential future harm that may arise from some present action or attribute or condition is almost certain.","High Risk | HIGH RISK",,,,,,,,,,,,,,,"37109703","High risk",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0060836","Fumonisin B1","C1107","A mycotoxin produced by Fusarium moniliforme.  It is a contaminant of cereals, especially corn.  It has been epidemiologically linked to high incidence of human esophageal cancer in South Africa and China and to hepatocarcinogenesis in animal models.","Fumonisin B1 | FB1 | FUMONISIN B1 | Fumonisin B(1) | Macrofusine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085180","Aflatoxin B1","C1315","A member of a group of mycotoxins produced by Aspergillus flavus and A. parasiticus. Alflatoxin B1 is the most hepatotoxic and hepatocarcinogenic of the aflatoxins and occurs as a contaminant in a variety of foods.","Aflatoxin B1 | (6AR-cis)-2,3,6a,9a-tetrahydro-4-methoxycyclopenta(c)furo(3',2':4,5)furo(2,3-h)(1)benzopyran-1,11-dione | AFB1 | AFLATOXIN B1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1337025","XRCC3 protein, human","C21569","DNA repair protein XRCC3 (346 aa, ~38 kDa) is encoded by the human XRCC3 gene. This protein is involved in homologous recombination repair of double-stranded DNA..","DNA Repair Protein XRCC3 | RAD51-Like | X-Ray Repair Cross Complementing Protein 3 | X-Ray Repair Cross Complementing Protein 3 | X-Ray Repair Cross-Complementing Protein 3 | X-Ray-Repair, Complementing Defective, Repair In Chinese Hamster | XRCC3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0212694","DNA-dependent protein kinase","C21483","DNA-dependent protein kinase catalytic subunit (4128 aa, ~469 kDa) is encoded by the human PRKDC gene. This protein is involved in both DNA damage response and protein phosphorylation.","DNA-Dependent Protein Kinase Catalytic Subunit | DNA-Activated Protein Kinase Catalytic Subunit | DNA-Dependent Protein Kinase | DNA-Dependent Protein Kinase, Catalytic Subunit | DNA-PK Catalytic Subunit | DNA-PKcs | DNAPK | DNPK1 | EC 2.7.11.1 | HYRC1 | Hyper-Radiosensitivity Of Murine SCID Mutation, Complementing 1 | PRKDC | XRCC7 | p350 | p460",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1442799","LIG4 protein, human","C21463","DNA ligase 4 (911 aa, ~104 kDa) is encoded by the human LIG4 gene. This protein plays a role in non-homologous end joining during both DNA repair and V(D)J recombination.","DNA Ligase 4 | DNA Joinase | DNA Ligase IV | DNA Repair Enzyme | EC 6.5.1.1 | LIG4 | Ligase IV, DNA, ATP-Dependent | Polydeoxyribonucleotide Synthase | Polydeoxyribonucleotide Synthase 4 | Polydeoxyribonucleotide Synthase [ATP] 4 | Polynucleotide Ligase | Sealase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1702213","NHEJ1 protein, human","C88515","Non-homologous end-joining factor 1 (299 aa, ~33 kDa) is encoded by the human NHEJ1 gene. This protein is involved in both the repair of double-strand breaks in DNA and nonhomologous end-joining.","Nonhomologous End-Joining Factor 1 | NHEJ1 | Protein Cernunnos | Protein XLF | XRCC4-Like Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034135","Purine Nucleoside Phosphorylase","C43241","Purine nucleoside phosphorylase (289 aa, ~32 kDa) is encoded by the human PNP gene. This protein plays a role in purine metabolism.","Purine Nucleoside Phosphorylase | EC 2.4.2.1 | Inosine-Guanosine Phosphorylase | NP | Nucleoside Phosphorylase | PNP | PNP Human | Purine-Nucleoside:Orthophosphate Ribosyltransferase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1870006","PTPRC protein, human","C17282","Receptor-type tyrosine-protein phosphatase C (1304 aa, ~147 kDa) is encoded by the human PTPRC gene. This protein plays a role in protein dephosphorylation.","Receptor-Type Tyrosine-Protein Phosphatase C | CD45 | CD45 Antigen | CD45RABC | EC 3.1.3.48 | L-CA | Leukocyte Common Antigen | PTPRC | Receptor-Type Tyrosine-Protein Phosphatase C Isoform 1 | T200 | T200 Glycoprotein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527940","Tyrosine-Protein Kinase ZAP-70, Human","C17596","Tyrosine-protein kinase ZAP-70 (619 aa, ~70 kDa) is encoded by the human ZAP70 gene. This protein plays a role in both tyrosine phosphorylation and adaptive immunity.","Tyrosine-Protein Kinase ZAP-70 | 70 kDa Zeta-Chain Associated Protein | E.C. 2.7.1.112 | EC 2.7.10.2 | Protein Tyrosine Kinase Zap70 | Syk-Related Tyrosine Kinase | ZAP-70 | ZAP70 | Zeta-Chain (TCR) Associated Protein Kinase | Zeta-Chain Associated Protein Kinase | Zeta-Chain Associated Protein Kinase | Zeta-Chain Associated Protein Kinase, 70kd",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0759310","CD3E protein, human","C25792","T-cell surface glycoprotein CD3 epsilon chain (207 aa, ~23 kDa) is encoded by the human CD3E gene. This protein plays a role in immune receptor signaling.","T-Cell Surface Glycoprotein CD3 Epsilon Chain | CD3-Epsilon | CD3E | CD3E Antigen Epsilon Polypeptide | CD3E Antigen, Epsilon Polypeptide (Tit3 Complex) | CD3E Protein | T-Cell Antigen Receptor Complex, Epsilon Subunit of T3 | T-Cell Surface Antigen T3/LEU-4 Epsilon Chain | T-Cell Surface Antigen T3/Leu-4 Epsilon Chain | T3E | TCRE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515132","CD3D protein, human","C38899","T-cell surface glycoprotein CD3 delta chain (171 aa, ~19 kDa) is encoded by the human CD3D gene. This protein is involved in T-cell-mediated immunity.","T-Cell Surface Glycoprotein CD3 Delta Chain | CD3 Delta | CD3D | CD3d | T-Cell Receptor T3 Delta Chain | T3D | TiT3 Complex CD3D Antigen Delta Polypeptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515134","T-Cell Surface Glycoprotein CD3 Gamma Chain","C38901","T-cell surface glycoprotein CD3 gamma chain (182 aa, ~20 kDa) is encoded by the human CD3G gene. This protein plays a role in T-cell receptor-mediated signaling.","T-Cell Surface Glycoprotein CD3 Gamma Chain | CD3g | T-Cell Receptor T3 Gamma Chain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL775331","IL7R protein, human","C26278","Interleukin-7 receptor subunit alpha (459 aa, ~52 kDa) is encoded by the human IL7R gene. This protein is involved in both interleukin binding and signal transduction.","Interleukin-7 Receptor Subunit Alpha | CD127 | CDw127 | IL-7 Receptor Subunit Alpha | IL-7R Subunit Alpha | IL-7R-Alpha | IL-7RA | IL7R | Interleukin 7 Receptor | Interleukin 7 Receptor Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1505108","RAG2 protein, human","C80073","V(D)J recombination-activating protein 2 (527 aa, ~59 kDa) is encoded by the human RAG2 gene. This protein plays a role in the mediation of V-D-J recombination.","V(D)J Recombination-Activating Protein 2 | RAG-2 | Recombination Activating Protein 2 | Recombination-Activating Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1506312","V(D)J Recombination-Activating Protein 1","C80072","V(D)J recombination-activating protein 1 (1043 aa, ~119 kDa) is encoded by the human RAG1 gene. This protein is involved in the regulation of V-D-J recombination.","V(D)J Recombination-Activating Protein 1 | E3 Ubiquitin-Protein Ligase RAG1 | EC 2.3.2.27 | EC 3.1.-.- | Endonuclease RAG1 | RAG-1 | RING Finger Protein 74 | RING-Type E3 Ubiquitin Transferase RAG1 | Recombination Activating Protein 1 | Recombination-Activating Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433552","KIAA1549/BRAF Fusion Gene","C99843","A fusion gene that results from a tandem duplication of approximately 2 Mb at 7q34 which fuses exon 15 or 16 of the KIAA1549 gene to exon 9 or 11 of the BRAF gene. This fusion is associated with pilocytic astrocytoma.","KIAA1549/BRAF Fusion Gene | BRAF/KIAA1549 Fusion Gene | KIAA1549-BRAF Fusion Gene | KIAA1549::BRAF Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332437","BRCA1-Associated RING Domain Protein 1, Human","C20980","BRCA1-associated RING domain protein 1 (777 aa, ~87 kDa) is encoded by the human BARD1 gene. This protein plays a role in cell cycle progression, DNA damage repair, ubiquitination and transcriptional regulation.","BRCA1-Associated RING Domain Protein 1 | BARD-1 | BARD1 | BRCA1 Associated RING Domain 1 | BRCA1 Associated RING Domain 1 Protein | BRCA1 Associated RING Domain Protein 1 | BRCA1-Associated RING Domain 1 | EC 2.3.2.27 | EC 6.3.2.-, Formerly | EC6.3.2.- | RING-Type E3 Ubiquitin Transferase BARD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1144061","CASP8 protein, human","C18182","Caspase-8 (479 aa, ~55 kDa) is encoded by the human CASP8 gene. This protein plays a role in proteolysis, angiogenesis and caspase-induction of apoptosis.","Caspase-8 | Apoptotic Cysteine Protease | Apoptotic Protease Mch-5 | CAP4 | CASP-8 | CASP8 | CASP8 Protein | Caspase 8 | Caspase-8/Flice | EC 3.4.22.61 | FADD-Homologous ICE/ced-3-Like Protease | FADD-Like ICE | FADD-homologous ICE/CED3-Like Protease | FLICE | ICE-Like Apoptotic Protease 5 | MACH | MCH5 | MORT1-Associated ced-3 Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413357","CFLAR Gene","C96016","This gene plays a role in the regulation of both proteolysis and apoptosis.","CFLAR Gene | CASP8 and FADD-Like Apoptosis Regulator Gene | CFLAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1452577","DNMT3B protein, human","C26112","DNA (cytosine-5)-methyltransferase 3B (853 aa, ~96 kDa) is encoded by the human DNMT3B gene. This protein is involved in DNA methylation.","DNA (Cytosine-5)-Methyltransferase 3B | DNA (Cytosine-5-)-Methyltransferase 3 Beta | DNA (Cytosine-5-)-Methyltransferase 3B | DNA (Cytosine-5-)-Methyltransferase 3B | DNA MTase HsaIIIB | DNA Methyltransferase 3B | DNA Methyltransferase HsaIIIB | DNMT3B | DNMT3B Protein | Dnmt3b | EC 2.1.1.37 | ICF | M.HsaIIIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0916548","ST7 protein, human","C30003","Suppressor of tumorigenicity 7 protein (585 aa, ~67 kDa) is encoded by the human ST7 gene. This protein may be involved in both autism and tumor suppression.","Suppressor of Tumorigenicity 7 Protein | Protein FAM4A1 | Protein HELG | ST7 | Suppression of Tumorigenicity 7 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3657722","Vitamin D3 Receptor, Human","C17485","Vitamin D3 receptor (427 aa, ~48 kDa) is encoded by the human VDR gene. This protein is involved in vitamin D-mediated transcriptional regulation.","Vitamin D3 Receptor | 1,25-Dihydroxyvitamin D3 Receptor | Calcitriol Receptor | Cholecalciferol Receptor | NR1I1 | Nuclear Receptor Subfamily 1 Group I Member 1 | Protein Phosphatase 1, Regulatory Subunit 163 | Receptors, Calcitriol | VDR | Vitamin D Hormone Receptor | Vitamin D Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229840","Brachial Lymph Node","C92221","An axillary lymph node along the brachial vein.","Brachial Lymph Node | BRACHIAL LYMPH NODE | LYMPH NODE, BRACHIAL | Structure of lateral axillary lymph node (body structure)",,,,,,,,,,,,,,,"4144239","Structure of lateral axillary lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0244656","Fosphenytoin","C65766","A water-soluble phosphate ester prodrug of phenytoin, a hydantoin derivative with anticonvulsant activity. Fosphenytoin is hydrolyzed to phenytoin by phosphatases. Phenytoin exerts its effect mainly by promoting sodium efflux and stabilizes neuronal membranes in the motor cortex. This leads to a suppression of excessive neuronal firing and limits the spread of seizure activity.","Fosphenytoin | FOSPHENYTOIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0771377","Spleen Tissue","C34086","The largest mass of lymphatic tissue in the body. It consists of cells and vessels contained within a capsule lined by mesothelium, from which trabecula enter the splenic parenchyma. The parenchyma is supported by a framework of reticular fibers. The spleen consists of two types of parenchymal tissue, the white and red pulp. The white pulp is composed of elongated cords of compact lymphatic tissue containing nodules. The red pulp is composed of pulp cords and splenic sinusoids.","Splenic Tissue | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227498","Transverse Fissure of Liver","C33806","A transverse fissure on the visceral surface of the liver between the caudate and quadrate lobes, lodging the portal vein, hepatic artery, hepatic nerve plexus, hepatic ducts, and lymphatic vessels.","Transverse Fissure | Porta Hepatis",,,,,,,,,,,,,,,"4010915","Structure of porta hepatis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2826587","Orbital Ridge","C82953","The bony elevation located beneath the eyebrow.","Orbital Ridge | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554614","Glatiramer Acetate","C65805","No Value Exists","Glatiramer Acetate | COP-1 | Copaxone | GLATIRAMER ACETATE | L-Glutamic acid peptide with L-alanine, L-lysine and L-tyrosine, acetate (salt)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2703118","Anti-KIR Monoclonal Antibody IPH 2101","C78464","A human monoclonal antibody directed against the human inhibitory killer IgG-like receptor (KIR) with potential immunostimulating and antineoplastic activities. Anti-KIR monoclonal antibody IPH 2101 binds to the KIR receptor expressed on human natural killer (NK) cells, which may prevent KIR-mediated inhibition of NK cells and permit NK cell-mediated anti-tumor cytotoxicity. KIRs are surface glycoproteins that bind to major histocompatibility complex (MHC)/human leukocyte antigen (HLA) class I subtypes on target cells; binding of KIRs inhibits NK cell-mediated cytotoxicity.","Anti-KIR Monoclonal Antibody IPH 2101 | 1-7F9 | IPH 2101 | IPH-2101 | IPH2101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641634","FACT-P Questionnaire","C103832","The FACT-P is a multidimensional, self-report quality of life instrument specifically designed for use with prostate cancer patients. It consists of 27 core items which assess patient function in four domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by 12 site specific items to assess for prostate related symptoms (from GEM website https://www.gem-beta.org/public/MeasureDetail.aspx?mid=1074&cat=2)","FACT-P Questionnaire | FACT-P | Functional Assessment of Cancer Therapy- Prostate | Functional Assessment of Cancer Therapy- Prostate (FACT-P version 4) | Functional Assessment of Cancer Therapy- Prostate (FACT-P version 4) ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084774","Losing Weight (question)","C103833","A question about whether an individual is losing or has lost weight.","Losing Weight | Have Lost Weight | Have Weight Loss | Have you lost weight | I am losing weight | Lost Weight | Weight Loss | Weight loss",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641635","Aches and Pains Bother Me","C103834","A question about whether an individual is or was bothered by aches and pains.","Aches and Pains Bother Me | I have aches and pains that bother me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641636","Have Painful Body Parts","C103835","A question about whether an individual has or had pain in certain parts of their body.","Have Painful Body Parts | I have certain parts of my body where I experience pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641637","Satisfied with Present Comfort Level","C103836","A question about an individual's satisfaction with their present comfort level.","Satisfied with Present Comfort Level | I am satisfied with my present comfort level",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641638","Feel Like a Man","C103837","A question about whether an individual feels or felt like a man.","Feel Like a Man | I am able to feel like a man",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641639","Trouble Moving Bowels","C103838","A question about a whether an individual has or had trouble moving their bowels.","Trouble Moving Bowels | I have trouble moving my bowels",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539028","Difficulty Urinating question","C103839","A question about whether an individual has or had difficulty urinating.","Difficulty Urinating | I have difficulty urinating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641640","Unusual Frequent Urination","C103840","A question about whether an individual urinates or was urinating more frequently than usual.","Unusual Frequent Urination | I urinate more frequently than usual",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641641","Activities Limited by Urination Problems","C103841","A question about whether an individual is or has limited their activities due to urination problems.","Activities Limited by Urination Problems | My problems with urinating limit my activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641642","Have and Maintain an Erection","C103842","A question about an individual's ability to have and maintain an erection.","Have and Maintain an Erection Question | Achieve and Maintain an Erection | Have and Maintain an Erection | Have and Maintain an Erection | I am able to have and maintain an erection | Sexual Function (problems with achieving / maintaining an erection)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641643","Patient Reported Outcomes Version of CTCAE","C103843","A library of items for patient self-reporting of symptoms and side effects associated with cancer treatment trials.","Patient Reported Outcomes Version of CTCAE | PRO-CTCAE | Patient-Reported Outcomes version of the CTCAE (PRO-CTCAE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641644","Worst Severity Past Seven Days Breast Enlargement or Tenderness","C103844","A question about an individual's observation of the worst severity they have experienced related to breast area enlargement or tenderness in the past seven days.","Worst Severity Past Seven Days Breast Enlargement or Tenderness | In the last 7 days, what was the SEVERITY of your BREAST AREA ENLARGEMENT OR TENDERNESS at its WORST | Worst Severity Last Seven Days Breast Enlargement or Tenderness | Worst Severity Last Seven Days Breast Enlargement or Tenderness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640292","Not Tested","C101887","Indicates that a test was not performed.","Not Tested | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641647","Portacaval","C103847","Of or pertaining to the portal vein and inferior vena cava.","Portacaval | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1550296","Preauricular","C103848","Of or pertaining to the area in front of the auricle of the ear.","Preauricular | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641649","FACT-Cognitive Function","C103850","The FACT-Cognitive Function questionnaire is a 37 item measure developed by Dr. David Cella to evaluate knowledge and information processing.","FACT-Cognitive Function | FAC075 | FACT-COG | FACT-COG V3 | FACT-COG Version 3 | FACT-Cognitive Function v3 | Functional Assessment of Cancer Therapy-Cognitive Function Version 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439550","Afternoon","C64935","The time period between noon and sunset.","Afternoon | ",,,,,,,,,,,,,,,"4223773","Afternoon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641650","Regardless","C103851","Lacking consideration or without thoughtful attention.","Regardless | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641651","Extra-Adrenal","C103852","Pertaining to tissues outside the adrenal gland.","Extra-Adrenal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541918","Biopathology Center","C103854","A College of American Pathologists (CAP) accredited biorepository with the primary objective of long-term acquisition and storage of a large number of cancer, normal and diseased biospecimens obtained from patients with Informed Consent, and related data for the purpose of supporting cutting edge research.","Biopathology Center | BPC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641653","Seattle Cancer Care Alliance","C103855","A world-class cancer treatment center that unites doctors from Fred Hutchinson Cancer Research Center, UW Medicine and Seattle Children's.","Seattle Cancer Care Alliance | SCCA | SCCA ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015250","Complete Excision","C51934","Surgical removal of an entire lesion as confirmed by pathology. Surgical margins are clear.","Complete Excision | ",,,,,,,,,,,,,,,"4193369","Complete excision",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3887967","PML/RARA Fusion Gene","C99186","A fusion gene that results from a chromosomal translocation t(15;17)(q22;q21) which fuses the first 3 exons of the PML gene with the last 7 exons of the RARA gene. This fusion is associated with acute promyelocytic leukemia. Three transcript variants are possible based on the three breakpoint clusters in the PML gene.","PML/RARA Fusion Gene | PML-RAR | PML-RAR Alpha Fusion Gene | PML-RARA Fusion Gene | PML::RARA Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2935436","Trastuzumab Emtansine","C82492","An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.","Trastuzumab Emtansine | ADO-Trastuzumab Emtansine | Ado Trastuzumab Emtansine | Immunoglobulin G1, Anti-(Human p185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide with Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide with N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine | Kadcyla | PRO 132365 | PRO-132365 | PRO132365 | RO5304020 | T-DM1 | TDM1 | TRASTUZUMAB EMTANSINE | Trastuzumab emtansine | Trastuzumab-DM1 | Trastuzumab-MCC-DM1 | Trastuzumab-MCC-DM1 Antibody-Drug Conjugate | Trastuzumab-MCC-DM1 Immunoconjugate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985548","Tissue Flap Breast Reconstruction","C93317","Breast reconstruction that uses tissues taken from other parts of the individual's body.","Tissue Flap Breast Reconstruction | Autogenous Reconstruction | Autologous Breast Reconstruction | Autologous Reconstruction | Tissue Flap Reconstruction | Tissue Flap Reconstruction | tissue flap reconstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985549","DIEP Flap","C93318","A type of breast reconstruction in which blood vessels called deep inferior epigastric perforators (DIEP), and the skin and fat connected to them are removed from the lower abdomen and used for reconstruction. Muscle is left in place.","DIEP Flap | DIEP flap | Deep Inferior Epigastric Artery Perforator Flap",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037088","Sign or Symptom","C100104","Objective evidence of disease perceptible to the examining practitioner (sign) and subjective evidence of disease perceived by the patient (symptom).","Sign or Symptom | CLINICAL FINDING | CLINICAL SIGNS | Clinical Finding | Clinical Signs | Clinical Signs or Symptoms | DESC | Signs or Symptoms",,,,,,,,,,,,,,,"441840","Clinical finding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1514486","Proliferation Marker","C18395","Refers to specific proteins or other factors in actively growing and dividing cells, whose presence serves as an indicator for such cells.  For instance, proliferating cell nuclear antigen (PCNA) or mitotic index.","Proliferation Marker | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0920508","Enzyme-linked Immunosorbent Spot Assay","C102632","A highly sensitive immunoassay capable of detecting secreted materials from individual cells upon activation. If the material of interest is secreted in response to a particular stimulus, then the material will bind to a specific immobilized antibody. Binding is then verified and visualized by applying other antibodies that have been tagged in some way.","Enzyme-linked Immunosorbent Spot Assay | ELISPOT | ELISpot",,,,,,,,,,,,,,,"4179081","Enzyme linked immunospot assay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0393053","Screening for Neuroblastoma","C15641","The use of any device, marker, or other means for the purpose of detecting the presence of neuroblastoma, usually before there are symptoms.","Screening for Neuroblastoma | early detection of neuroblastoma | neuroblastoma early detection | neuroblastoma screening",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919516","MAX Gene","C18576","This gene is involved in transcriptional regulation and plays a role in the mediation of DNA-protein interactions.","MAX Gene | MAX | MYC Associated Factor X Gene | MYC-Associated Factor X Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823386","TMEM127 Gene","C95303","This gene may play a role in signaling and protein trafficking.","TMEM127 Gene | TMEM127 | Transmembrane Protein 127 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2240298","SDHAF2 Gene","C97770","This gene is involved in the electron transport chain.","SDHAF2 Gene | SDHAF2 | Succinate Dehydrogenase Complex Assembly Factor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419909","SDHD Gene","C97779","This gene plays a role in the localization of succinate dehydrogenase activity.","SDHD Gene | SDHD | Succinate Dehydrogenase Complex Subunit D Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419908","SDHC Gene","C97776","This gene is involved in mitochondrial electron transport.","SDHC Gene | SDHC | Succinate Dehydrogenase Complex Subunit C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419907","SDHB Gene","C97773","This gene plays a role in electron transport in the mitochondria.","SDHB Gene | SDHB | Succinate Dehydrogenase Complex Iron Sulfur Subunit B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986548","New Lesion Identification","C94522","The identification of a lesion which has not been previously seen or characterized.","New Lesion Identification | NEW | New Lesion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641670","Dopamine-Secreting","C103871","A finding indicating that an excess amount of dopamine is secreted by a tumor.","Dopamine-Secreting | Dopamine Secreting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641668","Epinephrine-Secreting","C103869","A finding indicating that an excess amount of epinephrine is secreted by a tumor.","Epinephrine-Secreting | Epinephrine Secreting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641669","Metanephrine-Secreting","C103870","A finding indicating that an excess amount of metanephrine is secreted by a tumor.","Metanephrine-Secreting | Metanephrine Secreting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641671","Methoxytyramine-Secreting","C103872","A finding indicating that an excess amount of methoxytyramine is secreted by a tumor.","Methoxytyramine-Secreting | Methoxytyramine Secreting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641666","Norepinephrine-Secreting","C103867","A finding indicating that an excess amount of norepinephrine is secreted by a tumor.","Norepinephrine-Secreting | Norepinephrine Secreting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641667","Normetanephrine-Secreting","C103868","A finding indicating that an excess amount of normetanephrine is secreted by a tumor.","Normetanephrine-Secreting | Normetanephrine Secreting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419906","SDHA Gene","C103873","This gene is involved in the mitochondrial respiratory chain.","SDHA Gene | SDHA | Succinate Dehydrogenase Complex, Subunit A, Flavoprotein (Fp) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519276","Ovarian Sex Cord Tumor with Annular Tubules","C4208","An ovarian sex cord-stromal tumor characterized by the presence of Sertoli cells forming annular tubules. It may be associated with Peutz-Jeghers syndrome. Cases associated with Peutz-Jeghers syndrome have followed a benign clinical course. Cases which are not associated with Peutz-Jeghers syndrome have been reported having a clinically malignant course.","Ovarian Sex Cord Tumor with Annular Tubules | Ovarian Sertoli Cell Tumor, Annular Tubular Variant | Ovarian Sex Cord Neoplasm with Annular Tubules | Sex cord tumor with annular tubules","8623/1","Sex cord tumor with annular tubules",,,,,,,,,,,,,"4216552","Sex cord tumor with annular tubules",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334402","Granulosa Cell-Theca Cell Tumor","C66751","A general term used to describe sex cord-stromal tumors characterized by the presence of granulosa cells in a thecomatous/fibrothecomatous background.","Granulosa Cell-Theca Cell Tumor | ","8621/1","Granulosa cell-theca cell tumor",,,,,,,,,,,,,"4150367","Granulosa cell-theca cell tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C3641674","Imaging Quality Assurance Review Center","C103911","A research program that provides specialized radiotherapy quality assurance and diagnostic imaging data management services.","Imaging Quality Assurance Review Center | QARC | Quality Assurance Review Center | Quality Assurance Review Center",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348375","Echinoderm Microtubule-Associated Protein-Like 4, Human","C71005","Echinoderm microtubule-associated protein-like 4 (981 aa, ~109 kDa) is encoded by the human EML4 gene. This protein may play a role in the modification of microtubule assembly dynamics.","Echinoderm Microtubule-Associated Protein-Like 4 | EMAP-4 | EML4 | Echinoderm Microtubule Associated Protein Like 4 | Restrictedly Overexpressed Proliferation-Associated Protein | Ropp 120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448360","Adrenal Hormone","C2264","Hormones made from cholesterol and protein produced by the adrenal glands and regulate electrolyte balance, blood pressure, inflammation, blood sugar balance, and immune system control.","Adrenal Hormone | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641098","Related Record","C103162","A piece of data that is related to another piece of data.","Related Record | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516225","Cancer Research","C16199","Systematic investigation into the causes of cancer and development of strategies for prevention, diagnosis, treatment, and cure.","Cancer Research | Cancer Research Programs | Cancer Research Project",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026160","Mineralocorticoid","C2324","A class of corticosteroid hormones that maintains fluid and electrolyte balance. The main mineralocorticoid is Aldosterone.","Mineralocorticoid | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347501","Pharmacogenetic Test","C68761","An assay intended to study interindividual variations in DNA sequence related to drug absorption and disposition (pharmacokinetics) or drug action (pharmacodynamics), including polymorphic variation(s) in the genes that encode the functions of transporters, metabolizing enzymes, receptors, and other proteins. From: Pharmacogenomic Data Submissions, FDA Guidance for Industry","Pharmacogenetic Test | pharmacogenetic test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641680","Pain Keeps Me From Doing Things I Want to Do","C103967","A question about whether an individual has or had pain that kept them from doing things they wanted to do.","Pain Keeps Me From Doing Things I Want to Do | My pain keeps me from doing things I want to do",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514952","Stage at Diagnosis","C19251","The extent of cancer spread at the time of the original diagnosis.","Stage at Diagnosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985739","Clinically Significant Indicator","C93532","Specifies whether a finding or condition is clinically significant based on judgment.","Clinically Significant Indicator | clinicallySignificantIndicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514457","Prior Chemotherapy","C16171","Previous chemotherapy administered as treatment for this cancer.","Prior Chemotherapy | Prior Chemotherapy Regimens",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796355","TAL1 Gene","C18301","This gene plays a role in regulation of transcription and cell organization. It is involved in both embryonic hematopoiesis and adult erythropoiesis.","TAL1 Gene | T-Cell Acute Lymphocytic Leukemia 1 Gene | TAL bHLH Transcription Factor 1, Erythroid Differentiation Gene | TAL1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332425","BMP3 Gene","C21351","This gene is involved in bone and cartilage formation. It plays a role in the negative regulation of bone density.","BMP3 Gene | BMP3 | Bone Morphogenetic Protein 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417850","NRP2 Gene","C74468","This gene plays a role in both ligand binding and signal transduction.","NRP2 Gene | NRP2 | Neuropilin 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420563","TAC1 Gene","C39664","This gene plays a role in the induction of behavioral responses and in vasodilation.","TAC1 Gene | TAC1 | Tachykinin Precursor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538904","Welding Occupations","C103934","A class of professional or vocational positions of employment that involve work with welding.","Welding Occupations | Welding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412064","ABCA5 Gene","C103876","This gene is involved in both ATP binding and catabolism.","ABCA5 Gene | ABCA5 | ABCB5 | ATP Binding Cassette Subfamily A Member 5 Gene | ATP-Binding Cassette, Sub-Family A (ABC1), Member 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412080","ABCC5 Gene","C103949","This gene plays a role in the transport of organic anions and nucleotides.","ABCC5 Gene | ABCC5 | ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422571","BAALC Gene","C103991","This gene may be involved in neural and hematopoietic cell functions.","BAALC Gene | BAALC | Brain and Acute Leukemia, Cytoplasmic Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412753","BCCIP Gene","C103955","This gene may be involved in both cell cycle progression and DNA damage repair.","BCCIP Gene | BCCIP | BRCA2 and CDKN1A Interacting Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413155","CBR3 Gene","C103987","This gene plays a role in the reduction of carbonyl-containing compounds.","CBR3 Gene | CBR3 | Carbonyl Reductase 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414689","FPGS Gene","C103940","This gene plays a role in the metabolism of both folate and polyglutamate.","FPGS Gene | FPGS | Folylpolyglutamate Synthase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415051","GGH Gene","C103943","This gene is involved in polyglutamate hydrolysis.","GGH Gene | GGH | Gamma-Glutamyl Hydrolase (Conjugase, Folylpolygammaglutamyl Hydrolase) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641682","Human Anti-Human Antibody","C103990","Human antibodies which recognize other human antibodies. These can develop in certain disease states or in response to treatment with therapeutic antibodies which can limit the effectiveness of the treatment.","Human Anti-Human Antibody | HAHA | Human Anti-Human Antibodies",,,,,,,,,,,,,,,"36714754","Human anti-human antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1417407","MTAP Gene","C103994","This gene plays a role in purine salvage.","MTAP Gene | MTAP | Methylthioadenosine Phosphorylase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417745","NQO2 Gene","C103984","This gene is involved in the reduction of quinones.","NQO2 Gene | NAD(P)H Dehydrogenase, Quinone 2 Gene | NQO2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422123","PLVAP Gene","C103952","This gene may be involved in caveolae structure.","PLVAP Gene | PLVAP | Plasmalemma Vesicle Associated Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420117","SLC19A1 Gene","C103946","This gene plays a role in folate transport.","SLC19A1 Gene | SLC19A1 | Solute Carrier Family 19 (Folate Transporter), Member 1 Gene | Solute Carrier Family 19 Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537327","Heat Shock 70 kDa Protein 1A/1B","C104001","Heat shock 70 kDa protein 1A/1B (641 aa, ~70 kDa) is encoded by the human HSPA1A and HSPA1B genes. This protein is involved in the mediation of protein folding.","Heat Shock 70 kDa Protein 1A/1B | DnaK-Type Molecular Chaperone HSP70-1 | HSP70-1/HSP70-2 | HSP70.1/HSP70.2 | HSP72 | HSPA1 | HSPA1A/HSPA1B | Heat Shock 70 kDa Protein 1 | Heat Shock 70 kDa Protein 1/2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0057470","Deoxyuridine Triphosphate","C104002","A uracil nucleotide comprised of three phosphate groups esterified to the deoxyribose sugar moiety.","Deoxyuridine Triphosphate | 2'-Deoxyuridine 5'-(Tetrahydrogen Triphosphate) | 2'-Deoxyuridine 5'-Triphosphate | dUTP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641694","ENSAT Staging Finding v7","C104016","A finding about one or more characteristics of adrenal cancer, following the rules of the ENSAT staging v7 classification system.","ENSAT Staging Finding v7 | European Network for the Study of Adrenal Tumors Staging Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641695","Pathologic ENSAT Staging Finding v7","C104017","A pathologic finding about one or more characteristics of adrenal cancer, following the rules of the ENSAT staging v7 classification system.","Pathologic ENSAT Staging Finding v7 | ensat pathologic stage | ensat_pathologic_stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641696","Pathologic Primary Tumor ENSAT Staging Finding v7","C104018","A pathologic finding about one or more characteristics of adrenal cancer, following the rules of the ENSAT staging v7 classification system as they pertain to staging of the primary tumor.","Pathologic Primary Tumor ENSAT Staging Finding v7 | ensat pathologic t | ensat_pathologic_t",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641697","pT1 ENSAT Staging Finding v7","C104019","Adrenal cancer with tumor size equal or less than 5.0 cm.  There is no invasion of tissues outside the adrenal gland. (7th Ed, 2009)","pT1 ENSAT Staging Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641698","pT2 ENSAT Staging Finding v7","C104020","Adrenal cancer with tumor size more than 5.0 cm. There is no invasion of tissues outside the adrenal gland. (7th Ed, 2009)","pT2 ENSAT Staging Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641699","pT3 ENSAT Staging Finding v7","C104021","Adrenal cancer with tumor of any size.  There is invasion of the fat that surrounds the adrenal gland. (7th Ed, 2009)","pT3 ENSAT Staging Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641700","pT4 ENSAT Staging Finding v7","C104022","Adrenal cancer with tumor of any size.  There is invasion of nearby organs such as the kidney, pancreas, spleen or liver. (7th Ed, 2009)","pT4 ENSAT Staging Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641701","Pathologic Lymph Nodes ENSAT Staging Finding v7","C104023","A pathologic finding about one or more characteristics of adrenal cancer, following the rules of the ENSAT staging v7 classification system as they pertain to staging of the lymph nodes.","Pathologic Lymph Nodes ENSAT Staging Finding v7 | ensat pathologic n | ensat_pathologic_n",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641702","pN0 ENSAT Staging Finding v7","C104024","Adrenal cancer with no involvement of regional lymph nodes. (7th Ed, 2009)","pN0 ENSAT Staging Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641703","pN1 ENSAT Staging Finding v7","C104025","Adrenal cancer with involvement of regional lymph nodes. (7th Ed, 2009)","pN1 ENSAT Staging Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641704","Clinical ENSAT Staging Finding v7","C104026","A clinical finding about one or more characteristics of adrenal cancer, following the rules of the ENSAT staging v7 classification system.","Clinical ENSAT Staging Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641705","Clinical Distant Metastasis ENSAT Staging Finding v7","C104027","A clinical finding about one or more characteristics of adrenal cancer, following the rules of the ENSAT staging v7 classification system as they pertain to distant metastases.","Clinical Distant Metastasis ENSAT Staging Finding v7 | ensat clinical m | ensat_clinical_m",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641706","cM0 ENSAT Staging Finding v7","C104028","Adrenal cancer with no involvement of distant organs or tissues. (7th Ed, 2009)","cM0 ENSAT Staging Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641707","cM1 ENSAT Staging Finding v7","C104029","Adrenal cancer with involvement of distant organs or tissues such as liver, bone or brain. (7th Ed, 2009)","cM1 ENSAT Staging Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641708","Adrenal Cortical Carcinoma by ENSAT Stage","C104030","A term that refers to the staging of adrenal cortical carcinoma according to the European Network for the Study of Adrenal Tumors (ENSAT).","Adrenal Cortical Carcinoma by ENSAT Stage | Adrenal Cortex Carcinoma Overall ENSAT v7 Staging | Adrenal Cortex Carcinoma by ENSAT Stage | Adrenal Cortex Carcinoma by ENSAT Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641709","ENSAT Stage I Adrenal Cortex Cancer","C104031","Stage I includes: T1, N0, M0.  Tumor 5 cm or less in greatest dimension. The tumor has not invaded the surrounding tissues or organs and has not spread to lymph nodes or distant organs or tissues.  (ENSAT 7th Ed, 2009)","ENSAT Stage I Adrenal Cortical Carcinoma | ENSAT Stage I Adrenal Cortex Cancer | ENSAT Stage I Adrenal Cortex Carcinoma | ENSAT Stage I Adrenal Cortex Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641710","ENSAT Stage II Adrenal Cortex Cancer","C104032","Stage II includes: T2, N0, M0. Tumor greater than 5 cm. The tumor has not invaded surrounding tissues or organs and has not spread to lymph nodes or distant organs or tissues. (ENSAT 7th Ed, 2009)","ENSAT Stage II Adrenal Cortical Carcinoma | ENSAT Stage II Adrenal Cortex Cancer | ENSAT Stage II Adrenal Cortex Carcinoma | ENSAT Stage II Adrenal Cortex Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641711","ENSAT Stage III Adrenal Cortex Cancer","C104033","Stage III includes: T3/T4, N0/N1, M0.  Tumor of any size that has spread to the fat outside the adrenal gland or into nearby organs or tissues and/or has spread to the regional lymph nodes. (ENSAT 7th Ed, 2009)","ENSAT Stage III Adrenal Cortical Carcinoma | ENSAT Stage III Adrenal Cortex Cancer | ENSAT Stage III Adrenal Cortex Carcinoma | ENSAT Stage III Adrenal Cortex Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641712","ENSAT Stage IV Adrenal Cortex Cancer","C104034","Stage IV includes: Any T, Any N, M1. Tumor of any size that involves distant organs such as liver, bone or brain. The tumor may or may not involve nearby organs, tissues or lymph nodes. (ENSAT 7th Ed, 2009)","ENSAT Stage IV Adrenal Cortical Carcinoma | ENSAT Stage IV Adrenal Cortex Cancer | ENSAT Stage IV Adrenal Cortex Carcinoma | ENSAT Stage IV Adrenal Cortex Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641689","Nuclear Grade III or IV","C104011","Nuclear pleomorphism in tumor cells defined either as grade III or IV.","Nuclear Grade III or IV | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641691","Cytoplasm Presence of Less than or Equal to Twenty Five Percent","C104013","A morphologic finding indicating the presence of less than or equal to twenty five percent of clear or vacuolated cells that resemble the normal zona fasciculata in adrenocortical tumors.","Zona Fasciculata-Resembling Cells are Less Than or Equal to Twenty Five Percent | Cytoplasm Presence of Less than or Equal to Twenty Five Percent | Cytoplasm Presence of Less than or Equal to Twenty Five Percent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641692","WEISS System","C104014","An evaluation system that uses histologic criteria to assess and differentiate malignancy in adrenocortical tumors.","WEISS System | WEISS Assessment | weiss assessment score | weiss_assessment_score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641693","WEISS Criteria","C104015","Histopathologic criteria to evaluate adrenocortical tumors.  These criteria include nuclear grade III or IV, mitotic rate greater than five per fifty high power fields, presence of atypical mitotic figures, presence of less than or equal to twenty five percent of clear or vacuolated cells that resemble normal zona fasciculata, diffuse architecture, necrosis, venous invasion, sinusoid invasion, and invasion of tumor capsule.","WEISS Criteria | WEISS Category | weiss assessment findings | weiss_assessment_findings",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519333","Sinusoidal Infiltration","C39615","A microscopic finding indicating the invasion of sinusoidal spaces by malignant cells.","Sinusoidal Infiltration | Sinusoid Invasion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334928","Necrotic changes (finding)","C36184","A finding indicating the presence of cellular necrosis in a tissue specimen.","Necrotic Change | Necrosis | Necrosis (Y/N) | Necrosis type | Tissue Necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332352","Atypical Mitotic Figures","C35962","A morphologic finding indicating the presence of atypical mitoses in malignant cells.","Atypical Mitotic Figures | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709073","More than 5 Mitoses per 50HPF","C54007","A morphologic finding indicating the presence of more than five mitotic figures per fifty high power fields in a cellular infiltrate.","More than 5 Mitoses per 50 HPF | Mitotic Rate > 5/50 HPF | More than 5 Mitoses per 50HPF | More than 5 Mitoses per 50HPF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0057257","Defibrotide Sodium","C1064","A polydeoxyribonucleotide with antithrombotic, thrombolytic, and fibrinolytic properties.  Defibrotide induces the release of prostaglandin 12 and reduces the expression of adhesion molecules on endothelial cells, thereby interfering with platelet and leukocyte adhesion to the endothelium. (NCI04)","Defibrotide Sodium | DEFIBROTIDE SODIUM | Defibrinotide | Defibrotide | Defibrotide | Defitelio | Fraction P | Noravid | Prociclide | defibrotide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347024","Biological Clearance Rate","C70914","The rate at which an exogenous substance is removed or cleared from the whole or part of the body.","Biological Clearance Rate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522569","Recombinant Human Interleukin-15","C1545","A recombinant agent that is chemically identical or similar to the endogenous form of the human cytokine interleukin-15 (IL-15) with immunomodulating activity. IL-15, secreted by mononuclear phagocytes (and some other cell types) following viral infection, regulates T and natural killer cell activation and proliferation. This cytokine induces activation of transcription activators STAT3, STAT5, and STAT6 via JAK kinase signal transduction pathways in mast cells, T cells, and dendritic epidermal T cells. IL-15 and interleukin-2 (IL-2) are structurally similar and share many biological activities; both may bind to common hematopoietin receptor subunits, negatively regulating each other's activity. CD8+ memory T cell number has been shown to be regulated by a balance between IL-15 and IL-2.","Recombinant Human Interleukin-15 | IL15 | Interleukin 15 | RECOMBINANT HUMAN INTERLEUKIN-15 | Recombinant Interleukin-15 | rIL15 | rhIL-15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332754","CHGA Gene","C21167","This gene plays a role in the modulation of the neuroendocrine system.","CHGA Gene | CHGA | Chromogranin A (Parathyroid Secretory Protein 1) Gene | Chromogranin A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0920270","TLX1 Gene","C18608","This gene plays a role in transcriptional regulation and organogenesis. Translocations in the gene are associated with acute T-cell leukemia.","TLX1 Gene | T Cell Leukemia Homeobox 1 Gene | TLX1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812271","MECOM Gene","C18392","This gene plays a role in transcriptional regulation, histone methylation and leukemogenesis.","MECOM Gene | EVI1 | MDS1 and EVI1 Complex Locus Gene | MECOM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413246","CD9 Gene","C101154","This gene is involved in both cell adhesion and platelet function.","CD9 Gene | CD9 | CD9 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332708","CD22 Gene","C20990","This gene is involved in mediating the adhesion between B cells and is a molecular marker for B-cell precursor acute lymphocytic leukemia.","CD22 Gene | CD22 | CD22 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332715","CD58 Gene","C21016","This gene plays a role in facilitating contacts between helper T lymphocytes and antigen-presenting cells.","CD58 Gene | CD58 | CD58 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333714","GRP Gene","C38318","This gene plays a role in the regulation of several gastrointestinal and central nervous system functions.","GRP Gene | GRP | Gastrin-Releasing Peptide Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334098","IL10 Gene","C28600","This gene plays an anti-inflammatory role in immune processes and is involved in a variety of diseases.","IL10 Gene | IL10 | Interleukin 10 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334354","LYL1 Gene","C24564","This gene plays a role in transcriptional regulation and is involved in the pathogenesis of acute lymphoblastic leukemia.","LYL1 Gene | LYL1 | LYL1 Basic Helix-Loop-Helix Family Member Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0380093","LMO2 Gene","C17973","This gene plays a crucial role in hematopoietic development and is involved in transcriptional activation.","LMO2 Gene | LIM Domain Only 2 Gene | LMO2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416881","LMO1 Gene","C91263","This gene is involved in the regulation of transcription.","LMO1 Gene | LIM Domain Only 1 Gene | LMO1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828358","Lactating (finding)","C82463","An indication that the subject is currently producing milk.","Lactating | LACTATING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032982","Trimester","C69121","A period of three months; especially one of the three three-month periods into which human pregnancy is divided.","Trimester | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032980","Second Trimester","C92876","The period of gestation that ranges from the 13th to the 27th week of pregnancy.","Second Trimester | ",,,,,,,,,,,,,,,"4113140","Second trimester",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032979","First Trimester","C92799","The period of gestation that ranges from the first day of the last menstrual period in a woman up to the 12th week of her pregnancy.","First Trimester | ",,,,,,,,,,,,,,,"4113139","First trimester",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3274430","Physical Medical Procedure","C98769","A set of manual or instrumental activities that are intended to treat a health problem in order to achieve a positive result.","Physical Medical Procedure | Medical Procedure | PROCEDURE | Procedure | procedures (for participants)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0424131","Enjoyment of Life","C104080","The level of happiness or contentment that an individual professes, or is observed to display with regards to their life situation.","Enjoyment of Life | ",,,,,,,,,,,,,,,"4084573","Enjoyment of life",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1412616","ATF3 Gene","C103959","This gene plays a role in the negative regulation of transcription.","ATF3 Gene | ATF3 | Activating Transcription Factor 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412079","ABCC4 Gene","C103879","This gene plays a role in both cellular detoxification and platelet degranulation.","ABCC4 Gene | ABCC4 | ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413788","CTAG2 Gene","C104046","This gene may play a role in tumorigenesis.","CTAG2 Gene | CTAG2 | CTAG2r | Cancer/Testis Antigen 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023292","Leisure Activity","C104103","Activities done for the purpose of relaxation or diversion from routine work.","Leisure Activity | Leisure Activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427242","ANTXR1 Gene","C104093","This gene plays a role in cell-matrix adhesion.","ANTXR1 Gene | ANTXR1 | Anthrax Toxin Receptor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538915","APLN Gene","C104096","This gene is involved in the regulation of both immune responses and HIV-1 infection.","APLN Gene | APLN | Apelin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414460","ESM1 Gene","C104087","This gene may play a role in endothelial cell-leukocyte interactions.","ESM1 Gene | ESM1 | Endothelial Cell-Specific Molecule 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0244989","Glycogen Synthase Kinase 3","C104099","A family of serine/threonine protein kinases that is involved in intracellular signaling, cellular proliferation, cell migration, inflammation and immune responses, glucose regulation, and apoptosis.","Glycogen Synthase Kinase 3 | GSK-3 | GSK3 | Glycogen Synthase Kinase- 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0682639","Memory T-Lymphocyte","C104082","A mature T-lymphocyte that has encountered its cognate antigen and is primed to reproduce and elicit a stronger immune response upon a second encounter with the antigen. These cells are characterized by the presence CD45R0.","Memory T-Lymphocyte | Memory T Cell | Memory T Cells | Memory T Lymphocyte | Memory T-Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641721","Naive T-Lymphocyte","C104081","A mature T-lymphocyte that has differentiated in the bone marrow and undergone central tolerance selection in the thymus but has not interacted with its cognate antigen. These cells are characterized by the presence of the T-cell receptor, L-selectin and the IL-7 receptor and the absence of CD25, CD44, CD69 and CD45R0.","Naive T-Lymphocyte | Naive T Cell | Naive T Cells | Naive T Lymphocyte | Naive T-Cell | Th0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422666","NDRG2 Gene","C104084","This gene is involved in the regulation of cellular differentiation.","NDRG2 Gene | NDRG Family Member 2 Gene | NDRG2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0135194","Pancreastatin, Human","C104100","Pancreastatin (48 aa, ~5 kDa) is encoded by the human CHGA gene. This protein is released from the full length chromogranin-A protein by caspase cleavage and plays a role in the inhibition of the release of chromogranin-A, parathyroid hormone and somatostatin.","Pancreastatin | Chromogranin-A 272-319 Peptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427201","PLXDC1 Gene","C104090","This gene is involved in capillary formation.","PLXDC1 Gene | PLXDC1 | Plexin Domain Containing 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641724","PARP1 p85","C104102","Poly [ADP-ribose] polymerase 1 p85 (800 aa, ~89 kDa) is encoded by the human PARP1 gene. This protein is released from the full length poly [ADP-ribose] polymerase 1 protein by caspase-3 cleavage and is involved in DNA repair.","Poly [ADP-Ribose] Polymerase 1 p85 |  Poly(ADP Ribose) Polymerase p85 | ADP-Ribosyltransferase Diphtheria Toxin-Like 1 p85 | ADPRT 1 p85 | ARTD1 p85 | NAD(+) ADP-Ribosyltransferase 1 p85 | PARP p85 | PARP1 p85 | Poly [ADP-Rbose] Polymerase 1 p85 | Poly [ADP-Ribose] Polymerase p85 | Poly(ADP Ribose) Polymerase 1 p85 | Poly(ADP Ribose) Polymerase p85 | Poly[ADP-Ribose] Synthase 1 p85",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421331","UGT1A7 Gene","C104104","This gene plays a role in detoxification.","UGT1A7 Gene | UDP Glucuronosyltransferase 1 Family, Polypeptide A7 Gene | UGT1A7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919509","FGFR1 Gene","C19929","This gene plays a role in mitogenesis and differentiation.","FGFR1 Gene | FGFR1 | Fibroblast Growth Factor Receptor 1 (FMS-Related Tyrosine Kinase 2, Pfeiffer Syndrome) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274725","t(1;19)(q10;p10)","C99418","An unbalanced translocation between chromosomes 1 and 19.  It is observed in oligodendrogliomas and results in the co-deletion of 1p and 19q.","t(1;19)(q10;p10) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366555","DPYD Gene","C26542","This gene is involved in pyrimidine catabolism.","DPYD Gene | DPYD | Dihydropyrimidine Dehydrogenase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641714","Hot Flash Related Daily Inference Scale","C104044","A tool designed to measure the impact of hot flashes on overall quality of life as well as nine specific activities using a 10 point Likert scale.","Hot Flash Related Daily Inference Scale | HFRDIS | Hot Flash Related Daily Inference Scale (HFRDIS) | Hot Flash Related Daily Interference Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0556985","Twice Weekly","C64497","Two times per week.","Twice Weekly | 2 TIMES PER WEEK | BIS | Twice a week | Twice per week",,,,,,,,,,,,,,,"4047143","Twice weekly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2681403","ACER1 Gene","C103888","This gene is involved in ceramide metabolism.","ACER1 Gene | ACER1 | Alkaline Ceramidase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1540204","ACER2 Gene","C103893","This gene plays a role in sphingosine biosynthesis.","ACER2 Gene | ACER2 | Alkaline Ceramidase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423950","ACER3 Gene","C103896","This gene is involved in the catabolism of phytoceramides.","ACER3 Gene | ACER3 | Alkaline Ceramidase 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422396","ANLN Gene","C103962","This gene is involved in cytokinesis.","ANLN Gene | ANLN | Anillin Actin Binding Protein Gene | Anillin, Actin Binding Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412553","ARSA Gene","C103930","This gene is involved in the metabolism of cerebroside sulfate.","ARSA Gene |  ARSA | ARSA | Arylsulfatase A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412573","ASAH1 Gene","C103899","This gene plays a role in sphingolipid metabolism.","ASAH1 Gene | ASAH1 | N-Acylsphingosine Amidohydrolase (Acid Ceramidase ) 1 Gene | N-Acylsphingosine Amidohydrolase (Acid Ceramidase) 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425831","ASAH2 Gene","C103902","This gene is involved in sphingolipid-ceramide hydrolysis.","ASAH2 Gene | ASAH2 | N-Acylsphingosine Amidohydrolase (Non-Lysosomal Ceramidase ) 2 Gene | N-Acylsphingosine Amidohydrolase (Non-Lysosomal Ceramidase) 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1540202","ASAH2B Gene","C103905","This gene may play a role in sphingolipid metabolism.","ASAH2B Gene | ASAH2B | N-Acylsphingosine Amidohydrolase (Non-Lysosomal Ceramidase ) 2B Gene | N-Acylsphingosine Amidohydrolase 2B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1540203","ASAH2C gene","C103908","This gene may be involved in ceramide metabolism.","ASAH2C Gene | ASAH2B | ASAH2C | N-Acylsphingosine Amidohydrolase (Non-Lysosomal Ceramidase ) 2C Gene | N-Acylsphingosine Amidohydrolase (Non-Lysosomal Ceramidase) 2C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412724","B4GALT6 Gene","C103937","This gene plays a role in glycosphingolipid synthesis.","B4GALT6 Gene | B4GALT6 | UDP-Gal:BetaGlcNAc Beta 1,4- Galactosyltransferase, Polypeptide 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428348","BMF Gene","C104158","This gene plays a role in apoptosis.","BMF Gene | BMF | Bcl2 Modifying Factor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641730","Circulating Cell-Free RNA","C104154","RNA found in blood plasma and other bodily fluids that is not associated with cells.","Circulating Cell-Free RNA | Circulating RNA | cfRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824750","CLLU1 Gene","C104155","This gene may be involved in leukemia.","CLLU1 Gene | CLLU1 | Chronic Lymphocytic Leukemia Up-Regulated 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416697","KIF23 Gene","C104161","This gene is involved in cytokinesis and microtubule movement.","KIF23 Gene | KIF23 | Kinesin Family Member 23 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421227","TUBA3C Gene","C104168","This gene is involved in both the structure and functioning of microtubules.","TUBA3C Gene | TUBA3C | Tubulin, Alpha 3c Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421231","TUBB Gene","C104164","This gene plays a role in microtubule structure and function.","TUBB Gene | TUBB | Tubulin, Beta Class I Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413256","CDC20 Gene","C104110","This gene plays a role in cell cycle progression.","CDC20 Gene | CDC20 | Cell Division Cycle 20 Homolog (S. cerevisiae) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824709","CEP55 Gene","C104119","This gene is involved in mitotic exit and cytokinesis.","CEP55 Gene | CEP55 | Centrosomal Protein 55kDa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538439","CERKL Gene","C104122","This gene plays a role in apoptosis.","CERKL Gene | CERKL | Ceramide Kinase Like Gene | Ceramide Kinase-like Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3469891","CERS5 Gene","C104125","This gene is involved in ceramide synthesis and cell signaling.","CERS5 Gene | CERS5 | Ceramide Synthase 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514239","Portacath Placement","C38080","A surgical procedure to implant a subcutaneous venous access port in a central vein.","Portacath Placement | Port-a-cath Placement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439402","Milliliter per Kilogram per Minute","C73760","A dose calculation unit expressed in milliliter(s) per kilogram per period of time equal to sixty seconds.","Milliliter per Kilogram per Minute | (mL/min)/kg | (ml/min)/kg | Milliliter/Kilogram/Minute | mL/kg/min | ml/kg/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439426","Microgram per Day","C71205","A unit of mass flow rate equivalent to the rate at which one millionth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to twenty four hours. Microgram per 24 hours is also a dose administration rate unit equal to the rate at which one millionth of a gram of a product is administered per unit of time equal to twenty four hours.","Microgram per Day | Microgram per 24 Hours | mcg/24h | mcg/d | mcg/day | microgram per 24 hours | ug/24.h | ug/24h | ug/d | ug/day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272912","Reptilase Time Measurement","C96628","A measurement of the time it takes a plasma sample to clot after adding the snake venom enzyme batroxobin (reptilase). This procedure can be used to detect deficiencies or abnormalities in fibrinogen and this enzyme is resistant to both endogenous thrombin inhibitors and heparin.","Reptilase Time Measurement | RPTLTIME | Reptilase Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0388730","Cyclin D","C104194","A protein family that is synthesized during the G1 phase of the cell cycle and drives the G1/S phase transition through the positive regulation of cyclin-dependent kinase activity. There are 3 CCND genes in humans.","Cyclin D | CCND | Cyclin-D | G1/S-Specific Cyclin-D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0111429","Cyclin E","C104197","A protein family that is synthesized during the G1 phase of the cell cycle and drives the G1/S phase transition through the positive regulation of cyclin-dependent kinase 2 activity. There are 2 CCNE genes in humans.","Cyclin E | CCNE | Cyclin-E | G1/S-Specific Cyclin-E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413859","CYP1B1 Gene","C104233","This gene plays a role in eye development, steroid catabolism and xenobiotic metabolism.","CYP1B1 Gene | CYP1B1 | Cytochrome P450, Family 1, Subfamily B, Polypeptide 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414071","DLL3 Gene","C104254","This gene is involved in both notch-mediated signaling and neurogenesis.","DLL3 Gene | DLL3 | Delta Like Canonical Notch Ligand 3 Gene | Delta-Like 3 (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641733","Ganglioside GQ","C104201","A sialoglycosphingolipid that is a branched nonasaccharide containing five sialyl residues, two galactose residues, one N-acetylgalactosamine residue and a glucose residue. This ceramide is found associated with the surface of the plasma membrane in developing thymic epithelial cells, oligodendrocyte progenitors, neuroendocrine cells, neurons and neuroblastoma cells.","Ganglioside GQ | A2B5 | A2B5 Antigen | GQ Ganglioside",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539667","HES4 Gene","C104257","This gene plays a role in the repression of transcription.","HES4 Gene | HES4 | Hairy and Enhancer of Split 4 (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL439178","IkappaB Kinase Complex","C104199","An enzyme complex that is involved in serine/threonine phosphorylation, inflammation and the regulation of the nuclear factor kappa-light-chain-enhancer of activated B cells protein complex. I-kappa-B kinase is comprised of three proteins, inhibitor of nuclear factor kappa-B kinase subunit alpha, beta and gamma.","I-Kappa-B Kinase | IKK | IKappaB Kinase | IkappaB Kinase Complex | Inhibitor of Nuclear Factor Kappa-B Kinase | Nuclear Factor NF-Kappa-B Inhibitor Kinase | Nuclear Factor NFKappaB Inhibitor Kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416503","ITGB7 Gene","C104251","This gene plays a role in both cell-matrix adhesion and integrin-mediated signaling.","ITGB7 Gene | ITGB7 | Integrin, Beta 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024395","Lactate Dehydrogenase Isoenzyme 5","C104193","A protein complex that is comprised of a homotetramer of the L-lactate dehydrogenase A chain which is encoded by the human LDHA gene. This enzyme complex is involved in the last step of anaerobic glycolysis and is expressed in the liver and in skeletal muscle.","Lactate Dehydrogenase Isoenzyme 5 | HLDH5 | LD-5 | LDH Isoenzyme 5 | LDH-5 | Lactate Dehydrogenase Isoenzyme-5 | Lactic Dehydrogenase Isoenzyme 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541298","Oligodendrocyte Marker O4","C104202","A sulfated galactosylceramide that is a differentiation marker on the surface of oligodendrocyte precursors in the central nervous system.","Oligodendrocyte Marker O4 | O4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419096","PTPN13 Gene","C104212","This gene is involved in both protein dephosphorylation and signal transduction.","PTPN13 Gene | PTPN13 | Protein Tyrosine Phosphatase, Non-Receptor Type 13 (APO-1/CD95 (Fas)-Associated Phosphatase) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419150","PXN Gene","C104206","This gene plays a role in cytoskeleton remodeling.","PXN Gene | PXN | Paxillin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419237","RAD23B Gene","C104239","This gene is involved in DNA excision repair.","RAD23B Gene | RAD23 Homolog B (S. cerevisiae) Gene | RAD23B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419603","RORC Gene","C104245","This gene plays a role in steroid hormone receptor activity.","RORC Gene | RAR Related Orphan Receptor C Gene | RAR-Related Orphan Receptor C Gene | RORC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420610","TBX21 Gene","C104248","This gene is involved in the regulation of cytokine gene expression.","TBX21 Gene | T-Box 21 Gene | TBX21",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420826","TNNI3 Gene","C104223","This gene is involved in cardiac muscle contraction.","TNNI3 Gene | TNNI3 | TNNT2 | TNNT2 Gene | Troponin I3, Cardiac Type Gene | Troponin T Type 2 (Cardiac) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420828","TNNT2 Gene","C104216","This gene plays a role in muscle filament movement.","TNNT2 Gene | TNNT2 | Troponin T Type 2 (Cardiac) Gene | Troponin T2, Cardiac Type Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1540126","TUBB3 Gene","C104242","This gene is involved in microtubule function and structure.","TUBB3 Gene | TUBB3 | Tubulin Beta 3 Class III Gene | Tubulin, Beta 3 Class III Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0072054","Type III Procollagen N-Terminal Peptide","C104200","Type III procollagen N-terminal peptide (130 aa, ~13 kDa) is encoded by the human COL3A1 gene. This protein is produced by the cleavage of procollagen chains. Once the N-terminal peptides are removed, triple helical collagen fibrils can form. Increased serum levels of this peptide are associated with liver diseases.","Type III Procollagen N-Terminal Peptide | P3NP | PRO-C3 | Pro-Peptide of Type lll Collagen | Procollagen-3 N-Terminal Peptide | Procollagen-III N-Terminal Peptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985610","Stratum Group","C93397","A designation used to segregate study subjects into collections in order to balance the study for analysis. The stratum group is made up of a combination of stratification criterion answers, which ultimately is used to assign study subjects to arms on a study.","Stratum Group | StratumGroup",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522481","MART-1 Antigen","C28724","A tumor-associated melanocytic differentiation antigen. Vaccination with MART-1 antigen may stimulate a host cytotoxic T-cell response against tumor cells expressing the melanocytic differentiation antigen, resulting in tumor cell lysis. (NCI04)","MART-1 Antigen | Antigen LB39-AA | Antigen SK29-AA | MART-1 | MART-1 Tumor Antigen | MART-1 antigen | MART1 | MLANA | MLANA Protein | Melan A | Melan-A | Melan-A Protein | Melanoma Antigen Recognized by T-Cells 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346910","Cobimetinib","C68923","An orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. Cobimetinib specifically binds to and inhibits the catalytic activity of MEK1, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation and decreased tumor cell proliferation. Preclinical studies have demonstrated that this agent is effective in inhibiting the growth of tumor cells bearing a B-RAF mutation, which has been found to be associated with many tumor types. A threonine-tyrosine kinase and a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors, MEK1 is required for the transmission of growth-promoting signals from numerous receptor tyrosine kinases.","Cobimetinib | COBIMETINIB | Cotellic | GDC 0973 | GDC-0973 | GDC0973 | MEK Inhibitor GDC-0973 | MEK inhibitor GDC-0973 | XL 518 | XL-518 | XL518",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL408651","PI3K inhibitor GDC-0941 bismesylate","C82380","The orally bioavailable bismesylate salt of pictilisib, a small molecule inhibitor of class I phosphatidylinositol 3 kinase (PI3K), with potential antineoplastic activity. Upon administration, pictilisib selectively binds to PI3K in an ATP-competitive manner, inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K/Akt signaling pathway. This may result in inhibition of tumor cell growth, motility and survival in susceptible tumor cell populations. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis; dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","Pictilisib Bismesylate | 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1- ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine, bimesylate salt | GDC-0941 Bismesylate | GDC-0941 Dimesylate | PI3K Inhibitor GDC-0941 Bismesylate | PICTILISIB BISMESYLATE | Pictilisib Dimesylate | Thieno(3,2-d)pyrimidine, 2-(1H-indazol-4-yl)-6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)-, Methanesulfonate (1:2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152341","Internal Capsule","C13082","A white matter structure in the subcortical region of the brain that contains a high concentration of motor and sensory projection nerve fibers. It consists of the anterior limb, genu, posterior limb, and the retrolentiform and sublentiform parts.","Internal Capsule | BRAIN, INTERNAL CAPSULE | Internal capsule","C71.0","Internal capsule",,,,,,,,,,,,,"4311096","Internal capsule structure",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1822726","SIRPA Gene","C24710","This gene is involved in cellular signal transduction and tyrosine kinase-coupled signaling processes.","SIRPA Gene | SIRPA | Signal Regulatory Protein Alpha Gene | Signal-Regulatory Protein Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521061","20q13","C13466","A chromosome band present on 20q","20q13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517960","Loss of Chromosome 14q","C39795","A cytogenetic abnormality that refers to the loss of all or part of the long arm of chromosome 14 (14q).","Loss of Chromosome 14q | del(14q)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332713","CD47 Gene","C24278","This gene is involved in the regulation of calcium levels in cellular matrix adhesion processes.","CD47 Gene | CD47 | CD47 Antigen (Rh-Related Antigen, Integrin-Associated Signal Transducer) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336666","TRAF6 Gene","C21469","This gene plays a role in signal transduction and regulation of apoptosis. It is also involved in the immune response and bone homeostasis.","TRAF6 Gene | TNF Receptor Associated Factor 6 Gene | TRAF6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1446172","Retinol Binding Protein Measurement","C100437","The determination of the amount of retinol binding protein present in a sample.","Retinol Binding Protein Measurement | RBP | Retinol Binding Protein",,,,,,,,,,,,,,,"4135657","Retinol binding protein measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1335633","ROR1 Gene","C24745","This gene is thought to play a role in skeletal and cardiac development, but an exact function has yet to be determined.","ROR1 Gene | ROR1 | Receptor Tyrosine Kinase Like Orphan Receptor 1 Gene | Receptor Tyrosine Kinase-Like Orphan Receptor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0694872","CDH1 Gene","C18249","This gene plays a role in cell-cell adhesion and loss of function contributes to the progression of many carcinomas.","CDH1 Gene | CDH1 | Cadherin 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333925","HRK Gene","C20418","This gene plays a role in apoptotic activation.","HRK Gene | HRK | Harakiri Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413188","CCR2 Gene","C101577","This gene plays a role in chemokine signaling.","CCR2 Gene | CCR2 | Chemokine (C-C Motif) Receptor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202252","Vitamin B12 Measurement","C64817","A quantitative measurement of the amount of vitamin B12 present in a sample.","Vitamin B12 Measurement | Cobalamin | VITB12 | Vitamin B12",,,,,,,,,,,,,,,"4032173","Vitamin B12 measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1283048","Total Iron Binding Capacity","C74718","The determination of the saturation of iron binding sites on serum transferrin proteins.","Total Iron Binding Capacity | IBCT | TIBC",,,,,,,,,,,,,,,"4235028","Total iron binding capacity measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0337439","Iron Measurement","C74679","The determination of the amount of iron present in a sample.","Iron Measurement | FE | IRON | Iron",,,,,,,,,,,,,,,"4178785","Iron measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1336630","TIMP3 Gene","C28680","This gene plays a role in the degradation of the extracellular matrix. It is also involved in the induction of apoptosis and inhibition of angiogenesis.","TIMP3 Gene | TIMP3 | Tissue Inhibitor of Metalloproteinase 3 (Sorsby Fundus Dystrophy, Pseudoinflammatory) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414462","ESR2 Gene","C38363","This gene plays a role in extracellular signal transduction that is coupled to transcriptional responses.","ESR2 Gene | ESR2 | Estrogen Receptor 2  Gene | Estrogen Receptor 2 (ER Beta) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414461","ESR1 Gene","C38349","This gene is involved in ligand-activated transcriptional activity.","ESR1 Gene | ER | ESR1 | Estrogen Receptor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366496","CYP19A1 Gene","C26501","This gene is involved in development and estrogen metabolism.","CYP19A1 Gene | CYP19A1 | Cytochrome P450 Family 19 Subfamily A Member 1 Gene | Cytochrome P450, Family 19, Subfamily A, Polypeptide 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1337032","XRCC3 Gene","C20335","This gene plays a role in recombination and in the maintenance of DNA integrity.","XRCC3 Gene | X-Ray Repair Complementing Defective Repair in Chinese Hamster Cells 3 Gene | XRCC3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366475","XRCC1 Gene","C19675","This gene is involved in single-strand DNA break repair.","XRCC1 Gene | X-Ray Repair Complementing Defective Repair in Chinese Hamster Cells 1 Gene | XRCC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413873","CYP2C8 Gene","C46071","This gene plays a role in drug metabolism. It is also involved in the oxidation of both endobiotics and xenobiotics.","CYP2C8 Gene | CYP2C8 | Cytochrome P450, Family 2, Subfamily C, Polypeptide 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334089","IGF1 Gene","C24485","This gene is involved in cellular communication, growth and proliferation. It also plays a role in the regulation of muscular and skeletal development.","IGF1 Gene | IGF1 | Insulin-Like Growth Factor 1 (Somatomedin C) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919505","Fibroblast Growth Factor Gene Family","C18568","The Fibroblast Growth Factor Gene Family encodes Fibroblast Growth Factor peptides, potent mitogens that stimulate mesodermal cell growth, including chondrocytes, granulosa, and endothelia, and may be active in wound healing and regeneration. (NCI)","Fibroblast Growth Factor Gene Family | FGF | FGF Family Gene | FGF Gene Family | Fibroblast Growth Factor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333359","ERCC5 Gene","C20557","This gene plays a role in the nucleotide base excision repair of UV-induced DNA damage and mutations of the gene cause Cockayne syndrome.","ERCC5 Gene | ERCC Excision Repair 5, Endonuclease Gene | ERCC5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333358","ERCC4 Gene","C20558","This gene is involved in nucleotide excision repair and is involved in the correction of defective nucleotide excision repair in xeroderma pigmentosum cells of complementation group F.","ERCC4 Gene | ERCC Excision Repair 4, Endonuclease Catalytic Subunit Gene | ERCC4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421540","XPC Gene","C97870","This gene is involved in nucleotide excision repair.","XPC Gene | XPC | XPC Complex Subunit, DNA Damage Recognition and Repair Factor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1337030","XPA Gene","C20361","This gene facilitates DNA binding in repair processes and is associated with the disease xeroderma pigmentosum complementation group A.","XPA Gene | XPA | Xeroderma Pigmentosum, Complementation Group A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537846","MIR210 Gene","C81793","This gene is involved in the regulation of gene expression and plays a role in the development of carcinoma of the breast and acute promyelocytic leukemia.","MIR210 Gene | MIR210 | MicroRNA 210 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031869","Pia Mater","C33321","The delicate, highly vascular, innermost membrane encasing the brain and spinal cord.","Pia Mater | ",,,,,,,,,,,,,,,"4050717","Pia mater structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0228092","Ependymal Cell","C13003","A cell that lines cavities in the central nervous system.  It is considered to be a type of glial cell.","Ependymal Cell | Ependymal Cells | Ependymocyte | ependymal cell",,,,,,,,,,,,,,,"4263445","Ependymal cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518966","Zubrod Performance Status 0","C19998","Fully active, able to carry on all pre-disease performance without restriction. (Eastern Cooperative Oncology Group)","Zubrod Performance Status 0 | Performance Status 0 | Performance Status 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518967","Zubrod Performance Status 1","C19999","Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work (Eastern Cooperative Oncology Group)","Zubrod Performance Status 1 | Karnofsky 80-90 | Performance Status 1 | Performance Status 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029928","Ovarian Disorder","C26841","A non-neoplastic or neoplastic disorder that affects the ovary. Representative examples of non-neoplastic disorders include endometriosis and polycystic ovarian disease. Representative examples of neoplastic disorders include ovarian surface epithelial-stromal tumors, germ cell tumors, and sex cord-stromal tumors.","Ovarian Disorder | Ovarian Disease",,,,,,,,,,,,,,,"4207977","Disorder of ovary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641735","Eloquent Brain Areas","C104262","Areas of the brain that control speech, motor functions, and sensory processing which are required for an individual to understand and interact with others and the environment.","Eloquent Brain Areas | Eloquent Brain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518744","Ovarian Tissue","C33246","Tissue comprised of specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships in order to carry out the functions of production and ovulation of oocytes and the production and secretion of hormones.","Ovarian Tissue | Human Ovarian Tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981883","Breast Cancer Clinical Regional Lymph Nodes TNM Finding v7","C88366","A clinical finding about one or more characteristics of breast cancer, following the rules of the TNM AJCC v7 classification system as they pertain to staging of regional lymph nodes.","Breast Cancer Clinical Regional Lymph Nodes TNM Finding v7 | Breast Carcinoma Clinical Regional Lymph Nodes TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981867","Breast Cancer Pathologic Regional Lymph Nodes TNM Finding v7","C88348","A pathologic finding about one or more characteristics of breast cancer, following the rules of the TNM AJCC v7 classification system as they pertain to staging of regional lymph nodes.  The classification is based on axillary lymph node dissection with or without sentinel lymph node biopsy. (partially adapted from AJCC 7th Ed.)","Breast Cancer Pathologic Regional Lymph Nodes TNM Finding v7 | Breast Carcinoma Pathologic Regional Lymph Nodes TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981868","Breast Cancer pN0 TNM Finding v7","C88349","Breast cancer without histological evidence of regional lymph node involvement.  Lymph nodes containing only isolated tumor cell clusters are excluded from the total positive node count for purposes of regional lymph node classification, but should be included in the total number of nodes evaluated. (from AJCC 7th Ed.)","Breast Cancer pN0 TNM Finding v7 | Breast Carcinoma pN0 TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981870","Breast Cancer pN0(i+) TNM Finding v7","C88351","Breast cancer with malignant cells in regional lymph node(s) no greater than 0.2 mm (detected by H&E or immunohistochemistry including isolated tumor cell clusters).  (from AJCC 7th Ed.)","Breast Cancer pN0(i+) TNM Finding v7 | Breast Carcinoma pN0(i+) TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981869","Breast Cancer pN0(i-) TNM Finding v7","C88350","Breast cancer without histological evidence of regional lymph node involvement, and with negative immunohistochemistry.  (from AJCC 7th Ed.)","Breast Cancer pN0(i-) TNM Finding v7 | Breast Carcinoma pN0(i-) TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981871","Breast Cancer pN1 TNM Finding v7","C88352","Breast cancer with micrometastases; or metastases in 1 to 3 axillary lymph nodes; and/or metastases in internal mammary nodes, with the metastases detected by sentinel lymph node biopsy but not clinically detected.  'Not clinically detected' is defined by imaging studies (excluding lymphoscintigraphy) or by clinical examination. (from AJCC 7th Ed.)","Breast Cancer pN1 TNM Finding v7 | Breast Carcinoma pN1 TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981873","Breast Cancer pN1b TNM Finding v7","C88354","Breast cancer with metastases in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected.  'Not clinically detected' is defined by imaging studies (excluding lymphoscintigraphy) or by clinical examination. (from AJCC 7th Ed.)","Breast Cancer pN1b TNM Finding v7 | Breast Carcinoma pN1b TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981874","Breast Cancer pN1c TNM Finding v7","C88355","Breast cancer with metastases in 1 to 3 axillary lymph nodes and in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected.  'Not clinically detected' is defined by imaging studies (excluding lymphoscintigraphy) or by clinical examination. (from AJCC 7th Ed.)","Breast Cancer pN1c TNM Finding v7 | Breast Carcinoma pN1c TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981872","Breast Cancer pN1mi TNM Finding v7","C88353","Breast cancer with micrometastases (greater than 0.2 mm and/or more than 200 cells, but none greater than 2.0 mm) (from AJCC 7th Ed.)","Breast Cancer pN1mi TNM Finding v7 | Breast Carcinoma pN1mi TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981876","Breast Cancer pN2 TNM Finding v7","C88358","Breast cancer with metastases in 4 to 9 axillary lymph nodes, or metastases in clinically detected internal mammary lymph nodes in the absence of axillary lymph node metastases.  'Clinically detected' is defined as detected by imaging studies (excluding lymphoscintigraphy) or by clinical examination and having characteristics highly suspicious for malignancy or a presumed pathologic macrometastasis based on fine needle aspiration biopsy with cytologic examination. (from AJCC 7th Ed.)","Breast Cancer pN2 TNM Finding v7 | Breast Carcinoma pN2 TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981877","Breast Cancer pN2b TNM Finding v7","C88360","Breast cancer with metastases in clinically detected internal mammary lymph nodes in the absence of axillary lymph node metastases.  'Clinically detected' is defined as detected by imaging studies (excluding lymphoscintigraphy) or by clinical examination and having characteristics highly suspicious for malignancy or a presumed pathologic macrometastasis based on fine needle aspiration biopsy with cytologic examination. (from AJCC 7th Ed.)","Breast Cancer pN2b TNM Finding v7 | Breast Carcinoma pN2b TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981878","Breast Cancer pN3 TNM Finding v7","C88361","Breast cancer with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or in clinically detected ipsilateral internal mammary lymph nodes in the presence of 1 or more positive level I, II axillary lymph nodes; or in more than 3 axillary lymph nodes and in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected; or in ipsilateral supraclavicular lymph nodes. (from AJCC 7th Ed.)","Breast Cancer pN3 TNM Finding v7 | Breast Carcinoma pN3 TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981879","Breast Cancer pN3b TNM Finding v7","C88362","Breast cancer with metastases in clinically detected ipsilateral internal mammary lymph nodes in the presence of 1 or more positive axillary lymph nodes; or in more than 3 axillary lymph nodes and in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected. (from AJCC 7th Ed.)","Breast Cancer pN3b TNM Finding v7 | Breast Carcinoma pN3b TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1138427","Integrin alphaVbeta3","C38953","Involved in cell adhesion and signaling, human Integrin-aVBeta3 is composed of type I membrane protein chains Integrin Alpha V (disulfide-linked heavy and light chains) and Integrin Beta 3 that recognize RGD sequences. Multiple heterodimeric alpha/beta combinations result in different integrins. aV/beta-3 is a receptor for cytotactin, fibronectin, laminin, MMP-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin, and von Willebrand factor. (NCI)","Integrin AlphaV/Beta3 | Integrin Alpha-V/Beta-3 | Integrin aV/b3 | Integrin aVBeta3 | Integrin aVBeta3 | aV/b3 | aVBeta3 | aVBeta3 Integrin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415855","ID1 Gene","C99648","This gene plays a role in transcriptional repression.","ID1 Gene | ID1 | Inhibitor of DNA Binding 1, Dominant Negative Helix-Loop-Helix Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412182","ADAM12 Gene","C96034","This gene plays a role in the regulation of proteolysis.","ADAM12 Gene | ADAM Metallopeptidase Domain 12 Gene | ADAM12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418259","PAK1 Gene","C42592","This gene is involved in signal transduction and the regulation of both cell mobility and morphology.","PAK1 Gene | PAK1 | p21/Cdc42/Rac1-Activated Kinase 1 (STE20 Homolog, Yeast) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420466","AURKA Gene","C24838","This gene is involved in cell cycle regulation and cell survival.","AURKA Gene | AURKA | Aurora Kinase A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426958","BRIP1 Gene","C63526","This gene is involved in DNA double-strand break repair.","BRIP1 Gene | BRCA1 Interacting Protein C-Terminal Helicase 1 Gene | BRIP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0851194","Biliary Stenting","C62741","Surgical placement of a plastic or metal tube into the bile duct to treat bile duct stricture.","Biliary Stenting | ",,,,,,,,,,,,,,,"3656144|4341104","Insertion of biliary stent|Insertion of bile duct prosthesis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1366513","CASP4 Gene","C28429","This gene is involved in the promotion of apoptosis.","CASP4 Gene | CASP4 | Caspase 4, Apoptosis-Related Cysteine Protease Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538756","PYCARD Gene","C93105","This gene plays a role in the regulation of apoptosis.","PYCARD Gene | PYCARD | PYD and CARD Domain Containing Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332728","CDH13 Gene","C20723","This gene is a mediator of cell-cell adhesion and a negative regulator of neural growth.","CDH13 Gene | CDH13 | Cadherin 13, H-Cadherin (Heart) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366459","BCAR1 Gene","C20767","This gene plays a role in signal transduction and is involved in cell adhesion, migration and proliferation.","BCAR1 Gene | BCAR1 | BCAR1, Cas Family Scaffolding Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332433","BMX Gene","C21370","This gene plays a role in development. It is also involved in both cell growth and differentiation.","BMX Gene | BMX | BMX Non-Receptor Tyrosine Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003695","Arachidonic Acid","C282","An unsaturated, essential fatty acid. It is found in animal and human fat as well as in the liver, brain, and glandular organs, and is a constituent of animal phosphatides. It is formed by the synthesis from dietary linoleic acid and is a precursor in the biosynthesis of prostaglandins, thromboxanes, and leukotrienes.(ChemID Plus)","Arachidonic Acid | (all-Z)-5,8,11,14-Eicosatetraenoic Acid | ARACHIDONIC ACID | All-cis-icosa-5,8,11,14-tetraenoic acid | Arachidonate | Fatty Acid 20:4 n-6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023749","Linoleic Acid","C615","A polyunsaturated essential fatty acid found mostly in plant oils. It is used in the biosynthesis of prostaglandins and cell membranes.","Linoleic Acid | (Z,Z)-9,12-Octadecadienoic Acid | 9,12-Linoleic Acid | Cis, cis-octadeca-9,12-dienoic acid | Fatty Acid 18:2 n-6 | LINOLEIC ACID | Linoleic acid | Linolic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982752","Bladder Cancer Clinical TNM Finding v7","C89362","A clinical finding about one or more characteristics of bladder cancer, following the rules of the TNM AJCC v7 classification system.  Primary tumor assessment includes bimanual examination under anesthesia before and after endoscopic surgery (biopsy or transurethral resection) and histologic verification of the presence or absence of tumor when indicated.  Appropriate imaging techniques for extravesical extension of the primary tumor and lymph node evaluation should be incorporated into clinical staging. (from AJCC 7th Ed.)","Bladder Cancer Clinical TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596123","AHR Gene","C28523","This gene is involved in the regulation of xenobiotic-metabolizing enzymes.","AHR Gene | AHR | Aryl Hydrocarbon Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334868","NCOA3 Gene","C20699","This gene plays a role in regulation of transcription.","NCOA3 Gene | NCOA3 | Nuclear Receptor Coactivator 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366525","RGS1 Gene","C24735","This gene plays a role in signal transduction, protein binding and B-cell activation.","RGS1 Gene | RGS1 | Regulator of G-Protein Signaling 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279680","Bladder Urothelial Carcinoma","C39851","A carcinoma that arises from the urothelial lining of the bladder.  It is the most common morphologic type of urinary bladder carcinoma. It usually affects males in their sixth and seventh decades of life.  Hematuria is the most common symptom at presentation. Pathologic stage is the strongest predictor of survival.","Bladder Urothelial Carcinoma | BLCA | Bladder Transitional Cell Carcinoma | Bladder Urothelial Cancer | Transitional Cell Carcinoma of the Urinary Bladder | Urinary Bladder Transitional Cell Carcinoma | Urinary Bladder Urothelial Carcinoma | Urothelial Carcinoma of the Urinary Bladder",,,,,,,,,,,,,,,"4113111","Transitional cell carcinoma of bladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641779","Divergent Differentiation","C104333","A microscopic finding indicating that a tumor exhibits more than one line of histologic differentiation.","Divergent Differentiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519494","Squamous Differentiation","C38770","A microscopic finding indicating the presence of cells with squamous differentiation in a tumor sample.","Squamous Differentiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512748","Infiltrating Bladder Urothelial Carcinoma with Squamous Differentiation","C39816","An invasive urothelial carcinoma of the bladder that exhibits squamous differentiation.","Invasive Bladder Urothelial Carcinoma with Squamous Differentiation | Bladder Urothelial Carcinoma with Squamous Differentiation | Infiltrating Bladder Urothelial Carcinoma with Squamous | Infiltrating Bladder Urothelial Carcinoma with Squamous Differentiation | Infiltrating Bladder Urothelial Carcinoma with Squamous Differentiation | Urothelial carcinoma with squamous differentiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711212","Glandular Differentiation","C43573","A microscopic finding indicating the presence of cells with glandular differentiation in a tumor sample.","Glandular Differentiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512747","Infiltrating Bladder Urothelial Carcinoma with Glandular Differentiation","C39817","An invasive urothelial carcinoma of the bladder that exhibits glandular differentiation.","Invasive Bladder Urothelial Carcinoma with Glandular Differentiation | Bladder Urothelial Carcinoma with Glandular Differentiation | Infiltrating Bladder Urothelial Carcinoma with Glandular Differentiation | Infiltrating Bladder Urothelial Carcinoma with Glandular Differentiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519183","Sarcomatoid Features","C39694","A microscopic finding indicating the presence of cells with sarcomatoid, usually spindle cell differentiation in a tumor sample.","Sarcomatoid Features | Sarcomatoid Differentiation | Sarcomatoid Differentiation  | Sarcomatoid Element | sarcomatoid present | sarcomatoid_present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512743","Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant","C39824","An invasive urothelial carcinoma of the bladder that exhibits spindle cell sarcomatoid features.","Invasive Bladder Sarcomatoid Urothelial Carcinoma | Bladder Carcinosarcoma | Bladder Sarcomatoid Urothelial Carcinoma | Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant | Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant | Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant | Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant | Invasive Bladder Urothelial Carcinoma, Sarcomatoid Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887644","Inflammatory Infiltrate","C35978","A microscopic finding indicating the presence of acute, subacute or chronic inflammation in a tissue sample.","Inflammatory Infiltrate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336028","Solid Growth Pattern","C36182","A microscopic finding indicating that the neoplastic cells are arranged in solid sheets in a tumor sample.","Solid Growth Pattern | Solid | Solid Pattern",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334948","Nested Pattern","C35892","A microscopic finding indicating that the neoplastic cells are arranged in compact nests in a tumor sample.","Nested Pattern | Nested Proliferation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512752","Infiltrative Growth Pattern","C41453","A microscopic finding indicating that the neoplastic cells exhibit an infiltrating growth in a tumor sample.","Infiltrative Growth Pattern | Infiltrative Growth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336770","Trabecular Pattern","C35913","A microscopic finding indicating that the neoplastic cells are arranged in trabeculae in a tumor sample.","Trabecular Pattern | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704323","Nipple Paget Disease","C3301","A malignant epithelial cellular proliferation characterized by the presence of atypical cells with large nuclei and abundant pale cytoplasm within the squamous epithelium of the nipple.  In almost all cases there is an underlying intraductal breast carcinoma or intraductal and invasive carcinoma.  The skin changes range from redness to eczematous appearance.","Nipple Paget Disease | Nipple Paget's Disease | Paget Disease of the Nipple | Paget Disease of the Nipple | Paget's Disease of Nipple | Paget's Disease of the Nipple | Paget's disease of the nipple",,,,,,,,,,,,,,,"4301516","Paget's disease of nipple",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3839745","Nipple Syringomatous Tumor","C40363","An invasive, non-metastasizing neoplasm with sweat duct differentiation that arises in the area of the nipple.  Local recurrences have been reported.","Nipple Syringomatous Tumor | Infiltrating Nipple Syringomatous Adenoma | Nipple Syringomatous Adenoma | Nipple Syringomatous Adenoma | Syringomatous Tumor of the Nipple",,,,,,,,,,,,,,,"45766403","Syringomatous tumor of nipple",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334378","Nipple Adenoma","C4192","A benign epithelial neoplasm arising from the nipple. Signs and symptoms include serous or sanguineous nipple discharge and nipple erosion. It is characterized by the presence of aggregates of small tubules replacing the nipple stroma. The tubules are lined by epithelial and myoepithelial cells.","Nipple Adenoma | Adenoma of Nipple | Adenoma of nipple | Adenoma of the Nipple | Erosive Nipple Adenomatosis | Subareolar Duct Papillomatosis | Subareolar duct papillomatosis","8506/0","Adenoma of nipple",,,,,,,,,,,,,"4121329|4280667","Adenoma of nipple|Adenoma of the nipple",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1518974","Breast Periductal Myoepitheliosis","C40388","A neoplastic process characterized by the proliferation of spindle to cuboidal myoepithelial cells around small breast ducts.","Breast Periductal Myoepitheliosis | Periductal Breast Myoepitheliosis | Periductal Breast Myoepitheliosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037579","Soft Tissue Neoplasm","C3377","A benign, intermediate, or malignant neoplasm that arises from the soft tissue.  The most common types are lipomatous (fatty), vascular, smooth muscle, fibrous, and fibrohistiocytic neoplasms.","Soft Tissue Neoplasm | Neoplasm of Soft Tissue | Neoplasm of the Soft Tissue | Soft Tissue Tumor | Soft Tissue Tumors | Soft tissue neoplasm, NOS | Tumor of Soft Tissue | Tumor of the Soft Tissue",,,,,,,,,,,,,,,"4308811","Neoplasm of soft tissue",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1511307","Breast Ductal Adenoma","C40384","A benign, well circumscribed neoplasm that is located within the lumen of a duct in the breast parenchyma.  It is characterized by the presence of glandular structures at the periphery and fibrous tissue at the center of the tumor.","Breast Ductal Adenoma | Ductal Adenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334345","Apocrine Adenoma","C4168","A benign epithelial neoplasm arising from the apocrine sweat glands. Representative examples include tubular apocrine adenoma and external auditory canal ceruminous adenoma.","Apocrine Adenoma | Apocrine adenoma","8401/0","Apocrine adenoma",,,,,,,,,,,,,"4141246|4265396","Apocrine adenoma|Apocrine adenoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1266023","Lactating Adenoma","C9473","A tubular type adenoma of the breast in which, during pregnancy and lactation, the epithelial cells show extensive secretory changes.","Lactating Adenoma | Lactating adenoma | Pregnancy Adenoma","8204/0","Lactating adenoma",,,,,,,,,,,,,"4028537","Lactating adenoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334372","Breast Papillary Ductal Carcinoma In Situ","C4190","Breast ductal carcinoma in situ characterized by the presence of filiform arborizing fibrovascular cores lined by neoplastic ductal epithelium. (WHO 2019)","Breast Papillary Ductal Carcinoma In Situ | Breast Intracystic Papillary Carcinoma | Breast Intraductal Papillary Carcinoma | Breast Intraductal Papillary Carcinoma | Breast Papillary DCIS | Intraductal Papillary Adenocarcinoma | Intraductal Papillary Breast Adenocarcinoma | Intraductal Papillary Breast Carcinoma | Intraductal Papillary Breast Carcinoma | Intraductal Papillary Carcinoma | Intraductal papillary carcinoma | Non-Infiltrating Intraductal Papillary Adenocarcinoma | Non-Infiltrating Intraductal Papillary Carcinoma | Non-Infiltrating Papillary Breast Adenocarcinoma | Non-Infiltrating Papillary Breast Carcinoma | Non-Invasive Intraductal Papillary Adenocarcinoma | Non-Invasive Intraductal Papillary Carcinoma | Non-Invasive Papillary Breast Adenocarcinoma | Non-Invasive Papillary Breast Carcinoma | Papillary DCIS | Papillary Ductal Carcinoma In Situ","8503/2","Noninfiltrating intraductal papillary adenocarcinoma",,,,,,,,,,,,,"4148449","Noninfiltrating intraductal papillary adenocarcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1333620","Breast Flat Ductal Epithelial Atypia","C36086","A breast lesion characterized by the presence of dilated terminal ductal lobular units in which the epithelial lining has been replaced by a single layer of mildly atypical cells, or there is atypical, monotonous epithelial hyperplasia of three to five layers.  This lesion relates to columnar cell change with atypia and columnar cell hyperplasia with atypia.","Breast Flat Ductal Epithelial Atypia | Clinging Carcinoma | Clinging Carcinoma In Situ | DIN 1A | Ductal Intraepithelial Neoplasia, Grade 1A | FEA | Flat Ductal Epithelial Atypia | Flat Ductal Epithelial Atypia of the Breast | Flat Ductal Epithelial Atypia of the Breast | Flat Epithelial Atypia | Flat Epithelial Atypia of the Breast",,,,,,,,,,,,,,,"3655352","Flat epithelial atypia of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0861352","Breast Lobular Neoplasia","C27939","A spectrum of non-invasive neoplastic lesions that arise from the terminal ductal lobular units of the breast.  There is atypical small epithelial cell proliferation.  Pagetoid involvement of the terminal ducts may or may not be present.  In the minority of cases, there is a risk for subsequent development of invasive ductal or invasive lobular carcinoma.","Breast Lobular Neoplasia | Breast LN | LIN | LN | Lobular Intraepithelial Neoplasia | Lobular Neoplasia | Lobular Neoplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334318","Lipid-Rich Carcinoma","C4152","A carcinoma characterized by the presence of malignant epithelial cells with clear cytoplasm which contains neutral lipids. A representative example is the lipid-rich breast carcinoma.","Lipid-Rich Carcinoma | Lipid-rich carcinoma","8314/3","Lipid-rich carcinoma",,,,,,,,,,,,,"4244518","Lipid-rich carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1511304","Breast Carcinoma with Osteoclast-Like Stromal Giant Cells","C40349","An invasive breast adenocarcinoma characterised by the presence of non-neoplastic stromal osteoclastic giant cells.  The carcinomatous component is usually an invasive ductal carcinoma, although all other breast adenocarcinoma subtypes have also been described.  The prognosis depends on the characteristics of the adenocarcinomatous component, and is not related to the presence of the giant cells.","Breast Carcinoma with Osteoclast-Like Stromal Giant Cells | Breast Carcinoma with Osteoclastic Giant Cells | Breast Carcinoma with Osteoclastic Giant Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334233","Pleomorphic Carcinoma","C4094","A usually aggressive malignant epithelial neoplasm composed of cells with significant cytologic atypia and nuclear pleomorphism.","Pleomorphic Carcinoma | Pleomorphic carcinoma","8022/3","Pleomorphic carcinoma",,,,,,,,,,,,,"4055959","Pleomorphic carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"CL322828","Autologous Anti-MART-1 F5 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes","C38587","Human autologous peripheral blood lymphocytes (PBLs) transduced with a melanoma antigen MART-1 epitope-determined T cell receptor (TCR) gene, with potential antineoplastic activity. PBLs are isolated from a melanoma patient and pulsed with a viral vector that encodes the TCR specific for an epitope of MART-1 (F5 TCR). After expansion ex vivo, the transduced autologous PBLs, expressing this specific TCR, are reintroduced into the patient, and bind to melanoma cells expressing the MART-1 antigen, which may result in specific cytotoxic T-lymphocyte (CTL) killing of MART-1-expressing melanoma cells. MART-1 (melanoma antigen recognized by T cells 1), also known as Melan-A, is a melanocyte lineage-specific transmembrane protein.","Autologous Anti-MART-1 F5 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes | Anti-MART-1 TCR Retroviral Vector-Transduced Autologous PBL | MSGV1AIB (Anti-MART-1 TCR) Retroviral Vector-Transduced Autologous PBL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2931031","Pseudoangiomatous Stromal Hyperplasia","C104373","A benign proliferation of the stromal cells in the breast.  It is classified as simple, when associated with the presence of slit-like spaces without erythrocytes and as fascicular/proliferative, when spindle cell proliferation without atypia is present.  It is often seen in breast tissue specimens as small foci associated with benign epithelial lesions.  Pseudoangiomatous stromal hyperplasia presenting as a well-circumscribed palpable mass is rare.","Pseudoangiomatous Stromal Hyperplasia | Breast Pseudoangiomatous Stromal Hyperplasia | PASH",,,,,,,,,,,,,,,"45767676","Pseudoangiomatous stromal hyperplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517631","K-562","C19437","The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises. The K562 line is composed of undifferentiated blast cells that are rich in glycophorin and may be induced to produce fetal and embryonic hemoglobin in the presence of hemin.","K-562 | K562 | K562 blasts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641743","Trouble Taking Long Walk","C104281","A question about whether an individual has or had trouble taking a long walk.","Trouble Taking Long Walk Question | Do you have any trouble taking a long walk | Trouble Taking Long Walk | Trouble Taking Long Walk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641744","Trouble Taking Short Walk Outside House","C104282","A question about whether an individual has or had trouble taking a short walk outside the house.","Trouble Taking Short Walk Outside House Question | Do you have any trouble taking a short walk outside of the house | Trouble Taking Short Walk Outside House | Trouble Taking Short Walk Outside House",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641745","Stay in Bed or Chair During Day","C104283","A question about whether an individual needs or needed to stay in either a bed or a chair during the day.","Stay in Bed or Chair During Day Question | Do you need to stay in bed or a chair during the day | Stay in Bed or Chair During Day | Stay in Bed or Chair During Day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641746","Need Help with Eating, Dressing, Washing or Toilet","C104284","A question about whether an individual requires or required assistance with eating, dressing, washing themselves or using the toilet.","Need Help with Eating, Dressing, Washing or Toilet | Do you need help with eating, dressing, washing yourself or using the toilet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641748","Limited in Pursuing Hobbies or Leisure Activities","C104286","A question about whether an individual limits or was limited in pursuing their hobbies or leisure time activities.","Limited in Pursuing Hobbies or Leisure Activities | Were you limited in pursuing your hobbies or other leisure time activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641751","Need Rest","C104293","A question about whether an individual needs or needed rest.","Need Rest | Did you need to rest",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641752","Trouble Sleeping (question)","C104294","A question about whether an individual has or had trouble sleeping.","Trouble Sleeping | Did you have trouble with sleep | Difficulty Sleeping | Do you have trouble sleeping | Have Trouble Sleeping | Have you had trouble sleeping | I had trouble sleeping | I have trouble sleeping | Trouble falling/staying asleep or sleeping too much | Trouble falling/staying asleep or sleeping too much  | Trouble sleeping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538976","Have you felt weak (question)","C104295","A question about whether an individual feels or felt weak.","Feel Weak | Do you feel physically weak (not strong) | Feeling physically weak (not strong) | Felt Weak | Have you felt weak | I feel physically weak (not strong) | I felt weak | Weak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641753","Lacks Appetite","C104296","A question about whether an individual lacks or lacked an appetite.","Lacks Appetite | Have you lacked appetite | Lack of Appetite | Lack of appetite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641754","Have Emesis","C104298","A question about whether an individual has vomited.","Have Emesis | Had Emesis | Have you vomited",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641755","Have Constipation","C104299","A question about whether an individual is or has been constipated.","Have Constipation | Constipation | Had Constipation | Have Been Constipated | Have you been constipated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641756","Have Diarrhea","C104300","A question about whether an individual has or had diarrhea.","Have Diarrhea | Diarrhea | Had Diarrhea | Have you had diarrhea | I have diarrhea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539029","Feel Tired question","C104301","A question about whether an individual feels or felt tired.","Feel Tired | Do you feel tired | Feeling tired | Feeling tired or having little energy | Feeling tired or having little energy  | Felt Tired | I feel tired | Tired | Were you tired",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641757","Feel Tense","C104302","A question about whether an individual feels or has felt tense.","Feel Tense | Am Tense | Did you feel tense | Felt Tense | Have you felt tense or high-strung | I feel tense | I feel tense or wound up",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641758","Feel Worry","C104304","A question about whether an individual feels or felt worried.","Feel Worried | Did you worry | Feel Worry | Feel Worry | Felt Worried | Had Worrying | Have Worried | I felt worried | Worrying",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641759","Difficulty Concentrating Reading Newspaper or Watching Television","C104307","A question about whether an individual has or had difficulty concentrating while reading a newspaper or watching the television.","Difficulty Concentrating Reading Newspaper or Watching Television | Have you had difficulty in concentrating on things, like reading a newspaper or watching television | Trouble concentrating on things, such as reading the newspaper or watching television | Trouble concentrating on things, such as reading the newspaper or watching television ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641760","Feel Irritable","C104308","A question about whether an individual feels or felt irritable.","Feel Irritable | Do you feel irritable | Feeling irritable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539030","Feel Depressed question","C104309","A question about whether an individual feels or felt depressed.","Feel Depressed | Did you feel depressed | Do you feel depressed | Feeling down, depressed, or hopeless | Feeling down, depressed, or hopeless  | Felt Depressed | I felt depressed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641761","Interference with Family Life due to Physical Condition or Medical Treatment","C104310","A question about whether an individual's physical condition or medical treatment interferes or has interfered with their family life.","Interference with Family Life due to Physical Condition or Medical Treatment | Has your physical condition or medical treatment interfered with your family life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641762","Interference with Social Activities due to Physical Condition or Medical Treatment","C104311","A question about whether an individual's physical condition or medical treatment interferes or has interfered with their social activities.","Interference with Social Activities due to Physical Condition or Medical Treatment | Has your physical condition or medical treatment interfered with your social activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641763","Financial Difficulties due to Physical Condition or Medical Treatment","C104312","A question about whether an individual has or had financial difficulties due to their physical condition or medical treatment.","Financial Difficulties due to Physical Condition or Medical Treatment | Has your physical condition or medical treatment caused you financial difficulties",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641764","Overall Health Rating During Past Week","C104313","A question about an individual's rating of their overall health during the past week.","Overall Health Rating During Past Week | How would you rate your overall health during the past week",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641765","Overall Quality of Life Rating During Past Week","C104314","A question about an individual's rating of the overall quality of life during the past week.","Overall Quality of Life Rating During Past Week | How would you rate your overall quality of life during the past week",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641766","Very Poor","C104315","Of especially low value or worth.","Very Poor | Very poor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641780","European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30","C104355","A 30-item questionnaire about patient ability to function, symptoms related to the cancer and its treatment, overall health and quality of life, and perceived financial impact of cancer and its treatment.","European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 | EORTC QLC-C30 | EORTC QLC-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30  | The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641781","Concern About Home Life Disruption","C104365","A question about whether an individual has or had concerns about disruption of their home life.","Concern About Home Life Disruption | Concerned About Home Life Disruption | Were you concerned about disruption of home life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641783","Distress About Illness or Treatment to Those Close to You","C104367","A question about whether an individual feels those close to them are distressed by their disease or treatment.","Distress About Illness or Treatment to Those Close to You | How distressing has your illness or treatment been to those close to you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641772","Feel Abdomen is Bloated","C104323","A question about whether an individual feels or felt their abdomen is bloated.","Feel Abdomen is Bloated | Did you have a bloated feeling in your abdomen | Feel Bloated in Abdomen | Have Bloated Feeling | Have Bloated Feeling in Abdomen | Have you had a bloated feeling in your abdomen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641790","Feel Disease or Treatment Adversely Affects Sex Life","C104375","A question about whether an individual feels or felt that their disease or treatment adversely affected their sex life.","Feel Disease or Treatment Adversely Affects Sex Life | Has the disease or treatment affected your sex life (for the worse)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641771","Have Abdominal Discomfort","C104322","A question about whether an individual has or had abdominal discomfort.","Have Abdominal Discomfort | Do you have abdominal discomfort | Have you had abdominal discomfort",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641787","Have Aches or Pains in Muscles or Bones","C104371","A question about whether an individual has or had aches or pains in their muscles or bones.","Have Aches or Pains in Muscles or Bones | Have you had aches or pains in your muscles or bones",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641774","Have Heartburn","C104325","A question about whether an individual has or had heartburn.","Have Heartburn | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641767","Have Hot Flashes","C104318","A question about whether an individual has or had hot flashes.","Have Hot Flashes | Did you have hot flushes | Have Hot Flushes | Have Hot Flushes | I have hot flashes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641770","Have Night Sweats","C104321","A question about whether an individual has or had night sweats.","Have Night Sweats | Do you have night sweats | I have night sweats",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641789","Have Problem Receiving Adequate Disease and Treatment Information","C104374","A question about whether an individual has or had a problem receiving adequate disease and treatment information.","Have Problem Receiving Adequate Disease and Treatment Information | Have you had problems receiving adequate information about your disease and treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641777","Have Problem with Repeated Injections","C104329","A question about whether an individual has or had a problem with repeated injections.","Have Problem with Repeated Injections | Have you had a problem with repeated injections?",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641776","Have Side Effects From Treatment","C104328","A question about whether an individual has or had side effects from their treatment.","Have Side Effects From Treatment | Have you had side effects from your treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641786","Worry About Test Results","C104370","A question about whether an individual worries or worried about test results.","Worry About Test Results | Did you worry about the results of examinations and tests | Did you worry about the results of your tests | Worry About Results of Examinations and Tests",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641778","Worry About Tumor Recurrence in Other Body Areas","C104330","A question about whether an individual worries or worried about tumor recurrence in other areas of the body.","Worry About Tumor Recurrence in Other Body Areas | Were you worried about the tumour recurring in other areas of the body",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641788","Have Limited Ability to Travel","C104372","A question about whether an individual has or had limited ability to travel.","Have Limited Ability to Travel | Did you have any limitations in your ability to travel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641785","Have Weight Gain Problem","C104369","A question about whether an individual has or had a weight gain problem.","Have Weight Gain Problem | Has weight gain been a problem for you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641784","Have Weight Loss Problem","C104368","A question about whether an individual has or had a weight loss problem.","Have Weight Loss Problem | Has weight loss been a problem for you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641773","Have Problem with Flatulence","C104324","A question about whether an individual has or had a problem with flatulence.","Have Problem with Flatulence | Have you had a problem with passing wind / gas / flatulence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641775","Have Difficulty Eating","C104326","A question about whether an individual has or had difficulty eating.","Have Difficulty Eating | Have you had difficulties with eating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641769","Look Flushed or Red","C104320","A question about whether an individual appears or has appeared flushed or red.","Look Flushed or Red | Have you noticed or been told by others that you looked flushed/red",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641782","Worry About Future Health","C104366","A question about whether an individual worries or worried about their health in the future.","Worry About Future Health | Have you worried about your health in the future | Were you worried about your health in the future | Worried About Health in Future | Worried About Health in the Future",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641768","Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors 21","C104319","A questionnaire intended for use among patients with gastrointestinal-related neuroendocrine tumors, who vary in disease stage and treatments.","Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors 21 | EORTC QLQ-GINET21 | QLQ-G.I.NET21",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0055891","Clobazam","C81615","A 1,5-benzodiazepine and partial gamma-aminobutyric acid (GABA) receptor agonist, with anxiolytic, sedative, and anticonvulsant activities. Clobazam binds to a specific site, distinct from the inhibitory neurotransmitter GABA binding site, on the benzodiazepine-GABA-A-chloride ionophore receptor complex located in the central nervous system (CNS). This binding causes an allosteric modification of the receptor and enhances the affinity of GABA to the receptor leading to an increase in the opening of chloride-channels. This leads to an increase in chloride ion conductance, neuronal hyperpolarization, inhibition of the action potential and a decrease in neuronal excitability.","Clobazam | CLOBAZAM | Frisium | Onfi | Urbanol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3179154","Best Practice","C94396","An informed treatment recommendation that is expected to be helpful to the greatest number of people within a certain patient group.","Best Practice | best practice | standard of care | standard therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641819","Truncated BID","C104460","Truncated BID is encoded by the human BID gene and is a C-terminal peptide that results from caspase-8 cleavage of the BH3-interacting domain death agonist protein. This protein fragment localizes with the mitochondrial membrane and can stimulate the release of cytochrome c and promote the progression of apoptosis.","Truncated BID | Truncated BH3-Interacting Domain Death Agonist | tBID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1540054","TRIB2 Gene","C104575","This gene is involved in the regulation of mitogen activated protein kinase activity.","TRIB2 Gene | TRIB2 | Tribbles Homolog 2 (Drosophila) Gene | Tribbles Pseudokinase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420803","TNFRSF10C Gene","C104514","This gene is involved in both ligand binding and the negative regulation of apoptotic signaling.","TNFRSF10C Gene | TNFRSF10C | Tumor Necrosis Factor Receptor Superfamily, Member 10c, Decoy without an Intracellular Domain Gene C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418556","SERPINB9 Gene","C104578","This gene plays a role in the regulation of granzyme B-mediated proteolysis.","SERPINB9 Gene | SERPINB9 | Serpin Peptidase Inhibitor, Clade B (Ovalbumin), Member 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420600","TBL2 Gene","C104551","This gene may be involved in signaling.","TBL2 Gene | TBL2 | Transducin (Beta)-Like 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1442749","SLC29A2 Gene","C104542","This gene plays a role in nucleoside transport.","SLC29A2 Gene | SLC29A2 | Solute Carrier Family 29 (Nucleoside Transporters), Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425420","RAB40B Gene","C104558","This gene may be involved in protein ubiquitination and secretory vesicle transport.","RAB40B Gene | RAB40B | RAB40B, Member RAS Oncogene Family Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418455","PELO Gene","C104581","This gene may be involved in cell division and RNA degradation.","PELO Gene | PELO | Pelota Homolog (Drosophila) Gene | Pelota mRNA Surveillance and Ribosome Rescue Factor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416974","MAGEA2 Gene","C104499","This gene plays a role in p53-mediated signaling.","MAGEA2 Gene | MAGEA2 | Melanoma Antigen Family A, 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416971","MAGEA10 Gene","C104496","This gene may be involved in tumor transformation.","MAGEA10 Gene | MAGEA10 | Melanoma Antigen Family A, 10 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537422","IRF8 Gene","C104554","This gene plays a role in the regulation of cytokine gene expression.","IRF8 Gene | IRF8 | Interferon Regulatory Factor 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424988","HOMER3 Gene","C104569","This gene plays a role in the structure of the postsynaptic density.","HOMER3 Gene | HOMER3 | Homer Homolog 3 (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415525","HEY2 Gene","C104536","This gene is involved in both transcriptional regulation and Notch signaling pathways.","HEY2 Gene | HEY2 | Hairy/Enhancer-Of-Split Related With YRPW Motif 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825461","HES3 Gene","C104530","This gene plays a role in transcriptional repression.","HES3 Gene | HES3 | Hairy and Enhancer of Split 3 (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425399","HES6 Gene","C104533","This gene plays a role in the modulation of transcription.","HES6 Gene | HES6 | Hairy and Enhancer of Split 6 (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425333","HDAC10 Gene","C104506","This gene plays a role in the regulation of histone acetylation.","HDAC10 Gene | HDAC10 | Histone Deacetylase 10 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414931","GAGE2A Gene","C104376","This gene may play a role in tumorigenesis.","GAGE2A Gene | G Antigen 2A Gene | GAGE2A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414933","GAGE4 Gene","C104483","This gene may be involved in tumor malignancy.","GAGE4 Gene | G Antigen 4 Gene | GAGE4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414934","GAGE5 Gene","C104480","This gene may play a role in tumor antigenicity.","GAGE5 Gene | G Antigen 5 Gene | GAGE5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414935","GAGE6 Gene","C104473","This gene may be involved in tumor recognition.","GAGE6 Gene | G Antigen 6 Gene | GAGE6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414936","GAGE7 Gene","C104470","This gene may play a role in tumor progression.","GAGE7 Gene | G Antigen 7 Gene | GAGE7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414938","GAGE8 Gene","C104461","This gene may be involved in transformation.","GAGE8 Gene | G Antigen 8 Gene | GAGE8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412732","BAGE Gene","C104492","This gene may play a role in melanoma.","BAGE Gene | B Melanoma Antigen Gene | BAGE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2350332","Exosome","C104457","A secretory vesicle between 30 and 90 nm in diameter that can play a role in receptor recycling, plasma membrane protein shedding, and the secretion of proteins and RNA.","Exosome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641828","Disagree","C104479","To be at odds.","Disagree | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641827","Agree","C104478","To concur.","Agree | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641826","Strongly Disagree","C104476","Intensely at odds.","Strongly Disagree | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642483","Strongly Agree","C104475","Intense concurrence.","Strongly Agree | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641803","MD Anderson Dysphagia Inventory","C104443","A self-administered questionnaire designed specifically for evaluating the impact of dysphagia on the quality of life of patients with head and neck cancer.","MD Anderson Dysphagia Inventory | M.D. Anderson Dysphagia Inventory | M.D. Anderson Dysphagia Inventory | MDADI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641804","Ability to Swallow Limits Daily Activities","C104444","A question about whether an individual's ability to swallow limits or has limited their daily activities.","Ability to Swallow Limits Daily Activities | My swallowing ability limits my day-to-day activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641805","Embarrassed by My Eating Habits","C104445","A question about whether an individual is or has been embarrassed by their eating habits.","Embarrassed by My Eating Habits | Embarassed by My Eating Habits | I am embarrassed by my eating habits",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641806","Feel Like People Have Difficulty Cooking for Me","C104446","A question about whether an individual feels or felt that people had difficulty cooking for them.","Feel Like People Have Difficulty Cooking for Me | People have difficulty cooking for me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641807","Swallowing More Difficult at End of Day","C104447","A question about whether an individual's swallowing is or was more difficult at the end of the day.","Swallowing More Difficult at End of Day | Swallowing is more difficult at the end of the day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641809","Upset by Swallowing Problem","C104449","A question about whether an individual is or was upset by their swallowing problem.","Upset by Swallowing Problem | I am upset by my swallowing problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641810","Swallowing Takes Great Effort","C104450","A question about whether an individual feels or felt that swallowing takes great effort.","Swallowing Takes Great Effort | Swallowing takes great effort",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641811","Does Not Go Out due to Swallowing Problem","C104451","A question about whether an individual does or does not go out due to their swallowing problem.","Does Not Go Out due to Swallowing Problem | Do Not Go Out Due to Swallowing Problem | I do not go out because of my swallowing problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641812","Swallowing Difficulty Causes Lost Income","C104452","A question about whether an individual's swallowing difficulties result in or have resulted in lost income.","Swallowing Difficulty Causes Lost Income | My swallowing difficulty has caused me to lose income",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641813","Takes Longer to Eat due to Swallowing Problem","C104453","A question about whether an individual feels or felt it takes longer to eat because of their swallowing problem.","Takes Longer to Eat due to Swallowing Problem | It takes me longer to eat because of my swallowing problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641814","Asked Why Unable to Eat Something","C104454","A question about whether an individual is or was questioned about their ability to eat something.","Asked Why Unable to Eat Something Question | Asked Why Unable to Eat Something | Asked Why Unable to Eat Something | People ask me, Why can't you eat that",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641815","Others Irritated by My Eating Problem","C104455","A question about whether others are irritated by an individual's eating problem.","Others Irritated by My Eating Problem | Other people are irritated by my eating problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641816","Cough When Drinking Liquids","C104456","A question about whether an individual coughs or coughed when they drink liquids.","Cough When Drinking Liquids | I cough when I try to drink liquids",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641817","Swallowing Problems Limit Social and Personal Life","C104458","A question about whether an individual's swallowing problems limit or have limited their social and personal life.","Swallowing Problems Limit Social and Personal Life | My swallowing problems limit my social and personal life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641820","Feel Free to Go Out to Eat with Friends, Neighbors and Relatives","C104462","A question about whether an individual feels or felt free to go out to eat with friends, neighbors and relatives.","Feel Free to Go Out to Eat with Friends, Neighbors and Relatives | I feel free to go out to eat with my friends, neighbors, and relatives",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641821","Limit Food Intake due to Swallowing Difficulty","C104464","A question about whether an individual limits or has limited food intake due to swallowing difficulty.","Limit Food Intake due to Swallowing Difficulty | I limit my food intake because of my swallowing difficulty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641822","Unable to Maintain Weight due to Swallowing Problem","C104465","A question about whether an individual is or was unable to maintain weight due to their swallowing problem.","Unable to Maintain Weight due to Swallowing Problem Question | I cannot maintain my weight because of my swallowing problem | Unable to Maintain Weight due to Swallowing Problem | Unable to Maintain Weight due to Swallowing Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641823","Have Low Self-Esteem due to Swallowing Problem","C104466","A question about whether an individual has or had low self-esteem because of their swallowing problem.","Have Low Self-Esteem due to Swallowing Problem | I have low self-esteem because of my swallowing problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641824","Feel Like Swallowing Huge Amount of Food","C104467","A question about whether an individual feels or felt as though they are swallowing a huge amount of food.","Feel Like Swallowing Huge Amount of Food | Feels Like Swallowing Huge Amount of Food | I feel that I am swallowing a huge amount of food",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641825","Feel Excluded due to Eating Habits","C104468","A question about whether an individual feels or felt excluded due to their eating habits.","Feel Excluded due to Eating Habits | I feel excluded because of my eating habits",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987063","Handling Code","C95339","A coded value that represents a special handling requirement for the labeled material or object.","Handling Code | handlingCode",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987071","Stability Duration","C95348","The period of time during which a product is considered usable after it is activated or opened.","Stability Duration | stabilityDuration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987064","Local Variable Name","C95340","A label that represents the value of an observed result and serves as an input parameter used in the substance administration dose expression.","Local Variable Name | localVariableName",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987072","Study Day Range","C95349","The relative timing for a planned or performed activity expressed as the number of days offset from the study-defined reference activity (e.g., date of registration, start of treatment) for this particular experimental unit.  EXAMPLE(S): Day 1, Days 10-20 OTHER NAME(S): Study Day NOTE(S): The study-defined reference activity can be different from study to study. The study day for a date after this reference activity is a positive integer calculated as the difference in the two dates + 1.  The study day for dates before the reference activity is a negative integer calculated as the difference between the two dates.  Note that this means there is no 'Day 0.'","Study Day Range | studyDayRange",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883208","Substitution Permitted","C67005","A label that specifies whether substitution by a local brand with the same active substance is permitted.","Substitution Permitted | substitutionAllowedIndicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641797","Treatment Emergent Flag","C104437","An indication as to whether an event began or was made worse by the treatment.","Treatment Emergent Flag | treatmentEmergentFlag | treatmentEmergentIndicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641798","CE Mark","C104438","A label which indicates that a product conforms with the essential requirements of the applicable European Community directives.","CE Mark | ceMarkIndicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641799","First in Human","C104439","The first time an active substance or agent is administered to a human during a study.","First in Human | firstInHuman",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641800","Standard Time","C104440","Geographic local time without an offset for daylight saving time.","Standard Time | standardTime",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641801","Non-Reason Code","C104441","A coded value specifying that an expected reason for something occurring was not the motivation, cause or rationale in this particular case.","Non-Reason Code | nonReasonCode",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641802","Distinct Product Count","C104442","The determination of the number of distinct products.","Distinct Product Count | distinctProductCount",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416526","JAG2 Gene","C84307","This gene plays a role in cell fate determination.","JAG2 Gene | JAG2 | Jagged 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418915","OLIG2 Gene","C68575","This gene is involved in transcriptional regulation and oligodendrocyte and motor neuron differentiation. This gene may play a role in the development of brain tumors.","OLIG2 Gene | OLIG2 | Oligodendrocyte Lineage Transcription Factor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882496","Protein or Enzyme Type Measurement","C64430","A term that refers to a chemistry test measuring a specific protein or enzyme in the peripheral blood or body fluid.","Protein or Enzyme Type Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520544","13q14","C13816","A chromosome band present on 13q","13q14 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332120","ATR Gene","C20560","This gene is involved in cell cycle checkpoints and DNA recombination.","ATR Gene | ATR | ATR Serine/Threonine Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417405","MTA1 Gene","C92515","This gene plays a role in transcriptional regulation.","MTA1 Gene | MTA1 | Metastasis Associated 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366857","GNAI2 Gene","C24436","This gene plays a role in signal transduction and neurotransmission.","GNAI2 Gene | G Protein Subunit Alpha I2 Gene | GNAI2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227817","Fundus Uteri","C12315","The upper, rounded portion of the uterus which is opposite from the cervix.","Fundus Uteri | FUNDUS UTERI | Fundus | Fundus uteri",,,,,,,,,,,,,,,"4100467","Structure of fundus uteri",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1288329","Isthmus Uteri","C12312","An elongated constriction of the lower part of the uterus, located at the junction of the body of the uterus and the cervix, that is composed principally of smooth muscle.","Isthmus Uteri | Isthmus of Uterus | Isthmus uteri",,,,,,,,,,,,,,,"4203777","Isthmus uteri structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227844","Endometrial Cavity","C32514","A space inside the uterus lined by a layer of mucus membranes called the endometrium.","Endometrial Cavity | ENDOMETRIAL CAVITY",,,,,,,,,,,,,,,"4179487","Endometrial cavity structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0447577","Ureteric Orifice","C12337","The opening of the ureter in the bladder that is situated at the lateral angle of the trigone.","Ureteric Orifice | Orifice of the Ureter | URETERIC ORIFICE | Ureteral Opening | Ureteric orifice | Uteric Orifice | ureteral orifice",,,,,,,,,,,,,,,"4180566","Structure of ureteral orifice",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1417200","MMP10 Gene","C101759","This gene plays a role in degradation of proteoglycans and fibronectin.","MMP10 Gene | MMP10 | Matrix Metallopeptidase 10 (Stromelysin 2) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366358","MMP3 Gene","C26510","This gene plays a role in wound repair and the regulation of extracellular matrix remodeling.","MMP3 Gene | MMP3 | Matrix Metalloproteinase 3 (Stromelysin 1, Progelatinase) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415098","GCLM Gene","C38605","This gene is involved in the detoxification of endogenous reactive oxygen species. It also plays a role in drug and xenobiotic metabolism.","GCLM Gene | GCLM | Glutamate-Cysteine Ligase Modifier Subunit Gene | Glutamate-Cysteine Ligase, Modifier Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0076560","Thrombospondin","C17339","A glycoprotein that is incorporated into cells, including blood platelets (thrombocytes) from which they are named. Five distinct forms have been identified, and they play roles in a variety of processes such as: blood coagulation, cell adhesion, platelet aggregation, cell proliferation, angiogenesis, tumor metastasis, and tissue repair.","Thrombospondin | THBS | TSP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0083026","Integrin AlphaV/Beta5","C53624","Integrin alpha-V beta-5 is a heterodimeric protein with subunits designated alpha-V and beta-5. This complex is involved in both cellular adhesion, cell surface signaling, and angiogenesis.","Integrin AlphaV/Beta5 | Alpha-V/Beta-5 | Alpha-V/Beta-5 Integrin | Integrin Alpha-V Beta-5 Protein | Integrin Alpha-V Beta-5 Protein | Integrin Alpha-V/Beta-5 | Integrin aV/b5 | Integrin alpha (V) beta (5) | Integrin-aVBeta5 | aV/b5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336937","VTN Gene","C21047","This gene promotes the attachment and spreading of cells and plays a role in the regulation of cell-matrix interactions.","VTN Gene | VTN | Vitronectin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423594","MUC16 Gene","C71018","This gene is involved in both cellular adhesion and the maintenance of mucosal surfaces.","MUC16 Gene | MUC16 | Mucin 16, Cell Surface Associated Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332411","BIK Gene","C20417","This gene is involved in the regulation of apoptosis and induces apoptotic activity.","BIK Gene | BCL2-Interacting Killer Gene | BIK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420650","TCL1A Gene","C92699","This gene is involved in signal transduction.","TCL1A Gene | TCL1 Family AKT Coactivator A Gene | TCL1A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420358","SPIB Gene","C99651","This gene is involved in the modulation of gene transcription.","SPIB Gene | SPIB | Spi-B Transcription Factor (Spi-1/PU.1 Related) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812314","IRF4 Gene","C18430","This gene is involved in the regulation of B-cell differentiation and proliferation. It also plays a role in mediating the proliferation of mitogen-stimulated T cells.","IRF4 Gene | IRF4 | Interferon Regulatory Factor 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242621","Isochromosome","C3897","An abnormal chromosome with identical arms, formed by transverse splitting of the centromere during chromosomal replication.","Isochromosome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521299","3q","C13555","Distal (long) arm of chromosome 3","3q | Chromosome 3 Distal Arm | Chromosome 3 Long Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521075","21q","C13552","Distal (long) arm of chromosome 21","21q | Chromosome 21 Distal Arm | Chromosome 21 Long Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022984","Laminin","C16778","A family of basement membrane extracellular basement proteins. Each molecule is composed of 3 nonidentical chains which are arranged in a cross-shaped structure. There are at least 5 alpha, 4 beta, and 3 gamma laminin genes.","Laminin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333209","DDX1 Gene","C24334","This gene plays a role in the regulation of several processes involving the alteration of RNA secondary structure.","DDX1 Gene | DDX1 | DEAD-Box Helicase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332685","CCL22 Gene","C24776","This gene is involved in chemoattractant regulation and immune responses.","CCL22 Gene | CCL22 | Chemokine (C-C Motif) Ligand 22 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985507","Ampulla","C93230","A sac-like enlargement of a canal or duct.","Ampulla | ampulla",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415042","GFAP Gene","C68802","This gene may be involved in the regulation of astrocyte morphology and function.","GFAP Gene | GFAP | Glial Fibrillary Acidic Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336643","TNFRSF10A Gene","C21559","This gene is involved in cell death signal transduction and apoptosis mediation.","TNFRSF10A Gene | TNFRSF10A | Tumor Necrosis Factor Receptor Superfamily, Member 10A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420071","SIRT2 Gene","C101562","This gene plays a role in protein acetylation.","SIRT2 Gene | SIRT2 | Sirtuin 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520972","1p36","C13630","A chromosome band present on 1p","1p36 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016896","Ganglioside GM2","C516","A glycosphingolipid antigen expressed by a variety of human cancer cells. GM2 containing vaccines have been shown to elicit antibodies production in melanoma patients without deleterious effects associated with an immune response to GM2. Mutations in at least 1 of 3 recessive genes: HEXA, HEXB, and GM2A cause defects in GM2 catabolism, leading to lysosomal lipid storage disorders that manifest primarily as neurodegenerative diseases, including Tay-Sachs and Sandhoff Disease.","Ganglioside GM2 | GANGLIOSIDE GM2 | GM2 ganglioside",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416973","MAGEA12 Gene","C41052","This gene may be involved in carcinogenesis.","MAGEA12 Gene | MAGEA12 | Melanoma Antigen Family A, 12 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812312","JUND Gene","C18428","This gene plays a role in transcriptional regulation, apoptotic responses to cellular stress and signal transduction pathways.","JUND Gene | JUN D Proto-oncogene Gene | JUND | JunD Proto-Oncogene, AP-1 Transcription Factor Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0290149","Angiostatins","C17910","Angiostatin (388, ~40 kDa) is encoded by the human PLG gene. This protein fragment is involved in the inhibition of blood vessel formation.","Angiostatin | Kringles 1-4 of Plasminogen | PLG | angiostatin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0534628","COL18A1 protein, human","C18046","Endostatin (183 aa, ~20 kDa) is encoded by the human COL18A1 gene. This protein fragment is involved in the inhibition of both endothelial cell proliferation and blood vessel formation.","Endostatin | COL18A1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539747","SEPTIN4 Gene","C104502","This gene is involved in both cytoskeletal maintenance and GTPase activity.","SEPTIN4 Gene | SEPT4 | SEPT4 Gene | SEPT4 Gene | SEPTIN4 | Septin 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414930","GAGE1 Gene","C104489","This gene may be involved in tumorigenesis.","GAGE1 Gene | G Antigen 1 Gene | GAGE1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3463810","Proteomic Profile","C97139","A data set that both identifies all the proteins and quantifies the levels of their expression in a biological sample or specimen.","Proteomic Profile | protein expression profile | protein signature | proteomic profile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414359","EIF5 Gene","C104660","This gene plays a role in the initiation of translation.","EIF5 Gene | EIF5 | Eukaryotic Translation Initiation Factor 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0058610","HSP40 Heat-Shock Proteins","C104663","A family of proteins that is involved in protein folding. DNAJ proteins are co-chaperones that modulate the ATPase activity of DNAK (Hsp70) proteins.","DNAJ Protein | Chaperone DnaJ | DNA-J | DnaJ Co-Chaperone | DnaJ Family | Heat Shock Protein 40 | Hsp40",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641847","Epstein-Barr Nuclear Antigen 2","C104664","Epstein-Barr nuclear antigen 2 (487 aa, ~55 kDa) is encoded by the Epstein-Barr virus EBNA2 gene. This protein is involved in the activation of host B-cells.","Epstein-Barr Nuclear Antigen 2 | BYRF1 | EBNA-2 | EBNA2 | EBV Nuclear Antigen 2 | Epstein-Barr Virus Nuclear Antigen 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641849","KIT Exon 11 Mutation","C104668","A molecular genetic abnormality indicating the presence of a mutation in exon 11 of the KIT gene located within 4q11-q12.","KIT Exon 11 Mutation | CD117 Exon 11 Mutation | Exon 11 | KIT Proto-Oncogene Tyrosine Protein Kinase Gene Exon 11 Mutation | c-KIT Exon 11 Mutation | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Gene Exon 11 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641850","KIT Exon 9 Mutation","C104672","A molecular genetic abnormality indicating the presence of a mutation in exon 9 of the KIT gene located within 4q11-q12.","KIT Exon 9 Mutation | CD117 Exon 9 Mutation | Exon 9 | KIT Proto-Oncogene Tyrosine Protein Kinase Gene Exon 9 Mutation | c-KIT Exon 9 Mutation | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Gene Exon 9 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641851","KIT Exon 13 Mutation","C104673","A molecular genetic abnormality indicating the presence of a mutation in exon 13 of the KIT gene located within 4q11-q12.","KIT Exon 13 Mutation | CD117 Exon 13 Mutation | Exon 13 | KIT Proto-Oncogene Tyrosine Protein Kinase Gene Exon 13 Mutation | c-KIT Exon 13 Mutation | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Gene Exon 13 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641852","Genome-Wide DNA Copy Number","C104674","The number of DNA sequence copies found over the entire genome of an individual.","Genome-Wide DNA Copy Number | copy number | copy_number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0123263","Receptors, IgG","C104675","Receptors belonging to the immunoglobulin superfamily that bind to the Fc portion of IgG molecules and play a role in the phagocytosis of opsonized bacteria.","Fc-Gamma Receptor | FCGR | Fc Gamma R | Fc Gamma Receptor | Fc GammaR | Fc-Gamma R | Fc-GammaR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL445794","Tenascin Family","C104676","A protein family comprised of extracellular matrix-resident glycoproteins that play a role in embryonic development and wound healing.","Tenascin Family | Tenascin | Tenascin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540600","Microtubule-Associated Proteins 1A/1B Light Chain 3, Human","C104677","A protein family whose members bind to microtubule-associated protein 1A and 1B and are involved in the formation of autophagosomes.","Microtubule-Associated Proteins 1A/1B Light Chain 3 | Autophagy-Related Protein Lc3 | Autophagy-Related Ubiquitin-Like Modifier LC3 | LC3 | MAP1 Light Chain 3-Like Protein | MAP1A/MAP1B Light Chain 3 | MAP1LC3 | Microtubule-Associated Protein 1 Light Chain 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0665952","Killer-Cell Immunoglobulin-Like Receptor","C104678","A family of cell surface proteins found on natural killer cells that both interact with MHC class I molecules and modulate natural killer cell-mediated cytotoxicity.","Killer-Cell Immunoglobulin-Like Receptor | CD158 | CD158 Family | KIR | Killer Cell Immunoglobulin-Like Receptor | Killer Ig Receptor | Killer Ig-Like Receptor | Killer-Cell Immunoglobulin-Like Receptor Family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034819","Interleukin-2 Receptor","C104679","A heterotrimeric protein found on the cell surface of immune cells that binds to interleukin-2. This receptor is comprised of alpha, beta and gamma subunits; the alpha and beta subunits bind interleukin-2 while the downstream ligand-dependent signaling is mediated by the gamma subunit.","Interleukin-2 Receptor | High Affinity Interleukin-2 Receptor | IL-2 Receptor | IL-2R | IL2 Receptor | IL2R | Interleukin 2 Receptor",,,,,,,,,,,,,,,"4008899","Interleukin-2 receptor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3540472","Ancestry-Informative Marker","C104680","A set of genetic polymorphisms that are found in different frequencies between populations from different geographical regions.","Ancestry-Informative Marker | AIM | Ancestry Informative Marker",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412610","SERPINC1 Gene","C104681","This gene is involved in the regulation of the coagulation cascade.","SERPINC1 Gene | SERPINC1 | Serpin Peptidase Inhibitor, Clade C (Antithrombin), Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413825","CELF2 Gene","C104684","This gene plays a role in RNA processing.","CELF2 Gene | CELF2 | CUGBP, Elav-Like Family Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417106","MEIS2 Gene","C104687","This gene is involved in the regulation gene expression.","MEIS2 Gene | MEIS2 | Meis Homeobox 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417715","NFYA Gene","C104690","This gene plays a role in both DNA binding and transcriptional regulation.","NFYA Gene | NFYA | Nuclear Transcription Factor Y, Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL445944","STRA6 Gene (human)","C104693","This gene is involved in organogenesis.","STRA6 Gene | STRA6 | Stimulated By Retinoic Acid 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420852","TOB2 Gene","C104696","This gene plays a role in cell cycle regulation.","TOB2 Gene | TOB2 | Transducer of ERBB2, 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413828","CXADR Gene","C104699","This gene is involved in both cell-cell adhesion and viral infection.","CXADR Gene | CXADR | Coxsackie Virus and Adenovirus Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417509","MVP Gene","C104702","This gene plays a role in vault ribonucleoprotein complex structure.","MVP Gene | MVP | Major Vault Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413099","CAMK2A Gene","C104705","This gene is involved in both protein phosphorylation and signaling.","CAMK2A Gene | CAMK2A | Calcium/Calmodulin-Dependent Protein Kinase II Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1337016","Well Differentiated Leiomyosarcoma","C9389","Grade I malignant smooth muscle neoplasm.  It is characterized by a proliferation of neoplastic spindle cells.","Well Differentiated Leiomyosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349148","Well Differentiated Adrenal Cortex Cancer","C68635","A carcinoma that arises from the adrenal cortex and is characterized by the presence of twenty or less mitoses per ten square millimeters.","Adrenal Cortical Low Grade Carcinoma | Adrenal Cortex Low Grade Carcinoma | Adrenal Cortex Low Grade Carcinoma | Adrenal Cortex Low-Grade Carcinoma | Adrenal Cortical Low-Grade Carcinoma | Well Differentiated Adrenal Cortex Cancer | Well Differentiated Adrenal Cortex Carcinoma | Well Differentiated Adrenal Cortex Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518228","Malignant Oncocyte","C36942","A malignant epithelial cell with abundant eosinophilic or clear granular cytoplasm.","Malignant Oncocyte | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642323","Myxoid Changes Present","C39744","A morphologic finding indicating the presence of myxoid changes in a tissue sample.","Myxoid Changes Present | Myxoid Background",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825879","Beta Amyloid Measurement","C81999","The determination of the amount of beta amyloid present in a sample.","Beta Amyloid Measurement | AMYLOIDB | Amyloid, Beta | Beta Amyloid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824729","CFD Gene","C84324","This gene plays a role in complement pathway regulation.","CFD Gene | CFD | Complement Factor D (Adipsin) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414072","DLL4 Gene","C90317","This gene is involved in the notch signal transduction pathway.","DLL4 Gene | DLL4 | Delta-Like 4 (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414069","DLK1 Gene","C99660","This gene plays a role in cell-cell signaling.","DLK1 Gene | DLK1 | Delta-Like 1 Homolog (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414057","DKK1 Gene","C95416","This gene is involved in intercellular communication.","DKK1 Gene | DKK1 | Dickkopf Homolog 1 (Xenopus laevis) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421505","NSD2 Gene","C21416","This gene plays a role in histone-lysine methylation.","NSD2 Gene | NSD2 | Nuclear Receptor Binding SET Domain Protein 2 Gene | WHSC1 | WHSC1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416710","MAFB Gene","C97671","This gene plays a role in both hematopoiesis and transcriptional modulation.","MAFB Gene | MAF bZIP Transcription Factor B Gene | MAFB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919481","MAF Gene","C18417","This gene plays a role in transcriptional regulation and cellular differentiation.","MAF Gene | MAF | MAF bZIP Transcription Factor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332699","CCR1 Gene","C24269","This gene is involved in immune cell mobilization to promote pro-inflammatory responses; further, the gene plays a role in chemotaxis.","CCR1 Gene | CCR1 | Chemokine (C-C Motif) Receptor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0392400","Diffuse malignant mesothelioma","C8420","A diffuse malignant neoplasm that arises from mesothelial cells, usually in the pleura or peritoneum. Histologic variants include biphasic, epithelioid, sarcomatoid, and desmoplastic mesothelioma.","Diffuse Malignant Mesothelioma | Malignant Diffuse Mesothelioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1270206","Desmoplastic Mesothelioma","C6747","A malignant neoplasm arising from mesothelial cells. It is characterized by the presence of a dense collagenous tissue and atypical neoplastic cells. Sarcomatoid features, collagenous necrosis, and infiltration of muscle and adipose tissue may be present. It occurs in the pleura and less commonly in the peritoneum.","Desmoplastic Mesothelioma | Desmoplastic mesothelioma",,,,,,,,,,,,,,,"4303589","Desmoplastic mesothelioma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334515","Biphasic Mesothelioma","C4282","A malignant mesothelioma characterized by the presence of epithelioid and sarcomatoid components, with each component representing at least 10% of the tumor.","Biphasic Mesothelioma | Malignant Biphasic Mesothelioma | Malignant Mixed Mesothelioma | Mesothelioma, biphasic, NOS | Mixed Mesothelioma","9053/3","Mesothelioma, biphasic, malignant",,,,,,,,,,,,,"4147198","Mesothelioma, biphasic, malignant",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334513","Sarcomatoid Mesothelioma","C45655","A malignant neoplasm arising from mesothelial cells. It is characterized by the presence of spindle cells. Anaplastic morphologic features and multinucleated malignant cells may also be seen.","Sarcomatoid Mesothelioma | Sarcomatoid mesothelioma","9051/3","Fibrous mesothelioma, malignant",,,,,,,,,,,,,"4161548","Sarcomatoid mesothelioma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0862312","Epithelioid Mesothelioma","C7985","A malignant neoplasm arising from mesothelial cells. It is characterized by the presence of cells with epithelioid morphology. The epithelioid cells usually have eosinophilic cytoplasm, bland nuclei, and form tubulopapillary, microglandular, or sheet-like patterns.","Epithelioid Mesothelioma | Epithelial Mesothelioma | Epithelioid mesothelioma, NOS | Epithelioid mesothelioma, malignant | Malignant Epithelial Mesothelioma","9052/3","Epithelioid mesothelioma, malignant",,,,,,,,,,,,,"4275876","Epithelioid mesothelioma, malignant",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1334603","Malignant Mixed Mesodermal (Mullerian) Tumor","C8975","An aggressive malignant tumor of the female reproductive system, affecting predominantly elderly menopausal women.  The endometrium and ovary are the most common sites of tumor origin.  Morphologically, it is a high grade tumor, composed of carcinomatous and sarcomatous elements.","Female Reproductive System Carcinosarcoma | Carcinosarcoma, embryonal | MMMT | MULLERIAN TUMOR, MIXED, MALIGNANT | Malignant Mixed Mesodermal (Mullerian) Tumor | Malignant Mixed Mesodermal (Mullerian) Tumor | Malignant Mixed Mesodermal (Müllerian) Tumor | Malignant Mixed Mesodermal Tumor | Malignant Mixed Mullerian Tumor | Malignant Mixed Müllerian Tumor | malignant mixed Mullerian tumor","8981/3","Carcinosarcoma, embryonal",,,,,,,,,,,,,"4012802","Carcinosarcoma, embryonal",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1708358","Heterologous Elements Present","C54559","A morphologic finding indicating the presence of tissues that do not normally occur in the specific anatomic site or are found admixed with a neoplastic cellular infiltrate of a different cellular origin.","Heterologous Elements Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332139","Prostate Acinar Adenocarcinoma","C5596","An invasive adenocarcinoma of the prostate gland composed of secretory cells.  It is the most common histologic type of prostate adenocarcinoma.  Several morphologic variants exist, including atrophic, pseudohyperplastic, foamy gland, and oncocytic variants.","Prostate Acinar Adenocarcinoma | Acinar Adenocarcinoma of Prostate | Acinar Adenocarcinoma of the Prostate | Acinar Prostate Adenocarcinoma | Acinar Prostate Adenocarcinoma | Prostate Acinar adenocarcinoma | Prostate Adenocarcinoma, Acinar Type/NOS | Prostatic Acinar Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026578","Mosaicism","C92976","The presence of more than one genetically distinct cell line in germ and/or somatic cells.","Mosaicism | mosaicism",,,,,,,,,,,,,,,"4229274","Mosaicism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265497","Penta X Syndrome","C89802","A rare sex chromosome abnormality in which a female child has 3 extra X chromosomes.","Penta X Syndrome | 49, XXXXX Syndrome | XXXXX Syndrome",,,,,,,,,,,,,,,"4183443","Penta X syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265498","XXXY Syndrome","C89799","A rare sex chromosome abnormality in which a male child has 2 extra X chromosomes.","XXXY Syndrome | 48, XXXY Syndrome",,,,,,,,,,,,,,,"4302318","XXXY syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2936741","XXYY Syndrome","C89801","A rare sex chromosome abnormality in which a male child has an extra X and Y chromosome.","XXYY Syndrome | 48, XXYY Syndrome",,,,,,,,,,,,,,,"4300446","XXYY syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1831994","Selective Internal Radiation Therapy","C71591","A form of radiation therapy used to treat unresectable cancers, especially hepatic cell carcinoma or metastasis to the liver. The treatment involves injecting microspheres of radioactive material into the arteries that supply the tumor.","Selective Internal Radiation Therapy | SIRT",,,,,,,,,,,,,,,"36716242","Embolization of hepatic artery using selective internal radiation therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1413052","CA9 Gene","C104050","This gene may be involved in cell proliferation and transformation.","CA9 Gene | CA9 | Carbonic Anhydrase IX Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1327882","1q","C13528","Distal (long) arm of chromosome 1","1q | Chromosome 1 Distal Arm | Chromosome 1 Long Arm | Chromosome 1q",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812246","TNF Gene","C18368","This gene is involved in apoptosis, cell growth and cell proliferation. It also plays a role in immune and inflammatory responses.","TNF Gene | TNF | Tumor Necrosis Factor (TNF Superfamily, Member 2) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708107","Functioning Well Differentiated Pancreatic Endocrine Neoplasm","C45840","A well-differentiated, low-, intermediate-, or high-grade neoplasm with neuroendocrine differentiation that arises from the pancreas. It is characterized by the presence of a clinical syndrome that results from hormone hypersecretion.","Functioning Pancreatic Neuroendocrine Tumor | Functional Neuroendocrine Tumor | Functional Pancreatic NET | Functional Pancreatic Neuroendocrine Tumor | Functional Pancreatic Neuroendocrine Tumor | Functioning Pancreatic Endocrine Tumor | Functioning Pancreatic NET | Functioning Well Differentiated Pancreatic Endocrine Neoplasm | Functioning Well Differentiated Pancreatic Endocrine Tumor | Syndromic Pancreatic NET | Syndromic Pancreatic Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3839703","Non-Functioning Pancreatic Neuroendocrine Tumor","C45837","A well-differentiated, low-, intermediate-, or high-grade neoplasm with neuroendocrine differentiation that arises from the pancreas.  It is characterized by the absence of a hormone-related clinical syndrome.","Non-Functioning Pancreatic Neuroendocrine Tumor | Inactive Pancreatic Endocrine Tumor | NF-PanNET | Non-Functional Pancreatic Neuroendocrine Tumor | Non-Functional Pancreatic Neuroendocrine Tumor | Non-Functioning Pancreatic Endocrine Tumor | Non-Functioning Pancreatic NET | Non-Functioning Well Differentiated Pancreatic Endocrine Tumor | Non-Syndromic Pancreatic NET | Non-Syndromic Pancreatic Neuroendocrine Tumor | Nonfunctional Pancreatic NET | Nonfunctional Pancreatic Neuroendocrine Tumor | Nonfunctional Pancreatic Neuroendocrine Tumor | Nonfunctioning Pancreatic Neuroendocrine Tumor | Nonsyndromic Pancreatic Endocrine Tumor | Nonsyndromic Pancreatic Neuroendocrine Tumor | Pancreatic endocrine tumor, nonfunctioning",,,,,,,,,,,,,,,"45766613","Pancreatic neuroendocrine tumor, nonfunctioning",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512567","Hypopharyngeal Aspect of the Aryteno-Epiglottic Fold","C32757","The portion of the aryepiglottic fold in the area where the larynx and esophagus join.","Hypopharyngeal Aspect of the Aryteno-Epiglottic Fold | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030419","Paraganglion","C94826","A cluster of neural crest cells that are located adjacent to the adrenal gland, nerves, and blood vessels.","Paraganglion | paraganglia",,,,,,,,,,,,,,,"4144244","Paraganglia structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227160","Anterior Surface of the Epiglottis","C12238","The lingual or upper surface of the epiglottis.","Anterior Surface of the Epiglottis | Anterior surface of epiglottis",,,,,,,,,,,,,,,"4283238","Structure of anterior surface of epiglottis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0229549","Craniopharyngeal Duct","C12357","The slender tubular part of the hypophysial diverticulum; the stalk of Rathke's pocket.","Craniopharyngeal Duct | Bucconeural Duct | Craniopharyngeal duct | Hypophysial Duct",,,,,,,,,,,,,,,"4313718","Structure of craniopharyngeal duct",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1185742","Commissure","C32349","A bundle of nerve fibers crossing from one side to the other side of the brain or spinal cord.","Commissure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008779","Ciliary Body","C12345","Tissue located behind the iris and composed of muscle and epithelium. Its functions include the production of aqueous humor and changing the shape of the crystalline lens.","Ciliary Body | CILIARY BODY | Ciliary body | EYE, CILIARY BODY | ciliary body",,,,,,,,,,,,,,,"4105476","Ciliary body structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008520","Choroid","C12344","A blood vessel-containing membrane of the eye that lies between the retina and the sclera.","Choroid | CHOROID | EYE, CHOROID | choroid | optic choroid",,,,,,,,,,,,,,,"4287575","Choroidal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206187","Extrahepatic Bile Duct","C32573","The portion of the biliary tract outside the liver; the common hepatic duct joins the cystic duct to form the common bile duct.","Extrahepatic Bile Duct | EXTRAHEPATIC BILE DUCT | Extrahepatic bile duct | extrahepatic bile duct","C24.0","Extrahepatic bile duct",,,,,,,,,,,,,"4051422","Extrahepatic duct structure",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0227223","Greater Curvature of the Stomach","C12262","The lateral and inferior border of the stomach. Attached to it is the greater omentum.","Greater Curvature of the Stomach | GREATER CURVATURE OF THE STOMACH | Greater Curvature | Greater curvature of stomach, NOS",,,,,,,,,,,,,,,"4232156","Structure of greater curvature of stomach",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002421","Ambroxol","C74262","No Value Exists","Ambroxol | AMBROXOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0060400","Cefixime","C1100","A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins.","Cefixime | CEFIXIME | Cefixime Trihydrate | FK 027 | Suprax | cefixime",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348248","Dexlansoprazole","C73192","The R-isomer of lansoprazole and a substituted benzimidazole prodrug with selective and irreversible proton pump inhibitor activity. As a weak base, dexlansoprazole accumulates in the acidic environment of the secretory canaliculus of the gastric parietal cell where it is converted to an active sulfenamide form that binds to cysteine sulfhydryl groups on the luminal aspect of the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase), thereby inhibiting the pump's activity and the parietal cell secretion of H+ ions into the gastric lumen, the final step in gastric acid production.","Dexlansoprazole | (+)-2-((R)-{(3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl}sulfinyl)-1H-benzimidazole | DEXLANSOPRAZOLE | Kapidex | T-168390 | TAK-390MR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005320","Betaxolol","C61652","A racemic mixture and selective beta-1 adrenergic receptor antagonist with antihypertensive and anti-glaucoma activities and devoid of intrinsic sympathomimetic activity. Betaxolol selectively and competitively binds to and blocks beta-1 adrenergic receptors in the heart, thereby decreasing cardiac contractility and rate. This leads to a reduction in cardiac output and lowers blood pressure. When applied topically in the eye, this agent reduces aqueous humor secretion and lowers the intraocular pressure (IOP). In addition, betaxolol prevents the release of renin, a hormone secreted by the kidneys that causes constriction of blood vessels.","Betaxolol | 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-propanol | BETAXOLOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0052565","Astaxanthin","C63653","A natural and synthetic xanthophyll and nonprovitamin A carotenoid, with potential antioxidant, anti-inflammatory and antineoplastic activities. Upon administration, astaxanthin may act as an antioxidant and reduce oxidative stress, thereby preventing protein and lipid oxidation and DNA damage. By decreasing the production of reactive oxygen species (ROS) and free radicals, it may also prevent ROS-induced activation of nuclear factor-kappa B (NF-kB) transcription factor and the production of inflammatory cytokines such as interleukin-1beta (IL-1b), IL-6 and tumor necrosis factor-alpha (TNF-a). In addition, astaxanthin may inhibit cyclooxygenase-1 (COX-1) and nitric oxide (NO) activities, thereby reducing inflammation. Oxidative stress and inflammation play key roles in the pathogenesis of many diseases, including cardiovascular, neurological, autoimmune and neoplastic diseases.","Astaxanthin | (3S,3'S)-3,3'-Dihydroxy-beta,beta-carotene-4,4'-dione | ASTAXANTHIN | Astaxanthine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3853839","Blinatumomab","C62528","A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.","Blinatumomab | AMG 103 | AMG-103 | AMG103 | Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody | Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103 | BLINATUMOMAB | Blincyto | MEDI 538 | MEDI-538 | MEDI538 | MT 103 | MT-103 | MT103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346810","TRC105","C74010","A human/murine chimeric monoclonal antibody directed against endoglin (CD105) with potential antiangiogenic and antineoplastic activities. Carotuximab binds to endoglin, which may result in inhibition of tumor angiogenesis and decreased tumor cell proliferation. The glycoprotein endoglin is a transforming growth factor beta-1 (TGF beta-1) accessory receptor that is highly expressed on tumor vessel endothelial cells and appears to be essential for angiogenesis.","Carotuximab | Anti-Endoglin Chimeric Monoclonal Antibody TRC105 | CAROTUXIMAB | TRC 105 | TRC-105 | TRC105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538692","Linear Analogue Self-Assessment","C104593","A self-reported questionnaire used to measure general well-being and the major domains of quality of life (mental, physical, emotional, social, and spiritual well-being) in patients receiving cancer therapy.","Linear Analogue Self-Assessment | LASA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641830","Overall Quality of Life","C104594","A question about an individual's overall quality of life.","Overall Quality of Life | your overall Quality of Life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641831","Overall Intellectual Well-Being","C104595","A question about an individual's overall intellectual well-being.","Overall Intellectual Well-Being | Overall Intellectual Well Being | your overall mental (intellectual) well being",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641832","Overall Physical Well-Being","C104596","A question about an individual's overall physical well-being.","Overall Physical Well-Being | Overall Physical Well Being | your overall physical well being",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641833","Emotional Well-Being","C104597","A question about an individual's overall emotional well-being.","Overall Emotional Well-Being | Emotional Well-Being | Overall Emotional Well Being | your overall emotional well being",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641834","Level of Social Activity","C104598","A question about an individual's level of social activity.","Level of Social Activity Question | Level of Social Activity | Level of Social Activity | your level of social activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641835","Overall Spiritual Well-Being","C104599","A question about an individual's overall spiritual well-being.","Overall Spiritual Well-Being | Overall Spiritual Well Being | your overall spiritual well being",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0518090","Frequency of Pain","C104600","A question about an individual's frequency of pain.","Frequency of Pain | How Often Have Pain | How Often Pain | How often did you have pain | Pain | Pain Frequency | the frequency of your pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641836","Average Severity of Pain","C104601","A question about an individual's average severity of pain.","Average Severity of Pain | Pain on the Average | the severity of your pain, on the average",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641837","Average Level of Fatigue","C104602","A question about an individual's average level of fatigue.","Average Level of Fatigue | Fatigue on Average | How fatigued were you on average | your level of fatigue, on the average",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641838","Level of Support from Friends and Family","C104603","A question about an individual's level of support from their friends and family.","Level of Support from Friends and Family | Level of Support from Family and Friends | Support From Family and Friends | your level of support from friends and family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641839","Concern About Finances","C104604","A question about whether an individual has or had concerns about finances.","Concern About Finances | your financial concerns",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641840","Concern About Legal Matters - Will and Advanced Directives","C104605","A question about whether an individual has or had concerns about personal legal matters, such as a will and advanced directives.","Concern About Legal Matters - Will and Advanced Directives | your legal concerns (will, advanced directives, etc.)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641844","As Good As It Can Be","C104609","A response indicating the something is as good as can be expected or imagined.","As Good As It Can Be | As good as it can be",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642269","As Bad As It Can Be","C104610","A response indicating the something is as bad as can be expected or imagined.","As Bad As It Can Be | As Bad As You Can Imagine | As Bad as You Can Imagine | As bad as it can be",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0151599","Increased Drug Level","C54355","A laboratory test result demonstrating an increased concentration of a specific drug.","Increased Drug Level | INCREASED DRUG LEVEL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640903","Sub-therapeutic Drug Level","C102715","A drug serum concentration below therapeutic levels.","Sub-therapeutic Drug Level | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1384586","Forceps Delivery","C81248","Application of forceps to the fetal head to facilitate vaginal birth.","Forceps Delivery | Forceps Assistance | Forceps Assisted Vaginal Delivery | Forceps Operative Vaginal Delivery",,,,,,,,,,,,,,,"4114637","Forceps delivery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825567","Vacuum Assisted Vaginal Delivery","C81300","Application of a vacuum device to the fetal head to facilitate vaginal birth.","Vacuum Assisted Vaginal Delivery | Vacuum Assistance | Vacuum Operative Vaginal Delivery",,,,,,,,,,,,,,,"45757174","Vacuum assisted vaginal delivery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0080301","Vaginal Birth after Cesarean Delivery","C81302","A vaginal birth in a woman with one or more previous cesarean births. (reVITALize)","Vaginal Birth after Cesarean Delivery | VAGINAL BIRTH AFTER CESAREAN DELIVERY | VBAC | Vaginal Birth after Caesarean | Vaginal Birth after Caesarean Delivery | Vaginal Birth after Cesarean | Vaginal Birth after Cesarean",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334141","IRS2 Gene","C24523","This gene is involved in signal transduction and is associated with Diabetes Mellitus.","IRS2 Gene | IRS2 | Insulin Receptor Substrate 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1367453","NR4A1 Gene","C29959","This gene is involved in the induction of apoptosis. It also plays a role in regulation of transcription.","NR4A1 Gene | NR4A1 | Nuclear Receptor Subfamily 4, Group A, Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422387","HDAC7 Gene","C102489","This gene is involved in both histone modification and chromatin modeling.","HDAC7 Gene | HDAC7 | Histone Deacetylase 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334474","MAP2K1 Gene","C21222","This gene plays a role in signal transduction and regulation of transcription. It is also involved in cell differentiation, growth and proliferation.","MAP2K1 Gene | MAP2K1 | Mitogen-Activated Protein Kinase Kinase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419846","SCD Gene","C102776","This gene plays a role in fatty acid metabolism.","SCD Gene | SCD | Stearoyl-CoA Desaturase (Delta-9-Desaturase) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333906","HMGA2 Gene","C20577","This gene is involved in chromatin organization and regulation of gene transcription. It also plays a role in development.","HMGA2 Gene | HMGA2 | High Mobility Group AT-Hook 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348459","Epigallocatechin","C68453","A (-)-epicatechin with a hydroxyl group at C-5'.","Epigallocatechin | (2R,3R)-2-(3,4,5-trihydroxyphenyl)chroman-3,5,7-triol | EGC | EPIGALLOCATECHIN | cis-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1442756","SP3 Gene","C98042","This gene plays a role in both the positive and negative regulation of transcription.","SP3 Gene | SP3 | Sp3 Transcription Factor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333887","H19 Gene","C20058","This gene plays a role in genomic imprinting and may be involved in the negative regulation of cell growth.","H19 Gene | H19 | H19, Imprinted Maternally Expressed Untranslated mRNA Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812261","CTTN Gene","C18382","This gene plays a role in epithelial cytoskeletal organization and in cellular adhesion.","CTTN Gene | CTTN | Cortactin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812381","ABL2 Gene","C18451","This gene plays a role in signal transduction.","ABL2 Gene | ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase Gene | ABL2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417089","MDM4 Gene","C88218","This gene plays a role in both cell cycle arrest and the inhibition of apoptosis.","MDM4 Gene | MDM4 | MDM4, p53 Regulator Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1368111","Soluble ErbB-1","C18436","Soluble epidermal growth factor receptor is encoded by the human EGFR gene. This protein may be involved in the regulation of epidermal growth factor receptor signaling. There are 3 described isoforms; all soluble forms lack the transmembrane and intracellular domain of the epidermal growth factor receptor.","Soluble Epidermal Growth Factor Receptor | EGFR | EGFR ECD | EGFR Extracellular Domain | EGFR-ECD | Epidermal Growth Factor Receptor Extracellular Domain | Epidermal Growth Factor Receptor, Soluble | Soluble ErbB-1 | sEGFR | sErbB-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0140278","Retinoic Acid Receptor","C17532","Retinoid receptors (RARA, RARB, RARG) require co-regulators to increase selective binding to DNA response elements in target genes and enhance transcriptional activity.","Retinoic Acid Receptor | NR1B | Nuclear Receptor Subfamily 1 Group B | RAR | Retinoid Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334128","ILK Gene","C24510","This gene plays a role in the regulation of signal transduction and cell adhesion. It is also involved in cell organization.","ILK Gene | ILK | Integrin Linked Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641878","FACT-Hep Questionnaire","C104892","A subscale complement to the FACT-G questionnaire developed specifically for evaluating quality of life of patients with hepatobiliary cancer (liver, bile duct and pancreas).","FACT-Hep Questionnaire | FACT-Hep | Functional Assessment of Cancer Therapy-Hepatobilliary Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641879","Have Swelling or Cramps in Stomach","C104902","A question about whether an individual has or had swelling or cramps in the area of the stomach.","Have Swelling or Cramps in Stomach | I have swelling or cramps in my stomach area",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641881","Have Control of Bowels","C104906","A question about whether an individual has or had control of their bowels.","Have Control of Bowels | I have control of my bowels",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641883","Digests Food Well","C104908","A question about whether an individual digests or has digested their food well.","Digests Food Well | I can digest my food well",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0935661","22q","C13553","Distal (long) arm of chromosome 22","22q | Chromosome 22 Distal Arm | Chromosome 22 Long Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641888","Able to Perform Usual Activities","C104921","A question about whether an individual is or was able to perform their usual activities.","Able to Do Usual Activities Question | Able to Do Usual Activities | Able to Do Usual Activities | Able to Perform Usual Activities | Able to Perform Usual Activities | I am able to do my usual activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641884","Unhappy with Change in Appearance","C104910","A question about whether an individual is or was unhappy with a change in their appearance.","Unhappy with Change in Appearance | I am unhappy about a change in my appearance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641885","Have Back Pain","C104917","A question about whether an individual has or had back pain.","Have Back Pain | Have Pain in Back | Have you had back pain | Have you had pain in your back | I have pain in my back",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641886","Bothered by Constipation","C104918","A question about whether an individual is or has been bothered by constipation.","Bothered by Constipation | I am bothered by constipation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641889","Bothered by Jaundice or Yellow Skin Color","C104925","A question about whether an individual is or has been bothered by their jaundice or yellow skin color.","Bothered by Jaundice or Yellow Skin Color | I am bothered by jaundice or yellow color to my skin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641890","Have Fever","C104929","A question about whether an individual has or had a fever.","Have Fever | I have had fevers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641891","Have Itch","C104931","A question about whether an individual has or had itching.","Have Itch | Had Itching | Have Itching | Have you had itching | I have had itching | Itching",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641893","Notice Change in the Way Food Tastes","C104934","A question about whether an individual notices or noticed a change in the way food tastes.","Notice Change in the Way Food Tastes | Change in the way food tastes | Changes in taste | Have Change in the Way Food Tastes | I have had a change in the way food tastes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641894","Have Chills","C104935","A question about whether an individual has or had chills.","Have Chills | I have had chills",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641895","Have Dry Mouth","C104937","A question about whether an individual has or had a dry mouth.","Have Dry Mouth | Did you have a dry mouth | Do you often experience 'dry mouth' | Dry mouth | Experience Dry Mouth | My mouth is dry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641896","Have Discomfort or Pain in Stomach","C104939","A question about whether an individual has or had discomfort or pain in the stomach.","Have Discomfort or Pain in Stomach | I have discomfort or pain in my stomach area | I have pain in my stomach area",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334505","MGMT Gene","C21232","This gene is involved in DNA repair.","MGMT Gene | MGMT | O-6-Methylguanine-DNA Methyltransferase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332412","BIN1 Gene","C24265","This gene is involved in signal transduction and cell differentiation.","BIN1 Gene | BIN1 | Bridging Integrator 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335281","PTPN1 Gene","C24705","This gene plays a role in the regulation of insulin signaling and inhibition of cell growth.","PTPN1 Gene | PTPN1 | Protein Tyrosine Phosphatase, Non-Receptor Type 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334911","NUMA1 Gene","C24648","This gene plays an essential role in normal mitosis. It is also involved in cell organization/biogenesis.","NUMA1 Gene | NUMA1 | Nuclear Mitotic Apparatus Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416693","KIF11 Gene","C79078","This gene plays a role in mitosis.","KIF11 Gene | KIF11 | Kinesin Family Member 11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415314","GRPR Gene","C95065","This gene plays a role in the regulation of both signal transduction and cell proliferation.","GRPR Gene | GRPR | Gastrin Releasing Peptide Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336658","TOP2B Gene","C26593","This gene is involved in chromosome recombination, DNA replication and the regulation of DNA topology during transcription.","TOP2B Gene | DNA Topoisomerase II Beta Gene | TOP2B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334879","NGFR Gene","C24628","This gene is involved in apoptosis, neuronal growth and signaling.","NGFR Gene | NGFR | Nerve Growth Factor Receptor Gene | TNFRSF16",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227221","Lesser Curvature of the Stomach","C12261","The right border of the stomach.  It is concave in shape and extends from the cardiac orifice to the pyloric orifice.","Lesser Curvature of the Stomach | LESSER CURVATURE OF THE STOMACH | Lesser curvature of stomach, NOS | lesser curvature of stomach",,,,,,,,,,,,,,,"4198063","Structure of lesser curvature of stomach",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0229871","Lingual Tonsil","C32988","The lymphoid follicles on the dorsal surface in the posterior region of the tongue.","Lingual Tonsil | Lingual tonsil | TONSIL, LINGUAL",,,,,,,,,,,,,,,"4068841","Lingual tonsil structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023050","Laryngeal Cartilage","C12281","The nine cartilages that comprise the skeleton of the larynx, including the single thyroid, epiglottic, and cricoid cartilages, and the paired arytenoid, corniculate, and cuneiform cartilages.","Laryngeal Cartilage | Laryngeal cartilage",,,,,,,,,,,,,,,"4279711","Laryngeal cartilage structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022131","Islet of Langerhans","C12608","A specialized region of tissue located within the parenchyma of the pancreas that contains a mixed population of distinct endocrine cells, including beta, alpha, pancreatic polypeptide, delta, and epsilon cells, which respectively produce and secrete insulin, glucagon, pancreatic polypeptide, somatostatin, and ghrelin.","Islet of Langerhans | Endocrine Pancreas | Human Pancreatic Islet Cells | Islands of Langerhans | Islet Cells | Islets of Langerhans | Langerhans Islets | PANCREAS, ENDOCRINE | Pancreatic Islets | Pars Endocrina Pancreatis",,,,,,,,,,,,,,,"4301372","Endocrine pancreatic structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005401","Intrahepatic Bile Duct","C12677","The bile ducts which are located within the liver. They include the small interlobular bile ducts, intrahepatic large bile ducts, and the intrahepatic portions of the left and right hepatic ducts.","Intrahepatic Bile Duct | INTRAHEPATIC BILE DUCT | Intrahepatic bile duct | intrahepatic bile duct",,,,,,,,,,,,,,,"4234107","Intrahepatic biliary tract structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0919534","GSTM1 Gene","C18588","This gene plays a role in the phase II metabolism of both endogenous compounds and xenobiotics.","GSTM1 Gene | GSTM1 | Glutathione S-Transferase Mu 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919451","GSTP1 Gene","C18519","This gene is involved in phase II metabolism of both endogenous compounds and xenobiotics.","GSTP1 Gene | GSTP1 | GSTP1-1 | Glutathione S-Transferase Pi 1 Gene | Glutathione S-Transferase Pi Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333356","ERCC2 Gene","C20555","This gene is involved in nucleotide excision repair and corrects sensitivity to UV radiation and defective nucleotide excision repair in xeroderma pigmentosum cells of complementation group D.","ERCC2 Gene | ERCC Excision Repair 2, TFIIH Core Complex Helicase Subunit Gene | ERCC2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919427","MTHFR Gene","C18500","This gene is involved in folate metabolism and methionine biosynthesis.","MTHFR Gene | MTHFR | Methylenetetrahydrofolate Reductase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412291","AHCY Gene","C104863","This gene plays a role in amino acid metabolism.","AHCY Gene | AHCY | Adenosylhomocysteinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412456","APBA1 Gene","C104827","This gene is involved in synaptic vesicle exocytosis.","APBA1 Gene | APBA1 | Amyloid Beta (A4) Precursor Protein-Binding, Family A, Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412457","APBA2 Gene","C104843","This gene plays a role in neuronal transport.","APBA2 Gene | APBA2 | Amyloid Beta (A4) Precursor Protein-Binding, Family A, Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412458","APBA3 Gene","C104848","This gene is involved in the modulation of amyloid beta A4 precursor protein proteolysis.","APBA3 Gene | APBA3 | Amyloid Beta (A4) Precursor Protein-Binding, Family A, Member 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825497","ATG5 Gene","C104962","This gene plays a role in autophagy and may play a role in apoptosis.","ATG5 Gene | ATG5 | Autophagy Related 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412719","B4GALT1 Gene","C104851","This gene plays a role in carbohydrate synthesis.","B4GALT1 Gene | B4GALT1 | UDP-Gal:BetaGlcNAc Beta 1,4- Galactosyltransferase, Polypeptide 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412794","BHMT Gene","C104869","This gene is involved in homocysteine metabolism.","BHMT Gene | BHMT | Betaine--Homocysteine S-Methyltransferase Gene | Betaine-Homocysteine S-Methyltransferase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412795","BHMT2 Gene","C104881","This gene plays a role in the metabolism of homocysteine.","BHMT2 Gene | BHMT2 | Betaine--Homocysteine S-Methyltransferase 2 Gene | Betaine-Homocysteine S-Methyltransferase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413148","CBFA2T2 Gene","C104928","This gene may be involved in tumor suppression.","CBFA2T2 Gene | CBFA2T2 | Core-Binding Factor, Runt Domain, Alpha Subunit 2; Translocated to, 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413376","CHAT Gene","C104885","This gene is involved in neurotransmitter biosynthesis.","CHAT Gene | CHAT | Choline O-Acetyltransferase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538452","CHDH Gene","C104895","This gene is involved in choline metabolism.","CHDH Gene | CHDH | Choline Dehydrogenase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425131","CHPT1 Gene","C104909","This gene plays a role in phospholipid metabolism.","CHPT1 Gene | CHPT1 | Choline Phosphotransferase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425999","CKS1B Gene","C104980","This gene plays a role in the regulation of cyclin dependent kinase activity.","CKS1B Gene | CDC28 Protein Kinase Regulatory Subunit 1B Gene | CKS1B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413696","CR2 Gene","C104977","This gene plays a role in the innate immune response.","CR2 Gene | CD21 | CR2 | Complement Component (3d/Epstein Barr Virus) Receptor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413698","CRABP2 Gene","C104924","This gene plays a role in retinoic acid binding.","CRABP2 Gene | CRABP2 | Cellular Retinoic Acid Binding Protein 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1456379","CRIP2 Gene","C104936","This gene encodes a putative transcription factor that may play a role in differentiation of smooth muscle tissue.","CRIP2 Gene | CRIP2 | Cysteine-Rich Protein 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413713","CRLF1 Gene","C104950","This gene may be involved in regulating the immune system.","CRLF1 Gene | CRLF1 | Cytokine Receptor-Like Factor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427015","CYP26B1 Gene","C104874","This gene plays a role in the metabolism of retinoic acid.","CYP26B1 Gene | CYP26B1 | Cytochrome P450, Family 26, Subfamily B, Polypeptide 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428267","DND1 Gene","C104878","This gene is involved in regulation of gene expression.","DND1 Gene | DND1 | Dead End Homolog 1 (Zebrafish) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539312","DST Gene","C104889","This gene plays a structural role in cytoskeleton networks.","DST Gene | DST | Dystonin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414229","E2F6 Gene","C104893","This gene is involved in cell cycle entry.","E2F6 Gene | E2F Transcription Factor 6 Gene | E2F6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414664","FOLR2 Gene","C104913","This gene is involved in folic acid uptake.","FOLR2 Gene | FOLR2 | Folate Receptor 2 (Fetal) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415328","GSTA1 Gene","C104974","This gene is involved in glutathione metabolism.","GSTA1 Gene | GSTA1 | Glutathione S-Transferase Alpha 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416831","LGALS3 Gene","C104857","This gene plays a role in carbohydrate binding.","LGALS3 Gene | LGALS3 | Lectin, Galactoside-Binding, Soluble, 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416850","LHX3 Gene","C104955","This gene encodes a transcription factor that plays a role in both pituitary development and motor neuron specification.","LHX3 Gene | LHX3 | LIM Homeobox 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417420","MTHFD1 Gene","C104920","This gene plays a role in folate metabolism.","MTHFD1 Gene | MTHFD1 | Methylenetetrahydrofolate Dehydrogenase (NADP+ Dependent) 1, Methenyltetrahydrofolate Cyclohydrolase, Formyltetrahydrofolate Synthetase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417422","MTHFD2 Gene","C104943","This gene is involved in the metabolism of folic acid.","MTHFD2 Gene | MTHFD2 | Methylenetetrahydrofolate Dehydrogenase (NADP+ Dependent) 2, Methenyltetrahydrofolate Cyclohydrolase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417453","MTR Gene","C104946","This gene plays a role in methionine biosynthesis.","MTR Gene | 5-Methyltetrahydrofolate-Homocysteine Methyltransferase Gene | MTR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427754","NANOS3 Gene","C104839","This gene is involved in maintaining germ cell lineages.","NANOS3 Gene | NANOS3 | Nanos Homolog 3 (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417673","NEK3 Gene","C104842","This gene plays a role in neuronal morphogenesis.","NEK3 Gene | NEK3 | NIMA-Related Kinase 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418396","PCYT1A Gene","C104953","This gene is involved in phosphatidylcholine biosynthesis","PCYT1A Gene |  PCYT1A | PCYT1A | Phosphate Cytidylyltransferase 1, Choline, Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418456","PEMT Gene","C104965","This gene plays a role in phosphatidylethanolamine metabolism.","PEMT Gene | PEMT | Phosphatidylethanolamine N-Methyltransferase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641901","Phosphatidylinositol 3,4,5-Trisphosphate 5-Phosphatase 1 Isoform 3","C104986","Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 isoform 3 (976 aa, ~109 kDa) is encoded by the human INPP5D gene. This protein plays a role in the removal of phosphate from phosphatidylinositol trisphosphate and may play a role in stem cell maintenance.","Phosphatidylinositol 3,4,5-Trisphosphate 5-Phosphatase 1 Isoform 3 | Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatase 1 Isoform 3 | SIP-110 | Short-SHIP | Truncated INPP5D | s-SHIP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418617","PLA2G1B Gene","C104971","This gene plays a role in phospholipid metabolism.","PLA2G1B Gene | PLA2G1B | Phospholipase A2, Group IB (Pancreas) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641899","Protein Tyrosine Phosphatase Type IVA","C104984","A family of prenylated protein tyrosine phosphatases that plays a role in both phosphotyrosine catabolism and signal transduction pathways, which in turn modulate many different cellular processes.","Protein Tyrosine Phosphatase Type IVA | PTPN4A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428428","PSMG2 Gene","C104899","This gene plays a role in assembly of the 20S proteasome.","PSMG2 Gene | PSMG2 | Proteasome (Prosome, Macropain) Assembly Chaperone 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0072690","Pyridinoline","C104983","A non-reducible crosslinker for collagen. This compound is fluorescent and is found in mature bone and cartilage collagens. Pyridinoline found in the blood can be an indicator of bone degradation.","Pyridinoline | Hydroxylysylpyridinoline",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427882","SESN3 Gene","C104865","This gene is involved in regulating levels of intracellular reactive oxygen species.","SESN3 Gene | SESN3 | Sestrin 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420038","SHMT1 Gene","C104968","This gene is involved in amino acid metabolism.","SHMT1 Gene | SHMT1 | Serine Hydroxymethyltransferase 1 (Soluble) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420299","SNURF Gene","C104854","This gene may be involved in cerebral development.","SNURF Gene | SNRPN Upstream Reading Frame Gene | SNURF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823137","STRA8 Gene","C104903","This gene may be involved in spermatogenesis.","STRA8 Gene | STRA8 | Stimulated by Retinoic Acid 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420752","TLE1 Gene","C104860","This gene is involved in the modulation of gene transcription.","TLE1 Gene | TLE1 | Transducin-Like Enhancer of Split 1 (E(Sp1) Homolog, Drosophila) 3 Gene | Transducin-Like Enhancer of Split 1 (E(Sp1) Homolog, Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424525","ZNF423 Gene","C104959","This gene is involved in olfactory neurogenesis.","ZNF423 Gene | ZNF423 | Zinc Finger Protein 423 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366587","MCL1 Gene","C20412","This gene is a regulator of apoptosis and plays a role in differentiation.","MCL1 Gene | MCL1 | Myeloid Cell Leukemia Sequence 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412077","ABCC2 Gene","C103882","This gene is involved in drug efflux.","ABCC2 Gene | ABCC2 | ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002928","Spinal Block","C92887","A procedure in which a pharmaceutical agent is administered into the subarachnoid space, producing a loss of sensation at and below the level of the block.","Spinal Block | SAB | spinal anesthesia | spinal block | subarachnoid block",,,,,,,,,,,,,,,"4332593","Spinal anesthesia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002911","Regional Anesthesia Procedure","C64381","The administration of pharmaceutical agents intended to produce loss of sensation in a particular anatomical region.","Regional Anesthesia Procedure | Regional Analgesic Procedure | Regional Analgesic Technique | Regional Anesthesia | regional anesthesia",,,,,,,,,,,,,,,"4100052","Regional anesthesia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002915","General Anesthesia Procedure","C64380","Actions that render a patient unconscious for the purpose of performing a diagnostic or interventional procedure.","General Anesthesia Procedure | General Anesthesia | general anesthesia",,,,,,,,,,,,,,,"4174669","Administration of general anesthetic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002921","Local Anesthesia Procedure","C81260","The temporary suppression of sensation at a specific region of the body by pharmacological intervention. This type of anesthesia does not induce unconsciousness in the patient.","Local Anesthesia Procedure | Local Anesthesia | local anesthesia",,,,,,,,,,,,,,,"4303995","Local anesthesia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332698","CCNE2 Gene","C20958","This gene regulates the G1/S phase of the cell cycle.","CCNE2 Gene | CCNE2 | Cyclin E2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2715577","Ruxolitinib","C77888","An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","Ruxolitinib | (3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile | INCB 018424 | INCB-018424 | INCB-18424 | INCB18424 | Jakafi | Oral JAK Inhibitor INCB18424 | RUXOLITINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0051696","Amlodipine","C61635","A synthetic dihydropyridine and a calcium channel blocker with antihypertensive and antianginal properties. Amlodipine inhibits the influx of extracellular calcium ions into myocardial and peripheral vascular smooth muscle cells, thereby preventing vascular and myocardial contraction. This results in a dilatation of the main coronary and systemic arteries, decreased myocardial contractility, increased blood flow and oxygen delivery to the myocardial tissue, and decreased total peripheral resistance. This agent may also modulate multi-drug resistance (MDR) activity through inhibition of the p-glycoprotein efflux pump.","Amlodipine | AMLODIPINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0216784","Valsartan","C47781","An orally active nonpeptide triazole-derived antagonist of angiotensin (AT) II with antihypertensive properties. Valsartan selectively and competitively blocks the binding of angiotensin II to the AT1 subtype receptor in vascular smooth muscle and the adrenal gland, preventing AT II-mediated vasoconstriction, aldosterone synthesis and secretion, and renal reabsorption of sodium, and resulting in vasodilation, increased excretion of sodium and water, a reduction in plasma volume, and a reduction in blood pressure.","Valsartan | CGP 48933 | Diovan | L-Valine, N-(1-oxopentyl)-N-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)- | N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine | VALSARTAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0558292","Every Hour","C64510","Every hour.","Every Hour | Every hour | Hourly | QH | quaque hora",,,,,,,,,,,,,,,"4023341","Hourly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1948050","Twice","C65134","Two times.","Twice | TWICE | Two Times",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641911","FACT-H&N Questionnaire","C105034","A subscale complement to the FACT-G questionnaire developed specifically for evaluating quality of life of patients with head and neck cancer.","FACT-H&N Questionnaire | FACT Head and Neck Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641912","Able to Eat Liked Food","C105041","A question about whether an individual is or was able to eat the foods they like.","Able to Eat Liked Food Question | Able to Eat Liked Food | Able to Eat Liked Food | I am able to eat the foods that I like",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641913","Have Trouble Breathing","C105042","A question about whether an individual has or had trouble breathing.","Have Trouble Breathing | I have trouble breathing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641914","Voice Has Usual Quality and Strength","C105044","A question about whether an individual's voice has or had the usual quality and strength.","Voice Has Usual Quality and Strength | My voice has its usual quality and strength",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641915","Able to Eat as Much Food as Desired","C105046","A question about whether an individual is or was able to eat as much food as they want.","Able to Eat as Much Food as Desired Question | Able to Eat as Much Food as Desired | Able to Eat as Much Food as Desired | I am able to eat as much food as I want",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641916","Unhappy with Face and Neck Appearance","C105048","A question about whether an individual is or was unhappy with the appearance of their face and neck.","Unhappy with Face and Neck Appearance | I am unhappy with how my face and neck look",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641917","Swallowing Naturally and Easily","C105049","A question about whether an individual is or was able to swallow naturally and easily.","Swallowing Naturally and Easily | I can swallow naturally and easily",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641918","Smoke Cigarettes or Other Tobacco Products","C105050","A question about whether an individual smokes cigarettes or other tobacco products.","Smoke Cigarettes or Other Tobacco Products | I smoke cigarettes or other tobacco products",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641919","Drinks Alcohol Such as Beer or Wine","C105051","A question about whether an individual drinks alcohol, such as beer or wine.","Drinks Alcohol Such as Beer or Wine | I drink alcohol (e.g. beer, wine, etc.)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641920","Able to Communicate with Others","C105052","A question about whether an individual is or was able to communicate with others.","Able to Communicate with Others Question | Able to Communicate with Others | Able to Communicate with Others | I am able to communicate with others",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641921","Able to Eat Solid Food","C105053","A question about whether an individual is or was able to eat solid food.","Able to Eat Solid Food Question | Able to Eat Solid Food | Able to Eat Solid Food | I can eat solid foods",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641922","Have Pain in Mouth, Throat or Neck","C105054","A question about whether an individual has or had pain in the mouth, throat or neck.","Have Pain in Mouth, Throat or Neck | I have pain in my mouth, throat or neck",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0451131","Dubowitz Score","C81282","The numerical value that represents a clinical assessment of neurological and physical criteria, performed between birth and five days of age, to determine an infant's gestational age and maturity.","Dubowitz Score | Ballard Score | Ballard/Dubowitz Score",,,,,,,,,,,,,,,"4164832","Dubowitz score",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0678804","Prenatal","C81318","The time period after impregnation and before birth.","Prenatal | Antenatal",,,,,,,,,,,,,,,"4137020","Antenatal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0425932","Last Menstrual Period","C81257","The date of the first day of the most recent menstrual cycle.","Last Menstrual Period | LMP | LMPSTDTC | Last Menstrual Period Start Date",,,,,,,,,,,,,,,"4072438","Date of last menstrual period",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015944","Premature Rupture of Membrane","C87113","Spontaneous rupture of fetal membranes that occurs before the onset of labor. If rupture occurs before 37 weeks of gestation then the correct diagnosis is preterm premature rupture of membranes.","Premature Rupture of Membrane | PROM | Prelabor Rupture of Membranes | Premature Rupture of Membranes | Term Premature Rupture of Membranes",,,,,,,,,,,,,,,"194702","Premature rupture of membranes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0269845","Umbilical Cord Prolapse","C87126","A situation in which the umbilical cord is ahead of the presenting fetal part. If the cord becomes compressed it may cut off the flow of blood to the baby.","Umbilical Cord Prolapse | Prolapsed Cord",,,,,,,,,,,,,,,"440476","Prolapse of cord",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032046","Placenta Previa","C26858","A condition in which the placenta covers or is within 1 cm of the cervical os.","Placenta Previa | ",,,,,,,,,,,,,,,"4284028","Placenta previa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013537","Eclampsia","C87167","A potentially life-threatening pregnancy-related disorder characterized by tonic-clonic seizures in association with hypertension after the twentieth week of gestation and up to six weeks postpartum and in the absence of other potential causes of seizures.","Eclampsia | ",,,,,,,,,,,,,,,"443700","Eclampsia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2020625","Group B Streptococcal Infection","C87168","Group B Streptococcus, also known as Streptococcus agalactiae, colonizes the vaginal and gastrointestinal tracts of up to 45% of healthy women and may infect neonates in utero or during delivery, causing neonatal sepsis in 1-2% of colonized neonates. GBS infection may also occur in nonpregnant (particularly elderly) adults with underlying medical conditions, presenting as urinary tract infection, pneumonia, or soft-tissue infection.","Group B Streptococcal Infection | GBS | Streptococcus agalactiae Infection",,,,,,,,,,,,,,,"4143698","Streptococcus agalactiae infection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020450","Hyperemesis Gravidarum","C87084","Severe, intractable vomiting during pregnancy (usually the first trimester) accompanied by dehydration, weight loss, and electrolyte imbalances.","Hyperemesis Gravidarum | Hyperemesis",,,,,,,,,,,,,,,"4030872","Hyperemesis gravidarum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4011959","Large for Gestational Age","C87092","A fetus or infant who is larger than expected for the age or gender, or who has a birth weight greater than the 90th percentile.","Large for Gestational Age | LGA | Large for Dates Baby",,,,,,,,,,,,,,,"440532","Heavy-for-dates at birth regardless of gestation period",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4230930","Low Birth Weight","C34724","A birth weight that is less than 2500 grams.","Low Birth Weight | ",,,,,,,,,,,,,,,"4171115","Low birth weight infant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0233256","Fetal Malpresentation","C92793","Any presentation other than a vertex presentation. (reVITALize)","Fetal Malpresentation | Malpresentation",,,,,,,,,,,,,,,"4032626","Abnormal fetal presentation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL426345","Multiple Gestation","C87097","A pregnancy involving twins or higher-order multiple fetuses (e.g., triplets, quadruplets).","Multiple Gestation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0853694","Rhesus Hemolytic Disease of the Newborn","C87115","A disorder caused when there is a Rh-factor blood-type incompatibility between the mother and fetus, and the mother's immune system forms antibodies that attack the red blood cells of her unborn child. This disorder can only occur if the mother is Rh-negative and the fetus is Rh-positive.","Rhesus Hemolytic Disease of the Newborn | Erythroblastosis Fetalis, Rh Disease | Hemolytic Disease of the Newborn | RhD HDN | RhD Hemolytic Disease of the Newborn | Rhesus D Hemolytic Disease of the Newborn | Rhesus Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0269852","Vasa Previa","C87127","Umbilical blood vessels that have inserted into the amniotic membrane (membranous insertion) that in turn are above or adjacent to the cervical os and are at risk of rupture.","Vasa Previa | ",,,,,,,,,,,,,,,"442171","Vasa previa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1414351","EIF4E Gene","C105123","This gene is involved in translation initiation.","EIF4E Gene | EIF4E | Eukaryotic Translation Initiation Factor 4E Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538730","MAPKAP1 wt Allele","C105118","Human MAPKAP1 wild-type allele is located in the vicinity of 9q34.3 and is approximately 270 kb in length. This allele, which encodes target of rapamycin complex 2 subunit MAPKAP1 protein, plays a role in the regulation of cell growth and survival.","MAPKAP1 wt Allele | JC310 | MGC2745 | MIP1 | Mitogen-Activated Protein Kinase Associated Protein 1 wt Allele | RP11-269P11.1 | SIN1 | SIN1b | SIN1g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417458","MTRR Gene","C105126","This gene plays a role in the metabolism of vitamins and amino acids.","MTRR Gene | 5-Methyltetrahydrofolate-Homocysteine Methyltransferase Reductase Gene | MTRR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538682","PTGES2 wt Allele","C105115","Human PTGES2 wild-type allele is located in the vicinity of 9q34.11 and is approximately 8 kb in length. This allele, which encodes prostaglandin E synthase 2 protein, is involved in both transcriptional activation and the production of prostaglandin E2.","PTGES2 wt Allele | C9orf15 | Chromosome 9 Open Reading Frame 15 Gene | FLJ14038 | GBF-1 | GBF1 | PGES2 | Prostaglandin E Synthase 2 wt Allele | Prostaglandin E Synthase, Microsomal Gene | RP11-395P17.2 | mPGES-2 | p53-Induced Gene 12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420797","TNFAIP1 Gene","C105120","This gene plays a role in the regulation of protein ubiquitination.","TNFAIP1 Gene | TNFAIP1 | Tumor Necrosis Factor, Alpha-Induced Protein 1 (Endothelial) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335602","RBL2 Gene","C24728","This gene is involved in transcriptional regulation and cellular proliferation.","RBL2 Gene | RBL2 | Retinoblastoma-Like 2 (p130) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419295","RBL1 Gene","C91746","This gene plays a role in cell cycle regulation.","RBL1 Gene | RBL1 | Retinoblastoma-Like 1 (p107) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538717","PRKD2 Gene","C95259","This gene is involved in the protein kinase C signaling cascade.","PRKD2 Gene | PRKD2 | Protein Kinase D2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335821","SHC1 Gene","C24808","This gene is involved in signal transduction and plays a role in aging.","SHC1 Gene | SHC Adaptor Protein 1 Gene | SHC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333659","GAS2 Gene","C20747","This gene plays a role in the regulation of actin cytoskeletal components and in cellular motility.","GAS2 Gene | GAS2 | Growth Arrest-Specific 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414086","DMRT1 Gene","C99654","This gene plays a role in male gonad development.","DMRT1 Gene | DMRT1 | Doublesex and Mab-3 Related Transcription Factor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412621","ATF5 Gene","C101599","This gene is involved in the regulation of gene expression.","ATF5 Gene | ATF5 | Activating Transcription Factor 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537745","MIR34A Gene","C95831","This gene is involved in the modulation of gene expression.","MIR34A Gene | MIR34A | MicroRNA 34a Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1155661","Mismatch Repair","C20639","The mismatch repair (MMR) system promotes genomic fidelity by repairing base-base mismatches, insertion-deletion loops and heterologies generated during DNA replication and recombination. This function is critically dependent on the assembly of multimeric complexes involved in mismatch recognition and signal transduction to downstream repair events.","Mismatch Repair | DNA Mismatch Repair | MMR | Post-Replication Mismatch Repair",,,,,,,,,,,,,,,"764459","DNA mismatch repair",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1366764","DNA repair protein","C21170","Any of the proteins involved in the enzymatic restoration of DNA structure after chemical, radiation, or spontaneous damage.","DNA Repair Protein | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879390","PMS1 Gene","C18590","This gene is involved in mismatch repair and mutations in the gene result in hereditary non-polyposis colon cancer 3.","PMS1 Gene | MLH2 | PMS1 | PMS1 Postmeiotic Segregation Increased 1 (S. cerevisiae) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334491","MCM4 Gene","C20374","This gene plays a role in the cell cycle control of DNA replication.","MCM4 Gene | MCM4 | MCM4 Minichromosome Maintenance Deficient 4 (S. Cerevisiae) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229737","Retropharyngeal Lymph Node","C77649","A lymph node located in the retropharyngeal space behind the upper part of the pharynx.","Retropharyngeal Lymph Node | LYMPH NODE, RETROPHARYNGEAL | Lymph node level VIIA (qualifier value) | RETROPHARYNGEAL LYMPH NODE | Suprapharyngeal Lymph Node",,,,,,,,,,,,,,,"4105808","Structure of retropharyngeal lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004749","Barium","C61475","A naturally occurring alkaline metalloid element with atomic symbol Ba, atomic number 56, and atomic weight 137 that is only found in combination with other elements, typically barite (barium sulfate) and witherite (barium carbonate), or chemicals. Barium is used in many industrial processes, as well as in diagnostic testing, fireworks, and pesticides. It is characterized as a silvery white or yellow to white metallic solid that is odorless. Exposure occurs by inhalation, ingestion, or contact.","Barium | BARIUM | Ba",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706486","Swallow","C64927","Ingest through the mouth.","Swallow | ",,,,,,,,,,,,,,,"4228129","Swallow",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0059036","Peptide Elongation Factor 1","C38958","Heterotrimeric Elongation Factor 1 (containing alpha/beta/gamma or alpha/delta/gamma subunits) is responsible for delivery of aminoacyl tRNAs to the ribosome. Containing domains that bind guanine nucleotides, 80S ribosomes, and aminoacyl-tRNAs, the alpha EF-1 subunit interacts with beta/delta subunits and mediates delivery and GTP-dependent binding of aminoacyl-tRNAs to the 80S ribosome A-site. Homologous beta and delta subunits (guanine nucleotide exchange factors) stimulate GDP/GTP exchange bound to EF-1-alpha; phosphorylation affects the GDP/GTP exchange rate. The conserved gamma subunit contains an EEF1G domain and an N-terminal GST domain that may be involved in regulating EF-1 multisubunit assembly and anchorage to other cellular components. (NCI)","Elongation Factor 1 | E-F1 | EEF1 | Elongation Factor-1 | Eukaryotic Elongation Factor 1 | Eukaryotic Translation Elongation Factor 1 | eEF-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418630","PLAGL2 Gene","C91257","This gene is involved in DNA binding and transcriptional regulation.","PLAGL2 Gene | PLAGL2 | Pleiomorphic Adenoma Gene-Like 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919441","CCN3 Gene","C18510","This gene plays a role in growth factor modulation and cellular proliferation.","CCN3 Gene | CCN3 | Cellular Communication Network Factor 3 Gene | NOV | NOV Gene | NOV Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417217","MN1 Gene","C97618","This gene is involved in tumor suppression.","MN1 Gene | MN1 | MN1 Proto-Oncogene, Transcriptional Regulator Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812313","JUNB Gene","C18429","This gene plays a role in transcriptional regulation and myelopoiesis.","JUNB Gene | JUN B Proto-Oncogene Gene | JUNB | JunB Proto-Oncogene, AP-1 Transcription Factor Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511540","CpG Island Methylator Phenotype","C19821","A phenotype whereby a subset of tumors are characterized by the simultaneous hypermethylation of multiple promoter-associated CpG islands.","CpG Island Methylator Phenotype | CIMP | CIMP+",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416447","INPP5D Gene","C95111","This gene is involved in the modulation of signaling.","INPP5D Gene | INPP5D | Inositol Polyphosphate-5-Phosphatase D Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416806","LCN2 Gene","C71435","This gene may play a role in both the transport of hydrophobic molecules and the mediation of inflammation.","LCN2 Gene | LCN2 | Lipocalin 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332757","CHKA Gene","C24296","This gene is involved in the biosynthesis of phosphatidylcholine.","CHKA Gene | CHKA | Choline Kinase Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417701","NFE2L2 Gene","C54237","This gene plays a role in transcriptional regulation.","NFE2L2 Gene | NFE2L2 | Nuclear Factor (Erythroid-Derived 2)-Like 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1743497","SOD2 protein, human","C16819","Superoxide dismutase [Mn], mitochondrial (222 aa, ~25 kDa) is encoded by the human SOD2 gene. This protein plays a role in superoxide reduction.","Superoxide Dismutase [Mn], Mitochondrial | EC 1.15.1.1 | IPO-B | MNSOD | Manangese Superoxide Dismutase | Manganese Superoxide Dismutase | Mitochondrial Superoxide Dismutase | Mitochondrial Superoxide Dismutase 2 | Mn Superoxide Dismutase | SOD2 | Superoxide Dismutase 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162832","APC Gene","C17567","This gene plays a role in signal transduction. It is involved in both adhesion and migration of cells.","APC Gene | APC | APC Regulator of WNT Signaling Pathway Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414662","FOLR1 Gene","C39283","This gene is involved in the mediation of 5-methyltetrahydrofolate delivery to the cellular interior.","FOLR1 Gene | FOLR1 | Folate Receptor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025037","Meckel Diverticulum","C12264","A congenital pouch in the distal ileum. It may cause painless rectal bleeding and bowel obstruction.","Meckel Diverticulum | Meckel diverticulum | Meckel's Diverticulum",,,,,,,,,,,,,,,"4133967|441394","Meckel's diverticulum|Meckel's diverticulum",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0229872","Tonsillar Pillar","C12236","The anterior and posterior borders of the tonsillar fossa.  They are composed of muscle tissue.","Tonsillar Pillar | Tonsillar pillar",,,,,,,,,,,,,,,"4065073","Palatine arch structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512949","Urethral Gland","C12339","Any of the glands that secrete mucus into the urethra including the Cowper, Skene, and Littre glands.","Urethral Gland | Paraurethral Gland | Urethra Gland",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028938","Olfactory Nerve","C12759","The first cranial nerve. It is the shortest cranial nerve and of paramount importance in the sense of smell. Its neurons are in the olfactory mucosa in the nasal cavity.","Olfactory Nerve | Cranial Nerve I | First Cranial Nerve | OLFACTORY NERVE | Olfactory nerve",,,,,,,,,,,,,,,"4019908","Olfactory nerve structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0226920","Retromolar Trigone","C54223","A triangular-shaped area of mucosa located posterior the last mandibular molar tooth.","Retromolar Trigone | Retromolar area | retromolar triangle | retromolar trigone",,,,,,,,,,,,,,,"4312102","Structure of retromolar area of mouth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL415279","Prepuce","C12323","A covering fold of skin, often used alone to designate the preputium penis.","Prepuce | PREPUCE | Preputium Penis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225492","Superior Wall of the Nasopharynx","C12242","The roof of the nasopharynx.","Superior Wall of the Nasopharynx | Nasopharyngeal Roof | Roof of Nasopharynx | Superior Wall of Nasopharynx | Superior wall of nasopharynx",,,,,,,,,,,,,,,"4068978","Structure of superior wall of nasopharynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037885","Sphenoid Sinus","C12278","Either of the paired paranasal sinuses, located in the anterior part of the body of the sphenoid bone and communicating with the superior meatus of the nasal cavity on the same side.","Sphenoid Sinus | SPHENOID SINUS | Sinus, Sphenoid | Sphenoid sinus | Sphenoid sinus structure (body structure) | sphenoid sinus",,,,,,,,,,,,,,,"4097172","Sphenoid sinus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037855","Spermatic Cord","C12329","A tube-like structure composed of the vas deferens and surrounding tissue layers, that runs from the abdomen to each of the testicles.","Spermatic Cord | Spermatic cord | spermatic cord | testicular cord",,,,,,,,,,,,,,,"4172591","Spermatic cord structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0458718","Vestibule of the Ear","C33873","The central cavity of the osseous labyrinth.","Vestibule of the Ear | Vestibule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001575","Appendage of the Uterus","C12321","The accessory structures of the uterus, including the ovaries, fallopian tubes, broad ligament, and the ovarian and uterine ligaments.","Appendage of the Uterus | Uterine Adnexa | Uterine adnexa",,,,,,,,,,,,,,,"4044228","Structure of uterine adnexa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041916","Urachus","C12338","A cord of fibrous tissue that extends from the urinary bladder to the umbilicus. The urachus is a remnant of the fetal urinary canal.","Urachus | URACHAL TRACT | median umbilical ligament | urachus",,,,,,,,,,,,,,,"4030072","Structure of urachus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006131","Branchial Cleft Cyst","C2908","A congenital epithelial cyst that develops due to failure of obliteration of the second branchial cleft during embryonic development. It appears as a lump on the side of the neck.","Branchial Cleft Cyst | Branchial Cyst | Branchial Cyst | Branchioma | Cyst of Branchial Cleft | Cyst of the Branchial Cleft",,,,,,,,,,,,,,,"23567","Branchial cleft cyst",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0079037","Branchial Cleft Remnant","C104813","A congenital defect in the neck that occurs during early embryonic development.  It is caused by developmental abnormalities of the pharyngeal arches and results in the development of a cyst or a fissure in the side of the neck.","Branchial Cleft Remnant | Branchial Cleft | Branchial cleft",,,,,,,,,,,,,,,"4178668","Branchial cleft anomaly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0443181","Anal Transitional Zone","C32072","The middle segment of the anal canal between the colorectal and squamous zones.","Anal Transitional Zone | Cloacogenic Zone | Cloacogenic zone",,,,,,,,,,,,,,,"4139811","Cloacogenic zone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1867800","TCF3/PBX1 Fusion Gene","C99291","A fusion gene that results from a chromosomal translocation t(1;19)(q23;p13) which fuses intron 13 of the TCF3 gene with exon 2 of the PBX1 gene. This rearrangement is associated with pre-B cell acute lymphoblastic leukemia.","TCF3/PBX1 Fusion Gene | E2A-PBX1 Fusion Gene | E2A-PBX1 Fusion Mutation | E2A-PBX1 Translocation Mutation | E2A/PBX1 Fusion Gene | PBX1/E2A Fusion Gene | TCF3-PBX1 Fusion Gene | TCF3::PBX1 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415619","HMOX1 Gene","C43314","This gene is involved in heme catabolism and cellular homeostasis.","HMOX1 Gene | HMOX1 | Heme Oxygenase (Decycling) 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0728810","Butyrylcholinesterase","C45486","Cholinesterase (602 aa, ~68 kDa) is encoded by the human BCHE gene. This protein plays a role in choline metabolism.","Cholinesterase | Acylcholine Acylhydrolase | BCHE | Butyrylcholine Esterase | Butyrylcholinesterase | CHE1 | Choline Esterase II | EC 3.1.1.8 | Plasma Cholinesterase | Pseudocholinesterase | Pseudocholinesterase E1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825022","EBF1 Gene","C80023","This gene plays a role in transcriptional activation.","EBF1 Gene | EBF1 | Early B-Cell Factor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336596","TCF3 Gene","C24846","This gene plays a role in regulation of transcription. It is involved in the control of tissue-specific cell fate during embryogenesis.","TCF3 Gene | E2A | TCF3 | Transcription Factor 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879392","MSH3 Gene","C20211","This gene plays a role in DNA mismatch repair and has been implicated in several cancers.","MSH3 Gene | MSH3 | MutS Homolog 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413287","CDK6 Gene","C97384","This gene plays a role in the progression of the cell cycle.","CDK6 Gene | CDK6 | Cyclin Dependent Kinase 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919426","CYP2E1 Gene","C18499","This gene is involved in the metabolism of both endogenous and exogenous substrates.","CYP2E1 Gene | CYP2E1 | Cytochrome P450, Family 2, Subfamily E, Polypeptide 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366448","TERC Gene","C20463","This gene plays a role in chromosomal repair and telomere maintenance.","TERC Gene | TERC | Telomerase RNA Component Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987351","Iodine I 124-labeled Hsp90 Inhibitor PUH71","C95711","A radioconjugate containing the purine scaffold heat shock protein 90 (Hsp90) inhibitor PUH71 labeled with the radioisotope iodine I 124, with positron emitting activity. Hsp90 inhibitor PUH71 is thought to bind to cytosolic Hsp90 and the endoplasmic reticulum paralogue gp96 (HSP90B1), thereby inhibiting its molecular chaperone function and promoting the degradation of the oncogenic signaling proteins. This induces caspase-dependent apoptosis. The iodine I 124 moiety can be visualized using Positron emission tomography (PET) imaging, thereby allowing an assessment of the accumulation of PUH71 in vivo, particularly in tumors. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability and degradation of many oncogenic signaling proteins.","Iodine I 124-labeled Hsp90 Inhibitor PUH71 | 124I-PUH71 | Iodine I 124 PUH71",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1439347","BTG1 Gene","C80101","This gene is involved in the regulation of cell proliferation.","BTG1 Gene | BTG Anti-Proliferation Factor 1 Gene | BTG1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825590","IKZF3 Gene","C80029","This gene plays a role in both transcription in hematopoietic cells and lymphocyte development.","IKZF3 Gene | IKAROS Family Zinc Finger 3 (Aiolos) Gene | IKZF3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1384617","LEF1 Gene","C80032","This gene plays a role in both signal transduction and transcription.","LEF1 Gene | LEF1 | Lymphoid Enhancer-Binding Factor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334501","MEIS1 Gene","C24590","This gene plays a role in embryonic development and cell differentiation.","MEIS1 Gene | MEIS1 | Meis Homeobox 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418285","PBX1 Gene","C97317","This gene plays a role in the modulation of transcription.","PBX1 Gene | PBX1 | Pre-B-Cell Leukemia Homeobox 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642252","MD Anderson Symptom Inventory - Head and Neck","C105551","A self-administered questionnaire designed specifically for evaluating the severity of symptoms related to head and neck cancer.","MD Anderson Symptom Inventory - Head and Neck | MD Anderson Symptom Inventory - Head and Neck  | MDASI-HN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642250","Work Including Work Around the House","C105549","A question about an individual's work, including work around the house.","Work Including Work Around the House | Normal work (includes work both outside the home and daily chores) | Work (including work around the house)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642235","Problem with Lack of Appetite at its Worst","C105534","A question about an individual's lack of appetite at its worst.","Problem with Lack of Appetite at its Worst | Your problem with lack of appetite at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642232","Being Distressed at its Worst","C105531","A question about an individual's distress at its worst.","Being Distressed at its Worst | Your feeling of being distressed (upset) at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642244","Choking or Coughing - Food or Liquids Going Down the Wrong Pipe at its Worst","C105543","A question about an individual's choking or coughing - such as food or liquids going down the wrong pipe at its worst.","Choking or Coughing - Food or Liquids Going Down the Wrong Pipe at its Worst | Your choking/coughing (food/liquids going down the wrong pipe) at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642245","Constipation at its Worst","C105544","A question about an individual's constipation at its worst.","Constipation at its Worst | Your constipation at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642237","Dry Mouth at its Worst","C105536","A question about an individual's dry mouth at its worst.","Dry Mouth at its Worst | Your having a dry mouth at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642229","Fatigue at its Worst","C105528","A question about an individual's fatigue at its worst.","Fatigue at its Worst | Your fatigue (tiredness) at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642236","Feeling Drowsy at its Worst","C105535","A question about an individual's feeling drowsy at its worst.","Feeling Drowsy at its Worst | Worst Possible Drowsiness | Your feeling drowsy (sleepy) at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642238","Feeling Sad at its Worst","C105537","A question about an individual's feeling sad at its worst.","Feeling Sad at its Worst | Your feeling sad at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642251","Mouth or Throat Sores at its Worst","C105550","A question about an individual's mouth or throat sores at its worst.","Mouth or Throat Sores at its Worst | Your mouth/throat sores at their WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642241","Mucus in Mouth and Throat at its Worst","C105540","A question about an individual's mucus in mouth or throat at its worst.","Mucus in Mouth and Throat at its Worst | Mucous in Mouth and Throat at its Worst | Your problem with mucus in your mouth and throat at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642230","Nausea at its Worst","C105529","A question about an individual's nausea at its worst.","Nausea at its Worst | Your nausea at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642240","Numbness or Tingling at its Worst","C105539","A question about an individual's numbness and tingling at its worst.","Numbness or Tingling at its Worst | Your numbness or tingling at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642228","Pain at its Worst","C105527","A question about an individual's pain at its worst.","Pain at its Worst | Your pain at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642246","Problem Tasting Food at its Worst","C105545","A question about an individual's problem tasting food at its worst.","Problem Tasting Food at its Worst | Your problem with tasting food at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642234","Problem with Remembering Things at its Worst","C105533","A question about an individual's memory at its worst.","Problem with Remembering Things at its Worst | Your problem with remembering things at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642248","Problem with Teeth or Gums at its Worst","C105547","A question about an individual's teeth or gums at its worst.","Problem with Teeth or Gums at its Worst | Your problem with your teeth or gums at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642233","Shortness of Breath at its Worst","C105532","A question about an individual's shortness of breath at its worst.","Shortness of Breath at its Worst | Worst Possible Shortness of Breath | Your shortness of breath at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642249","Skin Pain or Burning or Rash at its Worst","C105548","A question about an individual's skin pain or burning or rash at its worst.","Skin Pain or Burning or Rash at its Worst | Your skin pain/burning/rash at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642242","Swallowing or Chewing Difficulties at its Worst","C105541","A question about an individual's swallowing or chewing difficulties at its worst.","Swallowing or Chewing Difficulties at its Worst | Swallowing or Chewing Diffculties at its Worst  | Your difficulty swallowing/chewing at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642247","Symptoms Interfere with Life","C105546","A question about an individual feeling that symptoms are or were interfering with their life.","Symptoms Interfere with Life | How have your symptoms interfered with your life | How much does it interfere with your activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642243","Voice or Speech Difficulties at its Worst","C105542","A question about an individual's voice or speech difficulties at its worst.","Voice or Speech Difficulties at its Worst | Your difficulty with voice/speech at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642239","Vomiting at its Worst","C105538","A question about an individual's vomiting at its worst.","Vomiting at its Worst | Your vomiting at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642146","6q11-q27","C105369","A chromosome band present on 6q.","6q11-q27 | 6q11-27",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412325","AKR1C2 Gene","C105426","This gene plays a role in the metabolism of steroid hormones.","AKR1C2 Gene | AKR1C2 | Aldo-Keto Reductase Family 1, Member C2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412324","AKR1C1 Gene","C105417","This gene is involved in the metabolism of aldehydes and ketones.","AKR1C1 Gene | AKR1C1 | Aldo-Keto Reductase Family 1, Member C1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412420","ANXA2 Gene","C105376","This gene is involved in skeletal system development.","ANXA2 Gene | ANXA2 | Annexin A2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0052201","Apolipoprotein E4","C105364","Apolipoprotein E4 (317 aa, ~36 kDa) is encoded by the human APOE gene. This protein is involved in triglyceride metabolism.","Apolipoprotein E4 | Apo-E4 | ApoE4 | NP_000032.1:p.C130R | NP_000032.1:p.C130R,R176R | NP_000032.1:p.Cys130Arg | NP_000032.1:p.Cys130Arg,Arg176Arg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537372","Bacterial 16S RNA","C105370","The RNA component of the small (30S) subunit of prokaryotic ribosomes.","Bacterial 16S RNA | 16S Ribosomal RNA | 16S rRNA | Bacterial 16S Ribosomal RNA | Bacterial 16S rRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412931","C1QA Gene","C105379","This gene plays a role in the classical complement pathway.","C1QA Gene | C1QA | Complement C1q A Chain Gene | Complement Component 1, q Subcomponent, A Chain Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413171","CCNC Gene","C105393","This gene plays a role in the modulation of gene transcription.","CCNC Gene | CCNC | Cyclin C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538924","High Affinity Nerve Growth Factor Receptor Isoform TrkA-III, human","C105368","High affinity nerve growth factor receptor isoform TrkA-III (698 aa, ~77 kDa) is encoded by the human NTRK1 gene. This protein is involved in constitutive signaling and tyrosine phosphorylation.","High Affinity Nerve Growth Factor Receptor Isoform TrkA-III | EC 2.7.10.1 | NTRK1 Isoform TrkA-III | Nerve Growth Factor Receptor Type 1 Isoform TrkA-III | Neurotrophic Tyrosine Kinase Receptor Type 1 Isoform TrkA-III | TRK1-Transforming Tyrosine Kinase Protein | TrkA-III | TrkAIII | Tropomyosin-Related Kinase A Isoform TrkA-III | Tyrosine Kinase Receptor A Isoform TrkA-III | Tyrosine Kinase Receptor Isoform TrkA-III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415661","HOXA7 Gene","C105432","This gene is involved in spatial and temporal regulation of gene expression during embryonic development.","HOXA7 Gene | HOXA7 | Homeobox A7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415667","HOXB4 Gene","C105435","This gene plays a role in spatial regulation of gene expression during embryonic development.","HOXB4 Gene | HOXB4 | Homeobox B4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415739","HSD17B3 Gene","C105148","This gene plays a role in the metabolism of testosterone.","HSD17B3 Gene | HSD17B3 | Hydroxysteroid (17-Beta) Dehydrogenase 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537381","HSD17B6 Gene","C105152","This gene is involved in androgen catabolism.","HSD17B6 Gene | HSD17B6 | Hydroxysteroid (17-Beta) Dehydrogenase 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415743","HSD3B2 Gene","C105155","This gene plays a role in the biosynthesis of hormonal steroids.","HSD3B2 Gene | HSD3B2 | Hydroxy-Delta-5-Steroid Dehydrogenase, 3 Beta- and Steroid Delta-Isomerase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642144","KIR Ligand","C105366","The major histocompatibility proteins that are ligands for the killer-cell immunoglobulin-like receptors found on natural killer cells. Binding of these ligands to their cognate receptors plays a role in the activation of natural killer cells.","KIR Ligand | Killer-Cell Immunoglobulin-Like Receptor Ligand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333922","HOXA9 Gene","C24474","This gene plays a role in transcriptional regulation, morphogenesis and differentiation.","HOXA9 Gene | HOXA9 | Homeobox A9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332420","BLNK Gene","C26635","This gene plays a role in signal transduction and B-cell development.","BLNK Gene | B-Cell Linker Gene | BLNK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642143","MicroRNA 29b","C105365","A 23 ribonucleotide sequence that is a final product of the processing of either MIR29B1 pre-miRNA or MIR29B2 pre-miRNA. This oligonucleotide may be involved in the negative regulation of gene expression.","MicroRNA 29b | MIR29B | MIRN29b | has-mir-29b | hsa-miR-29b-3p | miR29b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826088","MIR518E Gene","C105371","This gene may be involved in the repression of gene expression.","MIR518E Gene | MIR518E | MicroRNA 518e Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417395","MT1G Gene","C105397","This gene is involved in chelation.","MT1G Gene | MT1G | Metallothionein 1G Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417719","NGF Gene","C105374","This gene plays a role in the maintenance of sympathetic and sensory neurons.","NGF Gene | NGF | Nerve Growth Factor (Beta Polypeptide) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417816","NPY1R Gene","C105404","This gene is involved in diverse physiological functions as a receptor for neuropeptide Y.","NPY1R Gene | NPY1R | Neuropeptide Y Receptor Y1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1367148","IGFBP6 Gene","C24491","This gene plays an inhibitory role in the regulation of cellular growth.","IGFBP6 Gene | IGFBP6 | Insulin-Like Growth Factor Binding Protein 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334095","IGFBP4 Gene","C24489","This gene plays a role in insulin-like growth factor modulation and cellular growth inhibition.","IGFBP4 Gene | IGFBP4 | Insulin-Like Growth Factor Binding Protein 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417817","NPY2R Gene","C105408","This gene plays a role in diverse physiological functions as a peptide hormone receptor.","NPY2R Gene | NPY2R | Neuropeptide Y Receptor Y2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417818","NPY5R Gene","C105411","This gene is involved in binding to neuropeptide Y.","NPY5R Gene | NPY5R | Neuropeptide Y Receptor Y5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418549","PI3 Gene","C105389","This gene plays a role in the inhibition of elastase activity.","PI3 Gene | PI3 | Peptidase Inhibitor 3, Skin-Derived Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538823","REG3A Gene","C105382","This gene may be involved in pancreatic cell proliferation and differentiation.","REG3A Gene | REG3A | Regenerating Islet-Derived 3 Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419782","S100A10 Gene","C105414","This gene plays a role in cell cycle progression and cell differentiation.","S100A10 Gene | S100 Calcium Binding Protein A10 Gene | S100A10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420133","SLCO2B1 Gene","C105429","This gene is involved in transport of organic anions.","SLCO2B1 Gene | SLCO2B1 | Solute Carrier Organic Anion Transporter Family, Member 2B1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420395","SRD5A1 Gene","C105158","This gene is involved in the metabolism of androgens.","SRD5A1 Gene | SRD5A1 | Steroid-5-Alpha-Reductase, Alpha Polypeptide 1 (3-Oxo-5 Alpha-Steroid Delta 4-Dehydrogenase Alpha 1) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2240046","SRD5A3 Gene","C105161","This gene plays a role in the metabolism of testosterone.","SRD5A3 Gene | SRD5A3 | Steroid 5 Alpha-Reductase 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420442","ST2 gene","C105385","Human ST2 gene is located within 11p14.3-p12 and has no known gene product. This locus may play a role in tumor suppression.","ST2 Gene | ST2 | Suppression of Tumorigenicity 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421309","UCHL1 Gene","C105386","This gene plays a role in the metabolism of ubiquitinated proteins.","UCHL1 Gene | UCHL1 | Ubiquitin Carboxyl-Terminal Esterase L1 (Ubiquitin Thiolesterase) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421338","UGT2B15 Gene","C105420","This gene is involved in the metabolism of steroids and xenobiotics.","UGT2B15 Gene | UDP Glucuronosyltransferase 2 Family, Polypeptide B15 Gene | UGT2B15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421339","UGT2B17 Gene","C105423","This gene plays a role in detoxification of steroids and xenobiotics.","UGT2B17 Gene | UDP Glucuronosyltransferase 2 Family, Polypeptide B17 Gene | UGT2B17",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026825","Flaccidity","C34828","Lack of normal muscle tone.","Flaccidity | ",,,,,,,,,,,,,,,"4265740","Flaccidity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1414554","FCGR2B Gene","C38554","This gene plays a role in the inhibition of immune functions and cellular proliferation.","FCGR2B Gene | FCGR2B | Fc Gamma Receptor IIB Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521326","3q27","C13621","A chromosome band present on 3q","3q27 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446438","Intrathoracic","C105579","Within the thoracic cavity.","Intrathoracic | Internal Thorax",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0447583","Lateral Wall of the Bladder","C12333","The aspect of the bladder wall that is located on the side.","Lateral Wall of the Bladder | Lateral Wall of Bladder | Lateral wall of bladder | Lateral wall of the Bladder | Wall, Lateral",,,,,,,,,,,,,,,"4141174","Entire lateral wall of urinary bladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0225486","Lateral Wall of the Nasopharynx","C12244","The aspect of the nasopharyngeal wall that is located on the side.  It contains the pharyngeal opening of the auditory tube.","Lateral Wall of the Nasopharynx | Lateral Wall of Nasopharynx | Lateral wall of nasopharynx | Lateral wall of the Nasopharynx  | lateral wall of nasopharynx",,,,,,,,,,,,,,,"4323979","Structure of lateral wall of nasopharynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227156","Lateral Wall of the Oropharynx","C12239","The aspect of the oropharyngeal wall that is located on the side.","Lateral Wall of the Oropharynx | Lateral Wall of Oropharynx | Lateral wall of oropharynx | Lateral wall of the Oropharynx",,,,,,,,,,,,,,,"4078066","Structure of lateral wall of oropharynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0225516","Postcricoid Region","C54221","The portion of the hypopharynx that is located posteriorly to the larynx.","Postcricoid Region | Lower Hypopharyngeal Region | Lower Hypopharyngeal Region | Postcricoid region",,,,,,,,,,,,,,,"4147741","Structure of postcricoid region",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0682612","Sigmoid Flexure","C33550","The curving part of the colon that is in continuity with the rectum.","Sigmoid Flexure | Sigmoid Flexure of Colon | Sigmoid Flexure of the Colon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227157","Vallecula","C12237","A groove between the base of the tongue and the epiglottis.","Vallecula | ",,,,,,,,,,,,,,,"4173123","Structure of vallecula of epiglottis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641097","Planned Treatment Regimen","C103161","The intended treatment plan that specifies the dosage, the schedule, and the duration of treatment.","Planned Treatment Regimen | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0336570","Measuring Tape","C81261","A pliable length of fabric, plastic, paper or some composite that is has incremental lengths imprinted on the surface.","Measuring Tape | ",,,,,,,,,,,,,,,"4199004","Measuring tape",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825572","Lasso-O Measuring Tape","C81310","A measuring tape frequently used to measure head circumference in newborns.","Lasso-O Measuring Tape | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413100","CAMK2B Gene","C104830","This gene plays a role in calcium signaling.","CAMK2B Gene | CAMK2B | Calcium/Calmodulin-Dependent Protein Kinase II Beta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413102","CAMK2G Gene","C104833","This gene is involved in calcium signaling.","CAMK2G Gene | CAMK2G | Calcium/Calmodulin-Dependent Protein Kinase II Gamma Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413258","CDC25B Gene","C104836","This gene plays a role in mitotic progression.","CDC25B Gene | CDC25B | Cell Division Cycle 25B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982894","Neuromuscular Maturity Assessment","C89516","A neuromuscular examination of a newborn's developmental characteristics.","Neuromuscular Maturity Assessment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982897","Square Window","C89520","When testing the newborn infant for neuromuscular maturity, the 'square window' test measures wrist flexibility and resistance to extensor stretching, The examiner straightens the infant's fingers and applies gentle pressure on the dorsum of the hand, close to the fingers, and then estimates the angle between the palm of the hand and the forearm.","Square Window | Square Window Sign",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983697","Arm Recoil Test","C90496","A test commonly administered to assess the physiologic response to extending the arms as straight as possible alongside the body when lying down.","Arm Recoil Test | Arm Recoil | Arm Recoil | Arm Recoil Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982896","Popliteal Angle Measurement","C89519","An examination whereby the patient is placed supine, the hip is flexed 90 degrees, and the knee is extended until firm resistance is met. The popliteal angle is the angle from the tibia to the femur. This measurement is used to assess hamstring contracture in children with cerebral palsy.","Popliteal Angle Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982898","Scarf Sign","C89521","When testing the newborn infant for neuromuscular maturity, the 'scarf sign' test is carried out by drawing the newborn's arm across the chest to the opposite shoulder until resistance is felt. In term infants, the elbow should not cross the midline of the chest.","Scarf Sign | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982891","Heel to Ear Measurement","C89513","Useful in assessing neonatal neuromuscular development, this is obtained when the infant is placed in a supine position and the infant's feet are grasped pulled toward the ipsilateral ears. The examiner measures the angle made by the arc from the table to the infant's heels; increased angle for age suggests hypotonia, and decreased angle for age suggests hypertonia.","Heel to Ear Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982895","Physical Maturity Assessment","C89518","A physical examination of a newborn's developmental characteristics.","Physical Maturity Assessment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0423866","Lanugo","C34197","Fine downy hair that covers the body of a human fetus beginning in the fifth month of gestation; it is usually shed by the ninth month of gestation.","Lanugo | ",,,,,,,,,,,,,,,"4083922","Lanugo",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333520","Eye and Ear Finding","C36283","Symptoms, physical examination results, and/or laboratory test results related to the organs of special sense.","Eye and Ear Finding | SPECIAL SENSES SYSTEM | Special Sense Organ Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417815","NPY Gene","C39647","This gene plays a role in the cellular proliferation of neuronal precursor cells.","NPY Gene | NPY | Neuropeptide Y Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919429","SRD5A2 Gene","C18502","This gene is involved in androgen metabolism and sexual differentiation.","SRD5A2 Gene | SRD5A2 | Steroid-5-Alpha-Reductase, Alpha Polypeptide 2 (3-oxo-5 Alpha-Steroid Delta 4-Dehydrogenase Alpha 2) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334909","NTRK2 Gene","C24646","This gene plays a regulatory role in synaptic functions and in the long-term potentiation of brain synapses.","NTRK2 Gene | NTRK2 | Neurotrophic Tyrosine Kinase Receptor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919487","NTRK1 Gene","C18551","This gene is involved in cellular differentiation and neurotrophic functions.","NTRK1 Gene | NTRK1 | Neurotrophic Receptor Tyrosine Kinase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642253","Timeline Followback Method","C105552","A calendar-based measure for assessing self-reported retrospective daily estimates of alcohol, tobacco and/or illicit substance use.","Timeline Followback Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085163","Crack Cocaine","C105553","An illegal drug composed of the smokable, baseform of cocaine that is produced by dissolving cocaine hydrochloride in an alkali solution, usually sodium bicarbonate and water, and subsequent boiling. Cocaine causes euphoria, loss of appetite, insomnia, and is highly addictive.","Crack Cocaine | Crack",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018533","Hallucinogen","C105554","Any naturally-derived or synthetic substance that can induce hallucinations.","Hallucinogen | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3536852","Cannabinoid","C105578","Any compound capable of activating the cannabinoid receptor CB1 and/or CB2. Cannabinoids include phytocannabinoids, endocannabinoids and (semi-)synthetic cannabinoids. They exert a wide variety of biological activities including anti-inflammatory, anti-emetic, anticonvulsant, antiglaucoma, analgesic and neuroprotective effects; while some exert psychoactive effects, including euphoria.","Cannabinoid | Cannabinoids",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986775","Logarithm","C94925","For a specified base b, a function such that its argument results when b is raised to the power given by this function's value.","Logarithm | log",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025605","Methadone","C62044","A synthetic opioid with analgesic activity. Methadone mimics the actions of endogenous peptides at CNS opioid receptors, primarily on the mu-receptor and has actions similar to those of morphine and morphine-like agents. The characteristic morphine-like effects include analgesia, euphoria, sedation, respiratory depression, miosis, bradycardia and physical dependence. However, the detoxification symptoms between morphine-like agents and methadone differ in that the onset of methadone's withdrawal symptoms is slower, the course is more prolonged and the symptoms are less severe.","Methadone | METHADONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879535","Acetyl-L-Carnitine Hydrochloride","C61624","A nutritional supplement composed of the hydrochloride salt form of the acetylated form of the endogenously produced L-carnitine, with potential neuroprotective, cognitive-enhancing, anti-depressive and immunomodulating activities. L-carnitine is responsible for the transport of fatty acids into the mitochondria for breakdown. It may also relieve peripheral neuropathy induced by chemotherapy, diabetes or other diseases. In addition, acetyl-L-carnitine may modulate the immune response by increasing T-lymphocytes maturation and may downregulate pro-inflammatory cytokines in response to viruses, such as SARS-CoV-2.  It may also disrupt the ACE2 signaling pathway and inhibit the production of reactive oxygen species (ROS).","Acetyl-L-Carnitine Hydrochloride | 1-Propanaminium, 2-(acetyloxy)-3-carboxy-N,N,N-trimethyl-, chloride, (R)- | Acetylcarnitine Hydrochloride, L- | Acetylcarnitine L-form HCl | LEVACECARNINE HYDROCHLORIDE | acetyl-L-carnitine hydrochloride | o-Acetyl-L-carnitine hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2343849","Dabigatran Etexilate Mesylate","C90702","An orally available mesylate salt form of the etexilate prodrug of dabigatran, a benzimidazole and direct thrombin inhibitor with anticoagulant activity. Upon administration, dabigatran etexilate is hydrolyzed by esterases and is converted into dabigatran. Dabigatran reversibly binds to and inhibits the activity of thrombin, a serine protease that converts fibrinogen into fibrin. This disrupts the coagulation cascade and inhibits the formation of blood clots.","Dabigatran Etexilate Mesylate | BIBR 1048 MS | BIBR 1048MS | Beta-alanine, N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl] phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-,ethyl ester, methanesulfonate | DABIGATRAN ETEXILATE MESYLATE | Pradaxa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0077768","Brimonidine Tartrate","C47419","The tartrate salt form of brimonidine, an imidazole derivative and a selective alpha-2 adrenergic receptor agonist. Upon ocular administration, brimonidine tartrate acts on the blood vessels causing them to constrict which leads to a decrease in the production of aqueous humor. Brimonidine tartrate also enhances the outflow of aqueous humor. This drug is used in the treatment of glaucoma to reduce intraocular pressure.","Brimonidine Tartrate | 6-Quinoxalinamine, 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-,(2R,3R)-2,3-dihydroxybutanedioate(1:1) | Alphagan | BRIMONIDINE TARTRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0893445","inhibitor-of-apoptosis protein","C20934","A family of proteins that are related structurally and functionally and are inhibitors of apoptosis.","IAP Family Protein | IAP Protein | Inhibitor of Apoptosis Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335858","SP1 Gene","C20711","This gene plays a role in transcriptional regulation and is involved in several signal transduction pathways.","SP1 Gene | SP1 | Sp1 Transcription Factor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336694","TYRP1 Gene","C21236","This gene plays a role in melanogenesis and sensory transduction/vision.","TYRP1 Gene | TYRP1 | Tyrosinase-Related Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043297","X-Chromosome Inactivation","C20674","A human early embryonic event in which in any given cell one of a female's two X chromosomes becomes inactivated and converted into a Barr body.  After inactivation has occurred, all descendants of that cell have the same inactivated X chromosome. Thus, X-inactivation creates cell clones with differing effective gene content. An organism whose cells vary in effective gene content and hence in the expression of a trait, is called a genetic mosaic.","X-Chromosome Inactivation | Lyonization | X Chromosome Inactivation | X Inactivation | X-Inactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826007","MIR193A Gene","C81782","This gene is involved in the regulation of gene expression.","MIR193A Gene | MIR193A | MicroRNA 193a Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984589","Transoral Laser Microsurgery","C91840","A minimally invasive procedure in which a surgeon performs tumor resection through the mouth using a microscope for visualization and a CO2 laser for incisions.","Transoral Laser Microsurgery | TLM | Transoral Laser Excision | Transoral Laser Surgery | Transoral Laser Surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412800","Transoral Robotic Surgery","C94439","A minimally invasive procedure in which a surgeon performs surgical neck procedures through the mouth using a robotic surgical system.","Transoral Robotic Surgery | TORS | transoral robotic surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332701","CCR6 Gene","C24271","This gene is involved in B-cell differentiation, maturation, and the recruitment of cells during inflammatory responses.","CCR6 Gene | CCR6 | Chemokine (C-C Motif) Receptor 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426212","SOCS3 Gene","C97971","This gene is involved in the regulation of cytokine-mediated signaling.","SOCS3 Gene | SOCS3 | Suppressor of Cytokine Signaling 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333715","GSTT1 Gene","C24465","This gene plays a role in phase II metabolism of both endogenous compounds and xenobiotics.","GSTT1 Gene | GSTT1 | Glutathione S-Transferase Theta 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826778","ESRP1 Gene","C101497","This gene is involved in mRNA processing.","ESRP1 Gene | ESRP1 | Epithelial Splicing Regulatory Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516924","Epigenetic Process","C21051","Changes in the regulation of the expression of gene activity without alteration of genetic structure.","Epigenetic Process | Epigenetic Change | Epigenetic Mechanism | Epigenetics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515001","Chromosomal Rearrangement","C36541","Any change in the structure of one or more chromosomes.","Chromosomal Rearrangement | Chromosomal Rearrangements | Rearrangement | Rearrangement NOS | Rearrangement, NOS | Structural Chromosomal Abnormality | Structural Chromosome Aberration | Structural Chromosome Aberration; Structural Chromosome Anomalies | Structural Chromosome Anomalies | Structural Rearrangement | Structural rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366520","ST14 Gene","C26586","This gene is involved in the activation of proteases and latent growth factors in epithelial membranes.","ST14 Gene | ST14 | ST14 Transmembrane Serine Protease Matriptase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1367689","PLAUR Gene","C24681","This gene is involved in the activation of cell-surface plasminogen and localized degradation of the underlying extracellular matrix.","PLAUR Gene | PLAUR | Plasminogen Activator, Urokinase Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417820","NR0B1 Gene","C75864","This gene plays a role in both modulation of receptor signaling and transcription.","NR0B1 Gene | NR0B1 | Nuclear Receptor Subfamily 0, Group B, Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537840","MIR200C Gene","C81787","This gene is involved in the regulation of gene expression and plays a role in the development of carcinoma of the breast.","MIR200C Gene | MIR200C | MicroRNA 200c Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0887935","Allelic Imbalance","C105660","Any variance from the expected 1:1 ratio for the expression of the two inherited parental alleles for the same gene.","Allelic Imbalance | Allele Imbalance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538933","C-Circle","C105650","A stretch of telomeric DNA where the normally guanine-rich (TTAGGG)n overhanging sequence has gaps while the cytosine-rich (AATCCC)n opposite strand remains intact. The resulting partially single-stranded telomere can adopt a circular confirmation.","C-Circle | C-Circles | CC | Extrachromosomal Telomeric C-Rich DNA Circles | Partially Double-Stranded Circles of Telomeric C-Strand DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642282","Cancer/Testis Antigen Family 47 Gene","C105649","A family of genes that is comprised of 13 nearly identical loci that are clustered in the vicinity of Xq24.","Cancer/Testis Antigen Family 47 Gene | CT47 | CT47A | Cancer/Testis Antigen 47 | Cancer/Testis Antigen Family 47",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420322","SOX2 Gene","C61136","This gene is involved in embryonic development and in the determination of cell fate.","SOX2 Gene | SOX2 | SRY (Sex Determining Region Y)-Box 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412206","ADAM8 Gene","C90314","This gene is involved in the mediation of proteolysis.","ADAM8 Gene | ADAM Metallopeptidase Domain 8 Gene | ADAM8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427435","DACT2 Gene","C105717","This gene is involved in the regulation of signaling pathways.","DACT2 Gene | DACT2 | Dapper, Antagonist of Beta-Catenin, Homolog 2 (Xenopus laevis) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413900","DAD1 Gene","C105729","This gene plays a role in peptide glycosylation.","DAD1 Gene | DAD1 | Defender Against Cell Death 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427590","DIABLO Gene","C105651","This gene plays a role in the positive regulation of apoptosis.","DIABLO Gene | DIABLO | Diablo IAP-Binding Mitochondrial Protein Gene | Diablo, IAP-Binding Mitochondrial Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1257780","DNA Replication Timing","C105645","The process that establishes the temporal order of the replication of segments of DNA along a chromosome or in an entire genome.","DNA Replication Timing | Replication Timing | Replication Timing Program",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415337","GSTM4 Gene","C105664","This gene plays a role in the metabolism of both glutathione and xenobiotics.","GSTM4 Gene | GSTM4 | Glutathione S-Transferase Mu 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416520","ITSN1 Gene","C105657","This gene plays a role in both signal transduction and endocytosis.","ITSN1 Gene | ITSN1 | Intersectin 1 (SH3 Domain Protein) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416742","KRT5 Gene","C105679","This gene is involved in epidermal integrity.","KRT5 Gene | KRT5 | Keratin 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825760","KRT72 Gene","C105682","This gene plays a role in hair formation.","KRT72 Gene | KRT72 | Keratin 72 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825785","LAGE3 Gene","C105654","This gene has no known function.","LAGE3 Gene | L Antigen Family, Member 3 Gene | LAGE3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642279","Microtubule-Associated Proteins 1A/1B Light Chain 3-II","C105644","Microtubule-associated proteins 1A/1B light chain 3-II proteins (LC3-II) are products of the autophagy-dependent processing of microtubule-associated proteins 1A/1B light chain 3 family proteins (LC3). During autophagy, LC3 proteins are cleaved by cysteine protease ATG4B to form LC3-I intermediates which are located in the cytoplasm. As autophagy progresses, LC3-I proteins interact with both ubiquitin-like modifier-activating enzyme ATG7 and ubiquitin-like-conjugating enzyme ATG3. These interactions result in further proteolysis and the conjugation of a phospholipid anchor to form the membrane localized LC3-II.","Microtubule-Associated Proteins 1A/1B Light Chain 3-II | LC3 II | LC3-II | MAP1LC3-II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642280","MLL/MLLT11 Fusion Gene","C105646","A fusion gene that results from a chromosomal translocation t(1;11)(q21;q23) which fuses the first 6 exons of the MLL gene to the 5' untranslated region of the MLLT11 gene. This rearrangement is associated with acute myelomonocytic leukemia.","MLL/MLLT11 Fusion Gene | KMT2A::MLLT11 Fusion Gene | MLL-AF1q Fusion Gene | MLL-MLLT11 Fusion Gene | MLL/AF1q Fusion Gene | MLL::MLLT11 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417613","NCL Gene","C105661","This gene is involved in ribosome assembly.","NCL Gene | NCL | Nucleolin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422329","PDLIM2 Gene","C105695","This gene is involved in the regulation of both cell migration and cell adhesion.","PDLIM2 Gene | PDLIM2 | PDZ and LIM Domain 2 (Mystique) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426225","PGBD5 Gene","C105702","This gene may play a role in gene transposition.","PGBD5 Gene | PGBD5 | PiggyBac Transposable Element Derived 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419968","SELENOP Gene","C105737","This gene is involved in selenium metabolism.","SELENOP Gene | SELENOP | SEPP1 | SEPP1 Gene | Selenoprotein P Gene | Selenoprotein P, Plasma,1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2678009","XAGE1 Family Gene","C105648","A subfamily of the GAGE gene family that is comprised of at least 5 nearly identical loci clustered in the vicinity of Xp11.22.","XAGE1 Family Gene | CT12.1 | Cancer-Testis Antigen 12.1 Gene | Cancer/Testis Antigen Family 12, Member 1 Gene | G Antigen Family D Member 2 Gene | GAGED2 | X Antigen Family, Member 1 | X Antigen Family, Member 1 Gene | XAGE-1 | XAGE1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515592","del(1p36)","C36569","A chromosomal deletion involving the p36 band of chromosome 1. This deletion is associated with 1p36 deletion syndrome.","del(1p36) | 1p36 Deletion | Loss of Chromosome 1p36",,,,,,,,,,,,,,,"42537880","Deletion 1p36",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1421297","UBE4B Gene","C95841","This gene plays a role in polyubiquitination.","UBE4B Gene | UBE4B | Ubiquitination Factor E4B (UFD2 Homolog, Yeast) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812253","CRKL Gene","C18375","This gene plays a role in cell communication and signal transduction.","CRKL Gene | CRKL | V-Crk Sarcoma Virus CT10 Oncogene Homolog (Avian)-Like Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1367389","ITK Gene","C24526","This gene is involved in the differentiation and proliferation of T cells.","ITK Gene | IL2-Inducible T-Cell Kinase Gene | ITK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826257","MLLT11 Gene","C97387","This gene is involved in mitochondrial functions.","MLLT11 Gene | AF1Q | MLLT11 | Myeloid/Lymphoid or Mixed-Lineage Leukemia (Trithorax Homolog, Drosophila); Translocated to, 11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221910","Squamous Cell","C12849","Flat cell that looks like a fish scale under a microscope. These cells cover inside and outside surfaces of the body. They are found in the tissues that form the surface of the skin, the lining of the hollow organs of the body (such as the bladder, kidney, and uterus), and the passages of the respiratory and digestive tracts.","Squamous Cell | Squamous Cells | squamous cell",,,,,,,,,,,,,,,"4214741","Squamous epithelial cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512816","Serous Surface Papillary Carcinoma","C4182","An invasive serous adenocarcinoma arising from the ovary and rarely the peritoneum. Morphologically, it may be a well, moderately, or poorly differentiated neoplasm. It is characterized by a papillary growth pattern often associated with the presence of psammoma bodies.","Serous Surface Papillary Carcinoma | Serous surface papillary carcinoma",,,,,,,,,,,,,,,"37396737","Extraovarian primary peritoneal carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1420280","FSCN1 Gene","C101605","This gene is involved in actin filament assembly.","FSCN1 Gene | FSCN1 | Fascin Homolog 1, Actin-Bundling Protein (Strongylocentrotus purpuratus) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366557","TGFB1 Gene","C24856","This gene plays a role in cell growth, proliferation and biogenesis/organization. It is also involved in the inhibition of apoptosis.","TGFB1 Gene | TGFB1 | Transforming Growth Factor, Beta 1 (Camurati-Engelmann Disease) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1367601","PLAT Gene","C26546","This gene is involved in blood coagulation, cell migration and tissue remodeling.","PLAT Gene | PLAT | Plasminogen Activator, Tissue Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0530993","CYFRA 21-1","C18039","Fragments of keratin, type I cytoskeletal 19 (KRT19; cytokeratin 19) that are not sequestered in insoluble intermediate filament protein complexes. These KRT19 fragments are used as tumor markers and as prognostic markers for several neoplastic diseases.","CYFRA 21-1 | Cytokeratin 19 Fragment | Cytokeratin-19 Fragments 21-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3276534","CBFB/MYH11 Fusion Gene","C101051","A fusion gene that results from a chromosomal inversion inv(16)(p13q22) which fuses the 5' portion of the CBFB gene with the 3' part of the MYH11 gene. This rearrangement is associated with acute myeloid leukemia and myelodysplastic syndrome.","CBFB/MYH11 Fusion Gene | CBFB::MYH11 Fusion Gene | CBFb-MYH11 Fusion Gene | CBFbeta-MYH11 Fusion Gene | CBFbeta-SMMHC Fusion Gene | CBFbeta/SMMHC Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335208","PHB1 Gene","C20839","This gene plays a role in the negative regulation of both apoptosis and cell proliferation.","PHB1 Gene | PHB | PHB Gene | PHB Gene | PHB1 | Prohibitin 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417212","MMP7 Gene","C98111","This gene plays a role in proteolysis.","MMP7 Gene | MMP7 | Matrix Metallopeptidase 7 (Matrilysin, Uterine) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824798","CRTC1 Gene","C95449","This gene plays a role in the positive regulation of transcription.","CRTC1 Gene | CREB Regulated Transcription Coactivator 1 Gene | CRTC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520622","15q","C13539","Distal (long) arm of chromosome 15","15q | Chromosome 15 Distal Arm | Chromosome 15 Long Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1842690","NBAS Gene","C24622","This gene may play a role in the development of neuroblastoma.","NBAS Gene | NAG Gene | NBAS | Neuroblastoma Amplified Sequence Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1948061","Every (qualifier)","C64651","Including all possibilities or occurring at regular intervals.","Every | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027741","Neural Block","C21072","The use of anesthetics in the central or peripheral nervous system to diminish or eliminate the bombardment of the CNS with nociceptive input, which minimizes stress response, adverse spinal reflexes, and wind-up.  It may be performed for temporary or permanent pain palliation. (from Rowlingson)","Neural Block | Nerve Block | Neural Blockade | Neurolytic Block | nerve block",,,,,,,,,,,,,,,"4210480","Nerve block",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829612","How Much Does It Bother You","C105747","A question about how much something bothers an individual.","How Much Does It Bother You | How Much Bothered | How much does it bother you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831273","Breast Appears Redder","C105749","A question about whether an individual thinks the color of their breast is or was redder.","Breast Appears Redder | Is your breast redder in color",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831274","Breast Appears or Feels Swollen","C105746","A question about whether an individual feels their breast is or was swollen.","Breast Appears or Feels Swollen | Does your breast appear or feel swollen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831271","Breast Feels Heavy","C105748","A question about whether an individual feels their breast is or was heavy.","Breast Feels Heavy | Does your breast feel heavy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811663","Breast Lymphedema Symptom Survey","C105745","A self-administered questionnaire designed to measure the degree of distress associated with the signs and symptoms of lymphedema in an operated breast.","Breast Lymphedema Symptom Survey | BLSS | Breast Lymphedema Symptom Survey ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829812","Have Axillary Fullness or Numbness","C105751","A question about whether an individual has axillary fullness or numbness.","Have Axillary Fullness or Numbness | Do you have axillary fullness or numbness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829776","Have Pain, Tenderness, or Discomfort in Breast","C105750","A question about whether an individual has or had pain, tenderness or discomfort in their breast.","Have Pain, Tenderness, or Discomfort in Breast | Do you have pain, tenderness, or discomfort in your breast | Have Pain, Tenderness or Discomfort in Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830157","Feel Weakness in Arm or Hand","C105768","A question about whether an individual has or had weakness in their arm or hand.","Feel Weakness in Arm or Hand | Does your arm or hand feel weak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829817","Have Aching","C105779","A question about whether an individual has or had aching.","Have Aching | Have you experienced aching",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829808","Have Breast Swelling","C105781","A question about whether an individual has or had breast swelling.","Have Breast Swelling | Have you experienced breast swelling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829807","Have Chest Wall Swelling","C105780","A question about whether an individual has or had chest wall swelling.","Have Chest Wall Swelling | Have you experienced chest wall swelling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829795","Have Heaviness","C105776","A question about whether an individual has or had heaviness.","Have Heaviness | Have you experienced heaviness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829789","Have Increased Temperature in Arm","C105775","A question about whether an individual has or had increased temperature in arm.","Have Increased Temperature in Arm | Have you experienced increased temperature in your arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829786","Have Limited Movement of Elbow","C105765","A question about whether an individual has or had limited movement of their wrist.","Have Limited Movement of Elbow | Do you have limited movement of your elbow",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829785","Have Limited Movement of Fingers","C105767","A question about whether an individual has or had limited movement of their fingers.","Have Limited Movement of Fingers | Do you have limited movement of your fingers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537834","MIR198 Gene","C81786","This gene is involved in the regulation of gene expression. While it has no known role in oncogenesis, MIR198 plays a role in the development of schizophrenia.","MIR198 Gene | MIR198 | MicroRNA 198 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829784","Have Limited Movement of Shoulder","C105764","A question about whether an individual has or had limited movement of their shoulder.","Have Limited Movement of Shoulder | Do you have limited movement of your shoulder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829783","Have Limited Movement of Wrist","C105766","A question about whether an individual has or had limited movement of their wrist.","Have Limited Movement of Wrist | Do you have limited movement of your wrist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0423581","Have Numbness","C105777","A question about whether an individual has or had numbness.","Have Numbness | Have you experienced numbness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829779","Have Other Symptoms","C105783","A question about whether an individual has or had other symptoms.","Have Other Symptoms | Have you experienced other symptoms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829774","Have Pockets of Fluid Develop","C105782","A question about whether an individual has or had pockets of fluid develop.","Have Pockets of Fluid Develop | Have you experienced pockets of fluid developing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829770","Have Redness","C105772","A question about whether an individual has or had redness.","Have Redness | Have you experienced redness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829769","Have Stiffness","C105778","A question about whether an individual has or had stiffness.","Have Stiffness | Have you experienced stiffness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829766","Have Swelling with Pitting","C105771","A question about whether an individual has or had swelling or pitting; which occurs when you press firmly on your skin and the dent stays long enough to feel it when you slide the pad of your finger across it.","Have Swelling with Pitting | Have you experienced swelling with pitting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829767","Have Swelling","C105770","A question about whether an individual has or had swelling.","Have Swelling | Have you experienced swelling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829765","Have Tenderness","C105769","A question about whether an individual has or had tenderness.","Have Tenderness | Have you experienced tenderness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829236","Lymphedema and Breast Cancer Questionnaire","C105763","A condensed version of a self-administered or structured interview questionnaire designed specifically for evaluating lymphedema symptoms after surgery for breast cancer.","Lymphedema and Breast Cancer Questionnaire | LBCQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829800","Have Firmness or Tightness","C105774","A question about whether an individual has or had firmness or tightness.","Have Firmness or Tightness | Have you experienced firmness / tightness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829811","Have Blistering","C105773","A question about whether an individual has or had blistering.","Have Blistering | Have you experienced blistering",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL791432","WEE1 inhibitor AZD1775","C91725","A small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. Adavosertib selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDK1, CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents. Unlike normal cells, most p53 deficient or mutated human cancers lack the G1 checkpoint as p53 is the key regulator of the G1 checkpoint and these cells rely on the G2 checkpoint for DNA repair to damaged cells. Annulment of the G2 checkpoint may therefore make p53 deficient tumor cells more vulnerable to antineoplastic agents and enhance their cytotoxic effect.","Adavosertib | 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one | ADAVOSERTIB | AZD 1775 | AZD-1775 | AZD1775 | MK 1775 | MK-1775 | MK1775 | WEE1 Inhibitor AZD1775 | WEE1 Inhibitor MK-1775",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL426026","Choline Kinase Alpha Inhibitor TCD-717","C94213","A small-molecule inhibitor of choline kinase alpha (CHKA), with potential antineoplastic activity. TCD-717 targets and binds to CHKA, an enzyme that plays a key role in the synthesis of phosphatidylcholine, the major phospholipid in eukaryotic cell membranes. Blockade of this enzyme induces cells to activate a different route for phospholipid production which causes a toxic effect and eventually leads to cell destruction. CHKA, overexpressed in human cancer cells while only minimally expressed in normal cells, appears to play a significant role in cellular proliferation, evasion of apoptosis, increased cell motility and metastasis.","Choline Kinase Alpha Inhibitor TCD-717 | CHKA Inhibitor TCD-717 | RSM-932A | TCD-717",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2930789","Nintedanib","C62765","An orally bioavailable, indolinone-derived inhibitor of multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs), with potential antiangiogenic, antifibrotic and antineoplastic activities. Upon administration, nintedanib selectively binds to and inhibits vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), and colony stimulating factor 1 receptor (CSF1R) tyrosine kinases, which may result in the induction of endothelial cell apoptosis, the reduction in tumor vasculature, the inhibition of tumor cell proliferation and migration, and antifibrotic activity in pulmonary fibrosis. In addition, nintedanib also binds to and inhibits members of the Src family of tyrosine kinases, including Src, Lck and Lyn, and fms-like tyrosine kinase 3 (FLT-3). VEGFR, FGFR, PDGFR and CSF1R RTKs play key roles in tumor angiogenesis, tumor cell proliferation and metastasis, as well as pulmonary fibrosis.","Nintedanib | BIBF 1120 | BIBF-1120 | BIBF1120 | Intedanib | Methyl (3Z)-3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylidene)-2-oxo-2,3-dihydro-1H-indole-6-carboxylate | Multitargeted Tyrosine Kinase Inhibitor BIBF 1120 | NINTEDANIB | Vargatef | tyrosine kinase inhibitor BIBF 1120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704439","Neratinib","C49094","An orally available, 6,7-disubstituted-4-anilinoquinoline-3-carbonitrile irreversible inhibitor of the HER-2 receptor tyrosine kinase with potential antineoplastic activity. Neratinib binds to the HER-2 receptor irreversibly, thereby reducing autophosphorylation in cells, apparently by targeting a cysteine residue in the ATP-binding pocket of the receptor. Treatment of cells with this agent results in inhibition of downstream signal transduction events and cell cycle regulatory pathways; arrest at the G1-S (Gap 1/DNA synthesis)-phase transition of the cell division cycle; and ultimately decreased cellular proliferation. Neratinib also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells.","Neratinib | (2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide | 2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)- | HKI 272 | HKI-272 | HKI272 | NERATINIB | PB 272 | PB-272",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824799","CRTC2 Gene","C95453","This gene is involved in transcriptional activation.","CRTC2 Gene | CREB Regulated Transcription Coactivator 2 Gene | CRTC2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827302","Able to Concentrate","C105891","A question about whether an individual is or was able to concentrate.","Able to Concentrate Question | Able to Concentrate | Able to Concentrate | Concentration | Concentration Distress | I am able to concentrate | I can concentrate well | I have been able to concentrate",,,,,,,,,,,,,,,"3654765","Able to concentrate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3831759","Able to Get Around by Myself","C105885","A question about whether an individual is or was able to get around by themselves.","Able to Get Around by Myself Question | Able to Get Around by Myself | Able to Get Around by Myself | I am able to get around by myself",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831755","Able to Remember","C105890","A question about whether an individual is or was able to remember things.","Able to Remember Question | Able to Remember | Able to Remember | I can remember things | I have been able to remember things, like where I left my keys or wallet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831296","Bothered By Skin Problems","C105895","A question about whether an individual is or was bothered by skin problems.","Bothered By Skin Problems | I am bothered by skin problems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831304","Bothered by Food Taste Change","C105893","A question about whether an individual is or was bothered by changes in the taste of food.","Bothered by Food Taste Change | Bothered by Change in Food Taste | I am bothered by a change in the way food tastes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831032","Concerned About Keeping My Job, Including Work at Home","C105880","A question about whether an individual is or was concerned about keeping their job including their work at home.","Concerned About Keeping My Job, Including Work at Home | I am concerned about keeping my job (include work at home)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830163","Feel Distant from People","C105881","A question about whether an individual feels or felt distant from other people.","Feel Distant from People | I feel distant from other people",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829810","Have Blurry Eyesight","C105892","A question about whether an individual has or had blurry eyesight.","Have Blurry Eyesight | Did you have blurred vision | Have Blurred Vision | My eyesight is blurry | Was your vision blurred",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829809","Have Bowel Trouble","C105896","A question about whether an individual has or had bowel troubles.","Have Bowel Trouble | I have trouble with my bowels",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829805","Have Confidence in Nurse","C105888","A question about whether an individual has or had confidence in their nurse(s).","Have Confidence in Nurse | I have confidence in my nurse(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827350","Have Frequent Colds or Infections","C105899","A question about whether an individual has or had frequent colds or infections.","Have Frequent Colds or Infections | Have Frequent Colds/ Infections | Have Frequent Colds/Infections | I have frequent colds/infections",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829763","Have Tremor","C105894","A question about whether an individual has or had tremors.","Have Tremor | I have tremors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829568","Illness is Personal Hardship for Close Family Members","C105897","A question about whether an individual feels their illness is or was a personal hardship for close family members.","Illness is Personal Hardship for Close Family Members | My illness is a personal hardship for my close family members",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829530","Interested in Sex","C105886","A question about whether an individual is or was interested in sex.","Interested in Sex Question | Have you had any interest in sexual relations | I am interested in sex | Interest in Sexual Relations | Interested in Sex | Interested in Sex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829285","Like My Body Appearance","C105884","A question about whether an individual likes or liked the appearance of their body.","Like My Body Appearance | I like the appearance of my body",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828346","Regret Having Bone Marrow Transplant","C105889","A question about whether an individual regrets or regretted having a bone marrow transplant.","Regret Having Bone Marrow Transplant | I regret having the bone marrow transplant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827783","Treatment Cost is a Burden to Me or My Family","C105898","A question about whether an individual feels the cost of treatment is or was a burden to them or their family.","Treatment Cost is a Burden to Me or My Family | The cost of my treatment is a burden on me or my family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827782","Treatment Effects are Worse than Imagined","C105883","A question about whether an individual feels or felt the treatment effects are worse than imagined.","Treatment Effects are Worse than Imagined | The effects of treatment are worse than I had imagined",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827444","Worry the Transplant Will Not Work","C105882","A question about whether an individual worries or worried that the transplant will not work.","Worry the Transplant Will Not Work | I worry that the transplant will not work",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831033","Concern about Ability to Have Children","C105887","A question about whether an individual has or had concerns about their ability to have children.","Concern about Ability to Have Children | Concern About Ability to Have Children | Concerned about Ability to Have Children | Have Concerns About Ability to Have Children | I have concerns about my ability to have children | Were you concerned about your ability to have children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279638","Gastric Mixed Adenocarcinoma","C67526","An adenocarcinoma that arises from the gastric mucosa and is characterized by the presence of both glandular and poorly cohesive malignant cellular components.","Gastric Mixed Adenocarcinoma | Mixed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987393","Poorly Cohesive Gastric Adenocarcinoma","C95743","An adenocarcinoma that arises from the gastric mucosa and is characterized by the presence of isolated malignant cells or malignant cells that form small aggregates.  This category includes signet ring cell adenocarcinomas, adenocarcinomas that are composed of malignant cells resembling lymphocytes and histiocytes, and adenocarcinomas that are composed of malignant cells with deeply eosinophilic cytoplasm.","Gastric Poorly Cohesive Adenocarcinoma | Gastric Poorly Cohesive Carcinoma | Gastric Poorly Cohesive Carcinoma | Poorly Cohesive Gastric Adenocarcinoma | Poorly Cohesive Gastric Carcinoma | Poorly Cohesive Gastric Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335965","Gastric Signet Ring Cell Adenocarcinoma","C5250","A poorly cohesive gastric adenocarcinoma characterized by malignant cells containing intracytoplasmic mucin.","Gastric Signet Ring Cell Adenocarcinoma | Gastric Signet-Ring Cell Adenocarcinoma | Poorly cohesive carcinoma, including signet ring cell carcinoma | Signet Ring Cell Adenocarcinoma of Stomach | Signet Ring Cell Adenocarcinoma of the Stomach | Signet Ring Cell Gastric Adenocarcinoma | Signet Ring Cell Gastric Adenocarcinoma | Signet Ring Cell Stomach Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707997","FACT-BMT Questionnaire","C45900","A subscale complement to the FACT-G questionnaire developed specifically for evaluating quality of life of bone marrow transplant (BMT) patients.","FACT-BMT Questionnaire | FACT-BMT | Functional Assessment of Cancer Therapy Bone Marrow Transplant Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829311","Lauren Classification","C105904","A classification scheme in which gastric adenocarcinomas are separated into diffuse adenocarcinoma, intestinal type adenocarcinoma, mixed adenocarcinoma, or indeterminate type adenocarcinoma.","Lauren Classification | Histologic Type (Lauren Classification) | LAUREN CLASSIFICATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538919","Low Risk","C102403","The potential future harm that may arise from some present action or attribute or condition is small.","Low Risk | LOW RISK",,,,,,,,,,,,,,,"37109700","Low risk",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640764","Intermediate Risk","C102402","The potential future harm that may arise from some present action or attribute or condition is moderate.","Intermediate Risk | INTERMEDIATE RISK | Moderate Risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709846","Real Time PCR","C51962","An application of PCR that measures the products generated during each cycle of the polymerase chain reaction process in order to determine the starting amount of template in the reaction.","Real Time PCR | Molecular Real-Time Quantitative Polymerase Chain Reaction | Quantitative PCR | Quantitative Real Time PCR | Quantitative Real Time Polymerase Chain Reaction | REAL-TIME POLYMERASE CHAIN REACTION ASSAY | Real Time Polymerase Chain Reaction | Real Time-PCR | Real-Time PCR | qPCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001914","Alberta","C89819","A province located in western Canada, bounded by British Columbia to the west, Saskatchewan to the east, and the Northwest Territories to the north. Its capital is Edmonton.","Alberta | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700297","Yucatan Pig","C77108","Originating from Mexico and Central America, this breed has a straight back and no potbelly, short snout, sparse hair coat and medium size ears. The Yucatan pig is slate gray to black in color. Its uses in biomedical research are varied and include diabetes research, cardiovascular research, angiogenesis, and ophthalmological research among others.","Yucatan Pig | Mexican Hairless | YUCATAN | Yucatan | Yucatán | Yucatán Pig",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705968","Cartridge Dosing Unit","C48481","A dosing unit equal to the amount of active ingredient(s) contained in a cartridge.","Cartridge Dosing Unit | CARTRIDGE | CQ | Cartridge | {CARTRIDGE} | {Cartridge}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347488","Persistent or Significant Disability or Incapacity","C68606","An indication or description of a continuing and significant impairment.","Persistent or Significant Disability or Incapacity | SDISAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705258","HLA-DRB1 wt Allele","C52341","Human HLA-DRB1 wild-type allele is located in the vicinity of 6p21.3 and is approximately 11 kb in length. This allele, which encodes HLA class II histocompatibility antigen, DRB1-4 beta chain protein, plays a role in the mediation of antigen presentation.","HLA-DRB1 wt Allele | DRB Gene | HLA DRB1 | Major Histocompatibility Complex, Class II, DR Beta 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348924","HLA-DQB1 wt Allele","C70615","Human HLA-DQB1 wild-type allele is located in the vicinity of 6p21.3 and is approximately 7 kb in length. This allele, which encodes HLA class II histocompatibility antigen, DQ beta 1 chain protein, plays a role in the regulation of antigen presentation.","HLA-DQB1 wt Allele | CELIAC1 | HLA-DQB1 | IDDM1 | Major Histocompatibility Complex, Class II, DQ Beta 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705257","HLA-DPB1 wt Allele","C52342","Human HLA-DPB1 wild-type allele is located in the vicinity of 6p21.3 and is approximately 24 kb in length. This allele, which encodes HLA class II histocompatibility antigen, DP(W4) beta chain protein, is involved in the modulation of antigen presentation.","HLA-DPB1 wt Allele | HLA-DP1B | HLADPB1 | MHC DPB1 | Major Histocompatibility Complex, Class II, DP Beta 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0646611","12-Methyltetradecanoic Acid","C105827","A branched-chain saturated fatty acid that is comprised of tetradecanoic acid with a methyl group on the carbon in the twelfth position.","12-Methyltetradecanoic Acid | 12-MTA | 12-Methyl-Tetradecanoic Acid | Anteiso-Pentadecanoic Acid | Anteisopentadecanoic Acid | Aseanostatin P5 | Sarcinic Acid | Tetradecanoic Acid, 12-Methyl-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0044840","13-Methyltetradecanoic Acid","C105828","A branched-chain saturated fatty acid that is comprised of tetradecanoic acid with a methyl group on the carbon in the thirteenth position.","13-Methyltetradecanoic Acid | 13-METHYLTETRADECANOIC ACID | 13-MTA | 13-Methyl-Tetradecanoic Acid | Tetradecanoic Acid, 13-Methyl-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1122154","8-Oxoguanine","C105826","A derivative of the purine nucleoside guanine that is found in DNA that has been damaged due to exposure to reactive oxygen species or ionizing radiation.","8-Oxoguanine | 1H-Purine-6,8-Dione, 2-Amino- | 1H-Purine-6,8-Dione, 2-Amino-7,9-Dihydro- | 2-Amino-6,8-Dihydroxypurine | 2-Amino-7,9-Dihydro-1H-Purine-6,8-Dione | 2-Aminopurine-6,8-Diol | 7,8-Dihydro-8-Oxoguanine | 8-Hydroxyguanine | 8-Oxo-7,8-Dihydroguanine | 8-Oxo-Gua | 8OG | Purine-6,8(1H,9H)-Dione, 2-Amino- | Purine-6,8-Diol, 2-Amino-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034783","Adrenergic Receptor","C105824","A family of G protein-coupled receptors that bind catecholamines and play a role in the stimulation of the sympathetic nervous system.","Adrenergic Receptor | Adrenoceptor | Catecholamine Receptor | Norepinephrine Receptor",,,,,,,,,,,,,,,"4244263","Adrenergic receptor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1412659","ATP5F1E Gene","C105835","This gene is involved in ATP synthesis.","ATP5F1E Gene | ATP Synthase F1 Subunit Epsilon Gene | ATP5E | ATP5E Gene | ATP5E Gene | ATP5F1E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412792","BGN Gene","C105838","This gene plays a role in extracellular matrix structure.","BGN Gene | BGN | Biglycan Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812172","BRAF V600 Protein Variation","C105823","A change in the valine at position 600 of the serine/threonine-protein kinase B-raf protein to another amino acid.","BRAF NP_004324.2:p.V600X | BRAF Codon 600 Mutation | BRAF NP_004324.2:p.Val600 Mutation | BRAF NP_004324.2:p.Val600Xxx | BRAF V600 Mutation | BRAF V600 Protein Variation | BRAF V600 Protein Variation | BRAF V600X | BRAF p.V600 Mutation | BRAF p.V600X | BRAF p.Val600 Mutation | BRAF p.Val600Xxx | BRAFV600 | NP_004324.2:p.V600 Mutation | NP_004324.2:p.V600X | NP_004324.2:p.Val600 Mutation | NP_004324.2:p.Val600Xxx | Other BRAF V600 mutation | Serine/Threonine-Protein Kinase B-raf Protein V600 Mutation | Serine/Threonine-Protein Kinase B-raf Protein V600 Protein Variation | Serine/Threonine-Protein Kinase B-raf Protein V600X | Serine/Threonine-Protein Kinase B-raf Protein Val600 Mutation | Serine/Threonine-Protein Kinase B-raf Protein Val600Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413061","CACNA1G Gene","C105856","This gene is involved in calcium transport.","CACNA1G Gene | CACNA1G | Calcium Channel, Voltage-Dependent, T Type, Alpha 1G Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831174","CBFA2T3/GLIS2 Fusion Gene","C105819","A fusion gene that results from a chromosomal translocation inv(16)(p13q24) which fuses either the first 10 or 11 exons of the CBFA2T3 gene with either exon 1 or exon 3 of the GLIS2 gene. This fusion is associated with acute megakaryoblastic leukemia.","CBFA2T3/GLIS2 Fusion Gene | CBFA2T3-GLIS2 Fusion Gene | CBFA2T3::GLIS2 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413456","CLCN7 Gene","C105877","This gene plays a role in ion transport.","CLCN7 Gene | CLCN7 | Chloride Channel, Voltage-Sensitive 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414306","EFNB2 Gene","C105841","This gene is involved in cell-cell signaling.","EFNB2 Gene | EFNB2 | Ephrin-B2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414627","FKBP5 Gene","C105829","This gene plays a role in protein folding.","FKBP5 Gene | FK506 Binding Protein 5 Gene | FKBP5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414928","GADD45B Gene","C105844","This gene plays a role in signaling, apoptosis and cell growth.","GADD45B Gene | GADD45B | Growth Arrest and DNA-Damage-Inducible, Beta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415652","HOXA Gene Family","C105821","A family of genes found in a cluster on the p arm of chromosome 7. These genes encode transcription factors that play a role in gene expression, morphogenesis, and cell differentiation.","HOXA Gene Family | HOX1 | HOXA | HOXA Family | HOXA Gene | Homeo Box 1 | Homeo Box A | Homeo Box A Cluster | Homeobox A | Homeobox A Cluster | Hox-1 | Hox-A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415662","HOXB Gene Family","C105822","A family of genes found in a cluster on the q arm of chromosome 17. These genes encode transcription factors that play a role in gene expression, cell proliferation and cell differentiation.","HOXB Gene Family | HOX2 | HOXB | HOXB Family | HOXB Gene | Homeo Box 2 | Homeo Box B | Homeo Box B Cluster | Homeobox B | Homeobox B Cluster | Hox-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415803","HTR1A Gene","C105868","This gene is involved in serotonin-dependent signaling.","HTR1A Gene | 5-Hydroxytryptamine (Serotonin) Receptor 1A, G Protein-Coupled Gene | HTR1A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416801","LBP Gene","C105865","This gene plays a role in anti-bacterial response.","LBP Gene | LBP | Lipopolysaccharide Binding Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416959","MAD2L1 Gene","C105847","This gene is involved in mitosis.","MAD2L1 Gene | MAD2 Mitotic Arrest Deficient-Like 1 (Yeast) Gene | MAD2L1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828997","MNX1/ETV6 Fusion Gene","C105817","A fusion gene that results from a chromosomal translocation t(7;12)(q36;p13) which fuses the first exon of the MNX1 gene with exon 3 of the ETV6 gene. This aberration is associated with infant acute myeloid leukemia.","MNX1/ETV6 Fusion Gene | HLXB9-ETV6 Fusion Gene | HLXB9/ETV6 Fusion Gene | MNX1-ETV6 Fusion Gene | MNX1::ETV6 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538054","NEIL3 Gene","C105832","This gene plays a role in DNA repair.","NEIL3 Gene | NEIL3 | Nei Endonuclease VIII-Like 3 (E. coli) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417685","NEUROG1 Gene","C105859","This gene plays a role in both neuronal differentiation and transcriptional regulation.","NEUROG1 Gene | NEUROG1 | Neurogenin 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828744","NUP98/KDM5A Fusion Gene","C105815","A fusion gene that results from a chromosomal translocation t(11;12)(p15;p13) which fuses the first 13 exons of the NUP98 gene with exons 28-31 of the KDM5A gene. This fusion is associated with acute megakaryoblastic leukemia.","NUP98/KDM5A Fusion Gene | NUP98-KDM5A Fusion Gene | NUP98-RBBP2 Fusion Gene | NUP98/RBBP2 Fusion Gene | NUP98::KDM5A Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418508","PGK1 Gene","C105852","This gene plays a role in glycolysis.","PGK1 Gene | PGK1 | Phosphoglycerate Kinase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828461","Protein Carbonyl Content","C105825","The presence of carbonyl derivatives of certain amino acids in a biological sample is indicative of protein oxidation. Oxidized proteins can be markers for oxidative stress.","Protein Carbonyl Content | Protein Carbonyl Group | Protein Carbonyl Level",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420214","SLC6A4 Gene","C105874","This gene is involved in serotonin transport.","SLC6A4 Gene | SLC6A4 | Solute Carrier Family 6 (Neurotransmitter Transporter, Serotonin), Member 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420870","TPH1 Gene","C105871","This gene plays a role in amino acid metabolism.","TPH1 Gene | TPH1 | Tryptophan Hydroxylase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421333","UGT1A9 Gene","C105862","This gene is involved in phenol detoxification.","UGT1A9 Gene | UDP Glucuronosyltransferase 1 Family, Polypeptide A9 Gene | UGT1A9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272925","Unequivocal Progression","C96644","An overall level of substantial worsening in non-target disease that is of a magnitude that, even in the presence of SD or PR in target disease, the treating physician would feel it important to change therapy. (RECIST)","Unequivocal Progression | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0063125","3-Hydroxycotinine","C105948","A metabolite of nicotine that is detectable in the urine of smokers.","3-Hydroxycotinine | 1-Methyl-3-Hydroxy-5-(3-Pyridyl)-2-Pyrrolidinone | 3'-Hydroxycotinine | 3-HC | 3-Hydroxy-1-Methyl-5-(3-Pyridinyl)-2-Pyrrolidinone | 3-OH-Cotinine | 3HC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0295352","Serotonin 5-HT-3 Receptor","C105979","A protein complex that plays a role in neurotransmitter-gated ion transport. It is a pentamer that binds serotonin and is comprised of either five 5-hydroxytryptamine receptor 3A subunits or a combination of four 5-hydroxytryptamine receptor 3A molecules with one of the alternative subunits, 5-hydroxytryptamine receptor 3B, 3C, 3D or 3E.","5-HT3 Receptor | 5-HT-3 Receptor | 5-HT-3R | 5-HT3R | 5-Hydroxytryptamine 3 Receptor | 5HT3 Receptor | 5HT3R | Serotonin 5-HT-3 Receptor | Serotonin Receptor Type 3 | Type 3 Serotonin Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831767","5p15","C105921","A chromosome band present on 5p.","5p15 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412046","A2M Gene","C105922","This gene has activity as a protease inhibitor.","A2M Gene | A2M | Alpha-2-Macroglobulin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412078","ABCC3 Gene","C106021","This gene is involved in bile metabolism.","ABCC3 Gene | ABCC3 | ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1862595","APOB Gene","C106030","This gene plays a role in lipid transport.","APOB Gene | APOB | Apolipoprotein B (Including Ag(x) Antigen) Gene | Apolipoprotein B Gene",,,,,,,,,,,,,,,"40483178","Apolipoprotein B (including Ag(x) antigen) gene",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003592","Apolipoprotein A","C105952","A family of apolipoproteins that bind to and transport lipids. These proteins are involved in the structural integrity of high-density lipoprotein particles.","Apolipoprotein A | APOA | Apo A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003676","Arabinofuranosylcytosine Triphosphate","C105950","A triphosphate nucleotide analog that is the metabolized, biologically active form of cytarabine. This metabolite is a competitive inhibitor of DNA synthesis.","Arabinofuranosylcytosine Triphosphate | Ara-CTP | AraCTP | Arabinosylcytosine 5'-Triphosphate | Arabinosylcytosine 5'-Triphosphate;  | Arabinosylcytosine Triphosphate | CYTARABINE TRIPHOSPHATE | Cytarabine Triphosphate | Cytosine Arabinoside Triphosphate | Triphosphate, Arabinofuranosylcytosine | Triphosphate, Arabinosylcytosine | Triphosphate, Arabinosylcytosine;  | Triphosphate, Cytarabine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412731","BAG3 Gene","C105994","This gene is involved in the regulation of both protein folding and apoptosis.","BAG3 Gene | BAG3 | BCL2-Associated Athanogene 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0950624","Calprotectin","C105971","A heterodimeric or heterotetrameric protein complex comprised of protein S100A8 and protein S100A9. This complex is expressed in the cytosol of neutrophils and macrophages and plays a role in multiple host defense related processes including immunomodulation, neutrophil chemotaxis and both antibacterial and antifungal responses.","Calprotectin | Leukocyte L1 Complex | MRP-8/MRP-14 Complex | S100A8/A9 Complex | S100A8/S100A9 Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830537","Deoxyribonucleotide Triphosphate","C105951","A nucleotide comprised of either a purine or pyrimidine nitrogenous base bound to a deoxyribose sugar esterified with three phosphate groups. These molecules are essential for DNA synthesis.","Deoxyribonucleotide Triphosphate | dNTP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0208356","DNA Ligase","C105960","A family of enzymes that catalyze the formation of phosphodiester bonds to repair broken strands of DNA.","DNA Ligase | EC 6.5.1.1 | Polydeoxyribonucleotide Synthase | Polynucleotide Ligase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414187","DUSP6 Gene","C106024","This gene plays a role in MAP kinase dephosphorylation.","DUSP6 Gene | DUSP6 | Dual Specificity Phosphatase 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414263","EDNRB Gene","C105928","This gene is involved in cell signaling.","EDNRB Gene | EDNRB | Endothelin Receptor Type B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825057","EPGN Gene","C105918","This gene plays a role in epithelial cell growth.","EPGN Gene | EPGN | Epithelial Mitogen Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830298","Excision Repair Cross-Complementing Family","C105959","A family of DNA repair proteins.","Excision Repair Cross-Complementing Family | ERCC | Excision Repair Cross Complementing-Group | Excision Repair Cross-Complementing Protein Family | Excision Repair Cross-Complementing Rodent Repair Deficiency, Complementation Group Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0072436","F1.2","C105984","The two peptides that can be released by proteolytic activation of prothrombin to thrombin. The level of these fragments is directly proportional to the amount of active thrombin in a blood sample.","F1.2 | F1+2 | F1-2 | Pro-Thrombin Activation Fragment | Prothrombin Activation Fragment | Prothrombin Activation Fragment F1-2 | Prothrombin Activation Fragment F1.2",,,,,,,,,,,,,,,"4220024","Prothrombin fragment 1.2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1426023","FGD5 Gene","C105931","This gene plays a role in the reorganization of the actin cytoskeleton.","FGD5 Gene | FGD5 | FYVE, RhoGEF and PH Domain Containing 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0062802","HLA Class I Histocompatibility Antigen, A-24 Alpha Chain","C105976","HLA class I histocompatibility antigen, A-24 alpha chain protein (365 aa, ~41 kDa) is encoded by the human HLA-A gene. This protein plays a role in the presentation of foreign antigens to the immune system.","HLA Class I Histocompatibility Antigen, A-24 Alpha Chain | Aw-24 | HLA Class I Histocompatibility Antigen, A-9 Alpha Chain | HLA-A*24 | HLA-A24 | HLA-A24 Antigen | Leukocyte Antigen Class I-A24 | MHC Class I Antigen A*24 | MHC Class I Antigen HLA-A24 Heavy Chain | Major Histocompatibility Complex, Class I, A*24 | Major Histocompatibility Complex, Class I, A24 | Major Histocompatibility Complex, Class I, A24; ",,,,,,,,,,,,,,,"4029300","HLA-A24 antigen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0540179","HLA-DR15 Antigen","C105974","HLA-DR15 antigen is a set of polymorphic glycoprotein complexes encoded by the human HLA-DRA and HLA-DRB1 genes. This protein complex is involved in the presentation of antigens to CD4+ T lymphocytes.","HLA-DR15 Antigen | HLA Class II Histocompatibility Antigen Complex, DR15 | HLA-DR15 | Major Histocompatibility Complex, Class II, DR15",,,,,,,,,,,,,,,"4012856","HLA-DR15 antigen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019878","Homocysteine","C105949","An amino acid derivative and homolog of cysteine containing an additional methylene bridge. Homocysteine is a product of methionine metabolism and elevated plasma levels are associated with cardiovascular disease, Alzheimer disease and several metabolic diseases.","Homocysteine | 2-Amino-4-Mercapto-Butanoic Acid | 2-Amino-4-Mercapto-Butyric acid | 2-Amino-4-Mercaptobutyric Acid | 2-Amino-4-Sulfanylbutanoic Acid | 5-HT-3 Receptor | 5-HT-3R | 5-HT3R | 5-Hydroxytryptamine 3 Receptor | Butanoic Acid, 2-Amino-4-Mercapto- | Butyric Acid, 2-Amino-4-Mercapto- | HOMOCYSTEINE | Hcy | Homo-Cys | Serotonin 5-HT-3 Receptor | Serotonin Receptor Type 3 | Type 3 Serotonin Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416386","IL13RA2 Gene","C105972","This gene plays a role in both B-cell maturation and differentiation.","IL13RA2 Gene | IL13RA2 | Interleukin 13 Receptor Subunit Alpha 2 Gene | Interleukin 13 Receptor, Alpha 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416400","IL1RL1 Gene","C106006","This gene plays a role in interleukin binding and receptor signaling.","IL1RL1 Gene | IL1RL1 | Interleukin 1 Receptor Like 1 Gene | Interleukin 1 Receptor-Like 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423038","IL22 Gene","C105961","This gene is involved in the immune response.","IL22 Gene | IL22 | Interleukin 22 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829476","JAK2 NP_004963.1:p.E985K","C105913","A change in the amino acid residue at position 985 in the tyrosine-protein kinase JAK2 protein where glutamic acid has been replaced by lysine.","JAK2 NP_004963.1:p.E985K | JAK2 E985K | JAK2 Glu985Lys | JAK2 NP_004963.1:p.Glu985Lys | JAK2 p.E985K | JAK2 p.Glu985Lys | Janus Kinase 2 E985K | Janus Kinase 2 E985K;  | Janus Kinase 2 Glu985Lys | NP_004963.1:p.E985K | NP_004963.1:p.Glu985Lys | Tyrosine-Protein Kinase JAK2 E985K | Tyrosine-Protein Kinase JAK2 Glu985Lys",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829475","JAK2 NP_004963.1:p.G935R","C105914","A change in the amino acid residue at position 935 in the tyrosine-protein kinase JAK2 protein where glycine has been replaced by arginine.","JAK2 NP_004963.1:p.G935R | JAK2 G935R | JAK2 Gly935Arg | JAK2 NP_004963.1:p.Gly935Arg | JAK2 p.G935R | JAK2 p.Gly935Arg | Janus Kinase 2 G935R | Janus Kinase 2 Gly935Arg | NP_004963.1:p.G935R | NP_004963.1:p.Gly935Arg | Tyrosine-Protein Kinase JAK2 G935R | Tyrosine-Protein Kinase JAK2 G935R;  | Tyrosine-Protein Kinase JAK2 Gly935Arg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829474","JAK2 NP_004963.1:p.I960V","C105915","A change in the amino acid residue at position 960 in the tyrosine-protein kinase JAK2 protein where isoleucine has been replaced by valine.","JAK2 NP_004963.1:p.I960V | JAK2 I960V | JAK2 Ile960Val | JAK2 NP_004963.1:p.Ile690Val | JAK2 p.I960V | JAK2 p.Ile960Val | Janus Kinase 2 I960V | Janus Kinase 2 Ile960Val | Janus Kinase 2 Ile960Val;  | NP_004963.1:p.I960V | NP_004963.1:p.Ile960Val | Tyrosine-Protein Kinase JAK2 I960V | Tyrosine-Protein Kinase JAK2 Ile960Val",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829472","JAK2 NP_004963.1:p.R938L","C105917","A change in the amino acid residue at position 938 in the tyrosine-protein kinase JAK2 protein where arginine has been replaced by leucine.","JAK2 NP_004963.1:p.R938L | JAK2 Arg938Leu | JAK2 NP_004963.1:p.Arg938Leu | JAK2 R938L | JAK2 p.Arg938Leu | JAK2 p.R938L | Janus Kinase 2 Arg938Leu | Janus Kinase 2 R938L | NP_004963.1:p.Arg938Leu | NP_004963.1:p.Arg938Leu;  | NP_004963.1:p.R938L | Tyrosine-Protein Kinase JAK2 Arg938Leu | Tyrosine-Protein Kinase JAK2 R938L | Tyrosine-Protein Kinase JAK2 R938L; ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829470","JAK2 NP_004963.1:p.Y931C","C105912","A change in the amino acid residue at position 931 in the tyrosine-protein kinase JAK2 protein where tyrosine has been replaced by cysteine.","JAK2 NP_004963.1:p.Y931C | JAK2 NP_004963.1:p.Tyr931Cys | JAK2 Tyr931Cys | JAK2 Y931C | JAK2 p.Tyr931Cys | JAK2 p.Y931C | Janus Kinase 2 Tyr931Cys | Janus Kinase 2 Y931C | NP_004963.1:p.Tyr931Cys | NP_004963.1:p.Y931C | Tyrosine-Protein Kinase JAK2 Tyr931Cys | Tyrosine-Protein Kinase JAK2 Y931C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416717","KRT14 Gene","C105981","This gene is involved in the regulation of cell shape.","KRT14 Gene | KRT14 | Keratin 14 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416728","KRT17 Gene","C105977","This gene plays a role in the development of epidermal appendages.","KRT17 Gene | KRT17 | Keratin 17 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416810","LDB2 Gene","C105934","This gene is involved in the regulation of transcription.","LDB2 Gene | LDB2 | LIM Domain Binding 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537607","LRRC32 Gene","C106012","This gene plays a role in the regulation of immune cell function.","LRRC32 Gene | LRRC32 | Leucine Rich Repeat Containing 32 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537805","MIR150 Gene","C105985","This gene may be involved in the regulation of protein expression.","MIR150 Gene | MIR150 | MicroRNA 150 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537824","MIR191 Gene","C105988","This gene is involved in the regulation of gene expression.","MIR191 Gene | MIR191 | MicroRNA 191 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0169101","Mitogen-Activated Protein Kinase Kinases","C105947","A family of dual-specific protein kinases that are activated through phosphorylation by mitogen-activated protein kinase kinase kinase (MAP3K, MAPKKK) proteins and can subsequently phosphorylate and activate mitogen-activated protein kinases (MAPK).","Mitogen-Activated Protein Kinase Kinase | MAP Kinase Kinase | MAP2K | MAPKK | MAPKK1 | MEK | MEK1 | MEK2 | MKK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423769","PALMD Gene","C105937","This gene may play a role in plasma membrane dynamics.","PALMD Gene | PALMD | Palmdelphin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418774","PLPP3 Gene","C105941","This gene is involved in the metabolism of diacylglycerol.","PLPP3 Gene | PLPP3 | PPAP2B | PPAP2B Gene | Phosphatidic Acid Phosphatase Type 2B Gene | Phospholipid Phosphatase 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419336","RELB Gene","C105997","This gene is involved in transcriptional regulation of immune processes.","RELB Gene | RELB | v-rel Reticuloendotheliosis Viral Oncogene Homolog B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427538","RWDD3 Gene","C105964","This gene plays a role in sumoylation.","RWDD3 Gene | RWD Domain Containing 3 Gene | RWDD3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419946","SEMA3F Gene","C106007","This gene is involved in both cell signaling and axon guidance.","SEMA3F Gene | SEMA3F | Sema Domain, Immunoglobulin Domain (Ig), Short Basic Domain, Secreted, (Semaphorin) 3F Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420598","SERPINA7 Gene","C106000","This gene plays a role in thyroid hormone binding.","SERPINA7 Gene | SERPINA7 | Serpin Peptidase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423895","SERPINA9 Gene","C106015","This gene is involved in trypsin activity regulation.","SERPINA9 Gene | GCET1 | SERPINA9 | Serpin Family A Member 9 | Serpin Peptidase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002723","Serum Amyloid A","C105940","A family of apolipoproteins that are associated with high-density lipoprotein particles in the serum. These proteins may play a role in both the acute-phase of inflammation and in cholesterol transport.","Serum Amyloid A | SAA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420382","SPRY1 Gene","C105944","This gene may play a role in both signaling and organogenesis.","SPRY1 Gene | SPRY1 | Sprouty Homolog 1, Antagonist of FGF Signaling (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420383","SPRY2 Gene","C106027","This gene is involved in the negative regulation of growth factor signaling.","SPRY2 Gene | SPRY2 | Sprouty Homolog 2 (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420389","SPTBN2 Gene","C106018","This gene plays a role in actin filament function.","SPTBN2 Gene | SPTBN2 | Spectrin, Beta, Non-Erythrocytic 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539881","STEAP1 Gene","C106001","This gene plays a role at cell-cell junctions.","STEAP1 Gene | STEAP1 | Six Transmembrane Epithelial Antigen of the Prostate 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420459","SULT1E1 Gene","C105991","This gene plays a role in estrogen metabolism.","SULT1E1 Gene | SULT1E1 | Sulfotransferase Family 1E, Estrogen-Preferring, Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428989","SYNPO Gene","C105953","This gene is involved in both cell morphology and cell motility.","SYNPO Gene | SYNPO | Synaptopodin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420639","TCF4 Gene","C105956","This gene plays a role in transcriptional regulation.","TCF4 Gene | TCF4 | Transcription Factor 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823451","TMTC1 Gene","C105925","This gene is involved in serine/threonine mannosylation.","TMTC1 Gene | TMTC1 | Transmembrane O-Mannosyltransferase Targeting Cadherins 1 Gene | Transmembrane and Tetratricopeptide Repeat Containing 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420815","TNFSF13 Gene","C105967","This gene is involved in B cell development.","TNFSF13 Gene | TNFSF13 | Tumor Necrosis Factor (Ligand) Superfamily, Member 13 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424849","TRIM16 Gene","C106033","This gene is involved in both keratinocyte differentiation and histone acetylation.","TRIM16 Gene | TRIM16 | Tripartite Motif Containing 16 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831085","Claudin-Low","C105907","A genetic profile indicating low expression of cellular tight junction proteins, including E-cadherin, which is often associated with triple-negative breast cancer and tumor-infiltrating lymphocytes.","Claudin-Low | Claudin-Low Profile | Claudin-Low Transcriptional Profile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3888092","RBM15/MKL1 Fusion Gene","C99701","A fusion gene that results from a chromosomal translocation t(1;22)(p13;q13) which fuses the 5' portion of the RBM15 gene to the 3' portion of the MKL1 gene. This rearrangement is associated with infantile acute megakaryoblastic leukemia.","RBM15/MKL1 Fusion Gene | OTT-MAL Fusion Gene | OTT/MAL Fusion Gene | RBM15-MKL1 Fusion Gene | RBM15-MRTFA Fusion Gene | RBM15/MRTFA Fusion Gene | RBM15::MKL1 Fusion Gene | RBM15::MRTFA Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1852035","NUP98/TOP1 Fusion Gene","C99442","A fusion gene that results from a chromosomal translocation t(11;20)(p15;q11) which fuses the first half of the NUP98 gene with exon 7 of the TOP1 gene. This fusion is associated with both therapy-related acute myelogenous leukemia and therapy-related myelodysplastic syndrome.","NUP98/TOP1 Fusion Gene | NUP98-TOP1 Fusion Gene | NUP98::TOP1 Fusion Gene | TOP1/NUP98 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334882","NKX3-1 Gene","C24631","This gene plays a role in transcriptional regulation and is a putative prostate tumor suppressor.","NKX3-1 Gene | NK3 Transcription Factor Related, Locus 1 (Drosophila) Gene | NKX3-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433121","PAX3/FOXO1 Fusion Gene","C99712","A fusion gene (~3.2 kb) that results from a chromosomal translocation t(2;13)(q35;q14) which fuses intron 7 of the PAX3 gene with intron 1 of the FOXO1 gene. This rearrangement is associated with alveolar rhabdomyosarcoma.","PAX3/FOXO1 Fusion Gene | PAX3-FKHR Fusion Gene | PAX3-FOXO1 Fusion Gene | PAX3-FOXO1 fusion | PAX3/FKHR Fusion Gene | PAX3/Forkhead Transcription Factor Gene Fusion | PAX3::FOXO1 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412481","APOE Gene","C84468","This gene is involved in lipid transport and metabolism.","APOE Gene | APOE | Apolipoprotein E Gene",,,,,,,,,,,,,,,"4136441","Apolipoprotein E gene",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1413514","CLU Gene","C84429","This gene may be involved in immunity, lipid metabolism and apoptosis.","CLU Gene | CLU | Clusterin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1442762","TF Gene","C21580","This gene plays a regulatory role in iron transport to several different tissue types.","TF Gene | TF | Transferrin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333653","GAB2 Gene","C24417","This gene plays a role in signal transduction and regulates T-cell proliferation. It is also involved in bone homeostasis and mediates the differentiation of progenitor cells into osteopaths.","GAB2 Gene | GAB2 | GRB2 Associated Binding Protein 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413772","CST3 Gene","C88356","This gene is involved in enzyme inhibition.","CST3 Gene | CST3 | Cystatin C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334122","IL6 Gene","C24504","This gene is involved in immunoregulation processes by activating a cell-surface signaling assembly of proteins.","IL6 Gene | IL6 | Interleukin 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229699","Lymph Node Capsule","C33028","The dense connective tissue that surrounds a lymph node.","Lymph Node Capsule | ",,,,,,,,,,,,,,,"4286049","Structure of capsule of lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1366487","FAP Gene","C26582","This gene is involved in the regulation of fibroblast growth.","FAP Gene | FAP | Fibroblast Activation Protein Alpha Gene | Fibroblast Activation Protein, Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812238","BCL3 Gene","C18360","This gene is involved in transcriptional co-activation and signal transduction.","BCL3 Gene | BCL3 | BCL3 Transcription Coactivator Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1180307","F-Actin","C32581","A fibrillar actin polymer.","F-actin | FILAMENTOUS ACTIN | Filamentous Actin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825589","IKZF2 Gene","C80026","This gene is involved in both transcription and lymphocyte development.","IKZF2 Gene | IKAROS Family Zinc Finger 2 (Helios) Gene | IKZF2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1337090","CREBBP Gene","C26568","This gene plays a role in transcriptional regulation and in NF-kappa B signal transduction.","CREBBP Gene | CREB Binding Protein Gene | CREBBP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1337007","WRN Gene","C20070","This gene is involved in DNA repair and the unwinding of DNA.","WRN Gene | WRN | Werner Syndrome Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336931","VDAC2 Gene","C37293","This gene is involved in small molecule transport and apoptotic regulation.","VDAC2 Gene | VDAC2 | Voltage-Dependent Anion Channel 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421262","UBB Gene","C38431","This gene is involved in ubiquitin-dependent proteolysis.","UBB Gene | UBB | Ubiquitin B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335194","PAX7 Gene","C24660","This gene plays a role in the transcriptional regulation of target genes. It is involved in pattern formation during embryogenesis.","PAX7 Gene | PAX7 | Paired Box 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335192","PAX3 Gene","C24658","This gene plays a role in the transcriptional activation of target genes. It is involved in melanogenesis, neurogenesis and skeletal muscle development.","PAX3 Gene | PAX3 | Paired Box Gene 3 (Waardenburg Syndrome 1) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2980094","Regorafenib Anhydrous","C78204","The anhydrous form of regorafenib, an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling.","Regorafenib Anhydrous | 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide | BAY 73 4506 | BAY 73-4506 | BAY 734506 | REGORAFENIB ANHYDROUS | Regorafenib | Regorafenib | Regorafenib Anhydrous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539477","FAS Gene","C21555","This gene is involved in the mediation of cellular surface receptors and apoptotic signals.","FAS Gene | FAS | Fas Cell Surface Death Receptor Gene | TNFRSF6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034805","Fc Receptor","C17070","Receptors found on the cell surface of some B-lymphocytes, T-lymphocytes, and macrophages, which recognize the Fc (constant region fragment) portion of immunoglobulin molecules.","Fc Receptor | FcR",,,,,,,,,,,,,,,"4205447","Fc receptor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1416917","LRP5 Gene","C95410","This gene is involved in endocytosis and signaling.","LRP5 Gene | LRP5 | Low Density Lipoprotein Receptor-Related Protein 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332424","BMP2 Gene","C21349","This gene plays a role in bone formation via regulation of osteoblast differentiation. It is also involved in cell cycle regulation.","BMP2 Gene | BMP2 | Bone Morphogenetic Protein 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282625","SRC Family Tyrosine Kinase","C17893","The SRC family tyrosine kinases are a class of non-receptor protein-tyrosine kinases that exhibit amino acid sequence similarity with SRC and participate in signal transduction pathways in a variety of hematopoietic cells.","SRC Family Tyrosine Kinase | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334904","NRIP1 Gene","C20704","This gene is involved in regulation of transcription.","NRIP1 Gene | NRIP1 | Nuclear Receptor Interacting Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334870","NCOR1 Gene","C28640","This gene is involved in chromatin remodeling and repression of transcription.","NCOR1 Gene | NCOR1 | Nuclear Receptor Co-Repressor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412356","ALOX12 Gene","C103924","This gene plays a role in oxidation of fatty acids.","ALOX12 Gene | ALOX12 | Arachidonate 12-Lipoxygenase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523744","Lipid Measurement","C74949","A quantitative measurement of the amount of lipids (cholesterol, lipoproteins, and triglycerides) present in a sample.","Lipid Measurement | LIPID | Lipid | Total Lipid",,,,,,,,,,,,,,,"4017202","Lipids measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224206","Superior Constrictor Muscle","C33672","The uppermost of the three constrictor muscles of the pharynx.  It receives nerve supply from the pharyngeal plexus.","Superior Constrictor Muscle | Superior Pharyngeal Constrictor Muscle | Superior Pharyngeal Constrictor Muscle ",,,,,,,,,,,,,,,"4305653","Superior pharyngeal constrictor muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0176751","Percutaneous Endoscopic Gastrostomy","C106040","The placement of a feeding tube through the abdominal wall into the stomach using an endoscope.","Percutaneous Endoscopic Gastrostomy | PEG | Percutaneous Endoscopic Gastrostomy  | Percutaneous endoscopic gastrostomy (PEG) | Percutaneous endoscopic gastrostomy (PEG) ",,,,,,,,,,,,,,,"4122234","Percutaneous endoscopic gastrostomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2985437","Null Allele","C93103","A mutation that results in either no gene product or the absence of function at the phenotypic level.","Null Allele | null allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439565","Pre-dose Measure","C106037","A measure that relates specifically to the last value collected prior to the time of the first dose of a treatment.","Pre-dose Measure | Pre-dose",,,,,,,,,,,,,,,"4112236","Pre-dose",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016229","Flecainide","C62029","A synthetic agent derived from trifluoroethoxy-benzamide exhibiting antiarrhythmic and local anesthetic activity. As a class Ic antiarrhythmic that blocks sodium channels, flecainide depresses polarization phase 0 and decreases the induction velocity of the His-Purkinje system. It also decreases phase 4 slope and increases the depolarization threshold. (NCI04)","Flecainide | FLECAINIDE | flecainide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1701455","Armodafinil","C65241","The R-enantiomer of the racemic synthetic agent modafinil with central nervous system (CNS) stimulant and wakefulness-promoting activities. Although the exact mechanism of action has yet to be fully elucidated, armodafinil appears to inhibit the reuptake of dopamine by binding to the dopamine-reuptake pump, which leads to an increase in extracellular dopamine levels in some brain regions. This agent does not bind to or inhibit several receptors and enzymes that may be involved in sleep/wake regulation and is not a direct- or indirect-acting dopamine receptor agonist. Armodafinil has a longer half-life than modafinil.","Armodafinil | (-)-2-((R)-(Diphenylmethyl)sulfinyl)acetamide | ARMODAFINIL | Nuvigil | armodafinil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1530072","Vilazodone","C90716","A selective serotonin (5-HT) reuptake inhibitor (SSRI) and a 5-HT-1A receptor partial agonist, with antidepressant and anti-anxiety activities. Vilazodone inhibits the reuptake of serotonin from the synaptic cleft while stimulating the release of 5-HT into the synaptic cleft. This increases the concentration of 5-HT in the synaptic cleft and potentiates serotonergic neurotransmission in the central nervous system.","Vilazodone | 5-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}benzofuran-2-carboxamide | EMD 515259 | VILAZODONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641261","Not Measured Tumor Identification","C103425","The identification of a tumor that is present at baseline and will not be quantifiably measured over the course of the study.","Not Measured Tumor Identification | NOT MEASURED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420565","TACR1 Gene","C41021","This gene plays a regulatory role in phosphatidylinositol metabolism of substance P.","TACR1 Gene | TACR1 | Tachykinin Receptor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333206","DDR1 Gene","C20718","This gene plays a role in extracellular matrix communication processes.","DDR1 Gene | DDR1 | Discoidin Domain Receptor Family, Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413815","CTSK Gene","C90320","This gene is involved in osteoclastic bone resorption.","CTSK Gene | CTSK | Cathepsin K Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413868","CYP2A6 Gene","C48629","This gene plays a role in the oxidation of nicotine to its carcinogenic metabolites.","CYP2A6 Gene | CYP2A6 | Cytochrome P450, Family 2, Subfamily A, Polypeptide 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334444","Spindle Cell Melanoma","C4237","A melanoma characterized by the presence of malignant spindle-shaped melanocytes.","Spindle Cell Melanoma | Malignant Spindle Cell Melanoma | Spindle Cell Malignant Melanoma | Spindle cell melanoma, NOS","8772/3","Spindle cell melanoma, NOS",,,,,,,,,,,,,"4288627","Spindle cell melanoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334443","Epithelioid Cell Melanoma","C4236","A melanoma characterized by the presence of malignant large epithelioid melanocytes.","Epithelioid Cell Melanoma | Epithelioid Cell Malignant Melanoma | Epithelioid Melanoma | Epithelioid cell melanoma","8771/3","Epithelioid cell melanoma",,,,,,,,,,,,,"4290619","Epithelioid cell melanoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1456394","RXRG Gene","C38419","This gene plays a role in the mediation of the anti-proliferative effects of retinoic acid.","RXRG Gene | RXRG | Retinoid X Receptor, Gamma Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919432","SMAD3 Gene","C18504","This gene is involved in signal transduction and apoptosis. It also plays a role in the regulation of both steroid synthesis and T-cell response.","SMAD3 Gene | Mothers Against Decapentaplegic Homolog 3 Gene | SMAD3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334468","SMAD2 Gene","C24566","This gene plays a role in signal transduction and repression of transcription.","SMAD2 Gene | SMAD, Mothers Against DPP Homolog 2 (Drosophila) Gene | SMAD2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420705","TFPI Gene","C97260","This gene plays a role in blood coagulation.","TFPI Gene | TFPI | Tissue Factor Pathway Inhibitor (Lipoprotein-Associated Coagulation Inhibitor) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709998","SS18-SSX Fusion Protein Expression","C43306","The expression of fusion proteins that result from a chromosomal aberration, t(X;18)(p11.2;q11.2), which fuses the first 10 exons of the SS18 gene with exon six of one of three SSX genes (SSX1, SSX2 or SSX4) and is associated with synovial sarcoma.","SS18-SSX Fusion Protein Expression | SS18/SSX Fusion Protein Expression | SSXT-SSX Fusion Protein Expression | SYT-SSX Fusion Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0761783","SS18/SSX2 Fusion Protein, Human","C99396","A fusion protein (488, ~54 kDa) encoded by the SS18/SSX2 fusion gene. This protein is comprised of all but the last 8 amino acids of the C-terminus of protein SSXT, fused to the last 78 C-terminal amino acids of protein SSX2, including the SSX transcription repression domain.","SS18/SSX2 Fusion Protein | Protein SSXT/Protein SSX2 Fusion Protein | SS18-SSX2 Fusion Protein | SS18::SSX2 Fusion Protein | SYT-SSX2 Fusion Protein | SYT/SSX2 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274711","SS18/SSX1 Fusion Protein","C99394","A fusion protein (488 aa, ~54 kDa) encoded by the SS18/SSX1 fusion gene. This protein is comprised of all but the last 8 amino acids of the C-terminus of protein SSXT, fused to the last 78 C-terminal amino acids of protein SSX1, including the SSX transcription repression domain.","SS18/SSX1 Fusion Protein | Protein SSXT/Protein SSX1 Fusion Protein | SS18-SSX1 Fusion Protein | SS18::SSX1 Fusion Protein | SYT-SSX1 Fusion Protein | SYT/SSX1 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334932","Negative Test Result","C35681","A test result that indicates that a specific disease, condition, or attribute being assessed is not present.","Negative Test Result | Negative | negative test result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708351","Hereditary Lesion","C54062","A pathologic process inherited in a familial pattern.","Hereditary Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709243","Non-Hereditary Lesion","C53974","A pathologic process that is not inherited in a familial pattern.","Non-Hereditary Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826970","Percutaneous Fluoroscopic Gastrostomy","C106036","The placement of a feeding tube through the abdominal wall into the stomach with the assistance of fluoroscopic guidance.","Percutaneous Fluoroscopic Gastrostomy | PFG | Percutaneous fluoroscopic gastrostomy (PFG | Percutaneous fluoroscopic gastrostomy (PFG)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085678","Nasogastric Tube","C93310","A hollow tube that is directed into the stomach from the nose.","Nasogastric Tube | NG tube | gastric feeding tube | nasogastric tube",,,,,,,,,,,,,,,"4063122","Nasogastric tube",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0677984","Locally Advanced Malignant Neoplasm","C8524","A malignant neoplasm that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Malignant Neoplasm | Locally Advanced Cancer | Locally Metastatic Malignant Neoplasm | Locally advanced | Regional Malignant Neoplasm | locally advanced cancer | regional cancer",,,,,,,,,,,,,,,"37165616","Locally advanced malignant neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1300071","Tumor Mass","C98275","A benign or malignant pathologic structure in any part of the body, resulting from a neoplastic accumulation of cells.","Tumor Mass | Tumor",,,,,,,,,,,,,,,"4160350","Neoplasm weight",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1367578","AR Gene","C28539","This gene plays a role in the transcriptional activation of androgen responsive genes.","AR Gene | AR | Androgen Receptor (Dihydrotestosterone Receptor; Testicular Feminization; Spinal and Bulbar Muscular Atrophy; Kennedy Disease) Gene | Androgen Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366500","PGR Gene","C28656","This gene plays a role in the signal transduction processes that are involved in pregnancy.","PGR Gene | PGR | PR | Progesterone Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336626","THBS1 Gene","C28661","This gene plays a role in the mediation of both intercellular and cell-matrix interactions. It is also involved in platelet aggregation and angiogenesis.","THBS1 Gene | THBS1 | Thrombospondin 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030190","SERPINE1 protein, human","C16947","Plasminogen activator inhibitor 1 (402 aa, ~45 kDa) is encoded by the human SERPINE1 gene. This protein plays a role in both cell adhesion and the modulation of plasmin activity.","Plasminogen Activator Inhibitor 1 | Endothelial Plasminogen Activator Inhibitor | Nexin | PAI | PAI-1 | PAI1 | PLANH1 | Plasminogen Activator Inhibitor Type 1 | Plasminogen Activator Inhibitor-1 | SERPINE1 | Serine or Cysteine Proteinase Inhibitor Clade E Member 1 | Serpin E1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816734","Absence of Signs or Symptoms","C106101","Absence of detectable signs or symptoms.","Absence of Signs or Symptoms | No Clinical Signs, Symptoms or Conditions | Silent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828194","Sensate","C106102","Related to the perception of sensory stimuli.","Sensate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828570","Pharyngeal Residue","C106103","Substance remaining in the pharynx after swallowing.","Pharyngeal Residue | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830399","Double Strand Brachytherapy","C106073","An internal radiation treatment technique in which radioactive seeds are embedded in suture material and directly affixed to target cancerous tissue.","Double Strand Brachytherapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830100","Fletcher-suit Brachytherapy","C106074","An internal radiation treatment technique in which a curved, hollow applicator with a rounded reservoir at the tip is inserted into the uterus or cervix and then injected with radioactive sources for the treatment of gynecological cancers.","Fletcher-suit Brachytherapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829212","Manchester Ovoid","C106075","One of a pair of pre-loaded, ovoid-shaped applicators containing radium that is inserted into the vagina as part of the Manchester system for gynecologic intracavity brachytherapy delivery.","Manchester Ovoid | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827861","Tandem Brachytherapy","C106076","An internal radiation treatment technique in which a small metal tube filled with a radioactive source is placed inside the uterus for the treatment of gynecological cancers.","Tandem Brachytherapy | Tandem",,,,,,,,,,,,,,,"37165410","Brachytherapy tandem",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829057","Mini Ovoid Brachytherapy","C106077","An internal radiation treatment technique in which a small diameter hollow metal sphere filled with a radioactive source is placed inside the uterus for the treatment of gynecological cancers.","Mini Ovoid Brachytherapy | Ovoid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829121","Mesh Brachytherapy","C106078","An internal radiation treatment technique in which a piece of thin, flexible mesh made of vicryl and implanted with radioactive seeds is surgically attached to target tissue where it emits a low dose of radiation over a prolonged period of time.","Mesh Brachytherapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827671","Vaginal Cylinder","C106079","A metallic tube that is inserted into the vagina in order to facilitate delivery of vaginal intracavitary radiation therapy.","Vaginal Cylinder | Cylinder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419239","RAD50 Gene","C104708","This gene plays a role in DNA double-strand break repair.","RAD50 Gene | RAD50 | RAD50 Double Strand Break Repair Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332371","BAG1 Gene","C20952","This gene plays a role in signal transduction and is involved in the negative regulation of apoptosis.","BAG1 Gene | BAG1 | BCL2 Associated Athanogene 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333361","ETV1 Gene","C24377","This gene is involved in transcriptional activation and spinal cord development.","ETV1 Gene | ETS Variant Transcription Factor 1 Gene | ETV1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413791","CCN2 Gene","C62457","This gene is involved in mitogenesis for chondrocytes.","CCN2 Gene | CCN2 | CTGF | CTGF Gene | CTGF Gene | Cellular Communication Network Factor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334292","JAK3 Gene","C24530","This gene plays a role in signal transduction and non-receptor tyrosine protein kinase activity.","JAK3 Gene | JAK3 | Janus Kinase 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334096","IGFBP5 Gene","C24490","This gene plays a role in the intracellular transport of insulin-like growth factor moieties.","IGFBP5 Gene | IGFBP5 | Insulin-Like Growth Factor Binding Protein 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335239","PPBP Gene","C26611","This gene plays a variety of roles in cellular processes such as extracellular matrix synthesis, glucose metabolism, and megakaryocyte differentiation.","PPBP Gene | PPBP | Pro-Platelet Basic Protein (Chemokine (C-X-C Motif) Ligand 7) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812311","CXCL3 Gene","C18427","This gene plays a role in inflammatory processes and G-protein coupled receptor signaling.","CXCL3 Gene | CXCL3 | Chemokine (C-X-C Motif) Ligand 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796304","X-Ray Cross Complementing Group","C18297","A genetic complementation group for X-ray sensitivity.","X-Ray Cross Complementing Group | X-Ray Cross Complementing Family Gene | X-Ray Cross Complementing Gene Family | X-Ray Cross Complementing Group Gene | XRCC | XRCC Family Gene | XRCC Gene | XRCC Gene Family | XRCC Group",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242632","Type 1 Helper Cell","C12539","Type 1 Helper Cells are a subset of helper-inducer T-lymphocytes which synthesize and secrete interleukin-2, gamma-interferon, and interleukin-12. Due to their ability to kill antigen-presenting cells and their lymphokine-mediated effector activity, these cells are associated with delayed-type hypersensitivity reactions.","Type 1 Helper Cell | Th-1 Cell | Th1 Cell | Th1 Cells",,,,,,,,,,,,,,,"4305824","T helper subset 1 cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1879889","Blood Cell Count Ratio Measurement","C67208","The determination of the ratio of one blood cell component to another in a blood sample. The measurement may be expressed as either a ratio or a percentage.","Blood Cell Count Ratio Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419992","SRSF2 Gene","C101110","This gene plays a role in RNA splicing.","SRSF2 Gene | SRSF2 | Serine and Arginine Rich Splicing Factor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032433","Polyamine Compound","C759","A class or organic compounds composed of carbon, hydrogen, and nitrogen containing two or more amino groups with some compounds acting as essential growth factors for microorganisms.","Polyamine Compound | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1337110","CDH3 Gene","C20720","This gene is involved in the regulation of calcium-dependent cell-cell adhesion.","CDH3 Gene | CDH3 | Cadherin 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520647","15q25","C24961","A chromosome band present on 15q","15q25 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274226","EGFR NP_005219.2:p.E746_A750del","C98537","A deletion of five amino acids from the epidermal growth factor receptor protein from the glutamic acid at position 746 through the alanine at position 750.","EGFR NP_005219.2:p.E746_A750del | EGFR E746-A750 Mutation | EGFR E746_A750del | EGFR NP_005219.2:p.Glu746_Ala750del | EGFR p.E746_A750del | Epidermal Growth Factor Receptor E746_A750del | NP_005219.2:p.Glu746_Ala750del | Proto-Oncogene c-ErbB-1 E746_A750del | Receptor Tyrosine-Protein Kinase erbB-1 E746_A750del",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274211","EGFR NP_005219.2:p.G719C","C98522","A change in the amino acid residue at position 719 in the epidermal growth factor receptor protein where glycine has been replaced by cysteine.","EGFR NP_005219.2:p.G719C | EGFR G719C | EGFR Gly719Cys | EGFR NP_005219.2:p.Gly719Cys | EGFR p.G719C | EGFR p.Gly719Cys | Epidermal Growth Factor Receptor G719C | NP_005219.2:p.Gly719Cys | Proto-Oncogene c-ErbB-1 G719C | Receptor Tyrosine-Protein Kinase erbB-1 G719C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229613","Lymphoblast","C13013","An immature lymphocyte that has enlarged in response to antigenic stimulation.","Lymphoblast | lymphoblast | lymphoblastic",,,,,,,,,,,,,,,"4035453","Lymphoblast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1366824","TYMS Gene","C21229","This gene is involved in DNA replication and repair.","TYMS Gene | TYMS | Thymidylate Synthase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419741","RPS6 Gene","C91350","This gene plays a role in the modulation of cell growth and proliferation.","RPS6 Gene | RPS6 | Ribosomal Protein S6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334349","LOX Gene","C24559","This gene plays a role in cross-linking extracellular matrix proteins.","LOX Gene | LOX | Lysyl Oxidase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333683","GMNN Gene","C20395","This gene plays a role in DNA replication regulation.","GMNN Gene | GMNN | Geminin, DNA Replication Inhibitor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333212","DELEC1 Gene","C24337","This gene may play a role in tumor suppression.","DELEC1 Gene | DEC1 | DEC1 Gene | DEC1 Gene | DELEC1 | Deleted in Esophageal Cancer 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424714","CARD8 Gene","C84304","This gene is involved in the regulation of apoptosis.","CARD8 Gene | CARD8 | Caspase Recruitment Domain Family, Member 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416402","IL1RN Gene","C98164","This gene is involved in the inhibition of signaling.","IL1RN Gene | IL1RN | Interleukin 1 Receptor Antagonist Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334112","IL1B Gene","C28593","This gene is involved in the mediation of acute phase inflammatory responses.","IL1B Gene | IL1B | Interleukin 1, Beta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416972","MAGEA11 Gene","C91336","This gene is involved in androgen receptor function.","MAGEA11 Gene | MAGEA11 | Melanoma Antigen Family A, 11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414260","EDN1 Gene","C28577","This gene plays a role in active Na-K transport, vasoconstriction and pain mediation.","EDN1 Gene | EDN1 | Endothelin 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414688","FOXP1 Gene","C97549","This gene is involved in transcriptional modulation.","FOXP1 Gene | FOXP1 | Forkhead Box P1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417704","NFIB Gene","C38401","This gene plays a role in transcriptional regulation and mediates DNA-binding interactions.","NFIB Gene | NFIB | Nuclear Factor I/B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519622","Translocation Breakpoint","C13660","The point on a chromosome where the normal DNA sequence is juxtaposed with DNA from another chromosome.  Usually expressed as a band number designation (eg. t(9;22) (q34;q11) Philadelphia Chromosome)","Translocation Breakpoint | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0751994","Genes, myb","C28569","This gene plays a role in hematopoietic cell proliferation and development.","MYB Gene | MYB | MYB Proto-Oncogene, Transcription Factor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986505","Genomic Profile","C94411","Information about all the genes in an organism, including variations, gene expression, and the way those genes interact with each other and with the environment. A genomic profile may be used to discover why some people get certain diseases while other people do not, or why people respond differently to the same drug.","Genomic Profile | Genome Profile | Genomic Profiling | Genomic Test | Genomic Testing | genetic profile | genomic profile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332102","APEX1 Gene","C19677","This gene is involved in DNA repair processes.","APEX1 Gene | APEX Nuclease (Multifunctional DNA Repair Enzyme) 1 Gene | APEX1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520492","12q13-q14","C13583","A chromosome band present on 12q","12q13-q14 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334494","MCM7 Gene","C20378","This gene is involved in the initiation and licensing of DNA replication. It also plays a role in cell cycle inhibition following DNA damage.","MCM7 Gene | MCM7 | MCM7 Minichromosome Maintenance Deficient 7 (S. Cerevisiae) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008864","Citrulline","C53406","A non-essential amino acid. In hepatocytes, L-citrulline is synthesized in the urea cycle by the addition of carbon dioxide and ammonia to ornithine. L-citrulline is converted into L-arginine by the enzymes argininosuccinate synthetase and argininosuccinate lyase in the presence of L-aspartate and ATP. Subsequently, L-arginine is converted to nitric oxide by nitric oxide synthase and L-citrulline is regenerated as a by-product.","Citrulline | 2-Amino-5-(carbamoylamino)pentanoic Acid | CITRULLINE | L-Citrulline | N5-(Aminocarbonyl)-L-ornithine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333897","HIF1A Gene","C26372","This gene plays a role in cardiovascular development and systemic oxygen homeostasis.","HIF1A Gene | HIF1A | Hypoxia-Inducible Factor 1, Alpha Subunit (Basic Helix-Loop-Helix Transcription Factor) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639301","BPI - Throbbing","C100317","Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; throbbing.","BPI - Throbbing | BPI1-Throbbing | BPI122B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639308","BPI - Exhausting","C100324","Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; exhausting.","BPI - Exhausting | BPI1-Exhausting | BPI122I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639312","BPI - Numb","C100328","Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; numb.","BPI - Numb | BPI1-Numb | BPI122M",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639310","BPI - Penetrating","C100326","Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; penetrating.","BPI - Penetrating | BPI1-Penetrating | BPI122K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642046","PR - Pain Relief For Various Time Periods of Evaluation","C105267","Pain Intensity (PR v1) Pain relief for various time periods of evaluation.","PR - Pain Relief For Various Time Periods of Evaluation | PR01-Pain Relief | PR0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639337","BPI - Other Methods to Relieve Pain","C100353","Brief Pain Inventory (BPI) Other methods I use to relieve pain include; other.","BPI - Other Methods to Relieve Pain | BPI1-Other to Relieve Pain | BPI131G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639333","BPI - Relaxation Techniques Relieve Pain","C100349","Brief Pain Inventory (BPI) Other methods I use to relieve pain include; relaxation techniques.","BPI - Relaxation Techniques Relieve Pain | BPI1-Relaxation Techniques Relieve Pain | BPI131C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639336","BPI - Hypnosis to Relieve Pain","C100352","Brief Pain Inventory (BPI) Other methods I use to relieve pain include; hypnosis.","BPI - Hypnosis to Relieve Pain | BPI1-Hypnosis to Relieve Pain | BPI131F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639335","BPI - Biofeedback to Relieve Pain","C100351","Brief Pain Inventory (BPI) Other methods I use to relieve pain include; biofeedback.","BPI - Biofeedback to Relieve Pain | BPI1-Biofeedback to Relieve Pain | BPI131E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639332","BPI - Cold Compresses to Relieve Pain","C100348","Brief Pain Inventory (BPI) Other methods I use to relieve pain include; cold compresses.","BPI - Cold Compresses to Relieve Pain | BPI1-Cold Compresses to Relieve Pain | BPI131B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639334","BPI - Distraction to Relieve Pain","C100350","Brief Pain Inventory (BPI) Other methods I use to relieve pain include; distraction.","BPI - Distraction to Relieve Pain | BPI1-Distraction to Relieve Pain | BPI131D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639331","BPI - Warm Compresses to Relieve Pain","C100347","Brief Pain Inventory (BPI) Other methods I use to relieve pain include; warm compresses.","BPI - Warm Compresses to Relieve Pain | BPI1-Warm Compresses to Relieve Pain | BPI131A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639339","BPI - Medications not Prescribed Taken for Pain","C100355","Brief Pain Inventory (BPI) Medications not prescribed by my doctor that I take for pain are.","BPI - Medications not Prescribed Taken for Pain | BPI1-Meds not Prescribed Taken for Pain | BPI132",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816723","Fifty","C105785","A natural number greater than forty-nine and less than fifty-one and the quantity that it denotes.","Fifty | 50",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982341","Lung Cancer TNM Finding v7","C88865","A finding about one or more characteristics of lung cancer, following the rules of the TNM AJCC v7 classification system.  This classification is used for both non-small cell and small cell lung carcinomas and for carcinoid tumors of the lung.  Sarcomas and other rare tumors of the lung are not included. (from AJCC 7th Ed.)","Lung Cancer TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982351","Lung Cancer pT4 TNM Finding v7","C88875","Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe. (from AJCC 7th Ed.)","Lung Cancer pT4 TNM Finding v7 | pT4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982350","Lung Cancer pT3 TNM Finding v7","C88874","Lung cancer with a tumor size more than 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus (less than 2 cm distal to the carina but without involvement of the carina); or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe. (from AJCC 7th Ed.)","Lung Cancer pT3 TNM Finding v7 | pT3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982349","Lung Cancer pT2b TNM Finding v7","C88873","Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension. (from AJCC 7th Ed.)","Lung Cancer pT2b TNM Finding v7 | pT2b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982348","Lung Cancer pT2a TNM Finding v7","C88872","Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension. (from AJCC 7th Ed.)","Lung Cancer pT2a TNM Finding v7 | pT2a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982347","Lung Cancer pT2 TNM Finding v7","C88871","Lung cancer with a tumor size more than 3 cm but 7 cm or less or tumor with any of the following features (T2 tumors with these features are classified T2a if 5 cm or less): Involves main bronchus, 2 cm or more distal to the carina; Invades visceral pleura (PL1 or PL2); Associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung.  (from AJCC 7th Ed.)","Lung Cancer pT2 TNM Finding v7 | pT2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982346","Lung Cancer pT1b TNM Finding v7","C88870","Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a. (from AJCC 7th Ed.)","Lung Cancer pT1b TNM Finding v7 | pT1b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982345","Lung Cancer pT1a TNM Finding v7","C88869","Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a. (from AJCC 7th Ed.)","Lung Cancer pT1a TNM Finding v7 | pT1a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982344","Lung Cancer pT1 TNM Finding v7","C88868","Lung cancer with a tumor size of 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a. (from AJCC 7th Ed.)","Lung Cancer pT1 TNM Finding v7 | pT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881483","Lung Cancer pTis TNM Finding v6 and v7","C60967","Lung cancer with a finding of carcinoma in situ. (from AJCC 6th and 7th Eds.)","Lung Cancer pTis TNM Finding v6 and v7 | Lung Cancer pTis TNM Finding | Lung Cancer pTis TNM Finding | Lung Cancer pTis TNM Finding v6 | Lung Cancer pTis TNM Finding v7 | pTis Cancer of the Lung | pTis Carcinoma of the Lung | pTis Lung Cancer | pTis Lung Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982353","Lung Cancer pN1 TNM Finding v7","C88877","Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. (from AJCC 7th Ed.)","Lung Cancer pN1 TNM Finding v7 | pN1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982359","Lung Cancer Clinical Distant Metastasis TNM Finding v7","C88883","A clinical finding about one or more characteristics of lung cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.","Lung Cancer Clinical Distant Metastasis TNM Finding v7 | Clinical Staging: Distant Metastasis (cM)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982354","Lung Cancer Pathologic Distant Metastasis TNM Finding v7","C88878","A pathologic finding about one or more characteristics of lung cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  There is no pathologic M0 for lung cancer. (from AJCC 7th Ed.)","Lung Cancer Pathologic Distant Metastasis TNM Finding v7 | Pathologic Staging: Distant Metastasis (pM)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982357","Lung Cancer pM1b TNM Finding v7","C88881","Distant metastasis. (from AJCC 7th Ed.)","Lung Cancer pM1b TNM Finding v7 | pM1b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982356","Lung Cancer pM1a TNM Finding v7","C88880","Lung cancer with separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural (or pericardial) effusion.  Most pleural (and pericardial) effusions with lung cancer are due to tumor.  In a few patients, however, multiple cytopathologic examinations of pleural (or pericardial) fluid) are negative for tumor, and the fluid is nonbloody and is not an exudate.  Where these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging element and the patient should be classified as M0. (from AJCC 7th Ed.)","Lung Cancer pM1a TNM Finding v7 | pM1a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982355","Lung Cancer pM1 TNM Finding v7","C88879","Lung cancer with distant metastasis. (from AJCC 7th Ed.)","Lung Cancer pM1 TNM Finding v7 | pM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984096","Lung Cancer by AJCC v7 Stage","C91232","A term that refers to the staging of lung carcinoma according to the American Joint Committee on Cancer, 7th edition.","Lung Cancer by AJCC v7 Stage | Lung Carcinoma by AJCC v7 Stage | Lung Carcinoma by AJCC v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0855005","Stage IV Lung Cancer AJCC v7","C88891","Stage IV includes: (Any T, Any N, M1a); (Any T, Any N, M1b).  M1a: Lung cancer with separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural (or pericardial) effusion.  M1b: Distant metastasis. (AJCC 7th ed.)","Stage IV Lung Cancer AJCC v7 | Stage IV Lung Cancer | Stage IV Lung Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0862847","Stage III Lung Cancer AJCC v7","C88890","Stage III includes: IIIA (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0) and IIIB (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)","Stage III Lung Cancer AJCC v7 | Stage III Lung Cancer | Stage III Lung Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0862836","Stage II Lung Cancer AJCC v7","C88889","Stage II includes: IIA (T2b, N0, M0); (T1a, N1, M0); (T1b, N1, M0); (T2a, N1, M0) and IIB (T2b, N1, M0); (T3, N0, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  T3: Lung cancer with a tumor size more than 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus (less than 2 cm distal to the carina but without involvement of the carina); or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe. N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)","Stage II Lung Cancer AJCC v7 | Stage II Lung Cancer | Stage II Lung Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0855003","Stage I Lung Cancer AJCC v7","C88888","Stage I includes: IA: (T1a, N0, M0); (T1b, N0, M0) and IB: (T2a, N0, M0).  T1a: Lung cancer with a tumor size of 2 cm or less n greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage I Lung Cancer AJCC v7 | Stage I Lung Cancer | Stage I Lung Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278987","Stage IV Lung Non-Small Cell Cancer AJCC v7","C4012","Stage IV includes: (Any T, Any N, M1a); (Any T, Any N, M1b).  M1a: Lung cancer with separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural (or pericardial) effusion.  M1b: Distant metastasis. (AJCC 7th ed.)","Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage IV NSCLC | Stage IV Non-Oat Cell Carcinoma of Lung | Stage IV Non-Oat Cell Carcinoma of the Lung | Stage IV Non-Oat Cell Lung Carcinoma | Stage IV Non-Small Cell Carcinoma of Lung | Stage IV Non-Small Cell Carcinoma of the Lung | Stage IV Non-Small Cell Lung Cancer | Stage IV Non-Small Cell Lung Cancer | Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IV Non-Small Cell Lung Carcinoma | stage IV non-small cell lung cancer",,,,,,,,,,,,,,,"36684857","Metastatic non-small cell lung cancer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0278984","Stage IIIB Lung Non-Small Cell Cancer AJCC v7","C9103","Stage IIIB includes: (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Non Small Cell Lung Cancer Stage IIIB | Non Small Cell Lung Cancer, Stage IIIB | Stage IIIB NSCLC | Stage IIIB Non-Oat Cell Carcinoma of Lung | Stage IIIB Non-Oat Cell Carcinoma of the Lung | Stage IIIB Non-Oat Cell Lung Carcinoma | Stage IIIB Non-Small Cell Carcinoma of Lung | Stage IIIB Non-Small Cell Carcinoma of the Lung | Stage IIIB Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Carcinoma | stage IIIB non-small cell lung cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278983","Stage IIIA Lung Non-Small Cell Cancer AJCC v7","C9102","Stage IIIA includes: (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Non Small Cell Lung Cancer Stage IIIA | Non Small Cell Lung Cancer, Stage IIIA | Stage IIIA NSCLC | Stage IIIA Non-Oat Cell Carcinoma of Lung | Stage IIIA Non-Oat Cell Carcinoma of the Lung | Stage IIIA Non-Oat Cell Lung Carcinoma | Stage IIIA Non-Small Cell Carcinoma of Lung | Stage IIIA Non-Small Cell Carcinoma of the Lung | Stage IIIA Non-Small Cell Lung Cancer | Stage IIIA Non-Small Cell Lung Cancer | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage IIIA Non-Small Cell Lung Carcinoma | stage IIIA non-small cell lung cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336190","Stage IIB Non-Oat Cell Lung Carcinoma","C5654","Stage IIB includes: (T2b, N1, M0); (T3, N0, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T3: Lung cancer with a tumor size more than 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus (less than 2 cm distal to the carina but without involvement of the carina); or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe. N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)","Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Non-Oat Cell Carcinoma of Lung | Stage IIB Non-Oat Cell Carcinoma of the Lung | Stage IIB Non-Oat Cell Lung Carcinoma | Stage IIB Non-Small Cell Carcinoma of Lung | Stage IIB Non-Small Cell Carcinoma of the Lung | Stage IIB Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 | stage IIB non-small cell lung cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336167","Stage IIA Non-Oat Cell Lung Carcinoma","C5655","Stage IIA includes: (T2b, N0, M0); (T1a, N1, M0); (T1b, N1, M0); (T2a, N1, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)","Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIA Non-Oat Cell Carcinoma of Lung | Stage IIA Non-Oat Cell Carcinoma of the Lung | Stage IIA Non-Oat Cell Lung Carcinoma | Stage IIA Non-Small Cell Carcinoma of Lung | Stage IIA Non-Small Cell Carcinoma of the Lung | Stage IIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 | stage IIA non-small cell lung cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336139","Stage IB Non-Oat Cell Lung Carcinoma","C5653","Stage IB includes: T2a, N0, M0.  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IB Non-Oat Cell Carcinoma of Lung | Stage IB Non-Oat Cell Carcinoma of the Lung | Stage IB Non-Oat Cell Lung Carcinoma | Stage IB Non-Small Cell Carcinoma of Lung | Stage IB Non-Small Cell Carcinoma of the Lung | Stage IB Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma AJCC v7 | Stage IB Non-Small Cell Lung Carcinoma AJCC v7 | stage IB non-small cell lung cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336119","Stage IA Non-Oat Cell Lung Carcinoma","C5652","Stage IA includes: (T1a, N0, M0); (T1b, N0, M0).  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IA Non-Oat Cell Carcinoma of Lung | Stage IA Non-Oat Cell Carcinoma of the Lung | Stage IA Non-Oat Cell Lung Carcinoma | Stage IA Non-Small Cell Carcinoma of Lung | Stage IA Non-Small Cell Carcinoma of the Lung | Stage IA Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma AJCC v7 | Stage IA Non-Small Cell Lung Carcinoma AJCC v7 | stage IA non-small cell lung cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278986","Stage 0 Lung Non-Small Cell Cancer AJCC v6 and v7","C9104","Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage 0 Lung Non-Small Cell Cancer AJCC v6 and v7 | Lung Non-Small Cell Carcinoma in situ | Non-Small Cell Carcinoma in situ of Lung | Non-Small Cell Carcinoma in situ of the Lung | Stage 0 NSCLC | Stage 0 Non-Small Cell Carcinoma of Lung | Stage 0 Non-Small Cell Carcinoma of the Lung | Stage 0 Non-Small Cell Lung Cancer | Stage 0 Non-Small Cell Lung Cancer | Stage 0 Non-Small Cell Lung Cancer AJCC v6 | Stage 0 Non-Small Cell Lung Cancer AJCC v6 and v7 | Stage 0 Non-Small Cell Lung Cancer AJCC v6 and v7 | Stage 0 Non-Small Cell Lung Cancer AJCC v7 | Stage 0 Non-Small Cell Lung Carcinoma | stage 0 non-small cell lung carcinoma in situ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335098","occult non-small cell lung cancer","C9038","A non-small cell lung carcinoma detectable by sputum cytology only.  The primary tumor is undetectable radiographically or during bronchoscopy; therefore, it can not be assessed.","Occult Lung Non-Small Cell Carcinoma | Occult Non-Small Cell Carcinoma of Lung | Occult Non-Small Cell Carcinoma of the Lung | Occult Non-Small Cell Lung Cancer | Occult Non-Small Cell Lung Carcinoma | Occult Non-Small Cell Lung Carcinoma | occult stage non-small cell lung cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826858","Clinical Fellow - Speech Language Pathologist","C106122","A speech language pathologist who is providing services in a mentored, professional training setting prior to receiving a certificate of clinical competence.","Clinical Fellow - Speech Language Pathologist | CF-SLP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827025","Certificate of Clinical Competence - Speech Language Pathologist","C106125","A speech language pathologist who has received a certificate of clinical competence.","Certificate of Clinical Competence - Speech Language Pathologist | CCC-SLP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827028","Board Recognized Specialist - Swallowing","C106127","A certified speech language pathologist who is board recognized as an expert in swallowing disorders.","Board Recognized Specialist - Swallowing | BCS-S | BRS-S | Board Certified Specialist - Swallowing | Board Certified Specialist in Swallowing and Swallowing Disorders",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0083725","Neurofibromin","C17412","Neurofibromin (2839 aa, ~319 kDa) is encoded by the human NF1 gene. This protein plays a role in the regulation of Ras signaling.","Neurofibromin | NF1 | Neurofibromatosis-Related Protein NF-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0555191","Skin Sclerosing/Morphoeic Basal Cell Carcinoma","C27182","A histologic variant of basal cell carcinoma of the skin characterized by the presence of strands and nests of malignant cells that are embedded in a dense fibrotic stroma.","Skin Sclerosing/Morphoeic Basal Cell Carcinoma | Basal Cell Carcinoma Sclerosing Type | Morphea-Type (Sclerosing) Basal Cell Carcinoma | Morphea-Type Basal Cell Carcinoma | Morpheaform Basal Cell Carcinoma | Sclerosing Type Basal Cell Carcinoma | Skin Morphea-Type (Sclerosing) Basal Cell Carcinoma | Skin Morphea-Type (Sclerosing) Basal Cell Carcinoma",,,,,,,,,,,,,,,"4046560|4116194|4297183","Basal cell carcinoma - morpheic|Basal cell carcinoma - sclerosing type|Morpheic basal cell carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C0015645","Fasciitis","C50559","Inflammation process in fascia.","Fasciitis | Fascitis",,,,,,,,,,,,,,,"133569","Fasciitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332563","Papular Lesion","C39690","A small (less than 5-10 mm) elevation of skin that is non-suppurative.","Papular Lesion | Papule | Skin Papule",,,,,,,,,,,,,,,"40482959|4105835","Papule of skin|Papule",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1269776","Gray","C48324","An achromatic color of any lightness between the extremes of black and white.","Gray | GRAY | Gray Color | Grey",,,,,,,,,,,,,,,"4153956","Gray color",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1335280","PTPN11 Gene","C26337","This gene plays a role in the regulation of cell signaling. It is involved in cell migration, metabolic control, mitogenic activation and gene transcription.","PTPN11 Gene | PTPN11 | Protein Tyrosine Phosphatase Non-Receptor Type 11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1148438","General Appearance","C87079","The result of observation and overall assessment of a subject's outward aspect including appearance and movements; for example, in a human newborn general appearance includes skin color and tone, range of motion, and spontaneous movements.","General Appearance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3715212","Twenty","C105799","A natural number greater than nineteen and less than twenty-one and the quantity that it denotes.","Twenty | 20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1143949","Tumor Necrosis Factor Ligand Superfamily Member 10, Human","C20533","Tumor necrosis factor ligand superfamily member 10 (281 aa, ~33 kDa) is encoded by the human TNFSF10 gene. This protein plays a role in the induction of apoptosis.","Tumor Necrosis Factor Ligand Superfamily Member 10 | APO2 Ligand | APO2L | Apo-2 Ligand | Apo-2L | CD253 | CD253 Antigen | Chemokine Tumor Necrosis Factor Ligand Superfamily Member 10 | Protein TRAIL | TL2 | TNF-Related Apoptosis Inducing Ligand | TNF-Related Apoptosis Inducing Ligand TRAIL | TNF-Related Apoptosis-Inducing Ligand | TNF-related apoptosis-inducing ligand | TNFSF10 | TNFSF10 Protein | TRAIL | TRAIL Protein | TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 10 | Tumor Necrosis Factor Ligand Superfamily, Member 10 | tumor necrosis factor-related apoptosis-inducing ligand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831074","Clinical Variant","C106134","A form of a disease with clinical features that differ from other forms of the same disease.","Clinical Variant | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274373","Adaptive Design","C98704","A study design which includes a prospectively planned opportunity for modification of one or more specified aspects of the study design and/or hypotheses based on analysis of data, usually interim data.","Adaptive Design | Adaptive | adaptive design",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640078","Therapeutic Area","C101302","A knowledge field that focuses on research and development of treatments for diseases and pathologic findings, as well as prevention of conditions that negatively impact the health of an individual.","Therapeutic Area | THERAREA | Therapeutic Areas | therapeutic area",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273237","Resubmission","C97106","A submission that has been altered and resent.","Resubmission | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521306","Anticonvulsant Therapy","C64172","Drug treatment to prevent, stop, or reduce the severity of seizures or convulsions, commonly used in cases of epilepsy or other seizure disorders.","Anticonvulsant Therapy | Antiseizure Therapy | Antiseizure Treatment",,,,,,,,,,,,,,,"4186908","Anticonvulsant therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1515354","UCSF Helen Diller Family Comprehensive Cancer Center","C39532","The UCSF Helen Diller Family Comprehensive Cancer Center has an overarching goal of shepherding new approaches to cancer prevention, detection, and treatment into clinical and population settings, where they can be tested and evaluated. The Center integrates the work of researchers and clinicians. It was designated as an NCI comprehensive cancer center in 1999.","UCSF Helen Diller Family Comprehensive Cancer Center | The University of California San Francisco Cancer Center | The University of California San Francisco Cancer Center",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL445995","Photon Beam Radiation Therapy","C104914","Radiation therapy using photon beam.","Photon Beam Radiation Therapy | External beam radiation therapy using photons (procedure) | PHOTON Therapy | Photon | Photon EBRT | Photon External Beam Radiotherapy | Radiation, Photon Beam | photon beam radiation therapy",,,,,,,,,,,,,,,"607996","External beam radiation therapy using photons",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3831542","Analysis Project","C106135","A grouping of data of statistical interest generated from a specific research study.","Analysis Project | Statistical Data Grouping | Statistical Data Grouping ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517334","G-Banding","C19478","Use of Giemsa stain to produce a characteristic staining pattern on chromosomes","G-Banding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4014465","Hypergammaglobulinemia","C34705","A laboratory test result indicating abnormally high concentrations of gamma globulins in the blood.","Hypergammaglobulinemia | ",,,,,,,,,,,,,,,"4132570","Hypergammaglobulinemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0809246","NRAS Gene","C25786","This gene plays a role in signal transduction and cell cycle regulation.","NRAS Gene | NRAS | Neuroblastoma RAS Viral Oncogene Homolog Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812242","CBL Gene","C18364","This gene plays a role in signal transduction and the regulation of protein degradation.","CBL Gene | CBL | Cbl Proto-Oncogene Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829466","January","C106180","The first month of the year in the Gregorian calendar.","January | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830166","February","C106181","The second month of the year in the Gregorian calendar.","February | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829202","March","C106182","The third month of the year in the Gregorian calendar.","March | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3715024","April","C106183","The fourth month of the year in the Gregorian calendar.","April | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812381","May","C106184","The fifth month of the year in the Gregorian calendar.","May | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829443","June","C106185","The sixth month of the year in the Gregorian calendar.","June | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829447","July","C106186","The seventh month of the year in the Gregorian calendar.","July | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831448","August","C106187","The eighth month of the year in the Gregorian calendar.","August | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828193","September","C106188","The ninth month of the year in the Gregorian calendar.","September | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828732","October","C106189","The tenth month of the year in the Gregorian calendar.","October | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828767","November","C106191","The eleventh month of the year in the Gregorian calendar.","November | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3843930","December","C106192","The twelfth month of the year in the Gregorian calendar.","December | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827654","Veracruz","C106146","A state in east-central Mexico on the Gulf of Mexico east of Puebla. Its capital is Xalapa.","Veracruz | Free and Sovereign State of Veracruz | Veracruz  | Veracruz-Llave",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827397","Zacatecas","C106147","A state in north-central Mexico. Its capital is Zacatecas.","Zacatecas | Free and Sovereign State of Zacatecas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829077","Michoacan","C106148","A state in south western Mexico on the Pacific Ocean. Its capital is Morelia.","Michoacan | Free and Sovereign State of Michoacan | Free and Sovereign State of Michoacán | Michoacan de Ocampo | Michoacán | Michoacán de Ocampo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827369","Morelos","C106149","A state in south central Mexico. Its capital is Cuernavaca.","Morelos | Free and Sovereign State of Morelos",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828845","Nayarit","C106150","A state on the central Pacific coast of Mexico that includes the islands of Marias, Isabel, Tres Marietas and Farallon La Pena. Its capital is Tepic.","Nayarit | Free and Sovereign State of Nayarit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828746","Nuevo Leon","C106151","A state in the north eastern of Mexico. Its capital is Monterrey.","Nuevo Leon | Free and Sovereign State of Nuevo Leon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828740","Oaxaca","C106152","A state in the south of Mexico on the Pacific Ocean. Its capital is Oaxaca de Juarez.","Oaxaca | Free and Sovereign State of Oaxaca",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828441","Puebla","C106153","A state in south central Mexico. Its capital is Puebla de Zaragoza.","Puebla | Free and Sovereign State of Puebla",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828424","Queretaro","C106154","A state in central Mexico. Its capital is Santiago de Queretaro.","Queretaro | Free and Sovereign State of Queretaro | Free and Sovereign State of Querétaro | Queretaro de Arteaga | Querétaro | Querétaro de Arteaga",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828423","Quintana Roo","C106155","A state in south eastern Mexico, on the Yucatan peninsula. Its capital is Chetumal.","Quintana Roo | Free and Sovereign State of Quintana Roo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828019","Sinaloa","C106156","A state in western Mexico on the Gulf of California. Its capital is Culiacan.","Sinaloa | Free and Sovereign State of Sinaloa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828247","San Luis Potosi","C106157","A state in central Mexico. Its capital is San Luis Potosi.","San Luis Potosi | Free and Sovereign State of San Luis Potosi | Free and Sovereign State of San Luis Potosí | San Luis Potosí",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL443895","Sonora","C106158","A state in north western Mexico on the Gulf of California. Its capital is Hermosillo.","Sonora | Free and Sovereign State of Sonora",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827869","Tabasco","C106159","A state in south eastern Mexico on the Gulf of Mexico. Its capital is Villahermosa.","Tabasco | Free and Sovereign State of Tabasco",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827862","Tamaulipas","C106160","A state in north eastern Mexico on the Gulf of Mexico. Its capital is Ciudad Victoria.","Tamaulipas | Free and Sovereign State of Tamaulipas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827819","Tlaxcala","C106161","A state in southeastern central Mexico. Its capital is Tlaxcala.","Tlaxcala | Free and Sovereign State of Tlaxcala",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831588","Aguascalientes","C106195","A state in central Mexico. Its capital is Aguascalientes.","Aguascalientes | Free and Sovereign State of Aguascalientes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831422","Baja California","C106163","A state in Mexico comprising the northern half of the Baja California peninsula. Its capital is Mexicali.","Baja California | Free and Sovereign State of Baja California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831421","Baja California Sur","C106165","A state in Mexico comprising the southern half of the Baja California peninsula. Its capital is La Paz.","Baja California Sur | Free and Sovereign State of Baja California Sur",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831214","Campeche","C106196","A state in south eastern Mexico on the Yucatan Peninsula. Its capital is San Francisco de Campeche.","Campeche | Free and Sovereign State of Campeche",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814771","Chihuahua","C106197","A state in northern Mexico on the US border. Its capital is Chihuahua.","Chihuahua | Free and Sovereign State of Chihuahua",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831054","Colima","C106169","A state in south western Mexico bordering on the Pacific Ocean. Its capital is Colima.","Colima | Free and Sovereign State of Colima",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831120","Chiapas","C106166","The southernmost state of Mexico, bordering on the Pacific Ocean. Its capital is Tuxtla Gutierrez.","Chiapas | Free and Sovereign State of Chiapas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830417","Distrito Federal of Mexico","C106176","The capital of Mexico and seat of the federal powers of the Mexican Union. It is a federal entity separate from the 31 Mexican states.","Distrito Federal of Mexico | Distrito Federal | Mexico City",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830370","Durango","C106175","A state in northwestern central Mexico. Its capital is Durango.","Durango | Free and Sovereign State of Durango",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829921","Guerrero","C106170","A state in southern Mexico bordering on the Pacific Ocean. Its capital is Chilpancingo de los Bravo.","Guerrero | Free and Sovereign State of Guerrero",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829928","Guanajuato","C106171","A state in central Mexico. Its capital is Guanajuato.","Guanajuato | Free and Sovereign State of Guanajuato",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829700","Hidalgo","C106172","A state in east central Mexico. Its capital is Pachuca.","Hidalgo | Free and Sovereign State of Hidalgo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829468","Jalisco","C106173","A state in south western Mexico bordering on the Pacific Ocean. Its capital is Guadalajara.","Jalisco | Free and Sovereign State of Jalisco",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829074","Micronization","C106177","A process to reduce a solid material to particles with an average size described in microns.","Micronization | Micronize | Particle Sizing, Micronization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830287","Extended Release Depot Dosage Form","C106178","Parenteral sustained-release systems of microparticles, implants, or biodegradable polymer-excipients designed to release their active pharmaceutical ingredient over a prolonged period of time.","Extended Release Depot Dosage Form | DEPOT | Depot | Depot Dosage Form | Depot Extended Release Dosage Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831069","Coahuila","C106167","A state in northern Mexico bordering with Texas. Its capital is Saltillo.","Coahuila | Coahuila de Zaragoza | Free and Sovereign State of Coahuila",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510840","Albert Einstein Cancer Center","C39305","The goal of the Albert Einstein Cancer Center is to foster basic, clinical, population- based, and translational research in an effort to understand better the origins of cancer and its effective prevention, diagnosis, and treatment. It is affiliated with Albert Einstein College of Medicine, and became an NCI-designated Cancer Center in 1992.","Albert Einstein Cancer Center | AECC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1188853","Roseomonas","C86726","A genus of aerobic, Gram negative, rod shaped bacterium assigned to the phylum Proteobacteria and the family Acetobacteraceae.","Roseomonas | ROSEOMONAS",,,,,,,,,,,,,,,"4019893","Roseomonas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206419","Genus: Coronavirus","C26431","A genus of single-stranded, positive-sense RNA viruses in the family coronaviridae. The coronavirus genome exhibits helical symmetry.","Coronavirus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040145","Thyroidectomy","C51648","Surgery to remover part or all of the thyroid gland.","Thyroidectomy | thyroidectomy",,,,,,,,,,,,,,,"4030107","Thyroidectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0079746","Immunoblastic Lymphoma","C3461","A diffuse large B-cell lymphoma characterized by the presence of immunoblasts with uniformly round-to-oval nuclei, a prominent nucleolus, and abundant cytoplasm.","Immunoblastic Lymphoma | LYMPHOMA, IMMUNOBLASTIC, MALIGNANT","9684/3","Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS",,,,,,,,,,,,,"4003832","Diffuse non-Hodgkin's lymphoma, immunoblastic (clinical)",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0262662","Ventricular Bigeminy by ECG Finding","C71054","An electrocardiographic finding of a normal QRS followed by a premature ventricular contraction; a rhythmic pairing of normal and atypical beats originating in the ventricles in a 1-1 ratio.","Ventricular Bigeminy by ECG Finding | Bigeminy | VENTRICULAR BIGEMINY | Ventricular Bigeminy | Ventricular Bigeminy | Ventricular Bigeminy by EKG Finding",,,,,,,,,,,,,,,"4008580","Ventricular bigeminy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0700363","Idioventricular Rhythm","C50599","An electrocardiographic finding of three or more consecutive complexes of ventricular origin with a rate less than a certain threshold (100 or 120 beats per minute are commonly used). The QRS complexes are wide and have an abnormal morphology. (CDISC)","Idioventricular Rhythm | IDIOVENTRICULAR RHYTHM | Rhythm, idioventricular",,,,,,,,,,,,,,,"4171193","Idioventricular rhythm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0232202","Normal Sinus Rhythm","C102681","An electrocardiographic finding of an atrial rhythm which originates from the sinoatrial node that is considered normal for the population. There are no extra beats or conduction abnormalities. (CDISC)","Normal Sinus Rhythm | NORMAL SINUS RHYTHM",,,,,,,,,,,,,,,"4276669","Normal sinus rhythm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2981711","Paced Rhythm","C88140","An electrocardiographic finding in which the cardiac rhythm is controlled by an electrical impulse from an artificial cardiac pacemaker. (CDISC)","Paced Rhythm | Atrial and/or Ventricular Paced Rhythm | PACED RHYTHM | Paced rhythm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3551302","Ventricular Premature Complex by ECG Finding","C62256","An electrocardiographic finding of an ectopic impulse originating in the ventricles. The QRS morphology of these complexes is different from those of supraventricular origin. The QRS duration is often longer and the RR interval preceding the complexes is usually shorter than that of supraventricular beats. (CDISC)","Ventricular Premature Complex by ECG Finding | PREMATURE VENTRICULAR COMPLEX | PVC | Premature Ventricular Complex | Premature Ventricular Complexes | VE | VES | VPC | Ventricular Extra Beat | Ventricular Premature Complex | Ventricular Premature Complex | Ventricular Premature Complex by EKG Finding | Ventricular Premature Complexes",,,,,,,,,,,,,,,"4089462","Ventricular premature complex",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1963217","Prolonged QTc Interval, CTCAE","C54937","An adverse event characterized by an abnormally long interval between the start of the Q wave and the end of the T wave in the heart's electrical cycle, corrected for heart rate.","Prolonged QTc Interval, CTCAE | Prolonged QTc Interval Adverse Event | Prolonged QTc interval",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001396","Stokes-Adams Syndrome","C79765","An episode of sudden and transient loss of consciousness sometimes associated with seizures. It is caused by a sudden decrease of the cardiac output that results from a sudden cardiac dysrhythmia. Typically patients develop an initial pallor, followed by facial flush during recovery.","Stokes-Adams Syndrome | ",,,,,,,,,,,,,,,"4154638","Stokes-Adams attack",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1556187","Supraventricular Extrasystoles, CTCAE","C54944","An adverse event characterized by premature atrial contractions of the heart caused by signals originating from ectopic atrial sites or the atrioventricular node.","Supraventricular Extrasystoles, CTCAE | Supraventricular Extrasystoles Adverse Event | Supraventricular extrasystoles (Premature Atrial Contractions; Premature Nodal/Junctional Contractions)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0428999","Ventricular Trigeminy by ECG Finding","C71055","An electrocardiographic finding of two sinus beats followed by a premature ventricular complex for 3 or more consecutive cycles; a regularly irregular rhythm of normal and abnormal QRS complexes in a 2-1 ratio. (CDISC)","Ventricular Trigeminy by ECG Finding | Trigeminy | VENTRICULAR TRIGEMINY | Ventricular Trigeminy | Ventricular Trigeminy | Ventricular Trigeminy by EKG Finding",,,,,,,,,,,,,,,"4088505","Ventricular trigeminy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1663275","RORC protein, human","C106314","Nuclear receptor ROR-gamma T (497 aa, ~56 kDa) is encoded by the human RORC gene. This protein is involved in both ligand-dependent transcriptional regulation and the differentiation of helper T-cells.","Nuclear Receptor ROR-Gamma T | Nuclear Receptor ROR Gamma T | Nuclear Receptor ROR-Gamma Isoform 2 | Nuclear Receptor RORgamma(t) | Nuclear Receptor RZR-Gamma Isoform 2 | Nuclear Receptor Subfamily 1 Group F Member 3 Isoform 2 | RORgT | RORgammaT | Retinoic Acid-Binding Receptor Gamma Isoform 2 | Retinoic Acid-Related Orphan Receptor Gamma T | Retinoid-Related Orphan Receptor Gamma Isoform 2 | Retinoid-Related Orphan Receptor-Gamma Isoform 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447449","Hyperploidy","C106315","A chromosomal abnormality in that is characterized by an addition of chromosomes that results in a chromosome number that is not an exact multiple of the haploid number.","Hyperploidy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830412","DNA Hydroxymethylation","C106316","A DNA modification process where a hydrogen at the C5-position of a cytosine residue is replaced with a hydroxmethyl group.","DNA Hydroxymethylation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829004","Mitosis-Karyorrhexis Index","C106317","A tumor cell proliferation measurement represented by the number of cells in mitosis plus the number of cells in karyorrhexis per 5000 cells.","Mitosis-Karyorrhexis Index | MKI | mitosis karyorrhexis index | mitosis_karyorrhexis_index",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831770","3p14","C106318","A chromosome band present on 3p.","3p14 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0526873","Peripheral Lymph Node Addressin","C106319","A group of sulfated sialomucins that share a carbohydrate epitope synthesized by N-acetylglucosamine 6-O-sulfotransferase. The glycoproteins with this modification include sulfated ligands for L-selectin and are involved in tethering and rolling of lymphocytes along high endothelial venules (HEV) of lymphoid tissues.","Peripheral Lymph Node Addressin | L-Selectin Ligand | MECA-79 Antigen | PNAd | SELL Ligand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514492","Prominent Schwannian Stroma Present","C42049","A finding indicating the presence of a Schwann cell-rich stromal component in a neoplastic tissue specimen.","Prominent Schwannian Stroma Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517446","Ganglioneuroma Component Present","C42068","A finding indicating the presence of large ganglion cells, neural cellular infiltrates and a stroma with Schwannian differentiation in a neoplastic tissue specimen.","Ganglioneuroma Component Present | Ganglioneuromatous Element",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413374","CHAF1A Gene","C106136","This gene plays a role in both transcriptional regulation and nucleosome assembly.","CHAF1A Gene | CHAF1A | Chromatin Assembly Factor 1, Subunit A (p150) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413725","CRY2 Gene","C106139","This gene is involved in circadian rhythm.","CRY2 Gene | CRY2 | Cryptochrome 2 (Photolyase-Like) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425027","DCLRE1A Gene","C106142","This gene plays a role in both DNA repair and the cell cycle.","DCLRE1A Gene | DCLRE1A | DNA Cross-Link Repair 1A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417052","MBD4 Gene","C106162","This gene is involved in DNA mismatch repair.","MBD4 Gene | MBD4 | Methyl-CpG Binding Domain 4, DNA Glycosylase Gene | Methyl-CpG Binding Domain Protein 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417867","NTHL1 Gene","C106190","This gene plays a role in nucleotide-excision DNA repair.","NTHL1 Gene | NTHL1 | Nth Endonuclease III-Like 1 (E. Coli) Gene | Nth Like DNA Glycosylase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415223","GPER1 Gene","C106198","This gene plays a role in both estrogen binding and G protein-coupled receptor signaling.","GPER1 Gene | G Protein-Coupled Estrogen Receptor 1 Gene | GPER | GPER Gene | GPER1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416811","LDHA Gene","C106206","This gene is involved in carbohydrate metabolism.","LDHA Gene | LDHA | Lactate Dehydrogenase A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412687","ATP6AP1 Gene","C106209","This gene plays a role in organelle acidification.","ATP6AP1 Gene | ATP6AP1 | ATPase H+ Transporting Accessory Protein 1 Gene | ATPase, H+ Transporting, Lysosomal (Vacuolar Proton Pump), Subunit 1 Gene ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412278","AGER Gene","C106212","This gene is involved in binding to advanced glycation end products.","AGER Gene | AGER | Advanced Glycosylation End Product-Specific Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823861","WT1-AS Gene","C106215","This gene may play a role in the regulation of gene expression.","WT1-AS Gene | WT1 Antisense RNA Gene | WT1-AS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539924","TAOK3 Gene","C106218","This gene is involved in both protein phosphorylation and signal transduction.","TAOK3 Gene | TAO Kinase 3 Gene | TAOK3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538072","VTCN1 Gene","C106221","This gene plays a role in the regulation of cell-mediated immunity.","VTCN1 Gene | V-Set Domain Containing T Cell Activation Inhibitor 1 Gene | VTCN1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418727","POLD1 Gene","C106224","This gene is involved in DNA replication and proofreading.","POLD1 Gene | DNA Polymerase Delta 1, Catalytic Subunit Gene | POLD1 | Polymerase (DNA Directed), Delta 1, Catalytic Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427199","POLD3 Gene","C106227","This gene plays a role in the optimization of DNA replication.","POLD3 Gene | POLD3 | Polymerase (DNA Directed), Delta 3, Accessory Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418729","POLE Gene","C106232","This gene is involved in both DNA replication and DNA base-excision repair.","POLE Gene | DNA Polymerase Epsilon, Catalytic Subunit Gene | POLE | Polymerase (DNA Directed), Epsilon, Catalytic Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418734","POLI Gene","C106237","This gene plays a role in DNA damage repair.","POLI Gene | POLI | Polymerase (DNA Directed) Iota Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418735","POLK Gene","C106240","This gene is involved in translesion DNA synthesis.","POLK Gene | POLK | Polymerase (DNA Directed) Kappa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425416","RAD18 Gene","C106244","This gene plays a role in both protein ubiquitination and DNA repair.","RAD18 Gene | RAD18 | RAD18 Homolog (S. cerevisiae) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419236","RAD23A Gene","C106249","This gene is involved in both nucleotide excision repair and the regulation of protein degradation.","RAD23A Gene | RAD23 Homolog A (S. cerevisiae) Gene | RAD23A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419300","RBM4 Gene","C106255","This gene plays a role in both alternative splicing and mRNA translation.","RBM4 Gene | RBM4 | RNA Binding Motif Protein 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416373","CADM1 Gene","C106269","This gene plays a role in cell-cell adhesion.","CADM1 Gene | CADM1 | Cell Adhesion Molecule 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418273","PAX1 Gene","C106274","This gene is involved in both skeletal development and T-cell differentiation.","PAX1 Gene | PAX1 | Paired Box 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419245","RAD9A Gene","C106277","This gene plays a role in both cell cycle checkpoint control and DNA repair.","RAD9A Gene | RAD9 Homolog A (S. pombe) Gene | RAD9A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427703","RAD9B Gene","C106280","This gene is involved in both DNA repair and cell cycle progression.","RAD9B Gene | RAD9 Homolog B (S. pombe) Gene | RAD9B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826797","REV1 Gene","C106283","This gene plays a role in repair of DNA during replication.","REV1 Gene | REV1 | REV1, Polymerase (DNA Directed) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422420","NPRL3 Gene","C106286","This gene has no known function.","NPRL3 Gene | NPRL3 | Nitrogen Permease Regulator-Like 3 (S. cerevisiae) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539895","SUMO1 Gene","C106289","This gene plays a role in post-translational protein modification.","SUMO1 Gene | SMT3 Suppressor of Mif Two 3 Homolog 1 (S. cerevisiae) Gene | SUMO1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420830","TNP1 Gene","C106292","This gene is involved in spermatid maturation.","TNP1 Gene | TNP1 | Transition Protein 1 (During Histone to Protamine Replacement) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421169","TRPC2 Gene","C106295","Human TRPC2 gene is located within 11p15.4-p15.3 and is approximately 28 kb in length. This gene is a pseudogene that has no known functional product.","TRPC2 Gene | TRPC2 | Transient Receptor Potential Cation Channel, Subfamily C, Member 2 Gene | Transient Receptor Potential Cation Channel, Subfamily C, Member 2, Pseudogene Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421271","UBE2A Gene","C106298","This gene is involved in histone ubiquitination.","UBE2A Gene | UBE2A | Ubiquitin-Conjugating Enzyme E2A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421361","UNG Gene","C106306","This gene plays a role in DNA repair.","UNG Gene | UNG | Uracil DNA Glycosylase Gene | Uracil-DNA Glycosylase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427182","WRNIP1 Gene","C106309","This gene is involved in both ATP hydrolysis and DNA replication.","WRNIP1 Gene | WRNIP1 | Werner Helicase Interacting Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162574","Advanced Glycation End Product","C106312","Nonenzymatically glycosylated proteins or lipids which accumulate in vascular tissue during aging and at an accelerated rate in diabetes.","Advanced Glycation End Product | AGE | AGEs | Advanced Glycation End-Product | Advanced Glycation End-Product; Advanced Glycation Endproduct | Advanced Glycation Endproduct | Advanced Glycation Endproducts | Advanced Glycosylation End Product | Advanced Glycosylation End Product; Advanced Glycation Endproducts | Advanced Glycosylation End Products",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521863","estrogen receptor alpha, human","C38361","Estrogen receptor (595 aa, ~66 kDa) is encoded by the human ESR1 gene. This protein plays a role in the regulation of estradiol-dependent gene transcription.","Estrogen Receptor | ER | ER-Alpha | ERa | ERalpha | ESR1 | Estradiol Receptor | Estrogen Nuclear Receptor Alpha | Estrogen Receptor 1 | Estrogen Receptor Alpha | NR3A1 | Nuclear Receptor Subfamily 3 Group A Member 1 | estrogen receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333723","GTF2H1 Gene","C20656","This gene is involved in cell cycle regulation, transcriptional initiation and DNA repair.","GTF2H1 Gene | GTF2H1 | General Transcription Factor IIH, Polypeptide 1, 62kDa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414583","FEN1 Gene","C98120","This gene is involved in DNA replication and repair.","FEN1 Gene | FEN1 | Flap Structure-Specific Endonuclease 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333365","EXO1 Gene","C20345","This gene plays a role in DNA metabolic processes during stromal differentiation.","EXO1 Gene | EXO1 | Exonuclease 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412697","ATRX Gene","C74976","This gene plays a role in the regulation of both chromatin remodeling and transcription.","ATRX Gene | ATRX | ATRX, Chromatin Remodeler Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335081","OGG1 Gene","C20344","This gene is involved in base excision repair of oxidatively damaged DNA.","OGG1 Gene | 8-Oxoguanine DNA Glycosylase Gene | OGG1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417505","MUTYH Gene","C61056","This gene plays a role in the repair of oxidative DNA damage.","MUTYH Gene | MUTYH | MutY DNA Glycosylase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417239","MPG Gene","C94718","This gene plays a role in DNA metabolism and repair.","MPG Gene | MPG | N-Methylpurine-DNA Glycosylase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334511","MLH3 Gene","C20210","This gene plays a role in DNA mismatch repair and is associated with hereditary nonpolyposis colon cancer.","MLH3 Gene | MLH3 | MutL Homolog 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419289","RBBP4 Gene","C101726","This gene is involved in the regulation of both transcription and cell proliferation.","RBBP4 Gene | RBBP4 | Retinoblastoma Binding Protein 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416851","LIG1 Gene","C91269","This gene plays a role in both replication and base excision repair for DNA.","LIG1 Gene | LIG1 | Ligase I, DNA, ATP-Dependent Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415406","H2AX Gene","C28582","This gene is involved in histone and nucleosome organization and chromatin compaction regulation.","H2AX Gene | H2A.X Variant Histone Gene | H2AFX | H2AFX Gene | H2AFX Gene | H2AX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415344","GTF2H2 Gene","C89750","This gene plays a role in both RNA polymerase II-mediated transcription and nucleotide excision repair.","GTF2H2 Gene | GTF2H2 | General Transcription Factor IIH, Polypeptide 2, 44kDa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1847895","PINX1 Gene","C97214","This gene plays a role in both chromosome segregation and telomerase regulation.","PINX1 Gene | PIN2/TERF1 Interacting, Telomerase Inhibitor 1 Gene | PINX1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332362","B-Cell Neoplasm","C27907","A lymphoproliferative disorder composed of neoplastic B-cells. It includes B-cell non-Hodgkin lymphomas, B-cell leukemias, plasma cell neoplasms, and B-cell proliferations of uncertain malignant potential.","B-Cell Neoplasm | B-Cell Lymphocytic Neoplasm",,,,,,,,,,,,,,,"4187782","B-cell neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3273255","Unmutated Immunoglobulin Heavy Chain Variable Region Gene","C97146","A molecular finding indicating that the immunoglobulin heavy chain variable region has an unmutated germline configuration.","Unmutated Immunoglobulin Heavy Chain Variable Region Gene | IGHV Mutation Negative | IGHV Wildtype | Unmutated IGHV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517384","Gain of Chromosome 12q","C36441","A chromosomal aberration where there are 3 copies of the long arm of chromosome 12. This aberration is associated with 12q duplication syndrome.","Gain of Chromosome 12q | 12q Gain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332418","BIRC7 Gene","C20353","This gene regulates apoptosis through dual transcriptional activation pathways.","BIRC7 Gene | BIRC7 | Baculoviral IAP Repeat-Containing 7 (Livin) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225740","Lingula of the Lung","C40373","A small tongue-like projection from the lower portion of the upper lobe of the left lung.","Lingula of the Lung | LINGULA OF THE LUNG",,,,,,,,,,,,,,,"4178296","Structure of lingula of left lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0396585","Sleeve Lobectomy","C94448","Surgery to remove a lung tumor in a lobe of the lung and a part of the main bronchus (airway). The ends of the bronchus are rejoined and any remaining lobes are reattached to the bronchus. This surgery is done to save part of the lung.","Sleeve Lobectomy | sleeve lobectomy | sleeve resection",,,,,,,,,,,,,,,"4337608","Pneumonectomy with tracheobronchoplasty",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1364818","APP Gene","C28537","This gene is involved in transcriptional activation and mutations in the gene are correlated with Alzheimer disease.","APP Gene | APP | Amyloid Beta (A4) Precursor Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419232","RAD17 Gene","C91359","This gene is involved in cell cycle regulation and DNA repair.","RAD17 Gene | RAD17 | RAD17 Homolog (S. pombe) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418733","POLH Gene","C91285","This gene plays a role in DNA repair.","POLH Gene | POLH | Polymerase (DNA Directed), Eta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419241","RAD51B Gene","C90145","This gene plays a role in the mediation of homologous recombinational repair of DNA.","RAD51B Gene | RAD51 Paralog B Gene | RAD51B | RAD51L1 | RAD51L1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL387680","Anti-PD-L1 Monoclonal Antibody MDX-1105","C78852","A fully human monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1) with immune checkpoint inhibitory and potential antineoplastic activities. Anti-PD-L1 monoclonal antibody MDX-1105 binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells.","Anti-PD-L1 Monoclonal Antibody MDX-1105 | BMS 936559 | BMS-936559 | MDX-1105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414993","GATA2 Gene","C97552","This gene is involved in both DNA binding and transcriptional regulation.","GATA2 Gene | GATA Binding Protein 2 Gene | GATA2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426391","ZFPM1 Gene","C84286","This gene is involved in transcriptional regulation during erythroid and megakaryocytic cell differentiation.","ZFPM1 Gene | ZFPM1 | Zinc Finger Protein, Multitype 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812202","ETS2 Gene","C18328","This gene is involved in transcriptional activation and skeletal development.","ETS2 Gene | ETS Proto-Oncogene 2, Transcription Factor Gene | ETS2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812295","MPL Gene","C18411","This gene plays a regulatory role in megakaryocytopoiesis and platelet formation.","MPL Gene | MPL | MPL Proto-Oncogene, Thrombopoietin Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0228081","Neuropil","C12617","An area of dense, interwoven nerve cell fibers and synapses, glial processes, and dendrites that is located within the central or peripheral nervous system and contains very few cell bodies.","Neuropil | ",,,,,,,,,,,,,,,"4282474","Neuropil",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019652","Histones","C16687","Major protein component of chromatin.  Highly conserved basic proteins, originally classified into classes based on the relative amounts of arginine and lysine in each protein.  The various classes are now termed H1, H2A, H2B, H3, and H4.  In chromatin, they are found in an octamer, containing two each of H2A, H2B, H3, and H4, complexed with DNA in nucleosomes.  The histones in the octamer complex are also known as the core histones.  The H1 class of histones, termed the linker histones, is loosely associated with the nucleosome.","Histone | HISTONE | histone | histone family | histone_family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418951","PROX1 Gene","C74437","This gene may be involved in both neuronal development and transcriptional regulation.","PROX1 Gene | PROX1 | Prospero Homeobox 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422841","LYVE1 Gene","C97287","This gene is involved in hyaluronan binding.","LYVE1 Gene | LYVE1 | Lymphatic Vessel Endothelial Hyaluronan Receptor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0398408","Inguinofemoral Lymphadenectomy","C74540","The surgical removal of superficial inguinal lymph nodes and deep femoral lymph nodes.","Inguinofemoral Lymphadenectomy | ",,,,,,,,,,,,,,,"4120959","Inguinofemoral lymphadenectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0403855","Partial Vulvectomy","C94453","Surgery to remove an affected area of the vulva (the external female genital organs, including the clitoris, vaginal lips, and the opening to the vagina) along with a small amount of surrounding normal tissue.","Partial Vulvectomy | partial vulvectomy",,,,,,,,,,,,,,,"4074152","Partial vulvectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0177252","Radical Vulvectomy","C94455","Surgery to remove the entire vulva (the external female genital organs, including the clitoris, vaginal lips, and the opening to the vagina) and nearby lymph nodes.","Radical Vulvectomy | radical vulvectomy",,,,,,,,,,,,,,,"4117221","Radical vulvectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020700","Vaginal Hysterectomy","C51784","A surgical procedure to remove the uterine body and cervix, via the vaginal approach.","Vaginal Hysterectomy | Hysterectomy, Vaginal",,,,,,,,,,,,,,,"4138738","Vaginal hysterectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0542407","Total Abdominal Hysterectomy with Bilateral Salpingo-Oophorectomy","C51761","Surgical removal of all of the uterus, and the right and left fallopian tubes, and the right and left ovaries.","Total Abdominal Hysterectomy with Bilateral Salpingo-Oophorectomy | ",,,,,,,,,,,,,,,"4019096","Total abdominal hysterectomy with bilateral salpingo-oophorectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085198","Esophagectomy","C15357","Surgical removal of part or all of the esophagus.","Esophagectomy | esophagectomy | excision of the esophagus",,,,,,,,,,,,,,,"4187533","Esophagectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0149750","Partial Colectomy","C51887","Surgical removal of part of the colon.","Partial Colectomy | Partial Excision of Colon | Partial Resection of Colon | Subtotal Colectomy | open colectomy",,,,,,,,,,,,,,,"4181781","Partial resection of colon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3831121","Chest Tube Flutter Valve","C106373","A type of valve that connects to a chest tube and facilitates the drainage of fluid, air, and other materials out of the pleural cavity, while not permitting the flow back into the pleural cavity. The valve 'flutters' to open in one direction only.","Chest Tube Flutter Valve | Heimlich Valve",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828439","Pulmonary Hygiene","C106398","Non-invasive therapeutic modalities intended to assist in mobilizing and clearing excess bronchopulmonary secretions that are obstructive to airflow. Techniques include postural drainage, external percussive or vibratory therapy and facilitated expectoration.","Pulmonary Hygiene | Bronchial Hygiene Therapy | Bronchopulmonary Hygiene | Pulmonary Toilet | Respiratory Hygiene | Respiratory Toilet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826994","International Bone Marrow Transplant Registry","C106372","An international research organization based in Milwaukee, Wisconsin that collects and analyzes data of recipients of allogeneic and autologous hematopoietic stem cell transplants.","International Bone Marrow Transplant Registry | IBMTR | International Bone Marrow Transplant Registry ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827023","Center for International Blood and Marrow Transplant Research","C106396","A combined research program of the National Marrow Donor Program and the Medical College of Wisconsin that collaborates with the global scientific community to advance hematopoietic cell transplantation and cellular therapy research worldwide.","Center for International Blood and Marrow Transplant Research | CIBMTR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826859","European Group for Blood and Marrow Transplantation","C106397","A non-profit organization that allows scientists and physicians participating in clinical bone marrow transplantation to share their experience and develop co-operative studies.","European Group for Blood and Marrow Transplantation | EMBT | European Group for Blood and Marrow Transplantation ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714916","Charlson Comorbidity Index Derived from Chart Review","C106374","A method of predicting mortality by weighting comorbid conditions calculated by reviewing an individual's chart.","Charlson Comorbidity Index Derived from Chart Review | CCI | Charlson Comorbidity Index | Charlson Comorbidity Index Chart Review Version | Charlson Comorbidity Index Chart Review Version",,,,,,,,,,,,,,,"42538860","Charlson Comorbidity Index",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829910","Had a Myocardial Infarction","C106375","A question about whether an individual had a myocardial infarction.","Had a Myocardial Infarction | Has the patient had a myocardial infarction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829835","Has Alzheimer's, Dementia from any Etiology or any Serious Cognitive Impairment","C106389","A question about whether an individual has Alzheimer's, dementia from any etiology or any serious cognitive impairment.","Has Alzheimer's, Dementia from any Etiology or any Serious Cognitive Impairment | Does the patient have Alzheimer's, dementia from any etiology or any serious cognitive impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829833","Has Asthma, Chronic Lung Disease, Chronic Bronchitis or Emphysema","C106380","A question about whether an individual has or had asthma, chronic lung disease, chronic bronchitis or emphysema.","Has Asthma, Chronic Lung Disease, Chronic Bronchitis or Emphysema | Does the patient have asthma, chronic lung disease, chronic bronchitis or emphysema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829831","Has Chronic Liver Disease","C106384","A question about whether an individual has or had a chronic liver disease.","Has Chronic Liver Disease | Does the patient have a chronic liver disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827353","Has Decubitus Ulcer, Peripheral Skin Ulcer or Repeated Episodes of Cellulitis","C106393","A question about whether an individual has or had decubitus ulcers, peripheral skin ulcers or repeated episodes of cellulitis.","Has Decubitus Ulcer, Peripheral Skin Ulcer or Repeated Episodes of Cellulitis | Has the patient had decubitus ulcers, peripheral skin ulcers or repeated episodes of cellulitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829830","Has Depression","C106394","A question about whether an individual has or had depression.","Has Depression | Does the patient have depression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829829","Has Diabetes that Requires Treatment","C106381","A question about whether an individual has or had diabetes requiring treatment.","Has Diabetes that Requires Treatment | Does the patient have diabetes that requires treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829828","Has End Organ Damage from Diabetes","C106382","A question about whether an individual has or had end organ damage as a result of diabetes.","Has End Organ Damage from Diabetes | Does the patient have end organ damage from diabetes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829827","Has Gastric or Peptic Ulcer","C106386","A question about whether an individual has or had gastric or peptic ulcers.","Has Gastric or Peptic Ulcer | Has the patient had gastric or peptic ulcers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829825","Has HIV or AIDS","C106391","A question about whether an individual has HIV or AIDS.","Has HIV or AIDS | Does the patient have HIV or AIDS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829826","Has Hemiplegia","C106379","A question about whether an individual has or had hemiplegia.","Has Hemiplegia | Does the patient have hemiplegia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829824","Has Hypertension","C106392","A question about whether an individual has or had hypertension.","Has Hypertension | Does the patient have hypertension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829822","Has Metastatic Solid Tumor","C106388","A question about whether an individual has or had a metastatic solid tumor.","Has Metastatic Solid Tumor | Has the patient had a metastatic solid tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829821","Has Moderate or Severe Liver Disease","C106385","A question about whether an individual has or had moderate or severe liver disease.","Has Moderate or Severe Liver Disease | Does the patient have moderate to severe liver disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829820","Has Moderate or Severe Renal Disease","C106383","A question about whether an individual has or had moderate or severe renal disease.","Has Moderate or Severe Renal Disease | Does the patient have moderate or severe renal disease | Moderate to Severe Chronic Kidney Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827352","Has Peripheral Vascular Disease","C106377","A question about whether an individual has or had peripheral vascular disease.","Has Peripheral Vascular Disease | Does the patient have peripheral vascular disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829836","Has a Cerebrovascular Accident or Transient Ischemic Disease","C106378","A question about whether an individual has or had a cerebrovascular accident or transient ischemic disease.","Has a Cerebrovascular Accident or Transient Ischemic Disease | Has the patient had a CVA or transient ischemic disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829834","Has any Rheumatic or Connective Tissue Disease","C106390","A question about whether an individual has or had any rheumatic or connective tissue disease.","Has any Rheumatic or Connective Tissue Disease | Does the patient have any rheumatic or connective tissue disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829662","Hospitalized or Treated for Heart Failure","C106376","A question about whether an individual has been hospitalized or treated for heart failure.","Hospitalized or Treated for Heart Failure | Has the patient been hospitalized or treated for heart failure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827680","Using Warfarin or Coumadin","C106395","A question about whether an individual is or was using warfarin or coumadin.","Using Warfarin or Coumadin | Is the patient on warfarin or coumadin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3204189","Nasoduodenal Tube","C106399","A hollow tube that is directed into the duodenum from the nose.","Nasoduodenal Tube | Dobhoff Tube | ND Tube | Nasoduodenal Feeding Tube",,,,,,,,,,,,,,,"36674387","Nasoduodenal feeding tube",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1423760","SSBP2 Gene","C101503","This gene may be involved in DNA stability.","SSBP2 Gene | SSBP2 | Single-Stranded DNA Binding Protein 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0814005","Neuroblast","C12991","An embryonic nerve cell capable of differentiating into a neuron.","Neuroblast | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336670","TREX1 Gene","C20559","This gene is involved in DNA repair.","TREX1 Gene | TREX1 | Three Prime Repair Exonuclease 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1442760","TDG Gene","C101583","This gene is involved in catalyzing DNA repair.","TDG Gene | TDG | Thymine-DNA Glycosylase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413181","CCNH Gene","C89766","This gene plays a role in both basal transcription control and the cell cycle.","CCNH Gene | CCNH | Cyclin H Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511660","DNA Adduction","C25825","DNA Adduction involves formation of a covalent bond between a molecule and the DNA macromolecule.","DNA Adduction | DNA Adduct Formation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812289","MYCL Gene","C18407","This gene is involved in transcriptional regulation and is frequently amplified in small-cell lung cancer.","MYCL Gene | LMYC | MYCL | MYCL Proto-Oncogene, bHLH Transcription Factor Gene | MYCL1 | MYCL1 Gene | v-MYC Avian Myelocytomatosis Viral Oncogene Lung Carcinoma Derived Homolog Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421549","XRN2 Gene","C94708","This gene is involved in the metabolism of RNA.","XRN2 Gene | 5'-3' Exoribonuclease 2 Gene | XRN2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986711","Paperwork","C94844","The documents (e.g., forms, letters, reports) required for a particular activity.","Paperwork | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL426352","Power of Attorney","C93193","A power of attorney is a legal document that gives one person (such as a relative, lawyer, or friend) the authority to make legal, medical, or financial decisions for another person. It may go into effect right away, or when that person is no longer able to make decisions for himself or herself.","Power of Attorney | power of attorney",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0860594","Metastatic Melanoma","C8925","A melanoma that has spread from its primary site to another anatomic site.  Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","Metastatic Melanoma | ",,,,,,,,,,,,,,,"40481908|4157460","Metastatic malignant melanoma|Malignant melanoma, metastatic",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1282496","Metastatic Prostate Carcinoma","C8946","A carcinoma that arises from the prostate gland and has spread to other anatomic sites.","Metastatic Prostate Carcinoma | Metastatic Prostate Cancer | Prostate Cancer Metastatic | Prostate Carcinoma Metastatic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334714","Metastatic Breast Neuroendocrine Tumor G1","C5171","A neuroendocrine tumor G1 that arises from the breast and has metastasized to other anatomic sites.","Metastatic Breast Neuroendocrine Tumor G1 | Metastatic Breast Carcinoid Tumor | Metastatic Breast Carcinoid Tumor | Metastatic Carcinoid Tumor of Breast | Metastatic Carcinoid Tumor of the Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516465","Chemosensitivity Assay","C18215","A laboratory test to see how well a particular chemotherapy drug kills cancer cells. The test is done after the tumor cells are removed from the body. The assay may help in choosing the best drug or drugs for the cancer being treated.","Chemosensitivity Assay | Chemosensitivity Testing | chemosensitivity assay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987417","Ponatinib","C95777","An orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.","Ponatinib | AP 24534 | AP-24534 | AP24534 | Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl) | PONATINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831197","Carboxymethylcellulose Sodium-containing Eye Drop","C106410","An eye drop solution containing the sodium salt form of carboxymethylcellulose (CMC) used as artificial tears. Upon application of the drops into the eye, carboxymethylcellulose sodium lubricates the eye and prevents or relieves dryness and irritation.","Carboxymethylcellulose Sodium-containing Eye Drop | Cellufresh Eye Drop | Celluvisc | Refresh Artificial Tears | Refresh Celluvisc | Refresh Eye Drop | Theratears Lubricant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831302","Bothered by Hair Loss","C106401","A question about whether an individual is or was bothered by hair loss.","Bothered by Hair Loss | Did hair loss bother you | I am bothered by hair loss | Upset by Hair Loss | Were you upset by the loss of your hair",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447768","Feels Tightness in the Chest","C106402","A question about whether an individual feels or has felt tightness in the chest.","Feels Tightness in the Chest | I feel tightness in my chest",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831269","Breathing is Easy","C106403","A question about whether an individual's breathing is or was easy.","Breathing is Easy | Breathing is easy for me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3475470","Has Ever Smoked","C106404","A question about whether an individual has ever smoked.","Has Ever Smoked | Have you ever smoked",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828345","Regrets Smoking","C106405","A question about whether an individual regrets or regretted smoking.","Regrets Smoking | I regret my smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827732","Unable to Accommodate Disability or Language","C106461","Unable to meet the requirements of an individual's disability or language.","Unable to Accommodate Disability or Language | Unable to accommodate disability or language",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828769","Not Returned","C106464","An indication that an item was not returned.","Not Returned | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827242","Patient did not Complete Study","C106467","The status of a patient who did not complete a study.","Patient did not Complete Study | Patient Did Not Complete Study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831317","Booklet Return Not Requested","C106469","The return of a booklet is or was not requested.","Booklet Return Not Requested | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827780","Treatment on Hold","C106470","A treatment is suspended.","Treatment on Hold | Delayed | Treatment On Hold",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828222","Scheduled by Mistake","C106471","The erroneous scheduling of an event.","Scheduled by Mistake | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829552","Incorrect Booklet Given","C106473","The wrong booklet was provided to an individual.","Incorrect Booklet Given | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828455","Protocol Misinterpreted","C106476","A protocol was misinterpreted.","Protocol Misinterpreted | Misinterpreted Protocol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827957","Staff Error","C106477","An error made by a staff member.","Staff Error | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827956","Staff Not Available","C106486","A staff member is or was not available.","Staff Not Available | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828791","No Reason Given","C106487","There was no excuse provided.","No Reason Given | Not Given",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417708","NFKB1 Gene","C94295","This gene is involved in the regulation of apoptosis, signal transduction and gene transcription.","NFKB1 Gene | NFKB1 | Nuclear Factor of Kappa Light Polypeptide Gene Enhancer in B-Cells 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827241","Patient Did Not Like Question Content","C106490","Patient did not like the question content.","Patient Did Not Like Question Content | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714565","Individual Physical Condition","C106492","The physical condition of an individual.","Individual Physical Condition | Physical Condition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412104","ACACA Gene","C103885","This gene plays a role in the synthesis of long-chain fatty acids.","ACACA Gene | ACACA | Acetyl-CoA Carboxylase Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1444651","Not Offered","C102682","Is not an option.","Not Offered | Not offered",,,,,,,,,,,,,,,"4256475","Not offered",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033554","Prostaglandin","C782","A group of compounds derived from unsaturated 20-carbon fatty acids, primarily arachidonic acid, via the cyclooxygenase pathway. They are extremely potent mediators of a diverse group of physiological processes.","Prostaglandin | PG | Prostaglandins | prostaglandin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422524","RAB23 Gene","C106457","This gene is involved in intracellular membrane trafficking.","RAB23 Gene | RAB23 | RAB23, Member RAS Oncogene Family Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419950","SEMA4D Gene","C106608","This gene is involved in both cell-cell signaling and axonal growth cone guidance.","SEMA4D Gene | SEMA4D | Sema Domain, Immunoglobulin Domain (Ig), Transmembrane Domain (TM) and Short Cytoplasmic Domain, (semaphorin) 4D Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1442753","SLC7A5 Gene","C106588","This gene plays a role in high-affinity transport of large neutral amino acids.","SLC7A5 Gene | SLC7A5 | Solute Carrier Family 7 (Amino Acid Transporter Light Chain, L System), Member 5 Gene | Solute Carrier Family 7 Member 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420131","SLCO1B1 Gene","C106614","This gene is involved in sodium-independent uptake of numerous endogenous compounds in the liver.","SLCO1B1 Gene | SLCO1B1 | Solute Carrier Organic Anion Transporter Family, Member 1B1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420132","SLCO1B3 Gene","C106617","This gene plays a role in both the sodium-independent uptake of endogenous and xenobiotic compounds and the transport of bile acid and bilirubin.","SLCO1B3 Gene | SLCO1B3 | Solute Carrier Organic Anion Transporter Family, Member 1B3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416962","SMAD1 Gene","C106611","This gene plays a role in the regulation of bone morphogenetic proteins.","SMAD1 Gene | SMAD Family Member 1 Gene | SMAD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826867","Visual Analogue Fatigue Scale","C106624","A numeric scale used to describe an individual's global fatigue.","Visual Analogue Fatigue Scale | VAFS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828953","Motivation Lower When Fatigued","C106625","A question about whether an individual's motivation is or was lower when fatigued.","Motivation Lower When Fatigued | My motivation is lower when I am fatigued",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830296","Exercise Brings on Fatigue","C106626","A question about whether exercise brings or brought on an individual's fatigue.","Exercise Brings on Fatigue | Exercise brings on my fatigue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448195","Easily Fatigued","C106627","A question about whether an individual is or was easily fatigued.","Easily Fatigued | I am easily fatigued",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830177","Fatigue Interferes with Physical Functioning","C106628","A question about whether an individual's fatigue interferes or interfered with physical functioning.","Fatigue Interferes with Physical Functioning | Fatigue Interferes with Physical Functioning  | Fatigue interferes with my physical functioning",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830178","Fatigue Causes Frequent Problems","C106629","A question about whether an individual's fatigue causes or caused frequent problems.","Fatigue Causes Frequent Problems | Fatigue Causes Frequent Problems  | Fatigue causes frequent problems for me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830175","Fatigue Prevents Sustained Physical Functioning","C106630","A question about whether an individual's fatigue prevents or prevented sustained physical functioning.","Fatigue Prevents Sustained Physical Functioning | My fatigue prevents sustained physical functioning",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827387","Fatigue Interferes with Certain Duties and Responsibilities","C106631","A question about whether an individual's fatigue interferes or interfered with certain duties or responsibilities.","Fatigue Interferes with Certain Duties and Responsibilities | Fatigue Interferes with Certain Duties and Responsibilities  | Fatigue interferes with carrying out certain duties and responsibilities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830179","Fatigue among Most Disabling Symptoms","C106632","A question about whether an individual's fatigue is or was among their most disabling symptoms.","Fatigue among Most Disabling Symptoms | Fatigue is among my most disabling symptoms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830176","Fatigue Interferes with Work, Family, or Social Life","C106634","A question about whether an individual's fatigue interferes or interfered with work, family, or social life.","Fatigue Interferes with Work, Family, or Social Life | Fatigue interferes with my work, family, or social life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539965","TIE1 Gene","C24861","This gene plays a regulatory role in angiogenesis.","TIE1 Gene | TIE1 | Tyrosine Kinase with Immunoglobulin Like and EGF Like Domains 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427306","BTLA Gene","C82849","This gene is involved in the immune response.","BTLA Gene | B and T Lymphocyte Associated Gene | BTLA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333533","FBXW7 Gene","C20786","This gene is involved in ubiquitin-dependent proteolysis and regulation of the G1-S cell cycle checkpoint.","FBXW7 Gene | F-Box and WD Repeat Domain Containing 7 Gene | FBXW7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332126","AXIN2 Gene","C20763","This gene is involved in signal transduction and plays a role in development.","AXIN2 Gene | AXIN2 | Axin 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0877857","Immunoglobulin Variable Region","C13245","The portion of an antibody molecule that contains the three hypervariable regions in both the heavy and light chains. It is comprised of the amino terminal half of the light chains and at most a third of the heavy chains from the amino termini.","Immunoglobulin Variable Region | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1367656","NRG1 Gene","C20174","This gene plays a role in cellular differentiation, growth and proliferation.","NRG1 Gene | NRG1 | Neuregulin 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332421","CXCR5 Gene","C24266","This gene plays a role in cellular chemotaxis and B-cell migration.","CXCR5 Gene | BLR1 | BLR1 Gene | CXCR5 | Chemokine (C-X-C Motif) Receptor 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334877","NFKBIA Gene","C26430","This gene plays a role in signal transduction and transcriptional activation of target genes. It is also involved in the inhibition of apoptosis.","NFKBIA Gene | IKBA Gene | NFKBIA | Nuclear Factor of Kappa Light Polypeptide Gene Enhancer in B-Cells Inhibitor, Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985688","Treating Site","C93477","Any healthcare facility where care is provided as part of a cooperative group.","Treating Site | TreatingSite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816446","Thirty","C105797","A natural number greater than twenty-nine and less than thirty-one and the quantity that it denotes.","Thirty | 30",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333525","FABP2 Gene","C20926","This gene plays a role in fatty acid metabolism in the intestine.","FABP2 Gene | FABP2 | Fatty Acid Binding Protein 2, Intestinal Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421500","WEE1 Gene","C92675","This gene plays a role in cell cycle regulation.","WEE1 Gene | WEE1 | WEE1 Homolog (S. pombe) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812239","VAV2 Gene","C18361","This gene plays a role in signal transduction and negative regulation of T-cell activation.","VAV2 Gene | VAV2 | Vav Guanine Nucleotide Exchange Factor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332332","Gleason Score 7","C28091","A Gleason score that indicates an intermediate-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","Gleason Score 7 | ",,,,,,,,,,,,,,,"4211973","Gleason grade score 7 out of 10",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332333","Gleason Score 8","C28092","A Gleason score that indicates a histologically aggressive prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","Gleason Score 8 | ",,,,,,,,,,,,,,,"4140825","Gleason grade score 8 out of 10",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332334","Gleason Score 9","C28093","A Gleason score that indicates a high-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","Gleason Score 9 | ",,,,,,,,,,,,,,,"4240465","Gleason grade score 9 out of 10",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332335","Gleason Score 10","C28094","A Gleason score that indicates a highly aggressive prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","Gleason Score 10 | ",,,,,,,,,,,,,,,"4074238","Gleason grade score 10 out of 10",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0439526","Per Milliliter","C103452","A volume unit equal to one milliliter used as a denominator to build a derived unit expressed as a ratio. (NCI)","Per Milliliter | /mL | /ml | Per mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332331","Gleason Score 6","C28090","A Gleason score that indicates a low-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","Gleason Score 6 | ",,,,,,,,,,,,,,,"4224785","Gleason grade score 6 out of 10",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0286330","26S proteasome","C13970","Proteasomes are large multicatalytic proteolytic complexes found in all eukaryotic cells, and simpler forms have been found in archaebacteria and certain eubacteria.  In eukaryotes, the 20S proteasome also exists as the central core of the 26S (2000 kDa) proteasome complex, which catalyzes the degradation of ubiquitin-conjugated proteins and contains an additional 19S complex, composed of regulatory proteins and six ATPases.","26S ATP-Dependent Proteasome | 26S ATP-Dependent Protease | 26S Proteasome | 26S Proteasome Complex | 26S Proteosome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332112","RHOH Gene","C21320","This gene plays a role in signal transduction in hematopoietic cells.","RHOH Gene | RAS Homolog Family Member H Gene | RHOH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812237","AXL Gene","C18359","This gene plays a role in the tyrosine kinase receptor-mediated signal transduction pathway. The gene is also involved in cellular proliferation and aggregation.","AXL Gene | AXL | AXL Receptor Tyrosine Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513392","Molecular Fingerprint of Tumor","C19966","All cell types, depending on their functions, have unique, identifiable 'signatures' - special characteristics such as which genes are active and what proteins or other cellular products are manufactured by the cell.  During transformation of a normal cell to a cancer cell, the signature changes, and that change becomes a signal of the presence of cancer.  (Bypass Budget)","Molecular Fingerprint of Tumor | Molecular Profiles of Cancer Cells | Signatures of Cancer Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041368","Tumor Necrosis Factors","C20500","Family of cell surface proteins structurally related to tumor necrosis factor.  They are involved in lymphocyte homeostasis by their ability to induce apoptosis.","Tumor Necrosis Factor Family Protein | TNFSF Protein | Tumor Necrosis Factor Superfamily Protein | Tumor Necrosis Factors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333327","TYMP Gene","C24357","This gene is involved in angiogenesis and the stimulation of endothelial cell growth. It also plays a role in the negative regulation of glial cell proliferation.","TYMP Gene | TYMP | Thymidine Phosphorylase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0074830","Somatostatin Receptor","C17333","A family of G protein-coupled receptors that bind somatostatin and play a role in ligand-dependent signal transduction.","Somatostatin Receptor | SSTR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333578","FRS2 Gene","C24819","This gene plays a role in signal transduction.","FRS2 Gene | FRS2 | Fibroblast Growth Factor Receptor Substrate 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333543","FGFR3 Gene","C24393","This gene plays a role in bone development and maintenance and mutations in the gene are associated with craniosynostosis and several types of skeletal dysplasia.","FGFR3 Gene | FGFR3 | Fibroblast Growth Factor Receptor 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539902","SUZ12 Gene","C73545","This gene plays a role in embryonic development and histone methylation.","SUZ12 Gene | SUZ12 | Suppressor of Zeste 12 Homolog (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414995","GATA4 Gene","C75495","This gene is involved in transcriptional regulation.","GATA4 Gene | GATA Binding Protein 4 Gene | GATA4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1822614","SAT1 Gene","C39662","This gene is involved in catabolic polyamine metabolism and cell migration.","SAT1 Gene | SAT1 | Spermidine/Spermine N1-Acetyltransferase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539887","11-Dehydro-Thromboxane B2 Measurement","C103344","The determination of the amount of the 11-dehydro-thromboxane B2 in a sample.","11-Dehydro-Thromboxane B2 Measurement | 11-Dehydro-Thromboxane B2 | TXB2_D11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827829","Time-Consuming","C106683","Requiring a great amount of time.","Time-Consuming | Time-consuming",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334801","Monophasic Synovial Sarcoma","C6534","A synovial sarcoma characterized by the presence of an epithelial or a spindle cell component only.","Monophasic Synovial Sarcoma | Monophasic Sarcoma of Synovium | Monophasic Sarcoma of the Synovium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3472614","Plasmablastic Lymphoma","C7224","An aggressive diffuse large B-cell lymphoma frequently arising in the setting of HIV infection and characterized by the presence of large neoplastic cells resembling B-immunoblasts which have the immunophenotypic profile of plasma cells.  Sites of involvement include the oral cavity, sinonasal cavity, skin, soft tissues, gastrointestinal tract, and bone.","Plasmablastic Lymphoma | PBL | Plasmablastic lymphoma","9735/3","Plasmablastic lymphoma",,,,,,,,,,,,,"37110402|42872914","Plasmablastic lymphoma|Plasmablastic lymphoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0334401","Malignant Granulosa Cell Tumor","C4205","A granulosa cell tumor which has an aggressive clinical course and metastasizes to other anatomic sites.","Malignant Granulosa Cell Tumor | GRANULOSA CELL TUMOR, MALIGNANT | Granulosa cell carcinoma | Granulosa cell tumor, malignant | Malignant Granulosa Cell Neoplasm",,,,,,,,,,,,,,,"4077906","Granulosa cell tumor, malignant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1274034","Clinical Oncology","C19622","The medical specialty that focuses on clinical aspects of the diagnosis, treatment, and prevention of cancers. (NCI 2005)","Clinical Oncology | ",,,,,,,,,,,,,,,"4214568","Clinical oncology",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014137","Endocrinology","C16543","The science and medical specialty concerned with the metabolism, physiology, or hormonal secretions and their physiologic and pathologic relations.","Endocrinology | Endocrinology and Metabolism | Metabolism and Endocrinology",,,,,,,,,,,,,,,"4190428","Endocrinology",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018735","Health Policy","C16668","A set of decisions and courses of action undertaken to achieve specific health care goals within a community or society.","Health Policy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986385","Involuntary","C94195","An action that is not made by choice. In the body, involuntary actions (such as blushing) occur automatically, and cannot be controlled by choice.","Involuntary | involuntary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205255","Incarceration","C85521","The state of being confined to jail or prison.","Incarceration | INCARCERATION",,,,,,,,,,,,,,,"4166675","Imprisonment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3831563","Allogeneic Conditioning","C107095","A preparative treatment regimen given prior to a cell transplantation from a genetically non-identical donor. The regimen consists of chemotherapy with or without radiation and is intended to kill cancerous cells before the transplantation and to provide immunosuppression to prevent the rejection of the donor's stem cells.","Allogeneic Conditioning | Allo Conditioning | Allogeneic (allo) Conditioning",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831439","Autologous Conditioning","C107096","A preparative treatment regimen given prior to autologous cell transplantation. The regimen consists of chemotherapy with or without radiation and is intended to kill cancerous cells before the transplantation.","Autologous Conditioning | Auto Conditioning | Autologous (auto) Conditioning",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541276","Epworth Sleepiness Scale Questionnaire","C103517","A standardized rating scale used to assess an individual's general level of daytime sleepiness.","Epworth Sleepiness Scale Questionnaire | ESS | ESS01 | Epworth Sleepiness Scale",,,,,,,,,,,,,,,"46273534","Epworth Sleepiness Scale",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828013","Sitting and Reading","C106684","A question about an individual's activity of sitting and reading.","Sitting and Reading Question | Sitting and Reading | Sitting and Reading | Sitting and reading",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827501","Watching TV","C106685","A question about an individual's activity of watching television.","Watching TV Question | Watching TV | Watching TV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828011","Sitting Inactive in Public Place","C106686","A question about an individual's activity of sitting inactive in a public place.","Sitting Inactive in Public Place Question | Sitting Inactive in Public Place | Sitting Inactive in Public Place | Sitting inactive in a public place",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828654","Passenger in Car for Hour without Break","C106687","A question about an individual's activity of being a passenger in a car for an hour without a break.","Passenger in Car for Hour without Break | As a passenger in a car for an hour without a break",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829238","Lying Down for Afternoon Rest when Circumstances Permit","C106688","A question about an individual's activity of lying down to rest in the afternoon when circumstances permit.","Lying Down for Afternoon Rest when Circumstances Permit | Lying down to rest in the afternoon when circumstances permit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828010","Sitting Quietly after Lunch without Alcohol","C106690","A question about an individual's activity of sitting quietly after a lunch without alcohol.","Sitting Quietly after Lunch without Alcohol Question | Sitting Quietly after Lunch without Alcohol | Sitting Quietly after Lunch without Alcohol | Sitting quietly after a lunch without alcohol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827916","Stopped in Car for Few Minutes in Traffic","C106691","A question about an individual's activity of being in a car while stopped for a few minutes in traffic.","Stopped in Car for Few Minutes in Traffic | In a car, while stopped for a few minutes in traffic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827421","Would Never Doze","C106646","A question about the likelihood an individual would never doze.","Would Never Doze | would never doze",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828003","Slight Chance of Dozing","C106647","A question about whether an individual has or had a slight likelihood of dozing.","Slight Chance of Dozing | slight chance of dozing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828992","Moderate Chance of Dozing","C106648","A question about whether an individual has or had a moderate likelihood of dozing.","Moderate Chance of Dozing | moderate chance of dozing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829699","High Chance of Dozing","C106649","A question about whether an individual has or had a high likelihood of dozing.","High Chance of Dozing | high chance of dozing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830397","Doze or Fall Asleep","C106692","A question about an individuals likelihood to doze or fall asleep.","Doze or Fall Asleep | Doze Off or Fall Asleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1686499","TGF-Beta Receptor Type-1, Human","C30098","TGF-beta receptor type-1 (503 aa, ~56 kDa) is encoded by the human TGFBR1 gene. This protein plays a role in both TGF-beta-dependent signaling and serine/threonine phosphorylation.","TGF-Beta Receptor Type-1 | ALK-5 | ALK5 | Activin A Receptor Type II-Like Kinase 53kDa | Activin A Receptor Type II-Like Protein Kinase of 53kD | Activin Receptor-Like Kinase 5 | EC 2.7.11.30 | SKR4 | Serine/Threonine-Protein Kinase Receptor R4 | TGF-Beta Receptor Type I | TGF-Beta Type I Receptor | TGFBR1 | TGFR-1 | TbetaR-I | Transforming Growth Factor Beta Receptor 1 | Transforming Growth Factor Beta Receptor I | Transforming Growth Factor Beta Receptor Type I | Transforming Growth Factor-Beta Receptor Type I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037083","Signal Transduction","C17133","A cellular process that involves a chemical or mechanical stimulus and results in a specific cellular response. This process is a central feature of a broad variety of physiologic responses.","Signal Transduction | Cell Communication and Signaling | Cell Signaling | Intracellular Communication and Signaling | Signaling | signal transduction",,,,,,,,,,,,,,,"4190700","Signal transduction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1312139","Bone Morphogenetic Protein Receptor Type-1A, Human","C21367","Bone morphogenetic protein receptor type-1A (532 aa, ~60 kDa) is encoded by the human BMPR1A gene. This protein is involved in ligand binding, signal transduction and embryonic development.","Bone Morphogenetic Protein Receptor Type-1A | ALK-3 | Activin A Receptor, Type II-Like Kinase 3 | Activin Receptor-Like Kinase 3 | Antigen CD292 | BMP Type-1A Receptor | BMPR-1A | BMPR1A | CD292 | CD292 Antigen | EC 2.7.11.30 | SKR5 | Serine/Threonine-Protein Kinase Receptor R5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226727","Portal Venous System","C33344","A system of vessels in which blood, after passing through one capillary bed, is conveyed through a second set of capillaries before it returns to the systemic circulation. It pertains especially to the hepatic portal system.","Portal Venous System | Portal System",,,,,,,,,,,,,,,"4336535","Portal venous system structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3886769","Buparlisib","C90565","An orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases with potential antineoplastic activity. Buparlisib specifically inhibits class I PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway in an ATP-competitive manner, thereby inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate and activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","Buparlisib | AN 2025 | AN-2025 | AN2025 | BKM 120 | BKM-120 | BKM120 | BUPARLISIB | PI3K Inhibitor BKM120 | PI3K Inhibitor BKM120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1956491","Tasquinimod","C74080","A quinoline-3-carboxamide linomide analogue with antiangiogenic and potential antineoplastic activities. Tasquinimod has been shown to decrease blood vessel density but the exact mechanism of action is not known. This agent has also been shown to augment the antineoplastic effects of docetaxel and androgen ablation in a murine model of prostate cancer involving human prostate cancer xenografts.","Tasquinimod | ABR-215050 | TASQ | TASQUINIMOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541342","Radium Ra 223 Dichloride","C62535","A radiopharmaceutical composed of the dichloride salt of the alpha-emitting isotope radium Ra 223, with antineoplastic activity. Like calcium, radium targets bone tissue and preferentially accumulates in osteoblastic lesions, such as those seen in areas of bone metastases. Radium Ra 223 forms complexes with hydroxyapatite and becomes incorporated into the bone matrix. The radioisotope Ra 223 kills bone cancer cells through local emission of high energy alpha particles, causing DNA double-strand breaks and tumor regression in the skeleton. The short range effects of alpha emission allows for localized DNA damage with limited toxicity to nearby healthy bone tissue.","Radium Ra 223 Dichloride | Alpharadin | BAY 88-8223 | BAY88-8223 | RADIUM RA-223 DICHLORIDE | Radium 223 Dichloride | Radium Chloride Ra-223 | Radium-223 Chloride | Radium-223 Dichloride | Xofigo",,,,,,,,,,,,,,,"37110009","Radium (223-Ra) dichloride",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2830183","Cabazitaxel","C66937","A semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, this agent is a poor substrate for the membrane-associated, multidrug resistance (MDR), P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. In addition, cabazitaxel penetrates the blood-brain barrier (BBB).","Cabazitaxel | 1-hydroxy-7beta,10beta-dimethoxy-9-oxo-5beta,20-epoxytax-11-ene-2alpha,4,13alpha-triyl 4-acetate 2-benzoate 13-[(2R,3S)-3-{[(tertbutoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoate] | CABAZITAXEL | Jevtana | RPR 116258A | RPR-116258A | RPR116258A | TXD 258 | TXD-258 | TXD258 | Taxoid XRP6258 | XRP 6258 | XRP-6258 | XRP6258 | cabazitaxel | taxoid XRP6258",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700578","Prazosin Hydrochloride","C1507","A synthetic piperazine derivative with hypotensive antiadrenergic properties, Prazosin Hydrochloride reduces peripheral resistance and relaxes vascular smooth muscles as a selective adrenergic alpha-1 antagonist by a mechanism not completely known. It is used in the treatment of heart failure, hypertension, pheochromocytoma, Raynaud's syndrome, prostatic hypertrophy, and urinary retention. (NCI04)","Prazosin Hydrochloride | Alpress LP | CP-12299-1 | Duramipress | Eurex | Hypovase | Minipress | PRAZOSIN HYDROCHLORIDE | Peripress | Prazosin hydrochloride | Sinetens",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037874","Spermine","C106406","A polyamine that has a similar structure to tetradecane but the carbons at positions 1, 5, 10 and 14 are replaced by nitrogens. Spermine plays a broad role in cellular metabolic processes.","Spermine |  1,4-Butanediamine, N,N'-Bis(3-Aminopropyl)- | 1,4-Bis(Aminopropyl) Butanediamine | 1,4-Bis(Aminopropyl)Butanediamine | 1,4-Butanediamine, N,N'-Bis(3-Aminopropyl)- | 1,4-Butanediamine, N1,N4-Bis(3-Aminopropyl)- | 1,4-Diaminobutane, N,N'-Bis(3-Aminopropyl)- | 4,9-Diaza-1,12-Dodecanediamine | 4,9-Diazadodecamethylenediamine | Diaminopropyltetramethylenediamine | N,N'-Bis(3-Aminopropyl)-1,4-Butanediamine | SPERMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412398","ANGPT4 Gene","C106488","This gene plays a role in both vascular development and angiogenesis.","ANGPT4 Gene | ANGPT4 | Angiopoietin 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412399","ANGPTL1 Gene","C106472","This gene is involved in the regulation of hematopoietic stem cells.","ANGPTL1 Gene | ANGPTL1 | Angiopoietin-Like 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025746","Methylene Blue","C644","A synthetic basic dye. Methylene blue stains to negatively charged cell components like nucleic acids; when administered in the lymphatic bed of a tumor during oncologic surgery, methylene blue may stain lymph nodes draining from the tumor, thereby aiding in the visual localization of tumor sentinel lymph nodes. When administered intravenously in low doses, this agent may convert methemoglobin to hemoglobin.","Methylene Blue | Azul Metile | Azul de Metileno | Blu di Metilene | CI Basic Blue 9 | CI-52015 | Collubleu | Colour Index No. 52015 | Desmoidpillen | METHYLENE BLUE | Methylene blue | Methylenum Caeruleum | Methylthioninii Chloridum | Methylthioninium Chloride | Methylthioninium chloride | Schultz No. 1038 | Tetramethylthionine Chloride Trihydrate | Urolene Blue | Vitableu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0063908","Isosulfan Blue","C1386","A synthetic visual lymphatic imaging agent.  Injected into the periphery of the tumor site, isosulfan blue localizes to the lymphatic system and aids in the surgical identification of tumor sentinel nodes which stain blue. (NCI04)","Isosulfan Blue | ISOSULFAN BLUE | Lymphazurin | N-[4-[(4-(diethylamino)phenyl)(2,5-disulfophenyl)methylene]-2,5-cyclohexadien-1-ylidene]-N-ethyl-ethanaminium hydroxide | isosulfan blue",,,,,,,,,,,,,,,"4162990","Isosulfan blue",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1443145","BPI Gene","C106600","This gene is involved in lipopolysaccharide binding.","BPI Gene | BPI | Bactericidal/Permeability-Increasing Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413233","CD63 Gene","C106591","This gene is involved in signal transduction.","CD63 Gene | CD63 | CD63 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413844","CYBB Gene","C106594","This gene plays a role in the generation of superoxide in phagocytes.","CYBB Gene | CYBB | Cytochrome B-245 Beta Chain Gene | Cytochrome B-245, Beta Polypeptide Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414044","DHH Gene","C106442","This gene plays a role in regulating morphogenesis.","DHH Gene | DHH | Desert Hedgehog Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414070","DLL1 Gene","C106582","This gene is involved in notch signaling.","DLL1 Gene | DLL1 | Delta-Like 1 (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423876","DTX2 Gene","C106465","This gene plays a role in regulation of cell-cell communication.","DTX2 Gene | DTX2 | Deltex Homolog 2 (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414990","GAS1 Gene","C106451","This gene plays a role in cell growth suppression.","GAS1 Gene | GAS1 | Growth Arrest-Specific 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416377","IHH Gene","C106445","This gene is involved in growth, patterning and morphogenesis.","IHH Gene | IHH | Indian Hedgehog Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2675234","MACC1 Gene","C106603","This gene plays a role in regulation of the hepatocyte growth factor receptor pathway.","MACC1 Gene | MACC1 | Metastasis Associated in Colon Cancer 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417014","MAP3K5 Gene","C106620","This gene is involved in the MAP kinase signal transduction pathway.","MAP3K5 Gene | MAP3K5 | Mitogen-Activated Protein Kinase Kinase Kinase 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2743231","MicroRNA 124","C106407","A 20 ribonucleotide sequence that is a final product of the processing of either MIR124-1 pre-miRNA, MIR124-2 pre-miRNA or MIR124-3 pre-miRNA. This oligonucleotide may be involved in the negative regulation of gene expression.","MicroRNA 124 | MIR124 | MIRN124 | hsa-miR-124 | hsa-miR-124-3p | hsa-miR-124a | miR-124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0412375","Lymphoscintigraphy","C67262","A method used to check the lymph system for disease. A radioactive substance that flows through the lymph ducts and can be taken up by lymph nodes is injected into the body. A scanner or probe is used to follow the movement of this substance on a computer screen. Lymphoscintigraphy is used to find the sentinel lymph node (the first node to receive lymph from a tumor), which may be removed and checked for tumor cells. Lymphoscintigraphy is also used to diagnose certain diseases or conditions, such as lymphoma or lymphedema.","Lymphoscintigraphy | lymphoscintigraphy",,,,,,,,,,,,,,,"4060609","Radioisotope scan of lymphatic system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0810208","Quadrantectomy","C15695","The surgical removal of one quarter of the tissue in a breast tissue, including ipsilateral chest wall muscles within a given margin of the tumor.","Quadrantectomy | quadrantectomy",,,,,,,,,,,,,,,"4065449","Quadrantectomy of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3826848","Total Skin-Sparing Mastectomy","C106320","Mastectomy with preservation of the breast skin and the skin of the nipple and areola.","Total Skin-Sparing Mastectomy | TSSM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376260","17-Alpha-Hydroxypregnenolone","C107138","An endogenous steroid hormone synthesized by the hydroxylation of pregnenolone, which can act either as a neuroactive steroid or as a prohormone for progestogens, mineralocorticoids, glucocorticoids, androgens, estrogens, and the neuroactive steroids.","17-Alpha-Hydroxypregnenolone | 17-HYDROXYPREGNENOLONE | 17-Hydroxypregnenolone | 17-OH-Pregnenolone | 17a-Pregnenolone | 3-Beta,17-Alpha-Dihydroxypregn-5-En-20-One | 3-Beta,17-Dihydroxypregn-5-En-20-One | 5-Pregnen-3Beta,17Alpha-Diol-20-One | Pregn-5-En-20-One, 3-Beta,17-Dihydroxy-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0073815","3-Hydroxypropylmercapturic Acid","C107144","A modified form of acetylcysteine that is a metabolite of acrolein and may be found in the urine of smokers.","3-Hydroxypropylmercapturic Acid | 1-(N-Acetylcysteinyl)-Propan-3-Ol | 2-(N-Acetylcysteinyl)Butan-4-Ol | 2-Acetamido-3-(3'-Hydroxypropylthio)Propanoic Acid | 3-HPMA | 3-Hydroxypropyl Mercapturic Acid | 4-Hydroxybut-2-Yl Mercapturic Acid | HBMA | HPMA | N-Acetyl-S-(3-Hydroxypropyl)Cysteine | S-(3-Hydroxypropyl)Cysteine N-Acetate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831769","4-Hydroxybut-2-Ylmercapturic Acid","C107145","A modified form of acetylcysteine that is a metabolite of crotonaldehyde and may be found in the urine of smokers.","4-Hydroxybut-2-Ylmercapturic Acid | 2-(N-Acetylcysteinyl)Butan-4-Ol | 4-Hydroxybut-2-Yl Mercapturic Acid | HBMA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412125","ACLY Gene","C107107","This gene is involved in acetyl-CoA metabolism.","ACLY Gene | ACLY | ATP Citrate Lyase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831543","AMP-Activated Protein Kinase Beta","C107149","A family of proteins that function as a regulatory beta subunit for the 5'-AMP-activated protein kinase (AMPK) protein complex. AMPK is a heterotrimeric protein kinase complex that plays a key role in regulating cellular energy metabolism and is comprised of a catalytic alpha subunit and non-catalytic beta and gamma subunits. The beta subunit exists as two isoforms, each is encoded by a separate gene.","AMP-Activated Protein Kinase Beta | 5' AMP-Activated Protein Kinase Beta | 5' Adenosine Monophosphate-Activated Protein Kinase Beta | 5'-AMP-Activated Protein Kinase Beta | 5'-AMP-Activated Protein Kinase Subunit Beta | AMP-Activated Protein Kinase Beta | AMPK Subunit Beta | AMPKb | AMPKbeta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413379","CHD1 Gene","C107119","This gene is involved in the modification of chromatin structure.","CHD1 Gene | CHD1 | Chromodomain Helicase DNA Binding Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413592","COL7A1 Gene","C107113","This gene is involved in the organization of the epithelial basement membrane.","COL7A1 Gene | COL7A1 | Collagen Type VII Alpha 1 Chain Gene | Collagen, Type VII, Alpha 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0045968","Crotonaldehyde","C107141","An unsaturated aldehyde with commercial applications, including the manufacture of sorbic acid, that is also found in tobacco smoke, gasoline and diesel engine exhausts, and smoke from wood burning. Airborne exposure to this chemical can cause eyes, nose, throat, and lung irritation.","Crotonaldehyde | 1-Formylpropene | 2-Butenal | 2-Butenaldehyd | 2-Butenaldehyde | 3-Methylacrolein | Beta-Methylacrolein | CROTONALDEHYDE | Crotonal | Crotonic Aldehyde | Crotylaldehyde | Methylpropenal | Propylene Aldehyde",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830332","EGFR NP_005219.2:p.G719X","C107154","A change in the amino acid residue at position 719 in the epidermal growth factor receptor protein where glycine has been replaced by another amino acid.","EGFR NP_005219.2:p.G719X | Activating G719X Mutation | EGFR G719 Mutation | EGFR G719X | EGFR Gly719Xxx | EGFR NP_005219.2:p.Gly719Xxx | EGFR exon 18 G719X | EGFR p.G719X | Epidermal Growth Factor Receptor G719X | Exon 18 Gly719 | NP_005219.2:p.G719X | NP_005219.2:p.Gly719Xxx | Proto-Oncogene c-ErbB-1 G719X | Receptor Tyrosine-Protein Kinase erbB-1 G719X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414830","FST Gene","C107131","This gene is involved in the regulation of cell growth.","FST Gene | FST | Follistatin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421924","GABARAPL2 Gene","C107116","This gene plays a role in intra-Golgi trafficking.","GABARAPL2 Gene | GABA(A) Receptor-Associated Protein-Like 2 Gene | GABARAPL2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0049060","Androstanedione","C107155","A steroid hormone that is a mixture of alpha and beta isomers, which have different orientations for the hydrogen group at position 5. 5alpha-androstanedione is a metabolic precursor for both testosterone and estrone.","Androstanedione | Androstane-3,17-Dione | DIHYDROANDROSTENEDIONE | Dihydroandrostenedione | Etiocholane-3,17-Dione",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0769262","Glutathione S-Transferase Alpha","C107147","A homo- or heterodimeric form of the glutathione S-transferase enzyme that is comprised of two alpha family subunits.","Glutathione S-Transferase Alpha | GST-Alpha | GSTA | hGSTA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1741266","GSTM2-2 protein, human","C107148","A homo- or heterodimeric form of the glutathione S-transferase enzyme that is comprised of two mu family subunits.","Glutathione S-Transferase Mu | GST-Mu | GSTM | hGSTM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829687","H3K27me2","C107151","A post-translationally modified form of histone H3 where the lysine residue at position 28 is dimethylated. This modification may be a marker for transcriptional repression.","Histone H3 Dimethyl Lys28 | H3K27me2 | H3K27me2 Antigen | H3K28me2 | Histone H3 Dimethyl Lys27 | Histone H3 Dimethyl Lys27 | Histone H3 Dimethyl Lysine 28",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829686","Histone H3 Dimethyl Lys4","C107152","A post-translationally modified form of histone H3 where the lysine residue at position 4 is dimethylated. This modification may be a marker for transcriptionally active genes.","Histone H3 Dimethyl Lys4 | H3K4me2 | H3K4me2 Antigen | Histone H3 Dimethyl Lysine 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829683","Histone H3 Trimethyl Lys4","C107153","A post-translationally modified form of histone H3 where the lysine residue at position 4 is trimethylated. This modification may be a marker for areas of active gene expression.","Histone H3 Trimethyl Lys4 | H3K4me3 | H3K4me3 Antigen | Histone H3 Trimethyl Lysine 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0045010","Hydroxyprogesterone","C87242","A physiological progestin that is produced during glucocorticoid and steroid hormone synthesis and is increased during the third trimester of pregnancy. Hydroxyprogesterone binds to the cytoplasmic progesterone receptors in the reproductive system and subsequently activates progesterone receptor mediated gene expression.","Hydroxyprogesterone | 17-Alpha-Hydroxyprogesterone | 17-Hydroxypregn-4-Ene-3,20-Dione | 17-Hydroxyprogesterone | 17-OH Progesterone | 17.Alpha.-Hydroxyprogesterone | 17Alpha-Hydroxyprogesterone | 17OHP | 17alpha-Hydroxyprogesterone | Alpha Hydroxy Progesterone | Delta(4)-Pregnene-17Alpha-Ol-3,20-Dione | HYDROXYPROGESTERONE | Pregn-4-Ene-3,20-Dione, 17-Hydroxy-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416493","ITGAE Gene","C107128","This gene plays a role in cell adhesion.","ITGAE Gene | Alpha Polypeptide) Gene | ITGAE | Integrin, Alpha E (Antigen CD103, Human Mucosal Lymphocyte Antigen 1 | Integrin, Alpha E (Antigen CD103, Human Mucosal Lymphocyte Antigen 1; Alpha Polypeptide) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829377","Kinome Response Profile","C107137","A protein expression profile to define and quantitate the activity and drug responsiveness of the expressed kinome.","Kinome Response Profile | Kinome Response Signature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517807","Leukemic Hematopoietic Stem Cell","C41069","A malignant hematopoietic cell which may derive from mutations in normal hematopoietic stem cells. Leukemic hematopoietic stem cells can initiate or sustain neoplastic hematopoietic diseases because they are able to both proliferate and give rise to other malignant cells.","Leukemic Hematopoietic Stem Cell | LSC | Leukemic Stem Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417146","MGST2 Gene","C107110","This gene plays a role in the metabolism of leukotriene C4.","MGST2 Gene | MGST2 | Microsomal Glutathione S-Transferase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828973","Monohydroxybutylmercapturic Acid","C107143","A modified form of acetylcysteine that is a metabolite of 1,3-butadiene and may be found in the urine of smokers.","Monohydroxybutylmercapturic Acid | MHBMA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0067666","N-Acetyl-S-(2-Hydroxyethyl)Cysteine","C107146","A modified form of acetylcysteine that is a metabolite of ethylene oxide and may be found in the urine of smokers.","N-Acetyl-S-(2-Hydroxyethyl)Cysteine | (N-Acetylcysteinyl)Ethanol | 2-Hydroxyethyl Mercapturic Acid | 2-Hydroxyethylmercapturic Acid | Alanine, N-Acetyl-3-((2-Hydroxyethyl)Thio)- | HEMA | N-ACETYL-S-(2-HYDROXYETHYL)-L-CYSTEINE | N-Acetyl-S-2-Hydroxyethyl-L-Cysteine | S-(Beta-Hydroxyethyl)Mercapturic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417614","NDN Gene","C107134","This gene plays a role in cell cycle arrest.","NDN Gene | NDN | Necdin, MAGE Family Member Gene | Necdin, Melanoma Antigen (MAGE) Family Member Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421970","NID2 Gene","C107104","This gene plays a structural role in the basement membrane.","NID2 Gene | NID2 | Nidogen 2 (Osteonidogen) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0949791","Organic Anion Transport Polypeptides","C107150","A family of transmembrane proteins that play a role in the transport of organic anions including bile acids and bilirubin.","Organic Anion Transporter Protein | OATP | Organic Anion Transport Protein | Organic Anion Transporter | Organic Anion Transporting Polypeptide | Organic Anion-Transporting Polypeptide | SLCO | Solute Carrier Organic Anion | Solute Carrier Organic Anion; ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3181403","Phenanthrene Tetraol","C107140","A class of chemicals that are products of polycyclic aromatic hydrocarbon metabolism.","Phenanthrene Tetraol | Phe-Tetraol | Phenanthrene Tetraols",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538639","PHLPP2 Gene","C107125","This gene is involved in the regulation of apoptosis.","PHLPP2 Gene | PH Domain and Leucine Rich Repeat Protein Phosphatase 2 Gene | PHLPP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0073904","S-Phenyl-N-Acetylcysteine","C107142","A modified form of acetylcysteine that is a metabolite of benzene and may be found in the urine of smokers.","S-Phenyl-N-Acetylcysteine | 2-Acetamido-3-Phenylthiopropanoic Acid | L-Cysteine, N-Acetyl-S-Phenyl- | Phenylmercapturic Acid | S-Benzyl Mercapturic Acid | S-Phenylmercapturic Acid | SPMA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1997268","Skin-Sparing Mastectomy","C107211","Removal of the breast tissue, nipple, areola, and original biopsy scar, but not the breast skin.","Skin-Sparing Mastectomy | ",,,,,,,,,,,,,,,"4324062","Skin sparing mastectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016356","Fluoroscopy","C16588","Examination of the tissues and deep structures of the body by x-ray, using the fluoroscope, a device that produces an image when x-rays strike a fluorescent screen.","Fluoroscopy | FLUOROSCOPY | RF | Radio Fluoroscopy | Radiographic Fluoroscopy | fluoroscopy",,,,,,,,,,,,,,,"4195288","Fluoroscopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1831733","Intratumoral Therapy","C62722","Direct administration of a therapeutic agent into a malignant tumor.","Intratumoral Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828844","NCCN Guidelines Distress Management Distress Thermometer Screening Tool Version 1.2011","C107156","A single-item question screening tool developed by the National Comprehensive Cancer Network (NCCN) Distress Management Panel used to identify patient distress coming from any source.","NCCN Guidelines Distress Management Distress Thermometer Screening Tool Version 1.2011 | NCCN Guidelines Version 1.2011 Distress Management Distress Thermometer Screening Tool",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827270","NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011","C107157","A screening tool developed by the National Comprehensive Cancer Network (NCCN) Distress Management Panel used to identify patient problems in five categories.","NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011 | NCCN Guidelines Version 1.2011 Distress Management Problem List Screening Tool",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830455","Distressed During the Past Week on a Scale of 0 to 10","C107158","A question about an individual's level of distress during the past week.","Distressed During the Past Week on a Scale of 0 to 10 | How distressed have you been during the past week on a scale of 0 to 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830424","Distress over Practical Problem with Child Care","C107162","A question about an individual's distress related to their practical problems with child care.","Distress over Practical Problem with Child Care | Practical Problems Child Care",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830423","Distress over Practical Problem with Housing","C107170","A question about an individual's distress related to their practical problems with housing.","Distress over Practical Problem with Housing | Practical Problems Housing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830422","Distress over Practical Problem with Insurance or Finances","C107171","A question about an individual's distress related to their practical problems with insurance or finances.","Distress over Practical Problem with Insurance or Finances | Practical Problems Insurance/Financial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830421","Distress over Practical Problem with Transportation","C107172","A question about an individual's distress related to their practical problems with transportation.","Distress over Practical Problem with Transportation | Practical Problems Transportation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830419","Distress over Practical Problem with Work or School","C107173","A question about an individual's distress related to their practical problems with work or school.","Distress over Practical Problem with Work or School | Practical Problems Work/School",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830420","Distress over Practical Problem with Treatment Decisions","C107174","A question about an individual's distress related to their practical problems with treatment decisions.","Distress over Practical Problem with Treatment Decisions | Practical Problems Treatment decisions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437176","Pharyngeal Squamous Cell Carcinoma","C102872","A squamous cell carcinoma that arises from the pharynx.","Pharyngeal Squamous Cell Carcinoma | Pharyngeal (including Hypopharyngeal and Oropharyngeal) squamous cell carcinoma | Pharyngeal Throat Squamous Cell Cancer | Pharyngeal squam. cell carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280297","Lip and Oral Cavity Squamous Cell Carcinoma","C42690","A squamous cell carcinoma arising from the lip or the oral cavity.  The oral cavity squamous cell carcinoma usually arises from the buccal mucosa, tongue, or gums.  It occurs predominantly in adults who use tobacco and alcohol and has a tendency to metastasize early to lymph nodes.","Lip and Oral Cavity Squamous Cell Carcinoma | Lip and Oral Cavity Squamous Cell Cancer | Lip and oral cavity squamous cell carcinoma | Lip/oral cavity squam. cell car.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280324","Laryngeal Squamous Cell Carcinoma","C4044","A squamous cell carcinoma that arises from the larynx.  It is the most common histologic type of laryngeal carcinoma.  It can arise from the glottis, supraglottic area, or it can be transglottic.  Glottic squamous cell carcinoma is the most frequent laryngeal carcinoma in the United States.  The symptoms, clinical behavior and the prognosis depend on the site of origin within the larynx.","Laryngeal Squamous Cell Carcinoma | Epidermoid Carcinoma of Larynx | Epidermoid Carcinoma of the Larynx | Laryngeal Conventional Squamous Cell Carcinoma | Laryngeal Epidermoid Carcinoma | Laryngeal Throat Squamous Cell Cancer | Laryngeal squamous cell carcinoma | Larynx Epidermoid Carcinoma | Larynx Squamous Cell Carcinoma | Squamous Cell Carcinoma of Larynx | Squamous Cell Carcinoma of the Larynx",,,,,,,,,,,,,,,"4237016","Squamous cell carcinoma of larynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0752079","Maximum Tolerated Dose","C94489","The highest dose of a drug or treatment that does not cause unacceptable side effects. The maximum tolerated dose is determined in clinical trials by testing increasing doses on different groups of people until the highest dose with acceptable side effects is found.","Maximum Tolerated Dose | MTD | maximum tolerated dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013218","Combination Drug Therapy","C16144","Drug therapy with two or more drugs given separately or together for a combined effect.","Combination Drug Therapy | Drug Therapy, Combination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830448","Distress over Family Problem of Dealing with Partner","C107176","A question about an individual's distress related to their family problems dealing with partner.","Distress over Family Problem of Dealing with Partner | Family Problems Dealing with partner",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830447","Distress over Family Problem with Ability to Have Children","C107177","A question about an individual's distress related to their family problems with the ability to have children.","Distress over Family Problem with Ability to Have Children | Family Problems Ability to have children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830446","Distress over Family Problem with Family Health Issues","C107178","A question about an individual's distress related to their family problems dealing with family health issues.","Distress over Family Problem with Family Health Issues | Family Problems Family health issues",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830454","Distress over Emotional Problem with Depression","C107179","A question about an individual's distress related to their emotional problems with depression.","Distress over Emotional Problem with Depression | Emotional Problems Depression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830453","Distress over Emotional Problem with Fear","C107180","A question about an individual's distress related to their emotional problems with fear.","Distress over Emotional Problem with Fear | Emotional Problems Fears",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830451","Distress over Emotional Problem with Nervousness","C107181","A question about an individual's distress related to their emotional problems with nervousness.","Distress over Emotional Problem with Nervousness | Emotional Problems Nervousness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827348","Distress over Emotional Problem with Sadness","C107182","A question about an individual's distress related to their emotional problems with sadness.","Distress over Emotional Problem with Sadness | Emotional Problems Sadness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830450","Distress over Emotional Problem with Worry","C107183","A question about an individual's distress related to their emotional problems with worry.","Distress over Emotional Problem with Worry | Emotional Problems Worry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830452","Distress over Emotional Problem with Loss of Interest in Usual Activities","C107184","A question about an individual's distress related to their emotional problems with loss of interest in usual activities.","Distress over Emotional Problem with Loss of Interest in Usual Activities | Emotional Problems Loss of interest in usual activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830418","Distress over Spiritual or Religious Concerns","C107185","A question about an individual's distress related to their spiritual or religious concerns.","Distress over Spiritual or Religious Concerns | Spiritual/religious concerns",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830444","Distress over Physical Problem with Appearance","C107186","A question about an individual's distress related to their physical problems with appearance.","Distress over Physical Problem with Appearance | Physical Problems Appearance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830443","Distress over Physical Problem with Bathing or Dressing","C107187","A question about an individual's distress related to their physical problems with bathing or dressing.","Distress over Physical Problem with Bathing or Dressing | Physical Problems Bathing/dressing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830442","Distress over Physical Problem with Breathing","C107189","A question about an individual's distress related to their physical problems with breathing.","Distress over Physical Problem with Breathing | Physical Problems Breathing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830441","Distress over Physical Problem with Changes in Urination","C107192","A question about an individual's distress related to their physical problems with changes in urination.","Distress over Physical Problem with Changes in Urination | Physical Problems Changes in urination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830440","Distress over Physical Problem with Constipation","C107193","A question about an individual's distress related to their physical problems with constipation.","Distress over Physical Problem with Constipation | Physical Problems Constipation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830439","Distress over Physical Problem with Diarrhea","C107194","A question about an individual's distress related to their physical problems with diarrhea.","Distress over Physical Problem with Diarrhea | Physical Problems Diarrhea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830436","Distress over Physical Problem with Eating","C107195","A question about an individual's distress related to their physical problems with eating.","Distress over Physical Problem with Eating | Physical Problems Eating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830435","Distress over Physical Problem with Fatigue","C107196","A question about an individual's distress related to their physical problems with fatigue.","Distress over Physical Problem with Fatigue | Physical Problems Fatigue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830434","Distress over Physical Problem with Feeling Swollen","C107197","A question about an individual's distress related to their physical problems with feeling swollen.","Distress over Physical Problem with Feeling Swollen | Physical Problems Feeling Swollen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830433","Distress over Physical Problem with Fevers","C107198","A question about an individual's distress related to their physical problems with fevers.","Distress over Physical Problem with Fevers | Physical Problems Fevers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827347","Distress over Physical Problem with Getting Around","C107199","A question about an individual's distress related to their physical problems with getting around.","Distress over Physical Problem with Getting Around | Physical Problems Getting around",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830432","Distress over Physical Problem with Indigestion","C107200","A question about an individual's distress related to their physical problems with indigestion.","Distress over Physical Problem with Indigestion | Physical Problems Indigestion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830431","Distress over Physical Problem with Memory or Concentration","C107201","A question about an individual's distress related to their physical problems with memory or concentration.","Distress over Physical Problem with Memory or Concentration | Physical Problems Memory/concentration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830430","Distress over Physical Problem with Mouth Sores","C107202","A question about an individual's distress related to their physical problems with mouth sores.","Distress over Physical Problem with Mouth Sores | Physical Problems Mouth sores",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830429","Distress over Physical Problem with Nausea","C107203","A question about an individual's distress related to their physical problems with nausea.","Distress over Physical Problem with Nausea | Physical Problems Nausea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830438","Distress over Physical Problem with Dry or Congested Nose","C107204","A question about an individual's distress related to their physical problems with nose dryness or congestion.","Distress over Physical Problem with Dry or Congested Nose | Physical Problems Nose dry/congested",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830428","Distress over Physical Problem with Pain","C107205","A question about an individual's distress related to their physical problems with pain.","Distress over Physical Problem with Pain | Physical Problems Pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830427","Distress over Physical Problem with Sexual Activity","C107206","A question about an individual's distress related to their physical problems with sexual activity.","Distress over Physical Problem with Sexual Activity | Physical Problems Sexual",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830437","Distress over Physical Problem with Dry or Itchy Skin","C107207","A question about an individual's distress related to their physical problems with skin dryness or itchiness.","Distress over Physical Problem with Dry or Itchy Skin | Physical Problems Skin dry/itchy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830426","Distress over Physical Problem with Sleep","C107208","A question about an individual's distress related to their physical problems with sleep.","Distress over Physical Problem with Sleep | Physical Problems Sleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830425","Distress over Physical Problem with Tingling in Hands or Feet","C107209","A question about an individual's distress related to their physical problems with tingling in hands or feet.","Distress over Physical Problem with Tingling in Hands or Feet | Physical Problems Tingling in hands/feet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830445","Distress over Other Problem","C107210","A question about an individual's distress related to other problems not included in the list.","Distress over Other Problem | Other Problems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420169","SLC28A1 Gene","C96049","This gene is involved in nucleotide transport.","SLC28A1 Gene | SLC28A1 | Solute Carrier Family 28 (Sodium-Coupled Nucleoside Transporter), Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420171","SLC29A1 Gene","C105061","This gene is involved in mediating the cellular uptake of nucleosides.","SLC29A1 Gene | SLC29A1 | Solute Carrier Family 29 Member 1 (Augustine Blood Group) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413934","DCTD Gene","C53650","This gene plays a role in pyrimidine nucleotide metabolism.","DCTD Gene | DCTD | dCMP Deaminase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333205","DCK Gene","C21221","This gene is involved in deoxyribonucleoside phosphorylation.","DCK Gene | DCK | Deoxycytidine Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413247","CDA Gene","C79076","This gene is involved in pyrimidine metabolism.","CDA Gene | CDA | Cytidine Deaminase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433990","l-Norepinephrine","C2321","A naturally occurring catecholamine hormone that functions as a neurotransmitter in the sympathetic nervous system. Norepinephrine directly stimulates adrenergic receptors. Stimulation of alpha-adrenergic receptors causes vasoconstriction of the radial smooth muscle of the iris, arteries, arterioles, veins, urinary bladder, and the sphincter of the gastrointestinal tract. Stimulation of beta-1 adrenergic receptors causes an increase in myocardial contractility, heart rate, automaticity, and atrioventricular (AV) conduction while stimulation of beta-2 adrenergic receptors causes bronchiolar and vascular smooth muscle dilatation.","l-Norepinephrine | (-)-alpha-(aminomethyl)-3,4-dihydroxybenzyl Alcohol | (R)-4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol | NOREPINEPHRINE | l-3,4-Dihydroxyphenylethanolamine | l-Arterenol | l-Noradrenaline",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518010","Low Dose Radiation Therapy","C15811","Radiotherapy using radioactive particles that deposit a low amount of energy by radiation per unit length of travel.","Low Dose Radiation Therapy | Low Dose Radiation | Low Dose Radiation | Low Dose Radiation Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639411","Homeostatic Model Assessment of Insulin Resistance","C100447","An assessment of beta-cell function and insulin resistance based on fasting blood glucose and insulin concentrations.","Homeostatic Model Assessment of Insulin Resistance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419281","RASGRF1 Gene","C42625","This gene is involved in signal transduction and putatively plays a role in long-term memory.","RASGRF1 Gene | RASGRF1 | Ras Protein Specific Guanine Nucleotide Releasing Factor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415320","GSK3A Gene","C42618","This gene is involved in carbohydrate metabolism, signal transduction and the regulation of apoptosis.","GSK3A Gene | GSK3A | Glycogen Synthase Kinase 3 Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0056695","Cyclic AMP-Responsive DNA-Binding Protein","C17286","Ubiquitously or widely expressed human cAMP Responsive Element Binding Proteins (bZIP/CREB Family) are conserved nuclear bZIP domain dimeric transcription factors that bind to octameric DNA palindrome cAMP-response elements (CRE) present in many viral and cellular promoters and induce gene transcription in response to cAMP signaling pathways. CREB proteins bind to DNA as a homodimer or a heterodimer with JUN/c-Jun or ATF2/CREBP1. Increased cAMP levels following stimulation activate cAMP-dependent protein kinase A, which phosphorylates CREB proteins that stimulate transcription of cAMP-responsive genes.  Calcium-regulated CREB transcription factors integrate calcium and cAMP signals.  cAMP pathways provide a chief means by which cellular growth, differentiation, and function can be influenced by extracellular signals. (NCI)","cAMP Responsive Element Binding Protein | CRE Binding Protein | CREB | CREB Protein | Cyclic AMP Responsive Element Binding Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424302","SUFU Gene","C97819","This gene plays a role in the regulation of both transcription and signaling.","SUFU Gene | SUFU | SUFU Negative Regulator uf Hedgehog Signaling Gene | Suppressor of Fused Homolog (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334080","IFNA2 Gene","C24482","This gene plays a role in signal transduction, the immune response and positive regulation of apoptosis.","IFNA2 Gene | IFNA2 | Interferon, Alpha 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085114","NF2 Gene","C17425","This gene plays a role in cell adhesion and cytoskeletal remodeling. It is also involved in suppression of cell growth.","NF2 Gene | NF2 | Neurofibromin 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086411","Histone H2b","C17460","Histone H2B is a core subunit of the eukaryotic nucleosome complex. Histones are basic nuclear proteins responsible for the nucleosome structure of chromatin. Repeating nucleosome units contain two molecules each of Histones H2A, H2B, H3, and H4 that form an octamer complex around which approximately 146 base pairs of DNA is wrapped. Linker Histone H1 interacts with DNA between nucleosome units in mediating chromatin compaction into higher order structures. (NCI)","Histone H2B | H2B | HISTONE H2B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032458","Polycyclic Hydrocarbons, Aromatic","C761","Polycyclic aromatic hydrocarbons (PAH) are a large class of organic compounds containing two or more fused aromatic rings made up of carbon and hydrogen atoms. They have high melting and boiling-points, low vapour pressure, water solubility, and are highly lipophilic. PAH are produced during incomplete combustion or pyrolysis of organic matter, are found in cigarette smoke, motor vehicle exhaust, used motor lubricating oil, broiled meat, coal tar, crude oil, creosote, roofing tar, dyes, plastics, and pesticides. Some members of PAH class were shown to have carcinogenic, genotoxic, and immunotoxic properties, developmental toxicity and affect reproductive health. (NCI)","Polycyclic Aromatic Hydrocarbons | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883311","Thousand Cells","C67245","A unit of cell count expressed in thousands.","Thousand Cells | 10E3 Cells | 10^3 Cells | 10^3{Cells} | thousand cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699156","Cells per Milliliter","C74919","A unit of cell concentration expressed in cells per unit of volume equal to one milliliter.","Cells per Milliliter | Cells/Milliliter | Cells/mL | cells/cm3 | cells/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825692","TET2 Gene","C95252","This gene is involved in oxidation.","TET2 Gene | TET2 | Tet Methylcytosine Dioxygenase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414123","DNMT3A Gene","C73652","This gene is involved in epigenetic modification of DNA.","DNMT3A Gene | DNA Methyltransferase 3 Alpha Gene | DNMT3A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828706","Oncoplastic Partial Mastectomy/Lumpectomy with Oncoplastic Closure","C107212","A surgical procedure in which there is full-thickness excision of the malignant breast tumor and surrounding breast parenchyma to allow resection with wide surgical margins, while the remaining fibroglandular breast tissue is transposed to preserve the breast shape and cosmetic appearance in the best possible way.","Oncoplastic Partial Mastectomy/Lumpectomy with Oncoplastic Closure | Oncoplastic Surgery | Oncoplastic Surgical Procedure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021549","Inositol 1,4,5-Trisphosphate","C580","A phosphatidylinositol with phosphate covalently bound in the 4 and 5 positions of the inositol group. Inositol 1,4,5-trisphosphate acts as an intermediate in the IP3/DAG pathway, hydrolyzed by phospholipase C and liberating diacylglycerol and PIP2, which activate Protein Kinase C and calcium release from the endoplasmic reticulum, respectively.","Inositol 1,4,5-Trisphosphate | IP3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366753","STAT protein","C19618","A family of cytoplasmic proteins that are activated by phosphorylation in response to a large number of cytokines, growth factors, and hormones. They dimerize and translocate to the nucleus upon activation, where they bind to regulatory cis-elements of specific target genes.","Signal Transducer and Activator of Transcription | STAT | STAT Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919458","ABCC1 Gene","C18525","This gene plays a role in multi-drug resistance and organic anion transport.","ABCC1 Gene | ABCC1 | ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420368","SPOP Gene","C102534","This gene is involved in protein ubiquitination, which often leads to proteasomal degradation.","SPOP Gene | SPOP | Speckle Type BTB/POZ Protein Gene | Speckle-Type POZ Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538638","PHLPP1 Gene","C101355","This gene plays a role in the dephosphorylation of proteins.","PHLPP1 Gene | PH Domain and Leucine Rich Repeat Protein Phosphatase 1 Gene | PHLPP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537486","KLF6 Gene","C97448","This gene plays a role in transcriptional activation.","KLF6 Gene | KLF6 | Kruppel-Like Factor 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422386","HDAC9 Gene","C102492","This gene plays a role in chromatin modification.","HDAC9 Gene | HDAC9 | Histone Deacetylase 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424568","CHD5 Gene","C68557","This gene is involved in both chromatin structure regulation and tumor suppression.","CHD5 Gene | CHD5 | Chromodomain Helicase DNA Binding Protein 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274186","EGFR NP_005219.2:p.L861Q","C98497","A change in the amino acid residue at position 861 in the epidermal growth factor receptor protein where leucine has been replaced by glutamine.","EGFR NP_005219.2:p.L861Q | Activating L861Q Mutation | EGFR Exon 21 L861Q | EGFR L861Q | EGFR Leu861Gln | EGFR NP_005219.2:p.Leu861Gln | EGFR p.L861Q | EGFR p.Leu861Gln | Epidermal Growth Factor Receptor L861Q | NP_005219.2:p.Leu861Gln | Proto-Oncogene c-ErbB-1 L861Q | Receptor Tyrosine-Protein Kinase erbB-1 L861Q",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002865","Androsterone","C29783","A steroid metabolite derived from sex hormones, which displays weak androgenic properties.  In testes is formed from progesterone.  Androsterone sulfate is clinically recognized as one of the major androgen metabolites found in urine, in males and females.  It is made in the liver from the metabolism of testosterone.  Androsterone glucuronide, a dihydrotestosterone metabolite, is present in serum.  Androsterone is a weak anabolic hormone. (NCI04)","Androsterone | 3-Epihydroxyetioallocholan-17-one | ANDROSTERONE | Androtine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3152112","mTORC2","C96315","A protein complex that is involved in both serine/threonine phosphorylation and cytoskeleton remodeling in response to cellular stress.","mTORC2 | Mammalian Target of Rapamycin Complex 2 | Rictor-mTOR | Rictor/TORC2 | TOR Complex 2 | TORC2 | Target of Rapamycin Complex 2 | mTOR Complex 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3888046","mTORC1","C96314","A protein complex that is involved in the both serine/threonine phosphorylation and the regulation of protein synthesis in response to cellular stress.","mTORC1 | Mammalian Target of Rapamycin Complex 1 | Raptor-mTOR | Raptor/TORC1 | TOR Complex 1 | TORC1 | Target of Rapamycin Complex 1 | mTOR Complex 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015087","Ethylene Oxide","C29821","Colorless, odorless, flammable, toxic gaseous cyclic ether with a sweet ether-like smell. Ethylene oxide is used especially in the synthesis of ethylene glycol and as a sterilizing agent for medical supplies and foods, as a fumigant and as an insecticide. Exposure to this substance is highly irritating to the eyes, skin and respiratory tract, induces nausea and vomiting and causes central nervous system depression. Ethylene oxide is mutagenic in humans and chronic exposure is associated with an increased risk of leukemia, stomach cancer, pancreatic cancer and non-Hodgkin lymphoma. (NCI05)","Ethylene Oxide | 1,2-Epoxyethane | ETHYLENE OXIDE | Oxirane",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043902","1,3-Butadiene","C29790","A synthetic, colorless gas that is practically insoluble in water and soluble in ethanol, ether, acetone and benzene. It is used primarily as a monomer to manufacture many different types of polymers and copolymers and as a chemical intermediate in the production of industrial chemicals. When heated, 1,3-butadiene emits acrid fumes and is flammable. In the presence of air, it oxidizes to form explosive peroxides. The primary route of potential human exposure to this compound is inhalation. Acute exposure to 1,3-butadiene can cause irritation of the eyes, nasal passages and throat. At very high concentrations, inhalation of this gas can result in headache, fatigue, decreased blood pressure and pulse rate, central nervous system damage and unconsciousness. It is known to be a human carcinogen. (NCI05)","1,3-Butadiene | 1,3-BUTADIENE | Biethylene | Bivinyl | Divinyl | Erythrene | Vinylethylene | alpha, gamma-butadiene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1364081","MERTK Gene","C24591","This gene plays a role in tissue homeostasis and mutations in the gene are associated with the onset of autosomal recessive retinitis pigmentosa.","MERTK Gene | C-MER Proto-Oncogene Tyrosine Kinase Gene | MERTK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424881","DAB2IP Gene","C107122","This gene may play a role in tumor suppression.","DAB2IP Gene | DAB2 Interacting Protein Gene | DAB2IP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816728","Dose Escalation","C107213","A stepwise increase in the amount of a therapeutic or investigational agent given to an individual.","Dose Escalation | Dose-Escalation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708513","Injector System Device Component","C50316","A system designed to pump a gas or liquid into a space or environment.","Injection System Device | Injection System | Injection System Device Component | Injector System | Injector System Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516609","Clinical Endocrinology","C18700","The clinical specialty of endocrinology that focuses on the endocrine organs and their role in physiology and pathology.","Clinical Endocrinology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034060","Pulmonary Medicine","C105692","A medical specialty concerned with diagnosis and treatment of lung disorders and other breathing problems.","Pulmonary Medicine | Pulmonary | Pulmonology",,,,,,,,,,,,,,,"4167031","Pulmonary medicine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0191925","Augmentation Mammoplasty","C107225","A surgical procedure for increasing breast size using a prosthetic implant.","Augmentation Mammoplasty | Breast Augmentation",,,,,,,,,,,,,,,"4119274","Augmentation mammoplasty",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4083201","Patient Health Questionnaire - 9 Item","C103526","A 9-item scale using each of the 9 DSM-IV criteria with self-reported frequency of '0' (not at all) to '3' (nearly every day). One of the most widely used instruments to assess depression, PHQ-9 scores of 5, 10, 15, and 20 represent mild, moderate, moderately severe, and severe depression, respectively.","Patient Health Questionnaire - 9 Item | PHQ-9 | PHQ01 | Patient Health Questionnaire (PHQ-9) | Patient Health Questionnaire-9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829268","Little Interest or Pleasure in Doing Things","C107214","A question about whether an individual has or had little interest or pleasure in doing things.","Little Interest or Pleasure in Doing Things | Little interest or pleasure in doing things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828516","Poor Appetite or Overeating","C107215","A question about whether an individual has or had a poor appetite or was overeating.","Poor Appetite or Overeating | Poor appetite or overeating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830158","Feeling Bad about Yourself or Feeling Like a Failure or Have Let Yourself or Your Family Down","C107216","A question about whether an individual feels or felt bad about oneself or that one is a failure or has let oneself or their family down.","Feeling Bad about Yourself or Feeling Like a Failure or Have Let Yourself or Your Family Down | Feeling bad about yourself or that you are a failure or have let yourself or your family down",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828947","Moving or Speaking So Slowly that Other People Could Have Noticed","C107217","A question about whether an individual has or has been moving or speaking so slowly that other people could have noticed.","Moving or Speaking So Slowly that Other People Could Have Noticed | Moving or speaking so slowly that other people could have noticed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827996","So Fidgety or Restless that You Have Been Moving around More","C107218","A question about whether an individual was being so fidgety or restless that it seemed that one has been moving around more.","So Fidgety or Restless that You Have Been Moving around More | Being so fidgety or restless that you have been moving around more",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827834","Thoughts You Would be Better Off Dead or Hurting Yourself Some Way","C107219","A question about whether an individual has or had thoughts that one would be better off dead or of hurting oneself in some way.","Thoughts You Would be Better Off Dead or Hurting Yourself Some Way | Thoughts that you would be better off dead or of hurting yourself in some way",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828472","Problems Made It Difficult to Do Work, Take Care of Things at Home, or Get Along with Other People","C107220","A question about how difficult an individual's problems have made it to do their work, take care of things at home, or get along with other people.","Problems Made It Difficult to Do Work, Take Care of Things at Home, or Get Along with Other People | How difficult have these problems made it for you to do your work, take care of things at home, or get along with other people | Problems Make It Difficult to Do Work, Take Care of Things at Home, or Get Along with Other People",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828960","More than Half the Days","C107223","A time period that includes one-half of the total number of days plus at least one more.","More than Half the Days | More than one-half the days | Over half the days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828842","Nearly","C107222","Not quite or just short of.","Nearly | Almost",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443302","Several","C107221","An indefinite small quantity that is more than two but less than many.","Several | ",,,,,,,,,,,,,,,"4126856","Several",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040558","Toxoplasmosis","C3418","A parasitic disease contracted by the ingestion or fetal transmission of toxoplasma gondii.","Toxoplasmosis | ",,,,,,,,,,,,,,,"440653","Toxoplasmosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3826974","Neck Dissection Impairment Index","C107226","A health-related instrument to identify the factors that affect quality of life related to shoulder dysfunction following neck dissection for head and neck cancers.","Neck Dissection Impairment Index | NDII",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827326","Bothered by Neck or Shoulder Pain or Discomfort","C107227","A question about whether an individual is or was bothered by neck or shoulder pain or discomfort.","Bothered by Neck or Shoulder Pain or Discomfort | Are you bothered by neck or shoulder pain or discomfort",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831297","Bothered by Shoulder Stiffness","C107228","A question about whether an individual is or was bothered by shoulder stiffness.","Bothered by Shoulder Stiffness | Are you bothered by shoulder stiffness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831306","Bothered by Difficulty with Self-Care Activities Because of Neck or Shoulder","C107229","A question about whether an individual is or was bothered by difficulty with self-care activities because of their neck or shoulder.","Bothered by Difficulty with Self-Care Activities Because of Neck or Shoulder | Are you bothered by difficulty with self-care activities because of your neck or shoulder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829278","Limited in Ability to Lift Light Objects Because of Shoulder or Neck","C107230","A question about whether an individual is or was limited by their ability to lift light objects because of their shoulder or neck.","Limited in Ability to Lift Light Objects Because of Shoulder or Neck | Have you been limited in your ability to lift light objects because of your shoulder or neck",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827295","Limited in Ability to Lift Heavy Objects Because of Shoulder or Neck","C107231","A question about whether an individual is or was limited by their ability to lift heavy objects because of their shoulder or neck.","Limited in Ability to Lift Heavy Objects Because of Shoulder or Neck | Have you been limited in your ability to lift heavy objects because of your shoulder or neck",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829277","Limited in Ability to Reach above for Objects Because of Shoulder or Neck","C107232","A question about whether an individual is or was limited by their ability to reach above for objects because of their shoulder or neck.","Limited in Ability to Reach above for Objects Because of Shoulder or Neck | Have you been limited in your ability to reach above for objects because of your shoulder or neck",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831300","Bothered by Overall Activity Level Because of Shoulder or Neck","C107233","A question about whether an individual is or was bothered by overall activity level because of their shoulder or neck.","Bothered by Overall Activity Level Because of Shoulder or Neck Question | Are you bothered by your overall activity level because of your shoulder or neck | Bothered by Overall Activity Level Because of Shoulder or Neck | Bothered by Overall Activity Level Because of Shoulder or Neck",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827781","Treatment of Neck Affected Participation in Social Activities","C107234","A question about whether an individual's neck treatment affects or has affected their participation in social activities.","Treatment of Neck Affected Participation in Social Activities | Has the treatment of your neck affected your participation in social activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829279","Limited in Ability to do Work Because of Neck or Shoulder","C107236","A question about whether an individual is or was limited in doing work because of their neck or shoulder.","Limited in Ability to do Work Because of Neck or Shoulder | Have you been limited in your ability to do work because of your neck or shoulder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831118","Childbearing Potential","C106508","An indicator as to whether the female subject has the potential to become pregnant.","Childbearing Potential | CHILDPOT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828008","Burden","C85883","The quantity of something that is borne or carried by an individual or population.","Burden | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272878","Biological Paternal Cousin","C96582","A relative who is the offspring of a sibling of the biological father and thus sharing a common ancestor.","Biological Paternal Cousin | COUSIN, BIOLOGICAL PATERNAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272881","Biological Paternal Uncle","C96585","A male relative who is a sibling of the biological father, and who both share a common ancestor.","Biological Paternal Uncle | UNCLE, BIOLOGICAL PATERNAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272877","Biological Paternal Aunt","C96581","A female relative who is a sibling of the biological father, and who both share a common ancestor.","Biological Paternal Aunt | AUNT, BIOLOGICAL PATERNAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272873","Biological Maternal Cousin","C96576","A relative who is the offspring of a sibling of the biological mother and thus sharing a common ancestor.","Biological Maternal Cousin | COUSIN, BIOLOGICAL MATERNAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272876","Biological Maternal Uncle","C96579","A male relative who is a sibling of the biological mother, and who both share a common ancestor.","Biological Maternal Uncle | UNCLE, BIOLOGICAL MATERNAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272872","Biological Maternal Aunt","C96575","A female relative who is a sibling of the biological mother, and who both share a common ancestor.","Biological Maternal Aunt | AUNT, BIOLOGICAL MATERNAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337502","Biological Sibling","C100809","A person's brother or sister with whom they share a genetic makeup inherited from one or both of their shared biological parents.","Biological Sibling | Natural Sibling | SIBLING, BIOLOGICAL",,,,,,,,,,,,,,,"4218412","Natural sibling",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020095","HTLV-1 Antibody","C71691","An antibody produced by B lymphocytes in response to human T-cell leukemia virus type 1 infection.","HTLV-1 Antibody | Anti-HTLV-1 Antibody | Anti-HTLV-1Antibody | Anti-Human T-Lymphotropic Virus 1 Antibody | Anti-Human T-Lymphotropic Virus I Antibody | HTLV-I Antibody | Human T-Lymphotropic Virus 1 Antibody | Human T-Lymphotropic Virus I Antibody",,,,,,,,,,,,,,,"4025280","Human T-lymphotrophic virus type I antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3536731","Massage Therapy","C15276","A therapeutic method of manipulation, methodical pressure, friction, and kneading of the body. (from Taber's)","Massage Therapy | Massage | massage therapy",,,,,,,,,,,,,,,"4302819","Massage physiotherapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0596577","Flavonoid","C1745","One of a number of chemical compounds found in certain fruits, vegetables and seeds with antioxidant properties and potential antineoplastic properties. As polyphenolic, soluble plant pigments, flavonoids are usually subdivided into 5 subgroups flavonols, flavones, flavonones, flavan-3-ols, anthocyanidins.  Although not considered essential nutrients, some flavonoids may be beneficial to health by strengthening and protecting blood vessels and connective tissue and acting as anti-inflammatory, antihistaminic, and antiviral agents.  As antioxidants, some flavonoids may protect lipids from oxidative damage or retard the formation of cataracts. (NCI04)","Flavonoid | 2-Phenyl-Benzopyran | 2-Phenyl-Chromene | 3-Hydroxy-2-phenyl-4H-1-benzopyran-4-one | 3-Hydroxyflavone | Flavonol | Flavonols | flavonoid",,,,,,,,,,,,,,,"4312762","Flavonoid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706073","Table Device Component","C50371","A piece of furniture having a smooth flat top that is usually supported by one or more vertical legs, or any object of a similar appearance.","Table Device | Table | Table Device Component",,,,,,,,,,,,,,,"4314129","Table",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3874856","Generalized Anxiety Disorder - 7 Questionnaire","C103519","A seven item validated, self-reported questionnaire for screening, and assessing the severity of generalized anxiety disorder in clinical practice and research settings.","Generalized Anxiety Disorder - 7 Questionnaire | GAD-7 | GAD01 | General Anxiety Disorder-7 | General Anxiety Disorder-7 Questionnaire | Generalized Anxiety Disorder 7-item Scale (GAD-7)",,,,,,,,,,,,,,,"45772733","Generalized Anxiety Disorder 7 item scale",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829607","How Often Bothered by Problems","C107246","A question about how often an individual is or was bothered by problems.","How Often Bothered by Problems | How often bothered by problems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812214","Feeling Nervous, Anxious or on Edge","C107247","A question about whether an individual feels or felt nervous, anxious or on edge.","Feeling Nervous, Anxious or on Edge | Feeling Anxious | Feeling nervous, anxious or on edge",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828781","Not Able to Stop or Control Worrying","C107248","A question about whether an individual is not or was not able to stop or control worrying.","Not Able to Stop or Control Worrying Question | Not Able to Stop or Control Worrying | Not Able to Stop or Control Worrying | Not being able to stop or control worrying",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827445","Worrying too Much about Different Things","C107249","A question about whether an individual worries or worried too much about different things.","Worrying too Much about Different Things | Worrying too much about different things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827766","Trouble Relaxing","C107250","A question about whether an individual has or had trouble relaxing.","Trouble Relaxing | Trouble relaxing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831375","Being So Restless it is Hard to Sit Still","C107251","A question about whether an individual is or was so restless that it was hard to sit still.","Being So Restless it is Hard to Sit Still | Being so restless that it is hard to sit still",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831378","Becoming Easily Annoyed or Irritable","C107252","A question about whether an individual becomes or became easily annoyed or irritable.","Becoming Easily Annoyed or Irritable | Becoming easily annoyed or irritable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830159","Feeling Afraid as if Something Awful Might Happen","C107253","A question about whether an individual feels or felt afraid as if something awful might happen.","Feeling Afraid as if Something Awful Might Happen | Feeling afraid as if something awful might happen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829615","How Difficult have Problems Made it to do Work, Take Care of Things at Home, or Get Along with other People","C107254","A question about how difficult problems have made it for an individual to do work, take care of things at home, or get along with other people.","How Difficult have Problems Made it to do Work, Take Care of Things at Home, or Get Along with other People | How difficult have problems made it for you to do your work, take care of things at home, or get along with other people",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420342","SPARC Gene","C92666","This gene is involved in the regulation of cellular morphology, extracellular matrix deposition and cell cycle progression.","SPARC Gene | SPARC | Secreted Protein, Acidic, Cysteine-Rich (Osteonectin) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224362","Musculus Latissimus Dorsi","C33150","A triangular muscle in the back, connected to the vertebral column, arm, and shoulder. Its action involves adduction, medial rotation, and extension of the arm.","Musculus Latissimus Dorsi | LATISSIMUS DORSI MUSCLE | MUSCLE, LATISSIMUS","C49.3","Latissimus dorsi muscle",,,,,,,,,,,,,"4048566","Structure of latissimus dorsi muscle",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C3826983","MD Anderson Symptom Inventory - Core","C107378","A self-administered questionnaire designed to assess multiple symptoms experienced by cancer patients and the interference with daily living caused by these symptoms.","MD Anderson Symptom Inventory - Core | MD Anderson Symptom Inventory (Core MDASI) | MD Anderson Symptom Inventory (Core MDASI)  | MD Anderson Symptom Inventory - Core  | MDASI-Core",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826982","MD Anderson Symptom Inventory - Lung Chemoradiation","C107379","A self-administered questionnaire designed specifically for evaluating the severity of symptoms related to lung cancer and chemoradiation treatment.","MD Anderson Symptom Inventory - Lung Chemoradiation | MD Anderson Symptom Inventory - Lung Chemoradiation  | MD Anderson Symptom Inventory Lung Chemoradiation (MDASI-LC) | MD Anderson Symptom Inventory Lung Chemoradiation (MDASI-LC)  | MDASI-LC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830996","Coughing at its Worst","C107380","A question about an individual's coughing at its worst.","Coughing at its Worst | Your coughing at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827971","Sore Throat at its Worst","C107381","A question about an individual's sore throat at its worst.","Sore Throat at its Worst | Your sore throat at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827284","Difficulty Swallowing at its Worst","C107382","A question about an individual's difficulty swallowing at its worst.","Difficulty Swallowing at its Worst | Difficulty Swallowing at its Worst  | Your difficulty swallowing at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0961485","Eplerenone","C47513","A selective aldosterone receptor antagonist. Eplerenone binds to the mineralocorticoid receptor and blocks the binding of aldosterone, thereby decreasing sodium resorption and subsequently increasing water outflow. This leads to a decrease in blood pressure. Eplerenone is used in the treatment of hypertension and congestive heart failure.","Eplerenone | 9,11alpha-Epoxy-17-hydroxy-3-oxo-17alpha-pregn-4-ene-7alpha,21-dicarboxylic acid, gamma-lactone, Methyl Ester | EPLERENONE | Inspra",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1743502","Retaspimycin","C80378","A small-molecule inhibitor of heat shock protein 90 (HSP90) with antiproliferative and antineoplastic activities. Retaspimycin binds to and inhibits the cytosolic chaperone functions of HSP90, which maintains the stability and functional shape of many oncogenic signaling proteins and may be overexpressed or overactive in tumor cells. Retaspimycin-mediated inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins in susceptible tumor cell populations, which may result in the induction of apoptosis.","Retaspimycin | 17-Allylamino-17-demethoxygeldanamycin Hydroquinone | Geldanamycin, 18,21-didehydro-17-demethoxy-18,21-dideoxo-18,21-dihydroxy-17-(2-propenylamino)- | RETASPIMYCIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2830067","gamma secretase inhibitor PF-03084014","C82383","A selective gamma secretase (GS) inhibitor with antitumor activity. Upon administration, nirogacestat targets and binds to GS, thereby blocking the proteolytic activation of Notch receptors. This inhibits the Notch signaling pathway and results in the induction of apoptosis in tumor cells that overexpress Notch. The integral membrane protein GS is a multi-subunit protease complex that cleaves single-pass transmembrane proteins, such as Notch receptors, at residues within their transmembrane domains. Overexpression of the Notch signaling pathway has been correlated with increased tumor cell growth and survival.","Nirogacestat | (S)-2-(((S)-6,8-Difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide | Gamma Secretase Inhibitor PF-03084014 | NIROGACESTAT | PF 03084014 | PF-03084014 | PF03084014",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1568328","Dovitinib Lactate","C62435","The orally bioavailable lactate salt of a benzimidazole-quinolinone compound with potential antineoplastic activity. Dovitinib strongly binds to fibroblast growth factor receptor 3 (FGFR3) and inhibits its phosphorylation, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell death. In addition, this agent may inhibit other members of the RTK superfamily, including the vascular endothelial growth factor receptor; fibroblast growth factor receptor 1; platelet-derived growth factor receptor type 3; FMS-like tyrosine kinase 3; stem cell factor receptor (c-KIT); and colony-stimulating factor receptor 1; this may result in an additional reduction in cellular proliferation and angiogenesis, and the induction of tumor cell apoptosis. The activation of FGFR3 is associated with cell proliferation and survival in certain cancer cell types.","Dovitinib Lactate | 4-Amino-5-fluoro-3-(6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one mono 2-hydroxypropanoate Hydrate | CHIR 258 | CHIR-258 | CHIR258 | DOVITINIB LACTATE | RTK Inhibitor TKI258 | TKI 258 | TKI-258 | TKI258",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827736","Ultra Low Temperature Freezer","C107385","A type of freezer that can maintain temperatures between -80 and -86 degrees C.","Ultra Low Temperature Freezer | Ultra Cold Freezer | Ultra Low Freezer | Ultra-cold Freezer | Ultra-low Freezer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347927","Refrigerated Specimen","C70718","A specimen that has been kept or preserved at a low temperature in a refrigerator.","Refrigerated Specimen | REFRIGERATED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348236","Specimen at Room Temperature","C70719","A specimen that has been subjected to and adjusted to the average ambient temperature of a room, usually considered to be around 20 degrees C (68 degrees F).","Specimen at Room Temperature | Ambient | Ambient Temperature | Ambient Temperature Storage | ROOM TEMPERATURE | Room Temperature | Room Temperature Storage | Specimen at Ambient Temperature | Storage at Ambient Temperature | Storage at Room Temperature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0961209","Nepafenac","C66228","A topical nonsteroidal anti-inflammatory drug that is used in eye drops for the treatment of eye pain and swelling.","Nepafenac | NEPAFENAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009033","Clorazepate Dipotassium","C47459","A benzodiazepine with anxiolytic, sedative, hypnotic, and anticonvulsant properties. Clorazepate dipotassium exerts its effect by de-activating the nervous system through potentiation of the inhibitory effect of gamma-aminobutyric acid (GABA) on the GABA-A receptors by binding to a site that is distinct from the GABA binding site. Its inhibitory effect is caused by an increase in GABA-mediated chloride channel opening events, leading to hyperpolarization and synaptic inhibition.","Clorazepate Dipotassium | 1H-1,4-Benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-, Monopotassium Salt, compound with Potassium Hydroxide | CLORAZEPATE DIPOTASSIUM | Gen-Xene | Potassium 7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepine-3-carboxylate KOH | Tranxene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985640","Performed Imaging","C93428","The completed action of obtaining pictures of the interior or exterior of the body usually for diagnostic reasons.","Performed Imaging | PerformedImaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0595989","Laryngeal Carcinoma","C4855","Carcinoma that arises from the laryngeal epithelium. More than 90% of laryngeal carcinomas are squamous cell carcinomas. The remainder are adenoid cystic carcinomas, mucoepidermoid carcinomas and carcinomas with neuroendocrine differentiation.","Laryngeal Carcinoma | Cancer of Larynx | Cancer of the Larynx | Carcinoma of Larynx | Carcinoma of the Larynx | Laryngeal Cancer | Laryngeal Throat Cancer | Larynx Cancer | Larynx Carcinoma | laryngeal cancer",,,,,,,,,,,,,,,"4172359","Carcinoma of larynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1299240","Supraglottic Carcinoma","C5973","A carcinoma of the larynx that arises from the supraglottic area.","Supraglottic Carcinoma | Cancer of Supraglottis | Cancer of the Supraglottis | Carcinoma of Supraglottis | Carcinoma of the Supraglottis | Supraglottic Cancer | Supraglottic Throat Cancer | Supraglottis Carcinoma",,,,,,,,,,,,,,,"4162136","Carcinoma of supraglottis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0151546","Oral Cavity Carcinoma","C8990","A carcinoma arising in the oral cavity.  Most oral cavity carcinomas are squamous cell carcinomas of the tongue, buccal mucosa, or gums.  Less frequent morphologic variants include mucoepidermoid carcinoma and adenocarcinoma.","Oral Cavity Carcinoma | Carcinoma of Mouth | Carcinoma of Oral Cavity | Carcinoma of the Oral Cavity | Mouth Cancer | Mouth Carcinoma | Oral Cavity Cancer | oral cavity cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038940","Wound Breakdown","C35049","Disruption or deterioration of a surgical wound.","Wound Breakdown | ",,,,,,,,,,,,,,,"136580","Dehiscence of surgical wound",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704783","Lock","C50035","A fastening device designed to hold, close, or secure.","Lock Device | Lock | Lock Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831469","Asbestos Mining","C107390","An occupation that involves the extraction of asbestos from naturally-occurring silicate deposits. Asbestos miners were shown to have an increased risk of developing asbestosis, bronchogenic carcinoma and malignant mesothelioma.","Asbestos Mining | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826267","Evaluation Interval","C82534","The period of time during which an evaluation was performed.","Evaluation Interval | EVLINT | Evaluation Period",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3472649","Edmonton Symptom Assessment System","C107391","A self-report assessment tool to screen for the intensity of nine symptoms commonly experienced by cancer patients in palliative care.","Edmonton Symptom Assessment System | ESAS | Edmonton Symptom Assessment System (ESAS)",,,,,,,,,,,,,,,"42873028","Edmonton Symptom Assessment System",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710095","paranasal sinus and nasal cavity cancer","C54293","A carcinoma arising from the nasal cavity or paranasal sinuses.","Sinonasal Carcinoma | Nasal Cavity and Paranasal Sinus Cancer | Nasal Cavity and Paranasal Sinus Carcinoma | Nasal Cavity and Paranasal Sinus Carcinoma | paranasal sinus and nasal cavity cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827438","Worst Possible Pain","C107392","A question about an individual's experience of pain at its worst.","Worst Possible Pain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827436","Worst Possible Tiredness","C107393","A question about an individual's experience of tiredness at its worst.","Worst Possible Tiredness | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827439","Worst Possible Nausea","C107394","A question about an individual's experience of nausea at its worst.","Worst Possible Nausea | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827277","Worst Possible Depression","C107395","A question about an individual's experience of depression at its worst.","Worst Possible Depression | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827442","Worst Possible Anxiety","C107396","A question about an individual's experience of anxiety at its worst.","Worst Possible Anxiety | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830162","Feel Drowsy","C107397","A question about whether an individual feels or felt drowsy.","Feel Drowsy | Drowsy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827441","Worst Possible Appetite","C107398","A question about an individual's appetite at its worst.","Worst Possible Appetite | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827440","Worst Possible Feeling of Overall Well-Being","C107399","A question about an individual's experience of overall well-being at its worst.","Worst Possible Feeling of Overall Well-Being | Worst Possible Feeling of Overall Well Being | Worst Possible Feeling of Well-Being | Worst Possible Feeling of Wellbeing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449628","Overall Well-Being","C107400","A question about an individual's overall well-being.","Overall Well-Being | Overall Well Being | Well-Being | Wellbeing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827437","Worst Possible Symptom","C107401","A question about an individual's experience of a symptom at its worst.","Worst Possible Symptom | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2931822","Nasopharyngeal Carcinoma","C3871","A carcinoma arising from the nasopharyngeal epithelium.  It includes the following types: keratinizing squamous cell carcinoma, nonkeratinizing carcinoma (differentiated and undifferentiated), basaloid squamous cell carcinoma, and papillary adenocarcinoma.","Nasopharyngeal Carcinoma | Cancer of Nasopharynx | Cancer of the Nasopharynx | Carcinoma of Nasopharynx | Carcinoma of the Nasopharynx | NPC | Nasopharyngeal Cancer | Nasopharyngeal Throat Cancer | Nasopharyngeal carcinoma | Nasopharynx Cancer | nasopharyngeal cancer",,,,,,,,,,,,,,,"40486201","Nasopharyngeal carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334064","Hydrolase Gene","C25804","A gene that encodes an enzyme capable of catalyzing the hydrolysis of chemical bonds.","Hydrolase Gene | Hydrolase Family Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827433","Worst Severity Past Seven Days Fatigue, Tiredness, or Lack of Energy","C107402","A question about an individual's observation of the worst severity they have experienced related to fatigue, tiredness, or lack of energy over the past seven days.","Worst Severity Past Seven Days Fatigue, Tiredness, or Lack of Energy | Over the past 7 days, what was the SEVERITY of your FATIGUE, TIREDNESS, OR LACK OF ENERGY at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827432","Past Seven Days How Much Fatigue, Tiredness, or Lack of Energy Interfered with Usual or Daily Activities","C107403","A question about how much an individual's fatigue, tiredness, or lack of energy interfered with their usual or daily activities over the past seven days.","Past Seven Days How Much Fatigue, Tiredness, or Lack of Energy Interfered with Usual or Daily Activities | Over the past 7 days, how much did FATIGUE, TIREDNESS, OR LACK OF ENERGY at its WORST INTERFERE with your usual or daily activities | Worst Severity Past Seven Days Fatigue, Tiredness, or Lack of Energy Interfering with Usual or Daily Activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827428","Worst Severity Past Seven Days Numbness or Tingling in Hands or Feet","C107404","A question about an individual's observation of the worst severity they have experienced related to numbness or tingling in hands or feet over the past seven days.","Worst Severity Past Seven Days Numbness or Tingling in Hands or Feet | Over the past 7 days, what was the SEVERITY of your NUMBNESS OR TINGLING IN YOUR HANDS OR FEET at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828645","Past Seven Days Numbness or Tingling in Hands or Feet Interfering with Usual or Daily Activities","C107405","A question about an individual's numbness or tingling in hands or feet interfering with usual or daily activities over the past seven days.","Past Seven Days Numbness or Tingling in Hands or Feet Interfering with Usual or Daily Activities | Over the past 7 days, how much did NUMBNESS OR TINGLING IN YOUR HANDS OR FEET INTERFERE with your usual or daily activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827243","Past Seven Days Frequency of Pain","C107406","A question about an individual's frequency of pain over the past seven days.","Past Seven Days Frequency of Pain | Over the past 7 days, how OFTEN did you have PAIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827426","Worst Severity Past Seven Days Pain","C107407","A question about an individual's observation of the worst severity they have experienced related to pain over the past seven days.","Worst Severity Past Seven Days Pain | Over the past 7 days, what was the SEVERITY of your PAIN at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828643","Past Seven Days Pain Interfering with Usual or Daily Activities","C107408","A question about an individual's pain interfering with usual or daily activities over the past seven days.","Past Seven Days Pain Interfering with Usual or Daily Activities | Over the past 7 days, how much did PAIN INTERFERE with your usual or daily activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827435","Worst Severity Past Seven Days Constipation","C107409","A question about an individual's observation of the worst severity they have experienced related to constipation over the past seven days.","Worst Severity Past Seven Days Constipation | Over the past 7 days, what was the SEVERITY of your CONSTIPATION at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827424","Worst Severity Past Seven Days Problems with Concentration","C107410","A question about an individual's observation of the worst severity they have experienced related to problems with concentration over the past seven days.","Worst Severity Past Seven Days Problems with Concentration | Over the past 7 days, what was the SEVERITY of your PROBLEMS WITH CONCENTRATION at their WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828641","Past Seven Days Problems with Concentration Interfering with Usual or Daily Activities","C107411","A question about an individual's problems with concentration interfering with usual or daily activities over the past seven days.","Past Seven Days Problems with Concentration Interfering with Usual or Daily Activities | Over the past 7 days, how much did PROBLEMS WITH CONCENTRATION INTERFERE with your usual or daily activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828648","Past Seven Days Frequency of Tremors","C107412","A question about an individual's frequency of tremors over the past seven days.","Past Seven Days Frequency of Tremors | Over the past 7 days, how OFTEN did you have TREMORS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827423","Worst Severity Past Seven Days Tremors","C107413","A question about an individual's observation of the worst severity they have experienced related to tremors over the past seven days.","Worst Severity Past Seven Days Tremors | Over the past 7 days, what was the SEVERITY of your TREMORS at their WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828644","Past Seven Days Other Symptoms to Report","C107414","A question about an individual's other symptoms over the past seven days.","Past Seven Days Other Symptoms to Report | Over the past 7 days, do you have any other symptoms that you wish to report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827427","Worst Severity Past Seven Days Other Symptom","C107415","A question about an individual's observation of the worst severity they have experienced related to another symptom over the past seven days.","Worst Severity Past Seven Days Other Symptom | Over the past 7 days, what was the severity of this symptom at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697665","Imaging System","C78808","A group of instruments designed to view, capture, process and display an image.","Imaging System | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814820","Pedicle TRAM Flap Procedure","C107383","A type of breast reconstruction in which a section of skin, muscle, fat, and blood vessels from the abdomen is separated from surrounding tissue while retaining its blood supply, and tunneled under the skin to form a new breast mound.","Pedicle TRAM Flap Procedure | Pedicle TRAM flap | Pedicled Transverse Rectus Abdominis Myocutaneous Flap",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700368","Adjudication Committee","C78726","An external committee whose purpose is to evaluate study data and decide whether a study endpoint or other criterion has been met.","Adjudication Committee | ADJUDICATION COMMITTEE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0770694","trivalent influenza vaccine","C2643","A synthetic vaccine consisting of hemagglutinin (HA) antigens derived from three inactivated influenza viruses, two different influenza type A strains and one influenza type B strain. Trivalent influenza vaccine (TIV) is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season. Upon administration, the TIV provides active immunization against the three influenza virus strains, thereby protecting against influenza infection. A form of TIV containing higher concentrations of HA antigens may be used in older patients to elicit a more effective immune response.","Trivalent Influenza Vaccine | Agriflu | FluLaval | Fluarix | Flublok | Flushield | Fluvirin | Fluzone | Fluzone HD | Fluzone High-dose | Influenza Virus Vaccine, Trivalent, Types A and B | TIV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984509","Diphtheria Toxoid/Tetanus Toxoid Vaccine Adsorbed","C91718","A vaccine containing detoxified tetanus toxoid and detoxified diphtheria toxoid adsorbed on aluminum phosphate with active immunizing activity against diphtheria and tetanus. Intramuscular injection with this vaccine activates the immune system to develop antibodies against tetanus toxin and diphtheria toxin.","Diphtheria Toxoid/Tetanus Toxoid Vaccine Adsorbed | DT | Diphtheria Toxoid Tetanus Toxoid Vaccine Adsorbed | Diphtheria and Tetanus Toxoids Adsorbed USP (For Pediatric Use)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0065828","Measles-Mumps-Rubella Vaccine","C96403","A trivalent vaccine containing live attenuated viruses that can cause measles, mumps and rubella. It is an injection administered subcutaneously in two separate doses.","Measles/Mumps/Rubella Vaccine | M-M-R II | MMR | MMR Vaccine | Measles Mumps Rubella Vaccine | Measles, Mumps and Rubella Virus Vaccine, Live | Measles, Mumps, and Rubella Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1096415","Polio Vaccination","C96409","The administration a series of either live or inactivated poliovirus for the prophylaxis of poliomyelitis.","Polio Vaccination | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230197","Extraperitoneal Space","C92208","The space of the abdominal and pelvic cavities outside the peritoneum.","Extraperitoneal Space | BODY CAVITY, EXTRAPERITONEAL | Extraperitoneal Area",,,,,,,,,,,,,,,"4306293","Structure of extraperitoneal space",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0193883","Pelvic Lymphadenectomy","C51896","Surgical removal of one or more pelvic lymph nodes.","Pelvic Lymphadenectomy | Excision Pelvic Lymph Nodes | Pelvic Lymph Node Dissection | pelvic lymphadenectomy",,,,,,,,,,,,,,,"4030412","Pelvic lymphadenectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3814049","Social Security Death Index","C107424","A publically-accessible database derived from the Social Security Administration's (SSA) Death Master File Extract. It includes a listing of the vital statistics of a majority of decedents reported to the SSA since 1962.","Social Security Death Index | SSDI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828738","Obituary","C107426","A published record of a person's death that usually includes a brief biography and details of the funeral arrangements.","Obituary | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1565427","Focal Adhesion Kinase 1, Human","C17572","Focal adhesion kinase 1 (1052 aa, ~119 kDa) is encoded by the human PTK2 gene. This protein is involved in signaling, tyrosine phosphorylation, cell migration, angiogenesis and embryonic development.","Focal Adhesion Kinase 1 | EC 2.7.10.2 | FADK 1 | FAK | FAK1 | FRNK | Focal Adhesion Kinase | Focal Adhesion Kinase-Related Nonkinase | PPP1R71 | PTK2 | PTK2 Protein Tyrosine Kinase 2 | Protein Phosphatase 1 Regulatory Subunit 71 | p125FAK | pp125FAK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0657912","Pregabalin","C64625","A 3-isobutyl derivative of gamma-amino butyric acid (GABA) with anti-convulsant, anti-epileptic, anxiolytic, and analgesic activities. Although the exact mechanism of action is unknown, pregabalin selectively binds to alpha2delta (A2D) subunits of presynaptic voltage-dependent calcium channels (VDCCs) located in the central nervous system (CNS). Binding of pregabalin to VDCC A2D subunits prevents calcium influx and the subsequent calcium-dependent release of various neurotransmitters, including glutamate, norepinephrine, serotonin, dopamine, and substance P, from the presynaptic nerve terminals of hyperexcited neurons; synaptic transmission is inhibited and neuronal excitability is diminished. Pregabalin does not bind directly to GABA-A or GABA-B receptors and does not alter GABA uptake or degradation.","Pregabalin | 3-(Aminomethyl)-5-methyl-hexanoic Acid | 3-Isobutyl GABA | CI 1008 | Lyrica | PD 144723 | PREGABALIN | pregabalin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010995","Data Collection","C103159","The act or process of gathering data for testing or research purposes.","Data Collection | data collection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0591114","Trihexyphenidyl Hydrochloride","C47771","The hydrochloride salt form of trihexyphenidyl, a synthetic, substituted piperidine with parasympatholytic activity used mostly in Parkinson's disease. Trihexyphenidyl hydrochloride antagonizes activities of acetylcholine via muscarinic receptors. This balances the cholinergic and dopaminergic activity in the basal ganglia leading to an improvement of classic Parkinson symptoms such as rigidity and tremor. In addition, trihexyphenidyl hydrochloride exerts a direct antispasmodic effect on smooth muscle.","Trihexyphenidyl Hydrochloride | 1-Piperidinepropanol, alpha-cyclohexyl-alpha-phenyl-, Hydrochloride | Artane | Cyclodol | TRIHEXYPHENIDYL HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0386393","Olmesartan Medoxomil","C47640","A synthetic imidazole derivative prodrug with an antihypertensive property. Upon hydrolysis, olmesartan medoxomil is converted to olmesartan. Olmesartan selectively binds to the angiotensin type 1 (AT1) receptor of angiotensin II in vascular smooth muscle and adrenal gland, thereby competing angiotensin II binding to the receptor. This prevents angiotensin II-induced vasoconstriction and decreases aldosterone production, thereby preventing aldosterone-stimulated sodium retention and potassium excretion.","Olmesartan Medoxomil | 1H-Imidazole-5-carboxylic Acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-,(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl Ester | Benicar | CS 866 | OLMESARTAN MEDOXOMIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334507","Biphasic Synovial Sarcoma","C4279","A synovial sarcoma characterized by the presence of both an epithelial and a spindle cell component.","Biphasic Synovial Sarcoma | Biphasic Sarcoma of Synovium | Biphasic Sarcoma of the Synovium","9043/3","Synovial sarcoma, biphasic",,,,,,,,,,,,,"4085470","Synovial sarcoma, biphasic",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1334125","CXCR1 Gene","C24508","This gene is involved in pro-inflammatory cytokine cellular responses and neutrophil activation.","CXCR1 Gene | CXCR1 | Chemokine (C-X-C Motif) Receptor 1 Gene | IL8RA | IL8RA Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539696","RPSA Gene","C24540","This gene plays a role in several cellular processes including movement, signaling, and differentiation.","RPSA Gene | RPSA | Ribosomal Protein SA Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334554","Undifferentiated Pleomorphic Sarcoma with Osteoclast-Like Giant Cells","C8380","An undifferentiated pleomorphic sarcoma characterized by the presence of osteoclast-like giant cells and cellular pleomorphism.","Undifferentiated Pleomorphic Sarcoma with Osteoclast-Like Giant Cells | Giant Cell Fibrous Histiocytoma | Giant Cell Fibrous Histiocytoma | Giant Cell Malignant Fibrous Histiocytoma | Malignant Giant Cell Neoplasm of Soft Parts | Malignant Giant Cell Tumor of Soft Parts | Malignant giant cell tumor of soft parts","9251/3","Malignant giant cell tumor of soft parts",,,,,,,,,,,,,"4168150","Malignant giant cell tumor of soft parts",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1334180","Undifferentiated Pleomorphic Sarcoma, Inflammatory Variant","C6497","An undifferentiated pleomorphic sarcoma characterized by the presence of numerous inflammatory cells.","Undifferentiated Pleomorphic Sarcoma, Inflammatory Variant | Inflammatory MFH | Inflammatory Malignant Fibrous Histiocytoma | Inflammatory Malignant Fibrous Histiocytoma | Malignant Xanthogranuloma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0535968","Calcifediol Anhydrous","C77155","The anhydrous form of calcifediol, an orally available synthetic form of the calcitriol prohormone calcifediol (25-hydroxyvitamin D), which can be used for vitamin D supplementation, and with potential immunomodulating activity. Upon oral administration, calcifediol is taken up by the body and converted, in the kidneys, to the active form calcitriol (1,25-dihydroxyvitamin D or 1,25(OH)2D). This form increases and normalizes vitamin D plasma levels, which, in turn, regulates calcium plasma levels, and normalizes elevated parathyroid hormone (PTH) levels by suppressing both PTH synthesis, and secretion. Vitamin D modulates and enhances the innate and adaptive immune responses. This may improve unregulated inflammation and prevents the production of pro-inflammatory cytokines. Specifically, vitamin D binds to its receptor vitamin D receptor (VDR) which is widely expressed on immune cells and epithelial cells. This stimulates neutrophils, macrophages, and natural killer (NK) cells, and activates epithelial cells to produce antimicrobial peptides (AMPs). In addition, upon infection, vitamin D promotes the migration of myeloid dendritic cells (mDCs) to lymphoid organs where they activate B- and T-lymphocytes.","Calcifediol Anhydrous | (3S,5Z,7E)-9,10-Secocholesta-5,7,10-Triene-3,25-Diol | (3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-Triene-3,25-Diol | (5Z,7E)-(3S)-9,10-Secocholesta-5,7,10(19)-Triene-3,25-Diol | (5Z,7E)-9,10-Seco-5,7,10(19)-Cholestatrien-3beta,25-Diol | 25(OH)D3 | 25-Hydroxycholecalciferol | 25-Hydroxycholescalciferol | 25-Hydroxyvitamin D | 25-Hydroxyvitamin D3 | 5,6-cis-25-Hydroxyvitamin D3 | 5,6-trans-25-Hydroxycholescalciferol | 5,6-trans-9,10-Seco-5,7,10(19)-Cholestatrien-3beta,25-Diol | 9,10-Secocholesta-5,7,10(19)-Triene-3,25-Diol, (3beta,5Z,7E)- | 9,10-Secocholesta-5,7,10(19)-Triene-3beta,25-Diol | CALCIFEDIOL ANHYDROUS | Calcidiol | Cholecalciferol, 25-Hydroxy-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823635","DCAF1 Gene","C107420","This gene plays a role in both the ubiquitination and phosphorylation of proteins.","DCAF1 Gene | DCAF1 | DDB1 and CUL4 Associated Factor 1 Gene | VPRBP | VPRBP Gene | Vpr (HIV-1) Binding Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416982","MAGEB2 Gene","C107423","This gene is involved in protein ubiquitination.","MAGEB2 Gene | MAGEB2 | Melanoma Antigen Family B, 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829685","Histone H3 Lysine 4","C107427","The lysine residue found at amino acid position 4 in the histone H3 protein. Methylation of this residue may be a marker for transcriptionally active genes.","Histone H3 Lysine 4 | H3K4 | Histone H3 Lys4 | Lysine 4 of Histone H3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829684","Histone H3 Lysine 9","C107429","The lysine residue found at amino acid position 9 in the histone H3 protein. Methylation of this residue may be a marker for transcriptionally repressed genes.","Histone H3 Lysine 9 | H3K9 | Histone H3 Lys9 | Lysine 9 of Histone H3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815540","Human Anti-Ricin Antibody","C107430","A human antibody which recognizes ricin epitopes. These antibodies often develop in response to treatment with immunotoxins that are comprised of ricin immunoconjugates and limit the effectiveness of the treatment.","Human Anti-Ricin Antibody | HARA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829227","Macrovessel Density","C107431","The density of vessels with an internal diameter greater than 100 microns. Changes in density can occur in or near tumors.","Macrovessel Density | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376669","DNA Fragmentation","C107432","A process that results in the breaking of macromolecular DNA into small pieces.","DNA Fragmentation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828567","Phosphodiesterase Type 4","C107433","A family of phosphodiesterases that hydrolyze cyclic AMP to form AMP. This enzyme family is the primary cyclic nucleotide phosphodiesterase expressed by immune cells.","Phosphodiesterase Type 4 | 3',5'-Cyclic-AMP 5'-Nucleotidohydrolase Type 4 | 3',5'-Cyclic-AMP Phosphodiesterase Type 4 | PDE4 | cAMP-Specific 3',5'-Cyclic Phosphodiesterase 4 | cAMP-Specific PDE Type 4 | cAMP-Specific Phosphodiesterase 4 | cAMP-Specific Phosphodiesterase Type 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3715213","Twenty One","C107434","A natural number greater than twenty and less than twenty-two and the quantity that it denotes.","Twenty One | 21 | Twenty-One",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0428601","Fractional Excretion of Sodium","C107435","The percentage of the total sodium filtered by the kidney that is excreted in the urine. The fractional excretion is calculated by multiplying urinary sodium concentration by the plasma creatinine concentration, then dividing by the urinary creatinine concentration multiplied by the plasma sodium concentration. The resulting ratio is multiplied by 100.","Fractional Excretion of Sodium | FENA | FENa | FeNa | Fractional Excretion of Na | Fractional Sodium Excretion",,,,,,,,,,,,,,,"4108307","Measurement of fractional excretion of sodium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1415090","GLB1 Gene","C107436","This gene plays a role in ganglioside metabolism.","GLB1 Gene | GLB1 | Galactosidase, Beta 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL453083","Tetrahydrobiopterin","C107439","A cofactor that is essential for the activity of aromatic amino acid hydroxylases. Tetrahydrobiopterin degrades phenylalanine, and facilitates the biosynthesis of several neurotransmitters and the production of nitric oxide.","Tetrahydrobiopterin | (1R,2S)-(2-Amino-3,4,5,6,7,8-Hexahydro-4-Oxo-6-Pteridinyl)-1,2- Propandiol | 2-Amino-6-(1,2-Dihydroxypropyl)-5,6,7,8-Tetrahydoro-4(1H)-Pteridinone | 2-Amino-6-(1,2-Dihydroxypropyl)-5,6,7,8-Tetrahydropteridin-4(3H)-One | 4(1H)-Pteridinone, 5,6,7,8-Tetrahydro-2-Amino-6-(1,2-Dihydroxypropyl)- | 5,6,7,8-Tetrahydro-2-Amino-6-(1,2-Dihydroxypropyl)-4(1H)-Pteridinone | 5,6,7,8-Tetrahydrobiopterin | BH4 | Biopterin, 5,6,7,8-Tetrahydro- | L-Erythro-2-Amino-6-(1,2-Dihydroxypropyl)-5,6,7,8-Tetrahydro-4(3H)- Pteridinon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054463","Calcitroic Acid","C107440","A metabolite of calcidiol that is produced by 1,25-dihydroxyvitamin D3 24-hydroxylase (CYP24A1).","Calcitroic Acid | (1S,3R,5Z,7E)-1,3-Dihydroxy-24-Nor-9,10-Secochola-5,7,10(19)-Trien-23-Oic Acid | 1alpha,3beta-Dihydroxy-24-Nor-9,10-Seco-5,7,10(19)-Cholatrien-23-Oic Acid | 1alpha-Hydroxy-23-Carboxytetranorvitamin D | 1alpha-Hydroxy-24,25,26,27-Tetranorvitamin D3 23-Carboxylic Acid | 24-Nor-9,10-Secochola-5,7,10(19)-Trien-23-Oic Acid, 1,3-Dihydroxy-, (1alpha,3beta,5Z,7E)- | CALCITROIC ACID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420514","SULT1A1 Gene","C107441","This gene is involved in the metabolism of catecholamines, phenolic drugs and neurotransmitters.","SULT1A1 Gene | SULT1A1 | Sulfotransferase Family, Cytosolic, 1A, Phenol-Preferring, Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413762","CSNK2B Gene","C107444","This gene plays a role in the regulation of casein kinase II.","CSNK2B Gene | CSNK2B | Casein Kinase 2, Beta Polypeptide Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414919","GABRG1 Gene","C107447","This gene is involved in the regulation of neurotransmission.","GABRG1 Gene | GABRG1 | Gamma-Aminobutyric Acid (GABA) A Receptor, Gamma 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424501","DDX31 Gene","C107451","This gene plays a role in the regulation of RNA secondary structure.","DDX31 Gene | DDX31 | DEAD-Box Helicase 31 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414900","GAB1 Gene","C107454","This gene is involved in intracellular signaling.","GAB1 Gene | GAB1 | GRB2 Associated Binding Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412617","ATF4 Gene","C107457","This gene plays a role in transcription.","ATF4 Gene | ATF4 | Activating Transcription Factor 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420102","SLC16A1 Gene","C107460","This gene is involved in monocarboxylate transport.","SLC16A1 Gene | SLC16A1 | Solute Carrier Family 16 (Monocarboxylate Transporter), Member 1 Gene | Solute Carrier Family 16 Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420105","SLC16A4 Gene","C107463","This gene plays a role in monocarboxylate transport.","SLC16A4 Gene | SLC16A4 | Solute Carrier Family 16, Member 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1968832","SLC46A1 Gene","C107466","This gene plays a role in folate and antifolate transport.","SLC46A1 Gene | SLC46A1 | Solute Carrier Family 46 (Folate Transporter), Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413309","CEACAM6 Gene","C107469","This gene plays a probable role in both cell-cell signaling and cell adhesion.","CEACAM6 Gene | CEACAM6 | Carcinoembryonic Antigen Related Cell Adhesion Molecule 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417827","NR1I3 Gene","C107472","This gene is involved in both drug metabolism and bilirubin clearance.","NR1I3 Gene | NR1I3 | Nuclear Receptor Subfamily 1, Group I, Member 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414371","ELAVL1 Gene","C107475","This gene plays a role in the regulation of gene expression.","ELAVL1 Gene | ELAV (Embryonic Lethal, Abnormal Vision, Drosophila)-Like 1 (Hu Antigen R) Gene | ELAVL1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829363","KRAS NP_004976.2:p.Q61X","C107478","A change in the amino acid residue at position 61 in the GTPase KRas protein where glutamine has been replaced by another amino acid.","KRAS NP_004976.2:p.Q61X | GTPase KRas Gln61Xxx | GTPase KRas Q61X | K-Ras 2 Q61X | KRAS Codon 61 Mutation | KRAS Gln61Xxx | KRAS NP_004976.2:p.Gln61Xxx | KRAS Q61 Mutation | KRAS Q61X | KRAS p.Gln61Xxx | KRAS p.Q61X | Ki-Ras Q61X | NP_004976.2:p.Gln61Xxx | NP_004976.2:p.Q61X | Specific codon 61 mutation not stated | c-K-ras Q61X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829364","KRAS NP_004976.2:p.A146X","C107479","A change in the amino acid residue at position 146 in the GTPase KRas protein where alanine has been replaced by another amino acid.","KRAS NP_004976.2:p.A146X | GTPase KRas A146X | GTPase KRas Ala146Xxx | K-Ras 2 A146X | KRAS A146 Mutation | KRAS A146X | KRAS Ala146Xxx | KRAS NP_004976.2:p.Ala146Xxx | KRAS p.A146X | KRAS p.Ala146Xxx | Ki-Ras A146X | NP_004976.2:p.A146X | NP_004976.2:p.Ala146Xxx | c-K-ras A146X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828558","PIK3CA NP_006209.2:p.E542X","C107480","A change in the amino acid residue at position 542 in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform protein where glutamic acid has been replaced by another amino acid.","PIK3CA NP_006209.2:p.E542X | NP_006209.2:p.Glu542Xxx | PI3Kalpha E542X | PIK3CA E542 Mutation | PIK3CA E542X | PIK3CA Glu542Xxx | PIK3CA NP_006209.2:p.Glu542Xxx | PIK3CA p.E542X | PIK3CA p.Glu542Xxx | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 110 kDa Catalytic Subunit Alpha E542X | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Isoform E542X | Phosphoinositide-3-Kinase Catalytic Alpha Polypeptide E542X | p110alpha E542X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828557","PIK3CA NP_006209.2:p.E545X","C107481","A change in the amino acid residue at position 545 in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform protein where glutamic acid has been replaced by another amino acid.","PIK3CA NP_006209.2:p.E545X | NP_006209.2:p.Glu545Xxx | PI3Kalpha E545X | PIK3CA E545 Mutation | PIK3CA E545X | PIK3CA Glu545Xxx | PIK3CA NP_006209.2:p.Glu545Xxx | PIK3CA p.E545X | PIK3CA p.Glu545Xxx | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 110 kDa Catalytic Subunit Alpha E545X | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Isoform E545X | Phosphoinositide-3-Kinase Catalytic Alpha Polypeptide E545X | p110alpha E545X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828556","PIK3CA NP_006209.2:p.H1047X","C107482","A change in the amino acid residue at position 1047 in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform protein where histidine has been replaced by another amino acid.","PIK3CA NP_006209.2:p.H1047X | NP_006209.2:p.His1047Xxx | PI3Kalpha H1047X | PIK3CA H1047 Mutation | PIK3CA H1047X | PIK3CA His1047Xxx | PIK3CA NP_006209.2:p.His1047Xxx | PIK3CA p.H1047X | PIK3CA p.His1047Xxx | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 110 kDa Catalytic Subunit Alpha H1047X | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Isoform H1047X | Phosphoinositide-3-Kinase Catalytic Alpha Polypeptide H1047X | p110alpha H1047X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828752","NRAS NP_002515.1:p.G12X","C107483","A change in the amino acid residue at position 12 in the GTPase NRas protein where glycine has been replaced by another amino acid.","NRAS NP_002515.1:p.G12X | GTPase NRas G12X | NP_002515.1:p.G12X | NP_002515.1:p.Gly12Xxx | NRAS G12 Mutation | NRAS G12X | NRAS Gly12Xxx | NRAS NP_002515.1:p.Gly12Xxx | NRAS p.G12X | NRAS p.Gly12Xxx | Transforming Protein N-Ras G12X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828751","NRAS NP_002515.1:p.G13X","C107484","A change in the amino acid residue at position 13 in the GTPase NRas protein where glycine has been replaced by another amino acid.","NRAS NP_002515.1:p.G13X | GTPase NRas G13X | NP_002515.1:p.G13X | NP_002515.1:p.Gly13Xxx | NRAS G13 Mutation | NRAS G13X | NRAS Gly13Xxx | NRAS NP_002515.1:p.Gly13Xxx | NRAS p.G13X | NRAS p.Gly13Xxx | Transforming Protein N-Ras G13X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828750","NRAS NP_002515.1:p.Q61X","C107485","A change in the amino acid residue at position 61 in the GTPase NRas protein where glutamine has been replaced by another amino acid.","NRAS NP_002515.1:p.Q61X | GTPase NRas Q61X | NP_002515.1:p.Gln61Xxx | NP_002515.1:p.Q61X | NRAS Gln61Xxx | NRAS NP_002515.1:p.Gln61Xxx | NRAS Q61 Mutation | NRAS Q61X | NRAS p.Gln61Xxx | NRAS p.Q61X | Transforming Protein N-Ras Q61X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827753","Tumor Microenvironment of Metastasis Density","C107486","A marker of potential sites for tumor metastasis, where separate histological stains for perivascular macrophages, blood vessel-resident endothelial cells and tumor cells are co-localized in a tissue section.","Tumor Microenvironment of Metastasis Density | TMEM Density | TMEM Score | Tumor Microenvironment of Metastasis Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412365","ALPP Gene","C107487","This gene plays a role in phosphatase activity in the placenta.","ALPP Gene | ALPP | Alkaline Phosphatase, Placental Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425409","ENAH Gene","C73551","This gene is involved in the regulation of cytoskeletal structure.","ENAH Gene | ENAH | Enabled Homolog (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420248","SNAI2 Gene","C50877","This gene plays a role in development. It is also involved in repression of gene transcription and inhibition of apoptosis.","SNAI2 Gene | SNAI2 | Snail Homolog 2 (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424139","WNT16 Gene","C102965","This gene is involved in receptor signaling.","WNT16 Gene | WNT16 | Wingless-Type MMTV Integration Site Family, Member 16 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012860","DNA Damage","C16507","Drug-, radiation-induced, or spontaneous injuries to DNA that introduce deviations from its normal double-helical conformation. These changes include structural distortions that interfere with replication and transcription, as well as point mutations that disrupt base pairs and exert damaging effects on future generations through changes in DNA sequence. If the damage is minor, it can often be repaired (DNA repair); extensive damage can induce apoptosis.","DNA Damage | ",,,,,,,,,,,,,,,"4285282","DNA damage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704459","Device System","C50311","A group of independent but interrelated devices working together.","Device System | Device Component System | System | System of Devices",,,,,,,,,,,,,,,"45769143","Device system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0871685","Clinician","C85499","An individual, such as a physician or nurse practitioner, who takes responsibility for a patient's care during an encounter.","Clinician | CLINICIAN | clinician",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205185","Triphasic","C107488","Occurring in or characterized by three phases or stages.","Triphasic | ",,,,,,,,,,,,,,,"4262106","Triphasic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3827033","Australia-Modified Karnofsky Performance Scale","C107489","A measure of an individual's overall performance status or ability to perform their activities of daily living while undergoing care using a single score assigned by a clinician based on observations of a patient's ability to perform common tasks relating to activity, work and self-care.","Australia-Modified Karnofsky Performance Scale | AKPS | Australia-Modified Karnofsky Performance Scale  | Australia-Modified Karnofsky Performance Scale (AKPS) | Australia-Modified Karnofsky Performance Scale (AKPS) ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829431","Karnofsky Performance Status 100","C105707","Normal; no complaints; no evidence of disease.","Karnofsky Performance Status 100 | 100 | 100: Normal, no complaints; no evidence of disease | Australia-Modified Karnofsky Performance Status 100 | Australia-modified Karnofsky Performance Status 100 ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829422","Karnofsky Performance Status 90","C105709","Able to carry on normal activity; minor signs or symptoms of disease.","Karnofsky Performance Status 90 | 90 | 90: Able to carry on normal activity; minor signs or symptoms of disease | Australia-Modified Karnofsky Performance Status 90 | Australia-modified Karnofsky Performance Status 90",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829423","Karnofsky Performance Status 80","C105710","Normal activity with effort; some sign or symptoms of disease.","Karnofsky Performance Status 80 | 80 | 80: Normal activity with effort; some signs or symptoms of disease | Australia-Modified Karnofsky Performance Status 80 | Australia-modified Karnofsky Performance Status 80",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829424","Karnofsky Performance Status 70","C105711","Cares for self; unable to carry on normal activity or do active work.","Karnofsky Performance Status 70 | 70 | 70: Cares for self; unable to carry on normal activity or to do active work | Australia-Modified Karnofsky Performance Status 70 | Australia-modified Karnofsky Performance Status 70",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829425","Karnofsky Performance Status 60","C105712","Requires occasional assistance, but is able to care for most personal needs.","Karnofsky Performance Status 60 | 60 | 60: Requires occasional assistance; but is able to care for most of his/her needs | Australia-Modified Karnofsky Performance Status 60 | Australia-modified Karnofsky Performance Status 60 | Karnofsky Performance Status 60 ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829426","Karnofsky Performance Status 50","C105713","Requires considerable assistance and frequent medical care.","Karnofsky Performance Status 50 | 50 | 50: Requires considerable assistance and frequent medical care | Australia-Modified Karnofsky Performance Status 50 | Australia-modified Karnofsky Performance Status 50",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831442","Australia-Modified Karnofsky Performance Status 40","C107490","In bed more than 50% of the time.","Australia-Modified Karnofsky Performance Status 40 | Australia-modified Karnofsky Performance Status 40 | Australia-modified Karnofsky Performance Status 40",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831443","Australia-Modified Karnofsky Performance Status 30","C107491","Almost completely bedfast.","Australia-Modified Karnofsky Performance Status 30 | Australia-modified Karnofsky Performance Status 30 | Australia-modified Karnofsky Performance Status 30",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831444","Australia-Modified Karnofsky Performance Status 20","C107492","Totally bedfast and requiring extensive nursing care by professionals and/or family.","Australia-Modified Karnofsky Performance Status 20 | Australia-modified Karnofsky Performance Status 20 | Australia-modified Karnofsky Performance Status 20 ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831445","Australia-Modified Karnofsky Performance Status 10","C107493","Comatose or barely arousable.","Australia-Modified Karnofsky Performance Status 10 | Australia-modified Karnofsky Performance Status 10 | Australia-modified Karnofsky Performance Status 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829432","Karnofsky Performance Status 0","C105720","Dead.","Karnofsky Performance Status 0 | 0 | 0: Dead | Australia-Modified Karnofsky Performance Status 0 | Australia-modified Karnofsky Performance Status 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831431","Auto-triggered","C107494","Activation of a system without outside interference.","Auto-triggered | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811629","Anti-Drug Antibody","C107495","An antibody that binds to an administered drug or therapeutic agent. Expression of these antibodies is thought to be induced by (repeated) administration.","Anti-Drug Antibody | ADA | ATA | Anti-Drug Antibodies | Anti-Therapeutic Agent Antibody | Anti-Therapeutic Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816183","Neutralizing Anti-Drug Antibody","C107496","An antibody that binds to an administered drug and inhibits the biological activity of that drug. Expression of these antibodies is thought to be induced by (repeated) drug administration.","Neutralizing Anti-Drug Antibody | NADA | Neutralizing Anti-Drug Antibodies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826616","Stigmata of Chronic Liver Disease","C82996","Signs of chronic liver disease which include jaundice, ascites, palmar erythema, spider hemangiomas, gynecomastia, and encephalopathy.","Stigmata of Chronic Liver Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831015","Convenient","C107497","Suited for the intended purpose.","Convenient | Convenience",,,,,,,,,,,,,,,"764784","Convenient",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3827682","Useful","C107498","Helpful for doing or achieving something.","Useful | Usefulness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221423","Sickness","C107499","A state of ill health, bodily malfunction, or discomfort.","Sickness | Sick",,,,,,,,,,,,,,,"4192174","Illness",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3275122","Pacemaker Procedure","C99998","A procedure involving an electronic device that delivers electrical stimulation to the heart to treat bradycardia. (ACC)","Pacemaker Procedure | Cardiac Pacemaker Procedure | PACEMAKER | Pacemaker",,,,,,,,,,,,,,,"4051938","Cardiac pacemaker procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825184","Implantable Cardioverter-Defibrillator Placement","C80435","A surgical procedure in which a small, battery-powered device is placed in the chest wall to detect arrhythmias and correct them by delivering a jolt of electricity.","Implantable Cardioverter-Defibrillator Placement | ICD | IMPLANTABLE CARDIOVERTER DEFIBRILLATOR | Implantable Cardioverter Defibrillator Procedure | Implantable Cardioverter-Defibrillators | Implantation of a cardioverter-defibrillator performed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347642","Positive Air Pressure Device","C70912","A device for the delivery of forced air through a mask worn during sleeping hours, considered to be treatment for snoring and sleep apnea.","Positive Air Pressure Device | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030163","Cardiac Pacemaker","C94198","A battery-operated device that delivers electrical impulses to the heart to assist it to beat effectively.","Cardiac Pacemaker | Cardiac pacemaker, device (physical object) | artificial pacemaker | cardiac pacemaker | pacemaker",,,,,,,,,,,,,,,"4030875","Cardiac pacemaker",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0072973","Ramipril","C29411","A prodrug and nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Ramipril is converted in the liver by de-esterification into its active form ramiprilat, which inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This abolishes the potent vasoconstrictive actions of angiotensin II and leads to vasodilatation. This agent also causes an increase in bradykinin levels and a decrease in angiotensin II-induced aldosterone secretion by the adrenal cortex, thereby promoting diuresis and natriuresis.","Ramipril | Altace | RAMIPRIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1956415","Paroxysmal Nocturnal Dyspnea","C34561","Sudden onset of shortness of breath that causes one to awaken coughing or wheezing; it may be associated with congestive heart failure or chronic obstructive pulmonary disease.","Paroxysmal Nocturnal Dyspnea | Cardiac Asthma | Dyspnea Paroxysmal Nocturnal | PND | Paroxysmal nocturnal dyspnea",,,,,,,,,,,,,,,"4206307","Paroxysmal nocturnal dyspnea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0012359","Distension","C50537","The condition of being stretched beyond normal dimensions.","Distension | Distention | Distention",,,,,,,,,,,,,,,"4102695","Dilatation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829708","Hepatojugular","C107530","Of, or pertaining to, the liver and jugular vein.","Hepatojugular | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027757","Nerve Tissue","C13052","The tissue that generates and conducts electrical signals in the body.  It contains the neurons.","Nerve Tissue | Human Nerve Tissue | Nervous Tissue",,,,,,,,,,,,,,,"4237381","Structure of nervous tissue",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1421414","KDM6A Gene","C96334","This gene is involved in the modulation of histone methylation.","KDM6A Gene | KDM6A | Lysine Demethylase 6A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426001","CTDNEP1 Gene","C102888","This gene plays a role in protein dephosphorylation.","CTDNEP1 Gene | CTD Nuclear Envelope Phosphatase 1 Gene | CTDNEP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427193","BCOR Gene","C101091","This gene plays a role in the repression of gene transcription.","BCOR Gene | BCL6 Corepressor Gene | BCOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422165","KMT2C Gene","C93091","This gene plays a role in both methylation and transcriptional regulation","KMT2C Gene | KMT2C | Lysine Specific Methyltransferase 2C Gene | MLL3 | MLL3 Gene | MLL3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334512","KMT2D Gene","C24600","This gene plays a role in co-activation of gene expression.","KMT2D Gene | KMT2D | Lysine Methyltransferase 2D  Gene | Lysine Methyltransferase 2D Gene | MLL2 | MLL2 Gene | MLL2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335843","SMARCA4 Gene","C19878","This gene plays a role in chromatin remodeling, cell cycle control and regulation of transcription.","SMARCA4 Gene | SMARCA4 | SWI/SNF-Related, Matrix-Associated, Actin-Dependent Regulator of Chromatin, Subfamily A, Member 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812285","PVT1 Gene","C18403","This gene plays a role in the activation of transcription.","PVT1 Gene | PVT1 | Pvt1 Oncogene (Non-Protein Coding) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418202","OTX2 Gene","C102951","This gene is involved in both embryonic development and transcriptional regulation.","OTX2 Gene | OTX2 | Orthodenticle Homeobox 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823959","ZMYM3 Gene","C101617","This gene is involved in chromatin modification.","ZMYM3 Gene | ZMYM3 | Zinc Finger, MYM-Type 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427038","CHD7 Gene","C75309","This gene may play a role in the modulation of both chromatin structure modification and transcription.","CHD7 Gene | CHD7 | Chromodomain Helicase DNA Binding Protein 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079414","DCC Gene","C17358","This gene plays a role in the regulation of several processes that determine neuronal cell morphology.","DCC Gene | DCC | Deleted in Colorectal Carcinoma Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424985","HEMGN Gene","C84298","This gene plays a role in hematopoietic cell differentiation.","HEMGN Gene | HEMGN | Hemogen Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333670","GFI1B Gene","C24427","This gene plays a role in transcriptional regulation and erythroid cell growth. Translocations in the gene are associated with chronic myeloid leukemia.","GFI1B Gene | GFI1B | Growth Factor Independent 1B (Potential Regulator of CDKN1A, Translocated in CML) Gene | Growth Factor Independent 1B Transcriptional Repressor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333342","EPOR Gene","C21562","This gene plays a pivotal role in erythropoiesis.","EPOR Gene | EPOR | Erythropoietin Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412402","ANK1 Gene","C84301","This gene plays a role in red blood cell morphology.","ANK1 Gene | ANK1 | Ankyrin 1, Erythrocytic Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447285","Nineteen","C105801","A natural number greater than eighteen and less than twenty and the quantity that it denotes.","Nineteen | 19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424135","YAP1 Gene","C96030","This gene plays a role in both signal transduction and transcriptional regulation.","YAP1 Gene | YAP1 | Yes1 Associated Transcriptional Regulator Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0673028","PROM1 protein, human","C64344","Prominin-1 (865 aa, ~97 kDa) is encoded by the human PROM1 gene. This protein may play a role in hematopoiesis, but an exact function has yet to be elucidated. The protein has been implicated in tumor pathogenesis and formation in several cancers, including retinoblastoma, hemangioma, and glioblastoma phenotypes. Additionally, the protein has been used as a marker to distinguish cells that have the potential to become cancerous from the larger normal cell population.","Prominin-1 | Antigen AC133 | CD133 | CD133 Antigen | Prominin-like protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332797","CSPG4 Gene","C24316","This gene plays a role in cellular adhesion and cytoskeletal stabilization.","CSPG4 Gene | CSPG4 | Chondroitin Sulfate Proteoglycan 4 (Melanoma-Associated) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413306","CEACAM1 Gene","C104113","This gene is involved in cell-cell interactions.","CEACAM1 Gene | CEACAM1 | Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (Biliary Glycoprotein) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700042","F2 Isoprostane Measurement","C80180","The determination of the amount of F2 isoprostane present in a urine sample.","F2 Isoprostane Measurement | F2-Isoprostane | ISOPRF2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346499","Institutional Review Board Approval","C70800","A document containing the determination of the Institutional Review Board (IRB) that the clinical study with human subject participation has been reviewed and may be conducted at a particular study site within the constraints set forth by the IRB and other institutional and federal requirements. The regulations require that an IRB conduct continuing review of research at intervals appropriate to the degree of risk, but not less than once a year.","Institutional Review Board Approval | IRB Approval | IRB-IEC Approv | IRB-IEC Approval | IRB/IEC Submission Approval | Institutional Review Board Independent Ethics Committee Approval | approval (in relation to Institutional Review Boards)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421409","USP9X Gene","C101574","This gene plays a role in deubiquitination.","USP9X Gene | USP9X | Ubiquitin Specific Peptidase 9 X-Linked Gene | Ubiquitin Specific Peptidase 9, X-Linked Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335841","SMARCA2 Gene","C19879","This gene plays a role in chromatin remodeling and transcriptional activation of genes normally repressed by chromatin.","SMARCA2 Gene | SMARCA2 | SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily A, Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012929","Mitochondrial DNA","C28512","Typically small, circular, intronless, and maternally inherited, mitochondrial DNA (mtDNA) is the multicopy deoxyribonucleic acid genome of mitochondria, intracellular organelles responsible for vital respiratory chain and oxidative phosphorylation reactions in higher eukaryotes. Replicated and transcribed by a separate enzymatic machinery from that of nuclear DNA, mtDNA encodes only a subset of mitochondrial functions. (NCI04)","Mitochondrial DNA | Chromosome M | M Chromosome | Mitochondrial Chromosome | chrM | mDNA | mtDNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1456392","RXRA Gene","C38415","This gene plays a role in transcriptional regulation and in the retinoid response pathway.","RXRA Gene | RXRA | Retinoid X Receptor, Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014894","Esterase","C16561","Encoded by Esterase Genes, Esterases catalyze hydrolysis of ester bonds to produce alcohol and acid reaction products. (NCI)","Esterase | EC 3.1 | Ester Hydrolase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714902","Multinational Association of Supportive Care in Cancer Antiemesis Tool","C107507","A self-administered questionnaire designed to assess a patient's level of nausea and vomiting associated with chemotherapy.","Multinational Association of Supportive Care in Cancer Antiemesis Tool | MASCC Antiemesis Tool | MASCC Antiemesis Tool (MAT) | MAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831401","Baseline Nausea and Vomiting","C107508","A set of parameters established as a reference to gauge levels of nausea and vomiting.","Baseline Nausea and Vomiting | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827539","Vomiting in the Last 24 Hours","C107509","A question about whether an individual vomited in the last 24 hours.","Vomiting in the Last 24 Hours | In the last 24 hours, did you have any vomiting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829604","How Often Vomited During This Period","C107510","A question about how often an individual vomited during the specified time period.","How Often Vomited During This Period | If you vomited during this period, how many times did it happen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828849","Nausea in the Last 24 Hours","C107511","A question about whether an individual had nausea in the last 24 hours.","Nausea in the Last 24 Hours | In the last 24 hours, did you have any nausea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829610","How Much Nausea in the Last 24 Hours","C107512","A question about how much nausea an individual experienced in the last 24 hours.","How Much Nausea in the Last 24 Hours | How much nausea did you have in the last 24 hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828855","Nausea and Vomiting During the First 24 Hours After Chemotherapy","C107513","Nausea and vomiting occurring during the first 24 hours following chemotherapy.","Nausea and Vomiting During the First 24 Hours After Chemotherapy | Nausea and Vomiting during the first 24 hours after chemotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827540","Vomiting in the 24 Hours Since Chemotherapy","C107514","A question about whether an individual vomited in the 24 hours after chemotherapy.","Vomiting in the 24 Hours Since Chemotherapy | In the 24 hours since chemotherapy, did you have any vomiting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829603","How Often Vomited in the 24 Hours Since Chemotherapy","C107515","A question about how often an individual vomited in the 24 hours after chemotherapy.","How Often Vomited in the 24 Hours Since Chemotherapy | If you vomited in the 24 hours since chemotherapy, how many times did it happen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827271","Nausea in the 24 Hours Since Chemotherapy","C107516","A question about whether an individual had nausea in the 24 hours after chemotherapy.","Nausea in the 24 Hours Since Chemotherapy | In the 24 hours since chemotherapy, did you have any nausea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830545","Delayed Nausea and Vomiting","C107517","Nausea and vomiting occurring more than 24 hours following chemotherapy.","Delayed Nausea and Vomiting | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827541","Vomiting During This Period","C107518","A question about whether an individual vomited during the specified time period.","Vomiting During This Period | During this period, did you have any vomiting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828854","Nausea During This Period","C107519","A question about whether an individual had nausea during the specified time period.","Nausea During This Period | During this period, did you have any nausea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829611","How Much Nausea During This Period","C107520","A question about how much nausea an individual experienced during the specified time period.","How Much Nausea During This Period | How much nausea did you have during this period | Nausea | Nausea Frequency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831464","As Much As Possible","C107521","A response that indicates the largest amount imagined.","As Much As Possible | As much as possible",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830497","Did You Take Any Medication Except the Study Drug for Vomiting in the Past 24 Hours","C107522","A question about whether an individual took any medication, except the study drug, for vomiting in the past 24 hours.","Did You Take Any Medication Except the Study Drug for Vomiting in the Past 24 Hours | Did you take any medication (except study drug) for VOMITING in the past 24 hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830499","Did You Take Any Medication Except the Study Drug for Nausea in the Past 24 Hours","C107523","A question about whether an individual took any medication, except the study drug, for nausea in the past 24 hours.","Did You Take Any Medication Except the Study Drug for Nausea in the Past 24 Hours | Did you take any medication (except study drug) for NAUSEA in the past 24 hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828223","Scheduled By Doctor","C107524","Indicates that an event was planned in advance by a doctor.","Scheduled By Doctor | Scheduled by doctor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828841","Needed Help","C107525","The individual required assistance.","Needed Help | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831031","Concerned I Would Develop Symptoms","C107526","The individual was concerned they would develop symptoms.","Concerned I Would Develop Symptoms | Concerned I would develop symptoms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828491","Pregnancy-Related Nausea and/or Vomiting","C107527","Nausea and/or vomiting co-occurring with pregnancy.","Pregnancy-Related Nausea and/or Vomiting | Pregnancy-related nausea and/or vomiting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831126","Chemotherapy-Related Nausea and/or Vomiting","C107528","Nausea and/or vomiting co-occurring with a cycle of chemotherapy.","Chemotherapy-Related Nausea and/or Vomiting | Chemotherapy-Induced Nausea and Vomiting | Chemotherapy-related nausea and/or vomiting",,,,,,,,,,,,,,,"40385744","Chemotherapy-induced nausea and vomiting",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026603","Motion Sickness","C34824","A sensation of discomfort that results from a discordant relationship between visualized movement and any movement sensed by the vestibular system, which is characterized by dizziness, nausea, and vomiting.","Motion Sickness | Travel Sickness",,,,,,,,,,,,,,,"30284","Motion sickness",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828693","Osoba Nausea and Emesis Module","C107532","A self-administered questionnaire designed to measure the short-term impact of nausea, emesis, and retching on patients receiving emetogenic chemotherapy.","Osoba Nausea and Emesis Module | ONEM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828853","Nausea Interfered With Appetite During Past 24 Hours","C107533","A question about whether an individual had nausea that interfered with appetite during the past 24 hours.","Nausea Interfered With Appetite During Past 24 Hours | During the past 24 hours did NAUSEA interfere with your appetite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828856","Nausea Affected Sleep During Past 24 Hours","C107534","A question about whether an individual had nausea that affected sleep during the past 24 hours.","Nausea Affected Sleep During Past 24 Hours | During the past 24 hours did NAUSEA affect your sleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828851","Nausea Interfered With Physical Activities During Past 24 Hours","C107535","A question about whether an individual had nausea that interfered with physical activities during the past 24 hours.","Nausea Interfered with Physical Activities During Past 24 Hours Question | During the past 24 hours did NAUSEA interfere with your physical activities | Nausea Interfered With Physical Activities During Past 24 Hours | Nausea Interfered with Physical Activities During Past 24 Hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828850","Nausea Interfered With Social Life During Past 24 Hours","C107536","A question about whether an individual had nausea that interfered with social life during the past 24 hours.","Nausea Interfered With Social Life During Past 24 Hours | During the past 24 hours did NAUSEA interfere with your social life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828852","Nausea Interfered With Enjoyment of Life During Past 24 Hours","C107537","A question about whether an individual had nausea that interfered with enjoyment of life during the past 24 hours.","Nausea Interfered With Enjoyment of Life During Past 24 Hours | During the past 24 hours did NAUSEA interfere with your enjoyment of life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827537","Vomiting or Dry Heaves Interfered With Appetite During Past 24 Hours","C107538","A question about whether an individual had vomiting or dry heaves that interfered with appetite during the past 24 hours.","Vomiting or Dry Heaves Interfered With Appetite During Past 24 Hours | During the past 24 hours did VOMITING or DRY HEAVES interfere with your appetite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827538","Vomiting or Dry Heaves Affected Sleep During Past 24 Hours","C107539","A question about whether an individual had vomiting or dry heaves that affected sleep during the past 24 hours.","Vomiting or Dry Heaves Affected Sleep During Past 24 Hours | During the past 24 hours did VOMITING or DRY HEAVES affect your sleep | Vomiting or Dry Heaves Affected Sleep During Past 24 Hours ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827535","Vomiting or Dry Heaves Interfered With Physical Activities During Past 24 Hours","C107540","A question about whether an individual had vomiting or dry heaves that interfered with physical activities during the past 24 hours.","Vomiting or Dry Heaves Interfered with Physical Activities During Past 24 Hours Question | During the past 24 hours did VOMITING or DRY HEAVES interfere with your physical activities | Vomiting or Dry Heaves Interfered With Physical Activities During Past 24 Hours | Vomiting or Dry Heaves Interfered with Physical Activities During Past 24 Hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827534","Vomiting or Dry Heaves Interfered With Social Life During Past 24 Hours","C107541","A question about whether an individual had vomiting or dry heaves that interfered with social life during the past 24 hours.","Vomiting or Dry Heaves Interfered With Social Life During Past 24 Hours | During the past 24 hours did VOMITING or DRY HEAVES interfere with your social life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827536","Vomiting or Dry Heaves Interfered With Enjoyment of Life During Past 24 Hours","C107542","A question about whether an individual had vomiting or dry heaves that interfered with enjoyment of life during the past 24 hours.","Vomiting or Dry Heaves Interfered With Enjoyment of Life During Past 24 Hours | During the past 24 hours did VOMITING or DRY HEAVES interfere with your enjoyment of life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827778","Treatment Satisfaction Questionnaire for Medication","C107543","A 9 question subset of the Treatment Satisfaction Questionnaire for Medication that omits the five items of the side effects domain.","Treatment Satisfaction Questionnaire for Medication | TSQM-9 | Treatment Satisfaction Questionnaire for Medication  | Treatment Satisfaction Questionnaire for Medication (TSQM-9)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828232","Satisfaction with Ability of Medication to Prevent or Treat Condition","C107544","A question about how satisfied or dissatisfied an individual is with the ability of a medication to prevent or treat a condition.","Satisfaction with Ability of Medication to Prevent or Treat Condition | How satisfied or dissatisfied are you with the ability of the medication to prevent or treat your condition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828230","Satisfaction with Way Medication Relieves Symptoms","C107545","A question about how satisfied or dissatisfied an individual is with the way a medication relieves symptoms.","Satisfaction with Way Medication Relieves Symptoms | How satisfied or dissatisfied are you with the way the medication relieves your symptoms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827245","Satisfaction with Time it Takes Medication to Start Working","C107546","A question about how satisfied or dissatisfied an individual is with the amount of time is takes for a medication to start working.","Satisfaction with Time it Takes Medication to Start Working | How satisfied or dissatisfied are you with the amount of time it takes the medication to start working",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830359","Ease of Using Medication in its Present Form","C107547","A question about how easy or difficult it is to use a medication in its current form.","Ease of Using Medication in its Present Form | How easy or difficult is it to use the medication in its current form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830360","Ease of Planning When to Use Medication Each Time","C107548","A question about how easy or difficult it is to plan when to use a medication each time.","Ease of Planning When to Use Medication Each Time | How easy or difficult is it to plan when you will use the medication each time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831016","Convenience of Taking Medication as Instructed","C107549","A question about how convenient or inconvenient it is to take a medication as instructed.","Convenience of Taking Medication as Instructed | How convenient or inconvenient is it to take the medication as instructed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831025","Confidence that Taking Medication is a Good Thing","C107550","A question about how confident an individual is that taking the medication is a good thing.","Confidence that Taking Medication is a Good Thing | Overall, how confident are you that taking the medication is a good thing for you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831148","Certainty that Good Outweighs the Bad Things About Medication","C107551","A question about how certain an individual is that the good things about a medication outweigh the bad things.","Certainty that Good Outweighs the Bad Things About Medication | How certain are you that the good things about your medication outweigh the bad things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827320","CXCR4 Inhibitor","C107589","An antagonist of the C-X-C chemokine receptor type 4 (CXCR4). CXCR4, which belongs to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types.","CXCR4 Inhibitor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4228439","Failure to Thrive","C107587","A clinical finding indicating less than normal growth in an infant or child, or a state of global decline in an adult.","Failure to Thrive | Failure to thrive",,,,,,,,,,,,,,,"437986","Failure to thrive",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4014800","Interstitial Pneumonia","C27006","Inflammation of interstitial lung tissue, usually associated with infection.","Interstitial Pneumonia | Interstitial Pneumonitis",,,,,,,,,,,,,,,"4273378","Interstitial pneumonia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828231","Satisfaction with Medication","C107552","A question about how satisfied or dissatisfied an individual is with a medication.","Satisfaction with Medication | Taking all things into account, how satisfied or dissatisfied are you with this medication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412261","ADRA2C Gene","C107613","This gene is involved in the regulation of neurotransmitter release.","ADRA2C Gene | ADRA2C | Adrenoceptor Alpha 2C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002245","Alpha-Amylase","C107565","A family of hydrolases that cleaves alpha-linkages in polysaccharides, such as starch and glycogen, and yield glucose and maltose. This family includes the amylase forms that are produced by mammals. In humans, alpha-amylase is produced by salivary glands and the pancreas.","Alpha-Amylase | 1,4-Alpha-D-Glucan Glucanohydrolase | 4-Alpha-D-Glucan Glucanohydrolase | Alpha Amylase | EC 3.2.1.1 | Endoamylase | Glycogenase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003009","Angiotensin-2","C107562","Angiotensin-2 (8 aa, ~1 kDa) is encoded by the human AGT gene. This protein is involved in vasoconstriction, heart rate and renal absorption of water and sodium.","Angiotensin-2 | AGT | Ang2 | Angiotensin 1-8 | Angiotensin II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816168","B-Cell Receptor Complex","C107558","A membrane bound protein complex comprised of an immunoglobulin molecule associated with a heterodimer, called CD79, containing one CD79A protein and one CD79B protein. The immunoglobulin determines the ligand specificity of the complex and the CD79 heterodimer promotes signal transduction. This receptor is involved in antigen processing and presentation.","B-Cell Receptor Complex | B Cell Receptor | B Cell Receptor Complex | B-Cell Antigen Receptor Complex | B-Cell Receptor | BCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054205","Bufalin","C107555","An active ingredient and one of the glycosides in the traditional Chinese medicine ChanSu; it is also a bufadienolide toxin originally isolated from the venom of the Chinese toad Bufo gargarizans, with potential cardiotonic and antineoplastic activity. Although the mechanism of action of bufalin is still under investigation, this agent is a specific Na+/K+-ATPase inhibitor and can induce apoptosis in cancer cell lines through the activation of the transcription factor AP-1 via a mitogen activated protein kinase (MAPK) pathway.","Bufalin | 3,14-Dihydroxy-Bufa-20,22-Dienolide | 3-Beta,14-Dihydroxy-5-Beta-Bufa-20,22-Dienolide | 3beta,14beta-Dihydroxy-5beta-Bufa-20,22-Dienolide | 5-Beta-Bufa-20,22-Dienolide, 3-Beta,14-Dihydroxy- | 5beta-Bufa-20,22-Dienolide, 3beta,14-Dihydroxy- (8CI) | BUFALIN | Bufa-20,22-Dienolide, 3,14-Dihydroxy-, (3-Beta,5-Beta)- (9CI) | Bufa-20,22-Dienolide, 3,14-Dihydroxy-, (3beta,5beta)- (9CI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054208","Bufogenin","C77829","A bufadienolide toxin originally isolated from the venom of the Chinese toad Bufo gargarizans; it is also one of the glycosides in the traditional Chinese medicine ChanSu, with potential cardiotonic activity. Although the mechanism of action of bufogenin is still under investigation, this agent is a specific Na+/K+-ATPase inhibitor and has been shown to reduce blood pressure in a rat model of preeclampsia.","Bufogenin | 14,15-Beta-Epoxy-3-Beta-Hydroxy-5-Beta-Bufa-20,22-Dienolide | 14,15beta-Epoxy-3beta-Hydroxy-5beta-Bufa-20,22-Dienolide | 3-Beta-Hydroxy-14,15-Beta-Epoxy-5-Beta-Bufa-20,22-Dienolide | 3beta-Hydroxy-14,15beta-Epoxy-5beta-Bufa-20,22-Dienolide | 5-Beta-Bufa-20,22-Dienolide, 14,15-Beta-Epoxy-3-Beta-Hydroxy- | 5beta-Bufa-20,22-Dienolide, 14,15beta-Epoxy-3beta-Hydroxy- (8CI) | BUFOGENIN | Bufa-20,22-Dienolide, 14,15-Epoxy-3-Hydroxy-, (3beta,5beta,15beta)- (9CI) | Resibufogenin | Respigon",,,,,,,,,,,,,,,"4206322","Bufogenin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1101784","C-Telopeptide of Type I Collagen Generated by Matrix Metalloproteinases","C107567","This polypeptide is comprised of the carboxy-terminal portions of fibrillar collagen, which are joined through trivalent crosslinks and released during the degradation of mature type I collagen by matrix metalloproteinases. Increased serum concentrations of these peptides are associated with pathologies that cause bone lysis, such as multiple myeloma, osteolytic metastases, and rheumatoid arthritis. Increased blood levels of these peptides are associated with renal insufficiency.","C-Telopeptide of Type I Collagen Generated by Matrix Metalloproteinases | 1CTP | C-Terminal Telopeptide Type I Collagen | CTX-MMP | Cross-Linked C-Terminal Telopeptide of Type I Collagen Generated by Matrix Metalloproteinases | ICTP | MMP-Generated C-Terminal Telopeptide Type 1 Collagen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813556","Cancer/Testis Antigen","C107566","A family of immunogenic proteins that are found in a wide variety of tumors but are not expressed in adult somatic cells. Non-pathologic expression of these proteins is restricted to male germ cells.","Cancer/Testis Antigen | CT | CTA | CTAs | CTs | Cancer Testis Antigen | Cancer Testis Antigens | Cancer/Testis Antigens",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0108555","Casein Kinase II","C107559","A serine/threonine kinase that is a tetrameric protein complex comprised of 2 catalytic alpha subunits and 2 regulatory beta subunits. This kinase complex is involved in the modulation of many cellular processes, including cell cycle progression and apoptosis regulation.","Casein Kinase 2 | CK II | CK2 | CKII | Casein Kinase II | EC 2.7.11.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814396","CYP3A Gene Locus","C107557","Human CYP3A gene locus is located within 7q21.3-q22.1 and is approximately 218 kb in length. This locus includes four protein-encoding genes, CYP3A4, CYP3A5, CYP3A7 and CYP3A43, and two pseudogenes, CYP3A5P1 and CYP3A5P2. The protein-encoding genes are involved in drug metabolism and the biosynthesis of cholesterol, steroids and other lipids.","CYP3A Gene Locus | CYP3 | CYP3A | Cytochrome P450 Family 3 Subfamily A Gene Locus | Cytochrome P450, Family 3, Subfamily A Gene Locus | Cytochrome P450, Subfamily IIIA (Niphedipine Oxidase) Gene Locus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830136","FGFR2 NP_000132.3:p.C382R","C107597","A change in the amino acid residue at position 382 in the fibroblast growth factor receptor 2 protein where cysteine has been replaced by arginine.","FGFR2 NP_000132.3:p.C382R | CD332 Antigen C382R | CD332 Antigen Cys382Arg | FGFR-2 C382R | FGFR-2 Cys382Arg | FGFR2 C382R | FGFR2 Cys382Arg | FGFR2 NP_000132.3:p.Cys382Arg | FGFR2 p.C382R | FGFR2 p.Cys382Arg | Fibroblast Growth Factor Receptor 2 C382R | Fibroblast Growth Factor Receptor 2 Cys382Arg | KGFR C382R | KGFR Cys382Arg | Keratinocyte Growth Factor Receptor C382R | Keratinocyte Growth Factor Receptor Cys382Arg | NP_000132.3:p.C382R | NP_000132.3:p.Cys382Arg | NP_001138385.1:p.C383R | NP_001138385.1:p.Cys383Arg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830135","FGFR2 NP_000132.3:p.K659E","C107606","A change in the amino acid residue at position 659 in the fibroblast growth factor receptor 2 protein where lysine has been replaced by glutamic acid.","FGFR2 NP_000132.3:p.K659E | CD332 Antigen K659E | CD332 Antigen Lys659Glu | FGFR-2 K659E | FGFR-2 Lys659Glu | FGFR2 K659E | FGFR2 Lys659Glu | FGFR2 NP_000132.3:p.Lys659Glu | FGFR2 p.K659E | FGFR2 p.Lys659Glu | Fibroblast Growth Factor Receptor 2 K659E | Fibroblast Growth Factor Receptor 2 Lys659Glu | KGFR K659E | KGFR Lys659Glu | Keratinocyte Growth Factor Receptor K659E | Keratinocyte Growth Factor Receptor Lys659Glu | NP_000132.3:p.K659E | NP_000132.3:p.Lys659Glu | NP_001138385.1:p.K660E | NP_001138385.1:p.Lys660Glu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830134","FGFR2 NP_000132.3:p.N549H","C107604","A change in the amino acid residue at position 549 in the fibroblast growth factor receptor 2 protein where asparagine has been replaced by histidine.","FGFR2 NP_000132.3:p.N549H | CD332 Antigen Asn549His | CD332 Antigen N549H | FGFR-2 Asn549His | FGFR-2 N549H | FGFR2 Asn549His | FGFR2 N549H | FGFR2 NP_000132.3:p.Asn549His | FGFR2 p.Asn549His | FGFR2 p.N549H | Fibroblast Growth Factor Receptor 2 Asn549His | Fibroblast Growth Factor Receptor 2 N549H | KGFR Asn549His | KGFR N549H | Keratinocyte Growth Factor Receptor Asn549His | Keratinocyte Growth Factor Receptor N549H | NP_000132.3:p.Asn549His | NP_000132.3:p.N549H | NP_001138385.1:p.Asn550His | NP_001138385.1:p.N550H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830133","FGFR2 NP_000132.3:p.N549K","C107600","A change in the amino acid residue at position 549 in the fibroblast growth factor receptor 2 protein where asparagine has been replaced by lysine.","FGFR2 NP_000132.3:p.N549K | CD332 Antigen Asn549Lys | CD332 Antigen N549K | FGFR-2 Asn549Lys | FGFR-2 N549K | FGFR2 Asn549Lys | FGFR2 N549K | FGFR2 NP_000132.3:p.Asn549Lys | FGFR2 p.Asn549Lys | FGFR2 p.N549K | Fibroblast Growth Factor Receptor 2 Asn549Lys | Fibroblast Growth Factor Receptor 2 N549K | KGFR Asn549Lys | KGFR N549K | Keratinocyte Growth Factor Receptor Asn549Lys | Keratinocyte Growth Factor Receptor N549K | NP_000132.3:p.Asn549Lys | NP_000132.3:p.N549K | NP_001138385.1:p.Asn550Lys | NP_001138385.1:p.N550K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830132","FGFR2 NP_000132.3:p.P253R","C107591","A change in the amino acid residue at position 253 in the fibroblast growth factor receptor 2 protein where proline has been replaced by arginine.","FGFR2 NP_000132.3:p.P253R | CD332 Antigen P253R | CD332 Antigen Pro253Arg | FGFR-2 P253R | FGFR-2 Pro253Arg | FGFR2 NP_000132.3:p.Pro253Arg | FGFR2 P253R | FGFR2 Pro253Arg | FGFR2 p.P253R | FGFR2 p.Pro253Arg | Fibroblast Growth Factor Receptor 2 P253R | Fibroblast Growth Factor Receptor 2 Pro253Arg | KGFR P253R | KGFR Pro253Arg | Keratinocyte Growth Factor Receptor P253R | Keratinocyte Growth Factor Receptor Pro253Arg | NP_000132.3:p.P253R | NP_000132.3:p.Pro253Arg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830131","FGFR2 NP_000132.3:p.S252W","C107585","A change in the amino acid residue at position 252 in the fibroblast growth factor receptor 2 protein where serine has been replaced by tryptophan.","FGFR2 NP_000132.3:p.S252W | CD332 Antigen S252W | CD332 Antigen Ser252Trp | FGFR-2 S252W | FGFR-2 Ser252Trp | FGFR2 NP_000132.3:p.Ser252Trp | FGFR2 S252W | FGFR2 Ser252Trp | FGFR2 p.S252W | FGFR2 p.Ser252Trp | Fibroblast Growth Factor Receptor 2 S252W | Fibroblast Growth Factor Receptor 2 Ser252Trp | KGFR S252W | KGFR Ser252Trp | Keratinocyte Growth Factor Receptor S252W | Keratinocyte Growth Factor Receptor Ser252Trp | NP_000132.3:p.S252W | NP_000132.3:p.Ser252Trp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830130","FGFR2 NP_000132.3:p.S372C","C107593","A change in the amino acid residue at position 372 in the fibroblast growth factor receptor 2 protein where serine has been replaced by cysteine.","FGFR2 NP_000132.3:p.S372C | CD332 Antigen S372C | CD332 Antigen Ser372Cys | FGFR-2 S372C | FGFR-2 Ser372Cys | FGFR2 NP_000132.3:p.Ser372Cys | FGFR2 S372C | FGFR2 Ser372Cys | FGFR2 p.S372C | FGFR2 p.Ser372Cys | Fibroblast Growth Factor Receptor 2 S372C | Fibroblast Growth Factor Receptor 2 Ser372Cys | KGFR S372C | KGFR Ser372Cys | Keratinocyte Growth Factor Receptor S372C | Keratinocyte Growth Factor Receptor Ser372Cys | NP_000132.3:p.S372C | NP_000132.3:p.Ser372Cys | NP_001138385.1:p.S373C | NP_001138385.1:p.Ser373Cys",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827386","FGFR2 NP_000132.3:p.Y375C","C107595","A change in the amino acid residue at position 375 in the fibroblast growth factor receptor 2 protein where tyrosine has been replaced by cysteine.","FGFR2 NP_000132.3:p.Y375C | CD332 Antigen Tyr375Cys | CD332 Antigen Y375C | FGFR-2 Tyr375Cys | FGFR-2 Y375C | FGFR2 NP_000132.3:p.Tyr375Cys | FGFR2 Tyr375Cys | FGFR2 p.Tyr375Cys | FGFR2 p.Y375C | Fibroblast Growth Factor Receptor 2 Tyr375Cys | Fibroblast Growth Factor Receptor 2 Y375C | KGFR Y375C | Keratinocyte Growth Factor Receptor Tyr375Cys | Keratinocyte Growth Factor Receptor Y375C | NP_000132.3:p.Tyr375Cys | NP_000132.3:p.Y375C | NP_001138385.1:p.Tyr376Cys | NP_001138385.1:p.Y376C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0060327","Fibrin Monomer","C107563","Derivatives of thrombin-cleaved fibrinogen that are plasma soluble due to limiting amounts of the clot promoting protein factor XIII. Detection of these proteins may be used to aid in the diagnosis or exclusion of thrombotic events or determine if a patient is at risk for post-operative hemorrhage.","Fibrin Monomer | Soluble Fibrin Monomer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416381","IL10RA Gene","C107582","This gene plays a role in immunosuppression.","IL10RA Gene | IL10RA | Interleukin 10 Receptor, Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1721046","Interleukin-8 Receptor","C107588","A family of chemokine receptors that specifically bind to interleukin-8 and play a role in G-protein-coupled receptor-mediated signal transduction.","Interleukin-8 Receptor | IL8R | Interleukin 8 Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416716","KRT13 Gene","C107625","This gene is involved in epithelial cell structure.","KRT13 Gene | KRT13 | Keratin 13 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025562","Metanephrine","C107556","A product of the O-methylation of epinephrine by catechol O-methyltransferase, which has no physiologic activity. Increased levels of free metanephrine in patient blood plasma samples may be a diagnostic indicator for pheochromocytoma.","Metanephrine | 4-Hydroxy-3-Methoxy-Alpha-((Methylamino)Methyl)-Benzenemethanol | Benzenemethanol, 4-Hydroxy-3-Methoxy-Alpha-((Methylamino)Methyl)- | METANEPHRINE | METANEPHRINE, (+/-) | Metadrenaline",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2936598","Pancreatic Stellate Cell","C107531","A star-shaped, myofibroblast-like cell in the pancreas associated with tissue maintenance. When pancreatic stellate cells are activated in response to an injury, they proliferate and synthesize large amounts of extracellular matrix. Pancreatic cancer cells can increase the activation of pancreatic stellate cells, which leads to fibrosis.","Pancreatic Stellate Cell | PSC | PSCs | PaSC | PaSCs | Pancreatic Stellate Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827240","PDGFRA NP_006197.1:p.D842V","C107570","A change in the amino acid residue at position 842 in the platelet-derived growth factor receptor alpha protein where aspartic acid has been replaced by valine.","PDGFRA NP_006197.1:p.D842V | CD140a Antigen Asp842Val | CD140a Antigen D842V | NP_006197.1:p.Asp842Val | NP_006197.1:p.D842V | PDGFR Alpha D842V Mutation | PDGFR-Alpha Asp842Val | PDGFR-Alpha D842V | PDGFRA Asp842Val | PDGFRA D842V | PDGFRA D842V Mutation | PDGFRA NP_006197.1:p.Asp842Val | PDGFRA p.Asp842Val | PDGFRA p.D842V | Platelet-Derived Growth Factor Receptor Alpha Asp842Val | Platelet-Derived Growth Factor Receptor Alpha D842V",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418948","PROS1 Gene","C107571","This gene plays a role in inhibiting blood coagulation.","PROS1 Gene | PROS1 | Protein S (Alpha) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0534165","S-Nitroso-Hemoglobin","C107564","Hemoglobin that has a nitric oxide bound to the cysteine at position 93 in the beta-globin chain.","S-Nitroso-Hemoglobin | S-Nitrosated Hemoglobin | S-Nitrosohemoglobin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420114","SLC18A1 Gene","C107577","This gene is involved in the transport of biogenic monoamines.","SLC18A1 Gene | SLC18A1 | Solute Carrier Family 18 (Vesicular Monoamine Transporter), Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420137","SLC22A2 Gene","C107574","This gene is involved in mediating the uptake of organic compounds.","SLC22A2 Gene | SLC22A2 | Solute Carrier Family 22 (Organic Cation Transporter), Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420361","SPINT1 Gene","C107610","This gene plays a role in the regulation of hepatocyte growth factor maturation.","SPINT1 Gene | SPINT1 | Serine Peptidase Inhibitor, Kunitz Type 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040059","Thromboxane B2","C107560","An eicosanoid and biologically inactive metabolite of thromboxane A2. Thromboxane B2 is released during anaphylaxis. As thromboxane A2 has a short half-life, the levels of thromboxane B2 can be used to indirectly measure the production of thromboxane A2","Thromboxane B2 | (5Z,13E,15S)-9alpha,11,15-Trihydroxythromboxa-5,13-Dien-1-Oic Acid | 5-Heptenoic Acid, 7-(Tetrahydro-4,6-Dihydroxy-2-(3-Hydroxy-1-Octenyl)- 2H-Pyran-3-Yl)-, (2R-(2alpha(1E,3S*),3beta(Z),4beta,6alpha))- | THROMBOXANE B2 | TXB2 | Thromboxa-5,13-Dien-1-Oic Acid, 9,11,15-Trihydroxy-, (5Z,9alpha,13E,15S)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421218","TTF1 Gene","C107622","This gene plays a role in the termination of transcription.","TTF1 Gene | TTF1 | Transcription Termination Factor, RNA Polymerase I Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421248","TXNRD1 Gene","C107616","This gene plays a role in the maintenance of cellular redox signaling.","TXNRD1 Gene | TXNRD1 | Thioredoxin Reductase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425351","TXNRD2 Gene","C107619","This gene is involved in the reduction of thioredoxin.","TXNRD2 Gene | TXNRD2 | Thioredoxin Reductase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0182291","Pillow","C107529","A cushion or support for the head or other body part; usually consisting of a cloth case surrounding a filler of feathers, down, plastic fibers, latex, rubber, or other foam material.","Pillow | ",,,,,,,,,,,,,,,"4029473","Pillow",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0586859","Pulmonologist","C93080","A doctor who specializes in treating diseases of the lungs.","Pulmonologist | pulmonary specialist | pulmonologist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810535","Expanded Prostate Cancer Index Composite","C107630","A self-administered questionnaire designed to evaluate patient function and bother after prostate cancer treatment.","Expanded Prostate Cancer Index Composite | EPIC | Expanded Prostate Cancer Index Composite (EPIC)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827009","Expanded Prostate Cancer Index Composite, Sexual Medications/Devices Supplement","C107631","A component of the EPIC designed to assess the use of erectile aids among patients treated for prostate cancer.","Expanded Prostate Cancer Index Composite, Sexual Medications/Devices Supplement | EPIC-SMD | Sexual Medications/Devices Supplement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829775","Have Penile Prosthesis","C107632","A question about whether an individual has or had a penile prosthesis.","Have Penile Prosthesis | Do you have a penile prosthesis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827683","Used Medications or Devices to Aid or Improve Erections","C107633","A question about whether an individual uses or used medications or devices to aid or improve erections.","Used Medications or Devices to Aid or Improve Erections | Have you used any medications or devices to aid or improve erections",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829135","Medicine or Device Tried or Currently Used to Improve Erection","C107634","A question about which medicine or device an individual uses or has used to improve an erection.","Medicine or Device Tried or Currently Used to Improve Erection | Medicine or device tried or currently used to improve erection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828613","Penile Injection Therapy","C107635","Self-administered injections of vasodilators into the corpus cavernosa to promote engorgement and tumescence of the glans with sexual stimulation.","Penile Injection Therapy | Penile injection therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827672","Vacuum Erection Device","C107636","Device consisting of a plastic cylinder with an elastic retention band at its base attached to an external pump. The pump creates a vacuum that draws blood into the shaft of the penis and then the user slides the elastic ring down to the base to maintain the erection.","Vacuum Erection Device | Vacuum erection device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829782","Have Not Tried It","C107637","A response that something has not been tried by an individual.","Have Not Tried It | Have NOT tried it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827771","Tried It but Not Helpful","C107638","A response that something has been tried by an individual but it has not been found to be helpful.","Tried It but Not Helpful | Tried it, but was NOT HELPFUL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829718","Helped but Not Using It Now","C107639","A response that something has helped an individual but it is not being used now.","Helped but Not Using It Now | It HELPED, but I am NOT using it NOW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829719","Helped and Using It Sometimes","C107640","A response that something has helped an individual and it is being used sometimes.","Helped and Using It Sometimes | It HELPED, and I use it SOMETIMES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829720","Helped and Using It Always","C107641","A response that something has helped an individual and it is being used always.","Helped and Using It Always | It HELPED, and I use it ALWAYS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830533","Describe Usual Quality of Erections Without Assistance of Medicines or Devices During Last 4 Weeks","C107642","A question about how an individual would describe the usual quality of their erections without the assistance of medications or devices during the last four weeks.","Describe Usual Quality of Erections Without Assistance of Medicines or Devices During Last 4 Weeks | How would you describe the usual quality of your erections WITHOUT THE ASSISTANCE of medicines or devices DURING THE LAST 4 WEEKS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828773","Not Firm Enough for Sexual Activity","C107643","A response about an individual's erections not being firm enough for any sexual activity.","Not Firm Enough for Sexual Activity | Not firm enough for any sexual activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830112","Firm Enough for Masturbation and Foreplay Only","C107644","A response about an individual's erections being firm enough for masturbation and foreplay only.","Firm Enough for Masturbation and Foreplay Only | Firm enough for masturbation and foreplay only",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830113","Firm Enough for Intercourse","C107645","A response about an individual's erections being firm enough for intercourse.","Firm Enough for Intercourse | Firm enough for intercourse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830498","Did You Take Any Medication Except the Study Drug for Vomiting During This Period","C107628","A question about whether an individual took any medication, except the study drug, for vomiting during the specified time period.","Did You Take Any Medication Except the Study Drug for Vomiting During This Period | Did you take any medication (except study drug) for VOMITING during this period",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830500","Did You Take Any Medication Except the Study Drug for Nausea During This Period","C107629","A question about whether an individual took any medication, except the study drug, for nausea during the specified time period.","Did You Take Any Medication Except the Study Drug for Nausea During This Period | Did you take any medication (except study drug) for NAUSEA during this period",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205423","Certain","C107561","Having no doubts; definitely true.","Certain | Certainty | Confident | Sure",,,,,,,,,,,,,,,"4065908","Certain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3538993","Complete Response with Incomplete Bone Marrow Recovery","C103385","The disappearance of all signs of cancer in response to treatment accompanied by incomplete bone marrow recovery, as evidenced by persistent anemia, thrombocytopenia or neutropenia.","Complete Response with Incomplete Bone Marrow Recovery | CRi | Complete Remission with Incomplete Blood Count Recovery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677936","Refractory Carcinoma","C8511","A carcinoma that does not respond to treatment.","Refractory Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540846","Treatment Failure Reason","C102721","The reason the drug or therapy was unsuccessful in treating the condition.","Treatment Failure Reason | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335851","SNCG Gene","C20858","This gene plays a role in central nervous development and has implicated in the in the pathogenesis of neurodegenerative diseases.","SNCG Gene | SNCG | Synuclein Gamma Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823882","YBX1 Gene","C93119","This gene plays a role in both transcription and mRNA splicing.","YBX1 Gene | Y Box Binding Protein 1 Gene | YBX1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3251957","PAX7/FOXO1 Fusion Protein, Human","C99364","A fusion protein (828 aa, ~90 kDa) encoded by the PAX7/FOXO1 fusion gene. This protein is comprised of the N-terminal DNA binding domain of paired box protein Pax-7 and the C-terminal transactivation domain of forkhead box protein O1.","PAX7/FOXO1 Fusion Protein | PAX7-FKHR Fusion Protein | PAX7-FOXO1 Fusion Protein | PAX7/FKHR Fusion Protein | PAX7::FOXO1 Fusion Protein | Paired Box Protein Pax-7/Forkhead Box Protein O1 Fusion Protein | Pax7-Forkhead Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1850988","PAX7/FOXO1 Fusion Gene","C99363","A fusion gene (~2.5 kb) that results from a chromosomal translocation t(1;13)(p36;q14) which fuses intron 7 of the PAX7 gene with intron 1 of the FOXO1 gene. This rearrangement is associated with alveolar rhabdomyosarcoma and rare cases of embryonal rhabdomyosarcoma.","PAX7/FOXO1 Fusion Gene | PAX7-FKHR Fusion Gene | PAX7-FOXO1 Fusion Gene | PAX7/FKHR Fusion Gene | PAX7::FOXO1 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366486","LAMP3 Gene","C24539","This gene is involved in antigen processing and immune responses.","LAMP3 Gene | LAMP3 | Lysosomal-Associated Membrane Protein 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366618","CDKN1C Gene","C18371","This gene plays a regulatory role in the cell cycle.","CDKN1C Gene | CDKN1C | Cyclin Dependent Kinase Inhibitor 1C Gene | Cyclin-Dependent Kinase Inhibitor 1C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0055767","cinobufagin","C95021","A bufadienolide compound extracted from the dried venom secreted by the parotid glands of toads and one of the glycosides in the traditional Chinese medicine ChanSu, with potential antineoplastic activity. Although the mechanism of action of cinobufagin is still under investigation, it has been found to suppress cancer cell proliferation and cause apoptosis in cancer cells via a sequence of apoptotic modulators that include mitochondrial Bax and cytosolic chromosome c, and caspases 3, 8, and 9. Possible upstream mediators of cinobufagin-induced apoptosis include Fas and p53.","Cinobufagin | CINOBUFAGIN | Cinobufacini",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0724693","Sildenafil Citrate","C26670","The citrate salt form of sildenafil, an orally bioavailable pyrazolopyrimidinone derivative structurally related to zaprinast, with vasodilating and potential anti-inflammatory activities. Upon oral administration, sildenafil selectively targets and inhibits cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), thereby inhibiting the PDE5-mediated degradation of cGMP found in smooth muscle and increasing cGMP availability. This results in prolonged smooth muscle relaxation in the corpus cavernosum of the penis, thereby causing vasodilation, blood engorgement and a prolonged penile erection.  In the smooth muscle of the pulmonary vasculature, the increase in cGMP results in smooth muscle relaxation, vasodilation of the pulmonary vascular bed, relieving pulmonary hypertension and increasing blood flow in the lungs. In addition, sildenafil may reduce airway inflammation and mucus production.","Sildenafil Citrate | Revatio | SILDENAFIL CITRATE | Viagra | sildenafil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334493","MCM6 Gene","C20376","This gene plays a role in the initiation and licensing of DNA replication.","MCM6 Gene | MCM6 | MCM6 Minichromosome Maintenance Deficient 6 (MIS5 Homolog, S. Pombe) (S. Cerevisiae) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420631","HNF1A Gene","C97825","This gene plays a role in both DNA binding and transcriptional modulation.","HNF1A Gene | HNF1 Homeobox A Gene | HNF1A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0772415","Rivastigmine Tartrate","C47707","The tartrate salt form of rivastigmine, a phenylcarbamate derivative exhibiting cognitive stimulating property. Although the mechanism of action has not been fully elucidated, rivastigmine tartrate may bind reversibly to cholinesterase, thereby decreasing the breakdown of acetylcholine and enhancing cholinergic function.","Rivastigmine Tartrate | Carbamic Acid, Ethylmethyl-, 3-((1S)-1-(dimethylamino)ethyl)phenyl Ester,(2R,3R)-2,3-dihydroxybutanedioate(1:1) | Exelon | RIVASTIGMINE TARTRATE | SDZ-ENA 713",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698291","Azilsartan Medoxomil","C75110","A medoxomil prodrug of azilsartan, an angiotensin II receptor antagonist with antihypertensive activity. Upon hydrolysis, azilsartan selectively and competitively binds to the AT1 subtype angiotensin II receptor and blocks the binding of angiotensin II to the receptor, thus promoting vasodilatation and counteracting the effects of aldosterone. Converted from angiotensin I by angiotensin-converting enzyme (ACE), angiotensin II stimulates the adrenal cortex to synthesize and secrete aldosterone, decreasing sodium excretion and increasing potassium excretion, and acts as a vasoconstrictor in vascular smooth muscle.","Azilsartan Medoxomil | (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-((2'-(5-oxo-4,5-dihydro-1,2,4- oxadiazol-3-yl)biphenyl-2-yl)methyl)-1H-benzo(d)imidazole-7-carboxylate | AZILSARTAN MEDOXOMIL | Edarbi | TAK-491",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425758","MAPKAP1 Gene","C105117","This gene is involved in growth factor-mediated signaling.","MAPKAP1 Gene | MAPKAP1 | Mitogen-Activated Protein Kinase Associated Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0194401","Radical Cystectomy","C15396","The surgical removal of the entire bladder, a portion of the urethra, adjacent lymph nodes, and additional genitourinary structures, including the prostate and a portion of the vas deferens in men, and the ovaries, fallopian tubes, uterus, and a portion of the vagina in women.","Radical Cystectomy | Complete Cystectomy | radical cystectomy",,,,,,,,,,,,,,,"4273866","Radical cystectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2986547","Non-Target Lesion Identification","C94521","The identification of a lesion that is not considered a target lesion but may be affected by the therapeutic intervention.","Non-Target Lesion Identification | NON-TARGET | Non-Index",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0082584","Tacrolimus Binding Proteins","C17409","A class of immunosuppressant binding proteins (immunophilins) specific for FK506 (tacrolimus) and rapamycin.","FK506 Binding Protein | FKBP | KBP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1714000","Gadoxetate Disodium","C77548","A paramagnetic contrast agent consisting of the disodium salt of the gadolinium ion chelated with the lipophilic moiety ethoxybenzyl (EOB) bound to diethylenetriamine pentaacetic acid (DTPA). When placed in a magnetic field, gadolinium produces a large magnetic moment and so a large local magnetic field, which can enhance the relaxation rate of nearby protons; as a result, the signal intensity of tissue images observed with magnetic resonance imaging (MRI) may be enhanced. Because this agent is preferentially taken up by normal functioning hepatocytes, normal hepatic tissue is enhanced with MRI while tumor tissue is unenhanced. In addition, because this agent is excreted in the bile, it may be used to visualize the biliary system using MRI.","Gadoxetate Disodium | Disodium (N-((2S)-2-(bis(carboxymethyl)amino)-3-(p-ethoxyphenyl)propyl)-N-(2-(bis(carboxymethyl)amino)ethyl)glycinato(5-))gadolinate(2-) | Eovist | GADOXETATE DISODIUM | Gadolinium EOB DTPA | Gadolinium Ethoxybenzyl Diethylenetriamine Pentaacetic Acid | Gadolinium Ethoxybenzyl Diethylenetriaminepentaacetic Acid | Gadoxetic Acid Disodium | Gd-(S)-EOB-DTPA | Gd-EOB-DTPA | Primovist | ZK 139834",,,,,,,,,,,,,,,"4260238","Gadoxetate disodium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519839","Urothelial Cell","C33841","A cell found in the layer of transitional epithelium in the wall of the bladder, ureter, and renal pelvis, external to the lamina propria.","Urothelial Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539076","Pretreatment","C103339","Any relevant actions that were performed or occurred prior to a specific treatment.","Pretreatment | pretreatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242550","Risk Reduction","C19694","Personal behaviors designed to minimize and control the probability and/or impact of unfortunate events.","Risk Reduction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227599","Bladder Urothelial Cell","C32210","An epithelial cell, found in the bladder, originally thought to represent a transitional form between stratified squamous and columnar epithelial cells.  In the contracted condition the epithelium consists of many cell layers, whereas in the stretched condition usually only two layers of cells can be distinguished.","Bladder Urothelial Cell | Bladder Transitional Cell",,,,,,,,,,,,,,,"4069277","Urinary tract transitional epithelial cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0201976","Serum Creatinine Measurement","C61023","A quantitative measurement of the amount of creatinine present in a sample of serum.","Serum Creatinine Measurement | ",,,,,,,,,,,,,,,"4013964","Creatinine measurement, serum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042672","Vinca Alkaloid Compound","C932","A type of drug that blocks cell growth by stopping mitosis (cell division). Vinca alkaloids interfere with microtubules (cellular structures that help move chromosomes during mitosis). They are used to treat cancer. A vinca alkaloid is a type of mitotic inhibitor and a type of antimicrotubule agent.","Vinca Alkaloid Compound | Vinca Alkaloids | vinca alkaloid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337438","Glucose Measurement","C105585","The determination of the amount of glucose present in a sample.","Glucose Measurement | GLUC | Glucose",,,,,,,,,,,,,,,"4149519","Glucose measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828018","Single Chamber Power Injector","C110924","A pump system with one enclosed reservoir, designed to deliver intravenous contrast agent.","Single Chamber Power Injector | Single Chamber Contrast Agent Power Injector",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830381","Dual Chamber Power Injector","C110944","A pump system with two enclosed reservoirs, designed to deliver various concentrations of intravenous contrast media.","Dual Chamber Power Injector | Dual Chamber Contrast Agent Power Injector",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828271","Saline Flush","C110945","A saline solution used to force an agent from tubing and peripheral veins into the central blood volume.","Saline Flush | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828718","Older Americans Resource Scale Multidimensional Functional Assessment Questionnaire","C110946","A questionnaire that seeks information both on a person's level of functioning and on their need and utilization of services.","Older Americans Resource Scale Multidimensional Functional Assessment Questionnaire | OARS Multidimensional Functional Assessment Questionnaire | OMFAQ | Older Americans Resource Scale (OARS) Multidimensional Functional Assessment Questionnaire (OMFAQ) | Older Americans Resource Scale (OARS) Multidimensional Functional Assessment Questionnaire (OMFAQ) ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831740","Activities of Daily Living Dimension of Functioning Questionnaire","C110947","A section of the Older Americans Resource Scale Multidimensional Functional Assessment Questionnaire (OMFAQ) that seeks information on a person's level of functioning on daily activities of living.","Activities of Daily Living Dimension of Functioning Questionnaire | Activities of Daily Living Dimension of Functioning | Activities of Daily Living Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827681","Can you use the telephone","C110948","A question about whether an individual is able to use a telephone.","Use the Telephone Ability Question | Ability to Use Telephone | Ability to Use the Telephone | Can you use the telephone | Use the Telephone | Use the Telephone | Use the Telephone Ability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829984","Get to Places Out of Walking Distance","C110949","A question about whether an individual is able to get to places beyond walking distance.","Get to Places Out of Walking Distance | Can you get to places out of walking distance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829961","Go Shopping for Groceries or Clothes","C110950","A question about whether an individual is able to go shopping for groceries or clothes.","Go Shopping for Groceries or Clothes Question | Can you go shopping for groceries or clothes | Go Shopping for Groceries or Clothes | Go Shopping for Groceries or Clothes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828485","Prepare Your Meals","C110951","A question about whether an individual is able to prepare meals for themselves.","Prepare Your Meals | Ability to Prepare Food | Can you prepare your own meals | Food Preparation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL451689","Do Housework","C110952","A question about whether an individual is able to do housework.","Do Housework Question | Ability to Do Housekeeping | Can you do your housework | Do Housework | Do Housework | Housekeeping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827867","Take Your Medicines","C110953","A question about whether an individual is able to take their medicine.","Take Your Medicines | Can you take your own medicines",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829902","Handle Your Money","C110954","A question about whether an individual is able to handle their money.","Handle Your Money | Can you handle your own money",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827452","Without Help","C110956","A response indicating that an individual is able to do something without assistance.","Without Help | without help",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827451","With Some Help","C110957","A response indicating that an individual is able to do something only with assistance.","With Some Help | with some help",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831039","Completely Unable","C110958","A response indicating that an individual is completely unable to do something.","Completely Unable | Unable to Do | completely unable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828780","Not Answered","C110959","Indicates that no answer was given.","Not Answered | Not answered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827351","Have Current Illness","C110955","A question about whether an individual currently has a disease.","Have Current Illness | Do you have any of the following illnesses at the present time | Have Current Illness or Condition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831765","6-Item Orientation-Memory-Concentration Test","C110928","A screening test for cognitive impairment that is administered by a non-physician. This test is designed to discriminate between mild, moderate, and severe cognitive deficits.","6-Item Orientation-Memory-Concentration Test | OMC | Orientation-Memory-Concentration Test | Orientation-Memory-Concentration Test ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827478","What Year is it","C110929","A question asking an individual to state the current year.","What Year is it | What year is it now",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827479","What Month is it","C110930","A question asking an individual to state the current month.","What Month is it | What month is it now",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831748","About What Time is it","C110931","A question asking an individual to state the current time, to within 1 hour.","About What Time is it | About what time is it, within 1 hour",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830995","Count Backwards from 20 to 1","C110932","A request that an individual count backwards from 20 to 1.","Count Backwards from 20 to 1 | Count backwards 20 to 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828226","Say the Months in Reverse Order","C110933","A request that an individual say the months of the year in reverse order.","Say the Months in Reverse Order | Say the months in reverse order",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828340","Repeat the Memory Phrase","C110934","A request that an individual repeat a memory phrase.","Repeat the Memory Phrase | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811844","Estimated Glomerular Filtration Rate","C110935","A laboratory test that estimates kidney function. It is calculated using an individual's serum creatinine measurement, age, gender, and race. Actual results are reported when the estimated glomerular filtration rate is less than 60 ml/min.","Estimated Glomerular Filtration Rate | GFRE | Glomerular Filtration Rate, Estimated | eGFR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335332","Papillomavirus Transforming Protein E6","C19170","Binds to and promotes degradation of p53 protein resulting in disruption of cell cycle regulation.","Papillomavirus Transforming Protein E6 | E6 | HPV E6 | Viral Protein E6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334111","IL1A Gene","C28592","This gene plays a role in the mediation of inflammation and immunity.","IL1A Gene | IL1A | Interleukin 1, Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205112","Basal","C90067","The lowest layer of a structure.","Basal | BASAL",,,,,,,,,,,,,,,"4238021","Basal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0678579","Brown","C48332","Any of a group of colors between red and yellow in hue that are medium to low in lightness and low to moderate in saturation.","Brown | BROWN",,,,,,,,,,,,,,,"4153957","Brown color",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3812743","Organ Procurement and Transplantation Network","C110970","The transplant network established by the U.S. Congress under the National Organ Transplant Act of 1984. It is a public-private partnership, linking all professionals involved in the national donation and transplantation system.","Organ Procurement and Transplantation Network | OPTN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826868","United Network for Organ Sharing","C110972","The organization that administers the Organ Procurement and Transplantation Network under contract with the Health Resources and Services Administration of the U.S. Department of Health and Human Services.","United Network for Organ Sharing | UNOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1368107","Bone Marrow Aplasia","C110960","Depletion of stem cells in the bone marrow that results in the lack of production of hematopoietic cells.","Bone Marrow Aplasia | ",,,,,,,,,,,,,,,"4117422","Aplastic bone marrow",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829547","Index Lesion","C110961","The most clinically significant tumor lesion targeted by therapy. The lesion is typically the largest or highest graded of the tumor foci detected.","Index Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827266","Non-Index Lesion","C110962","Any tumor lesion other than the largest tumor lesion targeted by therapy.","Non-Index Lesion | BCR-ABL Tyrosine Kinase Inhibitor-Resistant Mutation ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831388","BCR-ABL TKI-Resistant Mutation","C110963","A molecular genetic abnormality in the kinase domain of the BCR-ABL fusion gene that results in resistance to tyrosine kinase inhibitors.","BCR-ABL TKI-Resistant Mutation | BCR-ABL Tyrosine Kinase Inhibitor-Resistant Mutation | BCR-ABL1 TKI-Resistant Mutation | BCR-ABL1 Tyrosine Kinase Inhibitor-Resistant Mutation | BCR/ABL TKI-Resistant Mutation | BCR/ABL1 TKI-Resistant Mutation | BCR/ABL1 Tyrosine Kinase Inhibitor-Resistant Mutation | BCR::ABL TKI-Resistant Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828770","Not Meeting Criteria","C110964","Indicates that an individual fails to meet the criteria for a particular study.","Not Meeting Criteria | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0150641","Instrumental Activities of Daily Living","C110966","A section of the Older Americans Resource Scale Multidimensional Functional Assessment Questionnaire (OMFAQ) that seeks information about a person's functional ability to conduct the complex activities of daily living that allow for independent living within a community.","Instrumental Activities of Daily Living | IADL",,,,,,,,,,,,,,,"4164981","Instrumental activities of daily living",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828719","Older Americans Resources and Services Comorbidity Scale","C110967","A section of the Older Americans Resources and Services (OARS) physical health questionnaire that rates the type of comorbidity and the impact of that comorbidity on an individual's daily function.","Older Americans Resources and Services Comorbidity Scale | OARS Comorbidity Scale | Older Americans Resources and Services (OARS) Comorbidity Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813178","Medical Outcomes Study Physical Functioning Scale","C110965","A survey of multiple dimensions of support, representing the physical functioning scale.","Medical Outcomes Study Physical Functioning Scale | MOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829281","Limited by Health","C110971","An indication that a person's activities are limited by their health condition.","Limited by Health | Health Limitation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827557","Vigorous Activities Such As Running, Lifting Heavy Objects, or Participating In Strenuous Sports","C110973","A question about vigorous activities such as running, lifting heavy objects, or participating in strenuous sports.","Vigorous Activities Such As Running, Lifting Heavy Objects, or Participating In Strenuous Sports Question | Vigorous Activities Such As Running, Lifting Heavy Objects, or Participating In Strenuous Sports | Vigorous Activities Such As Running, Lifting Heavy Objects, or Participating In Strenuous Sports | Vigorous activities such as: running, lifting heavy objects, participating in strenuous sports",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828994","Moderate Activities Such As Moving a Table, Pushing a Vacuum Cleaner, Bowling, or Playing Golf","C110974","A question about moderate activities such as moving a table, pushing a vacuum cleaner, bowling, or playing golf.","Moderate Activities Such As Moving a Table, Pushing a Vacuum Cleaner, Bowling, or Playing Golf Question | Moderate Activities Such As Moving a Table, Pushing a Vacuum Cleaner, Bowling, or Playing Golf | Moderate Activities Such As Moving a Table, Pushing a Vacuum Cleaner, Bowling, or Playing Golf | Moderate activities such as: moving a table, pushing a vacuum cleaner, bowling, or playing golf",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829286","Lifting or Carrying Groceries","C110975","A question about lifting or carrying groceries.","Lifting or Carrying Groceries Question | Lifting or Carrying Groceries | Lifting or Carrying Groceries | Lifting or carrying groceries",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831080","Climbing Several Flights of Stairs","C110976","A question about climbing several flights of stairs.","Climbing Several Flights of Stairs Question | Climbing Several Flights of Stairs | Climbing Several Flights of Stairs | Climbing several flights of stairs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831081","Climbing One Flight of Stairs","C110977","A question about climbing one flight of stairs.","Climbing One Flight of Stairs Question | Climbing One Flight of Stairs | Climbing One Flight of Stairs | Climbing one flight of stairs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831371","Bending, Kneeling, or Stooping","C110978","A question about bending, kneeling, or stooping.","Bending, Kneeling, or Stooping | Bending, kneeling, or stooping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827523","Walking More Than a Mile","C110979","A question about walking more than a mile.","Walking More Than a Mile Question | Walking More Than a Mile | Walking More Than a Mile | Walking more than a mile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827521","Walking Several Blocks","C110980","A question about walking several blocks.","Walking Several Blocks Question | Walking Several Blocks | Walking Several Blocks | Walking several blocks",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827522","Walking One Block","C110981","A question about walking one block.","Walking One Block Question | Walking One Block | Walking One Block | Walking one block",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831396","Bathing or Dressing Yourself","C110982","A question about bathing or dressing yourself.","Bathing or Dressing Yourself Question | Bathing or Dressing Yourself | Bathing or Dressing Yourself | Bathing or dressing yourself",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829282","Limited a Lot","C110983","A response indicating that an individual feels limited a lot.","Limited a Lot | Very Limited | Yes, Limited A Lot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829283","Limited a Little","C110984","A response indicating that an individual feels limited a little.","Limited a Little | Hardly Limited | Hardly limited at all | Slightly Limited | Yes, Limited A Little",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828772","Not Limited at All","C110985","A response indicating that an individual does not feel limited at all.","Not Limited at All | No, Not Limited At All | Not limited",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829138","Medical Outcomes Study Social Activities","C110968","A survey of multiple dimensions of quality of life, representing the social activities scale.","Medical Outcomes Study Social Activities | Medical Outcomes Study Social Activities Survey",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828653","Past 4 Weeks","C110986","A period of time consisting of the 28 days before the present.","Past 4 Weeks | Last 4 Weeks",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828652","Past 6 Months","C110987","A period of time consisting of the 6 months before the present.","Past 6 Months | Last 6 Months",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828563","Physical Health or Emotional Problems","C110988","The state of a person's physical and emotional well-being.","Physical Health or Emotional Problems | Physical Health or Emotional Well-Being | Physical health or emotional problems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829529","Interference with Social Activities","C110989","The act of impeding a person from their normal social activities.","Interference with Social Activities | Interference with social activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812891","All of the Time","C110990","A response indicating that something happens or happened all of the time.","All of the Time | All of the time | All of time | Always",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3843358","Most of the Time","C110991","A response indicating that something happens or happened most of the time.","Most of the Time | More than Half the Time | Most Times | Most Times (Much More Than Half the Time) | Most of the time | Most of time | Most times (more than half the time) | Much More Than Half the Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL453506","Some of the Time","C110992","A response indicating that something happens or happened some of the time.","Some of the Time | Some of the time | Some of time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL453507","A Little of the Time","C110993","A response indicating that something happens or happened a little of the time.","A Little of the Time | A Little Bit | A Little Bit of the Time | A little of the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812882","None of the Time","C110994","A response indicating that something happens or happened none of the time.","None of the Time | None of the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828887","Much Less Socially Active Than Before","C110995","A response indicating that an individual has been much less socially active than before.","Much Less Socially Active Than Before | Much less socially active than before",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827974","Somewhat Less Socially Active Than Before","C110996","A response indicating that an individual has been somewhat less socially active than before.","Somewhat Less Socially Active Than Before | Somewhat less socially active than before",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831750","About As Socially Active As Before","C110997","A response indicating that an individual has been about as socially active as before.","About As Socially Active As Before | About as socially active as before",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827972","Somewhat More Socially Active As Before","C110998","A response indicating that an individual has been somewhat more socially active than before.","Somewhat More Socially Active As Before | Somewhat more socially active as before",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828885","Much More Socially Active Than Before","C110999","A response indicating that an individual has been much more socially active than before.","Much More Socially Active Than Before | Much more socially active than before",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828886","Much More Limited Than Others","C111000","A response indicating that an individual feels much more limited than others.","Much More Limited Than Others | Much more limited than others",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827973","Somewhat More Limited Than Others","C111001","A response indicating that an individual feels somewhat more limited than others.","Somewhat More Limited Than Others | Somewhat more limited than others",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831749","About The Same As Others","C111002","A response indicating that an individual feels about the same limitations as others.","About The Same As Others | About the same as others",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827975","Somewhat Less Limited Than Others","C111003","A response indicating that an individual feels somewhat less limited than others.","Somewhat Less Limited Than Others | Somewhat less limited than others",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828888","Much Less Limited Than Others","C111004","A response indicating that an individual feels much less limited than others.","Much Less Limited Than Others | Much less limited than others",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827988","Someone to Help You If You Were Confined to Bed","C111005","A question about whether an individual has someone to help them if they were confined to bed.","Someone to Help You If You Were Confined to Bed | Someone to help you if you were confined to bed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827981","Someone Who Will Listen When You Need to Talk","C111006","A question about whether an individual has or had someone who will listen when they need to talk.","Someone Who Will Listen When You Need to Talk | I have someone who will listen to me when I need to talk | Someone You Can Count On to Listen to You When You Need to Talk | Someone You Can Count On to Listen to You When You Need to Talk | Someone you can count on to listen to you when you need to talk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827990","Someone to Give You Good Advice About a Crisis","C111007","A question about whether an individual has someone to give them good advice about a crisis.","Someone to Give You Good Advice About a Crisis | Someone to give you good advice about a crisis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827985","Someone to Take You to the Doctor If You Needed it","C111008","A question about whether an individual has someone to take them to the doctor when needed.","Someone to Take You to the Doctor If You Needed it | Someone to take you to the doctor if you needed it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827989","Someone to Give You Information to Help You Understand a Situation","C111009","A question about whether an individual has someone to give them information to help them understand a situation.","Someone to Give You Information to Help You Understand a Situation | Someone to give you information to help you understand a situation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951043","Someone to Confide in or Talk to About Yourself or Your Problem","C111010","A question about whether an individual has or had someone to confide in or talk to about themself or their problems.","Someone to Confide in or Talk to About Yourself or Your Problem | How often is there someone to confide in or talk to about yourself or your problems | I have someone to confide in or talk to about myself or my problems | Someone There to Confide in or Talk About Yourself or Your Problems | Someone to confide in or talk to about yourself or your problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827986","Someone to Prepare Your Meals if You Were Unable to Do it Yourself","C111011","A question about whether an individual has someone to prepare their meals if they were unable to do it themselves.","Someone to Prepare Your Meals if You Were Unable to Do it Yourself Question | Someone to Prepare Your Meals if You Were Unable to Do it Yourself | Someone to Prepare Your Meals if You Were Unable to Do it Yourself | Someone to prepare your meals if you were unable to do it yourself",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827983","Someone Whose Advice You Really Want","C111012","A question about whether an individual has someone whose advice they really want.","Someone Whose Advice You Really Want | Someone whose advice you really want",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827987","Someone to Help You With Daily Chores if You Were Sick","C111013","A question about whether an individual has someone to help them with daily chores if they were sick.","Someone to Help You With Daily Chores if You Were Sick | Someone to help you with daily chores if you were sick",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827363","Someone to Share Your Most Private Worries and Fears With","C111014","A question about whether an individual has someone to share their most private worries and fears with.","Someone to Share Your Most Private Worries and Fears With | Someone to share your most private worries and fears with",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827984","Someone to Turn to For Suggestions About How to Deal With a Personal Problem","C111015","A question about whether an individual has someone to turn to for suggestions about how to deal with a personal problem.","Someone to Turn to For Suggestions About How to Deal With a Personal Problem | Someone to turn to for suggestions about how to deal with a personal problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827982","Someone Who Understands Your Problems","C111016","A question about whether an individual has someone who understands their problems.","Someone Who Understands Your Problems | Someone who understands your problems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516516","Chromosomal Duplication","C6829","An irregularity in the number of chromosomes, usually in the form of a gain of genetic material. (NCI)","Chromosomal Duplication | Chromosomal Amplification | Duplication, Chromosomal | dup",,,,,,,,,,,,,,,"4004777","Duplication of chromosome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0598174","Chromosomal Loss","C36315","A cytogenetic abnormality that refers to the loss of an entire chromosome, a chromosome arm or a chromosomal band.","Chromosomal Loss | Chromosome Loss",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032371","Acute Poliomyelitis","C35550","An acute infectious disorder that affects the nervous system. It is caused by the poliovirus. The virus spreads by direct contact, and can be prevented by prophylaxis with the polio vaccine.","Acute Poliomyelitis | Polia | Polio | Poliomyelitis",,,,,,,,,,,,,,,"378679","Acute poliomyelitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524461","Lumen","C94478","The cavity or channel within a tube or tubular organ such as a blood vessel or the intestine.","Lumen | lumen",,,,,,,,,,,,,,,"4034508","Structure of lumen of body system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3714553","Amber Color","C111017","A yellowish-orange color.","Amber | ",,,,,,,,,,,,,,,"763964","Amber color",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL455349","Hazel","C111018","A color that consists of brown-gold and green.","Hazel | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0678580","Violet","C111019","A bluish-purple color.","Violet | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831088","Class 1 Uveal Melanoma","C111020","Gene expression profiling that classifies uveal melanomas into a low-grade group.","Uveal Class 1 Melanoma | Class 1 Uveal Melanoma | Class 1 Uveal Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831087","Class 2 Uveal Melanoma","C111021","Gene expression profiling that classifies uveal melanomas into a high-grade group.","Uveal Class 2 Melanoma | Class 2 Uveal Melanoma | Class 2 Uveal Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831090","Class 1a Uveal Melanoma","C111022","Uveal melanoma with low metastatic risk as defined by gene expression profiling.","Uveal Class 1a Melanoma | Class 1a Uveal Melanoma | Class 1a Uveal Melanoma | Uveal Class 1a  Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831089","Class 1b Uveal Melanoma","C111023","Uveal melanoma with intermediate metastatic risk as defined by gene expression profiling.","Uveal Class 1b Melanoma | Class 1b Uveal Melanoma | Class 1b Uveal Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828484","Presence of Extravascular Matrix Patterns","C111024","A microscopic finding indicating the presence of patterns formed by malignant cells outside the blood vessel circulation in uveal melanoma.  The patterns are detectable using PAS stain without counterstaining with hematoxylin.","Presence of Extravascular Matrix Patterns | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830280","Extravascular Matrix Loops","C111025","A microscopic finding indicating the presence or absence of extravascular matrix loops in uveal melanoma.","Extravascular Matrix Loops | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827289","Loops Forming Networks","C111026","A microscopic finding indicating the presence or absence of loops forming networks in uveal melanoma.","Loops Forming Networks | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828878","Mushroom-Shaped Lesion","C111029","A lesion having the shape of a mushroom.","Mushroom-Shaped Lesion | Mushroom",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829904","Hampton County, SC","C110028","Spread of uveal melanoma beyond the sclera.","Hampton County, SC | Extrascleral Extension of Uveal Melanoma | Hampton County | Hampton County, South Carolina | SC049",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517946","Loss of Chromosome 1","C36597","A cytogenetic abnormality that refers to loss of all or part of chromosome 1.","Loss of Chromosome 1 | del(1)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517980","Loss of Chromosome 3","C36586","A cytogenetic abnormality that refers to loss of all or part of chromosome 3.","Loss of Chromosome 3 | del(3)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517423","Gain of Chromosome 8q","C36488","A chromosomal abnormality that refers to the gain of genetic material in the long arm of chromosome 8.","Gain of Chromosome 8q | 8q Gain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0241886","Extraocular","C94415","Situated outside of the eye.","Extraocular | extraocular",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711316","Dome-Shaped Lesion","C54253","A lesion having the shape of a dome.","Dome-Shaped Lesion | Dome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007294","Genetic Carrier","C111031","An individual who carries an inheritable genetic mutation without manifestation of the associated condition.","Genetic Carrier | Carrier",,,,,,,,,,,,,,,"4168318","Genetic disorder carrier",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0599883","Trait","C85496","Any genetically determined characteristic.","Trait | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1657365","ACE2 protein, human","C102530","Angiotensin-converting enzyme 2 (805 aa, ~92 kDa) is encoded by the human ACE2 gene. This protein plays a role in both vasodilation and protein cleavage.","Angiotensin-Converting Enzyme 2 | ACE-Related Carboxypeptidase | ACE2 | ACEH | Angiotensin I Converting Enzyme 2 | Angiotensin I-Converting Enzyme 2 | Angiotensin-Converting Enzyme Homolog | EC 3.4.17.23 | Metalloprotease MPROT15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827754","Tumor Infiltrating Macrophages","C111027","Non-neoplastic macrophages that infiltrate a tumor.","Tumor Infiltrating Macrophages | TIM | Tumor Infiltrating Macrophage | Tumor-Infiltrating Macrophage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007158","Glycoside","C66894","Any compound in which a sugar group is covalently bonded through its anomeric carbon to another group via an O-glycosidic bond or an S-glycosidic bond; glycosides involving the latter are also called thioglycosides. However, substances containing N-glycosidic bonds, where the anomeric carbon is bound to some other group via a nitrogen atom, are called glycosylamines; the term 'N-glycoside' is considered a misnomer by IUPAC and is discouraged. Furthermore, the sugar group needs to be bonded to a non-sugar for the molecule to qualify as a glycoside, thus excluding the polysaccharides. The sugar group in glycosides is known as the glycone, which can be a single sugar group (monosaccharide) or several sugar groups (oligosaccharide); the non-sugar group is known as the aglycone or genin.","Glycoside | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012798","Diuretic","C448","A class of agents that increases the production of urine by the kidney. Via various mechanism of actions, diuretics retain water in urine, thus provides a means of forced diuresis.","Diuretic | Diuretics | diuretic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881681","Medical Device Failure or Malfunction","C62996","An adverse event and reportable event where a medical device may have caused or contributed to a death or serious injury.","Medical Device Failure or Malfunction | Device Failure or Malfunction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640163","No Longer Marketed","C101675","Indicates that a product was previously promoted for use, but currently is not being promoted.","No Longer Marketed | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0853959","Material Break","C62973","Problem associated with undesired damage or breakage of those materials used in the device construction.","Material Break | Break | Medical Device Break",,,,,,,,,,,,,,,"607859","Broken",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038425","Streptomycin","C61952","An aminoglycoside antibiotic derived from Streptomyces griseus with antibacterial activity. Streptomycin irreversibly binds to the 16S rRNA and S12 protein within the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, streptomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.","Streptomycin | STREPTOMYCIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028365","Norfloxacin","C47638","A synthetic, broad-spectrum fluoroquinolone with antibacterial activity. Norfloxacin inhibits activity of DNA gyrase, thereby blocking bacterial DNA replication. Norfloxacin concentrates in the renal tubules and bladder and is bactericidal against a wide range of aerobic gram-positive and gram-negative organisms.","Norfloxacin | 1,4-Dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic Acid | Baccidal | Fulgram | MK-366 | NORFLOXACIN | Noroxin | Sebercim",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027603","Neomycin","C683","A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.","Neomycin | NEOMYCIN | Neomycin Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027353","Nalidixic Acid","C47630","A synthetic quinolone and antibacterial agent with urinary tract antiseptic activity. Nalidixic acid concentrates in the renal tubules and bladder and exerts its local antibacterial actions by interference of DNA gyrase activity, thereby inhibiting DNA synthesis during bacterial replication in a dose-dependent manner. Nalidixic acid is active against most gram-negative organisms that cause urinary tract infections.","Nalidixic Acid | 1,8-Naphthyridine-3-carboxylic Acid, 1-ethyl-1,4-dihydro-7-methyl-4-oxo- | 3-Carboxy-1-ethyl-7-methyl-1,8-naphthidin-4-one | Acide Nalidixico | NALIDIXIC ACID | Nalidixin | NegGram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022487","Kanamycin","C65997","An aminoglycoside antibiotic with antimicrobial property. Amikacin irreversibly binds to the bacterial 30S ribosomal subunit, specifically in contact with 16S rRNA and S12 protein within the 30S subunit. This leads to interference with translational initiation complex and, misreading of mRNA, thereby hampering protein synthesis and resulting in bactericidal effect. This agent is usually used for treatment of E. coli, Proteus species (both indole-positive and indole-negative), E. aerogenes, K. pneumoniae, S. marcescens, and Acinetobacter species.","Kanamycin | KANAMYCIN | Kanamycin Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016610","Fosfomycin","C61772","A phosphoenolpyruvate analogue and a synthetic broad-spectrum antibiotic with antimicrobial and bactericidal properties. Fosfomycin binds to and inactivates the enzyme enolpyruvate transferase. This leads to an irreversible blockage of the condensation of uridine diphosphate-N-acetylglucosamine with p-enolpyruvate, which is one of the first steps of bacterial cell wall synthesis, thereby eventually causing cell lysis and bacterial cell death.","Fosfomycin | FOSFOMYCIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008168","Chloramphenicol","C363","A semisynthetic, broad-spectrum antibiotic derived from Streptomyces venequelae with primarily bacteriostatic activity. Chloramphenicol diffuses through the bacterial cell wall and reversibly binds to the bacterial 50S ribosomal subunit. The binding interferes with peptidyl transferase activity, thereby prevents transfer of amino acids to the growing peptide chains and blocks peptide bond formation. As a result bacterial protein synthesis is blocked and impede bacterial cell proliferation.","Chloramphenicol | CHLORAMPHENICOL | [R-(R*,R*)]-2,2-Dichloro-N-[2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]acetamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041041","Trimethoprim","C908","A synthetic derivative of trimethoxybenzyl-pyrimidine with antibacterial and antiprotozoal properties.  As a pyrimidine inhibitor of bacterial dihydrofolate reductase, trimethoprim binds tightly to the bacterial enzyme, blocking the production of tetrahydrofolic acid from dihydrofolic acid.  The antibacterial activity of this agent is potentiated by sulfonamides. (NCI04)","Trimethoprim | 2,4-Diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine | Proloprim | TRIMETHOPRIM | Trimpex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043262","Carpal Region","C111033","The area of the body located between the antebrachial and metacarpal regions.","Carpal Region | Wrist Region",,,,,,,,,,,,,,,"4220073","Wrist region structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033567","Epoprostenol","C61748","An oral prostacyclin and a metabolite of arachidonic acid with antihypertensive and platelet inhibitory properties. Epoprostenol binds to prostacyclin receptors on platelet surfaces, subsequently activating platelet membrane adenyl cyclase and resulting in increased cAMP levels. The elevated cAMP triggers signal transduction that leads to vasodilations. In addition, this agent also functions as an antagonist of thromboxane A2, thereby resulting in direct vasodilation of pulmonary and systemic arterial vascular beds, and inhibition of platelet aggregation.","Epoprostenol | EPOPROSTENOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272315","Transplant Waiting List","C100078","A registry of patients awaiting an organ transplant. (ACC)","Transplant Waiting List | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829797","Have Had Seizures","C111043","A question about whether an individual has or had seizures.","Have Had Seizures | Did you have seizures | Have Seizures | I have had seizures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827297","Can Remember New Things","C111044","A question about whether an individual can remember new things.","Can Remember New Things | I can remember new things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829987","Get Frustrated That I Cannot Do Things I Used To","C111046","A question about whether an individual gets frustrated because they can't do things that they used to be able to do.","Get Frustrated That I Cannot Do Things I Used To | I get frustrated that I cannot do things I used to",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831594","Afraid of Having a Seizure","C111047","A question about whether an individual is or was afraid of having a seizure.","Afraid of Having a Seizure | I am afraid of having a seizure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829755","Have Trouble with Eyesight","C111048","A question about whether an individual has or had trouble with their eyesight.","Have Trouble with Eyesight | I have trouble with my eyesight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830160","Feel Independent","C111049","A question about whether an individual feels or felt independent.","Feel Independent | I feel independent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829759","Have Trouble Hearing","C111050","A question about whether an individual has or had trouble hearing.","Have Trouble Hearing | I have trouble hearing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831760","Able to Find the Right Words to Say","C111051","A question about whether an individual is or was able to find the right words to say what they mean.","Able to Find the Right Words to Say Question | Able to Find the Right Words to Say | Able to Find the Right Words to Say | I am able to find the right word or words to say what I mean",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830494","Difficulty Expressing Thoughts","C111052","A question about whether an individual has or had difficulty expressing their thoughts.","Difficulty Expressing Thoughts | I have difficulty expressing my thoughts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831307","Bothered by Change in Personality","C111053","A question about whether an individual is or was bothered by the change in their personality.","Bothered by Change in Personality | I am bothered by the change in my personality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831758","Able to Make Decisions and Take Responsibility","C111054","A question about whether an individual is or was able to make decisions and take responsibility.","Able to Make Decisions and Take Responsibility Question | Able to Make Decisions and Take Responsibility | Able to Make Decisions and Take Responsibility | I am able to make decisions and take responsibility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831305","Bothered by Drop in Contribution to the Family","C111055","A question about whether an individual is or was bothered by the drop in their contribution to the family.","Bothered by Drop in Contribution to the Family | I am bothered by the drop in my contribution to the family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831756","Able to Put Thoughts Together","C111056","A question about whether an individual is or was able to put their thoughts together.","Able to Put Thoughts Together Question | Able to Put Thoughts Together | Able to Put Thoughts Together | I am able to put my thoughts together",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827269","Need Help in Caring for Self","C111057","A question about whether an individual needs or needed help in caring for themselves.","Need Help in Caring for Self | I need help in caring for myself",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831757","Able to Put Thoughts into Actions","C111058","A question about whether an individual is or was able to put their thoughts into action.","Able to Put Thoughts into Actions Question | Able to Put Thoughts into Actions | Able to Put Thoughts into Actions | I am able to put my thoughts into action",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827301","Able to Read Like They Used To","C111059","A question about whether an individual is or was able to read like they used to.","Able to Read Like They Used To Question | Able to Read Like They Used To | Able to Read Like They Used To | I am able to read like I used to",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831754","Able to Write Like They Used To","C111060","A question about whether an individual is or was able to write like they used to.","Able to Write Like They Used To Question | Able to Write Like They Used To | Able to Write Like They Used To | I am able to write like I used to",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831762","Able to Drive a Vehicle","C111061","A question about whether an individual is or was able to drive a vehicle.","Able to Drive a Vehicle Question | Able to Drive a Vehicle | Able to Drive a Vehicle | I am able to drive a vehicle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829761","Have Trouble Feeling Sensations in Limbs","C111062","A question about whether an individual has or had trouble feeling sensations in their arms, hands, or legs.","Have Trouble Feeling Sensations in Limbs | I have trouble feeling sensations in my arms, hands or legs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829753","Have Weakness in Limbs","C111063","A question about whether an individual has or had weakness in their arms or legs.","Have Weakness in Limbs | Did you feel weak in your arms and legs | Feel Weak in Arms and Legs | I have weakness in my arms or legs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827765","Trouble with Coordination","C111064","A question about whether an individual has or had trouble with their coordination.","Trouble with Coordination | Did you have trouble with your coordination | Have Trouble with Coordination | I have trouble with coordination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829986","Get Headaches question","C111065","A question about whether an individual gets headaches.","Get Headaches | Did you have headaches | Had Headaches | Have Headaches | Have you had headaches | I get headaches",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019683","HIV Antibody","C16688","Produced by B-cells, human immunodeficiency virus (HIV) antibodies reacts with HIV antigens. HIV is a virus which affects white blood cells and eventually destroys the body's natural ability to fight infections.","HIV Antibody | Anti-HIV Antibody | Anti-Human Immunodeficiency Virus Antibody | HIV antibody | Human Immunodeficiency Virus Antibody",,,,,,,,,,,,,,,"4127308","Human immunodeficiency virus antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829566","Image Slice Thickness","C106534","The dimension between two surfaces of an imaging plane.","Image Slice Thickness | STHICK | Slice Thickness | sliceThickness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0580793","French Catheter Gauge","C101680","A number representing the outer diameter of a catheter where each integer represents 1/3 of a millimeter.","French Catheter Gauge | Catheter Gauge | Fr | French | French Catheter Scale | French Gauge | French Scale",,,,,,,,,,,,,,,"4117441","French gauge",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025517","Metabolic Disorder","C3235","A congenital (due to inherited enzyme abnormality) or acquired (due to failure of a metabolic important organ) disorder resulting from an abnormal metabolic process.","Metabolic Disorder | Metabolic Disease | metabolic disorder",,,,,,,,,,,,,,,"436670","Metabolic disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829137","Medical Outcomes Study Social Support Survey","C110969","A survey of multiple dimensions of social support.","Medical Outcomes Study Social Support Survey | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242487","Living Arrangement","C94852","A description of a personal residence and the relationship between the occupants that reside there.","Living Arrangement | Living Arrangements",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021845","Intestinal Perforation","C39611","A rupture in the wall of the small or large intestine due to traumatic or pathologic processes.","Intestinal Perforation | Bowel Perforation | Perforation of Intestine",,,,,,,,,,,,,,,"193242","Perforation of intestine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026457","Monoamine Oxidase Inhibitor","C667","Any substance that inhibits monoamine oxidase (MAO), an enzyme that catalyzes the oxidative deamination of monoamines and plays a role in the inactivation of neurotransmitters.","Monoamine Oxidase Inhibitor | MAO Inhibitors | MAO inhibitor | MAOI | monoamine oxidase inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830979","Critical Organ Volume","C111079","The portion of the total volume of a critical organ that is exposed to a specified dose of radiation therapy.","Critical Organ Volume | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827303","AAV-DC-CTL Tumor Cell Targeting Therapy","C107677","A tumor-targeted therapy consisting of cytotoxic T lymphocytes (CTLs) that are exposed ex vivo to dendritic cells (DCs) transfected with a recombinant adeno-associated virus (rAAV) encoding a specific tumor associated antigen (TAA) gene. Autologous peripheral blood mononuclear cells (PBMC) are collected and separated into monocytes and lymphocytes. The monocytes are infected with the rAAV that carries the TAA gene; this is followed by co-culture of the monocyte-derived, mature rAAV-transfected DCs and the isolated lymphocytes to generate CTLs against the specific TAA. These CTLs are transfused back into the patient for cancer therapy. The CTLs specifically kill tumor cells expressing the TAA, which results in a reduction of tumor cell proliferation.","AAV-DC-CTL Tumor Cell Targeting Therapy | ACTL Therapy | Antigen-specific Cytotoxic T Lymphocytes Induced by Dendritic Cells Infected by Recombinant Adeno-associated Virus Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827838","Testicular Cancer Serum Markers Test Result","C111067","A laboratory test result in which markers for testicular cancer are tested in a blood sample for staging purposes.","Testicular Cancer Serum Markers Test Result | ajcc serum tumor markers | ajcc_serum_tumor_markers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815196","Testicular Cancer Serum Markers Test Result SX","C111068","Marker studies not available or not performed. (AJCC 7th ed.)","SX | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828286","S0","C111069","Marker study levels within normal limits. (AJCC 7th ed.)","S0 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814877","Testicular Cancer Serum Markers Test Result S1","C111070","LDH less than 1.5 x N and hCG (mIu/ml) less than 5,000 and AFP (ng/ml) less than 1,000.  N indicates the upper limit of normal for the LDH assay. (AJCC 7th ed.)","S1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812875","Testicular Cancer Serum Markers Test Result S2","C111071","LDH 1.5-10 x N or hCG (mIu/ml) 5,000-50,000 or AFP (ng/ml) 1,000-10,000. N indicates the upper limit of normal for the LDH assay. (AJCC 7th ed.)","S2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812877","Testicular Cancer Serum Markers Test Result S3","C111072","LDH more than 10 x N or hCG (mIu/ml) more than 50,000 or AFP (ng/ml) more than 10,000. N indicates the upper limit of normal for the LDH assay. (AJCC 7th ed.)","S3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829527","International Germ Cell Consensus Classification","C111073","A risk classification system for malignant germ cell tumors developed by the International Germ Cell Cancer Collaborative Group.","International Germ Cell Consensus Risk Classification | IGCCC | IGCCC_RISK_GROUP | International Germ Cell Consensus Classification | International Germ Cell Consensus Classification | igcccg stage | igcccg_stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677861","Bilateral Malignant Neoplasm","C7627","A malignant neoplasm that affects both sides of an organ in a simultaneous or non-simultaneous manner.","Bilateral Malignant Neoplasm | Bilateral Cancer | Bilateral Malignant Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227999","Tunica Albuginea","C33819","The dense whitish fibrous tissue that covers the testis.","Tunica Albuginea | ",,,,,,,,,,,,,,,"4242295","Structure of tunica albuginea of testis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705173","Packet","C43199","An envelope into which only one dose of a drug product, usually in the form of granules or powder, has been directly placed. An example includes glassine powder paper containing aspirin. Other examples include aluminum foil packets into which alcohol swabs and pledgets are placed.","Packet | PACKET",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830319","Emancipated Minor","C111081","A person under the age of majority who has been granted the legal status of adulthood.","Emancipated Minor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448884","Cleanser","C68987","A preparation used in cleaning something.","Cleanser | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986383","Lesion Identification","C94189","The identification of a non-neoplastic or neoplastic pathologic process during the diagnostic work-up of a disease.","Lesion Identification | LESIDENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827380","Modified Overall Immune Related Response Criterion, New Non-Measurable Lesion","C111083","The finding of a growth smaller than 5 mm x 5 mm that was not present at the previous evaluation. Its presence does not indicate disease progession but precludes a determination of complete remission based on the modified overall immune related response criteria.","Modified Overall Immune Related Response Criterion, New Non-Measurable Lesion | Modified irRC, New Non-Measurable Lesion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828988","Modified Overall Immune Related Response Criterion, Complete Remission","C111084","The evaluation of the antitumor response shows a complete disappearance of all lesions (whether measurable or not) and no new lesions. All measurable lymph nodes also have a reduction in short axis diameter to 10 mm.","Modified Overall Immune Related Response Criterion, Complete Remission | Modified irCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828987","Modified Overall Immune Related Response Criterion, Partial Response","C111085","The evaluation of the antitumor response shows that the sum of the longest diameters of target and new measurable lesions has decreased by at least 30%.","Modified Overall Immune Related Response Criterion, Partial Response | Modified irPR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828985","Modified Overall Immune Related Response Criterion, Stable Disease","C111086","The evaluation of the antitumor response shows that the sum of the longest diameters of target and new measurable lesions do not meet the criteria for complete remission, partial response (compared to baseline) or progressive disease (compared to nadir).","Modified Overall Immune Related Response Criterion, Stable Disease | Modified irSD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828986","Modified Overall Immune Related Response Criterion, Progressive Disease","C111087","The evaluation of the antitumor response shows that the sum of the longest diameters of target and new measurable lesions increases by at least 20% (compared to nadir), and is confirmed by repeated, consecutive observations at least 4 weeks (normally done at 6 weeks) from the date first documented.","Modified Overall Immune Related Response Criterion, Progressive Disease | Modified irPD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3552639","Undescended Testes","C12326","The failure of one or both testes of a male fetus to descend from the abdomen into the scrotum during the late part of pregnancy. If not surgically corrected in early childhood, males may be at increased risk for testicular cancer later in life.","Undescended Testes | Cryptorchidism | Undescended Testicle | Undescended Testis | Undescended Testis | Undescended testis | cryptorchidism | undescended testicles",,,,,,,,,,,,,,,"4133452|437655","Undescended testis|Undescended testicle",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0442952","Anterior Mediastinotomy","C15647","Surgical opening of the anterior mediastinum.","Anterior Mediastinotomy | Chamberlain procedure | anterior mediastinotomy",,,,,,,,,,,,,,,"4128942","Anterior mediastinotomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0193790","Partial Thyroidectomy","C51921","Surgery involving partial excision of the thyroid gland.","Partial Thyroidectomy | Subtotal Thyroidectomy",,,,,,,,,,,,,,,"4149106","Subtotal thyroidectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041692","Unilateral Salpingo-oophorectomy","C94469","The surgical removal of either the left or right ovary and its corresponding fallopian tube.","Unilateral Salpingo-oophorectomy | unilateral salpingo-oophorectomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0195331","Cervicectomy","C94466","The surgical removal of the uterine cervix.","Cervicectomy | Trachelectomy | cervicectomy | trachelectomy",,,,,,,,,,,,,,,"4300370","Amputation of cervix",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3806655","Liver Dysfunction","C50634","A finding that indicates abnormal liver function.","Liver Dysfunction | Hepatic Dysfunction | Liver Damage/Dysfunction",,,,,,,,,,,,,,,"4326594","Abnormal liver function",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334154","Testicular Immature Teratoma","C6353","An immature teratoma that arises from the testis.","Testicular Immature Teratoma | Immature Teratoma of Testis | Immature Teratoma of the Testis | Immature Testicular Teratoma | Immature Testicular Teratoma | Testicular Immature Teratoma",,,,,,,,,,,,,,,"4220146","Malignant teratoma of testis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334641","Mature Testicular Teratoma","C6355","A teratoma that arises from the testis and is composed of well differentiated, adult-type tissues.","Testicular Mature Teratoma | Mature Teratoma of Testis | Mature Teratoma of the Testis | Mature Testicular Teratoma | Mature Testicular Teratoma | Testicular Mature Teratoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279708","Testicular Yolk Sac Tumor","C8000","A non-seminomatous malignant germ cell tumor arising from the testis.  It affects infants, young children, and postpubertal males.  It is the most frequently seen testicular neoplasm during childhood.  The vast majority of patients present with an asymptomatic scrotal mass.  The tumor mimics the yolk sac of the embryo and produces alpha-fetoprotein (AFP).  It metastasizes to distant anatomic sites.  Prognostic factors relate to the clinical stage and the degree of AFP elevation.","Testicular Yolk Sac Tumor | Endodermal Sinus Neoplasm of Testis | Endodermal Sinus Neoplasm of the Testis | Endodermal Sinus Tumor of Testis | Endodermal Sinus Tumor of the Testis | Testicular Endodermal Sinus Neoplasm | Testicular Endodermal Sinus Tumor | Testicular Yolk Sac Neoplasm | Yolk Sac Neoplasm of Testis | Yolk Sac Neoplasm of the Testis | Yolk Sac Tumor of Testis | Yolk Sac Tumor of the Testis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0238448","Testicular Embryonal Carcinoma","C6341","A malignant germ cell neoplasm arising from the testis.  It is composed of primitive epithelial cells arranged in solid, papillary, and glandular configurations.  Most patients present with a testicular mass, which may be associated with pain.  More than half of the patients have metastatic disease at diagnosis.  The form of treatment following radical orchiectomy is stage dependent.","Testicular Embryonal Carcinoma | Embryonal Carcinoma of Testis | Embryonal Carcinoma of the Testis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0238449","Testicular Choriocarcinoma","C7733","A malignant germ cell tumor arising from the testis.  It represents the rarest of the testicular germ cell tumors. Histologically it is characterized by the presence of syncytiotrophoblasts and cytotrophoblasts.","Testicular Choriocarcinoma | Choriocarcinoma of Testis | Choriocarcinoma of the Testis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2242808","Testicular Seminoma","C7328","A malignant germ cell tumor arising from the testis.  It is believed that it is derived from the sexually undifferentiated embryonic gonad.  Treatment with radiotherapy is highly successful when the tumor is diagnosed in localized stages, which represents the majority of presentations of seminoma.","Testicular Seminoma | Seminoma of Testis | Seminoma of the Testis | Testicular Seminoma Pure | Testicular seminoma",,,,,,,,,,,,,,,"4114339","Seminoma of testis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035278","Rete Testis","C33467","A network of tubules that convey sperm from the seminiferous tubules within the testicles to the efferent ducts.","Rete Testis | RETE TESTIS",,,,,,,,,,,,,,,"4031336","Structure of rete testis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0228014","Tunica Vaginalis","C33822","Serous membrane that covers the testicles.","Tunica Vaginalis | TUNICA VAGINALIS","C63.7","Tunica vaginalis",,,,,,,,,,,,,"4134453","Tunica vaginalis structure",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C2982657","Testicular Cancer TNM Finding v7","C89236","A finding about one or more characteristics of testicular cancer, following the rules of the TNM AJCC v7 classification system.","Testicular Cancer TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346454","IL-2 Recombinant Fusion Protein ALT-801","C71743","A recombinant protein consisting of the cytokine interleukin-2 (IL-2) fused to a humanized soluble T-cell receptor (TCR) directed against a tumor suppressor p53-derived antigen with potential immunopotentiating and antineoplastic activities. The TCR moiety of IL-2 recombinant fusion protein ALT-801 binds to tumor cells displaying p53 epitope/MHC complexes; subsequently, the tumor cell-localized IL-2 moiety may stimulate natural killer (NK) cell and T cell cytotoxic immune responses against p53-expressing tumor cells.","IL-2 Recombinant Fusion Protein ALT-801 | ALT-801",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0722625","Aminophylline","C47393","A methylxanthine and derivative of theophylline. Aminophylline relaxes smooth muscles, particularly bronchial muscles. This xanthine most likely exerts its effect by inhibiting cAMP or cGMP phosphodiesterases, thereby increasing levels of the second messenger cAMP or cGMP intracellularly. Other mode of actions include an adenosine antagonistic effect on the activity of CD4 lymphocytes and mediator release from mast cells thereby decreasing lung sensitivity to allergens and other substances that cause inflammation. Aminophylline also acts as a CNS stimulant and exerts a positive chronotropic and inotropic effect on the heart.","Aminophylline | 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-, compound with 1,2-Ethanediamine(2:1) | AMINOPHYLLINE | Ammophyllin | Phyllocontin | Theophyline Ethylenediamine | Truphylline",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0903898","Nateglinide","C61858","A phenylalanine derivative of the meglitinide class of agents with hypoglycemic activity. Nateglinide, compared to repaglitinide, binds with a higher affinity to the SUR1 subunit and with a faster onset of action and a shorter duration of action. This agent is metabolized by the cytochrome P450 isoenzyme CYP2C9, and, to a lesser extent, by CYP3A4. The parent drug and metabolites are mainly excreted in the urine and its half-life is about 1.5 hours.","Nateglinide | NATEGLINIDE | Starlix",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012792","Succinylcholine Chloride","C47730","The chloride salt form of succinylcholine, a quaternary ammonium compound and depolarizing agent with short-term muscle relaxant properties. Succinylcholine chloride binds to nicotinic receptors at the neuromuscular junction and opening the ligand-gated channels in the same way as acetylcholine, resulting in depolarization and inhibition of neuromuscular transmission. Depolarization may be prolonged due to succinylcholine's resistance to acetylcholinesterases thereby leading to disorganized muscle contraction followed by skeletal muscle relaxation and flaccid paralysis.","Succinylcholine Chloride | Anectine | Ethanaminium, 2,2'-((1,4-Dioxo-1,4-butanediyl)bis(oxy))bis(N,N,N-trimethyl-) | Quelicin | SUCCINYLCHOLINE CHLORIDE | Suxamethonium Chloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1451502","Tafluprost","C87385","No Value Exists","Tafluprost | AFP-168 | Isopropyl (5z)-7-((1R,2R,3R,5S)-2-((1E)-3,3-Difluoro-4-Phenoxybut-1-Enyl)-3,5-Dihydroxycyclopentyl)Hept-5-Enoate | MK-2452 | TAFLUPROST | Zioptan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4231490","Hypospadias","C40341","A congenital abnormality in which the external urethral orifice is on the underside of the penis. In a minority of cases it is associated with other genitourinary abnormalities.","Hypospadias | HYPOSPADIAS | hypospadias",,,,,,,,,,,,,,,"4005933","Penile hypospadias",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1515286","Testicular Germ Cell Neoplasia In Situ","C40345","A non-invasive lesion of the testis, characterized by the presence of malignant large germ cells with abundant cytoplasm in the seminiferous tubules. It may be associated with undescended or atrophic testis and infertility. The vast majority of cases progress to invasive germ cell tumors.","Testicular Germ Cell Neoplasia In Situ | GCNIS | Gonocytoma In Situ | IGCNU | Intratubular malignant germ cells | Testicular Germ Cell Neoplasia In Situ | Testicular Germ Cell Neoplasia In Situ | Testicular Intraepithelial Neoplasia | Testicular Intratubular Germ Cell Neoplasia | Testicular Intratubular Germ Cell Neoplasia | Testicular Intratubular Germ Cell Neoplasia of Unclassified Type | Testicular Intratubular Germ Cell Neoplasia of the Unclassified Type | Testicular Intratubular Germ Cell Neoplasia, Unclassified | Testicular Intratubular Germ Cell Neoplasia, Unclassified","9064/2","Intratubular malignant germ cells",,,,,,,,,,,,,"4030282","Intratubular malignant germ cells",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0428402","Human Chorionic Gonadotropin Measurement","C75387","A laboratory test to detect the amount of human chorionic gonadotropin in a biospecimen.","Human Chorionic Gonadotropin Measurement | ",,,,,,,,,,,,,,,"4285271","Human chorionic gonadotropin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0598801","Diffusion Weighted Imaging","C111116","A diffusion MRI technique in which diffusion-sensitizing gradients are applied to the imaging sequence.","Diffusion Weighted Imaging | DIFFUSION WEIGHTED MRI | DW-MRI | DWI | DWI MRI | DWI-MRI | Diffusion Weighted MRI | Diffusion-Weighted MR Imaging | Diffusion-Weighted MRI | Diffusion-Weighted Magnetic Resonance Imaging | MR Diffusion-Weighted Imaging",,,,,,,,,,,,,,,"4260263","Diffusion weighted magnetic resonance imaging",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523912","Testosterone Measurement","C75378","The determination of the amount of testosterone present in a sample.","Testosterone Measurement | Testosterone",,,,,,,,,,,,,,,"4020107","Testosterone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1511421","CD30-Positive Neoplastic Cells Present","C39715","A finding indicating that a sample of neoplastic cells has detectable immunoreactivity for CD30 (TNFRSF8).","CD30-Positive Neoplastic Cells Present | CD30+ Neoplastic Cells Present | Ki-1 Positive Neoplastic Cells Present | TNFRSF8-Positive Neoplastic Cells Present | TNFRSF8-Positive Neoplastic Cells Present ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475276","Tumor Volume","C94515","The volume of tumor.","Tumor Volume | TUMOR_VOLUME | tumor volume | volume of tumor | volume_of_tumor",,,,,,,,,,,,,,,"4121185","Tumor volume",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227692","Bladder Urothelium","C32211","The epithelium of the bladder, which consists of multiple layers of transitional cells.","Bladder Urothelium | Bladder Transitional Cell Epithelium | Bladder Transitional Epithelium",,,,,,,,,,,,,,,"4103772","Urinary bladder transitional epithelium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017160","Gastroenteritis","C34632","An inflammatory disorder that affects the upper and lower gastrointestinal tract. Most commonly, this is attributed to viruses; however bacteria, parasites or adverse reactions can also be the culprit. Symptoms include acute diarrhea and vomiting.","Gastroenteritis | gastroenteritis",,,,,,,,,,,,,,,"4101468","Gastroenteritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038941","Surgical Wound Infection","C35050","Infection of a surgical incision.","Surgical Wound Infection | ",,,,,,,,,,,,,,,"4237450","Postoperative wound infection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0314787","Acinetobacter anitratus","C86089","A species of aerobic, Gram negative, rod shaped bacteria assigned to the phylum Proteobacteria. This bacteria is nonmotile, oxidase negative, catalase positive and produces acid from glucose. A. anitratus is thought to be a commensal organism of the skin but may become pathogenic in patients with underlying conditions.","Acinetobacter anitratus | ACINETOBACTER ANITRATUS | Acinetobacter baumannii | Acinetobacter calcoaceticus subsp. anitratus",,,,,,,,,,,,,,,"4235587","Acinetobacter baumannii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0315260","Klebsiella oxytoca","C86455","A species of facultatively anaerobic, Gram negative, rod shaped bacteria assigned to the phylum Proteobacteria. This species is nonmotile, oxidase negative and indole positive. K. oxytoca is pathogenic, causing urinary tract infections, and is one of the major causes of neonatal bacteremia and septicemia.","Klebsiella oxytoca | K. oxytoca | KLEBSIELLA OXYTOCA",,,,,,,,,,,,,,,"4254213","Klebsiella oxytoca",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001699","Klebsiella pneumoniae","C86457","A species of facultatively anaerobic, Gram negative, rod shaped bacteria assigned to the phylum Proteobacteria. This species is nonmotile, oxidase negative, and produces acid from glucose, mannitol, rhamnose, arabinose and amygdalin. K. ozaenae is pathogenic and a causative agent of ozena/atrophic rhinitis.","Klebsiella pneumoniae | K. pneumoniae | KLEBSIELLA PNEUMONIAE",,,,,,,,,,,,,,,"4209452","Klebsiella pneumoniae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024885","Segmental Mastectomy","C20749","The removal of a cancer as well as some of the breast tissue around the tumor and the lining over the chest muscles below the tumor. Usually some of the lymph nodes under the arm are also taken out. Also called partial mastectomy. (Cancer.gov)","Segmental Mastectomy | segmental mastectomy",,,,,,,,,,,,,,,"4275911","Partial mastectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332461","Plaque","C95603","Abnormal tissue that results from the progressive accumulation or deposit of certain substances in a body cavity, surface, or lumen.","Plaque | Plaque Tissue | plaque",,,,,,,,,,,,,,,"4035621","Plaque",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2962753","CYP3A4 Inhibitor","C111373","Any substance capable of decreasing the activity of cytochrome P450 3A4.","CYP3A4 Inhibitor | CYP3A4 Inhibitor | Cytochrome P450 3A4 Inhibitor | Cytochrome P450 3A4 Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3500476","Cytochrome P 450 CYP3A4 Inducers","C111374","Any substance capable of increasing the activity of cytochrome P450 3A4.","CYP3A4 Inducer | CYP3A4 Inducer | Cytochrome P450 3A4 Inducer | Cytochrome P450 3A4 Inducer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830527","Detectable","C111567","The capability of being noticed, identified or discovered.","Detectable | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827727","Undetectable","C111568","The inability to be noticed, identified or discovered.","Undetectable | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826980","Multi-Drug Resistant Organism","C111564","A microorganism, often a bacterium, that is not susceptible to standard antimicrobial therapies.","Multi-Drug Resistant Organism | MDRO | Multi-drug resistant organisms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003964","Peritoneal Fluid","C77612","The small amount of fluid that is generated in the abdominal cavity to lubricate the peritoneum.","Peritoneal Fluid | FLUID, PERITONEAL | PERITONEAL FLUID | peritoneal fluid",,,,,,,,,,,,,,,"4252848","Peritoneal fluid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0225432","Internal Nare","C32856","The inner portion of the nostrils of the nose.","Internal Nare | ",,,,,,,,,,,,,,,"4215482","Structure of choana",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448228","Coronal Plane","C94876","Pertaining to a plane containing a line parallel to the long axis of the subject's body and in addition presenting anterior and posterior views on each side of it. This plane is perpendicular to both the transaxial and sagittal.","Coronal Plane | Coronal",,,,,,,,,,,,,,,"4216982","Coronal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033464","Prophase Process","C17014","The first phase of mitosis, in which the chromosomes become visible, the nucleus starts to lose its identity, the spindle appears, and the centrioles migrate toward opposite poles.","Prophase Process | Mitotic Prophase | Prophase",,,,,,,,,,,,,,,"4197549","Prophase",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1335983","Small Cell Variant Anaplastic Large Cell Lymphoma","C7208","A histologic variant of anaplastic large cell lymphoma characterized by the presence of a predominant population of small to medium size malignant cells with irregular nuclei.","Small Cell Variant Anaplastic Large Cell Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0545080","Composite Lymphoma","C38661","Coexistence of Hodgkin and non-Hodgkin lymphoma in the same anatomic site.","Composite Lymphoma | composite lymphoma","9596/3","Composite Hodgkin and non-Hodgkin lymphoma",,,,,,,,,,,,,"607956","Composite Hodgkin and non-Hodgkin lymphoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1334463","Lymphohistiocytic Variant Anaplastic Large Cell Lymphoma","C7207","A histologic variant of anaplastic large cell lymphoma characterized by the presence of a large number of histiocytes admixed with the anaplastic lymphoma cells.","Lymphohistiocytic Variant Anaplastic Large Cell Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1434437","Leukosialin, Human","C101153","Leukosialin (400 aa, ~40 kDa) is encoded by the human SPN gene. This protein is involved in immune cell function.","Leukosialin | Antigen CD43 | CD43 | CD43 Antigen | GALGP | Galactoglycoprotein | Leukocyte Large Sialoglycoprotein | Leukocyte Sialoglycoprotein | Sialophorin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705984","TNFRSF8 wt Allele","C51385","Human TNFRSF8 wild-type allele is located in the vicinity of 1p36 and is approximately 81 kb in length. This allele, which encodes tumor necrosis factor receptor superfamily member 8 protein, plays a role in the modulation of both the nuclear factor kappa-B signal pathway and leukocyte transformation. The gene is involved in the activation of lymphoid cells in Hodgkin disease.","TNFRSF8 wt Allele | CD30 | KI-1 | Tumor Necrosis Factor Receptor Superfamily, Member 8 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519190","Scaly Skin Eruption","C39622","Peeling skin patches. Causes include psoriasis, eczema, and sunburns.","Scaly Skin Eruption | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448476","Dermatosis","C27554","A disorder involving lesions or eruptions of the skin, usually without inflammation.","Dermatosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830308","Epstein-Barr Virus Early RNA","C111618","Small non-coding RNA that is encoded by Epstein-Barr virus DNA and transcribed by virally-infected cells throughout the latent cycle. Expression of these oligonucleotides may be associated with the regulation of host ribosome function.","Epstein-Barr Virus Early RNA | EBER | Epstein-Barr Early RNA | Epstein-Barr Early Region RNA | Epstein-Barr Early Region RNA;  | Epstein-Barr Encoded RNA | Epstein-Barr Virus, Early RNA | Epstein-Barr Virus-Associated Early RNA | Epstein-Barr Virus-Encoded Small RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831018","Control Cleansing","C111376","The process of washing the skin using a cleaning agent that functions as a standard of comparison in a control experiment.","Control Cleansing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827255","Chlorhexidine Gluconate Cleansing","C111375","The process of washing the skin using chlorhexidine gluconate.","Chlorhexidine Gluconate Cleansing | CHG Cleansing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831569","ALK Break Apart FISH Probe Kit","C111619","A fluorescence in situ hybridization kit that detects the rearrangements between the ALK gene which is located at 2p23 and all known translocation partner loci in lymphomas and carcinomas.","ALK Break Apart FISH Probe Kit | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830266","FACT-Taxane Questionnaire","C111620","A subscale complement to the FACT-G developed specifically for evaluating the potential side effects of taxane therapy on cancer patients.","FACT-Taxane Questionnaire | FACT-Tax | FACT-Tax Questionnaire | FACT-Taxane | Functional Assessment of Cancer Therapy-Taxane",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829780","Have Numbness or Tingling in Hands","C111621","A question about whether an individual feels or felt numbness or tingling in their hands.","Have Numbness or Tingling in Hands | I have numbness or tingling in my hands",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829781","Have Numbness or Tingling in Feet","C111622","A question about whether an individual feels or felt numbness or tingling in their feet.","Have Numbness or Tingling in Feet | I have numbness or tingling in my feet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830164","Feel Discomfort in Hands","C111623","A question about whether an individual feels or felt discomfort in their hands.","Feel Discomfort in Hands | I feel discomfort in my hands",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830165","Feel Discomfort in Feet","C111624","A question about whether an individual feels or felt discomfort in their feet.","Feel Discomfort in Feet | I feel discomfort in my feet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829787","Have Joint Pain or Muscle Cramps","C111625","A question about whether an individual has or had joint pain or muscle cramps.","Have Joint Pain or Muscle Cramps | I have joint pain or muscle cramps",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829985","Get Ringing or Buzzing in Ears","C111626","A question about whether an individual gets or has gotten a ringing or buzzing in their ears.","Get Ringing or Buzzing in Ears | I get a ringing or buzzing in my ears",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829762","Have Trouble Buttoning Buttons","C111627","A question about whether an individual has or had trouble buttoning buttons.","Have Trouble Buttoning Buttons | I have trouble buttoning buttons",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829760","Have Trouble Feeling Shape of Small Objects in Hand","C111628","A question about whether an individual has or had trouble feeling the shape of small objects when they are in their hand.","Have Trouble Feeling Shape of Small Objects in Hand | I have trouble feeling the shape of small objects when they are in my hand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829756","Have Trouble Walking","C111629","A question about whether an individual has or had trouble walking.","Have Trouble Walking Question | Have Trouble Walking | Have Trouble Walking | I have trouble walking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL455344","Feel Bloated (question)","C111630","A question about whether an individual feels or felt bloated.","Feel Bloated | Feeling bloated | I feel bloated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829901","Hands Are Swollen","C111631","A question about whether an individual's hands are or were swollen.","Hands Are Swollen | My hands are swollen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829302","Legs or Feet Are Swollen","C111632","A question about whether an individual's legs or feet are or were swollen.","Legs or Feet Are Swollen | My legs or feet are swollen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829778","Have Pain in Fingertips","C111633","A question about whether an individual has or had pain in their fingertips.","Have Pain in Fingertips | I have pain in my fingertips",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831301","Bothered by Look of Hands or Nails","C111634","A question about whether an individual is or was bothered by the look of their hands or nails.","Bothered by Look of Hands or Nails | I am bothered by the way my hands or nails look",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830267","FACT-NP Questionnaire","C111635","A subscale complement to the FACT-G developed specifically for evaluating the quality of life of nasopharyngeal cancer patients.","FACT-NP Questionnaire | FACT-Nasopharyngeal Cancer | Functional Assessment of Cancer Therapy-Nasopharyngeal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830492","Difficulty Moving Neck and Shoulders due to Stiffness","C111636","A question about whether an individual has or had difficulty moving their neck or shoulders because of stiffness.","Difficulty Moving Neck and Shoulders due to Stiffness | I have difficulty moving my neck and shoulders because of stiffness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831298","Bothered by Ringing in Ears","C111637","A question about whether an individual is or was bothered by ringing in their ears.","Bothered by Ringing in Ears | I am bothered by ringing in my ear(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831295","Bothered by Worsening Eyesight","C111638","A question about whether an individual is or was bothered by worsening eyesight.","Bothered by Worsening Eyesight | I am bothered by worsening eyesight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829758","Have Trouble Smelling","C111639","A question about whether an individual has or had trouble smelling.","Have Trouble Smelling | I have trouble smelling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831209","Can Enjoy Taste of Food","C111640","A question about whether an individual can or could enjoy the taste of food.","Can Enjoy Taste of Food | I can enjoy the taste of food",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831308","Bothered by Blocked Nose","C111641","A question about whether an individual is or was bothered by having a blocked nose.","Bothered by Blocked Nose | I am bothered by having a blocked nose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456900","Ultrasound-Guided Biopsy","C93022","Biopsy of tissue using ultrasound imaging as an aid in directing a biopsy needle into the area of interest.","Ultrasound-Guided Biopsy | Ultrasound Biopsy | Ultrasound Guided Biopsy | Ultrasound-guided Biopsy | ultrasound-guided biopsy",,,,,,,,,,,,,,,"4082629","Ultrasound guided biopsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2697836","KRAS Mutation Analysis","C79418","A procedure to test for the presence of mutations in the KRAS gene.","KRAS Mutation Analysis | KRAS Mutation Status | KRAS-2 Mutation Analysis | KRAS2 Mutation Analysis | c-K-ras Mutation Analysis | v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Mutation Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003818","Arsenic","C28131","A naturally occurring allotropic pnictogen and metalloid trace element with atomic symbol As, atomic number 33, and atomic weight 74.92 that is found in water, air, food, and soil, and has a role as a micronutrient. Arsenic, which is highly toxic with acute or chronic exposure to moderate or high levels through an unknown mechanism of action, is used in many industrial processes, as well as in pharmaceuticals, feed additives, and pesticides. It is characterized as a white, yellow, gray metallic, or black solid that is odorless. Exposure occurs by inhalation, ingestion, or contact.","Arsenic | ARSENIC | As | arsenic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0237849","Desquamation","C111657","Shedding of the outer layer of skin or mucosal tissue.","Desquamation | EXFOLIATION",,,,,,,,,,,,,,,"135029|4032013","Peeling of skin|Desquamation",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1416409","IL6R Gene","C38920","This gene in involved in the regulation of cellular responses; such as the immune response, hematopoiesis, and acute-phase inflammatory reactions.","IL6R Gene | IL6R | Interleukin 6 Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1327799","Autologous Dendritic Cell-Adenovirus P53 Vaccine","C26445","An autologous vaccine composed of dendritic cells (DC) that have been transduced with a p53 tumor suppressor gene-modified virus. When the autologous dendritic cell-adenovirus p53 vaccine is administered, the host cytotoxic T lymphocytes (CTL) are directed against p53-positive tumor cells, which may result in tumor cell death and decreased tumor growth. (NCI04)","Autologous Dendritic Cell-Adenovirus P53 Vaccine | Augologous Dendritic Cell Adenovirus P53 Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3658706","Pembrolizumab","C106432","A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","Pembrolizumab | BCD-201 | GME 751 | GME751 | Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide with Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide | Keytruda | Lambrolizumab | Lambrolizumab | MK 3475 | MK-3475 | MK3475 | PEMBROLIZUMAB | Pembrolizumab Biosimilar BCD-201 | Pembrolizumab Biosimilar GME751 | Pembrolizumab Biosimilar QL2107 | Pembrolizumab Biosimilar RPH-075 | QL2107 | RPH 075 | RPH-075 | RPH075 | SCH 900475 | SCH-900475 | SCH900475 | pembrolizumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332392","pT2 Primary Tumor Finding","C48764","A pathologic primary tumor TNM finding. The definition of pT2 finding depends on the particular type of cancer that it refers to; for example, for breast cancer, pT2 finding is defined as follows: cancer with tumor size more than 2.0 cm, but not more than 5.0 cm in greatest dimension; for colorectal cancer, pT2 finding is defined as follows: cancer with invasion into the muscularis propria. (from AJCC 6th and 7th Eds.)","pT2 TNM Finding | Tumor Stage pT2 | pT2 | pT2 Cancer Stage Finding | pT2 Primary Tumor Finding | pT2 Primary Tumor Stage Finding | pT2 Stage | pT2 Stage Finding | pT2 TNM Finding | pT2 Tumor Finding | pT2 Tumor Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986655","Functioning Endocrine Neoplasm","C94759","A hormone producing endocrine neoplasm, associated with a hormonal syndrome.","Functioning Endocrine Neoplasm | functioning tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334926","Nasopharyngeal Nonkeratinizing Carcinoma","C7373","A nasopharyngeal carcinoma characterized by the lack of keratinization and the presence of a dense lymphoplasmacytic infiltrate. The vast majority of cases are associated with Epstein-Barr virus infection. It is subdivided into differentiated and undifferentiated types, based on the cytologic features of the malignant cells. The differentiated type (type II) is characterized by the presence of smaller cells and cellular stratification reminiscent of transitional cell carcinoma. The undifferentiated type (type III) is characterized by the presence of cells with large vesicular nuclei with prominent nucleoli and a syncytial pattern of growth.  While morphologically distinct, both types have similar clinical presentation and prognosis.","Nasopharyngeal Non-Keratinizing Carcinoma | EBV positive nasopharyngeal carcinoma | NK-NPC | Nasopharyngeal Non-Keratinizing Carcinoma | Nasopharyngeal Nonkeratinizing Carcinoma | Nasopharyngeal Nonkeratinizing Carcinoma | Nasopharyngeal Throat Nonkeratinizing Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515107","Synchronous Bilateral Breast Carcinoma","C40370","Carcinoma that is detected in one breast within two months from the diagnosis of carcinoma in the other breast.","Synchronous Bilateral Breast Carcinoma | Synchronous Bilateral Breast Cancer | Synchronous Contralateral Breast Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986664","Multicentric Breast Carcinoma","C94772","A breast carcinoma characterized by the presence of multiple cancerous tumors that originate from different clones and are usually located in different quadrants of the breast.","Multicentric Breast Carcinoma | Multicentric Breast Cancer | multicentric breast cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0235031","Neurological Signs and Symptoms","C3837","A term that refers to the clinical manifestations resulting from pathologic processes that affect the central and peripheral nervous system.","Neurological Signs and Symptoms | ",,,,,,,,,,,,,,,"4204047","Neurological symptom",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0278907","Somatostatin Analog Therapy","C15449","Endocrine drug therapy that uses analogs of somatostatin to treat neuroendocrine tumors.","Somatostatin Analog Therapy | Somatostatin Analogue Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704318","Needle","C50290","A device part with a long, slender, pointed shape.","Needle Device | Needle | Needle Device Component | Needle applicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513776","Mutate","C28031","To undergo or cause genetic mutation.","Mutate | mutate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982420","Nasopharyngeal Cancer TNM Finding v7","C88964","A finding about one or more characteristics of nasopharyngeal cancer, following the rules of the TNM AJCC v7 classification system.","Nasopharyngeal Cancer TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882027","Nasopharyngeal Cancer pT0 TNM Finding v6 and v7","C64456","Nasopharyngeal cancer with no evidence of a primary tumor. (from AJCC 6th and 7th Eds.)","Nasopharyngeal Cancer pT0 TNM Finding v6 and v7 | Nasopharyngeal Cancer pT0 TNM Finding | Nasopharyngeal Cancer pT0 TNM Finding | Nasopharyngeal Cancer pT0 TNM Finding v6 | Nasopharyngeal Cancer pT0 TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982423","Nasopharyngeal Cancer pT1 TNM Finding v7","C88967","Nasopharyngeal cancer with tumor confined to the nasopharynx, or tumor extending to oropharynx and/or nasal cavity without parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor.  (from AJCC 7th Ed.)","Nasopharyngeal Cancer pT1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982424","Nasopharyngeal Cancer pT2 TNM Finding v7","C88968","Nasopharyngeal cancer with parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor. (from AJCC 7th Ed.)","Nasopharyngeal Cancer pT2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982425","Nasopharyngeal Cancer pT3 TNM Finding v7","C88969","Nasopharyngeal cancer with tumor involving bony structures of skull base and/or paranasal sinuses. (from AJCC 7th Ed.)","Nasopharyngeal Cancer pT3 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982426","Nasopharyngeal Cancer pT4 TNM Finding v7","C88970","Nasopharyngeal cancer with intracranial extension and/or involvement of cranial nerves, hypopharynx, orbit, or with extension to the infratemporal fossa/masticator space. (from AJCC 7th Ed.)","Nasopharyngeal Cancer pT4 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882035","Nasopharyngeal Cancer pTis TNM Finding v6 and v7","C64457","Nasopharyngeal cancer with a finding of carcinoma in situ. (from AJCC 6th and 7th Eds.)","Nasopharyngeal Cancer pTis TNM Finding v6 and v7 | Nasopharyngeal Cancer pTis TNM Finding | Nasopharyngeal Cancer pTis TNM Finding | Nasopharyngeal Cancer pTis TNM Finding v6 | Nasopharyngeal Cancer pTis TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882034","Nasopharyngeal Cancer pTX TNM Finding v6 and v7","C64455","Nasopharyngeal cancer in which the primary tumor cannot be assessed. (from AJCC 6th and 7th Eds.)","Nasopharyngeal Cancer pTX TNM Finding v6 and v7 | Nasopharyngeal Cancer pTX TNM Finding | Nasopharyngeal Cancer pTX TNM Finding | Nasopharyngeal Cancer pTX TNM Finding v6 | Nasopharyngeal Cancer pTX TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982431","Nasopharyngeal Cancer pN3b TNM Finding v7","C88975","Nasopharyngeal cancer with extension to the supraclavicular fossa. Supraclavicular zone or fossa is relevant to the staging of nasopharyngeal carcinoma and is the triangular region originally described by Ho.  It is defined by three points: (1) the superior margin of the sternal end of the clavicle, (2) the superior margin of the lateral end of the clavicle, (3) the point where the neck meets the shoulder.  This would include caudal portions of levels IV and VB.  All cases with lymph nodes (whole or part) in the fossa are considered N3b. (from AJCC 7th Ed.)","Nasopharyngeal Cancer pN3b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882024","Nasopharyngeal Cancer pN3a TNM Finding v6 and v7","C64478","Nasopharyngeal cancer with metastasis to one or more lymph nodes greater than 6 cm in greatest dimension. (from AJCC 6th and 7th Eds.)","Nasopharyngeal Cancer pN3a TNM Finding v6 and v7 | Nasopharyngeal Cancer pN3a TNM Finding | Nasopharyngeal Cancer pN3a TNM Finding | Nasopharyngeal Cancer pN3a TNM Finding v6 | Nasopharyngeal Cancer pN3a TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882020","Nasopharyngeal Cancer pN0 TNM Finding v6 and v7","C64474","Nasopharyngeal cancer with no metastasis to regional lymph nodes. (from AJCC 6th and 7th Eds.)","Nasopharyngeal Cancer pN0 TNM Finding v6 and v7 | Nasopharyngeal Cancer pN0 TNM Finding | Nasopharyngeal Cancer pN0 TNM Finding | Nasopharyngeal Cancer pN0 TNM Finding v6 | Nasopharyngeal Cancer pN0 TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982428","Nasopharyngeal Cancer pN1 TNM Finding v7","C88972","Nasopharyngeal cancer with unilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa, and/or unilateral or bilateral, retropharyngeal lymph nodes, 6 cm or less in greatest dimension.  Midline nodes are considered ipsilateral nodes. (from AJCC 7th Ed.)","Nasopharyngeal Cancer pN1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982429","Nasopharyngeal Cancer pN2 TNM Finding v7","C88973","Nasopharyngeal cancer with bilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa.  Midline nodes are considered ipsilateral nodes. (from AJCC 7th Ed.)","Nasopharyngeal Cancer pN2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982430","Nasopharyngeal Cancer pN3 TNM Finding v7","C88974","Nasopharyngeal cancer with metastasis in a lymph node (s) more than 6 cm in greatest dimension and/or to supraclavicular fossa.  Supraclavicular zone or fossa is relevant to the staging of nasopharyngeal carcinoma and is the triangular region originally described by Ho.  It is defined by three points: (1) the superior margin of the sternal end of the clavicle, (2) the superior margin of the lateral end of the clavicle, (3) the point where the neck meets the shoulder.  This would include caudal portions of levels IV and VB.  All cases with lymph nodes (whole or part) in the fossa are considered N3b. (from AJCC 7th Ed.)","Nasopharyngeal Cancer pN3 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882026","Nasopharyngeal Cancer pNX TNM Finding v6 and v7","C64473","Nasopharyngeal cancer in which the regional lymph nodes cannot be assessed. (from AJCC 6th and 7th Eds.)","Nasopharyngeal Cancer pNX TNM Finding v6 and v7 | Nasopharyngeal Cancer pNX TNM Finding | Nasopharyngeal Cancer pNX TNM Finding | Nasopharyngeal Cancer pNX TNM Finding v6 | Nasopharyngeal Cancer pNX TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982434","Nasopharyngeal Cancer Clinical Distant Metastasis TNM Finding v7","C88978","A clinical finding about one or more characteristics of nasopharyngeal cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.","Nasopharyngeal Cancer Clinical Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982435","Nasopharyngeal Cancer cM0 TNM Finding v7","C88979","Nasopharyngeal cancer without evidence of distant metastasis. (from AJCC 7th Ed.)","Nasopharyngeal Cancer cM0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982436","Nasopharyngeal Cancer cM1 TNM Finding v7","C88980","Nasopharyngeal cancer with distant metastasis. (from AJCC 7th Ed.)","Nasopharyngeal Cancer cM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982432","Nasopharyngeal Cancer Pathologic Distant Metastasis TNM Finding v7","C88976","A pathologic finding about one or more characteristics of nasopharyngeal cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  There is no pathologic M0 for nasopharyngeal cancer.","Nasopharyngeal Cancer Pathologic Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882018","Nasopharyngeal Cancer pM1 TNM Finding v6 and v7","C64484","Nasopharyngeal cancer with distant metastasis. (from AJCC 6th and 7th Eds.)","Nasopharyngeal Cancer pM1 TNM Finding v6 and v7 | Nasopharyngeal Cancer pM1 TNM Finding | Nasopharyngeal Cancer pM1 TNM Finding | Nasopharyngeal Cancer pM1 TNM Finding v6 | Nasopharyngeal Cancer pM1 TNM Finding v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984108","Nasopharyngeal Carcinoma by AJCC v7 Stage","C91244","A term that refers to the staging of nasopharyngeal carcinoma according to the American Joint Committee on Cancer, 7th edition.","Nasopharyngeal Carcinoma by AJCC v7 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3146259","Stage IV Nasopharyngeal Carcinoma AJCC v7","C88984","Stage IV includes: IVA: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0); IVB (Any T, N3, M0); IVC (Any T, Any N, M1). T4: Nasopharyngeal cancer with intracranial extension and/or involvement of cranial nerves, hypopharynx, orbit, or with extension to the infratemporal fossa/masticator space.  N0: No regional lymph node metastasis. N1: Nasopharyngeal cancer with unilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa, and/or unilateral or bilateral, retropharyngeal lymph nodes, 6 cm or less in greatest dimension.  Midline nodes are considered ipsilateral nodes.  N2: Nasopharyngeal cancer with bilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa.  Midline nodes are considered ipsilateral nodes. N3: Nasopharyngeal cancer with metastasis in a lymph node (s) more than 6 cm in greatest dimension and/or to supraclavicular fossa.  Supraclavicular zone or fossa is relevant to the staging of nasopharyngeal carcinoma and is the triangular region originally described by Ho.  It is defined by three points: (1) the superior margin of the sternal end of the clavicle, (2) the superior margin of the lateral end of the clavicle, (3) the point where the neck meets the shoulder.  This would include caudal portions of levels IV and VB.  All cases with lymph nodes (whole or part) in the fossa are considered N3b.  M0: No distant metastasis. M1: Distant metastasis. (AJCC 7th ed.)","Stage IV Nasopharyngeal Carcinoma AJCC v7 | Stage IV Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336399","Stage IVC Nasopharyngeal Carcinoma AJCC v7","C5995","Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 7th ed.)","Stage IVC Nasopharyngeal Carcinoma AJCC v7 | Stage IVC Carcinoma of Nasopharynx | Stage IVC Carcinoma of the Nasopharynx | Stage IVC Nasopharyngeal Carcinoma | Stage IVC Nasopharyngeal Carcinoma | Stage IVC Nasopharyngeal Throat Cancer | Stage IVC Nasopharynx Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336348","Stage IVA Nasopharyngeal Carcinoma AJCC v7","C5997","Stage IVA includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Nasopharyngeal cancer with intracranial extension and/or involvement of cranial nerves, hypopharynx, orbit, or with extension to the infratemporal fossa/masticator space.  N0: No regional lymph node metastasis. N1: Nasopharyngeal cancer with unilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa, and/or unilateral or bilateral, retropharyngeal lymph nodes, 6 cm or less in greatest dimension.  Midline nodes are considered ipsilateral nodes.  N2: Nasopharyngeal cancer with bilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa.  Midline nodes are considered ipsilateral nodes. M0: No distant metastasis. (AJCC 7th ed.)","Stage IVA Nasopharyngeal Carcinoma AJCC v7 | Stage IVA Carcinoma of Nasopharynx | Stage IVA Carcinoma of the Nasopharynx | Stage IVA Nasopharyngeal Carcinoma | Stage IVA Nasopharyngeal Carcinoma | Stage IVA Nasopharyngeal Throat Cancer | Stage IVA Nasopharynx Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336379","Stage IVB Nasopharyngeal Carcinoma AJCC v7","C5996","Stage IVB includes: Any T, N3, M0.  N3: Nasopharyngeal cancer with metastasis in a lymph node (s) more than 6 cm in greatest dimension and/or to supraclavicular fossa.  Supraclavicular zone or fossa is relevant to the staging of nasopharyngeal carcinoma and is the triangular region originally described by Ho.  It is defined by three points: (1) the superior margin of the sternal end of the clavicle, (2) the superior margin of the lateral end of the clavicle, (3) the point where the neck meets the shoulder.  This would include caudal portions of levels IV and VB.  All cases with lymph nodes (whole or part) in the fossa are considered N3b.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IVB Nasopharyngeal Carcinoma AJCC v7 | Stage IVB Carcinoma of Nasopharynx | Stage IVB Carcinoma of the Nasopharynx | Stage IVB Nasopharyngeal Carcinoma | Stage IVB Nasopharyngeal Carcinoma | Stage IVB Nasopharyngeal Throat Cancer | Stage IVB Nasopharynx Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982437","Stage II Nasopharyngeal Carcinoma AJCC v7","C88982","Stage II includes: (T1, N1, M0); (T2, N0, M0); (T2, N1, M0).  T1: Nasopharyngeal cancer with tumor confined to the nasopharynx, or tumor extending to oropharynx and/or nasal cavity without parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor. T2: Nasopharyngeal cancer with parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor.  N0: No regional lymph node metastasis. N1: Nasopharyngeal cancer with unilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa, and/or unilateral or bilateral, retropharyngeal lymph nodes, 6 cm or less in greatest dimension.  Midline nodes are considered ipsilateral nodes.  M0: No distant metastasis. (AJCC 7th ed.)","Stage II Nasopharyngeal Carcinoma AJCC v7 | Stage II Nasopharyngeal Carcinoma | Stage II Nasopharyngeal Carcinoma | Stage II Nasopharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0347096","Stage 0 Nasopharyngeal Carcinoma AJCC v6, v7, and v8","C9099","Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th, 7th, and 8th eds.)","Stage 0 Nasopharyngeal Carcinoma AJCC v6, v7, and v8 | Carcinoma in situ of Nasopharynx | Carcinoma in situ of the Nasopharynx | Nasopharyngeal Carcinoma in situ | Stage 0 Carcinoma of Nasopharynx | Stage 0 Carcinoma of the Nasopharynx | Stage 0 Nasopharyngeal Cancer | Stage 0 Nasopharyngeal Carcinoma | Stage 0 Nasopharyngeal Carcinoma | Stage 0 Nasopharyngeal Carcinoma AJCC v6 | Stage 0 Nasopharyngeal Carcinoma AJCC v6 and v7 | Stage 0 Nasopharyngeal Carcinoma AJCC v7 | Stage 0 Nasopharyngeal Carcinoma AJCC v8 | Stage 0 Nasopharyngeal Throat Cancer | Stage 0 Nasopharynx Carcinoma | stage 0 nasopharyngeal carcinoma in situ",,,,,,,,,,,,,,,"4243891","Carcinoma in situ of nasopharynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL449079","Stage I Nasopharyngeal Carcinoma AJCC v7","C88981","Stage I includes: T1, N0, M0. T1: Nasopharyngeal cancer with tumor confined to the nasopharynx, or tumor extending to oropharynx and/or nasal cavity without parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage I Nasopharyngeal Carcinoma AJCC v7 | Stage I Nasopharyngeal Carcinoma | Stage I Nasopharyngeal Carcinoma | Stage I Nasopharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449080","Stage III Nasopharyngeal Carcinoma AJCC v7","C88983","Stage III includes: (T1, N2, M0); (T2, N2, M0); (T3, N0, M0); (T3, N1, M0); (T3, N2, M0). T1: Nasopharyngeal cancer with tumor confined to the nasopharynx, or tumor extending to oropharynx and/or nasal cavity without parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor. T2: Nasopharyngeal cancer with parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor.  T3: Nasopharyngeal cancer with tumor involving bony structures of skull base and/or paranasal sinuses.  N0: No regional lymph node metastasis. N1: Nasopharyngeal cancer with unilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa, and/or unilateral or bilateral, retropharyngeal lymph nodes, 6 cm or less in greatest dimension.  Midline nodes are considered ipsilateral nodes.  N2: Nasopharyngeal cancer with bilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa.  Midline nodes are considered ipsilateral nodes. M0: No distant metastasis. (AJCC 7th ed.)","Stage III Nasopharyngeal Carcinoma AJCC v7 | Stage III Nasopharyngeal Carcinoma | Stage III Nasopharyngeal Carcinoma | Stage III Nasopharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019637","Histological Procedure","C16680","Technique or procedure used for the study of the microanatomy of tissues and their cellular structure; usually involves microscopic examination of tissue slices.","Histological Procedure | Histologic Procedure | Histological Technique | Histological Techniques | histologic examination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640811","Planned Occurrence","C102557","An instance of an event or incident that is intended to take place.","Planned Occurrence | POCCUR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986746","Emission scan","C94892","The usual mode of scanner operation in which a tracer's distribution throughout a subject is detected for subsequent processing into an image.","Emission Scan | Emission scan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0243076","Antagonist","C94373","In medicine, a substance that stops the action or effect of another substance. For example, a drug that blocks the stimulating effect of estrogen on a tumor cell is called an estrogen receptor antagonist.","Antagonist | RECEPTOR ANTAGONIST | antagonist",,,,,,,,,,,,,,,"36675083","Receptor antagonist",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0229758","Anterior Mediastinal Lymph Node","C32097","A lymph node located in the anterior part of the mediastinum.","Anterior Mediastinal Lymph Node | ANTERIOR MEDIASTINAL LYMPH NODE | Prevascular Lymph Node",,,,,,,,,,,,,,,"4199904","Structure of anterior mediastinal lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0229754","Paratracheal Lymph Node","C103426","A lymph node located adjacent to the trachea within the mediastinum. (NCI)","Paratracheal Lymph Node | PARATRACHEAL LYMPH NODE",,,,,,,,,,,,,,,"4277752","Structure of paratracheal lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640700","Perihilar Lymph Node","C102330","A lymph node located in the area around the hilum of an organ.","Perihilar Lymph Node | Hilar Nodes | Lymph Node(s) Hilar | PERIHILAR LYMPH NODE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2953130","Retrocrural Lymph Node","C103439","A lymph node located within the most inferior portion of the posterior mediastinum. (NCI)","Retrocrural Lymph Node | RETROCRURAL LYMPH NODE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229745","Thoracic Lymph Node","C33769","Lymph node located in the thoracic cavity.","Thoracic Lymph Node | THORACIC LYMPH NODE",,,,,,,,,,,,,,,"4187362","Structure of lymph node of thorax",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1168328","Low Grade Prostatic Intraepithelial Neoplasia","C5542","Prostatic intraepithelial neoplasia characterized by the proliferation of secretory cells with irregular spacing in the ducts and acini.  Although some proliferating epithelial cells may contain prominent nucleoli, the cytologic atypia and architectural growth patterns that are seen in the high grade prostatic intraepithelial neoplasia are absent.  The presence of low grade prostatic intraepithelial neoplasia in needle biopsy is not a risk factor for the subsequent detection of carcinoma on repeat biopsy.","Low Grade Prostatic Intraepithelial Neoplasia | Grade 1 PIN | Grade 1 Prostatic Intraepithelial Neoplasia | Grade I PIN | Grade I Prostatic Intraepithelial Neoplasia | Low-Grade Intraepithelial Neoplasia of Prostate | Low-Grade Intraepithelial Neoplasia of the Prostate | Low-Grade PIN | Low-Grade Prostatic Intraepithelial Neoplasia | PIN-1",,,,,,,,,,,,,,,"40489289","Low grade prostatic intraepithelial neoplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347624","Pomalidomide","C72560","An orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). In addition, pomalidomide may inhibit tumor angiogenesis, promote cell cycle arrest in susceptible tumor cell populations, and stimulate erythropoeisis.","Pomalidomide | 3-Amino-N-(2,6-dioxo-3-piperidyl)phthalimide | 4-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione | 4-Aminothalidomide | Actimid | CC 4047 | CC-4047 | CC4047 | Imnovid | POMALIDOMIDE | Pomalyst | pomalidomide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0678117","Octreotide Acetate","C53447","The acetate salt of a synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Similar to somatostatin, this agent also suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.","Octreotide Acetate | D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide Acetate | D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hyroxymethyl)propyl]-L-cysteinamide, Cyclic (2->7)-disulfide, Acetate (Salt) | Longastatin | Longastatina | Mycapssa | OCTREOTIDE ACETATE | Octreotide acetate | SMS 201-995 | SMS 201-995 AC | Samilstin | Sandostatin | Sandostatin LAR | Sandostatin Lar Depot | Sandostatina | Sandostatine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520988","1q21","C13891","A chromosome band present on 1q","1q21 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1861172","Venous Thromboembolism","C99537","Occlusion of the lumen of a vein by a thrombus that has migrated from a distal site via the blood stream.","Venous Thromboembolism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0076959","Treosulfan","C1257","The prodrug of a bifunctional sulfonate alkylating agent with myeloablative, immunosuppressive, and antineoplastic activities. Under physiological conditions, treosulfan converts nonenzymatically to L-diepoxybutane via a monoepoxide intermediate. The monoepoxide intermediate and L-diepoxybutane alkylate DNA at guanine residues and produce DNA interstrand crosslinks, resulting in DNA fragmentation and apoptosis. In escalated doses, this agent also exhibits myeloablative and immunosuppressive activities.","Treosulfan | (S-(R*,R*))-1,2,3,4-butanetetrol,1,4-dimethanesulfonate | 1,2,3, 4-Butanetetrol, 1,4-dimethanesulfonate, [R-(R*,S*)]- | Dihydroxybusulfan | L-Threitol 1,4-dimethanesulfonate | Ovastat | TREOSULFAN | Trecondi | Treosulphan | Tresulfon | treosulfan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0931849","PALM","C33252","The undersurface of the hand.","Palmar Region | PALM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641250","Hepatitis B DNA Measurement","C103404","The determination of the amount of hepatitis B virus DNA in a sample.","Hepatitis B DNA Measurement | HBDNA | HBV DNA | HBV DNA Measurement | Hepatitis B Virus DNA | Hepatitis B Virus DNA Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829560","Immunoglobulin Heavy Chain Locus Variable Region Mutation","C111690","A change in the nucleotide sequence of the variable region of the immunoglobulin heavy chain locus.","Immunoglobulin Heavy Chain Locus Variable Region Mutation | IGHV Gene Mutation | IGHV Locus Mutation | IgVH Mutation | Immunoglobulin Heavy Chain Variable Region Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828793","No Problems Walking","C111663","A response indicating that an individual has or had no problems walking.","No Problems Walking | I have no problems in walking about | I have no problems walking | I have no problems walking about",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827979","Some Problems Walking","C111664","A response indicating that an individual has or had some problems walking.","Some Problems Walking | I have some problems in walking about | I have some problems walking about",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL455351","Confined to Bed (response)","C111665","A response indicating that an individual is confined to bed.","Confined to Bed | I am confined to bed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828792","No Problems with Self-Care","C111666","A response indicating that an individual has or had no problems with self-care.","No Problems with Self-Care | I have no problems washing or dressing myself | I have no problems with self-care",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827978","Some Problems with Washing and Dressing","C111667","A response indicating that an individual has or had some problems with washing or dressing their self.","Some Problems with Washing and Dressing | I have some problems washing or dressing myself",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827728","Unable to Wash or Dress","C111668","A response indicating that an individual is unable to wash or dress their self.","Unable to Wash or Dress | I am unable to wash or dress myself",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828794","No Problems Performing Usual Activities","C111669","A response indicating that an individual has or had no problems with performing their usual activities.","No Problems Performing Usual Activities | I have no problems doing my usual activities | I have no problems with performing my usual activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827980","Some Problems Performing Usual Activities","C111670","A response indicating that an individual has or had some problems with performing their usual activities.","Some Problems Performing Usual Activities | I have some problems doing my usual activities | I have some problems with performing my usual activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827729","Unable to Perform Usual Activities","C111671","A response indicating that an individual is unable to perform their usual activities.","Unable to Perform Usual Activities | I am unable to perform my usual activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827228","No Pain or Discomfort","C111672","A response indicating that an individual has or had no pain or discomfort.","No Pain or Discomfort | I have no pain or discomfort",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828990","Moderate Pain or Discomfort","C111673","A response indicating that an individual has or had moderate pain or discomfort.","Moderate Pain or Discomfort | I have moderate pain or discomfort",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830276","Extreme Pain or Discomfort","C111674","A response indicating that an individual has or had extreme pain or discomfort.","Extreme Pain or Discomfort | I have extreme pain or discomfort",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828779","Not Anxious or Depressed","C111675","A response indicating that an individual has or had no anxiety or depression.","Not Anxious or Depressed | I am not anxious or depressed | I am not worried, sad or unhappy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828991","Moderately Anxious or Depressed","C111676","A response indicating that an individual has or had moderate anxiety or depression.","Moderately Anxious or Depressed | I am moderately anxious or depressed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830279","Extremely Anxious or Depressed","C111677","A response indicating that an individual is extremely anxious or depressed.","Extremely Anxious or Depressed | I am extremely anxious or depressed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829732","Health State Thermometer Scale","C111678","A scale marked off like a thermometer from 0 to 100 that is used to help people indicate how good or bad their health state is; the best state that can be imagined is marked 100 and the worst state that can be imagined is marked 0.","Health State Thermometer Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827400","Your Health State Today","C111696","A question asking an individual about how good or bad they rate their own health today.","Your Health State Today | How Good or Bad Your Health is Today | How good or bad your own health is today, in your opinion | Your own health state today",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827443","Worst Imaginable Health","C111679","The worst state of well-being an individual can conceive of experiencing.","Worst Imaginable Health | Worst imaginable health state",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831358","Best Imaginable Health","C111680","The best state of well-being an individual can conceive of experiencing.","Best Imaginable Health | Best imaginable health state",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828414","Radionuclide Specific Activity","C111699","The radioactivity per unit mass of a stated element or compound.","Radionuclide Specific Activity | Specific Activity | Specific Activity for Radioactivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2343854","Fesoterodine Fumarate","C72779","The fumarate salt form of fesoterodine, a competitive muscarinic receptor antagonist with muscle relaxant and urinary antispasmodic properties. Fesoterodine is rapidly hydrolyzed in vivo into its active metabolite 5-hydroxy methyl tolterodine, which binds and inhibits muscarinic receptors on the bladder detrusor muscle, thereby preventing bladder contractions or spasms caused by acetylcholine. This results in the relaxation of bladder smooth muscle and greater bladder capacity, in addition to a reduction in involuntary muscle contractions and involuntary loss of urine. The active metabolite does not interact with alpha-adrenergic, serotonergic, histaminergic and excitatory amino acid receptors and is eliminated via renal excretion.","Fesoterodine Fumarate | 2-((1R)-3-(Diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl Isobutyrate | FESOTERODINE FUMARATE | SPM 8272 | SPM 907 | Toviaz",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2919692","Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A","C82403","An acute myeloid leukemia associated with t(9;11)(p21.3;q23.3) and MLLT3-KMT2A fusion protein expression. Morphologically it usually has monocytic features. It may present at any age but it is more commonly seen in children. Patients may present with disseminated intravascular coagulation.","Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A | AML with t(9;11)(p21.3;q23.3); KMT2A-MLLT3 | AML with t(9;11)(p22;q23); MLLT3-MLL | AML with t(9;11)(p22;q33);MLLT3-MLL | Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3 (AF9)-KMT2A | Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3- KMT2A | Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A | Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A | Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A Fusion | Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-MLL | Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-MLL | Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3::KMT2A | Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3::KMT2A Fusion | Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3::MLL | Acute Myeloid Leukemia with t(9;11)(p22.3;q23.3); MLLT3-KMT2A | Acute Myeloid Leukemia with t(9;11)(p22.3;q23.3); MLLT3-KMT2A | Acute Myeloid Leukemia with t(9;11)(p22.3;q23.3); MLLT3::KMT2A | Acute Myeloid Leukemia with t(9;11)(p22;q23); MLLT3-MLL | Acute Myeloid Leukemia with t(9;11)(p22;q23); MLLT3-MLL | Acute myeloid leukemia with t(9;11)(p22;q23); MLLT3-MLL",,,,,,,,,,,,,,,"4029663|40481524","Acute myeloid leukemia with KMT2A rearrangement|Acute myeloid leukemia with t(9:11)(p22;q23); MLLT3-MLL",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1334970","Medulloblastoma with Extensive Nodularity","C5407","A medulloblastoma characterized by nodularity and neuronal differentiation.","Medulloblastoma with Extensive Nodularity | Cerebellar Neuroblastoma | Medulloblastoma with Extensive Nodularity and Advanced Neuronal Differentiation | Medulloblastoma with extensive nodularity | Nodular Medulloblastoma",,,,,,,,,,,,,,,"37116880","Medulloblastoma with extensive nodularity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347761","Childhood Myelodysplastic Syndrome","C68744","An uncommon hematologic malignancy occurring during childhood. Many of the morphologic, immunophenotypic, and genetic changes seen in adult myelodysplastic syndromes are also observed in the childhood variants of the disease. Children present with neutropenia and thrombocytopenia more often than adults, and bone marrow hypocellularity is more often seen in children than adults.","Childhood Myelodysplastic Syndrome | Childhood MDS | Myelodysplastic Syndrome | cMDS",,,,,,,,,,,,,,,"45773547","Childhood myelodysplastic syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2026186","Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","C71720","A diffuse large B-cell lymphoma arising from the central nervous system.","Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System | CNS DLBCL | CNS Primary Large B-Cell Lymphoma | Central Nervous System Diffuse Large B-Cell Lymphoma | Central Nervous System Primary Large B-Cell Lymphoma | PCNS-LBCL | Primary DLBCL of the CNS | Primary Diffuse Large B-Cell Lymphoma of the CNS | Primary Large B-Cell Lymphoma of the CNS | Primary Large B-Cell Lymphoma of the Central Nervous System | Primary diffuse large B-cell lymphoma of the CNS",,,,,,,,,,,,,,,"37116982","Diffuse large B-cell lymphoma of central nervous system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332078","Anaplastic Large Cell Lymphoma, ALK-Negative","C37194","A T-cell peripheral lymphoma morphologically indistinguishable from anaplastic large cell lymphoma, ALK-positive.  It is characterized by the absence of the translocation involving the ALK gene and lacks expression of ALK fusion protein.","Anaplastic Large Cell Lymphoma, ALK-Negative | ALCL, ALK- | ALK-Negative Anaplastic Large Cell Lymphoma | Anaplastic large cell lymphoma, ALK negative",,,,,,,,,,,,,,,"37152117|40488896","ALK negative anaplastic large cell lymphoma|Anaplastic large cell lymphoma, ALK negative",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1332079","Anaplastic Large Cell Lymphoma, ALK-Positive","C37193","A T-cell peripheral lymphoma composed of usually large, pleomorphic, CD30 positive T-lymphocytes with abundant cytoplasm. It is characterized by the presence of a translocation involving the ALK gene and expression of ALK fusion protein. Most patients present with peripheral and/or abdominal lymphadenopathy, and often have advanced disease and extranodal involvement.","Anaplastic Large Cell Lymphoma, ALK-Positive | ALCL, ALK+ | ALK-Positive Anaplastic Large Cell Lymphoma | ALKoma | Anaplastic large cell lymphoma, ALK positive | Anaplastic large cell lymphoma, ALK-positive, unspecified site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1371159","Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorder","C7195","A spectrum of lymphoproliferative disorders characterized by CD30 (Ki-1)-positive cutaneous T-cell infiltrates. The two ends of the spectrum include lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma.","Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorder | Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorder | Primary cutaneous CD30+ T-cell lymphoproliferative disorder | Primary cutaneous CD30-positive T-cell proliferations",,,,,,,,,,,,,,,"4029041","Primary cutaneous CD30 antigen positive T-cell lymphoproliferative disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1321547","T-Cell/Histiocyte-Rich Large B-Cell Lymphoma","C9496","A large B-cell lymphoma characterized by the presence of a limited number of scattered neoplastic large B-lymphocytes which are admixed with numerous non-neoplastic T-lymphocytes and frequently histiocytes.","T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | T-Cell Rich/Histiocyte-Rich Large B-Cell Lymphoma | T-Cell/Histiocyte Rich Lymphoma | T-cell rich/histiocyte-rich large B-cell lymphoma | THRLBCL","9688/3","T-cell/histiocyte rich large B-cell lymphoma",,,,,,,,,,,,,"37110400|42872964","T-cell histiocyte rich large B-cell lymphoma|T-cell/histiocyte rich large B-cell lymphoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1333878","Gray-Zone Lymphoma","C37869","A group of lymphomas displaying molecular, morphologic, immunophenotypic, and clinical overlap between classic Hodgkin lymphoma and diffuse large B-cell lymphoma.  This term particularly applies to mediastinal lymphomas with overlapping features of mediastinal (thymic) large B-cell lymphoma and classic Hodgkin lymphoma.","Gray-Zone Lymphoma | B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma | B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma | B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma | B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma | B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma | Gray Zone Lymphoma | Hodgkin-Like Anaplastic Large Cell Lymphoma | Large B-Cell Lymphoma with Hodgkin Features",,,,,,,,,,,,,,,"36716775","B-cell lymphoma unclassifiable with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698294","High Grade B-Cell Lymphoma, Not Otherwise Specified","C80291","High-grade B-cell lymphoma with blastoid features or features between diffuse large B-cell lymphoma and Burkitt lymphoma that lacks MYC, BCL2, and BCL6 gene rearrangements.","High Grade B-Cell Lymphoma, Not Otherwise Specified | B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma | B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma | B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma | BCLU | HGBL, NOS | High Grade B-Cell Lymphoma, NOS | High-Grade B-Cell Lymphoma, NOS | High-Grade B-Cell Lymphoma, Not Otherwise Specified",,,,,,,,,,,,,,,"36712836","B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2699777","Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","C80280","A term referring to a group of diffuse large B-cell lymphomas which are biologically heterogeneous. These lymphomas have a centroblastic, immunoblastic, or anaplastic morphology.","Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2853827","Grade 3b Follicular Lymphoma","C7192","A grade 3 follicular lymphoma composed of solid sheets of centroblasts.","Grade 3b Follicular Lymphoma | FLBCL | Follicular Large B-Cell Lymphoma | Follicular Lymphoma Grade 3b | Follicular lymphoma grade IIIb, unspecified site | Follicular lymphoma, grade 3B | Grade 3b",,,,,,,,,,,,,,,"606914|607792","Follicular lymphoma grade 3b|Follicular lymphoma grade 3b",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1333846","Grade 3a Follicular Lymphoma","C7191","A grade 3 follicular lymphoma in which centrocytes are present.","Grade 3a Follicular Lymphoma | Follicular Lymphoma Grade 3a | Follicular lymphoma grade IIIa, unspecified site | Follicular lymphoma, grade 3A | Grade 3a | WHO Follicular Lymphoma Histologic Grade 3a",,,,,,,,,,,,,,,"606919|607791","Follicular lymphoma grade 3a|Follicular lymphoma grade 3a",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0238239","Light Chain Deposition Disease","C7727","A condition in which plasma cells secrete immunoglobulin light chains of only one type, kappa or lambda. Light chain deposition disease is often associated with multiple myeloma or lymphoproliferative disease, but as many as 50% of patients have no evidence of neoplastic plasma cell proliferation. Light chains excreted in the urine are known as Bence Jones protein. Amyloidosis and severe renal failure occur more frequently than in multiple myeloma. Also known as Bence Jones myeloma. L-chain disease, L-chain myeloma, and LCDD.","Light Chain Deposition Disease | Bence Jones Myeloma | Light Chain Disease | Light Chain Gammopathy",,,,,,,,,,,,,,,"4190326","Light chain deposition disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898068","Osteosclerotic Multiple Myeloma","C7765","Multiple myeloma associated with osteosclerotic and fibrotic changes in the bone trabeculae.  Often, the lymph nodes show changes resembling the plasma cell variant of Castleman disease.  It is often part of POEMS syndrome which is characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes.","Osteosclerotic Multiple Myeloma | Osteosclerotic Multiple Myeloma | Osteosclerotic Myeloma | Osteosclerotic Plasma Cell Myeloma | Osteosclerotic Plasma Cell Myeloma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272868","Biological Aunt","C96569","A female relative who is a sibling of either of the biological parents, and who share a common ancestor.","Biological Aunt | AUNT, BIOLOGICAL",,,,,,,,,,,,,,,"37168659","Natural aunt",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3272869","Biological Cousin","C96571","A relative who is the offspring of a sibling of either of the biological parents, and who share a common ancestor.","Biological Cousin | COUSIN, BIOLOGICAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272882","Biological Uncle","C96587","A male relative who is a sibling of either of the biological parents, and who share a common ancestor.","Biological Uncle | UNCLE, BIOLOGICAL",,,,,,,,,,,,,,,"37168660","Natural uncle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2346979","Becquerel per Gram","C70522","A unit of specific radioactivity (massic activity) equal to activity of one becquerel of the sample with total mass of one gram.","Becquerel per Gram | Becquerel/Gram | Bq/g | Kilobecquerel per Kilogram | becquerel(s)/gram | kBq/kg | kilobecquerel(s)/kilogram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346980","Becquerel per Kilogram","C70521","A unit of specific radioactivity (massic activity) equal to activity of one becquerel of the sample with total mass of one kilogram.","Becquerel per Kilogram | Becquerel/Kilogram | Bq/kg | becquerel(s)/kilogram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346982","Becquerel per Microgram","C70523","A unit of specific radioactivity (massic activity) equal to activity of one becquerel of the sample with total mass of one microgram.","Becquerel per Microgram | Becquerel/Microgram | Bq/mcg | Bq/ug | GBq/Kg | GBq/kg | Gigabecquerel per Kilogram | Kilobecquerel per Milligram | MBq/g | Megabecquerel per Gram | becquerel(s)/microgram | gigabecquerel/kilogram | kBq/mg | kilobecquerel(s)/milligram | megabecquerel(s)/gram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346983","Becquerel per Milligram","C70524","A unit of specific radioactivity (massic activity) equal to activity of one becquerel of the sample with total mass of one milligram.","Becquerel per Milligram | Becquerel/Milligram | Bq/mg | Kilobecquerel per Gram | MBq/kg | Megabecquerel per Kilogram | becquerel(s)/milligram | kBq/g | kilobecquerel(s)/gram | megabecquerel(s)/kilogram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348019","Curie per Gram","C70528","A unit of specific radioactivity (massic activity) equal to activity of one Curie of the sample with total mass of one gram.","Curie per Gram | Ci/g | Curie/Gram | Microcurie per Microgram | Millicurie per Milligram | curie(s)/gram | mCi/mg | microcurie(s)/microgram | millicurie(s)/milligram | uCi/ug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348020","Curie per Kilogram","C70529","A unit of specific radioactivity (massic activity) equal to activity of one Curie of the sample with total mass of one kilogram.","Curie per Kilogram | Ci/kg | Curie/Kilogram | Microcurie per Milligram | Millicurie per Gram | curie(s)/kilogram | mCi/g | microcurie(s)/milligram | millicurie(s)/gram | uCi/mg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348022","Curie per Microgram","C70530","A unit of specific radioactivity (massic activity) equal to activity of one Curie of the sample with total mass of one microgram.","Curie per Microgram | Ci/mcg | Ci/ug | Microcurie per Picogram | Millicurie per Nanogram | curie(s)/microgram | uCi/pg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348024","Curie per Milligram","C70531","A unit of specific radioactivity (massic activity) equal to activity of one Curie of the sample with total mass of one milligram.","Curie per Milligram | Ci/mg | Microcurie per Nanogram | Millicurie per Microgram | curie(s)/milligram | mCi/ug | millicurie(s)/microgram | uCi/ng",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348852","Gigabecquerel per Gram","C70525","A unit of specific radioactivity (massic activity) equal to activity of one gigabecquerel of the sample with total mass of one gram.","Gigabecquerel per Gram | GBq/g | Gigabecquerel/Gram | Kilobecquerel per Microgram | MBq/mg | Megabecquerel per Milligram | gigabecquerel/gram | kBq/mcg | kBq/ug | kilobecquerel(s)/microgram | megabecquerel(s)/milligram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348853","Gigabecquerel per Microgram","C70526","A unit of specific radioactivity (massic activity) equal to activity of one gigabecquerel of the sample with total mass of one microgram.","Gigabecquerel per Microgram | GBq/mcg | GBq/ug | Gigabecquerel/Microgram | MBq/ng | Megabecquerel per nanogram | gigabecquerel/microgram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348855","Gigabecquerel per Milligram","C70527","A unit of specific radioactivity (massic activity) equal to activity of one gigabecquerel of the sample with total mass of one milligram.","Gigabecquerel per Milligram | GBq/mg | Gigabecquerel/Milligram | MBq/mcg | MBq/ug | Megabecquerel per Microgram | gigabecquerel/milligram | megabecquerel(s)/microgram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347114","Microcurie per Kilogram","C70571","A unit of specific radioactivity (massic activity) equal to activity of one microcurie of the sample with total mass of one kilogram.","Microcurie per Kilogram | mcCi/kg | microcurie(s)/kilogram | uCi/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1532567","Millicurie per Kilogram","C70570","A unit of specific radioactivity (massic activity) equal to activity of one millicurie of the sample with total mass of one kilogram.","Millicurie per Kilogram | Microcurie per Gram | Millicurie/Kilogram | mCi/kg | microcurie(s)/gram | millicurie(s)/kilogram | uCi/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272695","Done","C111784","Indicates a task, process or examination that has been performed and completed.","Done | ",,,,,,,,,,,,,,,"4295937","Done",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829136","Medical Outcomes Study Your Feelings Questionnaire","C111697","A survey of multiple dimensions of functioning and well being, representing the feelings scale.","Medical Outcomes Study Your Feelings Questionnaire | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831592","A Good Bit of the Time","C111745","A response indicating that something happens or happened a good bit of the time.","A Good Bit of the Time | A good bit of the time",,,,,,,,,,,,,,,"763702","A good bit of the time",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829819","Has Your Daily Life Been Full of Things That Were Interesting to You","C111706","A question about whether an individual's life has or had been full of things that were interesting.","Has Your Daily Life Been Full of Things That Were Interesting to You | Has your daily life been full of things that were interesting to you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829740","Have You Felt Loved and Wanted","C111707","A question about whether an individual feels or felt loved and wanted.","Have You Felt Loved and Wanted | Have you felt loved and wanted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829750","Have You Been a Very Nervous Person","C111708","A question about whether an individual is or has been very nervous.","Have You Been a Very Nervous Person | Have you been a very nervous person",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829748","Have You Been in Firm Control of Your Behavior, Thoughts, Emotions, and Feelings","C111710","A question about whether an individual has or had been in firm control of their behavior, thoughts, emotions, or feelings.","Have You Been in Firm Control of Your Behavior, Thoughts, Emotions, and Feelings | Have you been in firm control of your behavior, thoughts, emotions, feelings",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830508","Did You Feel That You Had Nothing to Look Forward To","C111712","A question about whether an individual feels or felt that they had nothing to look forward to.","Did You Feel That You Had Nothing to Look Forward To | Did you feel that you had nothing to look forward to",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829745","Have You Felt Calm and Peaceful","C111713","A question about whether an individual feels or felt calm and peaceful.","Have You Felt Calm and Peaceful | Feel Calm and Peaceful | Have you felt calm and peaceful | I feel calm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829742","Have You Felt Emotionally Stable","C111714","A question about whether an individual feels or felt emotionally stable.","Have You Felt Emotionally Stable | Feel Emotionally Stable | Have you felt emotionally stable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829743","Have You Felt Downhearted and Blue","C111715","A question about whether an individual feels or felt downhearted and blue.","Have You Felt Downhearted and Blue | Feel Blue | Feel Downhearted | Have you felt downhearted and blue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829738","Have You Felt So Down in the Dumps That Nothing Could Cheer You Up","C111723","A question about whether an individual feels or felt so down in the dumps that nothing could cheer them up.","Have You Felt So Down in the Dumps That Nothing Could Cheer You Up | Have you felt so down in the dumps that nothing could cheer you up",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829739","Have You Felt Restless, Fidgety, or Impatient","C111725","A question about whether an individual feels or felt restless, fidgety, or impatient.","Have You Felt Restless, Fidgety, or Impatient | Have you felt restless, fidgety, or impatient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829746","Have You Been Moody or Brooded About Things","C111726","A question about whether an individual is or has been moody or brooded about things.","Have You Been Moody or Brooded About Things | Have you been moody or brooded about things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829751","Have You Been Anxious or Worried","C111729","A question about whether an individual is or has been anxious or worried.","Have You Been Anxious or Worried | Have you been anxious or worried",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829752","Have You Been a Happy Person","C111730","A question about whether an individual is or has been a happy person.","Have You Been a Happy Person | Have you been a happy person",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829747","Have You Been in Low or Very Low Spirits","C111732","A question about whether an individual is or has been in low or very low spirits.","Have You Been in Low or Very Low Spirits | Have you been in low or very low spirits",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829744","Have You Felt Cheerful or Lighthearted","C111733","A question about whether an individual feels or felt cheerful or lighthearted.","Have You Felt Cheerful or Lighthearted | Have you felt cheerful or lighthearted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829613","How Happy, Satisfied, or Pleased Are You With Your Personal Life","C111698","A question about the frequency or intensity an individual feels or felt happy, satisfied, or pleased with their personal life.","How Happy, Satisfied, or Pleased Are You With Your Personal Life | How happy, satisfied, or pleased have you been with your personal life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829606","How Often Did You Feel There Were People You Were Close To","C111700","A question about the frequency an individual feels or felt there were people close to them.","How Often Did You Feel There Were People You Were Close To | Frequency You Felt There Were People You Were Close To | How often did you feel there were people you were close to",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829605","How Often Has Feeling Depressed Interfered With What You Usually Do","C111701","A question about the frequency an individual feels or felt that depression interfered with what they usually do.","How Often Has Feeling Depressed Interfered With What You Usually Do | Frequency Feeling Depressed has Interfered with What You Usually Do | How often has feeling depressed interfered with what you usually do",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829609","How Much of the Time","C111702","A question about how much of the time something is occurring or has occurred.","How Much of the Time | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827285","Did You Have Difficulty Reasoning and Solving Problems","C111703","A question about whether an individual has or had difficulty reasoning and solving problems.","Did You Have Difficulty Reasoning and Solving Problems | Did you have difficulty reasoning and solving problems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829736","Have You Had Reason to Wonder If You Were Losing Your Mind, or Losing Control Over the Way You Act, Talk, Think, Feel, or of Your Memory","C111705","A question about whether an individual has or had reason to wonder if they were losing their mind or control over the way they act, talk, think, feel or of their memory.","Have You Had Reason to Wonder If You Were Losing Your Mind, or Losing Control Over the Way You Act, Talk, Think, Feel, or of Your Memory | Have you had any reason to wonder if you were losing your mind, or losing control over the way you act, talk, think, feel or of your memory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830503","Did You Have Difficulty Doing Activities Involving Concentration and Thinking","C111709","A question about whether an individual has or had difficulty doing activities involving concentration and reasoning.","Did You Have Difficulty Doing Activities Involving Concentration and Thinking | Did you have difficulty doing activities involving concentration and thinking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830513","Did You Become Confused and Start Several Actions at a Time","C111711","A question about whether an individual does or did become confused and start several actions at a time.","Did You Become Confused and Start Several Actions at a Time | Did you become confused and start several actions at a time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829741","Have You Felt Like Crying","C111716","A question about whether an individual feels or felt like crying.","Have You Felt Like Crying | Feel Like Crying | Have you felt like crying",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830510","Feel Left Out","C111717","A question about whether an individual feels or felt left out.","Feel Left Out | Did You Feel Left Out | Did You Feel Left Out | Did you feel left out | I feel left out | Left Out",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830509","Did You Feel That Others Would Be Better Off If You Were Dead","C111719","A question about whether an individual feels or felt that others would be better off if they were dead.","Did You Feel That Others Would Be Better Off If You Were Dead | Did you feel that others would be better off if you were dead",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830505","Did You Forget Things That Happened Recently or Where You Put Things or Appointments","C111718","A question about whether an individual does or did forget things that happened recently.","Did You Forget Things That Happened Recently or Where You Put Things or Appointments | Did you forget, for example, things that happened recently, where you put things, appointments",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830507","Did You Feel That Your Love Relationships Were Full and Complete","C111720","A question about whether an individual feels or felt that their love relationships are full and complete.","Did You Feel That Your Love Relationships Were Full and Complete | Did you feel that your love relationships, loving and being loved, were full and complete",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829749","Have You Been Bothered By Nervousness or Your Nerves","C111721","A question about whether an individual has or had been bothered by nervousness or their nerves.","Have You Been Bothered By Nervousness or Your Nerves | Have you been bothered by nervousness, or your nerves",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829823","Has Living Been a Wonderful Adventure","C111722","A question about whether an individual has or had been living a wonderful adventure.","Has Living Been a Wonderful Adventure | Has living been a wonderful adventure for you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830512","Did You Ever Think About Taking Your Own Life","C111724","A question about whether an individual does or did ever think about taking their own life.","Did You Ever Think About Taking Your Own Life | Did you ever think about taking your own life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830504","Did You Get Rattled, Upset, or Flustered","C111727","A question about whether an individual does or did get rattled or flustered.","Did You Get Rattled, Upset, or Flustered | Did you get rattled, upset, or flustered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830502","Did You Have Trouble Keeping Your Attention On Any Activity For Long","C111728","A question about whether an individual does or did have trouble keeping their attention on any activity for long.","Did You Have Trouble Keeping Your Attention On Any Activity For Long Question | Did You Have Trouble Keeping Your Attention On Any Activity For Long | Did You Have Trouble Keeping Your Attention On Any Activity For Long | Did you have trouble keeping your attention on any activity for long",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830506","Did You Find Yourself Having Difficulty Trying to Calm Down","C111731","A question about whether an individual does or did have difficulty trying to calm down.","Did You Find Yourself Having Difficulty Trying to Calm Down | Did you find yourself having difficulty trying to calm down",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829616","How Depressed Have You Felt at its Worst","C111734","A question about how intense an individual's depression feels or felt at its worst.","How Depressed Have You Felt at its Worst | How depressed at its worst have you felt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830501","Did You React Slowly to Things That Were Said or Done","C111735","A question about whether an individual reacts or reacted slowly to things that were said or done.","Did You React Slowly to Things That Were Said or Done | Did you react slowly to things that were said or done",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830511","Feel Isolated From Others","C111736","A question about whether an individual feels or felt isolated from others.","Feel Isolated From Others | Did You Feel Isolated From Others | Did You Feel Isolated From Others | Did you feel isolated from others | I feel isolated from others | Isolated From Others",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830277","Extremely Happy","C111739","A response indicating that an individual is or has been extremely happy and could not have been more satisfied or pleased.","Extremely Happy | Extremely happy, could not have been more satisfied or pleased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827648","Very Happy","C111740","A response indicating that an individual is or has been very happy most of the time.","Very Happy | Very happy most of the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4264468","Generally Satisfied or Pleased","C111741","A response indicating that an individual is or has been generally satisfied or pleased.","Generally Satisfied or Pleased | Generally Satisfied, Pleased | Generally satisfied, pleased | Pleased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827976","Sometimes Fairly Satisfied","C111742","A response indicating that an individual is or has been sometimes fairly satisfied and sometimes fairly unhappy.","Sometimes Fairly Satisfied | Sometimes fairly satisfied, sometimes fairly unhappy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829995","Generally Dissatisfied and Unhappy","C111743","A response indicating that an individual is or has been generally dissatisfied or unhappy.","Generally Dissatisfied and Unhappy | Generally dissatisfied, unhappy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827649","Very Dissatisfied and Unhappy","C111744","A response indicating that an individual is or has been very dissatisfied and unhappy most of the time.","Very Dissatisfied and Unhappy | Very dissatisfied, unhappy most of the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828774","Not Enough to Be Concerned or Worried","C111746","A response indicating that an individual is or has experienced something but that it was not enough to cause them concern or worry.","Not Enough to Be Concerned or Worried | Yes, but not enough to be concerned or worried",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831571","A Little Concerned","C111747","A response indicating that an individual is or has experienced something and that they are a little concerned.","A Little Concerned | Yes, and I have been a little concerned",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828422","Quite Concerned","C111748","A response indicating that an individual is or has experienced something and that they are quite concerned.","Quite Concerned | Yes, and I am quite concerned",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827647","Very Much Concerned","C111749","A response indicating that an individual is or has experienced something and that they are very much concerned.","Very Much Concerned | Yes, and I am very much concerned",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830278","Extremely Bothered","C111750","A response indicating that an individual is or was extremely bothered, to the point where they could not take care of things.","Extremely Bothered | Extremely so, to the point where I could not take care of things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831292","Bothered Very Much","C111751","A response indicating that an individual is or was very bothered.","Bothered Very Much | A lot | Very Bothered | Very much bothered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831294","Bothered Quite a Bit","C111752","A response indicating that an individual is or was quite a bit bothered.","Bothered Quite a Bit | Bothered quite a bit | Quite a Bit Bothered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831293","Bothered Some","C111753","A response indicating that an individual is or was bothered some, enough to notice.","Bothered Some | Bothered some, enough to notice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831310","Bothered a Little","C111754","A response indicating that an individual is or was bothered just a little.","Bothered a Little | Bothered a little bit | Bothered just a little",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828778","Not Bothered at All","C111755","A response indicating that an individual is or was not bothered at all.","Not Bothered at All | Bothered Not at All | Not at All Bothered | Not at all bothered | Not bothered at all",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714757","Juvenile Rheumatoid Arthritis","C27179","An older, deprecated term that encompassed three major types of autoimmune or autoinflammatory arthritis in children: systemic-onset, pauciarticular, or polyarticular arthritis. The juvenile rheumatoid arthritis classification system has been replaced by the International League of Associations for Rheumatology (ILAR) juvenile idiopathic arthritis classification system.","Juvenile Rheumatoid Arthritis | JRA | Juvenile Rheumatoid Arthritis (AQ)",,,,,,,,,,,,,,,"4132809","Juvenile seropositive polyarthritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698316","B Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.3); IL3-IGH","C80340","A precursor lymphoid neoplasm which is composed of B lymphoblasts and carries a translocation between the IL3 gene on chromosome 5 and the IGH locus on chromosome 14, (q31.1;q32.3). It results in eosinophilia.","B Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.3); IL3-IGH | B Lymphoblastic Leukemia/Lymphoma with IGH-IL3 Fusion | B Lymphoblastic Leukemia/Lymphoma with IGH::IL3 Fusion | B Lymphoblastic Leukemia/Lymphoma with IL3-IGH Fusion | B Lymphoblastic Leukemia/Lymphoma with IL3::IGH Fusion | B Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.3); IL3-IGH | B Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.3); IL3::IGH | B Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31;q32); IL3-IGH | B Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31;q32); IL3-IGH | B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); IL3-IGH | B-Lymphoblastic Leukemia/Lymphoma with IGH-IL3 Fusion | B-Lymphoblastic Leukemia/Lymphoma with IGH::IL3 Fusion | B-Lymphoblastic Leukemia/Lymphoma with IL3-IGH Fusion | B-Lymphoblastic Leukemia/Lymphoma with IL3::IGH Fusion | B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31;q32); IL3-IGH","9817/3","B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); IL3-IGH",,,,,,,,,,,,,"3654647|42872960","B lymphoblastic leukemia lymphoma with t(5;14)(q31;q32); IL3-IGH|B lymphoblastic leukemia lymphoma with t(5;14)(q31;q32); IL3-IGH",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C2698308","B Acute Lymphoblastic Leukemia with t(v;11q23.3); MLL Rearranged","C80342","A B-cell acute leukemia characterized by the presence of lymphoblasts that carry a translocation between the KMT2A gene at 11q23.3 and another gene partner resulting in the production of an KMT2A related fusion protein. It is the most commonly seen leukemia in the pediatric population under the age of one year. The prognosis is unfavorable.","B Acute Lymphoblastic Leukemia with t(v;11q23.3); KMT2A Rearranged | B Acute Lymphoblastic Leukemia with KMT2A Rearrangement | B Acute Lymphoblastic Leukemia with t(v;11q23); MLL Rearranged | B Acute Lymphoblastic Leukemia with t(v;11q23.3); KMT2A Rearranged | B Acute Lymphoblastic Leukemia with t(v;11q23.3); KMT2A Rearranged | B Acute Lymphoblastic Leukemia with t(v;11q23.3); MLL Rearranged | B Acute Lymphoblastic Leukemia with t(v;11q23.3); MLL Rearranged | B-ALL with t(v;11q23.3)/KMT2A Rearranged | B-ALL with t(v;11q23.3); KMT2A Rearranged | B-Acute Lymphoblastic Leukemia with KMT2A Rearrangement | B-Acute Lymphoblastic Leukemia with t(v;11q23); MLL Rearranged | B-Acute Lymphoblastic Leukemia with t(v;11q23.3); KMT2A Rearranged | B-Acute Lymphoblastic Leukemia with t(v;11q23.3); MLL Rearranged | B-Cell Acute Lymphoblastic Leukemia with t(v;11q23); MLL Rearranged | B-Cell Acute Lymphoblastic Leukemia with t(v;11q23.3); MLL Rearranged",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830376","Ductopenia","C111785","A morphologic finding indicating reduction in the numbers of interlobular and septal bile ducts in the liver tissue.","Ductopenia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830377","Ductal or Ductular Proliferation","C111786","A morphologic finding indicating the presence of typical or atypical proliferation of biliary epithelial cells in the portal tracts of the liver.","Ductal or Ductular Proliferation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831034","Concentric Fibrosis of Intrahepatic Duct","C111787","A morphologic finding indicating the presence of fibrosis around an intrahepatic bile duct in the liver tissue.","Concentric Fibrosis of Intrahepatic Duct | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0265965","Dyskeratosis Congenita","C111802","A rare genetic disorder characterized by nail dystrophy, reticulated skin pigmentation especially on the neck and chest, and oral leukoplakia.  In about half the cases mutations in the TERT, TERC, DKC1, or TINF2 genes are identified.  Patients are at an increased risk of developing bone marrow failure, myelodysplastic syndrome, leukemia, or cancer, especially in the head and neck region.","Dyskeratosis Congenita | DKC | Zinsser-Engman-Cole Syndrome",,,,,,,,,,,,,,,"4326230","Dyskeratosis congenita",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1868679","GRISCELLI SYNDROME, TYPE 2","C111814","A rare, autosomal recessive genetic syndrome caused by mutations in the RAB27A gene.  It is characterized by hypopigmentation of the skin, hair and eyes, recurrent infections, neutropenia, and immune system abnormalities.  Patients are prone to develop hemophagocytic lymphohistiocytosis.","Griscelli Syndrome Type 2 | GS2 | PAID Syndrome | Partial Albinism and Immunodeficiency Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985436","Deleterious Mutation","C93102","A genetic variation that is known to be associated with an increased risk of disease.","Deleterious Mutation | Deleterious | Driver Mutation | deleterious mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412237","ADH1C Gene","C111822","This gene is involved in the metabolism of alcohols.","ADH1C Gene | ADH1C | Alcohol Dehydrogenase 1C (Class I), Gamma Polypeptide Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412238","ADH4 Gene","C111829","This gene plays a role in the oxidation of alcohols.","ADH4 Gene | ADH4 | Alcohol Dehydrogenase 4 (Class II), Pi Polypeptide Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412330","ALAS1 Gene","C111872","This gene plays a role in both lipid metabolism and heme biosynthesis.","ALAS1 Gene | ALAS1 | Aminolevulinate, Delta-, Synthase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412626","ATOH1 Gene","C111875","This gene is involved in E-box dependent gene transcription.","ATOH1 Gene | ATOH1 | Atonal Homolog 1 (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425282","EMSY Gene","C111825","This gene is involved in transcription repression.","EMSY Gene | C11orf30 | C11orf30 Gene | Chromosome 11 Open Reading Frame 30 Gene | EMSY | EMSY Transcriptional Repressor, BRCA2 Interacting Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830637","CTAG2 Antibody","C111808","Any immunoglobulin that recognizes cancer/testis antigen 2.","CTAG2 Antibody | Anti-CTAG2 Antibody | Anti-Cancer/Testis Antigen 2 Antibody | Anti-L Antigen Family Member 1 Antibody | Anti-LAGE Antibody | Anti-LAGE1 Antibody | Anti-NY-ESO-2 Antibody | Cancer/Testis Antigen 2 Antibody | L Antigen Family Member 1 Antibody | LAGE Antibody | LAGE1 Antibody | NY-ESO-2 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424110","CTCFL Gene","C111818","This gene plays a role in gene regulation.","CTCFL Gene | CCCTC-Binding Factor (Zinc Finger Protein)-Like Gene | CTCFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414058","DKK2 Gene","C111878","This gene plays a role in the regulation of Wnt signaling.","DKK2 Gene | DKK2 | Dickkopf WNT Signaling Pathway Inhibitor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414060","DKK4 Gene","C111881","This gene is involved in the inhibition of the Wnt signaling pathway.","DKK4 Gene | DKK4 | Dickkopf WNT Signaling Pathway Inhibitor 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242958","DNA Adduct","C1510","A structure formed when a chemical is attached to DNA by a covalent bond.","DNA Adduct | Carcinogen-DNA Adducts | Drug-DNA Adduct",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414186","DUSP5 Gene","C111862","This gene is involved in the dephosphorylation of ERK family proteins.","DUSP5 Gene | DUSP5 | Dual Specificity Phosphatase 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3715206","Eighteen","C111798","A natural number greater than seventeen and less than nineteen and the quantity that it denotes.","Eighteen | 18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414430","EPHA7 Gene","C111841","This gene plays a role in mediation of developmental processes.","EPHA7 Gene | EPH Receptor A7 Gene | EPHA7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415796","HTC2 gene","C111821","Human HTC2 gene is located within Xq24-q27.1 and the size of this phenotypic locus is not reported. This gene region has no known protein product. Palindrome-mediated interchromosomal insertion in this locus is associated with congenital generalized hypertrichosis.","HTC2 Gene | CGH | CXINSq27.1 | Chromosome Xq27.1 Interchromosomal Insertion Syndrome Gene | HCG | HTC2 | Hypertrichosis 2 (Generalized, Congenital) Gene | Hypertrichosis, Congenital Generalized Gene | Hypertrichosis, Congenital Generalized, 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829569","IL7 Antibody","C111801","Any immunoglobulin that recognizes interleukin-7.","IL7 Antibody | Anti-IL-7 Antibody | Anti-IL7 Antibody | Anti-Interleukin 7 Antibody | Anti-Interleukin-7 Antibody | Anti-Lymphopoietin-1 Antibody | IL-7 Antibody | Interleukin 7 Antibody | Interleukin-7 Antibody | Lymphopoietin-1 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829508","inv(3)","C111789","A chromosomal rearrangement where a genetic segment of chromosome 3 has been inverted.","inv(3) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416731","KRT18 Gene","C111866","This gene plays a role in keratin filament structure.","KRT18 Gene | KRT18 | Keratin 18 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0125259","Lamin B","C111790","A family of class V intermediate filaments that interact with nuclear membrane-associated proteins to form the nuclear lamina. This family of lamins has two members (Lamin-B1 and -B2), are present in all cells and play a role in the disintegration and reformation of the nuclear envelop during mitosis.","Lamin B | B-Type Lamin | B-Type Lamins | Lamin-B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0427526","Large Granular Lymphocyte","C12921","A population of large-sized lymphocytes found in human peripheral blood with slightly eccentric nuclei and abundant cytoplasmic azurophilic granules. This population of cells can be comprised of normal natural killer (NK) cells.","Large Granular Lymphocyte | LGL | Large Granular Lymphocyte | Large Granular Lymphocytes | large granular lymphocyte",,,,,,,,,,,,,,,"4095350","Large granular lymphocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517955","Loss of Chromosome 12p","C36410","A cytogenetic abnormality that refers to the loss of all or part of the short arm of chromosome 12 (12p).","Loss of Chromosome 12p | 12p del | 12p deletion | 12p- | del(12p) | del(12p); ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416913","LRP1B Gene","C111830","This gene plays a role in low density lipoprotein metabolism.","LRP1B Gene | LRP1B | Low Density Lipoprotein Receptor-Related Protein 1B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829192","MART1 Antibody","C111806","Any immunoglobulin that recognizes melanoma antigen recognized by T-cells 1.","MART1 Antibody | Anti-MART1 Antibody | Anti-MLANA Antibody | Anti-Melan-A Antibody | Anti-Melanoma Antigen Recognized by T-Cells 1 Antibody | MLANA Antibody | Melan-A Antibody | Melanoma Antigen Recognized by T-Cells 1 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422672","NDRG4 Gene","C111838","This gene is involved in vascular smooth muscle cell mitogenesis, spatial learning and neuronal survival.","NDRG4 Gene | NDRG Family Member Gene | NDRG4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828811","NLRP4 Antibody","C111809","Any immunoglobulin that recognizes NACHT, LRR and PYD domains-containing protein 4.","NLRP4 Antibody | Anti-NACHT, LRR and PYD Domains-Containing Protein 4 Antibody | Anti-NALP4 Antibody | Anti-NLRP4 Antibody | NACHT, LRR and PYD Domains-Containing Protein 4 Antibody | NALP4 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828777","Notch Receptor Intracellular Domain","C111794","The free carboxy-terminal intracellular domain (ICD) of a notch family protein, which is a product of regulated intramembrane proteolysis mediated by the gamma-secretase enzyme complex. This protein fragment is involved in transcriptional regulation of target genes.","Notch Receptor Intracellular Domain | NICD | Neurogenic Locus Notch Homolog Protein ICD | Neurogenic Locus Notch Homolog Protein Intracellular Domain | Notch ICD | Notch Intracellular Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418520","PGP Gene","C111791","This gene may be involved in regulating oxygen transport.","PGP Gene | PGP | Phosphoglycolate Phosphatase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418919","PRKCG Gene","C111835","This gene is involved in signal transduction.","PRKCG Gene | PRKCG | Protein Kinase C, Gamma Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419922","SEC14L1 Gene","C111869","This gene is involved in transport.","SEC14L1 Gene | SEC14-Like 1 (S. cerevisiae) Gene | SEC14L1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420073","SIX2 Gene","C111800","This gene is involved in transcription regulation.","SIX2 Gene | SIX Homeobox 2 Gene | SIX homeobox 2 Gene | SIX2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420075","SIX4 Gene","C111805","This gene plays a role in transcription regulation.","SIX4 Gene | SIX Homeobox 4 Gene | SIX4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420076","SIX5 Gene","C111812","This gene is involved in transcription regulation.","SIX5 Gene | SIX Homeobox 5 Gene | SIX5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420174","SLC2A3P1 Gene","C111820","Human SLC2A3P1 gene is located in the vicinity of 5q34 and is approximately 1 kb in length. The product is a processed pseudogene, which produces an RNA transcript but does not encode a protein product and has no apparent cellular function.","SLC2A3P1 Gene | GLUT3P1 | GLUT6 | SLC2A3P | SLC2A3P1 | Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 3 Pseudogene | Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 3 Pseudogene 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1442750","SLC38A3 Gene","C111847","This gene is involved in neutral amino acid transport.","SLC38A3 Gene | SLC38A3 | Solute Carrier Family 38, Member 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420706","TFPI2 Gene","C111842","This gene plays a role in serine proteinase inhibition.","TFPI2 Gene | TFPI2 | Tissue Factor Pathway Inhibitor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827837","TG3 Antibody","C111799","A monoclonal antibody that recognizes phosphorylated nucleolin. Nucleolin phosphorylation is mediated by the Cdk1/Cyclin B1 complex and is a marker for cells undergoing mitosis.","TG3 Antibody | Monoclonal Antibody TG-3 | TG-3 | TG-3 Antibody | TG-3 Monoclonal Antibody | TG3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425064","TNFRSF13C Gene","C111795","This gene plays a role in peripheral B-cell survival.","TNFRSF13C Gene | TNF Receptor Superfamily Member 13C Gene | TNFRSF13C | Tumor Necrosis Factor Receptor Superfamily, Member 13C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827759","TSGA10 Antibody","C111811","Any immunoglobulin that recognizes testis-specific gene 10 protein.","TSGA10 Antibody | Anti-CT79 Antibody | Anti-TSGA10 Antibody | Anti-Testis-Specific Gene 10 Protein Antibody | CT79 Antibody | Testis-Specific Gene 10 Protein Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426228","ZMYND10 Gene","C111850","This gene plays a role in ciliary function.","ZMYND10 Gene | ZMYND10 | Zinc Finger, MYND-Type Containing 10 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013835","Electromagnetic Field","C16533","Field of force associated with a moving electric charge and consisting of electric and magnetic fields that are generated at right angles to each other.","Electromagnetic Field | EMF | Radiation, Electromagnetic Field | electromagnetic field",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707724","Transponder","C50232","An electrical device designed to send a specific response upon receiving a specific signal.","Transponder Device | Transponder | Transponder Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709250","Non-Neoplastic Liver and Intrahepatic Bile Duct Disorder","C53550","A non-neoplastic disorder that affects the liver parenchyma and the intrahepatic bile ducts. Representative examples include hepatitis, cirrhosis, and cholangitis.","Non-Neoplastic Liver and Intrahepatic Bile Duct Disorder | Non-Neoplastic Hepatic Disease | Non-Neoplastic Hepatic Disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829058","Minimal Response of Multiple Myeloma","C111788","Patients in whom some, but not all, the criteria for partial response are fulfilled are classified as minimal response (MR), provided the remaining criteria satisfy the requirements for minimal response.  MR requires all of the following: 1. 25-49% reduction in the level of the serum monoclonal paraprotein maintained for a minimum of 6 weeks; 2. 50-89% reduction in 24 h urinary light chain excretion, which still exceeds 200 mg/24 h, maintained for a minimum of 6 weeks; 3. for patients with non-secretory myeloma only, 25-49% reduction in plasma cells in a bone marrow aspirate and on trephine biopsy, if biopsy is performed, maintained for a minimum of 6 weeks; 4. 25-49% reduction in the size of soft tissue plasmacytomas (by radiography or clinical examination); 5. no increase in size or number of lytic bone lesions (development of a compression fracture does not exclude response) (adapted from National Comprehensive Cancer Network).","Minimal Response of Multiple Myeloma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826860","Naranjo Adverse Drug Reaction Probability Scale","C111889","A questionnaire developed by Naranjo et al that is designed to assess the likelihood that an adverse event is due to the drug administered rather than the result of other factors.","Naranjo Adverse Drug Reaction Probability Scale | NADRPS | Naranjo ADR Probability Scale | Naranjo Checklist | Naranjo Checklist;  | Naranjo Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828737","Objective Evidence","C111890","Information proven as true based on documentation, measurement, or facts; not subjective or speculative.","Objective Evidence | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419980","SF3B1 Gene","C98284","This gene is involved in mRNA splicing.","SF3B1 Gene | SF3B1 | Splicing Factor 3b Subunit 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538704","POT1 Gene","C107655","This gene plays a role in the regulation of telomere length.","POT1 Gene | POT1 | Protection of Telomeres Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417530","MYD88 Gene","C90089","This gene is involved in the modulation of proinflammatory gene expression.","MYD88 Gene | MYD88 | Myeloid Differentiation Primary Response 88 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425680","KLHL6 Gene","C99602","This gene may be involved in B-cell functioning.","KLHL6 Gene | KLHL6 | Kelch-Like Family Member 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366530","FH Gene","C95268","This gene plays a role in the Krebs cycle.","FH Gene | FH | Fumarate Hydratase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420072","SIX1 Gene","C84410","This gene may be involved in limb development.","SIX1 Gene | SIX Homeobox 1 Gene | SIX1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414490","EYA1 Gene","C75390","This gene may play a role in organ development.","EYA1 Gene | EYA1 | Eyes Absent Homolog 1 (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421544","XPO1 Gene","C99484","This gene plays a role in the regulation of nuclear export.","XPO1 Gene | Exportin 1 Gene | XPO1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334131","INHBA Gene","C24513","This gene is involved in the negative regulation of stromal cell proliferation in the gonads. It also plays a role in cell differentiation.","INHBA Gene | INHBA | Inhibin, Beta A (Activin A, Activin AB Alpha Polypeptide) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812263","EPHA3 Gene","C18384","This gene is involved in receptor tyrosine kinase signal transduction and plays a role in lymphoid function and differentiation.","EPHA3 Gene | EPH Receptor A3 Gene | EPHA3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332431","BMPR2 Gene","C21368","This gene is involved in receptor mediated ligand-induced signal transduction that is critical for endochondral bone formation and embryogenesis.","BMPR2 Gene | BMPR2 | Bone Morphogenetic Protein Receptor, Type II (Serine/Threonine Kinase) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412807","BMPR1B Gene","C73559","This gene is involved in the mediation of signal transduction.","BMPR1B Gene | BMPR1B | Bone Morphogenetic Protein Receptor, Type IB Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332430","BMPR1A Gene","C21366","This gene plays a role in the bone morphogenetic protein signaling pathway.","BMPR1A Gene | BMPR1A | Bone Morphogenetic Protein Receptor Type 1A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334862","NBN Gene","C21178","This gene plays a role in DNA repair and cell cycle checkpoints.","NBN Gene | NBN | Nibrin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334910","NTRK3 Gene","C24647","This gene plays a role in neuronal development and cellular differentiation. Mutations in the gene are associated with medulloblastomas, secretory breast carcinomas and other cancers.","NTRK3 Gene | NTRK3 | Neurotrophic Receptor Tyrosine Kinase 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334352","LTK Gene","C24562","This gene plays a role in leukocyte tyrosine kinase signal transduction and diverse cellular regulatory pathways.","LTK Gene | LTK | Leukocyte Receptor Tyrosine Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0676831","Basiliximab","C52186","A recombinant, chimeric, human-murine monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha) with immunosuppressant activity. Basiliximab selectively binds to and blocks IL-2R alpha, expressed on the surface of activated T-lymphocytes, thereby preventing interleukin-2 binding and inhibiting the interleukin-2-mediated activation of lymphocytes.","Basiliximab | BASILIXIMAB | SDZ-CHI-621 | Simulect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025684","Methoxsalen","C643","A naturally occurring substance isolated from the seeds of the plant Ammi majus with photoactivating properties.  As a member of the family of compounds known as psoralens or furocoumarins, methoxsalen's exact mechanism of action is unknown; upon photoactivation, methoxsalen has been observed to bind covalently to and crosslink DNA. (NCI04)","Methoxsalen | 8-MOP | 8-Methoxypsoralen | 9-Methoxy-7H-furo[3,2-g][1]benzopyran-7-one | Ammoidin | Deltasoralen | Dermox | Geralen | Geroxalen | METHOXSALEN | Meladinina | Meladinine | Methoxypsoralen | Metoxaleno | Mopsoralen | Oxsoralen | Oxsoralen-Ultra | Puvasoralen | Ultramop | Uvadex | XANTHOTOXIN | Xanthotoxin | methoxsalen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0068788","Nitazoxanide","C47637","A synthetic benzamide with antiprotozoal activity. Nitazoxanide exerts its antiprotozoal activity by interfering with the pyruvate ferredoxin/flavodoxin oxidoreductase dependent electron transfer reaction, which is essential to anaerobic energy metabolism. PFOR enzyme reduces nitazoxanide, thereby impairing the energy metabolism. However, interference with the PFOR enzyme-dependent electron transfer reaction may not be the only pathway by which nitazoxanide exhibits antiprotozoal activity. Nitazoxanide is active against Giardia lamblia and Cryptosporidium parvum.","Nitazoxanide | Alinia | Benzamide, 2-(acetyloxy)-N-(5-nitro-2-thiazolyl)- | NITAZOXANIDE | Salicylamide, N-(5-nitro-2-thiazolyl)-, Acetate(Ester)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831799","Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine","C61087","A non-infectious recombinant, quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid (L1) protein of human papillomavirus (HPV) types 6, 11, 16, and 18 with immunoprophylactic activity. L1 proteins are produced by separate fermentations in recombinant Saccharomyces cerevisiae, self-assembled into VLPs, and adsorbed onto amorphous aluminium hydroxyphosphate sulfate adjuvant following purification. The immunoprophylactic efficacy of L1 VLP vaccines, such as quadrivalent human papillomavirus (types 6,11,16,18) recombinant vaccine, appear to be mediated by the development of humoral immune responses. HPV Types 16 and 18 account for approximately 70% of cervical cancers and HPV Types 6 and 11 account for approximately 90% of genital warts.","Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine | Gardasil | Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle vaccine | Recombinant Human Papillomavirus (HPV) Quadrivalent Vaccine | V501 | quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL426557","Anti-human GITR Monoclonal Antibody TRX518","C95023","A humanized, Fc disabled anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody (MoAb) with immunomodulating activity. Anti-human GITR MoAb TRX518 blocks the interaction of GITR, found on multiple types of T cells, with its ligand, thereby inducing both the activation of tumor-antigen-specific T effector cells, as well as abrogating the suppression induced by inappropriately activated T regulatory cells. This agent is shown to act synergistically with chemotherapeutic drugs in multiple cancer models.","Anti-human GITR Monoclonal Antibody TRX518 | Anti-huGITR MoAb TRX518 | TRX518",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0681164","Religion and Spirituality","C15713","Used as subcategory of Mind-Body Medicine in CAM.  This area deals with the non-behavioral aspects of spirituality and religion that examine their relationship to biological function or clinical conditions.  It included activities such as prayer, soul retrieval, spiritual healing, Included are: Prayer, Confession, Nonlocality, Nontemporality, Consciousness studies, Spirituality constructs (Love, hope, faith, joy, etc.), Soul retrieval (see Indigenous practices), Spiritual healing, 'Special' healers (see 'Biofield').","Religion and Spirituality | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0562324","Church","C18069","A building for public worship or religious services. (WEBS84)","Church | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004951","Belief System","C16330","Faith based on a series of beliefs but not formalized into a religion; also, a fixed coherent set of beliefs prevalent in a community or society.","Belief System | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422762","STK33 Gene","C94749","This gene is involved in protein phosphorylation.","STK33 Gene | STK33 | Serine/Threonine Kinase 33 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419114","PTPRD Gene","C106110","This gene is involved in both dendrite morphology and protein dephosphorylation.","PTPRD Gene | PTPRD | Protein Tyrosine Phosphatase, Receptor Type, D Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335227","PLK1 Gene","C24683","This gene plays a role in mitotic regulation.","PLK1 Gene | PLK1 | Polo-Like Kinase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1328813","Metabolomics","C49019","Metabolomics is the study of the biological metabolic profile of a cellular specimen in a specific environment at an isolated timepoint. This discipline depicts the physiological states of cells and organisms by focusing on carbohydrates, lipids, and other metabolites. Several analytical techniques are utilized to quantify the metabolic content of specimens such as mass spectrometry and electrophoretic applications.","Metabolomics | Metabolic Profiling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0132555","Nitric Oxide Synthetase","C28511","Expressed in various cell types, Nitric Oxide Synthases (NOS Family) are constitutive or inducible calcium/calmodulin stimulated homodimers stabilized by BH4 that bind FAD and FMN cofactors, generally contain a flavodoxin-like domain, and synthesize reactive free radical nitric oxide messenger from L-arginine. NO can act as a neurotransmitter and has antimicrobial and antitumoral activities in macrophages. IL12 requires NOS to stimulate tyrosine-phosphorylation of STAT4 by TYK2 in NK cytotoxicity. Vascular NO (endothelia) inhibits muscle contraction through a cGMP pathway, inhibits platelet aggregation, and mediates VEGF-induced angiogenesis. Endothelial AKT phosphorylates and enhances NOS activity. Potentially influencing energy balance, NO can trigger cGMP-dependent mitochondrial biogenesis mediated by induction of the master regulator PPARGC1. (NCI)","Nitric Oxide Synthetase | EC 1.14.13.39 | NADPH-Diaphorase | NO Synthase | NOS Family | Nitric Oxide Synthase | Nitric Oxide Synthase Family | Nitric-Oxide Synthase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336681","TSLP Gene","C24883","This gene plays a regulatory role in the development of B lymphocytes.","TSLP Gene | TSLP | Thymic Stromal Lymphopoietin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419786","S100A4 Gene","C102437","This gene is involved in both signaling and calcium binding.","S100A4 Gene | S100 Calcium Binding Protein A4 Gene | S100A4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332455","BUB1 Gene","C21494","This gene is a modulator of the mitotic spindle cell cycle checkpoint.","BUB1 Gene | BUB1 | BUB1 Mitotic Checkpoint Serine/Threonine Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448906","TMPRSS2/ERG Fusion Gene","C79904","A fusion gene that results from a genetic translocation event which fuses the 5' end of the androgen-regulated TMPRSS2 gene with the entire coding region of the ERG gene. The androgen-dependent expression of this fusion gene results in overexpression of ERG activity.","TMPRSS2/ERG Fusion Gene | ERG/TMPRSS2 Fusion Gene | T2:ERG | TMPRSS2-ERG Fusion Gene | TMPRSS2::ERG Fusion Gene | Transmembrane Protease, Serine 2/V-Ets Erythroblastosis Virus E26 Oncogene Homolog (Avian) Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639713","KPS SCALE","C100768","A standardized rating scale originally developed by David A. Karnofsky and Joseph H. Burchenal in 1949 which is used to evaluate the degree to which a patient is functionally impaired. This instrument consists of 3 sections, no special care needed, unable to work, and unable to care for one's self and is completed by a clinician based on their observations. There are a total of eleven levels ranging from 0-100 where 0 indicates that the patient is dead and 100 indicates that the patient is normal.","Karnofsky Performance Status Scale Clinical Classification | KPS SCALE | KPSS01 | Karnofsky Performance Status Scale Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829897","Haploidentical","C111983","A donor who has only one haplotype in common with the recipient.","Haploidentical | Half-Matched Related Donor | Haploidentical Donor | PMRD | Partially-Matched Related Donor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815220","Time of Flight","C111985","Estimation of the difference in annihilation photon travel time from emission to detection within the imaging device to help localize the site of positron emission.","Time of Flight | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827886","Sustained Engraftment at Day 100","C111965","Sustained donor-derived neutrophil recovery with achievement of donor chimerism equal or greater than 90% at day 100.","Sustained Engraftment at Day 100 | Sustained Engraftment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828477","Primary Graft Failure After Hematopoietic Cell Transplantation","C111966","Failure of initial engraftment of donor hematopoietic cells.","Primary Graft Failure After Hematopoietic Cell Transplantation | Primary Graft Failure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828201","Secondary Graft Failure After Hematopoietic Cell Transplantation","C111968","Loss of donor hematopoietic cells following initial engraftment.","Secondary Graft Failure After Hematopoietic Cell Transplantation | Secondary Graft Failure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030617","Parvovirus","C14299","A family of very small DNA viruses containing a single linear molecule of single-stranded DNA and consisting of two subfamilies: parvovirinae and densovirinae. They infect both vertebrates and invertebrates.","Parvovirus | Parvoviridae",,,,,,,,,,,,,,,"4085751","Family Parvoviridae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2742509","Dacetuzumab","C62179","A humanized monoclonal antibody directed against the CD40 receptor with potential antineoplastic activity. Dacetuzumab specifically binds to and inhibits the CD40 receptor, thereby inducing apoptosis and inhibiting cellular proliferation via antibody-dependent cellular cytotoxicity (ADCC) in cells that overexpress this receptor. The CD40 receptor, a member of the tumor necrosis factor (TNF) receptor super-family, is highly expressed on most B lineage hematologic malignancies including multiple myeloma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Hodgkin's disease and acute lymphoblastic leukemia.","Dacetuzumab | Anti-huCD40 mAb | DACETUZUMAB | Monoclonal Antibody SGN-40 | SGN-40 | huS2C6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0947651","Silver","C84590","A metallic element with atomic symbol Ag, atomic number 47, and atomic weight 107.8682.","Silver | Ag | SILVER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005670","BK Virus","C89820","A double stranded DNA virus in the polyomavirus family. It is widespread but usually causes an asymptomatic infection, except in immunocompromised individuals.","BK Virus | BK POLYOMAVIRUS | BK Polyomavirus | BKV | Papovavirus BKV | Polyomavirus BK | Polyomavirus Type BK",,,,,,,,,,,,,,,"4308297","BK virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006145","Breast Disorder","C26709","A non-neoplastic or neoplastic disorder that affects the breast. Representative examples of non-neoplastic disorders include fibrocystic disease, gynecomastia, and mastitis. Representative examples of neoplastic disorders include fibroadenoma, lobular neoplasia, carcinoma, lymphoma, and sarcoma.","Breast Disorder | Breast Disease | Breast Diseases",,,,,,,,,,,,,,,"77030","Disorder of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0850639","Premalignant Lesion","C42624","A lesion characterized by the proliferation of atypical or dysplastic cells without evidence of stromal invasion.","Premalignant Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527757","Fibroblast Growth Factor Receptor 1, Human","C17590","Fibroblast growth factor receptor 1 (822 aa, ~92 kDa) is encoded by the human FGFR1 gene. This protein is involved in the regulation of embryonic development, cell proliferation, cell differentiation and cellular migration.","Fibroblast Growth Factor Receptor 1 | BFGFR | Basic Fibroblast Growth Factor Receptor 1 | CD331 Antigen | EC 2.7.10.1 | FGFR-1 | FGFR1 | FLT-2 | FMS-Like Tyrosine Kinase 2 | N-sam | Proto-Oncogene c-Fgr | bFGF-R-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827366","Thymoma by Masaoka-Koga Stage","C112006","A staging system for thymoma based on the anatomic extent of disease at the time of surgery.","Thymoma by Masaoka-Koga Stage | Masaoka Staging | Masaoka Staging System | Masaoka Staging System | Masaoka Staging System for Thymoma | Masaoka-Koga Staging System for Thymoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828873","Myasthenia Gravis Foundation of America Clinical Classification","C112013","A classification system developed by the Myasthenia Gravis Foundation of America (MGFA) for grading myasthenia gravis that divides the disease into 5 main classes and several subclasses.","Myasthenia Gravis Foundation of America Clinical Classification System | MGFA Clinical Classification | Myasthenia Class | Myasthenia Classification System | Myasthenia Gravis Foundation of America Clinical Classification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829188","Masaoka-Koga Stage I","C112007","The tumor is completely encapsulated.","Masaoka-Koga Stage I | Masaoka Stage I | Masaoka Stage I | Stage I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829187","Masaoka-Koga Stage IIa","C112008","The tumor shows microscopic invasion into the capsule.","Masaoka-Koga Stage IIa | Masaoka Stage IIa | Masaoka Stage IIa | Stage IIa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829186","Masaoka-Koga Stage IIb","C112009","The tumor shows invasion through the capsule and into the surrounding fatty tissue.","Masaoka-Koga Stage IIb | Masaoka Stage IIb | Masaoka Stage IIb | Stage IIb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829185","Masaoka-Koga Stage III","C112010","The tumor shows invasion into the neighboring tissues and organs of the lower neck or upper chest.","Masaoka-Koga Stage III | Masaoka Stage III | Masaoka Stage III | Stage III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829184","Masaoka-Koga Stage IVa","C112011","The tumor shows metastasis throughout the pleural and/or pericardial spaces.","Masaoka-Koga Stage IVa | Masaoka Stage IVa | Masaoka Stage IVa | Stage IVa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829183","Masaoka-Koga Stage IVb","C112012","The tumor shows lymphogenous or hematogenous metastasis to distant sites.","Masaoka-Koga Stage IVb | Masaoka Stage IVb | Masaoka Stage IVb | Stage IVb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828874","Myasthenia Class I","C112014","Myasthenia gravis presenting with any ocular weakness; may have weakness of eye closure. All other muscles strength is normal.","Myasthenia Gravis Foundation of America Class I | MGFA Class I | Myasthenia Class I | Myasthenia Class I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828872","Myasthenia Class II","C112015","Myasthenia gravis presenting with mild weakness affecting non-ocular muscles. May also have ocular muscle weakness of any severity.","Myasthenia Gravis Foundation of America Class II | MGFA Class II | Myasthenia Class II | Myasthenia Class II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828871","Myasthenia Class III","C112016","Myasthenia gravis presenting with moderate weakness affecting non-ocular muscles. May also have ocular muscle weakness of any severity.","Myasthenia Gravis Foundation of America Class III | MGFA Class III | Myasthenia Class III | Myasthenia Class III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828870","Myasthenia Class IV","C112017","Myasthenia gravis presenting with severe weakness affecting non-ocular muscles. May also have ocular muscle weakness of any severity.","Myasthenia Gravis Foundation of America Class IV | MGFA Class IV | Myasthenia Class IV | Myasthenia Class IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828869","Myasthenia Class V","C112018","Myasthenia gravis presenting with severe muscle weakness that requires intubation, with or without mechanical ventilation, except when employed during routine postoperative management.","Myasthenia Gravis Foundation of America Class V | MGFA Class V | Myasthenia Class V | Myasthenia Class V",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2316459","Surgical Site Infection","C112019","An infection that occurs at a surgical site within 30 days after an operation.","Surgical Site Infection | ",,,,,,,,,,,,,,,"4334801","Surgical site infection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2116713","Superficial Incision","C112020","An incision that involves only the skin or subcutaneous tissue.","Superficial Incision | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2116675","Deep Incision","C112021","An incision that involves deep soft tissues.","Deep Incision | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827892","Surgical Organ or Space","C112022","Any part of the anatomy, other than the incision, which was opened or manipulated during an operation.","Surgical Organ or Space | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333274","Purulent Discharge","C50717","Pus-containing fluid that is draining from an orifice or wound.","Purulent Discharge | ",,,,,,,,,,,,,,,"4148385","Purulent discharge",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2985535","radiologic exam","C93286","The use of x-rays, or other radiologic imaging modalities, for visualizing body spaces and organs, usually for diagnosis or screening of disease.","Radiologic Examination | Radiologic Evaluation | Radiologic Exam | Radiologic Exam | Radiologic Examination | radiologic exam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1536338","Duodenectomy","C51599","Surgical removal of part or all of the duodenum.","Duodenectomy | ",,,,,,,,,,,,,,,"4252245","Duodenectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0193062","Resection of Rectum","C51783","Surgical removal of the rectum.","Resection of Rectum | Proctectomy",,,,,,,,,,,,,,,"4226983","Resection of rectum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704298","Therapeutic LH","C612","Any recombinant form of the endogenously produced heterodimer glycoprotein luteinizing hormone (LH) normally made by the anterior pituitary gland, that can be used for the treatment of LH deficiency. Upon administration, recombinant LH mimics the biological activity of endogenous LH. In females, this triggers ovulation and the development of the corpus luteum. In males, LH stimulates Leydig cells to produce testosterone.","Recombinant Luteinizing Hormone | Interstitial Cell-Stimulating Hormone | LH | LUTEINIZING HORMONE | Leuteinizing Hormone | Luteinizing Hormone | Lutropin | Recombinant LH | Therapeutic LH | interstitial cell-stimulating hormone | luteinizing hormone | lutropin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705092","Applicator","C50341","A device designed to transfer a substance to a surface.","Applicator Device | Applicator | Applicator Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349025","Unit of Absorbed Radiation Dose Rate","C70567","A unit for measurement of the amount of energy imparted by ionizing radiation per unit mass of irradiated object per unit time.","Unit of Absorbed Radiation Dose Rate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538723","CD34 Measurement","C102260","The determination of the amount of CD34 expressing cells present in a sample.","CD34 Measurement | CD34 | CD34 Molecule | CD34 Protein | CD34 Sialomucin | CD34SM | Hematopoietic Progenitor Cell Antigen CD34",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0454169","Collimator Device Component","C49881","A diaphragm or system of diaphragms made of an absorbing material, designed to define and restrict the dimensions and direction of a beam of radiation.","Collimator Device | Collimation | Collimator | Collimator Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827431","Worst Severity Past Seven Days Insomnia","C112161","A question about an individual's observation of the worst severity they have experienced related to insomnia over the past seven days.","Worst Severity Past Seven Days Insomnia | Over the past seven days what was the severity of your insomnia, including difficulty falling asleep, staying asleep, or waking up early, at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827422","Worst Severity Past Seven Days Vomiting","C112162","A question about an individual's observation of the worst severity they have experienced related to vomiting over the past seven days.","Worst Severity Past Seven Days Vomiting | Over the past seven days what was the severity of your vomiting at its WORST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827425","Worst Severity Past Seven Days Hand-Foot Syndrome","C112163","A question about an individual's observation of the worst severity they have experienced related to hand-foot syndrome over the past seven days.","Worst Severity Past Seven Days Palmar-Plantar Erythrodysthesia | In the past 7 days, what was the severity of your hand-foot syndrome at its worst | Over the past seven days what was the severity of your hand-foot syndrome at its WORST | What was the severity of your hand-foot syndrome at its worst | Worst Severity Hand-Foot Syndrome | Worst Severity Last Seven Days Hand-Foot Syndrome | Worst Severity Past Seven Days Hand-Foot Syndrome | Worst Severity Past Seven Days Palmar-Plantar Erythodysthesia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827434","Worst Severity Past Seven Days Decreased Appetite","C112164","A question about an individual's observation of the worst severity they have experienced related to decreased appetite over the past seven days.","Worst Severity Past Seven Days Decreased Appetite | Over the past seven days what was the severity of your decreased appetite at its worst | Worst Severity Past Seven Days Loss of Appetite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827430","Worst Severity Past Seven Days Mouth or Throat Sores","C112165","A question about an individual's observation of the worst severity they have experienced related to mouth or throat sores over the past seven days.","Worst Severity Past Seven Days Mouth or Throat Sores | Over the past seven days what was the severity of your mouth or throat sores at their worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827429","Worst Severity Past Seven Days Nausea","C112166","A question about an individual's observation of the worst severity they have experienced related to nausea over the past seven days.","Worst Severity Past Seven Days Nausea | Over the past seven days what was the severity of your nausea at its worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828646","Past Seven Days Insomnia Interfering with Usual or Daily Activities","C112167","A question about how much an individual's insomnia interfered with usual or daily activities over the past seven days.","Past Seven Days Insomnia Interfering with Usual or Daily Activities | Over the past seven days how much did insomnia, including difficulty falling asleep, staying asleep, or waking up early, INTERFERE with your usual or daily activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828642","Past Seven Days Hand-Foot Syndrome Interfering with Usual or Daily Activities","C112168","A question about how much an individual's hand-foot syndrome interfered with usual or daily activities over the past seven days.","Past Seven Days Palmar-Plantar Erythrodysthesia Interfering with Usual or Daily Activities | Over the past seven days how much did hand-foot syndrome INTERFERE with your usual or daily activities | Past Seven Days Hand-Foot Syndrome Interfering with Usual or Daily Activities | Past Seven Days Palmar-Plantar Erythodysthesia Interfering with Usual or Daily Activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828647","Past Seven Days Frequency of Vomiting","C112170","A question about an individual's frequency of vomiting over the past seven days.","Past Seven Days Frequency of Vomiting | Over the past seven days how often did you have vomiting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828650","Past Seven Days Frequency of Diarrhea","C112171","A question about an individual's frequency of diarrhea over the past seven days.","Past Seven Days Frequency of Diarrhea | Over the past seven days how often did you have diarrhea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828649","Past Seven Days Frequency of Nausea","C112172","A question about an individual's frequency of nausea over the past seven days.","Past Seven Days Frequency of Nausea | Over the past seven days how often did you have nausea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828640","Past Seven Days Rash","C112173","A question about whether an individual had a rash over the past seven days.","Past Seven Days Rash | Over the past seven days did you have any rash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332681","CCL18 Gene","C24772","This gene plays a role in the modulation of immune responses.","CCL18 Gene | CCL18 | Chemokine (C-C Motif) Ligand 18 (Pulmonary and Activation-Regulated) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336638","TLR6 Gene","C24867","This gene is involved in immune responses through nuclear factor kappa-B signal transduction.","TLR6 Gene | TLR6 | Toll-Like Receptor 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366515","LEPR Gene","C24545","This gene plays a role in transcriptional regulation via activation of the STAT signal transduction pathway. The gene is also involved in the regulation of adipose tissue or lipid metabolism.","LEPR Gene | LEPR | Leptin Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332730","CDK10 Gene","C24283","This gene is involved in G2/M cell cycle regulation.","CDK10 Gene | CDK10 | Cyclin-Dependent Kinase (CDC2-like) 10 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336565","TAF2 Gene","C20501","This gene plays a role in transcriptional initiation.","TAF2 Gene | TAF2 | TAF2 RNA Polymerase II, TATA Box Binding Protein (TBP)-Associated Factor, 150kDa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085889","3-Hydroxyacyl-CoA Dehydrogenase","C112050","A family of enzymes that oxidize (S)-3-hydroxyacyl-CoA and NAD+ and produce 3-oxoacyl-CoA, NADH, and H+. These proteins are involved in the metabolism of both fatty acids and amino acids.","3-Hydroxyacyl-CoA Dehydrogenase | (S)-3-Hydroxyacyl-CoA:NAD+ Oxidoreductase | 1-Specific DPN-Linked Beta--Hydroxybutyric Dehydrogenase | 3-Hydroxyacetyl-Coenzyme A Dehydrogenase | 3-Hydroxyacyl CoA Dehydrogenase | 3-Hydroxyacyl Coenzyme A Dehydrogenase | 3-Hydroxybutyryl-CoA Dehydrogenase | 3-Hydroxyisobutyryl-CoA Dehydrogenase | 3-Hydroxyl-Co-A Dehydrogenase | 3-Keto Reductase | 3-L-Hydroxyacyl-CoA Dehydrogenase | 3Beta--Hydroxyacyl Coenzyme A Dehydrogenase | 3Beta—Hydroxyacyl Coenzyme A Dehydrogenase | ; 3-L-Hydroxyacyl-CoA Dehydrogenase | ; Beta--Hydroxyacyl-Coenzyme A Synthetase | Beta--Hydroxy Acid Dehydrogenase | Beta--Hydroxyacyl CoA Dehydrogenase | Beta--Hydroxyacyl Dehydrogenase | Beta--Hydroxyacyl-Coenzyme A Synthetase | Beta--Hydroxyacylcoenzyme A Dehydrogenase | Beta--Hydroxybutyrylcoenzyme A Dehydrogenase | Beta--Keto-Reductase | Beta--Ketoacyl-CoA Reductase | Beta—Hydroxy Acid Dehydrogenase | Beta—Hydroxyacyl CoA Dehydrogenase | Beta—Hydroxyacyl Dehydrogenase | Beta—Hydroxyacyl-Coenzyme A Synthetase | Beta—Hydroxyacylcoenzyme A Dehydrogenase | Beta—Hydroxybutyrylcoenzyme A Dehydrogenase | Beta—Keto-Reductase | Beta—Ketoacyl-CoA Reductase | EC 1.1.1.35 | L-3-Hydroxyacyl CoA Dehydrogenase | L-3-Hydroxyacyl Coenzyme A Dehydrogenase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831741","ACPP Antibody","C112058","Any immunoglobulin that recognizes prostatic acid phosphatase.","ACPP Antibody | ACPP Antibodies | Anti-ACPP Antibodies | Anti-ACPP Antibody | Anti-PAP Antibodies | Anti-PAP Antibody | Anti-Prostatic Acid Phosphatase Antibodies | Anti-Prostatic Acid Phosphatase Antibody | PAP Antibodies | PAP Antibody | Prostatic Acid Phosphatase Antibodies | Prostatic Acid Phosphatase Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0071649","Polyphenol","C28203","A substance that is found in many plants and gives some flowers, fruits, and vegetables their color. Polyphenols have antioxidant activity.","Polyphenol | polyphenol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412321","AKR1A1 Gene","C112101","This gene plays a role in the reduction of biogenic and xenobiotic aldehydes.","AKR1A1 Gene | AKR1A1 | Aldo-Keto Reductase Family 1, Member A1 (Aldehyde Reductase) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003161","Anthocyanin","C112040","A flavonoid that is a glycoside derivative of anthocyanidin. They are water-soluble plant pigments that exhibit bright coloration. Their color is dependent on the pH of the solvent; therefore, these polyphenols are used as pH indicators.","Anthocyanin | Anthocyanins",,,,,,,,,,,,,,,"4244744","Anthocyanin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3831389","BCG Antibody","C112055","Any immunoglobulin that recognizes Bacillus Calmette-Guerin antigen.","BCG Antibody | Anti-BCG Antibodies | Anti-BCG Antibody | Anti-BCG Antibody; Anti-Bacillus Calmette-Guerin Antibody | Anti-Bacillus Calmette-Guerin Antibodies | Anti-Bacillus Calmette-Guerin Antibody | BCG Antibodies | Bacillus Calmette-Guerin Antibodies | Bacillus Calmette-Guerin Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538973","C1GALT1 Gene","C112154","This gene is involved in generation of the common core 1 O-glycan structure.","C1GALT1 Gene | C1GALT1 | Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine 3-beta-Galactosyltransferase, 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538974","C1GALT1C1 Gene","C112157","This gene plays a role as a chaperone in generation of the common core 1 O-glycan structure.","C1GALT1C1 Gene | C1GALT1-Specific Chaperone 1 Gene | C1GALT1C1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413107","CANX Gene","C112099","This gene plays a role in both protein folding and antigen presentation.","CANX Gene | CANX | Calnexin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054741","Carboxylesterase","C112051","A family of enzymes that hydrolyze carboxylic esters.","Carboxylesterase | B-Esterase | Butyrate Esterase | Butyryl Esterase | Carboxyesterase | Carboxyl Ester Hydrolase | Carboxylate Esterase | Carboxylic Acid Esterase | Carboxylic Ester Hydrolase | Carboxylic Esterase | Carboxylic-Ester Hydrolase | EC 3.1.1- | Methylbutyrase | Methylbutyrate Esterase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0540651","CASP8 and FADD-Like Apoptosis Regulator Isoform 2","C112064","CASP8 and FADD-like apoptosis regulator isoform 2 (221 aa, ~25 kDa) is encoded by the human CFLAR gene. This protein is involved in the regulation of caspase-dependent apoptosis.","CASP8 and FADD-Like Apoptosis Regulator Isoform 2 | CASH Beta | CFLAR Isoform 2 | CLARP2 | Caspase Homolog Beta | Cellular FLICE-Like Inhibitory Protein Isoform 2 | Cellular FLICE-Like Inhibitory Protein Short Isoform | FLIP-S | FLIPS | MACH-Related Inducer of Toxicity Beta-1 | MRIT Beta-1 | c-FLIP(S) | c-FLIPS | cFLIP(S | cFLIP(S) | cFLIPS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425808","CTHRC1 Gene","C112069","This gene is involved in the cellular response to arterial injury.","CTHRC1 Gene | CTHRC1 | Collagen Triple Helix Repeat Containing 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830542","Delta13C","C112048","The ratio of the stable isotopes carbon-13 and carbon-12, reported in parts per thousand. In plant tissues, this ratio varies between those plants that utilize the C3 carbon fixation pathway and those that utilize the C4 pathway.","Delta13C | Carbon-13:Carbon-12 Isotopic Signature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414185","DUSP4 Gene","C112127","This gene is involved in the dephosphorylation of MAPK1 and MAPK3.","DUSP4 Gene | DUSP4 | Dual Specificity Phosphatase 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539453","CYRIB Gene","C112088","This gene plays a role in the regulation of RAC1 activity.","CYRIB Gene | CYFIP Related Rac1 Interactor B Gene | CYRIB | FAM49B | FAM49B Gene | FAM49B Gene | Family with Sequence Similarity 49, Member B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414633","FLG Gene","C112148","This gene is involved in intermediate filament structure.","FLG Gene | FLG | Filaggrin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830090","FOLH1 Antibody","C112059","Any immunoglobulin that recognizes glutamate carboxypeptidase 2 (folate hydrolase 1).","FOLH1 Antibody |  Folate Hydrolase 1 Antibody | Anti-FOLH1 Antibodies | Anti-FOLH1 Antibody | Anti-Folate Hydrolase 1 Antibodies | Anti-Folate Hydrolase 1 Antibody | Anti-Glutamate Carboxypeptidase 2 Antibodies | Anti-Glutamate Carboxypeptidase 2 Antibody | Anti-PSMA Antibodies | Anti-PSMA Antibody | Anti-Prostate-Specific Membrane Antigen Antibodies | Anti-Prostate-Specific Membrane Antigen Antibody | FOLH1 Antibodies | Folate Hydrolase 1 Antibodies | Folate Hydrolase 1 Antibody | Glutamate Carboxypeptidase 2 Antibodies | Glutamate Carboxypeptidase 2 Antibody | PSMA Antibodies | PSMA Antibody | Prostate-Specific Membrane Antigen Antibodies | Prostate-Specific Membrane Antigen Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016859","Furanocoumarin","C112046","A class of organic phytochemicals that consists of a furan ring fused with coumarin. Furanocoumarins are produced by plants as defensive toxins and, when ingested by humans, they can affect the metabolism of drugs by cytochrome P450 isoform CYP3A4.","Furanocoumarin | Furanocoumarins | Furocoumarin | Furocoumarins",,,,,,,,,,,,,,,"4266615","Furocoumarin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017767","Glucosinolate","C112047","A class of organic compounds that are derived from a glucose that has been modified by an amino acid. These compounds are anionic sulfur-containing glucosides, produced as secondary metabolites by plants of the order Brassicales, which includes cruciferous vegetables. Glucosinolates can be toxic if ingested at high doses but lower doses are under investigation as potential tumor inhibitors.","Glucosinolate | GLS | Glucosinolates",,,,,,,,,,,,,,,"4176004","Glucosinolate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1415336","GSTM3 Gene","C112072","This gene is involved in both glutathione metabolism and cellular detoxification.","GSTM3 Gene | GSTM3 | Glutathione S-Transferase Mu 3 (Brain) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427969","KEAP1 Gene","C112105","This gene is involved in ubiquitin-mediated protein degradation.","KEAP1 Gene | KEAP1 | Kelch-Like ECH-Associated Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825654","WASHC5 Gene","C112062","This gene is involved in actin polymerization.","WASHC5 Gene | KIAA0196 | KIAA0196 Gene | WASH Complex Subunit 5 Gene | WASHC5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416714","KRT10 Gene","C112151","This gene plays a role in intermediate filament structure.","KRT10 Gene | KRT10 | Keratin 10 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416769","L1CAM Gene","C112136","This gene plays a role in the development of the nervous system.","L1CAM Gene | L1 Cell Adhesion Molecule Gene | L1CAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416836","LGALS9 Gene","C112123","This gene plays a role in carbohydrate binding.","LGALS9 Gene | LGALS9 | Lectin, Galactoside-Binding, Soluble, 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1832097","LORICRIN Gene","C112145","This gene plays a role in the structure of keratinocyte cell envelopes.","LORICRIN Gene | LOR | LOR Gene | LOR Gene | LORICRIN | Loricrin Cornified Envelope Precursor Protein Gene | Loricrin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422553","LPAR3 Gene","C112084","This gene is involved in calcium mobilization.","LPAR3 Gene | LPAR3 | Lysophosphatidic Acid Receptor 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2350701","Macrophage Inflammatory Protein","C112052","A family of CC-motif cytokines that are produced by macrophages in response to endotoxin exposure. This family has two members C-C motif chemokine 3 and C-C motif chemokine 4. These chemokines promote the inflammatory response through the activation of human granulocytes and induction of the synthesis and release of other pro-inflammatory cytokines.","Macrophage Inflammatory Protein | MIP | MIP-1 | Macrophage Inflammatory Protein-1 | Macrophage Inhibitory Protein-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417534","MYH1 Gene","C112130","This gene plays a role in muscle contraction.","MYH1 Gene | MYH1 | Myosin, Heavy Chain 1, Skeletal Muscle, Adult Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417537","MYH2 Gene","C112133","This gene is involved in skeletal muscle contraction.","MYH2 Gene | MYH2 | Myosin, Heavy Chain 2, Skeletal Muscle, Adult Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538607","PDIA3 Gene","C112118","This gene is involved in both antigen presentation and formation of disulfide bonds in proteins.","PDIA3 Gene | PDIA3 | Protein Disulfide Isomerase Family A, Member 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813211","Prostaglandin E2","C112043","A prostaglandin with 2 double bonds that is generated by the action of prostaglandin E synthases on prostaglandin H2. Prostaglandin E2 is a mediator of active inflammation, and has important biologic effects including potent vasodilation, smooth muscle relaxation, stimulation of osteoclast-dependent bone resorption and induction of both pain and fever. It is also used as a vaginal suppository during labor to soften the cervix and promote uterine contractions.","Prostaglandin E2 | (5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-Oxoprosta-5,13-Dien-1-Oic Acid | (5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-Oxoprost-13-Enoate | (5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-Oxoprosta-5,13-Dienoate | (5Z,13E,15S)-11alpha,15-Dihydroxy-9-Oxoprosta-5,13-Dien-1-Oic Acid | (E,Z)-(1R,2R,3R)-7-(3-Hydroxy-2-((3S)-(3-Hydroxy-1-Octenyl))-5-Oxocyclopentyl)-5-Heptenoic Acid | (Z)-7-((1R,2R,3R)-3-Hydroxy-2-((S,E)-3-Hydroxyoct-1-Enyl)-5-Oxocyclopentyl)Hept-5-Enoic Acid | 5-Heptenoic Acid, 7-(3-Hydroxy-2-(3-Hydroxy-1-Octenyl)-5-Oxocyclopentyl)- (8CI) | 7-(3-Hydroxy-2-(3-Hydroxy-1-Octenyl)-5-Oxocyclopentyl)-5-Heptenoic Acid | PGE(2) | PGE2 | Prosta-5,13-Dien-1-Oic Acid, (5Z,11-Alpha,13E,15S)-11,15-Dihydroxy-9-Oxo- | Prosta-5,13-Dien-1-Oic Acid, 11,15-Dihydroxy-9-Oxo-, (5Z,11alpha,13E,15S)- | Prostaglandin E(2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828445","PSA Antibody","C112057","Any immunoglobulin that recognizes prostate-specific antigen.","PSA Antibody | Anti-PSA Antibodies | Anti-PSA Antibody | Anti-Prostate Specific Antigen Antibodies | Anti-Prostate Specific Antigen Antibody | PSA Antibodies | Prostate Specific Antigen Antibodies | Prostate Specific Antigen Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827331","PSCA Antibody","C112060","Any immunoglobulin that recognizes prostate stem cell antigen.","PSCA Antibody | Anti-PSCA Antibodies | Anti-PSCA Antibody | Anti-Prostate Stem Cell Antigen Antibody | PSCA Antibodies | Prostate Stem Cell Antigen Antibodies | Prostate Stem Cell Antigen Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419011","PSMB10 Gene","C112078","This gene is involved in antigen processing by the proteasome.","PSMB10 Gene | PSMB10 | Proteasome (Prosome, Macropain) Subunit, Beta Type, 10 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419018","PSMB8 Gene","C112075","This gene plays a role in both protein catabolism and antigen processing.","PSMB8 Gene | PSMB8 | Proteasome (Prosome, Macropain) Subunit, Beta Type, 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419067","PTGES Gene","C112108","This gene may play a role in TP53 induced apoptosis.","PTGES Gene | PTGES | Prostaglandin E Synthase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828361","Recent Thymic Emigrant","C112039","A T-lymphocyte that has completed intrathymic development and has exited the thymus. These cells are the youngest peripheral T-lymphocytes and migrate to secondary lymphoid organs where they slowly mature to become naive T-cells.","Recent Thymic Emigrant | RTE | RTEs | Recent Thymic Emigrants | Thymic Recent Emigrant | Thymic Recent Emigrants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828339","Replication Competent Retrovirus","C112045","A retroviral vector that contains all the genes that are required for virion synthesis and is able to propagate after the host is infected.","Replication Competent Retrovirus | RCR | Replication Competent Retroviruses | Replication-Competent Retrovirus | Replication-Competent Retroviruses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1822758","SLC44A1 Gene","C112081","This gene plays a role in choline transport.","SLC44A1 Gene | SLC44A1 | Solute Carrier Family 44 (Choline Transporter), Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420462","STIP1 Gene","C112066","This gene plays a role in chaperone protein function.","STIP1 Gene | STIP1 | Stress-Induced-Phosphoprotein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038615","Succinate Dehydrogenase","C112049","A heterotetrameric enzyme complex found in the inner mitochondrial membrane. This protein complex catalyzes the oxidation of succinate and reduction of ubiquinone and plays a role in both the citric acid cycle and the electron transport chain.","Succinate Dehydrogenase | Complex II | EC 1.3.5.1 | Mitochondrial Complex II | Mitochondrial Respiratory Chain Complex II | Respiratory Complex II | SDH | SQR | Succinate-CoQ Reductase | Succinate-Coenzyme Q Reductase | Succinic Dehydrogenase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420583","TAPBP Gene","C112139","This gene is involved in antigen presentation.","TAPBP Gene | TAP Binding Protein (Tapasin) Gene | TAPBP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0076765","Tn Antigen","C112044","A protein antigen that is comprised of the monosaccharide N-acetylgalactosamine (GalNAc) bound to serine or threonine by O-linked glycosylation. Aberrant expression of Tn antigen by all blood cell lineages is associated with a rare hematological disorder called Tn-syndrome. Increased expression of this monosaccharide modification is also associated with some cancers and this antigen is being investigated for use as either a biomarker or therapeutic target for these associated malignancies.","Tn Antigen | CD175 | Tn",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827687","Urolithin","C112042","Hydroxy-6H-dibenzo[b,d]pyran-6-one derivatives that are the products of the metabolism of ellagitannins by intestinal bacteria. The biological activity of urothilins is unknown; however, these compounds are under investigation to determine if they have a mechanism of action that is similar to other phytoestrogens.","Urolithin | Urolithins",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824261","UTP23 Gene","C112096","This gene is involved in rRNA-processing and ribosome biogenesis.","UTP23 Gene | UTP23 | UTP23, Small Subunit (SSU) Processome Component, Homolog (Yeast) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421428","VASP Gene","C112142","This gene is involved in both cell adhesion and motility.","VASP Gene | VASP | Vasodilator-Stimulated Phosphoprotein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029431","Osteoclast","C12570","A large, multinucleated cell that secretes bone-degrading enzymes in the processes of normal bone remodeling and pathological bone loss. Osteoclasts are derived from macrophages.","Osteoclast | Osteoclasts",,,,,,,,,,,,,,,"4100946","Osteoclast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029418","Osteoblast","C12568","Cells which secrete an extracellular matrix into which hydroxyapaetite crystals are deposited to form bone.","Osteoblast | Osteoblasts",,,,,,,,,,,,,,,"4167838","Osteoblast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829777","Have Pain Other Than Everyday Kind of Pain","C112184","A question about whether an individual has or had pain other than everyday kinds of pain.","Have Pain Other Than Everyday Kind of Pain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642228","Pain at its Worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828673","Pain at its Least","C112185","A question about an individual's pain at its least.","Pain at its Least | Pain at its Best",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828666","Pain Right Now","C112186","A question about an individual's pain right now.","Pain Right Now | Have Pain Right Now",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827779","Treatment or Medication Received for Pain","C112187","A question about which treatments or medications an individual is receiving or has received for pain.","Treatment or Medication Received for Pain | Pain Treatment or Medication Received | Treatment or Medication Receiving for Pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829608","How Much Relief Received from Treatment or Medication","C112188","A question about how much pain relief an individual is receiving or has received from treatment or medication.","How Much Relief Received from Treatment or Medication | How Much Pain Relief Received from Treatment or Medication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827374","Pain Interferes with General Activity","C112191","A question about whether a person's pain interferes or interfered with their general activities.","Pain Interferes with General Activity Question | Pain Interference with General Activity | Pain Interferes with General Activity | Pain Interferes with General Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828670","Pain Interferes with Mood","C112192","A question about whether a person has or had pain that interfered with their mood.","Pain Interferes with Mood | Pain Interference with Mood",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828667","Pain Interferes with Walking Ability","C112193","A question about whether a person has or had pain that interfered with their ability to walk.","Pain Interferes with Walking Ability Question | Pain Interference with Walking Ability | Pain Interferes with Walking Ability | Pain Interferes with Walking Ability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828669","Pain Interferes with Relations with Other People","C112194","A question about whether a person has or had pain that interfered with their relationships with other people.","Pain Interferes with Relations with Other People | Pain Interference with Relations with Other People",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828668","Pain Interferes with Sleep","C112195","A question about whether a person has or had pain that interfered with sleep.","Pain Interferes with Sleep | Pain Interference with Sleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828671","Pain Interferes with Enjoyment of Life","C112196","A question about whether a person has or had pain that interfered with their enjoyment of life.","Pain Interferes with Enjoyment of Life | Pain Interference with Enjoyment of Life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0540650","FLICE-Inhibitory Protein Long Form","C96018","CASP8 and FADD-like apoptosis regulator (480 aa, ~55 kDa) is encoded by the human CFLAR gene. This protein plays a role in the inhibition of caspase-dependent apoptosis.","CASP8 and FADD-Like Apoptosis Regulator | CASH | CASH Alpha | CASP8 and FADD-Like Apoptosis Regulator Isoform 1 | CLARP | CLARP1 | Caspase Homolog | Caspase-Eight-Related Protein | Caspase-Like Apoptosis Regulatory Protein | Casper | Cellular FLICE-Like Inhibitory Protein | Cellular FLICE-Like Inhibitory Protein Long Isoform | FADD-Like Antiapoptotic Molecule 1 | FLAME-1 | FLAME-1 Gamma | FLIP-L | I-FLICE | I-FLICE 1 | Inhibitor of FLICE | MACH-Related Inducer of Toxicity | MRIT | MRIT Alpha-1 | Usurpin | Usurpin Alpha | c-FLIP | c-FLIPL | cFLIP | cFLIP(L) | cFLIPL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698306","B-Acute Lymphoblastic Leukemia with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)","C80347","A B-cell acute leukemia characterized by the presence of lymphoblasts that carry a translocation between the E2A gene on chromosome 19 and the PBX1 gene on chromosome 1. It occurs in children and less often in adults.","B Acute Lymphoblastic Leukemia with t(1;19)(q23;p13.3); TCF3-PBX1 | B Acute Lymphoblastic Leukemia with TCF3-PBX1 Fusion | B Acute Lymphoblastic Leukemia with TCF3::PBX1 Fusion | B Acute Lymphoblastic Leukemia with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1) | B Acute Lymphoblastic Leukemia with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1) | B Acute Lymphoblastic Leukemia with t(1;19)(q23;p13.3); TCF3::PBX1 | B-ALL with t(1;19)(q23;p13.3); TCF3-PBX1 | B-ALL with t(1;19)(q23;p13.3); TCF3::PBX1 | B-Acute Lymphoblastic Leukemia with TCF3-PBX1 Fusion | B-Acute Lymphoblastic Leukemia with TCF3::PBX1 Fusion | B-Acute Lymphoblastic Leukemia with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1) | B-Acute Lymphoblastic Leukemia with t(1;19)(q23;p13.3); TCF3-PBX1 | B-Cell Acute Lymphoblastic Leukemia with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639706","Brief Pain Inventory Short Form Questionnaire","C100760","A standardized survey originally developed and copyrighted by Charles S. Cleeland in 1991 which is used to evaluate the severity of a patient's pain and the impact that their pain has on their daily activities. This shorter version of the Brief Pain Inventory (BPI) is more useful for clinical trials, can be completed by the patient or in an interview format, and consists of only 9 questions most of which can be answered on a 0-10 rating scale.","Brief Pain Inventory Short Form Questionnaire | BPI SHORT FORM | BPI2 | Brief Pain Inventory Short Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL455337","Pain Relief","C112216","A lessening of pain following an intervention.","Pain Relief | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816449","Forty","C105795","A natural number greater than thirty-nine and less than forty-one and the quantity that it denotes.","Forty | 40",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816957","70 (qualifier value)","C105790","A natural number greater than sixty-nine and less than seventy-one and the quantity that it denotes.","Seventy | 70",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816958","80 (qualifier value)","C105788","A natural number greater than seventy-nine and less than eighty-one and the quantity that it denotes.","Eighty | 80",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816959","Ninety","C105786","A natural number greater than eighty-nine and less than ninety-one and the quantity that it denotes.","Ninety | 90",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0074480","sialosyl-Tn antigen","C1226","A tumor-associated core-region carbohydrate antigen of epithelial mucin, expressed in most colon carcinoma, mucinous carcinoma, pancreatic cancer, gastric, lung, breast, and ovarian carcinoma. Sialosyl-Tn (STn) antigen has been shown to be highly sensitive and a specific marker of colorectal cancer, associated with more aggressive diseases and poor prognosis. STn antigen and its immediate precursor, Tn antigen, are mucin type glycoprotein structures associated with the earliest steps of mucin O-linked glycosylation. When combined with a carrier molecule, keyhole limpet hemocyanin (KLH), this antigen may be co-administered with oral cyclophosphamide as an immune modulator.","Sialyl Tn Antigen | CD175s | STn | STn Antigen | Sialyl-Tn | Sialyl-Tn Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335623","RIPK1 Gene","C21223","This gene plays a role in apoptosis and signal transduction.","RIPK1 Gene | RIPK1 | Receptor (TNFRSF)-Interacting Serine-Threonine Kinase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420808","TNFRSF14 Gene","C97843","This gene plays a role in receptor signaling.","TNFRSF14 Gene | TNFRSF14 | Tumor Necrosis Factor Receptor Superfamily, Member 14 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419019","PSMB9 Gene","C73446","This gene is involved in the mediation of antigen processing during non-lysosomal protein catabolism.","PSMB9 Gene | PSMB9 | Proteasome (Prosome, Macropain) Subunit, Beta Type, 9 (Large Multifunctional Peptidase 2) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334081","IFNAR1 Gene","C37275","This gene is involved in tyrosine-kinase signal transduction and receptor mediation.","IFNAR1 Gene | IFNAR1 | Interferon (Alpha, Beta and Omega) Receptor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332075","ALCAM Gene","C20994","This gene plays a role in cellular adhesion events involving immune cells, such as monocytes and leukocytes.","ALCAM Gene | ALCAM | Activated Leukocyte Cell Adhesion Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424853","SPDEF Gene","C102918","This gene may be involved in prostate development and prostate cancer.","SPDEF Gene | SAM Pointed Domain Containing ets Transcription Factor Gene | SPDEF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332380","BAP1 Gene","C20766","This gene is involved in cellular growth regulation and is purported to have tumor suppression activity.","BAP1 Gene | BAP1 | BRCA1 Associated Protein-1 (Ubiquitin Carboxy-Terminal Hydrolase) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006632","Cadmium","C44348","An element with atomic symbol Cd, atomic number 48, and atomic weight 112.4.","Cadmium | CADMIUM | Cadmium Metal | Cd | cadmium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002367","Aluminum","C93162","A metallic element in the boron group with atomic symbol Al, atomic number 13, and atomic weight 27.","Aluminum | aluminum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028128","Nitric Oxide","C695","An unstable free-radical gas which reacts rapidly with oxygen to form nitrogen oxides.  Water soluble, NO is produced normally in numerous tissues and is considered to be a mediator of cell-to cell communication; it functions in numerous processes including vasodilation, inflammation, and neurotransmission. (NCI04)","Nitric Oxide | EDRF | Endothelium-Derived Relaxing Factor | Inomax | Mononitrogen Monoxide | NITRIC OXIDE | NO | Nitrogen Monoxide | Nitrogen Oxide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039738","Thallium","C95188","A naturally occurring trace metalloid element with atomic symbol Tl, atomic number 81, and atomic weight 204.383. Thallium is used in manufacturing, as well as in some chemical reactions and medical procedures. Use as a pesticide has been banned in the United States due to toxicity from accidental exposure. It is characterized as an odorless, bluish-white, metallic soft solid that turns to a gray powder with an aromatic odor when exposed to air. Exposure occurs by inhalation of fumes, ingestion, or contact.","Thallium | THALLIUM | Thallium Metallicum | Tl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025424","Mercury","C66842","A naturally occurring trace metalloid element and known neurotoxin with atomic symbol Hg, atomic number 80, and atomic weight 200.59. Mercury has been used in manufacturing, as well as in dental and medical equipment, fertilizers, and pesticides. It is characterized as a heavy, silvery-white metallic liquid at room temperature that is odorless. Exposure occurs by inhalation of fumes, ingestion, or contact.","Mercury | Hg | Hydrargyrum | Liquid Silver | MERCURY | Quicksilver | mercury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023175","Lead Metal","C44396","An element with atomic symbol Pb, atomic number 82, and atomic weight 207.2.","Lead Metal | LEAD | Lead | Metallic Lead | Pb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013725","Eicosanoid","C463","A class of fatty acids derived from the oxidation of one of three 20-carbon fatty acids: eicosapentaenoic acid (EPA), arachidonic acid (AA), or dihomo-gamma-linolenic acid (DGLA). Eicosanoids act locally as autocrine or paracrine hormones to modulate a wide variety of biological processes.","Eicosanoid | Eicosanoids",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0045822","8-Methyl-IQX","C44308","A synthetic, pale orange to brown crystalline solid that is soluble in dimethylsulfoxide and methanol. It is produced in small quantities for research purposes. 2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline is formed naturally during the cooking of muscle-derived foods (meat and fish). Levels of this chemical produced in this manner are dependent on cooking temperature, cooking time and method of cooking (direct or indirect).  It is one of the most abundant heterocyclic amines in a typical Western diet. 2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline has also been detected in processed food flavorings, beer, wine, and cigarette smoke. It is reasonably anticipated to be a human carcinogen. (NCI05)","8-Methyl-IQX | 2-Amino-3,8-Dimethyl-3H-Imidazo(4,5-f)Quinoxaline | 2-Amino-3,8-Dimethylimidazo(4,5-f)Quinoxaline | 2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline | 3,8-DiMeIQX | 3,8-Dimethyl-3H-Imidazo(4,5-f)Quinoxalin-2-Amine | 3,8-Dimethyl-3H-imidazo[4,5-f]quinoxalin-2-amine | 3,8-Dimethylimidazo(4,5-f)Quinoxalin-2-Amine | 3H-Imidazo(4,5-f)Quinoxalin-2-Amine, 3,8-Dimethyl- | 3H-Imidazo(4,5-f)Quinoxaline, 2-Amino-3,8-Dimethyl- | 8-MeIQX | MEIQX | Me-IQX | MeIQX | Meiqx | Meiqx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0045811","2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","C29792","A synthetic, gray-white crystalline solid that is soluble in dimethylsulfoxide and methanol. It is produced in small quantities for research purposes. 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine is formed naturally during the cooking of muscle-derived foods (meat and fish). Levels of this chemical produced in this manner are dependent on cooking temperature, cooking time and method of cooking (direct or indirect). It is one of the most abundant heterocyclic amines in a typical Western diet. 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine has also been detected in processed food flavorings, beer, wine, and cigarette smoke. It is reasonably anticipated to be a human carcinogen. (NCI05)","2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine | 1-methyl-6-phenyl-1h-imidazo(4,5-b)pyridin-2-amine | 2-AMINO-1-METHYL-6-PHENYLIMIDAZO(4,5-B)PYRIDINE | PHIP | PhIP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512423","Heterocyclic Amines","C1926","Exhibiting a cyclic structure containing at least one amino (NH2) group, some Heterocyclic Amines are carcinogenic chemicals formed from cooking meat such as beef, pork, fowl, and fish when amino acids and creatine (found in muscle) react at high temperatures. About 17 identified heterocyclic amines that result from cooking meat may increase human cancer risk. Because of the high temperatures used, frying, broiling, and barbecuing produce the largest amounts of heterocyclic amines. (NCI04)","Heterocyclic Amines | HAA | HCA | Heterocyclic Aromatic Amine | Heterocyclic Aromatic Amines | heterocyclic amine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412384","AMH Gene","C101735","This gene plays a role in gonad development.","AMH Gene | AMH | Anti-Mullerian Hormone Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826244","Life Threatening","C82508","A situation that imperils the existence of an entity.","Life Threatening | SLIFE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2350202","Talaporfin Sodium","C26675","An agent consisting of chlorin e6, derived from chlorophyll, and L-aspartic acid with photosensitizing activity.  After intratumoral activation by light emitting diodes, taporfin sodium forms an extended high energy conformational state that generates singlet oxygen, resulting in free radical-mediated cell death. (NCI04)","Talaporfin Sodium | LS11 | Laserphyrin | ME2906 | Mono-L-aspartyl Chlorin e6 | NPe6 | TALAPORFIN SODIUM | Taporfin Sodium | talaporfin sodium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454683","Ultrasound-Guided Transesophageal Endoscopic Fine-Needle Aspiration","C112517","The use of endoscopic ultrasound imaging for real-time guidance of transesophageal fine-needle aspiration.","Ultrasound-Guided Transesophageal Endoscopic Fine-Needle Aspiration | Transesophageal Endoscopic Ultrasound-Guided Fine-Needle Aspiration | Transesophageal needle biopsy using endoscopic ultrasound",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827315","Endoscopic Ultrasound Biopsy","C112516","The use of ultrasound imaging for real-time guidance of an endoscope for a biopsy procedure.","Endoscopic Ultrasound Biopsy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714761","Daylight-Savings Time","C112506","A seasonal time adjustment in which clocks are set one hour ahead of local standard time.","Daylight-Savings Time | DST | Daylight Savings Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0179245","Water Bath","C112508","A device designed to regulate the temperature of a vessel by bathing it in water held at the desired temperature.","Water Bath | Water-bath | Waterbath",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830327","Electric Warmer","C112509","A device that converts electricity to heat.","Electric Warmer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2926602","Body Substance Discharge","C50437","The leakage of a substance from an orifice or wound.","Body Substance Discharge | Discharge",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714918","Monitor Unit","C112818","A unit of measure of ionization in a linear accelerator treatment beam within the treatment head.","Monitor Unit | MU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830630","Cumulative Meterset Weight","C112819","A factor used to determine at what point in the beam delivery the next change in setup is to take place.","Cumulative Meterset Weight | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827011","Dose Volume Histogram","C112816","A plot of a cumulative dose-volume frequency distribution that graphically summarizes the simulated radiation distribution within a volume of interest of a patient which would result from a proposed radiation treatment plan.","Dose Volume Histogram | DVH | DVH Curve",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0599956","Aqueous","C28273","Having to do with water.","Aqueous | aqueous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831017","Control Point","C112866","Any one of a set of linear accelerator parameters that define the segments from which a radiation beam is applied.","Control Point | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830346","ECOG Performance Status 0","C105722","Fully active, able to carry on all pre-disease performance without restriction.","ECOG Performance Status 0 | 0 | 0: Asymptomatic | ECOG 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830345","ECOG Performance Status 1","C105723","Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.","ECOG Performance Status 1 | 1 | 1: Symptomatic, but fully ambulatory | ECOG 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830344","ECOG Performance Status 2","C105725","Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours.","ECOG Performance Status 2 | 2 | 2: Symptomatic, in bed less than 50% of day | ECOG 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830343","ECOG Performance Status 3","C105726","Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours.","ECOG Performance Status 3 | 3 | 3: Symptomatic, in bed more than 50% of day, but not bed-ridden | ECOG 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830342","ECOG Performance Status 4","C105727","Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair.","ECOG Performance Status 4 | 4 | 4: Bed-ridden | ECOG 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830341","ECOG Performance Status 5","C105728","Dead.","ECOG Performance Status 5 | 5 | ECOG 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0384397","ESHAP Regimen","C63377","A regimen consisting of etoposide, methylprednisolone, high-dose cytarabine and cisplatin, used to treat relapsed and refractory Hodgkin and non-Hodgkin lymphoma, such as mycosis fungoides/Sezary syndrome.","ESHAP Regimen | ESHAP | Etoposide-Solumedrol-High Dose Ara-C-Platinol Regimen | Etoposide/Solumedrol/High Dose Ara-C/Platinol Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880228","DHAP Regimen","C63441","A regimen consisting of dexamethasone, high-dose cytarabine (Ara-C) and cisplatin that may be used in the treatment of Hodgkin's lymphoma, diffuse large B-cell lymphoma, mycosis fungoides/Sezary syndrome, and T-cell lymphoma.","DHAP Regimen | DHAP | Dexamethasone-High Dose AraC-Platinol Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882524","R-ICE Regimen","C63465","A regimen consisting of rituximab, ifosfamide, carboplatin and etoposide that can be used for the treatment of nodular lymphocyte-predominant Hodgkin lymphoma and certain forms of non-Hodgkin lymphoma (NHL), such as Burkitt lymphoma and diffuse large B-cell lymphoma.","R-ICE Regimen | ICE Plus Rituximab | Ifosfamide/Carboplatin/Etoposide/Rituximab | R-ICE | R-ICE (rituximab-abbs) | R-ICE (rituximab-arrx) | R-ICE (rituximab-blit) | R-ICE (rituximab-pvvr) | R-ICE (rituximab-rite) | R-ICE (rituximab-rixa) | R-ICE (rituximab-rixi) | RICE | RICE Regimen | Rituximab-Ifosfamide-Carboplatin-Etoposide Regimen | Rituximab/Ifosfamide/Carboplatin/Etoposide | Rituximab/Ifosfamide/Carboplatin/Etoposide Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883164","Stanford V Regimen","C63369","A regimen consisting of mechlorethamine, doxorubicin hydrochloride, vinblastine, vincristine, bleomycin, etoposide and prednisone, administered on a compressed schedule and used in the treatment of Hodgkin lymphoma; it may be followed by consolidative radiation therapy.","Stanford V Regimen | Stanford V | Stanford V regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527027","Romidepsin","C1544","A bicyclic depsipeptide antibiotic isolated from the bacterium Chromobacterium violaceum with antineoplastic activity. After intracellular activation, romidepsin binds to and inhibits histone deacetylase (HDAC), resulting in alterations in gene expression and the induction of cell differentiation, cell cycle arrest, and apoptosis. This agent also inhibits hypoxia-induced angiogenesis and depletes several heat shock protein 90 (Hsp90)-dependent oncoproteins.","Romidepsin | Antibiotic FR 901228 | Depsipeptide | FK 228 | FK-228 | FK228 | FR 901228 | FR-901228 | FR901228 | Istodax | L-Valine, N- (3-hydroxy-7-mercapto-1-oxo-4-heptenyl)valyl- cysteinyl-2, 3-didehydro-2-aminobutanoyl-,xi-lactone, cyclic (1-2)-disulfide | L-Valine, N-(3-Hydroxy-7-Mercapto-1-Oxo-4-Heptenyl)-D-Valyl-D-Cysteinyl-(Z)-2,3 -Didehydro-2-Aminobutanoyl-, xi-Lactone, Cyclic (1-2)-Disulfide, (S-(E))- | N-[(3S,4E)-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4-1) Lactone, Cyclic | N-[(3S,4E)-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4->1) Lactone, Cyclic | ROMIDEPSIN | depsipeptide | romidepsin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013840","Electron Beam","C28039","A stream of electrons (small negatively charged particles found in atoms) that can be used for radiation therapy.","Electron Beam | electron beam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335193","PAX5 Gene","C24659","This gene is involved in the transcriptional regulation of target genes. It plays a role in B-cell differentiation, neural development and spermatogenesis.","PAX5 Gene | PAX5 | Paired Box 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1141628","Integrin Alpha-E","C107130","Integrin alpha-E (1179 aa, ~130 kDa) is encoded by the human ITGAE gene. This protein plays a role in cell adhesion and may be involved in activation of intestinal intraepithelial lymphocytes.","Integrin Alpha-E | Antigen CD103, Human Mucosal Lymphocyte Antigen 1; Alpha Polypeptide | CD103 | CD103 Antigen | HML-1 Antigen | Integrin Alpha-IEL | Mucosal Lymphocyte 1 Antigen",,,,,,,,,,,,,,,"4011794","Lymphocyte antigen CD103",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1413227","CD5 Gene","C73121","This gene may be involved in the proliferation of T-cells.","CD5 Gene | CD5 | CD5 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714971","Anti-CD2 Monoclonal Antibody","C112882","Any monoclonal antibody directed against the cell surface glycoprotein CD2, regardless of the antibody type.","Anti-CD2 Monoclonal Antibody | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831520","Anti-CD3 Monoclonal Antibody","C112883","Any monoclonal antibody directed against the cell surface glycoprotein CD3.","Anti-CD3 Monoclonal Antibody | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831519","Anti-CD4 Monoclonal Antibody","C112884","Any monoclonal antibody directed against the cell surface glycoprotein CD4, regardless of the antibody type.","Anti-CD4 Monoclonal Antibody | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831518","Anti-CD5 Monoclonal Antibody","C112885","Any monoclonal antibody directed against the cell surface glycoprotein CD5, regardless of the antibody type.","Anti-CD5 Monoclonal Antibody | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827262","Anti-CD6 Monoclonal Antibody","C112886","Any monoclonal antibody directed against the cell surface glycoprotein CD6, regardless of the antibody type.","Anti-CD6 Monoclonal Antibody | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831517","Anti-CD7 Monoclonal Antibody","C112887","Any monoclonal antibody directed against the cell surface glycoprotein CD7, regardless of the antibody type.","Anti-CD7 Monoclonal Antibody | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831516","Anti-CD8 Monoclonal Antibody","C112888","Any monoclonal antibody directed against the cell surface glycoprotein CD8, regardless of the antibody type.","Anti-CD8 Monoclonal Antibody | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831521","Anti-CD19 Monoclonal Antibody","C112889","Any monoclonal antibody directed against the cell surface glycoprotein CD19.","Anti-CD19 Monoclonal Antibody | Anti-CD19 MoAb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831557","Alpha-Beta T-Cell Receptor Antibody","C112909","Any monoclonal antibody directed against an alpha-beta T-Cell receptor.","Alpha-Beta T-Cell Receptor Antibody | Anti-Alpha-Beta T-Cell Receptor Antibody | a/b T-Cell Receptor Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811810","Treated Volume","C112910","A volume enclosed by an isodose surface, selected and specified as being appropriate to achieve the purpose of treatment.","Treated Volume | TV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0454197","Irradiated Volume","C112911","A tissue volume which receives a dose that is considered significant in relation to healthy tissue tolerance.","Irradiated Volume | ",,,,,,,,,,,,,,,"4040590","Irradiated volume",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0454198","Clinical Target Volume","C112912","The tissue volume that contains a demonstrable gross target volume and/or sub-clinical microscopic malignant disease, which has to be eliminated. This volume must be treated adequately in order to achieve the aim of therapy, cure or palliation.","Clinical Target Volume | CTV | Clinical target volume (observable entity)",,,,,,,,,,,,,,,"4036401","Clinical target volume",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3827000","Gross Target Volume","C112913","The gross palpable or visible/demonstrable extent and location of malignant growth.","Gross Target Volume | GTV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812160","Radiotherapy Bolus","C112914","A tissue-equivalent material placed in contact with the skin to increase the surface dose and/or compensate for missing tissue. A bolus can also be used to compensate for lack of scatter, such as near the extremities or the head during total-body irradiation.","Radiotherapy Bolus | Bolus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2963249","Accessory","C112918","Something added to extend a whole and to make an addition.","Accessory | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831073","Clockwise","C113084","Circular movement in the direction of the rotation of the hands of a clock.","Clockwise | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830994","Counterclockwise","C113085","Circular movement in the direction opposite to the rotation of the hands of a clock.","Counterclockwise | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829147","MD Anderson Symptom Inventory - Brain Tumor","C113089","A self-administered questionnaire designed specifically for evaluating the severity of symptoms related to a brain tumor.","MD Anderson Symptom Inventory - Brain Tumor | MD Anderson Symptom Inventory - Brain Tumor  | MDASI-BT | MDASI-BT ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827494","Weakness on One Side of the Body at its Worst","C113090","A question about an individual's weakness on one side of the body at its worst.","Weakness on One Side of the Body at its Worst | Weakness on one side of the body at its worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830488","Difficulty Understanding at its Worst","C113091","A question about an individual's difficulty understanding at its worst.","Difficulty Understanding at its Worst | Difficulty understanding at its worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830491","Difficulty Speaking at its Worst","C113092","A question about an individual's difficulty speaking at its worst.","Difficulty Speaking at its Worst | Difficulty Speaking or Finding Words at its Worst | Difficulty speaking at its worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828197","Seizure at its Worst","C113093","A question about an individual's seizures at its worst.","Seizure at its Worst | Seizure at its worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830495","Difficulty Concentrating at its Worst","C113094","A question about an individual's difficulty concentrating at its worst.","Difficulty Concentrating at its Worst | Difficulty concentrating at its worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827550","Vision at its Worst","C113095","A question about an individual's vision at its worst.","Vision at its Worst | Vision at its worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831144","Change in Appearance at its Worst","C113096","A question about an individual's change in appearance at its worst.","Change in Appearance at its Worst | Change in appearance at its worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831143","Change in Bowel Pattern at its Worst","C113097","A question about an individual's change in bowel pattern at its worst.","Change in Bowel Pattern at its Worst | Change in bowel pattern at its worst | Your change in bowel pattern (diarrhea/constipation) at its worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829500","Irritability at its Worst","C113098","A question about an individual's irritability at its worst.","Irritability at its Worst | Irritability at its worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829430","Karnofsky Performance Status 10","C105718","Moribund; fatal processes progressing rapidly.","Karnofsky Performance Status 10 | 10 | 10: Moribund; fatal processes progressing rapidly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0442122","Intravaginal","C94327","Having to do with the inside of the vagina (the birth canal).","Intravaginal | intravaginal",,,,,,,,,,,,,,,"4136280","Intravaginal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1511884","Diagnostic Specificity","C41395","The probability that a test will produce a true negative result when used on non-effected subjects as compared to a reference or 'gold standard'. The specificity of a test can be determined by calculating: number of true negative results divided by the sum of true negative results plus number of false positive results.","Diagnostic Specificity | Specificity | Specificity of Diagnostic Test | specificity | specificity (medical test)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516221","Cancer Prognosis","C18672","A forecast of the probable course and outcome of a cancer.","Cancer Prognosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2363923","Metastasectomy","C94461","The surgical removal of metastases.","Metastasectomy | METASTASECTOMY | metastasectomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830489","Difficulty Swallowing Solid Foods","C113178","A question about whether an individual has or had difficulty swallowing solid foods.","Difficulty Swallowing Solid Foods | I have difficulty swallowing solid foods",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830490","Difficulty Swallowing Soft or Mashed Foods","C113179","A question about whether an individual has or had difficulty swallowing soft or mashed foods.","Difficulty Swallowing Soft or Mashed Foods | I have difficulty swallowing soft or mashed foods",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL455339","Difficulty Swallowing Liquids (question)","C113180","A question about whether an individual has or had difficulty swallowing liquids.","Difficulty Swallowing Liquids | I have difficulty swallowing liquids",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828672","Pain in Chest When Swallowing","C113181","A question about whether an individual has or had chest pain when swallowing.","Pain in Chest When Swallowing | I have pain in my chest when I swallow",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL455338","Choke When Swallowing (question)","C113182","A question about whether an individual chokes or has choked when swallowing.","Choke When Swallowing | I choke when I swallow",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831761","Able to Enjoy Meals with Family or Friends","C113183","A question about whether an individual is or has been able to enjoy meals with family or friends.","Able to Enjoy Meals with Family or Friends Question | Able to Enjoy Meals with Family or Friends | Able to Enjoy Meals with Family or Friends | I am able to enjoy meals with family or friends",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827527","Wake at Night Because of Coughing","C113184","A question about whether an individual awakens or has been awoken at night because of coughing.","Wake at Night Because of Coughing | I wake at night because of coughing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830270","FACT-Ga Questionnaire","C113185","A subscale complement to the FACT-G developed specifically for evaluating the quality of life of gastric cancer patients.","FACT-Ga Questionnaire | FACT-Ga | Functional Assessment of Cancer Therapy - Gastric Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830271","FACT-C Questionnaire","C113186","A subscale complement to the FACT-G developed specifically for evaluating the quality of life of colorectal cancer patients.","FACT-C Questionnaire | FACT-C | Functional Assessment of Cancer Therapy - Colorectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830272","FACT-An Questionnaire","C113187","A subscale complement to the FACT-G developed specifically for evaluating the quality of life of cancer patients with anemia and fatigue.","FACT-An Questionnaire | FACT-An | Functional Assessment of Cancer Therapy - Anemia/Fatigue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830269","FACT-Leu Questionnaire","C113188","A subscale complement to the FACT-G developed specifically for evaluating the quality of life of leukemia patients.","FACT-Leu Questionnaire | FACT-Leu | Functional Assessment of Cancer Therapy - Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831299","Bothered by Reflux or Heartburn","C113189","A question about whether an individual is or was bothered by reflux or heartburn.","Bothered by Reflux or Heartburn | Bothered By Reflux or Heartburn | Bothered by Acid Indigestion | Have you, during the past week, been bothered by acid indigestion | I am bothered by reflux or heartburn",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830476","Discomfort or Pain When Eating","C113190","A question about whether an individual has or had discomfort or pain when eating.","Discomfort or Pain When Eating | I have discomfort or pain when I eat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829801","Have Feeling of Fullness or Heaviness in Stomach Area","C113191","A question about whether an individual has or had a feeling of fullness or heaviness in the area of the stomach.","Have Feeling of Fullness or Heaviness in Stomach Area | I have a feeling of fullness or heaviness in my stomach area",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829757","Have Trouble Swallowing Food","C113192","A question about whether an individual has or had trouble swallowing food.","Have Trouble Swallowing Food | I have trouble swallowing food",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831309","Bothered By a Change in Eating Habits","C113193","A question about whether an individual is or was bothered by a change in their eating habits.","Bothered By a Change in Eating Habits | I am bothered by a change in my eating habits",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830486","Digestive Problems Interfere with Usual Activities","C113194","A question about whether an individual has or had digestive problems that interfered with their usual activities.","Digestive Problems Interfere with Usual Activities | My digestive problems interfere with my usual activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831429","Avoid Going Out to Eat Because of Illness","C113195","A question about whether an individual avoids or has avoided going out to eat because of their illness.","Avoid Going Out to Eat Because of Illness | I avoid going out to eat because of my illness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829768","Have Stomach Problems That Worry Me","C113196","A question about whether an individual has or had stomach problems that caused them to worry.","Have Stomach Problems That Worry Me | I have stomach problems that worry me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831303","Bothered by Gas or Flatulence","C113197","A question about whether an individual is or was bothered by gas or flatulence.","Bothered by Gas or Flatulence | Bothered by Gas | I am bothered by gas (flatulence) | Were you bothered by gas (flatulence)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829803","Have Difficulty Planning for Future Due to Illness","C113198","A question about whether an individual has or had difficulty planning for the future because of their illness.","Have Difficulty Planning for Future Due to Illness | Because of my illness, I have difficulty planning for the future",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454390","Anti-CD19-CAR-CD3zeta-4-1BB-Expressing Allogenic Natural Killer Cells","C112179","Allogeneic natural killer (NK) cells transduced with an mRNA expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. NK cells from haploidentical donors are expanded in culture and electroporated with the CAR mRNA. Upon transfusion of the transduced cultured cells, CD19CAR-CD3zeta-4-1BB-expressing allogeneic NK cells bind to and induce selective cytotoxicity in CD19-expressing tumor cells. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19. Its inclusion may also increase antitumor activity, when compared to the inclusion of the CD3-zeta chain alone. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.","Anti-CD19-CAR-CD3zeta-4-1BB-Expressing Allogenic Natural Killer Cells | Anti-CD19 Redirected NK Cells | Anti-CD19-CAR-CD3zeta-4-1BB-Expressing Allogenic NK Cells | Anti-CD19-CAR-CD3zeta-4-1BB-Expressing Donor NK Cells | Anti-CD19-CAR-CD3zeta-4-1BB-Expressing Donor Natural Killer Cells | Anti-CD19-CAR-CD3zeta-4-1BB-Expressing NK Cells | Anti-CD19-CAR-CD3zeta-4-1BB-Expressing Natural Killer Cells | NKCARCD19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0314619","Immunoglobulin Lambda Locus","C26423","This region represents the germline organization of the lambda light chain locus. The locus includes V (variable), J (joining), and C (constant) segments. During B cell development, a recombination event at the DNA level joins a single V segment with a J segment; the C segment is later joined by splicing at the RNA level. Recombination of many different V segments with several J segments provides a wide range of antigen recognition. Additional diversity is attained by junctional diversity, resulting from the random additional of nucleotides by terminal deoxynucleotidyltransferase, and by somatic hypermutation, which occurs during B cell maturation in the spleen and lymph nodes. (from LocusLink)","Immunoglobulin Lambda Locus | IGL | Immunoglobulin Lambda Gene | Lambda Light Chain Gene",,,,,,,,,,,,,,,"4029647","Immunoglobulin lambda light chain gene",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705090","CD3E wt Allele","C52022","Human CD3E wild-type allele is located within 11q23 and is approximately 11 kb in length. This allele, which encodes T-cell surface glycoprotein CD3 epsilon chain protein, is involved in signal transduction essential for T cell receptor signaling and synapse formation. Certain allelic variants of the CD3E gene are associated with T cell immunodeficiency.","CD3E wt Allele | CD3-Epsilon Gene | CD3E Antigen, Epsilon Polypeptide (TiT3 Complex) wt Allele | T-Cell Antigen Receptor Complex, Epsilon Subunit of T3 Gene | T-Cell Surface Antigen T3/LEU-4 Epsilon Chain Gene | T-Cell Surface Glycoprotein CD3 Epsilon Chain Gene | T3E | TCRE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279705","Thymoma Type B3","C7997","Also known as well-differentiated thymic carcinoma, atypical thymoma, or epithelial thymoma, this type of thymoma displays morphologic characteristics of a well-differentiated carcinoma.  The majority of cases occur in the anterior mediastinum as Masaoka stage II or stage III tumors.  It is almost always invasive, it recurs frequently, and metastasizes in approximately 20% of the cases.","Thymoma Type B3 | Atypical Thymoma | Epithelial Malignant Thymoma | Epithelial Thymoma | Malignant Thymoma Type B3 | Squamoid Thymoma | Thymoma, atypical, NOS | Thymoma, atypical, malignant | Thymoma, epithelial, NOS | Thymoma, epithelial, malignant | Thymoma, type B3, NOS | Thymoma, type B3, malignant | Well Differentiated Thymic Carcinoma | Well differentiated thymic carcinoma | Well-Differentiated Thymic Carcinoma",,,,,,,,,,,,,,,"4029518","Thymoma, type B3, malignant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266095","Thymoma Type B2","C6888","A thymic epithelial neoplasm characterized by the presence of neoplastic large, polygonal epithelial cells with large vesicular nuclei and prominent nucleoli. The neoplastic cells are arranged around perivascular spaces and along septa. Immature T-lymphocytes are also present. It may be associated with myasthenia gravis, pure red cell aplasia, and hypogammaglobulinemia. It is a tumor of moderate malignancy. The majority of cases occur in the anterior mediastinum as Masaoka stage I, stage II, or stage III tumors. Metastatic, stage IV tumors occur less frequently.","Thymoma Type B2 | Cortical Thymoma | Polygonal Cell Thymoma | Thymoma, type B2, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266094","Thymoma Type B1","C6887","A thymic epithelial neoplasm characterized by the presence of expanded areas which resemble the normal thymic cortex. The neoplastic epithelial cells are small and scant and there is a dense T-lymphocytic component present. Areas of medullary differentiation with or without Hassall's corpuscles are also present. It may be associated with myasthenia gravis, pure red cell aplasia, and hypogammaglobulinemia. It has a low grade malignant potential. The majority of cases occur in the anterior mediastinum as Masaoka stage I tumors. A minority of the cases occur as stage II tumors.","Thymoma Type B1 | Lymphocyte-Predominant Thymoma | Lymphocyte-Rich Thymoma | Organoid Thymoma | Predominantly Cortical Thymoma | Thymoma, type B1, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266092","Thymoma Type AB","C6885","A thymic epithelial neoplasm characterized by the presence of a lymphocyte-poor component similar to that seen in type A thymoma and a lymphocyte-rich component which contains neoplastic small polygonal epithelial cells. It may be associated with myasthenia gravis and pure red cell aplasia. The majority of cases occur in the anterior mediastinum as Masaoka stage I tumors. A minority of the cases occur as stage II or stage III tumors. The overall survival is reported to be 80-100% at 5 and 10 years.","Thymoma Type AB | Mixed Type Thymoma | Thymoma, type AB, NOS",,,,,,,,,,,,,,,"606387","Thymoma type AB",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266091","Thymoma Type A","C6454","A thymic epithelial neoplasm characterized by the presence of spindle and/or oval neoplastic epithelial cells. Lymphocytic infiltration is minimal or absent. It may be associated with myasthenia gravis or pure red cell aplasia. The majority of cases occur in the anterior mediastinum as Masaoka stage I tumors. Approximately 20% of the cases occur as stage II or stage III tumors. Type A thymoma generally behaves as a benign tumor and the overall survival is reported to be 100% at 5 and 10 years.","Thymoma Type A | Medullary Thymoma | Spindle Cell Thymoma",,,,,,,,,,,,,,,"606393","Thymoma type A",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL497918","Extra-Adrenal Paraganglioma","C3309","A paraganglioma arising from sympathetic or parasympathetic paraganglia outside the adrenal gland.","Extra-Adrenal Paraganglioma | Extra-Adrenal Paraganglionic Neoplasm | Extra-adrenal paraganglioma, NOS | Extraadrenal Paraganglioma",,,,,,,,,,,,,,,"4120307|4202039","Extra-adrenal paraganglioma|Extra-adrenal paraganglioma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1333308","Distal Bile Duct Carcinoma","C7109","A carcinoma that arises from the common bile duct distal to the insertion of the cystic duct.","Distal Bile Duct Carcinoma | Extrahepatic (Distal) Bile Duct Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830273","FAACT Questionnaire","C113301","A questionnaire used to assess general aspects of quality of life related to anorexia and cachexia.","FAACT Questionnaire | FAACT | Functional Assessment of Anorexia/Cachexia Treatment Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412094","ABCF2 Gene","C113327","This gene plays a role in ATP catabolism.","ABCF2 Gene | ABCF2 | ATP-Binding Cassette, Sub-Family F (GCN20), Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3544087","Absolute Blood Lymphocyte Count","C113237","The number of lymphocytes found in a given volume of blood.","Absolute Blood Lymphocyte Count | ALC | Absolute Lymphocyte Count",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412244","ADM Gene","C113264","This gene plays a role in both hormone signaling and vasodilation.","ADM Gene | ADM | Adrenomedullin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0618497","Angiokine","C113246","A family of soluble proteins that initiate signaling pathways involved in the process of new blood vessel formation. These proteins may be secreted by lymphocytes in response to tumor-related inflammation.","Angiokine | Angiogenic Lymphokine | Angiogenic Lymphokines | Angiokines",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412566","ARTN Gene","C113258","This gene plays a role in both neurogenesis and Peyer patch morphogenesis.","ARTN Gene | ARTN | Artemin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2240202","B9D2 Gene","C113279","This gene plays a role in cilia formation.","B9D2 Gene | B9 Protein Domain 2 Gene | B9D2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413086","CALD1 Gene","C113324","This gene is involved in the stabilization of actin filaments.","CALD1 Gene | CALD1 | Caldesmon 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831099","Circulating Proteasome","C113298","Cell free proteasome enzyme complexes. Elevated levels of these protein complexes in serum, plasma or blood may be associated with either increased tumor burden or a poor disease prognosis.","Circulating Proteasome | Circulating Proteasomes | cProteasome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827014","Circulating Tumor-Derived DNA","C113243","Neoplasm-derived DNA found in blood plasma and other bodily fluids that is not associated with cells.","Circulating Tumor-Derived DNA | Cell-Free Circulating Tumor DNA | Circulating Tumor DNA | ctDNA | ctdDNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443976","Clonal Gene Rearrangement","C36333","A DNA sequence rearrangement that results in the creation of novel immunoglobulins and T-cell receptors expressed by lymphocytes. This process occurs very early in the differentiation of B- and T-lymphocytes, such that individual B- and T-cell progenitors have unique genetic profiles that are passed down to their descendants. This leads to clonal populations of lymphocytes expressing the unique proteins selected during maturation.","Clonal Gene Rearrangement | Monoclonal Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827026","Cobblestone Area-Forming Cells","C113240","The number of hematopoietic stem cells (HSCs) that migrate between or beneath a co-cultured feeder cell layer and become trapped. When HSCs are cultured with a feeder layer and observed using phase contrast microscopy, the trapped cells appear less spherical and less refractile than the HSCs that are floating loosely on top of the feeder layer.","Cobblestone Area-Forming Cells | CAFC | Cobble Stone Area-Forming Cells | Cobblestone Forming Units",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827024","Colony-Forming Unit-Fibroblasts","C113241","A population of adherent cells in bone marrow cultures that resemble fibroblasts.","Colony-Forming Unit-Fibroblasts | CFU-F | Fibroblast Colony-Forming Units",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830986","CpG Antibody","C113244","Any immunoglobulin that recognizes cytosine/guanine (CpG) rich sequences in chromosomal DNA.","CpG Antibody | Anti-CpG Antibodies | Anti-CpG Antibody | CpG Antibodies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010287","Creatine Kinase","C113245","An enzyme complex that can reversibly convert ATP and creatine to phosphocreatine and ADP. Cytosolic creatine kinases are comprised of homodimers or heterodimers of creatine kinase B-type protein and creatine kinase M-type protein. Mitochondrial creatine kinases are octomers comprised of either four homodimers of creatine kinase U-type, mitochondrial protein or four creatine kinase S-type, mitochondrial protein homodimers.","Creatine Kinase | ATP:Creatine N-Phosphotransferase | ATP:Creatine Phosphotransferase | Adenosine Triphosphate-Creatine Transphosphorylase | CK | CPK | Creatine Phosphokinase | Creatine Phosphotransferase | Phosphocreatine Kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413896","CCN1 Gene","C113315","This gene plays a role in apoptosis, angiogenesis, heart development and many other processes.","CCN1 Gene | CCN1 | CYR61 | CYR61 Gene | CYR61 Gene | Cellular Communication Network Factor 1 Gene | Cysteine-Rich, Angiogenic Inducer, 61 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422782","ECI2 Gene","C113255","This gene is involved in the metabolism of unsaturated fatty acids.","ECI2 Gene | ECI2 | Enoyl-CoA Delta Isomerase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422480","ELAC2 Gene","C113285","This gene plays a role in the processing of transfer RNA.","ELAC2 Gene | ELAC2 | ElaC Ribonuclease Z 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830311","Ephrin-A","C113247","A family of glycosylphosphatidylinositol (GPI)-anchored proteins that are involved in forward and reverse cell-cell signaling through binding to ephrin-A receptors (EPHA).","Ephrin-A | EFNA | Ephrin A | Ephrin-A Family | Ephrin-A Ligands | Ephrin-A Protein Family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428398","EXOSC5 Gene","C113290","This gene is involved in RNA processing.","EXOSC5 Gene | EXOSC5 | Exosome Component 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416683","KLRC2 Gene","C113252","This gene plays a role in natural killer cell targeting.","KLRC2 Gene | KLRC2 | Killer Cell Lectin-Like Receptor Subfamily C, Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416870","LIPG Gene","C113269","This gene is involved in the metabolism of high density lipoproteins, triglycerides and phospholipids.","LIPG Gene |  LIPG | LIPG | Lipase, Endothelial Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416914","LRP2 Gene","C113299","This gene plays a role in receptor-mediated endocytosis.","LRP2 Gene | LRP2 | Low Density Lipoprotein Receptor-Related Protein 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537664","MARCHF9 Gene","C113305","This gene is involved in protein ubiquitination.","MARCHF9 Gene | MARCH9 | MARCH9 Gene | MARCH9 Gene | MARCHF9 | Membrane Associated Ring-CH-Type Finger 9 Gene | Membrane-Associated Ring Finger (C3HC4) 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812244","Minimal Disseminated Disease","C113242","A clinical finding that refers to the spread of a neoplastic disease to anatomic sites or systems other than the original neoplastic site through the detection of low or subclinical levels of a neoplastic marker.","Minimal Disseminated Disease | MDD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417374","MSR1 Gene","C112504","This gene plays a role in the transport of both lipoproteins and cholesterol.","MSR1 Gene | MSR1 | Macrophage Scavenger Receptor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417510","MX1 Gene","C113309","This gene plays a role in GTP hydrolysis, interferon signaling and apoptosis.","MX1 Gene | MX1 | Myxovirus (Influenza Virus) Resistance 1, Interferon-Inducible Protein p78 (Mouse) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418770","POU5F1B Gene","C113312","This gene is involved in transcriptional regulation and DNA binding.","POU5F1B Gene | POU Class 5 Homeobox 1B Gene | POU5F1B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0071899","prepro-gastrin-releasing peptide","C113250","Pre-progastrin-releasing peptide (148 aa, ~16 kDa) is encoded by the human GRP gene. This protein is involved in the regulation of both the gastrointestinal and nervous systems.","Pre-Progastrin-Releasing Peptide | Gastrin-Releasing Peptide Precursor | Prepro-GRP | PreproGRP | Pro-GRP | ProGRP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426033","PSAT1 Gene","C113276","This gene is involved in amino acid synthesis.","PSAT1 Gene | PSAT1 | Phosphoserine Aminotransferase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0072879","Quinolinic Acid","C113236","An intermediate product of the kynurenine pathway, which is responsible for the conversion of the amino acid tryptophan into nicotinamide adenine dinucleotide, with potential neurotoxic activity. If produced in excess, quinolinic acid can cross the blood-brain barrier (BBB) and function as an N-methyl-D-aspartate (NMDA) receptor agonist, which may lead to both neuronal damage and neurodegenerative brain disease. The NMDA receptor, a heterotetrameric, ligand-gated and voltage-dependent glutamate receptor, is critical for synaptic plasticity, learning and memory.","Quinolinic Acid | 2,3-Pyridinedicarboxylic Acid | Pyridine-2,3-Dicarboxylic Acid | QA | QUIN | QUINOLINIC ACID",,,,,,,,,,,,,,,"46271906","Quinolinic acid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828360","Receptor-Activated SMAD","C113248","A family of transcription factors that are activated by signaling mediated by tumor growth factor-beta (TGF-beta) superfamily ligand-receptor interactions. Once activated, R-SMADs play a role in the positive regulation of TGF-beta responsive gene expression.","Receptor-Activated SMAD | R-SMAD | R-SMADs | Receptor-Activated SMADs | Receptor-Regulated SMAD | Receptor-Regulated SMADs | rSMAD | rSMADs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420170","SLC28A2 Gene","C113318","This gene is involved in the transport of purines.","SLC28A2 Gene | SLC28A2 | Solute Carrier Family 28 (Concentrative Nucleoside Transporter), Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424316","SLC28A3 Gene","C113321","This gene plays a role in sodium-dependent nucleoside transport.","SLC28A3 Gene | SLC28A3 | Solute Carrier Family 28 (Concentrative Nucleoside Transporter), Member 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413763","VCAN Gene","C113261","This gene is involved in both cell adhesion and proteoglycan metabolism.","VCAN Gene |  VCAN | VCAN | Versican Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428113","WBP1L Gene","C113282","This gene may be involved in heme binding.","WBP1L Gene | WBP1L | WW Domain Binding Protein 1-Like Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823830","CFAP251 Gene","C113273","This gene plays a role in cilium motility.","CFAP251 Gene | CFAP251 | Cilia and Flagella Associated Protein 251 Gene | WD Repeat Domain 66 Gene | WDR66 | WDR66 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414420","EOMES Gene","C102927","This gene plays a role in both transcriptional activation and embryonic development.","EOMES Gene | EOMES | Eomesodermin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416385","IL13RA1 Gene","C41228","This gene plays a role in the modulation of cellular proliferation and signal transduction.","IL13RA1 Gene | IL13RA1 | Interleukin 13 Receptor, Alpha 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335283","PTPN6 Gene","C24708","This gene plays a role in the regulation of multiple signaling pathways in hematopoietic cells.","PTPN6 Gene | PTPN6 | Protein Tyrosine Phosphatase, Non-Receptor Type 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415478","HBA2 Gene","C75432","This gene plays a role in oxygen transport.","HBA2 Gene | HBA2 | Hemoglobin Subunit Alpha 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335224","PLAU Gene","C26581","This gene plays a role in blood coagulation and the regulation of monocyte/macrophage functions.","PLAU Gene | PLAU | Plasminogen Activator, Urokinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539518","FLCN Gene","C63514","This gene may play a role in tumor suppression.","FLCN Gene | FLCN | Folliculin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332792","CSF3R Gene","C24313","This gene plays an inhibitory role in cell survival and proliferation.","CSF3R Gene | CSF3R | Colony Stimulating Factor 3 Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334077","ID2 Gene","C28587","This gene plays a role in the regulation of both transcription and cell proliferation.","ID2 Gene | ID2 | Inhibitor of DNA Binding 2, Dominant Negative Helix-Loop-Helix Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1367466","MSMB Gene","C20804","This gene may play a role in the modulation of autocrine paracrine factor in reproductive tissues, however a specific function has not been elucidated.","MSMB Gene | MSMB | Microseminoprotein, Beta- Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515464","8q24","C13591","A chromosome band present on 8q","8q24 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333522","F3 Gene","C21098","This gene is involved in the blood coagulation process by initiating blood coagulation cascades.","F3 Gene | Coagulation Factor III, Tissue Factor Gene | F3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414224","E2F3 Gene","C96004","This gene is involved in the regulation of both transcription and cell cycle progression.","E2F3 Gene | E2F Transcription Factor 3 Gene | E2F3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812258","E2F1 Gene","C18379","This gene plays a regulatory role in G1/S cell cycle checkpoints and apoptosis.","E2F1 Gene | E2F Transcription Factor 1 Gene | E2F1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336986","WFDC1 Gene","C20806","This gene is involved in the control of cell growth.","WFDC1 Gene | WAP Four-Disulfide Core Domain 1 Gene | WFDC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4012312","Lactic Acidosis","C98969","Metabolic acidosis characterized by the accumulation of lactate in the body. It is caused by tissue hypoxia.","Lactic Acidosis | ",,,,,,,,,,,,,,,"4239233","Lactic acidosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL405282","Amrubicin","C80089","A synthetic 9-amino-anthracycline with antineoplastic activity. Amrubicin intercalates into DNA and inhibits the activity of topoisomerase II, resulting in inhibition of DNA replication, and RNA and protein synthesis, followed by cell growth inhibition and cell death. This agent has demonstrated a higher level of anti-tumor activity than conventional anthracycline drugs without exhibiting any indication of the cumulative cardiac toxicity common to this class of compounds.","Amrubicin | (+)-(7S,9S)-9-Acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)- 6,11-dihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione | AMRUBICIN | amrubicin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708690","Let-7 MicroRNA","C48183","A microRNA that has seven isofoms and is known to be a regulator of the RAS oncogene. The length of the miRNA is ~22 nucleotides, and the 3' UTR is the mechanistic path of regulation. The let-7 isoforms have been implicated in a variety of cancers, including lung and breast.","Let-7 | Let-7 MicroRNA | Let-7 miRNA | MIRLET7 | MicroRNA Let-7 | hsa-let-7 | miRNA Let-7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0908880","EWSR1/FLI1 Fusion Protein","C99205","A fusion protein encoded by the EWSR1/FLI1 fusion gene. This protein is comprised of the transactivation domain of the RNA-binding protein EWS fused to the C-terminal domain of the Friend leukemia integration 1 transcription factor protein, which includes the ETS DNA binding domain.","EWSR1/FLI1 Fusion Protein | EWS-FLI1 Fusion Protein | EWS/FLI1 Fusion Protein | EWSR1-FLI1 Fusion Protein | EWSR1::FLI1 Fusion Protein | RNA-Binding Protein EWS/Friend Leukemia Integration 1 Transcription Factor Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1860425","EWSR1/FLI1 Fusion Gene","C99202","A fusion gene that results from a chromosomal translocation t(11;22)(q24;q12) which fuses the first seven or ten exons of the EWSR1 gene with exon 5, 6 or 8 of the FLI1 gene. This rearrangement is associated with Ewing tumor/peripheral primitive neuroectodermal tumor.","EWSR1/FLI1 Fusion Gene | EWS-FLI1 Fusion Gene | EWS/FLI1 Fusion Gene | EWSR1-FLI1 | EWSR1-FLI1 Fusion Gene | EWSR1::FLI1 Fusion Gene | FLI1/EWS Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829731","Healthy Volunteer Medical History Questionnaire","C113401","A predetermined set of questions designed to identify individuals without significant health related issues to participate in a research study.","Healthy Volunteer Medical History Questionnaire | HVMHQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829754","Have Undergone a Transplant","C113402","A question about whether an individual has ever had a transplant.","Have Undergone a Transplant | Had a Transplant | Have you ever undergone an Organ, Bone Marrow or Peripheral Blood Stem Cell Transplant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829806","Have Chronic Infection","C113403","A question about whether an individual has a chronic infection.","Have Chronic Infection | Do you have a chronic infection such as HIV/AIDS, Herpes Simplex Virus, Mononucleosis, etc.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829798","Have Had Cold Sores","C113404","A question about whether an individual has a history of cold sores.","Have Had Cold Sores | Do you have a history of 'cold sores' on your lips or in your mouth | History of Cold Sores",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829813","Have Autoimmune or Inflammatory Condition","C113405","A question about whether an individual has any autoimmune or inflammatory conditions.","Have Autoimmune or Inflammatory Condition | Do you have any Autoimmune or Inflammatory conditions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829814","Have Arthritis, Rheumatism, Bursitis, Lupus or Sjogren Syndrome","C113406","A question about whether an individual has arthritis, rheumatism, bursitis, lupus or Sjogren's syndrome.","Have Arthritis, Rheumatism, Bursitis, Lupus or Sjogren Syndrome | Do you have Arthritis, Rheumatism, Bursitis, Lupus or Sjogren's Syndrome | Have Arthritis, Rheumatism, Bursitis, Lupus or Sjögren Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829804","Have Diabetes","C113407","A question about whether an individual has diabetes.","Have Diabetes | Are you Diabetic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829793","Have History of Opportunistic or Frequent Infection","C113408","A question about whether an individual has a history of opportunistic or frequent infections.","Have History of Opportunistic or Frequent Infection | Do you have a history of opportunistic or frequent infections",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829792","Have Immunodeficiency","C113409","A question about whether an individual is currently immunodeficient.","Have Immunodeficiency | Are you currently immunodeficient | Currently Immunodeficient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829799","Have Had a Tumor, Growth, Cyst, or Cancer","C113410","A question about whether an individual has or had a tumor, growth, cyst, or cancer.","Have Had a Tumor, Growth, Cyst, or Cancer | Have Had a Tumor, Growth, Cyst, or Cancer  | Have you ever had a tumor, growth, cyst or cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829815","Have Allergy","C113411","A question about whether an individual has allergies.","Have Allergy | Do you have any allergies | Have Allergies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829796","Have Had Severe Tooth or Gum Trouble","C113412","A question about whether an individual has or had severe tooth or gum trouble.","Have Had Severe Tooth or Gum Trouble | Had Severe Tooth or Gum Trouble | Have you ever had severe tooth or gum trouble",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829816","Have Adequate Moisture in Mouth","C113413","A question about whether an individual currently has adequate moisture in their mouth.","Have Adequate Moisture in Mouth | Do you feel like you have adequate moisture in your mouth right now",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830521","Dexamethasone Symptom Questionnaire","C113448","A self-administered questionnaire designed to determine the incidence, severity, and change of side effects between cycles of chemotherapy.","Dexamethasone Symptom Questionnaire | DSQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830520","Dexamethasone Symptom Questionnaire-Chronic","C113449","A self-administered questionnaire for patients with brain tumors that is designed to determine the incidence, severity, and change of side effects between cycles of chemotherapy.","Dexamethasone Symptom Questionnaire-Chronic | DSQ-Chronic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829788","Have Indigestion, Heartburn, Reflux, or Discomfort in Upper Abdomen","C113450","A question about whether an individual has or had indigestion, heartburn, reflux, or discomfort in the upper abdomen.","Have Indigestion, Heartburn, Reflux, or Discomfort in Upper Abdomen | Did you have indigestion/heartburn/reflux or discomfort in the upper abdomen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815569","Have Increased Appetite question","C113451","A question about whether an individual has or had increased appetite.","Have Increased Appetite | Have you had increased appetite | Increased Appetite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829794","Have Hiccups","C113452","A question about whether an individual has or had hiccups.","Have Hiccups | Have you had hiccups",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889988","Gaining Weight question","C113453","A question about whether an individual is gaining or has gained weight.","Have Gained Weight | Gained Weight | Gaining Weight | Gaining Weight | Have Weight Gain | Have you gained weight | I have gained weight | Weight Gain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829771","Have Rash or Acne on Face","C113454","A question about whether an individual has or had a rash or acne on their face.","Have Rash or Acne on Face | Have you had a rash/acne on your face",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829764","Have Thrush","C113455","A question about whether an individual has or had an oral yeast infection.","Have Thrush | Have you had thrush/yeast infection in your mouth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830536","Depression After Stopping Dexamethasone","C113456","A question about whether an individual had depression after stopping the use of dexamethasone.","Depression After Stopping Dexamethasone | Did you experience feelings of depression on stopping the dexamethasone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829790","Have Increased Roundness of Face","C113457","A question about whether an individual has or had an increased roundness of their face.","Have Increased Roundness of Face | Have you noticed increased roundness of your face",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827349","Have Low Mood, Sadness, or Depression","C113458","A question about whether an individual has or had a low mood, sadness, depression, or easy crying.","Have Low Mood, Sadness, or Depression | Have you experienced low mood, sadness, depression and/or easy crying",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829791","Have Increased Anger or Irritability","C113459","A question about whether an individual has or had an increase in anger or irritability.","Have Increased Anger or Irritability | Have you experienced increased levels of anger or irritability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829802","Have Difficulty Standing from a Seated Position or Walking Up Stairs","C113460","A question about whether an individual has or had difficulty standing from a seated position or walking up stairs.","Have Difficulty Standing from a Seated Position or Walking Up Stairs | Have you had difficulty standing from a seated position or walking up stairs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829772","Have Problem with Fragile Skin or Bruising","C113461","A question about whether an individual has or had a problem with their skin being fragile, easily bruised, or developing stretch marks.","Have Problem with Fragile Skin or Bruising | Have you had problems with your skin being fragile, developed stretch marks or easily bruised",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830519","Diabetes Diagnosis Since Steroid Treatment","C113463","A question about whether an individual's diabetes was diagnosed after they started steroid treatment.","Diabetes Diagnosis Since Steroid Treatment | Was the diabetes diagnosed since you started steroids (e.g. dexamethasone, prednisone)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827342","Have Trouble Controlling Blood Sugar","C113464","A question about whether an individual has or had trouble controlling their blood sugar.","Have Trouble Controlling Blood Sugar | Have you had trouble controlling your blood sugars",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829773","Have Problems Attributed to Steroids","C113465","A question about whether an individual has or had other problems they attribute to their steroid use.","Have Problems Attributed to Steroids | Have Problems Due to Steroids | Problem Noticed due to Steriod Use | What other problems have you noticed due to steroids",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828955","Most Bothersome Symptom Attributed to Steroids","C113466","A question about an individual's most bothersome symptom attributed to steroid use.","Most Bothersome Symptom Attributed to Steroids | List the most bothersome symptom you've experienced due to steriods | Most Bothersome Symptom Due to Steroids",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0854914","Bilateral Retinoblastoma","C8713","Retinoblastoma involving both eyes. This occurs in the majority of patients with the inherited variant. A minority of patient with bilateral retinoblastoma were found to have involvement of the pineal gland as well.","Bilateral Retinoblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882955","Rinsing","C65120","Wash lightly.","Rinse | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334107","Polypoid","C96279","A term that refers to a lesion that resembles a polyp.","Polypoid | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514628","Quantitative Reverse Transcriptase PCR","C28408","Quantitative PCR: a method to measure very small amounts of RNA transcripts as cDNA targets. There are two strategies currently used, one is called Competitive RTPCR and the other is called Real-Time PCR.","Quantitative Reverse Transcriptase PCR | QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION | Quantitative RTPCR | Real-Time Reverse Transcriptase PCR | qRT-PCR | qRTPCR | rRT-PCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0860814","Corrected QT Interval","C100391","The time interval between the start of the Q wave and the end of the T wave in the cardiac cycle as corrected with a non-specified correction formula.","Corrected QT Interval | QTCUNS | QTc | QTc Correction Method Unspecified | QTc Interval | QTc interval",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882513","QTcF - Fridericia's Correction Formula","C62113","A formula which takes into account the physiologic shortening of the QT interval which occurs as the heart rate increases, permitting comparison of the QT interval across a range of rates. It is mathematically defined as: QTcF = QT/CubeRootRR(seconds) and theoretically corrects the QT interval to that which would be observed at a heart rate of 1 cycle per second.","QTcF - Fridericia's Correction Formula | Fridericia's Correction Formula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882512","QTcB - Bazett's Correction Formula","C62112","A formula which takes into account the physiologic shortening of the QT interval which occurs as the heart rate increases, permitting comparison of the QT interval across a range of rates. It is mathematically defined as: QTcB = QT/SqRootRR(seconds) and theoretically corrects the QT interval to that which would be observed at a heart rate of 1 cycle per second.","QTcB - Bazett's Correction Formula | Bazett's Correction Formula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0854915","Unilateral Retinoblastoma","C8714","A retinoblastoma that only involves a single eye.","Unilateral Retinoblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697679","Infinity","C80213","A number that is greater than every real number.","Infinity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518923","Pediatric Brain Tumor Consortium","C19959","Network of medical centers that will evaluate promising treatments for children with brain malignancies.","Pediatric Brain Tumor Consortium | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0348007","Laser Ablation","C111241","Removal, separation, detachment, extirpation, or eradication of a body part, pathway, or function by light amplification by stimulated emission of radiation.","Laser Ablation | ABLATION, LASER | Photoablation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034602","Interventional Radiology","C17952","The branch of radiology concerned with the use of radiation to treat disease.","Interventional Radiology | ",,,,,,,,,,,,,,,"4247122","Interventional radiology - specialty",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704212","Embolus","C50547","A mass of clotted blood or other formed elements, such as bubbles of air, calcium fragments, etc. brought by the blood from another vessel and forced into a smaller one, thus obstructing the circulation.","Embolus | EMBOLUS | Emboli",,,,,,,,,,,,,,,"4210041","Embolus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022664","Renal Medulla","C12740","The inner part of the renal parenchyma. It consists mostly of collecting tubules and is organized in sections called pyramids.","Renal Medulla | KIDNEY, MEDULLA | Medullary Portion of Kidney | Medullary Portion of the Kidney",,,,,,,,,,,,,,,"4148798","Structure of medulla of kidney",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022655","Renal Cortex","C12739","The outer part of the renal parenchyma beneath the renal capsule. It contains glomeruli and tubules.","Renal Cortex | Cortical | Cortical Portion of Kidney | Cortical Portion of the Kidney | KIDNEY, CORTEX | Structure of cortex of kidney (body structure)",,,,,,,,,,,,,,,"4177348","Structure of cortex of kidney",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022077","Iris","C12737","The colored disc of the eye composed of connective tissue, epithelium, and endothelium. It separates the anterior chamber from the posterior chamber.","Iris | EYE, IRIS | Eye, Iris | IRIS | iris",,,,,,,,,,,,,,,"4184817","Iris structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3814874","Loss of Appetite question","C113630","A question about whether an individual has or had a loss of appetite.","Loss of Appetite | I have a loss of appetite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827340","Hearing Handicap Inventory for the Elderly, Screening Version","C113468","A 10-item questionnaire developed to assess how an individual perceives the social and emotional effects of hearing loss. It is designed to be administered face-to-face but can be given as a paper, self-reported instrument.","Hearing Handicap Inventory for the Elderly, Screening Version | HHIE-S | Hearing Handicap Inventory for the Elderly Screening Version | Screening Version of the Hearing Handicap Inventory for the Elderly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829725","Hearing Problem Causes Embarrassment When Meeting New People","C113470","A question about whether an individual's hearing problem causes them embarrassment when meeting new people.","Hearing Problem Causes Embarrassment When Meeting New People | Does a hearing problem cause you to feel embarrassed when you meet new people | Feel Embarrassed When Meeting New People Due to Hearing Problem | Hearing Problem Causes Embarrassment When Meeting New People ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829724","Hearing Problem Causes Frustration When Talking with Family","C113471","A question about whether an individual's hearing problem causes them frustration when talking with family members.","Hearing Problem Causes Frustration When Talking with Family | Does a hearing problem cause you to feel frustrated when talking to members of your family | Feel Frustrated When Talking to Members of Family Due to Hearing Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830493","Difficulty Hearing a Whisper","C113472","A question about whether an individual has or had difficulty hearing when someone speaks in a whisper.","Difficulty Hearing a Whisper | Difficulty Hearing a Whisper  | Do you have difficulty hearing when someone speaks in a whisper | Have Difficulty Hearing When Someone Speaks in a Whisper",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830161","Feel Handicapped by Hearing Problem","C113473","A question about whether an individual feels handicapped by their hearing problem.","Feel Handicapped by Hearing Problem | Do you feel handicapped by a hearing problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829726","Hearing Problem Causes Difficulty When Visiting with People","C113474","A question about whether an individual's hearing problem causes difficulty when visiting with people.","Hearing Problem Causes Difficulty When Visiting with People | Difficulty Visiting Friends, Relatives or Neighbors Due to Hearing Problem | Does a hearing problem cause you difficulty when visiting friends, relatives or neighbors | Hearing Problem Causes Difficulty When Visiting with People ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829723","Hearing Problem Causes Problem Attending Religious Services","C113475","A question about whether an individual's hearing problem causes them to attend religious services less often than desired.","Hearing Problem Causes Problem Attending Religious Services | Attend Religious Services Less Often than Like Due to Hearing Problem | Does a hearing problem cause you to attend religious services less often than you would like | Hearing Problem Causes Problem Attending Religious Services ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829729","Hearing Problem Causes Arguments with Family","C113476","A question about whether an individual's hearing problem causes arguments with family members.","Hearing Problem Causes Arguments with Family | Does a hearing problem cause you to have arguments with family members | Hearing Problem Causes Arguments with Family Members",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829727","Hearing Problem Causes Difficulty When Listening to TV or Radio","C113477","A question about whether an individual's hearing problem causes difficulty when listening to TV or radio.","Hearing Problem Causes Difficulty When Listening to TV or Radio | Difficulty Listening to TV or Radio Due to Hearing Problem | Does a hearing problem cause you difficulty when listening to TV or radio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829722","Hearing Problem Limits Personal or Social Life","C113478","A question about whether an individual's difficulty with hearing limits their personal or social life.","Hearing Problem Limits Personal or Social Life | Do you feel that any difficulty with your hearing limits or hampers your personal or social life | Personal or Social Life Hampered  Due to Hearing Problem | Personal or Social Life Hampered Due to Hearing Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829728","Hearing Problem Causes Difficulty in a Restaurant","C113479","A question about whether an individual's hearing problem causes difficulty when in a restaurant.","Hearing Problem Causes Difficulty in a Restaurant | Difficulty in Restaurant with Relatives or Friends Due to Hearing Problem | Does a hearing problem cause you difficulty when in a restaurant with relatives or friends",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348225","Solution for Reconstitution Dosage Form","C69028","A solution intended for reconstitution before administration.","Solution for Reconstitution Dosage Form | Sol for Reconstitution | Solution for Reconstitution | Solution for Reconstitution Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412096","ABCG1 Gene","C113598","This gene is involved in lipid transport.","ABCG1 Gene | ABCG1 | ATP-Binding Cassette, Sub-Family G (WHITE), Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811055","Absence of Biallelic TCRgamma Deletion","C113506","The absence of rearrangement of at least one allele of the T-cell receptor gamma gene locus. This lack of rearrangement is characteristic of early thymocyte precursors and a lack of V(D)J recombination. This genetic profile is a predictor of induction therapy failure in children with T-cell acute lymphoblastic leukemia.","Absence of Biallelic TCRgamma Deletion | ABD | Absence of Biallelic TCRgamma Locus Deletion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0051028","AICA ribonucleotide","C113498","A ribonucleotide analog of adenosine monophosphate that is an intermediate in the synthesis of inosine monophosphate with potential cardioprotective activity. During myocardial ischemia, AICA-ribotide activates AMP-dependent protein kinase (AMPK), inhibits adenosine deaminase (ADA) and causes increased synthesis of both adenosine and adenosine triphosphate (ATP). These activities prevent calcium overload, increase AMPK-dependent glucose uptake and improve blood flow to the heart. AMPK, a protein kinase complex, regulates several cellular systems including the uptake of glucose, the beta-oxidation of fatty acids, protein synthesis, and the biogenesis of both glucose transporter 4 (GLUT4) and mitochondria. ADA is a key enzyme involved in purine metabolism.","AICA-Ribotide | 1-(5'-Phosphoribosyl)-5-Amino-4-Imidazolecarboxamide | 1H-Imidazole-4-Carboxamide, 5-Amino-1-(5-O-Phosphono-Beta-D-Ribofuranosyl)- (9CI) | 5'-Phospho-Ribosyl-5-Amino-4-Imidazole Carboxamide | 5'-Phosphoribosyl-5-Amino-4-Imidazolecarboxamide | 5-Amino-1-(5-O-Phosphono-Beta-D-Ribofuranosyl)-1H-Imidazole-4-Carboxamide | 5-Amino-1-(5-Phospho-D-Ribosyl)Imidazole-4-Carboxamide | 5-Amino-4-Imidazole Carboxamide Ribonucleotide | 5-Amino-4-Imidazolecarboxamide Ribonucleoside 5'-Monophosphate | 5-Amino-4-Imidazolecarboxamide Ribotide | 5-Aminoimidazole-4-Carboxamide Ribonucleotide | 5-Phosphoribosyl-4-Carbamoyl-5-Aminoimidazole | AICA Ribonucleotide | AICA Ribotide | AICAR | Aminoimidazole Carboxamide Ribonucleotide | Imidazole-4-Carboxamide, 5-Amino-1-Beta-D-Ribofuranosyl-, 5'-(Dihydrogen Phosphate) (8CI) | ZMP | [(2R,3S,4R,5R)-5-(4-Carbamoyl-5-Aminoimidazol-1-yl)-3,4-Dihydroxyoxolan-2-yl]Methyl Dihydrogen Phosphate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412622","ATF6 Gene","C113616","This gene plays a role in both transcriptional regulation and the unfolded protein response.","ATF6 Gene | ATF6 | Activating Transcription Factor 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412739","BASP1 Gene","C113638","This gene may be involved in neurite outgrowth.","BASP1 Gene | BASP1 | Brain Abundant, Membrane Attached Signal Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0312399","Bone Specific Alkaline Phosphatase","C113515","An isoform of alkaline phosphatase found on the surface of osteoblasts. The level of this enzyme in a patient's serum is proportional to the amount of bone formation. This marker is used for monitoring the efficacy of both bone formation therapies and antiresorptive therapies.","Bone Specific Alkaline Phosphatase | Alkaline Phosphatase, Bone Specific | BAP | BSAP | Bone Alkaline Phosphatase | Bone-Specific Alkaline Phosphatase | bALP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828509","Positron Emission Tomography and Single Photon Emission Computed Tomography Scan","C111297","An imaging technique that utilizes positron emission tomography and single-photon emission computed tomography in a single machine.","Positron Emission Tomography and Single Photon Emission Computed Tomography Scan | PET/SPECT SCAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1699633","Positron Emission Tomography and Computed Tomography Scan","C103512","An imaging technique that utilizes positron emission tomography and computed tomography in a single machine.","Positron Emission Tomography and Computed Tomography Scan | PET-CT Scan | PET/CT SCAN | Positron Emission Tomography/Computed Tomography",,,,,,,,,,,,,,,"42872445","Positron emission tomography with computed tomography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL471723","Positron Emission Tomography and Magnetic Resonance Imaging","C103514","An imaging technique that utilizes positron emission tomography and magnetic resonance imaging in a single machine.","Positron Emission Tomography and Magnetic Resonance Imaging | PET-MRI Scan | PET/MRI | PET/MRI SCAN | Positron Emission Tomography/Magnetic Resonance Imaging Hybrid Imaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3472347","Digital Tomosynthesis Mammography","C70761","Mammography that uses multiple X-ray pictures of each breast to produce a 3-dimensional rendering of the entire breast.","Digital Tomosynthesis Mammography | DBT | Digital Breast Tomosynthesis | Digital Tomosynthesis of the Breast",,,,,,,,,,,,,,,"42872575","Digital breast tomosynthesis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1413049","CA6 Gene","C113531","This gene plays a role in the reversible hydration of carbon dioxide.","CA6 Gene | CA6 | Carbonic Anhydrase VI Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824675","CD177 Gene","C113573","This gene is involved in platelet function.","CD177 Gene | CD177 | CD177 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010139","Cortodoxone","C80813","A glucocorticoid that is an intermediate in the biosynthesis of cortisol in the adrenal gland.","Cortodoxone | 11-Deoxy-17-Hydroxycorticosterone | 11-Deoxycortisol | 11-Deoxyhydrocortisone | 11-Desoxy-17-Hydroxycorticosterone | 11-Desoxycortisol | 11-Desoxyhydrocortisone | 17-Alpha-Hydroxycortexone | 17-Hydroxy-11-Deoxycorticosterone | CORTODOXONE | Cortexolone | Pregn-4-ene-3,20-dione, 17,21-Dihydroxy | Pregn-4-ene-3,20-dione, 17,21-Dihydroxy-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413662","CPA1 Gene","C113582","This gene plays a role in enzyme metabolism.","CPA1 Gene | CPA1 | Carboxypeptidase A1 (Pancreatic) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830622","Cytomegalovirus MicroRNA","C113508","A sequence of single-stranded RNA, which is 20-25 nucleotides in length, that is transcribed from cytomegalovirus DNA but is not translated into a protein. This nucleic acid may regulate the transcription or translation of other cytomegalovirus or host genes.","Cytomegalovirus MicroRNA | CMV miRNA | CMV microRNA | Cytomegalovirus miRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830621","Cytomegalovirus mRNA","C113509","Any RNA molecule expressed by a cytomegalovirus strain that contains protein-coding information in its nucleotide sequence that can be translated into the amino acid sequence of a protein.","Cytomegalovirus mRNA | CMV mRNA | Cytomegalovirus Messenger RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515588","17p13 Deletion","C36424","A deletion of chromosomal material at 17p13. This chromosomal aberration includes deletion of the TP53 gene and is associated with multiple myeloma, chronic lymphocytic leukemia, acute myeloid leukemia and myelodysplastic syndrome.","del(17p13) | -17p13 | 17p13 Deletion | del(17)(p13)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011710","Desoxycorticosterone","C72737","A C-21 steroid hormone synthesized by the adrenal gland that is a precursor for cortisol and aldosterone and has potential mineralocorticoid activity.","Desoxycorticosterone | 21-Hydroxyprogesterone | DESOXYCORTONE | DOC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414056","DKC1 Gene","C113619","This gene is involved in both H/ACA small nucleolar RNA ribonucleoprotein assembly and telomerase stabilization and maintenance.","DKC1 Gene | DKC1 | Dyskeratosis Congenita 1, Dyskerin Gene | Dyskerin Pseudouridine Synthase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034798","Dopamine Receptor","C17066","A family of G protein-coupled receptors where dopamine is the primary ligand. These receptors are involved in neuroendocrine signaling.","Dopamine Receptor | Dopamine Receptor Family",,,,,,,,,,,,,,,"4292423","Dopamine receptor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1426334","EIF2AK4 Gene","C113595","This gene plays a role in protein phosphorylation.","EIF2AK4 Gene | EIF2AK4 | Eukaryotic Translation Initiation Factor 2-Alpha Kinase 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414412","ENTPD1 Gene","C113579","This gene is involved in platelet activation.","ENTPD1 Gene | ENTPD1 | Ectonucleoside Triphosphate Diphosphohydrolase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414444","ERN1 Gene","C113612","This gene is involved in both protein phosphorylation and mRNA splicing.","ERN1 Gene | ERN1 | Endoplasmic Reticulum To Nucleus Signaling 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414635","FLNA Gene","C113585","This gene is involved in remodeling of the cytoskeleton.","FLNA Gene | FLNA | Filamin A, Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423091","GPR101 Gene","C113540","This gene may play a role in receptor signaling.","GPR101 Gene | G Protein-Coupled Receptor 101 Gene | GPR101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025153","Mefloquine","C61827","A quinolinemethanol derivative with antimalarial, anti-inflammatory, and potential chemosensitization and radiosensitization activities. Although the exact mechanism remains to be elucidated, mefloquine, a weak base, preferentially accumulates in lysosomes and disrupts lysosomal function and integrity, thereby leading to host cell death. Similar to chloroquine, the chemosensitizing and radiosensitizing activities of this agent may be related to its inhibition of autophagocytosis, a cellular mechanism involving lysosomal degradation that minimizes the production of reactive oxygen species (ROS) related to tumor reoxygenation and tumor exposure to chemotherapeutic agents and radiation. Compared to chloroquine, mefloquine has better blood-brain-barrier (BBB) penetration.","Mefloquine | MEFLOQUINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827420","Wrong","C113666","Not accurate, correct, or appropriate.","Wrong | Incorrect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425936","ADGRF1 Gene","C113543","This gene plays an unknown role in cellular function.","ADGRF1 Gene | ADGRF1 | Adhesion G Protein-Coupled Receptor F1 Gene | G Protein-Coupled Receptor 110 Gene | GPR110 | GPR110 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415407","MACROH2A1 Gene","C113622","This gene plays a role in nucleosome structure.","MACROH2A1 Gene | H2A Histone Family, Member Y Gene | H2AFY | H2AFY Gene | H2AFY Gene | MACROH2A1 | MacroH2A.1 Histone Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421934","HDAC8 Gene","C113605","This gene is involved in the modification of histone proteins.","HDAC8 Gene | HDAC8 | Histone Deacetylase 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415529","HJV Gene","C113602","This gene plays a role in iron metabolism and bone morphogenetic protein (BMP) receptor signaling.","HJV Gene | HFE2 | HFE2 Gene | HFE2 Gene | HJV | Hemochromatosis Type 2 (Juvenile) Gene | Hemojuvelin BMP Co-Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1098634","HLA Class I Histocompatibility Antigen, A-2402 Alpha Chain","C113514","HLA class I histocompatibility antigen, A-2402 alpha chain (365 aa, ~41 kDa) is encoded by the human HLA-A gene. This protein is involved in the presentation of foreign antigens to the immune system. This isoform is associated with increased risk of type 1 diabetes and thymoma-induced myasthenia gravis.","HLA Class I Histocompatibility Antigen, A-2402 Alpha Chain | A*24:02 | A*24:02:01:01 | HLA-A*2402 | HLA-A*2402101 | HLA-A24.2 | HLA-A2402 | HLA-A2402 Antigen | Leukocyte Antigen Class I-A2402 | MHC Class I Antigen A*2402 | MHC Class I Antigen HLA-A2402 Heavy Chain | Major Histocompatibility Complex, Class I, A*2402 | Major Histocompatibility Complex, Class I, A*2402;  | Major Histocompatibility Complex, Class I, A2402",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829570","IGH/CRLF2 Fusion Gene","C113512","A fusion gene that results from a chromosomal translocation, either t(X;14)(p22;q32) or t(Y;14)(p11;q32), which fuses the transcriptional enhancers of the IGH gene locus with regulatory regions of the CRLF2 gene. This rearrangement is associated with acute lymphoblastic leukemia and expression of this fusion gene results in overexpression of the cytokine receptor-like factor 2 protein.","IGH/CRLF2 Fusion Gene | IGH-CRLF2 Fusion Gene | IGH::CRLF2 Fusion Gene | IGH@-CRLF2 Fusion Gene | IGH@/CRLF2 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416161","JCHAIN Gene","C113522","This gene plays a role in antibody-mediated immunity.","JCHAIN Gene | IGJ | IGJ Gene | Immunoglobulin J Polypeptide, Linker Protein for Immunoglobulin Alpha and Mu Polypeptides Gene | JCHAIN | Joining Chain of Multimeric IgA and IgM Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826992","Immature Myeloid Cell","C113503","Hematopoietic cells that express the common myeloid marker CD33 but do not express the MHC class II molecule HLA-DR or other markers of mature myeloid or lymphoid cells. An accumulation of these cells may be associated with a decreased number of dendritic cells in the peripheral blood of patients with head and neck, lung or breast cancer.","Immature Myeloid Cell | IMC | ImC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829001","Partial Tandem Duplication of MLL","C113507","A chromosomal rearrangement where exons 5 through 11 or 5 through 12 of the MLL gene are duplicated and inserted upstream of exon 4 of the gene. This duplication results in transcripts and proteins that have the N-terminal region, which contains the AT hook DNA-binding motifs, and the transcriptional repression domain duplicated. This mutation is associated with myelodysplastic syndrome (MDS) and susceptibility of MDS progression to acute myeloid leukemia.","KMT2A Partial Tandem Duplication | KMT2A PTD | KMT2A-PTD | MLL Partial Tandem Duplication | MLL Partial Tandem Duplication | MLL-PTD | Partial Tandem Duplication of MLL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2678527","NRARP Gene","C113608","This gene plays a role in both signal transduction and blood vessel patterning.","NRARP Gene | NOTCH-Regulated Ankyrin Repeat Protein Gene | NRARP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417853","NRXN3 Gene","C113536","This gene is involved in cell recognition and cell adhesion.","NRXN3 Gene | NRXN3 | Neurexin 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538532","OLFM4 Gene","C113592","This gene is involved in apoptosis regulation.","OLFM4 Gene | OLFM4 | Olfactomedin 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418575","PIK3CD Gene","C113628","This gene plays a role in the initiation of second messenger signaling.","PIK3CD Gene | PIK3CD | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Delta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815181","Platinum-Group Metal","C113467","Six transition metals (iridium, osmium, palladium, platinum, rhodium, and ruthenium) clustered in the d-block of the periodic table (groups 8, 9, and 10, periods 5 and 6) with potential antibiotic and chemotherapeutic activities. Administration of agents containing platinum-group metals can produce DNA crosslinks and adducts in rapidly dividing cells, which can lead to bacterial lysis or eukaryotic cell apoptosis. Additionally, these elements are highly resistant to chemical and thermal challenges, which allow these metals to be used in many industrial applications.","Platinum-Group Metal | PGE | PGM | Platidise | Platinide | Platinoid | Platinum Family | Platinum Group | Platinum Metal | Platinum-Group Element",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418667","PLXNC1 Gene","C113625","This gene is involved in both semaphorin recognition and signal transduction.","PLXNC1 Gene | PLXNC1 | Plexin C1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418755","PON2 Gene","C113555","This gene may play a role as a cellular antioxidant.","PON2 Gene | PON2 | Paraoxonase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033362","Proinsulin","C113517","Proinsulin (110 aa, ~12 kDa) is encoded by the human INS gene. This protein plays a role in the modulation of glucose metabolism.","Proinsulin | INS | Insulin Precursor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3178914","Regulatory B Cell","C113502","A subset of B-cells that can negatively regulate immune responses mediated by T-cells. These B-lymphocytes produce interleukin-10.","Regulatory B Cell | Breg | Bregs | Regulatory B Lymphocyte | Regulatory B-Cell | Regulatory B-Lymphocyte",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419338","REN Gene","C113589","This gene plays a role in angiotensin metabolism.","REN Gene | REN | Renin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426906","RETN Gene","C113641","This gene plays a role in the modulation of insulin activity.","RETN Gene | RETN | Resistin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2239883","RGL4 Gene","C113576","This gene plays a role in guanyl-nucleotide metabolism.","RGL4 Gene | RGL4 | Ral Guanine Nucleotide Dissociation Stimulator-Like 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828301","ROR1 Antibody","C113510","Any immunoglobulin that recognizes tyrosine-protein kinase transmembrane receptor ROR1.","ROR1 Antibody | Anti-NTRKR1 Antibody | Anti-ROR1 Antibody | Anti-Receptor Tyrosine Kinase-Like Orphan Receptor 1 Antibody | Anti-Tyrosine-Protein Kinase Transmembrane Receptor ROR1 Antibody | NTRKR1 Antibody | Receptor Tyrosine Kinase-Like Orphan Receptor 1 Antibody | Tyrosine-Protein Kinase Transmembrane Receptor ROR1 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539719","S100Z Gene","C113558","This gene plays a role in calcium ion binding.","S100Z Gene | S100 Calcium Binding Protein Z Gene | S100Z",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036228","Sarcosine","C113501","An amino acid that is an intermediate and byproduct in glycine synthesis and degradation with potential anti-depressant and anti-schizophrenic activities. Sarcosine is a product of dietary consumption of choline and creatine and is rapidly converted into glycine. Oral administration of sarcosine with certain antipsychotics may cause increased glycine concentration in the brain, which may lead to increased NMDA receptor activation and a reduction in symptoms.","Sarcosine | (Methylamino)Acetic Acid | (Methylamino)Ethanoic Acid | Acetic Acid, (Methylamino)- | Glycine, N-Methyl- | Methylglycine | N-Methylaminoacetic Acid | N-Methylglycine | SARCOSINE | Sarcosinic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425495","SCGB1D2 Gene","C113533","This gene is involved in steroid binding.","SCGB1D2 Gene | SCGB1D2 | Secretoglobin, Family 1D, Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417139","SCGB2A2 Gene","C113518","This gene may be involved in mammary development.","SCGB2A2 Gene | SCGB2A2 | Secretoglobin Family 2A Member 2 Gene | Secretoglobin, Family 2A, Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419956","SEMA6A Gene","C113552","This gene plays a role in development of the central nervous system.","SEMA6A Gene | SEMA6A | Sema Domain, Transmembrane Domain (TM), and Cytoplasmic Domain, (Semaphorin) 6A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415492","SERPIND1 Gene","C113635","This gene plays a role in thrombin inhibition.","SERPIND1 Gene | SERPIND1 | Serpin Peptidase Inhibitor, Clade D (Heparin Cofactor), Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420138","SLC22A3 Gene","C113561","This gene is involved in membrane potential-dependent transport of organic cations.","SLC22A3 Gene | SLC22A3 | Solute Carrier Family 22 (Organic Cation Transporter), Member 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427914","SLC29A4 Gene","C113570","This gene plays a role in transport of monoamines.","SLC29A4 Gene | SLC29A4 | Solute Carrier Family 29 (Equilibrative Nucleoside Transporter), Member 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1853262","SLC47A1 Gene","C113564","This gene plays a role in secretion of cationic drugs across brush border membranes.","SLC47A1 Gene | SLC47A1 | Solute Carrier Family 47 (Multidrug and Toxin Extrusion), Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1853261","SLC47A2 Gene","C113567","This gene is involved in excretion of toxic electrolytes.","SLC47A2 Gene | SLC47A2 | Solute Carrier Family 47 (Multidrug and Toxin Extrusion), Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420213","SLC6A3 Gene","C113524","This gene plays a role in dopamine uptake.","SLC6A3 Gene | SLC6A3 | Solute Carrier Family 6 (Neurotransmitter Transporter), Member 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828720","SPATS2L Gene","C113526","This gene is involved in protection from oxidative stress.","SPATS2L Gene | SPATS2L | Spermatogenesis Associated, Serine-Rich 2-Like Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827872","t(14;16)(q32;q23)","C113504","A chromosomal translocation between 14q32 and 16q23. This rearrangement is associated with MAF protein overexpression in plasma cell myeloma.","t(14;16)(q32;q23) | IGH-MAF Translocation | IGH/MAF Translocation | IGH@-MAF Translocation | IGH@/MAF Translocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827870","t(9;11)","C113505","A translocation between chromosome 9 and chromosome 11.","t(9;11) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827818","TMPRSS2/ETS Family Fusion Gene","C113511","A fusion gene that results from a chromosomal translocation which fuses the 5' end of the TMPRSS2 gene upstream of the coding region of an ETS family gene. This rearrangement is associated with prostate carcinoma and androgen-dependent expression of this fusion gene results in overexpression of ETS transcription factor family proteins.","TMPRSS2/ETS Family Fusion Gene | TMPRSS2-ETS Family Fusion Gene | TMPRSS2-ETS Fusion Gene | TMPRSS2-ETS Transcription Factor Family Fusion Gene | TMPRSS2-ETS Transcription Factor Gene Fusion Gene | TMPRSS2/ETS Fusion Gene | TMPRSS2/ETS Transcription Factor Family Fusion Gene | TMPRSS2/ETS Transcription Factor Gene Fusion Gene | TMPRSS2::ETS Family Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421328","UGT1A4 Gene","C113632","This gene is involved in xenobiotic metabolism.","UGT1A4 Gene | UDP Glucuronosyltransferase 1 Family, Polypeptide A4 Gene | UGT1A4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421347","UGT8 Gene","C113546","This gene is involved in galactocerebroside synthesis.","UGT8 Gene | UDP Glycosyltransferase 8 Gene | UGT8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1832049","Elotuzumab","C66982","A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells.","Elotuzumab | BMS 901608 | BMS-901608 | BMS901608 | ELOTUZUMAB | Empliciti | HuLuc-63 | HuLuc63 | PDL 063 | PDL-063 | PDL063",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2830202","Ixazomib Citrate","C82653","The citrate salt form of ixazomib, an orally bioavailable second generation proteasome inhibitor (PI) with potential antineoplastic activity. Ixazomib inhibits the activity of the proteasome, blocking the targeted proteolysis normally performed by the proteasome, which results in an accumulation of unwanted or misfolded proteins; disruption of various cell signaling pathways may follow, resulting in the induction of apoptosis. Compared to first generation PIs, second generation PIs may have an improved pharmacokinetic profile with increased potency and less toxicity. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquinated.","Ixazomib Citrate | 1,3,2-dioxaborinane-4-acetic acid, 4-carboxy-2-((1r)-1-((2-((2,5-dichlorobenzoyl)amino)acetyl)amino)-3-methylbutyl)-6-oxo- | IXAZOMIB CITRATE | MLN 9708 | MLN-9708 | MLN9708 | Ninlaro | Proteasome Inhibitor MLN9708",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883554","Wedge-Shaped Growth Pattern","C62464","A morphologic architectural pattern in which the tumor cells spread in a wedge-shaped pattern.","Wedge-Shaped Growth Pattern | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334078","IFITM1 Gene","C24480","This gene is involved in the regulation of cell growth and proliferation. It also plays a role in immunity/defense.","IFITM1 Gene | IFITM1 | Interferon Induced Transmembrane Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425248","TP53INP1 Gene","C92490","This gene plays a role in the regulation of apoptosis.","TP53INP1 Gene | TP53INP1 | Tumor Protein p53 Inducible Nuclear Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881367","Revlimid-Dexamethasone Regimen","C64732","A regimen consisting of lenalidomide and dexamethasone that can be used in the treatment of plasma cell myeloma and systemic light chain amyloidosis.","Dexamethasone/Lenalidomide Regimen | Lenalidomide and Dexamethasone (RD) | Lenalidomide and Dexamethasone (Rd) | Lenalidomide-Dexamethasone Regimen | Lenalidomide-Dexamethasone Regimen | Lenalidomide/Dexamethasone | RD Regimen | Revlimid-Dexamethasone Regimen | Revlimid/Dexamethasone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332743","CDX2 Gene","C24292","This gene plays a role in transcriptional initiation, embryonic axial elongation and patterning.","CDX2 Gene | CDX2 | Caudal Type Homeobox 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986942","t(4;14)","C95145","A chromosomal translocation that involves the chromosomes 4 and 14.","t(4;14) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418577","PIK3R2 Gene","C101283","This gene is involved in the regulation of receptor tyrosine kinase activity.","PIK3R2 Gene | PIK3R2 | Phosphoinositide-3-Kinase Regulatory Subunit 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812273","SMARCB1 Gene","C18394","This gene plays a role in chromatin remodeling and regulation of transcription.","SMARCB1 Gene | SMARCB1 | SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily B, Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333218","DICER1 Gene","C25956","This gene is involved in the RNA interference pathway.","DICER1 Gene | DICER1 | Dicer 1, Ribonuclease III Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012873","DNA Modification Methylases","C16508","DNA Methyltransferases are a subclass of transferase enzymes that catalyze the transfer of a methyl group from a donor compound to DNA.","DNA Methyltransferase | DNA MTase | DNA Modification Methylase | DNA methylase | DNA methyltransferase | DNA-Methyltransferase | Dnmt | Site-Specific DNA-methyltransferase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812377","SPINK1 Gene","C18448","This gene plays a role in the negative regulation of proteolysis.","SPINK1 Gene | SPINK1 | Serine Peptidase Inhibitor Kazal Type 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0518609","Consideration","C113416","Careful thought or deliberation.","Consideration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423740","GATA5 Gene","C60657","This gene is involved in transcriptional regulation.","GATA5 Gene | GATA Binding Protein 5 Gene | GATA5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828433","QTcB Prolongation","C107098","An electrocardiographic finding in which the QT interval corrected for heart rate using Bazett's formula is prolonged. Thresholds for different age, gender, and patient populations exist. (CDISC)","QTcB Prolongation | PROLONGED QTcB | QTCB PROLONGATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029944","Overdose","C50873","Exposure to, or intake of, an excessive amount of a substance.","Overdose | overdose",,,,,,,,,,,,,,,"607147","Overdose",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332012","ACVR1 Gene","C21267","This gene plays a role in the transforming growth factor-beta signal transduction pathway through serine/threonine specificity.","ACVR1 Gene | ACVR1 | Activin A Receptor Type 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420317","SOX10 Gene","C102891","This gene is involved in both transcriptional regulation and anatomic structure morphogenesis.","SOX10 Gene | SOX10 | SRY (Sex Determining Region Y)-Box 10 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417172","MITF Gene","C70584","This gene is involved in transcriptional promotion in melanocytes.","MITF Gene | MITF | Melanocyte Inducing Transcription Factor Gene | Microphthalmia-Associated Transcription Factor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021701","Integrins","C16748","Integrins are transmembrane glycoprotein receptors that mediate cell-matrix or cell-cell adhesion, and transduce signals that regulate gene expression and cell growth.  They are heterodimeric molecules consisting of noncovalently linked alpha and beta subunits. Different combinations of alpha and beta polypeptides form complexes that vary in their ligand-binding specificities. Both alpha and beta subunits display a cytoplasmic domain that interacts with the cytoskeleton (and possibly signaling molecules), a transmembrane region, and a large extracellular domain that interacts with the extracellular matrix. (from OMIM 147557)","Integrin | Extracellular Matrix, Integrins | Integrin Receptor | RGD Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537570","LGR5 Gene","C101484","This gene plays a role in receptor-mediated signaling.","LGR5 Gene | LGR5 | Leucine-Rich Repeat Containing G Protein-Coupled Receptor 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335214","PIK3CG Gene","C24673","This gene is involved in cell adhesion, signal transduction and maintenance of the structural and functional integrity of epithelia.","PIK3CG Gene | PIK3CG | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335213","PIK3CB Gene","C24672","This gene is involved in phosphorylation of phosphatidylinositol derivatives, apoptosis, cell growth and angiogenesis.","PIK3CB Gene | PIK3CB | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332662","CASP2 Gene","C26566","This gene is involved in either the promotion or inhibition of apoptosis depending on both the cell lineage and stage of development.","CASP2 Gene | CASP2 | Caspase 2, Apoptosis-Related Cysteine Protease Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414326","EIF2AK3 Gene","C102827","This gene plays a role in the regulation of translation.","EIF2AK3 Gene | EIF2AK3 | Eukaryotic Translation Initiation Factor 2 Alpha Kinase 3 Gene | Eukaryotic Translation Initiation Factor 2-Alpha Kinase 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336631","TINF2 Gene","C20564","This gene plays a role in the regulation of telomere length.","TINF2 Gene | TERF1 Interacting Nuclear Factor 2 Gene | TINF2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0694884","MEN1 Gene","C18254","This gene is involved in transcriptional regulation and has tumor suppressor activity.","MEN1 Gene | MEN1 | Menin 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333203","DAXX Gene","C24330","This gene plays a role in signal transduction, regulation of transcription and enhancement of apoptosis.","DAXX Gene | DAXX | Death-Domain Associated Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3275246","P2RY8/CRLF2 Fusion Gene","C99389","A fusion gene that results from an intrachromosomal deletion of the pseudoautosomal region 1of Xp22.3 and Yp11.3 which fuses the noncoding exon 1 of the P2RY8 gene to the entire coding region of the CRLF2 gene. This rearrangement is associated with Down syndrome-associated acute lymphoblastic leukemia.","P2RY8/CRLF2 Fusion Gene | CRLF2/P2RY8 Fusion Gene | P2RY8-CRLF2 Fusion Gene | P2RY8::CRLF2 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332670","CAV2 Gene","C21585","This gene is involved in apoptosis, cell growth regulation and signal transduction.","CAV2 Gene | CAV2 | Caveolin 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416407","IL21R Gene","C68736","This gene is involved in cytokine recognition.","IL21R Gene | IL21R | Interleukin 21 Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334347","MUCL1 Gene","C20800","This gene plays a role in cancer cell metastasis.","MUCL1 Gene | MUCL1 | Mucin-Like 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538440","CFH Gene","C97209","This gene is involved in the alternative pathway of complement activation.","CFH Gene | CFH | Complement Factor H Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334873","NDRG1 Gene","C24625","This gene plays a role in cellular stress responses. It is also involved in both cell growth and differentiation.","NDRG1 Gene | N-myc Downstream Regulated Gene 1 Gene | NDRG1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416657","KLF1 Gene","C84289","This gene is involved in both transcriptional regulation and erythrocyte differentiation.","KLF1 Gene | KLF1 | Kruppel Like Factor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413850","CYLD Gene","C92678","This gene is involved in protein deubiquitination.","CYLD Gene | CYLD | CYLD Lysine 63 Deubiquitinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009195","Cochlea","C12395","The snail shell-shaped auditory component of the inner ear. It contains the sensory organ of hearing.","Cochlea | Cochlear | Cochlear Organ | Cochlear structure (body structure) | EAR, COCHLEA",,,,,,,,,,,,,,,"4196642","Cochlear structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034790","T-Cell Receptor","C17065","Heterodimeric antigen receptors present on the surface of T-cells.  Two T-cell antigen receptors have been identified, consisting of heterodimeric 40-55 kD Ig-like alpha/beta or gamma/delta integral membrane glycoproteins.  Genes for TCR alpha, beta, gamma, and delta subunits are assembled during T-cell development by somatic rearrangement of germline gene segments, resembling B-cell Ig genes in their mechanisms of diversity generation and activation of expression.  Alpha/beta heterodimers are found on helper and cytotoxic T-cells and are specific for antigenic peptides presented by MHC gene products.  T-cells expressing gamma/delta heterodimers directly recognize proteins and non-proteinacious phospho-ligands.  T-cell receptors are non-covalently associated with CD3, forming the TCR-CD3 complex.  TCRs activate MAPKs and JNK1 through the CD3 antigens, the adaptor protein LAT, and tyrosine kinases LCK and ZAP70.  (from OMIM and NCI)","T-Cell Receptor | MHC Receptor | Major Histocompatibility Complex Receptor | TCR",,,,,,,,,,,,,,,"4217617","T-cell antigen receptor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1521610","Chromosome 7 Short Arm","C13561","Proximal (short) arm of chromosome 7","7p | Chromosome 7 Proximal Arm | Chromosome 7 Short Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517481","Gene Amplification or Deletion Detection","C19133","Typically, the use of hybridization techniques to detect amplification or deletion of specific DNA sequences.  The hybridization signal of a specific sequence is compared to that of a reference sequence, usually one known to be present once per haploid genome.","Gene Amplification or Deletion Detection | Gene Amplification Deletion and Detection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1135650","Basal Transcription Factor","C19851","Basal Transcription Factors are prokaryotic and eukaryotic proteins that cooperate with DNA-dependent RNA polymerases to initiate, inhibit or terminate transcription.","Basal Transcription Factor | General Transcription Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520599","14q32","C13941","A chromosome band present on 14q","14q32 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273253","Complex Karyotype","C97138","Karyotype with at least three chromosomal aberrations.","Complex Karyotype | Complex | Complex Chromosomal Abnormality | Complex Cytogenetic Abnormality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541269","Eastern Cooperative Oncology Group Performance Status Questionnaire","C102116","Eastern Cooperative Oncology Group (ECOG) Performance Status (Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55). CDISC believes this instrument to be in the public domain, but you should perform your own assessment.","Eastern Cooperative Oncology Group Performance Status Clinical Classification | ECOG | ECOG1 | Eastern Cooperative Oncology Group Performance Status Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826855","Extended-Field Radiation Therapy","C113811","Radiation treatment delivered to large areas of the body, used primarily in patients with Hodgkin lymphoma. It involves the treatment of the lymph nodes that are affected by the disease, as well as the surrounding lymph node areas that the disease may have affected but is not clinically detected.","Extended-Field Radiation Therapy | EFRT | Extended field radiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826993","Involved-Field Radiation Therapy","C113812","Radiation treatment delivered only to the areas of the body that are affected, used primarily in the treatment of lymphoma.","Involved-Field Radiation Therapy | IFRT | Involved field radiotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826991","Involved Node Radiation Therapy","C113813","Radiation treatment delivered only to the lymph nodes originally involved, used primarily in the treatment of Hodgkin lymphoma.","Involved Node Radiation Therapy | INRT | Involved node radiation therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1739768","Rivaroxaban","C77995","An orally bioavailable oxazolidinone derivative and direct inhibitor of the coagulation factor Xa with anticoagulant activity. Upon oral administration, rivaroxaban selectively binds to both free factor Xa and factor Xa bound in the prothrombinase complex. This interferes with the conversion of prothrombin (factor II) to thrombin and eventually prevents the formation of cross-linked fibrin clots. Rivaroxaban does not affect existing thrombin levels.","Rivaroxaban | 5-Chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)- 1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide | BAY 59 7939 | BAY 59-7939 | BAY 597939 | BAY-59-7939 | BAY597939 | RIVAROXABAN | Xarelto",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0815211","Social Setting","C102712","The surroundings or environment in which social activities occur.","Social Setting | SOCIAL SETTING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706208","Butchered","C53477","To slaughter or prepare an animal for market.","Butcher | Butchered | Butchering",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541261","CD4 Expressing Cell Count","C103810","The determination of the amount of the CD4 expressing cells in a sample.","CD4 Expressing Cell Count | CD4 | CD4 Count | CD4 Expressing Cells | cd4 count | cd4_count",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0562508","Emergency Room","C53513","The section of a hospital staffed and equipped to provide immediate medical treatment.","Emergency Room | EMER | EMERGENCY ROOM | Emergency | Emergency Care Center | Emergency Care Clinic | Emergency Care Clinic or Center | Emergency Department | Emergency Department - Hospital | Emergency Room - Hospital | Hospital Emergency Department | Hospital Emergency Room",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333694","Tetraploidy","C28450","A numerical chromosomal abnormality characterized by the presence of four complete sets of chromosomes.","Tetraploidy | Tetraploid",,,,,,,,,,,,,,,"37117272|4266846","Tetraploidy|Tetraploidy",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3536727","Triploidy","C8324","A numerical chromosomal abnormality characterized by the presence of three complete sets of chromosomes.","Triploidy | Triploid",,,,,,,,,,,,,,,"4032926|4282915","Triploidy|Triploidy syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0860896","Monoclonal Band","C113808","Monoclonal immunoglobulin or monoclonal light chain that is present in the serum and/or urine. It is the result of a clonal B-cell or plasma cell proliferation.","Monoclonal Band | M Protein Present | M Spike Present | M-Band | M-Band Present | M-Protein | M-Protein Present | M-Spike | M-Spike Present | Monoclonal Band Present | Monoclonal Protein Detected | Monoclonal Protein Positive | Monoclonal Protein Present | Monoclonal Spike | Monoclonal Spike Present | Paraprotein Present",,,,,,,,,,,,,,,"4186275","Paraprotein detected",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4048246","Oligoclonal Bands","C113809","The presence of more than one immunoglobulin band in the serum, urine, or cerebrospinal fluid. It usually results from infectious or immunologic disorders.","Oligoclonal Bands | OCBs | Oligoclonal Band | Oligoclonal Bands Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827339","High Sensitivity Troponin T Assay","C113810","A chemiluminescence immunoassay capable of detecting very low levels of troponin T in serum.","High Sensitivity Troponin T Assay | High Sensitivity Troponin T | High-Sensitivity Cardiac Troponin T Assay | High-Sensitivity Troponin T Assay | Trop-T HS | Troponin-T HS | hs-cTnT | hsTnT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826866","Bortezomib/Cyclophosphamide/Dexamethasone Regimen","C113826","A regimen consisting of bortezomib, cyclophosphamide and dexamethasone that can be used in the treatment of plasma cell (multiple) myeloma and systemic light chain amyloidosis. A dose-modified version may be used for the treatment of systemic light chain amyloidosis.","Bortezomib/Cyclophosphamide/Dexamethasone Regimen | CyBor-D | CyBorD | VCD | VDC | Velcade-Cyclophosphamide-Dexamethasone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810643","Bortezomib/Dexamethasone/Lenalidomide Regimen","C113827","A regimen consisting of bortezomib, dexamethasone and lenalidomide that can be used in the treatment of plasma cell (multiple) myeloma and systemic light chain amyloidosis.","RVD Regimen | Bortezomib/Dexamethasone/Lenalidomide | Bortezomib/Dexamethasone/Lenalidomide Regimen | Bortezomib/Dexamethasone/Lenalidomide Regimen | Bortezomib/Lenalidomide/Dexamethasone | Lenalidomide/Bortezomib/Dexamethasone Regimen | Lenalidomide/Bortezomib/Dexamethasone Regimen | RVD | Revlimid/Velcade/Dexamethasone | VRD | VRd | Velcade/Revlimid/Dexamethasone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810531","Bortezomib/Dexamethasone/Pegylated Liposomal Doxorubicin Regimen","C113828","A regimen consisting of bortezomib, dexamethasone and pegylated liposomal doxorubicin that can be used in the treatment of plasma cell (multiple) myeloma.","Bortezomib/Dexamethasone/Pegylated Liposomal Doxorubicin Regimen | Bortezomib/Doxil/Dexamethasone | Bortezomib/Liposomal Doxorubicin/Dexamethasone | Bortezomib/Pegylated Liposomal Doxorubicin/Dexamethasone | DVD | PAD (Pegylated liposomal doxorubicin substituted) | VDD | Velcade/Doxil/Dexamethasone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827305","16-Hydroxyestrogen","C113817","Any metabolite formed during the catabolism of estrogens by the liver through the hydroxylation of the carbon at position 16 by the enzymes, cytochrome P450 3A4 and 1B1. The 16-hydroxyestrogens may have high estrogenic activity and preferential formation of 16-hydroxyestrogen metabolites may be associated with an elevated risk for breast cancer.","16-Hydroxyestrogen | 16-Hydroxyestrogen Compound | 16-Hydroxyestrogens",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831771","2-Hydroxyestrogen","C113816","Any metabolite formed during the catabolism of estrogens by the liver through the hydroxylation of the carbon at position 2 by various cytochrome P450 (CYP) enzymes, including CYP3A4, 1A1 and 1A2. The 2-hydroxyestrogens have minimal estrogenic activity compared to the parent compounds.","2-Hydroxyestrogen | 2-Hydroxyestrogen Compound | 2-Hydroxyestrogens",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412296","AHSG Gene","C113821","This gene is involved in bone mineralization.","AHSG Gene | AHSG | Alpha-2-HS-Glycoprotein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0312594","Brachyury Protein Antibody","C113840","Any immunoglobulin that recognizes brachyury protein (protein T).","Brachyury Protein Antibody | Anti-Brachyury | Anti-Brachyury Antibody | Anti-Brachyury Protein | Anti-Brachyury Protein Antibody | Anti-Protein T | Anti-Protein T Antibody | Anti-Protein T Antibody  | Anti-T | Anti-T Antibody | Anti-T Protein | Anti-T Protein Antibody | Brachyury Antibody | Protein T Antibody | T Protein Antibody",,,,,,,,,,,,,,,"4300535","T cell antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1414431","EPHB4 Gene","C113830","This gene plays a role in both ephrin-B binding and signal transduction.","EPHB4 Gene | EPH Receptor B4 Gene | EPHB1 | EPHB4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415712","HPX Gene","C113818","This gene plays a role in both heme binding and iron metabolism.","HPX Gene | HPX | Hemopexin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811709","Hypoxia Inducible Factor Family","C113839","A family of basic helix-loop-helix heterodimeric transcription factors that activate gene expression when oxygen levels decrease in the cellular environment. Each HIF complex is comprised of an alpha subunit and beta subunit, which are encoded by separate genes.","Hypoxia Inducible Factor Family | HIF | HIF Factor | HIF Family | Hypoxia Inducible Factor | Hypoxia-Inducible Factor | Hypoxia-Inducible Factor Family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426200","IL31 Gene","C113834","This gene is involved in immunity.","IL31 Gene | IL31 | Interleukin 31 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812726","Melanoma-Associated Antigen Family","C113841","A family of proteins that were first detected in male germ cells, placenta and various tumors that were originally not found in normal tissues. Their genes are located in four clusters on the X chromosome. All of the members of the family share a stretch of about 200 amino acids, called the MAGE conserved domain, which is usually located near the C-terminal end of the protein and may allow MAGE proteins to interact with cellular receptors. For most members their entire coding sequences are located in the last exon of their respective genes.","Melanoma-Associated Antigen Family |  MAGE | MAGE | MAGE Family | Melanoma-Associated Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0682638","Memory B-Lymphocyte","C13123","A subset of mature B-lymphocytes that are formed during primary antigen exposure, survive for many years after the infection has resolved and maintain specificity toward the primary antigen. These cells can quickly produce a large amount of antigen-specific antibodies in response to a subsequent exposure.","Memory B-Lymphocyte | Memory B Cell | Memory B Lymphocyte | Memory B-Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1257975","Mesenchymal Stem Cell","C43423","An undifferentiated stromal cell with the ability to develop into the cells that form distinct mesenchymal tissues; such as bone, muscle, connective tissue, blood vessels, and lymphatic tissue.","Mesenchymal Stem Cell | MPC | Mesenchymal Progenitor Cell",,,,,,,,,,,,,,,"4170237","Mesenchymal stem cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0083792","Notch Family","C113838","A family of transmembrane receptors with multiple extracellular EGF repeats and a DSL (notch) domain. These proteins interact with their cell-bound ligands (from the delta and serrate protein families). This interaction stimulates cell-cell signaling pathways that regulate cell fate decisions during embryogenesis.","Notch Family | DSL Protein | Notch Protein | Notch Receptor Family | Notch Receptors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0072497","Protoporphyrin IX","C785","A tetrapyrrole containing 4 methyl, 2 propionic and 2 vinyl side chains that is a metabolic precursor for hemes, cytochrome c and chlorophyll. Protoporphyrin IX is produced by oxidation of the methylene bridge of protoporphyrinogen by the enzyme protoporphyrinogen oxidase.","Protoporphyrin IX | 2,18-Porphinedipropionic acid, 3,8,13,17-tetramethyl-7,12-divinyl- (8CI) | 21H,23H-Porphine-2,18-dipropanoic acid, 7,12-diethenyl-3,8,13,17-tetramethyl- | 21H,23H-Porphine-2,18-dipropanoic acid, 7,12-diethenyl-3,8,13,17-tetramethyl-;  | 3,3'-(3,7,12,17-Tetramethyl-8,13-divinylporphine-2,18-diyl)di(propionic acid) | 3,3'-(3,7,12,17-Tetramethyl-8,13-divinylporphine-2,18-diyl)di(propionic acid);  | 3,3'-(3,7,12,17-tetramethyl-8,13-divinyl-21H,23H-porphine-2,18-diyl)-bis-propionic acid | 3,7,12,17-Tetramethyl-8,13-divinyl-2,18-porphinedipropionic Acid | 3,7,12,17-tetramethyl-8,13-divinylporphyrin-2,18-dipropanoic acid | 7,12-diethenyl-3,8,13,17-tetramethylporphyrin-2,18-dipropanoic acid | Ooporphyrin | PROTOPORPHYRIN | PpIX | Protoporphyrin | Protoporphyrin | Protoporphyrin IX | Protoporpyrin IX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2936411","T Helper 17 Cell","C113815","A subset of helper T-lymphocytes which synthesize and secrete the interleukins (IL), IL-17A, -21 and -22. These cytokines mediate inflammation by increasing chemokine production, which leads to the recruitment of both monocytes and neutrophils to sites of infection or inflammation. Th17 cells modulate both host immunity against extracellular bacteria and fungi and inflammation. Overexpression of these cells is associated with tissue injury caused by autoimmune diseases.","T Helper 17 Cell | Th17 | Th17 Cell | Th17 cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830314","Enhancing Lesion","C113842","A well-defined area of unequivocally increased signal intensity on MRI or CT scan images compared with the normal-appearing surrounding tissues, following intravenous injection of an enhancing agent.","Enhancing Lesion | Contrast-Enhancing Lesion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518386","Non-Steroidal Aromatase Inhibitor","C2018","An aromatase inhibitor with a non-steroidal structure. Non-steroidal aromatase inhibitors work by reversible competition with the enzyme.","Non-Steroidal Aromatase Inhibitor | Non-Steroidal Androstenedione Aromatase Inhibitor | Non-Steroidal Estrogen Synthase Inhibitor | Non-Steroidal Estrogen Synthetase Inhibitor | nonsteroidal aromatase inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707741","Diesel Exhaust Particulate","C44374","A complex mixture of combustion products of diesel fuel including carbon monoxide, carbon dioxide, sulfur oxides, nitrogen oxides, volatile hydrocarbons, aldehydes, alkenes, alkanes and nitroarenes, polycyclic aromatic hydrocarbons and other derivates. Lymphocyte-DNA adduct formation is associated with exposure to diesel exhaust particulates and may be associated with an increased risk of developing lung cancer. Diesel Exhaust Particulate is reasonably anticipated to be a human carcinogen. (NCI05)","Diesel Exhaust Particulate | Diesel Exhaust Particulates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704679","Respirable Crystalline Silica","C44441","A widespread, naturally occurring, crystalline metal oxide that consists of different forms including quartz, cristobalite, tridymite, tripoli, ganister, chert and novaculite. Respirable crystalline silica is found in industry in metal and nonmetal mining and milling operations as well as in foundries, ceramic industries and at construction sites. Inhalation exposure to respirable crystalline silica causes chronic silicosis, emphysema, lymph node fibrosis and is associated with an increased risk of developing lung cancer. (NCI05)","Respirable Crystalline Silica | Quartz | Silica Anhydride | Tripoli",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0304063","Wood Dust","C44463","A light- to dark-colored granular solid mixture that is generated when timber is processed, such as when it is chipped, sawed, turned, drilled or sanded. The chemical composition of wood dust depends on the species of tree and consists mainly of cellulose, polyoses and lignin, with a large and variable number of substances with lower relative molecular mass. Wood dust is not typically produced for specific uses. However, it is used commercially for wood composts. The primary routes of potential human exposure to wood dust are inhalation and dermal contact. It is known to be a human carcinogen. (NCI05)","Wood Dust | Sanderdust | Sawdust | Wood Flour | Wood Meal",,,,,,,,,,,,,,,"4273257","Wood dust",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026162","Mineral","C656","A solid, homogeneous, inorganic substance occurring in nature and having a definite chemical composition.","Mineral | Minerals | mineral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336988","WFDC2 Gene","C20891","This gene plays a putative role in epithelial host defense.","WFDC2 Gene | WAP Four-Disulfide Core Domain 2 Gene | WFDC2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333655","GADD45A Gene","C24419","This gene plays a role in signal transduction and is induced in response to environmental stress. It is involved in apoptosis, DNA repair and negative regulation of cell growth.","GADD45A Gene | GADD45A | Growth Arrest and DNA Damage Inducible Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037900","Sphingolipid","C68425","Any lipid derived from the aliphatic amino alcohol sphingosine, in which a single fatty acid is covalently bound to sphingosine via an amide linkage. Various ester-linked substituents can result in generation of ceramides, sphingomyelins and glycosphingolipids.","Sphingolipid | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420251","ARID1A Gene","C92530","This gene plays a role in transcriptional regulation.","ARID1A Gene | ARID1A | AT Rich Interactive Domain 1A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812262","EPHA1 Gene","C18383","This gene is involved in the mediation of development in the nervous system.","EPHA1 Gene | EPH Receptor A1 Gene | EPHA1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334518","FOXO4 Gene","C24606","This gene plays a role in smooth muscle cell differentiation, cellular growth, cell cycle regulation and tumor suppression.","FOXO4 Gene | FOXO4 | Forkhead Box O4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812384","EMP1 Gene","C18454","This gene is involved in cell-cell interactions and the regulation of cellular proliferation.","EMP1 Gene | EMP1 | Epithelial Membrane Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537501","KNG1 Gene","C38188","This gene plays a role in inflammatory prostaglandin mediation and several other diverse cellular functions.","KNG1 Gene | KNG1 | Kininogen 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423497","GOLM1 Gene","C71021","This gene is involved in both the trafficking and posttranslational modification of proteins.","GOLM1 Gene | GOLM1 | Golgi Membrane Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335273","PTK2B Gene","C24700","This gene is involved in signal transduction and the regulation of ion channels.","PTK2B Gene | PTK2B | Protein Tyrosine Kinase 2 Beta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422728","MFGE8 Gene","C24592","This gene plays a regulatory role in the phagocytosis of apoptotic cells.","MFGE8 Gene | MFGE8 | Milk Fat Globule-EGF Factor 8 Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414685","FOXM1 Gene","C101580","This gene is involved in both transcriptional regulation and cell division.","FOXM1 Gene | FOXM1 | Forkhead Box M1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824738","CIITA Gene","C96013","This gene plays a role in transcriptional regulation.","CIITA Gene | CIITA | Class II Major Histocompatibility Complex Transactivator Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413833","OFD1 Gene","C75879","This gene may play a role in the regulation of embryonic development.","OFD1 Gene | OFD1 | Oral-Facial-Digital Syndrome 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425745","PDCD1LG2 Gene","C45437","This gene plays a role in the regulation of T-cell proliferation.","PDCD1LG2 Gene | PDCD1LG2 | Programmed Cell Death 1 Ligand 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825594","IL25 Gene","C97957","This gene is involved in the inflammatory response.","IL25 Gene | IL25 | Interleukin 25 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812666","Personal Contact","C113393","Direct or indirect interaction between individuals or organizations.","Personal Contact | Contact",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0223908","Head of the Fibula","C32719","The highest portion of the fibula that articulates with the patella.","Head of the Fibula | Fibula Head | Fibular Head | HEAD OF THE FIBULA",,,,,,,,,,,,,,,"4329995","Head of fibula structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3665420","Cervical Vertebra","C12693","Any one of the seven vertebrae that are caudal to the skull, denoted as C1, C2, C3, C4, C5, C6 or C7.","Cervical Vertebra | CERVICAL VERTEBRA | Cervical Vertebrae",,,,,,,,,,,,,,,"4223068","Bone structure of cervical vertebra",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037709","Sound","C64383","Mechanical vibrations transmitted by an elastic medium; the subjective sensation of hearing something; an audible event.","Sound | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0457405","Conduction","C61530","The transmission or conveying of something through a medium or passage, especially the transmission of heat or electricity or sound.","Conduction | ",,,,,,,,,,,,,,,"4083056","Conduction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016732","Frontal Bone","C32635","A bone of the skull forming the forehead, root of the nose and the roof of both orbits.","Frontal Bone | FRONTAL BONE | Frontal bone structure (body structure)",,,,,,,,,,,,,,,"4326407","Frontal bone structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039484","Temporal Bone","C12797","A large irregular bone situated at the base and side of the skull, connected with the mandible via the temporomandibular joint. The temporal bone consists of the squamous, tympanic and petrous parts. The petrous portion of the temporal bone contains the vestibulocochlear organ of the inner ear.","Temporal Bone | TEMPORAL BONE | Temporal bone structure (body structure)",,,,,,,,,,,,,,,"4246191","Temporal bone structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037884","Sphenoid Bone","C12790","The butterfly-shaped bone located at the base of the skull that helps to form the orbit of the eye.","Sphenoid Bone | SPHENOID BONE | Spheniod Bone | Sphenoid bone structure (body structure)",,,,,,,,,,,,,,,"4249599","Sphenoid bone structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030558","Parietal Bone","C12766","One of two cranial bones that by their union form the sides and roof of the skull.","Parietal Bone | PARIETAL BONE | Parietal bone structure (body structure)",,,,,,,,,,,,,,,"4096537","Parietal bone structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028784","Occipital Bone","C12757","The trapezoidal-shaped bone that forms the back and part of the base of the skull.","Occipital Bone | OCCIPITAL BONE | Occipital bone structure (body structure)",,,,,,,,,,,,,,,"4136359","Occipital bone structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027422","Nasal Bone","C33157","One of two small oblong bones placed side by side at the middle and upper part of the face.","Nasal Bone | NASAL BONE | Nasal bone structure (body structure)",,,,,,,,,,,,,,,"4253809","Nasal bone structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0222733","Lacrimal Bone","C32906","A small rectangular thin plate forming part of the medial orbit wall. It is located posterior to the frontal process of the maxilla and articulates with the inferior nasal concha, ethmoid, frontal, and maxillary bones.","Lacrimal Bone | LACRIMAL BONE | Lacrimal bone structure (body structure)",,,,,,,,,,,,,,,"4269639","Lacrimal bone structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3827022","Controlled Oral Word Association Test","C114144","A test that measures the verbal fluency of an individual. This tool measures both semantic fluency and phonetic fluency.","Controlled Oral Word Association Test | COWA | COWAT | COWAT1 | Controlled Oral Word Association",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3715157","Sixteen","C113430","A natural number greater than 15 and less than 17 and the quantity that it denotes.","Sixteen | 16",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3715153","Fifteen","C113429","A natural number greater than 14 and less than 16 and the quantity that it denotes.","Fifteen | 15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3715152","Fourteen","C113428","A natural number greater than 13 and less than 15 and the quantity that it denotes.","Fourteen | 14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3715149","Thirteen","C113427","A natural number greater than 12 and less than 14 and the quantity that it denotes.","Thirteen | 13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205458","Twelve","C113426","A natural number greater than 11 and less than 13 and the quantity that it denotes.","Twelve | 12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205457","Eleven","C113425","A natural number greater than 10 and less than 12 and the quantity that it denotes.","Eleven | 11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830456","Distant Lymph Node","C106042","A lymph node located distant to the anatomic site of interest.","Distant Lymph Node | DISTANT LYMPH NODE | Lymph Node(s) Distant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1287242","Antibody Titer","C71683","Concentration in serum of the antibody that recognizes a particular epitope expressed as the reciprocal of the highest serum dilution that produces the specific positive immunologic reaction in an appropriate test system.","Antibody Titer | ",,,,,,,,,,,,,,,"4267506","Antibody titer - finding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1335654","RUNX1 Gene","C18579","This gene plays a role in transcriptional regulation and cytogenetic aberrations are associated with several leukemias.","RUNX1 Gene | AML1 | RUNX1 | Runt-Related Transcription Factor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887573","CD99 Antigen, Human","C102941","CD99 antigen (185 aa, ~19 kDa) is encoded by the human CD99 gene. This protein plays a role in cell adhesion.","CD99 Antigen | 12E7 | CD99 | Cell Surface Antigen 12E7 | Cell Surface Antigen HBA-71 | Cell Surface Antigen O13 | E2 Antigen | MIC2 Surface Antigen | Protein MIC2 | Surface Antigen MIC2 | T-Cell Surface Glycoprotein E2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272964","Median Fluorescence Intensity","C96687","A unit of measure equal to the median fluorescence intensity of a log-normal distribution of fluorescence signals.","Median Fluorescence Intensity Unit | MFI | MdFI | Median Fluorescence Intensity | {MFI} | {MdFI}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416682","KLRC1 Gene","C104362","This gene is involved in the regulation of immune responses.","KLRC1 Gene | KLRC1 | Killer Cell Lectin-Like Receptor Subfamily C, Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828813","99 (qualifier value)","C105787","A natural number greater than ninety-eight and less than one hundred and the quantity that it denotes.","Ninety Nine | 99 | Ninety-Nine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412304","AIRE Gene","C114319","This gene is involved in both self-tolerance and the positive regulation of transcription.","AIRE Gene | AIRE | Autoimmune Regulator Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0051816","Anatabine","C114277","An alkaloid found in low concentrations in plants in the Solanaceae family, which includes tobacco and tomato plants, with potential nicotine mimetic and anti-inflammatory activities. Following oral administration, anatabine may mimic the neurological effects of nicotine exposure. This agent may not have the addictive properties of nicotine; therefore, it may be appropriate for use in treating nicotine withdrawal symptoms during smoking cessation. Anatabine may also exert its anti-inflammatory effect by the inhibition of the signal transducer and activator of transcription 3 (STAT3) which then prevents the activation of the nuclear factor kappa B (NF-kB), which is a key regulator of proinflammatory cytokine release. Urine concentrations of anatabine can be used to assess the extent of tobacco use.","Anatabine | (-)-Anatabine | (-)-Anatabine; 2,3'-Bipyridine, 1,2,3,6-tetrahydro-, (S)- (9CI) | (S)-1,2,3,6-Tetrahydro-2,3'-bipyridine | 1,2,3,6-Tetrahydro-2,3'-bipyridine | 2,3'-Bipyridine, 1,2,3,6-tetrahydro-, (S)- (9CI) | ANATABINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007061","Carboxyhemoglobin","C114300","Hemoglobin where the heme group has formed a stable complex with carbon monoxide (CO). This complex is produced after CO has been inhaled or as a byproduct of hemoglobin, protoporphyrin or dichloromethane catabolism. The heme-CO complex is approximately 200 times more stable than heme-oxygen complexes. Thus, high levels of carboxyhemoglobin in the circulation can lead to tissue hypoxia and death.","Carboxyhemoglobin | COHb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811668","Circulating Plasma Cell","C114278","A plasma cell myeloma-derived cell found in the peripheral blood.","Circulating Plasma Cell | CMMC | Circulating Multiple Myeloma Cell | Circulating PC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413816","CTSV Gene","C114303","This gene plays a role in protein catabolism.","CTSV Gene | CTSV | Cathepsin V Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415146","GNAO1 Gene","C114348","This gene is involved in the modulation of G protein signaling.","GNAO1 Gene | GNAO1 | Guanine Nucleotide Binding Protein (G Protein), Alpha Activating Activity Polypeptide O Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415154","GNG11 Gene","C114331","This gene is involved in both GTPase activity and signal transduction.","GNG11 Gene | GNG11 | Guanine Nucleotide Binding Protein (G Protein), Gamma 11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426313","GNG12 Gene","C114334","This gene plays a role in signal transduction mediated by G proteins.","GNG12 Gene | GNG12 | Guanine Nucleotide Binding Protein (G Protein), Gamma 12 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415155","GNG2 Gene","C114328","This gene plays a role in GTPase-dependent signaling.","GNG2 Gene | GNG2 | Guanine Nucleotide Binding Protein (G Protein), Gamma 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0062059","H-Y Antibody","C114302","Any immunoglobulin that recognizes male specific cellular antigens.","H-Y Antibody | Anti-H-Y Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812706","HOTS Gene","C114309","This gene may play a role in tumor suppression.","HOTS Gene | H19 Opposite Tumor Suppressor Gene | HOTS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415740","HSD17B4 Gene","C114364","This gene is involved in fatty acid oxidation.","HSD17B4 Gene | HSD17B4 | Hydroxysteroid (17-Beta) Dehydrogenase 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415742","HSD3B1 Gene","C114367","This gene plays a role in both ketosteroid metabolism and hormonal steroid biosynthesis.","HSD3B1 Gene | HSD3B1 | Hydroxy-Delta-5-Steroid Dehydrogenase, 3 Beta- and Steroid Delta-Isomerase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422385","IGF2-AS Gene","C114312","This gene is involved in Wilms tumor and may play a role in kidney development.","IGF2-AS Gene | IGF2 Antisense RNA Gene | IGF2-AS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416613","KCNQ1OT1 Gene","C114316","This gene plays a role in the epigenetic regulation of gene transcription.","KCNQ1OT1 Gene | KCNQ1 Opposite Strand/Antisense Transcript 1 (Non-Protein Coding) Gene | KCNQ1OT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1442514","MAPKAPK2 Gene","C114355","This gene is involved in signal transduction induced by cellular stress.","MAPKAPK2 Gene | MAPKAPK2 | Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828628","PDGFRA Antibody","C114301","Any immunoglobulin that recognizes platelet-derived growth factor receptor alpha protein.","PDGFRA Antibody | Anti-CD140A Antibody | Anti-PDGFR-Alpha Antibody | Anti-PDGFRA Antibody | Anti-Platelet-Derived Growth Factor Receptor Alpha Antibody | CD140A Antibody | PDGFR-Alpha Antibody | Platelet-Derived Growth Factor Receptor Alpha Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418448","PDZK1 Gene","C114322","This gene plays a role in the regulation of protein localization.","PDZK1 Gene | PDZ Domain Containing 1 Gene | PDZK1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418574","PIK3C3 Gene","C114360","This gene plays a role in autophagosome formation and transport to lysosomes and late endosomes.","PIK3C3 Gene | PIK3C3 | Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3 Gene | Phosphatidylinositol 3-Kinase, Catalytic Subunit Type 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418750","POLR2L Gene","C114340","This gene plays a role in DNA-dependent RNA synthesis.","POLR2L Gene | POLR2L | Polymerase (RNA) II (DNA Directed) Polypeptide L, 7.6kDa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418918","PRKCE Gene","C114337","This gene plays a role in diacylglycerol-dependent signaling.","PRKCE Gene | PRKCE | Protein Kinase C, Epsilon Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425081","RHOU Gene","C114325","This gene is involved in GTP binding, signal transduction and cell migration.","RHOU Gene | RHOU | Ras Homolog Family Member U Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714800","SCID-Repopulating Cell","C114279","A human hematopoietic stem cell that is able to repopulate the hematopoietic system of non-obese diabetic/severe combined immunodeficient mice (NOD/SCID). Ex vivo culture conditions that can enrich these stem cells from peripheral blood samples could potentially be used to treat immunodeficiency in human patients.","SCID-Repopulating Cell | SCID Repopulating Cell | SRC | SRCs | Severe Combined Immunodeficient Repopulating Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539733","SCUBE2 Gene","C114306","This gene may be involved in both cell proliferation and cell-cell adhesion.","SCUBE2 Gene | SCUBE2 | Signal Peptide, CUB Domain, EGF-Like 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420710","TGFB1I1 Gene","C114351","This gene plays a role in both adaptor molecule signaling and nuclear receptor coactivation.","TGFB1I1 Gene | TGFB1I1 | Transforming Growth Factor Beta 1 Induced Transcript 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416501","ITGB5 Gene","C53959","This gene is involved in cell communication and signal transduction.","ITGB5 Gene | ITGB5 | Integrin, Beta 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335221","PLA2G2A Gene","C24678","This gene is involved in the regulation of the inflammatory response.","PLA2G2A Gene | PLA2G2A | Phospholipase A2, Group IIA (Platelets, Synovial Fluid) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332083","AMFR Gene","C28525","This gene plays a role in tumor cell motility and is associated with several carcinomas.","AMFR Gene | AMFR | Autocrine Motility Factor Receptor, E3 Ubiquitin Protein Ligase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538716","PRKD1 Gene","C95256","This gene plays a role in protein phosphorylation and second messenger signaling.","PRKD1 Gene | PRKD1 | Protein Kinase D1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333689","GNB3 Gene","C24440","This gene is plays a role in signal transduction. It is associated with both hypertension and obesity.","GNB3 Gene | G Protein Subunit Beta 3 Gene | GNB3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332796","CSNK2A1 Gene","C24315","This gene is involved in DNA repair, intercellular communication and signal transduction.","CSNK2A1 Gene | CSNK2A1 | Casein Kinase 2, Alpha Prime Polypeptide Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333676","GIT1 Gene","C24430","This gene plays a role in signal transduction and cytoskeletal remodeling.","GIT1 Gene | GIT ArfGAP 1 Gene | GIT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414346","EIF3B Gene","C96374","This gene plays a role in the initiation of translation.","EIF3B Gene | EIF3B | Eukaryotic Translation Initiation Factor 3, Subunit B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332659","CALM1 Gene","C21540","This gene is involved in the cell cycle and in the regulation of cell growth.","CALM1 Gene | CALM1 | Calmodulin 1 (Phosphorylase Kinase, Delta) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416612","KCNQ1 Gene","C75622","This gene is involved in both potassium transport and cardiac repolarization.","KCNQ1 Gene | KCNQ1 | Potassium Voltage-Gated Channel, KQT-Like Subfamily, Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333708","GRB7 Gene","C24459","This gene is involved in signal transduction and protein binding.","GRB7 Gene | GRB7 | Growth Factor Receptor Bound Protein 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513872","Naive Pregerminal Center B-Lymphocyte","C38337","A mature B lymphocyte that expresses IgM and IgD. It is found in peripheral blood, lymph nodes and secondary lymphoid organs, but has not moved into the germinal center of lymphoid organs. Once this cell encounters an antigen in the presence of helper T cells and becomes activated, it moves to the next stage of B-lymphocyte development.","Naive Pregerminal Center B-Lymphocyte | Naive B Cell | Naive B Lymphocyte | Naive B-Cell | Naive B-Lymphocyte | Naive Pregerminal Center B-Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0047964","4-Methylnitrosamino-1,3-pyridyl-1-butanone","C29801","A yellowish crystalline solid nitrosamine that naturally occurs in tobacco products by oxidation and nitrosation of nicotine during the making and smoking of tobacco. 4-Methylnitrosamino-1,3-pyridyl-1-butanone is only used as a research chemical to induce tumorigenesis. This substance is reasonably anticipated to be a human carcinogen. (NCI05)","4-Methylnitrosamino-1,3-pyridyl-1-butanone | 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone | 4-N-Nitrosomethylamino-1-3-Pyridyl-1-Butanone | NNK | Nicotine-Derived Nitrosamine Ketone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033634","Protein Kinase C","C17017","A family of serine/threonine protein kinases that have a structurally conserved catalytic subunit and a regulatory subunit that are connected by a hinge domain.","Protein Kinase C | EC 2.7.11.13 | PKC | protein kinase C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418576","PIK3R1 Gene","C97733","This gene is involved in phosphoinositol signaling.","PIK3R1 Gene | PIK3R1 | Phosphoinositide-3-Kinase Regulatory Subunit 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705229","Disks (device)","C49925","Any device component shaped like a disk, especially those used for data storage.","Disk Device | Disc | Disk | Disk Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1269801","Operative Report","C114420","A detailed record of a surgical procedure by the clinician who performed the operation.","Operative Report | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1558965","Grade 3 Portal Vein Flow, CTCAE","C56688","Reversal/retrograde portal vein flow","Grade 3 Portal Vein Flow, CTCAE | CTCAE Grade 3 Portal Vein Flow | Grade 3 Portal vein flow",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL413620","Volume Modulated Arc Therapy","C104933","Radiation therapy delivered to the whole volume of target tissue by a single rotation of the linear accelerator gantry.","Volume Modulated Arc Therapy | VMAT | Volumetric Modulated Arc Therapy (procedure)",,,,,,,,,,,,,,,"603135","Volumetric modulated arc therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0215474","IL2-inducible T-cell kinase","C29753","Tyrosine-protein kinase ITK/TSK (620 aa, ~75 kDa) is encoded by the human ITK gene. This protein is involved in tyrosine phosphorylation and immunity.","Tyrosine-Protein Kinase ITK/TSK | EC 2.7.10.2 | EMT | IL2-Inducible T-Cell Kinase | ITK | Interleukin-2-Inducible T-Cell Kinase | Kinase EMT | LYK | PSCTK2 | T-Cell ITK/TSK Homolog | T-Cell-Specific Kinase | Tyrosine-Protein Kinase LYK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1622765","Perforin-1, Human","C97741","Perforin-1 (555 aa, ~61 kDa) is encoded by the human PRF1 gene. This protein is involved in the mediation of cytolysis of infected cells.","Perforin-1 | Cytolysin | Lymphocyte Pore-Forming Protein | P1 | PFP | PRF1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281267","bilateral breast cancer","C8287","Carcinoma that affects both breasts in a simultaneous or non-simultaneous manner.","Bilateral Breast Carcinoma | Bilateral Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1283188","Intraspinal","C96908","Within the spine.","Intraspinal | intraspinal",,,,,,,,,,,,,,,"4231022","Intraspinal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0066156","Methoxyamine","C78084","An orally bioavailable small molecule inhibitor with potential adjuvant activity. Methoxyamine covalently binds to apurinic/apyrimidinic (AP) DNA damage sites and inhibits base excision repair (BER), which may result in an increase in DNA strand breaks and apoptosis. This agent may potentiate the anti-tumor activity of alkylating agents.","Methoxyamine | METHOXYAMINE | TRC102 Base",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018590","Haploidy","C114473","A chromosomal abnormality in which a somatic cell has a single member of each pair of homologous chromosomes.","Haploidy | Haploid",,,,,,,,,,,,,,,"4098739","Haploidy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828843","Near-Haploidy","C114474","A chromosomal abnormality in which there are less than thirty chromosomes in a cell.","Near-Haploidy | Near-Haploid | Near-Haploid ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829182","Masked Near-Haploidy","C114475","A chromosomal abnormality in which a near-haploid cell line is masked by a co-existing hyperdiploid line.","Masked Near-Haploidy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831270","Breast Fibroglandular Tissue","C114467","Breast tissue that contains glandular epithelial and fibrous tissue.","Breast Fibroglandular Tissue | Fibroglandular | Fibroglandular Tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335212","PIK3CA Gene","C21220","This gene is involved in second messenger signaling, apoptosis, cell growth and angiogenesis.","PIK3CA Gene | PIK3CA | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3715070","Twenty Four","C113753","A natural number greater than twenty-three and less than twenty-five and the quantity that it denotes.","Twenty Four | 24 | Twenty-Four",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0048342","4-Hydroxyestrone","C114469","A metabolite formed during the catabolism of estrone by the liver through the hydroxylation of the carbon at position 4 by cytochrome P450 (CYP) family enzymes, with potential carcinogenic activity. The mechanism of action for the tumor promoting activity of 4-hydroxyestrone is not known but this metabolic product has increased estrogenic activity compared to the parent compound. Additionally, oxidation of 4-hydroxyestrone generates compounds with free radicals that are capable of removing purines from DNA, which can cause mutagenesis and can lead to tumorigenesis.","4-Hydroxyestrone | 3,4-Dihydroxyestra-1,3,5(10)-trien-17-one | 4-HYDROXYESTRONE | 4-OHE(1) | 4-OHE1 | Estra-1,3,5(10)-trien-17-one, 3,4-dihydroxy-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412188","ADAM19 Gene","C114511","This gene is involved in proteolytic processing.","ADAM19 Gene | ADAM Metallopeptidase Domain 19 Gene | ADAM19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524764","Androstenediol","C95979","A direct metabolite of dehydroepiandrosterone (DHEA) and a precursor for testosterone with immunostimulatory activity and minimal androgenic activity. Androstenediol stimulates the differentiation of hematopoietic precursor cells into leukocytes and platelets, which can counteract the immunotoxicity of radiation exposure.","Androstenediol | (3beta,17beta)-androst-5-ene-3,17-diol | 3beta,17beta-Dihydroxy-5-androstene | 3beta,17beta-Dihydroxyandrost-5-ene | 5-AED | ANDROSTENEDIOL | Androst-5-ene-3beta,17beta-diol | Androst-5-enediol | HE2100 | Neumune",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414199","DVL1 Gene","C114514","This gene plays a role in signaling modulated by the Wnt and frizzled protein families.","DVL1 Gene | DVL1 | Dishevelled Segment Polarity Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415306","GRM2 Gene","C114526","This gene plays a role in the inhibition of adenylate cyclase signaling.","GRM2 Gene | GRM2 | Glutamate Receptor, Metabotropic 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415307","GRM3 Gene","C114529","This gene is involved in ligand-depending signaling.","GRM3 Gene | GRM3 | Glutamate Receptor, Metabotropic 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415308","GRM4 Gene","C114532","This gene plays a role in neurotransmitter signaling.","GRM4 Gene | GRM4 | Glutamate Receptor, Metabotropic 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415309","GRM7 Gene","C114535","This gene is involved in neurotransmitter binding.","GRM7 Gene | GRM7 | Glutamate Receptor, Metabotropic 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415310","GRM8 Gene","C114538","This gene plays a role in G protein-coupled receptor signaling.","GRM8 Gene | GRM8 | Glutamate Receptor, Metabotropic 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332125","AXIN1 Gene","C19969","This gene plays a role in signal transduction and is involved in development.","AXIN1 Gene | AXIN1 | Axin 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519591","Transcription Elongation","C28586","The RNA polymerase moves along the DNA template, adding nucleotides to the growing RNA chain in accordance with the sequence of the template or coding strand.","Transcription Elongation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333576","FRAT1 Gene","C24405","This gene may play a role in tumor progression and in lymphomagenesis.","FRAT1 Gene | FRAT1 | FRAT1, WNT Signaling Pathway Regulator Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515186","Gamma/Delta T-Lymphocyte","C39585","A resting, mature T cell that probably plays a primary role in suppressor/cytotoxic phenomena.","Gamma/Delta T-Lymphocyte | Gamma Delta T Cell | Gamma Delta T Lymphocyte | Gamma Delta T-Cell | Gamma Delta T-Lymphocyte | Gamma/Delta T Cell | Gamma/Delta T Lymphocyte | Gamma/Delta T-Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414295","EEF2 Gene","C38584","This gene plays a role in nucleotide binding and protein biosynthesis.","EEF2 Gene | EEF2 | Eukaryotic Translation Elongation Factor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412688","ATP7A Gene","C74973","This gene is involved in copper transport.","ATP7A Gene | ATP7A | ATPase, Cu++ Transporting, Alpha Polypeptide Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539666","HES2 Gene","C114517","This gene is involved in the negative regulation of gene expression.","HES2 Gene | HES2 | Hes Family bHLH Transcription Factor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415526","HEYL Gene","C114520","This gene plays a role in both transcriptional regulation and cardiac development.","HEYL Gene | HEYL | Hes-Related Family bHLH Transcription Factor With YRPW Motif-Like Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889728","HHV8 K2 Gene","C114502","HHV8 K2, which encodes viral interleukin-6 homolog protein, plays a role in cell proliferation, cell differentiation and the prevention of apoptosis.","HHV8 K2 Gene | HHV-8 K2 | HHV-8 vIL6 | HHV8 K2 | HHV8 vIL6 | Human Herpesvirus 8 Viral Interleukin-6 Gene | Human Herpesvirus-8 Viral Interleukin-6 Gene | K2 | KSHV K2 | KSHV vIL6 | Kaposi Sarcoma Herpes Virus Interleukin-6 Gene | vIL-6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889271","HHV8 ORF50 Gene","C114492","HHV8 ORF50, which encodes putative transcription activator ORF50 protein, is involved in the conversion from the latent phase to the lytic phase of viral replication.","HHV8 ORF50 Gene | HHV-8 ORF50 | HHV-8 RTA | HHV8 ORF50 | HHV8 RTA | Human Herpesvirus 8 ORF50 Gene | Human Herpesvirus 8 Open Reading Frame 50 Gene | Human Herpesvirus 8 Replication Transactivation Activator Gene | Human Herpesvirus-8 ORF50 Gene | Human Herpesvirus-8 Open Reading Frame 50 Gene | Human Herpesvirus-8 Replication Transactivation Activator Gene | KIE-1 | KSHV ORF50 | KSHV RTA | Kaposi Sarcoma Herpes Virus ORF50 Gene | Kaposi Sarcoma Herpes Virus Open Reading Frame 50 Gene | Kaposi Sarcoma Herpes Virus Replication Transactivation Activator Gene | ORF50 | RTA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889258","HHV8 ORF59 Gene","C114506","HHV8 ORF59, which encodes DNA polymerase processivity factor protein, plays a role in viral DNA replication.","HHV8 ORF59 Gene | HHV-8 ORF59 | HHV8 ORF59 | Herpesvirus-8 ORF59 Gene | Human Herpesvirus 8 ORF59 Gene | Human Herpesvirus 8 Open Reading Frame 59 Gene | Human Herpesvirus-8 ORF59 Gene | Human Herpesvirus-8 Open Reading Frame 59 Gene | KSHV ORF59 | Kaposi Sarcoma Herpes Virus ORF59 Gene | Kaposi Sarcoma Herpes Virus Open Reading Frame 59 Gene | ORF59",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889260","HHV8 ORF71 Gene","C114490","HHV8 ORF71, which encodes FLICE inhibitory protein, plays a role in the regulation of host signaling pathways","HHV8 ORF71 Gene | HHV-8 vFLIP | HHV8 ORF71 | HHV8 vFLIP | Human Herpesvirus 8 ORF71 Gene | Human Herpesvirus 8 Open Reading Frame 71 Gene | Human Herpesvirus-8 ORF71 Gene | Human Herpesvirus-8 Open Reading Frame 71 Gene | KSHV ORF71 | KSHV vFLIP | Kaposi Sarcoma Herpes Virus ORF71 Gene | Kaposi Sarcoma Herpes Virus Open Reading Frame 71 Gene | ORF71 | ORF71/K13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891713","HHV8 ORF73 Gene","C114488","HHV8 ORF73, which encodes latent nuclear antigen protein, is involved in both transcriptional regulation and the inhibition of apoptosis.","HHV8 ORF73 Gene | HHV-8 LANA | HHV-8 ORF73 | HHV8 LANA | HHV8 ORF73 | Human Herpesvirus 8 ORF73 Gene | Human Herpesvirus 8 Open Reading Frame 73 Gene | Human Herpesvirus-8 ORF73 Gene | Human Herpesvirus-8 Open Reading Frame 73 Gene | KSHV LANA | Kaposi Sarcoma Herpes Virus ORF73 Gene | Kaposi Sarcoma Herpes Virus Open Reading Frame 73 Gene | LANA | ORF73",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889744","HHV8 ORF74 Gene","C114504","HHV8 ORF74, which encodes viral G-protein coupled receptor protein, is involved in the modulation of cell proliferation, cell migration, angiogenesis and cell survival.","HHV8 ORF74 Gene | HHV-8 ORF74 | HHV-8 vGPCR | HHV8 ORF74 | HHV8 vGPCR | Human Herpesvirus 8 ORF74 Gene | Human Herpesvirus 8 Open Reading Frame 74 Gene | Human Herpesvirus 8 Viral G-Protein Coupled Receptor Gene | Human Herpesvirus-8 ORF74 Gene | Human Herpesvirus-8 Open Reading Frame 74 Gene | Human Herpesvirus-8 Viral G-Protein Coupled Receptor Gene | KSHV ORF74 | KSHV vGPCR | Kaposi Sarcoma Herpes Virus ORF74 Gene | Kaposi Sarcoma Herpes Virus Open Reading Frame 74 Gene | Kaposi Sarcoma Herpes Virus Viral G-Protein Coupled Receptor Gene | ORF74 | vGPCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424252","IL17F Gene","C114481","This gene plays a role in the negative regulation of angiogenesis and the stimulation of the production of other cytokines.","IL17F Gene | IL17F | Interleukin 17F Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422120","MAML1 Gene","C114485","This gene is involved in notch-dependent gene expression.","MAML1 Gene | MAML1 | Mastermind Like Transcriptional Coactivator 1 Gene | Mastermind-Like 1 (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3888141","Radiosensitivity Index","C114480","A set of genetic markers that predicts the fraction of cells that could survive radiotherapy based on the expression levels of 10 genes (AR, JUN, STAT1, PKC, RELA, ABL, SUMO1, CDK1, HDAC1, and IRF1) in a patient's tumor.","Radiosensitivity Index | RSI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416171","RBPJ Gene","C114508","This gene plays a role in both cell-cell communication and transcriptional regulation.","RBPJ Gene | RBPJ | Recombination Signal Binding Protein For Immunoglobulin Kappa J Region Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420578","TAGLN Gene","C114523","This gene is involved in actin crosslinking.","TAGLN Gene | TAGLN | Transgelin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1719048","Shell Vial Culture","C114597","A method for virus culture and detection in which a virus sample is mixed with a susceptible cell type and then centrifuged into a single layer of cells. Following a short incubation, viral growth is determined using immunological detection techniques.","Shell Vial Culture | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0345979","Skin Acantholytic Squamous Cell Carcinoma","C4460","A histologic variant of squamous cell carcinoma that arises from the skin. It is characterized by loosening of the intercellular bridges between the malignant cells which results in acantholysis.","Skin Acantholytic Squamous Cell Carcinoma | Acantholytic Squamous Cell Carcinoma of Skin | Acantholytic Squamous Cell Carcinoma of the Skin | Acantholytic Squamous Cell Skin Carcinoma | Acantholytic Squamous Cell Skin Carcinoma | Acantholytic squamous cell carcinoma | Skin Adenoid Squamous Cell Carcinoma | Skin Pseudoglandular Squamous Cell Carcinoma",,,,,,,,,,,,,,,"4112744","Acantholytic squamous cell carcinoma of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0476144","Hemangiopericytic Neoplasm","C7076","A term that refers to vascular neoplasms with a prominent hemangiopericytic growth pattern.","Hemangiopericytic Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334283","Malignant Gastrinoma","C65188","A gastrin-producing neuroendocrine tumor.  It is characterized by inappropriate secretion of gastrin and associated with Zollinger Ellison syndrome.  It displays vascular invasion and metastasizes to other anatomic sites.","Malignant Gastrinoma | G cell tumor, malignant | Gastrin cell tumor, malignant | Gastrinoma, malignant",,,,,,,,,,,,,,,"4059440","Gastrinoma, malignant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517304","Foveolar Cell","C32632","An epithelial cell found in the glands of the gastric mucosa.","Foveolar Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279754","Estrogen Receptor Positive","C15492","An indication that estrogen receptor alpha expression has been detected in a sample.","Estrogen Receptor Positive | ER Alpha Positive | ER Positive | ER+ | ER-Alpha Positive | ERA Positive | ESR Positive | ESR1 Positive | ESRA Positive | ESTRR Positive | Estrogen Receptor 1 Positive | Estrogen Receptor Alpha Positive | NR3A1 Positive | Nuclear Receptor Subfamily 3 Group A Member 1 Positive | Positive | Positive Estrogen Receptor | estrogen receptor positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014603","Epithelioid Cell","C12559","A cell of mononuclear phagocyte system origin that resembles an epithelial cell and is involved in immune granuloma formation.","Epithelioid Cell | Epithelioid Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704273","Endometrial Polyp","C6433","A benign nodular lesion protruding above the surface of the endometrium. It is composed of a fibrous stroma that contains thick-walled blood vessels and dilated endometrial glands. Polypectomy is the treatment of choice. Only few cases with recurrence have been reported.","Endometrial Polyp | Endometrial Stromal Polyp | Endometrial polyp | POLYP, ENDOMETRIAL STROMAL, BENIGN | Polyp of Endometrium | Polyp of the Endometrium",,,,,,,,,,,,,,,"200779","Polyp of corpus uteri",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0920502","Embryonic tissue","C12950","Tissue that is formed during the embryonic stage of life of an organism.","Embryonic Tissue | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333190","Cystic Neoplasm","C6784","A benign or malignant neoplasm that contains a single or multiple cystic spaces.  Examples include cystadenoma, mucinous cystadenocarcinoma, and serous cystadenocarcinoma.","Cystic Neoplasm | Cystic Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335473","Primary Central Chondrosarcoma","C7155","A chondrosarcoma arising from the central portion of bone without a benign precursor.","Primary Central Chondrosarcoma | Conventional Chondrosarcoma | OSTEOCHONDROSARCOMA, MALIGNANT | Primary Bone Chondrosarcoma | Primary Chondrosarcoma | Primary Chondrosarcoma of Bone | Primary Chondrosarcoma of the Bone",,,,,,,,,,,,,,,"42539556","Primary chondrosarcoma of bone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008441","Chondroblastoma","C2945","A benign, chondroid-producing, well-circumscribed, lytic neoplasm usually arising from the epiphysis of long bones.  It is characterized by the presence of chondroblasts, osteoclast-like giant cells, chondroid formation, calcification, and mitotic activity. In aggressive cases, there is rearrangement of the 8q21 chromosome band.  It occurs most frequently in children and young adults and rarely metastasizes.","Chondroblastoma | Chondroblastoma, NOS | Chondroblastoma, Not Otherwise Specified",,,,,,,,,,,,,,,"4233968","Chondroblastoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332594","Borderline Lesion","C36116","A lesion characterized by the presence of atypical or low-grade neoplastic cells, which may or may not exhibit stromal microinvasion and cannot be qualified as completely malignant.","Borderline Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206736","Blue Nevus","C3803","A nevus characterized by the presence of benign pigmented dendritic spindle-shaped melanocytes. It most frequently occurs in the skin of the distal upper extremities, followed by the lower extremities, scalp, face, and buttocks. Extracutaneous presentations including in the conjunctiva, may also occur, but they are rare.","Blue Nevus | Blue Nevus of Skin | Blue Nevus of the Skin | Blue Skin Nevus | Blue nevus, NOS","8780/0","Blue nevus, NOS",,,,,,,,,,,,,"4271449","Blue nevus",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1332460","Barrett Adenocarcinoma","C7027","An adenocarcinoma arising from Barrett metaplastic epithelium in the esophagus.  There is evidence supporting the idea that the Barrett adenocarcinomas develop through a stepwise progression through intestinal metaplastic epithelium to epithelial dysplasia to malignancy.  Adenocarcinomas arising in the setting of Barrett esophagus are typically papillary and/or tubular.  In terms of grading, they are well or moderately differentiated adenocarcinomas.","Barrett Adenocarcinoma | Adenocarcinoma Arising in Barrett's Mucosa | Barrett's Adenocarcinoma",,,,,,,,,,,,,,,"36715844","Primary adenocarcinoma of lower third of esophagus due to Barrett esophagus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002793","Anaplastic Lesion","C36113","A morphologic finding indicating the presence of a malignant cellular infiltrate characterized by the presence of large pleomorphic cells, necrosis, and high mitotic activity in a tissue sample.","Anaplastic Lesion | Anaplasia | Anaplastic Change",,,,,,,,,,,,,,,"4233248","Dedifferentiation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3889724","UNC13D wt Allele","C114614","Human UNC13D wild-type allele is located in the vicinity of 17q25.1 and is approximately 17 kb in length. This allele, which encodes protein unc-13 homolog D protein, plays a role in the regulation of cytolytic granule secretion. Mutations in this gene are associated with familial hemophagocytic lymphohistiocytosis type 3.","UNC13D wt Allele | FHL3 | FHL3 / MUNC 13-4 (UNC13D) | HLH3 | HPLH3 | Munc13-4 | Unc-13 Homolog D (C. elegans) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889449","STX11 wt Allele","C114620","Human STX11 wild-type allele is located in the vicinity of 6q24.2 and is approximately 41 kb in length. This allele, which encodes syntaxin-11 protein, is involved in the regulation of protein transport between late endosomes and the trans-Golgi network. Mutations in this gene are associated with familial hemophagocytic lymphohistiocytosis type 4.","STX11 wt Allele | FHL4 | FHL4 / Syntaxin 11 (STX11) | HLH4 | HPLH4 | Syntaxin 11 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890002","STXBP2 wt Allele","C114623","Human STXBP2 wild-type allele is located within 19p13.3-p13.2 and is approximately 11 kb in length. This allele, which encodes syntaxin-binding protein 2, plays a role in intracellular vesicle trafficking and vesicle fusion with membranes. Mutations in this gene are associated with familial hemophagocytic lymphohistiocytosis type 5.","STXBP2 wt Allele | FHL5 | FHL5 / MUNC18-2 (STXBP2) | Hunc18b | MUNC18-2 | Syntaxin Binding Protein 2 wt Allele | UNC18, C. elegans, Homolog of, 2 Gene | UNC18-2 | UNC18B | pp10122 | unc-18B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1622891","Mast Cell Degranulation","C114629","The regulated exocytosis of secretory granules by a mast cell.","Mast Cell Degranulation | Degranulation | Mast Cell Granule Exocytosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0151311","Cranial Nerve Paralysis","C26941","Injury to any of the cranial nerves or their nuclei in the brain resulting in muscle weakness.","Cranial Nerve Paralysis | Cranial Nerve Palsy | Cranial Nerve Palsy | Cranial Nerve Paralysis | Cranial Nerve Paralysis | Cranial nerve palsies",,,,,,,,,,,,,,,"441848","Cranial nerve disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL414745","Cartilaginous Tissue","C32268","A type of connective tissue composed of chondrocytes and an extracellular matrix, composed of collagen, elastin, and ground substance. There are three types of cartilage; namely elastic, hyaline, and fibrocartilage.","Cartilaginous Tissue | CARTILAGE | Cartilaginous | Human Cartilage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014070","Encephalomyelitis","C34580","Inflammation of the brain and the spinal cord.","Encephalomyelitis | ",,,,,,,,,,,,,,,"373189","Encephalomyelitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334698","Meningothelial Cell Neoplasm","C6971","A neoplasm that arises from meningothelial cells. This category refers to meningiomas.","Meningothelial Cell Neoplasm | Meningothelial Cell Tumor | Primary Meningeal Neoplasm | Primary Meningeal Tumor | Tumor of Meningothelial Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334664","Mast Cell Neoplasm","C9295","A heterogeneous group of disorders characterized by the abnormal growth and accumulation of mast cells in one or more organ systems.  Recent data suggest that most variants of mast cell neoplasms are clonal disorders. (WHO, 2001)","Mast Cell Neoplasm | Mast Cell Proliferative Disease | Mast Cell Tumor | Mast Cell Tumors | Mast cell tumor, NOS | Neoplasm of Mast Cells | Neoplasm of the Mast Cells | Tumor of Mast Cells | Tumor of the Mast Cells | mast cell tumor",,,,,,,,,,,,,,,"4133301|443736","Mastocytosis|Mast cell neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0345967","Malignant Mesothelioma","C4456","A malignant neoplasm that arises from mesothelial cells, usually in the pleura or peritoneum. It is associated with exposure to asbestos.","Malignant Mesothelioma | MESOTHELIOMA, MALIGNANT | Malignant Mesothelial Neoplasm | Malignant Mesothelial Tumor | Malignant Neoplasm of Mesothelium | Malignant Neoplasm of the Mesothelium | Malignant Tumor of Mesothelium | Malignant Tumor of the Mesothelium | Mesothelioma, malignant | Mesothelioma, unspecified | malignant mesothelioma","9050/3","Mesothelioma, malignant",,,,,,,,,,,,,"4268158","Mesothelioma, malignant",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1832588","Potocki-Shaffer Syndrome","C75456","A very rare genetic syndrome caused by deletions on the proximal short arm of chromosome 11.  It is characterized by the presence of multiple exostoses and enlarged parietal foramina.","Potocki-Shaffer Syndrome | ",,,,,,,,,,,,,,,"45765414","Potocki-Shaffer syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334455","Sclerosing Pneumocytoma","C5656","A benign tumor that arises from the lung.  It is characterized by the presence of sclerotic, papillary, solid, and hemorrhagic patterns and hyperplastic type II pneumocytes.  Cholesterol clefts, hemosiderin deposition, chronic inflammation, and calcifications may be present.  In the majority of cases, it is a solitary and peripheral tumor.  Patients are usually asymptomatic.","Sclerosing Pneumocytoma | Lung Sclerosing Angioma | Lung Sclerosing Hemangioma | Lung Sclerosing Hemangioma | Pneumocytoma | Sclerosing Angioma of Lung | Sclerosing Angioma of the Lung | Sclerosing Hemangioma of Lung | Sclerosing Hemangioma of the Lung",,,,,,,,,,,,,,,"37111284","Sclerosing pneumocytoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0456487","Peutz-Jeghers Polyp","C4733","A hamartomatous polyp that occurs in the stomach, small and large intestines, and rarely within the esophagus, nasopharynx and the urinary tract.  The Peutz-Jeghers polyps are grossly lobulated and dark.  Microscopically, they have a central core of smooth muscle covered by mucosa.  The smooth muscle shows tree-like branching.  The question of whether or not the Peutz-Jeghers polyp is precancerous is a matter of controversy.  The loss of heterozygosity on chromosome 19p (where the responsible gene LKB1 is located) suggests that the increased risk of malignancy may be due to malignant transformation from hamartoma to adenocarcinoma. --2002","Peutz-Jeghers Polyp | Peutz Jeghers Polyp",,,,,,,,,,,,,,,"4174752","Peutz Jeghers polyp",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031110","Periosteum","C13184","The outer membrane that surrounds a bone. It contains connective tissue, capillaries, nerves, and a number of types of cell, including osteoclasts. The periosteum plays an important role in bone repair and growth.","Periosteum | ",,,,,,,,,,,,,,,"4143326","Periosteum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205875","Papillomatosis","C3713","Glandular or squamous cell neoplastic proliferations characterized by the formation of multiple papillary structures diffusely involving a specific anatomic site.","Papillomatosis | Papillomatosis, NOS",,,,,,,,,,,,,,,"4218400","Squamous papillomatosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518629","Osteoclast-Like Giant Cell","C36827","A large, multinucleated cell that expresses osteoclast-specific markers.","Osteoclast-Like Giant Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335059","Non-Seminomatous Lesion","C36127","A group of testicular cancers that begin in the germ cells (cells that give rise to sperm). Nonseminomas are identified by the type of cell in which they begin and include embryonal carcinoma, teratoma, choriocarcinoma, and yolk sac carcinoma.","Non-Seminomatous Lesion | Nonseminoma | Nonseminomatous Lesion | nonseminoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027430","Nasal Cavity Polyp","C3256","A soft and painless polypoid mass that arises from the mucosa in the nasal cavity.  It is usually the result of an inflammatory process.  It may recur following surgical resection.","Nasal Cavity Polyp | Nasal Polyp | Polyp of Nasal Cavity | Polyp of the Nasal Cavity",,,,,,,,,,,,,,,"42537252","Polyp of nasal cavity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1513794","Myoepithelial","C14164","Derived from epithelial cells and destined to become a part of the muscular system; having the characteristics of both muscle and epithelium.","Myoepithelial | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336956","Vertical Growth Phase","C35898","A morphologic architectural pattern in which the tumor cells spread vertically.","Vertical Growth Phase | Vertical",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL415120","Unilateral","C68598","Involving only one part or side.","Unilateral | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205645","Tubular Adenocarcinoma","C65192","An infiltrating adenocarcinoma in which the malignant cells form tubular structures. Representative examples include the tubular breast carcinoma and the gastric tubular adenocarcinoma.","Tubular Adenocarcinoma | CARCINOMA, TUBULAR CELL, MALIGNANT | Tubular adenocarcinoma","8211/3","Tubular adenocarcinoma",,,,,,,,,,,,,"4262548","Tubular adenocarcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0349658","Trichoblastoma","C27132","A benign hair follicle neoplasm with trichoblastic differentiation. It usually presents as a solitary papular lesion It most often presents on the head and neck area, but it may develop in any anatomic site containing hair follicles. Because of its benign nature, treatment usually is not required, provided that the diagnosis has been established with certainty.","Trichoblastoma | Brooke tumor | Brooke's Tumor | TRICHOEPITHELIOMA, BENIGN | Trichoblastic Fibroma | Trichoepithelioma | Trichogenic Adnexal Tumor | Trichogenic Trichoblastoma","8100/0","Trichoepithelioma",,,,,,,,,,,,,"4080713|618889","Trichoblastoma|Trichoblastoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1515432","T-Cell Differentiation in the Thymus","C19317","The progression of T cell precursors in the thymus through many stages of maturation.  These stages include regulated expression of the alpha and beta (or gamma and delta) chains of the T cell receptor, expression of both CD4 and CD8 molecules (double positive stage), down regulation to a single positive stage (CD4 or CD8), as well as allowing those thymocytes to die which are unable to bind to self MHC molecules (death by neglect), selecting those thymocytes with T Cell Receptors that are able to bind to self MHC molecules with moderate affinity (positive selection), and deleting those thymocytes having T Cell Receptors that bind with high affinity to self MHC (negative selection), before allowing mature T cells to emigrate to the periphery.","T-Cell Differentiation in the Thymus | Thymocyte Development",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206739","Spitz Nevus","C27007","An acquired or congenital benign skin melanocytic neoplasm. It can occur on any area of the body, but most commonly occurs on the face of children and the thighs of young females. It is characterized by a proliferation of large spindle, oval, or large epithelioid melanocytes in the dermal-epidermal junction. The melanocytic proliferation subsequently extends into the dermis.","Spitz Nevus | Benign Juvenile Melanoma | Epithelioid and spindle cell nevus | Juvenile Nevus | Juvenile nevus | Spindle and/ or Epithelioid Cell Nevus | Spindle cell nevus, NOS | Spitz nevus","8770/0|8772/0","Epithelioid and spindle cell nevus|Spindle cell nevus, NOS",,,,,,,,,,,,,"4110855|4338112","Epithelioid and spindle cell nevus|Epithelioid and spindle cell nevus",,,,,,,,,,,,,"--","--|--",,,,,,,,"--|--"
"C0206643","Fibroblastic Neoplasm","C7075","A benign, intermediate, or malignant mesenchymal neoplasm characterized by the presence of neoplastic fibroblasts.","Fibroblastic Neoplasm | Fibroblastic Tumor | Fibrocytic Neoplasm | Fibrocytic Neoplasm | Fibrocytic Tumor | Fibrogenic Neoplasm | FibrogenicTumor | Fibrous Neoplasm | Fibrous Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336029","Solid Pseudopapillary Carcinoma of the Pancreas","C5728","A malignant neoplasm arising from the exocrine pancreas. It occurs predominantly in young women. It is characterized by the presence of extensive necrosis and hemorrhage and is composed of polyhedral cells forming solid and pseudopapillary patterns. There is morphologic evidence of perineural invasion, vascular invasion, or extensive invasion into the surrounding tissues.","Solid Pseudopapillary Carcinoma of the Pancreas | ",,,,,,,,,,,,,,,"37204187|4019083","Solid pseudopapillary carcinoma of pancreas|Solid pseudopapillary carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL017991","Micropapillary Serous Carcinoma","C6882","An adenocarcinoma that usually arises from the ovary. It is characterized by the presence of complex micropapillary structures covered by round and cuboidal cells with a high nuclear to cytoplasmic ratio.","Micropapillary Serous Carcinoma | MPSC | Micropapillary Variant of Serous Borderline Tumor | Micropapillary serous carcinoma | SBT-MP",,,,,,,,,,,,,,,"45766411","Low grade serous carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1335656","Radial Growth Phase","C35897","A morphologic architectural pattern in which the tumor cells spread horizontally.","Radial Growth Phase | Radial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0457334","Acute Monoblastic Leukemia","C7171","An acute myeloid leukemia in which the monoblasts represent 80% or more of the total cellular population.  (WHO, 2001)","Acute Monoblastic Leukemia | Acute Monoblastic Leukemia (FAB M5a) | Acute monoblastic leukemia | M5a",,,,,,,,,,,,,,,"4319285","Acute monocytic leukemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0279641","Childhood Acute M3 Leukemia","C7968","An acute promyelocytic leukemia with t(15;17)(q24.1;q21.2); PML-RARA that occurs in children.","Childhood Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA | APL with PML-RARA | Acute Promyelocytic Leukemia with PML-RARA | Childhood APL | Childhood APL with t(15;17)(q22;q12); PML-RARA | Childhood APL with t(15;17)(q24.1;q21.2); PML-RARA | Childhood APML | Childhood APML with t(15;17)(q22;q12); PML-RARA | Childhood APML with t(15;17)(q24.1;q21.2); PML-RARA | Childhood Acute M3 Leukemia | Childhood Acute Progranulocytic Leukemia | Childhood Acute Promyelocytic Leukemia | Childhood Acute Promyelocytic Leukemia (M3) | Childhood Acute Promyelocytic Leukemia with PML-RARA | Childhood Acute Promyelocytic Leukemia with PML-RARA | Childhood Acute Promyelocytic Leukemia with t(15;17)(q22;q12); PML-RARA | Childhood Acute Promyelocytic Leukemia with t(15;17)(q22;q12); PML-RARA | Childhood Acute Promyelocytic Leukemia with t(15;17)(q22;q12); PML::RARA | Childhood Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA Fusion | Childhood Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML::RARA | Childhood Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML::RARA Fusion | Childhood M3 APL | M3 Childhood Acute Promyelocytic Leukemia | M3 Pediatric Acute Promyelocytic Leukemia | Pediatric APL | Pediatric Acute M3 Leukemia | Pediatric Acute Progranulocytic Leukemia | Pediatric Acute Promyelocytic Leukemia | Pediatric M3 APL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL031627","L2 Acute Lymphoblastic Leukemia","C27281","An antiquated term that refers to acute lymphoblastic leukemia with large and irregular lymphoblasts.","L2 Acute Lymphoblastic Leukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279589","Adult L1 Acute Lymphoblastic Leukemia","C27278","L1 acute lymphoblastic leukemia that occurs during adulthood.","Adult L1 Acute Lymphoblastic Leukemia | L1 Adult Acute Lymphoblastic Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206664","Mixed Embryonal Carcinoma and Teratoma","C3756","A germ cell tumor characterized by the presence of an embryonal carcinoma component and a teratoma component.","Mixed Embryonal Carcinoma and Teratoma | Mixed embryonal carcinoma and teratoma | Teratocarcinoma | teratocarcinoma","9081/3","Teratocarcinoma",,,,,,,,,,,,,"4284401","Teratocarcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1333713","GRM6 Gene","C24464","This gene is involved in G protein-coupled receptor signal transduction and synaptic transmission.","GRM6 Gene | GRM6 | Glutamate Receptor, Metabotropic 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333712","GRM5 Gene","C24463","This gene is involved in G protein-coupled receptor signal transduction and phospholipase C signal transduction.","GRM5 Gene | GRM5 | Glutamate Receptor, Metabotropic 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890036","Periodontal Screening and Recording","C114641","A system for assessing the health of the gums as based on the depth of the gingival sulci. The periodontal screening and recording (PSR) index divides the mouth into 6 segments (sextants) and the greatest probe depth in each sextant of the mouth is determined and recorded.","Periodontal Screening and Recording | PSR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899959","Ball-Tipped Periodontal Probe","C114643","A periodontal probe with a 0.5mm diameter ball tip and a color-coded band extending 3.5mm to 5.5 mm from the tip. It is typically used to determine sulcus depth for periodontal screening and recording.","Ball-Tipped Periodontal Probe | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897944","Periodontal Screening and Recording Code","C114647","A score that indicates the health of the gums based on the depth of the gingival sulci.","Periodontal Screening and Recording Code | Code 0 | PSR Code 0 | Periodontal Screening and Recording Code 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897947","Periodontal Screening and Recording Code 1","C114649","Indicates that all probing depth in the sextant is less than 3.5mm, but with bleeding present upon probing.","Periodontal Screening and Recording Code 1 | Code 1 | PSR Code 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897109","Periodontal Screening and Recording Code 2","C114650","Indicates that all probing depth in the sextant is less than 3.5mm, but with supragingival or subgingival calculus and/or defective margins present.","Periodontal Screening and Recording Code 2 | Code 2 | PSR Code 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897946","Periodontal Screening and Recording Code 3","C114651","Indicates that the deepest probing depth in the sextant is greater than 3.5mm but less than 5.5mm.","Periodontal Screening and Recording Code 3 | Code 3 | PSR Code 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897945","Periodontal Screening and Recording Code 4","C114652","Indicates that the deepest probing depth in the sextant is greater than 5.5mm.","Periodontal Screening and Recording Code 4 | Code 4 | PSR Code 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1848186","Malignant Sex Cord-Stromal Tumor","C67561","A gonadal sex cord-stromal tumor with malignant characteristics.  It includes the poorly differentiated ovarian Sertoli-Leydig cell tumor, malignant ovarian granulosa cell tumor, malignant ovarian steroid cell tumor, and malignant ovarian thecoma.","Malignant Sex Cord-Stromal Tumor | STROMAL TUMOR, GONADAL, MALIGNANT | Sex Cord Stromal Tumor, Malignant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0345832","Small Intestinal Neoplasm","C4432","A benign or malignant neoplasm that affects the small intestine.  Representative examples of benign neoplasms include lipoma and leiomyoma.  Representative examples of malignant neoplasms include carcinoma, lymphoma, and sarcoma.","Small Intestinal Neoplasm | Neoplasm of Small Bowel | Neoplasm of Small Intestine | Neoplasm of the Small Bowel | Neoplasm of the Small Intestine | Small Bowel Neoplasm | Small Bowel Tumor | Small Intestine Neoplasm | Small Intestine Tumor | Tumor of Small Bowel | Tumor of Small Intestine | Tumor of the Small Bowel | Tumor of the Small Intestine",,,,,,,,,,,,,,,"4131614","Neoplasm of small intestine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0151811","Subcutaneous Nodule","C39618","A small palpable mass in the subcutaneous tissues.","Subcutaneous Nodule | Subcutaneous nodules",,,,,,,,,,,,,,,"4316084","Subcutaneous nodule",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0342494","Adrenal Cortical Hyperplasia","C3506","Congenital or acquired hyperplasia of the cells of the adrenal cortex.","Adrenal Cortical Hyperplasia | Adrenal Cortex Hyperplasia | Adrenocortical Hyperplasia | Hyperplasia of Adrenal Cortex | Hyperplasia of the Adrenal Cortex",,,,,,,,,,,,,,,"4030215","Adrenocortical hyperplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023321","Lentigo","C3159","A flat, benign, pigmented spot on the skin caused by excessive deposition of melanin from an increased number of melanocytes in the cell layer directly above the basement membrane of the epidermis. Formation is usually related to sun exposure during youth, and the lesions do not typically progress to malignancy.","Lentigo | Lentiginosis",,,,,,,,,,,,,,,"35624562","Lentigo",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334281","Infiltrating Transitional Cell Carcinoma of the Urinary Bladder","C27885","An invasive urothelial carcinoma that arises from the urinary bladder urothelium.","Invasive Bladder Urothelial Carcinoma | Infiltrating Bladder Urothelial Carcinoma | Infiltrating Bladder Urothelial Carcinoma | Infiltrating Transitional Cell Carcinoma of the Urinary Bladder | Invasive Bladder Transitional Cell Carcinoma | Invasive Bladder Urothelial Carcinoma | Invasive Transitional Cell Carcinoma of the Urinary Bladder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1368683","Epithelial Neoplasm","C3709","A benign, borderline, or malignant neoplasm that arises from and is composed of epithelial cells. Representative examples include adenomas and carcinomas.","Epithelial Neoplasm | Epithelial Neoplasms, NOS | Epithelioma | Epithelioma, malignant",,,,,,,,,,,,,,,"4042149","Epithelial neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1265994","Clear Cell Neoplasm","C66752","A purely morphologic term that describes a neoplasm in which all or the majority of the neoplastic cells have a clear cytoplasm, when examined under light microscopy, using the conventional staining method (H-E). This term does not provide any information about the nature of the neoplasm (benign or malignant), cell of origin (e.g. epithelial versus mesenchymal versus hematopoietic), or prognosis. Further examination using special stains and/or immunohistochemistry is required to appropriately classify this tumor.","Clear Cell Neoplasm | ","8005/0","Clear cell tumor, NOS",,,,,,,,,,,,,"4028530","Clear cell tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0206740","Calcifying Cystic Odontogenic Tumor","C54319","A benign, intraosseous or extraosseous cystic neoplasm arising from tooth-forming tissues. It is characterized by the presence of a cyst lined by an ameloblastoma-like epithelium and ghost cells formation. The ghost cells may undergo calcification. It is treated with enucleation. Few recurrences have been reported for intraosseous neoplasms whereas no recurrences have been reported for extraosseous neoplasms.","Calcifying Cystic Odontogenic Tumor | Calcifying Odontogenic Cyst | Calcifying odontogenic cyst | Gorlin Cyst","9301/0","Calcifying odontogenic cyst",,,,,,,,,,,,,"4326726","Calcifying odontogenic cyst",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1708604","Odontogenic Keratocyst","C54302","A developmental cyst that arises from remnants of the dental lamina. It is characterized by a thin, regular lining of parakeratinized stratified squamous epithelium with palisading hyperchromatic basal cells. It occurs most frequently in the mandible. Most lesions present as painless radiolucencies and are found incidentally during radiographical examination for other reasons. Treatment is most often by enucleation, or by surgical resection for large lesions. Recurrences were more frequent in the past but are dramatically reduced with meticulous treatment. (WHO 2017)","Odontogenic Keratocyst | KCOT | KOT | Keratocystic Odontogenic Tumor | Keratocystic Odontogenic Tumor | OKC",,,,,,,,,,,,,,,"37017084","Odontogenic keratocyst",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027149","Myxoma","C6577","A benign soft tissue neoplasm characterized by the presence of spindle and stellate cells, lobulated growth pattern, and myxoid stroma formation.","Myxoma | MYXOMA, BENIGN | Myxoma, NOS","8840/0","Myxoma, NOS",,,,,,,,,,,,,"4212804|4299130","Myxoma|Myxoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0220656","Malignant Peritoneal Effusion","C3815","Accumulation of fluid in the peritoneal cavity resulting from the growth of primary or metastatic malignant neoplasms in the peritoneum.","Malignant Peritoneal Effusion | Ascites, Malignant | Malignant Ascites | Malignant Ascites | Malignant ascites, NOS | malignant ascites",,,,,,,,,,,,,,,"192735","Malignant ascites",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0598798","Lymphocytic Neoplasm","C7065","A neoplasm composed of a lymphocytic cell population which is usually malignant (clonal) by molecular genetic and/or immunophenotypic analysis.  Lymphocytic neoplasms include Hodgkin and non-Hodgkin lymphomas, acute and chronic lymphocytic leukemias, and plasma cell neoplasms.","Lymphocytic Neoplasm | Lymphocytic Tumor | Lymphocytic and Plasma Cell Neoplasm | Lymphocytic and Plasma Cell Tumor | Lymphocytic and Plasma Cell Tumour | Lymphocytic and Plasmacytic Neoplasm | Lymphoid Neoplasm | Lymphoid Tumor | Lymphoid and Plasma Cell Tumor | Lymphoid and Plasma Cell Tumour | Lymphoid and Plasmacytic Neoplasm | Lymphoid and Plasmacytic Tumor | Lymphoid and Plasmacytic Tumour",,,,,,,,,,,,,,,"4189325","Lymphoid neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512385","Hematopoietic and Lymphoid Cell","C32725","One of the cells of the blood or bone marrow, a leukocyte or erythrocyte.","Hematopoietic and Lymphoid Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227614","Left Kidney","C34006","A bean-shaped retroperitoneal organ situated below the diaphragm and posterior to the spleen.","Left Kidney | ",,,,,,,,,,,,,,,"4088232","Left kidney structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0012144","Diencephalon","C12456","The portion of the forebrain that is located between the telencephalon and the brainstem; it is composed of the thalamus, hypothalamus, subthalamus, and epithalamus, which functions to help regulate many activities of the autonomic nervous system.","Diencephalon | ",,,,,,,,,,,,,,,"4227118","Structure of diencephalon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001613","Adrenal Cortex","C12396","The outer region of the adrenal gland consisting of the zona glomerulosa, the zona fasciculata, and the zona reticularis. The adrenal cortex produces and secretes mineralocorticoids, glucocorticoids, and adrenal androgens.","Adrenal Cortex | Cortex of Adrenal Gland | Cortex of adrenal gland | Cortical | adrenal cortex",,,,,,,,,,,,,,,"4288477","Adrenal cortex structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL447292","One Hundred","C105814","A natural number greater than ninety-nine and less than one hundred-one and the quantity that it denotes.","One Hundred | 100",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346533","12 Lead Placement Standard","C71102","An electrocardiogram (ECG) lead placement whereby 12 leads are recorded, with each lead representing an electrical 'view' of the heart. The six leads recorded in the frontal plane are derived from the placement of 3 electrodes (RA or Right Arm, LA, or Left Arm, and LL or Left Leg). These bipolar frontal leads form the basis of Einthoven's triangle, and are represented by leads I, II, and III.  Three other derived (or augmented) bipolar frontal vectors are also recorded on a standard 12-lead EKG, aVR, aVF, and aVL. 6 unipolar leads, corresponding to V1 - V6 measure the electrical activity in the horizontal plane. The placement for the 'V' leads is as follows: V1: right 4th intercostal space,V2: left 4th intercostal space, V3: halfway between V2 and V4, V4: left 5th intercostal space, mid-clavicular line, V5: horizontal to V4, anterior axillary line, V6: horizontal to V5, mid-axillary line.","12 Lead Placement Standard | 12 LEAD STANDARD | 12 Lead Standard",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1328723","Coagulation Process","C21045","Any of the sequential processes by which coagulation factors interact to form a fibrin clot.","Coagulation Process | Blood Coagulation | Clotting | Coagulation | Coagulation-Related Process",,,,,,,,,,,,,,,"42537602","Coagulation process",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0223866","Lesser Trochanter","C32982","A cone-shaped projection in the shaft of the femur in which the iliopsoas muscle is attached.","Lesser Trochanter | LESSER TROCHANTER | Lesser Trochanter of the Femur",,,,,,,,,,,,,,,"4206318","Structure of lesser trochanter of femur",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227683","Left Ureter","C49324","The ureter connecting the left kidney to the bladder.","Left Ureter | ",,,,,,,,,,,,,,,"4131503","Structure of left ureter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227874","Left Ovary","C32969","The ovary that is located in the left side of the pelvis.","Left Ovary | Ovary, Left",,,,,,,,,,,,,,,"4185266","Structure of left ovary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0225730","Left Lung","C32967","The 2-lobed lung located on the left side of the body.","Left Lung | LUNG, LEFT",,,,,,,,,,,,,,,"4195613","Left lung structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2986387","Extragonadal","C94197","An area of the body other than the ovaries or testes.","Extragonadal | extragonadal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013455","Middle Ear","C12274","The part of the ear including the eardrum and ossicles. The middle ear leads to the inner ear.","Middle Ear | MIDDLE EAR | Middle ear | middle ear",,,,,,,,,,,,,,,"4100253","Middle ear structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0930553","Major Salivary Gland","C12999","One of the three larger salivary glands including the parotid, submandibular and sublingual glands.","Major Salivary Gland | Major salivary gland, NOS | major salivary gland",,,,,,,,,,,,,,,"4002730","Major salivary gland structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227486","Left Lobe of the Liver","C32965","The smaller lobe of the liver extending into the left side of the body.","Left Lobe of the Liver | LIVER, LEFT LOBE | Left Lobe",,,,,,,,,,,,,,,"4320619","Structure of left lobe of liver",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227189","Middle Third of the Esophagus","C12254","The middle one third of the esophagus in which the muscle layer is composed of muscle cells of the striated and smooth types.","Middle Third of the Esophagus | ESOPHAGUS, MIDDLE THIRD | Esophageal; Mid | Middle Third | Middle Third of Esophagus | Middle third of esophagus | middle part of esophagus",,,,,,,,,,,,,"UBERON:0013474","middle part of esophagus","4077602","Structure of middle third of esophagus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227187","Upper Third of the Esophagus","C12253","The upper one third of esophagus in which the muscle layer is composed of muscle cells of the striated type.","Upper Third of the Esophagus | ESOPHAGUS, UPPER THIRD | Esophageal; Proximal | Upper Third | Upper Third of Esophagus | Upper third of esophagus | upper esophagus",,,,,,,,,,,,,"UBERON:0013472","upper esophagus","4183397","Structure of upper third of esophagus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518248","Nerve Sheath","C41439","A protective cover encircling a nerve, nerve fiber or axon.","Nerve Sheath | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346538","12 Lead Placement Unspecified","C71101","An electrocardiogram (ECG) lead placement whereby 12 leadpoints are recorded but the position of the leads is unspecified.","12 Lead Placement Unspecified | 12 LEAD UNSPECIFIED | 12 Lead Unspecified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1331262","Striated Muscle Tissue","C12436","Striated muscles are appendicular and axial muscles typically connected at either or both ends to the bony skeleton of the body.  Striated muscle fibers contain a highly organized, contractile cytoskeletal apparatus with a striated microscopic appearance; muscle contraction is typically under voluntary control.","Striated Muscle Tissue | STRIATED MUSCLE TISSUE | Striated Muscle",,,,,,,,,,,,,,,"4040742","Striated muscle tissue",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882010","Sinonasal Tract","C54292","The area of the head comprised of the nasal cavity and paranasal sinuses.","Sinonasal Tract | Nasal Cavity and Paranasal Sinuses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227682","Right Ureter","C49327","The ureter connecting the right kidney to the bladder.","Right Ureter | ",,,,,,,,,,,,,,,"4099074","Structure of right ureter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227873","Right Ovary","C33487","The ovary that is located in the right side of the pelvis.","Right Ovary | Ovary, Right",,,,,,,,,,,,,,,"4049643","Structure of right ovary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0225706","Right Lung","C33483","The 3-lobed lung located on the right side of the body.","Right Lung | LUNG, RIGHT",,,,,,,,,,,,,,,"4141610","Right lung structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227613","Right Kidney","C34005","A bean-shaped retroperitoneal organ situated below the diaphragm and posterior to the liver.","Right Kidney | ",,,,,,,,,,,,,,,"4321753","Right kidney structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0229559","Right Adrenal Gland","C49325","The adrenal gland located on the right side of the body.","Right Adrenal Gland | ",,,,,,,,,,,,,,,"4105308","Structure of right adrenal gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042160","Uvea","C12811","The pigmented layer of the eyeball between the tough, white outer coat of the eye and the retina.","Uvea | EYE, UVEA | Iris, Ciliary Body and Choroid | Tunica Vasculosa of Eyeball | UVEA | Uveal Tract | uvea | uveal tract",,,,,,,,,,,,,,,"4254683","Uveal tract structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3539657","Hospital Anxiety and Depression Scale Questionnaire","C103520","A standardized survey developed and copyrighted by A. S. Zigmond and R. P. Snaith in 1983, 1992, 1994 and published in the Acta Psychiatrica Scandinavica journal (A.S. Zigmond and R.P. Snaith. The Hospital Anxiety and Depression Scale. Acta psychiart. scand. 1983, 67:361-370) which is used to detect depression and anxiety in individuals in a hospital or medical outpatient clinic. This instrument is a self-administered questionnaire consisting of 14 items that assess how the individual has felt over the past week. Each item as 4 response options that are associated with a score of 0 to 3.","Hospital Anxiety and Depression Scale Questionnaire | HADS | HADS Questionnaire | HADS01 | Hospital Anxiety and Depression Scale Questionnaire (HADS)",,,,,,,,,,,,,,,"4165145","Hospital anxiety and depression scale",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897491","Still Enjoy the Things I Used to Enjoy","C114635","A question about whether an individual still enjoys the things they used to enjoy.","Still Enjoy the Things I Used to Enjoy | I still enjoy the things I used to enjoy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899026","Get a Frightened Feeling Like Something Awful will Happen","C114636","A question about whether an individual feels or has felt frightened, as if something awful is about to happen.","Get a Frightened Feeling Like Something Awful will Happen | I get a sort of frightened feeling as if something awful is about to happen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899726","Can Laugh","C114637","A question about whether an individual feels or has felt that they can laugh at things.","Can Laugh | I can laugh and see the funny side of things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898913","Have Worrying Thoughts","C114638","A question about whether an individual has or had worrying thoughts.","Have Worrying Thoughts | Have Worrying Thought | Worrying thoughts go through my mind",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897065","Feel Cheerful","C114639","A question about whether an individual feels or has felt cheerful.","Feel Cheerful | I feel cheerful",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899724","Can Sit at Ease and Feel Relaxed","C114640","A question about whether an individual feels or has felt that they can sit at ease and feel relaxed.","Can Sit at Ease and Feel Relaxed | I can sit at ease and feel relaxed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899147","Feel Slowed Down","C114668","A question about whether an individual feels or has felt that they are slowed down.","Feel Slowed Down | I feel as if I am slowed down",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899027","Get a Frightened Feeling Like Butterflies in the Stomach","C114669","A question about whether an individual feels or has felt frightened, like butterflies in the stomach.","Get a Frightened Feeling Like Butterflies in the Stomach | I get a sort of frightened feeling like 'butterflies' in the stomach",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898952","Have Lost Interest in Appearance","C114670","A question about whether an individual feels or has felt that they have lost interest in their appearance.","Have Lost Interest in Appearance | I have lost interest in my appearance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2220023","Feel Restless","C114671","A question about whether an individual feels or has felt restless.","Feel Restless | I feel restless as if I have to be on the move",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898577","Look Forward with Enjoyment","C114674","A question about whether an individual looks forward to things with enjoyment.","Look Forward with Enjoyment | I look forward with enjoyment to things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899029","Get Feelings of Panic","C114676","A question about whether an individual feels or has felt sudden feelings of panic.","Get Feelings of Panic | I get sudden feelings of panic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899727","Can Enjoy a Book, Radio, or TV Program","C114677","A question about whether an individual feels or has felt that they can enjoy a book, radio, or TV program.","Can Enjoy a Book, Radio, or TV Program | I can enjoy a good book or radio or TV program",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900172","A Lot of the Time","C114678","A response indicating that something happens or happened a lot of the time.","A Lot of the Time | A lot | A lot of the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899395","Definitely as Much","C114679","A response indicating a certainty that something occurs with the same frequency or intensity as previously.","Definitely as Much | Definitely as much",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897106","Not Quite so Much","C114680","A response indicating that something occurs with a bit less frequency or intensity as previously.","Not Quite so Much | Not quite so much | Not quite so much now",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889124","Only a Little","C114684","A response indicating that something occurs with little frequency or intensity.","Only a Little | A Little | Little | Only a little",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898981","Hardly at All","C114685","A response indicating that something occurs rarely or with very little intensity.","Hardly at All | Hardly | Hardly at all | barely at all",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897194","Very Definitely and Quite Badly","C114686","A response indicating a certainty that something occurs with high intensity.","Very Definitely and Quite Badly | Very definitely and quite badly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897150","Yes, But Not Too Badly","C114692","A response indicating that something occurs with moderate intensity.","Yes, But Not Too Badly | Yes, but not too badly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900177","A Little, But it Doesn't Worry Me","C114694","A response indicating that something occurs, but causes little concern.","A Little, But it Doesn't Worry Me | A little, but it doesn't worry me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900013","As Much as Always","C114695","A response indicating that something occurs with the same frequency or intensity as previously.","As Much as Always | As much as I always could | As much as ever I did",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899396","Definitely Not So Much","C114704","A response indicating a certainty that something occurs with little frequency or intensity.","Definitely Not So Much | Definitely not so much now",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900180","A Great Deal of the Time","C114706","A response indicating that something happens or happened much of the time.","A Great Deal of the Time | A great deal of the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3842312","Not Often","C114709","A response indicating that something happens or happened infrequently.","Not Often | Not often",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899394","Definitely","C114710","A subjective answer of very strong agreement.","Definitely | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898155","Nearly All the Time","C114712","A response indicating that something happens or happened nearly all of the time.","Nearly All the Time | Nearly All of the Time | Nearly all the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897807","Quite Often","C114713","A response indicating that something happens or happened frequently.","Quite Often | Quite often",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899342","Don't Take Much Care","C114715","A response indicating that an individual does not take as much care as they should.","Don't Take Much Care | I don't take so much care as I should",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898453","May Not Take as Much Care","C114716","A response indicating that an individual may not take as much care as they should.","May Not Take as Much Care | I may not take quite as much care",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897373","Take as Much Care","C114718","A response indicating that an individual takes as much care as they always have.","Take as Much Care | I take just as much care as ever",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3841905","Not Very Much","C114719","A subjective answer of disagreement.","Not Very Much | Not very much",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897775","Rather Less","C114720","A response indicating that something occurs with less frequency or intensity as previously.","Rather Less | Rather less than I used to",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899397","Definitely Less","C114721","A response indicating a certainty that something occurs with much less frequency or intensity as previously.","Definitely Less | Definitely less than I used to",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555016","File Transfer Protocol","C100047","A network protocol designed to move files between a computer and a host over a TCP network, such as the Internet.","File Transfer Protocol | FTP | File Transfer Protocol (FTP)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898740","Intensity-Modulated Spot-Scanning Proton Therapy","C114761","A form of intensity-modulated radiation therapy that uses narrow pencil beams of protons to deliver radiation to a precise target while sparing surrounding tissues.","Intensity-Modulated Spot-Scanning Proton Therapy | Spot Scan Intensity-Modulated Proton Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899315","EGFRvIII Peptide Vaccine","C114755","An antineoplastic vaccine directed against a peptide found in the epidermal growth factor receptor class III variant (EGFRvIII), a constitutively activated mutant of the wild-type tyrosine kinase. This protein variant is present in a substantial proportion of malignant gliomas and other human cancers.","EGFRvIII Peptide Vaccine | EGFRvIII Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1832023","CDK inhibitor P276-00","C64762","A flavone and cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. Riviciclib selectively binds to and inhibits Cdk4/cyclin D1, Cdk1/cyclin B and Cdk9/cyclin T1, serine/threonine kinases that play key roles in the regulation of the cell cycle and cellular proliferation. Inhibition of these kinases leads to cell cycle arrest during the G1/S transition, thereby leading to an induction of apoptosis, and inhibition of tumor cell proliferation.","Riviciclib | CDK Inhibitor P276-00 | Cyclin Dependent Kinase Inhibitor P276 | P-276-00 Free Base | P276 | P276-00 | RIVICICLIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205229","Expand","C96889","To increase in size, volume or scope.","Expand | ",,,,,,,,,,,,,,,"4322011","Expanding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227514","Portal Triad","C33342","An anatomical unit of hepatic tissue, composed of an interlobular vein of liver, an interlobular artery of liver and an interlobular bile duct. The triads are embedded in the interlobular connective tissue and travel together throughout the liver parenchyma.","Portal Triad | ",,,,,,,,,,,,,,,"4298440","Portal triad structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3272903","Overall Response","C96613","An assessment of the overall response of the disease to the therapy.","Overall Response | OVRLRESP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641260","NOT ALL EVALUATED","C103424","Not all target lesions were assessed. Or not all non-target lesions were assessed.","Not All Lesions Evaluated | NOT ALL EVALUATED | Not All Evaluated | Not All Tumors Evaluated | Not Evaluated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3500483","P-glycoprotein Inhibitor","C114757","Any compound or agent that acts to prevent the activity of P-glycoprotein.","P-glycoprotein Inhibitor | P-gp inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0678054","Electroporation","C15707","A procedure in which in which an electrical field is applied to cells for the purpose of increasing the permeability of the cell membrane, allowing chemicals, drugs, or DNA to be introduced into the cell.","Electroporation | EPT | Electroporation | Electroporation Therapy | Electroporation Therapy | electroporation therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2603422","Rucaparib Phosphate","C78186","The phosphate salt form of rucaparib, an orally bioavailable tricyclic indole and inhibitor of poly(ADP-ribose) polymerases (PARPs) 1 (PARP1), 2 (PARP2) and 3 (PARP3), with potential chemo/radiosensitizing and antineoplastic activities. Upon administration, rucaparib selectively binds to PARP1, 2 and 3 and inhibits PARP-mediated DNA repair. This enhances the accumulation of DNA strand breaks, promotes genomic instability and induces cell cycle arrest and apoptosis. This may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy. PARPs are enzymes activated by single-strand DNA breaks that catalyze the post-translational ADP-ribosylation of nuclear proteins, which induces signaling and the recruitment of other proteins to repair damaged DNA. The PARP-mediated repair pathway plays a key role in DNA repair and is dysregulated in a variety of cancer cell types.","Rucaparib Phosphate | AG 014699 | AG-014699 | AG014699 | PARP-1 inhibitor AG014699 | PARP1 Inhibitor PF-01367338 | PF-01367338 | RUCAPARIB PHOSPHATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002057","Alkaline DNase","C114793","An enzyme that is present in human serum and catalyzes the hydrolytic cleavage of phosphodiester bond linkages in the DNA backbone. The relative activity of this enzyme can be used as a marker of therapeutic responses or disease relapse.","Alkaline DNase | Alkaline Deoxyribonuclease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412360","ALOX15B Gene","C114803","This gene plays a role in fatty acid oxidation.","ALOX15B Gene | ALOX15B | Arachidonate 15-Lipoxygenase, Type B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900018","Apoptosis Marker","C114790","A molecule or collection of biological compounds that can be objectively measured to evaluate the extent of programmed cell death occurring in a biological sample.","Apoptosis Marker | Apoptosis Biomarker | Marker of Apoptosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899955","Basement Membrane Coverage Measurement","C114791","The determination of the percentage of a blood vessel that is comprised of intact basement membrane structures.","Basement Membrane Coverage Measurement | Basement Membrane Coverage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899739","CXCL12-Abundant Reticular Cell","C114786","A fibroblast that expresses high levels of stromal cell-derived factor 1 (CXCL12), secretes type III collagen and forms processes that contact those of other similar cells to form a network of reticular fibers. These cells may play a role in hematopoietic stem cell maintenance.","CXCL12-Abundant Reticular Cell | CAR Cell | CAR Cells | CXCL12-Abundant Reticular Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899373","Dimethyl Ellagic Acid Glucuronide","C114788","An antioxidant and a methylated and glucuronidated derivative of ellagic acid that is a product of the metabolism of ellagitannins by intestinal bacteria.","Dimethyl Ellagic Acid Glucuronide | DMEAG | Dimethyl-Ellagic Acid Glucuronide | Dimethylellagic Acid Glucuronide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0067394","N,N-dimethylethylamine","C114787","An antioxidant and a methylated derivative of ellagic acid that is a product of the metabolism of ellagitannins by intestinal bacteria.","Dimethyl Ellagic Acid | DMEA | Dimethyl-Ellagic Acid | Dimethylellagic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899316","EGFRvIII Antibody","C114794","An antibody directed against the epidermal growth factor receptor class III variant (EGFRvIII).","EGFRvIII Antibody | Anti-EGFRvIII | Anti-EGFRvIII Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426797","EVL Gene","C114825","This gene is involved in actin dynamics.","EVL Gene | EVL | Enah/Vasp-Like Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898883","Histone H2","C114866","Proteins in the core histone families, histone H2A and histone H2B represent 2 of the 4 families of histones found in the core of nucleosomes. Histones in the H2A family dimerize with those in the H2B family, then two H2A/H2B dimers can associate with a tetramer containing 2 proteins from the histone H3 family and 2 proteins from the histone H4 family to form the octameric nucleosome core. The octameric complex is the basic unit for eukaryotic DNA packaging.","Histone H2 | Histone 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825597","IMP3 Gene","C114817","This gene plays a role in RNA processing.","IMP3 Gene | IMP3 | IMP3, U3 Small Nucleolar Ribonucleoprotein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898648","KIF5B/RET Fusion Gene","C114799","A fusion gene that results from a chromosomal inversion between the p and q arms of chromosome 10 which fuses the 5' portion of the KIF5B gene and the 3' portion of the RET gene. This rearrangement is associated with lung adenocarcinoma.","KIF5B/RET Fusion Gene | KIF5B-RET Fusion Gene | KIF5B::RET Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3493096","KIF5B/RET Fusion Protein, Human","C114800","A fusion protein encoded by the KIF5B/RET fusion gene. This protein is comprised of the motor domain and various portions the coiled-coil domain of the kinesin-1 heavy chain protein, fused with the C-terminal cytoplasmic domain of the proto-oncogene tyrosine-protein kinase receptor Ret protein, including the tyrosine kinase domain.","KIF5B/RET Fusion Protein | KIF5B-RET Fusion Protein | KIF5B::RET Fusion Protein | Kinesin-1 Heavy Chain/Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0050600","Melanotropin Alpha, human","C114797","Melanotropin alpha (13 aa, ~2 kDa) is encoded by the human POMC gene. This protein is involved in the positive regulation of melanin production.","Melanotropin Alpha | ACTH (1-13) | ACTH(1-13) | Alpha-Intermedin | Alpha-MSH | Alpha-Melanocortin | Alpha-Melanocyte-Stimulating Hormone | Alpha-Melanotropin | Melanocyte-Stimulating Hormone Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826495","NUF2 Gene","C114814","This gene is involved in mitosis.","NUF2 Gene | NUF2 | NUF2, NDC80 Kinetochore Complex Component Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897950","Pericyte Coverage Measurement","C114792","The determination of the percentage of a blood vessel that is comprised of pericyte processes or cell bodies.","Pericyte Coverage Measurement | Pericyte Coverage | Pericyte-Coverage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419867","SCN9A Gene","C114810","This gene is involved in the perception of pain.","SCN9A Gene | SCN9A | Sodium Channel, Voltage-Gated, Type IX, Alpha Subunit Gene | Sodium Voltage-Gated Channel Alpha Subunit 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425328","SOX17 Gene","C114832","This gene plays a role in both transcriptional regulation and embryonic development.","SOX17 Gene | SOX17 | SRY (Sex Determining Region Y)-Box 17 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420744","TJP1 Gene","C114822","This gene plays a role in cell-cell adhesion.","TJP1 Gene | TJP1 | Tight Junction Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897119","Response Assessment in Neuro-Oncology Criteria","C114879","An update to the MacDonald criteria for assessing disease progression and treatment response in glioblastoma multiforme (GBM).","Response Assessment in Neuro-Oncology Criteria | RANO | RANO Criteria | RANO Response Criteria | Response Assessment Criteria for Glioblastoma | Response Assessment in Neuro-Oncology (RANO) Response Criteria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0271819","Hurthle Cell Metaplasia of Thyroid Gland","C7763","A morphologic finding indicating transformation of follicular cells to large cells with abundant eosinophilic and granular cytoplasm (Hurthle cells) in the thyroid gland.","Hurthle Cell Metaplasia of Thyroid Gland | ",,,,,,,,,,,,,,,"4055363","Hurthle cell metaplasia of thyroid gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0456962","Rapidly","C65069","Acting or occurring in a brief period of time.","Rapidly | Fast | Rapid",,,,,,,,,,,,,,,"4303373","Rapidly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899528","Clustered Ring Enhancement","C114965","Thin rings of enhancement visible in MRI that are clustered together around breast ducts in an area that is neither a mass nor a foci.","Clustered Ring Enhancement | Clustered | Clustered Ring",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011905","Computer Assisted Diagnosis","C63604","The use of computers for the interpretation of medical images.","Computer-Aided Diagnosis | CAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963724","Antiretroviral Therapy","C94631","Treatment of retroviral infections with medications that target the virus directly, limiting the ability of infected cells to produce new virus particles.","Antiretroviral Therapy | ART | Anti-Retroviral Therapy | Anti-retroviral therapy | antiretroviral therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332690","CCL3 Gene","C24782","This gene is involved in intercellular communication.","CCL3 Gene | CCL3 | Chemokine (C-C Motif) Ligand 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640521","Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire","C102122","A standardized, multipurpose, general health survey developed by John E. Ware and copyrighted by Quality Metric Inc. and the Medical Outcomes Trust in 1996 and 2000 which is used to assess the patient's functional health and overall well-being. This second version contains 36 questions that refer to the patient's symptoms or status within the past four weeks and can be completed by the patient. For each question the patient must choose from five different responses.","Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire | Medical Outcomes Survey 36-Item Short-Form Health Survey | SF36 V2.0 STANDARD | SF36 v2.0 Standard | SF363 | Short Form 36 Health Survey",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898100","One Year Ago","C114880","The time period one year before the current time.","One Year Ago | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3841449","Much Better","C114881","In a much improved condition.","Much Better | ",,,,,,,,,,,,,,,"763707","Much better",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3841646","Somewhat Better","C114882","In a slightly improved condition.","Somewhat Better | Slightly Better",,,,,,,,,,,,,,,"763706","Slightly better",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL472528","Somewhat Worse","C114883","Showing some signs of deterioration or decline.","Somewhat Worse | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3841448","Much Worse","C114884","Showing many obvious signs of deterioration or decline.","Much Worse | ",,,,,,,,,,,,,,,"765710","Much worse",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899484","Cut Down on Amount of Time Spent on Work or Other Activities","C114885","A question about whether an individual has decreased the amount of time they have spent on work or other activities.","Cut Down on Amount of Time Spent on Work or Other Activities | Cut down on the amount of time you spent on work or other activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900126","Accomplished Less Than Liked","C114886","A question about whether an individual accomplished less than they liked.","Accomplished Less Than Liked | Accomplished less than you would like",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898591","Limited in the Kind of Work or Other Activities","C114887","A question about whether an individual is or was limited in the kind of work or other activities they could do.","Limited in the Kind of Work or Other Activities | Were limited in the kind of work or other activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898961","Have Difficulty Performing Work or Other Activities","C114888","A question about whether an individual has or had difficulty performing work or other activities.","Have Difficulty Performing Work or Other Activities | Had difficulty performing the work or other activities (for example, it took extra effort)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677660","Emotional Problem","C114900","A perceived issue with a person's emotional wellbeing.","Emotional Problem | ",,,,,,,,,,,,,,,"4305081","Emotional problems",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899381","Did Work or Other Activities Less Carefully than Usual","C114903","A question about whether an individual did work or other activities less carefully than usual.","Did Work or Other Activities Less Carefully than Usual | Did work or other activities less carefully than usual",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0741585","Bodily Pain","C114901","The sensation of acute or chronic suffering in a body region.","Bodily Pain | Body Pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898033","Pain Has Interfered with Normal Work","C114904","A question about whether an individual has or had pain that interferes with their normal work.","Pain Has Interfered with Normal Work | How much did pain interfere with your normal work",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899152","Feel Full of Life","C114905","A question about whether an individual feels or felt full of life.","Feel Full of Life | Did you feel full of life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898912","Have a Lot of Energy","C114913","A question about whether an individual has or had a lot of energy.","Have a Lot of Energy | Did you have a lot of energy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899145","Feel Worn Out","C114914","A question about whether an individual feels or felt worn out.","Feel Worn Out | Am Worn Out | Did you feel worn out | I am worn out",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899028","Get Sick Easier Than Others","C114915","A question about whether an individual thinks that they get sick easier than other people.","Get Sick Easier Than Others | I seem to get sick a little easier than other people",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900054","Am as Healthy as Anybody","C114917","A question about whether an individual feels or felt as healthy as other people.","Am as Healthy as Anybody | I am as healthy as anybody I know",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3476206","My Health is Excellent","C114922","A question about whether an individual feels or felt that their health is excellent.","My Health is Excellent | My health is excellent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0063817","Iopromide","C1137","A contrast medium.","Iopromide | IOPROMIDE | Ultravist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332725","CDC6 Gene","C20382","This gene plays a role in regulation of the early steps of DNA replication.","CDC6 Gene | CDC6 | Cell Division Cycle 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334492","MCM5 Gene","C20375","This gene is involved in the initiation and licensing of DNA replication. It also plays a role in the regulation of transcriptional activation.","MCM5 Gene | MCM5 | Minichromosome Maintenance Complex Component 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334490","MCM3 Gene","C20377","This gene is involved in regulation of DNA replication by ensuring that DNA is replicated only once during the cell cycle. It also plays a role in cell proliferation.","MCM3 Gene | MCM3 | Minichromosome Maintenance Complex Component 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427694","CD109 Gene","C102948","This gene may be involved in both signal regulation and inhibition of proteolysis.","CD109 Gene | CD109 | CD109 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899250","Exceptional Response","C115019","An achievement of either a complete disease response, or a partial disease response of at least 6 months duration in a trial or treatment where the overall response rate is less than 10 percent.","Exceptional Response | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054941","CD1 Glycoprotein","C114988","A family of glycoproteins expressed on the surface of various human antigen-presenting cells. They are related to the class I MHC molecules, and are involved in the presentation of lipid antigens to T-cells. The family is separated into group 1, expressed on cells specialized for antigen presentation, and group 2, expressed on a wider variety of cells.","CD1 Glycoprotein | CD1 | Differentiation Antigen CD1-Alpha-3",,,,,,,,,,,,,,,"4012713","Lymphocyte antigen CD1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899813","CD79","C114991","A transmembrane heterodimer consisting of B-cell antigen receptor complex-associated protein alpha chain (CD79A) and B-cell antigen receptor complex-associated protein beta chain (CD79B). CD79 is expressed almost exclusively on B cells and B-cell neoplasms and its presence is useful in the differential diagnosis of B-cell neoplasms from T-cell neoplasms or myeloid neoplasms.","CD79 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0299544","Interferon Regulatory Factor 4","C17926","Interferon regulatory factor 4 (451 aa, ~52 kDa) is encoded by the human IRF4 gene. This protein is involved in the mediation of both T-cell activation and interferon-stimulated response element promoter-dependent gene expression.","Interferon Regulatory Factor 4 | IRF-4 | IRF4 | IRF4 Protein | LSIRF | LSIRF Protein | Lymphocyte-Specific IRF | Lymphocyte-Specific Interferon Regulatory Factor | MUM1 | Multiple Myeloma Oncogene 1 | NF-EM5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1506239","CD79A protein, human","C97423","B-cell antigen receptor complex-associated protein alpha chain (226 aa, ~25 kDa) is encoded by the human CD79A gene. This protein is involved in the modulation of signaling in and proliferation of B-cells.","B-Cell Antigen Receptor Complex-Associated Protein Alpha Chain | Antigen CD79a | CD79A | CD79a | CD79a Antigen | Ig-Alpha | MB-1 Membrane Glycoprotein | Membrane-Bound Immunoglobulin-Associated Protein | Surface IgM-Associated Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986846","Standardized Uptake Value Maximum","C95012","The maximum standardized uptake value among the pixels (voxels) within a region of interest.","Standardized Uptake Value Maximum | Maximum Standardized Uptake Value | SUVMAX | SUVmax | imaging suv max | imaging_suv_max",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1536403","Cytolytic Process","C61553","Any cell death process resulting from rupture of cell membranes and loss of cytoplasm.","Cytolytic Process | Cytolysis | lysis",,,,,,,,,,,,,,,"4034461","Cytolysis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035327","Retinal Vein","C53063","A vein that drains the retina of the eye.","Retinal Vein | ",,,,,,,,,,,,,,,"4226046","Structure of retinal vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1289878","Ommaya Reservoir","C20640","A plastic, dome-shaped device, with a catheter attached to the underside used to deliver chemotherapy to the central nervous system.","Ommaya Reservoir | Ommaya reservoir",,,,,,,,,,,,,,,"4040918","Ommaya reservoir",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0730328","Central Serous Chorioretinopathy","C115124","A self-resolving eye condition characterized by fluid accumulation under the macula in the retina. It results from leakage of fluid from the choroid. It usually affects one eye only and the vast majority of patients regain full vision.","Central Serous Chorioretinopathy | CSC | Central Serous Retinopathy",,,,,,,,,,,,,,,"372894","Central serous chorioretinopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0456149","Intelligence Quotient","C115125","A score derived from a standardized test designed to assess an individual's intelligence as compared to the general population.","Intelligence Quotient | IQ",,,,,,,,,,,,,,,"4013685","Intelligence quotient",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0582638","Kaufman Assessment Battery for Children","C115126","A clinical tool used to assess a child's strengths and weaknesses in cognitive ability and mental processing.","Kaufman Assessment Battery for Children | KABC",,,,,,,,,,,,,,,"4128252","Kaufman assessment battery for children",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0475506","Raven's Progressive Matrices","C115127","A nonverbal group test typically used in educational settings, consisting of 60 multiple choice questions designed to measure the test-taker's reasoning ability.","Raven's Progressive Matrices | RPM | Raven's Matrices",,,,,,,,,,,,,,,"4165309","Raven Colored Progressive Matrices",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2609456","Wechsler Adult Intelligence Scale","C115128","A 60 question test designed to measure intelligence in adults and older adolescents.","Wechsler Adult Intelligence Scale | WAIS",,,,,,,,,,,,,,,"4241571","Intelligence test/WAIS",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3896583","Woodcock-Johnson Tests of Cognitive Abilities","C115129","A comprehensive, individually administered cognitive assessment that identifies strengths and weaknesses in cognitive abilities, processes, and academic performance.","Woodcock-Johnson Tests of Cognitive Abilities | WJ III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0871511","Test Method","C82535","The technique used to administer a particular examination or assessment.","Test Method | METHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985578","Defined Stratification Criterion","C93365","An activity defined at a global library level that identifies pre-treatment factors by which study subjects are segregated to assure balance of these factors before randomization to a study arm or some smaller segment of a study. The decisive factor used to help segregate the study subject into a stratum group.","Defined Stratification Criterion | DefinedStratificationCriterion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1173600","BIRC4 protein, human","C20947","Baculoviral IAP repeat-containing protein 4 (497 aa, ~57 kDa) is encoded by the human XIAP gene. This protein plays a role in both protein ubiquitination and the inhibition of apoptosis.","E3 Ubiquitin-Protein Ligase XIAP | Apoptosis Inhibitor 3 | BIRC4 | Baculoviral IAP Repeat-Containing Protein 4 | Baculoviral IAP Repeat-Containing Protein 4 | EC 2.3.2.27 | EC 6.3.2.-, Formerly | EC6.3.2.-, Formerly | HILP | IAP-3 | IAP-Like Protein | ILP | Inhibitor of Apoptosis Protein 3 | RING-Type E3 Ubiquitin Transferase XIAP | X-Linked IAP | X-Linked Inhibitor of Apoptosis Protein | X-linked Inhibitor of Apoptosis | hIAP-3 | hIAP3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699241","SH2D1A wt Allele","C75394","Human SH2D1A wild-type allele is located within Xq25-q26 and is approximately 27 kb in length. This allele, which encodes SH2 domain protein 1A, plays role in activation, proliferation and differentiation of B and T cells, induces production of IFN gamma, and changes the functional profile of subsets of T cells. Mutations in this gene are associated with X-linked lymphoproliferative syndrome 1 (Duncan Disease).","SH2D1A wt Allele | DSHP | EBVS | FLJ18687 | FLJ92177 | IMD5 | LYP | MTCP1 | RP5-1052M9.3 | SAP | SAP/SH2D1A | SH2 Domain Containing 1A wt Allele | SH2 Domain Protein 1A, Duncan's Disease (Lymphoproliferative Syndrome) Gene | XLP | XLPD | XLPD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521747","Mammary Gland Tissue","C12370","The glandular tissue of the breast.  In females, it is composed of numerous lobules with alveolar ducts and alveoli.  In males, it is composed of rudimentary glands.","Mammary Gland Tissue | Breast Tissue | Mammary Gland Parenchyma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017181","Gastrointestinal Hemorrhage","C48592","Bleeding originating from any part of the gastrointestinal tract.","Gastrointestinal Hemorrhage | GI Bleed | Gastrointestinal Bleed",,,,,,,,,,,,,,,"192671","Gastrointestinal hemorrhage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2985747","Contrast Agent Enhancement Indicator","C93542","Specifies whether the entity is enhanced by the use of a contrast agent.","Contrast Agent Enhancement Indicator | contrastAgentEnhancementIndicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2350467","Invariant Natural Killer T-Cell","C115216","A natural killer T-cell subtype bearing an invariant T-cell receptor. Invariant natural killer T-cells recognize a small variety of glycolipid antigens presented in the context of CD1d. These cells play a regulatory role during an immune response by producing cytokines.","Invariant Natural Killer T-Cell | Invariant natural killer T-cell | iNKT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891065","Mucosal-Associated Invariant T-Cell","C115217","A T-cell subtype bearing a semi-invariant T-cell receptor and restricted by the major histocompatibility complex related molecule MR1. These cells occupy peripheral tissues and are noted for their reactivity against various microorganisms of either bacterial or fungal origin.","Mucosal-Associated Invariant T-Cell | MAIT | Mucosal-associated invariant T-cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897682","SLAM-Associated Protein Expression Analysis","C115218","A laboratory test to determine the presence or absence of SH2 domain-containing protein 1A (SLAM-associated protein, SAP) expression. Loss of SAP expression is associated with X-linked lymphoproliferative syndrome 1.","SLAM-Associated Protein Expression Analysis | SH2D1A Expression Analysis | SH2D1A Gene Expression Analysis | Signaling lymphocyte activation molecule (SLAM)-associated protein (SAP) expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0239801","Fair Hair","C115219","A human hair color characterized by low levels of eumelanin.","Fair Hair | Fair hair",,,,,,,,,,,,,,,"4183963","Blonde hair",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1858570","Fair Skin","C115220","A human skin color characterized by low levels of eumelanin.","Fair Skin | Fair skin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1458140","Bleeding Diathesis","C115221","A coagulation disorder characterized by a tendency for excessive bleeding.","Bleeding Diathesis | Bleeding Disorder | Bleeding Predisposition | Bleeding Tendency | Bleeding diathesis",,,,,,,,,,,,,,,"432585","Blood coagulation disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3163616","Blood Loss","C50470","Loss of blood from the circulation, either internally or externally.","Blood Loss | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900205","17pter-q21","C115145","A chromosome band that encompasses the entire p arm and part of the q arm of chromosome 17.","17pter-q21 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412286","AGRP Gene","C115166","This gene plays a role in feeding behavior.","AGRP Gene | AGRP | Agouti Related Protein Homolog (Mouse) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427656","ANO1 Gene","C115173","This gene plays a role in chloride transport.","ANO1 Gene | ANO1 | Anoctamin 1, Calcium Activated Chloride Channel Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899972","BIRC5 Antibody","C115151","Any immunoglobulin that recognizes baculoviral IAP repeat-containing protein 5.","BIRC5 Antibody | Anti-BIRC5 Antibody | Anti-Baculoviral IAP Repeat-Containing Protein 5 Antibody | Anti-IAP4 Antibody | Anti-Survivin Antibody | Baculoviral IAP Repeat-Containing Protein 5 Antibody | IAP4 Antibody | Survivin Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414368","CELA1 Gene","C115176","This gene is involved in protein hydrolysis.","CELA1 Gene | CELA1 | Chymotrypsin-Like Elastase Family, Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899623","Circulating Stem Cell","C115116","A primitive cell found in the peripheral blood that has the ability either to divide and renew the primitive cell pool or to differentiate into various specialized cell types.","Circulating Stem Cell | Circulating Progenitor Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899455","DU-PAN-2","C115142","A sialylated carbohydrate antigen that is found in serum at elevated levels in pancreatic cancer and other neoplastic diseases. DU-PAN-2 is related to the type 1 Lewis blood antigen family and is a precursor for CA19-9.","DU-PAN-2 | DUPAN-2 | Sialyl Le(c) | Sialyl Le(c) Antigen | Sialyl LeC | Sialyl Lewis (c) | Sialyl Lewis C | Sialylated Lewis (c) | Sialylated Lewis (c) Antigen | Sialylated Lewis (c);  | Sialylated Lewis C | Sialylated Lewis C Antigen | sLeC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415068","GJA1 Gene","C115170","This gene is involved in gap junction assembly.","GJA1 Gene | GJA1 | Gap Junction Protein, Alpha 1, 43kDa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898558","MAGEA3 Antibody","C115157","Any immunoglobulin that recognizes melanoma-associated antigen 3 protein.","MAGEA3 Antibody | Anti-CT1.3 Antibody | Anti-Cancer/Testis Antigen 1.3 Antibody | Anti-MAGE3 Antibody | Anti-MAGEA3 Antibody | Anti-Melanoma-Associated Antigen 3 Antibody | CT1.3 Antibody | Cancer/Testis Antigen 1.3 Antibody | MAGE3 Antibody | Melanoma-Associated Antigen 3 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417215","MMRN1 Gene","C115182","This gene is involved in the storage of coagulation factor V/Va in platelets.","MMRN1 Gene | MMRN1 | Multimerin 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417494","MUC2 Gene","C115185","This gene plays a role in the lubrication of mucosal surfaces.","MUC2 Gene | MUC2 | Mucin 2, Oligomeric Mucus/Gel-Forming Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898051","PDGFR Antibody","C115146","Any immunoglobulin that recognizes any member of the platelet-derived growth factor receptor family.","PDGFR Antibody | Anti- Platelet-Derived Growth Factor Receptor Antibody | Anti-CD140 Antibody | Anti-PDGF-R Antibody | Anti-PDGFR Antibody | CD140 Antibody | PDGF-R Antibody | Platelet-Derived Growth Factor Receptor Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898043","PMEL Antibody","C115159","Any immunoglobulin that recognizes melanocyte protein PMEL.","PMEL Antibody | Anti-Melanocyte Protein PMEL Antibody | Anti-PMEL Antibody | Anti-SILV Antibody | Anti-gp100 Antibody | Melanocyte protein PMEL Antibody | SILV Antibody | gp100 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418795","PPIB Gene","C115179","This gene plays a role in catalyzing protein folding.","PPIB Gene | PPIB | Peptidylprolyl Isomerase B (Cyclophilin B) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420701","TFF2 Gene","C115188","This gene is involved in the inhibition of both gastric acid secretion and gastrointestinal motility.","TFF2 Gene | TFF2 | Trefoil Factor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897381","TP53 Antibody","C115155","Any immunoglobulin that recognizes cellular tumor antigen p53 protein.","TP53 Antibody | Anti-Cellular Tumor Antigen p53 Antibody | Anti-TP53 Antibody | Anti-Tumor Protein p53 Antibody | Anti-p53 Antibody | Cellular Tumor Antigen p53 Antibody | Tumor Protein p53 Antibody | p53 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897376","TUBA1B Antibody","C115148","Any immunoglobulin that recognizes tubulin alpha-1B chain protein.","TUBA1B Antibody | Anti-K-Alpha-1 Tubulin Antibody | Anti-TUBA1B Antibody | Anti-Tubulin Alpha-1B Chain Antibody | K-Alpha-1 Tubulin Antibody | Tubulin Alpha-1B Chain Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897022","Type V Collagen Antibody","C115147","Any immunoglobulin that recognizes type V collagen.","Type V Collagen Antibody | Anti-Collagen Type V Antibody | Anti-Collagen V Antibody | Anti-Type V Collagen Antibody | Anti-Type-V Collagen Antibody | Collagen Type V Antibody | Collagen V Antibody | Type-V Collagen Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL421088","Microscopic Examination","C90424","An assessment by microscope.","Microscopic Examination | MIEXAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0535996","Cytochrome P450 3A5, Human","C45999","Cytochrome P450 3A5 (502 aa, ~57 kDa) is encoded by the human CYP3A5 gene. This protein is involved in the oxidation of steroids, fatty acids, and xenobiotics.","Cytochrome P450 3A5 | CYP3A5 | CYPIIIA5 | Cytochrome P450-PCN3 | EC 1.14.14.1 | HLp2 | P450-PCN3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414172","DSP Gene","C88034","This gene is involved in desmosome structure.","DSP Gene | DSP | Desmoplakin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336622","TGFB3 Gene","C20913","This gene plays a role in cell growth, proliferation and biogenesis/organization. It is also involved in epithelial-mesenchymal interactions.","TGFB3 Gene | TGFB3 | Transforming Growth Factor, Beta 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919466","FGF4 Gene","C18532","This gene is involved in development and spermatogenesis.","FGF4 Gene | FGF4 | Fibroblast Growth Factor 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332763","CKB Gene","C21234","This gene plays a role in cellular energy homeostasis.","CKB Gene | CKB | Creatine Kinase, Brain Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334907","NTF3 Gene","C24644","This gene is involved in the development of embryonic neurons and maintenance of the adult nervous system.","NTF3 Gene | NTF3 | Neurotrophin 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417157","CD99 Gene","C102939","This gene plays a role in the cell adhesion process.","CD99 Gene | CD99 | CD99 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1367475","CD2 Gene","C21361","This gene is involved in T-cell activation and immune recognition.","CD2 Gene | CD2 | CD2 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1947932","Smear - instruction imperative","C65126","The action of spreading a thin layer of material across a surface.","Smear | SMEAR | Spread",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416396","IL1R2 Gene","C38913","This gene plays a role in the modulation of ligand interactions and cytokine regulation.","IL1R2 Gene | IL1R2 | Interleukin 1 Receptor, Type II Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420702","TFF3 Gene","C101769","This gene is involved in maintenance of the intestinal mucosa.","TFF3 Gene | TFF3 | Trefoil Factor 3 (Intestinal) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0076891","Trandolapril","C61978","A non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. As a prodrug, trandolapril is converted by de-esterification in the liver into its active form trandolaprilat. Trandolaprilat competitively binds to and inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the potent vasoconstrictive actions of angiotensin II and results in vasodilation. Trandolaprilat also decreases angiotensin II-induced aldosterone secretion by the adrenal cortex, which leads to an increase in sodium excretion and subsequently increases water outflow.","Trandolapril | Mavik | TRANDOLAPRIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897242","University of Washington Quality of Life Scale, Version 4","C115228","A questionnaire designed to assess health-related quality of life in head and neck cancer patients.","University of Washington Quality of Life Scale, Version 4 | UW QOLv4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898227","Most Important Issue","C115229","A question about a person's most important health issues.","Most Important Issue | Most Important Issues | Which issues have been the most important to you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898351","Mild Pain Not Needing Medication","C115230","A response indicating that an individual has mild pain, but that it does not require medication.","Mild Pain Not Needing Medication | There is mild pain not needing medication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898950","Have Moderate Pain that Requires Medication","C115231","A response indicating that an individual has moderate pain that requires medication to control.","Have Moderate Pain that Requires Medication | I have moderate pain - requires regular medication (codeine or nonnarcotic)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898936","Have Severe Pain Controlled Only By Narcotics","C115232","A response indicating that an individual has severe pain that is only controlled by narcotic medications.","Have Severe Pain Controlled Only By Narcotics | I have severe pain controlled only by narcotics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898935","Have Severe Pain Not Controlled By Medication","C115233","A response indicating that an individual has severe pain that is not controlled by medication.","Have Severe Pain Not Controlled By Medication | I have severe pain, not controlled by medication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898135","No Change in Personal Appearance","C115234","A response indicating that an individual has or had no change in their appearance.","No Change in Personal Appearance | There is no change in my appearance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898303","Minor Change in Appearance","C115235","A response indicating that an individual has or had a minor change in their appearance.","Minor Change in Appearance | The change in my appearance is minor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899913","Bothered by Appearance but Remain Active","C115236","A response indicating that an individual is bothered by a change in their appearance but that they remain active.","Bothered by Appearance but Remain Active | My appearance bothers me but I remain active",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899148","Feel Significantly Disfigured and Limit Activities Due to Appearance","C115237","A response indicating that an individual feels disfigured and that this change in their appearance limits their activities.","Feel Significantly Disfigured and Limit Activities Due to Appearance | I feel significantly disfigured and limit my activities due to my appearance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897135","Cannot Be With People Due to Appearance","C115238","A response indicating that an individual feels that they cannot be with other people due to a change in their appearance.","Cannot Be With People Due to Appearance | I cannot be with people due to my appearance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900014","As Active as Have Ever Been","C115239","A response indicating that an individual is as active as ever.","As Active as Have Ever Been | I am as active as I have ever been",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900009","At Times Can't Keep Up With Usual Pace","C115240","A response indicating that an individual cannot keep up their old pace, but that this is not often.","At Times Can't Keep Up With Usual Pace | There are times when I can't keep up my old pace, but not often",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898106","Often Tired and Have Slowed Down Activities But Still Get Out","C115241","A response indicating that an individual is often tired and has slowed down, but still gets out.","Often Tired and Have Slowed Down Activities But Still Get Out | I am often tired and have slowed down my activities although I still get out",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899343","Don't Go Out Because of Lack of Strength","C115242","A response indicating that an individual does not go out due to a lack of strength.","Don't Go Out Because of Lack of Strength | I don't go out because I don't have the strength",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897212","Usually in Bed or Chair and Don't Leave Home","C115243","A response indicating that an individual does not go out and is usually in bed or a chair.","Usually in Bed or Chair and Don't Leave Home | I am usually in bed or chair and don't leave home",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898134","No Limitations to Recreation at Home or Away","C115244","A response indicating that an individual is not limited in their recreation at home or away.","No Limitations to Recreation at Home or Away | There are no limitations to recreation at home or away from home",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899118","Few Limitations But Still Go Out and Enjoy Life","C115246","A response indicating that an individual has a few things they cannot do, but they still get out and enjoy life.","Few Limitations But Still Go Out and Enjoy Life | There are a few things I can't do but I still get out and enjoy life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898466","Many Times Wish to Go Out More But Not Up to It","C115247","A response indicating that an individual wishes to get out more, but is not up to it.","Many Times Wish to Go Out More But Not Up to It | There are many times when I wish I could get out more, but I'm not up to it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897639","Severe Limitations, Mostly Stay Home and Watch Television","C115249","A response indicating that an individual has severe limitations to what they can do and mostly stays at home watching TV.","Severe Limitations, Mostly Stay Home and Watch Television | There are severe limitations to what I can do, mostly I stay at home and watch TV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899718","Can't Do Anything Enjoyable","C115251","A response indicating that an individual can't do anything enjoyable.","Can't Do Anything Enjoyable | I can't do anything enjoyable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899723","Can Swallow as Well as Ever","C115256","A response indicating that an individual can swallow as well as ever.","Can Swallow as Well as Ever | I can swallow as well as ever",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899712","Cannot Swallow Certain Solid Foods","C115260","A response indicating that an individual cannot swallow certain solid foods.","Cannot Swallow Certain Solid Foods | I cannot swallow certain solid foods",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899725","Can Only Swallow Liquid Food","C115262","A response indicating that an individual can only swallow liquid foods.","Can Only Swallow Liquid Food | I can only swallow liquid food",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899713","Cannot Swallow Because it Causes Choking","C115264","A response indicating that an individual cannot swallow because it chokes them.","Cannot Swallow Because it Causes Choking | I cannot swallow because it 'goes down the wrong way' and chokes me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899728","Can Chew as Well as Ever","C115265","A response indicating that an individual can chew as well as ever.","Can Chew as Well as Ever | I can chew as well as ever",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897136","Can Eat Soft Solids But Cannot Chew Some Foods","C115271","A response indicating that an individual can eat soft solids but cannot chew some foods.","Can Eat Soft Solids But Cannot Chew Some Foods | I can eat soft solids but cannot chew some foods",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899714","Cannot Even Chew Soft Solids","C115272","A response indicating that an individual cannot chew soft solid foods.","Cannot Even Chew Soft Solids | I cannot even chew soft solids",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897547","Speech is Same as Always","C115273","A response indicating that an individual's speech has not changed.","Speech is Same as Always | My speech is the same as always",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898960","Have Difficulty Saying Some Words But Can Be Understood Over the Phone","C115276","A response indicating that an individual has difficulty saying some words, but can be understood over the phone.","Have Difficulty Saying Some Words But Can Be Understood Over the Phone | I have difficulty saying some words but I can be understood over the phone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898099","Only Family and Friends Can Understand Me","C115277","A response indicating that an individual can only be understood by friends and family.","Only Family and Friends Can Understand Me | Only my family and friends can understand me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899715","Cannot Be Understood","C115280","A response indicating that an individual cannot be understood.","Cannot Be Understood | I cannot be understood",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898948","Have No Problem with Shoulder","C115282","A response indicating that an individual has no problem with their shoulder.","Have No Problem with Shoulder | I have no problem with my shoulder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897617","Shoulder is Stiff But has Not Affected Activity or Strength","C115283","A response indicating that an individual has shoulder stiffness, but this has not affected their activity or strength.","Shoulder is Stiff But has Not Affected Activity or Strength | My shoulder is stiff but it has not affected my activity or strength",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898009","Pain or Weakness in Shoulder has Caused Work Change","C115285","A response indicating that an individual has or had shoulder pain or weakness that has caused a work change.","Pain or Weakness in Shoulder has Caused Work Change | Pain or weakness in my shoulder has caused me to change my work",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899710","Cannot Work Due to Problems with Shoulder","C115286","A response indicating that an individual cannot work due to shoulder problems.","Cannot Work Due to Problems with Shoulder | I cannot work due to problems with my shoulder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899721","Can Taste Food Normally","C115287","A response indicating that an individual can taste food normally.","Can Taste Food Normally | I can taste food normally",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899720","Can Taste Most Foods Normally","C115288","A response indicating that an individual can taste most foods normally.","Can Taste Most Foods Normally | I can taste most foods normally",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899719","Can Taste Some Foods","C115289","A response indicating that an individual can only taste some foods.","Can Taste Some Foods | I can taste some foods",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899711","Cannot Taste Any Foods","C115290","A response indicating that an individual cannot taste any foods.","Cannot Taste Any Foods | I cannot taste any foods",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897658","Saliva is of Normal Consistency","C115293","A response indicating that an individual has saliva of normal consistency.","Saliva is of Normal Consistency | My saliva is of normal consistency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898954","Have Less Saliva Than Normal, but it is Enough","C115294","A response indicating that an individual has less, but enough, saliva.","Have Less Saliva Than Normal, but it is Enough | I have less saliva than normal, but it is enough",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898932","Have Too Little Saliva","C115295","A response indicating that an individual has too little saliva.","Have Too Little Saliva | I have too little saliva",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898947","Have No Saliva","C115296","A response indicating that an individual has no saliva.","Have No Saliva | I have no saliva",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898259","Mood is Excellent and Unaffected by Cancer","C115298","A response indicating that an individual is in excellent mood unaffected by their cancer.","Mood is Excellent and Unaffected by Cancer | My mood is excellent and unaffected by my cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897077","Mood is Generally Good and Only Occasionally Affected by Cancer","C115299","A response indicating that an individual is in generally good mood, only occasionally affected by their cancer.","Mood is Generally Good and Only Occasionally Affected by Cancer | My mood is generally good and only occasionally affected by my cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898151","Neither in a Good Mood nor Depressed About My Cancer","C115300","A response indicating that an individual is neither in a good mood nor depressed about their cancer.","Neither in a Good Mood nor Depressed About My Cancer | I am neither in a good mood nor depressed about my cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897006","Somewhat Depressed About My Cancer","C115301","A response indicating that an individual is somewhat depressed about their cancer.","Somewhat Depressed About My Cancer | I am somewhat depressed about my cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899186","Extremely Depressed About My Cancer","C115303","A response indicating that an individual is extremely depressed about their cancer.","Extremely Depressed About My Cancer | I am extremely depressed about my cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898121","Not Anxious About My Cancer","C115305","A response indicating that an individual is not anxious about their cancer.","Not Anxious About My Cancer | I am not anxious about my cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897074","A Little Anxious About My Cancer","C115306","A response indicating that an individual is a little anxious about their cancer.","A Little Anxious About My Cancer | I am a little anxious about my cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896983","Anxious About My Cancer","C115307","A response indicating that an individual is anxious about their cancer.","Anxious About My Cancer | I am anxious about my cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897196","Very Anxious About My Cancer","C115308","A response indicating that an individual is very anxious about their cancer.","Very Anxious About My Cancer | I am very anxious about my cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898065","Outstanding","C115309","Superior or excellent in nature.","Outstanding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899276","Eat Sufficient Amount to Meet Needs","C115338","A question about whether an individual eats enough to meet their needs.","Eat Sufficient Amount to Meet Needs | The amount I eat is sufficient to meet my needs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897159","Worried About Weight","C115340","A question about whether an individual is worried about their weight.","Worried About Weight | I am worried about my weight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898228","Most Food Tastes Unpleasant","C115341","A question about whether an individual feels or felt that most food tastes unpleasant.","Most Food Tastes Unpleasant | Most food tastes unpleasant to me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899508","Concerned About Thinness of Appearance","C115342","A question about whether an individual is or was concerned about how thin they look.","Concerned About Thinness of Appearance | I am concerned about how thin I look",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898576","Lose Interest in Food when Trying to Eat","C115343","A question about whether an individual's interest in food drops as soon as they try to eat.","Lose Interest in Food when Trying to Eat | My interest in food drops as soon as I try to eat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898963","Have Difficulty Eating Rich or Heavy Foods","C115344","A question about whether an individual has or had difficulty eating rich or heavy foods.","Have Difficulty Eating Rich or Heavy Foods | I have difficulty eating rich or 'heavy' foods",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899236","Experience Pressure from Family or Friends to Eat","C115345","A question about whether an individual's family or friends are or have been pressuring them to eat.","Experience Pressure from Family or Friends to Eat | My family or friends are pressuring me to eat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898969","Have Been Vomiting","C115346","A question about whether an individual has been vomiting.","Have Been Vomiting | I have been vomiting | Vomiting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897646","Seem to Get Full Quickly","C115347","A question about whether an individual gets full quickly when they eat.","Seem to Get Full Quickly | When I eat, I seem to get full quickly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899035","General Health is Improving","C115348","A question about whether an individual feels or felt that their general health is improving.","General Health is Improving | My general health is improving",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2350866","Eribulin","C96748","An analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression.","Eribulin | 2-(3-Amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopentacosin-5-(4H)-one | E 7389 | E-7389 | ER 086526 | ER-086526 | ER086526 | ERIBULIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897072","Centrifuged Smear Slide","C115350","A microscope slide prepared by depositing cells directly onto a slide by centrifugation. The cytocentrifuge spins at an angle, at low speeds, allowing the cells to adhere to the slide in a monolayer format.","Centrifuged Smear Slide | Cytospin Slide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388343","Mucosal Melanoma","C114828","A melanoma that arises from a mucosal site.","Mucosal Melanoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4228122","Areflexia","C115420","A finding indicating the complete absence of neurological reflexes.","Areflexia | ",,,,,,,,,,,,,,,"4290597","Absent reflex",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1413716","CRP Gene","C60649","This gene plays a role in immune and inflammatory processes.","CRP Gene | C-Reactive Protein, Pentraxin-Related Gene | CRP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899251","Exceptional Responder","C115625","A cancer patient showing either a complete disease response, or a partial disease response of at least 6 months duration in a trial or treatment where the overall response rate is less than 10 percent.","Exceptional Responder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705519","NRAS wt Allele","C52549","Human NRAS wild-type allele is located in the vicinity of 1p13.2 and is approximately 53 kb in length. This allele, which encodes GTPase NRas protein, may be involved in cellular growth modulation. Mutations in the gene are frequent in juvenile and acute myelomonocytic leukemias.","NRAS wt Allele | ALPS4 | CMNS | N-RAS | NCMS | NRAS1 | NS6 | Neuroblastoma RAS Viral (v-Ras) Oncogene Homolog Gene | Neuroblastoma RAS Viral Oncogene Homolog wt Allele | V-Ras Neuroblastoma RAS Viral Oncogene Homolog Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0425092","Self-Employed","C116000","The earning of income directly from customers, clients, or other organizations rather than as a specified salary or wages from an employer.","Self-Employed | Self-Employment | Self-employed",,,,,,,,,,,,,,,"4059636","Self-employed",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897659","Salaried Annual Employment","C116001","An employment agreement where the employer pays an arranged amount at a steady yearly interval regardless of hours worked.","Salaried Annual Employment | Salaried Annual Worker | Salaried annual",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0681101","hourly wage","C116002","An employment arrangement where a worker is compensated a wage based on the number of hours worked.","Hourly Employment | Hourly Wage Employment | Wages hourly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022423","Judgment","C113685","The act of assessing a situation or event.","Judgment | Judgement | Judgement",,,,,,,,,,,,,,,"4247530","Judgement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030350","Papaverine","C726","An opiate alkaloid isolated from the plant Papaver somniferum and produced synthetically.  As a direct-acting smooth muscle relaxant, papaverine is not closely related to the other opium alkaloids in structure or pharmacological actions; its mechanism of action may involve the non-selective inhibition of phosphodiesterases and direct inhibition of calcium channels. This agent also exhibits antiviral activity against respiratory syncytial virus, cytomegalovirus, and HIV. (NCI04)","Papaverine | Cerebid | Cerespan | PAPAVERINE | Pavabid | Pavacap | Pavatym | Robaxapap",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040519","Tourniquet","C93057","A device, such as a strip of cloth or a band of rubber, that is wrapped tightly around a leg or an arm to prevent the flow of blood to the leg or the arm for a period of time. A tourniquet may be used when drawing blood or to stop bleeding after an injury.","Tourniquet | tourniquet",,,,,,,,,,,,,,,"4242387","Tourniquet",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL523864","Hard","C113682","Solid and firm to the touch; unyielding to pressure.","Hard | ",,,,,,,,,,,,,,,"4217645","Hard",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704584","Pin Device Component","C50101","A small, slender object designed to secure another object.","Pin Device | Pin | Pin Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0597345","biological radiation resistance","C116005","The property of being unsusceptible to the usual effects caused by exposure to a given level of radiation.","Radioresistance | Radiation Resistance | Radioresistant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896640","Prognosis Treatment and Perceptions Questionnaire","C115446","A 13-item questionnaire used to assess information preferences, perceptions of prognosis and goal of therapy, and communication about end-of-life care.","Prognosis Treatment and Perceptions Questionnaire | PTPQ | Prognosis Treatment and Perceptions Questionnaire (PTPQ)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897864","Preference for Details of Information About Diagnosis and Treatment","C115447","A question about a person's preference for details of information about the patient's diagnosis and treatment.","Preference for Details of Information About Diagnosis and Treatment | What is your loved one's preference for details of information about their diagnosis and treatment | What is your preference for details of information about your diagnosis and treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897774","Rating of the Quality of Information from Oncologist About Treatment Choices","C115448","A question about a person's rating of the quality of information they have received from an oncologist about treatment and treatment choices available.","Rating of the Quality of Information from Oncologist About Treatment Choices | How would you rate the quality of the information you have been given by your oncologist about treatment and the treatment choices available for you | How would you rate the quality of the information your loved one has been given by their oncologist about treatment and the treatment choices available",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897977","Patient's Primary Goal of Current Cancer Treatment","C115449","A question about a person's primary goal of the patient's current cancer treatment.","Patient's Primary Goal of Current Cancer Treatment | If you had to choose one, what would you say is your loved one's primary goal of their current cancer treatment | If you had to choose one, what would you say is your primary goal of your current cancer treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898102","Oncologist's Primary Goal of Current Cancer Treatment","C115450","A question about an oncologist's primary goal for the patient's current cancer treatment.","Oncologist's Primary Goal of Current Cancer Treatment | If you had to choose one, what would you say is your loved one's oncologist's primary goal of their current cancer treatment | If you had to choose one, what would you say is your oncologist's primary goal of your current cancer treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889659","Importance of Knowing About Cancer Prognosis","C115451","A question about a person's importance in knowing the prognosis of the patient's cancer.","Importance of Knowing About Cancer Prognosis | How important is it for you to know about the likely outcome of your cancer over time (i.e. your prognosis) | How important is it for your loved one to know about the likely outcome of their cancer over time (i.e. their prognosis)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889685","Conversation with Oncologist About Cancer Prognosis","C115452","A question about whether a person had a conversation with their oncologist about the prognosis of the patient's cancer.","Conversation with Oncologist About Cancer Prognosis | How often has your loved one had a conversation with their oncologist about the likely outcome of their cancer over time (i.e. their prognosis) | How often have you had a conversation with your oncologist about the likely outcome of your cancer over time (i.e. your prognosis)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899144","Feelings About the Amount of Information Known About Cancer Prognosis","C115453","A question about a person's feelings about the amount of information they know about the likely outcome of the patient's cancer.","Feelings About the Amount of Information Known About Cancer Prognosis | All things considered, how do you feel about the amount of information you know about the likely outcome of your cancer over time (i.e. your prognosis) | All things considered, how do you feel about the amount of information your loved one knows about the likely outcome of their cancer over time (i.e. their prognosis)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897015","Quality of the Information Received About Cancer Prognosis","C115454","A question about a person's rating of the quality of information they have received from an oncologist about treatment and treatment choices available.","Quality of the Information Received About Cancer Prognosis | How would you rate the quality of the information you have been given by your oncologist about the likely outcome of your cancer over time (i.e. your prognosis) | How would you rate the quality of the information your loved one has been given by their oncologist about the likely outcome of their cancer over time (i.e. their prognosis)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898852","How Helpful has Knowing Your Prognosis Been for Making Decisions About Treatment","C115455","A question about helpful it's been to a person to know about the patient's prognosis in making decisions about treatment.","How Helpful has Knowing Your Prognosis Been for Making Decisions About Treatment | How helpful has knowing about their prognosis been for your loved one in making decisions about treatment | How helpful has knowing about your prognosis been for making decisions about treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898851","How Helpful has Knowing Your Prognosis Been for Preparing for the Future","C115456","A question about helpful it's been to a person to know about the patient's prognosis in preparing for the future.","How Helpful has Knowing Your Prognosis Been for Preparing for the Future | How helpful has knowing about their prognosis been for your loved one in preparing for the future | How helpful has knowing about your prognosis been for preparing for the future",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898854","How Helpful has Knowing Your Prognosis Been for Coping with the Disease","C115622","A question about helpful it's been to a person to know about the patient's prognosis in coping with the patient's disease.","How Helpful has Knowing Your Prognosis Been for Coping with the Disease | How helpful has knowing about their prognosis been for your loved one in coping with their disease | How helpful has knowing about your prognosis been for coping with the disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898855","How Helpful has Knowing Your Prognosis Been Overall","C115624","A question about helpful, overall, it's been to a person to know about the patient's prognosis.","How Helpful has Knowing Your Prognosis Been Overall | Overall, how helpful has knowing about prognosis been for you | Overall, how helpful has knowing about prognosis been for your loved one",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899485","Current Medical Status","C115767","A question about a person's description of the patient's current medical status.","Current Medical Status | How would you describe your current medical status | How would you describe your loved one's current medical status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898602","Likelihood of Cancer Cure","C115768","A question about how likely a person thinks the patient's cancer cure will be.","Likelihood of Cancer Cure | How likely do you think it is that you will be cured of cancer | How likely do you think it is that your loved one will be cured of cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897167","Wishes About Care if Dying","C115770","A question about whether the patient has discussed with their oncologist the care they want to receive if they are dying.","Wishes About Care if Dying | Has your loved one and their oncologist discussed any particular wishes about the care they would want to receive if they were dying | Have you and your oncologist discussed any particular wishes you have about the care you would want to receive if you were dying",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899630","Chosen Course of Treatment","C115771","A question about whether a patient would prefer treatment to prolong their life or reduce their discomfort.","Chosen Course of Treatment | Chosen course of treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897867","Prefer Not to Hear a Lot of Details","C115773","A question about whether a person would prefer not to hear a lot of details.","Prefer Not to Hear a Lot of Details | I prefer not to hear a lot of details | They prefer not to hear a lot of details",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897866","Prefer to Hear Details in Certain Situations","C115774","A question about whether a person would prefer to hear details only in certain circumstances.","Prefer to Hear Details in Certain Situations | I want to hear details only in certain situations, such as when tests are abnormal or when treatment decisions need to be made | They want to hear details only in certain situations, such as when tests are abnormal or when treatment decisions need to be made",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897865","Prefer to Hear as Many Details as Possible","C115900","A question about whether a person would prefer to hear as many details as possible.","Prefer to Hear as Many Details as Possible | I want to hear as many details as possible in all situations relating to my cancer and its treatment | They want to hear as many details as possible in all situations relating to their cancer and its treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897856","Primary Goal to Lessen Suffering","C115901","A response indicating that a person's primary treatment goal is to reduce suffering.","Primary Goal to Lessen Suffering | To lessen my suffering as much as possible | To lessen their suffering as much as possible",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897857","Primary Goal to Keep Hoping","C115902","A response indicating that a person's primary treatment goal is to be able to keep hoping.","Primary Goal to Keep Hoping | For me and/or my family to be able to keep hoping | For them and/or their family to be able to keep hoping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897859","Primary Goal to Have Done Everything","C115903","A response indicating that a person's primary treatment goal is to make sure that everything has been done.","Primary Goal to Have Done Everything | To make sure I have done everything | To make sure they have done everything",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897860","Primary Goal to Extend Life","C115904","A response indicating that a person's primary treatment goal is to extend life as long as possible.","Primary Goal to Extend Life | To extend my life as long as possible | To extend their life as long as possible",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897861","Primary Goal to Cure the Cancer","C115906","A response indicating that a person's primary treatment goal is to cure the cancer.","Primary Goal to Cure the Cancer | To cure my cancer | To cure their cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897858","Primary Goal to Help Cancer Research","C115908","A response indicating that a person's primary treatment goal is to help cancer research.","Primary Goal to Help Cancer Research | To help cancer research",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897179","Want More Information About Prognosis","C115909","A response indicating that a person would like more information about the patient's prognosis.","Want More Information About Prognosis | I wish I had more information about my prognosis | They wish they had more information about their prognosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898938","Have Right Amount of Information About Prognosis","C115911","A response indicating that a person has the right amount of information about the patient's prognosis.","Have Right Amount of Information About Prognosis | I now have about the right amount of information | They now have about the right amount of information",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897180","Want Less Information About Prognosis","C115913","A response indicating that a person would have liked less information about the patient's prognosis.","Want Less Information About Prognosis | I wish I had less information about my prognosis | They wish they had less information about their prognosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899185","Extremely Important","C115918","A subjective answer of extreme agreement regarding the importance of something.","Extremely Important | Extremely important",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3844729","Very Important","C115921","A subjective answer of very strong agreement regarding the importance of something.","Very Important | Very important",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3844728","Somewhat Important","C115924","A subjective answer of mild agreement regarding the importance of something.","Somewhat Important | Somewhat important",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900178","A Little Important","C115925","A subjective answer of very mild agreement regarding the importance of something.","A Little Important | A little important",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3844726","Not at All Important","C115926","A subjective answer of non-agreement regarding the importance of something.","Not at All Important | Not at all important",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897193","Very Helpful","C115928","A subjective answer of very strong agreement regarding the helpfulness of something.","Very Helpful | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900179","A Little Helpful","C115931","A subjective answer of very mild agreement regarding the helpfulness of something.","A Little Helpful | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898120","Not at All Helpful","C115933","A subjective answer of non-agreement regarding the helpfulness of something.","Not at All Helpful | Not at all Helpful | Not at all Helpful",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897120","Relatively Healthy","C115936","A response indicating that an individual considers themselves to be of fairly good health.","Relatively Healthy | Relatively healthy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897724","Relatively Healthy and Terminally Ill","C115938","A response indicating that an individual considers themselves to be of fairly good health but also terminally ill.","Relatively Healthy and Terminally Ill | Relatively healthy and terminally ill",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897641","Seriously Ill and Not Terminally Ill","C115940","A response indicating that an individual considers themselves to be in seriously poor health but not terminally ill.","Seriously Ill and Not Terminally Ill | Seriously ill and not terminally ill",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897640","Seriously Ill and Terminally Ill","C115943","A response indicating that an individual considers themselves to be in seriously poor health and also terminally ill.","Seriously Ill and Terminally Ill | Seriously ill and terminally ill",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899194","Extend Life as Much as Possible","C115945","A response indicating that an individual would like a course of treatment that focuses on extending their life as long as possible.","Extend Life as Much as Possible | Extend Life as Long as Possible | Extend life as much as possible",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897723","Relieve Pain as Much as Possible","C115947","A response indicating that an individual would like a course of treatment that focuses on relieving pain as much as possible.","Relieve Pain as Much as Possible | Relieve pain as much as possible",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0068314","Valrubicin","C1340","A semisynthetic derivative of the antineoplastic anthracycline antibiotic doxorubicin. With a mechanism of action that appears to differ from doxorubicin, valrubicin is converted intracytoplasmically into N-trifluoroacetyladriamycin, which interacts with topoisomerase II, stabilizing the complex between the enzyme and DNA; consequently, DNA replication and repair and RNA and protein synthesis are inhibited and the cell cycle is arrested in the G2 phase. In addition, this agent accumulates in the cell cytoplasm where it inhibits protein kinase C (PKC). Valrubicin is less cardiotoxic than doxorubicin when administered systemically; applied topically, this agent shows excellent tissue penetration. Structurally, the trifluoro-acetyl moiety on the amino group of the glycoside and the valerate moiety appear to result in a lipophilicity that is greater than of doxorubicin, resulting in increased intracytoplasmic concentrations.","Valrubicin | AD 32 | AD-32 | AD32 | N-Trifluoroacetyladriamycin-14-valerate | VALRUBICIN | Valstar | Valtaxin | valrubicin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0442824","Very","C116076","Existing to a great degree.","Very | Very much",,,,,,,,,,,,,,,"4128638","Very",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0237506","Chance","C116077","The possibility or likelihood that something will happen.","Chance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2350348","AMP-Activated Protein Kinase alpha Subunits","C116019","A family comprised of two proteins that can each act as the catalytic alpha subunit for the 5'-AMP-activated protein kinase (AMPK) complex. The AMPK complex is involved in the regulation of glucose uptake, the oxidation of fatty acids and mitochondrial biogenesis through the phosphorylation of metabolic enzymes and transcription regulatory proteins.","5'-AMP-Activated Protein Kinase Catalytic Subunit Alpha | 5'-AMP-Activated Protein Kinase, Catalytic Alpha Chain | 5-AMP-Activated Protein Kinase Catalytic Subunit Alpha | ACACA Kinase Family | AMP-Activated Protein Kinase Alpha Subunit | AMP-Activated Protein Kinase Catalytic Subunit Alpha | AMPK Alpha | AMPK Subunit Alpha | AMPK-Alpha | AMPKa | AMPKalpha | Acetyl-CoA Carboxylase Kinase Family | EC 2.7.11.1 | EC 2.7.11.27 | EC 2.7.11.31 | HMGCR Kinase Family | Hydroxymethylglutaryl-CoA Reductase Kinase Family | PRKAA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677865","Brain Stem Glioma","C8501","A glioma that arises from the brain stem.","Brain Stem Glioma | Brain Stem Neuroglial Neoplasm | Brain Stem Neuroglial Tumor | Brainstem Glioma | Brainstem Neuroglial Neoplasm | Brainstem Neuroglial Tumor | Diffuse brainstem glioma | Glioma of Brain Stem | Glioma of Brainstem | Glioma of the Brain Stem | Glioma of the Brainstem | brain stem glioma",,,,,,,,,,,,,,,"40479836","Glioma of brainstem",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1412333","ALDH1A1 Gene","C116056","This gene is involved in the metabolism of retinal.","ALDH1A1 Gene | ALDH1A1 | Aldehyde Dehydrogenase 1 Family, Member A1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413347","CES1 Gene","C116034","This gene plays a role in the hydrolysis of aromatic and aliphatic esters.","CES1 Gene | CES1 | Carboxylesterase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413348","CES2 Gene","C116037","This gene is involved in xenobiotic detoxification.","CES2 Gene | CES2 | Carboxylesterase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899624","Circulating Adipose Stromal Cell","C116009","A precursor of fat-storing cells, which is located in the blood circulation. Detection of these cells is associated with obesity and elevated risk for obesity-related neoplastic diseases such as breast, colon and prostate carcinomas.","Circulating Adipose Stromal Cell | Circulating ASC | Circulating Perivascular Adipocyte Progenitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539087","CLEC2A Gene","C116028","This gene plays a role in both T-cell expansion and natural killer cell-mediated cytotoxicity.","CLEC2A Gene | C-Type Lectin Domain Family 2, Member A Gene | CLEC2A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899487","Crown-Like Structures of the Breast","C116011","An ultrastructural finding in breast adipose tissue that indicates macrophage infiltration to sites of adipocyte necrosis. This finding is associated with obesity and breast tissue inflammation and may be an indicator for increased risk of neoplastic breast disease.","Crown-Like Structures of the Breast | CLS-B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898881","Lysine 27 of Histone H3","C116018","The lysine residue found at amino acid position 28 in the histone H3 protein. Methylation of this residue may be a marker for transcriptionally repressed genes.","Histone H3 Lysine 28 | H3K27 | H3K28 | Histone H3 Lys27 | Histone H3 Lys28 | Histone H3 Lysine 27 | Histone H3 Lysine 27 | Lysine 27 of Histone H3 | Lysine 28 of Histone H3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416790","LAMP2 Gene","C116022","This gene plays a role in lysosomal maintenance.","LAMP2 Gene | LAMP2 | Lysosomal-Associated Membrane Protein 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416931","LTBR Gene","C116040","This gene plays a role in both lymphotoxin binding and the promotion of apoptosis.","LTBR Gene | LTBR | Lymphotoxin Beta Receptor (TNFR Superfamily, Member 3) Gene | TNFRSF3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898431","Melanoma-Associated Antigen Family A","C116017","A family of 12 proteins whose members were first detected in male germ cells, placenta and various tumors but originally not found in normal tissues. Their genes are located in the vicinity of Xq28. All of the members of the family share a stretch of about 200 amino acids, called the MAGE conserved domain, which is usually located near the C-terminal end of the protein and may allow these proteins to interact with cellular receptors.","Melanoma-Associated Antigen Family A | Class 1 Melanoma-Associated Antigen Family A | MAGE A Family | MAGE-A | MAGEA | Melanoma Antigen, Family A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898411","MicroRNA 181","C116021","A microRNA that has six isoforms that may play a role in the activity of phosphatidylinositol-4,5-bisphosphate 3-kinase and natural killer cells. The MIR181 isoforms have been implicated in a variety of cancers, including chronic lymphocytic leukemia, glioblastoma, multiple myeloma and hepatocellular carcinoma.","MicroRNA 181 | MIR181 | MIRN181 | hsa-mir-181 | mir-181",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418754","PON1 Gene","C116047","This gene plays a role in the metabolism of organophosphates, lactones and aromatic carboxylic acid esters.","PON1 Gene | PON1 | Paraoxonase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418897","PRKAA1 Gene","C116031","This gene is involved in serine/threonine phosphorylation.","PRKAA1 Gene | PRKAA1 | Protein Kinase, AMP-Activated, Alpha 1 Catalytic Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0072052","Procollagen Type I C-Terminal Peptide","C116020","This polypeptide is comprised of the carboxy-terminal portions of procollagen, which are proteolytically removed by bone morphogenetic protein 1 during the intracellular formation of type I collagen fibrils. Increased plasma or serum concentrations of these peptides are associated with both fibrillogenesis of type I collagen and bone formation.","Procollagen Type I C-Terminal Peptide | Collagen Type 1 C-Terminal Propeptide | Collagen Type I C-Terminal Propeptide | P1CP | PICP | Procollagen Type 1 C-Terminal Peptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033532","Prostaglandin D2","C116013","An eicosanoid that is generated by the action of prostaglandin D2 synthase on prostaglandin H2. Prostaglandin D2 mediates vasodilation, smooth muscle contraction and circadian rhythms. This prostanoid may also play a role in male pattern baldness.","Prostaglandin D2 | (5Z,13E)-(15S)-9alpha,15-Dihydroxy-11-Oxoprosta-5,13-Dienoate | (5Z,13E,15S)-9alpha,15-Dihydroxy-11-Oxoprosta-5,13-Dien-1-Oic Acid | 11-Dehydroprostaglandin F2-Alpha | PGD2 | PROSTAGLANDIN D2 | Prosta-5,13-Dien-1-Oic Acid, 9,15-Dihydroxy-11-Oxo-, (5Z,9-Alpha,13E,15S)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0244104","Pyruvate","C116012","A 2-oxo monocarboxylic acid anion that is the conjugate base of pyruvic acid, which is an important metabolic product for energy-producing biochemical pathways. Pyruvate is the final product of glycolysis and, when hypoxic conditions arise, can be metabolized anaerobically to form lactate. This chemical is a precursor of both acetyl-coenzyme A and oxaloacetate, which are involved in the citric acid cycle. Additionally, oxaloacetate is a substrate in the gluconeogenesis pathway.","Pyruvate | 2-Oxopropanoate | Propanoic Acid, 2-Oxo-, Ion(1-)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428293","SLX4 Gene","C116050","This gene is involved in both DNA repair and the positive regulation of endonuclease activity.","SLX4 Gene | SLX4 | SLX4 Structure-Specific Endonuclease Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426207","SOCS2 Gene","C116025","This gene is involved in the inhibition of cytokine-mediated signaling.","SOCS2 Gene | SOCS2 | Suppressor of Cytokine Signaling 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419989","SRSF1 Gene","C116043","This gene is involved in both RNA processing and transport.","SRSF1 Gene | SRSF1 | Serine/Arginine-Rich Splicing Factor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897142","t(14;20)","C116016","A chromosomal translocation involving chromosome 14 and chromosome 20.","t(14;20) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828339","t(16;16)(p13.1;q22)","C27759","A chromosomal translocation that involves chromosome 16. It is often associated with the development of acute myeloid leukemia CBFB-MYH11, acute myelomonocytic leukemia with abnormal eosinophils, and granulocytic sarcoma.","t(16;16)(p13.1;q22) | t(16;16)(p13.1;q22.1) | t(16;16)(p13.1q22) | t(16;16)(p13.1q22.1) | t(16;16)(p13;q22) | t(16;16)(p13q22)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897384","TMPRSS2/ETV4 Fusion Gene","C116015","A fusion gene that results from a chromosomal translocation t(17;21)(q21;q22) which fuses the 5' untranslated region of the TMPRSS2 gene upstream of exon 3 of the ETV4 gene. This rearrangement is associated with prostate carcinoma and androgen-dependent expression of this fusion gene results in overexpression of ETS translocation variant 4 protein activity.","TMPRSS2/ETV4 Fusion Gene | TMPRSS2-ETV4 Fusion Gene | TMPRSS2::ETV4 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897383","TMPRSS2/ETV5 Fusion Gene","C116014","A fusion gene that results from a chromosomal translocation t(3;21)(q28;q22) which fuses either the 5' untranslated region or the 5' end including exons 1 and 2 of the TMPRSS2 gene with exon 2 of the ETV5 gene. This rearrangement is associated with prostate carcinoma and androgen-dependent expression of this fusion gene results in overexpression of ETS translocation variant 5 protein activity.","TMPRSS2/ETV5 Fusion Gene | TMPRSS2-ETV5 Fusion Gene | TMPRSS2::ETV5 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420820","TNFSF8 Gene","C116059","This gene plays a role in the modulation of T-cell proliferation.","TNFSF8 Gene | TNFSF8 | Tumor Necrosis Factor (Ligand) Superfamily, Member 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2350277","Whole Genome Association Study","C93020","A study that looks at the genetic variations found in individuals to determine if either a variant or a set of variants is associated with a trait, biological process or disease.","Whole Genome Association Study | GWA Study | GWAS | Genome-Wide Association Analysis | Genome-Wide Association Study | WGA study | WGAS | genome-wide association study | whole genome association study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0730490","Stage IS","C28285","Testicular cancer found in the testicle, spermatic cord and scrotum, associated with slightly elevated levels of all tumor markers or moderately/highly elevated levels of one or more tumor markers.","Stage IS | Stage 1S | Stage IS | Stage Is",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515794","t(8;21)(q22;q22)","C13395","A cytogenetic abnormality that involves a translocation between 8q22 and 21q22. It is associated with the development of acute myeloid leukemia with RUNX1-RUNX1T1 fusion protein expression.","t(8;21)(q22;q22) | Eight-Twenty-One | t(8;21)(q21.3;q22) | t(8;21)(q22; q22.1)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415427","H3-3A Gene","C101443","This gene is involved in chromatin structure.","H3-3A Gene | H3-3A | H3.3 Histone A Gene | H3F3A | H3F3A Gene | H3F3A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1851466","RUNX1/RUNX1T1 Fusion Gene","C99294","A fusion gene (~4.3 kb) that results from a chromosomal translocation t(8;21)(q22;q22) which fuses the first 5 exons of the RUNX1 gene to exon 2 of the RUNX1T1 gene. This rearrangement is associated with acute myeloid leukemia.","RUNX1/RUNX1T1 Fusion Gene | AML-ETO Fusion Gene | AML/ETO Fusion Gene | AML1-ETO | AML1-MTG8 | AML1/ETO Fusion Gene | AML1/MTG8 | ETO/AML Fusion Gene | RUNX1-RUNX1T1 Fusion Gene | RUNX1::RUNX1T1 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0665119","RUNX1/RUNX1T1 Fusion Protein, Human","C19892","A fusion protein (752 aa, ~83 kDa) encoded by the RUNX1/RUNX1T1 fusion gene. This protein is comprised of the N-terminal runt domain of the runt-related transcription factor 1 protein fused to the 577 C-terminal residues of protein CBFA2T1.","RUNX1/RUNX1T1 Fusion Protein | AML-1/ETO | AML1-ETO Fusion Protein | AML1-MTG8 Fusion Protein | AML1/MTG8 Fusion Protein | Acute Myeloid Leukemia-1/Eight-Twenty-One Protein | RUNX1-RUNX1T1 Fusion Protein | RUNX1::RUNX1T1 Fusion Protein | Runt-Related Transcription Factor 1/Protein CBFA2T1 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812309","LTB Gene","C18425","This gene plays a role in the induction of the inflammatory response. It is also involved in the development of lymphoid tissues.","LTB Gene | LTB | Lymphotoxin Beta (TNF Superfamily, Member 3) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019646","Histone H2A","C16684","Slightly lysine rich histone.  One of four histones assembled into a nucleosomal core octamer.  Various posttranslationally modified forms and variants exist.  Combines with histone H2B in a heterodimer; two H2A/H2B dimers are incorporated in the nucleosomal octamer.","Histone H2A | H2A | HIST1H2A | HISTONE H2A | Histone 2A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412628","ATP1A1 Gene","C113762","This gene is involved in both ion transport and ATP metabolism.","ATP1A1 Gene | ATP1A1 | ATPase Na+/K+ Transporting Subunit Alpha 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334866","NCOA1 Gene","C20695","This gene plays a role in regulation of transcription.","NCOA1 Gene | NCOA1 | Nuclear Receptor Coactivator 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897320","Tumor Complete Metabolic Response by PET","C116095","A finding obtained using FDG-PET imaging demonstrating the disappearance of metabolic tumor activity in target and non-target lesions, marked by a decrease in tumor standardized uptake value to the level of surrounding normal tissue.","Tumor Complete Metabolic Response by PET | Definite Tumor Complete Metabolic Response | Definite complete metabolic response | FDG-PET Tumor CMR | FDG-PET Tumor Complete Metabolic Response | Tumor CMR | Tumor Complete Metabolic Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898599","Likely Tumor Complete Metabolic Response by PET","C116096","A finding of diffuse metabolic activity at the primary tumor or nodal sites that is greater than background uptake but less than liver uptake, detected by PDG-PET.","Likely Tumor Complete Metabolic Response by PET | FDG-PET Likely Tumor Complete Metabolic Response | Likely Tumor Complete Metabolic Response | Likely complete metabolic response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898600","Likely Residual Metabolic Tumor Activity by PET","C116098","A finding of focal metabolic activity at the primary or nodal sites that is greater than liver uptake, as detected by FDG-PET.","Likely Residual Metabolic Tumor Activity by PET | FDG-PET Likely Residual Metabolic Tumor Activity | Likely Residual Metabolic Disease | Likely Residual Metabolic Tumor Activity | Likely residual metabolic disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899398","Definite Residual Metabolic Tumor Activity by PET","C116100","A finding of strong focal metabolic activity at the primary or nodal sites that is greater than liver uptake, as detected by FDG-PET.","Definite Residual Metabolic Tumor Activity by PET | Definite Residual Metabolic Disease | Definite Residual Metabolic Tumor Activity | Definite residual metabolic disease | FDG-PET Definite Residual Metabolic Tumor Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898601","Likely Inflammatory Activity by PET","C116102","A finding of metabolic activity at the primary or nodal sites that is greater than liver uptake, but can be attributed to inflammation activity, as detected by FDG-PET.","Likely Inflammatory Activity by PET | FDG-PET Likely Inflammatory Activity | FDG-PET Post-Radiation Inflammation Activity | Likely Inflammatory Activity | Likely inflammatory | Post-Radiation Inflammation Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641719","Telapristone","C104057","An orally available 21-substituted-19-nor-progestin and selective progesterone receptor modulator (SPRM), with potential anti-progesterone and antineoplastic activities. Upon oral administration, telapristone competitively binds to the progesterone receptor (PR) in progesterone-responsive tissue and inhibits PR-mediated gene expression. This interferes with progesterone activity in the reproductive system. As a result, this agent may suppress ovulation and inhibit proliferation of endometrial tissue. Also, this agent may prevent cell growth and induce apoptosis in estrogen receptor (ER) and PR-positive breast cancer cells through a reduction in progesterone levels, ER downregulation and a suppression of the expression of cyclin-dependent kinases (CDK) 2 and 4, ultimately leading to G1/S cell cycle arrest. Unlike some other SPRMs, this agent does not exert any estrogenic, androgenic, anti-estrogenic, and anti-androgenic activities.","Telapristone | 11Beta-(4-(dimethylamino)phenyl)-17-hydroxy-21-methoxy-19- norpregna-4,9-diene-3,20-dione | TELAPRISTONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0349527","Skin Fibroblastic Neoplasm","C4634","A neoplasm that arises from the dermis and is characterized by the presence of neoplastic fibroblasts.","Skin Fibroblastic Neoplasm | Cutaneous Fibroblastic Neoplasm | Cutaneous Fibroblastic Neoplasm | Cutaneous Fibroblastic Tumor | Cutaneous Fibrocytic Neoplasm | Cutaneous Fibrocytic Neoplasm | Cutaneous Fibrocytic Tumor | Cutaneous Fibrous Tissue Neoplasm | Cutaneous Fibrous Tissue Tumor | Skin Fibrous Tissue Neoplasm | Skin Fibrous Tissue Tumor",,,,,,,,,,,,,,,"4110728","Fibrous tissue neoplasm of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010656","caspase","C18153","Caspases are a family of intracellular cysteine proteinases involved in inflammation and apoptosis.  These enzymes appear to be involved in the initial signaling events, as well as the downstream proteolytic cleavages, that result in apoptotic cell death.  They are specific for aspartic acid at the P1 position and are divided into two classes based on the lengths of their N-terminal pro-domains.  Caspases-1, -2, -4, -5, -8, and -10 have long pro-domains; caspases-3, -6, -7, and -9 have short pro-domains.  (from Science 1998. 281:1312 and Br Med Bull 1997. 53:478)","Caspase | Caspases | Cell-Death Protease | Cysteine-Dependent Aspartate-Directed Protease | Cysteine-aspartic Protease | ICE-like protease | ICE-like proteases | Peptidase Family C14 | TNF Alpha ICE Proteinases",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890593","Atlantic Daylight Time","C116256","Local daylight-savings time, based at the 60th meridian west of the Greenwich Observatory, established as three hours behind Coordinated Universal Time.","Atlantic Daylight Time | ADT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896678","Eastern Daylight Time","C116257","Local daylight-savings time, based at the 75th meridian west of the Greenwich Observatory, established as four hours behind Coordinated Universal Time.","Eastern Daylight Time | EDT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891659","Central Daylight Time","C116258","Local daylight-savings time, based at the 90th meridian west of the Greenwich Observatory, established as five hours behind Coordinated Universal Time.","Central Daylight Time | CDT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896649","Mountain Daylight Time","C116259","Local daylight-savings time, based at the 105th meridian west of the Greenwich Observatory, established as six hours behind Coordinated Universal Time.","Mountain Daylight Time | MDT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890886","Pacific Daylight Time","C116260","Local daylight-savings time, based at the 120th meridian west of the Greenwich Observatory, established as seven hours behind Coordinated Universal Time.","Pacific Daylight Time | PDT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896698","Alaska Daylight Time","C116261","Local daylight-savings time, based at the 135th meridian west of the Greenwich Observatory, established as eight hours behind Coordinated Universal Time.","Alaska Daylight Time | AKDT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891715","Hawaii-Aleutian Daylight Time","C116262","Local daylight-savings time, based at the 150th meridian west of the Greenwich Observatory, established as nine hours behind Coordinated Universal Time.","Hawaii-Aleutian Daylight Time | HADT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891303","Atlantic Standard Time","C116263","Local standard time, based at the 60th meridian west of the Greenwich Observatory, established as four hours behind Coordinated Universal Time.","Atlantic Standard Time | AST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890902","Eastern Standard Time","C116264","Local standard time, based at the 75th meridian west of the Greenwich Observatory, established as five hours behind Coordinated Universal Time.","Eastern Standard Time | EST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891160","Central Standard Time","C116265","Local standard time, based at the 90th meridian west of the Greenwich Observatory, established as six hours behind Coordinated Universal Time.","Central Standard Time | CST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891283","Mountain Standard Time","C116266","Local standard time, based at the 105th meridian west of the Greenwich Observatory, established as seven hours behind Coordinated Universal Time.","Mountain Standard Time | MST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889420","Pacific Standard Time","C116267","Local standard time, based at the 120th meridian west of the Greenwich Observatory, established as eight hours behind Coordinated Universal Time.","Pacific Standard Time | PST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896697","Alaska Standard Time","C116268","Local standard time, based at the 135th meridian west of the Greenwich Observatory, established as nine hours behind Coordinated Universal Time.","Alaska Standard Time | AKST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896656","Hawaii-Aleutian Standard Time","C116269","Local standard time, based at the 150th meridian west of the Greenwich Observatory, established as ten hours behind Coordinated Universal Time.","Hawaii-Aleutian Standard Time | HAST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890731","Samoa Standard Time","C116270","Local standard time, based at the 165th meridian west of the Greenwich Observatory, established as eleven hours behind Coordinated Universal Time.","Samoa Standard Time | SST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899691","Chamorro Standard Time","C116271","Local standard time, based at the 150th meridian east of the Greenwich Observatory, established as ten hours ahead of Coordinated Universal Time.","Chamorro Standard Time | ChST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420562","TBXT Gene","C84455","This gene is involved in both transcriptional regulation and mesoderm development.","TBXT Gene | Brachyury Gene | T | T Gene | T Gene | T-Box Transcription Factor T Gene | TBXT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018338","Cyclic GMP","C534","A cellular regulatory agent that acts as a second messenger.  Its levels increase in response to a variety of signals (acetylcholine, insulin, oxytocin) and activates specific protein kinases.","Cyclic GMP | CYCLIC GMP | Guanosine Cyclic 3',5'-(Hydrogen Phosphate) | cGMP | cyclic 3',5'-guanosine monophosphate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0373680","Myoglobin Measurement","C79436","The determination of the amount of myoglobin present in a sample.","Myoglobin Measurement | MGB | Myoglobin",,,,,,,,,,,,,,,"4143902","Myoglobin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL433245","TMPRSS2/ETV1 Fusion Gene","C99517","A fusion gene that results from a chromosomal translocation t(7;21)(p21;q22) which fuses the 5' end of the TMPRSS2 gene with exon 4 of the ETV1 gene. This rearrangement is associated with prostate carcinoma and androgen-dependent expression of this fusion gene results in overexpression of ETS translocation variant 1 protein activity.","TMPRSS2/ETV1 Fusion Gene | ETV1/TMPRSS2 Fusion Gene | TMPRSS2-ETV1 Fusion Gene | TMPRSS2::ETV1 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708025","ATAD5 Gene","C114945","This gene is involved in the DNA damage response.","ATAD5 Gene | ATAD5 | ATPase Family, AAA Domain Containing 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022369","JC Virus","C14229","One of two polyomaviruses found in humans. JC virus can infect the respiratory system, kidneys, or brain, sometimes causing the fatal progressive multifocal leukoencephalopathy in the latter case. It is very widespread with approximately 80 percent of the adult population in the United States having antibodies to and JC. (from WordIQ.com)","JC Virus | Human polyomavirus (type JC) | JC Polyomavirus | JC VIRUS | JCV | John Cunningham Virus | Polyomavirus hominis 2 | polyomavirus JC",,,,,,,,,,,,,,,"4265397","JC virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1415311","GRN Gene","C101401","This gene is involved in inflammation, wound healing and cell proliferation and in the regulation of lysosomal function.","GRN Gene | GRN | Granulin Gene | Granulin Precursor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898101","Oncotype DX DCIS Score","C116341","The derived result of a test that measures the gene expression profile in a tissue sample that contains ductal carcinoma in situ (DCIS). The score is used for treatment decisions tailored to the specific patient and to calculate the chances of recurrence.","Oncotype DX DCIS Score | Breast Oncotype DX Recurrence Risk Score | DCIS Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897642","Serious Adverse Event Report","C115587","Documentation describing a serious adverse event experienced by the subject in the clinical trial, which is defined by the clinical study protocol.","Clinical Trial Serious Adverse Event Report Documentation | SAE Report | SAE Rept | Serious Adverse Event Report | Serious Adverse Event Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897982","Past Seven Days Frequency of Aching Joints","C116282","A question about the frequency of an individual's aching joints over the past seven days.","Past Seven Days Frequency of Aching Joints | How often did you have aching joints (such as elbows, knees, shoulders)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897154","Worst Severity Past Seven Days Aching Joints","C116283","A question about an individual's observation of the worst severity they have experienced related to aching joints over the past seven days.","Worst Severity Past Seven Days Aching Joints | How much did aching joints (such as elbows, knees, shoulders) interfere with your usual or daily activities | What was the severity of your aching joints (such as elbows, knees, shoulders) at their worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897985","Past Seven Days Aching Joints Interfering with Usual or Daily Activities","C116286","A question about an individual's aching joints interfering with usual or daily activities over the past seven days.","Past Seven Days Aching Joints Interfering with Usual or Daily Activities | How much did aching joints (such as elbows, knees, shoulders) interfere with your usual or daily activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897981","Past Seven Days Frequency of Aching Muscles","C116281","A question about the frequency of an individual's aching muscles over the past seven days.","Past Seven Days Frequency of Aching Muscles | How often did you have aching muscles",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897153","Worst Severity Past Seven Days Aching Muscles","C116288","A question about an individual's observation of the worst severity they have experienced related to aching muscles over the past seven days.","Worst Severity Past Seven Days Aching Muscles | What was the severity of your aching muscles at their worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897984","Past Seven Days Aching Muscles Interfering with Usual or Daily Activities","C116289","A question about how much an individual's aching muscles interfered with usual or daily activities over the past seven days.","Past Seven Days Aching Muscles Interfering with Usual or Daily Activities | How much did aching muscles interfere with your usual or daily activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897983","Past Seven Days Bruise Easily","C116290","A question about whether an individual bruised easily over the last seven days.","Past Seven Days Bruise Easily | Did you bruise easily",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897097","Past Seven Days Frequency of Hiccups","C116291","A question about the frequency of an individual's hiccups over the past seven days.","Past Seven Days Frequency of Hiccups | How often did you have hiccups | Past Seven Days Frequency of Hiccups",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897152","Worst Severity Past Seven Days Hiccups","C116292","A question about an individual's observation of the worst severity they have experienced related to hiccups over the past seven days.","Worst Severity Past Seven Days Hiccups | What was the severity of your hiccups at their worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026538","Morbidity","C16877","Morbidity; the relative incidence of a particular disease in a population.","Morbidity | morbidity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201835","Adrenocorticotropic Hormone Measurement","C74780","The determination of the amount of adrenocorticotropic hormone present in a sample.","Adrenocorticotropic Hormone Measurement | ACTH | Adrenocorticotropic Hormone | Corticotropin",,,,,,,,,,,,,,,"4170855","Adrenocorticotropic hormone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1515868","Breast Acinic Cell Carcinoma","C40367","A breast adenocarcinoma characterized by the presence of serous (acinic cell) differentiation.","Breast Acinic Cell Carcinoma | Acinic Cell Breast Carcinoma | Acinic Cell Breast Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706762","Aldosterone Producing Adrenal Cortex Adenoma","C48451","An adenoma of the adrenal cortex that produces aldosterone. It may be associated with Conn syndrome. Clinical presentation includes hypertension, hypokalemia, and muscle weakness.","Aldosterone-Producing Adrenal Cortical Adenoma | Aldosterone Producing Adrenal Cortex Adenoma | Aldosterone Producing Adrenal Cortical Adenoma | Aldosterone-Producing Adrenal Cortex Adenoma | Aldosterone-Producing Adrenal Cortex Adenoma | Aldosterone-Producing Adrenal Gland Adenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2732473","Microinvasive Breast Carcinoma","C40374","Invasive breast carcinoma measuring 1 mm or less in size.","Microinvasive Breast Carcinoma | DCISM | Ductal Carcinoma In Situ with Microinvasion | MIC",,,,,,,,,,,,,,,"40484125","Ductal carcinoma in situ with microinvasion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0411881","Diagnostic Mammography","C79416","Mammography done after suspicious results on a screening mammogram or after other signs of possible breast cancer.","Diagnostic Mammography | diagnostic mammogram",,,,,,,,,,,,,,,"4081880","Mammogram - symptomatic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003195","Antiarrhythmic Agent","C47793","Agents used for the treatment or prevention of cardiac arrhythmias; they may effect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers.","Antiarrhythmic Agent | Anti-arrhythmic Agent | Cardiac Depressant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828431","QTcF Prolongation","C107099","An electrocardiographic finding in which the QT interval corrected for heart rate using Fridericia's formula is prolonged. Thresholds for different age, gender, and patient populations exist.","QTcF Prolongation | PROLONGED QTcF | Prolonged QTcF | QTCF PROLONGATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556322","Grade 2 Valvular Heart Disease, CTCAE","C55016","Asymptomatic; moderate regurgitation or stenosis by imaging","Grade 2 Valvular Heart Disease, CTCAE | CTCAE Grade 2 Valvular Heart Disease | Grade 2 Valvular heart disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700378","Left Ventricular Ejection Fraction","C99524","The fraction of the left ventricular end diastolic volume ejected with each beat. The left ventricular ejection fraction is equal to the left ventricular stroke volume divided by the left ventricular end diastolic volume.","Left Ventricular Ejection Fraction | EF, % | Ejection Fraction | LVEF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900053","Amenable","C116358","Having the appropriate qualities.","Amenable | Suitable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3818721","Ceritinib","C115112","An orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, ceritinib binds to and inhibits wild-type ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to both the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a variety of tumor cell types.","Ceritinib | 2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)- | CERITINIB | LDK 378 | LDK-378 | LDK378 | Zykadia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1431698","NAG protein, human","C33961","Neuroblastoma-amplified sequence (2371 aa, ~269 kDa) is encoded by the human NBAS gene. This protein is involved in retrograde (Golgi-to-endoplasmic reticulum (ER)) transport of intracellular vesicles.","Neuroblastoma-Amplified Sequence | NAG | Neuroblastoma-Amplified Gene Protein | Neuroblastoma-Amplified Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897818","Prostate Imaging-Reporting and Data System","C116385","A structured reporting scheme for multiparametric prostate cancer imaging and diagnosis. Prostate images are obtained using multiple MRI techniques including T2 weighted images, a dynamic contrast-enhanced study (DCE), diffusion weighted imaging (DWI), and possibly spectroscopy (MRS). Each lesion receives a score from 1 to 5 for each individual imaging parameter, as well as an overall 1-5 grading score reflecting the likelihood of clinically significant cancer, with 1 being most probably benign and 5 being highly suspicious of malignancy.","Prostate Imaging-Reporting and Data System | PI-RADS | PIRADS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826170","Immortalization","C82424","Laboratory methods used to generate cells that are able to reproduce indefinitely.","Immortalization | Immortalized",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL321546","Embryonic","C34100","Having to do with an embryo, which is an early stage in the development of a plant or animal.","Embryonic | embryonic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0161820","Urinary Complication","C115772","Any disorder of the organs of the urinary system occurring as a consequence of injury to the urinary system.","Urinary Complication | ",,,,,,,,,,,,,,,"80593","Urinary complication",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640077","Whole Exome Sequencing","C101295","A procedure that can determine the DNA sequence for all of the exons in an individual.","Whole Exome Sequencing | Exome | Exome Sequencing | WES | WHOLE EXOME SEQUENCING | WXS | WXS (whole exome sequencing) | Whole-Exome Sequencing | Whole-exome sequencing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230425","Right Thigh","C105637","A part of the lower limb, located between the hip and the knee and located on the right side of the body.","Right Thigh | RT",,,,,,,,,,,,,,,"4008238","Structure of right thigh",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0230426","Left Thigh","C105632","A part of the lower limb, located between the hip and the knee and located on the left side of the body.","Left Thigh | LT",,,,,,,,,,,,,,,"4264018","Structure of left thigh",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519007","Peripheral Zone of the Prostatic Parenchyma","C33308","Prostatic parenchyma that occupies the posterior and lateral aspects of the prostate gland. The glandular architecture consists of small, round acini amid loosely woven, randomly oriented stroma. The peripheral zone contains large, so-called main glands, whose ducts run posteriorly to open into the urethra. Approximately 70% of the prostate gland lies in the peripheral zone.","Peripheral Zone of the Prostatic Parenchyma | PZ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL413977","stage IIIC skin melanoma","C86053","Stage IIIC includes: (T1-4b, N1b, M0); (T1-4b, N2b, M0); (T1-4b, N2c, M0); (Any T, N3, M0).  T1-4b: Ulcerated cutaneous melanoma of any thickness.  N1b: Cutaneous melanoma with macrometastasis in one regional lymph node.  N2b: Cutaneous melanoma with macrometastases in 2-3 regional lymph nodes.  N2c: Cutaneous melanoma with intralymphatic metastases (in transit or satellite metastases) without metastatic nodes.  N3: Cutaneous melanoma with 4 or more metastatic nodes, or matted nodes, or in transit met(s)/satellite(s) with metastatic node(s).  M0: No detectable evidence of distant metastases. (from AJCC 7th Ed.)","Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIC Cutaneous (Skin) Melanoma | Stage IIIC Skin Melanoma | Stage IIIC Skin Melanoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL413976","stage IIIB skin melanoma","C86051","Stage IIIB includes: (T1-4b, N1a, M0); (T1-4b, N2a, M0); (T1-4a, N1b, M0); (T1-4a, N2b, M0); (T1-4a, N2c, M0).  T1-4b: Ulcerated cutaneous melanoma of any thickness.  T1-4a: Non-ulcerated cutaneous melanoma of any thickness.  N1a: Cutaneous melanoma with micrometastasis in one regional lymph node.  N2a: Cutaneous melanoma with micrometastases in 2-3 regional lymph nodes.  N1b: Cutaneous melanoma with macrometastasis in one regional lymph node.  N2b: Cutaneous melanoma with macrometastases in 2-3 regional lymph nodes.  N2c: Cutaneous melanoma with intralymphatic metastases (in transit or satellite metastases) without metastatic nodes.  M0: No detectable evidence of distant metastases. (from AJCC 7th Ed.)","Stage IIIB Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous (Skin) Melanoma | Stage IIIB Skin Melanoma | Stage IIIB Skin Melanoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL413975","stage IIIA skin melanoma","C86049","Stage IIIA includes: (T1-4a, N1a, M0); (T1-4a, N2a, M0).  T1-4a: Non-ulcerated cutaneous melanoma of any thickness.  N1a: Cutaneous melanoma with micrometastasis in one regional lymph node.  N2a: Cutaneous melanoma with micrometastases in 2-3 regional lymph nodes.  M0: No detectable evidence of distant metastases. (from AJCC 7th Ed.)","Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous (Skin) Melanoma | Stage IIIA Skin Melanoma | Stage IIIA Skin Melanoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708545","Intervention Required","C52668","A patient condition when action or ministration whose purpose is to improve health or to alter the course of a disease is considered essential and mandatory in order to prevent permanent impairment or damage.","Intervention Required | INTERVENTION REQUIRED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412058","ABCA1 Gene","C116408","This gene plays a role in intracellular cholesterol transport.","ABCA1 Gene | ABCA1 | ATP-Binding Cassette, Sub-Family A (ABC1), Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0236522","Adenovirus Antibody","C116403","An antibody produced by B-lymphocytes in response to adenovirus infection.","Adenovirus Antibody | Anti-Adenovirus Antibody",,,,,,,,,,,,,,,"4025444","Adenovirus antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0051380","Alpha-Hydroxyglutarate","C116390","The base form of alpha-hydroxyglutaric acid, which is an intermediate in the synthesis of alpha-ketoglutaric acid. Alpha-hydroxyglutarate accumulates in the blood of patients with 2-hydroxyglutaric aciduria; an organic acid metabolism disorder, which is caused by the genetic mutation of one of the enzymes responsible for the conversion of 2-hydroxyglutaric acid to alpha-ketoglutaric acid.","Alpha-Hydroxyglutarate | 2-HG | 2-Hydroxy-Pentanedioic Acid | 2-Hydroxyglutarate | 2-Hydroxyglutaric Acid | 2-Hydroxypentanedioic Acid | 2HG | Alpha-Hydroxyglutaric Acid | Pentanedioic Acid, 2-Hydroxy- | Pentanedioic Acid, 2-Hydroxy-; ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427959","CENPS Gene","C116620","This gene is involved in DNA binding and repair.","CENPS Gene | APITD1 | APITD1 Gene | Apoptosis-Inducing, TAF9-Like Domain 1 Gene | CENPS | Centromere Protein S Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412470","APOA4 Gene","C116603","This gene is involved in the transport of chylomicrons and very low density lipoproteins.","APOA4 Gene | APOA4 | Apolipoprotein A-IV Gene | Apolipoprotein A4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412696","ATRN Gene","C116672","This gene is involved in both ligand binding and immune cell clustering.","ATRN Gene | ATRN | Attractin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422210","BCO1 Gene","C116423","This gene is involved in the conversion of beta-carotene into retinal.","BCO1 Gene | BCMO1 | BCMO1 Gene | BCO1 | BMO1 | Beta-Carotene 15,15'-Monooxygenase 1 Gene | Beta-Carotene Oxygenase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896693","Bone Marrow-Derived Cell","C116388","A cell that is isolated from bone marrow.","Bone Marrow-Derived Cell | BMDC | Bone Marrow Derived Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413098","CAMK1 Gene","C116669","This gene plays a role in both protein phosphorylation and calcium/calmodulin-dependent signaling.","CAMK1 Gene | CAMK1 | Calcium/Calmodulin-Dependent Protein Kinase I Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426354","CLSPN Gene","C116689","This gene is involved in checkpoint mediated cell cycle arrest.","CLSPN Gene | CLSPN | Claspin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899480","Cytochrome P450 Family 11","C116407","A family of mitochondrial enzymes of the cytochrome P450 superfamily whose members are involved in steroidogenesis in the adrenal gland. There are 3 proteins in this family cholesterol side-chain cleavage enzyme, mitochondrial, cytochrome P450 11B1, mitochondrial and cytochrome P450 11B2, mitochondrial.","Cytochrome P450 Family 11 | CYP11 | CYPXI | Cytochrome P450 11 | Cytochrome P450 11, Mitochondrial | Cytochrome P450 Subfamily XI | Cytochrome P450, Family 11 | Mitochondrial Cytochrome P450 11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899478","Cytotoxic Granule Protein","C116392","A protein that is stored in the secretory granules of cytotoxic leukocytes and plays a role in cell-mediated cytolysis.","Cytotoxic Granule Protein | CGP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896581","Deoxysphingolipid","C116391","An atypical, cytotoxic sphingolipid produced during abnormal de novo sphingolipid synthesis in which the enzyme serine palmitoyltransferase (SPT) is mutated. During de novo sphingolipid synthesis, SPT normally converts L-serine and palmitoyl-Coenzyme A into 3-keto-dihydrosphingosine, which is processed further to form ceramide. Mutated forms of SPT can accommodate the alternative substrates L-alanine or L-glycine, which leads to the formation of the deoxysphingolipids, deoxysphinganine and deoxymethylsphinganine, respectively. These atypical lipids are neither converted to ceramide nor degraded by the cellular glycosphingolipid hydrolysis pathways. Therefore, deoxysphingolipids can accumulate to neurotoxic levels, which can lead to neuropathy. Elevated plasma levels of deoxysphingolipids may be associated with diabetes or metabolic syndrome.","Deoxysphingolipid | Deoxy-Sphingolipid | dSL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2829258","DEXI Gene","C116666","This gene may be involved in inflammation.","DEXI Gene | DEXI | Dexi Homolog (Mouse) Gene | Dexi Homolog Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896587","EMC-92-Gene Signature","C116389","A prognostic system used to assess if a patient has high-risk multiple myeloma. This system is based on the expression profile of 92 genes.","EMC-92-Gene Signature | EMC-92 | EMC-92 Gene Signature | SKY-92 | SKY-92 Gene Signature | SKY92 Gene Signature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422079","FBXO5 Gene","C116692","This gene plays a role in the modulation of cell cycle progression.","FBXO5 Gene | F-Box Protein 5 Gene | FBXO5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415015","GCKR Gene","C116609","This gene plays a role in the inhibition of carbohydrate phosphorylation.","GCKR Gene | GCKR | Glucokinase (Hexokinase 4) Regulator Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415111","GLRX Gene","C116580","This gene plays a role in the reduction of glutathione-disulfides and glutathione-conjugated proteins.","GLRX Gene | GLRX | Glutaredoxin (Thioltransferase) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415331","GSTA4 Gene","C116645","This gene is involved in the metabolism of small molecules and xenobiotics.","GSTA4 Gene | GSTA4 | Glutathione S-Transferase Alpha 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425141","HAVCR1 Gene","C116606","This gene is involved in viral infection, asthma and allergies.","HAVCR1 Gene | HAVCR1 | Hepatitis A Virus Cellular Receptor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0166049","Hepatitis C Antibody","C116400","An antibody produced by B-lymphocytes in response to hepatitis C virus infection.","Hepatitis C Antibody | Anti-HCV Antibody | Anti-Hepatitis C Antibody | HCV Antibody",,,,,,,,,,,,,,,"4216067","Antibody to hepatitis C virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1415411","H2BC5 Gene","C116683","This gene plays a role in the formation of nucleosomes.","H2BC5 Gene | H2B Clustered Histone 5 Gene | H2BC5 | HIST1H2BD | HIST1H2BD Gene | HIST1H2BD Gene | Histone Cluster 1, H2bd Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825625","ISX Gene","C116411","This gene is involved in gene expression regulation in the intestine.","ISX Gene | ISX | Intestine-Specific Homeobox Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898646","KIT Exon 17 Mutation","C116396","A molecular genetic abnormality indicating the presence of a mutation in exon 17 of the KIT gene located within 4q11-q12.","KIT Exon 17 Mutation | CD117 Exon 17 Mutation | CKIT Mutation - Ex17 | Exon 17 | KIT Proto-Oncogene Tyrosine Protein Kinase Gene Exon 17 Mutation | c-KIT Exon 17 Mutation | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Gene Exon 17 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416853","LIG3 Gene","C116584","This gene is involved in DNA double-strand break repair.","LIG3 Gene | DNA Ligase 3 Gene | LIG3 | Ligase III, DNA, ATP-Dependent Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416960","MAD2L2 Gene","C116589","This gene plays a role in both DNA translesion synthesis and the mitotic spindle assembly checkpoint.","MAD2L2 Gene | MAD2 Mitotic Arrest Deficient-Like 2 (Yeast) Gene | MAD2L2 | Mitotic Arrest Deficient 2 Like 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024544","Malate Dehydrogenase","C116405","A family of enzymes whose members reversibly catalyze the oxidation of malate to oxaloacetate using the reduction of NAD+ to NADH and are involved in multiple metabolic pathways. There are 2 proteins in this family, malate dehydrogenase, cytoplasmic and malate dehydrogenase, mitochondrial.","Malate Dehydrogenase | EC 1.1.1.37 | L-Malate Dehydrogenase | MDH | Malate (NAD) Dehydrogenase | Malic Acid Dehydrogenase | Malic Dehydrogenase | NAD-Dependent Malate Dehydrogenase | NAD-Dependent Malic Dehydrogenase | NAD-L-Malate Dehydrogenase | NAD-Linked Malate Dehydrogenase | NAD-Malate Dehydrogenase | NAD-Malic Dehydrogenase | NAD-Specific Malate Dehydrogenase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421946","MAP1LC3B Gene","C116658","This gene is involved in the formation of autophagosomal vacuoles.","MAP1LC3B Gene | MAP1LC3B | Microtubule-Associated Protein 1 Light Chain 3 Beta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825942","MAP1LC3C Gene","C116661","This gene plays a role in the formation of autophagosomes.","MAP1LC3C Gene | MAP1LC3C | Microtubule-Associated Protein 1 Light Chain 3 Gamma Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3884166","MicroRNA 9","C116401","A 23 ribonucleotide sequence that is a final product of the processing of MIR9-1 pre-miRNA, MIR9-2 pre-miRNA or MIR9-3 pre-miRNA. This oligonucleotide is involved in gene regulation and may play a role in nerve cell differentiation, insulin secretion and nervous system tumors which display neuronal differentiation.","MicroRNA 9 | MIR9 | MIRN9 | hsa-miR-9-5p | hsa-mir-9 | miR-9 | miRNA 9 | miRNA-9 | miRNA9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826328","MTTP Gene","C116414","This gene plays a role in lipid transport.","MTTP Gene | MTTP | Microsomal Triglyceride Transfer Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428895","MUS81 Gene","C116615","This gene plays a role in the metabolism of branched DNA structures.","MUS81 Gene | MUS81 | MUS81 Structure-Specific Endonuclease Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898052","PASD1 Antibody","C116406","Any immunoglobulin that recognizes PAS domain-containing protein 1.","PASD1 Antibody | Anti-CT63 Antibody | Anti-Cancer/Testis Antigen 63 Antibody | Anti-OX-TES-1 Antibody | Anti-OXTES1 Antibody | Anti-PAS Domain Containing 1 Antibody | Anti-PAS Domain-Containing Protein 1 Antibody | Anti-PASD1 Antibody | CT63 Antibody | Cancer/Testis Antigen 63 Antibody | OX-TES-1 Antibody | OXTES1 Antibody | PAS Domain Containing 1 Antibody | PAS Domain-Containing Protein 1 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898050","PDGFR-AA","C116394","A homodimeric protein complex comprised of 2 platelet-derived growth factor receptor alpha proteins. Formation of this complex is dependent on the binding of a disulfide-linked homodimer of platelet-derived growth factor alpha. The formation of the receptor dimer activates its intrinsic tyrosine-protein kinase activity and initiates signal transduction pathways.","PDGFR-AA | Platelet-Derived Growth Factor Receptor Alpha Homodimeric Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898049","PDGFR-BB","C116395","A homodimeric protein complex comprised of 2 platelet-derived growth factor receptor beta proteins. Formation of this complex is dependent on the binding of a disulfide-linked homodimer of platelet-derived growth factor beta. The formation of the receptor dimer activates its intrinsic tyrosine-protein kinase activity and initiates signal transduction pathways.","PDGFR-BB | Platelet-Derived Growth Factor Receptor Beta Homodimeric Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898048","PDGFRA Exon 12 Mutation","C116397","A molecular genetic abnormality indicating the presence of a mutation in exon 12 of the PDGFRA gene located within 4q11-q13.","PDGFRA Exon 12 Mutation | CD140A Exon 12 Mutation | Exon 12 | PDGFR-2 Exon 12 Mutation | PDGFR2 Exon 12 Mutation | RHEPDGFRA Exon 12 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898047","PDGFRA Exon 14 Mutation","C116398","A molecular genetic abnormality indicating the presence of a mutation in exon 14 of the PDGFRA gene located within 4q11-q13.","PDGFRA Exon 14 Mutation | CD140A Exon 14 Mutation | PDGFR-2 Exon 14 Mutation | PDGFR2 Exon 14 Mutation | RHEPDGFRA Exon 14 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898046","PDGFRA Exon 18 Mutation","C116399","A molecular genetic abnormality indicating the presence of a mutation in exon 18 of the PDGFRA gene located within 4q11-q13.","PDGFRA Exon 18 Mutation | CD140A Exon 18 Mutation | Exon 18 | PDGFR-2 Exon 18 Mutation | PDGFR2 Exon 18 Mutation | RHEPDGFRA Exon 18 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412234","PLIN2 Gene","C116426","This gene plays a role in lipid storage.","PLIN2 Gene | PLIN2 | Perilipin 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424792","PRDX4 Gene","C116654","This gene plays a role in both cellular redox and nuclear factor NF-kappa-B activity.","PRDX4 Gene | PRDX4 | Peroxiredoxin 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033384","Procollagen-Proline Dioxygenase","C116402","A tetrameric enzyme complex that catalyzes the post-translational formation of 4-hydroxyproline in the amino acid sequence -Xaa-Pro-Gly-, which is found in collagens and other proteins. The enzyme complex is comprised of two alpha chains and two beta chains. There are 3 separate genes that encode 3 distinct alpha proteins, prolyl 4-hydroxylase subunit alpha-1, -2 and -3. The beta chain is protein disulfide-isomerase.","Procollagen-Proline Dioxygenase | Collagen Proline Hydroxylase | EC 1.14.11.2 | Hydroxylase, Collagen Proline | P4H | Peptidyl Proline Hydroxylase | Procollagen-Proline 4-Dioxygenase | Proline Hydroxylase | Proline Protocollagen Hydroxylase | Proline, 2-Oxoglutarate Dioxygenase | Proline,2-Oxoglutarate 4-Dioxygenase | Prolyl 4-Hydroxylase | Prolyl Hydroxylase | Prolyl-Glycyl-Peptide, 2-Oxoglutarate:Oxygen Oxidoreductase, 4-Hydroxylating | Prolylprotocollagen Dioxygenase | Prolylprotocollagen Hydroxylase | Protocollagen Hydroxylase | Protocollagen Proline 4-Hydroxylase | Protocollagen Proline Dioxygenase | Protocollagen Proline Hydroxylase | Protocollagen Prolyl Hydroxylase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419015","PSMB5 Gene","C116675","This gene plays a role in proteasome-mediated proteolysis.","PSMB5 Gene | PSMB5 | Proteasome (Prosome, Macropain) Subunit, Beta Type, 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419619","RPA2 Gene","C116634","This gene is involved in DNA repair, recombination and replication.","RPA2 Gene | RPA2 | Replication Protein A2 Gene | Replication Protein A2, 32kDa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419620","RPA3 Gene","C116637","This gene plays a role in DNA replication, recombination and repair.","RPA3 Gene | RPA3 | Replication Protein A3 Gene | Replication Protein A3, 14kDa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419816","SAR1B Gene","C116420","This gene plays a role in vesicle transport.","SAR1B Gene | SAR1B | Secretion Associated, Ras Related GTPase 1B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412050","SERPINA3 Gene","C116577","This gene is involved in the regulation of neutrophil cathepsin G and mast cell chymase activity.","SERPINA3 Gene | SERPINA3 | Serpin Peptidase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1846919","SMG1 Gene","C116678","This gene is involved in protein phosphorylation, mRNA surveillance and genotoxic responses.","SMG1 Gene | SMG1 | SMG1 Phosphatidylinositol 3-Kinase-Related Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3888289","Stem Cell Growth Factor Beta, human","C116598","Stem cell growth factor beta (245 aa, ~27 kDa) is encoded by the human CLEC11A gene. This protein is involved in hematopoietic cell growth factor activity.","Stem Cell Growth Factor Beta | C-Type Lectin Domain Family 11 Member A-Beta | SCGF Beta | SCGF-Beta | Stem Cell Growth Factor-Beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420488","CENPX Gene","C116631","This gene plays a role in both DNA fork processing and DNA repair.","CENPX Gene | CENPX | Centromere Protein X Gene | STRA13 | STRA13 Gene | Stimulated By Retinoic Acid 13 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515716","t(12;16)(q13;p11)","C36317","A chromosomal translocation that involves chromosome 12 and chromosome 16. It is often associated with the development of angiomatoid fibrous histiocytoma or myxoid liposarcoma.","t(12;16)(q13;p11) | t(12;16)(q13;p11) (Liposarcoma)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897141","t(1;14)","C116386","A chromosomal translocation involving chromosome 1 and chromosome 14.","t(1;14) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515814","t(X;18)(p11;q11)","C36390","A chromosomal translocation that involves the X chromosome and chromosome 18. It is often associated with the development of synovial sarcoma.","t(X;18)(p11;q11) | t(X;18)(p11.2;q11.2) | t(X;18)(p11;q11) (Synovial sarcoma)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896585","Total Nicotine Equivalent","C116393","The sum of the molecules of nicotine and each of its metabolites, including cotinine, trans 3'-hydroxycotinine and their respective glucuronide conjugates, detected in a biological sample.","Total Nicotine Equivalent | TNE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891660","Tumor-Associated Macrophage","C116387","Non-neoplastic macrophages that are found in close proximity to or within a tumor mass.","Tumor-Associated Macrophage | TAM | Tumor Associated Macrophage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421350","ULK1 Gene","C116612","This gene is involved in the regulation of autophagy.","ULK1 Gene | ULK1 | Unc-51 Like Autophagy Activating Kinase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829429","Karnofsky Performance Status 20","C105716","Very sick; hospitalization necessary; active support treatment is necessary.","Karnofsky Performance Status 20 | 20 | 20: Very sick; requiring hospitalization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829428","Karnofsky Performance Status 30","C105715","Severely disabled; hospitalization is indicated, although death not imminent.","Karnofsky Performance Status 30 | 30 | 30: Severely disabled",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829427","Karnofsky Performance Status 40","C105714","Disabled; requires special care and assistance.","Karnofsky Performance Status 40 | 40 | 40: Disabled; requires special care",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086530","Attorney","C51959","A person who has been qualified and licensed to advise clients on legal matters and to provide legal services, including appearing in court.","Attorney | ATTORNEY | Attorney at Law | Lawyer",,,,,,,,,,,,,,,"4028691|4146191","Lawyer|Barrister",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL354435","Biomedical Engineer","C51960","An individual whose profession is to apply engineering principles to understand, modify, or control biologic systems, as well as design and manufacture products that can monitor physiologic functions and assist in the diagnosis and treatment of patients.","Biomedical Engineer | BIOMEDICAL ENGINEER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3536818","Dietitian","C28248","A professional trained and qualified to provide nutritional services at individual, institutional and community levels in term of assessing nutritional needs and coordinating them with medical ones, developing and implementing nutrition programs, evaluation and reporting their results, as well as to educate people on healthy eating, and diseases prevention and treatment by means of dietary modifications.","Dietitian | DIETICIAN | Dietician | Dietitian Nutritionist | Nutritionist | dietitian | nutritionist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708376","Home Health Aid","C53429","A person trained to for provide personal patient care and related services for ill or disabled patients, and elderly in home or home-like settings to get patients needs met. The tasks performed by home health aide include personal care, homemaking, communications, working with the patient occupational therapist, physical therapist and other caregivers to assure that the patients are reaching their best physical, mental and social well-being.","Home Health Aid | HOME HEALTH AID | Home Health Aide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0260281","Medical Technologist","C53418","A person with professional knowledge and competence in the field of medical technology that involves performing, advising on, or supervising clinical laboratory testing of human specimens, fluids and tissues, establishing and monitoring quality control systems and measures; developing data which may be used in clinical setting and in support of medical research in such areas as hematology, bacteriology, mycology, virology, parasitology, immunology, serology, immunohematology, clinical chemistry, endocrinology and toxicology, and urinalysis as they relate to clinical laboratory practice. The concept does not refer to professionals primarily involved in technical support work concerned with operating medical machines or instruments as part of the examination or treatment of patients.","Medical Technologist | MEDICAL TECHNOLOGIST | Medical Technician",,,,,,,,,,,,,,,"4297245","Medical technologist",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028807","Occupational Therapist","C28174","A health professional trained to help people who are ill or disabled learn to manage their daily activities.","Occupational Therapist | OCCUPATIONAL THERAPIST | occupational therapist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2362565","Physical Therapist","C53422","An individual trained and certified to apply knowledge of the concepts, principles, and practices of physical therapy for the treatment or prevention of physical disability or disease. Physical therapist plans and carries out treatment utilizing therapeutic exercise, massage, and physical agents such as air, water, electricity, sound, and radiant energy; performs tests and measurements involving manual or electrical means; and interpret results. Therapist also devises adaptations of equipment to meet the specific needs of patients.","Physical Therapist | PHYSICAL THERAPIST | PHYSIOTHERAPIST | Physiotherapist | physical therapist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0260282","Radiologic Technologist","C53424","A person trained and qualified to perform radiographic procedures by the application of ionizing radiation to produce images on film and on computer assisted equipment displays and perform other related duties including but not limited to the patient instruction on a radiographic procedure, patient positioning, immobilization, protection, and observation during the procedure; radiographs generation and images records maintenance; equipment operation, minor adjustments and evaluation for modification or replacement.","Radiologic Technologist | RADIOLOGIC TECHNOLOGIST | Radiologic Technician",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709924","Respiratory Therapist","C53425","A person trained and qualified to perform technical work concerned with administering therapeutic and diagnostic respiratory care and life support to patients with cardiopulmonary deficiencies and abnormalities. The work involves: operating and monitoring respiratory equipment such as ventilators, medical gas delivery apparatus, environmental control systems, incentive breathing/hyperinflation and aerosol devices; administering medical gases, humidification, and respiratory medications; maintaining clearance of patient natural and artificial airways; obtaining blood samples and interpreting blood gas data; and providing primary assistance in cardiopulmonary resuscitation.","Respiratory Therapist | Certified Respiratory Therapist | RESPIRATORY THERAPIST | Respiratory Therapist, Certified | respiratory therapist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709964","Risk Manager","C53448","A person trained and licensed to implement and oversight health care risk management programs aimed on assuring greater patient safety in health care facility or institution. The main thrust of the risk manager activity is in identifying incidents occurring in the health care organization, which have an outcome of patient injury and may reflect error in the course of the delivery of health care services, adverse incidents reporting, tracking, trending and elaboration of risk reduction and risk prevention strategies and measures.","Risk Manager | RISK MANAGER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710061","Service and Testing Personnel","C53441","Qualified professionals trained and assigned to conduct the device or equipment maintenance and testing.","Service and Testing Personnel | SERVICE AND TESTING PERSONNEL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0871904","Service Personnel","C53273","Qualified persons who have the appropriate technical expertise, training and experience necessary to provide assistance and support in medical device installation, maintenance, operation and repair.","Service Personnel | SERVICE PERSONNEL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0402015","Speech Therapist","C19177","A individual with specialized training/certification in the evaluation and treatment of speech, swallowing, and communication disorders.","Speech Therapist | SPEECH THERAPIST | Speech Pathologist | Speech-Language Pathologist | speech pathologist | speech therapist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709486","Patient Family Member Or Friend","C53432","A relative of the patient or an individual affiliated with the patient or/and patient family.","Patient Family Member Or Friend | PATIENT FAMILY MEMBER OR FRIEND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1271040","Other health professional","C53289","Health care professional other than listed in section D5 of FDA MedWatch form 3500A.","Other Health Care Professional | OTHER HEALTH CARE PROFESSIONAL | Other | Other Health Professional",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709355","Other Caregiver","C53427","Different from the previously specified or mentioned type of person who has primary responsibility for the assistance and supervision for an individual.","Other Caregiver | OTHER CAREGIVER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709282","Nuclear Medicine Technologist","C53419","A professional trained and certified in the field of medicine that utilizes the nuclear properties of radioactive and stable nuclides to make diagnostic evaluations of the anatomic or physiologic conditions of the body and to provide therapy with unsealed radioactive sources. The area of responsibilities of nuclear medicine technologist includes patient care (radiopharmaceuticals preparation and administration, use of radiation detection devices and other laboratory equipment to evaluate the quantity and distribution of radionuclides deposited in the patient or in a patient specimen, in vivo and in vitro diagnostic procedures, use of quality control and safety techniques), technical tasks, and administration.","Nuclear Medicine Technologist | NUCLEAR MEDICINE TECHNOLOGIST | Nuclear Medicine Technician",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708966","Medical Equipment Company Technician or Representative","C53442","A trained person who is delegated by medical equipment manufacturer to provide technical advice and assistance concerning the routine maintenance and service of equipment produced by the company.","Medical Equipment Company Technician or Representative | MEDICAL EQUIPMENT COMPANY TECHNICIAN OR REPRESENTATIVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831135","Chart Abstraction","C113748","The process of reading the record of a health encounter to determine and document the condition the patient had, the cause, and the treatment prescribed. This information is typically assigned standard clinical terminology codes.","Chart Abstraction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413218","SCARB1 Gene","C102461","This gene is involved in lipid and lipoprotein binding.","SCARB1 Gene | SCARB1 | Scavenger Receptor Class B, Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0087051","T-Cell Receptor gamma-Chain","C26428","One component of the gamma-delta T-cell receptor. Encoded by a locus on chromosome 7. Somatic recombination results in formation of the active gene.","T-Cell Receptor Gamma Chain | T-Cell Antigen Receptor, Gamma Polypeptide | T-Cell Receptor Gamma | TCR Gamma | TCRG | TRG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524892","T-Cell Receptor Gamma Locus","C26421","This region represents the germline organization of the T cell receptor gamma locus. The gamma locus includes V (variable), J (joining), and C (constant) segments. During T cell development, the gamma chain is synthesized by a recombination event at the DNA level joining a V segment with a J segment. The C segment is later joined by splicing at the RNA level. Recombination of many different V segments with several J segments provides a wide range of antigen recognition. Additional diversity is attained by junctional diversity, resulting from the random additional of nucleotides by terminal deoxynucleotidyltransferase. (from LocusLink)","T-Cell Receptor Gamma Locus | T-Cell Rearranging Gene, Gamma | T-Cell Receptor Gamma Gene | T-Cell Receptor, Gamma Cluster | TCRG | TRG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033908","Psychologist","C28181","A specialist who can talk with patients and their families about emotional and personal matters, and can help them make decisions.","Psychologist | psychologist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985482","Pastoral Counselor","C93182","A person trained in both psychology and theology who can provide psychological and spiritual guidance to individuals and families.","Pastoral Counselor | pastoral counselor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707479","Concomitant Therapy","C53630","Any pharmaceutical agent, other than the primary therapy, that is administered to or used by the subject prior to or during a specified time period.","Concomitant Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707725","Device Unattended","C53274","A situation when a procedure or operation involving use of medical device is performed without required level of care, supervision, or constant observation by a person who is qualified and knowledgeable regarding the device operation and safety procedures.","Device Unattended | DEVICE UNATTENDED | Device Operation Unattended",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037511","Monosodium Glutamate","C82288","No Value Exists","Monosodium Glutamate | MONOSODIUM GLUTAMATE | MSG Monohydrate | Sodium Glutamate Monohydrate",,,,,,,,,,,,,,,"4192848","Monosodium glutamate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL388411","Accelerated Radiation Therapy","C94422","Radiation treatment in which the total dose of radiation is given over a shorter period of time (fewer days) compared to standard radiation therapy.","Accelerated Radiation Therapy | accelerated radiation therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986517","Wide Local Excision","C94441","A surgical procedure in which normal tissue is cut out in addition to the lesion or tumor.","Wide Local Excision | Wide Resection | wide local excision",,,,,,,,,,,,,,,"37204075","Wide excision",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0402573","Importer","C53617","The party responsible for bringing goods into a country.","Importer | IMPORTER",,,,,,,,,,,,,,,"4050192","Importer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883483","User Facility Issue Medical Device Problem","C62808","Issue associated with the physical establishment and environment in which medical devices are transported, stored, processed, serviced or used within the user facility.","User Facility Issue Medical Device Problem | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079252","Do Not Resuscitate Order","C93313","A type of advance directive in which a person states that healthcare providers should not perform cardiopulmonary resuscitation (restarting the heart) if his or her heart or breathing stops.","Do Not Resuscitate Order | DNR | DNR order | Do Not Resuscitate | do not resuscitate order",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511695","DNA Sequence Rearrangement","C21069","Any process affecting a DNA sequence that results in the gain, loss or exchange of DNA between chromosomes and/or autonomous replicons.","DNA Sequence Rearrangement | Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890194","Apparent Diffusion Coefficient","C116753","A measurement of the magnitude of diffusion of water molecules within tissue.","Apparent Diffusion Coefficient | ADC | Effective Diffusion Coefficient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898884","High-B-Value Diffusion-Weighted Imaging","C116754","Diffusion-weighted imaging done under conditions of high diffusion gradients.","High-B-Value Diffusion-Weighted Imaging | High B-Value | High-B-Value Diffusion-Weighted MR Imaging | High-B-Value Diffusion-Weighted Magnetic Resonance Imaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279608","Epithelial Predominant Kidney Wilms Tumor","C9146","Wilms tumor of the kidney characterized by the predominance of the epithelial component.  The epithelial cells may form papillary and tubular patterns and pseudorosettes.","Epithelial Predominant Kidney Wilms Tumor | Epithelial Predominant Kidney Adenosarcoma | Epithelial Predominant Kidney Nephroblastoma | Epithelial Predominant Renal Adenosarcoma | Epithelial Predominant Renal Wilm's Tumor | Epithelial Predominant Renal Wilms Tumor | Epithelial Predominant Renal Wilms Tumor | Epithelial Predominant Renal Wilms' Tumor | Epithelial Predominant Wilms Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279609","Blastema Predominant Kidney Wilms Tumor","C9147","Wilms tumor of the kidney characterized by the predominance of the blastema component.","Blastema Predominant Kidney Wilms Tumor | Blastema Predominant Kidney Adenosarcoma | Blastema Predominant Nephroblastoma | Blastema Predominant Renal Adenosarcoma | Blastema Predominant Renal Wilm's Tumor | Blastema Predominant Renal Wilms Tumor | Blastema Predominant Renal Wilms Tumor | Blastema Predominant Renal Wilms' Tumor | Blastema Predominant Wilms Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896641","Ocular Surface Disease Index","C116755","A 12 item questionnaire designed to provide a rapid assessment of the symptoms of ocular irritation consistent with dry eye disease and their impact on vision-related functioning. The OSDI is assessed on a scale of 0 to 100, with higher scores representing greater disability.","Ocular Surface Disease Index | OSDI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698481","No Known Impact or Consequence To Patient","C76143","No Value Exists","No Known Impact or Consequence To Patient | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1112363","Underdose","C50428","An inadequate amount of a treatment.","Underdose | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706684","Abnormality of Ventricle","C50448","No Value Exists","Abnormality of Ventricle | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879528","Abnormal Patch Test Result","C61389","No Value Exists","Abnormal Patch Test Result | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001883","Airway Obstruction","C50456","Blockage of air flow in the respiratory tract.","Airway Obstruction | ",,,,,,,,,,,,,,,"4197065","Respiratory obstruction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706855","Atrial Perforation","C50467","A rupture in atrial tissue due to traumatic or pathologic processes.","Atrial Perforation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707419","Closed Capsulotomy","C50834","A procedure used to treat capsular contraction that uses physical manipulation of the breast to manually rupture scar tissue and release pressure on an implant.","Closed Capsulotomy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0344329","Collapse","C50497","Failure of a physiologic function or system.","Collapse | ",,,,,,,,,,,,,,,"443240","Collapse",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3281264","Corneal Haze","C50509","Opacity within the cornea.","Corneal Haze | Corneal Clouding/Hazing",,,,,,,,,,,,,,,"4187047","Corneal subepithelial haze",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010032","Corneal Abrasion","C26730","Injury to the epithelium of the cornea.","Corneal Abrasion | ",,,,,,,,,,,,,,,"4312493","Corneal abrasion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2348085","Decreased Sensitivy","C73504","Lower perceptual capacity in one or more senses.","Decreased Sensitivity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707644","Decreased Apgar Score","C50923","No Value Exists","Decreased Apgar Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707791","Disfigurement","C50536","Permanent deformation of appearance.","Disfigurement | Deformity/ Disfigurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708341","Heavier Menses","C50578","No Value Exists","Heavier Menses | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0546817","Hypervolemia","C50591","Fluid accumulation in tissues and body cavities.","Hypervolemia | Fluid Overload | VOLUME OVERLOAD",,,,,,,,,,,,,,,"434004","Hypervolemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0679838","Misdiagnosis","C50432","An incorrect diagnosis or classification of an illness or other problem.","Misdiagnosis | Misdiagnosis/ Misclassification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711235","Nonpyrogenic","C50405","No Value Exists","Nonpyrogenic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709372","Device Overstimulation","C50683","A level of stimulation delivered by a device that is greater than the intended level.","Device Overstimulation | Device Overstimulation of Tissue | Overstimulation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0542127","Oversedated","C50850","A level of sedation that is greater than the intended level.","Oversedated | Oversedation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709734","Prosthetic Disc Impingement","C50707","No Value Exists","Prosthetic Disc Impingement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0413402","Reaction to Antibiotics","C51222","No Value Exists","Reaction to Antibiotics | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL356003","Reocclusion","C50727","No Value Exists","Reocclusion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0877377","Skin Tear","C50744","A break in skin tissue caused by friction or shearing.","Skin Tear | Skin Tears",,,,,,,,,,,,,,,"4180738","Tear of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038045","Sprain","C35035","A stretching or tearing of a ligament.","Sprain | ",,,,,,,,,,,,,,,"4298490","Sprain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710262","Suture Abrasion","C50868","Wearing away of the surface of a suture as a result of bending and frictional forces.","Suture Abrasion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL364130","Tissue Dissection","C61409","The process of cutting apart or separating tissue, usually for further analysis or study.","Tissue Dissection | Vascular Dissection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883434","Unintended Radiation Exposure","C61401","The unintentional exposure to radiation of a person.","Unintended Radiation Exposure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1299683","Zonular Dehiscence","C72898","Rupture of the fibrous strands connecting the ciliary body and the crystalline lens of the eye.","Zonular Dehiscence | ",,,,,,,,,,,,,,,"4154681","Zonular dehiscence",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705106","Skin Wrinkling","C50435","A fold, ridge or crease of the skin.","Skin Wrinkling | Wrinkling | Wrinkling",,,,,,,,,,,,,,,"4099601","Wrinkle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706699","Acoustic Shock","C50452","Neurophysiological and psychological symptoms caused by sudden and unexpected loud noise.","Acoustic Shock | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1148522","Acoustic Trauma","C50453","Injury to the hearing mechanisms within the inner ear, caused by excessively loud noise.","Acoustic Trauma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0311394","Ambulation Difficulty","C50458","Any persistent problem with walking.","Ambulation Difficulty | Ambulation Difficulties | Ambulatory difficulty",,,,,,,,,,,,,,,"36714126|439405","Difficulty walking|Walking disability",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1706805","Anaphylactoid","C50410","Resembling anaphylaxis.","Anaphylactoid | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0546959","Atrial Tachycardia","C35481","A disorder characterized by an electrocardiographic finding of an organized, regular atrial rhythm with atrial rate between 101 and 240 beats per minute. The P wave morphology must be distinct from the sinus P wave morphology. (CDISC)","Atrial Tachycardia | ",,,,,,,,,,,,,,,"4171269","Atrial tachycardia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706846","Arm Or Hand Hypoesthesia","C50463","Consisting of abnormally decreased sensitivity, particularly to touch in the arm or hand.","Arm Or Hand Hypoesthesia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL054898","Arm Fracture","C27783","A traumatic break in one or more of the bones in the arm or forearm.","Arm Fracture | ",,,,,,,,,,,,,,,"4050747","Fracture of upper limb",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006285","Bronchopneumonia","C26710","Acute inflammation of the walls of the terminal bronchioles that spreads into the peribronchial alveoli and alveolar ducts.  It results in the creation of foci of consolidation, which are surrounded by normal parenchyma. It affects one or more lobes, and is frequently bilateral and basal.  It is usually caused by bacteria (e.g., Staphylococcus, Streptococcus, Haemophilus influenzae).  Signs and symptoms include fever, cough with production of brown-red sputum, dyspnea, and chest pain.","Bronchopneumonia | Bronchial Pneumonia | Lobular Pneumonia",,,,,,,,,,,,,,,"256722","Bronchopneumonia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706997","Breakdown of Optical Tissue","C50475","No Value Exists","Breakdown of Optical Tissue | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1390619","Bowel Burn","C50473","A thermal, chemical or radiation injury to the bowels.","Bowel Burn | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707264","Capsular Contracture","C50478","The tightening of scar tissue that forms around the implant.","Capsular Contracture | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707352","Change in Emotional State","C50489","Change from the affected person's usual emotional state.","Change in Emotional State | Emotional Changes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0239116","Corneal Burn","C50506","Chemical or radiant injury to the cornea.","Corneal Burn | Eye Burn",,,,,,,,,,,,,,,"443267","Corneal burn",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0349702","Corneal Scar","C50511","Replacement of corneal tissue with scar tissue as a result of injury to the deeper layers of the cornea.","Corneal Scar | ",,,,,,,,,,,,,,,"4318992","Corneal scar",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332679","Crush Injury","C35375","Traumatic compression of the body or a part of the body.","Crush Injury | Crushing Injury",,,,,,,,,,,,,,,"4060415","Crushing injury (morphology)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206178","Cytomegaloviral Retinitis","C50521","Inflammation of the retina due to cytomegalovirus.","Cytomegaloviral Retinitis | Cytomegalovirus retinitis",,,,,,,,,,,,,,,"4330151","Cytomegaloviral retinitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0232132","Diminished Pulse","C50533","Weak or absent palpable pulse due to decreased arterial pulse pressure.","Diminished Pulse | Diminished Pulse Pressure",,,,,,,,,,,,,,,"4274164","Thready pulse",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2700000","Physical Entrapment","C50548","Patient becomes entangled or caught in a bed, particularly in side rails, or mattress, or head/foot boards.","Physical Entrapment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707960","Excessive Blinking","C50551","No Value Exists","Excessive Blinking | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4227393","Feeding Problem","C50560","Interruption or disruption of the intake of food/nutrition.","Feeding Problem | ",,,,,,,,,,,,,,,"4299954","Feeding problem",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0854569","Failure To Anastomose","C50417","Failure of a surgically-induced connection between tubular structures in the body.","Failure To Anastomose | Failure to Anastomose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708257","Great Vessel Perforation","C52352","Damage to the venae cavae, pulmonary artery, pulmonary veins or aorta resulting from a full thickness disruption in the integrity of the vessel wall.","Great Vessel Perforation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346484","Increased Sensitivy","C73503","Higher perceptual capacity in one or more senses.","Increased Sensitivity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0151692","Impaired Healing","C50601","Improper body tissue repair due to factors affecting one or more of the phases of wound healing.","Impaired Healing | ",,,,,,,,,,,,,,,"4304198","Impaired tissue repair",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708461","Iatrogenic Source","C50598","No Value Exists","Iatrogenic Source | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708483","Inadequate Osteointegration","C50914","Insufficient structural and functional connection between living bone and the surface of a synthetic implant.","Inadequate Osteointegration | Inadequate Osseointegration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4227592","Impaired Vision","C50602","Sight that is impaired.","Impaired Vision | Vision difficulty | Visual Impairment",,,,,,,,,,,,,,,"4265433","Visual impairment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028173","Increased NPN","C34851","A laboratory test result indicating abnormally high concentration of non-protein nitrogen in the blood.","Increased Non-Protein Nitrogen | Increased NPN | Increased NPN | NPN Increased | Non-Protein Nitrogen Increased | Uremia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708484","Inadequate Pain Relief","C50605","Continuing discomfort due to a failure of current treatment.","Inadequate Pain Relief | ",,,,,,,,,,,,,,,"4012238","Inadequate analgesia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152031","Joint Swelling","C50627","The presence of swelling in a joint.","Joint Swelling | Swelling of Joint",,,,,,,,,,,,,,,"4154927","Joint swelling",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL387855","Joint Dislocation","C26750","An abnormal separation where two or more bones meet.","Joint Dislocation | ",,,,,,,,,,,,,,,"74726","Dislocation of joint",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708703","Limited Mobility of the Implanted Joint","C50909","No Value Exists","Limited Mobility of the Implanted Joint | Limited Mobility Of The Implanted Joint | Limited Mobility Of The Implanted Joint",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0853813","Local Reaction","C50419","A regionally-limited response to an antigen, which may include inflammation, induration, erythema, pruritus or pain.","Local Reaction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0347633","Liver Laceration","C50854","A cut or tear in the liver.","Liver Laceration | Liver Laceration(s)",,,,,,,,,,,,,,,"195392","Laceration of liver",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3550535","Loss of Vision","C50638","A condition in which the ability to see is impaired.","Loss of Vision | Loss Of Vision",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3552988","Macular Edema","C35468","Accumulation of intraretinal fluid and protein in the macula, which may result in swelling and decreased central vision.","Macular Edema | ",,,,,,,,,,,,,,,"4290333","Macular retinal edema",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1881758","Device Fragments in Patient","C62946","Issue associated with the inability to retrieve device and/or device fragments during medical procedures.","Device Fragments in Patient | Device Embedded In Tissue or Plaque | Medical Device or Device Fragments Remain in Patient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025874","Metrorrhagia","C34818","Uterine bleeding that occurs during a time not associated with the normal menstrual period.","Metrorrhagia | Intermenstrual Bleeding",,,,,,,,,,,,,,,"195012","Irregular intermenstrual bleeding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709048","Mitral Perforation","C50653","A rupture in the mitral valve tissue due to traumatic or pathologic processes.","Mitral Perforation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709098","Muscle Stimulation","C50657","No Value Exists","Muscle Stimulation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709211","Nerve Proximity","C50915","No Value Exists","Nerve Proximity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0151315","Neck Stiffness","C50664","Limited mobility of the neck, usually accompanied by pain.","Neck Stiffness | ",,,,,,,,,,,,,,,"4060220","Stiff neck",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0161479","Nerve Damage","C50669","Injury to nervous tissue.","Nerve Damage | Nerve Injury",,,,,,,,,,,,,,,"381732","Nerve injury",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027429","Nasal Obstruction","C50662","Blockage of the nasal passages.","Nasal Obstruction | ",,,,,,,,,,,,,,,"4334403","Nasal obstruction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709237","No Patient Involvement","C50912","No patient involvement when the adverse event occurred.","Adverse Event without Patient Involvement | No Patient Involvement | No Patient Involvement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709337","Organ Perforation","C50679","A rupture in an organ(s) due to traumatic or pathologic processes.","Organ Perforation | Internal Organ Perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0339293","Perforation of Cornea","C50692","A rupture in the corneal tissue due to traumatic or pathologic processes","Perforation of Cornea | Corneal Perforation | Perforation Of Cornea",,,,,,,,,,,,,,,"4326414","Perforation of cornea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709506","Peritoneal Laceration","C50695","A cut or tear of the peritoneum.","Peritoneal Laceration | Peritoneal Laceration(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL355398","Pulmonary Insufficiency","C51447","Impairment of gas exchange within the lungs secondary to a disease process, neoplasm, or trauma, possibly resulting in hypoxia, hypercarbia, or both, but not requiring intubation or mechanical ventilation. Patients are normally managed with pharmaceutical therapy, supplemental oxygen, or both.","Pulmonary Insufficiency | Respiratory Insufficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709770","Pulmonary Dysfunction","C50712","Impaired or abnormal functioning of the pulmonary system.","Pulmonary Dysfunction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709834","Radiation Underdose","C52354","An inadequate amount of a radiation treatment.","Radiation Underdose | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709832","Radiation Overdose","C50862","A higher than intended cumulative dose of radiation to a single field.","Radiation Overdose | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0235272","Retinal Damage","C50731","Injury to the retina due to advanced age, toxicity, exposure to bright lights, or trauma.","Retinal Damage | Retinal Injury",,,,,,,,,,,,,,,"4188175","Retinal damage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0852828","Scar Excision","C50827","A surgical procedure to reduce the appearance of a scar.","Scar Excision | Scar Revision",,,,,,,,,,,,,,,"40487348","Excision of scar",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883026","Shock From Lead","C61392","Unintended electric shock from patient leads.","Shock From Lead | Shock From Leads | Shock from Patient Lead(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0854572","Sinus Perforation","C50741","A rupture in the sinus tissue due to traumatic or pathologic processes.","Sinus Perforation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0859273","Spinal Injury","C50751","Damage to the spine that results in impaired function.","Spinal Injury | Spinal Column Injury",,,,,,,,,,,,,,,"141758","Spinal cord injury without spinal bone injury",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0851024","Thyroid Alteration","C50770","No Value Exists","Thyroid Alteration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0750173","Ventilator Dependent","C50430","A condition that requires mechanical life support due to inability to breath effectively to maintain normal levels of oxygen and carbon dioxide in the body.","Ventilator-Dependent | Ventilator Dependent | Ventilator-Dependent Patient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883524","Valvular Stenosis","C62433","Narrowing of the opening of one or more of the four valves of the heart.","Valvular Stenosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0241729","Weight Fluctuation","C50810","Repetitive loss and regain of body weight.","Weight Fluctuation | Weight Changes",,,,,,,,,,,,,,,"4093974","Weight fluctuates",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042907","Vitreous Detachment","C50807","The separation of the vitreous from the retina.","Vitreous Detachment | Posterior Vitreous Detatchment",,,,,,,,,,,,,,,"4202518","Vitreous detachment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0233105","Complete Abortion","C50500","Expulsion of all the products of conception following spontaneous, medical or operative pregnancy termination.","Complete Abortion | Complete Induced Abortion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812470","Incomplete Abortion","C50608","The uterus is not entirely emptied of products of conception following spontaneous, medical or operative pregnancy termination.","Incomplete Abortion | Incomplete Induced Abortion",,,,,,,,,,,,,,,"45768717","Incomplete induced termination of pregnancy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0850705","Adult Acquired Toxoplasmosis","C50454","Toxoplasmosis acquired in adulthood.","Adult Acquired Toxoplasmosis | Acquired Toxoplasmosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706680","Abnormal Blood Gas Measurement","C50447","Arterial blood gas test results that are outside normal limits.","Abnormal Blood Gas Measurement | Abnormal Blood Gases",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002631","Amnionitis","C50459","Inflammation of the amnion.","Amnionitis | ",,,,,,,,,,,,,,,"436180","Infection of amniotic cavity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL354378","Apicectomy","C50824","Excision of the apex of the petrous portion of the temporal bone.","Apicectomy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4228256","Aortic Valve Insufficiency","C51223","Dysfunction of the aortic valve characterized by incomplete valve closure.","Aortic Valve Insufficiency | Aortic Insufficiency | Aortic Valve Insufficiency/ Regurgitation",,,,,,,,,,,,,,,"315564","Aortic valve regurgitation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003130","Anoxia","C2876","Absence or reduction of oxygen in body tissue.","Anoxia | ",,,,,,,,,,,,,,,"313601","Oxygen supply absent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004044","Asphyxia","C50465","A state of general hypoxia and hypercapnea, resulting in acidosis, which affects all tissues in the body.","Asphyxia | ",,,,,,,,,,,,,,,"4279614","Asphyxiation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1707297","Cardiac Enzyme Elevation","C50480","An increase from the normal levels of cardiac enzymes measurement.","Cardiac Enzyme Elevation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0271298","Chemosis","C50490","Edema of the mucous membrane of the eyeball and eyelid lining.","Chemosis | ",,,,,,,,,,,,,,,"4218590","Chemosis of conjunctiva",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1707376","Chest Tightness or Pressure","C50491","No Value Exists","Chest Tightness or Pressure | Chest Tightness Or Pressure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3844593","Congenital Toxoplasmosis","C50503","Toxoplasma infection that is present from birth.","Congenital Toxoplasmosis | ",,,,,,,,,,,,,,,"4251491","Congenital toxoplasmosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006107","Concussion","C50502","A violent jar or shock, or the condition which results from such an injury.","Concussion | ",,,,,,,,,,,,,,,"4001336","Concussion injury of brain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1707457","Complaint Not Clearly Defined","C50499","No Value Exists","Complaint Not Clearly Defined | Ill-Defined Complaint",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707539","Cusp Tear","C50517","A split located on a leaflet of a heart valve that prevents its complete closing, which can result in valvular dysfunction.","Cusp Tear | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010543","Cyclitis","C50519","Inflammation of the ciliary body.","Cyclitis | ",,,,,,,,,,,,,,,"433187","Cyclitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1707628","Damage of Vaginal Mucosa","C50522","Injury to vaginal mucosa.","Damage of Vaginal Mucosa | Damage Of Vaginal Mucosa | Vaginal Mucosa Damage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0235827","Decreased Therapeutic Response","C50526","A reduction in the desirable and beneficial effects resulting from a medical  treatment.","Decreased Therapeutic Response | Therapeutic Response Decreased",,,,,,,,,,,,,,,"4010831","Decreased therapeutic response",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL354534","Electrocution","C50544","The passage of electrical current through the body.","Electrocution | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0232100","Exsanguination","C50856","Extensive loss of blood due to internal or external hemorrhage.","Exsanguination | ",,,,,,,,,,,,,,,"4170068","Exsanguination",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0553891","Extubation","C50819","The removal of a previously inserted tube from a hollow organ or passageway, often from the airway.","Extubation | Detubation",,,,,,,,,,,,,,,"4148972|4150627","Extubation of trachea|Removal of endotracheal tube",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL353946","Fainting","C50857","Extremely weak; threatened with syncope.","Fainting | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL353401","Fibromyositis","C50566","Inflammation and fibrous degeneration of a muscle.","Fibromyositis | ",,,,,,,,,,,,,,,"4080995","Fibromyositis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708069","Flap Tissue Necrosis","C50567","No Value Exists","Flap Tissue Necrosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017086","Gangrene","C50573","Death of tissue, usually in considerable mass and generally associated with loss of vascular (nutritive) supply and followed by bacterial invasion and putrefaction.","Gangrene | ",,,,,,,,,,,,,,,"4263116|439928","Gangrene|Gangrenous disorder",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0019116","Hemostasis","C50581","The arrest of bleeding, either by the natural processes of vasoconstriction and coagulation or by surgical means.","Hemostasis | ",,,,,,,,,,,,,,,"4254680","Hemostatic function",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0854379","Hemoconcentration","C50580","An increase in the concentration of blood cells resulting from the loss of plasma or water from the blood stream.","Hemoconcentration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020578","Hyperventilation","C50590","Abnormally prolonged, rapid, and deep breathing.","Hyperventilation | ",,,,,,,,,,,,,,,"316814","Hyperventilation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0546884","Hypovolemia","C50595","Abnormally decreased volume of circulating fluid (plasma) in body.","Hypovolemia | ",,,,,,,,,,,,,,,"37311319","Hypovolemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020641","Hypopyon","C50593","An accumulation of pus in the anterior chamber of the eye.","Hypopyon | ",,,,,,,,,,,,,,,"439018","Hypopyon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020452","Hyperemia","C50588","The presence of an increased amount of blood in a part or organ; engorgement.","Hyperemia | ",,,,,,,,,,,,,,,"4146766","Hyperemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0854676","Implant Failure","C50603","Malfunction of a medical implant.","Implant Failure | Failure of Implant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708498","Indirect Contact Transmission Infection","C50612","Infection transmitted by water, food or other means of conveyance.","Indirect Contact Transmission Infection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708473","Impaired Circulation","C50600","No Value Exists","Impaired Circulation | Circulation Impairment | Circulation trouble | Impairment of Circulation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0235821","Increased Therapeutic Response","C50611","An increase in the desirable and beneficial effects resulting from a medical  treatment.","Increased Therapeutic Response | Therapeutic Response Increased",,,,,,,,,,,,,,,"4010336","Increased therapeutic response",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708549","Intimal Dissection Of Blood Vessel","C50616","A dissection of an artery that occurs though a tear in the inner lining of the blood vessel.","Intimal Dissection Of Blood Vessel | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022081","Iritis","C50621","Inflammation of the iris.","Iritis | ",,,,,,,,,,,,,,,"4274964","Iritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0347629","Laceration of Esophagus","C50841","A torn, ragged, mangled wound, or an accidental cut of esophagus.","Laceration of Esophagus | Laceration Of Esophagus | Laceration(s) of Esophagus",,,,,,,,,,,,,,,"4096021","Laceration of esophagus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0435001","Ligament Injury","C50633","An injury to any of the fibrous bands of tissue that comprise an articulation (joint).","Ligament Injury | Damage To Ligament | Damage to Ligament(s)",,,,,,,,,,,,,,,"4136694","Ligament injury",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708740","Loss of Vitreous Fluid","C50639","Loss or prolapse of vitreous gel.","Loss of Vitreous Fluid | Loss Of Vitreous Fluid | Vitreous Loss",,,,,,,,,,,,,,,"4144744","Vitreous loss",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0264576","Mediastinal Shift","C50645","Displacement of structures in the thoracic cavity in one direction due to increased pleural pressure on the contralateral side.","Mediastinal Shift | ",,,,,,,,,,,,,,,"4055373","Mediastinal shift",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0000814","Missed Abortion","C50652","Retention in uterus of an abortus.","Missed Abortion | ",,,,,,,,,,,,,,,"76482","Missed miscarriage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709099","Muscular Tic","C50660","An involuntary, compulsive, repetitive stereotyped movement, usually of the face or shoulders.","Muscular Tic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0235990","Nipple Ulceration","C50674","Ulcer that develops in the nipple.  Causes include trauma and Paget disease.","Nipple Ulceration | ",,,,,,,,,,,,,,,"4319453","Ulcer of nipple",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709330","Optic Nerve Damage","C50849","Injury to the optic nerve.","Optic Nerve Damage | Optical Nerve Damage | Optical Nerve Damage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL355316","Ossification","C50680","The formation of bone or of a bony substance; the conversion of fibrous tissue or of cartilage into bone or a bony substance.","Ossification | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029435","Osteolysis","C50681","Dissolution of bone; applied especially to the removal or loss of the calcium of bone.","Osteolysis | ",,,,,,,,,,,,,,,"4147852|78308","Osteolysis|Osteolysis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0030552","Paresis","C50688","A slight or incomplete paralysis.","Paresis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0520893","Peeling","C50691","A peeling off or loss of epidermis, as in sunburn, postscarlatinal peeling, or toxic epidermal necrolysis.","Peeling | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4013788","Polydipsia","C50700","Chronic excessive intake of water; it may be from an organic cause, such as the dehydration of diabetes mellitus, diabetes insipidus, or a reaction to medication, or from a psychological cause. When untreated it can lead to water intoxication.","Polydipsia | ",,,,,,,,,,,,,,,"432454","Excessive thirst",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1264517","Wound Infection","C50705","Infection of a break in the skin or other tissue.","Wound Infection | Post Traumatic Wound Infection | Posttraumatic Wound Infection | Wound infection",,,,,,,,,,,,,,,"4153877","Post-traumatic wound infection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL354174","Postoperative Wound Infection","C50704","Infection of a surgical skin incision.","Postoperative Wound Infection | Post Operative Wound Infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709608","Posterior Capsular Bag Tear","C50702","A tear in the capsular bag housing the lens of the eye.","Posterior Capsular Bag Tear | Capsular Bag Tear",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033377","Prolapse","C36173","A condition in which an organ or body tissue drops or bulges out of place.","Prolapse | PROLAPSE | Procidentia",,,,,,,,,,,,,,,"4105753","Prolapse",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0854643","Reinfusion Procedure","C50820","The infusion of autogenic body fluid that has previously been withdrawn from the patient.","Reinfusion Procedure | Reinfusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3550534","Retinal Degeneration","C34979","Degeneration of the retina.","Retinal Degeneration | ",,,,,,,,,,,,,,,"4318985","Degeneration of retina",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002064","Respiratory Alkalosis","C50729","A condition in which the blood pH is greater than normal, secondary to impaired gas exchange.","Respiratory Alkalosis | ",,,,,,,,,,,,,,,"4006309","Respiratory alkalosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL480955","Spinal Arachnoiditis","C50749","A chronic adhesive arachnoiditis in the spinal arachnoid, with root and spinal cord symptoms similar to those caused by pressure from a tumor.","Spinal Arachnoiditis | ",,,,,,,,,,,,,,,"4138318","Spinal arachnoiditis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0277631","Strangulation","C50756","Choking or arrest of respiration due to occlusion of the air passages; arrest of circulation in a part due to compression.","Strangulation | ",,,,,,,,,,,,,,,"4102691","Death by strangulation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036984","Surgical Shock","C35019","Hypoperfusion of body tissues occurring during or after a surgical procedure, and resulting in cellular injury and vital organ dysfunction.","Surgical Shock | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0497156","Swollen Lymph Node","C50765","The presence of an enlarged lymph node.","Swollen Lymph Node | Swollen Lymph Nodes/Glands",,,,,,,,,,,,,,,"315085","Lymphadenopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0232910","Teratogenic Effect","C50916","The result of processes that negatively affect a developing fetus.","Teratogenic Effect | Teratogenic Effects",,,,,,,,,,,,,,,"4240324","Teratogenesis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001511","Tissue Adhesion","C54685","A fibrous band of tissue that connects normally separate body regions.","Tissue Adhesion | ADHESION | Adhesion | Adhesion(s)",,,,,,,,,,,,,,,"4175338","Adhesion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0231530","Twitching","C50785","The occurrence of a single contraction or a series of contractions of a muscle.","Twitching | ",,,,,,,,,,,,,,,"4093206","Spasmodic movement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0235735","Unexpected Therapeutic Effect","C50789","Unanticipated desirable and beneficial effects resulting from a medical  treatment.","Unexpected Therapeutic Effect | Unexpected Therapeutic Effects",,,,,,,,,,,,,,,"4010337","Unexpected therapeutic effect",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042396","Vasoconstriction","C40866","Vasoconstriction involves narrowing of a blood vessel lumen due to smooth muscle contraction in the vessel wall and leads to decreased blood flow.","Vasoconstriction | ",,,,,,,,,,,,,,,"4137788","Vascular constriction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0271188","Visual Halo","C50806","Hazy ring around bright lights seen by some patients with refractive error or optical defects, e.g. cataracts, or corneal swelling.","Visual Halo | Halo",,,,,,,,,,,,,,,"4308437","Visual halos",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042401","Vasodilation","C40867","Vasodilation involves widening of a blood vessel lumen due to smooth muscle relaxation in the vessel wall and leads to increased blood flow.","Vasodilation | Vasodilatation",,,,,,,,,,,,,,,"4107211|4237053","Vascular dilatation|Vasodilatation",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3809493","Ventriculomeglia","C50803","Abnormal enlargement of the cerebral ventricles.","Ventriculomeglia | Cerebral Ventriculomegaly | Ventriculomegaly",,,,,,,,,,,,,,,"4188846","Cerebral ventriculomegaly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0000880","Acanthamoeba Keratitis","C50450","Keratitis due to infection by acanthamoeba; it is usually associated with soft contact lens wear, particularly overnight wear.","Acanthamoeba Keratitis | ",,,,,,,,,,,,,,,"4338871","Acanthamoeba keratitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706826","Apgar Score Decreased or Low","C50416","An Apgar score less than seven.","Apgar Score Decreased or Low | Apgar Score Decreased Or Low | Low Apgar Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL100344","Autoimmune Reaction","C16313","A specific humoral or cell-mediated immune response against autologous (self) antigens.","Autoimmune Reaction | Autoimmune Process | Autoimmune Process | Autoimmune Response",,,,,,,,,,,,,,,"4033255","Autoimmune reaction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0231837","Bradypnea","C50474","Abnormal decrease of rate of breathing.","Bradypnea | Decreased Respiratory Rate",,,,,,,,,,,,,,,"4314808","Slow respiration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1879904","Burn From Lead","C61390","No Value Exists","Burn From Lead | Burn From Leads | Burns From Lead | Burns From Leads",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0742135","Cervical Change","C50488","An alteration in the cervix.","Cervical Change | Cervical Changes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0678803","Chemical Exposure","C36290","Contact with a chemical substance through touch, inhalation, or ingestion.","Chemical Exposure | Chemical | Chemical Exposure, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0311395","Claudication","C50495","Pain, cramping, and fatigue of the lower extremities upon ambulation due to ischemia.","Claudication | Lameness | Limping",,,,,,,,,,,,,,,"4060361","Limping",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0234535","Clonic Convulsion","C50496","A convulsion marked by alternating contracting and relaxing of the muscles.","Clonic Convulsion | Convulsion, Clonic",,,,,,,,,,,,,,,"4104853","Clonic epileptic seizure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0854719","Corneal Touch","C50513","Complications of intraocular lens surgery; usually refers to intraocular lens contact with cornea, can be intermittent or chronic.","Corneal Touch | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4231610","Corneal Edema","C50508","Hazy, swollen cornea.","Corneal Edema | ",,,,,,,,,,,,,,,"380102","Corneal edema",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332743","Delayed Union Fracture","C50529","A bone fracture that is taking an abnormally long time to heal.","Delayed Union Fracture | Nonunion Bone Fracture | Nonunion/Delayed-union Bone Fracture",,,,,,,,,,,,,,,"40305987|4102168","Delayed union of fracture|Delayed union of fracture",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1707736","Dialyzer First Use Syndrome","C50532","A symptom complex characterized by nervousness, chest pain, back pain, palpations, pruritus, and other usually mild symptoms occurring minutes following the initiation of dialysis with a new dialyzer.","Dialyzer First Use Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707737","Diaphoretic","C50403","Pertaining to, characterized by, or promoting sweating, e.g. procedure or an agent that promotes sweating.","Diaphoretic | Diaphoresis | Sudorific",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707758","Direct Contact Transmission Infection","C50534","Infection produced by direct contact with another person.","Direct Contact Transmission Infection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013781","Electric Shock","C50541","A brief, unintentional exposure to an electric current, which may result in local tissue damage due to thermal injury or in a cardiac dysrhythmia.","Electric Shock | ",,,,,,,,,,,,,,,"4073357|439396","Exposure to electric current, with passage of current through tissue|Injury due to electrical exposure",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1707936","Epithelial Microcyst","C50549","Very small, round vesicles containing fluid and cellular debris observed on the surface of the cornea under slit-lamp examination in some types of corneal dystrophy and in wearers of extended-wear lenses.","Epithelial Microcyst | Corneal Epithelial Microcysts",,,,,,,,,,,,,,,"4225186","Corneal epithelial dots",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0277794","Extreme Exhaustion","C50556","Extreme fatigue; inability to respond to stimuli.","Extreme Exhaustion | ",,,,,,,,,,,,,,,"4225748","Extreme exhaustion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332686","First-Degree Burn","C76130","A painful injury to the epidermis due to chemical, friction, radiation or thermal exposure. The affected area appears red and blanches when touched.","First-Degree Burn | First Degree Burn | Superficial (First Degree) Burn",,,,,,,,,,,,,,,"4298699","First degree burn injury",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708090","Foot Or Leg Hypoesthesia","C50571","Consisting of abnormally decreased sensitivity, particularly to touch in the foot or leg.","Foot Or Leg Hypoesthesia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016542","Foreign Body","C34620","Extraneous material within the body.","Foreign Body | FOREIGN MATERIAL | Foreign Body In Patient",,,,,,,,,,,,,,,"4053838|4078373","Foreign body|Foreign body",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0423602","Foreign Body Sensation","C50572","Feeling of grittiness or having something in the eye; frequently caused by a foreign body. Other possible causes include corneal abrasion, corneal ulcer, inturned eye lash or acute conjunctivitis.","Foreign Body Sensation | Foreign Body Sensation in Eye",,,,,,,,,,,,,,,"4090430","Foreign body sensation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016549","Foreign Body Reaction","C50444","A granulomatous inflammatory reaction evoked by the presence of an exogenous material in the tissues, a characteristic feature of which is the formation of foreign body giant cells.","Foreign Body Reaction | ",,,,,,,,,,,,,,,"4290186","Foreign body giant cell granuloma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020581","Hyphema","C50592","Hemorrhage within the anterior chamber of the eye; bloodshot.","Hyphema | Hyphemia",,,,,,,,,,,,,,,"432904","Hyphema",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007871","Incompetent Cervix","C50607","A clinical diagnosis presenting with painless cervical dilatation and spontaneous mid-trimester birth in recurrent pregnancies in the absence of spontaneous membrane rupture, bleeding or clinical chorioamnionitis.","Incompetent Cervix | Cervical Incompetence | Cervical Insufficiency",,,,,,,,,,,,,,,"436740","Cervical incompetence",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1328565","Insufficient Anesthesia","C51220","A state of consciousness that permits the formation of explicit and implicit memories while under general anesthesia.","Insufficient Anesthesia | Awareness during Anaesthesia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708502","Induced Cataract","C50614","A cataract that has been produced artificially or by induction, e.g. as a result of device use, medication, trauma, tears, falls, accidental injury, etc.","Induced Cataract | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708554","Intraocular Infection","C50617","Infection within the eye.","Intraocular Infection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0392684","Irregular Pulse","C50622","Not rhythmic pulse irregular in beat or accent.","Irregular Pulse | ",,,,,,,,,,,,,,,"4246862","Pulse irregular",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043246","Laceration","C50446","A cut or tear in any tissue.","Laceration | Laceration(s)",,,,,,,,,,,,,,,"4148390|443419","Laceration|Laceration - injury",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3552680","Left Ventricular Dysfunction","C50629","Impairment of the left ventricle to either fill or eject adequately.","Left Ventricular Dysfunction | ",,,,,,,,,,,,,,,"4173819","Impaired left ventricular function",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0347632","Liver Contusion","C50853","Bruising of the liver.","Liver Contusion | ",,,,,,,,,,,,,,,"4096646","Contusion of liver",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708738","Loss of Pulse","C50636","No Value Exists","Loss of Pulse | Loss Of Pulse | No Pulse | Pulse Lost",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0854677","Vessel Or Plaque, Device Embedded In","C50647","Device and/or fragments of device are embedded in patient's vessel and/or plaque.","Vessel Or Plaque, Device Embedded In | Medical Device Embedded In Vessel Or Plaque",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0474441","Microcystic Corneal Edema","C50901","Corneal edema of inflammatory origin associated with contact lens wear and morphologically characterized by presence of epithelial microcysts. Microcysts are small (typically 10-50 microns in diameter), clear, irregularly shaped high refractive inclusions that form in the basal layers of the epithelium and move towards the anterior surface of the cornea, surrounding epithelial haze. The cause of microcytic edema is related to the physical presence of contact lenses and possibly a mechanical effect of lens wear.","Microcystic Corneal Edema | Microcystic Edema | Microcytic Corneal Edema",,,,,,,,,,,,,,,"4094011","Fine corneal edema",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0344857","Mitral Valve Insufficiency","C50888","Dysfunction of the mitral valve characterized by incomplete valve closure.","Mitral Valve Insufficiency | Mitral Insufficiency | Mitral Valve Insufficiency/ Regurgitation",,,,,,,,,,,,,,,"443962","Mitral valve regurgitation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3805772","Muscular Rigidity","C50659","An involuntary, persistent state of firm, tense muscles with marked resistance to passive movement.","Muscular Rigidity | Muscle Rigidity | Muscles Rigid",,,,,,,,,,,,,,,"4050941","Muscle rigidity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0854679","Needlestick Puncture","C50665","A penetrating stab wound from a needle (or other sharp object) that may result in exposure to blood or other body fluids.","Needlestick Puncture | Needle Stick/Puncture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0751792","Nervous System Injury","C4974","Injury in the central or peripheral nervous system.","Nervous System Injury | Neurological Damage",,,,,,,,,,,,,,,"4134134","Injury of nervous system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0521786","Neonatal Hearing Loss","C50668","Partial or complete loss of the ability to detect or understand sounds present in an infant within its first month after birth.","Neonatal Hearing Loss | ",,,,,,,,,,,,,,,"4320813","Neonatal hearing loss",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709227","Nipple Sensation Change or Loss","C50673","Excessive sensitivity or changes in sensitivity in the nipple(s).","Nipple Sensation Change or Loss | Nipple Sensation Change Or Loss | Nipple Sensation Changes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709234","Adverse Event with No Consequence or Impact","C50675","No apparent harm occurred in relation to the adverse event.","Adverse Event with No Consequence or Impact | No Consequence or Impact to Patient | No Health Consequences or Impact",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709456","Pannus Formation","C50686","Superficial vascularization of the cornea with infiltration of granulation tissue; an inflammatory exudate overlying the lining layer of synovial cells on the inside of a joint.","Pannus Formation | Corneal Pannus",,,,,,,,,,,,,,,"377868","Corneal pannus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709528","Phosphene Visualization","C50697","An objective visual sensation that appears with the eyes closed and in the absence of visual light.","Phosphene Visualization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0854570","Pocket Erosion","C50699","Erosion of patient's skin pocket which houses a device.","Pocket Erosion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032792","Postoperative Shock","C50703","A state of shock following a surgical operation.","Postoperative Shock | ",,,,,,,,,,,,,,,"200618","Postoperative shock",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4228300","Quadriplegia","C50721","Paralysis of all four limbs.","Quadriplegia | Bilateral Diplegia | Quadriplegia, unspecified | Tetraplegia",,,,,,,,,,,,,,,"374914","Tetraplegia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709786","Pyogenic Infection","C50719","An infection caused by pus-producing organisms.","Pyogenic Infection | Pyrogenic Infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034074","Pulmonary Infarction","C50714","Localized necrosis of lung tissue caused by obstruction of the arterial blood supply, most often due to pulmonary embolism.","Pulmonary Infarction | ",,,,,,,,,,,,,,,"254662","Pulmonary infarction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1273758","Pupillary Block","C50716","An obstruction of the pupil.","Pupillary Block | ",,,,,,,,,,,,,,,"4298482","Pupillary block",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1504534","Radiation Burn","C50722","A burn caused by exposure to x-ray, radium, sunlight, atomic or any other type of radiant energy.","Radiation Burn | ",,,,,,,,,,,,,,,"4143235","Radiation burn",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL473769","Red Eye","C50725","Lay term applied to any condition with dilation of conjunctival or ciliary blood vessels; innumerable causes, especially irritation and infection.","Red Eye | Red Eye(s)",,,,,,,,,,,,,,,"45766466","Red eye",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332687","Second-Degree Burn","C76131","An injury that includes the entire epidermis and upper layers of the dermis due to a chemical, friction, radiation or thermal exposure. The affected area appears as moist red or white skin that does not blanch. Often it is painful with the presence of blisters.","Second-Degree Burn | Partial thickness (Second Degree) Burn | Second Degree Burn",,,,,,,,,,,,,,,"4263187|4296205","Second degree burn injury|Partial thickness burn",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3887524","Skin Erosion","C50845","Tearing or wearing off of skin.","Skin Erosion | Erosion | Skin Breakdown",,,,,,,,,,,,,,,"4247076","Superficial ulcer of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710178","Stacking Breath","C50752","Condition where there are a greater number of inhalations relative to the number of exhalations.","Stacking Breath | Stacking Breaths",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2242671","Sunset Syndrome","C50763","Decentration, or malposition of intraocular lens; zonular dehiscence or lens malposition caused by zonular or parsplana fixation.","Sunset Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL355521","Suffocation","C50762","The stopping of respiration or the asphyxia that results from it.","Suffocation | Asphyxiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0474444","Stromal Corneal Edema","C50859","Fluid from the aqueous humor enters the corneal stroma and causes swelling.","Stromal Corneal Edema | Corneal Stromal Edema",,,,,,,,,,,,,,,"4159968","Corneal stromal edema",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL354257","Tentorial Tear","C50844","Pertaining to tears involving the tentorium of the cerebellum.","Tentorial Tear | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0433445","Third-Degree Burn","C76132","An injury that includes all skin layers into the subcutaneous tissue due to chemical, friction, radiation or thermal exposure. The affected area appears dry and thickened; damage to nerve endings usually renders the wound painless.","Third-Degree Burn | Full thickness (Third Degree) Burn | Third Degree Burn",,,,,,,,,,,,,,,"4213471|4299128","Third degree burn injury|Full thickness burn",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0701836","Thermal Burn","C50768","A burn injury caused by heat or fire.","Thermal Burn | ",,,,,,,,,,,,,,,"4022094|4151452","Thermal burn|Thermal burn",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0011432","Tooth Sensitivity","C50778","Pain or discomfort caused by exposure of the dentin layer of tooth to thermal, tactile, or other stimuli.","Tooth Sensitivity | Sensitivity Of Tooth | Sensitivity of Teeth | Teeth Sensitivity",,,,,,,,,,,,,,,"4028685","Sensitive dentin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010957","Tissue Damage","C50773","No Value Exists","Tissue Damage | ",,,,,,,,,,,,,,,"4295343","Damage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0270844","Tonic Convulsion","C50776","Prolonged contraction of the muscles, as the result of an epileptic discharge.","Tonic Convulsion | Convulsion, Tonic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036986","Traumatic Shock","C50782","Any shock produced by trauma.","Traumatic Shock | ",,,,,,,,,,,,,,,"201478","Traumatic shock",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0854574","Twiddler's Syndrome","C50784","Dislodgement, breakdown, or other malfunction of an artificial cardiac pacemaker, chemotherapy port, drip infusion valve, or similar implanted diagnostic or therapeutic device as a result of unconscious or habitual manipulation by the patient.","Twiddler's Syndrome | Twiddlers Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011880","Diabetic Ketoacidosis","C50530","The metabolic condition resulted from uncontrolled diabetes mellitus, in which the shift of acid-base status of the body toward the acid side because of loss of base or retention of acids other than carbonic acid is accompanied by the accumulation of ketone bodies in body tissues and fluids.","Diabetic Ketoacidosis | DKA | Elevated Ketones/Diabetic Ketoacidosis",,,,,,,,,,,,,,,"443727","Diabetic ketoacidosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036983","Septic Shock","C35018","A state of acute circulatory failure characterized by persistent arterial hypotension despite adequate fluid resuscitation or by tissue hypoperfusion unexplained by other causes.","Septic Shock | Systemic Septic Shock",,,,,,,,,,,,,,,"196236","Septic shock",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL354930","Aortic Valve Regurgitation","C50861","The backward flow of blood from the aorta into the left ventricle, owing to insufficiency of the aortic semilunar valve; it may be chronic or acute.","Aortic Valve Regurgitation | AR | Aortic Regurgitation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0860361","Bone Shedding Debris","C50472","Shedding of accumulated bone fragments.","Bone Shedding Debris | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0270611","Brain Injury","C50440","Trauma to the brain.","Brain Injury | Brain Damage | Damage, brain",,,,,,,,,,,,,,,"4133611","Traumatic or nontraumatic brain injury",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007785","Cerebral Infarction","C50486","An ischemic condition of the brain, producing a persistent focal neurological deficit in the area of distribution of the cerebral arteries.","Cerebral Infarction | Cerebral Ischemia | Cerebral infarction",,,,,,,,,,,,,,,"443454","Cerebral infarction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007686","Central Opacity of Cornea","C34455","Clouding of the middle area of the cornea, usually as a result of scarring due to Infection, injury, or inflammation.","Central Opacity of Cornea | Central Corneal Clouding",,,,,,,,,,,,,,,"373203","Central opacity of cornea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006435","Chemical Burn","C34442","A burn caused by exposure to chemical substances.","Chemical Burn | Caustic Burn | Caustic/Chemical Burns",,,,,,,,,,,,,,,"4097541|4138484","Chemical burn|Chemical burn",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0853336","Corneal Infiltration","C50510","Discrete, small lesions present in the cornea as a result of corneal inflammation and, in some cases, after soft contact lens wear especially extended-wear lenses.","Corneal Infiltration | Corneal Infiltrate | Corneal Infiltrates",,,,,,,,,,,,,,,"4232690","Infiltrate of cornea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0948284","Corneal Decompensation","C50507","Endothelial decompensation that is manifested by opacity of the cornea. The condition often occurs as a nonspecific response to mechanical injury from incidental corneal contact by intraocular instruments during surgery; chemical injury from the improper use of intraocular drugs, drugs containing preservatives, or from residues from inadequate rinsing of detergents or other residues from surgical instruments. The most common causes of corneal endothelial decompensation in the adult population are cataract removal/IOL-related endothelial loss and Fuchs dystrophy. When severe, corneal endothelial decompensation requires corneal transplantation.","Corneal Decompensation | Corneal Endothelial Decompensation",,,,,,,,,,,,,,,"4137241","Corneal decompensation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0520843","Decreased Peak Expiratory Flowrate","C50525","Decreased expiratory peak flow measurement achieved during forced expiration that primarily reflects changes in upper airway conductance and may be of limited use in evaluation of changes in peripheral airway conductance. Evaluation of peak flow performance is subjective, and, therefore, acceptability criteria are lacking. Because the maneuver is effort and volume dependent, the patient must be encouraged to perform as vigorously as clinically feasible. The results of subjective evaluation may be difficult to interpret consistently. A validated dyspnea rating scale may be useful.","Decreased Peak Expiratory Flowrate | Decreased Peak Expiratory Flow rate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4227807","Dyskinesia","C50539","Abnormality or impairment of voluntary movement.","Dyskinesia | Dyscinesia | Dyskinesis",,,,,,,,,,,,,,,"4319906","Dyskinesia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708386","Host Tissue Response To Foreign Body","C50586","Growth of tissue in or around a foreign body as the body's antibody response to the foreign body.","Host Tissue Response To Foreign Body | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0852710","High Blood Oxygen Saturation","C50584","A high level of the degree to which oxygen is bound to hemoglobin given as a percentage calculated by dividing the maximum oxygen capacity into the actual oxygen content and multiplying by 100. Oxygen saturation usually is measured using pulse oximetry.","High Blood Oxygen Saturation | High Oxygen Saturation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3809741","Hypoesthesia","C50445","Impairment of tactile sensitivity manifesting as partial loss of sensitivity to sensory stimuli.","Hypoesthesia | Decreased Sensitivity | Hypesthesia | Hypoaesthesia",,,,,,,,,,,,,,,"4161682","Hypoesthesia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0520842","Increased Peak Expiratory Flowrate","C50610","An increase of the greatest rate of flow that can be achieved during forced expiration beginning with the lungs fully inflated.","Increased Peak Expiratory Flowrate | Increased Peak Expiratory Flow rate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527401","Insulin Shock","C50615","A hypoglycemic reaction to overdosage of insulin, a skipped meal, or strenuous exercise in an insulin-dependent diabetic.","Insulin Shock | Hypoglycemic Shock | Insulin Reaction",,,,,,,,,,,,,,,"4232212","Hypoglycemic shock",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023212","Left Ventricular Failure","C50630","Failure of adequate output by the left ventricle despite an increase in distending pressure and in end-diastolic volume, with dyspnea, orthopnea, and other signs and symptoms of pulmonary congestion and edema.","Left Ventricular Failure | Left ventricular failure, unspecified",,,,,,,,,,,,,,,"439846","Left heart failure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0746961","Low Blood Oxygen Saturation","C50640","A low level of the degree to which oxygen is bound to hemoglobin given as a percentage calculated by dividing the maximum oxygen capacity into the actual oxygen content and multiplying by 100. Oxygen saturation usually is measured using pulse oximetry.","Low Blood Oxygen Saturation | Desaturation | Low Oxygen Saturation | Oxygen Saturation Decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505195","Pseudoaneurysm","C50711","The creation of hematoma outside the arterial wall following bleeding due to puncture of the arterial wall. Pseudoaneurysms can also occur in the heart chambers following myocardial infarction and bleeding.","Pseudoaneurysm | False Aneurysm",,,,,,,,,,,,,,,"40479758|4328884","Pseudoaneurysm|Pseudoaneurysm",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1705254","Neonatal Deformity","C50666","A congenital anatomic abnormality manifested during the neonatal period.","Neonatal Deformity | Congenital Deformation | Congenital Deformity | Congenital Malformation | Neonatal Deformities | Neonatal Malformation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0544617","Neurogenic Shock","C50671","Shock resulting from neurogenic vasodilation, which can be produced by cerebral trauma or hemorrhage, spinal cord injury, deep general or spinal anesthesia, or toxic central nervous system depression.","Neurogenic Shock | Vasogenic Shock",,,,,,,,,,,,,,,"4305295","Neurogenic shock",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0751495","Partial Seizure","C50689","A transitory alteration in movement, sensation or autonomic nerve function due to abnormal electric activity in a localized area of the cerebral cortex, usually without change in awareness or alertness. Symptoms vary with different lesion locations and may include but not limited to the motor (e.g. rhythmic muscle contractions in one area of the body), somatosensory and sensory alterations manifested by abnormal numbness, paresthesias or other hallucinations, including several types of aura; autonomic and psychic symptoms, e.g. with changes in speech, thought, personality, mood, sensation of deja vu or hallucinations.","Partial Seizure | Focal Seizure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016399","Partial Motor Seizure","C50847","A simple partial seizure consisting of clonus or spasm of a muscle or muscle group; it may be single or in a continuous and repetitive series or may spread to adjacent muscles.","Partial Motor Seizure | Focal Motor Seizure",,,,,,,,,,,,,,,"4027257","Focal onset motor onset epileptic seizure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0270810","Peroneal Nerve Paralysis","C27061","Paralysis of the nerves located in the legs.","Peroneal Nerve Paralysis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347482","Perinatal Brain Injury","C73501","Injury to the brain of a newborn infant occurring around the time of birth.","Perinatal Brain Injury | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527358","Phototoxicity","C50698","A nonimmunologic, chemically induced type of photosensitivity.","Phototoxicity | phototoxicity",,,,,,,,,,,,,,,"4222909","Phototoxicity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL355399","Pulmonary Valvular Regurgitation","C50848","The backflow of blood from the pulmonary artery into the right ventricle, owing to insufficiency of the pulmonic semilunar valve.","Pulmonary Valvular Regurgitation | Pulmonary Valve Regurgitation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4014664","Ptosis","C27298","The drooping of the upper eyelid.","Ptosis | Eyelid Ptosis | ptosis",,,,,,,,,,,,,,,"374044","Ptosis of eyelid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709833","Radiation Sickness Syndrome","C50723","The complex of symptoms characterizing the disease known as radiation injury, resulting from excessive exposure (greater than 200 rads or 2 gray) of the whole body (or large part) to ionizing radiation. The earliest of these symptoms are nausea, fatigue, vomiting, and diarrhea, which may be followed by epilation, hemorrhage, inflammation of the mouth and throat, and general loss of energy. In severe cases, where the radiation exposure has been approximately 1000 Rad (10 gray) or more, death may occur within two to four weeks. Those who survive six weeks after the receipt of a single large dose of radiation to the whole body may generally be expected to recover. (U.S. Nuclear Regulatory Commission).","Radiation Sickness Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001127","Respiratory Acidosis","C50728","A condition in which the blood pH is less than normal, secondary to impaired gas exchange.","Respiratory Acidosis | Hypercapnic Acidosis",,,,,,,,,,,,,,,"4048509","Respiratory acidosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0235527","Right Ventricular Failure","C50846","Failure of proper functioning of the right ventricle, with venous engorgement, hepatic enlargement, and subcutaneous edema.","Right Ventricular Failure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037304","Skull Fracture","C50745","A traumatic or pathologic injury to the bones of the skull in which the continuity of the bones of the skull is broken.","Skull Fracture | Fracture of Skull",,,,,,,,,,,,,,,"4324690","Fracture of skull",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037929","Spinal Cord Injury","C50750","Traumatic damage of the spinal cord.","Spinal Cord Injury | ",,,,,,,,,,,,,,,"4235863","Spinal cord injury",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0475728","Subgaleal Hemorrhage","C50761","Bleeding between the scalp and the periosteum.","Subgaleal Hemorrhage | ",,,,,,,,,,,,,,,"439130","Subgaleal hemorrhage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0275522","Subclinical Infection","C50758","Infection associated with no detectable symptoms but caused by microorganisms capable of producing easily recognizable diseases, such a poliomyelitis or mumps.","Subclinical Infection | Asymptomatic Infection | Inapparent Infection",,,,,,,,,,,,,,,"4155635","Subclinical infection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039103","Synovitis","C50766","Inflammation of a synovial membrane.","Synovitis | synovitis",,,,,,,,,,,,,,,"4168183","Synovitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0344829","Tricuspid Valve Insufficiency","C50842","Dysfunction of the pulmonary valve characterized by incomplete valve closure.","Tricuspid Valve Insufficiency | Tricuspid Insufficiency | Tricuspid Valve Insufficiency/ Regurgitation",,,,,,,,,,,,,,,"4006971","Tricuspid valve regurgitation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710534","Undesired Nerve Stimulation","C50787","Unintended reaction in nervous system caused by electrical stimulation.","Undesired Nerve Stimulation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1271448","Uveitis Glaucoma and Hyphema Syndrome","C50794","Clinical triad of uveitis, glaucoma, and hyphema (UGH), especially associated with the early anterior chamber intraocular lens (IOL). Glaucoma is believed to be caused by movement of the IOL against the iris causing release of inflammatory and red blood cell debris, which obstruct the trabecular meshwork. The haptic also may cause direct damage to the trabecular meshwork contributing to the glaucoma. Incidence of UGH is dependent on both surgical methodology applied in the cataract population and type of IOL used. UGH is particularly common if metal clip lenses have been used. Components of the condition may be reversed if the offending IOL is removed before permanent damage has occurred.","Uveitis Glaucoma and Hyphema Syndrome | UGH (Uveitis Glaucoma Hyphema) Syndrome | Uveitis Glaucoma And Hyphema Syndrome",,,,,,,,,,,,,,,"4194237","Uveitis-glaucoma-hyphema syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0151907","Skin Discoloration","C3327","Abnormal skin coloration.","Skin Discoloration | Skin Dyschromia",,,,,,,,,,,,,,,"135030","Discoloration of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1392786","Alteration Of Cognitive Function","C50457","Pertaining to or characterized by cognition. That operation of the mind which we become aware of objects of thought or perception; it includes all aspects of perceiving, thinking, or remembering.","Alteration Of Cognitive Function | Alteration In Cognition | Cognitive Alteration | Cognitive Change | Cognitive Changes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4229129","Aortic Valve Stenosis","C50462","Narrowing of the orifice of the aortic valve.","Aortic Valve Stenosis | Aortic Stenosis",,,,,,,,,,,,,,,"4189343","Aortic valve stenosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0578033","Body Temperature Associated Symptom","C7941","An alteration in body temperature outside the normal range.","Body Temperature Associated Symptom | Alteration in Body Temperature | Body Temperature Associated Condition | Body Temperature Associated Finding",,,,,,,,,,,,,,,"4103474","Temperature-associated finding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1707497","Cross-Patient Exposure to Body Fluids","C50505","The patient becomes contaminated from contact with blood/fluids on a device.","Cross-Patient Exposure to Body Fluids | Contamination From Blood Or Body Fluids | Contamination from Blood or Body Fluids | Exposure to Body Fluids",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221040","Dialysis Encephalopathy","C50531","A severe, often fatal encephalopathy which has been attributed to accumulation in the brain of aluminum from dialysate prepared with inadequately purified water.","Dialysis Encephalopathy | Dialysis Dementia | Progressive Dialysis Encephalopathy",,,,,,,,,,,,,,,"4244346","Dialysis dementia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0855329","Electrocardiographic Change","C50543","An electrocardiographic finding of a change in cardiac electrical activity.","Electrocardiographic Change | Change in ECG | Non specific EKG/ECG Changes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018674","Head Injury","C34660","A traumatic injury to the head.","Head Injury | Injury of Head",,,,,,,,,,,,,,,"375415","Injury of head",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020683","Hypovolemic Shock","C50596","Shock resulting from insufficient blood volume for the maintenance of adequate cardiac output, blood pressure and tissue perfusion.","Hypovolemic Shock | Hematogenic Shock | Oligemic Shock",,,,,,,,,,,,,,,"4192647","Hypovolemic shock",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1867292","Hyalitis","C50587","Inflammatory intraocular reaction with clouding and cells in vitreous; often accompanies inflammation of ciliary body, iris, choroid, or retina.","Hyalitis | Hyaloiditis | Vitreitis | Vitritis",,,,,,,,,,,,,,,"4317991","Vitritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0270697","Lumbar Puncture Headache","C50643","Headache in erect position, after lumbar puncture; due to lowering of intracranial pressure by leakage of cerebrospinal fluid through the needle tract.","Lumbar Puncture Headache | ",,,,,,,,,,,,,,,"4163706","Headache following lumbar puncture",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1849616","Mitral Valve Stenosis","C50654","Narrowing of the left atrioventricular mitral orifice.","Mitral Valve Stenosis | Mitral Stenosis",,,,,,,,,,,,,,,"315273","Mitral valve stenosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0273112","Myocardial Contusion","C50661","A bruise to the heart.","Myocardial Contusion | ",,,,,,,,,,,,,,,"321710","Contusion to heart",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027686","Neovascularization","C16900","The formation of new or recent blood vessels. The vasculature network is critical to the development of neoplasms. As the tumor burden grows, vascular endothelial cells are recruited to form new blood vessels as an increased demand for blood and nourishment is required.","Neovascularization | NEOVASCULARIZATION | Neoangiogenesis | Neovascularization, Pathologic | Vascularization",,,,,,,,,,,,,,,"4045406","Neovascularization",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015408","Ocular Injury","C34602","Damage to the eye.","Ocular Injury | Eye Injury | Injury of Eye Region",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473756","Subdural Hemorrhage","C50759","Bleeding between the dura mater and the brain, usually secondary to a tear of the bridging vein.","Subdural Hemorrhage | Subdural hemorrhage",,,,,,,,,,,,,,,"439040","Subdural hemorrhage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4230507","Valvular Regurgitation","C50797","Regurgitation of the blood of the heart valves owning to imperfect closing, insufficiency or incompetency of the valves.","Valvular Regurgitation | Heart Valve Regurgitation | Unspecified Valve Regurgitation",,,,,,,,,,,,,,,"4011467","Valvular regurgitation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221232","Wheal","C50811","A smooth, slightly elevated area on the body surface, which is redder or paler than the surrounding skin. It is the typical lesion of urticaria, the dermal evidence of allergy, and in sensitive persons may be provoked by mechanical irritation of the skin.","Wheal | Hive | Welt | Wheal(s)",,,,,,,,,,,,,,,"4082588","Wheal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882089","Appropriate Term/Code Not Available","C64343","A device problem is not adequately described by any other term. Note: this code must not be used unless there is no other feasible code.","Appropriate Term/Code Not Available Problem Code | Appropriate Term/Code Not Available | No Code Available",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1301526","Contact Lens Overwear Syndrome","C50504","Ocular pain which may be very intense, accompanied by corneal epithelium damage, conjunctival injection, lacrimation, blepharospasm, photophobia and hazy vision following corneal edema caused by overwear of contact lenses, principally the PMMA type.","Contact Lens Overwear Syndrome | CLARE | Contact Lens-induced Acute Red Eye | Immobile Lens Syndrome | Overwear Syndrome",,,,,,,,,,,,,,,"4265437","Contact lens overwear syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0238154","Epidural Hemorrhage","C50555","Intracranial hemorrhage into the epidural space.","Epidural Hemorrhage | Epidural hemorrhage | Extradural Hemorrhage | Extradural Hemorrhage",,,,,,,,,,,,,,,"4306943","Epidural intracranial hemorrhage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0494475","Tonic-Clonic Seizure","C50574","A generalized seizure that is characterized by a loss of consciousness and violent muscle contractions. This type of seizure may be preceded by an aura and is frequently followed by a period of confusion and lethargy (post-ictal state).","Tonic-Clonic Seizure | Generalized Tonic-Clonic Seizure | Grand Mal | Grand Mal Seizure | Grand Mal Seizure | Grand-Mal Seizure",,,,,,,,,,,,,,,"37163505","Tonic-clonic epileptic seizure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0520850","High Pulmonary Arterial Wedge Pressure","C50585","The measurement of the mean left arterial pressure, as measured by a catheter introduced into the distal pulmonary artery, is high.","High Pulmonary Arterial Wedge Pressure | ",,,,,,,,,,,,,,,"4146751","Increased pulmonary arterial wedge pressure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0520851","Low Pulmonary Arterial Wedge Pressure","C50642","The measurement of the mean left pulmonary arterial pressure, as measured by a catheter introduced into the distal pulmonary artery, is low.","Low Pulmonary Arterial Wedge Pressure | ",,,,,,,,,,,,,,,"4210180","Decreased pulmonary arterial wedge pressure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL353540","Mitral Valve Regurgitation","C50852","The backward flow of blood from the left ventricle into the left atrium, owing to insufficiency of the mitral valve; it may be acute or chronic, usually due to mitral valve prolapse, rheumatic heart disease or a complication of cardiac dilatation.","Mitral Valve Regurgitation | Mitral Regurgitation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0520849","Normal Pulmonary Arterial Wedge Pressure","C50677","The measurement of the mean left arterial pressure, as measured by a catheter introduced into the distal pulmonary artery, is normal.","Normal Pulmonary Arterial Wedge Pressure | ",,,,,,,,,,,,,,,"4234554","Normal pulmonary arterial wedge pressure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1968880","Positive Antinuclear Antibody Test","C50701","Indicates that antibodies directed against nuclear antigens have been detected.","Positive Antinuclear Antibody Test | ANA Positive | Antinuclear Antibody (ANA) Positive | Antinuclear Antibody Positive | Positive ANA | Positive antinuclear antibodies (ANA)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4015490","Pulmonary Stenosis","C50715","Narrowing of the opening between the pulmonary artery and the right ventricle, usually at the level of the valve leaflets.","Pulmonary Stenosis | Pulmonary Valve Stenosis | Pulmonic Valve Stenosis",,,,,,,,,,,,,,,"4209011","Pulmonic valve stenosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036974","Shock","C35016","A life-threatening condition that requires immediate medical intervention. It is characterized by reduced blood flow that may result in damage of multiple organs. Types of shock include cardiogenic, hemorrhagic, septic, anaphylactic, and traumatic shock.","Shock | Circulatory Collapse",,,,,,,,,,,,,,,"201965","Shock",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040963","Tricuspid Valve Stenosis","C50783","Narrowing or stricture of the tricuspid orifice of the heart.","Tricuspid Valve Stenosis | TS | Tricuspid Stenosis | Tricuspid Stenosis",,,,,,,,,,,,,,,"4176099","Tricuspid valve stenosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL354298","Tricuspid Valve Regurgitation","C50843","The backflow of blood from the right ventricle into the right atrium, owning to imperfect functioning/insufficiency of the tricuspid valve.","Tricuspid Valve Regurgitation | Tricuspid Regurgitation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4013042","Intraocular Pressure Increased","C50618","Increased pressure of the intraocular fluid in the eye.","Intraocular Pressure Increased | Increased Ocular Pressure | Intraocular Pressure Rise | Intraocular Pressure Rise",,,,,,,,,,,,,,,"4011560","Raised intraocular pressure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3280334","Absence Seizure","C50436","Generalized seizure that manifests in the form of a brief episode of impairment of consciousness with or without accompanying motor phenomena such as clonic-tonic components, automatisms, or autonomic components.","Absence Seizure | Absence Seizure | Petit Mal | Petit Mal Seizure | Petit Mal Seizure | Petit-Mal Seizure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4229449","Cerebral Hemorrhage","C50485","Bleeding within the cerebrum.","Cerebral Hemorrhage | Intracerebral Hemorrhage | Intracerebral hemorrhage | Parenchymatous Hemorrhage",,,,,,,,,,,,,,,"376713","Cerebral hemorrhage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015930","Fetal Distress","C50563","Signs or symptoms which may be indicative of distress to a fetus, which may include repetitive variable decelerations, fetal tachycardia or bradycardia, late decelerations, or low biophysical profile.","Fetal Distress | Fetal Intolerance of Labor | Nonreassuring Fetal Status",,,,,,,,,,,,,,,"4305304","Nonreassuring fetal status",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0520836","Increased Forced Expiratory Volume","C50609","An increase in the fraction of the forced vital capacity that is exhaled in a specific number of seconds.","Increased Forced Expiratory Volume | Forced Expiratory Volume Increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4228519","Intraventricular Brain Hemorrhage","C50896","Bleeding into the brain's ventricles.","Intraventricular Brain Hemorrhage | Intraventricular Hemorrhage",,,,,,,,,,,,,,,"443752","Ventricular hemorrhage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0241158","Skin Scar","C50737","Formation of new tissue formed in the healing of a wound.","Skin Scar | Scar Tissue | scar tissue",,,,,,,,,,,,,,,"4323280","Scar of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710531","Uncontrolled Delayed Intraocular Pressure","C50786","Changes in the fluid pressure inside the eye.","Uncontrolled Delayed Intraocular Pressure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883344","Tissue Breakdown","C61375","A process caused by injury or disease or aging and characterized by a partial/complete disruption of tissue. The disruption may be temporary or permanent and may be associated with either (1) impairment or (2) loss of function of the affected organ(s) or system(s).","Tissue Breakdown | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1167782","Lung Overinflation","C50644","Abnormal permanent enlargement of the lung air spaces distal to terminal bronchiole not resulted from wall destruction, e.g. due to loss of opposite lung.","Lung Overinflation | Overinflation of Lung",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600327","Toxic Shock Syndrome","C35498","A rare acute life-threatening systemic bacterial noncontagious illness caused by any of several related staphylococcal exotoxins. It is characterized by high fever, hypotension, rash, multi-organ dysfunction, and cutaneous desquamation during the early convalescent period. The toxins affect the host immune system, causing an exuberant and pathological host inflammatory response. Laboratory findings include leukocytosis, elevated prothrombin time, hypoalbuminemia, hypocalcemia, and pyuria.","Toxic Shock Syndrome | TSS",,,,,,,,,,,,,,,"201214","Toxic shock syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1142256","Cardiac Perforation","C73502","The presence of an acquired hole in the heart. Cardiac perforation may or may not be symptomatic and may or may not be self sealing. (ACC)","Cardiac Perforation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3806127","Pallor","C50685","An unusual or extreme paleness, state of decreased skin or mucosal coloration.","Pallor | PALE | Paleness",,,,,,,,,,,,,,,"138858","Pale complexion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0340861","Electromechanical Dissociation by ECG Finding","C50542","An electrocardiographic finding of the presence of cardiac electrical rhythm without a proper response of the myocardial tissue and mechanical cardiac output.","Electromechanical Dissociation by ECG Finding | EMD | Electro-Mechanical Dissociation | Electromechanical Dissociation | Electromechanical Dissociation by EKG Finding | PEA | Pulseless Electrical Activity",,,,,,,,,,,,,,,"4122762","Electromechanical dissociation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4048276","Invasive Procedure","C93159","A procedure requiring physical intrusion of the body.","Invasive Procedure | Invasive | invasive procedure",,,,,,,,,,,,,,,"4044378","Open approach",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2750144","Cyanosis","C26737","A bluish or purplish discoloration of the skin and mucous membranes resulting from a reduced concentration of oxygenated hemoglobin in the blood.","Cyanosis | Blue Spells | cyanosis",,,,,,,,,,,,,,,"438555","Cyanosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007722","Cephalohematoma","C50484","A subperiosteal hemorrhage limited to the surface of one cranial bone, a usually benign condition seen in the newborn as a result of bone trauma.","Cephalohematoma | Cephalhematoma | Fetal Cephalhematoma",,,,,,,,,,,,,,,"4307826","Fetal cephalhematoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0349489","Fetal Hypoxia","C50564","Hypoxia in utero, caused by conditions such as inadequate placental function (often abruptio placentae), preeclamptic toxicity, prolapse of the umbilical cord, or complications from anesthetic administration.","Fetal Hypoxia | Hypoxia in Utero | In Utero Hypoxia",,,,,,,,,,,,,,,"4171120","Fetal hypoxia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2004489","Regurgitation","C50726","Flow in the opposite direction from normal, as the casting up of undigested food or gas from the stomach, or the backward flowing of blood into the heart, or between the chambers of the heart when a valve is incompetent.","Regurgitation | ",,,,,,,,,,,,,,,"4136152","Regurgitation - mechanism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1254481","Patient Problem","C54027","An issue is based on the patient.","Patient Problem | Medical Problem | PATIENT PROBLEM | PATIENT PROBLEM CODE | Patient Issue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882532","R On T Phenomenon by ECG Finding","C61395","An electrocardiographic finding in which the R wave of a premature ventricular complex occurs on top of the T wave of the preceding beat. (CDISC)","R On T Phenomenon by ECG Finding | R ON T PHENOMENON | R On T Phenomenon | R On T Phenomenon by EKG Finding | R on T phenomenon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0520886","ST Segment Elevation by ECG Finding","C50540","An electrocardiographic finding of ST segment elevation above the baseline.","ST Segment Elevation by ECG Finding | ST ELEVATION | ST Elevation | ST Segment Elevation | ST Segment Elevation by EKG Finding | ST elevation",,,,,,,,,,,,,,,"4064882|4295129","ST elevation|ST segment elevation",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3714639","Exit Block by ECG Finding","C50553","An electrocardiographic finding in which impaired conduction or automaticity within the sinus node results in the failure of impulse transmission from the sinoatrial node. This is manifested as dropped P waves during sinus rhythm. (CDISC)","Exit Block by ECG Finding | Exit Block | Exit Block by EKG Finding | SA Block | SINOATRIAL EXIT BLOCK | Sinoatrial Block | Sinoatrial Exit Block | Sinoatrial Node Exit Block | Sinoatrial exit block",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697621","Human-Device Interface Issue","C76121","Problem associated with an act or omission of an act that has a different result than that intended by the manufacturer or expected by the operator.","Human-Device Interface Issue | Human-Device Interface Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879676","Alarm Not Visible","C63309","A device does not display an alarm message when required.","Device Alarm not Visible | Alarm Not Visible | Alarm not Visible Medical Device Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879732","Arcing at Paddles","C63302","Problem associated with electrical current flowing through a gap between paddles (conductive surfaces), typically resulting in a visible flash of light.","Electrical Arcing at Paddles | Arcing at Paddles | Arcing at Paddles Medical Device Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879731","Arcing of Electrodes","C63303","Problem associated with electrical current flowing through a gap between electrodes (conductive surfaces), typically resulting in a visible flash of light.","Electrical Arcing at Electrodes | Arcing at Electrodes Medical Device Problem | Arcing of Electrodes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879721","Application Program Version or Upgrade Problem","C63304","Problem associated with installing updates to a software system that affects a device performance or communication with another device.","Application Program Version or Upgrade Problem | Application Program Version or Upgrade Problem Associated with Medical Device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879846","Biological Factor in Medical Device Environment","C63292","No Value Exists","Biological Factor in Medical Device Environment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879843","Biocompatibility","C63294","Problem associated with undesirable local or systemic effects due to exposure to device materials or leachates from those materials by a patient who has an implant or is receiving treatment with a device made from them.","Biocompatibility | Biocompatibility Issue Associated with Medical Device | Biocompatibility Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879885","Backflow","C63290","Continuous flow of fluid (e.g. liquid, gas) against the intended flow direction.","Backflow | Bleed Back Medical Device Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879994","Capacitative Coupling","C63283","Problem associated with the transfer of energy within an electrical network by means of the capacitance between circuit nodes. It occurs when energy is coupled from one circuit to another through an electric field.","Capacitative Coupling | Capacitive Coupling Medical Device Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880025","Charred Medical Device or Device Component","C63279","No Value Exists","Charred Medical Device or Device Component | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880115","Coiled Medical Device Problem","C63273","No Value Exists","Coiled Medical Device Problem | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699604","Device Difficult to Maintain","C79146","Problem associated with the user's ability to service a medical device according to the manufacturer specifications relating to a routine device maintenance, i.e., periodic inspection, failure detection, repair, and care of the device to sustain or restore acceptable operating conditions.","Device Difficult to Maintain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272406","Device Handling Problem","C95879","Handling of the device not in accordance with specification, prior to use on the patient.","Device Handling Problem | Device Handling Issue Medical Device Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880099","Contamination/Decontamination Problem","C63276","Problem associated with the presence of any unexpected foreign substance found in a device, on its surface or in the package materials, which may affect performance or intended use of the device, or problem that compromise effective decontamination of the device.","Contamination/Decontamination Problem | Cleaning Disinfecting or Sterilization Problem during Medical Device Use | Contamination /Decontamination Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348109","Device Unsafe to Use in Environment","C73118","Problem associated with environmental condition that results in the unsafe use of the device. (e.g. electromagnetic fields, noise, vibration, microbiological contamination etc.).","Device Unsafe to Use in Environment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880352","Disassembly of Medical Device","C63225","No Value Exists","Disassembly of Medical Device | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880486","Electrical Shorting","C63216","Problem associated with an electric current travelling along an accidental path (unintended path) in a circuit.","Electrical Shorting | Electrical Shorting Medical Device Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880551","Error Code Software Problem Associated with Medical Device","C63206","No Value Exists","Error Code Software Problem Associated with Medical Device | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880694","Failure to Form Staple","C64328","Problem associated with the device failing to connect tissue with a stapling device due to the staples not forming correctly.","Failure to Form Staple | Failure to Form Staple Medical Device Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272979","Activation Failure Including Expansion Failures","C96715","Problem associated with the device failing to be activated including expansion.","Activation Failure Including Expansion Failures | Activation Failure | Failure to Expand Medical Device Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881067","Hot Oil Leak Medical Device Problem","C63119","No Value Exists","Hot Oil Leak Medical Device Problem | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881145","Imprecision","C63113","Problem associated with the device providing imprecise measurements when compared to a reference standard.","Device Imprecision | Imprecision | Imprecision Medical Device Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984218","Data Problem","C91397","Event in which data (charting, orders, results) is not correctly stored, transferred, updated, or displayed.","Data Problem | Improper Data Manipulation Medical Device Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984219","Patient Data Problem","C91398","Event in which data is accessed by the healthcare provider and either the wrong patient or the wrong data is retrieved despite correct inquiry procedures.","Patient Data Problem | Incorrect Patient Data Retrieval Medical Device Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881159","Inaccurate Dispensing Medical Device Problem","C63103","No Value Exists","Inaccurate Dispensing Medical Device Problem | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881230","Sensing Intermittently","C63065","Problem with the device receiving an incoming signal on an intermittent basis when expected to be continuous.","Sensing Intermittently | Intermittent Sensing Medical Device Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881375","Light Interference Medical Device Problem","C63057","No Value Exists","Light Interference Medical Device Problem | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881441","Looping Medical Device Problem","C63056","No Value Exists","Looping Medical Device Problem | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347092","Power Problem","C63025","Problem associated with the energy to operate the device.","Power Problem | Medical Device Power Source Issue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881673","Device Emits Odor","C63004","Problem associated with an unexpected or inappropriate smell released by the device.","Device Emits Odor | Medical Device Emits Odor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881721","Device Misassembled during Manufacturing or Shipping","C62957","A device found incorrectly assembled when delivered to the user facility.","Device Misassembled during Manufacturing or Shipping | Device Misassembled During Manufacturing /Shipping | Medical Device Misassembled during Manufacturing or Shipping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984217","Application Program Problem: Medication Error","C91396","An error in medication preparation or administration attributed to software.","Medication Error due to Application Program Problem | Application Program Problem: Medication Error | Medication Error Due to Software Problem Associated with Medical Device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881680","Fail-Safe Problem","C62997","Problem associated with the feature that prevents the unsafe use of the device.","Fail-Safe Mechanism Problem | Fail-Safe Problem | Medical Device Fail-Safe Mechanism Issue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881676","Medical Device Energy Output to Patient Tissue Incorrect","C63001","No Value Exists","Medical Device Energy Output to Patient Tissue Incorrect | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881675","Energy Output Problem","C63002","Problem with the device's intended output of energy.","Energy Output Problem | Medical Device Energy Output Incorrect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881660","Medical Device Contamination with Biological Material","C63017","No Value Exists","Medical Device Contamination with Biological Material | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881677","Energy Spectrum Incorrect","C63000","Problem associated with the energy output from the device not being in the expected part of the spectrum.","Energy Spectrum Incorrect | Medical Device Energy Spectrum Incorrect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881745","Shipping Damage or Problem","C62925","Problem associated with shipping damage or problem prior to the use of the device.","Shipping Damage or Problem | Medical Device Shipping Damage or Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881669","Medical Device Disinfection or Sterilization Issue","C63008","No Value Exists","Medical Device Disinfection or Sterilization Issue | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881648","Battery Problem","C63030","Problem associated with the internal power of a device (e.g. battery, transformer, fuel cell or other power sources).","Battery Problem | Medical Device Battery Issue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881726","Medical Device Out-Of-Box Failure","C62944","No Value Exists","Medical Device Out-Of-Box Failure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698233","Misassembled by Users","C79147","Problem associated with incorrect assembly of a medical device or constituents by the users.","Misassembled by Users | Misassembly by Users",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881864","Misfocusing","C62913","The problem relates to the poor focusing of the object or the focus is on the wrong object or in the wrong area.","Misfocusing | Misfocusing Medical Device Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882095","No Pressure","C64243","Unintended complete loss of pressure, compromising the device's intended function.","No Pressure | No Pressure Medical Device Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882091","No Fail-Safe Mechanism","C62903","The device that does not have a fail-safe mechanism, although such mechanism would be required for its appropriate and/or safe functioning.","No Fail-Safe Mechanism | No Fail-Safe Mechanism Medical Device Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698480","Adverse Event Without Identified Device or Use Problem","C76126","An adverse event appears to have occurred, but there does not appear to have been a problem with a medical device or the way it was used.","Adverse Event without Identified Device or Use Problem | Adverse Event Without Identified Device or Use Problem | No Known Device Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418443","PDK4 Gene","C114746","This gene plays a role in the regulation of glucose and fatty acid metabolism.","PDK4 Gene | PDK4 | Pyruvate Dehydrogenase Kinase, Isozyme 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333527","FABP4 Gene","C20976","This gene plays a role in the regulation of intracellular transport and in fatty acid metabolism.","FABP4 Gene | FABP4 | Fatty Acid Binding Protein 4, Adipocyte Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521197","2q","C13548","Distal (long) arm of chromosome 2","2q | Chromosome 2 Distal Arm | Chromosome 2 Long Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272940","Hepatitis B Virus Core Antibody Measurement","C96660","The determination of the amount of Hepatitis B virus core antibody present in a sample.","Hepatitis B Virus Core Antibody Measurement | HBCAB | HBV Core Antibody | HBV Core Antibody Measurement | Hepatitis B Virus Core Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201477","Hepatitis B Virus Surface Antigen Measurement","C64850","A determination of the presence of hepatitis B virus surface antigen.","Hepatitis B Virus Surface Antigen Measurement | HBSAG | HBsAg | Hepatitis B Surface Antigen | Hepatitis B Virus Surface Antigen",,,,,,,,,,,,,,,"4168615","Hepatitis B surface antigen measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0201487","Hepatitis C Antibody Measurement","C92535","A quantitative measurement of the antibody reaction of a biological specimen to the Hepatitis C virus.","Hepatitis C Antibody Measurement | HCAB | Hepatitis C Antibody | Hepatitis C Virus Antibody",,,,,,,,,,,,,,,"4273104","Hepatitis C antibody measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1416384","IL12RB2 Gene","C38918","This gene is involved in cellular signaling. It is also involved in the immune response and host defense in Leprosy.","IL12RB2 Gene | IL12RB2 | Interleukin 12 Receptor, Beta 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036720","Serine","C29613","A non-essential amino acid in humans (synthesized by the body), Serine is present and functionally important in many proteins. With an alcohol group, serine is needed for the metabolism of fats, fatty acids, and cell membranes; muscle growth; and a healthy immune system. It also plays a major role in pyrimidine, purine, creatine, and porphyrin biosynthetic pathways. Serine is also found at the active site of the serine protease enzyme class that includes trypsin and chymotrypsin. (NCI04)","Serine | (S)-2-Amino-3-hydroxy-propanoic acid | 2-Amino-3-hydroxypropionic Acid | SERINE | Ser | beta-Hydroxyalanine | l-Serine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336608","TFE3 Gene","C24854","This gene plays a role in transcriptional activation. It is involved in melanogenesis.","TFE3 Gene | TFE3 | Transcription Factor Binding to IGHM Enhancer 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420699","TFEB Gene","C94761","This gene plays a role in transcription.","TFEB Gene | TFEB | Transcription Factor EB Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710589","User Facility","C53567","A hospital, ambulatory surgical facility, nursing home, outpatient diagnostic facility, or outpatient treatment facility which is not a physician's office.","User Facility | USER FACILITY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824481","FAAP24 Gene","C92470","This gene is involved in both binding to and repair of DNA.","FAAP24 Gene | C19orf40 | C19orf40 Gene | FAAP24 | Fanconi Anemia Core Complex Associated Protein 24 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708000","FANCM Gene","C54228","This gene plays a role in transcriptional regulation and ubiquitination.","FANCM Gene | FA Complementation Group M Gene | FANCM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1337033","XRCC4 Gene","C20362","This gene plays a role in the repair of double-strand DNA breaks and V(D)J recombination.","XRCC4 Gene | X-Ray Repair Complementing Defective Repair in Chinese Hamster Cells 4 Gene | XRCC4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539623","GTF2H5 Gene","C89756","This gene is involved in the regulation of both RNA polymerase II-mediated transcription and nucleotide excision repair.","GTF2H5 Gene | GTF2H5 | General Transcription Factor IIH, Polypeptide 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415346","GTF2H4 Gene","C89754","This gene plays a role in both mRNA synthesis from DNA templates and nucleotide excision repair.","GTF2H4 Gene | GTF2H4 | General Transcription Factor IIH, Polypeptide 4, 52kDa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003315","Antigen-Presenting Cells","C12621","A cell that enables a T-lymphocyte to recognize an antigen by engulfing the antigen, breaking down the antigen into smaller fragments which bind to MHC molecules on the surface of the antigen presenting cell. The T-lymphocyte can now recognize and bind with the MHC-linked antigen.","Antigen Presenting Cell | APC | Accessory Cell | Antigen Presenting Cells | Antigen Processing Cell | Antigen-Presenting Cell | Antigen-Presenting Cells | antigen-presenting cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986943","t(14;16)","C95146","A chromosomal translocation that involves the chromosomes 14 and 16.","t(14;16) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL354888","Ambulatory Surgical Facility","C51945","A publicly or privately owned institution which is primarily established and licensed for the purpose of providing elective surgical treatment of outpatients whose recovery, under normal and routine circumstances, will not require inpatient care. Such facility as herein defined does not include the offices of private physicians or dentists whether practicing individually or in groups.","Ambulatory Surgical Facility | AMBULATORY SURGICAL FACILITY | Ambulatory Surgical Center | OUTPATIENT CLINIC/SURGERY | Outpatient Surgical Facility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706973","Bloodmobile","C51964","A mobile unit staffed and equipped to collect blood donations for a blood bank.","Bloodmobile | BLOODMOBILE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708098","Free-Standing Cardiac Catheterization Laboratory","C51966","Cardiac catheterization laboratory that is not integrated with any other entity as a health care provider, a department of a provider, remote location of a hospital, satellite facility, or a provider-based entity.","Free-Standing Cardiac Catheterization Laboratory | FREE-STANDING CARDIAC CATHETERIZATION LABORATORY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707295","Cardiac Catheterization Suite","C53510","No Value Exists","Cardiac Catheterization Suite | CARDIAC CATHETERIZATION SUITE | CATHETERIZATION SUITE | Cardiovascular Catheterization Suite | Heart Catheterization Suite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707373","Chemotherapy Center","C51967","A health care organization staffed, equipped, and licensed for performing chemotherapy, biological therapy and associated oncology care.","Chemotherapy Center | CHEMOTHERAPY CENTER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707735","Dialysis Center","C53518","No Value Exists","Dialysis Center | DIALYSIS CENTER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1629858","Dialysis Unit","C53512","A medical facility specifically for administration of kidney dialysis.","Dialysis Unit | DIALYSIS UNIT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707823","Drug Rehabilitation Clinic","C53519","A mental health facility that specializes in the diagnosis and treatment of substance use disorders.","Drug Rehabilitation Clinic | DRUG CLINIC | Rehabilitation, Substance Use Disorder Unit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333247","DR1 Gene","C20600","This gene is involved in repression of transcription.","DR1 Gene | DR1 | Down-Regulator of Transcription 1, TBP-Binding (Negative Cofactor 2) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426393","HES5 Gene","C84295","This gene may play a role in the regulation of transcription.","HES5 Gene | HES5 | Hairy and Enhancer of Split 5, (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334498","MDK Gene","C24589","This gene is involved in nervous tissue development. It plays a role in neuronal differentiation, growth, regeneration and survival.","MDK Gene | MDK | Midkine (Neurite Growth-Promoting Factor 2) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812234","RHOA Gene","C18356","This gene plays a role in signal transduction. It is involved in several cellular functions including cell differentiation and cytoskeletal remodeling.","RHOA Gene | RAS Homolog Family Member A Gene | RHOA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414855","FUBP1 Gene","C99614","This gene plays a role in transcriptional modulation.","FUBP1 Gene | FUBP1 | Far Upstream Element (FUSE) Binding Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414314","EGR1 Gene","C99599","This gene is involved in transcriptional regulation.","EGR1 Gene | EGR1 | Early Growth Response 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334488","MCM10 Gene","C20383","This gene plays a role in DNA replication during progression through the S phase of the cell cycle.","MCM10 Gene | MCM10 | Minichromosome Maintenance Complex Component 10 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335191","PAWR Gene","C24657","This gene plays a role in repression of transcription. It is also involved in regulation of apoptosis.","PAWR Gene | PAWR | PRKC, Apoptosis, WT1, Regulator Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521758","Chromosome 4 Short Arm","C13557","Proximal (short) arm of chromosome 4","4p | Chromosome 4 Proximal Arm | Chromosome 4 Short Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796477","Chromosome 3 Short Arm","C13392","Proximal (short) arm of chromosome 3","3p | Chromosome 3 Proximal Arm | Chromosome 3 Short Arm | Chromosome 3p",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008546","Chromatin","C13201","The genetic material of the nucleus, consisting of deoxyribonucleoprotein, which occurs in two forms during the phase between mitotic divisions: 1) as heterochromatin, seen as condensed, readily stainable clumps; 2) as euchromatin, dispersed lightly staining or nonstaining material. During mitotic division the chromatin condenses into chromosomes.","Chromatin | CHROMATIN",,,,,,,,,,,,,,,"4247151","Chromatin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899591","Clinical Trial Expedited Safety Report","C115574","Documentation describing unexpected serious adverse events experienced by the subject and other safety information in the clinical trial, which are submitted to regulatory authorities and Institutional Review Boards or Independent Ethics Committees.","Clinical Trial Expedited Safety Report Documentation | CIOMS Report | Clinical Trial Expedited Safety Report | Exped Safe Rept | Expedited Safety Report | Investigational New Drug (IND) Safety Report | MedWatch | Suspected Unexpected Serious Adverse Reaction (SUSAR)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707453","Company Representative","C51968","A person appointed by the company to speak on its behalf and/or to provide defined service and work.","Company Representative | COMPANY REPRESENTATIVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707496","Consumer","C53568","A person who uses goods or services.","Consumer | CONSUMER/CONCERNED CITIZEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347344","New Drug Application","C72899","A regulatory document submitted to the FDA proposing the approval of a new drug to be marketed and sold in the U.S. It includes supporting data from both animal and human studies that was initially provided in the Investigational New Drug application (IND).","New Drug Application | NDA | New Drug Application (NDA)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347666","Premarket Approval Application","C70880","An application to FDA for a license to market a new device in the United States.","Pre-market Approval Application | Premarket Approval | Premarket Approval Application | pre-market approval application (PMA)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708065","Five-Day Report","C53573","No Value Exists","Five-Day Report | FIVE-DAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710063","Seven-Day Report","C53574","No Value Exists","Seven-Day Report | SEVEN-DAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710369","Ten-Day Report","C53575","No Value Exists","Ten-Day Report | TEN-DAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708058","Fifteen-Day Report","C53576","No Value Exists","Fifteen-Day Report | FIFTEEN-DAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710392","Thirty-Day Report","C53577","No Value Exists","Thirty-Day Report | THIRTY-DAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706381","Periodic Report","C53578","No Value Exists","Periodic Report | PERIODIC | Periodic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705684","Initial Adverse Event and Product Problem Report","C53620","No Value Exists","Initial Adverse Event and Product Problem Report | INITIAL | Initial Adverse Event Report | Initial Product Problem Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899751","CNS Involvement Status at Leukemia Diagnosis","C116832","The status describing the extent of central nervous system involvement at the time of leukemia diagnosis.","CNS Involvement Status at Leukemia Diagnosis | CNS Leukemia at Diagnosis | CNS Leukemia at Diagnosis | CNS Status/Disease Status | CNS_DISEASE_STATUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899750","CNS1 (classification)","C116833","The status of central nervous system leukemia at diagnosis, where there is an absence of blasts on a cerebral spinal fluid cytospin preparation, regardless of the number of white blood cells.","CNS 1 | CNS1 | CNS1 | Central Nervous System Status 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899749","CNS2","C116834","The status of central nervous system leukemia at diagnosis, where there are less than 5 white blood cells per microliter on a cerebral spinal fluid cytospin preparation that is positive for blasts; or greater than 5 white blood cells per microliter on a cerebral spinal fluid cytospin preparation that is considered negative by Steinherz/Bleyer algorithm.","CNS 2 | CNS2 | CNS2 | Central Nervous System Status 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899757","CNS 2a","C116836","The status of central nervous system leukemia at diagnosis, where there are less than 10 red blood cells and less than 5 white blood cells per microliter on a cerebral spinal fluid cytospin preparation that is positive for blasts.","CNS 2a | CNS2a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899756","CNS 2b","C116837","The status of central nervous system leukemia at diagnosis, where there are 10 or more red blood cells and less than 5 white blood cells per microliter on a cerebral spinal fluid cytospin preparation that is positive for blasts.","CNS 2b | CNS2b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899755","CNS 2c","C116838","The status of central nervous system leukemia at diagnosis, where there are 10 or more red blood cells and 5 or more white blood cells per microliter on a cerebral spinal fluid cytospin preparation that is positive for blasts and is considered negative by Steinherz/Bleyer algorithm.","CNS 2c | CNS2c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899748","CNS3","C116835","The status of central nervous system leukemia at diagnosis, where there are more than 5 white blood cells per microliter on a cerebral spinal fluid cytospin preparation that is positive for blasts; with or without clinical signs of CNS leukemia.","CNS 3 | CNS3 | CNS3 | Central Nervous System Status 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899754","CNS 3a","C116840","The status of central nervous system leukemia at diagnosis, where there are less than 10 red blood cells and 5 or more white blood cells per microliter on a cerebral spinal fluid cytospin preparation that is positive for blasts.","CNS 3a | CNS3a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899753","CNS 3b","C116841","The status of central nervous system leukemia at diagnosis, where there are 10 or more red blood cells and 5 or more white blood cells per microliter on a cerebral spinal fluid cytospin preparation that is considered positive by Steinherz/Bleyer algorithm.","CNS 3b | CNS3b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899752","CNS 3c","C116843","The status of central nervous system leukemia at diagnosis, where there are clinical signs of central system leukemia (such as facial nerve palsy, brain/eye involvement, or hypothalamic syndrome).","CNS 3c | CNS3c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831597","Adrenal Androgen Excess","C113209","Excessive secretion of the androgen hormones dehydroepiandrosterone (DHEA), DHEA sulfate, and androstenedione, from the adrenal gland. Clinical manifestations may include virilization.","Adrenal Androgen Excess | Adrenal Hyperandrogenism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414549","FCER2 Gene","C96899","This gene is involved in the production of IgE and B cell differentiation.","FCER2 Gene | FCER2 | Fc Fragment of IgE Receptor I Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512116","EGFR Gene Amplification","C36649","A molecular genetic abnormality indicating the presence of multiple copies of the EGFR gene.","EGFR Gene Amplification | Amplified | EGFR Amplification | EGFR Gene Activation | Epidermal Growth Factor Receptor Gene Activation | Epidermal Growth Factor Receptor Gene Amplification | HER1 Gene Amplification | Yes | c-erbB1 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517965","Loss of Chromosome 17p","C36499","A cytogenetic abnormality that refers to the loss of all or part of the short arm of chromosome 17 (17p).","Loss of Chromosome 17p | 17p Deletion | del(17p)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413206","CD19 Gene","C38886","This gene plays a role in signal transduction and regulates the response of B cells to antigens.","CD19 Gene | CD19 | CD19 Antigen Gene | CD19 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2676138","EML4/ALK Fusion Gene","C99724","A fusion gene that results from a chromosomal inversion inv(2)(p21p23) which fuses the 5' portion of the EML4 gene with exons 20-29 of the ALK gene. This fusion is associated with non-small cell lung cancer. Multiple transcript variants are possible based on the breakpoint for the EML4 gene.","EML4/ALK Fusion Gene | ALK/EML4 Fusion Gene | EML-4 ALK Translocation | EML-ALK Translocation | EML4-ALK Fusion Gene | EML4-ALK Gene Rearrangement | EML4-ALK Inversion | EML4-ALK Translocation | EML4/ALK Gene Mutation | EML4/ALK Gene Rearrangement | EML4/ALK Inversion | EML4/ALK Mutation | EML4/ALK Translocation | EML4::ALK Fusion Gene | Transforming Fusion Gene EML4-ALK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274885","EML4/ALK Fusion Gene Variant 4","C99730","A fusion gene (~3.4 kb) that results from a chromosomal inversion inv(2)(p21p23) which fuses exon 14 of the EML4 gene and an 11 nucleotide linker sequence with exons 20-29 of the ALK gene. This fusion is associated with non-small cell lung cancer.","EML4/ALK Fusion Gene Variant 4 | EML4-ALK Fusion Gene Variant 4 | EML4-ALK Variant 4 Fusion Gene | EML4::ALK Fusion Gene Variant 4 | Transforming Fusion Gene EML4-ALK Variant 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274881","EML4/ALK Fusion Gene Variant 2","C99726","A fusion gene (~4.7 kb) that results from a chromosomal inversion inv(2)(p21p23) which fuses exon 20 of the EML4 gene with exons 20-29 of the ALK gene. This fusion is associated with non-small cell lung cancer.","EML4/ALK Fusion Gene Variant 2 | EML4-ALK Fusion Gene Variant 2 | EML4-ALK Variant 2 Fusion Gene | EML4::ALK Fusion Gene Variant 2 | Transforming Fusion Gene EML4-ALK Variant 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274880","EML4/ALK Fusion Gene Variant 1","C99725","A fusion gene (~3.9 kb) that results from a chromosomal inversion inv(2)(p21p23) which fuses exon 13 of the EML4 gene with exons 20-29 of the ALK gene. This fusion is associated with non-small cell lung cancer.","EML4/ALK Fusion Gene Variant 1 | EML4-ALK Fusion Gene Variant 1 | EML4-ALK Variant 1 Fusion Gene | EML4::ALK Fusion Gene Variant 1 | Transforming Fusion Gene EML4-ALK Variant 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413239","CD79B Gene","C97424","This gene plays a role in signaling in B-cells.","CD79B Gene | CD79B | CD79b Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986463","Androgen Receptor Positive","C94297","An indication that expression of androgen receptor has been detected in a sample.","Androgen Receptor Positive | AR Positive | AR+ | Positive | androgen receptor positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272694","PIK3CA Gene Mutation","C96271","A change in the nucleotide sequence of the PIK3CA gene.","PIK3CA Gene Mutation | PI3K Gene Mutation | PI3K-Alpha Gene Mutation | PI3KCA Gene Mutation | PIK3CA | PIK3CA Mutation | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Gene Mutation | p110-alpha Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0432410","Trisomy 10","C81729","A chromosomal abnormality consisting of the presence of a third copy of chromosome 10 in somatic cells.","Trisomy 10 | ",,,,,,,,,,,,,,,"4005134","Trisomy 10",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519654","Trisomy 5","C36433","A chromosomal abnormality consisting of the presence of a third copy of chromosome 5 in somatic cells.","Trisomy 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421567","ZAP70 Gene","C26535","This gene is involved in tyrosine phosphorylation and T-cell activation.","ZAP70 Gene | ZAP70 | Zeta-Chain (TCR) Associated Protein Kinase 70kDa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279759","Progesterone Receptor Positive","C15496","An indication that progesterone receptor (PRG; PR) expression has been detected in a sample.","Progesterone Receptor Positive | PGR Positive | PR Positive | PR+ | Positive | progesterone receptor positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282637","Cell Lineage","C17895","The developmental history of a differentiated cell as traced from the division of a stem cell.","Cell Lineage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334433","Junctional Nevus","C4231","A nevus characterized by the presence of an intraepidermal proliferation of nevus cells. The nevus cells form multiple nests in the dermal-epidermal junction. It presents as a small, slightly raised, pigmented skin lesion.","Junctional Nevus | Intraepidermal Nevus | Intraepidermal Nevus of Skin | Intraepidermal Nevus of the Skin | Intraepidermal nevus | Junction Nevus | Junction nevus | Junctional Melanocytic Nevus | Junctional Melanocytoma | Junctional Nevus of Skin | Junctional Nevus of the Skin | Junctional Skin Nevus | Junctional nevus, NOS | junctional nevus","8740/0","Junctional nevus, NOS",,,,,,,,,,,,,"4147980","Junctional nevus",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C2348819","Triple-Negative Breast Cancer Finding","C71428","Triple-negative breast cancer finding is a negative test result that occurs when the cells in the tumor of a breast cancer patient lack the receptors for both estrogen and progesterone and the human epidermal growth factor receptor 2.","Triple-Negative Breast Cancer Finding | ER-Negative PR-Negative ERBB2-Negative | ER-PR-HER2/neu- | ER-negative PR-negative HER2/neu-negative | ER/PR/HER2 Negative | ESR1/PGR/ERBB2 Negative Finding | TNBC | Triple Negative Breast Cancer Finding | Triple Negative Breast Cancer Result | Triple-Negative Breast Cancer Result | triple-negative breast cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266009","Trichilemmal Carcinoma","C43326","A rare malignant tumor arising from the outer hair sheath and infundibulum on the face. It is considered the malignant counterpart of tricholemmoma. Complete surgical excision is required.","Trichilemmal Carcinoma | Trichilemmal carcinoma | Trichilemmocarcinoma | Trichilemmocarcinoma | Tricholemmal Carcinoma","8102/3","Trichilemmocarcinoma",,,,,,,,,,,,,"4029501|4301512","Trichilemmocarcinoma|Trichilemmal carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0227191","Lower Third of the Esophagus","C12255","The lower one third of the esophagus in which the muscle layer is composed of muscle cells predominantly of the smooth type.","Lower Third of the Esophagus | ESOPHAGUS, LOWER THIRD | Esophageal; Distal | Lower Third | Lower Third of Esophagus | Lower third of esophagus | lower esophagus",,,,,,,,,,,,,"UBERON:0013473","lower esophagus","4281852","Structure of lower third of esophagus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2986656","nonfunctioning tumor","C94760","A hormone producing or non-producing endocrine neoplasm, not associated with a hormonal syndrome.","Non-Functioning Endocrine Neoplasm | Non-Functioning Endocrine Neoplasm | Nonfunctional Endocrine Neoplasm | Nonfunctional Endocrine Neoplasm | Nonfunctioning Endocrine Neoplasm | endocrine-inactive tumor | nonfunctioning tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524462","Luminal region","C26456","Relating to the lumen of a blood vessel or other tubular structure.","Luminal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205945","Spindle Cell Sarcoma","C27005","A malignant mesenchymal neoplasm composed of spindle-shaped cells.  This is a morphologic term which can be applied to a wide range of sarcomas.","Spindle Cell Sarcoma | Spindle cell sarcoma | spindle cell sarcoma","8801/3","Spindle cell sarcoma",,,,,,,,,,,,,"4321133","Spindle cell sarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C3890429","Liquid Tumor","C116915","A malignant tumor that originates from myeloid or lymphoid cells i.e., leukemias and lymphomas.","Liquid Tumor | Blood Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811680","CD13 Expressing Cell Count","C111147","The determination of the amount of CD13 expressing cells per unit present in a sample.","CD13 Expressing Cell Count | ANPEP Expressing Cell Count | Aminopeptidase N Expressing Cell Count",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1375183","CD14 protein, human","C17488","Monocyte differentiation antigen CD14 (375 aa, ~40 kDa) is encoded by the human CD14 gene. This protein plays a role in the innate immune response to lipopolysaccharide exposure.","Monocyte Differentiation Antigen CD14 | CD14 | CD14 Antigen | Lipopolysaccharide Receptor | Myeloid Cell-Specific Leucine-Rich Glycoprotein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3491277","Myeloid Cell Surface Antigen CD33, Human","C97246","Myeloid cell surface antigen CD33 (364 aa, ~40 kDa) is encoded by the human CD33 gene. This protein is involved in the mediation of cell adhesion and the regulation of cell-cell signaling.","Myeloid Cell Surface Antigen CD33 | Antigen CD33 | CD33 | CD33 Antigen | Myeloid Differentiation Antigen CD33 | Sialic Acid-Binding Ig-Like Lectin 3 | Sialic Acid-Binding Immunoglobulin-Like Lectin 3 | Siglec-3 | gp67",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705979","IL2RA wt Allele","C51362","Human IL2RA wild-type allele is located within 10p15-p14 and is approximately 51 kb in length. This allele, which encodes interleukin-2 receptor alpha chain protein, plays a role in clathrin-independent endocytosis, cytokine activation and immune functions.","IL2RA wt Allele | CD25 | IDDM10 | IL2R | IL2R, Alpha Chain Gene | IMD41 | Interleukin 2 Receptor Subunit Alpha wt Allele | Interleukin 2 Receptor, Alpha Gene | Interleukin 2 Receptor, Alpha wt Allele | TCGFR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706240","PTPRC wt Allele","C49531","Human PTPRC wild-type allele is located in the vicinity of 1q31-q32 and is approximately 118 kb in length. This allele, which encodes receptor-type tyrosine-protein phosphatase C protein, plays a role in T-cell activation through the antigen receptor. Defects in the PTPRC gene are a cause of autosomal recessive severe combined immunodeficiency (SCID).","PTPRC wt Allele | B220 | CD45 | CD45R | GP180 | L-CA | LCA | LY5 | Protein Tyrosine Phosphatase, Receptor Type C wt Allele | Protein Tyrosine Phosphatase, Receptor Type, C Gene | T200",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705307","DNTT wt Allele","C51333","Human DNTT wild-type allele is located within 10q23-q24 and is approximately 34 kb in length. This allele, which encodes DNA nucleotidylexotransferase protein, plays a role in the template direction-independent addition of deoxyribonucleotides to the 3'-hydroxyl terminus of oligonucleotide primers.","DNTT wt Allele | Deoxynucleotidyltransferase, Terminal wt Allele | TDT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0149742","Non-Gonococcal Urethritis","C27079","Inflammation of the urethra secondary to infection with any bacteria other than Neisseria gonorrhoeae.","Non-Gonococcal Urethritis | NGU",,,,,,,,,,,,,,,"201792","Nongonococcal urethritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0055881","Clindamycin Phosphate","C47978","The phosphate salt form of clindamycin, a semi-synthetic, chlorinated broad spectrum antibiotic produced by chemical modification of lincomycin. Clindamycin phosphate is used in topical preparations.","Clindamycin Phosphate | 7(S)-Chloro-7-deoxylincomycin 2-phosphate | CLINDAMYCIN PHOSPHATE | U 28508",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704888","KIT wt Allele","C51741","Human KIT wild-type allele is located within 4q11-q12 and is approximately 83 kb in length. This allele, which encodes mast/stem cell growth factor receptor protein, plays a role in the mediation of transmembrane-receptor interactions. Mutations in the gene are associated with gastrointestinal stromal tumors, mast cell disease, acute myelogenous leukemia, and piebaldism.","KIT wt Allele | C-KIT | CD117 | KIT | SCF Receptor Gene | SCFR | Stem Cell Factor Receptor Gene | V-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412081","ABCC6 Gene","C116946","This gene is involved in the active transport of xenobiotics and glutathione conjugates into cells.","ABCC6 Gene | ABCC6 | ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413416","CHST3 Gene","C116934","This gene is involved in proteoglycan sulfation.","CHST3 Gene | CHST3 | Carbohydrate (Chondroitin 6) Sulfotransferase 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413869","CYP2A7 Gene","C116970","This gene may play a role in both electron transport and the metabolism of lipids and xenobiotics.","CYP2A7 Gene | CYP2A7 | Cytochrome P450, Family 2, Subfamily A, Polypeptide 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2611190","EGFR-GRB2 Complex","C116967","A protein complex comprised of two epidermal growth factor receptor (EGFR) family proteins, and one or two growth factor receptor-bound protein 2 (GRB2) adaptor proteins. These complexes form after epidermal growth factor (EGF) family ligands bind to EGFR proteins. Ligand binding triggers receptor dimerization and cross-receptor tyrosine phosphorylation, which allows the SH2 domains of each growth factor receptor-bound protein 2 to form a non-covalent bond with the phosphorylated EGFR proteins.","EGFR-GRB2 Complex | EGFR-GRB2 Signaling Complex | EGFR:GRB2 Complex | EGFR:GRB2 ComplexEGFR:GRB2 Complex | EGFR:GRB2 Signaling Complex | GRB2-EGFR Complex | GRB2:EGFR Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425984","FFAR4 Gene","C92546","This gene plays a role in fatty acid binding and glucagon-like peptide 1 secretion.","FFAR4 Gene | FFAR4 | FFAR4 Gene | Free Fatty Acid Receptor 4 Gene | GPR120 | GPR120 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414645","FMO3 Gene","C116952","This gene is involved in the oxidation of xenobiotics.","FMO3 Gene | FMO3 | Flavin Containing Dimethylaniline Monoxygenase 3 Gene | Flavin Containing Monooxygenase 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899163","FOXP3 Treg-Specific Demethylated Region","C116968","A genetic marker that distinguishes regulatory T-cells (Tregs) from other T-lymphocytes. This marker is comprised of a demethylated CpG motif that is within the 5' untranslated region of the FOXP3 gene, which is only found in Tregs. This CpG motif is methylated in other T-cell lineages. The methylation status of this region of the FOXP3 gene may influence the expression of the transcription factor, forkhead box protein P3.","FOXP3 Treg-Specific Demethylated Region | FOXP3 TSDR | FOXP3 Treg Specific Demethylated Region",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898990","HSPH1 T17 Repeat","C116969","A mononucleotide DNA repeat consisting of 17 thymine bases, which is found within intron 8 of the human HSPH1 gene. Variation in, or somatic mutation of this region causes the expression of an aberrant HSPH1 mRNA transcript that is missing exon 9 (HSPH1-deltaE9), which encodes a protein that lacks the HSPH1 substrate binding domain.","HSPH1 T17 Repeat | HSP105 T17 | HSP105 T17 Repeat | HSP110 T17 | HSP110 T17 Repeat | HSPH1 T17",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706439","ITGAM wt Allele","C51167","Human ITGAM wild-type allele is located in the vicinity of 16p11.2 and is approximately 83 kb in length. This allele, which encodes integrin alpha-M protein, plays a role in neutrophil and monocyte adherence to stimulated endothelium, and also in the phagocytosis of complement coated particles.","ITGAM wt Allele | Antigen CD11b (P170) Gene | CD11B | CR3A | Integrin, Alpha M (Complement Component 3 Receptor 3 Subunit) wt Allele | Integrin, Alpha M (Complement Component Receptor 3, Alpha; Also Known As CD11b (p170), Macrophage Antigen Alpha Polypeptide) Gene | Integrin, Alpha-M Gene | MAC-1 | MAC1A | MO1A | Mac1, Alpha Subunit Gene | Mo1, Alpha Subunit Gene | SLEB6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515648","i(17q)","C36477","A cytogenetic abnormality involving chromosome 17 that results from loss of the short arm and duplication of the long arm. This aberration is associated with a variety of neoplastic diseases, and is indicative of a poor prognosis for individuals with hematologic malignancies.","i(17q) | Isochromosome 17q",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898661","JAK2 NM_004972.3:c.2624C>A","C116965","A nucleotide substitution at position 2624 of the coding sequence of the JAK2 gene where cytosine has been mutated to adenine.","JAK2 NM_004972.3:c.2624C>A | JAK-2 c.2624C>A | JAK2 c.2624C>A | JTK10 c.2624C>A | Janus Kinase 2 c.2624C>A | NM_004972.3:c.2624C>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898660","JAK2 NP_004963.1:p.T875N","C116966","A change in the amino acid residue at position 875 in the tyrosine-protein kinase JAK2 protein where threonine has been replaced by asparagine.","JAK2 NP_004963.1:p.T875N | JAK2 NP_004963.1:p.Thr875Asn | JAK2 T875N | JAK2 Thr875Asn | JAK2 p.T875N | JAK2 p.Thr875Asn | Janus Kinase 2 T875N | Janus Kinase 2 Thr875Asn | NP_004963.1:p.T875N | NP_004963.1:p.Thr875Asn | Tyrosine-Protein Kinase JAK2 T875N | Tyrosine-Protein Kinase JAK2 Thr875Asn",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416927","LTA4H Gene","C116949","This gene plays a role in leukotriene metabolism.","LTA4H Gene | LTA4H | Leukotriene A4 Hydrolase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417956","OPCML Gene","C116960","This gene is involved in opioid binding.","OPCML Gene | OPCML | Opioid Binding Protein/Cell Adhesion Molecule-Like Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0072053","Procollagen Type I N-Terminal Peptide","C116963","A polypeptide comprised of the amino-terminal portions of procollagen, which are proteolytically removed during the intracellular formation of type I collagen fibrils. Increased plasma or serum concentrations of these peptides are associated with both fibrillogenesis of type I collagen and bone formation.","Procollagen Type I N-Terminal Peptide | Amino-Terminal Propeptide of Type 1 Procollagen | Amino-Terminal Propeptide of Type I Procollagen | P1NP | PINP | Procollagen Type 1 Amino-Terminal Peptide | Procollagen Type 1 N-Terminal Peptide | Procollagen Type I Amino-Terminal Peptide | Type 1 Procollagen Amino-Terminal Peptide | Type 1 Procollagen N-Terminal Peptide | Type I Procollagen Amino-Terminal Peptide | Type I Procollagen N-Terminal Peptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419242","RAD51D Gene","C116930","This gene plays a role in homologous recombination for DNA repair.","RAD51D Gene | RAD51 Paralog D Gene | RAD51D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1822768","SLFN11 Gene","C116956","This gene plays a role in anti-viral defense.","SLFN11 Gene | SLFN11 | Schlafen Family Member 11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420517","SULT1C2 Gene","C116940","This gene plays a role in the metabolism of small molecules and purine ribonucleotides.","SULT1C2 Gene | SULT1C2 | Sulfotransferase Family, Cytosolic, 1C, Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897367","Telomeric Repeat-Containing RNA","C116964","A large, non-coding RNA that can be encoded by any chromosomal telomeric DNA sequence, and is an integral part of the telomeric heterochromatin. These oligoribonucleotides may play a role in the regulation of both telomere replication and chromosomal remodeling. Their sizes are dependent on the telomere sequence length.","Telomeric Repeat-Containing RNA | TERRA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040919","Trichomonas","C89825","A genus of flagellate protozoa parasitic in birds and mammals, distinguished by the presence of four anterior flagella, an undulating membrane, and a trailing flagellum.","Trichomonas | TRICHOMONAS",,,,,,,,,,,,,,,"4293895","Trichomonas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085166","Bacterial Vaginosis","C116973","Infection caused by bacterial overgrowth in the vagina. Most affected women are asymptomatic. When symptoms occur, they include foul-smelling vaginal discharge, vaginal itching, and burning. Risk factors include sexual activity with multiple partners and the use of vaginal douches and intrauterine devices. Up to a third of cases resolve without treatment. Antibiotic treatment is recommended when symptoms are present and for women that are pregnant at the time of infection.","Bacterial Vaginosis | BV",,,,,,,,,,,,,,,"4303258","Bacterial vaginosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1825547","HSP90B2P Gene","C116982","This gene may play a role in protein folding.","HSP90B2P Gene | HSP90B2P | Heat Shock Protein 90kDa Beta (Grp94), Member 2, Pseudogene Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334100","IL11 Gene","C28601","This gene plays a role in the regulation of cell proliferation and differentiation.","IL11 Gene | IL11 | Interleukin 11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336652","TNF Receptor Family Gene","C21165","Human TNF Receptor Family Genes encode transmembrane receptor proteins regulated by TNF Family ligands. TNF receptors typically contain intracellular death domains involved in the formation of a signal transducing death-inducing complex that includes FADD and caspases that trigger an apoptotic caspase cascade. Some TNF receptors can activate NF-Kappa-B, MAPK3/ERK1, MAPK8/JNK, BIRC1, BIRC2, BAG4/SODD, TRADD, or TRAF2 and transduce inflammation or anti-apoptotic proliferating signals. Some TNF Family Receptors act as competitive decoy receptors in bone resorption or suppress FasL- and LIGHT-mediated cell death. (NCI)","TNF Receptor Family Gene | TNFRSF Gene | Tumor Necrosis Factor Receptor Family Gene | Tumor Necrosis Factor Receptor Superfamily Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0077503","Tumor Necrosis Factor Receptor","C19285","Members of the tumor necrosis factor receptor (TNFR) family play a key role in regulating the immune response to infection.  They are cell-surface proteins that interact with a corresponding TNF-related ligand family. The receptors share homology in the extracellular domain, which contains 3 to 6 cysteine-rich pseudorepeats, but are generally not related in their cytoplasmic regions. However, the intracellular domains (ICDs) of TNFR family members TNFR1 and FAS/APO1/CD95, which can activate apoptotic cell death, do have a region of homology in an oligomerization interface known as the death domain. (from OMIM 603366)","TNF Receptor Family Protein | TNF Receptor | TNF Receptor Superfamily | TNFR | TNFRSF Protein | Tumor Necrosis Factor Receptor | Tumor Necrosis Factor Receptor Family | Tumor Necrosis Factor Receptor Superfamily",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420728","THY1 Gene","C73526","This gene may be involved in the recognition of extracellular signals.","THY1 Gene | THY1 | Thy-1 Cell Surface Antigen Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336640","TLR8 Gene","C24869","This gene plays a role in receptor signaling and in immune responses.","TLR8 Gene | TLR8 | Toll Like Receptor 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538593","PAXIP1 Gene","C112902","This gene is involved in the regulation of both histone methylation and gene expression.","PAXIP1 Gene | PAX Interacting (With Transcription-Activation Domain) Protein 1 Gene | PAXIP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428785","KDM1A Gene","C78141","This gene is involved in the regulation of both transcription and histone methylation.","KDM1A Gene | AOF2 | KDM1A | Lysine (K)-Specific Demethylase 1A Gene | Lysine Demethylase 1A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1367551","CALCA Gene","C38189","This gene is involved in the regulation of bone incorporation and blood calcium and phosphate levels.","CALCA Gene | CALCA | Calcitonin Related Polypeptide Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896638","Quality of Life Questionnaire - Testicular Cancer 26","C116979","A questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) consisting of 26 questions designed to assess quality of life in testicular cancer patients.","Quality of Life Questionnaire - Testicular Cancer 26 | EORTC QLQ-TC26 | QLQ-TC26",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898953","Have Hair Loss","C116980","A question about whether an individual has or had hair loss.","Have Hair Loss | Had Hair Loss | Hair Loss | Hair loss | Have Lost Hair | Have Lost Hair | Have you had hair loss | Have you lost any hair",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896991","Have Problems with Sense of Taste or Smell","C116981","A question about whether an individual has or had problems with their sense of taste or smell.","Have Problems with Sense of Taste or Smell | Have you had problems with your sense of taste or smell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898944","Have Pain in Stomach Area","C116987","A question about whether an individual has or had pain in their stomach area.","Have Pain in Stomach Area | Have you had pain in your stomach area",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898979","Have Acid Reflux","C116988","A question about whether an individual has or had acid reflux.","Have Acid Reflux | Have you had acid reflux",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898946","Have Numbness or Tingling in Fingers or Toes","C116989","A question about whether an individual has or had tingling or numbness in their fingers or toes.","Have Numbness or Tingling in Fingers or Toes | Have you had tingling or numbness in your fingers or toes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898934","Have Skin Problem","C116990","A question about whether an individual has or had skin problems.","Have Skin Problem | Have you had skin problems (e.g. itchy, dry)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898942","Have Pale or Cold Fingers or Toes","C116991","A question about whether an individual has or had pale or cold fingers or toes.","Have Pale or Cold Fingers or Toes | Have you had pale/cold fingers or toes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898940","Have Problem with Hearing","C116992","A question about whether an individual has or had problems with hearing.","Have Problem with Hearing | Did you have problems with hearing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897654","Satisfied with Medical Care Received","C116993","A question about whether an individual is or was satisfied with the medical care they received.","Satisfied with Medical Care Received | Were you satisfied with the medical care you received",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897655","Satisfied with Information Received about Disease or Treatment","C117008","A question about whether an individual is or was satisfied with the information they received about their disease or treatment.","Satisfied with Information Received about Disease or Treatment | Were you satisfied with the information you received about your disease or treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899146","Feel Uncertain about the Future","C117010","A question about whether an individual feels or felt uncertain about the future.","Feel Uncertain about the Future | Did you feel uncertain about the future",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898975","Have Been Anxious about Possible Recurrence of Disease","C117012","A question about whether an individual is or was anxious about a possible recurrence of their disease.","Have Been Anxious about Possible Recurrence of Disease | Have you been anxious about a possible recurrence of the disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898939","Have Problem with Job or Education Because of Disease or Treatment","C117016","A question about whether an individual has or had problems with their job or education because of their disease or treatment.","Have Problem with Job or Education Because of Disease or Treatment | Have you had any problems with your job or your education because of your disease or treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898974","Have Been Physically Limited as a Result of Disease or Treatment","C117017","A question about whether an individual has or had physical limitations as a result of their disease or treatment.","Have Been Physically Limited as a Result of Disease or Treatment | Have you been physically limited as a result of your disease or treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899507","Concerned about Disruption of Family Life","C117018","A question about whether an individual is or was concerned about disruption of family life.","Concerned about Disruption of Family Life | Were you concerned about disruption of family life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900134","Ability to Talk about Disease with Partner or Person Closest to You","C117020","A question about whether an individual can talk about their disease with their partner or the person who is closest to them.","Ability to Talk about Disease with Partner or Person Closest to You Question | Ability to Talk about Disease with Partner or Person Closest to You | Ability to Talk about Disease with Partner or Person Closest to You | Can you talk about your disease with your partner or the person who is closest to you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899151","Feel Less Masculine as a Result of Disease or Treatment","C117023","A question about whether an individual feels or felt less masculine as a result of their disease or treatment.","Feel Less Masculine as a Result of Disease or Treatment | Have you felt less masculine as a result of your disease or treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899191","Extent of Interest in Sex","C117025","A question about the extent to which an individual is or was interested in sex.","Extent of Interest in Sex | To what extent were you interested in sex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899190","Extent of Sexual Activity","C117026","A question about the extent to which an individual is or was sexually active, with or without intercourse.","Extent of Sexual Activity | To what extent were you sexually active (with or without intercourse)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899722","Can Talk about Sexuality with Partner or Person Closest to You","C117027","A question about whether an individual can talk about sexuality with their partner or the person who is closest to them.","Can Talk about Sexuality with Partner or Person Closest to You | Can you talk about sexuality with your partner or the person who is closest to you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898962","Have Difficulty Getting or Maintaining an Erection","C117028","A question about whether an individual has or had difficulty getting or maintaining an erection.","Have Difficulty Getting or Maintaining an Erection | Did you have difficulty getting or maintaining an erection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898941","Have Problem with Ejaculation","C117029","A question about whether an individual has or had problems with ejaculation.","Have Problem with Ejaculation | Did you have ejaculation problems (e.g. dry ejaculation) | Did you have problems with ejaculation | Have Ejaculation Problems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899189","Extent of Sexual Enjoyment","C117030","A question about the extent to which sex is or was enjoyable.","Extent of Sexual Enjoyment | To what extent was sex enjoyable for you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898937","Have Satisfying Sexual Relationship with Partner","C117031","A question about whether the sexual relationship between an individual and their partner has been satisfying.","Have Satisfying Sexual Relationship with Partner | Has the sexual relationship with your partner been satisfying",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897653","Satisfied with Testicular Implant","C117032","A question about whether an individual is or was satisfied with the testicular implant.","Satisfied with Testicular Implant | Are you satisfied with your testicular implant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202670","MRI Without Contrast","C114184","A technique that uses radiofrequency waves and a magnet to image the body, in which the images are not enhanced by the addition of contrast agents.","MRI Without Contrast | MRI WITHOUT CONTRAST | Magnetic Resonance Imaging Without Contrast",,,,,,,,,,,,,,,"4231864","MRI without contrast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2936622","Next Generation Sequencing","C101293","Technologies that facilitate the rapid determination of the nucleotide sequence of large numbers of strands or segments of DNA or RNA.","Next Generation Sequencing | Massively Parallel DNA Sequencing | Massively Parallel Sequencing | NEXT GENERATION SEQUENCING | NGS | Next Generational Sequencing | Next-Generation Sequencing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514713","Raf Kinase Inhibitor","C2336","Any substance that inhibits Raf Kinase, an enzyme active in signal transduction in the Ras pathway. Inhibition of Raf kinase may result in reduced cell proliferation and cell death.","Raf Kinase Inhibitor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1835886","ACKR3 Gene","C91369","This gene is involved in the regulation of chemokine signaling.","ACKR3 Gene | ACKR3 | ACKR3 Gene | Atypical Chemokine Receptor 3 Gene | CXCR7 | CXCR7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1456454","Amyloid","C117187","An insoluble, fibrous aggregate of misfolded proteins or protein fragments. These fibrillar structures usually exhibit a cross-beta-sheet conformation. Deposition of amyloid aggregates is associated with a number of pathologies including amyloidosis and several neurodegenerative disorders.","Amyloid | Amyloid Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428822","ARRDC3 Gene","C117150","This gene plays a role in the positive regulation of receptor signaling.","ARRDC3 Gene | ARRDC3 | ARRDC3 Gene
 | Arrestin Domain Containing 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412762","BCL2L10 Gene","C117138","This gene plays a role in cell survival.","BCL2L10 Gene | BCL2-Like 10 (Apoptosis Facilitator) Gene | BCL2L10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413476","CLDN6 Gene","C117143","This gene is involved in tight junction formation.","CLDN6 Gene | CLDN6 | Claudin 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413867","CYP2A13 Gene","C117153","This gene is involved in the oxidation of flavoproteins.","CYP2A13 Gene | CYP2A13 | Cytochrome P450, Family 2, Subfamily A, Polypeptide 13 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539511","FCRL1 Gene","C117128","This gene may be involved in B-cell function.","FCRL1 Gene | FCRL1 | Fc Receptor-Like 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539512","FCRL2 Gene","C117132","This gene may play a role in B-cell development.","FCRL2 Gene | FCRL2 | Fc Receptor-Like 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416191","IGKV1D-13 Gene","C117123","This gene is involved in the modulation of epitope recognition.","IGKV1D-13 Gene | IGKV1D-13 | Immunoglobulin Kappa Variable 1D-13 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416270","IGKV4-1 Gene","C117118","This gene plays a role in immunoglobulin specificity.","IGKV4-1 Gene | IGKV4-1 | Immunoglobulin Kappa Variable 4-1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898643","KRAS NP_004976.2:p.G12X","C117180","A change in the amino acid residue at position 12 in the GTPase KRas protein where glycine has been replaced by another amino acid.","KRAS NP_004976.2:p.G12X | GTPase KRas G12X | GTPase KRas Gly12Xxx | K-Ras 2 G12X | KRAS Codon 12 Mutation | KRAS G12 Mutation | KRAS G12X | KRAS Gly12Xxx | KRAS NP_004976.2:p.Gly12Xxx | KRAS p.G12X | KRAS p.Gly12Xxx | Ki-Ras G12X | NP_004976.2:p.G12X | NP_004976.2:p.Gly12Xxx | Specific codon 12 mutation not stated | c-K-ras G12X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898642","KRAS NP_004976.2:p.G13X","C117177","A change in the amino acid residue at position 13 in the GTPase KRas protein where glycine has been replaced by another amino acid.","KRAS NP_004976.2:p.G13X | GTPase KRas G13X | GTPase KRas Gly13Xxx | K-Ras 2 G13X | KRAS Codon 13 Mutation | KRAS G13 Mutation | KRAS G13X | KRAS Gly13Xxx | KRAS NP_004976.2:p.Gly13Xxx | KRAS p.G13X | KRAS p.Gly13Xxx | Ki-Ras G13X | NP_004976.2:p.G13X | NP_004976.2:p.Gly13Xxx | Specific codon 13 mutation not stated | c-K-ras G13X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898410","MicroRNA 19B","C117149","A 23 ribonucleotide sequence that is a final product of the processing of either MIR19B1 pre-miRNA or MIR19B2 pre-miRNA. This oligonucleotide may be involved in the negative regulation of gene expression.","MicroRNA 19B | MIR19B | MIRN19b | hsa-miR-19b | hsa-miR-19b-3p | miR-19b | miR19b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035111","Reoviridae","C112026","A family of double stranded RNA viruses that carry 10-12 unique segments, which encode one to three proteins each. The RNA is surrounded by a three-layered icosahedral protein capsid and the viral particles are not enveloped. Members of this family can be transmitted orofecally, or via infected ticks or mosquitoes.","Reoviridae | Reovirus | Respiratory Enteric Orphan Virus",,,,,,,,,,,,,,,"4085752","Family Reoviridae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897553","Solute Carrier Family","C117186","A large group of integral membrane proteins that are involved in either facilitated or secondary active transport of solutes across cellular membranes. There are over 300 member proteins organized into approximately 50 families. The members of each family share both substrate preference and at least 20% amino acid sequence identity.","Solute Carrier Family | SLC Family | Solute Carrier Group",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897398","T-Cell Chemokine","C117185","A cytokine with chemoattractant activity that is involved in the recruitment of T-lymphocytes to sites of inflammation.","T-Cell Chemokine | T Cell Chemokine | T Lymphocyte Chemokine | T-Lymphocyte Chemokine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539952","TFAP2E Gene","C117146","This gene plays a role in the modification of gene expression.","TFAP2E Gene | TFAP2E | Transcription Factor AP-2 Epsilon (Activating Enhancer Binding Protein 2 Epsilon) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420727","THRSP Gene","C117172","This gene plays a role in the modulation of lipid biosynthesis.","THRSP Gene | THRSP | Thyroid Hormone Responsive Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897138","t(9;22)","C117116","A translocation between chromosome 9 and chromosome 22 that may be associated with Philadelphia chromosome and increased susceptibility to several types of leukemia.","t(9;22) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711370","Reportable Event","C54034","An event that must be reported to a regulatory or governing agency.","Reportable Event | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710055","Serious Injury","C53569","No Value Exists","Serious Injury | SERIOUS INJURY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705237","Device Evaluation Report","C53588","No Value Exists","Device Evaluation Report | DEVICE EVALUATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709927","Response to FDA Request","C53587","No Value Exists","Response to FDA Request | RESPONSE TO FDA REQUEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706499","Additional Information Report","C53586","No Value Exists","Additional Information Report | ADDITIONAL INFORMATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705565","Correction Report","C53585","No Value Exists","Correction Report | CORRECTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707712","Device Received in Condition Which Made Analysis Impossible","C53598","No Value Exists","Device Received in Condition Which Made Analysis Impossible | DEVICE RECEIVED IN CONDITION WHICH MADE ANALYSIS IMPOSSIBLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707702","Device Evaluation Anticipated But Not Yet Begun","C53601","No Value Exists","Device Evaluation Anticipated But Not Yet Begun | DEVICE EVALUATION ANTICIPATED BUT NOT YET BEGUN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707709","Device Not Made by Company","C53599","No Value Exists","Device Not Made by Company | DEVICE NOT MADE BY COMPANY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880294","Device Problem Already Known No Evaluation Necessary","C53600","No Value Exists","Device Problem Already Known No Evaluation Necessary | DEVICE PROBLEM ALREADY KNOWN NO EVALUATION NECESSARY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707715","Device Returned to Manufacturer for Evaluation","C53591","An indication that a device was returned to its manufacturer for evaluation.","Device Returned to Manufacturer for Evaluation | DEVICE RETURNED TO MANUFACTURER FOR EVALUATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984630","Actual Device Not Evaluated Evaluation Method","C91897","No Value Exists","Actual Device Not Evaluated Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984629","Testing of Actual/Suspected Device","C91896","The investigation employed relevant empirical testing of the actual device suspected in the reported adverse event in order to establish their functional and other properties and to identify possible causes for the adverse event. Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the latest relevant standards.","Testing of Actual/Suspected Device | Actual Device Evaluated Evaluation Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984679","Device Infrasound Testing Evaluation Method","C91946","No Value Exists","Device Infrasound Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984638","Device Biologic Evaluation Method","C91905","No Value Exists","Device Biologic Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984744","Device Test for High Temperature Condition Evaluation Method","C92011","No Value Exists","Device Test for High Temperature Condition Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984745","Device Test for Low Temperature Condition Evaluation Method","C92012","No Value Exists","Device Test for Low Temperature Condition Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984705","Device Photographic Inspection Evaluation Method","C91972","No Value Exists","Device Photographic Inspection Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984715","Device Radiographic Inspection Evaluation Method","C91982","No Value Exists","Device Radiographic Inspection Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984756","Device Visual Inspection Evaluation Method","C92023","No Value Exists","Device Visual Inspection Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984666","Device from Same Lot Evaluated Evaluation Method","C91933","The investigation employed relevant empirical testing of the device of the same lot or batch than that of the suspected device in the reported adverse event in order to support the identification of possible causes for the adverse event. Testing was performed using the device retained by the manufacturer (i.e. was not shipped). Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the latest relevant standards.","Device from Same Lot Evaluated Evaluation Method | Testing of Device from Same Lot/Batch Retained by Manufacturer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984720","Device Reserve Sample Tested from Same Lot No Failure Detected Evaluation Method","C91987","No Value Exists","Device Reserve Sample Tested from Same Lot No Failure Detected Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984665","Device from Reserve Sample Evaluated Evaluation Method","C91932","No Value Exists","Device from Reserve Sample Evaluated Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984719","Device Reserve Sample from Different Lot Tested No Failure Detected Evaluation Method","C91986","No Value Exists","Device Reserve Sample from Different Lot Tested No Failure Detected Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984726","Device Software Evaluation Method","C91993","No Value Exists","Device Software Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984664","Device from Controlled or Non-Released Sample Evaluated Evaluation Method","C91931","No Value Exists","Device from Controlled or Non-Released Sample Evaluated Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984694","Device Material and Chemistry Evaluation Method","C91961","Testing devices for malfunctions that arise from problems with its components or materials or how its materials or components react to other elements either within the device or within the environment.","Device Material and Chemistry Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984698","Device Microscopic Inspection Evaluation Method","C91965","Inspection of objects or surfaces requiring magnification using a microscope e.g. with electron, optical, or scanning probe microscopy.","Device Microscopic Inspection Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984667","Device Genotoxic Testing Evaluation Method","C91934","Testing the device's ability to cause damage to genetic material. (e.g., leading to outgrowths -- malignant tumors).","Device Genotoxic Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984693","Device Manufacturing Review Evaluation Method","C91960","Performing a review of the manufacturing steps and processes to ensure that they were met and followed and that the device records reflected these processes.","Device Manufacturing Review Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984681","Device Installation Review Evaluation Method","C91948","Performing a review of the processes used to install a device and the records reflecting these processes performed for a specific device.","Device Installation Review Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984687","Device Light Source Performance Evaluation Method","C91954","Testing the optical properties of a device such as diopter, glare, and irradiance or glistening.","Device Light Source Performance Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984668","Device Gradient Induced Field Effect Testing Evaluation Method","C91935","Testing the RF shield around the coils of an MRI device for its ability to provide effective screening against electrical (eddy) currents induced by gradient switching.","Device Gradient Induced Field Effect Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984688","Device Light Testing Evaluation Method","C91955","Testing the device's characteristics when subjected to variations of ambient light within its surroundings.","Device Light Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984691","Device Magnetically Induced Torque Testing Evaluation Method","C91958","Testing the static magnetic field gradients on medical imaging devices for their ability to rotate objects.","Device Magnetically Induced Torque Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984640","Device Cell Evaluation Method","C91907","Evaluating a device's characteristics that may affect cells.","Device Cell Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984671","Device Hematologic Testing Evaluation Method","C91938","Testing the device for its affect or impact on the blood or its components.","Device Hematologic Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984650","Device Design Validation Evaluation Method","C91917","Validating that the device meets the user's needs and intended uses.","Device Design Validation Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984689","Device Line Voltage Testing Evaluation Method","C91956","Tests to determine whether a device's insulation has the strength to prevent any current from reaching the operator.","Device Line Voltage Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984657","Device Electrostatic Discharge Testing Evaluation Method","C91924","Testing the device for malfunctions related to the transfer of an electrostatic charge (by direct contact or from electrostatic fields) between objects of different potentials.","Device Electrostatic Discharge Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984661","Device Flow Testing Evaluation Method","C91928","Testing the device to assess the volume of fluid moving per unit of time. This may also include filter testing.","Device Flow Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984685","Device Ionizing Radiation Testing Evaluation Method","C91952","Testing that ionizing radiation is delivered at the appropriate energy and dose to the appropriate region of interest for the exam or therapy under evaluation.","Device Ionizing Radiation Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984662","Device Fluid Pressure Testing Evaluation Method","C91929","Testing the fluid pressure (pressure at some point within a fluid e.g. water or air) within a device.","Device Fluid Pressure Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984658","Device Emissions Testing Evaluation Method","C91925","Testing the device for adequately controlled electromagnetic emissions.","Device Emissions Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984676","Device Impact Testing Evaluation Method","C91943","Testing the device's response to a suddenly applied stress. The test ascertains whether the material is tough or brittle.","Device Impact Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984633","Device Agent Contamination Testing Evaluation Method","C91900","Testing the device for the presence of chemicals or other agents that do not belong on the device (contamination).","Device Agent Contamination Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984700","Device No Testing Methods Performed Evaluation Method","C91967","Testing was not performed on the device.","Device No Testing Methods Performed Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984649","Device Degradation Corrosion Erosion Testing Evaluation Method","C91916","Testing the device for its corrosive behavior to specific environments or materials. Tests may include polarization, potentiostatic, galvanic, critical pitting/crevice temperature, and inhibitor testing.","Device Degradation Corrosion Erosion Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984636","Device Bioassay Evaluation Method","C91903","Measuring the effects of a substance on a living organism. Bioassays may be qualitative or quantitative. Qualitative bioassays are used for assessing the physical effects of a substance that may not be quantified, such as abnormal development or deformity.","Device Bioassay Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984642","Device Composition Testing Evaluation Method","C91909","Testing the device to determine if the correct combination of materials or elements is present (e.g., the composition of the materials of a capacitor).","Device Composition Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984673","Device Image Artifact Testing Evaluation Method","C91940","Testing an imaging device to determine the amount of distortion or signal loss (artifacts) produced in an image.","Device Image Artifact Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984675","Device Immunity Testing Evaluation Method","C91942","Testing the device for adequate immunity or capability to resist electromagnetic interference (EMI).","Device Immunity Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984646","Device Creep Strength Testing Evaluation Method","C91913","Testing the device's ability to withstand a constant tensile load at elevated temperatures. (Creep is the form of plastic deformation that takes place in steel held for long periods at high temperature.)","Device Creep Strength Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984632","Device Acoustic Noise Testing Evaluation Method","C91899","Testing the device's response to variations in air pressure for detecting any unwanted or unintentional sound.","Device Acoustic Noise Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984674","Device Image Inspection Evaluation Method","C91941","Macroscopic inspection commonly used to describe physical objects that are measurable and observable by the naked eye.","Device Image Inspection Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984643","Device Compression Testing Evaluation Method","C91910","Testing the device for problems that can occur as the result of excessive stress or pressure applied to the device resulting in its compaction (decrease of volume).","Device Compression Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984696","Device Mechanical Evaluation Method","C91963","Testing the device for problems that result from external forces including fluids, other objects, or environmental or physiologic influences.","Device Mechanical Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984682","Device Insulation Testing Evaluation Method","C91949","Testing the ability of a device's or component's material to resist the flow of electric current.","Device Insulation Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984692","Device Maintenance Review Evaluation Method","C91959","Performing a review the technical and corresponding administrative actions and records intended to retain an item in, or restore it to, a state in which it can perform its required function. This evaluation includes reviewing the user's maintenance procedures and processes as to whether they were followed.","Device Maintenance Review Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984654","Device Electrical Slow Fluctuation Testing Evaluation Method","C91921","Testing the device to detect malfunctions caused by a sudden reduction of the voltage at a particular point in an electricity supply system below a specified 'dip' threshold followed by its recovery after a brief interval.","Device Electrical Slow Fluctuation Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984695","Device Material or Material Leachate Pyrogenic Testing Evaluation Method","C91962","Testing the device for the presence of unwanted agents (e.g. pyrogens) caused by materials that permeate through the device.","Device Material or Material Leachate Pyrogenic Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984656","Device Electron Microscopy Evaluation Method","C91923","Inspection of objects or surfaces requiring magnification using an electron microscope.","Device Electron Microscopy Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984663","Device Fracture Toughness Testing Evaluation Method","C91930","Testing the device's ability to resist local separation into two, or more, pieces under the action of stress.","Device Fracture Toughness Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984684","Device Interoperability Evaluation Method","C91951","Testing devices for problems with the mechanical, electrical, or communication interface between two or more separate devices or components.","Device Interoperability Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984634","Device Agglutination Testing Evaluation Method","C91901","Evaluating the device for characteristics that may cause blood to clot.","Device Agglutination Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984699","Device Mutagenic Testing Evaluation Method","C91966","Testing the device's ability to change genetic information (usually DNA) of an organism and thus increasing the frequency of mutations.","Device Mutagenic Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984670","Device Hardness Testing Evaluation Method","C91937","Testing the device's ability to resist deformation. Hardness is the property of a material that enables it to resist plastic deformation, usually by penetration. However, the term hardness may also refer to resistance to bending, scratching, abrasion or cutting. The usual method to achieve a hardness value is to measure the depth or area of an indentation left by an indenter of a specific shape, with a specific force applied for a specific time.","Device Hardness Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984683","Device Interference Substance Testing Evaluation Method","C91950","A test used with in vitro diagnostic analytic systems to detect substances that may be interfering with test results and causing errors.","Device Interference Substance Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984659","Device Environmental Evaluation Method","C91926","Evaluating devices for responses to physical characteristics in their surroundings.","Device Environmental Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984637","Device Biocompatibility Testing Evaluation Method","C91904","Testing the device to determine if it elicits an undesirable local or systemic biological effect in the cells or tissues of the recipient of that device. This includes testing the device for its toxicity to cells.","Device Biocompatibility Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984653","Device Electrical Fast Burst Testing Evaluation Method","C91920","Testing the device for failures related to interference voltage tests which are bursts of electrical pulses (e.g. when a switch is turned on or off or the device is plugged in or out).","Device Electrical Fast Burst Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984624","No Failure Detected Device out of Specification Evaluation Conclusion","C91891","No Value Exists","No Failure Detected Device out of Specification Evaluation Conclusion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984631","Device Acoustic Energy Testing Evaluation Method","C91898","Testing the device for its response to variations in air pressure produced by the vibration of an object.","Device Acoustic Energy Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984686","Device Labeling Evaluation Method","C91953","Reviewing all labeling (including instructions for use, manuals, and packaging) for language related to reported device problems.","Device Labeling Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984635","Device Assembly and Packaging Review Evaluation Method","C91902","Performing a review of the assembly and packaging processes and records for a specific device or lot that may have contributed to problems with the device.","Device Assembly and Packaging Review Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984644","Device Conducted Emissions Testing Evaluation Method","C91911","Testing the ability of a device's conducted emissions to cause another device to fail (i.e. electromagnetic disturbance for which the energy is transferred via one or more conductors).","Device Conducted Emissions Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984655","Device Electromagnetic Compatibility Evaluation Method","C91922","Evaluating a device to detect malfunctions caused by electromagnetic interference (unwanted disturbances from an external force e.g. radios, cell phones, or unintentional disturbances of another device)","Device Electromagnetic Compatibility Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984678","Device In Situ Observation Evaluation Method","C91945","Observing the device in the exact same conditions and setting in which the device was used.","Device In Situ Observation Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984669","Device Growth Factor Evaluation Method","C91936","Evaluating a device's characteristics that may affect the self healing ability of an organism.","Device Growth Factor Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984647","Device Current Leakage Testing Evaluation Method","C91914","Testing to detect the amount of electricity leakage from the device.","Device Current Leakage Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984641","Device Complement Activation Testing Evaluation Method","C91908","Evaluating a device's ability to activate the process of clearing pathogens from a organism.","Device Complement Activation Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984690","Device Magnetically Induced Displacement Force Testing Evaluation Method","C91957","Testing the static magnetic field gradients on medical imaging devices for their ability to move objects.","Device Magnetically Induced Displacement Force Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984639","Device Carcinogenic Testing Evaluation Method","C91906","Testing the device's ability to promote cancer or facilitate its propagation.","Device Carcinogenic Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984660","Device Fatigue Testing Evaluation Method","C91927","Testing the device's capability to withstand the progressive and localized structural damage that occurs when a material is subjected to cyclic loading. This is a dynamic mechanical test for wear or fatigue.","Device Fatigue Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984645","Device Contamination Testing Evaluation Method","C91912","Testing the device to detect the presence of any substance that can cause infection or fever.","Device Contamination Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984672","Device Humidity Testing Evaluation Method","C91939","Testing the device's protective materials to prevent moisture penetration or ingress.","Device Humidity Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984648","Device Data Validation Evaluation Method","C91915","Ensuring that data used and generated by a program is correct.","Device Data Validation Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984697","Device Microbial Contamination Testing Evaluation Method","C91964","Testing the device for the presence of microorganisms such as bacteria, viruses, and fungi (yeasts and molds).","Device Microbial Contamination Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984680","Device Ingress Protection Testing Evaluation Method","C91947","Testing the device's ability to protect against ingress or access of unwanted fluids or solids.","Device Ingress Protection Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984651","Device Elasticity Testing Evaluation Method","C91918","Testing the device's ability to recover its size and shape after being deformed during the test.","Device Elasticity Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984733","Device Static Analysis Evaluation Method","C92000","The process of analyzing the software code without running it. For example, formal verification, which is proving or disproving the correctness of intended algorithms underlying a system with respect to a certain formal specification or property using formal methods of mathematics e.g. model checking, theorem proving, symbolic verification).","Device Static Analysis Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984728","Device Software Validation Evaluation Method","C91995","Validating that a system or component during or at the end of the development process satisfies specified requirements (the process may include algorithm evaluation).","Device Software Validation Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984709","Device Power Source Testing Evaluation Method","C91976","Testing the power sources in a device e.g., battery, internal power supply to detect any malfunction.","Device Power Source Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984738","Device Stress Testing Evaluation Method","C92005","Testing the device for failures caused by applying force per unit area. This test includes durability testing.","Device Stress Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984750","Device to Human Interaction Testing Evaluation Method","C92017","Tests conducted to assess the interaction between a device and the user","Device to Human Interaction Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984729","Device Software Verification Evaluation Method","C91996","Means of assessing a computer program's authenticity, accuracy and uniformity to ensure that it meets its intended specifications.","Device Software Verification Evaluation Method | software verification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984717","Device Reactivity Testing Evaluation Method","C91984","Testing the device for problems related to how the materials react to other factors (e.g. over-react or under-react).","Device Reactivity Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984707","Device Platelet Activation Testing Evaluation Method","C91974","Testing the device for characteristics that lead to the activation of platelets which are essential to stop bleeding and repair the tissue. Platelets also play a key role in the development of acute coronary syndromes and contribute to cerebrovascular events.","Device Platelet Activation Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984735","Device Sterilization Process Review Evaluation Method","C92002","Performing a review of the records and processes used to render a product free from viable microorganisms.","Device Sterilization Process Review Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984747","Device Thrombotic Testing Evaluation Method","C92014","Testing the device for characteristics related to forming blood clots along the walls of blood vessels which can cause blockages and affect blood flow through vessels.","Device Thrombotic Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984710","Device Pressure Testing Evaluation Method","C91977","Testing the device's characteristics when subjected to high or low pressure conditions.","Device Pressure Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984713","Device Radiated Emissions Testing Evaluation Method","C91980","Testing the ability of a device's radiated emissions to cause another device to fail (i.e. electromagnetic disturbance for which the energy is transferred through space in the form of electromagnetic waves).","Device Radiated Emissions Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984701","Device Optical Microscopy Evaluation Method","C91968","Inspection of objects or surfaces requiring magnification using an optical microscope.","Device Optical Microscopy Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984748","Device Tissue Engineering Evaluation Method","C92015","Evaluating a device's characteristics that may affect tissues (e.g. bone, cartilage, blood vessels, bladder).","Device Tissue Engineering Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640979","Analysis of Data Log","C102867","A record of data captured about device logging functions, error logs, keystroke logs and device alarm history.","Analysis of Data Log | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706385","Device Evaluation Method","C54028","No Value Exists","Device Evaluation Method | EVALUATION METHOD | Method of Device Evaluation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984751","Device Ultrasonic Sound Testing Evaluation Method","C92018","Testing the devices response to variations in air pressure for detecting sound with frequencies greater than upper limit of human hearing (> 20 kHz).","Device Ultrasonic Sound Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984749","Device to Device Interaction Testing Evaluation Method","C92016","Tests conducted to assess the mechanical, electrical, or electronic compatibility of two or more devices.","Device to Device Interaction Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984734","Device Sterility Method Verification Evaluation Method","C92001","Verifying that the methods used to free a medical device from viable microorganisms such as fungi, bacteria, and viruses were followed.","Device Sterility Method Verification Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984730","Device Source Code Review Evaluation Method","C91997","A systematic review of source code intended to find and fix mistakes possibly overlooked in the initial development phase.","Device Source Code Review Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984742","Device System Testing Evaluation Method","C92009","Tests conducted on a complete, integrated system to evaluate the system's compliance with its specified requirements.","Device System Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984725","Device Simulated Use Testing Evaluation Method","C91992","Testing the devices in situations that mimic real life settings but do not involve patients.","Device Simulated Use Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984758","Device Wear Testing Evaluation Method","C92025","Examining a device for signs of unexpected erosion on its surface or other components or parts.","Device Wear Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984722","Device Scaffold Evaluation Method","C91989","Evaluating a device's characteristics for its affects on the reproduction of tissues.","Device Scaffold Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984741","Device Surge Response Testing Evaluation Method","C92008","Testing for a response to a transient electrical current or voltage.","Device Surge Response Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984716","Device Radiologic Evaluation Method","C91983","Evaluating the safety provisions in a device used for medical imaging, i.e., if the device can cause injury to individuals during imaging process (visualizing the structure and function of the body).","Device Radiologic Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984737","Device Strength Testing Evaluation Method","C92004","Testing the device's ability to resist forces that attempt to break or deform the device. This evaluation includes testing tension such as pull testing.","Device Strength Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984718","Device Reproductive Toxicity Evaluation Method","C91985","Evaluating a device for chemicals or other agents that may have caused problems with the reproductive system. This includes evaluating a device for chemicals or agents that may have caused or contributed to birth defects or malformations (teratogenic evaluation).","Device Reproductive Toxicity Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984721","Device Radiofrequency Induced Heat Testing Evaluation Method","C91988","Testing the static magnetic field gradients on medical imaging devices for their ability to induce heat in objects.","Device Radiofrequency Induced Heat Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984755","Device Vibration Testing Evaluation Method","C92022","Evaluating a device for problems resulting from periodic or random mechanical oscillations which could induce damage.","Device Vibration Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984711","Analysis of Production Records","C91978","The investigation involved the analysis of relevant production records in view of supporting the identification of possible causes for the adverse event.","Analysis of Production Records | Device Process Evaluation Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984712","Device Quality Control Review Evaluation Method","C91979","Performing a review of the processes used in developing systems to ensure that products are designed and produced and services are developed to meet or exceed device specifications and customer expectations.","Device Quality Control Review Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984704","Device Pathological Examination Evaluation Method","C91971","Examining material that may have contributed to the disease or damage. Often performed using a microscope by measuring structural changes that occur along with the disease or damage.","Device Pathological Examination Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984746","Device Thermal Energy Evaluation Method","C92013","Testing the device for conditions related to extremes of temperature.","Device Thermal Energy Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984708","Device Power Frequency Magnetic Field Testing Evaluation Method","C91975","Tests performed to verify a device's level of protection (immunity) against magnetic disturbances while operating.","Device Power Frequency Magnetic Field Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984702","Device Overcurrent Protection Testing Evaluation Method","C91969","Testing the device's over-current protection circuitry for its response to situations of overload, short circuit, or ground fault.","Device Overcurrent Protection Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984757","Device Voltage Fluctuation Testing Evaluation Method","C92024","Testing the device for its immunity when subjected to positive and negative low amplitude voltage fluctuations.","Device Voltage Fluctuation Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984706","Device Physical Structure Testing Evaluation Method","C91973","Testing the device for problems related to the incorrect or inadequate arrangement of the parts, components, elements, or materials.","Device Physical Structure Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984731","Device Source Code Validation Evaluation Method","C91998","Ensuring that common error patterns and violations of best practices in coding have been followed.","Device Source Code Validation Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984736","Device Storage and Shipment Review Evaluation Method","C92003","Performing a review of the storage and shipping processes and requirements.","Device Storage and Shipment Review Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984732","Device Spectroscopy Evaluation Method","C91999","Testing the device using a spectrometer or spectrograph for the dispersion of visible light (includes electromagnetic, electron, and acoustic spectroscopy).","Device Spectroscopy Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984740","Device Surge Protection Testing Evaluation Method","C92007","Testing the device's ability to protect itself of other devices against sudden bursts of current or voltage.","Device Surge Protection Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984723","Device Scanning Probe Microscopy Evaluation Method","C91990","Inspection of objects or surfaces requiring magnification using a scanning probe microscope.","Device Scanning Probe Microscopy Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984724","Device Shock Testing Evaluation Method","C91991","Examining a device for problems resulting from transient physical insults such as dropping or shaking the device.","Device Shock Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984754","Device User Survey Evaluation Method","C92021","Questioning a pre-defined group of users about their practices.","Device User Survey Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984752","Device Unit Testing Evaluation Method","C92019","Testing a device or its components.","Device Unit Testing | Device Unit Testing Evaluation Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984703","Device Packaging Verification Evaluation Method","C91970","Verifying that the device packaging met proper sterilization conditions and that the effectiveness of the packaging kept the device free viable microorganisms.","Device Packaging Verification Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984727","Device Software Stress Testing Evaluation Method","C91994","Tests conducted to evaluate a software application at or beyond the limits of its specified requirements.","Device Software Stress Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984753","Device Use Testing Evaluation Method","C92020","Any testing performed that simulates real use situations experienced by users.","Device Use Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984739","Device Structure Testing Evaluation Method","C92006","Testing devices for problems related to the presence of an inappropriate molecular geometry somewhere in the device (i.e., the spatial arrangement of atoms in a molecule and the chemical bonds that hold the atoms together).","Device Structure Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984743","Device Temperature Testing Evaluation Method","C92010","Testing the device's characteristics when subjected to temperature change (cycling), and high or low temperatures.","Device Temperature Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984714","Device Radiofrequency Interference Testing Evaluation Method","C91981","Testing the device to detect device malfunctions caused by a disturbance affecting an electrical circuit due to electromagnetic radiation emitted from an external source. This includes susceptibility to interference via cables or air.","Device Radiofrequency Interference Testing Evaluation Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984778","Electrical Problem Identified","C92045","Events associated with an electrically powered device where an electrical malfunction results in a device problem (e.g. electrical circuitry, contact or component failed) even if the problem is intermittent.","Electrical Problem Identified | Device Electrical Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984763","Biological Problem Identified","C92030","Problems relating to, caused by or affecting biological processes or living organisms.","Biological Problem Identified | Device Biological Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984844","Software Problem Identified","C92113","Problems related to the device software.","Software Problem Identified | Device Software Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984821","Optical Problem Identified","C92089","Problems related to the optical properties of a device.","Optical Problem Identified | Device Optical Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984781","End of Life Problem Identified","C92048","Problems traced to the device reaching the end of its useful life.","End of Life Problem Identified | Device End of Life Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984807","Maintenance Problem Identified","C92075","A device malfunction or problem that occurs after production because the device was not properly maintained according to the instructions (e.g. maintenance may be performed by user facility, distributor, or service provider).","Maintenance Problem Identified | Device Maintenance Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984776","Dust or Dirt Problem Identified","C92043","A device that experienced problems due to ingress, or coating, of dust or dirt.","Dust or Dirt Problem Identified | Device Dust or Dirt Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984800","Insulation Problem Identified","C92068","Problems due to inadequate or incorrect electrical insulation material.","Insulation Problem Identified | Device Insulation Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984769","Device Migration Problem Identified","C92036","A device that has moved from its original location due to external forces (e.g. stent or lead movement).","Device Migration Problem Identified | Device Component Migration Evaluation Result | Device Migration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984790","Gradient Induced Field Problem","C92058","Problems that result from the gradient-induced fields generated during radiologic procedures e.g. magnetic resonance imaging.","Gradient Induced Field Problem | Device Gradient Induced Field Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984808","Manufacturing Process Problem Identified","C92076","Problems with a device that can be traced to a problem in the manufacturing and/or production process.","Manufacturing Process Problem Identified | Device Manufacturing Process Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984759","Device Agglutination Problem","C92026","The device affects the ability of the blood to clot which may be induced by chemical, mechanical, or thermal properties of the device.","Device Agglutination Problem | Agglutination Problem | Device Agglutination Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984791","Hardware Timing Problem Identified","C92059","Problems that results from improper sequential activation of components.","Hardware Timing Problem Identified | Device Hardware Timing Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984817","Non-Functional Defect","C92085","The device software contained software errors that did not impact its operation.","Non-Functional Defect | Device Non-Functional Defect Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984792","Device Hematologic Problem Identified","C92060","The device affects or impacts the blood or its components. (See ISO 10993 all parts)","Device Hematologic Problem Identified | Device Hematologic Problem Evaluation Result | Hematological Problem Identified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984765","Device Chemical Agent Damage Evaluation Result","C92032","A device that experienced damage as the result of a chemical agent used during the sterilization process e.g. excessive residual chemical or an incompatible sterilant.","Device Chemical Agent Damage Evaluation Result | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984809","Material or Material Leachate Pyrogenic Problem","C92077","The undesirable presence of pyrogens or fever-producing organisms caused by materials that permeate through the device.","Material or Material Leachate Pyrogenic Problem | Device Material or Material Leachate Pyrogenic Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984816","No Findings Available","C92084","Use when no investigation can be performed and therefore no results will be obtained.","No Findings Available | Device No Results Available Since No Evaluation Performed Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984789","Device Genotoxicity Problem Identified","C92057","The device's ability to cause damage to genetic material (e.g. leading to malignant tumors).","Device Genotoxicity Problem Identified | Device Genotoxic Problem Evaluation Result | Genotoxicity Problem Identified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984766","Device Cleaning Disinfecting Sterilization Problem Evaluation Result","C92033","A device problem that occurred during or as the result of the cleaning, disinfecting, or sterilizing process.","Device Cleaning Disinfecting Sterilization Problem Evaluation Result | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984786","Biological Contamination","C92054","The undesirable presence of living organisms such as bacteria, fungi, or viruses or their products (enzymes or toxins).","Biological Contamination | Device Foreign Material Contamination Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984798","Incompatible Component/Accessory","C92066","A device that malfunctions due to a component(s)/accessory that does not operate correctly and according to the device's specifications.","Incompatible Component/Accessory | Device Incompatible Component Evaluation Result | Incompatible Component/ Accessory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984774","Degradation Problem Identified","C92041","Problems that occur when the device becomes worn, weakened, corroded, or broken down due to processes such as aging, permeation, and corrosion.","Degradation Problem Identified | Device Degradation Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984810","Material and/or Chemistry Problem Identified","C92078","Problems with the device materials or how its materials react to other elements either within the device or within the environment.","Material and/or Chemistry Problem Identified | Device Materials and Chemistry Problem Evaluation Result | Material and/or Chemical Problem Identified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3154900","Device Failure to Calibrate Evaluation Result","C92052","A device that cannot calibrate (establish the relationship between a measuring device and the units of measure) or is used out of calibration to ensure accurate readings.","Failure to Calibrate or Used Out of Calibration | Device Failure to Calibrate Evaluation Result | Failure to Calibrate | Failure to Calibrate Identified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984811","Mechanical Problem Identified","C92079","Problems that result from internal or external forces including fluids, other objects, or environmental or physiologic influences.","Mechanical Problem Identified | Device Mechanical Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984818","Device Non-Terminating Software Code Evaluation Result","C92086","The device software failed to provide a safe exit from a repeating code segment.","Device Non-Terminating Software Code Evaluation Result | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984814","Mutagenic Problem","C92082","The device's ability to change genetic information (usually DNA) of an organism and thus increasing the frequency of mutations.","Mutagenic Problem | Device Mutagenic Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984787","Fracture Problem","C92055","Problems caused by the separation of a component, object, or material into two or more pieces including shear.","Device Fracture Problem | Device Fracture Problem Evaluation Result | Fracture Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984780","Electrostatic Discharge","C92047","Problems due to sudden and momentary bursts of electrical current flowing between two objects at different electrical potentials.","Electrostatic Discharge Problem | Device Electrostatic Discharge Evaluation Result | Electrostatic Discharge",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984762","Biocompatibility Problem Identified","C92029","The device causes cellular or tissue responses that elicit an undesirable local or systemic effect in the recipient or beneficiary of that therapy. (See ISO 10993)","Biocompatibility Problem Identified | Device Biocompatibility Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984812","Mechanical Shock Problem","C92080","Problems caused by the sudden violent blow or collision to the whole device (e.g. by dropping).","Mechanical Shock Problem | Device Mechanical Shock Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984768","Complement Activation Problem","C92035","The device affects the body's ability to activate the complement system of the immune system, thereby interfering with the ability to clear pathogens. This may be caused by an interaction of the device with chemicals or materials.","Complement Activation Problem | Device Complement Activation Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984805","Lubrication Problem Identified","C92073","Problems that occurred because of the presence of either too much or too little lubricant where required (e.g. connectors, leading to failure mechanisms such as corrosion).","Lubrication Problem Identified | Device Lubrication Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984804","Device Loss of Power Evaluation Result","C92072","A device that experienced problems due to a loss in the power supply.","Loss of Power Identified | Device Loss of Power Evaluation Result | Loss of Power",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984767","Communications Problem Identified","C92034","Devices that do not send or receive adequate signals (this speaks to the interoperability between devices).","Communications Problem Identified | Device Communications Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984801","Interface Design Error","C92069","The device software was found to contain errors in the user interface (including usability problems) or the interfaces with other systems.","Interface Design Error | Device Interface Design Error Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984788","Device Friction Problem Identified","C92056","Problems caused by its surface coming in contact with another surface or fluid.","Device Friction Problem Identified | Device Friction Problem Evaluation Result | Friction Problem Identified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984784","Environment Problem Identified","C92051","Problems that occurred due to factors within the environment e.g. dust, dirt, humidity, temperature.","Environment Problem Identified | Device Environment Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984797","Inappropriate Device Material","C92065","Problems that occur due to the presence of a material that should not be present or part of the device.","Inappropriate Device Material | Device Improper Material Problem Evaluation Result | Inappropriate Material",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984770","Conducted Interference","C92037","Problems related to electromagnetic interference (EMI) by physical contact with conductors (e.g. wires, resistors, terminals) as opposed to radiated EMI which is caused by induction (without physical contact of the conductors).","Conducted Interference | Device Conducted Interference Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984760","Device Arithmetic Error Evaluation Result","C92027","The device software performed an incorrect arithmetic operation.","Device Arithmetic Error Evaluation Result | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984782","Endotoxin Contamination","C92049","The undesirable presence of toxins associated with certain bacteria (e.g. gram negative bacteria).","Endotoxin Contamination | Device Endotoxin Contamination Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984764","Carcinogenic Problem","C92031","The device's ability to trigger development of cancer.","Device Carcinogenic Problem | Carcinogenic Problem | Device Carcinogenic Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984796","Device Improper Composition/Concentration","C92064","Problems associated with the improper combination of materials or elements present in the device (e.g. improper composition of the materials of a capacitor).","Device Improper Composition/Concentration | Device Improper Composition Evaluation Result | Improper Composition/ Concentration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984761","Assembly Problem Identified","C92028","Problems that occurred because the device was assembled incorrectly.","Assembly Problem Identified | Device Assembly Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984783","Energy Storage System Problem","C92050","Problems related to the energy storage system (e.g. the rechargeable battery, charging system, or capacitor) and includes problems such as premature power source depletion and battery explosions.","Energy Storage System Problem | Device Energy Storage System Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984771","Configuration Issue","C92038","Problems due to change control or incorrect version, including regional requirements.","Configuration Issue | Device Configuration Issue Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984803","Labeling and Instructions for Use/Maintenance","C92071","Insufficient, inadequate, or incorrect information provided on a device's label or documentation regarding e.g. its intended use, directions for use, and characteristics of the device, including its maintenance.","Labeling and Instructions for Use/Maintenance | Device Labeling Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984779","Electromagnetic Compatibility Problem Identified","C92046","Device-to-device or device-environment problem resulting from electromagnetic disturbances.","Electromagnetic Compatibility Problem Identified | Device Electromagnetic Compatibility Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984794","Image Artifact","C92062","The unacceptable distortion of an image due to signal loss that may occur during a radiologic procedure such as magnetic resonance imaging.","Image Artifact | Device Image Artifact Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984773","Deformation Problem","C92040","Problems caused by changes in the shape or size of the device due to an applied force. This can be a result of tensile forces, compressive forces, shear, bending, tensile (pulling), or torsion.","Deformation Problem | Device Deformation Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984793","Environmental Humidity Problem Identified","C92061","Device performance was affected by the humidity, or changes in humidity, of the environment in which it was used.","Environmental Humidity Problem Identified | Device Humidity Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984785","Fatigue Problem","C92053","Problems due to the weakening or breakdown of its material when subjected to stress or a series of repeated stresses.","Device Fatigue Problem | Device Fatigue Problem Evaluation Result | Fatigue Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984795","Impedance Problem Identified","C92063","Problems due to insufficient or excessive resistance to current flow either by the device or circuit.","Impedance Problem Identified | Device Impedance Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984772","Data Compression Error","C92039","Data was lost or corrupted during the operation of reducing storage space or communication bandwidth.","Data Compression Error | Device Data Compression Error Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984806","Magnetically Induced","C92074","Problems due to unintended or excessive movement created by the application of magnetic fields.","Magnetically Induced | Device Magnetically Induced Torque Problem Evaluation Result | Magnetically-Induced Movement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984815","No Device Problem Found","C92083","The device either functioned as intended or a problem was not found.","No Device Problem Found | Device No Failure Detected Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984799","Installation Problem Identified","C92067","A device that malfunctions because it was incorrectly installed, set-up, or configured (e.g. misconfiguration of an 'automatic' defibrillator to 'semi-automatic', thereby leading to failure).","Installation Problem Identified | Device Installation Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984777","Current Leakage Problem","C92044","Problems related to leakage currents which may cause electric shock. These currents usually flow through the protective ground conductor. In its absence, these currents could flow from the device to the ground via the human body.","Current Leakage Problem | Device Electrical Current Leakage Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984802","Interoperability Problem Identified","C92070","Problems with the mechanical, electrical, or communication interface between two or more separate devices.","Interoperability Problem Identified | Device Interoperability Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984813","Microbial Contamination","C92081","The undesirable presence of microorganisms or microbes such as bacteria and fungi (yeasts and molds).","Microbial Contamination | Device Microbial Contamination Evaluation Result | Microbiological",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984861","Wear Problem","C92130","Problems due to the premature or expected erosion of its material by use, deterioration, or change.","Wear Problem | Device Wear Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984856","Device Type Mismatch Evaluation Result","C92125","The device software assigned one type of value into a variable of another type.","Device Type Mismatch Evaluation Result | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984851","Stress Problem Identified","C92120","Problems caused by either excessive or inadequate physical force exerted on it by another object resulting in problems e.g. wear, bending, deformation, fracture, fatigue.","Stress Problem Identified | Device Stress Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984863","Wireless Communication Problem","C92132","Communications problems between devices within a wireless system.","Wireless Communication Problem Identified | Device Wireless Communication Problem Evaluation Result | Wireless Communication Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984859","Device Unused Device Returned in Sterile Packaging Evaluation Result","C92128","An unused device that has been returned in packaging that remains intact.","Device Unused Device Returned in Sterile Packaging Evaluation Result | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984852","Molecular Structure Problem","C92121","Problems related to the presence of an inappropriate molecular geometry somewhere in the device (i.e. the spatial arrangement of atoms in a molecule and the chemical bonds that hold the atoms together).","Molecular Structure Problem | Device Structure Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984862","Wired Communication Problem","C92131","Communications problems between devices within a wired system.","Wired Communication Problem | Device Wired Communication Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984824","Device Package Insert Problem Evaluation Result","C92092","Device packaging that is missing the insert or that contains an incorrect or inadequate insert (e.g. an insert with either the incorrect information or insufficient information).","Device Package Insert Problem Evaluation Result | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984848","Software Timing Problem","C92117","Problems that results from the incorrect sequencing or activation of software modules.","Software Timing Problem | Device Software Timing Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984835","Reactivity Problem Identified","C92103","Problems that occur due to the reactivity of materials (e.g. over-react or under-react).","Reactivity Problem Identified | Device Reactivity Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984842","Software Installation Problem Identified","C92111","The device software was not installed as per the specifications or failed to properly install.","Software Installation Problem Identified | Device Software Installation Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984840","Signal Loss","C92109","Problems due to the loss or weakening of an electrical signal or signals.","Signal Loss | Device Signal Loss Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984837","Device Runtime Memory Access Error Evaluation Result","C92105","The device software attempted to access an illegal or corrupted memory location.","Device Runtime Memory Access Error Evaluation Result | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984834","Clinical Imaging Problem Identified","C92102","Problems that occur with devices used for radiographic or imaging procedures e.g. CT scanners, magnetic resonance imaging.","Clinical Imaging Problem Identified | Device Radiographic Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984839","Short Circuit","C92108","Problems due to an unintentionally low-resistance connection between two points in an electric circuit, resulting in either excessive current flow that often causes damage or in a new shorter circuit that draws current away from the original pathways and components.","Short Circuit | Device Short Circuit Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984829","Power Source Problem Identified","C92097","Problems related to the source that provides electrical power to the device.","Power Source Problem Identified | Device Power Source Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984823","Device Out of Bounds Error Evaluation Result","C92091","The device software attempted to write data outside the allowed memory location.","Device Out of Bounds Error Evaluation Result | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984853","Thermal Problem","C92122","Problems related to the temperature of the device.","Thermal Problem | Device Thermal Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984822","Optical Transmission Problem Identified","C92090","Problems with the device's ability to pass light energy.","Optical Transmission Problem Identified | Device Optical Transmission Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984831","Quality Control Deficiency","C92099","Problems traced to the failure to maintain or establish techniques for controlling and verifying the product specifications identified by the manufacturer. Includes inadequacy of components or raw materials supplied to the manufacturer.","Quality Control Deficiency | Device Quality Control Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984854","Problem due to Thrombosis Activation","C92123","The device causes the formation of blood clots in or along blood vessels resulting in disturbed or disrupted blood flow.","Problem due to Thrombosis Activation | Device Thrombosis Activation Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984828","Power Fluctuation","C92096","The device failed due to fluctuations within the power supply (e.g. transient power, power spike, power dip, or power sequencing).","Power Fluctuation | Device Power Fluctuation Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984858","Device Unreachable Code Evaluation Result","C92127","The device software contained code that could never be executed under any circumstance.","Device Unreachable Code Evaluation Result | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984850","Storage Problem Identified","C92119","Problems that result from storing the device in an uncontrolled or improper environment (e.g. moisture sensitive devices stored in a humid environment).","Storage Problem Identified | Device Storage Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984819","Open Circuit","C92087","Problem due to an electrical circuit that does not conduct current because a switch is open, a wire is broken, etc.","Open Circuit | Device Open Circuit Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984849","Stiffness Problem Identified","C92118","Problems that occurred when its material is either too flexible/pliable or inflexible/rigid when in contact by an applied force.","Stiffness Problem Identified | Device Stiffness Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984820","Operational Problem Identified","C92088","Problems that occur during the performance, use, or functioning of the device.","Operational Problem Identified | Device Operational Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984857","Device Unhandled Interrupt or Exception Evaluation Result","C92126","The device software did not correctly address abnormal execution of the code.","Device Unhandled Interrupt or Exception Evaluation Result | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984836","Reproductive Toxicity Problem Identified","C92104","The device affects reproductive function, embryo development (teratogenicity), and prenatal and early postnatal development. (ISO 10993 part 3)","Reproductive Toxicity Problem Identified | Device Reproductive Toxicity Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984845","Software Requirement Error","C92114","The software requirements for the device are either incomplete, inadequate, or in conflict.","Software Requirement Error | Device Software Requirement Error Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984860","Vibration Problem","C92129","Problems that result from a combination of specification variances of the components.","Vibration Problem | Device Vibration Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984841","Device Software Deadlock Evaluation Result","C92110","The device software locked up because two or more processes were waiting for each other to finish.","Device Software Deadlock Evaluation Result | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984832","Radiofrequency Induced Overheating","C92100","Problems due to unintended radiofrequency-induced temperature increase that can occur in the vicinity of the device.","Radiofrequency Induced Overheating | Device Radiofrequency Induced Overheating Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984838","Transport Problem Identified","C92107","Problems traced to how the device was transported e.g. temperature of shipping compartment or method of transportation.","Transport Problem Identified | Device Shipping Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984833","Device Radiofrequency Interference Evaluation Result","C92101","Problems due to radiofrequency interference. RFI is a disturbance that affects an electrical circuit due to either electromagnetic conduction or electromagnetic radiation emitted from an external source.","Radiofrequency Interference Identified | Device Radiofrequency Interference Evaluation Result | Radiofrequency Interference (RFI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984847","Software Security Vulnerability","C92116","The device software failed to provide adequate authorization, access control, protection and accountability features.","Software Security Vulnerability | Device Software Security Vulnerability Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984830","Protective System Problem Identified","C92098","Problems related to the system(s) designed to prevent or warn about unsafe operation of the device.","Protective System Problem Identified | Device Protective System Failure Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3154899","Shelf Life/Expiration Date Exceeded","C92106","A device that has exceeded the period of time/date recommended by the manufacturer for storing the device without a degradation in quality.","Shelf Life/Expiration Date Exceeded | Device Shelf Life Exceeded Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984846","Software Runtime Error","C92115","The device software failed during operation as a result of a coding error.","Software Runtime Error | Device Software Runtime Error Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984825","Packaging Compromised","C92093","Problems that occurred because of a compromised packaging of the device (e.g. broken or incomplete seal).","Packaging Compromised | Device Packaging Compromised Evaluation Result Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984827","Platelet Activation Problem","C92095","The device affects the body's ability to activate platelet formation.","Platelet Activation Problem | Device Platelet Activation Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984826","Packaging Problem Identified","C92094","Problems that occurred because of the device packaging.","Packaging Problem Identified | Device Packaging Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984855","Tolerance Stack-Up","C92124","Problems that result from a combination of specification variances of the components.","Tolerance Stack-Up | Device Tolerance Stack-Up Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984872","Incorrect Data Definition","C92141","The device software was found to contain errors in specifying or manipulating data items.","Incorrect Data Definition | Incorrect Device Data Definition Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984873","Incorrect Algorithm","C92142","The device software was found to implement an incorrect sequence of steps for a specific computation.","Incorrect Algorithm | Incorrect Device Software Algorithm Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984864","Improper Physical Structure","C92133","Problems related to the incorrect or inadequate arrangement of the parts, components, elements, or materials.","Improper Physical Structure | Improper Device Physical Structure Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984865","Environmental Temperature Problem Identified","C92134","Device performance was affected by the temperature, or changes in temperature, of the environment in which it was used.","Environmental Temperature Problem Identified | Improper Device Temperature Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984869","Inappropriate or Insufficient Device Sterilization Evaluation Result","C92138","Inadequate sterilization of a device possibly resulting in the presence of microorganisms or other contaminants on the device.","Inappropriate or Insufficient Device Sterilization Evaluation Result | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984867","Incorrect Labeling and/or Instructions for Use","C92136","Missing, incorrect, or inappropriate information on the labels e.g. mislabeled contents or device labeling characteristics or package contents","Incorrect Labeling and/or Instructions for Use | Inadequate Device Labeling Content Problem Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984870","Incompatible Material","C92139","Problems that occur due to the incompatibility of materials that co-exist simultaneously as part of the device.","Incompatible Material | Incompatible Device Material Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984871","Incomplete Device Returned Evaluation Result","C92140","The device that was returned was not complete and/or is missing parts or components.","Incomplete Device Returned Evaluation Result | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984868","Inadequate Labeling and/or Instructions for Use","C92137","Inadequate information on the labels or in the instructions for use e.g. steps that are difficult to follow or that are missing.","Inadequate Labeling and/or Instructions for Use | Inadequate Instructions for Device Use Evaluation Result | Inadequate Labelling and/or Instructions for Use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984874","Results Pending Completion of Investigation","C92143","Investigation is ongoing and results are not yet available. Do not use this code if the investigation is complete.","Results Pending Completion of Investigation | Results Pending Completion of Device Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984875","Reused Device not Cleaned Evaluation Result","C92144","A device that has been used more than once without being cleaned according to the device's cleaning instructions.","Reused Device not Cleaned Evaluation Result | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707704","Device Evaluation Result","C54029","No Value Exists","Device Evaluation Result | EVALUATION RESULT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899000","HBV Genotype Assay","C117108","An assay used to determine which hepatitis B virus genome(s) is present in an infection. Seven genotypes of HBV (designated A through G) have been identified. Different genotypes are prevalent in different geographical areas and each carries a different risk of development of hepatocellular carcinoma.","HBV Genotype Assay | HBV Genotype | HBV Genotype Measurement | HBV Genotyping | Hepatitis B Virus Genotype Assay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1533728","HCV Genotype Assay","C117109","An assay for determining the genotype(s) of hepatitis C virus (HCV) in plasma or serum from HCV-infected individuals. Six major genotypes are recognized and they vary in their response to treatment.","HCV Genotype Assay | HCV Genotype | HCV Genotype Measurement | HCV Genotyping | Hepatitis C Virus Genotype Assay",,,,,,,,,,,,,,,"4262164","Hepatitis C virus genotype determination",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1420212","SLC6A2 Gene","C117242","This gene plays a role in neurotransmitter recycling.","SLC6A2 Gene | Member 2 Gene | SLC6A2 | Solute Carrier Family 6 (Neurotransmitter Transporter) | Solute Carrier Family 6 (Neurotransmitter Transporter), Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0314840","Alcaligenes faecalis","C86140","A species of obligately aerobic, Gram negative, rod shaped bacteria assigned to the phylum Proteobacteria. This bacteria is motile, oxidase positive, catalase positive, does not reduce nitrates and degrades urea. A. faecalis is found in soil, water, and fecal matter and is an opportunistic pathogen in humans.","Alcaligenes faecalis | ALCALIGENES FAECALIS | Alcaligenes odorans | Bacillus faecalis",,,,,,,,,,,,,,,"4098060","Alcaligenes faecalis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001705","Aeromonas","C86124","A genus of Gram negative, rod shaped bacterium assigned to the phylum Proteobacteria and the family Aeromonadaceae.","Aeromonas | AEROMONAS",,,,,,,,,,,,,,,"4229267","Aeromonas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085491","Aeromonas hydrophila","C86125","A species of aerobic or anaerobic, Gram negative, rod shaped bacteria assigned to the phylum Proteobacteria. This bacteria is motile by polar flagella, oxidase positive, produces Aerolysin Cytotoxic Enterotoxin, hydrolyzes esculin and is beta hemolytic. A. hydrophila is found in freshwater and marine environments and is pathogenic to fish, amphibians, and mammals.","Aeromonas hydrophila | AEROMONAS HYDROPHILA | Aeromonas group",,,,,,,,,,,,,,,"4312105","Aeromonas hydrophila",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1456432","Actinobacteria","C76195","A taxonomic phylum within kingdom Bacteria consisting of gram-positive soil bacteria with a high G+C ratio.","Actinobacteria | High G+C Gram-positive Bacteria",,,,,,,,,,,,,,,"4257650","Actinomycetota",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0392411","Acinetobacter lwoffii","C86095","A species of aerobic, Gram negative, rod and cocci shaped bacteria assigned to the phylum Proteobacteria. This bacteria is nonmotile, oxidase negative, catalase positive and does not produce acid from galactose, mannose, rhamnose or lactose. This bacteria is found in the normal flora of humans and can cause infections, such as meningitis, septicemia, and pneumonia.","Acinetobacter lwoffii | ACINETOBACTER LWOFFII | Acinetobacter calcoaceticus subsp. lwoffii",,,,,,,,,,,,,,,"4307075","Acinetobacter lwoffii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085467","Acinetobacter calcoaceticus","C86090","A species of aerobic, Gram negative, rod and cocci shaped bacteria assigned to the phylum Proteobacteria. This bacteria is nonmotile and oxidase negative. A. calcoaceticus is thought to be a commensal organism of the skin and throat but may become pathogenic in patients with underlying conditions, usually causing respiratory infection.","Acinetobacter calcoaceticus | ACINETOBACTER CALCOACETICUS",,,,,,,,,,,,,,,"4220355","Acinetobacter calcoaceticus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0314845","Achromobacter xylosoxidans","C86082","A species of aerobic, Gram negative bacteria assigned to the phylum Proteobacteria. This bacteria is motile by flagella, urease negative, oxidase and catalase positive, ferments glucose, and hydrolyzes esculin. A. xylosoxidans infection may occur in immunocompromised patients.","Achromobacter xylosoxidans | ACHROMOBACTER XYLOSOXIDANS | Alcaligenes xylosoxidans",,,,,,,,,,,,,,,"4189931","Achromobacter xylosoxidans",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001084","Achromobacter","C86079","A genus of aerobic, Gram negative bacterium assigned to the phylum Proteobacteria and the family Alcaligenaceae.","Achromobacter | ACHROMOBACTER",,,,,,,,,,,,,,,"4239076","Achromobacter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0314862","Arcanobacterium","C86147","A genus of facultatively anaerobic, Gram positive, rod shaped bacterium assigned to the phylum Actinobacteria and the family Actinomycetaceae.","Arcanobacterium | ARCANOBACTERIUM",,,,,,,,,,,,,,,"4197683","Arcanobacterium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0314863","Arcanobacterium haemolyticum","C86149","A species of facultatively anaerobic, Gram positive, rod shaped bacteria assigned to the phylum Actinobacteria. This bacteria is catalase negative, hemolytic on human blood agar plates and grows best in culture with added carbon dioxide and blood. A. haemolyticum is found on human skin and mucus membranes of the upper respiratory tract, and is associated with pharyngitis and skin and tissue infections.","Arcanobacterium haemolyticum | ARCANOBACTERIUM HAEMOLYTICUM | Corynebacterium haemolyticum | Corynebacterium haemolyticus",,,,,,,,,,,,,,,"4264344","Arcanobacterium haemolyticum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3274679","MLL/MLLT1 Fusion Gene","C99321","A fusion gene that results from a chromosomal translocation t(11;19)(q23;p13.3) which fuses the 5' half of the MLL gene to most of the MLLT1 gene. This rearrangement is associated with acute lymphocytic leukemia and other leukemia types.","MLL/MLLT1 Fusion Gene | KMT2A-MLLT1 Fusion Gene | KMT2A/MLLT1 Fusion Gene | KMT2A::MLLT1 Fusion Gene | MLL-ENL Fusion Gene | MLL-MLLT1 Fusion Gene | MLL/ENL Fusion Gene | MLL::MLLT1 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006013","Bordetella","C86202","A genus of aerobic, Gram-negative, coccobacilli-shaped bacterium assigned to the phylum Proteobacteria and the family Alcaligenaceae.","Bordetella | BORDETELLA",,,,,,,,,,,,,,,"4188054","Bordetella",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0314985","Bifidobacterium dentium","C86198","A species of anaerobic, Gram-positive, rod shaped bacteria assigned to the phylum Actinobacteria. This species nonmotile, non-spore forming, catalase and indole negative, does not reduce nitrate and ferments arabinose, xylose, ribose, gluconate, cellobiose, lactose, mannitol, melezitose, salicin, and starch. B. dentium is an opportunistic pathogen associated with tooth decay.","Bifidobacterium dentium | BIFIDOBACTERIUM DENTIUM | Bifidobacterium appendicitis",,,,,,,,,,,,,,,"4269144","Bifidobacterium dentium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004663","Bacteroides fragilis","C86172","A species of obligately anaerobic, Gram-negative, rod shaped bacteria assigned to the phylum Bacteroidetes. This species is nonmotile, non-spore forming, indole positive, produces hydrogen sulfide, does not reduce nitrate, hydrolyzes esculin and starch, does not ferment trehalose, melezitose or arabinose, and is penicillin resistant. B. fragilis is commensal and part of the normal human gastrointestinal tract flora, but may become pathogenic in other body regions.","Bacteroides fragilis | BACTEROIDES FRAGILIS",,,,,,,,,,,,,,,"4208525","Bacteroides fragilis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004590","Bacillus cereus","C86161","A species of aerobic or facultatively anaerobic, Gram-positive, rod shaped bacteria assigned to the phylum Firmicutes. This species is motile, spore forming, and catalase positive, hydrolyzes casein, starch, and gelatin, and produces the toxin cereulide. B. cereus is found in soil and associated with diarrheal and emetic forms of food-borne illness as well as opportunistic infections in both humans and domestic animals.","Bacillus cereus | BACILLUS CEREUS",,,,,,,,,,,,,,,"4309212","Bacillus cereus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1417705","NFIC Gene","C38403","This gene is involved in transcriptional regulation.","NFIC Gene | NFI | NFIC | Nuclear Factor I/C (CCAAT-Binding Transcription Factor) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006819","Campylobacter jejuni","C86235","A species of microaerophilic, Gram-negative, curved or spiral bacilli assigned to the phylum Proteobacteria. This species is motile with a flagellum at each pole, non-spore forming, oxidase positive, and hydrolyzes hippurate. C. jejuni is the most common pathogen in the United States causing bacterial diarrhea and gastroenteritis and is also linked to Guillain Barre syndrome.","Campylobacter jejuni | CAMPYLOBACTER JEJUNI",,,,,,,,,,,,,,,"4282778","Campylobacter jejuni",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0282676","Burkholderia","C86222","A genus of aerobic, Gram-negative, rod shaped bacteria assigned to the phylum Proteobacteria and the family Burkholderiaceae.","Burkholderia | BURKHOLDERIA",,,,,,,,,,,,,,,"4213231","Burkholderia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0315258","Hafnia","C86434","A genus of facultatively anaerobic, Gram negative, rod shaped bacterium assigned to the phylum Proteobacteria and the family Enterobacteriaceae.","Hafnia | HAFNIA",,,,,,,,,,,,,,,"4071894","Hafnia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0315259","Hafnia alvei","C86435","A species of facultatively anaerobic, Gram negative, rod shaped bacteria assigned to the phylum Proteobacteria. This species is oxidase negative, and ferments glucose, mannitol, and arabinose. H. alvei is found in water, soil and foods, is part of the gastrointestinal flora and is rarely pathogenic owing to the expression of few virulence factors.","Hafnia alvei | Enterobacter alvei | HAFNIA ALVEI",,,,,,,,,,,,,,,"4295899","Hafnia alvei",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0317570","Haemophilus parahaemolyticus","C86432","A species of facultatively anaerobic, Gram negative, coccobacilli shaped bacteria assigned to the phylum Proteobacteria. This species is oxidase and urease positive, catalase negative, porphyrin positive and can grow in culture with V factor alone. H. parahemolyticus is a commensal organism of the oropharyngeal and gastrointestinal tracts and rarely pathogenic in humans.","Haemophilus parahaemolyticus | HAEMOPHILUS PARAHAEMOLYTICUS",,,,,,,,,,,,,,,"4232469","Haemophilus parahaemolyticus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0317567","Haemophilus haemolyticus","C86430","A species of facultatively anaerobic, Gram negative, coccobacilli shaped bacteria assigned to the phylum Proteobacteria. This species is urease, catalase and oxidase positive, porphyrin negative and requires both X and V factors to grow in culture. H. haemolyticus is normally nonpathogenic but may cause disease in immunocompromised patients.","Haemophilus haemolyticus | HAEMOPHILUS HAEMOLYTICUS",,,,,,,,,,,,,,,"4204390","Haemophilus haemolyticus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0317576","Aggregatibacter aphrophilus","C86134","A species of facultatively anaerobic, Gram negative, rod shaped bacteria assigned to the phylum Proteobacteria. This bacteria is catalase and urease negative, oxidase variable, does not require X factor and acid is produced from glucose, fructose and mannose. A. aphrophilus is found in human oral flora, oropharyngeal flora and dental plaque, and is a cause of infectious endocarditis.","Aggregatibacter aphrophilus | AGGREGATIBACTER APHROPHILUS | Beta-Lactamase Negative Haemophilus paraphrophilus | CDC Group HB-2 | Haemophilus aphrophilus | Haemophilus paraphrophilus",,,,,,,,,,,,,,,"40484530","Aggregatibacter aphrophilus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0317563","Gemella","C86889","A genus of facultatively anaerobic, Gram positive, cocci shaped bacterium assigned to the phylum Firmicutes and the family Bacillales XI.","Gemella | GEMELLA",,,,,,,,,,,,,,,"4021869","Gemella",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0318152","Gemella morbillorum","C86892","A species of facultatively anaerobic, Gram positive, cocci shaped bacteria assigned to the phylum Firmicutes. This species does not form endospores, is oxidase and catalase negative, and non motile. G. morbillorum may be found in the mucous membranes of the oral cavity, upper respiratory tract and the intestines. It is an opportunistic pathogen and a causative agent of endocarditis.","Gemella morbillorum | GEMELLA MORBILLORUM | Streptococcus morbillorum",,,,,,,,,,,,,,,"4034522","Gemella morbillorum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0445938","Fusobacterium ulcerans","C86406","A species of anaerobic, Gram-negative, fusiform rod shaped bacteria in the phylum Fusobacteria. This species is non-spore forming, indole, catalase, urease, lipase, esculin and oxidase negative, does not produce hydrogen sulfide, but does reduce nitrate, produce large amounts of butyrate, and converts threonine to propionic acid. F. ulcerans causes ulcers in humans located in tropical nations however, this bacteria's natural habitat is unknown.","Fusobacterium ulcerans | FUSOBACTERIUM ULCERANS",,,,,,,,,,,,,,,"4034759","Fusobacterium ulcerans",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085479","Fusobacterium nucleatum","C86404","A species of anaerobic, Gram negative, fusiform rod shaped bacterium in the phylum Fusobacteria. This species is non-sporulating, ferments fructose and glutamate and produces butyric acid as a major metabolic by-product. F. nucleatum is ubiquitously found in the normal flora of the oral cavity but may be associated with periodontal disease as well as preterm births, where isolates have been found in amniotic fluid, placenta, and chorioamnionic membranes of women delivering prematurely.","Fusobacterium nucleatum | FUSOBACTERIUM NUCLEATUM",,,,,,,,,,,,,,,"4139265","Fusobacterium nucleatum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL414282","Fusobacterium necrophorum","C86401","A species of anaerobic, Gram-negative, rod shaped bacteria in the phylum Fusobacteria. This species is non-spore forming, does not hydrolyze dextran and is superoxide dismutase and lysine decarboxylase negative. F. necrophorum is found in the intestinal tract of humans and animals, but is more likely to be associated with infections in animals.","Fusobacterium necrophorum | FUSOBACTERIUM NECROPHORUM | Fusobacterium necrophorum Biovar B",,,,,,,,,,,,,,,"4099615","Fusobacterium necrophorum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0086300","Elizabethkingia meningoceptica","C86353","A species of obligately aerobic, Gram negative, rod shaped bacterium in the phylum Bacteroidetes. This species is catalase, oxidase and indole positive, does not reduce nitrate, urease negative and hydrolyzes esculin. E. meningoceptica is pathogenic, being the causative agent of meningitis in newborns.","Elizabethkingia meningoceptica | Chryseobacterium meningosepticum | ELIZABETHKINGIA MENINGOCEPTICA | Flavobacterium meningosepticum",,,,,,,,,,,,,,,"4138034","Elizabethkingia meningoseptica",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0315244","Escherichia hermannii","C86381","A species of facultatively anaerobic, Gram negative, rod shaped bacterium assigned to the phylum Proteobacteria. This species is motile, produces yellow pigment, ferments glucose, arabinose, mannitol, and rhamnose and is positive for ornithine decarboxylase and indole production. Negative reactions for lactose, melibiose, and sorbitol fermentation, arginine dihydrolase, H2S and urease production, lysine decarboxylase, and citrate. Most commonly isolated from environmental sources like drinking water distribution systems.","Escherichia hermannii | CDC Enteric Group 11 | ESCHERICHIA HERMANNII",,,,,,,,,,,,,,,"4312475","Escherichia hermannii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0317472","Enterococcus gallinarum","C86370","A species of facultatively anaerobic, Gram-positive, cocci shaped bacteria in the phylum Firmicutes. This species is nonmotile, non-spore forming, catalase negative, does not hydrolyze gelatin, does not produce hydrogen sulfide and is esculin and hippurate positive. E. gallinarum has been isolated from the gastrointestinal tract of domestic fowl and is pathogenic in humans with some resistance to vancomycin.","Enterococcus gallinarum | ENTEROCOCCUS GALLINARUM",,,,,,,,,,,,,,,"4180694","Enterococcus gallinarum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038404","Enterococcus faecalis","C86368","A species of facultatively anaerobic, Gram positive, cocci shaped bacteria in the phylum Firmicutes. This species is catalase positive, oxidase negative, ferments citrate, does not ferment arabinose or melibiose, reduces tetrazolium and is a lactic acid bacteria. E. faecalis is a leading agent of nosocomial infections in humans.","Enterococcus faecalis | ENTEROCOCCUS FAECALIS | Streptococcus faecalis",,,,,,,,,,,,,,,"4302157","Enterococcus faecalis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0317470","Enterococcus casseliflavus","C86365","A species of facultatively anaerobic, Gram-positive, cocci shaped bacteria in the phylum Firmicutes. This species is motile, non-spore forming, catalase negative, esculin positive, hippurate positive, does not produce hydrogen sulfide, does not reduce nitrate and does not hydrolyze casein, gelatin or urea. E. casseliflavus has been isolated from plants, silage, soil and is commensal in the human GI tract, but has been associated with various human infections and has low level vancomycin resistance.","Enterococcus casseliflavus | ENTEROCOCCUS CASSELIFLAVUS | Enterococcus flavescens",,,,,,,,,,,,,,,"4149104","Enterococcus casseliflavus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085484","Enterobacter cloacae","C86360","A species of facultatively anaerobic, Gram negative, rod shaped bacterium in the phylum Proteobacteria. This species is motile by peritrichous flagella, oxidase, urease and indole negative, catalase positive, reduces nitrate, does not degrade pectate and produces acid from sorbitol. E. cloacae is associated with hospital-acquired urinary and respiratory tract infections and is used in industry for explosives biodegradation.","Enterobacter cloacae | ENTEROBACTER CLOACAE | Enterobacter cloacae Strain 1",,,,,,,,,,,,,,,"4030716","Enterobacter cloacae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0315253","Enterobacter amnigenus","C86357","A species of facultatively anaerobic, Gram negative, rod shaped bacterium in the phylum Proteobacteria. This species is motile by peritrichous flagella, ferments lactose, indole negative, lysine decarboxylase negative and does not produce acid from sorbitol. E. amnigenus is an opportunistic pathogen in humans and can be found in water and soil.","Enterobacter amnigenus | ENTEROBACTER AMNIGENUS | Enterobacter amnigenus I | Lelliottia amnigena",,,,,,,,,,,,,,,"4223548","Lelliottia amnigena",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0315232","Pantoea agglomerans","C86632","A species of facultatively anaerobic, Gram-negative, rod shaped bacteria in the phylum Proteobacteria. This species is motile using peritrichous flagella, non-spore forming, indole and urease negative, noncapsulated, produces a yellow pigment, liquefies gelatin, reduces nitrate, hydrolyzes esculin, and is Voges-Proskauer reaction positive. P. agglomerans is found on plant surfaces, seeds, and water and is pathogenic in humans and some strains can be pathogenic to plants.","Pantoea agglomerans | Enterobacter agglomerans | PANTOEA AGGLOMERANS",,,,,,,,,,,,,,,"4018788","Pantoea agglomerans",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0728888","Enterobacter aerogenes",,,,,,,,,,,,,,,,,,"4267438","Klebsiella aerogenes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085482","Eikenella","C86350","A genus of facultatively anaerobic, Gram negative, rod shaped bacterium assigned to the phylum Proteobacteria and the family Neisseriaceae.","Eikenella | EIKENELLA",,,,,,,,,,,,,,,"4183325","Eikenella",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013738","Eikenella corrodens","C86351","A species of facultatively anaerobic, Gram negative, rod shaped bacterium assigned to the phylum Proteobacteria. This species is oxidase positive, catalase, urease and oxidase negative, indole negative and reduces nitrate. E. corrodens is generally classified as a commensal organism of the mouth and upper respiratory tract but may cause disease in patients with cancer.","Eikenella corrodens | CDC Group HB-1 | EIKENELLA CORRODENS",,,,,,,,,,,,,,,"4200857","Eikenella corrodens",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010416","Cryptococcus neoformans","C14195","A species of the fungus cryptococcus, the causative agent of cryptococcosis.","Cryptococcus neoformans | B. neoformans | Blastomyces neoformans | C. neoformans | CRYPTOCOCCUS NEOFORMANS | Crypto | D. neoformans | Debaryomyces neoformans | Filobasidiella neoformans | L. neoformans | Lipomyces neoformans | S. neoformans | Saccharomyces neoformans | T. neoformans | Torula neoformans | Torulopsis neoformans",,,,,,,,,,,,,,,"4284105","Cryptococcus neoformans",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010150","Corynebacterium diphtheriae","C86312","A species of aerobic or facultatively anaerobic, Gram-positive, coryneform, pleomorphic bacilli assigned to the phylum Actinobacteria. This species is nonmotile, non-spore forming, catalase positive, non-lipophilic, produces diphtheria toxin which inhibits elongation factor 2 (EF-2) thus preventing protein synthesis, forms polar granules, and is cultured in Loeffler's serum in a low iron environment or on tellurite agar. C diphtheriae is commensal in the skin and nasopharynx, but toxin producing strains are pathogenic to humans causing diphtheria; both an antitoxin and vaccine are available for disease prevention.","Corynebacterium diphtheriae | CORYNEBACTERIUM DIPHTHERIAE",,,,,,,,,,,,,,,"4241690","Corynebacterium diphtheriae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0315101","Clostridium tertium","C86297","A species of anaerobic, Gram positive, rod shaped bacteria assigned to the phylum Firmicutes. This species is aerotolerant, non-exotoxin producing, ferments glucose, lactose, maltose and sucrose, reduces nitrate and is nonproteolytic. C. tertium has traditionally been considered nonpathogenic but has since been designated an emerging pathogen in immunocompromised and wound patients, causing necrotizing fasciitis and gas gangrene.","Clostridium tertium | CLOSTRIDIUM TERTIUM",,,,,,,,,,,,,,,"4219232","Clostridium tertium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0315096","Clostridium septicum","C86292","A species of anaerobic, Gram positive, rod shaped bacteria assigned to the phylum Firmicutes. This species is sporeforming, hemolytic, produces exotoxins and is lecithinase, lipase, indole and urease negative. C. septicum is highly pathogenic; infection is most commonly associated with paraneoplastic syndrome and it is also a causative agent of gas gangrene.","Clostridium septicum | CLOSTRIDIUM SEPTICUM",,,,,,,,,,,,,,,"4141421","Clostridium septicum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0315111","Clostridium ramosum","C86290","A species of anaerobic, Gram positive, rod shaped bacteria assigned to the phylum Firmicutes. This species is nonsporulating, urease, catalase and indole negative, pyrrolidonyl negative, does not reduce nitrate, weakly ferments mannose and raffinose and may appear gram variable due to staining difficulty. C. ramosum is part of the RIC group of clostridium and is an opportunistic pathogen.","Clostridium ramosum | Actinomyces ramosus | Bacillus ramosus | CLOSTRIDIUM RAMOSUM | Erysipelatoclostridium ramosum | Nocardia ramosa | Ramibacterium ramosum",,,,,,,,,,,,,,,"4177528","Clostridium ramosum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009063","Clostridium perfringens","C86288","A species of anaerobic, Gram positive, rod shaped bacteria assigned to the phylum Proteobacteria. This species is motile, hydrolyzes gelatin, produces enterotoxin, is beta-hemolytic and catalase negative. C. perfringens is a food borne pathogen, being the causative agent of pig-bel syndrome and gas gangrene.","Clostridium perfringens | CLOSTRIDIUM PERFRINGENS | Clostridium welchii",,,,,,,,,,,,,,,"4307974","Clostridium perfringens",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0315093","Clostridium haemolyticum","C86281","A species of anaerobic, Gram positive, rod shaped bacteria assigned to the phylum Proteobacteria. This species is motile, produces the type G toxin and is hemolytic. C. haemolyticum is found in soil and water and is pathogenic, being the causative agent of Red Water disease in grazing animals.","Clostridium haemolyticum | CLOSTRIDIUM HAEMOLYTICUM",,,,,,,,,,,,,,,"4167019","Clostridium haemolyticum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085483","Citrobacter freundii","C86265","A species of facultatively anaerobic, gram negative, rod shaped bacteria assigned to the phylum Proteobacteria. This species is motile by peritrichous flagella, oxidase negative, catalase positive, grows in KCN medium, and successfully ferment sucrose, raffinose and melibiose. C. freundii is most commonly found in water, sewage, soil and food and is an opportunistic pathogen in neonates and immunocompromised patients.","Citrobacter freundii | CITROBACTER FREUNDII | Colobactrum freundii",,,,,,,,,,,,,,,"4269070","Citrobacter freundii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008150","Chlamydophila psittaci","C86255","A species of gram negative, obligately intracellular, spherical shaped bacteria belonging to the phylum Chlamydiae. This species survives outside of its host as an elementary body. C. psittaci is pathogenic, being the causative agent of endemic avian chlamydiosis and epizootic infection in mammals.","Chlamydophila psittaci | CHLAMYDOPHILA PSITTACI | Chlamydia psittaci",,,,,,,,,,,,,,,"4032644","Chlamydophila psittaci",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0079506","Human Herpesvirus 7","C112315","A species of enveloped and spherical viruses with a capsid with T=16 icosahedral symmetry and surrounded by amorphous tegument, in the Herpesviridae family and Roseolovirus genus. The genome is composed of monopartite, linear double-stranded DNA. Human herpesvirus 7 is found in humans and causes exanthema subitum in infants. Human herpesvirus 7 is transmitted via direct person-to-person contact.","Human Herpesvirus 7 | HHV-7 | HUMAN HERPESVIRUS 7 | Herpes Simplex Virus 7 | Herpes Virus 7 | Human Betaherpesvirus 7",,,,,,,,,,,,,,,"4086084","Human betaherpesvirus 7",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0317739","Moraxella lacunata","C86526","A species of aerobic, Gram negative, cocci shaped bacteria assigned to the phylum Proteobacteria. This species is oxidase positive, nonmotile, sensitive to penicillin, and requires serum for growth. M. lacunata is a commensal organism of the human upper respiratory tract and most commonly associated with eye infections, but has been reported to cause rare invasive infections in humans, including endocarditis, septic arthritis, cellulitis, meningitis, bacteremia and purulent pericarditis.","Moraxella lacunata | MORAXELLA LACUNATA | Moraxella liquefaciens",,,,,,,,,,,,,,,"4222464","Moraxella lacunata",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026913","Mycobacterium avium","C86535","A species of aerobic, Gram positive, rod shaped bacteria assigned to the phylum Actinobacteria. This species is acid fast, catalase positive, niacin, peroxidase, nitrate reductase, and urease negative, and may be susceptible to pnitrobenzoate, ethambutol, pyrazinamide, rifampin, and streptomycin. M. avium is found in soil and dust particles and can cause infection when inhaled or ingested, especially causing disseminated infection in immunocompromised patients.","Mycobacterium avium | MYCOBACTERIUM AVIUM",,,,,,,,,,,,,,,"4308737","Mycobacterium avium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3639966","MLL/ELL Fusion Gene","C101057","A fusion gene that results from a chromosomal translocation t(11;19)(q23;p13.1) which fuses the first 7 exons of the MLL gene to most of the coding sequence of the ELL gene. This rearrangement is associated with treatment-related acute myeloid leukemia.","MLL/ELL Fusion Gene | KMT2A-ELL Fusion Gene | KMT2A/ELL Fusion Gene | KMT2A::ELL Fusion Gene | MLL-ELL Fusion Gene | MLL::ELL Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0317838","Mycoplasma hominis","C86597","A species of anaerobic, Gram-negative, pseudo-cocci shaped bacteria assigned to the phylum Firmicutes. This species is nonmotile, metabolizes arginine with the subsequent release of ammonia into the broth medium, resistant to penicillins and cephalosporins, while tetracycline (adults only) and erythromycin are effective chemotherapeutic agents. M. hominis is commensal in the urogenital flora of adults, but is an opportunistic pathogen implicated in female genital infections and may also cause infections in newborns, especially in those that are immunosuppressed.","Mycoplasma hominis | MYCOPLASMA HOMINIS",,,,,,,,,,,,,,,"4043365","Metamycoplasma hominis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221084","Mycobacterium marinum","C86545","A species of aerobic, Gram positive, rod shaped bacterium assigned to the phylum Actinobacteria. This species is acid fast, nonmotile with optimum growth on Lowenstein-Jensen medium, urease and catalase positive, niacin and nitrate negative, and produces pigment when cultured and exposed to light. M. marinum is commonly found in bodies of fresh or saltwater and skin infections in humans are usually acquired from contact with aquariums or fish.","Mycobacterium marinum | MYCOBACTERIUM MARINUM | Mycobacterium balnei",,,,,,,,,,,,,,,"4239633","Mycobacterium marinum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0317751","Mycobacterium kansasii","C85543","A species of Mycobacterium that can cause tuberculosis and leprosy in mammals, but that is generally not dangerous to healthy people.","Mycobacterium kansasii | MYCOBACTERIUM KANSASII",,,,,,,,,,,,,,,"4035790","Mycobacterium kansasii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0086662","Mycobacterium intracellulare","C91843","Any bacterial organism that can be assigned to the species Mycobacterium intracellulare.","Mycobacterium intracellulare | MYCOBACTERIUM INTRACELLULARE",,,,,,,,,,,,,,,"4222607","Mycobacterium intracellulare",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0317763","Mycobacterium fortuitum","C86538","A species of aerobic, Gram positive, rod shaped bacterium assigned to the phylum Actinobacteria. This species is acid fast, nonmotile, urease negative and catalase, nitrate reductase, and esculin positive. M. fortuitum is found in natural and processed water sources, sewage and dirt, and can cause various clinical syndromes, including local disease after injury or surgical trauma, and disseminated infection in immunocompromised patients.","Mycobacterium fortuitum | MYCOBACTERIUM FORTUITUM",,,,,,,,,,,,,,,"4352641","Mycobacterium fortuitum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026917","Mycobacterium bovis","C85545","A species of Mycobacterium that is a member of the Mycobacterium tuberculosis complex. It is the causative agent of tuberculosis in cattle.","Mycobacterium bovis | MYCOBACTERIUM BOVIS",,,,,,,,,,,,,,,"4098115","Mycobacterium bovis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0317896","Nocardia brasiliensis","C86613","A species of aerobic, Gram-positive, rod shaped bacteria assigned to the phylum Actinobacteria. This species is nonmotile, catalase and urease positive, acid-fast, oxidase negative, hydrolyzes casein, elastin, esculin, hypoxanthine, testosterone, and tyrosine, but not xanthine, produces acid phosphatase, and reduces nitrate. N. brasiliensis is naturally found in soil and is one of the main causative agents of nocardiosis.","Nocardia brasiliensis | NOCARDIA BRASILIENSIS",,,,,,,,,,,,,,,"4243347","Nocardia brasiliensis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028241","Nocardia asteroides","C86611","A species of aerobic, Gram-positive, rod shaped bacteria assigned to the phylum Actinobacteria. This species is catalase and urease positive, acid-fast, hydrolyzes esculin but not casein, reduces nitrate, and characteristically produces a mycelium that fragments into bacillary and coccoid elements. N. asteroides is naturally found in soil, ans lake and marine sediment where it digests plant matter; but in humans it is an opportunistic pathogen and one of the causative agents of nocardiosis in immunocompromised individuals.","Nocardia asteroides | NOCARDIA ASTEROIDES",,,,,,,,,,,,,,,"4146906","Nocardia asteroides",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0317881","Neisseria subflava","C86609","A species of aerobic, Gram-negative, cocci shaped bacteria assigned to the phylum Proteobacteria. This species is catalase and oxidase positive, produces a yellowish pigment, non-hemolytic, utilizes glucose and maltose, but not mannose or lactose, reduces nitrite but not nitrate, and some strains spontaneously agglutinate in saline. N. subflava is commensal in the human nasopharynx, but has been isolated in the cerebrospinal fluid of individuals with meningitis.","Neisseria subflava | NEISSERIA SUBFLAVA",,,,,,,,,,,,,,,"4299086","Neisseria subflava",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026941","Mycoplasma pneumoniae","C86599","A species of anaerobic, Gram-negative, pseudo-cocci shaped bacteria assigned to the phylum Firmicutes. This species is motile, grows best in SP-4 medium supplemented with glucose and is positive for beta-hemolysis. M. pneumoniae is a common cause of community-acquired pneumonia, especially in people younger than 40.","Mycoplasma pneumoniae | MYCOPLASMA PNEUMONIAE",,,,,,,,,,,,,,,"4240327","Mycoplasma pneumoniae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0317831","Mycoplasma orale","C86598","A species of anaerobic, Gram-negative, pseudo-cocci shaped bacteria assigned to the phylum Firmicutes. This species is nonmotile, urease negative, does not hydrolyze carbohydrates, gelatin, or casein, and is sensitive to penicillin, erythromycin and aminoglycosides. M. orale is commensal in the human oropharynx and is usually non-pathogenic, but can cause infections in immunosuppressed patients and is a common contaminant found in cultured cells.","Mycoplasma orale | MYCOPLASMA ORALE",,,,,,,,,,,,,,,"4188196","Mycoplasma orale",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085470","Pseudomonas putida","C86705","A species of aerobic, Gram negative, rod shaped bacteria in the phylum Proteobacteria. This species is motile, non spore forming, oxidase positive and able to degrade styrene and many aromatic hydrocarbons found in fuel oil. P. putida is rarely pathogenic and one strain can convert morphine to hydromorphine.","Pseudomonas putida | PSEUDOMONAS PUTIDA",,,,,,,,,,,,,,,"4285455","Pseudomonas putida",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033819","Burkholderia pseudomallei","C86227","A species of aerobic, Gram-negative, rod shaped bacteria assigned to the phylum Proteobacteria. This species is motile, non-spore forming, oxidase and catalase positive and indole negative. B. pseudomallei is found in contaminated soil, water, and produce and causes melioidosis in humans with the highest rate of disease occurring in southeast Asia.","Burkholderia pseudomallei | BURKHOLDERIA PSEUDOMALLEI | Burkholderia pseudomalle | Pseudomonas pseudomallei",,,,,,,,,,,,,,,"4023067","Burkholderia pseudomallei",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033811","Pseudomonas fluorescens","C86700","A species of obligatively aerobic, Gram negative, rod shaped bacteria in the phylum Proteobacteria. This species is motile, non spore forming, a source of fluorescein and mupirocin and is used in the production of yogurt. P. fluorescens can be pathogenic to immunocompromised individuals.","Pseudomonas fluorescens | Bacterium fluorescen | Liquidomonas fluorescens | PSEUDOMONAS FLUORESCENS",,,,,,,,,,,,,,,"4191249","Pseudomonas fluorescens",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033702","Proteus vulgaris","C85250","A species of facultatively anaerobic, Gram-negative, rod shaped bacteria assigned to the phylum Proteobacteria. This species is motile, indole, methyl red, and urease positive, hydrolyzes esculin, ferments glucose and amygdalin, but not mannitol or lactose, and produces hydrogen sulfide. P. vulgaris is part of the normal human and animal intestinal flora and is widespread in the environment, but can also be an opportunistic pathogen in humans causing nosocomial, urinary tract, and other wound infections.","Proteus vulgaris | PROTEUS VULGARIS",,,,,,,,,,,,,,,"4164566","Proteus vulgaris",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0314929","Prevotella oralis","C86675","A species of obligately anaerobic, Gram-negative, rod shaped bacteria assigned to the phylum Bacteroidetes. This species is nonmotile, non-spore forming, nonpigmented, cellobiose, rhamnose, salicin sucrose, lactose, esculin hydrolysis, beta-N-acetyl-glucosaminidase, alpha-fucosidase, beta-glucosidase, and glycine aminopeptidase positive, but xylose, arabinose, indole, and beta-xylosidase negative. P. oralis is part of the normal human oral cavity flora, but is associated with oral and upper respiratory infections.","Prevotella oralis | Bacteroides oralis | PREVOTELLA ORALIS",,,,,,,,,,,,,,,"4015530","Prevotella oralis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004670","Prevotella melaninogenica","C86673","A species of anaerobic, Gram-negative, rod shaped bacteria assigned to the phylum Bacteroidetes. This species is non-motile, non-spore-forming, produces a tan to buff pigment on blood agar, fluoresces under UV (365 nm) light, sucrose, lactose, and beta-N-acetyl-glucosaminidase positive, but xylose arabinose, cellobiose, rhamnose, salicin, indole, esculin hydrolysis beta-glucosidase, and glycine aminopeptidase negative. P. melaninogenica is part of the normal human oral and vaginal flora, but can also be an opportunistic pathogen causing infections in both humans and animals.","Prevotella melaninogenica | Bacteroides melaninogenicus | PREVOTELLA MELANINOGENICA",,,,,,,,,,,,,,,"4015686","Prevotella melaninogenica",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0314940","Prevotella bivia","C86661","A species of obligately anaerobic, Gram-negative, rod shaped bacteria assigned to the phylum Bacteroidetes. This species is non-motile, non-spore forming, produces succinic and acetic acid from peptone-yeast-glucose medium, non-pigmented, indole negative, hydrolyzes starch, but not esculin, digests gelatin, milk, casein and meat, and ferments glucose, maltose, starch, lactose, galactose, and mannose, but not sucrose. P. bivia has been isolated from the oral cavity and the female genital tract and is associated with abscesses and a variety of systemic infections.","Prevotella bivia | Bacteroides bivia | Bacteroides bivia  | Bacteroides bivius | PREVOTELLA BIVIA",,,,,,,,,,,,,,,"4015683","Prevotella bivia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206347","Porphyromonas","C86653","A genus of anaerobic, Gram negative, rod shaped bacterium assigned to the phylum Bacteroidetes and the family Porphyromonadaceae.","Porphyromonas | PORPHYROMONAS",,,,,,,,,,,,,,,"4013782","Porphyromonas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030967","Peptostreptococcus","C86644","A genus of anaerobic, Gram positive, cocci shaped bacterium assigned to the phylum Firmicutes and the family Peptostreptococcaceae.","Peptostreptococcus | PEPTOSTREPTOCOCCUS",,,,,,,,,,,,,,,"4348178","Peptostreptococcus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0317944","Parvimonas micra","C86901","A species of anaerobic, Gram-positive, cocci shaped bacteria assigned to the phylum Firmicutes. This species is indole and urease negative, nonfermenting, beta-hemolytic, and does not reduce nitrate. P. micra is commensal to the human mouth, gastrointestinal tract and female genito-urinary tract, but may become pathogenic.","Parvimonas micra | Micromonas micros | PARVIMONAS MICRA | Peptostreptococcus micros",,,,,,,,,,,,,,,"4200633","Parvimonas micra",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0317947","Finegoldia magna","C86888","A species of anaerobic, Gram positive, cocci shaped bacterium assigned to the phylum Firmicutes. F. magna cannot ferment most sugars aside from fructose and possesses various aminopeptidase activities. A commensal bacterium, it's most notably involved in human skin and soft tissue infection.","Finegoldia magna | FINEGOLDIA MAGNA | Peptostreptococcus magnus",,,,,,,,,,,,,,,"4221055","Finegoldia magna",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1622989","Peptostreptococcus anaerobius","C86645","A species of obligately anaerobic, Gram-positive, coccobacillus shaped bacteria assigned to the phylum Firmicutes. This species is nonmotile, non-spore forming, catalase positive, indole, coagulase, and urease negative, produces gas from peptone-yeast-glucose medium, is moderately saccharolytic, but does not reduce nitrate, hydrolyze starch or esculin, produce propionate from lactate, or liquefy gelatin. P. anaerobius is commensal to human mucocutaneous surfaces, but can become pathogenic in other locations.","Peptostreptococcus anaerobius | PEPTOSTREPTOCOCCUS ANAEROBIUS",,,,,,,,,,,,,,,"4078522","Peptostreptococcus anaerobius",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0317941","Peptococcus niger","C86643","A species of obligately anaerobic, Gram-positive, cocci shaped bacteria assigned to the phylum Firmicutes. This species is nonmotile, nonhemolytic, produces hydrogen sulfide and a black pigment that disappears upon exposure to air, indole and esculin negative, and does not reduce nitrate, ferment carbohydrates, liquefy gelatin or serum, or utilize lactate, starch or hippurate. P. niger is commensal to the human intestinal tract and has been isolated from the human naval and urine of adult women.","Peptococcus niger | Micrococcus niger | PEPTOCOCCUS NIGER",,,,,,,,,,,,,,,"4011695","Peptococcus niger",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028422","Norwalk Virus","C112363","A species of non-enveloped and spherical viruses with a capsid with T=3 icosahedral symmetry in the Caliciviridae family and Norovirus genus. The genome is composed of single-stranded, positive-sense RNA. Norwalk viruses are found in humans and causes acute viral gastroenteritis. Norwalk viruses are transmitted via oral ingestion or fecal-oral contamination.","Norwalk Virus | NORWALK VIRUS | NV | Norwalk calicivirus",,,,,,,,,,,,,,,"4020841","Norwalk virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0445750","Salmonella enterica","C86731","A species of aerobic, Gram negative, rod shaped bacteria assigned to the phylum Proteobacteria. This species is oxidase and urease negative, catalase positive, reduces nitrate to nitrite, ferments glucose, and grows well on media containing peptone or meat extract. S. enterica is a causative agent of salmonellosis.","Salmonella enterica | SALMONELLA ENTERICA",,,,,,,,,,,,,,,"4005794","Salmonella enterica",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL415427","Rhodotorula rubra","C87517","No Value Exists","Rhodotorula rubra | Cryptococcus ruber | Eutorula rubra | RHODOTORULA RUBRA | Rhodotorula pilimanae | Saccharomyces ruber | Sporobolomyces albo-rubescens | Torula rubra | Torulopsis rubra",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010152","Rhodococcus equi","C86719","A species of aerobic, Gram positive, rod and cocci shaped bacteria assigned to the phylum Actinobacteria. This species has a pink color, is urease positive and grows on glycerol. R. equi is a lung pathogen that can infect grazing animals and immunocompromised people.","Rhodococcus equi | Corynebacterium equi | RHODOCOCCUS EQUI",,,,,,,,,,,,,,,"4184287","Rhodococcus hoagii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0318049","Gordonia bronchialis","C86416","A species of aerobic, Gram positive, coryneform bacteria assigned to the phylum Actinobacteria. This species is catalase positive, slightly acid fast, nonmotile and contains lipoparabinomannan like lipoglycans in the cell wall. G. bronchialis is an opportunistic pathogen, causing infection at medical device implantation sites and wound sites in surgical patients.","Gordonia bronchialis | GORDONIA BRONCHIALIS | Gordona bronchialis | Rhodococcus bronchialis",,,,,,,,,,,,,,,"4015390","Gordonia bronchialis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0318121","Staphylococcus xylosus","C86775","A species of facultatively anaerobic, Gram positive, cocci shaped bacteria in the phylum Firmicutes. This species is positive for catalase and urease, and negative for coagulase and oxidase. It can ferment xylose, trehalose, arabinose, mannose, fructose, lactose, sucrose, turanose, and mannitol, but not maltose, turanose, cellobiose, or xylitol. S. xylosus is commensal on the skin of humans and animals, is used in the production of cheese and sausage and is a rare opportunistic pathogen in humans that can cause dermititis, urinary tract infections and bacteremia.","Staphylococcus xylosus | STAPHYLOCOCCUS XYLOSUS",,,,,,,,,,,,,,,"4139779","Staphylococcus xylosus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0318122","Staphylococcus warneri","C86774","A species of facultatively anaerobic, Gram positive, cocci shaped bacteria in the phylum Firmicutes. This species is positive for catalase and urease and negative for oxidase, alkaline phosphatase and coagulase. It can ferment glucose, trehalose, sucrose, fructose, and maltose, but not xylitol, xylose, arabinose, mannose, lactose, turanose or cellobiose. S. warneri is a commensal organism on the skin of humans and animals and is a rare human pathogen that can cause a variety of opportunistic infections.","Staphylococcus warneri | STAPHYLOCOCCUS WARNERI",,,,,,,,,,,,,,,"4270057","Staphylococcus warneri",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0318112","Staphylococcus saprophyticus","C86770","A species of facultatively anaerobic, Gram positive, cocci shaped bacteria in the phylum Firmicutes. This species is positive for catalase and urease and negative for coagulase, oxidase, and alkaline phosphatase. It can metabolize glucose, maltose, sucrose, turanose, mannitol, glycerol, fructose, lactose, trehalose and xylitol but not mannose, rhamnose, xylose, arabinose, ribose or cellobiose. S. saprophyticus is a commensal organism in humans and is a pathogen that causes urinary tract infections in women.","Staphylococcus saprophyticus | Micrococcus Subgroup 3 | STAPHYLOCOCCUS SAPROPHYTICUS",,,,,,,,,,,,,,,"4055349","Staphylococcus saprophyticus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0318113","Staphylococcus hominis","C86762","A species of facultatively anaerobic, Gram positive, cocci shaped bacteria in the phylum Firmicutes. This species is positive for catalase and urease and negative for coagulase, oxidase, and alkaline phosphatase. It can ferment sucrose, maltose, glucose, fructose, glycerol and trehalose but not mannitol, mannose, ribose, rhamnose, xylose, arabinose, xylitol or cellobiose. S. hominis is a commensal organism found in the normal flora of human skin and can cause opportunistic infections in immunocompromised people.","Staphylococcus hominis | Coagulase Negative Staphylococcus hominis | STAPHYLOCOCCUS HOMINIS",,,,,,,,,,,,,,,"4264368","Staphylococcus hominis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0318114","Staphylococcus haemolyticus","C86761","A species of facultatively anaerobic, Gram positive, cocci shaped bacteria in the phylum Firmicutes. This species is positive for catalase and negative for coagulase, alkaline phosphatase, oxidase and urease. It can ferment glucose, glycerol sucrose, maltose, and trehalose, but not mannose, rhamnose, cellobiose, xylose, arabinose, ribose, or xylitol. S. haemolyticus is a commensal human skin organism and an opportunistic pathogen that can cause meningitis, skin or soft tissue infections, prosthetic joint infections, and bacteremia in humans.","Staphylococcus haemolyticus | STAPHYLOCOCCUS HAEMOLYTICUS | Staph. haemolyticus",,,,,,,,,,,,,,,"4308865","Staphylococcus haemolyticus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036960","Shigella sonnei","C86747","A species of facultatively anaerobic, Gram negative, rod shaped bacteria in the phylum Proteobacteria. This species is indole and citrate negative, ferments mannitol and ornithine and is beta-D-galactosidase positive. S. sonnei is found in the human gastrointestinal system and is pathogenic, being a causative agent of shigellosis.","Shigella sonnei | SHIGELLA SONNEI | Shigella Biogroup D",,,,,,,,,,,,,,,"4180726","Shigella sonnei",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036957","Shigella flexneri","C86746","A species of facultatively anaerobic, Gram negative, rod shaped bacteria in the phylum Proteobacteria. This species is oxidase and citrate negative, indole positive and can produce acid and gas from glucose. S. flexneri is a pathogen that causes shigellosis in primates.","Shigella flexneri | SHIGELLA FLEXNERI | Shigella Biogroup B",,,,,,,,,,,,,,,"4311807","Shigella flexneri",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036956","Shigella dysenteriae","C86745","A species of facultatively anaerobic, Gram negative, rod shaped bacteria in the phylum Proteobacteria. This species is non motile, indole negative, cannot ferment lactose and produces Shiga toxin. S. dysenteriae is a pathogen that causes severe forms of shigellosis in primates.","Shigella dysenteriae | SHIGELLA DYSENTERIAE | Shigella Biogroup A",,,,,,,,,,,,,,,"4185110","Shigella dysenteriae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036955","Shigella boydii","C86744","A species of facultatively anaerobic, Gram negative, rod shaped bacteria in the phylum Proteobacteria. This species is nonmotile, non spore forming, catalase positive, oxidase negative and has mixed indole reactivity. S. boydii is found only on the Indian subcontinent and is pathogenic, being a causative agent of shigellosis in primates.","Shigella boydii | SHIGELLA BOYDII | Shigella Biogroup C",,,,,,,,,,,,,,,"4206312","Shigella boydii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0318157","Streptococcus viridans Group","C86811","A non taxonomic grouping of species within the Streptococcus genus that are alpha hemolytic and do not express Lancefield antigens.","Streptococcus viridans Group | STREPTOCOCCUS VIRIDANS GROUP | Streptococcus viridans | Viridans streptococcus",,,,,,,,,,,,,,,"4136500","Streptococcus, viridans group",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0318241","Veillonella parvula","C86839","A species of anaerobic, Gram negative, cocci shaped bacteria assigned to the phylum Firmicutes. This species is catalase negative and does not require putrescine or cadaverine for growth. V. parvula is commensal, residing in the mouth, or the intestinal or respiratory tracts and is rarely pathogenic.","Veillonella parvula | Micrococcus lactilyticus | Staphylococcus parvulus | VEILLONELLA PARVULA | Veillonella alcalescens | Veillonella gazogenes",,,,,,,,,,,,,,,"4234709","Veillonella parvula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1095862","Trichosporon","C114129","A genus of yeasts in the family Trichosporonaceae and phylum Basidiomycota.","Trichosporon | TRICHOSPORON",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0318195","Streptomyces somaliensis","C86814","A species of aerobic, Gram positive, filamentous bacteria in the phylum Actinobacteria. This species is spore forming, does not demonstrate growth or metabolism of carbohydrates and can use organic esters as carbon sources. S. somaliensis is a known pathogen that can cause mycetoma.","Streptomyces somaliensis | STREPTOMYCES SOMALIENSIS",,,,,,,,,,,,,,,"4003854","Streptomyces somaliensis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038420","Streptomyces","C14278","A genus of Gram-positive bacteria in the phylum Actinobacteria that contains over 500 separate species. Streptomyces spp. produce over 60% of all clinically relevant antibiotics, including antibacterial and antifungal agents.","Streptomyces | STREPTOMYCES",,,,,,,,,,,,,,,"4186446","Streptomyces",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038412","Streptococcus sanguinis","C86806","A species of facultatively anaerobic, Gram positive, cocci shaped bacteria in the phylum Firmicutes. This species is alpha hemolytic, arginine deaminase positive, hydrolysis esculin, and urease and catalase negative. It can ferment inulin and trehalose but not mannitol, sorbitol, or raffinose. S. sanguinis is found in the normal oral flora of humans and is a pathogen that can cause dental caries, and endocarditis after dental injury.","Streptococcus sanguinis | STREPTOCOCCUS SANGUINIS | Streptococcus sanguis",,,,,,,,,,,,,,,"4015549","Streptococcus sanguinis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0318179","Streptococcus salivarius","C86804","A species of facultatively anaerobic, Gram positive, cocci shaped bacteria in the phylum Firmicutes. This species is alpha hemolytic, hydrolyzes esculin and is negative for arginine deaminase, and catalase. It can ferment inulin, salicin, and raffinose but not mannitol, or sorbitol. S. salivarius is found in the normal flora of the mouth and respiratory tract and is rarely a human pathogen causing opportunistic infections.","Streptococcus salivarius | STREPTOCOCCUS SALIVARIUS",,,,,,,,,,,,,,,"4220801","Streptococcus salivarius",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0318174","Streptococcus oralis","C86799","A species of facultatively anaerobic, Gram positive, cocci shaped bacteria in the phylum Firmicutes. This species is alpha hemolytic, urease and catalase negative, sialidase and alpha glucosidase positive and does not hydrolyze esculin. It can ferment ribose, raffinose, and trehalose but not inulin, cellobiose, mannitol, or sorbitol. S. oralis is found in the human oral cavity and respiratory tract and can be a pathogen that causes dental caries, gum disease, and endocarditis following oral trauma.","Streptococcus oralis | STREPTOCOCCUS ORALIS",,,,,,,,,,,,,,,"4057957","Streptococcus oralis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0579233","Streptococcus agalactiae","C86780","A species of facultatively anaerobic, Gram positive, cocci shaped bacteria in the phylum Firmicutes. This species is positive for beta hemolysis, CAMP test, Lancefield group B and arginine deamination and negative for esculin hydrolysis, pyrrolidonylarylamidase and catalase. It can ferment trehalose and ribose but not mannitol or sorbitol. S. agalactiae is a commensal organism of the human gastrointestinal and female genital tracts and is a pathogen is humans causing opportunistic infections and neonatal sepsis.","Streptococcus agalactiae | STREPT. GP B(AGALACT) | STREPTOCOCCUS AGALACTIAE | beta hemolytic streptococcus group B",,,,,,,,,,,,,,,"4183468","Group B streptococcus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0445842","Stenotrophomonas","C86776","A genus of aerobic, Gram negative, rod shaped bacterium assigned to the phylum Proteobacteria and the family Xanthomonadaceae.","Stenotrophomonas | STENOTROPHOMONAS",,,,,,,,,,,,,,,"4017688","Stenotrophomonas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0318115","Staphylococcus simulans","C86773","A species of facultatively anaerobic, Gram positive, cocci shaped bacteria in the phylum Firmicutes. This species is positive for catalase and urease and negative for oxidase, alkaline phosphatase and coagulase. It can ferment sucrose, mannitol, fructose, and lactose but not arabinose, cellobiose, turanose, xylose, or xylitol. S. simulans is found on human and animal skin and is a pathogen that can cause bumble foot disease and mastitis in animals and ostomyelitis and prosthesis related infections in humans.","Staphylococcus simulans | STAPHYLOCOCCUS SIMULANS",,,,,,,,,,,,,,,"4180267","Staphylococcus simulans",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2984866","Inadequate Device Immunity Problem Evaluation Result","C92135","Problems related to immunity or capabilities to resist electromagnetic interference (EMI).","Inadequate Device Immunity | Inadequate Device Immunity Problem Evaluation Result | Inadequate Immunity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984601","Cannot Complete Investigation Incomplete Device Returned Evaluation Conclusion","C91867","No Value Exists","Cannot Complete Investigation Incomplete Device Returned Evaluation Conclusion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984605","Device Discarded by User Unable to Follow-up Evaluation Conclusion","C91871","No Value Exists","Device Discarded by User Unable to Follow-up Evaluation Conclusion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984608","Device Inconclusive Investigation in Progress Evaluation Conclusion","C91875","No Value Exists","Device Inconclusive Investigation in Progress Evaluation Conclusion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL423204","Cause Traced to User","C91874","The adverse event was caused partially or wholly by the user of the device including sample handling.","Cause Traced to User | Device Human Factor Issue Evaluation Conclusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984616","Device not Returned Evaluation Conclusion","C91883","No Value Exists","Device not Returned Evaluation Conclusion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984615","Device not Manufactured by Reporting Firm Evaluation Conclusion","C91882","No Value Exists","Device not Manufactured by Reporting Firm Evaluation Conclusion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984619","Device Received in Condition Making Evaluation Impossible Evaluation Conclusion","C91886","No Value Exists","Device Received in Condition Making Evaluation Impossible Evaluation Conclusion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984620","Device Received Unused in Original Package Evaluation Conclusion","C91887","No Value Exists","Device Received Unused in Original Package Evaluation Conclusion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984623","No Failure Detected Device Operated within Specification Evaluation Conclusion","C91890","No Value Exists","No Failure Detected Device Operated within Specification Evaluation Conclusion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984602","Conclusion not Yet Available","C91868","A conclusion has yet to be established as the investigation is incomplete.","Conclusion not Yet Available | Conclusion Not Yet Available | Conclusion not Yet Available Device Evaluation in Progress Evaluation Conclusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984611","Known Inherent Risk of Device","C91878","Reported adverse event known and documented in the labeling (including both short or long term known complications or adverse reactions).","Known Inherent Risk of Device | Device Known Inherent Risk of Procedure Evaluation Conclusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984613","Cause Traced to Maintenance","C91880","Problems traced to improper routine or preventative maintenance.","Cause Traced to Maintenance | Device Maintenance Deficiency Evaluation Conclusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984603","Cause Traced to Device Design","C91869","Problems traced to the design specifications (e.g. in the requirements, testing processes, hazard analysis, implementation strategy).","Cause Traced to Device Design | Device Design Deficiency Evaluation Conclusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984604","Device Difficult to Operate","C91870","Problems including set-up, operation, and disassembly of equipment. Not including reprocessing.","Device Difficult to Operate | Device Difficult to Operate Evaluation Conclusion | Device Difficult to Operate Evaluation Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984606","Adverse Event Related to Patient Condition","C91872","An existing condition or disease is demonstrably responsible for the adverse event and use of the device has neither caused nor otherwise influenced this condition/disease-related adverse event.","Adverse Event Related to Patient Condition | Device Failure Related to Patient Condition Evaluation Conclusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984609","Device Incorrectly Prepared for Use or Modified Evaluation Conclusion","C91876","A device that is incorrectly modified or prepared for use by distributor, service provider, or user facility.","Device Incorrectly Prepared for Use or Modified Evaluation Conclusion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984610","Cause Traced to Infrastructure","C91877","The undesirable presence of living organisms such as bacteria, fungi, or viruses or their products (enzymes or toxins).","Cause Traced to Infrastructure | Device Infrastructure Failure Evaluation Conclusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984612","Cause Traced to Labeling","C91879","Problems that occur as the result of problems with the labeling (including package inserts, instruction manuals, instructions for use).","Cause Traced to Labeling | Device Labeling Deficiency Evaluation Conclusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984607","Failure To Follow Instructions","C91873","Problems traced to the user not following the manufacturer's instructions.","Failure to Follow Instructions | Device Failure to Follow Instructions Evaluation Conclusion | Failure To Follow Instructions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984614","Manufacturing Deficiency","C91881","Problems traced to manufacturing process.","Manufacturing Deficiency | Device Manufacturing Deficiency Evaluation Conclusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984621","Device Repaired and Returned Evaluation Conclusion","C91888","The device was repaired and returned to the user (reporter) following a reported device problem.","Device Repaired and Returned Evaluation Conclusion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984618","Cause Traced to Manufacturing","C91885","A defect in the processes or systems used in the manufacture of the device. Examples include problems within the change control, production, or quality control processes.","Cause Traced to Manufacturing | Device Quality System Deficiency Evaluation Conclusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984622","Cause Traced to Training","C91889","Problems caused by inadequate training.","Cause Traced to Training | Device Training Deficiency Evaluation Conclusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984617","Device Operational Context Caused or Contributed to Event Evaluation Conclusion","C91884","A device problem related to the operator's technique or use environment.","Device Operational Context Caused or Contributed to Event Evaluation Conclusion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984625","Cause Traced to Intentional Off-Label, Unapproved, or Contraindicated Use","C91892","Problems traced to the intentional use of the device in an unapproved procedure, for an unapproved patient, or for which it is contraindicated, or not listed on the label.","Cause Traced to Intentional Off-Label, Unapproved, or Contraindicated Use | Off-Label Unapproved or Contraindicated Device Use Evaluation Conclusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984626","Reuse of Single Use Device","C91893","Problems traced to the use of the device more than once when it is designed for only one use.","Reuse of Single Use Device | Reuse of Single Use Device Problem Evaluation Conclusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984627","No Problem Detected","C91894","Problem not confirmed or confirmation of no problem.","No Problem Detected | Unable to Confirm Device Complaint Evaluation Conclusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984628","Unintended Use Error Caused or Contributed to Event","C91895","The interaction between the user and device, or sample, caused or contributed to the error. This includes unintended inappropriate use of the device and incorrect sample preparation.","Unintended Use Error Caused or Contributed to Event | Use Error Caused or Contributed to Device Event Evaluation Conclusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707703","Device Evaluation Conclusion","C54030","No Value Exists","Device Evaluation Conclusion | EVALUATION CONCLUSION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710509","Type of Remedial Action","C53603","A specification of the type of remedial action that was taken.","Type of Remedial Action | TYPE OF REMEDIAL ACTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL357898","Inspection","C53604","No Value Exists","Inspection | INSPECTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030695","Patient Monitoring","C53607","The act of observing a disease, condition, or medical parameter over time.","Patient Monitoring | PATIENT MONITORING | medical monitoring | monitor",,,,,,,,,,,,,,,"4082264","Monitoring of patient",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347943","Relabel (action)","C73607","To affix a new label onto an item.","Relabel | RELABEL | RELABELING | Relabeling | Relabelling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707726","Device Usage","C53645","To employ an object for its specific purpose.","Device Usage | USAGE OF DEVICE | Usage of Device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709937","Device Reuse","C53613","To use a device again.","Device Reuse | REUSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1547650","Product Problem","C53054","An issue with quality, authenticity, performance, or/and safety of medication or medical device. The concept encompasses any problems that may occur during manufacturing, shipping, storage, or use of the medical product including but not limited to such concerns as suspect counterfeit product, product contamination, super potent or subpotent medication, defective item or its component, poor packaging or product confusion, questionable stability, device failure or malfunction, and labeling concerns.","Product Problem | Medical Product Problem | PRODUCT PROBLEM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641681","Product Use Error","C103983","No Value Exists","Product Use Error | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891162","Gynostemma pentaphyllum Supplement","C117275","A traditional Chinese medicine (TCM) derived from the plant Gynostemma pentaphyllum, an herbaceous climbing vine found in southern China and Southeast Asia, with potential antioxidant activity. Gynostemma pentaphyllum intake has also been used for its adaptogenic effect, to decrease cholesterol and high blood pressure, to strengthen the immune system, and to increase stamina and to improve memory.","Gynostemma pentaphyllum Supplement | Jiao Gu-lan | Jiaogulan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0721437","Benazepril/Hydrochlorothiazide","C117276","A combination preparation of the synthetic angiotensin-converting enzyme (ACE) inhibitor prodrug benazepril and the thiazide diuretic hydrochlorothiazide, with antihypertensive activity. Benazepril is de-esterified by the liver into its active form benazeprilat, which competitively inhibits ACE. ACE inhibition prevents the formation of angiotensin II, and blocks angiotensin II-mediated activities, including vasoconstriction and stimulation of synthesis and secretion of aldosterone, which leads to an increase in sodium excretion and increases water outflow. Hydrochlorothiazide inhibits electrolyte reabsorption via binding to the Na-Cl cotransporter on the renal distal tubules, thereby increasing excretion of sodium, potassium, chloride, bicarbonate and water. Together, these agents lead to a reduction in blood pressure.","Benazepril/Hydrochlorothiazide | Lotensin | Lotensin HCT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0590743","Atenolol/Chlorthalidone","C117274","A combination preparation composed of the adrenergic beta-1 receptor antagonist atenolol and thiazide-like diuretic chlorthalidone, with anti-hypertensive activity. Atenolol selectively binds to beta-1 adrenergic receptors in the heart and vascular smooth muscle, thereby inhibiting sympathetic stimulation. This results in a decrease in cardiac rate and muscle contractility, thereby reducing cardiac output. As a diuretic, chlorthalidone directly inhibits sodium and chloride reabsorption on the luminal membrane of the early segment in the distal convoluted tubule (DCT) in the kidney. This leads to an increase in sodium, chloride, bicarbonate, and potassium secretion and results in the excretion of water. Together, these agents lead to a reduction in blood pressure.","Atenolol/Chlorthalidone | Atenolol/Chlorthalidone
 | Tenoretic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0585733","Type of Report","C53571","No Value Exists","Type of Report | REPORT TYPE | TYPE OF REPORT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639956","Functional Bowel Obstruction","C101033","The blockage of bowel contents from evacuation; the causes are attributable to non-structural impediments, such as chemical imbalances or the side effects of medications, narcotics in particular.","Functional Bowel Obstruction | Functional Intestinal Obstruction | Intestinal Obstruction, Functional",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0318158","Beta-Hemolytic Streptococcus Group C","C86191","A non-taxonomic grouping of beta hemolytic species within the Streptococcus genus that are assigned to Lancefield group C.","Beta-Hemolytic Streptococcus Group C | BETA STREPTOCOCCUS, GROUP C | Beta Streptococcus Group C | GCS | Group C Streptococcus | Streptococcus Group C | Streptococcus sp. group C",,,,,,,,,,,,,,,"4229618","Streptococcus, group C",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0318162","Beta-Hemolytic Streptococcus Group G","C86193","A non-taxonomic grouping of beta hemolytic species within the Streptococcus genus that are assigned to Lancefield group G.","Beta-Hemolytic Streptococcus Group G | BETA STREPTOCOCCUS, GROUP G | Beta Streptococcus Group G | GGS | Group G Streptococcus | Streptococcus Group G | Streptococcus sp. group G",,,,,,,,,,,,,,,"4326764","Streptococcus, group G",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898826","IDH1 NP_005887.2:p.R132X","C117280","A change in the amino acid residue at position 132 in the isocitrate dehydrogenase [NADP] cytoplasmic protein where arginine has been replaced by another amino acid. Mutations at this position occur frequently in high-grade gliomas but not in other solid tumors.","IDH1 NP_005887.2:p.R132X | Cytosolic NADP-Isocitrate Dehydrogenase Protein Arg132Xxx | Cytosolic NADP-Isocitrate Dehydrogenase Protein R132X | IDH1 Arg132Xxx | IDH1 NP_005887.2:p.Arg132Xxx | IDH1 NP_005887.2:p.R132X 
 | IDH1 R132 | IDH1 R132 Mutation | IDH1 R132X | IDH1 R132X Mutation | IDH1 p.Arg132Xxx | IDH1 p.R132 | IDH1 p.R132X | IDH1-R132 Mutation | Isocitrate Dehydrogenase [NADP] Cytoplasmic Arg132Xxx | Isocitrate Dehydrogenase [NADP] Cytoplasmic R132X | NP_005887.2:p.Arg132Xxx | NP_005887.2:p.R132X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898823","IDH2 NP_002159.2:p.R140X","C117281","A change in the amino acid residue at position 140 in the isocitrate dehydrogenase [NADP], mitochondrial protein where arginine has been replaced by another amino acid. Mutations at this position are found in patients with acute myeloid leukemia following myelodysplastic syndromes and is associated with shorter overall survival.","IDH2 NP_002159.2:p.R140X | IDH2 Arg140Xxx | IDH2 R140 | IDH2 R140 Mutation | IDH2 R140X | IDH2 p.Arg140Xxx | IDH2 p.R140 | Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial Arg140Xxx | Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial R140X | Isocitrate Dehydrogenase [NADP], Mitochondrial Arg140Xxx | Isocitrate Dehydrogenase [NADP], Mitochondrial R140X | NP_002159.2:p.Arg140Xxx | NP_002159.2:p.R140X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898822","IDH2 NP_002159.2:p.R172X","C117282","A change in the amino acid residue at position 172 in the isocitrate dehydrogenase [NADP], mitochondrial protein where arginine has been replaced by another amino acid. Mutations at this position are found in patients with acute myeloid leukemia following myelodysplastic syndromes and is associated with shorter overall survival.","IDH2 NP_002159.2:p.R172X | IDH2 Arg172Xxx | IDH2 R172 | IDH2 R172 Mutation | IDH2 R172X | IDH2 p.Arg172Xxx | IDH2 p.R172 | IDH2(R172) | Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial  | Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial Arg172Xxx | Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial R172X | Isocitrate Dehydrogenase [NADP+], Mitochondrial R172X | Isocitrate Dehydrogenase [NADP], Mitochondrial Arg172Xxx | NP_002159.2:p.Arg172Xxx | NP_002159.2:p.R172X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898659","JAK2 NP_004963.1:p.V617X","C117283","A change in the amino acid residue at position 617 in the tyrosine-protein kinase JAK2 protein where valine has been replaced by another amino acid. A change to phenylalanine at this position is associated with polycythemia vera.","JAK2 NP_004963.1:p.V617X | JAK2 NP_004963.1:p.V617X  | JAK2 NP_004963.1:p.Val617Xxx | JAK2 V617 | JAK2 V617X | JAK2 Val617Xxx | JAK2 p.V617 | JAK2 p.V617X | JAK2 p.Val617Xxx | Janus Kinase 2 V617X | Janus Kinase 2 Val617Xxx | NP_004963.1:p.V617X | NP_004963.1:p.Val617Xxx | Tyrosine-Protein Kinase JAK2 V617X | Tyrosine-Protein Kinase JAK2 Val617Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899479","Cytoplasmic Nucleophosmin Expression","C117284","A variant form of nucleophosmin with cytoplasmic expression. These variants have either a 4-base or 9-base insertion in exon 12 of the NPM1 gene. Acute myelogenous leukemia with normal cytogenetics and cytoplasmic nucleophosmin (NPMc+ AML) constitutes about one third of the cases of primary AML in adults.","Cytoplasmic Nucleophosmin Expression | Cytoplasmic NPM1 | Cytoplasmic Nucleophosmin | Cytoplasmic Nucleophosmin  | NPM1 Cytoplasmic Localization | NPM1c | NPMc",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0320118","Scedosporium prolificans","C117362","A species of dematiaceous filamentous fungi in the phylum Ascomycota with small, delicate annellides with a distinct basal swelling peculiar to this species and absent in closely related species. L. prolificans causes opportunistic infection in immunocompetent and immunosuppressed individuals. The species exhibits varying tolerance to currently available antifungal agents.","Scedosporium prolificans | LOMENTOSPORA PROLIFICANS | Lomentospora prolificans | Scedosporium inflatum",,,,,,,,,,,,,,,"4289606","Scedosporium prolificans",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0318136","Rothia","C86727","A genus of aerobic, Gram positive, rod shaped bacterium assigned to the phylum Actinobacteria and the family Micrococcaceae.","Rothia | ROTHIA | Stomatococcus",,,,,,,,,,,,,,,"4234716","Rothia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320385","Pneumocystis jirovecii","C117361","A species of yeast-like fungus that is the causative organism of Pneumocystis pneumonia.","Pneumocystis jirovecii | PNEUMOCYSTIS JIROVECII | Pneumocystis carinii | Pneumocystis carinii f. sp. Hominis | Pneumocystis carinii f. sp. hominis | Pneumocystis carinii hominis | Pneumocystis jiroveci",,,,,,,,,,,,,,,"4197234","Pneumocystis jirovecii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0317948","Anaerococcus prevotii","C86875","A species of anaerobic, Gram positive, cocci shaped bacteria assigned to the phylum Firmicutes. This bacteria is indole and coagulase negative, urease positive and produces acid from raffinose, ribose and mannose. A. pervotii is an opportunist pathogen in immunocompromised individuals.","Anaerococcus prevotii | ANAEROCOCCUS PREVOTII | Micrococcus prevotii | Peptococcus prevotii | Peptostreptococcus prevotii",,,,,,,,,,,,,,,"4186052","Anaerococcus prevotii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009184","Coccidioides immitis","C117354","A species of pathogenic fungus in the family Onygenaceae that is one of the causative agents of coccidioidomycosis. It is found in the soil in southwestern United States and northern Mexico.","Coccidioides immitis | Ascomycete fungi | COCCIDIOIDES IMMITIS",,,,,,,,,,,,,,,"4052086","Coccidioides immitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005715","Blastomyces dermatitidis","C117352","A species of thermally dimorphic fungus in the family Ajellomycetaceae that behaves diversely at different temperatures and is the causative agent of blastomycosis. It is found in the soil in the midwestern and northern United States and Canada.","Blastomyces dermatitidis | Ajellomyces dermatitidis | BLASTOMYCES DERMATITIDIS | Blastomycoides dermatitidis",,,,,,,,,,,,,,,"4277275","Blastomyces dermatitidis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1319201","Timed Up and Go Functional Test","C115795","A standardized rating scale developed by Mathias et al in 1986 which is used to test basic mobility skills in frail elderly persons and other populations such as people with arthritis, stroke, and vertigo. This functional test measures the time in seconds for a person to stand up from a standard armchair, walk 3 meters, turn, walk back to the chair, and sit down again. Scoring of this test is based on the average of multiple completed and timed trials.","Timed Up and Go Functional Test | TUG | TUG01",,,,,,,,,,,,,,,"4225699","Timed up and go mobility test",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898148","Neobladder","C117718","A urinary diversion after the removal of the urinary bladder that uses a loop of intestine that is surgically fashioned into a pouch and placed in the location of the original bladder and then attached to the ureters and urethra simulating the function of the original organ.","Neobladder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827216","Serum Collection Tube","C113675","A blood collection tube that contains a coagulant, designed for the collection of serum.","Serum Collection Tube | Red Top Tube",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2756364","13-valent pneumococcal vaccine","C97121","A pneumococcal conjugate vaccine containing 13 different strains of the bacterium Streptococcus pneumoniae, used in children and studied in immunocompromised patients for the prevention of pneumococcal disease. The pneumococcal 13-valent conjugate vaccine contains capsular antigen polysaccharides derived from the S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F that are individually conjugated to a nontoxic diphtheria cross-reactive material (CRM) carrier protein (CRM197). Upon vaccination, pneumococcal 13-valent conjugate vaccine induces active immunization against 13 different serotypes of S. pneumoniae and protects against pneumococcal disease.","Pneumococcal 13-valent Conjugate Vaccine | PCV 13 | PCV13 Vaccine | Prevnar 13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900206","16q23","C118183","A chromosome band present on 16q.","16q23 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900203","20q11","C118182","A chromosome band present on 20q.","20q11 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0056195","Complement Component-4d","C118185","C4d (380 aa, ~41 kDa) is a fragment of complement component-4. This protein plays a role in the regulation of the classical and lectin complement pathways. It may be a biomarker for complement activation during antibody-mediated rejection of transplants and in other pathological conditions.","C4d | C4D | Complement C4d | Complement Component 4d | Complement Component-4d",,,,,,,,,,,,,,,"4012400","Complement component C4d",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1418482","CFP Gene","C118197","This gene plays a role in the promotion of the alternative complement pathway.","CFP Gene | CFP | Complement Factor Properdin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414564","FDPS Gene","C118210","This gene plays a role in the biosynthesis of isoprenoids.","FDPS Gene | FDPS | Farnesyl Diphosphate Synthase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899078","Fucosyl GM1 Antibody","C118195","Any immunoglobulin that recognizes the fucosyl form of ganglioside GM1.","Fucosyl GM1 Antibody | Anti-Fucosyl GM1 Antibody | Anti-Fucosyl Ganglioside GM1 Antibody | Fucosyl Ganglioside GM1 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899072","GD2L Antibody","C118193","Any immunoglobulin that recognizes the lactone form of ganglioside GD2.","GD2L Antibody | Anti-GD2L Antibody | Anti-Ganglioside Lactone GD2 Antibody | Ganglioside Lactone GD2 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899071","GD3L Antibody","C118192","Any immunoglobulin that recognizes the lactone form of ganglioside GD3.","GD3L Antibody | Anti-GD3L Antibody | Anti-Ganglioside Lactone GD3 Antibody | Ganglioside Lactone GD3 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899025","Globo H Antibody","C118194","Any immunoglobulin that recognizes the hexasaccharide antigen Globo H.","Globo H Antibody | Anti-Globo H Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415727","HS3ST1 Gene","C118216","This gene plays a role in heparan sulfate metabolism.","HS3ST1 Gene | HS3ST1 | Heparan Sulfate (Glucosamine) 3-O-Sulfotransferase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416293","IGLL1 Gene","C118230","This gene plays a role in B-cell development.","IGLL1 Gene | IGLL1 | Immunoglobulin Lambda Like Polypeptide 1 Gene | Immunoglobulin Lambda-Like Polypeptide 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0236493","Influenza Virus Antibody","C118191","Any immunoglobulin that recognizes the influenza virus.","Influenza Virus Antibody | Anti-Influenza Virus Antibody",,,,,,,,,,,,,,,"4123979","Influenza antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3529576","M65-Antigen, Human","C118181","An antibody epitope that is part of uncleaved cytokeratin 18 found in blood samples. This antigen may be a biomarker for cell death induced by either alcohol consumption or chemotherapeutics.","M65-Antigen | M-65 | M65 | M65 Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898214","N-Propionylated Polysialic Acid Antibody","C118196","Any immunoglobulin that recognizes N-propionylated polysialic acid (NPrPSA).","N-Propionylated Polysialic Acid Antibody | Anti-N-Propionylated Polysialic Acid Antibody | Anti-NPrPSA Antibody | NPrPSA Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0171406","NADH Dehydrogenase (Ubiquinone)","C118184","A complex of over 40 proteins found in the inner mitochondrial membrane. This protein complex catalyzes the transfer of electrons from NADH to ubiquinone (coenzyme Q10) and plays a role in the initiation of the mitochondrial electron transport chain.","NADH Dehydrogenase (Ubiquinone) | Coenzyme Q Reductase | Complex 1 Dehydrogenase | Complex I | Complex I (Electron Transport Chain) | Complex I (Mitochondrial Electron Transport) | Complex I (NADH:Q1 Oxidoreductase) | DPNH-Coenzyme Q Reductase | DPNH-Ubiquinone Reductase | Dihydronicotinamide Adenine Dinucleotide-Coenzyme Q Reductase | EC 1.6.5.3 | Electron Transfer Complex I | Mitochondrial Complex I | Mitochondrial Electron Transport Complex 1 | Mitochondrial Electron Transport Complex I | Mitochondrial Respiratory Chain Complex I | NADH Coenzyme Q1 Reductase | NADH-CoQ Oxidoreductase | NADH-CoQ Reductase | NADH-Coenzyme Q Oxidoreductase | NADH-Coenzyme Q Reductase | NADH-Q6 Oxidoreductase | NADH-Ubiquinone Oxidoreductase | NADH-Ubiquinone Reductase | NADH-Ubiquinone-1 Reductase | NADH2 Dehydrogenase (Ubiquinone) | NADH:Ubiquinone Oxidoreductase | NADH:Ubiquinone Oxidoreductase Complex | NADH:Ubiquinone Reductase (H(+)-Translocating) | Reduced Nicotinamide Adenine Dinucleotide-Coenzyme Q Reductase | Respiratory Complex I | Type 1 Dehydrogenase | Ubiquinone Reductase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514030","Neoplastic Multinucleated Giant Cell","C36819","A benign or malignant neoplastic large cell that contains multiple nuclei and an abundant amount of cytoplasm.","Neoplastic Multinucleated Giant Cell | Giant Cell, Neoplastic Multinucleated | MNTGC | Multinucleated Tumor Giant Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421976","PCLO Gene","C118213","This gene is involved in the organization of proteins at the synapse.","PCLO Gene | PCLO | Piccolo Presynaptic Cytomatrix Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418716","PNOC Gene","C118219","This gene is involved in the modulation of both pain and locomotion.","PNOC Gene | PNOC | Prepronociceptin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3809964","SCHLAP1 Gene","C118202","This gene is involved in the malignancy of prostate cancer.","SCHLAP1 Gene | SCHLAP1 | SWI/SNF Complex Antagonist Associated With Prostate Cancer 1 (Non-Protein Coding) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1822706","SH2D1B Gene","C118224","This gene plays a role in immune receptor signaling.","SH2D1B Gene | SH2 Domain Containing 1B Gene | SH2D1B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420229","SLC8A1 Gene","C118227","This gene is involved in the modulation of cardiac muscle cell relaxation.","SLC8A1 Gene | SLC8A1 | Solute Carrier Family 8 (Sodium/Calcium Exchanger), Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515792","t(8;14)(q24;q32)","C36319","A chromosomal translocation that fuses 8q24 with 14q32. This juxtaposes the MYC gene with the promoter regions of the immunoglobulin heavy chain gene locus, which results in overexpression of Myc proto-oncogene protein in B-cells bearing the translocation.","t(8;14)(q24;q32) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427202","TOMM20 Gene","C118207","This gene plays a role in the transport of proteins into the mitochondrion.","TOMM20 Gene | TOMM20 | Translocase of Outer Mitochondrial Membrane 20 Homolog (Yeast) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008819","Male Circumcision","C87068","Surgical removal of the penile foreskin.","Male Circumcision | Circumcision | circumcision",,,,,,,,,,,,,,,"4218438","Circumcision",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897986","Past 24 Hours","C118250","The 24 hour period occurring just before the present time.","Past 24 Hours | Last 24 Hours | Past 24 hours | Within last 24 hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896645","Myeloproliferative Neoplasm Symptom Assessment Form","C118251","A self-administered questionnaire for monitoring the most debilitating symptoms experienced by patients with myeloproliferative neoplasms.","Myeloproliferative Neoplasm Symptom Assessment Form | MPN-SAF | Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897155","Worst Imaginable","C118252","The most severe state an individual can conceive of experiencing.","Worst Imaginable | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL475599","Filling up quickly when you eat","C118253","A question about whether an individual has experienced early satiety.","Early Satiety | Filling Up Quickly | Filling up quickly when you eat (Early satiety)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205254","Inactivity","C118254","A sedentary activity level.","Inactivity | Inactive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0220870","Lightheadedness","C118255","A feeling of faintness; a reeling sensation. Lightheadedness is medically distinct from dizziness, unsteadiness, and vertigo.","Lightheadedness | Light-headedness | Lightheaded",,,,,,,,,,,,,,,"4297376","Lightheadedness",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0278092","Sexual Function","C118256","The bodily processes that include arousal, erection, orgasm, and ejaculation.","Sexual Function | ",,,,,,,,,,,,,,,"4297301","Sexual function",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1283932","Unintentional","C118257","Not done on purpose.","Unintentional | Inadvertant | Not Deliberate | Not Intended | Unintended",,,,,,,,,,,,,,,"4177259","Unintentional",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3165508","No Fatigue","C118259","A response indicating that an individual has not experienced any fatigue.","No Fatigue | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897156","Worst Imaginable Fatigue","C118260","A response indicating that an individual has experienced the worst fatigue that they can conceive of experiencing.","Worst Imaginable Fatigue | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL475628","Does Not Interfere with Enjoyment of Life","C118261","A response indicating that a symptom does not interfere with an individual's enjoyment of life.","Does Not Interfere with Enjoyment of Life | Does Not Interfere | Does Not Interfere",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899517","Completely Interferes","C118262","A response indicating that a symptom completely interferes with an individual's enjoyment of life.","Completely Interferes | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898945","Have Numbness or Tingling in Hands and Feet","C118263","A response indicating that an individual has or had numbness or tingling in their hands and feet.","Have Numbness or Tingling in Hands and Feet | Numbness/Tingling (in my hands and feet) | Numbness/tingling in hands/feet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899380","Difficulty Absent","C118264","A response indicating that an individual has not experienced a particular difficulty.","Difficulty Absent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897157","Worst Imaginable Difficulty","C118265","A response indicating that a particular difficulty is the worst that an individual can conceive of experiencing.","Worst Imaginable Difficulty | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889662","FACT-ES Questionnaire","C118266","A subscale complement to the FACT-G developed specifically for evaluating the quality of life of patients experiencing specific symptoms related to the endocrine system.","FACT-ES Questionnaire | FACT-ES | Functional Assessment of Cancer Therapy-Endocrine System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898965","Have Cold Sweats","C118269","A question about whether an individual has or had cold sweats.","Have Cold Sweats | I have cold sweats",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898917","Have Vaginal Discharge","C118270","A question about whether an individual has or had vaginal discharge.","Have Vaginal Discharge | I have vaginal discharge",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898915","Have Vaginal Itching or Irritation","C118271","A question about whether an individual has or had vaginal itching or vaginal irritation.","Have Vaginal Itching or Irritation | I have vaginal itching/irritation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898918","Have Vaginal Bleeding or Spotting","C118272","A question about whether an individual has or had vaginal bleeding or spotting.","Have Vaginal Bleeding or Spotting | I have vaginal bleeding or spotting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898916","Have Vaginal Dryness","C118273","A question about whether an individual has or had vaginal dryness.","Have Vaginal Dryness | Dryness | I have vaginal dryness | Vaginal Dryness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898943","Have Pain or Discomfort with Intercourse","C118274","A question about whether an individual has or had pain or discomfort with intercourse.","Have Pain or Discomfort with Intercourse Question | Have Pain or Discomfort with Intercourse | Have Pain or Discomfort with Intercourse | Have you had any pain during intercourse | I have pain or discomfort with intercourse | Pain During Intercourse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898951","Have Lost Interest in Sex","C118275","A question about whether an individual has lost interest in sex.","Have Lost Interest in Sex | I have lost interest in sex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899150","Feel Lightheaded or Dizzy","C118277","A question about whether an individual feels or felt lightheaded or dizzy.","Feel Lightheaded or Dizzy | I feel lightheaded (dizzy)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898966","Have Breast Sensitivity or Tenderness","C118278","A question about whether an individual has or had breast sensitivity or tenderness.","Have Breast Sensitivity or Tenderness | I have breast sensitivity/tenderness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898949","Have Mood Swings","C118279","A question about whether an individual has or had mood swings.","Have Mood Swings | I have mood swings",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896992","Have Painful Joints","C118280","A question about whether an individual has or had painful joints.","Have Painful Joints | Have Pain in Joints | Have Pain in My Joints | I have pain in my joints",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574893","Orthotopic","C94384","Occurring in its normal location.","Orthotopic | orthotopic",,,,,,,,,,,,,,,"4185019","Orthotopic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008555","Gas Chromatography","C30014","A chromatographic technique in which the stationary phase is solid while the mobile phase is gaseous samples. The gaseous samples are separated based on their different adsorption ability to the solid phase.","Gas Chromatography | GC",,,,,,,,,,,,,,,"4153099","Gas chromatography measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027573","Neisseria gonorrhoeae","C86603","A species of aerobic, Gram-negative, diplococci shaped bacteria assigned to the phylum Proteobacteria. This species is oxidase and catalase positive, grows best on blood agar medium or chocolate medium, is non-hemolytic, produces acid from glucose, but not from maltose, fructose, sucrose, mannose or lactose, does not synthesize polysaccharides, and reduces nitrite but not nitrate. N. gonorrhoeae is the causative agent of gonorrhea and is transmitted via sexual contact.","Neisseria gonorrhoeae | NEISSERIA GONORRHOEAE",,,,,,,,,,,,,,,"4285582","Neisseria gonorrhoeae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0333262","Skin Vesicle","C111969","A small (less than 5-10 mm) intraepidermal/subepidermal cavity filled with clear, serosanguineous or cloudy fluid.","Skin Vesicle | Vesicle",,,,,,,,,,,,,,,"37311183|4220828","Vesicle of skin|Vesicle",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0015256","Excoriation","C34599","Self-inflicted tearing or wearing off of skin.","Excoriation | Excoriation of Skin",,,,,,,,,,,,,,,"4219876","Excoriation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL449208","Labial","C96267","Occurring in, or located in the lips or vagina.","Labial | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230190","Mons Pubis","C33139","A rounded prominence of adipose tissue overlying the pubic symphysis and adjacent pubic bone.","Mons Pubis | ",,,,,,,,,,,,,,,"4220066","Mons pubis structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2982175","Melanoma of the Ciliary Body and Choroid pT2d TNM Finding v7","C88695","Tumor size category 2 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter. (from AJCC 7th Ed.)","Melanoma of the Ciliary Body and Choroid pT2d TNM Finding v7 | T2d",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982180","Melanoma of the Ciliary Body and Choroid pT3d TNM Finding v7","C88700","Tumor size category 3 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter. (from AJCC 7th Ed.)","Melanoma of the Ciliary Body and Choroid pT3d TNM Finding v7 | T3d",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982186","Melanoma of the Ciliary Body and Choroid pT4e TNM Finding v7","C88706","Any tumor size category with extraocular extension more than 5 mm in diameter. (from AJCC 7th Ed.)","Melanoma of the Ciliary Body and Choroid pT4e TNM Finding v7 | T4e",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899237","Exoresection","C118358","A surgical technique for the transscleral resection of large, anteriorly located uveal melanomas with ciliary body and/or iris involvement. This approach is most common when conservative therapy is either unlikely to help, or likely to cause complications.","Exoresection | Local Resection (Exoresection; wall resection)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899264","Endoresection","C118359","A surgical technique used for the resection of posteriorly located uveal melanomas without ciliary body involvement via pars plana vitrectomy.","Endoresection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040509","Total Lung Capacity","C111325","The total volume of air in the lungs after maximum inhalation.","Total Lung Capacity | TLC | TLUNGCAP | Total lung capacity",,,,,,,,,,,,,,,"4239808","Total lung capacity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028405","North America","C26275","North America is a continent in the western hemisphere of Earth, bordered to the west by the Pacific Ocean, the east by the Atlantic Ocean, the north by the Arctic Ocean, and connected at the south to South America by the Isthmus of Panama.","North America | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517392","Gain of Chromosome 17","C36466","A cytogenetic abnormality that refers to the allelic gain of all or part of chromosome 17.","Gain of Chromosome 17 | Chromosome 17 Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512127","ERBB2 Gene Amplification","C36638","A molecular genetic abnormality indicating the presence of multiple copies of the ERBB2 gene.","ERBB2 Gene Amplification | ERBB2 Amplification | HER-2 Gene Amplification | HER2 Amplification | HER2 Gene Amplification | HER2/Neu Amplification | Positive | c-erbB2 Gene Activation | c-erbB2 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984891","Activating EGFR Mutation","C92172","A somatic mutation of the epidermal growth factor receptor gene which encodes a constitutively active 170kDa transmembrane protein, a short transmembrane region, and an intracellular domain.","Activating EGFR Gene Mutation | Activating EGFR Gene Mutation | Activating EGFR Mutation | Activating ERBB1 Mutation | Activating HER1 Mutation | Activating c-erbB1 Mutation | EGFR Activating Mutation | EGFR Activating Mutation | EGFR Gain of Function Gene Mutation | Epidermal Growth Factor Receptor Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512117","EGFR Protein Overexpression","C39716","A molecular genetic abnormality indicating the presence of an abnormally high level of EGFR protein.","EGFR Protein Overexpression | EGFR Overexpression | Epidermal Growth Factor Receptor Overexpression | Proto-Oncogene c-ErbB-1 Overexpression | Receptor Tyrosine-Protein Kinase erbB-1 Overexpression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273084","EGFR-TKI Resistant Mutation","C96862","A molecular genetic abnormality indicating the presence of resistance in the epidermal growth factor receptor-tyrosine kinase inhibitor domain, due to secondary mutations of the EGFR gene.","EGFR-TKI Resistant Mutation | EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance | EGFR Tyrosine Kinase Inhibitor Resistant Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274884","EML4/ALK Fusion Gene Variant 3b","C99729","A fusion gene (~2.5 kb) that results from a chromosomal inversion inv(2)(p21p23) which fuses exon 6b of the EML4 gene with exons 20-29 of the ALK gene. This fusion is associated with non-small cell lung cancer. Multiple transcript variants are possible based on the breakpoint for the EML4 gene.","EML4/ALK Fusion Gene Variant 3b | EML4-ALK Fusion Gene Variant 3b | EML4-ALK Variant 3 Splicing Isoform b Fusion Gene | EML4::ALK Fusion Gene Variant 3b | Transforming Fusion Gene EML4-ALK Variant 3b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274882","EML4/ALK Fusion Gene Variant 3a","C99727","A fusion gene (~2.5 kb) that results from a chromosomal inversion inv(2)(p21p23) which fuses exon 6a of the EML4 gene with exons 20-29 of the ALK gene. This fusion is associated with non-small cell lung cancer. Multiple transcript variants are possible based on the breakpoint for the EML4 gene.","EML4/ALK Fusion Gene Variant 3a | EML4-ALK Fusion Gene Variant 3a | EML4-ALK Variant 3 Splicing Isoform a Fusion Gene | EML4::ALK Fusion Gene Variant 3a | Transforming Fusion Gene EML4-ALK Variant 3a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274887","EML4/ALK Fusion Gene Variant 5b","C99732","A fusion gene (~2.1 kb) that results from a chromosomal inversion inv(2)(p21p23) which fuses exon 2 of the EML4 gene with approximately 115 nucleotides of intron 19 and exons 20-29 of the ALK gene. This fusion is associated with non-small cell lung cancer.","EML4/ALK Fusion Gene Variant 5b | EML4-ALK Fusion Gene Variant 5b | EML4-ALK Variant 5 Splicing Isoform b Fusion Gene | EML4::ALK Fusion Gene Variant 5b | Transforming Fusion Gene EML4-ALK Variant 5b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274886","EML4/ALK Fusion Gene Variant 5a","C99731","A fusion gene (~2.0 kb) that results from a chromosomal inversion inv(2)(p21p23) which fuses exon 2 of the EML4 gene with exons 20-29 of the ALK gene. This fusion is associated with non-small cell lung cancer.","EML4/ALK Fusion Gene Variant 5a | EML4-ALK Fusion Gene Variant 5a | EML4-ALK Variant 5 Splicing Isoform a Fusion Gene | EML4::ALK Fusion Gene Variant 5a | Transforming Fusion Gene EML4-ALK Variant 5a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273087","ERBB2 Gene Mutation","C96866","A molecular genetic abnormality indicating the presence of a mutation in the ERBB2 gene on chromosome 17q12.","ERBB2 Gene Mutation | ERBB2 Mutation | Erb-B2 Receptor Tyrosine Kinase 2 Gene Mutation | Erb-B2 Receptor Tyrosine Kinase Gene Mutation | HER2 Gene Mutation | HER2/neu Gene Mutation | NEU Gene Mutation | Positive | v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707864","ERBB2 Gene Product","C45842","A protein encoded by the ERBB2 gene.","ERBB2 Gene Product | ERBB2 Protein | ERBB2 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517649","KRAS Gene Mutation","C41361","A change in the nucleotide sequence of the KRAS gene.","KRAS Gene Mutation | K-RAS Mutation | KRAS Mutation | KRAS-2 Gene Mutation | KRAS2 Gene Mutation | Positive | c-K-ras Gene Mutation | v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517648","KRAS Gene Amplification","C36665","A molecular genetic abnormality indicating the presence of multiple copies of the KRAS gene.","KRAS Gene Amplification | KRAS Gene Activation | KRAS-2 Gene Amplification | KRAS2 Gene Amplification | KRAS2 Gene Amplification | c-K-ras Gene Amplification | v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882495","Protein Expression Analysis","C63480","Any method of protein detection that can be used to quantify the level of a protein in a sample.","Protein Expression Analysis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879389","MLH1 Gene","C18482","This gene plays a role in DNA mismatch repair.","MLH1 Gene | MLH1 | MutL Homolog 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4255275","MSH2 protein, human","C21466","DNA mismatch repair protein Msh2 (934 aa, ~105 kDa) is encoded by the human MSH2 gene. This protein is involved in DNA mismatch repair.","DNA Mismatch Repair Protein Msh2 | DNA Mismatch Repair Protein MSH2 | MSH2 | MutS Homolog 2 | MutS Protein Homolog 2 | hMSH2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512430","High-Frequency Microsatellite Instability","C36493","The presence of genomic instability associated with defective DNA mismatch repair in greater than 30% of the microsatellite instability (MSI) biomarkers in a tumor sample.","High-Frequency Microsatellite Instability | High | MSI high | MSI-H | Microsatellite Instability High | Microsatellite Instability-High",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709126","NF2 Gene Mutation","C45669","A molecular genetic abnormality that refers to the mutation of the NF2 gene located at 22q12.2.","NF2 Gene Mutation | ACN Gene Mutation | BANF Gene Mutation | Merlin Gene Mutation | NF2 Mutation | Neurofibromin 2 Gene Mutation | SCH Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205644","Granular Cell Carcinoma","C3681","An adenocarcinoma characterized by the presence of malignant epithelial cells with granular cytoplasm.","Granular Cell Carcinoma | Granular Cell Adenocarcinoma | Granular cell adenocarcinoma | Granular cell carcinoma","8320/3","Granular cell carcinoma",,,,,,,,,,,,,"4288763","Granular cell carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C3891714","Growing Teratoma Syndrome","C118370","A condition characterized by the presence of a growing mature teratoma in a patient during or after chemotherapy for a non-seminomatous germ cell tumor, with normal serum markers for human chorionic gonadotropin and alpha fetoprotein. Complete surgical resection is the preferred treatment.","Growing Teratoma Syndrome | GTS",,,,,,,,,,,,,,,"37166831","Growing teratoma syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899174","FGF Gene Amplification","C118376","A molecular genetic abnormality indicating the presence of multiple copies of an FGF family gene.","FGF Gene Amplification | EGFR Overexpression | FGF Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899173","FGFR Gene Amplification","C118378","A molecular genetic abnormality indicating the presence of multiple copies of an FGFR family gene.","FGFR Gene Amplification | FGF Receptor Gene Amplification | FGF Receptor Gene Family Amplification | FGFR Amplification | FGFR Family Amplification | FGFR Family Gene Amplification | Fibroblast Growth Factor Receptor Family Gene Amplification | Fibroblast Growth Factor Receptor Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897100","FGFR Gene Translocation","C118377","A cytogenetic abnormality that refers to the translocation of an FGFR family gene to a new chromosomal location.","FGFR Gene Translocation | FGF Receptor Gene Family Translocation | FGF Receptor Gene Translocation | FGFR Family Gene Translocation | FGFR Family Translocation | FGFR Translocation | Fibroblast Growth Factor Receptor Gene Family Translocation | Fibroblast Growth Factor Receptor Gene Translocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899030","Germline Genotype Testing","C118383","An assay used to determine the genes and molecular markers present in the germline DNA of an individual.","Germline Genotype Testing | Germline Genotype Analysis | Germline Genotyping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899176","FAP Gene Mutation","C118386","A change in the nucleotide sequence of the FAP gene.","FAP Gene Mutation | FAP Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898552","MEN1 Gene Mutation","C118387","A change in the nucleotide sequence of the MEN1 gene.","MEN1 Gene Mutation | MEA I Gene Mutation | MEAI Gene Mutation | MEN I Gene Mutation | MEN1 Mutation | Menin 1 Gene Mutation | Menin Gene Mutation | Multiple Endocrine Neoplasia 1 Gene Mutation | Multiple Endocrine Neoplasia I Gene Mutation | SCG2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898206","NF1 Gene Mutation","C118388","A change in the nucleotide sequence of the NF1 gene.","NF1 Gene Mutation | NF1 Mutation | NF1 mutation | NFNS Gene Mutation | Neurofibromin 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898827","IDH1 Gene Mutation","C118389","A change in the nucleotide sequence of the IDH1 gene.","IDH1 Gene Mutation | IDH1 Mutation | Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic Gene Mutation | Isocitrate Dehydrogenase 1 (NADP+), Soluble Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898824","IDH2 Gene Mutation","C118390","A change in the nucleotide sequence of the IDH2 gene.","IDH2 Gene Mutation | C118390 | IDH2 Mutation | Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial Gene Mutation | Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898644","KRAS Activating Mutation","C118391","A change in the nucleotide sequence of the KRAS gene that that results in constitutive signal transduction, which stimulates downstream signaling pathways involved in cell growth, proliferation, invasion, and metastasis. The presence of KRAS activating mutations in colorectal cancer and non-small-cell lung cancer is used identify the subgroup of patients who are most likely to respond to EGFR antagonist chemotherapy.","KRAS Activating Mutation | Activating KRAS Mutation | KRAS Proto-Oncogene, GTPase Activating Mutation | KRAS-2 Activating Mutation | KRAS2 Activating Mutation | c-K-ras Activating Mutation | v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898547","MLH1 Gene Mutation","C118394","A change in the nucleotide sequence of the MLH1 gene.","MLH1 Gene Mutation | COCA2 Gene Mutation | HNPCC2 Gene Mutation | MLH1 Mutation | MutL Homolog 1 Gene Mutation | MutL, E. coli, Homolog of, 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898500","MSH6 Gene Mutation","C118395","A change in the nucleotide sequence of the MSH6 gene.","MSH6 Gene Mutation | HNPCC5 Gene Mutation | MSH6 Mutation | MutS Homolog 6 Gene Mutation | MutS, E. coli, Homolog of, 6 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897380","TP53 Gene Mutation","C118396","A change in the nucleotide sequence of the TP53 gene.","TP53 Gene Mutation | Abnormal | P53 Gene Mutation | Positive | TP53 | TP53 Mutated | TP53 Mutation | Tumor Protein p53 Gene Mutation | Yes | p53 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898042","PMS2 Gene Mutation","C118397","A change in the nucleotide sequence of the PMS2 gene.","PMS2 Gene Mutation | HNPCC4 Gene Mutation | MLH4 Gene Mutation | PMS1 Homolog 2, Mismatch Repair System Component Gene Mutation | PMS2 Mutation | PMS2CL Gene Mutation | PMSL2 Gene Mutation | Postmeiotic Segregation Increased (S. cerevisiae) 2 Gene Mutation | Postmeiotic Segregation Increased 2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897371","Tartrate Resistant Acid Phosphatase Staining Method","C118401","A staining method used to demonstrate the presence of acid phosphatase and tartrate resistant acid phosphatase (TRAP) in osteoclasts.","Tartrate Resistant Acid Phosphatase Staining Method | TRACP Staining | TRAP Stain | TRAP Staining",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897378","TSC1 Gene Mutation","C118398","A change in the nucleotide sequence of the TSC1 gene.","TSC1 Gene Mutation | Hamartin Gene Mutation | TSC Gene Mutation | TSC1 Mutation | Tuberous Sclerosis 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897377","TSC2 Gene Mutation","C118399","A change in the nucleotide sequence of the TSC2 gene.","TSC2 Gene Mutation | TSC2 Mutation | Tuberin Gene Mutation | Tuberous Sclerosis 2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897209","VHL Gene Mutation","C118400","A change in the nucleotide sequence of the VHL gene.","VHL Gene Mutation | HRCA1 Gene Mutation | RCA1 Gene Mutation | VHL Mutation | VHL1 Gene Mutation | Von Hippel-Lindau Syndrome Gene Mutation | Von Hippel-Lindau Tumor Gene Mutation | Von Hippel-Lindau Tumor Suppressor Gene Mutation | Von Hippel-Lindau Tumor Suppressor Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3715062","Twenty Five","C113663","A natural number greater than twenty-four and less than twenty-six and the quantity that it denotes.","Twenty Five | 25 | Twenty-Five",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2707644","PDGFRA Gene Rearrangement","C84271","Rearrangement of the PDGFRA gene, resulting in the formation of a fusion transcript and aberrant tyrosine kinase activity. It has been described in hematologic malignancies usually presenting as chronic eosinophilic leukemia.","PDGFRA Gene Rearrangement | CD140A Gene Rearrangement | PDGFR-2 Gene Rearrangement | PDGFR2 Gene Rearrangement | PDGFRA Rearrangement | PDGFRalpha Gene Rearrangement | Platelet-Derived Growth Factor Receptor Alpha Gene Rearrangement | RHEPDGFRA Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827357","PDGFRB Gene Rearrangement","C84272","Rearrangement of the PDGFRB gene, resulting in the formation of a fusion transcript and aberrant tyrosine kinase activity. It has been described in myeloid malignancies usually presenting as chronic myelomonocytic leukemia.","PDGFRB Gene Rearrangement | CD140b Gene Rearrangement | JTK12 Gene Rearrangement | PDGFR1 Gene Rearrangement | Platelet Derived Growth Factor Receptor Beta Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1563738","Oncolytic Virus Therapy","C62713","A targeted therapy that uses viral infection to cause the lysis of tumor cells.","Oncolytic Virus Therapy | Oncolytic virotherapy | oncolytic virotherapy | oncolytic virus therapy | viral therapy | virotherapy",,,,,,,,,,,,,,,"619602","Oncolytic viral therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0684199","Homeopathy Therapy","C15718","A method of treating disease with small amounts of remedies that, in large amounts in healthy people, produce symptoms similar to those being treated. Homeopathy seeks to stimulate the body's defense mechanisms and processes so as to prevent or treat illness.","Homeopathy Therapy | Homeopathic | Homeopathic Remedy | Homeopathy | homeopathic medicine | homeopathy",,,,,,,,,,,,,,,"4082729","Homeopathic therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0260314","Urologist","C17826","A doctor who specializes in diseases of the urinary organs in females and the urinary and sex organs in males.","Urologist | UROLOGIST | urologist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273907","Thiazolidinedione Antidiabetic Agent","C98241","Any antidiabetic agent with the glitazone (thiazolidinedione) base structure with antihyperglycemic activity. Glitazone antidiabetic agents selectively bind to and stimulate the nuclear receptor peroxisome proliferator-activated receptor (PPAR) gamma. This results in the selective transcription of a number of insulin-sensitive genes involved in glucose metabolism. This eventually enhances insulin sensitivity, reduces insulin resistance and decreases hepatic gluconeogenesis. PPARs function as transcription factors that regulate expressions of genes involved in cellular differentiation, development, and metabolism (carbohydrate, lipid, protein), as well as tumorigenesis; PPARgamma is expressed at high levels in adipose tissue.","Thiazolidinedione Antidiabetic Agent | Thiazolidinedione",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3472616","Mixed Phenotype Acute Leukemia, B/Myeloid","C82212","A rare mixed phenotype acute leukemia in which the blasts express B-lymphoid and myeloid lineage markers but are negative for KMT2A rearrangement and t(9;22)(q34;q11.2) translocation. The prognosis is usually unfavorable.","Mixed Phenotype Acute Leukemia, B/Myeloid | MPAL, B/Myeloid, NOS | Mixed Phenotype Acute Leukemia, B/Myeloid, NOS | Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified | Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified | Mixed phenotype acute leukemia, B/myeloid, NOS","9808/3","Mixed phenotype acute leukemia, B/myeloid, NOS",,,,,,,,,,,,,"42872921","Mixed phenotype acute leukemia B/myeloid",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C2826055","Mixed Phenotype Acute Leukemia, T/Myeloid","C82213","A rare mixed phenotype acute leukemia in which the blasts express T-lymphoid and myeloid lineage markers but are negative for KMT2A rearrangement and t(9;22)(q34;q11.2) translocation. The prognosis is usually unfavorable.","Mixed Phenotype Acute Leukemia, T/Myeloid | MPAL, T/Myeloid, NOS | Mixed Phenotype Acute Leukemia, T/Myeloid, NOS | Mixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified | Mixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified | Mixed phenotype acute leukemia, T/myeloid, NOS","9809/3","Mixed phenotype acute leukemia, T/myeloid, NOS",,,,,,,,,,,,,"42872922","Mixed phenotype acute leukemia T/myeloid",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0542080","Hypercellular Bone Marrow","C35788","An abnormal finding in a bone marrow aspirate or biopsy specimen indicating increased cellularity. It can result from hyperplasia of one or more hematopoietic cell lines or malignant neoplasms that affect the bone marrow.","Hypercellular Bone Marrow | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898794","Immunogenicity Specimen Assessments Original Result","C117559","The outcome of the immunogenicity specimen assessment as originally received or collected.","Immunogenicity Specimen Assessments Original Result | ISORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274478","Granulocyte to Total Cell Ratio Measurement","C98866","The determination of the ratio of granulocytes compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Granulocyte to Total Cell Ratio Measurement | GRANCE | Granulocytes to Total Cells Ratio Measurement | Granulocytes/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035295","Reticulum","C98777","Smallest forestomach of ruminants with complex honeycomb folding of mucosa.","Reticulum | RETICULUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1318478","Trichrome Staining Method","C23012","A histological staining method that uses acid dyes and washes to selectively dye the structural elements in tissue samples in three or more contrasting colors.","Trichrome Staining Method | TRICHROME STAIN",,,,,,,,,,,,,,,"4018451|45769418","Trichrome stain method|Trichrome stain",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL453628","Cellularity Measurement","C111153","The determination of the amount of degree, quality or condition of cells present in a sample.","Cellularity Measurement | CELLULAR | Cellularity | Cellularity Grade | Cellularity Index | Percent Cellularity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2919017","Distortion","C83007","An undesired change to the shape of an object, or to inaccurately alter the meaning of a concept.","Distortion | ",,,,,,,,,,,,,,,"4051449","Abnormal shape",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0080093","N-Methyl-D-Aspartate Receptors","C118457","A protein complex that plays a role in both NMDA binding and ion transport. It is a heterotetramer consisting of 2 glutamate [NMDA] receptor subunit zeta-1 proteins and 2 epsilon subunits (glutamate [NMDA] receptor subunit epsilon-1, -2, -3 or -4).","N-Methyl-D-Aspartate Receptor | N-Methyl-D-aspartate receptor | NMDA RECEPTOR | NMDA Receptor | NMDA Receptor Complex | NMDAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889656","Turbo Field Echo MRI","C118461","A magnetic resonance imaging modality that uses a gradient echo pulse sequence with data acquisition after an initial 180 degree preparation pulse for contrast enhancement. TFE provides contrast at shorter echo times and acquisition times, thus reducing related image artifacts.","Turbo Field Echo MRI | TFE | TFE MRI | Turbo Field Echo | Turbo field echo MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898475","Magnetization-Prepared Rapid Gradient Echo MRI","C118462","A magnetic resonance imaging modality that offers rapid imaging time, easy reconstruction of any plane, and three-dimensional surface contour rendering with cut away postprocessing. Especially useful for imaging brain, MP-RAGE captures high tissue contrast and provides high spatial resolution with whole brain coverage in a short scan time.","Magnetization-Prepared Rapid Gradient Echo MRI | MP RAGE | MP-RAGE | MP-RAGE MRI | MPRAGE | Magnetization-Prepared Rapid Gradient Echo | Magnetization-prepared rapid gradient echo MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897360","Three-Dimensional Spoiled Gradient MRI","C118463","A magnetic resonance imaging modality that uses acquisition in the steady state with semi-random changes in the phase of the radio frequency pulses to produce a spatially independent phase shift. This optimizes the signal-to-noise ratio to provide high resolution and a decrease in the partial volume phenomenon.","Three-Dimensional Spoiled Gradient MRI | 3-Dimensional Fast Spoiled Gradient | 3D FSPGR | 3D Fast Spoiled Gradient Definition: Recalled MRI | 3D Fast Spoiled Gradient Recalled MRI | 3DFSPGR | FSPGR | FSPGR MRI | SPGR | SPGR MRI | Three-Dimensional Spoiled Gradient-Echo MR | Three-dimensional spoiled gradient MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897397","T2 and Fluid Attenuated Inversion Recovery MRI","C118465","A magnetic resonance imaging modality that uses an inversion-recovery pulse sequence to nullify the signal from fluids.","T2 and Fluid Attenuated Inversion Recovery MRI | T2 and Fluid Attenuated Inversion Recovery Brain MRI | T2/FLAIR | T2/FLAIR MRI | T2/FLAIR Signal | Transverse relaxation time/Fluid attenuated inversion recovery MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899166","FKSI-15 Questionnaire","C118498","A 15 item questionnaire developed to assess the symptom burden for patients with kidney cancer.","FKSI-15 Questionnaire | FAC039 | FKSI-15 | Functional Assessment for Cancer Therapy-Kidney Symptom Index",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899182","FACT-BP Questionnaire","C118499","A subscale complement to the FACT-G developed specifically for evaluating the quality of life of cancer patients with bone pain associated with bone metastases.","FACT-BP Questionnaire | FACT-BP | FACT-Bone Pain Questionnaire | Functional Assessment of Cancer Therapy-Bone Pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897806","RCC Symptom Index","C118500","A 30 item questionnaire developed to assess the symptom burden and quality of life for patients with renal cell carcinoma.","RCC Symptom Index | RCC-SI | Renal Cell Carcinoma-Symptom Index",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898967","Have Bone Pain","C118501","A question about whether an individual has or had bone pain.","Have Bone Pain | I have bone pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897131","Bothered by Fevers","C118502","A question about whether an individual is or was bothered by fevers.","Bothered by Fevers | Bothered by Fever | I am bothered by fevers (episodes of high body temperature)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898968","Have Blood in Urine","C118503","A question about whether an individual has or had blood in their urine.","Have Blood in Urine | Blood in Urine | I have had blood in my urine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899183","FACT-B Questionnaire","C118506","A subscale complement to the FACT-G developed specifically for evaluating the quality of life of breast cancer patients.","FACT-B Questionnaire | FACT-B | Functional Assessment of Cancer Therapy-Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0585330","QPM","C64596","Every afternoon or evening, after 12:00pm.","QPM | Every Evening | quaque post meridiem",,,,,,,,,,,,,,,"4288400","Once a day, in the evening",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898501","MRI Ultrasound Fusion Guided Biopsy","C118510","A method for targeted biopsy that merges images captured by multiparametric MRI with real-time ultrasound, creating a synthetic, 3D image, which highlights the suspicious area within the image.","MRI Ultrasound Fusion Guided Biopsy | Fusion Biopsy | Fusion Guided Biopsy | Fusion-Guided Biopsy | MR Fusion Biopsy | MRI-Ultrasound Fusion Biopsy | MRI/US Biopsy | MRI/Ultrasound Fusion Biopsy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899483","Cutaneous Melanoma In-Transit Metastasis","C118512","Intralymphatic metastasis of cutaneous melanoma between the primary melanoma site and the regional lymph node basin. (from AJCC 7th Ed.)","Cutaneous Melanoma In-Transit Metastasis | In-Transit Metastasis of Cutaneous Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883256","Systemic Chemotherapy","C64261","Chemotherapy where the agent travels throughout the body by blood circulation.","Systemic Chemotherapy | systemic chemotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4023140","Neutrophilia","C35164","Abnormally high level of neutrophils in the blood.","Neutrophilia | Granulocytosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423585","SETBP1 Gene","C106635","This gene may be involved in the modulation of protein SET activity.","SETBP1 Gene | SET Binding Protein 1 Gene | SETBP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL378222","X-ray Angiography","C20080","Any nuclear medicine study that utilizes a radioactive tracer to image blood vessels or characterize blood flow.","X-ray Angiography | ANGIOGRAPHY | Angiography | Angiography | Radioangiography | angiography",,,,,,,,,,,,,,,"4299523","Angiography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0430876","Fluorescence Imaging","C116489","An imaging technique that uses fluorescent dye to achieve the desired image.","Fluorescence Imaging | ",,,,,,,,,,,,,,,"4099367","Fluorescence imaging",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899149","Feel Listless","C118594","A question about whether an individual feels or felt listless.","Feel Listless | I feel listless ('washed out')",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898919","Have Trouble Starting Things Because of Tiredness","C118595","A question about whether an individual has or had trouble starting things because they are tired.","Have Trouble Starting Things Because of Tiredness | I had trouble starting things because I was too tired | I have trouble starting things because I am tired",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898927","Have Trouble Finishing Things Because of Tiredness","C118596","A question about whether an individual has or had trouble finishing things because they are tired.","Have Trouble Finishing Things Because of Tiredness | I have trouble finishing things because I am tired",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898957","Have Energy","C118600","A question about whether an individual has or had energy.","Have Energy | I have energy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897008","Need to Sleep During Day","C118602","A question about whether an individual needs or needed to sleep during the day.","Need to Sleep During Day | I need to sleep during the day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897355","Too Tired to Eat","C118603","A question about whether an individual is or was too tired to eat.","Too Tired to Eat | I am too tired to eat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898152","Need Help Doing Usual Activities","C118604","A question about whether an individual needs or needed help doing their usual activities.","Need Help Doing Usual Activities | I need help doing my usual activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899079","Frustrated by Being Too Tired to Do Things","C118605","A question about whether an individual is or was frustrated by being too tired to do the things they want to do.","Frustrated by Being Too Tired to Do Things | I am frustrated by being too tired to do the things I want to do",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898911","Have to Limit Social Activities Because of Tiredness","C118606","A question about whether an individual has or had to limit social activity because they are tired.","Have to Limit Social Activities Because of Tiredness Question | Have to Limit Social Activities Because of Tiredness | Have to Limit Social Activities Because of Tiredness | I have to limit my social activity because I am tired",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899178","FACT-En Questionnaire","C118607","A subscale complement to the FACT-G developed specifically for evaluating the quality of life of patients with endometrial cancer.","FACT-En Questionnaire | FACT-En | Functional Assessment of Cancer Therapy-Endometrial Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899179","FACT-Cx Questionnaire","C118608","A subscale complement to the FACT-G developed specifically for evaluating the quality of life of patients with cancer of the cervix.","FACT-Cx Questionnaire | FACT-Cx | Functional Assessment of Cancer Therapy-Cervical Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900204","17q13","C118478","A chromosome band present on 17q.","17q13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825822","ABHD12 Gene","C118545","This gene plays a role in endocannabinoid metabolism.","ABHD12 Gene | ABHD12 | Abhydrolase Domain Containing 12 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0684287","aldehyde dehydrogenases","C118481","A family of enzymes that catalyze the oxidation and detoxification of aldehydes.","Aldehyde Dehydrogenase | ALDH | ALDH Family | Aldehyde Dehydrogenase (NAD) | Aldehyde Dehydrogenase (NADP) | Aldehyde Dehydrogenase Family | Aldehyde Dehydrogenase [NAD(P)+] | Aldehyde Dehydrogenase [NAD(P)] | Aldehyde:NAD(P)+ Oxidoreductase | Aldehyde:NADP+ Oxidoreductase | NAD-Aldehyde Dehydrogenase | NAD-Dependent 4-Hydroxynonenal Dehydrogenase | NAD-Dependent Aldehyde Dehydrogenase | NAD-Linked Aldehyde Dehydrogenase | NADP-Acetaldehyde Dehydrogenase | NADP-Dependent Aldehyde Dehydrogenase | Propionaldehyde Dehydrogenase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413944","ASAP1 Gene","C118597","This gene plays a role in the regulation of signal transduction pathways.","ASAP1 Gene | ASAP1 | ArfGAP with SH3 Domain, Ankyrin Repeat and PH Domain 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825092","ASS1 Gene","C118540","This gene is involved in amino acid biosynthesis.","ASS1 Gene | ASS1 | Argininosuccinate Synthase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412653","ATP5F1B Gene","C118525","This gene plays a role in both oxidative phosphorylation and ATP synthesis.","ATP5F1B Gene | ATP Synthase F1 Subunit Beta Gene | ATP Synthase, H+ Transporting, Mitochondrial F1 Complex, Beta Polypeptide Gene | ATP5B | ATP5B Gene | ATP5B Gene | ATP5F1B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986801","Planar Imaging","C94954","Implementation of a gamma camera to obtain 2D images with no tomographic reconstruction process being involved.","Planar Imaging | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0053932","Bone Morphogenetic Proteins","C17274","A protein family that is part of the transforming growth factor-beta superfamily. This family is comprised of structurally related, non-collagenous proteins that regulate bone and cartilage growth. These proteins are synthesized as precursor molecules, which are cleaved by proteolytic enzymes, and can form active homodimers or heterodimers.","Bone Morphogenetic Protein | BMP | BMP Family | Bone Morphogenetic Protein Family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423701","BPIFA1 Gene","C118516","This gene may be involved in innate immune responses in the upper airway.","BPIFA1 Gene | BPI Fold Containing Family A, Member 1 Gene | BPIFA1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413154","CBR1 Gene","C118563","This gene plays a role in the metabolism of a wide variety of carbonyl compounds.","CBR1 Gene | CBR1 | Carbonyl Reductase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0108790","CD45RB","C118493","CD45RB (1192 aa, ~136 kDa) is encoded by the human PTPRC gene. This protein is involved in both protein dephosphorylation and lymphocyte activity. It is an isoform of receptor-type tyrosine-protein phosphatase C that is missing the amino acids encoded by exons 4 and 6 of the PTPRC gene.","CD45RB | CD45RB Antigen | Receptor-Type Tyrosine-Protein Phosphatase C Isoform 7 | Receptor-Type Tyrosine-Protein Phosphatase C Isoform CD45RB",,,,,,,,,,,,,,,"4184443","Lymphocyte antigen CD45RB",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1413310","CEACAM8 Gene","C118588","This gene may play a role in the modulation of immunity.","CEACAM8 Gene | CEACAM8 | Carcinoembryonic Antigen-Related Cell Adhesion Molecule 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1842325","CHST15 Gene","C118522","This gene is involved in chondroitin sulfate metabolism.","CHST15 Gene | CHST15 | Carbohydrate (N-Acetylgalactosamine 4-Sulfate 6-O) Sulfotransferase 15 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890599","Circulating Melanoma Cell","C118497","A melanoma-derived cell found in the peripheral blood.","Circulating Melanoma Cell | CMC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413808","CTRC Gene","C118557","This gene plays a role in zymogen activation.","CTRC Gene | CTRC | Chymotrypsin C (Caldecrin) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2732647","Cytokine Antibody","C118490","Any immunoglobulin that recognizes a cytokine.","Cytokine Antibody | Anti-Cytokine Antibody",,,,,,,,,,,,,,,"40485444","Cytokine antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0236511","Cytomegalovirus Antibody","C118487","Any immunoglobulin that recognizes the cytomegalovirus virus.","Cytomegalovirus Antibody | Anti-CMV Antibody | Anti-Cytomegalovirus Antibody | CMV Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL480161","Damage-Associated Molecular Pattern Molecule","C118474","Molecules released during times of cellular stress or necrosis, that can induce or perpetuate the non-infectious immune response.","Damage-Associated Molecular Pattern Molecule | Alarmin | DAMP | Damage Associated Molecular Pattern | Damage-Associated Molecular Pattern | Danger Associated Molecular Pattern | Danger-Associated Molecular Pattern | Danger-Associated Molecular Pattern Molecule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414316","EGR3 Gene","C118519","This gene plays a role in mitogen-dependent transcriptional regulation.","EGR3 Gene | EGR3 | Early Growth Response 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420836","EP400 Gene","C118531","This gene plays a role in the regulation of histone acetylation.","EP400 Gene | E1A Binding Protein P400 Gene | EP400",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0236525","Epstein-Barr Virus Antibody","C118489","Any immunoglobulin that recognizes the Epstein-Barr virus.","Epstein-Barr Virus Antibody | Anti-EBV Antibody | Anti-Epstein-Barr Virus Antibody | Anti-HHV-4 Antibody | Anti-HHV4 Antibody | Anti-Human Herpesvirus 4 Antibody | EBV Antibody | HHV-4 Antibody | HHV4 Antibody | Human Herpesvirus 4 Antibody",,,,,,,,,,,,,,,"4024981","Epstein-Barr virus antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1422839","F11R Gene","C118591","This gene is involved in the formation of cell-cell junctions.","F11R Gene | F11 Receptor Gene | F11R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414598","FGF13 Gene","C118513","This gene plays a role in neural development.","FGF13 Gene | FGF13 | Fibroblast Growth Factor 13 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3893229","G1/S-Specific Cyclin-D1b, human","C118477","G1/S-specific cyclin-D1b is encoded by the human CCND1 gene. This protein may play a role in the promotion of tumor cell invasiveness and anchorage-independent growth.","G1/S-Specific Cyclin-D1b | CCND1b | Cyclin D1b | Cyclin-D1b | G1/S-Specific Cyclin D1b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889125","HLA Class I Histocompatibility Antigen, A-0301 Alpha Chain","C118485","HLA class I histocompatibility antigen, A-0301 alpha chain (365 aa, ~41 kDa) is encoded by the human HLA-A gene. This protein is involved in the presentation of foreign antigens to the immune system. This isoform is associated with increased risk for multiple sclerosis and is a secondary risk factor for myasthenia gravis.","HLA Class I Histocompatibility Antigen, A-0301 Alpha Chain | A*0301 | A*03010101 | A*03011 | A3.1 | HLA-A*03 | HLA-A*0301 | HLA-A*030101 | HLA-A*03011 | HLA-A0301 | HLA-A0301 Antigen | HLA-A3 | HLA-A3.1 | Leukocyte Antigen Class I-A0301 | MHC Class I Antigen A*0301 | MHC Class I Antigen HLA-A0301 Heavy Chain | Major Histocompatibility Complex, Class I, A*0301 | Major Histocompatibility Complex, Class I, A0301",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1291922","Human Herpesvirus 1 Antibody","C118488","Any immunoglobulin that recognizes the human herpesvirus 1.","Human Herpesvirus 1 Antibody | Anti-HHV-1 Antibody | Anti-HHV1 Antibody | Anti-HSV-1 Antibody | Anti-HSV1 Antibody | Anti-Herpes Simplex Virus 1 Antibody | Anti-Human Herpesvirus 1 Antibody | HHV-1 Antibody | HHV1 Antibody | HSV-1 Antibody | HSV1 Antibody | Herpes Simplex Virus 1 Antibody",,,,,,,,,,,,,,,"4044264","Human alphaherpesvirus 1 antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898781","Immunoglobulin Heavy Chain Diversity Region","C13443","The portion of the immunoglobulin heavy chain hypervariable region of immunoglobulin molecules that is found between the variable (V) and joining (J) elements.","Immunoglobulin Heavy Chain Diversity Region | IGH-D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898780","Immunoglobulin Heavy Chain Joining Region","C118496","The portion of the heavy chains of immunoglobulin molecules where the variable and constant regions meet.","Immunoglobulin Heavy Chain Joining Region | IGH-J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417001","MAOA Gene","C118615","This gene is involved in the metabolism of neuroactive and vasoactive amines.","MAOA Gene | MAOA | Monoamine Oxidase A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898549","MINT31","C118482","A gene promoter locus that regulates the expression of calcium channels. Methylation of this locus may be associated with colorectal carcinoma and other neoplastic diseases.","MINT31 | MINT-31",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3150976","NCR3LG1 Gene","C118528","This gene is involved in natural killer cell-dependent immunity.","NCR3LG1 Gene | NCR3LG1 | Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427121","PDLIM3 Gene","C118548","This gene may be involved in cytoskeletal rearrangement.","PDLIM3 Gene | PDLIM3 | PDZ and LIM Domain 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538625","PEX5L Gene","C118537","This gene plays a role in the regulation of nucleotide-dependent signaling.","PEX5L Gene | PEX5L | Peroxisomal Biogenesis Factor 5-Like Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1623167","Polycomb-Group Protein","C118479","A family of chromatin remodeling factors that contribute to epigenetic silencing during embryonic development.","Polycomb-Group Protein | PcG | Polycomb | Polycomb Family | Polycomb Family Protein | Polycomb Group | Polycomb Group Protein | Polycomb-Group",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418944","PROCR Gene","C118582","This gene plays a role in blood coagulation.","PROCR Gene | PROCR | Protein C Receptor, Endothelial Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826705","PROKR2 Gene","C118609","This gene is involved in both ligand binding and G protein-coupled receptor signaling.","PROKR2 Gene | PROKR2 | Prokineticin Receptor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418970","PRSS2 Gene","C118560","This gene is involved in proteolysis in the ileum.","PRSS2 Gene | PRSS2 | Protease, Serine, 2 (Trypsin 2) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419141","PVR Gene","C118554","This gene is involved in natural killer cell-adhesion and activation.","PVR Gene | PVR | PVR Cell Adhesion Molecule Gene | Poliovirus Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419142","NECTIN1 Gene","C118612","This gene plays a role in both cell-cell adhesion and viral entry.","NECTIN1 Gene | NECTIN1 | Nectin Cell Adhesion Molecule 1 Gene | PVRL1 | PVRL1 Gene | Poliovirus Receptor-Related 1 (Herpesvirus Entry Mediator C) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416963","SMAD5 Gene","C118585","This gene is involved in signal transduction-mediated transcriptional regulation.","SMAD5 Gene | SMAD Family Member 5 Gene | SMAD5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3501617","Somatostatin Receptor Type 2, Human","C17922","Somatostatin receptor type 2 (369 aa, ~41 kDa) is encoded by the human SSTR2 gene. This protein is involved in brain development, G protein-coupled receptor signaling, and the inhibition of cell proliferation.","Somatostatin Receptor Type 2 | SRIF-1 | SS-2-R | SS2-R | SS2R | SSR(2(a)) | SSR2a | SSTR2 | SSTR2A | Somatostatin Receptor 2 | Somatostatin Receptor Subtype 2a | Somatostatin Receptor Type 2 Isoform A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889625","Somatostatin Receptor Type 2b, human","C118484","Somatostatin receptor type 2b (356 aa, ~40 kDa) is encoded by the human SSTR2 gene. This protein plays a role in G protein-coupled receptor signaling.","Somatostatin Receptor Type 2b | SSR(2(b)) | SSR2b | SSTR2B | Somatostatin Receptor Subtype 2b | Somatostatin Receptor Type 2 Isoform B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823091","SPATA20 Gene","C118534","This gene may be involved in fertility.","SPATA20 Gene | SPATA20 | Spermatogenesis Associated 20 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890232","Trans-Activator Protein BZLF1","C118473","Trans-activator protein BZLF1 (245 aa, ~27 kDa) is encoded by the Epstein-Barr virus BZLF1 gene. This protein is involved in the induction of both the expression of early lytic cycle genes and the replication of the viral genome.","Trans-Activator Protein BZLF1 | EB1 | EBV BZLF-1 | EBV BZLF1 | Epstein-Barr Virus BZLF-1 | Epstein-Barr Virus Trans-Activator Protein BZLF-1 | Epstein-Barr Virus Trans-Activator Protein BZLF1 | Trans-Activator Protein BZLF-1 | Zebra",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1540152","UBQLN4 Gene","C118579","This gene may be involved in the regulation of protein degradation.","UBQLN4 Gene | UBQLN4 | Ubiquilin 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443710","Varicella zoster virus Antibody","C118486","Any immunoglobulin that recognizes the varicella-zoster virus.","Varicella-Zoster Virus Antibody | Anti-VZV Antibody | Anti-Varicella Zoster Virus Antibody | Anti-Varicella-Zoster Virus Antibody | VZV Antibody | Varicella Zoster Virus Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897634","Severity Criteria","C117962","A standard from which a judgment concerning an event severity can be established.","Severity Criteria | SEVCRIT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0965743","B7-DC antigen","C45438","Programmed cell death 1 ligand 2 (273 aa, ~31 kDa) is encoded by the human PDCD1LG2 gene. This protein is involved in the modulation of both T-cell proliferation and cytokine production.","Programmed Cell Death 1 Ligand 2 | B7 Dendritic Cell Molecule | B7-DC | B7DC | Butyrophilin B7-DC | CD273 | CD273 Antigen | PD-1 Ligand 2 | PD-1-Ligand 2 | PD-L2 | PD1 Ligand 2 Protein | PDCD1 Ligand 2 | PDCD1 Ligand 2 Protein | PDCD1L2 | PDCD1LG2 | PDL2 | Programmed Death Ligand 2 | Programmed Death Ligand 2 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229753","Subcarinal Lymph Node","C117873","A lymph node located in the thoracic cavity between the lungs. It is bordered by the carina of the trachea, lower lobe bronchus on the left and the bronchus intermedius on the right.","Subcarinal Lymph Node | Lymph Node, Subcarinal | SUBCARINAL LYMPH NODE",,,,,,,,,,,,,,,"4154911","Structure of subcarinal lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0230148","Anterior Mediastinum","C32098","The area between the lungs; it contains the thymus, some lymph nodes, and vessels and branches of the internal thoracic artery.","Anterior Mediastinum | Anterior mediastinum | MEDIASTINUM, ANTERIOR | anterior mediastinum | prevascular space",,,,,,,,,,,,,,,"4295128","Structure of anterior mediastinum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3810543","Human Epidermal Growth Factor Receptor 2 Measurement","C112312","The determination of the amount of human epidermal growth factor receptor 2 present in a sample.","Human Epidermal Growth Factor Receptor 2 Measurement | ERBB2 | HER2 | HER2/NEU | Human Epidermal Growth Factor Receptor 2 | Receptor Tyrosine-Protein Kinase erbB-2 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642345","Luminal A Breast Carcinoma","C53554","A biologic subset of breast carcinoma defined by high expression of genes characteristic of luminal epithelial cells, including estrogen receptor (ER), estrogen regulated protein LIV-1, and the transcription factors hepatocyte nuclear factor 3, HNF3A, XBP1, and GATA 3.  This subtype of breast cancer is associated with a good prognosis.","Luminal A Breast Carcinoma | Luminal A | Luminal A Breast Cancer | Luminal A Estrogen Receptor Positive Subtype of Breast Carcinoma | Luminal A Subtype of Breast Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642346","Luminal B Breast Carcinoma","C53555","A biologic subset of breast carcinoma defined by low to moderate expression of genes characteristic of luminal epithelial cells including estrogen receptor (ER), and high expression of GGH, LAPTM4B, and CCNE1.  This subtype of breast cancer is associated with a good prognosis, although not as favorable as the luminal A subtype.","Luminal B Breast Carcinoma | Luminal B | Luminal B Breast Cancer | Luminal B Estrogen Receptor Positive Subtype of Breast Carcinoma | Luminal B Subtype of Breast Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985554","In-Transit Metastasis","C93328","A type of metastasis in which skin cancer spreads through a lymph vessel and begins to grow more than 2 centimeters away from the primary tumor but before it reaches the nearest lymph node.","In-Transit Metastasis | In-transit Metastasis | in-transit metastasis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1134635","Screening Questionnaire","C62696","A questionnaire designed to identify a condition in the responding individual.","Screening Questionnaire | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033933","Psychophysiology","C17037","The branch of psychology concerned with the physiological basis of behavior.","Psychophysiology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033927","Psychopathology","C17035","The branch of pathology focusing on mental illness and abnormal behavior.","Psychopathology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4229418","Aggression","C117262","A verbal or physical act of hostility.","Aggression | ",,,,,,,,,,,,,,,"4266361","Aggressive behavior",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005789","Blood Coagulation Factor","C16354","Factors in the blood that are essential for blood coagulation. The absence or mutation of these factors can lead to hemophilia and blood clotting disorders.","Coagulation Factor | Blood Coagulation Factor | Clotting Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897868","Precarinal","C118773","Of or pertaining to the area in front of the bifurcation of the trachea.","Precarinal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899039","Gastrohepatic Lymph Node","C118774","A lymph node located in the gastrohepatic ligament.","Gastrohepatic Lymph Node | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229790","Aortocaval Lymph Node","C118775","A lymph node located in the area between the abdominal aorta and inferior vena cava.","Aortocaval Lymph Node | AORTOCAVAL LYMPH NODE",,,,,,,,,,,,,,,"4307370","Structure of lumbar lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3827784","Treatment Completed as Prescribed","C105740","Indicates that the patient was fully compliant with the full course of treatment.","Treatment Completed as Prescribed | Treatment Completed | Treatment completed (situation)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230347","Left Arm","C105633","The portion of the upper extremity between the shoulder and the wrist and located on the left side of the body.","Left Arm | LA",,,,,,,,,,,,,,,"4283159","Left upper arm structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4048756","Right Arm","C105636","The portion of the upper extremity between the shoulder and the wrist and located on the right side of the body.","Right Arm | RA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880435","Epirubicin-Cytoxan Regimen","C63421","A regimen consisting of cyclophosphamide and epirubicin that can be used for the treatment of breast cancer.","Cyclophosphamide/Epirubicin Regimen | Cyclophosphamide and Epirubicin (EC) | EC Breast Regimen | EC Breast Regimen | EC Regimen | Epirubicin-Cytoxan Regimen | Epirubicin/Cyclophosphamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900081","Adversity","C118791","A state of difficulty, misfortune, or affliction.","Adversity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899953","Beck Lethality Scale","C118792","A scale for scoring the potential degree of medical lethality of various means of suicide, consisting of zero, low, medium, or high.","Beck Lethality Scale | Lethality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016139","Firearm","C118793","A portable weapon that launches a projectile by an explosive force.","Firearm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891558","Anti-CD3 Antibody","C118796","Any antibody that recognizes the CD3 protein complex.","Anti-CD3 Antibody | Anti-T-Cell Surface Glycoprotein CD3 Antibody | CD3 Antibody | T-Cell Surface Glycoprotein CD3 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900024","Anti-Neprilysin Antibody","C118797","Any antibody that recognizes the neprilysin protein.","Anti-Neprilysin Antibody | Anti-CALLA Antibody | Anti-CD10 Antibody | Anti-MME Antibody | CALLA Antibody | CD10 Antibody | MME Antibody | Neprilysin Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900028","Anti-CD79a Antibody","C118799","Any antibody that recognizes B-cell antigen receptor complex-associated protein alpha chain protein.","Anti-CD79a Antibody | Anti-B-Cell Antigen Receptor Complex-Associated Protein Alpha Chain Antibody | B-Cell Antigen Receptor Complex-Associated Protein Alpha Chain Antibody | CD79a Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900025","Anti-MUM1 Antibody","C118800","Any antibody that recognizes interferon regulatory factor 4.","Anti-MUM1 Antibody | Anti-Interferon Regulatory Factor 4 Antibody | Interferon Regulatory Factor 4 Antibody | MUM1 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900031","Anti-BCL2 Antibody","C118801","Any antibody that recognizes apoptosis regulator Bcl-2 protein.","Anti-BCL2 Antibody | Anti-Apoptosis Regulator Bcl-2 Antibody | Apoptosis Regulator Bcl-2 Antibody | BCL2 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900030","Anti-BCL6 Antibody","C118802","Any antibody that recognizes B-cell lymphoma 6 protein.","Anti-BCL6 Antibody | Anti-B-Cell Lymphoma 6 Protein Antibody | B-Cell Lymphoma 6 Protein Antibody | BCL6 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900026","Anti-KI-67 Antibody","C118803","Any antibody that recognizes antigen KI-67 protein.","Anti-KI-67 Antibody | Anti-Antigen KI-67 Antibody | Antigen KI-67 Antibody | KI-67 Antibody | Ki67 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443949","Anti-Vimentin Antibody","C118804","Any antibody that recognizes vimentin protein.","Anti-Vimentin Antibody | Anti-VIM Antibody | VIM Antibody | Vimentin Antibody",,,,,,,,,,,,,,,"4125252","Vimentin antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897033","Anti-Estrogen Receptor Antibody","C118805","Any antibody that recognizes estrogen receptor protein.","Anti-Estrogen Receptor Antibody | Anti-ER Antibody | ER Antibody | Estrogen Receptor Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897645","Self-Conscious About the Way I Dress","C118654","A question about whether an individual is or was self-concious about the way they dress.","Self-Conscious About the Way I Dress | I am self-conscious about the way I dress",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897089","One or Both Arms Swollen or Tender","C118655","A question about whether one or both arms of an individual are or have been swollen or tender.","One or Both Arms Swollen or Tender | One or both of my arms are swollen or tender",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897116","Worry Other Family Members Might Someday Get Same Illness","C118656","A question about whether an individual worries or worried that other members of their family might someday get the same illness they have.","Worry Other Family Members Might Someday Get Same Illness | I worry that other members of my family might someday get the same illness I have",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900133","Able to Feel Like a Woman","C118657","A question about whether an individual is or was able to feel like a woman.","Able to Feel Like a Woman Question | Able to Feel Like a Woman | Able to Feel Like a Woman | I am able to feel like a woman",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898926","Have Trouble Forming Thoughts","C118658","A question about whether an individual has or had trouble forming thoughts.","Have Trouble Forming Thoughts | I have had trouble forming thoughts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897362","Thinking Has Been Slow","C118659","A question about whether an individual's thinking is or has been slow.","Thinking Has Been Slow | My thinking has been slow | My thinking was slow",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898928","Have Trouble Finding Way to Familiar Place","C118660","A question about whether an individual has or had trouble finding their way to a familiar place.","Have Trouble Finding Way to Familiar Place | I have had trouble finding my way to a familiar place",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898922","Have Trouble Remembering Where I Put Things","C118661","A question about whether an individual has or had trouble remembering where they put things.","Have Trouble Remembering Where I Put Things | I have had trouble remembering where I put things, like my keys or my wallet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898923","Have Trouble Remembering New Information","C118663","A question about whether an individual has or had trouble remembering new information.","Have Trouble Remembering New Information | Have Trouble Remembering New Things | I have had trouble remembering new information, like phone numbers or simple instructions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898924","Have Trouble Recalling the Name of Objects While Talking to Someone","C118664","A question about whether an individual has or had trouble recalling the name of an object while talking to someone.","Have Trouble Recalling the Name of Objects While Talking to Someone | I have had trouble recalling the name of an object while talking to someone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898929","Have Trouble Finding Right Words to Express Myself","C118665","A question about whether an individual has or had trouble finding the right word(s) to express themselves.","Have Trouble Finding Right Words to Express Myself | Did you have trouble finding the right words to express yourself | Have Trouble Finding the Right Words to Express Self | I have had trouble finding the right word(s) to express myself",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896990","Have Used Wrong Word When Referring to an Object","C118666","A question about whether an individual has or had used the wrong word when they referred to an object.","Have Used Wrong Word When Referring to an Object | I have used the wrong word when I referred to an object",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898921","Have Trouble Saying What I Mean in Conversation","C118667","A question about whether an individual has or had trouble saying what they mean in conversations with others.","Have Trouble Saying What I Mean in Conversation | I have had trouble saying what I mean in conversations with others",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898914","Have Walked into Room and Forgotten What I Meant to Get or Do","C118681","A question about whether an individual has or had walked into a room and forgotten what they meant to get or do there.","Have Walked into Room and Forgotten What I Meant to Get or Do | I have walked into a room and forgotten what I meant to get or do there",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3262038","Have to Work Really Hard to Pay Attention or Would Make Mistake","C118684","A question about whether an individual has or had to work really hard to pay attention or they would make a mistake.","Have to Work Really Hard to Pay Attention or Would Make Mistake | I had to work really hard to pay attention or I would make a mistake | I have had to work really hard to pay attention or I would make a mistake",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898956","Have Forgotten Names of People Soon After Being Introduced","C118685","A question about whether an individual has or had forgotten names of people soon after being introduced.","Have Forgotten Names of People Soon After Being Introduced | I have forgotten names of people soon after being introduced",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897771","Reactions in Everyday Situations Have Been Slow","C118687","A question about whether an individual's reactions in everyday situations have been slow.","Reactions in Everyday Situations Have Been Slow | My reactions in everyday situations have been slow",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898909","Have to Work Harder than Usual to Keep Track of What I Was Doing","C118694","A question about whether an individual has or had to work harder than usual to keep track of what they were doing.","Have to Work Harder than Usual to Keep Track of What I Was Doing | Have to Work Harder than Usual to Keep Track of What I am Doing | I have had to work harder than usual to keep track of what I was doing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897363","Thinking Has Been Slower than Usual","C118701","A question about whether an individual has or had slower than usual thinking.","Thinking Has Been Slower than Usual | My thinking has been slower than usual",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898908","Have to Work Harder to Express Myself Clearly","C118703","A question about whether an individual has or had to work harder than usual to express themselves clearly.","Have to Work Harder to Express Myself Clearly | I have had to work harder than usual to express myself clearly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898910","Have to Use Written Lists More Often than Usual to Not Forget Things","C118704","A question about whether an individual has or had to use written lists more often than usual so they would not forget things.","Have to Use Written Lists More Often than Usual to Not Forget Things | I have had to use written lists more often than usual so I would not forget things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898925","Have Trouble Keeping Track of What I Am Doing if Interrupted","C118705","A question about whether an individual has or had trouble keeping track of what they are doing if they are interrupted.","Have Trouble Keeping Track of What I Am Doing if Interrupted | I have trouble keeping track of what I am doing if I am interrupted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898920","Have Trouble Shifting Back and Forth Between Different Activities that Require Thinking","C118706","A question about whether an individual has or had trouble shifting back and forth between different activities that require thinking.","Have Trouble Shifting Back and Forth Between Different Activities that Require Thinking | Have Trouble Shifting Back and Forth Between Different Activities That Require Thinking | I have trouble shifting back and forth between different activities that require thinking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897013","Have Been Told that I Have Trouble Remembering Information","C118730","A question about whether an individual has or had been told by other people that they seem to have trouble remembering information.","Have Been Told that I Have Trouble Remembering Information | Have Been Told by Others that I Have Trouble Remembering Information | Other people have told me I seemed to have trouble remembering information",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898973","Have Been Told that I Have Trouble Speaking Clearly","C118735","A question about whether an individual has or had been told by other people that they seem to have trouble speaking clearly.","Have Been Told that I Have Trouble Speaking Clearly | Other people have told me I seemed to have trouble speaking clearly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898972","Have Been Told that I Have Trouble Thinking Clearly","C118738","A question about whether an individual has or had been told by other people that they seem to have trouble thinking clearly.","Have Been Told that I Have Trouble Thinking Clearly | Have Been Told by that I Have Trouble Thinking Clearly | Other people have told me I seemed to have trouble thinking clearly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898971","Have Been Told that I Seem Confused","C118743","A question about whether an individual has or had been told by other people that they seem confused.","Have Been Told that I Seem Confused | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898978","Have Been Able to Bring to Mind Words While Talking to Someone","C118746","A question about whether an individual has or had been able to bring to mind words that they wanted to use while talking to someone.","Have Been Able to Bring to Mind Words While Talking to Someone Question | Have Been Able to Bring to Mind Words While Talking to Someone | Have Been Able to Bring to Mind Words While Talking to Someone | I have been able to bring to mind words that I wanted to use while talking to someone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898976","Have Been Able to Remember to do Things","C118751","A question about whether an individual has or had been able to remember to do things, like take medicine or buy something they need.","Have Been Able to Remember to do Things Question | Have Been Able to Remember to do Things | Have Been Able to Remember to do Things | I have been able to remember to do things, like take medicine or buy something I needed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898977","Have Been Able to Pay Attention and Keep Track of What I am Doing Without Extra Effort","C118758","A question about whether an individual is or was able to pay attention and keep track of what they are doing without extra effort.","Have Been Able to Pay Attention and Keep Track of What I am Doing Without Extra Effort Question | Have Been Able to Pay Attention and Keep Track of What I am Doing Without Extra Effort | Have Been Able to Pay Attention and Keep Track of What I am Doing Without Extra Effort | I am able to pay attention and keep track of what I am doing without extra effort",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898311","Mind is as Sharp as it Always Has Been","C118761","A question about whether an individual's mind is or was as sharp as it always has been.","Mind is as Sharp as it Always Has Been | Mind is as Good as it Always Has Been | Mind is as Sharp as Always | My mind is as sharp as it has always been",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898429","Memory is as Good as it Always Has Been","C118766","A question about whether an individual's memory is or was as sharp as it always has been.","Memory is as Good as it Always Has Been | Memory as Good as Always | Memory is as Good as Always | Memory is as Sharp as Always | Memory is as Sharp as it Always Has Been | My memory is as good as it has always been",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900131","Able to Shift Back and Forth Between Two Activities that Require Thinking","C118767","A question about whether an individual is or was able to shift back and forth between two activities that require thinking.","Able to Shift Back and Forth Between Two Activities that Require Thinking Question | Able to Shift Back and Forth Between Two Activities that Require Thinking | Able to Shift Back and Forth Between Two Activities that Require Thinking | I am able to shift back and forth between two activities that require thinking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900132","Able to Keep Track of What I Am Doing Even When Interrupted","C118768","A question about whether an individual is or was able to keep track of what they are doing, even if they are interrupted.","Able to Keep Track of What I Am Doing Even When Interrupted Question | Able to Keep Track of What I Am Doing Even When Interrupted | Able to Keep Track of What I Am Doing Even When Interrupted | I am able to keep track of what I am doing, even if I am interrupted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898970","Have Been Upset About Cognitive Problems","C118769","A question about whether an individual had or has been upset about problems with cognitive function.","Have Been Upset About Cognitive Problems | I have been upset about these problems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899525","Cognitive Problems Have Interfered with Ability to Work","C118770","A question about whether an individual's problems with cognitive function interferes or interfered with their ability to work.","Cognitive Problems Have Interfered with Ability to Work | These problems have interfered with my ability to work",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899526","Cognitive Problems Have Interfered with Ability to Do Things I Enjoy","C118771","A question about whether an individual's problems with cognitive function interferes or interfered with their ability enjoy the things they do.","Cognitive Problems Have Interfered with Ability to Do Things I Enjoy | These problems have interfered with my ability to do things I enjoy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899524","Cognitive Problems Have Interfered with Quality of Life","C118772","A question about whether an individual's problems with cognitive function interferes or interfered with their quality of life.","Cognitive Problems Have Interfered with Quality of Life | These problems have interfered with the quality of my life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899177","FACT/GOG-Ntx Questionnaire","C118653","A subscale complement to the FACT-G developed specifically for evaluating platinum/paclitaxel-induced neurologic symptoms in patients with endometrial cancer.","FACT/GOG-Ntx Questionnaire | FACT&GOG-Ntx | FACT/GOG-NTX Questionnaire | FACT/GOG-Ntx Subscale | Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899912","Bothered by Vaginal Discharge or Bleeding","C118832","A question about whether an individual is or was bothered by discharge or bleeding from her vagina.","Bothered by Vaginal Discharge or Bleeding | I am bothered by discharge or bleeding from my vagina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899911","Bothered by Vaginal Odor","C118833","A question about whether an individual is or was bothered by odor coming from her vagina.","Bothered by Vaginal Odor | I am bothered by odor coming from my vagina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900080","Afraid to Have Sex","C118834","A question about whether an individual is or was afraid to have sex.","Afraid to Have Sex Question | Afraid to Have Sex | Afraid to Have Sex | Afraid to Have Sexual Intercourse | I am afraid to have sex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897208","Vagina Feels too Narrow or Short","C118835","A question about whether an individual feels or felt that her vagina is too narrow or short.","Vagina Feels too Narrow or Short | My vagina feels too narrow or short",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897026","Afraid Treatment May Harm Body","C118836","A question about whether an individual is or was afraid the treatment may harm their body.","Afraid Treatment May Harm Body Question | Afraid Treatment May Harm Body | Afraid Treatment May Harm Body | I am afraid the treatment may harm my body",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898959","Have Discomfort When Urinating","C118837","A question about whether an individual has or had discomfort when urinating.","Have Discomfort When Urinating | I have discomfort when I urinate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898931","Have Trouble Controlling Urine","C118838","A question about whether an individual has or had trouble controlling their urine.","Have Trouble Controlling Urine | I have trouble controlling my urine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899906","Burns When Urinating","C118839","A question about whether an individual has or had a burning sensation when urinating.","Burns When Urinating | It burns when I urinate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898930","Have Trouble Digesting Food","C118841","A question about whether an individual has or had trouble digesting food.","Have Trouble Digesting Food | Have Trouble with Digestion | I have trouble digesting food",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898958","Have Discomfort or Pain in Pelvic Area","C118842","A question about whether an individual has or had discomfort or pain in their pelvic area.","Have Discomfort or Pain in Pelvic Area | Have Discomfort or Pain in Pelvic Region | I have discomfort or pain in my pelvic area",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899181","FACT-Bl Questionnaire","C118830","A subscale complement to the FACT-G developed specifically for evaluating the quality of life of patents with bladder cancer.","FACT-Bl Questionnaire | FACT-Bl | Functional Assessment of Cancer Therapy - Bladder Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899180","FACT-CNS Questionnaire","C118831","A subscale complement to the FACT-G developed specifically for evaluating the quality of life of patients with cancer in the central nervous system.","FACT-CNS Questionnaire | FACT-CNS | Functional Assessment of Cancer Therapy - Cancer in the Central Nervous System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891559","Anti-Carcinoembryonic Antigen Antibody","C118806","Any antibody that recognizes a member of the carcinoembryonic antigen protein family.","Anti-Carcinoembryonic Antigen Antibody | Anti-CEA Antibody | CEA Antibody | Carcinoembryonic Antigen Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0346151","Breast Scirrhous Carcinoma","C7362","An infiltrating ductal breast carcinoma associated with stromal fibrosis.","Breast Scirrhous Carcinoma | Duct carcinoma, desmoplastic type | Infiltrating Carcinoma of Breast with Fibrotic Stroma | Infiltrating Carcinoma of the Breast with Fibrotic Stroma | Scirrhous Breast Carcinoma | Scirrhous Breast Carcinoma | Scirrhous Carcinoma of Breast | Scirrhous Carcinoma of the Breast","8514/3","Duct carcinoma, desmoplastic type",,,,,,,,,,,,,"4029515|4112073","Duct carcinoma, desmoplastic type|Scirrhous carcinoma of breast",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0222646","Appendicular Skeleton","C49477","The part of the skeleton that includes the bones of the upper and lower limbs.","Appendicular Skeleton | APPENDICULAR SKELETON | appendicular skeleton",,,,,,,,,,,,,,,"4307587","Structure of appendicular skeleton",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897780","Radiologic Imaging Procedure","C118849","Any imaging procedure that uses radiation to create an image for the purpose of assisting with the execution of an intervention.","Radiologic Imaging Procedure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900130","About Once Weekly","C118853","Scheduled or occurring at a frequency of approximately once per week.","About Once Weekly | About Once a Week",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0589079","Two to Three Times Weekly","C118854","Scheduled or occurring at a frequency of two or three times per week.","Two to Three Times Weekly | Two to Three Times a Week",,,,,,,,,,,,,,,"4026060","Two to three times a week",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3845713","Nearly Every Day","C118855","Scheduled or occurring at a frequency bordering on daily.","Nearly Every Day | Almost Every Day | Nearly Daily",,,,,,,,,,,,,,,"763699","Nearly every day",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3853132","Several Times Daily","C118856","Scheduled or occurring at a frequency of several times per day.","Several Times Daily | Several Times Each Day | Several Times a Day",,,,,,,,,,,,,,,"761069","More than once a day",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0920367","Optical Coherence Tomography","C20828","Optical Coherence Tomography (OCT) combines the principles of ultrasound with the imaging performance of a microscope.  OCT uses infrared light waves that reflect off the internal microstructure within the biological tissues. The frequencies and bandwidths of infrared light are orders of magnitude higher than medical ultrasound signals, resulting in greatly increased image resolution, 8-25 times greater than any existing modality. In addition to providing high-level resolutions for the evaluation of microanatomic structures OCT is also able to provide information regarding tissue composition.","Optical Coherence Tomography | OCT | OPTICAL COHERENCE TOMOGRAPHY | Optical Coherence Tomography (OCT) | optical coherence tomography",,,,,,,,,,,,,,,"4213040","Optical coherence tomography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0233762","Auditory Hallucination","C118174","Perception of sound in the absence of a corresponding stimulus.","Auditory Hallucination | ",,,,,,,,,,,,,,,"4164151","Auditory hallucinations",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0233763","Visual Hallucination","C118179","Optical perception of an object, person or event in the absence of a corresponding stimulus.","Visual Hallucination | ",,,,,,,,,,,,,,,"4275889","Visual hallucinations",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898838","How Often","C118873","A question about the frequency of an event or behavior.","How Often | Frequency | How Often Question",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879883","Blastemal Cell","C61288","An embryonic undifferentiated cell that can grow and differentiate into organs or body parts.","Blastemal Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336739","Thorotrast Exposure","C36187","Exposure to thorotrast, which contains particles of the radioactive compound thorium dioxide, as a radiocontrast agent. It is a carcinogenic compound, linked to the development of bile duct cancer, leukemia, and angiosarcoma.","Thorotrast Exposure | Thorotrast Contrast Exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0277005","Opisthorchis Viverrini Infection","C39295","An infection caused by the parasite Opisthorchis viverrini. It results from the ingestion of raw or undercooked food. The clinical features vary from mild to severe and include gastrointestinal symptoms, anorexia, weight loss, hepatomegaly, and cholangitis. Patients are at an increased risk of developing cholangiocarcinoma.","Opisthorchis Viverrini Infection | ",,,,,,,,,,,,,,,"4234839","Infection by Opisthorchis viverrini",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3889990","Clinical Trial Censoring","C118962","When information on time-to-event is not available due to loss to follow-up or non-occurrence of outcome event before the trial end. The data on that participant is banned or removed from the study data.","Clinical Trial Censoring | Censored | Censoring",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890211","Low Mitosis-Karyorrhexis Index","C118955","An index used in neuroblastic tumors indicating the presence of less than 100 mitoses and karyorrhexis per 5,000 cells.","Low Mitosis-Karyorrhexis Index | Low",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889971","Intermediate Mitosis-Karyorrhexis Index","C118957","An index used in neuroblastic tumors indicating the presence of between 100 and 200 mitoses and karyorrhexis per 5,000 cells.","Intermediate Mitosis-Karyorrhexis Index | Intermediate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012568","Diploidy","C118941","Having two sets of homologous chromosomes.","Diploidy | Diploid",,,,,,,,,,,,,,,"4232013","Diploidy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3889660","High Mitosis-Karyorrhexis Index","C118958","An index used in neuroblastic tumors indicating the presence of more than 200 mitoses and karyorrhexis per 5,000 cells.","High Mitosis-Karyorrhexis Index | High",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1609165","Tocilizumab","C84217","A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. IL-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders, certain types of cancers and possibly various other inflammatory conditions.","Tocilizumab | Actemra | IL-6 receptor monoclonal antibodies: tocilizumab | Immunoglobulin G1, Anti-(Human Interleukin 6 Receptor) (Human-Mouse Monoclonal MRA Heavy Chain), Disulfide with Human-Mouse Monoclonal MRA Kappa-Chain, Dimer | MRA | R-1569 | RoActemra | TOCILIZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438194","Common Iliac Lymph Node","C103384","A lymph node located adjacent to the common iliac artery. (NCI)","Common Iliac Lymph Node | COMMON ILIAC LYMPH NODE | Common iliac lymph node group (body structure) | Lymph Node(s) Iliac-Common | common iliac lymph node | common iliac node",,,,,,,,,,,,,"UBERON:0015878","common iliac lymph node",,,,,,,,,,,,,,,"--"
"C0047226","3-Aminoisobutyric Acid","C118876","A derivative of the amino acid alanine that is a product of thymine metabolism, which has the potential to induce downstream metabolic activity. During exercise, 3-aminoisobutyric acid is secreted by muscle cells into the blood. Once this molecule interacts with adipocytes, it may induce signaling pathways that regulate the metabolism of fats, insulin, and cholesterol.","3-Aminoisobutyric Acid | 2-(Aminomethyl)Propionic Acid | 2-Methyl-Beta-Alanine | 3-Amino-2-Methylpropanoate | 3-Amino-2-Methylpropanoic Acid | 3-Aminoisobutanoate | 3-Aminoisobutanoic Acid | Alpha-Methyl-Beta-Alanine | BAIB | BAIBA | Beta-Aminoisobutyric Acid",,,,,,,,,,,,,,,"4216438","Beta aminoisobutyric acid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4048291","5-hydroxylysine","C118878","A hydroxylated amino acid derivative of lysine that arises from post-translational modification. Lysine is converted into 5-hydroxylysine by lysyl hydroxylase, an oxoenzyme that catalyzes the hydroxylation of carbon-5 in lysyl residues found in proteins or peptides. Hydroxylysine residues are required for the formation and stability of triple helical collagen fibrils.","5-Hydroxylysine | (2S,5R)-2,6-Diamino-5-Hydroxyhexanoate | (2S,5R)-2,6-Diamino-5-Hydroxyhexanoic Acid | (2S,5R)-5-Hydroxylysine | 5-Hydroxy-Lysine | Alpha,Epsilon-Diamino-Delta-Hydroxycaproate | Alpha,Epsilon-Diamino-Delta-Hydroxycaproic Acid | Delta-Hydroxylysine | Erythro-5-Hydroxy-L-Lysine | HYDROXYLYSINE | Hydroxy-Lysine | Hydroxylysine | L-Delta-Hydroxylysine | L-Hydroxylysine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1167059","Aggresome","C118897","A ubiquitin-rich cytoplasmic inclusion encased in vimentin found near the microtubule organizing center. It is formed in response to cellular stresses that cause the production of misfolded proteins at levels that exceed the degradative capacity of the proteasome. This inclusion body is comprised of aggregated misfolded or denatured proteins that have been transported along microtubules to the pericentriolar space where they become encased in vimentin.","Aggresome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900168","ALK Kinase Domain","C118902","The intracellular portion of the ALK tyrosine kinase receptor protein that confers tyrosine kinase enzymatic activity.","ALK Kinase Domain | ALK Tyrosine Kinase Receptor Kinase Domain | Anaplastic Lymphoma Kinase Tyrosine Kinase Domain | CD246 Tyrosine Kinase Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002139","Alloisoleucine","C118884","The optically active form of the amino acid alloisoleucine with an L-(2S,3R)-configuration, derived from endogenous L-isoleucine, that is an intermediate in the metabolism of branched-chain amino acids. Detection of alloisoleucine in plasma is diagnostic for maple-syrup urine disease (MSUD).","Alloisoleucine | (2S,3R)-2-Amino-3-Methylpentanoic Acid | ALLOISOLEUCINE, L- | Allo-Ile | Allo-L-Isoleucine | AlloI | Alloisoleucine, L- | Isoleucine, Allo- | Isoleucine, Threo- | L-Isoleucine, 3-Methyl-, Threo- | L-Isoleucine, Allo- | L-Isoleucine, Threo- | L-Norvaline, 3-Methyl-, Threo- | Norvaline, 3-Methyl-, Threo- | Pentanoic Acid, 2-Amino-3-Methyl-, (S-(R*,S*))-",,,,,,,,,,,,,,,"4133395","Alloisoleucine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0191922","Reduction Mammoplasty","C51615","Surgery performed to reduce the size of the breast.","Reduction Mammoplasty | ",,,,,,,,,,,,,,,"4241100","Reduction mammoplasty",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0000257","Alpha-Aminoadipic Acid","C118881","An alpha-amino acid that is an intermediate in the lysine degradation pathway. It is synthesized from homoisocitrate and then converted to a semialdehyde that reacts with glutamic acid to form saccharopine. Alpha-aminoadipic acid levels are elevated in tissues of certain cancers and may potentially be used as a cancer biomarker.","Alpha-Aminoadipic Acid | 2-Aminoadipate | 2-Aminoadipic Acid | 2-Aminohexanedioic Acid | Alpha-Aminoadipate | Alpha-amino Adipic Acid | Hexanedioic Acid, 2-Amino-",,,,,,,,,,,,,,,"4318233","Alpha-aminoadipic acid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0054314","Alpha-Aminobutyric Acid","C81116","An alpha-amino acid that is a derivative of alanine with a side chain that is one carbon longer than the alanine side chain. It is synthesized through the transamination of oxobutyrate and is utilized in the biosynthesis of nonribosomal peptides.","Alpha-Aminobutyric Acid | .ALPHA.-AMINOBUTYRIC ACID | 2-Amino-N-Butyric Acid | 2-Aminobutanoic Acid | 2-Aminobutyric Acid | 2-Aminobutyric Acid, DL | AABA | Abu | Alpha-Amino-N-Butyric Acid | Butanoic Acid, 2-Amino- | Butanoic Acid, 2-amino- | Butyric Acid, 2-Amino-, DL- | Butyrine | DL-2-Amino-N-Butyric Acid | DL-Alpha-Amino-N-Butyric Acid | Homoalanine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003134","Anserine","C118877","A dipeptide comprised of a beta-alanine and a methylhistidine that is found in dietary red meat and has antioxidant activity.","Anserine | (2S)-2-(3-Aminopropanamido)-3-(1-Methyl-1H-Imidazol-5-Yl)Propanoic Acid | (2S)-2-[(3-Amino-1-Oxopropyl)Amino]-3-(3-Methyl-4-Imidazolyl)Propanoic Acid | ANSERINE | Beta-Alanyl-3-Methyl-L-Histidine | Beta-Alanyl-3-Methylhistidine | L-Anserine | L-Histidine, N-Beta-Alanyl-3-Methyl-",,,,,,,,,,,,,,,"4010512","Anserine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003777","Argininosuccinic Acid","C118879","An amino acid derivative formed through the binding of citrulline to aspartic acid catalyzed by argininosuccinic acid synthetase. Argininosuccinic acid is converted to arginine and fumarate by argininosuccinate lyase in the urea cycle.","Argininosuccinic Acid | L-Aspartic Acid, N-(((4-Amino-4-Carboxybutyl)Amino)Iminomethyl)-, (S)- | N-[{[(4S)-4-Amino-4-Carboxybutyl]Amino}(Imino)Methyl]-L-Aspartic Acid",,,,,,,,,,,,,,,"4294811","Argininosuccinic acid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1425978","ASPM Gene","C118989","This gene plays a role in mitotic spindle regulation.","ASPM Gene | ASPM | Asp (Abnormal Spindle) Homolog, Microcephaly Associated (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899952","Beta Isomer of C-Terminal Telopeptide of Type I Collagen","C118889","This polypeptide is comprised of the proteolytically released carboxy-terminal portions of fibrillar type I collagen where age has converted the alpha form of aspartic acid to its beta form. These peptides are joined through trivalent crosslinks and are products of the degradation of mature type I collagen. Elevated serum concentrations of beta-CTX are associated with increased bone resorption.","Beta Isomer of C-Terminal Telopeptide of Type I Collagen | Beta Isoform of the Carboxy-Terminal Cross-Linking Telopeptide of Type I Collagen | Beta Isoform of the Cross-Linked C-Terminal Telopeptide of Type I Collagen | Beta-C-Telopeptide of Type I Collagen | Beta-CTX | Beta-CTx | Beta-CrossLaps | BetaCTx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899966","BRAF NP_004324.2:p.T599_V600insT","C118894","A change in the amino acid sequence of the serine/threonine protein kinase B-raf protein where a threonine residue has been inserted between the threonine at position 599 and the valine at position 600.","BRAF NP_004324.2:p.T599_V600insT | BRAF Ins T | BRAF NP_004324.2:p.Thr599_Val600insThr | BRAF T599_V600insT | BRAF Thr599_Val600insThr | BRAF ins(T) | BRAF p.T599_V600insT | BRAF p.Thr599_Val600insThr | BRAF p.Thr599dup | BRAFinsT | NP_004324.2:p.T599_V600insT | NP_004324.2:p.T599dup | NP_004324.2:p.Thr599_Val600insThr | NP_004324.2:p.Thr599dup | Serine/Threonine-Protein Kinase B-raf T599_V600insT | Serine/Threonine-Protein Kinase B-raf Thr599_Val600insThr | Serine/Threonine-Protein Kinase B-raf Thr599dup",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424286","CARD14 Gene","C118910","This gene plays a role in both signaling and the inhibition of apoptosis.","CARD14 Gene | CARD14 | Caspase Recruitment Domain Family, Member 14 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007267","Carnosine","C118880","A dipeptide comprised of a beta-alanine and a 3-methyl-L-histidine, which is found in dietary red meat, with potential antioxidant, metal-chelating and anti-glycation activities. Carnosine scavenges both reactive oxygen species (ROS) and unsaturated aldehydes produced by cell membrane lipid peroxidation. Additionally, this dipeptide may reduce the rate of formation of advanced glycation end-products (AGE). Altogether, this may protect cells against oxidative damage. In addition, carnosine is able to chelate toxic metals.","Carnosine | (2S)-2-[(3-Amino-1-Oxopropyl)Amino]-3-(3H-Imidazol-4-Yl)Propanoic Acid | Beta-Alanyl-L-Histidine | Beta-Alanylhistidine | CARNOSINE | L-Histidine, Beta-Alanyl- | L-Histidine, N-Beta-Alanyl-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413209","CD1C Gene","C118907","This gene is involved in antigen presentation of lipids or glycolipid antigens.","CD1C Gene | CD1C | CD1c Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899746","CSF2 Antibody","C118899","Any antibody that recognizes the granulocyte-macrophage colony-stimulating factor protein.","CSF2 Antibody | Anti-CSF2 Antibody | Anti-GM-CSF Antibody | Anti-GMCSF Antibody | Anti-Granulocyte-Macrophage Colony-Stimulating Factor Antibody | GM-CSF Antibody | GMCSF Antibody | Granulocyte-Macrophage Colony-Stimulating Factor Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010640","Cystathionine","C118875","An amino acid derivative that is an intermediate in the biosynthesis of cysteine. It is the product of the ligation of homocysteine and serine by cystathionine beta synthase.","Cystathionine | 2-Amino-4-(2-Amino-2-Carboxy-Ethyl) Thio-Butanoic Acid | 2-Amino-4-[(2-Amino-2-Carboxyethyl)Sulfanyl]Butanoic Acid | DL-Allocystathionine | DL-Cystathionine | Homocysteine, S-(2-Amino-2-Carboxyethyl)- | S-(2-Amino-2-Carboxyethyl)Homocysteine",,,,,,,,,,,,,,,"4223991","Cystathionine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1422269","DDX39B Gene","C118922","This gene plays a role in both RNA splicing and mRNA transport.","DDX39B Gene | DDX39B | DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 39B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825043","EIF1B Gene","C118980","This gene is involved in the initiation of protein translation.","EIF1B Gene | EIF1B | Eukaryotic Translation Initiation Factor 1B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414515","FABP6 Gene","C118966","This gene plays a role in the transport of bile salts and acids.","FABP6 Gene | FABP6 | Fatty Acid Binding Protein 6, Ileal Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2919473","Fowlpox Virus Antibody","C118898","Any antibody that recognizes viruses in the fowlpox family.","Fowlpox Virus Antibody | Anti-Fowlpox Virus | Anti-Fowlpox Virus Antibody",,,,,,,,,,,,,,,"40480256","Fowlpox virus antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899164","FOXO Family","C118892","A subfamily within the forkhead box (FOX) protein family, which is a family of transcription factors that contain a forkhead DNA-binding domain. FOXO proteins regulate apoptosis, cell-cycle progression, oxidative-stress resistance, and tumor suppression. The transcriptional promoter activity of these factors is regulated by post-translational modifications, such as phosphorylation, acetylation, and monoubiquitination.","FOXO Family | FOXO | Fork Head Box Transcription Factor Class O | Forkhead Box Transcription Factor Class O | FoxO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1440756","HMB-45","C118893","A mouse monoclonal antibody that is used in anatomic pathology as a marker for melanocytic tumors. This antibody recognizes melanocyte protein PMEL (PMEL17 or SILV).","HMB-45 | HMB45 | Human Melanoma Black 45 | Melanoma (gp100) Antibody (HMB45) | Monoclonal Mouse Anti-Human Melanocyte Protein PMEL | Monoclonal Mouse Anti-Human Melanosome, Clone HMB-45",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3470489","HPP1 gene","C118954","Human HPP1 gene is located within 19pter-p13.1 and the size of this phenotypic locus is not reported. This phenotype-only gene has not been linked to a known protein product. This locus is associated with familial progressive hyperpigmentation.","HPP1 Gene | FPH1 | Familial Progressive Hyperpigmentation 1 Gene | HPP | HPP1 | Hyperpigmentation, Familial Progressive, 1 Gene | Hyperpigmentation, Progressive, 1 Gene | MUH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020388","Hydroxyproline","C76144","A nonessential amino acid derivative formed during post-translational protein modification through hydroxylation of the amino acid proline by the enzyme prolyl hydroxylase which requires vitamin C as a co-factor. Hydroxyproline is a major component of the protein collagen and plays a key role in the stability of the collagen triple helix. It can be used as an indicator to determine the amount of collagen. Increased hydroxyproline levels in the urine and/or serum are normally associated with degradation of connective tissue. Vitamin C deficiency decreases the conversion of proline to hydroxyproline, which leads to reduced collagen stability.","Hydroxyproline | 4-Hydroxy-L-proline | HYDROXYPROLINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424734","ICOSLG Gene","C118933","This gene is involved in the regulation of T- and B-cell proliferation.","ICOSLG Gene | ICOSLG | Inducible T-Cell Co-Stimulator Ligand Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416392","IL18BP Gene","C118904","This gene plays a role in interleukin sequestration.","IL18BP Gene | IL18BP | Interleukin 18 Binding Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416650","KIR2DS4 Gene","C118916","This gene plays a role in the recognition of HLA-bound antigens.","KIR2DS4 Gene | KIR2DS4 | Killer Cell Immunoglobulin-Like Receptor, Two Domains, Short Cytoplasmic Tail, 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416724","KRT16 Gene","C118928","This gene plays a role in the formation of both skin and hair.","KRT16 Gene | KRT16 | Keratin 16 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425201","LAMTOR5 Gene","C118944","This gene plays a role in both guanine nucleotide exchange and the inhibition of hepatitis B virus replication.","LAMTOR5 Gene | LAMTOR5 | Late Endosomal/Lysosomal Adaptor, MAPK and MTOR Activator 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206517","Leukotriene Receptor","C118888","A diverse group of transmembrane proteins that can initiate intracellular signaling pathways when leukotrienes are bound to their extracellular, ligand binding domains.","Leukotriene Receptor Family | Leukotriene Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426357","LGR6 Gene","C118963","This gene is involved in R-spondin-mediated signaling.","LGR6 Gene | LGR6 | Leucine-Rich Repeat Containing G Protein-Coupled Receptor 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416936","LUM Gene","C118986","This gene is involved in collagen binding.","LUM Gene | LUM | Lumican Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422239","LZTS1 Gene","C118977","This gene plays a role in gene transcription, cell growth regulation, cell cycle progression, and tumor suppression.","LZTS1 Gene | LZTS1 | Leucine Zipper, Putative Tumor Suppressor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0236524","Measles Virus Antibody","C118901","Any antibody that recognizes measles virus.","Measles Virus Antibody | Anti-Measles Virus | Anti-Measles Virus Antibody",,,,,,,,,,,,,,,"4025644","Measles virus antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898448","Measles Virus N mRNA","C118890","An oligoribonucleotide (~1.7 kbp) transcribed by RNA-dependent RNA polymerase from the measles virus N gene negative-sense RNA. This mRNA can be translated by host ribosomes to produce measles virus nucleoprotein, which is involved in viral encapsidation.","Measles Virus N mRNA | Measles Virus N Protein mRNA | Measles Virus Nucleocapsid Protein mRNA | Measles Virus Nucleoprotein mRNA | N mRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0065827","Measles Virus Nucleoprotein","C118891","Measles virus nucleoprotein (525 aa, ~58 kDa) is encoded by the measles virus N gene. This protein is involved in the encapsidation and mediation of nuclease resistance of the viral RNA genome.","Measles Virus Nucleoprotein | MV Nucleoprotein | Measles Virus N Protein | Measles Virus Nucleocapsid Protein | N Protein | NP | Nucleocapsid Protein | Nucleoprotein | Protein N",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513482","Monosomy 6","C36627","A chromosomal abnormality consisting of the absence of one complete copy of chromosome 6 in somatic cells.","Monosomy 6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0067684","N-Acetylaspartate","C118887","The acetylated form of aspartic acid synthesized in the mitochondria of neurons from aspartic acid and acetyl-coenzyme A. Although highly concentrated in neurons, the exact biological role of N-acetylaspartate has yet to be identified. N-acetylaspartate can act as a neuronal marker and brain levels are decreased in many neuropathological conditions.","N-Acetylaspartate | 2-Acetamidobutanedioic Acid | 2-Acetamidobutanedioic Acid;  | ACETYL ASPARTIC ACID | Acetylaspartatic Acid | N-Acetyl-L-Aspartic Acid | N-Acetylaspartatic Acid | NAA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417965","OPRM1 Gene","C118983","This gene plays a role in opioid-dependent G protein-coupled receptor signaling.","OPRM1 Gene | OPRM1 | Opioid Receptor, Mu 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0070939","Phosphorylethanolamine","C118882","A monophosphate ethanolamine ester that is an intermediate in the biosynthesis of sphingomyelins.","Phosphorylethanolamine | 2-Amino-Ethanol Dihydrogen Phosphate | 2-Amino-Ethanol Phosphate | 2-Aminoethyl Dihydrogen Phosphate | Colamine Phosphate | Colamine Phosphoric Acid | Colaminphosphoric Acid | EAP | Ethanolamine Acid Phosphate | Ethanolamine O-Phosphate | Ethanolamine Phosphate | Mono(2-Aminoethyl) Phosphate | Monoaminoethyl Phosphate | O-Phosphocolamine | O-Phosphoethanolamine | O-Phosphorylethanolamine | OPE | PE | PEA | PETN | PHOSPHORYLCOLAMINE | Phosphoethanolamine | Phosphonoethanolamine | Phosphoric Acid 2-Aminoethyl Phenyl Ester | Phosphoryl-Ethanolamine | pEtN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031721","Phosphoserine","C118883","A derivative of the amino acid serine where the side chain hydroxyl group has been substituted with a phosphono group. Post-translational phosphorylation of serine residues in proteins or peptides can regulate the progression of multiple intracellular signal transduction pathways. Monomeric phosphoserine is an intermediate in L-serine biosynthesis.","Phosphoserine | 2-Amino-3-(Oxyphosphinyloxyphosphinyl)Propanoic Acid | 2-Amino-3-(Phosphonooxy)Propanoic Acid | 2-Amino-3-Phosphonooxypropanoic Acid | 3-Phospho-Serine | ; 3-Phospho-Serine | DL-2-Amino-3-Hydroxypropanoic Acid 3-Phosphate | DL-O-Phosphorylserine | DL-Serine Dihydrogen Phosphate | DL-Serine, Dihydrogen Phosphate (Ester) | O-Phosphonoserine | P-Ser | P-Serine | Phosphorylserine | Serine Dihydrogen Phosphate | Serine-3-Phosphate",,,,,,,,,,,,,,,"4009428","Phosphoserine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034266","Pyridoxal Phosphate","C81627","The active form of vitamin B6 and a coenzyme for many pyridoxal phosphate (PLP)-dependent enzymes. PLP is involved in numerous enzymatic transamination, decarboxylation and deamination reactions; it is necessary for the synthesis of amino acids and amino acid metabolites, and for the synthesis and/or catabolism of certain neurotransmitters, including the conversion of glutamate into gamma-aminobutyric acid (GABA) and levodopa into dopamine. PLP can be used as a dietary supplement in cases of vitamin B6 deficiency. Reduced levels of PLP in the brain can cause neurological dysfunction.","Pyridoxal Phosphate | C81627 | PYRIDOXAL PHOSPHATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419893","SDC3 Gene","C118950","This gene is involved in the metabolism of glycosaminoglycans.","SDC3 Gene | SDC3 | Syndecan 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420123","SLC1A5 Gene","C118925","This gene is involved in both neutral amino acid transport and retrovirus binding.","SLC1A5 Gene | SLC1A5 | Solute Carrier Family 1 (Neutral Amino Acid Transporter), Member 5 Gene | Solute Carrier Family 1 Member 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420172","SLC2A2 Gene","C119007","This gene plays a role in carbohydrate transport.","SLC2A2 Gene | SLC2A2 | Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539786","SLC43A2 Gene","C118998","This gene is involved in the transport of large neutral amino acids.","SLC43A2 Gene | SLC43A2 | Solute Carrier Family 43 (Amino Acid System L Transporter), Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420201","SLC5A2 Gene","C119004","This gene is involved in the transport of both glucose and sodium.","SLC5A2 Gene | SLC5A2 | Solute Carrier Family 5 (Sodium/Glucose Cotransporter), Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420225","SLC7A6 Gene","C118992","This gene is involved in the transport of dibasic amino acids.","SLC7A6 Gene | SLC7A6 | Solute Carrier Family 7 (Amino Acid Transporter Light Chain, y+L System), Member 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420226","SLC7A7 Gene","C118995","This gene plays a role in the transport of cationic amino acids.","SLC7A7 Gene | SLC7A7 | Solute Carrier Family 7 (Amino Acid Transporter Light Chain, y+L System), Member 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420227","SLC7A8 Gene","C119001","This gene plays a role in the transport of small and large neutral amino acids.","SLC7A8 Gene | SLC7A8 | Solute Carrier Family 7 (Amino Acid Transporter Light Chain, L System), Member 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420232","SLC9A1 Gene","C118913","This gene is involved in pH regulation.","SLC9A1 Gene | SLC9A1 | Solute Carrier Family 9, Subfamily A (NHE1, Cation Proton Antiporter 1), Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428200","TIPARP Gene","C118974","This gene is involved in ADP-ribosylation of proteins.","TIPARP Gene | TCDD-Inducible Poly(ADP-Ribose) Polymerase Gene | TIPARP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896612","Tumor Antigen-reactive CD28+/CCR7+/CD27+/CD45RA- Cytotoxic T-lymphocyte","C118848","A subset of rapidly expanding, tumor antigen-reactive central memory cytotoxic T-lymphocytes (CTLs) with a broad expression profile for markers of immune function (MIF), and a particular phenotype of CD28+/CCR7+/CD27+/CD45RA-. These CTLs are formed in vivo following administration of AGS-003 (an autologous, CD40L and tumor antigen RNA-transfected dendritic cell (DC) immunotherapeutic agent), secrete multiple cytokines, including interferon-gamma (IFN-g), tumor necrosis factor-alpha (TNF-a), and interleukin-2 (IL-2), and cause cell lysis. These antigen-reactive, CD28+/CCR7+/CD27+/CD45RA- CTLs, and the phenotype changes in the patient's peripheral blood CTL pool, can be used as a marker to evaluate a patient's immune response against the administered immunotherapeutic agent AGS-003.","Tumor Antigen-reactive CD28+/CCR7+/CD27+/CD45RA- Cytotoxic T-lymphocyte |  REHA CTL | REHA CTL | Rapidly Expanding High-Avidity Cytotoxic T Cell | Rapidly Expanding High-Avidity Cytotoxic T Lymphocyte | Rapidly Expanding High-Avidity Cytotoxic T-Cell | Rapidly Expanding High-Avidity Cytotoxic T-Lymphocyte",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1155342","Unfolded Protein Response","C118900","A cellular stress response process that is activated by the accumulation of unfolded or misfolded proteins in the cell.","Unfolded Protein Response | Cellular Response to Unfolded Protein | UPR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512143","ETV6-NTRK3 Fusion Protein Expression","C37243","No Value Exists","ETV6-NTRK3 Fusion Protein Expression | ETV6/NTRK3 Fusion Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512145","EWSR1-ATF1 Fusion Protein Expression","C37232","No Value Exists","EWSR1-ATF1 Fusion Protein Expression | EWS-ATF1 Fusion Protein Expression | EWS/ATF1 Fusion Protein Expression | EWSR1/ATF1 Fusion Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708818","MECT1/MAML2 Fusion Protein Expression","C54218","Expression of a fusion protein that results from a fusion of the human genes CRTC1 and MAML2.","CRTC1-MAML2 Fusion Protein Expression | CRTC1/MAML2 Fusion Protein Expression | MECT1-MAML2 Fusion Protein Expression | MECT1-MAML2 Fusion Protein Expression | MECT1/MAML2 Fusion Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333538","FGF21 Gene","C24391","This gene plays a role in signal transduction.","FGF21 Gene | FGF21 | Fibroblast Growth Factor 21 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1439328","CRYAB Gene","C115113","This gene is involved in lens formation.","CRYAB Gene | CRYAB | Crystallin, Alpha B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897139","t(8;21)","C119608","A cytogenetic abnormality that involves a translocation between chromosomes 8 and 21.","t(8;21) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897144","inv(16)","C119609","A chromosomal inversion that involves chromosome 16.","inv(16) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897118","PROMIS Short Form - Pain Intensity","C119610","A questionnaire that measures a patient's self-reported health status related to the intensity of pain they are experiencing.","PROMIS Short Form - Pain Intensity | Patient Reported Outcomes Measurement Information System Short Form - Pain Intensity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898038","PROMIS Parent Proxy Short Form - Pain Interference","C119611","A questionnaire that measures a patient's health status related to pain and how that pain interferes with the patient's life, as reported by the patient's parent or legal guardian.","PROMIS Parent Proxy Short Form - Pain Interference | Patient Reported Outcomes Measurement Information System Parent Proxy Short Form - Pain Interference",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898037","PROMIS Pediatric Short Form - Pain Interference","C119612","A questionnaire that measures a pediatric patient's self-reported health status related to pain and how that pain interferes with the patient's life.","PROMIS Pediatric Short Form - Pain Interference | Patient Reported Outcomes Measurement Information System Pediatric Short Form - Pain Interference",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898039","PROMIS Adult Short Form - Pain Interference","C119613","A questionnaire that measures an adult patient's self-reported health status related to pain and how that pain interferes with the patient's life.","PROMIS Adult Short Form - Pain Interference | Patient Reported Outcomes Measurement Information System Adult Short Form - Pain Interference",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520396","11q22","C13916","A chromosome band present on 11q","11q22 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0238707","Decreased Attention","C117245","Impaired ability to focus on a subject or idea.","Decreased Attention | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827790","Transmammary Route of Administration","C111326","Administration into the body through colostrum or milk.","Transmammary Route of Administration | TRANSMAMMARY | Transmammary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1370196","Intrathecal Space","C12943","The fluid-filled space between the thin layers of tissue that cover the brain and spinal cord.","Intrathecal Space | Intrathecal | intrathecal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897941","Peritumoral","C119010","Located in tissues surrounding a tumor.","Peritumoral | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL480749","Hepatolithiasis","C119011","The presence of solitary or multiple stones in the intrahepatic bile ducts.","Hepatolithiasis | ",,,,,,,,,,,,,,,"4178553","Liver calculus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0193425","Hepaticojejunostomy","C119012","A reconstructive surgical procedure involving the anastomosis of the hepatic duct to the jejunum.","Hepaticojejunostomy | ",,,,,,,,,,,,,,,"4173612","Hepatojejunostomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1537799","MIR145 Gene","C81740","This gene is involved in the regulation of gene expression and plays a role in the development of colorectal and prostate carcinomas as well as chronic lymphocytic leukemia, Burkitt lymphoma and diffuse large B-cell lymphoma.","MIR145 Gene | MIR145 | MicroRNA 145 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897978","Patient Outcomes Registry","C119669","A registry that uses observational study methods to collect uniform data to evaluate specified outcomes for a defined patient population, and that serves a scientific, clinical, or policy purpose.","Patient Outcomes Registry | Outcomes Registry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963758","Immunomodulation Therapy","C116540","Any treatment modality that exercises its effects by inducing, enhancing, or suppressing an immune response.","Immunomodulation Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706584","MLL wt Allele","C53066","Human KMT2A wild-type allele is located in the vicinity of 11q23 and is approximately 89 kb in length. This allele, which encodes histone-lysine N-methyltransferase 2A protein, is involved in the modulation of transcription by RNA Polymerase II. Several acute leukemias are associated with translocations of the gene.","KMT2A wt Allele | ALL-1 | ALL1 | CXXC7 | HRX | HTRX | HTRX1 | Lysine (K)-Specific Methyltransferase 2A Gene | Lysine Methyltransferase 2A wt Allele | MLL | MLL wt Allele | MLL1 | MLL1A | Mixed Lineage Leukemia Gene | Myeloid-Lymphoid Leukemia Gene | Myeloid/Lymphoid Leukemia Gene | Myeloid/Lymphoid or Mixed Lineage Leukemia Gene | Myeloid/Lymphoid or Mixed-Lineage Leukemia (Trithorax (Drosophila) Homolog) Gene | Myeloid/Lymphoid or Mixed-Lineage Leukemia (Trithorax Homolog, Drosophila) Gene | TRX1 | Trithorax, Drosophila, Homolog of Gene | WDSTS | hCG_1732268",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418696","PRRX1 Gene","C98030","This gene plays a role in both transcriptional regulation and muscle cell development.","PRRX1 Gene | PRRX1 | Paired Related Homeobox 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1264183","Hodgkin's Disease, Nodular Sclerosis, Lymphocyte Predominance","C27270","No Value Exists","Hodgkin's Disease, Nodular Sclerosis, Lymphocyte Predominance | ",,,,,,,,,,,,,,,"4079689","Hodgkin's disease, nodular sclerosis - lymphocytic predominance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3274034","KRAS NM_004985.3:c.34G>C","C98387","A nucleotide substitution at position 34 of the coding sequence of the KRAS gene where guanine has been mutated to cytosine.","KRAS NM_004985.3:c.34G>C | C-K-RAS c.34G>C | Codon 12, Gly12 Arg (GGT>CGT) | KI-RAS c.34G>C | KRAS c.34G>C | KRAS1 c.34G>C | KRAS2 c.34G>C | NM_004985.3:c.34G>C | v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog c.34G>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274013","KRAS NM_004985.3:c.34G>T","C98366","A nucleotide substitution at position 34 of the coding sequence of the KRAS gene where guanine has been mutated to thymine.","KRAS NM_004985.3:c.34G>T | C-K-RAS c.34G>T | Codon 12, Gly12Cys (GGT>TGT) | KI-RAS c.34G>T | KRAS c.34G>T | KRAS1 c.34G>T | KRAS2 c.34G>T | NM_004985.3:c.34G>T | v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog c.34G>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274017","KRAS NM_004985.3:c.35G>A","C98370","A nucleotide substitution at position 35 of the coding sequence of the KRAS gene where guanine has been mutated to adenine.","KRAS NM_004985.3:c.35G>A | C-K-RAS c.35G>A | Codon 12, Gly12Asp (GGT>GAT) | KI-RAS c.35G>A | KRAS c.35G>A | KRAS1 c.35G>A | KRAS2 c.35G>A | NM_004985.3:c.35G>A | v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog c.35G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274039","KRAS NM_004985.3:c.35G>T","C98392","A nucleotide substitution at position 35 of the coding sequence of the KRAS gene where guanine has been mutated to thymine.","KRAS NM_004985.3:c.35G>T | C-K-RAS c.35G>T | Codon 12, Gly12Val (GGT>GTT) | KI-RAS c.35G>T | KRAS c.35G>T | KRAS1 c.35G>T | KRAS2 c.35G>T | NM_004985.3:c.35G>T | v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog c.35G>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006933","Capsid","C16383","The outer protective shell of a virus. The structure of the shell is icosahedral with either helical or complex symmetry. Capsid proteins surround and protect the viral nucleic acid core.","Capsid Protein | Capsid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890735","Complete Response with Incomplete Platelet Recovery","C118794","The disappearance of all signs of cancer in response to treatment, accompanied by incomplete platelet recovery (platelet count is less than 100,000/uL).","Complete Response with Incomplete Platelet Recovery | CRp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986526","Germline DNA","C94480","The DNA in germ cells (egg or sperm).","Germline DNA | GERMLINE DNA | germline DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039468","Temazepam","C29488","A benzodiazepine derivative with antidepressant, sedative, hypnotic and anticonvulsant properties. Temazepam potentiates the inhibitory activities of gamma-aminobutyric acid (GABA) by binding to the GABA receptor, located in the limbic, neocortical and mesencephalic reticular system. This increases the frequency of chloride channel opening events, allowing the flow of chloride ions into the neuron leading to membrane hyperpolarization and decreases neuronal excitability.","Temazepam | 10-chloro-4-hydroxy-6-methyl-2-phenyl-3,6-diazabicyclo[5.4.0]undeca-2,8,10,12-tetraen-5-one | Oxydiazepam | Ro 5-5345 | TEMAZEPAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0135166","Pamabrom","C81076","A mixture containing 2-amino-2-methyl-1-propanol and 8-bromotheophylline (a methylxanthine) in a 1:1 ratio, with mild diuretic activity.","Pamabrom | PAMABROM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376520","Dietary Iron","C68256","Forms of the element iron found in foods.","Dietary Iron | Fe | Iron",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033229","Prochlorperazine","C774","A synthetic propylpiperazine derivative of phenothiazine with antiemetic, antipsychotic, antihistaminic, and anticholinergic activities.  Prochlorperazine antagonizes the dopamine D2-receptor in the chemoreceptor trigger zone (CTZ) of the brain and may prevent chemotherapy-induced emesis. (NCI04)","Prochlorperazine | 2-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine | Compro | PROCHLORPERAZINE | RP 6140 | SKF-4657 | prochlorperazine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032825","Potassium Chloride","C47679","A metal halide composed of potassium and chloride. Potassium maintains intracellular tonicity, is required for nerve conduction, cardiac, skeletal and smooth muscle contraction, production of energy, the synthesis of nucleic acids, maintenance of blood pressure and normal renal function. This agent has potential antihypertensive effects and when taken as a nutritional supplement may prevent hypokalemia.","Potassium Chloride | Cena-K | K-Lor | Klorvess | Klotrix | POTASSIUM CHLORIDE | Potasalan | Slow-K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028978","Omeprazole","C716","A benzimidazole with selective and irreversible proton pump inhibition activity. Omeprazole forms a stable disulfide bond with the sulfhydryl group of the hydrogen-potassium (H+ - K+) ATPase found on the secretory surface of parietal cells, thereby inhibiting the final transport of hydrogen ions (via exchange with potassium ions) into the gastric lumen and suppressing gastric acid secretion. This agent exhibits no anticholinergic activities and does not antagonize histamine H2 receptors.","Omeprazole | 5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole | H168/68 | Losec | OMEP | OMEPRAZOLE | Prilosec | omeprazole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898933","Have Swelling in Stomach Area","C119698","A question about whether an individual has or had swelling in the area of the stomach.","Have Swelling in Stomach Area | I have swelling in my stomach area",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898964","Have Cramps in Stomach Area","C119699","A question about whether an individual has or had cramps in the area of the stomach.","Have Cramps in Stomach Area | I have cramps in my stomach area",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537708","MIR10B Gene","C81759","This gene is involved in the regulation of gene expression and plays a role in the development of carcinoma of the breast.","MIR10B Gene | MIR10B | MicroRNA 10b Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537861","MIR223 Gene","C80727","This gene is involved in the regulation of gene expression and plays a role in the development of hepatocellular and ovarian carcinomas, acute promyelocytic leukemia and chronic myeloid leukemia.","MIR223 Gene | MIR223 | MicroRNA 223 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537713","MIR17 Gene","C80715","This gene is involved in the regulation of gene expression and plays an oncogenic role in hepatocellular, lung, colorectal, thyoid and breast carcinomas, various leukemias and lymphomas, and neuroblastoma..","MIR17 Gene | MIR17 | MicroRNA 17 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537816","MIR182 Gene","C81747","This gene is involved in the regulation of gene expression.","MIR182 Gene | MIR182 | MicroRNA 182 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537798","MIR144 Gene","C81778","This gene is involved in the regulation of gene expression. While it has no known role in oncogenesis, MIR144 plays a role in the development of thalassemia.","MIR144 Gene | MIR144 | MicroRNA 144 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511671","DNA Image Cytometry","C20098","A technique for quantitation of cell DNA content.","DNA Image Cytometry | DNA Content Analysis | DNA ICM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641247","FDG-Positron Emission Tomography","C103400","An imaging technique that utilizes positron emission tomography to produce a three-dimensional image of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced into the body on the biologically active molecule (fludeoxyglucose) FDG. FDG is an analogue of glucose which when imaged will give tissue metabolic activity, in terms of regional glucose uptake.","FDG-Positron Emission Tomography | FDG | FDG-PET | FDG-PET Imaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527304","Allergic Reaction","C114476","An immune response that occurs following re-exposure to an innocuous antigen, and that requires the presence of existing antibodies against that antigen. This response involves the binding of IgE to mast cells, and may worsen with repeated exposures.","Allergic Reaction | Allergic reaction | Allergies | Allergy | allergic response",,,,,,,,,,,,,,,"40589905","Allergic reaction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898598","Likert Score 0","C119732","A subjective score of 0 on a Likert scale.","Likert Score 0 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898597","Likert Score 10","C119733","A subjective score of 10 on a Likert scale.","Likert Score 10 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897621","Shade in the Areas Where You Feel Pain","C119753","Instruction that an individual indicate by shading on a diagram of the body the area where they feel pain.","Shade in the Areas Where You Feel Pain | Shade in the areas where you feel pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898464","Mark the Area of Most Intense Pain","C119754","Instruction that an individual mark on a diagram of the body the area where they feel the most intense pain.","Mark the Area of Most Intense Pain | Area that hurts the most",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897620","Shade","C119755","To darken on a drawing or illustration.","Shade | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035328","Retinal Vein Occlusion","C34981","An occlusion of the retinal vein.","Retinal Vein Occlusion | ",,,,,,,,,,,,,,,"37165085","Retinal vein occlusion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3900196","6 Minute Walk Functional Test","C115789","A standardized rating scale developed by Bruno Blake in 1963, which is a performance-based evaluation of functional exercise capacity in subjects with chronic respiratory disease and heart failure, as well as other populations such as healthy older adults and people suffering from fibromyalgia and scleroderma. This functional test contains 6 items and measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface.","6 Minute Walk Functional Test | 6MWT | SIX MINUTE WALK | SIXMW1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898741","Intensity of Pain at its Worst","C119955","A question about the intensity of an individual's pain at its worst.","Intensity of Pain at its Worst | How intense was your pain at its worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898742","Intensity of Average Pain","C119956","A question about the intensity of an individual's average pain.","Intensity of Average Pain | Average Pain Intensity | How bad was your pain on average | How intense was your average pain | Level of Average Pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3840282","Level of Current Pain","C119957","A question about the level of an individual's current pain.","Level of Current Pain | Intensity of Current Pain | Intensity of Pain Right Now | Level of Pain Right Now | What is your level of pain right now",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897323","Trouble Sleeping When in Pain","C119958","A question about whether a person had trouble sleeping when they had pain.","Trouble Sleeping When in Pain | I had trouble sleeping when I had pain | Trouble Sleeping Due to Pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899143","Felt Angry When in Pain","C119959","A question about whether a person felt angry when they had pain.","Felt Angry When in Pain | Felt Angry Due to Pain | I felt angry when I had pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897324","Trouble Doing Schoolwork When in Pain","C119960","A question about whether a person had trouble doing schoolwork when they had pain.","Trouble Doing Schoolwork When in Pain | I had trouble doing schoolwork when I had pain | Trouble Doing Schoolwork Due to Pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898984","Hard to Pay Attention When in Pain","C119961","A question about whether a person had trouble paying attention when they had pain.","Hard to Pay Attention When in Pain | Hard to Pay Attention Due to Pain | It was hard for me to pay attention when I had pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897014","Hard to Run When in Pain","C119962","A question about whether a person had trouble running when they had pain.","Hard to Run When in Pain Question | Hard to Run Due to Pain | Hard to Run When in Pain | Hard to Run When in Pain | It was hard for me to run when I had pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898982","Hard to Walk One Block When in Pain","C119963","A question about whether a person had trouble walking one block when they had pain.","Hard to Walk One Block When in Pain Question | Hard to Walk One Block Due to Pain | Hard to Walk One Block When in Pain | Hard to Walk One Block When in Pain | It was hard for me to walk one block when I had pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898985","Hard to Have Fun When in Pain","C119964","A question about whether a person had trouble having fun when they had pain.","Hard to Have Fun When in Pain | Hard to Have Fun Due to Pain | It was hard to have fun when I had pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898983","Hard to Stay Standing When in Pain","C119965","A question about whether a person had trouble staying standing when they had pain.","Hard to Stay Standing When in Pain | Hard to Stay Standing Due to Pain | It was hard to stay standing when I had pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899680","Child Had Trouble Sleeping When in Pain","C119966","A question about whether a person's child had trouble sleeping when they had pain.","Child Had Trouble Sleeping When in Pain | Child Had Trouble Sleeping Due to Pain | My child had trouble sleeping when he/she had pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899685","Child Felt Angry When in Pain","C119967","A question about whether a person's child felt angry when they had pain.","Child Felt Angry When in Pain | Child Felt Angry Due to Pain | My child felt angry when he/she had pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899684","Child Had Trouble Doing Schoolwork When in Pain","C119968","A question about whether a person's child had trouble doing schoolwork when they had pain.","Child Had Trouble Doing Schoolwork When in Pain | Child Had Trouble Doing Schoolwork Due to Pain | My child had trouble doing schoolwork when he/she had pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899682","Child Had Trouble Paying Attention When in Pain","C119969","A question about whether a person's child had trouble paying attention when they had pain.","Child Had Trouble Paying Attention When in Pain | Child Had Trouble Paying Attention Due to Pain | It was hard for my child to pay attention when he/she had pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899681","Child Had Trouble Running When in Pain","C119970","A question about whether a person's child had trouble running when they had pain.","Child Had Trouble Running When in Pain | Child Had Trouble Running Due to Pain | It was hard for my child to run when he/she had pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899678","Child Had Trouble Walking One Block When in Pain","C119971","A question about whether a person's child had trouble walking one block when they had pain.","Child Had Trouble Walking One Block When in Pain Question | Child Had Trouble Walking One Block Due to Pain | Child Had Trouble Walking One Block When in Pain | Child Had Trouble Walking One Block When in Pain | It was hard for my child to walk one block when he/she had pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899683","Child Had Trouble Having Fun When in Pain","C119972","A question about whether a person's child had trouble having fun when they had pain.","Child Had Trouble Having Fun When in Pain | Child Had Trouble Having Fun Due to Pain | It was hard for my child to have fun when he/she had pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899679","Child Had Trouble Staying Standing When in Pain","C119973","A question about whether a person's child had trouble staying standing when they had pain.","Child Had Trouble Staying Standing When in Pain | Child Had Trouble Staying Standing Due to Pain | It was hard for my child to stay standing when he/she had pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898848","How Much Did Pain Interfere with Day to Day Activity","C119974","A question about how much a person's pain interferes or interfered with their day to day activities.","How Much Did Pain Interfere with Day to Day Activity Question | How Much Did Pain Interfere with Day to Day Activity | How Much Did Pain Interfere with Day to Day Activity | How Much Did Pain Interfere with General Activity | How much did pain interfere with your day to day activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898840","How Much Did Pain Interfere with Work Around the Home","C119975","A question about how much a person's pain interferes or interfered with their work around the home.","How Much Did Pain Interfere with Work Around the Home | How much did pain interfere with work around the home",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898849","How Much Did Pain Interfere with Ability to Participate in Social Activities","C119976","A question about how much a person's pain interferes or interfered with their ability to participate in social activities.","How Much Did Pain Interfere with Ability to Participate in Social Activities | How much did pain interfere with your ability to participate in social activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898846","How Much Did Pain Interfere with Enjoyment of Life","C119977","A question about how much a person's pain interferes or interfered with their enjoyment of life.","How Much Did Pain Interfere with Enjoyment of Life | How much did pain interfere with your enjoyment of life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898841","How Much Did Pain Interfere with Things Usually Done for Fun","C119978","A question about how much a person's pain interferes or interfered with the things they do for fun.","How Much Did Pain Interfere with Things Usually Done for Fun | How much did pain interfere with the things you usually do for fun",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898844","How Much Did Pain Interfere with Enjoyment of Social Activities","C119979","A question about how much a person's pain interferes or interfered with their enjoyment of social activities.","How Much Did Pain Interfere with Enjoyment of Social Activities | How much did pain interfere with your enjoyment of social activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898842","How Much Did Pain Interfere with Household Chores","C119980","A question about how much a person's pain interferes or interfered with their ability to do their household chores.","How Much Did Pain Interfere with Household Chores | How much did pain interfere with your household chores",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898843","How Much Did Pain Interfere with Family Life","C119981","A question about how much a person's pain interferes or interfered with family life.","How Much Did Pain Interfere with Family Life | How much did pain interfere with your family life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898850","How Much Did Pain Interfere with Ability to Concentrate","C119982","A question about how much a person's pain interferes or interfered with their ability to concentrate.","How Much Did Pain Interfere with Ability to Concentrate | How much did pain interfere with your ability to concentrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898845","How Much Did Pain Interfere with Enjoyment of Recreational Activities","C119983","A question about how much a person's pain interferes or interfered with their enjoyment of recreational activities.","How Much Did Pain Interfere with Enjoyment of Recreational Activities | How much did pain interfere with your enjoyment of recreational activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898847","How Much Did Pain Interfere with Doing Tasks Away from Home","C119984","A question about how much a person's pain interferes or interfered with their ability to do tasks outside the home.","How Much Did Pain Interfere with Doing Tasks Away from Home | How much did pain interfere with doing your tasks away from home (e.g., getting groceries, running errands)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898839","How Often Did Pain Prevent Socializing","C119985","A question about how often a person's pain kept them from socializing with others.","How Often Did Pain Prevent Socializing | How often did pain keep you from socializing with others",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3844113","Almost All of the Time","C119986","A response indicating that something happens or happened almost all of the time.","Almost All of the Time | Almost All | Almost Always | Almost all the Time | Almost all the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891813","Had No Pain","C119987","A response indicating that an individual has or had no pain.","Had No Pain | Had no pain | No Pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520381","11q13","C13484","A chromosome band present on 11q","11q13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421249","TYK2 Gene","C101546","This gene is involved in both protein phosphorylation and interferon-mediated signaling.","TYK2 Gene | TYK2 | Tyrosine Kinase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1822705","SH2B3 Gene","C102802","This gene plays a role in T-cell activation.","SH2B3 Gene | SH2B Adaptor Protein 3 Gene | SH2B3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420343","SPARCL1 Gene","C106064","This gene may be involved in leukocyte transendothelial migration.","SPARCL1 Gene | SPARC-Like 1 (Hevin) Gene | SPARCL1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521378","4p16.3","C14033","A chromosome band present on 4p","4p16.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332435","BNIP3L Gene","C21373","This gene is involved in the regulation of apoptosis and induces cell death.","BNIP3L Gene | BCL2/Adenovirus E1B 19kd Interacting Protein 3-Like Gene | BNIP3L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520751","17p13.1","C13628","A chromosome band present on 17p","17p13.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422599","PPP1R15A Gene","C97251","This gene is involved in phosphatase regulation.","PPP1R15A Gene | PPP1R15A | Protein Phosphatase 1, Regulatory Subunit 15A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079471","HRAS Gene","C17060","This gene plays a role in signal transduction and cellular communication.","HRAS Gene | H-ras gene | HRAS | HRas Proto-Oncogene, GTPase Gene | Hras gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896997","Marrow Toxic Injury","C120064","An injury to the bone marrow resulting from exposure to high levels of ionizing radiation or exposure to other hazardous material.","Marrow Toxic Injury | Toxic Injury | Toxic Marrow Injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273373","South Sudan","C97351","A country in east central Africa south of Sudan, north of Uganda and Kenya, and west of Ethiopia.","South Sudan | 728 | Republic of South Sudan | SOUTH SUDAN | SS | SSD | Southern Sudan",,,,,,,,,,,,,,,"37162257","South Sudan",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0454684","Sint Maarten (Dutch Part)","C101226","A country comprising the southern portion of an island in the Caribbean sea, between Anguilla and Saint Barthelemy, a constituent country of the Kingdom of the Netherlands.","Sint Maarten (Dutch Part) | 534 | SINT MAARTEN | SINT MAARTEN (DUTCH PART) | SINT MAARTEN (DUTCH) | SX | SXM | Saint Martin, Dutch | Saint Martin, Netherlands",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0454665","Curacao","C101225","An island in the Caribbean Sea, north of Venezuela and east of Aruba, a constituent country of the Kingdom of the Netherlands.","Curacao | 531 | CURACAO | CURAÇAO | CUW | CW | Curaçao",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541236","Bonaire, Sint Eustatius and Saba","C101224","Three islands comprising the Caribbean portion of the Netherlands, north of Venezuela and east of Curacao.","Bonaire, Sint Eustatius and Saba | 535 | BES | BONAIRE, SINT EUSTATIUS AND SABA | BONAIRE, SINT EUSTATIUS, AND SABA | BQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0338656","Cognitive Impairment","C116921","Diminished mental function.","Cognitive Impairment | Cognitive difficulty",,,,,,,,,,,,,,,"443432","Impaired cognition",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518472","Numerical Chromosomal Abnormality","C6825","An irregularity in the number of chromosomes.","Numerical Chromosomal Abnormality | Numerical Chromosomal Abnormalities | Numerical Chromosome Aberration | Numerical Chromosome Anomalies | Numerical Chromosome Anomaly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521452","Chromosome 5 Short Arm","C13558","Proximal (short) arm of chromosome 5","5p | Chromosome 5 Proximal Arm | Chromosome 5 Short Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521380","4q","C13556","Distal (long) arm of chromosome 4","4q | Chromosome 4 Distal Arm | Chromosome 4 Long Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520354","Chromosome 11 Short Arm","C13529","Proximal (short) arm of chromosome 11","11p | Chromosome 11 Proximal Arm | Chromosome 11 Short Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796348","Chromosome 8 Short Arm","C13381","Proximal (short) arm of chromosome 8","8p | Chromosome 8 Proximal Arm | Chromosome 8 Short Arm | Chromosome 8p",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520214","Yp","C26045","The proximal (short) arm of chromosome Y.","Yp | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520179","Chromosome X Long Arm","C13566","Distal (long) arm of chromosome X","Xq | Chromosome X Distal Arm | Chromosome X Long Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520168","Chromosome X Short Arm","C13565","Proximal (short) arm of chromosome X","Xp | Chromosome X Proximal Arm | Chromosome X Short Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520795","Chromosome 18 Short Arm","C13544","Proximal (short) arm of chromosome 18","18p | Chromosome 18 Proximal Arm | Chromosome 18 Short Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1291204","2-Hydroxybutyrate","C120002","A hydroxy fatty acid anion and conjugate base of 2-hydroxybutyric acid. 2-Hydroxybutyrate is a metabolite produced by the conversion of cystathionine to cysteine in the glutathione biosynthesis pathway. The amount of 2-hydroxybutyrate secreted in the urine can reflect changes in the rate of glutathione synthesis, which is altered by oxidative stress or toxin exposure.","2-Hydroxybutyrate | 2-Hydroxybutanoate | 2-OH Butyrate | 2-OH-Butyrate | Alpha-Hydroxybutanoate | Alpha-Hydroxybutyrate | a-HB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0106006","3-Hydroxybutyrate","C120003","A hydroxy fatty acid anion and ketone body synthesized in the liver from acetyl-Coenzyme A (acetyl-CoA) by the enzyme 3-hydroxybutyrate dehydrogenase. 3-hydroxybutyrate can be used as an energy source when glucose levels drop. Elevated urine and serum levels of 3-hydroxybutyrate are seen in ketosis and ketoacidosis.","3-Hydroxybutyrate | 3-Hydroxybutanoate | 3-OH Butyrate | 3-OH-Butyrate | Beta-Hydroxy-n-Butyrate | Beta-Hydroxybutanoate | b-HB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001109","Acid Phosphatase","C120022","A family of phosphatases that add monophosphates to substrates. The optimal pH for activity of these enzymes is below 7.","Acid Phosphatase | Acid Monophosphatase | Acid Nucleoside Diphosphate Phosphatase | Acid Phosphohydrolase | Acid Phosphomonoester Hydrolase | Acid Phosphomonoesterase | EC 3.1.3.2 | Glycerophosphatase | Orthophosphoric-Monoester Phosphohydrolase (Acid Optimum) | Orthophosphoric-Monoester Phosphohydrolase (Acid Optimum);  | Phosphate-Monoester Phosphohydrolase (Acid Optimum) | Phosphomonoesterase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896701","Aminoadipic Semialdehyde","C120012","An amino acid derivative that is a product of lysine degradation. This metabolite is associated with oxidative stress. Elevated urine levels of aminoadipic semialdehyde (AASA) are seen in patients with AASA dehydrogenase deficiency.","Aminoadipic Semialdehyde | AASA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0051834","androsterone glucuronide","C120007","A glucuronosyltransferase-modified, liver metabolite of the steroid androsterone and metabolite of the steroid dihydrotestosterone found in serum, with weak androgenic activity.","Androsterone Glucuronide | 3alpha-Hydroxy-5alpha-Androstan-17-One Glucuronide | ADT-G | ANDROSTERONE GLUCURONIDE | Androsterone 3-Glucosiduronic Acid | Androsterone 3-Glucuronide | Androsterone Glucosiduronate | Androsterone-G | Beta-D-Glucopyranosiduronic Acid, (3alpha,5alpha)-17-Oxoandrostan-3-Yl | Etiocholanolone Glucuronide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0051835","Androsterone Sulfate","C120008","A sulfated form of androsterone and a steroid metabolite derived from testosterone found in urine, with weak androgenic activity.","Androsterone Sulfate | (5alpha)-17-Oxoandrostan-3alpha-Yl Hydrogen Sulfate | 3alpha-Hydroxy-5alpha-Androstan-17-One Monosulfate | 3alpha-Hydroxy-5alpha-Androstan-17-One Sulfate | 5alpha-Androsterone Sulfate | ANDROSTERONE SULFATE | Andros-S | Androstan-17-One, 3-(Sulfooxy)-, (3alpha,5alpha)- | Androsterone 3alpha-Sulfate | Androsterone Monosulfate | Androsterone, Hydrogen Sulfate | Androsterone-S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899842","CA125 II Assay","C120015","A second generation radioimmunoassay to measure serum levels of CA-125.","CA125 II Assay | CA125 II | CA125-II | CA125-II Assay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413391","CHIT1 Gene","C120051","This gene is involved in the catabolism of chitins.","CHIT1 Gene | CHIT1 | Chitinase 1 (Chitotriosidase) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0109497","Cholate","C120004","An ester or salt of the bile acid cholic acid that is synthesized in the liver from cholesterol, with surfactant and signaling activities in the liver and intestine. In the intestine, cholate acts as a surfactant that promotes the absorption of dietary lipids and fat-soluble vitamins. In the liver, cholate's surfactant activity facilitates biliary excretion of xenobiotics and metal cations. Cholate binds to nuclear receptors, including farnesoid X receptor (FXR), pregnane X receptor (PXR), and the vitamin D receptor (VDR), which directly modulate gene transcription. Cholate may also be used as a biomarker for hepatotoxicity.","Cholate | 3alpha,7alpha,12alpha-Trihydroxy-5beta-Cholan-24-Oate | 3alpha,7alpha,12alpha-Trihydroxy-5beta-Cholanate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0631180","Cross-Linked C-Terminal Telopeptide of Type I Collagen","C120031","This polypeptide is comprised of the carboxy-terminal portions of fibrillar collagen, which are joined through trivalent crosslinks and released during the degradation of mature type I collagen by cathepsin K. Serum concentrations of these peptides can be correlated with the rate of bone metabolism.","CTX | C-Telopeptide | C-Terminal Telopeptide Type 1 Collagen | C-Terminal Telopeptide Type I Collagen | CTX-I | CTXI | Collagen Type 1 Cross-linked C-Telopeptide | Cross-Linked C-Terminal Telopeptide of Type I Collagen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896680","Dehydroepiandrosterone 3-Glucuronide","C120009","A glucuronosyltransferase-catalyzed, liver metabolite of the steroid dehydroepiandrosterone (DHEA), which is an intermediate in the conversion of cholesterol to androgens and estrogens.","Dehydroepiandrosterone 3-Glucuronide | (3beta)-17-Oxoandrost-5-En-3-Yl Beta-D-Glucopyranosiduronic Acid | DHEA-G | Dehydroepiandrosterone Glucopyranuronoside | Dehydroisoandrosterone Glucopyranuronoside",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011535","Deoxyuridine","C120006","A nucleoside consisting of uracil and deoxyribose, which can act as an intermediate in thymidine synthesis. Deoxyuridine (dU) is used to indirectly determine if there are sufficient levels of folate and cobalamin in cell or tissue samples.","Deoxyuridine | 1-(2-Deoxy-Beta-D-Erythro-Pentofuranosyl)Uracil | 1-(2-Deoxy-Beta-D-Erythro-Pentofuranoxyl)Uracil | 2'-Deoxyuridine | 2'-Desoxyuridine | 2,4(1H,3H)-Pyrimidinedione, 1-(2-Deoxy-Beta-D-Erythro-Ribofuranosyl)- | 2,4(1H,3H)-Pyrimidinedione, 1-(2-Deoxy-Beta-D-Erythro-Ribofuranosyl)-; | 2,4(1H,3H)-Pyrimidinedione, 1-(2-Deoxy-Beta-D-Ribofuranosyl)- | 2,4(1H,3H)-Pyrimidinedione, 1-(2-Deoxy-Beta-D-Ribofuranosyl)-;  | 2-Deoxyuridine | DEOXYURIDINE | Deoxyribose Uracil | Uracil Deoxyriboside | Uridine, 2'-Deoxy- | dU | dURD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012063","Dicarboxylic Acid","C120005","An organic acid that contains oxygen and two carboxyl groups.","Dicarboxylic Acid | Dicarboxylic Acids",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899312","ENAH Protein Isoform Expression Assay","C120021","A proprietary immunofluorescent assay that quantifies the relative expression levels of all isoforms of the actin regulatory protein, protein enabled homolog (Mena or ENAH), including Mena(INV) and Mena11a. Mena(INV) expression is elevated and Mena11a expression is diminished or absent in invasive tumor cells, which may have increased metastatic potential. Therefore, this assay may be able to predict a patient's risk for tumor metastasis.","ENAH Protein Isoform Expression Assay | Mena Protein Isoform Expression Assay | MenaCalc | MenaCalc Platform | Protein Enabled Homolog Isoform Expression Assay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3156618","Endothelial Cell-Derived Microparticle","C120028","A small, membrane bound vesicle circulating in the blood that was shed by an endothelial cell. Increased concentrations of endothelial microparticles in plasma may be a marker for cardiovascular disease.","Endothelial Cell-Derived Microparticle | Endothelial Microparticle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899239","Exhausted T-Cell","C120000","An effector T-lymphocyte that is losing or has lost the ability to kill virally infected cells. T-cell exhaustion occurs during infections with high viral loads and/or prolonged duration. These T-lymphocytes undergo a gradual phenotype change and in the final stage they are unable to mount a T-cell antiviral response and are highly susceptible to apoptosis.","Exhausted T-Cell | Exhausted T Cell | Exhausted T Lymphocyte | Exhausted T-Lymphocyte",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899184","F4-Isoprostane","C120010","A prostaglandin-like compound derived from the peroxidation of docosahexaenoic acid. This modified lipid may be used as a marker for oxidative damage and may be associated with neuropathy and aging.","F4-Isoprostane | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899165","FLT3 Activation Loop Mutation","C120063","A mutation in the region of the FLT3 gene that encodes the second tyrosine kinase domain of the receptor-type tyrosine-protein kinase FLT3 that causes the stabilization of the activation loop of the kinase domain. FLT3 activation loop mutations lead to constitutive tyrosine kinase activity and are associated with acute myeloid leukemia.","FLT3 Activation Loop Mutation | FLT3 A-Loop Mutation | FLT3 Tyrosine Kinase Domain Mutation | FLT3- TKD mutations | FLT3-ALM | FLT3-TKD Mutation | FLT3/TKD Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899031","Germinal Center B-Cell Gene Expression Signature","C120019","A gene expression profile found in a subset of diffuse large B-cell lymphomas. This expression profile is associated with better overall survival.","Germinal Center B-Cell Gene Expression Signature | Germinal Center B Cell Gene Expression Signature | Germinal Center B Cell-Like Gene Expression Signature | Germinal Center B-Cell-Like Gene Expression Signature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898882","H3K27ac","C120023","A post-translationally modified form of histone H3 where the lysine residue at position 28 is acetylated. This modification may be a marker for transcriptional enhancement.","Histone H3 Acetyl Lys28 | H3K27ac | H3K28ac | Histone H3 Acetyl Lys27 | Histone H3 Acetyl Lys27 | Histone H3 Acetyl Lysine 28",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896986","Histone H3 Methyl Lys4","C120024","A form of histone H3 where the lysine residue at position 4 has been post-translationally modified with a single methyl group. This modification may be a marker for transcriptionally active genes.","Histone H3 Methyl Lys4 | H3K4me1 | Histone H3 Methyl Lysine 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422104","KDM2B Gene","C120057","This gene is involved in demethylation of histone H3.","KDM2B Gene | KDM2B | Lysine (K)-Specific Demethylase 2B Gene | Lysine Specific Demethylase 2B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600472","Long Interspersed Nucleotide Element-1","C120020","A long interspersed element (LINE) found in mammals. The LINE-1 element is the only active LINE in humans and is approximately 6,000 base pairs long. This nucleotide sequence consists of two non-overlapping open reading frames (ORF) flanked by a 5' untranslated region (UTR), which contains a strong RNA polymerase II promoter sequence, and target side duplications. The first ORF encodes a 500 amino acid, ~40 kDa leucine zipper-containing RNA-binding protein. The second ORF encodes an ~150 kDa protein that has endonuclease and reverse transcriptase activity. Increased LINE-1 copy number is associated with cancer and neuropathy.","Long Interspersed Nucleotide Element-1 | L-1 | L-1 Element | L1 | L1-Element | LINE-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898563","Lymph Node Gene Expression Signature","C120016","A gene expression profile that indicates that a patient sample may have originated in or adopted the behavior of lymph node tissue. This gene signature may be associated with a better prognosis for melanoma patients.","Lymph Node Gene Expression Signature | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL481276","Malondialdehyde-Lysine","C120014","A lysine modification found in proteins resulting from a malondialdehyde attachment to the protein lysine residue. This advanced glycation end product (AGE) is elevated in certain diseases and is associated with aging.","Malondialdehyde-Lysine | MDA-Lys | MDAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1294297","Masson Trichrome Staining Method","C120047","A method that sequentially exposes tissues samples to three acid dyes and acid washes, which can differentiate between collagen and smooth muscle in those samples. The classic recipe for this histological staining method uses Weigert's Iron hematoxylin, which stains nuclei brown or black, Biebrich Scarlet, which dyes the cytoplasm, muscle and keratin pink or red, and aniline blue, which stains collagen and bone blue or green.","Masson Trichrome Staining Method | Masson Trichrome | Masson Trichrome Stain | Masson's Trichrome | Masson's Trichrome Stain | Masson's Trichrome Staining Method",,,,,,,,,,,,,,,"4024959","Masson trichrome stain method",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898551","MHC Class II Gene Expression Signature","C120017","A gene expression profile that provides diagnostic information in diffuse large B-cell lymphoma. Loss of MHC class II expression is correlated with poor patient outcome.","MHC Class II Gene Expression Signature |  Major Histocompatibility Complex Class II Gene Expression Signature | Major Histocompatibility Complex Class II Gene Expression Signature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891282","Monocyte-Derived Microparticle","C120027","A small, membrane bound vesicle circulating in the blood that was shed by a monocyte. These particles may induce coagulation or cell apoptosis.","Monocyte-Derived Microparticle | MDMP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0208736","N(6)-(1-carboxyethyl)lysine","C120011","A lysine derivative found in proteins where the epsilon nitrogen of the amino acid residue is modified by a carboxyethyl group. This advanced glycation end product (AGE) is elevated in certain diseases and may be associated with aging.","N(6)-(1-Carboxyethyl)Lysine | CEL | L-Lysine, N6-(1-Carboxyethyl)- | N(Epsilon)-(1-(1-Carboxy)Ethyl)Lysine | N(Epsilon)-(Carboxyethyl)Lysine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0083528","N(6)-carboxymethyllysine","C120013","A lysine derivative found in proteins where the epsilon nitrogen of the amino acid residue is modified by a carboxymethyl group. This advanced glycation end product (AGE) is elevated in certain diseases and is associated with aging.","N(6)-Carboxymethyllysine | CML | L-Lysine, N6-(Carboxymethyl)- | L-Lysine, N6-(Carboxymethyl)-;  | N(6)-CARBOXYMETHYLLYSINE | N(Epsilon)-(Carboxymethyl)Lysine | N(Epsilon)-Carboxymethyl-L-Lysine | NECML",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418582","PIN1 Gene","C120048","This gene plays a role in the regulation of the post-phosphorylation conformation of protein substrates.","PIN1 Gene | PIN1 | Peptidylprolyl Cis/Trans Isomerase, NIMA-Interacting 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890885","Platelet-Derived Microparticle","C120026","A small, membrane bound vesicle circulating in the blood that was shed by a platelet. This is the most abundant type of microparticle in human blood. Since they contain platelet chemokines and surface proteins, these particles may modulate vascular processes, such as blood coagulation.","Platelet-Derived Microparticle | PDMP | Platelet Microparticle | Platelet-Derived MP | Pt-MP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419007","PSMA5 Gene","C120065","This gene is involved in ATP-dependent protein catabolism.","PSMA5 Gene | PSMA5 | Proteasome (Prosome, Macropain) Subunit, Alpha Type, 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035285","Reticular Fiber","C33468","Proteinaceous fibrils found in connective tissue that are comprised of type III collagen and form a mesh that can support soft tissue structure.","Reticular Fiber | Reticulin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424731","SYNE2 Gene","C120060","This gene plays a role in organelle localization.","SYNE2 Gene | SYNE2 | Spectrin Repeat Containing, Nuclear Envelope 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897394","TARP Antibody","C120032","Any immunoglobulin that recognizes T-cell receptor gamma chain alternative reading frame protein.","TARP Antibody | Anti-CD3G Antibody | Anti-T-Cell Receptor Gamma Chain Alternative Reading Frame Protein Antibody | Anti-TARP Antibody | Anti-TCRg Antibody | CD3G Antibody | T-Cell Receptor Gamma Chain Alternative Reading Frame Protein Antibody | TCRg Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896646","Tissue Factor-Derived Microparticle","C120029","A small, membrane bound vesicle circulating in the blood that was shed by a cell that expresses the coagulation protein, tissue factor (factor III). The presence of microparticles with tissue factor in the plasma of cancer patients is associated with an increased risk for venous thrombosis.","Tissue Factor-Derived Microparticle | MP-TF | Microparticle Tissue Factor | Microparticle-Derived Tissue Factor | TFMP | Tissue Factor-Bearing Microparticle | Tissue Factor-Positive Microparticle | Tissue-Factor-Derived Microparticle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0147080","Tryptase","C120030","A family of serine endoproteinases usually expressed in mast cell secretory granules. These enzymes cleave protein substrates after arginine or lysine residues and play a role in allergic responses.","Tryptase | EC 3.4.21.59",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897283","Tumor Proliferation Gene Expression Signature","C120018","A gene expression profile that predicts survival in mantle cell lymphoma. The lowest expression levels of cyclin D1 were associated with increased survival.","Tumor Proliferation Gene Expression Signature | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1857782","USP17L2 Gene","C120054","This gene plays a role in the deubiquitination of protein substrates.","USP17L2 Gene | USP17L2 | Ubiquitin Specific Peptidase 17-Like Family Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897149","Yq","C120098","The distal (long) arm of chromosome Y.","Yq | Chromosome Y Distal Arm | Chromosome Y Long Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897633","Severity of Symptom Likert Scale","C120071","A scale for the subjective scoring of symptoms that ranges from 0: Not Present to 10: As Bad as You Can Imagine.","Severity of Symptom Likert Scale | MDASI Severity of Symptom Likert Scale | Severity of Symptom Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897632","Severity of Symptom Score 0","C120072","A subjective score of 0 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.","Severity of Symptom Score 0 | 0 | MDASI Severity of Symptom Score 0 | Not Present | Not at all | Score 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897630","Severity of Symptom Score 1","C120073","A subjective score of 1 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.","Severity of Symptom Score 1 | 1 | MDASI Severity of Symptom Score 1 | Score 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897629","Severity of Symptom Score 2","C120074","A subjective score of 2 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.","Severity of Symptom Score 2 | 2 | MDASI Severity of Symptom Score 2 | Score 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897628","Severity of Symptom Score 3","C120075","A subjective score of 3 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.","Severity of Symptom Score 3 | 3 | MDASI Severity of Symptom Score 3 | Score 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897627","Severity of Symptom Score 4","C120076","A subjective score of 4 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.","Severity of Symptom Score 4 | 4 | MDASI Severity of Symptom Score 4 | Score 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897626","Severity of Symptom Score 5","C120077","A subjective score of 5 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.","Severity of Symptom Score 5 | 5 | MDASI Severity of Symptom Score 5 | Score 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897625","Severity of Symptom Score 6","C120078","A subjective score of 6 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.","Severity of Symptom Score 6 | 6 | MDASI Severity of Symptom Score 6 | Score 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897624","Severity of Symptom Score 7","C120079","A subjective score of 7 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.","Severity of Symptom Score 7 | 7 | MDASI Severity of Symptom Score 7 | Score 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897623","Severity of Symptom Score 8","C120080","A subjective score of 8 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.","Severity of Symptom Score 8 | 8 | MDASI Severity of Symptom Score 8 | Score 8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897622","Severity of Symptom Score 9","C120081","A subjective score of 9 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.","Severity of Symptom Score 9 | 9 | MDASI Severity of Symptom Score 9 | Score 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897631","Severity of Symptom Score 10","C120082","A subjective score of 10 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.","Severity of Symptom Score 10 | 10 | As Bad as You Can Imagine | As bad as it can be | MDASI Severity of Symptom Score 10 | Score 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897421","Symptom Interference with Life Likert Scale","C120085","A scale for the subjective scoring of a symptom's interference with life that ranges from 0: Did Not Interfere to 10: Interfered Completely.","Symptom Interference with Life Likert Scale | MDASI Symptom Interference with Life Likert Scale | Symptom Interference with Life Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897420","Symptom Interference with Life Score 0","C120086","A subjective score of 0 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.","Symptom Interference with Life Score 0 | MDASI Symptom Interference with Life Score 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897418","Symptom Interference with Life Score 1","C120087","A subjective score of 1 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.","Symptom Interference with Life Score 1 | MDASI Symptom Interference with Life Score 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897417","Symptom Interference with Life Score 2","C120088","A subjective score of 2 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.","Symptom Interference with Life Score 2 | MDASI Symptom Interference with Life Score 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897416","Symptom Interference with Life Score 3","C120089","A subjective score of 3 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.","Symptom Interference with Life Score 3 | MDASI Symptom Interference with Life Score 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897415","Symptom Interference with Life Score 4","C120090","A subjective score of 4 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.","Symptom Interference with Life Score 4 | MDASI Symptom Interference with Life Score 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897414","Symptom Interference with Life Score 5","C120091","A subjective score of 5 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.","Symptom Interference with Life Score 5 | MDASI Symptom Interference with Life Score 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897413","Symptom Interference with Life Score 6","C120092","A subjective score of 6 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.","Symptom Interference with Life Score 6 | MDASI Symptom Interference with Life Score 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897053","Symptom Interference with Life Score 7","C120093","A subjective score of 7 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.","Symptom Interference with Life Score 7 | MDASI Symptom Interference with Life Score 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897412","Symptom Interference with Life Score 8","C120094","A subjective score of 8 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.","Symptom Interference with Life Score 8 | MDASI Symptom Interference with Life Score 8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897411","Symptom Interference with Life Score 9","C120095","A subjective score of 9 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.","Symptom Interference with Life Score 9 | MDASI Symptom Interference with Life Score 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897419","Symptom Interference with Life Score 10","C120096","A subjective score of 10 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.","Symptom Interference with Life Score 10 | MDASI Symptom Interference with Life Score 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412812","BNIP3 Gene","C120108","This gene plays a role in the stimulation of both apoptosis and autophagy.","BNIP3 Gene | BCL2/Adenovirus E1B 19kDa Interacting Protein 3 Gene | BNIP3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899970","BPI Pain Rating Likert Scale","C120111","A scale for the subjective scoring of pain that ranges from 0: No Pain to 10: Pain as bad as you can imagine.","BPI Pain Rating Likert Scale | BPI Pain Rating Scale | Brief Pain Inventory Pain Rating Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898021","Pain Rating Score 0","C120112","A subjective score of 0 on a scale that ranges from 0: No Pain to 10: Pain As Bad As You Can Imagine.","Pain Rating Score 0 | BPI Pain Rating Score 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898019","Pain Rating Score 1","C120116","A subjective score of 1 on a scale that ranges from 0: No Pain to 10: Pain As Bad As You Can Imagine.","Pain Rating Score 1 | BPI Pain Rating Score 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897112","Pain Rating Score 2","C120117","A subjective score of 2 on a scale that ranges from 0: No Pain to 10: Pain As Bad As You Can Imagine.","Pain Rating Score 2 | BPI Pain Rating Score 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898018","Pain Rating Score 3","C120119","A subjective score of 3 on a scale that ranges from 0: No Pain to 10: Pain As Bad As You Can Imagine.","Pain Rating Score 3 | BPI Pain Rating Score 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898017","Pain Rating Score 4","C120120","A subjective score of 4 on a scale that ranges from 0: No Pain to 10: Pain As Bad As You Can Imagine.","Pain Rating Score 4 | BPI Pain Rating Score 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898016","Pain Rating Score 5","C120122","A subjective score of 5 on a scale that ranges from 0: No Pain to 10: Pain As Bad As You Can Imagine.","Pain Rating Score 5 | BPI Pain Rating Score 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898015","Pain Rating Score 6","C120123","A subjective score of 6 on a scale that ranges from 0: No Pain to 10: Pain As Bad As You Can Imagine.","Pain Rating Score 6 | BPI Pain Rating Score 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898014","Pain Rating Score 7","C120124","A subjective score of 7 on a scale that ranges from 0: No Pain to 10: Pain As Bad As You Can Imagine.","Pain Rating Score 7 | BPI Pain Rating Score 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898013","Pain Rating Score 8","C120125","A subjective score of 8 on a scale that ranges from 0: No Pain to 10: Pain As Bad As You Can Imagine.","Pain Rating Score 8 | BPI Pain Rating Score 8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898012","Pain Rating Score 9","C120126","A subjective score of 9 on a scale that ranges from 0: No Pain to 10: Pain As Bad As You Can Imagine.","Pain Rating Score 9 | BPI Pain Rating Score 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898020","Pain Rating Score 10","C120127","A subjective score of 10 on a scale that ranges from 0: No Pain to 10: Pain As Bad As You Can Imagine.","Pain Rating Score 10 | BPI Pain Rating Score 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899969","BPI Percentage Relief From Pain Treatment or Medication Likert Scale","C120130","A scale for the subjective scoring of the percentage of relief from pain medication or treatment that ranges from 0%: No Relief to 10: Complete Relief.","BPI Percentage Relief From Pain Treatment or Medication Likert Scale | BPI Percentage Relief From Pain Treatment or Medication Scale | Brief Pain Inventory Percentage Relief From Pain Treatment or Medication Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897964","Percentage Relief From Pain Treatment or Medication Score 0","C120131","A subjective score of 0% on a scale that ranges from 0%: No Relief to 100%: Complete Relief.","Percentage Relief From Pain Treatment or Medication Score 0 | BPI Percentage Relief From Pain Treatment or Medication Score 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054203","Percentage Relief From Pain Treatment or Medication Score 10","C120132","A subjective score of 10% on a scale that ranges from 0%: No Relief to 100%: Complete Relief.","Percentage Relief From Pain Treatment or Medication Score 10 | BPI Percentage Relief From Pain Treatment or Medication Score 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053791","Percentage Relief From Pain Treatment or Medication Score 20","C120133","A subjective score of 20% on a scale that ranges from 0%: No Relief to 100%: Complete Relief.","Percentage Relief From Pain Treatment or Medication Score 20 | BPI Percentage Relief From Pain Treatment or Medication Score 20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054202","Percentage Relief From Pain Treatment or Medication Score 30","C120134","A subjective score of 30% on a scale that ranges from 0%: No Relief to 100%: Complete Relief.","Percentage Relief From Pain Treatment or Medication Score 30 | BPI Percentage Relief From Pain Treatment or Medication Score 30",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054201","Percentage Relief From Pain Treatment or Medication Score 40","C120135","A subjective score of 40% on a scale that ranges from 0%: No Relief to 100%: Complete Relief.","Percentage Relief From Pain Treatment or Medication Score 40 | BPI Percentage Relief From Pain Treatment or Medication Score 40",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054200","Percentage Relief From Pain Treatment or Medication Score 50","C120136","A subjective score of 50% on a scale that ranges from 0%: No Relief to 100%: Complete Relief.","Percentage Relief From Pain Treatment or Medication Score 50 | BPI Percentage Relief From Pain Treatment or Medication Score 50",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054199","Percentage Relief From Pain Treatment or Medication Score 60","C120137","A subjective score of 60% on a scale that ranges from 0%: No Relief to 100%: Complete Relief.","Percentage Relief From Pain Treatment or Medication Score 60 | BPI Percentage Relief From Pain Treatment or Medication Score 60",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054198","Percentage Relief From Pain Treatment or Medication Score 70","C120138","A subjective score of 70% on a scale that ranges from 0%: No Relief to 100%: Complete Relief.","Percentage Relief From Pain Treatment or Medication Score 70 | BPI Percentage Relief From Pain Treatment or Medication Score 70",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054197","Percentage Relief From Pain Treatment or Medication Score 80","C120139","A subjective score of 80% on a scale that ranges from 0%: No Relief to 100%: Complete Relief.","Percentage Relief From Pain Treatment or Medication Score 80 | BPI Percentage Relief From Pain Treatment or Medication Score 80",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054196","Percentage Relief From Pain Treatment or Medication Score 90","C120141","A subjective score of 90% on a scale that ranges from 0%: No Relief to 100%: Complete Relief.","Percentage Relief From Pain Treatment or Medication Score 90 | BPI Percentage Relief From Pain Treatment or Medication Score 90",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054204","Percentage Relief From Pain Treatment or Medication Score 100","C120142","A subjective score of 100% on a scale that ranges from 0%: No Relief to 100%: Complete Relief.","Percentage Relief From Pain Treatment or Medication Score 100 | BPI Percentage Relief From Pain Treatment or Medication Score 100",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899971","BPI Pain Interference Likert Scale","C120147","A scale for the subjective scoring of pain interference that ranges from 0: Does Not Interfere to 10: Completely Interferes.","BPI Pain Interference Likert Scale | BPI Pain Interference Scale | Brief Pain Inventory Pain Interference Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898030","Pain Interference Score 1","C120150","A subjective score of 1 on a scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.","Pain Interference Score 1 | BPI Pain Interference Score 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898029","Pain Interference Score 2","C120151","A subjective score of 2 on a scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.","Pain Interference Score 2 | BPI Pain Interference Score 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898028","Pain Interference Score 3","C120152","A subjective score of 3 on a scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.","Pain Interference Score 3 | BPI Pain Interference Score 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898027","Pain Interference Score 4","C120153","A subjective score of 4 on a scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.","Pain Interference Score 4 | BPI Pain Interference Score 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898026","Pain Interference Score 5","C120154","A subjective score of 5 on a scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.","Pain Interference Score 5 | BPI Pain Interference Score 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898025","Pain Interference Score 6","C120155","A subjective score of 6 on a scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.","Pain Interference Score 6 | BPI Pain Interference Score 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898024","Pain Interference Score 7","C120156","A subjective score of 7 on a scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.","Pain Interference Score 7 | BPI Pain Interference Score 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898023","Pain Interference Score 8","C120157","A subjective score of 8 on a scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.","Pain Interference Score 8 | BPI Pain Interference Score 8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898022","Pain Interference Score 9","C120158","A subjective score of 9 on a scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.","Pain Interference Score 9 | BPI Pain Interference Score 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898031","Pain Interference Score 10","C120159","A subjective score of 10 on a scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.","Pain Interference Score 10 | BPI Pain Interference Score 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0679083","Computer Modeling","C16461","A technique which attempts to provide an abstract model of a particular system. It utilizes a mathematical model, which attempts to predict the behavior of the system from a set of parameters and initial conditions.","Computer Modeling | Mathematical Models and Simulations | Simulation | simulation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899076","Functional Assessment of Chronic Illness Therapy-Diarrhea","C120170","A symptom-specific subscale of the FACIT scales that is used to assess how diarrhea affects an individual's life.","Functional Assessment of Chronic Illness Therapy-Diarrhea | FACIT-D | Functional Assessment of Chronic Illness Therapy-Diarrhea (FACIT-D) | Functional Assessment of Chronic Illness Therapy-Diarrhea Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898592","Limit Social Activity Because of Diarrhea","C120171","A question about whether an individual has or had to limit their social activity because of diarrhea.","Limit Social Activity Because of Diarrhea Question | I have to limit my social activity because of diarrhea | Limit Social Activity Because of Diarrhea | Limit Social Activity Because of Diarrhea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898594","Limit Physical Activity Because of Diarrhea","C120172","A question about whether an individual has or had to limit their physical activity because of diarrhea.","Limit Physical Activity Because of Diarrhea Question | I have to limit my physical activity because of diarrhea | Limit Physical Activity Because of Diarrhea | Limit Physical Activity Because of Diarrhea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898593","Limit Sexual Activity Because of Diarrhea","C120173","A question about whether an individual has or had to limit their sexual activity because of diarrhea.","Limit Sexual Activity Because of Diarrhea | I have to limit my sexual activity because of diarrhea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896970","Embarrassed by Diarrhea","C120174","A question about whether an individual is or was embarrassed by having diarrhea.","Embarrassed by Diarrhea | I am embarrassed by having diarrhea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898980","Have Abdominal Cramps or Discomfort Due to Diarrhea","C120175","A question about whether an individual has or had abdominal cramps or discomfort due to diarrhea.","Have Abdominal Cramps or Discomfort Due to Diarrhea | I have abdominal cramps or discomfort due to my diarrhea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897852","Problem with Diarrhea Wakes Me or Keeps Me Awake at Night","C120176","A question about whether an individual is or was kept awake or awakened at night by diarrhea.","Problem with Diarrhea Wakes Me or Keeps Me Awake at Night | My problem with diarrhea keeps/wakes me up at night",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899075","Functional Assessment of Incontinence Therapy-Fecal","C120177","A symptom-specific subscale of the FACIT scales that is used to assess how fecal incontinence interferes affects an individual's life.","Functional Assessment of Incontinence Therapy-Fecal | FAIT-F | Functional Assessment of Incontinence Therapy-Fecal (FAIT-F) | Functional Assessment of Incontinence Therapy-Fecal Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898223","Move Bowels More Frequently Than Usual","C120178","A question about whether an individual moves or moved their bowels more frequently than usual.","Move Bowels More Frequently Than Usual | I move my bowels more frequently than usual",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900079","Afraid to be Far from a Toilet","C120179","A question about whether an individual is or was afraid to be far from a toilet.","Afraid to be Far from a Toilet Question | Afraid to be Far from a Toilet | Afraid to be Far from a Toilet | I am afraid to be far from a toilet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898215","Must Move Bowels Frequently to Avoid Accidents","C120180","A question about whether an individual must move their bowels frequently to avoid accidents.","Must Move Bowels Frequently to Avoid Accidents | I must move my bowels frequently to avoid accidents",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897177","Wear Protection to Prevent Soiling of Stool","C120181","to A question about whether an individual wears or wore protection to prevent soiling of stool.","Wear Protection to Prevent Soiling of Stool | I wear pads or protection to prevent soiling my underwear | Wear Pads or Protection to Prevent Soiling Underwear | Wear Pads or Protection to Prevent Soiling Underwear",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879391","PMS2 Gene","C18591","This gene is involved in mismatch repair and mutations in the gene result in hereditary non-polyposis colon cancer 4.","PMS2 Gene | PMS2 | PMS2 Postmeiotic Segregation Increased 2 (S. cerevisiae) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879290","MSH2 Gene","C18481","This gene plays a role in DNA mismatch repair mutations in the gene result in hereditary nonpolyposis colorectal cancer-1.","MSH2 Gene | MSH2 | MutS Homolog 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986693","Clark Level I","C94812","A morphologic finding indicating that the cutaneous melanoma is confined to the epidermis and does not invade the dermis.","Clark Level I | Clark level I melanoma | I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986694","Clark Level II","C94813","A morphologic finding indicating that the cutaneous melanoma has invaded part of the papillary dermis but the malignant cellular infiltrate has not reached the papillary-reticular dermis interface.","Clark Level II | Clark level II melanoma | II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986695","Clark Level III","C94814","A morphologic finding indicating that the cutaneous melanoma has invaded the entire thickness of the papillary dermis but the malignant cellular infiltrate does not extend into the reticular dermis.","Clark Level III | Clark level III melanoma | III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986696","Clark Level IV","C94815","A morphologic finding indicating that the cutaneous melanoma has invaded the reticular dermis.","Clark Level IV | Clark level IV melanoma | IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986697","Clark Level V","C94816","A morphologic finding indicating that the cutaneous melanoma has invaded the subcutaneous tissue.","Clark Level V | Clark level V melanoma | V",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0303472","Iridium Ir 192","C104270","A radioactive isotope of iridium. Iridium-192 emits gamma rays and has a half-life of 74 days. A high dose rate of this radioisotope can be used in brachytherapy to treat tumors by selectively delivering a cytotoxic dose of radiation to the tumor site.","Iridium Ir 192 | IRIDIUM IR-192 | Ir-192 | Iridium-192",,,,,,,,,,,,,,,"4168006","Iridium-192",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332390","pT0 Primary Tumor Finding","C48758","No morphologic evidence of primary tumor, in accordance with TNM classification system guidelines.","pT0 TNM Finding | Tumor Stage pT0 | pT0 | pT0 Cancer Stage Finding | pT0 Primary Tumor Finding | pT0 Primary Tumor Stage Finding | pT0 Stage | pT0 Stage Finding | pT0 TNM Finding | pT0 Tumor Finding | pT0 Tumor Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332391","pT1 stage","C48759","A pathologic primary tumor TNM finding.  The definition of pT1 finding depends on the particular type of cancer that it refers to; for example, for breast cancer, pT1 finding is defined as follows: cancer with tumor size 2.0 cm or less in greatest dimension; for colorectal cancer, pT1 stage finding is defined as follows: cancer with invasion into the submucosa. (from AJCC 6th and 7th Eds.)","pT1 TNM Finding | Tumor Stage pT1 | pT1 | pT1 Cancer Stage Finding | pT1 Primary Tumor Finding | pT1 Primary Tumor Stage Finding | pT1 Stage | pT1 Stage Finding | pT1 TNM Finding | pT1 Tumor Finding | pT1 Tumor Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711128","pT1a TNM Finding","C48760","A pathologic primary tumor TNM finding.  The definition of pT1a finding depends on the particular type of cancer that it refers to; for example, for breast cancer, pT1a finding is defined as follows: cancer with tumor size more than 0.1 cm, but not more than 0.5 cm in greatest dimension; for lung cancer, pT1a finding is defined as follows: cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a. (from AJCC 7th Ed.)","pT1a TNM Finding | Tumor Stage pT1a | pT1a | pT1a Cancer Stage Finding | pT1a Primary Tumor Finding | pT1a Primary Tumor Stage Finding | pT1a Stage | pT1a Stage Finding | pT1a TNM Finding | pT1a Tumor Finding | pT1a Tumor Stage",,,,,,,,,,,,,,,"37164147","pT1a",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1711129","pT1b TNM Finding","C48761","A pathologic primary tumor TNM finding. The definition of pT1b finding depends on the particular type of cancer that it refers to; for example, for breast cancer, pT1b finding is defined as follows: cancer with tumor size more than 0.5 cm, but not more than 1.0 cm in greatest dimension; for lung cancer, pT1b finding is defined as follows: cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). (from AJCC 7th Ed.)","pT1b TNM Finding | Tumor Stage pT1b | pT1b | pT1b Cancer Stage Finding | pT1b Primary Tumor Finding | pT1b Primary Tumor Stage Finding | pT1b Stage | pT1b Stage Finding | pT1b TNM Finding | pT1b Tumor Finding | pT1b Tumor Stage",,,,,,,,,,,,,,,"37164150","pT1b",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1711130","pT1c TNM Finding","C48763","A pathologic primary tumor TNM finding. The definition of pT1c  finding depends on the particular type of cancer that it refers to; for example, for breast cancer, pT1c finding is defined as follows: cancer with tumor size more than 1.0 cm, but not more than 2.0 cm in greatest dimension; for fallopian tube cancer, pT1c finding is defined as follows: cancer with tumor limited to one or both tubes with extension onto or through the tubal serosa, or with malignant cells in ascites or peritoneal washings. (from AJCC 7th Ed.)","pT1c TNM Finding | Tumor Stage pT1c | pT1c | pT1c Cancer Stage Finding | pT1c Primary Tumor Finding | pT1c Primary Tumor Stage Finding | pT1c Stage | pT1c Stage Finding | pT1c TNM Finding | pT1c Tumor Finding | pT1c Tumor Stage",,,,,,,,,,,,,,,"37164166","pT1c",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1556085","German","C43855","Denotes the inhabitants of Germany, a person from there, or their descendants elsewhere.","German | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3476354","Residential Telephone Number","C81284","The sequence of numbers or characters, that when dialed, connects to a particular residential telephone.","Residential Telephone Number | Home Phone Number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549671","Business Telephone Number","C96961","The sequence of numbers or characters, that when dialed, connects to a work related telephone.","Business Telephone Number | Work No. | Work Number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825539","Cellular Telephone Number","C81240","The sequence of numbers or characters, that when dialed, connects to a particular cellular telephone.","Cellular Telephone Number | Cell Phone No.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332156","Acute Myelomonocytic Leukemia with Abnormal Eosinophils","C9020","Acute myelomonocytic leukemia characterized by the presence of abnormal bone marrow eosinophils. It is associated with inv(16)(p13.1;q22) or t(16;16)(p13.1;q22). It has a favorable prognosis.","Acute Myelomonocytic Leukemia with Abnormal Eosinophils | AMML Eo | Acute myelomonocytic leukemia with abnormal eosinophils | FAB M4Eo | M4 eo | M4 eos | M4eo | M4eos",,,,,,,,,,,,,,,"4304355","Acute myeloid leukemia with CBFB::MYH11 fusion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899187","Extranodal Involvement","C117309","Extension of a malignant neoplasm beyond the lymph node capsule.","Extranodal Involvement | Extranodal Extension | Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336840","Type 2 Papillary Renal Cell Carcinoma","C27887","A papillary renal cell carcinoma characterized by the presence of papillae covered by cells of a higher nuclear grade as compared to type 1 papillary renal cell carcinoma. The cells have eosinophilic cytoplasm and pseudostratified nuclei.","Type 2 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336839","Type 1 Papillary Renal Cell Carcinoma","C27886","A papillary renal cell carcinoma characterized by the presence of papillae covered by small cells with scant amount of cytoplasm. The cells are arranged in a single layer on the basement membrane of the papillae.","Type 1 Papillary Renal Cell Carcinoma | Type 1 Papillary Renal Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706711","Additional Surgical Procedure","C50831","Any surgical procedure performed subsequent to a primary or initial surgical procedure.","Additional Surgical Procedure | Additional Surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827677","Uterine Carcinosarcoma, Homologous Type","C113238","A carcinosarcoma of the uterus characterized by the presence of sarcomatous elements that arise from the tissues of the uterus.","Uterine Carcinosarcoma, Homologous Type | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812310","CXCL2 Gene","C18426","This gene is involved in the regulation of angiogenesis.","CXCL2 Gene | CXCL2 | Chemokine (C-X-C Motif) Ligand 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1970415","FTO Gene","C99468","This gene is involved in the demethylation of nucleic acids.","FTO Gene | FTO | Fat Mass and Obesity Associated Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418913","PRKCB Gene","C39597","This gene is involved in diverse cell processes such as apoptosis, B cell activation and endothelial cell proliferation.","PRKCB Gene | PRKCB | Protein Kinase C, Beta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899077","Functional Assessment of Chronic Illness Therapy - Abdominal Discomfort","C120217","A symptom-specific subscale of the FACIT scales that that uses a 5-point Likert scale to measure a person's self-reported abdominal symptoms.","Functional Assessment of Chronic Illness Therapy - Abdominal Discomfort | FACIT-AD Questionnaire | Functional Assessment of Chronic Illness Therapy-Abdominal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897490","Stomach Pain Interferes With Daily Functioning","C120218","A question about whether an individual's stomach pain interferes with their daily functioning.","Stomach Pain Interferes With Daily Functioning | Stomach pain interferes with my daily functioning",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898011","Pain in Hands or Feet When Exposed to Cold Temperatures","C120219","A question about whether an individual has or had pain in their hands or feet when exposed to cold temperatures.","Pain in Hands or Feet When Exposed to Cold Temperatures | I have pain in my hands or feet when I am exposed to cold temperatures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1367469","HPSE Gene","C24477","This gene plays a role in the disassembly of the extracellular matrix by invading cells.","HPSE Gene | HPSE | Heparanase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419227","RAC1 Gene","C99663","This gene is involved in both cell motility and signal transduction.","RAC1 Gene | RAC1 | Ras-Related C3 Botulinum Toxin Substrate 1 (Rho Family, Small GTP Binding Protein Rac1) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812284","RALA Gene","C18402","This gene plays a role in signal transduction and mediates receptor signaling.","RALA Gene | RALA | RAS Like Proto-Oncogene A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812283","RALB Gene","C18401","This gene is involved in signal transduction and regulates receptor signaling.","RALB Gene | RALB | RAS Like Proto-Oncogene B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1548372","Autopsy Report","C68623","No Value Exists","Autopsy Report | Necropsy Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890394","Children's Memory Scale","C120253","A test designed to make a comprehensive assessment of learning and memory in children and adolescents ranging in age from 5 to 16 years.","Children's Memory Scale | CMS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897176","Wechsler Adult Intelligence Scale - Fourth Edition","C120254","The fourth version of the Wechsler Adult Intelligence Scale that was published in 2008. It is a test designed to measure intelligence in individuals ranging in age from 16 to 90 years.","Wechsler Adult Intelligence Scale - Fourth Edition | WAIS-IV | Wechsler Adult Intelligence Scale - Fourth Edition  | Wechsler Adult Intelligence Scale 4th Edition | Wechsler Adult Intelligence Scale IV",,,,,,,,,,,,,,,"37168546","Wechsler Adult Intelligence Scale fourth edition",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897175","Wechsler Intelligence Scale for Children - Fifth Edition","C120255","The fifth version of the Wechsler Intelligence Scale for Children that was published in 2014. It is an individually administered clinical instrument for assessing the cognitive ability of children aged 6 years through 16 years 11 months. It is a psychometric test that assesses a child's current cognitive abilities in both verbal and nonverbal areas, including verbal comprehension, perceptual reasoning, working memory, and processing speed.","Wechsler Intelligence Scale for Children - Fifth Edition | WISC-V | Wechsler Intelligence Scale for Children 5th Edition | Wechsler Intelligence Scale for Children V",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897173","Wechsler Preschool and Primary Scale of Intelligence - Fourth Edition","C120256","The fourth version of the Wechsler Preschool & Primary Scale of Intelligence, published in 2012. It is a test designed for children ages 2 years 6 months to 7 years 3 months that provides subtest and composite scores that represent intellectual functioning in verbal and performance cognitive domains, and provides a composite score that represents a child's general intellectual ability.","Wechsler Preschool and Primary Scale of Intelligence - Fourth Edition | WPPSI-IV | Wechsler Preschool & Primary Scale of Intelligence 4th Edition | Wechsler Preschool and Primary Scale of Intelligence - Fourth Edition  | Wechsler Preschool and Primary Scale of Intelligence IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899729","California Verbal Learning Test - Second Edition","C120257","The second version of California Verbal Learning Test, a neuropsychological test developed to make a comprehensive and detailed assessment of verbal learning and memory in individuals ranging in age from 16 to 89 years.","California Verbal Learning Test - Second Edition | CVLT-II | California Verbal Learning Test 2nd Edition | California Verbal Learning Test II | California Verbal Learning Test, Second Edition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897174","Wechsler Memory Scale - Fourth Edition","C120258","The fourth version of the Wechsler Memory Scale that was published in 2009. It is a neuropsychological test designed to measure different memory functions in individuals ranging in age from 16 to 90 years.","Wechsler Memory Scale - Fourth Edition | WMS-IV | Wechsler Memory Scale 4th Edition | Wechsler Memory Scale IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896676","European Quality of Life Five Dimension Three Level Youth Questionnaire","C120225","A standardized rating scale which is used as a measure of health outcome for children and adolescents aged 8-18. This instrument is a descriptive system consisting of 5 dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. Each dimension has 3 levels ranging from no problem to extreme problem or incapable, which are assessed by the patient.","European Quality of Life Five Dimension Three Level Youth Questionnaire | EQ-5D-Y | European Quality of Life Five Dimension Three Level Youth Questionnaire ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897181","Walking Mobility Today","C120226","A question about an individual's current walking mobility.","Walking Mobility Today Question | Mobility (walking about) | Mobility (walking about)  | Walking Mobility Today | Walking Mobility Today",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897571","Slight Problems Walking","C120227","A response indicating that an individual has or had slight problems walking.","Slight Problems Walking | I have slight problems walking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898277","Moderate Problems Walking","C120228","A response indicating that an individual has or had moderate problems walking.","Moderate Problems Walking | I have moderate problems walking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897636","Severe Problems Walking","C120229","A response indicating that an individual has or had severe problems walking.","Severe Problems Walking | I have severe problems walking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4228638","Unable to Walk","C120230","A response indicating that an individual is or was unable to walk.","Unable to Walk | I am unable to walk | Unable to walk",,,,,,,,,,,,,,,"4086548","Unable to walk",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897178","Washing or Dressing Self-Care Today","C120231","A question about an individual's current self-care ability with washing or dressing.","Washing or Dressing Self-Care Today Question | Looking after myself | Washing or Dressing Self-Care Today | Washing or Dressing Self-Care Today",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897570","Slight Problems with Washing or Dressing","C120233","A response indicating that an individual has or had slight problems with washing or dressing.","Slight Problems with Washing or Dressing | I have slight problems washing or dressing myself",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898276","Moderate Problems with Washing or Dressing","C120234","A response indicating that an individual has or had moderate problems with washing or dressing.","Moderate Problems with Washing or Dressing | I have moderate problems washing or dressing myself",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897047","Severe Problems with Washing or Dressing","C120235","A response indicating that an individual has or had severe problems with washing or dressing.","Severe Problems with Washing or Dressing | I have severe problems washing or dressing myself",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897213","Usual Activities Today","C120236","A question about an individual's current ability to do their usual activities.","Usual Activities Today | Doing usual activities (for example, going to school, hobbies, sports, playing, doing things with family or friends) | Doing usual activities (for example, going to school, hobbies, sports, playing, doing things with family or friends) ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898278","Moderate Problems Performing Usual Activities","C120238","A response indicating that an individual has or had moderate problems with performing their usual activities.","Moderate Problems Performing Usual Activities | I have moderate problems doing my usual activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897637","Severe Problems Performing Usual Activities","C120239","A response indicating that an individual has or had severe problems with performing their usual activities.","Severe Problems Performing Usual Activities | I have severe problems doing my usual activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898010","Pain or Discomfort Today","C120240","A question about an individual's current pain or discomfort.","Pain or Discomfort Today | Having pain or discomfort",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897573","Slight Pain or Discomfort","C120241","A response indicating that an individual has or had slight pain or discomfort.","Slight Pain or Discomfort | I have slight pain or discomfort",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897638","Severe Pain or Discomfort","C120242","A response indicating that an individual has or had severe pain or discomfort.","Severe Pain or Discomfort | I have severe pain or discomfort",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900020","Anxiety or Depression Today","C120243","A question about an individual's current anxiety or depression.","Anxiety or Depression Today | Feeling worried, sad or unhappy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897043","Slightly Anxious or Depressed","C120244","A response indicating that an individual has or had slight anxiety or depression.","Slightly Anxious or Depressed | I am slightly anxious or depressed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897635","Severely Anxious or Depressed","C120245","A response indicating that an individual has or had severe anxiety or depression.","Severely Anxious or Depressed | I am severely anxious or depressed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900174","A Lot of Problems Walking","C120246","A response indicating that an individual has or had a lot of problems walking.","A Lot of Problems Walking | I have a lot of problems walking about",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900173","A Lot of Problems with Washing and Dressing","C120247","A response indicating that an individual has or had a lot of problems with washing or dressing their self.","A Lot of Problems with Washing and Dressing | A Lot of Problems with Washing or Dressing | I have a lot of problems washing or dressing myself",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900175","A Lot of Problems Performing Usual Activities","C120248","A response indicating that an individual has or had a lot of problems with performing their usual activities.","A Lot of Problems Performing Usual Activities | I have a lot of problems doing my usual activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272602","Delayed Testing","C96151","Sample is not tested immediately.","Delayed Testing | Delayed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272601","Immediate Testing","C96150","Sample is tested immediately.","Immediate Testing | Immediate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897552","Some Pain or Discomfort","C120249","A response indicating that an individual has or had some pain or discomfort.","Some Pain or Discomfort | I have some pain or discomfort",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900176","A Lot of Pain or Discomfort","C120250","A response indicating that an individual has or had a lot of pain or discomfort.","A Lot of Pain or Discomfort | I have a lot of pain or discomfort",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900181","A Bit Anxious or Depressed","C120251","A response indicating that an individual has or had a bit of anxiety or depression.","A Bit Anxious or Depressed | I am a bit worried, sad or unhappy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897195","Very Anxious or Depressed","C120252","A response indicating that an individual is or was very anxious or depressed.","Very Anxious or Depressed | I am very worried, sad or unhappy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415636","HNRNPA2B1 Gene","C97496","This gene is involved in RNA processing and transport.","HNRNPA2B1 Gene | HNRNPA2B1 | Heterogeneous Nuclear Ribonucleoprotein A2/B1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415549","HIRA Gene","C75507","This gene plays a role in heterochromatin formation.","HIRA Gene | HIRA | Histone Cell Cycle Regulator Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518406","Nonhomologous DNA End Joining","C20207","Non-homologous DNA end joining (NHEJ) can only repair double-strand breaks in which two DNA ends are rejoined by DNA ligase at regions of little or no homology to avoid degradation by DNA nucleases or noncomplementary overhanging ends. However, the disadvantage is that it can lead to loss of information from the DNA because of resection of the broken ends. NHEJ is operational throughout the cell cycle but may be more important during G1, prior to DNA replication, or in cells that are no longer cycling.","Nonhomologous DNA End Joining | NHEJ | Non-Homologous End Joining",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332428","BMP7 Gene","C21357","This gene is involved in calcium regulation and bone homeostasis. It also plays a role in the control of cellular development and differentiation.","BMP7 Gene | BMP7 | Bone Morphogenetic Protein 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3850046","CYP2C9 Inducer","C120269","Any substance capable of causing an increase in the synthesis of cytochrome P450 2C9.","CYP2C9 Inducer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899737","CYP1A2 Substrate","C120265","Any substance acted upon by cytochrome P450 1A2.","CYP1A2 Substrate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899735","CYP2C9 Substrate","C120266","Any substance acted upon by cytochrome P450 2C9.","CYP2C9 Substrate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899736","CYP2C19 Substrate","C120267","Any substance acted upon by cytochrome P450 2C19.","CYP2C19 Substrate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889681","Narrow Therapeutic Index","C120270","A therapeutic index of less than 2-fold difference between the median lethal dose and median effective dose values, or less than 2-fold difference between the minimum toxic concentration and minimum effective concentrations in the blood.","Narrow Therapeutic Index | NTI | Narrow Therapeutic Indices",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1564904","Catenin Family Protein","C118480","A family of adaptor proteins that bind to cadherin proteins and promote the association of cadherins with the actin cytoskeleton. Catenins play a role in the formation of adherens junctions, the regulation of cell proliferation and the modulation of Wnt signaling pathways.","Catenin Family Protein | Catenin | Catenin Family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428393","ZNF521 Gene","C97885","This gene plays a role in both the positive and negative regulation of transcription.","ZNF521 Gene | ZNF521 | Zinc Finger Protein 521 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332072","AKAP9 Gene","C21305","This gene plays a role in signal transduction and modulates synaptic transmission.","AKAP9 Gene | A-Kinase Anchor Protein 9 Gene | AKAP9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334538","MYH11 Gene","C29957","This gene plays a regulatory role in muscle contraction and the required ATP hydrolysis.","MYH11 Gene | MYH11 | Myosin Heavy Chain 11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423592","PDE4DIP Gene","C97718","This gene plays a role in protein complex localization.","PDE4DIP Gene | PDE4DIP | Phosphodiesterase 4D Interacting Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539715","RUNX1T1 Gene","C28570","This gene plays a role in transcriptional regulation and hematopoiesis.","RUNX1T1 Gene | RUNX1 Partner Transcriptional Co-Repressor 1 Gene | RUNX1T1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425790","CAMTA1 Gene","C101440","This gene is involved in both DNA binding and transcription.","CAMTA1 Gene | CAMTA1 | Calmodulin Binding Transcription Activator 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521889","Immunoreceptor Tyrosine-Based Activation Motif","C14048","ITAM (Immunoreceptor Tyrosine-based Activation Motif) or ARAM (Ag Recognition Activation Motif) (Y-X-X-L-(X)6-8-Y-X-X-L), a protein domain involved in STP, binds to SH2 domain, e.g. in CD247/x chain, FceRI g chain, or DAP12. Phosphorylated immunoreceptor signaling motifs (ITAMs) exhibit unique abilities to bind and activate Lyn and Syk tyrosine kinases. Motif may be dually phosphorylated on tyrosine that links antigen receptors to downstream signaling machinery.","ITAM | ARAM | Ag Recognition Activation Motif | Antigen Recognition Activation Motif | Immunoreceptor Tyr-Based Activation Motif | Immunoreceptor Tyrosine-Based Activation Motif | TAM | Tyrosine-Based Activation Motif",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425565","RNF43 Gene","C107649","This gene is involved in both protein ubiquitination and the Wnt signaling pathway.","RNF43 Gene | RNF43 | Ring Finger Protein 43 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418965","PRSS1 Gene","C113757","This gene is involved in protein catabolism.","PRSS1 Gene | PRSS1 | Protease, Serine, 1 (Trypsin 1) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012899","DNA Repair","C16513","Enzymatic restoration of DNA structure after chemical, radiation, or spontaneous damage.","DNA Repair | DNA Damage Repair | Unscheduled DNA Synthesis",,,,,,,,,,,,,,,"4278978","DNA repair",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516893","Enzyme Kinetics (discipline)","C20626","A subdiscipline of Kinetics that studies the rates and mechanics of enzymes and enzyme-driven reactions.","Enzyme Kinetics | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366464","F9 Gene","C28481","This gene plays a role in the regulation of blood coagulation and is modulated by Ca+2 ions, membrane phospholipids, and factor VIII.","F9 Gene | Coagulation Factor IX Gene | F9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334903","NRG3 Gene","C26550","This gene plays a role in cellular differentiation, growth and proliferation.","NRG3 Gene | NRG3 | Neuregulin 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521106","22q11.22","C25022","A chromosome band present on 22q","22q11.22 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422394","BACH2 Gene","C97234","This gene is involved in the modulation of transcription.","BACH2 Gene | BACH2 | BTB and CNC Homology 1, Basic Leucine Zipper Transcription Factor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333692","CCR10 Gene","C24443","This gene is involved in the regulation of T cell-mediated inflammatory skin reactions and angiogenesis.","CCR10 Gene | CCR10 | Chemokine (C-C Motif) Receptor 10 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427106","FANCL Gene","C92476","This gene is involved in the mediation of protein ubiquitination.","FANCL Gene | FA Complementation Group L Gene | FANCL | PHF9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0078752","Zeaxanthin","C68310","Carotenoid having a chemical structure similar to beta-carotene with addition of hydroxyl groups at the number 3 and 3' carbon atoms.","Zeaxanthin | 4-[18-(4-hydroxy-2,6,6-trimethyl-1-cyclohexenyl)-3,7,12,16-tetramethyl-octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-3,5,5-trimethyl-cyclohex-3-en-1-ol | ZEAXANTHIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427164","NANOG Gene","C61133","This gene plays a role in the underlying pluripotency of inner cell mass and embryonic stem cells.","NANOG Gene | NANOG | Nanog Homeobox Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521487","5q31.1","C13988","A chromosome band present on 5q","5q31.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206364","Receptor Protein-Tyrosine Kinases","C17660","A class of membrane receptors that contain protein tyrosine kinase activity.  This enzymatic activity is integral to the function of the receptor as a signal transducer; the phosphorylation event alters the functional activity of its protein substrate.","Receptor Tyrosine Kinase | EC 2.7.10.1 | EGF Receptor-Tyrosine Kinase Family | RTK | Receptor Protein-Tyrosine Kinase | Receptor-Type Protein-Tyrosine Kinase | Receptor-Tyrosine Kinase | TKR | TRK | Transmembrane Receptor Protein Tyrosine Kinase | Tyrosine Kinase Growth Factor Receptor | Tyrosine Kinase Receptor | Tyrosine Receptor Kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332661","CASP10 Gene","C28400","This gene is involved in the activation of apoptosis.","CASP10 Gene | CASP10 | Caspase 10 Gene | Caspase 10, Apoptosis-Related Cysteine Peptidase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515514","9q22","C25130","A chromosome band present on 9q","9q22 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028197","Nitrosamine","C698","Any of a class of organic compounds with the general formula R2NNO or RNHNO, present in various foods and other products and found to be carcinogenic in laboratory animals. (dictionary.com)","Nitrosamine | NITROSAMINE | Nitrosamines | nitrosamine",,,,,,,,,,,,,,,"4094093","Nitrosamine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0908130","macroH2A histone","C95407","A histone protein that is comprised of a histone H2A domain, which allows interaction with the nucleosome, and a macro domain, which may bind to ADP-ribose. This protein can substitute for histone H2A in the nucleosomal complex and plays a role in transcriptional repression and X chromosome inactivation.","Core Histone Macro-H2A | Histone MacroH2A | MacroH2A | mH2A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899369","Direct Extension","C120271","The spread or migration of cancer cells through the wall of an organ into surrounding organs and/or adjacent tissues.","Direct Extension | Contiguous Spread | Direct Tumor Extension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521131","Transnasal","C120272","Passing through the nose.","Transnasal | ",,,,,,,,,,,,,,,"4050374","Transnasal approach",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0442392","Transventricular","C120273","Passing through a ventricle.","Transventricular | ",,,,,,,,,,,,,,,"4129305","Transventricular cardiac approach",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898478","Macroscopically Positive Surgical Margin","C120274","The presence of macroscopically visible residual tumor at the edge of a surgically excised specimen.","Macroscopically Positive Surgical Margin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL481475","Intracardiac Pneumonectomy","C120275","Excision of a lung and part of the pericardium.","Intracardiac Pneumonectomy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897428","Sublobar","C120276","Pertaining to a portion of a lobe.","Sublobar | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899008","Grossly Negative and Microscopically Positive Surgical Margin","C120277","The presence of microscopically visible residual tumor at the edge of a surgically excised specimen that otherwise looks macroscopically normal.","Grossly Negative and Microscopically Positive Surgical Margin | Grossly negative and microscopically positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899009","Grossly Negative and Microscopically Negative Surgical Margin","C120288","The absence of tumor cells at the edge of a surgically excised specimen, both macroscopically and microscopically.","Grossly Negative and Microscopically Negative Surgical Margin | Grossly negative and microscopically negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1275544","Every One to Two Hours","C120278","Every one to two hours.","Every One to Two Hours | Every 1 to 2 hours",,,,,,,,,,,,,,,"4244845","Every one to two hours",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0589080","Every Three to Four Hours","C120279","Every three to four hours.","Every Three to Four Hours | Every 3 to 4 hours",,,,,,,,,,,,,,,"4026062","Every three to four hours",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899255","Every Four to Five Hours","C120280","Every four to five hours.","Every Four to Five Hours | Every 4 to 5 hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0589082","Every Four to Six Hours","C120281","Every four to six hours.","Every Four to Six Hours | Every 4 to 6 hours",,,,,,,,,,,,,,,"4026063","Every four to six hours",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897284","Tumor Less than or Equal to 2.0 cm","C120285","A tumor where the greatest dimension is less than or equal to 2.0 cm.","Tumor Less than or Equal to 2.0 cm | Less than or equal to 2.0 cm | Tumor Less Than or Equal to 2.0 Centimeters | Tumor Less than or Equal to 2.0 Centimeters",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897301","Tumor Greater than or Equal to 2.1 cm","C120286","A tumor where the greatest dimension is greater than or equal to 2.1 cm.","Tumor Greater than or Equal to 2.1 cm | Greater than or equal to 2.1 cm | Tumor Greater Than or Equal to 2.1 Centimeters | Tumor Greater than or Equal to 2.1 Centimeters",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898304","Minimum of 6 Axillary Nodes","C120287","Lymph node dissection of at least 6 axillary lymph nodes.","Minimum of 6 Axillary Nodes | With a minimum of 6 axillary nodes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899047","GP5+/GP6+ PCR Assay","C120294","A PCR technique that uses the GP5+/GP6+ primer set for HPV detection. It amplifies a 150 bp region from the L1 region of the HPV genome.","GP5+/GP6+ PCR Assay | GP+-PCR | GP5+/GP6+ | GP5+/GP6+;  | General Primer Mediated 5+/6+",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897677","SPF10-LiPA PCR Assay","C120293","A PCR technique that uses the SPF10 primer set for HPV detection. It amplifies a 65 bp region from the L1 region of the HPV genome. Genotype identification is achieved by using a reverse line probe assay (LiPA).","SPF10-LiPA PCR Assay | Isa Line Probe Assay | SPF10-LiPA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641646","Retrocrural","C103846","Of or pertaining to the most inferior portion of the posterior mediastinum.","Retrocrural | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898044","PGMY09/PGMY11 PCR Assay","C120295","A PCR technique that uses a pool of 5 upstream and 13 downstream primers, which are based on the binding sites for the MY09/MY11 degenerate primer set, for HPV detection. It amplifies a 450 bp region from the L1 region of the HPV genome.","PGMY09/PGMY11 PCR Assay | PGMY09/PGMY11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898499","MY09/MY11 PCR Assay","C120296","A PCR technique that uses the MY09/MY11 degenerate primer set for HPV detection. It amplifies a 450 bp region from the L1 region of the HPV genome.","MY09/MY11 PCR Assay | MY-PCR | MY09/MY11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898590","Linear Array HPV Genotyping Test","C120297","A proprietary PCR technique that uses a pool of primers to amplify a 450 bp region in the L1 region of the HPV genome. It is capable of detecting 37 high- and low-risk human papillomavirus genotypes.","Linear Array HPV Genotyping Test | HPV Linear Array | LA HPV Genotyping | Roche Linear Array | Roche Linear Array Genotyping Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0913641","Integrin Alpha-D, Human","C120292","Integrin alpha-D (1161 aa, ~127 kDa) is encoded by the human ITGAD gene. This protein plays a role in cell-cell and cell-extracellular matrix interactions.","Integrin Alpha-D | CD11 Antigen-Like Family Member D | CD11d | CD11d Antigen | ITGAD | Leukointegrin Alpha D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890380","Ceramide Dodecasaccharide","C120289","A carbohydrate cell-surface antigen formed by fucosylation of the inner lactosamine unit of alpha-2,3-sialylated polylactosamine by alpha-1,3-fucosyltransferase. Its presence is associated with a high risk for extravascular infiltration of acute myeloid leukemia cells.","Ceramide Dodecasaccharide | CD65 | VIM-2 | VIM2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0447647","Thyroid Gland Lobe","C33784","Either one of the two lateral lobes of the thyroid gland, or the additional pyramidal lobe that is found superior to the isthmus between the lateral lobes in approximately one-third of cases as a normal variant. The pyramidal lobe is a remnant of the thyroglossal duct that is also called Lalouette's pyramid.","Thyroid Gland Lobe | ",,,,,,,,,,,,,,,"4000517","Structure of lobe of thyroid gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897644","Sentinel Lymph Node Biopsy Followed by Axillary Lymph Node Biopsy","C120282","A staging procedure consisting of sentinel node biopsy followed by surgical evaluation of the axillary lymph nodes.","Sentinel Lymph Node Biopsy Followed by Axillary Lymph Node Biopsy | Sentinel node biopsy followed by surgical evaluation of axilla",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897243","Uninterpretable","C120283","Not able to be understood in terms of meaning or significance.","Uninterpretable | Non-Interpretable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709236","No Evidence of Metastatic Disease","C48558","Diagnostic tests fail to detect presence of metastatic lesions.","No Evidence of Metastatic Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814420","Full Term Birth","C114095","Birth at 39 weeks and 0 days through 40 weeks and 6 days.","Full Term Birth | Full Term | Full Term Pregnancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827068","Histopathology Result","C83490","A finding resulting from the examination of a tissue sample under light or electron microscopy.","Histopathology Result | Histopathologic Result | Microscopic Finding | Microscopic Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0556987","Three Times Weekly","C64528","Three times per week.","Three Times Weekly | 3 TIMES PER WEEK | TIS | Three times a week",,,,,,,,,,,,,,,"4044573","Three times weekly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0585292","Five Times Daily","C98849","Five times per day.","Five Times Daily | 5 TIMES PER DAY | 5 Times Daily",,,,,,,,,,,,,,,"4144038","Five times daily",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0558293","Once Weekly","C64526","One time per week.","Once Weekly | 1 TIME PER WEEK | Once a week | One Time Per Week",,,,,,,,,,,,,,,"4021821","Once a week",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1880601","Every Seven Hours","C64521","Every seven hours.","Every Seven Hours | Every 7 hours | Q7H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880599","Every Nine Hours","C64524","Every nine hours.","Every Nine Hours | Every 9 hours | Q9H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880603","Every Ten Hours","C64500","Every ten hours.","Every Ten Hours | Every 10 hours | Q10H",,,,,,,,,,,,,,,"4325020","Every ten hours",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1880596","Every Eleven Hours","C64501","Every eleven hours.","Every Eleven Hours | Every 11 hours | Q11H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880604","Every Thirteen Hours","C64503","Every thirteen hours.","Every Thirteen Hours | Every 13 hours | Q13H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880598","Every Fourteen Hours","C64504","Every fourteen hours.","Every Fourteen Hours | Every 14 hours | Q14H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880597","Every Fifteen Hours","C64505","Every fifteen hours.","Every Fifteen Hours | Every 15 hours | Q15H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880602","Every Seventeen Hours","C64507","Every seventeen hours.","Every Seventeen Hours | Every 17 hours | Q17H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880600","Every Nineteen Hours","C64509","Every nineteen hours.","Every Nineteen Hours | Every 19 hours | Q19H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880608","Every Twenty Hours","C64511","Every twenty hours.","Every Twenty Hours | Every 20 hours | Q20H",,,,,,,,,,,,,,,"762154","Every twenty hours",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1880605","Every Twenty-One Hours","C64512","Every twenty-one hours.","Every Twenty-One Hours | Every 21 hours | Q21H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880607","Every Twenty-Two Hours","C64513","Every twenty-two hours.","Every Twenty-Two Hours | Every 22 hours | Q22H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880606","Every Twenty-Three Hours","C64514","Every twenty-three hours.","Every Twenty-Three Hours | Every 23 hours | Q23H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640997","Human Papillomavirus-Related Malignant Neoplasm in AIDS Patient","C102884","A malignant neoplasm caused by human papillomavirus in an a patient with a history of AIDS.","Human Papillomavirus-Related Malignant Neoplasm in AIDS Patient | AIDS-related HPV-related cancer | AIDS-related HPV-related cancer, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641182","AIDS-Related Human Papillomavirus Infection","C103296","An opportunistic infection caused by the human papillomavirus in a patient with AIDS.","AIDS-Related Human Papillomavirus Infection | AIDS-Related HPV Infection | AIDS-Related Human Papilloma Virus Infection | AIDS-related HPV infections",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332040","AIDS-Related Cervical Carcinoma","C7432","A carcinoma that arises from the cervix in a patient with acquired immunodeficiency syndrome.","AIDS-Related Cervical Carcinoma | AIDS Related Carcinoma of Uterine Cervix | AIDS Related Carcinoma of the Uterine Cervix | AIDS Related Cervical Cancer | AIDS-Related Cancer of Uterine Cervix | AIDS-Related Cancer of the Uterine Cervix | AIDS-Related Cervical Cancer | AIDS-Related Cervix Carcinoma | AIDS-Related Uterine Cervix Cancer | AIDS-Related Uterine Cervix Carcinoma | AIDS-related cervical cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332038","AIDS-Related Anal Carcinoma","C9278","A carcinoma arising from the anus and occurring in HIV-positive patients. Homosexual HIV-positive men have an increased risk of developing anal squamous cell carcinoma in comparison to the general male population. Sexually transmitted human papillomavirus is detected in the majority of the cases.","AIDS-Related Anal Carcinoma | AIDS-Related Anal Cancer | AIDS-related anal cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898434","Medicare Beneficiary ID","C120299","An identification code, composed of the individual's social security number plus a suffix code, used by the Medicare system to uniquely identify a user and how that user qualifies for Medicare.","Medicare Beneficiary ID | HICN | Medicare Beneficiary Identification Number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891916","National Radiology Data Registry","C120300","An information system created and managed by the American College of Radiology that provides accurate, objective measures of both regional and national practice processes and outcomes for the purpose of improving quality and enhancing patient care.","National Radiology Data Registry | NRDR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889680","National Death Index","C120301","A centralized database of death record information established as a resource to aid epidemiologists and other health and medical investigators with mortality ascertainment activities.","National Death Index | NDI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0558528","Percutaneous Needle Biopsy","C51763","A needle biopsy that is done through the skin.","Percutaneous Needle Biopsy | ",,,,,,,,,,,,,,,"4170791","Percutaneous needle biopsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332051","AIDS-Related Non-Hodgkin Lymphoma","C5051","A non-Hodgkin lymphoma that develops in a patient with AIDS.","AIDS-Related Non-Hodgkin Lymphoma | AIDS-Related Non-Hodgkin's Lymphoma | AIDS-related NHL | AIDS-related Non-Hodgkin lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281293","AIDS-Related Hodgkin Lymphoma","C9279","Hodgkin lymphoma secondary to AIDS. An increased incidence of Hodgkin lymphomas has been observed in HIV positive patients. Most cases are morphologically classified as lymphocyte depleted or mixed cellularity Hodgkin lymphomas.","AIDS-Related Hodgkin Lymphoma | AIDS-Associated Hodgkin's Disease | AIDS-Associated Hodgkin's Lymphoma | AIDS-Related Hodgkin's Disease | AIDS-Related Hodgkin's Lymphoma | AIDS-related Hodgkin lymphoma | HIV-Associated Hodgkin's Disease | HIV-Associated Hodgkin's Lymphoma | HIV-Related Hodgkin's Disease | HIV-Related Hodgkin's Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019699","Human Immunodeficiency Virus Positive","C15175","A laboratory test result indicating the presence of the human immunodeficiency virus (HIV) in a sample.","Human Immunodeficiency Virus Positive | HIV Positive | HIV Positivity | HIV Positivity | HIV positive | HIV test positive | Positive",,,,,,,,,,,,,,,"4013106","HIV detected",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333292","Diffuse Infiltrative Lymphocytosis Syndrome","C35699","This is usually an oligoclonal CD8+ lymphocytic infiltration of various organs.","Diffuse Infiltrative Lymphocytosis Syndrome | Diffuse infiltra. lymph. syndrome | Diffuse infiltrative lymphocytosis syndrome",,,,,,,,,,,,,,,"42709912","Diffuse infiltrative lymphocytosis syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0281241","AIDS-Related Primary Central Nervous System Lymphoma","C8284","A lymphoma (non-Hodgkin or Hodgkin) arising from the central nervous system and occurring in HIV-positive patients.","AIDS-Related Primary Central Nervous System Lymphoma | AIDS Related Lymphoma of Primary Central Nervous System | AIDS Related Lymphoma of the Primary Central Nervous System | AIDS Related Primary CNS Lymphoma | AIDS Related Primary Central Nervous System Lymphoma | AIDS-Related Lymphoma of Primary Central Nervous System | AIDS-Related Lymphoma of the Primary Central Nervous System | AIDS-Related Primary CNS Lymphoma | AIDS-related primary CNS lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009241","Cognitive Disorder","C92196","A category of psychiatric disorders which are characterized by a deficit in cognition or memory.","Cognitive Disorder | ",,,,,,,,,,,,,,,"40480615","Cognitive disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0751571","Malignant Urinary System Neoplasm","C9297","A primary or metastatic malignant neoplasm involving the urinary system.","Malignant Urinary System Neoplasm | Malignant Urinary System Tumor | Malignant Urinary Tract Neoplasm | Malignant neoplasm of urinary organ, unspecified | Urinary Tract Cancer | Urothelial tract/bladder cancer, NOS | Urothelial/bladder cancer, NOS",,,,,,,,,,,,,,,"4180915","Malignant tumor of urinary tract proper",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0553723","Skin Squamous Cell Carcinoma","C4819","A carcinoma arising from the squamous cells of the epidermis.  Skin squamous cell carcinoma is most commonly found on sun-exposed areas.  The majority of the tumors are well-differentiated.","Skin Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | Epidermoid Carcinoma of Skin | Epidermoid Carcinoma of the Skin | Epidermoid Skin Carcinoma | Skin Squamous Cell Cancer | Squamous Cell Carcinoma of Skin | Squamous Cell Carcinoma of the Skin | Squamous Cell Skin Carcinoma | Squamous cell carcinoma - skin | Squamous cell carcinoma of the skin",,,,,,,,,,,,,,,"4111921","Squamous cell carcinoma of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0751620","Primary Central Nervous System Neoplasm","C102871","A benign or malignant neoplasm that arises from the brain or the spinal cord.","Primary Central Nervous System Neoplasm | CNS primary tumor, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640999","High Grade Astrocytic Tumor","C102897","An astrocytic tumor exhibiting high-grade morphological characteristics. This category includes anaplastic astrocytoma, glioblastoma, and astrocytoma, IDH-mutant, grade 4.","High Grade Astrocytic Tumor | High Grade Astrocytic Neoplasm | High-Grade Astrocytic Neoplasm | High-Grade Astrocytic Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1696109","Central Nervous System Nongerminomatous Germ Cell Tumor","C100093","Germ cell tumors of the central nervous system other than germinoma.  This category includes teratoma, choriocarcinoma, embryonal carcinoma, and yolk sac tumor.","Central Nervous System Nongerminomatous Germ Cell Tumor | Nongerminomatous GCT - CNS | Nongerminomatous Germ Cell Tumor | Nongerminomatous germ cell tumor of the CNS",,,,,,,,,,,,,,,"604297","Nongerminomatous germ cell tumor of central nervous system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3539081","NCI CTEP SDC Vaginal Intraepithelial Neoplasia (VIN) Sub-Category Terminology","C103105","Vaginal Intraepithelial Neoplasia (VIN) is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Vaginal Intraepithelial Neoplasia (VIN) Sub-Category Terminology | NCI CTEP Simple Disease Classification Vaginal Intraepithelial Neoplasia (VIN) Sub-Category Terminology | Vaginal Intraepithelial Neoplasia (VIN)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333813","Central Nervous System Germinoma","C7009","A malignant germ cell tumor arising from the central nervous system.  It is composed of uniform cells resembling primitive germ cells.  These cells have large, vesicular nuclei, prominent nucleoli and a clear, glycogen-rich cytoplasm.  Additional features are lymphoid or lymphoplasmacytic infiltrates and, less frequently, scattered syncytiotrophoblastic giant cells.  (Adapted from WHO)","Central Nervous System Germinoma | Germinoma | Germinoma of CNS | Germinoma of Central Nervous System | Germinoma of the CNS | Germinoma of the Central Nervous System","9064/3","Germinoma",,,,,,,,,,,,,"608084","Germinoma of central nervous system",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0153606","Malignant Male Reproductive System Neoplasm","C8561","A primary or metastatic malignant neoplasm involving the male reproductive system.  Representative examples include prostate carcinoma, penile carcinoma, testicular seminoma, and testicular embryonal carcinoma.","Malignant Male Reproductive System Neoplasm | Male reprod. system cancer, NOS | Male reproductive system cancer, NOS | Malignant Male Reproductive System Tumor | Malignant Neoplasm of Male Reproductive System | Malignant Neoplasm of the Male Reproductive System | Malignant Tumor of Male Reproductive System | Malignant Tumor of the Male Reproductive System | Malignant neoplasm of male genital organ, unspecified",,,,,,,,,,,,,,,"4181487","Malignant tumor of male genital organ",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221286","Penile Paget Disease","C27817","A rare, usually non-invasive intraepithelial adenocarcinoma that arises from the penile skin or mucosal surface. It is characterized by the presence of neoplastic large cells with abundant pale cytoplasm and large nuclei with prominent nucleoli.","Penile Paget Disease | Paget Disease of the Penis | Paget Disease of the Penis | Paget's Disease of Penis | Paget's Disease of the Penis | Penile adenocarcinoma",,,,,,,,,,,,,,,"35622691","Adenocarcinoma of penis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0853105","Penile Carcinoma","C9061","A carcinoma that arises from the penis. Risk factors include phimosis and human papillomavirus infection. The majority of penile carcinomas are squamous cell carcinomas. The most frequent clinical presentation is an irregular mass in the glans of the penis. Treatment includes surgical management and radiation therapy.","Penile Carcinoma | Cancer of Penis | Cancer of the Penis | Carcinoma of Penis | Carcinoma of the Penis | Penile Cancer | Penile cancer, NOS | penile cancer",,,,,,,,,,,,,,,"4162137","Carcinoma of penis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0238348","Penile Squamous Cell Carcinoma","C7729","A squamous cell carcinoma arising from the penis.  It occurs chiefly in the squamous epithelium of the glans, coronal sulcus, and foreskin.  Etiologic factors include phimosis, lichen sclerosus, smoking, ultraviolet irradiation, history of warts or condylomas, and lack of circumcision.  Human papilloma virus is present in a subset of penile squamous cell carcinomas.  Patients may present with an exophytic or flat ulcerative mass in the glans or a large primary tumor with inguinal nodal and skin metastases. (WHO, 2004)","Penile Squamous Cell Carcinoma | Epidermoid Carcinoma of Penis | Epidermoid Carcinoma of the Penis | Epidermoid Cell Carcinoma of Penis | Epidermoid Cell Carcinoma of the Penis | Penile Epidermoid Carcinoma | Penile Epidermoid Cell Carcinoma | Penile Squamous Cell Cancer | Penile Squamous Cell Carcinoma | Penile squamous car.(epidermoid) | Penile squamous carcinoma (epidermoid) | Squamous Cell Carcinoma of Penis | Squamous Cell Carcinoma of the Penis | Squamous Cell Carcinoma of the Penis",,,,,,,,,,,,,,,"4296498","Squamous cell carcinoma of penis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518236","Malignant Ovarian Epithelial Tumor","C40026","An invasive malignant tumor that originates from the surface epithelium of the ovary.  It is composed of malignant epithelial cells and stroma.  Representative examples include serous adenocarcinoma, mucinous adenocarcinoma, endometrioid adenocarcinoma, clear cell adenocarcinoma, and malignant Brenner tumor.","Malignant Ovarian Epithelial Tumor | Malignant Ovarian Surface Epithelial-Stromal Neoplasm | Malignant Ovarian Surface Epithelial-Stromal Tumor | Malignant Ovarian Surface Epithelial-Stromal Tumor | Ovarian stromal cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027668","Vascular Neoplasm","C7388","A benign, intermediate, or malignant neoplasm arising from vascular tissue including arteries, veins, venous sinuses, lymphatic vessels, arterioles and capillaries. It may occur in essentially any body location and is characterized by the presence of vascular channel formation and endothelial cells.","Vascular Neoplasm | Neoplasm of Vascular Tissue | Neoplasms, Vascular | Tumor of Vascular Tissue | Tumors, Vascular | Vascular Neoplasms | Vascular Tissue Neoplasm | Vascular Tissue Tumor | Vascular Tumor | Vascular Tumors | Vascular tumor, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279672","Cervical Adenocarcinoma","C4029","An adenocarcinoma arising from the endocervical glandular epithelium. It is classified as either human papillomavirus-related or human papillomavirus-independent adenocarcinoma. Histologic variants include usual-type, mucinous, mesonephric, serous, clear cell, and endometrioid adenocarcinoma.","Cervical Adenocarcinoma | Adenocarcinoma | Adenocarcinoma - cervix | Adenocarcinoma of Cervix | Adenocarcinoma of Cervix Uteri | Adenocarcinoma of Uterine Cervix | Adenocarcinoma of the Cervix | Adenocarcinoma of the Cervix Uteri | Adenocarcinoma of the Uterine Cervix | Adenocarcinoma of the cervix | Carcinoma of Endocervix | Carcinoma of the Endocervix | Cervix Adenocarcinoma | Cervix Uteri Adenocarcinoma | Endocervical Adenocarcinoma | Endocervical Cancer | Endocervical Carcinoma | Uterine Cervix Adenocarcinoma",,,,,,,,,,,,,,,"4047649|4110872|4162134","Endocervical adenocarcinoma|Adenocarcinoma of cervix|Carcinoma of endocervix",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C3274428","Pancreatic Amylase Measurement","C98767","The determination of the amount of pancreatic amylase present in a sample.","Pancreatic Amylase Measurement | AMYLASEP | Amylase, Pancreatic | Pancreatic Amylase Isoenzyme",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0153687","Metastatic Malignant Neoplasm in the Skin","C5629","The spread of a malignant neoplasm to the skin.  This may be from a primary skin malignant neoplasm, or from a malignant neoplasm at a distant site.","Metastatic Malignant Neoplasm in the Skin | Metastases to Skin | Metastases to skin, NOS | Metastasis to Skin | Metastatic Malignant Neoplasm to the Skin | Metastatic Neoplasm to the Skin | Metastatic Tumor to the Skin | Secondary malignant neoplasm of skin | Skin Metastases | Skin Metastasis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540828","Miscellaneous Neoplasm","C102883","A benign or malignant neoplasm which is not further characterized.","Miscellaneous Neoplasm | Miscellaneous Tumors | Miscellaneous neoplasm, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334159","Immunodeficiency-Related Disorder","C35686","A non-neoplastic or neoplastic disorder that develops in a patient with immunodeficiency. Representative examples include AIDS-related disorders and disorders that develop following organ transplantation.","Immunodeficiency-Related Disorder | Immunodepression-Related Disorder | Immunosuppression disorders | Immunosuppression-Related Disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334458","Lymphadenopathy with Polyclonal Hypergammaglobulinemia","C9307","A finding indicating the presence of enlarged lymph nodes and associated polyclonal hypergammaglobulinemia.","Lymphadenopathy with Polyclonal Hypergammaglobulinemia | Lymphoadenopathy w/ polyclonal | Lymphoadenopathy with polyclonal hypergammaglobulinemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0264511","Lymphocytic Interstitial Pneumonia","C27558","Interstitial pneumonia characterized by the presence of bibasilar pulmonary interstitial infiltrates composed of lymphocytes and plasma cells.  It may be associated with autoimmune and lymphoproliferative disorders.  Signs and symptoms include fever, cough, and dyspnea.  Symptomatic patients may require immunosuppressive treatment.","Lymphocytic Interstitial Pneumonia | Diffuse Hyperplasia of Bronchus-Associated Lymphoid Tissue | LIP | Lymphocytic Interstitial Pneumonitis | Lymphocytic interst. pneumonitis | Lymphocytic interstitial pneumonitis",,,,,,,,,,,,,,,"4195014","Lymphoid interstitial pneumonia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3274439","Salivary Amylase Measurement","C98780","The determination of the amount of salivary amylase present in a sample.","Salivary Amylase Measurement | AMYLASES | Amylase, Salivary | Salivary Amylase Isoenzyme",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL421626","EGFR Tyrosine Kinase Inhibitor Therapy","C116534","The use of EGFR tyrosine kinase inhibitors to disrupt the activation of EGFR, effectively halting the signaling cascade for cell growth, thereby decreasing tumor proliferation and migration.","EGFR Tyrosine Kinase Inhibitor Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334798","Monomorphic Post-Transplant Lymphoproliferative Disorder","C7233","A clonal lymphoproliferative disorder arising as a result of post-transplant immunosuppression therapy. It is characterized by destructive infiltration of lymph nodes and extranodal sites by a monotonous population of transformed lymphocytes or plasma cells.  It includes two variants: monomorphic B-cell and monomorphic T/NK cell post-transplant lymphoproliferative disorders.","Monomorphic Post-Transplant Lymphoproliferative Disorder | Monomorphic PTLD | PTLD (Monoclonal) | Post-transplant lymphoproliferative disorder (Monoclonal), NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1292757","B Lymphoblastic Lymphoma","C8868","An uncommon type of lymphoma.  It constitutes approximately 10% of cases of lymphoblastic lymphoma.  Approximately 75% of cases reported in a literature review involved patients who were less than 18 years of age.  The most commonly affected sites are the skin, bone, soft tissue, and lymph nodes.  It has a high remission rate with a median survival of approximately 60 months.  (WHO, 2001)","B Lymphoblastic Lymphoma | B-Lymphoblastic Lymphoma | Precur. B-lymphoblastic lymphoma | Precursor B-Lymphoblastic Lymphoma | Precursor B-cell lymphoblastic lymphoma | Precursor B-lymphoblastic lymphoma",,,,,,,,,,,,,,,"4028705","Precursor B-cell lymphoblastic lymphoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3714636","Pneumonitis","C113159","An inflammatory process affecting the lung parenchyma. It is a milder form of lung inflammation compared to pneumonia.","Pneumonitis | ",,,,,,,,,,,,,,,"253506","Pneumonitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0238337","Pancreatic Cystadenocarcinoma","C3874","A cystic adenocarcinoma that arises from the pancreas. It includes the acinar cell and serous cystadenocarcinoma subtypes.","Pancreatic Cystadenocarcinoma | Cystadenocarcinoma - pancreas | Cystadenocarcinoma of Pancreas | Cystadenocarcinoma of the Pancreas | Cystadenocarcinoma of the pancreas",,,,,,,,,,,,,,,"4340498","Cystadenocarcinoma of pancreas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0279626","Esophageal Squamous Cell Carcinoma","C4024","A squamous cell carcinoma arising from the esophagus.  It is associated with a long history of tobacco and alcohol abuse and is exceedingly rare before the age of 30.  The median age is around 65 in both males and females.  It is located mostly in the middle and lower third of the esophagus.  Grossly, polypoid, ulcerated, plaque-like and occult lesions have been described.  The microscopic features are the same as in other squamous cell carcinomas.  Any degree of differentiation may occur, and variation within a single tumor is common.  The prognosis is poor.","Esophageal Squamous Cell Carcinoma | ESCC | Esophageal Epidermoid Carcinoma | Esophageal SCC | Esophageal Squamous Cell Cancer | Esophageal Squamous Cell Carcinoma, NOS | Esophageal Squamous Cell Carcinoma, Not Otherwise Specified | Esophagus SCC | Esophagus Squamous Cell Carcinoma | SCC of Esophagus | SCC of the Esophagus | Squamous Cell Carcinoma of Esophagus | Squamous Cell Carcinoma of the Esophagus | Squamous cell car. - esophagus | Squamous cell carcinoma of the esophagus",,,,,,,,,,,,,,,"4081044","Squamous cell carcinoma of esophagus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332166","Gastroesophageal Junction Adenocarcinoma","C9296","An adenocarcinoma that arises from and straddles the junction of the stomach and esophagus. The category of adenocarcinomas of the gastroesophageal junction also includes the majority of adenocarcinomas previously called gastric cardia adenocarcinomas. Squamous cell carcinomas that affect or cross the junction of the stomach and esophagus are classified as carcinomas of the distal esophagus. Adenocarcinoma of the gastroesophageal junction occurs more often in Caucasian middle aged and elderly males. Clinical signs and symptoms include dysphagia, abdominal pain, and weight loss. The prognosis depends on the completeness of the surgical resection, the number of lymph nodes involved by cancer, and the presence or absence of postoperative complications. The presence of TP53 mutations indicates worse prognosis.","Gastroesophageal Junction Adenocarcinoma | Adenocarcinoma - GEJ | Adenocarcinoma of Cardioesophageal Junction | Adenocarcinoma of Gastroesophageal Junction | Adenocarcinoma of the Cardioesophageal Junction | Adenocarcinoma of the EG Junction | Adenocarcinoma of the Esophagogastric Junction | Adenocarcinoma of the GE Junction | Adenocarcinoma of the Gastroesophageal Junction | Adenocarcinoma of the Gastroesophageal Junction | Adenocarcinoma of the gastroesophageal junction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279628","Esophageal Adenocarcinoma","C4025","A malignant tumor with glandular differentiation arising predominantly from Barrett mucosa in the lower third of the esophagus.  Rare examples of esophageal adenocarcinoma deriving from ectopic gastric mucosa in the upper esophagus have also been reported.  Grossly, esophageal adenocarcinomas are similar to esophageal squamous cell carcinomas.  Microscopically, adenocarcinomas arising in the setting of Barrett esophagus are typically papillary and/or tubular.  The prognosis is poor.","Esophageal Adenocarcinoma | Adenocarcinoma | Adenocarcinoma - esophagus | Adenocarcinoma of Esophagus | Adenocarcinoma of the Esophagus | Adenocarcinoma of the esophagus | Esophagus Adenocarcinoma",,,,,,,,,,,,,,,"4081043","Adenocarcinoma of esophagus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0949541","Thyroid Gland Oncocytic Neoplasm","C46068","An adenoma or carcinoma arising from the follicular cells of the thyroid gland.  It is composed of large oncocytic cells with abundant granular eosinophilic cytoplasm.","Thyroid Gland Oncocytic Neoplasm | Hurthle Cell Neoplasm | Hurthle Cell Tumor | Hurthle cell neoplasm | Hurthle cell neoplasm (thyroid) | Hurthle cell tumor | Thyroid Gland Hurthle (Oncocytic) Cell Neoplasm | Thyroid Gland Hurthle (Oncocytic) Cell Neoplasm | Thyroid Gland Hurthle (Oncocytic) Cell Tumor | Thyroid Gland Hurthle Cell Neoplasm | Thyroid Gland Oncocytic Neoplasm | Thyroid Gland Oncocytic Neoplasm",,,,,,,,,,,,,,,"4181504","Hurthle cell neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153658","Malignant Endocrine Neoplasm","C3575","A malignant neoplasm affecting the endocrine glands.  Representative examples include thyroid gland carcinoma, parathyroid gland carcinoma, pituitary gland carcinoma, and adrenal cortex carcinoma.","Malignant Endocrine Neoplasm | Endocrine Neoplasm, Malignant | Endocrine cancer, NOS | Malignant Endocrine Gland Neoplasm | Malignant Endocrine Gland Tumor | Malignant Endocrine Tumor | Malignant Neoplasm of Endocrine Gland | Malignant Neoplasm of the Endocrine Gland | Malignant Tumor of Endocrine Gland | Malignant Tumor of the Endocrine Gland | Malignant neoplasm of endocrine gland, unspecified | endocrine cancer",,,,,,,,,,,,,,,"4156115","Malignant neoplasm of endocrine gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0346300","Metastatic Pituitary Neuroendocrine Tumor","C4536","Pituitary neuroendocrine tumor that has spread from its original site of growth to another anatomic site.","Metastatic Pituitary Neuroendocrine Tumor | Cancer of Pituitary | Cancer of Pituitary Gland | Cancer of the Pituitary | Cancer of the Pituitary Gland | Carcinoma of Pituitary | Carcinoma of Pituitary Gland | Carcinoma of the Pituitary | Carcinoma of the Pituitary Gland | Metastatic PitNET | Metastatic Pituitary Gland Carcinoma | Pituitary Carcinoma | Pituitary Gland Adenocarcinoma | Pituitary Gland Cancer | Pituitary Gland Carcinoma | Pituitary Gland Carcinoma | Pituitary carcinoma, NOS | Pituitary gland cancer, NOS","8272/3","Pituitary carcinoma, NOS",,,,,,,,,,,,,"37161446|4028542|4114193","Adenocarcinoma of pituitary gland|Pituitary carcinoma|Pituitary carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--|--"
"C0852469","Aggressive Non-Hodgkin Lymphoma","C9244","A non-Hodgkin lymphoma with an aggressive clinical course.  Representative examples include Burkitt lymphoma, mantle cell lymphoma, and angioimmunoblastic T-cell lymphoma.","Aggressive Non-Hodgkin Lymphoma | Aggressive Non-Hodgkin's Lymphoma | NHL, aggressive, NOS | Non-Hodgkin lymphoma, aggressive, NOS | aggressive lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334170","Indolent Non-Hodgkin Lymphoma","C8504","A non-Hodgkin lymphoma with an indolent clinical course.","Indolent Non-Hodgkin Lymphoma | Indolent Non-Hodgkin's Lymphoma | NHL, indolent, NOS | Non-Hodgkin lymphoma, indolent, NOS | indolent lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1832021","Isavuconazole","C64543","A water-soluble triazole prodrug with broad-spectrum antifungal activity. Isavuconazole is absorbed easily, given either orally or intravenously, and is hydrolyzed to its active moiety BAL4815 by plasma esterases. BAL4815 inhibits fungal cytochrome P450 lanosterol 14-alpha-demethylase (CYP51) that catalyzes the conversion of lanosterol to ergosterol, an important component of the fungal cell membrane. Enzyme inhibition by this agent leads to a decrease in ergosterol pool and therefore disturbs synthesis of fungal cell membrane, thereby increasing cell membrane permeability and promoting loss of essential intracellular elements. This ultimately causes fungal cell lysis and death.","Isavuconazole | BAL8557 | ISAVUCONAZOLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0220636","Malignant Salivary Gland Neoplasm","C3811","A primary or metastatic malignant neoplasm that affects the major or minor salivary glands.  Representative examples include carcinoma, lymphoma, and sarcoma.","Malignant Salivary Gland Neoplasm | Cancer of Salivary Gland | Cancer of the Salivary Gland | Malignant Neoplasm of Salivary Gland | Malignant Neoplasm of the Salivary Gland | Malignant Salivary Gland Tumor | Malignant Tumor of Salivary Gland | Malignant Tumor of the Salivary Gland | Salivary Gland Cancer | Salivary gland cancer | salivary gland cancer",,,,,,,,,,,,,,,"4116235","Malignant tumor of salivary gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333945","Head and Neck Precancerous Condition","C27642","A premalignant pathologic process that affects the anatomic structures of the head and neck.  Representative examples include oral leukoplakia and leukoplakia of the vocal cords.","Head and Neck Precancerous Condition | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334625","Malignant Testicular Non-Seminomatous Germ Cell Tumor","C5027","A classification of testicular cancers that arise in specialized sex cells called germ cells. Nonseminomas include embryonal carcinoma, teratoma, choriocarcinoma, and yolk sac tumor.","Malignant Testicular Non-Seminomatous Germ Cell Tumor | Malignant Non-Seminomatous Germ Cell Cancer of Testis | Malignant Non-Seminomatous Germ Cell Cancer of the Testis | Malignant Non-Seminomatous Germ Cell Neoplasm of Testis | Malignant Non-Seminomatous Germ Cell Neoplasm of the Testis | Malignant Non-Seminomatous Germ Cell Tumor of Testis | Malignant Non-Seminomatous Germ Cell Tumor of the Testis | Malignant Testicular Non-Seminomatous Germ Cell Neoplasm | Testicular Non-Seminomatous Germ Cell Cancer | Testicular Non-Seminomatous Malignant Germ Cell Neoplasm | Testicular nonseminomat. GCT, NOS | Testicular nonseminomatous germ cell tumor, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640983","Ovarian Non-Dysgerminomatous Germ Cell Tumor","C102870","A malignant germ cell tumor other than dysgerminoma that arises from the ovary.","Ovarian Non-Dysgerminomatous Germ Cell Tumor | Ovarian Nondysgerminomatous Germ Cell Tumor | Ovarian Nondysgerminomatous Germ Cell Tumor | Ovarian nondysgerm. GCT, NOS | Ovarian nondysgerminomatous germ cell tumor, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0346185","Ovarian Dysgerminoma","C8106","A malignant germ cell tumor arising from the ovary.  Morphologically, it is identical to seminoma and consists of a monotonous population of germ cells with abundant pale cytoplasm and uniform nuclei.  The stroma invariably contains chronic inflammatory cells, mostly T-lymphocytes. It responds to chemotherapy or radiotherapy and the prognosis relates to the tumor stage.","Ovarian Dysgerminoma | DYSGERMINOMA, MALIGNANT | Dysgerminoma | Dysgerminoma of Ovary | Dysgerminoma of the Ovary | Germ Cell Dysgerminoma of Ovary | Germ Cell Dysgerminoma of the Ovary | Ovarian Germ Cell Dysgerminoma | Ovarian dysgerminoma | dysgerminoma","9060/3","Dysgerminoma",,,,,,,,,,,,,"4116077","Malignant dysgerminoma of ovary",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0740345","Malignant Germ Cell Tumor","C4925","A gonadal or extragonadal malignant neoplasm that arises from germ cells. Representative examples include embryonal carcinoma, yolk sac tumor, and seminoma.","Malignant Germ Cell Tumor | Germ cell cancer, NOS | Malignant Germ Cell Neoplasm | Malignant Neoplasm of Germ Cell | Malignant Neoplasm of the Germ Cell | Malignant Tumor of Germ Cell | Malignant Tumor of the Germ Cell",,,,,,,,,,,,,,,"37017328","Malignant germ cell neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0278803","Small Intestinal Adenocarcinoma","C7888","An adenocarcinoma that arises from the small intestine.  Histologic variants include mucinous adenocarcinoma and signet ring cell carcinoma.","Small Intestinal Adenocarcinoma | Adenocarcinoma - small intest. | Adenocarcinoma of Small Bowel | Adenocarcinoma of Small Intestine | Adenocarcinoma of the Small Bowel | Adenocarcinoma of the Small Intestine | Adenocarcinoma of the small intestine | Non-Ampullary Adenocarcinoma | Small Bowel Adenocarcinoma",,,,,,,,,,,,,,,"4313335","Adenocarcinoma of small intestine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709520","Pharmacokinetic Effect","C54386","Processes that effect the level of a drug in the body.","Pharmacokinetic Effect | PHARMACOKINETIC EFFECT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0238031","Breast Phyllodes Tumor","C7575","A benign, malignant, or borderline circumscribed biphasic neoplasm that arises from the breast.  It usually affects middle-aged women.  It is characterized by the presence of a double layer of epithelial cells that are arranged in clefts, surrounded by a spindle cell mesenchymal (stromal) component.","Breast Phyllodes Tumor | Breast Cystosarcoma Phyllodes | Breast Phyllodes Neoplasm | Cystosarcoma Phyllodes of Breast | Cystosarcoma Phyllodes of the Breast | Cystosarcoma phylloides - breast | Cystosarcoma phylloides of the breast | Phyllodes Breast Neoplasm | Phyllodes Breast Tumor | Phyllodes Neoplasm of Breast | Phyllodes Neoplasm of the Breast | Phyllodes Tumor of Breast | Phyllodes Tumor of the Breast",,,,,,,,,,,,,,,"37016850","Phyllodes tumor of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0496920","Borderline Ovarian Epithelial Tumor","C4783","A low grade epithelial tumor arising from the ovary. It is characterized by an atypical proliferation of epithelial cells. There is no evidence of stromal invasion.","Borderline Ovarian Epithelial Tumor | Borderline Epithelial Neoplasm of Ovary | Borderline Epithelial Neoplasm of the Ovary | Borderline Epithelial Tumor of Ovary | Borderline Epithelial Tumor of the Ovary | Borderline Ovarian Epithelial Neoplasm | Borderline Ovarian Surface Epithelial-Stromal Tumor | Borderline Ovarian Surface Epithelial-Stromal Tumor | Epithelial Neoplasm of Ovary of Borderline Malignancy | Epithelial Neoplasm of the Ovary of Borderline Malignancy | Epithelial Ovarian Neoplasm of Borderline Malignancy | Epithelial Ovarian Tumor of Borderline Malignancy | Epithelial Tumor of Ovary of Borderline Malignancy | Epithelial Tumor of the Ovary of Borderline Malignancy | Low Malignant Potential Ovarian Tumor | Ovarian tum. of low malig. poten. | Ovarian tumors of low malignant potential | ovarian borderline malignant tumor | ovarian low malignant potential tumor",,,,,,,,,,,,,,,"200675|37018857","Neoplasm of uncertain behavior of ovary|Neoplasm of low malignant potential behavior of ovary",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1335035","Non-Neoplastic Post-Transplant Lymphoproliferative Disorder","C7234","A lymphoproliferative disorder arising as a result of post-transplant immunosuppression therapy. It is characterized by the lack of tissue destruction and the architectural preservation of the involved tissues.  It includes two morphologic variants: plasmacytic hyperplasia and infectious mononucleosis-like lymphoproliferative disorders.","Non-Destructive Post-Transplant Lymphoproliferative Disorder | Non-Destructive PTLD | Non-Neoplastic Post-Transplant Lymphoproliferative Disorder | PTLD (Polyclonal) | Post-Transplant Lymphoproliferative Disorder, Early Lesion | Post-Transplant Lymphoproliferative Disorder, Early Lesion | Post-transplant lymphoproliferative disorder (Polyclonal), NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882413","Poly (ADP-Ribose) Polymerase Inhibitor","C62554","Any substance that inhibits Poly (ADP-Ribose) polymerase, an enzyme involved in detecting DNA single strand breaks and the initiation of DNA repair. Inhibition of Poly (ADP-Ribose) polymerase has direct cytotoxic effects by inhibiting DNA repair and causing cell death.","Poly (ADP-Ribose) Polymerase Inhibitor | PARP Inhibitor | PARP inhibitor | Poly(ADP-Ribose) Polymerase Inhibitor | poly (ADP-ribose) polymerase inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0969586","Valganciclovir Hydrochloride","C66648","A hydrochloride salt form of valganciclovir, a prodrug form of ganciclovir, a nucleoside analog of 2'-deoxyguanosine, with antiviral activity. After phosphorylation, valganciclovir is incorporated into DNA, resulting in inhibition of viral DNA polymerase, and viral replication.","Valganciclovir Hydrochloride | L-Valine, ester with 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine, Monohydrochloride | RS 079070-194 | RS-079070-194 | Ro 107-9070/194 | Ro107-9070/194 | VALGANCICLOVIR HYDROCHLORIDE | Valcyt | Valcyte",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0678034","Negative Lymph Node","C36174","A clinical finding that a lymph node is free from cancer spread.","Negative Lymph Node | Negative | node-negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012383","Dimercaprol","C47494","A metal chelating agent that is used as an antidote in arsenic, gold, lead, mercury and other heavy metal poisoning. Metals form ligands in the body with the sulfhydryl groups of the pyruvate-oxidase enzyme system. This leads to an inhibition of the normal functioning of these enzymes that are dependent on free sulfhydryl groups for their activity. Dimercaprol reverses the enzyme inhibition by chelating the metal and regenerates free sulfhydryl groups, thereby preventing and reversing the metals toxic effects.","Dimercaprol | 1,2-Dithioglycerol | 2,3-Dimercapto-1-propanol | BAL in Oil | DIMERCAPROL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006692","Edetate Calcium Disodium","C334","Contracted name for a salt of ethylenediaminetetraacetate, an agent used as a chelator of lead and some other heavy metals. C10H12CaN2Na2O8.","Edetate Calcium Disodium | C10H12CaN2Na2O8 | Calcium Disodium Ethylenediaminetetraacetate | Calcium Disodium Versenate | Calcium EDTA | Calcium disodium edetate | Calcium disodium ethylenediaminetetraacetate | Disodium calcium ethylenediaminetetraacetate | EDETATE CALCIUM DISODIUM | EDTA Calcium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030817","Penicillamine","C729","A beta dimethyl analog of the amino acid cysteine.  As a degradation product of penicillin antibiotics, penicillamine chelates with heavy metals and increases their urinary excretion.  Possessing antineoplastic properties, penicillamine induces apoptosis by a p53-mediated mechanism and inhibits angiogenesis by chelating with copper, a cofactor for angiogenesis. (NCI04)","Penicillamine | .beta.,.beta.-Dimethylcysteine | 3-Mercapto-D-valine | Alpha-amino-beta-methyl-beta-mercaptobutyric Acid | Atamir | Beta,Beta-dimethylcysteine | Beta-thiovaline | Cuprenil | Cuprimine | Cupripen | D-Mercaptovaline | D-Penicillamine | Depamine | Depen | Distamine | Kelatin | Mercaptyl | Metalcaptase | PENICILLAMINE | Pendramine | Perdolat | Sufortan | Trolovol | penicillamine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0071778","Potassium Phosphate","C29373","An inorganic compound used as a laxative, dietary supplement and for electrolyte-replacement purposes. Phosphate, a predominant intracellular anion, plays an important role in energy storage, osteoblastic and osteoclastic activities, regulating serum calcium concentrations and numerous cellular phosphate-transfer reactions. Potassium phosphate increases fluidity of the intestinal contents by retention of water by osmotic forces, thereby indirectly inducing intestinal smooth muscle constriction.","Potassium Phosphate | POTASSIUM PHOSPHATE, UNSPECIFIED FORM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023395","Integrin Alpha-X","C16789","Integrin alpha-X (1163 aa, ~128 kDa) is encoded by the human ITGAX gene. This protein is involved in cell-matrix interactions and integrin signaling.","Integrin Alpha-X | Alphax Integrin Chain | Antigen Cd11c (P150), Alpha Polypeptide | Axb2 | CD11 Antigen-Like Family Member C | CD11c | Cr4 | ITGAX | Integrin Alpha X | Integrin Alpha X | Leu M5 | Leukocyte Adhesion Glycoprotein P150,95, Alpha Chain | Leukocyte Adhesion Receptor P150,95 | Leukocyte Surface Antigen P150, 95 | Myeloid Membrane Antigen, Alpha Subunit | p150 95 Integrin Alpha Chain",,,,,,,,,,,,,,,"4187221","Lymphocyte antigen CD11c",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033511","Propylthiouracil","C781","A thiourea derivative with antithyroid property. Propylthiouracil (PTU) interferes with the oxidation of iodine possibly by interaction with peroxidase or a peroxidase-mediated complex reaction, thereby inhibiting synthesis of thyroid hormones tri-iodothyronine (T3) and thyroxine (T4). In addition, this agent inhibits the Type I 5'-deiodinase (D1), an enzyme involved in the peripheral conversion of thyroxine to tri-iodothyronine. This results in decreased plasma triodothyronine concentrations and decreased entrance of thyroxine into cells thereby reducing thyroid hormone activity.","Propylthiouracil | 6-Propyl-2-Thiouracil | 6-Propyl-2-thiouracil | PROPYLTHIOURACIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054943","Aminopeptidase N","C94661","Aminopeptidase N (967 aa, ~110 kDa) is encoded by the human ANPEP gene. This protein plays a role in the mediation both of peptide hydrolysis and infection by certain viruses.","Aminopeptidase N | AAP | ANPEP | AP-M | AP-N | Alanyl Aminopeptidase | Aminopeptidase M | Antigen CD13 | CD13 | CD13 Antigen | EC 3.4.11.2 | Microsomal Aminopeptidase | Myeloid Plasma Membrane Glycoprotein CD13 | alanine aminopeptidase | gp150 | hAPN",,,,,,,,,,,,,,,"4176320","Lymphocyte antigen CD13",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0303918","Ferric Ferrocyanide","C47532","A chelating agent with strong binding affinity for thallium, cesium, and other ions. Ferric hexacyanoferrate is used for the treatment of acute and chronic thallium and cesium poisoning. This agent is not absorbed in the gastrointestinal tract and it chelates thallium or cesium ion in the intestines. The resulting complex is eliminated via the feces.","Ferric Ferrocyanide | Antidotum Thallii-Heyl | FERRIC FERROCYANIDE | Ferric Hexacyanoferrate (II) | Ferrocin | Insoluble Prussian Blue | Iron Ferrocyanide | Radiogardase-Cs",,,,,,,,,,,,,,,"4264047","Insoluble berlin blue stain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0074722","Sodium Bicarbonate","C29457","The monosodium salt of carbonic acid with alkalinizing and electrolyte replacement properties. Upon dissociation, sodium bicarbonate forms sodium and bicarbonate ions. Ion formation increases plasma bicarbonate and buffers excess hydrogen ion concentration, resulting in raised blood pH.","Sodium Bicarbonate | Baking Soda | Bicarbonate of Soda | NaHCO3 | SODIUM BICARBONATE | Sodium Hydrogen Carbonate | Sodium bicarbonate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0074757","Sodium Phosphate","C29459","An inorganic compound used as a laxative, dietary supplement and for electrolyte-replacement purposes. Phosphate, a predominant intracellular anion, plays an important role in energy storage, osteoblastic and osteoclastic activities, regulating serum calcium concentrations, and numerous cellular phosphate-transfer reactions. Sodium phosphate increases fluidity of the intestinal contents by retention of water by osmotic forces, thereby indirectly inducing intestinal smooth muscle constriction. Sodium phosphate is also used in the renal excretion of hydrogen ions while promoting the reabsorption of sodium ions.","Sodium Phosphate | Hemisodium Phosphate | Instant Calgon | Phosphoral | Phosphosoda | SODIUM PHOSPHATE | Turrixin ST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054954","Platelet Glycoprotein 4","C18400","Platelet glycoprotein 4 (472 aa, ~53 kDa) is encoded by the human CD36 gene. This protein is involved in blood coagulation, fatty acid binding, and cell adhesion.","Platelet Glycoprotein 4 | CD36 | CD36 Antigen | CSVTCG-Specific Receptor | CSVTCG-Specific TSP-1 Receptor | Cluster Determinant 36 | Cysteine-Serine-Valine-Threonine-Cysteine-Glycine Specific TSP-1 Receptor | FAT | Fatty Acid Translocase | GP IIIb | GP IV | GPIIIB | GPIV | Glycoprotein IIIb | Leukocyte Differentiation Antigen CD36 | PAS IV | PAS-4 | PAS-4 Protein | Platelet Collagen Receptor | Platelet Glycoprotein IV | Scavenger Receptor Class B Member 3 | Thrombospondin Receptor",,,,,,,,,,,,,,,"4239403","Lymphocyte antigen CD36",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1567019","CD38 protein, human","C84323","ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (300 aa, ~34 kDa) is encoded by the human CD38 gene. This protein is involved in both ADP-ribose metabolism and signal transduction.","ADP-Ribosyl Cyclase/Cyclic ADP-Ribose Hydrolase 1 | 2'-Phospho-ADP-Ribosyl Cyclase | 2'-Phospho-ADP-Ribosyl Cyclase/2'-Phospho-Cyclic-ADP-Ribose Transferase | 2'-Phospho-Cyclic-ADP-Ribose Transferase | ADP-Ribosyl Cyclase 1 | ADP-Ribosyl Cyclase 1 | ADP-Ribosyl Cyclase/Cyclic ADP-Ribose Hydrolase | ADPRC 1 | CD38 | CD38 Antigen | Cyclic ADP-Ribose Hydrolase 1 | EC 3.2.2.- | EC 3.2.2.5 | EC 3.2.2.6 | EC3.2.2.5 | Ecto-Nicotinamide Adenine Dinucleotide Glycohydrolase | T10 | cADPr Hydrolase 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0189233","Hemilaryngectomy","C51906","Surgery to remove one half of the larynx.","Hemilaryngectomy | Vertical Hemilaryngectomy | Vertical Partial Laryngectomy | hemilaryngectomy",,,,,,,,,,,,,,,"4191258","Hemilaryngectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0108796","High Affinity Immunoglobulin Gamma Fc Receptor I","C104238","High affinity immunoglobulin gamma Fc receptor I (374 aa, ~43 kDa) is encoded by the human FCGR1A gene. This protein is involved in the immune response and signal transduction.","High Affinity Immunoglobulin Gamma Fc Receptor I | CD64 | CD64 Antigen | FCGR1A | Fc Gamma Receptor | Fc Gamma Receptor I A1 | Fc-Gamma RI | Fc-Gamma RIA | IgG Fc Receptor I",,,,,,,,,,,,,,,"4185708","Lymphocyte antigen CD64",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3853579","Cup","C43187","A bowl-shaped container.","Cup | CUP",,,,,,,,,,,,,,,"45768320","Cup",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897488","Stories Delayed","C120327","A component of the Children's Memory Scale. Two stories are read to the child. After a delay of about 30 minutes the child is asked to retell each story.","Stories Delayed | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899338","Dot Locations Short Delay","C120324","A component of the Children's Memory Scale. A child is presented with an array of dots (6 or 8 positions depending upon the child's age), which is learned over 3 trials. Immediately following a distractor array the child is asked to reproduce the initial array.","Dot Locations Short Delay | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899339","Dot Locations Long Delay","C120325","A component of the Children's Memory Scale. A child is presented with an array of dots (6 or 8 positions depending upon the child's age), which is learned over 3 trials. A distractor array is then presented. Following a 30 minute delay, the child is then asked to reproduce the initial array.","Dot Locations Long Delay | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899337","Dot Locations Total Score","C120337","The total score from the Children's Memory Scale Dot Locations Short Delay and Dot Locations Long Delay.","Dot Locations Total Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897487","Stories Immediate","C120326","A component of the Children's Memory Scale. Two stories are read to the child, and the child is asked to repeat each story immediately after it is told.","Stories Immediate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335870","SSTR5 Gene","C28639","This gene plays a role in G protein-coupled receptor signal transduction and stimulates DNA synthesis and cellular proliferation rates.","SSTR5 Gene | SSTR5 | Somatostatin Receptor 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897489","Stories Delayed Recognition","C120328","A component of the Children's Memory Scale. Two stories are read to the child. After a delay of about 30 minutes the child is asked yes/no questions about each story.","Stories Delayed Recognition | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899161","Faces Immediate","C120329","A component of the Children's Memory Scale. A series of faces are presented one at a time. The child is then asked to say yes or no if the face being presented was one of the faces from the initial list.","Faces Immediate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899162","Faces Delayed","C120330","A component of the Children's Memory Scale. A series of faces are presented one at a time. After a delay of about 30 minutes the child is asked whether or not each face was one of the faces on the initial list.","Faces Delayed | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897163","Word Pairs Learning","C120331","A component of the Children's Memory Scale. A child is read a list of paired words and then asked to say the second word after being told the first. The list is presented three times in this fashion.","Word Pairs Learning | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897164","Word Pairs Immediate","C120332","A component of the Children's Memory Scale. A child is read a list of paired words and then asked to say the second word after being told the first. The list is presented three times in this fashion. After the third list/cued recall trial the child is asked to tell the examiner as many word pairs as they can with no cues.","Word Pairs Immediate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335868","SSTR3 Gene","C24828","This gene plays a role in G protein-coupled receptor signal transduction and is involved in adenylyl cyclase regulation.","SSTR3 Gene | SSTR3 | Somatostatin Receptor 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897165","Word Pairs Delayed","C120333","A component of the Children's Memory Scale. A child is read a list of paired words and then asked to say the second word after being told the first. The list is presented three times in this fashion. After about 30 minutes the child is given the cued recall trial again.","Word Pairs Delayed | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897166","Word Pairs Delayed Recognition","C120334","A component of the Children's Memory Scale. A child is read a list of paired words and then asked to say the second word after being told the first. The list is presented three times in this fashion. After about 30 minutes the child is asked whether or not various pairs were on the list.","Word Pairs Delayed Recognition | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897162","Word Pairs Total Score","C120338","The total score from the Children's Memory Scale Word Pairs Immediate, Word Pairs Delayed, and Word Pairs Delayed Recognition.","Word Pairs Total Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898117","Numbers Forward","C120335","A component of the Children's Memory Scale. A child is asked to repeat a series of numbers of gradually increasing length.","Numbers Forward | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897105","Numbers Backward","C120336","A component of the Children's Memory Scale. A child is asked to repeat a series of numbers of gradually increasing length, but in reverse order.","Numbers Backward | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898116","Numbers Total Score","C120339","The total score from the Children's Memory Scale Numbers Forward and Numbers Backward.","Numbers Total Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897643","Sequences Total Score","C120340","The total score from the Children's Memory Scale Sequences subtests.","Sequences Total Score | Total Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897652","Scaled Score","C120341","Conversion of a raw score on a test to a common scale that allows for a numerical comparison.","Scaled Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898129","Non-Glabrous Skin","C120321","Hairy skin.","Non-Glabrous Skin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1180283","Glabrous Skin","C120320","Skin that is naturally hairless.","Glabrous Skin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229843","Pectoral Lymph Node","C120322","An axillary lymph node located along the lower edge of the pectoralis minor.","Pectoral Lymph Node | PECTORAL LYMPH NODE | Pectoral Nodes | Structure of pectoral axillary lymph node (body structure)",,,,,,,,,,,,,,,"4288282","Structure of pectoral axillary lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0812445","CXCL1 Gene","C18460","This gene is involved in immune processes and has been implicated in cancer metastasis.","CXCL1 Gene | CXCL1 | Chemokine (C-X-C Motif) Ligand 1 (Melanoma Growth Stimulating Activity, Alpha) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0238324","Ovarian Germ Cell Tumor","C3873","A neoplasm that arises from the ovary and originates from germ cells. Representative examples include teratoma, embryonal carcinoma, yolk sac tumor, and dysgerminoma.","Ovarian Germ Cell Tumor | Germ Cell Neoplasm of Ovary | Germ Cell Neoplasm of the Ovary | Germ Cell Tumor of Ovary | Germ Cell Tumor of the Ovary | Ovarian Germ Cell Neoplasm | ovarian germ cell tumor",,,,,,,,,,,,,,,"4130336","Germ cell tumor of ovary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1337342","Thrombin","C87773","No Value Exists","Thrombin | THROMBIN | Thrombin Bovine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538580","PARP2 Gene","C104717","This gene is involved in base excision repair of DNA.","PARP2 Gene | PARP2 | Poly(ADP-Ribose) Polymerase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0750887","Malignant Adrenal Gland Neoplasm","C9338","A primary or metastatic malignant neoplasm affecting the adrenal gland.","Malignant Adrenal Gland Neoplasm | Malignant Adrenal Gland Tumor | Malignant Adrenal Neoplasm | Malignant Adrenal Tumor | Malignant Neoplasm of Adrenal Gland | Malignant Neoplasm of the Adrenal Gland | Malignant Tumor of Adrenal Gland | Malignant Tumor of the Adrenal Gland | Malignant neoplasm of unspecified part of unspecified adrenal gland | adrenal cancer",,,,,,,,,,,,,,,"4181328","Malignant tumor of adrenal gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007102","Malignant Colon Neoplasm","C9242","A primary or metastatic malignant neoplasm that affects the colon.  Representative examples include carcinoma, lymphoma, and sarcoma.","Malignant Colon Neoplasm | Colon Neoplasm, Malignant | Colon Tumor, Malignant | Malignant Colon Tumor | Malignant Colonic Neoplasm | Malignant Colonic Tumor | Malignant Neoplasm of Colon | Malignant Neoplasm of the Colon | Malignant Tumor of Colon | Malignant Tumor of the Colon | Malignant neoplasm of colon, unspecified",,,,,,,,,,,,,,,"4180790","Malignant tumor of colon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0546837","Malignant Esophageal Neoplasm","C7478","A primary or metastatic malignant neoplasm involving the esophagus.","Malignant Esophageal Neoplasm | Malignant Esophageal Tumor | Malignant Esophagus Tumor | Malignant Neoplasm of Esophagus | Malignant Neoplasm of the Esophagus | Malignant Tumor of Esophagus | Malignant Tumor of the Esophagus | Malignant neoplasm of esophagus, unspecified",,,,,,,,,,,,,,,"4181343","Malignant tumor of esophagus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153579","Malignant Fallopian Tube Neoplasm","C7480","A primary or metastatic malignant neoplasm that affects the fallopian tube.  Representative examples include carcinoma, carcinosarcoma, and leiomyosarcoma.","Malignant Fallopian Tube Neoplasm | Fallopian Tube Malignant Neoplasm | Fallopian Tube Malignant Tumor | Malignant Fallopian Tube Tumor | Malignant Neoplasm of Fallopian Tube | Malignant Neoplasm of the Fallopian Tube | Malignant Tumor of Fallopian Tube | Malignant Tumor of the Fallopian Tube | Malignant neoplasm of unspecified fallopian tube | Neoplasm, Fallopian Tube, Malignant | Tumor, Fallopian Tube, Malignant",,,,,,,,,,,,,,,"4178969","Malignant tumor of fallopian tube",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153452","Gallbladder Malignant Neoplasm","C7481","A primary or metastatic malignant neoplasm that affects the gallbladder.  Representative examples include carcinoma, lymphoma, melanoma, and sarcoma.","Gallbladder Malignant Neoplasm | Malignant Gallbladder Neoplasm | Malignant Gallbladder Neoplasm | Malignant Gallbladder Tumor | Malignant Neoplasm of Gallbladder | Malignant Neoplasm of the Gallbladder | Malignant Tumor of Gallbladder | Malignant Tumor of the Gallbladder | Malignant neoplasm of gallbladder",,,,,,,,,,,,,,,"4181327","Malignant tumor of gallbladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024623","Malignant Gastric Neoplasm","C9331","A primary or metastatic malignant neoplasm involving the stomach.","Malignant Gastric Neoplasm | Malignant Gastric Tumor | Malignant Neoplasm of Stomach | Malignant Neoplasm of the Stomach | Malignant Tumor of Stomach | Malignant Tumor of the Stomach | Malignant neoplasm of stomach, unspecified",,,,,,,,,,,,,,,"443387","Malignant tumor of stomach",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2826651","Exposure Dose","C83039","The amount of exposure that a subject actually receives.","Exposure Dose | EXDOSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023466","Chronic Monocytic Leukemia","C34774","No Value Exists","Chronic Monocytic Leukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024620","Primary Malignant Liver Neoplasm","C34803","An epithelial or non-epithelial malignant neoplasm that arises from the liver. Representative examples include hepatocellular carcinoma, intrahepatic cholangiocarcinoma, lymphoma, and sarcoma.","Primary Malignant Liver Neoplasm | Malignant neoplasm of liver, primary, unspecified as to type | Primary Malignant Neoplasm of Liver",,,,,,,,,,,,,,,"201519","Primary malignant neoplasm of liver",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242379","Malignant Lung Neoplasm","C7377","A primary or metastatic malignant neoplasm involving the lung.","Malignant Lung Neoplasm | Malignant Lung Tumor | Malignant Neoplasm of Lung | Malignant Neoplasm of the Lung | Malignant Tumor of Lung | Malignant Tumor of the Lung",,,,,,,,,,,,,,,"443388","Malignant tumor of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0560132","Sievert","C42553","The international system (SI) unit for radiation dose equivalent equal to 1 Joule/kilogram. 1 sievert = 100 rem.","Sievert | Sv | sievert",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0751428","Malignant Peripheral Nervous System Neoplasm","C4961","Malignant growth of cells in the peripheral nervous system (PNS)or Autonomic Nervous System (ANS), without specification as to location","Malignant Peripheral Nervous System Neoplasm | Malignant Neoplasm of PNS | Malignant Neoplasm of Peripheral Nerve | Malignant Neoplasm of Peripheral Nervous System | Malignant Neoplasm of the PNS | Malignant Neoplasm of the Peripheral Nerve | Malignant Neoplasm of the Peripheral Nervous System | Malignant Neoplasms, Peripheral Nerve | Malignant PNS Neoplasm | Malignant PNS Tumor | Malignant Peripheral Nerve Neoplasm | Malignant Peripheral Nerve Tumor | Malignant Peripheral Nervous System Tumor | Malignant Tumor of PNS | Malignant Tumor of Peripheral Nerve | Malignant Tumor of Peripheral Nervous System | Malignant Tumor of the PNS | Malignant Tumor of the Peripheral Nerve | Malignant Tumor of the Peripheral Nervous System | Malignant neoplasm of peripheral nerves and autonomic nervous system, unspecified | Peripheral Nervous System Neoplasms, Malignant",,,,,,,,,,,,,,,"4094260|4112974","Malignant neoplasm of peripheral nerves and autonomic nervous system|Malignant tumor of peripheral nerve",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0600113","Ovarian Sex Cord-Stromal Tumor","C4862","A benign or malignant neoplasm that arises from the ovary and is composed of granulosa cells, Sertoli cells, Leydig cells, theca cells, and fibroblasts.  Representative examples include thecoma, fibroma, Sertoli cell tumor, and granulosa cell tumor.","Ovarian Sex Cord-Stromal Tumor | Ovarian Sex Cord-Stromal Neoplasm | Ovarian stromal tumor | Sex Cord-Stromal Neoplasm of Ovary | Sex Cord-Stromal Neoplasm of the Ovary | Sex Cord-Stromal Tumor of Ovary | Sex Cord-Stromal Tumor of the Ovary",,,,,,,,,,,,,,,"4127395","Sex cord tumor of ovary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153653","Malignant Parathyroid Gland Neoplasm","C9322","A primary or metastatic malignant neoplasm affecting the parathyroid glands.","Malignant Parathyroid Gland Neoplasm | Malignant Neoplasm of Parathyroid | Malignant Neoplasm of Parathyroid Gland | Malignant Neoplasm of the Parathyroid | Malignant Neoplasm of the Parathyroid Gland | Malignant Parathyroid Gland Tumor | Malignant Parathyroid Neoplasm | Malignant Parathyroid Tumor | Malignant Tumor of Parathyroid | Malignant Tumor of Parathyroid Gland | Malignant Tumor of the Parathyroid | Malignant Tumor of the Parathyroid Gland | Malignant neoplasm of parathyroid gland",,,,,,,,,,,,,,,"4181483","Malignant tumor of parathyroid gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153494","Malignant Pleural Neoplasm","C3547","A primary or metastatic malignant neoplasm affecting the pleura.  A representative example of primary malignant pleural neoplasm is the malignant pleural mesothelioma.  A representative example of metastatic malignant neoplasm to the pleura is metastatic carcinoma that has spread to the pleura from another anatomic site.","Malignant Pleural Neoplasm | Cancer of Pleura | Cancer of the Pleura | Malignant Neoplasm of Pleura | Malignant Neoplasm of the Pleura | Malignant Pleural Tumor | Malignant Tumor of Pleura | Malignant Tumor of the Pleura | Malignant neoplasm of pleura | Pleural Cancer",,,,,,,,,,,,,,,"4180795","Malignant tumor of pleura",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL336320","Malignant Soft Tissue Neoplasm","C4867","A malignant neoplasm arising exclusively from the soft tissues.","Malignant Soft Tissue Neoplasm | Malignant Neoplasm of Soft Tissue | Malignant Neoplasm of the Soft Tissue | Malignant Soft Tissue Tumor | Malignant Tumor of Soft Tissue | Malignant Tumor of the Soft Tissue | Soft tissue tumor, malignant",,,,,,,,,,,,,,,"4153882","Malignant neoplasm of soft tissue",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641000","NCI CTEP Simplified Disease Classification Terminology","C102905","The NCI Cancer Therapy Evaluation Program (CTEP) Simplified Disease Classification (SDC), a three level hierarchy of Category, Sub-Category, and coding Term intended to provide an intuitive classification of neoplastic diseases to meet the needs of CTEP while still allowing reporting based on the Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.  All CTEP SDC Terms are matched to NCIt concepts, which are linked to SDC Categories and Sub-Categories through Concept_In_Subset association relationships.","NCI CTEP Simplified Disease Classification Terminology | NCI CTEP SDC Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899340","Dot Locations Learning","C120323","A component of the Children's Memory Scale. A child is presented with an array of dots (6 or 8 positions depending upon the child's age), which is learned over 3 trials. A distractor array is then presented. The child is then asked to reproduce the initial array either immediately, or following a 30 minute delay.","Dot Locations Learning | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0243032","MRI-Based Angiogram","C114867","An image of blood vessels constructed using magnetic resonance imaging.","MRI-Based Angiogram | MAGNETIC RESONANCE ANGIOGRAPHY | MRA | Magnetic Resonance Angiogram",,,,,,,,,,,,,,,"4082989","Magnetic resonance imaging (MRI) of vessels",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3887651","Palsy","C116721","Muscle weakness or paralysis of neurologic origin.","Palsy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900120","Acquired Facial Nerve Palsy","C116902","A condition characterized by reduced or absent movement of the ipsilateral face as a consequence of an injury to the seventh cranial nerve that has occurred after birth.","Acquired Facial Nerve Palsy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4230560","Visual Field Defect","C118727","An absolute or relative reduction in the extent of the normal field of vision.","Visual Field Defect | ",,,,,,,,,,,,,,,"377286","Visual field defect",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4027321","Logical Memory I Subtest (WMS-IV)","C120342","A subtest of the Wechsler Memory Scale, 4th Edition that assesses narrative memory under a free recall condition. A short story is presented orally. Immediately after presentation of the story the subject is asked to recall the story from memory.","Logical Memory I Subtest (WMS-IV) | Logical Memory I | WMS-IV Logical Memory I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4027320","Logical Memory II Subtest (WMS-IV)","C120343","A subtest of the Wechsler Memory Scale, 4th Edition that assesses narrative memory under a free recall condition. A short story is presented orally. After a delay, the subject is asked to recall the story from memory.","Logical Memory II Subtest (WMS-IV) | Logical Memory II | WMS-IV Logical Memory II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053875","Verbal Paired Associates I Subtest (WMS-IV)","C120344","A subtest of the Wechsler Memory Scale, 4th Edition that evaluates verbal memory for associated word pairs. After 10 or 14 word pairs are read to the subject, the first word of each pair is read, and the subject is asked to provide the corresponding word.","Verbal Paired Associates I Subtest (WMS-IV) | Verbal Paired Associates I | WMS-IV Verbal Paired Associates I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053726","Verbal Paired Associates II Subtest (WMS-IV)","C120345","A subtest of the Wechsler Memory Scale, 4th Edition that evaluates verbal memory for associated word pairs. 10 or 14 word pairs are read to the subject. After a delay, the first word of each pair is read, and the subject is asked to provide the corresponding word.","Verbal Paired Associates II Subtest (WMS-IV) | Verbal Paired Associates II | WMS-IV Verbal Paired Associates II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055155","Designs I Subtest (WMS-IV)","C120346","A subtest of the Wechsler Memory Scale, 4th Edition that evaluates immediate recall. The subject is shown a grid with 4-8 designs on a page for 10 seconds, which is then removed from view. The subject then selects the designs from a set of cards and places the cards in a grid in the same place as previously shown.","Designs I Subtest (WMS-IV) | Designs I | WMS-IV Designs I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055154","Designs II Subtest (WMS-IV)","C120347","A subtest of the Wechsler Memory Scale, 4th Edition that evaluates delayed recall as well as delayed recognition. The subject is shown a grid with 4-8 designs on a page for 10 seconds, which is then removed from view. After a delay, the subject is asked to recreate the pages shown in the immediate condition. Then, the subject is shown a series of grids and asked to select the two designs that are correct and in the same place as on the page shown in the immediate condition.","Designs II Subtest (WMS-IV) | Designs II | WMS-IV Designs II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053860","Visual Reproduction I Subtest (WMS-IV)","C120348","A subtest of the Wechsler Memory Scale, 4th Edition that assesses memory for nonverbal visual stimuli. A series of five designs is shown, one at a time, for 10 seconds each. After each design is presented, the subject is asked to draw the design from memory.","Visual Reproduction I Subtest (WMS-IV) | Visual Reproduction I | WMS-IV Visual Reproduction I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053725","Visual Reproduction II Subtest (WMS-IV)","C120349","A subtest of the Wechsler Memory Scale, 4th Edition that assesses long-term visual-spatial memory for nonverbal visual stimuli. A series of five designs is shown, one at a time, for 10 seconds each. After a delay, the subject is asked to draw the designs shown in any order. Then, the subject is asked to choose which of six designs on a page matches the original design shown.","Visual Reproduction II Subtest (WMS-IV) | Visual Reproduction II | WMS-IV Visual Reproduction II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054004","Spatial Addition Subtest (WMS-IV)","C120350","A subtest of the Wechsler Memory Scale, 4th Edition that evaluates visual-spatial working memory using a visual addition task. The subject is shown, sequentially, two grids with blue and red circles. The subject is then asked to add or subtract the location of the circles based on a set of rules.","Spatial Addition Subtest (WMS-IV) | Spatial Addition | WMS-IV Spatial Addition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050145","Block Design Subtest (WPPSI-IV)","C120352","A subtest of the Wechsler Preschool and Primary Scale of Intelligence, 4th Edition that measures ability to analyze and synthesize abstract visual stimuli. The child views a model and/or a picture in a book and uses one- or two-color blocks to recreate the design.","Block Design Subtest (WPPSI-IV) | BD | Block Design | WPPSI-IV Block Design",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049640","Picture Naming Subtest (WPPSI-IV)","C120353","A subtest of the Wechsler Preschool and Primary Scale of Intelligence, 4th Edition that measures expressive language ability and language development. The child names depicted objects.","Picture Naming Subtest (WPPSI-IV) | PM | PN | Picture Memory | WPPSI-IV Picture Memory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050217","Bug Search Subtest (WPPSI-IV)","C120354","A subtest of the Wechsler Preschool and Primary Scale of Intelligence, 4th Edition that measures short-term visual memory, visual-motor coordination, cognitive flexibility, visual discrimination, and concentration. Working within a specified time limit, the child marks the bug in the search group that matches the target bug.","Bug Search Subtest (WPPSI-IV) | BS | Bug Search | WPPSI-IV Bug Search",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050422","Vocabulary Subtest (WPPSI-IV)","C120355","A subtest of the Wechsler Preschool and Primary Scale of Intelligence, 4th Edition. Depending on the age of the child, this subtest measures either receptive vocabulary or verbal comprehension.","Vocabulary Subtest (WPPSI-IV) | Vocabulary | Vocabulary Subtest | WPPSI-IV Vocabulary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698399","Myeloperoxidase Measurement","C80198","The determination of the amount of myeloperoxidase present in a sample.","Myeloperoxidase Measurement | MPO | Myeloperoxidase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050146","Block Design Subtest (WISC-V)","C120356","A subtest of the Wechsler Intelligence Scale for Children, Fifth Edition that measures spatial perception, visual abstract processing, and problem solving.","Block Design Subtest (WISC-V) | Block Design | WISC-V Block Design",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055136","Digit Span Forward Subtest (WISC-V)","C120357","A subtest of the Wechsler Intelligence Scale for Children, Fifth Edition. The subject is read a sequence of numbers and recalls the numbers in the same order.","Digit Span Forward Subtest (WISC-V) | Digit Span Forward | WISC-V Digit Span Forward",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055138","Digit Span Backward Subtest (WISC-V)","C120358","A subtest of the Wechsler Intelligence Scale for Children, Fifth Edition. The subject is read a sequence of numbers and recalls the numbers in reverse order.","Digit Span Backward Subtest (WISC-V) | Digit Span Backward | WISC-V Digit Span Backward",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055134","Digit Span Sequencing Subtest (WISC-V)","C120359","A subtest of the Wechsler Intelligence Scale for Children, Fifth Edition. The subject is read a sequence of numbers and recalls the numbers in ascending order.","Digit Span Sequencing Subtest (WISC-V) | Digit Span Sequencing | WISC-V Digit Span Sequencing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050310","Coding Subtest (WISC-V)","C120360","A visual, paper, and pencil task subtest of the Wechsler Intelligence Scale for Children that requires the child to match numbers with symbols based on a 'key' at the top of the page by drawing the correct symbol in the boxes provided. Coding measures visual processing speed, short-term visual memory, and the ability to shift the eyes efficiently back and forth between the 'key' and the responses. This task requires fine motor skills (using a pencil) but does not require expressive language.","Coding Subtest (WISC-V) | Coding | WISC-V Coding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050421","Vocabulary Subtest (WISC-V)","C120361","A subtest of the Wechsler Intelligence Scale for Children, Fifth Edition. The subject either names objects presented visually or defines words that are presented visually and orally.","Vocabulary Subtest (WISC-V Subtest) | Vocabulary Subtest | Vocabulary Subtest (WISC-V) | WISC-V Vocabulary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049635","Symbol Search Subtest (WISC-V)","C120362","A subtest of the Wechsler Intelligence Scale for Children that measures visual-perceptual and decision-making speed, as well as short-term visual memory, visual-motor coordination, inhibitory control, visual discrimination, psychomotor speed, sustained attention, and concentration.","Symbol Search Subtest (WISC-V) | Symbol Search | WISC-V Symbol Search",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050311","Coding Subtest (WAIS-IV)","C120363","A subtest of the Wechsler Adult Intelligence Scale, 4th Edition that is sensitive to brain damage, dementia, age and depression. Using a paper key, the subject copies symbols that are paired with numbers within a specified time limit.","Coding Subtest (WAIS-IV) | Coding | WAIS-IV Coding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4027399","wais-iv subtests block design","C120364","A subtest of the Wechsler Adult Intelligence Scale, 4th Edition that measures spatial perception, visual abstract processing, and problem solving.","Block Design Subtest (WAIS-IV) | Block Design | WAIS-IV Block Design",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055133","Digit Span Subtest (WAIS-IV)","C120365","A subtest of the Wechsler Adult Intelligence Scale, 4th Edition that measures working memory, mental manipulation, cognitive flexibility, rote memory and learning, attention, and encoding. The subject is asked to recall numbers in the same order presented (digit span forward), reverse order (digit span backward), or recall the numbers in ascending order (digit span sequencing).","Digit Span Subtest (WAIS-IV) | Digit Span | WAIS-IV Digit Span",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049619","Symbol Search Subtest (WAIS-IV)","C120366","A subtest of the Wechsler Adult Intelligence Scale, 4th Edition that measures processing speed, short-term visual memory, visual-motor coordination, cognitive flexibility, visual discrimination, psychomotor speed, and speed of mental operation. The subject scans a search group and indicates whether one of the symbols in the target group matches.","Symbol Search Subtest (WAIS-IV) | Symbol Search | WAIS-IV Symbol Search",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050420","Vocabulary Subtest (WAIS-IV)","C120367","Wechsler Adult Intelligence Scale, 4th Edition. The subject either names objects presented visually or defines words that are presented visually and orally.","Vocabulary Subtest (WAIS-IV) | Vocabulary | Vocabulary Subtest | WAIS-IV Vocabulary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332884","Central Nervous System Leukemia","C5440","Leukemia infiltrating the central nervous system structures.","Central Nervous System Leukemia | CNS Leukemia | Leukemia of CNS | Leukemia of Central Nervous System | Leukemia of the CNS | Leukemia of the Central Nervous System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042487","Venous Thrombosis","C99107","The formation of a blood clot (thrombus) in the lumen of a vein.","Venous Thrombosis | ",,,,,,,,,,,,,,,"444247","Venous thrombosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2239290","Hodgkin's Paragranuloma","C26956","An obsolete term that includes cases currently classified as nodular lymphocyte predominant Hodgkin lymphoma.","Hodgkin's Paragranuloma | ",,,,,,,,,,,,,,,"4038839|4322613","Hodgkin lymphoma, nodular lymphocyte predominance (clinical)|Hodgkin lymphoma, nodular lymphocyte predominance",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3831117","Child-Pugh Class A","C113691","Child-Pugh score indicating one-year survival of 100% in patients with chronic liver disease and cirrhosis.  This score is determined by the study of the following five factors: bilirubin, albumin, international normalized ratio, presence and degree of ascites, and presence and degree of encephalopathy.","Child-Pugh Class A | A | Grade A (5-6 points) Well Compensated Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831116","Child-Pugh Class B","C113692","Child-Pugh score indicating one-year survival of 80% in patients with chronic liver disease and cirrhosis.  This score is determined by the study of the following five factors: bilirubin, albumin, international normalized ratio, presence and degree of ascites, and presence and degree of encephalopathy.","Child-Pugh Class B | B | Grade B (7-9 points) Significant Functional Compromise",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831115","Child-Pugh Class C","C113694","Child-Pugh score indicating one-year survival of 45% in patients with chronic liver disease and cirrhosis.  This score is determined by the study of the following five factors: bilirubin, albumin, international normalized ratio, presence and degree of ascites, and presence and degree of encephalopathy.","Child-Pugh Class C | C | Grade C (10-15 points) Decompensated Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226398","External Iliac Artery","C32558","An artery arising from the bifurcation of the common iliac artery in the lower torso. The external iliac artery becomes the femoral artery and is the main blood supply for the leg.","External Iliac Artery | EXTERNAL ILIAC ARTERY | Structure of external iliac artery (body structure)",,,,,,,,,,,,,,,"4034036","Structure of external iliac artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0226364","Internal Iliac Artery","C32845","A short thick blood vessel arising from the bifurcation of the common iliac artery with numerous branches that supply the organs, walls and viscera of the pelvis as well as the inner thigh.","Internal Iliac Artery | INTERNAL ILIAC ARTERY | Structure of internal iliac artery (body structure)",,,,,,,,,,,,,,,"4233369","Structure of internal iliac artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0229713","Preauricular Lymph Node","C103429","A lymph node located anterior to the auricle of the ear.","Preauricular Lymph Node | PREAURICULAR LYMPH NODE | Pre-auricular Nodes | Preauricular Nodes",,,,,,,,,,,,,,,"4098344","Structure of anterior auricular lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054272","PML/RARA Single Fusion Probe","C120387","A set of two DNA probes designed for use in FISH; one hybridizes to either the 15q22 region containing the PML gene or the 17q21.1 region containing the RARA gene. This probe set detects the PML/RARA fusion gene.","PML/RARA Single Fusion Probe | PML/RARA Dual Color Single Fusion Probe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054271","PML/RARa Dual Fusion Probe","C120388","A mixture of three FISH DNA probes. Two probes hybridize to the 15q22 region containing the PML gene, one recognizes the 5' side of the break point and the other binds to the 3' side, while the third hybridizes to the 17q21.1 region containing the RARA gene. The PML probes are labeled with one fluorescent dye and the RARA probe is labeled with a different color fluorescence dye; therefore this probe set can uniquely distinguish intact and rearranged genes.","PML/RARa Dual Fusion Probe | PML/RARA Dual Color, Dual Fusion Translocation Probe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054134","RARA Dual Color Break-Apart Rearrangement Probe","C120389","A DNA FISH probe designed to detect chromosomal rearrangements involving the RARA gene region at chromosome 17q21.1. It is designed to differentially label the proximal and distal regions of RARA and can detect rearrangements between the RARA gene and any translocation partner.","RARA Dual Color Break-Apart Rearrangement Probe | RARA Break-Apart Rearrangement Probe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279021","Non-Specific Immune-Modulator Therapy","C15461","No Value Exists","Non-Specific Immune-Modulator Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055270","Cardiothoracic","C120450","Relating to the heart and chest.","Cardiothoracic | Cardiothoracic

",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037435","Social Security Program","C120451","The money received by retired workers who have paid in to the Social Security system during their working years.","Social Security Retirement Benefit | Social Security",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030854","Pension","C120452","A fixed sum paid regularly to a person by their former employer.","Pension | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036245","Financial savings","C120453","Money assets set aside, especially in a bank or other financial organization.","Savings | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054850","Have Felt Unusual Fatigue","C120410","A question about whether an individual feels or felt unusual fatigue.","Have Felt Unusual Fatigue | Have you felt unusually tired or fatigued in the last week",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054989","Fatigue Right Now","C120411","A question about how an individual rates their fatigue right now.","Fatigue Right Now | Rate your fatigue right now",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053889","Usual Level of Fatigue","C120412","A question about how an individual rates their usual level of fatigue.","Usual Level of Fatigue | Rate your usual level of fatigue during past 24 hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053836","Worst Level of Fatigue","C120413","A question about how an individual rates their worst level of fatigue.","Worst Level of Fatigue | Rate your worst level of fatigue during past 24 hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055004","Fatigue Interferes with General Activity","C120414","A question about how an individual's fatigue interfered or interferes with their general activity.","Fatigue Interferes with General Activity Question | Fatigue Interferes with General Activity | Fatigue Interferes with General Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055003","Fatigue Interferes with Mood","C120415","A question aboout how an individual's fatigue interfered or interferes with their mood.","Fatigue Interferes with Mood | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055001","Fatigue Interferes with Walking Ability","C120416","A question aboout how an individual's fatigue interfered or interferes with their ability to walk.","Fatigue Interferes with Walking Ability Question | Fatigue Interferes with Walking Ability | Fatigue Interferes with Walking Ability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055000","Fatigue Interferes with Work","C120417","A question aboout how an individual's fatigue interfered or interferes with their work.","Fatigue Interferes with Work | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055002","Fatigue Interferes with Relations with Other People","C120418","A question aboout how an individual's fatigue interfered or interferes with their relations with other people.","Fatigue Interferes with Relations with Other People | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055005","Fatigue Interferes with Enjoyment of Life","C120419","A question aboout how an individual's fatigue interfered or interferes with their enjoyment of life.","Fatigue Interferes with Enjoyment of Life | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055401","BFI Fatigue Rating Likert Scale","C120420","A scale for the subjective scoring of fatigue that ranges from 0: No Fatigue to 10: Fatigue As Bad As You Can Imagine.","BFI Fatigue Rating Likert Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054999","Fatigue Rating Score 0","C120422","A subjective score of 0 on a fatigue scale that ranges from 0: No Fatigue to 10: Fatigue as bad as you can imagine.","Fatigue Rating Score 0 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054997","Fatigue Rating Score 1","C120423","A subjective score of 1 on a fatigue scale that ranges from 0: No Fatigue to 10: Fatigue as bad as you can imagine.","Fatigue Rating Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054996","Fatigue Rating Score 2","C120424","A subjective score of 2 on a fatigue scale that ranges from 0: No Fatigue to 10: Fatigue as bad as you can imagine.","Fatigue Rating Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053799","Fatigue Rating Score 3","C120425","A subjective score of 3 on a fatigue scale that ranges from 0: No Fatigue to 10: Fatigue as bad as you can imagine.","Fatigue Rating Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054995","Fatigue Rating Score 4","C120426","A subjective score of 4 on a fatigue scale that ranges from 0: No Fatigue to 10: Fatigue as bad as you can imagine.","Fatigue Rating Score 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054994","Fatigue Rating Score 5","C120427","A subjective score of 5 on a fatigue scale that ranges from 0: No Fatigue to 10: Fatigue as bad as you can imagine.","Fatigue Rating Score 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054993","Fatigue Rating Score 6","C120428","A subjective score of 6 on a fatigue scale that ranges from 0: No Fatigue to 10: Fatigue as bad as you can imagine.","Fatigue Rating Score 6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054992","Fatigue Rating Score 7","C120429","A subjective score of 7 on a fatigue scale that ranges from 0: No Fatigue to 10: Fatigue as bad as you can imagine.","Fatigue Rating Score 7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054991","Fatigue Rating Score 8","C120430","A subjective score of 8 on a fatigue scale that ranges from 0: No Fatigue to 10: Fatigue as bad as you can imagine.","Fatigue Rating Score 8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054990","Fatigue Rating Score 9","C120431","A subjective score of 9 on a fatigue scale that ranges from 0: No Fatigue to 10: Fatigue as bad as you can imagine.","Fatigue Rating Score 9 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054998","Fatigue Rating Score 10","C120432","A subjective score of 10 on a fatigue scale that ranges from 0: No Fatigue to 10: Fatigue as bad as you can imagine.","Fatigue Rating Score 10 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055402","BFI Fatigue Interference Likert Scale","C120421","A scale for the subjective scoring of fatigue interference that ranges from 0: Does Not Interfere to 10: Completely Interferes.","BFI Fatigue Interference Likert Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053800","Fatigue Interference Score 0","C120435","A subjective score of 0 on a fatigue scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.","Fatigue Interference Score 0 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055015","Fatigue Interference Score 1","C120436","A subjective score of 1 on a fatigue scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.","Fatigue Interference Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055014","Fatigue Interference Score 2","C120438","A subjective score of 2 on a fatigue scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.","Fatigue Interference Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055013","Fatigue Interference Score 3","C120439","A subjective score of 3 on a fatigue scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.","Fatigue Interference Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055012","Fatigue Interference Score 4","C120440","A subjective score of 4 on a fatigue scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.","Fatigue Interference Score 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055011","Fatigue Interference Score 5","C120441","A subjective score of 5 on a fatigue scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.","Fatigue Interference Score 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055010","Fatigue Interference Score 6","C120443","A subjective score of 6 on a fatigue scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.","Fatigue Interference Score 6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055009","Fatigue Interference Score 7","C120444","A subjective score of 7 on a fatigue scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.","Fatigue Interference Score 7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055008","Fatigue Interference Score 8","C120445","A subjective score of 8 on a fatigue scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.","Fatigue Interference Score 8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055007","Fatigue Interference Score 9","C120447","A subjective score of 9 on a fatigue scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.","Fatigue Interference Score 9 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055016","Fatigue Interference Score 10","C120448","A subjective score of 10 on a fatigue scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.","Fatigue Interference Score 10 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0679739","Peer","C120458","Persons who are equal in one or more respects, including age, education, religion, sex, or social class.","Peer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049978","Timeline Follow-back Protocol","C120459","A clinical research method that entails using key calendar events or dates to prompt respondents to provide daily retrospective estimates over a specified time-period.","Timeline Follow-back Protocol | TLFB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4012821","Renal Impairment","C114592","Diminished kidney function.","Renal Impairment | Kidney Impairment",,,,,,,,,,,,,,,"4030518","Renal impairment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038727","Sulfatide Compound","C120471","A class of sulfated galactosylceramides and a major lipid component in myelin.","Sulfatide Compound | Cerebroside 3-Sulfate | SM4 | SULFATIDE | Sulfatide | Sulfatides | Sulphatide | Sulphatides",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3849993","Electronic Cigarette","C120482","A battery-powered electronic device designed to atomize a nicotine-containing liquid solution for inhalation in a manner that simulates smoking a tobacco cigarette.","Electronic Cigarette | Electronic Nicotine Delivery System | e-Cigarette",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055104","EORTC QLQ-C30 Health and Quality of Life Rating Scale","C120497","A scale used both for the subjective scoring of a person's overall health, and for their quality of life, that ranges from 1: Very Poor to 7: Excellent.","EORTC QLQ-C30 Health and Quality of Life Rating Scale | EORTC QLQ-C30 | Health and Quality of Life Likert Scale | Health and Quality of Life Rating Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054806","Health and Quality of Life Rating Score 1","C120498","A subjective score of 1 on a scale that ranges from 1: Very Poor to 7: Excellent.","Health and Quality of Life Rating Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054805","Health and Quality of Life Rating Score 2","C120499","A subjective score of 2 on a scale that ranges from 1: Very Poor to 7: Excellent.","Health and Quality of Life Rating Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054804","Health and Quality of Life Rating Score 3","C120500","A subjective score of 3 on a scale that ranges from 1: Very Poor to 7: Excellent.","Health and Quality of Life Rating Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054803","Health and Quality of Life Rating Score 4","C120501","A subjective score of 4 on a scale that ranges from 1: Very Poor to 7: Excellent.","Health and Quality of Life Rating Score 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054802","Health and Quality of Life Rating Score 5","C120502","A subjective score of 5 on a scale that ranges from 1: Very Poor to 7: Excellent.","Health and Quality of Life Rating Score 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054801","Health and Quality of Life Rating Score 6","C120503","A subjective score of 6 on a scale that ranges from 1: Very Poor to 7: Excellent.","Health and Quality of Life Rating Score 6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054800","Health and Quality of Life Rating Score 7","C120504","A subjective score of 7 on a scale that ranges from 1: Very Poor to 7: Excellent.","Health and Quality of Life Rating Score 7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714796","Growth Hormone Deficiency","C112835","Insufficient production of growth hormone.","Growth Hormone Deficiency | GH Deficiency | Somatotropin Deficiency",,,,,,,,,,,,,,,"4266035","Growth hormone deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0151701","Pulmonary Hemorrhage","C78578","Bleeding from the lung parenchyma.","Pulmonary Hemorrhage | ",,,,,,,,,,,,,,,"4301606","Pulmonary hemorrhage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0852879","Pulmonary Alveolar Hemorrhage","C116334","Bleeding in the alveoli.","Pulmonary Alveolar Hemorrhage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538978","Avascular Necrosis","C118385","Tissue death resulting from an interruption to the blood supply.","Avascular Necrosis | AVN | Avascular-Necrosis",,,,,,,,,,,,,,,"4313576","Avascular necrosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054640","List A Trials 1-5","C120390","The first part of the California Verbal Learning Test for Children. For the first five trials, a 15-item list, List A, is read to the child and he or she is asked to recall words from the list after each presentation.","List A Trials 1-5 | List A Trials 1-5 (Total Trials)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054642","List A Trial 1 Free Recall","C120391","The first free recall task from List A of the California Verbal Learning Test for Children.","List A Trial 1 Free Recall | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054641","List A Trial 5 Free Recall","C120392","The final free recall task from List A of the California Verbal Learning Test for Children.","List A Trial 5 Free Recall | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054639","List B Free Recall (CVLT-C)","C120395","The second part of the California Verbal Learning Test for Children. A second list, List B, is presented, and the child is asked to recall as many words from this list as he or she can.","List B Free Recall (CVLT-C) | List B Free Recall",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054643","List A Short Delay Free Recall","C120396","The third part of the California Verbal Learning Test for Children. Following the List B test, the child is asked to recall words from List A, without an additional presentation of the List A words.","List A Short Delay Free Recall | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054598","Long Delay Free Recall (CVLT-C)","C120397","The fourth part of the California Verbal Learning Test for Children. After a 20-minute non-verbal task, the child is asked to recall as many words as he or she can from List A.","Long Delay Free Recall (CVLT-C) | Long Delay Free Recall",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL494680","Perseverations","C120398","Repeats of words that have been previously mentioned on the same trial.","Perseverations | Repetitions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049623","Intrusions","C120399","Inclusions of words that were not on the test list.","Intrusions | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055132","Discriminability Index","C120400","A measure of the ability of a child to identify correct words (hits) relative to the ability to reject wrong words (false positives).","Discriminability Index | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3854607","bone densitometry T score","C120401","A method for converting an individual score into a standard form. While similar to a z-score, t-score is used when the conversion is made without knowledge of the population standard deviation and mean.","T-Score | T Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054929","Free Recall Trial 1","C120402","The first free recall task from the California Verbal Learning Test, second edition.","Free Recall Trial 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054928","Free Recall Trial 5","C120403","The final free recall task from the California Verbal Learning Test, second edition.","Free Recall Trial 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054927","Free Recall Trials 1-5","C120404","The first part of the California Verbal Learning Test, second edition. For the first five trials, a 15-item list, List A, is read to the subject and he or she is asked to recall words from the list after each presentation.","Free Recall Trials 1-5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054029","Short Delay Free Recall","C120405","A part of the California Verbal Learning Test, second edition. Following a delay, the subject is asked to recall words, without an additional presentation of those words.","Short Delay Free Recall | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053858","Voice Handicap Index-10","C120505","A 10 item self-assessment for adults to evaluate a patient's perception of their voice and the effects of their voice on their life.","Voice Handicap Index-10 | VHI-10 | Voice Handicap Index-10 (VHI-10)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3257863","Voice Makes it Difficult to Hear Me","C120506","A question about how often an individual's voice makes it difficult for people to hear them.","Voice Makes it Difficult to Hear Me | My voice makes it difficult for people to hear me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3260724","Run Out of Air When Talking","C120507","A question about how often an individual runs out of air when talking.","Run Out of Air When Talking | I run out of air when I talk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3258030","Difficulty Understanding Me in Noisy Room","C120508","A question about how often other people have difficulty understanding an individual in a noisy room.","Difficulty Understanding Me in Noisy Room | People have difficulty understanding me in a noisy room",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3258231","Sound of Voice Varies Throughout Day","C120509","A question about how often the sound of an individual's voice varies throughout the day.","Sound of Voice Varies Throughout Day | The sound of my voice varies throughout the day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3257841","Family Has Difficulty Hearing Me When I Call Them in the House","C120510","A question about how often an individual's family has difficulty hearing them when they call out in the house.","Family Has Difficulty Hearing Me When I Call Them in the House | My family has difficulty hearing me when I call them throughout the house",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3260743","Use Phone Less Often","C120511","A question about how much less an individual uses the phone than they would like.","Use Phone Less Often | I use the phone less often than I would like to",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3260747","Tend to Avoid Groups Because of My Voice","C120513","A question about how often an individual avoids groups because of their voice.","Tend to Avoid Groups Because of My Voice | A question about how often an individual avoids groups because of their voice. | I tend to avoid groups of people because of my voice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3258034","People Irritated by My Voice","C120514","A question about how often people seem irritated by an individual's voice.","People Irritated by My Voice | People seem irritated with my voice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3258025","People Question Voice Problem","C120515","A question about how often an individual is questioned about what is wrong with their voice.","People Question Voice Problem | People ask, What's wrong with your voice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055137","Digit Span Forward Subtest (WAIS-IV)","C120516","A subtest of the Wechsler Adult Intelligence Scale - Fourth Edition. The subject is read a sequence of numbers and recalls the numbers in the same order.","Digit Span Forward Subtest (WAIS-IV) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055139","Digit Span Backward Subtest (WAIS-IV)","C120517","A subtest of the Wechsler Adult Intelligence Scale - Fourth Edition. The subject is read a sequence of numbers and recalls the numbers in reverse order.","Digit Span Backward Subtest (WAIS-IV) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055135","Digit Span Sequencing Subtest (WAIS-IV)","C120518","A subtest of the Wechsler Adult Intelligence Scale - Fourth Edition. The subject is read a sequence of numbers and recalls the numbers in ascending order.","Digit Span Sequencing Subtest (WAIS-IV) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054117","Receptive Vocabulary Subtest (WPPSI-IV)","C120519","A subtest of the Wechsler Preschool and Primary Scale of Intelligence - Fourth Edition. It tests verbal comprehension by asking the child to select the picture that best represents the word the examiner reads aloud.","Receptive Vocabulary Subtest (WPPSI-IV) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055284","Cancellation Subtest (WPPSI-IV)","C120520","A subtest of the Wechsler Preschool and Primary Scale of Intelligence - Fourth Edition. As a test of processing speed the child scans two arrangements of objects (one random, one structured) and marks target objects.","Cancellation Subtest (WPPSI-IV) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519354","Skin squamous cell","C33562","A flat, scale-like epithelial cell found on the outer covering of the body.","Skin Squamous Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054638","List B Free Recall (CVLT-II)","C120547","Part of the second section of the California Verbal Learning Test - Second Edition. A second list, List B, is presented, and the subject is asked to recall as many words from this list as he or she can.","List B Free Recall (CVLT-II) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054597","Long Delay Free Recall (CVLT-II)","C120548","The fourth part of the California Verbal Learning Test - Second Edition. After a 20-minute non-verbal task, the subject is asked to recall as many words as he or she can from List A.","Long Delay Free Recall (CVLT-II) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420720","THBD Gene","C101378","This gene plays a role in the modulation of blood coagulation.","THBD Gene | THBD | Thrombomodulin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0140279","retinoic acid receptor alpha","C17533","Retinoic acid receptor alpha (462 aa, ~51 kDa) is encoded by the human RARA gene. This protein is involved in the regulation of both retinoic acid-dependent transcription and the cell cycle.","Retinoic Acid Receptor Alpha | NR1B1 | Nuclear Receptor Subfamily 1 Group B Member 1 | RARA | RARalpha | Retinoic Acid Receptor Alpha Isoform Alpha-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2976183","Oprozomib","C91388","An orally bioavailable proteasome inhibitor with potential antineoplastic activity. Proteasome inhibitor ONX 0912 inhibits the activity of the proteasome, thereby blocking the targeted proteolysis normally performed by the proteasome; this may result in an accumulation of unwanted or misfolded proteins. Disruption of various cell signaling pathways may follow, eventually leading to the induction of apoptosis and inhibition of tumor growth. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquitinated.","Oprozomib | O-methyl-N-((2-methylthiazol-5-yl)carbonyl)-l-seryl-O-methyl-N-((1S)-1-benzyl-2-((2R)-2-methyloxiran-2-yl)-2-oxoethyl)-l-serinamide | ONX 0912 | ONX-0912 | ONX0912 | OPROZOMIB | PR-047 | Proteasome Inhibitor ONX 0912",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042839","Vitamin A","C938","A compound containing vitamin A, a natural, fat-soluble vitamin that plays a vital role in a variety of physiologic processes including immune function, vision, reproduction, and cellular growth and differentiation. Upon administration, the various forms of vitamin A are solubilized into micelles in the intestinal lumen and absorbed by duodenal mucosal cells.","Vitamin A Compound | 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol | A 313 | Anti-Infective Vitamin | Anti-Infective vitamin | Antixerophthalmic Vitamin | Antixerophthalmic vitamin | Aquasol A | Arovit | Avibon | Avitol | Axerol | Axerophthol | Axerophtholum | Biosterol | Biovit-A | Del-VI-A | Del-Vi-A | Ido A 50 | Idrurto A | Lard Factor | Lard-Factor | Ledovit A | Micelle A | Mulsal A Megadosis | Oleovitamin A | Ophthalamin | Pedi-Vit-A | Retinol, all trans- | Rinocusi Vitaminico | VITAMIN A | Vitamin A | Vitamin A Alcohol | Vitamin A USP | Vitamin A1 | Vitaminoftalmina | Vitaminum A | Vogan | vitamin A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053931","Tolerable","C120574","Capable of being endured either physically or mentally.","Tolerable | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055051","Excruciating","C120575","Intensely painful.","Excruciating | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049864","Improvised Nuclear Device","C120576","A crude nuclear device built from the components of a stolen weapon or from scratch using nuclear material (plutonium or highly enriched uranium).","Improvised Nuclear Device | IND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049926","Radiological Exposure Device","C120579","A device constructed from partially or fully unshielded radioactive material intended to expose people to significant doses of ionizing radiation without their knowledge.","Radiological Exposure Device | Hidden Radioactive Source | RED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL494688","Radiological Dispersal Device","C120580","A device that disperses radioactive material by conventional explosive or other mechanical means, such as a spray.","Radiological Dispersal Device | Dirty Bomb | RDD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054332","Nuclear Power Plant Accident","C120582","A release of nuclides and radiation at a nuclear power plant that has led to significant consequences to people, the environment or the facility.","Nuclear Power Plant Accident | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054589","Lymphocyte Depletion Kinetics","C120584","A method for estimating the dose of an external radiation exposure following whole- or partial- body exposure. Serial CBCs are obtained and the absolute lymphocyte count is calculated and tracked over time. The dose absorbed is correlated with the rate of decline of peripheral blood lymphocytes and the lowest value for absolute lymphocyte depletion.","Lymphocyte Depletion Kinetics | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376250","Portuguese Language","C120586","An Indo-European language that originated in Portugal. It is the official language of Portugal, Brazil, Mozambique, Angola, Cape Verde, Guinea-Bissau, and São Tomé and Príncipe.","Portuguese Language | POR | Portuguese",,,,,,,,,,,,,,,"4181536","Portuguese language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037750","Spanish Language","C120587","An Indo-European Romance language that originated in Spain. It is the primary language of 20 countries worldwide.","Spanish Language | Castilian | Castilian Language | SPA | Spanish",,,,,,,,,,,,,,,"4182511","Spanish language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008120","Chinese Language","C120588","A family of languages that originated in China. The major dialect is Mandarin. It is the official language of China and Taiwan.","Chinese Language | Chinese | ZHO",,,,,,,,,,,,,,,"4182948","Chinese language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017477","German Language","C120589","An Indo-European, West Germanic language that originated in Germany. It is the official language of Germany, Austria, and Liechtenstein.","German Language | DEU | German",,,,,,,,,,,,,,,"4182504","German language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022774","Korean Language","C120590","An East Asian language that originated in the Korean peninsula. It is the official language of South Korea and North Korea.","Korean Language | KOR | Korean",,,,,,,,,,,,,,,"4175771","Korean language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042660","Vietnamese Language","C120591","An Austroasiatic language that is the native and official language of Viet Nam.","Vietnamese Language | VIE | Vietnamese",,,,,,,,,,,,,,,"4181526","Vietnamese language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054124","Radionuclide Decorporation Agent","C120558","Any agent that is able to prevent absorption or facilitate the removal of internal radionuclide contamination.","Radionuclide Decorporation Agent | Decorporation Agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0301464","Aluminum Carbonate","C120559","The aluminum salt form of carbonic acid, an antacid with phosphate binding activity. Upon oral administration of aluminum carbonate, aluminum is able to bind to phosphate in the intestines, including the radionuclide phosphate P-32, thereby preventing phosphate uptake.","Aluminum Carbonate | ALUMINUM CARBONATE | Carbonic Acid, Aluminum Salt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006711","Calcium Phosphate","C120560","The calcium salt of phosphoric acid with widely used applications. This agent can be used as a countermeasure for exposure to strontium and radium radionuclides. Upon oral uptake, calcium phosphate competes for and blocks the absorption of radium (Ra-226) and strontium (Sr-90) in the gastrointestinal (GI) tract.","Calcium Phosphate | CALCIUM PHOSPHATE, UNSPECIFIED FORM | Phosphoric Acid, Calcium Salt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0520458","Pentetate Calcium Trisodium","C74576","The trisodium salt form of calcium diethylene triamine pentaacetate (Ca-DTPA or pentetate calcium) with chelating activity. Upon administration, Ca-DTPA loses the Ca ion to form stable chelates with metal ions because DTPA has a higher affinity for heavy metal ions than for Ca ions. Specifically, this agent is able to bind to and form strong complexes with radioactive plutonium, americium, and cerium after internal contamination with any of these radionuclides thereby increasing their excretion.","Pentetate Calcium Trisodium | Calcium Trisodium DTPA | Ditripentat-Heyl | PENTETATE CALCIUM TRISODIUM | Pentacine | Trisodium Calcium Diethylenetriaminepentaacetate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1337329","Pentetate Zinc Trisodium","C77835","The trisodium salt form of zinc diethylene triamine pentaacetate (Zn-DTPA or pentetate zinc) with chelating activity. Upon administration, Zn-DTPA loses the Zn ion to form stable chelates with metal ions because DTPA has a higher affinity for heavy metal ions than for Zn ions. Specifically, this agent is able to bind to and form strong complexes with the radioactive plutonium, americium, and cerium after internal contamination. The formation of these heavy metal chelates enhances radionuclide excretion.","Pentetate Zinc Trisodium | PENTETATE ZINC TRISODIUM | Trisodium Zinc DTPA | Trisodium Zinc Diethylenetriaminepentaacetate | Zinc Trisodium DTPA | Zinc Trisodium Diethylenetriaminepentaacetate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0138037","Potassium Phosphate, Dibasic","C66452","The dipotassium form of phosphoric acid, that can be used as an electrolyte replenisher and with radio-protective activity. Upon oral administration, potassium phosphate is able to block the uptake of the radioactive isotope phosphorus P 32 (P-32).","Potassium Phosphate, Dibasic | DIBASIC POTASSIUM PHOSPHATE | Dibasic Potassium Phosphate | Dipotassium Phosphate | Phosphoric Acid, Dipotassium Salt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0142791","Sodium Alginate","C84148","The sodium salt form of alginic acid and gum mainly extracted from the cell walls of brown algae, with chelating activity. Upon oral administration, sodium alginate binds to and blocks the intestinal absorption of various radioactive isotopes, such as radium Ra 226 (Ra-226) and strontium Sr 90 (Sr-90).","Sodium Alginate | Alginic Acid, Sodium Salt | SODIUM ALGINATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0377349","Sodium Glycerophosphate","C120561","The sodium salt form of an organic phosphate compound that provides phosphate for nutritional purposes. In addition, sodium glycerophosphate can be used as a phosphate diluting agent upon internal contamination with the beta-emiting radioisotope phosphate P 32 (P-32) that competes with P-32 for absorption. As sodium glycerophosphate is administered in high amounts, the absorption of P-32 is prevented or minimalized.","Sodium Glycerophosphate | 1,2,3-Propanetriol, Mono(dihydrogen Phosphate), Disodium Salt, Hydrate | SODIUM GLYCEROPHOSPHATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012384","Succimer","C61953","An orally active mercaptodicarboxylic acid, with heavy metal chelating activity. As a strong chelator, succimer is able to bind to heavy metals, such as lead, in the bloodstream, thereby forming a water-soluble complex that can be eliminated via urinary excretion. This prevents heavy metal poisoning. In addition, succimer is able to chelate the alpha particle emitter and radionuclide polonium Po 210 ((Po-210), thereby increasing its excretion and reducing the toxic effects of Po-210.","Succimer | Butanedioic Acid, 2,3-Dimercapto-, (2R,3S)-rel- | Chemet | DMSA | Meso 2, 3-Dimercaptosuccinic Acid | SUCCIMER | meso-2,3-Dimercaptosuccinic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022173","Isozyme","C19567","The term 'isoenzyme' or 'isozyme' refers to variants of the same enzyme which can be separated on special conducting media using electrophoresis. It should apply only to those multiple forms of enzymes arising from genetically determined differences in primary structure and not to those derived by modification of the same primary sequence.","Isozyme | Isoenzyme",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0059696","Monoethanolamine","C61756","A first generation monoethanolamine with antihistaminic property. Ethanolamine competes with free histamine for binding at the histamine (H)-1 receptor thereby acting as an inverse agonist that combines with and stabilizes the inactive form of the H1-receptor thereby shifting the equilibrium toward the inactive state. This leads to a reduction of the negative symptoms brought on by H1-receptor binding.","Monoethanolamine | 1-Amino-2-hydroxyethane | 2-AMINOETHANOL | 2-Amino-1-ethanol | Colamine | Ethanolamine | MONOETHANOLAMINE | Olamine | Thiofaco M-50 | beta-Aminoethyl Alcohol | beta-Hydroxyethylamine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023401","Leucine","C29599","One of nine essential amino acids in humans (provided by food), Leucine is important for protein synthesis and many metabolic functions. Leucine contributes to regulation of blood-sugar levels; growth and repair of muscle and bone tissue; growth hormone production; and wound healing. Leucine also prevents breakdown of muscle proteins after trauma or severe stress and may be beneficial for individuals with phenylketonuria. Leucine is available in many foods and deficiency is rare. (NCI04)","Leucine | (S)-2-Amino-4-methylpentanoic acid | L-Leucine | LEUCINE | Leu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029277","Ornithine","C29611","A naturally occurring amino acid found in meat, fish, dairy and eggs. Ornithine is one of the key reactants in the urea cycle that is responsible for 80% of the nitrogen excretion in the body. Ornithine enhances liver function and helps detoxify harmful substances.","Ornithine | ORNITHINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031453","Phenylalanine","C29601","An essential aromatic amino acid in humans (provided by food), Phenylalanine plays a key role in the biosynthesis of other amino acids and is important in the structure and function of many proteins and enzymes. Phenylalanine is converted to tyrosine, used in the biosynthesis of dopamine and norepinephrine neurotransmitters. The L-form of Phenylalanine is incorporated into proteins, while the D-form acts as a painkiller. Absorption of ultraviolet radiation by Phenylalanine is used to quantify protein amounts. (NCI04)","Phenylalanine | 2-Amino-3-phenyl-pronanoic acid | L-Phenylalanine | PHENYLALANINE | Phe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039350","Taurine","C61962","Non-protein amino acid with sulfonic acid group.","Taurine | TAURINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040005","Threonine","C29602","An essential amino acid in humans (provided by food), Threonine is an important residue of many proteins, such as tooth enamel, collagen, and elastin. An important amino acid for the nervous system, threonine also plays an important role in porphyrin and fat metabolism and prevents fat buildup in the liver. Useful with intestinal disorders and indigestion, threonine has also been used to alleviate anxiety and mild depression. (NCI04)","Threonine | (2S,3R)-2-Amino-3-hydroxybutanoic acid | THREONINE | Thr",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041485","L-Tyrosine","C915","The levorotatory isomer of the aromatic amino acid tyrosine. L-tyrosine is a naturally occurring tyrosine and is synthesized in vivo from L-phenylalanine. It is considered a non-essential amino acid; however, in patients with phenylketonuria who lack phenylalanine hydroxylase and cannot convert phenylalanine into tyrosine, it is considered an essential nutrient. In vivo, tyrosine plays a role in protein synthesis and serves as a precursor for the synthesis of catecholamines, thyroxine, and melanin.","L-Tyrosine | (S)-2-Amino-3-(4-hydroxy-phenyl)propanoic acid | L-Phenylalanine, 4-hydroxy- | TYR | TYROSINE | TYROSINE, (L) | Tyr | Tyrosine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042285","Valine","C29604","An aliphatic and extremely hydrophobic essential amino acid in humans related to leucine, Valine is found in many proteins, mostly in the interior of globular proteins helping to determine three-dimensional structure. A glycogenic amino acid, valine maintains mental vigor, muscle coordination, and emotional calm. Valine is obtained from soy, cheese, fish, meats and vegetables. Valine supplements are used for muscle growth, tissue repair, and energy. (NCI04)","Valine | (S)-2-Amino-3-methylbutanoic acid | VALINE | Val",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0044470","1-Methylhistidine","C118886","A histidine derivative that has a methyl group bound to the nitrogen at position 1 and results from the metabolism of the dipeptide anserine. Urinary levels of 1-methylhistidine may be indicative of myofibrillar protein degradation or a high protein diet.","1-Methylhistidine | 1-METHYLHISTIDINE | 1-MeHis | 1MH | 2-Amino-3-(1-Methyl-1H-Imidazol-4-Yl)Propanoic Acid | Pi-Methylhistidine",,,,,,,,,,,,,,,"4270160","1-methyl histidine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0047600","3-Methylhistidine","C118885","A post-translationally modified amino acid found in actin and myosin and a derivative of histidine that has a methyl group bound to the nitrogen at position 3. Urinary levels of 3-methylhistidine are proportional to protein turnover and can be an indicator for myofibrillar protein degradation or a high protein diet.","3-Methylhistidine | 3 MEH | 3-METHYLHISTIDINE | 3-MeHis | 3-Methyl-L-Histidine | 3MH | N(tau)-Methylhistidine | Ntau-Methylhistidine",,,,,,,,,,,,,,,"4135212","3-methyl histidine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010682","Cystine","C29610","Not considered one of the 20 amino acids, Cystine is a sulfur-containing derivative obtained from oxidation of cysteine amino acid thiol side chains.  It functions as an antioxidant and protects tissues against radiation and pollution, slowing the aging process.  It also aids protein synthesis. Cystine is abundant in many proteins of skeletal tissues and skin, and found in insulin and digestive enzymes chromotrypsinogen A, papain, and trypsinogen. (NCI04)","Cystine | (2R,2'R)-3,3'-disulfanediylbis(2-aminopropanoic acid) | (R-(R*,R*))-3,3'-Dithiobis(2-Aminopropanoic Acid) | 1-Cystine | 3,3'-Dithiobis(2-Aminopropanoic Acid) | 3,3'-Dithiobis(2-Aminopropanoic Acid), (R-(R*,R*))- | 3,3'-Dithiodialanine | Alanine, 3,3'-Dithiobis- | Alanine, 3,3'-Dithiodi- | Beta,Beta'-Diamino-Beta,Beta'-Dicarboxydiethyl Disulfide | Beta,Beta'-Diamino-Beta,Beta'-Dicarboxydiethyldisulfide | Beta,Beta'-Dithioalanine, L- | Beta,Beta'-Dithiodialanine | Bis(Beta-Amino-Beta-Carboxyethyl)Disulfide | CYSTINE | Cysteine Disulfide | Cystine (L)- | Cystine Acid | Cystine, L- | Dicysteine | L-Alanine, 3,3'-Dithiobis- | L-Alpha-Diamino-Beta-Dithiolactic Acid | L-Cysteine Disulfide | L-Cystine | L-Dicysteine | Oxidized L-Cysteine | Propanoic Acid, 3,3'-Dithiobis(2-Amino-, (R-(R*,R*))-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0061472","Glutamic Acid","C1115","A non-essential alpha-amino acid and excitatory neurotransmitter. Glutamic acid can serve as a precursor for the synthesis of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA).","Glutamic Acid | (S)-2-Aminopentanedioic acid | GLUTAMIC ACID | Glu | Glutamate | L-Glutamate | L-Glutamic Acid | L-glutamic acid | glutamic acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019602","Histidine","C29597","A semi-essential amino acid (children should obtain it from food) needed in humans for growth and tissue repair, Histidine is important for maintenance of myelin sheaths that protect nerve cells and is metabolized to the neurotransmitter histamine. Histamines play many roles in immunity, gastric secretion, and sexual functions. Histidine is also required for blood cell manufacture and protects tissues against damage caused by radiation and heavy metals. (NCI04)","Histidine | (S)-2-Amino-3-(1H-imidazol-4-yl)propanoic acid | HISTIDINE | His | l-Histidine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022192","Isoleucine","C29598","One of nine essential amino acids in humans (present in dietary proteins), Isoleucine has diverse physiological functions, such as assisting wound healing, detoxification of nitrogenous wastes, stimulating immune function, and promoting secretion of several hormones. Necessary for hemoglobin formation and regulating blood sugar and energy levels, isoleucine is concentrated in muscle tissues in humans. Isoleucine is found especially in meats, fish, cheese, eggs, and most seeds and nuts. (NCI04)","Isoleucine | (2S,3S)-2-Amino-3-methylpentanoic acid | ISOLEUCINE | Ile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425766","SLC36A1 Gene","C118919","This gene is involved in the transport of neutral amino acids.","SLC36A1 Gene | SLC36A1 | Solute Carrier Family 36 (Proton/Amino Acid Symporter), Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333530","FADD Gene","C24384","This gene is involved in signal transduction and the activation of caspase-dependent apoptosis.","FADD Gene | FADD | Fas Associated via Death Domain Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039840","Thiamine","C874","A heat-labile and water-soluble essential vitamin, belonging to the vitamin B family, with antioxidant, erythropoietic, mood modulating, and glucose-regulating activities. Thiamine reacts with adenosine triphosphate (ATP) to form an active coenzyme, thiamine pyrophosphate. Thiamine pyrophosphate is necessary for the actions of pyruvate dehydrogenase and alpha-ketoglutarate in carbohydrate metabolism and for the actions of transketolase, an enzyme that plays an important role in the pentose phosphate pathway. Thiamine plays a key role in intracellular glucose metabolism and may inhibit the action of glucose and insulin on arterial smooth muscle cell proliferation. Thiamine may also protect against lead toxicity by inhibiting lead-induced lipid peroxidation.","Thiamine | 2-[3-[(4-amino-2-methyl-pyrimidin-5-yl)methyl]-4-methyl-1-thia-3-azoniacyclopenta-2,4-dien-5-yl]ethanol | Aneurin | B1 Vitamin | THIAMINE | Thiamin | Vit B1 | Vitamin B1 | Vitamin-B1 | thiamine | vitamin B1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335223","PLAGL1 Gene","C24680","This gene plays an inhibitory role in the regulation of cellular proliferation and is a tumor suppressor.","PLAGL1 Gene | PLAGL1 | Pleiomorphic Adenoma Gene-Like 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334896","NR0B2 Gene","C20707","This gene is involved in transcriptional regulation and can stimulate transcriptional repression.","NR0B2 Gene | NR0B2 | Nuclear Receptor Subfamily 0, Group B, Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413893","CYP7A1 Gene","C40052","This gene is involved in bile acid synthesis and steroid metabolism.","CYP7A1 Gene | CYP7A1 | Cytochrome P450, Family 7, Subfamily A, Polypeptide 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539291","DIRAS3 Gene","C20761","This gene plays a role in signal transduction and suppression of cell growth.","DIRAS3 Gene | DIRAS Family GTPase 3 Gene | DIRAS3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412374","AMACR Gene","C48210","This gene plays a role in the formation of cholic acid in peroxisomes.","AMACR Gene | AMACR | Alpha-methylacyl-CoA Racemase Gene | RACE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334880","NID1 Gene","C28643","This gene plays a role in the compositional regulation of basement membranes and has anti-angiogenic activity.","NID1 Gene | NID1 | Nidogen 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336623","TGFBI Gene","C24858","This gene may play a role in cellular adhesion; however, this function has not been substantiated.","TGFBI Gene | TGFBI | Transforming Growth Factor, Beta-Induced, 68kDa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL421682","Palliative Radiation Therapy","C116433","Any radiation treatment done with the intent to relieve symptoms and reduce the suffering caused by the cancer, and not with the intent of curing the cancer.","Palliative Radiation Therapy | Palliative Radiotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0346372","Malignant Iris Neoplasm","C4554","A malignant neoplasm that affects the iris. This category includes primary iris melanoma and metastatic malignant neoplasms in the iris.","Malignant Iris Neoplasm | Malignant Iris Tumor | Malignant Neoplasm of Iris | Malignant Neoplasm of the Iris | Malignant Tumor of Iris | Malignant Tumor of the Iris",,,,,,,,,,,,,,,"4095762","Malignant tumor of iris",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054939","Follow-Up Outcome Expectations Questionnaire","C120953","A set of questions and responses designed to evaluate an individual's self-reported expectations with the outcome of treatment.","Follow-Up Outcome Expectations Questionnaire | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055050","Expected Length of Time to Recover After Treatment","C121117","A question about an individual's expectation of the length of time for recovery after treatment.","Expected Length of Time to Recover After Treatment | Was the length of time it took you to recover after your treatment what you expected",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055142","Difficulty to Recover After Treatment","C121118","A question about how difficult it was for an individual to recover after treatment.","Difficulty to Recover After Treatment | How difficult was your recovery after your treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054961","Feelings About Ability to Deal with Treatment and Recovery","C121119","A question about an individual's feelings regarding their ability to deal with treatment and recovery.","Feelings About Ability to Deal with Treatment and Recovery | How did you feel about your ability to deal with your treatment and recovery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054116","Recovered Ability to do Daily Activities as Expected","C121120","A question about whether an individual has recovered their ability to do daily activities as expected.","Recovered Ability to do Daily Activities as Expected | Have you recovered your ability to do your daily activities as you expected",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053930","Took Less Time than Expected","C121121","A subjective response indicating that something took less time than expected.","Took Less Time than Expected | It took less time than I expected",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053928","Took the Expected Time","C121122","A subjective response indicating that something took the time that was expected.","Took the Expected Time | It took the time I expected",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053929","Took Longer Than Expected","C121123","A subjective response indicating that something took longer than expected.","Took Longer Than Expected | It took longer than I expected | Took More Time Than Expected",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055149","Did Not Know What to Expect","C121124","A subjective response indicating that an individual does or didn't know what to expect.","Did Not Know What to Expect | I didn't know what to expect | I don't know what to expect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055084","Easier than Expected","C121125","A subjective response indicating that something was easier than expected.","Easier than Expected | It was easier than I expected",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055439","As Expected","C121126","A subjective response indicating that something was as expected.","As Expected | About as Expected | It was about what I expected | Same as Expected | The same as I expected",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054471","More Difficult than Expected","C121127","A subjective response indicating that something was more difficult than expected.","More Difficult than Expected | Harder than Expected | It was more difficult than I expected",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055384","Better than Expected","C121128","A subjective response indicating something was better than expected.","Better than Expected | Better than I expected",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053837","Worse than Expected","C121129","A subjective response indicating something was worse than expected.","Worse than Expected | Worse than I expected",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054290","Outcome Satisfaction Questionnaire","C120952","A set of questions and responses designed to evaluate an individual's self-reported satisfaction with the outcome of treatment.","Outcome Satisfaction Questionnaire | Treatment Outcome Satisfaction Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055517","Ability to do Self-Care After Treatment","C120956","A question about an individual's ability to do self-care since treatment.","Ability to do Self-Care After Treatment Question | Ability to do Self-Care After Treatment | Ability to do Self-Care After Treatment | Doing self-care, such as washing and dressing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055551","Ability to Get Out and About After Treatment","C120957","A question about an individual's ability to get out and about since treatment.","Ability to Get Out and About After Treatment Question | Ability to Get Out and About After Treatment | Ability to Get Out and About After Treatment | Getting out and about",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055519","Ability to do Household Chores After Treatment","C120959","A question about an individual's ability to do household chores since treatment.","Ability to do Household Chores After Treatment Question | Ability to do Household Chores After Treatment | Ability to do Household Chores After Treatment | Doing household chores, such as cleaning and yard work",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050403","Ability to Sleep After Treatment question","C120960","A question about an individual's ability to sleep since treatment.","Ability to Sleep After Treatment Question | Ability to Sleep After Treatment | Ability to Sleep After Treatment | Sleeping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055518","Ability to do Recreation and Leisure Activities After Treatment","C120961","A question about an individual's ability to do recreation and leisure activities since treatment.","Ability to do Recreation and Leisure Activities After Treatment Question | Ability to do Recreation and Leisure Activities After Treatment | Ability to do Recreation and Leisure Activities After Treatment | Doing recreational and leisure activities, such as hobbies and sports",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055516","Ability to do Social Activities After Treatment","C120962","A question about an individual's ability to do social activities since treatment.","Ability to do Social Activities After Treatment Question | Ability to do Social Activities After Treatment | Ability to do Social Activities After Treatment | Doing social activities with family, friends, neighbors, and groups",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055520","Ability to do Current Work or School Activities After Treatment","C120964","A question about an individual's ability to do current work or school activities since treatment.","Ability to do Current Work or School Activities After Treatment Question | Ability to do Current Work or School Activities After Treatment | Ability to do Current Work or School Activities After Treatment | Doing current work or school activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055446","Appearance of Arm or Leg After Treatment","C120965","A question about the appearance of an individual's arm or leg since treatment.","Appearance of Arm or Leg After Treatment | How satisfied are you with the appearance of your arm/leg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053764","Sensations in Arm or Leg After Treatment","C120967","A question about the sensations in an individual's arm or leg since treatment.","Sensations in Arm or Leg After Treatment | How satisfied are you with how your arm/leg feels, that is any sensations, such as pain, numbness, tingling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054286","Overall Satisfaction with Results of Treatment","C120968","A question about an individual's overall satisfaction with results of treatment since treatment.","Overall Satisfaction with Results of Treatment | All things considered, how satisfied are you with the results of your treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055044","Extremely Satisfied","C120970","A subjective response indicating that an individual is extremely satisfied.","Extremely Satisfied | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053811","Somewhat Satisfied","C120971","A subjective response indicating that an individual is somewhat satisfied.","Somewhat Satisfied | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050008","Neither Satisfied nor Dissatisfied","C120972","A subjective response indication that an individual is neither satisfied nor dissatisfied.","Neither Satisfied nor Dissatisfied | Neutral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054006","Somewhat Dissatisfied","C120974","A subjective response indicating that an individual is somewhat dissatisfied.","Somewhat Dissatisfied | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055045","Extremely Dissatisfied","C120975","A subjective response indicating that an individual is extremely dissatisfied.","Extremely Dissatisfied | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1860064","Muscle Stiffness","C118433","A feeling of tension or tightness in one or more muscles.","Muscle Stiffness | Stiff Muscles",,,,,,,,,,,,,,,"4050941","Muscle rigidity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1418772","SLC43A1 Gene","C24687","This gene plays a role in transport and is frequently overexpressed in prostate cancers.","SLC43A1 Gene | SLC43A1 | Solute Carrier Family 43 (Amino Acid System L Transporter), Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424662","POSTN Gene","C101422","This gene plays a role in both heparin binding and cell adhesion.","POSTN Gene | POSTN | Periostin, Osteoblast Specific Factor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413930","DCN Gene","C112873","This gene plays a role in proteoglycan synthesis.","DCN Gene | DCN | Decorin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053547","16alpha-Hydroxyestrone","C120468","A metabolite formed during the catabolism of estrone by the liver through the hydroxylation of the carbon at position 16 by cytochrome P450 (CYP) family enzymes, including CYP3A4 and 3A5, with potential carcinogenic activity. With increased estrogenic activity compared to the parent compound, 16alpha-hydroxyestrone (16alpha-OHE1) increases the expression of ER-responsive genes, which leads to increased proliferation of susceptible tumor cells. The ratio between the two estrogen metabolites, 2-hydroxyestrone (2-OHE1), a weak estrogen and metabolite from the 2-hydroxylation pathway, and 16alpha-OHE1, a metabolite from the 16-hydroxylation pathway, may be used to assess the risk of certain cancers; a higher ratio of 2-OHE1:16alpha-OHE1 correlates with decreased cancer risk.","16alpha-Hydroxyestrone | 16 Alpha OHE | 16-alphaOHE1 | 16.ALPHA.-HYDROXYESTRONE | 16alpha-Hydroxy E1 | 16alpha-OH Estrone | 16alpha-OHE | 3,16alpha-Dihydroxyestra-1,3,5(10)-Trien-17-One | Estra-1,3,5(10)-Trien-17-One, 3,16-Dihydroxy-, (16alpha)- | Estra-1,3,5(10)-Triene-3,16alpha-Diol-17-One | Hydroxyestrone-16alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0046196","2-Hydroxyestradiol","C120474","A metabolite formed during the metabolism of 17beta-estradiol by hydroxylation of the carbon at position 2 by the CYP450 enzymes 1A1/1A2. Theoretically, 2-hydroxyestradiol (2-OHE2) is able to undergo redox cycling, which generates active radicals and induces DNA damage; however, this estradiol metabolite is very unstable in vivo and is quickly inactivated by catechol-O-methyltransferase (COMT)-mediated O-methylation and converted to 2-methoxyestradiol (2-MeE2). 2-MeE2 exerts antineoplastic activities through its estrogen receptor antagonistic effect and the induction of apoptosis in susceptible cancer cells.","2-Hydroxyestradiol | (17beta)-Estra-1,3,5(10)-Triene-2,3,17-Triol | 2-HYDROXYESTRADIOL | 2-Hydroxy-17beta-Estradiol | 2-Hydroxyestradiol-17beta | 2-OH-E2 | 2-OH-Estradiol | 2-OHE2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0046322","2-Methoxyestrone","C120472","A metabolite formed during the methylation of 2-hydroxyestrone (2-OHE1) by catechol-O-methyltransferase (COMT), with potential anticarcinogenic and minimal estrogen activities. The mechanism of action for the antitumor activity of 2-methoxyestrone (2-OMeE1) is not known. A high 2-methoxyestrone (2-OMeE1)/2-OHE1 ratio indicates higher methylation efficiency and correlates with a lower cancer risk.","2-Methoxyestrone | 2-METHOXYESTRONE | 2-MeE1 | 2-MeOE1 | 2-OMeE1 | 3-Hydroxy-2-Methoxyestra-1,3,5(10)-Trien-17-One",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0097109","4-Hydroxyestradiol","C120473","A metabolite formed during the metabolism of 17beta-estradiol by hydroxylation of the carbon at position 4 by cytochrome P450 1B1, with potential carcinogenic activity. The mechanism of action for the tumor promoting activity of 4-hydroxyestradiol (4-OHE2) is not entirely known but this metabolite undergoes metabolic redox cycling with its oxidized quinoid form, estradiol 3,4-quinone, and generates reactive oxygen species (ROS), which induce oxidative DNA damage. 4-OHE2 also activates nuclear factor-kappaB (NF-kB) and extracellular signal-regulated kinase/mitogen-activated protein kinase pathways, and induces the expression of certain genes through activation of the estrogen receptor (ER), which stimulates cellular proliferation in susceptible cells.","4-Hydroxyestradiol | 3,4,17beta-Estriol | 3,4,17beta-Trihydroxy-1,3,5[10]-Estratriene | 4-HYDROXYESTRADIOL | 4-Hydroxy-17-Beta-Estradiol | 4-Hydroxyestradiol-17beta | 4-OH-Estradiol | 4-OHE2 | 4OHE2 | Estra-1,3,5(10)-Triene-3,14,17beta-Triol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0048460","4-Methoxyestradiol","C120469","An endogenous metabolite formed during the O-methylation of the highly carcinogenic catechol estrogen 4-hydroxyestradiol (4-OHE2) by catechol-O-methyltransferase (COMT), with potential anti-proliferative activity. Even though the exact mechanism of action through which 4-methoxyestradiol (4-MeE2) exerts its effect is not fully elucidated, this chemical appears to have antiproliferative and apoptosis-inducing activities in susceptible tumor cells.","4-Methoxyestradiol | 4-MeE2 | 4-MeOE2 | 4-Methoxyestradiol-17 Beta | 4-Methoxyestradiol-17beta | Estra-1,3,5(10)-Triene-3,17-Diol, 4-Methoxy-, (17beta)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053546","4-Methoxyestrone","C120470","A metabolite formed during the methylation of 4-hydroxyestrone (4-OHE1) by catechol-O-methyltransferase (COMT) and devoid of any oncogenic or anticarcinogenic activities. The 4-methoxyestrone (4-MeOE1):4-OHE1 ratio can be used to assess methylation efficiency and cancer risk. Lower 4-MeOE1:4-OHE1 ratios suggest inadequate methylation and increased risk of certain cancers.","4-Methoxyestrone | 4-MeE1 | 4-MeOE1 | 4-OMeE1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420173","SLC2A3 Gene","C115020","This gene plays a role in facilitated transport of glucose.","SLC2A3 Gene | SLC2A3 | Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420200","SLC5A1 Gene","C77165","This gene is involved in carbohydrate transport.","SLC5A1 Gene | SLC5A1 | Solute Carrier Family 5 (Sodium/Glucose Cotransporter), Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054951","Fc-Gamma Receptor II","C18308","A family of low affinity receptors for aggregates of gamma immunoglobulins (IgG). These receptors are expressed on the surface of monocytes, macrophages, polymorphonuclear cells, natural killer cells, T- and B-lymphocytes, and platelets. IgG binding initiates cellular responses against foreign pathogens and soluble antigens, induces phagocytosis of antigen-antibody complexes, and modulates antibody production.","Fc-Gamma Receptor II | CD32 | CD32 Antigen | CDw32 | FCG2 | FCGR2 | FCRII | Fc Fragment of IgG, Low Affinity II, Receptor (CD32) | Fc Fragment of IgG, Low Affinity II, Receptor for | Fc Fragment of IgG, Low Affinity II, Receptor for (CD32) | Fc Gamma RII | Fc Gamma Receptor II | Fc-Gamma RII | Fc-Gamma-RII | FcGR | IGFR2 | IgG Fc Receptor II | Immunoglobulin G Fc Receptor II | Low Affinity IgG Fc Fragment Receptor II | Low Affinity Immunoglobulin Gamma Fc Region Receptor II",,,,,,,,,,,,,,,"4069459","Lymphocyte antigen CD32",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1521989","FCGR2C Gene","C38556","This gene is involved in the initiation of host immune responses against pathogens and phagocytosis.","FCGR2C Gene | FCGR2C | Fc Fragment of IgG, Low Affinity IIc, Receptor for (CD32) (Gene/Pseudogene) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004391","Autophagy","C71427","Autophagy is a biological process that involves the lysosomal degradation of intracellular components using it a cell's own machinery. This process can play a role in cellular defense, embryonic development, and cell growth.","Autophagy | Autophagocytosis | autophagy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229990","Feminine","C37951","Associated with women; befitting or characteristic of a woman.","Feminine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0948966","Female Malignant Nipple Neoplasm","C120455","A malignant neoplasm that affects the area of the nipple in females.","Female Malignant Nipple Neoplasm | Malignant Nipple Neoplasm | Malignant neoplasm of nipple and areola, unspecified female breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0948587","Male Malignant Nipple Neoplasm","C120454","A malignant neoplasm that affects the area of the nipple in males.","Male Malignant Nipple Neoplasm | Malignant neoplasm of nipple and areola, unspecified male breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0494158","Malignant Kidney Neoplasm Except Pelvis","C120456","A malignant neoplasm that affects the renal parenchyma but not the pelvis.","Malignant Kidney Neoplasm Except Pelvis | Malignant Neoplasm of Kidney Except Pelvis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054021","Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy","C121139","A modification of intensity modulated radiation therapy that allows for the simultaneous delivery of different dose levels to different target volumes within a single treatment fraction. This can result in better sparing of critical structures, more efficient delivery, shorter treatment duration, and better biologic effectiveness.","Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy | IMRT-SIB | Intensity Modulated Radiation Therapy Simultaneous Integrated Boost | SIB-IMRT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414350","EIF4B Gene","C121143","This gene plays a role in the binding of mRNA to ribosomes.","EIF4B Gene | EIF4B | Eukaryotic Translation Initiation Factor 4B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055491","Adenovirus Type 5 Antibody","C120480","An antibody produced in response to exposure to adenovirus serotype 5.","Adenovirus Type 5 Antibody | Ad5 Antibody | Adenovirus Serotype 5 Antibody | Anti-Ad5 Antibody | Anti-Adenovirus Serotype 5 Antibody | Anti-Adenovirus Type 5 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055468","Androgen Receptor-Dependent Gene Signature","C120485","A system that specifically determines the expression of genes that are dependent on the hormone-dependent transcriptional activation associated with androgen binding to the androgen receptor.","Androgen Receptor-Dependent Gene Signature | AR Gene Signature | AR-Dependent Gene Signature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053743","Anti-Yeast Antibody","C120496","An antibody produced in response to exposure to yeast.","Anti-Yeast Antibody | Yeast Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825498","ATG7 Gene","C120963","This gene plays a role in both autophagy and the transport of cytoplasmic molecules to vacuoles.","ATG7 Gene | ATG7 | Autophagy Related 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824302","VSIR Gene","C120577","This gene may be involved in the regulation of immunity.","VSIR Gene | C10orf54 | C10orf54 Gene | Chromosome 10 Open Reading Frame 54 Gene | V-Set Immunoregulatory Receptor Gene | VSIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424685","CD160 Gene","C120593","This gene plays a role in binding to class I major histocompatibility complexes.","CD160 Gene | CD160 | CD160 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413226","CD48 Gene","C120949","This gene plays a role in the activation and differentiation of lymphocytes, dendritic cells and endothelial cells.","CD48 Gene | CD48 | CD48 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055234","Circulating Clonotypic B-Cell","C120462","A B-lymphocyte that is hyperdiploid, has clonotypic IgH gene rearrangements, and is found in the peripheral blood of patients with monoclonal gammopathy of undetermined significance or multiple myeloma.","Circulating Clonotypic B-Cell | CCBC | Circulating Clonotypic B Cell | Circulating Clonotypic B Lymphocyte | Circulating Clonotypic B-Cell | Circulating Clonotypic B-Lymphocyte",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079679","Lentivirus","C14290","A genus of the family Retroviridae consisting of non-oncogenic retroviruses that produce multi-organ diseases characterized by long incubation periods and persistent infection. Lentiviruses are unique in that they contain open reading frames (ORFs) between the pol and env genes and in the 3' env region. Five serogroups are recognized, reflecting the mammalian hosts with which they are associated. HIV-1 is the type species.","Lentivirus | LENTIVIRUS | Lentivirinae | Virus-Lenti",,,,,,,,,,,,,,,"4231257","Genus Lentivirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1414543","FBN2 Gene","C120566","This gene is involved in the formation of extracellular calcium-binding microfibrils.","FBN2 Gene | FBN2 | Fibrillin 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414604","FGF22 Gene","C120954","This gene is involved in glucose and lipid metabolism.","FGF22 Gene | FGF22 | Fibroblast Growth Factor 22 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225332","Fibrocyte","C120463","A quiescent connective tissue cell with minimal cytoplasm and little to no evidence of protein synthesis. These cells may be able to differentiate into fibroblasts.","Fibrocyte | ",,,,,,,,,,,,,,,"4090432","Fibrocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1954252","Ganglioside GM2 Antibody","C120490","Any immunoglobulin that recognizes the glycosphingolipid antigen ganglioside GM2.","Ganglioside GM2 Antibody | Anti-GM2 Antibody | Anti-Ganglioside GM2 Antibody | GM2 Antibody",,,,,,,,,,,,,,,"35624256","Ganglioside GM2 Ab",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054894","Glycoprotein K8.1 Antibody","C120479","Any immunoglobulin that recognizes the human herpesvirus 8 glycoprotein K8.1.","Glycoprotein K8.1 Antibody | Anti-Glycoprotein K8.1 Antibody | Anti-KSHV ORF K 8.1 Antibody | Anti-k 8.1 Antibody | Anti-k 8.1 Antibody; K 8.1 Antibody | K 8.1 Antibody | KSHV ORF K 8.1 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415164","GNLY Gene","C120946","This gene is involved in the antimicrobial activity of cytotoxic T-lymphocytes and natural killer cells.","GNLY Gene | GNLY | Granulysin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1721080","Hedgehog Family","C120493","A family of extracellular proteins that act as signaling molecules and regulate embryonic patterning events during development. They are synthesized as inactive precursors with an N-terminal signaling domain linked to a C-terminal autoprocessing domain, which has a structure that resembles intein protein splicing domains.","Hedgehog Family | Hedgehog Family Protein | Hedgehog Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049599","Homologous Recombination Deficiency","C120465","A DNA repair abnormality caused by mutations in one or more genes that are involved in homologous recombination repair. Deficient homologous recombination is associated with numerous neoplastic diseases and developmental disorders related to chromosomal nondisjunction.","Homologous Recombination Deficiency | HRD | HRR Deficiency | Homologous Recombination Repair Deficiency",,,,,,,,,,,,,,,"37165708","Deficiency of homologous recombination deoxyribonucleic acid repair",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4049897","Insulin-Like Growth Factor 1 Receptor Beta Chain, Human","C120492","Insulin-like growth factor 1 receptor beta chain (627 aa, ~71 kDa) is encoded by the human IGF1R gene. This protein plays a role in growth factor-mediated receptor tyrosine kinase activity.","Insulin-Like Growth Factor 1 Receptor Beta Chain | CD221 Antigen Beta Chain | IGF-IR Beta | IGF-IR Beta Chain | IGF1R Beta | IGF1R Beta Chain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054700","Intratumoral Genetic Heterogeneity","C120464","A heterogeneous distribution of mutations within a single neoplasm.","Intratumoral Genetic Heterogeneity | Intratumoral Genetic Diversity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054690","Keyhole Limpet Hemocyanin Antibody","C120495","Any immunoglobulin that recognizes keyhole limpet hemocyanin protein.","Keyhole Limpet Hemocyanin Antibody | Anti-KLH Antibody | Anti-Keyhole Limpet Hemocyanin Antibody | KLH Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049852","L-Type Amino Acid Transporter","C120483","A family of heterodimeric protein complexes that mediate the transport of neutral amino acids, including L-leucine. These complexes are comprised of an invariant heavy chain 4F2 cell-surface antigen heavy chain, which is encoded by the SLC3A2 gene, and one of four light chains, large neutral amino acids transporter small subunit 1 (SLC7A5), Y+L amino acid transporter 2 (SLC7A6), Y+L amino acid transporter 1 (SLC7A7), or large neutral amino acids transporter small subunit 2 (SLC7A8).","L-Type Amino Acid Transporter | LAT | Leucine Type Transporter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054667","Large-Scale State Transition","C120466","Chromosomal breakage that generates 10 Mb or larger fragments. The quantification of these breaks can be used as a surrogate measure for genomic instability, which may be caused by mutation of DNA repair genes, including BRCA1 or BRCA2.","Large-Scale State Transition | LST | Large Scale State Transition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054662","Latent Nuclear Antigen Antibody","C120478","Any immunoglobulin that recognizes the human herpesvirus 8 latent nuclear antigen protein.","Latent Nuclear Antigen Antibody | Anti-HHV8 ORF73 | Anti-KSHV LANA Antibody | Anti-LANA Antibody | Anti-Latency-Associated Nuclear Antigen Antibody | Anti-Latent Nuclear Antigen Antibody | HHV8 ORF73 Antibody | KSHV LANA Antibody | LANA Antibody | Latency-Associated Nuclear Antigen Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427946","MAFA Gene","C120571","This gene plays a role in the regulation of insulin gene expression.","MAFA Gene | MAF bZIP Transcription Factor A Gene | MAFA | v-Maf Avian Musculoaponeurotic Fibrosarcoma Oncogene Homolog A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054411","Neoantigen Peptide","C120475","An immunogenic peptide sequence that is specifically expressed by a tumor and is not found in normal tissues. One or more of these tumor-associated antigens (TAAs) can be used to develop patient-specific tumor vaccines.","Neoantigen Peptide | Neo-Antigen Peptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL494656","Nitrite","C120467","A nitrogen oxoanion that is formed when nitrous acid is deprotonated. As nitrite is a metabolic end product for nitric oxide (NO), which is increased during inflammation; nitrite levels can be used to assess NO production and thus inflammation.","Nitrite | NITRITE ION | Nitrite Anion | Nitrite Ion | Nitrite(1-) | Nitrogen Dioxide Ion(1-) | Nitrogen Peroxide Ion(1-) | Nitrogen Protoxide | Nitrous Acid, Ion(1-)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054282","Oxylipin Metabolomic Profile","C120484","The identification and quantification of oxidized polyunsaturated fatty acids (oxylipins) in a biospecimen. In humans, the oxidized products are usually eicosanoids and the enzymes that produce specific eicosanoids are well characterized. Therefore, the oxylipin profile can indirectly identify the fatty acid oxidizing enzymes that are active in the sample.","Oxylipin Metabolomic Profile | Oxylipin Metabolome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054276","PAM50 Gene Expression Signature","C120494","A diagnostic and prognostic system for breast cancer that can both classify a tumor as one of four intrinsic subtypes (luminal A, luminal B, HER2-enriched, or basal-like) and generate a score that reflects the patient's risk of disease recurrence. This system is based on the expression profile of 50 genes in a surgically resected breast cancer sample.","PAM50 Gene Expression Signature | PAM50 | Prediction Analysis of Microarray 50 | Prosigna Breast Cancer Prognostic Gene Signature Assay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1159123","S-Nitrosylation","C120476","A biochemical reaction that covalently attaches nitric oxide to the sulfur atom in an organic thiol.","S-Nitrosylation | SNO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053720","Sialyl-Tn Antigen Antibody","C120488","Any immunoglobulin that recognizes the sialylated form of the Tn antigen.","Sialyl-Tn Antigen Antibody | Anti-Sialyl Tn Antibody | Anti-Sialyl-Tn Antigen Antibody | Anti-sTn Antibody | Sialyl Tn Antibody | Sialyl-Tn Antigen Antibody | sTn Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428127","TCERG1L Gene","C120563","This gene may play a role in insulin activity.","TCERG1L Gene | TCERG1L | Transcription Elongation Regulator 1-Like Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053938","Thomsen-Friedenreich Antigen Antibody","C120489","Any immunoglobulin that recognizes Thomsen-Friedenreich antigen, a disaccharide, comprised of galactose and N-acetylgalactosamine, that is bound through O-linked glycosylation serine or threonine residues in mucin proteins.","Thomsen-Friedenreich Antigen Antibody | Anti-TF Antigen Antibody | Anti-Thomsen-Friedenreich Antigen Antibody | TF Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053933","Tn Antigen Antibody","C120487","Any immunoglobulin that recognizes Tn antigen, which is comprised of N-acetylgalactosamine (GalNAc) bound to serine or threonine protein residues by O-linked glycosylation.","Tn Antigen Antibody | Anti-Tn Antibody | Anti-Tn Antigen Antibody | Tn Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053932","Tn Antigen-MUC1-32mer Antibody","C120486","Any immunoglobulin that recognizes a conjugate immunogen comprised of the carbohydrate antigen Tn and 32 amino acids of mucin-1 protein.","Tn Antigen-MUC1-32mer Antibody | Anti-Tn Antigen-MUC1-32mer Antibody | Anti-Tn-MUC1-32mer | Anti-Tn-MUC1-32mer Antibody | Tn-MUC1-32mer Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420798","TNFAIP2 Gene","C120973","This gene may be involved in the mediation of both inflammation and angiogenesis.","TNFAIP2 Gene | TNFAIP2 | Tumor Necrosis Factor, Alpha-Induced Protein 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1854276","TP53AIP1 Gene","C121114","This gene plays a role in the regulation of p53-induced apoptosis.","TP53AIP1 Gene | TP53AIP1 | Tumor Protein p53 Regulated Apoptosis Inducing Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050156","Tyrosine Nitration","C120477","A biochemical reaction that covalently attaches a nitro group to the carbon at position 3 of the side chain benzene ring of L-tyrosine.","Tyrosine Nitration | NT | Nitration of Tyrosine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412299","Allele-Specific Oligonucleotide Real-Time Quantitative Polymerase Chain Reaction","C116549","An application of real time PCR that is capable of detecting and quantifying a specific allelic version of a gene.","Allele-Specific Oligonucleotide Real-Time Quantitative Polymerase Chain Reaction | ASO-RQ-PCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050620","Distressed by Trouble Falling Asleep","C121160","A question about whether an individual is or has been distressed because they have trouble falling asleep.","Distressed by Trouble Falling Asleep | Trouble falling asleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055123","Distressed by Awakening in the Early Morning","C121161","A question about whether an individual is or has been distressed because they are awakening in the early morning.","Distressed by Awakening in the Early Morning | Awakening in the early morning",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055122","Distressed by Sleep that is Restless and Disturbed","C121162","A question about whether an individual is or has been distressed because they have sleep that is restless and disturbed.","Distressed by Sleep that is Restless and Disturbed | Sleep that is restless and disturbed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054713","Initial Outcome Satisfaction Questionnaire","C121163","A set of questions and responses designed to evaluate an individual's self-reported initial expectations for recovery after treatment.","Initial Outcome Satisfaction Questionnaire | Initial Outcome Expectations Questionnaire | Initial Outcome Expectations Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055120","Do Not Expect a Full Recovery","C121164","A subjective response indicating that an individual does not expect a complete recovery.","Do Not Expect a Full Recovery | I do not expect a full recovery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3843068","Somewhat Difficult","C121165","A subjective response indicating that an individual finds something to be somewhat difficult.","Somewhat Difficult | Somewhat difficult",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3843354","Extremely Difficult","C121166","A subjective response indicating that an individual finds something to be extremely difficult.","Extremely Difficult | Extremely difficult",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055103","EORTC/ROTG Late Radiation Morbidity Scoring Criteria","C121168","A set of questions and responses designed to establish criteria and scoring for adverse events occurring greater than 90 days after radiation therapy.","EORTC/ROTG Late Radiation Morbidity Scoring Criteria | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054681","LRMSC Grade 0, Skin","C121169","No symptoms.","LRMSC Grade 0, Skin | LRMSC Grade 0 Skin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054679","LRMSC Grade 1, Skin","C121170","Slight atrophy; pigmentation change; some hair loss.","LRMSC Grade 1, Skin | LRMSC Grade 1 Skin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053739","LRMSC Grade 2, Skin","C121171","Patch atrophy; moderate telangiectasia; total hair loss.","LRMSC Grade 2, Skin | LRMSC Grade 2 Skin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054676","LRMSC Grade 3, Skin","C121172","Marked atrophy; gross telangiectasia.","LRMSC Grade 3, Skin | LRMSC Grade 3 Skin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054674","LRMSC Grade 4, Skin","C121173","Ulceration.","LRMSC Grade 4, Skin | LRMSC Grade 4 Skin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054672","LRMSC Grade 5, Skin","C121174","Death directly related to radiation late effects.","LRMSC Grade 5, Skin | LRMSC Grade 5 Skin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054680","LRMSC Grade 0, Subcutaneous Tissue","C121175","No symptoms.","LRMSC Grade 0, Subcutaneous Tissue | LRMSC Grade 0 Subcutaneous Tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054678","LRMSC Grade 1, Subcutaneous Tissue","C121176","Slight induration (fibrosis) and loss of subcutaneous fat.","LRMSC Grade 1, Subcutaneous Tissue | LRMSC Grade 1 Subcutaneous Tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054677","LRMSC Grade 2, Subcutaneous Tissue","C121177","Moderate fibrosis but asymptomatic; slight field contracture; 10% linear reduction.","LRMSC Grade 2, Subcutaneous Tissue | LRMSC Grade 2 Subcutaneous Tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054675","LRMSC Grade 3, Subcutaneous Tissue","C121178","Severe induration and loss of subcutaneous tissue; field contracture > 10% linear measurement.","LRMSC Grade 3, Subcutaneous Tissue | LRMSC Grade 3 Subcutaneous Tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054673","LRMSC Grade 4, Subcutaneous Tissue","C121179","Necrosis.","LRMSC Grade 4, Subcutaneous Tissue | LRMSC Grade 4 Subcutaneous Tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054671","LRMSC Grade 5, Subcutaneous Tissue","C121180","Death directly related to radiation late effects.","LRMSC Grade 5, Subcutaneous Tissue | LRMSC Grade 5 Subcutaneous Tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027524","Nebulizer","C28172","A device for administration of medicinal substance(s) in form of a liquid mist to the patient airways. Nebulizer pumps air or oxygen through a liquid medicine to turn it into a vapor, which is then inhaled by the patient.","Nebulizer | nebulizer",,,,,,,,,,,,,,,"4219814","Nebulizer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0000930","Industrial Accident","C34343","An accident taking place on the site of a commercial enterprise.","Industrial Accident | ",,,,,,,,,,,,,,,"437748","Industrial accident",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4050585","Toronto Extremity Salvage Score, Lower Extremity","C121218","A self-administered questionnaire designed to assess physical disability for patients undergoing lower limb salvage sugery for musculoskeletal tumors.","Toronto Extremity Salvage Score, Lower Extremity | Lower Extremity Questionnaire | TESS | TESS Lower | TESS Lower Extremity | Toronto Extremity Salvage Score | Toronto Extremity Salvage Score (TESS) Lower Extremity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053772","Ability to Put on Shoes","C121220","A question about an individual's ability to tie shoe laces.","Ability to Put on Shoes Question | Ability to Put on Shoes | Ability to Put on Shoes | Putting on shoes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055557","Ability to Do Light Household Chores","C121221","A question about an individual's ability to do light household chores such as tidying and dusting.","Ability to Do Light Household Chores Question | Ability to Do Light Household Chores | Ability to Do Light Household Chores | Doing light household chores | Light household chores such as tidying and dusting | light housework/household jobs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055554","Ability to Garden or Do Yard Work","C121222","A question about an individuals' ability to do gardening and yard work.","Ability to Garden or Do Yard Work Question | Ability to Garden or Do Yard Work | Ability to Garden or Do Yard Work | Gardening and yard work | Gardening or yard work",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055558","Ability to Do Heavy Household Chores","C121223","A question about an individual's ability to do heavy household chores such as vacuuming and moving furniture.","Ability to Do Heavy Household Chores Question | Ability to Do Heavy Household Chores | Ability to Do Heavy Household Chores | Do heavy household chores | Heavy household chores such as vacuuming and moving furniture | Performing heavy household chores | heavy housework/household jobs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055552","Ability to Get In and Out of the Bath Tub","C121224","A question about an individual's ability to get in and out of the bath tub.","Ability to Get In and Out of the Bath Tub Question | Ability to Get In and Out of the Bath Tub | Ability to Get In and Out of the Bath Tub | Getting in and out of the bath tub",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055550","Ability to Get Out of Bed","C121225","A question about an individual's ability to get out of bed.","Ability to Get Out of Bed Question | Ability to Get Out of Bed | Ability to Get Out of Bed | Getting out of bed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055533","Ability to Rise from a Chair","C121226","A question about an individual's ability to rise from a chair.","Ability to Rise from a Chair Question | Ability to Rise from a Chair | Ability to Rise from a Chair | Ability to Stand Up From Chair | Rising from a chair | Stand up from a straight chair",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050149","Ability to Kneel question","C121227","A question about an individual's ability to kneel.","Ability to Kneel Question | Ability to Kneel | Ability to Kneel | Kneeling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055565","Ability to Bend to Pick Something Up Off the Floor","C121228","A question about an individual's ability to pick something up off the floor.","Ability to Bend to Pick Something Up Off the Floor Question | Ability to Bend to Pick Something Up Off the Floor | Ability to Bend to Pick Something Up Off the Floor | Bending to pick something up off the floor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055524","Ability to Walk Up Stairs","C121229","A question about an individual's ability to walk up stairs.","Ability to Walk Up Stairs Question | Ability to Climb Stairs | Ability to Walk Up Stairs | Ability to Walk Up Stairs | Walking upstairs | climb stairs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055527","Ability to Walk Downstairs","C121230","A question about an individual's ability to walk downstairs.","Ability to Walk Downstairs Question | Ability to Walk Downstairs | Ability to Walk Downstairs | Walking downstairs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050139","Ability to Drive","C121232","A question about an individual's ability to drive.","Ability to Drive Question | Ability to Drive | Ability to Drive | Driving",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055523","Ability to Walk Within the House","C121233","A question about an individual's ability to walk within the house.","Ability to Walk Within the House Question | Ability to Walk Within the House | Ability to Walk Within the House | Walking within the house | walk about the house",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055526","Ability to Walk Outdoors","C121234","A question about an individual's ability to walk outdoors.","Ability to Walk Outdoors Question | Ability to Walk Outdoors | Ability to Walk Outdoors | Walk outdoors on flat ground | Walking outdoors | walk out of doors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0560879","Ability to Sit","C121235","A question about an individual's ability to sit.","Ability to Sit Question | Ability to Sit | Ability to Sit | Sitting",,,,,,,,,,,,,,,"4106662","Ability to sit",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055525","Ability to Walk Up or Down Hills or a Ramp","C121236","A question about an individual's ability to walk up or down hills or a ramp.","Ability to Walk Up or Down Hills or a Ramp Question | Ability to Walk Up or Down Hills or a Ramp | Ability to Walk Up or Down Hills or a Ramp | Walking up or down hills or a ramp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055530","Ability to Stand Upright","C121237","A question about an individual's ability to stand upright.","Ability to Stand Upright Question | Ability to Stand Upright | Ability to Stand Upright | Standing upright",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055549","Ability to Get Up from Kneeling","C121238","A question about an individual's ability to get up from kneeling.","Ability to Get Up from Kneeling Question | Ability to Get Up from Kneeling | Ability to Get Up from Kneeling | Getting up from kneeling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055553","Ability to Get In and Out of a Car","C121239","A question about an individual's ability to get in and out of a car.","Ability to Get In and Out of a Car Question | Ability to Get In and Out of a Car | Ability to Get In and Out of a Car | Getting in and out of a car",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055542","Ability to Participate in Sexual Activities","C121240","A question about an individual's ability to participate in sexual activities.","Ability to Participate in Sexual Activities Question | Ability to Participate in Sexual Activities | Ability to Participate in Sexual Activities | Participating in sexual activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055534","Ability to Put on a Pair of Pants","C121241","A question about an individual's ability to put on a pair of pants.","Ability to Put on a Pair of Pants Question | Ability to Put on a Pair of Pants | Ability to Put on a Pair of Pants | Putting on a pair of pants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0581197","Ability to Tie Shoe Laces (question)","C121242","A question about an individual's ability to tie shoe laces.","Ability to Tie Shoe Laces Question | Ability to Tie Shoe Laces | Ability to Tie Shoe Laces | Tying shoe laces",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055535","Ability to Put on Socks or Stockings","C121243","A question about an individual's ability to put on socks or stockings.","Ability to Put on Socks or Stockings Question | Ability to Put on Socks or Stockings | Ability to Put on Socks or Stockings | Putting on socks or stockings",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050468","Ability to Shower","C121244","A question about an individual's ability to shower.","Ability to Shower Question | Ability to Shower | Ability to Shower | Showering",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055556","Ability to Dress My Arms and Upper Body","C121245","A question about an individual's ability to dress their arms and upper body.","Ability to Dress My Arms and Upper Body Question | Ability to Dress My Arms and Upper Body | Ability to Dress My Arms and Upper Body | Dressing my arms and upper body",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055562","Ability to Button a Shirt","C121246","A question about an individual's ability to button a shirt.","Ability to Button a Shirt Question | Ability to Button a Shirt | Ability to Button a Shirt | Buttoning a shirt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055529","Ability to Tie a Tie or Bow at the Neck of a Blouse","C121247","A question about an individual's ability to tie a tie or bow at the neck of a blouse.","Ability to Tie a Tie or Bow at the Neck of a Blouse Question | Ability to Tie a Tie or Bow at the Neck of a Blouse | Ability to Tie a Tie or Bow at the Neck of a Blouse | Tying a tie or bow at the neck of a blouse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055536","Ability to Put on Make-Up or Shave","C121248","A question about an individual's ability to put on make-up or shave.","Ability to Put on Make-Up or Shave Question | Ability to Put on Make-Up or Shave | Ability to Put on Make-Up or Shave | Putting on make-up or shaving",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055563","Ability to Brush Your Teeth","C121249","A question about an individual's ability to brush their teeth.","Ability to Brush Your Teeth Question | Ability to Brush Your Teeth | Ability to Brush Your Teeth | Brushing your teeth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055564","Ability to Brush Your Hair","C121250","A question about an individual's ability to brush their hair.","Ability to Brush Your Hair Question | Ability to Brush Your Hair | Ability to Brush Your Hair | Brushing your hair",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055538","Ability to Prepare and Serve Meals","C121251","A question about an individual's ability to prepare and serve meals.","Ability to Prepare and Serve Meals Question | Ability to Prepare and Serve Meals | Ability to Prepare and Serve Meals | Preparing and serving meals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055559","Ability to Cut Food While Eating","C121252","A question about an individual's ability to cut food while eating.","Ability to Cut Food While Eating Question | Ability to Cut Food While Eating | Ability to Cut Food While Eating | Cutting food while eating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055555","Ability to Drink From a Glass","C121253","A question about an individual's ability to drink from a glass.","Ability to Drink From a Glass Question | Ability to Drink From a Glass | Ability to Drink From a Glass | Drinking from a glass",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055547","Ability to Go Shopping","C121254","A question about an individual's ability to go shopping.","Ability to Go Shopping Question | Ability to Go Shopping | Ability to Go Shopping | Going shopping | Shopping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055548","Ability to Give or Receive Change","C121255","A question about an individual's ability to give or receive change such as coins or bills.","Ability to Give or Receive Change Question | Ability to Give or Receive Change | Ability to Give or Receive Change | Giving or receiving change (i.e., coins or bills)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055561","Ability to Carry a Shopping Bag or Briefcase","C121256","A question about an individual's ability to carry a shopping bag or briefcase.","Ability to Carry a Shopping Bag or Briefcase Question | Ability to Carry a Shopping Bag or Briefcase | Ability to Carry a Shopping Bag or Briefcase | Carry a shopping bag or briefcase | Carrying a shopping bag or briefcase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055546","Ability to Lift a Box to an Overhead Shelf","C121257","A question about an individual's ability to lift a box to an overhead shelf.","Ability to Lift a Box to an Overhead Shelf Question | Ability to Lift a Box to an Overhead Shelf | Ability to Lift a Box to an Overhead Shelf | Lifting a box to an overhead shelf",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055528","Ability to Turn a Key in a Lock","C121258","A question about an individual's ability to turn a key in a lock.","Ability to Turn a Key in a Lock Question | Ability to Turn a Key in a Lock | Ability to Turn a Key in a Lock | Turning a key in a lock",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055537","Ability to Push or Pull Open a Door","C121259","A question about an individual's ability to push or pull open a door.","Ability to Push or Pull Open a Door Question | Ability to Push or Pull Open a Door | Ability to Push or Pull Open a Door | Pushing or pulling open a door",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050126","Ability to Write question","C121260","A question about an individual's ability to write.","Ability to Write Question | Ability to Write | Ability to Write | Writing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055539","Ability to Pick Up Small Items","C121261","A question about an individual's ability to pick up small items.","Ability to Pick Up Small Items Question | Ability to Pick Up Small Items | Ability to Pick Up Small Items | Picking up small items",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055560","Ability to Complete My Usual Duties at Work","C121262","A question about an individual's ability to complete my usual duties at work including a job outside the home or as a homemaker.","Ability to Complete My Usual Duties at Work Question | Ability to Complete My Usual Duties at Work | Ability to Complete My Usual Duties at Work | Completing my usual duties at work (a job outside the home or as a homemaker)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055521","Ability to Work My Usual Number of Hours","C121263","A question about an individual's ability to work their usual number of hours including a job outside the home and as a homemaker.","Ability to Work My Usual Number of Hours Question | Ability to Work My Usual Number of Hours | Ability to Work My Usual Number of Hours | Working my usual number of hours (a job outside the home or as a homemaker)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055544","Ability to Participate in My Usual Leisure Activities","C121264","A question about an individual's ability to participate in their usual leisure activities.","Ability to Participate in My Usual Leisure Activities Question | Ability to Participate in My Usual Leisure Activities | Ability to Participate in My Usual Leisure Activities | Participating in my usual leisure activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055531","Ability to Socialize with Friends and Family","C121265","A question about an individual's ability to socialize with friends and family.","Ability to Socialize with Friends and Family Question | Ability to Socialize with Friends and Family | Ability to Socialize with Friends and Family | Socializing with friends and family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055543","Ability to Participate in My Usual Sporting Activities","C121266","A question about an individual's ability to participate in their usual sporting activities.","Ability to Participate in My Usual Sporting Activities Question | Ability to Participate in My Usual Sporting Activities | Ability to Participate in My Usual Sporting Activities | Participating in my usual sporting activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055540","Ability to Perform all the Activities in Which I Participate in Daily Life","C121267","A question about an individual's ability to perform all the activities in which they participate in daily life.","Ability to Perform all the Activities in Which I Participate in Daily Life Question | Ability to Perform all the Activities in Which I Participate in Daily Life | Ability to Perform all the Activities in Which I Participate in Daily Life | Ability to perform all the activities in which I participate in daily life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054119","Rating Myself","C121268","A question about an individual's total assessment of their abilities.","Rating Myself | I would rate myself as being | Self Rating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493771","Adaptive Behavior Assessment System, Adult Rating Form","C121187","A comprehensive norm-referenced assessment of the adaptive skills of individuals ages 16 to 89 years that is used to evaluate adults with intellectual and developmental disabilities. This form is completed by family members, professional caregivers, supervisors, or the individual.","Adaptive Behavior Assessment System, Adult Rating Form | ABAS-II | Adaptive Behavior Assessment System - Adult Rating Form | Adaptive Behavior Assessment System - Second Edition (ABAS-II) Adult Rating Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493772","Adaptive Behavior Assessment System, Parent Rating Form","C121188","A comprehensive norm-referenced assessment of the adaptive skills of individuals ages 5 to 21 years that is used to evaluate children with intellectual and developmental disabilities. This form is completed by parents or others responsible for the child's primary care.","Adaptive Behavior Assessment System, Parent Rating Form | ABAS-II | Adaptive Behavior Assessment System - Parent Rating Form | Adaptive Behavior Assessment System - Second Edition (ABAS-II) Parent Rating Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493773","Communication Skills","C121189","An assessment of the Adaptive Behavior Assessment System, Second Edition where communication skills such as speech, language, listening, and conversation are evaluated.","Communication Skills | ABAS-II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493774","Community Use Skills","C121190","An assessment of the Adaptive Behavior Assessment System where community use skills, such as shopping, getting around the community, and using community resources, are evaluated.","Community Use Skills | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493775","Functional Pre-Academics Skills","C121191","An assessment of the Adaptive Behavior Assessment System, Second Edition where functional pre-academic skills such as the future use of basic reading, writing, and math are evaluated.","Functional Pre-Academics Skills | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493776","Functional Academics Skills","C121192","An assessment of the Adaptive Behavior Assessment System, Second Edition where functional academic skills such as basic reading, writing, and math are evaluated.","Functional Academics Skills | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493777","Home Living Skills","C121193","An assessment of the Adaptive Behavior Assessment System where home living skills such as cleaning, property maintenance, food preparation, and chores are evaluated.","Home Living Skills | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493778","Health and Safety Skills","C121194","An assessment of the Adaptive Behavior Assessment System where health and safety skills such as response to illness or injury, using medicines, and showing caution are evaluated.","Health and Safety Skills | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493779","Leisure Skills","C121195","An assessment of the Adaptive Behavior Assessment System, where leisure skills such as planning recreational activities, playing with others, and following rules of games are evaluated.","Leisure Skills | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL494705","Self-Care Skills","C121196","An assessment of the Adaptive Behavior Assessment System where self-care skills such as eating, dressing, bathing, toileting, grooming, and hygiene are evaluated.","Self-Care Skills | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493781","Self-Direction Skills","C121199","An assessment of the Adaptive Behavior Assessment System, where self-directed skills needed for independence, responsibility, self-control, starting and completing tasks, following directions, and making choices are evaluated.","Self-Direction Skills | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL494658","Social Skills","C121201","An assessment of the Adaptive Behavior Assessment System where social skills needed to interact socially, get along with others, have friends, show and recognize emotions, and using manners are evaluated.","Social Skills | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL494706","Motor Skills","C121202","An assessment of the Adaptive Behavior Assessment System, where fine and gross motor skills needed for locomotion, manipulation of the environment and development of more complex activities are evaluated.","Motor Skills Assessment | Motor Skills | Motor Skills",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493783","Work Skills","C121203","An assessment of the Adaptive Behavior Assessment System where skills needed for successful functioning and holding a job in a work setting are evaluated.","Work Skills | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054902","General Adaptive Composite Score","C121204","An overall score of the Adaptive Behavior Assessment System that consists of the three domains of conceptual, social, and practical.","General Adaptive Composite Score | GAC | General Adaptive Composite | General Adaptive Composite (GAC) Composite Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493785","Conceptual Domain","C121205","A domain of the General Adaptive Composite Score that is made up of scores from communication, functional academics, and self-direction skills assessments.","Conceptual Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493786","Social Domain","C121206","A domain of the General Adaptive Composite Score that is made up of scores from social and leisure skills assessments.","Social Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493787","Practical Domain","C121208","A domain of the General Adaptive Composite Score that is made up of scores from self-care, home/school living, community use, and health and safety skills assessments.","Practical Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055389","Behavior Assessment System for Children, Second Edition","C121269","A comprehensive set of rating scales designed to facilitate the differential diagnosis and classification of a variety of emotional and behavioral disorders of children, aid in the design of treatment plans, and provide insight into an individual's thoughts and feelings.","Behavior Assessment System for Children, Second Edition | BASC-2 | Behavior Assessment System for Children",,,,,,,,,,,,,,,"3655797","Behavior Assessment System for Children, Second Edition",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4050206","Self-Report of Personality","C121270","A clinical assessment tool that uses targeted forms for monitoring changes in behavior or emotional status. It provides insight into a child's or adult's thoughts and feelings.","Self-Report of Personality | BASC-2 SRP | Behavior Assessment System for Children, Second Edition, Self-Report of Personality (BASC-2 SRP) | SRP | Self-Report of Personality (BASC-2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493843","Atypicality Scale","C121273","A rating scale included in the Behavior Assessment System for Children that measures mood swings, bizarre thought, subjective experiences associated with obsessive compulsive disorder, and odd behaviors in the subject.","Atypicality Scale | Atypicality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL494708","Locus of Control Scale","C121274","A rating scale included in the Behavior Assessment System for Children that measures the subject's belief that rewards and punishment are controlled by external stimulus.","Locus of Control Scale | Locus of Control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL494707","Social Stress Scale","C121275","A rating scale included in the Behavior Assessment System for Children that measures the subject's feelings of stress and tension, and feeling excluded in personal relationships.","Social Stress Scale | Social Stress",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493844","Anxiety Scale","C121276","A rating scale included in the Behavior Assessment System for Children that measures the tendency of the subject to be nervous, fearful, or worried about real or imagined problems.","Anxiety Scale | Anxiety",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0679604","Depression Scale","C121277","A rating scale included in the Behavior Assessment System for Children that measures the tendency of the subject to have feelings of unhappiness, sadness, and stress that may result in an inability to carry out everyday activities.","Depression Scale | Depression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493845","Sense of Inadequacy Scale","C121278","A rating scale included in the Behavior Assessment System for Children that measures the subject's perception of being unsuccessful and inadequate in school.","Sense of Inadequacy Scale | Sense of Inadequacy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493846","Somatization Scale (BASC-2)","C121279","A rating scale included in the Behavior Assessment System for Children that measures the tendency of the subject to be overly sensitive or to complain about relatively minor physical problems or discomfort.","Somatization Scale | Somatization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493847","Internalizing Problems Composite Score","C121280","A composite score of the Behavior Assessment System for Children that combines the anxiety, depression, and somatization scales. This composite measures a broad index of distress that reflects the clinical, internalizing problems a child may be experiencing.","Internalizing Problems Composite Score | Internalizing Problems Composite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493848","Attention Problems Scale","C121281","A rating scale included in the Behavior Assessment System for Children that measures the tendency of the subject to be distracted and unable to concentrate.","Attention Problems Scale | Attention Problems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493849","Hyperactivity Scale","C121282","A rating scale included in the Behavior Assessment System for Children that measures the tendency to be overly active, rush through work or activities, and act without thinking.","Hyperactivity Scale | Hyperactivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493850","Emotional Symptoms Index","C121283","An index of the Behavior Assessment System for Children that measures the subject's overall emotional development.","Emotional Symptoms Index | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493851","Sensation Seeking Scale","C121284","A rating scale included in the Behavior Assessment System for Children that measures the tendency of the subject to take risks and seek excitement.","Sensation Seeking Scale | Sensation Seeking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054036","Self-Report of Personality, College Version","C121271","The Self-Report of Personality, College Version provides insight into the thoughts and feelings of college-aged individuals (ages 18 to 25).","Self-Report of Personality, College Version | BASC-2 SRP-COL | Behavior Assessment System for Children, Second Edition, Self-Report of Personality, College Version (BASC-2 SRP-COL) | SRP-COL | Self-Report of Personality, College Version (BASC-2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493852","Alcohol Abuse Scale","C121285","A rating scale included in the Behavior Assessment System for Children, College Version, that identifies subjects who engage in drinking behaviors that have the potential to lead to alcohol abuse and those who experience academic, social, or functional problems due to their alcohol consumption.","Alcohol Abuse Scale | Alcohol Abuse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL494709","School Maladjustment Scale","C121286","A rating scale included in the Behavior Assessment System for Children, College Version that provides an indication of how the subject is responding to the academic demands of college.","School Maladjustment Scale | School Maladjustment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493853","Relations with Parents Scale","C121287","A rating scale included in the Behavior Assessment System for Children that measures a subject's positive regard towards parents and a feeling of being esteemed by them.","Relations with Parents Scale | Relations with Parents",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493854","Interpersonal Relations Scale","C121288","A rating scale included in the Behavior Assessment System for Children that measures a subject's perception of having good social relationships and friendships with peers.","Interpersonal Relations Scale | Interpersonal Relations",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493855","Self-Esteem Scale (BASC-2)","C121289","A rating scale included in the Behavior Assessment System for Children that measures a subject's feelings about self, respect, and self-acceptance.","Self-Esteem Scale | Self-Esteem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL494712","Self-Reliance Scale","C121290","A rating scale included in the Behavior Assessment System for Children that measures a subject's confidence in their ability to solve problems and their dependability and decisiveness.","Self-Reliance Scale | Self-Reliance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493856","Personal Adjustment Composite Score","C121291","A composite score of the Behavior Assessment System for Children that combines the interpersonal relationships, ego strength and identity development scales.","Personal Adjustment Composite Score | Personal Adjustment Composite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054247","Parent Rating Scales","C121272","The Parent Rating Scales is used to measure both adaptive behavior and problem behavior in the community and home setting in individuals aged 2-21.","Parent Rating Scales | BASC-2 PRS | Behavior Assessment System for Children, Parent Rating Scales | Behavior Assessment System for Children, Second Edition, Parent Rating Scales (BASC-2 PRS) | Parent Rating Scales (BASC-2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493857","Aggression Scale","C121292","A rating scale included in the Behavior Assessment System for Children that measures the tendency of the subject to act in a hostile manner, either verbally or physically, that is threatening to others.","Aggression Scale | Aggression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493858","Conduct Problems Scale","C121293","A rating scale included in the Behavior Assessment System for Children that measures the tendency of the subject to engage in antisocial and rule breaking behavior.","Conduct Problems Scale | Conduct Problems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL494687","Withdrawal Scale (BASC-2)","C121294","A rating scale included in the Behavior Assessment System for Children that measures the tendency of the subject to evade others to avoid social contact.","Withdrawal Scale | Withdrawal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL494710","Adaptability Scale","C121295","A rating scale included in the Behavior Assessment System for Children that measures the ability of the subject to adapt readily to changes in the environment.","Adaptability Scale | Adaptability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL494659","Social Skills Scale","C121296","A rating scale included in the Behavior Assessment System for Children that measures the skills necessary for the subject to interact successfully with peers and adults in home, school, and community settings.","Social Skills Scale | Social Skills",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL494711","Leadership Scale","C121297","A rating scale included in the Behavior Assessment System for Children that measures the skills associated with the subject being able to accomplish academic, social, or community goals, including the ability to work well with others.","Leadership Scale | Leadership",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493859","Activities of Daily Living Scale","C121298","A rating scale included in the Behavior Assessment System for Children that measures the subject's ability to follow through or complete simple daily tasks.","Activities of Daily Living Scale | Activities of Daily Living",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493860","Functional Communication Scale","C121299","A rating scale included in the Behavior Assessment System for Children that measures the subject's ability to express ideas and communicate in a way others can easily understand.","Functional Communication Scale | Functional Communication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493861","Externalizing Problems Composite Score","C121300","A composite score of the Behavior Assessment System for Children that combines the hyperactivity, aggression, and conduct problems scales. This composite score measures disruptive behavior problems.","Externalizing Problems Composite Score | Externalizing Problems Composite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493862","Behavioral Symptoms Index Composite Score","C121301","An index of the Behavior Assessment System for Children that combines the hyperactivity, aggression, depression, atypicality, withdrawal, and attention problem scales. This composite score measures the overall level of behavioral problems.","Behavioral Symptoms Index Composite Score | BSI | Behavioral Symptoms Index | Behavioral Symptoms Index Composite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493863","Adaptive Skills Composite Score","C121302","A composite score of the Behavior Assessment System for Children that combines the adaptability, social skills, leadership, study skills, and functional communication scales. This composite score summarizes prosocial, organizational, study, and other adaptive skills.","Adaptive Skills Composite Score | Adaptive Skills Composite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054521","Military Nuclear Weapon","C121304","A military device designed to release energy in an explosive manner as a result of nuclear fission, nuclear fusion, or a combination of the two processes.","Military Nuclear Weapon | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0522487","Long Axis","C94857","Line through and in the direction of an object's characteristic feature that is longer than any other feature.","Long Axis | ",,,,,,,,,,,,,,,"4011459","Long axis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL426528","Short Axis","C94982","Line through and perpendicular to an object's long axis. This line may intersect the long axis anywhere within the object.","Short Axis | ",,,,,,,,,,,,,,,"4013719","Short axis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053988","Stern's Rating Scale for Edema","C121309","A subjective, physician-rated measure of edema with scores ranging from 0 to 4.","Stern's Rating Scale for Edema | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053781","Edema Rating 0","C121310","No edema.","Edema Rating 0 | Stern's Edema Rating 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055080","Edema Rating 2","C121312","Moderate edema.","Edema Rating 2 | Stern's Edema Rating 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055079","Edema Rating 3","C121313","Severe edema (considerable swelling).","Edema Rating 3 | Stern's Edema Rating 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055078","Edema Rating 4","C121314","Very severe edema (skin shiny and tight with or without skin cracking).","Edema Rating 4 | Stern's Edema Rating 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054940","Follow-Up Embodiment/Outcomes Questionnaire","C121315","A set of questions and responses designed to evaluate an individual's self-reported feeling about their limbs.","Follow-Up Embodiment/Outcomes Questionnaire | Follow-Up Embodiment/Outcomes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054960","Feelings About Arm or Leg","C121316","A question about an individual's feelings about their arm or leg most of the time.","Feelings About Arm or Leg | Feelings About Arm or Leg Most of the Time | How I feel about my arm or leg most of the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050003","Arm or Leg Response Group 1","C121317","A response indicating: I don't even know my arm/leg is there; my arm/leg is back to normal as far as I am concerned; I rarely or never think about my arm/leg.","Arm or Leg Response Group 1 | Group 1 | Response Group 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050004","Arm or Leg Response Group 2","C121318","A response indicating: I'm very aware of my arm/leg; my arm/leg feels like an alien part; my arm/leg has a mind of its own; I hide or cover my arm/leg; it seems that my arm/leg is not part of me.","Arm or Leg Response Group 2 | Group 2 | Response Group 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050005","Arm or Leg Response Group 3","C121319","A response indicating: I've got to accept my arm/leg the way it is; I'm learning how to use my arm/leg more and just trying to not really concentrate on it, but try to adapt my arm/leg to different ways of life; I'm going to have to learn to live with arm/leg the way it is now.","Arm or Leg Response Group 3 | Group 3 | Response Group 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972934","Arm or Leg Response Group 4","C121320","A response indicating: I never realized I could do so many things with my arm/leg; I'm used to my arm/leg now, it's part of me; it's amazing what you can learn to do.","Arm or Leg Response Group 4 | Group 4 | Response Group 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227608","Hilar Area of the Kidney","C32740","The concave area of the kidney through which the renal artery enters and the renal vein and ureter exit the organ.","Hilar Area of the Kidney | Hilar Area of Kidney | Hilum of Kidney | Hilum of the Kidney | KIDNEY, HILUM | Renal Hilum | Structure of hilum of kidney (body structure)",,,,,,,,,,,,,,,"4250904","Structure of hilum of kidney",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055077","Edmonton Symptom Assessment System-Sarcoma Modified","C121371","A subset of the Edmonton symptom assessment system designed to measure the severity of symptoms in patients being treated for sarcoma.","Edmonton Symptom Assessment System-Sarcoma Modified | ESAS-SM | Edmonton Symptom Assessment System-Sarcoma Modified (ESAS-SM)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055545","Ability to Move Normally","C121370","The quality of being able to change positions within regular limits.","Ability to Move Normally | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055383","Biggest Problem","C121372","The largest difficulty, disorder, or condition needing resolution.","Biggest Problem | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053838","Worse than Ever","C121373","In the all-time most severe or unfavorable condition.","Worse than Ever | Worse than ever",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831040","Complete Blood Count Collection Tube","C113676","A blood collection tube that contains the anti-coagulant EDTA, designed for complete blood counts and blood films.","Complete Blood Count Collection Tube | Lavender Top Tube | Purple Top Tube",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0184104","Blood Collection Tube","C113122","A test tube, capillary tube, or other tube designed for the collection of blood.","Blood Collection Tube | BCT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827777","Treatment Terminated Due to Toxicity","C105741","Indicates that the patient terminated the treatment due to toxicity related to the treatment.","Treatment Terminated Due to Toxicity | Treatment Stopped Due to Toxicity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054451","Musculoskeletal Tumor Society Rating Scale","C121380","A physician-completed measure used to assess extremity function in patients undergoing surgery for musculoskeletal cancer. The scale scores for function and acceptance by 6 variables for upper extremities and 6 variables for lower extremities.","Musculoskeletal Tumor Society Rating Scale | Enneking Score | MSTS Rating Scale | MSTS Rating Scale; Enneking Score | MSTS93 | Musculoskeletal Tumor Rating Scale | Musculoskeletal Tumor Rating Scale, 1993",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050173","Extremity Pain question","C121381","A question about the pain in a person's extremity.","Extremity Pain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050153","No Extremity Pain","C121390","A response indicating that a person has no extremity pain and is using no medication.","No Extremity Pain | No Pain | None (no use of medication)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055034","Extremity Pain Between None and Modest","C121391","A response indicating that a person's extremity pain is at an intermediate level: between none and modest.","Extremity Pain Between None and Modest | Between none and modest | None to Modest Pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054480","Modest Extremity Pain","C121392","A response indicating that a person's extremity pain is modest: intermittent but not disabling and requiring intermittent use of anti-inflammatory or non-narcotic medication for pain relief.","Modest Extremity Pain | Modest | Modest Pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055035","Extremity Pain Between Modest and Moderate","C121393","A response indicating that a person's extremity pain is at an intermediate level between modest and moderate.","Extremity Pain Between Modest and Moderate | Between modest and moderate | Modest to Moderate Pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049705","Moderate Extremity Pain","C121394","A response indicating that a person's extremity pain is at a moderate level: not continuous but disabling when present and requiring occasional or intermittent use of narcotic (or equivalent) medication.","Moderate Extremity Pain | Moderate | Moderate Pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050465","Severe Extremity Pain","C121395","A response indicating that a person's extremity pain is severe: continuous and disabling and requiring continuous use of narcotic (or equivalent) medication.","Severe Extremity Pain | Severe | Severe Pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055042","Extremity Functional Activity","C121382","A question about the functional activity of a person's extremity.","Extremity Functional Activity Question | Extremity Functional Activity | Extremity Functional Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054353","No Extremity Functional Restrictions","C121396","A response indicating no restrictions for functional activity of the person's extremity.","No Extremity Functional Restrictions | No Functional Restriction | No restrictions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054007","Some Extremity Functional Restrictions","C121397","A response indicating that a person's functional extremity restrictions are at an intermediate level between no restrictions and recreational restrictions only.","Some Extremity Functional Restrictions | Between no restrictions and recreational restrictions only",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054115","Recreational Extremity Functional Restrictions","C121398","A response indicating that a person's functional extremity restrictions are only recreational: do not seriously affect the person's life-style or occupation.","Recreational Extremity Functional Restrictions | Recreational Restriction | Recreational restrictions only",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054733","Increased Extremity Functional Restrictions","C121399","A response indicating that a person's functional extremity restrictions are at an intermediate level between recreational restrictions only and partial disability.","Increased Extremity Functional Restrictions | Between recreational restrictions only and partial disability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055041","Partial disability","C121400","A response indicating that a person's functional extremity restrictions are at a level of partial disability: significantly affecting the person's life-style or producing partial occupational disability.","Extremity Functional Restrictions, Partial Disability | Extremity Functional Restrictions Partial Disability | Partial disability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055040","Total disability","C121401","A response indicating that a person's functional extremity restrictions are at a level of total disability: causing major alterations in life-style or preventing the person from resuming their occupation.","Extremity Functional Restrictions, Total Disability | Extremity Functional Restrictions Total Disability | Total disability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055043","Extremity Emotional Acceptance","C121383","A question about a person's emotional acceptance of their extremity.","Extremity Emotional Acceptance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050581","Enthusiastic Acceptance of Extremity","C121402","A response indicating that a person has enthusiastic emotional acceptance of their extremity.","Enthusiastic Acceptance of Extremity | Enthusiastic | Enthusiastic Acceptance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054110","Reduced Acceptance of Extremity","C121403","A response indicating that a person's emotional acceptance of their extremity is at an intermediate level between enthusiastic and satisfied.","Reduced Acceptance of Extremity | Between enthusiastic and satisfied | Reduced Acceptance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049977","Emotionally Satisfied with Extremity","C121404","A response indicating that a person is emotionally satisfied with their extremity.","Emotionally Satisfied with Extremity | Emotional Satisfaction with Extremity | Satisfied | Satisfied with Extremity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054483","Moderate Satisfaction with Extremity","C121405","A response indicating that a person's emotional acceptance of their extremity is at an intermediate level between satisfied and acceptable.","Moderate Satisfaction with Extremity | Between satisfied and accepts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050131","Accepting of Extremity","C121406","A response indicating that a person finds their extremity to be emotionally acceptable.","Accepting of Extremity | Accepts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055069","Emotional Dislike of Extremity","C121407","A response indicating that a person emotionally dislikes their extremity.","Emotional Dislike of Extremity | Dislike of Extremity | Dislikes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055038","Extremity Hand Positioning","C121384","A question about the range of movement of a person's upper extremity.","Extremity Hand Positioning | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049609","Unlimited Hand Positioning","C121408","A response indicating that a person has unlimited range of motion for their upper extremity (180 degree elevation for hand positioning).","Unlimited Hand Positioning | Unlimited",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054109","Reduced Hand Positioning","C121409","A response indicating that a person has a reduced range of motion of their upper extremity: able to lift their arm and hand to an intermediate level between unlimited and not above shoulder, with no pronation or supination of the hand.","Reduced Hand Positioning | Between unlimited and not above shoulder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054862","Hand Positioning Not Above Shoulder","C121410","A response indicating that a person has a reduced range of motion of their upper extremity, unable to lift their arm and hand above the shoulder, with no pronation or supination of the hand.","Hand Positioning Not Above Shoulder | Not Above 90 Degrees | Not above shoulder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054646","Limited Hand Positioning","C121411","A response indicating that a person has a limited range of motion of their upper extremity: only able to lift their hand to a level intermediate between their shoulder and their waist, with no pronation or supination of the hand.","Limited Hand Positioning | Between not above shoulder; and not above waist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054886","Greatly Limited Hand Positioning","C121412","A response indicating that a person has a greatly reduced range of motion of their upper extremity, unable to lift their arm and hand above the waist, 30 degree elevation.","Greatly Limited Hand Positioning | Not Above 30 Degrees | Not above waist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050154","No Hand Mobility","C121413","A response indicating that a person has no ability to lift their arm and hand.","No Hand Mobility | 0 Degree Elevation | None",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055036","Extremity Manual Dexterity","C121385","A question about a person's manual dexterity.","Extremity Manual Dexterity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050368","Unlimited Manual Dexterity","C121414","A response indicating that a person has normal manual dexterity and sensitivity.","Unlimited Manual Dexterity | Manual Dexterity Unlimited | Unlimited",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054107","Reduced Manual Dexterity","C121415","A response indicating that a person's manual dexterity is at a level between unlimited and loss of fine movements.","Reduced Manual Dexterity | Between unlimited and loss of fine movements",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054595","Loss of Fine Movements","C121416","A response indicating that a person has lost their ability for fine movement: cannot button, write, eat, etc., or minor loss of sensitivity.","Loss of Fine Movements | Loss of fine movements",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054645","Limited Manual Dexterity","C121417","A response indicating that a person's manual dexterity is at a level between loss of fine movements and cannot pinch.","Limited Manual Dexterity | Between loss of fine movement and cannot pinch",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053744","Cannot Pinch","C121418","A response indicating that a person cannot pinch and has major sensory loss.","Cannot Pinch | Cannot pinch | Cannot pinch; major sensory loss | major sensory loss",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055276","Cannot Grasp","C121419","A response indicating that a person cannot grasp and has complete sensory loss.","Cannot Grasp | Cannot grasp | Cannot grasp; anesthetic hand | anesthetic hand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055037","Extremity Lifting Ability","C121386","A question about a person's ability to lift with their upper extremity.","Extremity Lifting Ability | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054336","Normal Lifting Ability","C121420","A response indicating that a person can lift a normal load, the same as for their unaffected limb.","Normal Lifting Ability | Normal load",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054108","Reduced Lifting Ability","C121421","A response indicating that a person's lifting ability is at a level between normal and limited.","Reduced Lifting Ability | Between normal load and intermediate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050251","Limited Lifting Ability","C121422","A response indicating that a person can only lift a minor load.","Limited Lifting Ability | Limited | Minor Load Only",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054885","Greatly Limited Lifting Ability","C121423","A response indicating that a person's lifting ability is at a level between limited and helping only.","Greatly Limited Lifting Ability | Between limited and helping only",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054796","Helping Only Lifting Ability","C121424","A response indicating that a person cannot overcome gravity and is only able to assist the contralateral extremity.","Helping Only Lifting Ability | Cannot Overcome Gravity | Helping Only",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054350","No Lifting Ability","C121425","A response indicating that a person has no lifting ability and cannot move their upper extremity.","No Lifting Ability | Cannot Move | Cannot help",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055033","Extremity Supports","C121387","A question about the physical support that a person requires.","Extremity Supports | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050155","No Support Needed","C121426","A response indicating that a person requires no physical support.","No Support Needed | No Support | None",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054323","Occasional Support Needed","C121427","A response indicating that a person requires a level of support between none and occasional use of a brace.","Occasional Support Needed | Between none and brace used most of the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055351","Brace Support Needed","C121428","A response indicating that a person requires use of a brace most of the time.","Brace Support Needed | Brace used most of the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053970","Support Needed Most of Time","C121430","A response indicating that a person requires a level of support between occasional use of a brace and need for one cane or crutch most of the time.","Support Needed Most of Time | Between brace used most of the time and one cane or crutch used most of the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055279","Cane or Crutch Needed Most of Time","C121431","A response indicating that a person requires use of one cane or crutch most of the time.","Cane or Crutch Needed Most of Time | One cane or crutch used most of the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053971","Support Always Needed","C121432","A response indicating that a person always requires use of two canes or crutches.","Support Always Needed | Two canes or crutches used",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055032","Extremity Walking Ability","C121388","A question about a person's walking ability.","Extremity Walking Ability Question | Extremity Walking Ability | Extremity Walking Ability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049610","Unlimited Walking Ability","C121433","A response indicating that a person has an unlimited walking ability, the same as their preoperative ability.","Unlimited Walking Ability | Unlimited",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054106","Reduced Walking Ability","C121434","A response indicating that a person's walking ability is between unlimited and limited.","Reduced Walking Ability | Between unlimited and limited",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2674459","Limited Walking Ability","C121435","A response indicating that a person's walking ability is limited, significantly less postoperatively.","Limited Walking Ability | Limited",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054884","Greatly Limited Walking Ability","C121436","A response indicating that a person's walking ability is between limited and inside only.","Greatly Limited Walking Ability | Between limited and inside only",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054711","Inside Only Walking Ability","C121437","A response indicating that a person's walking ability is limited to inside the home only.","Inside Only Walking Ability | Inside only",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054351","No Independent Walking Ability","C121438","A response indicating that a person can only walk with assistance or that they are wheelchair-bound.","No Independent Walking Ability | Not independent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055039","Extremity Gait","C121389","A question about a person's walking gait.","Extremity Gait | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0231683","Normal Gait","C121439","A response indicating that a person's walking is normal postoperatively, with no alteration to gait.","Normal Gait | Normal",,,,,,,,,,,,,,,"4215889","Gait normal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054907","Gait Between Normal and Minor Cosmetic Change","C121440","A response indicating that a person's gait is between normal and having a minor cosmetic alteration.","Gait Between Normal and Minor Cosmetic Change | Between normal and minor cosmetic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054487","Minor Cosmetic Gait Change","C121441","A response indicating that a person's gait has a minor cosmetic alteration.","Minor Cosmetic Gait Change | Minor cosmetic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054908","Gait Between Minor and Major Cosmetic Change","C121442","A response indicating that a person's gait is between minor cosmetic alteration and major cosmetic alteration.","Gait Between Minor and Major Cosmetic Change | Between minor cosmetic and major cosmetic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054583","Major Cosmetic Gait Change","C121443","A response indicating that a person's gait has a major cosmetic alteration with a minor functional deficit.","Major Cosmetic Gait Change | Major cosmetic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053748","Major Handicap Gait Change","C121444","A response indicating that a person's gait creates a major handicap with a major functional deficit.","Major Handicap Gait Change | Major Gait Handicap | Major Handicap",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521687","Clavien-Dindo Classification","C121446","A classification of adverse events that grades complications according to the treatment that is induced to treat the complication. The classification is designed to eliminate subjective interpretation of serious adverse events and tendency to down-rate complications, being based on data that is usually well documented and easy to verify. It is also well suited for retrospective analyses.","Clavien-Dindo Classification | Clavien-Dindo Classification of Surgical Complications | Clavien-Dindo Scale",,,,,,,,,,,,,,,"37311607","Clavien-Dindo complication scale",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4049998","Clavien-Dindo Grade I","C121447","Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic, and radiological interventions.","Clavien-Dindo Grade I | Grade I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049999","Clavien-Dindo Grade II","C121448","A complication requiring pharmacological treatment with drug other than such allowed for Grade I complications.","Clavien-Dindo Grade II | Grade II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050000","Clavien-Dindo Grade III","C121449","A complication requiring surgical, endoscopic, or radiological intervention.","Clavien-Dindo Grade III | Grade III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055230","Clavien-Dindo Grade IIIa","C121450","A complication requiring intervention not under general anesthesia.","Clavien-Dindo Grade IIIa | Grade IIIa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055229","Clavien-Dindo Grade IIIb","C121451","A complication requiring intervention under general anesthesia.","Clavien-Dindo Grade IIIb | Grade IIIb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050001","Clavien-Dindo Grade IV","C121452","A life-threatening complication.","Clavien-Dindo Grade IV | Grade IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055228","Clavien-Dindo Grade IVa","C121453","Single organ dysfunction.","Clavien-Dindo Grade IVa | Clavien-Dindo Grade Iva | Grade IVa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055227","Clavien-Dindo Grade IVb","C121454","Multiorgan dysfunction.","Clavien-Dindo Grade IVb | Grade IVb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050002","Clavien-Dindo Grade V","C121455","Death of a patient.","Clavien-Dindo Grade V | Grade V",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054194","Perform Daily Activities Post Limb Therapeutic Procedure Recovery","C121487","A question about a person's expected ability to perform daily activities after recovering from treatment for their arm or leg.","Perform Daily Activities Post Limb Therapeutic Procedure Recovery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055387","Behavior Rating Inventory of Executive Function, Preschool Version","C121458","A standardized rating scale designed to specifically measure executive function in children aged 2 to 5 years. Parents, teachers, or other caregivers rate a child's executive functions within the context of the child's home or preschool environments.","Behavior Rating Inventory of Executive Function, Preschool Version | BRIEF-P | Behavior Rating Inventory of Executive Function-Preschool Version (BRIEF-P)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050216","Behavior Rating Inventory of Executive Function","C121459","A standardized rating scale designed to assess the executive function behaviors in the school and home environments for children and adolescents as observed by a parent or teacher.","Behavior Rating Inventory of Executive Function | BRIEF | Behavior Rating Inventory of Executive Function (BRIEF)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055394","BRIEF Parent Form Questionnaire","C121461","A questionnaire included in the Behavior Rating Inventory of Executive Function. The parent form is completed by one or both parents who must have recent and extensive contact with the child over the past 6 months.","BRIEF Parent Form Questionnaire | Parent Form | Parent Form Questionnaire | Parent Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055393","BRIEF Teacher Form Questionnaire","C121462","A questionnaire included in the Behavior Rating Inventory of Executive Function. The teacher form is completed by any adult with extended contact with the child in an academic setting, typically a teacher, but an aide is acceptable. The adult must have at least 1 month familiarity with the child.","BRIEF Teacher Form Questionnaire | Teacher Form | Teacher Form Questionnaire | Teacher Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055388","Behavior Rating Inventory of Executive Function, Adult Version","C121460","A standardized measure that assesses the executive functions of adults aged 18-90 years in their everyday environment. Both a self-report and an informant report are used.","Behavior Rating Inventory of Executive Function, Adult Version | BRIEF-A | Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054715","Inhibit Scale","C121463","A rating scale included in the Behavior Rating Inventory of Executive Function that measures the ability of an individual to control impulses (inhibitory control) and to stop engaging in a behavior at the appropriate time.","Inhibit Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054030","Shift Scale","C121464","A rating scale included in the Behavior Rating Inventory of Executive Function that measures the ability of an individual to move freely from one activity or situation to another, to tolerate change, to be flexible when solving problems, and to switch or alternate attention.","Shift Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055070","Emotional Control Scale","C121465","A rating scale included in the Behavior Rating Inventory of Executive Function that measures the ability of an individual to regulate emotional responses appropriately.","Emotional Control Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054039","Self Monitor Scale","C121466","A rating scale included in the Behavior Rating Inventory of Executive Function (BRIEF) that assesses aspects of social or interpersonal awareness. It captures the degree to which a person is aware of the effect that their behavior has on others and how it compares with standards or expectations for behavior.","Self Monitor Scale | Self-Monitor Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054712","Initiate Scale","C121467","A rating scale included in the Behavior Rating Inventory of Executive Function that reflects an individual's ability to begin a task or activity and to independently generate ideas, responses, or problem-solving strategies.","Initiate Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053843","Working Memory Scale","C121468","A rating scale included in the Behavior Rating Inventory of Executive Function that measures the ability of an individual to hold information when completing a task, encoding information, or generating goals and plans in a sequential manner.","Working Memory Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054175","Plan/Organize Scale","C121469","A rating scale included in the Behavior Rating Inventory of Executive Function that measures the ability of an individual to manage current and future-oriented task demands within the situational context. The plan component relates to the ability to anticipate future events, implement instructions or goals, and develop appropriate steps ahead of time in order to carry out a task or activity. The organize component refers to the ability to bring order to information, actions, or materials to achieve a goal or to follow an established organized routine.","Plan/Organize Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053947","Task Monitor Scale","C121470","A rating scale included in the Behavior Rating Inventory of Executive Function (BRIEF) that reflects the ability to keep track of one's problem-solving success or failure, and to identify and correct mistakes during performance of a goal.","Task Monitor Scale | Task-Monitor Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054316","Organization of Materials Scale","C121471","A rating scale included in the Behavior Rating Inventory of Executive Function that measures orderliness of living, work, play, and storage spaces (e.g., rooms, desks, lockers, backpacks, and bedrooms).","Organization of Materials Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054478","Monitor Scale","C121472","A rating scale included in the Behavior Rating Inventory of Executive Function that assesses work-checking habits and interpersonal awareness. The task monitoring portion of the scale captures whether a child assesses his or her own performance during or shortly after finishing a task to ensure accuracy or appropriate attainment of a goal. The self-monitoring portion of the scale evaluates whether a child keeps track of the effect that his or her behavior has on others.","Monitor Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054896","Global Executive Composite","C121474","An overall index of the Behavior Rating Inventory of Executive Function which takes into account all of the clinical scales and represents the individual's overall executive function.","Global Executive Composite | GEC | Global Executive Composite (GEC)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054714","Inhibitory Self-Control Index","C121476","An index of the Behavior Rating Inventory of Executive Function, Preschool Version that combines the Inhibit and Emotional Control scales.","Inhibitory Self-Control Index | ISCI | Inhibitory Self-Control Index (ISCI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050619","Flexibility Index","C121479","An index of the Behavior Rating Inventory of Executive Function, Preschool Version that combines the Shift and Emotional Control scales.","Flexibility Index | FI | Flexibility Index (FI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053757","Emergent Metacognition Index","C121481","An index of the Behavior Rating Inventory of Executive Function, Preschool Version that combines the Working Memory and Plan/Organize scales.","Emergent Metacognition Index | EMI | Emergent Metacognition Index (EMI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055386","Behavior Regulation Index","C121482","An index of the Behavior Rating Inventory of Executive Function that captures the individual's ability to shift cognitive set and modulate emotions and behavior via appropriate inhibitory control. It combines the Inhibit, Shift, and Emotional Control scales.","Behavior Regulation Index | Behavior Regulation Index (BRI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054529","Metacognition Index","C121483","An index of the Behavior Rating Inventory of Executive Function that reflects the individual's ability to initiate, plan, organize, self-monitor, and sustain working memory. It combines the Initiate, Working Memory, Plan/Organize, Organization of Materials, and Monitor scales.","Metacognition Index | Metacognition Index (MI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4227420","Movement Disorder","C116757","Neurological conditions resulting in abnormal voluntary or involuntary movement, which may impact the speed, fluency, quality and ease of movement.","Movement Disorder | Movement Disorders",,,,,,,,,,,,,,,"372604","Movement disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053773","Linear Analogue Self-Assessment-6","C121507","A six-item, self-reported questionnaire designed to measure general well-being and the major domains of quality of life (mental, physical, emotional, social, and spiritual well-being) using a linear analogue scale to describe the assessment responses.","Linear Analogue Self-Assessment-6 | LASA-6 | Linear Analogue Self-Assessment-6 (LASA-6)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054687","LASA-6 Feeling Intensity Scale","C121508","A scale for the subjective scoring of the intensity of a person's feelings that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.","LASA-6 Feeling Intensity Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054971","Feeling Intensity Score 0","C121510","A subjective score of 0 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.","Feeling Intensity Score 0 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054969","Feeling Intensity Score 1","C121511","A subjective score of 1 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be","Feeling Intensity Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053798","Feeling Intensity Score 2","C121512","A subjective score of 2 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.","Feeling Intensity Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054968","Feeling Intensity Score 3","C121513","A subjective score of 3 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.","Feeling Intensity Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054967","Feeling Intensity Score 4","C121514","A subjective score of 4 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.","Feeling Intensity Score 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054966","Feeling Intensity Score 5","C121515","A subjective score of 5 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.","Feeling Intensity Score 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054965","Feeling Intensity Score 6","C121516","A subjective score of 6 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.","Feeling Intensity Score 6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054964","Feeling Intensity Score 7","C121517","A subjective score of 7 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.","Feeling Intensity Score 7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054963","Feeling Intensity Score 8","C121518","A subjective score of 8 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.","Feeling Intensity Score 8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054962","Feeling Intensity Score 9","C121519","A subjective score of 9 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.","Feeling Intensity Score 9 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054970","Feeling Intensity Score 10","C121520","A subjective score of 10 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.","Feeling Intensity Score 10 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897820","Promyeloblasts Measurement","C117847","The determination of the amount of promyeloblasts present in a sample.","Promyeloblasts Measurement | PROMYB | Promyeloblasts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054219","Pediatric Quality of Life Inventory, Version 4","C121522","A modular instrument for measuring health-related quality of life in children and adolescents ages 2 to 18. The PedsQL combines both generic core scales and disease-specific modules.","Pediatric Quality of Life Inventory, Version 4 | Pediatric Quality of Life Inventory Version 4 (PedsQL 4.0) | Pediatric Quality of Life Inventory Version 4 (PedsQL 4.0);  | PedsQL 4.0 | PedsQL v4 | PedsQL-4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054217","PedsQL-4 Child Report","C121523","A self-report questionnaire that assesses health-related quality of life in children and adolescents ages 8 to 12.","PedsQL-4 Child Report | Child Report | Child-Self Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054215","PedsQL-4 Parent Report","C121524","A questionnaire, completed by a parent, that assesses health-related quality of life in children and adolescents ages 8 to 12.","PedsQL-4 Parent Report | Parent Report | Parent Report for Children | Parent-Proxy Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054214","PedsQL-4 Physical Functioning Scale","C121525","A rating scale included in the Pediatric Quality of Life Inventory Version 4 (PedsQL 4.0) that measures problems with a child's physical health and activities.","PedsQL-4 Physical Functioning Scale | Physical Functioning Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054216","PedsQL-4 Emotional Functioning Scale","C121526","A rating scale included in the Pediatric Quality of Life Inventory Version 4 (PedsQL 4.0) that measures problems with a child's feelings and emotions.","PedsQL-4 Emotional Functioning Scale | Emotional Functioning Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049976","PedsQL-4 Social Functioning Scale","C121527","A rating scale included in the Pediatric Quality of Life Inventory Version 4 (PedsQL 4.0) that measures problems with how well a child gets along with others.","PedsQL-4 Social Functioning Scale | Social Functioning Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054212","PedsQL-4 School Functioning Scale","C121528","A rating scale included in the Pediatric Quality of Life Inventory Version 4 (PedsQL 4.0) that measures problems with a child's experiences related to attending school.","PedsQL-4 School Functioning Scale | School Functioning Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054213","PedsQL-4 Psychosocial Health Summary Score","C121529","The mean value computed as the sum of the score of individual items over the number of items answered in the Emotional, Social, and School Functioning Scales.","PedsQL-4 Psychosocial Health Summary Score | Psychosocial Health Summary Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049715","PedsQL-4 Scale Score","C121530","The mean value computed as the sum of the individual items in a scale over the number of items answered in that scale.","PedsQL-4 Scale Score | Scale Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054211","PedsQL-4 Total Scale Score","C121531","The mean value computed as the sum of all individual items over the number of items answered on all the Scales.","PedsQL-4 Total Scale Score | Total Scale Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2191320","Prophylactic Mastectomy","C94445","Surgery to reduce the risk of developing breast cancer by removing one or both breasts before disease develops.","Prophylactic Mastectomy | preventive mastectomy | prophylactic mastectomy",,,,,,,,,,,,,,,"40492422","Prophylactic mastectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3827146","Telaglenastat","C114381","An orally bioavailable inhibitor of glutaminase, with potential antineoplastic activity. Upon oral administration, CB-839 selectively and irreversibly inhibits glutaminase, a mitochondrial enzyme that is essential for the conversion of the amino acid glutamine into glutamate. By blocking glutamine utilization, proliferation in rapidly growing cells is impaired. Glutamine-dependent tumors rely on the conversion of exogenous glutamine into glutamate and glutamate metabolites to both provide energy and generate building blocks for the production of macromolecules, which are needed for cellular growth and survival.","Telaglenastat | CB-839 | Glutaminase Inhibitor CB-839 | TELAGLENASTAT | WHO 10815",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055476","Alpha-Gal Antibody","C121503","Any immunoglobulin that recognizes the disaccharide epitope galactose-alpha-1,3-galactose (alpha-gal).","Alpha-Gal Antibody | Alpha Gal Antibody | Anti-Alpha Gal | Anti-Alpha Gal Antibody | Anti-Alpha-Gal | Anti-Alpha-Gal Antibody | Anti-Galactose-Alpha-1,3-Galactose | Anti-Galactose-Alpha-1,3-Galactose Antibody | Galactose-Alpha-1,3-Galactose Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412717","B3GAT2 Gene","C121491","This gene is involved in the biosynthesis of glycolipids and glycoproteins.","B3GAT2 Gene | B3GAT2 | Beta-1,3-Glucuronyltransferase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055289","CTLA-4 Ligand","C121501","Proteins that bind to cytotoxic T-lymphocyte protein 4, which is expressed on T-cells, and stimulate signaling that may play a role in the inhibition of T-cell activation. This group of proteins includes the T-lymphocyte activation antigens CD80 and CD86, which are expressed on antigen-presenting cells.","CTLA-4 Ligand | CTLA4 Ligand | Cytotoxic T-Lymphocyte-Associated Protein 4 Ligand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1449693","Ellagitannin","C121484","A class of polyphenols that are formed by the oxidative linkage of galloyl groups to the pentahydroxy gallic acid ester of glucose where the galloyl groups are linked through C-C bonds. Ellagitannins have diverse effects including anti-oxidant, anti-proliferative, anti-viral, and anti-microbial activities.","Ellagitannin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1257771","Erythroid Burst Forming Unit","C121480","A unit of viable cell concentration defined as the minimum number of hematopoietic stem cells able to produce a detectable colony of erythroid burst forming cells.","Erythroid Burst Forming Unit | BFU-E | Burst Forming Unit-Erythroid | Burst-Forming Unit, Erythroid",,,,,,,,,,,,,,,"4127164","Burst-forming unit erythroid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4049988","Estrone Conjugate","C121485","A metabolite formed during the catabolism of estrone. The levels of estrone metabolites may be used to indirectly measure estrone plasma levels and to assess female reproductive function.","Estrone Conjugate | E1C | E1c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054958","Fibroblast Growth Factor Receptor Family Isoform IIIb","C121505","An isoform of fibroblast growth factor receptor-1, -2, or -3, where alternative splicing leads to the expression of the IIIb exon encoding the second half of the third immunoglobulin-like domain, which is located in the extracellular domain of these receptors. This variant is expressed in epithelial lineage cells and has differential ligand binding activity when compared to the IIIa and IIIc forms.","Fibroblast Growth Factor Receptor Family Isoform IIIb | FGFR IIIb | FGFR-IIIb | Fgfr(IIIb)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054957","Fibroblast Growth Factor Receptor Family Isoform IIIc","C121506","An isoform of fibroblast growth factor receptor-1, -2, or -3, where alternative splicing leads the expression of the IIIc exon encoding the second half of the third immunoglobulin-like domain, which is located in the extracellular domain of these receptors. This variant is expressed in mesenchymal lineage cells and has differential ligand binding activity when compared to the IIIa and IIIb forms.","Fibroblast Growth Factor Receptor Family Isoform IIIc | FGFR IIIc | FGFR-IIIc | Fgfr(IIIc)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0314589","Granulocyte-Macrophage Colony Forming Units","C121475","A unit of viable cell concentration defined as the minimum number of hematopoietic stem cells able to produce a detectable colony of granulocyte-macrophage lineage cells.","Granulocyte-Macrophage Colony Forming Unit | CFU-GM | Colony Forming Unit-Granulocyte-Macrophage | GM-CFU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415379","GZMA Gene","C121488","This gene plays a role in natural killer and T-cell activated cytolysis.","GZMA Gene | GZMA | Granzyme A (Granzyme 1, Cytotoxic T-Lymphocyte-Associated Serine Esterase 3) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2613367","Hypomethylation","C121521","An epigenetic process that either inhibits DNA methyltransferase activity or promotes DNA demethylase activity, and results in a net loss of 5-methylcytosines and a net gain of unmethylated cytosine nucleotides either in specific repetitive DNA sequences or across the bulk of the genome. This phenomenon is associated with aging, genomic instability and tumorigenesis.","Hypomethylation | DNA Hypomethylation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054683","LGALS3 Antibody","C121502","Any immunoglobulin that recognizes galectin-3.","LGALS3 Antibody | Anti-Galectin-3 Antibody | Anti-LGALS3 Antibody | Galectin-3 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493997","Megakaryocyte Colony Forming Unit","C121478","A unit of viable cell concentration defined as the minimum number of hematopoietic stem cells able to produce a detectable colony of megakaryocyte lineage cells.","Megakaryocyte Colony Forming Unit | CFU-Meg | CFU-Mega | Colony Forming Unit-Megakaryocyte",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054277","PA2024 Antibody","C121504","Any immunoglobulin that recognizes PA2024, which is a fusion protein comprised of prostatic acid phosphatase fused to granulocyte-macrophage stimulating factor.","PA2024 Antibody | Anti-PA2024 | Anti-PA2024 Antibody | Anti-PAP/GM-CSF | Anti-PAP/GM-CSF Antibody | Anti-PAP/GM-CSF Fusion Protein Antibody | Anti-Prostatic Acid Phosphatase-Granulocyte-Macrophage Colony-Stimulating Factor Fusion Protein Antibody | Anti-Prostatic Acid Phosphatase-Sargramostim Fusion Protein | PAP/GM-CSF Fusion Protein Antibody | Prostatic Acid Phosphatase-Granulocyte-Macrophage Colony-Stimulating Factor Fusion Protein Antibody | Prostatic Acid Phosphatase-Sargramostim Fusion Protein Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0071863","pregnanediol-3 alpha-glucuronide","C121486","A metabolite formed during the catabolism of progesterone. The urinary levels of this progesterone metabolite may be used to indirectly measure progesterone levels and to assess female reproductive function.","Pregnanediol-3alpha-Glucuronide |  PDG | (3alpha,5beta,20S)-20-Hydroxypregnan-3-Yl Beta-D-Glucopyranosiduronic Acid | 20alpha-Hydroxy-5beta-Pregnan-3alpha-Yl-Beta-D-Glucopyranosiduronic Acid | 5beta-Pregnane-3alpha,20alpha-Diol-3alpha-Glucuronide | Beta-D-Glucopyranosiduronic Acid, (3alpha,5beta,20S)-20-Hydroxypregnan-3-Yl | PDG | PdG | Pregnanediol Glucuronide | Pregnanediol-3-Glucuronide | SLC5A8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426025","SLC5A8 Gene","C121497","This gene is involved in the transport of sodium cations, chloride anions, iodide and monocarboxylates.","SLC5A8 Gene | SLC5A8 | Solute Carrier Family 5 (Sodium/Monocarboxylate Cotransporter), Member 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2362049","Microalbumin","C121532","Albumin protein in urine samples, which is a marker for kidney dysfunction. Persistently elevated concentrations of albumin in the urine can be diagnostic for kidney damage caused by diabetes, high blood pressure, heart failure, cirrhosis, or lupus.","Urine Albumin | Microalbumin | Urinary Albumin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053873","VeriStrat","C121473","A prognostic scoring system designed to predict non-small-cell lung cancer patients who will benefit from treatment with EGFR inhibitor therapy. A serum or plasma sample is obtained from a patient and is subjected to matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry. An algorithm is applied to the absorption peaks obtained and translated into a score of good or poor.","VeriStrat | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824066","ZNF793 Gene","C121494","This gene may play a role in the modulation of transcription.","ZNF793 Gene | ZNF793 | Zinc Finger Protein 793 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053784","ERG Deregulation","C121534","A molecular genetic abnormality indicating deregulation of the ERG oncogene.","ERG Deregulation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL054934","Pre-B Acute Lymphoblastic Leukemia","C27798","An acute lymphoblastic leukemia that originates from pre-B lymphocytes. The pre-B lymphoblasts contain cytoplasmic immunoglobulin.","Pre-B Acute Lymphoblastic Leukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079366","Fluorescence-Activated Cell Sorting","C17353","Selection and deposition of individual cells of a particular phenotype from a mixed population into a separate tube or tissue culture plate by the use of a fluorescence-activated cell sorter (FACS) and fluorescently-labeled antibodies specific for surface molecules on the cells to be sorted.","Fluorescence Activated Cell Sorting | FACS | Fractionation, Fluorescence Activated Cell Sorting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055271","Cardiophrenic Lymph Node","C121555","A lymph node located in the angle between the heart and diaphragm.","Cardiophrenic Lymph Node | CARDIOPHRENIC LYMPH NODE | Cardiophrenic Angle Lymph Node",,,,,,,,,,,,,,,"4159639","Cardiophrenic angle lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334246","Metastatic Squamous Cell Carcinoma","C4104","A carcinoma that arises from squamous cells and has spread from its original site of growth to another anatomic site.","Metastatic Squamous Cell Carcinoma | Squamous cell carcinoma, metastatic, NOS","8070/6","Squamous cell carcinoma, metastatic, NOS",,,,,,,,,,,,,"4271714|4301510","Squamous cell carcinoma, metastatic|Metastatic squamous cell carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C3897462","Study Subject MRI Report","C115512","Reports pertaining to the findings from a study subject's magnetic resonance imaging results.","Study Subject MRI Report | Study Subj MRI Rept | Study Subject Magnetic Resonance Imaging Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697638","Hypodiploid B Acute Lymphoblastic Leukemia","C80345","A B-cell acute leukemia characterized by the presence of lymphoblasts which contain less than 46 chromosomes. It occurs in both children and adults. It has an unfavorable clinical outcome.","Hypodiploid B Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia with Hypodiploidy | B-Acute Lymphoblastic Leukemia with Hypodiploidy | Hypodiploid ALL | Hypodiploid Acute Lymphoblastic Leukemia | Hypodiploid B-Acute Lymphoblastic Leukemia | Hypodiploid B-Cell Acute Lymphoblastic Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023453","B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1","C36312","A B-cell acute leukemia characterized by the presence of lymphoblasts that carry a translocation between the BCR gene on chromosome 22 and the ABL1 gene on chromosome 9. It results in the production of the p190 kd or p210 kd fusion protein. It has an unfavorable clinical outcome.","B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 | Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive | B Acute Lymphoblastic Leukemia with BCR-ABL1 Fusion | B Acute Lymphoblastic Leukemia with BCR::ABL1 Fusion | B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR::ABL1 | B Acute Lymphoblastic Leukemia with t(9;22)(q34;q11.2); BCR-ABL1 | B Acute Lymphoblastic Leukemia with t(9;22)(q34;q11.2); BCR-ABL1 | B-Acute Lymphoblastic Leukemia with BCR-ABL1 Fusion | B-Acute Lymphoblastic Leukemia with BCR::ABL1 Fusion | B-Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 | B-Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR::ABL1 | B-Cell Acute Lymphoblastic Leukemia with t(9;22)(q34;q11.2); BCR-ABL1 | Philadelphia Positive Acute Lymphoblastic Leukemia | Philadelphia Positive Precursor Lymphoblastic Leukemia",,,,,,,,,,,,,,,"4030260","Precursor cell lymphoblastic leukemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1840636","TCF3/HLF Fusion Gene","C99289","A fusion gene (~4.4 kb) that results from a chromosomal translocation t(17;19)(q22;p13) which fuses intron 13 of the TCF3 gene with intron 3 of the HLF gene. This rearrangement is associated with childhood pre-B cell acute lymphoblastic leukemia.","TCF3/HLF Fusion Gene | E2A-HLF Fusion Gene | E2A/HLF Fusion Gene | HLF/E2A Fusion Gene | TCF3-HLF Fusion Gene | TCF3::HLF Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698305","B Acute Lymphoblastic Leukemia with t(12;21)(p13.2;q22.1); ETV6-RUNX1","C80343","A B-cell acute leukemia characterized by the presence of lymphoblasts that carry a translocation between the TEL gene on chromosome 12 and the AML1 gene on chromosome 21, (p13.2;q22.1). It results in the production of the TEL-AML1 (ETV6-RUNX1) fusion protein. It is commonly seen in children and rarely in adults. It has a favorable clinical outcome.","B Acute Lymphoblastic Leukemia with t(12;21)(p13.2;q22.1); ETV6-RUNX1 | B Acute Lymphoblastic Leukemia with ETV6-RUNX1 Fusion | B Acute Lymphoblastic Leukemia with ETV6::RUNX1 Fusion | B Acute Lymphoblastic Leukemia with t(12;21)(p13.2;q22.1); ETV6::RUNX1 | B Acute Lymphoblastic Leukemia with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1) | B Acute Lymphoblastic Leukemia with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1) | B-ALL with t(12;21)(p13.2;q22.1)/ETV6-RUNX1 | B-ALL with t(12;21)(p13.2;q22.1); ETV6-RUNX1 | B-Acute Lymphoblastic Leukemia with ETV6-RUNX1 Fusion | B-Acute Lymphoblastic Leukemia with ETV6::RUNX1 Fusion | B-Acute Lymphoblastic Leukemia with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1) | B-Cell Acute Lymphoblastic Leukemia with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697636","Hyperdiploid B Acute Lymphoblastic Leukemia","C80344","A B-cell acute leukemia characterized by the presence of lymphoblasts which contain more than 50 and usually less than 66 chromosomes. It is commonly seen in children and rarely in adults. It has a favorable clinical outcome.","Hyperdiploid B Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia with High Hyperdiploidy | B-Acute Lymphoblastic Leukemia with High Hyperdiploidy | Hyperdiploid ALL | Hyperdiploid Acute Lymphoblastic Leukemia | Hyperdiploid B-Acute Lymphoblastic Leukemia | Hyperdiploid B-Cell Acute Lymphoblastic Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0062609","Very Long Chain Fatty Acid","C68439","A class of dietary fatty acids that have an alkyl chain length above 21 carbon atoms.","Very Long Chain Fatty Acid | C26:0 | C26:0 (VLCFA) | Cerotic Acid | Hexacosanoic Acid | VLCFA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0212874","Lorenzo's Oil","C121561","An orally-administered oil composed of the monounsaturated fatty acids glyceryl trioleate (GTO), the triacylglycerol form of oleic acid derived from olive oil, and glyceryl trierucate (GTE), the triacylglycerol form of erucic acid derived from rapeseed oil, in a 4:1 ratio, that can be used in the treatment of adrenoleukodystrophy (ALD). Upon oral administration of Lorenzo's oil, the monounsaturated fatty acids compete with saturated fatty acids as substrates for enzymes in the elongation of very long-chain fatty acids (ELOVL) family. This results in the elongation and production of monounsaturated very long-chain fatty acids (VLCFAs) and reduces the elongation of saturated VLCFAs. This reduces the plasma levels of saturated VLCFAs and prevents their accumulation in the brain, thereby preventing demyelination of cerebral nerves and halting the progression of ALD.","Lorenzo's Oil | GTO:GTE Oil",,,,,,,,,,,,,,,"4209772","Lorenzo's oil liquid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0449721","Chromosome Arm","C13355","Under the microscope chromosomes appear as thin, thread-like structures. They all have a short arm and long arm separated by a primary constriction called the centromere. The short arm is designated as p and the long arm as q.","Chromosome Arm | chromosome arm | chromosome_arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230403","Hand Digit 5","C52838","The fifth and smallest finger from the radial side of the hand.","Hand Digit 5 | 5th digit of hand | 5th finger | HAND DIGIT 5 | Little Finger | Pinkie | Small Finger | digit 5 of fore-paw | fifth digit of hand | fifth finger | finger 5 | fore digit V | fore limb digit 5 | hand digit 5 | manual digit 5 | manual digit V",,,,,,,,,,,,,"UBERON:0003625","manual digit 5","4050605","Little finger structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0230398","Hand Digit 4","C52837","The fourth finger from the radial side of the hand.","Hand Digit 4 | 4th digit of hand | 4th finger | HAND DIGIT 4 | Ring Finger | digit 4 of fore-paw | finger 4 | fore digit IV | fore limb digit 4 | fourth digit of hand | fourth finger | hand digit 4 | manual digit 4 | manual digit IV",,,,,,,,,,,,,"UBERON:0003624","manual digit 4","4217762","Ring finger structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0230393","Hand Digit 3","C52836","The middle or third finger from the radial side of the hand.","Hand Digit 3 | HAND DIGIT 3 | Middle Finger",,,,,,,,,,,,,,,"4276516","Middle finger structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0230388","Hand Digit 2","C52835","The second finger from the radial side of the hand, next to the thumb.","Hand Digit 2 | 2nd digit of hand | 2nd finger | HAND DIGIT 2 | Index Finger | digit 2 of fore-paw | finger 2 | fore digit II | fore limb digit 2 | hand digit 2 | manual digit 2 | manual digit II | second digit of hand | second finger",,,,,,,,,,,,,"UBERON:0003622","manual digit 2","4309041","Index finger structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333877","Granzymes","C20619","A family of serine endopeptidases. Members of this family are stored in the granules of cytotoxic T cells. Upon release of the granules, these enzymes enter infected cells where they can proteolytically stimulate caspase activation and initiate apoptosis.","Granzyme | EC 3.4.21.- | Granule-Secreted Enzyme | Granzymes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086222","Enhancer of transcription","C13296","A 50-150bp DNA sequence that increases the rate of transcription of coding sequences. It may be located at various distances and in either orientation upstream from, downstream from or within a structural gene.  When bound by a specific transcription factor it increases the levels of expression of the gene, but is not sufficient alone to cause expression. Distinguished from a promoter, that is alone sufficient to cause expression of the gene when bound.","Enhancer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415475","HAS2 Gene","C98002","This gene plays a role in the synthesis of glycosaminoglycans.","HAS2 Gene | HAS2 | Hyaluronan Synthase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016011","Integrin Alpha-IIb/Beta-3","C77161","Integrin alpha-IIb/beta3 is a protein complex comprised of a heterodimer of integrin alpha 2b and integrin beta 3. This complex is involved in cell adhesion and blood clot formation.","Integrin Alpha-IIb/Beta-3 | Alpha 2b/Beta 3 | Alpha 2b/Beta 3 Integrin | Alpha-IIb/Beta-3 | Alpha-IIb/Beta-3 Integrin | Alpha2b/Beta3 | Alpha2b/Beta3 Integrin | CD41/61 | GP IIb/IIIa | Glycoprotein IIb/IIIa | Integrin Alpha IIb/Beta 3 | Integrin Alpha-2b/Beta-3 | PLATELET GLYCOPROTEIN IIB/IIIA | Platelet GPIIb/IIIa | gpIIb/IIIa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982391","Long Intergenic Non-Protein Coding RNA","C88924","A molecule of RNA 200-17000 nucleotides in length that is transcribed by non-protein coding areas of DNA. These ribonucleotides may play a role in a variety of biological processes.","LincRNA | LONG NON-CODING RNA | Large Intervening Non-Coding RNA | Large Non-Coding RNA | Long Intergenic Non-Coding RNA | Long Intergenic Noncoding RNA | Long Non Coding RNA | Long Non-Coding RNA | Long ncRNA | lincRNA | lncRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879585","prostatic acid phosphatase-sargramostim fusion protein","C2548","A genetically-engineered protein formed by the fusion of prostatic acid phosphatase (PAP) and sargramostim (GM-CSF). Vaccination with antigen-presenting cells (APC) loaded with prostatic acid phosphatase-sargramostim fusion protein may elicit a cytotoxic T-cell response against tumor cells that express PAP. (NCI05)","Prostatic Acid Phosphatase-Sargramostim Fusion Protein PA2024 | PA2024 | PROSTATIC ACID PHOSPHATASE (PAP)-GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) FUSION PROTEIN | Prostatic Acid Phosphatase-Sargramostim Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418797","PPID Gene","C118130","This gene plays a role in the catalysis of protein folding.","PPID Gene | PPID | Peptidylprolyl Isomerase D Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332719","CDC25A Gene","C20960","This oncogene is involved in cell cycle control.","CDC25A Gene | CDC25A | Cell Division Cycle 25A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1853685","PBRM1 Gene","C95438","This gene plays a role in chromatin remodeling.","PBRM1 Gene | PBRM1 | Polybromo 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539790","KDM5C Gene","C97598","This gene is involved in histone modification.","KDM5C Gene | KDM5C | Lysine (K)-Specific Demethylase 5C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1822686","SETD2 Gene","C73662","This gene is involved in epigenetic control of gene expression through histone methylation.","SETD2 Gene | SET Domain Containing 2 Gene | SET Domain Containing 2, Histone Lysine Methyltransferase Gene | SETD2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206116","Microglia","C12616","A type of glial cell that mediates immune responses by clearing cellular debris and dead neurons from nervous tissue through phagocytosis.","Microglia | Hortega cell | Microglial Cell | Microgliocyte",,,,,,,,,,,,,,,"4272035","Microgliocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333336","EP300 Gene","C26569","This gene plays a role in DNA repair and regulation of transcription.","EP300 Gene | E1A Binding Protein p300 Gene | EP300",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420809","TNFRSF17 Gene","C97846","This gene is involved in the modulation of cytokine signaling.","TNFRSF17 Gene | TNFRSF17 | Tumor Necrosis Factor Receptor Superfamily, Member 17 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0948967","Breast Intraductal Neoplasm","C36083","A benign or malignant epithelial neoplasm that arises anywhere in the ductal system of the breast.  This category includes intraductal papilloma, intraductal papillary carcinoma, ductal hyperplasia with or without atypia, and ductal carcinoma in situ.","Breast Intraductal Neoplasm | Breast Intraductal  Neoplasm | Intraductal Breast Neoplasm | Intraductal Breast Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0526091","Neomycin Sulfate/Polymyxin B Sulfate/Dexamethasone","C121617","A topical combination preparation containing the sulfate salt form of the aminoglycoside antibiotic neomycin, the sulfate salt form of the polypeptide antibiotic polymyxin B, and the glucocorticoid dexamethasone, with antimicrobial, anti-infective and anti-inflammatory activities. Upon topical application, neomycin irreversibly binds to the bacterial 30S ribosomal subunit, thereby preventing mRNA from binding, causing both misreading and the inhibition of protein synthesis. Polymyxin B binds, with its positively charged amino groups, to negatively charged phospholipids in the outer cell membrane of Gram-negative bacteria, thereby disrupting cell wall integrity and altering the permeability of the bacterial cytoplasmic membrane. Dexamethasone binds to the cytoplasmic glucocorticoid receptor, and this receptor-ligand complex is translocated to the nucleus where it initiates the transcription of genes encoding for anti-inflammatory mediators, such as cytokines and lipocortins.","Neomycin Sulfate/Polymyxin B Sulfate/Dexamethasone | Maxitrol | Maxitrol Eye Drops",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016957","Galactocerebrosidase","C121620","Galactocerebrosidase (685 aa, ~77 kDa) is encoded by the human GALC gene. This protein is involved in hydrolysis of galactose ester bonds of galactosylceramide, galactosylsphingosine, lactosylceramide, and monogalactosyldiglyceride.","Galactocerebrosidase | EC 3.2.1.46 | GALC | GALCERase | Galactocerebroside Beta-Galactosidase | Galactosylceramidase | Galactosylceramide Beta-Galactosidase | Testis Tissue Sperm-Binding Protein Li 88E | Testis Tissue Sperm-Binding Protein Li 89A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412468","APOA1 Gene","C116417","This gene is involved in cholesterol transport and metabolism.","APOA1 Gene | APOA1 | Apolipoprotein A1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335648","RRM1 Gene","C20848","This gene plays a role in the inhibition of cell migration, invasion, and metastasis.","RRM1 Gene | RRM1 | Ribonucleotide Reductase M1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711106","c-MET Gene Amplification","C43532","A molecular genetic abnormality indicating the presence of multiple copies of the MET gene.","c-MET Gene Amplification | HGFR Gene Amplification | Hepatocyte Growth Factor Receptor Gene Amplification | MET Amplification | MET Gene Amplification | MET Proto-Oncogene, Receptor Tyrosine Kinase Gene Amplification | Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Gene Amplification | Positive | c-Met Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053861","VisionTree","C121652","A proprietary system designed to provide a secure cloud-based patient and provider portal system.","VisionTree | VisonTree Patient Portal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3697468","Pittsburgh Sleep Quality Index","C103849","A self-rated questionnaire which assesses sleep quality and disturbances over a one month time interval.","Pittsburgh Sleep Quality Index | PSQI | PSQI1 | Pittsburgh Sleep Quality Index | Pittsburgh Sleep Quality Index (PSQI) SF-10",,,,,,,,,,,,,,,"44783153","Pittsburgh sleep quality index",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053890","Usual Bedtime at Night","C121575","A question about an individual's usual bedtime at night.","Usual Bedtime at Night | What time have you usually gone to bed at night",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053887","Usual Time it Takes to Fall Asleep at Night","C121576","A question about the amount of time it usually takes for an individual to fall asleep at night.","Usual Time it Takes to Fall Asleep at Night | How long (in minutes) has it usually taken you to fall asleep each night | Usual Amount of Time to Fall Asleep at Night",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053888","Usual Time in Morning to Get Up","C121580","A question about an individual's usual time to get up in the morning.","Usual Time in Morning to Get Up | Usual Morning Waking Time | What time have you usually gotten up in the morning",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054766","Hours of Actual Sleep at Night","C121581","A question about an individual's hours of actual sleep at night.","Hours of Actual Sleep at Night | How many hours of actual sleep did you get at night",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053918","Trouble Sleeping, Cannot Get to Sleep Within 30 Minutes","C121584","A question about an individual's trouble sleeping because they are not able to get to sleep within 30 minutes.","Trouble Sleeping, Cannot Get to Sleep Within 30 Minutes | Have trouble sleeping because cannot get to sleep within 30 minutes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053912","Trouble Sleeping, Waking Up in the Middle of the Night or Early Morning","C121585","A question about an individual's trouble sleeping because of waking up in the middle of the night or early morning.","Trouble Sleeping, Waking Up in the Middle of the Night or Early Morning | Have trouble sleeping because of waking up in the middle of the night or early morning",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053914","Trouble Sleeping, Get Up to Use the Bathroom","C121586","A question about an individual's trouble sleeping because of getting up to use the bathroom.","Trouble Sleeping, Get Up to Use the Bathroom | Have Trouble Sleeping Because of Getting Up to Use the Bathroom | Have trouble sleeping because have to get up to use the bathroom",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053919","Trouble Sleeping, Cannot Breathe Comfortably","C121587","A question about an individual's trouble sleeping because they cannot breathe comfortably.","Trouble Sleeping, Cannot Breathe Comfortably | Have trouble sleeping because cannot breathe comfortably",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0699771","flavor perception","C121659","The distinctive taste of something as detected in the mouth and also by the nose.","Flavor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054723","Influence","C121660","The power to have an effect on people, things, or events.","Influence | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053917","Trouble Sleeping, Cough or Snoring Loudly","C121590","A question about an individual's trouble sleeping because of coughing or snoring loudly.","Trouble Sleeping, Cough or Snoring Loudly | Have Trouble Sleeping Because of Coughing or Snoring Loudly | Have trouble sleeping because of cough or snoring loudly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053916","Trouble Sleeping, Feel Too Cold","C121591","A question about an individual's trouble sleeping because of feeling too cold.","Trouble Sleeping, Feel Too Cold | Have Trouble Sleeping Because of Feeling Too Cold | Have trouble sleeping because feel too cold",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053915","Trouble Sleeping, Feel Too Hot","C121592","A question about an individual's trouble sleeping because of feeling too hot.","Trouble Sleeping, Feel Too Hot | Have Trouble Sleeping Because of Feeling Too Hot | Have trouble sleeping because feel too hot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053913","Trouble Sleeping, Having Bad Dreams","C121593","A question about an individual's trouble sleeping because of having bad dreams.","Trouble Sleeping, Having Bad Dreams | Have trouble sleeping because of having bad dreams",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053920","Trouble Sleeping Because of Pain","C121594","A question about an individual's trouble sleeping because of pain.","Trouble Sleeping Because of Pain | Have trouble sleeping because of pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053921","Trouble Sleeping Because of Other Reason","C121595","A question about an individual's trouble sleeping because of a reason not already mentioned.","Trouble Sleeping Because of Other Reason | Have trouble sleeping because of other reason",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054285","Overall Sleep Quality Rating","C121596","A question about how an individual would rate their overall sleep quality.","Overall Sleep Quality Rating | How would you rate your sleep quality overall | Overall Sleep Quality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053949","Take Medicine to Help Sleep","C121597","A question about whether an individual has taken medicine to help them sleep.","Take Medicine to Help Sleep | Have you taken medicine to help you sleep | Take Medicine to Help You Sleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054835","Have Trouble Staying Awake","C121598","A question about an individual's trouble staying awake while driving, eating meals, or engaging in social activity.","Have Trouble Staying Awake | Have Trouble Staying Awake While Driving, Eating Meals, or Engaging in Social Activity | Have you had trouble staying awake while driving, eating meals, or engaging in social activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055061","Enough Enthusiasm to Get Things Done","C121599","A question about how much of a problem it has been for an individual to keep up enough enthusiasm to get thing done.","Enough Enthusiasm to Get Things Done | How much of a problem has it been for you to keep up enough enthusiasm to get things done | Keeping Up Enough Enthusiasm to Get Things Done",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054860","Have Bed Partner Or Roommate","C121600","A question about whether an individual has a bed partner or roommate.","Have Bed Partner Or Roommate | Do you have a bed partner or room mate | Have Bed Partner or Roommate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054846","Have Loud Snoring","C121601","A question about whether an individual has loud snoring.","Have Loud Snoring | Has Loud Snoring | Have loud snoring | Snores Loudly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054847","Have Long Pauses Between Breaths While Asleep","C121602","A question about whether an individual has or had long pauses between breaths while asleep.","Have Long Pauses Between Breaths While Asleep | Have long pauses between breaths while asleep | Pauses Between Breaths While Asleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054848","Have Legs Twitching or Jerking While Asleep","C121603","A question about whether an individual has or had twitching or jerking legs while asleep.","Have Legs Twitching or Jerking While Asleep | Have legs twitching or jerking while you sleep | Legs Twitch or Jerk While Asleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054851","Have Episodes of Disorientation or Confusion During Sleep","C121605","A question about whether an individual has or had episodes of disorientation or confusion while asleep.","Have Episodes of Disorientation or Confusion During Sleep | Disoriented or Confused During Sleep | Have episodes of disorientation or confusion during sleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053807","Have Other Restlessness While Asleep","C121606","A question about whether an individual has a type of restlessness while asleep not previously mentioned.","Have Other Restlessness While Asleep | Have other restlessness while you sleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054333","Not During the Past Month","C121608","An indication that something has not occurred during the past month.","Not During the Past Month | Not during the past month",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1275808","Congenital Central Hypoventilation","C98889","A disorder characterized by hypoventilation and hypoxemia. It appears early in life and is not associated with cardiopulmonary or neuromuscular abnormalities.","Congenital Central Hypoventilation  | Central Hypoventilation Syndrome | Congenital Central Hypoventilation | Congenital Central Hypoventilation | Congenital Central Hypoventilation Syndrome",,,,,,,,,,,,,,,"319793","Congenital central hypoventilation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3845368","Less than Once a Week","C121631","An indication that something occurs or occurred less than once a week.","Less than Once a Week | Less than Once Weekly | Less than Once per Week | Less than once a week",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3845472","Once or Twice a Week","C121632","An indication that something occurs or occurred once or twice a week.","Once or Twice a Week | Once or Twice Weekly | Once or Twice per Week | Once or twice a week",,,,,,,,,,,,,,,"761038","One to two times per week",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3845469","Three or More Times a Week","C121633","An indication that something occurs or occurred three or more times a week.","Three or More Times a Week | Three or More Times Weekly | Three or More Times per Week | Three or more times a week",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055019","Fairly Good","C121634","An indication that something has a moderate degree of quality, value or worth.","Fairly Good | Fairly good",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055020","Fairly Bad","C121635","An indication that something has little quality, value or worth.","Fairly Bad | Fairly bad",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3840984","Very Bad","C121636","An indication that something has very little quality, value or worth.","Very Bad | Very bad",,,,,,,,,,,,,,,"765711","Very bad",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054320","Only Very Slight Problem","C121609","A subjective response indicating that something is a minor difficulty requiring resolution.","Only Very Slight Problem | Only a Very Slight Problem | Only very slight problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054005","Somewhat of a Problem","C121610","A subjective response indicating that something is a difficulty requiring resolution.","Somewhat of a Problem | Somewhat of a problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055624","A Very Big Problem","C121611","A subjective response indicating that something is a major difficulty requiring resolution.","A Very Big Problem | A very big problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054354","No Bed Partner or Roommate","C121612","A response indicating that an individual does not have a bed partner or roommate.","No Bed Partner or Roommate | No bed partner or room mate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054241","Partner or Roommate in Other Room","C121613","A response indicating that an individual has a partner or roommate who does not share their bedroom.","Partner or Roommate in Other Room | Partner/room mate in other room",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054242","Partner in Same Room, But Not Same Bed","C121614","A response indicating that an individual has a partner who shares their bedroom but does not share the same bed.","Partner in Same Room, But Not Same Bed | Partner in same room, but not same bed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054243","Partner in Same Bed","C121615","A response indicating that an individual has a partner who shares their bed.","Partner in Same Bed | Partner in same bed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448270","Development","C18732","Processes that involve and promote formation of more mature organs, organ systems, or organisms; general development. (NCI)","Development | Development, Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0203608","Isotope Therapy","C15470","Treatment of a disease by means of exposure of the target to radioisotopes.","Isotope Therapy | RADPHARM Therapy | Radiation, Radioisotope | Radioactive Isotope Therapy | Radioisotope Therapy | therapy, isotope, radioactive",,,,,,,,,,,,,,,"4161415","Radionuclide therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014432","Enzyme Inhibitor","C471","A pharmacological agent that inhibits the catalytic activity of an enzyme.","Enzyme Inhibitor | Enzyme Antagonist | Enzyme Inhibitor Agent | Enzyme Inhibitor Drug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029216","Organ Transplantation","C15289","The transfer of an organ, organ part, or tissue from one body to another, for the purpose of replacing the recipient's damaged or failing organ with a working one from the donor. Donors can be living, or cadaveric (dead).","Organ Transplantation | Anatomical Gift | Clinical, Transplantation, Organ | Organ Donation | Organ Donation Procedure | Organ Transplants | Organ transplant (site) | organ grafting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2718056","Growth Chart","C121663","Graphic record of the range of various physical attributes mapped against chronological age. The attributes measured vary according to an individual's age, and the accepted normal values vary within reference populations.","Growth Chart | Growth Charts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0529793","Sildenafil","C61940","An orally bioavailable pyrazolopyrimidinone derivative structurally related to zaprinast, with vasodilating and potential anti-inflammatory activities. Upon oral administration, sildenafil selectively targets and inhibits cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), thereby inhibiting the PDE5-mediated degradation of cGMP found in smooth muscle and increasing cGMP availability. This results in prolonged smooth muscle relaxation in the corpus cavernosum of the penis, thereby causing vasodilation, blood engorgement and a prolonged penile erection.  In the smooth muscle of the pulmonary vasculature, the increase in cGMP results in smooth muscle relaxation, vasodilation of the pulmonary vascular bed, relieving pulmonary hypertension and increasing blood flow in the lungs. In addition, sildenafil may reduce airway inflammation and mucus production.","Sildenafil | SILDENAFIL | sildenafil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040805","Trazodone","C29510","A synthetic triazolopyridine derivative, antidepressant and sedative Trazodone acts as a serotonin uptake inhibitor, chemically unrelated to tricyclic, tetracyclic, or other antidepressants. It is effective in patients with schizoaffective disorders; major depressive disorders; and depressive disorders associated with insomnia and anxiety. (NCI04)","Trazodone | TRAZODONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030049","Oxycodone","C29309","A semi-synthetic, morphine-like opioid alkaloid with analgesic activity. Oxycodone exerts its analgesic activity by binding to the mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids. Binding of the opiate receptor stimulates the exchange of GTP for GDP on the G-protein complex and inhibits adenylate cyclase, thereby preventing cAMP production. Subsequently, the release of nociceptive neurotransmitters, such as substance P, gamma-aminobutyric acid (GABA), dopamine, acetylcholine, and noradrenaline, is inhibited. Oxycodone also inhibits the release of vasopressin, somatostatin, insulin, and glucagon. In addition, oxycodone closes N-type voltage-gated calcium channels and opens G-protein-coupled inwardly rectifying potassium channels resulting in hyperpolarization and reduction of neuronal excitability.","Oxycodone | 4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one | OXYCODONE | Oxycodone SR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982394","TARP Gene","C88928","This gene may be involved in prostate function.","TARP Gene | TARP | TCR Gamma Alternate Reading Frame Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415205","GPNMB Gene","C113114","This gene may play a role in the regulation of cell proliferation.","GPNMB Gene | GPNMB | Glycoprotein Nmb Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1367673","MAP3K14 Gene","C24573","This gene plays a role in signal transduction and apoptosis. It is also involved in both nucleotide and protein binding.","MAP3K14 Gene | MAP3K14 | Mitogen-Activated Protein Kinase Kinase Kinase 14 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416488","ITGA5 Gene","C38956","This gene is involved in receptor signaling and plays a role in cellular adhesion.","ITGA5 Gene | ITGA5 | Integrin, Alpha 5 (Fibronectin Receptor, Alpha Polypeptide) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336648","TNFSF4 Gene","C21149","This gene is involved in T-cell regulation.","TNFSF4 Gene | TNFSF4 | Tumor Necrosis Factor (Ligand) Superfamily, Member 4 (Tax-Transcriptionally Activated Glycoprotein 1, 34kDa) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3277001","Peripheral Neuropathy","C119734","A disorder affecting the peripheral nervous system. It manifests with pain, tingling, numbness, and muscle weakness. It may be the result of physical injury, toxic substances, viral diseases, diabetes, renal failure, cancer, and drugs.","Peripheral Neuropathy | Peripheral Nerve Disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0176531","Pleural Biopsy","C51897","Removal of a portion of pleural tissue, for microscopic examination.","Pleural Biopsy | Biopsy of Pleura",,,,,,,,,,,,,,,"4021362","Biopsy of pleura",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054265","PROMIS-43 Adult Profile v2.0","C121683","A 43-item multidimensional and universal measure of health intended for use across a variety of conditions. It measures an adult patient's self-reported health status in seven domains: physical function, anxiety, depression, fatigue, sleep disturbance, pain interference, and participation in social roles.","PROMIS-43 Adult Profile v2.0 | PROMIS 43 Adult Profile v2.0 | PROMIS-43 | PROMIS-43 Profile | PROMIS-43 Profile v2.0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2963286","Ability to do Vacuuming and Yardwork","C121684","A question about the ability of an individual to do chores such as vacuuming and yardwork.","Ability to do Vacuuming and Yardwork Question | Ability to do Household Chores | Ability to do Vacuuming and Yardwork | Ability to do Vacuuming and Yardwork | Able to do Household Chores | Able to do Vacuuming and Yardwork | Are you able to do chores such as vacuuming or yard work",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2963298","Ability to Go Up and Down Stairs at a Normal Pace","C121685","A question about the ability of an individual to go up and down stairs at a normal pace.","Ability to Go Up and Down Stairs at a Normal Pace Question | Ability to Go Up and Down Stairs at a Normal Pace | Ability to Go Up and Down Stairs at a Normal Pace | Able to Go Up and Down Stairs at a Normal Pace | Are you able to go up and down stairs at a normal pace",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2963297","Ability to Walk for Fifteen Minutes","C121689","A question about the ability of an individual to go for a walk of at least fifteen minutes.","Ability to Walk for Fifteen Minutes Question | Ability to Walk for Fifteen Minutes | Ability to Walk for Fifteen Minutes | Ability to Walk for at least Fifteen Minutes | Able to Walk for Fifteen Minutes | Able to Walk for at least Fifteen Minutes | Are you able to go for a walk of at least 15 minutes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2963331","Ability to Run Errands and Shop","C121690","A question about the ability of an individual to run errands and shop.","Ability to Run Errands and Shop Question | Ability to Run Errands and Shop | Ability to Run Errands and Shop | Able to Run Errands and Shop | Are you able to run errands and shop",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053760","Current Health Limits Doing Two Hours of Physical Labor","C121691","A question about whether an individual's health now limits them in doing two hours of physical labor.","Current Health Limits Doing Two Hours of Physical Labor Question | Current Health Limits Doing Two Hours of Physical Labor | Current Health Limits Doing Two Hours of Physical Labor | Does your health now limit you in doing two hours of physical labor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2963463","Current Health Limits Doing Moderate Work Around the House","C121692","A question about whether an individual's health now limits them in doing moderate work around the house.","Current Health Limits Doing Moderate Work Around the House | Does your health now limit you in doing moderate work around the house like vacuuming, sweeping floors or carrying in groceries",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054984","Feel Fearful","C121693","A question about whether an individual feels or felt fearful.","Feel Fearful | Felt Fearful | I felt fearful",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053922","Trouble Focusing Except on Anxiety","C121694","A question about whether an individual finds or found it hard to focus on anything other than their anxiety.","Trouble Focusing Except on Anxiety | Hard to Focus | Hard to Focus Except on Anxiety | I found it hard to focus on anything other than my anxiety | Trouble Focusing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443892","Myelin-Associated Glycoprotein Antibody","C121771","An autoantibody directed against myelin-associated glycoprotein (MAG). It is associated with active demyelination in peripheral neuropathy and is detected in about 50% of patients with IgM paraproteinemia and may occur in some patients with multiple sclerosis, Guillain-Barre syndrome, chronic polyneuropathy, or myasthenia gravis.","Myelin-Associated Glycoprotein Antibody | Anti-MAG | Anti-MAG Antibody | Anti-Myelin-Associated Glycoprotein Antibody | MAG Antibody | Myelin-Associated Glycoprotein | Myelin-associated glycoprotein antibody",,,,,,,,,,,,,,,"4037220","Antibody to myelin associated glycoprotein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053842","Worries Overwhelm Me","C121695","A question about whether an individual's worries overwhelmed them.","Worries Overwhelm Me | My worries overwhelmed me | Worries Overwhelmed Me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054975","Feel Uneasy","C121696","A question about whether an individual feels or felt uneasy.","Feel Uneasy | Felt Uneasy | I felt uneasy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054981","Feel Like Help is Needed for Anxiety","C121697","A question about whether an individual feels or felt like they need help for their anxiety.","Feel Like Help is Needed for Anxiety | I felt like I needed help for my anxiety",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054973","Feel Worthless","C121698","A question about whether an individual feels or felt worthless.","Feel Worthless | Felt Worthless | I felt worthless",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL497258","Feel Helpless (question)","C121699","A question about whether an individual feels or felt helpless.","Feel Helpless | Felt Helpless | I felt helpless",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054982","Feel Hopeless","C121700","A question about whether an individual feels or felt hopeless.","Feel Hopeless | Felt Hopeless | I felt hopeless",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054980","Feel Like a Failure","C121753","A question about whether an individual feels or felt like a failure.","Feel Like a Failure | Felt Like a Failure | I felt like a failure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1688635","Feel Unhappy (question)","C121754","A question about whether an individual feels or felt unhappy.","Feel Unhappy | Felt Unhappy | I felt unhappy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054054","Run Down Feeling on Average","C121701","A question about the degree that an individual feels or felt run down on average.","Run Down Feeling on Average | How run down did you feel on average",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053716","Bothered by Fatigue on Average","C121703","A question about how much an individual is or was bothered by fatigue on average.","Bothered by Fatigue on Average | How much were you bothered by fatigue on average",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055006","Fatigue Interference with Physical Function","C121704","A question about the degree to which an individual's fatigue interferes or interfered with their physical functioning.","Fatigue Interference with Physical Function | Degree Fatigue Interfered with Physical Functioning | To what degree did your fatigue interfere with your physical functioning",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL497259","Sleep Quality (question)","C121705","A question about an individual's sleep quality.","Sleep Quality | Insomnia | Insomnia Distress | My sleep quality was",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054082","Refreshing Sleep","C121706","A question about whether an individual's sleep is or was refreshing.","Refreshing Sleep | My sleep was refreshing | Sleep Was Refreshing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL497207","Problem with Sleep","C121707","A question about whether an individual has or had a problem with their sleep.","Problem with Sleep | Have Problem with Slee | Have Problem with Sleep | I had a problem with my sleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050401","Difficulty Falling Asleep question","C121708","A question about whether an individual has or had difficulty falling asleep.","Difficulty Falling Asleep | Have Difficulty Falling Asleep | I had difficulty falling alseep. | I had difficulty falling asleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054013","Sleep is Restless","C121709","A question about whether an individual's sleep is or was restless.","Sleep is Restless | My sleep was restless | Sleep Was Restless",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053911","Try Hard to Get to Sleep","C121710","A question about whether an individual tries or tried hard to get to sleep.","Try Hard to Get to Sleep | I tried hard to get to sleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3869753","Have Trouble Doing Regular Leisure Activities with Others","C121714","A question about whether an individual has or had trouble doing all of their regular leisure activities with others.","Have Trouble Doing Regular Leisure Activities with Others | Have Trouble Doing All Regular Leisure Activities with Others | I have trouble doing all my regular leisure activities with others | Trouble Doing Regular Leisure Activities with Others",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4034918","Have Trouble Doing Regular Family Activities","C121715","A question about whether an individual has or had trouble doing all of the family activities that they want to do.","Have Trouble Doing Regular Family Activities | Have Trouble Doing All Regular Family Activities | I have trouble doing all of the family activities that I want to do | Trouble Doing Regular Family Activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4034917","Have Trouble Doing Usual Work","C121716","A question about whether an individual has or had trouble doing all of their usual work.","Have Trouble Doing Usual Work | Have Trouble Doing All Usual Work | I have trouble doing all of my usual work (include work at home) | Trouble Doing Usual Work",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4034914","Have Trouble Doing Activities with Friends","C121717","A question about whether an individual has or had trouble doing all of the activities with friends that they want to do.","Have Trouble Doing Activities with Friends | Have Trouble Doing All Activities with Friends | I have trouble doing all of the activities with friends that I want to do | Trouble Doing Activities with Friends",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4034919","Have to Limit Things Done for Fun with Others","C121718","A question about whether an individual has or had to limit the things they do for fun with others.","Have to Limit Things Done for Fun with Others | I have to limit the things I do for fun with others",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4034915","Have to Limit Regular Activities with Friends","C121722","A question about whether an individual has or had to limit their regular activities with friends.","Have to Limit Regular Activities with Friends | I have to limit my regular activities with friends",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054266","PROMIS Pain Rating Scale","C121723","A linear analogue scale for the subjective scoring of a person's average pain rating for the past seven days that ranges from 0: No pain to 10: Worst imaginable pain.","PROMIS Pain Rating Scale | PROMIS Pain Rating Linear Analogue Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054262","Pain Rating Average Score 0","C121724","A subjective score of 0 on a scale for average pain that ranges from 0: No Pain to 10: Worst imaginable pain.","Pain Rating Average Score 0 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054260","Pain Rating Average Score 1","C121725","A subjective score of 1 on a scale for average pain that ranges from 0: No Pain to 10: Worst imaginable pain.","Pain Rating Average Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054259","Pain Rating Average Score 2","C121726","A subjective score of 2 on a scale for average pain that ranges from 0: No Pain to 10: Worst imaginable pain.","Pain Rating Average Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054258","Pain Rating Average Score 3","C121728","A subjective score of 3 on a scale for average pain that ranges from 0: No Pain to 10: Worst imaginable pain.","Pain Rating Average Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053793","Pain Rating Average Score 4","C121729","A subjective score of 4 on a scale for average pain that ranges from 0: No Pain to 10: Worst imaginable pain.","Pain Rating Average Score 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054257","Pain Rating Average Score 5","C121730","A subjective score of 5 on a scale for average pain that ranges from 0: No Pain to 10: Worst imaginable pain.","Pain Rating Average Score 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054256","Pain Rating Average Score 6","C121731","A subjective score of 6 on a scale for average pain that ranges from 0: No Pain to 10: Worst imaginable pain.","Pain Rating Average Score 6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054255","Pain Rating Average Score 7","C121732","A subjective score of 7 on a scale for average pain that ranges from 0: No Pain to 10: Worst imaginable pain.","Pain Rating Average Score 7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054254","Pain Rating Average Score 8","C121733","A subjective score of 8 on a scale for average pain that ranges from 0: No Pain to 10: Worst imaginable pain.","Pain Rating Average Score 8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054253","Pain Rating Average Score 9","C121734","A subjective score of 9 on a scale for average pain that ranges from 0: No Pain to 10: Worst imaginable pain.","Pain Rating Average Score 9 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054261","Pain Rating Average Score 10","C121735","A subjective score of 10 on a scale for average pain that ranges from 0: No Pain to 10: Worst imaginable pain.","Pain Rating Average Score 10 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3842554","Can Do Without Any Difficulty","C121736","A response indicating that an individual is able to do something without any difficulty.","Can Do Without Any Difficulty | No Difficulty | No difficulty | Without Any Difficulty | Without any difficulty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3843248","Can Do With a Little Difficulty","C121737","A response indicating that an individual is able to do something with a little difficulty.","Can Do With a Little Difficulty | A Little Difficulty | A little difficulty | With a Little Difficulty | With a little difficulty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3844120","Can Do With Some Difficulty","C121739","A response indicating that an individual is able to do something with some difficulty.","Can Do With Some Difficulty | Some Difficulty | Some difficulty | With Some Difficulty | With some difficulty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3842553","Can Do With Much Difficulty","C121740","A response indicating that an individual is able to do something with much difficulty.","Can Do With Much Difficulty | Much Difficulty | Much difficulty | With Much Difficulty | With much difficulty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4048706","Unable to Do","C121742","A response indicating that an individual is unable to do something.","Unable to Do | Not Able | Not Able to Do | Not able to do | Not at All | Not at All Able | Unable To | Unable to do | unable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1299582","Unable","C121744","A response indicating that an individual cannot do something.","Cannot Do | Cannot do",,,,,,,,,,,,,,,"4159758","Unable",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3844126","Can Do Very Little","C121746","A response indicating that an individual is able to do something for the smallest amount of effort or duration of time.","Can Do Very Little | Can Do Very little | Very little",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054237","Past Seven Days Frequency of Arm or Leg Swelling","C121755","A question about the frequency of an individual's arm or leg swelling during the past seven days.","Past Seven Days Frequency of Arm or Leg Swelling | Frequency of Arm or Leg Swelling Past Seven Days | How often did you have arm or leg swelling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053835","Worst Severity Past Seven Days Arm or Leg Swelling","C121756","A question about the worst severity of an individual's arm or leg pain during the past seven days.","Worst Severity Past Seven Days Arm or Leg Swelling | What was the severity of your arm or leg swelling at its worst | Worst Severity of Arm or Leg Swelling Past Seven Days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054239","Past Seven Days Arm or Leg Swelling Interfering with Usual or Daily Activities","C121757","A question about how much an individual's arm or leg pain interfered with their usual or daily activities during the past seven days.","Past Seven Days Arm or Leg Swelling Interfering with Usual or Daily Activities | Arm or Leg Swelling Interfering with Usual or Daily Activities Past Seven Days | How much did arm or leg swelling interfere with your usual or daily activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054234","Past Seven Days Frequency of Shortness of Breath","C121758","A question about the frequency of an individual's shortness of breath during the past seven days.","Past Seven Days Frequency of Shortness of Breath | Frequency of Shortness of Breath Past Seven Days | How often did you have shortness of breath",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053830","Worst Severity Past Seven Days Shortness of Breath","C121759","A question about the worst severity of an individual's shortness of breath during the past seven days.","Worst Severity Past Seven Days Shortness of Breath | What was the severity of your shortness of breath at its worst | Worst Severity of Shortness of Breath Past Seven Days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334340","LIG4 Gene","C20565","This gene plays a critical role in the regulation of nonhomologous DNA end joining and in V(D)J recombination.","LIG4 Gene | DNA Ligase 4 Gene | LIG4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054231","Past Seven Days Shortness of Breath Interfering with Usual or Daily Activities","C121760","A question about how much an individual's shortness of breath interfered with their usual or daily activities during the past seven days.","Past Seven Days Shortness of Breath Interfering with Usual or Daily Activities | How much did your shortness of breath interfere with your usual or daily activities | Shortness of Breath Interfering with Usual or Daily Activities Past Seven Days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538115","WWP1 Gene","C98117","This gene plays a role in protein ubiquitination.","WWP1 Gene | WW Domain Containing E3 Ubiquitin Protein Ligase 1 Gene | WWP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413942","DDB2 Gene","C93075","This gene plays a role in DNA repair.","DDB2 Gene | DDB2 | Damage-Specific DNA Binding Protein 2, 48kDa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521376","4p16","C14027","A chromosome band present on 4p","4p16 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053832","Worst Severity Past Seven Days Itchy Skin","C121761","A question about the worst severity of an individual's itchy skin during the past seven days.","Worst Severity Past Seven Days Itchy Skin | What was the severity of your itchy skin at its worst | Worst Severity of Itchy Skin Past Seven Days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053834","Worst Severity Past Seven Days Cough","C121762","A question about the worst severity of an individual's cough during the past seven days.","Worst Severity Past Seven Days Cough | What was the severity of your cough at its worst | Worst Severity of Cough Past Seven Days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054238","Past Seven Days Cough Interfering with Usual or Daily Activities","C121763","A question about how much an individual's cough interfered with their usual or daily activities during the past seven days.","Past Seven Days Cough Interfering with Usual or Daily Activities | Cough Interfering with Usual or Daily Activities Past Seven Days | How much does your cough interfere with your usual or daily activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054236","Past Seven Days Frequency of Headache","C121764","A question about the frequency of an individual's headaches over the past seven days.","Past Seven Days Frequency of Headache | Frequency of Headache Past Seven Days | How often did you have a headache",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053833","Worst Severity Past Seven Days Headache","C121765","A question about an individual's observation of the worst severity they have experienced related to headache over the past seven days.","Worst Severity Past Seven Days Headache | What was the severity of your headache at its worst | Worst Severity of Headache Past Seven Days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054233","Past Seven Days Headache Interfering with Usual or Daily Activities","C121766","A question about how much an individual's headaches interfered with their usual or daily activities during the past seven days.","Past Seven Days Headache Interfering with Usual or Daily Activities | Headache Interfering with Usual or Daily Activities Past Seven Days | How Much Headache Interfered with Usual or Daily Activities | How much did your headache interfere with your usual or daily activities | Past Seven Days How Much Headache Interfered with Usual or Daily Activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054235","Past Seven Days Frequency of Pain in the Abdomen","C121767","A question about the frequency of an individual's abdominal pain during the past seven days.","Past Seven Days Frequency of Pain in the Abdomen | Frequency of Abdominal Pain Past Seven Days | Frequency of Pain in the Abdomen Past Seven Days | How often did you have pain in the abdomen (belly)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053831","Worst Severity Past Seven Days Pain in the Abdomen","C121768","A question about the worst severity of an individual's abdominal pain during the past seven days.","Worst Severity Past Seven Days Pain in the Abdomen | What was the severity of your pain in the abdomen (belly) at its worst | Worst Severity of Abdominal Pain Past Seven Days | Worst Severity of Pain in the Abdomen Past Seven Days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054232","Past Seven Days Pain in the Abdomen Interfering with Usual or Daily Activities","C121769","A question about how much an individual's abdominal pain interfered with their usual or daily activities during the past seven days.","Past Seven Days Pain in the Abdomen Interfering with Usual or Daily Activities | Abdominal Pain Interfering with Usual or Daily Activities Past Seven Days | How much did pain in the abdomen (belly) interfere with your usual or daily activities | Pain in the Abdomen Interfering with Usual or Daily Activities Past Seven Days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028125","Nitrate","C80487","A class of ester compounds of nitric acid (HNO3) and alcohols.","Nitrate | Nitrates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417752","NODAL Gene","C96043","This gene is involved in cytokine signaling and maturation.","NODAL Gene | NODAL | Nodal Growth Differentiation Factor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333567","FLT3LG Gene","C21551","This gene plays a role in the proliferation of hematopoietic progenitor cells.","FLT3LG Gene | FLT3LG | FMS-Related Tyrosine Kinase 3 Ligand Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420465","AURKC Gene","C95265","This gene is involved in protein phosphorylation and mitosis.","AURKC Gene | AURKC | Aurora Kinase C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333539","FGF8 Gene","C24392","This gene is involved in development and organogenesis.","FGF8 Gene | FGF8 | Fibroblast Growth Factor 8 (Androgen-Induced) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333535","FGF10 Gene","C24389","This gene is involved in development and wound healing. It also plays a role in cellular biogenesis, organization and proliferation.","FGF10 Gene | FGF10 | Fibroblast Growth Factor 10 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1970157","ABRAXAS1 Gene","C101797","This gene is involved in the repair of DNA double-strand breaks.","ABRAXAS1 Gene | ABRAXAS1 | Abraxas 1, BRCA1 A Complex Subunit Gene | FAM175A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3146228","HER-2/neu Intracellular Domain Protein","C2593","The cytoplasmic domain or intracellular domain (ICD) of the HER2/neu protein that exhibits tyrosine kinase activity. Based on sensitization theory, co-administration of trastuzumab (anti-HER-2/neu monoclonal antibody) and HER-2/neu intracellular domain protein may result in the potentiation of a HER2/neu-specific cytotoxic T lymphocyte (CTL) response against tumor cells overexpressing the HER2/neu protein. HER-2/neu protein, a glycoprotein cell surface receptor that is composed of an extracellular domain (ECD), a transmembrane domain, and an ICD, is overexpressed by many adenocarcinomas including breast adenocarcinoma.","HER-2/neu Intracellular Domain Protein | HER-2 ICD Peptide | HER-2/neu ICD Protein | HER2 ICD | HER2 Intracellular Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537859","MIR221 Gene","C81756","This gene is involved in the regulation of gene expression and acts as an oncogene in hepatocellular, ovarian, breast, lung, thyroid and prostate carcinomas as well as melanoma and glioblastoma multiforme.","MIR221 Gene | MIR221 | MicroRNA 221 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521561","6q21","C13521","A chromosome band present on 6q","6q21 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427539","SLAMF7 Gene","C95306","This gene is involved in the activation of natural killer cells.","SLAMF7 Gene | SLAM Family Member 7 Gene | SLAMF7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0920330","Pancreatic Enzyme","C18296","Pancreatic enzymes are comprised primarily of proteases, lipase and amylase that catalyze the breakdown of fats, carbohydrates and proteins during the digestion of food. However, the pancreas also produces many other digestive enzymes such as ribonuclease, deoxyribonuclease, gelatinase and elastase.","Pancreatic Enzyme | pancreatic enzyme",,,,,,,,,,,,,,,"40482350","Pancreatic enzyme",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2986476","Somatic","C94322","Having to do with the body.","Somatic | somatic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054141","Quality of Life Questionnaire-Brain Neoplasm 20","C121794","A questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) consisting of 20 questions designed to assess quality of life in brain cancer patients.","Quality of Life Questionnaire-Brain Neoplasm 20 | EOR04 | EORTC QLQ-BN20 | QLQ-BN20 | Quality of Life Questionnaire - Brain Neoplasm 20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054878","Had Setbacks in Condition","C121796","A question about whether an individual feels or felt that they had setbacks in their condition.","Had Setbacks in Condition | Did you feel you had setbacks in your condition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054289","Outlook on the Future Worsened","C121800","A question about whether an individual's outlook on the future has or had worsened.","Outlook on the Future Worsened | Did your outlook on the future worsen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054853","Have Double Vision","C121801","A question about whether an individual has or had double vision.","Have Double Vision | Did you have double vision",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054855","Have Difficulty Reading Because of Vision","C121803","A question about whether an individual has or had difficulty reading because of vision.","Have Difficulty Reading Because of Vision | Did you have difficulty reading because of your vision",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054831","Have Weakness on One Side of Body","C121805","A question about whether an individual has or had weakness on one side of the body.","Have Weakness on One Side of Body | Did you have weakness on one side of your body",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054854","Have Difficulty Speaking","C121806","A question about whether an individual has or had difficulty speaking.","Have Difficulty Speaking | Did you have difficulty speaking | Difficulty speaking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054837","Have Trouble Communicating Thoughts","C121807","A question about whether an individual has or had trouble communicating their thoughts.","Have Trouble Communicating Thoughts | Did you have trouble communicating your thoughts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054985","Feel Drowsy During the Daytime","C121808","A question about whether an individual feels or felt drowsy during the daytime.","Feel Drowsy During the Daytime | Did you feel drowsy during the daytime",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055352","Bothered by Itching Skin","C121809","A question about whether an individual is or was bothered by itchy skin.","Bothered by Itching Skin | Bothered by Itchy Skin | Did itching of your skin bother you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054832","Have Weakness of Both Legs","C121810","A question about whether an individual has or had weakness of both legs.","Have Weakness of Both Legs | Did you have weakness of both legs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054974","Feel Unsteady on Feet","C121811","A question about whether an individual feels or felt unsteady on their feet.","Feel Unsteady on Feet | Did you feel unsteady on your feet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054836","Have Trouble Controlling Bladder","C121812","A question about whether an individual has or had trouble controlling their bladder.","Have Trouble Controlling Bladder | Bladder Control | Did you have trouble controlling your bladder | Leaking Urine/ Poor Bladder Control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054315","Organomegaly","C121827","An abnormal enlargement of an organ, particularly an organ of the abdominal cavity.","Organomegaly | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050363","Comprehensive Score for Financial Toxicity","C121814","A patient-reported outcome measure designed specifically to evaluate the financial distress experienced by cancer patients.","Comprehensive Score for Financial Toxicity | COST | COST-FACIT | Comprehensive Score for Financial Toxicity - FACIT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054852","Have Enough Money to Cover Cost of Treatment","C121815","A question about whether an individual knows they have enough money in their savings, retirement, or assets to cover the cost of their treatment.","Have Enough Money to Cover Cost of Treatment | I know that I have enough money in savings, retirement, or assets to cover the costs of my treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054291","Out-of-Pocket Medical Expenses are More Than Expected","C121816","A question about whether an individual's out-of-pocket medical expenses are more than they thought they would be.","Out-of-Pocket Medical Expenses are More Than Expected | My out-of-pocket medical expenses are more than I thought they would be",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053839","Worry about Future Financial Problems as a Result of Illness or Treatment","C121818","A question about whether an individual worries or worried about the financial problems they will have in the future as a result of their illness or treatment.","Worry about Future Financial Problems as a Result of Illness or Treatment | I worry about the financial problems I will have in the future as a result of my illness or treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054979","Feel No Choice about Amount of Money Spent on Care","C121819","A question about whether an individual feels or felt they have no choice about the amount of money they spend on care.","Feel No Choice about Amount of Money Spent on Care | I feel I have no choice about the amount of money I spend on care",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054924","Frustrated Cannot Work or Contribute as Much as Usual","C121820","A question about whether an individual is or was frustrated that they cannot work or contribute as much as they usually do.","Frustrated Cannot Work or Contribute as Much as Usual | I am frustrated that I cannot work or contribute as much as I usually do",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054050","Satisfied with Current Financial Situation","C121821","A question about whether an individual is satisfied with their current financial situation.","Satisfied with Current Financial Situation | I am satisfied with my current financial situation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055515","Able to Meet Monthly Expenses","C121822","A question about whether an individual is able to meet their monthly expenses.","Able to Meet Monthly Expenses Question | Able to Meet Monthly Expenses | Able to Meet Monthly Expenses | I am able to meet my monthly expenses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054983","Feel Financially Stressed","C121823","A question about whether an individual feels or felt financially stressed.","Feel Financially Stressed | I feel financially stressed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055209","Concerned about Keeping Job and Income","C121824","A question about whether an individual is or was concerned about keeping their job and income, including work at home.","Concerned about Keeping Job and Income | I am concerned about keeping my job and income, including work at home",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055282","Cancer or Treatment has Reduced Satisfaction with Present Financial Situation","C121825","A question about whether cancer or treatment has reduced an individual's satisfaction with their present financial situation.","Cancer or Treatment has Reduced Satisfaction with Present Financial Situation | My cancer or treatment has reduced my satisfaction with my present financial situation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054972","Feel in Control of Financial Situation","C121826","A question about whether an individual feels or felt in control of their financial situation.","Feel in Control of Financial Situation | I feel in control of my financial situation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4014978","Esophageal Varices","C53506","Abnormally dilated veins of the esophagus.","Esophageal Varices | Esophageal Varix",,,,,,,,,,,,,,,"24966","Esophageal varices",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266129","Atypical Lipomatous Tumor/Well Differentiated Liposarcoma","C6505","A locally aggressive mesenchymal neoplasm composed either entirely or partly of an adipocytic proliferation showing at least focal nuclear atypia in both adipocytes and stromal cells. 'Atypical lipomatous tumor' and 'well-differentiated liposarcoma' are synonyms describing lesions that are morphologically and genetically identical. Amplification of MDM2 and/or CDK4 is almost always present. (WHO 2020)","Atypical Lipomatous Tumor/Well Differentiated Liposarcoma | ALT | ALT/WDLPS | Atypical Lipoma | Atypical Lipomatous Tumor | Atypical Lipomatous Tumor | Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma | Atypical lipoma | Liposarcoma, differentiated | Liposarcoma, well differentiated | Well Differentiated Liposarcoma | Well-Differentiated Liposarcoma",,,,,,,,,,,,,,,"4021372","Atypical lipomatous tumor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205822","Hibernoma","C3702","A rare benign slow growing adipose tissue tumor, characterized by the presence of polygonal brown fat cells with multivacuolated and/or granular cytoplasm.  The tumor is usually painless and is most often seen in young adults.","Hibernoma | Brown Fat Neoplasm | Brown Fat Tumor | Brown fat tumor | Fetal Fat Cell Lipoma | Fetal fat cell lipoma | HIBERNOMA, BENIGN","8880/0","Hibernoma",,,,,,,,,,,,,"4298677|4301651","Hibernoma|Hibernoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0206632","Angiolipoma","C3733","A lipoma with prominent vascularity. The vascular tissue is more abundant at the periphery of the tumor and contains fibrin thrombi. It occurs more frequently in younger individuals as a painful subcutaneous nodule, often on the arms.","Angiolipoma | ANGIOLIPOMA, BENIGN | Angiolipoma, NOS","8861/0","Angiolipoma, NOS",,,,,,,,,,,,,"4250341|4298236","Angiolipoma|Angiolipoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1266131","Chondroid Lipoma","C6503","A rare benign adipose tissue neoplasm characterized by nests and cord of abundant univacuolated and multivacuolated lipoblasts and mature adipocytes in a prominent myxoid to hyalinized chondroid matrix admix. It predominantly affects females.","Chondroid Lipoma | Chondroid lipoma","8862/0","Chondroid lipoma",,,,,,,,,,,,,"4029022|4298237","Chondroid lipoma|Chondroid lipoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1260965","Lipoblastoma","C27483","A lipoma usually occurring in the extremities of young children (usually boys). It is characterized by lobules of adipose tissue, separated by fibrous septa.  The adipose tissue is composed of mature adipocytes and lipoblasts. The lipoblasts may be scarce, depending on the age of the patient.","Lipoblastoma | Embryonic Lipoma | Fetal Lipoma | Infantile Lipoma",,,,,,,,,,,,,,,"4272185|4290972","Lipoblastomatosis|Lipoblastoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0334475","Lipoblastomatosis","C4255","A neoplastic process characterized by the presence of multiple lipoblastomas.","Lipoblastomatosis | Fetal Lipomatosis | Fetal lipomatosis","8881/0","Lipoblastomatosis",,,,,,,,,,,,,"4271025|4272185","Lipoblastomatosis|Lipoblastomatosis",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C2931642","Lipomatosis","C3193","A neoplastic process characterized by diffuse overgrowth of mature adipose tissue.","Lipomatosis | Launois-Bensaude Syndrome | Madelung Disease | Madelung's Disease",,,,,,,,,,,,,,,"4290348|4292547","Lipomatosis|Lipomatosis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1335389","Lipomatosis of Nerve","C5431","A tumor composed of mature adipocytes and fibrous tissue infiltrating the epineurium and peripheral nerves.  It is often seen at birth or during childhood and may be associated with macrodactyly.","Lipomatosis of Nerve | Fibrolipomatous Hamartoma of Peripheral Nerve | Neural Fibrolipoma | Peripheral Nerve Fibrolipomatous Hamartoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1096309","Myolipoma","C9502","A benign extrauterine tumor composed of mature adipocytes and smooth muscle cells.","Myolipoma | Extrauterine Lipoleiomyoma | Myolipoma of Soft Tissue",,,,,,,,,,,,,,,"4300685|4330059","Myolipoma|Myolipoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1336053","Spindle Cell/Pleomorphic Lipoma","C7180","A benign lipomatous neoplasm characterized by the presence of an admixture of mature adipose tissue and bland spindle cells.  The pleomorphic variant contains in addition multinucleated giant cells.  It usually arises in the neck and upper trunk in older males.","Spindle Cell/Pleomorphic Lipoma | SCL/PL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002992","Angiomatosis","C27503","A benign diffuse vascular proliferation usually occurring in young adults. It is characterized by the formation of capillary-sized and cavernous vascular spaces. Patients present with diffuse persistent swelling.","Angiomatosis | Diffuse Angiomatosis | Diffuse Hemangioma | Multiple Hemangiomas",,,,,,,,,,,,,,,"4006951|4030709","Angiomatosis|Angiomatosis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0334532","Venous Hemangioma","C4296","A hemangioma composed of veins.","Venous Hemangioma | Venous Angioma | Venous Malformation | Venous hemangioma","9122/0","Venous hemangioma",,,,,,,,,,,,,"4211103|4300577","Venous hemangioma|Venous hemangioma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1336546","Synovial Hemangioma","C6525","A rare hemangioma arising from synovium lining surfaces.","Synovial Hemangioma | Angioma of Synovium | Angioma of the Synovium | Hemangioma of Synovium | Hemangioma of the Synovium | Synovial Angioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206653","Angioleiomyoma","C3747","A benign, slow-growing neoplasm that arises from the dermis or subcutaneous tissue. It is characterized by the presence of well-differentiated smooth muscle cells which are arranged around numerous vessels.","Angioleiomyoma | Angiomyoma | Vascular Leiomyoma | Vascular leiomyoma",,,,,,,,,,,,,,,"4336682","Angiomyoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1302808","Myopericytoma","C50401","A usually slow growing, subcutaneous nodular neoplasm arising from myopericytes.  It is composed of myoid cells arranged in a perivascular growth pattern.  The vast majority of cases have a benign clinical course.","Myopericytoma | Hemangiopericytoma | MPC | Solitary Myofibroma",,,,,,,,,,,,,,,"4290967|608279","Myopericytoma|Myopericytoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1333824","Glomangiomatosis","C27496","A benign multifocal proliferation of glomus cells forming clusters around dilated vascular spaces.","Glomangiomatosis | ",,,,,,,,,,,,,,,"45766446","Glomangiomatosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333266","Deep Leiomyoma","C6512","A rare benign smooth muscle neoplasm arising from deep tissue. It is characterized by the presence of spindle cells with cigar-shaped nuclei, interlacing fascicles, and a whorled pattern.","Deep Leiomyoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334553","Giant Cell Tumor of Soft Tissue","C49107","A painless, well circumscribed tumor arising in soft tissue, usually of the upper and lower extremities. Morphologically, it is characterized by a multinodular growth pattern. The cellular infiltrate is composed of mononuclear round or oval cells and multinucleated osteoclast-like giant cells, in a rich vascular stroma.  It rarely metastasizes.","Giant Cell Tumor of Soft Tissue | GCT-ST | Giant Cell Tumor of Low Malignant Potential | Giant cell tumor of soft parts, NOS | Osteoclastoma of Soft Tissue","9251/1","Giant cell tumor of soft parts, NOS",,,,,,,,,,,,,"4218898","Giant cell tumor of soft parts",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1266126","Plexiform Fibrohistiocytic Tumor","C6493","An intermediate fibrohistiocytic neoplasm of the skin that usually affects children and young adults. It is a multinodular, poorly circumscribed tumor characterized by the presence of multinucleated giant cells, mononuclear histiocyte-like cells, and spindle fibroblast-like cells arranged in a plexiform pattern.","Plexiform Fibrohistiocytic Tumor | PFHT | Plexiform Fibrohistiocytic Neoplasm | Plexiform fibrohistiocytic tumor","8835/1","Plexiform fibrohistiocytic tumor",,,,,,,,,,,,,"4029525","Plexiform fibrohistiocytic tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1266125","Deep Fibrous Histiocytoma","C6492","A rare, well-circumscribed, pseudo-encapsulated benign fibrous histiocytoma that arises entirely within the subcutaneous tissue or deep soft tissue.  It usually affects the extremities or the head and neck region.  It recurs locally in a minority of cases.","Deep Fibrous Histiocytoma | Benign Deep Fibrous Histiocytoma | Deep Benign Fibrous Histiocytoma | Deep Benign Fibrous Histiocytoma",,,,,,,,,,,,,,,"4028564|607923","Deep histiocytoma|Juvenile histiocytoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0039106","Tenosynovial Giant Cell Tumor, Diffuse Type","C3401","A locally aggressive, diffusely infiltrating tumor, arising in the tendon sheath.  It is composed of synovial-like mononuclear cells, hemosiderin-laden macrophages, foam cells, and inflammatory cells.  Multinucleated osteoclast-like giant cells are usually present, although in a minority of cases they may be absent or rare.  It predominantly affects young adults.  Symptoms include joint swelling, pain, and joint effusion.","Tenosynovial Giant Cell Tumor, Diffuse Type | Diffuse Giant Cell Neoplasm of Tendon Sheath | Diffuse Giant Cell Neoplasm of Tenosynovium | Diffuse Giant Cell Neoplasm of the Tenosynovium | Diffuse Giant Cell Tumor of Tendon Sheath | Diffuse Giant Cell Tumor of Tenosynovium | Diffuse Giant Cell Tumor of the Tenosynovium | Diffuse Tenosynovial Giant Cell Neoplasm | Diffuse Tenosynovial Giant Cell Tumor | Pigmented Villonodular Synovitis",,,,,,,,,,,,,,,"45766525|81382","Tenosynovial giant cell tumor, diffuse|Pigmented villonodular synovitis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1318543","Giant Cell Tumor of Tendon Sheath","C3402","A tumor usually arising in the synovium of joints, bursa or tendon sheath. It is characterized by the presence of mononuclear cells, multinucleated osteoclast-like giant cells, hemosiderin-laden macrophages, foam cells, and an inflammatory infiltrate. According to the growth pattern, it is classified as localized or diffuse.","Tenosynovial Giant Cell Tumor | Fibrous Histiocytoma of Tendon Sheath | Fibrous histiocytoma of tendon sheath | Giant Cell Neoplasm of Tendon Sheath | Giant Cell Neoplasm of Tenosynovium | Giant Cell Neoplasm of the Tenosynovium | Giant Cell Tumor of Tendon Sheath | Giant Cell Tumor of Tendon Sheath | Giant Cell Tumor of Tenosynovium | Giant Cell Tumor of the Tenosynovium | Giant cell tumor of tendon sheath | Tendon Sheath Giant Cell Neoplasm | Tendon Sheath Giant Cell Tumor | Tenosynovial Giant Cell Neoplasm | Tenosynovial giant cell tumor",,,,,,,,,,,,,,,"4030140|436200","Tenosynovial giant cell tumor|Nodular tenosynovitis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL324520","Adult Fibrosarcoma","C7809","A malignant mesenchymal neoplasm composed of fibroblasts.  It is characterized by collagen production and a herringbone architectural pattern.  It is more commonly seen in middle-aged and older adults.  It usually affects the deep soft tissues of extremities, trunk, head and neck.  Adult fibrosarcomas may recur and metastasize to the lungs and bones.","Adult Fibrosarcoma | Fibrosarcoma | Fibrosarcoma (excluding infantile fibrosarcoma) | Fibrosarcoma - not infantile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334464","Pigmented Dermatofibrosarcoma Protuberans","C9430","A morphologic variant of dermatofibrosarcoma protuberans characterized by the presence of melanin-pigmented dendritic cells.","Pigmented Dermatofibrosarcoma Protuberans | Bednar Tumor | Bednar tumor | Pigmented DFSP | Pigmented Dermatofibrosarcoma Protuberans (Bednar Tumor) | Pigmented dermatofibrosarcoma protuberans",,,,,,,,,,,,,,,"4266824","Pigmented dermatofibrosarcoma protuberans",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3665732","Fibrosarcomatous Dermatofibrosarcoma Protuberans","C27547","A morphologic variant of dermatofibrosarcoma protuberans characterized by the presence of a fibrosarcomatous component.","Fibrosarcomatous Dermatofibrosarcoma Protuberans | Fibrosarcomatous DFSP | Fibrosarcomatous dermatofibrosarcoma protuberans",,,,,,,,,,,,,,,"37117782","Fibrosarcomatous dermatofibrosarcoma protuberans",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3274592","Lipofibromatosis","C99180","A rare, slow-growing, painless tumor of infancy and early childhood that usually affects the distal extremities. It is characterized by the presence of alternating bands of mature adipose tissue and spindle-cell fibrous tissue, without destruction of the adipose tissue architecture. It does not metastasize, however the rate of local recurrences is high.","Lipofibromatosis | Infantile Fibromatosis, Non-Desmoid Type",,,,,,,,,,,,,,,"45766468","Lipofibromatosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332833","Calcifying Fibrous Tumor","C6488","A benign well-circumscribed lesion arising from the soft tissues. It is characterized by the presence of fibroblasts, lymphoplasmacytic infiltrates, collagenous stroma formation, psammoma bodies, and dystrophic calcifications.","Calcifying Fibrous Tumor | CFT | Calcifying Fibrous Pseudotumor",,,,,,,,,,,,,,,"45773101","Calcifying fibrous tumor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708187","Gardner Fibroma","C49017","An uncommon, poorly circumscribed, benign neoplasm arising in the soft tissues of infants, children and adolescents. It is characterized by the presence of haphazardly arranged spindle-shaped fibroblasts, collagenous stroma formation, and plaque-like growth pattern. There is a strong genetic component associating the neoplasm with Gardner syndrome and deep fibromatosis/desmoid tumor.","Gardner Fibroma | Desmoid Precursor Lesion | Gardner's Fibroma | Gardner-Associated Fibroma",,,,,,,,,,,,,,,"45766449","Gardner fibroma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1532393","Nuchal-Type Fibroma","C6486","A rare non-encapsulated and poorly circumscribed tumor that usually arises from the posterior neck and is characterized by the presence of thick collagen fibers. It is seen more frequently in men. It may recur but does not metastasize.","Nuchal-Type Fibroma | Nuchal Fibroma",,,,,,,,,,,,,,,"4189655","Nuchal-type fibroma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1367534","Cellular Angiofibroma","C27257","A benign mesenchymal neoplasm that usually arises in the superficial soft tissues of the vulva or inguinal and scrotal regions.  It is characterized by the presence of a cellular fibroblastic proliferation in an edematous to fibrous stroma containing numerous vessels.","Cellular Angiofibroma | Cellular angiofibroma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266123","Angiomyofibroblastoma","C49016","A benign myofibroblastic neoplasm, usually arising in the pelviperineal region. It is characterized by the presence of neoplastic spindle to round cells, dilated thin walled vessels, and stromal edema.  Most patients present with painless circumscribed masses.","Angiomyofibroblastoma | ","8826/0","Angiomyofibroblastoma",,,,,,,,,,,,,"4029523","Angiomyofibroblastoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0553647","Calcifying Aponeurotic Fibroma","C4818","A rare slow-growing benign neoplasm arising from the soft tissues in children. It is a poorly circumscribed tumor characterized by the presence of chondrocyte-like cells, nodular calcification, nuclear palisading, and in some cases osteoclastic giant cells.","Calcifying Aponeurotic Fibroma | Aponeurotic Fibroma | CAF | Juvenile Aponeurotic Fibrosis",,,,,,,,,,,,,,,"45766453|45771360","Calcifying aponeurotic fibroma|Calcifying aponeurotic fibroma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C4054575","Mammary-Type Myofibroblastoma","C121181","A benign mesenchymal neoplasm characterized by the presence of spindle shaped myofibroblasts and mast cells in a collagenous stroma.  It is histologically identical to the myofibroblastoma of breast.  It usually arises from the subcutaneous tissue and the most common sites of involvement are the inguinal/groin, paratesticular, and vulvovaginal areas.","Mammary-Type Myofibroblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1300346","Desmoplastic Fibroblastoma","C27515","A rare benign soft tissue neoplasm characterized by the presence of an abundant collagenous or myxocollagenous matrix, spindle-shaped, and stellate-shaped fibroblasts.  It usually presents as an asymptomatic, slowly growing subcutaneous mass. The most common sites of involvement are the upper arm, shoulder, and lower limb.","Desmoplastic Fibroblastoma | Collagenous Fibroma | Collagenous Fibroma | Desmoplastic Fibroblastoma","8823/0","Sclerotic fibroma",,,,,,,,,,,,,"4189236","Desmoplastic fibroblastoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1318562","Inclusion Body Fibromatosis","C3456","A benign myofibroblastic neoplasm that affects young children and is characterized by the presence of neoplastic spindle cells and intracytoplasmic eosinophilic spherical inclusions. It arises from the soft tissues of the digits or extradigital areas including the extremities, breasts, and tongue.","Inclusion Body Fibromatosis | Digital Fibrous Tumor of Reye | Infantile Digital Fibroma/Fibromatosis | Infantile Digital Fibromatosis | Reye Tumor | Reye's Tumor",,,,,,,,,,,,,,,"4266642","Infantile digital fibromatosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2745948","Juvenile Hyaline Fibromatosis","C98297","A non-neoplastic connective and soft tissue disorder that usually affects infants. It is characterized by the deposition of extracellular hyaline material in the skin, soft tissues and bones. This results in the development of tumor-like masses. Surgical excision is the treatment of choice, however, local recurrences are common.","Juvenile Hyaline Fibromatosis | Hyaline Fibromatosis Syndrome | Infantile Systemic Hyalinosis",,,,,,,,,,,,,,,"4033881","Juvenile hyaline fibromatosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0549175","Fibromatosis Colli","C4811","A congenital benign lesion that occurs in the distal sternocleidomastoid muscle of infants. It is characterized by the presence of plump spindle cells, and collagenous stroma formation.","Fibromatosis Colli | Congenital Muscular Torticollis",,,,,,,,,,,,,,,"4033883","Fibromatosis colli",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265979","Fibrous Hamartoma of Infancy","C3942","A poorly circumscribed neoplasm arising from the soft tissues in infants. It is characterized by the presence of bland fibroblastic spindle cells, collagenous stroma formation, primitive mesenchymal round cells, and mature fat cells. These components combined form a distinct organoid pattern.","Fibrous Hamartoma of Infancy | Fibrous Hamartoma | Infantile Fibrous Hamartoma",,,,,,,,,,,,,,,"4210596","Fibrous hamartoma of infancy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1304514","Ischemic Fasciitis","C6483","A reactive, painless lesion which is characterized by a pseudosarcomatous proliferation of fibroblasts and myofibroblasts usually in the deep subcutaneous tissue. It occurs mainly around the limb girdles, sacral region, and greater trochanter.  It affects mainly elderly patients and sometimes is associated with physical immobility. Local excision is usually curative.","Ischemic Fasciitis | Atypical Decubital Fibroplasia",,,,,,,,,,,,,,,"4301525","Ischemic fasciitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333612","Fibroosseous Digital Pseudotumor","C6573","A self-limited benign neoplasm composed of spindle cells and osteoblasts. It usually occurs in the subcutaneous tissue of the proximal phalanx. Less frequently, it involves the toe. It presents with swelling and pain of the affected area. The prognosis is excellent. However, incomplete excision may lead to the re-growth of the lesion.","Fibroosseous Pseudotumor of Digits | FOPD | FOT | FP | FPD | Fibroosseous Digital Pseudotumor | Fibroosseous Pseudotumor of the Digits | Fibroosseous Pseudotumor of the Digits | Fibroosseous Tumor of Digits",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0544796","Proliferative Myositis","C121154","A rapidly growing, poorly circumscribed, mass-forming proliferation that arises from the skeletal muscle. It is characterized by the presence of spindle-shaped fibroblasts, round ganglion-like cells, myxoid to collagenous stroma formation, and high mitotic activity. It recurs only rarely following local excision and does not metastasize.","Proliferative Myositis | ",,,,,,,,,,,,,,,"4031115","Proliferative myositis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043119","Werner Syndrome","C3447","A rare, autosomal recessive syndrome caused by mutations in the WRN gene. It is characterized by the appearance of accelerated aging following puberty. It is associated with the development of diabetes mellitus, atherosclerosis, cataracts, and cancer.","Werner Syndrome | Adult Progeria | WS | Werner syndrome | Werner's Syndrome | adult progeria",,,,,,,,,,,,,,,"4197821","Werner syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0751483","Hereditary Retinoblastoma","C8495","An inherited malignant tumor that originates in the nuclear layer of the retina. A predisposition to retinoblastoma has been associated with 13q14 cytogenetic abnormalities affecting the RB1 gene. Patients with the inherited form appear to be at increased risk for secondary non-ocular malignancies such as osteosarcoma, malignant fibrous histiocytoma, and fibrosarcoma.","Hereditary Retinoblastoma | Familial Retinoblastoma | Retinoblastoma Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024454","Maffucci Syndrome","C3213","A rare non-inherited disorder primarily affecting the skin and skeletal system. It is classified as a mesodermal dysplasia. Clinical signs appear within the first decade and are characterized by multiple soft tissue hemiangiomas and enchondromas leading to skeletal deformities. Clinical course is progressive with variable development of associated malignancies.","Maffucci Syndrome | Chondrodysplasia with Hemangioma | Chondroplasia Angiomatosis | Dyschondroplasia and Cavernous Hemangioma | Enchondromatosis with Hemangiomata | Hemangiomata with Dyschondroplasia | Maffucci's Anomalad",,,,,,,,,,,,,,,"4187683","Maffucci syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706921","Fibrous Histiocytoma of Bone","C53963","A rare, benign neoplasm usually arising from the non-metaphyseal regions of long bones or pelvis. It is characterized by the presence of fibroblastic spindle cells arranged in a whorled storiform pattern, osteoclast-like giant cells, foam cells, inflammatory cells, hemosiderin deposition and stromal hemorrhage.","Fibrous Histiocytoma of Bone | Benign Fibrous Histiocytoma of Bone | Benign Fibrous Histiocytoma of Bone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4048303","Osteoclastic Giant Cell-Rich Tumor of Bone","C3738","A benign, intermediate, or malignant bone tumor characterized by the presence of osteoclast-like giant cells. Clinical presentation includes pain, edema, and decreased range of motion in the affected joint.","Osteoclastic Giant Cell-Rich Tumor of Bone | Giant Cell Tumor of Bone | Osteoclastic Giant Cell-Rich Tumor of the Bone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704328","Osteoblastic Osteosarcoma","C53953","A conventional osteosarcoma characterized by the predominance of osteoid matrix.","Osteoblastic Osteosarcoma | Osteoblastic sarcoma",,,,,,,,,,,,,,,"37152049","Osteosarcoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0279602","Fibroblastic Osteosarcoma","C4020","A conventional osteosarcoma characterized by the presence of spindle shaped cells.","Fibroblastic Osteosarcoma | FIBROSARCOMA, OSTEOGENIC, MALIGNANT | Fibroblastic Osteogenic Sarcoma | Fibroblastic osteosarcoma | Fibrosarcomatous Osteogenic Sarcoma | Fibrosarcomatous Osteosarcoma | Osteogenic Fibrosarcoma","9182/3","Fibroblastic osteosarcoma",,,,,,,,,,,,,"4130530","Fibroblastic osteosarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0279603","Chondroblastic Osteosarcoma","C4021","An osteosarcoma characterised by the presence of atypical cartilage of variable cellularity.  It may or may not be associated with the presence of myxoid areas or focal bone formation.","Chondroblastic Osteosarcoma | Chondroblastic Osteogenic Sarcoma | Chondroblastic osteosarcoma","9181/3","Chondroblastic osteosarcoma",,,,,,,,,,,,,"4296312","Chondroblastic osteosarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0029440","Osteoma","C3296","A benign, well-circumscribed bone-forming neoplasm predominantly composed of lamellar bone. It usually arises from the calvarial, facial, or jaw bones.  It is usually asymptomatic but it may cause local swelling or obstruction of the paranasal sinuses.  Asymptomatic cases have an indolent clinical course.","Osteoma | OSTEOMA, BENIGN | Osteoma, NOS","9180/0","Osteoma, NOS",,,,,,,,,,,,,"4116204","Osteoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1337014","Atypical Cartilaginous Tumor/Grade I Chondrosarcoma","C9027","A low-grade chondrosarcoma characterized by the presence of moderate cellularity, hyperchromatic and plump nuclei of uniform size, and occasional binucleated cells.  Mitotic figures are absent.","Atypical Cartilaginous Tumor/Chondrosarcoma, Grade 1 | ACT/CS1 | Atypical Cartilaginous Tumor/Grade I Chondrosarcoma | Grade I Chondrosarcoma | Well Differentiated Chondrosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008476","Synovial Chondromatosis","C34467","An uncommon, benign cartilaginous neoplasm usually occurring in adults.  The nodular tumor arises from the synovial membranes of joints.  It is characterized by the presence of chondrocytes, nuclear pleomorphism, and hyaline cartilage differentiation.  Clinical presentation may include joint pain, swelling, and limited range of motion.","Synovial Chondromatosis | Henderson-Jones Syndrome | Reichel Syndrome | Reichel's Syndrome",,,,,,,,,,,,,,,"4347303","Synovial chondromatosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4076530","Periosteal Chondroma","C4302","A benign neoplasm of bone surface composed of hyaline cartilage.  It arises beneath the periosteum and is characterized by the presence of chondrocytes, a lobulated growth pattern, and calcification.","Periosteal Chondroma | Juxtacortical Chondroma | Juxtacortical chondroma | Periosteal chondroma",,,,,,,,,,,,,,,"4243890","Juxtacortical chondroma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704356","Enchondroma","C3007","A common benign hyaline cartilage neoplasm arising in the intramedullary bone.  It is characterized by the presence of chondrocytes, low mitotic activity, and in some cases, a nodular pattern and calcification. The small bones of the hands and feet are the most frequently affected sites.","Enchondroma | Central Chondroma | enchondroma",,,,,,,,,,,,,,,"4313772","Enchondroma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0936248","Chondroma","C53459","A benign well circumscribed neoplasm of hyaline cartilage arising from bone or soft tissue. It is characterized by the presence of chondrocytes.","Chondroma | CHONDROMA, BENIGN | Chondroma, NOS","9220/0","Chondroma, NOS",,,,,,,,,,,,,"4149908","Chondroma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1300127","PEComa","C38150","A soft tissue mesenchymal tumor with perivascular epithelioid cell differentiation. Representative examples include angiomyolipoma, clear cell-sugar-tumor of the lung, and lymphangioleiomyomatosis.","PEComa | Neoplasm with Perivascular Epithelioid Cell Differentiation | Neoplasm with Perivascular Epithelioid Cell Differentiation | Tumor with Perivascular Epithelioid Cell Differentiation",,,,,,,,,,,,,,,"4304780","Perivascular epithelioid cell tumor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334505","Spindle Cell Synovial Sarcoma","C4277","A synovial sarcoma characterized by the presence of a spindle cell component only.","Spindle Cell Synovial Sarcoma | Synovial Sarcoma with Spindle Cell Components | Synovial sarcoma, spindle cell","9041/3","Synovial sarcoma, spindle cell",,,,,,,,,,,,,"4289992","Synovial sarcoma, spindle cell",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1831619","Phosphaturic Mesenchymal Tumor","C67237","An extremely rare, benign or malignant mesenchymal tumor arising from soft tissue or bone. It is a distinctive tumor, usually displaying the following morphologic characteristics: low cellularity, myxoid changes, presence of spindled cells and osteoclasts, hemangiopericytoma-like vessels, hemorrhage, and osteoid-like matrix. It is associated with the presence of a paraneoplastic syndrome called oncogenic osteomalacia. This syndrome usually precedes the appearance of the tumor, and it is characterized by phosphaturia, hypophosphatemia, normal serum calcium levels, and decreased levels of 1,25-dihydroxyvitamin D3. Patients present with bone and muscle pain, severe muscle weakness, fractures, gait disturbances, skeletal deformity, height loss, and slow growth. The metabolic disturbances improve or completely disappear after the complete resection of the tumor.","Phosphaturic Mesenchymal Tumor | PMT | Phosphaturic Mesenchymal Tumor, Mixed Connective Tissue Type | Phosphaturic Mesenchymal Tumor, Mixed Connective Tissue Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027070","Myoepithelial Tumor","C40392","A benign or malignant tumor characterized by the presence of cells that show myoepithelial differentiation. Based on its morphologic features, it is classified as benign or malignant. A representative example of benign myoepithelioma is benign salivary gland myoepithelioma. Representative examples of malignant myoepithelioma or myoepithelial carcinoma are malignant breast myoepithelioma and salivary gland myoepithelial carcinoma.","Myoepithelial Tumor | Myoepithelial Neoplasm | Myoepithelial Neoplasm | Myoepithelial Tumor of Soft Tissue | Myoepithelial tumor | Myoepithelioma",,,,,,,,,,,,,,,"4239519","Myoepithelioma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206625","Malignant Mixed Neoplasm","C3729","A malignant neoplasm composed of a carcinomatous epithelial component and a sarcomatous mesenchymal component. Representative examples include malignant mixed mesodermal (Mullerian) tumor of the female reproductive system and carcinosarcoma of the salivary gland and the lung.","Malignant Mixed Neoplasm | Malignant Mixed Tumor | Mixed tumor, malignant, NOS | TUMOR, MIXED, MALIGNANT","8940/3","Mixed tumor, malignant, NOS",,,,,,,,,,,,,"4216834","Mixed tumor, malignant",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1266127","Angiomatoid Fibrous Histiocytoma","C6494","A low malignant potential soft tissue neoplasm of uncertain differentiation.  It typically affects young patients, presenting as a slowly growing nodular or cystic tumor mass, most often in the subcutaneous tissues of the extremities.  Occasionally, patients have systemic symptoms (anemia, fever, and weight loss).  This tumor has a relatively good prognosis.  A minority of patients develop local recurrences.  Metastases are rare.","Angiomatoid Fibrous Histiocytoma | AFH | Angiomatoid Malignant Fibrous Histiocytoma | Angiomatoid fibrous histiocytoma","8836/1","Angiomatoid fibrous histiocytoma",,,,,,,,,,,,,"4029526","Angiomatoid fibrous histiocytoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1266098","Branchioma","C53595","A rare, benign, well-circumscribed or encapsulated tumor that arises from the neck and occurs in adults. It is characterized by the presence of spindle cells, epithelial islands, and adipose tissue.","Branchioma | Biphenotypic Branchioma | Branchial Anlage Mixed Tumor | Ectopic Hamartomatous Thymoma | Ectopic Hamartomatous Thymoma | Ectopic hamartomatous thymoma | Neck Branchioma","8587/0","Ectopic hamartomatous thymoma",,,,,,,,,,,,,"4029519","Ectopic hamartomatous thymoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1709569","Pleomorphic Hyalinizing Angiectatic Tumor of Soft Parts","C53594","A non-metastasizing soft tissue neoplasm characterized by the presence of a neoplastic stroma containing spindle cells, dilated thin-walled vessels lined by fibrin, and a chronic inflammatory infiltrate.  The majority of cases develop in the subcutaneous tissues usually in the lower extremities and present as slow growing masses.  Recurrences occur in approximately half of the cases.","Pleomorphic Hyalinizing Angiectatic Tumor of Soft Parts | Early Pleomorphic Hyalinizing Angiectatic Tumor | PHAT","8802/1","Pleomorphic hyalinizing angiectatic tumor",,,,,,,,,,,,,"36715025","Pleomorphic hyalinizing angiectatic tumor of soft tissue",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1306242","Deep (Aggressive) Angiomyxoma","C6936","A locally infiltrating, non-metastasizing angiomyxoma arising from the pelviperineal region.  It may recur following resection","Deep (Aggressive) Angiomyxoma | Aggressive Angiomyxoma | Aggressive angiomyxoma | Deep 'Aggressive' Angiomyxoma | Deep 'Aggressive' Angiomyxoma | Deep Angiomyxoma",,,,,,,,,,,,,,,"4299131","Aggressive angiomyxoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334305","Juxta-Articular Myxoma","C6580","A rare myxoma that usually arises in an area close to a large joint.  Morphologically it resembles a cellular myxoma.  In contrast to an intramuscular myxoma, it is not associated with mutations of the GNAS gene.","Juxta-Articular Myxoma | Juxtaarticular Myxoma | Parameniscal Cyst | Periarticular Myxoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334260","Intramuscular Myxoma","C6579","A benign, painless soft tissue tumor that arises in a muscle, usually in a large muscle of the thigh, buttocks, shoulder, or upper arm.  It is associated with point mutations of the GNAS gene.  Grossly it is characterized by a gelatinous and lobulated cut surface.  Morphologically it is composed of uniform spindled and stellate-shaped cells without atypia.  The cells are separated by myxoid stroma.  No recurrences have been reported.","Intramuscular Myxoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334618","Malignant Granular Cell Tumor","C4336","An uncommon granular cell tumor which may metastasize to other anatomic sites. Morphologic characteristics include the presence of spindling neoplastic cells, necrosis, extensive pleomorphism, prominent nucleoli, and increased mitiotic activity.","Malignant Granular Cell Tumor | GRANULAR CELL TUMOR, MALIGNANT | Granular cell myoblastoma, malignant | Granular cell tumor, malignant | Malignant Granular Cell Myoblastoma | Malignant Granular Cell Neoplasm | Myoblastoma, Malignant","9580/3","Granular cell tumor, malignant",,,,,,,,,,,,,"4027842|4298154","Granular cell tumor, malignant|Malignant granular cell tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0334616","Malignant Triton Tumor","C4335","A malignant peripheral nerve sheath tumor which shows rhabdomyosarcomatous differentiation. More than half of the patients have neurofibromatosis type 1. The prognosis is usually poor.","Malignant Triton Tumor | MPNST with Rhabdomyosarcoma | Malignant Neoplasm of Peripheral Nerve Sheath with Rhabdomyosarcoma | Malignant Neoplasm of the Peripheral Nerve Sheath with Rhabdomyosarcoma | Malignant Peripheral Nerve Sheath Neoplasm with Rhabdomyosarcoma | Malignant Peripheral Nerve Sheath Tumor with Rhabdomyosarcoma | Malignant Tumor of Peripheral Nerve Sheath with Rhabdomyosarcoma | Malignant Tumor of the Peripheral Nerve Sheath with Rhabdomyosarcoma | Triton tumor, malignant","9561/3","Malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation",,,,,,,,,,,,,"4300679","Malignant Triton tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1333373","Ectopic Meningioma","C5308","A meningothelial neoplasm that arises from an anatomic site outside the intracranial and intraspinal compartments.","Ectopic Meningioma | Primary Ectopic Meningioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206730","Nerve Sheath Myxoma","C7018","A benign neoplasm with nerve sheath features that usually arises from the dermis and subcutaneous tissue. It is composed of spindle and epithelioid cells in a myxoid stroma.","Nerve Sheath Myxoma | Myxoid Neurothekeoma | Nerve sheath myxoma | Neurothekeoma | Neurothekeoma",,,,,,,,,,,,,,,"4202059","Neurothekeoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266188","Malignant Peripheral Nerve Sheath Tumor with Perineurial Differentiation",,,,,,,,,,,,,,,,,,"4028700","Perineurioma, malignant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0751691","Perineurioma","C4973","A rare, usually benign tumor composed entirely of neoplastic perineurial cells. It may occur in the soft tissues, intraneurally, or in mucosal sites.","Perineurioma | Perineurioma, NOS","9571/0","Perineurioma, NOS",,,,,,,,,,,,,"4300678","Perineurioma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"CL497447","Malignant Gastrointestinal Stromal Tumor","C53999","A gastrointestinal stromal tumor that is characterized by large size (diameter greater than 10 cm for gastric localization and greater than 5 cm for intestinal localization) or more than 5 mitotic figures per 50 high power fields.","Malignant Gastrointestinal Stromal Tumor | GASTROINTESTINAL STROMAL TUMOR, MALIGNANT | GIST, Malignant | GIST, malignant | Gastrointestinal stromal tumor, malignant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449186","Benign Gastrointestinal Stromal Tumor","C53998","A gastrointestinal stromal tumor that is characterized by a maximum diameter equal or less than 5 cm (gastric localization), or equal or less than 2 cm (intestinal localization) and no more than 5 mitotic figures per 50 high power fields.","Benign Gastrointestinal Stromal Tumor | GASTROINTESTINAL STROMAL TUMOR, BENIGN | GIST, Benign | GIST, benign | Gastrointestinal stromal tumor, benign",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055466","Soft Tissue Angiosarcoma","C121671","An angiosarcoma that arises from the soft tissues, usually in the deep muscles of the lower extremities, retroperitoneum, mediastinum, and mesentery.","Soft Tissue Angiosarcoma | Angiosarcoma of Soft Tissue | Angiosarcoma of Soft Tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332328","Gleason Score 3","C28096","A Gleason score that is exceptionally assigned and indicates a low-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","Gleason Score 3 | ",,,,,,,,,,,,,,,"4263220","Gleason grade score 3 out of 10",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1276442","Gleason Score 4","C28097","A Gleason score that is relatively uncommon and indicates a low-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","Gleason Score 4 | ",,,,,,,,,,,,,,,"4086970","Gleason grade score 4 out of 10",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0860209","Gallbladder Sludge","C121868","A mixture of cholesterol and calcium particles in excess bile in the gallbladder.","Gallbladder Sludge | Sludge",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050405","Suspicious for Malignancy","C121869","A microscopic finding indicating the presence of a cellular infiltrate or isolated cells that have features suspicious for malignancy.","Suspicious for Malignancy | Atypical and/or suspicious | Suspicious",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1318509","Esophagram","C17640","A series of x-ray pictures of the esophagus taken after a patient drinks a liquid containing barium sulfate (a form of the silver-white metallic element barium). The barium sulfate coats and outlines the inner wall of the esophagus so that it can be seen on the x-ray pictures.","Esophagram | Contrast Esophagram | Esophagogram | contrast esophagram | esophagram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3840252","Pseudomyogenic Hemangioendothelioma","C121668","An intermediate, rarely metastasizing blood vessel neoplasm that more frequently affects young adult males and usually arises in the lower limbs.  In approximately half of the affected patients the tumor is painful and in two-thirds of the patients the tumor is multifocal.  Morphologically it is characterized by the presence of sheets and fascicles of spindle cells with abundant eosinophilic cytoplasm and vesicular nuclei.  Cytologic atypia is usually mild.  Approximately 60% of the patients develop local recurrences or additional tumors in the same anatomic region.","Pseudomyogenic Hemangioendothelioma | Epithelioid Sarcoma-Like Hemangioendothelioma | Pseudomyogenic (Epithelioid Sarcoma-Like) Hemangioendothelioma",,,,,,,,,,,,,,,"45766492","Pseudomyogenic (epithelioid sarcoma-like) hemangioendothelioma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053999","Spindle Cell/Sclerosing Rhabdomyosarcoma","C121654","An uncommon variant of rhabdomyosarcoma with spindle cell or sclerosing morphology.  It affects both children and adults and it is more common in males.","Spindle Cell/Sclerosing Rhabdomyosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1275265","Dermal Nerve Sheath Myxoma","C121680","A benign neoplasm with nerve sheath features that arises from the dermis and subcutaneous tissue. It manifests as an asymptomatic nodule and most often arises from the extremities. It is composed of spindle and epithelioid cells in a myxoid stroma.","Dermal Nerve Sheath Myxoma | Classic Variant of Neurothekeoma | Myxoid Variant of Neurothekeoma",,,,,,,,,,,,,,,"4301639","Dermal nerve sheath myxoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0431126","Solitary Circumscribed Neuroma","C121681","A benign peripheral nerve sheath tumor characterized by the presence of Schwann cells, axons, and perineurial fibroblasts.  It usually arises from the skin of the head and neck or the oral mucosa.  It presents as a solitary and painless nodular mass.","Solitary Circumscribed Neuroma | Palisaded Encapsulated Neuroma | SCN",,,,,,,,,,,,,,,"4099825|4298150","Solitary circumscribed neuroma|Palisaded encapsulated neuroma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3839433","Hybrid Nerve Sheath Tumor","C121686","A benign nerve sheath tumor characterized by the combination of histologic features seen in schwannomas, neurofibromas, and perineuriomas.","Hybrid Nerve Sheath Tumor | HNST | Hybrid Nerve Sheath Neoplasm | Hybrid Neurofibroma-Perineurioma | Hybrid Neurofibroma-Schwannoma | Hybrid Schwannoma-Perineurioma | Nerve Sheath Tumor, NOS | Nerve Sheath Tumor, Not Otherwise Specified",,,,,,,,,,,,,,,"45766530","Hybrid nerve sheath tumor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0346056","Benign Triton Tumor","C121687","A very rare intraneural mass in a large nerve characterized by the interposition of mature skeletal muscle fibers and nerve fibers.","Benign Triton Tumor | Benign Triton Tumor  | Ectomesenchymal Hamartoma | NMC | Nerve Rhabdomyoma | Neuromuscular Choristoma | Neuromuscular Hamartoma | Rhabdomyoma/Choristoma",,,,,,,,,,,,,,,"4112765","Neuromuscular hamartoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0266490","Nasal Glial Heterotopia","C121688","A collection of heterotopic neuroglial tissue which is isolated from the cranial cavity, usually located in or around the nose.  Complete excision is curative.","Nasal Glial Heterotopia | Ectopic Glial Tissue | Glial Choristoma | Nasal Glioma | Neuroglial Heterotopia",,,,,,,,,,,,,,,"4209461","Nasal glial heterotopia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055500","Superficial Acral Fibromyxoma","C121713","A benign fibroblastic neoplasm that arises from acral sites, usually the periungual area of the digits.  It is characterized by the proliferation of spindled and stellate-shaped fibroblasts in the dermis in a myxoid or collagenous stroma.  Nuclear atypia is usually minimal.  It usually presents as a solitary and slow-growing dome-shaped mass on a digit. The recurrence rate is low.","Superficial Acral Fibromyxoma | Acral Fibromyxoma | Acral Fibromyxoma | Cellular Digital Fibroma | Digital Fibromyxoma | SAF | Superficial Acral Fibromyxoma | Superficial Acral Fibromyxoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053521","Hemosiderotic Fibrolipomatous Tumor","C121752","A non-encapsulated, slow-growing, locally aggressive subcutaneous tumor characterized by the presence of adipocytes, hemosiderin-laden spindle cells, hemosiderin-laden macrophages, osteoclast-like giant cells, and scattered chronic inflammatory cells. It usually arises from the dorsum of the foot, ankle, dorsum of the hand, thigh, calf, or cheek.  It may recur if it is not completely excised but does not metastasize.","Hemosiderotic Fibrolipomatous Tumor | HFLT | Hemosiderotic Fibrohistiocytic Lipomatous Lesion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3839955","Malignant Ossifying Fibromyxoid Tumor","C121774","An ossifying fibromyxoid tumor characterized by the presence of high grade nuclear features or increased cellularity and more than two mitotic figures per 50 HPFs.","Malignant Ossifying Fibromyxoid Tumor | Malignant Ossifying Fibromyxoid Tumor  | Ossifying fibromyxoid tumor, malignant",,,,,,,,,,,,,,,"45766467","Ossifying fibromyxoid tumor, malignant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4049618","Mixed Tumor, Not Otherwise Specified","C121786","A benign myoepithelioma characterized by the presence of a minor ductal component.","Mixed Tumor, Not Otherwise Specified | Mixed Tumor, NOS | Mixed tumor, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054577","Malignant Mixed Tumor, Not Otherwise Specified","C121787","A malignant myoepithelioma characterized by the presence of a minor ductal component.","Malignant Mixed Tumor, Not Otherwise Specified | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814879","Benign Phosphaturic Mesenchymal Tumor","C121788","A phosphaturic mesenchymal tumor with benign histologic features.  It may recur locally but does not metastasize.  Complete excision is curative.","Benign Phosphaturic Mesenchymal Tumor | ",,,,,,,,,,,,,,,"45766484","Phosphaturic mesenchymal tumor, benign",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3839061","Malignant Phosphaturic Mesenchymal Tumor","C121789","A phosphaturic mesenchymal tumor characterized by the presence of nuclear atypia, high mitotic activity, increased cellularity, marked pleomorphism, and necrosis. It usually develops in lesions that have recurred locally and metastasizes to other sites.","Malignant Phosphaturic Mesenchymal Tumor | Phosphaturic mesenchymal tumor, malignant",,,,,,,,,,,,,,,"45766485","Phosphaturic mesenchymal tumor, malignant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3839685","Benign PEComa","C121791","A tumor with perivascular epithelioid cell differentiation characterized by the absence of pleomorphism and scarcity or absence of mitotic figures.","Benign PEComa | Benign PEComa, NOS | Benign PEComa, Not Otherwise Specified | Typical PEComa",,,,,,,,,,,,,,,"45771358","Perivascular epithelioid tumor, benign",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3839062","Malignant PEComa","C121792","A usually large and aggressive tumor with perivascular epithelioid cell differentiation characterized by the presence of marked nuclear atypia, pleomorphism, increased mitotic activity, necrosis, and infiltrative margins.  The most common metastatic sites are liver, lungs, lymph nodes, and bone.","Malignant PEComa | Malignant PEComa, NOS | Malignant PEComa, Not Otherwise Specified | PEComa, malignant | Perivascular epithelioid cell tumor, malignant",,,,,,,,,,,,,,,"37162643|45766447","Malignant perivascular epithelioid cell neoplasm|Perivascular epithelioid tumor, malignant",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C4048304","Undifferentiated Round Cell Sarcoma","C121799","An undifferentiated soft tissue sarcoma characterized by the presence of uniform round or ovoid malignant cells with a high nuclear to cytoplasmic ratio.","Undifferentiated Round Cell Sarcoma | Undifferentiated Ewing Tumor | Undifferentiated round cell sarcoma",,,,,,,,,,,,,,,"4249150","Small cell sarcoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053898","Undifferentiated Epithelioid Sarcoma","C121802","An undifferentiated soft tissue sarcoma characterized by the presence of a malignant cellular infiltrate with epithelioid morphology.","Undifferentiated Sarcoma with Epithelioid Features | Undifferentiated Epithelioid Sarcoma | Undifferentiated Epithelioid Sarcoma | Undifferentiated epithelioid sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053897","Undifferentiated Sarcoma, Not Otherwise Specified","C121804","An undifferentiated soft tissue sarcoma which cannot be further characterized.","Undifferentiated Sarcoma, Not Otherwise Specified | Undifferentiated Sarcoma, NOS",,,,,,,,,,,,,,,"4029021","Undifferentiated sarcoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3839106","Osteochondromyxoma","C121842","A rare benign chondroid and osteoid matrix-producing neoplasm of bone characterized by extensive myxoid changes.  It may be a locally destructive neoplasm and has been reported in patients with Carney complex.","Osteochondromyxoma | Carney Bone Tumor",,,,,,,,,,,,,,,"45766520","Osteochondromyxoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038604","Subungual Exostosis","C121844","A benign tumor that affects the distal phalanx, most often the great toe. Grossly it consists of a cartilage cap and a bony stalk. Microscopically it is characterized by an osteochondromatous proliferation with a gradual transition of a peripheral spindle-cell proliferation to hyaline cartilage to trabecular bone. Pain and swelling are present. Simple resection is usually curative.","Subungual Exostosis | Dupuytren Exostosis",,,,,,,,,,,,,,,"4097530|45766522","Subungual exostosis|Subungual exostosis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2960319","Bizarre Parosteal Osteochondromatous Proliferation","C121845","A benign lesion that usually affects the proximal small bones of the hands or feet.  Grossly it consists of a cartilage cap and a bony stalk.  Microscopically it is characterized by the presence of spindle cells, cartilage, and bone, usually in a disorganized pattern compared to subungual exostosis.  Enlarged (bizarre) chondrocytes are present in the cartilage.  Swelling with or without pain is present.  Recurrences following resection have been reported in approximately half of cases.","Bizarre Parosteal Osteochondromatous Proliferation | BPOP | Bizarre Parosteal Osteochondromatous Prolifeartion | Nora Lesion | Nora's Lesion",,,,,,,,,,,,,,,"40488376|45766521","Bizarre parosteal osteochondromatous proliferation|Bizarre parosteal osteochondromatous proliferation",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C4054892","Chondrosarcoma, Grade 2","C121870","An intermediate-grade chondrosarcoma arising in the medulla of bone or within the cartilaginous cap of a pre-existing osteochondroma. It is characterized by the presence of increased cellularity and a greater degree of nuclear atypia and hyperchromasia as compared to grade 1 chondrosarcoma. Mitotic activity is present.","Chondrosarcoma, Grade 2 | Grade II Chondrosarcoma | Grade II Chondrosarcoma | Intermediate Grade Chondrosarcoma | Intermediate-Grade Chondrosarcoma",,,,,,,,,,,,,,,"45773107","Chondrosarcoma, grade 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054891","Chondrosarcoma, Grade 3","C121871","A high-grade chondrosarcoma arising in the medulla of bone or within the cartilaginous cap of a pre-existing osteochondroma. It is characterized by the presence of increased cellularity and a greater degree of nuclear atypia, hyperchromasia, and mitotic activity as compared to grade 2 chondrosarcoma.","Chondrosarcoma, Grade 3 | Grade III Chondrosarcoma | Grade III Chondrosarcoma | High Grade Chondrosarcoma | High-Grade Chondrosarcoma",,,,,,,,,,,,,,,"45766523","Chondrosarcoma, grade 3",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4048700","Sclerosing Rhabdomyosarcoma","C121655","An uncommon variant of rhabdomyosarcoma with sclerosing morphology.  It usually arises from the limbs.","Sclerosing Rhabdomyosarcoma | Sclerosing rhabdomyosarcoma",,,,,,,,,,,,,,,"4029528","Spindle cell rhabdomyosarcoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4050147","Benign Notochordal Cell Tumor","C121901","An intraosseous benign tumor of notochord origin that arises in the bones of the base of the skull, vertebral bodies, sacrum or coccyx.  It contains vacuolated tumor cells without atypia, but lacks myxoid matrix, necrosis, and lobular architecture, which are features that characterize its malignant counterpart, chordoma.  Most lesions are incidental findings.","Benign Notochordal Cell Tumor | BNCT | Intraosseous Benign Notochordal Cell Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162375","Giant Cell Lesion of Small Bones","C121893","A rare tumor-like lesion of the hands and feet characterized by the presence of hemorrhagic fibrous tissue, hemosiderin deposition, osteoclast-like giant cells which are irregularly distributed, and reactive bone formation.  Pain and swelling are the most frequent symptoms.  It may recur following curettage, but is usually cured after a second procedure.","Giant Cell Lesion of Small Bones | GCLSB | Giant Cell Reparative Granuloma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055031","FACIT-Dyspnea 10 Item Short Form","C121853","A patient-reported outcome measure designed to evaluate an individual's shortness of breath across ten functional activities over the past 7 days.","FACIT-Dyspnea 10 Item Short Form | FAC084 | FACIT-DYSPNEA SF | FACIT-Dyspnea | Functional Assessment of Chronic Illness Therapy-Dyspnea | Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049924","Dyspnea Severity Dressing Yourself Without Help","C121855","A question about how short of breath an individual gets or got when dressing themselves without help.","Dyspnea Severity Dressing Yourself Without Help | Dressing yourself without help",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050471","Dyspnea Severity Walking on Flat Ground Without Stopping","C121857","A question about how short of breath an individual gets or got when walking 50 steps/paces on flat ground at a normal speed without stopping.","Dyspnea Severity Walking on Flat Ground Without Stopping | Dyspnea Severity Walking 50 Steps or Paces on Flat Ground at Normal Speed Without Stopping | Walking 50 steps/paces on flat ground at a normal speed without stopping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049708","Dyspnea Severity Walking up 20 Stairs Without Stopping","C121858","A question about how short of breath an individual gets or got when walking up 20 stairs without stopping.","Dyspnea Severity Walking up 20 Stairs Without Stopping | Walking up 20 stairs (2 flights) without stopping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050136","Dyspnea Severity Preparing Meals","C121860","A question about how short of breath an individual gets or got when preparing meals.","Dyspnea Severity Preparing Meals | Preparing meals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049639","Dyspnea Severity Washing Dishes","C121861","A question about how short of breath an individual gets or got when washing dishes.","Dyspnea Severity Washing Dishes | Washing dishes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050582","Dyspnea Severity Sweeping or Mopping","C121862","A question about how short of breath an individual gets or got when sweeping or mopping.","Dyspnea Severity While Sweeping or Mopping Question | Dyspnea Severity Sweeping or Mopping | Dyspnea Severity While Sweeping or Mopping | Sweeping or mopping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050304","Dyspnea Severity Making a Bed","C121863","A question about how short of breath an individual gets or got when making a bed.","Dyspnea Severity Making a Bed | Making a bed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049651","Dyspnea Severity Lifting Something Weighing 10-20 Pounds","C121864","A question about how short of breath an individual gets or got when lifting something weighing 10-20 pounds.","Dyspnea Severity Lifting Something Weighing 10-20 Pounds | Lifting something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050245","Dyspnea Severity Carrying Something Weighing 10-20 Pounds","C121865","A question about how short of breath an individual gets or got when carrying something weighing 10-20 pounds from one room to another.","Dyspnea Severity Carrying Something Weighing 10-20 Pounds Question | Carrying something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries) from one room to another | Dyspnea Severity Carrying Something Weighing 10-20 Pounds | Dyspnea Severity Carrying Something Weighing 10-20 Pounds | Dyspnea Severity Carrying Something Weighing 10-20 lbs from One Room to Another",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049624","Dyspnea Severity Walking Faster than Your Normal Speed Without Stopping","C121866","A question about how short of breath an individual gets or got when walking faster than their usual speed for one half mile without stopping.","Dyspnea Severity Walking Faster than Your Normal Speed Without Stopping | Dyspnea Severity Walking Faster than Your Normal Speed for Half a Mile Without Stopping | Walking (faster than your usual speed) for a half mile (almost 1 km) without stopping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050222","Did Not Dress Without Help","C121867","A question about the reason why an individual did not dress themselves without help.","Did Not Dress Without Help Question | Did Not Dress Without Help | Did Not Dress Without Help | Did Not Dress Yourself Without Help | Please indicate why you did not dress yourself without help in the past 7 days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055145","Did Not Walk on Flat Ground Without Stopping","C121872","A question about the reason why an individual did not walk 50 steps/paces on flat ground at a normal speed without stopping.","Did Not Walk on Flat Ground Without Stopping Question | Did Not Walk 50 Steps or Paces on Flat Ground at Normal Speed Without Stopping | Did Not Walk on Flat Ground Without Stopping | Did Not Walk on Flat Ground Without Stopping | Please indicate why you did not walk 50 steps/paces on flat ground at a normal speed without stopping in the past 7 days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055144","Did Not Walk up 20 Stairs Without Stopping","C121873","A question about the reason why an individual did not walk up 20 stairs without stopping.","Did Not Walk up 20 Stairs Without Stopping Question | Did Not Walk up 20 Stairs Without Stopping | Did Not Walk up 20 Stairs Without Stopping | Please indicate why you did not walk up 20 stairs (2 flights) without stopping in the past 7 days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL497260","Did Not Prepare Meals (question)","C121874","A question about the reason why an individual did not prepare meals.","Did Not Prepare Meals Reason Question | Did Not Prepare Meals | Did Not Prepare Meals | Did Not Prepare Meals Reason | Please indicate why you did not prepare meals in the past 7 days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055143","Did Not Wash Dishes","C121875","A question about the reason why an individual did not wash dishes.","Did Not Wash Dishes Reason Question | Did Not Wash Dishes | Did Not Wash Dishes | Did Not Wash Dishes Reason | Please indicate why you did not wash dishes in the past 7 days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055146","Did Not Sweep or Mop","C121876","A question about the reason why an individual did not sweep or mop.","Did Not Sweep or Mop Reason Question | Did Not Sweep or Mop | Did Not Sweep or Mop | Did Not Sweep or Mop Reason | Please indicate why you did not sweep or mop in the past 7 days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055147","Did Not Make a Bed","C121877","A question about the reason why an individual did not make a bed.","Did Not Make a Bed Reason Question | Did Not Make a Bed | Did Not Make a Bed | Did Not Make a Bed Reason | Please indicate why you did not make a bed in the past 7 days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055148","Did Not Lift Something Weighing 10-20 Pounds","C121878","A question about the reason why an individual did not lift something weighing 10-20 pounds.","Did Not Lift Something Weighing 10-20 Pounds Reason Question | Did Not Lift Something Weighing 10-20 Pounds | Did Not Lift Something Weighing 10-20 Pounds | Did Not Lift Something Weighing 10-20 Pounds Reason | Please indicate why you did not lift something weighing 10-20 pounds in the past 7 days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055151","Did Not Carry Something Weighing 10-20 Pounds","C121879","A question about the reason why an individual did not carry something weighing 10-20 pounds from one room to another.","Did Not Carry Something Weighing 10-20 Pounds Question | Did Not Carry Something Weighing 10-20 Pounds | Did Not Carry Something Weighing 10-20 Pounds | Did Not Carry Something Weighing 10-20 Pounds from One Room to Another | Please indicate why you did not carry something weighing 10-20 pounds from one room to another in the past 7 days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049643","Did Not Walk Faster than Normal Speed Without Stopping","C121880","A question about the reason why an individual did not walk faster than their usual speed for one half mile without stopping.","Did Not Walk Faster than Normal Speed Without Stopping Question | Did Not Walk Faster than Normal Speed Without Stopping | Did Not Walk Faster than Normal Speed Without Stopping | Did Not Walk Faster than Your Normal Speed for Half a Mile Without Stopping | Please indicate why you did not dress yourself without help in the past 7 days | Please indicate why you did not walk faster than your normal speed without stopping in the past 7 days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2198640","Dressing Without Help","C121883","A question about an individual's difficulty dressing themselves without help.","Dressing Without Help Question | Dressing Without Help | Dressing Without Help | Dressing yourself without help",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050470","Walking on Flat Ground Without Stopping","C121884","A question about an individual's difficulty walking 50 steps/paces on flat ground at a normal speed without stopping.","Walking on Flat Ground Without Stopping Question | Walking 50 Steps or Paces on Flat Ground at Normal Speed Without Stopping | Walking 50 steps/paces on flat ground at a normal speed without stopping | Walking on Flat Ground Without Stopping | Walking on Flat Ground Without Stopping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050472","Walking up 20 Stairs Without Stopping","C121885","A question about an individual's difficulty walking up 20 stairs without stopping.","Walking up 20 Stairs Without Stopping Question | Walking up 20 Stairs Without Stopping | Walking up 20 Stairs Without Stopping | Walking up 20 stairs (2 flights) without stopping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL497232","Preparing Meals","C121886","A question about an individual's difficulty preparing meals.","Preparing Meals | Preparing meals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050473","Washing Dishes","C121887","A question about an individual's difficulty washing dishes.","Washing Dishes Question | Washing Dishes | Washing Dishes | Washing dishes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050583","Sweeping or Mopping","C121888","A question about an individual's difficulty sweeping or mopping.","Sweeping or Mopping Ability Question | Sweeping or Mopping | Sweeping or Mopping Ability | Sweeping or mopping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049642","Making a Bed","C121889","A question about an individual's difficulty making a bed.","Difficulty Making a Bed | Making a Bed | Making a bed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050246","Lifting Something Weighing 10-20 Pounds","C121890","A question about an individual's difficulty lifting something weighing 10-20 pounds.","Lifting Something Weighing 10-20 Pounds Question | Lifting Something Weighing 10-20 Pounds | Lifting Something Weighing 10-20 Pounds | Lifting something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049646","Carrying Something Weighing 10-20 Pounds","C121891","A question about an individual's difficulty carrying something weighing 10-20 pounds from one room to another.","Carrying Something Weighing 10-20 Pounds Question | Carrying Something Weighing 10-20 Pounds | Carrying Something Weighing 10-20 Pounds | Carrying something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries) from one room to another",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050423","Walking Faster than Your Normal Speed Without Stopping","C121892","A question about an individual's difficulty walking faster than their usual speed for one half mile without stopping.","Walking Faster than Your Normal Speed Without Stopping Question | Walking (faster than your usual speed) for a half mile (almost 1 km) without stopping | Walking Faster than Your Normal Speed Without Stopping | Walking Faster than Your Normal Speed Without Stopping | Walking Faster than Your Normal Speed for Half a Mile Without Stopping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054349","No Shortness of Breath","C121894","A response indicating that an individual has or had no shortness of breath.","No Shortness of Breath | No shortness of breath",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054523","Mildly Short of Breath","C121895","A response indicating that an individual has or had mild shortness of breath.","Mildly Short of Breath | Mild Shortness of Breath | Mildly short of breath",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054481","Moderately Short of Breath","C121896","A response indicating that an individual has or had moderate shortness of breath.","Moderately Short of Breath | Moderate Shortness of Breath | Moderately short of breath",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4255032","Severely Short of Breath","C121897","A response indicating that an individual has or had severe shortness of breath.","Severely Short of Breath | Severe Shortness of Breath | Severely short of breath",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055150","Did Not Do This Past 7 Days","C121898","A response indicating that an individual has not done something in the past 7 days.","Did Not Do This Past 7 Days | Did Not Do This During the Past 7 Days | Did Not Do This in the Past 7 Days | I did not do this in the past 7 days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4035162","Have Stopped Trying Because of Shortness of Breath","C121899","A response indicating that an individual has stopped trying, or knew they could not do this activity because of their shortness of breath.","Have Stopped Trying Because of Shortness of Breath | Have Stopped Trying or Knew I Could Not Do This Activity Because of Shortness of Breath | I have stopped trying, or knew I could not do this activity because of my shortness of breath",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4036144","Did Not Do This Activity for Some Other Reason","C121900","A response indicating that an individual has not done an activity for some reason not listed.","Did Not Do This Activity for Some Other Reason | I did not do this activity for some other reason (including not having a chance to do it, other health issues etc) | Some other reason",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890371","Natural Killer Cell Activity Measurement","C116203","The determination of the amount of natural killer cell activity in a sample.","Natural Killer Cell Activity Measurement | NKCEFUNC | Natural Killer Cell Activity | Natural Killer Cell Function",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054921","Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-General","C121902","A patient-reported outcome measure designed specifically to evaluate general satisfaction with treatment.","Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-General | FACIT-TS-G | Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3483266","Treatment Effectiveness So Far Compared to Expected","C121903","A question about how an individual would rate the effectiveness of their treatment so far compared to what they expected.","Treatment Effectiveness So Far Compared to Expected | Compared to what you expected, how do you rate the effectiveness of the treatment so far",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3483268","Treatment Side Effects So Far Compared to Expected","C121904","A question about how an individual would rate the side effects of their treatment so far compared to what they expected.","Treatment Side Effects So Far Compared to Expected | Compared to what you expected, how do you rate the side effects of treatment so far",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055119","Doctor Helped with Evaluation of Treatment Effects","C121905","A question about whether a doctor helped an individual evaluate the effects of their treatment so far.","Doctor Helped with Evaluation of Treatment Effects | Did your doctor(s) help you evaluate the effects of your treatment so far",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3483272","Feel Treatment was Right","C121906","A question about whether an individual feels or felt that the treatment they received was right for them.","Feel Treatment was Right | Do you feel you received the treatment that was right for you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3483274","Satisfied with Treatment Effects","C121907","A question about whether an individual is or was satisfied with the effects of their treatment so far.","Satisfied with Treatment Effects | Are you satisfied with the effects of this treatment so far | Satisfaction with Treatment Effects",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3476762","Recommend Treatment to Others with Same Illness","C121908","A question about whether an individual would recommend their treatment to others with their illness.","Recommend Treatment to Others with Same Illness | Would you recommend this treatment to others with your illness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3476759","Would Choose Treatment Again","C121909","A question about whether an individual would choose their treatment again.","Would Choose Treatment Again | Choose Treatment Again | Would you choose this treatment again",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3475495","Treatment Rating Overall","C121910","A question about how an individual would rate their treatment overall.","Treatment Rating Overall | How do you rate this treatment overall | Overall Treatment Rating | Treatment Overall Rating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4036143","A Lot Worse","C121911","A response indicating that something is a lot worse.","A Lot Worse | A lot worse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3841647","A Little Worse","C121912","A response indicating that something is a little worse.","A Little Worse | A little worse",,,,,,,,,,,,,,,"763694","Slightly worse",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4049139","A Little Better","C121913","A response indicating that something is a little better.","A Little Better | A little better",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4036142","A Lot Better","C121914","A response indicating that something is a lot better.","A Lot Better | A lot better",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL497265","To Some Extent","C121915","An indication that something has been accomplished to some degree or has resulted in some amount of satisfaction.","To Some Extent | To some extent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054936","For the Most Part","C121916","An indication that something has been mostly accomplished or has been mostly satisfying.","For the Most Part | For the most part",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3844350","Maybe","C121917","An indication that something is possible, but not uncertain.","Maybe | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040137","Thyroid Gland Nodule","C3415","A nodular lesion that develops in the thyroid gland.  Causes include adenoma, thyroiditis, fluid-filled cyst, multinodular goiter, and carcinoma.","Thyroid Gland Nodule | Nodule of Thyroid | Nodule of Thyroid Gland | Nodule of the Thyroid | Nodule of the Thyroid Gland | Thyroid Nodule",,,,,,,,,,,,,,,"4030041","Thyroid nodule",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1835381","Polycystic Ovary Syndrome","C26862","A disorder that manifests as multiple cysts on the ovaries. It results in hormonal imbalances and leads to irregular and abnormal menstrual periods, excess growth of hair, acne eruptions and obesity.","Polycystic Ovary Syndrome | PCOS | Polycystic Ovarian Disease | Polycystic Ovarian Syndrome (PCOS) | Stein-Leventhal Syndrome | Stein-Leventhal Syndrome | polycystic ovary syndrome",,,,,,,,,,,,,,,"40443308","Polycystic ovary syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018621","Seasonal Allergic Rhinitis","C92188","Allergic rhinitis caused by outdoor allergens.","Seasonal Allergic Rhinitis | Hay Fever",,,,,,,,,,,,,,,"4280726","Seasonal allergic rhinitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4018332","Lenvatinib Mesylate","C48636","A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. E7080 blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis.","Lenvatinib Mesylate | 4-[3-Chloro-4-(N'-cyclopropylureido)phenoxy]7-methoxyquinoline-6-carboxamide Mesylate | 6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]- 7-methoxy-, methanesulfonate (1:1) | E7080 Mesylate | LENVATINIB MESYLATE | Lenvima | Multi-Kinase Inhibitor E7080 Mesylate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2830125","Binimetinib","C84865","An orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. Inhibition of MEK1/2 prevents the activation of MEK1/2 dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling. This may eventually lead to an inhibition of tumor cell proliferation and an inhibition in production of various inflammatory cytokines including interleukin-1, -6 and tumor necrosis factor. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.","Binimetinib | ARRY 162 | ARRY 438162 | ARRY-162 | ARRY-438162 | ARRY162 | ARRY438162 | BINIMETINIB | MEK 162 | MEK-162 | MEK162 | Mektovi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3853921","Alectinib","C101790","An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, alectinib binds to and inhibits ALK kinase, ALK fusion proteins as well as the gatekeeper mutation ALKL1196M known as one of the mechanisms of acquired resistance to small-molecule kinase inhibitors. The inhibition leads to disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","Alectinib | 5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo- | AF 802 | AF-802 | AF802 | ALECTINIB | ALK Inhibitor RO5424802 | Alecensa | CH 5424802 | CH-5424802 | CH5424802 | RG 7853 | RG-7853 | RG7853 | RO 5424802 | RO-5424802 | RO5424802",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515127","T-Cell Large Granular Lymphocyte","C38673","A thymus-dependent white blood cell that has been activated by contact with antigen and has enlarged by macromolecular synthesis with presence of large granules visible by light microscopy.","T-Cell Large Granular Lymphocyte | T-LGL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422163","CTCF Gene","C73679","This gene is involved in epigenetic control of gene expression.","CTCF Gene | CCCTC-Binding Factor (Zinc Finger Protein) Gene | CTCF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420314","SOS1 Gene","C116308","This gene is involved in guanine nucleotide exchange.","SOS1 Gene | SOS Ras/Rho Guanine Nucleotide Exchange Factor 1 Gene | SOS1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413795","CTNNA1 Gene","C88985","This gene is involved in cell adhesion.","CTNNA1 Gene | CTNNA1 | Catenin (Cadherin-Associated Protein), Alpha 1, 102kDa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984172","F5 Leiden Allele","C91334","A nucleotide substitution at position 20 of the coding sequence of the HBB gene where adenine has been mutated to thymine. This gene variant, which encodes coagulation factor V Leiden protein, is involved in hypercoagulability due to resistance to degradation by activated protein C.","F5 NM_000130.4:c.1601G>A | Coagulation Factor V (Proaccelerin, Labile Factor) Leiden Allele | Coagulation Factor V (Proaccelerin, Labile Factor) c.1601G>A | Coagulation Factor V Leiden Allele | Coagulation Factor V R534Q | Coagulation Factor V c.1601G>A | F5 1601G>A | F5 1691G-A Transition Mutation | F5 Arg534Gln | F5 Leiden Allele | F5 Leiden Allele | F5 NM_000130.4:c.1601G>A | F5 NP_000121.2:p.Arg534Gln | F5 NP_000121.2:p.R534Q | F5 R506Q | F5 R534Q | F5 c.1601G>A | F5 g.41721G>A | F5 p. R534Q | F5 p.Arg534Gln | FVL | Factor V Leiden Allele | NG_011806.1:g.41721A>G | NG_011806.1:g.41721G>A | NM_000130.4:c.1601G>A | NP_000121.2:p.Arg534Gln",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419131","PTX3 Gene","C119680","This gene is involved in complement recognition of pathogens.","PTX3 Gene | PTX3 | Pentraxin 3, Long Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019351","Human Herpesvirus 2","C112313","A species of enveloped and spherical viruses with a capsid with T=16 icosahedral symmetry and surrounded by amorphous tegument, in the Herpesviridae family and Simplexvirus genus. The genome is composed of monopartite, linear double-stranded DNA. Human herpesvirus 2 is found in humans and causes genital herpes in the form of watery blisters. Human herpesvirus 2 is transmitted mainly via direct sexual contact.","Human Herpesvirus 2 | HERPES SIMPLEX VIRUS 2 | HHV-2 | HSV-2 | HUMAN HERPESVIRUS 2 | Herpes Simplex Virus 2 | Herpes Simplex Virus Type 2 | Human Alphaherpesvirus 2 | Human alphaherpesvirus 2",,,,,,,,,,,,,,,"4030223","Human alphaherpesvirus 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2346866","Assortment","C69085","A collection of things containing a variety of sorts or kinds, a variety.","Assortment | Variety",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699298","Shot Dosing Unit","C78753","A dosing unit equal to the amount of active ingredient(s) contained usually in a syringe or a small cup and is to be administered in full at once.","Shot Dosing Unit | Shot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028013","Nickel","C690","An element with atomic symbol Ni, atomic number 28, and atomic weight 58.69.","Nickel | Metallic Nickel | NICKEL | Ni",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025698","Methyl Chloride","C77476","A colorless, flammable, toxic gas that was used widely as a refrigerant and has many current industrial applications, including use as a local anesthetic, a chemical intermediate in silicone polymer production and drug manufacturing, an extractant for oils and resins, a solvent in butyl rubber and petroleum refining, a propellant in polystyrene foam production, a methylating and chlorinating agent in organic chemistry and an herbicide. Exposure to methyl chloride can cause a wide variety of issues from frostbite, drowsiness and dizziness to paralysis, seizures and coma depending on the route and level (concentration and duration) of exposure.","Methyl Chloride | Chloromethane | METHYL CHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011041","Clofenotane","C44364","A white, odorless and tasteless, very stable, water-insoluble, synthetic, crystalline chlorinated hydrocarbon that is soluble in most organic solvents, fat and oils and tends to accumulate in ecosystems. Clofenotane was once widely used as a pesticide to control insects in agriculture and to control malaria, typhus and body lice, but its use is now limited. Exposure to clofenotane mainly affects the nervous system resulting in tremors, dizziness, nausea, incoordination, convulsions and seizures. This substance is reasonably anticipated to be a human carcinogen based on evidence of carcinogenicity in experimental animals.","Clofenotane | 1,1'-(2,2,2-Trichloroethylidene)-bis[4-chlorobenzene] | 1,1,1-Trichloro-2,2-bis(p-chlorophenyl)ethane | 1,1-Bis(4-chlorophenyl)-2,2,2-trichloroethane | CLOFENOTANE | Chlorophenothane | Chlorophenothane | DDT | Dichlorodiphenyltrichloroethane | p,p'-DDT | p,p'-Dichlorodiphenyltrichloroethane",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008574","Chromium","C370","An element with atomic symbol Cr, atomic number 24, and atomic weight 52.","Chromium | CHROMIUM | Cr",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707276","Carcinogenic Chlorinated Hydrocarbon","C45386","A hydrocarbon compound consisting of carbons with one or more chloride atom incorporated in its structure that can increase the risk of human cancer. (NCI05)","Carcinogenic Chlorinated Hydrocarbon | CHC | Chlorinated Hydrocarbons | Chlorinated hydrocarbons (CHC)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0303174","Cadmium Compound","C44349","An inorganic substance that contains the metallic element cadmium usually in its positive-2 valence state and forms toxic fumes of cadmium oxide when heated. Cadmium compounds are used in industry in electroplating and coating, in pigments, in batteries, in alloys, and as stabilizers. Exposure to these substances affects the lungs and kidneys and is associated with an increased risk of developing lung cancer. (NCI05)","Cadmium Compound | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0000300","2-Naphthylamine","C44311","A synthetic, air-sensitive, colorless crystalline solid that is soluble in hot water, alcohol, ether and many organic solvents. Currently, it is only used in laboratory research. Because the commercial production and use of 2-naphthylamine are banned, the potential for human exposure is low. The general population may be exposed to this chemical through inhalation of emissions from sources where nitrogen-containing organic matter is burned, such as coal furnaces and cigarettes. At greatest risk of occupational exposure to 2-naphthylamine are laboratory technicians and scientists who use it in research. Acute inhalation exposure to high levels of 2-naphthylamine can result in methemoglobinemia, dyspnea, ataxia, hematuria, dysuria and hemorrhagic cystitis. It is known to be a human carcinogen. (NCI05)","2-Naphthylamine | 2-Aminonaphthalene | 2-NAPHTHYLAMINE | Beta-naphthylamine | Fast Scarlet Base B",,,,,,,,,,,,,,,"4098285","2-naphthylamine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003819","Arsenic Compound","C45557","A white, odorless, inorganic substance that contains the semi-metallic element arsenic usually in the 3 and 5-valence state, and emits toxic arsenic fumes when heated to decomposition. Arsenic compounds are primarily used in wood preservation. Exposure to this substance irritates skin and mucous membranes, and can affect the gastrointestinal tract, CNS, cardiovascular system, liver, kidneys and blood. Arsenic compounds are known human carcinogens and are associated with an increased risk of developing lung, skin, bladder, kidney, liver, prostate, digestive tract and colon cancer as well as cancer of the lymphatic and hematopoietic system. (NCI05)","Arsenic Compound | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0050961","Agent Orange","C33901","Code name for a synthetic defoliant developed for military use.  Agent Orange is a mixture of two chemicals, 2,4, dichlorophenoxyacetic acid (2,4-D) and 2,4,5 trichlorophenoxyacetic acid (2,4,5-T).  The toxicity of Agent Orange is due to by-products from metabolic processes upon intake. The toxic by products are dioxin derivatives, which have been linked to the wasting syndrome, gastric ulcer, cancer, immunotoxicity, hepatotoxicity, vascular lesions, teratogenicity, and impaired reproductive performance. (NCI04)","Agent Orange | 2,4,D/2,4,5,T | AGENT ORANGE",,,,,,,,,,,,,,,"4288533","Agent Orange",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021764","Interleukin","C20497","Interleukin is the generic name for a group of well-characterized cytokines that are produced by leukocytes and other cell types.  They have a broad spectrum of functional activities that regulate the activities and capabilities of a wide variety of cell types.  They are particularly important as members of the cytokine networks that regulate inflammatory and immune responses.","Interleukin | IL | Interleukins | interleukin",,,,,,,,,,,,,,,"4244671","Interleukin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0747102","Ovarian Failure","C113351","The inability of the ovaries to function.","Ovarian Failure | Ovarian Hypofunction | Ovarian Insufficiency",,,,,,,,,,,,,,,"193739","Ovarian failure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054014","Skin-Directed Therapy","C121969","Any therapy that treats the skin directly. This includes surgery, radiation therapy, phototherapy, and topical preparations.","Skin-Directed Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473799","Seventeen","C113431","A natural number greater than 16 and less than 18 and the quantity that it denotes.","Seventeen | 17",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036605","Assistive Device","C93300","Devices that help an individual accomplish a task.","Assistive Device | Assistive Devices | assistive device | assistive technology",,,,,,,,,,,,,,,"605931","Assistive device",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0584895","Hamstring","C53042","A group of muscles including the biceps femoris, semimembranosus and semitendinosus that extend down the back of the thigh.","Hamstring | HAMSTRING MUSCLE | Hamstring Muscle",,,,,,,,,,,,,,,"4027740","Posterior muscle of thigh structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224440","Quadriceps Muscle of the Thigh","C33441","A group of four powerful muscles in the front of the thigh. Their actions involve the extension of the knee joint.","Quadriceps Muscle of the Thigh | MUSCLE, QUADRICEPS FEMORIS | QUADRICEPS MUSCLE",,,,,,,,,,,,,,,"4317518","Structure of quadriceps femoris muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4050132","PROMIS Adult Mental Health Domain","C121994","A Patient Reported Outcomes Measurement Information System (PROMIS) domain that assesses the status of an individual's mental health.","PROMIS Adult Mental Health Domain | Adult Mental Health | Adult Mental Health Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055219","Cognitive Function-Abilities","C121995","A patient reported outcome instrument that assesses patient-perceived functional abilities related to cognitive tasks.","Cognitive Function-Abilities | Applied Cognition Abilities | Cognitive Function Abilities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054492","Mind Has Been as Sharp as Usual","C121997","A question about whether an individual's mind is or has been as sharp as usual.","Mind Has Been as Sharp as Usual | My mind has been as sharp as usual",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054535","Memory Has Been as Good as Usual","C121998","A question about whether an individual's memory is or has been as good as usual.","Memory Has Been as Good as Usual | My memory has been as good as usual",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053939","Thinking Has Been as Fast as Usual","C121999","A question about whether an individual's thinking is or has been as fast as usual.","Thinking Has Been as Fast as Usual | My thinking has been as fast as usual",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055512","Able to Think Clearly Without Extra Effort","C122000","A question about whether an individual is or was able to think clearly without extra effort.","Able to Think Clearly Without Extra Effort Question | Able to Think Clearly Without Extra Effort | Able to Think Clearly Without Extra Effort | I have been able to think clearly without extra effort",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055514","Able to Pay Attention and Keep Track of What I am Doing Without Extra Effort","C122001","A question about whether an individual is or was able to pay attention and keep track of what they are doing without extra effort.","Able to Pay Attention and Keep Track of What I am Doing Without Extra Effort Question | Able to Pay Attention and Keep Track of What I am Doing Without Extra Effort | Able to Pay Attention and Keep Track of What I am Doing Without Extra Effort | I have been able to pay attention and keep track of what I am doing without extra effort",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055513","Able to Remember Things as Easily as Usual Without Extra Effort","C122002","A question about whether an individual is or was able to remember things as easily as usual without extra effort.","Able to Remember Things as Easily as Usual Without Extra Effort Question | Able to Remember Things as Easily as Usual Without Extra Effort | Able to Remember Things as Easily as Usual Without Extra Effort | I have been able to remember things as easily as usual without extra effort",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2959886","Cardiopulmonary Exercise Testing","C116517","A clinical tool to evaluate exercise capacity and to assess cardiac function under stress.","Cardiopulmonary Exercise Testing | CPET | CPX",,,,,,,,,,,,,,,"40492338","Cardiopulmonary exercise test",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005938","Bone Mineral Density","C96950","A measure of the amount of minerals (mostly calcium and phosphorous) contained in a certain volume of bone. Bone mass measurements are used to diagnose osteoporosis (a condition marked by decreased bone mass), to see how well osteoporosis treatments are working, and to predict how likely the bones are to break. Low bone mass can occur in patients treated for cancer.","Bone Mineral Density | BMD | bone mass | bone mineral density",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0179847","Chair","C122026","A seat, typically for one person, that has a back and legs.","Chair | ",,,,,,,,,,,,,,,"45768394","Chair",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4049927","Lap","C122027","One circuit around a track or course.","Lap | Laps",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050303","Rating of Perceived Exertion","C122028","A scale for a subject to rate their perception of the intensity of their own physical effort.","Rating of Perceived Exertion | RPE | Rated Perceived Exertion | Relative Perceived Exertion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2350169","Warm-Up","C122029","A period of lower-intensity activity designed to prepare the body for more vigorous exercise.","Warm-Up | Warm-Up Exercise",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049979","Priming Exercise","C122030","High-intensity exercise performed to enhance performance during subsequent high-intensity exercise by accelerating oxygen uptake.","Priming Exercise | Priming",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054047","Seated Row","C122031","An exercise performed by using the arms to pull a bar, lever, or cables toward the body while seated.","Seated Rowing | Indoor Rowing | Seated Row | Seated Row | Seated Rowing | Seated row",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055260","Chest Press","C122032","An exercise performed by using the arms to push a weighted bar or lever away from the chest while seated or reclined.","Chest Press | Chest press",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054656","Leg Press","C122033","An exercise performed by using the legs to push a weighted bar or lever away from the body while seated or reclined.","Leg Press | Leg press",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054321","One Repetition Maximum","C122034","The maximum amount of force that can be generated in one maximal muscle contraction or the maximum amount of weight that can be cycled through one repetition of a particular movement or exercise.","One Repetition Maximum | 1RM | 1Rm | One Rep Maximum | One Repetition Maximum Test | One-Rep Maximum | One-Repetition Maximum | One-Repetition Maximum Muscular Strength Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054757","Hybrid Capture 2 High-Risk HPV DNA Test","C122035","A proprietary in vitro nucleic acid hybridization-based assay kit that can demonstrate the absence or presence of DNA from 13 types of human papillomavirus (HPV) in cervical specimens.","Hybrid Capture 2 High-Risk HPV DNA Test | Digene Hybrid Capture 2 High-Risk HPV DNA Test | High-Risk HPV DNA Test Kit | Qiagen - digene HC2 | digene HC2 | digene HC2 High-Risk HPV DNA Test | hc2 High-Risk HPV DNA Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897672","ST Segment Deviation Aggregate","C117799","An aggregate ST segment deviation value based on the measurement of ST segment deviation from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)","ST Segment Deviation Aggregate | ST Segment Deviation, Aggregate | STDVAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018784","Sensorineural Hearing Loss","C26739","Hearing loss resulting from damage to the cochlea, auditory nerve and/or brainstem.","Sensorineural Hearing Loss | SNHL | Sensorineural Deafness",,,,,,,,,,,,,,,"374366","Sensorineural hearing loss",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0282548","Leukostasis","C4062","A disorder involving the aberrant infiltration and aggregation of leukocytes into the vasculature of the body. Leukostasis is typically detected in the brain and lungs of persons with leukemia. It requires substantial ablative modalities to both reduce the number of cells present and to ensure dispersion of the aggregates.","Leukostasis | ",,,,,,,,,,,,,,,"4147999","Leukostasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1567723","UDP-Glucuronosyltransferase 1-1, Human","C28288","UDP-glucuronosyltransferase 1-1 (533 aa, ~60 kDa) is encoded by the human UGT1A1 gene. This protein is involved in the glucuronidation of bilirubin, simple phenols, flavones, and C18 steroids.","UDP-Glucuronosyltransferase 1-1 | Bilirubin Specific UDPGT Isozyme 1 | Bilirubin UDP-Glucuronosyltransferase | Bilirubin UDP-Glucuronosyltransferase 1-1 | Bilirubin UDP-Glucuronosyltransferase Isozyme 1 | EC 2.4.1.17 | HUG-BR1 | UDP-Glucuronosyltransferase 1-A | UDP-Glucuronosyltransferase 1A1 | UDPGT | UDPGT 1-1 | UGT-1A | UGT1*1 | UGT1-01 | UGT1.1 | UGT1A | UGT1A1 | hUG-BR1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883530","Ventricular Heart Rate","C62151","The number of ventricular beats per unit of time, usually expressed as beats per minute.","Ventricular Heart Rate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0344419","AV Block Third Degree by ECG Finding","C111091","An electrocardiographic finding of complete failure of atrial electrical impulse conduction to the ventricles. This is manifested on the ECG by disassociation of atrial and ventricular rhythms. The atrial rate must be faster than the ventricular rate. (CDISC)","AV Block Third Degree by ECG Finding | 3RD DEGREE AV BLOCK | 3rd Degree Heart Block | AV Block Third Degree | AV Block Third Degree by EKG Finding | AV block, complete (third-degree) | Complete AV Block | Complete Heart Block | Third Degree AV Block | Third Degree Atrioventricular Block",,,,,,,,,,,,,,,"4064874","EKG: complete atrioventricular block",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054731","Induction Death","C121972","Death of the patient due to the toxic side effects of induction therapy.","Induction Death | Death After Induction Therapy | Death During Induction Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054188","Ph-Like Acute Lymphoblastic Leukemia","C121974","B acute lymphoblastic leukemia characterized by a gene-expression profile similar to that of BCR-ABL1-positive B acute lymphoblastic leukemia, absence of the pathognomonic BCR-ABL1 rearrangement, alterations of lymphoid transcription factor genes, and a poor outcome.","B Acute Lymphoblastic Leukemia, BCR-ABL1-Like | B Acute Lymphoblastic Leukemia with BCR-ABL1-Like Features | B Acute Lymphoblastic Leukemia with BCR-ABL1-Like Features | B Acute Lymphoblastic Leukemia with BCR::ABL1-Like Features | B Acute Lymphoblastic Leukemia, BCR-ABL1-Like | B Acute Lymphoblastic Leukemia, BCR::ABL1-Like | B Lymphoblastic Leukemia, Philadelphia-like | B-Acute Lymphoblastic Leukemia with BCR-ABL1-Like Features | B-Acute Lymphoblastic Leukemia with BCR::ABL1-Like Features | B-Acute Lymphoblastic Leukemia, BCR-ABL1-Like | B-Acute Lymphoblastic Leukemia, BCR::ABL1-Like | B-Lymphoblastic Leukemia, Philadelphia-like | BCR-ABL1-like ALL | BCR-ABL1-like Acute Lymphoblastic Leukemia | BCR::ABL1-like features | Ph-Like | Ph-Like ALL | Ph-Like Acute Lymphoblastic Leukemia | Ph-Like Acute Lymphoblastic Leukemia | Ph-like ALL | Philadelphia-Like Acute Lymphoblastic Leukemia | Philadelphia-like ALL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050413","DDIT4L Acute Lymphoblastic Leukemia","C121975","A gene expression subtype of acute lymphoblastic leukemia characterized by its expression level of the DDIT4L gene.","DDIT4L Acute Lymphoblastic Leukemia | DDIT4L | DDIT4L ALL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055497","Acute Lymphoblastic Leukemia by ROSE Cluster","C121978","Unique gene expression-based patient cluster groups in high-risk B-precursor acute lymphoblastic leukemia determined by Recognition of Outliers by Sampling Ends (ROSE).","Acute Lymphoblastic Leukemia by ROSE Cluster | ALL Gene Expression Cluster | ALL ROSE Cluster | Acute Lymphoblastic Leukemia Gene Expression Cluster | Acute Lymphoblastic Leukemia ROSE Cluster",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973075","ROSE Cluster 1","C121980","Gene expression cluster 1 as determined by Recognition of Outliers by Sampling Ends (ROSE) in high-risk B-precursor acute lymphoblastic leukemia.","ROSE Cluster 1 | R1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050313","ROSE Cluster 2","C121981","Gene expression cluster 2 as determined by Recognition of Outliers by Sampling Ends (ROSE) in high-risk B-precursor acute lymphoblastic leukemia.","ROSE Cluster 2 | R2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050314","ROSE Cluster 3","C121982","Gene expression cluster 3 as determined by Recognition of Outliers by Sampling Ends (ROSE) in high-risk B-precursor acute lymphoblastic leukemia.","ROSE Cluster 3 | R3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049710","ROSE Cluster 4","C121983","Gene expression cluster 4 as determined by Recognition of Outliers by Sampling Ends (ROSE) in high-risk B-precursor acute lymphoblastic leukemia.","ROSE Cluster 4 | R4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050064","ROSE Cluster 5","C121984","Gene expression cluster 5 as determined by Recognition of Outliers by Sampling Ends (ROSE) in high-risk B-precursor acute lymphoblastic leukemia.","ROSE Cluster 5 | R5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054130","ROSE Cluster 6","C121985","Gene expression cluster 6 as determined by Recognition of Outliers by Sampling Ends (ROSE) in high-risk B-precursor acute lymphoblastic leukemia.","ROSE Cluster 6 | R6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050315","ROSE Cluster 7","C121986","Gene expression cluster 7 as determined by Recognition of Outliers by Sampling Ends (ROSE) in high-risk B-precursor acute lymphoblastic leukemia.","ROSE Cluster 7 | R7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054129","ROSE Cluster 8","C121988","Gene expression cluster 8 as determined by Recognition of Outliers by Sampling Ends (ROSE) in high-risk B-precursor acute lymphoblastic leukemia.","ROSE Cluster 8 | R8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879958","CDISC SDTM Yes No Unknown or Not Applicable Response Terminology","C66742","Terminology codelist used with Yes No Unknown or Not Applicable Response within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.","CDISC SDTM Yes No Unknown or Not Applicable Response Terminology | NY | No Yes Response | SDTM-NY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0051832","Androstane-3,17-Diol Glucuronide","C121965","A glucuronosyltransferase-modified, alcohol-conjugated metabolite of the steroid androsterone and metabolite of the steroid dihydrotestosterone produced in visceral adipose tissue, with weak androgenic activity. Androstane-3,17-diol glucuronide may be used as a marker for peripheral androgen activity.","Androstane-3,17-Diol Glucuronide | 3,17-Androstanediol Glucuronide | 3-Alpha-Androstanediol Glucuronide | 3-Hydroxyandrostan-17-Yl-Glucopyranosiduronic Acid | 3alpha-DIOL-G | 3alpha-Diol G | 5-Alpha-Androstane-3alpha,17beta-Diol Glucuronide | 5-Androstane-3alpha,17beta-Diol Glucuronide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055467","Angiome","C121987","The collective identity of the angiogenic and inflammatory factors in an organism or biospecimen.","Angiome | Angiome Profile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055403","BASE47 Gene Signature","C121996","A diagnostic system for high grade bladder cancer that can classify a tumor as one of two intrinsic subtypes (luminal or basal-like). This system is based on the expression profile of 47 genes.","BASE47 Gene Signature | BASE47 Gene Set | Bladder Cancer Analysis of Subtypes by Expression 47",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055392","BROCA Gene Signature","C121989","A prognostic system used to assess if a patient has an increased risk for developing hereditary cancer, with a focus on ovarian and breast cancers. This system is based on the use of massively parallel DNA sequencing to detect cancer predisposing mutations in a panel of more than 45 specific genes.","BROCA Gene Signature | BROCA - Cancer Risk Panel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055391","BROCA-HR Gene Signature","C121990","A prognostic system used to assess if a patient has an increased risk for developing hereditary cancer caused by homologous recombination (HR) deficiency. This system leverages massively parallel DNA sequencing to detect cancer predisposing mutations in the genes in the BROCA panel and several additional genes in the Fanconi anemia-BRCA pathway and other DNA repair pathways.","BROCA-HR Gene Signature | BROCA-HR Gene Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055332","CEP 7 Probe","C121976","A set of DNA probes designed for use in FISH. This probe set amplifies a region of chromosome 7 spanning from 7p11.1 to 7q11.1 which includes the centromere. This probe set can facilitate the detection of copy number alterations.","CEP 7 Probe | 7p11.1-q11.1 | CEP7 | Chromosome 7 Centromere Probe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824714","CEP72 Gene","C122056","This gene is involved in mitotic spindle formation.","CEP72 Gene | CEP72 | Centrosomal Protein 72 Gene | Centrosomal Protein 72kDa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055164","DT2219 Antibody","C121979","Any immunoglobulin that recognizes the DT2219 immunotoxin.","DT2219 Antibody | Anti-DT2219 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425690","FAM3C Gene","C122076","This gene is involved in the induction of epithelial-mesenchymal transition.","FAM3C Gene | FAM3C | Family With Sequence Similarity 3, Member C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423498","GOLPH3 Gene","C122037","This gene is involved in cellular trafficking and Golgi shape.","GOLPH3 Gene | GOLPH3 | Golgi Phosphoprotein 3 (Coat-Protein) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0082874","Heterochromatin Protein 1","C121992","A protein family comprised of chromo and chromo shadow domain-containing, methyl-lysine binding proteins that are localized to heterochromatin. These proteins are involved in gene silencing, transcriptional activation, and the formation and stabilization of heterochromatin.","Heterochromatin Protein 1 | HP1 | Heterochromatin Protein-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2327792","Human leukocyte antigen complex","C121977","A family of proteins that are essential for the presentation of peptide antigens on cell surfaces that modulate the host defensive activities of T-cells. This protein family includes major histocompatibility complex (MHC) class I and class II proteins.","HLA Complex | HLA | HLA Family | Histocompatibility Antigen | Human Leukocyte Antigen | Human Leukocyte Antigen Complex | Human Leukocyte Antigen Family | MHC | Major Histocompatibility Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824430","IL34 Gene","C122067","This gene plays a role in receptor binding and cytokine-dependent signaling.","IL34 Gene | IL34 | Interleukin 34 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0648695","Integrin Alpha4/Beta7","C121993","Integrin alpha4/beta7 is a protein complex comprised of a heterodimer of integrin alpha4 and integrin beta7. This complex plays a role in cell-cell adhesion, cell-matrix adhesion, lymphocyte homing and host defense mechanisms.","Integrin Alpha4/Beta7 | Alpha 4 Beta 7 | Alpha 4 Beta 7 Integrin | Alpha(4)Beta(7) Integrin | Alpha4 Beta7 Integrin | Alpha4-Beta7 | Alpha4-Beta7 Integrin | Alpha4/Beta7 | Alpha4/Beta7 Integrin | Integrin Alpha-4/Beta-7 | Integrin Alpha4 Beta7 | Integrin Alpha4-Beta7 | Integrin a4b7 | LPAM | LPAM-1 | Lymphocyte Peyer Patch Adhesion Molecule | alpha4beta7 Integrin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1442491","ITGA6 Gene","C122059","This gene plays a role in both laminin binding and cell adhesion.","ITGA6 Gene | ITGA6 | Integrin Subunit Alpha 6 Gene | Integrin, Alpha 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026004","Presence of micronuclei (toxicology screening result)","C121964","A toxicology screening result where proliferating cells that are exposed to a genotoxic chemical produce some daughter cells containing cytoplasmic bodies that are comprised of chromosomes or chromosome fragments, which were not sorted properly during mitosis or meiosis, and are bounded by a nuclear membrane.","Micronucleus | Micronuclei",,,,,,,,,,,,,,,"4110823","Micronucleus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1417205","MMP16 Gene","C122073","This gene plays a role in both extracellular matrix protein degradation and 72 kDa type IV collagenase activation.","MMP16 Gene | MMP16 | Matrix Metallopeptidase 16 (Membrane-Inserted) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418308","PCDH7 Gene","C122003","This gene plays a role in calcium-dependent cell-cell adhesion.","PCDH7 Gene | PCDH7 | Protocadherin 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418625","PLA2G7 Gene","C122064","This gene is involved in platelet-activating factor modification.","PLA2G7 Gene | PLA2G7 | Phospholipase A2, Group VII (Platelet-Activating Factor Acetylhydrolase, Plasma) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0072275","Prostaglandin E3","C121971","An eicosanoid that is generated by the action of cyclooxygenases on the omega-3 fatty acid eicosapentaenoic acid (EPA). Prostaglandin E3 regulates ocular pressure, exerts anti-inflammatory activities and may inhibit tumor cell proliferation. Prostaglandin E3 may be used as a biomarker for EPA to evaluate the association between EPA and its antineoplastic activity.","Prostaglandin E3 | (5Z,11alpha,13E,15S,17Z)-11,15-Dihydroxy-9-Oxoprosta-5,13,17-Trien-1-Oic Acid | (5Z,13E,15S,17Z)-11alpha,15-Dihydroxy-9-Oxoprosta-5,13,17-Trien-1-Oic Acid | 9-Oxo-11R,15S-Dihydroxy-5Z,13E,17Z-Prostatrienoic Acid | Delta(17)-PGE1 | Delta(17)-Prostaglandin E1 | PGE(3) | PGE1, Delta(17)- | PGE3 | PROSTAGLANDIN E3 | Prosta-5,13,17-Trien-1-Oic Acid, 11,15-Dihydroxy-9-Oxo-, (5Z,11alpha,13E,15S,17Z)- | Prostaglandin E(3)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539685","RPRM Gene","C122053","This gene plays a role in cell cycle arrest.","RPRM Gene | RPRM | Reprimo, TP53 Dependent G2 Arrest Mediator Candidate Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422733","SPAG11B Gene","C122070","This gene may be involved in sperm maturation and motility.","SPAG11B Gene | SPAG11B | Sperm Associated Antigen 11B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049863","Radiologic Impression","C122081","The summary or conclusion of the most important radiologic findings.","Radiologic Impression | Impression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825149","Myeloid Leukemia Associated with Down Syndrome","C43223","Acute myeloid leukemia or myelodysplastic syndrome occurring in children with Down syndrome.  The acute myeloid leukemia is usually an acute megakaryoblastic leukemia, and is associated with GATA1 gene mutation.","Myeloid Leukemia Associated with Down Syndrome | AML Occurring in Children with Down Syndrome | Acute Myeloid Leukemia Occurring in Children with Down syndrome | Acute Myeloid Leukemia with GATA1 Mutations | MLDS | Myeloid leukemia associated with Down Syndrome",,,,,,,,,,,,,,,"42872940","Myeloid leukemia associated with Down Syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1834582","Transient Abnormal Myelopoiesis Associated with Down Syndrome","C82339","A myeloid proliferation occurring in newborns with Down syndrome.  It is clinically and morphologically indistinguishable from acute myeloid leukemia and is associated with GATA1 mutations.  The blasts display morphologic and immunophenotypic features of megakaryocytic lineage.  In the majority of patients the myeloid proliferation undergoes spontaneous remission.","Transient Abnormal Myelopoiesis Associated with Down Syndrome | TAM | Transient Abnormal Myelopoiesis | Transient Abnormal Myelopoiesis | Transient Abnormal Myelopoiesis (TAM) | Transient Myeloproliferative Disorder | Transient abnormal myelopoiesis","9898/1","Transient abnormal myelopoiesis",,,,,,,,,,,,,"36715588|42872939","Transient abnormal myelopoiesis|Transient abnormal myelopoiesis",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"CL028054","Pure Erythroid Leukemia","C7467","Acute erythroid leukemia characterized by the presence of immature erythroid cells in the bone marrow (at least 80% of the cellular component), without evidence of a significant myeloblastic cell population present.","Pure Erythroid Leukemia | Acute Erythremic Myelosis | Acute Myeloid Leukemia M6b | Acute erythremic myelosis | Di Guglielmo Disease | Di Guglielmo disease | Di Guglielmo's Disease | Erythremic Myelosis | M6B | M6b | PEL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053794","PROMIS Adult Social Health Domain","C122340","A Patient Reported Outcomes Measurement Information System (PROMIS) domain that assesses the status of an individual's social health.","PROMIS Adult Social Health Domain | Adult Social Health | Adult Social Health Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055541","Ability to Participate in Social Roles and Activities Subordinate Domain","C122341","The collection of PROMIS item scales that assess an individual's perceived ability to perform their usual social roles and activities.","Ability to Participate in Social Roles and Activities Subordinate Domain | Ability to Participate in Social Roles and Activities | Ability to Participate in Social Roles and Activities Item Bank",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4034916","Have Trouble Doing the Work that is Important to Me","C122342","A question about whether an individual has or had trouble doing all of the work that is really important to them.","Have Trouble Doing the Work that is Important to Me | I have trouble doing all of the work that is really important to me (include work at home)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055068","Emotional Distress-Anxiety Subordinate Domain","C122343","The collection of PROMIS item scales that assess fear, anxious misery, hyperarousal, and somatic symptoms related to arousal.","Emotional Distress-Anxiety Subordinate Domain | Emotional Distress-Anxiety | Emotional Distress-Anxiety Item Bank",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049824","Feel Anxious","C122344","A question about whether an individual feels or felt anxious.","Feel Anxious | Felt Anxious | Have Anxiety | I felt anxious | I have anxiety",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054267","PROMIS Adult Physical Health Domain","C122346","A Patient Reported Outcomes Measurement Information System (PROMIS) domain that assesses the status of an individual's physical health.","PROMIS Adult Physical Health Domain | Adult Physical Health | Adult Physical Health Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050243","Fatigue Subordinate Domain","C122347","The collection of PROMIS item scales that assess fatigue that is likely to decrease an individual's ability to carry out daily activities, including the ability to work effectively and to function at their usual level in family or social roles.","Fatigue Subordinate Domain | Fatigue | Fatigue Item Bank",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054763","How Often Feel Tired","C122348","A question about how often an individual feels or felt tired.","How Often Feel Tired | Frequency Feeling Tired | How often did you feel tired",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054764","How Often Experience Extreme Exhaustion","C122349","A question about how often an individual experiences or experienced extreme exhaustion.","How Often Experience Extreme Exhaustion | Frequency Experiencing Extreme Exhaustion | How often did you experience extreme exhaustion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054761","How Often Run Out of Energy","C122350","A question about how often an individual ran or runs out of energy.","How Often Run Out of Energy | Frequency Run Out of Energy | How often did you run out of energy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054765","How Often Did Fatigue Limit Work","C122351","A question about how often fatigue limits an individual at work.","How Often Did Fatigue Limit Work | Frequency that Fatigue Limited Work | Frequency that Fatigue Limits Work | How Often Does Fatigue Limit Work | How often did your fatigue limit you at work (include work at home)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054759","How Often Too Tired to Think Clearly","C122352","A question about how often an individual is or was too tired to think clearly.","How Often Too Tired to Think Clearly | Frequency Too Tired to Think Clearly | How often were you too tired to think clearly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054760","How Often Too Tired to Bathe or Shower","C122353","A question about how often an individual is or was too tired to take a bath or shower.","How Often Too Tired to Bathe or Shower | Frequency Too Tired to Bathe or Shower | How often were you too tired to take a bath or shower",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054762","How Often Have Enough Energy to Exercise Strenuously","C122354","A question about how often an individual has or had enough energy to exercise strenuously.","How Often Have Enough Energy to Exercise Strenuously | Frequency Have Enough Energy to Exercise Strenuously | How often did you have enough energy to exercise strenuously",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054268","PROMIS Adult Global Health Domain","C122355","A Patient Reported Outcomes Measurement Information System (PROMIS) domain that assesses overall health in general, including global ratings of the five primary PROMIS domains (physical function, fatigue, pain, emotional distress, social health) as well as perceptions of general health that cut across domains.","PROMIS Adult Global Health Domain | Adult Global Health | PROMIS Adult Global Health",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049916","Physical Function Subordinate Domain","C122356","The collection of PROMIS item scales that assess an individual's ability to carry out activities that require physical actions including more complex activities that require a combination of skills, often within a social context.","Physical Function Subordinate Domain | Physical Function | Physical Function Item Bank",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2963465","Current Health Limits Vigorous Activities","C122357","A question about whether an individual's current health limits them in doing vigorous activities.","Current Health Limits Vigorous Activities Question | Current Health Limits Vigorous Activities | Current Health Limits Vigorous Activities | Does your health now limit you in doing vigorous activities, such as running, lifting heavy objects, participating in strenuous sports",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3484323","Current Health Limits Walking More Than a Mile","C122358","A question about whether an individual's current health limits them in walking more than a mile.","Current Health Limits Walking More Than a Mile Question | Current Health Limits Walking More Than a Mile | Current Health Limits Walking More Than a Mile | Does your health now limit you in walking more than a mile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3484319","Current Health Limits Climbing One Flight of Stairs","C122359","A question about whether an individual's current health limits them in climbing one flight of stairs.","Current Health Limits Climbing One Flight of Stairs | Does your health now limit you in climbing one flight of stairs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2963460","Current Health Limits Bending, Kneeling or Stooping","C122360","A question about whether an individual's current health limits them in bending, kneeling, or stooping.","Current Health Limits Bending, Kneeling or Stooping | Does your health now limit you in bending, kneeling, or stooping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2963288","Ability to Dress Yourself","C122361","A question about the ability of an individual to dress, including tying shoelaces and doing buttons.","Ability to Dress Yourself Question | Ability to Dress Yourself | Ability to Dress Yourself | Ability to Dress Yourself Including Tying Shoelaces and Doing Buttons | Are you able to dress yourself, including tying shoelaces and doing buttons",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055532","Ability to Shampoo Your Hair","C122362","A question about the ability of an individual to shampoo their hair.","Ability to Shampoo Your Hair Question | Ability to Shampoo Your Hair | Ability to Shampoo Your Hair",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055522","Ability to Wash and Dry Your Body","C122363","A question about the ability of an individual to wash and dry their body.","Ability to Wash and Dry Your Body Question | Ability to Wash and Dry Your Body | Ability to Wash and Dry Your Body",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0578240","Ability to Get On and Off the Toilet","C122364","A question about the ability of an individual to get on and off the toilet.","Ability to Get On and Off the Toilet Question | Ability to Get On and Off the Toilet | Ability to Get On and Off the Toilet",,,,,,,,,,,,,,,"4199719|4200808","Ability to get off toilet|Ability to get on and off toilet",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C4049871","Frequency Thinking Has Been Slow","C122388","A question about how often an individual's thinking has or had been slow.","Frequency Thinking Has Been Slow | How Often Thinking Has Been Slow | My thinking has been slow",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054041","Seems Like Brain is Not Working as Well as Usual","C122366","A question about how often it seems like an individual's brain is not working as well as usual.","Seems Like Brain is Not Working as Well as Usual | It has seemed like my brain was not working as well as usual",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054926","Frequency Have Trouble Shifting Back and Forth Between Different Activities that Require Thinking","C122389","A question about how often an individual has or had trouble shifting back and forth between different activities that require thinking.","Frequency Have Trouble Shifting Back and Forth Between Different Activities that Require Thinking | How Often Have Trouble Shifting Back and Forth Between Different Activities that Require Thinking | I have had trouble shifting back and forth between different activities that require thinking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054838","Have Trouble Adding or Subtracting Numbers in My Head","C122368","A question about how often an individual has or had trouble adding or subtracting numbers in their head.","Have Trouble Adding or Subtracting Numbers in My Head | I have had trouble adding or subtracting numbers in my head",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055239","Choi Response Criteria in the Evaluation of Gastrointestinal Stromal Tumors","C122394","A composite set of criteria developed by Choi et al. using imaging techniques in the evaluation of gastrointestinal stromal tumors response to imatinib mesylate treatment. These criteria integrate changes in tumor size and tumor density.","Choi Response Criteria in the Evaluation of Gastrointestinal Stromal Tumors | CHOI GIST 2008 | Choi | Choi Criteria | Choi Response Criteria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4034920","Have to Limit Regular Activities with Family","C122417","A question about whether an individual has or had to limit their regular activities with family.","Have to Limit Regular Activities with Family | I have to limit my regular family activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0724672","Polyethylene Glycol 3350","C80131","No Value Exists","Polyethylene Glycol 3350 | POLYETHYLENE GLYCOL 3350",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0074332","Sennosides","C29448","Anthraquinone glycosides found in senna plant, usually referring to the sennosides A and B, with laxative activity. Sennosides act on and irritate the lining of the intestine wall, thereby causing increased intestinal muscle contractions leading to vigorous bowel movement.","Sennosides | Nature's Remedy | Perdiem | SENNOSIDES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053991","Standard Risk Acute Leukemia","C122457","Acute leukemia patients are stratified into the standard risk group when their minimal residual disease levels are lower than 0.05%.","Standard Risk Acute Leukemia | Standard Risk | Standard Risk (MRD <0.05%)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050568","High Risk Acute Leukemia","C122458","Acute leukemia patients are stratified into the high risk group when their minimal residual disease levels are higher than 0.05%.","High Risk Acute Leukemia | High Risk | High Risk (MRD > 0.05%)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448850","Aggregation","C62344","A process by which particles collect to form a cohesive mass or cluster. The resulting structure is called an aggregate.","Aggregation | AGGREGATE | Aggregates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4229003","Osteosclerosis","C41236","Abnormally high bone density.","Osteosclerosis | ",,,,,,,,,,,,,,,"4174195","Osteosclerosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4050225","Often - answer to question","C120595","A subjective answer that something occurs frequently.","Often | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0200665","Mean Platelet Volume Measurement","C74730","The determination of the average size of the platelets present in a blood sample.","Mean Platelet Volume Measurement | MPV | Mean Platelet Volume",,,,,,,,,,,,,,,"4192368","Platelet mean volume determination",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055028","FACT-N Questionnaire","C122565","A subscale complement to the FACT-G developed specifically for evaluating the quality of life of cancer patients with neutropenia.","FACT-N Questionnaire | FACT-N | Functional Assessment of Cancer Therapy-Neutropenia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053841","Worry About Getting Infections","C122567","A question about whether an individual worries or worried about getting infections.","Worry About Getting Infections | I worry about getting infections",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054986","Feel Discouraged About Illness","C122568","A question about whether an individual feels or felt discouraged about their illness.","Feel Discouraged About Illness | I feel discouraged about my illness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053840","Worry About Getting New Symptoms","C122569","A question about whether an individual worries or worried that they might get new symptoms of their illness.","Worry About Getting New Symptoms | I worry that I might get new symptoms of my illness | Worry Might Get New Symptoms of My Illness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053808","Have Emotional Ups and Downs","C122570","A question about whether an individual has or had emotional ups and downs.","Have Emotional Ups and Downs | I have emotional ups and downs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055029","FACT-MM Questionnaire","C122566","A subscale complement to the FACT-G developed specifically for evaluating the quality of life of patients with multiple myeloma.","FACT-MM Questionnaire | FACT-MM | Functional Assessment of Cancer Therapy-Multiple Myeloma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054834","Have Trouble Walking Because of Pain","C122571","A question about whether an individual has or had trouble walking because of pain.","Have Trouble Walking Because of Pain Question | Have Trouble Walking Because of Pain | Have Trouble Walking Because of Pain | I have trouble walking because of pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521879","GAGE Tumor Antigen","C1939","A family of tumor antigens.  Expressed in adult normal testis and some sarcomas, melanomas, nonsmall cell lung carcinomas, head and neck tumors, and bladder tumors.","GAGE | G Antigen Family | GAGE Family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333579","FRS3 Gene","C24820","This gene is involved in signal transduction.","FRS3 Gene | FRS3 | Fibroblast Growth Factor Receptor Substrate 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919936","No Prior Therapy","C118903","No prior treatment for the study disorder.","No Prior Therapy | Therapy Naive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3179112","Feeder Layer","C112957","A layer of supportive cells that are irradiated to prevent replication but can still secrete growth enhancing factors for use in co-culture","Feeder Layer | Production, Feeder Cell Layer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1565020","Monomethyl Auristatin E","C122637","A dolastatin-10 peptide derivative with potent antimitotic activity and potential antineoplastic activity as part of an antibody-drug conjugate (ADC). Monomethyl auristatin E (MMAE) binds to tubulin, blocks tubulin polymerization, and inhibits microtubule formation, which results in both disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. To minimize toxicity and maximize efficacy, MMAE is conjugated, via a cleavable peptide linker, to a monoclonal antibody that specifically targets a patient's tumor. The linker is stable in the extracellular milieu but is readily cleaved to release MMAE following binding and internalization of the ADC by the target cells.","Monomethyl Auristatin E | (S)-N-((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)-N,3-dimethyl-2-((S)-3-methyl-2-(methylamino)butanamido)butanamide | L-Valinamide, N-methyl-L-valyl-N-((1S,2R)-4-((2S)-2-((1R,2R)-3-(((1R,2S)-2-hydroxy-1- methyl-2-phenylethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)-1-pyrrolidinyl)-2- methoxy-1-((1S)-1-methylpropyl)-4-oxobutyl)-N-methyl- | L-Valinamide, N-methyl-L-valyl-N-((1S,2R)-4-((2S)-2-((1R,2R)-3-(((1R,2S)-2-hydroxy-1- methyl-2-phenylethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)-1-pyrrolidinyl)-2- methoxy-1-((1S)-1-methylpropyl)-4-oxobutyl)-N-methyl-  | MMAE | MONOMETHYL AURISTATIN E | Monomethylauristatin E | N(sup 2)-(N-methyl-L-valyl)-N(sup 1)-((1S,2R)-4-((2S)-2-((1R,2R)-3-(((1R,2S)-2-hydroxy-1-methyl-2- phenylethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-2-methoxy-1-((1S)-1-methylpropyl)-4-oxobutyl)-N(sup 1)-methyl-L-valinamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055486","Advertising, Marketing, Promotions, Public Relations, and Sales Managers","C122418","Workers who plan programs to generate interest in a product or service, plan and direct the creation of material that will maintain or enhance the public image of their employer or client, and/or direct an organization's sales teams.","Advertising, Marketing, Promotions, Public Relations, and Sales Managers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4048190","Agricultural Workers","C122421","Workers who maintain the quality of farms, crops, and livestock by operating machinery and doing physical labor under the supervision of farmers, ranchers, and other agricultural managers.","Agricultural Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055483","Air Transportation Workers","C122422","Workers involved with the transportation of passengers and/or cargo using aircraft. This includes aircraft mechanics and service technicians; airline pilots, copilots, and flight engineers; cargo and freight agents; and reservation and transportation ticket agents and travel clerks.","Air Transportation Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055465","Animal Care and Service Workers","C122423","Workers who provide care for animals. They feed, water, groom, bathe, and exercise pets and other nonfarm animals. Job tasks vary by position and place of work.","Animal Care and Service Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055443","Architects, Surveyors, and Cartographers","C122424","Workers who plan and design houses, office buildings, and other structures, make precise measurements to determine property boundaries, and/or collect, measure, and interpret geographic information to create maps and charts for political, educational, and other purposes.","Architects, Surveyors, and Cartographers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698156","Glembatumumab Vedotin","C78449","An antibody-drug conjugate, consisting of the fully human monoclonal antibody CR011 directed against glycoprotein NMB (GPNMB) and conjugated via a cathepsin B-sensitive valine-citrulline (vc) linkage to the cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration, the monoclonal antibody CR011 moiety binds to glycoprotein nmb (GPNMB), expressed on the surfaces of a variety of cancer cell types; upon endocytosis, the synthetic dolastin analogue MMAE is released via enzymatic cleavage into the tumor cell cytosol, where it binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and apoptosis. The vc linkage system is highly stable in serum, rendering the cytotoxicity of glembatumumab vedotin specific for GPNMB-positive cells. GPNMB is a transmembrane protein overexpressed on the surfaces of various cancer cell types, including melanoma, breast, and prostate cancer cells.","Glembatumumab Vedotin | Antibody-Drug Conjugate CR011-vcMMAE | CDX-011 | CR011-vcMMAE | CR011-vcMMAE Immunotoxin | GLEMBATUMUMAB VEDOTIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055441","Art and Design Workers","C122428","Workers who are responsible for the visual style of: consumer and industrial products, movie and television productions, product images in magazines and newspapers, interior design, and visual effects.","Art and Design Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055435","Assemblers and Fabricators","C122429","Workers who use tools, machines, and their hands to assemble finished products and the parts that go into them.","Assemblers and Fabricators | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055345","Building Cleaning and Pest Control Workers","C122431","Workers who keep buildings and their surrounding grounds in clean, orderly, and good condition, and/or control unwanted creatures.","Building Cleaning and Pest Control Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055344","Business Operations Specialists","C122432","Workers whose general job duties include analyzing a business's current operations, identifying customer needs, creating reports, developing improvement plans, assisting departments in implementing changes, management and staffing, fundraising, and/or appraisals and investigations.","Business Operations Specialists | Business Operations Specialist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055214","Communications Equipment Operators","C122433","Workers who operate telephone business systems equipment or switchboards, and/or provide information by accessing directories, assist customers with special billing requests.","Communications Equipment Operators | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055210","Computer Specialists","C122434","Workers who provide help and advice to people and organizations using computer software or equipment. Some support information technology (IT) employees and others assist non-IT users who are having computer problems.","Computer Specialists | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055187","Construction Trades Workers","C122436","A tradesman, laborer (an unskilled tradesman), or professional employed in the physical construction of the built environment and its infrastructure.","Construction Trades Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055181","Cooks and Food Preparation Workers","C122440","Workers who prepare, season, and cook foods, as well as workers who perform routine tasks under the direction of cooks, chefs, or food service managers.","Cooks and Food Preparation Workers | Cook | Cooks",,,,,,,,,,,,,,,"4024309","Cook",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055179","Counselors, Social Workers, and Other Community and Social Service Specialists","C122441","Workers who make arrangements for needed services and treatments for individuals and families and/or develop and implement specialized treatment programs within a community. Others provide front line support and social assistance for individuals, families, and communities in need.","Counselors, Social Workers, and Other Community and Social Service Specialists | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055117","Drafters, Engineering, and Mapping Technicians","C122442","Workers who use software to convert the designs of engineers and architects into technical drawings and plans.","Drafters, Engineering, and Mapping Technicians | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055072","Electrical and Electronic Equipment Mechanics, Installers, and Repairers","C122446","Workers who install, repair, or replace a variety of electrical equipment in telecommunications, transportation, utilities, and other industries.","Electrical and Electronic Equipment Mechanics, Installers, and Repairers | Electrical Equipment Installer and Repairer | Electrical Equipment Installers and Repairers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0878517","Engineers","C122447","A professional practitioner of engineering, concerned with applying scientific knowledge, mathematics, and ingenuity to develop solutions for technical, societal and commercial problems. Engineers design materials, structures, and systems while considering the limitations imposed by practicality, regulation, safety, and cost.","Engineers | Engineering Professional (Excluding Electrotechnology) | Engineering Professionals (excluding Electrotechnology)",,,,,,,,,,,,,,,"4023457","Engineer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055059","Entertainers and Performers, Sports and Related Workers","C122448","The actors, producers, directors, dancers and choreographers, musicians, singers, directors, and composers employed in the entertainment fields, as well as the athletes, coaches, scouts, managers, trainers, and umpires employed in professional sports.","Entertainers and Performers, Sports and Related Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055058","Entertainment Attendants and Related Workers","C122449","The ushers, lobby attendants, ticket takers, and projectionists employed in theaters, amusement and recreation attendants, costume attendants, locker room, coatroom, and dressing room attendants, and workers in the gaming and gambling industries.","Entertainment Attendants and Related Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053802","Extraction Workers","C122450","Any worker involved in extracting resources from the ground or the sea.","Extraction Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054956","Financial Clerks","C122451","Workers who do administrative work for financial institutions or within the financial industries.","Financial Clerks | Teller, Money Collector and Related Clerk | Tellers, Money Collectors and Related Clerks",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054955","Financial Specialists","C122452","Workers who meet with customers to help them determine their short-term and long-term financial goals and provide insurance, investment services, certificates of deposits and other financial instruments. They also contact prospective customers, evaluate costs and revenue, make financial presentations and review business trends.","Financial Specialists | Finance Professional | Finance Professionals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054954","Fire Fighting and Prevention Workers","C122453","Workers engaged in fire fighting and fire prevention and control.","Fire Fighting and Prevention Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054952","First-Line Enlisted Military Supervisor and Managers","C122454","Workers who directly supervise and coordinate the activities of enlisted military personnel.","First-Line Enlisted Military Supervisor and Managers | First-Line Enlisted Military Supervisor and Managers; First-Line Enlisted Military Supervisor/Managers | First-Line Enlisted Military Supervisor/Managers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054951","First-Line Protective Service Worker Supervisors and Managers","C122455","Workers who directly supervise and coordinate the activities of protective service workers.","First-Line Protective Service Worker Supervisors and Managers | First-Line Protective Service Worker Supervisors and Managers; First-Line Supervisors/Managers, Protective Service Workers | First-Line Supervisors/Managers, Protective Service Workers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054950","Fishing and Hunting Workers","C122459","Workers who gather fish or other aquatic animals for human consumption or other uses and/or hunt and trap wild animals for human consumption, fur, feed, bait, or other purposes.","Fishing and Hunting Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054937","Food and Beverage Serving Workers","C122460","Workers who perform a variety of customer service, food preparation, and cleaning duties in restaurants, cafeterias, and other eating and drinking establishments.","Food and Beverage Serving Workers | Waiter and Bartender | Waiters and Bartenders",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054938","Food Processing Workers","C122461","Workers who operate equipment that mixes, cooks, or processes ingredients used in the manufacturing of food.","Food Processing Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054933","Forest, Conservation, and Logging Workers","C122462","Workers who measure and improve the quality of forests, develop, maintain, and protect forests, and/or harvest timber that provides the raw material for many consumer goods and industrial products.","Forest, Conservation, and Logging Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054915","Funeral Service Workers","C122463","Workers who organize and manage the details of a funeral.","Funeral Service Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054883","Grounds Maintenance Workers","C122464","Workers who provide a pleasant outdoor environment by ensuring that the grounds of houses, businesses, and parks are attractive, orderly, and healthy.","Grounds Maintenance Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054830","Health Diagnosing and Treating Practitioners","C122465","The group of professions that include chiropractors, dentists, dietitians and nutritionists, optometrists, pharmacists, physicians and surgeons, physicians assistants, podiatrists, registered nurses, therapists, and veterinarians.","Health Diagnosing and Treating Practitioners | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054807","Health Technologists and Technicians","C122466","Technicians who prepare specimens, operate automated analyzers and perform manual tests with detailed instructions, and technologists who problem solve, conduct data interpretation, establish and monitor programs, type and cross match blood samples and act as project managers.","Health Technologists and Technicians | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054797","Helpers, Construction Trades","C122467","Workers who perform basic tasks that require physical labor on construction sites.","Helpers, Construction Trades | Construction Trades Helpers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054717","Information and Record Clerks","C122468","Workers who perform routine clerical duties such as maintaining records, collecting data, and providing information to customers.","Information and Record Clerks | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0682241","Law Enforcement Workers","C122469","The group of professions that include bailiffs, correctional officers, and jailers; detectives and criminal investigators; fish and game wardens; parking enforcement workers; and police officers.","Law Enforcement Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054661","Lawyers, Judges, and Related Workers","C122471","Lawyers advise and represent individuals, businesses, and government agencies on legal issues and disputes. Judges and hearing officers apply the law by overseeing the legal process in courts. They also conduct pretrial hearings, resolve administrative disputes, facilitate negotiations between opposing parties, and issue legal decisions.","Lawyers, Judges, and Related Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054655","Legal Support Workers","C122472","Paralegals and legal assistants assist lawyers by investigating facts, preparing legal documents, or researching legal precedent. Court reporters use verbatim methods and equipment to capture, store, retrieve, and transcribe pretrial and trial proceedings or other information. Title examiners, abstractors, and searchers search real estate records, examine titles, or summarize pertinent legal or insurance documents or details for a variety of purposes.","Legal Support Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0335110","Librarians, Curators, and Archivists","C122473","Workers who appraise, edit, and maintain permanent records and historically valuable documents; oversee collections of artwork and historic items; restore objects and documents in museum collections and exhibits, and/or help people find information and conduct research for personal and professional use.","Librarians, Curators, and Archivists | Librarian, Archivist and Curator | Librarians, Archivists and Curators",,,,,,,,,,,,,,,"4023477","Librarian, archivist AND/OR curator",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054649","Life Scientists","C122474","The group of science professions that include animal scientists, biochemists and biophysicists, epidemiologists, food scientists and technologists, medical scientists, microbiologists, zoologists and wildlife biologists, and soil and plant scientists.","Life Scientists | Life Science Professional | Life Science Professionals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054648","Life, Physical, and Social Science Technicians","C122475","Life science technicians typically work in laboratories assisting scientists in the research of living organisms and organic substances. Physical science technicians assist senior resource scientists by collecting, managing, analyzing, and interpreting a wide array of physical science information. Social science technicians do nonprofessional work of a technical, specialized, or support nature in one or more of the social science fields.","Life, Physical, and Social Science Technicians | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054573","Material Moving Workers","C122476","The group of professions that include delivery truck drivers and driver/sales workers, hand laborers and material movers, heavy and tractor-trailer truck drivers, and material moving machine operators.","Material Moving Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054572","Material Recording, Scheduling, Dispatching, and Distributing Workers","C122477","Workers who compile records concerning quantity, cost, and type of material received, stored or issued, or who schedule and coordinate flow of work within or between departments.","Material Recording, Scheduling, Dispatching, and Distributing Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054570","Mathematical Science Occupations","C122480","The group of professions that include actuaries, mathematicians, statisticians, and mathematical technicians.","Mathematical Science Occupations | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054556","Media and Communication Equipment Workers","C122481","The group of professions that include broadcast and sound engineering technicians and radio operators; photographers; and television, video, and motion picture camera operators and editors.","Media and Communication Equipment Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054555","Media and Communication Workers","C122482","The group of professions that include announcers, news analysts, reporters and correspondents, public relations specialists, writers and editors.","Media and Communication Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054528","Metal Workers and Plastic Workers","C122483","The group of professions that include computer control programmers and operators; forming machine setters, operators, and tenders; machine tool cutting setters, operators, and tenders; machinists, metal furnace operators, tenders, pourers, and casters; model makers and patternmakers; molders and molding machine setters, operators, and tenders; multiple machine tool setters, operators, and tenders; tool and die makers; and welding, soldering, and brazing workers.","Metal Workers and Plastic Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054520","Military Officer Special and Tactical Operations Leaders and Managers","C122484","The group of professions that include air crew officers, aircraft launch and recovery officers, armored assault vehicle officers, artillery and missile officers, command and control center officers, infantry officers, and special forces officers.","Military Officer Special and Tactical Operations Leaders and Managers | Military Officer Special and Tactical Operations Leaders and Managers; Military Officer Special and Tactical Operations Leaders/Managers | Military Officer Special and Tactical Operations Leaders/Managers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054522","Military Enlisted Tactical Operations and Air/Weapons Specialists and Crew Members","C122485","The group of professions that include air crew members, aircraft launch and recovery specialists, armored assault vehicle crew members, artillery and missile crew members, command and control center specialists, infantry members, radar and sonar technicians, and special forces members.","Military Enlisted Tactical Operations and Air/Weapons Specialists and Crew Members | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054456","Motor Vehicle Operators","C122486","The group of professions that include ambulance drivers and attendants, bus drivers, driver/sales workers, heavy and tractor-trailer truck drivers, light truck or delivery service drivers, and taxi drivers and chauffeurs.","Motor Vehicle Operators | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054326","Nursing, Psychiatric, and Home Health Aides","C122487","Nursing aides, orderlies, and attendants provide basic patient care under direction of nursing staff; performed duties include feeding, bathing, dressing, grooming, moving patients, and changing linens. Psychiatric aides assist mentally impaired or emotionally disturbed patients, working under direction of nursing and medical staff. Home health aides provide routine, personal healthcare, such as bathing, dressing, or grooming, to elderly, convalescent, or disabled persons in the home of patients or in a residential care facility.","Nursing, Psychiatric, and Home Health Aides | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054322","Occupational and Physical Therapist Assistants and Aides","C122488","Occupational therapy assistants and aides work under the direction of occupational therapists, helping patients develop, recover, and improve the skills needed for daily living and working. Occupational therapy assistants are directly involved in providing therapy to patients, while occupational therapy aides typically perform support activities. Physical therapist assistants and physical therapist aides work under the direction and supervision of physical therapists, helping patients who are recovering from injuries and illnesses regain movement and manage pain.","Occupational and Physical Therapist Assistants and Aides | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054319","Operations Specialties Managers","C122489","The group of professions that include administrative services managers, computer and information systems managers, financial managers, human resources managers, training and development managers, and transportation, storage, and distribution managers.","Operations Specialties Managers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054190","Personal Appearance Workers","C122496","Barbers provide services, such as cutting, trimming, shampooing, and styling hair, trimming beards, or giving shaves. Hairdressers, hairstylists, and cosmetologists provide beauty services, such as shampooing, cutting, coloring, and styling hair, and massaging and treating scalp. They may also apply makeup, dress wigs, perform hair removal, and provide nail and skin care services. Makeup artists, theatrical and performance apply makeup to performers to reflect period, setting, and situation of their role. Manicurists and pedicurists clean, shape, and decorate customers' fingernails and toenails. Shampooers clean and rinse customers' hair. Skin care specialists provide skin care treatments to face and body to enhance an individual's appearance.","Personal Appearance Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334723","Physical Scientists","C122497","The group of science professions that include astronomers, physicists, atmospheric and space scientists, chemists, materials scientists, environmental scientists and specialists, geoscientists, and hydrologists.","Physical Scientists | ",,,,,,,,,,,,,,,"4025374","Physical scientist",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054174","Plant and System Operators","C122498","The group of professions that include chemical plant system operators, nuclear power reactor operators, power distributors and dispatchers, power plant operators, water and wastewater treatment plant and system operators, stationary engineers and boiler operators, and gas plant operators, petroleum pump system operators, refinery operators, and gaugers.","Plant and System Operators | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054161","Postsecondary Teachers","C122499","Postsecondary teachers instruct students in a wide variety of academic and vocational subjects beyond the high school level. They also conduct research and publish scholarly papers and books.","Postsecondary Teachers | University and Higher Education Teacher | University and Higher Education Teachers",,,,,,,,,,,,,,,"4025384","University AND/OR higher education teacher",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054153","Primary, Secondary, and Special Education School Teachers","C122500","The teaching professions that include elementary school teachers, middle school teachers, middle school career/technical education teachers, secondary school teachers, secondary school career/technical education teachers, middle school special education teachers, and secondary school special education teachers.","Primary, Secondary, and Special Education School Teachers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053770","Printing Workers","C122501","Printing workers produce print material in three stages: prepress, press, and binding and finishing. They review specifications, calibrate color settings on printers, identify and fix problems with printing equipment, and assemble pages.","Printing Workers | Printing Trades Worker | Printing Trades Workers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053767","Rail Transportation Workers","C122502","Workers in railroad occupations ensure that passenger and freight trains run on time and travel safely. Some workers drive trains, some coordinate the activities of the trains, while others operate signals and switches in the rail yard.","Rail Transportation Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0335021","Religious Workers","C122503","Clergy conduct religious worship and perform other spiritual functions associated with beliefs and practices of religious faith or denomination. They also provide spiritual and moral guidance and assistance to members. Directors of religious activities and education plan, direct, or coordinate programs designed to promote the religious education or activities of a denominational group. They may provide counseling and guidance relative to marital, health, financial, and religious problems.","Religious Workers | ",,,,,,,,,,,,,,,"4024857","Worker in religion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054064","Retail Sales Workers","C122504","Retail sales workers include both those who sell retail merchandise, such as clothing, furniture, and automobiles, (retail salespersons) and those who sell spare and replacement parts and equipment, especially car parts (parts salespersons). Both types of workers help customers find the products they want and process customers' payments.","Retail Sales Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054052","Sales Representatives, Services","C122505","Advertising sales agents sell or solicit advertising, including graphic art, advertising space in publications, custom made signs, or TV and radio advertising time. They may obtain leases for outdoor advertising sites or persuade retailer to use sales promotion display items. Insurance sales agents sell life, property, casualty, health, automotive, or other types of insurance. They may refer clients to independent brokers, work as an independent broker, or be employed by an insurance company. Travel agents plan and sell transportation and accommodations for travel agency customers. They help determine destination, modes of transportation, travel dates, costs, and accommodations required.","Sales Representatives, Services | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054051","Sales Representatives, Wholesale and Manufacturing","C122506","Wholesale and manufacturing sales representatives sell goods for wholesalers or manufacturers to businesses, government agencies, and other organizations. They contact customers, explain product features, answer any questions that their customers may have, and negotiate prices.","Sales Representatives, Wholesale and Manufacturing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054042","Secretaries and Administrative Assistants","C122508","Secretaries and administrative assistants perform routine clerical and administrative duties. They organize files, draft messages, schedule appointments, and support other staff.","Secretaries and Administrative Assistants | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054009","Social Scientists and Related Workers","C122509","The group of professions that include economists, marketing research analysts, survey researchers, clinical, counseling, and school psychologists, industrial-organizational psychologists, sociologists, urban and regional planners, anthropologists and archeologists, geographers, historians, and political scientists.","Social Scientists and Related Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053981","Supervisors of Installation, Maintenance, and Repair Workers","C122510","Workers who directly supervise and coordinate the activities of mechanics, installers, and repairers.","Supervisors of Installation, Maintenance, and Repair Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053980","Supervisors, Building and Grounds Cleaning and Maintenance Workers","C122511","Workers who directly supervise housekeeping and janitorial workers, landscaping, lawn service, and groundskeeping workers.","Supervisors, Building and Grounds Cleaning and Maintenance Workers | Supervisors of Building and Grounds Cleaning and Maintenance Workers | Supervisors, Building and Grounds Cleaning and Maintenance Workers; Supervisors of Building and Grounds Cleaning and Maintenance Workers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053979","Supervisors, Construction and Extraction Workers","C122514","Workers who directly supervise and coordinate activities of construction or extraction workers.","Supervisors, Construction and Extraction Workers | Supervisors of Construction and Extraction Workers | Supervisors, Construction and Extraction Workers; Supervisors of Construction and Extraction Workers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053978","Supervisors, Farming, Fishing, and Forestry Workers","C122515","Workers who directly supervise and coordinate the activities of agricultural, forestry, aquacultural, and related workers.","Supervisors, Farming, Fishing, and Forestry Workers | Supervisors of Farming, Fishing, and Forestry Workers | Supervisors, Farming, Fishing, and Forestry Workers; Supervisors of Farming, Fishing, and Forestry Workers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053977","Supervisors, Food Preparation and Serving Workers","C122517","Workers who directly supervise and coordinate activities of workers engaged in preparing and serving food.","Supervisors, Food Preparation and Serving Workers | Supervisors of Food Preparation and Serving Workers | Supervisors, Food Preparation and Serving Workers; Supervisors of Food Preparation and Serving Workers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053976","Supervisors, Office and Administrative Support Workers","C122518","Workers who directly supervise and coordinate the activities of clerical and administrative support workers.","Supervisors, Office and Administrative Support Workers | Supervisors of Office and Administrative Support Workers | Supervisors, Office and Administrative Support Workers; Supervisors of Office and Administrative Support Workers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053975","Supervisors, Personal Care and Service Workers","C122519","Workers who directly supervise and coordinate activities of personal service workers, such as flight attendants, hairdressers, or caddies.","Supervisors, Personal Care and Service Workers | Supervisors of Personal Care and Service Workers | Supervisors, Personal Care and Service Workers; Supervisors of Personal Care and Service Workers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054027","Side Effects of Treatment are Worse than Imagined","C122652","A question about whether an individual feels or felt the treatment side effects are worse than imagined.","Side Effects of Treatment are Worse than Imagined | The side effects of treatment are worse than I had imagined",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274397","Free Kappa Light Chain Measurement","C98730","The determination of the amount of free kappa light chain present in a sample.","Free Kappa Light Chain Measurement | Bence-Jones, Kappa | KLCFR | Kappa Light Chain, Free | Serum Free Immunoglobulin Light Chain, Kappa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274399","Free Lambda Light Chain Measurement","C98732","The determination of the amount of free lambda light chain present in a sample.","Free Lambda Light Chain Measurement | Bence-Jones, Lambda | LLCFR | Lambda Light Chain, Free | Serum Free Immunoglobulin Light Chain, Lambda",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033414","Promotion","C61391","Encouragement of the progress or growth or acceptance of something.","Promotion | Promote | Promoting",,,,,,,,,,,,,,,"46271870","Promotion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0949214","Advertisements","C115435","An act, practice or form of communication used to encourage, persuade, or manipulate an audience to take or continue to take a certain action.","Advertisement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053974","Supervisors, Production Workers","C122520","Workers who directly supervise and coordinate the activities of production and operating workers, such as inspectors, precision workers, machine setters and operators, assemblers, fabricators, and plant and system operators.","Supervisors, Production Workers | Supervisors of Production Workers | Supervisors, Production Workers; Supervisors of Production Workers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053973","Supervisors, Sales Workers","C122521","Workers who directly supervise and coordinate activities of sales workers other than retail sales workers. May perform duties, such as budgeting, accounting, and personnel work, in addition to supervisory duties.","Supervisors, Sales Workers | Supervisors of Sales Workers | Supervisors, Sales Workers; Supervisors of Sales Workers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053972","Supervisors, Transportation and Material Moving Workers","C122522","Workers who directly supervise and coordinate activities of aircraft cargo handlers; helpers, laborers, and hand material movers; and transportation and material-moving machine and vehicle operators.","Supervisors, Transportation and Material Moving Workers | Supervisors of Transportation and Material Moving Workers | Supervisors, Transportation and Material Moving Workers; Supervisors of Transportation and Material Moving Workers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053941","Textile, Apparel, and Furnishings Workers","C122524","The group of professions that include laundry and dry-cleaning workers, pressers of textile, garment, and related materials, sewing machine operators, shoe and leather workers, tailors, dressmakers, and sewers, textile machine setters, operators, and tenders, and other miscellaneous textile, apparel, and furnishings workers.","Textile, Apparel, and Furnishings Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053927","Top Executives","C122525","Upper-level managers who devise strategies and policies to ensure that an organization meets its goals. They plan, direct, and coordinate operational activities of companies and organizations.","Top Executives | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053923","Transportation, Tourism, and Lodging Attendants","C122530","The group of professions that include baggage porters, bellhops, and concierges, tour and travel guides, and flight attendants.","Transportation, Tourism, and Lodging Attendants | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053718","Vehicle and Mobile Equipment Mechanics, Installers, and Repairers","C122531","The group of professions that include aircraft mechanics and service technicians, automotive technicians and repairers, bus and truck mechanics and diesel engine specialists, heavy vehicle and mobile equipment service technicians and mechanics, small engine mechanics, bicycle repairers, recreational vehicle service technicians and tire repairers and changers.","Vehicle and Mobile Equipment Mechanics, Installers, and Repairers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053850","Water Transportation Workers","C122532","Workers in water transportation occupations who operate and maintain vessels that take cargo and people over water.","Water Transportation Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0341663","Woodworkers","C122533","Workers who use wood, veneers, and laminates to manufacture a variety of products such as cabinets and furniture.","Woodworkers | ",,,,,,,,,,,,,,,"4142689","Woodworker",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054312","Other Architecture and Engineering Workers","C122534","Architecture and engineering workers not specifically identified elsewhere.","Other Architecture and Engineering Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054311","Other Arts, Design, Entertainment, Sports, and Media Workers","C122535","Arts, design, entertainment, sports, and media workers not specifically identified elsewhere.","Other Arts, Design, Entertainment, Sports, and Media Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054310","Other Building and Grounds Cleaning and Maintenance Workers","C122536","Building and grounds cleaning and maintenance workers not specifically identified elsewhere.","Other Building and Grounds Cleaning and Maintenance Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054309","Other Business and Financial Operations Workers","C122537","Business and financial operations workers not specifically identified elsewhere.","Other Business and Financial Operations Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054308","Other Community and Social Services Workers","C122538","Community and social services workers not specifically identified elsewhere.","Other Community and Social Services Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054307","Other Computer and Mathematical Workers","C122539","Computer and mathematical workers not specifically identified elsewhere.","Other Computer and Mathematical Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054306","Other Construction and Related Workers","C122540","Construction and related workers not specifically identified elsewhere.","Other Construction and Related Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054305","Other Education, Training, and Library Occupations","C122541","Education, training, and library occupations not specifically identified elsewhere.","Other Education, Training, and Library Occupations | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054304","Other Farming, Fishing, and Forestry Workers","C122542","Farming, fishing, and forestry workers not specifically identified elsewhere.","Other Farming, Fishing, and Forestry Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053763","Other Food Preparation and Serving Related Workers","C122543","Food preparation and serving related workers not specifically identified elsewhere.","Other Food Preparation and Serving Related Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054303","Other Healthcare Practitioners and Technical Occupations","C122544","Healthcare practitioners and technical occupations not specifically identified elsewhere.","Other Healthcare Practitioners and Technical Occupations | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054302","Other Healthcare Support Occupations","C122545","Healthcare support occupations not specifically identified elsewhere.","Other Healthcare Support Occupations | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054301","Other Installation, Maintenance, and Repair Occupations","C122546","Installation, maintenance, and repair occupations not specifically identified elsewhere.","Other Installation, Maintenance, and Repair Occupations | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054300","Other Legal Workers","C122547","Legal workers not specifically identified elsewhere.","Other Legal Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054299","Other Life, Physical, and Social Science Workers","C122548","Life, physical, and social science workers not specifically identified elsewhere.","Other Life, Physical, and Social Science Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054298","Other Management Occupations","C122549","Management occupations not specifically identified elsewhere.","Other Management Occupations | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054297","Other Military Specific Workers","C122550","Military specific workers not specifically identified elsewhere.","Other Military Specific Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054296","Other Office and Administrative Support Workers","C122551","Office and administrative support workers not specifically identified elsewhere.","Other Office and Administrative Support Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054295","Other Personal Care and Service Workers","C122552","Personal care and service workers not specifically identified elsewhere.","Other Personal Care and Service Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054294","Other Production Occupations","C122553","Production occupations not specifically identified elsewhere.","Other Production Occupations | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0335391","Other Protective Service Workers","C122554","Protective service workers not specifically identified elsewhere.","Other Protective Service Workers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054293","Other Sales and Related Workers","C122555","Sales and related workers not specifically identified elsewhere.","Other Sales and Related Workers | Other Sales Worker | Other Sales Workers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0401921","Other Teachers and Instructors","C122556","Teachers and instructors not specifically identified elsewhere.","Other Teachers and Instructors | Other Teaching Professional | Other Teaching Professionals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054292","Other Transportation Workers","C122557","Transportation workers not specifically identified elsewhere.","Other Transportation Workers | iCaRe2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055220","Coal Gas, Coal Tar, Coal Tar Pitch, and Derivatives","C122563","A complex chemical mixture of condensed-ring aromatic hydrocarbons produced by the destructive distillation (pyrolysis) of coal. The lower viscosity byproducts are generally regarded as tar, whereas the viscous, semisolid, or solid byproducts are designated as pitch. Coal tar and coal tar pitch are known to be human carcinogens.","Coal Gas, Coal Tar, Coal Tar Pitch, and Derivatives | Coal Gas/Tar Pitch Derivatives | Coal gas/tar pitch derivatives",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0301020","Cutting Fluid","C122491","Any fluid that is used for lubrication and cooling during metalworking and machining processes. They may be made from petroleum distillates, animal fats, plant oils, water, or other ingredients. Toxicity or irritation can result from contact with cutting fluids. The hazard can be the result of the fluid itself, the metal particles that are borne in the fluid, the bacterial or fungal contaminants that tend to grow in the fluid over time, the biocides that are added to inhibit those life forms, or the corrosion inhibitors that are added to protect the machine and tooling.","Cutting Fluid | Cutting Compound | Cutting Fluids | Cutting Oil | Cutting fluids",,,,,,,,,,,,,,,"4007989","Cutting oil",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0729428","Dry Cleaning Fluid","C122492","Any of the non-water-based solvents used to remove soil and stains from clothes. The most common of these is tetrachloroethylene (perchloroethylene), a known human carcinogen. Alternative compounds include glycol ethers, petroleum-based solvents, liquid silicone (decamethylcyclopentasiloxane or D5), modified hydrocarbon blends, brominated solvents, and supercritical CO2.","Dry Cleaning Fluid | Dry Cleaning",,,,,,,,,,,,,,,"4057445","Dry cleaning agent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054949","Floor Cleaning Agent","C122493","Any of the compounds used for floor polishing, waxing and stripping. Chemicals in these products include diethylene glycol ethyl ether, aliphatic petroleum distillates and nonylphenol ethoxylate, ethanolamine, butoxyethanol, and sodium hydroxide. Exposure to these chemicals may cause headaches, dizziness, nausea, difficulty concentrating, fatigue, wheezing, coughing, asthma attacks, hypersensitivity pneumonitis, and eye, nose, throat, and skin irritation.","Floor Cleaning Agent | Floor Cleaning Agents | Floor cleaning agents",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0440124","Rubber Chemical","C122564","Any of the monomers, resins, solvents, emulsifiers, intermediates, additives, and others used in the manufacture of rubber and rubber products. Excess deaths from bladder, stomach, lung, hematopoietic, and other cancers have occurred among workers involved in the manufacture of rubber products.","Rubber Chemical | Rubber Chemicals",,,,,,,,,,,,,,,"4302444","Rubber compound",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017095","Trash","C122627","Anything discarded or thrown away; waste material.","Trash | Garbage | Refuse | Rubbish",,,,,,,,,,,,,,,"4237742","Trash",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011740","Detergent","C122626","A water-soluble surfactant that functions to emulsify oils and hold dirt in suspension.","Detergent | Detergents",,,,,,,,,,,,,,,"4139481","Detergent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4050366","Petroleum Hydrocarbon Compound","C122495","Any chemical compound that is derived from crude oil. Petroleum hydrocarbon compounds can enter the environment through accidents, industrial releases, or as byproducts of commercial or private uses.","Petroleum Hydrocarbon Compound | PHC | Petroleum / petroleum compounds | Petroleum Compound | Petroleum compounds",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015078","Ethylene Chlorohydrin","C122479","An organochlorine compound and hazardous substance. Ethylene chlorohydrin is used as a solvent and in the manufacture of a variety of industrial agents.","Ethylene Chlorohydrin | 2-Chloroethanol | 2-Hydroxyethyl Chloride | 2-Monochloroethanol | ETHYLENE CHLOROHYDRIN | Ethanol, 2-Chloro- | Ethylchlorohydrin | Ethylene Glycol, Chlorohydrin | Ethylene chlorohydrin | Glycomonochlorhydrin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986658","Diffuse Intrinsic Pontine Glioma","C94764","A glioma that grows diffusely in the pons. It usually affects children and has a poor prognosis.","Diffuse Intrinsic Pontine Glioma | DIPG | Pontine (DIPG) | diffuse intrinsic pontine glioma",,,,,,,,,,,,,,,"3656333|600696","Diffuse intrinsic pontine glioma|Diffuse intrinsic pontine glioma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0080759","Propylene Chlorohydrin","C122490","An organochlorine compound mainly used as a chemical intermediate for the manufacture of propylene oxide.","Propylene Chlorohydrin | 1-Hydroxy-2-chloropropane | 1-Propanol, 2-Chloro- | 2-Chloro-1-propanol | 2-Chloropropan-1-ol | 2-Chloropropanol | 2-Chloropropyl Alcohol | PROPYLENE CHLOROHYDRIN | Propylene chlorohydrin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812269","Positive Number","C113772","A quantity having a value greater than zero.","Positive Number | Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986497","Cumulative Dose","C94394","The total amount of an agent (e.g., drug, biologic, radiation, etc.) administered to a subject over a defined period of time.","Cumulative Dose | TOTAL_DOSE_ADMINISTERED | Total Dose | cumulative dose | dosage | periodProductDoseTotal | total dose | total_dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055124","Dissolvable Tobacco","C122671","Any of various proprietary tobacco products that deliver nicotine as they dissolve or melt in the user's mouth.","Dissolvable Tobacco | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0870238","Purchase","C122672","The action of obtaining something by payment.","Purchase | Buy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0680851","Sponsorship","C122673","Money, or other support, given to an individual or group to help pay for something or carry out an event, usually in return for advertisement.","Sponsorship | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0680332","Hookah","C122674","A tobacco pipe with a long flexible tube that cools the smoke by passing it through water.","Hookah | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0220913","Manufactured sign","C122675","A group or system of signs, used to show information about something.","Signage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055456","Anti-Tobacco Advertisement","C122676","Advertisement designed to persuade individuals to cease, or not start, the use of tobacco.","Anti-Tobacco Advertisement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054172","Point of Sale","C122670","A location where products or services can be purchased.","Point of Sale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054741","Illicit Tobacco Product","C122666","A product containing or derived from tobacco that is not compliant with legislative requirements.","Illicit Tobacco Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3179065","Internet Social Media","C97003","Online communities that allow for the creation and exchange of information and ideas.","Internet Social Media | Social Media | www-soc-med",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055235","Cigarette Filter Ventilation Blocking","C122665","A smoking behavior characterized by covering the filter ventilation holes on a cigarette with the fingers or lips while smoking.","Cigarette Filter Ventilation Blocking | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034770","Recollect","C122669","The act of recalling information by mental effort.","Recollect | Recall | Recollect | Recollection | Remember",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707393","Chromium Hexavalent Compound","C44357","A highly corrosive, inorganic substance that contains the metallic element chromium in its positive-6 valence state. Chromium hexavalent compounds are used in stainless steel production, in chrome plating, in the manufacture of dyes and pigments, in leather tanning, in wood preservation and are used as corrosion inhibitors. Inhalation exposure of these compounds mainly affects the respiratory tract causing shortness of breath, nasal itching, asthma, coughing, bronchitis and pneumonia, but can also affect the liver, kidneys, gastrointestinal tract and the immune system. Chromium hexavalent compounds are carcinogenic in humans and are associated with an increased risk of developing lung cancer and cancer of the sinonasal cavity. (NCI05)","Chromium Hexavalent Compound | Chromium Hexavalent (VI) Compounds | Chromium compounds",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015081","Ethylene Dichloride","C44383","A clear, colorless, oily, synthetic, flammable liquid chlorinated hydrocarbon with a pleasant chloroform-like smell that emits toxic fumes of hydrochloric acid when heated to decomposition. Ethylene dichloride is primarily used to produce vinyl chloride. Inhalation exposure to this substance induces respiratory distress, nausea and vomiting and affects the central nervous system, liver and kidneys. It is mutagenic in animals and is reasonably anticipated to be a human carcinogen. (NCI05)","Ethylene Dichloride | 1,2-Dichloroethane | 1,2-Ethylene Dichloride | Dichloroethylene | EDC | ETHYLENE DICHLORIDE | Ethane Dichloride | Ethylene Chloride | Ethylene dichloride | Glycol Dichloride | NCI-C00511 | NU-G00511",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021265","Industrial Waste","C577","Materials that are discarded following industrial processes.","Industrial Waste | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0392412","Count per Minute","C73688","A unit of frequency expressed as a number of events per minute.","Count per Minute | Count/Minute | Counts per Minute | cpm | {counts}/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882120","Not Obtained","C67325","Not acquired, gained or come to the possession.","Not Obtained | Not obtained | {Not Obtained}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899402","Decreased Uncorrected Visual Acuity","C118716","Diminished clarity of vision without optical correction (glasses and/or contacts).","Decreased Uncorrected Visual Acuity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229089","Right Eye","C119333","The eye positioned in the right orbit.","Right Eye | OD | Oculus Dexter | Oculus Dexter (Right Eye)",,,,,,,,,,,,,,,"4078078","Right eye structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0229090","Left Eye","C119334","The eye positioned in the left orbit.","Left Eye | OS | Oculus Sinister | Oculus Sinister (Left Eye)",,,,,,,,,,,,,,,"4232319","Left eye structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2963469","Current Health Limits Lifting or Carrying Groceries","C122706","A question about whether an individual's current health limits them in lifting or carrying groceries.","Current Health Limits Lifting or Carrying Groceries | Does your health now limit you in lifting or carrying groceries",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054140","Quality of Life Questionnaire-Multiple Myeloma 20","C122694","A questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) consisting of 20 questions designed to assess quality of life in multiple myeloma patients.","Quality of Life Questionnaire-Multiple Myeloma 20 | EOR19 | EORTC Multiple Myeloma Module | EORTC Multiple Myeloma Module (QLQ-MY20) | EORTC QLQ-MY20 | QLQ-MY20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054861","Have Aches or Pains in Bones","C122695","A question about whether an individual has or had aches or pains in their bones.","Have Aches or Pains in Bones | Have Bone Aches or Pain | Have you had bone aches or pain | I have aches and pains in my bones",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054849","Have Hip Pain","C122696","A question about whether an individual has or had pain in their hip.","Have Hip Pain | Have Pain in Hip | Have you had pain in your hip",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972896","Have Pain in Arm or Shoulder","C122697","A question about whether an individual has or had pain in their arm or shoulder.","Have Pain in Arm or Shoulder | Had Pain in Arm or Shoulder | Have Shoulder or Arm Pain | Have you had pain in your arm or shoulder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972893","Have Pain in Chest","C122698","A question about whether an individual has or had pain in their chest.","Had Pain in Chest | Have Chest Pain | Have Chest Pain | Have Pain in Chest | Have you had pain in your chest",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054844","Have Pain Increase with Activity","C122699","A question about whether an individual's pain increases with activity.","Have Pain Increase with Activity Question | Have Pain Increase with Activity | Have Pain Increase with Activity | If you had pain did it increase with activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054977","Feel Thirsty","C122700","A question about whether an individual feels or felt thirsty.","Feel Thirsty | Did you feel thirsty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054839","Have Tingling in Hands or Feet","C122701","A question about whether an individual has or had tingling in their hands or feet.","Have Tingling in Hands or Feet | Did you have tingling hands or feet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054978","Feel Restless or Agitated","C122702","A question about whether an individual feels or felt restless or agitated.","Feel Restless or Agitated | Did you feel restless or agitated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050007","Have Acid Indigestion or Heartburn","C122703","A question about whether an individual has or had acid indigestion or heartburn.","Have Acid Indigestion or Heartburn | Have you had acid indigestion or heartburn",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054857","Have Burning or Sore Eyes","C122704","A question about whether an individual has or had burning or sore eyes.","Have Burning or Sore Eyes | Have you had burning or sore eyes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054858","Have Been Thinking About Illness","C122705","A question about whether an individual has or had been thinking about their illness.","Have Been Thinking About Illness | Have you been thinking about your illness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1444582","Indirect Ophthalmoscopy","C94199","An exam of the inside of the back of the eye using a beam of light and a hand-held lens. Indirect ophthalmoscopy gives a wider view inside the eye than an exam using an ophthalmoscope does.","Indirect Ophthalmoscopy | Indirect Fundoscopy | indirect ophthalmoscopy",,,,,,,,,,,,,,,"4259494","Indirect ophthalmoscopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523806","Oxygen Measurement","C111284","The determination of the amount of oxygen content present in a sample.","Oxygen Measurement | O2CT | Oxygen Content",,,,,,,,,,,,,,,"4021125","Oxygen measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1335226","PLCG2 Gene","C28655","This gene is involved in the generation of second messengers in the transmembrane signaling of ligand-activated growth factor receptors.","PLCG2 Gene | PLCG2 | Phospholipase C Gamma 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422496","NSD1 Gene","C75876","This gene is involved in the mediation of histone methylation.","NSD1 Gene | NSD1 | Nuclear Receptor Binding SET Domain Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426808","AJUBA Gene","C115436","This gene plays a role in the assembly of protein complexes, which are involved in a number of cellular processes.","AJUBA Gene | AJUBA | Ajuba LIM Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812278","FAT1 Gene","C18397","This gene is involved in both cellular polarization and cell-cell adhesion.","FAT1 Gene | FAT | FAT Atypical Cadherin 1 Gene | FAT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1956385","Plasmacytoid Dendritic Cells","C45236","A cell found in peripheral blood, lymphoid tissue, and some inflamed tissue. It produces vast amounts of type I interferons especially in response to viruses, therefore playing an important role in antiviral immunity and triggers for adaptive immune responses.","Plasmacytoid Dendritic Cell | PDCs | Plasmacytoid Monocyte | Plasmacytoid Monocyte | Precursor of Plasmacytoid Dendritic Cell | Professional Type I Interferon-Producing Cell | pDC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521007","1q32","C13881","A chromosome band present on 1q","1q32 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512896","International Union Against Cancer","C39434","A global cancer organisation comprising over 1200 organisations in 172 countries with activities covering all aspects of cancer control. It was founded in 1933 as the International Union Against Cancer. The organisation is dedicated to taking the lead in convening, capacity building and advocacy initiatives that unite and support the cancer community to reduce the global cancer burden, promote greater equity, and to ensure cancer control continues to be a priority in the world health and development agenda.","Union for International Cancer Control | International Union Against Cancer | International Union Against Cancer | UICC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1559308","Grade 1 Diarrhea, CTCAE","C57170","Increase of <4 stools per day over baseline; mild increase in ostomy output compared to baseline","Grade 1 Diarrhea, CTCAE | CTCAE Grade 1 Diarrhea | Grade 1 Diarrhea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL426693","c-Met Inhibitor AMG 337","C95203","An orally bioavailable inhibitor of the proto-oncogene c-Met with potential antineoplastic activity. c-Met inhibitor AMG 337 selectively binds to c-Met, thereby disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein, the product of the proto-oncogene c-Met, is a receptor tyrosine kinase also known as hepatocyte growth factor receptor (HGFR); this protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis.","c-Met Inhibitor AMG 337 | 1,6-Naphthyridin-5(6H)-one, 6-((1R)-1-(8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazolo(4,3-a)pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)- | AMG 337 | AMG-337 | AMG337",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348582","Subject Screened for Study","C70733","An indication that an individual was screened for eligibility criteria to participate in a clinical study.","Subject Screened for Study | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2703169","Defactinib","C79809","An orally bioavailable, small-molecule focal adhesion kinase (FAK) inhibitor with potential antiangiogenic and antineoplastic activities. Defactinib inhibits FAK, which may prevent the integrin-mediated activation of several downstream signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, thus inhibiting tumor cell migration, proliferation, survival, and tumor angiogenesis. The tyrosine kinase FAK, a signal transducer for integrins, is normally activated by binding to integrins in the extracellular matrix (ECM) but may be upregulated and constitutively activated in various tumor cell types.","Defactinib | Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)- | DEFACTINIB | PF-04554878 | VS-6063",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981865","FAK Inhibitor GSK2256098","C88346","A focal adhesion kinase-1 (FAK) inhibitor with potential antiangiogenic and antineoplastic activities. FAK inhibitor GSK2256098 inhibits FAK, which may prevent the integrin-mediated activation of several downstream signal transduction pathways, including ERK, JNK/MAPK and PI3K/Akt, thereby inhibiting tumor cell migration, proliferation and survival, and tumor angiogenesis. The tyrosine kinase FAK is normally activated by binding to integrins in the extracellular matrix (ECM) but may be upregulated and constitutively activated in various tumor cell types.","FAK Inhibitor GSK2256098 | Focal Adhesion Kinase Inhibitor GSK2256098 | GSK-2256098 | GSK2256098",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049997","5-Iodo-2-pyrimidinone","C122723","A 5-iodo-substituted pyrimidinone and metabolite of 5-iodo-2-pyrimidinone-based deoxyribose analogs, such as 5-iodo-2-pyrimidinone-2'-deoxyribose (IPdR).","5-Iodo-2-pyrimidinone | 5 Iodo-2-pyrimidinone | IP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0049272","5-iodouracil","C122724","A halogenated pyrimidine analog containing an iodine atom linked to a pyrimidine ring. 5-Iodouracil (IU) gets incorporated into DNA. IU is a metabolite of idoxuridine (IUdR; 5-iododeoxyuridine) and the IUdR prodrug ropidoxuridine (IPdR).","5-Iodouracil | 2,4(1H,3H)-Pyrimidinedione, 5-Iodo- | 2,4-Dihydroxy-5-iodopyrimidine | 5-IODOURACIL | IU | NSC 57848 | Uracil, 5-Iodo-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335762","Reticulin Fibrosis of the Bone Marrow","C35820","Increased reticular fiber deposition within bone marrow.","Reticulin Fibrosis of the Bone Marrow | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414059","DKK3 Gene","C95419","This gene plays a role in signaling and morphogenesis.","DKK3 Gene | DKK3 | Dickkopf WNT Signaling Pathway Inhibitor 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0920274","TACSTD2 Gene","C17774","This gene plays a regulatory role in intracellular calcium signal transduction.","TACSTD2 Gene | TACSTD2 | Tumor Associated Calcium Signal Transducer 2 Gene | Tumor-Associated Calcium Signal Transducer 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1138555","Pharmacogenomics","C20050","The investigation of the collective impact of variations across a genome on drug responses.","Pharmacogenomics | PGx | Pharmacogenetics | pharmacogenomics",,,,,,,,,,,,,,,"37158357","Pharmacogenomics",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024880","Mast Cell","C12747","Mast cells are hematopoietic tissue cells that contain coarse, basophilic, metachromatic granules.  They are believed to contain heparin and histamine and derive from hematopoietic progenitor cells.","Mast Cell | Mast Cells | Mastocyte | mast cell",,,,,,,,,,,,,,,"4272652","Mast cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019369","Herpesvirus","C14217","A heterogeneous family of morphologically similar viruses, all of which contain double-stranded DNA and which infect man and a wide variety of other vertebrates. Infections produce type A inclusion bodies; in many instances, infection may remain latent for many years, even in the presence of specific circulating antibodies. Virions are enveloped, ether-sensitive, and vary up to 200 nm in diameter; the nucleocapsids are 100 nm in diameter and of icosahedral symmetry, with 162 capsomeres. The family includes herpes simplex virus, cytomegalovirus, EB virus (all of which infect humans) and many others.","Herpesvirus | Herpes Virus | Herpesviridae | Virus-Herpes | herpesvirus",,,,,,,,,,,,,,,"4027708","Family Herpesviridae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1523298","Epithelial-to-Mesenchymal Transition","C97304","A cellular process where an epithelial cell loses polarity, disassembles adhesive junctions, degrades its basement membrane and transforms into a migratory mesenchymal cell.","Epithelial-to-Mesenchymal Transition | EMT | Epithelial Mesenchymal Transition | Epithelial to Mesenchymal Transition | Epithelial-Mesenchymal Transition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053734","Childhood Cancer Registry","C122734","A North American pediatric cancer research registry established by the Children's Oncology Group for member institutions in the United States and Canada. It provides a centralized pediatric cancer research registry for investigators conducting epidemiology, biology, late effects, and cancer control studies.","Childhood Cancer Registry | Childhood Cancer Research Network Registry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985612","Document Identifier","C93399","The unique identification of a document in a specified context.","Document Identifier | Document.identifier | DocumentIdentifier | document number | document_number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898139","New or Worsening Symptom","C119238","The subjective evidence of disease perceived by the patient that can be classified as new or worsening","New or Worsening Symptom | NWSYMP | New or Worsening Symptoms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281374","Pressor Support","C15570","The use of vasopressor agents to elevate arterial blood pressure.","Pressor Support | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0741135","Anticoagulation Therapy","C63341","Drug treatment to thin the blood in order to prevent or reduce blood clot formation.","Anticoagulation Therapy | Anticoagulation Treatment",,,,,,,,,,,,,,,"4056822","Anticoagulant therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055262","Central Memory Immune Cell","C122730","A population of long-lived antigen-specific immune cells, usually T-lymphocytes expressing CD45RO, L-selectin and CCR7, that are maintained by the immune system. Upon subsequent exposure to their target antigen, these cells rapidly proliferate and differentiate into effector cells.","Central Memory Immune Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055238","Chromosome 17 Centromere Probe","C122781","A DNA probe designed for in situ hybridization. This probe is complementary to DNA sequences found in the centromeric region of chromosome 17. This probe can be used to determine gene copy number alterations.","Chromosome 17 Centromere Probe | CEN-17 | CEN17 | CEP17 | Centromere 17 | Centromere 17 Probe | Chromosome 17 Centromere",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053532","Circulating Epithelial Cell","C122733","A cell derived from an epithelial membrane that is found in the blood. These cells are associated with epithelial-mesenchymal transition and may be markers for neoplastic diseases.","Circulating Epithelial Cell | CEpC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539104","CLEC10A Gene","C122764","This gene is involved in regulating adaptive and innate immune responses.","CLEC10A Gene | C-type Lectin Domain Family 10, Member A Gene | CLEC10A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539102","CLEC7A Gene","C122761","This gene plays a role in the innate immune response.","CLEC7A Gene | C-type Lectin Domain Family 7, Member A Gene | CLEC7A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010290","Creatine Kinase MB","C122778","An isoenzyme complex comprised of a heterodimer of creatine kinase M-type and B-type.","Creatine Kinase MB | CK-MB | CKMB | CPK-MB | Creatine Kinase-MB | Creatine Phosphokinase-MB | MM-CK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055074","Effector Memory Immune Cell","C122731","A population of long-lived antigen-specific immune cells, usually T-lymphocytes expressing CD8 and effector cytokines, that are maintained by the immune system. Upon subsequent exposure to their target antigen, these cells rapidly become effector cells.","Effector Memory Immune Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055105","EGFR Antibody","C122777","Any immunoglobulin that recognizes epidermal growth factor receptor protein.","EGFR Antibody | Anti-EGFR | Anti-EGFR Antibody | Anti-ERBB1 | Anti-ERBB1 Antibody | Anti-Epidermal Growth Factor Receptor | Anti-Epidermal Growth Factor Receptor Antibody | Anti-HER1 | Anti-HER1 Antibody | ERBB1 Antibody | Epidermal Growth Factor Receptor Antibody | HER1 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414638","FLOT1 Gene","C122747","This gene may be involved in the structure of caveolae.","FLOT1 Gene | FLOT1 | Flotillin 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054895","Glycan Antibody","C122767","An antibody that recognizes polysaccharide chains, usually those that are associated with cell surfaces.","Glycan Antibody | Anti-Glycan Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053741","KIT Exon 14 Mutation","C122768","A molecular genetic abnormality indicating the presence of a mutation in exon 14 of the KIT gene located within 4q11-q12.","KIT Exon 14 Mutation | CD117 Exon 14 Mutation | Exon 14 | KIT Proto-Oncogene Tyrosine Protein Kinase Gene Exon 14 Mutation | c-KIT Exon 14 Mutation | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Gene Exon 14 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054686","LCP1 Antibody","C122774","Any immunoglobulin that recognizes L-plastin protein.","LCP1 Antibody | Anti-L-Plastin | Anti-L-Plastin Antibody | Anti-LCP1 Antibody | Anti-Lymphocyte Cytosolic Protein 1 | Anti-Lymphocyte Cytosolic Protein 1 Antibody | L-Plastin Antibody | Lymphocyte Cytosolic Protein 1 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050247","Leucine-Rich Repeats and Immunoglobulin-Like Domains Protein Family","C122769","A family of membrane bound proteins comprised of 15 leucine-rich repeats that are flanked both N- and C- terminally by cysteine-rich regions, three C2-type immunoglobulin-like domains, a transmembrane domain, and a cytoplasmic tail. The members of this protein family may be involved in the suppression of growth factor receptor signaling.","Leucine-Rich Repeats and Immunoglobulin-Like Domains Protein Family | LIG | LIG Family | LRIG | LRIG Family | Leucine-Rich Repeats and Immunoglobulin-Like Domains Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416956","MARCKS Gene","C122753","This gene plays a role in actin filament crosslinking.","MARCKS Gene | MARCKS | Myristoylated Alanine-rich Protein Kinase C Substrate Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054191","Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-Alpha Isoform 4","C122780","Peroxisome proliferator-activated receptor gamma coactivator 1-alpha isoform 4 (466 aa, ~29 kDa) is encoded by the human PPARGC1A gene. This protein plays a role in the regulation of both gene transcription in and growth of skeletal muscle.","Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-Alpha Isoform 4 | PGC-1 Alpha 4 | PGC-1 Alpha-4 | PGC-1alpha4 | PPAR-Gamma Coactivator 1-Alpha 4 | PPAR-Gamma Coactivator 1-Alpha4 | PPARGC-1-Alpha 4 | PPARGC-1-Alpha4 | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1 Alpha 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418643","PLEC Gene","C122741","This gene plays a role in hemidesmosome structure.","PLEC Gene | PLEC | Plectin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054171","Poliovirus Receptor Antibody","C122772","Any immunoglobulin that recognizes the poliovirus receptor protein.","Poliovirus Receptor Antibody | Anti-CD155 Antibody | Anti-Nectin-Like Protein 5 Antibody | Anti-PVR Antibody | Anti-Poliovirus Receptor Antibody | CD155 Antibody | Nectin-Like Protein 5 Antibody | PVR Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419034","PSMD4 Gene","C122750","This gene is involved in protein degradation.","PSMD4 Gene | PSMD4 | Proteasome (Prosome, Macropain) 26S Subunit, Non-ATPase, 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419346","REST Gene","C122744","This gene is involved in the repression of neuronal gene expression.","REST Gene | RE1-Silencing Transcription Factor Gene | REST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054133","REST-003 ncRNA","C122773","REST-003 ncRNA (~460 base pairs) is encoded by the human REST gene. This transcript includes all of exon 1 and a portion of exon 2 of the gene and may play a role in the negative regulation of cellular invasiveness.","REST-003 ncRNA | ENST00000503522 | OTTHUMT00000362230 | REST-003 | REST-003 Non-coding RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049828","Retinoic Acid Receptor Alpha Isoform Alpha-2","C122776","Retinoic acid receptor alpha isoform alpha-2 (457 aa, ~51 kDa) is encoded by the human RARA gene. This protein may be involved in the regulation of brain development, retinoic acid-dependent transcription and the cell cycle.","Retinoic Acid Receptor Alpha Isoform Alpha-2 | RAR-alpha 2 | RAR-alpha2 | RARalpha2 | Retinoic Acid Receptor Alpha Isoform 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201360","Scl-70 Antibody","C122770","An anti-nuclear autoantibody that recognizes a 70 kDa fragment of DNA topoisomerase 1. It is associated with scleroderma.","Scl-70 Antibody | Anti-Scl 70 | Anti-Scl 70 Antibody | Anti-Scl-70 | Anti-Scl-70 Antibody | Anti-Topoisomerase 1 | Anti-Topoisomerase 1 Antibody | Anti-Topoisomerase I | Anti-Topoisomerase I Antibody | Scl 70 Antibody | Topoisomerase 1 Antibody | Topoisomerase I Antibody",,,,,,,,,,,,,,,"4125246","Topoisomerase-1 antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1835836","SLC35B2 Gene","C122735","This gene plays a role in the transport of adenosine 3'-phospho 5'-phosphosulfate (PAPS).","SLC35B2 Gene | SLC35B2 | Solute Carrier Family 35 (Adenosine 3'-Phospho 5'-Phosphosulfate Transporter), Member B2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424127","STK35 Gene","C122738","This gene may be involved in the regulation of actin stress fibers in nonmuscle cells.","STK35 Gene | STK35 | Serine/Threonine Kinase 35 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053969","Suppressive Monocyte","C122732","A population of monocytes that express CD14 and low or non-detectable levels of HLA-DR. The cells are able to suppress cellular immunity by inhibiting both T-cell proliferation and dendritic cell maturation.","Suppressive Monocyte | Monocytic Suppressive Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1540067","TRIM63 Gene","C122758","This gene is involved in myosin protein catabolism.","TRIM63 Gene | TRIM63 | Tripartite Motif Containing 63, E3 Ubiquitin Protein Ligase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823521","TSPO Gene","C122727","This gene is involved in cholesterol trafficking.","TSPO Gene | TSPO | Translocator Protein (18kDa) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053885","VEGF:VEGFR Complex","C122771","A ligand-receptor complex comprised of a homodimer of vascular endothelial growth factor (VEGF) family proteins bound to a heterodimer of vascular endothelial growth factor receptor (VEGFR) family proteins. Ligand binding triggers receptor dimerization and cross-receptor tyrosine phosphorylation, which promotes downstream signal transduction.","VEGF:VEGFR Complex | VEGF-VEGFR Complex | VEGF/VEGFR Complex | Vascular Endothelial Growth Factor-Vascular Endothelial Growth Factor Receptor Complex | Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Complex | Vascular Endothelial Growth Factor:Vascular Endothelial Growth Factor Receptor Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896906","Osimertinib","C116377","A third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, osimertinib covalently binds to and inhibits the activity of numerous mutant forms of EGFR, including the secondarily-acquired resistance mutation T790M, L858R, and exon 19 deletions, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.","Osimertinib | 2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)- | AZD 9291 | AZD-9291 | AZD9291 | EGFR Inhibitor AZD9291 | Mereletinib | OSIMERTINIB | Tagrisso",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4045493","CO-1686","C99905","An orally available small molecule, irreversible inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Rociletinib binds to and inhibits mutant forms of EGFR, including T790M, thereby leading to cell death of resistant tumor cells. Compared to other EGFR inhibitors, CO-1686 inhibits T790M, a secondary acquired resistance mutation, as well as other mutant EGFRs and may have therapeutic benefits in tumors with T790M-mediated resistance to other EGFR tyrosine kinase inhibitors. This agent shows minimal activity against wild-type EGFR, hence does not cause certain dose-limiting toxicities.","Rociletinib | CO 1686 | CO-1686 | CO1686 | EGFR Inhibitor CO-1686 | N-(3-((2-((4-(4-Acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)prop-2-enamide | ROCILETINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435909","EGFR inhibitor HM61713","C101791","An orally available small molecule, mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Olmutinib binds to and inhibits mutant forms of EGFR, thereby leading to cell death of EGFR-expressing tumor cells. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors which also inhibit the EGFR wild type form.","Olmutinib | 2-Propenamide, N-(3-((2-((4-(4-methyl-1-piperazinyl)phenyl)amino)thieno(3,2-d)pyrimidin-4-yl)oxy)phenyl)- | BI 1482694 | EGFR Inhibitor HM61713 | HM61713 | OLMUTINIB | Olmutinib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472640","EGFR inhibitor EGF816","C115109","An orally available, irreversible, third-generation, mutant-selective epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, nazartinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. EGF816 preferentially inhibits mutated forms of EGFR including T790M, a secondarily acquired resistance mutation, and may have therapeutic benefits in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.","Nazartinib | EGF 816 | EGF816 | EGFR Inhibitor EGF816 | NAZARTINIB | Nazartinib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472641","EGFR inhibitor ASP8273","C115110","An orally available, irreversible, third-generation, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, ASP8273 covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. ASP8273 preferentially inhibits mutated forms of EGFR including T790M, a secondarily acquired resistance mutation, and may have therapeutic benefits in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.","Naquotinib | 2-Pyrazinecarboxamide, 6-Ethyl-3-((4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-(((3R)-1-(1-oxo-2-propen-1-yl)-3-pyrrolidinyl)oxy)- | ASP8273 | EGFR Inhibitor ASP8273 | NAQUOTINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273952","AKT1 Gene Mutation","C98304","A change in the nucleotide sequence of the AKT1 gene.","AKT1 Gene Mutation | AKT Gene Mutation | PKB Gene Mutation | PRKBA Gene Mutation | RAC Gene Mutation | RAC-ALPHA Gene Mutation | RAC-PK-Alpha Gene Mutation | v-akt Murine Thymoma Viral Oncogene Homolog 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020975","Booster","C28320","A second or later vaccine dose, separated from the first by time, to increase, extend, or maintain the immune response of the previous vaccination.","Booster | booster",,,,,,,,,,,,,,,"4230536","Booster vaccination",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0175795","Oral Medication","C102246","A pharmacological medication intended for administration through the mouth.","Oral Medication | ORAL MEDICATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0148199","Vascular Endothelial Growth Factor Receptor","C17293","There are three signaling VEGF receptors. The VEGF family members PIGF and VEGF-B with exclusive binding capacities to the VEGFR-1 can influence monocyte activation and differentiation. The VEGFR-2 and VEGFR-3 binding VEGF homologues, VEGF-C and VEGF-D, are mitogens for both vascular and lymphatic endothelial cells. The orf virus encoded VEGF-E homologue binds and activates only the VEGFR-2 and thus may be the prototype of a vascular endothelial cell-specific growth factor.  Further specific activities of VEGF and its homologues result from receptor-specific signaling and differential expression of ligands or receptors. A naturally occurring soluble form of the VEGFR-1 suggests a regulatory role for this receptor.","Vascular Endothelial Growth Factor Receptor | Receptor, Vascular Endothelial Growth Factor | VEGFR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0151620","Hypertensive Encephalopathy","C3503","Encephalopathy resulting from hypertension.","Hypertensive Encephalopathy | Hypertensive encephalopathy",,,,,,,,,,,,,,,"312938","Hypertensive encephalopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0151664","Digestive System Perforation","C79470","A rupture in the wall of any structure of the digestive system caused by traumatic or pathologic processes.","Digestive System Perforation | Gastrointestinal Perforation",,,,,,,,,,,,,,,"4202064","Gastrointestinal perforation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0345906","Liver Sarcoma","C4437","A malignant soft tissue neoplasm that arises from the liver.  Representative examples include angiosarcoma, undifferentiated (embryonal) sarcoma, rhabdomyosarcoma, and leiomyosarcoma.","Liver Sarcoma | Hepatic Sarcoma | Sarcoma of Liver | Sarcoma of the Liver",,,,,,,,,,,,,,,"4115271","Sarcoma of liver",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023870","Lithium","C95186","An element with atomic symbol Li, atomic number 3, and atomic weight 6.941.","Lithium | LITHIUM | Li | Lithium Metallicum | lithium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553430","Serum Separator Tube","C112825","A blood collection tube that contains a gel that separates blood cells from serum.","Serum Separator Tube | Gold-Topped Tube | Red/Black Tiger Top Tube | SST | Serum-Separating Tube",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523212","Wright-Giemsa Staining Method","C23041","Geimsa is a polychromatic stain that permits the differentiation of cells present in hematopoietic tissues and for the demonstration of certain microorganisms. It is used for the detection of helicobacter pylori. The H. pylori and nuclei stain dark blue and cytoplasm stain pink with this stain (From BioGenex).","Wright-Giemsa Staining Method | WRIGHT-GIEMSA STAIN | Wright-Giemsa Staining",,,,,,,,,,,,,,,"4016370|45769419","Wright-Giemsa stain method|Wright-Giemsa stain",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1882198","Ossifying Renal Tumor of Infancy","C66774","A benign neoplasm of the kidney occurring in infants. It develops as an intracalyceal mass and is characterized by the presence of osteoid formation, osteoblast-like cells, and spindle cells.","Ossifying Renal Tumor of Infancy | ORTI | Ossifying renal tumor","8967/0","Ossifying renal tumor",,,,,,,,,,,,,"4029534","Ossifying renal tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1880323","Diffuse Hyperplastic Perilobar Nephroblastomatosis","C66851","A childhood condition in which abnormal tissue grows on the outer part of one or both kidneys. Diffuse hyperplastic perilobar nephroblastomatosis usually develops into Wilms tumor (a type of childhood kidney cancer) if not treated.","Diffuse Hyperplastic Perilobar Nephroblastomatosis | DHPLN | NEPHROBLASTEMATOSIS | diffuse hyperplastic perilobar nephroblastomatosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335866","SSTR1 Gene","C24827","This gene is involved in the inhibitory regulation of hormones and secretory proteins.","SSTR1 Gene | SSTR1 | Somatostatin Receptor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335869","SSTR4 Gene","C24829","This gene is involved in the inhibitory regulation of hormones, secretory proteins, and G protein-coupled receptor signal transduction.","SSTR4 Gene | SSTR4 | Somatostatin Receptor 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055395","BRCA Rearrangement","C122866","A molecular abnormality indicating the presence of rearrangement mutations in either the BRCA1 gene at 17q21 or the BRCA2 gene at 13q12.3.","BRCA Rearrangement | BRCA Family Gene Rearrangement | BRCA Family Rearrangement | BRCA Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826305","Reference Start Time Point","C82575","The description or date and/or time of a time point that acts as a fixed reference for characterizing the start of an observation.","Reference Start Time Point | STTPT | Zero Hour",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0872104","Assisted Reproductive Technology","C93282","Fertility treatments in which eggs and embryos are handled.","Assisted Reproductive Technology | ART | Assisted Reproductive Technologies | assisted reproductive technology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008925","Cleft Palate","C87069","A congenital abnormality consisting of a fissure in the midline of the hard and/or soft palate; it is the result of the failure of the two sides of the palate to fuse during embryonic development.","Cleft Palate | ",,,,,,,,,,,,,,,"135923","Cleft palate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008924","Cleft Lip","C87175","A congenital abnormality consisting of one or more clefts (splits) in the upper lip, which may be accompanied by a cleft palate; it is the result of the failure of the embryonic parts of the lip to fuse.","Cleft Lip | Cheiloschisis",,,,,,,,,,,,,,,"133861","Cleft lip",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0581714","Buccal Swab","C113747","The collection of cells from the inside of a person's cheek using a swab collection device.","Buccal Swab | Buccal Scraping | Buccal Smear | Buccal Swabbing | Buccal swab/scraping",,,,,,,,,,,,,,,"4124709","Buccal smear procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1521838","Mouse Myeloproliferative Disease","C21903","A. Erythrocytosis, leukocytosis of myeloid cells, or thrombocytosis/circulating megakaryocytes AND B. Increased non-lymphoid hematopoietic cells in spleen and/or bone marrow; Comment: may be designated as having features of a named human MD/MPD or MPD","Mouse Myeloproliferative Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553379","Cuban","C107608","A person of Cuban culture or origin, regardless of race.","Cuban | CUBAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332812","CUL4A Gene","C24324","This gene is involved in protein degradation. It also plays a role in cell cycle arrest and DNA repair.","CUL4A Gene | CUL4A | Cullin 4A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0587072","Anti-Smith Antibody","C121324","An antinuclear antibody directed against small nuclear ribonucleoproteins (snRNPs), that is highly specific, but has poor sensitivity for systemic lupus erythematosus (SLE). Presence of anti-Sm antibodies are associated with central nervous system, kidney, lung and cardiac involvement in SLE, but are not indicative of disease activity.","Anti-Smith Antibody | Anti-Sm Antibody | Anti-Sm-RNP Antibody | Anti-Sm/RNP Antibody",,,,,,,,,,,,,,,"37111694","Smith Antigen Ab",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1537844","MIR206 Gene","C81790","This gene is involved in the regulation of gene expression.","MIR206 Gene | MIR206 | MicroRNA 206 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274210","EGFR NM_005228.3:c.2156G>C","C98521","A nucleotide substitution at position 2156 of the coding sequence of the EGFR gene where guanine has been mutated to cytosine.","EGFR NM_005228.3:c.2156G>C | EGFR c.2156G>C | ERBB c.2156G>C | ERBB1 c.2156G>C | Epidermal Growth Factor Receptor Gene c.2156G>C | HER1 c.2156G>C | NM_005228.3:c.2156G>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274209","EGFR NP_005219.2:p.G719A","C98520","A change in the amino acid residue at position 719 in the epidermal growth factor receptor protein where glycine has been replaced by alanine.","EGFR NP_005219.2:p.G719A | EGFR G719A | EGFR Gly719Ala | EGFR NP_005219.2:p.Gly719Ala | EGFR p.G719A | EGFR p.Gly719Ala | Epidermal Growth Factor Receptor G719A | NP_005219.2:p.Gly719Ala | Proto-Oncogene c-ErbB-1 G719A | Receptor Tyrosine-Protein Kinase erbB-1 G719A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274215","EGFR NM_005228.3:c.2156G>A","C98526","A nucleotide substitution at position 2156 of the coding sequence of the EGFR gene where guanine has been mutated to adenine.","EGFR NM_005228.3:c.2156G>A | EGFR c.2156G>A | ERBB c.2156G>A | ERBB1 c.2156G>A | Epidermal Growth Factor Receptor Gene c.2156G>A | HER1 c.2156G>A | NM_005228.3:c.2156G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274214","EGFR NP_005219.2:p.G719D","C98525","A change in the amino acid residue at position 719 in the epidermal growth factor receptor protein where glycine has been replaced by aspartic acid.","EGFR NP_005219.2:p.G719D | EGFR G719D | EGFR Gly719Asp | EGFR NP_005219.2:p.Gly719Asp | EGFR p.G719D | EGFR p.Gly719Asp | Epidermal Growth Factor Receptor G719D | NP_005219.2:p.Gly719Asp | Proto-Oncogene c-ErbB-1 G719D | Receptor Tyrosine-Protein Kinase erbB-1 G719D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274217","EGFR NM_005228.3:c.2155G>A","C98528","A nucleotide substitution at position 2155 of the coding sequence of the EGFR gene where guanine has been mutated to adenine.","EGFR NM_005228.3:c.2155G>A | EGFR c.2155G>A | ERBB c.2155G>A | ERBB1 c.2155G>A | Epidermal Growth Factor Receptor Gene c.2155G>A | HER1 c.2155G>A | NM_005228.3:c.2155G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274216","EGFR NP_005219.2:p.G719S","C98527","A change in the amino acid residue at position 719 in the epidermal growth factor receptor protein where glycine has been replaced by serine.","EGFR NP_005219.2:p.G719S | EGFR G719S | EGFR Gly719Ser | EGFR NP_005219.2:p.Gly719Ser | EGFR p.G719S | EGFR p.Gly719Ser | Epidermal Growth Factor Receptor G719S | NP_005219.2:p.Gly719Ser | Proto-Oncogene c-ErbB-1 G719S | Receptor Tyrosine-Protein Kinase erbB-1 G719S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0598800","Pericyte","C12656","A multipotent perivascular cell that is embedded in the basement membrane of capillaries and contributes to tissue repair in response to injury.","Pericyte | Adventitial Cell | Pericapillary Cell | Pericytes | Perivascular Cell | Rouget Cell | Rouget Cells",,,,,,,,,,,,,,,"4146501","Pericyte of Rouget",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1413405","CHRNA5 Gene","C77122","This gene plays a role in ion transport.","CHRNA5 Gene | CHRNA5 | Cholinergic Receptor, Nicotinic, Alpha 5 (Neuronal) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333584","FZD2 Gene","C24411","This gene plays a regulatory role in signal transduction by calcium release from intracellular stores.","FZD2 Gene | FZD2 | Frizzled Class Receptor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0436548","Transcranial Magnetic Stimulation","C116655","A procedure that uses electromagnets to stimulate neuronal activity, allowing for both imaging and study of the brain's functioning.","Transcranial Magnetic Stimulation | TMS",,,,,,,,,,,,,,,"4130731","Transcranial magnetic stimulation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0220824","Equipment used","C84337","An object used in scientific research that is not consumed.","Scientific Equipment | Equipment | Tool",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049917","Intelligence Scale","C122920","An assessment tool designed to measure an individual's cognitive capabilities. It may be general or it may assess abilities in more discrete cognitive domains.","Intelligence Scale | Intelligence Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428918","PPARGC1B Gene","C101766","This gene is involved in the positive regulation of transcription.","PPARGC1B Gene | PPARGC1B | Peroxisome Proliferator-Activated Receptor Gamma, Coactivator 1 Beta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333667","MSTN Gene","C24425","This gene plays a role in cell differentiation and the regulation of transcription. It is also involved in the regulation of muscle mass.","MSTN Gene | MSTN | Myostatin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424661","TXNIP Gene","C113216","This gene plays a role in the regulation of stress response signaling.","TXNIP Gene | TXNIP | Thioredoxin Interacting Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448707","Dependency","C45996","Related so that change in one leads to change in the other.","Dependency | Dependence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013473","Eating Disorder","C89332","A broad group of psychological disorders with abnormal eating behaviors leading to physiological effects from overeating or insufficient food intake.","Eating Disorder | ",,,,,,,,,,,,,,,"439002","Eating disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0937846","Esomeprazole","C65538","The S-isomer of omeprazole, with gastric proton pump inhibitor activity. In the acidic compartment of parietal cells, esomeprazole is protonated and converted into the active achiral sulfenamide; the active sulfenamide forms one or more covalent disulfide bonds with the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase), thereby inhibiting its activity and the parietal cell secretion of H+ ions into the gastric lumen, the final step in gastric acid production. H+/K+ ATPase is an integral membrane protein of the gastric parietal cell.","Esomeprazole | ESOMEPRAZOLE | esomeprazole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881717","Mechanical Problem","C62961","Problems associated with mechanical actions or defects of the device, which includes any moving parts or subassemblies, etc.","Mechanical Issue | Mechanical Problem | Medical Device Mechanical Issue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054657","Leg Fatigue Right Now","C122942","A question about how an individual rates their leg fatigue right now.","Leg Fatigue Right Now | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055107","Dyspnea Right Now","C122943","A question about how an individual rates their dyspnea right now.","Dyspnea Right Now | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050152","Borg Category-Ratio 10 Perceived Exertion Score 0","C122945","A subjective score of 0 on a perceived exertion scale that ranges from 0: Nothing at all to 10: Maximal.","Borg Category-Ratio 10 Perceived Exertion Score 0 | No Exertion at All | Nothing at all",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055370","Borg Category-Ratio 10 Perceived Exertion Score 0.5","C122946","A subjective score of 0.5 on a perceived exertion scale that ranges from 0: Nothing at all to 10: Maximal.","Borg Category-Ratio 10 Perceived Exertion Score 0.5 | Very, Very Slight Exertion | Very, very slight (just noticeable)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055369","Borg Category-Ratio 10 Perceived Exertion Score 1","C122947","A subjective score of 1 on a perceived exertion scale that ranges from 0: Nothing at all to 10: Maximal.","Borg Category-Ratio 10 Perceived Exertion Score 1 | Very Slight Exertion | Very slight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050469","Borg Category-Ratio 10 Perceived Exertion Score 2","C122948","A subjective score of 2 on a perceived exertion scale that ranges from 0: Nothing at all to 10: Maximal.","Borg Category-Ratio 10 Perceived Exertion Score 2 | Slight | Slight Exertion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049706","Borg Category-Ratio 10 Perceived Exertion Score 3","C122949","A subjective score of 3 on a perceived exertion scale that ranges from 0: Nothing at all to 10: Maximal.","Borg Category-Ratio 10 Perceived Exertion Score 3 | Moderate | Moderate Exertion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055368","Borg Category-Ratio 10 Perceived Exertion Score 4","C122950","A subjective score of 4 on a perceived exertion scale that ranges from 0: Nothing at all to 10: Maximal.","Borg Category-Ratio 10 Perceived Exertion Score 4 | Somewhat Severe Exertion | Somewhat severe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050466","Borg Category-Ratio 10 Perceived Exertion Score 5","C122951","A subjective score of 5 on a perceived exertion scale that ranges from 0: Nothing at all to 10: Maximal.","Borg Category-Ratio 10 Perceived Exertion Score 5 | Severe | Severe Exertion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055367","Borg Category-Ratio 10 Perceived Exertion Score 6","C122952","A subjective score of 6 on a perceived exertion scale that ranges from 0: Nothing at all to 10: Maximal.","Borg Category-Ratio 10 Perceived Exertion Score 6 | Between Severe and Very severe | Severe to Very Severe Exertion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050419","Borg Category-Ratio 10 Perceived Exertion Score 7","C122953","A subjective score of 7 on a perceived exertion scale that ranges from 0: Nothing at all to 10: Maximal.","Borg Category-Ratio 10 Perceived Exertion Score 7 | Very Severe Exertion | Very severe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055366","Borg Category-Ratio 10 Perceived Exertion Score 8","C122954","A subjective score of 8 on a perceived exertion scale that ranges from 0: Nothing at all to 10: Maximal.","Borg Category-Ratio 10 Perceived Exertion Score 8 | Between Very severe and Very, very severe (almost maximal) | Very Severe to Very, Very Severe Exertion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055365","Borg Category-Ratio 10 Perceived Exertion Score 9","C122955","A subjective score of 9 on a perceived exertion scale that ranges from 0: Nothing at all to 10: Maximal.","Borg Category-Ratio 10 Perceived Exertion Score 9 | Very, Very Severe Exertion | Very, very severe (almost maximal)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049713","Borg Category-Ratio 10 Perceived Exertion Score 10","C122956","A subjective score of 10 on a perceived exertion scale that ranges from 0: Nothing at all to 10: Maximal.","Borg Category-Ratio 10 Perceived Exertion Score 10 | Maximal | Maximal Exertion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055363","Borg Scale Rating of Perceived Exertion Questionnaire","C122957","A scale for the subjective scoring of perceived exertion that ranges from 6: No exertion at all to 20: Maximal exertion. This scale was developed for use with healthy individuals where the score, multiplied by 10, might give an approximation of exercise heart rate.","Borg Scale Rating of Perceived Exertion Questionnaire | BORG RPE SCALE | BRPE01 | Borg RPE | Borg Scale Rating of Perceived Exertion Score 15 Point Scale",,,,,,,,,,,,,,,"37311860","Borg Rating of Perceived Exertion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4049641","Borg Scale Rating of Perceived Exertion Score 6","C122958","A subjective score of 6 on a perceived exertion scale that ranges from 6: No exertion at all to 20: Maximal exertion.","Borg Scale Rating of Perceived Exertion Score 6 | No exertion at all",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055355","Borg Scale Rating of Perceived Exertion Score 7","C122959","A subjective score of 7 on a perceived exertion scale that ranges from 6: No exertion at all to 20: Maximal exertion.","Borg Scale Rating of Perceived Exertion Score 7 | Extremely Light Exertion | Extremely light",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055354","Borg Scale Rating of Perceived Exertion Score 8","C122960","A subjective score of 8 on a perceived exertion scale that ranges from 6: No exertion at all to 20: Maximal exertion.","Borg Scale Rating of Perceived Exertion Score 8 | Between extremely light and very light | Extremely Light to Very Light Exertion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050240","Borg Scale Rating of Perceived Exertion Score 9","C122961","A subjective score of 9 on a perceived exertion scale that ranges from 6: No exertion at all to 20: Maximal exertion.","Borg Scale Rating of Perceived Exertion Score 9 | Very Light Exertion | Very light",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055362","Borg Scale Rating of Perceived Exertion Score 10","C122962","A subjective score of 10 on a perceived exertion scale that ranges from 6: No exertion at all to 20: Maximal exertion.","Borg Scale Rating of Perceived Exertion Score 10 | Between very light and light | Very Light to Light Exertion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050248","Borg Scale Rating of Perceived Exertion Score 11","C122963","A subjective score of 11 on a perceived exertion scale that ranges from 6: No exertion at all to 20: Maximal exertion.","Borg Scale Rating of Perceived Exertion Score 11 | Light | Light Exertion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055361","Borg Scale Rating of Perceived Exertion Score 12","C122964","A subjective score of 12 on a perceived exertion scale that ranges from 6: No exertion at all to 20: Maximal exertion.","Borg Scale Rating of Perceived Exertion Score 12 | Between light and somewhat hard | Light to Somewhat Hard Exertion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050070","Borg Scale Rating of Perceived Exertion Score 13","C122965","A subjective score of 13 on a perceived exertion scale that ranges from 6: No exertion at all to 20: Maximal exertion.","Borg Scale Rating of Perceived Exertion Score 13 | Somewhat Hard Exertion | Somewhat hard",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055360","Borg Scale Rating of Perceived Exertion Score 14","C122966","A subjective score of 14 on a perceived exertion scale that ranges from 6: No exertion at all to 20: Maximal exertion.","Borg Scale Rating of Perceived Exertion Score 14 | Between somewhat hard and hard (heavy) | Somewhat Hard to Hard Exertion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055359","Borg Scale Rating of Perceived Exertion Score 15","C122967","A subjective score of 15 on a perceived exertion scale that ranges from 6: No exertion at all to 20: Maximal exertion.","Borg Scale Rating of Perceived Exertion Score 15 | Hard (heavy) | Hard Exertion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055358","Borg Scale Rating of Perceived Exertion Score 16","C122968","A subjective score of 16 on a perceived exertion scale that ranges from 6: No exertion at all to 20: Maximal exertion.","Borg Scale Rating of Perceived Exertion Score 16 | Between hard (heavy) and very hard | Hard to Very Hard Exertion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3842677","Borg Scale Rating of Perceived Exertion Score 17","C122969","A subjective score of 17 on a perceived exertion scale that ranges from 6: No exertion at all to 20: Maximal exertion.","Borg Scale Rating of Perceived Exertion Score 17 | Very Hard Exertion | Very hard",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055357","Borg Scale Rating of Perceived Exertion Score 18","C122970","A subjective score of 18 on a perceived exertion scale that ranges from 6: No exertion at all to 20: Maximal exertion.","Borg Scale Rating of Perceived Exertion Score 18 | Between very hard and extremely hard | Very Hard to Extremely Hard Exertion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055356","Borg Scale Rating of Perceived Exertion Score 19","C122971","A subjective score of 19 on a perceived exertion scale that ranges from 6: No exertion at all to 20: Maximal exertion.","Borg Scale Rating of Perceived Exertion Score 19 | Extremely Hard Exertion | Extremely hard",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050305","Borg Scale Rating of Perceived Exertion Score 20","C122972","A subjective score of 20 on a perceived exertion scale that ranges from 6: No exertion at all to 20: Maximal exertion.","Borg Scale Rating of Perceived Exertion Score 20 | Maximal Exertion | Maximal exertion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055112","Duke Psychosocial Questionnaire","C122993","A questionnaire designed to evaluate the psychosocial effects of exercise on patients with prostate cancer.","Duke Psychosocial Questionnaire | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053758","How Motivated to Exercise","C122994","A question about an individual's motivation level for exercise.","How Motivated to Exercise Question | How Motivated to Exercise | How Motivated to Exercise | How motivated are you to exercise",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055627","30 Minutes per Day for 5 Days a Week Over Next 24 Weeks","C122996","A time period of 30 minutes per day for 5 days per week over the next 24 weeks.","30 Minutes per Day for 5 Days a Week Over Next 24 Weeks | 30 minutes a day at least 5 days a week over the next 24 weeks",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055199","Confidence that You Could Exercise","C122995","A question about an individual's confidence that they can exercise.","Confidence that You Could Exercise | How Confident that You Could Exercise | How confident are you that you could exercise",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054457","Motivation Visual Analogue Scale","C122997","A scale for the subjective scoring of an individual's motivation that ranges from 1: Not at all motivated to 7: Extremely motivated.","Motivation Visual Analogue Scale | Motivation VAS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054464","Motivation Score 1","C122999","A subjective score of 1 on a motivation scale that ranges from 1: Not at all motivated to 7: Extremely motivated.","Motivation Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054463","Motivation Score 2","C123000","A subjective score of 2 on a motivation scale that ranges from 1: Not at all motivated to 7: Extremely motivated.","Motivation Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054462","Motivation Score 3","C123001","A subjective score of 3 on a motivation scale that ranges from 1: Not at all motivated to 7: Extremely motivated.","Motivation Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054461","Motivation Score 4","C123002","A subjective score of 4 on a motivation scale that ranges from 1: Not at all motivated to 7: Extremely motivated.","Motivation Score 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054460","Motivation Score 5","C123003","A subjective score of 5 on a motivation scale that ranges from 1: Not at all motivated to 7: Extremely motivated.","Motivation Score 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054459","Motivation Score 6","C123004","A subjective score of 6 on a motivation scale that ranges from 1: Not at all motivated to 7: Extremely motivated.","Motivation Score 6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054458","Motivation Score 7","C123005","A subjective score of 7 on a motivation scale that ranges from 1: Not at all motivated to 7: Extremely motivated.","Motivation Score 7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055200","Confidence Visual Analogue Scale","C122998","A scale for the subjective scoring of an individual's confidence that ranges from 1: Not at all confident to 7: Extremely confident.","Confidence Visual Analogue Scale | Confidence VAS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055207","Confidence Score 1","C123006","A subjective score of 1 on a confidence scale that ranges from 1: Not at all confident to 7: Extremely confident.","Confidence Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055206","Confidence Score 2","C123007","A subjective score of 2 on a confidence scale that ranges from 1: Not at all confident to 7: Extremely confident.","Confidence Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055205","Confidence Score 3","C123008","A subjective score of 3 on a confidence scale that ranges from 1: Not at all confident to 7: Extremely confident.","Confidence Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055204","Confidence Score 4","C123009","A subjective score of 4 on a confidence scale that ranges from 1: Not at all confident to 7: Extremely confident.","Confidence Score 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055203","Confidence Score 5","C123010","A subjective score of 5 on a confidence scale that ranges from 1: Not at all confident to 7: Extremely confident.","Confidence Score 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055202","Confidence Score 6","C123011","A subjective score of 6 on a confidence scale that ranges from 1: Not at all confident to 7: Extremely confident.","Confidence Score 6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055201","Confidence Score 7","C123012","A subjective score of 7 on a confidence scale that ranges from 1: Not at all confident to 7: Extremely confident.","Confidence Score 7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3482639","Have Ostomy Appliance","C122973","A question about whether an individual has an ostomy appliance.","Have Ostomy Appliance | Do you have an ostomy appliance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055071","Embarrassed by Ostomy Appliance","C122974","A question about whether an individual is or was bothered by their ostomy appliance.","Embarrassed by Ostomy Appliance | I am embarrassed by my ostomy appliance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055269","Caring for Ostomy Appliance is Difficult","C122975","A question about whether an individual thinks caring for their ostomy appliance is difficult.","Caring for Ostomy Appliance is Difficult | Caring for my ostomy appliance is difficult",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055030","FACT-B+4 Questionnaire","C122976","A subscale complement to the FACT-G developed specifically for use with the FACT-B questionnaire for evaluating the quality of life of breast cancer patients with lymphedema.","FACT-B+4 Questionnaire | FACT-B+4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3476286","Side of Breast Operation (question)","C122977","A question about on which side an individual had breast surgery.","Side of Breast Operation | Breast Operation Laterality | Laterality of Breast Operation | On which side was your breast operation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054843","Have Pain Moving Arm on Side of Breast Operation","C122978","A question about whether an individual has or had pain when moving their arm on the side of their breast surgery.","Have Pain Moving Arm on Side of Breast Operation | Movement of my arm on this side is painful",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054841","Have Poor Range of Arm Movement on Side of Breast Operation","C122979","A question about whether an individual has or had poor range of arm movement on the side of their breast surgery.","Have Poor Range of Arm Movement on Side of Breast Operation | I have a poor range of arm movements on this side",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055442","Arm Feels Numb on Side of Breast Operation","C122980","A question about whether an individual's arm feels or felt numb on the side of their breast surgery.","Arm Feels Numb on Side of Breast Operation | My arm on this side feels numb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054840","Have Stiffness of Arm on Side of Breast Operation","C122981","A question about whether an individual has or had stiffness of their arm on the side of their breast surgery.","Have Stiffness of Arm on Side of Breast Operation | I have stiffness of my arm on this side",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054845","Have Mouth Sores","C122982","A question about whether an individual has or had mouth sores.","Have Mouth Sores | I have mouth sores | Mouth sores",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054419","National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy Prostate Symptom Index","C122983","A 10 item symptom index scale developed from the FACT H&N questionnaire with the National Comprehensive Cancer Network to evaluate response to chemotherapy for patients with prostate cancer.","National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy Prostate Symptom Index | FACT/NCCN-Prostate Symptom Index | FPSI-17 | NCCN-FACT FPSI-17 | National Comprehensive Cancer Network - Functional Assessment of Cancer Therapy Prostate Symptom Index",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054833","Have Weakness in Legs","C122984","A question about whether an individual has or had weakness in their legs.","Have Weakness in Legs | Have Leg Weakness | I have weakness in my legs | My legs feel weak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827029","Borg Category-Ratio 10 Scale Questionnaire","C113872","A standardized rating scale developed by Gunnar Borg in 1998, which is used primarily in clinical diagnosis to measure perceived exertion or intensities of most kinds of experiences and feelings, such as breathlessness. The questionnaire contains 1 item which is scored ranging from 0 (nothing at all) to infinity.","Borg Category-Ratio 10 Scale Questionnaire | BCR101 | BORG CR10 | Borg CR10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054165","Positive and Negative Perfectionism Scale","C123143","A 40-item self-report inventory designed to assess levels of positive and negative perfectionism, and distinguish between 'normal' and 'neurotic' perfectionism. Participants use a 5-point Likert scale that ranges from strongly disagree to strongly agree.","Positive and Negative Perfectionism Scale | PANPS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641071","NCI CTEP SDC Non-Rhabdomyosarcoma Soft Tissue Sarcoma Sub-Category Terminology","C103117","Non-Rhabdomyosarcoma Soft Tissue Sarcoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Non-Rhabdomyosarcoma Soft Tissue Sarcoma Sub-Category Terminology | NCI CTEP Simple Disease Classification Non-Rhabdomyosarcoma Soft Tissue Sarcoma Sub-Category Terminology | Non-Rhabdomyosarcoma Soft Tissue Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516436","Cervical Warty Carcinoma","C40191","A human papillomavirus-related cervical squamous cell carcinoma characterized by the presence of a warty surface and koilocytotic atypia.","Cervical Warty Carcinoma | Cervical Condylomatous Squamous Cell Carcinoma | Cervical Warty Squamous Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206706","Verrucous Carcinoma","C3781","A well differentiated squamous cell carcinoma characterized by a papillary growth pattern, acanthosis, mild cytologic atypia, and pushing tumor margins. The most commonly affected anatomic sites are the oral cavity, nasal cavity, larynx, esophagus, anus, vagina, vulva, and the plantar region of the foot.","Verrucous Carcinoma | Condylomatous carcinoma | Verrucous Epidermoid Carcinoma | Verrucous Epidermoid Cell Carcinoma | Verrucous Squamous Carcinoma | Verrucous Squamous Cell Carcinoma | Verrucous carcinoma | Verrucous carcinoma, NOS | Verrucous epidermoid carcinoma | Verrucous squamous cell carcinoma | Warty carcinoma","8051/3","Verrucous carcinoma, NOS",,,,,,,,,,,,,"4233949","Verrucous carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C4055049","Extent of Friend and Family Support of Effort to Increase Amount of Exercise","C123156","A question about the extent to which friends and family would support an individual's efforts to increase their amount of exercise.","Extent of Friend and Family Support of Effort to Increase Amount of Exercise | To what extent would your friends and family support your efforts to increase your amount of exercise",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881856","Minimally Invasive Lesion","C60986","A lesion in which the neoplastic epithelial cells invade into but not through the capsule that surround the neoplasm, or invade the entire thickness of the capsule, or invade vessels surrounding the capsule.  Unlike widely invasive lesions, the minimally invasive lesions cannot be recognized as carcinomas on clinical and surgical grounds.  The diagnosis can only be established microscopically.","Minimally Invasive Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049711","Lepidic Adenocarcinoma","C123160","A lung adenocarcinoma characterized by the presence of mildly and moderately differentiated adenocarcinoma cells across the alveolar walls with at least one focus of invasive carcinoma measuring more than 5 mm in greatest dimension.","Lepidic Adenocarcinoma | LPA | Lepidic Predominant Adenocarcinoma | Lepidic Predominant Adenocarcinoma | Lepidic Predominant Lung Adenocarcinoma | Lepidic adenocarcinoma | Lepidic predominant adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049986","Impact","C122929","The effect or consequence of an event or condition.","Impact | Impacted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206077","Transcranial Doppler Ultrasonography","C122930","A diagnostic technique that uses pulsed Doppler ultrasound to measure the velocity of blood flow through the major blood vessels of the brain.","Transcranial Doppler Ultrasonography | Non-imaging TCD | TCD | Transcranial Doppler | Transcranial Doppler (TCD) Ultrasonography | Transcranial Doppler Sonography | Transcranial Doppler Ultrasound",,,,,,,,,,,,,,,"4330519","Transcranial Doppler ultrasonography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054740","Imaging Transcranial Doppler Ultrasonography","C122931","A diagnostic technique that uses pulsed Doppler ultrasound to both identify blood vessels in the brain and measure the velocity of blood flow through those vessels. It allows a more accurate estimation of stroke risk because it allows outlining of parenchymal structures and visualization of the examined vessels.","Imaging Transcranial Doppler Ultrasonography | Imaging TCD | Imaging Transcranial Doppler (iTCD) Ultrasonography | Imaging Transcranial Doppler Sonography | TCDI | iTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041190","Tropicamide","C47776","A synthetic muscarinic antagonist with actions similar to atropine and with an anticholinergic property. Upon ocular administration, tropicamide binds to and blocks the muscarinic receptors in the sphincter and ciliary muscle in the eye.  This inhibits the responses from cholinergic stimulation, producing dilation of the pupil and paralysis of the ciliary muscle. Tropicamide is a diagnostic agent and is used to produce short-duration mydriasis and cycloplegia.","Tropicamide | Benzeneacetamide, N-ethyl-alpha-(hydroxymethyl)-N-(4-pyridinylmethyl)- | Mydral | Mydriacyl | N-Ethyl-2-phenyl-N-(4-pyridylmethyl)hydracrylamide | Opticyl | Ro 1-7683 | TROPICAMIDE | Tropicacyl | Tropimil | l-Picamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055233","Circulating MicroRNA","C123153","MicroRNA found in the peripheral blood.","Circulating MicroRNA | Circulating Micro RNA | Circulating miRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0057142","DAPI","C122989","A lipid soluble fluorochrome dye that binds to adenine-thymine (A-T) rich regions in DNA and, to a lesser extent, RNA. During fluorescence microscopy and flow cytometry, this agent binds to and detects endogenous and exogenous DNA in cellular samples. DAPI is excited with ultraviolet (UV) light (maximum absorption at 358 nm) and upon binding, emits light in the blue portion of the spectrum (461 nm for DNA and ~500 nm for RNA).","DAPI | 1H-Indole-6-Carboximidamide, 2-(4-(Aminoiminomethyl)phenyl)- | 2-(4-(Aminoiminomethyl)phenyl)-1H-Indole-6-Carboximidamide | 2-(4-Carbamimidoylphenyl)-1H-Indole-6-Carboximidamide | 4',6-Diamidino-2-Phenylindole | 4',6-Diamidinophenyl-Indole | 4',6-Diamino-2-Phenylindol | BRN 3557399 | DATI | Indole-6-Carboximidamide, 2-(4-(Aminoiminomethyl)phenyl)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050123","DNA Damage Response Deficiency","C123152","A decrease in the ability of cells to respond to damaged DNA and to repair the damage. This DNA repair deficiency can be caused by mutations in the genes involved in the DNA damage response and/or DNA repair.","DNA Damage Response Deficiency | DDRD | DNA Damage Repair Deficiency | DNA Damage Response and Repair Deficiency | Deficient DNA Damage Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537386","HSPA4L Gene","C123144","This gene is involved in the prevention of protein aggregation.","HSPA4L Gene | HSPA4L | Heat Shock 70kDa Protein 4-Like Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049922","Immunoglobulin Heavy Chain Complementarity Determining Region 3","C123154","An amino acid sequence within the hypervariable region of an immunoglobulin heavy chain that includes parts of the variable (V), diversity (D), and joining (J) regions.","Immunoglobulin Heavy Chain Complementarity Determining Region 3 | Antibody Heavy Chain Complementarity Determining Region 3 | CDR-H3 | CDR3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054343","Non-Gaussian Water Diffusion Pattern","C123151","The deviation of the existing water-tissue diffusion pattern from that of a perfect Gaussian curve, which is usually demonstrated via an image finding derived from a form of magnetic resonance imaging, known as diffusional kurtosis imaging.","Non-Gaussian Water Diffusion Pattern | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0074214","Scyllitol","C122987","A stereoisomer of inositol and a plant sugar alcohol found most abundantly in coconut palm trees, with potential amyloid plaque formation inhibitory activity. Following oral administration, scyllitol crosses the blood brain barrier and inhibits amyloid beta plaque formation in the brain through as of yet unknown mechanism(s). This may lead to reduced disease progression and improvement in cognitive function in patients with Alzheimer disease.","Scyllitol | (1r,2r,3r,4r,5r,6r)-Cyclohexane-1,2,3,4,5,6-Hexol | 1,3,5/2,4,6-Cyclohexanehexol | AXD 103 | AZD-103 | AZD103 | Cocositol | Cyclohexane-1,2,3,4,5,6-Hexol | ELND005 | Quercinitol | SCYLLO-INOSITOL | Scyllo-Inositol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420308","SOD3 Gene","C123147","This gene plays a role in the metabolism of extracellular superoxides.","SOD3 Gene | SOD3 | Superoxide Dismutase 3, Extracellular Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040057","Thromboxane A2","C122988","An eicosanoid and short-lived intermediate product between prostaglandin endoperoxides and thromboxane B2, with prothrombotic and vasoconstrictive activities. Thromboxane A (TXA2) binds to its cognate receptor thromboxane A2 receptor (TBXA2R) and stimulates increased expression of glycoprotein IIb/IIIa (GPIIb/IIIa) on platelet membranes, which induces platelet activation and aggregation. Circulating fibrinogen binds to GPIIb/IIIa on platelet surfaces, which promotes clotting. TXA2 also binds to TBXA2R expressed by glomerular cells, which induces signaling pathways that promote vasoconstriction.","Thromboxane A2 | (5Z,13E)-(15S)-9alpha,11alpha-Epoxy-15-Hydroxythromboxa-5,13-Dienoate | (5Z,13E,15S)-9alpha,11alpha-Epoxy-15-Hydroxythromboxa-5,13-Dien-1-Oic Acid | (5Z,9alpha,11alpha,13E,15S)-9,11-Epoxy-15-Hydroxythromboxa-5,13-Dien-1-Oic Acid | 5-Heptenoic Acid, 7-(3-(3-Hydroxy-1-Octenyl)-2,6-Dioxabicyclo(3.1.1)Hept-4-Yl)-, (1S-(1alpha,3alpha,3R*),4beta(Z),5alpha)- | 9S,11S-Epoxy,15S-Hydroxy-Thromboxa-5Z,13E-Dien-1-Oic Acid | THROMBOXANE A2 | TXA-2 | TXA2 | Thromboxa-5,13-Dien-1-Oic Acid, 9,11-Epoxy-15-Hydroxy-, (5Z,9alpha,11alpha,13E,15S)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202227","Total Testosterone Measurement","C74793","The determination of the amount of free and bound testosterone present in a sample.","Total Testosterone Measurement | TESTOS | Testosterone | Total Testosterone",,,,,,,,,,,,,,,"4309944","Testosterone measurement, total",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0405532","Thyroid Lobectomy","C51649","Surgery involving complete excision of a lobe of the thyroid gland.","Thyroid Lobectomy | Lobectomy of Thyroid Gland | Unilateral Thyroid Lobectomy",,,,,,,,,,,,,,,"4118958","Lobectomy of thyroid gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054418","Near Complete Response of Multiple Myeloma or Plasma Cell Leukemia","C123275","A subgroup of complete response of multiple myeloma or plasma cell leukemia.  It is characterized by less than 5% plasma cells in the bone marrow, unmeasurable serum and urine monoclonal proteins by electrophoresis, and positive serum and/or urine immunofixation.","Near Complete Response of Multiple Myeloma or Plasma Cell Leukemia | nCR of MM or PCL | nCR of Multiple Myeloma or Plasma Cell Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880883","Gadolinium-Chelate","C62358","A coordination complex consisting of a gadolinium ion bound to a hexadentate organic chelating agent such as diethylenetriaminepentaacetic acid. Chelates of gadolinium are frequently utilized as magnetic resonance imaging (MRI) contrast agents and can be used to track nanoparticle-mediated drug delivery.","Gadolinium-Chelate | Gadolinium Coordination Complex | Gadolinium-Chelant Complex | Gadolinium-based Contrast Agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448480","Therapeutic Glucocorticoid","C521","Synthetically derived forms of the naturally occurring Glucocorticoids.","Therapeutic Glucocorticoid | Glucocorticoid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL086014","Myelogenous","C13394","Referring to myelocytes, a type of white blood cell. Also called myeloid.","Myelogenous | myelogenous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054080","Regimen-Limiting Toxicity","C123282","A side effect of a drug or other treatment that is serious enough to necessitate a dose modification.","Regimen-Limiting Toxicity | DLT | Dose Limiting Toxicity | Dose-Limiting Toxicity | RLT | dose limiting toxicity | dose_limiting_toxicity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512090","Dukes' Classification","C28352","A staging system used to describe the extent of colorectal cancer. Stages range from A (early stage) to D (advanced stage).","Dukes' Classification | Dukes classification | Dukes' Staging System",,,,,,,,,,,,,,,"4111642","Dukes staging system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0751484","Sporadic Retinoblastoma","C42596","A retinoblastoma that occurs in a patient without a family history of the disease.","Sporadic Retinoblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266144","Pleuropulmonary Blastoma","C5669","A malignant neoplasm affecting the lungs and/or the pleura. Pleuropulmonary blastoma is seen in children. Microscopically, the tumor may show features of chondrosarcoma, leiomyosarcoma, rhabdomyosarcoma, liposarcoma, or undifferentiated sarcoma. In approximately 25% of patients with pleuropulmonary blastoma, there are other lesions or neoplasms that may affect patients or their families, including lung or kidney cysts, and ovarian or testicular neoplasms. Heterozygous germline mutations in DICER1 gene have been identified in families harboring pleuropulmonary blastomas.","Pleuropulmonary Blastoma | PPB | Pleuropulmonary blastoma | Pulmonary Blastoma of Childhood | pleuropulmonary blastoma","8973/3","Pleuropulmonary blastoma",,,,,,,,,,,,,"4029650|45769094","Pleuropulmonary blastoma|Pleuropulmonary blastoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1709668","Primary Site Unknown","C48322","Referring to the fact that the original site of growth of a metastatic cancer is unknown or uncertain.","Primary Site Unknown | SITE, UNCERTAIN PRIMARY | Unknown primary site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986474","Adrenocortical","C94318","Having to do with or made by the outer layer of the adrenal gland, which produces steroid hormones. There is an adrenal gland on top of each kidney.","Adrenocortical | adrenocortical",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1275420","Extraabdominal Fibromatosis","C6489","An insidious poorly circumscribed neoplasm arising from the soft tissues outside the abdomen. It is characterized by the presence of elongated spindle-shaped fibroblasts, vascular collagenous stroma formation, and an infiltrative growth pattern.","Extraabdominal Fibromatosis | Extra-abdominal desmoid | Extraabdominal Desmoid | Extraabdominal Desmoid Tumor",,,,,,,,,,,,,,,"4267548","Extra-abdominal fibromatosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1744681","Congenital","C99210","Denoting something that is present at birth.","Congenital | ",,,,,,,,,,,,,,,"4116830","Congenital",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3839822","DICER1 Syndrome","C123317","A rare, autosomal dominant inherited syndrome caused by mutations in the DICER1 gene. People with this syndrome are at an increased risk of developing pleuropulmonary blastoma, cystic nephroma, Sertoli-Leydig cell tumor of the ovary, and multinodular goiter.","DICER1 Syndrome | ",,,,,,,,,,,,,,,"45771258","DICER1 syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4048306","Multiple endocrine neoplasia Type 2","C123329","Multiple endocrine neoplasia caused by mutation of the RET gene. It includes the following neoplastic processes: multiple endocrine neoplasia type 2A, multiple endocrine neoplasia type 2B, and hereditary thyroid gland medullary carcinoma.","Multiple Endocrine Neoplasia Type 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053845","Work Productivity and Activity Impairment General Health V2.0 Questionnaire","C123285","The second version of a standardized survey originally developed by Margaret C. Reilly in 1993 which is used to evaluate the extent to which a patient's general health problems effects their ability to work and perform daily activities. This instrument consists of 6 questions which can be completed by the patient or in an interview format.","Work Productivity and Activity Impairment General Health V2.0 Questionnaire | WPAI-GH V2.0 | WPAI-GH Version 2 | WPAI02 | WPAI:GH | Work Productivity and Activity Impairment General Health V2.0 Questionnaire (WPAI:GH) | Work Productivity and Activity Impairment General Health Version 2.0 Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055174","Currently Employed","C123286","A question about whether an individual is currently employed.","Currently Employed | Are you currently employed (working for pay) | Currently Working for Pay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054768","Hours Missed from Work Because of Health Problems","C123287","A question about how many hours an individual missed from work because of their health problems.","Hours Missed from Work Because of Health Problems | How many hours did you miss from work because of your health problems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054769","Hours Missed From Work Because of other Reasons","C123288","A question about how many hours an individual missed from work because of any reason other than their health problems.","Hours Missed From Work Because of other Reasons | Hours Missed from Work Because of Any Other Reason | Hours Missed from Work Because of other Reasons | How many hours did you miss from work because of any other reason",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054767","Hours Worked","C123289","A question about how many hours an individual actually worked.","Hours Worked | Hours Actually Worked | How many hours did you actually work",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054828","Health Problems Affect Productivity While Working","C123290","A question about how much an individual's health problems affects or affected their productivity while they were working.","Health Problems Affect Productivity While Working | How much did your health problems affect your productivity while you were working",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054829","Health Problems Affect Ability to do Regular Daily Activities other than Work at Job","C123291","A question about how much an individual's health problems affects or affected their ability to do regular daily activities other than work at a job.","Health Problems Affect Ability to do Regular Daily Activities other than Work at Job Question | Health Problems Affect Ability to do Regular Daily Activities | Health Problems Affect Ability to do Regular Daily Activities other than Work at Job | Health Problems Affect Ability to do Regular Daily Activities other than Work at Job | How much did your health problems affect your ability to do your regular daily activities, other than work at a job",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055075","Effect of Health Problems on Work Likert Scale","C123292","A scale for the subjective scoring of the effect of an individual's health problems on their ability to work that ranges from 0: Health problems had no effect on my work to 10: Health problems completely prevented me from working.","Effect of Health Problems on Work Likert Scale | Effect of Health Problems on Work Scale | WPAI Effect of Health Problems on Work Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054816","Health Problems Effect on Work Score 0","C123294","A subjective score of 0 on a scale that ranges from 0: Health problems had no effect on my work to 10: Health problems completely prevented me from working.","Health Problems Effect on Work Score 0 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054815","Health Problems Effect on Work Score 1","C123295","A subjective score of 1 on a scale that ranges from 0: Health problems had no effect on my work to 10: Health problems completely prevented me from working.","Health Problems Effect on Work Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054814","Health Problems Effect on Work Score 2","C123296","A subjective score of 2 on a scale that ranges from 0: Health problems had no effect on my work to 10: Health problems completely prevented me from working.","Health Problems Effect on Work Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053805","Health Problems Effect on Work Score 3","C123297","A subjective score of 3 on a scale that ranges from 0: Health problems had no effect on my work to 10: Health problems completely prevented me from working.","Health Problems Effect on Work Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054813","Health Problems Effect on Work Score 4","C123298","A subjective score of 4 on a scale that ranges from 0: Health problems had no effect on my work to 10: Health problems completely prevented me from working.","Health Problems Effect on Work Score 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054811","Health Problems Effect on Work Score 6","C123300","A subjective score of 6 on a scale that ranges from 0: Health problems had no effect on my work to 10: Health problems completely prevented me from working.","Health Problems Effect on Work Score 6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054810","Health Problems Effect on Work Score 7","C123301","A subjective score of 7 on a scale that ranges from 0: Health problems had no effect on my work to 10: Health problems completely prevented me from working.","Health Problems Effect on Work Score 7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054809","Health Problems Effect on Work Score 8","C123302","A subjective score of 8 on a scale that ranges from 0: Health problems had no effect on my work to 10: Health problems completely prevented me from working.","Health Problems Effect on Work Score 8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054808","Health Problems Effect on Work Score 9","C123303","A subjective score of 9 on a scale that ranges from 0: Health problems had no effect on my work to 10: Health problems completely prevented me from working.","Health Problems Effect on Work Score 9 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053806","Health Problems Effect on Work Score 10","C123304","A subjective score of 10 on a scale that ranges from 0: Health problems had no effect on my work to 10: Health problems completely prevented me from working.","Health Problems Effect on Work Score 10 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055076","Effect of Health Problems on Daily Activities Likert Scale","C123293","A scale for the subjective scoring of the effect of an individual's health problems on their ability to do daily activities that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.","Effect of Health Problems on Daily Activities Likert Scale | Effect of Health Problems on Daily Activities Scale | WPAI Effect of Health Problems on Daily Activities Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054827","Health Problems Effect on Daily Activities Score 0","C123305","A subjective score of 0 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.","Health Problems Effect on Daily Activities Score 0 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054825","Health Problems Effect on Daily Activities Score 1","C123306","A subjective score of 1 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.","Health Problems Effect on Daily Activities Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054824","Health Problems Effect on Daily Activities Score 2","C123307","A subjective score of 2 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.","Health Problems Effect on Daily Activities Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054823","Health Problems Effect on Daily Activities Score 3","C123309","A subjective score of 3 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.","Health Problems Effect on Daily Activities Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054822","Health Problems Effect on Daily Activities Score 4","C123310","A subjective score of 4 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.","Health Problems Effect on Daily Activities Score 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054821","Health Problems Effect on Daily Activities Score 5","C123311","A subjective score of 5 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.","Health Problems Effect on Daily Activities Score 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054820","Health Problems Effect on Daily Activities Score 6","C123312","A subjective score of 6 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.","Health Problems Effect on Daily Activities Score 6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054819","Health Problems Effect on Daily Activities Score 7","C123313","A subjective score of 7 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.","Health Problems Effect on Daily Activities Score 7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054818","Health Problems Effect on Daily Activities Score 8","C123314","A subjective score of 8 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.","Health Problems Effect on Daily Activities Score 8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054817","Health Problems Effect on Daily Activities Score 9","C123315","A subjective score of 9 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.","Health Problems Effect on Daily Activities Score 9 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054826","Health Problems Effect on Daily Activities Score 10","C123316","A subjective score of 10 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.","Health Problems Effect on Daily Activities Score 10 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0582666","Rosenberg Self-Esteem Scale","C123318","A 10-item scale for the subjective scoring of a person's self esteem, developed by Dr. Morris Rosenberg, that ranges from strongly agree to strongly disagree. Five of the items have positively worded statements and five have negatively worded statements.","Rosenberg Self-Esteem Scale | RSES | Rosenberg Self Esteem Scale",,,,,,,,,,,,,,,"4121654","Rosenberg self-esteem scale",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3257936","Satisfied with Myself on the Whole","C123319","A question about whether an individual is satisfied with themself on the whole.","Satisfied with Myself on the Whole | On the whole, I am satisfied with myself",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3259659","Am No Good at All at Times","C123320","A question about whether an individual thinks they are no good at all at times.","Am No Good at All at Times | At times, I think I am no good at all",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3259931","Have a Number of Good Qualities","C123321","A question about whether an individual feels they have a number of good qualities.","Have a Number of Good Qualities | I feel that I have a number of good qualities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3259648","Able to do Things as Well as Most People","C123322","A question about whether an individual is able to do things as well as most other people.","Able to do Things as Well as Most People Question | Able to do Things as Well as Most People | Able to do Things as Well as Most People | I am able to do things as well as most other people",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3259650","Do Not Have Much to be Proud of","C123323","A question about whether an individual feels they do not have much to be proud feeling.","Do Not Have Much to be Proud of | I feel I do not have much to be proud of",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3259657","Feel Useless at Times","C123324","A question about whether an individual feels useless at times.","Feel Useless at Times | Certainly Feel Useless at Times | I certainly feel useless at times",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3259929","Am a Person of Worth on Equal Plane with Others","C123325","A question about whether an individual feels they are a person of worth on an equal plane with others.","Am a Person of Worth on Equal Plane with Others | I feel that I'm a person of worth, at least on an equal plane with others",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3259655","Wish I Could Have More Respect for Myself","C123326","A question about whether an individual wishes they could have more respect for themself.","Wish I Could Have More Respect for Myself | I wish I could have more respect for myself",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3259646","Inclined to Feel That I am a Failure","C123327","A question about whether an individual is inclined to feel that they are a failure overall.","Inclined to Feel That I am a Failure | All in all, I am inclined to feel that I am a failure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3259652","Take a Positive Attitude Toward Myself","C123328","A question about whether an individual takes a positive attitude towards themselves.","Take a Positive Attitude Toward Myself | I take a positive attitude toward myself",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0346378","Ciliary Body Malignant Medulloepithelioma","C4557","A rare, unilateral, malignant embryonal neoplasm typically presenting as a ciliary body mass during childhood. It arises from primitive medullary epithelium.","Ciliary Body Malignant Medulloepithelioma | Ciliary Body Medulloepithelioma | Malignant Ciliary Body Medulloepithelioma | Malignant Ciliary Body Medulloepithelioma | Malignant Medulloepithelioma of Ciliary Body | Malignant Medulloepithelioma of the Ciliary Body",,,,,,,,,,,,,,,"4218170","Malignant medulloepithelioma of ciliary body",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3816447","Thirty Nine","C105798","A natural number greater than thirty-eight and less than forty and the quantity that it denotes.","Thirty Nine | 39 | Thirty-Nine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0450351","numeral 29","C105800","A natural number greater than twenty-eight and less than thirty and the quantity that it denotes.","Twenty Nine | 29 | Twenty-Nine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274571","Clinical Study Follow-up","C99158","A period in a clinical study during which information about the health status of an individual is obtained after study procedures and treatments have concluded.","Clinical Study Follow-up | FOLLOW-UP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0936282","Blastoma","C8997","A rare embryonal neoplasm affecting children. It is associated with DICER1 gene mutation. This category includes pituitary gland blastoma and pleuropulmonary blastoma.","Blastoma | Blastoma, NOS | Embryoma | embryoma",,,,,,,,,,,,,,,"37153816","Malignant neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0427418","Red Blood Cell Folate Measurement","C123334","The determination of the concentration of folic acid present in a sample of red blood cells.","Red Blood Cell Folate Measurement | RBC Folate | RBC Folate Status | RBC Folic Acid | Red Blood Cell Folate | Red Blood Cell Folate Status | Red Cell Folate",,,,,,,,,,,,,,,"4290096","Folic acid measurement, RBC",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054091","Reese-Ellsworth Staging System","C123333","A staging system for intraocular retinoblastoma that was developed in the 1960s, when children were treated with external beam radiation therapy. This system can help determine the likelihood of preserving the vision while the tumor is being treated. It is divided into 5 stages, and each stage predicts the potential to save the eye with external beam radiation therapy. Today, radiation therapy is reserved as a last resort to save a second eye, when all other treatments have failed. As a result, the Reese-Ellsworth classification is now rarely used.","Reese-Ellsworth Staging System | R-E System | Reese-Ellsworth Classification | Reese-Ellsworth Classification for Intraocular Tumors | Reese-Ellsworth System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982787","Adrenal Cancer TNM Finding v7","C89396","A finding about one or more characteristics of adrenal cancer, following the rules of the TNM AJCC v7 classification system.","Adrenal Cancer TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982791","Adrenal Cancer pT0 TNM Finding v7","C89400","Adrenal cancer with no evidence of a primary tumor. (from AJCC 7th Ed.)","Adrenal Cancer pT0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982792","Adrenal Cancer pT1 TNM Finding v7","C89401","Adrenal cancer with tumor measuring 5 cm or less in greatest dimension, without extra-adrenal invasion. (from AJCC 7th Ed.)","Adrenal Cancer pT1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982793","Adrenal Cancer pT2 TNM Finding v7","C89402","Adrenal cancer with tumor measuring more than 5 cm in greatest dimension without extra-adrenal invasion. (from AJCC 7th Ed.)","Adrenal Cancer pT2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982794","Adrenal Cancer pT3 TNM Finding v7","C89403","Adrenal cancer with tumor of any size with local invasion, without invasion of adjacent organs.  Adjacent organs include kidney, diaphragm, great vessels, pancreas, spleen, and liver. (from AJCC 7th Ed.)","Adrenal Cancer pT3 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982795","Adrenal Cancer pT4 TNM Finding v7","C89404","Adrenal cancer with tumor of any size, with invasion of adjacent organs.  Adjacent organs include kidney, diaphragm, great vessels, pancreas, spleen, and liver. (from AJCC 7th Ed.)","Adrenal Cancer pT4 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982790","Adrenal Cancer pTX TNM Finding v7","C89399","Adrenal cancer in which the primary tumor cannot be assessed. (from AJCC 7th Ed.)","Adrenal Cancer pTX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982798","Adrenal Cancer pN0 TNM Finding v7","C89407","Adrenal cancer with no regional lymph node metastasis. (from AJCC 7th Ed.)","Adrenal Cancer pN0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982799","Adrenal Cancer pN1 TNM Finding v7","C89408","Adrenal cancer with metastasis in regional lymph node(s). (from AJCC 7th Ed.)","Adrenal Cancer pN1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982797","Adrenal Cancer pNX TNM Finding v7","C89406","Adrenal cancer in which the regional lymph nodes cannot be assessed.  (from AJCC 7th Ed.)","Adrenal Cancer pNX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982803","Adrenal Cancer Clinical Distant Metastasis TNM Finding v7","C89412","A clinical finding about one or more characteristics of adrenal cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.","Adrenal Cancer Clinical Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982804","Adrenal Cancer cM0 TNM Finding v7","C89413","Adrenal cancer without evidence of distant metastasis. (from AJCC 7th Ed.)","Adrenal Cancer cM0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982805","Adrenal Cancer cM1 TNM Finding v7","C89414","Adrenal cancer with distant metastasis.  (from AJCC 7th Ed.)","Adrenal Cancer cM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982800","Adrenal Cancer Pathologic Distant Metastasis TNM Finding v7","C89409","A pathologic finding about one or more characteristics of adrenal cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  There is no pathologic M0 for adrenal cancer. (from AJCC 7th Ed.)","Adrenal Cancer Pathologic Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982801","Adrenal Cancer pM1 TNM Finding v7","C89410","Adrenal cancer with distant metastasis. (from AJCC 7th Ed.)","Adrenal Cancer pM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0678050","Stage I Carcinoma of Adrenal Cortex","C9214","Stage I includes: T1, N0, M0.  T1: Tumor 5 cm or less in greatest dimension, no extra-adrenal invasion. N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)","Stage I Adrenal Cortical Carcinoma AJCC v7 | Stage I Adrenal Cortex Cancer | Stage I Adrenal Cortex Carcinoma | Stage I Adrenal Cortex Carcinoma | Stage I Adrenal Cortex Carcinoma AJCC v7 | Stage I Adrenal Cortex Carcinoma AJCC v7 | Stage I Adrenocortical Carcinoma | Stage I Carcinoma of Adrenal Cortex | Stage I Carcinoma of the Adrenal Cortex | stage I adrenocortical cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0678051","Stage II Carcinoma of Adrenal Cortex","C9215","Stage II includes: T2, N0, M0.  T2: Tumor greater than 5 cm, no extra-adrenal invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage II Adrenal Cortical Carcinoma AJCC v7 | Stage II Adrenal Cortex Cancer | Stage II Adrenal Cortex Carcinoma | Stage II Adrenal Cortex Carcinoma | Stage II Adrenal Cortex Carcinoma AJCC v7 | Stage II Adrenal Cortex Carcinoma AJCC v7 | Stage II Adrenocortical Carcinoma | Stage II Carcinoma of Adrenal Cortex | Stage II Carcinoma of the Adrenal Cortex | stage II adrenocortical cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0678052","Stage III Carcinoma of Adrenal Cortex","C9216","Stage III includes: (T1, N1, M0); (T2, N1, M0); (T3, N0, M0).  T1: Tumor 5 cm or less in greatest dimension, no extra-adrenal invasion.  T2: Tumor greater than 5 cm, no extra-adrenal invasion.  T3: Tumor of any size with local invasion, but not invading adjacent organs.  N1: Metastasis in regional lymph node(s).  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage III Adrenal Cortical Carcinoma AJCC v7 | Stage III Adrenal Cortex Cancer | Stage III Adrenal Cortex Carcinoma | Stage III Adrenal Cortex Carcinoma | Stage III Adrenal Cortex Carcinoma AJCC v7 | Stage III Adrenal Cortex Carcinoma AJCC v7 | Stage III Adrenocortical Carcinoma | Stage III Carcinoma of Adrenal Cortex | Stage III Carcinoma of the Adrenal Cortex | stage III adrenocortical cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0678053","Stage IV Carcinoma of Adrenal Cortex","C9217","Stage IV includes: (T3, N1, M0); (T4, N0, M0); (T4, N1, M0); (Any T, Any N, M1).  T3: Tumor of any size with local invasion, but not invading adjacent organs.  T4: Tumor of any size with invasion of adjacent organs.  N1: Metastasis in regional lymph node(s).  N0: No regional lymph node metastasis.  M0: No distant metastasis. M1: Distant metastasis.  (AJCC 7th ed.)","Stage IV Adrenal Cortical Carcinoma AJCC v7 | Stage IV Adrenal Cortex Cancer | Stage IV Adrenal Cortex Carcinoma | Stage IV Adrenal Cortex Carcinoma | Stage IV Adrenal Cortex Carcinoma AJCC v7 | Stage IV Adrenal Cortex Carcinoma AJCC v7 | Stage IV Adrenocortical Carcinoma | Stage IV Carcinoma of Adrenal Cortex | Stage IV Carcinoma of the Adrenal Cortex | stage IV adrenocortical cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983314","Gastrointestinal Stromal Tumor TNM Finding v7","C90043","A finding about one or more characteristics of gastrointestinal stromal tumor, following the rules of the TNM AJCC v7 classification system.","Gastrointestinal Stromal Tumor TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983318","Gastrointestinal Stromal Tumor pT0 TNM Finding v7","C90047","Gastrointestinal stromal tumor with no evidence of a primary tumor. (from AJCC 7th Ed.)","Gastrointestinal Stromal Tumor pT0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983319","Gastrointestinal Stromal Tumor pT1 TNM Finding v7","C90048","Gastrointestinal stromal tumor with tumor size 2 cm or less in greatest dimension. (from AJCC 7th Ed.)","Gastrointestinal Stromal Tumor pT1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983320","Gastrointestinal Stromal Tumor pT2 TNM Finding v7","C90049","Gastrointestinal stromal tumor with tumor size more than 2 cm, but not more than 5 cm, in greatest dimension. (from AJCC 7th Ed.)","Gastrointestinal Stromal Tumor pT2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983322","Gastrointestinal Stromal Tumor pT4 TNM Finding v7","C90051","Gastrointestinal stromal tumor with tumor size more than 10 cm in greatest dimension. (from AJCC 7th Ed.)","Gastrointestinal Stromal Tumor pT4 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983317","Gastrointestinal Stromal Tumor pTX TNM Finding v7","C90046","Gastrointestinal stromal tumor in which the primary tumor cannot be assessed. (from AJCC 7th Ed.)","Gastrointestinal Stromal Tumor pTX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983325","Gastrointestinal Stromal Tumor pN0 TNM Finding v7","C90054","Gastrointestinal stromal tumor with no evidence of metastasis to regional lymph nodes. (from AJCC 7th Ed.)","Gastrointestinal Stromal Tumor pN0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983326","Gastrointestinal Stromal Tumor pN1 TNM Finding v7","C90055","Gastrointestinal stromal tumor with regional lymph node metastasis. (from AJCC 7th Ed.)","Gastrointestinal Stromal Tumor pN1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983330","Gastrointestinal Stromal Tumor Clinical Distant Metastasis TNM Finding v7","C90059","A clinical finding about one or more characteristics of gastrointestinal stromal tumor, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.","Gastrointestinal Stromal Tumor Clinical Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983331","Gastrointestinal Stromal Tumor cM0 TNM Finding v7","C90060","Gastrointestinal stromal tumor without evidence of distant metastasis. (from AJCC 7th Ed.)","Gastrointestinal Stromal Tumor cM0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983332","Gastrointestinal Stromal Tumor cM1 TNM Finding v7","C90061","Gastrointestinal stromal tumor with distant metastasis. (from AJCC 7th Ed.)","Gastrointestinal Stromal Tumor cM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983327","Gastrointestinal Stromal Tumor Pathologic Distant Metastasis TNM Finding v7","C90056","A pathologic finding about one or more characteristics of gastrointestinal stromal tumor, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  There is no pathologic M0 for gastrointestinal stromal tumor. (from AJCC 7th Ed.)","Gastrointestinal Stromal Tumor Pathologic Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983328","Gastrointestinal Stromal Tumor pM1 TNM Finding v7","C90057","Gastrointestinal stromal tumor with distant metastasis. (from AJCC 7th Ed.)","Gastrointestinal Stromal Tumor pM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333768","Gastric Gastrointestinal Stromal Tumor","C5806","A gastrointestinal stromal tumor that arises from the stomach.  It covers a spectrum of benign to malignant soft tissue neoplasms and includes most gastric smooth muscle tumors, leiomyoblastomas, and tumors formerly called gastrointestinal autonomic nerve tumors.","Gastric Gastrointestinal Stromal Tumor | Digestive Stromal Neoplasm of Stomach | Digestive Stromal Neoplasm of the Stomach | Digestive Stromal Tumor of Stomach | Digestive Stromal Tumor of the Stomach | GIST of Stomach | GIST of the Stomach | Gastric (Stomach) Gastrointestinal Stromal Tumor (GIST) | Gastric Digestive Stromal Neoplasm | Gastric Digestive Stromal Tumor | Gastric GIST | Gastrointestinal Stromal Neoplasm of Stomach | Gastrointestinal Stromal Neoplasm of the Stomach | Gastrointestinal Stromal Tumor of Stomach | Gastrointestinal Stromal Tumor of the Stomach | Gastrointestinal stromal tumor of stomach | Stomach Digestive Stromal Neoplasm | Stomach Digestive Stromal Tumor",,,,,,,,,,,,,,,"40492266","Gastrointestinal stromal tumor of stomach",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2981413","Stage IIIB Gastric Gastrointestinal Stromal Tumor","C87829","Stage IIIB includes: T4, N0, M0, Mitotic rate: High. T4: Tumor more than 10 cm in greatest dimension. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IIIB Gastric Gastrointestinal Stromal Tumor AJCC v7 | Stage IIIB Gastric (Stomach) Gastrointestinal Stromal Tumor (GIST) | Stage IIIB Gastric Gastrointestinal Stromal Tumor | Stage IIIB Gastric Gastrointestinal Stromal Tumor AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981410","Stage IB Gastric Gastrointestinal Stromal Tumor","C87826","Stage IB includes: T3, N0, M0, Mitotic rate: Low.  T3: Tumor more than 5 cm, but not more than 10 cm, in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IB Gastric Gastrointestinal Stromal Tumor AJCC v7 | Stage IB Gastric (Stomach) Gastrointestinal Stromal Tumor (GIST) | Stage IB Gastric Gastrointestinal Stromal Tumor | Stage IB Gastric Gastrointestinal Stromal Tumor AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981409","Stage IA Gastric Gastrointestinal Stromal Tumor","C87825","Stage IA includes: T1 or T2, N0, M0, Mitotic rate: Low.  T1: Tumor 2 cm or less in greatest dimension.  T2: Tumor more than 2 cm, but not more than 5 cm, in greatest dimension. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IA Gastric Gastrointestinal Stromal Tumor AJCC v7 | Stage IA Gastric (Stomach) Gastrointestinal Stromal Tumor (GIST) | Stage IA Gastric Gastrointestinal Stromal Tumor | Stage IA Gastric Gastrointestinal Stromal Tumor AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981412","Stage IIIA Gastric Gastrointestinal Stromal Tumor","C87828","Stage IIIA includes: T3, N0, M0, Mitotic rate: High. T3: Tumor more than 5 cm, but not more than 10 cm, in greatest dimension. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IIIA Gastric Gastrointestinal Stromal Tumor AJCC v7 | Stage IIIA Gastric (Stomach) Gastrointestinal Stromal Tumor (GIST) | Stage IIIA Gastric Gastrointestinal Stromal Tumor | Stage IIIA Gastric Gastrointestinal Stromal Tumor AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981414","Stage IV Gastric Gastrointestinal Stromal Tumor","C87830","Stage IV includes: (Any T, N1, M0, Mitotic rate: Any rate); (Any T, Any N, M1, Mitotic rate: Any rate). N1: Regional lymph node metastasis. M0: No distant metastasis.  M1: Distant metastasis.  (AJCC 7th ed.)","Stage IV Gastric Gastrointestinal Stromal Tumor AJCC v7 | Stage IV Gastric (Stomach) Gastrointestinal Stromal Tumor (GIST) | Stage IV Gastric Gastrointestinal Stromal Tumor | Stage IV Gastric Gastrointestinal Stromal Tumor AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335996","Small Intestinal Gastrointestinal Stromal Tumor","C5811","A gastrointestinal stromal tumor that arises from the small intestine.  It usually affects adults over fifty years of age.  The majority of cases have spindle cell morphology.  The prognosis depends on the tumor size and the mitotic activity.","Small Intestinal Gastrointestinal Stromal Tumor | Digestive Stromal Neoplasm of Small Intestine | Digestive Stromal Neoplasm of the Small Intestine | Digestive Stromal Tumor of Small Intestine | Digestive Stromal Tumor of the Small Intestine | Gastrointestinal Stromal Neoplasm of Small Intestine | Gastrointestinal Stromal Neoplasm of the Small Intestine | Gastrointestinal Stromal Tumor of Small Intestine | Gastrointestinal Stromal Tumor of the Small Intestine | Gastrointestinal stromal tumor of small intestine | Small Intestinal GIST | Small Intestinal Gastrointestinal Stromal Tumor (GIST) | Small Intestine Digestive Stromal Neoplasm | Small Intestine Digestive Stromal Tumor | Small Intestine Gastrointestinal Stromal Neoplasm",,,,,,,,,,,,,,,"40492267","Gastrointestinal stromal tumor of small intestine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2981415","Stage I Small Intestinal Gastrointestinal Stromal Tumor","C87831","Stage I includes: T1 or T2, N0, M0, Mitotic rate: Low.  T1: Tumor 2 cm or less in greatest dimension.  T2: Tumor more than 2 cm, but not more than 5 cm, in greatest dimension. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage I Small Intestinal Gastrointestinal Stromal Tumor AJCC v7 | Stage I Small Intestinal Gastrointestinal Stromal Tumor | Stage I Small Intestinal Gastrointestinal Stromal Tumor (GIST) | Stage I Small Intestinal Gastrointestinal Stromal Tumor AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981416","Stage II Small Intestinal Gastrointestinal Stromal Tumor","C87832","Stage II includes: T3, N0, M0, Mitotic rate: Low.  T3: Tumor more than 5 cm, but not more than 10 cm, in greatest dimension. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage II Small Intestinal Gastrointestinal Stromal Tumor AJCC v7 | Stage II Small Intestinal Gastrointestinal Stromal Tumor | Stage II Small Intestinal Gastrointestinal Stromal Tumor (GIST) | Stage II Small Intestinal Gastrointestinal Stromal Tumor AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981417","Stage IIIA Small Intestinal Gastrointestinal Stromal Tumor","C87833","Stage IIIA includes: (T1, N0, M0, Mitotic rate: High); (T4, N0, M0, Mitotic rate: Low).  T1: Tumor 2 cm or less in greatest dimension.  T4: Tumor more than 10 cm in greatest dimension. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IIIA Small Intestinal Gastrointestinal Stromal Tumor AJCC v7 | Stage IIIA Small Intestinal Gastrointestinal Stromal Tumor | Stage IIIA Small Intestinal Gastrointestinal Stromal Tumor (GIST) | Stage IIIA Small Intestinal Gastrointestinal Stromal Tumor AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981418","Stage IIIB Small Intestinal Gastrointestinal Stromal Tumor","C87834","Stage IIIB includes: (T2, N0, M0, Mitotic rate: High); (T3, N0, M0, Mitotic rate: High); (T4, N0, M0, Mitotic rate: High).  T2: Tumor more than 2 cm, but not more than 5 cm, in greatest dimension. T3: Tumor more than 5 cm, but not more than 10 cm, in greatest dimension. T4: Tumor more than 10 cm in greatest dimension. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IIIB Small Intestinal Gastrointestinal Stromal Tumor AJCC v7 | Stage IIIB Small Intestinal Gastrointestinal Stromal Tumor | Stage IIIB Small Intestinal Gastrointestinal Stromal Tumor (GIST) | Stage IIIB Small Intestinal Gastrointestinal Stromal Tumor AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981419","Stage IV Small Intestinal Gastrointestinal Stromal Tumor","C87835","Stage IV includes: (Any T, N1, M0, Mitotic rate: Any rate); (Any T, Any N, M1, Mitotic rate: Any rate).  N1: Regional lymph node metastasis.  M1: Distant metastasis. (AJCC 7th ed.)","Stage IV Small Intestinal Gastrointestinal Stromal Tumor AJCC v7 | Stage IV Small Intestinal Gastrointestinal Stromal Tumor | Stage IV Small Intestinal Gastrointestinal Stromal Tumor (GIST) | Stage IV Small Intestinal Gastrointestinal Stromal Tumor AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333783","Gastric Neuroendocrine Neoplasm","C5696","A neoplasm with neuroendocrine differentiation that arises from the stomach. It includes neuroendocrine tumors (well-differentiated neuroendocrine neoplasms) and neuroendocrine carcinomas (poorly differentiated neuroendocrine neoplasms).","Gastric Neuroendocrine Neoplasm | Neuroendocrine Neoplasm of Stomach | Neuroendocrine Neoplasm of the Stomach | Stomach Neuroendocrine Neoplasm",,,,,,,,,,,,,,,"36715499","Neuroendocrine neoplasm of stomach",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333799","Digestive System Neuroendocrine Neoplasm","C27721","A neoplasm with neuroendocrine differentiation arising from the digestive system. It includes neuroendocrine tumors (well-differentiated neuroendocrine neoplasms) and neuroendocrine carcinomas (poorly differentiated neuroendocrine neoplasms).","Digestive System Neuroendocrine Neoplasm | Gastroenteropancreatic Neuroendocrine Neoplasm | Gastrointestinal Neuroendocrine Neoplasm | Gastrointestinal System Neuroendocrine Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272603","Colorectal Neuroendocrine Neoplasm","C96152","A neoplasm with neuroendocrine differentiation that arises from the colon or rectum. It includes neuroendocrine tumors (well-differentiated neuroendocrine neoplasms) and neuroendocrine carcinomas (poorly differentiated neuroendocrine neoplasms).","Colorectal Neuroendocrine Neoplasm | Large Intestinal Neuroendocrine Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272399","Gastric Neuroendocrine Tumor","C95871","A well-differentiated, low-, intermediate-, or high-grade neoplasm with neuroendocrine differentiation that arises from the stomach.","Gastric Neuroendocrine Tumor | Gastric NET | Gastric Well Differentiated Endocrine Tumor | Gastric Well Differentiated Endocrine Tumor/Carcinoma | Gastric Well Differentiated Neuroendocrine Neoplasm | Gastric Well-Differentiated Neuroendocrine Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983337","Gastric Neuroendocrine Tumor pT0 TNM Finding v7","C90070","Gastric neuroendocrine tumor with no evidence of a primary tumor. (from AJCC 7th Ed.)","Gastric Neuroendocrine Tumor pT0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983339","Gastric Neuroendocrine Tumor pT1 TNM Finding v7","C90072","Gastric neuroendocrine tumor invading lamina propria or submucosa and is 1 cm or less in size. (from AJCC 7th Ed.)","Gastric Neuroendocrine Tumor pT1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983340","Gastric Neuroendocrine Tumor pT2 TNM Finding v7","C90073","Gastric neuroendocrine tumor invading muscularis propria or is more than 1 cm in size. (from AJCC 7th Ed.)","Gastric Neuroendocrine Tumor pT2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983341","Gastric Neuroendocrine Tumor pT3 TNM Finding v7","C90074","Gastric neuroendocrine tumor penetrating subserosa.  (from AJCC 7th Ed.)","Gastric Neuroendocrine Tumor pT3 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983342","Gastric Neuroendocrine Tumor pT4 TNM Finding v7","C90075","Gastric neuroendocrine tumor invading visceral peritoneum (serosa) or other organs or adjacent structures. (from AJCC 7th Ed.)","Gastric Neuroendocrine Tumor pT4 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983338","Gastric Neuroendocrine Tumor pTis TNM Finding v7","C90071","Gastric neuroendocrine tumor with a finding of carcinoma in situ/dysplasia (tumor size less than 0.5 mm), confined to mucosa. (from AJCC 7th Ed.)","Gastric Neuroendocrine Tumor pTis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983336","Gastric Neuroendocrine Tumor pTX TNM Finding v7","C90068","Gastric neuroendocrine tumor in which the primary tumor cannot be assessed. (from AJCC 7th Ed.)","Gastric Neuroendocrine Tumor pTX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983351","Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pT0 TNM Finding v7","C90084","Duodenum/ampulla/jejunum/ileum neuroendocrine tumor with no evidence of a primary tumor. (from AJCC 7th Ed.)","Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pT0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983352","Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pT1 TNM Finding v7","C90085","Duodenum/ampulla/jejunum/ileum neuroendocrine tumor invading lamina propria or submucosa and is 1 cm or less in size (small intestinal tumors); for ampullary tumors: tumor 1 cm or less. (from AJCC 7th Ed.)","Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pT1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983353","Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pT2 TNM Finding v7","C90086","Duodenum/ampulla/jejunum/ileum neuroendocrine tumor invading muscularis propria or is more than 1 cm in size (small intestinal tumors); for ampullary tumors: tumor more than 1 cm. (from AJCC 7th Ed.)","Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pT2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983354","Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pT3 TNM Finding v7","C90087","Duodenum/ampulla/jejunum/ileum neuroendocrine tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa (jejunal or ileal tumors) or invading pancreas or retroperitoneum (ampullary or duodenal tumors) or into non-peritonealized tissues. (from AJCC 7th Ed.)","Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pT3 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983355","Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pT4 TNM Finding v7","C90090","Duodenum/ampulla/jejunum/ileum neuroendocrine tumor invading visceral peritoneum (serosa) or invading other organs. (from AJCC 7th Ed.)","Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pT4 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983350","Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pTX TNM Finding v7","C90083","Duodenum/ampulla/jejunum/ileum neuroendocrine tumor in which the primary tumor cannot be assessed. (from AJCC 7th Ed.)","Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pTX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983369","Colon or Rectum Neuroendocrine Tumor pT1b TNM Finding v7","C90105","Colon or rectum neuroendocrine tumor invading lamina propria or submucosa and is 1-2 cm in greatest dimension. (from AJCC 7th Ed.)","Colon or Rectum Neuroendocrine Tumor pT1b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983368","Colon or Rectum Neuroendocrine Tumor pT1a TNM Finding v7","C90104","Colon or rectum neuroendocrine tumor invading lamina propria or submucosa and is less than 1 cm in greatest dimension. (from AJCC 7th Ed.)","Colon or Rectum Neuroendocrine Tumor pT1a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983366","Colon or Rectum Neuroendocrine Tumor pT0 TNM Finding v7","C90102","Colon or rectum neuroendocrine tumor with no evidence of a primary tumor. (from AJCC 7th Ed.)","Colon or Rectum Neuroendocrine Tumor pT0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983367","Colon or Rectum Neuroendocrine Tumor pT1 TNM Finding v7","C90103","Colon or rectum neuroendocrine tumor invading lamina propria or submucosa and is 2 cm or less in size. (from AJCC 7th Ed.)","Colon or Rectum Neuroendocrine Tumor pT1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983370","Colon or Rectum Neuroendocrine Tumor pT2 TNM Finding v7","C90106","Colon or rectum neuroendocrine tumor invading muscularis propria or is more than 2 cm in size with invasion of lamina propria or submucosa. (from AJCC 7th Ed.)","Colon or Rectum Neuroendocrine Tumor pT2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983371","Colon or Rectum Neuroendocrine Tumor pT3 TNM Finding v7","C90107","Colon or rectum neuroendocrine tumor invading through the muscularis propria into the subserosa, or into non-peritonealized pericolic or perirectal tissues.  (from AJCC 7th Ed.)","Colon or Rectum Neuroendocrine Tumor pT3 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983372","Colon or Rectum Neuroendocrine Tumor pT4 TNM Finding v7","C90108","Colon or rectum neuroendocrine tumor invading peritoneum or other organs. (from AJCC 7th Ed.)","Colon or Rectum Neuroendocrine Tumor pT4 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983364","Colon or Rectum Neuroendocrine Tumor pTX TNM Finding v7","C90099","Colon or rectum neuroendocrine tumor in which the primary tumor cannot be assessed. (from AJCC 7th Ed.)","Colon or Rectum Neuroendocrine Tumor pTX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983345","Gastric Neuroendocrine Tumor pN0 TNM Finding v7","C90078","Gastric neuroendocrine tumor with no regional lymph node metastasis. (from AJCC 7th Ed.)","Gastric Neuroendocrine Tumor pN0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983346","Gastric Neuroendocrine Tumor pN1 TNM Finding v7","C90079","Gastric neuroendocrine tumor with regional lymph node metastasis. (from AJCC 7th Ed.)","Gastric Neuroendocrine Tumor pN1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983344","Gastric Neuroendocrine Tumor pNX TNM Finding v7","C90077","Gastric neuroendocrine tumor in which regional lymph nodes cannot be assessed. (from AJCC 7th Ed.)","Gastric Neuroendocrine Tumor pNX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983358","Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pN0 TNM Finding v7","C90093","Duodenum/ampulla/jejunum/ileum neuroendocrine tumor with no regional lymph node metastasis. (from AJCC 7th Ed.)","Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pN0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983359","Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pN1 TNM Finding v7","C90094","Duodenum/ampulla/jejunum/ileum neuroendocrine tumor with regional lymph node metastasis. (from AJCC 7th Ed.)","Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pN1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983357","Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pNX TNM Finding v7","C90092","Duodenum/ampulla/jejunum/ileum neuroendocrine tumor in which regional lymph nodes cannot be assessed. (from AJCC 7th Ed.)","Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pNX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983375","Colon or Rectum Neuroendocrine Tumor pN0 TNM Finding v7","C90111","Colon or rectum neuroendocrine tumor with no regional lymph node metastasis. (from AJCC 7th Ed.)","Colon or Rectum Neuroendocrine Tumor pN0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983376","Colon or Rectum Neuroendocrine Tumor pN1 TNM Finding v7","C90112","Colon or rectum neuroendocrine tumor with regional lymph node metastasis. (from AJCC 7th Ed.)","Colon or Rectum Neuroendocrine Tumor pN1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983374","Colon or Rectum Neuroendocrine Tumor pNX TNM Finding v7","C90110","Colon or rectum neuroendocrine tumor in which regional lymph nodes cannot be assessed. (from AJCC 7th Ed.)","Colon or Rectum Neuroendocrine Tumor pNX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983381","Gastric Neuroendocrine Tumor Clinical Distant Metastasis TNM Finding v7","C90118","A clinical finding about one or more characteristics of gastric neuroendocrine tumor, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.","Gastric Neuroendocrine Tumor Clinical Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983382","Gastric Neuroendocrine Tumor cM0 TNM Finding v7","C90120","Gastric neuroendocrine tumor without evidence of distant metastasis. (from AJCC 7th Ed.)","Gastric Neuroendocrine Tumor cM0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983383","Gastric Neuroendocrine Tumor cM1 TNM Finding v7","C90121","Gastric neuroendocrine tumor with distant metastasis. (from AJCC 7th Ed.)","Gastric Neuroendocrine Tumor cM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983385","Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor cM0 TNM Finding v7","C90128","Duodenum/ampulla/jejunum/ileum neuroendocrine tumor without evidence of distant metastasis. (from AJCC 7th Ed.)","Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor cM0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983387","Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor cM1 TNM Finding v7","C90131","Duodenum/ampulla/jejunum/ileum neuroendocrine tumor with distant metastasis. (from AJCC 7th Ed.)","Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor cM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983388","Colon or Rectum Neuroendocrine Tumor Clinical Distant Metastasis TNM Finding v7","C90132","A clinical finding about one or more characteristics of colon or rectum neuroendocrine tumor, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.","Colon or Rectum Neuroendocrine Tumor Clinical Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983390","Colon or Rectum Neuroendocrine Tumor cM0 TNM Finding v7","C90134","Colon or rectum neuroendocrine tumor without evidence of distant metastasis. (from AJCC 7th Ed.)","Colon or Rectum Neuroendocrine Tumor cM0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983391","Colon or Rectum Neuroendocrine Tumor cM1 TNM Finding v7","C90135","Colon or rectum neuroendocrine tumor with distant metastasis. (from AJCC 7th Ed.)","Colon or Rectum Neuroendocrine Tumor cM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983347","Gastric Neuroendocrine Tumor Pathologic Distant Metastasis TNM Finding v7","C90080","A pathologic finding about one or more characteristics of gastric neuroendocrine tumor, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  There is no pathologic M0 for gastric neuroendocrine tumor. (from AJCC 7th Ed.)","Gastric Neuroendocrine Tumor Pathologic Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983348","Gastric Neuroendocrine Tumor pM1 TNM Finding v7","C90081","Gastric neuroendocrine tumor with distant metastasis. (from AJCC 7th Ed.)","Gastric Neuroendocrine Tumor pM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983361","Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor Pathologic Distant Metastasis TNM Finding v7","C90096","A pathologic finding about one or more characteristics of duodenum/ampulla/jejunum/ileum neuroendocrine tumor, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  There is no pathologic M0 for duodenum/ampulla/jejunum/ileum neuroendocrine tumor. (from AJCC 7th Ed.)","Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor Pathologic Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983362","Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pM1 TNM Finding v7","C90097","Duodenum/ampulla/jejunum/ileum neuroendocrine tumor with distant metastasis. (from AJCC 7th Ed.)","Duodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor pM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983378","Colon or Rectum Neuroendocrine Tumor Pathologic Distant Metastasis TNM Finding v7","C90115","A pathologic finding about one or more characteristics of colon or rectum neuroendocrine tumor, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  There is no pathologic M0 for colon or rectum neuroendocrine tumor. (from AJCC 7th Ed.)","Colon or Rectum Neuroendocrine Tumor Pathologic Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983379","Colon or Rectum Neuroendocrine Tumor pM1 TNM Finding v7","C90116","Colon or rectum neuroendocrine tumor with distant metastasis. (from AJCC 7th Ed.)","Colon or Rectum Neuroendocrine Tumor pM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981614","Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7","C88032","Stage IIIB includes: Any T, N1, M0. N1: Regional lymph node metastasis. M0: No distant metastasis.  (AJCC 7th ed.)","Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7 | Stage IIIB Digestive System Neuroendocrine Neoplasm | Stage IIIB Digestive System Neuroendocrine Neoplasm | Stage IIIB Digestive System Neuroendocrine Neoplasm AJCC v7 | Stage IIIB Digestive System Neuroendocrine Tumor | Stage IIIB Gastrointestinal Neuroendocrine Neoplasm | Stage IIIB Gastrointestinal Neuroendocrine Neoplasm AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981613","Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7","C88031","Stage IIIA includes: T4, N0, M0.  T4: Stomach/duodenum/ampulla/jejunum/ileum: tumor invades visceral peritoneum (serosa) or invades other organs or adjacent structures; colon or rectum: tumor invades peritoneum or other organs.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7 | Stage IIIA Digestive System Neuroendocrine Neoplasm | Stage IIIA Digestive System Neuroendocrine Neoplasm | Stage IIIA Digestive System Neuroendocrine Neoplasm AJCC v7 | Stage IIIA Digestive System Neuroendocrine Tumor | Stage IIIA Gastrointestinal Neuroendocrine Neoplasm | Stage IIIA Gastrointestinal Neuroendocrine Neoplasm AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981610","Stage I Digestive System Neuroendocrine Tumor AJCC v7","C88028","Stage I includes: T1, N0, M0.  T1: Stomach: tumor invades lamina propria or submucosa and is 1 cm or less in size; duodenum /jejunum/ileum: tumor invades lamina propria or submucosa and is 1 cm or less in size; ampulla: tumor 1 cm or less; colon or rectum: tumor invades lamina propria or submucosa and is 2 cm or less.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage I Digestive System Neuroendocrine Tumor AJCC v7 | Stage I Digestive System Neuroendocrine Neoplasm | Stage I Digestive System Neuroendocrine Neoplasm | Stage I Digestive System Neuroendocrine Neoplasm AJCC v7 | Stage I Digestive System Neuroendocrine Tumor | Stage I Gastrointestinal Neuroendocrine Neoplasm | Stage I Gastrointestinal Neuroendocrine Neoplasm AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981609","Stage 0 Digestive System Neuroendocrine Tumor AJCC v7","C88027","Stage 0 includes: Tis, N0, M0.  Tis (applies only to stomach): Carcinoma in situ/dysplasia (tumor size less than 0.5 mm), confined to mucosa. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage 0 Digestive System Neuroendocrine Tumor AJCC v7 | Stage 0 Digestive System Neuroendocrine Neoplasm | Stage 0 Digestive System Neuroendocrine Neoplasm | Stage 0 Digestive System Neuroendocrine Neoplasm AJCC v7 | Stage 0 Digestive System Neuroendocrine Tumor | Stage 0 Gastrointestinal Neuroendocrine Neoplasm | Stage 0 Gastrointestinal Neuroendocrine Neoplasm AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981611","Stage IIA Digestive System Neuroendocrine Tumor AJCC v7","C88029","Stage IIA includes: T2, N0, M0.  T2: Stomach/ duodenum /jejunum/ileum: tumor invades muscularis propria or is more than 1 cm in size; ampulla: tumor is more than 1 cm in size; colon or rectum: tumor invades muscularis propria or is more than 2 cm in size with invasion of lamina propria or submucosa.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IIA Digestive System Neuroendocrine Tumor AJCC v7 | Stage IIA Digestive System Neuroendocrine Neoplasm | Stage IIA Digestive System Neuroendocrine Neoplasm | Stage IIA Digestive System Neuroendocrine Neoplasm AJCC v7 | Stage IIA Digestive System Neuroendocrine Tumor | Stage IIA Gastrointestinal Neuroendocrine Neoplasm | Stage IIA Gastrointestinal Neuroendocrine Neoplasm AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981612","Stage IIB Digestive System Neuroendocrine Tumor AJCC v7","C88030","Stage IIB includes: T3, N0, M0.  T3: Stomach: tumor penetrates subserosa; jejunum/ileum: tumor invades through the muscularis propria into subserosal tissue without penetration of overlying serosa or invades into non-peritonealized tissues; ampulla/duodenum: tumor invades pancreas or retroperitoneum or into non-peritonealized tissues; colon or rectum: tumor invades through the muscularis propria into the subserosa, or into non-peritonealized pericolic or perirectal tissues. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IIB Digestive System Neuroendocrine Tumor AJCC v7 | Stage IIB Digestive System Neuroendocrine Neoplasm | Stage IIB Digestive System Neuroendocrine Neoplasm | Stage IIB Digestive System Neuroendocrine Neoplasm AJCC v7 | Stage IIB Digestive System Neuroendocrine Tumor | Stage IIB Gastrointestinal Neuroendocrine Neoplasm | Stage IIB Gastrointestinal Neuroendocrine Neoplasm AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981615","Stage IV Digestive System Neuroendocrine Tumor AJCC v7","C88033","Stage IV includes: Any T, Any N, M1. M1: Distant metastasis.  (AJCC 7th ed.)","Stage IV Digestive System Neuroendocrine Tumor AJCC v7 | Stage IV Digestive System Neuroendocrine Neoplasm | Stage IV Digestive System Neuroendocrine Neoplasm | Stage IV Digestive System Neuroendocrine Neoplasm AJCC v7 | Stage IV Digestive System Neuroendocrine Tumor | Stage IV Gastrointestinal Neuroendocrine Neoplasm | Stage IV Gastrointestinal Neuroendocrine Neoplasm AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049621","Peritoneal Cancer Index","C123361","A method for detailed evaluation of the peritoneal spread of tumors of gastrointestinal origin. The index is based on tumor size in 13 separate regions, 9 regions in the abdomen and 4 in the small intestine. Each region is given a score from 0 to 3, based on the size of any tumors present, and the cancer index is the sum of all scores, ranging from 0 to 39. This score has been found to be a prognostic indicator of survival.","Peritoneal Cancer Index | PCI | Peritoneal Carcinomatosis Index",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049628","Adult Hope Scale","C123340","A 12-item measure of a respondent's level of hope. Each item is answered using an 8-point Likert-type scale ranging from Definitely False to Definitely True.","Adult Hope Scale | AHS | Adult Hope Scale (AHS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055286","Can Think of Many Ways to Get Out of a Jam","C123341","A question about whether an individual can think of many ways to get out of a jam.","Can Think of Many Ways to Get Out of a Jam | I can think of many ways to get out of a jam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055063","Energetically Pursue Goals","C123342","A question about whether an individual energetically pursue their goals.","Energetically Pursue Goals | I energetically pursue my goals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054976","Feel Tired Most of Time","C123343","A question about whether an individual feels or felt tired most of the time.","Feel Tired Most of Time | I feel tired most of the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054593","Lots of Ways Around Any Problem","C123344","A question about whether an individual believes there are lots of ways around any problem.","Lots of Ways Around Any Problem | There are lots of ways around any problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055083","Easily Downed in Argument","C123345","A question about whether an individual is or was easily downed in an argument.","Easily Downed in Argument | I am easily downed in an argument",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055285","Can Think of Many Ways to Get the Things in Life that are Important to Me","C123346","A question about whether an individual can think of many ways to get the things in life that are important to them.","Can Think of Many Ways to Get the Things in Life that are Important to Me | I can think of many ways to get the things in life that are important to me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055287","Can Find Way to Solve Problem Even When Others Get Discouraged","C123347","A question about whether an individual can find a way to solve a problem even when others get discouraged.","Can Find Way to Solve Problem Even When Others Get Discouraged | Even when others get discouraged, I know I can find a way to solve the problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054240","Past Experiences Have Prepared Me Well for Future","C123348","A question about whether an individual feels of felt their past experiences have prepared them well for the future.","Past Experiences Have Prepared Me Well for Future | My past experiences have prepared me well for my future",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054859","Have Been Pretty Successful in Life","C123349","A question about whether an individual is or has been pretty successful in life.","Have Been Pretty Successful in Life | I've been pretty successful in life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053886","Usually Find Myself Worrying About Something","C123350","A question about whether an individual usually finds themself worrying about something.","Usually Find Myself Worrying About Something | I usually find myself worrying about something",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054548","Meet Goals Set for Myself","C123351","A question about whether an individual meets the goals they set for themself.","Meet Goals Set for Myself | I meet the goals that I set for myself",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049700","Worry About My Health, How True","C123352","A question about whether an individual worries about their health.","Worry About My Health, How True | How True Worry About My Health | I worry about my health",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3842802","Definitely False","C123353","A subjective response indicating that something is definitely false.","Definitely False | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3840595","Mostly False","C123354","A subjective response indicating that something is mostly false.","Mostly False | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3843211","Somewhat False","C123355","A subjective response indicating that something is somewhat false.","Somewhat False | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054012","Slightly False","C123356","A subjective response indicating that something is slightly false.","Slightly False | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054011","Slightly True","C123357","A subjective response indicating that something is slightly true.","Slightly True | A little true",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3843212","Somewhat True","C123358","A subjective response indicating that something is somewhat true.","Somewhat True | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3842803","Mostly True","C123359","A subjective response indicating that something is mostly true.","Mostly True | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3842804","Definitely True","C123360","A subjective response indicating that something is definitely true.","Definitely True | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054102","Reese-Ellsworth Classification Group I","C123363","Very favorable for maintenance of sight.","Reese-Ellsworth Classification Group I | Reese-Ellsworth Group I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054100","Reese-Ellsworth Classification IA","C123368","Solitary tumor, smaller than 4 disc diameters, tumor at or behind the equator.","Reese-Ellsworth Classification IA | Reese-Ellsworth IA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054099","Reese-Ellsworth Classification IB","C123369","Multiple tumors, none larger than 4 disc diameters, all tumors at or behind the equator.","Reese-Ellsworth Classification IB | Reese-Ellsworth IB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054104","Reese-Ellsworth Classification Group II","C123364","Favorable for maintenance of sight.","Reese-Ellsworth Classification Group II | Reese-Ellsworth Group II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053723","Reese-Ellsworth Classification IIA","C123370","Solitary tumor, 4 to 10 disc diameters, tumor at or behind the equator.","Reese-Ellsworth Classification IIA | Reese-Ellsworth IIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054098","Reese-Ellsworth Classification IIB","C123371","Multiple tumors, 4 to 10 disc diameters, all tumors behind the equator.","Reese-Ellsworth Classification IIB | Reese-Ellsworth IIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054105","Reese-Ellsworth Classification Group III","C123365","Possible for maintenance of sight.","Reese-Ellsworth Classification Group III | Reese-Ellsworth Group III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054097","Reese-Ellsworth Classification IIIA","C123372","Any lesion anterior to the equator.","Reese-Ellsworth Classification IIIA | Reese-Ellsworth IIIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054096","Reese-Ellsworth Classification IIIB","C123373","Solitary tumor, larger than 10 disc diameters, tumor behind the equator.","Reese-Ellsworth Classification IIIB | Reese-Ellsworth IIIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054103","Reese-Ellsworth Classification Group IV","C123366","Unfavorable for maintenance of sight.","Reese-Ellsworth Classification Group IV | Reese-Ellsworth Group IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054095","Reese-Ellsworth Classification IVA","C123374","Multiple tumors, some larger than 10 disc diameters.","Reese-Ellsworth Classification IVA | Reese-Ellsworth IVA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054094","Reese-Ellsworth Classification IVB","C123375","Any lesion extending anteriorly to the ora serrata.","Reese-Ellsworth Classification IVB | Reese-Ellsworth IVB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054101","Reese-Ellsworth Classification Group V","C123367","Very unfavorable for maintenance of sight.","Reese-Ellsworth Classification Group V | Reese-Ellsworth Group V",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054093","Reese-Ellsworth Classification VA","C123376","Massive tumors involving more than one-half of the retina.","Reese-Ellsworth Classification VA | Reese-Ellsworth VA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054092","Reese-Ellsworth Classification VB","C123377","Vitreous seeding.","Reese-Ellsworth Classification VB | Reese-Ellsworth VB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1541530","Cediranib Maleate","C48379","The maleate salt of an indole ether quinazoline derivative with antineoplastic activities. Competing with adenosine triphosphate, cediranib binds to and inhibits all three vascular endothelial growth factor receptor (VEGFR-1,-2,-3) tyrosine kinases, thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth.","Cediranib Maleate | AZD2171 | AZD2171 Maleate | CEDIRANIB MALEATE | Quinazoline, 4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(1-pyrrolidinyl)propoxy)- | Recentin | cediranib maleate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3468008","Cabozantinib S-malate","C97938","The s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.","Cabozantinib S-malate | BMS-907351 | Butanedioic acid, 2-hydroxy-, (2S)-, compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1) | CABOZANTINIB S-MALATE | Cabometyx | Cometriq | XL 184 | XL-184 | XL184",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2246617","Adipocytokine Signaling Pathway","C91486","Increased adipocyte volume and number are positively correlated with leptin production, and negatively correlated with production of adiponectin.","Adipocytokine Signaling Pathway | Adipocytokine signaling pathway",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986782","Metabolic Rate Quantification","C94933","A quantification method to determine metabolic rate.","Metabolic Rate Quantification | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2706101","Patient Health Questionnaire-2","C123386","A 2-item scale used to screen for depression and anhedonia over the past 2 weeks. It is comprised of the first 2 items of the Patient Health Questionnaire-9.","Patient Health Questionnaire-2 | PHQ-2 | PHQ04 | Patient Health Questionnaire (PHQ-2) | Patient Health Questionnaire-2 (PHQ-2) | Patient Health Questionnaire-2 Item",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054452","Muscle Enhancement Product Use","C123390","This is a single item, three part measure taken from the Growing Up Today Study (GUTS) that assesses use and frequency of various products (e.g., creatine, growth hormone, steroids) to improve muscle mass or strength in the past year.","Muscle Enhancement Product Use | Muscle Enhancement Product(s) Use | Use of Muscle Enhancement Products",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055489","Adipocytokine Assay","C123391","Any bioassay designed to detect and quantify adipose-associated cytokines.","Adipocytokine Assay | Adipocytokine Detection | Adipocytokine Measurement | Adipokine Assay | Adipokine Detection | Adipokine Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016745","Fructose","C68480","A hexose with a keto group, also called a keto-hexose. Aside from the keto group, each of the 5 remaining carbons has one hydroxyl group, in the S,R, and R configuration counting from the first hydroxyl containing asymmetric carbon next to the ketone in the straight chain (=Fisher) projection. All other carbons are bound to hydrogen exclusively. Occurs mostly as furan and rarely as pyran or straight chain. When fructose forms a ring an additional ''anomeric'' asymmetric carbon is created which is denoted as ''alpha'' or ''beta''. For isomers see http://en.wikipedia.org/wiki/fructose.","Fructose | FRUCTOSE | Levulose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424935","ARID5B Gene","C84416","This gene may play a role in transcriptional regulation.","ARID5B Gene | ARID5B | AT Rich Interactive Domain 5B (MRF1-Like) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332750","CEBPE Gene","C28532","This gene plays a role in cellular differentiation and transcriptional regulation.","CEBPE Gene | CCAAT/Enhancer Binding Protein (C/EBP), Epsilon Gene | CEBPE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335219","PIP4K2A Gene","C24676","This gene plays a role in cellular differentiation, growth and proliferation.","PIP4K2A Gene | PIP4K2A | PIP5K2A | Phosphatidylinositol-5-Phosphate 4-Kinase, Type II, Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538117","WWTR1 Gene","C24844","This gene is involved in regulation of transcription. It is involved in fetal/neonatal cardiac and muscle development.","WWTR1 Gene | WW Domain Containing Transcription Regulator 1 Gene | WWTR1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537894","MIR373 Gene","C81806","This gene is involved in the regulation of gene expression and acts as an oncogene in breast carcinoma and testicular germ cell tumors.","MIR373 Gene | MIR373 | MicroRNA 373 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201405","Rapid Plasma Reagin Measurement","C74716","The determination of the antibodies produced by cellular damage caused by Treponema pallidum present in a sample.","Rapid Plasma Reagin Measurement | REAAB | RPR | Rapid Plasma Reagin | Reagin Antibody | VDRL | Venereal Disease Research Laboratory Test",,,,,,,,,,,,,,,"4058393","Rapid plasma reagin test",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1425775","KLRK1 Gene","C101750","This gene plays a role in the activation of natural killer cells.","KLRK1 Gene | KLRK1 | Killer Cell Lectin-Like Receptor Subfamily K, Member 1 Gene | NKG2D Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1444581","Direct Ophthalmoscopy","C94200","An exam of the inside of the back of the eye using an ophthalmoscope (a flashlight-sized instrument with a light source and a set of rotating lenses).","Direct Ophthalmoscopy | Direct Fundoscopy | Ophthalmoscopy | direct ophthalmoscopy",,,,,,,,,,,,,,,"4252041","Direct ophthalmoscopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1541483","Eculizumab","C48386","A humanized monoclonal antibody directed against terminal complement protein C5. Eculizumab binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and blocking the complement-mediated destruction of paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. (NCI05)","Eculizumab | ABP 959 | ABP-959 | ABP959 | Alexion | BCD 148 | BCD-148 | BCD148 | ECULIZUMAB | Eculizumab Biosimilar ABP 959 | Eculizumab Biosimilar BCD-148 | Eculizumab Biosimilar SB12 | Eculizumab-beke | Eculizumab-epys | Elizaria | Immunoglobulin, Anti-(Human Complement C5 Alpha-Chain) (Human-Mouse Monoclonal 5G1.1 Heavy Chain), Disulfide with Human-Mouse Monoclonal 5G.1.1 Light Chain, Dimer | Monoclonal antibody 5G1.1 | SB 12 | SB-12 | SB12 | Soliris | eculizumab | h5G1.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827293","JAK-2 c.1848_1849TG>CT","C105909","A complex substitution where the nucleotide sequence at positions 1848 and 1849 of the coding sequence of the JAK2 gene has changed from thymine-guanine to cytosine-thymine.","JAK2 NM_004972.3:c.1848_1849delinsCT | JAK-2 c.1848_1849TG>CT | JAK-2 c.1848_1849delTGinsCT | JAK2 NM_004972.3:c.1848_1849TG>CT | JAK2 NM_004972.3:c.1848_1849TG>CT | JAK2 NM_004972.3:c.1848_1849delTGinsCT | JAK2 NM_004972.3:c.1848_1849delTGinsCT | JAK2 c.1848_1849TG>CT | JAK2 c.1848_1849delTGinsCT | JTK10 c.1848_1849TG>CT | JTK10 c.1848_1849delTGinsCT | Janus Kinase 2 c.1848_1849TG>CT | Janus Kinase 2 c.1848_1849delTGinsCT | NM_004972.3:c.1848_1849TG>CT | NM_004972.3:c.1848_1849delTGinsCT | NM_004972.3:c.1848_1849delinsCT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829478","JAK2 NM_004972.3:c.1849G>T","C105910","A nucleotide substitution at position 1849 of the coding sequence of the JAK2 gene where guanine has been mutated to thymine.","JAK2 NM_004972.3:c.1849G>T | JAK-2 c.1849G>T | JAK2 c.1849G>T | JTK10 c.1849G>T | Janus Kinase 2 c.1849G>T | NM_004972.3:c.1849G>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829471","JAK2 NP_004963.1:p.V617F","C105908","A change in the amino acid residue at position 617 in the tyrosine-protein kinase JAK2 protein where valine has been replaced by phenylalanine.","JAK2 NP_004963.1:p.V617F | JAK2 NP_004963.1:p.Val617Phe | JAK2 V617F | JAK2 Val617Phe | JAK2 p.V617F | JAK2 p.Val617Phe | Janus Kinase 2 V617F | Janus Kinase 2 Val617Phe | Janus Kinase-2 V617F | Janus Kinase-2 Val617Phe | NP_004963.1:p.V617F | NP_004963.1:p.Val617Phe | Tyrosine-Protein Kinase JAK2 V617F | Tyrosine-Protein Kinase JAK2 Val617Phe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419742","RPS6KA1 Gene","C104764","This gene is involved in controlling cell growth and differentiation.","RPS6KA1 Gene | RPS6KA1 | Ribosomal Protein S6 Kinase A1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL432820","Triceps Skinfold Thickness","C98793","A measurement of the thickness of a pinch of skin on the triceps.","Triceps Skinfold Thickness | TRSKNF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0518023","Subscapular Skinfold Thickness","C98785","A measurement of the thickness of a pinch of skin situated below or on the underside of the scapula.","Subscapular Skinfold Thickness | SSSKNF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035190","Residual Volume","C89836","The volume of air remaining in the lungs after a maximal exhalation.","Residual Volume | RV",,,,,,,,,,,,,,,"4174410","Residual respiratory volume",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3714541","Forced Vital Capacity","C111361","The maximum volume of air that can be exhaled after forced maximum inhalation.","Forced Vital Capacity | FVC",,,,,,,,,,,,,,,"4176265","Forced vital capacity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899093","Forced Expiratory Flow at 25-75 Percent","C119545","The mean forced expiratory flow rate at 25-75% of the forced vital capacity.","Forced Expiratory Flow at 25-75 Percent | FEF2575 | Forced Expiratory Flow 25-75%",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815113","Forced Expiratory Volume in 1 Second to Forced Vital Capacity Ratio Measurement","C111359","The proportion of total forced vital capacity that is expelled during the first second of a forced exhalation.","Forced Expiratory Volume in 1 Second to Forced Vital Capacity Ratio Measurement | FEV1/FVC | FEV1FVC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641223","Abdominal Skinfold Thickness","C103346","A measurement for determining the subcutaneous fat layer thickness whereby a pinch of skin approximately five centimeters to the right of the umbilicus is measured using calipers.","Abdominal Skinfold Thickness | ABSKNF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054790","Hemoglobin Corrected Diffusion Capacity of the Lung for Carbon Monoxide","C120825","An assessment of the diffusion capacity of the lungs for carbon monoxide adjusted for hemoglobin concentration.","Hemoglobin Corrected Diffusion Capacity of the Lung for Carbon Monoxide | DLCOHC | HGB Corrected DLCO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272665","Widespread Alveolar Pneumocyte Damage Present","C96237","A morphologic finding indicating the presence of extensive injury of the alveolar pneumocytes in a lung tissue sample.","Widespread Alveolar Pneumocyte Damage Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987402","Indefinite for Gastric Dysplasia","C95758","A term used to describe an ambiguous morphologic pattern in the gastric mucosa, when there is doubt whether the findings represent a non-neoplastic or neoplastic pathologic process.","Indefinite for Gastric Dysplasia | Indefinite for Gastric Intraepithelial Neoplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987401","Negative for Gastric Dysplasia","C95756","A morphologic finding indicating the absence of dysplastic changes in the gastric mucosal epithelium.  It includes non-neoplastic inflammatory, reactive, or metaplastic pathologic processes.","Negative for Gastric Dysplasia | Negative for Gastric Intraepithelial Neoplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987120","Intramucosal Adenocarcinoma","C95397","A neoplastic lesion that shows morphologic evidence of invasion into the lamina propria or muscularis mucosa.  There is no evidence of invasion into the submucosa.  Evidence of invasion may refer to stromal invasion by single cells or clusters of cells, presence of atypical and complex glandular architectural patterns beyond those that are present in normal mucosa, desmoplasia, and/or vascular invasion.","Intramucosal Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334003","High Grade Dysplasia in Barrett Esophagus","C27835","A finding indicating the presence of Barrett esophagus in which there is marked nuclear pleomorphism and loss of polarity, increased number of atypical mitotic figures, and crypt budding, branching, and crowding.","High Grade Dysplasia in Barrett Esophagus | High Grade Dysplasia in Barrett's Esophagus",,,,,,,,,,,,,,,"46269824","Barretts esophagus with high grade dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334414","Low Grade Dysplasia in Barrett Esophagus","C27834","A finding indicating the presence of Barrett esophagus in which the crypts are preserved or mildly distorted.  There is nuclear elongation, mild pleomorphism and loss of polarity, mucin depletion, and increased number of mitotic figures.","Low Grade Dysplasia in Barrett Esophagus | Low Grade Dysplasia in Barrett's Esophagus",,,,,,,,,,,,,,,"46269825","Barretts esophagus with low grade dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2987258","Barrett Esophagus-Negative for Dysplasia","C95614","A finding indicating the presence of Barrett esophagus with regenerative changes only.","Barrett Esophagus-Negative for Dysplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987259","Barrett Esophagus-Indefinite for Dysplasia","C95615","A finding indicating the presence of Barrett esophagus in which technical reasons make the interpretation of atypia difficult, atypia is present but it is not quite to the level of dysplasia, or atypia is present at the bases of the crypts but does not reach the surface of the crypts.","Barrett Esophagus-Indefinite for Dysplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334415","Low Grade Gastric Intraepithelial Neoplasia","C27436","A gastric intraepithelial lesion characterized by the presence of neoplastic cells with mild cytologic atypia, mild architectural changes, and low number of mitotic figures.","Low Grade Gastric Intraepithelial Neoplasia | Gastric Mild Intraepithelial Neoplasia (Dysplasia) | Low Grade Gastric Intraepithelial Neoplasia (Dysplasia) | Low-Grade Gastric Glandular Intraepithelial Neoplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334004","High Grade Gastric Intraepithelial Neoplasia","C27437","A gastric intraepithelial lesion characterized by the presence of neoplastic cells that are cuboidal with a high nucleus to cytoplasmic ratio, prominent nucleoli, significant architectural changes, and increased number of mitotic figures.","High Grade Gastric Intraepithelial Neoplasia | High-Grade Gastric Glandular Intraepithelial Neoplasia | High-Grade Gastric Glandular Intraepithelial Neoplasia (Dysplasia) | High-Grade Gastric Intraepithelial Neoplasia (Dysplasia)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018932","Hematochezia","C98936","The passage of fresh blood from the anus. The blood is usually seen in the stools. The most common cause is lower gastrointestinal tract hemorrhage.","Hematochezia | Bloody Stool",,,,,,,,,,,,,,,"443530","Hematochezia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2713876","Herbal Polysaccharide Saliva Substitute","C95735","A plant-based, proprietary formulation of saliva substitute with potential anti-xerostomia activity. Extracted from the plant called yerba santa (holy herb), herbal polysaccharide saliva substitute contains plant mucins, which is nearly identical to that of human mucous membranes. Upon direct application using the polysaccharide-containing spray, a protective film of moisture is deposited over the mucous membranes of the mouth and throat. The xylitol in this preparation protects against the formation of harmful oral flora and thus helps to prevent cavities. Moreover, this agent has shown a demineralization effect on dentin.","Herbal Polysaccharide Saliva Substitute | Saliva Natura",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055153","Diaphragmatic Pinch","C123757","The location where the diaphragmatic crura constrict the esophagus as it passes through the diaphragm.","Diaphragmatic Pinch | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053968","Suprailiac Skinfold Thickness","C123758","A measurement of the thickness of a pinch of skin at a location above the hip bone, used in estimating an individual's body fat.","Suprailiac Skinfold Thickness | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0235896","Pulmonary Infiltrate","C102531","A finding indicating the presence of an inflammatory or neoplastic cellular infiltrate in the lung parenchyma.","Pulmonary Infiltrate | Lung Infiltrate | Pulmonary infiltrates",,,,,,,,,,,,,,,"4249557","Radiologic infiltrate of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0700124","Dilation","C113136","The condition of being dilated or stretched.","Dilation | DILATATION | Dilatation | Dilated",,,,,,,,,,,,,,,"4112260","Ectatic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3827002","Ground Glass Opacity","C113718","A CT scan finding in the lungs indicating the presence of hazy areas of attenuation in the air spaces.  It is caused by interstitial fibrosis, alveolar collapse, edema, inflammation, or cancer with lepidic spread.","Ground Glass Opacity | GGO",,,,,,,,,,,,,,,"37163565","Ground glass opacity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1655202","Phosphorylated Epidermal Growth Factor Receptor","C123765","Epidermal growth factor receptor protein (EGFR) bearing phosphorylated tyrosine residues within the 194 amino acids of the carboxyl-terminal intracellular domain of the protein. Five ligand-dependent autophosphorylation sites have been identified; overexpression or mutation of EGFR can decouple ligand-binding from autophosphorylation and the subsequent activation of downstream signaling pathways. The presence of phosphorylated EGFR in a malignant tumor is generally correlated with poor prognosis and could be used as a predictive biomarker to identify individuals who may respond to EGFR-tyrosine kinase inhibitor treatment.","Phosphorylated Epidermal Growth Factor Receptor | Autophosphorylated Epidermal Growth Factor Receptor | Phospho-EGFR | Phosphorylated EGFR | p-EGFR | pEGFR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1579314","Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed","C91717","A vaccine containing detoxified tetanus toxoid, detoxified diphtheria toxoid and acellular pertussis antigens, adsorbed on aluminum phosphate, with active immunizing activity against diphtheria, tetanus and pertussis. The acellular pertussis vaccine components, produced by Bordetella pertussis, are detoxified pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (PRN) and fimbriae types 2 and 3 (FIM). Intramuscular injection with this vaccine activates the immune system to develop antibodies against tetanus toxin, diphtheria toxin and B. pertussis antigens.","Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed | Adacel | DTaP | Daptacel | Diphtheria Toxoid Tetanus Toxoid Acellular Pertussis Vaccine Adsorbed | Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine | Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed | Infanrix | Tripedia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512457","High Resolution Computed Tomography","C20644","Defined as thin section (1-2 mm collimation) CT optimized by using a high-spatial-frequency (bone) algorithm. (from Radiol Clin North Am 1991;29:1043-9)","High Resolution Computed Tomography | HIGH RESOLUTION CT | HRCT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811131","Estrogen Receptor Measurement","C112274","The determination of the amount of estrogen receptor present in a sample.","Estrogen Receptor Measurement | ER | ESR | ESTRCPT | Estrogen Receptor | Oestrogen Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697571","Heat Shock Protein Inhibitor","C74526","Any agent that inhibits functions of heat shock proteins (Hsp). Hsps are a group of homodimeric molecular chaperones that interact with a diverse group of proteins, assisting in their folding and in the elimination of any misfolded or damaged molecules. Although transiently expressed during cell cycle in normal cells, Hsps are constitutively elevated in various types of cancer which raises the apoptosis threshold of these tumor cells and provides protection against cytotoxic agents. Hsp inhibitors may destabilize, and facilitate degradation of proto-oncoproteins leading to reversal of apoptosis regulation and cell death.","Heat Shock Protein Inhibitor | Hsp Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898575","Loss of BAF250a Expression","C114559","Loss of protein expression of the BRG-associated factor 250a (BAF250a).  It is caused by mutation of the tumor-suppressor gene ARID1A. It is linked to tumor progression and poor prognosis in various cancers.","Loss of BAF250a Expression | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449159","Inhalation","C95464","To draw in with the breath through the nose or mouth.","Inhalation | Inhale | Inhaled",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054586","MD Anderson Symptom Inventory - Spine Tumor","C123776","A self-administered questionnaire designed specifically for evaluating the severity of symptoms related to a spine tumor.","MD Anderson Symptom Inventory - Spine Tumor | M. D. Anderson Symptom Inventory - Spine Tumor | MD Anderson Symptom Inventory - Spine Tumor (MDASI-SP) | MDASI-SP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054128","Radiating Spine Pain at its Worst","C123777","A question about an individual's radiating spine pain at its worst.","Radiating Spine Pain at its Worst | Your radiating spine pain at its worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053849","Weakness in Arms and/or Legs at its Worst","C123778","A question about an individual's weakness in their arms and/or legs at its worst.","Weakness in Arms and/or Legs at its Worst | Your weakness in the arms and/or legs at its worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054596","Loss of Bowel and/or Bladder Control at its Worst","C123779","A question about an individual's loss of control of bowel and/or bladder at its worst.","Loss of Bowel and/or Bladder Control at its Worst | Your loss of control of bowel and/or bladder at its worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053721","Sexual Function at its Worst","C123780","A question about an individual's sexual function at its worst.","Sexual Function at its Worst | Your sexual function at its worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039255","Filipino Language","C123784","A standardized form of the Tagalog language spoken as the national language in the Philippines.","Filipino Language | FIL | Filipino | Pilipino",,,,,,,,,,,,,,,"4180216","Tagalog language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0376246","French Language","C123785","A romance language spoken as the official language in France and 28 other countries.","French Language | FRA | French",,,,,,,,,,,,,,,"4180190","French language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4038906","Hmong Language","C123786","A dialect of the Hmongic languages spoken by the Hmong people of Sichuan, Yunnan, Guizhou, Guangxi, northern Vietnam, Thailand, and Laos.","Hmong Language | First Vernacular Chuanqiandian Miao | HMN | Hmong | Mong | Mong Language",,,,,,,,,,,,,,,"46270898","Hmong language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020173","Hungarian Language","C123787","A member of the Uralic language family that is spoken as the official language of Hungary.","Hungarian Language | HUN | Hungarian | Magyar",,,,,,,,,,,,,,,"4183945","Hungarian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022275","Italian Language","C123788","A romance language spoken as the official language of Italy and San Marino.","Italian Language | ITA | Italian",,,,,,,,,,,,,,,"4182507","Italian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0376247","Japanese Language","C123789","An East Asian language spoken as the official language of Japan.","Japanese Language | JPN | Japanese",,,,,,,,,,,,,,,"4181524","Japanese language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035967","Russian Language","C123790","An East Slavic language spoken as an official language in Russia, Belarus, Kazakhstan, and Kyrgyzstan.","Russian Language | RUS | Russian",,,,,,,,,,,,,,,"4181539","Russian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574161","Somali Language","C123791","An Afroasiatic language spoken as the native language by the Somali people within the Horn of Africa. It is an official language of the Federal Republic of Somalia, a national language in Djibouti, and a working language in the Somali region of Ethiopia.","Somali Language | SOM | Somali",,,,,,,,,,,,,,,"4182350","Somali language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037138","Simethicone","C29453","A mixture of polydimethylsiloxanes with antifoaming and anti-bloating effects. Simethicone reduces the surface tension of gas bubbles causing them to coalesce into larger bubbles that can be passed more easily by belching or flatulence.","Simethicone | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0150450","Altered Level of Consciousness","C121627","A level of awareness and arousal other than normal.","Altered Level of Consciousness | Altered LOC | Altered State of Consciousness | Impaired consciousness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4228133","Myoclonic Jerk","C34832","A sudden, involuntary contraction of a muscle or group of muscles; these movements may develop as a symptom of a number of neurological diseases, including epilepsy, Parkinson's disease, Alzheimer's disease, or Creutzfeldt-Jacob disease.","Myoclonic Jerk | myoclonic jerk",,,,,,,,,,,,,,,"4133719|441553","Myoclonic disorder|Myoclonus",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0043240","Wound Repair","C17260","Restoration of diseased or damaged tissues naturally by healing processes.","Wound Repair | Wound Healing",,,,,,,,,,,,,,,"4077450|4177611","Tissue repair|Finding of wound healing",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0184923","Shave Biopsy","C15387","Removal skin tissue, for microscopic examination, using a blade oriented in the horizontal plane of the skin surface.","Shave Biopsy | shave biopsy",,,,,,,,,,,,,,,"4086391|4219090","Shave biopsy - action|Shave biopsy",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1627767","Folliculotropic Mycosis Fungoides","C35685","A rare variant of mycosis fungoides, characterized by cerebriform lymphocytic infiltration of the hair follicles of the head and neck.  Most cases show mucinous degeneration of the hair follicles, and are designated as mycosis fungoides-associated follicular mucinosis.  Cases without mucinous degeneration have been reported as pilotropic mycosis fungoides.  There is no difference in clinical presentation or outcome between mycosis fungoides-associated follicular mucinosis and pilotropic mycosis fungoides.  In the recent WHO-EORTC classification, folliculotropic mycosis fungoides is the preferred term for all cases.","Folliculotropic Mycosis Fungoides | Follicular Mycosis Fungoides | Mycosis Fungoides-Associated Follicular Mucinosis",,,,,,,,,,,,,,,"4301661","Follicular mucinosis type mycosis fungoides",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1515136","T-Cell Transformation","C19054","Morphologic alteration of small T lymphocytes in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by interleukins, mitogens such as phytohemagglutinins, and by specific antigens. It may also occur in vivo, as in graft rejection and chronic myelogenous leukemia, or the process that a normal T lymphocyte goes through when induced by a pathologic agent such as human T-lymphotropic virus 1 (HTLV-1) to become an adult T cell leukemia or other aggressive malignancy where neoplastic T cells apparently use IL-2 as an autocrine growth factor. (from Fundamental Immunology, 3rd ed., William Paul, ed., Raven Press, NY 1993, p.768)","T-Cell Transformation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272887","Circulating Tumor Cell Count","C96593","The determination of the amount of circulating tumor cells present in a sample.","Circulating Tumor Cell Count | CTC | Circulating Tumor Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412437","Robot-Assisted Laparoscopic Surgery","C116509","A surgical technique that uses a specially designed robotic system to aid with a laparoscopic surgical procedure.","Robot-Assisted Laparoscopic Surgery | RoboticLaparoscopic Surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3494227","Craniospinal Irradiation","C116437","The use of radiation therapy directed at the brain and spinal cord to kill cancer cells.","Craniospinal Irradiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0172934","27-Hydroxycholesterol","C123794","An endogenous metabolite of cholesterol produced by the hydroxylation of the carbon at position 27 by the enzyme sterol 26-hydroxylase, mitochondrial (CYP27A1). Some neoplasms produce excess of 27-hydroxycholesterol (27HC) or inhibit its catabolism, and high cholesterol levels are correlated with elevated levels of 27HC; under these conditions, 27HC may have deleterious selective estrogen receptor modulator (SERM) and liver X receptor (LXR) agonistic activities. As a SERM, 27HC binds to and prevents the activation of estrogen receptors (ERs) in the vasculature. This prevents ER-mediated vasodilation and abrogates the cardiovascular protective effects of estrogen. However, 27HC binds to and activates ERs and LXRs in breast tissue, which stimulates ER-dependent breast cancer cell growth and metastasis.","27-Hydroxycholesterol | (25R)-Cholest-5-Ene-3beta,26-Diol | 27HC | 27OHC | 5-Cholestene-3 beta,27-Diol | CHOLEST-5-ENE-3.BETA.,26-DIOL, (25R)- | Cholest-5-Ene-3,26,Diol, (3beta,25R)- | Cholest-5-Ene-3beta,26-Diol, (25R)- | Cholest-5-Ene-3beta,27-Diol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412070","ABCB11 Gene","C123859","This gene plays a role in the secretion of bile salts.","ABCB11 Gene | ABCB11 | ATP Binding Cassette Subfamily B Member 11  Gene | ATP Binding Cassette Subfamily B Member 11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412071","ABCB4 Gene","C123862","This gene is involved in the cellular export of organic anions and drugs and the intramembrane transport of phosphatidylcholine.","ABCB4 Gene | ABCB4 | ATP Binding Cassette Subfamily B Member 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1955907","Adipokine","C123810","A cytokine that is expressed and secreted by adipose tissue.","Adipokine | Adipocytokine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085983","Anti-Poliovirus Antibody","C123800","An antibody produced in response to exposure to poliovirus.","Anti-Poliovirus Antibody | Poliovirus Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0369921","Anti-Reovirus Antibody","C123805","An antibody produced in response to exposure to reovirus.","Anti-Reovirus Antibody | Reovirus Antibody",,,,,,,,,,,,,,,"4025614","Reovirus antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4084937","Antimicrobial Peptide","C123795","A natural or synthetically-derived peptide that selectively kills or inhibits the growth of microorganisms; it may also have immunomodulatory activity.","Antimicrobial Peptide | AMP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086014","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.944C>T Mutation","C123845","A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where cytosine has been substituted with thymine at nucleotide position 944 of the ABL1 gene. This mutation is associated with imatinib-resistant leukemias.","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.944C>T Mutation | BCR/ABL Fusion Gene with NM_005157.4:c.944C>T | BCR/ABL Fusion Gene with NM_005157.5:c.944C>T | BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.944C>T | BCR/ABL1 Fusion Gene with NM_005157.4:c.944C>T | BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.944C>T Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL373038","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.T315I","C123846","A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.944C>T mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the threonine at position 315 of the ABL1 protein has been replaced by isoleucine.","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.T315I | BCR-ABL T315I Mutation | BCR-ABL Thr315Ile Mutation | BCR-ABL1 T315I Mutation | BCR-ABL1 Thr315Ile Mutation | BCR/ABL Fusion Protein with T315I | BCR/ABL Fusion Protein with Thr315Ile | BCR/ABL T315I Mutation | BCR/ABL Thr315Ile Mutation | BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Thr315Ile | BCR/ABL1 Fusion Protein with NP_005148.2:p.T315I | BCR/ABL1 Fusion Protein with NP_005148.2:p.Thr315Ile | BCR/ABL1 T315I Mutation | BCR/ABL1 Thr315Ile Mutation | BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.T315I | T315I | T315I Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282682","Blocking Antibody","C17898","An antibody that binds to endogenous or exogenous compounds and inhibits the biological activity of that compound.","Blocking Antibody | NAb | Neutralizing Antibody",,,,,,,,,,,,,,,"4100938","Blocking antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1413081","CALB2 Gene","C123856","This gene is involved in calcium ion homeostasis.","CALB2 Gene | CALB2 | Calbindin 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413109","CAPN1 Gene","C123832","This gene is involved in proteolytic processing.","CAPN1 Gene | CAPN1 | Calpain 1, (Mu/I) Large Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086044","CD159 Family","C123802","A family of cell surface receptors found on natural killer cells and some T-lymphocytes that both interact with MHC class I HLA-E molecules and modulate cell-mediated cytotoxicity. There are two CD159 proteins, NKG2-A/NKG2-B type II integral membrane protein and NKG2-C type II integral membrane protein.","CD159 Family | CD159 | CD159 Antigen | KLRC1/2 | Killer-Cell Lectin-Like Receptor Subfamily C 1/2 | NKG2-A/NKG2-B/NKG2-C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084731","Cell Response Index","C123799","An in vitro assay that determines the magnitude of calcium mobilization by a cellular sample following exposure to various stimuli. A range of concentrations may be used to calculate the amount that yields a 50% response rate.","Cell Response Index | CRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085194","Conventional Dendritic Cell","C123782","A subset of dendritic cells that are derived from myeloid precursors. They express toll-like receptors 2 and 4 and secrete interleukin-12.","Conventional Dendritic Cell | Classical Dendritic Cell | Myeloid Dendritic Cell | cDC | mDC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086230","Cytokine and Angiogenic Factor Profile","C123804","A data set that both identifies and quantifies the levels of expression for all the cytokines and angiogenic factors present in a biological sample or specimen.","Cytokine and Angiogenic Factor Profile | CAF Profile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1136119","EphA Receptor Family","C123797","A family of tyrosine kinase receptors that are involved in forward and reverse cell-cell signaling through binding to glycosylphosphatidylinositol (GPI)-anchored ephrin-A family ligands (EFNA) expressed on adjacent cells.","EphA Receptor Family | EPHA | Ephrin Type-A Receptor | Ephrin Type-A Receptor Family | Ephrin-A Receptor | Ephrin-A Receptor Family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539515","FCRL5 Gene","C123872","This gene may play a role in the development, differentiation and immunoregulation of B-cells.","FCRL5 Gene | FCRL5 | Fc Receptor-Like 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086358","Genome-Wide 5-Hydroxymethylcytosine Profile","C123801","The characterization and quantitation of sites within DNA sequences that contain 5-hydroxymethylcytosine modifications across the entire genome of biological sample or specimen.","Genome-Wide 5-Hydroxymethylcytosine Profile | Genome-Wide 5-Hydroxymethylcytosine Analysis | Genome-Wide 5-hmC | Genome-Wide 5-hmC Profile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415194","GPC2 Gene","C123850","This gene is involved in heparin sulfate binding to cell surfaces.","GPC2 Gene | GPC2 | Glypican 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086352","GUCY2C Antibody","C123806","Any immunoglobulin that recognizes heat-stable enterotoxin receptor.","GUCY2C Antibody | Anti-GC-C Antibody | Anti-GCC Antibody | Anti-GUCY2C Antibody | Anti-Guanylyl Cyclase C Antibody | Anti-Heat-Stable Enterotoxin Receptor Antibody | Anti-STAR Antibody | Anti-hSTAR Antibody | GC-C Antibody | GCC Antibody | Guanylyl Cyclase C Antibody | Heat-Stable Enterotoxin Receptor Antibody | STAR Antibody | hSTAR Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086500","Human Anti-Human Minibody Antibody","C123803","Human antibodies which recognize humanized minibodies. These can develop in response to treatment with therapeutic minibodies and may limit the effectiveness of the treatment.","Human Anti-Human Minibody Antibody | HAMBA | Human Anti-Human Minibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424650","IFI44 Gene","C123866","This gene may play a role in the response to viral infection.","IFI44 Gene | IFI44 | Interferon-Induced Protein 44 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086506","IGF2BP3 Autoantibody","C123807","An autoantibody that recognizes insulin-like growth factor 2 mRNA-binding protein 3.","IGF2BP3 Autoantibody | Anti-IGF-II mRNA-Binding Protein 3 Autoantibody | Anti-IGF2 mRNA-Binding Protein 3 Autoantibody | Anti-IGF2BP3 Autoantibody | Anti-IMP-3 Autoantibody | Anti-IMP3 Antibody | Anti-IMP3 Autoantibody | Anti-Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 Autoantibody | Anti-KOC Autoantibody | IGF-II mRNA-Binding Protein 3 Autoantibody | IGF2 mRNA-Binding Protein 3 Autoantibody | IMP-3 Autoantibody | Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 Autoantibody | KOC Autoantibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086522","Interferon-Induced Protein with Tetratricopeptide Repeats Family","C123809","A family of proteins that are expressed during viral infection, pathogen recognition or during interferon (IFN) treatment. These proteins are localized in the cytoplasm and contain multiple tetratricopeptide repeats; they are involved in antiviral immune processes.","Interferon-Induced Protein with Tetratricopeptide Repeats Family | IFIT | IFIT Family | IFN-Induced Protein with Tetratricopeptide Repeats Family | Interferon Induced Protein with Tetratricopeptide Repeats | Interferon Induced Protein with Tetratricopeptide Repeats Family | Interferon Induced Proteins with Tetratricopeptide Repeats Family | Interferon-Induced Proteins with Tetratricopeptide Repeats Family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416687","KLRG1 Gene","C123853","This gene plays a role in the inhibition of cytotoxic immune cells.","KLRG1 Gene | KLRG1 | Killer Cell Lectin-Like Receptor Subfamily G, Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086555","M2 Macrophage","C123783","A macrophage that produces high levels of interleukin (IL)-10, TGF-beta and low levels of IL-12 and converts arginine to ornithine. These cells may both encourage tissue repair and inhibit inflammation.","M2 Macrophage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031659","Phosphoglycerate Mutase Family","C123808","A family of proteins whose members are involved in glycolysis. This family is comprised of three isozymes that are either homodimers or heterodimers of phosphoglycerate mutase 1 and 2. These enzymes have multiple reversible isomerase and phosphatase activities. During glycolysis these enzymes can interconvert 3-phosphoglycerate to 2-phosphoglycerate through a 2,3-bisphosphoglycerate intermediate.","Phosphoglycerate Mutase Family | BPG-Dependent PGAM | PGAM | Phosphoglycerate Mutase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498421","Prostate Health Index","C123798","An assay system that indirectly measures the amount of three forms of prostate-specific antigen (PSA) in a patient serum sample and then uses those values to calculate a score that estimates the patient's probability of having prostate cancer. The PSA forms that are examined are total PSA, free PSA, and an isoform of PSA that has a propeptide comprised of two amino acid residues ([-2]proPSA).","Prostate Health Index | PHI | phi-index",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036884","Sex Steroid Hormone","C123796","A class of steroid hormones that specifically binds to and activates androgen, progesterone or estrogen receptors. Sex steroids activate various signaling pathways involved in the development and maintenance of secondary sexual characteristics, reproductive processes, blood salt balance, response to stress, neuronal function and a number of metabolic processes.","Sex Steroid Hormone | Sex Hormone | Sex Steroid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420064","SIGLEC9 Gene","C123869","This gene is involved in sialic acid binding and cell adhesion.","SIGLEC9 Gene | SIGLEC9 | Sialic Acid Binding Ig-Like Lectin 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0078791","Zinc Protoporphyrin","C123793","An ionized form of the tetrazole protoporphryin IX that contains zinc in the metal ion binding pocket. Zinc protoporphyrin (ZPP) is formed in circulating red blood cells (RBC) either in the presence of lead or in the absence of sufficient iron, as both of these conditions inhibit the insertion of a ferrous ion into protoporphryin IX to form heme. Therefore, elevated levels of ZPP is associated with heme deficiency. Elevated RBC molar ratios of ZPP to heme are indicative of multiple pathologies including lead poisoning, iron deficiency, protoporphyria, and various types of anemia.","Zinc Protoporphyrin | (SP-4-2)-Dihydrogen (7,12-Diethenyl-3,8,13,17-Tetramethyl-21H,23H-Porphine-2,18-Dipropanoato(4-)- N(21),N(22),N(23),N(24))Zincate(2-) | Dihydrogen (3,8,13,17-Tetramethyl-7,12-Divinyl-21H,23H-Porphine-2,18-Dipropionato(4-)-N21,N22,N23,N24)Zincate(4-) | Protoporphyrin IX, Zinc Chelate | ZINC PROTOPORPHYRIN | ZP | ZPP | Zinc Protoporphyrin IX | Zinc-Protoporphyrin | Zincate(2-), (7,12-Diethenyl-3,8,13,17-Tetramethyl-21H,23H-Porphine-2,18-Dipropanoato(4-)-KappaN21,KappaN22,KappaN23,KappaN24)-, Hydrogen (1:2), (SP-4-2)- | ZnPP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349983","Percent of Lymphocytes","C70462","A quantitative measurement of the percent of lymphocytes compared to the number of total cells present in a sample.","Percent of Lymphocytes | % Lymphs | Percent Lymphocytes | percent lymphocyte infiltration | percent_lymphocyte_infiltration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0200635","Lymphocyte Count","C51949","The determination of the number of lymphocytes in a blood sample.","Lymphocyte Count | LYM | Lymphocytes",,,,,,,,,,,,,,,"4254663","Lymphocyte count",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0812443","THPO Gene","C18458","This gene plays a role in promoting megakaryocytopoiesis, the cellular development process that leads to platelet production.","THPO Gene | THPO | Thrombopoietin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983100","Metabolic Equivalent of Task","C89729","A mathematic formula used to estimate individual oxygen consumption, and thus energy expenditure, at rest and for various physical activities.","Metabolic Equivalent of Task | MET | Metabolic Equivalent of Task (MET)",,,,,,,,,,,,,,,"44782837","Metabolic equivalent of task",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4049826","Respiratory Exchange Ratio","C123568","The ratio of the amount of carbon dioxide produced to the amount of oxygen consumed in one breath. This ratio is used to estimate the respiratory quotient, which indicates what type of fuel source the body is metabolising to provide energy.","Respiratory Exchange Ratio | RER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336660","TOPBP1 Gene","C20359","This gene is involved in DNA replication and apoptosis regulation.","TOPBP1 Gene | TOPBP1 | Topoisomerase (DNA) II Binding Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413269","CDH11 Gene","C97427","This gene is involved in the adherens junction.","CDH11 Gene | CDH11 | Cadherin 11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418977","PSCA Gene","C50892","This gene plays a role in immunity/defense.","PSCA Gene | PSCA | Prostate Stem Cell Antigen Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417861","NT5E Gene","C114924","This gene is involved in nucleotide hydrolysis.","NT5E Gene | 5'-Nucleotidase, Ecto (CD73) Gene | NT5E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162833","CD45RO","C118495","CD45RO (1145 aa, ~131 kDa) is encoded by the human PTPRC gene. This protein is involved in both tyrosine dephosphorylation and lymphocyte activity. It is an isoform of receptor-type tyrosine-protein phosphatase C that is missing the amino acids encoded by exons 4, 5 and 6 of the PTPRC gene.","CD45RO | CD45R0 | CD45R0 Antigen | CD45RO Antigen | Receptor-Type Tyrosine-Protein Phosphatase C Isoform 2 | Receptor-Type Tyrosine-Protein Phosphatase C Isoform CD45RO",,,,,,,,,,,,,,,"4311253","Lymphocyte antigen CD45RO",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1825064","ERRFI1 Gene","C101729","This gene plays a role in the modulation of receptor signaling.","ERRFI1 Gene | ERBB Receptor Feedback Inhibitor 1 Gene | ERRFI1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423844","UBE2C Gene","C92499","This gene is involved in the regulation of protein ubiquitination.","UBE2C Gene | UBE2C | Ubiquitin-Conjugating Enzyme E2C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415615","HMGCR Gene","C60877","This gene plays a role in the biosynthesis of steroids.","HMGCR Gene | 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Gene | HMGCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414860","FUS Gene","C91852","This gene is involved in gene expression, genomic integrity and RNA processing.","FUS Gene | FUS | FUS RNA Binding Protein Gene | TLS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883708","Then","C65106","Occurring at a time in the near future.","Then | Next | Soon After",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704292","Ophthalmologist","C17822","A physician with a Doctor of Medicine or Doctor of Osteopathic Medicine degree (or analogous) who specializes in diagnosing and treating eye disorders, including more complex disorders that require surgery.","Ophthalmologist | OPHTHALMOLOGIST | ophthalmologist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021932","Tracheal Intubation","C116648","The insertion of a plastic tube through the mouth or nose that extends past the vocal cords and into the trachea for the purpose of oxygenating and ventilating the patient, and to prevent the passage of unwanted material into the lungs.","Tracheal Intubation | ",,,,,,,,,,,,,,,"4013354","Insertion of endotracheal tube",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086945","Ventilatory Threshold","C123909","The point during exercise at which pulmonary ventilation becomes disproportionately high with respect to oxygen consumption.","Ventilatory Threshold | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086301","Feature Dataset","C123884","A collection of data records from which common expression features can be derived.","Feature Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086240","Differential Methylation","C123883","Differences in methylation between a test sample and a normal comparison sample.","Differential Methylation | DM-value",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086355","Gene Enrichment Probability","C123885","The probability of a cell line being positive for an enriched feature by chance.","Gene Enrichment Probability | Enrichment P-Value | Gene Enrichment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085934","Absolute Genomic Position","C123886","Coordinates corresponding to the start or end of a chromosome.","Absolute Genomic Position | Chromosome Start and End",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086210","Concentration Response","C123887","The reaction to a specific amount of a compound.","Concentration Response | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086833","Robust Z-Score","C123888","A variation of the z-score, which substitutes the outlier-insensitive median and median absolute deviation (MAD) for mean and standard deviation in the z-score calculation.","Robust Z-Score | Robust Z Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086357","GeneData Screener","C123889","Proprietary software that is designed to import data from any screening instrument and analyze and manage all types of screening data.","GeneData Screener | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087011","Condensed Activity","C123890","The value obtained from condensing three replicate measures using a strategy provided by GeneData Screener software.","Condensed Activity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498259","Gene Cluster Text Format","C123891","A tab delimited, matrix file text format that describes a gene expression dataset; the columns of the matrix correspond to profiles, the rows correspond to genes, and the values of the cells correspond to an expression measurement.","Gene Cluster Text Format | GCT | Gene Cluster Text File",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086370","Growth Behavior","C123892","An increase in size or volume of cells in culture.","Growth Behavior | Cell Growth Behavior | Cell Line Growth Behavior",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2930586","Short Hairpin RNA","C123893","An artificial RNA molecule with a tight hairpin turn that can be used to silence target gene expression via RNA interference (RNAi).","Short Hairpin RNA | Short Hairpin Sequence RNA | shRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085938","Affymetrix","C123894","An American company that manufactures DNA microarrays for the analysis of biological systems at the cell, protein, and gene level.","Affymetrix | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162524","Chemiluminescence","C123895","The emission of light as the result of a chemical reaction.","Chemiluminescence | ",,,,,,,,,,,,,,,"4207524","Chemiluminescence assay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4085951","Analytic Technique for Assessment of RNAi by Similarity","C123896","A computational method designed to analyze phenotypic readouts from multiple-sample RNAi screens in which each gene is targeted by multiple RNAi reagents. ATARiS takes advantage of patterns in RNAi data across multiple samples in order to enrich for RNAi reagents whose phenotypic effects relate to suppression of their intended targets. By summarizing only such reagent effects for each gene, ATARiS produces quantitative, gene-level phenotype values, which provide a measure of the effect of gene suppression in each sample.","Analytic Technique for Assessment of RNAi by Similarity | ATARiS | Analytic Technique for Assessment of RNAi by Similarity (ATARiS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086356","Gene Solution","C123897","A type of ATARiS output for RNAi reagents that produce a significantly similar phenotypic pattern across the screened samples. It consists of one phenotype value for each sample, representing the phenotypic outcome of suppressing the target gene in that sample relative to the outcome in other screened samples.","Gene Solution | Gene Solution Output",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0374082","Decalcification","C51943","The process of removing mineral from bone or other calcified tissue so that paraffin sections can be prepared.","Decalcification | Decalcification Procedure | Tissue Decalcification",,,,,,,,,,,,,,,"4231958","Decalcification procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0439521","Millimoles per Minute per Kilopascal","C116242","A unit of gas diffusion capacity equal to one millimole per minute per kilopascal.","Millimoles per Minute per Kilopascal | mmol/min/kPa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024057","Loxapine Succinate","C47590","The succinate salt form of loxapine, a tricyclic dibenzoxazepine antipsychotic agent with antiemetic, sedative, anticholinergic, and antiadrenergic actions. Loxapine succinate exerts its actions by blocking the dopamine receptors at postsynaptic receptor sites in the limbic system, cortical system and basal ganglia, thereby reducing the hallucinations and delusions that are associated with schizophrenia. This agent also exerts extrapyramidal side effects.","Loxapine Succinate | 2-Chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine Succinate(1:1) | Butanedioic Acid, compound with 2-Chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine(1:1) | Cloxazepin | Daxolin | LOXAPINE SUCCINATE | Loxapac | Loxitane",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498396","Biphasic Positive Airway Pressure","C124039","A form of non-invasive mechanical pressure support ventilation that uses a time-cycled change of the applied positive airway pressure level to support spontaneous breathing activity.","Biphasic Positive Airway Pressure | BILEVEL POSITIVE AIRWAY PRESSURE VENTILATION | BIPAP Ventilation | BPAP Ventilation | BiPAP | Bilevel Positive Airway Pressure Ventilation | Biphasic positive airway pressure (BiPAP)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0199451","Continuous Positive Airway Pressure","C124040","A form of non-invasive mechanical pressure support ventilation that uses a continuous positive airway pressure level to support spontaneous breathing activity.","Continuous Positive Airway Pressure | CONTINUOUS POSITIVE AIRWAY PRESSURE VENTILATION | CPAP | CPAP Ventilation | Continuous positive airway pressure (CPAP) | Positive Pressure Ventilation",,,,,,,,,,,,,,,"4165535","Continuous positive airway pressure ventilation treatment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086504","Hypoattenuation","C124041","Describes areas on an x-ray or CT scan that show up as darker than surrounding tissues.","Hypoattenuation | Hypoattenuated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0231819","Air Trapping","C124042","An abnormal retention of gas in the lungs during expiration, either as a result of complete or partial airway obstruction or as a result of abnormalities in pulmonary compliance.","Air Trapping | Air trapping (gas trapping) | Gas Trapping",,,,,,,,,,,,,,,"4296888","Air trapping",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086746","Portal Flow Reversal","C124043","An abnormal flow pattern where the portal venous flow is from the periphery of the liver towards the porta and backwards along the portal vein. It is most typically associated with liver disease.","Portal Flow Reversal | Hepatofugal Flow | Portal Vein Flow Reversal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086334","Fresenius Biotech","C124044","A German company that researches, develops, and markets biopharmaceuticals for the treatment of severe diseases.","Fresenius Biotech | Fresenius | Fresenius Biotech GmbH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086507","IL2 Receptor Antibody","C124045","Any antibody that recognizes an interleukin 2 receptor protein.","IL2 Receptor Antibody | Anti-IL-2R Antibody | Anti-IL2 Receptor | Anti-IL2 Receptor Antibody | Anti-IL2R Antibody | IL-2R Antibody | IL2R Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086508","IL6 Receptor Antibody","C124046","Any antibody that recognizes an interleukin 6 receptor protein.","IL6 Receptor Antibody | Anti-IL-6R Antibody | Anti-IL6 Receptor | Anti-IL6 Receptor Antibody | Anti-IL6R Antibody | IL-6R Antibody | IL6R Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1531853","Copies per Milliliter","C100900","A unit of concentration expressed as a number of copies per unit volume equal to one milliliter.","Copies per Milliliter | copies/mL | {copies}/mL | {copies}/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709795","Quantitative Result","C49148","An outcome or conclusion that can be arrived at by measurement.","Quantitative Result | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274388","Epstein-Barr Virus Viral Load Measurement","C98721","The determination of the amount of Epstein-Barr virus viral load present in a sample.","Epstein-Barr Virus Viral Load Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054751","Hypomethylation Therapy","C122369","Therapies that target the activity of DNA methyltransferases. Hypomethylating agents, including azacitidine and decitabine, have been used in the therapy of myelodysplastic syndrome and secondary acute myeloid leukemia. Although it is not curative, it can induce an improvement in hematopoiesis and lead to prolonged overall survival. Use of hypomethylating agents in the treatment of sickle cell anemia and other hemoglobin disorders can trigger the expression of fetal hemoglobin, leading to significant improvements in clinical symptoms.","Hypomethylation Therapy | Hypomethylating Agent-Based Therapy | Hypomethylating Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017260","Gene Deletion","C16606","A deletion that results in the loss of a DNA segment encompassing an entire gene sequence.","Gene Deletion | Gene Deletion Mutation | Transcript Ablation | Whole Gene Deletion | gene deletion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1155631","Chromosome Condensation","C19395","A process of progressive and tight packing of dispersed replicated interphase chromatin into compact structures in metaphase prior to mitotic or meiotic nuclear division or during apoptosis in eukaryotic cells.","Chromosome Condensation | Condensed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0813145","Genetic Screening","C92803","Testing to determine if there is a predisposition or indication of a possible genetic or a chromosomal abnormality.","Genetic Screening | genetic screening",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0597997","Superconducting Quantum Interference Device","C124066","A device designed to measure extremely weak magnetic fields. It is comprised of a Josephson junction with two superconducting loops separated by an insulating layer thin enough to allow electrons to pass through.","Superconducting Quantum Interference Device | SQUID | Superconducting Quantum Interference Device (SQUID)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086551","Liver Iron Concentration","C124065","A measurement of the concentration of iron in the liver as an estimate of body iron load.","Liver Iron Concentration | Hepatic Iron Concentration | LIC | Liver/Hepatic Iron Concentration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3653320","Interleukin Inhibitor","C124064","Any agent that inhibits the action of an interleukin. These agents inhibit various immune functions.","Interleukin Inhibitor | ",,,,,,,,,,,,,,,"37396287","Interleukin receptor antagonist",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL503127","Pulmonary Consolidation","C124059","A chest X-ray finding indicating the presence of a radio-opaque area in the lung. The opacification is caused by fluid or solid material within the airways or lung parenchyma.","Pulmonary Consolidation | Air Space Opacification | Air-Space Shadowing | Airspace Consolidation | Airspace Opacification | Consolidation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1868833","Peribronchial Cuffing","C124060","A radiologic finding that describes haziness around a bronchus or large bronchiole seen end on. It may either represent bronchial wall thickening or fluid around the bronchi.","Peribronchial Cuffing | Bronchial Wall Thickening | Peribronchial Thickening",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086149","Centrilobular Opacity","C124061","A radiologic finding indicating the presence of radio-opaque areas in the central parts of lung lobules.","Centrilobular Opacity | Centrilobular Lung Nodules",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086623","Nodular Opacity","C124062","A radiologic finding indicating the presence of a solitary, round, circumscribed shadow in the lung on chest x-ray.","Nodular Opacity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086768","Reactivation","C124063","The restoration of activity to something that has been inactivated.","Reactivation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273168","Printed Advertisement","C96995","Print Advertisement (CAD/PAD)","Printed Advertisement | Print Ad",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034546","Radio","C96980","Radio (CRD/PRD)","Radio | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985532","Fatty-replaced Breast Tissue Present","C93279","A term used in mammography that refers to the replacement of breast tissue with fatty tissue. This commonly occurs as a woman ages.","Fatty-replaced Breast Tissue Present | fatty-replaced breast tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3277168","Esophageal Web","C98925","A thin membrane that is present in the esophageal lumen. It is composed of mucosa and submucosa and it may be associated with Plummer-Vinson syndrome.","Esophageal Web | ",,,,,,,,,,,,,,,"4078921","Esophageal web",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448702","Medical Science","C45427","The science of dealing with the maintenance of health and the prevention and treatment of disease.","Medical Science | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1721789","human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine","C48395","A recombinant, bivalent, human papillomavirus (HPV) vaccine, containing virus-like particles for HPV types 16 and 18 linked to the adjuvant ASO4, with potential immunoprotective and antineoplastic properties. Upon administration, HPV 16/18 L1 virus-like particle/ASO4 vaccine may generate humoral and cellular immunity against HPV types-16 and -18 antigens, thereby preventing cervical infection upon exposure to HPV types 16 and 18. In addition, this agent may stimulate an antitumoral cellular immune response against cervical cancer associated with HPV infection.","Recombinant Human Papillomavirus Bivalent Vaccine | Cervarix | GSK-580299 | HPV 16/18 L1 VLP/AS04 VAC | HPV-16/18 VLP/AS04 Vaccine | Human Papillomavirus 16/18 L1 Virus-Like Particle/AS04 Vaccine | Human Papillomavirus 16/18 L1 Virus-Like Particle/AS04 Vaccine | Human Papillomavirus Bivalent Types 16 and 18 Vaccine, Recombinant | Human Papillomavirus Vaccine L1 16,18 | Human Papillomavirus Vaccine, L1 Type 16, 18 | Recombinant HPV Bivalent Vaccine | human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0195344","Endocervical Curettage","C15403","A procedure in which the mucous membrane of the cervical canal is scraped using a curette.","Endocervical Curettage | endocervical curettage",,,,,,,,,,,,,,,"4200235","Endocervical curettage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448865","Up to","C64643","Used to indicate a limit or boundary.","Up to | Ad | ad",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700095","Twenty Pack","C78771","A product containing twenty individual units.","Twenty Pack | 20 Pack",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0440790","Solid Organ","C124068","An internal organ with firm consistency without a liquid or hollow structural component.","Solid Organ | ",,,,,,,,,,,,,,,"4105056","Solid organ",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086724","Papulosquamous Lesion","C124069","A skin lesion characterized by the presence of scaly papules and plaques.","Papulosquamous Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4073145","Keratosis Pilaris","C124070","A very common, non-neoplastic dermatologic disorder characterized by keratinization of hair follicles of the skin. It manifests as small, rough folliculocentric keratotic papules, usually in the outer-upper arms and thighs. It affects children and adolescents and usually improves with age.","Keratosis Pilaris | KP",,,,,,,,,,,,,,,"4197127","Keratosis pilaris",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516695","Collected","C45262","Indicates the person, group, or institution who performed the collection act.","Collected By | Collector | Obtained By",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473786","Abrupt","C113683","Marked by sudden change.","Abrupt | Sudden",,,,,,,,,,,,,,,"4112255","Sudden",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002743","Anabasine","C124073","A nicotine analog that is an alkaloid found in tree tobacco (Nicotiana glauca) and is comprised of a pyridine substituted by a piperidin-2-yl group at position 3. Anabasine has been used as an industrial insecticide and, since it is present in trace amounts in tobacco smoke, its detection in urine can be used as an indicator of exposure to tobacco smoke.","Anabasine | (-)-2-(3'-Pyridyl)piperidine | (S)-3-(2-Piperidinyl)pyridine | -(-)-Anabasine | 2-(3'-Pyridyl) Piperidine | 3-(2-Piperidinyl)pyridine | ANABASINE | L-3-(2'-Piperidyl)pyridine | Neonicotine | Piperidine, 2-(3-Pyridyl)- | Piperidine, 2-(3-Pyridyl)- (8CI) | Pyridine, 3-(2-Piperidinyl)-, (S)- | Pyridine, 3-(2-Piperidinyl)-, (S)- (9CI) | Pyridine, 3-(2-Piperidyl)- | Pyridine, 3-(2-pyridyl) Piperidine | Pyridine, 3-(2S)-2-Piperidinyl-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2240326","BABAM1 Gene","C124112","This gene is involved in the formation of the BRISC and BRCA1-A complex.","BABAM1 Gene | BABAM1 | BRISC and BRCA1 A Complex Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826632","BRCC3 Gene","C124109","This gene plays a role in the deubiquitination of histones.","BRCC3 Gene | BRCA1/BRCA2-Containing Complex, Subunit 3 Gene | BRCC3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412823","BABAM2 Gene","C124104","This gene is involved in the cellular response to DNA damage and binding to ubiquitinated histones.","BABAM2 Gene | BABAM2 | BRE | BRE Gene | BRISC and BRCA1 A Complex Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086112","CXCR4 WHIM-Like Mutation","C124130","Somatic point mutations or frameshift mutations in the CXCR4 gene that result in the truncation of between 10 and 19 amino acid residues from the carboxyl terminus of C-X-C chemokine receptor type 4 protein (CXCR-4) and are associated with Waldenstrom Macroglobulinemia. These mutations are similar to those found in the hereditary disease WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome and encode a constitutively active form of the CXCR-4 protein.","CXCR4 WHIM-Like Mutation | C-X-C Chemokine Receptor Type 4 WHIM-Like Mutation | CXCR-4 WHIM-Like Mutation | Chemokine (C-X-C Motif) Receptor 4 WHIM-Like Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011702","Desmosine","C124071","An amino acid derivative comprised of three allysyl side chains plus one unaltered lysyl side chain from the same or neighboring polypeptides condensed into a pyridinium ring. Desmosine is found in elastin and its detection in urine, plasma, or sputum samples can be used as a marker for excessive elastin degradation, which is associated with chronic obstructive pulmonary disease (COPD) and other pathologies.","Desmosine | 4-[(4S)-4-Amino-4-Carboxybutyl]-1-[(5S)-5-Amino-5-Carboxypentyl]-3,5-Bis[(3S)-3-Amino-3-Carboxypropyl]Pyridinium | 6-{4-[(4S)-4-Amino-4-Carboxybutyl]-3,5-Bis[(3S)-3-Amino-3-Carboxypropyl]-1-Pyridiniumyl}-L-Norleucine | DESMOSINE | Des | Pyridinium, 4-(4-Amino-4-Carboxybutyl)-1-(5-Amino-5-Carboxypentyl)-3,5-Bis(3-Amino-3-Carboxypropyl)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084718","Fibroblast Growth Factor Receptor 2 Isoform IIIb","C124075","An isoform of fibroblast growth factor receptor 2 where alternative splicing leads to the expression of the IIIb exon encoding the second half of the third immunoglobulin-like domain, which is located in the extracellular domain of these receptors. This variant is expressed in epithelial lineage cells and has differential ligand binding activity when compared to the IIIa and IIIc forms.","Fibroblast Growth Factor Receptor 2 Isoform IIIb | BFR-1 | FGFR-2 IIIb | FGFR2 IIIb | FGFR2(IIIb) | FGFR2-IIIb | FGFR2IIIb | FGFR2b | KGFR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2239486","GEN1 Gene","C124101","This gene plays a role in the resolution of Holliday junctions.","GEN1 Gene | GEN1 | GEN1 Holliday Junction 5' Flap Endonuclease Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415679","HOXC5 Gene","C124121","This gene plays a role in anterior-posterior axis specification.","HOXC5 Gene | HOXC5 | Homeobox C5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415681","HOXC9 Gene","C124118","This gene is involved in the regulation of gene transcription and anterior-posterior patterning.","HOXC9 Gene | HOXC9 | Homeobox C9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541708","IFNL4 Gene","C124079","This gene plays a role in antiviral responses and JAK-STAT pathway activation.","IFNL4 Gene | IFNL4 | Interferon, Lambda 4 (Gene/Pseudogene) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416393","IL18R1 Gene","C124082","This gene is involved in interleukin-mediated signaling.","IL18R1 Gene | IL18R1 | Interleukin 18 Receptor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425400","ITLN1 Gene","C124076","This gene is involved in the modulation of insulin-dependent signaling.","ITLN1 Gene | ITLN1 | Intelectin 1 (Galactofuranose Binding) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023776","Lipid Peroxides","C124072","Highly reactive, non-radical peroxols comprised of a fatty acid modified by a hydroperoxide group (-OOH) that are produced by lipid peroxidation. Lipid hydroperoxides are formed by sequential abstraction of allylic hydrogens from unsaturated fatty acids, which occurs in the presence of reactive oxygen species. These modified lipids can be further modified to create cytotoxic reactive aldehydes, such as malondialdehyde (MDA) and 4-hydroxy-2-nonenal (HNE). Lipid hydroperoxide levels can be measured to assess the extent of oxidative stress.","Lipid Hydroperoxide | HO2R | LOOH | LPO | ROOH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425521","NEIL1 Gene","C124095","This gene plays a role in base excision repair of DNA.","NEIL1 Gene | NEIL1 | Nei-Like DNA Glycosylase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0072225","Propylene Glycol","C29388","A propanediol that exists as a clear, colorless and hygroscopic liquid and consists of propane where the hydrogens at positions 1 and 2 are substituted by hydroxyl groups. Propylene glycol is used as an organic solvent and diluent in pharmaceuticals and many other industrial applications.","Propylene Glycol | 1,2-Dihydroxypropane | 1,2-Propanediol | 2-Hydroxypropanol | Isopropylene Glycol | MEG | Methyl Ethyl Glycol | Methyl Glycol | Methylethylene Glycol | Monopropylene Glycol | PG | PROPYLENE GLYCOL | Propane-1,2-Diol | alpha-Propylene Glycol | alpha-Propyleneglycol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0072354","Protein Disulfide-Isomerase Family","C124127","A family of isomerase enzymes that reside in the endoplasmic reticulum and act as chaperones during protein folding. They catalyze the rearrangement of disulfide bonds between cysteine residues within proteins as they undergo the folding step of protein maturation.","Protein Disulfide-Isomerase Family | EC 5.3.4.1 | PDI | PDI Family | Protein Disulfide Isomerase | Protein Disulfide Isomerase Family | Protein Disulfide-Isomerase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538841","RIF1 Gene","C124092","This gene is involved in checkpoint-mediated cell cycle arrest.","RIF1 Gene | RIF1 | Replication Timing Regulatory Factor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420104","SLC16A3 Gene","C124124","This gene is involved in transmembrane transport of monocarboxylates.","SLC16A3 Gene | SLC16A3 | Solute Carrier Family 16 (Monocarboxylate Transporter), Member 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420192","SLC3A2 Gene","C124115","This gene plays a role in promoting the transport of amino acids.","SLC3A2 Gene | SLC3A2 | Solute Carrier Family 3 (Amino Acid Transporter Heavy Chain), Member 2 Gene | Solute Carrier Family 3 Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420743","TIMP4 Gene","C124086","This gene plays a role in the inhibition of matrix metalloproteinases.","TIMP4 Gene | TIMP Metallopeptidase Inhibitor 4 Gene | TIMP4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086919","Tumor Antigen-specific Antibody","C124128","Any antibody that recognizes antigens that are overexpressed by, mutated in, or predominantly expressed by tumors compared with normal tissues.","Tumor Antigen-specific Antibody | Anti-TAA Antibody | Anti-Tumor Antibody | Anti-Tumor Antigen Antibody | Anti-Tumor-Associated Antigen Antibody | Tumor-Associated Antigen Antibody | Tumor-Specific Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041455","Type I Collagen","C124129","A heterotrimeric fibrillar protein complex comprised of two collagen alpha-1(I) chains and one collagen alpha-2(I) chains. Type I collagen is the most abundant fibrillar collagen in humans and is present in scar tissue, tendons, ligaments, bone, dermis, dentin, and organ capsules.","Type I Collagen | Collagen 1 | Collagen I | Collagen Type 1 | Collagen Type I | Type 1 Collagen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823597","UIMC1 Gene","C124098","This gene is involved in ubiquitin binding and DNA damage responses.","UIMC1 Gene | UIMC1 | Ubiquitin Interaction Motif Containing 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421403","USP28 Gene","C124089","This gene plays a role in both protein deubiquitination and DNA damage responses.","USP28 Gene | USP28 | Ubiquitin Specific Peptidase 28 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0000905","Accessory Nerve","C32041","The 11th cranial nerve, which sends motor impulses to the muscles of the upper thorax, back, shoulders, and pharynx.","Accessory Nerve | ACCESSORY NERVE | Accessory nerve structure (body structure) | CRANIAL ACCESSORY NERVE | Eleventh Cranial Nerve | SPINAL ACCESSORY NERVE | Spinal Accessory Nerve",,,,,,,,,,,,,,,"4034709","Accessory nerve structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2732619","Intramedullary","C96266","Occurring in, or located within the spinal cord or the marrow space of a bone.","Intramedullary | Intra-Medullary",,,,,,,,,,,,,,,"40481870","Intramedullary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512938","Intradural Extramedullary Spinal Canal Space","C41450","An area within the dura sheath but outside of the spinal cord.","Intradural Extramedullary Spinal Canal Space | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522407","Supratentorial Brain","C12512","The part of the brain that is located superior to the tentorium cerebelli.","Supratentorial Brain | SUPRATENTORIAL BRAIN | Supratentorial Anatomy | Supratentorial Nervous System",,,,,,,,,,,,,,,"4319142","Supratentorial brain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0581669","Sacral Spinal Cord","C12896","The portion of the spinal cord located in the sacral region.","Sacral Spinal Cord | SPINAL CORD, SACRAL | Sacral spinal cord structure (body structure)",,,,,,,,,,,,,,,"4015790","Sacral spinal cord structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334255","Intradural Extramedullary Spinal Canal Neoplasm","C5135","A neoplasm that occurs within the spinal canal in the space between the spinal cord and the dura mater.  Representative examples include meningioma, neurofibroma, and sarcoma.  Signs and symptoms include local and radicular pain, weakness and spinal cord compression.","Intradural Extramedullary Spinal Canal Neoplasm | Intradural Extramedullary Neoplasm of Spinal Canal | Intradural Extramedullary Neoplasm of the Spinal Canal | Intradural Extramedullary Spinal Canal Tumor | Intradural Extramedullary Spinal Canal Tumors | Intradural Extramedullary Spinal Neoplasms | Intradural Extramedullary Spinal Tumors | Intradural Extramedullary Tumor of Spinal Canal | Intradural Extramedullary Tumor of the Spinal Canal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028864","Oculomotor Nerve","C12758","The third cranial nerve that originates originating at the oculomotor nerve nucleus at the level of the superior colliculus in the midbrain, provides motor innervation to the levator palpebrae superioris, the superior, inferior, and medial rectus muscles, and the inferior oblique muscles, and provides parasympathetic innervation to the ciliary ganglion.","Oculomotor Nerve | Cranial Nerve III | NERVE, OCULOMOTOR | OCULOMOTOR NERVE | Oculomotor nerve structure (body structure) | Third Cranial Nerve",,,,,,,,,,,,,,,"4206911","Oculomotor nerve structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0230045","Middle Cranial Fossa","C33117","A depression of the skull base lying posterior and inferior to the anterior cranial fossa and separated from the posterior cranial fossa by the clivus and the petrous crest. It supports the temporal lobes of the cerebrum and the pituitary gland.","Middle Cranial Fossa | ",,,,,,,,,,,,,,,"4175328","Structure of middle fossa of cranial cavity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0581621","Lumbar Spinal Cord","C12895","The portion of the spinal cord located in the lumbar region.","Lumbar Spinal Cord | Lumbar Portion of Spinal Cord | Lumbar spinal cord structure (body structure) | SPINAL CORD, LUMBAR | lumbar spinal cord",,,,,,,,,,,,,,,"4244556","Lumbar spinal cord structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0228067","Infratentorial Brain","C12509","A region in the brain that is located below the tentorium cerebelli and contains the cerebellum.","Infratentorial Brain | INFRATENTORIAL BRAIN | Infratentorial Anatomy | Infratentorial Nervous System",,,,,,,,,,,,,,,"4049949","Infratentorial brain structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL449004","Central Lobe","C32278","An invaginated portion of the cerebral cortex forming the base of the sylvian fissure.  It is part of the lateral side of the cortex and its function includes the processing of emotions, memory, and higher autonomic control.","Central Lobe | INSULAR CORTEX | Insula | Insular Cortex | Insular Region of the Brain | Island of Reil | Lobus Insularis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020614","Hypoglossal Nerve","C12732","The twelfth cranial nerve. It arises from the hypoglossal nucleus and leads to the tongue.","Hypoglossal Nerve | HYPOGLOSSAL NERVE | Hypoglossal nerve structure (body structure) | Twelfth Cranial Nerve",,,,,,,,,,,,,,,"4243481","Hypoglossal nerve structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017679","Glossopharyngeal Nerve","C12723","The ninth cranial nerve. It originates in the brainstem and passes through the jugular foramen. It has motor and sensory functions that relate to the tongue, pharynx and middle ear.","Glossopharyngeal Nerve | Cranial Nerve IX | GLOSSOPHARYNGEAL NERVE | Glossopharyngeal nerve structure (body structure) | Nervus Glossopharyngeus | Ninth Cranial Nerve",,,,,,,,,,,,,,,"4055060","Glossopharyngeal nerve structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706995","Brain White Matter","C49334","No Value Exists","Brain White Matter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152295","Cerebral White Matter","C49347","A type of brain tissue in the cerebrum consisting of myelinated axons and glial cells.","Cerebral White Matter | ","C71.0","Cerebral white matter",,,,,,,,,,,,,"4287415","Cerebral white matter structure",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0228465","Hemisphere of the Cerebellum","C32726","Either side of the cerebellum separated by the vermis.","Hemisphere of the Cerebellum | Cerebellar hemisphere structure (body structure) | cerebellar hemisphere",,,,,,,,,,,,,,,"4280523","Cerebellar hemisphere structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014472","Ependyma","C13078","A thin membrane that lines the ventricles of the brain and the central canal of the spinal cord.","Ependyma | Ependymal Tissue | ependyma",,,,,,,,,,,,,,,"4133834","Ependyma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0149601","Conus Medullaris","C12832","The terminal, cone-shaped end of the spinal cord.","Conus Medullaris | ",,,,,,,,,,,,,,,"4138386","Structure of conus medullaris",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152405","Optic Tract","C33218","A continuation of the optic nerves just dorsal to the optic chiasm, formed by temporal fibers of the ipsilateral optic nerve and nasal fibers of the contralateral optic nerve, that carries axons to nuclei within the thalamus and relays visual information to the primary visual cortex of the occipital lobe.","Optic Tract | optic tract",,,,,,,,,,,,,,,"4183268","Optic tract structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1510913","Anterior Supratentorial Cistern","C32106","One of the supratentorial cisterns. It is also called parasellar supratentorial cistern.","Anterior Supratentorial Cistern | Parasellar Cistern",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041159","Trochlear Nerve","C12808","The cranial nerve that controls the superior oblique muscle of the eye.","Trochlear Nerve | Cranial Nerve IV | Fourth Cranial Nerve | TROCHLEAR NERVE",,,,,,,,,,,,,,,"4190294","Trochlear nerve structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042276","Vagus Nerve","C12812","The tenth cranial nerve. It is the longest cranial nerve. It originates in the medulla and exits the cranium through the jugular foramen. It supplies various muscles, including muscles of the pharynx and soft palate.","Vagus Nerve | Cranial Nerve X | NERVE, VAGUS | Pneumogastric Nerve | Tenth Cranial Nerve | VAGUS NERVE",,,,,,,,,,,,,,,"4229593","Vagus nerve structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001162","Vestibulocochlear Nerve","C12996","The eighth cranial nerve composed of the acoustic nerve and the vestibular nerve. The nerve travels from the inner ear, enters the cranial cavity through the internal auditory foramen and joins the brainstem. The auditory nerve conveys impulses from the cochlea of the inner ear to the auditory nuclei of the brainstem. The vestibular nerve carries information from the labyrinths of the inner ear to the vestibular nuclei of the brainstem.","Vestibulocochlear Nerve | Cranial Nerve Eight | Cranial Nerve VIII | Eighth Cranial Nerve | NERVE, VESTIBULOCOCHLEAR | VESTIBULOCOCHLEAR NERVE | VIIIth Cranial Nerve | Vestibulocochlear nerve structure (body structure)",,,,,,,,,,,,,,,"4312223","Vestibulocochlear nerve structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0432409","Trisomy 11","C37191","The presence of a third copy of chromosome 11 in somatic cells.","Trisomy 11 | ",,,,,,,,,,,,,,,"4007419","Trisomy 11",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2936830","Trisomy 13","C36529","A chromosomal abnormality characterized by the presence of three copies of genetic material for chromosome 13, instead of the normal two. It leads to a variety of abnormalities that include mental retardation, microcephaly, low-set ears, eye structural defects, polydactyly, and limb abnormalities.","Trisomy 13 | Trisomy-13",,,,,,,,,,,,,,,"37111422","Partial trisomy of chromosome 13",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0795851","Trisomy 14","C116344","A chromosomal abnormality consisting of the presence of a third copy of chromosome 14 in somatic cells.","Trisomy 14 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0265490","Trisomy 22","C114765","A chromosomal abnormality consisting of the presence of a third copy of chromosome 22 in somatic cells.","Trisomy 22 | ",,,,,,,,,,,,,,,"4007421","Trisomy 22",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0581672","Sacral Spinal Nerve Root","C12925","The initial portion of any one of the five paired sacral nerves, which is formed by the union of a dorsal sensory root and ventral motor root; collectively, these roots are called the cauda equina.","Sacral Spinal Nerve Root | Sacral Spinal Nerve Roots",,,,,,,,,,,,,,,"4134457","Sacral spinal nerve root structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0446731","Thoracic Spinal Nerve Root","C12926","The initial portion of any one of the twelve-paired thoracic nerves, formed by the union of a dorsal sensory root and ventral motor root, as it exits from the spinal cord.","Thoracic Spinal Nerve Root | Thoracic Spinal Nerve Roots",,,,,,,,,,,,,,,"4283068","Thoracic spinal nerve root structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0581666","Lumbar Spinal Nerve Root","C12924","The initial portion of a lumbar spinal nerve, formed by the union of a dorsal sensory root and ventral motor root, as it originates from the spinal cord; there are five lumbar nerve roots on each side of the vertebral column, which exit the column inferior to their corresponding vertebral body level.","Lumbar Spinal Nerve Root | Lumbar Spinal Nerve Roots",,,,,,,,,,,,,,,"4027397","Lumbar spinal nerve root structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0228815","Cervical Nerve","C32299","Any of the eight nerves arising from one of the seven cervical vertebrae.","Cervical Nerve | ",,,,,,,,,,,,,,,"4268782","Structure of cervical spinal nerve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0559685","Laminectomy","C21061","The excision of one or more vertebral posterior arches to alleviate pressure on the spinal cord or nerves.","Laminectomy | Decompression Laminectomy | Decompression Surgery | Spinal Decompression",,,,,,,,,,,,,,,"4306206","Laminectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2363903","Angiocentric Glioma","C92552","A WHO grade 1, slow-growing brain neoplasm of children and young adults, associated with epilepsy.  Morphologically it is characterized by an angiocentric pattern, monomorphic cellular infiltrate, and ependymal differentiation.","Angiocentric Glioma | Angiocentric Glioma (WHO Grade 1) | Angiocentric Glioma (WHO Grade I) | Angiocentric Neuroepithelial Tumor | Angiocentric glioma | Monomorphus Angiocentric Glioma","9431/1","Angiocentric glioma",,,,,,,,,,,,,"42872905","Angiocentric glioma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C2985223","Central Nervous System Ganglioneuroblastoma","C92629","A malignant central nervous system neoplasm characterized by the presence of poorly differentiated or undifferentiated neuroepithelial cells and ganglion cells.","Central Nervous System Ganglioneuroblastoma | Cerebral Ganglioneuroblastoma | Cerebral Ganglioneuroblastoma",,,,,,,,,,,,,,,"37116899","Ganglioneuroblastoma of central nervous system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1513123","Meningothelial Cell","C33095","The cellular components of the meninges.","Meningothelial Cell | Arachnoidal Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986550","Pituicytoma","C94524","An extremely rare, WHO grade 1, circumscribed and slow-growing tumor that arises from the neurohypophysis or infundibulum and described in adults.  It is characterized by the presence of elongated, spindle-shaped neoplastic glial cells that form storiform patterns or interlacing fascicular arrangements.  Signs and symptoms include visual disturbances, headache, amenorrhea, and decreased libido.","Pituicytoma | PITUICYTOMA, BENIGN | Pituicytoma (WHO Grade 1) | Pituicytoma (WHO Grade I) | Posterior Pituitary Astrocytoma","9432/1","Pituicytoma",,,,,,,,,,,,,"42872906|43531118","Pituicytoma|Pituicytoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1519086","Pilomyxoid Astrocytoma","C40315","An astrocytic tumor of uncertain relation to pilocytic astrocytoma.  It occurs predominantly in infants and young children.  It is characterized by a monomorphic architectural pattern, usually associated with the absence of Rosenthal fibers and eosinophilic granular bodies.  The clinical course is usually aggressive.","Pilomyxoid Astrocytoma | Pilomyxoid astrocytoma","9425/3","Pilomyxoid astrocytoma",,,,,,,,,,,,,"4309900","Pilomyxoid astrocytoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C2985219","Papillary Tumor of the Pineal Region","C92624","A rare tumor that arises from the pineal region and affects adults.  It is characterized by the presence of neuroepithelial cells and a papillary architecture.  Electron microscopic studies suggest ependymal differentiation.  The clinical course is variable.","Papillary Tumor of the Pineal Region | PTPR | Papillary tumor of the pineal region",,,,,,,,,,,,,,,"42872904","Papillary tumor of the pineal region",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2985174","Papillary Glioneuronal Tumor","C92554","A WHO grade 1, indolent and relatively circumscribed brain tumor.  Morphologically it is characterized by the presence of astrocytes that line vascular and hyalinized pseudopapillae.  In between the pseudopapillae aggregates of neurocytes, large neurons, and ganglioid cells are present.","Papillary Glioneuronal Tumor | PGNT | Papillary Glioneuronal Tumor (WHO Grade 1) | Papillary Glioneuronal Tumor (WHO Grade I) | Papillary glioneuronal tumor","9509/1","Papillary glioneuronal tumor",,,,,,,,,,,,,"42872907","Papillary glioneuronal tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C2986561","Spindle Cell Oncocytoma","C94537","A very rare, WHO grade 1 neoplasm of the posterior pituitary. It is characterized by the presence of spindle cells with eosinophilic, granular cytoplasm forming fascicles.  Electron microscopic studies demonstrate the accumulation of intracytoplasmic mitochondria and lack of secretory granules.  Immunohistochemical studies are negative for pituitary hormones.  Patients may present with pituitary hypofunction, visual disturbances, headache, nausea and vomiting.  The clinical course is usually benign.","Spindle Cell Oncocytoma | Folliculo-Stellate Cell Tumor of the Pituitary | SCO | Spindle Cell Oncocytoma of the Adenohypophysis | Spindle Cell Oncocytoma of the Adenohypophysis | Spindle Cell Oncocytoma of the Adenohypophysis (WHO Grade 1) | Spindle Cell Oncocytoma/Oncocytic Pituicytoma | Spindle cell oncocytoma",,,,,,,,,,,,,,,"45766637","Spindle cell oncocytoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347979","Rosette-Forming Glioneuronal Tumor of the Fourth Ventricle","C67559","A central nervous system neoplasm arising from the fourth ventricle. It is characterized by the presence of neurocytes forming pseudorosettes and astrocytes which contain Rosenthal fibers. Cytologic atypia is minimal.","Rosette-Forming Glioneuronal Tumor of the Fourth Ventricle | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086268","Exacerbation","C124138","A worsening of a problem, condition, or disease.","Exacerbation | EXACERBATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502630","Production Assistance for Cellular Therapies","C124139","An initiative of the National Heart, Lung, and Blood Institute (NHLBI) for the establishment of a coordinating center and facilities for the production and testing of novel cell therapies.","Production Assistance for Cellular Therapies | PACT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0408670","Spinal Cord Decompression","C124141","Any of various procedures intended to relieve symptoms caused by pressure on the spinal cord and/or nerve roots.","Spinal Cord Decompression | Spinal Decompression Surgery",,,,,,,,,,,,,,,"4030312","Decompression of spinal cord",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0596683","Cardiac Ventriculography","C124142","A medical imaging test that involves injecting contrast media into the heart's ventricle(s) to determine a patient's cardiac function.","Cardiac Ventriculography | Invasive contrast left ventriculography",,,,,,,,,,,,,,,"4098040","Cardiac ventriculography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0410480","Avascular Necrosis of Femoral Head","C35447","Necrotic changes in the bone tissue of the femoral head due to interruption of blood supply.","Avascular Necrosis of Femoral Head | Osteonecrosis of the Femoral Head",,,,,,,,,,,,,,,"37396002|4069309","Familial avascular necrosis of femoral head|Avascular necrosis of the head of femur",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL502629","Cardiac Stem Cell","C124143","Multipotent progenitor cells that are found in the fetal and adult heart that provide the myocardium with limited regenerating capability.","Cardiac Stem Cell | CPC | Cardiac Progenitor Cell | Endogenous Cardiac Stem Cell | eCSC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2717959","Induced Pluripotent Stem Cell","C124144","Adult cells that have been genetically reprogrammed to an embryonic stem cell-like state by the expression of genes and factors important for maintaining the defining properties of embryonic stem cells.","Induced Pluripotent Stem Cell | iPSC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3850017","Endothelial Progenitor Cell","C124145","Circulating cells that express a variety of cell surface markers similar to those expressed by vascular endothelial cells, adhere to endothelium at sites of hypoxia or ischemia, and participate in new vessel formation.","Endothelial Progenitor Cell | CEP | Circulating Endothelial Progenitor Cell | EPC | Endothelial Precursor Cell | Endothelial Stem Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086501","Human Umbilical Cord Perivascular Cell","C124146","Mesenchymal stem cells isolated from umbilical cord blood capable of high proliferation potential and colony formation capacity in vitro and the ability to proliferate and differentiate to an osteogenic phenotype in culture.","Human Umbilical Cord Perivascular Cell | HUCPVC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502624","Symptom Distress Scale","C124147","A patient reported questionnaire composed of rating scales developed to measure the degree of distress experienced by the patient for specific symptoms.","Symptom Distress Scale | SDS | Symptom Distress Scale (SDS) | Symptom Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086847","Seldom Have Nausea","C124148","A response indicating that an individual seldom, if ever, has or had nausea.","Seldom Have Nausea | I seldom if ever have nausea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086395","Have Nausea Once in a While","C124149","A response indicating that an individual has or had nausea once in a while.","Have Nausea Once in a While | I have nausea once in a while",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086393","Have Nausea Fairly Often","C124150","A response indicating that an individual has or had nausea fairly often.","Have Nausea Fairly Often | I have nausea fairly often",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086397","Have Nausea at Least Half the Time","C124151","A response indicating that an individual has or had nausea half the time at least.","Have Nausea at Least Half the Time | I have nausea half the time at least",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086392","Have Nausea Continually","C124152","A response indicating that an individual has or had nausea continually.","Have Nausea Continually | I have nausea continually",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086620","Nausea Distress","C124153","A question about how nausea effects an individual.","Nausea Distress | Nausea Effect | Nausea Severity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086414","Have Very Mild Nausea","C124154","A response indicating that when an individual has or had nausea, it was very mild.","Have Very Mild Nausea | When I do have nausea, it is very mild",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086390","Have Mildly Distressing Nausea","C124155","A response indicating that when an individual has or had nausea, it was mildly distressing.","Have Mildly Distressing Nausea | When I do have nausea, it is mildly distressing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086396","Have Nausea Usually Feel Very Sick","C124157","A response indicating that when an individual has or had nausea, they usually felt very sick.","Have Nausea Usually Feel Very Sick | When I have nausea, I usually feel very sick",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087088","Have Nausea Am as Sick as I Could Possibly Be","C124158","A response indicating that when an individual has or had nausea, they were as sick as they could possibly be.","Have Nausea Am as Sick as I Could Possibly Be | When I have nausea, I am as sick as I could possibly be",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085635","Appetite Quality","C124159","A question about the state of an individual's appetite.","Appetite Quality | Appetite | Appetite Distress",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086399","Have Normal Appetite and Enjoy Good Food","C124160","A response indicating that an individual has or had a normal appetite and enjoyed good food.","Have Normal Appetite and Enjoy Good Food | I have my normal appetite and enjoy good food",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085996","Appetite is Usually Good but Not Always","C124161","A response indicating that an individual has or had an appetite that was usually good but not always good.","Appetite is Usually Good but Not Always | My appetite is usually, but not always, pretty good",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086252","Don't Really Enjoy Food","C124162","A response indicating that an individual does not really enjoy food.","Don't Really Enjoy Food | I don't really enjoy my food",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086416","Have to Force Myself to Eat","C124163","A response indicating that an individual has or had to force themselves to eat their food.","Have to Force Myself to Eat | I have to force myself to eat my food",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086116","Cannot Stand Thought of Food","C124164","A response indicating that an individual cannot stand the thought of food.","Cannot Stand Thought of Food | I cannot stand the thought of food",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086855","Sleep as Well as Always","C124165","A response indicating that an individual sleeps or slept as well as they always have.","Sleep as Well as Always | I sleep as well as I always have",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086654","Occasionally Have Trouble Getting to Sleep and Staying Asleep","C124166","A response indicating that an individual occasionally has or had trouble getting to sleep and staying asleep.","Occasionally Have Trouble Getting to Sleep and Staying Asleep | I occasionally have trouble getting to sleep and staying asleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087039","Frequently Have Trouble Getting to Sleep","C124167","A response indicating that an individual frequently has or had trouble getting to sleep.","Frequently Have Trouble Getting to Sleep | I frequently have trouble getting to sleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086382","Have Difficulty Getting to Sleep and Staying Asleep","C124168","A response indicating that an individual has or had difficulty getting to sleep and staying asleep almost every night.","Have Difficulty Getting to Sleep and Staying Asleep | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085947","Almost Impossible to Get a Decent Night's Sleep","C124169","A response indicating that it is or was almost impossible for an individual to get a decent night's sleep.","Almost Impossible to Get a Decent Night's Sleep | It is almost impossible for me to get a decent night's sleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085948","Almost Never Have Pain","C124170","A response indicating that an individual almost never has or had pain.","Almost Never Have Pain | I almost never have pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086405","Have Pain Once in a While","C124171","A response indicating that an individual has or had pain once in a while.","Have Pain Once in a While | I have pain once in a while",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086406","Have Pain Several Times a Week","C124172","A response indicating that an individual has or had pain several times a week.","Have Pain Several Times a Week | I have pain several times a week",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086940","Usually in Some Degree of Pain","C124173","A response indicating that an individual usually is or was in some degree of pain.","Usually in Some Degree of Pain | I am usually in some degree of pain | Usually in Some Pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086517","In Some Degree of Pain Almost Constantly","C124174","A response indicating that an individual is or was some degree of pain almost constantly.","In Some Degree of Pain Almost Constantly | I am in some degree of pain almost constantly | In Some Pain Almost Constantly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1320357","Pain Distress","C124175","A question about the intensity of an individual's pain.","Pain Distress | Pain | Pain Intensity | Pain Severity | Severity of Pain",,,,,,,,,,,,,,,"4235567","Pain intensity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086415","Have Very Mild Pain","C124176","A response indicating that when an individual has or had pain, it was very mild.","Have Very Mild Pain | When I do have pain, it is very mild",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086391","Have Mildly Distressing Pain","C124177","A response indicating that when an individual has or had pain, was mildly distressing.","Have Mildly Distressing Pain | When I do have pain, it is mildly distressing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086935","Usually Have Fairly Intense Pain","C124178","A response indicating that when an individual has or had pain, it was usually fairly intense.","Usually Have Fairly Intense Pain | When I do have pain, it is usually fairly intense",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086413","Have Very Intense Pain","C124179","A response indicating that an individual's pain is or was very intense.","Have Very Intense Pain | The pain I have is very intense",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086379","Have Almost Unbearable Pain","C124180","A response indicating that an individual's pain is or was almost unbearable.","Have Almost Unbearable Pain | The pain I have is almost unbearable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086846","Seldom Feel Tired or Fatigued","C124181","A response indicating that an individual seldom feels or felt tired or fatigued.","Seldom Feel Tired or Fatigued | I seldom feel tired or fatigued",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086409","Have Periods When Rather Tired or Fatigued","C124182","A response indicating that an individual has or had periods when they were rather tired or fatigued.","Have Periods When Rather Tired or Fatigued | There are periods when I am rather tired or fatigued",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086408","Have Periods When Quite Tired or Fatigued","C124183","A response indicating that an individual has or had periods when they were quite tired and fatigued.","Have Periods When Quite Tired or Fatigued | There are periods when I am quite tired and fatigued",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086938","Usually Very Tired and Fatigued","C124184","A response indicating that an individual is or was usually very tired and fatigued.","Usually Very Tired and Fatigued | I am usually very tired and fatigued",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086302","Feel Exhausted Most of the Time","C124185","A response indicating that an individual feels or felt exhausted most of the time.","Feel Exhausted Most of the Time | Most of the time, I feel exhausted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4083257","Pattern of Bowel Movements","C124186","A question about the pattern of an individual's bowel movements.","Pattern of Bowel Movements | Bowel | Bowel Pattern | Bowel Pattern Distress",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086400","Have Normal Bowel Pattern","C124187","A response indicating that an individual has or had a normal pattern of bowel movements.","Have Normal Bowel Pattern | Have Normal Pattern of Bowel Movements | I have my normal bowel pattern",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086041","Bowel Pattern Occasionally Causes Some Discomfort","C124188","A response indicating that an individual's pattern of bowel movements occasionally causes or caused them some discomfort.","Bowel Pattern Occasionally Causes Some Discomfort | My bowel pattern occasionally causes me some discomfort | Pattern of Bowel Movements Occasionally Causes Some Discomfort",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086040","Bowel Pattern Causes Considerable Discomfort","C124189","A response indicating that an individual's present pattern of bowel movements occasionally causes them considerable discomfort.","Bowel Pattern Causes Considerable Discomfort | My present bowel pattern occasionally causes me considerable discomfort | Pattern of Bowel Movements Causes Considerable Discomfort",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086939","Usually in Considerable Discomfort Because of Bowel Pattern","C124190","A response indicating that an individual's present pattern of bowel movements usually causes them considerable discomfort.","Usually in Considerable Discomfort Because of Bowel Pattern | I am usually in considerable discomfort because of my present bowel pattern | Usually in Considerable Discomfort Because of Pattern of Bowel Movements",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086516","In Almost Constant Discomfort Because of Bowel Pattern","C124191","A response indicating that an individual's pattern of bowel movements causes or caused them almost constant discomfort.","In Almost Constant Discomfort Because of Bowel Pattern | I am in almost constant discomfort because of my bowel pattern | In Almost Constant Discomfort Because of Pattern of Bowel Movements",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086398","Have Normal Ability to Concentrate","C124192","A response indicating that an individual has or had their normal ability to concentrate.","Have Normal Ability to Concentrate | I have my normal ability to concentrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086404","Have Occasional Trouble Concentrating","C124193","A response indicating that an individual occasionally has or had trouble concentrating.","Have Occasional Trouble Concentrating | I occasionally have trouble concentrating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086653","Occasionally Have Considerable Trouble Concentrating","C124194","A response indicating that an individual occasionally has or had considerable trouble concentrating.","Occasionally Have Considerable Trouble Concentrating | I occasionally have considerable trouble concentrating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016979","Gallic Acid","C63648","A hydrolyzable tannin with three additional hydroxyl groups attached at the 3, 4, and 5 positions of the phenyl ring. The chemical structure is C1=C(C=C(C(=C1O)O)O)C(=O)O.","Gallic Acid | 3,4,5-Trihydroxybenzoic Acid | 3,4,5-hydroxybenzoic acid | Benzoic acid, 3,4,5-trihydroxy- | GALLIC ACID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086934","Usually Have Considerable Trouble Concentrating","C124195","A response indicating that an individual usually has or had considerable difficulty concentrating.","Usually Have Considerable Trouble Concentrating | I usually have considerable difficulty concentrating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086113","Can't Concentrate at All","C124196","A response indicating that an individual just can't seem to concentrate at all.","Can't Concentrate at All Question | Am Unable to Concentrate | Can't Concentrate | Can't Concentrate at All | Can't Concentrate at All | Can't Seem to Concentrate at All | I am unable to concentrate | I just can't seem to concentrate at all | Unable to Concentrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084721","Appearance Distress","C124197","A question about an individual's concern with their physical appearance.","Appearance Distress | Appearance | Concern about Appearance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085995","Appearance Has Not Changed","C124198","A response indicating that an individual's appearance has not changed.","Appearance Has Not Changed | Appearance Has Basically Not Changed | My appearance has basically not changed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086652","Occasionally Concerned about Worsening of Physical Appearance","C124199","A response indicating that an individual is or was occasionally concerned about worsening of their physical appearance.","Occasionally Concerned about Worsening of Physical Appearance | Occasionally I am concerned about the worsening of my physical appearance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086631","Not Often Concerned that Appearance is Worsening","C124200","A response indicating that an individual is not or was not often concerned that their appearance is worsening.","Not Often Concerned that Appearance is Worsening | I am not often concerned that my appearance is worsening",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087053","Most of the Time Concerned that Physical Appearance is Worsening","C124201","A response indicating that most of the time an individual is or was concerned that their physical appearance is worsening.","Most of the Time Concerned that Physical Appearance is Worsening | Most of the time I am concerned that my physical appearance is worsening",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086970","Worsening of Physical Appearance is Constant Preoccupying Concern","C124202","A response indicating that the worsening of an individual's physical appearance is or was a constant, preoccupying concern.","Worsening of Physical Appearance is Constant Preoccupying Concern | The worsening of my physical appearance is a constant, preoccupying concern",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084858","Breathing Distress","C124203","A question about an individual's difficulty with breathing.","Breathing Distress | Breathing | Breathing Ability | Breathing Effort",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086933","Usually Breathe Normally","C124204","A response indicating that an individual usually breathes normally.","Usually Breathe Normally | I usually breathe normally",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086403","Have Occasional Trouble Breathing","C124205","A response indicating that an individual occasionally has of had trouble breathing.","Have Occasional Trouble Breathing | I occasionally have trouble breathing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086658","Often Have Trouble Breathing","C124206","A response indicating that an individual often has or had trouble breathing.","Often Have Trouble Breathing | I often have trouble breathing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086376","Hardly Ever Breathe Easily","C124207","A response indicating that an individual can hardly ever breathe as easily as they want.","Hardly Ever Breathe Easily | Hardly Ever Breathe as Easily as Wanted | I can hardly ever breathe as easily as I want",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085946","Almost Always Have Severe Trouble Breathing","C124208","A response indicating that an individual almost always has or had severe trouble with their breathing.","Almost Always Have Severe Trouble Breathing | I almost always have severe trouble with my breathing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084884","Outlook Distress","C124209","A question about an individual's fear about the future.","Outlook Distress | Fear about Future | Outlook",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086633","Not Worried or Frightened About the Future","C124210","A response indicating that an individual is not or was not worried or frightened about the future.","Not Worried or Frightened About the Future | I am not worried or frightened about the future",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086856","Slightly Worried but Not Frightened About Things","C124211","A response indicating that an individual is or was slightly worried but not frightened about things.","Slightly Worried but Not Frightened About Things | I am slightly worried but not frightened about things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086968","Worried and Frightened About Things","C124212","A response indicating that an individual is or was worried and frightened about things.","Worried and Frightened About Things | I am worried and frightened about things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086950","Very Worried and Frightened About Things","C124213","A response indicating that an individual is or was very worried and frightened about things.","Very Worried and Frightened About Things | I am very worried and frightened about things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086898","Terrified by Thoughts of the Future","C124214","A response indicating that an individual is or was terrified by thoughts of the future.","Terrified by Thoughts of the Future | I am terrified by thoughts of the future",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084727","Cough Frequency","C124215","A question about the frequency of an individual's cough.","Cough Frequency | Cough | Cough Distress | Cough Distress | Frequency of Coughing | How Often Cough",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086845","Seldom Cough","C124216","A response indicating that an individual seldom coughs or coughed.","Seldom Cough | I seldom cough",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086402","Have Occasional Cough","C124217","A response indicating that an individual has or had an occasional cough.","Have Occasional Cough | I have an occasional cough",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086656","Often Cough","C124218","A response indicating that an individual often coughs or coughed.","Often Cough | I often cough",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086655","Often Cough and Have Occasionally Severe Coughing Spells","C124219","A response indicating that an individual often coughs or coughed and occasionally has or had severe coughing spells.","Often Cough and Have Occasionally Severe Coughing Spells | I often cough, and occasionally have severe coughing spells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086657","Often Have Persistent and Severe Coughing Spells","C124220","A response indicating that an individual often has or had persistent and severe coughing spells.","Often Have Persistent and Severe Coughing Spells | I often have persistent and severe coughing spells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416786","LAMC2 Gene","C116275","This gene plays a role in both extracellular matrix assembly and epidermal development.","LAMC2 Gene | LAMC2 | Laminin, Gamma 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417213","MMP8 Gene","C41045","This gene is involved in proteolysis and the regulation of matrix remodeling.","MMP8 Gene | MMP8 | Matrix Metallopeptidase 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225360","Myofibroblast","C33153","A spindle-shaped cell that exhibits characteristics of both fibroblasts and smooth muscle cells. It has an elongated nucleus and does not have basal lamina. The cytoplasm can be distinguished from the surrounding matrix because of actin filaments, myosin and other muscle proteins arranged to suggest a contractile ability.","Myofibroblast | ",,,,,,,,,,,,,,,"4237003","Myofibroblast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1419891","SDC1 Gene","C96912","This gene is involved in cell adhesion, signal transduction and cytoskeleton organization.","SDC1 Gene | CD138 | SDC1 | Syndecan 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827983","Clinical Trial Site","C85838","Any healthcare organization, institution, facility or provider directly involved in conducting or facilitating a particular clinical trial.","Clinical Trial Site | Investigative Site | Investigator Site | Trial Site | trial site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086188","Clinical Relapse of Multiple Myeloma or Plasma Cell Leukemia by IMWG","C123908","Relapse of multiple myeloma or plasma cell leukemia is defined as follows: Development of new soft tissue plasmacytomas or bone lesions; Definite increase in the size of existing plasmacytomas or bone lesions. A definite increase is defined as a 50% (and at least 1 cm) increase as measured serially by the sum of the products of the cross-diameters of the measurable lesion; Hypercalcemia (> 11.5 mg/dL) [2.65 mmol/L]; Decrease in hemoglobin of > 2 g/dL [1.25 mmol/L]; and rise in serum creatinine by 2 mg/dL or more [177 mmol/L or more]. (International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma. <http://myeloma.org/ArticlePage.action?articleId=2994>)","Clinical Relapse of Multiple Myeloma or Plasma Cell Leukemia by IMWG | Clinical Relapse of Multiple Myeloma or Plasma Cell Leukemia (IMWG) | Relapse of Multiple Myeloma or Plasma Cell Leukemia | Relapse of Multiple Myeloma or Plasma Cell Leukemia (IMWG) | Relapse of Multiple Myeloma or Plasma Cell Leukemia by IMWG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0060483","Fludarabine Phosphate","C1102","The phosphate salt of a fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.","Fludarabine Phosphate | 2-F-ara-AMP | 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)- | 9H-purin-6-amine, 2-fluoro-9-(5-O-phosphono-beta-D-arabinofuranosyl) | Beneflur | FLUDARABINE PHOSPHATE | Fludara | Fludarabine-5'-Monophosphate | Oforta | SH T 586 | fludarabine phosphate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1847531","HELQ Gene","C113137","This gene plays a role in DNA unwinding.","HELQ Gene | HELQ | Helicase, POLQ-Like Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418816","PPM1D Gene","C88179","This gene plays a role in the modulation of cell cycle arrest.","PPM1D Gene | PPM1D | Protein Phosphatase 1D Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826831","RINT1 Gene","C114919","This gene plays a role in both telomere length maintenance and cellular trafficking.","RINT1 Gene | RAD50 Interactor 1 Gene | RINT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366757","ERCC6 Gene","C19881","This gene plays a role in transcription-coupled and global genome-DNA repair.","ERCC6 Gene | ERCC Excision Repair 6, Chromatin Remodeling Factor Gene | ERCC6 | Excision-Repair Cross-Complementing Rodent Repair Deficiency, Complementation Group 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415664","HOXB13 Gene","C112822","This gene is involved in anterior-posterior axis formation.","HOXB13 Gene | HOXB13 | Homeobox B13 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419293","RBBP8 Gene","C73440","This gene is involved in cell cycle regulation.","RBBP8 Gene | RBBP8 | Retinoblastoma Binding Protein 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824794","CDK12 Gene","C101095","This gene is involved in protein phosphorylation, RNA splicing and transcription elongation.","CDK12 Gene | CDK12 | Cyclin Dependent Kinase 12 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413279","CDH4 Gene","C115313","This gene is involved in both retinal development and cell adhesion.","CDH4 Gene | CDH4 | Cadherin 4, Type 1, R-Cadherin (Retinal) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040021","Buerger Disease","C35070","An inflammatory vascular disorder that affects small and medium-sized arteries and veins in the extremities. The inflammatory process is initiated in the tunica intima and results in thrombosis and vascular obstruction with subsequent ischemia and ulceration of the limbs and digits. It affects males more often than females and usually occurs at age 20-45 years.  It is strongly associated with heavy tobacco use.","Buerger Disease | Buerger's Disease | Thromboangiitis Obliterans | Thromboangiitis obliterans [Buerger's disease]",,,,,,,,,,,,,,,"312939|4111732","Thromboangiitis obliterans|Presenile gangrene",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0015462","Facial Nerve","C12714","Cranial nerve VII, which originates in the brainstem between the pons and the medulla. It controls the facial expression muscles and transports taste and sensation from the tongue and mouth.","Facial Nerve | FACIAL NERVE | Facial nerve structure (body structure) | NERVE, FACIAL | Seventh Cranial Nerve",,,,,,,,,,,,,,,"4209146","Facial nerve structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0456190","Left Ventricular End Diastolic Pressure","C120919","The pressure within the left ventricle following the completion of diastolic filling, just prior to systole.","Left Ventricular End Diastolic Pressure | LVEDP | Left ventricular end-diastolic pressure (mm Hg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456189","Left Ventricular Systolic Pressure","C120920","The pressure in the left ventricle at any point prior to the ejection of its contents into the aorta (systole).","Left Ventricular Systolic Pressure | LVSYSBP",,,,,,,,,,,,,,,"4174755","Left ventricular systolic pressure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0210403","Triapine","C2242","A synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity. Triapine inhibits the enzyme ribonucleotide reductase, resulting in the inhibition of the conversion of ribonucleoside diphosphates to deoxyribonucleotides necessary for DNA synthesis. This agent has been shown to inhibit tumor growth in vitro. (NCI04)","Triapine | 3-AP | 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone | 3-Apct | 3-aminopyridine-2-carboxaldehyde thiosemicarbazone | OCX-0191 | OCX-191 | OCX191 | PAN-811",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336936","VIPR1 Gene","C21413","This gene is involved in the regulation of intestinal cell processes that are affected by vasoactive intestinal peptides.","VIPR1 Gene | VIPR1 | Vasoactive Intestinal Peptide Receptor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1540289","CD200 Gene","C80105","This gene may play a role in the regulation of both function and proliferation in myeloid lineage cells.","CD200 Gene | CD200 | CD200 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417575","MYOG Gene","C94702","This gene is involved in muscle differentiation and transcription.","MYOG Gene | MYOG | Myogenin (Myogenic Factor 4) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417759","NOS1 Gene","C38562","This gene plays a role in cell-cell signaling, muscle contraction and synaptic transmission.","NOS1 Gene | NOS1 | Nitric Oxide Synthase 1 (Neuronal) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366502","TFAP2B Gene","C28543","This gene plays a role in regulation of transcription and cell differentiation. It is also involved in apoptosis, cell-cycle control and morphogenesis.","TFAP2B Gene | TFAP2B | Transcription Factor AP-2 Beta (Activating Enhancer Binding Protein 2 Beta) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332766","CLIC4 Gene","C21179","This gene plays a role in the regulation of several cellular processes, including cellular transport.","CLIC4 Gene | CLIC4 | Chloride Intracellular Channel 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707448","Columnar Cell Lesion of Breast","C54180","A morphologic spectrum of lesions that arise in the terminal ductal lobular units of the breast parenchyma.  These lesions are characterized by the presence of columnar epithelial cells that line dilated terminal ductal lobular units.  Cytological and architectural atypia may be absent or minimal, or significant enough to raise the possibility of atypical ductal hyperplasia or ductal carcinoma in situ.  Columnar cell lesions are frequently found in breast biopsies but their biologic significance is not known.","Breast Columnar Cell Lesion | Columnar Cell Lesion of Breast | Columnar Cell Lesion of the Breast | Columnar Cell Lesion of the Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0249880","Cyclin-Dependent Kinase Inhibitor 2A","C17786","Cyclin-dependent kinase inhibitor 2A (156 aa, ~17 kDa) is encoded by the human CDKN2A gene. This protein is involved in the inhibition of both cell proliferation and cell cycle progression.","Cyclin-Dependent Kinase Inhibitor 2A | CDK4 Inhibitor | CDK4 Inhibitor p16-INK4 | CDK4I | CDKN2A | CDKN2A Protein | CDKN2A-p16(INK4a) | Cell Cycle Negative Regulator Beta | Cyclin-Dependent Kinase 4 Inhibitor A | Cyclin-Dependent Kinase Inhibitor 2A, Isoforms 1/2/3 | Cyclin-Dependent Kinase Inhibitor 2A, Isoforms 1/2/3 | Cyclin-Dependent Kinase Inhibitor p12 | Cyclin-Dependent Kinase Inhibitor p16 | MTS-1 | MTS1 | MTS1 Protein | Multiple Tumor Suppressor 1 | P16 (CDKN2A) | P16(INK4A) | p16 | p16(INK4) | p16(INK4a) | p16-INK4 | p16-INK4a | p16INK4A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537736","MIR30A Gene","C80747","This gene is involved in the regulation of gene expression. While it has no known role in oncogenesis, MIR30A plays a role in the development of glomerular disease.","MIR30A Gene | MIR30A | MicroRNA 30a Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537775","MIR128-1 Gene","C81769","This gene is involved in the regulation of gene expression and plays a role in the development of glioma and carcinoma of the lung.","MIR128-1 Gene | MIR128-1 | MicroRNA 128-1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086511","Immunoglobulin Heavy Chain Variable, Diversity, and Joining Region Gene Rearrangement","C124221","A molecular abnormality indicating the presence of gene rearrangement(s) of the IGH locus in the regions encoding the variable, diversity and/or joining regions.","Immunoglobulin Heavy Chain Variable, Diversity, and Joining Region Gene Rearrangement | IGH-VDJ Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1155266","Inflammatory Response","C20151","A part of innate immunity, the Inflammatory Response occurs when injured tissues induce release of vasodilatory, opsonizing, and chemotactic mediators that attract macrophages and leukocytes to phagocytize and destroy foreign substances; dilate local blood vessels increasing local blood flow; increase capillary permeability; produce edematous swelling; and induce pain. Plasma- and cell-derived inflammatory mediators include Prostaglandins, Leukotrines, Cytokines, Lymphokines, Monokines, PAF, Histamine, Bradykinin, Complement, and Interferons.","Inflammatory Response | Inflammation Process | Inflammation Process, Multicellular",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087376","HER2/Neu Negative","C68749","The absence of detectable HER2/Neu in a tissue sample.","HER2/Neu Negative | ERBB2 Negative | HER-2 Negative | HER2 Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086510","Immunoglobulin Heavy Chain Diversity and Joining Region Gene Rearrangement","C124222","A molecular abnormality indicating the presence of gene rearrangement(s) of the immunoglobulin heavy chain (IGH) locus in the regions encoding the diversity and/or joining regions.","Immunoglobulin Heavy Chain Diversity and Joining Region Gene Rearrangement | IGH-DJ Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333542","FGFR2 Gene","C19931","This gene plays a role in mitogenesis and differentiation and mutations in the gene are associated with craniosynostotic syndromes and bone malformations.","FGFR2 Gene | FGFR2 | Fibroblast Growth Factor Receptor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1259992","Fibroblast Growth Factor Receptor 2, Human","C17411","Fibroblast growth factor receptor 2 (821 aa, ~92 kDa) is encoded by the human FGFR2 gene. This protein plays a role in heparin-dependent fibroblast growth factor signaling.","Fibroblast Growth Factor Receptor 2 | BEK | CD332 Antigen | EC 2.7.10.1 | FGFR-2 | FGFR-2 IIIc | FGFR2 | FGFR2 IIIc | FGFR2(IIIc) | FGFR2-IIIc | FGFR2IIIc | Fibroblast Growth Factor Receptor 2 Isoform IIIc | K-sam | KGF Receptor | KGFR | Keratinocyte Growth Factor Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831472","Arterial Hypervascularization","C113113","A radiologic finding indicating the presence of new vessels on arterial phase imaging within or surrounding a lesion.","Arterial Hypervascularization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985723","Baseline Indicator","C93514","Specifies whether the entity is a starting point to which other things may be compared.","Baseline Indicator | baselineIndicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985816","Original Quantity","C93614","The amount, including units, of something as first specified.","Original Quantity | originalQuantity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4024583","Adipose Tissue Deposition","C113303","The deposition of lipids in tissue.","Adipose Tissue Deposition | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510885","Angiogenic Switch","C19664","Loss of the balance between stimulation and inhibition of new blood vessel growth.  A required early step in cancer growth and metastasis.","Angiogenic Switch | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1321898","Blood in Stool","C113391","A finding indicating the presence of blood in stool. It is the result of gastrointestinal hemorrhage and it may be easily seen in stool or may be identified microscopically.","Blood in Stool | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333127","Comedo Necrosis","C36128","A morphologic finding that indicates the presence of a cancerous tumor with a central area that contains necrotic cancer cells.","Comedo Necrosis | Comedo Change | Comedo Lesion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334802","Morphologic Architectural Pattern","C35886","A microscopic finding that relates to the architectural patterns of a normal or abnormal cellular population in a tissue specimen.","Morphologic Architectural Pattern | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0733755","Position","C104788","A reference to the alignment of an object, a particular situation or view of a situation, or the location of an object.","Position | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0868996","Notation","C52087","A set of well defined rules for representing quantities and operations with symbols. (mathworld.wolfram.com)","Notation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986663","Multicentric Lesion","C94771","A term that usually refers to cancer growth and is defined by the presence of multiple lesions, each originating from a different clonal cellular population.","Multicentric Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985792","Location Description","C93589","The textual representation of the physical location of the subject or entity.","Location Description | locationDescription",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828224","Scarff-Bloom-Richardson Grading System","C113399","A breast cancer grading system that was the precursor of the Nottingham system.","Scarff-Bloom-Richardson Grading System | SBR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1301142","WHO Classification of Tumors","C113304","A classification of benign and malignant tumors by World Health Organization (WHO) experts based primarily on histologic findings.","WHO Classification of Tumors | Histologic Type (WHO)",,,,,,,,,,,,,,,"4264111","WHO tumor classification",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332629","Breast Fibrocystic Change, Proliferative Type","C6940","Breast fibrocystic change characterized by the presence of epithelial cell hyperplasia.  Epithelial atypia may be present or absent.","Breast Fibrocystic Change, Proliferative Type | Benign Proliferative Breast Disease | Proliferative Breast Disease | Proliferative Breast Lesion | Proliferative Fibrocystic Change | Proliferative Type Fibrocystic Change of Breast | Proliferative Type Fibrocystic Change of the Breast | benign proliferative breast disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987435","Bladder Cancer Pathologic Primary Tumor TNM Finding v6","C61202","A pathologic finding about one or more characteristics of bladder cancer, following the rules of the TNM AJCC v6 classification system as they pertain to staging of the primary tumor. TNM pathologic primary tumor findings are based on clinical findings supplemented by histopathologic examination of one or more tissue specimens acquired during surgery.","Bladder Cancer Pathologic Primary Tumor TNM Finding v6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1289829","Biomedical Packing Material","C42796","A material used in medical and dental practice for filling a natural cavity or deep or tunneled wound. The packing absorbs drainage from the wound so the tissues can heal from the inside out. Without the packing, the wound could close without healing the deep areas of the wound.","Biomedical Packing Material | Packing | Packing Material",,,,,,,,,,,,,,,"4041621","Packing material",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1272654","Wound Care Management","C116681","Any action taken to for the purpose of helping a wound heal; this generally involves keeping the affected area clean and dry, and may involve periodic debridement of any necrotic tissue, or washing of the area with antibacterial solution.","Wound Care Management | Wound Care | Wound Care Treatment | Wound Management | Wound Treatment",,,,,,,,,,,,,,,"4300828","Wound care management",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205641","Salivary Gland Basal Cell Adenocarcinoma","C3678","A rare adenocarcinoma of the major and minor salivary glands, originating from basaloid, myoepithelial and ductal cells.  While morphologically resembling basal cell carcinomas, it is a distinct entity.  The tumor is not encapsulated, may invade locally, and less frequently may metastasize.  It usually occurs in older patients.","Salivary Gland Basal Cell Adenocarcinoma | Basal Cell Adenocarcinoma | Basal Cell Adenocarcinoma of Salivary Gland | Basal Cell Adenocarcinoma of the Salivary Gland | Basal cell adenocarcinoma","8147/3","Basal cell adenocarcinoma",,,,,,,,,,,,,"4146684","Basal cell adenocarcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"CL521603","Bowel Preparation","C62659","Purging and cleansing of fecal and other matter from the bowel to assure subsequent clear evaluation of the bowel or to limit complications due to accidental surgical bowel perforation.","Bowel Preparation | ",,,,,,,,,,,,,,,"4074335","Preparation of bowel for procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2983695","Cervical Cancer by AJCC v6 Stage","C90493","A term that refers to the staging of cervical cancer according to the American Joint Committee on Cancer, 6th edition.","Cervical Cancer by AJCC v6 Stage | Cervical Carcinoma by AJCC v6 Stage | Cervical Carcinoma by AJCC v6 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1319315","Colorectal Adenocarcinoma","C5105","The most common type of colorectal carcinoma.  It is characterized by the presence of malignant glandular epithelial cells invading through the muscularis mucosa into the submucosa.  Histologic variants include mucinous adenocarcinoma, signet ring cell carcinoma, medullary carcinoma, serrated adenocarcinoma, cribriform comedo-type adenocarcinoma, and micropapillary adenocarcinoma.","Colorectal Adenocarcinoma | Adenocarcinoma of Large Bowel | Adenocarcinoma of Large Intestine | Adenocarcinoma of the Large Bowel | Adenocarcinoma of the Large Intestine | Colorectal (Colon or Rectal) Adenocarcinoma | Large Bowel Adenocarcinoma | Large Intestine Adenocarcinoma",,,,,,,,,,,,,,,"4256776","Adenocarcinoma of large intestine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1322279","Dilate","C28023","The act of expanding an aperture.","Dilate | Dilation | dilate",,,,,,,,,,,,,,,"4044550","Dilation - action",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009438","Common Bile Duct Stone","C34499","The presence of one or more stones in the common bile duct. They are composed either of cholesterol or, less commonly, calcium salts and bilirubin.","Common Bile Duct Stone | ",,,,,,,,,,,,,,,"4145717","Common bile duct calculus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828004","Slice Number","C111314","The numeric identifier used to identify an image slice.","Slice Number | SLICNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829581","Hyperechoic Focus","C113199","A radiologic finding describing a region in an image with a signal higher than that of the surrounding regions.","Hyperechoic Focus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829580","Hyperechoic Strand","C113200","A radiologic finding describing thin lines in an image with a signal higher than that of the surrounding tissue.","Hyperechoic Strand | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0182885","Embedding Medium","C113307","A material that infiltrates and supports a specimen and preserves its shape and structure for sectioning and microscopy.","Embedding Medium | Embedding Agent | Embedding Media",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830284","Extended Template Biopsy","C113105","Biopsy of the prostate that extends beyond the standard 10 to 12 cores.","Extended Template Biopsy | Extended Template Prostate Biopsy | MARCH9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829578","Hypoechoic Focus","C113127","A radiologic finding describing a region in an image with a signal lower than that of the surrounding regions.","Hypoechoic Focus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1659543","Breast Density","C94305","Describes the relative amount of different tissues present in the breast. A dense breast has less fat than glandular and connective tissue. Mammogram films of breasts with higher density are harder to read and interpret than those of less dense breasts.","Breast Density | Breast Composition | breast density",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830110","Fish-Mouth Papilla with Mucin Hypersecretion","C113103","An endoscopic finding indicating the presence of a wide-opened papilla filled with mucin.","Fish-Mouth Papilla with Mucin Hypersecretion | Fish-Mouth Papilla with Mucin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714556","Papilla","C113267","A small protruding portion of tissue.","Papilla | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827723","Anteroposterior Orientation","C85512","Directed from front to back.","Anteroposterior Orientation | ANTEROPOSTERIOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4229675","Pancreatic Cyst","C3304","A fluid-filled, epithelium-lined cyst located in the pancreas.","Pancreatic Cyst | Cyst of Pancreas | Cyst of the Pancreas | Pancreas Cyst",,,,,,,,,,,,,,,"4151134","Cyst of pancreas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039991","Thoracotomy","C15337","A surgical procedure in which an large incision is made into the chest wall, for the purpose of accessing organs inside the thoracic cavity.","Thoracotomy | Incision of Thorax | incision of Chest Wall | thoracotomy",,,,,,,,,,,,,,,"4073393","Opening of chest",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020256","Congenital Hydrocephalus","C98876","Hydrocephalus that is present at birth.","Congenital Hydrocephalus | ",,,,,,,,,,,,,,,"438244","Congenital hydrocephalus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086204","ClinicalTrials.gov","C124233","A Web-based resource that provides patients, their family members, health care professionals, researchers, and the public with access to information on publicly and privately supported clinical studies. A service of the National Institutes of Health (NIH), ClinicalTrials.gov is both a registry and a results database.","ClinicalTrials.gov | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829661","Hot Lesion","C113289","An area where large amounts of the radiotracer have accumulated and where there is a high level of chemical or metabolic activity.","Hot Lesion | Hot Spot | Hot Target",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879853","Bladder Cancer Clinical TNM Finding v6","C61200","A clinical finding about one or more characteristics of bladder cancer, following the rules of the TNM AJCC v6 classification system. TNM clinical findings are based on information obtained prior to the first definitive treatment through physical examination, diagnostic imaging, and biopsy.","Bladder Cancer Clinical TNM Finding v6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985452","Progesterone Receptor Test","C93129","A lab test to find out if cancer cells have progesterone receptors (proteins to which the hormone progesterone will bind). If the cells have progesterone receptors, they may need progesterone to grow, and this can affect how the cancer is treated.","Progesterone Receptor Test | progesterone receptor test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333895","Atypia Suspicious for Malignancy","C8350","A microscopic finding indicating the presence of an atypical neoplastic cellular infiltrate with cytologic characteristics and/or architectural patterns that are not diagnostic, but raise the possibility of malignancy.","Atypia Suspicious for Malignancy | ",,,,,,,,,,,,,,,"4194986","Atypia suspicious for malignancy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828463","Prostate Saturation Biopsy","C113288","Transperineal prostate biopsy that removes more than 20 cores. This is typically reserved for high-risk patients.","Prostate Saturation Biopsy | Extensive Prostate Biopsy | Prostate Saturation Needle Biopsy | Saturation Biopsy | Transperineal Template-Guided Stereotactic Saturation Prostate Biopsy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883008","Serum Alanine Aminotransferase Measurement","C61017","A quantitative measurement of the amount of alanine aminotransferase present in a sample of serum.","Serum Alanine Aminotransferase Measurement | Serum Alanine Transaminase Measurement | Serum SGPT Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523891","Serum Sodium Measurement","C61029","A quantitative measurement of the amount of sodium present in a sample of serum.","Serum Sodium Measurement | ",,,,,,,,,,,,,,,"4021154","Sodium measurement, serum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0587953","Urine Cytology","C94473","An examination of cells obtained from a sample of urine.","Urine Cytology | urine cytology",,,,,,,,,,,,,,,"4151045","Urine cytology",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3827469","Whole Blood Collection Tube","C113392","A blood collection tube used for the collection of whole blood.","Whole Blood Collection Tube | Yellow Top Blood Collection Tube | Yellowtop Blood Collection Tube",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020963","Immunologic Tolerance","C17712","An innate tolerance that prevents the body from attacking native proteins and tissue.","Immunologic Tolerance | Immune Tolerance | Immunological Tolerance | Self Tolerance | Tolerance | immune system tolerance",,,,,,,,,,,,,,,"4300753","Immunologic tolerance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0333418","Non-Necrotizing Granuloma","C113731","A granuloma that is not associated with necrotic changes.  The majority of cases are of non-infectious origin.  Causes include sarcoidosis, hypersensitivity pneumonitis, drug reactions, and Crohn disease.","Non-Necrotizing Granuloma | Granuloma, non necrotizing",,,,,,,,,,,,,,,"4322821","Non-necrotizing granulomatous inflammation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021386","Necrotizing Granuloma","C113732","A granuloma that contains areas of necrosis.  The majority of cases are of infectious origin.","Necrotizing Granuloma | Granuloma, necrotizing",,,,,,,,,,,,,,,"4098272","Necrotizing granulomatous inflammation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1452466","Thyroid Transcription Factor 1, Human","C73445","Thyroid transcription factor 1 (371 aa, ~39 kDa) is encoded by the human NKX2-1 gene. This protein is involved in transcriptional regulation.","Thyroid Transcription Factor 1 | Homeobox protein NK-2 homolog A | Homeobox protein Nkx-2.1 | NKX2-1 | TTF-1 | Thyroid Transcription Factor | Thyroid nuclear factor 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342952","Hypermetabolism","C124268","A finding indicating an abnormal increase in the body's basal metabolic rate.","Hypermetabolism | Increased Basal Metabolic Rate",,,,,,,,,,,,,,,"4242214","Hypermetabolism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0067385","Asymmetric Dimethylarginine","C124264","A dimethylated derivative of L-arginine where the two methyl groups are attached to arginine in an asymmetrical configuration. Asymmetric dimethylarginine (ADMA) is a competitive inhibitor of nitric oxide synthase (NOS) that is formed when S-adenosylmethionine protein N-methyltransferases transfer two methyl groups from S-adenosylmethionine to one of the two guanidine nitrogen groups of an arginine residue in a protein. ADMA is released when the protein is degraded and is a substrate for dimethylarginine dimethylaminohydrolase (DDAH). Free ADMA in plasma competes with the L-arginine for binding to the heme in NOS and inhibits nitric oxide (NO) synthesis. Decreased synthesis of NO inhibits vasodilation and leads to endothelial dysfunction. Elevated plasma levels of ADMA are seen in certain types of cancer, cardiovascular disease, hypertension, hyperlipidemia, type 2 diabetes mellitus, and increased oxidative stress.","Asymmetric Dimethylarginine | ADMA | Guanidino-N(1),N(1)-Dimethylarginine | Guanidino-N,N-Dimethylarginine | N(G),N(G)-Dimethylarginine | N(G1),N(G1)-Dimethylarginine | N,N-DIMETHYLARGININE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413516","CMA1 Gene","C124243","This gene plays a role in both extracellular matrix degradation and vasoactive peptide formation.","CMA1 Gene | CMA1 | Chymase 1, Mast Cell Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085863","Flow-Mediated Vasodilation","C124262","The percent change in arterial vessel diameter in response to an increase in blood flow caused by mechanical or chemical stimuli, which is usually measured using ultrasound-based methods. This measurement can reflect the functionality of the endothelium in the observed blood vessels.","Flow-Mediated Vasodilation | FMD | Flow-Mediated Vascular Reactivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086371","HPV Regulatory Protein E2 Antibody","C124259","Any immunoglobulin that recognizes human papillomavirus regulatory protein E2.","HPV Regulatory Protein E2 Antibody | Anti-HPV E2 Antibody | Anti-HPV Regulatory Protein E2 Antibody | Anti-Human Papillomavirus E2 Antibody | Anti-Human Papillomavirus Regulatory Protein E2 Antibody | HPV E2 Antibody | Human Papillomavirus E2 Antibody | Human Papillomavirus Regulatory Protein E2 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086372","HPV Replication Protein E1 Antibody","C124260","Any immunoglobulin that recognizes human papillomavirus replication protein E1.","HPV Replication Protein E1 Antibody | Anti-HPV ATP-Dependent Helicase E1 Antibody | Anti-HPV E1 Antibody | Anti-HPV Replication Protein E1 Antibody | Anti-Human Papillomavirus ATP-Dependent Helicase E1 Antibody | Anti-Human Papillomavirus E1 Antibody | Anti-Human Papillomavirus Replication Protein E1 Antibody | HPV ATP-Dependent Helicase E1 Antibody | HPV E1 Antibody | Human Papillomavirus ATP-Dependent Helicase E1 Antibody | Human Papillomavirus E1 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0166814","Integrin AlphaV/Beta6","C124258","Integrin alphaV/beta6 is a protein complex comprised of a heterodimer of integrin alpha-V and integrin beta-6. This complex plays a role in cell-matrix adhesion and viral entry.","Integrin AlphaV/Beta6 | Alpha(V)Beta(6) Integrin | Alpha-V Beta-6 | Alpha-V Beta-6 Integrin | Alpha-V/Beta-6 | Alpha-V/Beta-6 Integrin | Alpha-VBeta-6 | AlphaV Beta6 | AlphaV-Beta6 | AlphaV/Beta6 | Integrin Alpha-V Beta-6 | Integrin Alpha-V Beta-6 Protein | Integrin Alpha-V/Beta-6 | Integrin Alpha-VBeta-6 | Integrin AlphaV Beta6 | Integrin AlphaV-Beta6 | Integrin aVb6 | Integrin alpha (V) beta (6) | Integrin-aVBeta6 | aVb6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416857","LILRB1 Gene","C124240","This gene is involved in binding to class I MHC antigens.","LILRB1 Gene | LILRB1 | Leukocyte Immunoglobulin-Like Receptor, Subfamily B (With TM and ITIM Domains), Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086556","MAGEA1 Antibody","C124263","Any immunoglobulin that recognizes melanoma-associated antigen 1 protein.","MAGEA1 Antibody | Anti-CT1.1 Antibody | Anti-Cancer/Testis Antigen 1.1 Antibody | Anti-MAGE1 Antibody | Anti-MAGEA1 Antibody | Anti-Melanoma-Associated Antigen 1 Antibody | Antigen MZ2 E Antibody | Antigen MZ2-E Antibody | CT1.1 Antibody | Cancer/Testis Antigen 1.1 Antibody | MAGE1 Antibody | Melanoma-Associated Antigen 1 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538647","PIK3R5 Gene","C124254","This gene plays a role in the regulation of phosphoinositide-3-kinase gamma activity.","PIK3R5 Gene | PIK3R5 | Phosphoinositide-3-Kinase Regulatory Subunit 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1822730","SKAP1 Gene","C124237","This gene plays a role in T-cell receptor signaling.","SKAP1 Gene | SKAP1 | Src Kinase Associated Phosphoprotein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1822764","SLC45A2 Gene","C124234","This gene is involved in melanocyte differentiation.","SLC45A2 Gene | SLC45A2 | Solute Carrier Family 45 Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422417","TPSB2 Gene","C124246","This gene is involved in mast cell granule proteolytic activity.","TPSB2 Gene | TPSB2 | Tryptase Beta 2 (Gene/Pseudogene) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086963","Whole Transcriptome Sequencing","C124261","A procedure that can determine the nucleotide sequence for all of the RNA transcripts in an individual.","Whole Transcriptome Sequencing | RNA Sequencing | RNA-Seq | RNA-seq  (transcriptome sequencing) | RNA-seq (transcriptome sequencing) | RNAseq | Sequencing, Total RN | Total RNA Sequencing | Total RNA-Seq | Transcriptome Sequencing | WHOLE TRANSCRIPTOME SEQUENCING | WTSS | Whole Transcriptome Shotgun Sequencing | Whole-Transcriptome Sequencing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0519160","Free Triiodothyronine Measurement","C74787","The determination of the amount of free triiodothyronine present in a sample.","Free Triiodothyronine Measurement | Free T3 | T3FR | Triiodothyronine, Free",,,,,,,,,,,,,,,"4017355","Triiodothyronine, free measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1431519","Tumor Protein 63, Human","C91793","Tumor protein 63 (680 aa, ~77 kDa) is encoded by the human TP63 gene. This protein plays a role in the mediation of both transcription and limb morphogenesis.","Tumor Protein 63 | CUSP | Chronic Ulcerative Stomatitis Protein | Keratinocyte Transcription Factor KET | TP63 | Transformation-Related Protein 63 | Tumor Protein p73-Like | p40 | p51 | p63 | p73L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085692","Hemorrhagic Cystitis","C114666","Inflammation of the bladder resulting in bloody urine.","Hemorrhagic Cystitis | ",,,,,,,,,,,,,,,"4227291","Hemorrhagic cystitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3852463","Letermovir","C115099","An orally bioavailable, non-nucleoside, 3,4-dihydroquinazolinyl acetic acid and inhibitor of the pUL56 subunit of the viral terminase complex of cytomegalovirus (CMV), with potential CMV-specific antiviral activity. Upon oral administration, letermovir binds to the pUL56 subunit of the viral terminase complex of CMV and prevents the cleavage of concatemeric DNA into monomeric genome length DNA. As this agent interferes with viral DNA processing and subsequent viral DNA packaging into procapsids, CMV replication is blocked and CMV infection is prevented.","Letermovir | 2-((4S)-8-Fluoro-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-4H-quinazolin-4-yl)acetic Acid | AIC246 | LETERMOVIR | MK-8228 | Prevymis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3886763","Brincidofovir","C90587","An alkoxyalkyl ester prodrug containing the synthetic, acyclic nucleoside monophosphate analog cidofovir linked, through its phosphonate group, to a lipid, 3-hexadecyloxy-1-propanol, with antiviral activity against double-stranded DNA viruses. Upon oral administration, brincidofovir crosses the intestinal wall and penetrates target viral-infected cells before being cleaved to the free antiviral agent cidofovir. In turn, cidofovir is phosphorylated by pyruvate kinases to its active metabolite cidofovir diphosphate. Cidofovir diphosphate, bearing structural similarity to nucleotides, competes with deoxycytosine-5-triphosphate (dCTP) for viral DNA polymerase and gets incorporated into the growing viral DNA strands. As a result, it prevents further DNA polymerization and disrupts DNA replication of viruses. Compared to cidofovir, which is given intravenously, hexadecyloxypropyl-cidofovir shows better oral bioavailability, less toxicity and enhanced cellular penetration.","Brincidofovir | 1-O-hexadecylpropanediol-CDV | BCV | BRINCIDOFOVIR | CMX001 | Cidofovir Hexadecyloxypropyl Ester | HDP-CDV | HDP-Cidofovir | Hexadecyloxypropyl-Cidofovir | Phosphonic Acid, p-(((1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy)methyl)-, Mono(3-(hexadecyloxy)propyl) Ester",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515410","Therapy Evaluation","C15857","Determining the efficacy of a particular therapy or treatment","Therapy Evaluation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274660","Catalog Number","C99286","The identifier assigned to a product, usually in the list of products published by a reseller or manufacturer.","Catalog Number | CATNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640205","Primary Device Identifier","C101722","The main identifier for a device.","Primary Device Identifier | Primary DI Number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1136454","Refusal to Participate","C124784","Declining to take part in activities or procedures that are available to, or requested or expected of, an individual.","Refusal to Participate | Decline to Participate | Declined to Participate | Refused to Participate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086671","Oral Mucositis WHO Grading Scale","C124785","A grading system for mucositis based on clinical appearance and functional status.","Oral Mucositis WHO Grading Scale | OMGS | Oral Mucositis Grading Scale | WHO OMGS | WHO Oral Mucositis Grading Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086667","Oral Mucositis WHO Grade 0","C124786","None; no oral mucositis.","Oral Mucositis WHO Grade 0 | Oral Mucositis Grade 0 | WHO Oral Mucositis Grade 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086670","Oral Mucositis WHO Grade I","C124787","Mild mucositis with oral soreness and erythema.","Oral Mucositis WHO Grade I | Oral Mucositis Grade I | Oral Mucositis WHO Grade 1 | WHO Oral Mucositis Grade 1 | WHO Oral Mucositis Grade I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086668","Oral Mucositis WHO Grade II","C124788","Moderate mucositis with oral erythema and ulcers; solid diet tolerated.","Oral Mucositis WHO Grade II | Oral Mucositis Grade II | Oral Mucositis WHO Grade 2 | WHO Oral Mucositis Grade 2 | WHO Oral Mucositis Grade II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087064","Oral Mucositis WHO Grade III","C124789","Severe mucositis with oral ulcers; liquid diet only.","Oral Mucositis WHO Grade III | Oral Mucositis Grade III | Oral Mucositis WHO Grade 3 | WHO Oral Mucositis Grade 3 | WHO Oral Mucositis Grade III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086669","Oral Mucositis WHO Grade IV","C124790","Life-threatening mucositis with oral ulcers; oral alimentation impossible.","Oral Mucositis WHO Grade IV | Oral Mucositis Grade IV | Oral Mucositis WHO Grade 4 | WHO Oral Mucositis Grade 4 | WHO Oral Mucositis Grade IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423062","SIRT1 Gene","C80113","This gene may be involved in the regulation of protein acetylation.","SIRT1 Gene | SIRT1 | Sirtuin 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826538","PALLD Gene","C79791","This gene is involved in the organization of the actin cytoskeleton.","PALLD Gene | PALLD | Palladin, Cytoskeletal Associated Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413750","CSF2RA Gene","C39047","This gene plays an important role in cellular proliferation and differentiation.","CSF2RA Gene | CSF2RA | Colony Stimulating Factor 2 Receptor, Alpha, Low-Affinity (Granulocyte-Macrophage) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987530","Lorvotuzumab Mertansine","C38714","An immunoconjugate of a humanized murine monoclonal antibody (huN-901) and DMI, a semi-synthetic derivative of the plant-derived ansa macrolide maytansine. The antibody moiety of BB-10901 selectively attaches to CD56 antigen, a neural cell adhesion molecule (NCAM)) expressed on the surface of cells of small cell lung cancer (SCLC) and other neuroendocrine (NE) tumors. Thus, the DMI conjugate is targeted specifically to CD56-expressing tumor cells, where it inhibits tubulin polymerization and assembly, resulting in inhibition of mitosis and cell cycle arrest in the S phase. (NCI04)","Lorvotuzumab Mertansine | Anti-Human NCAM-1 Monoclonal Antibody N901 | BB-10901 | IMGN901 | LORVOTUZUMAB MERTANSINE | huN901-DM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280849","monoclonal antibody 3F8","C2370","A murine monoclonal antibody directed against the cell-surface, tumor-associated antigen ganglioside GD2. Vaccination with monoclonal antibody 3F8 may stimulate a host cytotoxic immune response against tumors that express ganglioside GD2. (NCI04)","Monoclonal Antibody 3F8 | 3F8 | 3F8 Monoclonal Antibody | ANTI-GD2 MONOCLONAL ANTIBODY 3F8 | MoAb 3F8 | anti-Ganglioside (GD2) Monoclonal Antibody 3F8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830167","FDA Unique Device Identifier","C112279","A unique numeric or alphanumeric code that contains the device identifier and a production identifier such as the lot or batch number, the serial number and/or expiration date.","FDA Unique Device Identifier | FDA Unique Device Identification | FDAUDI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640203","Unit of Use Device Identifier","C101717","An identifier to associate the use of device on a patient when the Universal Device Identifier is applied to a package of multiple devices.","Unit of Use Device Identifier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274659","Model Number","C99285","The identifier assigned to a particular design of a device.","Model Number | MODEL | Model Identifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826996","Human Cells or Tissue Product","C101674","A product that contains human cells or tissue.","Human Cells or Tissue Product | HCT/P | Human Cell, Tissue, or Cellular or Tissue-based Product",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705212","Kit","C50021","A collection of objects or devices collected together for a particular function or purpose.","Kit Device | Kit | Kit Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880146","Combination Product","C54696","A product comprised of two or more regulated components, i.e., drug and device, biologic and device, that are physically, chemically, or otherwise combined or mixed and produced as a single entity; or two or more separate products packaged together in a single package or as a unit and comprised of drug and device products, device and biological products, or biological and drug products; or a drug, device, or biological product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, device, or biological product where both are required to achieve the intended use, indication, or effect and where upon approval of the proposed product the labeling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant change in dose; or any investigational drug, device, or biological product packaged separately that according to its proposed labeling is for use only with another individually specified investigational drug, device, or biological product where both are required to achieve the intended use, indication, or effect.","Combination Product | COMBINATION PRODUCT | Combination Medical Product | combination product",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493882","Intravenous Immunoglobulin Therapy","C121331","The administration of a blood product derived from pooled IgG antibodies extracted from donor plasma delivered intravenously. It is used to treat multiple disorders, including immunodeficiencies, autoimmune disorders, and active infections.","Intravenous Immunoglobulin Therapy | Gamma Globulin | Gamma Globulin Therapy | IVIG | IVIG Therapy | Immune Globulin | Immune Globulin Therapy | Intravenous Immunoglobulin | Intravenous immunoglobulin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985556","Liquid-based Pap Test","C93331","A type of Pap test. A Pap test is a procedure in which cells are scraped from the cervix for examination under a microscope. It is used to detect cancer or changes that may lead to cancer. A Pap test can also show conditions that are not cancer, such as infection or inflammation. In a liquid-based Pap test, the cells are rinsed into a small container of liquid. The cells are then placed onto slides by a special machine and examined under a microscope to see if the cells are abnormal.","Liquid-based Pap Test | liquid-based Pap test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085994","Antipneumocystis Agent","C124791","Any agent used in the treatment of Pneumocystis jiroveci pneumonia (PJP), formerly known as Pneumocystis carinii pneumonia (PCP).","Antipneumocystis Agent | Anti-pneumocystis Agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085795","Amphotericin Product","C124792","Any formulation containing amphotericin B as the active agent for the treatment of fungal infections.","Amphotericin Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1541677","Lestaurtinib","C48402","An orally bioavailable indolocarbazole derivative with antineoplastic properties. Lestaurtinib inhibits autophosphorylation of FMS-like tyrosine kinase 3 (FLT3), resulting in inhibition of FLT3 activity and induction of apoptosis in tumor cells that overexpress FLT3. (NCI05)","Lestaurtinib | 9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)- | CEP 701 | CEP-701 | CEP701 | KT-5555 | LESTAURTINIB | SPM-924 | lestaurtinib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2980091","Quizartinib","C68936","An orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases.","Quizartinib | (2E)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3S)-Oxolan-3-Yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)but-2-Enamide | AC 220 | AC-220 | AC010220 | AC220 | ASP 2689 | ASP-2689 | ASP2689 | N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo [2,1-b] [1,3] benzothiazol 2-yl]phenyl}urea | QUIZARTINIB | Vanflyta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3467949","Ixazomib","C97940","An active metabolite of MLN9708, a second generation, boron containing peptide proteasome inhibitor (PI) with potential antineoplastic activity. Ixazomib binds to and inhibits the 20S catalytic core of the proteasome, thereby blocking the targeted proteolysis normally performed by the proteasome, which results in an accumulation of unwanted or misfolded proteins; disruption of various cell signaling pathways may follow, resulting in the induction of apoptosis. Compared to first generation PIs, second generation PIs may have an improved pharmacokinetic profile with increased potency and less toxicity. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquinated.","Ixazomib | IXAZOMIB | MLN 2238 | MLN-2238 | MLN2238 | {(1R)-1-[(2,5-dichlorobenzamido)acetamido]-3-methylbutyl}boronic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1443643","Proteasome Inhibitor","C2160","Any substance that inhibits the proteasome complex, an enzyme complex responsible for degradation of ubiquitinated proteins. Inhibition of proteasome activity and ubiquitin-proteasome mediated proteolysis results in an accumulation of poly-ubiquitinated proteins, which may result in the disruption of cellular processes, cell cycle arrest, the induction of apoptosis, and the inhibition of tumor growth and angiogenesis.","Proteasome Inhibitor | proteasome inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086297","FLT3 Inhibitor","C124800","Any drug or substance that inhibits the activity of receptor-type tyrosine-protein kinase FLT3 protein.","FLT3 Inhibitor | Receptor-Type Tyrosine-Protein Kinase FLT3 Protein Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086017","BTK Inhibitor","C124801","Any drug or substance that inhibits the activity of tyrosine-protein kinase BTK protein.","BTK Inhibitor | Tyrosine-Protein Kinase BTK Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0142160","Oxiconazole Nitrate","C47644","The nitrate salt form of oxiconazole, a broad spectrum imidazole derivative with antifungal activity. Although the exact mechanism of action has yet to be fully elucidated, oxiconazole, like other azole antifungals, most likely inhibits the cytochrome P450-dependent demethylation of lanosterol. This prevents the synthesis of ergosterol which is a crucial component of fungal cell membrane. By disrupting fungal cell membrane synthesis and integrity, oxiconazole alters fungal cell membrane permeability, promotes loss of essential intracellular components and eventually inhibits fungal cell growth.","Oxiconazole Nitrate | (Z)-1-(2-(2,4-Dichlorophenyl)-2-(((2,4-dichlorophenyl)oxy)imino)ethyl)-1H-imidazole Mononitrate | Ethanone, 1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)-, O-((2,4-dichlorophenyl)methyl)oxime,(Z)-, Mononitrate | OXICONAZOLE NITRATE | Oxistat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086538","Knowledge, Understanding and Judgment Scale","C124803","A questionnaire developed to assess a patient's knowledge of prostate cancer, understanding of treatment choices, and judgment of survival with and without treatment.","Knowledge, Understanding and Judgment Scale | KUJ | KUJ Scale | Knowledge, Understanding and Judgement (KUJ) Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086867","Stage of Your Cancer","C124804","A question about the self-reported stage of an individual's cancer.","Stage of Your Cancer | The stage of your cancer is | Your Cancer Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086366","Grade of Your Cancer","C124805","A question about the self-reported grade of an individual's cancer.","Grade of Your Cancer | The grade, or aggressiveness, of your cancer is | Your Cancer Grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086604","Most Recent PSA Level","C124806","A question about an individual's most recent self-reported PSA level.","Most Recent PSA Level | Your Most Recent PSA Level | Your most recent PSA level is",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086602","Most Common Complication After Surgery for Prostate Cancer","C124807","A question about an individual's knowledge of the most common complication after surgery for prostate cancer.","Most Common Complication After Surgery for Prostate Cancer | After surgery, the most common complication is",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086601","Most Common Complication After Radiotherapy for Prostate Cancer","C124808","A question about an individual's knowledge of the most common complication after radiotherapy for prostate cancer.","Most Common Complication After Radiotherapy for Prostate Cancer | After radiotherapy, the most common complication is",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086603","Most Common Complication Without Treatment for Prostate Cancer","C124809","A question about an individual's knowledge of the most common complication without treatment for prostate cancer.","Most Common Complication Without Treatment for Prostate Cancer | After no treatment, the most common complication is",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086599","More Than Half of Patients Will Have Sexual or Urinary Symptoms Within Five Years Without Treatment for Prostate Cancer","C124810","A question about whether an individual thinks that, without treatment, more than half of patients will have sexual or urinary symptoms in 5 years.","More Than Half of Patients Will Have Sexual or Urinary Symptoms Within Five Years Without Treatment for Prostate Cancer | Without treatment, more than half of patients will have sexual or urinary symptoms in 5 years",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086665","One of Three Patients Will Have Urine Control Problem After Surgery for Prostate Cancer","C124811","A question about whether an individual thinks that one of three patients who has surgery will have some problem with control of urine after surgery.","One of Three Patients Will Have Urine Control Problem After Surgery for Prostate Cancer | One of three patients who has surgery will have some problem with control of urine after surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086663","One of Ten Patients Will Need Diapers Due to Very Poor Urine Control After Surgery for Prostate Cancer","C124813","A question about whether an individual thinks that one of ten patients who has surgery will need diapers due to very poor control of urine after surgery.","One of Ten Patients Will Need Diapers Due to Very Poor Urine Control After Surgery for Prostate Cancer | One of 10 patients who has surgery will need diapers due to very poor control of urine after surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086905","Three of Four Patients Will Have Penile Erections Firm Enough to Have Sexual Intercourse After Surgery for Prostate Cancer","C124814","A question about whether an individual thinks that three of four patients who have surgery will have penile erections firm enough to have sexual intercourse after surgery.","Three of Four Patients Will Have Penile Erections Firm Enough to Have Sexual Intercourse After Surgery for Prostate Cancer | Three of four patients who have surgery will have penile erections firm enough to have sexual intercourse after surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086327","Four of Five Patients Are Able to Have Erections Firm Enough to Have Sexual Intercourse After External Radiation Therapy for Prostate Cancer","C124815","A question about whether an individual thinks that four of five patients who get external radiation therapy are able to have erections firm enough to have intercourse after treatment.","Four of Five Patients Are Able to Have Erections Firm Enough to Have Sexual Intercourse After External Radiation Therapy for Prostate Cancer | Four of five patients who get radiation rays (not seeds) are able to have erections firm enough to have intercourse after radiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086328","Four of Five Patients Are Able to Have Erections Firm Enough to Have Sexual Intercourse After Radiation Seeds for Prostate Cancer","C124816","A question about whether an individual thinks that four of five patients who get radiation seeds are able to have erections firm enough to have intercourse after treatment.","Four of Five Patients Are Able to Have Erections Firm Enough to Have Sexual Intercourse After Radiation Seeds for Prostate Cancer | Four of five patients who get radiation seeds are able to have erections firm enough to have intercourse after radiation seeds",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086664","One of Three Patients Will Die Within Ten Years Due to Prostate Cancer Without Treatment","C124817","A question about whether an individual thinks that, without treatment, one out of three patients will die within ten years due to prostate cancer.","One of Three Patients Will Die Within Ten Years Due to Prostate Cancer Without Treatment | Without treatment, one out of three patients will die within 10 years due to prostate cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086915","Treatment Decisions Should be Made Within Six Months or Prostate Cancer Can Spread Beyond Cure","C124818","A question about whether an individual thinks that you should make your decision within six months about which kind of treatment to receive, or the cancer can spread beyond curable.","Treatment Decisions Should be Made Within Six Months or Prostate Cancer Can Spread Beyond Cure | You should make your decision about which kind of treatment within 6 months, or the cancer can spread beyond cure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086758","Prostate Cancer Will Spread in One of Three Patients Within Ten Years Without Treatment","C124819","A question about whether an individual thinks that, without treatment, cancer will spread in one of three patients within ten years.","Prostate Cancer Will Spread in One of Three Patients Within Ten Years Without Treatment | Without treatment, cancer will spread in one of three patients within 10 years",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086465","How Long Do You Expect to Live Without Any Treatment for Prostate Cancer","C124820","A question about how long an individual expects to live without any treatment for prostate cancer, keeping in mind their age and health at present.","How Long Do You Expect to Live Without Any Treatment for Prostate Cancer | Keeping in mind your age and health at present, how long do you expect you will live without any treatment for prostate cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086464","How Long Do You Expect to Live After Treatment for Prostate Cancer","C124821","A question about how long an individual expects to live after the treatment of their choice for prostate cancer, keeping in mind their age and health at present.","How Long Do You Expect to Live After Treatment for Prostate Cancer | Keeping in mind your age and health at present, how long do you expect you will live after the treatment of your choice for prostate cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086857","Slow Growing","C124823","An indication that something is growing at a slow rate.","Slow Growing | Slow Growth Rate | Slow growing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503117","Medium Growth Rate","C124824","An indication that something is growing at an intermediate rate.","Medium Growth Rate | Medium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086299","Fast Growing","C124825","An indication that something is growing at a fast rate.","Fast Growing | Fast Growth Rate | Fast growing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086946","Very Fast Growing","C124826","An indication that something is growing at a very fast rate.","Very Fast Growing | Very Fast Growth Rate | Very fast growing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439075","PSA Level Less than Five","C124828","A blood concentration of prostate specific antigen below 5 ng/mL.","PSA Level Less than Five | <5 | Less than Five | PSA Level Less than 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086718","PSA Level Five to Ten","C124829","A blood concentration of prostate specific antigen between 5 and 10 ng/mL.","PSA Level Five to Ten | 5-10 | Five to Ten | PSA Level 5 to 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055223","Clinical Response","C123619","An evaluation of the clinical changes that result from treatment.","Clinical Response | CLINRESP | Clinical",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086719","PSA Level Ten to Fifty","C124830","A blood concentration of prostate specific antigen between 10 and 50 ng/mL.","PSA Level Ten to Fifty | 10-50 | PSA Level 10 to 50 | Ten to Fifty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084918","PSA Level Greater than Fifty","C124831","A blood concentration of prostate specific antigen above 50 ng/mL.","PSA Level Greater than Fifty | >50 | Greater than Fifty | PSA Level Greater than 50",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4032686","No Complication","C124832","An indication that no complication occurred.","No Complication | No complication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086543","Life Expectancy Less than Five Years","C124833","A response indicating that an individual expects to, or is expected to, live less than five years.","Life Expectancy Less than Five Years | < 5 years | Less Than Five Years",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086544","Life Expectancy Less than Ten Years","C124834","A response indicating that an individual expects to, or is expected to, live less than ten years.","Life Expectancy Less than Ten Years | < 10 years | Less Than Ten Years",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084914","Life Expectancy Less than Twenty Years","C124835","A response indicating that an individual expects to, or is expected to, live less than twenty years.","Life Expectancy Less than Twenty Years | < 20 years | Less Than Twenty Years",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084911","Life Expectancy Greater than Twenty Years","C124836","A response indicating that an individual expects to, or is expected to, live greater than twenty years.","Life Expectancy Greater than Twenty Years | > 20 years | Greater Than Twenty Years",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825186","Exempt Device","C80438","A medical device that is exempt from FDA premarket notification requirements.","Exempt Device | EXEMPT DEVICE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825189","Premarket Device Notification","C80442","A premarket submission made to FDA to demonstrate that a device to be marketed is at least as safe and effective as a legally marketed device that is not subject to PMA (Premarket Authorization).","Premarket Device Notification | 510(k) | PMN | PREMARKET NOTIFICATION | Premarket Device Notification (510k) | Premarket Notification | Premarket Notification 510(K) | Premarket Notification Submission",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825188","Premarket Device Application","C80441","A premarket submission made to FDA to review and evaluate the safety and effectiveness of a Class III medical device.","Premarket Device Application | PMA | PREMARKET APPLICATION | Premarket Approval",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348610","Supplemental Regulatory Submission","C70862","Additional documentary support presented to a regulatory agency to bolster a previous submission.","Supplemental Regulatory Submission | Supplement Number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518572","Ommaya Reservoir Tap","C38077","A procedure to remove cerebrospinal fluid from an Ommaya reservoir to detect any abnormal cells.","Ommaya Reservoir Tap | Ommaya Reservoir Access",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021060","Immunologic Techniques","C116640","Any method that is used to elicit and/or measure an immune response, or to identify and/or measure antigens triggering antibodies.","Immunologic Technique | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0887950","Genomics","C84343","The study of the structure, function, expression, evolution, mapping and editing of genomes.","Genomics | Genomics Research | Genomics Research | genomics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086726","Past Seven Days Frequency of Loss of Control of Bowel Movements","C124857","A question about the frequency of an individual's loss of control of bowel movements over the past seven days.","Past Seven Days Frequency of Loss of Control of Bowel Movements | Frequency of Loss of Control of Bowel Movements Past Seven Days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086727","Past Seven Days Loss of Control of Bowel Movements Interferes with Usual or Daily Activities","C124858","A question about how much an individual's loss of control of bowel movements interfered with usual or daily activities over the past seven days.","Past Seven Days Loss of Control of Bowel Movements Interferes with Usual or Daily Activities | Loss of Control of Bowel Movements Interferes with Usual or Daily Activities Past Seven Days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086503","Hyperdiploid with Status of Chromosomes 4 and 10 Unknown","C124873","Having a chromosomal number greater than the normal diploid number, with the status of chromosomes 4 and 10 unknown.","Hyperdiploid with Status of Chromosomes 4 and 10 Unknown | Hyperdiploid with Status of 4 and 10 Unknown | Hyperdiploid; Status of 4 and 10 Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086524","Intrachromosomal Amplification of Chromosome 21","C124874","A cytogenetic abnormality that refers to the allelic gain of an internal part of chromosome 21. It is a rare high-risk chromosomal abnormality that occurs in approximately 2-5% of pediatric patients with B-cell precursor Acute Lymphoblastic Leukemia. This abnormality has been associated with a poor outcome in patients treated by standard protocols.","Intrachromosomal Amplification of Chromosome 21 | iAMP21",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086776","Readiness to Quit Smoking Score 6","C124866","A subjective score of 6: I am thinking about cutting down or quitting on a scale that ranges from 0: I am not ready to quit to 10: I am ready to quit now.","Readiness to Quit Smoking Score 6 | I am thinking about cutting down or quitting | Readiness Score 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086222","Contemplation Ladder for Smoking Cessation","C124859","A self-administered questionnaire that measures a person's readiness to consider smoking cessation.","Contemplation Ladder for Smoking Cessation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086780","Readiness to Quit Smoking","C124860","A question about a person's readiness to quit smoking.","Readiness to Quit Smoking | Please complete the following concerning your readiness to quit smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086221","Contemplation Ladder Readiness to Quit Smoking Likert Scale","C124861","A scale for the subjective scoring of readiness to quit smoking that ranges from 0: I am not ready to quit to 10: I am ready to quit now.","Contemplation Ladder Readiness to Quit Smoking Likert Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086770","Readiness to Quit Smoking Score 10","C124862","A subjective score of 10 on a scale that ranges from 0: I am not ready to quit to 10: I am ready to quit now.","Readiness to Quit Smoking Score 10 | I am ready to quit now | Readiness Score 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086779","Readiness to Quit Smoking Score 9","C124863","A subjective score of 9 on a scale that ranges from 0: I am not ready to quit to 10: I am ready to quit now.","Readiness to Quit Smoking Score 9 | Readiness Score 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086778","Readiness to Quit Smoking Score 8","C124864","A subjective score of 8: I have cut down or am seriously thinking of quitting on a scale that ranges from 0: I am not ready to quit to 10: I am ready to quit now.","Readiness to Quit Smoking Score 8 | I have cut down or am seriously thinking of quitting | Readiness Score 8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086777","Readiness to Quit Smoking Score 7","C124865","A subjective score of 7 on a scale that ranges from 0: I am not ready to quit to 10: I am ready to quit now.","Readiness to Quit Smoking Score 7 | Readiness Score 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086775","Readiness to Quit Smoking Score 5","C124867","A subjective score of 5 on a scale that ranges from 0: I am not ready to quit to 10: I am ready to quit now.","Readiness to Quit Smoking Score 5 | Readiness Score 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086774","Readiness to Quit Smoking Score 4","C124868","A subjective score of 4: I think I should quit but I'm not quite ready on a scale that ranges from 0: I am not ready to quit to 10: I am ready to quit now.","Readiness to Quit Smoking Score 4 | I think I should quit but I'm not quite ready | Readiness Score 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086773","Readiness to Quit Smoking Score 3","C124869","A subjective score of 3 on a scale that ranges from 0: I am not ready to quit to 10: I am ready to quit now.","Readiness to Quit Smoking Score 3 | Readiness Score 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086772","Readiness to Quit Smoking Score 2","C124870","A subjective score of 2: I think I need to consider quitting some day on a scale that ranges from 0: I am not ready to quit to 10: I am ready to quit now.","Readiness to Quit Smoking Score 2 | I think I need to consider quitting some day | Readiness Score 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086771","Readiness to Quit Smoking Score 1","C124871","A subjective score of 1 on a scale that ranges from 0: I am not ready to quit to 10: I am ready to quit now.","Readiness to Quit Smoking Score 1 | Readiness Score 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086769","Readiness to Quit Smoking Score 0","C124872","A subjective score of 0 on a scale that ranges from 0: I am not ready to quit to 10: I am ready to quit now.","Readiness to Quit Smoking Score 0 | I am not ready to quit | Readiness Score 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086860","Smoking Self-Efficacy Questionnaire","C124884","A questionnaire measuring the confidence of current and former smokers in their ability to abstain from smoking in high-risk situations. Two six-item subscales measure confidence in ability to refrain from smoking when facing internal and external stimuli.","Smoking Self-Efficacy Questionnaire | SEQ12 | Smoking Self-Efficacy Questionnaire (SEQ-12)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086793","Refrain from Smoking when Nervous","C124885","A question about an individual's certainty that they can avoid smoking when they are feeling nervous.","Refrain from Smoking when Nervous | When I feel nervous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086789","Refrain from Smoking when Depressed","C124886","A question about an individual's certainty that they can avoid smoking when they are feeling depressed.","Refrain from Smoking when Depressed | When I feel depressed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086787","Refrain from Smoking when Angry","C124887","A question about an individual's certainty that they can avoid smoking when they are feeling angry.","Refrain from Smoking when Angry | When I am angry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086795","Refrain from Smoking when Very Anxious","C124888","A question about an individual's certainty that they can avoid smoking when they are feeling very anxious.","Refrain from Smoking when Very Anxious | When I Feel Very Anxious",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086794","Refrain from Smoking when Thinking about a Difficult Problem","C124889","A question about an individual's certainty that they can avoid smoking when they are thinking about a difficult problem.","Refrain from Smoking when Thinking about a Difficult Problem | When I want to think about a difficult problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086791","Refrain from Smoking when Feeling the Urge to Smoke","C124893","A question about an individual's certainty that they can avoid smoking when they are feeling the urge to smoke.","Refrain from Smoking when Feeling the Urge to Smoke | When I feel the urge to smoke",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086792","Refrain from Smoking when Having a Drink with Friends","C124894","A question about an individual's certainty that they can avoid smoking when having a drink with friends.","Refrain from Smoking when Having a Drink with Friends | When having a drink with friends",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086788","Refrain from Smoking when Celebrating Something","C124895","A question about an individual's certainty that they can avoid smoking when celebrating something.","Refrain from Smoking when Celebrating Something | When celebrating something",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086790","Refrain from Smoking when Drinking Alcohol","C124896","A question about an individual's certainty that they can avoid smoking when drinking alcohol.","Refrain from Smoking when Drinking Alcohol | When drinking beer, wine or other spirits",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086796","Refrain from Smoking when with Other Smokers","C124897","A question about an individual's certainty that they can avoid smoking when they are with other smokers.","Refrain from Smoking when with Other Smokers | When I am with smokers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084851","Refrain from Smoking After a Meal","C124898","A question about an individual's certainty that they can avoid smoking after a meal.","Refrain from Smoking After a Meal | After a meal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086786","Refrain from Smoking When Having Coffee or Tea","C124899","A question about an individual's certainty that they can avoid smoking when having coffee or tea.","Refrain from Smoking When Having Coffee or Tea | When having coffee or tea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086629","Not At All Sure","C124900","A subjective answer of non-agreement regarding the certainty of something.","Not At All Sure | Not at All Certain | Not at all sure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086632","Not Very Sure","C124901","A subjective answer of weak agreement regarding the certainty of something.","Not Very Sure | Not Very Certain | Not very sure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086600","More or Less Sure","C124904","A subjective answer of partial agreement regarding the certainty of something.","More or Less Sure | More or Less Certain | More or less sure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086298","Fairly Sure","C124905","A subjective answer of agreement regarding the certainty of something.","Fairly Sure | Fairly Certain | Fairly sure | Relatively Certain | relatively certain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086990","Absolutely Sure","C124906","A subjective answer of strong agreement regarding the certainty of something.","Absolutely Sure | Absolutely Certain | Absolutely sure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0814442","smoking abstinence","C124908","To abstain or keep oneself from smoking.","Refrain from Smoking | Abstain from Smoking | Abstinence from Cigarette Smoking | Abstinence from Cigarettes | Smoking Abstinence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984310","Primary Immunodeficiency Pathway","C91500","Primary immunodeficiencies (PIs) are a heterogeneous group of disorders, which affect cellular and humoral immunity or non-specific host defense mechanisms mediated by complement proteins, and cells such as phagocytes and natural killer (NK) cells. These disorders of the immune system cause increased susceptibility to infection, autoimmune disease, and malignancy. Most of PIs are due to genetic defects that affect cell maturation or function at different levels during hematopoiesis. Disruption of the cellular immunity is observed in patients with defects in T cells or both T and B cells. These cellular immunodeficiencies comprise 20% of all PIs. Disorders of humoral immunity affect B-cell differentiation and antibody production. They account for 70% of all PIs.","Primary Immunodeficiency Pathway | Primary immunodeficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206491","Bispecific Monoclonal Antibody","C28227","Any monoclonal antibody that targets two different antigens. A bispecific monoclonal antibody is made up of two different monoclonal antibodies or antibody fragments and contains two different antigen-binding sites.","Bispecific Monoclonal Antibody | bispecific monoclonal antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896738","Gilteritinib","C116722","An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), with potential antineoplastic activity. Upon administration, gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL, ALK and LTK. This may result in an inhibition of FLT3-, AXL-, ALK-, and LTK-mediated signal transduction pathways and reduced proliferation in cancer cells that overexpress these RTKs. FLT3, AXL, ALK, and LTK, which are overexpressed or mutated in a variety of cancer cell types, play key roles in tumor cell growth and survival.","Gilteritinib | 6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide | ASP 2215 | ASP-2215 | ASP2215 | GILTERITINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086713","PD1 Inhibitor","C124946","An agent designed to interfere with the activity of programmed cell death protein 1 (PD1). PD1 inhibitors block T-cell apoptosis and act as non-specific activators of the immune system.","PD1 Inhibitor | Anti-PD-1 Agent | PD-1 Inhibitor | PD-1-targeting Agent | Programmed Cell Death Protein 1 Inhibitor | Protein PD-1 Inhibitor",,,,,,,,,,,,,,,"36683612","Programmed cell death protein 1 inhibitor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0330090","Flower","C79636","The reproductive structure of a tree or other plant, consisting of at least one pistil or stamen, and often including petals and sepals.","Flower | Flos",,,,,,,,,,,,,,,"4042227","Flowers",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1313858","Orange","C48331","The hue of that portion of the visible spectrum lying between red and yellow, evoked in the human observer by radiant energy with wavelengths of approximately 590 to 630 nanometers; any of a group of colors between red and yellow in hue, of medium lightness and moderate saturation.","Orange | ORANGE",,,,,,,,,,,,,,,"4159774","Orange color",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0439542","Purple","C48327","Any of a group of colors with a hue between that of violet and red.","Purple | PURPLE",,,,,,,,,,,,,,,"4160085","Purple color",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1710496","Turquoise","C48334","A light to brilliant bluish green resembling the blue to blue-green mineral of aluminum and copper.","Turquoise | TURQUOISE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033968","Psychotherapy","C15308","A method of treating disease, esp. psychic disorders, by mental rather than pharmacological means (e.g., suggestion, re-education, hypnotism, and psychoanalysis). (Taber's)","Psychotherapy | psychotherapy | talk therapy",,,,,,,,,,,,,,,"4327941","Psychotherapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0279158","Pediatric Oncologist","C17853","Oncologists who specialize in treating children","Pediatric Oncologist | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3241936","Noncardiogenic Pulmonary Edema","C124947","Pulmonary edema that is not a result of cardiac dysfunction.","Noncardiogenic Pulmonary Edema | Non-Cardiogenic Pulmonary Edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3277113","Joint Contracture","C124948","Permanent shortening of a joint, usually resulting from prolonged spasticity in a muscle area.","Joint Contracture | ",,,,,,,,,,,,,,,"73290","Contracture of joint",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2699276","Schistocyte Count","C74706","The determination of the number of schistocytes present in a sample.","Schistocyte Count | SCHISTO | Schistocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827734","1+ Score","C85525","A finding of 1-9 bacilli per 10 250x fields.","1+ Score | 1 Plus Score | 1+",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827735","2+ Score","C85526","A finding of 1-9 bacilli per 250x field.","2+ Score | 2 Plus Score | 2+",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827736","3+ Score","C85527","A finding of 10-90 bacilli per 250x field.","3+ Score | 3 Plus Score | 3+",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827737","4+ Score","C85528","A finding of greater than 90 bacilli per 250x field.","4+ Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2742503","Obinutuzumab","C70741","A glycoengineered, humanized IgG1 monoclonal antibody with potential antineoplastic activity. Obinutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells. The Fc region carbohydrates of the antibody, enriched in bisected non-fucosylated glycosylation variants, contribute to its higher binding affinity for human FcgammaRIII receptors compared to non-glycoengineered antibodies, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) and caspase-independent apoptosis. In addition, modification of elbow hinge sequences within the antibody variable framework regions may account for the strong apoptosis-inducing activity of R7159 upon binding to CD20 on target cells.","Obinutuzumab | Afutuzumab | Anti-CD20 Monoclonal Antibody R7159 | GA 101 | GA-101 | GA101 | Gazyva | OBINUTUZUMAB | R 7159 | R-7159 | R7159 | RO 5072759 | RO-5072759 | RO5072759 | huMAB(CD20)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698692","Idelalisib","C78825","An orally bioavailable, small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities.  Idelalisib inhibits the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells.","Idelalisib | 5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H- quinazolin-4-one | CAL 101 | CAL-101 | CAL101 | GS 1101 | GS-1101 | GS1101 | IDELALISIB | Phosphoinositide-3 Kinase Delta Inhibitor CAL-101 | Zydelig",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335333","Papillomavirus Transforming Protein E7","C19171","Complexes with and inactivates Rb protein resulting in disruption of cell cycle regulation.","Papillomavirus Transforming Protein E7 | E7 | Viral Protein E7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086594","Modified 18-Item Memorial Anxiety Scale for Prostate Cancer","C124959","An 18-item questionnaire designed to facilitate the identification and assessment of men with prostate cancer-related anxiety.","Modified 18-Item Memorial Anxiety Scale for Prostate Cancer | MODMAX-PC | Modified 18-Item MAX-PC | Modified 18-Item Memorial Anxiety Scale for Prostate Cancer (Modified 18-item MAX-PC) | Modified Memorial Anxiety Scale for Prostate Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086995","Reference to Prostate Cancer Brought Up Strong Feelings","C124960","A question about how frequently a reference to prostate cancer brings up or brought up strong feelings in an individual.","Reference to Prostate Cancer Brought Up Strong Feelings | Any reference to prostate cancer brought up strong feelings in me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087022","Getting a PSA Test Scared Me","C124961","A question about how frequently an individual finds or found that the idea of getting a PSA test scared them.","Getting a PSA Test Scared Me | Even though it's a good idea, I found that getting a PSA test scared me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086597","More Anxious about Having Prostate Cancer Whenever Hearing about Friend or Public Figure with Prostate Cancer","C124962","A question about how frequently an individual is or was more anxious about having prostate cancer whenever they heard about a friend or public figure with prostate cancer.","More Anxious about Having Prostate Cancer Whenever Hearing about Friend or Public Figure with Prostate Cancer | Whenever I heard about a friend or public figure with prostate cancer, I got more anxious about my having prostate cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086596","More Anxious About Having Prostate Cancer When Thinking about Having a PSA Test","C124964","A question about how frequently an individual is or was more anxious about having prostate cancer when thinking about having a PSA test.","More Anxious About Having Prostate Cancer When Thinking about Having a PSA Test | When I thought about having a PSA test, I got more anxious about my having prostate cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086673","Other Things Made Me Think about Prostate Cancer","C124966","A question about how frequently other things make or made an individual think about prostate cancer.","Other Things Made Me Think about Prostate Cancer | Other things kept making me think about prostate cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086310","Felt Numb When Thinking about Prostate Cancer","C124967","A question about how frequently an individual feels of felt numb when they thought about prostate cancer.","Felt Numb When Thinking about Prostate Cancer | I felt kind of numb when I thought about prostate cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086904","Thought about Prostate Cancer Even Though Didn't Mean To","C124968","A question about how frequently an individual thinks or thought about prostate cancer even when they didn't mean to.","Thought about Prostate Cancer Even Though Didn't Mean To | I thought about prostate cancer even though I didn't mean to",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086387","Have Feelings about Prostate Cancer but Don't Want to Deal with Them","C124969","A question about how frequently an individual has or had feelings about prostate cancer but they didn't want to deal with them.","Have Feelings about Prostate Cancer but Don't Want to Deal with Them | I had a lot of feelings about prostate cancer, but I didn't want to deal with them",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086374","Had More Trouble Falling Asleep Because of Thoughts of Prostate Cancer","C124970","A question about how frequently an individual has or had more trouble falling asleep because they couldn't get thoughts of prostate cancer out of their mind.","Had More Trouble Falling Asleep Because of Thoughts of Prostate Cancer | I had more trouble falling asleep because I couldn't get thoughts of prostate cancer out of my mind",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087041","Afraid That Results from PSA Test Would Show That Disease was Getting Worse","C124971","A question about how frequently an individual is or was afraid that results from a PSA test would show that their disease is getting worse.","Afraid That Results from PSA Test Would Show That Disease was Getting Worse Question | Afraid That Results from PSA Test Would Show That Disease was Getting Worse | Afraid That Results from PSA Test Would Show That Disease was Getting Worse | I was afraid that the results from my PSA test would show that my disease was getting worse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086441","Hearing the Words Prostate Cancer Scared Me","C124972","A question about how frequently an individual is or was scared just hearing the words 'prostate cancer'.","Hearing the Words Prostate Cancer Scared Me | Just hearing the words 'prostate cancer' scared me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087040","Have Been so Anxious about PSA Test Have Thought About Delaying It","C124973","A question about how frequently an individual is or was so anxious about their PSA test that they have thought about delaying it.","Have Been so Anxious about PSA Test Have Thought About Delaying It | I have been so anxious about my PSA test that I have thought about delaying it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086381","Have Been so Worried about PSA Test Result Have Thought about Asking Doctor To Repeat It","C124974","A question about how frequently an individual is or was so worried about their PSA test result that they have thought about asking their doctor to repeat it.","Have Been so Worried about PSA Test Result Have Thought about Asking Doctor To Repeat It | I have been so worried about my PSA test result that I have thought about asking my doctor to repeat it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086380","Have Been so Concerned about PSA Test Result Have Thought about Having Test Repeated at Another Lab","C124975","A question about how frequently an individual is or was so concerned about their PSA test result that they have thought about having the test repeated at another lab to make sure it was accurate.","Have Been so Concerned about PSA Test Result Have Thought about Having Test Repeated at Another Lab | I have been so concerned about my PSA test result that I have thought about having the test repeated at another lab to make sure they were accurate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086115","Cannot Plan for the Future Because Cancer is Unpredictable","C124976","A question about an individual's agreement concerning not being able to plan for the future because cancer is unpredictable.","Cannot Plan for the Future Because Cancer is Unpredictable | Because cancer is unpredictable, I feel I cannot plan for the future",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086300","Fear of Cancer Getting Worse Gets in Way of Enjoying Life","C124977","A question about an individual's agreement concerning fear of their cancer getting worse getting in the way of enjoying their life.","Fear of Cancer Getting Worse Gets in Way of Enjoying Life | My fear of having my cancer getting worse gets in the way of my enjoying life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085939","Afraid of Cancer Getting Worse","C124978","A question about an individual's agreement concerning being afraid of their cancer getting worse.","Afraid of Cancer Getting Worse Question | Afraid of Cancer Getting Worse | Afraid of Cancer Getting Worse | I am afraid of my cancer getting worse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086598","More Nervous Since Prostate Cancer Diagnosis","C124979","A question about an individual's agreement concerning being more nervous since they were diagnosed with prostate cancer.","More Nervous Since Prostate Cancer Diagnosis | I am more nervous since I was diagnosed with prostate cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0481667","Live Birth","C114091","The complete expulsion or extraction from the mother of a fetus, irrespective of the duration of pregnancy, which, after such expulsion or extraction, breathes or shows any other evidence of life, such as beating of the heart, pulsation of the umbilical cord, or definite movement of voluntary muscles.","Live Birth | Live Born",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333378","Central Nervous System Embryonal Tumor","C6990","A malignant neoplasm of embryonal origin, arising from the central nervous system.  It usually affects children.  Representative examples include ependymoblastoma, medulloblastoma, and atypical teratoid/rhabdoid tumor.","Central Nervous System Embryonal Tumor | CNS Embryonal Neoplasm | CNS Embryonal Tumor | Central Nervous System Embryonal Neoplasm | Central Nervous System Embryonal Neoplasm | Embryonal Neoplasm of CNS | Embryonal Neoplasm of Central Nervous System | Embryonal Neoplasm of the CNS | Embryonal Neoplasm of the Central Nervous System | Embryonal Tumor of CNS | Embryonal Tumor of Central Nervous System | Embryonal Tumor of the CNS | Embryonal Tumor of the Central Nervous System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085138","Choroid Plexus Neoplasm","C3473","An intraventricular neoplasm that originates from the choroid plexus.  The vast majority of choroid plexus neoplasms originate from the epithelial layer and include the choroid plexus papilloma, atypical choroid plexus papilloma, and choroid plexus carcinoma.","Choroid Plexus Neoplasm | Choroid Plexus Tumor | Neoplasm of Choroid Plexus | Neoplasm of the Choroid Plexus | Tumor of Choroid Plexus | Tumor of the Choroid Plexus | choroid plexus tumor",,,,,,,,,,,,,,,"4114189","Tumor of choroid plexus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005967","Bone Neoplasm","C9343","A benign, intermediate, or malignant neoplasm involving the bone or articular cartilage.","Bone Neoplasm | Bone Neoplasms | Bone Tumor | Bone Tumors | Neoplasm of Bone | Neoplasm of the Bone | Osseous Neoplasm | Osseous Tumor | Tumor of Bone | Tumor of the Bone",,,,,,,,,,,,,,,"4019913|444204","Bone tumor|Neoplasm of bone",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1155008","B Cell Proliferation","C19385","Growth and reproduction of B-lymphocytes.","B Cell Proliferation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333407","Ependymal Tumor","C6770","A group of neoplasms which arise from the ependymal lining of the cerebral ventricles and from the remnants of the central canal of the spinal cord.  Ependymal tumors occur predominantly in children and young adults with varied morphological features and biological behavior.  There are 4 types: ependymoma, anaplastic ependymoma, myxopapillary ependymoma and subependymoma. (WHO)","Ependymal Tumor | Ependymal Neoplasm | ependymal tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017185","Digestive System Neoplasm","C3052","A benign or malignant neoplasm involving any part of the digestive system.","Digestive System Neoplasm | Digestive Neoplasm | Digestive System Tumor | Digestive Tumor | GI Neoplasm | GI System Neoplasm | GI System Tumor | GI Tumor | Gastrointestinal Neoplasm | Gastrointestinal System Neoplasm | Gastrointestinal System Tumor | Gastrointestinal Tumor | Neoplasm of Digestive System | Neoplasm of GI System | Neoplasm of Gastrointestinal System | Neoplasm of the Digestive System | Neoplasm of the GI System | Neoplasm of the Gastrointestinal System | Tumor of Digestive System | Tumor of GI System | Tumor of Gastrointestinal System | Tumor of the Digestive System | Tumor of the GI System | Tumor of the Gastrointestinal System",,,,,,,,,,,,,,,"4130373","Neoplasm of gastrointestinal tract",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3537823","NCI CTEP SDC Gastroesophageal Cancer Sub-Category Terminology","C103064","Gastroesophageal Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Gastroesophageal Cancer Sub-Category Terminology | Gastroesophageal Cancer | NCI CTEP Simple Disease Classification Gastroesophageal Cancer Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963704","Male Reproductive System","C12722","The sex organs of the male.","Male Reproductive System | Body System, Reproductive, Male | Genital System, Male | MALE REPRODUCTIVE SYSTEM | Male Genital Tract | Male Reproductive Body System | Male Reproductive Organ System | Male Reproductive Tract | Organ System, Male Reproductive | Penis and Other Genital | Reproductive System, Male","C63.9|C63.9","Male genital organs, NOS|Male genital tract, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--|--"
"C0585293","Six Times Daily","C98855","Six times per day.","Six Times Daily | 6 TIMES PER DAY | 6 Times Daily | 6 times daily",,,,,,,,,,,,,,,"4141094","Six times daily",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0556983","Once Daily","C125004","Scheduled or occurring at a frequency of once per day.","Once Daily | Once a day | Once per Day | One Time Daily",,,,,,,,,,,,,,,"4041300","Once daily",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153504","Malignant Mediastinal Neoplasm","C3549","A primary or metastatic malignant neoplasm affecting the mediastinum.  Representative examples of primary malignant mediastinal neoplasms include malignant germ cell tumors, malignant mesenchymal tumors, lymphomas, and malignant peripheral nerve sheath tumors.  A representative example of metastatic malignant neoplasm to the mediastinum is the metastatic carcinoma to the mediastinum from another anatomic site.","Malignant Mediastinal Neoplasm | Cancer of Mediastinum | Cancer of the Mediastinum | Malignant Mediastinal Neoplasm NOS | Malignant Mediastinal Tumor | Malignant Neoplasm of Mediastinum | Malignant Neoplasm of the Mediastinum | Malignant Tumor of Mediastinum | Malignant Tumor of the Mediastinum | Malignant neoplasm of mediastinum, part unspecified | Mediastinal Cancer",,,,,,,,,,,,,,,"4181484","Malignant tumor of mediastinum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037286","Skin Neoplasm","C3372","A benign, intermediate, or malignant neoplasm involving the skin.","Skin Neoplasm | Neoplasm of Skin | Neoplasm of the Skin | Skin Neoplasms | Skin Tumor | Tumor of Skin | Tumor of the Skin",,,,,,,,,,,,,,,"444209","Neoplasm of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3538805","NCI CTEP SDC Anal Cancer Sub-Category Terminology","C103062","Anal Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Anal Cancer Sub-Category Terminology | Anal Cancer | NCI CTEP Simple Disease Classification Anal Cancer Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641056","NCI CTEP SDC Immune Disorder (excluding AIDS and malignancy), Miscellaneous Sub-Category Terminology","C103080","Immune Disorder (excluding AIDS and malignancy), Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Immune Disorder (excluding AIDS and malignancy), Miscellaneous Sub-Category Terminology | Immune Disorder (excluding AIDS and malignancy), Miscellaneous | NCI CTEP Simple Disease Classification Immune Disorder (excluding AIDS and malignancy), Miscellaneous Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539532","NCI CTEP SDC Adrenal Cancer Sub-Category Terminology","C103055","Adrenal Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Adrenal Cancer Sub-Category Terminology | Adrenal Cancer | NCI CTEP Simple Disease Classification Adrenal Cancer Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641036","NCI CTEP SDC Bone Neoplasm, Miscellaneous Sub-Category Terminology","C103036","Bone Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Bone Neoplasm, Miscellaneous Sub-Category Terminology | Bone Neoplasm, Miscellaneous | NCI CTEP Simple Disease Classification Bone Neoplasm, Miscellaneous Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641079","NCI CTEP SDC B-Cell Proliferations of Uncertain Malignant Potential Sub-Category Terminology","C103134","B-Cell Proliferations of Uncertain Malignant Potential is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC B-Cell Proliferations of Uncertain Malignant Potential Sub-Category Terminology | B-Cell Proliferations of Uncertain Malignant Potential | NCI CTEP Simple Disease Classification B-Cell Proliferations of Uncertain Malignant Potential Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540686","NCI CTEP SDC Basal Cell Carcinoma Sub-Category Terminology","C103112","Basal Cell Carcinoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Basal Cell Carcinoma Sub-Category Terminology | Basal Cell Carcinoma | NCI CTEP Simple Disease Classification Basal Cell Carcinoma Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641045","NCI CTEP SDC CNS-excluded Nervous System Neoplasm, Miscellaneous Sub-Category Terminology","C103052","CNS-excluded Nervous System Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC CNS-excluded Nervous System Neoplasm, Miscellaneous Sub-Category Terminology | CNS-excluded Nervous System Neoplasm, Miscellaneous | NCI CTEP Simple Disease Classification CNS-excluded Nervous System Neoplasm, Miscellaneous Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641040","NCI CTEP SDC CNS Neoplasm (Primary Tumor), Miscellaneous Sub-Category Terminology","C103045","CNS Neoplasm (Primary Tumor), Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC CNS Neoplasm (Primary Tumor), Miscellaneous Sub-Category Terminology | CNS Neoplasm (Primary Tumor), Miscellaneous | NCI CTEP Simple Disease Classification CNS Neoplasm (Primary Tumor), Miscellaneous Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540841","NCI CTEP SDC Choroid Plexus Tumors Sub-Category Terminology","C103044","Choroid Plexus Tumors is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Choroid Plexus Tumors Sub-Category Terminology | Choroid Plexus Tumors | NCI CTEP Simple Disease Classification Choroid Plexus Tumors Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641060","NCI CTEP SDC Carcinoma, Miscellaneous Sub-Category Terminology","C103092","Carcinoma, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Carcinoma, Miscellaneous Sub-Category Terminology | Carcinoma, Miscellaneous | NCI CTEP Simple Disease Classification Carcinoma, Miscellaneous Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641062","NCI CTEP SDC Solid Tumor, Miscellaneous Sub-Category Terminology","C103095","Solid Tumor, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Solid Tumor, Miscellaneous Sub-Category Terminology | NCI CTEP Simple Disease Classification Solid Tumor, Miscellaneous Sub-Category Terminology | Solid Tumor, Miscellaneous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641072","NCI CTEP SDC Soft Tissue Neoplasm, Miscellaneous Sub-Category Terminology","C103119","Soft Tissue Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Soft Tissue Neoplasm, Miscellaneous Sub-Category Terminology | NCI CTEP Simple Disease Classification Soft Tissue Neoplasm, Miscellaneous Sub-Category Terminology | Soft Tissue Neoplasm, Miscellaneous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641070","NCI CTEP SDC Skin Neoplasm, Miscellaneous Sub-Category Terminology","C103115","Skin Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Skin Neoplasm, Miscellaneous Sub-Category Terminology | NCI CTEP Simple Disease Classification Skin Neoplasm, Miscellaneous Sub-Category Terminology | Skin Neoplasm, Miscellaneous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641051","NCI CTEP SDC Pancreatic Cancer (excluding Islets) Sub-Category Terminology","C103067","Pancreatic Cancer (excluding Islets) is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Pancreatic Cancer (excluding Islets) Sub-Category Terminology | NCI CTEP Simple Disease Classification Pancreatic Cancer (excluding Islets) Sub-Category Terminology | Pancreatic Cancer (excluding Islets)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641064","NCI CTEP SDC Non-neoplastic Disorder, Miscellaneous Sub-Category Terminology","C103097","Non-neoplastic Disorder, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Non-neoplastic Disorder, Miscellaneous Sub-Category Terminology | NCI CTEP Simple Disease Classification Non-neoplastic Disorder, Miscellaneous Sub-Category Terminology | Non-neoplastic Disorder, Miscellaneous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641061","NCI CTEP SDC Metastases, Distant (excluding specified site of origin) Sub-Category Terminology","C103093","Metastases, Distant (excluding specified site of origin) is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Metastases, Distant (excluding specified site of origin) Sub-Category Terminology | Metastases, Distant (excluding specified site of origin) | NCI CTEP Simple Disease Classification Metastases, Distant (excluding specified site of origin) Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541354","NCI CTEP SDC Meningeal Tumors Sub-Category Terminology","C103049","Meningeal Tumors is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Meningeal Tumors Sub-Category Terminology | Meningeal Tumors | NCI CTEP Simple Disease Classification Meningeal Tumors Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641048","NCI CTEP SDC Malignant Eye Neoplasm, Miscellaneous Sub-Category Terminology","C103060","Malignant Eye Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Malignant Eye Neoplasm, Miscellaneous Sub-Category Terminology | Malignant Eye Neoplasm, Miscellaneous | NCI CTEP Simple Disease Classification Malignant Eye Neoplasm, Miscellaneous Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641067","NCI CTEP SDC Male Reproductive System Neoplasm, Miscellaneous Sub-Category Terminology","C103107","Male Reproductive System Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Male Reproductive System Neoplasm, Miscellaneous Sub-Category Terminology | Male Reproductive System Neoplasm, Miscellaneous | NCI CTEP Simple Disease Classification Male Reproductive System Neoplasm, Miscellaneous Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641080","NCI CTEP SDC Lymphoma, Miscellaneous Sub-Category Terminology","C103136","Lymphoma, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Lymphoma, Miscellaneous Sub-Category Terminology | Lymphoma, Miscellaneous | NCI CTEP Simple Disease Classification Lymphoma, Miscellaneous Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641059","NCI CTEP SDC Lung, Mediastinal and Pleural Neoplasm, Miscellaneous Sub-Category Terminology","C103087","Lung, Mediastinal and Pleural Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Lung, Mediastinal and Pleural Neoplasm, Miscellaneous Sub-Category Terminology | Lung, Mediastinal and Pleural Neoplasm, Miscellaneous | NCI CTEP Simple Disease Classification Lung, Mediastinal and Pleural Neoplasm, Miscellaneous Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641058","NCI CTEP SDC Kidney Neoplasm, Miscellaneous Sub-Category Terminology","C103083","Kidney Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Kidney Neoplasm, Miscellaneous Sub-Category Terminology | Kidney Neoplasm, Miscellaneous | NCI CTEP Simple Disease Classification Kidney Neoplasm, Miscellaneous Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641055","NCI CTEP SDC Hematopoietic Neoplasm, Miscellaneous Sub-Category Terminology","C103078","Hematopoietic Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Hematopoietic Neoplasm, Miscellaneous Sub-Category Terminology | Hematopoietic Neoplasm, Miscellaneous | NCI CTEP Simple Disease Classification Hematopoietic Neoplasm, Miscellaneous Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641053","NCI CTEP SDC Germ Cell Neoplasm, Miscellaneous Sub-Category Terminology","C103070","Germ Cell Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Germ Cell Neoplasm, Miscellaneous Sub-Category Terminology | Germ Cell Neoplasm, Miscellaneous | NCI CTEP Simple Disease Classification Germ Cell Neoplasm, Miscellaneous Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641049","NCI CTEP SDC Gastrointestinal Neoplasm, Miscellaneous Sub-Category Terminology","C103065","Gastrointestinal Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Gastrointestinal Neoplasm, Miscellaneous Sub-Category Terminology | Gastrointestinal Neoplasm, Miscellaneous | NCI CTEP Simple Disease Classification Gastrointestinal Neoplasm, Miscellaneous Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641065","NCI CTEP SDC Female Reproductive System Neoplasm, Miscellaneous Sub-Category Terminology","C103100","Female Reproductive System Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Female Reproductive System Neoplasm, Miscellaneous Sub-Category Terminology | Female Reproductive System Neoplasm, Miscellaneous | NCI CTEP Simple Disease Classification Female Reproductive System Neoplasm, Miscellaneous Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641052","NCI CTEP SDC Extragonadal Germ Cell Cancer (excluding Gestational Trophoblastic Disease and Germ Cell Tumors of the CNS) Sub-Category Terminology","C103069","Extragonadal Germ Cell Cancer (excluding Gestational Trophoblastic Disease and Germ Cell Tumors of the CNS) is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Extragonadal Germ Cell Cancer (excluding Gestational Trophoblastic Disease and Germ Cell Tumors of the CNS) Sub-Category Terminology | Extragonadal Germ Cell Cancer (excluding Gestational Trophoblastic Disease and Germ Cell Tumors of the CNS) | NCI CTEP Simple Disease Classification Extragonadal Germ Cell Cancer (excluding Gestational Trophoblastic Disease and Germ Cell Tumors of the CNS) Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641046","NCI CTEP SDC Endocrine Neoplasm, Miscellaneous Sub-Category Terminology","C103056","Endocrine Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Endocrine Neoplasm, Miscellaneous Sub-Category Terminology | Endocrine Neoplasm, Miscellaneous | NCI CTEP Simple Disease Classification Endocrine Neoplasm, Miscellaneous Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641041","NCI CTEP SDC Embryonal Tumors of the CNS Sub-Category Terminology","C103046","Embryonal Tumors of the CNS is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Embryonal Tumors of the CNS Sub-Category Terminology | Embryonal Tumors of the CNS | NCI CTEP Simple Disease Classification Embryonal Tumors of the CNS Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641063","NCI CTEP SDC Vascular Tumor, Miscellaneous Sub-Category Terminology","C103096","Vascular Tumor, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Vascular Tumor, Miscellaneous Sub-Category Terminology | NCI CTEP Simple Disease Classification Vascular Tumor, Miscellaneous Sub-Category Terminology | Vascular Tumor, Miscellaneous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641077","NCI CTEP SDC Urothelial Tract/Bladder Cancer Sub-Category Terminology","C103131","Urothelial Tract/Bladder Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Urothelial Tract/Bladder Cancer Sub-Category Terminology | NCI CTEP Simple Disease Classification Urothelial Tract/Bladder Cancer Sub-Category Terminology | Urothelial Tract/Bladder Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641044","NCI CTEP SDC Tumors of the Sellar Region Sub-Category Terminology","C103051","Tumors of the Sellar Region is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Tumors of the Sellar Region Sub-Category Terminology | NCI CTEP Simple Disease Classification Tumors of the Sellar Region Sub-Category Terminology | Tumors of the Sellar Region",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086035","Bothered by Chills","C125073","A question about whether an individual is or was bothered by the chills.","Bothered by Chills | I am bothered by the chills",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086038","Bothered by Lumps or Swelling in Certain Parts of My Body","C125074","A question about whether an individual is or was bothered by lumps or swelling in certain parts of their body.","Bothered by Lumps or Swelling in Certain Parts of My Body | I am bothered by lumps or swelling in certain parts of my body (e.g., neck, armpits, or groin)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086306","Feel Uncertain About My Future Health","C125075","A question about whether an individual feels or felt uncertain about their future health.","Feel Uncertain About My Future Health | I feel uncertain about my future health",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086303","Feel Isolated from Others Because of My Illness or Treatment","C125076","A question about whether an individual feels or felt isolated from others because of their illness or treatment.","Feel Isolated from Others Because of My Illness or Treatment | I feel isolated from others because of my illness or treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086291","FACT-Th11 Questionnaire","C125079","A subscale complement to the FACT-G developed specifically for evaluating the quality of life of cancer patients with thrombocytopenia.","FACT-Th11 Questionnaire | FACT-Th11 | Functional Assessment of Cancer Therapy - Thrombocytopenia | Functional Assessment of Cancer Therapy Thrombocytopenia Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085309","Bleed Easily","C125077","A question about whether an individual bleeds or bled easily.","Bleed Easily | I bleed easily",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084860","Bruise Easily","C125078","A question about whether an individual bruises or bruised easily.","Bruise Easily | I bruise easily",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086476","How Often Have You Leaked Urine","C125011","A question about how often an individual has leaked urine.","How Often Have You Leaked Urine | How often have you leaked urine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086477","How Often Have You Urinated Blood","C125012","A question about how often an individual has urinated blood.","How Often Have You Urinated Blood | How often have you urinated blood",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086475","How Often Have You Had Pain or Burning with Urination","C125013","A question about how often an individual has had pain or burning with urination.","How Often Have You Had Pain or Burning with Urination | How often have you had pain or burning with urination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085870","Ability to Control Urination","C125014","A question about an individual's ability to control their urination.","Ability to Control Urination Question | Ability to Control Urination | Ability to Control Urination | Urinary Control | Which of the following best describes your urinary control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086467","How Many Pads or Adult Diapers per Day Did You Use to Control Leakage","C125015","A question about how many pads or adult diapers an individual used each day to control leakage.","How Many Pads or Adult Diapers per Day Did You Use to Control Leakage | How many pads or adult diapers per day did you usually use to control leakage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086453","How Big a Problem is Dripping or Leaking Urine","C125016","A question about an individual's assessment of how big a problem dripping or leaking urine has been.","How Big a Problem is Dripping or Leaking Urine | Dripping or leaking urine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086456","How Big a Problem is Pain or Burning on Urination","C125017","A question about an individual's assessment of how big a problem pain or burning urination has been.","How Big a Problem is Pain or Burning on Urination | Pain or burning on urination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086451","How Big a Problem is Bleeding with Urination","C125018","A question about an individual's assessment of how big a problem bleeding with urination has been.","How Big a Problem is Bleeding with Urination | Bleeding with urination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086460","How Big a Problem is Weak Urine Stream or Incomplete Emptying","C125019","A question about an individual's assessment of how big a problem a weak urine stream or incompletely emptying has been.","How Big a Problem is Weak Urine Stream or Incomplete Emptying | Weak urine stream or incomplete emptying",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086458","How Big a Problem is Waking Up to Urinate","C125020","A question about an individual's assessment of how big a problem waking up to urinate has been.","How Big a Problem is Waking Up to Urinate | Waking up to urinate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086463","How Big a Problem is the Need to Urinate Frequently During the Day","C125021","A question about an individual's assessment of how big a problem the need to urinate frequently during the day has been.","How Big a Problem is the Need to Urinate Frequently During the Day | Need to urinate frequently during the day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086677","Overall How Big a Problem is Urinary Function","C125022","A question about an individual's overall assessment of how big a problem their urinary function has been.","Overall How Big a Problem is Urinary Function | Overall, how big a problem has your urinary function been for you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086483","How Often had Rectal Urgency","C125023","A question about how often an individual had rectal urgency.","How Often had Rectal Urgency | How often have you had rectal urgency (felt like I had to pass stool, but did not)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086486","How Often had Uncontrolled Leakage of Stool or Feces","C125024","A question about how often an individual had uncontrolled leakage of stool or feces.","How Often had Uncontrolled Leakage of Stool or Feces | How often have you had uncontrolled leakage of stool or feces",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086485","How Often had Stools That Were Loose or Liquid","C125025","A question about how often an individual had stools that were loose or liquid.","How Often had Stools That Were Loose or Liquid | How often have you had stools (bowel movements) that were loose or liquid (no form, watery, mushy)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086480","How Often had Bloody Stools","C125026","A question about how often an individual had bloody stools.","How Often had Bloody Stools | How often have you had bloody stools",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086478","How Often Have Your Bowel Movements Been Painful","C125027","A question about how often an individual had bowel movements that were painful.","How Often Have Your Bowel Movements Been Painful | How often have your bowel movements been painful",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086466","How Many Bowel Movements on a Typical Day","C125028","A question about how many bowel movements an individual had on a typical day.","How Many Bowel Movements on a Typical Day | How many bowel movements have you had on a typical day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086482","How Often had Crampy Pain in Abdomen, Pelvis, or Rectum","C125029","A question about how often an individual had crampy pain in their abdomen, pelvis or rectum.","How Often had Crampy Pain in Abdomen, Pelvis, or Rectum | How often have you had crampy pain in your abdomen, pelvis or rectum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086457","How Big a Problem is Urgency to Have Bowel Movement","C125030","A question about an individual's assessment of how big a problem urgency to have bowel movements has been.","How Big a Problem is Urgency to Have Bowel Movement | Urgency to have a bowel movement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086454","How Big a Problem is Increased Frequency of Bowel Movements","C125031","A question about an individual's assessment of how big a problem increased frequency of bowel movements has been.","How Big a Problem is Increased Frequency of Bowel Movements | Increased frequency of bowel movements",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086459","How Big a Problem is Watery Bowel Movements","C125032","A question about an individual's assessment of how big a problem watery bowel movements have been.","How Big a Problem is Watery Bowel Movements | Watery bowel movements",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086455","How Big a Problem is Losing Control of Stools","C125033","A question about an individual's assessment of how big a problem losing control of their stools has been.","How Big a Problem is Losing Control of Stools | Losing control of your stools",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084720","How Big a Problem is Bloody Stools","C125034","A question about an individual's assessment of how big a problem bloody stools have been.","How Big a Problem is Bloody Stools | Bloody stools",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086450","How Big a Problem is Abdominal, Pelvic, or Rectal Pain","C125035","A question about an individual's assessment of how big a problem abdominal, pelvic, or rectal pain has been.","How Big a Problem is Abdominal, Pelvic, or Rectal Pain | Abdominal/Pelvic/Rectal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086676","Overall How Big a Problem Have Your Bowel Habits Been","C125036","A question about an individual's overall assessment of how big a problem their bowel habits have been.","Overall How Big a Problem Have Your Bowel Habits Been | Overall how big a problem have your bowel habits been for you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084903","Level of Sexual Desire","C125037","A question about an individual's level of sexual desire.","Level of Sexual Desire | Desire for Sexual Intimacy | My desire for sexual intimacy | Your level of sexual desire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084805","Ability to Have An Erection","C125038","A question about an individual's ability to have an erection.","Ability to Have An Erection Question | Ability to Have An Erection | Ability to Have An Erection | Your ability to have an erection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085926","Ability to Reach Orgasm","C125039","A question about an individual's ability to reach orgasm.","Ability to Reach Orgasm Question Question | Ability to Reach Orgasm | Ability to Reach Orgasm | Ability to Reach Orgasm Question | Have you reached orgasm | Your ability to reach orgasm (climax)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086932","Usual Quality of Erections","C125040","A question about the usual quality of an individual's erections.","Usual Quality of Erections | How would you describe the usual QUALITY of your erections",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086333","Frequency of Erections","C125041","A question about the frequency of an individual's erections.","Frequency of Erections | How would you describe the FREQUENCY of your erections",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086472","How Often Awakened in the Morning or Night with an Erection","C125042","A question about how often an individual awoke in the morning or night with an erection.","How Often Awakened in the Morning or Night with an Erection | How often have you awakened in the morning or night with an erection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086479","How Often had Any Sexual Activity","C125043","A question about how often an individual had any sexual activity.","How Often had Any Sexual Activity | How often did you have any sexual activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086484","How Often had Sexual Intercourse","C125044","A question about often an individual had sexual intercourse.","How Often had Sexual Intercourse | How often did you have sexual intercourse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087065","Overall Ability to Function Sexually","C125045","A question about an individual's overall assessment of their ability to function sexually.","Overall Ability to Function Sexually | Overall, how would you rate your ability to function sexually",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084904","How Big a Problem is Your Level of Sexual Desire","C125046","A question about an individual's assessment of how big a problem their level of sexual desire has been.","How Big a Problem is Your Level of Sexual Desire | Your level of sexual desire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084800","How Big a Problem is Your Ability to Have an Erection","C125047","A question about an individual's assessment of how big a problem their ability to have an erection has been.","How Big a Problem is Your Ability to Have an Erection | Your ability to have an erection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086461","How Big a Problem is Your Ability to Reach an Orgasm","C125048","A question about an individual's assessment of how big a problem their ability to reach an orgasm has been.","How Big a Problem is Your Ability to Reach an Orgasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086678","Overall How Big a Problem is Your Sexual Function or Lack of Sexual Function","C125049","A question about an individual's overall assessment of how big a problem their sexual function or lack of sexual function has been.","Overall How Big a Problem is Your Sexual Function or Lack of Sexual Function | Overall , how big a problem has your sexual function or lack of sexual function been for you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086473","How Often Experienced Hot Flashes","C125050","A question about how often an individual experienced hot flashes.","How Often Experienced Hot Flashes | How often have you experienced hot flashes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086481","How Often had Breast Tenderness","C125051","A question about often an individual had breast tenderness.","How Often had Breast Tenderness | How often have you had breast tenderness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086474","How Often Felt Depressed","C125052","A question about how often an individual felt depressed.","How Often Felt Depressed | How often have you felt depressed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085659","How Often Felt a Lack of Energy","C125053","A question about how often an individual feels or felt a lack of energy.","How Often Felt a Lack of Energy | How Often Lack of Energy | How often have you felt a lack of energy | Lack of Energy Frequency | Lack of energy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086468","How Much Change in Weight Have You Experienced","C125054","A question about how much weight change an individual has experienced.","How Much Change in Weight Have You Experienced | How much change in your weight have you experienced, if any",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085328","How Big a Problem Are Hot Flashes","C125055","A question about an individual's assessment of how big a problem hot flashes have been.","How Big a Problem Are Hot Flashes | Hot flashes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086452","How Big a Problem is Breast Tenderness or Enlargement","C125056","A question about an individual's assessment of how big a problem breast tenderness or enlargement has been.","How Big a Problem is Breast Tenderness or Enlargement | Breast tenderness/enlargement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084737","How Big a Problem is Loss of Body Hair","C125057","A question about an individual's assessment of how big a problem loss of body hair has been.","How Big a Problem is Loss of Body Hair | Loss of Body Hair",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084803","How Big a Problem is Feeling Depressed","C125058","A question about an individual's assessment of how big a problem feeling depressed has been.","How Big a Problem is Feeling Depressed | Feeling depressed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085860","How Big a Problem is Lack of Energy","C125059","A question about an individual's assessment of how big a problem lack of energy has been.","How Big a Problem is Lack of Energy | Lack of energy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086462","How Big a Problem is Your Change in Body Weight","C125060","A question about an individual's assessment of how big a problem their body weight change has been.","How Big a Problem is Your Change in Body Weight | Change in body weight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086680","Overall Satisfaction with Treatment Received for Prostate Cancer","C125061","A question about an individual's overall satisfaction with the treatment they received for their prostate cancer.","Overall Satisfaction with Treatment Received for Prostate Cancer | Overall Satisfaction | Overall, how satisfied are you with the treatment you received for your prostate cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086028","Body Weight Gain Exceeding 10 Pounds","C125065","A subjective response indicating that an individual has gained 10 pounds or more.","Body Weight Gain Exceeding 10 Pounds | Gained 10 pounds or more | Weight Gain Exceeding 10 Pounds",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086029","Body Weight Gain Less Than 10 Pounds","C125066","A subjective response indicating that an individual has gained less than 10 pounds.","Body Weight Gain Less Than 10 Pounds | Gained less than 10 pounds | Weight Gain Less Than 10 Pounds",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086622","No Change in Body Weight","C125067","A subjective response indicating that an individual has had no change in weight.","No Change in Body Weight | No Change in Weight | No change in weight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086031","Body Weight Loss Less Than 10 Pounds","C125068","A subjective response indicating that an individual has lost less than 10 pounds.","Body Weight Loss Less Than 10 Pounds | Lost less than 10 pounds | Weight Loss Less Than 10 Pounds",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086030","Body Weight Loss Exceeding 10 Pounds","C125069","A subjective response indicating that an individual has lost 10 pounds or more.","Body Weight Loss Exceeding 10 Pounds | Lost 10 pounds or more | Weight Loss Exceeding 10 Pounds",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085546","Dissatisfied","C125070","A subjective response indicating that an individual is displeased and discontent.","Dissatisfied | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085655","Uncertain if Satisfied or Dissatisfied","C125071","A subjective response indicating that an individual is unsure if they are satisfied or dissatisfied.","Uncertain if Satisfied or Dissatisfied | Uncertain | Uncertain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084799","Satisfied","C125072","A subjective response indicating that an individual is pleased and content.","Satisfied | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505123","Decisional Conflict Scale","C125082","A questionnaire that measures health-care consumers' uncertainty in making a health-related decisions, the modifiable factors contributing to the uncertainty, and health-care consumers' perceived effective decision making.","Decisional Conflict Scale | DCS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086535","Know Which Options Are Available","C125083","A question about an individual's assessment of whether they know or knew which options were available to them.","Know Which Options Are Available | I know which options are available to me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086536","Know the Benefits of Each Option","C125084","A question about an individual's assessment of whether they know or knew the benefits of each option.","Know the Benefits of Each Option | I know the benefits of each option",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086537","Know the Risks and Side Effects of Each Option","C125085","A question about an individual's assessment of whether they know or knew the risks and side effects of each option.","Know the Risks and Side Effects of Each Option | I know the risks and side effects of each option",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086182","Clear About Which Benefits Matter Most","C125086","A question about an individual's assessment of whether they are or were clear about which benefits matter most to them.","Clear About Which Benefits Matter Most | I am clear about which benefits matter most to me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086183","Clear About Which Risks and Side Effects Matter Most","C125087","A question about an individual's assessment of whether they are or were clear about which risks and side effects matter most.","Clear About Which Risks and Side Effects Matter Most | I am clear about which risks and side effects matter most",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086181","Clear About Whether Benefits or Risks are More Important","C125088","A question about an individual's assessment of whether they are or were clear about whether the benefits or the risks and side effects were more important to them.","Clear About Whether Benefits or Risks are More Important | I am clear about which is more important to me (the benefits or the risks and side effects)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086386","Have Enough Support From Others to Make a Choice","C125089","A question about an individual's assessment of whether they have or had enough support from others to make a choice.","Have Enough Support From Others to Make a Choice | I have enough support from others to make a choice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086385","Have Enough Advice to Make a Choice","C125091","A question about an individual's assessment of whether they have or had enough advice to make a choice.","Have Enough Advice to Make a Choice | I have enough advice to make a choice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086184","Clear About the Best Choice","C125092","A question about an individual's assessment of whether they are or were clear about the best choice for them.","Clear About the Best Choice | I am clear about the best choice for me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087038","Sure About What to Choose","C125093","A question about an individual's assessment of whether they are or were sure about what to choose.","Sure About What to Choose | I feel sure about what to choose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086235","Decision is Easy to Make","C125094","A question about an individual's assessment of whether the decision is or was easy for them.","Decision is Easy to Make | This decision is easy for me to make",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086389","Have Made an Informed Choice","C125095","A question about an individual's assessment of whether they feel or felt they made an informed choice.","Have Made an Informed Choice | I feel I have made an informed choice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086234","Decision Shows What is Important","C125096","A question about an individual's assessment of whether the decision shows or showed what is important to them.","Decision Shows What is Important | My decision shows what is important to me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086271","Expect to Stick With Decision","C125097","A question about an individual's assessment of whether they expect or expected to stick with their decision.","Expect to Stick With Decision | I expect to stick with my decision",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086843","Satisfied With Decision","C125098","A question about an individual's assessment of whether they are or were satisfied with their decision.","Satisfied With Decision | I am satisfied with my decision",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349113","Vectorcardiograph Uncorrected","C71093","A measurement of electric heart vectors whereby this type of measurement does not consider the distortions caused by the boundary and internal inhomogeneities of the body. These lead systems assure the direction of the spatial line connecting an electrode pair and yields the orientation of the corresponding lead vectors.","Vectorcardiograph Uncorrected | VECTORCARDIOGRAPH UNCORRECTED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505082","TAPS Tool - Interviewer Version","C125105","An instrument designed to screen and assess adult primary care patients for tobacco, alcohol, prescription drug, and drug use and problems related to their use.","TAPS Tool - Interviewer Version | TAPS | TAPS Tool | TAPS Tool Part 1 - Interviewer Version (QSC) | The Tobacco, Alcohol, Prescription Medication and Other Substances Tool - Interviewer Version",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086725","Past 3 Months","C125104","A period of time consisting of the 3 months before the present.","Past 3 Months | Last 3 Months | Last 3 months | Past Three Months",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086858","Smoke Cigarette Containing Tobacco","C125115","A question about whether an individual smokes or smoked a cigarette containing tobacco.","Smoke Cigarette Containing Tobacco | Did you smoke a cigarette containing tobacco | Smoked Cigarette Containing Tobacco",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086936","Usually Smoke More Than 10 Cigarettes Each Day","C125116","A question about whether an individual usually smokes or smoked more than 10 cigarettes each day.","Usually Smoke More Than 10 Cigarettes Each Day | Did you usually smoke more than 10 cigarettes each day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086937","Usually Smoke Within 30 Minutes After Waking","C125117","A question about whether an individual usually smokes or smoked within 30 minutes after waking.","Usually Smoke Within 30 Minutes After Waking | Did you usually smoke within 30 minutes after waking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087012","Have Drink Containing Alcohol","C125118","A question about whether an individual has or had a drink containing alcohol.","Have Drink Containing Alcohol | Did you have a drink containing alcohol | Do You Drink | Do You Drink Alcohol | Have Alcoholic Drink",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086659","On Occasion Drink More Than 4 Standard Drinks of Alcohol","C125119","A question about whether an individual drinks or drank more than 4 standard drinks of alcohol on any occasion.","On Occasion Drink More Than 4 Standard Drinks of Alcohol | On Occasion Drink More Than 4 Alcoholic Drinks | On Occasion Drink More Than 4 Standard Alcoholic Drinks | On any occasion, did you drink more than 4 standard drinks of alcohol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086660","On Occasion Drink More Than 5 Standard Drinks of Alcohol","C125120","A question about whether an individual drinks or drank more than 5 standard drinks of alcohol on any occasion.","On Occasion Drink More Than 5 Standard Drinks of Alcohol | On Occasion Drink More Than 5 Alcoholic Drinks | On Occasion Drink More Than 5 Standard Alcoholic Drinks | On any occasion, did you drink more than 5 standard drinks of alcohol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086916","Tried and Failed to Control, Cut Down, or Stop Drinking","C125121","A question about whether an individual tried and failed to control, cut down, or stop drinking alcohol.","Tried and Failed to Control, Cut Down, or Stop Drinking | Have Tried and Failed to Control, Cut Down or Stop Drinking | Have you tried and failed to control, cut down or stop drinking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084815","Use Marijuana","C125123","A question about whether an individual uses or used marijuana.","Use Marijuana | Did you use marijuana (cannabis, weed)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086869","Strong Desire to Use Marijuana at Least Once a Week","C125124","A question about whether an individual has or had a strong desire or urge to use marijuana at least once a week or more often.","Strong Desire to Use Marijuana at Least Once a Week | Have you had a strong desire or urge to use marijuana at least once a week or more often | Strong Desire to Use Marijuana Once a Week or More Often",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086214","Concern About Your Use of Marijuana","C125125","A question about whether anyone has expressed concern about an individual's use of marijuana.","Concern About Your Use of Marijuana | Has anyone expressed concern about your use of marijuana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086931","Use of Stimulant Medication Not as Prescribed or Without a Prescription","C125126","A question about whether an individual uses or used a stimulant medication not as prescribed or without a prescription.","Use of Stimulant Medication Not as Prescribed or Without a Prescription | Did you use a stimulant medication (e.g., amphetamine, Ritalin) not as prescribed or without a prescription | Use of Stimulant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086930","Use Stimulant at Least Once a Week","C125127","A question about whether an individual uses or used a stimulant at least once a week or more often.","Use Stimulant at Least Once a Week | Did you use a stimulant at least once a week or more often | Use Stimulant Once a Week or More Often",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086216","Concern About Your Use of a Stimulant","C125128","A question about whether anyone has expressed concern about an individual's use of a stimulant.","Concern About Your Use of a Stimulant | Has anyone expressed concern about your use of a stimulant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086927","Use Cocaine or Methamphetamine","C125129","A question about whether an individual uses or used cocaine or methamphetamine.","Use Cocaine or Methamphetamine | Did you use cocaine or methamphetamine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086926","Use Cocaine or Methamphetamine at Least Once a Week","C125130","A question about whether an individual uses or used cocaine or methamphetamine at least once a week or more often.","Use Cocaine or Methamphetamine at Least Once a Week | Did you use cocaine or methamphetamine at least once a week or more often | Use Cocaine or Methamphetamine Once a Week or More Often",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086212","Concern About Your Use of Cocaine or Methamphetamine","C125131","A question about whether anyone has expressed concern about an individual's use of cocaine or methamphetamine.","Concern About Your Use of Cocaine or Methamphetamine | Has anyone expressed concern about your use of cocaine or methamphetamine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086929","Use Sedative or Sleeping Medication Not as Prescribed or Without a Prescription","C125132","A question about whether an individual uses or used a sedative or sleeping medication not as prescribed or without a prescription.","Use Sedative or Sleeping Medication Not as Prescribed or Without a Prescription | Did you use a sedative or sleeping medication (e.g., benzodiazepine, Xanax, Klonopin) not as prescribed or without a prescription",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086870","Strong Desire to Use Sedative or Sleeping Medication at Least Once a Week","C125134","A question about whether an individual has or had a strong desire or urge to use a sedative or sleeping medication at least once a week or more often.","Strong Desire to Use Sedative or Sleeping Medication at Least Once a Week | Have you had a strong desire or urge to use such a medication at least once a week or more often | Strong Desire to Use Sedative or Sleeping Medication Once a Week or More Often",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086215","Concern About Your Use of Sedative or Sleeping Medication","C125135","A question about whether anyone has expressed concern about an individual's use of a sedative or sleeping medication.","Concern About Your Use of Sedative or Sleeping Medication | Has anyone expressed concern about your use of a sedative or sleeping medication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087013","Use Opioid-Containing Medication Not as Prescribed or Without a Prescription","C125133","A question about whether an individual use an opioid-containing medication not as prescribed or without a prescription.","Use Opioid-Containing Medication Not as Prescribed or Without a Prescription | Did you use an opioid-containing medication (e.g., OxyContin, Vicodin, Percocet, Suboxone or Buprenorphine, methadone) not as prescribed or without a prescription",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086918","Tried and Failed to Control, Cut Down, or Stop Using an Opioid Medication","C125136","A question about whether an individual tried and failed to control, cut down, or stop using an opioid medication.","Tried and Failed to Control, Cut Down, or Stop Using an Opioid Medication | Have you tried and failed to control, cut down or stop using an opioid medication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086217","Concern About Your Use of an Opioid Medication","C125137","A question about whether anyone has expressed concern about an individual's use of an opioid medication.","Concern About Your Use of an Opioid Medication | Has anyone expressed concern about your use of an opioid medication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086928","Use Heroin","C125138","A question about whether an individual uses or used heroin.","Use Heroin | Did you use heroin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086917","Tried and Failed to Control, Cut Down, or Stop Using Heroin","C125139","A question about whether an individual tried and failed to control, cut down, or stop using heroin.","Tried and Failed to Control, Cut Down, or Stop Using Heroin | Have you tried and failed to control, cut down or stop using heroin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086213","Concern About Your Use of Heroin","C125140","A question about whether anyone has expressed concern about an individual's use of heroin.","Concern About Your Use of Heroin | Has anyone expressed concern about your use of heroin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086925","Use Any Other Drug","C125141","A question about whether an individual uses or used any other drug.","Use Any Other Drug | Did you use any other drug | Use Another Drug | Use Other Drug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086672","Other Drug Taken","C125142","A question about what other drug an individual is taking or took.","Other Drug Taken | What did you take",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086290","FACT-M Questionnaire","C125144","A subscale complement to the FACT-G developed specifically for evaluating the quality of life of melanoma patients.","FACT-M Questionnaire | FACT-M | Functional Assessment of Cancer Therapy - Melanoma | Functional Assessment of Cancer Therapy Melanoma Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086407","Have Pain at Melanoma Site","C125145","A question about whether an individual has or had pain at their melanoma site or surgical site.","Have Pain at Melanoma Site | I have pain at my melanoma site or surgical site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084930","Have Noticed New Changes in Skin","C125146","A question about whether an individual has or had noticed changes in their skin.","Have Noticed New Changes in Skin | Changes in skin | Have Changes in Skin | I have noticed new changes in my skin (lumps, bumps, color)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086969","Worry About Appearance of Surgical Scars","C125147","A question about whether an individual worries or worried about the appearance of surgical scars.","Worry About Appearance of Surgical Scars | I worry about the appearance of surgical scars",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086401","Have Noticed Blood in Stool","C125148","A question about whether an individual has or had noticed blood in their stool.","Have Noticed Blood in Stool | I have noticed blood in my stool",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086528","Isolate Myself from Others Because of Condition","C125149","A question about whether an individual isolates or isolated themselves from others because of their condition.","Isolate Myself from Others Because of Condition | I isolate myself from others because of my condition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086383","Have Difficulty Thinking Clearly","C125150","A question about whether an individual has or had difficulty thinking clearly.","Have Difficulty Thinking Clearly | I have difficulty thinking clearly (remembering, concentrating)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086412","Have Swelling at Melanoma Site","C125151","A question about whether an individual has or had swelling at their melanoma site.","Have Swelling at Melanoma Site | I have swelling at my melanoma site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086411","Have Swelling as Result of Surgery","C125152","A question about whether an individual has or had swelling as a result of surgery.","Have Swelling as Result of Surgery | I have swelling as a result of surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086033","Bothered by Amount of Swelling","C125153","A question about whether an individual is or was bothered by the amount of swelling.","Bothered by Amount of Swelling | I am bothered by the amount of swelling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086610","Movement of Swollen Area is Painful","C125154","A question about whether the movement of an individual's swollen area is or was painful.","Movement of Swollen Area is Painful | Movement of my swollen area is painful",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086877","Swelling Keeps Me from Doing Things I Want to Do","C125155","A question about whether an individual's swelling keeps or kept them from doing the things they want to do.","Swelling Keeps Me from Doing Things I Want to Do | Swelling keeps me from doing the things I want to do",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086876","Swelling Keeps Me From Wearing What I Want to Wear","C125156","A question about whether an individual's swelling keeps or kept them from wearing clothes or shoes they want or wanted to wear.","Swelling Keeps Me From Wearing What I Want to Wear | Swelling keeps me from wearing clothes or shoes I want to wear",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086304","Feel Numbness at Surgical Site","C125157","A question about whether an individual feels or felt numbness at their surgical site.","Feel Numbness at Surgical Site | Feel Surgical Site Numbness | I feel numbness at my surgical site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086388","Have Good Range of Movement in My Arm or Leg","C125158","A question about whether an individual has or had good range of movement in their arm or leg.","Have Good Range of Movement in My Arm or Leg | I have good range of movement in my arm or leg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086292","FAIT-U Questionnaire","C125159","A symptom-specific subscale of the FACIT scales that is used to assess how urinary incontinence affects an individual's life.","FAIT-U Questionnaire | FAIT-U | Functional Assessment of Incontinence Therapy - Urinary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086417","Have to Limit Physical Activity Because of Condition","C125160","A question about whether an individual has or had to limit their physical activity because of their condition.","Have to Limit Physical Activity Because of Condition Question | Have to Limit Physical Activity Because of Condition | Have to Limit Physical Activity Because of Condition | I have to limit my physical activity because of my condition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086418","Have to Limit Social Activity Because of Condition","C125161","A question about whether an individual has or had to limit their social activity because of their condition.","Have to Limit Social Activity Because of Condition Question | Have to Limit Social Activity Because of Condition | Have to Limit Social Activity Because of Condition | I have to limit my social activity because of my condition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086305","Feel Overwhelmed by Condition","C125163","A question about whether an individual feels or felt overwhelmed by their condition.","Feel Overwhelmed by Condition | I feel overwhelmed by my condition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086564","Mass Effect","C125178","The pressure and/or displacement of adjacent tissues that results from the growth of a mass.","Mass Effect | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086580","Midline Shift","C125179","A radiologic finding that describes the movement of the brain beyond the center line.","Midline Shift | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1186706","Alimentary Bolus","C125189","A soft mass or lump of chewed food that is passed from the mouth into the esophagus and the stomach.","Alimentary Bolus | Bolus | Bolus of Food | Bolus of Ingested Food",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0193398","Partial Hepatectomy","C15394","Partial removal of the liver","Partial Hepatectomy | partial excision of liver | subtotal hepatectomy",,,,,,,,,,,,,,,"4322818","Partial hepatectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086728","Past Year","C125217","A period of time consisting of the 12 months before the present.","Past Year | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086331","Frequency Any Tobacco Use","C125218","A question about how often an individual uses or used any tobacco product.","Frequency Any Tobacco Use | How Often Use Any Tobacco Product | Used any tobacco product (cigarettes, e-cigarettes, cigars, pipes, or smokeless tobacco)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086378","Have 5 or More Drinks in One Day","C125219","A question about how often an individual has or had five or more alcoholic drinks in one day.","Have 5 or More Drinks in One Day | Had 5 or more drinks in one day | Have 5 or More Alcoholic Drinks in One Day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086377","Have 4 or More Drinks in One Day","C125220","A question about how often an individual has or had four or more alcoholic drinks in one day.","Have 4 or More Drinks in One Day | Had 4 or more drinks in one day | Have 4 or More Alcoholic Drinks in One Day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086332","Frequency Medication Use For the Feeling, To Get High, More Often, or in Larger Doses than Prescribed","C125222","A question about how often an individual uses or used any medication just for the feeling, to get high, or more often or in larger doses than prescribed.","Frequency Medication Use For the Feeling, To Get High, More Often, or in Larger Doses than Prescribed | How Often Use Medication For the Feeling, To Get High, More Often, or in Larger Doses than Prescribed | Used any of the following medications just for the feeling, to get high, or more often or in larger doses than prescribed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086330","Frequency Any Illegal Drug Use","C125223","A question about how often an individual uses or used any illegal drugs.","Frequency Any Illegal Drug Use | How Often Use Any Illegal Drugs | Used any illegal drugs including marijuana, cocaine or crack, heroin, methamphetamine, hallucinogens, ecstasy/MDMA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3841784","Daily or Almost Daily Response","C125224","A subjective response that something happens daily or almost daily.","Daily or Almost Daily Response | Daily or Almost Daily",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3853087","Once or Twice Response","C125226","An indication that something occurs or occurred once or twice.","Once or Twice Response | Once or Twice | Once or Twice",,,,,,,,,,,,,,,"763744","One to two times",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0451394","Profile of Mood States Questionnaire","C125221","A 65-item self-report questionnaire that utilizes a 5-point Likert Scale rating system to assess an individual's mood state.","Profile of Mood States Questionnaire | POMS Questionnaire | Profile of Mood States",,,,,,,,,,,,,,,"4166593","Profile of mood states",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4085326","How True Feel Exhausted Right Now","C125225","A question about the degree to which an individual feels exhausted right now.","How True Feel Exhausted Right Now | Exhausted | How Exhausted at Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087037","How True Feel Ready to Fight Right Now","C125227","A question about the degree to which an individual feels ready to fight right now.","How True Feel Ready to Fight Right Now | How Ready to Fight at Present | Ready to Fight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086494","How True Feel Good-natured Right Now","C125229","A question about the degree to which an individual feels good-natured right now.","How True Feel Good-natured Right Now | Good-natured | How Good-natured at Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084751","How True Feel Gloomy Right Now","C125232","A question about the degree to which an individual feels gloomy right now.","How True Feel Gloomy Right Now | Gloomy | How Gloomy at Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086491","How True Feel Desperate Right Now","C125233","A question about the degree to which an individual feels desperate right now.","How True Feel Desperate Right Now | Desperate | How Desperate at Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084898","How True Feel Sluggish Right Now","C125234","A question about the degree to which an individual feels sluggish right now.","How True Feel Sluggish Right Now | How Sluggish at Present | Sluggish",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086495","How True Feel Rebellious Right Now","C125235","A question about the degree to which an individual feels rebellious right now.","How True Feel Rebellious Right Now | How Rebellious at Present | Rebellious",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086498","How True Feel Weary Right Now","C125236","A question about the degree to which an individual feels weary right now.","How True Feel Weary Right Now | How Weary at Present | Weary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084717","How True Feel Bewildered Right Now","C125237","A question about the degree to which an individual feels bewildered right now.","How True Feel Bewildered Right Now | Bewildered | How Bewildered at Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084853","How True Feel Alert Right Now","C125240","A question about the degree to which an individual feels alert right now.","How True Feel Alert Right Now | Alert | How Alert at Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086490","How True Feel Deceived Right Now","C125242","A question about the degree to which an individual feels deceived right now.","How True Feel Deceived Right Now | Deceived | How Deceived at Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086493","How True Feel Furious Right Now","C125244","A question about the degree to which an individual feels furious right now.","How True Feel Furious Right Now | Furious | How Furious at Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087021","How True Feel Effacious Right Now","C125245","A question about the degree to which an individual feels effacious right now.","How True Feel Effacious Right Now | Effacious | How Effacious at Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085650","How True Feel Trusting Right Now","C125246","A question about the degree to which an individual feels trusting right now.","How True Feel Trusting Right Now | How Trusting at Present | Trusting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086492","How True Feel Full of Pep Right Now","C125247","A question about the degree to which an individual feels full of pep right now.","How True Feel Full of Pep Right Now | Full of pep | How Full of Pep at Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086487","How True Feel Bad-tempered Right Now","C125248","A question about the degree to which an individual feels bad-tempered right now.","How True Feel Bad-tempered Right Now | Bad-tempered | How Bad-tempered at Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085864","How True Feel Forgetful Right Now","C125249","A question about the degree to which an individual feels forgetful right now.","How True Feel Forgetful Right Now | Forgetful | How Forgetful at Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086489","How True Feel Carefree Right Now","C125250","A question about the degree to which an individual feels carefree right now.","How True Feel Carefree Right Now | Carefree | How Carefree at Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085331","How True Feel Terrified Right Now","C125251","A question about the degree to which an individual feels terrified right now.","How True Feel Terrified Right Now | How Terrified at Present | Terrified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084891","How True Feel Guilty Right Now","C125252","A question about the degree to which an individual feels guilty right now.","How True Feel Guilty Right Now | Guilty | How Guilty at Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086497","How True Feel Vigorous Right Now","C125253","A question about the degree to which an individual feels vigorous right now.","How True Feel Vigorous Right Now | How Vigorous at Present | Vigorous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086496","How True Feel Uncertain About Things Right Now","C125254","A question about the degree to which an individual feels uncertain about things right now.","How True Feel Uncertain About Things Right Now | How Uncertain About Things at Present | Uncertain about things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086488","How True Feel Bushed Right Now","C125255","A question about the degree to which an individual feels bushed right now.","How True Feel Bushed Right Now | Bushed | How Bushed at Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085643","Moderate Response","C125256","A subjective answer of a degree of agreement that is approximately halfway between the highest and lowest degrees of agreement.","Moderate Response | Moderate | Moderately",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085555","Extreme Response","C125257","A subjective answer of the highest degree of agreement.","Extreme Response | Extreme | Extremely",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505128","Memorial Symptom Assessment Scale","C125238","A patient-rated instrument developed to provide multidimensional information about a diverse group of common symptoms. This 32-question, self-rated questionnaire evaluates the prevalence, characteristics, and distress associated with each of the symptoms.","Memorial Symptom Assessment Scale | MSAS | Memorial Symptom Assessment Scale - MSAS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086568","Memorial Symptom Assessment Scale - Short Form","C125239","An abbreviated version of the Memorial Symptom Assessment Scale designed to evaluate the burden of physical and psychological symptoms in advanced cancer patients.","Memorial Symptom Assessment Scale - Short Form | MSAS-SF | Memorial Symptom Assessment Scale - Short Form - MSAS-SF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084785","How Often Difficulty Concentrating","C125241","A question about how often an individual has or had difficulty concentrating.","How Often Difficulty Concentrating | Difficulty Concentrating Frequency | Difficulty concentrating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085646","How Often Feeling Nervous","C125268","A question about how often an individual feels or felt nervous.","How Often Feeling Nervous | Feeling nervous | Frequency of Feeling Nervous | Frequency of Nervous Feelings | How Often Nervous Feelings",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085552","How Often Dry Mouth","C125270","A question about how often an individual has or had dry mouth.","How Often Dry Mouth | Dry Mouth Frequency | Dry mouth | Frequency of Dry Mouth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084796","How Often Nausea","C125272","A question about how often an individual has or had nausea.","How Often Nausea | Frequency of Nausea | How Often Have Nausea | Nausea | Nausea Frequency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084789","How Often Feeling Drowsy","C125273","A question about how often an individual feels or felt drowsy.","How Often Feeling Drowsy | Drowsiness Frequency | Feeling drowsy | Frequency Feeling Drowsy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084743","How Often Have Numbness or Tingling in Hands or Feet","C125274","A question about how often an individual has or had numbness or tingling in their hands or feet.","How Often Have Numbness or Tingling in Hands or Feet | Frequency of Numbness or Tingling in Hands or Feet | Numbness/tingling in hands/feet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085223","How Often Difficulty Sleeping","C125275","A question about how often an individual has or had difficulty sleeping.","How Often Difficulty Sleeping | Difficulty Sleeping Frequency | Difficulty sleeping | Frequency of Difficulty Sleeping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085559","How Often Feeling Bloated","C125276","A question about how often an individual feels or felt bloated.","How Often Feeling Bloated | Feeling Bloated Frequency | Feeling bloated | Frequency Feeling Bloated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085563","How Often Problems with Urination","C125277","A question about how often an individual has or had problems with urination.","How Often Problems with Urination | Frequency Problem with Urination | Frequency Urination Problem | How Often Urination Problem | Problems with urination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084769","How Often Vomiting","C125278","A question about how often an individual vomits or vomited.","How Often Vomiting | Frequency of Vomiting | How Often Vomited | Vomiting | Vomiting Frequency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084763","How Often Shortness of Breath","C125279","A question about how often an individual has or had shortness or breath.","How Often Shortness of Breath | Frequency of Shortness of Breath | Shortness of Breath Frequency | Shortness of breath",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085317","How Often Diarrhea","C125280","A question about how often an individual has or had diarrhea.","How Often Diarrhea | Diarrhea | Diarrhea Frequency | Frequency of Diarrhea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085226","How Often Feel Sad","C125281","A question about how often an individual feels or felt sad.","How Often Feel Sad | Feeling sad | Frequency Feeling Sad | Frequency of Sadness | Sadness Frequency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085205","How Often Sweats","C125282","A question about how often an individual has or had sweats.","How Often Sweats | Frequency of Sweats | Sweats",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084900","How Often Worry","C125283","A question about how often an individual worries or worried.","How Often Worry | Frequency of Worrying | Worry Frequency | Worrying",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085561","How Often Problems with Sexual Interest or Activity","C125284","A question about how often an individual has or had problems with sexual interest or activity.","How Often Problems with Sexual Interest or Activity | Frequency of Problems with Sexual Interest or Activity | Problems with sexual interest or activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505127","How Often Itching","C125285","A question about how often an individual has or had itching.","How Often Itching | Frequency of Itching | Itching | Itching Frequency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085657","How Often Lack of Appetite","C125286","A question about how often an individual has or had a lack of appetite.","How Often Lack of Appetite | Frequency of Lack of Appetite | Lack of Appetite Frequency | Lack of appetite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828730","Off-Site","C113778","Taking place or located away from the study site.","Off-Site | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085547","How Often Dizzy","C125287","A question about how often an individual feels or felt dizzy.","How Often Dizzy | Dizziness | Dizzy Frequency | Frequency of Dizziness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085224","How Often Difficulty Swallowing","C125288","A question about how often an individual has or had difficulty swallowing.","How Often Difficulty Swallowing | Difficulty Swallowing Frequency | Difficulty swallowing | Frequency of Difficulty Swallowing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085225","How Often Feel Irritable","C125289","A question about how often an individual feels or felt irritable.","How Often Feel Irritable | Feeling irritable | Frequency of Feeling Irritable | How Often Felt Irritable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085644","How Often Mouth Sores","C125290","A question about how often an individual has or had mouth sores.","How Often Mouth Sores | Frequency of Mouth Sores | Mouth Sores Frequency | Mouth sores",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085639","How Often Change in Food Tastes","C125291","A question about how often an individual has or had a change in how food tastes.","How Often Change in Food Tastes | Change in the way food tastes | Frequency of Change in Food Tastes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084776","How Often Weight Loss","C125292","A question about how often an individual has or had weight loss.","How Often Weight Loss | Frequency of Weight Loss | Weight Loss Frequency | Weight loss",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084893","How Often Hair Loss","C125293","A question about how often an individual has or had hair loss.","How Often Hair Loss | Frequency of Hair Loss | Hair Loss Frequency | Hair loss",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084722","How Often Constipation","C125294","A question about how often an individual has or had constipation.","How Often Constipation | Constipation | Constipation Frequency | Frequency of Constipation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085206","How Often Swelling of Arms or Legs","C125295","A question about how often an individual has or had swelling of their arms or legs.","How Often Swelling of Arms or Legs | Frequency of Swelling of Arms or Legs | Swelling of Arms or Legs Frequency | Swelling of arms or legs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084866","How Often Don't Look Like Myself","C125296","A question about how often an individual feels or felt that they don't look like themselves.","How Often Don't Look Like Myself | Frequency Don't Look Like Myself | I don't look like myself",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085852","How Often Changes in Skin","C125297","A question about how often an individual has or had skin changes.","How Often Changes in Skin | Changes in skin | Frequency of Changes in Skin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085319","Usual Severity Difficulty Concentrating","C125298","A question about the usual severity of an individual's difficulty concentrating.","Usual Severity Difficulty Concentrating | Difficulty concentrating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085210","Usual Severity Pain","C125299","A question about the usual severity of an individual's pain.","Usual Severity Pain | Pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084913","Usual Severity Lack of Energy","C125300","A question about the usual severity of an individual's lack of energy.","Usual Severity Lack of Energy | Lack of energy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084725","Usual Severity Cough","C125301","A question about the usual severity of an individual's cough.","Usual Severity Cough | Cough",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085232","Usual Severity Feeling Nervous","C125302","A question about the usual severity of an individual's feeling of nervousness.","Usual Severity Feeling Nervous | Feeling nervous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085551","Usual Severity Dry Mouth","C125303","A question about the usual severity of an individual's dry mouth.","Usual Severity Dry Mouth | Dry mouth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085661","Usual Severity Nausea","C125304","A question about the usual severity of an individual's nausea.","Usual Severity Nausea | Nausea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084907","Usual Severity Feeling of Drowsiness","C125305","A question about the usual severity of an individual's drowsiness.","Usual Severity Feeling of Drowsiness | Feeling drowsy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084745","Usual Severity Numbness or Tingling in Hands or Feet","C125306","A question about the usual severity of an individual's numbness or tingling in their hands or feet.","Usual Severity Numbness or Tingling in Hands or Feet | Numbness/tingling in hands/feet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085321","Usual Severity Difficulty Sleeping","C125307","A question about the usual severity of an individual's difficulty sleeping.","Usual Severity Difficulty Sleeping | Difficulty sleeping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085233","Usual Severity Feeling of Bloatedness","C125308","A question about the usual severity of an individual's feeling of bloatedness","Usual Severity Feeling of Bloatedness | Feeling bloated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084797","Usual Severity Problems with Urination","C125309","A question about the usual severity of an individual's problems with urination.","Usual Severity Problems with Urination | Problems with urination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084768","Usual Severity Vomiting","C125310","A question about the usual severity of an individual's vomiting.","Usual Severity Vomiting | Vomiting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084762","Usual Severity Shortness of Breath","C125311","A question about the usual severity of an individual's shortness of breath.","Usual Severity Shortness of Breath | Shortness of breath",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084802","Usual Severity Diarrhea","C125312","A question about the usual severity of an individual's diarrhea.","Usual Severity Diarrhea | Diarrhea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084780","Usual Severity Feeling of Sadness","C125313","A question about the usual severity of an individual's feeling of sadness.","Usual Severity Feeling of Sadness | Feeling sad",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084779","Usual Severity Sweats","C125314","A question about the usual severity of an individual's sweats.","Usual Severity Sweats | Sweats",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084781","Usual Severity Worry","C125315","A question about the usual severity of an individual's worry.","Usual Severity Worry | Worrying",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085235","Usual Severity Problems with Sexual Interest or Activity","C125316","A question about the usual severity of an individual's problems with sexual interest or activity.","Usual Severity Problems with Sexual Interest or Activity | Problems with sexual interest or activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504098","Usual Severity Itching","C125317","A question about the usual severity of an individual's itching.","Usual Severity Itching | Itching",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085658","Usual Severity Lack of Appetite","C125318","A question about the usual severity of an individual's appetite.","Usual Severity Lack of Appetite | Lack of appetite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085548","Usual Severity Dizziness","C125319","A question about the usual severity of an individual's dizziness.","Usual Severity Dizziness | Dizziness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085231","Usual Severity Difficulty Swallowing","C125320","A question about the usual severity of an individual's difficulty swallowing.","Usual Severity Difficulty Swallowing | Difficulty swallowing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084811","Usual Severity Feeling Irritable","C125321","A question about the usual severity of an individual's feeling irritable.","Usual Severity Feeling Irritable | Feeling irritable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085234","Usual Severity Mouth Sores","C125322","A question about the usual severity of an individual's mouth sores.","Usual Severity Mouth Sores | Mouth sores",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085230","Usual Severity Change in the Way Food Tastes","C125323","A question about the usual severity of an individual's change in the way food tastes.","Usual Severity Change in the Way Food Tastes | Change in the way food tastes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084775","Usual Severity Weight Loss","C125324","A question about the usual severity of an individual's weight loss.","Usual Severity Weight Loss | Weight loss",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084792","Usual Severity Hair Loss","C125325","A question about the usual severity of an individual's hair loss.","Usual Severity Hair Loss | Hair loss",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084724","Usual Severity Constipation","C125326","A question about the usual severity of an individual's constipation.","Usual Severity Constipation | Constipation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085207","Usual Severity Swelling of Arms or Legs","C125327","A question about the usual severity of an individual's swelling of arms or legs.","Usual Severity Swelling of Arms or Legs | Swelling of arms or legs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084867","Usual Severity Feeling of I Don't Look Like Myself","C125328","A question about the usual severity of an individual's feeling of not looking like themselves.","Usual Severity Feeling of I Don't Look Like Myself | I don't look like myself",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085853","Usual Severity Changes in Skin","C125329","A question about the usual severity of an individual's changes in skin.","Usual Severity Changes in Skin | Changes in skin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085320","How Much Distress Difficulty Concentrating","C125330","A question about an individual's distress from their difficulty concentrating.","How Much Distress Difficulty Concentrating | Difficulty concentrating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085212","How Much Distress Pain","C125331","A question about an individual's distress from their pain.","How Much Distress Pain | Pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085220","How Much Distress Lack of Energy","C125332","A question about an individual's distress from their lack of energy.","How Much Distress Lack of Energy | Lack of energy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084726","How Much Distress Cough","C125333","A question about an individual's distress from their cough.","How Much Distress Cough | Cough",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085645","How Much Distress Feeling Nervous","C125334","A question about an individual's distress from their feeling of nervousness.","How Much Distress Feeling Nervous | Feeling nervous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084910","How Much Distress Dry Mouth","C125335","A question about an individual's distress from their dry mouth.","How Much Distress Dry Mouth | Dry mouth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085222","How Much Distress Nausea","C125336","A question about an individual's distress from their nausea.","How Much Distress Nausea | Nausea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085218","How Much Distress Feeling Drowsy","C125337","A question about an individual's distress from feeling of drowsy.","How Much Distress Feeling Drowsy | Feeling drowsy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084744","How Much Distress Numbness or Tingling in Hands or Feet","C125338","A question about an individual's distress from their numbness or tingling in hands or feet.","How Much Distress Numbness or Tingling in Hands or Feet | Numbness/tingling in hands/feet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085322","How Much Distress Difficulty Sleeping","C125339","A question about an individual's distress from their difficulty sleeping.","How Much Distress Difficulty Sleeping | Difficulty sleeping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085558","How Much Distress Feeling Bloated","C125340","A question about an individual's distress from feeling bloated.","How Much Distress Feeling Bloated | Feeling bloated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085562","How Much Distress Problems with Urination","C125341","A question about an individual's distress from their problems with urination.","How Much Distress Problems with Urination | Problems with urination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084766","How Much Distress Vomiting","C125342","A question about an individual's distress from their vomiting.","How Much Distress Vomiting | Vomiting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084764","How Much Distress Shortness of Breath","C125343","A question about an individual's distress from their shortness of breath.","How Much Distress Shortness of Breath | Shortness of breath",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084784","How Much Distress Diarrhea","C125344","A question about an individual's distress from their diarrhea.","How Much Distress Diarrhea | Diarrhea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085647","How Much Distress Feeling Sad","C125345","A question about an individual's distress from their feeling of sadness.","How Much Distress Feeling Sad | Feeling sad",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085204","How Much Distress Sweats","C125346","A question about an individual's distress from their sweats.","How Much Distress Sweats | Sweats",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084901","How Much Distress Worrying","C125347","A question about an individual's distress from their worrying.","How Much Distress Worrying | Worrying",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085560","How Much Distress Problems with Sexual Interest or Activity","C125348","A question about an individual's distress from their problems with sexual interest or activity.","How Much Distress Problems with Sexual Interest or Activity | Problems with sexual interest or activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504128","How Much Distress Itching","C125349","A question about an individual's distress from their itching.","How Much Distress Itching | Itching",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084806","How Much Distress Lack of Appetite","C125350","A question about an individual's distress from their lack of appetite.","How Much Distress Lack of Appetite | Lack of appetite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085549","How Much Distress Dizziness","C125351","A question about an individual's distress from their dizziness.","How Much Distress Dizziness | Dizziness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084786","How Much Distress Difficulty Swallowing","C125352","A question about an individual's distress from their difficulty swallowing.","How Much Distress Difficulty Swallowing | Difficulty swallowing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084790","How Much Distress Feeling Irritable","C125353","A question about an individual's distress from feeling irritable.","How Much Distress Feeling Irritable | Feeling irritable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085221","How Much Distress Mouth Sores","C125354","A question about an individual's distress from their mouth sores.","How Much Distress Mouth Sores | Mouth sores",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085638","How Much Distress Change in the Way Food Tastes","C125355","A question about an individual's distress from a change in the way food tastes.","How Much Distress Change in the Way Food Tastes | Change in the way food tastes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084777","How Much Distress Weight Loss","C125356","A question about an individual's distress from their weight loss.","How Much Distress Weight Loss | Weight loss",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084894","How Much Distress Hair Loss","C125357","A question about an individual's distress from their hair loss.","How Much Distress Hair Loss | Hair loss",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084807","How Much Distress Swelling of Arms or Legs","C125359","A question about an individual's distress from their swelling of arms or legs.","How Much Distress Swelling of Arms or Legs | How Much Distress Swelling of arms or legs | Swelling of arms or legs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084794","How Much Distress I Don't Look Like Myself","C125360","A question about an individual's distress from their not looking like themselves.","How Much Distress I Don't Look Like Myself | I don't look like myself",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085217","How Much Distress Changes in Skin","C125361","A question about an individual's distress from their changes in skin.","How Much Distress Changes in Skin | Changes in skin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086558","MSAS Global Distress Index","C125362","A subscale of the Memorial Symptom Assessment Scale that measures overall symptom distress.","MSAS Global Distress Index | MSAS-GDI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086559","MSAS Physical Symptom Subscale","C125363","A subscale of the Memorial Symptom Assessment Scale that is the average of the frequency, severity, and distress associated with the symptoms of lack of appetite, lack of energy, pain, feeling drowsy, constipation, dry mouth, nausea, vomiting, change in taste, weight loss, feeling bloated, and dizziness.","MSAS Physical Symptom Subscale | MSAS-PHYS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086560","MSAS Psychological Symptom Subscale","C125364","A subscale of the Memorial Symptom Assessment Scale that is the average of the frequency, severity, and distress associated with worrying, feeling sad, feeling nervous, difficulty sleeping, feeling irritable, and difficulty concentrating.","MSAS Psychological Symptom Subscale | MSAS-PSYCH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504144","Total MSAS Score","C125365","A subscale of the Memorial Symptom Assessment Scale that is the average of the symptom scores of all 32 symptoms in the full MSAS instrument.","Total MSAS Score | TMSAS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086764","Rarely or None of the Time","C125366","A response indicating that something happens or happened never or almost never.","Rarely or None of the Time | Rarely or none of the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086861","Some or a Little of the Time","C125367","A response indicating that something happens or happened a small amount of the time but not often.","Some or a Little of the Time | Some or a little of the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087062","Occasionally or a Moderate Amount of Time","C125368","A response indicating that something happens or happened from time to time but not excessively.","Occasionally or a Moderate Amount of Time | Occasionally or a moderate amount of time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3174325","Bothered by Things That Usually Don't Bother Me","C125369","A question about whether an individual is or was bothered by things that aren't usually bothersome.","Bothered by Things That Usually Don't Bother Me | I was bothered by things that usually don't bother me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086225","Could Not Shake Off the Blues Even with Help from Family","C125371","A question about whether an individual feels or felt that they could not shake off the blues even with the help from family.","Could Not Shake Off the Blues Even with Help from Family | I felt that I could not shake off the blues even with help from my family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086308","Felt Just as Good as Other People","C125372","A question about whether an individual feels or felt that they were just as good as other people.","Felt Just as Good as Other People | I felt that I was just as good as other people",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086375","Had Trouble Keeping My Mind on What I was Doing","C125373","A question about whether an individual has or had trouble keeping their mind on what they were doing.","Had Trouble Keeping My Mind on What I was Doing | I had trouble keeping my mind on what I was doing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086307","Felt Everything was an Effort","C125374","A question about whether an individual feels or felt that everything they did was an effort.","Felt Everything was an Effort | I felt that everything I did was an effort",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086545","Life Has Been a Failure","C125375","A question about whether an individual thinks or thought their life has been a failure.","Life Has Been a Failure | I thought my life had been a failure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084868","Felt Happy","C125376","A question about whether an individual is or was happy.","Felt Happy | Feel Happy | I was happy | Was Happy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086887","Talked Less Than Usual","C125377","A question about whether an individual talks or talked less than usual.","Talked Less Than Usual | I talked less than usual | Talked Less",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086309","Felt Lonely","C125378","A question about whether an individual feels or felt lonely.","Felt Lonely | Feel Lonely | I felt lonely",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086738","People Were Unfriendly","C125379","A question about whether an individual feels or felt people were unfriendly.","People Were Unfriendly | People were unfriendly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086373","Had Crying Spells","C125380","A question about whether an individual has or had crying spells.","Had Crying Spells | Cried | I had crying spells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086224","Could Not Get Going","C125382","A question about whether an individual can or could not get going.","Could Not Get Going | I could not get going",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0184633","Oxygen Therapy","C94624","The administration of oxygen to an individual, usually to aid in respiration.","Oxygen Therapy | Oxygen therapy | oxygen therapy | supplemental oxygen therapy",,,,,,,,,,,,,,,"4239130","Oxygen therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4085969","Anti-Chimeric Antigen Receptor Antibody","C125207","Any antibody that recognizes a chimeric antigen receptor complex.","Anti-Chimeric Antigen Receptor Antibody | Anti-CAR Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087005","Cell Cycle Profile","C125206","The identification and quantitation of cells found in each phase of the cell cycle.","Cell Cycle Profile | Cell Cycle Analysis | Cell-Cycle Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086255","EGFR NM_005228.3:c.2303G>T","C125209","A nucleotide substitution at position 2303 of the coding sequence of the EGFR gene where guanine has been mutated to thymine.","EGFR NM_005228.3:c.2303G>T | EGFR c.2303G>T | ERBB c.2303G>T | ERBB1 c.2303G>T | Epidermal Growth Factor Receptor Gene c.2303G>T | HER1 c.2303G>T | NM_005228.3:c.2303G>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086256","EGFR NP_005219.2:p.S768I","C125210","A change in the amino acid residue at position 768 in the epidermal growth factor receptor protein where serine has been replaced by isoleucine.","EGFR NP_005219.2:p.S768I | Activating S768I Mutation | EGFR Exon 20 S768I | EGFR NP_005219.2:p.Ser768Ile | EGFR S768I | EGFR S768I Mutation | EGFR Ser768Ile | EGFR p.S768I | EGFR p.Ser768Ile | Epidermal Growth Factor Receptor S768I | NP_005219.2:p.Ser768Ile | Proto-Oncogene c-ErbB-1 S768I | Receptor Tyrosine-Protein Kinase erbB-1 S768I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086502","Hydroxylated Polybrominated Diphenyl Ether","C125230","Hydroxylated metabolites of polybrominated diphenyl ether (PBDE)-based flame retardants. PBDEs are being phased out of use because of their environmental persistence and potential hormone-disrupting effects in humans. In addition to the potential toxicity of OH-PBDEs in humans, OH-PBDE exposure may also disrupt oxidative phosphorylation.","Hydroxylated Polybrominated Diphenyl Ether | OH-PBDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086540","Lead Pb-207","C125228","A stable isotope of lead (Pb) and the final non-radioactive product of radioactive decay in the actinium series (uranium-235) or plutonium cascade (plutonium-239), which both include the daughter radionuclide radium-223 (Ra-223). As Ra-223 is used to treat metastatic bone disease and Ra-223 decays to the stable isotope Pb-207, the concentration of Pb-207 found in bone metastases may be used to estimate the amount of Ra-223 that accumulated in the bone during treatment.","Lead Pb-207 | Lead 207 | Lead Pb 207 | Lead-207 | Pb-207 | Pb207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417006","MAP2 Gene","C125214","This gene may play a role in maintaining microtubules.","MAP2 Gene | MAP2 | Microtubule Associated Protein 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0597134","oral bacteria","C125208","The collection of microorganisms existing in the oral cavity of an organism.","Oral Microbiome | OMC Profile | Oral Flora | Oral Microbial Community Profile | Oral Microbiota | Oral Microflora",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2350562","Polybrominated Diphenyl Ether","C125231","A mixture of synthetic solids, containing aromatic rings connected by an ether bond and containing one or more bromine atoms, that is virtually insoluble in water but is soluble in fat and various organic solvents and have been used in industrial applications as flame retardants. These compounds are being phased out of industrial use because of their environmental persistence and potential hormone-disrupting effects in humans. The primary routes of potential human exposure to polybrominated diphenyl ethers (PBDEs) are ingestion, inhalation, and dermal contact either for personnel associated with the manufacture or recycling of PDBEs or for people exposed to domestic products containing these chemicals.","Polybrominated Diphenyl Ether | PBDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1540007","TMEM37 Gene","C125211","This gene may be involved in the regulation of voltage-gated calcium transport.","TMEM37 Gene | TMEM37 | Transmembrane Protein 37 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0872262","RNA Analysis","C18473","Molecular biology procedures, including Northern Blot, Differential display, RT-PCR, and RNase protection for qualifying or quantifying RNA. (NCI/OSP)","RNA Analysis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0214828","Crofelemer","C125392","An oligomeric proanthocyanidin extracted from the latex produced by the tree Croton lechleri (Euphorbiaceae), with antidiarrheal, and potential antiviral and antimicrobial activities. Upon oral administration, crofelemer acts locally within the gastrointestinal (GI) tract by inhibiting both the cystic fibrosis transmembrane conductance regulator (CFTR) chloride ion (Cl-) channel and the calcium-activated Cl- channel (CaCC) expressed on the luminal surface of enterocytes. This inhibits the secretion of chloride ions into the intestinal lumen and prevents high volume water loss. By normalizing Cl- and water balance in the intestines, crofelemer relieves secretory diarrhea.","Crofelemer | CROFELEMER | Fulyzaq | SP 303 | SP-303 | Virend",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1997606","Bristol Stool Scale","C125393","A medical scale designed to classify human feces into seven categories by form.","Bristol Stool Scale | BSF | BSF Scale | BSFS | BSFS01 | Bristol Stool Chart | Bristol Stool Form Scale",,,,,,,,,,,,,,,"4177991","Bristol stool form scale",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0441729","Bristol Stool Type 1","C125394","Separate hard lumps, hard to pass; indicative of severe constipation.","Bristol Stool Type 1 | Type 1",,,,,,,,,,,,,,,"4120169","Type 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0441730","Bristol Stool Type 2","C125395","Lumpy and sausage-like; indicative of constipation.","Bristol Stool Type 2 | Type 2",,,,,,,,,,,,,,,"4120171","Type 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0441731","Bristol Stool Type 3","C125396","A sausage shape with cracks in the surface; normal stool.","Bristol Stool Type 3 | Type 3",,,,,,,,,,,,,,,"4123013","Type 3",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0441732","Bristol Stool Type 4","C125397","Like a smooth, soft sausage or snake; normal stool.","Bristol Stool Type 4 | Type 4",,,,,,,,,,,,,,,"4123014","Type 4",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0457499","Bristol Stool Type 5","C125398","Soft blobs with clear-cut edges, passed easily.","Bristol Stool Type 5 | Type 5",,,,,,,,,,,,,,,"4175862","Type 5",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1960442","Bristol Stool Type 6","C125399","Mushy pieces with ragged edges.","Bristol Stool Type 6 | Type 6",,,,,,,,,,,,,,,"4144164","Type 6",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086043","Bristol Stool Type 7","C125400","Liquid consistency with no solid pieces; indicative of diarrhea.","Bristol Stool Type 7 | Type 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085318","Have Difficulty Concentrating","C125405","A question about whether an individual has or had difficulty concentrating.","Have Difficulty Concentrating | Difficulty concentrating | Had Difficulty Concentrating | I have difficulty concentrating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085888","Problem with Urination","C125406","A question about whether an individual has or had a problem with urination.","Problem with Urination | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084908","Have Sweats","C125407","A question about whether an individual has or had sweats.","Have Sweats | Sweats",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085656","Problem with Sexual Interest or Activity","C125408","A question about whether an individual has or had problems with sexual interest or activity.","Problem with Sexual Interest or Activity | Problems with sexual interest or activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084788","Have Dizziness","C125409","A question about whether an individual has or had dizziness.","Have Dizziness | Dizziness | Have Been Dizzy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084787","Have Difficulty Swallowing","C125410","A question about whether an individual has or had difficulty in swallowing.","Have Difficulty Swallowing | Difficulty swallowing | Had Trouble Swallowing | Have you had trouble swallowing | Trouble Swallowing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084931","Have Swelling of Arms and/or Legs","C125413","A question about whether an individual has or had swelling of their arms or legs.","Have Swelling of Arms and/or Legs | Swelling of arms or legs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084865","Don't Look Like Myself","C125414","A question about whether an individual feels or felt like they don't look like themselves.","Don't Look Like Myself | I don't look like myself",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086469","How Much Distress Other Symptom 1","C125401","A question about an individual's distress from the first of their other symptoms.","How Much Distress Other Symptom 1 | Other 1 | Other Symptom 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086470","How Much Distress Other Symptom 2","C125402","A question about an individual's distress from the second of their other symptoms.","How Much Distress Other Symptom 2 | Other 2 | Other Symptom 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086471","How Much Distress Other Symptom 3","C125403","A question about an individual's distress from the third of their other symptoms.","How Much Distress Other Symptom 3 | Other 3 | Other Symptom 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3844702","Almost Constantly","C125404","A response indicating that something was occurring or recurring nearly continually without interruption.","Almost Constantly | Almost constantly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825195","Date of Therapeutic Procedure","C80454","The date that a specific therapeutic procedure was performed.","Date of Therapeutic Procedure | Date of Procedure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419384","RHEB Gene","C115281","This gene plays a role in the regulation of MTORC1-dependent signaling.","RHEB Gene | RHEB | Ras Homolog, mTORC1 Binding Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824746","CLIP1 Gene","C84464","This gene plays a role in both endocytosis and mitosis.","CLIP1 Gene | CAP-GLY Domain Containing Linker Protein 1 Gene | CLIP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812393","ErbB Receptors","C18506","A family of cellular proteins encoded by the c-erbB genes, including epidermal growth factor receptor. They are normally expressed in a variety of tissues of epithelial, mesenchymal, and neuronal origin.  They are overexpressed in a significant portion of adenocarcinomas found at various sites, especially in the breast. Gene amplification appears to be the predominant method leading to overexpression.","ErbB Receptor Family Protein | EGF Receptor Family | EGFR Family | ERBB Family | ERBB Receptor-Tyrosine Kinase Family | Epidermal Growth Factor Receptor Family | ErbB Receptor Tyrosine Kinase Family | HER Family | HER Family Receptor | Human Epidermal Growth Factor Receptor Family | erbB Receptor Family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416498","ITGB3 Gene","C38954","This gene plays a role in the mediation of platelet aggregation and wound repair.","ITGB3 Gene | ITGB3 | Integrin Subunit Beta 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824082","ZRSR2 Gene","C101120","This gene is involved in mRNA processing.","ZRSR2 Gene | ZRSR2 | Zinc Finger CCCH-type, RNA Binding Motif and Serine/Arginine Rich 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416485","ITGA2B Gene","C77162","This gene is involved in platelet aggregation.","ITGA2B Gene | ITGA2B | Integrin Subunit Alpha 2b Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274205","EGFR NM_005228.3:c.2573T>G","C98516","A nucleotide substitution at position 2573 of the coding sequence of the EGFR gene where thymine has been mutated to guanine.","EGFR NM_005228.3:c.2573T>G | EGFR c.2573T>G | ERBB c.2573T>G | ERBB1 c.2573T>G | Epidermal Growth Factor Receptor Gene c.2573T>G | HER1 c.2573T>G | NM_005228.3:c.2573T>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274206","ERBB c.2573_2574TG>GT","C98517","A complex substitution where the nucleotide sequence at positions 2573 and 2574 of the coding sequence of the EGFR gene has changed from thymine-guanine to guanine-thymine.","EGFR NM_005228.3:c.2573_2574delinsGT | EGFR NM_005228.3:c.2573_2574delTGinsGT | EGFR NM_005228.3:c.2573_2574delTGinsGT | EGFR c.2573_2574TG>GT | EGFR c.2573_2574delTGinsGT | ERBB c.2573_2574TG>GT | ERBB1 c.2573_2574TG>GT | Epidermal Growth Factor Receptor Gene c.2573_2574TG>GT | HER1 c.2573_2574TG>GT | NM_005228.3:c.2573_2574TG>GT | NM_005228.3:c.2573_2574delTGinsGT | NM_005228.3:c.2573_2574delinsGT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274207","NM_005228.3:c.2572_2573delCTinsAG","C98518","A complex substitution where the nucleotide sequence at positions 2572 and 2573 of the coding sequence of the EGFR gene has changed from cytosine-thymine to adenine-guanine.","EGFR NM_005228.3:c.2572_2573delinsAG | EGFR NM_005228.3:c.2572_2573delCTinsAG | EGFR NM_005228.3:c.2572_2573delCTinsAG | EGFR c.2572_2573CT>AG | EGFR c.2572_2573delCTinsAG | ERBB c.2572_2573CT>AG | ERBB1 c.2572_2573CT>AG | Epidermal Growth Factor Receptor Gene c.2572_2573CT>AG | HER1 c.2572_2573CT>AG | NM_005228.3:c.2572_2573CT>AG | NM_005228.3:c.2572_2573delCTinsAG | NM_005228.3:c.2572_2573delinsAG | NM_005228.3:c.2572_2573inv",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085255","SYP protein, human","C101146","Synaptophysin (313 aa, ~34 kDa) is encoded by the human SYP gene. This protein is involved in the targeting of synaptic vesicles.","Synaptophysin | Major Synaptic Vesicle Protein p38 | SYP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006629","Cadaver","C113674","The dead body of a human being.","Cadaver | ",,,,,,,,,,,,,,,"4126198","Cadaver",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL776663","Siltuximab","C61084","A chimeric, human-murine, monoclonal antibody targeting the pro-inflammatory cytokine interleukin 6 (IL-6), with antitumor and anti-inflammatory activities. Upon intravenous administration of siltuximab, this agent targets and binds to IL-6. This inhibits the binding of IL-6 to the IL-6 receptor (IL-6R), which results in the blockade of the IL-6/IL-6R-mediated signal transduction pathway. This inhibits cancer cell growth in tumors overexpressing IL-6.","Siltuximab | Anti-IL-6 Chimeric Monoclonal Antibody | CNTO 328 | CNTO-328 | CNTO328 | SILTUXIMAB | Sylvant | anti-IL-6 chimeric monoclonal antibody | cCLB8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086960","Was It Worth It Questionnaire","C125451","A questionnaire designed to measure a patient's opinion of their participation in a phase II or III treatment trial and their decision making regarding treatment.","Was It Worth It Questionnaire | WIWI | Was It Worth It (WIWI) Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086971","Worthwhile to Participate in Research Study","C125452","A question about whether an individual thinks it was worthwhile to participate in a research study.","Worthwhile to Participate in Research Study | Was it worthwhile for you to participate in this research study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086974","Would Participate in Research Study Again","C125453","A question about whether an individual would participate in a research study again.","Would Participate in Research Study Again | If you had it to do over, would you participate in this research study again",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086781","Recommend Participating in Research Study to Others","C125454","A question about whether an individual would recommend participation in a research study.","Recommend Participating in Research Study to Others | Would you recommend participating in this research study to others",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086679","Overall Quality of Life Change by Participating in Research Study","C125455","A question about how an individual's quality of life is or was changed by participation in a research study.","Overall Quality of Life Change by Participating in Research Study | Overall, did your quality of life change by participating in this research study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086675","Overall Experience Participating in Research Study","C125456","A question about an individual's experience while participating in a research study.","Overall Experience Participating in Research Study | Overall how was your experience of participating in this research study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086662","One Thing to Improve Experience Participating in Research Study","C125457","A question about the one thing an individual would recommend to improve their experience participating in a research study.","One Thing to Improve Experience Participating in Research Study | If there was one thing that could have been done to improve your experience in this research study, what would it be",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086886","Talk with Someone about Concerns","C125458","A question about whether an individual would like to talk to someone about their concerns.","Talk with Someone about Concerns | Would you like to talk with someone about your concerns",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084203","Improved","C125459","A subjective response indicating that something improved.","Improved | Better | IMPROVED | It improved",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086868","Stayed the Same","C125460","A subjective response indicating that something is unchanged.","Stayed the Same | It stayed the same",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084902","Got Worse","C125461","A subjective response indicating that something got worse.","Got Worse | It got worse | Worsened",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0304369","Tranylcypromine Sulfate","C61980","The sulfate salt form of tranylcypromine, an orally bioavailable, nonselective, irreversible, non-hydrazine inhibitor of both monoamine oxidase (MAO) and lysine-specific demethylase 1 (LSD1/BHC110), with antidepressant and anxiolytic activities, and potential antineoplastic activities. Upon oral administration, tranylcypromine exerts its antidepressant and anxiolytic effects through the inhibition of MAO, an enzyme that catalyzes the breakdown of the monoamine neurotransmitters serotonin, norepinephrine, epinephrine and dopamine. This increases the concentrations and activity of these neurotransmitters. Tranylcypromine exerts its antineoplastic effect through the inhibition of LSD1. Inhibition of LSD1 prevents the transcription of LSD1 target genes. LSD1, a flavin-dependent monoamine oxidoreductase and a histone demethylase, is upregulated in a variety of cancers and plays a key role in tumor cell proliferation, migration, and invasion.","Tranylcypromine Sulfate | (+-)-Trans-2-Phenylcyclopropylamine Sulfate (2:1) | 1-Amino-2-phenylcyclopropane Sulfate | Parnate | TRANYLCYPROMINE SULFATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085956","Ann Arbor Clinical Stage I","C125472","A clinical stage that refers to lymphoma involving a single lymph node region or a single extranodal organ (Ie).","Ann Arbor Clinical Stage I | Stage I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085960","Ann Arbor Pathologic Stage I","C125473","A pathologic stage that refers to lymphoma involving a single lymph node region or a single extranodal organ (Ie).","Ann Arbor Pathologic Stage I | Stage I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085954","Ann Arbor Clinical Stage II","C125474","A clinical stage that refers to lymphoma involving two or more node regions on the same side of the diaphragm or a single extranodal organ plus its regional lymph nodes with or without other nodes on the same side of the diaphragm (IIe).","Ann Arbor Clinical Stage II | Stage II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085958","Ann Arbor Pathologic Stage II","C125475","A pathologic stage that refers to lymphoma involving two or more node regions on the same side of the diaphragm or a single extranodal organ plus its regional lymph nodes with or without other nodes on the same side of the diaphragm (IIe).","Ann Arbor Pathologic Stage II | Stage II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085953","Ann Arbor Clinical Stage III","C125476","A clinical stage that refers to lymphoma involving node regions on both sides of the diaphragm, or an extralymphatic organ or site plus nodes on both sides of the diaphragm (IIIe), or lymph nodes on both sides of the diaphragm plus spleen (IIIs).","Ann Arbor Clinical Stage III | Stage III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085957","Ann Arbor Pathologic Stage III","C125477","A pathologic stage that refers to lymphoma involving node regions on both sides of the diaphragm, or an extralymphatic organ or site plus nodes on both sides of the diaphragm (IIIe), or lymph nodes on both sides of the diaphragm plus spleen (IIIs).","Ann Arbor Pathologic Stage III | Stage III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085955","Ann Arbor Clinical Stage IV","C125478","A clinical stage that refers to diffuse extralymphatic involvement by lymphoma.","Ann Arbor Clinical Stage IV | Stage IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085959","Ann Arbor Pathologic Stage IV","C125479","A pathologic stage that refers to diffuse extralymphatic involvement by lymphoma.","Ann Arbor Pathologic Stage IV | Stage IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086731","Patient Satisfaction Questionnaire Short Form","C125501","A short-form version of the 50-item Patient Satisfaction Questionnaire III designed to evaluate patient satisfaction with seven aspects of medical care.","Patient Satisfaction Questionnaire Short Form | PSQ-18 | Short-Form Patient Satisfaction Questionnaire (PSQ-18)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086251","Doctors are Good About Explaining the Reasons for Medical Tests","C125503","A question about whether an individual feels their doctors are good about explaining the reasons for medical tests.","Doctors are Good About Explaining the Reasons for Medical Tests | Doctors are good about explaining the reasons for medical tests",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086246","Doctor's Office Has Everything Needed to Provide Complete Medical Care","C125506","A question about whether an individual feels their doctor's office has everything it needs to provide complete medical care.","Doctor's Office Has Everything Needed to Provide Complete Medical Care | I think my doctor's office has everything needed to provide complete medical care",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086530","JAK2 Inhibitor","C125450","Any substance that inhibits JAK2 tyrosine protein kinase, an enzyme that phosphorylates the hydroxyl group of tyrosine on various proteins in various signaling cascades.","JAK2 Inhibitor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086566","Medical Care I Have Been Receiving is Just About Perfect","C125507","A question about whether an individual feels the medical care they have received is just about perfect.","Medical Care I Have Been Receiving is Just About Perfect | The medical care I have been receiving is just about perfect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086862","Sometimes Doctors Make Me Wonder if Their Diagnosis is Correct","C125508","A question about whether an individual sometimes wonders if their doctor's diagnosis is correct.","Sometimes Doctors Make Me Wonder if Their Diagnosis is Correct | Sometimes doctors make me wonder if their diagnosis is correct",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086218","Confident That I Can Get the Medical Care I Need Without Being Set Back Financially","C125509","A question about whether an individual feels confident they can get the medical care they need without being set back financially.","Confident That I Can Get the Medical Care I Need Without Being Set Back Financially | I feel confident that I can get the medical care I need without being set back financially",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086250","Doctors are Careful to Check Everything When Treating and Examining Me","C125510","A question about whether an individual feels their doctors are careful to check everything when treating and examining them.","Doctors are Careful to Check Everything When Treating and Examining Me | When I go for medical care, they are careful to check everything when treating and examining me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086419","Have to Pay More of My Medical Care Than I Can Afford","C125511","A question about whether an individual feels they have to pay for more of their medical care than they can afford.","Have to Pay More of My Medical Care Than I Can Afford | I have to pay for more of my medical care than I can afford",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086384","Have Easy Access to the Medical Specialists I Need","C125512","A question about whether an individual feels they have easy access to the medical specialists they need.","Have Easy Access to the Medical Specialists I Need | I have easy access to the medical specialists I need",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086959","Wait for Emergency Treatment is Too Long Where I Get Medical Care","C125513","A question about whether an individual feels that the wait is too long for emergency treatment where they get their medical care.","Wait for Emergency Treatment is Too Long Where I Get Medical Care | Where I get medical care, people have to wait too long for emergency treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087018","Doctors Act Too Businesslike and Impersonal Toward Me","C125514","A question about whether an individual feels doctors act too businesslike and impersonal toward them.","Doctors Act Too Businesslike and Impersonal Toward Me | Doctors act too businesslike and impersonal toward me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086248","Doctors Treat Me In a Very Friendly and Courteous Manner","C125515","A question about whether an individual feels doctors treat them in a very friendly and courteous manner.","Doctors Treat Me In a Very Friendly and Courteous Manner | My doctors treat me in a very friendly and courteous manner",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086903","Those Providing Medical Care Sometimes Hurry Too Much When They Treat Me","C125516","A question about whether an individual feels those providing medical care sometimes hurry too much when they are being treated.","Those Providing Medical Care Sometimes Hurry Too Much When They Treat Me | Those who provide my medical care sometimes hurry too much when they treat me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086247","Doctors Sometimes Ignore What I Tell Them","C125517","A question about whether an individual feels doctors sometimes ignore what they tell them.","Doctors Sometimes Ignore What I Tell Them | Doctors sometimes ignore what I tell them",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086410","Have Some Doubts About the Ability of the Doctors Who Treat Me","C125518","A question about whether an individual has some doubts about the ability of the doctors who treat them.","Have Some Doubts About the Ability of the Doctors Who Treat Me | I have some doubts about the ability of the doctors who treat me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086249","Doctors Usually Spend Plenty of Time With Me","C125519","A question about whether an individual feels doctors usually spend plenty of time with them.","Doctors Usually Spend Plenty of Time With Me | Doctors usually spend plenty of time with me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086314","Find it Hard to Get an Appointment for Medical Care Right Away","C125520","A question about whether an individual finds it hard to get an appointment for medical care right away.","Find it Hard to Get an Appointment for Medical Care Right Away | I find it hard to get an appointment for medical care right away",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086243","Dissatisfied With Some Things About the Medical Care I Receive","C125521","A question about whether an individual is dissatisfied with some things about the medical care they receive.","Dissatisfied With Some Things About the Medical Care I Receive | I am dissatisfied with some things about the medical care I receive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085927","Able to Get Medical Care Whenever I Need It","C125522","A question about whether an individual feels they are able to get medical care whenever they need it.","Able to Get Medical Care Whenever I Need It Question | Able to Get Medical Care Whenever I Need It | Able to Get Medical Care Whenever I Need It | I am able to get medical care whenever I need it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022675","Collecting Tube","C32344","The final section of a renal tubule in the nephron between the distal convoluted tubule and the ureter comprising of principal and intercalated cells. The collecting tube acts to reabsorb sodium and water while secreting potassium and maintaining acid-base homeostasis.","Collecting Tube | Straight Tube | collecting duct | renal collecting tubule",,,,,,,,,,,,,,,"4245296","Structure of collecting tubule",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333811","Genitourinary Signs and Symptoms","C5035","Patient complaints (symptoms), physical or laboratory findings (signs) related to the genitourinary system.","Genitourinary Signs and Symptoms | Genital or Reproductive Signs and Symptoms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831551","American Urological Association Symptom Score","C113436","A questionnaire designed to help men determine how bothersome their benign prostatic hyperplasia urinary symptoms are and to determine how effective their treatment is.","American Urological Association Symptom Score | AUA SI | AUA SS | AUA Symptom Score | American Urological Association BPH Symptom Score Index | American Urological Association Symptom Index Score | American Urological Association Symptom Index for Benign Prostatic Hyperplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825877","Interferon Gamma Measurement","C81996","The determination of the amount of interferon gamma present in a sample.","Interferon Gamma Measurement | IFNG | Interferon Gamma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2945590","Unit per Milliliter","C77607","An arbitrary unit of substance content expressed in unit(s) per milliliter.","Unit per Milliliter | U/mL | Unit/Milliliter | kU/L | {Unit}/mL | {Unit}/ml | {U}/mL | {U}/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4228459","Cystic Lesion","C41421","A pathologic process that contains a single or multiple sac-like spaces.","Cystic Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2735362","Implanted Medical Device","C80457","A finding referring to a medical device that has been placed in the body, usually during a surgical procedure.","Implanted Medical Device | IMPLANTED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3277372","Thyroid Gland Disorder","C26893","A non-neoplastic or neoplastic disorder that affects the thyroid gland.  Representative examples include hyperthyroidism, hypothyroidism, thyroiditis, follicular adenoma, and carcinoma.","Thyroid Gland Disorder | Thyroid Disorder | Thyroid Gland Disease | Thyroid Gland Diseases | Thyroid Gland Disorders",,,,,,,,,,,,,,,"141253","Disorder of thyroid gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3826979","Model for End-Stage Liver Disease","C113394","A scoring system of disease severity in patients with end-stage liver disease. It is used to help prioritize allocation of liver allografts for transplantation and replaces the Child-Pugh score.","Model for End-Stage Liver Disease | MELD | MELD Score",,,,,,,,,,,,,,,"764364","Model for end-stage liver disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4084919","How Important Treatment Based on Tumor Molecular Profile Extends Survival","C125530","A question about how an individual rates the importance that treatment based on the molecular profile of their specific tumor extends survival.","How Important Treatment Based on Tumor Molecular Profile Extends Survival | Extends Survival",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084920","How Important Treatment Based on Tumor Molecular Profile Improves Symptoms","C125531","A question about how an individual rates the importance that treatment based on the molecular profile of their specific tumor improves symptoms.","How Important Treatment Based on Tumor Molecular Profile Improves Symptoms | Improves symptoms (e.g., reduces pain, increases appetite)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085850","How Important Treatment Based on Tumor Molecular Profile Avoids Side Effects from Treatment","C125532","A question about how an individual rates the importance that treatment based on the molecular profile of their specific tumor avoids side effects from treatment.","How Important Treatment Based on Tumor Molecular Profile Avoids Side Effects from Treatment | Avoids side effects from treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085216","How Important Treatment Based on Tumor Molecular Profile Improves Quality of Life","C125534","A question about how an individual rates the importance that treatment based on the molecular profile of their specific tumor improves quality of life.","How Important Treatment Based on Tumor Molecular Profile Improves Quality of Life | Improves quality of life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084923","How Important Standard Treatment Extends Survival","C125537","A question about how an individual rates the importance that standard treatment extends survival.","How Important Standard Treatment Extends Survival | Extends Survival",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084917","How Important Standard Treatment Improves Symptoms","C125538","A question about how an individual rates the importance that standard treatment improves symptoms.","How Important Standard Treatment Improves Symptoms | Improves symptoms (e.g., reduces pain, increases appetite)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084915","How Important Standard Treatment Avoids Side Effects from Treatment","C125539","A question about how an individual rates the importance that standard treatment avoids side effects from treatment.","How Important Standard Treatment Avoids Side Effects from Treatment | Avoids side effects from treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085215","How Important Standard Treatment Improves Quality of Life","C125540","A question about how an individual rates the importance that standard treatment improves quality of life.","How Important Standard Treatment Improves Quality of Life | Improves quality of life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086682","Overall Value Treatment Based on Tumor Molecular Profile","C125541","A question about how an individual rates the overall value of a treatment based on their tumor's molecular profile.","Overall Value Treatment Based on Tumor Molecular Profile | How would you rate the overall value of a treatment that is based on your own tumor's molecular profile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084912","Importance Rating Score 0","C125543","A subjective score of 0 on a scale that ranges from 0: Not at all important to 4: Extremely important.","Importance Rating Score 0 | Importance 0 | Importance Score 0 | Important",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086513","Importance Rating Score 1","C125544","A subjective score of 1 on a scale that ranges from 0: Not at all important to 4: Extremely important.","Importance Rating Score 1 | Importance 1 | Importance Score 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086514","Importance Rating Score 2","C125545","A subjective score of 2 on a scale that ranges from 0: Not at all important to 4: Extremely important.","Importance Rating Score 2 | Importance 2 | Importance Score 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086515","Importance Rating Score 3","C125546","A subjective score of 3 on a scale that ranges from 0: Not at all important to 4: Extremely important.","Importance Rating Score 3 | Importance 3 | Importance Score 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084808","Importance Rating Score 4","C125547","A subjective score of 4 on a scale that ranges from 0: Not at all important to 4: Extremely important.","Importance Rating Score 4 | Extremely Important | Importance 4 | Importance Score 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086756","Preference for Decision About Choosing a Treatment","C125550","A question about an individual's preference for ways to decide about choosing a treatment.","Preference for Decision About Choosing a Treatment | Which of the following best describes what you prefer for choosing a treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086754","Prefer to Make Final Selection About Which Treatment I Will Receive","C125554","A response indicating that an individual prefers to make the final selection about which treatment they will receive.","Prefer to Make Final Selection About Which Treatment I Will Receive | I prefer to make the decision about which treatment I will receive | I prefer to make the final selection about which treatment I will receive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086755","Prefer to Make Final Selection of My Treatment After Seriously Considering My Doctor's Opinion","C125555","A response indicating that an individual prefers to make the final selection of their treatment after seriously considering their doctor's opinion.","Prefer to Make Final Selection of My Treatment After Seriously Considering My Doctor's Opinion | I prefer to make the final decision about my treatment after seriously considering my doctor's opinion | I prefer to make the final selection of my treatment after seriously considering my doctor's opinion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086752","Prefer My Doctor and I Share Responsibility for Deciding Which Treatment is Best","C125556","A response indicating that an individual prefers that they and their doctor share responsibility for deciding which treatment is best for them.","Prefer My Doctor and I Share Responsibility for Deciding Which Treatment is Best | I prefer that my doctor and I share responsibility for deciding which treatment is best for me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086751","Prefer My Doctor Makes Final Decision About Which Treatment is Used but Seriously Considers My Opinion","C125557","A response indicating that an individual prefers that their doctor makes the final decision about which treatment will be used but seriously considers their opinion.","Prefer My Doctor Makes Final Decision About Which Treatment is Used but Seriously Considers My Opinion | I prefer that my doctor makes the final decision about which treatment will be used but seriously considers my opinion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086753","Prefer to Leave All Decisions Regarding Treatment to My Doctor","C125558","A response indicating that an individual prefers to leave all decisions regarding treatment to their doctor.","Prefer to Leave All Decisions Regarding Treatment to My Doctor | I prefer leaving all decisions regarding treatment to my doctors | I prefer to leave all decisions regarding my treatment to my doctor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086977","You and Your Doctor's Cancer Treatment Decision","C125559","A question about how an individual and their doctor(s) decided their cancer treatment.","You and Your Doctor's Cancer Treatment Decision | How did you and your doctor(s) decide about your cancer treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086561","Made Final Selection About Which Treatment I Will Receive","C125560","A response indicating that an individual made the final selection about which treatment they will receive.","Made Final Selection About Which Treatment I Will Receive | I made the final selection about which treatment I will receive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086562","Made Final Selection of My Treatment After Seriously Considering Doctor's Opinion","C125561","A response indicating that an individual made the final selection of their treatment after seriously considering their doctor's opinion.","Made Final Selection of My Treatment After Seriously Considering Doctor's Opinion | I made the final selection of my treatment after seriously considering my doctor's opinion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086245","Doctor and I Shared Responsibility for Deciding Which Treatment is Best for Me","C125562","A response indicating that an individual and their doctor shared responsibility for deciding which treatment is best for them.","Doctor and I Shared Responsibility for Deciding Which Treatment is Best for Me | My doctor and I shared responsibility for deciding which treatment is best for me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086244","Doctor Made Final Decision About Which Treatment Will Be Used but Seriously Considered My Opinion","C125563","A response indicating that an individual's doctor made the final decision about which treatment will be used but seriously considered their opinion.","Doctor Made Final Decision About Which Treatment Will Be Used but Seriously Considered My Opinion | My doctor made the final decision about which treatment will be used but seriously considered my opinion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086219","Conflicting Expert Opinions About a Medical Test or Treatment Would Lower My Trust in the Experts","C125564","A question about an individual's agreement that expert opinions about a medical test or treatment would lower their trust in the experts.","Conflicting Expert Opinions About a Medical Test or Treatment Would Lower My Trust in the Experts | Conflicting expert opinions about a medical test or treatment would lower my trust in the experts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086973","Would Not Have Confidence in a Medical Test or Treatment if Experts Had Conflicting Opinions","C125565","A question about an individual's agreement that they would not have confidence in a medical test or treatment if experts had conflicting opinions about it.","Would Not Have Confidence in a Medical Test or Treatment if Experts Had Conflicting Opinions | I would not have confidence in a medical test or treatment if experts had conflicting opinions about it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086220","Conflicting Expert Opinions About a Medical Test or Treatment Would Make Me Upset","C125566","A question about an individual's agreement that conflicting expert opinions about a medical test or treatment would make them upset.","Conflicting Expert Opinions About a Medical Test or Treatment Would Make Me Upset | Conflicting expert opinions about a medical test or treatment would make me upset",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086628","Not Afraid of Trying a Medical Test or Treatment Even If Experts Had Conflicting Opinions","C125567","A question about an individual's agreement that they would not be afraid of trying a medical test or treatment even if experts had conflicting opinions about it.","Not Afraid of Trying a Medical Test or Treatment Even If Experts Had Conflicting Opinions | I would not be afraid of trying a medical test or treatment even if experts had conflicting opinions about it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086972","Would Avoid Making Decisions About A Medical Test or Treatment if Experts Had Conflicting Opinions","C125569","A question about an individual's agreement that they would avoid making a decision about a medical test or treatment if experts had conflicting opinions about it.","Would Avoid Making Decisions About A Medical Test or Treatment if Experts Had Conflicting Opinions | I would avoid making a decision about a medical test or treatment if experts had conflicting opinions about it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3843224","Slightly Disagree","C125570","A response indicating that an individual is in slight disagreement with something.","Slightly Disagree | Disagree Slightly | Disagree Somewhat | Somewhat Disagree",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3843225","Slightly Agree","C125571","A response indicating that an individual is in slight agreement with something.","Slightly Agree | Agree Slightly | Agree Somewhat | Slightly | Somewhat Agree",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1096117","Off-Label Treatment","C125600","The use of an FDA-approved device, drug, or treatment for a purpose other than that for which it was approved.","Off-Label Treatment | Off-Label | Off-Label Use | off-label",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086541","Left All Decisions Regarding My Treatment to My Doctor","C125602","A response indicating that an individual left all decisions about treatment to their doctor.","Left All Decisions Regarding My Treatment to My Doctor | I left all decisions regarding my treatment to my doctor.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086016","BRAT Diet","C125606","A bland-food diet consisting of bananas, rice, applesauce, and toast. It may be recommended for recovery from an upset stomach or diarrhea.","BRAT Diet | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085919","4D PET Scan","C125609","Positron emission tomography imaging collected over time. It is designed to capture the internal movement of organs and the metabolism of the tumor.  It creates the most complete and accurate information on the tumor and provides information how the tumor moves with breathing and other body motions.","4D PET Scan | 4D Gated PET | 4D Gated PET Scan | 4D PET",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830297","Excepted from Direct Marking","C101679","An indication that a device is excepted from direct marking requirements.","Excepted from Direct Marking | Excepted from Direct Marking (DM) | Exempt from Direct Marking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830478","Direct Marking Device Identifier","C101678","An identifier that is marked directly on a device.","Direct Marking Device Identifier | DM DI Number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640206","Secondary Device Identifier","C101724","An alternate identification number for a device.","Secondary Device Identifier | Secondary DI Number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086324","Formalin-Fixed Paraffin-Embedded B-Cell (CD20) Slide","C125610","A biospecimen consisting of formalin-fixed, paraffin embedded CD20-positive B-cells affixed to a slide for light microscopy","Formalin-Fixed Paraffin-Embedded B-Cell (CD20) Slide | Physical Slide-FFPE B-Cell (CD20) Slide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086326","Formalin-Fixed Paraffin-Embedded T-Cell (CD3) Slide","C125611","A biospecimen consisting of formalin-fixed, paraffin embedded CD3-positive B-cells affixed to a slide for light microscopy.","Formalin-Fixed Paraffin-Embedded T-Cell (CD3) Slide | Physical Slide-FFPE T-Cell (CD3) Slide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086323","Formalin-Fixed Paraffin-Embedded B-Cell (CD20) Digital Image","C125612","A digital image obtained from a formalin-fixed, paraffin embedded CD20-positive B-cell specimen.","Formalin-Fixed Paraffin-Embedded B-Cell (CD20) Digital Image | Digital Image-FFPE B-Cell (CD20) Slide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086325","Formalin-Fixed Paraffin-Embedded T-Cell (CD3) Digital Image","C125613","A digital image obtained from a formalin-fixed, paraffin embedded CD3-positive T-cell specimen.","Formalin-Fixed Paraffin-Embedded T-Cell (CD3) Digital Image | Digital Image-FFPE T-Cell (CD3) Slide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086520","Inconsistency Due to Macrodissection","C125614","The inconsistency was caused because macrodissection was performed at the tissue source site to select a region containing an acceptable diagnosis, and the sample histological subtype of the resulting sample was different from the original pathology report.","Inconsistency Due to Macrodissection | Macrodissection Performed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086446","Histological Subtype Different, Other Pathology Review","C125615","Pathology analysis not related to the pathologic prescreen review determined a specific histological subtype that is different from the original pathology report.","Histological Subtype Different, Other Pathology Review | Other Pathology Review",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086447","Histological Subtype Different, Pathology Review for this Project","C125616","The pathologic prescreen review for this project determined that the histologic subtype is different from the pathology report.","Histological Subtype Different, Pathology Review for this Project | Pathology Review for this Project",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084909","Depression Subordinate Domain","C125617","The collection of PROMIS item scales that assess negative mood, negative views of the self, negative social cognition, and decreased positive affect and engagement.","Depression Subordinate Domain | Depression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084897","Sleep Disturbance Subordinate Domain","C125618","The collection of PROMIS item scales that assess perceptions of sleep quality, sleep depth, and restoration associated with sleep; perceived difficulties and concerns with getting to sleep or staying asleep; and perceptions of the adequacy of and satisfaction with sleep.","Sleep Disturbance Subordinate Domain | Sleep Disturbance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086721","Pain Interference Subordinate Domain","C125619","The collection of PROMIS item scales that assess the consequences of pain on relevant aspects of a person's life, including the impact of pain on social, cognitive, emotional, physical, and recreational activities as well as sleep and enjoyment in life.","Pain Interference Subordinate Domain | Pain Interference",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347524","Planned Change of Dose Made","C70894","An indication that the change in the agent dose regimen was in the original documented treatment plan.","Planned Change of Dose Made | Planned Change of Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349080","Unplanned Change of Dose Made","C70893","An indication that the change in the agent dose regimen was not in the original documented treatment plan.","Unplanned Change of Dose Made | Unplanned Change of Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281182","Breast Cancer Screening","C15546","Early detection of breast cancer involving asymptomatic women. Generally done in the population with higher risk, due to environmental or genetic factors.","Breast Cancer Screening | Screening for Breast Cancer",,,,,,,,,,,,,,,"4147961","Screening for malignant neoplasm of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640187","Primary Package Identifier","C101699","The main identifier of a package type.","Primary Package Identifier | Package DI Number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640195","Device Labeler Customer Contact","C101708","Customer contact information for a device labeler.","Device Labeler Customer Contact | Customer Contact | Device Labeler Support Contact",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830169","FDA Device Listing Number","C101677","A number assigned by the FDA to a device during Registration and Listing.","FDA Device Listing Number | FDA Listing Number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086363","Global Rating of Change in Joint Pain and Stiffness Questionnaire","C125621","A questionnaire designed to measure joint pain and stiffness over a 36 month period.","Global Rating of Change in Joint Pain and Stiffness Questionnaire | GRC-JPS | Global Rating of Change - Joint Pain and Stiffness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086150","Change Since Last Time Questionnaire Filled Out","C125622","A question about whether an individual has experienced a change in joint pain and stiffness since the last time they filled out a questionnaire.","Change Since Last Time Questionnaire Filled Out | Change in Joint Pain and Stiffness Since Last Time Questionnaire Filled Out | Change since the last time you filled out a questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085641","Level of Joint Pain","C125623","A question about the level of joint pain experienced by an individual.","Level of Joint Pain | Joint Pain | Your level of joint pain is",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085642","Level of Joint Stiffness","C125625","A question about the level of joint stiffness experienced by an individual.","Level of Joint Stiffness | Joint Stiffness | Your level of joint stiffness is",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086947","Very Much Better","C125626","A subjective response indicating that something is very much better.","Very Much Better | Very much better",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086592","Moderately Better","C125627","A subjective response indicating that something is moderately better.","Moderately Better | Moderately better",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084715","About the Same Response","C125628","A subjective response indicating that something is about the same.","About the Same Response | About the same",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3853088","Moderately Worse","C125629","A subjective response indicating that something is moderately worse.","Moderately Worse | Moderately worse",,,,,,,,,,,,,,,"763743","Moderately bad",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018483","Haemophilus influenzae","C86431","A species of facultatively anaerobic or aerobic, Gram negative, rod shaped bacteria assigned to the phylum Proteobacteria. This species is nonmotile, catalase and oxidase positive, porphyrin negative, requires both X and V factors to grow in culture, and may be encapsulated or nonencapsulated. H. influenzae is an opportunistic pathogen causing a wide variety of infections including osteomyelitis, meningitis, conjunctivitis and pneumonia.","Haemophilus influenzae | H-Flu | H-flu | HAEMOPHILUS INFLUENZAE",,,,,,,,,,,,,,,"4195939","Haemophilus influenzae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023238","Legionella pneumophila","C86489","A species of aerobic, gram negative, rod shaped bacteria in the phylum Proteobacteria. This species is motile by flagella, nonacid fast, pleomorphic, nonencapsulated, nonfermentative, urease negative and oxidase and catalase positive. L. pneumophila is pathogenic, being the causative agent of legionellosis or Legionnaires disease.","Legionella pneumophila | LEGIONELLA PNEUMOPHILA",,,,,,,,,,,,,,,"4216497","Legionella pneumophila",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085441","Mycobacterium chelonae","C86536","A species of aerobic, Gram positive, rods assigned to the phylum Actinobacteria. This species is acid fast, oxidase negative, urease and catalase positive, nonmotile and nonsporulating. M. chelonae is a fast growing mycobacterium isolated from environmental, animal and human sources and is often associated with post-operative soft tissue infection.","Mycobacterium chelonae | MYCOBACTERIUM CHELONAE | Mycobacterium chelonae subsp. chelonae",,,,,,,,,,,,,,,"4348175","Mycobacteroides chelonae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0445910","Mycobacterium abscessus","C86533","A species of aerobic, Gram positive, rod shaped bacteria assigned to the phylum Actinobacteria. This species is acid-fast, nonmotile, does not reduce nitrate, is amidase, urease and nicotinamidase positive and benzamidase, isonicotinamidase, succinamidase and acetamidase negative. M. abscessus is a rapidly growing mycobacterium found in water, soil and dust, and can cause a variety of serious infections of the skin, soft tissues and lungs, especially in persons with chronic lung diseases.","Mycobacterium abscessus | MYCOBACTERIUM ABSCESSUS | Mycobacterium chelonae subsp. abscessus",,,,,,,,,,,,,,,"45767545","Mycobacteroides abscessus subspecies abscessus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242615","Mycobacterium haemophilum","C86542","A species of aerobic, Gram positive, rod shaped bacterium assigned to the phylum Actinobacteria. This species is acid fast, nonmotile, catalase negative, requires haemin for growth and is characterized by exclusively intracellular development. M. haemophilum has an unknown reservoir and mode of transmission and is known to be pathogenic in immunocompromised individuals.","Mycobacterium haemophilum | MYCOBACTERIUM HAEMOPHILUM",,,,,,,,,,,,,,,"4329433","Mycobacterium haemophilum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027575","Neisseria meningitidis","C86605","A species of aerobic, Gram-negative, diplococci shaped bacteria assigned to the phylum Proteobacteria. This species is catalase and oxidase positive, non-hemolytic, non-pigmented, does not reduce nitrate or nitrite, does not synthesize polysaccharides, grows on blood, chocolate, or Muller-Hinton agar, and produces acid from glucose and maltose but not fructose, sucrose, mannose, or lactose. N. meningitidis, known commonly as meningococcus, is the causative agent of cerebrospinal meningitis, but is also associated with other human infections, but can be commensal in the oropharynx and nasopharynx of carriers.","Neisseria meningitidis | Beta-Lactamase Negative Neisseria meningitidis | NEISSERIA MENINGITIDIS",,,,,,,,,,,,,,,"4076436","Neisseria meningitidis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033809","Pseudomonas aeruginosa","C86696","A species of facultatively anaerobic, Gram negative, rod shaped bacteria in the phylum Proteobacteria. This species is motile, non spore forming, produces pyorubin, pyocyanin and fluorescein and has minimal nutrient requirements. P. aeruginosa is an opportunistic pathogen found in soil, water and as a part of skin flora that can cause lethal infections in cystic fibrosis patients, burn victims and immunocompromised individuals.","Pseudomonas aeruginosa | PSEUDOMONAS AERUGINOSA",,,,,,,,,,,,,,,"4198675","Pseudomonas aeruginosa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0318154","Beta-Hemolytic Streptococcus","C86190","A bacterium that is assigned to the genus Streptococcus that is able to facilitate the complete rupturing of red blood cells, thus producing wide, clear, zones around colonies on blood agar plates.","Beta-Hemolytic Streptococcus | STREPTOCOCCUS BETA-HEMOLYTIC",,,,,,,,,,,,,,,"4200707","Beta-hemolytic streptococcus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0318153","Alpha-Hemolytic Streptococcus","C86141","A bacterium that is assigned to the genus Streptococcus that is able to reduce the iron content in hemoglobin in red blood cells, thus producing green colored colonies on blood agar plates.","Alpha-Hemolytic Streptococcus | STREPTOCOCCUS ALPHA-HEMOLYTIC",,,,,,,,,,,,,,,"4246064","Alpha-hemolytic streptococcus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319923","Aspergillus terreus","C87511","A species of fungi belonging to the genus Aspergillus that is found in soil, decomposing vegetation, and dust; it is a human pathogen, causing opportunistic infections in immunocompromised patients.","Aspergillus terreus | ASPERGILLUS TERREUS | Aspergillus boedijnii | Aspergillus terrestrius",,,,,,,,,,,,,,,"4097212","Aspergillus terreus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0446010","Cryptococcus gattii","C114268","An encapsulated yeast in the phylum Basidiomycota. This species is globose to ovoid shaped, urease-positive, pseudohyphae- and nitrate-negative, does not ferment sugars, and assimilates glucose, maltose, sucrose, galactose, trehalose, raffinose, inositol, cellobiose, rhamnose, arabinose, melezitose and xylose. C. gattii is a human opportunistic pathogen and causes pulmonary cryptococcosis, basal meningitis and cerebral cryptococcomas in immunocompromised hosts. It is also associated with skin, soft tissue, lymph node, bone, and joint infections.","Cryptococcus gattii | C. bacillisporus | C. gattii | CRYPTOCOCCUS GATTII | Cryptococcus bacillisporus",,,,,,,,,,,,,,,"42872867","Cryptococcus gattii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011315","Dengue Virus","C112036","A species of enveloped and spherical viruses with a capsid with T=3 icosahedral symmetry in the Flaviviridae family and Flavivirus genus. The genome is composed of non-segmented, single-stranded, positive-sense RNA. Dengue viruses are found in non-human primates and humans and cause dengue fever in humans. Dengue viruses are transmitted mainly via the bite of infected mosquitoes of the genus Aedes.","Dengue Virus | DENGUE VIRUS",,,,,,,,,,,,,,,"4144528","Dengue virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085294","Hepatitis E Virus","C14295","A member of the genus Hepevirus, it is a single-stranded, positive-sense RNA virus with icosahedral shape that causes Hepatitis E.","Hepatitis E Virus | HEPATITIS E VIRUS | HEV | hepatitis E virus",,,,,,,,,,,,,,,"4302461","Hepatitis E virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0949920","Norovirus","C112362","A genus of non-enveloped, capsid covered viruses with T=3 icosahedral symmetry, in the family Caliciviridae. The genome is composed of a linear, single-strand of positive sense RNA. Noroviruses are transmitted by the fecal-oral route and cause gastroenteritis in humans.","Norovirus | NOROVIRUS | NoV | Norwalk-like virus",,,,,,,,,,,,,,,"4248366","Norovirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829254","Lot or Batch Number Production Identifier","C101672","The production identifier is the lot or batch number.","Lot or Batch Number Production Identifier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640159","Serial Number Production Identifier","C101671","The production identifier is the serial number.","Serial Number Production Identifier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640158","Expiration Date Production Identifier","C101670","The production identifier is the expiration date.","Expiration Date Production Identifier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1265292","Methicillin Resistant Staphylococcus Aureus","C123515","A species of Gram-positive coccus-shaped bacterium in the family Micrococcaceae. This strain of S. aureus is resistant to methicillin and other beta-lactam antibiotics through the expression of penicillin-binding proteins acquired from other species.","Methicillin Resistant Staphylococcus Aureus | AB MRSA | METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS | MRSA | Methicillin Resistant Staphylococcus aureus | Methicillin-Resistant Staphylococcus aureus | Methicillin-resistant Staphylococcus aureus | STAPHYLOCOCCUS AUREUS, METHICILLIN-RESISTANT",,,,,,,,,,,,,,,"4019195","Methicillin resistant Staphylococcus aureus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1635274","Methicillin Susceptible Staphylococcus Aureus","C123516","A species of Gram-positive coccus-shaped bacterium in the family Micrococcaceae. This strain of S. aureus retains its native sensitivity to methicillin and other beta-lactam antibiotics.","Methicillin Susceptible Staphylococcus Aureus | METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS | MSSA | Methicillin Susceptible Staphylococcus aureus | Methicillin-Susceptible Staphylococcus aureus",,,,,,,,,,,,,,,"4168510","Methicillin susceptible Staphylococcus aureus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1019638","Mycobacterium mucogenicum","C125636","A species of nonpigmented, nonmotile, and weakly Gram-positive bacteria in the family Mycobacteriaceae. M. mucogenicum has been identified as a water contaminant in hospitals and infection is associated with clinical diseases in both immunocompromised and immunocompetent individuals. The species is tolerant to disinfection by chlorination and extreme temperatures, and to traditional antimycobacterial agents, but is susceptible to amikacin, imipenem, cefoxitin, clarithromycin, ciprofloxacin, the new fluoroquinolones, and trimethoprim/sulfamethoxazole.","Mycobacterium mucogenicum | MYCOLICIBACTERIUM MUCOGENICUM | Mycolicibacterium mucogenicum",,,,,,,,,,,,,,,"4034212","Mycobacterium mucogenicum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319928","Aspergillus ustus","C87512","A species of fungi in the family Aspergillaceae, characterized by elongated conidial heads with bent Hulle cells scattered in a pigmented mycelium, with conidia that are large, rough-walled, and spherical and range in color from green to yellow-brown. A. ustus infections in humans are occur mostly in immunocompromised individuals.","Aspergillus ustus | ASPERGILLUS USTUS | Sterigmatocystis ustus",,,,,,,,,,,,,,,"4047474","Aspergillus ustus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026717","Mucorales","C125637","An order of fungi in the subdivision Mucoromycotina. Mucorales species are typically fast-growing, with wide hyphae lacking septa; the hyphae may be simple or ramified and support sac-like sporangia filled with asexual sporangiospores. Many species are known to damage stored food, but others can cause mycosis, generally in patients already infected with other diseases.","Mucorales | ",,,,,,,,,,,,,,,"4026935","Order Mucorales",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008056","Chikungunya Virus","C125638","A species of alpha virus in the Togaviridae family. The virus is transmitted to people by mosquitoes. The most common symptoms of chikungunya virus infection are fever and joint pain.","Chikungunya Virus | CHIKUNGUNYA VIRUS",,,,,,,,,,,,,,,"4084793","Chikungunya virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0318428","Enterovirus D68","C125639","A species of enterovirus in the family Picornaviridae. EV-D68 can cause respiratory illness with symptoms ranging from runny nose, sneezing, cough, and body and muscle aches to wheezing and difficulty breathing.","Enterovirus D68 | EV-D68 | Enterovirus 68 | Enterovirus D68 (EV-D68) | Human Enterovirus 68 | Human Enterovirus D68 | Human Enterovirus EV68",,,,,,,,,,,,,,,"4045233","Human enterovirus 68",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1258014","Human Metapneumovirus","C125640","A species of nonsegmented, negative-strand ssRNA viruses in the family Paramyxoviridae. Infections with human metapneumovirus can cause upper and lower respiratory tract infections in patients of all ages. This virus is second only to respiratory syncytial virus as the most commonly identified cause of pediatric lower respiratory illness.","Human Metapneumovirus | HMPV | HUMAN METAPNEUMOVIRUS | hMPV",,,,,,,,,,,,,,,"4211957","Human metapneumovirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1319861","Human Parainfluenza Virus","C125641","A non-taxonomic group of paramyxoviruses that are cause of respiratory tract infections in humans. Infection is most common in infants and young children and symptoms may include fever, runny nose, and cough. Infection is usually self-limiting but can also cause more severe illness, such as croup or pneumonia.","Human Parainfluenza Virus | HPIV | HUMAN PARAINFLUENZA VIRUS",,,,,,,,,,,,,,,"4232900","Human parainfluenza viruses",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018893","Helminth","C125642","A non-taxonomic group of parasitic worms. The term may be used to describe flatworms (Platyhelminthes), namely cestodes (tapeworms) and trematodes (flukes), and roundworms (Nematoda). These are common infectious agents of humans in developing countries.","Helminth | Helminths",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038462","Strongyloides stercoralis","C125643","A species of human pathogenic parasitic roundworm in the family Strongyloididae. The species alternates between free-living and parasitic cycles, with the potential for autoinfection and multiplication within the host. Infection with S. stercoralis usually results in asymptomatic chronic infestation of the gut, but may also cause a severe, persistent diarrhea.","Strongyloides stercoralis | STRONGYLOIDES STERCORALIS",,,,,,,,,,,,,,,"4174850","Strongyloides stercoralis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040557","Toxoplasma gondii","C125644","A species of obligate intracellular, parasitic protozoa in the family Sarcocystidae. Birds and rodents act as intermediate hosts with wild and domestic cats acting as the definitive hosts. Animals bred for human consumption may also become infected with tissue cysts after ingestion of sporulated oocysts in the environment. Humans may become infected by ingestion of contaminated meat or water or through contact with feline feces. More rarely, infection may occur by congenital transmission or by receiving infected infected blood or organs.","Toxoplasma gondii | TOXOPLASMA GONDII",,,,,,,,,,,,,,,"4188059","Toxoplasma gondii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3642347","Basal-Like Breast Carcinoma","C53558","A biologic subset of breast carcinoma defined by high expression of genes characteristic of basal epithelial cells, including KRT5 and KRT17, annexin 8, CX3CL1, and TRIM29, and usually by lack of expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). It is the most common subtype of breast cancer associated with BRCA1 mutations, and is associated with a poor prognosis.","Basal-Like Breast Carcinoma | Basal-Like Breast Cancer | Basal-Like Subtype of Breast Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830406","Donation Identification Number Production Identifier","C113843","A number assigned to a device that contains human cells or tissue. The number can be found on the device label or packaging.","Donation Identification Number Production Identifier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829359","Labeled as Containing Natural Rubber Latex","C101673","The device label indicates natural rubber latex as a component.","Labeled as Containing Natural Rubber Latex | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828771","Not Made with Natural Rubber Latex","C106038","The composition of the materials of an item do not contain natural rubber latex.","Not Made with Natural Rubber Latex | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829224","Magnetic Resonance Imaging Safety Labeling Information","C106044","Safety information about the MRI device that is included on the device label.","Magnetic Resonance Imaging Safety Labeling Information | MRI Safety Labeling Information | Magnetic Resonance Imaging Safety Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830524","Device Size Text","C106041","Information about the size of the device that is not represented elsewhere.","Device Size Text | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640173","Inner Diameter","C101685","The length of a straight line passing through the center of the inner open space of a circular or spheroid object that connects two points on the circumference.","Inner Diameter | Inner/Lumen Diameter | Lumen Diameter | Lumen Diameter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640175","Needle Gauge","C101687","A number representing the outer diameter of a hypodermic needle.","Needle Gauge | NDLGAUGE | {NEEDLE GAUGE} | {Needle Gauge}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829176","Material Pore Size","C112332","A quantitative or qualitative measurement of the physical dimensions of the pores in a material.","Material Pore Size | PORESIZE | Pore Size",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439198","Kilometer","C71177","A metric unit of distance equal to 1000 meters, 0.621 miles, 1094 yards, or 3281 feet.","Kilometer | km",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439205","Yard","C48553","A traditional unit of length equal to 3 feet, or 36 inches, or 0.9144 meter.","Yard | YARD | Yard International | Yard US | [yd_i] | yard | yd",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0560748","Square Foot","C48461","A traditional unit of area equal to 144 square inches, 929.0304 square centimeters, or 9.290304E-2 square meters.","Square Foot | FEET, SQUARE | [ft_i]2 | [sft_i] | foot squared | ft2 | sq. ft. | square foot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0560749","Square Inch","C68871","A traditional unit of area equal to the area of a square with sides of one inch. It is equal to 6.4516 square centimeters.","Square Inch | [in_i]2 | [sin_i] | in2 | sq. in | sq. inch | square inch",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439216","Ton","C48546","A metric unit of mass equal to 1000 kilograms, or 2204.623 pounds avoirdupois.","Ton | Metric ton | TON | t | tonne",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475212","Centiliter","C69087","The unit of volume equal to one hundredth of a liter or 10 milliliters. One centiliter is equivalent to 0.6102 cubic inch, or 0.338 U.S. fluid ounce.","Centiliter | cL | cl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0560015","Cubic Inch","C48488","A traditional unit of volume equal to 16.3871 cubic centimeters, or 0.5541 US fluid ounce.","Cubic Inch | CUBIC INCH | [cin_i] | [in_i]3 | cu. in. | cubic inch | in3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2949743","Cup Dosing Unit","C54703","A dosing unit equal to the amount of active ingredient(s) contained in a cup.","Cup Dosing Unit | CUP | Cup | {CUP} | {cup}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0560011","Fluid Ounce US","C48494","A traditional unit of liquid volume equal in the US customary system to 1/16 pint, or 1.804 687 cubic inches or 29.573 531 milliliters.","Fluid Ounce US | FLUID OUNCE | FO | Fluid Ounce | [foz_us] | fl oz | foz_us",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773654","Pint","C48529","A United States liquid unit equal to 16 fluid ounces; two pints equal one quart.","Pint | PINT | PT | US Pint | [pt_us] | pints (US Dry) | pt_us",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1552934","quart - US","C48534","A United States liquid unit equal to 32 fluid ounces; four quarts equal one gallon.","Quart | QUART | qt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640169","Recommended Handling Atmospheric Pressure","C101681","The recommended atmospheric pressure for handling or operating a device.","Recommended Handling Atmospheric Pressure | Handling Environment Atmospheric Pressure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640170","Recommended Handling Humidity","C101682","The recommended humidity level for handling or operating a device.","Recommended Handling Humidity | Handling Environment Humidity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640171","Recommended Handling Temperature","C101683","The recommended temperature of the environment when handling or operating a device.","Recommended Handling Temperature | Handling Environment Temperature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640192","Recommended Storage Atmospheric Pressure","C101705","The recommended storage atmospheric pressure for a device.","Recommended Storage Atmospheric Pressure | Storage Environment Atmospheric Pressure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640193","Recommended Storage Humidity","C101706","The recommended storage humidity level for a device.","Recommended Storage Humidity | Storage Environment Humidity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640194","Recommended Storage Temperature","C101707","The recommended storage temperature for a device.","Recommended Storage Temperature | Storage Environment Temperature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640191","Special Storage Condition","C101704","Specific conditions under which a device should be stored.","Special Storage Condition | Special Storage Conditions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640164","Packaged as Sterile","C101676","A device is packaged as being free of any living organisms.","Packaged as Sterile | Device is Packaged as Sterile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053960","Systemic Corticosteroid Therapy","C122080","Treatment with corticosteroids via a delivery method that will affect the entire body (oral, intramuscular, intravenous).","Systemic Corticosteroid Therapy | Systemic Corticosteroid | Systemic corticosteroid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3280176","Short Stature","C118686","Height greater than two standard deviations below the mean of the appropriate reference population for the age and sex of the individual.","Short Stature | ",,,,,,,,,,,,,,,"440076","Short stature disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0333355","Mucositis","C115965","Inflammation of the mucous membranes.","Mucositis | ",,,,,,,,,,,,,,,"432661","Inflammatory disease of mucous membrane",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2733085","Osteoporotic Fracture","C80097","A pathologic bone fracture due to osteoporosis. It is generally caused by a fall from a standing height or lower and usually involves the spine, hip, or wrist.","Osteoporotic Fracture | Low-Trauma Fracture",,,,,,,,,,,,,,,"40480160|4188189","Osteoporotic fracture|Osteoporotic fracture",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C4086042","Breast Cancer Prevention Trial Symptom Scales","C125635","A questionnaire designed to assess side effects, and to examine correlates, of the derived symptom dimensions among patient populations who had previously been diagnosed with breast cancer or were at risk for the disease.","Breast Cancer Prevention Trial Symptom Scales | BCPT | BCPTSS | Breast Cancer Prevention Trial Symptom Scales (BCPT)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085327","Bothered by Hot Flashes","C125645","A question about whether an individual is or was bothered by hot flashes.","Bothered by Hot Flashes | Hot flashes | Hot flushes or flashes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085862","Bothered by Nausea","C125646","A question about whether an individual is or was bothered by nausea.","Bothered by Nausea | Nausea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084767","Bothered by Vomiting","C125647","A question about whether an individual is or was bothered by vomiting.","Bothered by Vomiting | Vomiting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086037","Bothered by Difficulty with Bladder Control when Laughing or Crying","C125648","A question about whether an individual is or was bothered by difficulty with bladder control when laughing or crying.","Bothered by Difficulty with Bladder Control when Laughing or Crying | Difficulty with bladder control when laughing or crying",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087014","Bothered by Difficulty with Bladder Control at Other Times","C125649","A question about whether an individual is or was bothered by difficulty with bladder control at other times.","Bothered by Difficulty with Bladder Control at Other Times | Difficulty with bladder control at other times",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085872","Bothered by Vaginal Dryness","C125650","A question about whether an individual is or was bothered by vaginal dryness.","Bothered by Vaginal Dryness | Vaginal dryness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087068","Bothered by Pain with Intercourse","C125669","A question about whether an individual is or was bothered by pain with intercourse.","Bothered by Pain with Intercourse | Pain with intercourse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084749","Bothered by General Aches and Pains","C125670","A question about whether an individual is or was bothered by general aches and pains.","Bothered by General Aches and Pains | General aches and pains",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084928","Bothered by Joint Pains","C125671","A question about whether an individual is or was bothered by joint pains.","Bothered by Joint Pains | Joint pains",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085861","Bothered by Muscle Stiffness","C125672","A question about whether an individual is or was bothered by muscle stiffness.","Bothered by Muscle Stiffness | Muscle stiffness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084773","Bothered by Weight Gain","C125673","A question about whether an individual is or was bothered by weight gain.","Bothered by Weight Gain | Weight gain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085865","Bothered by Forgetfulness","C125674","A question about whether an individual is or was bothered by forgetfulness.","Bothered by Forgetfulness | Forgetfulness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086039","Bothered by the Appearance of My Body","C125675","A question about whether an individual is or was bothered by unhappiness with the appearance of their body.","Bothered by the Appearance of My Body | Bothered by Unhappiness with the Appearance of My Body | Unhappy with the appearance of my body",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084742","Bothered by Night Sweats","C125676","A question about whether an individual is or was bothered by night sweats.","Bothered by Night Sweats | Night sweats",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084927","Bothered by Difficulty Concentrating","C125677","A question about whether an individual is or was bothered by difficulty concentrating.","Bothered by Difficulty Concentrating | Difficulty concentrating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085633","Bothered by Being Easily Distracted","C125678","A question about whether an individual is or was bothered by being easily distracted.","Bothered by Being Easily Distracted | Easily distracted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086034","Bothered by Arm Swelling","C125679","A question about whether an individual is or was bothered by arm swelling.","Bothered by Arm Swelling | Arm swelling (lymphedema)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086036","Bothered by Decreased Range of Motion in Arm on Surgery Side","C125680","A question about whether an individual is or was bothered by decreased range of motion in arm on surgery side.","Bothered by Decreased Range of Motion in Arm on Surgery Side | Decreased range of motion in arm on surgery side",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085556","Extremely Agree","C125681","A response indicating that an individual is in extreme agreement with something.","Extremely Agree | Extreme Agreement | Extremely",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086863","Somewhat Bothered","C125683","A response indicating that an individual is or was somewhat bothered.","Somewhat Bothered | Somewhat bothered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087016","A Little Disrupted","C125684","A response indicating that an individual is or was a little disrupted.","A Little Disrupted | Disrupted a little",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086762","Quite a Bit Disrupted","C125685","A response indicating that an individual is or was quite a bit disrupted.","Quite a Bit Disrupted | Disrupted quite a bit | Quite Disrupted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086864","Somewhat Disrupted","C125686","A response indicating that an individual is or was somewhat disrupted.","Somewhat Disrupted | Disrupted somewhat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086910","Totally Disrupted","C125687","A response indicating that an individual is or was totally disrupted.","Totally Disrupted | Disrupted totally",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086634","Not at All Disrupted","C125688","A response indicating that an individual is or was not at all disrupted.","Not at All Disrupted | Not Disrupted | Not disrupted at all",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640179","Chlorine Dioxide Sterilization","C101691","A sterilization process that uses chlorine dioxide at ambient temperatures to kill microorganisms. This process can be used in large spaces.","Chlorine Dioxide Sterilization | Chlorine Dioxide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640198","Dry Heat Sterilization","C101712","A sterilization process that uses high temperature and dry air to kill microorganisms on the surface of objects. This process is restricted to objects that can withstand high temperatures.","Dry Heat Sterilization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811133","Ethylene Oxide Sterilization","C101713","A sterilization process that uses ethylene oxide gas to kill microorganisms.","Ethylene Oxide Sterilization | Ethylene Oxide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640181","High Intensity Light or Pulse Light Sterilization","C101693","A sterilization process that involves the pulsing of a high-power xenon lamp. This process kills microorganisms through the high ultraviolet content of the light and the brief heating effects.","High Intensity Light or Pulse Light Sterilization | High Intensity Light or Pulse Light",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640182","Microwave Radiation Sterilization","C101694","A sterilization process that uses microwave radiation to kill microorganisms. This process is restricted to materials that contain water and is typically used for food.","Microwave Radiation Sterilization | Microwave Radiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640200","Moist Heat or Steam Sterilization","C101714","A sterilization process that uses high temperature and moist air to kill microorganisms. The moist air is typically applied at increased atmospheric pressure and the process is restricted to objects that can withstand high temperature and pressure.","Moist Heat or Steam Sterilization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640178","Ozone Sterilization","C101690","A sterilization process that uses ozone gas to kill microorganisms. This process may be used on objects that cannot withstand high temperatures.","Ozone Sterilization | Ozone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435863","Vaporized Peracetic Acid Sterilization","C101697","A sterilization process that uses the vaporized form of peracetic acid to kill microorganisms.","Vaporized Peracetic Acid Sterilization | Peracetic Acid | Vaporized Paracetic Acid Sterilization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640201","Radiation Sterilization","C101715","A sterilization process that uses radiation such as electron beams, X-rays, gamma rays, or subatomic particles to kill microorganisms.","Radiation Sterilization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640183","Sound Wave Sterilization","C101695","A sterilization process that uses high-frequency sound waves to kill microorganisms.","Sound Wave Sterilization | Sound Waves",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640184","Ultraviolet Light Sterilization","C101696","A sterilization process that uses short wavelength radiation to kill microorganisms. This process is used primarily in medical sanitation and sterile work facilities but also has applications for the sterilization of drinking water and waste water.","Ultraviolet Light Sterilization | Ultraviolet Light",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700618","Cavitation (process)","C78135","The formation and rapid collapse of bubbles in a fluid. The creation of bubbles is driven by mechanical force.","Cavitation | Cavitate | Cavitating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517886","Limited stage (cancer stage)","C28065","Cancer that is localized in its original site of growth, or involves adjacent lymph nodes but has not spread to other anatomic sites.","Limited Stage | Early Stage | Early-Stage Cancer | Limited Metastatic Disease | early-stage cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517031","Extensive Stage","C28064","Cancer that has spread from the original site of growth to other anatomic sites.","Extensive Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412841","BTK Gene","C75013","This gene is involved in both signaling and B-cell development.","BTK Gene | BTK | Bruton Tyrosine Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827738","Interim","C85530","The time between one event, process, or period and another.","Interim | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415699","HPGD Gene","C78137","This gene is involved in prostaglandin metabolism.","HPGD Gene | HPGD | Hydroxyprostaglandin Dehydrogenase 15-(NAD) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0854615","Multiple Agent Systemic Chemotherapy","C118618","Systemic chemotherapy with a multiple agent regimen. All routes of administration are acceptable as long as the regimen is intended for systemic therapy.","Multiple Agent Systemic Chemotherapy | Chemotherapy multiple agents systemic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020204","Hybridoma","C16700","A tumor of hybrid cells used in the in vitro production of specific monoclonal antibodies; produced by fusion of an established tissue culture line of lymphocyte tumor cells (e.g., mouse plasmacytoma cells) and specific antibody-producing cells (e.g., splenocytes from specifically immunized mice); fusions are accomplished by use of polyethylene glycol or other methods.","Hybridoma | ",,,,,,,,,,,,,,,"4100730","Hybridoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028944","Oligodendrocyte","C12618","A type of large glial cell located in the central nervous system that produces myelin as its main function.","Oligodendrocyte | Oligodendrocytes | Oligodendroglia | Oligodendroglia Cell | oligodendrocyte",,,,,,,,,,,,,,,"4279441","Oligodendrocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504388","Have Difficulty Opening a Jar or Bottle Because of Weakness in Hands","C125732","A question about whether an individual has or had difficulty opening a jar or bottle because of weakness in their hands.","Have Difficulty Opening a Jar or Bottle Because of Weakness in Hands | Did you have difficulty opening a jar or bottle because of weakness in your hands",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504389","Have Difficulty Walking Because Feet Drop Downwards","C125733","A question about whether an individual has or had difficulty walking because their feet drop downwards.","Have Difficulty Walking Because Feet Drop Downwards Question | Did you have difficulty walking because your feet dropped downwards | Have Difficulty Walking Because Feet Drop Downwards | Have Difficulty Walking Because Feet Drop Downwards",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504390","Have Difficulty Climbing Stairs or Getting Out of Chair Because of Weakness in Legs","C125734","A question about whether an individual has or had difficulty climbing stairs or getting up out of a chair because of weakness in their legs.","Have Difficulty Climbing Stairs or Getting Out of Chair Because of Weakness in Legs | Did you have difficulty climbing stairs or getting up out of a chair because of weakness in your legs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504391","Dizzy When Standing Up from a Sitting or Lying Position","C125735","A question about whether an individual is or was dizzy when standing up from a sitting or lying position.","Dizzy When Standing Up from a Sitting or Lying Position | Were you dizzy when standing up from a sitting or lying position",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504392","Have Difficulty Hearing","C125736","A question about whether an individual has or had difficulty hearing.","Have Difficulty Hearing | Did you have difficulty hearing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504393","Have Difficulty Using Car Pedals","C125737","A question about whether an individual has or had difficulty using the pedals of a car.","Have Difficulty Using Car Pedals | Did you have difficulty using the pedals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504375","Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20","C125719","A questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) consisting of 20 questions designed to assess quality of life related to symptoms and functional limitations in patients with Chemotherapy-Induced Peripheral Neuropathy (CIPN).","Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20 | CIPN20 Questionnaire | EOR25 | EORTC QLQ-CIPN20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504376","Have Tingling Fingers or Hands","C125720","A question about whether an individual has or had tingling in their fingers or hands.","Have Tingling Fingers or Hands | Did you have tingling fingers or hands",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504377","Have Tingling Toes or Feet","C125721","A question about whether an individual has or had tingling in their toes or feet.","Have Tingling Toes or Feet | Did you have tingling toes or feet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504378","Have Numbness in Fingers or Hands","C125722","A question about whether an individual has or had numbness in their fingers or hands.","Have Numbness in Fingers or Hands | Did you have numbness in your fingers or hands",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504379","Have Numbness in Toes or Feet","C125723","A question about whether an individual has or had numbness in their toes or feet.","Have Numbness in Toes or Feet | Did you have numbness in your toes or feet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504380","Have Shooting or Burning Pain in Fingers or Hands","C125724","A question about whether an individual has or had shooting or burning pain in their fingers or hands.","Have Shooting or Burning Pain in Fingers or Hands | Did you have shooting or burning pain in your fingers or hands",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504381","Have Shooting or Burning Pain in Toes or Feet","C125725","A question about whether an individual has or had shooting or burning pain in their toes or feet.","Have Shooting or Burning Pain in Toes or Feet | Did you have shooting or burning pain in your toes or feet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504382","Have Cramps in Hands","C125726","A question about whether an individual has or had cramps in their hands.","Have Cramps in Hands | Did you have cramps in your hands",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504383","Have Cramps in Feet","C125727","A question about whether an individual has or had cramps in their feet.","Have Cramps in Feet | Did you have cramps in your feet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504384","Have Problems Standing or Walking Because of Difficulty Feeling the Ground Under Feet","C125728","A question about whether an individual has or had problems standing or walking because of difficulty feeling the ground under their feet.","Have Problems Standing or Walking Because of Difficulty Feeling the Ground Under Feet | Did you have problems standing or walking because of difficulty feeling the ground under your feet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504385","Have Difficulty Distinguishing Between Hot and Cold Water","C125729","A question about whether an individual has or had difficulty distinguishing between hot and cold water.","Have Difficulty Distinguishing Between Hot and Cold Water | Did you have difficulty distinguishing between hot and cold water",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504386","Have Problem Holding a Pen Which Makes Writing Difficult","C125730","A question about whether an individual has or had a problem holding a pen, which makes or made writing difficult.","Have Problem Holding a Pen Which Makes Writing Difficult | Did you have a problem holding a pen, which made writing difficult",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504387","Have Difficulty Manipulating Small Objects with Fingers","C125731","A question about whether an individual has or had difficulty manipulating small objects with their fingers.","Have Difficulty Manipulating Small Objects with Fingers | Did you have difficulty manipulating small objects with your fingers (for example, fastening small buttons)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504540","Disruptive TP53 Mutation","C125888","Any mutation of the TP53 gene that results in a nonconservative mutation within the key DNA-binding domain (L2-L3 region) of the p53 protein, or a stop codon in any region.","Disruptive TP53 Mutation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504541","Non-Disruptive TP53 Mutation","C125889","Any conservative mutation in the coding region of the TP53 gene that maintains the structure and function of the p53 protein.","Non-Disruptive TP53 Mutation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504544","Ion Semiconductor Sequencing","C125894","A method of DNA sequencing based on the detection of hydrogen ions that are released during synthesis of a complementary strand polymerized on a template strand. This technology differs from other sequencing technologies in that no modified nucleotides or optics are used. It claims to be simpler, faster, and more cost effective and scalable than any other technology available.","Ion Semiconductor Sequencing | Ion Torrent | Ion Torrent Sequencing | Ion Torrent Sequencing Technology | Semiconductor Sequencing | Silicon Sequencing | pH-Mediated Sequencing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504543","Moderately or Much of the Time","C125893","An indication that something happens or happened moderately or much of the time.","Moderately or Much of the Time | Moderately or much of the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504542","Most or Almost All of the Time","C125892","An indication that something happens or happened most or almost most of the time.","Most or Almost All of the Time | Most or almost all of the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242966","Systemic Inflammatory Response Syndrome","C94832","A generalized state of dysregulated inflammation induced by noninfectious processes. It is characterized by two or more of the following signs and symptoms: fever or hypothermia, increased heart rate, increased respiratory rate, and abnormal white blood cell count.","Systemic Inflammatory Response Syndrome | SIRS | systemic inflammatory response syndrome",,,,,,,,,,,,,,,"434821","Systemic inflammatory response syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035366","Retroviridae","C14268","A family of viruses that possess RNA-dependent DNA polymerases (reverse transcriptases) and contain two identical molecules of positive sense, single-stranded RNA of high molecular weight.  This RNA serves as a template for the synthesis of a complementary DNA, which may be integrated into the host DNA. Virions are enveloped.","Retroviridae | Retrovirus | Retroviruses | Virus-Retrovirus | retrovirus",,,,,,,,,,,,,,,"4300298","Family Retroviridae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504558","Modified Barium Swallow","C125909","A fluoroscopic procedure that examines a person's swallowing pattern. Liquid and solid food that contains barium sulfate is digested to determine if it is entering a person's larynx and trachea.","Modified Barium Swallow | MBS | VFSS | Videofluoroscopic Swallowing Study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1257902","Jumping Genes","C95942","A genetic element that is able to move from one genomic position to another.","Transposon | Jumping Gene | Jumping Genes | TRANSPOSABLE ELEMENT | TRANSPOSON | Transposable Element",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986734","Counting Efficiency","C94879","The observed count rate divided by that expected if all events were counted.","Counting Efficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504555","Quality of Life Questionnaire - Pancreatic Cancer 26","C125906","A questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) consisting of 26 questions designed to assess pain, dietary changes, jaundice, altered bowel habit, emotional problems related to pancreatic cancer, and other symptoms (cachexia, indigestion, flatulence, dry mouth, taste changes).","Quality of Life Questionnaire - Pancreatic Cancer 26 | EORTC QLQ-PAN26 | PAN26 Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504556","Have Pain During the Night","C125907","A question about whether an individual has or had pain during the night.","Have Pain During the Night | Did you have pain during the night",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504557","Uncomfortable in Certain Positions","C125908","A question about whether an individual is or was uncomfortable in certain positions.","Uncomfortable in Certain Positions | Did you find it uncomfortable in certain positions (e.g. lying down)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504559","Restricted in the Types of Food You Can Eat as a Result of Disease or Treatment","C125910","A question about whether an individual is or was restricted in the types of food they can eat as a result of their disease or treatment.","Restricted in the Types of Food You Can Eat as a Result of Disease or Treatment | Were you restricted in the types of food you can eat as a result of your disease or treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504560","Restricted in the Amount of Food You Can Eat as a Result of Disease or Treatment","C125911","A question about whether an individual is or was restricted in the amounts of food they could eat as a result of their disease or treatment.","Restricted in the Amount of Food You Can Eat as a Result of Disease or Treatment | Were you restricted in the amounts of food you could eat as a result of your disease or treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504561","Food and Drink Taste Different from Usual","C125912","A question about whether food or drink tastes or tasted different from usual.","Food and Drink Taste Different from Usual | Did food and drink taste different from usual",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504562","Have Indigestion","C125913","A question about whether an individual has or had indigestion.","Have Indigestion | Have you had indigestion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504563","Worried About Weight Being Too Low","C125914","A question about whether an individual worries or worried about their weight being too low.","Worried About Weight Being Too Low | Have you worried about your weight being too low",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504564","Have Yellow Skin","C125915","A question about the extent to which an individual has or had yellow skin.","Have Yellow Skin | Extent of Yellow Skin | To what extent was your skin yellow",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504565","Have Frequent Bowel Movements","C125916","A question about whether an individual has or had frequent bowel movements.","Have Frequent Bowel Movements | Did you have frequent bowel movements",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504566","Feel Urge to Move Bowels Quickly","C125917","A question about whether an individual feels or felt the urge to move their bowels quickly.","Feel Urge to Move Bowels Quickly | Did you feel the urge to move your bowels quickly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504567","Troubled with Side Effects from Treatment","C125918","A question about the extent to which an individual is or was troubled with side effects from their treatment.","Troubled with Side Effects from Treatment | Extent Troubled with Side Effects from Treatment | To what extent have you been troubled with side-effects from your treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504568","Limited in Planning Activities in Advance","C125919","A question about whether an individual is or was limited in planning activities in advance.","Limited in Planning Activities in Advance | Were you limited in planning activities in advance (e.g. meeting friends)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504569","Receive Adequate Support from Health Care Professionals","C125920","A question about whether an individual receives or received adequate support from their health care professionals.","Receive Adequate Support from Health Care Professionals | Have you received adequate support from your health care professionals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504570","Adequate Information Given About Physical Condition and Treatment","C125921","A question about whether the information given to an individual about their physical condition and treatment is or was adequate.","Adequate Information Given About Physical Condition and Treatment | Has the information given about your physical condition and treatment been adequate | Information Given About Physical Condition and Treatment is Adequate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504574","Feel Less Interest in Sex","C125933","A question about whether an individual feels or felt less interest in sex.","Feel Less Interest in Sex | Have you felt less interest in sex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504575","Feel Less Sexual Enjoyment","C125934","A question about whether an individual feels or felt less sexual enjoyment.","Feel Less Sexual Enjoyment | Have you felt less sexual enjoyment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0298751","Lewis Y Antigen","C1627","A carbohydrate molecule expressed on the surface of solid tumors including lung, intestinal, breast, prostate, pancreatic, esophageal, stomach, colon, rectal or ovarian cancers.","Lewis Y Antigen | LEWIS Y ANTIGEN | LeY Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1504735","TNFRSF17 protein, human","C97848","Tumor necrosis factor receptor superfamily member 17 (184 aa, ~20 kDa) is encoded by the human TNFRSF17 gene. This protein is involved in both ligand binding and cytokine signaling.","Tumor Necrosis Factor Receptor Superfamily Member 17 | B-Cell Maturation Protein | BCMA | CD Antigen CD269 | CD269 | CD269 Antigen | TNFRSF17",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504692","Perceived Stress Scale - 14 Questionnaire","C126095","A 14 item self-report questionnaire that utilizes a 5-point Likert Scale rating system to assess an individual's perception of the stressfulness of life situations in the past month.","Perceived Stress Scale - 14 Questionnaire | PSS-14 | PSS-14 Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504693","How Often Dealt Successfully with Day to Day Problems and Annoyances in the Last Month","C126096","A question about the frequency an individual dealt successfully with day to day problems and annoyances in the last month.","How Often Dealt Successfully with Day to Day Problems and Annoyances in the Last Month | In the last month, how often have you dealt successfully with day to day problems and annoyances",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504694","How Often Felt You Were Effectively Coping with Important Changes Occurring in Life in the Last Month","C126097","A question about the frequency an individual felt that they were effectively coping with important changes occurring in their life in the last month.","How Often Felt You Were Effectively Coping with Important Changes Occurring in Life in the Last Month | In the last month, how often have you felt that you were effectively coping with important changes that were occurring in your life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504695","How Often Found Yourself Thinking About Things That You Have to Accomplish in the Last Month","C126098","A question about the frequency an individual found themself thinking about things that they had to accomplish in the last month.","How Often Found Yourself Thinking About Things That You Have to Accomplish in the Last Month | In the last month, how often have you found yourself thinking about things that you have to accomplish",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504696","How Often Able to Control the Way You Spend Your Time in the Last Month","C126099","A question about the frequency an individual has been able to control the way they spent their time in the last month.","How Often Able to Control the Way You Spend Your Time in the Last Month Question | How Often Able to Control the Way You Spend Your Time in the Last Month | How Often Able to Control the Way You Spend Your Time in the Last Month | In the last month, how often have you been able to control the way you spend your time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376335","Functional Magnetic Resonance Imaging","C17958","The principle of functional MRI imaging is to take a series of images of an organ in quick succession and to statistically analyze the images for differences among them.  Most commonly used in studies of brain function.","Functional Magnetic Resonance Imaging | FUNCTIONAL MRI | Functional MRI | fMRI | functional magnetic resonance imaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504698","Urine Pellet","C126103","The cells, crystals, casts, bacteria, yeast, or other particles collected by centrifugation of a urine sample.","Urine Pellet | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041221","Trypanosoma cruzi","C125977","A species of parasitic euglenoid protozoan in the family Trypanosomatidae. T. cruzi is passed between mammalian hosts through the feces of a triatomine insect vector. Infection in humans causes Chagas disease.","Trypanosoma cruzi | TRYPANOSOMA CRUZI",,,,,,,,,,,,,,,"4339423","Trypanosoma cruzi",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4039583","Chimeric Antigen Receptor","C126108","A cell-surface receptor that has been engineered to combine novel features and specificities from various sources in order to enhance its antigen specificity. Engineered T-cells or B-cells will produce the specialized receptor that will be capable of binding to an epitope on its target cell.","Chimeric Antigen Receptor | Artificial Antigen Receptor | CAR | Non-Native Antigen Receptor",,,,,,,,,,,,,,,"46271101","Chimeric antigen receptor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034788","Antigen Receptor","C126107","A cell-surface receptor found on T-cells or B-cells that recognize specific antigenic peptides. Each cell naturally produces a unique receptor that binds to a unique epitope on a target cell.","Antigen Receptor | Native Antigen Receptor",,,,,,,,,,,,,,,"4324404","Antigen receptor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4277689","Gene Editing","C126104","Any gene manipulation method used to generate a product with an altered sequence, structure, or conformation.","Gene Modification | Gene Editing | Genetic Modification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015491","Coagulation Factor IX, Human, Endogenous","C28482","Coagulation factor IX (461 aa, ~52 kDa) is encoded by the human F9 gene. This protein plays a role in the intrinsic pathway of blood coagulation through the mediation of proteolysis that converts factor X into an active protease.","Coagulation Factor IX | COAGULATION FACTOR IX | Christmas Factor | EC 3.4.21.22 | F9 | FIX | Factor 9 | Factor IX | PTC | Plasma Thromboplastic Component | Plasma Thromboplastin Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332700","CCR5 Gene","C24270","This gene is involved in G protein-coupled signal transduction and chemotaxis.","CCR5 Gene | C-C Motif Chemokine Receptor 5 Gene | CCR5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036447","Scopoletin","C126100","A coumarin compound found in several plants including those in the genus Scopolia and the genus Brunfelsia, as well as chicory (Cichorium), redstem wormwood (Artemisia scoparia), stinging nettle (Urtica dioica), passion flower (Passiflora), noni (Morinda citrifolia fruit) and European black nightshade (Solanum nigrum) that is comprised of umbelliferone with a methoxy group substituent at position 6. Scopoletin is used to standardize and establish pharmacokinetic properties for products derived from the plants that produce it, such as noni extract. Although the mechanism(s) of action have not yet been established, this agent has potential antineoplastic, antidopaminergic, antioxidant, anti-inflammatory and anticholinesterase effects.","Scopoletin | 2H-1-Benzopyran-2-One, 7-Hydroxy-6-Methoxy- | 2H-1-Benzopyran-2-One, 7-Hydroxy-6-Methoxy- (9CI) | 6-Methoxyumbelliferone | 6-Methylesculetin | 6-O-Methylesculetin | 7-Hydroxy-5-Methoxycoumarin | 7-Hydroxy-6-Methoxychromen-2-One | 7-Hydroxy-6-Methoxycoumarin | Chrysatropic Acid | Coumarin, 7-Hydroxy-6-Methoxy- | Escopoletin | Esculetin-6-Methyl Ether | Gelseminic Acid | Methylesculetin | Murrayetin | SCOPOLETIN | Scopoletine | Scopoletol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0250414","Phospholipase C Gamma","C126114","A family of phospholipases that are activated by receptor tyrosine kinases, bind to the non-catalytic domains of src-family protein tyrosine kinases, and catalyze the biosynthesis of second messenger signaling molecules.","Phospholipase C Gamma | 1-Phosphatidylinositol-4,5-Bisphosphate Phosphodiesterase Gamma | PLC-Gamma | PLCG | PLCgamma | Phosphoinositide Phospholipase C-Gamma | Phospholipase C-Gamma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504707","Kinase Inhibitor Sensitivity","C126115","A metabolic marker that predicts which kinase inhibitor agent could be an effective treatment for a patient's tumor based on the in vitro treatment response for cells extracted from the tumor.","Kinase Inhibitor Sensitivity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504709","Placental Growth Factor 1 Isoform","C126117","Placenta growth factor isoform 1 (149 aa, ~17 kDa) is encoded by the human PGF gene. This protein may be involved in the positive regulation of endothelial cell growth.","Placenta Growth Factor Isoform 1 | Isoform PlGF-1 | PLGF-1 | PLGF1 | PlGF-131 | Placental Growth Factor 1 Isoform | Placental Growth Factor Isoform 1 | Placental Growth Factor Isoform 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1643204","HLA-Cw","C126118","A subset of serotypes for the HLA class I histocompatibility antigen, C alpha chain protein (HLA-C) found in the human population. Expression of Cw1 is associated with multinodular goiters, Cw6 is associated with susceptibility to psoriasis and alleles of Cw7 are associated with increased risk of age-related macular degeneration. Expression of Cw5 may be associated with increased risk of rheumatoid arthritis (RA) and expression of Cw4 may protect patients from RA, while Cw3 expression may be associated with increased risk of developing vascular complications for patients with RA. Expression of Cw4 may also be associated with reduced susceptibility to HIV-1 viremia.","HLA-Cw Serotype | HLA-Cw",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504710","Polysomy 7","C126119","A numerical chromosomal abnormality characterized by the presence of more than two copies of chromosome 7 in a cell.","Polysomy 7 | Chromosome 7 Polysomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030069","Oxygenated Hemoglobin","C126120","Hemoglobin where the heme group has formed a reversible complex with oxygen (O2) in the lungs. This molecule is found in the systemic arteries and transports O2 from the lungs to the tissues where it is readily released.","Oxygenated Hemoglobin | HbO2 | Oxyhemoglobin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0057437","Deoxyhemoglobin","C126121","Hemoglobin containing a heme group that is not bound to oxygen (O2). This molecule is normally found in the systemic veins following transit through capillaries and release of O2 into the tissues. Excess deoxyhemoglobin can be associated with hypoxia.","Deoxygenated Hemoglobin | Deoxyhemoglobin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504711","CD42 Complex","C126122","A heterotetrameric protein complex expressed on the surface of platelets that is involved in promoting platelet adhesion to von Willebrand factor during wound healing. This non-covalent complex is comprised of glycoprotein 5 (GPV; CD42d), glycoprotein 9 (GPIX; CD42a), and glycoprotein Ib (GPIb). GPIb is a heterodimer comprised of platelet glycoprotein Ib alpha chain (GPIba; CD42b) covalently bound to platelet glycoprotein Ib beta chain (GPIbb; CD42c).","CD42 Complex | CD42 | CD42 Antigen | CD42a-d Complex | GPIb-V-IX | GPIb/V/IX | Glycoprotein Ib-V-IX | Glycoprotein Ib/V/IX Complex | Platelet Glycoprotein Ib-V-IX | Platelet Glycoprotein Ib/V/IX Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823649","TIGIT Gene","C126123","This gene is involved in cell-cell adhesion and the regulation of T-cell and dendritic cell activity.","TIGIT Gene | T-Cell Immunoreceptor with Ig and ITIM Domains Gene | TIGIT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417240","KIF20B Gene","C126126","This gene plays a role in microtubule-based transport, cytokinesis and cell polarity.","KIF20B Gene | KIF20B | Kinesin Family Member 20B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427804","DEPDC1 Gene","C126129","This gene is involved in the negative regulation of gene transcription.","DEPDC1 Gene | DEP Domain Containing 1 Gene | DEPDC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537625","LY6K Gene","C126132","This gene may be involved in cell growth regulation.","LY6K Gene | LY6K | Lymphocyte Antigen 6 Complex, Locus K Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3146638","ATG13 Gene","C126135","This gene plays a role in both autophagosome formation and mitophagy.","ATG13 Gene | ATG13 | Autophagy Related 13 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1608540","TNFRSF4 protein, human","C94790","Tumor necrosis factor receptor superfamily member 4 (277 aa, ~29 kDa) is encoded by the human TNFRSF4 gene. This protein plays a role in signal transduction pathways that mediate apoptosis inhibition and inflammatory responses.","Tumor Necrosis Factor Receptor Superfamily Member 4 | ACT35 Antigen | Antigen CD134 | CD134 | CD134 Antigen | OX-40 | OX40 | OX40L Receptor | TAX Transcriptionally-Activated Glycoprotein 1 Receptor | TNFRSF4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0075747","CD28 Antigen","C17336","T-cell-specific surface glycoprotein CD28 (220 aa, ~25 kDa) is encoded by the human CD28 gene. This protein is involved in the survival and activation of T-lymphocytes.","T-Cell-Specific Surface Glycoprotein CD28 | Antigen CD28 | CD28 | CD28 Antigen | T-Cell Antigen CD28 | T-Cell Specific Surface Glycoprotein CD28 | T-Cell Specific Surface Glycoprotein CD28 | T-Cell-Specific Surface Glycoprotein | T90/44 | Tp44",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824668","CD27 Gene","C104071","This gene is involved in maintenance of T cell immunity.","CD27 Gene | CD27 | CD27 Molecule Gene | TNFRSF7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0247111","Tumor Necrosis Factor Receptor Superfamily Member 9","C105113","Tumor necrosis factor receptor superfamily member 9 (255 aa, ~28 kDa) is encoded by the human TNFRSF9 gene. This protein plays a role in receptor signal transduction in activated T-lymphocytes.","Tumor Necrosis Factor Receptor Superfamily Member 9 | 4-1BB Ligand Receptor | CD137 | CD137 Antigen | CDw137 | Receptor Protein 4-1BB | T Cell Antigen ILA | T-Cell Antigen 4-1BB Homolog | T-Cell Antigen ILA | TNFRSF9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333572","FOXO1 Gene","C24402","This gene is involved in transcriptional regulation and may play a role in myogenic growth and differentiation.","FOXO1 Gene | FOXO1 | Forkhead Box O1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448503","Gene Fusion","C20195","Any hybrid gene formed from two previously separate genes. Such fusions occur as a result of translocation, intersititial deletion or chromosomal inversion, and often result in gene products with functions different from the two fusion partners. Gene fusions are associated frequently with hematological cancers, sarcomas and prostate cancer.","Gene Fusion | Fusion | Rearrangement Fusion | Rearrangement, Fusion | gene fusion variant | gene_fusion_variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514934","Rhabdomyoblast","C36744","A mesenchymal cell showing variable degrees of skeletal muscle differentiation. It is a polygonal, fusiform, round, or bizarre cell with a usually eccentric nucleus and bright eosinophilic cytoplasm sometimes exhibiting cross-striations.","Rhabdomyoblast | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706477","Human Activity Profile Test","C48948","A self-administered instrument designed to measure energy expenditure or physical fitness. It was originally developed to measure quality of life achieved by patients in rehabilitation programs for chronic obstructive pulmonary disease, but has also been used as a measure of physical activity in both healthy and impaired populations. The profile consists of 94 common daily activities listed in ascending order according to the energy required to perform them. Activities including self-care tasks, personal/household work, entertainment/social activities, and independent exercise pursuits and respondents are requested to indicate if they are currently able to perform the activity (unassisted), they have stopped performing the activity, or they have never performed the activity.","Human Activity Profile | ADAPT | Additive Daily Activities Profile Test | HAP | Human Activity Profile Questionnaire | Human Activity Profile Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504721","Getting In and Out of Chairs or Bed Without Assistance","C126138","A question about an individual's ability to get in and out of chairs or bed without assistance.","Getting In and Out of Chairs or Bed Without Assistance Question | Getting In and Out of Chairs or Bed Without Assistance | Getting In and Out of Chairs or Bed Without Assistance | Getting In and Out of Chairs or Bed Without Help | Getting in and out of chairs or bed (without assistance)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504722","Listening to the Radio","C126139","A question about an individual's ability to listen to the radio.","Listening to the Radio | Listening to the radio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505107","Reading Ability","C126140","A question about an individual's ability to read books, magazines, or newspapers.","Reading Ability Question | Reading | Reading Ability | Reading Ability | Reading books, magazines, or newspapers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505110","Writing Ability","C126141","A question about an individual's ability to write letters or notes.","Writing Ability | Writing | Writing (letters, notes)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504723","Working at a Desk or Table","C126142","A question about an individual's ability to work at a desk or table.","Working at a Desk or Table Question | Working at a Desk or Table | Working at a Desk or Table | Working at a desk or table",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504724","Standing for More Than 1 Minute","C126143","A question about an individual's ability to stand for more than 1 minute.","Standing for More Than 1 Minute Question | Standing (for more than 1 minute) | Standing for More Than 1 Minute | Standing for More Than 1 Minute",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504725","Standing for More Than 5 Minutes","C126144","A question about an individual's ability to stand more than 5 minutes.","Standing for More Than 5 Minutes Question | Standing (more than 5 minutes) | Standing for More Than 5 Minutes | Standing for More Than 5 Minutes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504726","Dressing or Undressing Without Assistance","C126145","A question about an individual's ability to dress or undress without assistance.","Dressing or Undressing Without Assistance Question | Dressing or Undressing Without Assistance | Dressing or Undressing Without Assistance | Dressing or Undressing Without Help | Dressing or undressing (without assistance)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504727","Getting Clothes from Drawers or Closets","C126146","A question about an individual's ability to get clothes from drawers or closets.","Getting Clothes from Drawers or Closets Question | Getting Clothes from Drawers or Closets | Getting Clothes from Drawers or Closets | Getting clothes from drawers or closets",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504728","Getting In or Out of a Car Without Assistance","C126147","A question about an individual's ability to get in or out of a car without assistance.","Getting In or Out of a Car Without Assistance Question | Getting In or Out of a Car Without Assistance | Getting In or Out of a Car Without Assistance | Getting In or Out of a Car Without Help | Getting in or out of a car (without assistance)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504729","Dining at a Restaurant","C126148","A question about an individual's ability to dine at a restaurant.","Dining at a Restaurant Question | Dining at a Restaurant | Dining at a Restaurant | Dining at a restaurant | Eating at a Restaurant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504730","Playing Cards or Table Games","C126149","A question about an individual's ability to play cards or table games.","Playing Cards or Table Games Question | Playing Cards or Table Games | Playing Cards or Table Games | Playing cards/table games",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504731","Bathing Without Assistance","C126150","A question about an individual's ability to take a bath with no assistance needed.","Bathing Without Assistance Question | Bathing Without Assistance | Bathing Without Assistance | Bathing Without Help | Bathing with No Assistance Needed | Taking a Bath Without Assistance | Taking a Bath Without Help | Taking a Bath with No Assistance Needed | Taking a bath (no assistance needed)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504732","Putting on Shoes, Stockings, or Socks Without Rest or a Break","C126151","A question about an individual's ability to put on shoes, stockings, or socks with no rest or break needed.","Putting on Shoes, Stockings, or Socks Without Rest or a Break Question | Putting on Shoes, Stockings, or Socks Without Rest or a Break | Putting on Shoes, Stockings, or Socks Without Rest or a Break | Putting on Shoes, Stockings, or Socks with No Rest or Break Needed | Putting on shoes, stockings, or socks (no rest or break needed)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504733","Attending a Movie, Play, Church Event, or Sports Activity","C126152","A question about an individual's ability to attend a movie, play, church event or sports activity.","Attending a Movie, Play, Church Event, or Sports Activity | Attending a movie, play, church event or sports activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504734","Walking 30 Yards","C126153","A question about an individual's ability to walk 30 yards (27 meters).","Walking 30 Yards Question | Walking 27 Meters | Walking 30 Yards | Walking 30 Yards | Walking 30 yards (27 meters)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504736","Walking 30 Yards Nonstop","C126155","A question about an individual's ability to walk 30 yards nonstop.","Walking 30 Yards Nonstop Question | Walking 30 Yards Nonstop | Walking 30 Yards Nonstop | Walking 30 yards (nonstop)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504735","Dressing or Undressing Without Rest or a Break","C126154","A question about an individual's ability to dress or undress with no rest break needed.","Dressing or Undressing Without Rest or a Break Question | Dressing or Undressing Without Rest or a Break | Dressing or Undressing Without Rest or a Break | Dressing or Undressing with No Rest or Break Needed | Dressing/undressing (no rest break needed)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504737","Using Public Transport or Driving a Car, 99 Miles or Less","C126156","A question about an individual's ability to use public transport or drive a car for 99 miles or less.","Using Public Transport or Driving a Car, 99 Miles or Less | Using public transport or driving a car (99 miles or less)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504738","Using Public Transport or Driving a Car, 100 Miles or More","C126157","A question about an individual's ability to use public transport or driving a car for 100 miles or more.","Using Public Transport or Driving a Car, 100 Miles or More | Using public transport or driving a car (100 miles or more)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504739","Cooking Your Own Meals","C126158","A question about an individual's ability to cook their own meals.","Cooking Your Own Meals Question | Cooking Your Own Meals | Cooking Your Own Meals | Cooking your own meals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504740","Washing or Drying Dishes","C126159","A question about an individual's ability to wash or dry dishes.","Washing or Drying Dishes Question | Washing or Drying Dishes | Washing or Drying Dishes | Washing or drying dishes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504741","Putting Groceries on Shelves","C126160","A question about an individual's ability to put groceries on shelves.","Putting Groceries on Shelves Question | Putting Groceries on Shelves | Putting Groceries on Shelves | Putting groceries on shelves",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504742","Ironing or Folding Clothes","C126161","A question about an individual's ability to iron or fold clothes.","Ironing or Folding Clothes Question | Ironing or Folding Clothes | Ironing or Folding Clothes | Ironing or folding clothes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504744","Climbing 6 Steps","C126163","A question about an individual's ability to climb 6 steps.","Climbing 6 Steps Question | Climbing 6 Steps | Climbing 6 Steps | Climbing 6 steps",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504745","Climbing 6 Steps Nonstop","C126164","A question about an individual's ability to climb 6 steps nonstop.","Climbing 6 Steps Nonstop Question | Climbing 6 Steps Nonstop | Climbing 6 Steps Nonstop | Climbing 6 steps (nonstop)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504746","Climbing 9 Steps","C126165","A question about an individual's ability to climb 9 steps.","Climbing 9 Steps Question | Climbing 9 Steps | Climbing 9 Steps | Climbing 9 steps",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504747","Climbing 12 Steps","C126166","A question about an individual's ability to climb 12 steps.","Climbing 12 Steps Question | Climbing 12 Steps | Climbing 12 Steps | Climbing 12 steps",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504748","Walking Half a Block on Level Ground","C126167","A question about an individual's ability to walk 1/2 block on level ground.","Walking Half a Block on Level Ground Question | Walking 1/2 Block on Level Ground | Walking 1/2 block on level ground | Walking Half a Block on Level Ground | Walking Half a Block on Level Ground",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504749","Walking Half Block on Level Ground Nonstop","C126168","A question about an individual's ability to walk 1/2 block on level ground nonstop.","Walking Half Block on Level Ground Nonstop Question | Walking 1/2 Block on Level Ground Nonstop | Walking 1/2 block on level ground (nonstop) | Walking Half Block on Level Ground Nonstop | Walking Half Block on Level Ground Nonstop",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504750","Ability to Make a Bed","C126169","A question about an individual's ability to make a bed, not changing sheets.","Ability to Make a Bed Question | Ability to Make a Bed | Ability to Make a Bed | Make a Bed | Making a Bed | Making a Bed, Not Changing Sheets | Making a bed (not changing sheets)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505119","Cleaning Windows","C126170","A question about an individual's ability to clean windows.","Cleaning Windows Question | Cleaning Windows | Cleaning Windows | Cleaning windows",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504751","Kneeling or Squatting to Do Light Work","C126171","A question about an individual's ability to kneel or squat to do light work.","Kneeling or Squatting to Do Light Work Question | Kneeling or Squatting to Do Light Work | Kneeling or Squatting to Do Light Work | Kneeling or squatting to do light work",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504752","Carrying a Light Load of Groceries","C126172","A question about an individual's ability to carry a light load of groceries.","Carrying a Light Load of Groceries Question | Carrying a Light Load of Groceries | Carrying a Light Load of Groceries | Carrying a light load of groceries",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504753","Climbing 9 Steps Nonstop","C126173","A question about an individual's ability to climb 9 steps nonstop.","Climbing 9 Steps Nonstop Question | Climbing 9 Steps Nonstop | Climbing 9 Steps Nonstop | Climbing 9 steps (nonstop)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504754","Climbing 12 Steps Nonstop","C126174","A question about an individual's ability to climb 12 steps nonstop.","Climbing 12 Steps Nonstop Question | Climbing 12 Steps Nonstop | Climbing 12 Steps Nonstop | Climbing 12 steps (nonstop)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504755","Walking Half Block Uphill","C126175","A question about an individual's ability to walk 1/2 block uphill.","Walking Half Block Uphill Question | Walking 1/2 Block Uphill | Walking 1/2 block uphill | Walking Half Block Uphill | Walking Half Block Uphill",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504756","Walking Half Block Uphill Nonstop","C126176","A question about an individual's ability to walk 1/2 block uphill nonstop.","Walking Half Block Uphill Nonstop Question | Walking 1/2 Block Uphill Nonstop | Walking 1/2 block uphill (nonstop) | Walking Half Block Uphill Nonstop | Walking Half Block Uphill Nonstop",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504757","Shopping by Yourself","C126177","A question about an individual's ability to shop alone.","Shopping by Yourself | Shopping (by yourself)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504758","Washing Clothes by Yourself","C126178","A question about an individual's ability to wash clothes alone.","Washing Clothes by Yourself Question | Washing Clothes by Yourself | Washing Clothes by Yourself | Washing clothes (by yourself)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504759","Walking 1 Block on Level Ground","C126179","A question about an individual's ability to walk 1 block on level ground.","Walking 1 Block on Level Ground Question | Walking 1 Block on Level Ground | Walking 1 Block on Level Ground | Walking 1 block on level ground",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504760","Walking 2 Blocks on Level Ground","C126180","A question about an individual's ability to walk 2 blocks on level ground.","Walking 2 Blocks on Level Ground Question | Walking 2 Blocks on Level Ground | Walking 2 Blocks on Level Ground | Walking 2 blocks on level ground",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504761","Walking 1 Block on Level Ground Nonstop","C126181","A question about an individual's ability to walk 1 block on level ground nonstop.","Walking 1 Block on Level Ground Nonstop Question | Walking 1 Block on Level Ground Nonstop | Walking 1 Block on Level Ground Nonstop | Walking 1 block on level ground (nonstop)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504762","Walking 2 Blocks on Level Ground Nonstop","C126182","A question about an individual's ability to walk 2 blocks on level ground nonstop.","Walking 2 Blocks on Level Ground Nonstop Question | Walking 2 Blocks on Level Ground Nonstop | Walking 2 Blocks on Level Ground Nonstop | Walking 2 blocks on level ground (nonstop)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504763","Scrubbing Doors, Walls, or Cars","C126183","A question about an individual's ability to scrub doors, walls, or cars.","Scrubbing Doors, Walls, or Cars Question | Scrubbing (doors, walls, or cars) | Scrubbing Doors, Walls, or Cars | Scrubbing Doors, Walls, or Cars",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504764","Making a Bed and Changing Sheets","C126184","A question about an individual's ability to make a bed, changing sheets.","Making a Bed and Changing Sheets | Making a Bed, Changing Sheets | Making a bed (changing sheets)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504765","Sweeping","C126185","A question about an individual's ability to sweep.","Sweeping Ability Question | Sweeping | Sweeping | Sweeping Ability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504766","Sweeping 5 Minutes Nonstop","C126186","A question about an individual's ability to sweep 5 minutes nonstop.","Sweeping 5 Minutes Nonstop Question | Sweeping (5 minutes nonstop) | Sweeping 5 Minutes Nonstop | Sweeping 5 Minutes Nonstop",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504767","Carrying a Large Suitcase or Bowling 1 Game","C126187","A question about an individual's ability to carry a large suitcase or bowl 1 game.","Carrying a Large Suitcase or Bowling 1 Game Question | Carrying a Large Suitcase or Bowling 1 Game | Carrying a Large Suitcase or Bowling 1 Game | Carrying a large suitcase or bowling (1 game)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504768","Vacuuming Carpets","C126188","A question about an individual's ability to vacuum carpets.","Vacuuming Carpets Ability Question | Vacuuming Carpets | Vacuuming Carpets | Vacuuming Carpets Ability | Vacuuming carpets",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504769","Vacuuming Carpets 5 Minutes Nonstop","C126189","A question about an individual's ability to vacuum carpets 5 minutes nonstop.","Vacuuming Carpets 5 Minutes Nonstop Ability Question | Vacuuming Carpets 5 Minutes Nonstop | Vacuuming Carpets 5 Minutes Nonstop | Vacuuming Carpets 5 Minutes Nonstop Ability | Vacuuming carpets (5 minutes nonstop)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504770","House Painting","C126190","A question about an individual's ability to paint interior/exterior.","House Painting Ability Question | House Painting | House Painting | House Painting Ability | Painting (interior/exterior) | Painting, Interior or Exterior",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504771","Walking 6 Blocks on Level Ground","C126191","A question about an individual's ability to walk 6 blocks on level ground.","Walking 6 Blocks on Level Ground Question | Walking 6 Blocks on Level Ground | Walking 6 Blocks on Level Ground | Walking 6 blocks on level ground",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504772","Walking 6 Blocks on Level Ground Nonstop","C126192","A question about an individual's ability to walk 6 blocks on level ground nonstop.","Walking 6 Blocks on Level Ground Nonstop Question | Walking 6 Blocks on Level Ground Nonstop | Walking 6 Blocks on Level Ground Nonstop | Walking 6 blocks on level ground (nonstop)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504773","Carrying Out the Garbage","C126193","A question about an individual's ability to carry out the garbage.","Carrying Out the Garbage Question | Carrying Out the Garbage | Carrying Out the Garbage | Carrying out the garbage | Taking Out the Garbage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504774","Carrying a Heavy Load of Groceries","C126194","A question about an individual's ability to carry a heavy load of groceries.","Carrying a Heavy Load of Groceries Question | Carrying a Heavy Load of Groceries | Carrying a Heavy Load of Groceries",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504775","Climbing 24 Steps","C126195","A question about an individual's ability to climb 24 steps.","Climbing 24 Steps Question | Climbing 24 Steps | Climbing 24 Steps | Climbing 24 steps",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504776","Climbing 36 Steps","C126196","A question about an individual's ability to climb 36 steps.","Climbing 36 Steps Question | Climbing 36 Steps | Climbing 36 Steps | Climbing 36 steps",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504777","Climbing 24 Steps Nonstop","C126197","A question about an individual's ability to climb 24 steps nonstop.","Climbing 24 Steps Nonstop Question | Climbing 24 Steps Nonstop | Climbing 24 Steps Nonstop | Climbing 24 steps (nonstop)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504778","Climbing 36 Steps Nonstop","C126198","A question about an individual's ability to climb 36 steps nonstop.","Climbing 36 Steps Nonstop Question | Climbing 36 Steps Nonstop | Climbing 36 Steps Nonstop | Climbing 36 steps (nonstop)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504779","Walking 1 Mile","C126199","A question about an individual's ability to walk 1 mile.","Walking 1 Mile Question | Walking 1 Mile | Walking 1 Mile | Walking 1 mile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504780","Walking 1 Mile Nonstop","C126200","A question about an individual's ability to walk 1 mile nonstop.","Walking 1 Mile Nonstop Question | Walking 1 Mile Nonstop | Walking 1 Mile Nonstop | Walking 1 mile (nonstop)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504781","Running 110 Yards or Playing Softball or Baseball","C126201","A question about an individual's ability to run 110 yards or 100 meters or play softball or baseball.","Running 110 Yards or Playing Softball or Baseball Question | Running 100 Meters or Playing Softball or Baseball | Running 110 Yards or Playing Softball or Baseball | Running 110 Yards or Playing Softball or Baseball | Running 110 yards (100 meters) or playing softball/baseball",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504782","Social Dancing","C126202","A question about an individual's ability to do social dancing.","Social Dancing Ability Question | Dancing (social) | Social Dancing | Social Dancing | Social Dancing Ability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504783","Doing Calisthenics or Aerobic Dancing 5 Minutes Nonstop","C126203","A question about an individual's ability to do calisthenics or aerobic dancing 5 minutes nonstop.","Doing Calisthenics or Aerobic Dancing 5 Minutes Nonstop Question | Doing Calisthenics or Aerobic Dancing 5 Minutes Nonstop | Doing Calisthenics or Aerobic Dancing 5 Minutes Nonstop | Doing calisthenics or aerobic dancing (5 minutes nonstop)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504784","Mowing The Lawn with a Power Mower","C126204","A question about an individual's ability to mow the lawn using a power mower, not a riding mower.","Mowing The Lawn with a Power Mower Question | Mowing The Lawn with a Power Mower | Mowing The Lawn with a Power Mower | Mowing The Lawn with a Power Mower, Not a Riding Mower | Mowing the lawn (power mower, not a riding mower)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504785","Walking 2 miles","C126205","A question about an individual's ability to walk 2 miles.","Walking 2 Miles Question | Walking 2 Miles | Walking 2 miles | Walking 2 miles",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504786","Walking 2 miles Nonstop","C126206","A question about an individual's ability to walk 2 miles nonstop.","Walking 2 Miles Nonstop Question | Walking 2 Miles Nonstop | Walking 2 miles (nonstop) | Walking 2 miles Nonstop",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504787","Climbing 50 Steps or 2 1/2 Floors","C126207","A question about an individual's ability to climb 50 steps 2 1/2 floors.","Climbing 50 Steps or 2 1/2 Floors Question | Climbing 50 Steps or 2 1/2 Floors | Climbing 50 Steps or 2 1/2 Floors | Climbing 50 steps (2 1/2 floors)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504788","Shoveling, Digging, or Spading","C126208","A question about an individual's ability to shovel, dig, or spade.","Shoveling, Digging, or Spading Question | Shoveling, Digging, or Spading | Shoveling, Digging, or Spading | Shoveling, digging, or spading",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504789","Shoveling, Digging, or Spading 5 Minutes Nonstop","C126209","A question about an individual's ability to shovel, dig, or spade 5 minutes nonstop.","Shoveling, Digging, or Spading 5 Minutes Nonstop Question | Shoveling, Digging, or Spading 5 Minutes Nonstop | Shoveling, Digging, or Spading 5 Minutes Nonstop | Shoveling, digging, or spading (5 minutes nonstop)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504790","Climbing 50 Steps Nonstop","C126210","A question about an individual's ability to climb 50 steps nonstop.","Climbing 50 Steps Nonstop Question | Climbing 50 Steps Nonstop | Climbing 50 Steps Nonstop | Climbing 50 steps (nonstop)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504791","Walking 3 Miles or Golfing 18 Holes Without a Riding Cart","C126211","A question about an individual's ability to walk 3 miles or golf 18 holes without a riding cart.","Walking 3 Miles or Golfing 18 Holes Without a Riding Cart Question | Walking 3 Miles or Golfing 18 Holes Without a Riding Cart | Walking 3 Miles or Golfing 18 Holes Without a Riding Cart | Walking 3 miles or golfing 18 holes without a riding cart",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504792","Walking 3 Miles Nonstop","C126212","A question about an individual's ability to walk 3 miles nonstop.","Walking 3 Miles Nonstop Question | Walking 3 Miles Nonstop | Walking 3 Miles Nonstop | Walking 3 miles (nonstop)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504793","Swimming 25 Yards","C126213","A question about an individual's ability to swim 25 yards.","Swimming 25 Yards Ability Question | Swimming 25 Yards | Swimming 25 Yards | Swimming 25 Yards Ability | Swimming 25 yards",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504794","Swimming 25 Yards Nonstop","C126214","A question about an individual's ability to swim 25 yards nonstop.","Swimming 25 Yards Nonstop Ability Question | Swimming 25 Yards Nonstop | Swimming 25 Yards Nonstop | Swimming 25 Yards Nonstop Ability | Swimming 25 yards (nonstop)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504795","Bicycling 1 Mile","C126215","A question about an individual's ability to bicycle 1 mile.","Bicycling 1 Mile Question | Bicycling 1 Mile | Bicycling 1 Mile | Bicycling 1 mile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504796","Bicycling 2 Miles","C126216","A question about an individual's ability to bicycle 2 miles.","Bicycling 2 Miles Question | Bicycling 2 Miles | Bicycling 2 Miles | Bicycling 2 miles",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504797","Bicycling 1 Mile Nonstop","C126217","A question about an individual's ability to bicycle 1 mile nonstop.","Bicycling 1 Mile Nonstop Question | Bicycling 1 Mile Nonstop | Bicycling 1 Mile Nonstop | Bicycling 1 mile (nonstop)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504798","Bicycling 2 Miles Nonstop","C126218","A question about an individual's ability to bicycle 2 miles nonstop.","Bicycling 2 Miles Nonstop Question | Bicycling 2 Miles Nonstop | Bicycling 2 Miles Nonstop | Bicycling 2 miles (nonstop)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504799","Running or Jogging 1/4 Mile","C126219","A question about an individual's ability to run or jog 1/4 mile.","Running or Jogging 1/4 Mile Question | Running or Jogging 1/4 Mile | Running or Jogging 1/4 Mile | Running or jogging 1/4 mile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504800","Running or Jogging 1/2 Mile","C126220","A question about an individual's ability to run or jog 1/2 mile.","Running or Jogging 1/2 Mile Question | Running or Jogging 1/2 Mile | Running or Jogging 1/2 Mile | Running or jogging 1/2 mile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504801","Playing Tennis or Racquetball","C126221","A question about an individual's ability to play tennis or racquetball.","Playing Tennis or Racquetball Question | Playing Tennis or Racquetball | Playing Tennis or Racquetball | Playing tennis or racquetball",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504802","Playing a Basketball or Soccer Game","C126222","A question about an individual's ability to play basketball or soccer.","Playing a Basketball or Soccer Game Question | Playing a Basketball or Soccer Game | Playing a Basketball or Soccer Game | Playing basketball/soccer (game play)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504803","Running or Jogging 1/4 Mile Nonstop","C126223","A question about an individual's ability to run or jog 1/4 mile nonstop.","Running or Jogging 1/4 Mile Nonstop Question | Running or Jogging 1/4 Mile Nonstop | Running or Jogging 1/4 Mile Nonstop | Running or jogging 1/4 mile (nonstop)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504804","Running or Jogging 1/2 Mile Nonstop","C126224","A question about an individual's ability to run or jog 1/2 mile nonstop.","Running or Jogging 1/2 Mile Nonstop Question | Running or Jogging 1/2 Mile Nonstop | Running or Jogging 1/2 Mile Nonstop | Running or jogging 1/2 mile (nonstop)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504805","Running or Jogging 1 Mile","C126225","A question about an individual's ability to run or jog 1 mile.","Running or Jogging 1 Mile Question | Running or Jogging 1 Mile | Running or Jogging 1 Mile | Running or jogging 1 mile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504806","Running or Jogging 2 Miles","C126226","A question about an individual's ability to run or jog 2 miles.","Running or Jogging 2 Miles Question | Running or Jogging 2 Miles | Running or Jogging 2 Miles | Running or jogging 2 miles",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504807","Running or Jogging 3 Miles","C126227","A question about an individual's ability to run or jog 3 miles.","Running or Jogging 3 Miles Question | Running or Jogging 3 Miles | Running or Jogging 3 Miles | Running or jogging 3 miles",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504808","Running or Jogging 1 Mile in 12 Minutes or Less","C126228","A question about an individual's ability to run or jog 1 mile in 12 minutes or less.","Running or Jogging 1 Mile in 12 Minutes or Less Question | Running or Jogging 1 Mile in 12 Minutes or Less | Running or Jogging 1 Mile in 12 Minutes or Less | Running or jogging 1 mile in 12 minutes or less",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504809","Running or Jogging 2 Miles in 20 Minutes or Less","C126229","A question about an individual's ability to run or jog 2 miles in 20 minutes or less.","Running or Jogging 2 Miles in 20 Minutes or Less Question | Running or Jogging 2 Miles in 20 Minutes or Less | Running or Jogging 2 Miles in 20 Minutes or Less | Running or jogging 2 miles in 20 minutes or less",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504810","Running or Jogging 3 Miles in 30 Minutes or Less","C126230","A question about an individual's ability to run or jog 3 miles in 30 minutes or less.","Running or Jogging 3 Miles in 30 Minutes or Less Question | Running or Jogging 3 Miles in 30 Minutes or Less | Running or Jogging 3 Miles in 30 Minutes or Less | Running or jogging 3 miles in 30 minutes or less",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504811","Still Doing This Activity","C126231","A response indicating that an individual is still doing an activity.","Still Doing This Activity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504812","Have Stopped Doing This Activity","C126232","A response indicating that an individual has stopped doing an activity.","Have Stopped Doing This Activity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504813","Never Did This Activity","C126233","A response indicating that an individual is never did an activity.","Never Did This Activity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1608735","MYOG protein, human","C94704","Myogenin (224 aa, ~25 kDa) is encoded by the human MYOG gene. This protein is involved in both transcription and myogenesis.","Myogenin | Class C Basic Helix-Loop-Helix Protein 3 | Myf-4 | Myogenic Factor 4 | bHLHc3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1456736","Transcription Factor AP-2-Beta, Human","C17970","Transcription factor AP-2-beta (460 aa, ~50 kDa) is encoded by the human TFAP2B gene. This protein plays a role in transcriptional regulation, face and limb development, and differentiation and function of renal tubules.","Transcription Factor AP-2-Beta | AP-2 Beta | AP-2 Transcription Factor Beta | AP-2-Beta | AP2-Beta | Activating Enhancer Binding Protein 2 Beta | Activating Enhancer-Binding Protein 2 Beta | Activating Enhancer-Binding Protein 2-Beta | TFAP2B | TFAP2B Protein | Transcription Factor AP-2 Beta | Transcription Factor AP2-Beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0339897","Transjugular Intrahepatic Portosystemic Shunt","C126288","An interventional radiologic procedure in which a shunt is created in the liver that establishes communication between the portal vein and hepatic vein for the treatment of portal hypertension. The shunt is created using an image-guided endovascular approach, with the jugular vein as the entry site.","Transjugular Intrahepatic Portosystemic Shunt | TIPS | TIPS Placement | TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT PLACEMENT",,,,,,,,,,,,,,,"4052390","Transjugular intrahepatic portosystemic shunt",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL382698","Variceal Banding","C126289","An endoscopic procedure in which an elastic ring is placed around an enlarged esophageal vein to cut off the blood flow through the vein. It is used to prevent bleeding from esophageal varices.","Variceal Banding | Endoscopic Variceal Banding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504815","Nurses' Health Study II Activity and Inactivity Questionnaire","C126235","A self-reported questionnaire designed to measure physical activity and inactivity in a cohort of nurses who were recruited in 1989 and were between the ages of 25 and 42 at recruitment.","Nurses' Health Study II Activity and Inactivity Questionnaire | NHS II-PAQ | Nurses' Health Study II Physical Activity Questionnaire | Nurses' Health Study II: Activity and Inactivity Questionnaire (NHS II)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504816","Average Time Per Week Spent on Activity","C126236","A question about the average time per week that an individual spent on a specific activity.","Average Time Per Week Spent on Activity Question | Activity Average Time Per Week Spent | Average Time Per Week Spent on Activity | Average Time Per Week Spent on Activity | During the past year, what was your average time per week spent at each of the following recreational activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504817","Time Spent Walking or Hiking Outdoors","C126237","A question about time spent walking or hiking outdoors.","Time Spent Walking or Hiking Outdoors | Walking or hiking outdoors (include walking to work)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504818","Time Spent Jogging Slower than 10 Minutes per Mile","C126238","A question about time spent jogging slower than 10 minutes per mile.","Time Spent Jogging Slower than 10 Minutes per Mile Question | Jogging (slower than 10 minutes/mile) | Time Spent Jogging Slower than 10 Minutes per Mile | Time Spent Jogging Slower than 10 Minutes per Mile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504819","Time Spent Running 10 Minutes per Mile or Faster","C126239","A question about time spent running 10 minutes per mile or faster.","Time Spent Running 10 Minutes per Mile or Faster Question | Running (10 minutes/mile or faster) | Time Spent Running 10 Minutes per Mile or Faster | Time Spent Running 10 Minutes per Mile or Faster",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504820","Time Spent Bicycling","C126240","A question about time spent bicycling.","Time Spent Bicycling Question | Bicycling (include stationary machine) | Time Spent Bicycling | Time Spent Bicycling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504821","Time Spent Doing Calisthenics, Aerobics, Aerobic Dance, Rowing Machine","C126241","A question about time spent doing calisthenics, aerobics, aerobic dance, or rowing machine use.","Time Spent Doing Calisthenics, Aerobics, Aerobic Dance, Rowing Machine Question | Calisthenics/aerobics/aerobic dance/rowing machine | Time Spent Doing Calisthenics, Aerobics, Aerobic Dance, Rowing Machine | Time Spent Doing Calisthenics, Aerobics, Aerobic Dance, Rowing Machine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504822","Time Spent Playing Tennis, Squash, or Racquetball","C126242","A question about time spent playing tennis, squash or racquetball.","Time Spent Playing Tennis, Squash, or Racquetball Question | Tennis, squash, or racquetball | Time Spent Playing Tennis, Squash, or Racquetball | Time Spent Playing Tennis, Squash, or Racquetball",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504823","Time Spent Lap Swimming","C126243","A question about time spent lap swimming.","Time Spent Lap Swimming Question | Lap swimming | Time Spent Lap Swimming | Time Spent Lap Swimming",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504824","Time Spent on Other Aerobic Recreation","C126244","A question about time spent on other aerobic recreation.","Time Spent on Other Aerobic Recreation Question | Other aerobic recreation (e.g. lawn mowing) | Time Spent on Other Aerobic Recreation | Time Spent on Other Aerobic Recreation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504825","Average Hours Per Week Spent on Activity","C126245","A question about the average hours per week that an individual spent on a specific activity.","Average Hours Per Week Spent on Activity Question | Average Hours Per Week Spent on Activity | Average Hours Per Week Spent on Activity | On average, how many hours per week do you spend",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504826","Time Spent Standing or Walking at Work","C126246","A question about time spent standing or walking around at work.","Time Spent Standing or Walking at Work | Standing or walking around at work | Time Spent Standing or Walking Around at Work",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504827","Time Spent Standing or Walking at Home","C126247","A question about time spent standing or walking around at home.","Time Spent Standing or Walking at Home Question | Standing or walking around at home | Time Spent Standing or Walking Around at Home | Time Spent Standing or Walking at Home | Time Spent Standing or Walking at Home",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504828","Time Spent Sitting at Work or While Driving","C126248","A question about time spent sitting at work or while driving.","Time Spent Sitting at Work or While Driving | Sitting at work or while driving",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504829","Time Spent Sitting at Home","C126249","A question about time spent sitting at home.","Time Spent Sitting at Home | Sitting at home",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504830","Usual Walking Pace Outdoors","C126250","A question about an individual's usual walking pace outdoors.","Usual Walking Pace Outdoors Question | Usual Walking Pace Outdoors | Usual Walking Pace Outdoors | What is your usual walking pace outdoors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504831","Flights of Stairs Climbed Daily","C126251","A question about how many flights of stairs an individual climbs daily.","Flights of Stairs Climbed Daily Question | Flights of Stairs Climbed Daily | Flights of Stairs Climbed Daily | How many flights of stairs (not individual steps) do you climb daily",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504832","Zero Activity Time","C126252","A response indicating that no time was spent on an activity.","Zero Activity Time | No Active Time | No Activity Time | Zero | Zero Active Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504833","One to Four Activity Minutes","C126253","A response indicating that 1 to 4 minutes were spent on an activity.","One to Four Activity Minutes | 1-4 min. | One to Four Active Minutes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504834","Five to Nineteen Activity Minutes","C126254","A response indicating that 5 to 19 minutes were spent on an activity.","Five to Nineteen Activity Minutes | 5-19 min. | Five to Nineteen Active Minutes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504835","Twenty to Fifty-Nine Activity Minutes","C126255","A response indicating that 20 to 59 minutes were spent on an activity.","Twenty to Fifty-Nine Activity Minutes | 20-59 min. | Twenty to Fifty-Nine Active Minutes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504836","One Activity Hour","C126256","A response indicating that one hour (60 minutes) was spent on an activity.","One Activity Hour | One Active Hour | One hour",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504837","One to One and One Half Activity Hours","C126257","A response indicating that 1 to 1 1/2 hours were spent on an activity.","One to One and One Half Activity Hours | 1-1.5 hr | One to One and One Half Active Hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504838","Two to Three Activity Hours","C126258","A response indicating that 2 to 3 hours were spent on an activity.","Two to Three Activity Hours | 2-3 hr | Two to Three Active Hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3843790","Four to Six Activity Hours","C126259","A response indicating that 4 to 6 hours were spent on an activity.","Four to Six Activity Hours | 4-6 hr | Four to Six Active Hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3843789","Seven to Ten Activity Hours","C126260","A response indicating that 7 to 10 hours were spent on an activity.","Seven to Ten Activity Hours | 7-10 hr | Seven to Ten Active Hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL442602","Eleven or More Activity Hours","C126261","A response indicating that 11 or more hours were spent on an activity.","Eleven or More Activity Hours | 11+ hr | Eleven or More Active Hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504839","Two to Five Activity Hours","C126262","A response indicating that 2 to 5 hours were spent on an activity.","Two to Five Activity Hours | 2-5 hr | Two to Five Active Hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504840","Six to Ten Activity Hours","C126263","A response indicating that 6 to 10 hours were spent on an activity.","Six to Ten Activity Hours | 6-10 hr | Six to Ten Active Hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504841","Eleven to Twenty Activity Hours","C126264","A response indicating that 11 to 20 hours were spent on an activity.","Eleven to Twenty Activity Hours | 11-20 hr | Eleven to Twenty Active Hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504863","TERC Deficiency","C126290","A condition of decreased or absent presence of telomerase RNA component. Deficiency of telomerase RNA component is associated with autosomal dominant dyskeratosis congenita 1, telomere-related pulmonary fibrosis, and bone marrow failure 2.","TERC Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504864","TERT Deficiency","C126291","A condition of decreased or absent presence of telomerase reverse transcriptase. Deficiency of this protein is associated with autosomal dominant dyskeratosis congenital 2, autosomal recessive dyskeratosis congenita 4, telomere-related pulmonary fibrosis, and bone marrow failure 1.","TERT Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504865","Perforin Deficiency","C126292","A condition of decreased or absent presence of perforin. Deficiency of this protein is associated with T-cell lymphoblastic lymphoma, aplastic anemia, hemophagocytic lymphohistiocytosis familial type 2, autoimmune lymphoproliferative syndrome and other lymphoproliferative disorders, including various forms of lymphoma.","Perforin Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504866","UNC13D Deficiency","C126293","A condition of decreased or absent presence of protein unc-13 homolog D. Deficiency of this protein is associated with familial hemophagocytic lymphohistiocytosis 3.","UNC13D Deficiency | MUNC13-4 Deficiency | MUNC13-4 Deficiency/UNC13D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504867","STXBP2 Deficiency","C126294","A condition of decreased or absent presence of syntaxin-binding protein 2. Deficiency of this protein is associated with familial hemophagocytic lymphohistiocytosis type 5.","STXBP2 Deficiency | MUNC18-2 Deficiency | MUNC18-2 Deficiency/STXBP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1845076","XIAP Deficiency","C126295","An X-linked lymphoproliferative disorder caused by mutations in the XIAP gene. Clinical manifestations include hemophagocytic lymphohistiocytosis (often associated with EBV), dysgammaglobulinemia, and inflammatory bowel disease. Patients are at an increased risk of developing lymphoma, typically B-cell non-Hodgkin lymphoma.","X-linked Lymphoproliferative Syndrome 2 | XIAP Deficiency | XIAP Deficiency | XIAP Deficiency/XLPs | XLP2 | XLP2/XIAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040642","Transcobalamin","C129396","A family of proteins that bind cobalamin (vitamin B12).","Transcobalamin | Immunodeficiency of Unknown Origin | TC | TCN | Vitamin B12 Binding Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003537","Aphasia","C34393","Impairment of the expression or comprehension of verbal and written language.","Aphasia | ",,,,,,,,,,,,,,,"440424","Aphasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0278061","Altered Mental Status","C121628","A change to an individual's judgment, orientation (to place, time, and self), intellectual functioning, or mood from their baseline.","Altered Mental Status | Altered mental state",,,,,,,,,,,,,,,"436222","Altered mental status",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4014211","Hemiparesis","C122583","Weakness or incomplete paralysis of either the left or right side of the body.","Hemiparesis | ",,,,,,,,,,,,,,,"4065756","Hemiparesis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL473871","Motor Deficit","C116600","Loss of movement function.","Motor Deficit | Motor Deficits",,,,,,,,,,,,,,,"4203631","Motor dysfunction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL505116","Cancer Rehabilitation Evaluation System for Research","C126278","A self-reported, clinically relevant instrument designed to assess the rehabilitation needs and daily problems of patients with cancer.","Cancer Rehabilitation Evaluation System for Research | CARES | CAncer Rehabilitation Evaluation System for Research (CARES)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504856","Clothes Do Not Look Good","C126280","A question about whether an individual finds that clothes do not look good on them.","Clothes Do Not Look Good | Clothes Do Not Look Good on Me | I find that my clothes do not look good on me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504857","Clothes Do Not Fit","C126281","A question about whether an individual finds that their clothes do not fit.","Clothes Do Not Fit | I find that my clothes do not fit | My Clothes Do Not Fit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504858","Difficulty Finding Clothes to Fit","C126282","A question about whether an individual has difficulty finding clothes to fit.","Difficulty Finding Clothes to Fit | Difficult to Find Clothes to Fit | I have difficulty finding clothes to fit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504859","Embarrassed to Show Body Because of Illness","C126283","A question about whether an individual is embarrassed to show their body to others because of their illness.","Embarrassed to Show Body Because of Illness | I am embarrassed to show my body to others because of my illness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504860","Uncomfortable Showing Scars","C126284","A question about whether an individual is uncomfortable showing their scars to others.","Uncomfortable Showing Scars | I am uncomfortable showing my scars to others",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504861","Uncomfortable with Changes in Body","C126285","A question about whether an individual is uncomfortable with changes in their body.","Uncomfortable with Changes in Body | I am uncomfortable with the changes in my body",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504862","A Fair Amount","C126286","A subjective response indicating that something is or was a fair amount.","A Fair Amount | A fair amount",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505166","Much","C126287","A subjective response indicating that something is or was a large amount.","Much | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504873","Graft-versus-Host Unidirectional Mismatch","C126301","The state when a recipient of a hematopoietic stem cell transplantation is not fully matched with their unrelated adult volunteer donor for HLA-A, HLA-B, HLA-C, and HLA-DRB1 and the heterozygous recipient is receiving a graft from a homozygous donor.","Graft-versus-Host Unidirectional Mismatch | GVH Unidirectional Mismatch | Graft-versus-Host Unidirectional HLA Allele Mismatch | Graft-versus-Host Unidirectional HLA Locus Mismatch | Graft-versus-Host Unidirectional HLA Mismatch",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504874","Host-versus-Graft Unidirectional Mismatch","C126302","The state when recipients of hematopoietic stem cell transplantations are not fully matched with their unrelated adult volunteer donors for HLA-A, HLA-B, HLA-C, and HLA-DRB1 and the homozygous recipient is receiving a graft from a heterozygous donor.","Host-versus-Graft Unidirectional Mismatch | HVG Unidirectional Mismatch | Host-versus-Graft Unidirectional HLA Allele Mismatch | Host-versus-Graft Unidirectional HLA Locus Mismatch | Host-versus-Graft Unidirectional HLA Mismatch",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707713","Processor","C50122","A device designed for preparing or treating a material.","Processor Device | Processor | Processor Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825578","IGF2BP3 Gene","C24536","This gene plays a role in RNA binding interactions, which effects insulin regulation.","IGF2BP3 Gene | IGF2BP3 | Insulin-Like Growth Factor 2 mRNA Binding Protein 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641829","Batch Number","C104504","A distinctive alpha-numeric identification code assigned by the manufacturer or distributor to a specific quantity of manufactured material or product that is produced in a manner that is expected to render it homogeneous.","Batch Number | BATCH | Batch Code | Batch Identifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2973985","Interleukin-27, Human","C118114","A heterodimeric cytokine that is comprised of interleukin-27 subunits alpha and beta. This protein complex is involved in the regulation of B- and T-lymphocyte activities.","Interleukin-27 | IL-27 | IL27 | Interleukin 27",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521659","7q34","C13480","A chromosome band present on 7q","7q34 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421705","ZNF217 Gene","C21433","This gene plays a role in transcriptional activation and DNA binding interactions.","ZNF217 Gene | ZNF217 | Zinc Finger Protein 217 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332707","CD209 Gene","C21568","This gene plays a role in the regulation of host defense responses and mediates pathogen-binding properties.","CD209 Gene | CD209 | CD209 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812292","MYBL1 Gene","C18410","This gene plays a role in transcriptional regulation and cellular differentiation.","MYBL1 Gene | MYB Proto-Oncogene Like 1 Gene | MYBL1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697540","HIV-1 HIV-2 Antibody Measurement","C74714","The determination of the antibody reaction of a sample to the HIV-1 or HIV-2 virus.","HIV-1 HIV-2 Antibody Measurement | HIV-1/2 Antibody | HIV12AB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014935","Estrogen Replacement Therapy","C15231","The administration of estrogen, especially in postmenopausal women, to relieve menopausal symptoms and to protect against osteoporosis and heart disease. (Bartleby.com)","Estrogen Replacement Therapy | ERT | Estrogen Replacement | estrogen replacement therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514806","Red Meat Consumption","C20046","A risk factor for colorectal, stomach, and pancreatic cancer.","Red Meat Consumption | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0421272","Ideal Body Weight","C117976","A person's optimum weight as calculated by a standard methodology.","Ideal Body Weight | IDEALWT",,,,,,,,,,,,,,,"4062985","Ideal body weight",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL421549","Vaginal Ring Dosage Form","C91199","A ring composed of active and/or inert ingredient(s), intended for administration in or around the vagina.","Vaginal Ring Dosage Form | VAGINAL RING | Vag Ring | Vaginal Ring | Vaginal Ring Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504882","Easy or Casual Walking Pace","C126312","A response indicating a usual walking pace that is easy or casual, less than 2 mph.","Easy or Casual Walking Pace | Easy, casual (less than 2 mph) | Less than 2 mph Pace",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504883","Normal or Average Walking Pace","C126313","A response indicating a usual walking pace that is normal or average, 2-2.9 mph.","Normal or Average Walking Pace | 2-2.9 mpg Pace | Normal, average (2-2.9 mph)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504884","Brisk Walking Pace","C126314","A response indicating a usual walking pace that is brisk, 3-3.9 mph.","Brisk Walking Pace | 3-3.9 mph Pace | Brisk pace (3-3.9 mph)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504885","Very Brisk or Striding Pace","C126315","A response indicating a usual walking pace that is very brisk or striding, 4 mph or faster.","Very Brisk or Striding Pace | 4 mph or Faster Pace | Very brisk/striding (4 mph or faster)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504886","Two or Less Flights of Steps Daily","C126316","A response that indicates climbing two or less flights of stairs daily.","Two or Less Flights of Steps Daily | 2 flights or less | Two or Less Flights Daily",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504887","Three to Four Flights of Steps Daily","C126317","A response that indicates climbing three to four flights of stairs daily.","Three to Four Flights of Steps Daily | 3-4 flights | Three to Four Flights Daily",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504888","Five to Nine Flights of Steps Daily","C126318","A response that indicates climbing five to nine flights of stairs daily.","Five to Nine Flights of Steps Daily | 5-9 flights | Five to Nine Flights Daily",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504889","Ten to Fourteen Flights of Steps Daily","C126319","A response that indicates climbing ten to 14 flights of stairs daily.","Ten to Fourteen Flights of Steps Daily | 10-14 flights | Ten to Fourteen Flights Daily",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504890","Fifteen or More Flights of Steps Daily","C126320","A response that indicates climbing 15 or more flights of stairs daily.","Fifteen or More Flights of Steps Daily | 15 or more flights | Fifteen or More Flights Daily",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037098","Silicon Dioxide","C29853","A natural compound of silicon and oxygen found mostly in sand, Silica has three main crystalline varieties: quartz, tridymite, and cristobalite. Fine particulate silica dust from quartz rock causes over a long-term progressive lung injury, silicosis. (NCI04)","Silicon Dioxide | Cab-O-Sil M-5P | Colloidal Silicon Dioxide | Light Anhydrous Silicic Acid | Quso F-22 | SILICON DIOXIDE | Silica",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012151","Diesel Exhaust","C113679","The airborne components that result from the combustion of diesel fuel. It includes both gaseous products of complete and incomplete combustion and particulates.","Diesel Exhaust | Diesel exhaust",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001275","Activated Charcoal","C77524","Carbon that has been treated to create small, low-volume pores that increase the surface area available for adsorption.","Activated Charcoal | ACTIVATED CHARCOAL | Activated Carbon | Activated Coal | Charcoal, Activated | Medicinal Carbon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504902","X-Linked Immunodeficiency with Magnesium Defect, Epstein-Barr Virus Infection and Neoplasia","C126336","An X-linked recessive condition caused by mutation(s) in the MAGT1 gene, encoding magnesium transporter protein 1. It is characterized by CD4 lymphopenia, defective T-cell activation and susceptibility to severe chronic viral infections, particularly Epstein-Barr virus (EBV), which may lead to the development of EBV-associated B-cell lymphoproliferative disorders.","X-Linked Immunodeficiency with Magnesium Defect, Epstein-Barr Virus Infection and Neoplasia | MAGT1 Deficiency | MAGT1 Deficiency | X-Linked Immunodeficiency with Magnesium Defect Epstein-Barr Virus Infection and Neoplasia | XMEN",,,,,,,,,,,,,,,"46273013","X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504906","Activating PI3K Gene Mutation","C126340","A change in the nucleotide sequence of any one of the genes encoding proteins in the phosphatidylinositol 3-kinase (PI3K) family that results in constitutive PI3K activity and aberrant activation of PI3K-dependent signaling pathways.","Activating PI3K Gene Mutation | Activating 1-Phosphatidylinositol 3-Kinase Gene Mutation | Activating PI3 Kinase Gene Mutation | Activating PI3-Kinase Gene Mutation | Activating PI3K Family Gene Mutation | Activating PI3K Gene Mutation | Activating PI3K Mutation | Activating PI3K Mutation | Activating PIK3 Gene Mutation | Activating Phosphatidylinositide 3-Kinase Gene Mutation | Activating Phosphatidylinositol 3 Kinase Gene Mutation | Activating Phosphatidylinositol 3-Kinase Gene Mutation | Activating Phosphatidylinositol-3-Kinase Gene Mutation | Activating Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4015214","CTLA4 Deficiency","C126341","A genetic condition caused by mutation(s) in the CTLA4 gene, encoding cytotoxic T-lymphocyte protein 4. Cytotoxic T-lymphocyte protein 4 is an inhibitory receptor acting as a negative regulator of T-cells, and two functional copies of the gene are required for normal immune function. Clinically, it may be characterized by gastrointestinal symptoms, lymphadenopathy, hepatomegaly, and splenomegaly, and autoimmune disorders. Mutations(s) in CTLA4 are also associated with autoimmune lymphoproliferative syndrome, type V.","CTLA4 Deficiency | CHAI | CTLA4 Haploinsufficiency | CTLA4 Haploinsufficiency | CTLA4 Haploinsufficiency; CHAI; ALPS5 | CTLA4 haploinsufficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504903","IFN-gamma Receptor 1 Deficiency","C126337","A condition of decreased or absent presence or activity of interferon gamma receptor 1. Deficiency of this protein is associated with immunodeficiency 27A and immunodeficiency 27B.","IFN-gamma Receptor 1 Deficiency | IFN-gamma receptor 1 deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887645","STAT3 Deficiency","C126342","A condition of decreased or absent presence or activity of signal transducer and activator of transcription 3 protein. Deficiency of this protein is associated with hyper-IgE syndrome.","STAT3 Deficiency | Autosomal dominant hyper-IgE syndrome | Hyper-IgE Recurrent Infection Syndrome | Job Syndrome | Job's syndrome | STAT3 deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504907","STAT3 gain of function","C126345","A mutation in the STAT3 gene that results in an increase in cytokine-related function. STAT3 mutations of this type are associated with infantile-onset multisystem autoimmune disease.","Activating STAT3 Gene Mutation | Activating STAT3 Gene Mutation | Activating STAT3 Mutation | STAT-3 GOF | STAT3 Activating Gene Mutation | STAT3 Activating Mutation | STAT3 Gain of Function | STAT3 Gain of Function | STAT3 Gain of Function Gene Mutation | STAT3 Gain of Function Mutation | STAT3 gain of function",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504908","STAT1 gain of function","C126346","A mutation in the STAT1 gene that results in an increase in cytokine-related functions associated with IFN-alpha/beta, IFN-gamma, IFN-delta, and IL-27. STAT1 mutations of this type are associated with autosomal dominant immunodeficiency 31C.","Activating STAT1 Gene Mutation | Activating STAT1 Gene Mutation | Activating STAT1 Mutation | STAT-1 GOF | STAT1 Activating Gene Mutation | STAT1 Activating Mutation | STAT1 Gain of Function | STAT1 Gain of Function | STAT1 Gain of Function Gene Mutation | STAT1 Gain of Function Mutation | STAT1 gain of function",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504904","Hypomorphic RAG1 Deficiency","C126338","A condition of decreased or absent presence or activity of V(D)J recombination-activating protein 1. Deficiency of this protein is associated with Omenn syndrome, severe combined immunodeficiency, b cell-negative, combined cellular and humoral immune defects with granulomas, and alpha/beta T-cell lymphopenia with gamma/delta T-cell expansion, severe cytomegalovirus infection, and autoimmunity.","Hypomorphic RAG1 Deficiency | Hypomorphic Rag1 deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504909","Adenosine Deaminase 2 Deficiency","C126347","A disorder characterized by abnormal inflammation of various tissues, particularly the blood vessels, with intermittent. fevers, areas of net-like, mottled skin discoloration (livedo racemosa), hepatosplenomegaly, and recurrent strokes.","Adenosine Deaminase 2 Deficiency | Adenosine deaminase 2 deficiency/DAD2 | DADA2 | VAIHS",,,,,,,,,,,,,,,"602598","Adenosine deaminase 2 deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504910","Chronic Active EBV Disease","C126348","An EBV-positive T-cell/NK-cell lymphoproliferative disorder characterized by repeated infectious mononucleosis-like symptoms, a very high titer of anti-EBV antibodies, and high levels of Epstein-Barr virus nucleic acids. Patients often develop progressive cellular and humoral immunodeficiency with pancytopenia and hypogammaglobulinemia.","Chronic Active EBV Disease | CAEBV | CAEBV Infection | Chronic Active EBV Infection | Chronic Active EBV Infection | Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form | Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form | Chronic Active Epstein-Barr Virus | Chronic Active Epstein-Barr Virus | Chronic Active Epstein-Barr Virus Disease | Chronic active Epstein-Barr virus (without identified mutation) | Systemic CAEBV of T-and NK-Cell Type | Systemic Chronic Active EBV Disease | Systemic Chronic Active EBV Infection of T-Cell and NK-Cell Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504905","IMMUNODEFICIENCY 23","C126339","A condition of decreased or absent presence or activity of phosphoglucomutase 3. Deficiency of this protein is associated with immunodeficiency 23.","PGM3-Associated Immunodeficiency | IMD 23 | Immunodeficiency 23 | PGM3 Deficiency | PGM3 Deficiency | PGM3 Phosphoglucomutase Deficiency | PGM3 deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1968689","DOCK8 Deficiency","C126343","A condition of decreased or absent presence or activity of dedicator of cytokinesis protein 8. Deficiency of this protein is associated with autosomal recessive hyper-IgE recurrent infection syndrome.","DOCK8 Deficiency | Autosomal Recessive hyper IgE syndrome | DOCK8 deficiency | Dedicator of Cytokinesis 8 Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412309","GATA2 Deficiency","C126349","A condition of decreased or absent presence or activity of endothelial transcription factor GATA-2 protein. Deficiency of this protein is associated with immunodeficiency 21 and autosomal dominant and sporadic monocytopenia and mycobacterial infection syndrome (MonoMAC).","GATA2 Deficiency | GATA2 deficiency/MonoMac syndrome | Immunodeficiency 21 | MonoMAC Syndrome | Monocytopenia and Mycobacterial Infection Syndrome",,,,,,,,,,,,,,,"36674516","Monocytopenia with susceptibility to infections",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3552634","LPFS1","C126344","An autosomal recessive immunodeficiency caused but mutation(s) in the ITK gene, encoding tyrosine-protein kinase ITK/TSK. It is characterized by the early childhood onset of Epstein-Barr virus (EBV)-associated immune dysregulation leading to lymphoma, lymphomatoid granulomatosis, hemophagocytic lymphohistiocytosis, and/or hypogammaglobulinemia.","Lymphoproliferative Syndrome 1 | IL-2 Inducible T-cell Kinase Deficiency | ITK Deficiency | ITK Deficiency | LPFS1 | Lymphoproliferative Syndrome 1/ITK Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1148551","X-Linked Dyskeratosis Congenita","C126352","Dyskeratosis congenita inherited in an X-linked recessive pattern. It is caused by mutations in the DKC1 gene.","X-Linked Dyskeratosis Congenita | Hoyeraal Hreidarsson Syndrome | X-linked Dyskeratosis Congenita",,,,,,,,,,,,,,,"45769808","X-linked dyskeratosis congenita",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL360008","SERPINC1 protein, human","C104683","Antithrombin-III (464 aa, ~53 kDa) is encoded by the human SERPINC1 gene. This protein is involved in the negative regulation of serine proteinase activity during blood coagulation.","Antithrombin-III | ATIII | Antithrombin III | SERPINC1 | Serine-Cysteine Proteinase Inhibitor Clade C Member 1 | Serpin C1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034993","Rehabilitation Center","C53535","A healthcare facility designed for improving, maintaining, or restoring physical strength, cognition, or mobility.","Rehabilitation Center | REHABILITATION CENTER | REHABILITATION FACILITY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0543419","Disease Sequela","C126361","A pathologic condition that results from a disease, treatment, or injury.","Disease Sequela | Pathologic Sequela | Sequela | Sequelae",,,,,,,,,,,,,,,"4201705","Sequela of disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504842","Twenty-One to Forty Activity Hours","C126265","A response indicating that 21 to 40 hours were spent on an activity.","Twenty-One to Forty Activity Hours | 21-40 hr | Twenty-One to Forty Active Hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504843","Forty-One to Sixty Activity Hours","C126266","A response indicating that 41 to 60 hours were spent on an activity.","Forty-One to Sixty Activity Hours | 41-60 hr | Forty-One to Sixty Active Hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504844","Sixty-One to Ninety Activity Hours","C126267","A response indicating that 61 to 90 hours were spent on an activity.","Sixty-One to Ninety Activity Hours | 61-90 hr | Sixty-One to Ninety Active Hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504845","Over Ninety Activity Hours","C126268","A response indicating that over 90 hours were spent on an activity.","Over Ninety Activity Hours | Over 90 hr | Over Ninety Active Hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504920","Age of Majority","C126362","The age at which a minor assumes legal control over their person, actions, and decisions.","Age of Majority | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2316467","Packed Red Blood Cells","C126363","The red blood cells from a unit of whole blood following removal of most of the plasma, leaving a unit with a hematocrit of about 60%.","Packed Red Blood Cells | PRBCs | Packed Cells | Packed Red Cells",,,,,,,,,,,,,,,"4336080","Packed red blood cells",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL505085","Face (object surface)","C126364","A flat surface of an object.","Face | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504921","Blood Pressure Excursion","C126365","Instances where blood pressure is outside of established parameters.","Blood Pressure Excursion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505100","Placement","C126366","The act of putting something into a position or location.","Placement | Place | Placed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504922","Centrifugation Tube","C126367","A high-strength tube of glass or plastic designed for spinning in a centrifuge.","Centrifugation Tube | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505122","Witness","C126368","To attest to the genuineness of a document or signature.","Witness | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504923","Dehydration","C126369","Any procedure designed to remove the water from a substance or sample.","Dehydration | Dehydration Procedure | Dehydration Technique",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504924","Cover Slip","C126370","A thin flat piece of transparent material that is placed over a specimen for viewing with a microscope.","Cover Slip | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504925","Local Pathology Review","C126371","Microscopic examination of tissue specimen(s) by a pathologist in the local institution where a patient had a procedure performed, using local standardized methods and criteria.","Local Pathology Review | LPR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0179323","Blades (device)","C126372","The thin, sharp part of a knife, tool, or weapon designed to cut things.","Blade | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0181856","Microtome","C126373","An instrument that cuts thin slices of something for microscopic examination.","Microtome | ",,,,,,,,,,,,,,,"45767724","Microtome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL505118","Notable","C126374","When something is worthy of attention or notice.","Notable | Noted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504926","Pathology Ink","C126375","Medical grade dye or pigment that is applied to surgically removed tissue specimens to maintain orientation and indicate tumor resection margins.","Pathology Ink | Marking Ink",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504927","Unusable","C126376","Not fit for the intended purpose.","Unusable | Not Usable | Not Useable | Unuseable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504930","Non-Drinker","C126379","An individual who does not drink at the present time. This is a heterogeneous group comprising both lifelong teetotallers and ex-drinkers.","Non-Drinker | Abstainer | Nondrinker",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0457801","Lifelong Non-Drinker","C126380","An individual who does not drink at the present time and who claims that they have never been a drinker.","Lifelong Non-Drinker | Lifelong non-drinker | Teetotaller",,,,,,,,,,,,,,,"4022664","Non - drinker",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504932","Fisher Scientific","C126385","A commercial provider of laboratory equipment, chemicals, supplies, and services used in scientific research, safety, healthcare, and education.","Fisher Scientific | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3843862","In-House","C126386","Created, done, or existing within a company or organization.","In-House | In-house",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0843593","Laparoscopically Assisted Vaginal Hysterectomy","C126387","A surgical procedure that uses a laparoscope to guide the removal of the uterus and/or Fallopian tubes and ovaries through the vagina.","Laparoscopically Assisted Vaginal Hysterectomy | LAVH | Laparoscopically Assisted Vaginal Hysterectomy (LAVH)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504933","Leico Peloris Rapid Tissue Processor","C126388","A proprietary automated tissue processor designed to do fast, high quality tissue processing for histology laboratories.","Leico Peloris Rapid Tissue Processor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504934","Microm Ergostar HM200 Microtome","C126389","A multi-purpose, proprietary specimen preparation system that integrates rotary and sliding microtomes.","Microm Ergostar HM200 Microtome | Microm Ergostar HM200",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504935","Neither","C126390","Not either one; not the one or the other.","Neither | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504936","Open Surgical Procedure","C126391","Traditional surgery using a long incision for visualization and for the insertion of instruments.","Open Surgical Procedure | Open | Open Surgery | Surgery, Open",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504937","PAXgene Blood Tissue System","C126392","A system of proprietary reagents and supplies utilizing formalin-free solutions for the simultaneous preservation of histomorphology and biomolecules and the purification of RNA, DNA, miRNA, proteins, and phosphoproteins from the same sample.","PAXgene Blood Tissue System | PAXgene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504938","PAXgene Blood DNA Tube","C126393","A blood collection tube that uses proprietary reagents for whole blood collection and stabilization prior to genomic DNA isolation.","PAXgene Blood DNA Tube | PAXgene DNA Vacutainer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504939","PAXgene Blood RNA Tube","C126394","A blood collection tube that uses proprietary reagents for whole blood collection and stabilization prior to isolation of cellular RNA.","PAXgene Blood RNA Tube | PAXgene RNA Vacutainer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282114","Recycle","C126395","To use again following processing.","Recycle | Recycled",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504940","Sakura Low Profile Accu-Edge Blade","C126396","A proprietary disposable microtome blade with an 8-mm height.","Sakura Low Profile Accu-Edge Blade | Sakura Finetek Low Profile Microtome Blade | Sakura Low Profile Accu-Edge | Tissue-Tek Accu-Edge Disposable Low Profile Microtome Blade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1270948","Supracervical Hysterectomy","C126397","A hysterectomy that removes the uterus and leaves the cervix in place.","Supracervical Hysterectomy | SCH | Supracervical",,,,,,,,,,,,,,,"4306070","Supracervical hysterectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504941","Uncharged","C126398","Not carrying an electric charge.","Uncharged | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504875","Tubulocystic Renal Cell Carcinoma","C126303","A rare, cytologically high grade carcinoma that arises from the renal parenchyma. It is characterized by the presence of prominently dilated cystic spaces in a bland, fibrotic stroma. The lining cells have large irregular nuclei with prominent nucleoli and abundant eosinophilic cytoplasm. Necrosis and mitotic figures are not present. It rarely metastasizes.","Tubulocystic Renal Cell Carcinoma | TcRCC | Tubulocystic Renal Cell Cancer | Tubulocystic renal cell carcinoma",,,,,,,,,,,,,,,"37116725|37116726","Tubulocystic renal cell carcinoma|Tubulocystic renal cell carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL504944","Novartis","C126403","A Swiss multinational pharmaceutical company that is engaged in the development, manufacturing, and marketing of healthcare products.","Novartis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504945","Juno Therapeutics","C126404","A clinical-stage company developing cellular immunotherapies based on Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies.","Juno Therapeutics | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504946","Celgene","C126405","An American biotechnology company that manufactures drug therapies for cancer and inflammatory disorders.","Celgene | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504947","Kite Pharma","C126406","A clinical-stage biopharmaceutical company engaged in the development of cancer immunotherapy products with a primary focus on engineered autologous T cell therapy designed to restore the immune system's ability to recognize and eliminate tumors.","Kite Pharma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504948","Bluebird Bio","C126407","A clinical-stage biotechnology company using gene therapy, cancer immunotherapy, and gene editing to treat and cure genetic diseases and cancer.","Bluebird Bio | Blue Bird Biotec",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205721","Nosocomial Infection","C115164","An infection acquired in a hospital or other healthcare setting.","Nosocomial Infection | HAI | Healthcare-Associated Infection | Hospital-Acquired Infection | Hospital-Onset Infection",,,,,,,,,,,,,,,"4256893","Healthcare associated infectious disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206074","Renal Replacement Therapy","C126400","Treatments that substitute for the blood-filtering function of the kidneys. It includes dialysis (hemodialysis or peritoneal dialysis), hemofiltration, and hemodiafiltration. Kidney transplant may also be considered a renal replacement therapy.","Renal Replacement Therapy | RENAL REPLACEMENT THERAPY | RRT | Renal replacement therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983726","AJCC v7 Stage","C90530","A cancer stage defined according to the AJCC 7th edition criteria.","AJCC v7 Stage | 7th",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1337036","Xp11.2 Translocation-Related Renal Cell Carcinoma","C27891","A group of renal cell carcinomas characterized by the presence of different translocations involving the chromosome Xp11.2. These translocations result in the creation of gene fusions involving the TFE3 gene. Patients are usually children and young adults. Morphologically, the malignant epithelial cells form papillary patterns.","TFE3-Rearranged Renal Cell Carcinoma | Renal Cell Cancer Associated with Xp11.2 Translocations/TFE3 Gene Fusions | Renal Cell Carcinoma Associated with Xp11.2 Translocations/TFE3 Gene Fusions | Renal Cell Carcinoma Associated with Xp11.2 Translocations/TFE3 Gene Fusions | TFE3-Rearranged Renal Cell Carcinoma | Xp11 Translocation Renal Cell Carcinoma | Xp11.2 Translocation-Related Renal Cell Carcinoma | tRCC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049328","Kidney Medullary Carcinoma","C7572","A type of renal carcinoma affecting mostly young African-Americans.  It is located in the medulla of the kidney, and follows an aggressive clinical course.  Most reported cases have shown metastatic disease at the time of diagnosis.","Kidney Medullary Carcinoma | Renal Medullary Carcinoma | Renal medullary carcinoma",,,,,,,,,,,,,,,"35612355","Renal medullary carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0346249","Multilocular Cystic Renal Neoplasm of Low Malignant Potential","C4524","A rare kidney neoplasm of low malignant potential.  It is a well-circumscribed multicystic mass without solid areas.  The inner lining of the cystic structures is composed of clear cells. It usually presents as a unilateral solitary mass.","Multilocular Cystic Renal Neoplasm of Low Malignant Potential | Multilocular Clear Cell Renal Cell Carcinoma | Multilocular Cystic Renal Cell Cancer | Multilocular Cystic Renal Cell Carcinoma | Renal Cystadenocarcinoma",,,,,,,,,,,,,,,"4112879","Cystadenocarcinoma of kidney",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1513719","Mucinous Tubular and Spindle Cell Carcinoma of the Kidney","C39807","A low grade carcinoma of the kidney characterized by the presence of tubules which are separated by mucinous stroma. Often the tubular structures have a spindle cell appearance.  Patients are usually asymptomatic and occasionally they may present with hematuria or flank pain.","Mucinous Tubular and Spindle Cell Carcinoma of the Kidney | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272295","Renal Cell Carcinoma Associated with Neuroblastoma","C100051","Renal cell carcinoma that develops in patients who are long-term survivors of childhood neuroblastoma.","Renal Cell Carcinoma Associated with Neuroblastoma | Renal Cell Cancer Associated with Neuroblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504554","Non-Cellular Component","C125905","A term that refers to the non-cellular component of the innate immune system which includes cytokines, chemokines, complements, and other mediators of inflammation, to the non-cellular component of blood (plasma), or the non-cellular component of body fluids and broncoalveolar lavage fluid.","Non-Cellular Component | Non-Cellular Component of Tissue | Non-Cellular Tissue Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0346180","Malignant Ovarian Germ Cell Tumor","C4514","An invasive malignant neoplasm that arises from the ovary and originates from primordial germ cells.  Representative examples include embryonal carcinoma, yolk sac tumor, dysgerminoma, and non-gestational choriocarcinoma.","Malignant Ovarian Germ Cell Tumor | Malignant Germ Cell Neoplasm of Ovary | Malignant Germ Cell Neoplasm of the Ovary | Malignant Germ Cell Tumor of Ovary | Malignant Germ Cell Tumor of the Ovary | Malignant Ovarian Germ Cell Neoplasm | Ovarian Germ Cell Cancer",,,,,,,,,,,,,,,"4112864","Malignant germ cell tumor of ovary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3814800","Tumor Grade GX","C113730","A morphologic qualifier indicating that the grade of a neoplasm cannot be assessed.","Grade X | GRADE X | GX | GX Grade cannot be assessed | Grade Cannot Be Assessed | Grade cannot be assessed",,,,,,,,,,,,,,,"37164072","GX",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0346167","Ovarian Undifferentiated Carcinoma","C4509","An aggressive carcinoma arising from the ovary.  Most patients present with advanced disease.  Microscopically, it is characterized by significant cytologic atypia, increased mitotic activity, and necrosis.  The prognosis is usually poor.","Ovarian Undifferentiated Carcinoma | Anaplastic Carcinoma of Ovary | Anaplastic Carcinoma of the Ovary | Anaplastic Ovarian Carcinoma | Undifferentiated Carcinoma of Ovary | Undifferentiated Carcinoma of the Ovary | Undifferentiated Ovarian Cancer | Undifferentiated Ovarian Carcinoma | Undifferentiated Ovarian Carcinoma",,,,,,,,,,,,,,,"4110863","Undifferentiated carcinoma of ovary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1335184","Ovarian Transitional Cell Carcinoma","C5240","A carcinoma that arises from the ovary and is characterized by the presence of malignant epithelial cells that resemble malignant urothelial cells.","Ovarian Transitional Cell Carcinoma | Ovarian Transitional Cell Cancer | Transitional Cell Carcinoma of Ovary | Transitional Cell Carcinoma of the Ovary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2019443","Ovarian Squamous Cell Carcinoma","C40093","A usually high grade squamous cell carcinoma that arises from the ovary and is not associated with a germ cell tumor.  The prognosis is poor.","Ovarian Squamous Cell Carcinoma | Ovarian Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279663","Ovarian Serous Cystadenocarcinoma","C7978","A malignant serous cystic epithelial neoplasm arising from the ovary.  It is characterized by the presence of glandular, papillary, or solid structures.  Psammoma bodies may be present.  In well differentiated cases the malignant epithelial cells resemble the cells of fallopian tube epithelium.  In poorly differentiated cases the malignant epithelial cells show anaplastic features.","Ovarian Serous Cystadenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279665","Ovarian Mucinous Cystadenocarcinoma","C4026","An invasive cystic adenocarcinoma arising from the ovary.  It is characterized by the presence of malignant glandular epithelial cells which contain intracytoplasmic mucin.  The malignant cells invade the ovarian stroma and the cystic spaces contain mucoid material.  In a minority of cases both ovaries are involved by the tumor.  The prognosis for stage I tumors is excellent.  Patients with metastases usually have a poor prognosis.","Ovarian Mucinous Cystadenocarcinoma | Mucinous Cystadenocarcinoma of Ovary | Mucinous Cystadenocarcinoma of the Ovary",,,,,,,,,,,,,,,"4112856","Mucinous cystadenocarcinoma of ovary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1335167","Ovarian Mucinous Adenocarcinoma","C5243","An invasive adenocarcinoma that arises from the ovary and is characterized by the presence of malignant epithelial cells that contain intracytoplasmic mucin.  There is cellular atypia, increased layering of cells, complexity of glands, and papillary formations.","Ovarian Mucinous Adenocarcinoma | Mucinous Adenocarcinoma of Ovary | Mucinous Adenocarcinoma of the Ovary | Mucinous Carcinoma of Ovary | Mucinous Carcinoma of the Ovary | Mucinous carcinoma | Ovarian Mucinous Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511265","Borderline Ovarian Mucinous Tumor, Intestinal Type","C40037","A neoplasm of low malignant potential arising from the ovary.  It is characterized by the proliferation of neoplastic mucinous epithelial cells that resemble intestinal epithelial cells.  There is no evidence of stromal invasion.","Borderline Ovarian Mucinous Tumor, Intestinal Type | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511264","Borderline Ovarian Mucinous Tumor, Endocervical-Like","C40038","A neoplasm of low malignant potential arising from the ovary.  It is characterized by the proliferation of neoplastic epithelial cells that resemble endocervical epithelial cells.  There is no evidence of stromal invasion.","Borderline Ovarian Mucinous Tumor, Endocervical-Like | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1370419","Ovarian Granulosa Cell Tumor","C6261","A granulosa-stromal cell tumor that arises from the ovary.  It is characterized by the presence of granulosa cells that comprise at least ten percent of the cellular population.  The granulosa cells are often found in a background that contains theca and fibrous cells.  There are two major subtypes recognized, adult and juvenile granulosa cell tumor.  Clinically, patients may present with an abdominal mass.  Symptoms depend on the patient's age.  The most important indicator of prognosis is tumor stage.  Age over forty years at the time of the initial diagnosis, large tumor size, bilaterality, cellular atypia, and increased mitotic activity are factors indicating a potentially aggressive clinical course and relative poor prognosis.","Ovarian Granulosa Cell Tumor | Granulosa Cell Neoplasm of Ovary | Granulosa Cell Neoplasm of the Ovary | Granulosa Cell Tumor of Ovary | Granulosa Cell Tumor of the Ovary | Ovarian Granulosa Cell Neoplasm",,,,,,,,,,,,,,,"4112862","Malignant granulosa cell tumor of ovary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0346163","Ovarian Endometrioid Adenocarcinoma","C7979","An endometrioid adenocarcinoma arising from the ovary.  It comprises 10% to 25% of all primary ovarian carcinomas.  Grossly, endometrioid carcinoma may present as a cystic or solid mass.  Microscopically, the tumor greatly resembles the appearance of the ordinary type of endometrial adenocarcinoma.  As a group, endometrioid carcinoma has a prognosis twice as good as that of serous or mucinous carcinoma.","Ovarian Endometrioid Adenocarcinoma | Endometrioid Adenocarcinoma of Ovary | Endometrioid Adenocarcinoma of the Ovary | Endometrioid Cancer of Ovary | Endometrioid Cancer of the Ovary | Endometrioid Carcinoma of Ovary | Endometrioid Carcinoma of the Ovary | Ovarian Endometrioid Adenocarcinoma NOS | Ovarian Endometrioid Adenocarcinoma Not Otherwise Specified | Ovarian Endometrioid Cancer | Ovarian Endometrioid Carcinoma",,,,,,,,,,,,,,,"4112857","Endometrioid carcinoma ovary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1336026","Solid Lung Adenocarcinoma","C5651","A morphologic variant of lung adenocarcinoma characterized by the presence of polygonal malignant cells forming sheets. Acinar, papillary, micropapillary, or lepidic growth patterns are absent.  If the tumor is 100 percent solid, intracellular mucin should be present in at least five tumor cells in each of two high-power fields and confirmed with mucin immunohistochemical stains. Tumors formerly classified as large cell carcinomas expressing pneumocyte immunohistochemical markers, even if intracellular mucin is absent, are now included in this category.","Solid Lung Adenocarcinoma | Lung Solid Adenocarcinoma with Mucin | Pulmonary Solid Adenocarcinoma with Mucin | Solid Adenocarcinoma of Lung with Mucin | Solid Adenocarcinoma of the Lung with Mucin | Solid Lung Adenocarcinoma with Mucin Production | Solid adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708782","Lung Signet Ring Cell Carcinoma","C45514","A morphologic variant of lung adenocarcinoma characterized by the presence of signet ring cells.","Lung Signet Ring Cell Carcinoma | Lung Signet Ring Adenocarcinoma | Lung Signet-Ring Cell Carcinoma",,,,,,,,,,,,,,,"37165750","Signet ring cell carcinoma of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708776","Lung Colloid Adenocarcinoma","C45512","A morphologic variant of lung adenocarcinoma characterized by the presence of mucin pools containing islands of well differentiated adenocarcinoma cells.","Lung Colloid Adenocarcinoma | Lung Mucinous Adenocarcinoma | Lung Mucinous Cystadenocarcinoma | Lung Mucinous Cystic Tumor of Borderline Malignancy | Mucinous cystic tumor of borderline malignancy",,,,,,,,,,,,,,,"37166760|37166768","Mucinous adenocarcinoma of lung|Mucinous cystadenocarcinoma of lung",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1708765","Lung Adenocarcinoma, Mixed Subtype","C45508","The most frequently seen morphologic variant of lung adenocarcinoma characterized by a mixture of architectural patterns, including acinar, papillary, bronchioloalveolar, and solid pattern.","Lung Adenocarcinoma, Mixed Subtype | ","8255/3","Adenocarcinoma with mixed subtypes",,,,,,,,,,,,,"37166795","Mixed subtype adenocarcinoma of lung",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1708769","Lung Clear Cell Adenocarcinoma","C45516","A well differentiated morphologic variant of lung adenocarcinoma characterized by the predominance of clear cells.","Lung Clear Cell Adenocarcinoma | ",,,,,,,,,,,,,,,"37166735","Clear cell adenocarcinoma of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266034","Minimally Invasive Lung Non-Mucinous Adenocarcinoma","C7269","A morphologic variant of minimally invasive lung  adenocarcinoma characterized by the presence of Clara cells and/or type II cells.","Minimally Invasive Lung Non-Mucinous Adenocarcinoma | Minimally Invasive Non-Mucinous Lung Adenocarcinoma | Non-Mucinous Bronchioloalveolar Carcinoma | Non-Mucinous Bronchioloalveolar Carcinoma | Non-Mucinous Bronchioloalveolar Lung Carcinoma | Non-Mucinous Bronchoalveolar Lung Carcinoma | Non-Mucinous Minimally Invasive Lung Adenocarcinoma | Non-Mucinous Minimally Invasive Lung Adenocarcinoma","8256/3","Minimally invasive adenocarcinoma, non-mucinous",,,,,,,,,,,,,"4029984","Bronchiolo-alveolar carcinoma, non-mucinous",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1266036","Minimally Invasive Lung Mixed Non-Mucinous and Mucinous Adenocarcinoma","C7270","A morphologic variant of minimally invasive lung adenocarcinoma characterized by the presence of Clara cells and/or type II cells, tall columnar cells, and mucin production.","Minimally Invasive Lung Mixed Non-Mucinous and Mucinous Adenocarcinoma | Indeterminate Bronchioloalveolar Carcinoma | Mixed Mucinous and Non-Mucinous Bronchioloalveolar Carcinoma | Mixed Mucinous and Non-Mucinous Bronchioloalveolar Carcinoma | Mixed Mucinous and Non-Mucinous Bronchioloalveolar Lung Carcinoma | Mixed Mucinous and Non-Mucinous Bronchoalveolar Lung Carcinoma","8254/3","Adenocarcinoma of lung, mixed mucinous and non-mucinous",,,,,,,,,,,,,"4029986","Bronchiolo-alveolar carcinoma, mixed mucinous and non-mucinous",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"CL504963","Hepatopetal Portal Venous Flow","C126426","The normal pattern of blood flow towards the liver through the portal vein.","Hepatopetal Portal Venous Flow | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2355642","Colon Undifferentiated Carcinoma","C7100","An invasive malignant epithelial tumor that arises from the colon.  There is no morphologic, immunophenotypic, or molecular biological evidence of glandular or squamous differentiation.","Colon Undifferentiated Carcinoma | Carcinoma Simplex of the Colon. | Colon Anaplastic Carcinoma | Undifferentiated Carcinoma of Colon | Undifferentiated Carcinoma of the Colon | Undifferentiated Colon Cancer | Undifferentiated Colonic Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333100","Colon Squamous Cell Carcinoma","C5490","A very rare colon carcinoma characterized by the presence of a malignant squamous cell infiltrate.","Colon Squamous Cell Carcinoma | Colon Epidermoid Carcinoma | Colon Squamous Cell Cancer | Colonic Epidermoid Carcinoma | Colonic Squamous Cell Carcinoma | Epidermoid Carcinoma of Colon | Epidermoid Carcinoma of the Colon | Squamous Cell Carcinoma of Colon | Squamous Cell Carcinoma of the Colon | Squamous Cell Colon Carcinoma",,,,,,,,,,,,,,,"35624316","Squamous cell carcinoma of colon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333099","Colon Oat Cell Carcinoma","C6761","An aggressive high-grade carcinoma with neuroendocrine differentiation that arises from the colon and is composed of malignant small cells. The mitotic count is more than 20 per 2 mm2 and/or the Ki-67 index is more than 20%.","Colon Small Cell Neuroendocrine Carcinoma | Colon Oat Cell Carcinoma | Colon Small Cell Carcinoma | Colon Small Cell Carcinoma | Colon Small Cell Neuroendocrine Cancer | Colon Small Cell Neuroendocrine Carcinoma | Colonic Oat Cell Carcinoma | Colonic Small Cell Carcinoma | Oat Cell Carcinoma of Colon | Oat Cell Carcinoma of the Colon | Oat Cell Colon Carcinoma | Small Cell Carcinoma of Colon | Small Cell Carcinoma of the Colon | Small Cell Colon Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707440","Colorectal Signet Ring Cell Carcinoma","C43586","An invasive colorectal adenocarcinoma characterized by the presence of malignant glandular epithelial cells with prominent intracytoplasmic mucin resulting in the displacement of the nuclei.  The malignant glandular cells with intracytoplasmic mucin constitute more than 50% of the malignant cellular infiltrate.","Colorectal Signet Ring Cell Adenocarcinoma | Colorectal Signet Ring Cell Carcinoma | Colorectal Signet Ring Cell Carcinoma | Colorectal Signet-Ring Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880119","Colon Medullary Carcinoma","C60641","A rare, invasive colon adenocarcinoma characterized by the presence of sheets of malignant epithelial cells with vesicular nuclei, prominent nucleoli, and abundant eosinophilic cytoplasm.  It usually has a favorable prognosis.","Colon Medullary Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333082","Colon Adenosquamous Carcinoma","C5491","An unusual colon carcinoma characterized by the presence of glandular and squamous carcinomatous components.  The two carcinomatous components may be admixed within the tumor, or the two may appear separately in different areas.","Colon Adenosquamous Carcinoma | Adenosquamous Carcinoma of Colon | Adenosquamous Carcinoma of the Colon | Adenosquamous Colon Carcinoma | Colon Adenosquamous Cancer | Colonic Adenosquamous Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025376","Meperidine","C71632","A synthetic piperidine ester with opioid analgesic activity. Meperidine mimics the actions of endogenous neuropeptides via opioid receptors, thereby producing the characteristic morphine-like effects on the mu-opioid receptor, including analgesia, euphoria, sedation, respiratory depression, miosis, bradycardia and physical dependence.","Meperidine | MEPERIDINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012306","Hydromorphone","C62034","The hydrogenated ketone of morphine, a semi-synthetic opioid with analgesic effects. Hydromorphone selectively binds the mu-opioid receptor which is linked through G-proteins. Binding stimulates the exchange of guanosine triphosphate (GTP) for guanosine diphosphate (GDP) on the G-protein complex and interacts with and inhibits adenylate cyclase located at the inner surface of the plasma membrane. This leads to a reduction in intracellular cyclic 3',5'-adenosine monophosphate (cAMP). Further, voltage-gated potassium channels are activated, thereby causing hyperpolarization and reducing neuronal excitability. In addition, the opening of voltage-gated calcium channels is inhibited, thereby leading to an inhibition of calcium entry and a reduction in the release of various neurotransmitters, including GABA, vasopressin, somatostatin, insulin and glucagons.","Hydromorphone | (-)-Hydromorphone | Dihydromorphinone | HYDROMORPHONE | Hydromorphon | hydromorphone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034665","Ranitidine","C29412","A member of the class of histamine H2-receptor antagonists with antacid activity. Ranitidine is a competitive and reversible inhibitor of the action of histamine, released by enterochromaffin-like (ECL) cells, at the histamine H2-receptors on parietal cells in the stomach, thereby inhibiting the normal and meal-stimulated secretion of stomach acid. In addition, other substances that promote acid secretion have a reduced effect on parietal cells when the H2 receptors are blocked.","Ranitidine | N-[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine | RANITIDINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1579433","Therapeutic Insulin","C581","A synthetic or animal-derived form of insulin used in the treatment of diabetes mellitus. Therapeutic insulin is formulated to be short-, intermediate- and long-acting in order to individualize an insulin regimen according to individual differences in glucose and insulin metabolism. Therapeutic insulin may be derived from porcine, bovine or recombinant sources. Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats and has anabolic effects on many types of tissues.","Therapeutic Insulin | INSULIN | Insulin | Recombinant Insulin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504966","Center for Epidemiologic Studies Depression Scale Revised","C126429","A self-report screening test for depression and depressive disorder measuring symptoms defined by the American Psychiatric Association Diagnostic and Statistical Manual (DSM-V) for a major depressive episode.","Center for Epidemiologic Studies Depression Scale Revised | CESD-R | Center for Epidemiologic Studies Depression Scale - Revised | Center for Epidemiologic Studies Depression Scale - Revised (CESD-R)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935575","Poor Appetite","C126430","A question about whether an individual's appetite is or was poor.","Poor Appetite | Appetite Poor | My appetite was poor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504967","Could not Shake Off the Blues","C126431","A question about whether an individual could or could not shake off the blues.","Could not Shake Off the Blues | I could not shake off the blues",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504968","Nothing Made Me Happy","C126432","A question about whether nothing makes or made an individual happy.","Nothing Made Me Happy | Nothing made me happy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504970","Feel Like a Bad Person","C126436","A question about whether an individual feels or felt like a bad person.","Feel Like a Bad Person | I felt like a bad person",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504971","Lost Interest in Usual Activities","C126437","A question about whether an individual loses or lost interest in their usual activities.","Lost Interest in Usual Activities | I lost interest in my usual activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504972","Slept Much More than Usual","C126438","A question about whether an individual sleeps or slept much more than usual.","Slept Much More than Usual | I slept much more than usual | Sleeping Much More than Usual",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504973","Feel Like Moving too Slowly","C126439","A question about whether an individual feels or felt like they are moving too slowly.","Feel Like Moving too Slowly | Feel Like I'm Moving too Slowly | I felt like I was moving too slowly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504974","Feel Fidgety","C126440","A question about whether an individual feels or felt fidgety.","Feel Fidgety | I felt fidgety",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504975","Wish I Were Dead","C126441","A question about whether an individual wishes or wished they were dead.","Wish I Were Dead | I wished I were dead | Wished I Were Dead",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504976","Want to Hurt Myself","C126442","A question about whether an individual wants or wanted to hurt themself.","Want to Hurt Myself | I wanted to hurt myself | Wanted to Hurt Myself",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504977","Tired All the Time","C126443","A question about whether an individual is or was tired all the time.","Tired All the Time | I was tired all the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504978","Do Not Like Myself","C126444","A question about whether an individual does not like themself.","Do Not Like Myself | I did not like myself | I don't like myself",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504979","Lost a Lot of Weight Without Trying","C126445","A question about whether an individual lost a lot of weight without trying to.","Lost a Lot of Weight Without Trying | I lost a lot of weight without trying to",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504980","Have a Lot of Trouble Getting to Sleep","C126446","A question about whether an individual has or had a lot of trouble getting to sleep.","Have a Lot of Trouble Getting to Sleep | I had a lot of trouble getting to sleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504985","Nearly Every Day for 2 Weeks","C126452","A response indicating that something happens or happened nearly every day for two weeks.","Nearly Every Day for 2 Weeks | Nearly every day for 2 weeks",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504984","Five to Seven Days","C126451","A response indicating that something happens or happened between five and seven days.","Five to Seven Days | 5 - 7 days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504983","Three or Four Days","C126450","A response indicating that something happens or happened on three or four days.","Three or Four Days | 3 - 4 days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3843197","One or Two Days","C126448","A response indicating that something happens or happened on one or two days.","One or Two Days | 1 - 2 days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504981","Could Not Focus on Important Things","C126447","A question about whether an individual could or could not focus on the important things.","Could Not Focus on Important Things | I could not focus on the important things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641255","Lavage Fluid","C103411","Fluid introduced into, and collected from, a body cavity by lavage procedure.","Lavage Fluid | LAVAGE FLUID | Wash Fluid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033218","Procaine","C61906","A benzoic acid derivative with local anesthetic and antiarrhythmic properties. Procaine binds to and inhibits voltage-gated sodium channels, thereby inhibiting the ionic flux required for the initiation and conduction of impulses. In addition, this agent increases electrical excitation threshold, reduces rate of rise of action potential and slows nerve impulse propagation thereby causing loss of sensation.","Procaine | PROCAINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006400","Bupivacaine","C62011","An amide-type, long-acting local anesthetic. Bupivicaine reversibly binds to specific sodium ion channels in the neuronal membrane, resulting in a decrease in the voltage-dependent membrane permeability to sodium ions and membrane stabilization; inhibition of depolarization and nerve impulse conduction; and a reversible loss of sensation.","Bupivacaine | 1-Butyl-2',6'-pipecoloxylidide | AH 250 | BUPIVACAINE | bupivacaine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0936073","Thiopental Sodium","C66599","The sodium salt form of thiopental, an ultrashort-acting barbituric acid derivative, with anesthetic activity. Thiopental binds to the chloride ionophore site of the gamma-aminobutyric acid (GABA)-A/chloride ionophore receptor complex, thereby enhancing the inhibitory actions of GABA-A in the brain. This leads to synaptic inhibition, decreased neuronal excitability and induction of anesthesia. In addition, this agent decreases glutamate (Glu) responses.","Thiopental Sodium | 4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-(1-methylbutyl)-2-thioxo-, Monosodium Salt | Pentothal | Sodium Penthiobarbital | Sodium Thiopental | THIOPENTAL SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033487","Propofol","C29384","A hypnotic alkylphenol derivative. Formulated for intravenous induction of sedation and hypnosis during anesthesia, propofol facilitates inhibitory neurotransmission mediated by gamma-aminobutyric acid (GABA). This agent is associated with minimal respiratory depression and has a short half-life with a duration of action of 2 to 10 minutes.","Propofol | Diprivan | PROPOFOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022614","Ketamine","C61797","A cyclohexanone derivative with analgesic and anesthetic properties. Although its mechanism of action is not well understood, ketamine appears exerts complex pharmacological actions including inhibition of biogenic amine uptake, binding to opioid receptors, and inhibition of N-methyl D-aspartate (NMDA) receptors. Because of the involvement of spinal NMDA receptors in the process of central sensitization, this agent may reduce pain perception and induce sedation.","Ketamine | KETAMINE | ketamine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030310","Pancuronium","C61876","A synthetic, long-acting bis-quaternary steroid and non-depolarizing neuromuscular blocking agent, with muscle relaxant activity. Pancuronium competitively binds to and blocks the nicotinic acetylcholine receptor at the neuromuscular junction, thereby preventing acetylcholine (ACh) binding and resulting in skeletal muscle relaxation and paralysis.","Pancuronium | 1,1'-(3,17-Bis(acetyloxy)androstane-2,16-diyl)bis(1-methylpiperidinium) | PANCURONIUM | Piperidinium, 1,1'-((2Beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1-methyl)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0404186","Right Salpingo-Oophorectomy","C51926","Surgical removal of the right fallopian tube and right ovary.","Right Salpingo-Oophorectomy | ",,,,,,,,,,,,,,,"4072837","Right salpingo-oophorectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0404187","Left Salpingo-Oophorectomy","C51925","Surgical removal of the left fallopian tube and left ovary.","Left Salpingo-Oophorectomy | ",,,,,,,,,,,,,,,"4074876","Left salpingo-oophorectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0193063","Rectosigmoidectomy","C51611","Surgical removal part or all of the sigmoid colon, and part or all of the rectum.","Rectosigmoidectomy | ",,,,,,,,,,,,,,,"4181584","Rectosigmoidectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3814448","Low Anterior Resection","C113716","Resection of the rectum for cancer through an incision in the lower abdomen.","Low Anterior Resection | Anterior Resection of Rectum | LAR | LOW ANTERIOR RESECTION | Lower Anterior Rectal Resection",,,,,,,,,,,,,,,"4166855","Anterior resection of rectum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2718014","Compassionate Use Trials","C71724","Providing experimental therapies to very sick individuals even though they don't meet the critera for inclusion in a trial.","Compassionate Treatment | Compassionate Use | Expanded Access | Expanded access | compassionate use trial | expanded access trial | pre-approval access",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898767","Inducer","C120268","A chemical or physical agent that turns on gene expression.","Inducer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4277610","APOBEC Deaminases","C126414","A family of enzymes involved in cytidine deamination, which converts cytidine into uracil, in DNA or RNA. These enzymes play a role in mRNA editing and retroviral host defenses.","APOBEC Family Protein | APOBEC Family | APOBEC Protein | Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like | Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like Family | Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like Protein | Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like Protein Family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504956","Butyrate-Producing Bacteria","C126417","Any anaerobic bacteria that metabolizes complex carbohydrates to produce butyrate. These microorganisms may form colonies in the intestines of mammals; their presence may aid the host by catabolizing undigested fiber and starch. Additionally, butyrate is metabolized by colonic epithelial cells and may protect the host against ulcerative colitis and cancer.","Butyrate-Producing Bacteria | BPB | Butyrate-Producing Microbe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1858663","CABIN1 Gene","C126453","This gene may be involved in both chromatin assembly and the inhibition of calcineurin-dependent signaling.","CABIN1 Gene | CABIN1 | Calcineurin Binding Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413217","CD2BP2 Gene","C126500","This gene plays a role in both spliceosome assembly and T-cell activation.","CD2BP2 Gene | CD2 (Cytoplasmic Tail) Binding Protein 2 Gene | CD2BP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422801","CDCA8 Gene","C126506","This gene plays a role in the regulation of mitosis.","CDCA8 Gene | CDCA8 | Cell Division Cycle Associated 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504959","Central Memory T-Lymphocyte","C126420","Long-lived antigen-specific T-lymphocytes, which express CD45RO, L-selectin and CCR7. Upon subsequent exposure to their target antigen, these cells rapidly proliferate and differentiate into effector cells.","Central Memory T-Lymphocyte | Central Memory T Cell | Central Memory T Lymphocyte | Central Memory T-Cell | Tcm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413430","CITED2 Gene","C126433","This gene plays a role in transcription coactivation.","CITED2 Gene | CITED2 | Cbp/p300 Interacting Transactivator, With Glu/Asp-Rich Carboxy-Terminal Domain 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504958","Effector Memory T-Lymphocyte","C126419","Long-lived antigen-specific T-lymphocytes, which express CD8 and effector cytokines. Upon subsequent exposure to their target antigen, these cells rapidly become effector cells.","Effector Memory T-Lymphocyte | Effector Memory T Cell | Effector Memory T Lymphocyte | Effector Memory T-Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414318","EHD1 Gene","C126473","This gene is involved in endocytosis and recycling of the plasma membrane.","EHD1 Gene | EH Domain Containing 1 Gene | EHD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415385","H1-1 Gene","C126423","This gene is involved in both DNA binding and nucleosome formation.","H1-1 Gene | H1-1 | H1.1 Linker Histone, Cluster Member Gene | HIST1H1A | HIST1H1A Gene | HIST1H1A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504955","HLA-KIR Compound Genotype","C126415","The combination of polymorphisms in the DNA encoding human leukocyte antigens (HLA) and killer-cell immunoglobulin-like receptors (KIR) found in an individual's genome. Certain combinations may indicate that the subject is more likely to develop certain diseases such as autoimmune disorders, viral infections, and cancer.","HLA-KIR Compound Genotype | HLA/KIR Compound Genotype | Human Leukocyte Antigens - Killer-Cell Immunoglobulin-Like Receptors Compound Genotype | Human Leukocyte Antigens/Killer-Cell Immunoglobulin-Like Receptors Compound Genotype | KIR-HLA Compound Genotype | KIR/HLA Compound Genotype | KIR/HLA Genotype",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0946129","Human Papillomavirus Antibody","C126416","Any immunoglobulin that recognizes antigens expressed by human papillomaviruses.","Human Papillomavirus Antibody | Anti-HPV Antibody | Anti-Human Papilloma Virus Antibody | Anti-Human Papillomavirus Antibody | HPV Antibody | Human Papilloma Virus Antibody",,,,,,,,,,,,,,,"4025292","Human papillomavirus antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504957","Immunizing Neoantigen Peptide Antibody","C126418","Any antibody that recognizes tumor-associated peptide antigens that are in neoantigen peptide-based vaccines.","Immunizing Neoantigen Peptide Antibody | Anti-Immunizing Neoantigen Peptide Antibody | Anti-Immunizing Peptide Antibody | Anti-Neoantigen Peptide Antibody | Immunizing Peptide Antibody | Neoantigen Peptide Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414387","MARK2 Gene","C126470","This gene plays a role in microtubule dynamics.","MARK2 Gene | MAP/Microtubule Affinity-Regulating Kinase 2 Gene | MARK2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505006","Neurotensin/Neuromedin N","C126488","Neurotensin/neuromedin N (170 aa, ~20 kDa) is encoded by the human NTS gene. This protein may play a role in both the digestion of fat in the gut and anti-bacterial/fungal activity.","Neurotensin/Neuromedin N | Neurotensin/Neuromedin | Pro-NT | Pro-NT/N | Pro-NTS | Pro-Neurotensin | Pro-Neurotensin/Neuromedin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425583","NUSAP1 Gene","C126503","This gene is involved in microtubule stabilization and mitosis.","NUSAP1 Gene | NUSAP1 | Nucleolar and Spindle Associated Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418457","PENK Gene","C126492","This gene is involved in neuropeptide signaling.","PENK Gene | PENK | Proenkephalin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504964","Protectin","C126427","Fatty acids belonging to a group of specialized pro-resolving mediators (SPM) that are either endogenously-derived from the fatty acid docosahexaenoic acid (DHA) or chemically synthesized, with potential anti-inflammatory and protective activities. Protectins promote the resolution of inflammatory responses in various tissues and may prevent tissue damage.","Protectin | Protectins",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419101","PTPN21 Gene","C126458","This gene plays a role in peptidyl-tyrosine dephosphorylation.","PTPN21 Gene | PTPN21 | Protein Tyrosine Phosphatase, Non-Receptor Type 21 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504965","Resolvin","C126428","Dihydroxy or trihydroxy polyunsaturated fatty acids (PUFAs) belonging to a group of specialized pro-resolving mediators (SPM) that are either endogenously-derived from polyunsaturated omega-3 fatty acids or chemically synthesized, with potential anti-inflammatory and protective activities. Resolvins may promote the resolution of inflammatory responses by interacting with specific G protein-coupled receptors on inflammatory cells in various tissues and may prevent tissue damage.","Resolvin | Resolution-Phase Interaction Products | Resolvins",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1999501","Vascular Endothelial Growth Factor A 165 Isoform","C126413","Vascular endothelial growth factor A 165 isoform (191 aa, ~22 kDa) is encoded by the human VEGFA gene. This protein plays a role in the positive regulation of both cell proliferation and angiogenesis.","Vascular Endothelial Growth Factor A 165 Isoform | VEGF 164 | VEGF 165 | VEGF(164) | VEGF-164 | VEGF-164 Isoform | VEGF-165 | VEGF164 | VEGF164(165) | VEGF165 | Vascular Endothelial Growth Factor A 164 Isoform",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0452956","Processed Meat","C126483","Meat that has been modified to either extend its shelf life or change its taste.","Processed Meat | Processed meat",,,,,,,,,,,,,,,"4026819","Processed meat",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL505007","The Cancer Human Biobank","C126485","A derived program of the National Cancer Institute's Biorepositories and Biospecimen Research Branch (NCI BBRB) that carries out specialized biospecimen and data procurements to support biospecimen science activities. The caHUB network consists of Biospecimen Source Sites (BSSs), The Comprehensive Biospecimen Resource (CBR), The Comprehensive Data Resource (CDR), The Pathology Resource Center (PRC), and Molecular Analysis Facilities (MAFs).","The Cancer Human Biobank | caHUB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505010","Biospecimen Pre-analytical Variables Program","C126489","A program designed to systematically investigate the effects of individual pre-analytical factors on the molecular profiles of biospecimens. The results of this study will be used to develop evidence-based protocols and best practices for optimal collection, processing, and storage of biospecimens.","Biospecimen Pre-analytical Variables Program | BPV | Biospecimen Pre-Analytical Variables | Biospecimen Pre-analytical Variables",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0562366","Peer Pressure","C38452","Comprises a set of group dynamics whereby a group in which one feels comfortable may override personal habits, individual moral inhibitions or idiosyncratic desires to impose a group norm of attitudes and/or behaviors.","Peer Pressure | ",,,,,,,,,,,,,,,"4026083","Pressured by peers",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206155","Caribbean region","C26320","A group of islands in the Caribbean Sea. These islands curve southward from the bottom tip of Florida to the Northwest of Venezuela in South America. There are at least 7,000 islands, islets, reefs and cayes in the region. There exist twenty-five territories, including sovereign states, overseas departments and dependencies.","Caribbean | West Indies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0194396","Partial Cystectomy","C51636","The surgical removal of a portion of the bladder.","Partial Cystectomy | Segmental Cystectomy | partial cystectomy | segmental cystectomy",,,,,,,,,,,,,,,"4010266","Partial cystectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1421512","WNT11 Gene","C21424","This gene plays a role in signal transduction, cell organization and intercellular communication. It is involved in development of the heart, kidneys, lungs and skeleton.","WNT11 Gene | WNT11 | Wnt Family Member 11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0492712","Clearing Agent","C121157","Any substance that is administered to facilitate the removal of another substance.","Clearing Agent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1328957","Tissue Processing","C113056","Cleaning and preparation of tissues for further use in biological products.","Tissue Processing | Processing, Tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831012","Cooling/Congealing Particle Sizing","C113038","Formation of particles by solidification of dispersed droplets within a cooler gas.","Cooling/Congealing Particle Sizing | Particle Sizing, Cooling/Congealing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706357","Oven Device","C50092","An enclosed structural device designed for heating an object.","Oven Device | Oven | Oven Device Component",,,,,,,,,,,,,,,"4214017","Oven",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1366441","EPHB1 Gene","C24366","This gene is involved in receptor tyrosine kinase signal transduction and development.","EPHB1 Gene | EPH Receptor B1 Gene | EPHB1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0238602","Central African","C126528","Denotes a person whose ancestry is in any of the countries of the central part of the African continent: Burundi, the Central African Republic, Chad, the Democratic Republic of the Congo, and Rwanda.","Central African | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0238604","North African","C126529","Denotes a person whose ancestry is in any of the countries of the northern part of the African continent: Algeria, Egypt, Libya, Morocco, Sudan, Tunisia, and Western Sahara.","North African | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0238605","South African","C126530","Denotes a person whose ancestry is in the country of South Africa.","South African | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553378","Latin American","C126531","Denotes a person whose ancestry is in any of the countries of the Americas or the Caribbean where Spanish or Portuguese is spoken.","Latin American | LATIN AMERICAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0425359","South American","C126532","Denotes a person whose ancestry is in any of the countries of South America.","South American | SOUTH AMERICAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0238697","Southeast Asian","C126533","Denotes a person whose ancestry is in any of the Asian countries south of China, east of India, west of New Guinea and north of Australia.","Southeast Asian | SOUTHEAST ASIAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0238696","Central Asian","C126534","Denotes a person whose ancestry is in any of the Asian countries between the Caspian Sea in the west, China in the east, Afghanistan in the south, and Russia in the north.","Central Asian | CENTRAL ASIAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0238711","Australian","C126535","Denotes a person whose ancestry is in the country or continent of Australia.","Australian | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505027","New Zealander","C126536","Denotes a person whose ancestry is in the country of New Zealand.","New Zealander | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337808","Icelander","C126537","Denotes a person whose ancestry is in the country of Iceland.","Icelander | Icelandic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0240951","Scandinavian","C126538","Denotes a person whose ancestry is in the countries of Scandinavia: Denmark, Norway and Sweden. Finland and Iceland are generally included as part of the Scandinavian region.","Scandinavian | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511761","Denatured Absolute Ethanol","C28805","No Value Exists","Denatured Absolute Ethanol | Absolute Ethanol | Absolute Ethanol, Denatured",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412854","BUB1B Gene","C95592","This gene is involved in mitotic progression.","BUB1B Gene | BUB1 Mitotic Checkpoint Serine/Threonine Kinase B Gene | BUB1B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043367","Xylene","C126304","An aromatic hydrocarbon composed of a benzene ring linked to two methyl groups and that exists in three isoforms depending on the sites where the methyl groups are attached. Xylene is used for various industrial applications.","Xylene | Benzene, Dimethyl- | Dimethylbenzene | Methyl Toluene | Methyltoluene | XYLENE (MIXED ISOMERS) | Xylol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985572","Study Site Research Coordinator","C93358","A person who handles the administrative responsibilities of a study on behalf of a study site, acts as a liaison between the study site and the study investigator and/or study sponsor, and reviews all data and records before a monitor's visit.","Study Site Research Coordinator | StudySiteResearchCoordinator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1554746","Anesthesiologist","C93067","A doctor who specializes in giving drugs or other agents to prevent or relieve pain during surgery or other procedures being done in the hospital.","Anesthesiologist | anesthesiologist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982363","Lung Cancer cM1b TNM Finding v7","C88887","Distant metastasis. (from AJCC 7th Ed.)","Lung Cancer cM1b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982362","Lung Cancer cM1a TNM Finding v7","C88886","Lung cancer with separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural (or pericardial) effusion.  Most pleural (and pericardial) effusions with lung cancer are due to tumor.  In a few patients, however, multiple cytopathologic examinations of pleural (or pericardial) fluid) are negative for tumor, and the fluid is nonbloody and is not an exudate.  Where these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging element and the patient should be classified as M0. (from AJCC 7th Ed.)","Lung Cancer cM1a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982360","Lung Cancer cM0 TNM Finding v7","C88884","Lung cancer without evidence of distant metastasis. (from AJCC 7th Ed.)","Lung Cancer cM0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982361","Lung Cancer cM1 TNM Finding v7","C88885","Lung cancer with distant metastasis. (from AJCC 7th Ed.)","Lung Cancer cM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983609","Gross Pathologic Examination","C90390","An assessment of macroscopic pathological findings that are caused by disease.","Gross Pathologic Examination | GROSPATH | GROSS PATHOLOGY | Gross Pathological Examination | Gross Pathological Examination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042397","Vasopressor","C126567","Any substance used in the treatment of hypotension. A vasopressor agent increases reduced blood pressure.","Vasopressor | Anti-hypotensive Agent | Antihypotensive Agent | IV vasopressors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880989","Glucuronidation Pathway","C63811","An inactivating and detoxification pathway for a variety of exogenous and endogenous molecules, including drugs, pollutants, bilirubin, androgens, estrogens, mineralocorticoids, glucocorticoids, fatty acid derivatives, retinoids and bile acids. Glucuronic acid is highly soluble in water and is often linked to poisonous substances to allow for subsequent elimination and to hormones to allow for easier transport. Also, drugs are commonly conjugated to glucuronic acid to allow for easier delivery. Excretion occurs via urine or bile.","Glucuronidation Pathway | Glucuronidation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831156","Cell Pellet","C113745","A cell sample collected and compacted by centrifugation of a liquid suspension.","Cell Pellet | CELL PELLET | Whole Cell Pellet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025668","Methohexital","C66116","A rapid, short-acting barbituric acid derivative, with anesthetic activity. Methohexital binds to the chloride ionophore site of the gamma-aminobutyric acid (GABA)-A/chloride ionophore receptor complex, thereby enhancing the inhibitory actions of GABA-A in the brain. This leads to synaptic inhibition, decreased neuronal excitability, and induction of anesthesia. In addition, this agent decreases glutamate (Glu) responses.","Methohexital | (+-)-5-Allyl-1-methyl-5-(1-methyl-2-pentynyl)barbituric Acid | 2,4,6(1H,3H,5H)-Pyrimidinetrione, 1-methyl-5-(1-methyl-2-pentynyl)-5-(2-propenyl)-, (+-)- | METHOHEXITAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242531","Vecuronium","C87317","A synthetic, intermediate-acting mono-quaternary steroid and non-depolarizing neuromuscular blocking agent, with muscle relaxant activity. Vecuronium competitively binds to and blocks the nicotinic acetylcholine receptor at the neuromuscular junction, thereby preventing acetylcholine (ACh) binding and resulting in skeletal muscle relaxation and paralysis. Vecuronium has a shorter duration of action than pancuronium.","Vecuronium | Piperidinium, 1-((2Beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)-2-(1-piperidinyl)androstan-16-yl)-1-methyl- | VECURONIUM | Vercuronium | Vercuronium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1548635","Eligible","C126586","Satisfying the appropriate conditions for inclusion.","Eligible | Eligibility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0696628","Applicant (person)","C61186","A person who requests or seeks something such as assistance or employment or admission.","Applicant | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348829","Twice Per Month","C71129","Twice per month.","Twice Per Month | BIM | Bi-Monthly | Twice per month",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982692","Kidney Cancer TNM Finding v7","C89280","A finding about one or more characteristics of kidney cancer, following the rules of the TNM AJCC v7 classification system.  Renal pelvis and ureter cancers are not included in this classification. (from AJCC 7th Ed.)","Kidney Cancer TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982695","Kidney Cancer pT2a TNM Finding v7","C89285","Kidney cancer with tumor more than 7 cm but less than or equal to 10 cm in greatest dimension, limited to the kidney. (from AJCC 7th Ed.)","Kidney Cancer pT2a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982696","Kidney Cancer pT2b TNM Finding v7","C89286","Kidney cancer with tumor more than 10 cm in greatest dimension, limited to the kidney. (from AJCC 7th Ed.)","Kidney Cancer pT2b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982697","Kidney Cancer pT3 TNM Finding v7","C89287","Kidney cancer with tumor extending into major veins or perinephric tissues but not into the ipsilateral adrenal gland and not beyond Gerota's fascia. (from AJCC 7th Ed.)","Kidney Cancer pT3 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982698","Kidney Cancer pT3a TNM Finding v7","C89288","Kidney cancer with tumor grossly extending into the renal vein or its segmental (muscle containing) branches or tumor invading perirenal and/or renal sinus fat but not beyond Gerota's fascia. (from AJCC 7th Ed.)","Kidney Cancer pT3a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982699","Kidney Cancer pT3b TNM Finding v7","C89289","Kidney cancer with tumor grossly extending into the vena cava below the diaphragm. (from AJCC 7th Ed.)","Kidney Cancer pT3b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982701","Kidney Cancer pT4 TNM Finding v7","C89293","Kidney cancer with tumor invading beyond Gerota's fascia (including contiguous extension into the ipsilateral adrenal gland). (from AJCC 7th Ed.)","Kidney Cancer pT4 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982700","Kidney Cancer pT3c TNM Finding v7","C89290","Kidney cancer with tumor grossly extending into the vena cava above the diaphragm, or invading the wall of the vena cava. (from AJCC 7th Ed.)","Kidney Cancer pT3c TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982703","Kidney Cancer pN1 TNM Finding v7","C89295","Kidney cancer with metastasis in regional lymph node(s). (from AJCC 7th Ed.)","Kidney Cancer pN1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982706","Kidney Cancer Clinical Distant Metastasis TNM Finding v7","C89298","A clinical finding about one or more characteristics of kidney cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.","Kidney Cancer Clinical Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982708","Kidney Cancer cM1 TNM Finding v7","C89300","Kidney cancer with distant metastasis. (from AJCC 7th Ed.)","Kidney Cancer cM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982707","Kidney Cancer cM0 TNM Finding v7","C89299","Kidney cancer without evidence of distant metastasis. (from AJCC 7th Ed.)","Kidney Cancer cM0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982704","Kidney Cancer Pathologic Distant Metastasis TNM Finding v7","C89296","A pathologic finding about one or more characteristics of kidney cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  There is no pathologic M0 for kidney cancer. (from AJCC 7th Ed.)","Kidney Cancer Pathologic Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881314","Kidney Cancer pM1 TNM Finding v6 and v7","C63577","Kidney cancer with distant metastasis. (from AJCC 6th and 7th Eds.)","Kidney Cancer pM1 TNM Finding v6 and v7 | Kidney Cancer pM1 TNM Finding | Kidney Cancer pM1 TNM Finding | Kidney Cancer pM1 TNM Finding v6 | Kidney Cancer pM1 TNM Finding v7 | pM1 Kidney Cancer | pM1 Kidney Carcinoma | pM1 Renal Cancer | pM1 Renal Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984067","Renal Cell Cancer by AJCC v7 Stage","C91201","A term that refers to the staging of renal cell cancer according to the American Joint Committee on Cancer, 7th edition.","Renal Cell Cancer by AJCC v7 Stage | Renal Cell Carcinoma by AJCC v7 Stage | Renal Cell Carcinoma by AJCC v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3146249","Stage IV Renal Cell Cancer AJCC v7","C89303","Stage IV includes: (T4, Any N, M0); (Any T, Any N, M1). T4: Tumor invades beyond Gerota's fascia (including contiguous extension into the ipsilateral adrenal gland).  M0: No distant metastasis. M1: Distant metastasis. (AJCC 7th ed.)","Stage IV Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer | Stage IV Renal Cell Cancer | Stage IV Renal Cell Carcinoma | Stage IV Renal Cell Carcinoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3146248","Stage III Renal Cell Cancer AJCC v7","C89302","Stage III includes: (T1 or T2, N1, M0); (T3, N0 or N1, M0).  T1: Lesions have been divided into T1a and T1b.  T1a is defined as tumor 4 cm or less in greatest dimension, limited to the kidney.  T1b is defined as tumor greater than 4 cm but not more than 7 cm in greatest dimension, limited to the kidney. T2: Lesions have been divided into T2a and T2b.  T2a is defined as tumor more than 7 cm but less than or equal to 10 cm in greatest dimension, limited to the kidney.  T2b is defined as tumor greater than 10 cm, limited to the kidney.  T3: Tumor extends into major veins or perinephric tissues, but not into the ipsilateral adrenal gland and not beyond Gerota's fascia. Lesions have been divided into T3a, T3b, and T3c. T3a: Tumor grossly extends into the renal vein or its segmental (muscle containing) branches, or tumor invades perirenal and/or renal sinus fat but not beyond Gerota's fascia.  T3b: Tumor grossly extends into the vena cava below the diaphragm. T3c: Tumor grossly extends into the vena cava above the diaphragm or invades the wall of the vena cava.  N0: No regional lymph node metastasis.  N1: Metastasis in regional lymph node(s). M0: No distant metastasis. (AJCC 7th ed.)","Stage III Renal Cell Cancer AJCC v7 | Stage III Renal Cell Cancer | Stage III Renal Cell Cancer | Stage III Renal Cell Carcinoma | Stage III Renal Cell Carcinoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3146247","Stage II Renal Cell Cancer AJCC v7","C89301","Stage II includes: T2, N0, M0.  T2: Lesions have been divided into T2a and T2b.  T2a is defined as tumor more than 7 cm but less than or equal to 10 cm in greatest dimension, limited to the kidney.  T2b is defined as tumor greater than 10 cm, limited to the kidney.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)","Stage II Renal Cell Cancer AJCC v7 | Stage II Renal Cell Cancer | Stage II Renal Cell Cancer | Stage II Renal Cell Carcinoma | Stage II Renal Cell Carcinoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278675","Stage I Renal Cell Cancer AJCC v6 and v7","C7823","Stage I includes: T1, N0, M0.  T1: Lesions have been divided into T1a and T1b.  T1a is defined as tumor 4 cm or less in greatest dimension, limited to the kidney.  T1b is defined as tumor greater than 4 cm but not more than 7 cm in greatest dimension, limited to the kidney.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th Eds.)","Stage I Renal Cell Cancer AJCC v6 and v7 | Renal Cell Cancer Stage I | Renal Cell Carcinoma, Stage I | Stage I Renal Cell Cancer | Stage I Renal Cell Cancer | Stage I Renal Cell Cancer AJCC v6 | Stage I Renal Cell Cancer AJCC v7 | Stage I Renal Cell Carcinoma | stage I kidney cancer | stage I renal cell cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0424790","Rigor","C111658","Severe chills accompanied by vigorous shaking.","Rigor | Repeated shaking with chills | Rigors",,,,,,,,,,,,,,,"4190045","Rigor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519110","Roswell Park Cancer Institute","C39509","The Roswell Park Institute was founded in 1898 as America's first cancer center. The Institute's goal is to reduce the burden of cancer through close cooperation among basic and translational research, multidisciplinary oncology teams, and educational programs. It was designated as an NCI comprehensive cancer center in 1974 and is a member of the National Comprehensive Cancer Network.","Roswell Park Cancer Institute | RPCI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503768","Genotype-Tissue Expression Program","C126654","A program sponsored by the National Institutes of Health's Common Fund, designed to provide insights into the mechanisms of gene regulation by studying human gene expression and regulation in multiple tissues from healthy individuals, exploring disease-related perturbations in a variety of human diseases, and examining sexual dimorphisms in gene expression and regulation in multiple tissues. Genetic variation between individuals will be examined for correlation with differences in gene expression level to identify regions of the genome that influence whether and how much a gene is expressed.","Genotype-Tissue Expression Program | GTEx | Genotype-Tissue Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503769","Unexplained","C126655","Having a reason or cause that is not known.","Unexplained | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0522560","Track Marks","C126656","Visible marks on the skin caused by puncture wounds, most commonly associated with intravenous drug use.","Track Marks | Needle Track Marks | Needle track",,,,,,,,,,,,,,,"4304344","Needle track",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0848128","Body Piercing","C126657","The practice of puncturing a part of the human body to create an opening in which jewelry, or other objects, may be worn.","Body Piercing | Piercing",,,,,,,,,,,,,,,"618923","Body piercing",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL503770","National Disease Research Interchange","C126658","A federally-funded non-profit organization that acts as a liaison between tissue and organ donors and the scientific community.","National Disease Research Interchange | NDRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699758","Aclidinium Bromide","C75999","No Value Exists","Aclidinium Bromide | ACLIDINIUM BROMIDE | Bretaris | Eklira | LAS 34273 | LAS W-330",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831808","Apixaban","C61308","An orally active inhibitor of coagulation factor Xa with anticoagulant activity. Apixaban directly inhibits factor Xa, thereby interfering with the conversion of prothrombin to thrombin and preventing formation of cross-linked fibrin clots.","Apixaban | 1H-Pyrazolo(3,4-c)pyridine-3-carboxamide, 4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxo-1-piperidinyl)phenyl)- | APIXABAN | BMS-562247 | BMS-562247-01 | Eliquis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503773","Skin Itching at its Worst","C126662","A question about an individual's skin itching at its worst.","Skin Itching at its Worst | Your skin itching at its worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503774","Skin and/or Joint Tightening at its Worst","C126663","A question about an individual's skin and/or joint tightening at its worst.","Skin and/or Joint Tightening at its Worst | Your skin and/or joint tightening at their worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503775","Mouth Sensitivity at its Worst","C126664","A question about an individual's mouth sensitivity at its worst.","Mouth Sensitivity at its Worst | Your mouth sensitivity at its worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503776","Genital Discomfort at its Worst","C126665","A question about an individual's genital discomfort at its worst.","Genital Discomfort at its Worst | Your genital discomfort at its worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503777","Global Rating","C126666","A question relating to the overall ranking of something based on a comparative assessment.","Global Rating | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503778","Severity Score 0","C126667","A subjective score of 0 on a severity scale that ranges from 0: Not at all severe to 10: most severe.","Severity Score 0 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503779","Severity Score 1","C126668","A subjective score of 1 on a severity scale that ranges from 0: Not at all severe to 10: most severe.","Severity Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503780","Severity Score 2","C126669","A subjective score of 2 on a severity scale that ranges from 0: Not at all severe to 10: most severe.","Severity Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503781","Severity Score 3","C126670","A subjective score of 3 on a severity scale that ranges from 0: Not at all severe to 10: most severe.","Severity Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503783","Severity Score 5","C126672","A subjective score of 5 on a severity scale that ranges from 0: Not at all severe to 10: most severe.","Severity Score 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503784","Severity Score 6","C126673","A subjective score of 6 on a severity scale that ranges from 0: Not at all severe to 10: most severe.","Severity Score 6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503785","Severity Score 7","C126674","A subjective score of 7 on a severity scale that ranges from 0: Not at all severe to 10: most severe.","Severity Score 7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503786","Severity Score 8","C126675","A subjective score of 8 on a severity scale that ranges from 0: Not at all severe to 10: most severe.","Severity Score 8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503787","Severity Score 9","C126676","A subjective score of 9 on a severity scale that ranges from 0: Not at all severe to 10: most severe.","Severity Score 9 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503788","Severity Score 10","C126677","A subjective score of 10 on a severity scale that ranges from 0: Not at all severe to 10: most severe.","Severity Score 10 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503789","Comparative Score 3+","C126678","A score of 3+ on a comparative scale that ranges from 3+: Very much better to -3: Very much worse.","Comparative Score 3+ | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503790","Comparative Score 2+","C126679","A score of 2+ on a comparative scale that ranges from 3+: Very much better to -3: Very much worse.","Comparative Score 2+ | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503791","Comparative Score 1+","C126680","A score of 1+ on a comparative scale that ranges from 3+: Very much better to -3: Very much worse.","Comparative Score 1+ | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503792","Comparative Score 0","C126681","A score of 0 on a comparative scale that ranges from 3+: Very much better to -3: Very much worse.","Comparative Score 0 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503793","Comparative Score -1","C126682","A score of -1 on a comparative scale that ranges from 3+: Very much better to -3: Very much worse.","Comparative Score -1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503794","Comparative Score -2","C126683","A score of -2 on a comparative scale that ranges from 3+: Very much better to -3: Very much worse.","Comparative Score -2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503795","Comparative Score -3","C126684","A score of -3 on a comparative scale that ranges from 3+: Very much better to -3: Very much worse.","Comparative Score -3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517547","Gifts and Donations","C19466","A funding source comprising money received through outside gifts or donations.","Gifts and Donations | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0199961","Whole Blood Transfusion","C62749","The intravenous administration of whole blood (blood that contains plasma and red blood cells) into an individual.","Whole Blood Transfusion | ",,,,,,,,,,,,,,,"4142651","Transfusion of whole blood",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0740299","Positive Blood Culture","C122437","A laboratory test result demonstrating the presence of a specific organism in a blood sample after culture.","Positive Blood Culture | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1096243","Central Line Infection","C121607","An infectious process related to a central venous catheter.","Central Line Infection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710428","Tissue Or Organ Transplant","C50920","A biospecimen that was obtained from tissue or organ collected for transplantation.","Tissue or Organ Transplant | Tissue Or Organ Transplant | Tissue or Organ Transplant Specimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938161","Bite Injury","C121559","A wound inflicted by the teeth or fangs of an individual or animal.","Bite Injury | ",,,,,,,,,,,,,,,"36684076","Bite",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3163775","Acute Normovolemic Hemodilution","C116547","A method of intraoperative blood conservation in which whole blood is drained by gravity into a collection bag where it is mixed with anticoagulants and maintained at room temperature. As the blood is collected, an intravenous fluid is infused to maintain normal blood volume. The collected blood can be transfused to the patient during and/or after surgery as needed.","Acute Normovolemic Hemodilution | Acute Isovolemic Hemodilution | IAD | Intraoperative Autologous Donation",,,,,,,,,,,,,,,"40487525","Acute normovolemic hemodilution",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1175743","SARS Coronavirus","C112432","A species of enveloped, spherical or pleomorphic, kidney-shaped or rod-shaped viruses in the Coronaviridae family and Coronavirus genus. The genome is composed of linear, single-stranded, positive-sense RNA. SARS coronaviruses are found in humans and cause severe acute respiratory syndrome (SARS). SARS coronaviruses are transmitted via direct person-to-person contact with infected secretions or excretions, and aerosols of respiratory droplets.","SARS Coronavirus | HCoV-SARS | SARS | SARS CORONAVIRUS | SARS-CoV | SARS-CoV-1 | SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS | Severe Acute Respiratory Syndrome Coronavirus",,,,,,,,,,,,,,,"37150979","SARSr-CoV",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1366940","Skin Tattoo","C113681","A permanent mark created by the insertion of pigment below the skin.","Skin Tattoo | Tattoo",,,,,,,,,,,,,,,"42872418","Tattoo of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347958","Resident (person)","C71416","Someone who lives at a particular place for a prolonged period or who was born there.","Resident | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511576","Cyclin-Dependent Kinase Inhibitor Agents","C2185","Any substance that inhibits cyclin-dependent kinase (CDK), an enzyme that catalyzes the addition of a phosphate group to a protein in the cell cycle regulation pathway. Inhibition of cyclin-dependent kinase results in cell cycle arrest and apoptosis.","Cyclin-Dependent Kinase Inhibitor | CDK Inhibitor | CDKI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029206","Organ Donor","C100810","Someone from whom an organ is removed for transplantation or other purpose.","Organ Donor | DONOR, ORGAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0580205","Postmortem","C94193","Occurring after death.","Postmortem | After Death | Post-Mortem | Upon Death | postmortem",,,,,,,,,,,,,,,"4121980","Postmortem period",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706503","Thermometer Device","C50059","A device designed to measure temperature.","Thermometer Device | Thermometer | Thermometer Device Component",,,,,,,,,,,,,,,"4102004","Thermometer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3274942","Prosector","C99796","An individual who dissects cadavers. Usually, this is performed for tissue procurement for pathology or autopsy.","Prosector | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539024","Brief Pain Inventory Questionnaire","C100759","A standardized survey originally developed and copyrighted by Charles S. Cleeland in 1991 which is used to evaluate the severity of a patient's pain and the impact that their pain has on their daily activities. This longer version is more clinically useful, can be completed by the patient or in an interview format and consists of 32 multi-level questions covering areas such as location, type, and severity of pain as well as the use of pain medications.","Brief Pain Inventory Questionnaire | BPI | BPI1 | Brief Pain Inventory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227177","Esophageal Muscularis Mucosa","C32540","The layer of muscularis mucosa in the esophageal wall. It is thicker than the muscularis mucosa of the stomach and intestine. It is composed of longitudinal muscle fibers.","Esophageal Muscularis Mucosa | Esophagus-muscularis",,,,,,,,,,,,,,,"4166346","Lamina muscularis of esophageal mucous membrane",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448652","Atrial","C37914","Of or relating to a cavity or chamber in the body, especially one of the upper chambers of the heart.","Atrial | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0598782","Appendage","C61460","A natural prolongation or projection from a part of an organism either animal or plant; a part that is joined to something larger.","Appendage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040186","Tibial Nerve","C52809","One of two major branches of the sciatic nerve. It innervates the muscles of the posterior aspect of the lower limb, the muscles of the plantar aspect of the foot, as well as the skin on the posterior aspect of the leg and on the sole of the foot.","Tibial Nerve | NERVE, TIBIAL | TIBIAL NERVE",,,,,,,,,,,,,,,"4163990","Structure of tibial nerve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085427","Tibial Artery","C12824","Any of the tibial arteries including the anterior and posterior tibial arteries and the anterior and posterior recurrent tibial arteries.","Tibial Artery | Tibial Arteries",,,,,,,,,,,,,,,"4055799","Tibial artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0228175","Right Cerebral Hemisphere","C33472","The right half of the cerebrum that controls the muscles on the left side of the body.","Right Cerebral Hemisphere | CEREBRAL HEMISPHERE, RIGHT | Right Brain Hemisphere | Right Hemisphere",,,,,,,,,,,,,,,"4179358","Right cerebral hemisphere structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242691","Gastrocnemius Muscle","C32666","A large muscle in the back of the lower leg. Its action involves the plantar flexion of the foot.","Gastrocnemius Muscle | GASTROCNEMIUS MUSCLE | MUSCLE, GASTROCNEMIUS",,,,,,,,,,,,,,,"4261824","Gastrocnemius muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1513751","Multiple Tumor Masses","C39787","A finding indicating the presence of more than two tumor masses in a single anatomic site or different anatomic sites.","Multiple Tumor Masses | Multiple Masses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342649","Vascular Calcification","C114846","Deposition of calcium in vascular structures.","Vascular Calcification | ",,,,,,,,,,,,,,,"4030365","Vascular calcification",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3282898","Tip","C90069","The pointed end of a linear structure.","Tip | TIP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0447541","Liver Lobe","C49579","Any of the four large divisions of the liver.","Liver Lobe | LIVER LOBE",,,,,,,,,,,,,,,"4075388","Lobe of liver",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227997","Right Testis","C49326","The testis on the right side of the body.","Right Testis | ",,,,,,,,,,,,,,,"4048865","Structure of right testis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227998","Left Testis","C49323","The testis on the left side of the body.","Left Testis | ",,,,,,,,,,,,,,,"4268604","Structure of left testis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0672663","Vinflunine","C61564","A bi-fluorinated derivative of the semi-synthetic vinca alkaloid vinorelbine with antitubulin, antineoplastic, and antiangiogenic activities. Vinflunine inhibits tubulin assembly without any stablization of assembled microtubules at concentrations comparable to those of other vinca alkaloids such as vincristine, vinblastine and vinorelbine; this effect on microtubule dynamics results in cell cycle arrest in mitosis and apoptosis. Compared to other vinca alkaloids, this agent binds weakly to the vinca-binding site, indicating that vinflunine may exhibit reduced neurotoxicity.","Vinflunine | 4'-Deoxy-20',20'-difluoro-C'-norvincaleukoblastine | VINFLUNINE | vinflunine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827082","Atezolizumab","C106250","A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1; PDCD1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 (CD80) expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).","Atezolizumab | ATEZOLIZUMAB | Immunoglobulin G1, Anti-(human CD Antigen cd274) (Human Monoclonal MPDL3280A Heavy Chain), Disulfide with Human Monoclonal MPDL3280A Kappa-chain, Dimer | MPDL 3280A | MPDL 328OA | MPDL-3280A | MPDL3280A | MPDL328OA | RG 7446 | RG-7446 | RG7446 | RO 5541267 | RO-5541267 | RO5541267 | Tecentriq",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0241232","spring (season)","C94731","The season between the vernal equinox and the summer solstice.","Spring | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709359","Outdoors","C53541","Any area outside a building or shelter.","Outdoors | OUTDOORS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0241301","Summer","C94732","The season between the summer solstice and the autumnal equinox.","Summer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0238715","Autumn","C94733","The season between the autumnal equinox and the winter solstice.","Autumn | Fall",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0241737","Winter","C94730","The season between the winter solstice and the vernal equinox.","Winter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0401496","Transurethral Resection of Bladder Tumor","C116651","A surgical procedure used to treat bladder tumors, during which a resectoscope is passed through the urethra and into the bladder.","Transurethral Resection of Bladder Tumor | TRANSURETHRAL RESECTION OF BLADDER TUMOR | TURBT | Transurethral resection (TURBT)",,,,,,,,,,,,,,,"4305077","Transurethral resection of neoplasm of bladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1531189","CTNNB1 protein, human","C17478","Catenin beta-1 (781 aa, ~85 kDa) is encoded by the human CTNNB1 gene. This protein is involved in Wnt signaling, adherens junction structure, and the regulation of cell growth.","Catenin Beta-1 | Beta Catenin | Beta Catenin | Beta-Catenin | CTNNB1 | Cadherin-Associated Protein, Beta | Cadherin-Associated Protein, Beta 1 (88kD) | Catenin, Beta-1 | PRO2286 | beta-catenin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522548","Synaptophysin Staining Method","C23029","This is an immunohistochemical technique utilizing antibody to synaptophysin, an integral membrane glycoprotein present in presynaptic vesicles in neurons. The antibody labels neuroendocrine cells and neurons of the brain, spinal cord and retina. Used to detect neuroendocrine neoplasms including neuroblastomas, ganglioneuroblastomas, ganglioneuromas, pheochromocytomas, chromaffin, and non-chromaffin paragangliomas.","Synaptophysin Staining Method | SYP Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508237","Aqua","C126753","A light bluish-green to light greenish-blue color.","Aqua | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508076","Skin Complete Response GvHD","C126700","An NIH skin score of 0 after previous GvHD involvement.","Skin Complete Response GvHD | Skin Complete GvHD Response | Skin Complete Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508006","Eyes Complete Response GvHD","C126701","An NIH eye score of 0 after previous GvHD involvement.","Eyes Complete Response GvHD | Eyes Complete GvHD Response | Eyes Complete Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508235","Mouth Complete Response GvHD","C126702","An NIH modified Oral Mucosa Rating Scale (OMRS) score of 0 following previous GvHD involvement.","Mouth Complete Response GvHD | Mouth Complete GvHD Response | Mouth Complete Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508000","Esophagus Complete Response GvHD","C126703","An NIH esophagus score of 0 after previous GvHD involvement.","Esophagus Complete Response GvHD | Esophagus Complete GvHD Response | Esophagus Complete Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508090","Upper GI Complete Response GvHD","C126704","An NIH upper GI score of 0 after previous GvHD involvement.","Upper GI Complete Response GvHD | Upper GI Complete GvHD Response | Upper GI Complete Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508034","Lower GI Complete Response GvHD","C126705","An NIH lower GI score of 0 after previous GvHD involvement.","Lower GI Complete Response GvHD | Lower GI Complete GvHD Response | Lower GI Complete Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508031","Liver Complete Response GvHD","C126706","Normal ALT, alkaline phosphatase, and total bilirubin after previous elevation of 1 or more following GvHD involvement.","Liver Complete Response GvHD | Liver Complete GvHD Response | Liver Complete Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507979","Upper GI Progression GvHD","C126729","An NIH upper GI score that has increased by 1 or more points, except 0 to 1.","Upper GI Progression GvHD | GvHD Upper GI Progression | Upper GI Progression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3275630","Unipolar Depression","C35094","A mood disorder having a clinical course involving one or more episodes of serious psychological depression that last two or more weeks each, do not have intervening episodes of mania or hypomania, and are characterized by a loss of interest or pleasure in almost all activities and by some or all of disturbances of appetite, sleep, or psychomotor functioning, a decrease in energy, difficulties in thinking or making decisions, loss of self-esteem or feelings of guilt, and suicidal thoughts or attempts.","Unipolar Depression | Major Depression | Major Depressive Disorder",,,,,,,,,,,,,,,"4152280","Major depressive disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518033","Lower Respiratory System","C33012","The part of the respiratory system below the bifurcation of the trachea. It includes the lungs and the parts of the lungs such as the bronchioles and alveoli.","Lower Respiratory System | LOWER RESPIRATORY SYSTEM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274944","Pronounced Dead","C99799","The status of an individual is officially declared not living by an authority.","Pronounced Dead | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376297","Cardiac Death","C54196","The cessation of life due to heart abnormalities or disease.","Cardiac Death | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274943","Presumed Dead","C99798","The status of an individual who in all likelihood is not living, but has not been officially declared dead.","Presumed Dead | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274946","Decedent","C99802","A reference to a dead individual.","Decedent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708733","Long-Term Care Facility","C53530","A healthcare facility that provides rehabilitative, restorative, and/or ongoing skilled nursing care to patients or residents in need of assistance with activities of daily living.","Long-Term Care Facility | LONG-TERM CARE FACILITY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006110","Brain Death","C116340","Irreversible absence of cortical and brain stem functioning.","Brain Death | Brain death",,,,,,,,,,,,,,,"4048809","Brainstem death",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3536725","Undetermined Disease","C89084","A term referring to the lack of definitive clinical or pathologic criteria for a tumor to predict its clinical course or to classify it as benign or malignant.","Undetermined | UNDETERMINED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829672","Homicide and Legal Intervention","C105735","Causes of death attributable to homicide or resulting from legal police intervention.","Homicide and Legal Intervention | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0277610","Death by Natural Cause","C82465","Death that is attributed to the progression of a disease or pre-existing condition, and which is not attributable to any outside action or force.","Death by Natural Cause | DIED - NATURALLY",,,,,,,,,,,,,,,"4297089","Natural death",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508088","Anesthesia Probe","C126768","An ultrasound probe suitable for use during an anesthesia procedure to facilitate the placement of local or regional anesthetics.","Anesthesia Probe | Anesthesia probe | Ultrasound Probe for Anesthesia Procedure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508100","Suprapubic Skin","C126736","The skin above the pubic area.","Suprapubic Skin | Suprapubic skin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0149546","Frontal Pole","C126737","The anterior pointed end of a cerebral hemisphere.","Frontal Pole | Frontal pole",,,,,,,,,,,,,,,"4216380","Structure of frontal pole",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227176","Esophageal Mucosa","C32538","The lining of the esophagus. It is composed of non-keratinized stratified squamous epithelium, lamina propria, and muscularis mucosa.","Esophageal Mucosa | ESOPHAGEAL MUCOSA | Esophagus - mucosa | esophageal mucosa | esophageal mucous membrane | esophagus mucosa | esophagus mucous membrane | lamina muscularis mucosae esophageae | mucosa of esophagus | mucous membrane of esophagus | tunica mucosa esophageae | tunica mucosa esophagi",,,,,,,,,,,,,"UBERON:0002469","esophagus mucosa","4218887","Esophageal mucous membrane structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1425218","ROBO4 Gene","C74444","This gene plays a role in blood vessel development and maturation.","ROBO4 Gene | ROBO4 | Roundabout Guidance Receptor 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1456385","MAP2K2 Gene","C106606","This gene plays a role in both protein phosphorylation and signal transduction.","MAP2K2 Gene | MAP2K2 | Mitogen-Activated Protein Kinase Kinase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413403","CHRNA3 Gene","C77118","This gene plays a role in the regulation of ion transport.","CHRNA3 Gene | CHRNA3 | Cholinergic Receptor Nicotinic Alpha 3 Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413410","CHRNB4 Gene","C77120","This gene is involved in ion transport.","CHRNB4 Gene | CHRNB4 | Cholinergic Receptor Nicotinic Beta 4 Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508036","Lungs Complete Response GvHD","C126707","Either normal %FEV1, alkaline phosphatase, and total bilirubin after previous elevation of 1 or more or an NIH lung symptom score of 0 following GvHD involvement.","Lungs Complete Response GvHD | Lungs Complete GvHD Response | Lungs Complete Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508052","Joints and Fascia Complete Response GvHD","C126708","Both an NIH joint and fascia score of 0 and a P-ROM score of 25 after previous GvHD involvement by at least 1 measure.","Joints and Fascia Complete Response GvHD | Joints and Fascia Complete GvHD Response | Joints and Fascia Complete Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508147","Global Complete Response GvHD","C126709","A clinician overall severity score 0 following GvHD response.","Global Complete Response GvHD | Global Complete GvHD Response | Global Complete Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508077","Skin Partial Response GvHD","C126714","An NIH skin score that has decreased by 1 or more points.","Skin Partial Response GvHD | Skin Partial GvHD Response | Skin Partial Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508007","Eyes Partial Response GvHD","C126715","An NIH eye score that has decreased by 1 or more points.","Eyes Partial Response GvHD | Eyes Partial GvHD Response | Eyes Partial Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508236","Mouth Partial Response GvHD","C126716","An NIH modified Oral Mucosa Rating Scale (OMRS) score that has decreased by 2 or more points.","Mouth Partial Response GvHD | Mouth Partial GvHD Response | Mouth Partial Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508001","Esophagus Partial Response GvHD","C126717","An NIH esophagus score that has decreased by 1 or more points.","Esophagus Partial Response GvHD | Esophagus Partial GvHD Response | Esophagus Partial Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508091","Upper GI Partial Response GvHD","C126718","An NIH upper GI score that has decreased by 1 or more points.","Upper GI Partial Response GvHD | Upper GI Partial GvHD Response | Upper GI Partial Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508035","Lower GI Partial Response GvHD","C126719","An NIH lower GI score that has decreased by 1 or more points.","Lower GI Partial Response GvHD | Lower GI Partial GvHD Response | Lower GI Partial Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508032","Liver Partial Response GvHD","C126720","A decrease by 50% for ALT, alkaline phosphatase, and total bilirubin.","Liver Partial Response GvHD | Liver Partial GvHD Response | Liver Partial Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508037","Lungs Partial Response GvHD","C126721","Either an increase by 10% predicted absolute value of %FEV1 or an NIH lung symptom score that has decreased by 1 or more points.","Lungs Partial Response GvHD | Lungs Partial GvHD Response | Lungs Partial Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508053","Joints and Fascia Partial Response GvHD","C126722","A NIH Joint and Fascia score that has decreased by 1 or more points or an increase in P-ROM score by 1 point for any site.","Joints and Fascia Partial Response GvHD | Joints and Fascia Partial GvHD Response | Joints and Fascia Partial Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508148","Global Partial Response GvHD","C126723","A clinician overall severity score that has decreased by 2 or more points on a 0-10 scale.","Global Partial Response GvHD | Global Partial GvHD Response | Global Partial Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507977","Skin Progression GvHD","C126725","An NIH skin score that has increased by 1 or more points, except 0 to 1.","Skin Progression GvHD | GvHD Skin Progression | Skin Progression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507971","Eyes Progression GvHD","C126726","An NIH eye score that has increased by 1 or more points, except 0 to 1.","Eyes Progression GvHD | Eyes Progression | GvHD Eyes Progression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507976","Mouth Progression GvHD","C126727","An NIH modified Oral Mucosa Rating Scale (OMRS) score that has increased by 2 or more points.","Mouth Progression GvHD | GvHD Mouth Progression | Mouth Progression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507970","Esophagus Progression GvHD","C126728","An NIH esophagus score that has increased by 1 or more points, except 0 to 1.","Esophagus Progression GvHD | Esophagus Progression | GvHD Esophagus Progression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507975","Lower GI Progression GvHD","C126730","An NIH lower GI score that has increased by 1 or more points, except 0 to 1.","Lower GI Progression GvHD | GvHD Lower GI Progression | Lower GI Progression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507974","Liver Progression GvHD","C126732","An increase by two times the upper limit of normal for ALT, alkaline phosphatase, and total bilirubin.","Liver Progression GvHD | GvHD Liver Progression | Liver Progression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507978","Lung Progression GvHD","C126733","Either a decrease by 10% predicted absolute value of %FEV1 or an NIH lung symptom score that has increased by 1 or more points, except 0 to 1.","Lung Progression GvHD | GvHD Lung Progression | Lung Progression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507973","Joints and Fascia Progression GvHD","C126734","A NIH joint and fascia score that has increased by 1 or more points or a decrease in P-ROM score by 1 point for any site.","Joints and Fascia Progression GvHD | GvHD Joints and Fascia Progression | Joints and Fascia Progression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507972","Global Progression GvHD","C126735","A clinician overall severity score that has increased by 2 or more points on a 0-10 scale.","Global Progression GvHD | Global Progression | GvHD Global Progression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332803","CTNNB1 Gene","C20987","This gene is involved in signal transduction and regulation of transcription.","CTNNB1 Gene | CTNNB1 | Catenin Beta 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0972314","Etoricoxib","C52188","A synthetic, nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic, and potential antineoplastic properties. Etoricoxib specifically binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in inhibition of the conversion of arachidonic acid into prostaglandins. Inhibition of COX-2 may induce apoptosis and inhibit tumor cell proliferation and angiogenesis.","Etoricoxib | 5-Chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl) Pyridine | Arcoxia | ETORICOXIB | L-791456 | MK-0663",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0795597","Liposomal Cytarabine","C2388","A liposomal intrathecal formulation of the antimetabolite cytarabine. As an S-phase-specific antimetabolite, cytarabine is phosphorylated by deoxycytidine kinase to a triphosphate form which competes with thymidine for incorporation into DNA; the incorporation of cytarabine triphosphate into DNA appears to inhibit DNA polymerase and so DNA synthesis, resulting in cell death. (NCI04)","Liposomal Cytarabine | Cytarabine Liposomal | Cytarabine Liposome | Cytarabine liposomal | DTC 101 | Depo-Cyt | DepoCyt | DepoCyte | DepoFoam Encapsulated Cytarabine | Encapsulated Cytarabine | Liposomal Ara-C | Liposomal cytarabine | cytarabine liposome | liposomal cytarabine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202363","Cotinine Measurement","C92249","The determination of the amount of cotinine present in a sample.","Cotinine Measurement | COTININE | Cotinine",,,,,,,,,,,,,,,"4141885","Cotinine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0443290","Reversal","C125005","A change in something from one state to the opposite state.","Reversal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0045611","2,6-Dimethoxyquinone","C126754","A methoxy-substituted benzoquinone and bioactive compound found in fermented wheat germ extracts, with potential antineoplastic and immune-enhancing activity. 2,6-Dimethoxyquinone (2,6-DMBQ) inhibits anaerobic glycolysis thereby preventing cellular metabolism and inducing apoptosis. As cancer cells use the anaerobic glycolysis pathway to metabolize glucose and cancer cells proliferate at an increased rate as compared to normal, healthy cells, this agent is specifically cytotoxic towards cancer cells. In addition, 2,6-DMBQ exerts immune-enhancing effects by increasing natural killer (NK) cell and T-cell activity against cancer cells.","2,6-Dimethoxyquinone | 2,5-Cyclohexadiene-1,4-Dione, 2,6-Dimethoxy- | 2,5-Cyclohexadiene-1,4-Dione, 2,6-Dimethoxy- (9CI) | 2,6-DIMETHOXYQUINONE | 2,6-DMBQ | 2,6-Dimethoxy-1,4-Benzoquinone | 2,6-Dimethoxy-p-Benzoquinone | 2,6-Dimethoxy-p-Quinone | 2,6-Dimethoxybenzoquinone | 2,6-Dimethoxycyclohexa-2,5-Diene-1,4-Dione | p-Benzoquinone, 2,6-Dimethoxy-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413302","CDX4 Gene","C126761","This gene plays a role in the modulation of gene expression during development.","CDX4 Gene | CDX4 | Caudal Type Homeobox 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415408","H2AZ1 Gene","C126764","This gene is involved in nucleosome formation.","H2AZ1 Gene | H2A.Z Variant Histone Gene | H2AFZ | H2AFZ Gene | H2AFZ Gene | H2AZ1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424690","PRICKLE1 Gene","C126758","This gene is involved in gastrulation and the regulation of Wnt signaling.","PRICKLE1 Gene | PRICKLE1 | Prickle Planar Cell Polarity Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419597","ROBO2 Gene","C126774","This gene plays a role in ligand binding, axon guidance and cell migration.","ROBO2 Gene | ROBO2 | Roundabout Guidance Receptor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538879","ROBO3 Gene","C126777","This gene is involved in neuronal cell shape.","ROBO3 Gene | ROBO3 | Roundabout Guidance Receptor 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420243","SLIT1 Gene","C126782","This gene plays a role in axon guidance and angiogenesis.","SLIT1 Gene | SLIT1 | Slit Guidance Ligand 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420244","SLIT2 Gene","C126785","This gene is involved in cell migration and nervous system development.","SLIT2 Gene | SLIT2 | Slit Guidance Ligand 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420245","SLIT3 Gene","C126788","This gene plays a role in the regulation of cell migration.","SLIT3 Gene | SLIT3 | Slit Guidance Ligand 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1563925","Type 1 Regulatory T-Cell","C126755","A population of CD4+, CD25-, and FoxP3- T-lymphocytes that are involved in immunotolerance. These cells secrete the immunosuppressive cytokines, tumor growth factor-beta (TGF-B) and interleukin-10, and may induce cell cycle arrest or apoptosis in effector T-cells.","Type 1 Regulatory T-Cell | T Regulatory Cell 1 | Tr1 | Tr1 Cell | Type 1 Regulatory T Cell | Type 1 Regulatory T Lymphocyte | Type 1 Regulatory T-Lymphocyte | Type 1 T reg | Type 1 Treg | Type-1 T Regulatory Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508099","Study Site Temporarily Closed to Accrual and Intervention","C126839","Trial is temporarily not accruing and patients are not receiving therapy/intervention.","Study Site Temporarily Closed to Accrual and Intervention | Suspended",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439856","Unsatisfactory","C126862","Failing to meet the quantitative or qualitative measures for the needs of a situation.","Unsatisfactory | Inadequate | Insufficient",,,,,,,,,,,,,,,"4116822","Unsatisfactory",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0450355","31","C126863","A natural number greater than thirty and less than thirty-two and the quantity that it denotes.","Thirty One | 31 | Thirty-One",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016927","Gagging","C34630","The sudden, coordinated, involuntary contraction of pharyngeal muscles in an attempt to prevent any matter from passing into the posterior pharynx; it is stimulated by touching the posterior palate, tongue, or pharynx, or by psychic stimuli.","Gagging | ",,,,,,,,,,,,,,,"4091505","Gagging",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010082","Coroner","C126807","An appointed public official whose job is to identify and certify an individual's death.","Coroner | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025082","Medical Examiner","C126808","A physician, usually a forensic pathologist by training, whose job is to determine the cause of an individual's death and perform autopsies.","Medical Examiner | ME",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896746","ATR kinase inhibitor VX-970","C116355","An inhibitor of ataxia telangiectasia and rad3-related (ATR) kinase, a DNA damage response kinase, with potential antineoplastic activity. Upon administration, berzosertib selectively binds to and inhibits ATR kinase activity and prevents ATR-mediated signaling in the ATR-checkpoint kinase 1 (Chk1) signaling pathway. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, and induces tumor cell apoptosis. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression, and survival; it is activated by DNA damage caused during DNA replication-associated stress.","Berzosertib | 2-Pyrazinamine, 3-(3-(4-((Methylamino)methyl)phenyl)-5-isoxazolyl)-5-(4-((1-methylethyl)sulfonyl)phenyl)- | ATR Kinase Inhibitor M6620 | ATR Kinase Inhibitor VX-970 | BERZOSERTIB | M 6620 | M6620 | VX 970 | VX-970 | VX970",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831896","cyclodextrin-based polymer-camptothecin CRLX101","C62600","A formulation of camptothecin, an alkaloid isolated from the Chinese tree Camptotheca acuminata, conjugated with to a hydrophilic, cyclodextrin-based linear polymer with potential antineoplastic activity. Upon intravenous administration of davamotecan pegadexamer, camptothecin is slowly released from the formulation at the tumor site and taken up by tumor cells. During the S phase of the cell cycle, camptothecin selectively stabilizes topoisomerase I-DNA covalent complexes, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. Compared to camptothecin alone, the cyclodextrin-based polymer formulation has a prolonged half life and greatly improves the biodistribution of camptothecin resulting in an accumulation of camptothecin at the tumor site, which enhances tumor exposure while greatly reducing toxic side effects. In addition, cyclodextrin-based polymer-camptothecin may be able to overcome certain kinds of multidrug resistance.","Davamotecan Pegadexamer | CRLX101 | Camptothecin-Polymer Conjugate IT-101 | Cyclodextrin-Based Polymer-Camptothecin CRLX101 | Cyclodextrin-Based Polymer-Camptothecin CRLX101 | DAVAMOTECAN PEGADEXAMER | EP0057 | IT-101 | Linear Cyclodextrin-cysteine-PEG Based Polymer Conjugate of Camptothecin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981820","Pexidartinib","C88303","A small-molecule receptor tyrosine kinase (RTK) inhibitor of proto-oncogene receptor tyrosine kinase (KIT), colony-stimulating factor-1 receptor (CSF1R) and FMS-like tyrosine kinase 3 (FLT3), with antineoplastic activity. Upon oral administration, pexidartinib targets, binds to and inhibits phosphorylation of KIT, CSF1R and FLT3 harboring an internal tandem duplication (ITD) mutation. This results in the inhibition of tumor cell proliferation. FLT3, CSF1R and FLT3 are overexpressed or mutated in many cancer cell types and play major roles in tumor cell proliferation and metastasis.","Pexidartinib | 3-Pyridinemethanamine, N-(5-((5-chloro-1H-pyrrolo(2,3-b)pyridin-3-yl)methyl)-2-pyridinyl)-6-(trifluoromethyl)- | CML-261 | Multitargeted Tyrosine Kinase Inhibitor PLX3397 | PEXIDARTINIB | PLX 3397 | PLX-3397 | PLX3397",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0049315","L-methylfolate","C107240","A nutritional supplement containing the biologically active form of the B9 vitamin folate, 5-methyltetrahydrofolate (L-methylfolate), with potential antineoplastic activity. Upon administration, L-methylfolate is able to provide methyl groups allowing an increase in the level of DNA methylation in the promoter regions of certain tumor-promoting genes, thereby reversing the DNA hypomethylation of these genes and inactivating them. This may result in a decrease of both tumor cell proliferation and tumor progression. In addition, administration of L-methylfolate may sensitize tumor cells to the cytotoxic effects of other chemotherapeutic agents. Unlike folic acid, L-methylfolate is able to cross the blood brain barrier and could be beneficial in the treatment of brain tumors. DNA hypomethylation of certain genes leads to chromosome instability and contributes to tumor development.","L-methylfolate | 5-MTHF | 5-Methyl terahydrofolic Acid | 5-Methyltetrahydrofolate | Deplin | L-Glutamic Acid, N-(4-(((2-amino-1,4,5,6,7,8-hexahydro-5- methyl-4-oxo-6-pteridinyl)methyl)amino)benzoyl)- | L-methyltetrahydrofolate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508177","Inattention/Hyperactivity Composite Score","C126881","A composite score of the Behavior Assessment System for Children that combines the Attention Problems scale and the Hyperactivity scale.","Inattention/Hyperactivity Composite Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508105","Zoo Locations Subtest","C126882","A subtest of the Wechsler Preschool and Primary Scale of Intelligence, that measures visual as well as spatial dimension skills. Working within a specified time limit, the child views pictures of animals placed on a zoo layout and them must place the proper animal in the correct location.","Zoo Locations Subtest | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508152","Digit Span Total Score","C126883","The sum of the scores for the Digit Span Forward, Digit Span Backward, and Digit Span Sequencing scales of the Wechsler Intelligence Scale for Children.","Digit Span Total Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508245","Twenty Two","C126884","A natural number greater than twenty-one and less than twenty-three and the quantity that it denotes.","Twenty Two | 22 | Twenty-Two",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0450348","23","C126885","A natural number greater than twenty-two and less than twenty-four and the quantity that it denotes.","Twenty Three | 23 | Twenty-Three",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0450349","numeral 26","C126886","A natural number greater than twenty-five and less than twenty-seven and the quantity that it denotes.","Twenty Six | 26 | Twenty-Six",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508246","Twenty Seven","C126887","A natural number greater than twenty-six and less than twenty-eight and the quantity that it denotes.","Twenty Seven | 27 | Twenty-Seven",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508247","Twenty Eight","C126888","A natural number greater than twenty-seven and less than twenty-nine and the quantity that it denotes.","Twenty Eight | 28 | Twenty-Eight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508050","Personal Care Product","C126889","A consumer product used for personal hygiene or for beautification.","Personal Care Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346802","Daratumumab","C74007","A human immunoglobulin G1-kappa (IgG1k) monoclonal antibody directed against the cell surface glycoprotein CD38, with immunomodulating and antineoplastic activities. Upon administration, daratumumab targets and binds to CD38 expressed on tumor cells. This triggers direct cell killing, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell mediated phagocytosis (ADCP) and antibody-mediated complement dependent cytotoxicity (CDC) in CD38-expressing tumor cells. In addition, binding to CD38 by daratumumab depletes CD38-expressing immunosuppressive regulatory T- and B-cells and myeloid-derived suppressor cells (MDSCs). CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies.","Daratumumab | Anti-CD38 Monoclonal Antibody | DARATUMUMAB | Daratumumab Biosimilar HLX15 | Daratumumab-fihj | Darzalex | HLX15 | HuMax-CD38 | JNJ 54767414 | JNJ-54767414 | JNJ54767414",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985701","Abnormal Indicator","C93491","Specifies whether an interpreted event or entity is abnormal.","Abnormal Indicator | abnormalIndicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1167874","Endocrine Test","C74971","A laboratory procedure that tests the function of an endocrine organ and measures the amount of a hormone present in a sample.","Endocrine Test | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004372","Autolysis","C99673","The destruction of organism cells or tissues by the organism's own enzymes or processes.","Autolysis | AUTOLYSIS | Autolytic",,,,,,,,,,,,,,,"4312484","Autolysis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2828395","Packing (action)","C84731","Performance of the packaging part of the manufacturing process.","Packing | PACK | Pack | Packaging | packaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508117","Chronic Respiratory Questionnaire Self-Administered Standardized Format","C126891","A standardized rating scale developed by Schunemann et al in 2003, which is a self-administered instrument used to measure the health-related quality of life (HRQL) in patients with chronic airflow limitation.","Chronic Respiratory Questionnaire Self-Administered Standardized Format | CRQ-SAS | Chronic Respiratory Questionnaire Self-Administered Standardized Format (CRQ-SAS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508101","Take Care of Basic Needs","C126905","A question about an individual taking care of their basic needs including bathing, showering, eating or dressing.","Take Care of Basic Needs | Taking care of your basic needs (bathing, showering, eating or dressing)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508170","How Much Shortness of Breath During Activity","C126902","A question about how much shortness of breath an individual had or has while doing a specific activity.","How Much Shortness of Breath During Activity Question | How Much Shortness of Breath | How Much Shortness of Breath During Activity | How Much Shortness of Breath During Activity | How much shortness of breath you have had while doing that activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508010","Feel Emotional","C126904","A question about an individual feeling emotional, such as angry or upset.","Feel Emotional | Feeling emotional such as angry or upset",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508049","Perform Chores","C126906","A question about an individual performing chores such as housework, shopping groceries.","Perform Chores Question | Perform Chores | Perform Chores | Performing Chores | Performing chores (such as housework, shopping groceries)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508047","Participate in Social Activities","C126909","A question about an individual participating in social activities.","Participate in Social Activities Question | Participate in Social Activities | Participate in Social Activities | Participating in social activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508012","Feel Frustrated or Impatient","C126912","A question about an individual feeling frustrated or impatient.","Feel Frustrated or Impatient | How much of the time have you felt frustrated or impatient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508011","Feel Fear or Panic When Difficult to Get Breath","C126914","A question about an individual feeling fear or panic when they had difficulty getting their breath.","Feel Fear or Panic When Difficult to Get Breath | How often did you have a feeling of fear or panic when you had difficulty getting your breath",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508009","Feel Embarrassed by Coughing or Heavy Breathing","C126915","A question about an individual feeling embarrassed by their coughing or heavy breathing.","Feel Embarrassed by Coughing or Heavy Breathing | How often have you felt embarrassed by your coughing or heavy breathing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508018","Feel Very Confident Can Deal with Illness","C126916","A question about an individual feeling very confident and sure that you could deal with your illness.","Feel Very Confident Can Deal with Illness | How much of the time did you feel very confident and sure that you could deal with your illness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508017","Feel Upset, Worried, or Depressed","C126917","A question about an individual feeling upset, worried, or depressed.","Feel Upset, Worried, or Depressed | How much of the time did you feel upset, worried, or depressed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508020","Feel in Complete Control of Breathing Problems","C126918","A question about an individual feeling they had complete control of their breathing problems.","Feel in Complete Control of Breathing Problems | How often did you feel you had complete control of your breathing problems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508014","Feel Relaxed and Free of Tension","C126919","A question about an individual feeling relaxed and free of tension.","Feel Relaxed and Free of Tension | How much of the time did you feel relaxed and free of tension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508013","Feel Low in Energy","C126920","A question about whether an individual feels or felt low in energy.","Feel Low in Energy Question | Do you ever feel too tired to play | Feel Low in Energy | Feel Low in Energy | Have Low Energy | How often have you felt low in energy | I have low energy | Low Energy | Low energy level",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508008","Feel Discouraged or Down in Dumps","C126921","A question about an individual feeling discouraged or down in the dumps.","Feel Discouraged or Down in Dumps | How often have you felt discouraged or down in the dumps",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508019","Feel Worn Out or Sluggish","C126922","A question about an individual feeling worn out or sluggish.","Feel Worn Out or Sluggish | Feel Sluggish | How often have you felt worn out or sluggish | I feel sluggish",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508227","Happy, Satisfied, or Pleased with Personal Life","C126923","A question about an individual feeling happy, satisfied, or pleased with their personal life.","Happy, Satisfied, or Pleased with Personal Life | How happy, satisfied, or pleased have you been with your personal life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508016","Feel Upset or Scared When Having Difficulty Getting Breath","C126924","A question about an individual feeling upset or scared when they had difficulty getting their breath.","Feel Upset or Scared When Having Difficulty Getting Breath | How often did you feel upset or scared when you had difficulty getting your breath",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508015","Feel Restless, Tense, or Uptight","C126925","A question about an individual feeling restless, tense, or uptight.","Feel Restless, Tense, or Uptight | How often have you felt restless, tense, or uptight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508004","Extremely Short of Breath","C126926","A response indicating that an individual is or was extremely short of breath.","Extremely Short of Breath | Extremely short of breath",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508219","Very Short of Breath","C126927","A response indicating that an individual is or was very short of breath.","Very Short of Breath | Very short of breath",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508071","Quite a Bit Short of Breath","C126928","A response indicating that an individual is or was quite a bit short of breath.","Quite a Bit Short of Breath | Quite a bit short of breath",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508083","Some Shortness of Breath","C126929","A response indicating that an individual experiences or experienced some shortness of breath.","Some Shortness of Breath | Some shortness of breath",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507960","A Little Short of Breath","C126930","A response indicating that an individual is or was a little short of breath.","A Little Short of Breath | A Little Shortness of Breath | A little shortness of breath",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508183","Not at All Short of Breath","C126932","A response indicating that an individual is or was not at all short of breath.","Not at All Short of Breath | Not at all short of breath",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508005","Extremely Tired","C126933","A response indicating that an individual is or was extremely tired.","Extremely Tired | Extremely tired",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508220","Very Tired","C126934","A response indicating that an individual is or was very tired.","Very Tired | Very tired",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508069","Quite a Bit of Tiredness","C126935","A response indicating that an individual is or was quite a bit of tired.","Quite a Bit of Tiredness | Quite a Bit Tired | Quite a bit of tiredness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508234","Moderately Tired","C126936","A response indicating that an individual is or was moderately tired.","Moderately Tired | Moderately tired",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508085","Somewhat Tired","C126937","A response indicating that an individual is or was somewhat tired.","Somewhat Tired | Somewhat tired",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507961","A Little Tired","C126938","A response indicating that an individual is or was a little tired.","A Little Tired | A little tired",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508184","Not at All Tired","C126939","A response indicating that an individual is or was not at all tired.","Not at All Tired | Not at all tired",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508181","No Energy at All","C126940","A response indicating that an individual has or had no energy at all.","No Energy at All | No energy at all",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507959","A Little Energy","C126941","A response indicating that an individual has or had a little energy.","A Little Energy | A little energy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508082","Some Energy","C126942","A response indicating that an individual has or had some energy.","Some Energy | Some energy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508233","Moderately Energetic","C126943","A response indicating that an individual is or was moderately energetic.","Moderately Energetic | Moderately energetic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508070","Quite a Bit of Energy","C126944","A response indicating that an individual has or had quite a bit of energy.","Quite a Bit of Energy | Quite a bit of energy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508218","Very Energetic","C126945","A response indicating that an individual is or was very energetic.","Very Energetic | Very energetic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508084","Somewhat Dissatisfied, Unhappy","C126947","A response indicating that an individual is or has been somewhat dissatisfied or unhappy.","Somewhat Dissatisfied, Unhappy | Somewhat dissatisfied, unhappy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507989","Happy Most of the Time","C126949","A response indicating that an individual is or has been happy most of the time.","Happy Most of the Time | Happy most of the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508048","Past 2 Weeks","C126890","A period of time consisting of the 14 days before the present.","Past 2 Weeks | Last 2 Weeks | Last 2 weeks | Last Two Weeks | Past Two Weeks",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508211","Sorted Cells","C126974","Cells separated and collected from a heterogeneous population based on physical, phenotypic, biochemical, and/or molecular properties, regardless of technique.","Sorted Cells | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508209","Smoked a Cigarette Today","C127026","A response indicating that an individual smoked at least one puff of a cigarette today.","Smoked a Cigarette Today | I smoked a cigarette today (at least one puff)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508027","Last Smoked a Cigarette Between One and Seven Days Ago","C127027","A response indicating that it has been between one and seven days since an individual smoked a cigarette.","Last Smoked a Cigarette Between One and Seven Days Ago | 1-7 days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508028","Last Smoked a Cigarette Less than One Month Ago","C127028","A response indicating that it has been less than one month since an individual smoked a cigarette.","Last Smoked a Cigarette Less than One Month Ago | Less than 1 month",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508248","Last Smoked a Cigarette Less than One Year Ago","C127029","A response indicating that it has been less than one year since an individual smoked a cigarette.","Last Smoked a Cigarette Less than One Year Ago | Less than 1 year",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508029","Last Smoked a Cigarette More than One Year Ago","C127030","A response indicating that it has been more than one year since an individual smoked a cigarette.","Last Smoked a Cigarette More than One Year Ago | More than 1 year",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508124","Don't Know or Remember When Last Smoked a Cigarette","C127031","A response indicating that an individual doesn't know and/or remember how long it has been since they last smoked a cigarette.","Don't Know or Remember When Last Smoked a Cigarette | Don't know/don't remember",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508080","Smoked a Cigarette Every Day","C127032","A response indicating that an individual smoked a cigarette every day.","Smoked a Cigarette Every Day | Smoked every day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508081","Smoked a Cigarette Some Days","C127033","A response indicating that an individual smoked a cigarette some days.","Smoked a Cigarette Some Days | Smoked some days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508122","Did Not Smoke at All","C127034","A response indicating that an individual didn't smoke a cigarette at all.","Did Not Smoke at All | Didn't smoke at all",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508153","Don't Know or Not Sure When Smoked a Cigarette","C127035","A response indicating that an individual doesn't know or is not sure whether they smoked a cigarette.","Don't Know or Not Sure When Smoked a Cigarette | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508182","Have Not Smoked Since Diagnosis","C127036","A response indicating that an individual has not smoked since they have been diagnosed with cancer.","Have Not Smoked Since Diagnosis | Not applicable; I have not smoked cigarettes since my diagnosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508228","Have Not Been Diagnosed","C127037","A response indicating that an individual has not been diagnosed with cancer.","Have Not Been Diagnosed | I have not been diagnosed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508230","Have Not Had Cancer Surgery","C127038","A response indicating that an individual has not had surgery for cancer.","Have Not Had Cancer Surgery | I have not had cancer surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508231","Have Not Received Treatment","C127039","A response indicating that an individual has not been treated for cancer.","Have Not Received Treatment | I have not received treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508229","Have Not Completed Treatment","C127040","A response indicating that an individual has not completed treatment for cancer.","Have Not Completed Treatment | I have not completed treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508022","First Visit to This Clinic","C127041","A response indicating that this is an individual's first visit to the clinic.","First Visit to This Clinic | This is my first visit to this clinic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508094","Stayed Off Cigarettes Entire Time Since Diagnosis","C127042","A response indicating that an individual stayed off cigarettes the entire time since their diagnosis.","Stayed Off Cigarettes Entire Time Since Diagnosis | Stayed off cigarettes entire time since diagnosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508095","Stayed Off Cigarettes Less than One Day Since Diagnosis","C127043","A response indicating that an individual stayed off cigarettes less than one day since their diagnosis.","Stayed Off Cigarettes Less than One Day Since Diagnosis | Stayed off cigarettes less than one day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508096","Stayed Off Cigarettes Less than One Month Since Diagnosis","C127044","A response indicating that an individual stayed off cigarettes less than one month since their diagnosis.","Stayed Off Cigarettes Less than One Month Since Diagnosis | Less than 1 month",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508097","Stayed Off Cigarettes Less than One Year Since Diagnosis","C127045","A response indicating that an individual stayed off cigarettes less than one year since their diagnosis.","Stayed Off Cigarettes Less than One Year Since Diagnosis | Less than 1 year",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508098","Stayed Off Cigarettes More than One Year Since Diagnosis","C127046","A response indicating that an individual stayed off cigarettes more than one year since their diagnosis.","Stayed Off Cigarettes More than One Year Since Diagnosis | More than 1 year",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508123","Don't Know or Remember if Stayed Off Cigarettes Since Diagnosis","C127047","A response indicating that an individual doesn't know or remember if they stayed off cigarettes since their diagnosis.","Don't Know or Remember if Stayed Off Cigarettes Since Diagnosis | Don't know/Don't remember",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508021","Filtered Cigar","C127051","A smaller cigar that is combined with a filter intended to reduce the amount of smoke, tar, and fine particles inhaled.","Filtered Cigar | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508210","Snus","C127052","A moist powder tobacco product that is used by placing it under the upper lip for extended periods.","Snus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508045","Paan with Tobacco","C127053","A combination of betel leaf, areca nut, and tobacco. It is chewed for its stimulant and psychoactive effects.","Paan with Tobacco | Paan Tobacco | Paan with tobacco",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507969","Gutka","C127054","A combination of crushed areca nut, tobacco, catechu, paraffin wax, slaked lime, and sweet or savory flavorings. It is placed between the cheek and gum and is a mild stimulant.","Gutka | Gutka Tobacco",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508104","Zarda","C127055","A combination of tobacco, lime, spices, vegetable dyes, and areca nut. It is typically chewed for its stimulant effects.","Zarda | Zarda Tobacco",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508026","Khaini","C127056","A combination of tobacco and slaked lime paste with or without areca nut. It is placed between the cheek and gum and is a mild stimulant.","Khaini | Khaini Tobacco",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031322","Pharmacy","C114863","A commercial or private facility where medications are prepared, dispensed and/or sold.","Pharmacy | Pharmacy/Drug Store",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508178","Invalid Reason","C127109","Why something is not recognized or acceptable for a purpose.","Invalid Reason | Reason Invalid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508089","Drug Enforcement Administration","C127110","The federal law enforcement agency, under the U.S. Department of Justice, tasked with enforcing the controlled substances laws and regulations of the United States.","Drug Enforcement Administration | DEA | United States Drug Enforcement Administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508155","Drug Refills","C127111","The number of refills permitted for a prescribed medication.","Drug Refills | Number of Refills",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827995","Software Version","C111093","A form or variant of software; one of a sequence of copies of a software program, each incorporating new modifications.","Software Version | SFTWRVER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507995","Cancer Patient Tobacco Use Questionnaire","C127024","A questionnaire developed for the baseline and longitudinal assessment of tobacco use in the cancer setting. Domains include cigarette smoking history and current use, use relative to cancer diagnosis and treatment, other tobacco product use, cessation, and second-hand exposure.","Cancer Patient Tobacco Use Questionnaire | C-TUQ | Cancer Patient Tobacco Use Questionnaire (C-TUQ)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507990","Smoked at Least 100 Cigarettes in Entire Life","C127059","A question about whether an individual has smoked at least 100 cigarettes in their entire lifetime.","Smoked at Least 100 Cigarettes in Entire Life | Have you smoked at least 100 cigarettes (5 packs=100 cigarettes) in your entire life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508172","Enter age at which the participant started smoking","C127060","A question about how old an individual was when they first smoked a cigarette.","Age When First Smoked a Cigarette | AGESTSMK | Age Started Smoking | Enter age at which the participant started smoking | How Old When First Smoked a Cigarette | How old were you when you first smoked a cigarette (even one or two puffs)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508171","How Old When First Began Smoking Cigarettes Regularly","C127061","A question about how old an individual was when they first began smoking cigarettes regularly.","How Old When First Began Smoking Cigarettes Regularly | How old were you when you first began smoking cigarettes regularly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508116","Never Smoked Cigarettes Regularly","C127062","A response indicating that an individual never smoked cigarettes regularly.","Never Smoked Cigarettes Regularly | Check here if you have never smoked cigarettes regularly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508087","Total Years Have Smoked Cigarettes","C127063","A question about the total years an individual smoked or currently smokes cigarettes.","Total Years Have Smoked Cigarettes | How many total years have you smoked (or did you smoke) cigarettes | Total Years of Cigarette Smoking | years smoked | years_smoked",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508062","Average Number Cigarettes Smoked a Day","C127064","A question about the average number of cigarettes an individual smoked or smokes in one day.","Average Number Cigarettes Smoked a Day | On average when you have smoked, about how many cigarettes do you (or did you) smoke a day | cigarettes per day | cigarettes_per_day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508169","How Long Since Last Cigarette","C127065","A question about how long it has been since an individual last smoked a cigarette.","How Long Since Last Cigarette | How Long Since Last Smoked Cigarette | How long has it been since you last smoked a cigarette (even one or two puffs)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508185","Number of Days Since Last Cigarette","C127066","A question about the number of days since an individual last smoked a cigarette.","Number of Days Since Last Cigarette | Number of days since last cigarette",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508187","Number of Months Since Last Cigarette","C127068","A question about the number of months since an individual last smoked a cigarette.","Number of Months Since Last Cigarette | Number of months since last cigarette",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508191","Number of Years Since Last Cigarette","C127069","A question about the number of years since an individual last smoked a cigarette.","Number of Years Since Last Cigarette | Number of years since last cigarette",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508079","Smoked Cigarettes During Year Before First Diagnosed with Cancer","C127070","A question about whether an individual smoked cigarettes the year before they were first told they had cancer.","Smoked Cigarettes During Year Before First Diagnosed with Cancer | Smoked Cigarettes Year Before First Told You Had Cancer | The year before you were first told you had cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508206","Smoked Cigarettes After Diagnosis and Before Treatment Start","C127073","A question about whether an individual smoked cigarettes after diagnosis and before treatment started.","Smoked Cigarettes After Diagnosis and Before Treatment Start | After diagnosis, and before treatment started",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508208","Smoked Cigarettes From Two Days Before Last Cancer Surgery to Two Days After","C127074","A question about whether an individual smoked cigarettes from two days before to two days after their last cancer surgery.","Smoked Cigarettes From Two Days Before Last Cancer Surgery to Two Days After | From 2 days before your last cancer surgery to 2 days after",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508126","Smoked Cigarettes During the Course of Treatment","C127075","A question about whether an individual smoked cigarettes during the course of treatment.","Smoked Cigarettes During the Course of Treatment | During the course of treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508207","Smoked Cigarettes After Treatment End","C127076","A question about whether an individual smoked cigarettes after treatment ended.","Smoked Cigarettes After Treatment End | After treatment ended",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508075","Smoked Cigarettes Since Last Visit to This Clinic","C127078","A question about whether an individual smoked cigarettes since their last visit to this clinic.","Smoked Cigarettes Since Last Visit to This Clinic | Since your last visit to this clinic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508073","Products Used Regularly Since Cancer Diagnosis","C127079","A question about the tobacco-containing products an individual has used regularly since they were first told they had cancer.","Products Used Regularly Since Cancer Diagnosis | Products Used Regularly Since First Told You Had Cancer | Since you were first told you had cancer, which of the following products have you used regularly | Tobacco Products Used Regularly Since Cancer Diagnosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508065","Other Products Used Regularly Since Cancer Diagnosis","C127080","A question about the use of tobacco-containing products not previously mentioned or specified that an individual has used regularly since they were first told they had cancer.","Other Products Used Regularly Since Cancer Diagnosis | Other Products Used Regularly Since First Told You Had Cancer | Other Tobacco Products Used Regularly Since Cancer Diagnosis | What other product have you used regularly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508033","Longest Time Stayed off Cigarettes Since Cancer Diagnosis","C127081","A question about the longest time an individual has stayed off cigarettes since they were first told they had cancer.","Longest Time Stayed off Cigarettes Since Cancer Diagnosis | Longest Time Stayed off Cigarettes Since First Told You Had Cancer | Since you were first told you had cancer, what was the longest time you stayed (or have stayed) off cigarettes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508186","Number of Days Stayed Off Cigarettes","C127082","A question about the number of days an individual stayed off cigarettes.","Number of Days Stayed Off Cigarettes | Number of days stayed off cigarettes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508190","Number of Weeks Stayed Off Cigarettes","C127083","A question about the number of weeks an individual stayed off cigarettes.","Number of Weeks Stayed Off Cigarettes | Number of weeks stayed off cigarettes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508188","Number of Months Stayed Off Cigarettes","C127084","A question about the number of months an individual stayed off cigarettes.","Number of Months Stayed Off Cigarettes | Number of months stayed off cigarettes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508192","Number of Years Stayed Off Cigarettes","C127085","A question about the number of years an individual stayed off cigarettes.","Number of Years Stayed Off Cigarettes | Number of years stayed off cigarettes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508162","Smoked Any Cigarettes Past 30 Days","C127086","A question about whether an individual has smoked any cigarettes in the past 30 days.","Smoked Any Cigarettes Past 30 Days | In the past 30 days, have you smoked any cigarettes, even one or two puffs | Past 30 Days Smoked Any Cigarettes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508163","Number of Days Smoked Cigarettes Past 30 Days","C127087","A question about how many days an individual has smoked in the past 30 days.","Number of Days Smoked Cigarettes Past 30 Days | In the past 30 days, on how many days did you smoke cigarettes | Past 30 Days Number of Days Smoked Cigarettes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508074","Products Used to Quit or Stay Off Smoking Cigarettes Since Diagnosis","C127088","A question about the products an individual has used to quit or stay off smoking cigarettes since they were first told they had cancer.","Products Used to Quit or Stay Off Smoking Cigarettes Since Diagnosis | Products Used to Quit or Stay Off Smoking Cigarettes Since First Told You Had Cancer | Since you were first told you had cancer, which of the following products have you used to quit (or to stay off) smoking cigarettes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508066","Other Products Used to Quit or Stay Off Smoking Cigarettes Since Diagnosis","C127089","A question about the use of products not previously mentioned or specified that an individual has used since they were first told they had cancer.","Other Products Used to Quit or Stay Off Smoking Cigarettes Since Diagnosis | Other Products Used to Quit or Stay Off Smoking Cigarettes Since First Told You Had Cancer | What other products have you used to quit (or to stay off) smoking cigarettes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508072","Assistance Used to Quit or Stay Off Smoking Cigarettes Since Diagnosis","C127090","A question about what assistance an individual has used to quit or stay off smoking cigarettes since they were first told they first had cancer.","Assistance Used to Quit or Stay Off Smoking Cigarettes Since Diagnosis | Assistance Used to Quit or Stay Off Smoking Cigarettes Since First Told You Had Cancer | Since you were first told you had cancer, what assistance have you used to quit (or to stay off) smoking cigarettes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508063","Other Assistance Used to Quit or Stay Off Smoking Cigarettes Since Diagnosis","C127091","A question about the use of assistance not previously mentioned or specified that an individual has used to quit or stay off smoking cigarettes since they were first told they had cancer.","Other Assistance Used to Quit or Stay Off Smoking Cigarettes Since Diagnosis | Other Assistance Used to Quit or Stay Off Smoking Cigarettes Since First Told You Had Cancer | What other assistance have you used to quit (or to stay off) smoking cigarettes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507991","Cancer Doctor Advised to Quit Smoking Cigarettes","C127092","A question about whether an individual's cancer doctor has advised them to quit smoking cigarettes.","Cancer Doctor Advised to Quit Smoking Cigarettes | Cancer Doctor Advised Quit Cigarette Smoking | Have your cancer doctors advised you to quit smoking cigarettes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508161","Trying to Quit or Stay Off Smoking Cigarettes Past 30 Days","C127093","A question about whether an individual has tried or has been trying to quit or stay off smoking cigarettes.","Trying to Quit or Stay Off Smoking Cigarettes Past 30 Days | In the past 30 days, have you been trying to quit (or trying to stay off) smoking cigarettes | Past 30 Days Trying to Quit or Stay Off Smoking Cigarettes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508165","Products Used to Quit or Stay Off Smoking Cigarettes Past 30 Days","C127094","A question about the products an individual used in the past 30 days to quit or stay off smoking cigarettes.","Products Used to Quit or Stay Off Smoking Cigarettes Past 30 Days | In the past 30 days, what, if any, products have you used to quit (or to stay off) smoking cigarettes | Past 30 Days Products Used to Quit or Stay Off Smoking Cigarettes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508200","Other Products Used to Quit or Stay Off Smoking Cigarettes Past 30 Days","C127095","A question about products not previously mentioned or specified that an individual used in the past 30 days to quit or stay off smoking cigarettes.","Other Products Used to Quit or Stay Off Smoking Cigarettes Past 30 Days | Past 30 Days Other Products Used to Quit or Stay Off Smoking Cigarettes | What other products have you used to quit (or to stay off) smoking cigarettes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508164","Assistance Used to Quit or Stay Off Smoking Cigarettes Past 30 Days","C127096","A question about the assistance an individual used in the past 30 days to quit or stay off smoking cigarettes.","Assistance Used to Quit or Stay Off Smoking Cigarettes Past 30 Days | In the past 30 days, what assistance have you used to quit (or to stay off) smoking cigarettes | Past 30 Days Assistance Used to Quit or Stay Off Smoking Cigarettes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508199","Other Assistance Used to Quit or Stay Off Smoking Cigarettes Past 30 Days","C127097","A question about assistance not previously mentioned or specified that an individual used in the past 30 days to quit or stay off smoking cigarettes.","Other Assistance Used to Quit or Stay Off Smoking Cigarettes Past 30 Days | Past 30 Days Other Assistance Used to Quit or Stay Off Smoking Cigarettes | What other assistance have you used to quit (or to stay off) smoking cigarettes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508193","Smoking Products Ever Used Regularly","C127098","A question about the smoking products an individual has ever used regularly.","Smoking Products Ever Used Regularly | Products Ever Used Regularly | Which of the following products have you ever used regularly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508064","Other Smoking Products Ever Used Regularly","C127099","A question about smoking products not previously mentioned or specified that an individual has ever used regularly.","Other Smoking Products Ever Used Regularly | Other Products Ever Used Regularly | Which other products have you ever used regularly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508166","Smoking Products Used Past 30 Days","C127100","A question about which smoking products an individual has used in the past 30 days.","Smoking Products Used Past 30 Days | In the past 30 days, which of the following products have you used | Past 30 Days Smoking Products Used",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508167","Other Smoking Products Used Past 30 Days","C127101","A question about which smoking products not previously mentioned or specified that an individual has used in the past 30 days.","Other Smoking Products Used Past 30 Days | In the past 30 days, which other products have you used | Past 30 Days Other Smoking Products Used",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508110","Currently Living with Smoker","C127102","A question about whether an individual is currently living with a smoker.","Currently Living with Smoker | Are you currently living with a smoker | Living with Smoker",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508030","Lived in Place Where Other People Smoked Cigarettes Indoors Past 30 Days","C127103","A question about whether an individual has lived in a place where other people smoked cigarettes indoors in the past 30 days.","Lived in Place Where Other People Smoked Cigarettes Indoors Past 30 Days | Lived in a place where other people smoked cigarettes indoors | Past 30 Days Lived in Place Where Other People Smoked Cigarettes Indoors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508221","Worked in Place Where Other People Smoked Cigarettes Indoors Past 30 Days","C127104","A question about whether an individual has worked in a place where other people smoked cigarettes indoors in the past 30 days.","Worked in Place Where Other People Smoked Cigarettes Indoors Past 30 Days | Past 30 Days Worked in Place Where Other People Smoked Cigarettes Indoors | Worked in a place where other people smoked cigarettes indoors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508002","Ever Lived in Place Where Other People Smoked Cigarettes Indoors","C127105","A question about whether a person, over all their childhood and adult years, has ever lived in a place where other people smoked cigarettes indoors.","Ever Lived in Place Where Other People Smoked Cigarettes Indoors | Childhood or Adult Life Ever Lived in Place Where Other People Smoked Cigarettes Indoors | Thinking of all your childhood and adult years, have you ever lived in a place where other people smoked cigarettes indoors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508086","Total Years Lived in Place Where Other People Smoked Cigarettes Indoors","C127106","A question about the total number of years a person, over all their childhood and adult years, has ever lived in a place where other people smoked cigarettes indoors.","Total Years Lived in Place Where Other People Smoked Cigarettes Indoors | In total, for about how many years | Total Years Lived in Place Where Other People Smoked Cigarettes Indoors Childhood or Adult Life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508003","Ever Worked in Place Where Other People Smoked Cigarettes Indoors","C127107","A question about whether a person, over all the years they have worked, has ever worked in a place where other people smoked cigarettes indoors.","Ever Worked in Place Where Other People Smoked Cigarettes Indoors | All Work Years Have Ever Worked in Place Where Other People Smoked Cigarettes Indoors | Thinking of all the years you have worked, have you ever worked in a place where other people smoked cigarettes indoors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508168","Total Years Worked in Place Where Other People Smoked Cigarettes Indoors","C127108","A question about the total number of years a person, over all the years they have worked, has ever worked in a place where other people smoked cigarettes indoors.","Total Years Worked in Place Where Other People Smoked Cigarettes Indoors | All Work Years How Many Total Years Worked in Place Where Other People Smoked Cigarettes Indoors | In total, for about how many years",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0265385","Autosomal Dominant Disorder","C98829","An inherited disorder that manifests when one copy of a mutated gene is present.","Autosomal Dominant Disorder | ",,,,,,,,,,,,,,,"4006473","Autosomal dominant hereditary disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882168","Image Orientation Incorrect","C62887","Problem associated with an incorrect image orientation on the device display.","Image Orientation Incorrect | Orientation Incorrect Medical Device Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881186","Incorrect Programming Calculation Associated with Medical Device","C63081","No Value Exists","Incorrect Programming Calculation Associated with Medical Device | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826184","12 Months or Longer","C82439","No Value Exists","12 Months or Longer | 12 MONTHS OR LONGER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0935952","Oncophage","C2432","An autologous cancer vaccine derived from tumor-specific gp96 heat shock proteins.  Heat shock proteins chaperone peptides through the endoplasmic reticulum, are key regulators of dendritic cell maturation, migration and antigen processing, and are involved in T-cell activation. (NCI04)","Vitespen | Autologous gp96 Heat Shock Protein Peptide Complex Vaccine | HSP gp96-Peptide Complex | HSPPC-96 | Heat Shock Protein Peptide Complex-96 | Oncophage | Recombinant Human Tumor Rejection Antigen 1 | VITESPEN | gp96 HSP-Peptide Complex | gp96 HSP-peptide complex | gp96 Heat Shock Protein-Peptide Complex | gp96 heat shock protein-peptide complex vaccine | vitespen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509623","Medical Research Council Breathlessness Score","C127143","A self-administered questionnaire designed to rate an individual's respiratory disability from none to almost complete incapacity.","Medical Research Council Breathlessness Score | MRC Dyspnea Scale | MRC-BS | Medical Research Council Breathlessness Score (MRC)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509674","Troubled By Breathlessness Other Than on Strenuous Exertion","C127144","A question about whether an individual is or was ever troubled by breathlessness other than during strenuous exertion.","Troubled By Breathlessness Other Than on Strenuous Exertion | Are you ever troubled by breathlessness except on strenuous exertion | Troubled By Breathlessness Except on Strenuous Exertion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509554","Short of Breath When Hurrying on Level Ground or Walking Up a Slight Hill","C127145","A question about whether an individual is or was short of breath when hurrying on level ground or walking up a slight hill.","Short of Breath When Hurrying on Level Ground or Walking Up a Slight Hill Question | Are you short of breath when hurrying on the level or walking up a slight hill | Short of Breath When Hurrying on Level Ground or Walking Up a Slight Hill | Short of Breath When Hurrying on Level Ground or Walking Up a Slight Hill",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509450","Have to Walk Slower Than Most People on Level Ground","C127146","A question about whether an individual has or had to walk slower than most people on level ground.","Have to Walk Slower Than Most People on Level Ground Question | Do you have to walk slower than most people on the level | Have to Walk Slower Than Most People on Level Ground | Have to Walk Slower Than Most People on Level Ground",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509448","Have to Stop After Walking a Mile, or After One Quarter Hour, on Level Ground at Own Pace","C127147","A question about whether an individual has or had to stop after walking a mile, or after a quarter of an hour, on level ground at their own pace.","Have to Stop After Walking a Mile, or After One Quarter Hour, on Level Ground at Own Pace Question | Do you have to stop after a mile or so (or after one quarter hour) on the level at your own pace | Have to Stop After Walking a Mile, or After One Quarter Hour, on Level Ground at Own Pace | Have to Stop After Walking a Mile, or After One Quarter Hour, on Level Ground at Own Pace",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509449","Have to Stop for Breath After Walking About 100 Yards on Level Ground","C127148","A question about whether an individual has or had to stop for breath after walking about 100 yards, or after a few minutes, on level ground.","Have to Stop for Breath After Walking About 100 Yards on Level Ground Question | Do you have to stop for breath after walking about 100 yds. (or after a few minutes) on the level | Have to Stop for Breath After Walking About 100 Yards on Level Ground | Have to Stop for Breath After Walking About 100 Yards on Level Ground",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509778","Too Breathless to Leave the House or Breathless After Undressing","C127149","A question about whether an individual is or was too breathless to leave the house, or breathless after undressing.","Too Breathless to Leave the House or Breathless After Undressing | Are you too breathless to leave the house, or breathless after undressing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201968","Cortisol Measurement","C74781","The determination of the amount of cortisol present in a sample.","Cortisol Measurement | CORTISOL | Cortisol | Cortisol Level | Cortisol Level Measurement | Total Cortisol",,,,,,,,,,,,,,,"4265057","Cortisol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508651","4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol Glucuronide","C127128","A non-carcinogenic and detoxified glucuronidated form of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (nicotine-derived nitrosamine alcohol; NNAL), which is the primary metabolite of the potentially carcinogenic nitrosamine 4-methylnitrosamino-1,3-pyridyl-1-butanone (nicotine-derived nitrosamine ketone; NNK). NNAL-gluconuronide is detected in the urine of subjects exposed to tobacco products.","4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol Glucuronide | 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-(Beta-D-Glucopyranuronosyl)Butanol | 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol Beta-D-Glucuronide | 4-(Methylnitrosoamino)-1-(3-Pyridyl)-1-Butanol Beta-D-Glucuronide | Glucuronidated-NNAL | NNAL-Gluc | NNAL-Glucuronide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417092","ME1 Gene","C127139","This gene plays a role in the metabolism of malate, pyruvate and oxaloacetate.","ME1 Gene | ME1 | Malic Enzyme 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508909","MET Exon 14 Mutation","C127129","A molecular genetic abnormality indicating the presence of a mutation in exon 14 of the MET gene located in the vicinity of 7q31.","MET Exon 14 Mutation | HGFR Exon 14 Mutation | MET Proto-Oncogene, Receptor Tyrosine Kinase Exon 14 Mutation | Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Exon 14 Mutation | c-Met Exon 14 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509273","MicroRNA 205-5p","C127135","A 22 ribonucleotide sequence that is a final product of the processing of MIR205 pre-miRNA. This oligonucleotide may be involved in the negative regulation of gene expression.","MicroRNA 205-5p | MIR205-5p | Micro RNA 205-5p | hsa-miR-205 | hsa-miR-205-5p | miR-205-5p",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3180006","MIRN335 microRNA, human","C127134","A 23 ribonucleotide sequence that is a final product of the processing of MIR335 pre-miRNA. This oligonucleotide may be involved in the negative regulation of gene expression.","MicroRNA 335-5p | MIR335-5p | Micro RNA 335-5p | hsa-miR-335 | hsa-miR-335-5p | miR-335-5p",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714086","MicroRNA 574-3p, Human","C127133","A 22 ribonucleotide sequence that is a final product of the processing of the human MIR574 pre-miRNA. This oligonucleotide may be involved in the negative regulation of gene expression.","MicroRNA 574-3p | MIR574-3p | Micro RNA 574-3p | hsa-miR-574-3p | hsa-mir-574 | miR-574-3p",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419255","RAMP2 Gene","C127150","This gene is involved in adrenomedullin binding and signaling.","RAMP2 Gene | RAMP2 | Receptor Activity Modifying Protein 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509433","DNA Repair Capacity","C127142","A cellular metabolic marker that may indicate an increased risk for neoplastic disease that is based on a semi-quantitative determination of the ability of cells in a biological sample to maintain the integrity of its genome.","DNA Repair Capacity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509730","Continent Urinary Diversion","C127175","A surgical procedure in which segments of the both small and large intestine are incorporated into the urinary tract to create a pouch that collects the urine.","Continent Urinary Diversion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509728","Continent Catheterizable Diversion","C127176","Continent urinary diversion procedure in which the surgically-created pouch requires a catheter to be inserted to drain the urine.","Continent Catheterizable Diversion | Continent Non-Orthotopic Catheterizable Diversion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509729","Continent Orthotopic Diversion","C127177","Continent urinary diversion procedure in which the ureters are connected to a surgically-created neo-bladder that is also connected to the urethra so that the patient can empty the bladder normally.","Continent Orthotopic Diversion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984220","Bidi","C91399","An Indian cigarette consisting of tobacco wrapped in a tendu leaf.","Bidi | Beedi | Beedie | bidi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984221","Kretek","C91400","An Indonesian cigarette made of tobacco and cloves.","Kretek | kretek",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508976","Stayed Off Cigarettes Between One and Seven Days","C127244","A response indicating that an individual stayed off cigarettes between one and seven days since their diagnosis.","Stayed Off Cigarettes Between One and Seven Days | 1-7 days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509791","Used Individual or Group Counseling to Quit Cigarette Smoking","C127245","A response indicating that an individual used individual or group counseling to quit smoking cigarettes.","Used Individual or Group Counseling to Quit Cigarette Smoking | Individual or group counseling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509596","Used Telephone Help Line or Quit Cigarette Smoking Line","C127246","A response indicating that an individual used a telephone help line or quit line to quit smoking cigarettes.","Used Telephone Help Line or Quit Cigarette Smoking Line | A telephone help line or quit line",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509021","Used Quit Cigarette Smoking Books and/or Pamphlets","C127247","A response indicating that an individual used books and/or pamphlets to quit smoking cigarettes.","Used Quit Cigarette Smoking Books and/or Pamphlets | Books, pamphlets",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509810","Used Quit Cigarette Smoking Videos","C127248","A response indicating that an individual used videos to quit smoking cigarettes.","Used Quit Cigarette Smoking Videos | Videos",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509595","Used Quit Tobacco Clinic, Class, or Support Group","C127249","A response indicating that an individual used a quit tobacco clinic, class, or support group to quit smoking cigarettes.","Used Quit Tobacco Clinic, Class, or Support Group | A quit tobacco clinic, class, or support group",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509792","Used Quit Cigarette Smoking Internet or Web-Based Program","C127250","A response indicating that an individual used an internet or web-based program to quit smoking cigarettes.","Used Quit Cigarette Smoking Internet or Web-Based Program | An internet or web-based program",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509597","Used Text Message-Based Smoking Cessation Program","C127251","A response indicating that an individual used a text message-based smoking cessation program to quit smoking cigarettes.","Used Text Message-Based Smoking Cessation Program | A text-message based smoking cessation program",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509349","Used Support of Friends and Family to Quit Cigarette Smoking","C127252","A response indicating that an individual used the support of friends and family to quit smoking cigarettes.","Used Support of Friends and Family to Quit Cigarette Smoking | Support of friends and family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899033","Genetically Engineered Hematopoietic Stem Progenitor Cells","C119988","Gene modified hematopoietic stem progenitor cells (HSPCs).","Genetically Engineered Hematopoietic Stem Progenitor Cells | Genetically Engineered HSPCs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005836","Blood Substitute","C314","Any agent that is able to increase blood volume and/or increase the oxygen transport in the blood.","Blood Substitute | Artificial Blood | Blood Surrogate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517497","Gene Therapy and Vector Shared Resource","C39410","The Gene Therapy and Vector Shared Resource is dedicated to the construction and production of viral and non-viral vectors to Cancer Center faculty members for use in human preclinical and clinical, and animal gene therapy studies, supports protocol development, study strategy development, and gene therapy adverse event risk assessment.","Gene Therapy and Vector Shared Resource | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509266","Modified Barium Swallow Impairment Profile","C127178","An evidence-based, standardization of the Modified Barium Swallow Study in adults. The protocol assesses 17 critical components of swallowing and provides an objective profile of the physiologic impairment affecting adult swallowing function.","Modified Barium Swallow Impairment Profile | MBSImP | Modified Barium Swallow Impairment Profile (MBSImP)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508912","Oral Impairment During Swallowing","C127179","An assessment of an individual's oral impairment during swallowing.","Oral Impairment During Swallowing | Oral Impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509828","Impairment of Lip Closure","C127182","An observation of an individual's lip closure during swallowing.","Impairment of Lip Closure | Lip Closure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509508","No Labial Escape","C127183","A finding of no labial escape during swallowing.","No Labial Escape | No labial escape",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509476","Interlabial Escape; No Progression to Anterior Lip","C127184","A finding of interlabial escape during swallowing, but no progression to anterior lip.","Interlabial Escape; No Progression to Anterior Lip | Interlabial escape; no progression to anterior lip",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508744","Escape From Interlabial Space or Lateral Juncture; No Extension","C127185","A finding of escape from interlabial space or lateral juncture during swallowing, but no extension.","Escape From Interlabial Space or Lateral Juncture; No Extension | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508743","Escape Beyond Vermilion Border","C127186","A finding of escape beyond the vermilion border during swallowing.","Escape Beyond Vermilion Border | Beyond vermilion border",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508745","Escape Progressing to Mid-Chin","C127187","A finding of escape progressing to mid-chin during swallowing.","Escape Progressing to Mid-Chin | Escape progressing to mid-chin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508742","Escape Beyond Mid-Chin","C127188","A finding of escape beyond mid-chin during swallowing.","Escape Beyond Mid-Chin | Escape beyond mid-chin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509469","Impairment of Tongue Control During Bolus Hold","C127189","An observation of an individual's tongue control during bolus hold.","Impairment of Tongue Control During Bolus Hold | Tongue Control During Bolus Hold",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509044","Cohesive Bolus Between Tongue to Palatal Seal","C127190","A finding of cohesive bolus between tongue to palatal seal during swallowing.","Cohesive Bolus Between Tongue to Palatal Seal | Cohesive bolus between tongue to palatal seal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508746","Escape to Lateral Buccal Cavity/Floor of Mouth","C127191","A finding of escape to lateral buccal cavity/floor of mouth during swallowing.","Escape to Lateral Buccal Cavity/Floor of Mouth | Escape to lateral buccal cavity/floor of mouth (FOM)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509762","Posterior Escape of Less Than Half of Bolus","C127192","A finding of posterior escape of less than half of bolus during swallowing.","Posterior Escape of Less Than Half of Bolus | Posterior escape of less than half of bolus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509761","Posterior Escape of Greater Than Half of Bolus","C127193","A finding of posterior escape of greater than half of bolus during swallowing.","Posterior Escape of Greater Than Half of Bolus | Posterior escape of greater than half of bolus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509015","Impairment of Bolus Preparation or Mastication","C127197","An observation of an individual's bolus preparation and/or mastication prior to swallowing.","Impairment of Bolus Preparation or Mastication | Bolus Preparation/Mastication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509776","Timely and Efficient Chewing and Mashing","C127198","A finding of timely and efficient chewing and mashing prior to swallowing.","Timely and Efficient Chewing and Mashing | Timely and efficient chewing and mashing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509559","Slow Prolonged Chewing or Mashing with Complete Re-Collection","C127199","A finding of slow prolonged chewing or mashing with complete re-collection prior to swallowing.","Slow Prolonged Chewing or Mashing with Complete Re-Collection | Slow prolonged chewing/mashing with complete re-collection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509441","Disorganized Chewing or Mashing with Solid Pieces of Bolus Unchewed","C127200","A finding of disorganized chewing or mashing with solid pieces of bolus unchewed prior to swallowing.","Disorganized Chewing or Mashing with Solid Pieces of Bolus Unchewed | Disorganized chewing/mashing with solid pieces of bolus unchewed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509629","Minimal Chewing or Mashing with Majority of Bolus Unchewed","C127201","A finding of minimal chewing or mashing with majority of bolus unchewed prior to swallowing.","Minimal Chewing or Mashing with Majority of Bolus Unchewed | Minimal chewing/mashing with majority of bolus unchewed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509016","Impairment of Bolus Transport or Lingual Motion","C127202","An observation of an individual's bolus transport and lingual motion during swallowing.","Impairment of Bolus Transport or Lingual Motion | Bolus Transport/Lingual Motion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509023","Brisk Tongue Motion","C127203","A finding of brisk tongue motion during swallowing.","Brisk Tongue Motion | Brisk tongue motion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509436","Delayed Initiation of Tongue Motion","C127204","A finding of delayed initiation of tongue motion during swallowing.","Delayed Initiation of Tongue Motion | Delayed initiation of tongue motion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509560","Slowed Tongue Motion","C127205","A finding of slowed tongue motion during swallowing.","Slowed Tongue Motion | Slowed tongue motion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509310","Repetitive or Disorganized Tongue Motion","C127206","A finding of repetitive or disorganized tongue motion during swallowing.","Repetitive or Disorganized Tongue Motion | Repetitive/disorganized tongue motion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509634","Minimal to No Tongue Motion","C127207","A finding of minimal to no tongue motion during swallowing.","Minimal to No Tongue Motion | Minimal to no tongue motion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508913","Oral Residue Following Swallowing","C127208","An observation of oral residue remaining after an individual swallows.","Oral Residue Following Swallowing | Oral Residue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509594","Complete Oral Clearance","C127209","A finding of complete oral clearance after swallowing.","Complete Oral Clearance | A finding of complete oral clearance after swallowing.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509783","Trace Residue Lining Oral Structures","C127210","A finding of trace residue lining oral structures after swallowing.","Trace Residue Lining Oral Structures | Trace residue lining oral structures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509314","Residue Collection on Oral Structures","C127211","A finding of residue collection on oral structures after swallowing.","Residue Collection on Oral Structures | Residue collection on oral structures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509748","Majority of Bolus Remaining","C127212","A finding of the majority of bolus remaining after swallowing.","Majority of Bolus Remaining | Majority of bolus remaining",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509631","Minimal to No Bolus Clearance","C127213","A finding of minimal to no clearance of bolus after swallowing.","Minimal to No Bolus Clearance | Minimal to no clearance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509819","Location of Oral Residue Following Swallowing","C127214","An observation of the location of oral residue remaining after an individual swallows.","Location of Oral Residue Following Swallowing | Location",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509523","Residue on Floor of Mouth","C127215","A finding of oral residue remaining on floor of mouth after an individual swallows.","Residue on Floor of Mouth | Floor of mouth (FOM)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509305","Residue on Palate","C127216","A finding of oral residue remaining on palate after an individual swallows.","Residue on Palate | Palate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509527","Residue on Tongue","C127217","A finding of oral residue remaining on tongue after an individual swallows.","Residue on Tongue | Tongue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509524","Residue on Lateral Sulci","C127218","A finding of oral residue remaining on lateral sulci after an individual swallows.","Residue on Lateral Sulci | Lateral sulci",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509473","Initiation of Pharyngeal Swallow","C127219","An observation of an individual's initiation of pharyngeal swallow.","Initiation of Pharyngeal Swallow | Impairment of Initiation of Pharyngeal Swallow",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509017","Initiation of Pharyngeal Swallow with Bolus Head at Posterior Angle of Ramus","C127220","A finding of pharyngeal swallow initiated with bolus head at posterior angle of ramus.","Initiation of Pharyngeal Swallow with Bolus Head at Posterior Angle of Ramus | Bolus head at posterior angle of ramus (first hyoid excursion)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509020","Initiation of Pharyngeal Swallow with Bolus Head in Valleculae","C127221","A finding of pharyngeal swallow initiated with bolus head in valleculae.","Initiation of Pharyngeal Swallow with Bolus Head in Valleculae | Bolus head in valleculae",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509018","Bolus head at posterior laryngeal surface of epiglottis","C127222","A finding of pharyngeal swallow initiated with bolus head at posterior laryngeal surface of epiglottis.","Initiation of Pharyngeal Swallow with Bolus Head at Posterior Laryngeal Surface of Epiglottis | Bolus head at posterior laryngeal surface of epiglottis | Initiation of Pharyngeal Swallow with Bolus Head a Posterior Laryngeal Surface of Epiglottis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509019","Bolus head in pyriforms","C127223","A finding of pharyngeal swallow initiated with bolus head in the pyriform sinus.","Initiation of Pharyngeal Swallow with Bolus Head in Pyriform Sinus | Bolus head in pyriforms | Initiation of Pharyngeal Swallow with Bolus Head in Pyriforms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509511","No Visible Initiation of Pharyngeal Swallow at Any Location","C127224","A finding of no visible initiation of pharyngeal swallow at any location.","No Visible Initiation of Pharyngeal Swallow at Any Location | No visible initiation at any location",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508965","Pharyngeal Impairment During Swallowing","C127180","An assessment of an individual's pharyngeal impairment during swallowing.","Pharyngeal Impairment During Swallowing | Pharyngeal Impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509467","Impairment of Soft Palate Elevation","C127225","An observation of an individual's soft palate elevation during swallowing.","Impairment of Soft Palate Elevation | Soft Palate Elevation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509504","No Bolus Between Soft Palate/Pharyngeal Wall During Swallowing","C127226","A finding of no bolus between soft palate/pharyngeal wall during swallowing.","No Bolus Between Soft Palate/Pharyngeal Wall During Swallowing | No bolus between soft palate (SP)/pharyngeal wall (PW)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509781","Trace Column of Contrast or Air Between Soft Palate and Pharyngeal Wall During Swallowing","C127227","A finding of a trace column of contrast or air between soft palate and pharyngeal wall during swallowing.","Trace Column of Contrast or Air Between Soft Palate and Pharyngeal Wall During Swallowing | Trace column of contrast or air between SP and PW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508748","Escape to Nasopharynx During Swallowing","C127228","A finding of escape to nasopharynx during swallowing.","Escape to Nasopharynx During Swallowing | Escape to nasopharynx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508747","Escape to Nasal Cavity During Swallowing","C127229","A finding of escape to nasal cavity during swallowing.","Escape to Nasal Cavity During Swallowing | Escape to nasal cavity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508749","Escape to Nostril with or without Emission During Swallowing","C127230","A finding of escape to nostril with or without emission during swallowing.","Escape to Nostril with or without Emission During Swallowing | Escape to nostril with/without emission",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509465","Impairment of Laryngeal Elevation","C127231","An observation of an individual's larygeal elevation during swallowing.","Impairment of Laryngeal Elevation | Laryngeal Elevation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509724","Complete Superior Movement of Thyroid Cartilage During Swallowing","C127232","A finding of complete superior movement of thyroid cartilage with complete approximation of arytenoids to epiglottic petiole during swallowing.","Complete Superior Movement of Thyroid Cartilage During Swallowing | Complete superior movement of thyroid cartilage with complete approximation of arytenoids to epiglottic petiole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508946","Partial Superior Movement of Thyroid Cartilage During Swallowing","C127233","A finding of partial superior movement of thyroid cartilage/partial approximation of arytenoids to epiglottic petiole during swallowing.","Partial Superior Movement of Thyroid Cartilage During Swallowing | Partial superior movement of thyroid cartilage/partial approximation of arytenoids to epiglottic petiole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508947","Partial Superior Movement of Thyroid Cartilage with Minimal Approximation of Arytenoids to Epiglottic Petiole During Swallowing","C127234","A finding of minimal superior movement of thyroid cartilage with minimal approximation of arytenoids to epiglottic petiole during swallowing.","Partial Superior Movement of Thyroid Cartilage with Minimal Approximation of Arytenoids to Epiglottic Petiole During Swallowing | Partial superior movement of thyroid cartilage with minimal approximation of arytenoids to epiglottic petiole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509510","No Superior Movement of Thyroid Cartilage During Swallowing","C127235","A finding of no superior movement of thyroid cartilage during swallowing.","No Superior Movement of Thyroid Cartilage During Swallowing | No superior movement of thyroid cartilage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509462","Impairment of Anterior Hyoid Excursion","C127236","An observation of an individual's anterior hyoid excursion during swallowing.","Impairment of Anterior Hyoid Excursion | Anterior Hyoid Excursion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509715","Complete Anterior Movement of Hyoid During Swallowing","C127237","A finding of complete anterior movement of hyoid during swallowing.","Complete Anterior Movement of Hyoid During Swallowing | Complete anterior movement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508943","Partial Anterior Movement of Hyoid During Swallowing","C127238","A finding of partial anterior movement of hyoid during swallowing.","Partial Anterior Movement of Hyoid During Swallowing | Partial anterior movement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509503","No Anterior Movement of Hyoid During Swallowing","C127239","A finding of no anterior movement of hyoid during swallowing.","No Anterior Movement of Hyoid During Swallowing | No anterior movement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509463","Impairment of Epiglottic Movement","C127240","An observation of an individual's epiglottic movement during swallowing.","Impairment of Epiglottic Movement | Epiglottic Movement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509719","Complete Inversion of Epiglottis During Swallowing","C127241","A finding of complete inversion of epiglottis during swallowing.","Complete Inversion of Epiglottis During Swallowing | Complete inversion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508945","Partial Inversion of Epiglottis During Swallowing","C127242","A finding of partial inversion of epiglottis during swallowing.","Partial Inversion of Epiglottis During Swallowing | Partial inversion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509507","No Inversion of Epiglottis During Swallowing","C127243","A finding of no inversion of epiglottis during swallowing.","No Inversion of Epiglottis During Swallowing | No inversion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509466","Impairment of Laryngeal Vestibular Closure, Height of Swallow","C127253","An observation of an individual's laryngeal vestibular closing and height of swallowing.","Impairment of Laryngeal Vestibular Closure, Height of Swallow | Laryngeal Vestibular Closure - Height of Swallow",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509720","Complete Laryngeal Vestibular Closure","C127254","A finding of complete laryngeal vestibular closure; no air/contrast in laryngeal vestibule.","Complete Laryngeal Vestibular Closure | Complete; no air/contrast in laryngeal vestibule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509261","Incomplete Laryngeal Vestibular Closure","C127255","A finding of incomplete laryngeal vestibular closure; narrow column air/contrast in laryngeal vestibule.","Incomplete Laryngeal Vestibular Closure | Incomplete; narrow column air/contrast in laryngeal vestibule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509509","No Laryngeal Vestibular Closure","C127256","A finding of no laryngeal vestibular closure; wide column air/contrast in laryngeal vestibule.","No Laryngeal Vestibular Closure | None; wide column air/contrast in laryngeal vestibule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509308","Impairment of Pharyngeal Stripping Wave","C127310","An observation of an individual's pharyngeal stripping wave during swallowing.","Impairment of Pharyngeal Stripping Wave | Pharyngeal Stripping Wave",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508968","Pharyngeal Stripping Wave Present and Complete","C127311","A finding of a pharyngeal stripping wave present and complete.","Pharyngeal Stripping Wave Present and Complete | Present - complete",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508969","Pharyngeal Stripping Wave Present but Diminished","C127312","A finding of a pharyngeal stripping wave present but diminished.","Pharyngeal Stripping Wave Present but Diminished | Present - diminished",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508967","Pharyngeal Stripping Wave Absent","C127313","A finding of an absent pharyngeal stripping wave.","Pharyngeal Stripping Wave Absent | Absent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509307","Impairment of Pharyngeal Contraction","C127314","An observation of an individual's pharyngeal contraction during swallowing.","Impairment of Pharyngeal Contraction | Pharyngeal Contraction - Anterior Posterior View Only",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509801","Complete Pharyngeal Contraction","C127315","A finding of complete pharyngeal contraction during swallowing.","Complete Pharyngeal Contraction | Complete",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509260","Incomplete Pharyngeal Contraction","C127316","A finding of incomplete pharyngeal contraction during swallowing.","Incomplete Pharyngeal Contraction | Incomplete (Pseudodiverticulae)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509678","Unilateral Bulging on Pharyngeal Contraction","C127317","A finding of unilateral bulging on pharyngeal contraction during swallowing.","Unilateral Bulging on Pharyngeal Contraction | Unilateral Bulging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509370","Bilateral Bulging on Pharyngeal Contraction","C127318","A finding of bilateral bulging on pharyngeal contraction during swallowing.","Bilateral Bulging on Pharyngeal Contraction | Bilateral Bulging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509309","Impairment of Pharyngoesophageal Segment Opening","C127319","An observation of an individual's pharyngoesophageal segment opening during swallowing.","Impairment of Pharyngoesophageal Segment Opening | Pharyngoesophageal Segment Opening",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509716","Complete Distension and Complete Duration of Pharyngoesophageal Segment Opening During Swallowing","C127320","A finding of complete distension and complete duration of pharyngoesophageal segment opening during swallowing; no obstruction of flow.","Complete Distension and Complete Duration of Pharyngoesophageal Segment Opening During Swallowing | Complete distension and complete duration; no obstruction of flow",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508944","Partial Distension or Partial Duration of Pharyngoesophageal Segment Opening During Swallowing","C127321","A finding of partial distension or partial duration of pharyngoesophageal segment opening during swallowing; partial obstruction of flow.","Partial Distension or Partial Duration of Pharyngoesophageal Segment Opening During Swallowing | Partial distension/partial duration; partial obstruction of flow",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509630","Minimal Distension or Minimal Duration of Pharyngoesophageal Segment Opening During Swallowing","C127322","A finding of minimal distension or minimal duration of pharyngoesophageal segment opening during swallowing; marked obstruction of flow.","Minimal Distension or Minimal Duration of Pharyngoesophageal Segment Opening During Swallowing | Minimal distension/minimal duration; marked obstruction of flow",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509506","No Distension of Pharyngoesophageal Segment Opening During Swallowing","C127323","A finding of no distension of pharyngoesophageal segment opening during swallowing with total obstruction of flow.","No Distension of Pharyngoesophageal Segment Opening During Swallowing | No distension with total obstruction of flow",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509468","Impairment of Tongue Base Retraction","C127324","An observation of an individual's tongue base retraction during swallowing.","Impairment of Tongue Base Retraction | Tongue Base (TB) Retraction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509505","No Contrast Between Tongue Base and Posterior Pharyngeal Wall During Swallowing","C127325","A finding of no contrast between tongue base and posterior pharyngeal wall during swallowing.","No Contrast Between Tongue Base and Posterior Pharyngeal Wall During Swallowing | No contrast between TB and posterior pharyngeal wall (PW)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509782","Trace Column of Contrast or Air Between Tongue Base and Posterior Pharyngeal Wall During Swallowing","C127326","A finding of a trace column of contrast or air between tongue base and posterior pharyngeal wall during swallowing.","Trace Column of Contrast or Air Between Tongue Base and Posterior Pharyngeal Wall During Swallowing | Trace column of contrast or air between TB and PW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509290","Narrow Column of Contrast or Air Between Tongue Base and Posterior Pharyngeal Wall During Swallowing","C127327","A finding of a narrow column of contrast or air between tongue base and posterior pharyngeal wall during swallowing.","Narrow Column of Contrast or Air Between Tongue Base and Posterior Pharyngeal Wall During Swallowing | Narrow column of contrast or air between TB and PW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509368","Wide Column of Contrast or Air Between Tongue Base and Posterior Pharyngeal Wall During Swallowing","C127328","A finding of a wide column of contrast or air between tongue base and posterior pharyngeal wall during swallowing.","Wide Column of Contrast or Air Between Tongue Base and Posterior Pharyngeal Wall During Swallowing | Wide column of contrast or air between TB and PW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509512","No Visible Posterior Motion of Tongue Base During Swallowing","C127329","A finding of no visible posterior motion of tongue base during swallowing.","No Visible Posterior Motion of Tongue Base During Swallowing | No visible posterior motion of TB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508966","Pharyngeal Residue Following Swallowing","C127330","An observation of the pharyngeal residue remaining after an individual swallows.","Pharyngeal Residue Following Swallowing | Pharyngeal Residue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509723","Complete Pharyngeal Clearance Following Swallowing","C127331","A finding of complete pharyngeal clearance following swallowing.","Complete Pharyngeal Clearance Following Swallowing | Complete pharyngeal clearance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509784","Trace Residue Within or On Pharyngeal Structures Following Swallowing","C127332","A finding of trace residue within or on pharyngeal structures following swallowing.","Trace Residue Within or On Pharyngeal Structures Following Swallowing | Trace residue within or on pharyngeal structures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509046","Collection of Residue Within or On Pharyngeal Structures Following Swallowing","C127333","A finding of collection of residue within or on pharyngeal structures following swallowing.","Collection of Residue Within or On Pharyngeal Structures Following Swallowing | Collection of residue within or on pharyngeal structures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509749","Majority of Contrast Within or On Pharyngeal Structures Following Swallowing","C127334","A finding of the majority of contrast within or on pharyngeal structures following swallowing.","Majority of Contrast Within or On Pharyngeal Structures Following Swallowing | Majority of contrast within or on pharyngeal structures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509633","Minimal to No Pharyngeal Clearance Following Swallowing","C127335","A finding of minimal to no pharyngeal clearance following swallowing.","Minimal to No Pharyngeal Clearance Following Swallowing | Minimal to no pharyngeal clearance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509818","Location of Pharyngeal Residue Following Swallowing","C127336","An observation of the location of pharyngeal residue remaining after an individual swallows.","Location of Pharyngeal Residue Following Swallowing | Location",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509526","Residue on Tongue Base Following Swallowing","C127337","A finding of residue on tongue base following swallowing.","Residue on Tongue Base Following Swallowing | Tongue Base",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509358","Residue on Valleculae Following Swallowing","C127338","A finding of residue on valleculae following swallowing.","Residue on Valleculae Following Swallowing | Valleculae",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509827","Residue on Pharyngeal Wall Following Swallowing","C127339","A finding of residue on pharyngeal wall following swallowing.","Residue on Pharyngeal Wall Following Swallowing | Pharyngeal wall",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509826","Residue on Aryepiglottic Folds Following Swallowing","C127340","A finding of residue on aryepiglottic folds following swallowing.","Residue on Aryepiglottic Folds Following Swallowing | Aryepiglottic folds",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509525","Residue on Pyriform Sinuses Following Swallowing","C127341","A finding of residue on pyriform sinuses following swallowing.","Residue on Pyriform Sinuses Following Swallowing | Pyriform sinuses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509439","Diffuse Residue Following Swallowing","C127342","A finding of diffuse residue following swallowing.","Diffuse Residue Following Swallowing | Diffuse (>3 areas)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508750","Esophageal Impairment During Swallowing","C127181","An assessment of an individual's esophageal impairment during swallowing.","Esophageal Impairment During Swallowing | Esophageal Impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509464","Impairment of Esophageal Clearance Following Swallowing in Upright Position","C127343","An observation of an individual's esophageal clearance after swallowing in an upright position.","Impairment of Esophageal Clearance Following Swallowing in Upright Position | Esophageal Clearance Upright Position",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509717","Complete Esophageal Clearance Following Swallowing","C127344","A finding of complete esophageal clearance following swallowing.","Complete Esophageal Clearance Following Swallowing | Complete clearance; esophageal coating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508751","Esophageal Retention Following Swallowing","C127345","A finding of esophageal retention following swallowing.","Esophageal Retention Following Swallowing | Esophageal retention",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508752","Esophageal Retention with Retrograde Flow Below Pharyngoesophageal Segment Following Swallowing","C127346","A finding of esophageal retention with retrograde flow below the pharyngoesophageal segment.","Esophageal Retention with Retrograde Flow Below Pharyngoesophageal Segment Following Swallowing | Esophageal retention with retrograde flow below pharyngoesophageal segment (PES)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508753","Esophageal Retention with Retrograde Flow Through Pharyngoesophageal Segment Following Swallowing","C127347","A finding of esophageal retention with retrograde flow through the pharyngoesophageal segment.","Esophageal Retention with Retrograde Flow Through Pharyngoesophageal Segment Following Swallowing | Esophageal retention with retrograde flow through PES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509632","Minimal to No Esophageal Clearance Following Swallowing","C127348","A finding of minimal to no esophageal clearance.","Minimal to No Esophageal Clearance Following Swallowing | Minimal to no esophageal clearance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1853132","MIR214 Gene","C81755","This gene is involved in the regulation of gene expression and plays a role in the development of ovarian carcinoma.","MIR214 Gene | MIR214 | MicroRNA 214 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515508","9p24.1","C28630","A chromosome band present on 9p","9p24.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334136","IRAK3 Gene","C24519","This gene is involved in signal transduction and the immune response.","IRAK3 Gene | IRAK3 | Interleukin 1 Receptor Associated Kinase 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414297","EFEMP1 Gene","C106346","This gene is involved in receptor binding.","EFEMP1 Gene | EFEMP1 | EGF Containing Fibulin Like Extracellular Matrix Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549463","Active Duty Status","C114854","The status of an individual who is serving on active duty in any branch of the United States Uniformed Services.","Active Duty Status | Active Duty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889646","Reserve Status","C114857","The status of an individual who is serving in a reserve branch of any of the United States Uniformed Services.","Reserve Status | Reserve",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898156","National Guard Status","C114858","The status of an individual who is serving in the National Guard.","National Guard Status | National Guard",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510749","Academic Detailing","C20054","An approach to educating physicians in their offices.  It uses relatively inexpensive, focused educational mechanisms that can be used during short one-on-one conversations with physicians.","Academic Detailing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600563","Distance Learning","C18157","Refers to the process by which students and teachers at different sites carry out learning and instruction via cable connection, conventional phone lines, or computer networks.","Distance Learning | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0914297","Oblimersen","C1870","A phosphorothioate antisense oligonucleotide. Targeted to the initiation codon region of the bcl-2 mRNA, oblimersen inhibits bcl-2 mRNA translation, resulting in decreased expression of the bcl-2 protein, an apoptotic inhibitor expressed in some types of cancer and linked to tumor drug resistance. This agent may enhance the efficacy of standard cytotoxic chemotherapy. (NCI04)","Oblimersen | 5'-tct ccc agc gtg cgc cat | OBLIMERSEN | olbimersen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3659811","Venetoclax","C103147","An orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. Venetoclax mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of Bcl-2 proteins thereby repressing Bcl-2 activity and restoring apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in some cancers and plays an important role in the regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival. Compared to the Bcl-2 inhibitor navitoclax, this agent does not inhibit bcl-XL and does not cause bcl-XL-mediated thrombocytopenia.","Venetoclax | 4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide | ABT 199 | ABT-0199 | ABT-199 | ABT199 | GDC 0199 | GDC-0199 | GDC0199 | RG7601 | VENETOCLAX | Venclexta | Venclyxto",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL337370","Canister (medical container)","C43181","A type of can for holding a drug product.","Canister | CANISTER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707529","Cover Device","C49896","An object designed to conceal, enclose, cap, or protect something.","Cover Device | Cover | Cover Device Component",,,,,,,,,,,,,,,"45768342","Cover",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512347","Health Communication","C19355","No Value Exists","Health Communication | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038536","Subcutaneous Emphysema","C127819","The presence of air or gas in subcutaneous tissue.","Subcutaneous Emphysema | ",,,,,,,,,,,,,,,"4244061","Subcutaneous emphysema",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0339152","Orbital Emphysema","C127820","The presence of air or gas in the subcutaneous tissue of the orbit of the eye.","Orbital Emphysema | ",,,,,,,,,,,,,,,"4335886","Orbital emphysema",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003834","Arterial Insufficiency","C127821","A condition in which there is inadequate blood flow through an artery.","Arterial Insufficiency | ",,,,,,,,,,,,,,,"4109870","Arterial insufficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042485","Venous Insufficiency","C127822","A condition in which there is inadequate blood flow through a vein.","Venous Insufficiency | ",,,,,,,,,,,,,,,"321596","Peripheral venous insufficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508970","Pharyngocutaneous Fistula","C127823","An abnormal communication between the skin and the pharynx.","Pharyngocutaneous Fistula | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3532496","Orocutaneous Fistula","C127824","An abnormal communication between the skin and the oral cavity.","Orocutaneous Fistula | ",,,,,,,,,,,,,,,"43021179","Orocutaneous fistula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509785","Tracheoarterial Fistula","C127825","An erosion through the tracheal wall into an artery.","Tracheoarterial Fistula | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0178148","Decannulation","C127826","The process of removing a tracheostomy tube.","Decannulation | Tracheostomy Tube Removal",,,,,,,,,,,,,,,"4012607","Removal of tracheostomy tube",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508905","Loss of Stoma","C127827","The unplanned closing of a stoma.","Loss of Stoma | Loss of Puncture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509555","Sialocele","C127828","A fluid-filled cavity containing saliva.","Sialocele | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032268","Pneumocephalus","C127829","The presence of air or gas within the cranial cavity.","Pneumocephalus | ",,,,,,,,,,,,,,,"4032015","Pneumocephalus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL381319","Subdural","C127831","Beneath the dura mater.","Subdural | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055646","Unexpected","C127832","Something that is not planned or anticipated.","Unexpected | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509789","Unrecognized","C127833","Not identified from previous encounters or knowledge.","Unrecognized | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0228754","Marginal Mandibular Branch of the Facial Nerve","C127834","A branch of the facial nerve that innervates the musculature of the lower lip.","Marginal Mandibular Branch of the Facial Nerve | ",,,,,,,,,,,,,,,"4150225","Structure of facial nerve marginal mandibular branch",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023740","Lingual Nerve","C127835","A branch of the mandibular division of the trigeminal nerve that supplies sensory innervation to the tongue.","Lingual Nerve | ",,,,,,,,,,,,,,,"4277943","Structure of lingual nerve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1379970","Progestin","C776","Any synthetic steroid hormone that resembles the naturally occurring hormone and has progesterone-like properties.","Progestin | Progestins | Synthetic Progestagen | progestin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053459","Personal Vaporizer","C120481","A battery-powered atomizer designed to aerosolize a liquid solution for inhalation.","Personal Vaporizer | Vape Pen | Vaporizer | Vaporizer Device | Vaporizer Pen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811660","Block Unit of Distance","C111140","A unit of measure to quantify the number of rectangular areas in a city surrounded by streets that the patient has traveled.","Block Unit of Distance | BLOCKS | {BLOCKS}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273153","Drug Sample","C96974","A unit of a pharmaceutical product intended to promote the use of the drug and not intended for sale.","Drug Sample | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509714","Combs Prognostic Index","C127861","A prognostic index developed to predict the outcome of reirradiation for recurrent glioma. The index accounts for histology, patient age, and time between initial radiation and re-irradiation.","Combs Prognostic Index | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508756","Excellent Survival after Reirradiation","C127863","A score of 0 on the Combs Prognostic Index scale.","Excellent Survival after Reirradiation | Combs Score 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509048","Good Survival after Reirradiation","C127865","A score of 1 on the Combs Prognostic Index scale.","Good Survival after Reirradiation | Combs Score 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509049","Moderate Survival after Reirradiation","C127866","A score of 2 on the Combs Prognostic Index scale.","Moderate Survival after Reirradiation | Combs Score 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509050","Poor Survival after Reirradiation","C127868","A score of 3 on the Combs Prognostic Index scale.","Poor Survival after Reirradiation | Combs Score 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509051","Very Poor Survival after Reirradiation","C127870","A score of 4 on the Combs Prognostic Index scale.","Very Poor Survival after Reirradiation | Combs Score 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334889","NOTCH1 Gene","C24636","This gene is involved in intercellular signal transduction that plays a key role in development.","NOTCH1 Gene | NOTCH1 | Notch 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508755","European Treatment Outcome Study Score","C127872","A method for assessing prognosis for patients with chronic myeloid leukemia. Patients are classified as a high or low risk on the basis of the percentage of basophils in the peripheral blood and spleen size at diagnosis.","European Treatment Outcome Study Score | EUTOS | European Treatment Outcome Study (EUTOS) Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509619","Hasford Score","C127873","A method for assessing prognosis for patients with chronic myeloid leukemia. Patients are classified as a high, medium, or low risk on the basis of age, spleen size, and eosinophil, basophil, and platelet counts.","Hasford Score | Hasford",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508972","Sokal Score","C127875","A method for assessing prognosis for patients with chronic myeloid leukemia. The numerical value is calculated at diagnosis from the percentage of blast cells in peripheral blood, the platelet count, the spleen size, and the age of the patient.","Sokal Score | Sokal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509798","International Scale for BCR-ABL1 Measurement","C127877","A scale established in 2005 to standardize quantitative BCR-ABL1 measurements across tests and laboratories, so as to facilitate interlaboratory studies, patient portability, and a harmonized definition of treatment response.","International Scale for BCR-ABL1 Measurement | IS | International Scale | International Scale for Quantitative BCR-ABL1 Result Reporting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509726","Consensus PCR","C127879","Polymerase chain reaction that uses primers designed to amplify sequences from a group of genetically related targets, using specific or degenerate primer sets.","Consensus PCR | Consensus Polymerase Chain Reaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242574","Nested PCR","C127880","Polymerase chain reaction that uses two sets of primers, in two sequential runs of amplification, with the second set intended to amplify a target within the first run product.","Nested PCR | NESTED POLYMERASE CHAIN REACTION | Nested Polymerase Chain Reaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508666","Allele-Specific Oligonucleotide","C127881","An oligonucleotide designed to be specific for only one allele of a gene.","Allele-Specific Oligonucleotide | ASO | Allele-specific oligonucleotide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512343","Head and Neck Surgery","C15454","Any surgery involving a structure in the head and neck region.","Head and Neck Surgery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281980","Skin Injury","C99062","Damage to the skin.","Skin Injury | ",,,,,,,,,,,,,,,"4053826","Injury of integument",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038925","Flap graft","C127814","A unit of tissue that is transferred from one site to another while maintaining its own blood supply.","Flap | Flap Graft | Flap Transplant | Reconstructive Flap",,,,,,,,,,,,,,,"4105678","Flap",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0489903","Vascular System","C33854","The cardiovascular and lymphatic systems, collectively.","Vascular System | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0150936","Peripheral Blood Vessel","C83001","A blood vessel located in the following sites: upper extremities, lower extremities, lower abdomen, head, or neck.","Peripheral Blood Vessel | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008730","Chyle","C93166","A milky-white fluid that forms in the small intestine during digestion. It is made of lymph fluid and fats. Special lymph vessels carry chyle from the intestines to the blood.","Chyle | chyle",,,,,,,,,,,,,,,"4081767","Chyle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1511235","Body Fluid Leakage","C40419","The loss of any normal body fluid into the surrounding tissue or body cavity.","Body Fluid Leakage | Body Fluid Spillage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4011453","Ophthalmoplegia","C79697","Weakness or paralysis of at least one of the muscles controlling the movement of the eye. It results from degeneration of the muscles or the neural pathways involved in the eye movement. Representative disorders causing ophthalmoplegia include ocular myopathies and multiple sclerosis.","Ophthalmoplegia | ",,,,,,,,,,,,,,,"4052337","Ophthalmoplegia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0472569","Tracheoesophageal Puncture","C15915","A surgical procedure that creates a fistula between the trachea and esophagus in a patient who has previously undergone a total laryngectomy for the purpose of inserting a voice prosthesis to allow for esophageal speech.","Tracheoesophageal Puncture | tracheoesophageal puncture",,,,,,,,,,,,,,,"4068778","Tracheo-esophageal puncture procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3665947","Dislodged Catheter","C122439","A catheter that has moved from its intended location.","Dislodged Catheter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0184159","Tracheostomy Tube","C17629","A 2-inch- to 3-inch-long curved metal or plastic tube that is placed in a surgically created opening (tracheostomy) in the windpipe to maintain patency.","Tracheostomy Tube | trach tube | tracheostomy tube",,,,,,,,,,,,,,,"4044008","Tracheostomy tube",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0333042","Malpositioned","C124554","A physical quality in which the entity or structure is not appropriately or correctly placed.","Malpositioned | MALPOSITIONED",,,,,,,,,,,,,,,"4254066","Malposition",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4229460","Vocal Cord Paralysis","C47814","Paralysis of the muscles of one or both vocal cords. Signs and symptoms include hoarseness, weak voice, dyspnea, and coughing. Affected individuals are at risk for aspiration pneumonia.","Vocal Cord Paralysis | Vocal Cord Palsy",,,,,,,,,,,,,,,"261599","Vocal cord paralysis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0012691","Dislocation","C35724","A displacement of a part (especially a bone) from its normal position.","Dislocation | Dislocated | LUXATED",,,,,,,,,,,,,,,"4227147","Dislocation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL433369","Arterial Dissection","C99704","A tear within the wall of the artery.","Arterial Dissection | Dissection of unspecified artery",,,,,,,,,,,,,,,"46272492","Dissection of artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006090","Brachial Plexus","C12682","A nerve network originating from C5 to T1 that supplies cutaneous and muscular innervation to the arm and hand.","Brachial Plexus | BRACHIAL PLEXUS | Brachial plexus structure (body structure) | NERVE, BRACHIAL PLEXUS | brachial plexus",,,,,,,,,,,,,,,"4275339","Brachial plexus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2077203","Recurrent Laryngeal Nerve Injury","C103171","Damage to the recurrent laryngeal nerve.","Recurrent Laryngeal Nerve Injury | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0262593","Peripheral Nerve Injury","C101250","Sensory or motor loss of peripheral nerve function due to a traumatic event. (ACC)","Peripheral Nerve Injury | Peripheral Nervous Injury",,,,,,,,,,,,,,,"4248551","Injury of peripheral nerve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025062","Pneumomediastinum","C98981","The presence of air in the mediastinum. It is caused by injury, most often esophageal or intestinal perforation.","Pneumomediastinum | Mediastinal Emphysema",,,,,,,,,,,,,,,"4057432","Mediastinal emphysema",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162297","Respiratory Arrest","C101772","Cessation of breathing function.","Respiratory Arrest | Pulmonary Arrest",,,,,,,,,,,,,,,"317109","Respiratory arrest",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1536220","ST Elevation Myocardial Infarction by ECG Finding","C101888","A myocardial infarction that produces elevation in the ST segments of the ECG.","ST Elevation Myocardial Infarction by ECG Finding | ST ELEVATION MYOCARDIAL INFARCTION | ST Elevation Myocardial Infarction by EKG Finding | STEMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1276061","Non-ST Elevation Myocardial Infarction by ECG Finding","C80383","An electrocardiographic finding of a myocardial infarction that does not produce elevations in the ST segment of the EKG.","Non-ST Elevation Myocardial Infarction by ECG Finding | NON-ST ELEVATION MYOCARDIAL INFARCTION | NON-STEMI | NSTEMI | Non-ST Elevation Myocardial Infarction by EKG Finding",,,,,,,,,,,,,,,"4270024","Acute non-ST segment elevation myocardial infarction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040127","Thyroid Storm","C112836","Acute onset of severe, life-threatening hyperthyroidism caused by a sudden release of excessive thyroid hormone.","Thyroid Storm | ",,,,,,,,,,,,,,,"133436","Thyrotoxic crisis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3830105","Flare-up","C113680","A sudden worsening of a condition.","Flare-up | FLARE | Flare Episode",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985553","Mindfulness Relaxation","C93327","Therapy designed to improve psychological well-being through reduced anxiety, depressive symptoms, and distress, and improved mood.","Mindfulness Relaxation | MBSR | Mindful Meditation | Mindfulness Meditation | Mindfulness-Based Stress Reduction | mindfulness relaxation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021610","Inspiratory Capacity","C111362","The maximum volume of air a subject can inhale into the lungs after a tidal exhalation (IRV plus TV).","Inspiratory Capacity | IC",,,,,,,,,,,,,,,"4105475","Inspiratory capacity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3715135","CD38 Expressing Cell Count","C111151","The determination of the amount of CD38 expressing cells per unit present in a sample.","CD38 Expressing Cell Count | ADP-Ribosyl Cyclase 1 Expressing Cell Count | CD38 Antigen Expressing Cell Count",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205539","Scheduled","C125937","To order a planned list of activities or events.","Scheduled | SCHEDULED",,,,,,,,,,,,,,,"4166091","Scheduled - procedure status",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708110","Furnace","C49965","An enclosed chamber designed to produce heat.","Furnace Device | Furnace | Furnace Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509562","Voice Handicap Index Functional Subscale","C128065","A subscale of the Voice Handicap Index that measures an individual's perception of the effect of their voice handicap on their daily activity.","Voice Handicap Index Functional Subscale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509563","Voice Handicap Index Physical Subscale","C128067","A subscale of the Voice Handicap Index that measures an individual's perception of the characteristics of their vocal production and laryngeal discomfort.","Voice Handicap Index Physical Subscale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509561","Voice Handicap Index Emotional Subscale","C128068","A subscale of the Voice Handicap Index that measures an individual's perception of the emotional impact of their voice handicap.","Voice Handicap Index Emotional Subscale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3257860","Voice Difficulties Restrict Personal and Social Life","C128070","A question about how frequently an individual's voice difficulties restrict their personal and social life.","Voice Difficulties Restrict Personal and Social Life | My voice difficulties restrict my personal and social life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3260763","Feel Left Out of Conversation Because of Voice","C128071","A question about how frequently an individual feels left out of conversation because of their voice.","Feel Left Out of Conversation Because of Voice | I feel left out of conversation because of my voice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3257866","Voice Problem Causes Loss of Income","C128072","A question about how frequently an individual's voice problem causes them to lose income.","Voice Problem Causes Loss of Income | My voice problem causes me to lose income",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3260755","Feel Like Have to Strain to Produce Voice","C128074","A question about how frequently an individual feels as though they have to strain to produce voice.","Feel Like Have to Strain to Produce Voice | I feel as though I have to strain to produce voice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3258223","Clarity of Voice is Unpredictable","C128076","A question about how frequently the clarity of an individual's voice is unpredictable.","Clarity of Voice is Unpredictable | The clarity of my voice is unpredictable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3257867","Voice Problem Upsets Me","C128077","A question about how frequently an individual's voice problem upsets them.","Voice Problem Upsets Me | My voice problem upsets me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3257864","Voice Makes Me Feel Handicapped","C128078","A question about how frequently an individual's voice makes them feel handicapped.","Voice Makes Me Feel Handicapped | My voice makes me feel handicapped",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508911","Optimal Debulking","C128096","Visible residual tumor less than or equal to one centimeter in diameter after cytoreductive surgery.","Optimal Debulking | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508987","Suboptimal Debulking","C128097","Residual tumor greater than one centimeter in diameter after cytoreductive surgery.","Suboptimal Debulking | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509754","Maximal Debulking","C128098","No macroscopic residual tumor after cytoreductive surgery.","Maximal Debulking | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538720","CD8 Expressing Cell Count","C103811","The determination of the amount of the CD8 expressing cells in a sample.","CD8 Expressing Cell Count | CD8 | CD8 Expressing Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508916","Ovarian Cancer by FIGO Stage","C128081","A category of staging terms for ovarian cancer according to the International Federation of Gynecology and Obstetrics (FIGO), 2014. AJCC ovarian cancer stage terms from the 6th and 7th editions that are synonymous to the FIGO ovarian cancer staging classification of 2014 are included as preferred terms.","Ovarian Cancer by FIGO Stage 2014 | Ovarian Cancer by FIGO Stage | Ovarian Carcinoma by FIGO Stage 2014",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508830","FIGO Stage IC1 Ovarian Cancer","C128082","Stage IC ovarian cancer with surgical spill. (FIGO 2014)","FIGO Stage IC1 Ovarian Cancer 2014 | FIGO Stage IC1 Ovarian Cancer | FIGO Stage IC1 Ovarian Cancer | FIGO Stage IC1 Ovarian Carcinoma | FIGO Stage IC1 Ovarian Carcinoma 2014",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508832","FIGO Stage IC2 Ovarian Cancer","C128083","Stage IC ovarian cancer with capsule rupture before surgery or tumor on ovarian surface. (FIGO 2014)","FIGO Stage IC2 Ovarian Cancer 2014 | FIGO Stage IC2 Ovarian Cancer | FIGO Stage IC2 Ovarian Cancer | FIGO Stage IC2 Ovarian Carcinoma | FIGO Stage IC2 Ovarian Carcinoma 2014",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508834","FIGO Stage IC3 Ovarian Cancer","C128084","Stage IC ovarian cancer with malignant cells in the ascites or peritoneal washings. (FIGO 2014)","FIGO Stage IC3 Ovarian Cancer 2014 | FIGO Stage IC3 Ovarian Cancer | FIGO Stage IC3 Ovarian Cancer | FIGO Stage IC3 Ovarian Carcinoma | FIGO Stage IC3 Ovarian Carcinoma 2014",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508836","FIGO Stage II Ovarian Cancer","C128085","Ovarian cancer involving one or both ovaries with pelvic extension (below the pelvic brim) or primary peritoneal cancer. (FIGO 2014)","FIGO Stage II Ovarian Cancer 2014 | FIGO Stage II Ovarian Cancer | FIGO Stage II Ovarian Cancer | FIGO Stage II Ovarian Carcinoma | FIGO Stage II Ovarian Carcinoma 2014",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508837","FIGO Stage III Ovarian Cancer","C128086","Ovarian cancer involving 1 or both ovaries with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes. (FIGO 2014)","FIGO Stage III Ovarian Cancer 2014 | FIGO Stage III Ovarian Cancer | FIGO Stage III Ovarian Cancer | FIGO Stage III Ovarian Carcinoma | FIGO Stage III Ovarian Carcinoma 2014",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508838","FIGO Stage IIIA Ovarian Cancer","C128087","Ovarian cancer with positive retroperitoneal lymph nodes and/or microscopic metastasis beyond the pelvis. (FIGO 2014)","FIGO Stage IIIA Ovarian Cancer 2014 | FIGO Stage IIIA Ovarian Cancer | FIGO Stage IIIA Ovarian Cancer | FIGO Stage IIIA Ovarian Carcinoma | FIGO Stage IIIA Ovarian Carcinoma 2014",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508839","FIGO Stage IIIA1 Ovarian Cancer","C128088","Ovarian cancer with positive retroperitoneal lymph nodes only. (FIGO 2014)","FIGO Stage IIIA1 Ovarian Cancer | FIGO Stage IIIA1 Ovarian Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508840","FIGO Stage IIIA1(i) Ovarian Cancer","C128089","Ovarian cancer with positive retroperitoneal lymph nodes only. Metastasis equal or less than 10 mm. (FIGO 2014)","FIGO Stage IIIA1(i) Ovarian Cancer | FIGO Stage IIIA1(i) Ovarian Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508842","FIGO Stage IIIA1(ii) Ovarian Cancer","C128090","Ovarian cancer with positive retroperitoneal lymph nodes only. Metastasis greater than 10 mm. (FIGO 2014)","FIGO Stage IIIA1(ii) Ovarian Cancer | FIGO Stage IIIA1(ii) Ovarian Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508845","FIGO Stage IIIA2 Ovarian Cancer","C128091","Ovarian cancer with microscopic, extrapelvic (above the brim) peritoneal involvement +/- positive retroperitoneal lymph nodes. (FIGO 2014)","FIGO Stage IIIA2 Ovarian Cancer | FIGO Stage IIIA2 Ovarian Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508848","FIGO Stage IIIC Ovarian Cancer","C128093","Ovarian cancer with macroscopic, extrapelvic, peritoneal metastasis greater than 2 cm +/- positive retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen. (FIGO 2014)","FIGO Stage IIIC Ovarian Cancer 2014 | FIGO Stage IIIC Ovarian Cancer | FIGO Stage IIIC Ovarian Cancer | FIGO Stage IIIC Ovarian Carcinoma | FIGO Stage IIIC Ovarian Carcinoma 2014",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507823","FIGO Stage IVA Ovarian Cancer","C128094","Ovarian cancer with pleural effusion with positive cytology. (FIGO 2014)","FIGO Stage IVA Ovarian Cancer 2014 | FIGO Stage IVA Ovarian Cancer | FIGO Stage IVA Ovarian Cancer | FIGO Stage IVA Ovarian Carcinoma | FIGO Stage IVA Ovarian Carcinoma 2014 | Stage IVA Ovarian Epithelial Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507824","FIGO Stage IVB Ovarian Cancer","C128095","Ovarian cancer with hepatic and/or splenic parenchymal metastasis, metastasis to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside of the abdominal cavity). (FIGO 2014)","FIGO Stage IVB Ovarian Cancer 2014 | FIGO Stage IVB Ovarian Cancer | FIGO Stage IVB Ovarian Cancer | FIGO Stage IVB Ovarian Carcinoma | FIGO Stage IVB Ovarian Carcinoma 2014 | Stage IVB Ovarian Epithelial Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509255","Worst Severity Past Seven Days Dry Mouth","C128127","A question about the worst severity of an individual's dry mouth during the past seven days.","Worst Severity Past Seven Days Dry Mouth | In the last 7 days, what was the severity of your dry mouth at its worst | Worst Severity of Dry Mouth Past Seven Days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508952","Past Seven Days Frequency of Heartburn","C128129","A question about the frequency of an individual's heartburn during the past seven days.","Past Seven Days Frequency of Heartburn | Frequency of Heartburn Past Seven Days | In the last 7 days, how often did you have heartburn",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508951","Past Seven Days Frequency of Bloating of the Abdomen","C128131","A question about the frequency of an individual's bloating of the abdomen during the past seven days.","Past Seven Days Frequency of Bloating of the Abdomen | Frequency of Bloating of the Abdomen Past Seven Days | In the last 7 days, how often did you have bloating of the abdomen (belly)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509254","Worst Severity Past Seven Days Bloating of the Abdomen","C128133","A question about the worst severity of an individual's bloating of the abdomen during the past seven days.","Worst Severity Past Seven Days Bloating of the Abdomen | In the last 7 days, what was the severity of your bloating of the abdomen (belly) at its worst | Worst Severity of Bloating of the Abdomen Past Seven Days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508950","Past Seven Days Frequency of Anxiety","C128134","A question about the frequency of an individual's anxiety during the past seven days.","Past Seven Days Frequency of Anxiety | Frequency of Anxiety Past Seven Days | In the last 7 days, how often did you feel anxiety",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509253","Worst Severity Past Seven Days Anxiety","C128135","A question about the worst severity of an individual's anxiety during the past seven days.","Worst Severity Past Seven Days Anxiety | In the last 7 days, what was the severity of your anxiety at its worst | Worst Severity of Anxiety Past Seven Days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508949","Past Seven Days Anxiety Interfering with Usual or Daily Activities","C128136","A question about how much an individual's anxiety interfered with their usual or daily activities during the past seven days.","Past Seven Days Anxiety Interfering with Usual or Daily Activities | Anxiety Interfering with Usual or Daily Activities Past Seven Days | In the last 7 days, how much did anxiety interfere with your usual or daily activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508953","Past Seven Days Frequency of Sad or Unhappy Feelings","C128137","A question about the frequency of an individual's sad or unhappy feelings during the past seven days.","Past Seven Days Frequency of Sad or Unhappy Feelings | Frequency of Sad or Unhappy Feelings Past Seven Days | In the last 7 days, how often did you have sad or unhappy feelings",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509258","Worst Severity Past Seven Days Sad or Unhappy Feelings","C128139","A question about the worst severity of an individual's sad or unhappy feelings during the past seven days.","Worst Severity Past Seven Days Sad or Unhappy Feelings | In the last 7 days, what was the severity of your sad or unhappy feelings at their worst | Worst Severity of Sad or Unhappy Feelings Past Seven Days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508954","Past Seven Days Sad or Unhappy Feelings Interfering with Usual or Daily Activities","C128140","A question about how much an individual's sad or unhappy feelings interfered with their usual or daily activities during the past seven days.","Past Seven Days Sad or Unhappy Feelings Interfering with Usual or Daily Activities | In the last 7 days, how much did sad or unhappy feelings interfere with your usual or daily activities | Sad or Unhappy Feelings Interfering with Usual or Daily Activities Past Seven Days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987293","Encapsulated Data Text Data Type","C95652","A data type comprised of encapsulated data in the form of text.","Encapsulated Data Text Data Type | ED.TEXT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508973","Spiritual Well-being","C128148","A question regarding the status of one's sense of meaning and purpose in life and ability to relate to their religious beliefs.","Spiritual Well-being | Spiritual Well Being",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509474","Intellectual Well-being","C128149","A question regarding the status of one's mental capacity and ability to think clearly, concentrate, and remember things.","Intellectual Well-being | Intellectual Well Being",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509652","Quality Rating Score 0","C128151","A subjective rating score of 0 on a linear analogue scale with anchor point descriptions of 0: As bad as it can be and 10: As good as it can be.","Quality Rating Score 0 | Quality of Life Rating Score 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509654","Quality Rating Score 1","C128152","A subjective rating score of 1 on a linear analogue scale with anchor point descriptions of 0: As bad as it can be and 10: As good as it can be.","Quality Rating Score 1 | Quality of Life Rating Score 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509655","Quality Rating Score 2","C128153","A subjective rating score of 2 on a linear analogue scale with anchor point descriptions of 0:As bad as it can be and 10: As good as it can be.","Quality Rating Score 2 | Quality of Life Rating Score 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509656","Quality Rating Score 3","C128154","A subjective rating score of 3 on a linear analogue scale with anchor point descriptions of 0: As bad as it can be and 10: As good as it can be.","Quality Rating Score 3 | Quality of Life Rating Score 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509657","Quality Rating Score 4","C128155","A subjective rating score of 4 on a linear analogue scale with anchor point descriptions of 0: As bad as it can be and 10: As good as it can be.","Quality Rating Score 4 | Quality of Life Rating Score 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509658","Quality Rating Score 5","C128156","A subjective rating score of 5 on a linear analogue scale with anchor point descriptions of 0: As bad as it can be and 10: As good as it can be.","Quality Rating Score 5 | Quality of Life Rating Score 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509659","Quality Rating Score 6","C128157","A subjective rating score of 6 on a linear analogue scale with anchor point descriptions of 0: As bad as it can be and 10: As good as it can be.","Quality Rating Score 6 | Quality of Life Rating Score 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509660","Quality Rating Score 7","C128158","A subjective rating score of 7 on a linear analogue scale with anchor point descriptions of 0: As bad as it can be and 10: As good as it can be.","Quality Rating Score 7 | Quality of Life Rating Score 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509661","Quality Rating Score 8","C128159","A subjective rating score of 8 on a linear analogue scale with anchor point descriptions of 0: As bad as it can be and 10: As good as it can be.","Quality Rating Score 8 | Quality of Life Rating Score 8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509662","Quality Rating Score 9","C128160","A subjective rating score of 9 on a linear analogue scale with anchor point descriptions of 0: As bad as it can be and 10: As good as it can be.","Quality Rating Score 9 | Quality of Life Rating Score 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509653","Quality Rating Score 10","C128161","A subjective rating score of 10 on a linear analogue scale with anchor point descriptions of 0: As bad as it can be and 10: As good as it can be.","Quality Rating Score 10 | Quality of Life Rating Score 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509651","Quality of Life Linear Analogue Scale","C128150","A linear analogue scale for the subjective scoring of quality of life with anchor point descriptions of 0: As bad as it can be and 10: As good as it can be.","Quality of Life Linear Analogue Scale | Quality Rating Linear Analogue Scale | Quality Rating Scale | Quality of Life Rating Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021432","Infratentorial Neoplasm","C3139","A benign or malignant neoplasm that occurs in brain parenchymal tissue below the tentorium cerebelli.","Infratentorial Neoplasm | Brain Neoplasms, Infratentorial | Infratentorial Neoplasms | Infratentorial Tumor | Infratentorial Tumors | Neoplasm of uncertain behavior of brain, infratentorial | Neoplasms, Infratentorial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1558209","Adverse Event Associated with Surgery and Intra-Operative Injury","C53798","An adverse event associated with surgery or an intra-operative injury.","Adverse Event Associated with Surgery and Intra-Operative Injury | SURGERY/INTRA-OPERATIVE INJURY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509435","Decipher Prostate Cancer Test","C128181","A proprietary genetic test that evaluates a prostate cancer tumor for its potential for metastasis. Decipher measures the expression levels of 22 RNA biomarkers involved in multiple biological pathways that are associated with metastasis and aggressive prostate cancer to classify tumors as high, average, or low risk of metastasis.","Decipher Prostate Cancer Test | DECIPHER | Decipher | Decipher Metastasis Test | Decipher Prostate Cancer Test
 | Decipher Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512224","Glycogen-Rich, Clear Cell Breast Carcinoma","C40368","An uncommon, usually aggressive adenocarcinoma of the breast characterized by the presence of clear cells that contain glycogen.","Glycogen-Rich, Clear Cell Breast Carcinoma | Breast Glycogen-Rich Carcinoma | Breast Glycogen-Rich, Clear Cell Carcinoma | Breast Glycogen-Rich, Clear Cell Carcinoma | Glycogen-Rich, Clear Cell Breast Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518574","Breast Oncocytic Carcinoma","C40366","A rare breast adenocarcinoma characterized by the presence of malignant oncocytic cells. The oncocytic cells comprise more than 70 percent of the malignant cellular population.","Breast Oncocytic Carcinoma | Oncocytic Breast Carcinoma | Oncocytic Breast Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509043","Coexpression Extrapolation","C128196","A measure of drug sensitivity and resistance predictions for bladder cancers based on the COXEN gene expression profile method.","Coexpression Extrapolation | COXEN | Coexpression Extrapolation (COXEN)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509418","COXEN Sensitivity Scale","C128197","A scale that represents drug sensitivity and resistance predictions for bladder tumors, ranging from 1 for the most drug-resistant to 40 for the most drug-sensitive.","COXEN Sensitivity Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509388","COXEN Score 1","C128198","A score of 1 on the COXEN Sensitivity Scale.","COXEN Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509399","COXEN Score 2","C128199","A score of 2 on the COXEN Sensitivity Scale.","COXEN Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509410","COXEN Score 3","C128200","A score of 3 on the COXEN Sensitivity Scale.","COXEN Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509412","COXEN Score 4","C128201","A score of 4 on the COXEN Sensitivity Scale.","COXEN Score 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509413","COXEN Score 5","C128202","A score of 5 on the COXEN Sensitivity Scale.","COXEN Score 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509414","COXEN Score 6","C128203","A score of 6 on the COXEN Sensitivity Scale.","COXEN Score 6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509415","COXEN Score 7","C128204","A score of 7 on the COXEN Sensitivity Scale.","COXEN Score 7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509416","COXEN Score 8","C128205","A score of 8 on the COXEN Sensitivity Scale.","COXEN Score 8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509417","COXEN Score 9","C128206","A score of 9 on the COXEN Sensitivity Scale.","COXEN Score 9 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509378","COXEN Score 10","C128207","A score of 10 on the COXEN Sensitivity Scale.","COXEN Score 10 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509379","COXEN Score 11","C128208","A score of 11 on the COXEN Sensitivity Scale.","COXEN Score 11 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509380","COXEN Score 12","C128209","A score of 12 on the COXEN Sensitivity Scale.","COXEN Score 12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509381","COXEN Score 13","C128210","A score of 13 on the COXEN Sensitivity Scale.","COXEN Score 13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509382","COXEN Score 14","C128211","A score of 14 on the COXEN Sensitivity Scale.","COXEN Score 14 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509383","COXEN Score 15","C128212","A score of 15 on the COXEN Sensitivity Scale.","COXEN Score 15 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509384","COXEN Score 16","C128213","A score of 16 on the COXEN Sensitivity Scale.","COXEN Score 16 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509385","COXEN Score 17","C128214","A score of 17 on the COXEN Sensitivity Scale.","COXEN Score 17 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509386","COXEN Score 18","C128215","A score of 18 on the COXEN Sensitivity Scale.","COXEN Score 18 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509387","COXEN Score 19","C128216","A score of 19 on the COXEN Sensitivity Scale.","COXEN Score 19 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509389","COXEN Score 20","C128217","A score of 20 on the COXEN Sensitivity Scale.","COXEN Score 20 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509390","COXEN Score 21","C128218","A score of 21 on the COXEN Sensitivity Scale.","COXEN Score 21 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509391","COXEN Score 22","C128219","A score of 22 on the COXEN Sensitivity Scale.","COXEN Score 22 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509392","COXEN Score 23","C128220","A score of 23 on the COXEN Sensitivity Scale.","COXEN Score 23 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509393","COXEN Score 24","C128221","A score of 24 on the COXEN Sensitivity Scale.","COXEN Score 24 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509394","COXEN Score 25","C128222","A score of 25 on the COXEN Sensitivity Scale.","COXEN Score 25 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509395","COXEN Score 26","C128223","A score of 26 on the COXEN Sensitivity Scale.","COXEN Score 26 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509396","COXEN Score 27","C128224","A score of 27 on the COXEN Sensitivity Scale.","COXEN Score 27 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509397","COXEN Score 28","C128225","A score of 28 on the COXEN Sensitivity Scale.","COXEN Score 28 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509398","COXEN Score 29","C128226","A score of 29 on the COXEN Sensitivity Scale.","COXEN Score 29 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509400","COXEN Score 30","C128227","A score of 30 on the COXEN Sensitivity Scale.","COXEN Score 30 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509401","COXEN Score 31","C128228","A score of 31 on the COXEN Sensitivity Scale.","COXEN Score 31 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509402","COXEN Score 32","C128229","A score of 32 on the COXEN Sensitivity Scale.","COXEN Score 32 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509403","COXEN Score 33","C128230","A score of 33 on the COXEN Sensitivity Scale.","COXEN Score 33 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509404","COXEN Score 34","C128231","A score of 34 on the COXEN Sensitivity Scale.","COXEN Score 34 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509405","COXEN Score 35","C128232","A score of 35 on the COXEN Sensitivity Scale.","COXEN Score 35 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509406","COXEN Score 36","C128233","A score of 36 on the COXEN Sensitivity Scale.","COXEN Score 36 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509407","COXEN Score 37","C128234","A score of 37 on the COXEN Sensitivity Scale.","COXEN Score 37 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509408","COXEN Score 38","C128235","A score of 38 on the COXEN Sensitivity Scale.","COXEN Score 38 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509409","COXEN Score 39","C128236","A score of 39 on the COXEN Sensitivity Scale.","COXEN Score 39 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509411","COXEN Score 40","C128237","A score of 40 on the COXEN Sensitivity Scale.","COXEN Score 40 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509552","Sensitive Anticancer Agent","C128238","An FDA-approved anticancer agent that an NCI-60 cell line is predicted to be sensitive to.","Sensitive Anticancer Agent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509809","Glutaminase Family","C128179","An enzyme family that cleaves amide bonds to generate glutamate from glutamine. There are two human glutaminase genes that are expressed in a tissue specific pattern.","Glutaminase Family | EC 3.5.1.2 | Glutaminase | Glutaminase I | Glutaminase I Family | Glutamine Aminohydrolase | Glutamine Aminohydrolase Family | L-Glutaminase | L-Glutaminase Family | L-Glutamine Amidohydrolase | L-Glutamine Amidohydrolase Family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2673202","GREB1 Gene","C128182","This gene may be involved in hormone-dependent cell proliferation.","GREB1 Gene | GREB1 | Growth Regulation By Estrogen In Breast Cancer 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508858","Isofuran","C128239","A group of eicosanoids that contain a substituted tetrahydrofuran ring formed by free radical mediated peroxidation of arachidonic acid. Isofuran production is favored over isoprostane production when elevated levels of oxygen are present. As isofurans are stable byproducts of lipid peroxidation, they can be used as biomarkers for oxidative stress.","Isofuran | IsoF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509280","Mycobiome","C128180","The microbial fungi that are present in an environment or in a biological sample.","Mycobiome | Mycobiome Profile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509282","MYD88 NM_002468.4:c.794T>C","C128176","A nucleotide substitution at position 794 of the coding sequence of the MYD88 gene where thymine has been mutated to cytosine.","MYD88 NM_002468.4:c.794T>C | MYD88 c.794T>C | Myeloid Differentiation Primary Response 88 c.794T>C | NM_002468.4:c.794T>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4012638","MYD88 NP_002459.2:p.L265P","C128178","A change in the amino acid residue at position 265 in the myeloid differentiation primary response protein MyD88 where leucine has been replaced by proline.","MYD88 NP_002459.2:p.L265P | MYD88 L265P | MYD88 Leu265Pro | MYD88 NP_002459.2:p.Leu265Pro | MYD88 p.L265P | MYD88 p.Leu265Pro | Myeloid Differentiation Primary Response Protein MyD88 L265P | Myeloid Differentiation Primary Response Protein MyD88 Leu265Pro | NP_002459.2:p.L265P | NP_002459.2:p.Leu265Pro",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508923","PDGFRB NP_002600.1:p.T681I","C128174","A change in the amino acid residue at position 681 in the platelet-derived growth factor receptor beta protein where threonine has been replaced by isoleucine.","PDGFRB NP_002600.1:p.T681I | Beta Platelet-Derived Growth Factor Receptor T681I | Beta Platelet-Derived Growth Factor Receptor Thr681Ile | Beta-Type Platelet-Derived Growth Factor Receptor T681I | Beta-Type Platelet-Derived Growth Factor Receptor Thr681Ile | CD140 Antigen-Like Family Member B T681I | CD140 Antigen-Like Family Member B Thr681Ile | CD140b T681I | CD140b Thr681Ile | NP_002600.1:pT681I | NP_002600.1:pThr681Ile | PDGF-R-Beta T681I | PDGF-R-Beta Thr681Ile | PDGFR-1 T681I | PDGFR-1 Thr681Ile | PDGFR-Beta T681I | PDGFR-Beta Thr681Ile | PDGFRB NP_002600.1:pThr681Ile | PDGFRB T681I | PDGFRB Thr681Ile | PDGFRB p.T681I | PDGFRB p.Thr681Ile | Platelet-Derived Growth Factor Receptor 1 T681I | Platelet-Derived Growth Factor Receptor 1 Thr681Ile | Platelet-Derived Growth Factor Receptor Beta T681I | Platelet-Derived Growth Factor Receptor Beta Thr681Ile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419064","PTGER4 Gene","C128185","This gene plays a role in prostaglandin-dependent signaling.","PTGER4 Gene | PTGER4 | Prostaglandin E Receptor 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512090","Cobalt Gray Equivalent","C128269","A unit of relative biological effectiveness of protons equivalent to 60 cobalt gamma rays.","Cobalt Gray Equivalent | CGE | cGE | {CGE}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335823","SEM1 Gene","C20916","This gene is involved in the ATP-dependent degradation of ubiquitinated proteins.","SEM1 Gene | DSS1 | SEM1 | SEM1 26S Proteasome Complex Subunit Gene | SHFM1 | SHFM1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706403","UGT1A1 wt Allele","C51018","Human UGT1A1 wild-type allele is located in the vicinity of 2q37 and is approximately 13 kb in length. This allele, which encodes UDP-glucuronosyltransferase 1-1 protein, plays a role in the transformation of small lipophilic molecules into water-soluble metabolites. Certain allelic variants of the UGT1A1 gene cause Crigler-Najjar syndrome type I, type II, Gilbert syndrome or transient familial neonatal hyperbilirubinemia.","UGT1A1 wt Allele | BILIQTL1 | GNT1 | HUG-BR1 | UDP Glucuronosyltransferase Family 1 Member A1 wt Allele | UDP Glycosyltransferase 1 Family, Polypeptide A1 Gene | UDP glycosyltransferase gene 1 | UDPGT | UDPGT 1-1 | UGT1 | UGT1A | UGT1A1*1 Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509646","Pulmonary Function Test Reference Value","C128264","A standardized value that allows for the comparison of an individual's pulmonary function test results to those same results obtained from a reference population, which establishes a context through which individual results can be interpreted.","Pulmonary Function Test Reference Value | PFT Reference Value",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274123","PIK3CA NM_006218.1:c.1624G>A","C98475","A nucleotide substitution at position 1624 of the coding sequence of the PIK3CA gene where guanine has been mutated to adenine.","PIK3CA NM_006218.1:c.1624G>A | NM_006218.1:c.1624G>A | PI3K c.1624G>A | PIK3CA c.1624G>A | Phosphoinositide-3-Kinase, Catalytic, Alpha Polypeptide c.1624G>A | p110-alpha c.1624G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274122","PIK3CA NP_006209.2:p.E542K","C98474","A change in the amino acid residue at position 542 in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform protein where glutamic acid has been replaced by lysine.","PIK3CA NP_006209.2:p.E542K | NP_006209.2:p.Glu542Lys | PI3Kalpha E542K | PIK3CA E542K | PIK3CA Glu542Lys | PIK3CA NP_006209.2:p.Glu542Lys | PIK3CA p.E542K | PIK3CA p.Glu542Lys | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 110 kDa Catalytic Subunit Alpha E542K | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Isoform E542K | Phosphoinositide-3-Kinase Catalytic Alpha Polypeptide E542K | p110alpha E542K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274117","PIK3CA NM_006218.1:c.1633G>A","C98469","A nucleotide substitution at position 1633 of the coding sequence of the PIK3CA gene where guanine has been mutated to adenine.","PIK3CA NM_006218.1:c.1633G>A | NM_006218.1:c.1633G>A | PI3K c.1633G>A | PIK3CA c.1633G>A | Phosphoinositide-3-Kinase, Catalytic, Alpha Polypeptide c.1633G>A | p110-alpha c.1633G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274116","PIK3CA NP_006209.2:p.E545K","C98468","A change in the amino acid residue at position 545 in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform protein where glutamic acid has been replaced by lysine.","PIK3CA NP_006209.2:p.E545K | NP_006209.2:p.Glu545Lys | PI3Kalpha E545K | PIK3CA E545K | PIK3CA Glu545Lys | PIK3CA NP_006209.2:p.Glu545Lys | PIK3CA p.E545K | PIK3CA p.Glu545Lys | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 110 kDa Catalytic Subunit Alpha E545K | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Isoform E545K | Phosphoinositide-3-Kinase Catalytic Alpha Polypeptide E545K | p110alpha E545K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274133","PIK3CA NM_006218.1:c.3140A>G","C98485","A nucleotide substitution at position 3140 of the coding sequence of the PIK3CA gene where adenine has been mutated to guanine.","PIK3CA NM_006218.1:c.3140A>G | NM_006218.1:c.3140A>G | PI3K c.3140A>G | PIK3CA c.3140A>G | Phosphoinositide-3-Kinase, Catalytic, Alpha Polypeptide c.3140A>G | p110-alpha c.3140A>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274132","PIK3CA NP_006209.2:p.H1047R","C98484","A change in the amino acid residue at position 1047 in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform protein where histidine has been replaced by arginine.","PIK3CA NP_006209.2:p.H1047R | NP_006209.2:p.Glu1047Arg | PI3Kalpha H1047R | PIK3CA Glu1047Arg | PIK3CA H1047R | PIK3CA NP_006209.2:p.His1047Arg | PIK3CA p.Glu1047Arg | PIK3CA p.H1047R | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 110 kDa Catalytic Subunit Alpha H1047R | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Isoform H1047R | Phosphoinositide-3-Kinase Catalytic Alpha Polypeptide H1047R | p110alpha H1047R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017056","Gamma-Tubulin","C32650","A family of globular proteins that plays a role in the nucleation and orientation of microtubules.","Gamma-Tubulin | Gamma Tubulin | TUBG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415653","HOXA1 Gene","C115064","This gene plays a role in embryonic pattern formation.","HOXA1 Gene | HOXA1 | Homeobox A1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825490","Positive Charge","C81172","Having a deficiency of electrons; having a higher electric potential.","Positive Charge | Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0392535","Induced Abortion Procedure","C92954","A surgical or medical procedure that terminates a pregnancy by removing the products of conception.","Induced Abortion Procedure | Induced Abortion",,,,,,,,,,,,,,,"37018340|4297250","Induced termination of pregnancy|Termination of pregnancy",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL509608","Bayer Classification for Corneal Epitheliopathy","C128435","A grading system for changes in corneal morphology following treatment with anetumab ravtansine (BAY 94-9343).","Bayer Classification for Corneal Epitheliopathy | Bayer Classification for Cornea Morphology | Bayer Corneal Morphology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509241","Bayer Corneal Epitheliopathy Grade 0","C128437","No pathologic changes.","Bayer Corneal Epitheliopathy Grade 0 | Grade 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509243","Bayer Corneal Epitheliopathy Grade 1","C128440","Any stage of superficial punctate keratitis.","Bayer Corneal Epitheliopathy Grade 1 | Grade 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509691","Bayer Corneal Epitheliopathy Grade 3","C128443","Corneal ulcer without risk of acute rupture; central stromal opacity.","Bayer Corneal Epitheliopathy Grade 3 | Grade 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509692","Bayer Corneal Epitheliopathy Grade 4","C128444","Corneal ulcer more severe than grade 3.","Bayer Corneal Epitheliopathy Grade 4 | Grade 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509609","Bayer Classification of Visual Acuity Changes","C128445","A grading system for best corrected visual acuity following treatment with anetumab ravtansine (BAY 94-9343).","Bayer Classification of Visual Acuity Changes | Bayer Visual Acuity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509242","Bayer Visual Acuity Changes Grade 0","C128446","No findings, no reporting from the patient.","Bayer Visual Acuity Changes Grade 0 | Grade 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509244","Bayer Visual Acuity Changes Grade 1","C128447","Symptomatic visual acuity loss of less than 3 lines. (ETDRS equivalent: each loss of 3 lines corresponds to halving the visual acuity)","Bayer Visual Acuity Changes Grade 1 | Grade 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509823","Bayer Visual Acuity Changes Grade 2","C128448","Visual acuity loss greater than or equal to 3 lines, but less than 6 lines. (ETDRS equivalent: each loss of 3 lines corresponds to halving the visual acuity)","Bayer Visual Acuity Changes Grade 2 | Grade 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509693","Bayer Visual Acuity Changes Grade 3","C128449","Visual acuity loss greater than or equal to 6 lines. (ETDRS equivalent: each loss of 3 lines corresponds to halving the visual acuity)","Bayer Visual Acuity Changes Grade 3 | Grade 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509822","Bayer Visual Acuity Changes Grade 4","C128450","Visual acuity loss greater than or equal to 6 lines, leading to blindness. (ETDRS equivalent: each loss of 3 lines corresponds to halving the visual acuity)","Bayer Visual Acuity Changes Grade 4 | Grade 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509690","Bayer Corneal Epitheliopathy Grade 2","C128442","Epithelial opacities; micro-cysts; micro-deposits; corneal erosion; non-central stromal opacity.","Bayer Corneal Epitheliopathy Grade 2 | Grade 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003980","Asia","C26273","The world's largest continent; it occupies the eastern part of the Eurasian landmass and its adjacent islands and is separated from Europe by the Ural Mountains.","Asia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829717","Hemoglobin A1C to Hemoglobin Ratio Measurement","C111207","The determination of the ratio of the glycosylated hemoglobin compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.","Hemoglobin A1C to Hemoglobin Ratio Measurement | HBA1CHGB | Hemoglobin A1C/Hemoglobin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0872304","Voucher","C128456","A document that can be exchanged for particular goods or services or one serving as a record of money paid.","Voucher | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596070","American Ethnicity","C128457","A collection of ethnic geographical categories including African American, North American, Latin American, Caribbean, and South American.","American Ethnicity | American | Americas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509475","Intercontinental Ethnicity","C128459","A collection of ethnic geographical categories including Middle Eastern and Hispanic.","Intercontinental Ethnicity | Intercontinental",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825858","B4GALNT1 Gene","C128482","This gene is involved in ganglioside biosynthesis.","B4GALNT1 Gene | B4GALNT1 | Beta-1,4-N-Acetyl-Galactosaminyltransferase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509029","CD16+ CD56+ CD69+ Lymphocyte","C128465","A population of activated lymphocytes that express CD16 (Fc-gamma receptor III), CD56 (neural cell adhesion molecule 1) and CD69 (early activation antigen CD69), which is mainly comprised of natural killer cells with an activated phenotype.","CD16+ CD56+ CD69+ Lymphocyte | CD16, CD56, CD69 Triple-Positive Activated Lymphocyte | TrPAL | Triple-Positive Activated Lymphocyte",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1867605","F2 NM_000506.4:c.*97G>A","C128467","A nucleotide substitution at position *97 in the 3' untranslated region of the F2 gene where guanine has been mutated to adenine.","F2 NM_000506.4:c.*97G>A | Coagulation Factor II (Thrombin) 20210G>A | Coagulation Factor II, Thrombin 20210G>A | F2 20210G-A | F2 20210G>A | F2 G20210A | F2 c.*97G>A | F2 c.20210G>A | F2 g.25313G>A | F2, 20210G-A | Factor II 20210G-A Mutation | NG_008953.1:g.25313G>A | NM_000506.4:c.*97G>A | Prothrombin 20210G>A | Prothrombin G20210A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509240","Glycan Profile","C128469","A set of data that both identifies and quantifies all the polysaccharides and the protein or lipid conjugated polysaccharides in a biological sample or specimen.","Glycan Profile | Glycan Analysis | Glycan Characterization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509644","Modified Vaccinia Virus Ankara Antibody","C128468","Any antibody that recognizes modified vaccinia Ankara virus.","Modified Vaccinia Virus Ankara Antibody | Anti-MVA Antibody | Anti-Modified Vaccinia Ankara Virus Antibody | Anti-Modified Vaccinia Virus Ankara Antibody | MVA Antibody | Modified Vaccinia Ankara Virus Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704864","Molecular Signature","C48181","The set of characteristics, including the expression of certain genes, proteins, polysaccharides and/or lipids, that can identify what cells or tissues are present in a biological sample and/or indicate whether abnormal cells or tissues are present.","Molecular Signature | Molecular Fingerprint | Molecular Profile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030095","Oxytocin","C2283","Oxytocin (9 aa, ~1 kDa) is encoded by the human OXT gene. This protein plays a role in smooth muscle contraction in both the mammary gland and uterus. Oxytocin also may also be involved in maternal-newborn bonding, cognition and many other psychological and physiological processes.","Oxytocin | 1-({(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-(4-hydroxybenzyl)-13-[(1S)-1-methylpropyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-L-prolyl-L-leucylglycinamide | 3-Isoleucine-8-Leucine Vasopressin | CYIQNCPLG-NH2 | Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 | OXT | Ocytocin | Vasporessin, 3-Isoleucine-8-Leucine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538611","PDIA6 Gene","C128479","This gene plays a role in protein folding and platelet aggregation.","PDIA6 Gene | PDIA6 | Protein Disulfide Isomerase Family A Member 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423971","PGRMC1 Gene","C128473","This gene plays a role in progesterone binding.","PGRMC1 Gene | PGRMC1 | Progesterone Receptor Membrane Component 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419941","SELPLG Gene","C128476","This gene is involved in the mediation of leukocyte rolling and cell adhesion.","SELPLG Gene | SELPLG | Selectin P Ligand Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425830","SPHK2 Gene","C128470","This gene is involved in the biosynthesis of sphingosine 1- phosphate.","SPHK2 Gene | SPHK2 | Sphingosine Kinase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827751","Tumor Size Measurement","C106303","The measurement of the size of a tumor mass either clinically or in a surgically resected specimen.","Tumor Size Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698259","Monoclonal B-Cell Lymphocytosis","C80310","A monoclonal expansion of B-lymphocytes with or without the characteristic immunophenotype of chronic lymphocytic leukemia. It precedes virtually all cases of chronic lymphocytic leukemia/small lymphocytic lymphoma.","Monoclonal B-Cell Lymphocytosis | MBL | monoclonal B-cell lymphocytosis",,,,,,,,,,,,,,,"37312111|37397341","Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0349633","Hairy Cell Leukemia Variant","C7401","An indolent chronic B-cell leukemia resembling classic hairy cell leukemia but shows variant cytologic, hematologic, and immunophenotypic features and is resistant to the conventional therapy applied to hairy cell leukemia.  Biologically, it is not related to hairy cell leukemia.","Hairy Cell Leukemia Variant | HCL-V | Hairy cell leukaemia variant | Hairy cell leukemia variant | Prolymphocytic Variant of Hairy Cell Leukemia",,,,,,,,,,,,,,,"37151345|4082459","Hairy cell leukemia variant|Hairy cell leukemia variant",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1334110","IL19 Gene","C28612","This gene is involved in the induction and regulation of inflammatory cytokines.","IL19 Gene | IL19 | Interleukin 19 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412815","FOXL2 Gene","C75472","This gene plays a role in ovarian function.","FOXL2 Gene | FOXL2 | Forkhead Box L2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274872","ASPSCR1/TFE3 Fusion Protein","C99706","A fusion protein encoded by the ASPSCR1/TFE3 fusion gene. This protein is comprised of 311 N-terminal amino acids from the tether containing UBX domain for GLUT4 protein fused to the C-terminal part of the transcription factor E3 protein, including the helix-loop-helix, and leucine zipper domains.","ASPSCR1/TFE3 Fusion Protein | ASPL-TFE3 Fusion Protein | ASPL/TFE3 Fusion Protein | ASPSCR1-TFE3 Fusion Protein | ASPSCR1::TFE3 Fusion Protein | Tether Containing UBX Domain for GLUT4/Transcription Factor E3 Fusion Protein | Tether Containing UBX Domain for GLUT4::Transcription Factor E3 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3888091","ASPSCR1/TFE3 Fusion Gene","C99705","A fusion gene that results from chromosomal translocation t(X;17)(p11.2;q25) or der(X)t(X;17)(p11;q25) which fuses the 5' half of the ASPSCR1 gene to either exon 3 or 4 of the TFE gene. This fusion is associated with both alveolar soft part sarcoma and primary renal tumor.","ASPSCR1/TFE3 Fusion Gene | ASPL-TFE3 Fusion Gene | ASPL/TFE3 Fusion Gene | ASPSCR1-TFE3 Fusion Gene | ASPSCR1::TFE3 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL321357","True Vocal Cord","C33815","The lower pair of vocal folds located below the glottis, which are the primary source of phonation","True Vocal Cord | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0149596","False Vocal Cord","C32583","One of two folds of a mucous membrane spanning the larynx. The two folds aid in breathing and preventing regurgitation to a greater extent than producing sounds.","False Vocal Cord | Ventricular Fold",,,,,,,,,,,,,,,"4253521","Structure of ventricular fold of larynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224177","Aryepiglottic Muscle","C32146","A band of muscular fibers of the oblique arytenoid muscle that extends from the summit of the arytenoid cartilage to the side of the epiglottis and whose action constricts the laryngeal aperture.","Aryepiglottic Muscle | ",,,,,,,,,,,,,,,"4271466","Structure of aryepiglottic muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL317977","Laryngeal","C13305","Referring to the larynx.","Laryngeal | Laryngeal (qualifier value) | laryngeal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3853659","Driver's License","C122899","A document that authorizes a person to operate a motor vehicle on public roads.","Driver's License | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428933","NAMPT Gene","C24661","This gene plays a role in the regulation of B-cell colony formation.","NAMPT Gene | NAMPT | Nicotinamide Phosphoribosyltransferase Gene | PBEF1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015691","Short Chain Fatty Acid","C68424","A class of dietary fatty acids that have an alkyl chain length from 2 up to 5 carbon atoms.","Short Chain Fatty Acid | SCFA | Short-Chain Fatty Acid | VFA | Volatile Fatty Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508975","Staining Intensity","C127762","The degree or magnitude of staining by a dye or reagent within a microscopic specimen.","Staining Intensity | STAINING INTENSITY | staining intensity scale | staining intensity value | staining_intensity_scale | staining_intensity_value",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL436752","ECOG - Performance Status","C102408","Eastern Cooperative Oncology Group (ECOG) Performance status.","ECOG - Performance Status | ECOG1-Performance Status | ECOG101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509557","Simpson Grading System","C128616","A scale that defines the extent of resection involved in the removal of intracranial meningiomas.","Simpson Grading System | Simpson Grading System for Removal of Meningiomas | Simpson Grading of Meningioma Resection | Simpson Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509821","Simpson Grade 1","C128617","Macroscopically complete removal of the tumor, with excision of its dural attachment, and of any abnormal bone. Includes resection of venous sinus if involved.","Simpson Grade 1 | Grade 1 | Grade I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441802","Simpson Grade 2","C128618","Macroscopically complete removal of the tumor and its visible extensions with coagulation of its dural attachment.","Simpson Grade 2 | Grade 2 | Grade II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509820","Simpson Grade 3","C128619","Macroscopically complete removal of the intradural tumor, without resection or coagulation of its dural attachment or its extradural extensions.","Simpson Grade 3 | Grade 3 | Grade III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509556","Simpson Grade 4","C128620","Partial removal, leaving the intradural tumor in situ.","Simpson Grade 4 | Grade 4 | Grade IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512087","Simpson Grade 5","C128621","Simple decompression, with or without biopsy.","Simpson Grade 5 | Grade 5 | Grade V",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898150","Nelipepimut-S","C117985","A cancer vaccine comprised of a human leukocyte antigen (HLA) A2/A3 restricted HER2/neu (human epidermal growth factor receptor 2; ErbB2) nonapeptide derived from the extracellular domain of the HER2 protein, with potential immunomodulating and antineoplastic activities. Upon intradermal injection, nelipepimut-S may induce a specific cytotoxic T-lymphocyte (CTL) response against HER2/neu-expressing tumor cells. HER2/neu, a tumor-associated antigen and a member of the epidermal growth factor receptor family of tyrosine kinases, is overexpressed in various tumor cell types and plays a key role in tumorigenesis.","Nelipepimut-S | E75 Peptide | Human Receptor Tyrosine-Protein Kinase erbB-2 (Proto-Oncogene Neu, Tyrosine Kinase- type Cell Surface Receptor HER2, CD340)-(347-355)-Peptide | L-Leucine, L-lysyl-L-isoleucyl-L-phenylalanylglycyl-L-seryl-L-leucyl-L-alanyl-L- phenylalanyl- | NELIPEPIMUT-S | Nelipepimut S | NeuVax",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003943","Arytenoid Cartilage","C32148","Either of a pair of small pyramidal laryngeal cartilages that articulate with the lamina of the cricoid cartilage and give attachment to the posterior part of the corresponding vocal ligament and to several muscles.","Arytenoid Cartilage | Arytenoid cartilage structure (body structure) | Arytenoids",,,,,,,,,,,,,,,"4300780","Arytenoid cartilage structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162861","Superior Mesenteric Artery","C33685","An artery arising from the abdominal aorta with numerous branches that supply the intestines from the duodenum to the transverse colon and the pancreas.","Superior Mesenteric Artery | Superior mesenteric artery structure (body structure)",,,,,,,,,,,,,,,"4172495","Superior mesenteric artery structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0225578","Laryngeal Anterior Commissure","C128630","The anterior-most portion of the vocal cord, located within the larynx, that constitutes the junction of the conus elasticus and the thyroepiglottic, vestibular, and vocal ligaments.","Laryngeal Anterior Commissure | Anterior Glottic Commissure | GLOTTIS, ANTERIOR COMMISSURE",,,,,,,,,,,,,,,"4084988","Structure of anterior commissure of larynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0175730","Tube Device","C50236","Any device or component shaped like a hollow cylinder.","Tube Device | Tube | Tube Device Component",,,,,,,,,,,,,,,"4306146","Tube",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0181909","Mounts","C50079","A structural device designed to facilitate the attachment of one object to another.","Mount Device | Mount | Mount Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707698","Cooling Module","C50319","A device designed to regulate and lower the temperature of a heat generating device or system.","Cooling Module Device | Cooling Module | Cooling Module Device Component | Cooling System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0678568","Cool","C128635","To lower the temperature of something.","Cool | Cooling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054227","Patient-Reported Outcomes Measurement Information System Measures","C121345","Psychometrically validated measures designed for precise and efficient self-report measurement of physical, mental, and social health across chronic conditions. Items can be administered in static (short-form) or dynamic form (as computer adaptive tests).","Patient-Reported Outcomes Measurement Information System Measures | PROMIS Measures | PRO_MEASURES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508851","Faced Block","C128636","A block that has been cut down to the desired tissue plane, with the overlaying support material removed.","Faced Block | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0183953","Histology Cassette","C128638","A device designed to hold tissue specimens during processing, embedding and storage.","Histology Cassette | Biopsy Cassette | Tissue Cassette | Tissue Processing Cassette",,,,,,,,,,,,,,,"4200898","Tissue cassette",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509014","Blister Wallet Card","C128665","A multi-panel, re-closable end-user pack for tablet blisters.","Wallet Pack Dosage Form | Blister Wallet | Blister Wallet Card | Wallet Pack | Wallet Pack | Wallet Package",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1319688","Blister Dosing Unit","C54564","A dosing unit equal to the amount of active ingredient(s) contained in a blister.","Blister Dosing Unit | BLISTER | Blister",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041095","Triplet Multiple Birth","C128668","Any of three offspring born from the same pregnancy.","Triplet | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205172","More","C128667","Greater in size, amount, extent, or degree.","More | ",,,,,,,,,,,,,,,"4054695","More",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1138480","International Classification of Diseases, Tenth Revision, Clinical Modification","C128691","An extension of the ICD-10 created by the U.S. National Center for Health Statistics so that the system could be used to capture more morbidity data. This extension included a section of procedure codes.","International Classification of Diseases, Tenth Revision, Clinical Modification | ICD-10-CM | ICD-10-CM | ICD10-CM | International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036911","Sexual Partner","C100812","A person with whom one has had sexual relations.","Sexual Partner | SEXUAL PARTNER",,,,,,,,,,,,,,,"4023050","Sexual partners",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504410","AJCC Cancer Staging Manual 7th Edition","C125755","The 7th edition of the criteria developed by the American Joint Committee on Cancer (AJCC) in 2010, used for the classification and staging of neoplastic diseases.","AJCC Cancer Staging Manual 7th Edition | 7th | AJCC V7 | AJCC v7 | AJCC1 | AJCC7 | Seventh Edition (2010)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2718533","degarelix acetate","C80443","The acetate form of a long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial (Leydig) cells in the testes.","Degarelix Acetate | D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3- pyridinyl)-D-alanyl-L- seryl-4-[[[(4S)-hexahydro-2,6-dioxo-4-pyrimidinyl]carbonyl]amino]- L-phenylalanyl-4-[(aminocarbonyl)amino]-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L- lysyl-L-prolyl, Acetate, Hydrate | DEGARELIX ACETATE | FE200486 Acetate Hydrate | Gonax",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2607886","Abiraterone Acetate","C68845","An orally active acetate ester form of the steroidal compound abiraterone with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.","Abiraterone Acetate | 17-(3-Pyridyl)-5,16-androstadien-3beta-acetate | ABIRATERONE ACETATE | Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, acetate (ester), (3beta)- | BR9004 | BR9004-1 | CB 7630 | CB-7630 | CB7630 | JNJ-212082 | Yonsa | Zytiga | abiraterone acetate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272697","Remnant","C96280","An embryonic structure that remains after the completion of the embryonic development of an organ or system.","Remnant | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449259","Clinical Course of Disease","C35461","A term that refers to the nature and/or clinical outcome of a disease (e.g., acute or chronic disease, aggressive or indolent disease, recurrent disease, etc.).","Clinical Course of Disease | Clinical Course | LONGCRSE | Longitudinal Course",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827752","Tumor Regression Grade","C106304","A pathologic grading system used to evaluate the tumor response to preoperative chemotherapy and radiation.","Tumor Regression Grade | tumor regression grade | tumor_regression_grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443354","Analyte","C128639","The sample or material being subjected to analysis.","Analyte | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508737","Electronic Nicotine Delivery Device","C128795","A battery-powered electronic device designed to atomize a nicotine-containing liquid solution for inhalation.","Electronic Nicotine Delivery Device | ELECTRONIC NICOTINE DELIVERY SYSTEMS (ENDS) | Electronic Nicotine Product Device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509071","GenomePlex Whole Genome Amplification","C128787","A proprietary method for whole genome amplification (WGA) from very small samples using random fragmentation of genomic DNA and conversion of the resulting small fragments to a library of PCR-amplifiable molecules flanked by universal priming sites.","GenomePlex Whole Genome Amplification | GenomePlex | GenomePlex (Rubicon) | GenomePlex (Rubricon) | Genomeplex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509311","REPLI-g Whole Genome Amplification","C128788","A proprietary method for whole genome amplification (WGA) from small samples using high-fidelity enzyme Phi 29 polymerase to amplify complex genomic DNA using Multiple Displacement Amplification (MDA) technology.","REPLI-g Whole Genome Amplification | Repli-G | Repli-g (Qiagen)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3839010","RNA Isolation","C128789","Any method that extracts RNA from biological samples, which includes the proper handling of biological samples prior to nucleic acid isolation, the separation of RNA from the rest of the components in the samples, and the storage of the RNA isolates.","RNA Isolation | RNA Extraction",,,,,,,,,,,,,,,"45765892","Ribonucleic acid extraction technique",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509816","Hybrid","C128790","Being comprised of mixed attributes or parts.","Hybrid | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509455","Human Origin","C128791","An indication that cells, tissues, or other material are, or are derived from, human specimens.","Human Origin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0200810","Surgical Pathology Procedure","C128792","A laboratory procedure that involves the examination of surgical resection or biopsy tissue samples for diagnostic or research purposes.","Surgical Pathology Procedure | ",,,,,,,,,,,,,,,"4213297","Surgical pathology procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509802","Microplate Well","C128793","Any of the individual wells on a microwell plate.","Microplate Well | Plate Well | Well",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009132","Coal Dust","C113678","Fine powder derived by the crushing of coal.","Coal Dust | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509817","Blunt","C128809","Marijuana rolled in the outer leaves of a cigar or hidden in a hollowed-out cigar.","Blunt | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0140283","Retinoid X Receptors","C17534","Human nuclear Retinoid X Receptors RXRA, RXRB, and RXRG (NR2/RXR Family) are transcriptional regulators composed of N-terminal modulating domain, DNA-binding domain (AGGTCA response elements), and C-terminal 9-cis RA-binding domain. RXR homodimers and RXR/RAR heterodimers mediate distinct retinoic acid response pathways.  RXRs also interact with TH- and vitamin D receptors, and with NCOA3, NCOA6, PML, and PPARG coactivators; and mediate RA biological effects by binding to specific target gene promoters and inducing target gene transcription. RXRs/LXRs and RXRs/FXR may mediate cholesterol homeostasis, by governing cholesterol transport from peripheral cells, inhibiting cholesterol absorption in the small intestine, and repressing bile acid synthesis through upregulation of ABC1 and repression of CYP7A1 expression. (NCI)","Retinoid X Receptor | NR2B | Nuclear Receptor Subfamily 2 Group B | RXR | Retinoic Acid Receptor RXR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0553534","Cardiopulmonary","C13362","Pertaining to both the heart and the lungs.","Cardiopulmonary | cardiopulmonary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266035","Minimally Invasive Lung Mucinous Adenocarcinoma","C7268","A morphologic variant of minimally invasive lung adenocarcinoma characterized by tall columnar cells and mucin production.","Minimally Invasive Lung Mucinous Adenocarcinoma | Minimally Invasive Mucinous Lung Adenocarcinoma | Mucinous Bronchioloalveolar Carcinoma | Mucinous Bronchioloalveolar Carcinoma | Mucinous Bronchioloalveolar Lung Carcinoma | Mucinous Bronchoalveolar Lung Carcinoma | Mucinous Minimally Invasive Lung Adenocarcinoma | Mucinous Minimally Invasive Lung Adenocarcinoma","8257/3","Minimally invasive adenocarcinoma, mucinous",,,,,,,,,,,,,"4028539","Bronchiolo-alveolar carcinoma, mucinous",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0013973","Emetic","C94257","Describes a substance that causes vomiting.","Emetic | emetic | emetogenic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL536215","Lung Micropapillary Adenocarcinoma","C128847","An aggressive variant of lung adenocarcinoma that exhibits a micropapillary architectural pattern. The prognosis is usually poor.","Lung Micropapillary Adenocarcinoma | Micropapillary Lung Adenocarcinoma | Micropapillary adenocarcinoma | Micropapillary carcinoma, NOS","8265/3","Micropapillary carcinoma, NOS",,,,,,,,,,,,,"37116860","Micropapillary adenocarcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1511357","C-Myc Translocation","C27703","A cytogenetic abnormality that refers to the translocation of the MYC gene to a new chromosomal location.","C-Myc Translocation | C-MycT | MYC Gene Translocation | MYC Translocation | MYCC Gene Translocation | bHLHe39 Gene Translocation | v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog Gene Translocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826677","Laboratory Test Performed","C83065","An indication or description that a laboratory test has been performed.","Laboratory Test Performed | LBPERF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512136","Derkay Staging System","C128932","A staging system for assessment of recurrent respiratory papillomatosis (RRP). The staging system includes a functional assessment of severity as well as an anatomic assessment of disease distribution. The anatomic score can then be used in combination with the functional assessment to measure an individual patient's clinical course and response to therapy over time.","Derkay Staging System | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1692321","Cellular infiltrate","C42077","An influx of cells, generally leukocytes, in locations or numbers not normally found, without other features of inflammation.","Cellular Infiltrate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0237427","Neurological surgery - physician","C17722","A surgeon who specializes in treating diseases and disorders of the brain and nervous system.","Neurosurgeon | neurosurgeon | surgeon, neuro-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512259","Activating RAS Mutation","C128901","A mutation in a RAS family gene (HRAS, KRAS or NRAS) that causes the encoded GTPase to be resistant to GTP hydrolysis and results in constitutive activation of its activity and downstream pathways.","Activating RAS Mutation | Activating RAS | Activating RAS Family Gene Mutation | Activating RAS Family Mutation | Activating RAS Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0065042","Annexin Family Protein","C128917","A family of proteins that are capable of binding negatively charged phospholipids in a calcium-dependent manner and contain four annexin repeats. This family has been linked with a wide variety of biological processes, including inhibition of phospholipase activity, exocytosis, endocytosis, coagulation, fibrinolysis, the regulation of inflammation and membrane organization.","Annexin Family Protein | Annexin | Annexin Family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414079","DLX5 Gene","C128926","This gene is involved in osteoblast differentiation.","DLX5 Gene | DLX5 | Distal-Less Homeobox 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512272","EBF1/PDGFRB Fusion Gene","C128923","A fusion gene resulting from a rearrangement of the q arm of chromosome 5 that fuses the first 15 exons of the EBF1 gene to exon 11 of the PDGFRB gene. This fusion may be associated with Ph-like acute lymphoblastic leukemia.","EBF1/PDGFRB Fusion Gene | EBF-PDGFRB Fusion Gene | EBF/PDGFRB Fusion Gene | EBF1-PDGFRB Fusion Gene | EBF1::PDGFRB Fusion Gene | Early B-Cell Factor 1/Platelet Derived Growth Factor Receptor Beta Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512273","EBF1/PDGFRB Fusion Protein","C128924","A fusion protein encoded by the EBF1/PDGFRB fusion gene. This protein is comprised of the first 600 amino acids of transcription factor COE1, including the DNA binding domain, fused to the C-terminal transmembrane and cytoplasmic domains of the platelet-derived growth factor receptor beta protein, including the protein kinase domain.","EBF1/PDGFRB Fusion Protein | EBF1-PDGFRB Fusion Protein | EBF1::PDGFRB Fusion Protein | Transcription Factor COE1/Beta-Type Platelet-Derived Growth Factor Receptor Fusion Protein | Transcription Factor COE1/PDGFR-Beta Fusion Protein | Transcription Factor COE1/Platelet-Derived Growth Factor Receptor Beta Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512274","Epstein Barr Nuclear Antigen Antibody","C128902","Any immunoglobulin that recognizes Epstein-Barr nuclear antigen proteins.","Epstein Barr Nuclear Antigen Antibody | Anti-EBNA Antibody | Anti-Epstein Barr Nuclear Antigen Antibody | Anti-Epstein-Barr Nuclear Antigen Antibody | EBNA Antibody | Epstein-Barr Nuclear Antigen Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL373765","FGFR3 NM_000142.4:c.1108G>T","C128912","A nucleotide substitution at position 1108 of the coding sequence of the FGFR3 gene where guanine has been mutated to thymine.","FGFR3 NM_000142.4:c.1108G>T | CD333 c.1108G>T | FGFR3 c.1108G>T | Fibroblast Growth Factor Receptor 3 c.1108G>T | JKT4 c.1108G>T | JTK4 c.1108G>T | NM_000142.4:c.1108G>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL373766","FGFR3 NM_000142.4:c.1111A>T","C128908","A nucleotide substitution at position 1111 of the coding sequence of the FGFR3 gene where adenine has been mutated to thymine.","FGFR3 NM_000142.4:c.1111A>T | CD333 c.1111A>T | FGFR3 c.1111A>T | Fibroblast Growth Factor Receptor 3 c.1111A>T | JKT4 c.1111A>T | JTK4 c.1111A>T | NM_000142.4:c.1111A>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL373767","FGFR3 NM_000142.4:c.1118A>G","C128910","A nucleotide substitution at position 1118 of the coding sequence of the FGFR3 gene where adenine has been mutated to guanine.","FGFR3 NM_000142.4:c.1118A>G | CD333 c.1118A>G | FGFR3 c.1118A>G | Fibroblast Growth Factor Receptor 3 c.1118A>G | JKT4 c.1118A>G | JTK4 c.1118A>G | NM_000142.4:c.1118A>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL338558","FGFR3 NM_000142.4:c.1138G>A","C128906","A nucleotide substitution at position 1138 of the coding sequence of the FGFR3 gene where guanine has been mutated to adenine.","FGFR3 NM_000142.4:c.1138G>A | CD333 c.1138G>A | FGFR3 c.1138G>A | Fibroblast Growth Factor Receptor 3 c.1138G>A | JKT4 c.1138G>A | JTK4 c.1138G>A | NM_000142.4:c.1138G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL373786","FGFR3 NM_000142.4:c.742C>T","C128904","A nucleotide substitution at position 742 of the coding sequence of the FGFR3 gene where cytosine has been mutated to thymine.","FGFR3 NM_000142.4:c.742C>T | CD333 c.742C>T | FGFR3 c.742C>T | Fibroblast Growth Factor Receptor 3 c.742C>T | JKT4 c.742C>T | JTK4 c.742C>T | NM_000142.4:c.742C>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL373787","FGFR3 NM_000142.4:c.746C>G","C128914","A nucleotide substitution at position 746 of the coding sequence of the FGFR3 gene where cytosine has been mutated to guanine.","FGFR3 NM_000142.4:c.746C>G | CD333 c.746C>G | FGFR3 c.746C>G | Fibroblast Growth Factor Receptor 3 c.746C>G | JKT4 c.746C>G | JTK4 c.746C>G | NM_000142.4:c.746C>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1851183","FGFR3 NP_000133.1:p.G370C","C128913","A change in the amino acid residue at position 370 in the fibroblast growth factor receptor 3 protein where glycine has been replaced by cysteine.","FGFR3 NP_000133.1:p.G370C | CD333 Antigen G370C | CD333 Antigen Gly370Cys | FGFR-3 G370C | FGFR-3 Gly370Cys | FGFR-3 p.G370C | FGFR-3 p.Gly370Cys | FGFR3 G370C | FGFR3 Gly370Cys | FGFR3 NP_000133.1:p.Gly370Cys | FGFR3 p.G370C | FGFR3 p.Gly370Cys | Fibroblast Growth Factor Receptor 3 G370C | Fibroblast Growth Factor Receptor 3 Gly370Cys | NP_000133.1:p.G370C | NP_000133.1:p.Gly370Cys | Tyrosine Kinase JKT4 G370C | Tyrosine Kinase JKT4 Gly370Cys | Tyrosine Kinase JTK4 G370C | Tyrosine Kinase JTK4 Gly370Cys",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL338559","FGFR3 NP_000133.1:p.G380R","C128907","A change in the amino acid residue at position 380 in the fibroblast growth factor receptor 3 protein where glycine has been replaced by arginine.","FGFR3 NP_000133.1:p.G380R | CD333 Antigen G380R | CD333 Antigen Gly380Arg | FGFR-3 G380R | FGFR-3 Gly380Arg | FGFR-3 p.G380R | FGFR-3 p.Gly380Arg | FGFR3 G380R | FGFR3 Gly380Arg | FGFR3 NP_000133.1:p.Gly380Arg | FGFR3 p.G380R | FGFR3 p.Gly380Arg | Fibroblast Growth Factor Receptor 3 G380R | Fibroblast Growth Factor Receptor 3 Gly380Arg | NP_000133.1:p.G380R | NP_000133.1:p.Gly380Arg | Tyrosine Kinase JKT4 G380R | Tyrosine Kinase JKT4 Gly380Arg | Tyrosine Kinase JTK4 G380R | Tyrosine Kinase JTK4 Gly380Arg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1851151","FGFR3 NP_000133.1:p.R248C","C128905","A change in the amino acid residue at position 284 in the fibroblast growth factor receptor 3 protein where arginine has been replaced by cysteine.","FGFR3 NP_000133.1:p.R248C | CD333 Antigen Arg248Cys | CD333 Antigen R248C | FGFR-3 Arg248Cys | FGFR-3 R248C | FGFR-3 p.Arg248Cys | FGFR-3 p.R248C | FGFR3 Arg248Cys | FGFR3 NP_000133.1:p.Arg248Cys | FGFR3 R248C | FGFR3 p.Arg248Cys | FGFR3 p.R248C | Fibroblast Growth Factor Receptor 3 Arg248Cys | Fibroblast Growth Factor Receptor 3 R248C | NP_000133.1:p.Arg248Cys | NP_000133.1:p.R248C | Tyrosine Kinase JKT4 Arg248Cys | Tyrosine Kinase JKT4 R248C | Tyrosine Kinase JTK4 Arg248Cys | Tyrosine Kinase JTK4 R248C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1851160","FGFR3 NP_000133.1:p.S249C","C128916","A change in the amino acid residue at position 249 in the fibroblast growth factor receptor 3 protein where serine has been replaced by cysteine.","FGFR3 NP_000133.1:p.S249C | CD333 Antigen S249C | CD333 Antigen Ser249Cys | FGFR-3 S249C | FGFR-3 Ser249Cys | FGFR-3 p.S249C | FGFR-3 p.Ser249Cys | FGFR3 NP_000133.1:p.Ser249Cys | FGFR3 S249C | FGFR3 Ser249Cys | FGFR3 p.S249C | FGFR3 p.Ser249Cys | Fibroblast Growth Factor Receptor 3 S249C | Fibroblast Growth Factor Receptor 3 Ser249Cys | NP_000133.1:p.S249C | NP_000133.1:p.Ser249Cys | Tyrosine Kinase JKT4 S249C | Tyrosine Kinase JKT4 Ser249Cys | Tyrosine Kinase JTK4 S249C | Tyrosine Kinase JTK4 Ser249Cys",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1851153","FGFR3 NP_000133.1:p.S371C","C128909","A change in the amino acid residue at position 371 in the fibroblast growth factor receptor 3 protein where serine has been replaced by cysteine.","FGFR3 NP_000133.1:p.S371C | CD333 Antigen S371C | CD333 Antigen Ser371Cys | FGFR-3 S371C | FGFR-3 Ser371Cys | FGFR-3 p.S371C | FGFR-3 p.Ser371Cys | FGFR3 NP_000133.1:p.Ser371Cys | FGFR3 S371C | FGFR3 Ser371Cys | FGFR3 p.S371C | FGFR3 p.Ser371Cys | Fibroblast Growth Factor Receptor 3 S371C | Fibroblast Growth Factor Receptor 3 Ser371Cys | NP_000133.1:p.S371C | NP_000133.1:p.Ser371Cys | Tyrosine Kinase JKT4 S371C | Tyrosine Kinase JKT4 Ser371Cys | Tyrosine Kinase JTK4 S371C | Tyrosine Kinase JTK4 Ser371Cys",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1851167","FGFR3 NP_000133.1:p.Y373C","C128911","A change in the amino acid residue at position 373 in the fibroblast growth factor receptor 3 protein where tyrosine has been replaced by cysteine.","FGFR3 NP_000133.1:p.Y373C | CD333 Antigen Tyr373Cys | CD333 Antigen Y373C | FGFR-3 Tyr373Cys | FGFR-3 Y373C | FGFR-3 p.Tyr373Cys | FGFR-3 p.Y373C | FGFR3 NP_000133.1:p.Tyr373Cys | FGFR3 Tyr373Cys | FGFR3 Y373C | FGFR3 p.Tyr373Cys | FGFR3 p.Y373C | Fibroblast Growth Factor Receptor 3 Tyr373Cys | Fibroblast Growth Factor Receptor 3 Y373C | NP_000133.1:p.Tyr373Cys | NP_000133.1:p.Y373C | Tyrosine Kinase JKT4 Tyr373Cys | Tyrosine Kinase JKT4 Y373C | Tyrosine Kinase JTK4 Tyr373Cys | Tyrosine Kinase JTK4 Y373C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512262","FLT3 NP_004110.2:p.D835X","C128921","A change in the amino acid residue at position 835 in the receptor-type tyrosine-protein kinase FLT3 protein where asparagine has been replaced by another amino acid.","FLT3 NP_004110.2:p.D835X | CD135 Antigen Asp835Xxx | CD135 Antigen D835X | D835 | D835X | FLT3 Asp835 Mutation | FLT3 Asp835Xxx | FLT3 D835 Mutation | FLT3 D835X | FLT3 NP_004110.2:p.Asp835Xxx | FLT3 p.Asp835Xxx | FLT3 p.D835X | FLT3-D835 | FLT3-TKD/D835 Mutation | Fetal Liver Kinase-2 Asp835Xxx | Fetal Liver Kinase-2 D835X | Flt-3 Receptor Asp835Xxx | Flt-3 Receptor D835X | Fms-Related Tyrosine Kinase 3 Asp835Xxx | Fms-Related Tyrosine Kinase 3 D835X | NP_004110.2:p.Asp835Xxx | NP_004110.2:p.D835X | Receptor-Type Tyrosine-Protein Kinase FLT3 Asp835Xxx | Receptor-Type Tyrosine-Protein Kinase FLT3 D835X | Stem Cell Tyrosine Kinase 1 Asp835Xxx | Stem Cell Tyrosine Kinase 1 D835X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825572","IFT88 Gene","C128944","This gene is involved in cilium morphology and autophagy.","IFT88 Gene | IFT88 | Intraflagellar Transport 88 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826129","MIR551A Gene","C128929","This gene plays a role in the inhibition of target gene expression.","MIR551A Gene | MIR551A | MicroRNA 551a Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537985","MT-CO1 Gene","C128941","This gene plays a role in oxidative phosphorylation.","MT-CO1 Gene | MT-CO1 | Mitochondrially Encoded Cytochrome C Oxidase I Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417676","NELL1 Gene","C128934","This gene is involved in the positive regulation of osteoblast differentiation.","NELL1 Gene | NELL1 | Neural EGFL Like 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415363","GUCY2C Gene","C123875","This gene is involved in ligand-dependent cGMP synthase activity.","GUCY2C Gene | GUCY2C | Guanylate Cyclase 2C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420882","TPT1 Gene","C101389","This gene is involved in both microtubule stabilization and calcium binding.","TPT1 Gene | TPT1 | Tumor Protein, Translationally-Controlled 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1337111","POMC Gene","C38178","This gene is involved in several diverse cellular functions.","POMC Gene | POMC | Proopiomelanocortin (Adrenocorticotropin/ Beta-Lipotropin/ Alpha-Melanocyte Stimulating Hormone/ Beta-Melanocyte Stimulating Hormone/ Beta-Endorphin) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332070","AKAP12 Gene","C21306","This gene plays a role in signal transduction and angiogenesis.","AKAP12 Gene | A-Kinase Anchoring Protein 12 Gene | AKAP12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509070","GREB1 wt Allele","C128183","Human GREB1 wild-type allele is located in the vicinity of 2p25.1 and is approximately 160 kb in length. This allele, which encodes protein GREB1, may plays a role in tissue responses to estrogen. Aberrant expression may be associated with estrogen receptor-positive breast carcinoma and other hormone-responsive neoplasms.","GREB1 wt Allele | Gene Regulated By Estrogen In Breast Cancer | Growth Regulation By Estrogen In Breast Cancer 1 wt Allele | KIAA0575",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512382","ALK Positive","C128831","Indicates that ALK expression has been detected in a sample.","ALK Positive | ALK+ | ALK-Positive | Anaplastic Lymphoma Kinase Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512345","Castration Levels of Testosterone","C129259","A finding of low concentrations of testosterone in a subject's serum that results from the use of surgical or chemical castration procedures.","Castration Levels of Testosterone | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512110","CD19 Positive","C129255","Indicates that CD19 expression has been detected in a sample.","CD19 Positive | B4 Positive | CD19 Antigen Positive | CD19 Molecule Positive | CD19+",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512124","CDKN2A-p16 Positive","C129258","Indicates that CDKN2A-p16 expression has been detected in a sample.","CDKN2A-p16 Positive | CDKN2A-p16(INK4a) Positive | CDKN2A-p16+ | Cyclin-Dependent Kinase 4 Inhibitor A Positive | Cyclin-Dependent Kinase Inhibitor 2A Positive | p16 Positive | p16(INK4a) Positive | p16+ | p16-INK4 Positive | p16-INK4+ | p16INK4 Positive | p16INK4+ | p16INK4a Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512148","Human Anti-Mouse Antibodies Negative","C128838","Indicates that human anti-mouse antibodies have not been detected in a sample.","Human Anti-Mouse Antibodies Negative | HAMA Negative | Human Anti-Mouse Antibodies Absent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512518","Human Immunodeficiency Virus 1 Positive","C129253","Indicates that human immunodeficiency virus 1 has been detected in a sample.","Human Immunodeficiency Virus 1 Positive | HIV-1 Positive | HIV-1+ | HIV1 Positive | HIV1+",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512517","Human Papillomavirus Positive","C128839","Indicates that human papillomavirus has been detected in a sample.","Human Papillomavirus Positive | HPV Positive | HPV+ | Human Papilloma Virus Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512372","Mesothelin Positive","C128841","Indicates that mesothelin expression has been detected in a sample.","Mesothelin Positive | MSLN Positive | Mesothelin-Expressing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512515","NCAM1 Positive","C129251","Indicates that NCAM1 expression has been detected in a sample.","NCAM1 Positive | CD56 Antigen Positive | CD56 Positive | CD56+ | NCAM1+ | Neural Cell Adhesion Molecule 1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0856536","Philadelphia Chromosome Positive","C128843","Indicates that the Philadelphia chromosome abnormality, t(9;22)(q34;q11), has been detected in a sample.","Philadelphia Chromosome Positive | Ph Positive | Ph+",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512327","RB1 Positive","C128842","Indicates that RB1 expression has been detected in a sample.","RB1 Positive | RB Positive | RB+ | RB1+ | Retinoblastoma 1 Positive | Retinoblastoma Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512377","RET Gene Translocation","C129252","A cytogenetic abnormality that refers to any translocation involving the RET gene.","RET Gene Translocation | RET Translocation | RET/PTC Translocation | Ret Proto-Oncogene Translocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3888910","TNFRSF8 Positive","C129257","Indicates that TNFRSF8 expression has been detected in a sample.","TNFRSF8 Positive | CD30 Antigen Positive | CD30 Positive | CD30+ | Ki-1 Antigen Positive | Ki-1 Positive | TNFRSF8+ | Tumor Necrosis Factor Receptor Superfamily Member 8 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512248","Worst Severity Past Seven Days Difficulty Swallowing","C129266","A question about an individual's observation of the worst severity they have experienced related to difficulty swallowing over the past seven days.","Worst Severity Past Seven Days Difficulty Swallowing | In the last 7 days, what was the severity of your difficulty swallowing at its worst | Past Seven Days Worst Severity Difficulty Swallowing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512322","Past Seven Days Mouth or Throat Sores Interfering with Usual or Daily Activities","C129269","A question about how much an individual's mouth or throat sores interfered with their usual or daily activities over the past seven days.","Past Seven Days Mouth or Throat Sores Interfering with Usual or Daily Activities | In the last 7 days, how much did mouth or throat sores interfere with your usual or daily activities | Past Seven Days How Much Mouth or Throat Sores Interfered with Usual or Daily Activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512252","Worst Severity Past Seven Days Skin Cracking at the Corners of Mouth","C129270","A question about an individual's observation of the worst severity they have experienced related to skin cracking at the corners of their mouth over the past seven days.","Worst Severity Past Seven Days Skin Cracking at the Corners of Mouth | In the last 7 days, what was the severity of skin cracking at the corners of your mouth at its worst | Past Seven Days Worst Severity Skin Cracking at the Corners of Mouth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512320","Past Seven Days Voice Change","C129273","A question about whether or not an individual had any voice changes over the past seven days.","Past Seven Days Voice Change | In the last 7 days, did you have any voice changes | Past Seven Days Any Voice Change",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512250","Worst Severity Past Seven Days Hoarse Voice","C129275","A question about an individual's observation of the worst severity they have experienced related to hoarse voice over the past seven days.","Worst Severity Past Seven Days Hoarse Voice | In the last 7 days, what was the severity of your hoarse voice at its worst | Past Seven Days Worst Severity Hoarse Voice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512316","Past Seven Days Increased Passing of Gas","C129276","A question about whether or not an individual had any increased passing of gas (flatulence) over the past seven days.","Past Seven Days Increased Passing of Gas | In the last 7 days, did you have any increased passing of gas (flatulence) | Past Seven Days Any Increased Passing of Gas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512315","Past Seven Days Hives","C129278","A question about whether or not an individual had any hives over the past seven days.","Past Seven Days Hives | In the past 7 days, did you have any hives (itchy red bumps on the skin) | Past Seven Days Any Hives",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512318","Past Seven Days Loss of Fingernails or Toenails","C129279","A question about whether or not an individual lost any fingernails or toenails over the past seven days.","Past Seven Days Loss of Fingernails or Toenails | In the last 7 days, did you lose any fingernails or toenails | Past Seven Days Any Loss of Fingernails or Toenails",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512319","Past Seven Days Ridges or Bumps on Fingernails or Toenails","C129280","A question about whether or not an individual had any ridges or bumps on their fingernails or toenails over the past seven days.","Past Seven Days Ridges or Bumps on Fingernails or Toenails | In the last 7 days, did you have any ridges or bumps on your fingernails or toenails | Past Seven Days Any Ridges or Bumps on Fingernails or Toenails",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512314","Past Seven Days Color Change of Fingernails or Toenails","C129281","A question about whether or not an individual had any change in color of their fingernails or toenails over the past seven days.","Past Seven Days Color Change of Fingernails or Toenails | In the last 7 days, did you have any change in the color of your fingernails or toenails | Past Seven Days Any Color Change of Fingernails or Toenails",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512317","Past Seven Days Increased Skin Sensitivity to Sunlight","C129282","A question about whether or not an individual had any increased skin sensitivity to sunlight over the past seven days.","Past Seven Days Increased Skin Sensitivity to Sunlight | In the last 7 days, did you have any increased skin sensitivity to sunlight | Past Seven Days Any Increased Skin Sensitivity to Sunlight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512251","Worst Severity Past Seven Days Problems with Memory","C129283","A question about an individual's observation of the worst severity they have experienced related to problems with memory over the past seven days.","Worst Severity Past Seven Days Problems with Memory | In the past 7 days, what was the severity of your problems with memory at their worst | Past Seven Days Worst Severity Problems with Memory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512323","Past Seven Days Problems with Memory Interfering with Usual or Daily Activities","C129284","A question about how much an individual's problems with memory interfered with their usual or daily activities over the past seven days.","Past Seven Days Problems with Memory Interfering with Usual or Daily Activities | In the past 7 days, how much did problems with memory interfere with your usual or daily activities | Past Seven Days How Much Problems with Memory Interfered with Usual or Daily Activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512490","Past Seven Days Frequency of Feeling Nothing Could Cheer You Up","C129285","A question about the frequency of an individual's feelings that nothing could cheer them up over the past seven days.","Past Seven Days Frequency of Feeling Nothing Could Cheer You Up | In the past 7 days, how often did you feel that nothing could cheer you up",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512249","Worst Severity Past Seven Days Feeling Nothing Could Cheer You Up","C129286","A question about an individual's observation of the worst severity they have experienced related to feeling that nothing could cheer them up over the past seven days.","Worst Severity Past Seven Days Feeling Nothing Could Cheer You Up | In the past 7 days, what was the severity of your feelings that nothing could cheer you up at their worst | Past Seven Days Worst Severity Feeling Nothing Could Cheer You Up",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512321","Past Seven Days Feeling Nothing Could Cheer You Up Interfering with Usual or Daily Activities","C129287","A question about how much an individual's feeling that nothing could cheer them up interfered with their usual or daily activities over the past seven days.","Past Seven Days Feeling Nothing Could Cheer You Up Interfering with Usual or Daily Activities | In the past 7 days, how much did feeling that nothing could cheer you up interfere with your usual or daily activities | Past Seven Days How Much Feeling Nothing Could Cheer You Up Interfered with Usual or Daily Activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1273404","Stereotactic Body Radiation Therapy","C118286","Stereotactic radiation therapy in which one or several maximum dose radiation treatments are delivered targeting cancers of the body, excluding the brain or spine.","Stereotactic Body Radiation Therapy | SABR | SBRT | Stereotactic Ablative Body Radiation Therapy | stereotactic body radiation therapy",,,,,,,,,,,,,,,"4215577","Stereotactic radiotherapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897240","Untreated Central Nervous System Neoplasm","C114994","A finding of central nervous system neoplasm that has not been treated.","Untreated Central Nervous System Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085080","Chinese Hamster Ovary Cell","C17421","The parental CHO cell line initiated from a biopsy of an ovary of an adult Chinese hamster.","CHO Cells | CHO | Chinese Hamster Ovary Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1832030","Recombinant Human Anti-TGF-beta Monoclonal Antibody","C84873","A recombinant human IgG4 monoclonal antibody directed against transforming growth factor-beta (TGFb) with potential antineoplastic activity. Recombinant human anti-TGF-beta monoclonal antibody specifically targets and binds to all 3 isoforms of TGFb, thereby neutralizing TGFb isoforms 1, 2 and 3. This prevents activation of TGFb-mediated signaling pathways. TGFb, a pleiotropic cytokine, is often overexpressed in a number of cancer cell types and is involved in cancer cell proliferation, differentiation, migration, invasion and angiogenesis.","Recombinant Human Anti-TGF-beta Monoclonal Antibody | GC1008 | Recombinant Human Anti-Transforming Growth Factor-beta Monoclonal Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274673","BCR/ABL1 Fusion Gene p230","C99307","A fusion gene that results from a chromosomal translocation t(9;22)(q34;q11) that fuses exon 19 of the BCR gene to the 5' side of exon 2 of the ABL1 gene. This rearrangement is associated with chronic myelogenous leukemia.","BCR/ABL1 Fusion Gene p230 | BCR-ABL1 Fusion Gene p230 | BCR/ABL Fusion Gene p230 | BCR::ABL1 Fusion Gene p230",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274672","BCR/ABL1 Fusion Gene p210","C99306","A fusion gene that results from a chromosomal translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene between exons 12 and 16 to the 5' side of exon 2 of the ABL1 gene. This rearrangement is associated with chronic myelogenous leukemia, acute lymphoblastic leukemia and acute myeloid leukemia.","BCR/ABL1 Fusion Gene p210 | BCR-ABL1 Fusion Gene p210 | BCR/ABL Fusion Gene p210 | BCR::ABL1 Fusion Gene p210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274671","BCR/ABL1 Fusion Gene p190","C99305","A fusion gene that results from a chromosomal translocation t(9;22)(q34;q11) that fuses exon 1 of the BCR gene to the 5' side of exon 2 of the ABL1 gene. This rearrangement is associated with acute lymphoblastic leukemia.","BCR/ABL1 Fusion Gene p190 | BCR-ABL1 Fusion Gene p190 | BCR/ABL Fusion Gene p190 | BCR::ABL1 Fusion Gene p190",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512383","Female Sexual Function Index","C129328","A 19-item self-report questionnaire designed to measure sexual function in women. It was developed for assessing domains of sexual functioning (e.g. sexual arousal, orgasm, satisfaction, pain) in women participating in clinical trials for arousal disorders.","Female Sexual Function Index | FSFI | Female Sexual Function Index (FSFI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512291","Frequency of Sexual Desire or Interest","C129329","A question about how often an individual felt sexual desire or interest.","Frequency of Sexual Desire or Interest | How often did you feel sexual desire or interest",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512296","Level of Sexual Desire or Interest","C129330","A question about an individual's level or degree of sexual desire or interest.","Level of Sexual Desire or Interest | How would you rate your level (degree) of sexual desire or interest | Sexual Interest / Drive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512292","Frequency of Sexual Arousal During Sexual Activity or Intercourse","C129331","A question about how often an individual felt sexually aroused during sexual activity or intercourse.","Frequency of Sexual Arousal During Sexual Activity or Intercourse | How often did you feel sexually aroused ('turned on') during sexual activity or intercourse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512297","Level of Sexual Arousal During Sexual Activity or Intercourse","C129332","A question about an individual's level or degree of sexual arousal during sexual activity or intercourse.","Level of Sexual Arousal During Sexual Activity or Intercourse | How would you rate your level of sexual arousal ('turn on') during sexual activity or intercourse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512287","Confidence of Becoming Sexually Aroused During Sexual Activity or Intercourse","C129333","A question about how confident an individual is or was to become sexually aroused during sexual activity or intercourse.","Confidence of Becoming Sexually Aroused During Sexual Activity or Intercourse | How confident were you about becoming sexually aroused during sexual activity or intercourse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512294","Frequency of Satisfaction with Arousal During Sexual Activity or Intercourse","C129334","A question about how often an individual is or was satisfied with sexual arousal or excitement during sexual activity or intercourse.","Frequency of Satisfaction with Arousal During Sexual Activity or Intercourse | How often have you been satisfied with your arousal (excitement) during sexual activity or intercourse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512288","Frequency of Lubrication During Sexual Activity or Intercourse","C129335","A question about how often an individual became lubricated during sexual activity or intercourse.","Frequency of Lubrication During Sexual Activity or Intercourse | How often did you become lubricated ('wet') during sexual activity or intercourse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512137","Difficulty Becoming Lubricated During Sexual Activity or Intercourse","C129336","A question about how difficult it is or was for an individual to become lubricated during sexual activity or intercourse.","Difficulty Becoming Lubricated During Sexual Activity or Intercourse | How difficult was it to become lubricated ('wet') during sexual activity or intercourse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512293","Frequency in Maintenance of Lubrication Until Completion of Sexual Activity or Intercourse","C129337","A question about how often an individual is or was able to maintain lubrication until completion of sexual activity or intercourse.","Frequency in Maintenance of Lubrication Until Completion of Sexual Activity or Intercourse | How often did you maintain your lubrication ('wetness') until completion of sexual activity of intercourse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512138","Difficulty in Maintenance of Lubrication Until Completion of Sexual Activity or Intercourse","C129338","A question about how difficult it is or was for an individual to maintain lubrication until completion of sexual activity or intercourse.","Difficulty in Maintenance of Lubrication Until Completion of Sexual Activity or Intercourse | How difficult was it to maintain your lubrication ('wetness') until completion of sexual activity or intercourse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512351","Frequency of Reaching Orgasm with Sexual Stimulation or Intercourse","C129339","A question about how often orgasm or climax is or was reached when an individual had sexual stimulation or intercourse.","Frequency of Reaching Orgasm with Sexual Stimulation or Intercourse | When you had sexual stimulation or intercourse, how often did you reach orgasm (climax)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512139","Difficulty of Reaching Orgasm with Sexual Stimulation or Intercourse","C129340","A question about how difficult it is or was to reach orgasm or climax when an individual had sexual stimulation or intercourse.","Difficulty of Reaching Orgasm with Sexual Stimulation or Intercourse | When you had sexual stimulation or intercourse, how difficult was it for you reach orgasm (climax)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512237","Satisfaction of Ability to Reach Orgasm During Sexual Activity or Intercourse","C129341","A question about how satisfied an individual is or was with the ability to reach orgasm or climax during sexual activity or intercourse.","Satisfaction of Ability to Reach Orgasm During Sexual Activity or Intercourse | How satisfied were you with your ability to reach orgasm (climax) during sexual activity or intercourse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512238","Satisfaction of Emotional Closeness During Sexual Activity with Partner","C129342","A question about how satisfied an individual is or has been with the amount of emotional closeness during sexual activity with their partner.","Satisfaction of Emotional Closeness During Sexual Activity with Partner | How satisfied have you been with the amount of emotional closeness during sexual activity between you and your partner",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512239","Satisfaction of Sexual Relationship with Partner","C129343","A question about how satisfied an individual is or has been with the sexual relationship with their partner.","Satisfaction of Sexual Relationship with Partner | How satisfied have you been with your sexual relationship with your partner",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512240","Satisfaction with Overall Sexual Life","C129344","A question about how satisfied an individual is or has been with their overall sexual life.","Satisfaction with Overall Sexual Life | How satisfied have you been with your overall sexual life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512289","Frequency of Experiencing Discomfort or Pain During Vaginal Penetration","C129345","A question about how often an individual has experienced discomfort or pain during vaginal penetration.","Frequency of Experiencing Discomfort or Pain During Vaginal Penetration | How often did you experience discomfort or pain during vaginal penetration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512290","Frequency of Experiencing Discomfort or Pain Following Vaginal Penetration","C129346","A question about how often an individual has experienced discomfort or pain following vaginal penetration.","Frequency of Experiencing Discomfort or Pain Following Vaginal Penetration | How often did you experience discomfort or pain following vaginal penetration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512295","Level of Discomfort or Pain During or Following Vaginal Penetration","C129347","A question about the level or degree of discomfort or pain an individual has experienced during or following vaginal penetration.","Level of Discomfort or Pain During or Following Vaginal Penetration | How would you rate your level (degree) of discomfort or pain during or following vaginal penetration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3844157","Always or Almost Always","C129348","A response indicating that something happened always or almost always.","Always or Almost Always | Almost always or always",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3843272","A Few Times","C129349","A response indicating that something happened less than half the time.","A Few Times | A Few Times (Much Less Than Half the Time) | A few times (less than half the time) | Less Than Half the Time | Much Less than Half the Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3844158","Never or Almost Never","C129350","A response indicating that something happened never or almost never.","Never or Almost Never | Almost never or never",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020492","Hyperostosis","C34712","Excessive thickening of bone.","Hyperostosis | Bone Hypertrophy",,,,,,,,,,,,,,,"4069318","Hypertrophy of bone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015786","Female Sexual Arousal Disorder","C94339","A disorder characterized by a recurrent or persistent inability to attain or maintain until completion of sexual activity an adequate physical response of sexual excitement, consisting of vasocongestion in the pelvis, vaginal lubrication and expansion, and swelling of the external genitalia.","Female Sexual Arousal Disorder | ",,,,,,,,,,,,,,,"4262519","Female sexual arousal disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512281","Symptoms Interfered with General Activity","C129356","A question about how much an individual's symptoms interfere or interfered with their general activity.","Symptoms Interfered with General Activity Question | General activity | Symptoms Interfered with General Activity | Symptoms Interfered with General Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512510","Symptoms Interfered with Mood","C129357","A question about how much an individual's symptoms interfere or interfered with their mood.","Symptoms Interfered with Mood | Mood",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512506","Symptoms Interfered with Work","C129358","A question about how much an individual's symptoms interfere or interfered with their work.","Symptoms Interfered with Work | Work (including work around the house)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512325","Symptoms Interfered with Relations with Other People","C129359","A question about how much an individual's symptoms interfere or interfered with their relations with other people.","Symptoms Interfered with Relations with Other People | Relations with other people",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512508","Symptoms Interfered with Walking","C129360","A question about how much an individual's symptoms interfere or interfered with their walking.","Symptoms Interfered with Walking Question | Symptoms Interfered with Walking | Symptoms Interfered with Walking | Walking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512505","Symptoms Interfered with Enjoyment of Life","C129361","A question about how much an individual's symptoms interfere or interfered with their enjoyment of life.","Symptoms Interfered with Enjoyment of Life | Enjoyment of life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512495","Symptom Interference Likert Scale","C129362","A scale for the subjective scoring of a symptom's interference that ranges from 0: Did Not Interfere to 10: Interfered Completely.","Symptom Interference Likert Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512330","Symptom Interference Score 0","C129363","A subjective score of 0 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.","Symptom Interference Score 0 | Symptoms Did Not Interfere",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512496","Symptom Interference Score 1","C129364","A subjective score of 1 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.","Symptom Interference Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512497","Symptom Interference Score 2","C129365","A subjective score of 2 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.","Symptom Interference Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512498","Symptom Interference Score 3","C129366","A subjective score of 3 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.","Symptom Interference Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512499","Symptom Interference Score 4","C129367","A subjective score of 4 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.","Symptom Interference Score 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512500","Symptom Interference Score 5","C129368","A subjective score of 5 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.","Symptom Interference Score 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512501","Symptom Interference Score 6","C129369","A subjective score of 6 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.","Symptom Interference Score 6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512502","Symptom Interference Score 7","C129370","A subjective score of 7 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.","Symptom Interference Score 7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512503","Symptom Interference Score 8","C129371","A subjective score of 8 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.","Symptom Interference Score 8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512504","Symptom Interference Score 9","C129372","A subjective score of 9 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.","Symptom Interference Score 9 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512331","Symptom Interference Score 10","C129373","A subjective score of 10 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.","Symptom Interference Score 10 | Symptoms Interfered Completely",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031538","Phimosis","C26852","A condition in which there is constriction in the tip of the foreskin resulting in inability to fully retract the foreskin over the glans penis.  Causes include balanoposthitis, balanitis xerotica obliterans, and untreated diabetes.","Phimosis | ",,,,,,,,,,,,,,,"42709954","Phimosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0392707","Atopy","C41366","A genetic predisposition to form IgE antibodies in response to exposure to allergens and therefore, for the development of immediate (type I) hypersensitivity and atopic conditions, such as allergic rhinitis; bronchial asthma, atopic dermatitis, and food allergy. Mutations of specific alleles on the long arm of chromosome 5 have been associated with higher levels of IL-4 and IgE and are known as IL-4 promoter polymorphisms.","Atopy | Atopic Allergy",,,,,,,,,,,,,,,"4019380","Atopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0228120","Falx Cerebri","C12890","A double-fold of dura mater that lies within the medial longitudinal fissure, and which separates the two cerebral hemispheres. It is attached rostrally to the crista galli and caudally to the surface of the tentorium cerebelli.","Falx Cerebri | Cerebral Falx | Falx of Cerebrum",,,,,,,,,,,,,,,"4213056","Structure of falx cerebri",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512797","Cerebral Convexity","C129428","Area within the sulci of the brain, usually anterior to the rolandic fissure.","Cerebral Convexity | Convexity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512782","Olfactory Groove","C129429","Cranial cavity between the brow and nose in the frontal area of the brain.","Olfactory Groove | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1283566","Sphenoid Wing","C129430","One of two strong processes of the sphenoid bone, which arise from the sides of the body, and are curved upward, laterally, and backward. The superior or cerebral surface of each greater wing forms part of the middle cranial fossa.","Sphenoid Wing | ALISPHENOID PROCESS | Alisphenoid Process | Greater Wing of the Sphenoid Bone",,,,,,,,,,,,,,,"4331955","Structure of wing of sphenoid bone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0279756","Estrogen receptor negative","C15493","The absence of detectable estrogen receptor alpha in a tissue sample.","Estrogen Receptor Negative | ER Alpha Negative | ER Negative | ER- | ER-Alpha Negative | ERA Negative | ESR Negative | ESR1 Negative | ESRA Negative | ESTRR Negative | Estrogen Receptor 1 Negative | Estrogen Receptor Alpha Negative | NR3A1 Negative | Negative | Negative Estrogen Receptor | Nuclear Receptor Subfamily 3 Group A Member 1 Negative | estrogen receptor negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279766","progesterone receptor negative","C15497","An indication that progesterone receptor (PRG; PR) expression has not been detected in a sample.","Progesterone Receptor Negative | Negative | PGR Negative | PR Negative | PR- | progesterone receptor negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348909","HER2/Neu Positive","C68748","A laboratory test result indicating the presence of HER2/Neu in a tissue sample.","HER2/Neu Positive | ERBB2 Positive | HER+ | HER-2 Positive | HER2 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3888518","CD20 Positive","C128631","A finding indicating that CD20 is present on cells or expressed by cells.","CD20 Positive | CD20 Antigen Positive | CD20 Expressing | CD20 Present | CD20+ | Leu-16 Positive | MS4A1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0178415","PSA Progression","C123611","The amount of prostate specific antigen is increased, based on pre-defined thresholds.","PSA Progression | Elevated PSA | Elevated Prostate Specific Antigen | Increasing PSA | PSA Elevated | PSA PROGRESSION | Prostate Specific Antigen Progression | Rising PSA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1222822","Dickeya","C127280","A genus of gram-negative facultatively anaerobic bacillus bacteria in the family Enterobacteriaceae comprising mainly pathogens from herbaceous plants.","Dickeya | Erwinia",,,,,,,,,,,,,,,"4221920","Dickeya",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512776","European LeukemiaNet","C129456","A publicly funded research network of excellence with a goal of curing leukemia. The European LeukemiaNet aims to strengthen and develop scientific and technological excellence in research and therapy of leukemia (CML, AML, ALL, CLL, MDS, CMPD) by integration of the leading national leukemia networks and their interdisciplinary partner groups in Europe.","European LeukemiaNet | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272950","Immature Cell Count (laboratory procedure)","C96672","The determination of the amount of immature cells present in a sample.","Immature Cell Count | CELLSIM | Immature Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055168","Cytogenetic Response","C123620","An evaluation of the cytogenetic response of the disease to the therapy.","Cytogenetic Response | CYTORESP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898579","Log Score","C117890","A number or range of numeric values on the log scale that measures performance, function, quality, or ability.","Log Score | LOGSCORE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL494647","Total Score","C120457","The sum of a set of numeric values.","Total Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512724","Temporooccipital","C129458","Pertaining to the temporal and occipital bones of the skull or lobes of the brain.","Temporooccipital | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512700","Frontotemporal","C129459","Pertaining to the frontal and temporal bones of the skull or lobes of the brain.","Frontotemporal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512788","Subungual","C129460","Pertaining to the area underneath a finger nail or toe nail.","Subungual | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL018341","Anorectal","C129464","Pertaining to the anus and rectum.","Anorectal | Anorectum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512775","Sun-exposed Site","C129465","An area of the body exposed to sunlight.","Sun-exposed Site | Sun exposed site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512692","Chronically Sun-exposed Site","C129466","An area of the body subjected to consistent and repetitive sun exposure.","Chronically Sun-exposed Site | Chronically sun exposed site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512571","Nonchronically Sun-exposed Site","C129467","An area of the body subjected to inconsistent sun exposure.","Nonchronically Sun-exposed Site | Intermittently Sun-exposed Site | Nonchronically sun exposed site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152255","Pinguecula","C129468","Yellowish deposits on the conjunctiva close to the edge of the cornea.","Pinguecula | Pingueculum",,,,,,,,,,,,,,,"376124","Pinguecula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0442145","Paraspinal","C129461","Pertaining to muscles and/or tissue adjacent to the spinal column.","Paraspinal | ",,,,,,,,,,,,,,,"4126060","Paraspinal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512676","Cellular Dedifferentiation","C129469","A morphologic finding indicating the presence of a high-grade cellular component adjacent to or admixed with a low-grade cellular infiltrate.","Cellular Dedifferentiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512793","Classic Histology","C129470","A term that refers to the histologic image of a lesion which carries all the characteristic morphologic findings which are necessary to define this lesion.","Classic Histology | Classic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512786","Submandibular","C129462","Pertaining to the area below the lower jaw or mandible.","Submandibular | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512787","Submaxillary","C129463","Pertaining to the area underneath the upper jaw or maxilla.","Submaxillary | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513997","Neoplastic Large Cell","C37162","A neoplastic cell with abundant amount of cytoplasm and/or large nucleus.","Neoplastic Large Cell | Large Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017963","Glycoprotein Hormones Alpha Polypeptide","C65745","The alpha polypeptide chain of any of the four human glycoprotein hormones chorionic gonadotropin (CG), luteinizing hormone (LH), follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH). Overexpressed in certain estrogen receptor (ER)-positive cancers, glycoprotein hormones alpha polypeptide (choriogonadotropin alpha; CGA) may be used as a biomarker for these types of cancer or as a predictor for the responsiveness of certain anti-estrogen therapy.","Glycoprotein Hormones Alpha Polypeptide | Anterior Pituitary Glycoprotein Hormones Common Alpha Subunit | CG-alpha | Choriogonadotropin Alpha Chain | Chorionic Gonadotrophin Alpha Subunit | FSH-alpha | Follicle-Stimulating Hormone Alpha Chain | Follitropin Alfa | Follitropin Alpha Chain | GLYCOPROTEIN HORMONES ALPHA POLYPEPTIDE | LSH-alpha | Luteinizing Hormone Alpha Chain | Luteinizing Hormone Subunit Alpha | Lutropin Alpha Chain | TSH-alpha | Thyroid-Stimulating Hormone Alpha Chain | Thyrotropin Alpha Chain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512785","Small Cell Adenocarcinoma","C129449","An adenocarcinoma composed of small malignant cells.","Small Cell Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512718","Medulloblastoma, WNT-Activated","C129440","A molecular subtype of medulloblastoma associated with activation of the WNT pathway. TP53 mutations may be present or absent. WNT pathway activation in medulloblastomas is associated with good outcome.","Medulloblastoma, WNT-Activated | Medulloblastoma, WNT-activated | WNT Signaling Pathway Aberrant Medulloblastoma | WNT-Activated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0805508","CDKN2A Gene Deletion","C41615","A molecular abnormality referring to the loss of at least one copy of the CDKN2A gene.","CDKN2A Gene Deletion | CDK4I Gene Deletion | CDKN2A Copy Number Loss | CDKN2A Deletion | CDKN2A deletion | CDKN2A-p16 Gene Deletion | p14ARF Gene Deletion | p16 Gene Deletion | p16-INK4A Gene Deletion | p16INK4a Gene Deletion | p19ARF Gene Deletion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512615","Epstein-Barr Virus Positive","C129454","Indicates that Epstein-Barr virus has been detected in a sample.","Epstein-Barr Virus Positive | EBV Positive | EBV-Positive | Epstein Barr Virus Positive | Epstein-Barr Virus-Positive | HHV-4 Positive | HHV4 Positive | Human Herpesvirus 4 Positive | Human Herpesvirus-4 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512528","Hepatitis C Virus Positive","C129452","Indicates that hepatitis C virus has been detected in a sample.","Hepatitis C Virus Positive | HCV Positive | Hep C Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512704","HLA Class I Histocompatibility Antigen, A-0201 Alpha Chain Positive","C129450","Indicates that HLA class I histocompatibility antigen, A-0201 alpha chain expression has been detected in a sample.","HLA Class I Histocompatibility Antigen, A-0201 Alpha Chain Positive | C129450 | HLA-A*0201 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512557","Human Papillomavirus-16 Positive","C129455","Indicates that human papillomavirus-16 has been detected in a sample.","Human Papillomavirus-16 Positive | HPV-16 Positive | HPV16 Positive | Human Papilloma Virus 16 Positive | Human Papilloma Virus-16 Positive | Human Papillomavirus 16 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512584","Wnt Positive","C129451","Indicates that expression of one or more Wnt family members has been detected in a sample.","Wnt Positive | Wingless-Type MMTV Integration Site Family Positive | Wnt Family Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512583","WT1 Positive","C129453","Indicates that WT1 expression has been detected in a sample.","WT1 Positive | Wilms Tumor 1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334323","Mixed Cell Adenoma","C4157","An adenoma characterized by the presence of a mixed epithelial cell population.","Mixed Cell Adenoma | Mixed cell adenoma","8323/0","Mixed cell adenoma",,,,,,,,,,,,,"4232795","Mixed cell adenoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1336913","Endometrial Endometrioid Adenocarcinoma with Spindled Epithelial Cells","C27850","A primary endometrioid adenocarcinoma of the endometrium characterized by the presence of spindled malignant epithelial cells.","Endometrial Endometrioid Adenocarcinoma with Spindled Epithelial Cells | Sarcomatoid Uterine Corpus Endometrioid Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3805992","Pterygium Colli","C87130","A congenital, usually bilateral, thick web-like fold of skin that extends from the acromion to the mastoid process. This deformity is associated with Turner Syndrome and Noonan Syndrome.","Pterygium Colli | Neck Webbing | Webbed Neck",,,,,,,,,,,,,,,"23304","Neck webbing",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL054281","Psammoma Body Formation","C27709","A structure found in some benign (not cancer) or malignant (cancer) tumor cells. Psammoma bodies look like hardened concentric rings when viewed under a microscope. They can be a sign of chronic inflammation.","Psammoma Body Formation | psammoma body",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL481467","Virilization","C120262","The development of normal male puberty due to testosterone effect or the abnormal development of male secondary sexual characteristics in children and females due to excessive androgens.","Virilization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509788","Not Otherwise Specified Lesion","C128698","A lesion in which further histopathological and/or molecular characterization is not possible, available, or reported.","Not Otherwise Specified Lesion | NOS Lesion | Not Further Specified Lesion | Unclassifiable Lesion | Unclassifiable/Not Further Specified Lesion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1955928","Elastography","C106517","An ultrasound-based imaging technique used to examine the stiffness or elasticity of a tissue by applying mechanical compression or vibration to the tissue being imaged.","Elastography | ELASTOGRAPHY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518156","Magnetic Resonance Elastography","C19338","This imaging technique returns information about the mechanical properties (feel) of tissues by combining MRI with ultrasound.  A properly equipped MRI machine captures a cross sectional image of the sound waves, produced by ultrasound techniques, which are then processed by computer to produce an image showing the hardness or elasticity of tissues within the cross section.","Magnetic Resonance Elastography | MAGNETIC RESONANCE ELASTOGRAPHY | MRE",,,,,,,,,,,,,,,"37396258","Magnetic resonance elastography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3843357","Did Not Attempt Intercourse","C129471","A response indicating that sexual intercourse was not attempted.","Did Not Attempt Intercourse | Did not attempt intercourse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3840693","No Sexual Activity","C129472","A response indicating the absence of sexual activity.","No Sexual Activity | No sexual activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512792","Very High Level","C129473","A response indicating a very high level.","Very High Level | Very high",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512790","High Level","C129474","A response indicating a high level.","High Level | High",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512647","Moderate Level","C129475","A response indicating a moderate level.","Moderate Level | Moderate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512789","Low Level","C129476","A response indicating a low level.","Low Level | Low",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512581","Very Low Level or None at All","C129477","A response indicating a very low level or an absence.","Very Low Level or None at All | Very low or none at all",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512579","Very High Confidence","C129478","A response indicating a very high level of confidence.","Very High Confidence | Very high confidence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512529","High Confidence","C129479","A response indicating a high level of confidence.","High Confidence | High confidence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4036199","Moderate Confidence","C129480","A response indicating a moderate level of confidence.","Moderate Confidence | Moderate confidence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512645","Low Confidence","C129481","A response indicating a low level of confidence.","Low Confidence | Low confidence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512580","Very Low Confidence or No Confidence","C129482","A response indicating a very low level of confidence or an absence.","Very Low Confidence or No Confidence | Very low or no confidence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512772","Extremely Difficult or Impossible","C129483","A response indicating that something is or was extremely difficult or impossible.","Extremely Difficult or Impossible | Extremely difficult or impossible",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3843353","Very Difficult","C129484","A response indicating that something is or was very difficult.","Very Difficult | Very difficult",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512525","Difficult","C129485","A response indicating that something is or was difficult.","Difficult | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3843356","Slightly Difficult","C129486","A response indicating that something is or was slightly difficult.","Slightly Difficult | Slightly difficult",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3843355","Not Difficult","C129487","A response indicating that something is or was not difficult.","Not Difficult | Not difficult",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3840671","Very Satisfied","C129488","A response indicating a high level of satisfaction.","Very Satisfied | Very satisfied",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3843336","Moderately Satisfied","C129489","A response indicating a moderate level of satisfaction.","Moderately Satisfied | Moderately satisfied",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3843337","About Equally Satisfied and Dissatisfied","C129490","A response indicating an equal level of satisfaction and dissatisfaction.","About Equally Satisfied and Dissatisfied | About equally satisfied and dissatisfied | Equally Satisfied and Dissatisfied | Mixed Satisfaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3843338","Moderately Dissatisfied","C129491","A response indicating a moderate level of dissatisfaction.","Moderately Dissatisfied | Moderately dissatisfied",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3843339","Very Dissatisfied","C129492","A response indicating a high level of dissatisfaction.","Very Dissatisfied | Very dissatisfied",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054793","Hematologic Response","C123622","An evaluation of the hematologic response of the disease to the therapy.","Hematologic Response | HEMARESP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055172","Cytogenetic Minimal Response","C123579","A minimal decrease in abnormal karyotype, based on pre-defined thresholds.","Cytogenetic Minimal Response | CYTOGENETIC MINIMAL RESPONSE | Minimal CgR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050308","Molecular Complete Response","C123593","The disappearance of all signs of cancer, supported by molecular analysis.","Molecular Complete Response | CMR | Complete Molecular Response | MOLECULAR CR | Molecular CR | Molecular Complete Remission",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049637","Molecular Major Response","C123594","A decrease in signs of cancer, supported by molecular analysis.","Molecular Major Response | MMR | MMolR | MOLECULAR MAJOR RESPONSE | Major Molecular Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050364","Cytogenetic Complete Response","C123578","The disappearance of all signs of cancer, including the absence of a detectable disease-related genetic abnormality, as determined by techniques such as karyotyping or FISH, in response to treatment.","Cytogenetic Complete Response | CCgR | CCyR | CRc | CYTOGENETIC CR | Complete Cytogenetic Response | Cytogenetic Complete Remission",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055169","Cytogenetic Partial Response","C123582","A partial decrease in abnormal karyotype, based on pre-defined thresholds.","Cytogenetic Partial Response | CYTOGENETIC PR | Cytogenetic PR | Partial CgR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055171","Cytogenetic Minor Response","C123580","A minor decrease in abnormal karyotype, based on pre-defined thresholds.","Cytogenetic Minor Response | CYTOGENETIC MINOR RESPONSE | Minor CgR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055170","Cytogenetic No Response","C123581","No change in abnormal karyotype, based on pre-defined thresholds.","Cytogenetic No Response | CYTOGENETIC NO RESPONSE | No CgR | No Cytogenetic Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0267187","Intestinal Metaplasia of Gastric Mucosa","C3956","A morphologic finding indicating the replacement of part of the gastric mucosal epithelium with intestinal-type epithelium.  Using immunohistochemical staining, gastric intestinal metaplasia is classified as complete or incomplete.  Complete intestinal metaplasia is defined by the decreased expression of gastric mucins and expression of the intestinal mucin MUC2.  Incomplete intestinal metaplasia is defined by the co-expression of both gastric mucins and MUC2.","Intestinal Metaplasia of Gastric Mucosa | Gastric Intestinal Metaplasia",,,,,,,,,,,,,,,"4217648","Intestinal metaplasia of gastric mucosa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1513808","NRAS Gene Mutation","C41381","A change in the structure of the NRAS gene.","NRAS Gene Mutation | N-RAS Gene Mutation | N-RAS Mutation | NRAS mutation | Neuroblastoma RAS Viral Oncogene Homolog Gene Mutation | Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512123","CDKN2A Gene Mutation","C128817","A change in the nucleotide sequence of the CDKN2A gene.","CDKN2A Gene Mutation | CDK4I Gene Mutation | CDKN2A | CDKN2A Mutation | Cyclin-Dependent Kinase Inhibitor 2A Gene Mutation | p14ARF Gene Mutation | p16 Gene Mutation | p16-INK4A Gene Mutation | p16INK4 Gene Mutation | p16INK4a Gene Mutation | p19ARF Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512530","How Much Bothered by Fatigue on Average","C129494","A question about how much an individual is or was bothered by fatigue on average.","How Much Bothered by Fatigue on Average | How much were you bothered by your fatigue on average",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512543","How Often Have to Push to Get Things Done Because of Fatigue","C129496","A question about how often an individual has or had to push to get things done because of their fatigue.","How Often Have to Push to Get Things Done Because of Fatigue | How often did you have to push yourself to get things done because of your fatigue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512541","How Often Have Trouble Finishing Things Because of Fatigue","C129497","A question about how often an individual has or had trouble finishing things because of their fatigue.","How Often Have Trouble Finishing Things Because of Fatigue | How often did you have trouble finishing things because of your fatigue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0360105","Selective Serotonin Reuptake Inhibitor","C94725","Any agent that increases the extracellular level of the neurotransmitter serotonin (5-HT) by inhibiting its reuptake into the presynaptic cell. Increased level in the synaptic cleft prolongs the action of 5-HT on the postsynaptic receptor. This type of agent is typically used as an antidepressant and in the treatment of anxiety disorders and some personality disorders. They are also typically effective and used in treating some cases of insomnia.","Selective Serotonin Reuptake Inhibitor | SSRI | selective serotonin reuptake inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221150","Odynophagia","C129502","Pain upon swallowing.","Odynophagia | ",,,,,,,,,,,,,,,"4147218","Swallowing painful",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512268","TNFRSF17 Positive","C128845","Indicates that TNFRSF17 expression has been detected in a sample.","TNFRSF17 Positive | B Cell Maturation Antigen Positive | BCMA Positive | CD269 Antigen Positive | CD269 Positive | Tumor Necrosis Factor Receptor Superfamily Member 1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512492","Somatostatin Receptor Positive","C128873","A laboratory test result indicating the presence or expression of somatostatin receptor in a sample.","Somatostatin Receptor Positive | SSTR Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086836","SMO Gene Mutation","C124793","A molecular genetic abnormality that refers to the mutation of the SMO gene located on chromosome 7q32.3.","SMO Gene Mutation | FZD11 Gene Mutation | Frizzled Family Member 11 Gene Mutation | SMOH Gene Mutation | Smoothened Homolog (Drosophila) Gene Mutation | Smoothened Homolog Gene Mutation | Smoothened, Frizzled Class Receptor Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512134","Deleterious BRCA1 Gene Mutation","C128814","A change in the nucleotide sequence of the BRCA1 gene that is associated with increased risk of disease.","Deleterious BRCA1 Gene Mutation | Deleterious BROVCA1 Gene Mutation | Deleterious Breast Cancer Type 1 Susceptibility Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512135","Deleterious BRCA2 Gene Mutation","C128815","A change in the nucleotide sequence of the BRCA2 gene that is associated with increased risk of disease.","Deleterious BRCA2 Gene Mutation | Deleterious Breast Cancer Type 2 Susceptibility Gene Mutation | Deleterious FANCD1 Gene Mutation | Deleterious XRCC11 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274049","KRAS NP_004976.2:p.G13C","C98401","A change in the amino acid residue at position 13 in the GTPase KRas protein where glycine has been replaced by cysteine.","KRAS NP_004976.2:p.G13C | GTPase KRas G13C | K-Ras 2 G13C | KRAS G13C | KRAS Gly13Cys | KRAS NP_004976.2:p.Gly13Cys | KRAS p.G13C | KRAS p.Gly13Cys | Ki-Ras G13C | NP_004976.2:p.Gly13Cys | c-K-ras G13C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274022","KRAS NP_004976.2:p.G12F","C98375","A change in the amino acid residue at position 12 in the GTPase KRas protein where glycine has been replaced by phenylalanine.","KRAS NP_004976.2:p.G12F | GTPase KRas G12F | K-Ras 2 G12F | KRAS G12F | KRAS Gly12Phe | KRAS NP_004976.2:p.Gly12Phe | KRAS p.G12F | KRAS p.Gly12Phe | Ki-Ras G12F | NP_004976.2:p.Gly12Phe | c-K-ras G12F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274052","KRAS NM_004985.3:c.38G>A","C98404","A nucleotide substitution at position 38 of the coding sequence of the KRAS gene where guanine has been mutated to adenine.","KRAS NM_004985.3:c.38G>A | C-K-RAS c.38G>A | Codon 13, Gly13Asp (GGC>GAC) | KI-RAS c.38G>A | KRAS c.38G>A | KRAS1 c.38G>A | KRAS2 c.38G>A | NM_004985.3:c.38G>A | v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog c.38G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274050","KRAS NM_004985.3:c.37G>T","C98402","A nucleotide substitution at position 37 of the coding sequence of the KRAS gene where guanine has been mutated to thymine.","KRAS NM_004985.3:c.37G>T | C-K-RAS c.37G>T | Codon 13, Gly13Cys (GGC>TGC) | KI-RAS c.37G>T | KRAS c.37G>T | KRAS1 c.37G>T | KRAS2 c.37G>T | NM_004985.3:c.37G>T | v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog c.37G>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274011","KRAS NM_004985.3:c.35G>C","C98364","A nucleotide substitution at position 35 of the coding sequence of the KRAS gene where guanine has been mutated to cytosine.","KRAS NM_004985.3:c.35G>C | C-K-RAS c.35G>C | Codon 12, Gly12Ala (GGT>GCT) | KI-RAS c.35G>C | KRAS c.35G>C | KRAS1 c.35G>C | KRAS2 c.35G>C | NM_004985.3:c.35G>C | v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog c.35G>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274037","KRAS NM_004985.3:c.34G>A","C98390","A nucleotide substitution at position 34 of the coding sequence of the KRAS gene where guanine has been mutated to adenine.","KRAS NM_004985.3:c.34G>A | C-K-RAS c.34G>A | Codon 12, Gly12Ser (GGT>AGT) | KI-RAS c.34G>A | KRAS c.34G>A | KRAS1 c.34G>A | KRAS2 c.34G>A | NM_004985.3:c.34G>A | v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog c.34G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274075","KRAS NM_004985.3:c.183A>T","C98427","A nucleotide substitution at position 183 of the coding sequence of the KRAS gene where adenine has been mutated to thymine.","KRAS NM_004985.3:c.183A>T | C-K-RAS c.183A>T | KI-RAS c.183A>T | KRAS c.183A>T | KRAS1 c.183A>T | KRAS2 c.183A>T | NM_004985.3:c.183A>T | v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog c.183A>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274076","KRAS NM_004985.3:c.183A>C","C98428","A nucleotide substitution at position 183 of the coding sequence of the KRAS gene where adenine has been mutated to cytosine.","KRAS NM_004985.3:c.183A>C | C-K-RAS c.183A>C | KI-RAS c.183A>C | KRAS c.183A>C | KRAS1 c.183A>C | KRAS2 c.183A>C | NM_004985.3:c.183A>C | v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog c.183A>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274082","KRAS NM_004985.3:c.182A>T","C98434","A nucleotide substitution at position 182 of the coding sequence of the KRAS gene where adenine has been mutated to thymine.","KRAS NM_004985.3:c.182A>T | C-K-RAS c.182A>T | Codon 61, Gln61Leu (CAA>CTA) | KI-RAS c.182A>T | KRAS c.182A>T | KRAS1 c.182A>T | KRAS2 c.182A>T | NM_004985.3:c.182A>T | v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog c.182A>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274086","KRAS NM_004985.3:c.182A>G","C98438","A nucleotide substitution at position 182 of the coding sequence of the KRAS gene where adenine has been mutated to guanine.","KRAS NM_004985.3:c.182A>G | C-K-RAS c.182A>G | KI-RAS c.182A>G | KRAS c.182A>G | KRAS1 c.182A>G | KRAS2 c.182A>G | NM_004985.3:c.182A>G | v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog c.182A>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3258006","Patient Health Questionnaire-4","C129505","An ultra-brief self-report questionnaire that consists of a 2-item depression scale that uses the first 2 questions from the Patient Health Questionnaire-9 (PHQ-9) and a 2-item anxiety scale that uses the first two questions from the Generalized Anxiety Disorder 7-item scale (GAD-7).","Patient Health Questionnaire-4 | PHQ-4 | Patient Health Questionnaire - 4 Item",,,,,,,,,,,,,,,"3655510","Patient Health Questionnaire-4",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003855","Arteriovenous Fistula","C36192","An unintended connection between an artery and vein.","Arteriovenous Fistula | AV Fistula | Pathologic AV Fistula | Pathologic Arteriovenous Fistula",,,,,,,,,,,,,,,"4029967|4234480","Arteriovenous fistula|Arteriovenous fistula",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0125644","Leukotriene E4","C129009","The final and most stable product of the pathway where 5-lipoxygenase converts arachidonic acid to cysteinyl leukotrienes, with inflammatory activity. Because of its inherent stability, leukotriene E4 is used as a marker for leukotriene production.","Leukotriene E4 | (5S,6R,7E,9E,11Z,14Z)-6-(2-Amino-2-Carboxyethyl)Sulfanyl-5-Hydroxyicosa-7,9,11,14-Tetraenoic Acid | (5S-(5R*,6S*(S*),7E,9E,11Z,14Z))-6-((2-Amino-2-Carboxyethyl)Thio)-5-Hydroxy-7,9,11,14-Eicosatetraenoic Acid | (7E,9E,11Z,14Z)-(5S,6R)-6-(Cystein-S-yl)-5-Hydroxyeicosa-7,9,11,14-Tetraenoate | (7E,9E,11Z,14Z)-(5S,6R)-6-(Cystein-S-yl)-5-Hydroxyicosa-7,9,11,14-Tetraenoate | 5S-Hydroxy,6R-(S-Cysteinyl),7E,9E,11Z,14Z-Eicosatetraenoic Acid | 7,9,11,14-Eicosatetraenoic Acid, 6-((2-Amino-2-Carboxyethyl)Thio)-5-Hydroxy-, (5S-(5R*,6S*(S*),7E,9E,11Z,14Z))- | LEUKOTRIENE E4 | LTE4 | Leukotriene E(4) | S-{(1R,2E,4E,6Z,9Z)-1-[(1S)-4-Carboxy-1-Hydroxybutyl]Pentadeca-2,4,6,9-Tetraen-1-yl}-L-Cysteine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418252","SERPINE1 Gene","C39650","This gene is involved in the control of blood coagulation.","SERPINE1 Gene | SERPINE1 | Serpin Family E Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512604","KRAS NM_004985.3:c.436G>A","C129523","A nucleotide substitution at position 436 of the coding sequence of the KRAS gene where guanine has been mutated to adenine.","KRAS NM_004985.3:c.436G>A | C-K-RAS c.436G>A | KI-RAS c.436G>A | KRAS c.436G>A | KRAS1 c.436G>A | KRAS2 c.436G>A | NM_004985.3:c.436G>A | v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog c.436G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512624","KRAS NP_004976.2:p.A146T","C129524","A change in the amino acid residue at position 146 in the GTPase Kras protein where alanine has been replaced by threonine.","KRAS NP_004976.2:p.A146T | GTPase KRas A146T | GTPase KRas Ala146Thr | K-Ras 2 A146T | K-Ras 2 Ala146Thr | KRAS A146T | KRAS Ala146Thr | KRAS NP_004976.2:p.Ala146Thr | KRAS NP_004976.2:p.Ala146Thr | KRAS p.A146T | KRAS p.Ala146Thr | Ki-Ras A146T | Ki-Ras Ala146Thr | NP_004976.2:p.A146T | NP_004976.2:p.Ala146Thr | c-K-ras A146T | c-K-ras Ala146Thr",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512708","Major Cytogenetic Response in Chronic Myelogenous Leukemia, BCR-ABL1 Positive","C129529","A cytogenetic finding indicating Philadelphia chromosome positivity less than or equal to 35% in a patient treated for chronic myelogenous leukemia, BCR-ABL1 positive.","Major Cytogenetic Response in Chronic Myelogenous Leukemia, BCR-ABL1 Positive | MCyR in Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Major Cytogenetic Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512591","Worst Severity Past Seven Days Wheezing","C129508","A question about an individual's observation of the worst severity they have experienced related to wheezing (whistling noise in the chest with breathing) over the past seven days.","Worst Severity Past Seven Days Wheezing | What was the severity of your wheezing (whistling noise in the chest with breathing) at its worst | Worst Severity of Wheezing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512622","Past Seven Days Frequency of Pounding or Racing Heartbeat","C129509","A question about the frequency of an individual's pounding or racing heartbeat (palpitations) over the past seven days.","Past Seven Days Frequency of Pounding or Racing Heartbeat | Frequency of Pounding or Racing Heartbeat | How often did you feel a pounding or racing heartbeat (palpitations)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512589","Worst Severity Past Seven Days Pounding or Racing Heartbeat","C129510","A question about an individual's observation of the worst severity they have experienced related to pounding or racing heartbeat (palpitations) over the past seven days.","Worst Severity Past Seven Days Pounding or Racing Heartbeat | What was the severity of your pounding or racing heartbeat (palpitations) at its worst | Worst Severity Pounding or Racing Heartbeat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512587","Worst Severity Past Seven Days Dry Skin","C129511","A question about an individual's observation of the worst severity they have experienced related to dry skin over the past seven days.","Worst Severity Past Seven Days Dry Skin | What was the severity of your dry skin at its worst | Worst Severity Dry Skin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512585","Worst Severity Past Seven Days Acne or Pimples on the Face or Chest","C129512","A question about an individual's observation of the worst severity they have experienced related to acne or pimples on the face or chest over the past seven days.","Worst Severity Past Seven Days Acne or Pimples on the Face or Chest | What was the severity of your acne or pimples on the face or chest at its worst | Worst Severity Acne or Pimples on the Face or Chest",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512728","Past Seven Days Any Hair Loss","C129513","A question about whether or not an individual had any hair loss over the past seven days.","Past Seven Days Any Hair Loss | Any Hair Loss | Did you have any hair loss | Did you have any hair loss over the past 7 days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512727","Past Seven Days Any Bed Sores","C129515","A question about whether or not an individual had any bed sores over the past seven days.","Past Seven Days Any Bed Sores | Any Bed Sores | Did you have any bed sores | Did you have any bed sores over the past 7 days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512590","Worst Severity Past Seven Days Skin Burns from Radiation","C129516","A question about an individual's observation of the worst severity they have experienced related to skin burns from radiation over the past seven days.","Worst Severity Past Seven Days Skin Burns from Radiation | What was the severity of your skin burns from radiation at their worst | Worst Severity Skin Burns from Radiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512730","Past Seven Days Any Unusual Darkening of the Skin","C129517","A question about whether or not an individual had any unusual darkening of the skin over the past seven days.","Past Seven Days Any Unusual Darkening of the Skin | Any Unusual Darkening of the Skin | Did you have any unusual darkening of the skin | Did you have any unusual darkening of the skin over the past 7 days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512729","Past Seven Days Any Stretch Marks","C129518","A question about whether or not an individual had any stretch marks over the past seven days.","Past Seven Days Any Stretch Marks | Any Stretch Marks | Did you have any stretch marks | Did you have any stretch marks over the past 7 days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512586","Worst Severity Past Seven Days Dizziness","C129519","A question about an individual's observation of the worst severity they have experienced related to dizziness over the past seven days.","Worst Severity Past Seven Days Dizziness | What was the severity of your dizziness at its worst | Worst Severity Dizziness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512628","Past Seven Days How Much Dizziness Interfered with Usual or Daily Activities","C129520","A question about how much an individual's dizziness interfered with their usual or daily activities over the past seven days.","Past Seven Days How Much Dizziness Interfered with Usual or Daily Activities | How Much Dizziness Interfered with Usual or Daily Activities | How much did dizziness interfere with your usual or daily activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274023","C-K-RAS c.34_35GG>TT","C98376","A complex substitution where the nucleotide sequence at positions 34 through 35 of the coding sequence of the KRAS gene has changed from guanine-guanine to thymine-thymine.","KRAS NM_004985.3:c.34_35delinsTT | C-K-RAS c.34_35GG>TT | KI-RAS c.34_35GG>TT | KRAS NM_004985.3:c.34_35delGGinsTT | KRAS NM_004985.3:c.34_35delGGinsTT | KRAS c.34_35GG>TT | KRAS c.34_35delGGinsTT | KRAS1 c.34_35GG>TT | KRAS2 c.34_35GG>TT | NM_004985.3:c.34_35GG>TT | NM_004985.3:c.34_35delGGinsTT | NM_004985.3:c.34_35delinsTT | v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog c.34_35GG>TT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512339","Anaplastic Pleomorphic Xanthoastrocytoma","C129327","A WHO grade 3 pleomorphic xanthoastrocytoma characterized by the presence of five or more mitoses per 10 high-power fields. Necrosis may be present. Patients have shorter survival rates when compared to those with WHO grade 2 pleomorphic xanthoastrocytoma.","Anaplastic Pleomorphic Xanthoastrocytoma | APX | Anaplastic pleomorphic xanthroastrocytoma | WHO Grade 3 Pleomorphic Xanthoastrocytoma | WHO Grade III Pleomorphic Xanthoastrocytoma",,,,,,,,,,,,,,,"37116840","Anaplastic pleomorphic xanthoastrocytoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512576","Retailer","C129531","A merchant who sells goods directly to consumers.","Retailer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512783","150 (qualifier value)","C129532","A natural number greater than 149 and less than 151 and the quantity that it denotes.","One Hundred Fifty | 150",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512569","Needle Tract Seeding","C129533","The implantation of tumor cells to surrounding tissue along the course of a contaminated instrument such as a biopsy needle or laparoscope.","Needle Tract Seeding | Needle Seeding | Needle Track Seeding | Neoplastic Seeding | Track Seeding | Tract Seeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714514","Infection","C128320","The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.","Infection | Infection, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512791","Revised Dyadic Adjustment Scale","C129539","A 14 item self report questionnaire that assess seven dimensions of couple relationship satisfaction. This revised version of the Dyadic Adjustment Scale is shorter and offers improved psychometric properties.","Revised Dyadic Adjustment Scale | RDAS | Revised Dyadic Adjustment Scale (RDAS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512773","Extent of Agreement or Disagreement on Religious Matters","C129540","A question about the extent of agreement or disagreement between an individual and their partner regarding religious matters.","Extent of Agreement or Disagreement on Religious Matters | Religious matters",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512726","Extent of Agreement or Disagreement on Demonstrations of Affection","C129541","A question about the extent of agreement or disagreement between an individual and their partner regarding demonstrations of affection.","Extent of Agreement or Disagreement on Demonstrations of Affection | Demonstrations of affection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512736","Extent of Agreement or Disagreement on Making Major Decisions","C129542","A question about the extent of agreement or disagreement between an individual and their partner regarding making major decisions.","Extent of Agreement or Disagreement on Making Major Decisions | Making major decisions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512739","Extent of Agreement or Disagreement on Sex Relations","C129543","A question about the extent of agreement or disagreement between an individual and their partner regarding sex relations.","Extent of Agreement or Disagreement on Sex Relations | Sex relations",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512771","Extent of Agreement or Disagreement on Conventionality","C129544","A question about the extent of agreement or disagreement between an individual and their partner regarding conventionality of behavior.","Extent of Agreement or Disagreement on Conventionality | Conventionality (correct or proper behavior)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512609","Extent of Agreement or Disagreement on Career Decisions","C129545","A question about the extent of agreement or disagreement between an individual and their partner regarding career decisions.","Extent of Agreement or Disagreement on Career Decisions | Career decisions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512535","How Often Discuss or Consider Divorce, Separation or Terminating Relationship","C129547","A question about how often an individual has discussed or considered divorce, separation, or termination of their relationship.","How Often Discuss or Consider Divorce, Separation or Terminating Relationship | How often do you discuss or have you considered divorce, separation, or terminating your relationship",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512544","How Often Quarrel With Partner","C129550","A question about how often an individual quarrels with their partner.","How Often Quarrel With Partner | How Often Quarrel with Partner | How often do you and your partner quarrel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512573","Regret Marriage or Living Together","C129552","A question about whether an individual regrets having married or lived together.","Regret Marriage or Living Together | Do you ever regret that you married (or lived together)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512539","How Often Get on Each Other's Nerves","C129553","A question about how often an individual and their partner get on each other's nerves.","How Often Get on Each Other's Nerves | How often do you and your mate 'get on each other's nerves'",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512537","How Often Engage in Outside Interests Together","C129554","A question about how often an individual and their partner engage in outside interests together.","How Often Engage in Outside Interests Together | Do you and your mate engage in outside interests together",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512540","How Often Have Stimulating Exchange of Ideas","C129556","A question about how often an individual and their partner have stimulating exchange of ideas.","How Often Have Stimulating Exchange of Ideas | Have a stimulating exchange of ideas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512554","How Often Work Together on Projects","C129557","A question about how often an individual and their partner work together on a project.","How Often Work Together on Projects | Work together on a project",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512534","How Often Calmly Discuss Something","C129558","A question about how often an individual and their partner calmly discuss something.","How Often Calmly Discuss Something | Calmly discuss something",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512665","Always Agree","C129559","A response indicating agreement at all times.","Always Agree | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512663","Almost Always Agree","C129560","A response indicating agreement at almost all times.","Almost Always Agree | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512781","Occasionally Agree","C129561","A response indicating occasional agreement.","Occasionally Agree | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512699","Frequently Disagree","C129562","A response indicating frequent disagreement.","Frequently Disagree | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512664","Almost Always Disagree","C129563","A response indicating disagreement at almost all times.","Almost Always Disagree | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512666","Always Disagree","C129564","A response indicating disagreement at all times.","Always Disagree | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512562","More Often than Not","C129565","A response indicating that something occurs more than half the time.","More Often than Not | More often than not",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3841785","Less than Once a Month","C129567","An indication that something is scheduled, or occurs, less than once a month.","Less than Once a Month | Less than once a month",,,,,,,,,,,,,,,"765734","Less than once a month",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512737","Once or Twice a Month","C129568","An indication that something is scheduled, or occurs, once or twice a month.","Once or Twice a Month | Once or twice a month",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512563","More Often than Once a Day","C129570","An indication that something is scheduled, or occurs, more than once a day.","More Often than Once a Day | More often",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421254","U2AF1 Gene","C101113","This gene is involved in the splicing of mRNA.","U2AF1 Gene | U2 Small Nuclear RNA Auxiliary Factor 1 Gene | U2AF1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2930696","Tofacitinib","C95800","An orally available inhibitor of Janus kinases (JAK), with immunomodulatory and anti-inflammatory activities. Upon administration, tofacitinib binds to JAK and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of pro-inflammatory cytokines, such as interleukin (IL)-6, -7, -15, -21, interferon-alpha and -beta, and may prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases. JAK kinases are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation.","Tofacitinib | 3-((3R,4R)-4-Methyl-3-(Methyl(7H-Pyrrolo(2,3-D)Pyrimidin-4-yl)Amino)Piperidin-1-yl)-3-Oxopropanenitrile | CP 690550 | CP-690,550 Free Base | CP-690550 | CP690550 | JAK inhibitors: tofacitinib | TOFACITINIB | Tasocitinib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0410000","Overlap Syndrome","C116801","An autoimmune, connective tissue disorder in which the patient exhibits features from two or more diseases. These typically include systemic sclerosis, dermatomyositis, polymyositis, rheumatoid arthritis, systemic lupus erythematosus, and Sjogren syndrome; in pediatrics the respective pediatric entities are encountered.","Overlap Syndrome | ",,,,,,,,,,,,,,,"4079978","Overlap syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1178967","Superoinferior","C129603","Pertaining to the relationship between superior and inferior.","Superoinferior | Supero-Inferior",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1550101","Supernatant","C106485","The liquid lying above a liquid, solid or semi-solid residue, which is separated by crystallization, precipitation or centrifugation of a biological sample.","Supernatant | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2756969","Semen","C13277","The thick, whitish secretion of the male reproductive organs. It is composed of spermatozoa in their nutrient plasma, secretions from the prostate, seminal vesicles, and various other glands, epithelial cells, and minor constituents.","Semen | Human Semen (Sperm) | SEMEN | Seminal Plasma | semen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829114","Methanol/Water-based Buffered Preservative Solution","C113702","A methanol-water solution for the preservation of cervical cells for automated Pap testing.","Methanol/Water-based Buffered Preservative Solution | Methanol/Water-based Buffered Transport Medium | PreservCyt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812761","Prepared Material","C113500","The amount of material produced by an activity.","Prepared Material | Preparation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230267","Paracolic Gutter","C89787","Either of the two naturally ocurring spaces between the colon and the abdominal wall, lateral to the ascending and descending colons.","Paracolic Gutter | PARACOLIC GUTTER",,,,,,,,,,,,,,,"4105674","Structure of paracolic gutter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013075","Cul-de-sac","C113599","A pouch or tube that is open only at one end.","Cul-de-sac | ",,,,,,,,,,,,,,,"4207210","Structure of rectouterine pouch",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3826986","Heparin Potassium","C113690","The potassium salt form of heparin, a sulfur-rich glycosaminoglycan with anticoagulant activity. Heparin binds to antithrombin III to form a heparin-antithrombin III complex. The complex binds to and inactivates thrombin (factor IIa) and other activated clotting factors, such as factors IXa, Xa, XIa, and XIIa. The inactivation of thrombin prevents the polymerization of fibrinogen to fibrin and the subsequent formation of blood clots.","Heparin Potassium | Clarin | HEPARIN POTASSIUM | KHep | Potassium Acid Heparin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711131","pT2a Primary Tumor Finding","C48765","A pathologic primary tumor TNM finding. The definition of pT2a finding depends on the particular type of cancer that it refers to; for example, for prostate cancer, pT2a  finding is defined as follows: cancer limited to one-half or less of one lobe of the prostate gland; for lung cancer, pT2a finding is defined as follows: cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension. (from AJCC 7th Ed.)","pT2a TNM Finding | Tumor Stage pT2a | pT2a | pT2a Cancer Stage Finding | pT2a Primary Tumor Finding | pT2a Primary Tumor Stage Finding | pT2a Stage | pT2a Stage Finding | pT2a TNM Finding | pT2a Tumor Finding | pT2a Tumor Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711132","pT2b Primary Tumor Finding","C48766","A pathologic primary tumor TNM finding. The definition of pT2b finding depends on the particular type of cancer that it refers to; for example, for prostate cancer, pT2b finding is defined as follows: cancer involving more than one-half of one lobe, but not both lobes of the prostate gland; for lung cancer, pT2b finding is defined as follows: cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension. (from AJCC 7th Ed.)","pT2b TNM Finding | Tumor Stage pT2b | pT2b | pT2b Cancer Stage Finding | pT2b Primary Tumor Finding | pT2b Primary Tumor Stage Finding | pT2b Stage | pT2b Stage Finding | pT2b TNM Finding | pT2b Tumor Finding | pT2b Tumor Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332393","pT3 Primary Tumor Finding","C48768","A pathologic primary tumor TNM finding. The definition of pT3 finding depends on the particular type of cancer that it refers to; for example, for breast cancer, pT3 finding is defined as follows: cancer with tumor size more than 5.0 cm in greatest dimension; for kidney cancer, pT3 finding is defined as follows: cancer with tumor extending into major veins or perinephric tissues but not into the ipsilateral adrenal gland and not beyond Gerota's fascia. (from AJCC 7th Ed.)","pT3 TNM Finding | Tumor Stage pT3 | pT3 | pT3 Cancer Stage Finding | pT3 Primary Tumor Finding | pT3 Primary Tumor Stage Finding | pT3 Stage | pT3 Stage Finding | pT3 TNM Finding | pT3 Tumor Finding | pT3 Tumor Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332394","pT4 Primary Tumor Finding","C48772","A pathologic primary tumor TNM finding. The definition of pT4 finding depends on the particular type of cancer that it refers to; for example, for breast cancer, pT4 finding is defined as follows: cancer with tumor of any size with direct extension to chest wall or skin, but only as described in pT4 sub-categories, in accordance with TNM guidelines; for cervical cancer, pT4 finding is defined as follows: cancer invades mucosa of bladder or rectum, and/or extends beyond true pelvis (bullous edema is not sufficient to classify a tumor as T4). (from AJCC 7th Ed.)","pT4 TNM Finding | Tumor Stage pT4 | pT4 | pT4 Cancer Stage Finding | pT4 Primary Tumor Finding | pT4 Primary Tumor Stage Finding | pT4 Stage | pT4 Stage Finding | pT4 TNM Finding | pT4 Tumor Finding | pT4 Tumor Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332396","pN0 TNM Finding","C48745","No morphologic evidence of regional lymph node metastasis by routine histologic staining, in accordance with TNM classification system guidelines.","pN0 TNM Finding | Lymph Node Stage pN0 | Node Stage pN0 | pN0 | pN0 Cancer Stage Finding | pN0 Lymph Node Finding | pN0 Lymph Node Stage | pN0 Node Finding | pN0 Node Stage | pN0 Regional Lymph Node Stage Finding | pN0 Regional Lymph Nodes Finding | pN0 Stage | pN0 Stage Finding | pN0 TNM Finding",,,,,,,,,,,,,,,"4164612","No regional lymph node metastasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332402","pM0 Distant Metastasis Finding","C48740","No morphologic evidence of distant metastasis, in accordance with TNM classification system guidelines.","pM0 TNM Finding | Metastasis Stage pM0 | pM0 | pM0 Cancer Stage Finding | pM0 Distant Metastasis Finding | pM0 Distant Metastasis Stage Finding | pM0 Metastasis Finding | pM0 Metastasis Stage | pM0 Stage | pM0 Stage Finding | pM0 TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711134","pT3a Primary Tumor Finding","C48769","A pathologic primary tumor TNM finding. The definition of pT3a finding depends on the particular type of cancer that it refers to; for example, for cervical cancer, pT3a finding is defined as follows: cancer involves lower third of vagina, without extension to pelvic wall; for kidney cancer, pT3a finding is defined as follows: cancer with tumor grossly extending into the renal vein or its segmental (muscle containing) branches or tumor invading perirenal and/or renal sinus fat but not beyond Gerota's fascia. (from AJCC 7th Ed.)","pT3a TNM Finding | Tumor Stage pT3a | pT3a | pT3a Cancer Stage Finding | pT3a Primary Tumor Finding | pT3a Primary Tumor Stage Finding | pT3a Stage | pT3a Stage Finding | pT3a TNM Finding | pT3a Tumor Finding | pT3a Tumor Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711135","pT3b Primary Tumor Finding","C48770","A pathologic primary tumor TNM finding. The definition of pT3b finding depends on the particular type of cancer that it refers to; for example, for cervical cancer, pT3b finding is defined as follows:cancer extends to pelvic wall and/or causes hydronephrosis or nonfunctioning kidney; for kidney cancer, pT3b finding is defined as follows: cancer with tumor grossly extending into the vena cava below the diaphragm. (from AJCC 7th Ed.)","pT3b TNM Finding | Tumor Stage pT3b | pT3b | pT3b Cancer Stage Finding | pT3b Primary Tumor Finding | pT3b Primary Tumor Stage Finding | pT3b Stage | pT3b Stage Finding | pT3b TNM Finding | pT3b Tumor Finding | pT3b Tumor Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711137","pT4a Primary Tumor Finding","C48773","A pathologic primary tumor TNM finding. The definition of pT4a finding depends on the particular type of cancer that it refers to; for example, for breast cancer, pT4a finding is defined as follows: cancer with extension to the chest wall, not including the pectoralis muscle; for thyroid cancer, pT4a finding is defined as follows: cancer with moderately advanced local disease. Tumor of any size extending beyond the thyroid gland capsule to invade subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve. (from AJCC 7th Ed.)","pT4a TNM Finding | Tumor Stage pT4a | pT4a | pT4a Cancer Stage Finding | pT4a Primary Tumor Finding | pT4a Primary Tumor Stage Finding | pT4a Stage | pT4a Stage Finding | pT4a TNM Finding | pT4a Tumor Finding | pT4a Tumor Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711138","pT4b Primary Tumor Finding","C48774","A pathologic primary tumor TNM finding. The definition of pT4b finding depends on the particular type of cancer that it refers to; for example, for breast cancer, pT4b finding is defined as follows: cancer with ulceration and/or ipsilateral satellite nodules and/or edema (including peau d'orange) of the skin, which do not meet the criteria for inflammatory carcinoma; for gastric cancer, pT4b finding is defined as follows: cancer with tumor invading adjacent structures. (from AJCC 7th Ed.)","pT4b TNM Finding | Tumor Stage pT4b | pT4b | pT4b Cancer Stage Finding | pT4b Primary Tumor Finding | pT4b Primary Tumor Stage Finding | pT4b Stage | pT4b Stage Finding | pT4b TNM Finding | pT4b Tumor Finding | pT4b Tumor Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL378230","Intravenous Pyelography","C20177","The creation of an image of the kidneys and urinary system using an intravenously administered contrast medium. By taking several X-rays over a short period of time, it is possible to check for the proper functioning of both kidneys and the urinary system.","Intravenous Pyelography | INTRAVENOUS PYELOGRAPHY | IVP | Intravenous Urography | intravenous pyelography",,,,,,,,,,,,,,,"4138256","Intravenous pyelogram",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL971205","Retrograde pyelogram","C28654","X-ray images of the ureters and kidneys obtained by injection of a radioopaque substance into the ureter, usually done via a cystoscope.","Retrograde Pyelogram | RETROGRADE PYELOGRAPHY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0994163","Magnetic Resonance Cholangiopancreatography","C113775","A non-invasive procedure in which magnetic resonance imaging is used to visualize the intrahepatic and extrahepatic bile ducts, the pancreatic duct, and the surrounding parenchyma.","Magnetic Resonance Cholangiopancreatography | MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY | MRCP",,,,,,,,,,,,,,,"4194588","Magnetic resonance cholangiopancreatography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205330","Punctate","C113776","Having tiny spots or depressions.","Punctate | ",,,,,,,,,,,,,,,"4301012","Punctate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3827731","Unable to Collect Voided Urine","C113726","Indicates that an individual is unable to self-collect a urine specimen.","Unable to Collect Voided Urine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4068350","ALK Gene Rearrangement","C129574","A molecular abnormality indicating rearrangement of the ALK gene.","ALK Gene Rearrangement | ALK Rearrangement | ALK rearranged | Anaplastic Lymphoma Kinase Gene Rearrangement | Anaplastic Lymphoma Receptor Tyrosine Kinase Gene Rearrangement | CD246 Gene Rearrangement | Rearrangement identified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512734","EGFR Driver Mutation Negative","C129575","A genetic finding indicating that disease-causing (driver) mutations in the EGFR gene are not present in a sample.","EGFR Driver Mutation Negative | Deleterious EGFR Gene Mutation Negative | ERBB1 Driver Mutation Negative | Epidermal Growth Factor Receptor Driver Mutation Negative | HER1 Driver Mutation Negative | c-erbB1 Driver Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333137","Breast Complex Fibroadenoma","C5194","A breast fibroadenoma that displays fibrocystic changes including apocrine metaplasia, sclerosing adenosis, and cyst formation.","Breast Complex Fibroadenoma | Complex Breast Fibroadenoma | Complex Fibroadenoma | Complex Fibroadenoma of Breast | Complex Fibroadenoma of the Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831393","Bayer Immuno-1 PSA Test","C113701","A proprietary system designed to measure protein-complexed prostate-specific antigen (cPSA) in the blood.","Bayer Immuno-1 PSA Test | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831595","ADVIA Centaur","C113737","A proprietary high-throughput chemiluminescent immunoassay system manufactured by Siemens.","ADVIA Centaur | Siemens ADVIA Centaur",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830481","Dimension with Heterogeneous Module","C113738","A proprietary integrated chemistry system for high-throughput integration of chemistry and immunoassay testing manufactured by Siemens.","Dimension with Heterogeneous Module | Dimension with HM | Siemens Dimension HM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829562","Immulite","C113739","A proprietary instrument for immunoassay analysis manufactured by Siemens.","Immulite | Siemens Immulite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827805","Tosoh Bioscience","C113704","A manufacturer of reagents and instruments for the separation, purification, and analysis of biospecimens.","Tosoh Bioscience | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829584","Hybritech PSA Test","C113700","A proprietary immunoenzymatic assay system designed to measure prostate-specific antigen in serum samples.","Hybritech PSA Test | Access Hybritech PSA Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828313","Roche Diagnostics Free PSA Test","C113699","A proprietary in vitro diagnostic laboratory test designed to measure free prostate-specific antigen (fPSA) in human serum.","Roche Diagnostics Free PSA Test | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711133","pT2c Primary Tumor Finding","C48767","A pathologic primary tumor TNM finding. The definition of pT2c finding depends on the particular type of cancer that it refers to; for example, for prostate cancer, pT2c finding is defined as follows: cancer involving both lobes of the prostate gland; for fallopian tube cancer, pT2c finding is defined as follows: cancer with pelvic extension and malignant cells in ascites or peritoneal washings. (from AJCC 7th Ed.)","pT2c TNM Finding | Tumor Stage pT2c | pT2c | pT2c Cancer Stage Finding | pT2c Primary Tumor Finding | pT2c Primary Tumor Stage Finding | pT2c Stage | pT2c Stage Finding | pT2c TNM Finding | pT2c Tumor Finding | pT2c Tumor Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711136","pT3c TNM Finding","C48771","A pathologic primary tumor TNM finding. The definition of pT3c finding depends on the particular type of cancer that it refers to; for example, for kidney cancer, pT3c finding is defined as follows: cancer with tumor grossly extending into the vena cava above the diaphragm, or invading the wall of the vena cava; for fallopian tube cancer, pT3c finding is defined as follows: cancer with peritoneal metastasis outside the pelvis and more than 2 cm in diameter. (from AJCC 7th Ed.)","pT3c TNM Finding | Tumor Stage pT3c | pT3c | pT3c Cancer Stage Finding | pT3c Primary Tumor Finding | pT3c Primary Tumor Stage Finding | pT3c Stage | pT3c Stage Finding | pT3c TNM Finding | pT3c Tumor Finding | pT3c Tumor Stage",,,,,,,,,,,,,,,"37151068","pT3c",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828817","Nickel Peroxidase Method","C113774","An immunohistochemistry staining method using horseradish peroxidase, DAB substrate, and nickel chloride.","Nickel Peroxidase Method | Nickel method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827244","Scattered Microscopic Foci","C113715","A microscopic finding indicating the presence of scattered islands of pathologic processes in a tissue sample.  The pathologic processes may refer to various abnormalities, including the presence of islands of malignant cells, presence of necrotic foci, and presence of islands of connective tissue that lack fibers.","Scattered Microscopic Foci | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827791","Transition Zone-Like","C113735","A morphologic finding indicating the presence of an epithelial infiltrate resembling the cells of the transition zone of the prostate gland.","Transition Zone-Like | Transition zone like",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035281","Retention Cyst","C113736","A cyst that is formed because of the blockage of the duct of a glandular organ. This results in the retention of the glandular secretions.","Retention Cyst | ",,,,,,,,,,,,,,,"4275662","Retention cyst",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2987191","Pancreatic Intraductal Papillary Mucinous Neoplasm, Gastric-Type","C95508","A pancreatic intraductal papillary mucinous neoplasm characterized by the presence of neoplastic epithelial cells that are similar to gastric foveolar epithelial cells.","Pancreatic Intraductal Papillary Mucinous Neoplasm, Gastric-Type | Gastric foveolar",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334050","Adenosis","C120861","Any disease or disorder of a gland, characterized by abnormal development or enlargement of the gland.","Adenosis | ADENOSIS",,,,,,,,,,,,,,,"4239158","Adenosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512617","EGFR Protein Translocation","C129572","A molecular abnormality indicating that the epidermal growth factor receptor protein has been localized to the membrane of an internal cellular compartment.","EGFR Protein Translocation | EGFR Translocation | ERBB1 Translocation | Epidermal Growth Factor Receptor Protein Translocation | HER1 Translocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512618","EML4/ALK Fusion Negative","C129576","Indicates that expression of the EML4/ALK fusion has not been detected in a sample.","EML4/ALK Fusion Negative | EML4-ALK Fusion Negative | EML4-ALK Negative | EML4/ALK Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517401","Gain of Chromosome 1q","C36482","A cytogenetic abnormality that refers to allelic gain within the chromosomal arm 1q.","Gain of Chromosome 1q | 1q Amplification | 1q Duplication | 1q Gain | Chromosome 1q Amplification | Chromosome 1q Duplication | dup(1q)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512702","Gain of Chromosome 1q21","C129571","A cytogenetic abnormality that refers to allelic gain within the chromosomal region 1q21.","Gain of Chromosome 1q21 | 1q21 Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512623","Ganglioside GD2 Positive","C129573","Indicates that expression of ganglioside GD2 has been detected in a sample.","Ganglioside GD2 Positive | GD2 Ganglioside Positive | GD2 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512705","HLA Class I Histocompatibility Antigen, A-0205 Alpha Chain","C129577","HLA class I histocompatibility antigen, A-0205 alpha chain (365 aa, ~41 kDa) is encoded by the human HLA-A gene. This protein plays a role in the presentation of foreign antigens to the immune system.","HLA Class I Histocompatibility Antigen, A-0205 Alpha Chain | HLA-A Class I Antigen 0205 | HLA-A Histocompatibility Type Antigen 0205 | HLA-A*0205 | HLA-A*02:05 | MHC Class I Antigen A*0205 | Major Histocompatibility Complex, Class I, A0205 Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512706","HLA Class I Histocompatibility Antigen, A-0206 Alpha Chain","C129578","HLA class I histocompatibility antigen, A-0206 alpha chain (365 aa, ~41 kDa) is encoded by the human HLA-A gene. This protein is involved in the presentation of foreign antigens to the immune system.","HLA Class I Histocompatibility Antigen, A-0206 Alpha Chain | HLA-A Class I Antigen 0206 | HLA-A Histocompatibility Type Antigen 0206 | HLA-A*0206 | HLA-A*02:06 | MHC Class I Antigen A*0206 | Major Histocompatibility Complex, Class I, A0206 Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640004","EGFR NM_005228.3:c.334_1137del804","C101139","A deletion of exons 2-7 of the EGFR gene corresponding to 804 nucleotides starting at position 334 through position 1137.","EGFR NM_005228.3:c.334_1137del804 | EGFR c.334_1137del804 | EGFRvIII Extracellular Domain Mutation | EGFRvIII Extracellular Domain Variant | EGFRvIII Gene Mutation | Epidermal Growth Factor Receptor Gene c.334_1137del804",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0915629","epidermal growth factor receptor VIII","C101140","A deletion of 268 amino acids of the epidermal growth factor receptor protein from the valine at position 30 through the arginine at position 297 followed by the insertion of a glycine between the lysine at position 29 and the asparagine at position 298.","EGFR NP_005219.2:p.K29_N298insG | Activating EGFRvIII Mutation | EGFR NP_005219.2:p.Lys29_Asn298insGly | EGFR NP_005219.2:p.V30_R297delK29_N298insG | EGFR NP_005219.2:p.Val30_Arg297delLys29_Asn298insGly | EGFR p. K29_N298insG | EGFR p. Lys29_Asn298insGly | EGFRvIII | EGFRvIII Ectodomain Insertion/Deletion Mutation | EGFRvIII Extracellular Domain Insertion/Deletion Mutation | EGFRvIII Protein Variant | Epidermal Growth Factor Receptor Variant III | Epidermal Growth Factor Receptor vIII | NP_005219.2:p.K29_N298insG | NP_005219.2:p.Lys29_Asn298insGly | NP_005219.2:p.V30_R297delK29_N298insG | NP_005219.2:p.Val30_Arg297delLys29_Asn298insGly | Type III EGF Deletion-Mutant Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414989","GART Gene","C128848","This gene is involved in purine nucleotide biosynthesis.","GART Gene | GART | Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415169","GNRH1 Gene","C38491","This gene is involved in female reproductive regulation and intercellular communication.","GNRH1 Gene | GNRH1 | Gonadotropin Releasing Hormone 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0047420","3-Hydroxy-3-Methylglutaryl-Coenzyme A","C129007","An intermediate for the synthesis of mevalonic acid, ketone bodies and cholesterol and a metabolic product for leucine; it can be formed de novo from acetyl coenzyme A (CoA) and acetoacetyl CoA by HMG-CoA (3-Hydroxy-3-Methylglutaryl-Coenzyme A) synthase.","3-Hydroxy-3-Methylglutaryl-Coenzyme A | (3S)-3-Hydroxy-3-Methylglutaryl-CoA | (S)-3-Hydroxy-3-Methylglutaryl-Coenzyme A | 3-Hydroxy-3-Methylglutaryl-CoA | HMG-CoA | HMG-Coenzyme A | Hydroxymethylglutaroyl Coenzyme A | Hydroxymethylglutaryl-CoA | S-(Hydrogen 3-Hydroxy-3-Methylglutaryl)Coenzyme A | S-(Hydrogen 3-Hydroxy-3-Methylpentanedioate) Coenzyme A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414824","FSHB Gene","C104397","This gene plays a role in induction of egg and sperm production.","FSHB Gene | FSHB | Follicle Stimulating Hormone, Beta Polypeptide Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0223651","Iliac Crest","C103818","The thick curved ridge in the upper area of the ilium.","Iliac Crest | ILIAC CREST",,,,,,,,,,,,,,,"4106907","Iliac crest structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3888511","Philadelphia Chromosome Negative","C128844","Indicates that the Philadelphia chromosome abnormality, t(9;22)(q34;q11), has not been detected in a sample.","Philadelphia Chromosome Negative | Ph Negative | Ph-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1506987","KMT2A Gene Rearrangement","C122623","A molecular abnormality indicating rearrangement of the KMT2A (MLL) gene.","KMT2A Gene Rearrangement | KMT2A Gene Rearrangement | KMT2A Gene Rearrangement | KMT2A Rearrangement | KMT2Ar | Lysine (K)-Specific Methyltransferase 2A Gene Rearrangement | Lysine Methyltransferase 2A Gene Rearrangement | MLL | MLL Gene Rearrangement | MLL Gene Rearrangement | MLL Rearrangement | Mixed Lineage Leukemia Gene Rearrangement | Myeloid/Lymphoid Leukemia Gene Rearrangement | Myeloid/Lymphoid or Mixed Lineage Leukemia Gene Rearrangement | Myeloid/Lymphoid or Mixed-Lineage Leukemia (Trithorax Homolog, Drosophila) Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512264","FLT3 Gene Mutation","C128919","A change in the nucleotide sequence of the FLT3 gene.","FLT3 Gene Mutation | CD135 Gene Mutation | FLK2 Gene Mutation | FLT3 | FLT3 Gene Mutant | FLT3 Gene Mutant | FLT3 Mutation | FMS-Related Tyrosine Kinase 3 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511021","BRAF Gene Mutation","C40430","A change in the nucleotide sequence of the BRAF gene.","BRAF Gene Mutation | B-RAF Gene Mutation | B-RAF1 Gene Mutation | BRAF Mutation | BRAF1 Gene Mutation | v-raf Murine Sarcoma Viral Oncogene Homolog B1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050175","Complete Hematologic Response","C123575","The disappearance of cancer in response to treatment, including platelet and white blood cell counts returning to normal levels, a non-palpable spleen, and no immature white blood cells present in the blood unless it is a regenerating marrow following treatment.","Complete Hematologic Response | CHR | Complete Hematologic Remission",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512794","Breast-Impact of Treatment Scale","C129607","A 13-item self-report questionnaire that uses a 4-point rating scale to assess body change stress for women with breast cancer.","Breast-Impact of Treatment Scale | BIT | Breast Impact of Treatment Scale | The Breast-Impact of Treatment Scale (BIT)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512547","How Often Think About How Body Has Changed","C129608","A question about how often an individual's body changes pops into their mind.","How Often Think About How Body Has Changed | How Body Has Changed Pops Into Mind | How my body has changed pops into my mind",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512542","How Often Have Waves of Strong Feelings About the Way Body Looks","C129609","A question about how often an individual has strong feelings about the way their body looks.","How Often Have Waves of Strong Feelings About the Way Body Looks | Have Waves of Strong Feelings About the Way Body Looks | I have waves of strong feeling about the way my body looks",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512548","How Often Think About How Body Used to Look","C129610","A question about how often an individual thinks about how their body used to look.","How Often Think About How Body Used to Look | I think about how my body used to look | Think About How Body Used to Look",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512545","How Often Reminded by Things That are Seen or Heard that Body is Different Now","C129612","A question about how often an individual sees or hears things that remind them that their body is different now.","How Often Reminded by Things That are Seen or Heard that Body is Different Now | Reminded That Body is Different Now by Things That are Seen or Heard | Things I see or hear remind me that my body is different now",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512550","How Often Think That Body Appears Different Than Other Women","C129614","A question about how often an individual sees other women's bodies and thinks that their body appears different.","How Often Think That Body Appears Different Than Other Women | Think That Body Appears Different Than Other Women | When I see other women, I think that my body appears different from theirs | When I see other women, I think that my body appears different than theirs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512538","How Often Feel Uncomfortable About Being Seen Naked","C129616","A question about how often an individual feels uncomfortable about being seen naked.","How Often Feel Uncomfortable About Being Seen Naked | Feel Uncomfortable About Being Seen Naked | I feel uncomfortable about being seen naked",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512533","How Often Bothered by Feelings or Thoughts About Body Changes","C129617","A question about how often an individual is bothered by feelings or thoughts about changes to their body.","How Often Bothered by Feelings or Thoughts About Body Changes | How Often Bothered by Feelings or Thoughts About Body Disfigurement | I am bothered by feelings or thoughts about changes to my body | I am bothered by feelings or thoughts of body disfigurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512546","How Often Reminded of Breasts When Picking Clothes to Wear","C129620","A question about how often an individual is reminded of their breasts when picking out clothes to wear.","How Often Reminded of Breasts When Picking Clothes to Wear | I am reminded of my breasts when I pick out clothes to wear",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512536","How Often Don't Want to Deal with How Body Looks","C129623","A question about how often an individual does not want to deal with how their body looks.","How Often Don't Want to Deal with How Body Looks | Doesn't Want to Deal with How Body Looks | I don't want to deal with how my body looks",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512531","How Often Avoid Getting Emotional When Thinking of How Body Has Changed","C129624","A question about how often an individual avoids getting emotional when they think of how their body has changed.","How Often Avoid Getting Emotional When Thinking of How Body Has Changed | Avoid Getting Emotional When Thinking of How Body Has Changed | I avoid letting myself get emotional when I think of how my body has changed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512552","How Often Try Not to Think About Size and Shape of Breasts","C129626","A question about how often an individual tries not to think about the size and shape of their breasts.","How Often Try Not to Think About Size and Shape of Breasts | I try not to think about the size and shape of my breasts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512532","How Often Avoid Looking at or Touching Body","C129627","A question about how often an individual avoids looking at or touching their body.","How Often Avoid Looking at or Touching Body | Avoid Looking at or Touching Body | I avoid looking at and/or touching my body | I avoid looking at and/or touching my breasts.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512553","How Often Turn Away When Undressing In Front of Partner","C129630","A question about how often an individual turns away when they have to undress in front of their partner.","How Often Turn Away When Undressing In Front of Partner | I feel self-conscious about letting my partner see my breast | I turn away when I have to undress in front of my partner | Turn Away When Undressing In Front of Partner",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512549","How Often Think About How Health May Affect Sex Life","C129631","A question about how often an individual thinks about how their health may affect their sex life.","How Often Think About How Health May Affect Sex Life | I think about how my health may affect my sex life | Think About How Health May Affect Sex Life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512551","How Often Try Not to Think About Body Being Different","C129633","A question about how often an individual tries not to think about their body being different.","How Often Try Not to Think About Body Being Different | I try not to think about my body being different | Try Not to Think About Body Being Different",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031307","Phagocytic Cell","C12657","A type of immune cell that can surround and kill microorganisms, ingest foreign material, and remove dead cells. It can also boost immune responses. Monocytes, macrophages, and neutrophils are phagocytes. A phagocyte is a type of white blood cell.","Phagocytic Cell | Phagocyte | Phagocytes | phagocyte",,,,,,,,,,,,,,,"4251201","Phagocytic cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019612","Histiocyte","C12563","A macrophage present in connective tissue.","Histiocyte | Fixed Macrophage | Histiocytes | Mature Tissue Histiocyte",,,,,,,,,,,,,,,"4031354","Resident tissue macrophage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706712","Additional Therapy","C50424","No Value Exists","Additional Therapy | Additional Non-Surgical Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815865","CD22 Expressing Cell Count","C111148","The determination of the amount of CD22 expressing cells per unit present in a sample.","CD22 Expressing Cell Count | B-Cell Receptor CD22 Expressing Cell Count",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538992","CD5 Expressing Cell Measurement","C103369","A count of the CD5 expressing cells per unit of a biological specimen.","CD5 Expressing Cell Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811679","CD10 Expressing Cell Count","C111146","The determination of the amount of CD10 expressing cells per unit present in a sample.","CD10 Expressing Cell Count | MME Expressing Cell Count | Neprilysin Expressing Cell Count",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347259","CD45-Positive Neoplastic Cells Present","C72561","An immunophenotypic finding indicating that expression of CD45 has been detected in a sample of neoplastic cells.","CD45-Positive Neoplastic Cells Present | B220 Positive Neoplastic Cells Present | CD45 Antigen Positive Neoplastic Cells Present | CD45 Expressing Neoplastic Cells Present | CD45-Expressing Neoplastic Cells Present | CD45R Positive Neoplastic Cells Present | GP180 Positive Neoplastic Cells Present | L-CA Positive Neoplastic Cells Present | LCA Positive Neoplastic Cells Present | Leukocyte Common Antigen Positive Neoplastic Cells Present | PTPRC Positive Neoplastic Cells Present | Protein Tyrosine Phosphatase, Receptor Type C Positive Neoplastic Cells Present | Receptor-Type Tyrosine-Protein Phosphatase C Positive Neoplastic Cells Present | T200 Positive Neoplastic Cells Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539926","CD56 Expressing Cell Measurement","C103370","A count of the CD56 expressing cells per unit of a biological specimen.","CD56 Expressing Cell Measurement | CD56 | CD56 Expressing Cells | NCAM1 Expressing Cell Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347261","CD57-Positive Neoplastic Cells Present","C71619","An indication that expression of CD57 has been detected in a sample of neoplastic cells.","CD57-Positive Neoplastic Cells Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348510","Fasting Specimen","C70701","A specimen obtained from a subject who has abstained from food and possibly water, according to the prescribed amount of time.","Fasting Specimen | Fasting Biospecimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0392201","Blood Glucose Measurement","C92744","A quantitative measurement for assessing the amount of glucose present in a blood sample.","Blood Glucose Measurement | Blood Glucose Monitoring | Glucose Measurement, Blood",,,,,,,,,,,,,,,"4144235","Glucose measurement, blood",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1261322","Clinical Evaluation","C124351","An assessment of an individual's physical, mental, or emotional condition; information can be gathered from multiple sources, including physical exam, personal interview and observation, medical history, laboratory and imaging tests.","Clinical Evaluation | CLINICAL EVALUATION | Clinical Assessment",,,,,,,,,,,,,,,"4044176|4297090","Evaluation - action|Evaluation procedure",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2986605","Third-Line Therapy","C94628","Treatment that is given when both initial treatment (first-line therapy) and subsequent treatment (second-line therapy) don't work, or stop working.","Third-Line Therapy | Third Line Treatment | Third line of therapy | third-line therapy",,,,,,,,,,,,,,,"45769572","Third line treatment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3539878","Triple-Negative Breast Carcinoma","C71732","An invasive breast carcinoma which is negative for expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).","Triple-Negative Breast Carcinoma | Triple Negative Breast Carcinoma | Triple-Negative Breast Cancer",,,,,,,,,,,,,,,"45768522","Triple-negative breast cancer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1963250","TORSADES DE POINTES","C54946","A type of polymorphic ventricular tachycardia (VT) characterized by a gradual change in the amplitude and twisting of the QRS complexes around the isoelectric line.","Torsade de Pointes, CTCAE | Torsade de Pointes Adverse Event | Torsade de pointes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512527","Dynamic International Prognostic Scoring System","C129683","A time-dependent risk evaluation system for primary myelofibrosis that evaluates disease progression over time. This model includes age older than 65 years, hemoglobin level lower than 10 g/dL, white blood cell count more than 25x10^9/L, peripheral blood blasts equal to or higher than 1%, and constitutional symptoms in order to assign a patient to one of 4 risk categories.","Dynamic International Prognostic Scoring System | DIPSS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0381246","CBFB/MYH11 Fusion Protein","C101052","A fusion protein encoded by the CBFB/MYH11 fusion gene. This protein is comprised of most of the core-binding factor subunit beta fused to the C-terminal dimerization domain of myosin-11.","CBFB/MYH11 Fusion Protein | CBFB::MYH11 Fusion Protein | CBFb-MYH11 Fusion Protein | CBFbeta-MYH11 Fusion Protein | CBFbeta-SMMHC Fusion Protein | CBFbeta/SMMHC Fusion Protein | Core-Binding Factor Subunit Beta/Myosin-11 Fusion Protein | Core-Binding Factor Subunit Beta::Myosin-11 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420554","SYP Gene","C101144","This gene is involved in vesicle targeting and synaptic plasticity.","SYP Gene | SYP | Synaptophysin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420364","SPN Gene","C101151","This gene is involved in leukocyte migration.","SPN Gene | CD43 | SPN | Sialophorin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420393","SQSTM1 Gene","C101491","This gene is involved in signal transduction.","SQSTM1 Gene | SQSTM1 | Sequestosome 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420010","SGK1 Gene","C101559","This gene plays a role in both protein phosphorylation and cellular stress response.","SGK1 Gene | SGK1 | Serum/Glucocorticoid Regulated Kinase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413962","DDX3X Gene","C101565","This gene is involved in RNA binding.","DDX3X Gene | DDX3X | DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 3, X-Linked Gene | DEAD-Box Helicase 3 X-Linked Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428707","AKT1S1 Gene","C101614","This gene plays a role in the regulation of mTOR signaling.","AKT1S1 Gene | AKT1 Substrate 1 (Proline-Rich) Gene | AKT1 Substrate 1 Gene | AKT1S1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417890","NUMB Gene","C101635","This gene plays a role in neurogenesis.","NUMB Gene | NUMB | Numb Homolog (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418450","SERPINF1 Gene","C101643","This gene is involved in the regulation of cell proliferation.","SERPINF1 Gene | SERPINF1 | Serpin Peptidase Inhibitor, Clade F (Alpha-2 Antiplasmin, Pigment Epithelium Derived Factor), Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415626","FOXA1 Gene","C101646","This gene plays a role in the modulation of gene expression.","FOXA1 Gene | FOXA1 | Forkhead Box A1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412716","B3GAT1 Gene","C101762","This gene plays a role in glycoprotein modification.","B3GAT1 Gene | B3GAT1 | Beta-1,3-Glucuronyltransferase 1 (Glucuronosyltransferase P) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825595","IL33 Gene","C101774","This gene plays a role in cytokine signaling.","IL33 Gene | IL33 | Interleukin 33 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023810","Lipopolysaccharide","C101788","An endotoxin and biologically active component of the Gram-negative bacterial cell wall that is a Toll-like receptor 4 (TLR4) agonist with potential immunostimulatory activity. Upon internalization, lipopolysaccharide (LPS) activates TLR4 which in turn activates the NFkappaB pathway, in addition to mitogen-activated protein kinases signaling pathways.  This leads to the release of proinflammatory cytokines and stimulates an innate immune response against vaccine antigens.","Lipopolysaccharide | LPS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425322","KHDRBS1 Gene","C102427","This gene is involved in cell cycle progression, RNA splicing and signal transduction regulation.","KHDRBS1 Gene | KH Domain Containing, RNA Binding, Signal Transduction Associated 1 Gene | KHDRBS1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419856","SCN1A Gene","C102447","This gene is involved in sodium transport.","SCN1A Gene | SCN1A | Sodium Voltage-Gated Channel Alpha Subunit 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412515","ARG1 Gene","C103927","This gene plays a role in the urea cycle.","ARG1 Gene | ARG1 | Arginase, Liver Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513001","Ficoll-Hypaque Method","C129690","A centrifugation procedure that utilizes a density-gradient medium to separate mononuclear and polymorphonuclear leukocytes from other formed elements in the blood.","Ficoll-Hypaque Method | Ficoll WBC | Ficoll WBC Isolation | Ficolled WBC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512934","White Blood Cell Lysis","C129692","Disruption and destruction of the white blood cell membrane.","White Blood Cell Lysis | Lysed WBC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0250494","reduced folate carrier","C103948","Folate transporter 1 (591 aa, ~65 kDa) is encoded by the human SLC19A1 gene. This protein plays a role in the transmembrane transport of folate.","Folate Transporter 1 | FOLT | IFC-1 | Intestinal Folate Carrier 1 | Placental Folate Transporter | RFC | RFT-1 | Reduced Folate Carrier 1 | Reduced Folate Carrier Protein | Reduced Folate Transporter 1 | SLC19A1 | Solute Carrier Family 19 Member 1 | hRFC1 | hSLC19A1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1384510","ACTB Gene","C103965","This gene is involved in both cytoskeletal arrangement and cell motility.","ACTB Gene | ACTB | Actin Beta Gene | Actin, Beta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412137","ACTA2 Gene","C103970","This gene plays a role in both cell morphology and cell motility.","ACTA2 Gene | ACTA2 | Actin Alpha 2, Smooth Muscle Gene | Actin, Alpha 2, Smooth Muscle, Aorta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1540188","ADIPOR1 Gene","C103973","This gene is involved in hormone binding and signal transduction.","ADIPOR1 Gene | ADIPOR1 | Adiponectin Receptor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1540189","ADIPOR2 Gene","C103976","This gene plays a role in adiponectin binding and ligand-mediated signaling.","ADIPOR2 Gene | ADIPOR2 | Adiponectin Receptor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412761","BCL2A1 Gene","C104038","This gene plays a role in the inflammatory process.","BCL2A1 Gene | BCL2-Related Protein A1 Gene | BCL2A1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824522","CAMK2N1 Gene","C104041","This gene is involved in intracellular signaling.","CAMK2N1 Gene | CAMK2N1 | Calcium/Calmodulin-Dependent Protein Kinase II Inhibitor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413814","CTSG Gene","C104053","This gene plays a role in protein degradation.","CTSG Gene | CTSG | Cathepsin G Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420084","SLAMF1 Gene","C104059","This gene is involved in immune cell function.","SLAMF1 Gene | SLAMF1 | Signaling Lymphocytic Activation Molecule Family Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413204","CD163 Gene","C104062","This gene plays a role in endocytosis by macrophages.","CD163 Gene | CD163 | CD163 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424664","CD226 Gene","C104065","This gene is involved in megakaryocytic cell maturation.","CD226 Gene | CD226 | CD226 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425360","CD244 Gene","C104068","This gene plays a role in leukocyte activation and immune function.","CD244 Gene | CD244 | CD244 Molecule, Natural Killer Cell Receptor 2B4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413235","CD69 Gene","C104074","This gene plays a role in signal transduction.","CD69 Gene | CD69 | CD69 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824671","CD70 Gene","C104077","This gene is involved in immune function.","CD70 Gene | CD70 | CD70 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641722","Effector T-Lymphocyte","C104083","A mature T-lymphocyte that has differentiated into a form that can mount an antigen-specific immune response.","Effector T-Lymphocyte | Effector T Cell | Effector T Cells | Effector T Lymphocyte | Effector T-Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1861281","CD8A Gene","C104107","This gene is involved in immune function.","CD8A Gene | CD8A | CD8a Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413323","CEBPB Gene","C104116","This gene plays a role in immune and inflammatory responses.","CEBPB Gene | CCAAT/Enhancer Binding Protein (C/EBP), Beta Gene | CEBPB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413191","CCR7 Gene","C104128","This gene plays a role in immune function.","CCR7 Gene | CCR7 | Chemokine (C-C motif) Receptor 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539094","CLEC4C Gene","C104131","This gene is involved in immune function.","CLEC4C Gene | C-type Lectin Domain Family 4, Member C Gene | CLEC4C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413259","CDC25C Gene","C104134","This gene plays a role in regulation of cell division.","CDC25C Gene | CDC25C | Cell Division Cycle 25 Homolog C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1439306","CP Gene","C104137","This gene is a metalloprotein involved in copper binding in plasma.","CP Gene | CP | Ceruloplasmin (Ferroxidase) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539136","CRBN Gene","C104140","This gene plays a role in limb outgrowth and may play a role in brain development.","CRBN Gene | CRBN | Cereblon Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424460","CXCL16 Gene","C104143","This gene may be involved in immune-cell chemotaxis.","CXCL16 Gene | CXCL16 | Chemokine (C-X-C motif) Ligand 16 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413862","CYP24A1 Gene","C104146","This gene plays a role in vitamin D3 metabolism and calcium homeostasis.","CYP24A1 Gene | CYP24A1 | Cytochrome P450 Family 24 Subfamily A Member 1 Gene | Cytochrome P450, Family 24, Subfamily A, Polypeptide 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413864","CYP27A1 Gene","C104149","This gene is involved in cholesterol homeostasis and bile synthesis.","CYP27A1 Gene | CYP27A1 | Cytochrome P450, Family 27, Subfamily A, Polypeptide 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824797","CRTAM Gene","C104172","This gene is involved in immune function.","CRTAM Gene | CRTAM | Cytotoxic and Regulatory T-Cell Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539265","DEGS1 Gene","C104175","This gene plays a role in fatty acid biosynthesis.","DEGS1 Gene | DEGS1 | Delta 4-Desaturase, Sphingolipid 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539266","DEGS2 Gene","C104178","This gene is involved in sphingolipid biosynthesis.","DEGS2 Gene | DEGS2 | Delta(4)-Desaturase, Sphingolipid 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823832","DCAF7 Gene","C104181","This gene may play a role in regulation of transcription.","DCAF7 Gene | DCAF7 | DDB1 and CUL4 Associated Factor 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428430","DDIT4 Gene","C104184","This gene is involved in responses to cellular energy levels and cellular stress.","DDIT4 Gene | DDIT4 | DNA-Damage-Inducible Transcript 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414334","EIF2S1 Gene","C104187","This gene plays a role in translation initiation.","EIF2S1 Gene | EIF2S1 | Eukaryotic Translation Initiation Factor 2, Subunit 1 Alpha, 35kDa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414347","EIF4A1 Gene","C104190","This gene is involved in translation initiation.","EIF4A1 Gene | EIF4A1 | Eukaryotic Translation Initiation Factor 4A1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414369","ELANE Gene","C104195","This gene plays a role in innate host defense.","ELANE Gene | ELANE | Elastase, Neutrophil Expressed Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414402","ENO1 Gene","C104203","This gene is involved in glycolysis.","ENO1 Gene | ENO1 | Enolase 1, (Alpha) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414408","ENPP2 Gene","C104209","This gene plays a role in the hydrolysis of lysophospholipids.","ENPP2 Gene | ENPP2 | Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414499","F12 Gene","C104215","This gene is involved in blood coagulation and fibrinolysis.","F12 Gene | Coagulation Factor XII (Hageman Factor) Gene | F12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424509","FBXO32 Gene","C104221","This gene plays a role in protein ubiquitination and degradation.","FBXO32 Gene | F-Box Protein 32 Gene | FBXO32",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512659","JAK1 Inhibitor","C129650","Any substance that inhibits the biological action of tyrosine-protein kinase JAK1, an enzyme that plays a key role in certain types of cancer and cytokine signaling.","JAK1 Inhibitor | Janus Kinase 1 Inhibitor | Tyrosine-Protein Kinase JAK1 Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512889","Since Beginning Study Agent","C129696","The study-associated time period following the first timepoint where the study agent was administered and continuing through the present.","Since Beginning Study Agent | Since beginning the study agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512870","Feelings About Own Sexuality","C129697","A question about an individual's feelings about their own sexuality.","Feelings About Own Sexuality | My feelings about my own sexuality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512880","Overall Energy Level","C129698","A question about an individual's overall energy level.","Overall Energy Level | Energy | My overall energy level",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512868","Feel Self-Conscious About Letting Partner See My Breasts","C129708","A question about how often an individual feels self-conscious about letting their breasts be seen by their partner.","Feel Self-Conscious About Letting Partner See My Breasts | I feel self-conscious about letting my partner see my breasts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512852","Activating ERBB2 Mutation","C129700","A change in the nucleotide sequence of the ERBB2 gene that results in constitutive receptor tyrosine-protein kinase erbB-2-dependent signal transduction and activation of downstream signaling pathways.","Activating ERBB2 Mutation | Activating ERBB2 Gene Mutation | Activating HER2 Mutation | CD340 Activating Mutation | ERBB2 Activating Mutation | HER-2 Activating Mutation | HER2/Neu Activating Mutation | c-erbB2 Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512853","MET Activating Mutation","C129701","A change in the nucleotide sequence of the MET gene that that results in constitutive hepatocyte growth factor receptor-dependent signal transduction and activation of downstream signaling pathways.","Activating MET Gene Mutation | Activating HGFR Mutation | Activating Hepatocyte Growth Factor Receptor Mutation | Activating MET Mutation | Activating MET Mutation | Activating MET Proto-Oncogene, Receptor Tyrosine Kinase Gene Mutation | Activating Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Mutation | Activating c-Met Mutation | MET Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512854","RET Activating Mutation","C129702","A change in the nucleotide sequence of the RET gene that results in constitutive proto-oncogene tyrosine-protein kinase receptor Ret-dependent signal transduction and activation of downstream signaling pathways.","Activating RET Gene Mutation | Activating RET Mutation | Activating RET Mutation | Activating Ret Proto-Oncogene Mutation | RET Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512849","ALK Gene Translocation","C129703","A cytogenetic abnormality that refers to any translocation involving the ALK gene.","ALK Gene Translocation | ALK Translocation | Anaplastic Lymphoma Kinase Gene Translocation | Anaplastic Lymphoma Receptor Tyrosine Kinase Gene Translocation | CD246 Gene Translocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517090","FGFR1 Gene Amplification","C36650","A molecular genetic abnormality indicating the presence of multiple copies of the FGFR1 gene.","FGFR1 Gene Amplification | BFGFR Gene Amplification | CD331 Gene Amplification | CEK Gene Amplification | FGFBR Gene Amplification | FGFR-1 Gene Amplification | FGFR1 Amplification | FGFR1 Gene Activation | FLG Gene Amplification | FLT-2 Gene Amplification | FLT2 Gene Amplification | FMS-Like Tyrosine Kinase 2 Gene Amplification | Fibroblast Growth Factor Receptor 1 Gene Activation | Fibroblast Growth Factor Receptor 1 Gene Amplification | KAL2 Gene Amplification | N-SAM Gene Amplification | OGD Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512725","FGFR1 Gene Mutation","C129632","A change in the nucleotide sequence of the FGFR1 gene.","FGFR1 Gene Mutation | BFGFR Gene Mutation | CD331 Gene Mutation | CEK Gene Mutation | FGFBR Gene Mutation | FGFR-1 Gene Mutation | FLG Gene Mutation | FLT-2 Gene Mutation | FLT2 Gene Mutation | FMS-Like Tyrosine Kinase 2 Gene Mutation | Fibroblast Growth Factor Receptor 1 Gene Mutation | KAL2 Gene Mutation | N-SAM Gene Mutation | OGD Gene Mutation | Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517092","FGFR2 Gene Amplification","C36651","A molecular genetic abnormality indicating the presence of multiple copies of the FGFR2 gene.","FGFR2 Gene Amplification | BEK Gene Amplification | CD332 Gene Amplification | ECT1 Gene Amplification | FGFR-2 Gene Amplification | FGFR2 Amplification | FGFR2 Gene Activation | Fibroblast Growth Factor Receptor 2 Gene Activation | Fibroblast Growth Factor Receptor 2 Gene Amplification | K-SAM Gene Amplification | KGFR Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512733","FGFR3 Gene Amplification","C129621","A molecular genetic abnormality indicating the presence of multiple copies of the FGFR3 gene.","FGFR3 Gene Amplification | CD333 Gene Amplification | FGFR-3 Gene Amplification | FGFR3 Amplification | Fibroblast Growth Factor Receptor 3 Gene Amplification | JKT4 Gene Amplification | JTK4 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512620","FLT1 Gene Amplification","C129611","A molecular genetic abnormality indicating the presence of multiple copies of the FLT1 gene.","FLT1 Gene Amplification | FLT Gene Amplification | FLT-1 Gene Amplification | FMS-Related Tyrosine Kinase 1 Gene Amplification | FRT Gene Amplification | Fms Related Tyrosine Kinase 1 Gene Amplification | VEGFR-1 Gene Amplification | VEGFR1 Amplification | VEGFR1 Gene Amplification | Vascular Endothelial Growth Factor Receptor 1 Gene Amplification | Vascular Endothelial Growth Factor/Vascular Permeability Factor Receptor Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512621","FLT1 Gene Mutation","C129625","A change in the nucleotide sequence of the FLT1 gene.","FLT1 Gene Mutation | FLT Gene Mutation | FLT-1 Gene Mutation | FMS-Related Tyrosine Kinase 1 Gene Mutation | FRT Gene Mutation | Fms Related Tyrosine Kinase 1 Gene Mutation | VEGFR-1 Gene Mutation | VEGFR1 Gene Mutation | Vascular Endothelial Growth Factor Receptor 1 Gene Mutation | Vascular Endothelial Growth Factor/Vascular Permeability Factor Receptor Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512649","FLT4 Gene Amplification","C129618","A molecular genetic abnormality indicating the presence of multiple copies of the FLT4 gene.","FLT4 Gene Amplification | FMS Related Tyrosine Kinase 4 Gene Amplification | PCL Gene Amplification | VEGFR-3 Gene Amplification | VEGFR3 Amplification | VEGFR3 Gene Amplification | VGR3 Gene Amplification | Vascular Endothelial Growth Factor Receptor 3 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512650","FLT4 Gene Mutation","C129629","A change in the nucleotide sequence of the FLT4 gene.","FLT4 Gene Mutation | FMS Related Tyrosine Kinase 4 Gene Mutation | PCL Gene Mutation | VEGFR-3 Gene Mutation | VEGFR3 Gene Mutation | VGR3 Gene Mutation | Vascular Endothelial Growth Factor Receptor 3 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512941","GATA2 Gene Mutation","C129705","A change in the nucleotide sequence of the GATA2 gene.","GATA2 Gene Mutation | GATA Binding Protein 2 Gene Mutation | NFE1B Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512920","IL2RA Positive","C129706","Indicates that IL2RA expression has been detected in a sample.","IL2RA Positive | CD25 Positive | IL-2 Receptor Positive | IL-2 Receptor Subunit Alpha Positive | IL-2-RA Positive | IL-2R Positive | IL-2R Subunit Alpha Positive | IL2-RA Positive | Interleukin 2 Receptor Subunit Alpha Positive | Interleukin-2 Receptor Subunit Alpha Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512731","KDR Gene Amplification","C129613","A molecular genetic abnormality indicating the presence of multiple copies of the KDR gene.","KDR Gene Amplification | CD309 Gene Amplification | FLK1 Gene Amplification | Kinase Insert Domain Receptor Gene Amplification | VEGFR-2 Gene Amplification | VEGFR2 Amplification | VEGFR2 Gene Amplification | Vascular Endothelial Growth Factor Receptor 2 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512732","KDR Gene Mutation","C129628","A change in the nucleotide sequence of the KDR gene.","KDR Gene Mutation | CD309 Gene Mutation | FLK1 Gene Mutation | Kinase Insert Domain Receptor Gene Mutation | VEGFR-2 Gene Mutation | VEGFR2 Gene Mutation | Vascular Endothelial Growth Factor Receptor 2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512651","PDGFRB Gene Amplification","C129619","A molecular genetic abnormality indicating the presence of multiple copies of the PDGFRB gene.","PDGFRB Gene Amplification | CD140b Gene Amplification | JTK12 Gene Amplification | PDGFR-1 Gene Amplification | PDGFR1 Gene Amplification | PDGFRB Amplification | PDGFRbeta Gene Amplification | Platelet-Derived Growth Factor Receptor Beta Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512936","ROS1 Gene Translocation","C129704","A cytogenetic abnormality that refers to any translocation involving the ROS1 gene.","ROS1 Gene Translocation | MCF3 Gene Translocation | ROS Gene Translocation | ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene Translocation | ROS1 Translocation | c-ros-1 Gene Translocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512634","TP53 Gene Amplification","C129622","A molecular genetic abnormality indicating the presence of multiple copies of the TP53 gene.","TP53 Gene Amplification | LFS1 Gene Amplification | Li-Fraumeni Syndrome Gene Amplification | P53 Gene Amplification | TP53 Amplification | Tumor Protein p53 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413170","CCNA1 Gene","C104227","This gene is involved in cell cycle regulation.","CCNA1 Gene | CCNA1 | Cyclin A1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412364","ALPL Gene","C104230","This gene may play a role in matrix mineralization.","ALPL Gene | ALPL | Alkaline Phosphatase, Biomineralization Associated Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414550","FCGR1A Gene","C104234","This gene is involved in the immune response.","FCGR1A Gene | CD64 | FCGR1A | Fc Fragment of IgG, High Affinity Ia, Receptor (CD64) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415380","GZMB Gene","C104263","This gene plays a role in cell-mediated cytolysis.","GZMB Gene | GZMB | Granzyme B (Granzyme 2, Cytotoxic T-Lymphocyte-Associated Serine Esterase 1) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423607","HAMP Gene","C104271","This gene is involved in both iron metabolism and antimicrobial activity.","HAMP Gene | HAMP | Hepcidin Antimicrobial Peptide Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425514","HAVCR2 Gene","C104276","This gene plays a role in macrophage and T helper cell activation.","HAVCR2 Gene | HAVCR2 | Hepatitis A Virus Cellular Receptor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426002","HDAC11 Gene","C104287","This gene is involved in deacetylation of histones.","HDAC11 Gene | HDAC11 | Histone Deacetylase 11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414421","EPAS1 Gene","C104303","This gene plays a role in the cellular response to hypoxia.","EPAS1 Gene | EPAS1 | Endothelial PAS Domain Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415587","HLA-G Gene","C104316","This gene is involved in antigen processing and presentation.","HLA-G Gene | HLA-G | Major Histocompatibility Complex, Class I, G Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415657","HOXA3 Gene","C104331","This gene plays a role in both transcription and anterior/posterior axis formation.","HOXA3 Gene | HOXA3 | Homeobox A3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415669","HOXB6 Gene","C104335","This gene is involved in the modulation of embryonic gene expression.","HOXB6 Gene | HOXB6 | Homeobox B6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415782","HSPD1 Gene","C104338","This gene plays a role in protein folding.","HSPD1 Gene | HSPD1 | Heat Shock 60kDa Protein 1 (Chaperonin) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416403","IL20 Gene","C104341","This gene is involved in cytokine signaling.","IL20 Gene | IL20 | Interleukin 20 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416406","IL21 Gene","C104344","This gene plays a role in both cytokine signaling and immune responses.","IL21 Gene | IL21 | Interleukin 21 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425474","IFNL2 Gene","C104347","This gene is involved in both immunomodulation and antiviral responses.","IFNL2 Gene | IFNL2 | Interferon, Lambda 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425473","IFNL1 Gene","C104350","This gene plays a role in both the antiviral response and signaling.","IFNL1 Gene | IFNL1 | Interferon, Lambda 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416698","KIF2C Gene","C104356","This gene is involved in microtubule dynamics.","KIF2C Gene | KIF2C | Kinesin Family Member 2C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416652","KIR3DL1 Gene","C104359","This gene plays a role in natural killer cell activity.","KIR3DL1 Gene | KIR3DL1 | Killer Cell Immunoglobulin Like Receptor, Three Ig Domains and Long Cytoplasmic Tail 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426031","FGD4 Gene","C104379","This gene plays a role in regulation of the actin cytoskeleton and cell shape.","FGD4 Gene | FGD4 | FYVE, RhoGEF and PH Domain Containing 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414605","FGF23 Gene","C104382","This gene is involved in phosphate homeostasis.","FGF23 Gene | FGF23 | Fibroblast Growth Factor 23 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414615","VEGFD Gene","C104385","This gene plays a role in angiogenesis, lymphangiogenesis, and endothelial cell growth.","VEGFD Gene | FIGF | FIGF Gene | VEGFD | Vascular Endothelial Growth Factor D Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414630","FKBP8 Gene","C104388","This gene is involved in immunoregulation.","FKBP8 Gene | FK506 Binding Protein 8, 38kDa Gene | FKBP8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414648","FMOD Gene","C104391","This gene may play a role in the assembly of the extracellular matrix.","FMOD Gene | FMOD | Fibromodulin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416467","FOXP3 Gene","C104394","This gene is involved in transcription regulation and the immune response.","FOXP3 Gene | FOXP3 | Forkhead Box P3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414865","FUT4 Gene","C104400","This gene is involved in the generation of fucosylated carbohydrate structures.","FUT4 Gene | FUT4 | Fucosyltransferase 4 (Alpha (1,3) Fucosyltransferase, Myeloid-Specific) Gene | Fucosyltransferase 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414889","FZD8 Gene","C104403","This gene plays a role in cell signaling.","FZD8 Gene | FZD8 | Frizzled Class Receptor 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416829","LGALS1 Gene","C104406","This gene may play a role in modulating cell-cell and cell-matrix interactions.","LGALS1 Gene | LGALS1 | Lectin, Galactoside-Binding, Soluble, 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414968","GAPDH Gene","C104409","This gene is involved in carbohydrate metabolism.","GAPDH Gene | GAPDH | Glyceraldehyde-3-Phosphate Dehydrogenase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414996","GATA6 Gene","C104416","This gene plays a role in regulation of cellular differentiation and organogenesis during development.","GATA6 Gene | GATA Binding Protein 6 Gene | GATA6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414998","GBA1 Gene","C104421","This gene plays a role in the turnover of cellular membranes through the hydrolysis of glucosylceramides and other complex lipids.","GBA1 Gene | GBA | GBA Gene | GBA Gene | GBA1 | Glucosidase, Beta, Acid Gene | Glucosylceramidase Beta 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425933","GBA2 Gene","C104424","This gene plays a role in bile acid hydrolysis.","GBA2 Gene | GBA2 | Glucosidase, Beta (Bile Acid) 2 Gene | Glucosylceramidase Beta 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825346","GHRL Gene","C104427","This gene is involved in regulating growth hormone release and satiety, thirst and anxiety.","GHRL Gene | GHRL | Ghrelin/Obestatin Prepropeptide Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415067","GIP Gene","C104430","This gene plays a role in glucose homeostasis.","GIP Gene | GIP | Gastric Inhibitory Polypeptide Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415276","GPX2 Gene","C104434","This gene is involved in digestion.","GPX2 Gene | GPX2 | Glutathione Peroxidase 2 (Gastrointestinal) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416970","MAGEA1 Gene","C104509","This gene may play a role in embryonal development, tumor transformation, or tumor progression.","MAGEA1 Gene | MAGEA1 | Melanoma Antigen Family A, 1 (Directs Expression of Antigen MZ2-E) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504870","HLA Mismatch","C126298","The state when a recipient of a hematopoietic stem cell transplant is not fully matched with their donor for HLA-A, HLA-B, HLA-C, and HLA-DRB1.","HLA Mismatch | HLA Allele Mismatch | HLA Locus Mismatch | HLA Serotype Mismatch | Mismatch | Non-match",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416975","MAGEA4 Gene","C104512","This gene may be involved in embryonal development, tumor transformation, or tumor progression.","MAGEA4 Gene | MAGEA4 | Melanoma Antigen Family A, 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416977","MAGEA6 Gene","C104517","This gene may enhance ubiquitin ligase activity.","MAGEA6 Gene | MAGEA6 | Melanoma Antigen Family A, 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825936","MAGEB18 Gene","C104521","This gene may enhance ubiquitin ligase activity.","MAGEB18 Gene | MAGE Family Member B18 Gene | MAGEB18 | Melanoma Antigen Family B, 18 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422072","MAGEC2 Gene","C104527","This gene may enhance ubiquitin ligase activity.","MAGEC2 Gene | MAGEC2 | Melanoma Antigen Family C, 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826435","NLRP1 Gene","C104538","This gene plays a role in the induction of apoptosis.","NLRP1 Gene | NALP1 | NLR Family Pyrin Domain Containing 1 Gene | NLRP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416942","NCR2 Gene","C104543","This gene is involved in natural killer cell function.","NCR2 Gene | NCR2 | Natural Cytotoxicity Triggering Receptor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425993","NCR3 Gene","C104548","This gene plays a role in natural killer cell function.","NCR3 Gene | NCR3 | Natural Cytotoxicity Triggering Receptor 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417679","NES Gene","C104557","This gene is involved in mitosis.","NES Gene | NES | Nestin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417609","NCF2 Gene","C104563","This gene plays a role in the generation of superoxide in neutrophils.","NCF2 Gene | NCF2 | Neutrophil Cytosolic Factor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417748","NNMT Gene","C104566","This gene is involved in the detoxification of xenobiotic compounds.","NNMT Gene | NNMT | Nicotinamide N-Methyltransferase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417771","NOX4 Gene","C104570","This gene plays a role as an oxygen sensor in signal transduction.","NOX4 Gene | NADPH Oxidase 4 Gene | NOX4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417858","NSMAF Gene","C104584","This gene is involved in TNF-mediated cell signaling.","NSMAF Gene | NSMAF | Neutral Sphingomyelinase (N-SMase) Activation Associated Factor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412791","BGLAP Gene","C104590","This gene is involved in bone structure and the regulation of bone formation.","BGLAP Gene | BGLAP | Bone Gamma-Carboxyglutamate (Gla) Protein Gene | Bone Gamma-Carboxyglutamate Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417005","MAP1LC3A Gene","C104611","This gene plays a role in autophagocytosis.","MAP1LC3A Gene | MAP1LC3A | Microtubule-Associated Protein 1 Light Chain 3 Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416902","LPL Gene","C104614","This gene is involved in both lipoprotein uptake and triglyceride metabolism.","LPL Gene | LPL | Lipoprotein Lipase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428058","LRRC19 Gene","C104617","This gene may play a role in inducing innate immune responses in kidney and other tissues.","LRRC19 Gene | LRRC19 | Leucine Rich Repeat Containing 19 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416771","LAG3 Gene","C104620","This gene is involved in the activation of T-cells and natural killer cells.","LAG3 Gene | LAG3 | Lymphocyte Activation 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416943","LYPLA1 Gene","C104624","This gene plays a role in regulating membrane lysophospholipids.","LYPLA1 Gene | LYPLA1 | Lysophospholipase I Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416788","LAMP1 Gene","C104627","This gene is involved in cell adhesion and may be involved in tumor cell metastasis.","LAMP1 Gene | LAMP1 | Lysosomal-Associated Membrane Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005802","Blood Glucose","C94312","Glucose present in circulating blood.","Blood Glucose | blood sugar | glycemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512956","Bowel Function Diary for Assessing Opioid-Induced Constipation","C129737","A questionnaire designed to capture relevant patient information regarding opioid-induced constipation in a clinical trial setting. Three modules record information on bowel movements, symptoms experienced, and treatments used to relieve constipation.","Bowel Function Diary for Assessing Opioid-Induced Constipation | BF-Diary | BFD-OIC | Bowel Function Diary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512974","How Able to Fully Empty Bowels","C129740","A question about how much an individual feels they were able to fully empty their bowels.","How Able to Fully Empty Bowels Question | How Able to Fully Empty Bowels | How Able to Fully Empty Bowels | How much did you feel that you were able to fully empty your bowels",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512991","Shape and Consistency of Stool","C129750","A question about how an individual would describe the shape and consistency of their stool.","Shape and Consistency of Stool | Describe Shape and Consistency of Stool | How would you describe the shape and consistency of your stool",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512979","How Often Unable to Have Bowel Movement Even Though Felt Had to","C129751","A question about how often an individual was unable to have a bowel movement even though they felt like they had to.","How Often Unable to Have Bowel Movement Even Though Felt Had to Question | How Often Unable to Have Bowel Movement | How Often Unable to Have Bowel Movement Even Though Felt Had to | How Often Unable to Have Bowel Movement Even Though Felt Had to | How often were you unable to have a bowel movement even though you felt like you had to",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512975","How Much Bloating Felt Because of Constipation","C129752","A question about how much bloating an individual felt because of constipation.","How Much Bloating Felt Because of Constipation | How much bloating did you feel because of constipation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512886","Pain Felt in Abdomen Because of Constipation","C129753","A question about how much pain an individual felt in their abdomen because of constipation.","Pain Felt in Abdomen Because of Constipation | How Much Pain Felt in Abdomen Because of Constipation | How much pain did you feel in your abdomen because of constipation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512976","How Much Bothered by Gas","C129754","A question about how much an individual was bothered by gas.","How Much Bothered by Gas | Bothered by Gas | How much were you bothered by gas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512977","How Much Bothered by Lack of Appetite Because of Constipation","C129755","A question about how much an individual was bothered by a lack of appetite because of constipation.","How Much Bothered by Lack of Appetite Because of Constipation | How much were you bothered by a lack of appetite because of constipation | Lack of Appetite Because of Constipation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512864","During this Bowel Movement","C129756","Occurring in the course of the current bowel movement.","During this Bowel Movement | This Bowel Movement | While in the process of this bowel movement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512895","Complete Agreement","C129762","A subjective answer of complete agreement.","Complete Agreement | Agree Completely | Completely | Completely Agree | Full Agreement | Fully Agree",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417862","NT5C2 Gene","C104587","This gene plays a role in purine metabolism.","NT5C2 Gene | 5'-Nucleotidase, Cytosolic II Gene | NT5C2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415592","MR1 Gene","C104630","This gene plays a role in antigen presentation.","MR1 Gene | MR1 | Major Histocompatibility Complex, Class I-Related Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417249","MRC1 Gene","C104633","This gene is involved in endocytosis of glycoproteins by macrophages.","MRC1 Gene | MRC1 | Mannose Receptor, C Type 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417017","MAP4 Gene","C104636","This gene plays a role in promoting microtubule assembly.","MAP4 Gene | MAP4 | Microtubule-Associated Protein 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413108","CAPG Gene","C104639","This gene is involved in actin-based motility in non-muscle cells.","CAPG Gene | CAPG | Capping Protein (Actin Filament), Gelsolin-Like Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427378","MDC1 Gene","C104642","This gene plays a role in cell cycle progression.","MDC1 Gene | MDC1 | Mediator of DNA Damage Checkpoint 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424610","MRC2 Gene","C104645","This gene is involved in extracellular matrix remodeling.","MRC2 Gene | MRC2 | Mannose Receptor, C type 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417163","MICB Gene","C104648","This gene plays a role in activation of the immune cytolytic response.","MICB Gene | MHC Class I Polypeptide-Related Sequence B Gene | MICB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537692","MIB1 Gene","C104651","This gene is involved in both ubiquitination and cell signaling.","MIB1 Gene | MIB1 | Mindbomb E3 Ubiquitin Protein Ligase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416479","IRF9 Gene","C104654","This gene plays a role in both transcription regulation and cell signaling.","IRF9 Gene | IRF9 | Interferon Regulatory Factor 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825621","ISG15 Gene","C104657","This gene is involved in both protein tagging and cell signaling.","ISG15 Gene | ISG15 | ISG15 Ubiquitin-Like Modifier Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537903","MIR382 Gene","C104665","This gene plays a role in the regulation of transcription.","MIR382 Gene | MIR382 | MicroRNA 382 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417386","MST1L Gene","C104669","This gene encodes a non-functional member of the peptidase S1 family.","MST1L Gene | MST1L | MST1P9 | Macrophage Stimulating 1 Like (Pseudogene) Gene | Macrophage Stimulating 1-Like Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419240","RAD51 Gene","C104711","This gene is involved in both homologous recombination and repair of DNA.","RAD51 Gene | RAD51 | RAD51 Recombinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227170","Pyriform Sinus","C33439","A pear-shaped fossa in the wall of the laryngeal pharynx lateral to the arytenoid cartilage and medial to the lamina of the thyroid cartilage.","Pyriform Sinus | Piriform Recess | Piriform Sinus | Pyriform sinus",,,,,,,,,,,,,,,"4268741","Structure of piriform recess",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1424222","PARK7 Gene","C104714","This gene plays a role in the modulation of apoptotic signaling.","PARK7 Gene | PARK7 | Parkinson Protein 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425011","RASSF5 Gene","C104719","This gene plays a role in both lymphocyte adhesion and suppression of cell growth.","RASSF5 Gene | RAS Association (RalGDS/AF-6) Domain Family Member 5 Gene | RASSF5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427230","RPP40 Gene","C104723","This gene is involved in tRNA metabolism.","RPP40 Gene | RPP40 | Ribonuclease P/MRP 40kDa Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419703","RPS14 Gene","C104726","This gene plays a role in translation as a structural protein of the 40S ribosome subunit.","RPS14 Gene | RPS14 | Ribosomal Protein S14 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273719","Rolapitant","C97952","An orally bioavailable, centrally-acting, selective, neurokinin 1 receptor (NK1-receptor) antagonist, with potential antiemetic activity. Upon oral administration, rolapitant competitively binds to and blocks the activity of the NK1-receptor in the central nervous system, thereby inhibiting the binding of the endogenous ligand, substance P (SP). This may prevent both SP-induced emesis and chemotherapy-induced nausea and vomiting (CINV). The interaction of SP with the NK1-receptor plays a key role in the induction of nausea and vomiting caused by emetogenic cancer chemotherapy. Compared to other NK1-receptor antagonists, rolapitant has both a more rapid onset of action and a much longer half-life.","Rolapitant | 1,7-diazaspiro(4.5)decan-2-one, 8-(((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-, (5S,8S)- | ROLAPITANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427407","PBXIP1 Gene","C104729","This gene plays a role in the negative regulation of transcription.","PBXIP1 Gene | PBXIP1 | Pre-B-Cell Leukemia Homeobox Interacting Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1836945","RICTOR Gene","C104735","This gene is involved in the regulation of cell growth.","RICTOR Gene | RICTOR | RPTOR Independent Companion of MTOR, Complex 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418417","PDE2A Gene","C104739","This gene is involved in second messenger molecule metabolism.","PDE2A Gene | PDE2A | Phosphodiesterase 2A, cGMP-Stimulated Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418436","PDGFC Gene","C104749","This gene plays a role in growth factor signaling.","PDGFC Gene | PDGFC | Platelet Derived Growth Factor C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419392","RLF Gene","C104752","This gene may play a role in transcriptional regulation.","RLF Gene | RLF | Rearranged L-myc Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419618","RPA1 Gene","C104755","This gene is involved in DNA metabolism.","RPA1 Gene | RPA1 | Replication Protein A1, 70kDa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418440","PDK1 Gene","C104758","This gene is involved in glucose metabolism.","PDK1 Gene | PDK1 | Pyruvate Dehydrogenase Kinase, Isozyme 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419630","RPL13A Gene","C104760","This gene plays a role in translation as a structural protein of the 60S ribosome subunit.","RPL13A Gene | RPL13A | Ribosomal Protein L13a Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1846723","RPTOR Gene","C104767","This gene is involved in regulating cell growth.","RPTOR Gene | RPTOR | Regulatory Associated Protein of mTOR Complex 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424883","RRM2B Gene","C104770","This gene plays a role in deoxyribonucleoside diphosphate metabolism.","RRM2B Gene | RRM2B | Ribonucleotide Reductase M2 B (TP53 Inducible) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414257","S1PR2 Gene","C104773","This gene is involved in both cell proliferation and cell survival.","S1PR2 Gene | S1PR2 | Sphingosine-1-Phosphate Receptor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040423","Tonsillectomy","C51679","Surgical removal of the tonsils.","Tonsillectomy | ",,,,,,,,,,,,,,,"4070719","Tonsillectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040421","Palatine Tonsil","C33250","Two masses of lymphatic tissue located one on either side of the oropharynx in the oropharyngeal isthmus.","Palatine Tonsil | TONSIL, PALATINE",,,,,,,,,,,,,,,"4327174","Palatine tonsillar structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1414255","S1PR3 Gene","C104776","This gene encodes a G protein-coupled receptor that may play a role in the regulation of angiogenesis and vascular endothelial cell function.","S1PR3 Gene | S1PR3 | Sphingosine-1-Phosphate Receptor 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414258","S1PR4 Gene","C104779","This gene encodes a G protein-coupled receptor that may be involved in cell migration processes in lymphocytes.","S1PR4 Gene | S1PR4 | Sphingosine-1-Phosphate Receptor 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422554","S1PR5 Gene","C104782","This gene plays a role in regulating cell proliferation, apoptosis, motility, and neurite retraction.","S1PR5 Gene | S1PR5 | Sphingosine-1-Phosphate Receptor 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826560","PDPN Gene","C104785","This gene plays a role in cell shape.","PDPN Gene | PDPN | Podoplanin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418492","PFKM Gene","C104789","This gene is involved in glycolysis in muscle cells.","PFKM Gene | PFKM | Phosphofructokinase, Muscle Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418563","PIGF Gene","C104792","This gene plays a role in the synthesis of glycophosphatidyl inositol anchors.","PIGF Gene | PIGF | Phosphatidylinositol Glycan Anchor Biosynthesis, Class F Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413968","PIAS1 Gene","C104795","This gene is involved in both signal transduction and the sumoylation of proteins.","PIAS1 Gene | PIAS | PIAS1 | Protein Inhibitor of Activated STAT, 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418581","PIM2 Gene","C104798","This gene plays a role in protein phosphorylation, cell proliferation and the regulation of apoptosis.","PIM2 Gene | PIM2 | Pim-2 Oncogene Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418921","PRKCI Gene","C104801","This gene plays a role in the negative regulation of apoptosis.","PRKCI Gene | PRKCI | Protein Kinase C, Iota Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826727","PRUNE2 Gene","C104804","This gene may be involved in apoptosis.","PRUNE2 Gene | PRUNE2 | Prune Homolog 2 (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538738","PSENEN Gene","C104807","This gene plays a role in the regulation of both gamma-secretase activity and Notch signaling pathways.","PSENEN Gene | PSENEN | Presenilin Enhancer 2 Homolog (C. elegans) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419178","PYY Gene","C104810","This gene is involved in gastrointestinal function.","PYY Gene | PYY | Peptide YY Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419214","RAB5C Gene","C104814","This gene plays a role in GTP hydrolysis.","RAB5C Gene | RAB5C | RAB5C, Member RAS Oncogene Family Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419229","RAC3 Gene","C104817","This gene is involved in both cytoskeletal remodeling and GTPase activity.","RAC3 Gene | RAC3 | Ras-Related C3 Botulinum Toxin Substrate 3 (Rho Family, Small GTP Binding Protein Rac3) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418640","PLCG1 Gene","C104821","This gene is involved in both intracellular signaling and second messenger production.","PLCG1 Gene | PLCG1 | Phospholipase C, Gamma 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425488","SCGB3A1 Gene","C104995","This gene encodes a secreted protein of unknown function.","SCGB3A1 Gene | SCGB3A1 | Secretoglobin, Family 3A, Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419892","SDC2 Gene","C104998","This gene is involved in cell proliferation, cell migration and cell-matrix interactions.","SDC2 Gene | SDC2 | Syndecan 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419987","SFRP2 Gene","C105001","This gene is involved in regulating cell growth and differentiation as a modulator of Wnt signaling.","SFRP2 Gene | SFRP2 | Secreted Frizzled-Related Protein 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419988","SFRP5 Gene","C105004","This gene may play a role in determining the polarity of photoreceptor cells in the retina.","SFRP5 Gene | SFRP5 | Secreted Frizzled-Related Protein 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419939","SEL1L Gene","C105007","This gene is involved in protein degradation.","SEL1L Gene | SEL1L | Sel-1 Suppressor of Lin-12-Like (C. elegans) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418544","SERPINA1 Gene","C105010","This gene plays a role in both coagulation and the regulation of proteolysis.","SERPINA1 Gene | SERPINA1 | Serpin Family A Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419974","SETMAR Gene","C105013","This gene is involved in epigenetic transcriptional activation.","SETMAR Gene | SET Domain and Mariner Transposase Fusion Gene | SETMAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428890","SGMS1 Gene","C105016","This gene plays a role in phosphatidylcholine and ceramide metabolism.","SGMS1 Gene | SGMS1 | Sphingomyelin Synthase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420259","SMPD1 Gene","C105019","This gene plays a role in ceramide metabolism.","SMPD1 Gene | SMPD1 | Sphingomyelin Phosphodiesterase 1, Acid Lysosomal Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420260","SMPD2 Gene","C105022","This gene is involved in sphingomyelin catabolism.","SMPD2 Gene | SMPD2 | Sphingomyelin Phosphodiesterase 2, Neutral Membrane (Neutral Sphingomyelinase) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420014","SGPL1 Gene","C105028","This gene plays a role in the metabolism of phosphorylated sphingoid bases.","SGPL1 Gene | SGPL1 | Sphingosine-1-Phosphate Lyase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422502","SMPD3 Gene","C105029","This gene plays a role in phospholipid metabolism.","SMPD3 Gene | SMPD3 | Sphingomyelin Phosphodiesterase 3, Neutral Membrane (Neutral Sphingomyelinase II) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1822791","SMPD4 Gene","C105035","This gene is involved in ceramide biosynthesis.","SMPD4 Gene | SMPD4 | Sphingomyelin Phosphodiesterase 4, Neutral Membrane (Neutral Sphingomyelinase-3) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425046","SGPP1 Gene","C105037","This gene is involved in sphingosine-1-phosphate degradation.","SGPP1 Gene | SGPP1 | Sphingosine-1-Phosphate Phosphatase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426555","SGPP2 Gene","C105043","This gene plays a role in sphingosine-1-phosphate catabolism.","SGPP2 Gene | SGPP2 | Sphingosine-1-Phosphate Phosphatase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427537","SLAMF6 Gene","C105055","This gene acts as a coreceptor in the process of natural killer cell activation.","SLAMF6 Gene | SLAM Family Member 6 Gene | SLAMF6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420122","SLC1A4 Gene","C105058","This gene plays a role in amino acid transport.","SLC1A4 Gene | SLC1A4 | Solute Carrier Family 1 (Glutamate/Neutral Amino Acid Transporter), Member 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420193","SLC4A1 Gene","C105064","This gene plays a role in carbon dioxide transport from tissues to lungs.","SLC4A1 Gene | SLC4A1 | Solute Carrier Family 4, Anion Exchanger, Member 1 (Erythrocyte Membrane Protein Band 3, Diego Blood Group) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420195","SLC4A3 Gene","C105067","This gene is involved in mediating chloride/bicarbonate exchange in cardiac myocytes.","SLC4A3 Gene | SLC4A3 | Solute Carrier Family 4, Anion Exchanger, Member 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420115","SLC18A2 Gene","C105070","This gene plays a role in neurotransmitter transport.","SLC18A2 Gene | SLC18A2 | Solute Carrier Family 18 (Vesicular Monoamine), Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420134","SLC22A1 Gene","C105073","This gene is involved in cation transport.","SLC22A1 Gene | SLC22A1 | Solute Carrier Family 22 (Organic Cation Transporter), Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422190","SOST Gene","C105076","This gene plays a role in bone growth.","SOST Gene | SOST | Sclerostin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420318","SOX11 Gene","C105079","This gene is involved in the negative regulation of transcription.","SOX11 Gene | SOX11 | SRY-Box 11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423560","SPRY4 Gene","C105082","This gene plays a role in the inhibition of receptor signaling.","SPRY4 Gene | SPRY4 | Sprouty Homolog 4 (Drosophila) Gene | Sprouty RTK Signaling Antagonist 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420398","SREBF1 Gene","C105085","This gene is involved in both transcriptional regulation and lipid homeostasis.","SREBF1 Gene | SREBF1 | Sterol Regulatory Element Binding Transcription Factor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426909","SULF2 Gene","C105088","This gene plays a role in heparan sulfate metabolism.","SULF2 Gene | SULF2 | Sulfatase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420619","TBXA2R Gene","C105091","This gene is involved in platelet aggregation.","TBXA2R Gene | TBXA2R | Thromboxane A2 Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425854","TDP1 Gene","C105094","This gene plays a role in the repair of both single and double strand breaks in DNA.","TDP1 Gene | TDP1 | Tyrosyl-DNA Phosphodiesterase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423842","NELFCD Gene","C105097","This gene is involved in the negative regulation of transcript elongation.","NELFCD Gene | NELFCD | Negative Elongation Factor Complex Member C/D Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420783","TMPO Gene","C105100","This gene plays a role in nuclear structure.","TMPO Gene | TMPO | Thymopoietin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422452","TMEM204 Gene","C105105","This gene is involved in cell-cell adhesion.","TMEM204 Gene | TMEM204 | Transmembrane Protein 204 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420887","TRAF1 Gene","C105108","This gene plays a role in TNF receptor family-mediated signaling.","TRAF1 Gene | TNF Receptor-Associated Factor 1 Gene | TRAF1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420813","TNFRSF9 Gene","C105111","This gene plays a role in receptor signaling in T-cells.","TNFRSF9 Gene | TNF Receptor Superfamily Member 9 Gene | TNFRSF9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420871","TPI1 Gene","C105557","This gene plays a role in glycolysis and gluconeogenesis.","TPI1 Gene | TPI1 | Triosephosphate Isomerase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823482","TRDMT1 Gene","C105560","This gene is involved in methylation of aspartic acid transfer RNA.","TRDMT1 Gene | TRDMT1 | tRNA Aspartic Acid Methyltransferase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639708","Clinical Global Impression Original Version Questionnaire","C100763","A standardized survey developed by W. Guy in 1976 which is used to evaluate the efficacy of a therapeutic intervention. This instrument consists of 3 sections pertaining to the severity of the patient's illness, their level of improvement and a comparison of the therapeutic effect versus the side effects. The questionnaire is completed by a clinician familiar with the patient's medical history.","Clinical Global Impression Original Version Questionnaire | CGI Original Version | Clinical Global Impression Questionnaire | Clinical Global Impressions Scale | Clinical Global Impressions Scale - CGI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1540075","TSC22D3 Gene","C105563","This gene plays a role in the function of both T-cells and macrophages.","TSC22D3 Gene | TSC22 Domain Family, Member 3 Gene | TSC22D3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420810","TNFRSF18 Gene","C105566","This gene is involved in T-cell function.","TNFRSF18 Gene | TNFRSF18 | Tumor Necrosis Factor Receptor Superfamily Member 18 Gene | Tumor Necrosis Factor Receptor Superfamily, Member 18 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422006","TNFRSF21 Gene","C105569","This gene plays a role in the induction of apoptosis.","TNFRSF21 Gene | TNFRSF21 | Tumor Necrosis Factor Receptor Superfamily, Member 21 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421330","UGT1A6 Gene","C105572","This gene is involved in the excretion of phenolic metabolites.","UGT1A6 Gene | UDP Glucuronosyltransferase 1 Family, Polypeptide A6 Gene | UGT1A6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421346","UGT2B7 Gene","C105575","This gene plays a role in estrogen metabolism.","UGT2B7 Gene | UDP Glucuronosyltransferase 2 Family, Polypeptide B7 Gene | UGT2B7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423032","ULBP1 Gene","C105580","This gene is involved in the function of natural killer cells.","ULBP1 Gene | UL16 Binding Protein 1 Gene | ULBP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423033","ULBP2 Gene","C105583","This gene plays a role in the function of natural killer cells.","ULBP2 Gene | UL16 Binding Protein 2 Gene | ULBP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423034","ULBP3 Gene","C105592","This gene is involved in the function of natural killer cells.","ULBP3 Gene | UL16 Binding Protein 3 Gene | ULBP3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421446","VEGFB Gene","C105596","This gene plays a role in regulation of blood vessel physiology.","VEGFB Gene | VEGFB | Vascular Endothelial Growth Factor B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423875","VPS18 Gene","C105599","This gene is involved in intracellular trafficking.","VPS18 Gene | VPS18 | Vacuolar Protein Sorting 18 Homolog (S. cerevisiae) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538110","WNK1 Gene","C105602","This gene plays a role in regulation of electrolyte homeostasis.","WNK1 Gene | WNK Lysine Deficient Protein Kinase 1 Gene | WNK1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420645","ZEB1 Gene","C105605","This gene is involved in the transcriptional repression of interleukin 2.","ZEB1 Gene | ZEB1 | Zinc Finger E-Box Binding Homeobox 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418914","ZMYND8 Gene","C105608","This gene plays a role in protein kinase C function.","ZMYND8 Gene | ZMYND8 | Zinc Finger, MYND-Type Containing 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416443","INPP4B Gene","C106327","This gene is involved in phosphatidylinositol metabolism.","INPP4B Gene | INPP4B | Inositol Polyphosphate-4-Phosphatase Type II B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417768","NOTCH3 Gene","C106436","This gene plays a role in both intercellular signaling and cell fate determination.","NOTCH3 Gene | NOTCH3 | Notch 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413210","CD1D Gene","C106493","This gene is involved in antigen presentation.","CD1D Gene | CD1D | CD1d Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011501","2-Deoxy-D-glucose","C116618","A non-metabolizable glucose analog in which the hydroxyl group at position 2 of glucose is replaced by hydrogen, with potential glycolysis inhibiting and antineoplastic activities. Although the exact mechanism of action has yet to be fully elucidated, upon administration of 2-deoxy-D-glucose (2-DG), this agent competes with glucose for uptake by proliferating cells, such as tumor cells. 2-DG inhibits the first step of glycolysis and therefore prevents cellular energy production, which may result in decreased tumor cell proliferation.","2-Deoxy-D-glucose | 2-DEOXYGLUCOSE | 2-DG | Deoxyglucose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0108789","CD45RA","C118492","CD45RA (1211 aa, ~138 kDa) is encoded by the human PTPRC gene. This protein plays a role in both lymphocyte function and protein dephosphorylation. It is an isoform of receptor-type tyrosine-protein phosphatase C that is missing the amino acids encoded by exons 5 and 6 of the PTPRC gene.","CD45RA | CD45RA Antigen | Receptor-Type Tyrosine-Protein Phosphatase C Isoform 6 | Receptor-Type Tyrosine-Protein Phosphatase C Isoform CD45RA",,,,,,,,,,,,,,,"4205140","Lymphocyte antigen CD45RA",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512916","CALR NM_004343.3:c.1092_1143del52","C129834","A deletion of 52 nucleotides from the coding sequence of the CALR gene from positions 1092 through 1143.","CALR NM_004343.3:c.1092_1143del52 | Autoantigen Ro Gene c.1092_1143del52 | CALR Type 1 Gene Mutation | CALR c.1092_1143del52 | CALR1 | CALR1 Gene Mutation | CRT c.1092_1143del52 | Calreticulin Gene c.1092_1143del52 | NM_004343.3:c.1092_1143del52 | RO c.1092_1143del52 | Type 1 CALR Gene Variant | cC1qR c.1092_1143del52",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512917","CALR NM_004343.3:c.1154_1155insTTGTC","C129835","An insertion of five nucleotides, TTGTC, between positions 1154 and 1155 of the coding sequence of the CALR gene.","CALR NM_004343.3:c.1154_1155insTTGTC | Autoantigen Ro Gene c.1154_1155ins5 | Autoantigen Ro Gene c.1154_1155insTTGTC | CALR NM_004343.3:c.1154_1155ins5 | CALR Type 2 Gene Mutation | CALR c.1154_1155ins5 | CALR c.1154_1155insTTGTC | CALR2 | CALR2 Gene Mutation | CRT c.1154_1155ins5 | CRT c.1154_1155insTTGTC | Calreticulin Gene c.1154_1155ins5 | Calreticulin Gene c.1154_1155insTTGTC | NM_004343.3:c.1154_1155ins5 | NM_004343.3:c.1154_1155insTTGTC | RO c.1154_1155ins5 | RO c.1154_1155insTTGTC | Type 2 CALR Gene Variant | cC1qR c.1154_1155ins5 | cC1qR c.1154_1155insTTGTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512954","Bladder Cancer Muscle-Invasive 30 Questionnaire","C129791","A questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) consisting of 30 questions designed to assess quality of life in patients with muscle-invasive bladder cancer (BLM).","Bladder Cancer Muscle-Invasive 30 Questionnaire | BLM30 | EORTC QLQ-BLM30 | QLQ-BLM30 | Quality of Life Questionnaire-Bladder Cancer Muscle Invasive 30",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512971","Have to Urinate Frequently During Day","C129792","A question about the extent to which an individual has or had to urinate frequently during the day.","Have to Urinate Frequently During Day | Extent Have to Urinate Frequently During Day | Have you had to urinate frequently during the day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512972","Have to Urinate Frequently at Night","C129793","A question about the extent to which an individual has or had to urinate frequently at night.","Have to Urinate Frequently at Night | Extent Have to Urinate Frequently at Night | Have you had to urinate frequently at night",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512994","When Feel Urge to Pass Urine Have to Hurry to Get to Toilet","C129794","A question about the extent to which an individual has or had to hurry to get to the toilet when they feel or felt the urge to pass urine.","When Feel Urge to Pass Urine Have to Hurry to Get to Toilet | Extent Feel Urge to Pass Urine and Have to Hurry to Get to Toilet | When you felt the urge to pass urine, did you have to hurry to get to the toilet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512951","Difficult Getting Enough Sleep Because of Need to Get Up Frequently at Night to Urinate","C129795","A question about the extent to which an individual has or had difficulty getting enough sleep because they need to get up frequently at night to urinate.","Difficult Getting Enough Sleep Because of Need to Get Up Frequently at Night to Urinate | Extent of Difficulty Getting Enough Sleep Because of Need to Get Up Frequently at Night to Urinate | Was it difficult for you to get enough sleep, because you needed to get up frequently at night to urinate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512963","Have Difficulty Going Out of House Because of Need to be Close to Toilet","C129796","A question about the extent to which an individual has or had difficulty going out of the house because they need to be close to a toilet.","Have Difficulty Going Out of House Because of Need to be Close to Toilet | Extent Difficulty Going Out of House Because of Need to be Close to Toilet | Have you had difficulty going out of the house, because you needed to be close to a toilet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512968","Have Unintentional Release of Urine","C129797","A question about the extent to which an individual has or had unintentional release or leakage of urine.","Degree of Urinary Incontinence | Extent of Urinary Incontinence | Have Unintentional Release of Urine | Have Urinary Incontinence | Have Urinary Incontinence | Have you had any unintentional release (leakage) of urine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512965","Have Pain or Burning with Urination","C129798","A question about the extent to which an individual has or had pain or a burning feeling when urinating.","Have Pain or Burning with Urination | Extent of Pain or Burning with Urination | Have Pain or Burning Feeling When Urinating | Have Pain or Burning on Urination | Have you had pain or a burning feeling when urinating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512950","Have Urine Leak from Urostomy Bag","C129799","A question about the extent to which an individual has or had urine leak from their urostomy bag.","Have Urine Leak from Urostomy Bag | Extent of Urine Leakage from Urostomy Bag | Has urine leaked from your urostomy bag | Urine Leakage from Urostomy Bag",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512966","Have Problem Caring for Urostomy","C129800","A question about the extent to which an individual has or had problems caring for their urostomy.","Have Problem Caring for Urostomy | Did you have problems with caring for your urostomy | Extent of Problem Caring for Urostomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512952","Have Irritated Skin Around Urostomy","C129801","A question about the extent to which an individual has or had irritated skin around their urostomy.","Have Irritated Skin Around Urostomy | Extent of Irritated Skin Around Urostomy | Was your skin around the urostomy irritated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512866","Feel Embarrassed Because of Urostomy","C129802","A question about the extent to which an individual feels or felt embarrassed because of their urostomy.","Feel Embarrassed Because of Urostomy | Extent Feel Embarrassed Because of Urostomy | Have you felt embarrassed because of your urostomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512962","Dependent on Others for Urostomy Care","C129803","A question about the extent to which an individual is or was dependent on others for caring for their urostomy.","Dependent on Others for Urostomy Care | Extent Dependent on Others for Urostomy Care | Have you been dependent on others for caring for your urostomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512970","Have to Change Urostomy Bag Frequently","C129804","A question about the frequency that an individual has or had to change their urostomy bag.","Have to Change Urostomy Bag Frequently | Did you frequently have to change the urostomy bag | Frequently Have to Change Urostomy Bag",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512967","Have Problems with Self-Catherization","C129805","A question about the extent to which an individual has or had problems with inserting a tube in the bladder to pass urine.","Have Problems with Self-Catherization | Extent of Problems with Self-Catherization | Have you had problems with self-catheterization (inserting a tube in the bladder to pass urine)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512996","Worry About Possible Future Treatments","C129809","A question about the extent to which an individual worries or worried about possible treatments in the future.","Worry About Possible Future Treatments | Did you worry about possible future treatments | Extent of Worry About Possible Future Treatments | Worry About Future Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512964","Have Flatulence or Gas","C129810","A question about the extent to which an individual has or had flatulence or gas.","Have Flatulence or Gas | Extent Have Flatulence or Gas | Have you had flatulence or gas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512867","Feel Less Feminine or Masculine as a Result of Illness or Treatment","C129811","A question about whether an individual feels or felt less feminine or masculine as a result of their illness or treatment.","Feel Less Feminine or Masculine as a Result of Illness or Treatment | Have you felt less feminine/masculine as a result of your illness or treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512869","Feel Uncomfortable About Sexual Intimacy","C129812","A question about the extent to which an individual feels or felt uncomfortable about being sexually intimate.","Feel Uncomfortable About Sexual Intimacy | Extent Feel Uncomfortable About Sexual Intimacy | Feel Uncomfortable About Being Sexually Intimate | Have you felt uncomfortable about being sexually intimate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512995","Worry About Contaminating Partner During Sexual Contact Due to Bladder Treatment","C129813","A question about the extent to which an individual worries or worried that they may contaminate their partner during sexual contact with the bladder treatment they have been receiving.","Worry About Contaminating Partner During Sexual Contact Due to Bladder Treatment | Extent of Worry About Contaminating Partner During Sexual Contact Due to Bladder Treatment | Have you worried that you may contaminate your partner during sexual contact with the bladder treatment you have been receiving",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512969","Have Vaginal Dryness or Other Problem During Intercourse","C129814","A question about the extent to which a woman experiences a dry vagina or other problems during intercourse.","Have Vaginal Dryness or Other Problem During Intercourse | Did you have a dry vagina or other problems during intercourse | Extent of Vaginal Dryness or Other Problem During Intercourse | Have Dry Vagina or Other Problem During Intercourse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698311","Hyperdiploid B Lymphoblastic Leukemia/Lymphoma","C80335","A precursor lymphoid neoplasm composed of B lymphoblasts which contain more than 50 and usually less than 66 chromosomes. It has a favorable clinical outcome.","Hyperdiploid B Lymphoblastic Leukemia/Lymphoma | B Lymphoblastic Leukemia/Lymphoma with High Hyperdiploidy | B Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy | B Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy | B lymphoblastic leukemia/lymphoma with hyperdiploidy | B-Lymphoblastic Leukemia/Lymphoma with High Hyperdiploidy | B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy | High Hyperdiploidy","9815/3","B lymphoblastic leukemia/lymphoma with hyperdiploidy",,,,,,,,,,,,,"3654653|42872958","B lymphoblastic leukemia lymphoma with hyperdiploidy|B lymphoblastic leukemia lymphoma with hyperdiploidy",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C2698312","Hypodiploid B Lymphoblastic Leukemia/Lymphoma","C80338","A precursor lymphoid neoplasm composed of B lymphoblasts which contain less than 46 chromosomes. It has an unfavorable clinical outcome.","Hypodiploid B Lymphoblastic Leukemia/Lymphoma | B Lymphoblastic Leukemia/Lymphoma with Hypodiploidy | B Lymphoblastic Leukemia/Lymphoma with Hypodiploidy | B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy | Hypodiploid  B Lymphoblastic Leukemia/Lymphoma","9816/3","B lymphoblastic leukemia/lymphoma with hypodiploidy (Hypodiploid ALL)",,,,,,,,,,,,,"3654651","B lymphoblastic leukemia lymphoma with hypodiploidy",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C2698314","B Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1","C80334","A precursor lymphoid neoplasm which is composed of B lymphoblasts and carries a translocation between the TEL gene on chromosome 12 and the AML1 gene on chromosome 21, (p13.2;q22.1). It results in the production of the TEL-AML1 (ETV6-RUNX1) fusion protein. It has a favorable clinical outcome.","B Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1 | B Lymphoblastic Leukemia/Lymphoma with ETV6-RUNX1 Fusion | B Lymphoblastic Leukemia/Lymphoma with ETV6::RUNX1 Fusion | B Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1 | B Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6::RUNX1 | B Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1) | B Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1) | B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1) | B-Lymphoblastic Leukemia/Lymphoma with ETV6-RUNX1 Fusion | B-Lymphoblastic Leukemia/Lymphoma with ETV6::RUNX1 Fusion | B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)","9814/3","B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)",,,,,,,,,,,,,"3654649|42872957","B lymphoblastic leukemia lymphoma with t(12;21) (p13;q22); TEL/AML1 (ETV6-RUNX1)|B lymphoblastic leukemia lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C2698317","B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1","C80331","A precursor lymphoid neoplasm which is composed of B lymphoblasts and carries a translocation between the BCR gene on chromosome 22 and the ABL1 gene on chromosome 9. It results in the production of the p190 kd or p210 kd fusion protein. It has an unfavorable clinical outcome.","B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 | B Lymphoblastic Leukemia/Lymphoma with BCR-ABL1 Fusion | B Lymphoblastic Leukemia/Lymphoma with BCR::ABL1 Fusion | B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 | B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR::ABL1 | B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34;q11.2); BCR-ABL1 | B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34;q11.2); BCR-ABL1 | B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1 | B-Lymphoblastic Leukemia/Lymphoma with BCR-ABL1 Fusion | B-Lymphoblastic Leukemia/Lymphoma with BCR::ABL1 Fusion | B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34;q11.2); BCR-ABL1","9812/3","B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1",,,,,,,,,,,,,"42872955","B lymphoblastic leukemia lymphoma with t(9;22)(q34;q11.2); BCR-ABL1",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C2698309","B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A Rearranged","C80332","A precursor lymphoid neoplasm which is composed of B lymphoblasts and carries a translocation between the KMT2A gene at 11q23.3 and another gene partner resulting in the production of an KMT2A related fusion protein.","B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A Rearranged | B Lymphoblastic Leukemia/Lymphoma with KMT2A Rearrangement | B Lymphoblastic Leukemia/Lymphoma with T(V;11Q23); MLL Rearranged | B Lymphoblastic Leukemia/Lymphoma with t(v;11q23); MLL Rearranged | B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A Rearranged | B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A Rearranged | B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); MLL Rearranged | B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); MLL Rearranged | B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged | B-Lymphoblastic Leukemia/Lymphoma with KMT2A Rearrangement | B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23); MLL Rearranged | B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); MLL Rearranged","9813/3","B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged",,,,,,,,,,,,,"3654648|42872956","B lymphoblastic leukemia lymphoma with t(v;11q23); MLL rearranged|B lymphoblastic leukemia lymphoma with t(v;11q23); MLL rearranged",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C3266994","ALK Gene Mutation","C81945","A molecular genetic abnormality that refers to the presence of a mutation in the ALK gene.","ALK Gene Mutation | ALK Mutation | ALK Receptor Tyrosine Kinase Gene Mutation | Anaplastic Lymphoma Kinase (Ki-1) Gene Mutation | Anaplastic Lymphoma Kinase Receptor Gene Mutation | Anaplastic Lymphoma Receptor Tyrosine Kinase Gene Mutation | CD246 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826059","Natural Killer Cell Lymphoblastic Leukemia/Lymphoma","C82217","A precursor lymphoid neoplasm that expresses CD56 and immature T-cell markers, lacks B-lymphoid and myeloid markers, and has immunoglobulin and T-cell receptor genes in the germline configuration.","Natural Killer Cell Lymphoblastic Leukemia/Lymphoma | NK Cell Lymphoblastic Leukemia/Lymphoma | NK Lymphoblastic Leukemia/Lymphoma | NK-ALL/LBL | NK-Lymphoblastic Leukemia/Lymphoma | Precursor NK Cell Lymphoblastic Leukemia/Lymphoma | Precursor Natural Killer Cell Lymphoblastic Leukemia/Lymphoma",,,,,,,,,,,,,,,"37204662","NK-lymphoblastic leukemia/lymphoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1711381","RET Gene Mutation","C43293","A change in the structure of the RET gene.","RET Gene Mutation | RET/PTC Gene Mutation | Ret Proto-Oncogene Gene Mutation | Ret Proto-Oncogene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512132","DOCK8 Gene Mutation","C128819","A change in the nucleotide sequence of the DOCK8 gene.","DOCK8 Gene Mutation | DOCK8 Mutation | Dedicator of Cytokinesis 8 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830146","FGFR2 Gene Mutation","C107579","A change in the nucleotide sequence of the FGFR2 gene.","FGFR2 Gene Mutation | BEK Gene Mutation | CD332 Gene Mutation | ECT1 Gene Mutation | FGFR-2 Gene Mutation | Fibroblast Growth Factor Receptor 2 Gene Mutation | K-SAM Gene Mutation | KGFR Gene Mutation | Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517091","FGFR3 Gene Mutation","C39877","A change in the nucleotide sequence of the FGFR3 gene.","FGFR3 Gene Mutation | CD333 Gene Mutation | FGFR-3 Gene Mutation | Fibroblast Growth Factor Receptor 3 Gene Mutation | JKT4 Gene Mutation | JTK4 Gene Mutation | Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518782","PDGFRA Gene Mutation","C39718","A molecular genetic abnormality indicating the presence of a mutation in the PDGFRA (platelet-derived growth factor receptor, alpha polypeptide) gene on chromosome 4q12.","PDGFRA Gene Mutation | CD140A Gene Mutation | PDGFR-2 Gene Mutation | PDGFR2 Gene Mutation | PDGFRA Mutation | PDGFRalpha Gene Mutation | Platelet-Derived Growth Factor Receptor Alpha Gene Mutation | RHEPDGFRA Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508922","PDGFRB Gene Mutation","C128172","A change in the nucleotide sequence of the PDGRFB gene.","PDGFRB Gene Mutation | CD140b Gene Mutation | JTK12 Gene Mutation | PDGFR1 Gene Mutation | Platelet Derived Growth Factor Receptor Beta Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273088","PDGFRA Gene Amplification","C96868","A molecular genetic abnormality indicating the presence of multiple copies of the PDGFRA (platelet-derived growth factor receptor, alpha polypeptide) gene.","PDGFRA Gene Amplification | CD140A Gene Amplification | PDGFR-2 Gene Amplification | PDGFR2 Gene Amplification | PDGFRA Amplification | PDGFRalpha Gene Amplification | Platelet-Derived Growth Factor Receptor Alpha Gene Amplification | RHEPDGFRA Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697913","Leukemic Blast Count","C74630","The determination of the number of leukemic blasts present in a sample.","Leukemic Blast Count | BLASTLM | Leukemic Blasts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053942","Testicular Involvement","C122714","A finding indicating the involvement of the testis by a malignant neoplasm.","Testicular Involvement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1567130","Inotuzumab Ozogamicin","C71542","A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","Inotuzumab Ozogamicin | Besponsa | CMC 544 | CMC-544 | CMC544 | INOTUZUMAB OZOGAMICIN | Inotuzumab ozogamicin | WAY-207294 | Way 207294",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899763","CIC-DUX4 Fusion Protein Expression","C120220","Expression of a fusion protein that results from a t(4;19)(q35;q13) translocation, which involves the human genes CIC (capicua transcriptional suppressor) and DUX4 (double homeobox 4).","CIC-DUX4 Fusion Protein Expression | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0075128","Anti-Ro Antibody","C121322","An antinuclear antibody directed against 52 or 60 kDa RNA-binding proteins in the nucleus. They can be associated with multiple autoimmune disorders, primarily Sjogren syndrome and system lupus erythematosus. Maternal anti-Ro antibody positivity can be associated with neonatal lupus.","Anti-Ro Antibody | Anti-SSA/Ro Antibody",,,,,,,,,,,,,,,"4194997","Anti SS-A antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0443933","Anti-La Antibody","C121323","An antinuclear antibody directed against a 47 kDa RNA-binding protein in the nucleus. They can be associated with Sjogren syndrome and system lupus erythematosus. Maternal anti-La antibody positivity can be associated with neonatal lupus.","Anti-La Antibody | Anti-SSB/La Antibody",,,,,,,,,,,,,,,"4136221","Lupus La protein antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162595","Antiphospholipid Antibody","C121327","A class of autoantibodies directed against phospholipids or phospholipoproteins. Its presence may indicate an increased risk for hypercoagulability, pregnancy loss or autoimmune disease.","Antiphospholipid Antibody | APLA | Anti-Phospholipid Antibody",,,,,,,,,,,,,,,"4125245","Anti-phospholipid antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1414946","GALC Gene","C121621","This gene plays a role in hydrolysis of galactose ester bonds.","GALC Gene | GALC | Galactosylceramidase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413387","CHI3L1 Gene","C125183","This gene plays a role in carbohydrate binding, inflammation and tissue remodeling.","CHI3L1 Gene | CHI3L1 | Chitinase 3-Like 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415857","ID4 Gene","C125498","This gene plays a role in the negative regulation of gene expression.","ID4 Gene | ID4 | Inhibitor of DNA Binding 4, Dominant Negative Helix-Loop-Helix Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027930","Neurotensin","C126490","Neurotensin (13 aa, ~2 kDa) is encoded by the human NTS gene. This protein may be involved in the regulation of fat metabolism in the gut.","Neurotensin | Gln-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu | NT | NTS | QLYENKPRRPYIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415186","GP1BA Gene","C126546","This gene plays a role in platelet aggregation.","GP1BA Gene | GP1BA | Glycoprotein Ib Platelet Alpha Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419596","ROBO1 Gene","C126588","This gene is involved in neuroblast migration and axon guidance.","ROBO1 Gene | ROBO1 | Roundabout Guidance Receptor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL374082","KIT NM_000222.2:c.2447A>T","C126818","A nucleotide substitution at position 2447 of the coding sequence of the KIT gene where adenine has been mutated to thymine.","KIT NM_000222.2:c.2447A>T | CD117 c.2447A>T | KIT Proto-Oncogene Tyrosine Protein Kinase c.2447A>T | KIT c.2447A>T | NM_000222.2:c.2447A>T | V-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.2447A>T | c-KIT c.2447A>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2674716","KIT NP_000213.1:p.D816V","C126820","A change in the amino acid residue at position 816 in the mast/stem cell growth factor receptor Kit protein where aspartic acid has been replaced by valine.","KIT NP_000213.1:p.D816V | CD117 Antigen Asp816Val | CD117 Antigen D816V | KIT Asp816Val | KIT D816V | KIT NP_000213.1:p.Asp816Val | KIT p.Asp816Val | KIT p.D816V | Mast/Stem Cell Growth Factor Receptor Kit Asp816Val | Mast/Stem Cell Growth Factor Receptor Kit D816V | NP_000213.1:p.Asp816Val | NP_000213.1:p.D816V | Proto-Oncogene Tyrosine-Protein Kinase Kit Asp816Val | Proto-Oncogene Tyrosine-Protein Kinase Kit D816V | Proto-Oncogene c-Kit Asp816Val | Proto-Oncogene c-Kit D816V | Stem Cell Factor Receptor Asp816Val | Stem Cell Factor Receptor D816V | Tyrosine-Protein Kinase Kit Asp816Val | Tyrosine-Protein Kinase Kit D816V | c-KIT Asp816Val | c-KIT D816V | c-KIT p.Asp816Val | c-KIT p.D816V | cKIT D816V Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL410024","MPL NP_005364.1:p.W515K","C126825","A change in the amino acid residue at position 515 in the thrombopoietin receptor protein where tryptophan has been replaced by lysine.","MPL NP_005364.1:p.W515K | CD110 Antigen Trp515Lys | CD110 Antigen W515K | MPL NP_005364.1:p.Trp515Lys | MPL Trp515Lys | MPL W515K | MPL p.Trp515Lys | MPL p.W515K | Myeloproliferative Leukemia Protein Trp515Lys | Myeloproliferative Leukemia Protein W515K | NP_005364.1:p.Trp515Lys | NP_005364.1:p.W515K | Proto-Oncogene c-Mpl Trp515Lys | Proto-Oncogene c-Mpl W515K | TPO-R Trp515Lys | TPO-R W515K | TPO-R W515L | Thrombopoietin Receptor Trp515Lys | Thrombopoietin Receptor W515K | c-MPL Trp515Lys | c-MPL W515K | c-MPL p.Trp515Lys | c-MPL p.W515K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL410025","MPL NP_005364.1:p.W515L","C126824","A change in the amino acid residue at position 515 in the thrombopoietin receptor protein where tryptophan has been replaced by leucine.","MPL NP_005364.1:p.W515L | CD110 Antigen Trp515Leu | CD110 Antigen W515L | MPL NP_005364.1:p.Trp515Leu | MPL Trp515Leu | MPL W515L | MPL p.Trp515Leu | MPL p.W515L | Myeloproliferative Leukemia Protein Trp515Leu | Myeloproliferative Leukemia Protein W515L | NP_005364.1:p.Trp515Leu | NP_005364.1:p.W515L | Proto-Oncogene c-Mpl Trp515Leu | Proto-Oncogene c-Mpl W515L | TPO-R Trp515Leu | TPO-R W515L | Thrombopoietin Receptor Trp515Leu | Thrombopoietin Receptor W515L | c-MPL Trp515Leu | c-MPL W515L | c-MPL p.Trp515Leu | c-MPL p.W515L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508194","SDHA NM_004168.3:c.1660C>T","C126831","A nucleotide substitution at position 1660 of the coding sequence of the SDHA gene where cytosine has been mutated to thymine.","SDHA NM_004168.3:c.1660C>T | NM_004168.3:c.1660C>T | SDHA c.1660C>T | Succinate Dehydrogenase Complex Flavoprotein Subunit A c.1660C>T | Succinate Dehydrogenase Complex, Subunit A, Flavoprotein (Fp) c.1660C>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1833237","SDHA NP_004159.2:p.R554W","C126833","A change in the amino acid sequence at position 544 of the the succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial protein where arginine has been replaced by tryptophan.","SDHA NP_004159.2:p.R554W | NP_004159.2:p.Arg554Trp | NP_004159.2:p.R554W | SDHA Arg554Trp | SDHA NP_004159.2:p.Arg554Trp | SDHA R554W | SDHA p.Arg554Trp | SDHA p.R554W | Succinate Dehydrogenase [Ubiquinone] Flavoprotein Subunit, Mitochondrial Arg554Trp | Succinate Dehydrogenase [Ubiquinone] Flavoprotein Subunit, Mitochondrial R554W",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508120","DRD2 NM_000795.3:c.957C>T","C126837","A nucleotide substitution at position 957 of the coding sequence of the DRD2 gene where cytosine has been mutated to thymine.","DRD2 NM_000795.3:c.957C>T | DRD2 957T Indel Mutation | DRD2 C957T Indel Mutation | DRD2 c.957C>T | Dopamine Receptor D2 c.957C>T | NM_000795.3:c.957C>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508119","DRD2 NM_000795.3:c.-486_-485insC","C126838","A nucleotide insertion of a cytosine between positions -486 and -485 in the 5' promoter region of the DRD2 gene.","DRD2 NM_000795.3:c.-486_-485insC | DRD2 -141 indel | DRD2 -141C Ins/Del | DRD2 -141insC Mutation | DRD2 c.-486_-485insC | Dopamine Receptor D2 c.-486_-485insC | NM_000795.3:c.-486_-485insC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508149","Globohexaosylceramide","C126893","A hexasaccharide glycosphingolipid and human cancer antigen expressed on the surface of many types of tumor cells. Globohexaosylceramide (Globo H) is minimally or not expressed on healthy, normal cells; its expression on cancer cells is associated with increased proliferation and poor prognosis.","Globohexaosylceramide | Globo H | Globo-H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0060805","Fucosyl Monosialotetrahexosylganglioside","C126894","A fucosylated derivative of monosialotetrahexosylganglioside (GM1) and tumor antigen associated with small-cell lung cancer (SCLC). Fucosyl-GM1 is specifically expressed in SCLC while minimally or not expressed on healthy, normal cells; it plays a key role in tumor cell proliferation and may be a biomarker to detect the presence of these cancer cells.","Fucosyl Monosialotetrahexosylganglioside | Fuc-GM1 | Fucosyl GM1 | Fucosyl-GM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508232","Monoclonal Antibody M30","C126895","A mouse monoclonal antibody that recognizes the soluble caspase-cleaved (cc) form of human keratin, type I cytoskeletal 18 (cytokeratin 18, K18, KRT18, CK18). Monoclonal antibody M30 binds to a neo-epitope (NE) exposed after caspase cleavage after the aspartic acid residue at position 396 of K18 (K18Asp396). This neo-epitope results from the proteolytic activity of caspase-3, -7 or -9, which are active during apoptosis. Thus, M30 can be used to indirectly identify caspase activation and to determine if the cell death in a sample is due to apoptosis rather than necrosis.","Monoclonal Antibody M30 | M30 | Mouse Anti-Human Caspase Cleaved Keratin 18 Monoclonal Antibody | Mouse Anti-Human K18Asp396 Monoclonal Antibody | Mouse Anti-Human K18Asp396 Neo-Epitope Monoclonal Antibody | Mouse Anti-Human K18Asp396-NE Monoclonal Antibody | Mouse Anti-Human ccK18 Monoclonal Antibody | Mouse Monoclonal Antibody M30",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010734","Cytidine Triphosphate","C126896","A cytosine derived nucleotide comprised of three phosphate groups esterified to the deoxyribose sugar moiety. Nucleotide metabolism is upregulated in cancer cells; therefore, this nucleotide could be used as a biomarker to detect the presence of cancer cells.","Cytidine Triphosphate | 5'-CTP | CTP | CYTIDINE TRIPHOSPHATE | Cytidine 3'-Triphosphate | Cytidine 5'-(Tetrahydrogen Triphosphate) | Cytidine 5'-Triphosphoric Acid | Cytidine-5'-Triphosphate | Deoxycytidine Triphosphate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0057455","Deoxypyridinoline","C126897","A pyridinium-derived moiety that forms crosslinks in type I collagen in bone. Urine levels of deoxypyridinoline are used as a correlative marker for bone resorption and osteoclast activity; both of these activities may be increased in certain diseases.","Deoxypyridinoline | D-PYR | D-Pyrilinks | DPD | DPYD | DeoxyPYD | Deoxypyridinium | Lysylpyridinoline | N-(5-Amino-5-Carboxypentyl)-3-Hydroxy-4-(2-Amino-2-Carboxyethyl)-5-(3-Amino-3-Carboxypropyl)Pyridine | Pyridinium, 4-((2S)-2-Amino-2-Carboxyethyl)-1-((5S)-5-Amino-5-Carboxypentyl)-3-((3S)-3-Amino-3-Carboxypropyl)-5-Hydroxy-, Inner Salt | Pyridinium, 4-(2-Amino-2-Carboxyethyl)-1-(5-Amino-5-Carboxypentyl)-3-(3-Amino-3-Carboxypropyl)-5-Hydroxy-, Hydroxide, Inner Salt, Stereoisomer | Pyrilinks-D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508118","Anti-Hairy Cell Leukemia Antibody DBA.44","C126899","A mouse monoclonal antibody directed against an epitope expressed by the DEAU B-lymphoma cell line, with potential diagnostic applications ex vivo. Anti-hairy cell leukemia antibody DBA.44 detects an antigen expressed on a subpopulation of B-lymphocytes in the mantle zone of lymphoid follicles. DBA.44 reacts with the majority of lymphocytes of hairy cell leukemia (HCL).","Anti-Hairy Cell Leukemia Antibody DBA.44 | Anti-Hairy Cell Leukemia Antibody (Clone DBA.44) | Anti-Hairy Cell Leukemia Antibody (DBA.44) | Anti-Hairy Cell Leukemia Antibody [DBA.44] | DBA.44 | DBA44",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508108","HLA-DR Antigen 1D10","C126900","A polymorphic epitope on the HLA-DR beta chain that is expressed on normal and neoplastic B-cells.","HLA-DR Antigen 1D10 | 1D10 Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0071008","Phytoene","C126901","A 40 carbon dietary fatty acid produced by the conversion of two molecules of geranylgeranyl pyrophosphate by the enzyme phytoene synthase that is an intermediate in carotenoid biosynthesis in plants with potential to absorb ultraviolet radiation (UV), and potential antioxidant, chemopreventive, and anti-inflammatory activities in skin. Following ingestion and digestion, phytoene may accumulate in the epidermis where it may prevent UV-mediated sun damage and carcinogenesis. In addition, phytofluene may prevent carcinogenesis by protecting cells against DNA damage through its free radical scavenger effects.","Phytoene | (6E,10E,14E,16E,18E,22E,26E)-2,6,10,14,19,23,27,31-Octamethyldotriaconta-2,6,10,14,16,18,22,26,30-Nonaene | 7,7',8,8',11,11',12,12'-Octahydro-Psi,Psi-Carotene | All-Trans-Phytoene | PHYTOENE | Psi,Psi-Carotene, 7,7',8,8',11,11',12,12'-Octahydro-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0071013","Phytofluene","C126903","A 40 carbon dietary fatty acid that is an intermediate in carotenoid biosynthesis in plants and is derived from the desaturation of double bonds in phytoene with potential to absorb ultraviolet radiation (UV), and potential antioxidant, chemopreventive and anti-inflammatory activities. Following ingestion and digestion, phytofluene may accumulate in the skin where it may prevent UV-mediated sun damage and carcinogenesis. In addition, phytofluene may prevent carcinogenesis by protecting cells against DNA damage through its free radical scavenger effects.","Phytofluene | (6E,10E,12E,14E,16Z,18E,22E,26E)-2,6,10,14,19,23,27,31-Octamethyldotriaconta- 2,6,10,12,14,16,18,22,26,30-Decaene | 15-Cis-7,8,11,12,7',8'-Hexahydro-Psi,Psi-Carotene | 15-Cis-Phytofluene (SY) | All-Trans-Phytofluene | PHYTOFLUENE, ALL-TRANS-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0074992","Sphingosine 1-Phosphate","C126907","A bioactive sphingolipid comprised of a sphingosine with a phosphate group attached to the carbon at position 1. Sphingosine 1-phosphate (S1P) binds to G protein-coupled S1P receptors (S1PRs) and initiates signaling pathways involved in the regulation of angiogenesis, the proliferation of skin cells, vascular stability and permeability, and T- and B-cell trafficking.","Sphingosine 1-Phosphate | (2-Amino-3-Hydroxy-Octadec-4-Enoxy)Phosphonic Acid | (2S,3R,4E)-2-Amino-3-Hydroxyoctadec-4-En-1-Yl Dihydrogen Phosphate | (2S,3R,4E)-2-Amino-4-Octadecene-1,3-Diol 1-(Dihydrogen Phosphate) | 4-Octadecene-1,3-Diol, 2-Amino-, 1-(Dihydrogen Phosphate), (2S,3R,4E) | 4-Octadecene-1,3-Diol, 2-Amino-, 1-(Dihydrogen Phosphate), (R-(R*,S*-(E)))- | D-Erythro-Sphingosine 1-Phosphate | S1P | SPHINGOSINE 1-PHOSPHATE | SPP | Sphing-4-Enine 1-Phosphate | Sphingosine 1-Phosphic Acid | Sphingosine-1-Phosphate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507999","Epoxyeicosatrienoic Acid","C126908","A class of eicosanoids produced by the epoxidation of one of the double bonds of arachidonic acid by some of the members of the cytochrome P450 family of epoxygenases. Epoxides in the epoxyeicosatrienoic acid (EET) family act locally to stimulate signaling pathways involved in the regulation of blood pressure, vascular maintenance, inflammation, and pain responses. EETs may promote the proliferation and survival of certain types of cancer cells.","Epoxyeicosatrienoic Acid | EET | EETs | Epoxyicosatrienoic Acid | Epoxyicosatrienoic Acids",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0045143","2',5'-oligoadenylate","C126910","An oligonucleotide synthesized from adenosine triphosphate (ATP) by enzymes in the 2'-5'-oligoadenylate synthase family. The production of 2'-5'-oligoadenylate is stimulated by the presence of double stranded RNA (dsRNA) and binds to inactive monomeric forms of ribonuclease L (RNase L), thereby promoting RNase L dimerization and activation. Active RNase L degrades both cellular and viral RNAs, which inhibits protein translation and leads to the abrogation of viral replication. 2'-5'-oligoadenylates play a key role in the innate immunity against viruses.","2'-5'-Oligoadenylate | 2'-5' Oligoadenylate | 2-5-Oligoadenylate | 2-5A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0047645","3-Nitrotyrosine","C126911","A tyrosine derivative with a nitro group attached to carbon 3 on the phenyl ring that is a product of tyrosine nitration mediated by reactive nitrogen species, including peroxynitrite anion and nitrogen dioxide. 3-nitrotyrosine is a biomarker of cell damage, inflammation, and NO (nitric oxide) production; it is overproduced in many diseases where oxidative stress plays a key role.","3-Nitrotyrosine | 3-Mononitrotyrosine | 3-NITRO-L-TYROSINE | 3-NT | Tyrosine, 3-Nitro-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0000334","24,25-Dihydroxycholecalciferol","C126931","A vitamin D derivative that is produced by the conversion of calcifediol by 1,25-dihydroxyvitamin D3 24-hydroxylase (CYP24A1). 24,25-dihydroxycholecalciferol is a marker for calcifediol catabolism because it is the major metabolite of calcifediol, and its urine levels are increased in certain diseases, such as chronic kidney disease (CKD).","24,25-Dihydroxycholecalciferol | (3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-Triene-3,24,25-Triol | 24,25(OH)(2)D | 24,25(OH)2 D3 | 24,25-DIHYDROXYCHOLECALCIFEROL | 24,25-Dihydroxyvitamin D | 24,25-Dihydroxyvitamin D 3 | 24,25-Dihydroxyvitamin D3 | 24,25-Hydroxy Vitamin D3 | 9,10-Secocholesta-5,7,10(19)-Triene-3,24,25-Triol, (3-beta,5Z,7E)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507963","ADGRE1 wt Allele","C126951","Human ADGRE1 wild-type allele is located in the vicinity of 19p13.3 and is approximately 53 kb in length. This allele, which encodes adhesion G protein-coupled receptor E1 protein, plays a role in cell-cell adhesion of immune cells.","ADGRE1 wt Allele | Adhesion G Protein-Coupled Receptor E1 wt Allele | EGF-Like Module-Containing, Mucin-Like, Hormone Receptor 1 Gene | EMR1 | Egf-Like Module Containing, Mucin-Like, Hormone Receptor-Like 1 Gene | Egf-Like Module Containing, Mucin-Like, Hormone Receptor-Like Sequence 1 Gene | F4/80 | F4/80 Homolog Gene | TM7LN3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1853479","SELENOF Gene","C126953","This gene plays a role in selenium binding.","SELENOF Gene | SELENOF | SEP15 | SEP15 Gene | Selenoprotein F Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412938","C2 Gene","C126956","This gene is involved in the classical pathway of the complement system.","C2 Gene | C2 | Complement Component 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417162","MICA Gene","C126959","This gene plays a role in the immune response to stress.","MICA Gene | MHC Class I Polypeptide-Related Sequence A Gene | MICA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416746","KRT8 Gene","C126962","This gene is involved in muscle and epithelial structures.","KRT8 Gene | KRT8 | Keratin 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418186","ORM1 Gene","C126965","This gene plays a role in immune modulation and transport.","ORM1 Gene | ORM1 | Orosomucoid 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416387","IL15RA Gene","C126968","This gene is involved in interleukin binding and signaling.","IL15RA Gene | IL15RA | Interleukin 15 Receptor Subunit Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1439274","ADRB3 Gene","C126971","This gene plays a role in the modulation of the physiological effects of catecholamines.","ADRB3 Gene | ADRB3 | Adrenoceptor Beta 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824669","CD46 Gene","C126977","This gene is involved in fertilization, pathogen binding, complement activation and T-regulatory cell differentiation.","CD46 Gene | CD46 | CD46 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413290","CDK9 Gene","C126980","This gene plays a role in cyclin-dependent phosphorylation of protein substrates.","CDK9 Gene | CDK9 | Cyclin-Dependent Kinase 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL414476","Immunostimulant","C2139","Substances that stimulate the immune system.","Immunostimulant | Immunostimulating Agent | immunostimulant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413863","CYP26A1 Gene","C126983","This gene is involved in retinoic acid metabolism.","CYP26A1 Gene | CYP26A1 | Cytochrome P450 Family 26 Subfamily A Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415754","DNAJA1 Gene","C126986","This gene plays a role in both folding and intracellular trafficking of proteins.","DNAJA1 Gene | DNAJA1 | DnaJ Heat Shock Protein Family (Hsp40) Member A1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414151","DRG1 Gene","C126989","This gene is involved in both GTP binding and cell growth regulation.","DRG1 Gene | DRG1 | Developmentally Regulated GTP Binding Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426810","GCSAM Gene","C126992","This gene plays a role in both signaling and cell motility","GCSAM Gene | GCSAM | Germinal Center Associated Signaling and Motility Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415033","GDF2 Gene","C126995","This gene is involved in the inhibition of angiogenesis.","GDF2 Gene | GDF2 | Growth Differentiation Factor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415077","GJB2 Gene","C126999","This gene plays a role in gap junction function.","GJB2 Gene | GJB2 | Gap Junction Protein Beta 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415277","GPX3 Gene","C127002","This gene is involved in the metabolism of hydrogen peroxide and lipid peroxides.","GPX3 Gene | GPX3 | Glutathione Peroxidase 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415534","HGFAC Gene","C127006","This gene is involved in growth factor processing.","HGFAC Gene | HGF Activator Gene | HGFAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423009","HHIP Gene","C127009","This gene plays a role in hedgehog signaling pathways.","HHIP Gene | HHIP | Hedgehog Interacting Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416035","IGHV3-21 Gene","C127013","This gene is involved in immunoglobulin heavy chain structure.","IGHV3-21 Gene | IGHV3-21 | Immunoglobulin Heavy Variable 3-21 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423036","ITPKC Gene","C127016","This gene plays a role in both second messenger metabolism and calcium homeostasis.","ITPKC Gene | ITPKC | Inositol-Trisphosphate 3-Kinase C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825684","ELAPOR1 Gene","C127019","This gene is involved in autophagy and RNA binding.","ELAPOR1 Gene | ELAPOR1 | Endosome-Lysosome Associated Apoptosis and Autophagy Regulator 1 Gene | KIAA1324 | KIAA1324 Gene | KIAA1324 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417057","MBP Gene","C127022","This gene plays a role in myelin sheath formation.","MBP Gene | MBP | Myelin Basic Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1259728","4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol","C127127","The major metabolite of the potentially carcinogenic nitrosamine 4-methylnitrosamino-1,3-pyridyl-1-butanone (nicotine-derived nitrosamine ketone; NNK) that is detected in the urine of subjects exposed to tobacco products. 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (nicotine-derived nitrosamine alcohol; NNAL) is produced by carbonyl reduction of NNK and may also be a carcinogen.","4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol | 3-Pyridinemethanol, Alpha-(3-(Methylnitrosoamino)Propyl)- | 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANOL | 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butan-1-Ol | 4-(Methylnitrosoamino)-1-(3-Pyridyl)-1-Butanol | 4-[Methyl(Nitroso)Amino]-1-(Pyridin-3-Yl)Butan-1-Ol | Alpha-(3-(Methylnitrosoamino)Propyl)-3-Pyridinemethanol | NNAL | Nicotine-Derived Nitrosamine Alcohol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417826","NR1I2 Gene","C127842","This gene is involved in the regulation of genes that affect steroid and xenobiotic metabolism.","NR1I2 Gene | NR1I2 | Nuclear Receptor Subfamily 1 Group I Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826048","Mixed Phenotype Acute Leukemia with KMT2A Rearrangement","C82203","A rare mixed phenotype acute leukemia in which the blasts carry a translocation between the KMT2A gene at 11q23.3 and another gene partner. The prognosis is usually unfavorable.","Mixed Phenotype Acute Leukemia with KMT2A Rearrangement | MPAL with t(v;11q23.3); KMT2A Rearranged | MPAL, with t(v;11q23.3); KMT2A Rearranged | Mixed Phenotype Acute Leukemia with t(v;11q23); MLL Rearranged | Mixed Phenotype Acute Leukemia with t(v;11q23); MLL Rearranged | Mixed Phenotype Acute Leukemia with t(v;11q23.3); KMT2A Rearranged | Mixed Phenotype Acute Leukemia with t(v;11q23.3); KMT2A Rearranged | Mixed Phenotype Acute Leukemia with t(v;11q23.3); MLL Rearranged | Mixed Phenotype Acute Leukemia with t(v;11q23.3); MLL Rearranged | Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged | Mixed-Phenotype Acute Leukemia with KMT2A Rearrangement","9807/3","Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged",,,,,,,,,,,,,"42872920","Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C2826037","Mixed Phenotype Acute Leukemia with BCR-ABL1 Fusion","C82192","A rare mixed phenotype acute leukemia in which the blasts carry the chromosomal translocation t(9;22)(q34.1;q11.2) that results in BCR-ABL1 gene fusion. The prognosis is usually unfavorable.","Mixed Phenotype Acute Leukemia with BCR-ABL1 Fusion | MPAL with t(9;22)(q34.1;q11.2); BCR-ABL1 | MPAL with t(9;22)(q34.1;q11.2); BCR::ABL1 | Mixed Phenotype Acute Leukemia with BCR::ABL1 Fusion | Mixed Phenotype Acute Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 | Mixed Phenotype Acute Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 | Mixed Phenotype Acute Leukemia with t(9;22)(q34.1;q11.2); BCR::ABL1 | Mixed Phenotype Acute Leukemia with t(9;22)(q34;q11.2); BCR-ABL1 | Mixed Phenotype Acute Leukemia with t(9;22)(q34;q11.2); BCR-ABL1 | Mixed phenotype acute leukemia with t(9;22)(q34;q11.2); BCR-ABL1 | Mixed-Phenotype Acute Leukemia with BCR-ABL1 Fusion | Mixed-Phenotype Acute Leukemia with BCR::ABL1 Fusion","9806/3","Mixed phenotype acute leukemia with t(9;22)(q34;q11.2); BCR-ABL1",,,,,,,,,,,,,"42872919|607405","Mixed phenotype acute leukemia with t(9;22)(q34;q11.2); BCR-ABL1|Mixed phenotype acute leukemia with t(9;22) (q34;q11.2); BCR-ABL1",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1417960","OPHN1 Gene","C127845","This gene plays a role in the mediation of GTP hydrolysis of Rho subfamily members.","OPHN1 Gene | OPHN1 | Oligophrenin 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418261","PAK3 Gene","C127849","This gene is involved in signal transduction and the modulation of cell shape and cellular migration.","PAK3 Gene | PAK3 | p21 (RAC1) Activated Kinase 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418388","PCSK1 Gene","C127852","This gene plays a role in the metabolism of prohormones and neuropeptides.","PCSK1 Gene | PCSK1 | Proprotein Convertase Subtilisin/Kexin Type 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826700","PRMT5 Gene","C127855","This gene is involved in both histone methylation and the formation of omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA).","PRMT5 Gene | PRMT5 | Protein Arginine Methyltransferase 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420182","SLC31A1 Gene","C127858","This gene plays a role in copper transport.","SLC31A1 Gene | SLC31A1 | Solute Carrier Family 31 Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420257","SMN1 Gene","C127862","This gene plays a role in assembly of small nuclear ribonucleoproteins.","SMN1 Gene | SMN1 | Survival of Motor Neuron 1, Telomeric Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420270","SNAP25 Gene","C127882","This gene plays a role in neurotransmitter release and plasma membrane recycling.","SNAP25 Gene | SNAP25 | Synaptosomal Associated Protein 25kDa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1968839","SPHKAP Gene","C127885","This gene is involved in the modulation of cAMP- and sphingosine-mediated signaling.","SPHKAP Gene | SPHK1 Interactor, AKAP Domain Containing Gene | SPHKAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420390","SPTLC1 Gene","C127888","This gene plays a role in lipid modification.","SPTLC1 Gene | SPTLC1 | Serine Palmitoyltransferase, Long Chain Base Subunit 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539893","SUMF1 Gene","C127891","This gene is involved in the activation of sulfatase.","SUMF1 Gene | SUMF1 | Sulfatase Modifying Factor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420718","TH Gene","C127894","This gene plays a role in dopamine biosynthesis.","TH Gene | TH | Tyrosine Hydroxylase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420729","TIA1 Gene","C127897","This gene is involved in nucleolysis, RNA binding and alternative splicing.","TIA1 Gene | TIA1 | TIA1 Cytotoxic Granule-Associated RNA Binding Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425349","TNFRSF13B Gene","C127901","This gene plays a role in cytokine-dependent signaling and lymphocyte activation.","TNFRSF13B Gene | TNFRSF13B | Tumor Necrosis Factor Receptor Superfamily Member 13B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420952","TRAP1 Gene","C127909","This gene is involved in protein folding and ATPase activity.","TRAP1 Gene | TNF Receptor Associated Protein 1 Gene | TRAP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427070","TWIST2 Gene","C127913","This gene plays a role in the negative regulation of both gene transcription and osteoblast differentiation.","TWIST2 Gene | TWIST2 | Twist Family bHLH Transcription Factor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421319","UGCG Gene","C127917","This gene is involved in glucosylceramide synthesis.","UGCG Gene | UDP-Glucose Ceramide Glucosyltransferase Gene | UGCG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424137","WNT5B Gene","C127921","This gene plays a role in the modulation of Wnt-frizzled signaling pathways.","WNT5B Gene | WNT5B | Wnt family member 5B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537404","IL32 Gene","C127924","This gene is involved in cytokine-mediated immunity.","IL32 Gene | IL32 | Interleukin 32 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421322","UGT1A Locus","C127927","Human UGT1A gene locus is located in the vicinity of 2q37 and is approximately 188 kb in length. This locus includes nine protein-encoding genes and four pseudogenes. The protein-encoding genes are involved in glucuronidation of toxins, drugs and xenobiotics.","UGT1A Locus | GNT1 | UDP Glucuronosyltransferase 1 Family, Polypeptide A Cluster | UDP Glucuronosyltransferase 1 Family, Polypeptide A Complex Locus | UDP Glucuronosyltransferase Family 1 Member A Complex Locus | UDP Glycosyltransferase 1 Family, Polypeptide A Cluster | UGT | UGT1 | UGT1A | Uridine Phosphate Glycosyltransferase Family 1 Member A Locus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418865","PRAME Gene","C127928","This gene plays a role in the repression of retinoic acid receptor signaling.","PRAME Gene | PRAME | Preferentially Expressed Antigen in Melanoma Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512856","Acute Myeloid Leukemia with Biallelic CEBPA Mutation","C129782","An acute myeloid leukemia with double mutations of the CEBPA gene.","Acute Myeloid Leukemia with Biallelic CEBPA Mutation | AML with biallelic mutations of CEBPA | Acute Myeloid Leukemia with Biallelic Mutations of CEBPA | Acute Myeloid Leukemia with Biallelic Mutations of CEBPA",,,,,,,,,,,,,,,"37312067","Acute myeloid leukemia with biallelic CEBPA mutation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512855","Acute Myeloid Leukemia with BCR-ABL1","C129785","A rare, de novo acute myeloid leukemia in which the blasts harbor BCR-ABL1 translocation in the absence of a history and clinical and laboratory features of chronic myelogenous leukemia.","Acute Myeloid Leukemia with BCR-ABL1 | Acute Myeloid Leukemia with BCR-ABL1 Fusion | Acute Myeloid Leukemia with BCR::ABL1 | Acute Myeloid Leukemia with BCR::ABL1 Fusion | Provisional Entity: AML with BCR-ABL1",,,,,,,,,,,,,,,"37165057|37204375","Acute myeloid leukemia with BCR-ABL1|Acute myeloid leukemia with BCR::ABL1 fusion",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL512858","Acute Myeloid Leukemia with RUNX1 Mutation","C129786","Acute myeloid leukemia characterized by the presence of RUNX1 gene mutation.","Acute Myeloid Leukemia with RUNX1 Mutation | Acute Myeloid Leukemia with Mutated RUNX1 | Acute Myeloid Leukemia with Mutated RUNX1 | Acute Myeloid Leukemia with Non-Germline Mutated RUNX1 | Acute Myeloid Leukemia with RUNX1 Gene Mutation | Provisional entity: AML with mutated RUNX1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512919","B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like","C129787","B lymphoblastic leukemia/lymphoma characterized by a gene-expression profile similar to that of BCR-ABL1-positive B lymphoblastic leukemia/lymphoma, absence of the pathognomonic BCR-ABL1 rearrangement, alterations of lymphoid transcription factor genes, and a poor outcome.","B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | B Lymphoblastic Leukemia/Lymphoma with BCR-ABL1-Like Features | B Lymphoblastic Leukemia/Lymphoma with BCR::ABL1-Like Features | B Lymphoblastic Leukemia/Lymphoma with Translocations Involving Tyrosine Kinases or Cytokine Receptors | B Lymphoblastic Leukemia/Lymphoma, BCR::ABL1-Like | B Lymphoblastic Leukemia/Lymphoma, Philadelphia-like | B-Lymphoblastic Leukemia/Lymphoma with BCR-ABL1-Like Features | B-Lymphoblastic Leukemia/Lymphoma with BCR::ABL1-Like Features | B-Lymphoblastic Leukemia/Lymphoma, Philadelphia-like",,,,,,,,,,,,,,,"37204838","B-lymphoblastic leukemia lymphoma BCR-ABL1-like",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040336","Tobacco Use Disorder","C35074","Any disease or disorder that is caused by the use of tobacco.","Tobacco Use Disorder | ",,,,,,,,,,,,,,,"437264","Tobacco dependence syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1537996","MT-RNR1 Gene","C128260","This gene is involved in the translation of mitochondrial proteins and cellular metabolic processes.","MT-RNR1 Gene | 12S Mitochondrial Ribosomal RNA Gene | MT-RNR1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509041","Circulating Cell-Free DNA","C128274","DNA found in blood plasma and other bodily fluids that is not associated with cells.","Circulating Cell-Free DNA | Cell Free Circulating DNA | Cell Free DNA | Circulating Cell Free DNA | Circulating DNA | cfDNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508903","Liver X Receptor-Like Family","C128275","A nuclear receptor family that binds oxysterols or bile acids and, after forming a heterodimer with a member of the retinoid X receptor (RXR) family, modulates the expression of genes that are involved in cholesterol, fatty acid, and glucose homeostasis. The members of this family include oxysterols receptor LXR-alpha (NR1H3), oxysterols receptor LXR-beta (NR1H2) and bile acid receptor (NR1H4).","Liver X Receptor-Like Family | LXR | LXR Family | NR1H | Nuclear Receptor Subfamily 1 Group H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508660","Activated Caspase-3","C128277","Activated caspase-3 (249 aa, ~29 kDa) is encoded by the human CASP3 gene. This protein plays a role in the promotion of apoptosis.","Activated Caspase-3 | Activated CASP-3 | Activated CASP3 | Activated Caspase 3 | Cleaved CASP-3 | Cleaved CASP3 | Cleaved Caspase 3 | Cleaved Caspase-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509248","Interferon-Related DNA Damage Resistance Gene Signature","C128278","An experimental therapy-predictive system used to assess if patient's tumor may be resistant to chemotherapy. This system is based on the expression profile of a panel of genes that are associated with both interferon signaling pathways and resistance to radiation-induced DNA damage.","Interferon-Related DNA Damage Resistance Gene Signature | IFN-Related DNA Damage Resistance Signature | IRDS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509012","Human Adenovirus Type 5 Early Region 1","C128279","A region of the adenovirus type 5 genome that contains the transforming early genes E1A and E1B.","Human Adenovirus Type 5 Early Region 1 | Ad5E1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0058989","Eukaryotic Initiation Factor-4F","C128282","A protein complex comprised of a heterotetrameric core, eukaryotic initiation factor 4A, 4E, and 4 gamma, bound to other factors; the exact composition of varies with the cellular environmental conditions. This complex recognizes the 5' cap of mRNA and promotes the initiation of translation.","Eukaryotic Translation Initiation Factor 4F | eIF-4F | eIF4F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508906","Low Molecular Weight Cyclin E","C128284","Proteolytically processed forms of cyclin E proteins, which are specifically generated in tumors that overexpress cyclin E proteins.","Low Molecular Weight Cyclin E | LMW-E | Low Molecular Weight Cyclin-E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0210108","Platelet-Derived Growth Factor-AA","C128285","A disulfide-linked homodimeric protein complex comprised of 2 platelet-derived growth factor subunit A proteins. This dimeric growth factor binds to a homodimeric receptor comprised of two platelet-derived growth factor receptor alpha proteins. Ligand binding activates the intrinsic tyrosine-protein kinase activity of the receptor complex and initiates signal transduction pathways.","Platelet-Derived Growth Factor-AA | PDGF-AA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0381163","Platelet-Derived Growth Factor-AB","C128286","A disulfide-linked heterodimeric protein complex comprised of one platelet-derived growth factor subunit A and one platelet-derived growth factor subunit B. This dimeric growth factor binds to a heterodimeric receptor comprised of one platelet-derived growth factor receptor alpha and one platelet-derived growth factor receptor beta. Ligand binding activates the intrinsic tyrosine-protein kinase activity of the receptor complex and initiates signal transduction pathways.","Platelet-Derived Growth Factor-AB | PDGF-AB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512923","Completely Able","C129878","A response indicating that an individual is completely able to do something.","Completely Able | Completely",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512978","How Much Strain","C129879","A question about how much an individual had to strain.","How Much Strain | How much did you have to strain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512885","Pain Felt Around Rectum","C129880","A question about how much pain an individual had around their rectum.","Pain Felt Around Rectum | How Much Pain Felt Around Rectum | How much pain did you have around your rectum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0246681","Platelet-Derived Growth Factor-BB","C128287","A disulfide-linked homodimeric protein complex comprised of 2 platelet-derived growth factor subunit B proteins. This dimeric growth factor binds to a homodimeric receptor comprised of two platelet-derived growth factor receptor beta proteins. Ligand binding activates the intrinsic tyrosine-protein kinase activity of the receptor complex and initiates signal transduction pathways.","Platelet-Derived Growth Factor-BB | PDGF-BB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509605","Androgen Receptor Splice Variant 5,6,7es","C128291","Androgen receptor protein that is missing the amino acids encoded by exons 5-7 and part of the 5' end of exon 8 of the human AR gene. This variant protein contains nuclear receptor transcriptional activation and DNA binding domains and is missing the nuclear receptor ligand binding and activation function-2 domains. Expression of this variant is associated with a gain-of-function phenotype and may be associated with prostate cancer.","Androgen Receptor Splice Variant 5,6,7es | ARv567es | Androgen Receptor Splice Variant 12 | Arv-12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509601","Androgen Receptor Splice Variant 3","C128292","Androgen receptor protein that is comprised of the amino acids encoded by exons 1-3 and those encoded by cryptic exon 3 (CE3) of the human AR gene. This variant protein contains nuclear receptor transcriptional activation and DNA binding domains and is missing the hinge region and the nuclear receptor ligand binding and activation function-2 domains. Expression of this variant is associated with both a constitutively active, gain-of-function phenotype and prostate cancer.","Androgen Receptor Splice Variant 3 | AR-v7 | AR3 | Androgen Receptor Splice Variant 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0971226","Epstein-Barr Nuclear Antigen 1","C128296","Epstein-Barr nuclear antigen 1 (641 aa, ~56 kDa) is encoded by the Epstein-Barr virus EBNA1 gene. This protein is involved in the replication of viral DNA during the latent phase.","Epstein-Barr Nuclear Antigen 1 | EBNA-1 | EBNA1 | EBV Nuclear Antigen 1 | EPSTEIN-BARR VIRUS NUCLEAR ANTIGEN 1 | Epstein Barr Nuclear Antigen 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512081","Tumor Protein 63 Isoform 2, Human","C128298","Tumor protein 63 isoform 2 (586 aa, ~66 kDa) is encoded by the human TP63 gene. This protein plays a role in the mediation of both transcription and skin development.","Tumor Protein 63 Isoform 2 | Delta Np63 Alpha | Delta-N p63-Alpha | DeltaN-Alpha | DeltaNp63 Alpha | P51delNalpha | p51",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509677","UBE2E Family","C128299","A family of E2 ubiquitin-conjugating enzymes (UBE2) that transfer ubiquitin from E1 ubiquitin-activating enzyme to the active site cysteine of the E2 enzyme. Then the ubiquitin is transferred from the E2 enzyme to the target protein by E3 ubiquitin ligases. The N-terminal extension found in UBE2E proteins may confer a strong preference for the monoubiquitination of substrates rather than polyubiquitination.","UBE2E Family | Ubiquitin-Conjugating Enzyme E2 E Family | Ubiquitin-Conjugating Enzyme E2E Family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509026","Chromosome 1 Satellite 2","C128300","A satellite DNA located in the large heterochromatin regions of chromosome 1.","Chromosome 1 Satellite 2 | C1S2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508681","ELN Allele with Mm Haplotype for INT20/INT23","C128301","Human ELN allele containing a pair of single nucleotide polymorphisms with a major allele of intron-20 (INT20), where nucleotide position +17 is a thymine, and the minor allele for intron-23 (INT23), where nucleotide position +24 is a cytosine. This haplotype may be associated with increased susceptibility for intracranial aneurysms.","ELN Allele with Mm Haplotype for INT20/INT23 | ELN with Major Allele for Intron-20 and Minor Allele for Intron-23 | Mm INT20/INT23 Haplotype",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509454","Human Herpesvirus-8 Immediate-Early Region-4 Gene Locus","C128302","A leftward transcribed region of the human herpesvirus-8 genome containing the immediate early genes ORF48 and ORF29b.","Human Herpesvirus-8 Immediate-Early Region-4 Gene Locus | HHV-8 Immediate-Early Region-4 Gene Locus | KIE-4 | KIE-4 Transcription Region | KSHV Immediate-Early Region-4 Gene Locus | Kaposi Sarcoma-Associated Herpesvirus Immediate-Early Region-4 Gene Locus | Kaposi's Sarcoma-Associated Herpesvirus Immediate-Early Region-4 Gene Locus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1012096","HERV-K","C128305","A biologically active family of human endogenous retroviral elements that are found in human and primate genomes and resemble or are derived from retroviral genomic material. Aberrant expression of these elements may be associated with testicular germ cell tumors, breast cancer, type 1 diabetes mellitus, motor neuron disease.","HERV-K | Endogenous Retroviral Sequence K | Endogenous Retrovirus Group K | HERV-K Provirus | HERVK | Human Endogenous Retroviral Sequence K | Human Endogenous Retrovirus Group K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1097566","HLA Class I Histocompatibility Antigen, A-0201 Alpha Chain","C128306","HLA class I histocompatibility antigen, A-0201 alpha chain (365 aa, ~41 kDa) is encoded by the human HLA-A gene. This protein plays a role in the presentation of foreign antigens to the immune system.","HLA Class I Histocompatibility Antigen, A-0201 Alpha Chain | HLA-A Class I Antigen 0201 | HLA-A Histocompatibility Type Antigen 0201 | HLA-A*0201 | HLA-A*02:01 | MHC Class I Antigen A*0201 | Major Histocompatibility Complex, Class I, A0201 Antigen",,,,,,,,,,,,,,,"4104407","A*0201",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3178875","HLA Class I Histocompatibility Antigen, A-11 Alpha Chain","C128307","HLA class I histocompatibility antigen, A-11 alpha chain (365 aa, ~41 kDa) is encoded by the human HLA-A gene. This protein is involved in the presentation of foreign antigens to the immune system. Expression of this serotype may be associated with increased susceptibility to papillomavirus infection.","HLA Class I Histocompatibility Antigen, A-11 Alpha Chain | HLA-A Class I Antigen 11 | HLA-A Histocompatibility Type Antigen 11 | HLA-A*11 | HLA-A11 | MHC Class I Antigen A*11 | Major Histocompatibility Complex, Class I, A11 Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3178888","HLA Class I Histocompatibility Antigen, B-44 Alpha Chain","C128309","HLA class I histocompatibility antigen, B-44 alpha chain (362 aa, ~40 kDa) is encoded by the human HLA-B gene. This protein plays a role in the presentation of foreign antigens to the immune system. Expression of this serotype may be associated with recurrent sinopulmonary infections and ankylosing spondylitis.","HLA Class I Histocompatibility Antigen, B-44 Alpha Chain | Bw-44 | HLA-B44 | HLA-B44 Antigen | MHC Class I Antigen B*44",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0062863","HLA-DP4 Antigen","C128310","HLA-DP4 antigen is a protein complex of the major histocompatibility complex, class II DP protein in which the alpha subunit is encoded by the HLA-DPA1*0103 allele and the beta subunit serotype is encoded by either the *0401 allele or the *0402 allele of the HLA-DPB1 gene. This antigen represents the most common haplotype.","HLA-DP4 Antigen | HLA-DP4",,,,,,,,,,,,,,,"4240838","HLA-DPw4 antigen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0385112","HLA-DR13 Antigen","C128311","HLA-DR13 antigen is a protein complex of the major histocompatibility complex, class II DR protein in which the alpha subunit encoded by the HLA-DRA*01 allele and the beta subunit serotype is encoded by certain alleles in the HLA-DRB1*13 group.","HLA-DR13 Antigen | DR13 | HLA-DR13",,,,,,,,,,,,,,,"4287696","HLA-DRw13 antigen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509617","HPV Major Capsid Protein L1","C128312","HPV major capsid protein L1 is encoded by the human papillomavirus L1 gene. This protein plays a role in viral capsid formation.","HPV Major Capsid Protein L1 | HPV L1 | Human Papillomavirus Major Capsid Protein L1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022185","Isohemagglutinin","C128313","The antibodies produced by an individual that target the antigens (A or B or both) found on the red blood cells (RBC) of individuals with incompatible blood groups.","Isohemagglutinin | Isoagglutinin | Isoagglutinins | Isohemagglutinins",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0529131","Progesterone Receptor Isoform A","C128315","Progesterone receptor isoform A (769 aa, ~82 kDa) is encoded by the human PGR gene. This protein plays a role in the regulation of gene transcription.","Progesterone Receptor Isoform A | PRA | Progesterone Receptor A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1651474","Megakaryocyte-Potentiating Factor, Human","C128317","Megakaryocyte-potentiating factor (250 aa, ~27 kDa) is encoded by the human MSLN gene. This protein plays a role in megakaryocyte colony formation.","Megakaryocyte-Potentiating Factor | MPF | Megakaryocyte Potentiating Factor | OV569 Antigen | SMR | SMRP | Soluble MPF Mesothelin Related Protein | Soluble MPF/Mesothelin Related Protein | Soluble MPF/Mesothelin-Related Protein | Soluble Mesothelin Related Protein | Soluble Mesothelin/MPF-Related Protein | Soluble Mpf/Mesothelin-Related Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509001","Viral Protease p15","C128318","An aspartyl protease that is a portion of the polyprotein encoded by the gag gene found in the retrovirus myeloblastosis-associated virus (MAV; avian myeloblastosis virus).","Viral Protease p15 | 15gag Proteinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0767524","delta catenins","C128319","A catenin protein with 10 armadillo repeats involved in the regulation of cell adhesion and tissue morphogenesis. Catenin delta-1 (CTNND1) is expressed in vascular endothelium, keratinocytes and melanocytes, and catenin delta-2 (CTNND2) is expressed in brain.","Delta Catenin | Catenin Delta | Delta-Catenin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509579","t(11;14)","C128641","A cytogenetic abnormality that involves a translocation between chromosomes 11 and 14.","t(11;14) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509580","t(11;22)","C128642","A cytogenetic abnormality that involves a translocation between chromosomes 11 and 22.","t(11;22) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509582","t(14;18)","C128643","A cytogenetic abnormality that involves a translocation between chromosomes 14 and 18.","t(14;18) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509587","t(21;22)","C128644","A cytogenetic abnormality that involves a translocation between chromosomes 21 and 22.","t(21;22) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509584","t(16;16)","C128645","A cytogenetic abnormality that involves a translocation occurring within chromosome 16.","t(16;16) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509589","t(3;3)","C128647","A cytogenetic abnormality that involves a translocation occurring within chromosome 3.","t(3;3) | T(3;3)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508732","EWSR1 Gene Translocation","C128648","A cytogenetic abnormality that refers to a translocation involving the EWSR1 gene.","EWSR1 Gene Translocation | EWS Gene Translocation | EWS Translocation | EWSR1 Translocation | Ewing Sarcoma Breakpoint Region 1 Gene Translocation | Ewing's Sarcoma Gene Translocation Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509593","t(8;14)","C128649","A cytogenetic abnormality that involves a translocation between chromosomes 8 and 14.","t(8;14) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509592","t(6;9)","C128650","A cytogenetic abnormality that involves a translocation between chromosomes 6 and 9.","t(6;9) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509591","t(6;11)","C128651","A cytogenetic abnormality that involves a translocation between chromosomes 6 and 11.","t(6;11) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509590","t(4;11)","C128652","A cytogenetic abnormality that involves a translocation between chromosomes 4 and 11.","t(4;11) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509588","t(2;13)","C128653","A cytogenetic abnormality that involves a translocation between chromosomes 2 and 13.","t(2;13) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509586","t(1;19)","C128654","A cytogenetic abnormality that involves a translocation between chromosomes 1 and 19.","t(1;19) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509585","t(1;13)","C128655","A cytogenetic abnormality that involves a translocation between chromosomes 1 and 13.","t(1;13) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509583","t(15;17)","C128656","A cytogenetic abnormality that involves a translocation between chromosomes 15 and 17.","t(15;17) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509581","t(12;21)","C128657","A cytogenetic abnormality that involves a translocation between chromosomes 12 and 21.","t(12;21) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL428549","t(4;14)(p16;q32)","C128658","A cytogenetic abnormality that refers to the translocation of the short arm (p16) of chromosome 4 and the long arm (q32) of chromosome 14.","t(4;14)(p16;q32) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830128","59 (qualifier value)","C105794","A natural number greater than fifty-eight and less than sixty and the quantity that it denotes.","Fifty Nine | 59 | Fifty-Nine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828184","Seventy Nine","C105791","A natural number greater than seventy-eight and less than eighty and the quantity that it denotes.","Seventy Nine | 79 | Seventy-Nine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509038","CHFR Promoter Methylation","C128659","An epigenetic modification involving methylation of CpG islands in the promoter region of the CHFR gene.","CHFR Promoter Methylation | Checkpoint with Forkhead and Ring Finger Domains Gene Promoter Methylation | RNF196 Promoter Methylation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508859","KIT Exon 8 Mutation","C128660","A molecular genetic abnormality indicating the presence of a mutation in exon 8 of the KIT gene located within 4q11-q12.","KIT Exon 8 Mutation | CD117 Exon 8 Mutation | CKIT Mutation - Ex8 | KIT Proto-Oncogene Tyrosine Protein Kinase Gene Exon 8 Mutation | c-KIT Exon 8 Mutation | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Gene Exon 8 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508677","EGFR Exon 18 Mutation","C128661","A molecular genetic abnormality indicating the presence of a mutation in exon 18 of the EGFR gene.","EGFR Exon 18 Mutation | ERBB Exon 18 Mutation | ERBB1 Exon 18 Mutation | Epidermal Growth Factor Receptor Gene Exon 18 Mutation | HER1 Exon 18 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508678","EGFR Exon 19 Mutation","C128662","A molecular genetic abnormality indicating the presence of a mutation in exon 19 of the EGFR gene.","EGFR Exon 19 Mutation | EGFR DEL19 | EGFR DEL19 Mutation | EGFR Exon 19 Gene Mutation | ERBB Exon 19 Mutation | ERBB1 Exon 19 Mutation | Epidermal Growth Factor Receptor Gene Exon 19 Mutation | HER1 Exon 19 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508679","EGFR Exon 20 Mutation","C128663","A molecular genetic abnormality indicating the presence of a mutation in exon 20 of the EGFR gene.","EGFR Exon 20 Mutation | ERBB Exon 20 Mutation | ERBB1 Exon 20 Mutation | Epidermal Growth Factor Receptor Gene Exon 20 Mutation | HER1 Exon 20 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508680","EGFR Exon 21 Mutation","C128666","A molecular genetic abnormality indicating the presence of a mutation in exon 21 of the EGFR gene.","EGFR Exon 21 Mutation | EGFR Exon 21 Gene Mutation | ERBB Exon 21 Mutation | ERBB1 Exon 21 Mutation | Epidermal Growth Factor Receptor Gene Exon 21 Mutation | HER1 Exon 21 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413167","CCK Gene","C128851","This gene is involved in digestion.","CCK Gene | CCK | Cholecystokinin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417496","MUC4 Gene","C128854","This gene is involved in both cell adhesion and receptor signaling.","MUC4 Gene | MUC4 | Mucin 4, Cell Surface Associated Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412999","C4A Gene","C128857","This gene plays a role in the progression of the classical complement pathway.","C4A Gene | C4A | Complement Component 4A (Rodgers Blood Group) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413778","CSTA Gene","C128867","This gene plays a role in both thiol proteinase inhibition and epidermal structure.","CSTA Gene | CSTA | Cystatin A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332798","CSTB Gene","C128870","This gene is involved in the inhibition of cathepsins.","CSTB Gene | CSTB | Cystatin B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413943","DDC Gene","C128874","This gene plays a role in the synthesis of monoamine neurotransmitters.","DDC Gene | DDC | Dopa Decarboxylase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414429","EPHA5 Gene","C128877","This gene is involved in brain development.","EPHA5 Gene | EPH Receptor A5 Gene | EPHA5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416475","IRF7 Gene","C128881","This gene plays a role in the modulation of the innate immune response against DNA and RNA viruses.","IRF7 Gene | IRF7 | Interferon Regulatory Factor 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0431750","Urethral Meatus Stenosis","C35452","A narrowing of the opening of the urethra at the external meatus.","Urethral Meatus Stenosis | Meatal Stenosis",,,,,,,,,,,,,,,"4056050|4143768","Stenosis of urinary meatus|Pinhole meatus",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL512973","Hidebound","C129926","Skin that is abnormally dry and stiff, lacking pliancy and closely adhered to the underlying flesh.","Hidebound | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415321","GSK3B Gene","C128884","This gene plays a role in the inhibition of glycogen synthesis.","GSK3B Gene | GSK3B | Glycogen Synthase Kinase 3 Beta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0049308","5-Methylcytosine","C129008","A methylated form of the nucleobase cytosine occurring predominantly in cytosine-phosphate-guanine (CpG) islands that are produced by DNA methyltransferases and may regulate gene expression. Like cytosine, the DNA sequence containing 5-methylcytosine (5-mC) is able to be replicated without error and 5-mC can pair with guanine in double stranded DNA. However, DNA sequences containing a high local concentration of 5-mC may be less transcriptionally active than areas with higher ratios of unmodified cytosine.","5-Methylcytosine | 5-METHYLCYTOSINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0068527","Neopterin","C129010","A pteridine that is a metabolite of guanine triphosphate (GTP) and a precursor for biopterin. Neopterin is released from interferon-gamma (IFNg) stimulated macrophages and dendritic cells (DCs); therefore, urine or serum levels may be used as a marker of immune system activation.","Neopterin | 2-Amino-6-(1,2,3-Trihydroxypropyl)-4(3H)-Pteridinone | 4(1H)-Pteridinone, 2-Amino-6-(1,2,3-Trihydroxypropyl)- | NEOPTERIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034170","Putrescine","C129011","A four carbon diamine produced during tissue decomposition by the decarboxylation of amino acids. Polyamines, including putrescine, may act as growth factors that promote cell division; however, putrescine is toxic at high doses.","Putrescine | 1,4-Butanediamine | 1,4-Butylenediamine | 1,4-Diaminobutane | 1,4-Tetramethylenediamine | Butane-1,4-Diamine | PUTRESCINE | Tetramethylenediamine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037871","Spermidine","C129012","A polyamine derived from putrescine that is involved in many biological processes, including the regulation of membrane potential, the inhibition of nitric oxide synthase (NOS) and the induction of autophagy.","Spermidine | 1,4-Butanediamine, N-(3-Aminopropyl)- | 1,4-Butanediamine, N1-(3-Aminopropyl)- | 1,4-Diaminobutane, N-(3-Aminopropyl)- | 1,5,10-Triazadecane | 4-Azaoctamethylenediamine | 4-Azaoctane-1,8-Diamine | N-(3-Aminopropyl)-1,4-Butane-Diamine | SPERMIDINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512379","Tocopherylhydroquinone","C129014","A reduced form of the vitamin E metabolite tocopherylquinone with potential antioxidant activity. Although the mechanism of action has not been fully elucidated, tocopherylhydroquinone may donate a hydrogen atom to reactive oxygen species, which could transform oxygen radicals into non-toxic compounds and block their genotoxic and carcinogenic effects.","Tocopherylhydroquinone | .ALPHA.-TOCOPHERYLHYDROQUINONE | Alpha-TQH2 | Alpha-Tocopheryl Hydroquinone | Alpha-Tocopheryl-Hydroquinone | Alpha-Tocopherylhydroquinone | AlphaTQH2 | TQH2 | Tocopheryl Hydroquinone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416643","KIR2DL1 Gene","C129016","This gene is involved in the regulation of natural killer cell activity.","KIR2DL1 Gene | KIR2DL1 | Killer Cell Immunoglobulin Like Receptor, Two Ig Domains and Long Cytoplasmic Tail 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416644","KIR2DL2 Gene","C129036","This gene plays a role in the negative regulation of natural killer cell activity.","KIR2DL2 Gene | KIR2DL2 | Killer Cell Immunoglobulin Like Receptor, Two Ig Domains and Long Cytoplasmic Tail 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416645","KIR2DL3 Gene","C129039","This gene is involved in the inhibition of natural killer cell-mediated cell lysis.","KIR2DL3 Gene | KIR2DL3 | Killer Cell Immunoglobulin Like Receptor, Two Ig Domains and Long Cytoplasmic Tail 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416797","STMN1 Gene","C129042","This gene plays a role in the promotion of microtubule disassembly.","STMN1 Gene | STMN1 | Stathmin 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412552","ARRB2 Gene","C129045","This gene is involved in receptor desensitization.","ARRB2 Gene | ARRB2 | Arrestin Beta 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1439329","CBS Gene","C129049","This gene plays a role in transsulfuration.","CBS Gene | CBS | Cystathionine-Beta-Synthase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412326","AKR1C3 Gene","C129052","This gene is involved in the conversion of aldehydes and ketones to alcohols.","AKR1C3 Gene | AKR1C3 | Aldo-Keto Reductase Family 1 Member C3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414181","DUSP10 Gene","C129055","This gene plays a role in the negative regulation of MAP kinase activity.","DUSP10 Gene | DUSP10 | Dual Specificity Phosphatase 10 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416941","NCR1 Gene","C129058","This gene is involved in the activation of natural killer cell-mediated cytotoxicity.","NCR1 Gene | NCR1 | Natural Cytotoxicity Triggering Receptor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413190","CCR4 Gene","C129065","This gene is involved in chemokine-dependent G protein-coupled receptor signaling.","CCR4 Gene | C-C Motif Chemokine Receptor 4 Gene | CCR4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419385","RHO Gene","C129078","This gene plays a role in vision.","RHO Gene | RHO | Rhodopsin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419819","SART1 Gene","C129081","This gene is involved in spliceosome activity.","SART1 Gene | SART1 | Squamous Cell Carcinoma Antigen Recognized By T-Cells 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426121","CERK Gene","C129084","This gene plays a role in ceramide metabolism.","CERK Gene | CERK | Ceramide Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880239","DNA Methylation Analysis","C63328","The analysis of the methylated deoxyribonucleotides present in the genome in a biological sample.","DNA Methylation Analysis | DNA Methylation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512796","T-Cell Receptor Profile","C129657","A data set that both identifies and quantifies the alpha/beta or gamma/delta T-cell receptors in a biological sample or specimen.","T-Cell Receptor Profile | T Cell Receptor Clone Assessment | T Cell Receptor Profile | T Cell Receptor Repertoire | T-Cell Receptor Repertoire | TCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0752248","Gene Expression Profiling","C63479","Procedures that examine how genes are transcribed to produce functional products. These analyses can include the study of factors that influence gene transcription or the determination of the presence, absence or level of expression for one more genes.","Gene Expression Analysis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517938","Long Interspersed Elements","C13803","A highly repetitive retrotransposon-like sequence that is 6000-8000 base pairs in length. It may contain an RNA polymerase II promoter domain, repetitive target sequences, and open reading frames encoding proteins with endonuclease and reverse transcriptase activity.","Long Interspersed Element | LINE | LINES | Long Interspersed Nucleotide Elements",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017037","Gamma-Glutamylcysteine Synthetase","C16602","Glutamate-cysteine ligase, also known as gamma-glutamylcysteine synthetase is the first rate limiting enzyme of glutathione synthesis. The enzyme consists of two subunits, a heavy catalytic subunit and a light regulatory subunit. The gene encoding the catalytic subunit encodes a protein of 367 amino acids with a calculated molecular weight of 72.773 kDa and maps to chromosome 6. The regulatory subunit is derived from a different gene located on chromosome 1p22-p21. Deficiency of gamma-glutamylcysteine synthetase in human is associated with enzymopathic hemolytic anemia. (LocusLink)","Gamma-Glutamylcysteine Synthetase | EC 6.3.2.2 | Gamma-Glutamylcysteinyl Synthetase | Glutamate-Cysteine Ligase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038838","Superoxide Dismutase","C17172","Proteins that protect cells against elevated levels of superoxide a reactive oxygen species. These antioxidant enzymes catalyze the formation of molecular oxygen and hydrogen peroxide from the superoxide anion. They are also potential therapeutic agents in diseases related to oxidative stress and in the regulation of the aging process.","Superoxide Dismutase | E.C. 1.15.1.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085296","JUN protein, human","C17437","Transcription factor AP-1 (331 aa, ~36 kDa) is encoded by the human JUN gene. This protein plays a role in transcriptional activation.","Transcription Factor AP-1 | AP1 | Activator Protein 1 | JUN | JUN Protein | JUN Protein Transcription Factor | Proto-Oncogene c-Jun | c-JUN Protein | p39 | v-jun Avian Sarcoma Virus 17 Oncogene Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0288011","NF-AT","C17903","NFAT is a multi-subunit transcription complex that includes homo- or hetero-dimers of FOS and JUN proteins.  NFATC, the Dorsal/Rel family cytosolic component of NFAT, is translocated to the nucleus following TCR-induced PKC stimulation and calmodulin-dependent calcineurin-mediated dephosphorylation.  Phosphoprotein NFATP, the 'preexisting component' of NFAT present in the unstimulated T-cell cytosol, locates in the nucleus as part of NFAT after activation.","NF-AT | NFAT-1 | Nuclear Factor of Activated T-cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677907","MAGEA3 Gene","C17951","This gene may be involved in embryonal development. It may also play a role in carcinogenesis.","MAGEA3 Gene | MAGEA3 | Melanoma Antigen, Family A, 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1291910","Human Anti-Mouse Antibody","C18062","Human antibodies which recognize mouse antibodies.  These often develop in response to treatment with antibodies and limit the effectiveness of the treatment.","Human Anti-Mouse Antibody | HAMA",,,,,,,,,,,,,,,"4019750","Human anti-mouse antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1367342","TERT Gene","C18173","This gene is involved in cell cycle regulation and telomere maintenance.","TERT Gene | TERT | Telomerase Reverse Transcriptase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0694873","CDK4 Gene","C18250","This gene is involved in G1 stage cell cycle progression.","CDK4 Gene | CDK4 | Cyclin-Dependent Kinase 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0694894","TSC1 Gene","C18259","This gene is involved in cell cycle regulation and the loss of cellular adhesion.","TSC1 Gene | TSC1 | Tuberous Sclerosis 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0694895","TSC2 Gene","C18260","This gene plays a role in signal transduction and cell cycle control. It is involved in cell adhesion, differentiation, growth and migration.","TSC2 Gene | TSC2 | Tuberous Sclerosis 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0809183","CDKN2B Gene","C18323","This gene is involved in cell cycle regulation and arrest.","CDKN2B Gene | CDKN2B | Cyclin-Dependent Kinase Inhibitor 2B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812198","BAX Gene","C18324","This gene is involved in the regulation of apoptosis by binding p53 protein, which accelerates this mechanism of cell death.","BAX Gene | BAX | BCL2 Associated X, Apoptosis Regulator Gene | BCL2-Associated X Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812229","WNT5A Gene","C18351","This gene plays a role in signal transduction and intercellular communication. It is involved in the regulation of cell signaling during organogenesis.","WNT5A Gene | WNT5A | Wnt Family Member 5A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812236","RHOC Gene","C18358","This gene plays a role in signal transduction. It is involved in several cellular functions including cytoskeletal remodeling and cell differentiation.","RHOC Gene | RAS Homolog Gene Family Member C Gene | RHOC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812244","TP73 Gene","C18366","This gene is involved in the apoptotic pathway and can have anti or pro apoptotic effects.","TP73 Gene | TP73 | Tumor Protein p73 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812305","EPCAM Gene","C18421","This gene is involved in calcium-independent cellular adhesion and in the regulation of immune responses.","EPCAM Gene | EPCAM | Epithelial Cell Adhesion Molecule Gene | TACSTD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812307","LYN Gene","C18423","This gene plays a role in signal transduction.","LYN Gene | LYN | LYN Proto-Oncogene, Src Family Tyrosine Kinase Gene | v-YES-1 Yamaguchi Sarcoma Viral Related Oncogene Homolog Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812317","HCK Gene","C18433","This gene plays a role in the regulation of myeloid cell signaling.","HCK Gene | HCK | Hemopoietic Cell Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812385","BCR Gene","C18455","This gene plays a role in signal transduction.","BCR Gene | BCR | BCR, RhoGEF and GTPase Activating Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812446","ELK1 Gene","C18461","This gene plays a role in transcriptional regulation and mediates DNA-binding interactions. The gene is also involved in MAP kinase signal transduction.","ELK1 Gene | ELK1 | ELK1, Member of ETS Oncogene Family Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919430","VDR Gene","C18503","This gene plays a role in transcriptional regulation and in vitamin D3 metabolism.","VDR Gene | VDR | Vitamin D Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879468","CSF1R Gene","C18516","This gene is essential for the regulation of the production, differentiation, and function of macrophages.","CSF1R Gene | CSF1R | Colony Stimulating Factor 1 Receptor, Formerly McDonough Feline Sarcoma Viral (v-fms) Oncogene Homolog Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0531832","ETV6/RUNX1 Fusion Protein","C18040","A fusion protein encoded by the ETV6/RUNX1 fusion gene. This protein is comprised of the N-terminal DNA binding helix-loop-helix domain of the transcription factor ETV6 protein fused to nearly the entire runt-related transcription factor 1 protein.","ETV6/RUNX1 Fusion Protein | ETV6-RUNX1 Fusion Protein | ETV6::RUNX1 Fusion Protein | TEL-AML1 | TEL-AML1 Fusion Protein | TEL/AML1 Fusion Protein | Transcription Factor ETV6/Runt-Related Transcription Factor 1 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456181","Right Ventricular Systolic Pressure","C129953","The maximum pressure exerted into the systemic arterial circulation during the contraction of the right ventricle of the heart.","Right Ventricular Systolic Pressure | RVSP",,,,,,,,,,,,,,,"4081030","Right ventricular systolic pressure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512877","Lung Tissue Drug Concentration","C129954","The level of drug in lung tissue, expressed as a concentration.","Lung Tissue Drug Concentration | Lung Tissue Drug Volume | Lung Tissue Volume",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513053","Dynamic Compliance","C129956","Pulmonary compliance measured during the movement of air, such as during active inspiration.","Dynamic Compliance | Cdyn | Pulmonary Dynamic Compliance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513052","Static Compliance","C129957","Pulmonary compliance measured without air flow, such as during an inspiratory pause.","Static Compliance | Cstat | Pulmonary Static Compliance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0428642","Pulmonary Artery Pressure","C129958","Blood pressure in the pulmonary artery.","Pulmonary Artery Pressure | PAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456170","Left Atrial Pressure","C129959","Blood pressure within the left atrium. It is commonly measured indirectly by a pulmonary capillary wedge pressure.","Left Atrial Pressure | LAP | PLA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513006","Mixed Venous Oxygen Tension","C129960","The partial pressure of oxygen in venous blood, representing the balance between oxygen consumption and oxygen delivery.","Mixed Venous Oxygen Tension | PvO2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513037","Precipitate","C129961","The solid that can be caused to settle out of a solution.","Precipitate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1720881","Solid Phase Microextraction","C129962","A sampling technique that uses a polymer-coated fiber to absorb to directly extract and concentrate an analyte from a fluid.","Solid Phase Microextraction | SPME | Solid Phase Micro Extraction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919478","FGR Gene","C18542","This gene plays a role in the regulation of cell migration and adhesion.","FGR Gene | FGR | Gardner-Rasheed Feline Sarcoma Viral (V-FGR) Oncogene Homolog Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919479","YES1 Gene","C18543","This gene plays a role in the formation of intercellular junctions.","YES1 Gene | YES Proto-Oncogene 1, Src Family Tyrosine Kinase Gene | YES1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919490","SPI1 Gene","C18553","This gene plays a role in transcriptional activation, cellular development and hematopoiesis.","SPI1 Gene | SPI1 | Spi-1 Proto-Oncogene Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919506","FGF2 Gene","C18569","This gene is involved in angiogenesis, development and cell cycle control.","FGF2 Gene | FGF2 | Fibroblast Growth Factor 2 (Basic) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335611","CCDC6/RET Fusion Protein","C19945","A fusion protein encoded by the CCDC6/RET fusion gene. This protein is comprised of the N-terminal leucine zipper of the coiled-coil domain-containing protein 6 fused to almost the entire C-terminal cytoplasmic domain of the proto-oncogene tyrosine-protein kinase receptor Ret protein, including the tyrosine kinase domain.","CCDC6/RET Fusion Protein | CCDC6-RET Fusion Protein | CCDC6::RET Fusion Protein | Coiled-Coil Domain-Containing Protein 6/::Proto-OncoProtein Tyrosine-Protein Kinase Receptor Ret Fusion Protein | Coiled-Coil Domain-Containing Protein 6/Proto-OncoProtein Tyrosine-Protein Kinase Receptor Ret Fusion Protein | Coiled-Coil Domain-Containing Protein 6::Proto-OncoProtein Tyrosine-Protein Kinase Receptor Ret Fusion Protein | D10S170/RET Fusion Protein | H4-RET Fusion Protein | H4/RET Fusion Protein | PTC-1 Fusion Protein | PTC1 Fusion Protein | RET/H4 Chimeric Oncoprotein | RET/H4 Oncoprotein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1865982","CCDC6/RET Fusion Gene","C18573","A fusion gene that results from a chromosomal inversion inv(10)(q11q21) which fuses the 5' part of the CCDC6 gene with the 3' part of the RET gene. This gene fusion is associated with papillary thyroid carcinoma.","CCDC6/RET Fusion Gene | CCDC6-RET Fusion Gene | CCDC6::RET Fusion Gene | D10S170/RET Fusion Gene | H4-RET Fusion Gene | H4/RET Fusion Gene | PTC-1 | PTC1 Chimeric Oncogene | PTC1 Fusion Gene | RET/D10S170 Oncogene | RET/H4 Oncogene | RET/PTC1 Oncogene | TST1 Oncogene | Transforming Sequence, Thyroid 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919538","TGFBR2 Gene","C18592","This gene plays a role in cellular proliferation and mitogenic responses.","TGFBR2 Gene | TGFBR2 | Transforming Growth Factor, Beta Receptor II (70/80kDa) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512988","Red/Gray Tiger Top Serum Separator Tube","C129963","A blood collection tube with a coagulant and a gel, used for serum determinations in chemistry.","Red/Gray Tiger Top Serum Separator Tube | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513030","Green/Gray Tiger Top Plasma Separation Tube","C129964","A blood collection tube with lithium heparin and a gel, used for plasma determinations in chemistry.","Green/Gray Tiger Top Plasma Separation Tube | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512943","Red/Light Gray Tiger Top Secondary Collection Tube","C129965","A blood collection tube with no additives, used as a discard tube or secondary specimen tube.","Red/Light Gray Tiger Top Secondary Collection Tube | Red/Light Gray Tiger Top Secondary Tube | Red/Light Gray Tiger Top Tube | Tiger Top Secondary Tube",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513000","Tiger Top Discard Tube","C129966","A blood collection tube designed to be filled and then thrown away.","Tiger Top Discard Tube | Discard Tube | Tiger Top Discard Tube ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439674","Intrinsic","C129970","Relating to the essential qualities or features of something.","Intrinsic | ",,,,,,,,,,,,,,,"4114527","Intrinsic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0175671","Universal","C129971","Present or occurring everywhere or in all things; applicable to all within a particular group.","Universal | ",,,,,,,,,,,,,,,"4251194","Universal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519724","Tyrosine Kinase Domain","C14075","A protein domain that binds a protein and catalyzes the covalent addition of a phosphate group specifically to a tyrosine residue.","Tyrosine Kinase Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513031","HLA Match","C129972","The state when a recipient and their donor have the same alleles for tissue markers. A full match includes HLA-A, HLA-B, HLA-C, and HLA-DRB1. HLA match typing may also include alleles in the HLA-DQ serogroup.","HLA Match | HLA Allele Match | HLA Locus Match | HLA Serotype Match | Match",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0087140","FOS Gene","C19532","This gene plays a role in several cellular processes such as: proliferation, differentiation, and transformation.","FOS Gene | FOS | Fos Proto-Oncogene, AP-1 Transcription Factor Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1337006","WNT Family Protein","C20394","Encoded by WNT Family Genes, secreted structurally related signaling WNT Family Proteins are implicated in oncogenesis and in several developmental processes, including regulation of cell fate and embryonic patterning. (NCI)","WNT Family Protein | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0935995","WNT Family Gene","C20100","WNT Family Genes encode secreted structurally related signaling WNT Family Proteins, implicated in oncogenesis and in several developmental processes, including regulation of cell fate and embryonic patterning. (NCI)","WNT Family Gene | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332109","AREG Gene","C20155","This gene plays a role in the regulation of epithelial cell growth.","AREG Gene | AREG | Amphiregulin (Schwannoma-Derived Growth Factor) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1337031","XRCC2 Gene","C20334","This gene is involved in the repair of DNA double-strand breaks by homologous recombination.","XRCC2 Gene | X-Ray Repair Cross Complementing 2 Gene | XRCC2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335262","PRKDC Gene","C20337","This gene plays a role in cellular homeostasis by transcription modulation. The gene is also involved in V(D)J recombination.","PRKDC Gene | PRKDC | Protein Kinase, DNA-Activated, Catalytic Polypeptide Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1337109","XIAP Gene","C20357","This gene is involved in apoptotic regulation through caspase interaction.","XIAP Gene | X-Linked Inhibitor of Apoptosis Gene | XIAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332397","BCL2L1 Gene","C20410","This gene is an apoptotic regulator that can have anti or pro apoptotic effects.","BCL2L1 Gene | BCL2-Like 1 Gene | BCL2L1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1337096","BCL2L11 Gene","C20416","This gene is involved in the regulation of apoptosis and promotes cell death.","BCL2L11 Gene | BCL2-like 11 (Apoptosis Facilitator) Gene | BCL2L11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016026","Fibroblast Growth Factor","C20426","A family of structurally-related growth factors with high affinity for heparin. These proteins modulate cell proliferation, angiogenesis, wound healing, embryogenesis and paracrine signaling pathways. Fibroblast growth factors (FGF) stimulate signal transduction through binding to specific members of the fibroblast growth factor receptors (FGFR) family tyrosine kinases.","Fibroblast Growth Factor | DNA Synthesis Factor | ECGF | Endothelial Cell Growth Factor | FGF | FGF Family | Fibroblast Growth Factor Family | Fibroblast Growth Regulatory Factor",,,,,,,,,,,,,,,"4229602","Fibroblast growth factor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1823878","XRCC6 Gene","C20568","This gene is involved in DNA repair and DNA metabolic processes.","XRCC6 Gene | G22P1 | X-Ray Repair Cross Complementing 6 Gene | XRCC6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333908","HMGB1 Gene","C20578","This gene plays a role in chromatin remodeling, signal transduction and the regulation of gene transcription. It is also involved in the pro-inflammatory response.","HMGB1 Gene | HMGB1 | High-Mobility Group Box 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333935","HYOU1 Gene","C20790","This gene plays in the regulation of cellular response to ischemic stress conditions.","HYOU1 Gene | HYOU1 | Hypoxia Up-Regulated 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336690","TXN Gene","C20816","This gene plays a role in intercellular signaling, signal transduction and protection against cellular oxidative stress.","TXN Gene | TXN | Thioredoxin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366565","SLPI Gene","C20902","This gene is involved in the immune response.","SLPI Gene | SLPI | Secretory Leukocyte Protease Inhibitor (Antileukoproteinase) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332694","CCNA2 Gene","C20957","This gene is involved in G1/S and G2/M transitions in the cell cycle.","CCNA2 Gene | CCNA2 | Cyclin A2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332712","CD44 Gene","C20999","This gene plays a role in cellular matrix adhesion and in lymphocyte activation.","CD44 Gene | CD44 | CD44 Molecule (Indian Blood Group) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334863","NCAM1 Gene","C21004","This gene plays a role in cellular adhesion mechanisms that involve cell-cell and cell-matrix interactions.","NCAM1 Gene | NCAM1 | Neural Cell Adhesion Molecule 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334074","ICAM1 Gene","C21006","This gene is involved in mediating integrin-binding interactions that result in cellular adhesion.","ICAM1 Gene | ICAM1 | Intercellular Adhesion Molecule 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334144","ITGAL Gene","C21033","This gene plays a role in leukocyte intercellular adhesion.","ITGAL Gene | ITGAL | Integrin Subunit Alpha L Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539081","CD40 Gene","C21121","This gene is involved in the regulation of apoptosis, inflammatory responses, and immune responses.","CD40 Gene | CD40 | CD40 Molecule, TNF Receptor Superfamily Member 5 Gene | TNFRSF5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539478","FASLG Gene","C21148","This gene is an important regulator of apoptosis.","FASLG Gene | FASLG | Fas Ligand (TNF Superfamily, Member 6) Gene | Fas Ligand Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366562","ITGAM Gene","C21162","This gene plays a role in extracellular matrix interactions and cellular adhesion.","ITGAM Gene | ITGAM | Integrin, Alpha M (Complement Component 3 Receptor 3 Subunit) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334146","ITGB2 Gene","C21263","This gene is involved in the mediation of cellular adhesion and cell-surface signal transduction.","ITGB2 Gene | ITGB2 | Integrin Subunit Beta 2 Gene | Integrin, Beta 2 (Antigen CD18 (p95), Lymphocyte Function-Associated Antigen 1; Macrophage Antigen 1 (MAC-1) Beta Subunit) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1367477","CD14 Gene","C21290","This gene plays a role in apoptosis and in ligand-binding interactions.","CD14 Gene | CD14 | CD14 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332088","ANGPT1 Gene","C21311","This gene plays a role in blood vessel maturation and stability.","ANGPT1 Gene | ANGPT1 | Angiopoietin 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332089","ANGPT2 Gene","C21312","This gene is involved in vascular remodeling.","ANGPT2 Gene | ANGPT2 | Angiopoietin 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332082","ALOX15 Gene","C21316","This gene is involved in hormonal signaling and inflammation.","ALOX15 Gene | ALOX15 | Arachidonate 15-Lipoxygenase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456261","Pulmonary Vascular Resistance","C119247","The resistance to blood flow offered by the pulmonary vasculature, which is normally one sixth of SVR. The major determinant of PVR is pulmonary vessel constriction, most often caused by hypoxia and/or hypercarbia. Prolonged elevated PVR can cause right heart failure.","Pulmonary Vascular Resistance | PVR | Pulmonary vascular resistance",,,,,,,,,,,,,,,"4081062","Pulmonary vascular resistance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0201931","Partial Pressure of Carbon Dioxide Measurement","C82625","A measurement of the partial pressure of carbon dioxide in a sample.","Partial Pressure of Carbon Dioxide Measurement | PCO2 | Partial Pressure Carbon Dioxide",,,,,,,,,,,,,,,"4099545","Carbon dioxide measurement, partial pressure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332714","CD4 Gene","C21362","This gene is involved in the initiation of T-cell activation.","CD4 Gene | CD4 | CD4 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823619","VEGFA Gene","C21408","This gene is involved in the regulation of blood vessel growth. It also plays a role as a neurotrophic factor for motor neurons.","VEGFA Gene | VEGFA | Vascular Endothelial Growth Factor A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336933","VEGFC Gene","C21410","This gene plays a role in vasculogenesis.","VEGFC Gene | VEGFC | Vascular Endothelial Growth Factor C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1363982","TNFRSF1B Gene","C21553","This gene is involved in the regulation of apoptotic receptor-mediated signal transduction and inflammatory responses.","TNFRSF1B Gene | TNFR2 | TNFRSF1B | Tumor Necrosis Factor Receptor Superfamily, Member 1B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1363984","TNFRSF1A Gene","C21554","This gene modulates a variety of cellular functions such as apoptosis and inflammatory responses.","TNFRSF1A Gene | TNFRSF1A | Tumor Necrosis Factor Receptor Superfamily, Member 1A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332373","BAG5 Gene","C24253","This gene is involved in signal transduction and regulation of apoptosis.","BAG5 Gene | BAG5 | BCL2 Associated Athanogene 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332753","CHEK1 Gene","C24295","This gene is involved in the negative regulation of cell growth.","CHEK1 Gene | CHEK1 | CHK1 Checkpoint Homolog (S.Pombe) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332774","COL4A3 Gene","C24306","This gene plays a role in the compositional and structural regulation of basement membranes.","COL4A3 Gene | COL4A3 | Collagen Type IV Alpha 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332791","CSF2 Gene","C24310","This gene plays a role in the regulation of hematopoietic cellular processes.","CSF2 Gene | CSF2 | Colony Stimulating Factor 2 (Granulocyte-Macrophage) Gene | GMCSF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332793","CSF3 Gene","C24312","The gene is involved in the regulation of the progenitor cells for granulocytes.","CSF3 Gene | CSF3 | Colony Stimulating Factor 3 (Granulocyte) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332823","CXCR4 Gene","C24327","This gene is involved in the mediation of viral entry into cells and cellular migration and chemotaxis.","CXCR4 Gene | CXCR4 | Chemokine (C-X-C Motif) Receptor 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333207","DDR2 Gene","C24333","This gene plays a role in extracellular matrix communication processes and receptor-mediated signal transduction.","DDR2 Gene | DDR2 | Discoidin Domain Receptor Family Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1367721","EGF Gene","C24359","This gene is involved in the differentiation and proliferation of cells.","EGF Gene | EGF | Epidermal Growth Factor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333569","FLT4 Gene","C24400","This gene plays an essential role in the development of embryonic cardiovasculature and lymphatic vessel formation.","FLT4 Gene | FLT4 | FMS Related Tyrosine Kinase 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333574","FPR1 Gene","C24403","This gene plays a role in G protein-coupled receptor signal transduction and chemotaxis.","FPR1 Gene | FPR1 | Formyl Peptide Receptor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333583","KDSR Gene","C24410","This gene plays a role in glycosphingolipid metabolism.","KDSR Gene | 3-Ketodihydrosphingosine Reductase Gene | FVT1 | KDSR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812304","GLI1 Gene","C24432","This gene plays a regulatory role in transcription and embryonic development.","GLI1 Gene | GLI Family Zinc Finger 1 Gene | GLI1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366503","HOXA10 Gene","C24473","This gene is involved in transcriptional regulation and in the regulation of endometrial development.","HOXA10 Gene | HOXA10 | Homeo Box A10 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334090","IGF2R Gene","C24487","This gene is involved in intracellular trafficking and receptor signaling.","IGF2R Gene | IGF2R | Insulin-Like Growth Factor 2 Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334103","IL13 Gene","C24496","This gene is involved in inflammatory processes and has been identified as a therapeutic target in persons with asthma.","IL13 Gene | IL13 | Interleukin 13 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879590","IL2 Gene","C24498","This gene is involved in growth and lymphokine regulation.","IL2 Gene | IL2 | Interleukin 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334121","IL5 Gene","C24502","This gene plays a role in eosinophil differentiation.","IL5 Gene | IL5 | Interleukin 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1325331","IL6ST Gene","C24505","This gene plays a role in signal transduction and is putatively involved in embryonic development.","IL6ST Gene | IL6ST | Interleukin 6 Signal Transducer Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334123","IL7R Gene","C24506","This gene is involved in the regulation of lymphopoiesis.","IL7R Gene | IL7R | Interleukin 7 Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334126","CXCR2 Gene","C24509","This gene is involved in pro-inflammatory cytokine cellular responses, neutrophil activation, and chemotaxis.","CXCR2 Gene | CXCR2 | Chemokine (C-X-C Motif) Receptor 2 Gene | IL8RB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334140","IRS1 Gene","C24522","This gene plays a role in signal transduction and carbohydrate metabolism. It is involved in mediation of the insulin response.","IRS1 Gene | IRS1 | Insulin Receptor Substrate 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334311","KLRD1 Gene","C24535","This gene plays a role in the regulation of natural killer cell activity.","KLRD1 Gene | KLRD1 | Killer Cell Lectin-Like Receptor Subfamily D, Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332821","CXCL9 Gene","C24597","This gene plays a role in T-cell trafficking.","CXCL9 Gene | C-X-C Motif Chemokine Ligand 9 Gene | CXCL9 | Chemokine (C-X-C Motif) Ligand 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366499","MME Gene","C24607","This gene is involved in the inactivation of peptide hormones.","MME Gene | CD10 | MME | Membrane Metalloendopeptidase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1364082","MST1R Gene","C24616","This gene plays a diverse regulatory role in several processes such as: proliferation, migration, host defense and fertilization.","MST1R Gene | MST1R | Macrophage Stimulating 1 Receptor (C-MET-Related Tyrosine Kinase) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891717","Laboratory Test (name)","C117142","A character or string that represents the full name of the laboratory assessment.","Laboratory Test Name | LAB_TEST | LBTEST | Lab Name | Lab Test | Laboratory Test | Laboratory Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221102","Excretion","C94618","THe process by which waste matter is discharged from the body","Excretion | excrete | excretion",,,,,,,,,,,,,,,"37397755|4271038","Excretory process|Excretory function",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C4086588","Minimal Residual Disease Response","C124433","An assessment of the minimal residual disease response to therapy.","Measurable Residual Disease Response | MRD Response | MRDRESP | MRD_RESULT | Minimal Residual Disease Response | Minimal Residual Disease Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085672","Microbiology Test","C49188","A laboratory procedure to detect microorganisms in a sample.","Microbiology Test | Laboratory Testing, Microbiology",,,,,,,,,,,,,,,"4057955","Microbiology procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3890583","Subject Diary","C115589","Documentation used to capture data recorded by the subject.","Subject Diary Documentation | Patient Diary | Subj Diary Form | Subject Diary | Subject Diary | Subject Diary Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335201","PDGFRA Gene","C24666","This gene plays a role in mitogenic activities affecting mesenchymal cells and is involved in receptor tyrosine kinase signal transduction.","PDGFRA Gene | PDGFRA | Platelet-Derived Growth Factor Receptor, Alpha Polypeptide Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335202","PDGFRB Gene","C24667","This gene plays a role in mitogenic activities affecting mesenchymal cells and a translocation in the gene results in chronic myelomonocytic leukemia.","PDGFRB Gene | PDGFRB | Platelet-Derived Growth Factor Receptor, Beta Polypeptide Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335207","PGF Gene","C24670","This gene plays a role in the growth, proliferation and migration of endothelial cells. It is also involved in angiogenesis.","PGF Gene | PGF | Placental Growth Factor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335222","GDF15 Gene","C24679","This gene is involved in the regulation of tissue differentiation. It also plays a role in controlling the growth of granulocytes and macrophages.","GDF15 Gene | GDF15 | Growth Differentiation Factor 15 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1321914","PMAIP1 Gene","C24685","This gene is a regulator of apoptosis through transcriptional activation.","PMAIP1 Gene | PMAIP1 | Phorbol-12-Myristate-13-Acetate-Induced Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366894","PTK2 Gene","C24699","This gene plays a role in apoptosis, cell motility and proliferation.","PTK2 Gene | PTK2 | PTK2 Protein Tyrosine Kinase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419102","PTPN22 Gene","C24707","This gene plays a role in the regulation of the immune system, the development of autoimmunity and the cellular response to pathogens.","PTPN22 Gene | PTPN22 | Protein Tyrosine Phosphatase, Non-Receptor Type 22 (Lymphoid) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335285","PTPRC Gene","C24711","This gene plays a role in suppression of cytokine receptor signaling and the regulation of signal transduction in lymphocytes.","PTPRC Gene | CD45 | PTPRC | Protein Tyrosine Phosphatase, Receptor Type C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332683","CCL1 Gene","C24766","This gene is involved in the regulation and modulation of inflammatory processes.","CCL1 Gene | CCL1 | Chemokine (C-C Motif) Ligand 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332676","CCL11 Gene","C24767","This gene is involved in cell migration and chemotaxis.","CCL11 Gene | CCL11 | Chemokine (C-C motif) Ligand 11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1337091","CCL4 Gene","C24784","This gene plays a role in inflammatory and antiviral responses.","CCL4 Gene | CCL4 | Chemokine (C-C Motif) Ligand 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332691","CCL5 Gene","C24785","This gene plays a role in antiviral responses.","CCL5 Gene | CCL5 | Chemokine (C-C Motif) Ligand 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086242","Disease Phenotype","C125204","Measurable developmental, cognitive, behavioral, morphological, or biological traits or characteristics more often found in patients with a condition or disease than in those without.","Disease Phenotype | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332693","CCL8 Gene","C24787","This gene is involved in the modulation of immune functions.","CCL8 Gene | CCL8 | Chemokine (C-C Motif) Ligand 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1367714","CXCL10 Gene","C24788","This gene plays a role in immune system processes and is involved in angiogenesis.","CXCL10 Gene | C-X-C Motif Chemokine Ligand 10 Gene | CXCL10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335814","SFRP4 Gene","C24804","This gene plays a role in signal transduction, apoptosis and cell proliferation.","SFRP4 Gene | SFRP4 | Secreted Frizzled Related Protein 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335872","STAT1 Gene","C24831","This gene plays a role in signal transduction and activation of transcription. It is involved in cell organization/biogenesis.","STAT1 Gene | STAT1 | Signal Transducer and Activator of Transcription 1, 91kDa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335873","STAT2 Gene","C24832","This gene is involved in signal transduction and activation of transcription.","STAT2 Gene | STAT2 | Signal Transducer and Activator of Transcription 2, 113kDa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335875","STAT5A Gene","C24834","This gene plays a role in signal transduction and activation of transcription. It is involved in the immune response via stimulation of T-cell proliferation.","STAT5A Gene | STAT5A | Signal Transducer and Activator of Transcription 5A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336601","TEC Gene","C24850","This gene is involved in signal transduction and regulation of immune function.","TEC Gene | TEC | Tec Protein Tyrosine Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336602","TEK Gene","C24851","This gene plays a role in vascular development and angiogenesis.","TEK Gene | TEK | TEK Receptor Tyrosine Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336624","TGFBR1 Gene","C24859","This gene is involved in transcriptional regulation and cell cycle progression regulation.","TGFBR1 Gene | TGFBR1 | Transforming Growth Factor Beta Receptor 1  Gene | Transforming Growth Factor Beta Receptor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336636","TLR4 Gene","C24865","This gene is involved in the mediation of immune responses and in signal transduction events induced by lipopolysaccharide.","TLR4 Gene | TLR4 | Toll-Like Receptor 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336641","TMPRSS2 Gene","C24871","This gene plays a role in the activation of pathway signaling.","TMPRSS2 Gene | TMPRSS2 | Transmembrane Serine Protease 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514212","Airway Plateau Pressure","C130051","The static pressure of the entire respiratory system during inspiratory pause. It reflects the elastic retraction of the entire respiratory system.","Airway Plateau Pressure | Inspiratory Pause Pressure | Plateau Pressure | Pplat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335874","STAT4 Gene","C26139","This gene is involved in signal transduction and activation of transcription. It plays a role in regulation of T-helper cell differentiation.","STAT4 Gene | STAT4 | Signal Transducer and Activator of Transcription 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0087049","Antigen T Cell Receptor, beta Chain","C26427","One component of the alpha-beta T-cell receptor. Encoded by a locus on chromosome 7. Somatic recombination results in formation of the active gene.","T-Cell Receptor Beta Chain | T-Cell Receptor Beta | TCRB | TRB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524891","T-Cell Receptor Beta Locus","C26418","This region represents the germline organization of the T cell receptor beta locus. The beta locus includes V (variable), J (joining), diversity (D), and C (constant) segments. During T cell development, the beta chain is synthesized by a recombination event at the DNA level joining a D segment with a J segment; a V segment is then joined to the D-J gene. The C segment is later joined by splicing at the RNA level. Recombination of many different V segments with several D and J segments provides a wide range of antigen recognition. Additional diversity is attained by junctional diversity, resulting from the random additional of nucleotides by terminal deoxynucleotidyltransferase.  Chromosomal abnormalities involving the T-cell receptor beta locus have been associated with T-cell lymphomas. (from LocusLink)","T-Cell Receptor Beta Locus | T-Cell Receptor Beta Gene | TCRB | TRB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334522","MMP2 Gene","C26514","This gene is involved in angiogenesis, inflammation and the regulation of extracellular matrix remodeling.","MMP2 Gene | MMP2 | Matrix Metalloproteinase 2 (Gelatinase A, 72kDa Gelatinase, 72kDa type IV Collagenase) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335271","PTGS1 Gene","C26596","This gene plays a role in the regulation of angiogenesis in endothelial cells.","PTGS1 Gene | COX1 | PTGS1 | Prostaglandin-Endoperoxide Synthase 1 (Prostaglandin G/H Synthase and Cyclooxygenase) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335649","RRM2 Gene","C26616","This gene is involved in the promotion of cell cycle-specific gene expression.","RRM2 Gene | RRM2 | Ribonucleotide Reductase M2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1567180","CASP9 protein, human","C28427","Caspase-9 (416 aa, ~46 kDa) is encoded by the human CASP9 gene. This protein is involved in proteolysis and caspase-dependent apoptosis.","Caspase-9 | APAF-3 | APAF3 | Apoptotic Protease Activating Factor 3 | Apoptotic Protease MCH-6 | CASP-9 | CASP9 | CASP9 Protein | Caspase 9, Apoptosis-Related Cysteine Protease | EC 3.4.22.62 | ICE-LAP6 | ICE-Like Apoptotic Protease 6 | MCH6 | Pro-Caspase 9 | Pro-Caspase-9 | Procaspase 9 | Procaspase-9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332666","CASP7 Gene","C28438","This gene plays a role in the execution phase of apoptosis and is also involved in the regulation of lipogenic and cholesterogenic gene transcription.","CASP7 Gene | CASP7 | Caspase 7, Apoptosis-Related Cysteine Protease Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332807","CTSL Gene","C28461","This gene is involved in intracellular protein catabolism.","CTSL Gene | CTSL | CTSL1 | Cathepsin L Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336938","VWF Gene","C28483","This gene is critical for cellular homeostasis and plays a role in the regulation of blood coagulation by platelet function modulation.","VWF Gene | VWF | Von Willebrand Factor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334145","ITGAX Gene","C28529","This gene is involved in the initiation of immune cell chemotaxis and phagocytosis.","ITGAX Gene | ITGAX | Integrin, Alpha X (Complement Component 3 Receptor 4 Subunit) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332802","CTLA4 Gene","C28567","This gene is involved in T-cell mediation and receptor signal transduction.","CTLA4 Gene | CTLA4 | Cytotoxic T-Lymphocyte Associated Protein 4 Gene | Cytotoxic T-Lymphocyte-Associated Protein 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366583","ENG Gene","C28573","This gene in involved in endothelial cell proliferation.","ENG Gene | CD105 | ENG | Endoglin (Osler-Rendu-Weber Syndrome 1) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333663","GATA1 Gene","C28575","This gene is involved in erythropoiesis and transcriptional activation.","GATA1 Gene | GATA Binding Protein 1 Gene | GATA1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334092","IGFBP1 Gene","C28588","This gene plays a role in insulin-like growth factor modulation and degradation.","IGFBP1 Gene | IGFBP1 | Insulin-Like Growth Factor Binding Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334119","IL4 Gene","C28596","This gene is involved in the regulation of the proliferation and differentiation of B-cells.","IL4 Gene | IL4 | Interleukin 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334124","IL7 Gene","C28598","This gene is involved in regulating immune responses in the intestinal mucosa.","IL7 Gene | IL7 | Interleukin 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514228","Activity Card Sort","C129985","An assessment tool developed to measure levels of activity engagement in older adults. Participants sort cards depicting people engaged in various activities into categories representing whether the activity is part of the individual's routine.","Activity Card Sort | ACS | Activity Card Sort (ACS)",,,,,,,,,,,,,,,"37111179","ACS - Activity Card Sort",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514164","Instrumental Activities Domain","C129987","A domain of the Activity Card Sort (ACS) related to crucial activities that may be part of an individual's routine such as driving, paying bills, and child care.","Instrumental Activities Domain | Instrumental | Instrumental Activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513967","Low-Demand Leisure Activities Domain","C129989","A domain of the Activity Card Sort (ACS) related to low-physical-demand leisure activities that may be part of an individual's routine such as puzzles, quilting, and photography.","Low-Demand Leisure Activities Domain | Low-Demand Leisure Activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514086","High-Demand Leisure Activities Domain","C129990","A domain of the Activity Card Sort (ACS) related to high physical demand leisure activities that may be part of an individual's routine such as bicycling, woodworking, and hiking.","High-Demand Leisure Activities Domain | High-Demand Leisure Activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513996","Social Activities Domain","C129991","A domain of the Activity Card Sort (ACS) related to social activities that may be part of an individual's routine such as volunteer work, visiting with friends, and traveling.","Social Activities Domain | Social Activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514084","Ability to Get In and Out of Bed","C129994","A question about the ability of an individual to get in and out of bed.","Ability to Get In and Out of Bed Question | Ability to Get In and Out of Bed | Ability to Get In and Out of Bed | Get in and out of bed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513820","Ability to Cut Meat","C129995","A question about the ability of an individual to cut their own meat.","Ability to Cut Meat Question | Ability to Cut Meat | Ability to Cut Meat | Cut your own meat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514166","Ability to Lift a Full Cup or Glass to Mouth","C129997","A question about the ability of an individual to lift a full cup or glass to their mouth.","Ability to Lift a Full Cup or Glass to Mouth Question | Ability to Lift a Full Cup or Glass to Mouth | Ability to Lift a Full Cup or Glass to Mouth | Lift a full cup or glass to your mouth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514203","Ability to Open New Milk Carton","C129998","A question about the ability of an individual to open a new milk carton.","Ability to Open New Milk Carton Question | Ability to Open New Milk Carton | Ability to Open New Milk Carton | Open a new milk carton",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514082","Ability to Climb 5 Steps","C129999","A question about the ability of an individual to climb five steps.","Ability to Climb 5 Steps Question | Ability to Climb 5 Steps | Ability to Climb 5 Steps | Climb up five steps",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514076","Use Aid or Device for Activity","C130000","A question about an individual's use of equipment to assist with activities.","Use Aid or Device for Activity Question | Aids or devices that you usually use for activities | Use Aid or Device for Activity | Use Aid or Device for Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514180","Need Help from Another Person","C130002","A question about an individual's need of help from another person to assist with activities.","Need Help from Another Person | Categories for which you usually need help from another person",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514205","Ability to Take a Tub Bath","C130003","A question about the ability of an individual to take a bath in a tub.","Ability to Take a Tub Bath Question | Ability to Take a Tub Bath | Ability to Take a Tub Bath | Take a tub bath",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514071","Ability to Reach and Get Down 5 Pound Object From Above Head","C130004","A question about the ability of an individual to reach and get down a 5 pound object (such as a bag of sugar) from above their head.","Ability to Reach and Get Down 5 Pound Object From Above Head Question | Ability to Reach and Get Down 5 Pound Object From Above Head | Ability to Reach and Get Down 5 Pound Object From Above Head | Reach and get down a 5 pound object (such as a bag of sugar) from above your head",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514201","Ability to Bend Down to Pick up Clothing from the Floor","C130005","A question about the ability of an individual to bend down to pick up clothing from the floor.","Ability to Bend Down to Pick up Clothing from the Floor Question | Ability to Bend Down to Pick up Clothing from the Floor | Ability to Bend Down to Pick up Clothing from the Floor | Bend down to pick up clothing from the floor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514202","Ability to Open Car Door","C130006","A question about the ability of an individual to open a car door.","Ability to Open Car Door Question | Ability to Open Car Door | Ability to Open Car Door | Open car doors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514204","Ability to Open Previously Opened Jar","C130007","A question about the ability of an individual to open a jar that was previously opened.","Ability to Open Previously Opened Jar Question | Ability to Open Previously Opened Jar | Ability to Open Previously Opened Jar | Open previously opened jars",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514073","Ability to Turn Faucets On and Off","C130008","A question about the ability of an individual to turn faucets on and off.","Ability to Turn Faucets On and Off Question | Ability to Turn Faucets On and Off | Ability to Turn Faucets On and Off | Turn faucets on and off",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514070","How Well Doing Health Rating","C130009","A question about how well an individual is doing as related to their health.","How Well Doing Health Rating | Rate how well you are doing regarding your health",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513086","Feel Fit","C130013","A question about whether an individual feels or felt fit.","Feel Fit | I feel fit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513088","Feel Physically Able to Only Do a Little","C130015","A question about whether an individual physically feels or felt able to do a little.","Feel Physically Able to Only Do a Little Question | Feel Physically Able to Only Do a Little | Feel Physically Able to Only Do a Little | Physically I feel only able to do a little",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513089","Feel Very Active","C130016","A question about whether an individual feels or felt very active.","Feel Very Active | I feel very active",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513087","Feel Like Doing All Sorts of Nice Things","C130017","A question about whether an individual feels or felt like doing all sorts of nice things.","Feel Like Doing All Sorts of Nice Things | I feel like doing all sorts of nice things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513457","Do a Lot in a Day","C130018","A question about whether an individual thinks or thought they do a lot in a day.","Do a Lot in a Day | I think I do a lot in a day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513754","When Doing Something Can Keep Thoughts on It","C130019","A question about whether an individual, when they are doing something, can keep their thoughts on it.","When Doing Something Can Keep Thoughts on It | When I am doing something, I can keep my thoughts on it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513179","Physically Can Take on a Lot","C130021","A question about whether an individual physically can take on a lot.","Physically Can Take on a Lot | Can Take on a Lot Physically | Physically I can take on a lot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513463","Dread Having to do Things","C130022","A question about whether an individual dreads or dreaded having to do things.","Dread Having to do Things | I dread having to do things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513456","Do Very Little in a Day","C130023","A question about whether an individual thinks or thought they do very little in a day.","Do Very Little in a Day | I think I do very little in a day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514009","Am Rested","C130025","A question about whether an individual is or was rested.","Am Rested Question | Am Rested | Am Rested | I am rested",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513365","Takes a Lot of Effort to Concentrate on Things","C130026","A question about whether an individual takes a lot of effort to concentrate on things.","Takes a Lot of Effort to Concentrate on Things | It takes a lot of effort to concentrate on things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513180","Physically Feel in Bad Condition","C130027","A question about whether an individual physically feels or felt in bad condition.","Physically Feel in Bad Condition | Feel in Bad Condition Physically | Physically I feel I am in a bad condition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514096","Have Lots of Plans","C130028","A question about whether an individual has or had lots of plans.","Have Lots of Plans | I have a lot of plans",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513099","Get Little Done","C130030","A question about whether an individual gets or got little done.","Get Little Done | I get little done",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513462","Don't Feel Like Doing Anything","C130031","A question about whether an individual doesn't feel like doing anything.","Don't Feel Like Doing Anything | I don't feel like doing anything",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513368","Thoughts Easily Wander","C130032","A question about whether an individual's thoughts easily wander.","Thoughts Easily Wander | My thoughts easily wander | Thoughts Wander Easily",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513181","Physically Feel in Excellent Condition","C130034","A question about whether an individual physically feels or felt in excellent condition.","Physically Feel in Excellent Condition | Feel in Excellent Condition Physically | Physically I feel I am in an excellent condition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334127","IL9 Gene","C28599","This gene plays a role in inflammatory processes and has been implicated in the pathogenesis of asthma.","IL9 Gene | IL9 | Interleukin 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334105","IL15 Gene","C28604","This gene is involved in the regulation of memory T cells and cytokine production.","IL15 Gene | IL15 | Interleukin 15 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825592","IL17A Gene","C28608","This gene is involved in the regulation of osteoclastogenesis and plays a role in rheumatoid arthritis.","IL17A Gene | IL17 | IL17A | Interleukin 17A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334510","MLANA Gene","C28629","This gene plays a role in the development and maturation of melanosomes.","MLANA Gene | MLANA | Melan-A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335233","POU2F1 Gene","C28649","This gene plays a role in transcriptional activation and modulates immunoglobulin activity.","POU2F1 Gene | POU Domain, Class 2, Transcription Factor 1 Gene | POU2F1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1367459","TIMP1 Gene","C28675","This gene plays a role in the degradation of the extracellular matrix. It is also involved in the promotion of cell proliferation and inhibition of apoptosis.","TIMP1 Gene | TIMP1 | Tissue Inhibitor of Metalloproteinase 1 (Erythroid Potentiating Activity, Collagenase Inhibitor) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001898","Alanine","C29605","A small non-essential amino acid in humans, Alanine is one of the most widely used for protein construction and is involved in the metabolism of tryptophan and vitamin pyridoxine. Alanine is an important source of energy for muscles and central nervous system, strengthens the immune system, helps in the metabolism of sugars and organic acids, and displays a cholesterol-reducing effect in animals. (NCI04)","Alanine | (S)-2-Aminopropanoic acid | ALANINE | Ala",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515714","t(v;11q23.3)","C36517","A chromosomal abnormality consisting of the translocation of genetic material from any one of several chromosomes to the 11q23.3 region, resulting in an MLL gene rearrangement.","t(v;11q23.3) | 11q23.3 Translocation | MLL Other Partner | t(11;v)(q23.3;v) | t(11;v)(q23;v) | t(11;v)(q23;v) | t(V;11)(v;q23) | t(V;11)(v;q23.3)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366645","CD36 Gene","C38191","This gene is involved in the regulation of cellular transport and adhesion.","CD36 Gene | CD36 | CD36 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554669","GYPA Gene","C38319","This gene plays a role in erythrocyte regulation.","GYPA Gene | GYPA | Glycophorin A (Includes MN Blood Group) Gene | Glycophorin A (MNS Blood Group) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414555","FCGR3A Gene","C38558","This gene plays a role in the mediation of antibody-dependent cytotoxicity and phagocytosis.","FCGR3A Gene | FCGR3A | Fc Fragment of IgG, Low Affinity IIIA, Receptor (CD16A) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417760","NOS2 Gene","C38564","This gene is involved in vasodilation and regulation of the bactericidal/tumoricidal actions of macrophages.","NOS2 Gene | NOS2 | NOS2A | Nitric Oxide Synthase 2, Inducible Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416395","IL1R1 Gene","C38911","This gene is involved in a variety of cytokine induced immune and inflammatory responses.","IL1R1 Gene | IL1R1 | Interleukin 1 Receptor, Type I Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414805","MTOR Gene","C38928","This gene plays a role in apoptosis, cell growth, differentiation and proliferation.","MTOR Gene | MTOR | Mechanistic Target of Rapamycin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416408","IL3RA Gene","C39274","This gene is involved in signal transduction and several diverse biological processes.","IL3RA Gene | IL3RA | Interleukin 3 Receptor, Alpha (Low Affinity) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0298130","Montelukast","C66189","A selective cysteinyl leukotriene receptor antagonist with anti-inflammatory and bronchodilating activities. Upon administration, montelukast selectively and competitively blocks the cysteinyl leukotriene 1 (CysLT1) receptor, preventing binding of the inflammatory mediator leukotriene D4 (LTD4). Inhibition of LTD4 activity results in inhibition of leukotriene-mediated inflammatory events including migration of eosinophils and neutrophils, adhesion of leukocytes to vascular endothelium, monocyte and neutrophil aggregation, increased airway edema, increased capillary permeability, and bronchoconstriction. The CysLT1 receptor is found in a number of tissues including spleen, lung, placenta, small intestine, and nasal mucosa, and in a variety of cell types including monocyte/macrophages, mast cells, eosinophils, CD34-positive hemopoietic progenitor cells, neutrophils and endothelial cells.","Montelukast | MONTELUKAST | montelukast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL557620","Macrolide Antibiotic","C261","An anti-microbial compound comprised of a macrocyclic lactone with a ring of twelve or more members linked to one or more monosaccharides, with bacteriostatic and potential antifungal activities. Macrolide antibiotics generally inhibit protein synthesis by binding to the 50S subunit of the bacterial ribosome.","Macrolide Antibiotic | Macrolides",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013081","Transcriptional Repression","C16521","Decreased expression of some gene product.","Transcriptional Repression | Gene Down-Regulation | Gene Repression | Transcription Repression",,,,,,,,,,,,,,,"4175954","Down-regulation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1294198","Gene Rearrangement Analysis","C51961","No Value Exists","Gene Rearrangement Analysis | ",,,,,,,,,,,,,,,"4038338","Gene rearrangement analysis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3274438","Run-in Period","C98779","A period in a clinical study that occurs before the commencement of the primary clinical study investigation, during which subjects may be assessed for suitability in the clinical study, withdrawn from existing therapy, trained in study methodology or evaluated for any other protocol-specified reason.","Run-in Period | RUN-IN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513788","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.L248V","C130203","A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.742C>G mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the leucine at position 248 of the ABL1 protein has been replaced by valine.","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.L248V | BCR-ABL L248V Mutation | BCR-ABL Leu248Val Mutation | BCR-ABL1 L248V Mutation | BCR-ABL1 Leu248Val Mutation | BCR/ABL Fusion Protein with L248V | BCR/ABL Fusion Protein with Leu248Val | BCR/ABL L248V Mutation | BCR/ABL Leu248Val Mutation | BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Leu248Val | BCR/ABL1 Fusion Protein with NP_005148.2:p.L248V | BCR/ABL1 Fusion Protein with NP_005148.2:p.Leu248Val | BCR/ABL1 L248V Mutation | BCR/ABL1 Leu248Val Mutation | BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.L248V | L248V",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513783","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.G250E","C130205","A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.749G>A mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the glycine at position 250 of the ABL1 protein has been replaced by glutamic acid.","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.G250E | BCR-ABL G250E Mutation | BCR-ABL Gly250Glu Mutation | BCR-ABL1 G250E Mutation | BCR-ABL1 Gly250Glu Mutation | BCR/ABL Fusion Protein with G250E | BCR/ABL Fusion Protein with Gly250Glu | BCR/ABL G250E Mutation | BCR/ABL Gly250Glu Mutation | BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Gly250Glu | BCR/ABL1 Fusion Protein with NP_005148.2:p.G250E | BCR/ABL1 Fusion Protein with NP_005148.2:p.Gly250Glu | BCR/ABL1 G250E Mutation | BCR/ABL1 Gly250Glu Mutation | BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.G250E | G250E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513785","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Q252H","C130208","A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.756G>T or c.756G>C mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the glutamine at position 252 of the ABL1 protein has been replaced by histidine.","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Q252H | BCR-ABL Gln252His Mutation | BCR-ABL Q252H Mutation | BCR-ABL1 Gln252His Mutation | BCR-ABL1 Q252H Mutation | BCR/ABL Fusion Protein with Gln252His | BCR/ABL Fusion Protein with Q252H | BCR/ABL Gln252His Mutation | BCR/ABL Q252H Mutation | BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Gln252His | BCR/ABL1 Fusion Protein with NP_005148.2:p.Gln252His | BCR/ABL1 Fusion Protein with NP_005148.2:p.Q252H | BCR/ABL1 Gln252His Mutation | BCR/ABL1 Q252H Mutation | BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.Q252H | Q252H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513791","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Y253F","C130210","A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.758A>T mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the tyrosine at position 253 of the ABL1 protein has been replaced by phenylalanine.","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Y253F | BCR-ABL Tyr253Phe Mutation | BCR-ABL Y253F Mutation | BCR-ABL1 Tyr253Phe Mutation | BCR-ABL1 Y253F Mutation | BCR/ABL Fusion Protein with Tyr253Phe | BCR/ABL Fusion Protein with Y253F | BCR/ABL Tyr253Phe Mutation | BCR/ABL Y253F Mutation | BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Tyr253Phe | BCR/ABL1 Fusion Protein with NP_005148.2:p.Tyr253Phe | BCR/ABL1 Fusion Protein with NP_005148.2:p.Y253F | BCR/ABL1 Tyr253Phe Mutation | BCR/ABL1 Y253F Mutation | BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.Y253F | Y253F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513777","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.E255K","C130212","A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.763G>A mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the glutamic acid at position 255 of the ABL1 protein has been replaced by lysine.","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.E255K | BCR-ABL E255K Mutation | BCR-ABL Glu255Lys Mutation | BCR-ABL1 E255K Mutation | BCR-ABL1 Glu255Lys Mutation | BCR/ABL E255K Mutation | BCR/ABL Fusion Protein with E255K | BCR/ABL Fusion Protein with Glu255Lys | BCR/ABL Glu255Lys Mutation | BCR/ABL1 E255K Mutation | BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Glu255Lys | BCR/ABL1 Fusion Protein with NP_005148.2:p.E255K | BCR/ABL1 Fusion Protein with NP_005148.2:p.Glu255Lys | BCR/ABL1 Glu255Lys Mutation | BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.E255K | E255K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513792","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.V299L","C130215","A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.895G>C or c.895G>T mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the valine at position 299 of the ABL1 protein has been replaced by leucine.","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.V299L | BCR-ABL V299L Mutation | BCR-ABL Val299Leu Mutation | BCR-ABL1 V299L Mutation | BCR-ABL1 Val299Leu Mutation | BCR/ABL Fusion Protein with V299L | BCR/ABL Fusion Protein with Val299Leu | BCR/ABL V299L Mutation | BCR/ABL Val299Leu Mutation | BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Val299Leu | BCR/ABL1 Fusion Protein with NP_005148.2:p.V299L | BCR/ABL1 Fusion Protein with NP_005148.2:p.Val299Leu | BCR/ABL1 V299L Mutation | BCR/ABL1 Val299Leu Mutation | BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.V299L | V299L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513780","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.F317L","C130219","A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.951C>A, c.951C>G or c.949T>C mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the phenylalanine at position 317 of the ABL1 protein has been replaced by leucine.","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.F317L | BCR-ABL F317L Mutation | BCR-ABL Phe317Leu Mutation | BCR-ABL1 F317L Mutation | BCR-ABL1 Phe317Leu Mutation | BCR/ABL F317L Mutation | BCR/ABL Fusion Protein with F317L | BCR/ABL Fusion Protein with Phe317Leu | BCR/ABL Phe317Leu Mutation | BCR/ABL1 F317L Mutation | BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Phe317Leu | BCR/ABL1 Fusion Protein with NP_005148.2:p.Phe317Leu | BCR/ABL1 Fusion Protein with NP_005148.2:pF317L | BCR/ABL1 Phe317Leu Mutation | BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.F317L | F317L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513790","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.M351T","C130221","A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.1052T>C mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the methionine at position 351 of the ABL1 protein has been replaced by threonine.","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.M351T | BCR-ABL M351T Mutation | BCR-ABL Met351Thr Mutation | BCR-ABL1 M351T Mutation | BCR-ABL1 Met351Thr Mutation | BCR/ABL Fusion Protein with M351T | BCR/ABL Fusion Protein with Met351Thr | BCR/ABL M351T Mutation | BCR/ABL Met351Thr Mutation | BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Met351Thr | BCR/ABL1 Fusion Protein with NP_005148.2:p.M351T | BCR/ABL1 Fusion Protein with NP_005148.2:p.Met351Thr | BCR/ABL1 M351T Mutation | BCR/ABL1 Met351Thr Mutation | BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.M351T | M351T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513781","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.F359V","C130223","A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.1075T>G mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the phenylalanine at position 359 of the ABL1 protein has been replaced by valine.","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.F359V | BCR-ABL F359V Mutation | BCR-ABL Phe359Val Mutation | BCR-ABL1 F359V Mutation | BCR-ABL1 Phe359Val Mutation | BCR/ABL F359V Mutation | BCR/ABL Fusion Protein with F359V | BCR/ABL Fusion Protein with Phe359Val | BCR/ABL Phe359Val Mutation | BCR/ABL1 F359V Mutation | BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Phe359Val | BCR/ABL1 Fusion Protein with NP_005148.2:p.F359V | BCR/ABL1 Fusion Protein with NP_005148.2:p.Phe359Val | BCR/ABL1 Phe359Val Mutation | BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.F359V | F359V",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513789","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.L384M","C130225","A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.1150C>A mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the leucine at position 384 of the ABL1 protein has been replaced by methionine.","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.L384M | BCR-ABL L384M Mutation | BCR-ABL Leu384Met Mutation | BCR-ABL1 L384M Mutation | BCR-ABL1 Leu384Met Mutation | BCR/ABL Fusion Protein with L384M | BCR/ABL Fusion Protein with Leu384Met | BCR/ABL L384M Mutation | BCR/ABL Leu384Met Mutation | BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Leu384Met | BCR/ABL1 Fusion Protein with NP_005148.2:p.L384M | BCR/ABL1 Fusion Protein with NP_005148.2:p.Leu384Met | BCR/ABL1 L384M Mutation | BCR/ABL1 Leu384Met Mutation | BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.L384M | L384M",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513786","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.H396P","C130228","A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.1187A>C mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the histidine at position 396 of the ABL1 protein has been replaced by proline.","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.H396P | BCR-ABL H396P Mutation | BCR-ABL His396Pro Mutation | BCR-ABL1 H396P Mutation | BCR-ABL1 His396Pro Mutation | BCR/ABL Fusion Protein with H396P | BCR/ABL Fusion Protein with His396Pro | BCR/ABL H396P Mutation | BCR/ABL His396Pro Mutation | BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.His396Pro | BCR/ABL1 Fusion Protein with NP_005148.2:p.H396P | BCR/ABL1 Fusion Protein with NP_005148.2:p.His396Pro | BCR/ABL1 H396P Mutation | BCR/ABL1 His396Pro Mutation | BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.H396P | H396P",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513787","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.H396R","C130230","A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.1187A>G mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the histidine at position 396 of the ABL1 protein has been replaced by arginine.","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.H396R | BCR-ABL H396R Mutation | BCR-ABL His396Arg Mutation | BCR-ABL1 H396R Mutation | BCR-ABL1 His396Arg Mutation | BCR/ABL Fusion Protein with H396R | BCR/ABL Fusion Protein with His396Arg | BCR/ABL H396R Mutation | BCR/ABL His396Arg Mutation | BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.His396Arg | BCR/ABL1 Fusion Protein with NP_005148.2:p.H396R | BCR/ABL1 Fusion Protein with NP_005148.2:p.His396Arg | BCR/ABL1 H396R Mutation | BCR/ABL1 His396Arg Mutation | BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.H396R | H396R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513784","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.G398R","C130231","A fusion protein encoded by the BCR/ABL1 fusion gene with a mutation located in exon 7 of the ABL1 gene. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the glycine at position 398 of the ABL1 protein has been replaced by arginine.","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.G398R | BCR-ABL G398R Mutation | BCR-ABL Gly398Arg Mutation | BCR-ABL1 G398R Mutation | BCR-ABL1 Gly398Arg Mutation | BCR/ABL Fusion Protein with G398R | BCR/ABL Fusion Protein with Gly398Arg | BCR/ABL G398R Mutation | BCR/ABL Gly398Arg Mutation | BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Gly398Arg | BCR/ABL1 Fusion Protein with NP_005148.2:p.G398R | BCR/ABL1 Fusion Protein with NP_005148.2:p.Gly398Arg | BCR/ABL1 G398R Mutation | BCR/ABL1 Gly398Arg Mutation | BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.G398R | G398R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513782","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.F486S","C130233","A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.1457T>C mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the phenylalanine at position 486 of the ABL1 protein has been replaced by serine.","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.F486S | BCR-ABL F486S Mutation | BCR-ABL Phe486Ser Mutation | BCR-ABL1 F486S Mutation | BCR-ABL1 Phe486Ser Mutation | BCR/ABL F486S Mutation | BCR/ABL Fusion Protein with F486S | BCR/ABL Fusion Protein with Phe486Ser | BCR/ABL Phe486Ser Mutation | BCR/ABL1 F486S Mutation | BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Phe486Ser | BCR/ABL1 Fusion Protein with NP_005148.2:p.F486S | BCR/ABL1 Fusion Protein with NP_005148.2:p.Phe486Ser | BCR/ABL1 Phe486Ser Mutation | BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.F486S | F486S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698315","B Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1","C80341","A precursor lymphoid neoplasm which is composed of B lymphoblasts and carries a translocation between the E2A gene on chromosome 19 and the PBX1 gene on chromosome 1.","B Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1 | B Lymphoblastic Leukemia/Lymphoma with TCF3-PBX1 Fusion | B Lymphoblastic Leukemia/Lymphoma with TCF3::PBX1 Fusion | B Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1) | B Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1) | B Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3::PBX1 | B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1) | B-Lymphoblastic Leukemia/Lymphoma with TCF3-PBX1 Fusion | B-Lymphoblastic Leukemia/Lymphoma with TCF3::PBX1 Fusion | B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)","9818/3","B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)",,,,,,,,,,,,,"3654650|42872961","B lymphoblastic leukemia lymphoma with t(1;19)(Q23;P13.3); E2A-PBX1 (TCF3/PBX1)|B lymphoblastic leukemia lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"CL513816","Constitutional Mismatch Repair Deficiency Syndrome","C130202","A rare childhood cancer predisposition syndrome caused by biallelic inheritance of mutations in MLH1, MSH2, MSH6, or PMS2 genes. It is characterized by the development of childhood cancers, usually hematological malignancies and/or brain tumors, and colorectal cancers with multiple intestinal polyps. The majority of patients show signs of neurofibromatosis type 1.","Constitutional Mismatch Repair Deficiency Syndrome | BMMRD | Biallelic Mismatch Repair Deficiency | Biallelic Mismatch Repair Deficiency Syndrome | CMMR-D | CMMRD | Constitutional MMR Deficiency | Constitutional Mis-Match Repair Deficiency Syndrome | Constitutional Mismatch Repair Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413787","CTAG1B Gene","C39285","This gene plays a role in humoral and cellular immune responses.","CTAG1B Gene | CTAG1B | Cancer/Testis Antigen 1B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420307","SOD2 Gene","C39642","This gene is involved in the detoxification of superoxide radicals produced within mitochondria.","SOD2 Gene | SOD2 | Superoxide Dismutase 2, Mitochondrial Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420066","PMEL Gene","C41033","This gene plays a role in melanosome biogenesis. It is also involved in T-cell recognition.","PMEL Gene | PMEL | Premelanosome Protein Gene | SILV | SILV Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416671","KLK11 Gene","C43294","This gene is involved in protein degradation.","KLK11 Gene | KLK11 | Kallikrein 11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709071","Monosomy 3","C43305","A chromosomal abnormality consisting of the absence of a copy (homolog) of chromosome 3.","Monosomy 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413884","CYP3A7 Gene","C46077","This gene plays a role in the metabolism of drugs, xenobiotics, fatty acids and steroids. It is also involved in the synthesis of estriol during pregnancy.","CYP3A7 Gene | CYP3A7 | Cytochrome P450, Family 3, Subfamily A, Polypeptide 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421435","VCAM1 Gene","C48213","This gene is involved in the regulation of leukocyte-endothelial cell adhesion interactions.","VCAM1 Gene | VCAM1 | Vascular Cell Adhesion Molecule 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420306","SOD1 Gene","C54578","This gene plays a role in the detoxification of superoxide radicals in the cytosol.","SOD1 Gene | SOD1 | Superoxide Dismutase 1, Soluble (Amyotrophic Lateral Sclerosis 1 (Adult)) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413906","DAPK1 Gene","C60652","This gene is involved in pro-apoptotic regulation.","DAPK1 Gene | DAPK1 | Death-Associated Protein Kinase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424244","CARD11 Gene","C60668","This gene plays a role in apoptotic regulation.","CARD11 Gene | CARD11 | Caspase Recruitment Domain Family Member 11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007367","CAT protein, human","C61062","Catalase (527 aa, ~60 kDa) is encoded by the human CAT gene. This protein plays a role in the detoxification of hydrogen peroxide.","Catalase | CAT | CAT Protein | EC 1.11.1.6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416877","LMNA Gene","C61148","This gene is involved in the architecture of nuclear membrane construction.","LMNA Gene | LMNA | Lamin A/C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423526","IL23A Gene","C61150","This gene plays a role in transcriptional regulation and in the production of interferon-gamma.","IL23A Gene | IL23A | Interleukin 23, Alpha Subunit p19 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418946","PROM1 Gene","C64209","This gene plays a role in myogenesis.","PROM1 Gene | CD133 | PROM1 | Prominin 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413212","CD24 Gene","C68585","This gene is involved in the immune responsiveness of B-cells.","CD24 Gene | CD24 | CD24 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420464","AURKB Gene","C68592","This gene is involved in mitosis and meiosis.","AURKB Gene | AURKB | Aurora Kinase B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412361","ALOX5 Gene","C68726","This gene plays a role in inflammation.","ALOX5 Gene | ALOX5 | Arachidonate 5-Lipoxygenase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2304881","Merkel cell polyomavirus","C73535","Merkel cell polyomavirus is a polyomavirus that can infect humans.","Merkel Cell Polyomavirus | MCPyV | MCV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417335","MSI1 Gene","C74471","This gene is involved in the modulation of translation.","MSI1 Gene | MSI1 | Musashi RNA Binding Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413938","DCX Gene","C75320","This gene is involved in neuronal migration.","DCX Gene | DCX | Doublecortex; Lissencephaly, X-Linked (Doublecortin) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416525","JAG1 Gene","C75613","This gene may be involved in hematopoiesis.","JAG1 Gene | JAG1 | Jagged 1 (Alagille Syndrome) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1446659","MAPT Gene","C75635","This gene may be involved in the mediation of neuronal polarity.","MAPT Gene | MAPT | Microtubule-Associated Protein Tau Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413243","CD86 Gene","C78145","This gene plays a role in the modulation of T-cell proliferation and interleukin production.","CD86 Gene | CD86 | CD86 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416433","IDO1 Gene","C79778","This gene is involved in the metabolism of the amino acid tryptophan.","IDO1 Gene | IDO1 | INDO | INDO Gene | Indoleamine 2,3-Dioxygenase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416867","LIPC Gene","C82869","This gene is involved in lipid metabolism.","LIPC Gene | LIPC | Lipase, Hepatic Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3805232","Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase","C41233","Progression of polycythemia vera characterized by decreased erythropoiesis and granulopoiesis, reticulin and collagen fibrosis of the bone marrow, leucoerythroblastic reaction in the peripheral blood, poikilocytosis, tear-drop shaped red blood cells, and splenomegaly.","Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Polycythemia Vera, 'Spent' Phase | Polycythemia Vera, Post-Polycythemic Myelofibrosis and Myeloid Metaplasia Stage | Post-PV MF | Post-polycythemia Vera Myelofibrosis | Spent Phase and Post-Polycythemic Myelofibrosis",,,,,,,,,,,,,,,"3656046","Post-polycythemia vera myelofibrosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3805233","Post-Essential Thrombocythemia Myelofibrosis","C126806","Myelofibrosis that develops in a patient with history of essential thrombocythemia.","Post-Essential Thrombocythemia Myelofibrosis | Myelofibrosis Transformation in Essential Thrombocythemia | Myelofibrosis Transformation in Essential Thrombocythemia | Post Essential Thrombocythemia Myelofibrosis | Post-ET MF | Post-ET Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis | Post-Essential Thrombocytosis Myelofibrosis",,,,,,,,,,,,,,,"3656047","Post-essential thrombocythemia myelofibrosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1413241","CD83 Gene","C84311","This gene may play a role in antigen presentation.","CD83 Gene | CD83 | CD83 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413221","CD38 Gene","C84321","This gene is involved in both signal transduction and the metabolism of ADP-ribose.","CD38 Gene | CD38 | CD38 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420799","TNFAIP3 Gene","C84928","This gene may play a role in the regulation of apoptosis.","TNFAIP3 Gene | TNF Alpha Induced Protein 3 Gene | TNFAIP3 | Tumor Necrosis Factor, Alpha-Induced Protein 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422129","LAPTM4B Gene","C88215","This gene may play a role in transport processes.","LAPTM4B Gene | LAPTM4B | Lysosomal Protein Transmembrane 4 Beta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417808","NPPB Gene","C88520","This gene is involved in cardiac homeostasis.","NPPB Gene | NPPB | Natriuretic Peptide Precursor B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415138","GNA11 Gene","C89717","This gene is involved in signal transduction.","GNA11 Gene | G Protein Subunit Alpha 11 Gene | GNA11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420267","SNAI1 Gene","C91260","This gene plays a role in the regulation of both transcription and embryonic development.","SNAI1 Gene | SNAI1 | Snail Homolog 1 (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022818","Kynurenine","C129555","A ketone and an amino acid derivative that is synthesized by either tryptophan 2,3-dioxygenase (TDO)- or indoleamine 2,3-dioxygenase (IDO)-mediated oxidation of tryptophan with diverse biological functions, including vasodilatory, immunoregulatory and neuromodulatory activities. Kynurenine is a precursor for niacin. Additionally, kynurenine can be further metabolized into anthranilic acid, kynurenic acid, and 3-hydroxykynurenine; aberrant production of kynurenine is associated with neurological disease-related cognitive deficits and depressive symptoms. Overexpressed in certain cancer cell types, kynurenine could potentially be used as a biomarker to assess cancer risk.","Kynurenine | (2S)-2-Amino-4-(2-Aminophenyl)-4-Oxobutanoic Acid | (S)-Kynurenine | 3-Anthraniloyl-L-Alanine | KYN | KYNURENINE | Kynurenine, L- | L-Kynurenine",,,,,,,,,,,,,,,"45769050","Kynurenine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512801","MicroRNA 16","C129416","A 22 ribonucleotide sequence that is a final product of the processing of either MIR16-1 pre-miRNA or MIR16-2 pre-miRNA. This oligonucleotide may be involved in the negative regulation of gene expression.","MicroRNA 16 | MIR16 | MIRN16 | MiR-16 | MiRNA16 | hsa-miR-16 | hsa-miR-16-5p",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512561","Monoclonal Antibody CAM 5.2","C129417","A mouse monoclonal antibody that reacts with cytokeratin 8 and to a lesser extent with cytokeratin 7. Monoclonal antibody CAM 5.2 can be used in immunohistochemistry to determine the epithelial nature of tissue, tumors or components of tumors found in a sample.","Monoclonal Antibody CAM 5.2 | Anti-Cytokeratin (CAM 5.2) | Anti-Cytokeratin Monoclonal Antibody CAM 5.2 | CAM 5.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512735","KDR Intron 2 VNTR","C129418","A repetitive sequence found in intron 2 of the KDR gene.","KDR Intron 2 VNTR | KDR Intron 2VNTR | VEGFR2 Intron 2 VNTR | VEGFR2 Intron 2VNTR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512568","NOS3 Intron 4 VNTR","C129419","A repetitive sequence found in intron 4 of the NOS3 gene.","NOS3 Intron 4 VNTR | NOS3 Intron 4VNTR | eNOS Intron 4 VNTR | eNOS Intron 4VNTR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512795","Mismatch Repair Protein","C129420","A DNA repair protein family that is comprised of the active components of the DNA mismatch repair system.","Mismatch Repair Protein | DNA Mismatch Repair Protein | MMR Protein | Mut | Mut Family | Mut Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1156199","Histone Modification","C129422","Post-translational processing of amino acids within a histone protein.","Histone Modification | Post-Translational Histone Modification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512596","mRNA Sequencing","C129432","A procedure that can determine the RNA sequences for all or part of the poly-A tail-containing messenger RNA transcripts in an individual.","mRNA Sequencing | Messenger RNA Sequencing | Poly(A) RNA Sequencing | Poly-A RNA Sequencing | mRNA-Seq",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512607","Cancer-Testis Antigen Family 45 Gene","C129433","A family of genes that is comprised of nine protein coding genes and one pseudogene, which are nearly identical in sequence and are clustered in the vicinity of Xq26.3.","Cancer-Testis Antigen Family 45 Gene | CT45 | CT45A | Cancer/Testis Antigen 45 | Cancer/Testis Antigen Family 45",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0538135","Aldehyde Dehydrogenase 1","C129434","A polymorphic family of intracellular enzymes that catalyze the oxidation of aldehydes and yield carboxylic acids. High aldehyde dehydrogenase 1 activity may indicate the presence of stem cells or cancer stem cells (CSC) in a sample.","Aldehyde Dehydrogenase 1 Family | ALDH1 | ALDH1 Family | Aldehyde Dehydrogenase 1 | Aldehyde Dehydrogenase Class 1 | Aldehyde Dehydrogenase Family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512646","Microsomal Prostaglandin E Synthase Family","C129435","A family of membrane bound enzymes that catalyze the biosynthesis of prostaglandin E2 from prostaglandin H2.","Microsomal Prostaglandin E Synthase Family | Membrane-Associated PGE Synthase | Microsomal PGES Family | mPGES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002358","Alu Element","C129404","A family of short interspersed nuclear elements found in the human genome that are substrates for the Arthrobacter luteus restriction endonuclease. Alu elements are highly conserved within primate genomes and have been used in the investigation of human population genetics, primate and human evolution, and human diseases, including cancer.","Alu Element | Alu Repeat | Alu Sequence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2350236","Idiopathic Interstitial Pneumonia","C35714","Non-infectious inflammation of the interstitial lung tissue of unknown etiology. This category includes desquamative interstitial pneumonia, usual interstitial pneumonia, lymphocytic interstitial pneumonia, acute interstitial pneumonia, and nonspecific interstitial pneumonia.","Idiopathic Interstitial Pneumonia | IIP | Idiopathic Interstitial Pneumonitis",,,,,,,,,,,,,,,"45763749","Idiopathic interstitial pneumonia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019094","Tacaribe Complex Virus","C129405","A family of arenaviruses predominantly found in North and South America with family Muridae, subfamily Sigmodontinae as the most common reservoir. Several of these viruses are known to cause severe hemorrhagic disease in humans.","Tacaribe Complex Virus | New World Arenavirus Complex | TACV Complex | TCRV | Tacaribe Complex | Tacaribe Complex Arenavirus | Tacaribe Serocomplex Virus",,,,,,,,,,,,,,,"4246188","Tacaribe virus complex",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055183","Contrast - Induced Nephropathy","C123129","Kidney damage resulting from exposure to contrast agents.","Contrast - Induced Nephropathy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009766","Atopic Conjunctivitis","C34506","Acute allergic conjunctivitis.","Atopic Conjunctivitis | Allergic Conjunctivitis",,,,,,,,,,,,,,,"4335888","Atopic conjunctivitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0079185","Cyclin B","C129406","A protein family whose members form complexes with cyclin-dependent kinase 1 to form maturation promoting factor (mitosis promoting factor; MPF), which is essential for the progression through the G2/M and DNA damage cell cycle checkpoints.","Cyclin B | CCNB | Cyclin-B | G2/Mitotic-Specific Cyclin-B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0291672","CA27-29","C129408","An antigenic epitope that is a 20 amino acid sequence from the extracellular portion of the transmembrane protein mucin-1 (MUC1). Overexpression of MUC1 induces the shedding of its extracellular domain into the bloodstream. Increased MUC1 in the blood may be a marker for breast cancer.","CA27-29 | CA 27-29 | CA 27.29 | CA27.29 | Cancer Antigen 27-29 | Cancer Antigen 27.29",,,,,,,,,,,,,,,"4011779","Cancer antigen 27-29",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512605","Core Binding Factor Complex Mutation","C129409","Mutations in the genes that encode proteins found in the core binding factor (CBF) complex. These genes may be involved in chromosomal rearrangements that are associated with acute myeloid leukemia.","Core Binding Factor Complex Mutation | CBF Mutation | Core Binding Factor Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0760170","Plasmin-Antiplasmin Complex","C129410","A protein complex comprised of the serine proteinase plasmin irreversibly bound to its corresponding serine proteinase inhibitor protein (SERPIN) alpha-2-antiplasmin.","Plasmin-Antiplasmin Complex | PAP | Plasmin/Alpha-2-Antiplasmin Complex | Plasmin/Antiplasmin Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512693","Clostridium Cluster IV","C129412","A group of at least 8 bacterial species, four in the Clostridium genus and 4 that are classified outside the Clostridium genus. This cluster is based on comparative sequence analysis of their 16S ribosomal RNA gene sequences. These species are commensal in humans.","Clostridium Cluster IV | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512694","Clostridium Cluster XIV","C129413","A group comprised of more than 20 bacterial species, most are in the Clostridium genus but a few are outside the Clostridium genus. This cluster is based on comparative sequence analysis of their 16S ribosomal RNA gene sequences. Some of these species are commensal in humans.","Clostridium Cluster XIV | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2974762","MicroRNA 181b","C129415","A 23 ribonucleotide sequence that is a final product of the processing of either MIR181B1 pre-miRNA or MIR181B2 pre-miRNA. This oligonucleotide may be involved in the negative regulation of gene expression.","MicroRNA 181b | MIR181B | MIRN181b | MiR-181b | MiRNA181b | hsa-miR-181b | hsa-miR-181b-5p",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826998","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale Questionnaire","C106699","A standardized questionnaire developed by James F. Fries in 1983, which is originally used to measure outcome in patients with Rheumatoid Arthritis. It has also been applied to patients with HIV/AIDS and in studies of normal aging. The HAQ-DI With VAS is a generic instrument which focuses on self-reported, patient-oriented outcome measures. The questionnaire contains 8 categories of 46 items; dressing and grooming, arising, eating, walking, hygiene, reaching, grip, and activities. A 0-3 grade scale is used, where grade 0 represents category performed without any difficulty and grade 3 represents category performed with the greatest difficulty (unable to do).","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale Questionnaire | HAQ-DI WITH VAS | HAQ-DI With VAS | HAQ01 | Health Assessment Questionnaire Disability Index Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0341439","Chronic Liver Disease","C113609","Hepatic necrosis, inflammation, or scarring due to any cause that persists for more than 6 months. Manifestations may include signs and symptoms of cholestasis, portal hypertension, and/or abnormal liver function tests.","Chronic Liver Disease | Chronic liver disease | Chronic_Liver_Disease",,,,,,,,,,,,,,,"4212540","Chronic liver disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034348","Pyruvate Kinase","C129392","A family of enzymes that catalyzes the transfer of a phosphate group from phosphoenolpyruvate (PEP) to adenosine diphosphate (ADP), yielding one molecule of pyruvate and one molecule of adenosine triphosphate (ATP). This reaction is the final step of the glycolysis pathway.","Pyruvate Kinase | ATP:Pyruvate 2-O-Phosphotransferase | EC 2.7.1.40 | Fluorokinase | Fluorokinase (Phosphorylating) | PK | Phosphoenol Transphosphorylase | Phosphoenolpyruvate Kinase | Pyruvate Kinase (Phosphorylating) | Pyruvate Phosphotransferase | Pyruvic Kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001990","Aldolase","C129393","A family of enzymes that either create or cleave aldols (aldehyde alcohols).","Aldolase | Aldehyde-Lyase | EC 4.1.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881923","Multidimensional Fatigue Inventory","C54719","A 20-item self-report instrument designed to measure fatigue. It covers the following dimensions: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation and Reduced Activity.","Multidimensional Fatigue Inventory | MFI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021088","Inosine Monophosphate Dehydrogenase","C129395","A family of enzymes that converts inosine monophosphate to xanthosine monophosphate. This reaction is the rate limiting step in de novo guanosine triphosphate (GTP) synthesis.","Inosine Monophosphate Dehydrogenase | EC 1.1.1.205 | IMP Dehydrogenase | IMP Oxidoreductase | IMP:NAD+ Oxidoreductase | IMPDH | Inosinate Dehydrogenase | Inosine 5'-Monophosphate Dehydrogenase | Inosine Monophosphate Oxidoreductase | Inosine-5'-Phosphate Dehydrogenase | Inosinic Acid Dehydrogenase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0101589","Adenovirus E4 Protein","C129397","A group of proteins encoded by the adenovirus early transcription locus 4 (E4). These proteins are required for viral replication.","Adenovirus E4 Protein | E4 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512555","Human Anti-Chimeric Antibody","C129399","An autoantibody that recognizes engineered antibodies that contain human and non-human domains.","Human Anti-Chimeric Antibody | HACA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0103647","Antineutrophil Cytoplasmic Antibody","C129400","An autoantibody that recognizes antigens found in the cytoplasm of neutrophils.","Antineutrophil Cytoplasmic Antibody | ANCA | Anti-Neutrophil Cytoplasmic Antibody",,,,,,,,,,,,,,,"4049401","Anti neutrophilic cytoplasm antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512603","BTA Stat","C129402","An immunoassay that detects bladder cancer antigen, which is comprised of various members of the complement factor H-related protein (CFHrp) family, in urine.","BTA Stat | Bladder Tumor Antigen Stat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512567","NMP22 Assay","C129403","An immunoassay that detects the head domain of nuclear mitotic apparatus protein 1 (NuMA) in urine.","NMP22 Assay | NMP-22 Assay | Nuclear Matrix Protein 22 Assay | Nuclear Matrix Protein-22 Assay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417245","MPO Gene","C91742","This gene is involved in the modulation of neutrophil microbicidal activity.","MPO Gene | MPO | Myeloperoxidase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425143","BBC3 Gene","C91772","This gene plays a role in the regulation of apoptosis.","BBC3 Gene | BBC3 | BCL2 Binding Component 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422009","TP63 Gene","C91791","This gene plays a role in both transcriptional regulation and limb development.","TP63 Gene | TP63 | Tumor Protein p63 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825278","FANCI Gene","C92474","This gene plays a role in the mediation of DNA repair.","FANCI Gene | FA Complementation Group I Gene | FANCI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985398","Intestinal Microbiome","C93019","The collection of microorganisms existing in the intestines of an organism.","Intestinal Flora | Gut Flora | Gut Microbiome | Gut Microbiota | Gut Microflora | Intestinal Microbiome | Intestinal Microbiota | Intestinal Microflora | gut flora | gut microflora | intestinal flora | intestinal microflora | microflora",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419235","RAD21 Gene","C93082","This gene is involved in chromosomal cohesion, DNA repair and apoptosis.","RAD21 Gene | RAD21 | RAD21 Cohesin Complex Component Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412409","ANPEP Gene","C94622","This gene plays a role in peptide hydrolysis.","ANPEP Gene | ANPEP | Alanyl (Membrane) Aminopeptidase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412785","BECN1 Gene","C94669","This gene is involved in apoptosis regulation.","BECN1 Gene | BECN1 | Beclin 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420812","TNFRSF4 Gene","C95045","This gene plays a role in inflammatory responses, intracellular signaling and apoptosis regulation.","TNFRSF4 Gene | TNFRSF4 | Tumor Necrosis Factor Receptor Superfamily, Member 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419986","SFRP1 Gene","C95300","This gene is involved in signaling.","SFRP1 Gene | SFRP1 | Secreted Frizzled-Related Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419071","PTGIS Gene","C96438","This gene plays a role in prostaglandin catabolism.","PTGIS Gene | PTGIS | Prostaglandin I2 (Prostacyclin) Synthase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416745","KRT7 Gene","C96444","This gene plays a role in DNA replication.","KRT7 Gene | KRT7 | Keratin 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416713","KRT1 Gene","C96454","This gene is involved in skin development.","KRT1 Gene | KRT1 | Keratin 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416496","ITGB1 Gene","C96906","This gene plays a role in both cell adhesion and ligand-mediated signaling.","ITGB1 Gene | ITGB1 | Integrin, Beta 1 (Fibronectin Receptor, Beta Polypeptide, Antigen CD29 Includes MDF2, MSK12) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1439292","CD33 Gene","C97244","This gene is involved in both cell adhesion and cell-cell signaling.","CD33 Gene | CD33 | CD33 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274879","London Deauville Criteria Point Scale","C99723","A 5 point scale devised to assess the response to treatment of Hodgkin and Aggressive Non-Hodgkin Lymphoma.","London Deauville Criteria Point Scale | DEAUVILLE_SCORE | FDG PET Lymphoma 5PS Score | FDPL5PS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422572","MRTFA Gene","C97296","This gene is involved in transcriptional modulation and muscle cell differentiation.","MRTFA Gene | MKL1 | MKL1 Gene | MKL1 Gene | MRTFA | Myocardin Related Transcription Factor A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0173532","cyclin D3","C97383","G1/S-specific cyclin-D3 (292 aa, ~33 kDa) is encoded by the human CCND3 gene. This protein is involved in the progression of the cell cycle.","G1/S-Specific Cyclin-D3 | CCND3 | Cyclin D3 | Cyclin-D3 | G1/S-Specific Cyclin D3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418887","PRF1 Gene","C97739","This gene is involved in cytolysis.","PRF1 Gene | PRF1 | Perforin 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273605","Disseminated Tumor Cell","C97750","Metastatic tumor cells found singly or in small clusters in the tissues.","Disseminated Tumor Cell | DTC | Disseminated Malignant Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426208","SOCS1 Gene","C97794","This gene is involved in the attenuation of cytokine signaling.","SOCS1 Gene | SOCS1 | Suppressor of Cytokine Signaling 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420434","SSX1 Gene","C97806","This gene may be involved in the regulation of transcription.","SSX1 Gene | SSX Family Member 1 Gene | SSX1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420435","SSX2 Gene","C97809","This gene may play a role in transcriptional regulation.","SSX2 Gene | SSX Family Member 2 Gene | SSX2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420437","SSX4 Gene","C97814","This gene may be involved in transcriptional modulation.","SSX4 Gene | SSX Family Member 4 Gene | SSX4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419790","S100B Gene","C98127","This gene is involved in metal-ion binding.","S100B Gene | S100 Calcium Binding Protein B Gene | S100B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273996","v-raf Murine Sarcoma Viral Oncogene Homolog B1 c.1798_1799GT>AA","C98348","A complex substitution where the nucleotide sequence at positions 1798 and 1799 of the coding sequence of the BRAF gene has changed from guanine-thymine to adenine-adenine.","BRAF NM_004333.4:c.1798_1799delinsAA | B-RAF1 c.1798_1799GT>AA | BRAF NM_004333.4:c.1798_1799delGTinsAA | BRAF NM_004333.4:c.1798_1799delGTinsAA | BRAF V600K (c.1798_1799GT>AA) mutation | BRAF c.1798_1799GT>AA | BRAF c.1798_1799delGTinsAA | NM_004333.4:c.1798_1799GT>AA | NM_004333.4:c.1798_1799delGTinsAA | NM_004333.4:c.1798_1799delinsAA | v-raf Murine Sarcoma Viral Oncogene Homolog B1 c.1798_1799GT>AA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274193","EGFR NM_005228.3:c.2369C>T","C98504","A nucleotide substitution at position 2369 of the coding sequence of the EGFR gene where cytosine has been mutated to thymine.","EGFR NM_005228.3:c.2369C>T | EGFR c.2369C>T | ERBB c.2369C>T | ERBB1 c.2369C>T | Epidermal Growth Factor Receptor Gene c.2369C>T | HER1 c.2369C>T | NM_005228.3:c.2369C>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709412","PML/RARA Fusion Protein","C53622","A fusion protein (797 aa, ~106 kDa) that is encoded by the human PML/RARA fusion gene. This protein contains the B-box and the RING-finger domain from protein PML and the DNA-binding domain, ligand binding domain and coactivator recognition site from the retinoic acid receptor alpha protein.","PML/RARA Fusion Protein | Inducer of Acute Promyelocytic Leukemia | PML-RAR Alpha Fusion Protein | PML-RAR Protein | PML-RARA Fusion Protein | PML-RARalpha Fusion Protein | PML::RARA Fusion Protein | Protein PML/Retinoic Acid Receptor Alpha Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029006","BCR/ABL1 Fusion Protein p190","C99308","A fusion protein encoded by the BCR/ABL1 fusion gene. This protein is comprised of the first 427 amino acids from the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein.","BCR/ABL1 Fusion Protein p190 | BCR-ABL1 Fusion Protein p190 | BCR/ABL Fusion Protein p190 | BCR::ABL1 Fusion Protein p190 | Breakpoint Cluster Region/Tyrosine-Protein Kinase ABL1 Fusion Protein p190",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029008","BCR/ABL1 Fusion Protein p210","C99309","A fusion protein encoded by the BCR/ABL1 fusion gene. This protein is comprised of the first 902 or 927 amino acids from the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein.","BCR/ABL1 Fusion Protein p210 | BCR-ABL1 Fusion Protein p210 | BCR/ABL Fusion Protein p210 | BCR::ABL1 Fusion Protein p210 | Breakpoint Cluster Region/Tyrosine-Protein Kinase ABL1 Fusion Protein p210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514223","Bathtub Bar Usually Used","C130968","A response indicating that an individual usually uses a bathtub bar.","Bathtub Bar Usually Used | Bathtub bar",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514024","Bathtub Seat Usually Used","C130967","A response indicating that an individual usually uses a bathtub seat.","Bathtub Seat Usually Used | Bathtub seat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514216","Cane Usually Used","C130962","A response indicating that an individual usually uses a cane.","Cane Usually Used | Cane",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513448","Crutches Usually Used","C130964","A response indicating that an individual usually uses crutches.","Crutches Usually Used | Crutches",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513455","Device for Dressing Usually Used","C130959","A response indicating that an individual usually uses an aid or device for dressing, such as a button hook or zipper pull.","Device for Dressing Usually Used | Devices used for Dressing (button hook, zipper pull, etc.)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4035768","Jar Opener Usually Used","C130971","A response indicating that an individual usually uses a jar opener for jars that were previously opened.","Jar Opener Usually Used | Jar opener (for jars previously opened)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514224","Long-handled Appliances for Reach Usually Used","C130970","A response indicating that an individual usually uses a long-handled appliance for reach.","Long-handled Appliances for Reach Usually Used | Long-handled appliances for reach",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514225","Long-handled Appliances in Bathroom Usually Used","C130969","A response indicating that an individual usually uses a long-handled appliance in the bathroom.","Long-handled Appliances in Bathroom Usually Used | Long-handled appliances in bathroom",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514221","Raised Toilet Seat Usually Used","C130966","A response indicating that an individual usually uses a raised toilet seat.","Raised Toilet Seat Usually Used | Raised toilet seat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513998","Special or Built Up Chair Usually Used","C130960","A response indicating that an individual usually uses a special or built up chair.","Special or Built Up Chair Usually Used | Special or built up chair",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513999","Special or Built Up Utensils Usually Used","C130961","A response indicating that an individual usually uses special or built up utensils.","Special or Built Up Utensils Usually Used | Built up or special utensils",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513384","Truth Agreement Scale","C130953","A subjective scale for the scoring of truth agreement that ranges from 1: yes, that is true to 5: no, that is not true.","Truth Agreement Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513385","Truth Agreement Score 1","C130954","A subjective score of 1 on a scale that ranges from 1: yes, that is true to 5: no, that is not true.","Truth Agreement Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513386","Truth Agreement Score 2","C130955","A subjective score of 2 on a scale that ranges from 1: yes, that is true to 5: no, that is not true.","Truth Agreement Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513387","Truth Agreement Score 3","C130956","A subjective score of 3 on a scale that ranges from 1: yes, that is true to 5: no, that is not true.","Truth Agreement Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513388","Truth Agreement Score 4","C130957","A subjective score of 4 on a scale that ranges from 1: yes, that is true to 5: no, that is not true.","Truth Agreement Score 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513389","Truth Agreement Score 5","C130958","A subjective score of 5 on a scale that ranges from 1: yes, that is true to 5: no, that is not true.","Truth Agreement Score 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514209","Usually Need Help from Another Person for Arising","C130974","A response indicating that an individual needs help from another person for getting up.","Usually Need Help from Another Person for Arising | Arising | Getting Up | Usually Need Help from Another Person for Getting Up",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514219","Usually Need Help from Another Person for Dressing and Grooming","C130972","A response indicating that an individual needs help from another person for dressing and grooming.","Usually Need Help from Another Person for Dressing and Grooming | Dressing and grooming",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514083","Usually Need Help from Another Person for Eating","C130973","A response indicating that an individual needs help from another person for eating.","Usually Need Help from Another Person for Eating | Eating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514220","Usually Need Help from Another Person for Errands and Chores","C130979","A response indicating that an individual needs help from another person for errands and chores.","Usually Need Help from Another Person for Errands and Chores | Errands and chores",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4035764","Usually Need Help from Another Person for Gripping and Opening Things","C130978","A response indicating that an individual needs help from another person for gripping and opening things.","Usually Need Help from Another Person for Gripping and Opening Things | Gripping and opening things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514210","Usually Need Help from Another Person for Hygiene","C130976","A response indicating that an individual needs help from another person for hygiene.","Usually Need Help from Another Person for Hygiene | Hygiene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514208","Usually Need Help from Another Person for Reach","C130977","A response indicating that an individual needs help from another person for reach.","Usually Need Help from Another Person for Reach | Reach",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600108","Usually Need Help from Another Person for Walking","C130975","A response indicating that an individual needs help from another person for walking.","Usually Need Help from Another Person for Walking | Walking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514218","Walker Usually Used","C130963","A response indicating that an individual usually uses a walker.","Walker Usually Used | Walker",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514222","Wheelchair Usually Used","C130965","A response indicating that an individual usually uses a wheelchair.","Wheelchair Usually Used | Wheelchair",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1504772","MLL/AFF1 Fusion Protein, Human","C99320","A fusion protein (~2250 aa, ~240 kDa) encoded by the MLL/AFF1 fusion gene. This protein is comprised of the N-terminal half of the histone-lysine N-methyltransferase MLL protein, including the AT hook DNA binding domain and the DNA methyltransferase domain, fused to the C-terminal half of the AF4/FMR2 family member 1 protein.","MLL/AFF1 Fusion Protein | Histone-Lysine N-Methyltransferase MLL/AF4/FMR2 Family Member 1 Fusion Protein | KMT2A-AFF1 Fusion Protein | KMT2A::AFF1 Fusion Protein | MLL-AF4 Fusion Protein | MLL-AFF1 Fusion Protein | MLL-MLLT2 Fusion Protein | MLL/AF4 Fusion Protein | MLL/MLLT2 Fusion Protein | MLL::AFF1 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2674774","MLL/AFF1 Fusion Gene","C99319","A fusion gene (~12 kb) that results from a chromosomal translocation t(4;11)(q21;q23) which fuses the 5' half of the MLL gene to the 3' half of the AFF1 gene. This rearrangement is associated with acute lymphocytic leukemia and other leukemia types.","MLL/AFF1 Fusion Gene | KMT2A-AFF1 Fusion Gene | KMT2A/AFF1 Fusion Gene | KMT2A::AFF1 Fusion Gene | MLL-AF4 Fusion Gene | MLL-AFF1 Fusion Gene | MLL-MLLT2 Fusion Gene | MLL/AF4 Fusion Gene | MLL/MLLT2 Fusion Gene | MLL::AFF1 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1258809","MLL/MLLT3 Fusion Protein, Human","C99324","A fusion protein encoded by the MLL/MLLT3 fusion gene. This protein is comprised of the N-terminal half of the histone-lysine N-methyltransferase MLL protein, including the AT hook DNA binding domain and the DNA methyltransferase domain, fused to the C-terminal domain of the protein AF9.","MLL/MLLT3 Fusion Protein | Histone-Lysine N-Methyltransferase MLL/Protein AF9 Fusion Protein | KMT2A-MLLT3 Fusion Protein | KMT2A/MLLT3 Fusion Protein | KMT2A::MLLT3 Fusion Protein | MLL-AF9 Fusion Protein | MLL-MLLT3 Fusion Protein | MLL/AF9 Fusion Protein | MLL::MLLT3 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274681","MLL/MLLT3 Fusion Gene","C99323","A fusion gene that results from a chromosomal translocation t(9;11)(p22;q23) which fuses the 5' half of the KMT2A gene to the 3' end of the MLLT3 gene. This rearrangement is associated with acute lymphocytic leukemia and other leukemia types.","KMT2A/MLLT3 Fusion Gene | KMT2A::MLLT3 Fusion Gene | MLL-AF9 Fusion Gene | MLL-MLLT3 Fusion Gene | MLL/AF9 Fusion Gene | MLL/MLLT3 Fusion Gene | MLL/MLLT3 Fusion Gene | MLL::MLLT3 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1173651","MLL/MLLT10 Fusion Protein, Human","C99348","A fusion protein encoded by the MLL/MLLT10 fusion gene. This protein is comprised of the N-terminal half of the histone-lysine N-methyltransferase MLL protein, including the AT hook DNA binding domain and the DNA methyltransferase domain, fused to the C-terminal leucine zipper domain of protein AF-10.","MLL/MLLT10 Fusion Protein | Histone-Lysine N-Methyltransferase MLL/Protein AF-10 Fusion Protein | KMT2A::MLLT10 Fusion Protein | MLL-AF10 Fusion Protein | MLL-MLLT10 Fusion Protein | MLL/AF-10 Fusion Protein | MLL/AF10 Fusion Protein | MLL/Protein AF-10 Fusion Protein | MLL::MLLT10 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1865579","MLL/MLLT10 Fusion Gene","C99347","A fusion gene that results from a chromosomal translocation t(10;11)(p12;q23) which fuses the 5' half of the MLL gene to the 3' half of the MLLT10 gene. This rearrangement is associated with acute myeloid leukemia.","MLL/MLLT10 Fusion Gene | AF10/MLL Fusion Gene | KMT2A::MLLT10 Fusion Gene | MLL-AF10 Fusion Gene | MLL-MLLT10 Fusion Gene | MLL/AF10 Fusion Gene | MLL::MLLT10 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1120441","MLL/MLLT4 Fusion Protein, Human","C99352","A fusion protein encoded by the MLL/MLLT4 fusion gene. This protein is comprised of the N-terminal half of the histone-lysine N-methyltransferase MLL protein, including the AT hook DNA binding domain and the DNA methyltransferase domain, fused to most of the afadin protein.","MLL/MLLT4 Fusion Protein | Histone-Lysine N-Methyltransferase 2A/Afadin Fusion Protein | Histone-Lysine N-Methyltransferase MLL/Afadin Fusion Protein | Histone-Lysine N-Methyltransferase MLL/Protein AF-6 Fusion Protein | KMT2A-AFDN Fusion Protein | KMT2A/AFDN Fusion Protein | KMT2A::AFDN Fusion Protein | MLL-AF6 Fusion Protein | MLL-MLLT4 Fusion Protein | MLL/AF6 Fusion Protein | MLL::MLLT4 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1834588","MLL/MLLT4 Fusion Gene","C99351","A fusion gene that results from a chromosomal translocation t(6;11)(q27;q23) which fuses the 5' half of the MLL gene to most of the MLLT4 gene. This rearrangement is associated with acute myeloid leukemia.","MLL/MLLT4 Fusion Gene | AF6/MLL Fusion Gene | KMT2A-AFDN Fusion Gene | KMT2A/AFDN Fusion Gene | KMT2A::AFDN Fusion Gene | MLL-AF6 Fusion Gene | MLL-MLLT4 Fusion Gene | MLL/AF6 Fusion Gene | MLL::MLLT4 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274701","PAX8/PPARG Fusion Protein","C99366","A fusion protein encoded by the PAX8/PPARG fusion gene. This protein is comprised of the N-terminal DNA binding domain of paired box protein Pax-8 and the entire peroxisome proliferator-activated receptor gamma protein, including the ligand binding, DNA binding and activation domains.","PAX8/PPARG Fusion Protein | PAX8-PPARG Fusion Protein | PAX8/PPARgamma1 Fusion Protein | PAX8::PPARG Fusion Protein | Paired Box Protein Pax-8/Peroxisome Proliferator-Activated Receptor Gamma Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2605829","RBM15/MKL1 Fusion Protein, Human","C99702","A fusion protein that is encoded by the RBM15/MKL1 fusion gene. This protein consists of most of the RNA-binding protein 15, including the RNA recognition motifs and the SPOC domain, fused to most of the MKL/myocardin-like protein 1, including the scaffold attachment factor box.","RBM15/MKL1 Fusion Protein | OTT-MAL Fusion Protein | OTT/MAL Fusion Protein | RBM15-MKL1 Fusion Protein | RBM15-MRTFA Fusion Protein | RBM15/MRTFA Fusion Protein | RBM15::MKL1 Fusion Protein | RBM15::MRTFA Fusion Protein | RNA-Binding Protein 15/MKL/Myocardin-Like Protein 1 Fusion Protein | RNA-Binding Protein 15::MKL/Myocardin-Like Protein 1 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274877","GOPC/ROS1 Fusion Protein","C99720","A fusion protein (878, ~109 kDa) encoded by the GOPC/ROS1 fusion gene. This protein is comprised of most of the Golgi-associated PDZ and coiled-coil motif-containing protein, including the coiled-coil and PDZ domains, fused to almost the entire C-terminal cytoplasmic domain of the proto-oncogene tyrosine-protein kinase ROS protein, including the protein kinase domain.","GOPC/ROS1 Fusion Protein | GOPC-ROS1 Fusion Protein | GOPC::ROS1 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1847375","GOPC/ROS1 Fusion Gene","C99719","A fusion gene (~4.1 kb) that results from an interstitial deletion of 240 kb on 6q21 which fuses the first 7 exons of the GOPC gene to the last 9 exons of the ROS1 gene. This fusion is associated with glioblastoma multiforme.","GOPC/ROS1 Fusion Gene | FIG-ROS1 Fusion Gene | FIG/ROS1 Fusion Gene | FIG1-ROS1 Fusion Gene | FIG1/ROS1 Fusion Gene | GOPC-ROS1 Fusion Gene | GOPC::ROS1 Fusion Gene | ROS1/FIG Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2002015","EML4/ALK Fusion Protein, Human","C99733","A fusion protein encoded by the EML4/ALK fusion gene. This protein is comprised of the N-terminal portion of the echinoderm microtubule-associated protein-like 4 fused to the C-terminus of the ALK tyrosine kinase receptor protein including the entire cytoplasmic portion with the tyrosine kinase domain.","EML4/ALK Fusion Protein | EML4-ALK Fusion Protein | EML4::ALK Fusion Protein | Echinoderm Microtubule-Associated Protein-Like 4/ALK Tyrosine Kinase Receptor Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274998","KIAA1549/BRAF Fusion Protein","C99844","A fusion protein encoded by the KIAA1549/BRAF fusion gene. This protein is comprised of half of the N-terminus of the putative UPF0606 protein KIAA1549 fused to the C-terminal half of the serine/threonine-protein kinase B-raf protein.","KIAA1549/BRAF Fusion Protein | KIAA1549-BRAF Fusion Protein | KIAA1549::BRAF Fusion Protein | Putative UPF0606 Protein KIAA1549/Serine/Threonine-Protein Kinase B-Raf Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3275000","NCOA4/RET Fusion Protein","C99848","A fusion protein encoded by the NCOA4/RET fusion gene. This protein is comprised of approximately 240 N-terminal amino acids of the nuclear receptor coactivator 4 protein, fused with most of the C-terminal cytoplasmic domain of the proto-oncogene tyrosine-protein kinase receptor Ret protein, including the tyrosine kinase domain.","NCOA4/RET Fusion Protein | ELE1-RET Fusion Protein | ELE1/RET Fusion Protein | NCOA4-RET Fusion Protein | NCOA4::RET Fusion Protein | Nuclear Receptor Coactivator 4/Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret Fusion Protein | PTC3 Chimeric Oncoprotein | RET/NCOA4 Oncoprotein | RFG-RET Fusion Protein | RFG/RET Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1865984","NCOA4/RET Fusion Gene","C99847","A fusion gene that results from a paracentric inversion inv(10)(q11q11) which fuses the 5' portion of the NCOA4 gene and the 3' portion of the RET gene. This rearrangement is associated with papillary thyroid carcinoma.","NCOA4/RET Fusion Gene | ELE1-RET Fusion Gene | ELE1/RET Fusion Gene | NCOA4-RET Fusion Gene | NCOA4::RET Fusion Gene | PTC3 Chimeric Oncogene | PTC3/4 | RET/NCOA4 Oncogene | RET/PTC3 | RFG-RET Fusion Gene | RFG/RET Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512722","TNFd3 Repeat","C129377","One of 6 forms of the TNFd microsatellite repeat, which consists of three regions containing the repetitive dinucleotide sequence, (GA)n, each separated by a single diguanine repeat and is located 15 kb downstream of the TNF gene in intron 3 of the LST1 gene. TNFd3 three repeat regions contain 13 GA repeats, 9 GA repeats and 3 GA repeats, respectively. The TNFd3 polymorphism may influence tumor necrosis factor protein expression and may be associated with increased susceptibility to either inflammatory diseases or post-transplant complications.","TNFd3 Repeat | TNFd3 Allele | TNFd3 Haplotype | TNFd3 Microsatellite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512595","hTM5 Allele","C129378","Human hTM5 allele is a variant form of the human TPM3 gene located 1q21.2 and is approximately 39 kb in length. This allele, which encodes tropomyosin alpha-3 chain low isoform 2, is involved in maintenance of the cytoskeleton.","hTM5 Allele | TM-5 | TM30 | TM30nm | TM5 | TPM3 hTM5 Allele | Tropomyosin 3 hTM5 Allele | hTM5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512655","TC22 Allele","C129380","Human TC22 allele is a variant form of the human TPM3 gene located 1q21.2 and is approximately 39 kb in length. This allele, which encodes tropomyosin alpha-3 chain isoform 3, may be involved in carcinogenesis in the colon.","TC22 Allele | TC22 | TPM3 TC22 Allele | Tropomyosin 3 TC22 Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0151849","Elevated Urine Alkaline Phosphatase","C122821","An elevated concentration of alkaline phosphatase in the urine.","Elevated Urine Alkaline Phosphatase | Elevated Alkaline Phosphatase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513358","Surface Mail","C130980","Mail that is transported by land or sea, rather than by air.","Surface Mail | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513509","Have Very Mild Bloating","C130981","A response indicating that when an individual has or had bloating, it was very mild.","Have Very Mild Bloating | Very Mild Bloating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513778","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.E255V","C131015","A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.764A>T mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the glutamic acid at position 255 of the ABL1 protein has been replaced by valine.","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.E255V | BCR-ABL E255V Mutation | BCR-ABL Glu255Val Mutation | BCR-ABL1 E255V Mutation | BCR-ABL1 Glu255Val Mutation | BCR/ABL E255V Mutation | BCR/ABL Fusion Protein with E255V | BCR/ABL Fusion Protein with Glu255Val | BCR/ABL Glu255Val Mutation | BCR/ABL1 E255V Mutation | BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Glu255Val | BCR/ABL1 Fusion Protein with NP_005148.2:p.E255V | BCR/ABL1 Fusion Protein with NP_005148.2:p.Glu255Val | BCR/ABL1 Glu255Val Mutation | BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.E255V | E255V",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513776","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.D276G","C131016","A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.827A>G mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the aspartic acid at position 276 of the ABL1 protein has been replaced by glycine.","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.D276G | BCR-ABL Asp276Gly Mutation | BCR-ABL D276G Mutation | BCR-ABL1 Asp276Gly Mutation | BCR-ABL1 D276G Mutation | BCR/ABL Asp276Gly Mutation | BCR/ABL D276G Mutation | BCR/ABL Fusion Protein with Asp276Gly | BCR/ABL Fusion Protein with D276G | BCR/ABL1 Asp276Gly Mutation | BCR/ABL1 D276G Mutation | BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Asp276Gly | BCR/ABL1 Fusion Protein with NP_005148.2:p.Asp276Gly | BCR/ABL1 Fusion Protein with NP_005148.2:p.D276G | BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.D276G | D276G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513779","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.E279K","C131017","A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.835G>A mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the glutamic acid at position 279 of the ABL1 protein has been replaced by lysine.","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.E279K | BCR-ABL E279K Mutation | BCR-ABL Glu279Lys Mutation | BCR-ABL1 E279K Mutation | BCR-ABL1 Glu279Lys Mutation | BCR/ABL E279K Mutation | BCR/ABL Fusion Protein with E279K | BCR/ABL Fusion Protein with Glu279Lys | BCR/ABL Glu279Lys Mutation | BCR/ABL1 E279K Mutation | BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Glu279Lys | BCR/ABL1 Fusion Protein with NP_005148.2:p.E279K | BCR/ABL1 Fusion Protein with NP_005148.2:p.Glu279Lys | BCR/ABL1 Glu279Lys Mutation | BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.E279K | E279K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513775","BCR/ABL1 Fusion Protein Negative","C131067","Indicates that expression of the BCR/ABL1 fusion protein has not been detected in a sample.","BCR/ABL1 Fusion Protein Negative | BCR ABL Fusion Protein Negative | BCR-ABL1 Fusion Protein Negative | BCR-ABL1 Protein Negative | BCR/ABL Chimeric Protein Negative | BCR/ABL Fusion Protein Negative | BCR/ABL Oncoprotein Negative | BCR/ABL1 Protein Negative | Breakpoint Cluster Region/Tyrosine-Protein Kinase ABL1 Fusion Protein Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511578","CCND1 Protein Overexpression","C36485","A molecular abnormality indicating the presence of an abnormally high level of the G1/S-specific cyclin-D1 protein.","CCND1 Protein Overexpression | B-Cell Lymphoma 1 Protein Overexpression | BCL-1 Protein Overexpression | BCL1 Protein Overexpression | CCND1 Protein Overexpression | Cyclin D1 Overexpression | Cyclin D1 Protein Overexpression | Cyclin D1 Protein Overexpression | Cyclin-D1 Protein Overexpression | G1/S-Specific Cyclin-D1 Protein Overexpression | PRAD1 Protein Overexpression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513402","CD22 Positive","C131066","Indicates that CD22 expression has been detected in a sample.","CD22 Positive | B-Cell Antigen CD22 Positive | B-Cell Receptor CD22 Positive | B-Lymphocyte Cell Adhesion Molecule Positive | BL-CAM Positive | CD22 Antigen Positive | CD22 Molecule Positive | SIGLEC-2 Positive | SIGLEC2 Positive | Sialic Acid-Binding Ig-Like Lectin 2 Positive | Sialic Acid-Binding Immunoglobulin-Like Lectin 2 Positive | T-Cell Surface Antigen Leu-14 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514213","CD5 Positive","C131063","Indicates that CD5 expression has been detected in a sample.","CD5 Positive | CD5 Antigen Positive | CD5 Molecule Positive | LEU1 Positive | Lymphocyte Antigen CD5 Positive | Lymphocyte Antigen T1/Leu-1 Positive | T-Cell Surface Glycoprotein CD5 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514043","EPHA2 Protein Overexpression","C131065","A molecular abnormality indicating the presence of an abnormally high level of the ephrin type-A receptor 2 protein.","EPHA2 Protein Overexpression | EPH Receptor A2 Protein Overexpression | EphA2 Overexpression | Ephrin Type-A Receptor 2 Protein Overexpression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513170","MET Positive","C131068","Indicates that MET expression has been detected in a sample.","MET Positive | HGFR Positive | Hepatocyte Growth Factor Receptor Positive | MET Proto-Oncogene, Receptor Tyrosine Kinase Positive | Met Proto-Oncogene Positive | c-met Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513172","MYC Positive","C131061","Indicates that MYC expression has been detected in a sample.","MYC Positive | MYC Expression | Myc Proto-Oncogene Positive | Proto-Oncogene c-Myc Positive | c-MYC Positive | v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513173","MYCN Positive","C131062","Indicates that MYCN expression has been detected in a sample.","MYCN Positive | N-Myc Positive | N-Myc Proto-Oncogene Positive | NMYC Positive | Neuroblastoma MYC Positive | v-myc Avian Myelocytomatosis Viral Oncogene Neuroblastoma Derived Homolog Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513487","NTRK1 Fusion Positive","C131070","Indicates that the expression of a NTRK1 fusion has been detected in a sample.","NTRK1 Fusion Positive | High Affinity Nerve Growth Factor Receptor Fusion Positive | NTRK1 Fusion | NTRK1 fusion | Neurotrophic Receptor Tyrosine Kinase 1 Fusion Positive | TRK1 Fusion Positive | TRKA Fusion Positive | Trk-A Fusion Positive | Tropomyosin-Related Kinase A Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513357","RET Fusion Positive","C131069","Indicates that the expression of a RET fusion has been detected in a sample.","RET Fusion Positive | Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret Fusion Positive | Proto-Oncogene c-Ret Fusion Positive | RET Fusion | RET/PTC Fusion Positive | Ret Proto-Oncogene Fusion Positive | Tyrosine-Protein Kinase Receptor RET Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514069","ROS1 Fusion Positive","C131071","Indicates that the expression of a ROS1 fusion has been detected in a sample.","ROS1 Fusion Positive | MCF3 Fusion Positive | Proto-Oncogene Tyrosine-Protein Kinase ROS Fusion Positive | Proto-Oncogene c-Ros Fusion Positive | Proto-Oncogene c-Ros-1 Fusion Positive | ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Fusion Positive | ROS1 Fusion | Receptor Tyrosine Kinase c-Ros Oncogene 1 Fusion Positive | c-Ros-1 Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514196","t(11;14) Negative","C131064","A cytogenetic finding indicating that the translocation t(11;14) has not been detected in a sample.","t(11;14) Negative | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596764","Impression","C131082","An effect produced upon the mind or senses as a consequence of experience.","Impression | IMPRESSION | Imp | Mental Impression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162449","Phosphofructokinases","C129388","A family of enzymes that synthesize fructose bisphosphate by phosphorylating fructose 6-phosphate during glycolysis.","Phosphofructokinase | PFK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002318","Alpha Tubulin","C129386","A family of globular proteins that form dimers with beta tubulins. The alpha-beta tubulin dimers polymerize in a guanosine triphosphate (GTP)-dependent fashion to form microtubules.","Alpha Tubulin | Alpha-Tubulin | TUBA | Tubulin Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0597721","Janus kinase","C129387","A family of intracellular, non-receptor tyrosine-protein kinases. These enzymes transduce signals from certain cytokine receptors by phosphorylating and activating members of the Signal Transducer and Activator of Transcription (STAT) family of transcription factor proteins.","Janus Kinase Family | JAK | JAK Family | Janus Kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031653","Phosphoglucomutase","C129389","A family of enzymes that catalyzes the interconversion of glucose 1-phosphate and glucose 6-phosphate.","Phosphoglucomutase | Alpha-D-Glucose 1,6-Phosphomutase | EC 5.4.2.2 | Glucose Phosphomutase | PGM | Phosphoglucose Mutase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031656","Phosphoglycerate Kinase","C129390","A family of enzymes that catalyzes the transfer of a phosphate group from 1,3-bisphosphoglycerate (1,3-BPG) to adenosine diphosphate (ADP) yielding 3-phosphoglycerate (3-PG) and adenosine triphosphate (ATP) and also catalyzes the reverse reaction that transfers a phosphate group from ATP to 3-PG yielding 1,3-BPG and ADP.","Phosphoglycerate Kinase | 3-PGK | 3-Phosphoglycerate Kinase | 3-Phosphoglycerate Phosphokinase | 3-Phosphoglyceric Acid Kinase | 3-Phosphoglyceric Acid Phosphokinase | 3-Phosphoglyceric Kinase | ATP-3-Phospho-D-Glycerate-1-Phosphotransferase | ATP:3-Phospho-D-Glycerate 1-Phosphotransferase | ATP:D-3-Phosphoglycerate 1-Phosphotransferase | EC 2.7.2.3 | Glycerate 3-Phosphate Kinase | Glycerophosphate Kinase | PGK | Phosphoglyceric Acid Kinase | Phosphoglyceric Kinase | Phosphoglycerokinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019472","Hexokinase","C129391","A family of enzymes that transfers phosphate groups to six-carbon sugars (hexoses).","Hexokinase | ATP-Dependent Hexokinase | ATP:D-Hexose 6-Phosphotransferase | Glucose ATP Phosphotransferase | HK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706111","EGFR wt Allele","C51744","Human EGFR wild-type allele is located within 7p12 and is approximately 188 kb in length. This allele, which encodes epidermal growth factor receptor protein, is involved in several different processes such as receptor signaling, differentiation, proliferation responses and signal transduction.","EGFR wt Allele | Avian Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog Gene | ERBB | ERBB1 | Epidermal Growth Factor Receptor (Erythroblastic Leukemia Viral (V-ERB-B) Oncogene Homolog, Avian) Gene | Epidermal Growth Factor Receptor wt Allele | Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog (Avian) Gene | HER1 | MENA | NISBD2 | Oncogene ERBB | PIG61 | SA7 | Species Antigen 7 Gene | V-ERB-B Avian Erythroblastic Leukemia Viral Oncogene Homolog Gene | mENA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513038","Promoter-specific Methylation Profile","C129890","The analysis of all of the methylation of all promoter sequences in the genome in a biological sample","Promoter-specific Methylation Profile | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0949688","Molecular Diagnostic Method","C18194","Methods for diagnosis or monitoring of disease predisposition by translation and validation of molecular discoveries in medicine into the clinical diagnostic setting.","Molecular Diagnostic Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1317395","Immature Granulocyte","C13113","A not-yet-mature white blood cell with staining granules in its cytoplasm. The staining granules may be neutrophilic, acidophilic, or basophilic in character. There are indications that an immature granulocyte count is a better measure of infection and sepsis than a total white blood cell count and comparable to absolute neutrophil count.","Immature Granulocyte | ",,,,,,,,,,,,,,,"37118031","Immature granulocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514008","3-Log Reduction in Ph+ Cells","C131092","A 1000 times reduction in the Philadelphia Chromosome positive cells.","3-Log Reduction in Ph+ Cells | 3-Log Reduction | 3-Log Reduction in Philadelphia Chromosome Positive Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513054","Slightly Able","C129950","A response indicating that an individual is somewhat able to do something.","Slightly Able | Slightly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513005","Moderately Able","C129951","A response indicating that an individual is moderately able to do something.","Moderately Able | Moderately",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513007","Quite Able","C129952","A response indicating that an individual is quite able to do something.","Quite Able | Quite a Bit Able | Quite a bit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0754515","TERT protein, human","C20183","Telomerase reverse transcriptase (1132 aa, ~127 kDa) is encoded by the human TERT gene. This protein plays a role in both the replication and maintenance of telomeres.","Telomere Reverse Transcriptase | EC 2.7.7.49 | HEST2 | TERT | TP2 | Telomerase Catalytic Subunit | Telomerase Reverse Transcriptase Protein | Telomerase-Associated Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1506530","poliovirus receptor, human","C118556","Poliovirus receptor (417 aa, ~45 kDa) is encoded by the human PVR gene. This protein is involved in both natural killer cell activation and poliovirus binding.","Poliovirus Receptor | CD155 | CD155 Antigen | NECL-5 | Nectin-Like Protein 5 | PVR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4011622","IDH1 NP_005887.2:p.R132H","C128827","A change in the amino acid residue at position 132 in the isocitrate dehydrogenase [NADP] cytoplasmic protein where arginine has been replaced by histidine.","IDH1 NP_005887.2:p.R132H | Cytosolic NADP-Isocitrate Dehydrogenase Protein Arg132His | Cytosolic NADP-Isocitrate Dehydrogenase Protein R132H | IDH1 Arg132His | IDH1 NP_005887.2:p.Arg132His | IDH1 R132H | IDH1 R132H Mutation | IDH1 p.Arg132His | IDH1 p.R132H | Isocitrate Dehydrogenase [NADP] Cytoplasmic Arg132His | Isocitrate Dehydrogenase [NADP] Cytoplasmic R132H | NP_005887.2:p.Arg132His | NP_005887.2:p.R132H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512152","IDH1 NM_005896.3:c.395G>A","C128826","A nucleotide substitution at position 395 of the coding sequence of the IDH1 gene where guanine has been mutated to adenine.","IDH1 NM_005896.3:c.395G>A | G395A | IDH c.395G>A | IDH1 c.395G>A | Isocitrate Dehydrogenase 1 (NADP(+)), Cytosolic c.395G>A | Isocitrate Dehydrogenase 1 (NADP+), Soluble c.395G>A | NM_005896.3:c.395G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514019","BSA Involvement Score 0","C131035","No body surface area involved.","BSA Involvement Score 0 | Body Surface Area Involvement Score 0 | Score 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514020","BSA Involvement Score 1","C131036","1-18% of body surface area involved.","BSA Involvement Score 1 | Body Surface Area Involvement Score 1 | Score 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514021","BSA Involvement Score 2","C131037","19-50% of body surface area involved.","BSA Involvement Score 2 | Body Surface Area Involvement Score 2 | Score 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514022","BSA Involvement Score 3","C131038","Greater than 50% of body surface area involved.","BSA Involvement Score 3 | Body Surface Area Involvement Score 3 | Score 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513106","GvHD Body Surface Area Involvement Score","C131033","A score for graft versus host disease based on the percentage of of body surface area (BSA) involved.","GvHD Body Surface Area Involvement Score | Graft versus Host Disease Body Surface Area Involvement Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513111","GvHD Final Lung Score","C131043","A scoring system for graft versus host disease that combines a symptoms score with a score for FEV1.","GvHD Final Lung Score | Final GVHD Lung Score | Graft versus Host Disease Final Lung Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513107","GvHD Final Lung Score 0","C131044","FEV1 is greater than or equal to 80 percent with or without lung symptoms.","GvHD Final Lung Score 0 | Graft versus Host Disease GvHD Final Lung Score 0 | Score 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513109","GvHD Final Lung Score 2","C131047","FEV1 is 40 to 59 percent and lung symptoms are none to moderate.","GvHD Final Lung Score 2 | Graft versus Host Disease GvHD Final Lung Score 2 | Score 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513110","GvHD Final Lung Score 3","C131048","FEV1 is less than or equal to 39 percent and lung symptoms are none to severe.","GvHD Final Lung Score 3 | Graft versus Host Disease GvHD Final Lung Score 3 | Score 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513116","GvHD Final Skin Score","C131024","A scoring system for graft versus host disease that combines a score for percentage of body surface area (BSA) involved with a score for disease signs and cutaneous features.","GvHD Final Skin Score | Final GVHD Skin Score | Graft versus Host Disease Final Skin Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513112","GvHD Final Skin Score 0","C131026","Body surface area involvement is 0 percent and there are no sclerotic features.","GvHD Final Skin Score 0 | Graft versus Host Disease Final Skin Score 0 | Score 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513113","GvHD Final Skin Score 1","C131027","Body surface area involvement is 1-18 percent.","GvHD Final Skin Score 1 | Graft versus Host Disease Final Skin Score 1 | Score 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513114","GvHD Final Skin Score 2","C131028","Body surface area involvement is 19-50 percent and there are superficial sclerotic features.","GvHD Final Skin Score 2 | Graft versus Host Disease Final Skin Score 2 | Score 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513115","GvHD Final Skin Score 3","C131029","Body surface area involvement is greater than 50 percent and there are any skin features that are Score 3. This score is also used when superficial sclerotic features are present (Score 2), but there is impaired mobility or ulceration (Score 3).","GvHD Final Skin Score 3 | Graft versus Host Disease Final Skin Score 3 | Score 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513117","GvHD Lung Obstructive Function Score","C131054","A score for graft versus host disease based on FEV1.","GvHD Lung Obstructive Function Score | Graft versus Host Disease Lung Obstructive Function Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513122","GvHD Lung Symptom Score","C131049","A score for graft versus host disease based on the severity of lung symptoms.","GvHD Lung Symptom Score | Graft versus Host Disease Lung Symptom Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513118","GvHD Lung Symptom Score 0","C131050","No symptoms.","GvHD Lung Symptom Score 0 | Graft versus Host Disease Lung Symptom Score 0 | Score 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513119","GvHD Lung Symptom Score 1","C131051","Mild symptoms (shortness of breath after climbing one flight of steps).","GvHD Lung Symptom Score 1 | Graft versus Host Disease Lung Symptom Score 1 | Score 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513120","GvHD Lung Symptom Score 2","C131052","Moderate symptoms (shortness of breath after walking on flat ground).","GvHD Lung Symptom Score 2 | Graft versus Host Disease Lung Symptom Score 2 | Score 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513121","GvHD Lung Symptom Score 3","C131053","Severe symptoms (shortness of breath at rest; requiring O2).","GvHD Lung Symptom Score 3 | Graft versus Host Disease Lung Symptom Score 3 | Score 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513123","GvHD Skin Features Score","C131039","A score for graft versus host disease based on features of skin involvement.","GvHD Skin Features Score | Graft versus Host Disease Skin Features Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513165","Lung Obstructive Function Score 0","C131055","FEV1 greater than or equal to 80%.","Lung Obstructive Function Score 0 | Score 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513166","Lung Obstructive Function Score 1","C131056","FEV1 60-79%.","Lung Obstructive Function Score 1 | Score 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513167","Lung Obstructive Function Score 2","C131057","FEV1 40-59%.","Lung Obstructive Function Score 2 | Score 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513168","Lung Obstructive Function Score 3","C131058","FEV1 less than or equal to 39%.","Lung Obstructive Function Score 3 | Score 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513993","Skin Features Score 0","C131040","No sclerotic features.","Skin Features Score 0 | Score 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513994","Skin Features Score 2","C131041","Superficial sclerotic features; not hidebound (able to pinch).","Skin Features Score 2 | Score 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513995","Skin Features Score 3","C131042","One or more of: deep sclerotic features; hidebound; impaired mobility; ulceration.","Skin Features Score 3 | Score 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513184","Poliovirus Receptor 3+ Staining Finding","C131116","A finding of 3+ staining for poliovirus receptor in a sample.","Poliovirus Receptor 3+ Staining Finding | 3+ PVR Staining | Poliovirus Receptor 3+ Staining",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513183","Poliovirus Receptor 2+ Staining Finding","C131117","A finding of 2+ staining for poliovirus receptor in a sample.","Poliovirus Receptor 2+ Staining Finding | 2+ PVR Staining | Poliovirus Receptor 2+ Staining",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513182","Poliovirus Receptor 1+ Staining Finding","C131118","A finding of 1+ staining for poliovirus receptor in a sample.","Poliovirus Receptor 1+ Staining Finding | 1+ PVR Staining | Poliovirus Receptor 1+ Staining",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513366","Test Not Ordered","C131119","An indication that a test was not ordered.","Test Not Ordered | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513392","Unable to Perform","C131120","An indication that an action, task, or function was not done due to a lack of skill, means, or opportunity.","Unable to Perform | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514217","Insufficient Sample","C131121","An indication that there was not enough sample available.","Insufficient Sample Volume | Insufficient Sample | Insufficient Sample",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513398","Block Depleted","C131122","An indication that a sample block has been depleted by testing.","Block Depleted | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513474","IDH1 NM_005896.3:c.394C>A","C131093","A nucleotide substitution at position 394 of the coding sequence of the IDH1 gene where cytosine has been mutated to adenine.","IDH1 NM_005896.3:c.394C>A | C394A | IDH c.394C>A | IDH1 c.394C>A | Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic c.394C>A | Isocitrate Dehydrogenase 1 (NADP+), Soluble c.394C>A | NM_005896.3:c.394C>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513475","IDH1 NM_005896.3:c.394C>G","C131096","A nucleotide substitution at position 394 of the coding sequence of the IDH1 gene where cytosine has been mutated to guanine.","IDH1 NM_005896.3:c.394C>G | C394G | IDH c.394C>G | IDH1 c.394C>G | Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic c.394C>G | Isocitrate Dehydrogenase 1 (NADP+), Soluble c.394C>G | NM_005896.3:c.394C>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513476","IDH1 NM_005896.3:c.394C>T","C131098","A nucleotide substitution at position 394 of the coding sequence of the IDH1 gene where cytosine has been mutated to thymine.","IDH1 NM_005896.3:c.394C>T | C394T | IDH c.394C>T | IDH1 c.394C>T | Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic c.394C>T | Isocitrate Dehydrogenase 1 (NADP+), Soluble c.394C>T | NM_005896.3:c.394C>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513478","IDH1 NM_005896.3:c.395G>T","C131100","A nucleotide substitution at position 395 of the coding sequence of the IDH1 gene where guanine has been mutated to thymine.","IDH1 NM_005896.3:c.395G>T | G395T | IDH c.395G>T | IDH1 c.395G>T | Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic c.395G>T | Isocitrate Dehydrogenase 1 (NADP+), Soluble c.395G>T | NM_005896.3:c.395G>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513473","IDH1 NM_005896.3:c.356G>A","C131102","A nucleotide substitution at position 356 of the coding sequence of the IDH1 gene where guanine has been mutated to adenine.","IDH1 NM_005896.3:c.356G>A | G356A | IDH c.356G>A | IDH1 c.356G>A | Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic c.356G>A | Isocitrate Dehydrogenase 1 (NADP+), Soluble c.356G>A | NM_005896.3:c.356G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513470","IDH2 NM_002168.3:c.515G>A","C131110","A nucleotide substitution at position 515 of the coding sequence of the IDH2 gene where guanine has been mutated to adenine.","IDH2 NM_002168.3:c.515G>A | G515A | IDH c.515G>A | IDH2 c.515G>A | Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial c.515G>A | Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial c.515G>A | NM_002168.3:c.515G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513471","IDH2 NM_002168.3:c.515G>T","C131113","A nucleotide substitution at position 515 of the coding sequence of the IDH2 gene where guanine has been mutated to thymine.","IDH2 NM_002168.3:c.515G>T | G515T | IDH c.515G>T | IDH2 c.515G>T | Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial c.515G>T | Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial c.515G>T | NM_002168.3:c.515G>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513480","IDH2 NP_002159.2:p.R172K","C131112","A change in the amino acid residue at position 172 in the isocitrate dehydrogenase [NADP], mitochondrial protein where arginine has been replaced by lysine.","IDH2 NP_002159.2:p.R172K | IDH2 Arg172Lys | IDH2 NP_002159.2:p.Arg172Lys | IDH2 R172K | IDH2 R172K Mutation | IDH2 p.Arg172Lys | Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial Arg172Lys | Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial R172K | Isocitrate Dehydrogenase [NADP], Mitochondrial Arg172Lys | Isocitrate Dehydrogenase [NADP], Mitochondrial R172K | NP_002159.2:p.Arg172Lys | NP_002159.2:p.R172K | R172K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513479","IDH2 NP_002159.2:p.R172G","C131109","A change in the amino acid residue at position 172 in the isocitrate dehydrogenase [NADP], mitochondrial protein where arginine has been replaced by glycine.","IDH2 NP_002159.2:p.R172G | IDH2 Arg172Gly | IDH2 NP_002159.2:p.Arg172Gly | IDH2 R172G | IDH2 R172G Mutation | IDH2 p.Arg172Gly | Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial Arg172Gly | Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial R172G | Isocitrate Dehydrogenase [NADP], Mitochondrial Arg172Gly | Isocitrate Dehydrogenase [NADP], Mitochondrial R172G | NP_002159.2:p.Arg172Gly | NP_002159.2:p.R172G | R172G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513481","IDH2 NP_002159.2:p.R172M","C131114","A change in the amino acid residue at position 172 in the isocitrate dehydrogenase [NADP], mitochondrial protein where arginine has been replaced by methionine.","IDH2 NP_002159.2:p.R172M | IDH2 Arg172Met | IDH2 NP_002159.2:p.Arg172Met | IDH2 R172M | IDH2 R172M Mutation | IDH2 p.Arg172Met | Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial Arg172Met | Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial R172M | Isocitrate Dehydrogenase [NADP], Mitochondrial Arg172Met | Isocitrate Dehydrogenase [NADP], Mitochondrial R172M | NP_002159.2:p.Arg172Met | NP_002159.2:p.R172M | R172M",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513469","IDH2 NM_002168.3:c.514A>G","C131108","A nucleotide substitution at position 514 of the coding sequence of the IDH2 gene where adenine has been mutated to guanine.","IDH2 NM_002168.3:c.514A>G | A514G | IDH c.514A>G | IDH2 c.514A>G | Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial c.514A>G | Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial c.514A>G | NM_002168.3:c.514A>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513360","TERT NM_198253.2:c.1-124C>T","C131107","A nucleotide substitution in the 5' promoter region of the TERT gene at a position that is 124 nucleotides upstream of the translation start site where cytosine has been mutated to thymine.","TERT NM_198253.2:c.1-124C>T | 1 295 228 C>T | C228T | NM_198253.2:c.1-124C>T | TERT 1 295 228 C>T | TERT C228T | TERT:c.1-124C>T | Telomerase Reverse Transcriptase c.1-124C>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513361","TERT NM_198253.2:c.1-146C>T","C131106","A nucleotide substitution in the 5' promoter region of the TERT gene at a position that is 146 nucleotides upstream of the translation start site where cytosine has been mutated to thymine.","TERT NM_198253.2:c.1-146C>T | 1 295 250 C>T | C250T | NM_198253.2:c.1-146C>T | TERT 1 295 228 C>T | TERT 1 295 250 C>T | TERT C250T | TERT:c.1-146C>T | Telomerase Reverse Transcriptase c.1-146C>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514074","Immunotherapy Response Assessment in Neuro-Oncology Criteria","C131131","Response assessment criteria for the evaluation of patients undergoing immunotherapy for the treatment of malignant glioma. These recommendations integrate guidance for the determination and confirmation of tumor progression based on the response assessment in neuro-oncology (RANO) working group and the immune-related response criteria (irRC).","Immunotherapy Response Assessment in Neuro-Oncology Criteria | Immunotherapy Response Assessment for Neuro-Oncology | iRANO | iRANO Criteria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1122087","Adalimumab","C65216","A recombinant, human IgG1 monoclonal antibody directed against tumor necrosis factor-alpha (TNF-alpha), with immunomodulating activity. Upon administration, adalimumab binds to TNF-alpha, thereby preventing its binding to the p55 and p75 TNF cell surface receptors and inhibiting TNF-mediated immune responses. TNF-alpha, a pro-inflammatory cytokine, is upregulated in various autoimmune diseases.","Adalimumab | ABP 501 | ADALIMUMAB | Adalimumab Biosimilar ABP 501 | D2E7 | Humira | Immunoglobulin G1, anti-(human tumor necrosis factor) (human monoclonal D2E7 heavy chain), disulfide with human monoclonal D2E7 light chain, dimer | LU200134",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1379971","Therapeutic Testosterone","C862","A synthetic form of the endogenous androgenic steroid testosterone. In vivo, testosterone is irreversibly converted to dihydrotestosterone (DHT) in target tissues by the enzyme 5-alpha reductase. Testosterone or DHT ligand-androgen receptor complexes act as transcription factor complexes, stimulating the expression of various responsive genes. DHT binds with higher affinity to androgen receptors than testosterone, activating gene expression more efficiently. In addition, testosterone is irreversibly converted to estradiol by the enzyme complex aromatase, particularly in the liver and adipose tissue. Testosterone and DHT promote the development and maintenance of male sex characteristics related to the internal and external genitalia, skeletal muscle, and hair follicles; estradiol promotes epiphyseal maturation and bone mineralization. Due to rapid metabolism by the liver, therapeutic testosterone is generally administered as an ester derivative.","Therapeutic Testosterone | (17Beta)-17-hydroxyandrost-4-en-3-one | Delta4-Androsten-17beta-ol-3-one | Mertestate | TESTOSTERONE | Testoderm | Testolin | Testosterone | Testostroval | Testostroval-PA | Testro AQ | Trans-Testosterone | Virosterone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050513","Minor Response","C123598","A finding indicating that there is an improvement in the measures of disease burden, meeting a predetermined threshold, but not meeting partial response criteria.","Minimal Response | MR | MR-Minimal/Marginal Response | MR-Minimal/Marginal response | Minor Response | Minor Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508634","PMS1 Gene Mutation","C128822","A change in the nucleotide sequence of the PMS1 gene.","PMS1 Gene Mutation | HNPCC3 Gene Mutation | MLH2 Gene Mutation | PMS1 Mutation | PMSL1 Gene Mutation | Postmeiotic Segregation Increased (S. cerevisiae) 1 Gene Mutation | Postmeiotic Segregation Increased 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508629","MSH2 Gene Mutation","C128821","A change in the nucleotide sequence of the MSH2 gene.","MSH2 Gene Mutation | COCA1 Gene Mutation | HNPCC Gene Mutation | HNPCC1 Gene Mutation | MSH2 Mutation | MutS Homolog 2 Gene Mutation | MutS, E. coli, Homolog of, 2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640153","PALB2 Gene Mutation","C101641","A molecular genetic abnormality that refers to a change in the nucleotide sequence of the PALB2 gene.","PALB2 Gene Mutation | FANCN Gene Mutation | Fanconi Anemia, Complementation Group N Gene Mutation | PNCA3 Gene Mutation | Partner and Localizer of BRCA2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510697","ATM Gene Mutation","C40459","A change in the nucleotide sequence of the ATM gene.","ATM Gene Mutation | A-T Mutated Gene Mutation | AT Mutated Gene Mutation | ATM | ATM Serine/Threonine Kinase Gene Mutation | ATM mutation | Ataxia Telangiectasia Mutated Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512779","KEAP1 Gene Mutation","C129685","A change in the nucleotide sequence of the KEAP1 gene.","KEAP1 Gene Mutation | INRF2 Gene Mutation | KLHL19 Gene Mutation | Kelch-Like ECH-Associated Protein 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512566","NFE2L2 Gene Mutation","C129684","A change in the nucleotide sequence of the NFE2L2 gene.","NFE2L2 Gene Mutation | NRF2 Gene Mutation | Nuclear Factor (Erythroid-Derived 2)-Like 2 Gene Mutation | Nuclear Factor, Erythroid 2 Like 2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512235","STK11 Gene Mutation","C128825","A change in the nucleotide sequence of the STK11 gene.","STK11 Gene Mutation | LKB1 Gene Mutation | Liver Kinase B1 Gene Mutation | STK11 Mutation | Serine/Threonine Kinase 11 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512277","EPCAM Gene Mutation","C128820","A change in the nucleotide sequence of the EPCAM gene.","EPCAM Gene Mutation | EPCAM Mutation | Ep-CAM Gene Mutation | Epithelial Cell Adhesion Molecule Gene Mutation | HNPCC8 Gene Mutation | TACSTD1 Gene Mutation | Tumor-Associated Calcium Signal Transducer 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1155874","Cell Cycle Checkpoint","C18689","Phases or points in the cell cycle at which a cell is prevented from progressing into the next phase of the cycle unless certain necessary and sufficient cellular conditions exist.  The checkpoints help maintain the proper order and timing of cell transition events, especially important for DNA replication and chromosome segregation.","Cell Cycle Checkpoint | Checkpoint",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1256770","Vascular Endothelial Growth Factor Family","C129646","A sub-family of the cysteine knot platelet-derived growth factor family. Members of the vascular endothelial growth factor (VEGF) family play a role in the promotion of embryonic vasculogenesis and the stimulation of angiogenesis during physiologic and pathologic processes.","Vascular Endothelial Growth Factor Family | VEGF | VEGF Family | Vascular Endothelial Growth Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514077","ALK Gene Amplification","C131136","A molecular genetic abnormality indicating the presence of multiple copies of the ALK gene.","ALK Gene Amplification | Anaplastic Lymphoma Kinase Receptor Gene Amplification | Anaplastic Lymphoma Receptor Tyrosine Kinase Gene Amplification | CD246 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514165","Renal Bed","C131138","The cavity evident following excision of a kidney. The renal bed is a potential site of recurrent disease post-nephrectomy.","Renal Bed | Kidney Bed | RENAL BED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087225","Immune-Mediated Adverse Reaction","C131137","An adverse event resulting from an immune system reaction to a drug or device. It can affect any organ or system.","Immune-Mediated Adverse Reaction | Immune Related Side Effect | Immune-Mediated Adverse Event | Immune-Related Adverse Event | irAE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513188","Pseudoresponse","C131142","A marked decrease in contrast enhancement that is not due to actual tumor shrinkage, but that may be due to anti-angiogenic therapy or an increase in steroid dosage.","Pseudoresponse | PSEUDORESPONSE | PSR-Pseudoresponse | PsR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514172","Immunoprogression","C131143","A marked increase in contrast enhancement that is not due to actual tumor growth, but that may be due to a reaction to immunotherapy.","Immunoprogression | IPD-Immunoprogression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514173","Immunoresponse Finding","C131144","A marked decrease in contrast enhancement that is not due to actual tumor shrinkage, but that may be due to immunotherapy.","Immunoresponse | IMR-Immunoresponse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827348","JAK2 Gene Mutation","C84255","Mutation of the Janus 2 kinase gene at chromosome 9. It is seen in most patients with polycythemia vera and less frequently in other myeloproliferative neoplasms.","JAK2 Gene Mutation | JAK-2 Gene Mutation | JAK2 | JAK2 Gene Variant | JAK2 Mutation | JTK10 Gene Mutation | Janus Kinase 2 (A Protein Tyrosine Kinase) Gene Variant | Janus Kinase 2 Gene Mutation | Janus Kinase 2 Gene Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512871","JAK1 Gene Mutation","C129949","A change in the nucleotide sequence of the JAK1 gene.","JAK1 Gene Mutation | JAK1 Mutation | JTK3 Gene Mutation | Janus Kinase 1 (A Protein Tyrosine Kinase) Gene Mutation | Janus Kinase 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513978","PROMIS Sexual Function and Satisfaction Measures","C131154","A questionnaire for self-reported satisfaction with sexual function that includes 79 items in 11 domains: interest in sexual activity, lubrication, vaginal discomfort, erectile function, global satisfaction with sex life, orgasm, anal discomfort, therapeutic aids, sexual activities, interfering factors, and screener questions.","PROMIS Sexual Function and Satisfaction Measures | PROMIS SexFS | PROMIS Sexual Function and Satisfaction | SexFS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513100","Global Satisfaction with Sex Life Subordinate Domain","C131155","The collection of PROMIS item scales that assess self-reported perceptions of overall sexual satisfaction in men and women.","Global Satisfaction with Sex Life Subordinate Domain | Global Satisfaction with Sex Life | Global Satisfaction with Sex Life Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514094","How Satisfied with Sex Life","C131158","A question about how satisfied an individual is or was with their sex life.","How Satisfied with Sex Life | How satisfied have you been with your sex life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514092","How Often Thought Sex Life is Wonderful","C131160","A question about how often an individual thinks or thought their sex life was wonderful.","How Often Thought Sex Life is Wonderful | How often have you thought that your sex life is wonderful",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514095","How Satisfied with Sexual Relationship with Partner","C131161","A question about how satisfied an individual is or was with their sexual relationship with their partner.","How Satisfied with Sexual Relationship with Partner | How satisfied have you been with your sexual relationship with a partner",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513755","How Much Enjoyment from Sexual Activity","C131162","A question about how much an individual enjoys or enjoyed sexual activity.","How Much Enjoyment from Sexual Activity | When you have had sexual activity, how much have you enjoyed it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513756","How Satisfied with Sexual Activity","C131163","A question about how satisfied an individual is or was with their sexual activity.","How Satisfied with Sexual Activity | When you have had sexual activity, how satisfying has it been",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513958","Interest in Sexual Activity Subordinate Domain","C131156","The collection of PROMIS item scales that assess self-reported perceptions of interest in sexual activity in men and women.","Interest in Sexual Activity Subordinate Domain | Interest in Sexual Activity | Interest in Sexual Activity Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514088","How Interested in Sexual Activity","C131164","A question about how interested an individual is or was in sexual activity.","How Interested in Sexual Activity | How interested have you been in sexual activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514087","How Often Feel Like Want to Have Sex","C131165","A question about how often an individual feels or felt like they wanted to have sex.","How Often Feel Like Want to Have Sex | How Often Feel Like Having Sex | How Often Feel Want to Have Sex | How often have you felt like you wanted to have sex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514091","How Often Have Sexual Thoughts or Fantasies While Awake","C131166","A question about how often an individual has or had sexual fantasies while awake.","How Often Have Sexual Thoughts or Fantasies While Awake | How often have you had sexual thoughts or fantasies while you were awake",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514093","How Often Interested Enough to Start Sexual Activity","C131167","A question about how often an individual is or was interested enough to start a sexual activity.","How Often Interested Enough to Start Sexual Activity | How often were you interested enough to start a sexual activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513984","Sexual Function and Satisfaction Interfering Factors Subordinate Domain","C131157","A subgroup of PROMIS Sexual Function and Satisfaction item scales that assess self-reported perceptions of the degree to which various factors affect satisfaction with sex life in men and women.","Sexual Function and Satisfaction Interfering Factors Subordinate Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514089","How Much Fatigue or Lack of Energy Affects Satisfaction with Sex Life","C131168","A question about how much an individual's fatigue or lack of energy affects or affected satisfaction with their sex life.","How Much Fatigue or Lack of Energy Affects Satisfaction with Sex Life | How much has fatigue or lack of energy affected your satisfaction with your sex life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513491","Past 30 Days No Partner","C131169","A response indicating that an individual has not had a partner in the past 30 days.","Past 30 Days No Partner | Have not had a partner in the past 30 days | No Partner Past 30 Days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513490","Past 30 Days No Fatigue or Lack of Energy","C131170","A response indicating that an individual has not had fatigue or lack of energy in the past 30 days.","Past 30 Days No Fatigue or Lack of Energy | Have not had fatigue or lack of energy in the past 30 days | No Fatigue or Lack of Energy Past 30 Days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827560","IDH2 wt Allele","C84949","Human IDH2 wt allele is located in the vicinity of 15q26.1 and is approximately 18 kb in length. This allele, which encodes isocitrate dehydrogenase 2 (NADP+) mitochondrial protein, plays a role in intermediary metabolism. Mutations in this gene are associated with astrocytoma, oligodendroglioma and secondary glioblastoma.","IDH2 wt Allele | D2HGA2 | ICD-M | IDH | IDHM | IDP | IDPM | Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial wt Allele | mNADP-IDH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518121","MET Gene Mutation","C39788","A change in the nucleotide sequence of the MET gene.","MET Gene Mutation | HGFR Gene Mutation | Hepatocyte Growth Factor Receptor Gene Mutation | MET Mutation | MET Proto-Oncogene, Receptor Tyrosine Kinase Gene Mutation | Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Gene Mutation | c-met Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512959","CRLF2 Gene Rearrangement","C129969","A molecular abnormality indicating rearrangement of the CRLF2 gene.","CRLF2 Gene Rearrangement | CRLF2 Rearrangement | Cytokine Receptor Crl2 Gene Rearrangement | Cytokine Receptor Like Factor 2 Gene Rearrangement | Cytokine Receptor-Like Factor 2 Gene Rearrangement | TSLPR Gene Rearrangement | Thymic Stromal-Derived Lymphopoietin Receptor Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514226","a.m.","C131181","The time period between midnight and noon.","a.m. | Anti Meridiem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0587118","p.m.","C131183","The time period between noon and midnight.","p.m. | Post Meridiem",,,,,,,,,,,,,,,"4114361","During afternoon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2826254","Interruption Duration","C82519","The time span of a disruption in an event.","Interruption Duration | INTRP | interruptionDuration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2964135","Infusion Rate","C94916","The volume of a substance injected into a subject in a unit time.","Infusion Rate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514171","Immune-mediated","C131176","Resulting from the activity of the immune system.","Immune-mediated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053896","Unequivocal","C123645","Leaving no doubt; not open to question.","Unequivocal | UNEQUIVOCAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519530","Person Role Title","C113644","An identifying designation assigned to an individual that corresponds with their function.","Person Role Title | Person Role | Role Title | Title | title",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1270004","Pathologic Primary Tumor TNM Finding","C48888","A pathologic finding about one or more characteristics of a specific cancer, following the rules of the TNM classification system as they pertain to evaluating the primary tumor.","Pathologic Primary Tumor TNM Finding | Pathologic T Category",,,,,,,,,,,,,,,"4293617","pT category",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205648","Microcystic Adenoma","C3685","A benign epithelial neoplasm characterized by a microcystic pattern. The cystic spaces are lined by small cuboidal cells without evidence of significant cytologic atypia.","Microcystic Adenoma | Microcystic adenoma","8202/0","Microcystic adenoma",,,,,,,,,,,,,"4196183","Microcystic adenoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0034079","Pulmonary Nodule","C122407","A benign or malignant small, oval or round growth in the lung. It can be due to infectious, inflammatory or neoplastic processes.","Pulmonary Nodule | Lung Nodule",,,,,,,,,,,,,,,"37206719","Nodule of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708369","Hilar Area of the Right Lung","C49281","The area associated with the hilum of the right lung.","Hilar Area of the Right Lung | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708367","Hilar Area of the Left Lung","C49253","The area associated with the hilum of the left lung.","Hilar Area of the Left Lung | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709226","Nidus Formation","C53694","No Value Exists","Nidus Formation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514583","Reason Form Not Complete","C131222","A question about why a form or questionnaire was not completed.","Reason Form Not Complete | Reason parent did not complete",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519128","Hard to Walk More Than One Block","C131223","A question about whether it is or was hard for an individual to walk more than one block.","Hard to Walk More Than One Block Question | Hard to Walk More Than One Block | Hard to Walk More Than One Block | Is it hard for you to walk | It is hard for me to walk more than one block | Walking | Walking more than one block",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514697","Hard to Run","C131225","A question about whether it is or was hard for an individual to run.","Hard to Run Question | Hard to Run | Hard to Run | Is it hard for you to run | It is hard for me to run | Running",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514439","Hard to do Sports Activity or Exercise","C131227","A question about whether it is or was hard for an individual to do sports activities or exercise.","Hard to do Sports Activity or Exercise Question | Hard to do Sports Activity or Exercise | Hard to do Sports Activity or Exercise | Is it hard for you to play sports or exercise | It is hard for me to do sports activity or exercise | Participating in active play or exercise | Participating in sports activity or exercise",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514577","Hard to Lift Something Heavy","C131229","A question about whether it is or was hard for an individual to lift something heavy.","Hard to Lift Something Heavy | Is it hard for you to pick up big things | It is hard for me to lift something heavy | Lifting something heavy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514693","Hard to Bathe or Shower","C131230","A question about whether it is or was hard for an individual to bathe or shower.","Hard to Bathe or Shower Question | Bathing | Hard to Bathe or Shower | Hard to Bathe or Shower | Is it hard for you to take a bath or shower | It is hard for me to take a bath or shower by myself | Taking a bath or shower by him or herself",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514645","Hard to do Chores","C131231","A question about whether it is or was hard for an individual to do chores.","Hard to do Chores | Doing chores around the house | Doing chores, like picking up his or her toys | Helping to pick up his or her toys | Is it hard for you to do chores (like pick up your toys) | It is hard for me to do chores around the house",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514567","Hurt or Ache","C131232","A question about whether an individual has or had hurts or aches.","Hurt or Ache | Do you have hurts or aches (Where?) | Having hurts or aches | Hurting or Aching | I hurt or ache",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514279","Feel Afraid or Scared","C131233","A question about whether an individual feels or felt afraid or scared.","Feel Afraid or Scared | Do you feel scared | Feeling afraid or scared | I feel afraid or scared",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514281","Feel Sad or Blue","C131234","A question about whether an individual feels or felt sad or blue.","Feel Sad or Blue | Do you feel sad | Feeling sad or blue | I feel sad or blue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514280","Feel Angry","C131235","A question about whether an individual feels or felt angry.","Feel Angry | Do you feel mad | Feel mad | Feeling angry | I feel angry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514694","Worry About What Will Happen","C131236","A question about whether an individual worries or worried about what will happen.","Worry About What Will Happen | Do you worry about what will happen to you | I worry about what will happen to me | Worrying | Worrying about what will happen to him or her",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514345","Trouble Getting Along with Others","C131239","A question about whether an individual has or had trouble getting along with others.","Trouble Getting Along with Others | Getting along with other children | Getting along with other teens | I have trouble getting along with other kids | I have trouble getting along with other teens | Is it hard for you to get long with other kids | Playing with other children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514535","Others Not Want to be Friends","C131241","A question about whether others do not want to be friends with an individual.","Others Not Want to be Friends | Do other kids say they do not want to play with you | Other kids do not want to be my friend | Other kids not wanting to be his or her friend | Other kids not wanting to play with him or her | Other teens do not want to be my friend | Other teens not wanting to be his or her friend",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514536","Others Tease Me","C131242","A question about whether others tease an individual.","Others Tease Me | Do other kids tease you | Getting teased by other children | Getting teased by other teens | Other kids tease me | Other teens tease me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514485","Cannot Do Things Others Same Age Can","C131243","A question about whether an individual can do the same things as others their age.","Cannot Do Things Others Same Age Can | Can other kids do things that you cannot do | I cannot do things that other kids my age can do | I cannot do things that other teens my age can do | Not able to do things that other children his or her age can do | Not able to do things that other teens his or her age can do",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514640","Hard to Keep up With Peers","C131244","A question about whether it is hard for an individual to keep up with peers.","Hard to Keep up with Peers Question | Hard to Keep up With Peers | Hard to Keep up with Peers | Is it hard for you to keep up when you play with other kids | It is hard to keep up when I play with other kids | It is hard to keep up with my peers | Keeping up when playing with other children | Keeping up with other teens",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514443","Hard to Pay Attention in Class","C131245","A question about whether it is hard for an individual to pay attention in class.","Hard to Pay Attention in Class | Is it hard for you to pay attention in school | It is hard to pay attention in class | Paying attention in class",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514289","Forget Things","C131246","A question about whether an individual forgets things.","Forget Things | Do you forget things | Forgetting things | I forget things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514570","Have Trouble Keeping Up with Schoolwork","C131247","A question about whether an individual has trouble keeping up with schoolwork.","Have Trouble Keeping Up with Schoolwork | Doing the same school activities as peers | I have trouble keeping up with my schoolwork | Is it hard to keep up with schoolwork | Keeping up with school activities | Keeping up with schoolwork",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514574","Miss School Because of Not Feeling Well","C131248","A question about whether an individual misses school because of not feeling well.","Miss School Because of Not Feeling Well | Do you miss school because of not feeling good | I miss school because of not feeling well | Missing school because of not feeling well | Missing school/daycare because of not feeling well",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514575","Miss School to go to Doctor or Hospital","C131249","A question about whether an individual misses school because of doctor or hospital visits.","Miss School to go to Doctor or Hospital | Do you miss school because you have to go to the doctors or hospital | I miss school to go to the doctor or hospital | Missing school to go to the doctor or hospital | Missing school/daycare to go to the doctor or hospital",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514290","Form Not Presented or Mailed to Parent","C131250","A response indicating that a form was not presented or mail to a parent.","Form Not Presented or Mailed to Parent | Form not presented or mailed to parent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514438","Parental Refusal for Current Questionnaire","C131251","A response indicating that a parent refused the current questionnaire.","Parental Refusal for Current Questionnaire | Parental refusal for current questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514435","Parent Given Form and Form not Returned","C131252","A response indicating that a form was given to a parent, but that it was not returned.","Parent Given Form and Form not Returned | Parent Given Form but Form not Returned | Parent given form and form not returned",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514436","Parent Wishes to Withdraw From Further Participation in the Study","C131253","A response indicating that a parent wishes to withdraw from further participation.","Parent Wishes to Withdraw From Further Participation in the Study | Parent Wishes to Withdraw From Further Participation | Parent wishes to withdraw from further participation in the quality of life study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514441","Parent Did Not Come to Clinic and Mailed Form Not Returned","C131254","A response indicating that a parent did not come to a clinic and that a mailed form was not returned.","Parent Did Not Come to Clinic and Mailed Form Not Returned | Patient did not come to clinic and mailed form was not returned",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514442","Patient Too Ill to Complete Form at this Assessment","C131255","A response indicating that a patient was too ill to complete a form at this assessment.","Patient Too Ill to Complete Form at this Assessment | Patient felt too ill to complete the quality of life form at this assessment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514437","Parent or Guardian Does Not Speak English","C131256","A response indicating that a parent or guardian did not speak English.","Parent or Guardian Does Not Speak English | Parent/guardian does not speak English",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514700","Severe Cognitive Impairments","C131257","A response indicating that a patient has or had severe cognitive impairments.","Severe Cognitive Impairments | Severe cognitive impairments",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0750493","Suspicious","C131271","Of a questionable or potentially dangerous nature.","Suspicious | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514410","Past Seven Days Frequency of Nosebleeds","C131340","A question about the frequency of an individual's nose bleeds over the past seven days.","Past Seven Days Frequency of Nosebleeds | In the past 7 days, how often did you have nosebleeds",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514414","Worst Severity Past Seven Days Nosebleeds","C131344","A question about an individual's observation of the worst severity they have experienced related to nosebleeds over the past seven days.","Worst Severity Past Seven Days Nosebleeds | In the past 7 days, what was the severity of your nosebleeds at their worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514405","Past Seven Days Any Flashing Lights in Front of Your Eyes","C131345","A question about whether or not an individual had any flashing lights in front of their eyes over the past seven days.","Past Seven Days Any Flashing Lights in Front of Your Eyes | In the past 7 days, did you have any flashing lights in front of your eyes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514408","Past Seven Days Any Urine Color Change","C131347","A question about whether an individual had any color change in their urine over the past seven days.","Past Seven Days Any Urine Color Change | In the past 7 days, did you have any urine color change",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514404","Past Seven Days Unexpected Decrease in Sweating","C131348","A question about whether an individual had any unexpected decrease in sweating over the past seven days.","Past Seven Days Unexpected Decrease in Sweating | In the past 7 days, did you have an unexpected decrease in sweating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514411","Past Seven Days Frequency of Shivering or Shaking Chills","C131351","A question about the frequency of an individual's shivering or shaking chills over the past seven days.","Past Seven Days Frequency of Shivering or Shaking Chills | In the past 7 days, how often did you have shivering or shaking chills",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514409","Past Seven Days Frequency of Hot Flashes","C131353","A question about the frequency of an individual's hot flashes over the past seven days.","Past Seven Days Frequency of Hot Flashes | In the past 7 days, how often did you have hot flashes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514412","Past Seven Days Frequency of Unexpected or Excessive Sweating During the Day or Nighttime","C131357","A question about the frequency of an individual's unexpected or excessive daytime or nighttime sweating over the past seven days.","Past Seven Days Frequency of Unexpected or Excessive Sweating During the Day or Nighttime | In the past 7 days, how often did you have unexpected or excessive sweating during the day or nighttime (not related to hot flashes) | Past Seven Days Frequency of Unexpected or Excessive Daytime or Nighttime Sweating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514416","Worst Severity Past Seven Days Unexpected or Excessive Sweating During the Day or Nighttime","C131358","A question about an individual's observation of the worst severity they have experienced related to unexpected or excessive daytime or nighttime sweating over the past seven days.","Worst Severity Past Seven Days Unexpected or Excessive Sweating During the Day or Nighttime | In the past 7 days, what was the severity of your unexpected or excessive sweating during the day or nighttime (not related to hot flashes) at its worst | Worst Severity Past Seven Days Unexpected or Excessive Daytime or Nighttime Sweating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514440","Past 30 days","C131330","A period of time consisting of the 30 days before the present.","Past 30 days | In the last month | Last 30 Days | Last Month | Past 30 Days | Past Month",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388363","Ischemia Procedure","C131331","A surgical procedure during which the blood supply to an organ or tissue is interrupted and then later reestablished.","Ischemia Procedure | Ischemia | Therapeutic Ischemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205501","Transperitoneal","C131332","Passing through the peritoneum.","Transperitoneal | ",,,,,,,,,,,,,,,"4276351","Transperitoneal approach",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL388364","Cold Ischemia Procedure","C116556","The act of decreasing both the temperature and blood flow to an organ or tissue for the purpose of preserving it for transplantation.","Cold Ischemia Procedure | Cold Ischemia During Surgery | cold ischemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388365","Warm Ischemia Procedure","C116557","A surgical procedure during which the blood supply to an organ or tissue is interrupted and then later reestablished, while maintaining the organ at physiologic body temperature.","Warm Ischemia Procedure | Warm Ischemia | Warm Ischemia During Surgery | warm ischemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514284","Feel Too Tired to do Things I Like to Do","C131370","A question about whether an individual feels or felt too tired to do the things they like to do.","Feel Too Tired to do Things I Like to Do | Do you feel too tired to do the things you like to do | Feeling too tired to do the things that he/she likes to do | I feel too tired to do the things I like to do | Too Tired to do Things I Like to Do",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514283","Feel Too Tired to Spend Time with Friends","C131371","A question about whether an individual feels or felt too tired to spend time with friends.","Feel Too Tired to Spend Time with Friends | Do you feel too tired to spend time with your friends | Feeling too tired to spend time with his/her friends | I feel too tired to spend time with my friends | Too Tired to Spend Time with Friends",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514569","Have Trouble Finishing Things","C131372","A question about whether an individual has or had trouble finishing things.","Have Trouble Finishing Things | Do you have trouble finishing things | I have trouble finishing things | Trouble Finishing Things | Trouble finishing things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514573","Have Trouble Starting Things","C131373","A question about whether an individual has or had trouble starting things.","Have Trouble Starting Things | Do you have trouble starting things | I have trouble starting things | Trouble Starting Things | Trouble starting things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514549","Sleep a Lot","C131374","A question about whether an individual sleeps or slept a lot.","Sleep a Lot | Do you sleep a lot | I sleep a lot | Sleeping a lot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514643","Hard to Sleep Through Night","C131375","A question about whether an individual finds or found it hard to sleep through the night.","Hard to Sleep Through Night | Difficulty sleeping through the night | Is it hard for you to sleep through the night | It is hard for me to sleep through the night",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514282","Feel Tired When Wake Up","C131376","A question about whether an individual feels or felt tired upon waking up in the morning.","Feel Tired When Wake Up | Do you feel tired when you wake up in the morning | Feeling tired when he/she wakes up in the morning | I feel tired when I wake up in the morning | Tired When Wake Up",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514446","Rest a Lot","C131377","A question about whether an individual rests or rested a lot.","Rest a Lot | Do you rest a lot | I rest a lot | Resting a lot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514333","Take Lots of Naps","C131378","A question about whether an individual takes or took a lot of naps.","Take Lots of Naps | Do you take a lot of naps | I take a lot of naps | Taking a lot of naps",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514552","Spend a Lot of Time in Bed","C131379","A question about whether an individual spends or spent a lot of time in bed.","Spend a Lot of Time in Bed | Do you spend a lot of time in bed | I spend a lot of time in bed | Spending a lot of time in bed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514639","Hard to Keep Attention on Things","C131380","A question about whether an individual finds or found it hard to keep their attention on things.","Hard to Keep Attention on Things | Difficulty keeping his/her attention on things | Is it hard for you to keep your attention on things | It is hard for me to keep my attention on things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514642","Hard to Remember What People Tell Me","C131381","A question about whether an individual finds or found it hard to remember what people told them.","Hard to Remember What People Tell Me | Difficulty remembering what people tell him/her | Is it hard for you to remember what people tell you | It is hard for me to remember what people tell me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514641","Hard to Remember What I Just Heard","C131382","A question about whether an individual finds or found it hard to remember what they just heard.","Hard to Remember What I Just Heard | Difficulty remembering what he/she just heard | Is it hard for you to remember what you just heard | It is hard for me to remember what I just heard",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514644","Hard to Think Quickly","C131383","A question about whether an individual finds or found it hard to think quickly.","Hard to Think Quickly | Difficulty thinking quickly | Is it hard for you to think quickly | It is hard for me to think quickly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514572","Have Trouble Remembering What I Was Just Thinking","C131384","A question about whether an individual has or had trouble remembering what they were just thinking.","Have Trouble Remembering What I Was Just Thinking | Do you have trouble remembering what you were just thinking | I have trouble remembering what I was just thinking | Trouble remembering what he/she was just thinking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514571","Have Trouble Remembering More Than One Thing at a Time","C131385","A question about whether an individual has or had trouble remembering more than one thing at a time.","Have Trouble Remembering More Than One Thing at a Time | Do you have trouble remembering more than one thing at a time | I have trouble remembering more than one thing at a time | Trouble remembering more than one thing at a time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1259854","Marizomib","C64634","A naturally-occurring salinosporamide, isolated from the marine actinomycete Salinospora tropica, with potential antineoplastic activity. Marizomib irreversibly binds to and inhibits the 20S catalytic core subunit of the proteasome by covalently modifying its active site threonine residues; inhibition of ubiquitin-proteasome mediated proteolysis results in an accumulation of poly-ubiquitinated proteins, which may result in the disruption of cellular processes, cell cycle arrest, the induction of apoptosis, and the inhibition of tumor growth and angiogenesis. This agent more may more potent and selective than the proteasome inhibitor bortezomib.","Marizomib | (1R,4R,5S)-4-(2-chloroethyl)-1-{(S)-[(1S)-cyclohex-2-en-1-yl]hydroxymethyl}-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione | MARIZOMIB | ML 858 | NPI-0052 | Salinosporamide A | Salinosporin A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021022","Immunoglobulin Therapy","C62710","The use of immunoglobulins in the treatment of any disease or disorder.","Immunoglobulin Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437013","Tisagenlecleucel","C102758","Autologous T-lymphocytes transduced with a modified lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. Upon transfusion, tisagenlecleucel directs the T-lymphocytes to CD19-expressing tumor cells, thereby inducing a selective toxicity in CD19-expressing tumor cells. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19 and the inclusion of this signaling domain may increase the antitumor activity compared to the inclusion of the CD3-zeta chain alone. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. CD3-zeta (or CD247) is a transmembrane signaling adaptor polypeptide that regulates the assembly of complete TCR complexes and their expression on the cell surface.","Tisagenlecleucel | CART-19 | CART19 | CD19CAR-CD3zeta-4-1BB-expressing Autologous T-lymphocytes | CTL 019 | CTL-019 | CTL019 | CTL019 T-cells | Kymriah | TISAGENLECLEUCEL | Tisa-cel | Tisagenlecleucel-T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454389","HDAC inhibitor CXD101","C112177","A novel histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Although the exact therapeutic mechanism of action for CXD101 is not known, oral administration of this agent should inhibit the catalytic activity of HDAC, which results in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling and an altered pattern of gene expression. HDAC, a family of enzymes upregulated in many tumor types, deacetylates chromatin-associated histone proteins.","Zabadinostat | AZD 9468 | AZD9468 | CXD-101 | CXD101 | HDAC Inhibitor CXD101 | HDAC Inhibitor CXD101 | Histone Deacetylase Inhibitor CXD101 | ZABADINOSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010206","Coumarin","C397","O hydroxycinnamic acid. Pleasant smelling compound found in many plants and released on wilting. Has anticoagulant activity by competing with Vitamin K.","Coumarin | 1,2-Benzopyrone | 2H-1-Benzopyran-2-one | COUMARIN | Chromen-2-one | Tonka Bean Camphor | Tonka bean camphor | coumarin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0750197","Sustained Ventricular Tachycardia by ECG Finding","C71052","An electrocardiographic finding of ventricular tachycardia greater than 30 seconds in duration.","Sustained Ventricular Tachycardia by ECG Finding | SUSTAINED VENTRICULAR TACHYCARDIA | Sustained VT | Sustained Ventricular Tachycardia | Sustained Ventricular Tachycardia by EKG Finding | Sustained ventricular tachycardia | Ventricular Tachycardia, Sustained",,,,,,,,,,,,,,,"4139206","Sustained ventricular tachycardia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0344435","Ventricular Fibrillation by ECG Finding","C111102","An electrocardiographic finding of a rapid grossly irregular ventricular rhythm with marked variability in QRS cycle length, morphology, and amplitude. The rate is typically greater than 300 bpm. (CDISC)","Ventricular Fibrillation by ECG Finding | VENTRICULAR FIBRILLATION | VF | VFib | Ventricular Fibrillation | Ventricular Fibrillation by EKG Finding | Ventricular fibrillation",,,,,,,,,,,,,,,"4064455","EKG: ventricular fibrillation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0264914","Bifascicular Block by ECG Finding","C71046","An electrocardiographic finding comprising right bundle branch block and left anterior fascicular block, or right bundle branch block and left posterior fascicular block. Defects occurring in two of the three divisions of the conduction system of the heart are considered bifascicular blocks. Technically left bundle branch block may be considered a bifascicular block.","Bifascicular Block by ECG Finding | BIFASCICULAR BLOCK | Bifascicular Block | Bifascicular Block by EKG Finding | Bifascicular block",,,,,,,,,,,,,,,"4250169","Bifascicular block",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0877341","Coronary Revascularization Procedure","C119202","Any procedure that is undertaken to reestablish blood flow to the heart.","Coronary Revascularization Procedure | CORONARY REVASCULARIZATION | Coronary Reperfusion Procedure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388501","Transarterial Chemoembolization","C101513","A hepatic artery embolization technique involving the injection of a blocking agent and a chemotherapy agent to treat liver cancers.","Transarterial Chemoembolization | TACE",,,,,,,,,,,,,,,"40482212","Transarterial chemoembolization of hepatic artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0400979","Biliary Obstruction","C60698","Blockage in the biliary tract that carries bile from the liver to the gallbladder and small intestine.  Causes include gallstones, biliary tract strictures and inflammation, pancreatitis, cirrhosis, lymph node enlargement, and bile duct and pancreas neoplasms.","Biliary Obstruction | ",,,,,,,,,,,,,,,"4340396","Obstruction of biliary tree",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0450368","Arabic numeral 43","C126587","A natural number greater than forty-two and less than forty-four and the quantity that it denotes.","Forty Three | 43 | Forty-Three | Forty-Three | Forty-three",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334405","Lobulated Growth Pattern","C35891","A morphologic finding indicating the presence of a cellular infiltrate forming lobules in a tissue sample.","Lobulated Growth Pattern | Lobular Pattern",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986562","Spiculated Mass","C94538","A lump of tissue with spikes or points on the surface.","Spiculated Mass | spiculated mass",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0549206","Pregnant","C124295","Observed to be or have been pregnant.","Pregnant | PREGNANT",,,,,,,,,,,,,,,"4299535","Pregnancy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0341074","Excision of Bile Duct","C51577","Surgical removal of part or all of the bile duct.","Excision of Bile Duct | ",,,,,,,,,,,,,,,"4266622","Excision of bile duct",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514451","Rotterdam Symptom Checklist","C131387","A questionnaire designed to measure both physical and psychological aspects of quality of life as an outcome measure of symptom control.","Rotterdam Symptom Checklist | RSCL | Rotterdam Symptom Checklist (RSCL)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514606","Bothered by Lack of Appetite","C131388","A question about whether an individual is or was bothered by lack of appetite.","Bothered by Lack of Appetite | Have you, during the past week, been bothered by lack of appetite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514605","Bothered by Irritability","C131389","A question about whether an individual is or was bothered by irritability.","Bothered by Irritability | Have you, during the past week, been bothered by irritability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514616","Bothered by Tiredness","C131390","A question about whether an individual is or was bothered by tiredness.","Bothered by Tiredness | Have you, during the past week, been bothered by tiredness | Tiredness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514617","Bothered by Worrying","C131391","A question about whether an individual is or was bothered by worrying.","Bothered by Worrying | Have you, during the past week, been bothered by worrying",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514598","Bothered by Depressed Mood","C131393","A question about whether an individual is or was bothered by depressed mood.","Bothered by Depressed Mood | Bothered by Depression | Feeling depressed, down or blue | Have you, during the past week, been bothered by depressed mood",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514607","Bothered by Lack of Energy","C131394","A question about whether an individual is or was bothered by lack of energy.","Bothered by Lack of Energy | Bothered by Feeling a Lack of Energy | Have you, during the past week, been bothered by lack of energy | Lack of energy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514608","Bothered by Low Back Pain","C131395","A question about whether an individual is or was bothered by low back pain.","Bothered by Low Back Pain | Have you, during the past week, been bothered by low back pain | Low backache",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514609","Bothered by Nervousness","C131396","A question about whether an individual is or was bothered by nervousness.","Bothered by Nervousness | Have you, during the past week, been bothered by nervousness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514599","Bothered by Despairing About the Future","C131397","A question about whether an individual is or was bothered by despairing about the future.","Bothered by Despairing About the Future | Bothered by Despair About the Future | Despair About the Future | Have you, during the past week, been bothered by despairing about the future",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514601","Bothered by Difficulty Sleeping","C131398","A question about whether an individual is or was bothered by difficulty sleeping.","Bothered by Difficulty Sleeping | Have you, during the past week, been bothered by difficulty sleeping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514604","Bothered by Headaches","C131399","A question about whether an individual is or was bothered by headaches.","Bothered by Headaches | Have you, during the past week, been bothered by headaches",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514602","Bothered by Dizziness","C131400","A question about whether an individual is or was bothered by dizziness.","Bothered by Dizziness | Have you, during the past week, been bothered by dizziness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514597","Bothered by Decreased Sexual Interest","C131401","A question about whether an individual is or was bothered by decreased sexual interest.","Bothered by Decreased Sexual Interest | Have you, during the past week, been bothered by decreased sexual interest",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514614","Bothered by Tension","C131402","A question about whether an individual is or was bothered by tension.","Bothered by Tension | Have you, during the past week, been bothered by tension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514594","Bothered by Abdominal Aches","C131403","A question about whether an individual is or was bothered by abdominal (stomach) aches.","Bothered by Abdominal Aches | Have you, during the past week, been bothered by abdominal (stomach) aches",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514595","Bothered by Anxiety","C131404","A question about whether an individual is or was bothered by anxiety.","Bothered by Anxiety | Have you, during the past week, been bothered by anxiety",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514600","Bothered by Diarrhea","C131405","A question about whether an individual is or was bothered by diarrhea.","Bothered by Diarrhea | Have you, during the past week, been bothered by diarrhoea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520584","Autologous EGFRt/19-28z/4-1BBL CAR T-Lymphocytes","C133189","Genetically modified autologous T-lymphocytes transduced with a replication incompetent retroviral vector expressing both tumor necrosis factor ligand superfamily (TNFSF) member 9 (TNFSF9; 4-1BBL) and a chimeric T cell antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment), fused to the extracellular, transmembrane and intracellular signaling domains of the T-cell co-stimulatory receptor CD28, the cytoplasmic signaling domain of the zeta chain of the TCR/CD3 complex (CD3-zeta) (19-28z), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous EGFRt/19-28z/4-1BBL CAR T-lymphocytes are directed to CD19-expressing tumor cells, which induces selective toxicity in CD19-expressing tumor cells. These cells also express 4-1BBL, a secreted protein and member of the TNFSF of growth factors, that induces proliferation of T-cells and may help reverse immunosuppression in the tumor environment. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. The CD28 co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19. The inclusion of the CD28 signaling domain may increase proliferation of T-cells and antitumor activity compared to the inclusion of the CD3-zeta chain alone. Devoid of both ligand binding domains and tyrosine kinase activity, EGFRt both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a cetuximab-induced antibody dependent cellular cytotoxicity (ADCC) response.","Autologous EGFRt/19-28z/4-1BBL CAR T-Lymphocytes | Autologous EGFRt/19-28z/4-1BBL CAR T Cells | Bothered By Reflux or Heartburn | CD19-Targeted EGFRt/19-28z/4-1BBL 'Armored' CAR Modified T Cells | CD19-Targeted EGFRt/19-28z/4-1BBL 'Armored' Chimeric Antigen Receptor Modified T-Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514610","Bothered by Shivering","C131406","A question about whether an individual is or was bothered by shivering.","Bothered by Shivering | Have you, during the past week, been bothered by shivering",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514615","Bothered by Tingling Hands or Feet","C131407","A question about whether an individual is or was bothered by tingling hands or feet.","Bothered by Tingling Hands or Feet | Have you, during the past week, been bothered by tingling hands or feet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514612","Bothered by Sore Mouth and/or Pain When Swallowing","C131408","A question about whether an individual is or was bothered by sore mouth/pain when swallowing.","Bothered by Sore Mouth and/or Pain When Swallowing | Have you, during the past week, been bothered by sore mouth/pain when swallowing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514596","Bothered by Burning and/or Sore Eyes","C131409","A question about whether an individual is or was bothered by burning/sore eyes.","Bothered by Burning and/or Sore Eyes | Have you, during the past week, been bothered by burning/sore eyes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514611","Bothered by Shortness of Breath","C131410","A question about whether an individual is or was bothered by shortness of breath.","Bothered by Shortness of Breath | Have you, during the past week, been bothered by shortness of breath",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514603","Bothered by Dry Mouth","C131411","A question about whether an individual is or was bothered by dry mouth.","Bothered by Dry Mouth | Have you, during the past week, been bothered by dry mouth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514472","Ability to Care for Myself","C131412","A question about the ability of an individual to care for themself.","Ability to Care for Myself Question | Ability to Care for Myself | Ability to Care for Myself | care for myself",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514473","Ability to Go to Work","C131413","A question about the ability of an individual to go to work.","Ability to Go to Work Question | Ability to Go to Work | Ability to Go to Work | go to work",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514463","Only with Help","C131414","A response indicating that an individual is only able to do an activity with help.","Only with Help | only with help",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514688","Without Help, With Difficulty","C131415","A response indicating that an individual is able to do an activity without help but it is difficult.","Without Help, With Difficulty | without help, with difficulty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3853089","Moderately Good","C131416","A subjective response indicating that something is moderately good.","Moderately Good | moderately good",,,,,,,,,,,,,,,"763742","Moderately good",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514462","Neither Good nor Bad","C131417","A subjective response indicating that something is neither good nor bad.","Neither Good nor Bad | neither good or bad",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514465","Rather Poor","C131418","A subjective response indicating that something is rather poor.","Rather Poor | rather poor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514494","Extremely Poor","C131419","A subjective response indicating that something is extremely poor.","Extremely Poor | extremely poor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829541","Inferior Mediastinal Lymph Node","C113695","A group of lymph nodes located in the inferior part of the mediastinum.","Inferior Mediastinal Lymph Node | INFERIOR MEDIASTINAL LYMPH NODE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332529","Consistency","C95110","A description about the firmness, uniformity or make-up of an entity.","Consistency | CONSIST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0460078","Icteric Specimen","C98744","A specimen that exhibits a yellowish pigmentation due to jaundice.","Icteric Specimen | ICTERIC",,,,,,,,,,,,,,,"4041969","Sample icteric",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0123677","Insulin Aspart","C47563","A recombinant human insulin analog with rapid-acting, blood glucose-lowering activity. Insulin aspart, acting faster than regular human insulin, regulates glucose metabolism by binding to insulin receptors on muscle and fat cells, thereby facilitating the cellular uptake of glucose. This lowers blood glucose levels. At the same time, insulin aspart inhibits the liver's conversion of stored glycogen into glucose, which also contributes to lower blood glucose levels. Insulin aspart also inhibits lipolysis in adipose tissue, inhibits proteolysis, and enhances protein synthesis. (NCI05)","Insulin Aspart | INSULIN ASPART | Insulin Aspart Recombinant | Novolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2974540","Canagliflozin","C91018","A C-glucoside with a thiophene ring that is an orally available inhibitor of sodium-glucose transporter 2 (SGLT2) with antihyperglycemic activity. Canagliflozin is also able to reduce body weight and has a low risk for hypoglycemia.","Canagliflozin | CANAGLIFLOZIN | JNJ-24831754-ZAE | JNJ-28431754 | JNJ-28431754-AAA | TA-7284",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448978","Side","C80158","A line segment forming part of the perimeter of a plane figure.","Side | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033148","Primidone","C47686","An analog of phenobarbital with antiepileptic property. Although the mechanism of action has not been fully elucidated, primidone probably exerts its actions, in a manner similar to phenobarbital, via activation of gamma-aminobutyric acid (GABA)-A receptor/chloride ionophore complex, which leads to prolonged and increased frequency of opening of the chloride channel within the receptor complex. This results in an alteration in the electrical activity of the nerve cell membrane, causing hyperpolarization and prevention of partial and tonic-clonic seizures. In addition, this agent is partially metabolized to phenobarbital and phenylethylmalonamide (PEMA), which may also contribute to its anti-seizure properties.","Primidone | 2-Deoxyphenobarbital | 4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl- | Myidone | Mysedon | Mysoline, Apo-Primidone | Neurosyn | PRIMIDONE | Primaclone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0069751","Oxcarbazepine","C47643","A dibenzazepine carboxamide derivative with an anticonvulsant property. As a prodrug, oxcarbazepine is converted to its active metabolite, 10-monohydroxy. Although the mechanism of action has not been fully elucidated, electrophysiological studies indicate this agent blocks voltage-gated sodium channels, thereby stabilizing hyper-excited neural membranes, inhibiting repetitive neuronal firing, and decreasing the propagation of synaptic impulses.","Oxcarbazepine | 10,11-Dihydro-10-oxo-5H-dibenz(b,f)azepine-5-carboxamide | OXCARBAZEPINE | Trileptal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0060135","Felbamate","C47530","A propanediol compound with anticonvulsant and antiepileptic properties. Although the exact mechanism of action is unknown, Felbamate may be an antagonist at the strychnine-insensitive glycine-recognition site of the N-methyl-D-aspartate (NMDA) receptor-ionophore complex, thereby blocking the effects of the excitatory amino acids, suppressing neuronal firing, and preventing seizure activity. Felbamate also has weak inhibitory effects on gamma-aminobutyric acid (GABA) receptor binding sites which may contribute to its inhibitory effect on neuronal excitatory.","Felbamate | 2-Phenyl-1,3-propanediol Dicarbamate | Carbamic Acid, 2-phenyltrimethylene Ester | FELBAMATE | Felbatol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507842","Irreversible Electroporation","C131483","A non-thermal ablation modality that is used in the treatment of locally advanced soft tissue tumors. This technique uses ultra-short, but strong, electrical fields to create permanent, lethal nanopores in cell membranes, disrupting cellular homeostasis and causing cell death. The technique may be performed intraoperatively, laparoscopically, or percutaneously.","Irreversible Electroporation | IRE",,,,,,,,,,,,,,,"36684842","Irreversible electroporation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3887636","Ever","C113445","At any time in the past, present, or future.","Ever | At Any Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3146251","Stage IV Colorectal Cancer AJCC v7","C89998","Stage IV includes: IVA: (Any T, Any N, M1a); IVB: (Any T, Any N, M1b).  M1a: Metastasis confined to one organ or site (e.g., liver, lung, ovary, nonregional node).  M1b: Metastases in more than one organ/site or the peritoneum. (AJCC 7th ed.)","Stage IV Colorectal Cancer AJCC v7 | Stage IV Colorectal (Colon or Rectal) Cancer | Stage IV Colorectal Cancer | Stage IV Colorectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032483","Polyethylene Glycol","C762","A polymer made by joining molecules of ethylene oxide and water together in a repeating pattern. Polyethylene glycol can be a liquid or a waxy solid. In medicine, forms of polyethylene glycol can be used in ointments, in drugs or substances to make them stay in the body longer, or in laxatives.","Polyethylene Glycol | Ethanol, 2,2'-(oxybis(2,1-ethanediyloxy)bis)- | Glycol, Polyethylene | Glycol, polyethylene | PEG | POLYETHYLENE GLYCOL, UNSPECIFIED | Poly(oxyethylene) | Polyethylene Glycol 400 | Polyethylene Glycol 8000 | Polyethylene Oxide | polyethylene glycol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152245","Urinary Leakage","C118167","Extravasation of urine outside the urinary collecting system.","Urinary Leakage | Urinary Leak",,,,,,,,,,,,,,,"193598|4283820","Extravasation of urine|Extravasation of urine",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3827806","Tortuous Colon","C113709","A colon that is longer than a normal colon, with additional bends and twists.","Tortuous Colon | ",,,,,,,,,,,,,,,"37108567","Tortuous colon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513505","Viable Cell Count","C130166","The determination of the number of viable cells in a sample.","Viable Cell Count | VBCE | Viable Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514351","ABL1 Gene Rearrangement","C131490","A molecular abnormality indicating rearrangement of the ABL1 gene.","ABL1 Gene Rearrangement | ABL Proto-Oncogene 1, Non-Receptor Tyrosine Kinase Gene Rearrangement | JTK7 Gene Rearrangement | c-ABL1 Gene Rearrangement | v-Abl Abelson Murine Leukemia Viral Oncogene Homolog 1 Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514352","ABL2 Gene Rearrangement","C131489","A molecular abnormality indicating rearrangement of the ABL2 gene.","ABL2 Gene Rearrangement | ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase Gene Rearrangement | ABLL Gene Rearrangement | ARG Gene Rearrangement | Abelson-Related Gene Rearrangement | v-Abl Abelson Murine Leukemia Viral Oncogene Homolog 2 Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514357","ATR Gene Mutation","C131479","A change in the nucleotide sequence of the ATR gene.","ATR Gene Mutation | ATR Serine/Threonine Kinase Gene Mutation | Ataxia Telangiectasia and Rad3 Related Gene Mutation | FRP1 Gene Mutation | MEC1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL373145","BLM c.2207-2212delATCTGAinsTAGATTC","C131464","A complex mutation in the BLM gene consisting of a 6 base pair deletion of the nucleotide sequence ATCTGA encompassing nucleic acid positions 2207 through 2212 accompanied by an insertion of 7 base pairs with the sequence TAGATTC.","BLM NM_000057.3:c.2207_2212delinsTAGATTC | BLM NM_000057.3:c.2207_2212delATCTGAins7 | BLM NM_000057.3:c.2207_2212delATCTGAinsTAGATTC | BLM NM_000057.3:c.2207_2212delATCTGAinsTAGATTC | BLM c.2207-2212delATCTGAinsTAGATTC | BLM c.2207_2212delATCTGAins7 | BLM c.2207_2212delATCTGAinsTAGATTC | BLM c2281delATCTGAinsTAGATTC | BLM(Ash) Mutation | BS c.2207_2212delATCTGAinsTAGATTC | Bloom Syndrome c.2207_2212delATCTGAinsTAGATTC | NM_000057.3:c.2207_2212delATCTGAins7 | NM_000057.3:c.2207_2212delATCTGAinsTAGATTC | NM_000057.3:c.2207_2212delinsTAGATTC | RECQ2 c.2207_2212elATCTGAinsTAGATTC | RECQL2 c.2207_2212delATCTGAinsTAGATTC | RECQL3 c.2207_2212delATCTGAinsTAGATTC | blmAsh Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514252","BLM NP_000048.1:p.Y736fs*4","C131466","A change in the amino acid sequence of Bloom syndrome protein where a frameshift mutation results in the replacement of a tyrosine residue at position 736 with 3 non-canonic amino acids followed by a stop codon.","BLM NP_000048.1:p.Y736fs*4 | BLM NP_000048.1:p.Tyr736fs*4 | BLM Tyr736fs*4 | BLM Y736fs*4 | BLM p.Tyr736fs*4 | BLM p.Y736fs*4 | BLM(Ash) Protein | Bloom Syndrome Protein Tyr736fs*4 | Bloom Syndrome Protein Y736fs*4 | DNA Helicase, RecQ-Like Type 2 Tyr736fs*4 | DNA Helicase, RecQ-Like Type 2 Y736fs*4 | NP_000048.1:p.Tyr736fs*4 | NP_000048.1:p.Y736fs*4 | RecQ Protein-Like 3 Tyr736fs*4 | RecQ Protein-Like 3 Y736fs*4 | RecQ2 Tyr736fs*4 | RecQ2 Y736fs*4 | blmAsh Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514254","BRCA1 NM_007294.3:c.5265_5266insC","C131475","An insertion of a single cytosine nucleotide between positions 5265 and 5266 of the coding sequence of the BRCA1 gene.","BRCA1 NM_007294.3:c.5265_5266insC | BRCA-1 c.5265_5266insC | BRCA1 5382_5383insC,5382insC | BRCA1 5382insC | BRCA1 c.5265_5266insC | BRCA1 c.5266dup | BRCA1 c.5266dupC | BROVCA1 c.5265_5266insC | Breast Cancer 1 c.5265_5266insC | Breast Cancer 1, Early Onset c.5265_5266insC | Breast Cancer Type 1 Susceptibility c.5265_5266insC | NM_007294.3:c.5265_5266insC | NM_007294.3:c.5266dup | NM_007294.3c.5266dupC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514255","BRCA1 NM_007294.3:c.68_69delAG","C131473","A deletion of the two nucleotides in positions 68 and 69 from the coding sequence of the BRCA1 gene.","BRCA1 NM_007294.3:c.68_69delAG | BRCA-1 c.68_69delAG | BRCA1 185delAG | BRCA1 187delAG | BRCA1 c.68_69delAG | BROVCA1 c.68_69delAG | Breast Cancer 1 c.68_69delAG | Breast Cancer 1, Early Onset c.68_69delAG | Breast Cancer Type 1 Susceptibility c.68_69delAG | NM_007294.3:c.68_69delAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514256","BRCA1 NP_009225.1:p.Glu23Valfs","C131474","A change in the amino acid sequence of breast cancer type 1 susceptibility protein where a deletion mutation results in the replacement of the glutamic acid at position 23 with a valine immediately by 16 non-canonical amino acids and a stop codon.","BRCA1 NP_009225.1:p.E23Vfs*17 | BRCA1 E23Vfs*17 | BRCA1 Glu23Valfs | BRCA1 NP_009225.1:p.E23Vfs | BRCA1 NP_009225.1:p.E23Vfs | BRCA1 NP_009225.1:p.Glu23Valfs | BRCA1 NP_009225.1:p.Glu23ValfsTer17 | BRCA1 p.(Glu23ValfsTer17) | BRCA1 p.Glu23Valfs | BRCA1/BRCA2-Containing Complex, Subunit 1 Protein E23Vfs | BRCA1/BRCA2-Containing Complex, Subunit 1 Protein Glu23Valfs | Breast Cancer Type 1 Susceptibility Protein E23Vfs | Breast Cancer Type 1 Susceptibility Protein Glu23Valfs | Breast and Ovarian Cancer Susceptibility Protein 1 Protein E23Vfs | Breast and Ovarian Cancer Susceptibility Protein 1 Protein Glu23Valfs | Breast-Ovarian Cancer Protein E23Vfs | Breast-Ovarian Cancer Protein Glu23Valfs | Fanconi Anemia, Complementation Group S E23Vfs | Fanconi Anemia, Complementation Group S Glu23Valfs | NP_009225.1:p.E23Vfs | NP_009225.1:p.Glu23Valfs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514257","BRCA1 NP_009225.1:p.Q1756Pfs","C131476","A change in the amino acid sequence of breast cancer type 1 susceptibility protein where an insertion mutation results in the replacement of the glutamine at position 1756 with a proline immediately followed by a stop codon.","BRCA1 NP_009225.1:p.Q1756Pfs | BRCA1 Gln1756Profs | BRCA1 NP_009225.1:p.Gln1756Profs | BRCA1 Q1756Pfs | BRCA1 Q1756Pfs*74 | BRCA1 p.(Gln1756ProfsTer74) | BRCA1 p.Gln1756Profs | BRCA1 p.Q1756Pfs | BRCA1/BRCA2-Containing Complex, Subunit 1 Protein Gln1756Profs | BRCA1/BRCA2-Containing Complex, Subunit 1 Protein Q1756Pfs | Breast Cancer Type 1 Susceptibility Protein Gln1756Profs | Breast Cancer Type 1 Susceptibility Protein Q1756Pfs | Breast and Ovarian Cancer Susceptibility Protein 1 Protein Gln1756Profs | Breast and Ovarian Cancer Susceptibility Protein 1 Protein Q1756Pfs | Breast-Ovarian Cancer Protein Gln1756Profs | Breast-Ovarian Cancer Protein Q1756Pfs | Fanconi Anemia, Complementation Group S Gln1756Profs | Fanconi Anemia, Complementation Group S Q1756Pfs | NP_009225.1:p.Gln1756Profs | NP_009225.1:p.Q1756Pfs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL373194","BRCA2 NM_000059.3:c.5946delT","C131477","A deletion of the thymine nucleotide at position 5946 of the coding sequence of the BRCA2 gene.","BRCA2 NM_000059.3:c.5946delT | BRCA2 6174delT | BRCA2 NM_000059.3:c.5946_5946delT | BRCA2 c.5946_5946delT | BRCA2 c.5946delT | BRCC2 c.5946delT | BROVCA2 c.5946delT | Breast Cancer 2 c.5946delT | Breast Cancer 2, Early Onset Gene c.5946delT | Breast Cancer Type 2 Susceptibility Gene c.5946delT | FANCD1 c.5946delT | NM_000059.3:c.5946_5946delT | NM_000059.3:c.5946delT | XRCC11 c.5946delT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514259","Breast Cancer 2 Tumor Suppressor S1982Rfs","C131478","A change in the amino acid sequence of breast cancer type 2 susceptibility protein where a deletion mutation results in the replacement of the serine at position 1982 with an arginine followed by 21 non-canonical amino acids and a stop codon.","BRCA2 NP_000050.2:p.S1982Rfs*22 | BRCA1/BRCA2-Containing Complex, Subunit 2 S1982Rfs | BRCA1/BRCA2-Containing Complex, Subunit 2 Ser1982Argfs | BRCA2 NP_000050.2:p.S1982Rfs | BRCA2 NP_000050.2:p.S1982Rfs | BRCA2 NP_000050.2:p.Ser1982ArgfsTer22 | BRCA2 S1982Rfs | BRCA2 Ser1982Argfs | BRCA2 p.S1982Rfs | BRCA2 p.Ser1982Argfs | Breast Cancer 2 Tumor Suppressor S1982Rfs | Breast Cancer 2 Tumor Suppressor Ser1982Argfs | Breast Cancer 2, Early Onset Protein S1982Rfs | Breast Cancer 2, Early Onset Protein Ser1982Argfs | Breast Cancer Type 2 Susceptibility Protein S1982Rfs | Breast Cancer Type 2 Susceptibility Protein Ser1982Argfs | Breast and Ovarian Cancer Susceptibility Protein 2 S1982Rfs | Breast and Ovarian Cancer Susceptibility Protein 2 Ser1982Argfs | Fanconi Anemia Group D1 Protein S1982Rfs | Fanconi Anemia Group D1 Protein Ser1982Argfs | NP_000050.2:p.S1982Rfs | NP_000050.2:p.Ser1982Argfs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511414","CCNE1 Gene Amplification","C36682","A molecular genetic abnormality indicating the presence of multiple copies of the CCNE1 gene.","CCNE1 Gene Amplification | CCNE Gene Amplification | CCNE1 Amplification | CCNE1 Copy Number Gain | Cyclin E1 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511442","CHEK2 Gene Mutation","C40458","A change in the nucleotide sequence of the CHEK2 gene.","CHEK2 Gene Mutation | CDS1 Gene Mutation | CHK2 Checkpoint Homolog (S. pombe) Gene Mutation | CHK2 Gene Mutation | Checkpoint Kinase 2 Gene Mutation | LFS2 Gene Mutation | RAD53 Gene Mutation | hCds1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1317175","Clonal CCND1 Gene Rearrangement","C27714","A molecular abnormality indicating rearrangement of the CCND1 gene in clonal populations of either lymphocytes or lymphocyte lineage neoplastic cells.","Clonal CCND1 Gene Rearrangement | BCL-1 Rearrangement | CCND1 Gene Rearrangement | Clonal BCL-1 Gene Rearrangement | Clonal Cyclin D1 Gene Rearrangement | Cyclin D1 Gene Rearrangement | Monoclonal BCL-1 Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516673","Clonal Immunoglobulin Heavy Chain Gene Rearrangement","C36444","A molecular abnormality indicating rearrangement of the IGH gene in clonal populations of either lymphocytes or lymphocyte lineage neoplastic cells.","Clonal Immunoglobulin Heavy Chain Gene Rearrangement | Clonal IGH Gene Rearrangement | IGH Gene Rearrangement | Monoclonal Immunoglobulin Heavy Chain Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514368","Cytomegalovirus Positive","C131328","An indication that cytomegalovirus has been detected in a sample.","Cytomegalovirus Positive | CMV Positive | HHV-5 Positive | Human Herpesvirus 5 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515575","del(11q22q23)","C36422","A chromosomal aberration where there is a loss of part of the long arm of chromosome 11, which deletes the chromosomal bands q22 and q23.","del(11q22q23) | 11q22-23 Deletion | 11q22-q23 Deletion | del(11)(q22-q23) | del(11)(q22q23) | del(11q22-q23)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514489","EMSY Gene Amplification","C131453","A molecular genetic abnormality indicating the presence of multiple copies of the EMSY gene.","EMSY Gene Amplification | C11orf30 Gene Amplification | EMSY, BRCA2 Interacting Transcriptional Repressor Gene Amplification | EMSY, BRCA2-Interacting Transcriptional Repressor Gene Amplification | GL002 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514389","FANCA Gene Amplification","C131457","A molecular genetic abnormality indicating the presence of multiple copies of the FANCA gene.","FANCA Gene Amplification | FA Gene Amplification | FA-H Gene Amplification | FA1 Gene Amplification | FAA Gene Amplification | FACA Gene Amplification | FAH Gene Amplification | FANCH Gene Amplification | Fanconi Anemia Complementation Group A Gene Amplification | Fanconi Anemia, Complementation Group A Gene Amplification | Fanconi Anemia, Complementation Group H Gene Amplification | Fanconi Anemia, Type 1 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514393","FANCC Gene Amplification","C131456","A molecular genetic abnormality indicating the presence of multiple copies of the FANCC gene.","FANCC Gene Amplification | FA3 Gene Amplification | FAC Gene Amplification | FACC Gene Amplification | Fanconi Anemia Complementation Group C Gene Amplification | Fanconi Anemia, Complementation Group C Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514391","FANCD2 Gene Amplification","C131454","A molecular genetic abnormality indicating the presence of multiple copies of the FANCD2 gene.","FANCD2 Gene Amplification | FA-D2 Gene Amplification | FA4 Gene Amplification | FACD Gene Amplification | FAD Gene Amplification | FAD2 Gene Amplification | FANCD Gene Amplification | Fanconi Anemia Complementation Group D2 Gene Amplification | Fanconi Anemia, Complementation Group D2 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514396","FANCE Gene Amplification","C131455","A molecular genetic abnormality indicating the presence of multiple copies of the FANCE gene.","FANCE Gene Amplification | FACE Gene Amplification | FAE Gene Amplification | Fanconi Anemia Complementation Group E Gene Amplification | Fanconi Anemia, Complementation Group E Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514354","FBXW7 Gene Mutation","C131484","A change in the nucleotide sequence of the FBXW7 gene.","FBXW7 Gene Mutation | AGO Gene Mutation | Archipelago Homolog Gene Mutation | Archipelago Homolog, Drosophila Gene Mutation | CDC4 Gene Mutation | F-Box and WD Repeat Domain Containing 7 Gene Mutation | F-box and WD-40 Domain Protein 7 (Archipelago Homolog, Drosophila) Gene Mutation | FBW6 Gene Mutation | FBW7 Gene Mutation | FBX30 Gene Mutation | FBXW6 Gene Mutation | FBXW7 mutation | SEL-10 Gene Mutation | SEL10 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514498","FCER2 Negative","C131487","Indicates that expression of FCER2 has not been detected in a sample.","FCER2 Negative | CD23 Antigen Negative | CD23 Negative | Fc Fragment of IgE Receptor I Negative | Fc-Epsilon-RII Negative | Immunoglobulin E-Binding Factor Negative | Low Affinity Immunoglobulin Epsilon Fc Receptor Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514566","Human Papillomavirus Negative","C131488","Indicates that human papillomavirus has not been detected in a sample.","Human Papillomavirus Negative | HPV Negative | Human Papilloma Virus Negative | None",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514518","JAK2 Fusion Positive","C131486","Indicates that expression of a fusion containing sequences from JAK2 has been detected in a sample.","JAK2 Fusion Positive | JAK-2 Fusion Positive | JTK10 Fusion Positive | Janus Kinase 2 Fusion Positive | Tyrosine-Protein Kinase JAK2 Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514319","Microsatellite Stable","C131459","Indicates that no positive loci have been detected in the microsatellite instability (MSI) biomarkers in a sample.","Microsatellite Stable | MSI Stable | MSI stable | MSS | Stable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514423","Mismatch Repair Protein Proficient","C131458","Indicates that normal concentrations of unmutated mismatch repair proteins have been detected in a sample.","Mismatch Repair Protein Proficient | MMR-P | MMRP | Mismatch Repair Protein-Proficient | pMMR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514309","MSH2 NM_000251.2:c.1906G>C","C131461","A nucleotide substitution at position 1906 of the coding sequence of the MSH2 gene where guanine has been mutated to cytosine.","MSH2 NM_000251.2:c.1906G>C | HNPCC c.1906G>C | HNPCC1 c.1906G>C | MSH2 c.1906G>C | MutS Homolog 2 c.1906G>C | NM_000251.2:c.1906G>C | Postmeiotic Segregation Increased 1 c.1906G>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1836362","MSH2 NP_000242.1:p.A636P","C131463","A change in the amino acid residue at position 636 in DNA mismatch repair protein Msh2 where alanine has been replaced by proline.","MSH2 NP_000242.1:p.A636P | DNA Mismatch Repair Protein Msh2 A636P | DNA Mismatch Repair Protein Msh2 Ala636Pro | MSH2 A636P | MSH2 Ala636Pro | MSH2 NP_000242.1:p.Ala636Pro | MSH2 p.A636P | MSH2 p.Ala636Pro | MutS Homolog 2 A636P | MutS Homolog 2 Ala636Pro | MutS Protein Homolog 2 A636P | MutS Protein Homolog 2 Ala636Pro | NP_000242.1:p.A636P | NP_000242.1:p.Ala636Pro",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515562","MYC Gene Amplification","C36641","A molecular genetic abnormality indicating the presence of multiple copies of the MYC gene.","MYC Gene Amplification | MRTL Gene Amplification | MYC Amplification | MYCC Gene Amplification | bHLHe39 Gene Amplification | c-myc Gene Activation | c-myc Gene Amplification | v-MYC Myelocytomatosis Viral Oncogene Homolog (Avian) Gene Amplification | v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514538","PDGFRA Positive","C131460","Indicates that PDGFRA expression has been detected in a sample.","PDGFRA Positive | CD140A Positive | PDGFR-2 Positive | PDGFR2 Positive | PDGFRalpha Positive | Platelet Derived Growth Factor Receptor Alpha Positive | Platelet-Derived Growth Factor Receptor Alpha Positive | RHEPDGFRA Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514398","RAD51C Gene Mutation","C131480","A change in the nucleotide sequence of the RAD51C gene.","RAD51C Gene Mutation | BROVCA3 Gene Mutation | FANCO Gene Mutation | RAD51 Homolog C Gene Mutation | RAD51 Paralog C Gene Mutation | RAD51L2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514581","RAD51D Gene Mutation","C131481","A change in the nucleotide sequence of the RAD51D gene.","RAD51D Gene Mutation | BROVCA4 Gene Mutation | R51H3 Gene Mutation | RAD51 Homolog D Gene Mutation | RAD51 Paralog D Gene Mutation | RAD51-Like 3 Gene Mutation | RAD51L3 Gene Mutation | TRAD Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514447","RB1 Negative","C131482","Indicates that expression of RB1 has not been detected in a sample.","RB1 Negative | RB Negative | RB1 Loss | Rb Loss | Retinoblastoma 1 Negative | Retinoblastoma Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514330","TNFRSF8 Low","C131485","Indicates that low expression of TNFRSF8 has been detected in a sample.","TNFRSF8 Low | CD30 Antigen Low | CD30 Low | Ki-1 Antigen Low | Ki-1 Low | Low Expression of CD30 | Low Expression of TNFRSF8 | Tumor Necrosis Factor Receptor Superfamily Member 8 Low",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987195","Pancreatic Intraductal Papillary Mucinous Neoplasm, Pancreatobiliary-Type","C95512","A pancreatic intraductal papillary mucinous neoplasm characterized by the presence of neoplastic epithelial cells that form thin-branching papillae and exhibit high grade dysplasia.","Pancreatic Intraductal Papillary Mucinous Neoplasm, Pancreatobiliary-Type | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987197","Pancreatic Intraductal Papillary Mucinous Neoplasm, Oncocytic-Type","C95514","A pancreatic intraductal papillary mucinous neoplasm characterized by the presence of neoplastic epithelial cells with abundant eosinophilic granular cytoplasm.","Pancreatic Intraductal Papillary Mucinous Neoplasm, Oncocytic-Type | Intraductal papillary-mucinous adenoma | Pancreatic IOPN | Pancreatic Intraductal Oncocytic Papillary Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987189","Pancreatic Intraductal Tubulopapillary Neoplasm","C95506","An epithelial neoplasm that arises from the exocrine pancreas characterized by the formation of tubular structures, high grade dysplasia, and ductal differentiation. Grossly, it is characterized by the presence of intraductal nodular masses. Morphologically, there are nodules of tubular glands and occasional papillary structures growing in dilated ducts.  There is no significant mucin production. Signs and symptoms include epigastric pain, weight loss, vomiting, steatorrhea, and diabetes mellitus.","Pancreatic Intraductal Tubulopapillary Neoplasm | ITPN | Pancreatic ITPN | Pancreatic Intraductal Tubular Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707090","CCR1 wt Allele","C51318","Human CCR1 wild-type allele is located within 3p21 and is approximately 6 kb in length. This allele, which encodes C-C chemokine receptor type 1 protein, is involved in signal transduction and recruitment of effector immune cells to the site of inflammation. This allele has purported roles in host protection from inflammatory responses, and susceptibility to virus and parasite invasion.","CCR1 wt Allele | C-C CKR-1 Gene | C-C Chemokine Receptor Type 1 Gene | CC-CKR-1 Gene | CCR-1 Gene | CD191 | CKR-1 Gene | CKR1 | CMKBR1 Gene | CMKR1 Gene | Chemokine (C-C Motif) Receptor 1 wt Allele | Chemokine, CC Motif, Receptor 1 Gene | HM145 Gene | LD78 Receptor Gene | MIP-1Alpha-R Gene | MIP1aR Gene | Macrophage Inflammatory Protein-1 Alpha Receptor Gene | RANTES Receptor Gene | RANTES-R Gene | SCYAR1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514407","Past Seven Days Any Spots or Lines that Drift in Front of Your Eyes","C131346","A question about whether or not an individual had any spots or drifting lines in front of their eyes over the past seven days.","Past Seven Days Any Spots or Lines that Drift in Front of Your Eyes | In the past 7 days, did you have any spots or lines (floaters) that drift in front of your eyes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335472","Premalignant Neoplasm","C36032","A neoplasm that is composed of dysplastic cells and there is no morphologic evidence of infiltration of the surrounding tissues.","Premalignant Neoplasm | Premalignant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514406","Past Seven Days Any Pain, Swelling, or Redness at Site of Drug Injection or IV","C131350","A question about whether an individual had any pain, swelling, or redness at the site of a drug injection or IV over the past seven days.","Past Seven Days Any Pain, Swelling, or Redness at Site of Drug Injection or IV | In the past 7 days, did you have any pain, swelling, or redness at a site of drug injection or IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514415","Worst Severity Past Seven Days Shivering or Shaking Chills","C131352","A question about the worst severity of an individual's shivering or shaking chills over the past seven days.","Worst Severity Past Seven Days Shivering or Shaking Chills | In the past 7 days, what was the severity of your shivering or shaking chills at their worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514413","Worst Severity Past Seven Days Hot Flashes","C131355","A question about an individual's observation of the worst severity they have experienced related to hot flashes over the past seven days.","Worst Severity Past Seven Days Hot Flashes | In the past 7 days, what was the severity of your hot flashes at their worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514007","Neoplastic Large Pleomorphic Germ Cell","C36905","No Value Exists","Neoplastic Large Pleomorphic Germ Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332638","Small Cell Carcinoma of Breast","C6760","A poorly differentiated neuroendocrine carcinoma that arises from the breast.  It is characterized by the presence of small neuroendocrine cells and high mitotic activity.","Breast Small Cell Neuroendocrine Carcinoma | Breast Small Cell Carcinoma | Breast Small Cell Carcinoma | Oat Cell Carcinoma of Breast | Oat Cell Carcinoma of the Breast | Small Cell Carcinoma of Breast | Small Cell Carcinoma of the Breast | Small Cell Neuroendocrine Carcinoma of Breast | Small Cell Neuroendocrine Carcinoma of the Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896675","Extrapyramidal Symptom Rating Scale-Abbreviated Clinical Classification","C117997","A standardized rating scale originally developed by Chouinard et al in 1980, which is used to measure drug-induced extrapyramidal symptoms (EPS) or 4 types of drug-induced movement disorders (DIMD): parkinsonism, akathisia, dystonia, and tardive dyskinesia. The questionnaire contains 28 questions and generates 4 subscales and 4 clinical global impression severity (CGI-S) scales.","Extrapyramidal Symptom Rating Scale-Abbreviated Clinical Classification | ESRS-A | ESRSA | ESRSA1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040615","Antipsychotic Agent","C29710","Also known as neuroleptics, major tranquilizers, or antischizophrenics, natural or synthetic. Antipsychotic Agents relieve and control the symptoms of schizophrenic illness (hallucinations, delusions, dementia). Most antipsychotic agents interfere with various neurotransmitter functions, often blocking dopamine receptors, and induce diverse behavioral, endocrine, motor-kinetic effects. (NCI04)","Antipsychotic Agent | Antischizophrenic Agent | Major Tranquilizer | Neuroleptic Agent | antipsychotic | antipsychotic agent | neuroleptic agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512982","Monoallelic Mutation","C129830","A mutation that occurs on one allele of a gene.","Monoallelic Mutation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512953","Biallelic Mutation","C129829","A mutation that occurs on both alleles of a single gene.","Biallelic Mutation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055022","FLT3-Internal Tandem Duplication High Allelic Ratio","C123406","A molecular genetic finding in acute myeloid leukemias indicating that FLT3-internal tandem duplication (FLT3-ITD) is the dominant lesion, and which is present in the majority or all of the leukemic cells.","FLT3-Internal Tandem Duplication High Allelic Ratio | FLT3-ITD High Allelic Ratio | FLT3-Internal Tandem Duplication Amplification | FLT3/ITD High Allelic Ratio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509521","Occurrence Indicator","C127786","An indication as to whether something has happened, such as an event or intervention.","Occurrence Indicator | OCCUR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517952","Loss of Chromosome 11q","C37312","A cytogenetic abnormality that refers to the loss of all or part of the long arm of chromosome 11 (11q).","Loss of Chromosome 11q | 11q Deletion | Loss of Chromosome 11q (Deletion) | del(11q)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333281","Desmoplastic Stroma Formation","C36003","No Value Exists","Desmoplastic Stroma Formation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828515","Poorly Formed Pattern","C113734","A morphologic finding indicating the presence of a malignant cellular infiltrate with poorly defined glands in a tissue sample.","Poorly Formed Pattern | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227276","Paneth Cell","C12593","A granule-rich columnar epithelial cell found in the mucous membrane lining at the base of the small intestine crypts of Lieberkühn. Paneth Cells secrete antimicrobial peptides that contribute to microbial density in the lumen of the small intestine and in the maintenance of the gastrointestinal barrier.","Paneth Cell | Paneth Cells",,,,,,,,,,,,,,,"4225270","Paneth cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1515863","Prostate Acinar Foamy Gland Adenocarcinoma","C39882","Acinar prostate adenocarcinoma characterized by the presence of malignant cells with abundant xanthomatous appearing cytoplasm.","Prostate Acinar Foamy Gland Adenocarcinoma | Acinar Prostate Adenocarcinoma, Foamy Gland Variant | Acinar Prostate Adenocarcinoma, Foamy Gland Variant | Prostate Acinar Adenocarcinoma, Foamy Gland Variant | Prostate Foamy Gland Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333163","Cribriform Pattern","C35920","A morphologic finding indicating the presence of sheets of malignant epithelial cells punctuated by gland-like spaces in a tissue sample.","Cribriform Pattern | CRIBRIFORM CHANGE | Cribiform | Pseudoglandular Formation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812213","Fetal Bovine Serum","C113696","The serum blood fraction obtained from cow fetuses and used as a component of growth medium.","Fetal Bovine Serum | FBS | FCS | Fetal Calf Serum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831579","Alcohol/Polyethylene Glycol-based Cytology Fixative","C113703","A partial fixative used for the preparation of cytology specimens from sputum samples.","Alcohol/Polyethylene Glycol-based Cytology Fixative | Saccomanno Fixative | Saccomanno's Cytology Fixative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332628","Breast Fibrocystic Change, Non-Proliferative Type","C6943","Breast fibrocystic change characterized by the absence of epithelial cell hyperplasia.","Breast Fibrocystic Change, Non-Proliferative Type | Non-Proliferative Fibrocystic Change | Non-Proliferative Fibrocystic Change of Breast | Non-Proliferative Fibrocystic Change of the Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0189395","Bronchoscopy with Bronchoalveolar Lavage","C38042","A procedure in which cells are taken from the inside of the airways that lead to the lungs. A bronchoscope (a thin, tube-like instrument with a light and a lens for viewing) is inserted through the nose or mouth into the lungs.  A mild salt solution is washed over the surface of the airways to collect cells, which are then looked at under a microscope. Bronchial washing is used to find infections. It may also help find cancer or changes in cells that may lead to cancer.","Bronchoscopy with Bronchoalveolar Lavage | Bronchoscopy/Lavage | bronchial washing",,,,,,,,,,,,,,,"4287484","Bronchoscopy and bronchoalveolar lavage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL938072","Bladder Urothelial Proliferation of Uncertain Malignant Potential","C27880","Marked thickening of the bladder urothelium with minimal or absent cytologic atypia and absence of true papillary formations. It is found most commonly on routine follow-up cystoscopy in patients with a history of papillary urothelial neoplasms. (WHO 2016)","Bladder Urothelial Proliferation of Uncertain Malignant Potential | Intraurothelial Neoplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL374463","Laser Interstitial Thermal Therapy","C68680","A thermal ablation therapy in which neoplasms are heated with prolonged and moderate temperature elevations.  It results in coagulative necrosis in the heated tissue.","Laser Interstitial Thermal Therapy | LITT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3275049","Skilled Nursing Facility with Medicare Certification in Anticipation of Covered Skilled Care","C99914","A medical center equipped with a trained nursing staff that is eligible to receive Medicare funding. (ACC)","Skilled Nursing Facility with Medicare Certification in Anticipation of Covered Skilled Care | SKILLED NURSING FACILITY (SNF) WITH MEDICARE CERTIFICATION IN ANTICIPATION OF COVERED SKILLED CARE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514695","Premorbid Adjustment Scale","C131525","A 26-item, retrospective questionnaire designed to assess the degree of an individual's achievement of developmental goals from childhood through adulthood, prior to the onset of schizophrenia. This rating scale includes measures for sociability and social withdrawal, peer relationships, scholastic performance, adaptation to school, and ability to form socio-sexual relationships. Performance is scored on a 7-point scale ranging from 0 (healthiest adjustment) to 6 (lowest adjustment).","Premorbid Adjustment Scale | PAS | Premorbid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514362","Brief Psychiatric Rating Scale - version 4","C131527","A clinician-administered rating scale for assessing the severity of psychopathology in individuals diagnosed with psychotic disorders, especially schizophrenia. The measure consists of 18 symptom constructs covering positive symptoms, negative symptoms, and mood with each item rated from 1 (not present) to 7 (extremely severe).","Brief Psychiatric Rating Scale - version 4 | BPRS-4 | BPRS-v4 | Brief Psychiatric Rating Scale Expanded Version (4.0) | Brief Psychiatric Rating Scale v4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514275","Computerized Neurocognitive Battery","C131528","A series of tests designed to measure performance accuracy and speed on specific neurobehavioral tasks. The included tests measure: abstraction and mental flexibility, attention, working memory, episodic memory (word, face, and spatial recognition memory), language reasoning, spatial processing, sensorimotor, motor speed, and emotion identification. Accuracy is scored as the total number of correct responses and speed is scored as the median response time (RT) for correct items.","Computerized Neurocognitive Battery | CNB | Computerized Neurocognitive Battery (CNB)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514349","AX-Continuous Performance Test","C131530","A measure of sustained attention where the subject is instructed to respond one way whenever the stimulus is an X that was preceded by an A and another way for all other stimuli, including an A, an X that was not preceded by an A, and any other letter.","AX-Continuous Performance Test | A-X CPT | AX Continuous Performance Test | AX-CPT | AX-type CPT | Continuous Performance Test - AX version",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514716","Auditory Continuous Performance Test","C131529","A test designed to identify auditory attention deficits. The test requires that a subject listen to a list of single words and respond when hearing the targeted word. The test can aid in the diagnosis of ADD or ADHD in children 6 through 11.","Auditory Continuous Performance Test | ACPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514341","Three-Dimensional Magnetization-Prepared Rapid Gradient Echo Imaging","C131532","A 3-dimensional imaging technique that combines the power of magnetization-prepared imaging and rapid 3-D gradient echo acquisition techniques to provide excellent tissue contrasts, high spatial resolution, and full tissue coverage in a short scan time. This technique is applicable for 3D imaging throughout the body.","Three-Dimensional Magnetization-Prepared Rapid Gradient Echo Imaging | 3-Dimensional Magnetization-Prepared Rapid Gradient Echo Imaging | 3D MP RAGE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514453","Structured Clinical Interview for DSM-5","C131531","A semi-structured interview designed to guide a clinician or trained mental health professional through the DSM-5 diagnostic process. The included interview questions correspond to specific DSM-5 criteria and aids in rating each as either present or absent.","Structured Clinical Interview for DSM-5 | SCID-5 | Structured Clinical Interview for DSM-5 (SCID-5) | Structured Clinical Interview for DSM-5 Disorders",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0185317","Joint Replacement","C131579","A surgical procedure to replace part, or all structures, of a joint with an orthopedic prosthesis.","Joint Replacement | Arthroplasty (Total Joint Replacement Surgery) | Joint Replacement Surgery | Replacement Arthroplasty | Total Joint Replacement Surgery",,,,,,,,,,,,,,,"4189532","Implantation of joint prosthesis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0071767","Potassium Hydroxide","C28204","A toxic and highly corrosive chemical used to make soap, in bleaching, and as a paint remover. It is used in small amounts as a food additive and in the preparation of some drugs.","Potassium Hydroxide | KOH | POTASSIUM HYDROXIDE | potassium hydroxide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0200971","Calcofluor White Staining Method","C85577","A microscopy staining method that utilizes calcofluor, a fluorescent dye that preferentially stains chitin and cellulose on the cell walls of fungi, parasites, and some cysts of the Pneumocystis genus.","Calcofluor White Staining Method | CALCOFLUOR WHITE STAIN",,,,,,,,,,,,,,,"4299504","Calcofluor white stain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523205","Giemsa Staining Method","C85598","A microscopy staining method that utilizes Giemsa, a mixture of ethylene blue and eosin, which forms purplish-black crystals when dried. This stain preferentially binds to the phosphate groups of DNA and aggregates at areas with an increase in adenine-thymine binding, thus leading to chromosomal staining patterns that lend themselves to g-banding analysis. Additionally Giemsa can be used as a differential stain to determine microbial cell adherence to human cells as well as in the diagnosis of malaria, spirochete, and protozoal infections.","Giemsa Staining Method | GIEMSA STAIN",,,,,,,,,,,,,,,"4016367","Giemsa stain method",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1508759","Maribavir","C82254","An orally available benzimidazole riboside compound with activity against cytomegalovirus (CMV). Maribavir is a selective ATP competitor of viral UL97 kinase, which is involved in viral nuclear maturation events, such as viral DNA assembly and movement of viral capsids from the nucleus of infected cells. Maribavir has activity against strains of CMV that are resistant to standard anti-CMV agents.","Maribavir | BW 1263W94 | Benzimidazol-2-amine | LIVTENCITY | MARIBAVIR | NTBC | maribavir",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3806752","Central Nervous System Involvement","C122715","A finding indicating the involvement of the central nervous system by a malignant neoplasm.","Central Nervous System Involvement | CNS Involvement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0679228","Diagnostic Criteria","C117960","A standard from which a judgment concerning a medical diagnosis can be established.","Diagnostic Criteria | DXCRIT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514568","Have Difficulty Breathing When Exposed to Cold Temperatures","C131636","A question about whether an individual has or had difficulty breathing when exposed to cold temperatures","Have Difficulty Breathing When Exposed to Cold Temperatures | I have difficulty breathing when I am exposed to cold temperatures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514565","Beta-D-Glucan Assay","C131637","A laboratory assay designed to detect elevated levels of (1,3)-beta-D-glucan in serum as an indication of infection by certain fungi species.","Beta-D-Glucan Assay | Beta-D-Glucan Serum Assay | Fungitell Assay | Fungitell beta-D Glucan Assay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4048785","MELD - Score","C121076","Model for End Stage Liver Disease (MELD) MELD score.","MELD - Score | MELD01-Score | MELD0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984267","Arrhythmogenic Right Ventricular Cardiomyopathy Pathway","C91454","Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart muscle disease that may result in arrhythmia, heart failure, and sudden death. The hallmark pathological findings are progressive myocyte loss and fibrofatty replacement, with a predilection for the right ventricle. A number of genetic studies have identified mutations in various components of the cardiac desmosome that have important roles in the pathogenesis of ARVD/C. Disruption of desmosomal function by defective proteins might lead to death of myocytes under mechanical stress. The myocardial injury may be accompanied by inflammation. Since regeneration of cardiac myocytes is limited, repair by fibrofatty replacement occurs. Several studies have implicated that desmosome dysfunction results in the delocalization and nuclear translocation of plakoglobin. As a result, competition between plakoglobin and beta-catenin will lead to the inhibition of Wnt/beta-catenin signaling, resulting in a shift from a myocyte fate towards an adipocyte fate of cells. The ryanodine receptor plays a crucial part in electromechanical coupling by control of release of calcium from the sarcoplasmic reticulum into the cytosol. Therefore, defects in this receptor could result in an imbalance of calcium homeostasis that might trigger cell death.","Arrhythmogenic Right Ventricular Cardiomyopathy Pathway | ARVC Pathway | Arrhythmogenic right ventricular cardiomyopathy (ARVC)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL366102","Cardiovascular Complication","C115199","Any heart or vascular disorder occurring as a consequence of injury to the cardiovascular system.","Cardiovascular Complication | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281169","Pulmonary Complication","C115337","Any pulmonary disorder occurring as a consequence of injury to the lungs.","Pulmonary Complication | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0161819","Digestive System Complication","C115214","Any disorder of the organs of the digestive system occurring as a consequence of injury to the digestive system.","Digestive System Complication | Gastrointestinal Complication",,,,,,,,,,,,,,,"200447","Gastrointestinal complication",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0216660","Zanamivir","C47786","A sialic acid-analogue neuraminidase inhibitor with antiviral activity. Administered into the respiratory tract by aerosol inhalation, zanamivir selectively binds to and inhibits influenza A and B virus neuraminidase-mediated cleavage of sialic acid residues in host cell membrane-bound glycoprotein receptors for influenza viruses, preventing the release of progeny viruses from host cell surfaces and, so, further viral replication.","Zanamivir | 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic Acid | 5-Acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic Acid | GANA | GG 167 | Relenza | ZANAMIVIR | zanamivir",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035629","Rimantadine","C61927","A cyclic amine and alpha-methyl derivative of amantadine with antiviral activity. Although the exact mechanism of action of rimantadine is not understood, this agent appears to exert its antiviral effect against influenza A virus by interfering with the function of the transmembrane domain of the viral M2 protein, thereby preventing the uncoating of the virus and subsequent release of infectious viral nucleic acids into the cytoplasm of infected cells.","Rimantadine | 1-(1-Adamantyl)ethylamin | HSDB 7438 | RIMANTADINE | Tricyclo(3.3.1.1(sup 3,7))decane-1-methanamine, alpha-methyl- | alpha-Methyl-1-adamantanemethylamine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0672596","Palivizumab","C2625","A humanized monoclonal antibody against the fusion protein (F protein) of human respiratory syncytial virus (RSV), with prophylactic application in respiratory syncytial virus infections. RSV F protein, a small envelop glycoprotein, is not only required for cytopathic syncytia resulting from cell-to-cell fusion, but is also necessary for viral spreading and evading neutralizing antibody. Palivizumab neutralizes and inhibits fusion activity of RSV, thereby preventing syncytia formation. Administration of this antibody does not interfere with other immunizations.","Palivizumab | MEDI 493 | PALIVIZUMAB | Synagis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1675326","Peramivir","C81611","A cyclopentane derivative with activity against influenza A and B viruses. Peramivir is a neuraminidase inhibitor which prevents normal processing of virus particles such that virus particles are not released from infected cells.","Peramivir | (1S,2S,3R,4R)-3-((1S)-1-acetylamino-2-ethylbutyl))-4-((aminoiminomethyl)amino-2-hydroxycyclopentanecarboxylic acid, trihydrate | 3-(1'-acetylamino-2'-ethyl)butyl-4-((aminoimino)methyl)amino-2-hydroxycyclopentane-1-carboxylic acid | BCX1812 | PERAMIVIR | RWJ270201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002403","Amantadine","C61632","A synthetic tricyclic amine with antiviral, antiparkinsonian, and antihyperalgesic activities. Amantadine appears to exert its antiviral effect against the influenza A virus by interfering with the function of the transmembrane domain of the viral M2 protein, thereby preventing the release of infectious viral nucleic acids into host cells. Furthermore, this agent prevents virus assembly during virus replication. Amantadine exerts its antiparkinsonian effects by stimulating the release of dopamine from striatal dopaminergic nerve terminals and inhibiting its pre-synaptic reuptake. This agent may also exert some anticholinergic effect through inhibition of N-methyl-D-aspartic acid (NMDA) receptor-mediated stimulation of acetylcholine, resulting in antihyperalgesia.","Amantadine | AMANTADINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1552961","point - UnitsOfMeasure","C113499","A numeric unit used to quantify a score.","Point | POINT | {POINT} | {point}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1962945","Radiographic Examination","C128940","A radiographic procedure using the emission of penetrating energy waves to form an image of the structure penetrated by the radiation.","Radiographic Examination | RADIOGRAPHY | Radiographic Exam | Radiographic examination | Radiography",,,,,,,,,,,,,,,"4178367","Radiographic imaging procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0070570","Phenol","C1191","Hydroxybenzene; Carbolic Acid. Used as a germicidal agent and as an intermediate in chemical synthesis.  Highly toxic; corrosive to the skin.","Phenol | PHENOL | carbolic acid | phenol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030398","Paraben","C92608","An alkyl ester of p-hydroxybenzoic acid (PHBA) that is used most often as a preservative in various personal care products. Parabens are active against a broad spectrum of microorganisms and exert their activity by disrupting the integrity of the cell membrane, causing leakage of intracellular proteins and interference with membrane transport processes, by inhibiting synthesis of DNA and RNA or by inhibiting the activity of certain enzymes, such as ATPases and phosphotransferases.","Paraben | Paraben Derivatives | Parabens | para-Hydroxybenzoic Acid Ester",,,,,,,,,,,,,,,"4115741","Paraben mix",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032447","Polychlorinated Biphenyl","C760","Polychlorinated Biphenyls (PCBs) are a family of more than 200 chemical compounds (congeners) with 1 to 10 chlorine atoms attached to biphenyl and a general structure of C12H10-xClx. PCBs were commercially produced as complex mixtures of congeners at different degrees of chlorination for a variety of applications. Their use was based on their chemical stability, and desirable physical properties. According to WHO, several congeners are now considered to be 'dioxin-like' because of their toxicity and certain features of their structure similar to 2,3,7,8-tetrachlorodibenzo-p-dioxin. PCBs are not readily biodegradable, their use declined and was essentially terminated because of environmental concerns. USA stopped producing PCBs in 1977. (NCI)","Polychlorinated Biphenyl | Chlorinated Biphenyls | Chlorinated Biphenylsl | Chlorobiphenyls | PCB | PCBs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221074","Postpartum Depression","C92852","A type of clinical depression that occurs after childbirth.","Postpartum Depression | Depressive Episode with Postpartum Onset | Major Depressive Episode with Peripartum Onset | Postnatal Depression",,,,,,,,,,,,,,,"4239471","Postpartum depression",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514444","Pediatric Quality of Life Inventory-Multidimensional Fatigue Scale","C131369","An 18 item component of the Pediatric Quality of Life Inventory is a generic symptom-specific instrument to measure fatigue in pediatric patients ages 2-18 comprised of General Fatigue, Sleep/Rest Fatigue, and Cognitive Fatigue domains.","Pediatric Quality of Life Inventory-Multidimensional Fatigue Scale | PedsQL Multi-Dimensional Fatigue Scale | PedsQL Multidimensional Fatigue Scale | PedsQL-Fatigue | PedsQL-Fatigue Scale | PedsQL-MFS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054467","Morphologic Complete Response","C123595","The disappearance of all signs of cancer, supported by morphological analysis.","Morphologic Complete Response | MORPHOLOGIC CR | Morphologic CR | Morphologic Complete Remission",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205408","Vague","C96303","A term that refers to something not explicit or clear in meaning.","Vague | ",,,,,,,,,,,,,,,"4104614","Vague",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3642217","Per Liter","C105515","A volume unit equal to one liter used as a denominator to build a derived unit expressed as a ratio.","Per Liter | /L | /l",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0920210","Troponin I Measurement","C74749","The determination of the amount of troponin I present in a blood sample.","Troponin I Measurement | TROPONI | Troponin I",,,,,,,,,,,,,,,"4007805","Troponin I measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1141947","Troponin T Measurement","C74750","The determination of the amount of troponin T present in a blood sample.","Troponin T Measurement | TROPONT | Troponin T",,,,,,,,,,,,,,,"4005525","Troponin T measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2982661","Testicular Cancer pT0 TNM Finding v7","C89240","No evidence of primary tumor (e.g., histologic scar in testis). (from AJCC 7th Ed.)","Testicular Cancer pT0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982663","Testicular Cancer pT1 TNM Finding v7","C89242","Testicular cancer with tumor limited to the testis and epididymis without vascular/lymphatic invasion; tumor may invade into the tunica albuginea but not the tunica vaginalis. (from AJCC 7th Ed.)","Testicular Cancer pT1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982664","Testicular Cancer pT2 TNM Finding v7","C89243","Testicular cancer with tumor limited to the testis and epididymis with vascular/lymphatic invasion, or tumor extending through the tunica albuginea with involvement of the tunica vaginalis. (from AJCC 7th Ed.)","Testicular Cancer pT2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982665","Testicular Cancer pT3 TNM Finding v7","C89244","Testicular cancer with tumor invading the spermatic cord with or without vascular/lymphatic invasion. (from AJCC 7th Ed.)","Testicular Cancer pT3 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982666","Testicular Cancer pT4 TNM Finding v7","C89245","Testicular cancer with tumor invading the scrotum with or without vascular/lymphatic invasion. (from AJCC 7th Ed.)","Testicular Cancer pT4 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982662","Testicular Cancer pTis TNM Finding v7","C89241","Intratubular germ cell neoplasia (carcinoma in situ). (from AJCC 7th Ed.)","Testicular Cancer pTis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982660","Testicular Cancer pTX TNM Finding v7","C89239","Testicular cancer in which the primary tumor cannot be assessed. (from AJCC 7th Ed.)","Testicular Cancer pTX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982678","Testicular Cancer Clinical Regional Lymph Nodes TNM Finding v7","C89258","A clinical finding about one or more characteristics of testicular cancer, following the rules of the TNM AJCC v7 classification system as they pertain to staging of regional lymph nodes.  (from AJCC 7th Ed.)","Testicular Cancer Clinical Regional Lymph Nodes TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982680","Testicular Cancer cN0 TNM Finding v7","C89260","Testicular cancer with no regional lymph node metastasis. (from AJCC 7th Ed.)","Testicular Cancer cN0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982681","Testicular Cancer cN1 TNM Finding v7","C89261","Metastasis with a lymph node mass 2 cm or less in greatest dimension; or multiple lymph nodes, none more than 2 cm in greatest dimension. (from AJCC 7th Ed.)","Testicular Cancer cN1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982682","Testicular Cancer cN2 TNM Finding v7","C89262","Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or multiple lymph nodes, any one mass greater than 2 cm but not more than 5 cm in greatest dimension. (from AJCC 7th Ed.)","Testicular Cancer cN2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982683","Testicular Cancer cN3 TNM Finding v7","C89263","Metastasis with a lymph node mass more than 5 cm in greatest dimension. (from AJCC 7th Ed.)","Testicular Cancer cN3 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982679","Testicular Cancer cNX TNM Finding v7","C89259","Testicular cancer in which the regional lymph nodes cannot be assessed.  (from AJCC 7th Ed.)","Testicular Cancer cNX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982684","Testicular Cancer Clinical Distant Metastasis TNM Finding v7","C89264","A clinical finding about one or more characteristics of testicular cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.","Testicular Cancer Clinical Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982685","Testicular Cancer cM0 TNM Finding v7","C89265","Testicular cancer without evidence of distant metastasis. (from AJCC 7th Ed.)","Testicular Cancer cM0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982686","Testicular Cancer cM1 TNM Finding v7","C89266","Testicular cancer with distant metastasis. (from AJCC 7th Ed.)","Testicular Cancer cM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982687","Testicular Cancer cM1a TNM Finding v7","C89267","Testicular cancer with non-regional nodal or pulmonary metastasis. (from AJCC 7th Ed.)","Testicular Cancer cM1a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982688","Testicular Cancer cM1b TNM Finding v7","C89268","Testicular cancer with distant metastasis other than to non-regional lymph nodes and lung.  (from AJCC 7th Ed.)","Testicular Cancer cM1b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982667","Testicular Cancer Pathologic Regional Lymph Nodes TNM Finding v7","C89246","A pathologic finding about one or more characteristics of testicular cancer, following the rules of the TNM AJCC v7 classification system as they pertain to staging of regional lymph nodes.  (from AJCC 7th Ed.)","Testicular Cancer Pathologic Regional Lymph Nodes TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982669","Testicular Cancer pN0 TNM Finding v7","C89248","Testicular cancer with no regional lymph node metastasis. (from AJCC 7th Ed.)","Testicular Cancer pN0 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982670","Testicular Cancer pN1 TNM Finding v7","C89249","Metastasis with a lymph node mass 2 cm or less in greatest dimension and less than or equal to five nodes positive, none more than 2 cm in greatest dimension. (from AJCC 7th Ed.)","Testicular Cancer pN1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982671","Testicular Cancer pN2 TNM Finding v7","C89250","Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or more than five nodes positive, none more than 5 cm; or evidence of extranodal extension of tumor. (from AJCC 7th Ed.)","Testicular Cancer pN2 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982672","Testicular Cancer pN3 TNM Finding v7","C89251","Metastasis with a lymph node mass more than 5 cm in greatest dimension. (from AJCC 7th Ed.)","Testicular Cancer pN3 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982668","Testicular Cancer pNX TNM Finding v7","C89247","Testicular cancer in which regional lymph nodes cannot be assessed.  (from AJCC 7th Ed.)","Testicular Cancer pNX TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982673","Testicular Cancer Pathologic Distant Metastasis TNM Finding v7","C89253","A pathologic finding about one or more characteristics of testicular cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  There is no pathologic M0 for testicular cancer. (from AJCC 7th Ed.)","Testicular Cancer Pathologic Distant Metastasis TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982674","Testicular Cancer pM1 TNM Finding v7","C89254","Testicular cancer with distant metastasis. (from AJCC 7th Ed.)","Testicular Cancer pM1 TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982675","Testicular Cancer pM1a TNM Finding v7","C89255","Testicular cancer with non-regional nodal or pulmonary metastasis. (from AJCC 7th Ed.)","Testicular Cancer pM1a TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982676","Testicular Cancer pM1b TNM Finding v7","C89256","Testicular cancer with metastasis other than to non-regional lymph nodes and lung. (from AJCC 7th Ed.)","Testicular Cancer pM1b TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2217644","stage IIIB testicular cancer","C6368","Stage IIIB includes: (Any pT/TX, N1-3, M0, S2); (Any pT/TX, Any N, M1a, S2).  N1: Metastasis with a lymph node mass 2 cm or less in greatest dimension; or multiple lymph nodes, none more than 2cm in greatest dimension.  N2: Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or multiple lymph nodes, any one mass greater than 2 cm but not more than 5 cm in greatest dimension.  N3: Metastasis with a lymph node mass more than 5 cm in greatest dimension. M0: No distant metastasis. M1a: Non-regional nodal or pulmonary metastasis. S2: LDH 1.5-10 x N (N indicates the upper limit of normal for the LDH assay) or hCG 5,000-50,000 or AFP 1,000-10,000.  (AJCC 6th and 7th eds.)","Stage IIIB Testicular Cancer AJCC v6 and v7 | Stage IIIB | Stage IIIB Cancer of Testis | Stage IIIB Cancer of the Testis | Stage IIIB Testicular Cancer | Stage IIIB Testicular Cancer | Stage IIIB Testicular Cancer AJCC v6 | Stage IIIB Testicular Cancer AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2217643","Testicular Cancer Stage IIIA","C6369","Stage IIIA includes: (Any pT/TX, Any N, M1a, S0); (Any pT/TX, Any N, M1a, S1).  M1a: Non-regional nodal or pulmonary metastasis. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N (N indicates the upper limit of normal for the LDH assay) and hCG less than 5,000 and AFP less than 1,000.  (AJCC 6th and 7th eds.)","Stage IIIA Testicular Cancer AJCC v6 and v7 | Stage IIIA | Stage IIIA Cancer of Testis | Stage IIIA Cancer of the Testis | Stage IIIA Testicular Cancer | Stage IIIA Testicular Cancer | Stage IIIA Testicular Cancer AJCC v7 | Testicular Cancer Stage IIIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278833","stage III testicular cancer","C9074","Stage III includes: Any pT/TX, Any N, M1, SX.  M1: Distant metastasis. SX: Marker studies not available or not performed.  (AJCC 6th and 7th eds.)","Stage III Testicular Cancer AJCC v6 and v7 | Stage III | Stage III Cancer of Testis | Stage III Cancer of the Testis | Stage III Testicular Cancer | Stage III Testicular Cancer | Stage III Testicular Cancer AJCC v6 | Stage III Testicular Cancer AJCC v7 | stage III testicular cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336202","stage IIC testicular cancer","C6366","Stage IIC includes: (Any pT/TX, N3, M0, S0); (Any pT/TX, N3, M0, S1).  pTX: Primary tumor cannot be assessed.  N3: Metastasis with a lymph node mass more than 5 cm in greatest dimension. M0: No distant metastasis. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N (N indicates the upper limit of normal for the LDH assay) and hCG less than 5,000 and AFP less than 1,000.  (AJCC 6th and 7th eds.)","Stage IIC Testicular Cancer AJCC v6 and v7 | Stage IIC | Stage IIC Cancer of Testis | Stage IIC Cancer of the Testis | Stage IIC Testicular Cancer | Stage IIC Testicular Cancer | Stage IIC Testicular Cancer AJCC v6 | Stage IIC Testicular Cancer AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2217641","stage IIB testicular cancer","C6365","Stage IIB includes: (Any pT/TX, N2, M0, S0); (Any pT/TX, N2, M0, S1).  pTX: Primary tumor cannot be assessed.  N2: Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or multiple lymph nodes, any one mass greater than 2 cm but not more than 5 cm in greatest dimension.  M0: No distant metastasis. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N (N indicates the upper limit of normal for the LDH assay) and hCG less than 5,000 and AFP less than 1,000.  (AJCC 6th and 7th eds.)","Stage IIB Testicular Cancer AJCC v6 and v7 | Stage IIB | Stage IIB Cancer of Testis | Stage IIB Cancer of the Testis | Stage IIB Testicular Cancer | Stage IIB Testicular Cancer | Stage IIB Testicular Cancer AJCC v6 | Stage IIB Testicular Cancer AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2217640","stage IIA testicular cancer","C6364","Stage IIA includes: (Any pT/TX, N1, M0, S0); (Any pT/TX, N1, M0, S1).  pTX: Primary tumor cannot be assessed.  N1: Metastasis with a lymph node mass 2 cm or less in greatest dimension; or multiple lymph nodes, none more than 2cm in greatest dimension.  M0: No distant metastasis. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N (N indicates the upper limit of normal for the LDH assay) and hCG less than 5,000 and AFP less than 1,000. (AJCC 6th and 7th eds.)","Stage IIA Testicular Cancer AJCC v6 and v7 | Stage IIA | Stage IIA Cancer of Testis | Stage IIA Cancer of the Testis | Stage IIA Testicular Cancer | Stage IIA Testicular Cancer | Stage IIA Testicular Cancer AJCC v6 | Stage IIA Testicular Cancer AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278832","stage II testicular cancer","C9073","Stage II includes: Any pT/TX, N1-3, M0, SX.  pTX: Primary tumor cannot be assessed.  N1: Metastasis with a lymph node mass 2 cm or less in greatest dimension; or multiple lymph nodes, none more than 2cm in greatest dimension.  N2: Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or multiple lymph nodes, any one mass greater than 2 cm but not more than 5 cm in greatest dimension.  N3: Metastasis with a lymph node mass more than 5 cm in greatest dimension. M0: No distant metastasis. SX: Marker studies not available or not performed.  (AJCC 6th and 7th eds.)","Stage II Testicular Cancer AJCC v6 and v7 | Stage II | Stage II Cancer of Testis | Stage II Cancer of the Testis | Stage II Testicular Cancer | Stage II Testicular Cancer | Stage II Testicular Cancer AJCC v6 | Stage II Testicular Cancer AJCC v7 | stage II testicular cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2217646","stage IS testicular cancer","C6363","Stage IS includes: Any pT/TX, N0, M0, S1-3.  pTX: Primary tumor cannot be assessed.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  S1: LDH less than 1.5 x N (N indicates the upper limit of normal for the LDH assay) and hCG less than 5,000 and AFP less than 1,000.  S2: LDH 1.5-10 x N or hCG 5,000-50,000 or AFP 1,000-10,000.  S3: LDH more than 10 x N or hCG more than 50,000 or AFP more than 10,000. (AJCC 6th and 7th eds.)","Stage IS Testicular Cancer AJCC v6 and v7 | Stage IS | Stage IS Cancer of Testis | Stage IS Cancer of the Testis | Stage IS Testicular Cancer | Stage IS Testicular Cancer | Stage IS Testicular Cancer AJCC v6 | Stage IS Testicular Cancer AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2217638","stage IB testicular cancer","C6362","Stage IB includes: (pT2, N0, M0, S0); (pT3, N0, M0, S0); (pT4, N0, M0, S0).  pT2: Tumor limited to the testis and epididymis with vascular/lymphatic invasion, or tumor extending through the tunica albuginea with involvement of the tunica vaginalis.  pT3: Tumor invades the spermatic cord with or without vascular/lymphatic invasion.  pT4: Tumor invades the scrotum with or without vascular/lymphatic invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  S0: Marker study levels within normal limits. (AJCC 6th and 7th eds.)","Stage IB Testicular Cancer AJCC v6 and v7 | Stage IB | Stage IB Cancer of Testis | Stage IB Cancer of the Testis | Stage IB Testicular Cancer | Stage IB Testicular Cancer | Stage IB Testicular Cancer AJCC v6 | Stage IB Testicular Cancer AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2217637","stage IA testicular cancer","C6361","Stage IA includes: pT1, N0, M0, S0.  pT1: Tumor limited to the testis and epididymis without vascular/lymphatic invasion; tumor may invade into the tunica albuginea but not the tunica vaginalis.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  S0: Marker study levels within normal limits. (AJCC 6th and 7th eds.)","Stage IA Testicular Cancer AJCC v6 and v7 | Stage IA | Stage IA Cancer of Testis | Stage IA Cancer of the Testis | Stage IA Testicular Cancer | Stage IA Testicular Cancer | Stage IA Testicular Cancer AJCC v6 | Stage IA Testicular Cancer AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278831","stage I testicular cancer","C7901","Stage I includes: pT1-4, N0, M0, SX.  pT1: Tumor limited to the testis and epididymis without vascular/lymphatic invasion; tumor may invade into the tunica albuginea but not the tunica vaginalis.  pT2: Tumor limited to the testis and epididymis with vascular/lymphatic invasion, or tumor extending through the tunica albuginea with involvement of the tunica vaginalis.  pT3: Tumor invades the spermatic cord with or without vascular/lymphatic invasion.  pT4: Tumor invades the scrotum with or without vascular/lymphatic invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  SX: Marker studies not available or not performed. (AJCC 6th and 7th eds.)","Stage I Testicular Cancer AJCC v6 and v7 | Stage I | Stage I Cancer of Testis | Stage I Cancer of the Testis | Stage I Testicular Cancer | Stage I Testicular Cancer | Stage I Testicular Cancer AJCC v6 | Stage I Testicular Cancer AJCC v7 | stage I testicular cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0346237","Stage 0 Testicular Cancer AJCC v6 and v7","C4523","Stage 0 includes: pTis, N0, M0, S0.  pTis: Intratubular germ cell neoplasia (carcinoma in situ).  N0: regional lymph node metastasis.  M0: No distant metastasis.  S0: Marker study levels within normal limits. (AJCC 6th and 7th eds.)","Stage 0 Testicular Cancer AJCC v6 and v7 | Stage 0 | Stage 0 Cancer of Testis | Stage 0 Cancer of the Testis | Stage 0 Testicular Cancer | Stage 0 Testicular Cancer | Stage 0 Testicular Cancer AJCC v6 | Stage 0 Testicular Cancer AJCC v7 | stage 0 testicular carcinoma in situ",,,,,,,,,,,,,,,"4244656","Carcinoma in situ of testis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0451144","Edinburgh Postnatal Depression Scale","C131844","A 10-item, self-rating questionnaire designed to screen postpartum women for indications of depression.","Edinburgh Postnatal Depression Scale | EPDS | Edinburgh Postnatal Depression Scale (EPDS)",,,,,,,,,,,,,,,"4164838","Edinburgh postnatal depression scale",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL520307","Virus-specific Cytotoxic T-lymphocytes","C131870","A population of cytotoxic T-lymphocytes (CTLs) specifically reactive to one or more pre-selected viruses, with potential antiviral activity. Upon infusion, after an allogeneic hematopoietic cell transplant (HCT) or in other immunodeficient states, these CTLs help reconstitute viral-specific CTL responses and kill virally infected cells, thereby inhibiting viral infection in immunocompromised patients.","Virus-specific Cytotoxic T-lymphocytes | Virus-specific CTLs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521351","Relational and Item-Specific Encoding Task","C131877","A clinical test designed to assess episodic memory encoding and retrieval processes in individuals with cognitive impairment.","Relational and Item-Specific Encoding Task | Relational and Item-Specific Encoding | Relational and Item-Specific Encoding (RiSE) | RiSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521164","AYA-HEARS","C131878","A questionnaire designed to measure hearing loss or problems experienced by patients who have received treatment for cancer.","AYA-HEARS | Adolescent and Young Adult Hearing Screen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519984","How Often Have Problem with Hearing","C131879","A question about how often an individual had problems with hearing.","How Often Have Problem with Hearing | How often did you have a problem with hearing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519988","How Severe Were Hearing Problems","C131880","A question about how severe an individual's hearing problems are or were.","How Severe Were Hearing Problems | How severe were your hearing problems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519977","How Much Did Hearing Problems Bother You","C131881","A question about how much an individual's hearing problems bothers or bothered them.","How Much Did Hearing Problems Bother You | How much did hearing problems bother you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519978","How Much Did Hearing Problems Interfere with Daily Activities","C131882","A question about how much an individual's hearing problems interferes or interfered with their daily activities.","How Much Did Hearing Problems Interfere with Daily Activities | How much did hearing problems interfere with your daily activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519976","How Hard to Hear When You Talk to One Other Person in Quiet Place","C131883","A question about how hard it was for an individual to hear when they talked to one other person in a quiet place.","How Hard to Hear When You Talk to One Other Person in Quiet Place | How hard was it to hear when you talked to one other person in a quiet place",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519974","How Hard to Hear When You Talk to Group of People in Quiet Place","C131884","A question about how hard it was for an individual to hear when they talked to a group of people in a quiet place.","How Hard to Hear When You Talk to Group of People in Quiet Place | How hard was it to hear when you talked to a group of people in a quiet place",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519975","How Hard to Hear When You Talk to One Other Person in Noisy Place","C131885","A question about how hard it was for an individual to hear when they talked to one other person in a noisy place.","How Hard to Hear When You Talk to One Other Person in Noisy Place | How hard was it to hear when you talked to one other person in a noisy place",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519973","How Hard to Hear When You Talk to Group of People in Noisy Place","C131886","A question about how hard it was for an individual to hear when they talked to a group of people in a noisy place.","How Hard to Hear When You Talk to Group of People in Noisy Place | How hard was it to hear when you talked to a group of people in a noisy place",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520315","When in Group of People and Could Not See Speaker, How Hard to Know Where That Person Was","C131887","A question about how hard it was for an individual to know where a person was if they couldn't see them speaking.","When in Group of People and Could Not See Speaker, How Hard to Know Where That Person Was | When you were in a group of people and couldn't see who was speaking, how hard was it to know where that person was",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519986","How Often Turn Up Volume Watching TV","C131888","A question about how often an individual has or had to turn up the volume when watching TV.","How Often Turn Up Volume Watching TV | How often did you have to turn up the volume when you watched TV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519987","How Often Turn Up Volume When Talking on Phone","C131889","A question about how often an individual has or had to turn up the volume when talking on the phone.","How Often Turn Up Volume When Talking on Phone | How often did you have to turn up the volume when you talked on a phone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796661","Childhood Extracranial Germ Cell Tumor","C68627","A childhood benign or malignant germ cell tumor arising from an anatomic site other than the brain.","Childhood Extracranial Germ Cell Tumor | Extracranial Germ Cell Tumor | extracranial germ cell tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520314","When You Talk on Phone, How Hard to Understand What Other Person Was Saying","C131890","A question about how hard it was for an individual to understand what the other person was saying while talking on a telephone.","When You Talk on Phone, How Hard to Understand What Other Person Was Saying | When you talked on a phone, how hard was it to understand what the other person was saying",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519985","How Often Hear Ringing, Buzzing, Whistling Noises Only You Could Hear","C131891","A question about how often an individual heard ringing, buzzing or whistling noises that only they could hear.","How Often Hear Ringing, Buzzing, Whistling Noises Only You Could Hear | How often did you hear ringing, buzzing or whistling noises that only you could hear",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519989","How Severe Were Ringing, Buzzing, Whistling Noises that Only You Could Hear","C131892","A question about the severity of the ringing, buzzing, or whistling noises that only an individual could hear.","How Severe Were Ringing, Buzzing, Whistling Noises that Only You Could Hear | How severe were the ringing, buzzing, or whistling noises that only you could hear",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519979","How Much Did Ringing, Buzzing, Whistling Noises Bother You","C131893","A question about how much an individual was bothered by ringing, buzzing, or whistling noises.","How Much Did Ringing, Buzzing, Whistling Noises Bother You | How much did ringing, buzzing, or whistling noises bother you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519980","How Much Did Ringing, Buzzing, Whistling Noises Interfere with Your Daily Activities","C131894","A question about how much an individual's daily activities were interfered with by ringing, buzzing, or whistling noises.","How Much Did Ringing, Buzzing, Whistling Noises Interfere with Your Daily Activities | How much did ringing, buzzing, or whistling noises interfere with your daily activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519981","How Much Did Ringing, Buzzing, Whistling Noises Make it Hard to Pay Attention to Things","C131895","A question about how hard it was for an individual to concentrate because of ringing, buzzing, or whistling noises.","How Much Did Ringing, Buzzing, Whistling Noises Make it Hard to Pay Attention to Things | How much did ringing, buzzing, or whistling noises make it hard to pay attention to things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519982","How Often Did Ringing, Buzzing, Whistling Noises Make it Hard to Fall Asleep","C131896","A question about how often ringing, buzzing, or whistling noises make or made it hard for an individual to fall asleep.","How Often Did Ringing, Buzzing, Whistling Noises Make it Hard to Fall Asleep | How often did ringing, buzzing, or whistling noises make it hard to fall asleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519983","How Often Did Ringing, Buzzing, Whistling Noises Wake You from Sleep","C131897","A question about how often ringing, buzzing, or whistling noises woke an individual up from sleep.","How Often Did Ringing, Buzzing, Whistling Noises Wake You from Sleep | How often did ringing, buzzing, or whistling noises wake you up from sleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521218","No Hearing Problems","C131898","A response indicating that an individual did not have hearing problems.","No Hearing Problems | Did not have hearing problems | No Hearing Problems or Hearing Problems Did Not Bother Me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0044837","13-Hydroxyoctadecadienoic Acid","C131741","A monohydroxy fatty acid resulting from the oxidation of linoleic acid or 13-hydroperoxy-9,11-octadecadienoic acid (13-HpODE). 13-HODE may mediate physiological and pathological responses and is a potential biomarker of various human diseases, and could contribute to the progression of certain diseases.","13-Hydroxyoctadecadienoic Acid | 13-HODE | 13-Hydroxy-9,11-Octadecadienoic Acid | 13-Lox | 9,11-Octadecadienoic Acid, 13-Hydroxy-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514250","BARD1 Gene Mutation","C131789","A change in the nucleotide sequence of the BARD1 gene.","BARD1 Gene Mutation | BARD-1 Gene Mutation | BARD1 Gene Mutaton | BRCA1 Associated RING Domain 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511413","CCND1 Gene Amplification","C36652","A molecular genetic abnormality indicating the presence of multiple copies of the CCND1 gene.","CCND1 Gene Amplification | BCL-1 Gene Amplification | BCL1 Gene Amplification | CCND1 Gene Activation | CCND1 amplification | Cyclin D1 Gene Activation | Cyclin D1 Gene Amplification | PRAD1 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514375","CCND2 Gene Amplification","C131785","A molecular genetic abnormality indicating the presence of multiple copies of the CCND2 gene.","CCND2 Gene Amplification | CCND2 Amplification | CCND2 amplification | Cyclin D2 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514376","CCND3 Gene Amplification","C131784","A molecular genetic abnormality indicating the presence of multiple copies of the CCND3 gene.","CCND3 Gene Amplification | CCND3 Amplification | CCND3 amplification | Cyclin D3 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514371","CDK12 Gene Mutation","C131796","A change in the nucleotide sequence of the CDK12 gene.","CDK12 Gene Mutation | CDC2 Related Protein Kinase 7 Gene Mutation | CRK7 Gene Mutation | CRKR Gene Mutation | CRKRS Gene Mutation | Cdc2-Related Kinase, Arginine/Serine-Rich Gene Mutation | Cyclin Dependent Kinase 12 Gene Mutation | Cyclin-Dependent Kinase 12 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514377","CDK4 Gene Amplification","C131786","A molecular genetic abnormality indicating the presence of multiple copies of the CDK4 gene.","CDK4 Gene Amplification | CDK4 Amplification | CDK4 amplification | Cell Division Kinase 4 Gene Amplification | Cyclin Dependent Kinase 4 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514378","CDKN2A Negative","C131787","Indicates that expression of CDKN2A has not been detected in a sample.","CDKN2A Negative | CDKN2A Loss | CDKN2A Null | Cyclin-Dependent Kinase 4 Inhibitor A Negative | Cyclin-Dependent Kinase Inhibitor 2A Negative | Cyclin-Dependent Kinase Inhibitor 2A Null",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514364","CHEK1 Gene Mutation","C131788","A change in the nucleotide sequence of the CHEK1 gene.","CHEK1 Gene Mutation | CHK1 Checkpoint Homolog (S. pombe) Gene Mutation | CHK1 Gene Mutation | Checkpoint Kinase 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514367","Cytomegalovirus Negative","C131807","Indicates that cytomegalovirus has not been detected in a sample.","Cytomegalovirus Negative | CMV Negative | HHV-5 Negative | HHV5 Negative | Human Herpesvirus 5 Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514626","Deleterious BARD1 Gene Mutation","C131776","A change in the nucleotide sequence of the BARD1 gene that is associated with increased risk of disease.","Deleterious BARD1 Gene Mutation | Deleterious BARD-1 Gene Mutation | Deleterious BRCA1 Associated RING Domain 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514627","Deleterious BRIP1 Gene Mutation","C131774","A change in the nucleotide sequence of the BRIP1 gene that is associated with increased risk of disease.","Deleterious BRIP1 Gene Mutation | Deleterious BACH1 Gene Mutation | Deleterious BRCA1 Interacting Protein C-Terminal Helicase 1 Gene Mutation | Deleterious FANCJ Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514578","Deleterious MLH1 Gene Mutation","C131779","A change in the nucleotide sequence of the MLH1 gene that is associated with increased risk of disease.","Deleterious MLH1 Gene Mutation | Deleterious COCA2 Gene Mutation | Deleterious HNPCC2 Gene Mutation | Deleterious MutL Homolog 1 Gene Mutation | Deleterious MutL, E. coli, Homolog of, 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514579","Deleterious MSH2 Gene Mutation","C131777","A change in the nucleotide sequence of the MSH2 gene that is associated with increased risk of disease.","Deleterious MSH2 Gene Mutation | Deleterious COCA1 Gene Mutation | Deleterious HNPCC Gene Mutation | Deleterious HNPCC1 Gene Mutation | Deleterious MutS Homolog 2 Gene Mutation | Deleterious MutS, E. coli, Homolog of, 2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514629","Deleterious MSH6 Gene Mutation","C131778","A change in the nucleotide sequence of the MSH6 gene that is associated with increased risk of disease.","Deleterious MSH6 Gene Mutation | Deleterious HNPCC5 Gene Mutation | Deleterious MutS Homolog 6 Gene Mutation | Deleterious MutS, E. coli, Homolog of, 6 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514630","Deleterious PALB2 Gene Mutation","C131775","A change in the nucleotide sequence of the PALB2 gene that is associated with increased risk of disease.","Deleterious PALB2 Gene Mutation | Deleterious FANCN Gene Mutation | Deleterious Fanconi Anemia, Complementation Group N Gene Mutation | Deleterious PNCA3 Gene Mutation | Deleterious Partner and Localizer of BRCA2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514631","Deleterious PMS2 Gene Mutation","C131780","A change in the nucleotide sequence of the PMS2 gene that is associated with increased risk of disease.","Deleterious PMS2 Gene Mutation | Deleterious HNPCC4 Gene Mutation | Deleterious MLH4 Gene Mutation | Deleterious PMS1 Homolog 2, Mismatch Repair System Component Gene Mutation | Deleterious PMS2CL Gene Mutation | Deleterious PMSL2 Gene Mutation | Deleterious Postmeiotic Segregation Increased (S. cerevisiae) 2 Gene Mutation | Deleterious Postmeiotic Segregation Increased 2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514632","Deleterious RAD51C Gene Mutation","C131781","A change in the nucleotide sequence of the RAD51C gene that is associated with increased risk of disease.","Deleterious RAD51C Gene Mutation | Deleterious BROVCA3 Gene Mutation | Deleterious FANCO Gene Mutation | Deleterious RAD51 Homolog C Gene Mutation | Deleterious RAD51 Paralog C Gene Mutation | Deleterious RAD51L2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514633","Deleterious RAD51D Gene Mutation","C131782","A change in the nucleotide sequence of the RAD51D gene that is associated with increased risk of disease.","Deleterious RAD51D Gene Mutation | Deleterious BROVCA4 Gene Mutation | Deleterious R51H3 Gene Mutatio | Deleterious RAD51 Homolog D Gene Mutation | Deleterious RAD51 Paralog D Gene Mutation | Deleterious RAD51-Like 3 Gene Mutation | Deleterious RAD51L3 Gene Mutation | Deleterious TRAD Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514622","DNA Repair Gene Mutation","C131783","A change in the nucleotide sequence of a gene involved in DNA repair.","DNA Repair Gene Mutation | DNA Repair Mutation | DNA Repair Mutation Positive | DNA Repair Mutation Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514386","ERCC2 Gene Mutation","C131800","A change in the nucleotide sequence of the ERCC2 gene.","ERCC2 Gene Mutation | CXPD Gene Mutation | EM9 Gene Mutation | ERCC Excision Repair 2, TFIIH Core Complex Helicase Subunit Gene Mutation | Excision Repair Cross-Complementing Rodent Repair Deficiency, Complementation Group 2 Gene Mutation | Excision-Repair, Complementing Defective, In Chinese Hamster, 2 Gene Mutation | MAG Gene Mutation | TTD Gene Mutation | TTD1 Gene Mutation | XP4 Gene Mutation | XPD Gene Mutation | XPDC Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514390","FANCA Gene Mutation","C131794","A change in the nucleotide sequence of the FANCA gene.","FANCA Gene Mutation | FA Gene Mutation | FA-H Gene Mutation | FA1 Gene Mutation | FAA Gene Mutation | FACA Gene Mutation | FAH Gene Mutation | FANCH Gene Mutation | Fanconi Anemia Complementation Group A Gene Mutation | Fanconi Anemia, Complementation Group A Gene Mutation | Fanconi Anemia, Complementation Group H Gene Mutation | Fanconi Anemia, Type 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514394","FANCC Gene Mutation","C131792","A change in the nucleotide sequence of the FANCC gene.","FANCC Gene Mutation | FA3 Gene Mutation | FAC Gene Mutation | FACC Gene Mutation | Fanconi Anemia Complementation Group C Gene Mutation | Fanconi Anemia, Complementation Group C Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514392","FANCD2 Gene Mutation","C131790","A change in the nucleotide sequence of the FANCD2 gene.","FANCD2 Gene Mutation | FA-D2 Gene Mutation | FA4 Gene Mutation | FACD Gene Mutation | FAD Gene Mutation | FAD2 Gene Mutation | FANCD Gene Mutation | Fanconi Anemia Complementation Group D2 Gene Mutation | Fanconi Anemia, Complementation Group D2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514397","FANCE Gene Mutation","C131791","A change in the nucleotide sequence of the FANCE gene.","FANCE Gene Mutation | FACE Gene Mutation | FAE Gene Mutation | Fanconi Anemia Complementation Group E Gene Mutation | Fanconi Anemia, Complementation Group E Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3266989","HRAS Gene Mutation","C45934","A change in the nucleotide sequence of the HRAS gene.","HRAS Gene Mutation | C-H-RAS Gene Mutation | C-HA-RAS1 Gene Mutation | H-ras Gene Mutation | HRAS mutation | HRAS1 Gene Mutation | HRas Proto-Oncogene, GTPase Gene Mutation | Ha-ras Gene Mutation | Harvey Rat Sarcoma Viral Oncogene Homolog Gene Mutation | Positive | RASH1 Gene Mutation | v-Ha-ras Harvey Rat Sarcoma Viral Oncogene Homolog Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514308","MRE11 Gene Mutation","C131805","A change in the nucleotide sequence of the MRE11 gene.","MRE11 Gene Mutation | ATLD Gene Mutation | HNGS1 Gene Mutation | MRE11 Homolog A, Double Strand Break Repair Nuclease Gene Mutation | MRE11 Homolog, Double Strand Break Repair Nuclease Gene Mutation | MRE11 Meiotic Recombination 11 Homolog A (S. cerevisiae) Gene Mutation | MRE11A Gene Mutation | MRE11B Gene Mutation | Meiotic Recombination (S. cerevisiae) 11 Homolog A Gene Mutation | Meiotic Recombination 11, S. cerevisiae, Homolog of, A Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517684","MYCL Gene Amplification","C36675","A molecular genetic abnormality indicating the presence of multiple copies of the MYCL gene.","MYCL Gene Amplification | L-myc Gene Amplification | LMYC Gene Amplification | MYCL1 Gene Amplification | v-MYC Avian Myelocytomatosis Viral Oncogene Lung Carcinoma Derived Homolog Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514427","NBN Gene Mutation","C131806","A change in the nucleotide sequence of the NBN gene.","NBN Gene Mutation | AT-V1 Gene Mutation | AT-V2 Gene Mutation | ATV Gene Mutation | NBS Gene Mutation | NBS1 Gene Mutation | Nibrin Gene Mutation | Nijmegen Breakage Syndrome 1 Gene Mutation | P95 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514370","POLD1 Gene Mutation","C131798","A change in the nucleotide sequence of the POLD1 gene.","POLD1 Gene Mutation | CDC2 Gene Mutation | CDC2 Homolog (S. cerevisiae) Gene Mutation | CRCS10 Gene Mutation | DNA Polymerase Delta 1, Catalytic Subunit Gene Mutation | MDPL Gene Mutation | POLD Gene Mutation | Polymerase (DNA Directed), Delta 1, Catalytic Subunit (125kD) Gene Mutation | Polymerase (DNA Directed), Delta 1, Catalytic Subunit Gene Mutation | Polymerase (DNA) Delta 1, Catalytic Subunit Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514540","POLE Gene Mutation","C131797","A change in the nucleotide sequence of the POLE gene.","POLE Gene Mutation | DNA Polymerase Epsilon Catalytic Subunit A Exonuclease Gene Mutation | DNA Polymerase Epsilon, Catalytic Subunit Exonuclease Gene Mutation | POLE1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514541","POLQ Gene Mutation","C131804","A change in the nucleotide sequence of the POLQ gene.","POLQ Gene Mutation | DNA Polymerase Theta Gene Mutation | Polymerase (DNA Directed), Theta Gene Mutation | Polymerase (DNA) Theta Gene Mutation | Polymerase, DNA, Theta Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514464","PRKDC Gene Mutation","C131799","A change in the nucleotide sequence of the PRKDC gene.","PRKDC Gene Mutation | DNA-PKcs Gene Mutation | DNAPK Gene Mutation | DNPK1 Gene Mutation | HYRC Gene Mutation | HYRC1 Gene Mutation | Hyper-Radiosensitivity of Murine SCID Mutation, Complementing 1 Gene Mutation | Hyperradiosensitivity Complementing 1, Mouse, Homolog of Gene Mutation | Protein Kinase, DNA-Activated, Catalytic Polypeptide Gene Mutation | XRCC7 Gene Mutation | p350 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514428","RAD50 Gene Mutation","C131793","A change in the nucleotide sequence of the RAD50 gene.","RAD50 Gene Mutation | NBSLD Gene Mutation | RAD50 (S. cerevisiae) Homolog Gene Mutation | RAD50 Double Strand Break Repair Protein Gene Mutation | RAD50 Homolog (S. cerevisiae) Gene Mutation | RAD50 Homolog, Double Strand Break Repair Protein Gene Mutation | RAD50, S. cerevisiae, Homolog of Gene Mutation | RAD50-2 Gene Mutation | RAD502 Gene Mutation | hRad50 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515719","t(12;22)(q13;q12)","C36374","A cytogenetic abnormality that refers to the a translocation involving the long arm (q13) of chromosome 12 and the long arm (q12) of chromosome 22.","t(12;22)(q13;q12) | t(12;22)(q13;q12) (Clear cell sarcoma) | t(12;22)(q13;q12) (Liposarcoma)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514690","t(2;8)","C131808","A cytogenetic abnormality that involves a translocation between chromosomes 2 and 8.","t(2;8) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514692","t(8;22)","C131810","A cytogenetic abnormality that involves a translocation between chromosomes 8 and 22.","t(8;22) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0235280","Ototoxicity","C66929","Damage to the inner ear as a result of exposure to drugs or chemicals.","Ototoxicity | ",,,,,,,,,,,,,,,"4236623","Ototoxicity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0451019","Barthel Index of Activities of Daily Living","C131914","A clinical assessment tool designed to measure functional independence and need for assistance in mobility, self-care, and activities of daily living.","Barthel Index of Activities of Daily Living | Barthel ADL Index | Barthel Activities of Daily Living (ADL) Index | Barthel Index | Barthel Index of ADL",,,,,,,,,,,,,,,"4167605","Barthel index",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL520844","Past 24 to 48 Hours","C131915","The 24-48 hour period occurring just before the present time.","Past 24 to 48 Hours | Preceding 24 to 48 Hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1290944","Bowel Continence","C131916","A question about an individual's ability to control their bowels.","Bowel Continence | Bowels",,,,,,,,,,,,,,,"4040647","Anorectal continence",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521312","Bladder Continence","C131917","A question about an individual's ability to control their bladder.","Bladder Continence | Bladder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521322","Grooming Ability","C131918","A question about an individual's ability to perform personal hygiene tasks.","Grooming Ability Question | Grooming | Grooming Ability | Grooming Ability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521340","Toilet Use","C131919","A question about an individual's ability to use the toilet.","Toilet Use | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521290","Feeding Ability","C131920","A question about an individual's ability to self feed.","Feeding Ability Question | Feeding | Feeding Ability | Feeding Ability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521289","Transfer Ability","C131921","A question about an individual's ability to move from a bed to a chair and back.","Transfer Ability Question | Transfer | Transfer Ability | Transfer Ability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521308","Mobility Ability","C131922","A question about an individual's ability to move about the house or indoors.","Mobility Ability Question | Mobility | Mobility Ability | Mobility Ability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521295","Dressing Ability","C131923","A question about an individual's ability to select and put on clothes.","Dressing Ability Question | Dressing | Dressing Ability | Dressing Ability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520525","Ability to Use Stairs","C131924","A question about an individual's ability to walk up and down stairs.","Ability to Use Stairs Question | Ability to Use Stairs | Ability to Use Stairs | Stairs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521297","Bathing Ability","C131925","A question about an individual's ability to get in and out of a bathtub or shower and clean their body.","Bathing Ability Question | Bathing | Bathing Ability | Bathing Ability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520649","Fecal Incontinence or Requires Enema","C131926","A response indicating that an individual has fecal incontinence or requires enemas.","Fecal Incontinence or Requires Enema | incontinent (or needs to be given enemata)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520564","Occasional Fecal Accident, Once per Week","C131927","A response indicating that an individual has a fecal accident about once per week.","Occasional Fecal Accident, Once per Week | occasional accident (once/week)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521321","Fecal Continence","C131928","A response indicating that an individual is fecally continent.","Fecal Continence | Continent | Controlling bowels independent | Controls Bowels without Help | Independent for Controlling Bowels",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520303","Urinary Incontinent, or Catheterized and Unable to Manage","C131929","A response indicating that an individual is urinary incontinent or catheterized and unable to manage.","Urinary Incontinent, or Catheterized and Unable to Manage | incontinent, or catheterized and unable to manage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520563","Occasional Urinary Accident, Maximum of Once per 24 Hours","C131930","A response indicating that an individual has urinary accidents, but no more than once per 24 hours.","Occasional Urinary Accident, Maximum of Once per 24 Hours | occasional accident (max. once per 24 hours)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520302","Urinary Continent Over 7 Days","C131931","A response indicating that an individual is or has been urinary continent for over 7 days.","Urinary Continent Over 7 Days | continent (for over 7 days)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520560","Needs Help with Personal Grooming","C131932","A response indicating that an individual needs help with personal grooming care.","Needs Help with Personal Grooming | Does Personal Grooming with Help | Personal toilet (wash face, comb hair, shave, clean teeth) with help | needs help with personal care",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521345","Independent for Personal Grooming","C131933","A response indicating that an individual requires no help with their personal grooming care.","Independent for Personal Grooming | Does Personal Grooming without Help | Personal toilet (wash face, comb hair, shave, clean teeth) independent | independent face/hair/teeth/shaving (implements provided)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521291","Dependent for Toilet Use","C131934","A response indicating that an individual is dependent on others for using the toilet.","Dependent for Toilet Use | dependent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520562","Needs Some Help for Toilet Use","C131935","A response indicating that an individual needs some help but can do something alone.","Needs Some Help for Toilet Use | needs some help, but can do something alone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521156","Independent for Toilet Use","C131936","A response indicating that an individual can use the toilet independently of help from others.","Independent for Toilet Use | Getting on and off toilet (handling clothes, wipe, flush) independent | Uses Toilet without Help | independent (on and off, dressing, wiping)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521309","Unable to Feed Self","C131937","A response indicating that an individual is unable to do feed themself.","Unable to Feed Self | unable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520559","Needs Help with Eating Tasks","C131938","A response indicating that an individual needs help with tasks related to eating, such as cutting food, spreading butter, etc.","Needs Help with Eating Tasks | Feeding with help | Feeds Self with Help | needs help cutting, spreading butter, etc.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521155","Independent for Eating","C131939","A response indicating that an individual can eat independently of help from others when food is provided within reach.","Independent for Eating | independent (food provided within reach)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520267","Unable to Transfer","C131940","A response indicating that an individual lacks sitting balance and is unable to sit or transfer.","Unable to Transfer | unable, no sitting balance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520556","Major Help to Transfer","C131941","A response indicating that an individual can transfer and sit, but needs major, physical help from one or two people.","Major Help to Transfer | major help (one or two people, physical), can sit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520063","Minor Help to Transfer","C131942","A response indicating that an individual needs minor verbal or physical help to transfer.","Minor Help to Transfer | minor help (verbal or physical)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521307","Independent for Transfer","C131943","A response indicating that an individual can transfer independently of help from others.","Independent for Transfer | Independent for Transfer Between Wheelchair and Bed | Independent for Wheelchair Transfer | Moving from wheelchair to bed and return independent | independent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521316","Immobile","C131944","A response indicating that an individual is not mobile.","Immobile | immobile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521343","Wheelchair Independent","C131945","A response indicating that an individual is independent with use of a wheelchair.","Wheelchair Independent | wheelchair independent, including corners, etc.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520311","Walks with Help of One Person","C131946","A response indicating that an individual can walk with verbal or physical help of one person.","Walks with Help of One Person | walks with help of one person (verbal or physical)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520065","Mobily Independent, but May Require a Walking Aid","C131947","A response indicating that an individual is independently mobile but may require the use of an aid, such as a cane or stick.","Mobily Independent, but May Require a Walking Aid | independent (but may use any aid, e.g., stick)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521292","Dependent Dressing","C131948","A response indicating that an individual is dependent on others for dressing.","Dependent Dressing | Dresses with Help | Dressing (includes tying shoes, fastening fasteners) with help | dependent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520561","Needs Help with Dressing but Can Do About Half Unaided","C131949","A response indicating that an individual needs help with dressing but can do about half unaided.","Needs Help with Dressing but Can Do About Half Unaided | needs help, but can do about half unaided",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521344","Independent for Dressing","C131950","A response indicating that an individual can dress independently of help from others.","Independent for Dressing | Dresses without Help | Dressing (includes tying shoes, fastening fasteners) independent | Independent Dressing | Independent Dressing | independent (including buttons, zips, laces, etc.)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520268","Unable to Use Stairs","C131951","A response indicating that an individual is unable to use stairs.","Unable to Use Stairs | unable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520558","Needs Help to Use Stairs","C131952","A response indicating that an individual needs verbal or physical help or a carrying aid to use stairs.","Needs Help to Use Stairs | Ascend and descend stairs with help | Uses Stairs with Help | needs help (verbal, physical, carrying aid)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521342","Independent for Stairs","C131953","A response indicating that an individual can go up and down stairs independently of help from others.","Independent for Stairs | Ascend and descend stairs independent | Uses Stairs without Help | independent up and down",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521293","Dependent Bathing","C131954","A response indicating that an individual is dependent on others to bathe.","Dependent Bathing | Bathes with Help | Bathing self with help | dependent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521157","Independent Bathing or in Shower","C131955","A response indicating that an individual is independent of others for bathing in the tub or shower.","Independent Bathing or in Shower | Bathes without Help | Bathing self independent | independent (or in shower)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519829","Difficulty Falling Asleep Score 0","C131960","A subjective score of 0 on a difficulty falling asleep scale that ranges from 0: No difficulty to 10: Didn't fall asleep.","Difficulty Falling Asleep Score 0 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519831","Difficulty Falling Asleep Score 1","C131961","A subjective score of 1 on a difficulty falling asleep scale that ranges from 0: No difficulty to 10: Didn't fall asleep.","Difficulty Falling Asleep Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514484","Can Easily Swallow Liquid or Soft Food","C131731","A question about whether an individual can easily swallow liquids or soft foods.","Can Easily Swallow Liquid or Soft Food | Can you easily swallow liquid/soft foods",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514634","Difficult to Open Mouth Wide","C131720","A question about whether an individual has or had difficulty opening their mouth wide.","Difficult to Open Mouth Wide | Difficulty Opening Mouth Wide | Is it difficult to open your mouth wide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514355","Easily Full","C131729","A question about whether an individual gets or got easily full.","Easily Full | Are you easily full | Easily Satiated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514495","Eye Dryness Affects Vision or Prevents Working","C131707","A question about whether an individual's eye dryness affects their vision or prevents them from working.","Eye Dryness Affects Vision or Prevents Working | Does your eye dryness affect your vision or prevent you from working",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514388","Eyes Feel Dry or Gritty","C131700","A question about whether an individual's eyes feel or felt dry or gritty.","Eyes Feel Dry or Gritty | Do your eyes feel dry or gritty | Eyes Dry or Gritty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514288","Foods or Pills Get Stuck","C131730","A question about whether an individual experiences or experienced having food or pills get stuck in their throat.","Foods or Pills Get Stuck | Do foods or pills get stuck",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514558","Had Recent Sinus Infection","C131726","A question about whether an individual has or had recent sinus infections.","Had Recent Sinus Infection | Any recent sinus infections",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514560","Had Sinus Drainage Surgery","C131727","A question about whether an individual has or had sinus drainage surgery.","Had Sinus Drainage Surgery | Any sinus drainage surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514638","Hair Thinning or Falling Out","C131698","A question about whether an individual's hair is thinning or falling out.","Hair Thinning or Falling Out | Is your hair thinning or falling out",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514646","Have Difficulty Opening Eyes on Waking","C131703","A question about whether an individual's eyes are difficult to open on waking.","Have Difficulty Opening Eyes on Waking | Difficulty Opening Eyes on Waking | Do your eyes have difficulty opening on waking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514586","Have Dry or Itchy Skin","C131693","A question about whether an individual's skin feels or felt dry or itchy.","Have Dry or Itchy Skin | Does any part of your skin feel dry or itchy | Skin Dry or Itchy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514385","Have Excessive Tearing","C131701","A question about whether an individual's eyes have or had excessive tearing.","Have Excessive Tearing | Do your eyes have excessive tearing | Excessive Tearing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514387","Have Eye Pain in Wind","C131702","A question about whether an individual's eyes hurt because of the wind.","Have Eye Pain in Wind | Do your eyes hurt because of wind | Eye Pain in Wind | Eyes Hurt Because of Wind",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514555","Have Mouth Discomfort with Carbonated Beverage","C131718","A question about whether an individual has or had mouth discomfort with carbonated beverages.","Have Mouth Discomfort with Carbonated Beverage | Any mouth discomfort with soda/pop | Have Mouth Discomfort from Carbonated Beverage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514554","Have Mouth Discomfort with Hot or Cold","C131715","A question about whether an individual has or had mouth discomfort with hot or cold.","Have Mouth Discomfort with Hot or Cold | Any mouth discomfort with hot/cold",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514556","Have Mouth Discomfort with Spicy Food","C131717","A question about whether an individual has or had mouth discomfort with spicy food.","Have Mouth Discomfort with Spicy Food | Any mouth discomfort with spicy food | Have Mouth Discomfort from Spicy Food",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514557","Have Mouth Discomfort with Toothpaste","C131716","A question about whether an individual has or had mouth discomfort with toothpaste.","Have Mouth Discomfort with Toothpaste | Any mouth discomfort with toothpaste | Have Mouth Discomfort from Toothpaste",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514553","Have Mouth or Lip Sores or Ulcers","C131713","A question about whether an individual has or had mouth or lip sores or ulcers.","Have Mouth or Lip Sores or Ulcers | Any mouth (or lip) sores or ulcers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514647","Have Muscle Cramps or Pain","C131733","A question about whether an individual has or had muscle cramps or pains.","Have Muscle Cramps or Pain | Do you have muscle cramps or pains",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514648","Have Poor or Reduced Appetite","C131728","A question about whether an individual's appetite is or was reduced from normal.","Have Poor or Reduced Appetite | Is your appetite poor or reduced from normal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514588","Have Raw or Sore Skin","C131692","A question about whether an individual's skin feels or felt raw or sore.","Have Raw or Sore Skin | Does any part of your skin feel raw or sore | Skin Raw or Sore",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514589","Have Scaly or Flaky Skin","C131696","A question about whether an individual's skin looks or looked scaly or flaky.","Have Scaly or Flaky Skin | Does any part of your skin look scaly or flaky | Skin Scaly or Flaky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514590","Have Shiny Skin Scar","C131695","A question about whether an individual has or had a shiny scar.","Have Shiny Skin Scar | Does any part of your skin look like a shiny scar | Have Shiny Scar | Shiny Skin Scar | Skin Shiny Scar",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514559","Have Sinus Congestion or Pain","C131725","A question about whether an individual has or had sinus congestion or pain.","Have Sinus Congestion or Pain | Any sinus congestion or pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514699","Have Skin Tightness","C131691","A question about whether an individual's skin feels or felt tight.","Have Skin Tightness | Does any part of your skin feel tight | Skin Tightness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514649","Have Swollen Feet, Ankles, or Joints","C131734","A question about whether an individual has or had swollen feet, ankles, or joints.","Have Swollen Feet, Ankles, or Joints | Do you have swollen feet, ankles, or joints",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514650","Have Tear Ducts Plugged or Cauterized","C131705","A question about whether an individual has had their tear ducts plugged or cauterized.","Have Tear Ducts Plugged or Cauterized | Have you had your tear ducts plugged or cauterized | Tear Ducts Plugged or Cauterized",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514356","Have Tightness in Arms, Legs, or Joints","C131732","A question about whether an individual has or had tight arms, legs, or joints.","Have Tightness in Arms, Legs, or Joints | Are your arms, legs, or joints tight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514587","Have a Skin Rash","C131694","A question about whether an individual has or had a skin rash.","Have a Skin Rash | Does any part of your skin have a rash | Skin Rash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514672","Mouth Feels Dry Most of the Time","C131719","A question about whether an individual's feels or felt dry most of the time.","Mouth Feels Dry Most of the Time | Does your mouth feel dry most of the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514673","Mouth Symptoms Cause Major Limit to Oral Intake","C131723","A question about whether an individual majorly limits their oral intake due to mouth symptoms.","Mouth Symptoms Cause Major Limit to Oral Intake | Do mouth symptoms cause major limit to your oral intake",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514674","Mouth Symptoms Limit Oral Intake","C131721","A question about whether an individual limits their oral intake due to mouth symptoms.","Mouth Symptoms Limit Oral Intake | Do mouth symptoms limit your oral intake",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514675","Mouth Symptoms Partially Limit Oral Intake","C131722","A question about whether an individual partially limits their oral intake due to mouth symptoms.","Mouth Symptoms Partially Limit Oral Intake | Do mouth symptoms partially limit your oral intake",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514677","Nails Look Unusual","C131699","A question about whether an individual's nails look or looked unusual.","Nails Look Unusual | Do your nails look unusual",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514548","Sinus Draining of Liquid Into Throat","C131724","A question about whether an individual has or had sinus fluids draining into their throat.","Sinus Draining of Liquid Into Throat | Any draining of liquid into your throat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3844034","Some Days","C131735","A response indicating that an individual experiences or experienced something on some days.","Some Days | Some days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514457","Unable to Eat Because of Mouth Pain","C131714","A question about whether an individual is or was unable to eat because of mouth pain.","Unable to Eat Because of Mouth Pain Question | Unable to Eat Because of Mouth Pain | Unable to Eat Because of Mouth Pain | Unable to eat because of pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514682","Use Artificial Tears","C131704","A question about whether an individual uses artificial tears.","Use Artificial Tears | Do you use artificial tears",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514458","Using Narcotics to Relieve Mouth Symptoms","C131712","A question about whether an individual uses narcotic products to relieve mouth symptoms.","Using Narcotics to Relieve Mouth Symptoms | Using narcotics to relieve mouth symptoms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514686","Walking on Flat Ground","C131736","A response indicating that an individual experiences or experienced something when walking on flat ground.","Walking on Flat Ground | When walking on flat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514687","Wear Special Eyewear or Scleral Lenses to Relieve Eye Pain","C131706","A question about whether an individual wears special eyewear or scleral lenses to relieve eye pain.","Wear Special Eyewear or Scleral Lenses to Relieve Eye Pain | Do you wear special eyewear or scleral lenses to relieve eye pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519832","Difficulty Falling Asleep Score 2","C131962","A subjective score of 2 on a difficulty falling asleep scale that ranges from 0: No difficulty to 10: Didn't fall asleep.","Difficulty Falling Asleep Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519833","Difficulty Falling Asleep Score 3","C131963","A subjective score of 3 on a difficulty falling asleep scale that ranges from 0: No difficulty to 10: Didn't fall asleep.","Difficulty Falling Asleep Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519834","Difficulty Falling Asleep Score 4","C131964","A subjective score of 4 on a difficulty falling asleep scale that ranges from 0: No difficulty to 10: Didn't fall asleep.","Difficulty Falling Asleep Score 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519835","Difficulty Falling Asleep Score 5","C131965","A subjective score of 5 on a difficulty falling asleep scale that ranges from 0: No difficulty to 10: Didn't fall asleep.","Difficulty Falling Asleep Score 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519836","Difficulty Falling Asleep Score 6","C131966","A subjective score of 6 on a difficulty falling asleep scale that ranges from 0: No difficulty to 10: Didn't fall asleep.","Difficulty Falling Asleep Score 6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519837","Difficulty Falling Asleep Score 7","C131967","A subjective score of 7 on a difficulty falling asleep scale that ranges from 0: No difficulty to 10: Didn't fall asleep.","Difficulty Falling Asleep Score 7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519838","Difficulty Falling Asleep Score 8","C131968","A subjective score of 8 on a difficulty falling asleep scale that ranges from 0: No difficulty to 10: Didn't fall asleep.","Difficulty Falling Asleep Score 8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519839","Difficulty Falling Asleep Score 9","C131969","A subjective score of 9 on a difficulty falling asleep scale that ranges from 0: No difficulty to 10: Didn't fall asleep.","Difficulty Falling Asleep Score 9 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519830","Difficulty Falling Asleep Score 10","C131970","A subjective score of 10 on a difficulty falling asleep scale that ranges from 0: No difficulty to 10: Didn't fall asleep.","Difficulty Falling Asleep Score 10 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520898","Percentage Food Eaten Score 0","C131971","A subjective score of 0% on a scale that ranges from 0%: None to 100%: All of my food.","Percentage Food Eaten Score 0 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520900","Percentage Food Eaten Score 10","C131972","A subjective score of 10% on a scale that ranges from 0%: None to 100%: All of my food.","Percentage Food Eaten Score 10 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520901","Percentage Food Eaten Score 20","C131973","A subjective score of 20% on a scale that ranges from 0%: None to 100%: All of my food.","Percentage Food Eaten Score 20 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520902","Percentage Food Eaten Score 30","C131974","A subjective score of 30% on a scale that ranges from 0%: None to 100%: All of my food.","Percentage Food Eaten Score 30 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520903","Percentage Food Eaten Score 40","C131975","A subjective score of 40% on a scale that ranges from 0%: None to 100%: All of my food.","Percentage Food Eaten Score 40 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520904","Percentage Food Eaten Score 50","C131976","A subjective score of 50% on a scale that ranges from 0%: None to 100%: All of my food.","Percentage Food Eaten Score 50 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520905","Percentage Food Eaten Score 60","C131977","A subjective score of 60% on a scale that ranges from 0%: None to 100%: All of my food.","Percentage Food Eaten Score 60 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520906","Percentage Food Eaten Score 70","C131978","A subjective score of 70% on a scale that ranges from 0%: None to 100%: All of my food.","Percentage Food Eaten Score 70 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520907","Percentage Food Eaten Score 80","C131979","A subjective score of 80% on a scale that ranges from 0%: None to 100%: All of my food.","Percentage Food Eaten Score 80 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520908","Percentage Food Eaten Score 90","C131980","A subjective score of 90% on a scale that ranges from 0%: None to 100%: All of my food.","Percentage Food Eaten Score 90 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520899","Percentage Food Eaten Score 100","C131981","A subjective score of 100% on a scale that ranges from 0%: None to 100%: All of my food.","Percentage Food Eaten Score 100 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520181","Nausea Score 0","C131982","A subjective score of 0 on a scale that ranges from 0: None to 10: The worst you can think of.","Nausea Score 0 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520183","Nausea Score 1","C131983","A subjective score of 1 on a scale that ranges from 0: None to 10: The worst you can think of.","Nausea Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520184","Nausea Score 2","C131984","A subjective score of 2 on a scale that ranges from 0: None to 10: The worst you can think of.","Nausea Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520185","Nausea Score 3","C131985","A subjective score of 3 on a scale that ranges from 0: None to 10: The worst you can think of.","Nausea Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520186","Nausea Score 4","C131986","A subjective score of 4 on a scale that ranges from 0: None to 10: The worst you can think of.","Nausea Score 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520187","Nausea Score 5","C131987","A subjective score of 5 on a scale that ranges from 0: None to 10: The worst you can think of.","Nausea Score 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520188","Nausea Score 6","C131988","A subjective score of 6 on a scale that ranges from 0: None to 10: The worst you can think of.","Nausea Score 6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520189","Nausea Score 7","C131989","A subjective score of 7 on a scale that ranges from 0: None to 10: The worst you can think of.","Nausea Score 7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520190","Nausea Score 8","C131990","A subjective score of 8 on a scale that ranges from 0: None to 10: The worst you can think of.","Nausea Score 8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520191","Nausea Score 9","C131991","A subjective score of 9 on a scale that ranges from 0: None to 10: The worst you can think of.","Nausea Score 9 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520182","Nausea Score 10","C131992","A subjective score of 10 on a scale that ranges from 0: None to 10: The worst you can think of.","Nausea Score 10 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519958","Hearing Problems Did Not Interfere with Activities","C131995","A response indicating that an individual did not have hearing problems or hearing problems did not interfere with activities.","Hearing Problems Did Not Interfere with Activities | Hearing problems did not interfere with activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519826","Did Not Hear Ringing or Other Noises","C131996","A response indicating that an individual did not hear ringing or other noises.","Did Not Hear Ringing or Other Noises | Did not hear ringing or other noises",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520249","Ringing or Other Noises Did Not Bother","C131997","A response indicating that an individual was not bothered by or ringing or other noises.","Ringing or Other Noises Did Not Bother | Ringing or other noises did not bother me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520250","Ringing or Other Noises Did Not Interfere with Activities","C131998","A response indicating that ringing or other noises did not interfere with an individual's activities.","Ringing or Other Noises Did Not Interfere with Activities | Ringing or other noises did not interfere with activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520252","Ringing or Other Noises Did Not Make it Hard to Pay Attention","C131999","A response indicating that ringing or other noises did not make it hard for an individual to pay attention.","Ringing or Other Noises Did Not Make it Hard to Pay Attention | Ringing or other noises did not make it hard to pay attention",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520251","Ringing or Other Noises Did Not Make it Hard to Fall Asleep","C132000","A response indicating that ringing or other noises did not make it hard for an individual to fall asleep.","Ringing or Other Noises Did Not Make it Hard to Fall Asleep | Ringing or other noises did not make it hard to fall asleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520253","Ringing or Other Noises Did Not Wake Me From Sleep","C132001","A response indicating that ringing or other noises did not wake an individual from sleep.","Ringing or Other Noises Did Not Wake Me From Sleep | Ringing or other noises did not wake me from sleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1268125","Pancreas Part","C13024","Any component of the organ behind the lower part of the stomach that is fish-shaped and is a compound gland composed of both exocrine and endocrine tissues that make and secrete insulin and enzymes that help the body digest food.","Pancreas Part | ",,,,,,,,,,,,,,,"4001209","Pancreas part",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1881471","Lung Cancer pMX TNM Finding v6","C60977","Lung cancer in which distant metastasis cannot be assessed. (from AJCC 6th Ed.)","Lung Cancer pMX TNM Finding v6 | pMX Cancer of the Lung v6 | pMX Carcinoma of the Lung v6 | pMX Lung Cancer v6 | pMX Lung Carcinoma v6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881469","Lung Cancer pM0 TNM Finding","C60978","Lung cancer with no evidence of distant metastasis. (from AJCC 6th Ed.)","Lung Cancer pM0 TNM Finding | Lung Cancer pM0 TNM Finding v6 | pM0 Cancer of the Lung | pM0 Cancer of the Lung TNM Finding | pM0 Carcinoma of the Lung | pM0 Lung Cancer | pM0 Lung Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707006","Breast Cancer pMX TNM Finding v6","C49010","Breast cancer in which the status of distant metastasis cannot be assessed. (from AJCC 6th Ed.)","Breast Cancer pMX TNM Finding v6 | pMX Breast Cancer v6 | pMX Breast Carcinoma v6 | pMX Cancer of Breast v6 | pMX Cancer of the Breast v6 | pMX Carcinoma of Breast v6 | pMX Carcinoma of the Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0044800","12-Hydroxy-5,8,10,14-eicosatetraenoic Acid","C959","A metabolite generated from arachidonic acid by 12S-type arachidonate 12-lipoxygenase in platelets. 12-hydroxy-5,8,10,14-eicosatetraenoic acid (12(S)-HETE) may be involved in inflammation and pruritus.","12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 12-HETE | 12-HETE, (+/-)- | 12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID | 12-Hydroxyeicosatetraenoic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513169","MET Exon 14 Skipping Mutation","C131179","A molecular genetic abnormality indicating the presence of a splice site mutation that results in a loss of transcription of exon 14 of the MET gene.","MET Exon 14 Skipping Mutation | Deletion of MET Exon 14 | Deletion of c-MET Exon 14 | HGFR Exon 14 Skipping Alteration | HGFR Exon 14 Skipping Mutation | HGFR Exon 14 Splice Mutation | Loss of MET Exon 14 | Loss of c-MET Exon 14 | MET Exon 14 Deletion Mutation | MET Exon 14 Skipping Alteration | MET Exon 14 Splice Mutation | MET Proto-Oncogene, Receptor Tyrosine Kinase Exon 14 Skipping Alteration | MET Proto-Oncogene, Receptor Tyrosine Kinase Exon 14 Skipping Mutation | MET exon 14 deletion detected | Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Exon 14 Skipping Alteration | Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Exon 14 Skipping Mutation | Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Exon 14 Splice Mutation | c-MET Exon 14 Deletion Mutation | c-MET Exon 14 Splice Mutation | c-Met Exon 14 Skipping Alteration | c-Met Exon 14 Skipping Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982352","Lung Cancer Pathologic Regional Lymph Nodes TNM Finding v7","C88876","A pathologic finding about one or more characteristics of lung cancer, following the rules of the TNM AJCC v7 classification system as they pertain to staging of regional lymph nodes.","Lung Cancer Pathologic Regional Lymph Nodes TNM Finding v7 | Pathologic Staging: Regional Lymph Nodes (pN)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL383586","5-[18F]Fluorouracil","C78203","The fluorine-18 (18F)-radiolabeled pyrimidine analog 5-fluorouracil (5-FU) with positron-emitting activity. Upon administration, 5-[18F]fluorouracil distribution in tumor tissue may be measured with positron emission tomography (PET). The degree of 5-[18F]fluorouracil uptake in tumor tissue may help to predict the response to 5-fluorouracil-based chemotherapy or to determine the response to other therapeutic agents used to treat 5-FU-sensitive tumors.","5-[18F]Fluorouracil | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498430","No Disease Response","C123600","No apparent change or worsening in lesion staging classification.","No Response | NR | NR-No Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984265","Allograft Rejection Pathway","C91452","After transplantation of organ allografts, there are two pathways of antigen presentation. In the direct pathway, recipient T cells react to intact allogeneic MHC molecules expressed on the surface of donor cells. This pathway would activate host CD4 or CD8 T cells. In contrast, donor MHC molecules (and all other proteins) shed from the graft can be taken up by host APCs and presented to recipient T cells in the context of self-MHC molecules - the indirect pathway. Such presentation activates predominantly CD4 T cells. A direct cytotoxic T-cell attack on graft cells can be made only by T cells that recognize the graft MHC molecules directly. Nontheless, T cells with indirect allospecificity can contribute to graft rejection by activating macrophages, which cause tissue injury and fibrosis, and are also likely to be important in the development of an alloantibody response to graft.","Allograft Rejection Pathway | Allograft rejection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982343","Lung Cancer Pathologic Primary Tumor TNM Finding v7","C88867","A pathologic finding about one or more characteristics of lung cancer, following the rules of the TNM AJCC v7 classification system as they pertain to staging of the primary tumor.","Lung Cancer Pathologic Primary Tumor TNM Finding v7 | Pathologic Staging: Primary Tumor (pT)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982741","Bladder Cancer Pathologic Primary Tumor TNM Finding v7","C89351","A pathologic finding about one or more characteristics of bladder cancer, following the rules of the TNM AJCC v7 classification system as they pertain to staging of the primary tumor.","Bladder Cancer Pathologic Primary Tumor TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012923","DNA Virus","C14200","A virus that has DNA as its genetic material and does not use an RNA intermediate during replication.","DNA Virus | Virus, DNA | Virus-DNA | Viruses, DNA",,,,,,,,,,,,,,,"4138705","DNA virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086585","MRD Negativity","C124428","Absence of residual disease based on laboratory techniques.","Measurable Residual Disease Negativity | MRD NEGATIVITY | MRD Negative | MRD Negativity | MRDneg | Measurable Residual Disease Negative | Minimal Residual Disease Negative | Minimal Residual Disease Negativity | Minimal Residual Disease Negativity | U-MRD | Undetectable Measurable Residual Disease | Undetectable Minimal Residual Disease | Undetectable Minimal Residual Disease U-MRD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512342","BAP1 Gene Mutation","C128813","A change in the nucleotide sequence of the BAP1 gene.","BAP1 Gene Mutation | BAP1 Mutation | BRCA1 Associated Protein 1 Gene Mutation | BRCA1-Associated Protein 1 Gene Mutation | Positive | UCHL2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520239","Restaging","C132008","Staging that is performed to determine the extent of cancer that has reoccurred following treatment or how the cancer responded to treatment.","Restaging | RESTAGING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515791","t(8;14)(q24;q11)","C36347","A chromosomal abnormality consisting of the translocation of 8q24 with 14q11, which juxtaposes the c-MYC gene with the gene for the T cell receptor alpha chain resulting in overexpression of c-MYC in T cells bearing the translocation.","t(8;14)(q24;q11) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512107","CCND1 Positive","C128832","Indicates that CCND1 expression has been detected in a sample.","CCND1 Positive | BCL-1 Positive | BCL1 Positive | Cyclin D1 Positive | Cyclin-D1 Positive | PRAD1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982767","Urothelial (Transitional Cell) Carcinoma of the Prostate Pathologic Primary Tumor TNM Finding v7","C89378","A pathologic finding about one or more characteristics of urothelial (transitional cell) carcinoma of the prostate, following the rules of the TNM AJCC v7 classification system as they pertain to staging of the primary tumor.","Urothelial (Transitional Cell) Carcinoma of the Prostate Pathologic Primary Tumor TNM Finding v7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523952","Troponin Measurement","C111327","The determination of the amount of total troponin present in a sample.","Troponin Measurement | TROPONIN | Troponin",,,,,,,,,,,,,,,"4021291","Troponin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0260880","Examination","C131902","A formal or careful inspection of an object or subject.","Examination | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509058","CDISC SDTM Collected Ethnicity Terminology","C128690","Terminology associated with the ethnicity as collected codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Collected Ethnicity Terminology | ETHNICC | Ethnicity As Collected | SDTM-ETHNICC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333803","Digestive System Finding","C36279","Symptoms, physical examination results, and/or laboratory test results related to the digestive system.","Digestive System Finding | GASTROINTESTINAL SYSTEM | Gastrointestinal | Gastrointestinal System Finding",,,,,,,,,,,,,,,"4302537","Digestive system finding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0203028","Screening Mammography","C79417","X-rays of the breasts taken to check for breast cancer in the absence of signs or symptoms.","Screening Mammography | screening mammogram",,,,,,,,,,,,,,,"4077697","Screening mammography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3826981","Main Duct Pancreatic Intraductal Papillary-Mucinous Neoplasm","C113664","An intraductal papillary-mucinous neoplasm of the pancreas that arises from the main pancreatic duct.","Main Duct Pancreatic Intraductal Papillary-Mucinous Neoplasm | Pancreatic MD-IPMN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826890","Branch Duct Pancreatic Intraductal Papillary-Mucinous Neoplasm","C113665","An intraductal papillary-mucinous neoplasm of the pancreas that arises in one of the branches of the main pancreatic duct.  It usually has an indolent behavior.","Branch Duct Pancreatic Intraductal Papillary-Mucinous Neoplasm | Pancreatic BD-IPMN | Pancreatic SB-IPMN | Side Branch Pancreatic Intraductal Papillary-Mucinous Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086730","Pathology Result","C125581","The outcome of a pathologic examination.","Pathology Result | Pathologic Examination Result | Pathologic Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2315323","Procedure Indication","C117517","The condition, disease or disorder that the procedure is intended to investigate or address.","Procedure Indication | PRINDC",,,,,,,,,,,,,,,"4197035","Indication for procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1422539","CRLF2 Gene","C97430","This gene is involved in cytokine binding and signaling.","CRLF2 Gene | CRLF2 | Cytokine Receptor Like Factor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0192601","Small Intestine Resection","C51510","Surgical removal of part or all of the small intestine.","Small Intestine Resection | Small Bowel Excision | Small Bowel Resection | Small Intestine: Excision | Small Intestine: Excisions",,,,,,,,,,,,,,,"4030148","Small intestine excision",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3850079","Cytoreductive Surgery","C132068","A surgical procedure that refers to the removal of as many malignant cells as possible from an anatomic site affected by cancer.","Cytoreductive Surgery | Cytoreduction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2609147","Peritonectomy","C132069","A surgical procedure that refers to the removal of the peritoneal sites affected by cancer.","Peritonectomy | Peritoneal Stripping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4041361","Diaphragmatic Stripping","C132070","A surgical procedure that refers to the removal of the diaphragmatic sites affected by cancer.","Diaphragmatic Stripping | Diaphragm Stripping",,,,,,,,,,,,,,,"46272918","Diaphragm stripping",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0105421","BCR protein, human","C17477","Breakpoint cluster region protein (1271 aa, ~143 kDa) is encoded by the human BCR gene. This protein is involved in both serine/threonine-protein kinase and GTPase-activating protein activities.","Breakpoint Cluster Region Protein | ALL | BCR | BCR Protein | BCR Protein | BCR1 | CML | D22S11 | D22S662 | EC 2.7.11.1 | PHL | Renal Carcinoma Antigen NY-REN-26",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1265601","Solitary Mass","C41051","A single isolated mass.","Solitary Mass | ",,,,,,,,,,,,,,,"4052431","Solitary mass",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2984073","Cervical Cancer by AJCC v7 Stage","C91208","A term that refers to the staging of cervical cancer according to the American Joint Committee on Cancer, 7th edition.","Cervical Cancer by AJCC v7 Stage | Cervical Carcinoma by AJCC v7 Stage | Cervical Carcinoma by AJCC v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983696","Uterine Corpus Cancer by AJCC v6 Stage","C90494","A term that refers to the staging of uterine corpus cancer according to the American Joint Committee on Cancer, 6th edition.","Uterine Corpus Cancer by AJCC v6 Stage | Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v6 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0491832","Amsler Grid","C123464","A diagrammatic method to test visual acuity and presence of macular degeneration, which utilizes a uniform square grid of lines with a dot in the center.","Amsler Grid | AMSLER GRID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521302","Nasal Swab","C132119","A method used to collect biological material from within the nasal passages. A cotton swab is inserted into the nasal opening and rotated against the anterior nasal mucosa and then withdrawn.","Nasal Swab | Nasal Swab Test | Nasopharyngeal Swab | Nasopharyngeal Swab Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520996","T5 Stage Finding","C132010","An antiquated primary tumor finding term that refers to colorectal cancer which has spread by direct extension beyond the immediately adjacent organs or tissues. (AJCC 1st Ed.)","T5 TNM Finding | T5 Stage Finding | T5 Stage Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512960","Cytokine Expression Profile","C129886","The identification and quantitation of all of the cytokines expressed in a biological sample.","Cytokine Expression Profile | Cytokine Profile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513120","Memorial Sloan-Kettering Cancer Center","C39457","The Memorial Sloan-Kettering Cancer Center is the world's oldest and largest private cancer center. The Center fosters a close collaboration between physicians and scientists to provide patients with the best care available while working to discover more-effective strategies to prevent, control, and ultimately cure cancer in the future. It became an NCI-designated Comprehensive Cancer Center in 1971.","Memorial Sloan-Kettering Cancer Center | MSKCC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0683838","Academia","C18240","College, University or institute with scholastic life or environment.","Academia | Academic | Academics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520048","Immune Checkpoint Functional Assay","C132165","Various bioassays designed to measure levels of key regulatory molecules, such as PD-1 (PDCD1), CTLA-4, GITR (TNFRSF18), 4-1BB (TNFRSF9), OX40 (TNFRSF4), and TIGIT, that mediate immune checkpoint receptor pathways or assays to measure proliferation, expression of cell surface activation markers, and cytokine expression induced by these pathways.","Immune Checkpoint Functional Assay | Checkpoint Signaling Assay | Immune Checkpoint Profile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520179","National Cancer Institute Community Oncology Research Program","C132164","A national network of investigators, cancer care providers, academic institutions, and other organizations that conduct multi-site cancer clinical trials and studies in diverse populations in community-based healthcare systems across the United States and Puerto Rico.","National Cancer Institute Community Oncology Research Program | NCI Community Oncology Research Program | NCORP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1306043","Nasal Wash and Collection","C132126","A method used to collect biological material from within the nasal passages. A saline solution is introduced into the nasal passages, retained briefly, and then expelled.","Nasal Wash and Collection | Nasal Lavage | Nasal Wash | Nasopharyngeal Lavage | Nasopharyngeal Wash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227937","Corpora Cavernosa","C32382","One of two chambers along the shaft of the penis containing spongy erectile tissue, which, combined with the Corpus Spongiosum, fill with blood to create a penile erection.","Corpora Cavernosa | Corpus cavernosum structure (body structure)",,,,,,,,,,,,,,,"4245106","Corpus cavernosum of penis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL412801","Computer-Assisted Cognitive Training","C116532","The use of a computer to help an individual improve cognitive skills including focus, attention, memory, and information processing.","Computer-Assisted Cognitive Training | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1277794","Cytomegalovirus IgG Antibody Measurement","C96596","The determination of the amount of cytomegalovirus IgG antibody present in a sample.","Cytomegalovirus IgG Antibody Measurement | CMVIGGAB | Cytomegalovirus IgG Antibody",,,,,,,,,,,,,,,"4196849","Cytomegalovirus IgG antibody measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3272889","Cytomegalovirus IgM Antibody Measurement","C96597","The determination of the amount of cytomegalovirus IgM antibody present in a sample.","Cytomegalovirus IgM Antibody Measurement | CMVIGMAB | Cytomegalovirus IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520994","Supplemental Testing","C132223","Additional, or secondary, testing done to confirm a preliminary result.","Supplemental Testing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272835","Test Kit","C69035","A packaged system consisting of the main component materials necessary to perform one or more designated diagnostic tests or procedures.","Test Kit | Test Kits",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520410","Past Seven Days Frequency of Feeling Urge to Urinate All of a Sudden","C132197","A question about the frequency of an individual's feeling an urge to urinate all of a sudden over the past seven days.","Past Seven Days Frequency of Feeling Urge to Urinate All of a Sudden | In the past 7 days, how often did you feel an urge to urinate all of a sudden",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520413","Past Seven Days How Often Times When Have to Urinate Frequently","C132198","A question about how often an individual had times when they had to urinate frequently over the past seven days.","Past Seven Days How Often Times When Have to Urinate Frequently | In the past 7 days, were there times when you had to urinate frequently",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520412","Past Seven Days Frequency of Urinary Incontinence","C132199","A question about the frequency of an individual's loss of control of urine (leakage) over the past seven days.","Past Seven Days Frequency of Urinary Incontinence | In the past 7 days, how often did you have loss of control of urine (leakage) | Past Seven Days Frequency of Loss of Control of Urine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520411","Past Seven Days Frequency of Ejaculation Problems","C132200","A question about the frequency of an individual's ejaculation problems over the past seven days.","Past Seven Days Frequency of Ejaculation Problems | In the past 7 days, how often did you have ejaculation problems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520416","Worst Severity Past Seven Days Blurry Vision","C132201","A question about an individual's observation of the worst severity they have experienced related to blurry vision over the past seven days.","Worst Severity Past Seven Days Blurry Vision | In the past 7 days, what was the severity of your blurry vision at its worst | Worst Severity Past Seven Days Blurred Vision",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520424","Worst Severity Past Seven Days Watery Eyes","C132202","A question about an individual's observation of the worst severity they have experienced related to watery eyes (tearing) over the past seven days.","Worst Severity Past Seven Days Watery Eyes | In the past 7 days, what was the severity of your watery eyes (tearing) at their worst | Worst Severity Past Seven Days Tearing Eyes | Worst Severity Past Seven Days Watering Eyes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520415","Worst Severity Past Seven Days Ringing in Ears","C132203","A question about an individual's observation of the worst severity they have experienced related to ringing in their ears over the past seven days.","Worst Severity Past Seven Days Ringing in Ears | In the past 7 days, what was the severity of ringing in your ears at its worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520423","Worst Severity Past Seven Days Vaginal Dryness","C132204","A question about an individual's observation of the worst severity they have experienced related to vaginal dryness over the past seven days.","Worst Severity Past Seven Days Vaginal Dryness | In the past 7 days, what was the severity of your vaginal dryness at its worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520422","Worst Severity Past Seven Days Pain or Burning with Urination","C132205","A question about an individual's observation of the worst severity they have experienced related to pain or burning with urination over the past seven days.","Worst Severity Past Seven Days Pain or Burning with Urination | In the past 7 days, what was the severity of your pain or burning with urination at its worst | Worst Severity Past Seven Days Painful Urination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520420","Worst Severity Past Seven Days Difficulty Getting or Keeping an Erection","C132206","A question about an individual's observation of the worst severity they have experienced related to difficulty getting or keeping an erection over the past seven days.","Worst Severity Past Seven Days Difficulty Getting or Keeping an Erection | In the past 7 days, what was the severity of your difficulty getting or keeping an erection at its worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520419","Worst Severity Past Seven Days Decreased Sexual Interest","C132207","A question about an individual's observation of the worst severity they have experienced related to decreased sexual interest over the past seven days.","Worst Severity Past Seven Days Decreased Sexual Interest | In the past 7 days, what was the severity of your decreased sexual interest at its worst | Worst Severity Past Seven Days Decreased Sexual Desire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520421","Worst Severity Past Seven Days Pain During Vaginal Sex","C132208","A question about an individual's observation of the worst severity they have experienced related to pain during vaginal sex over the past seven days.","Worst Severity Past Seven Days Pain During Vaginal Sex | In the past 7 days, what was the severity of your pain during vaginal sex at its worst | Worst Severity Past Seven Days Pain During Vaginal Intercourse | Worst Severity Past Seven Days Pain During Vaginal Penetration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520418","Worst Severity Past Seven Days Breast Area Enlargement or Tenderness","C132209","A question about an individual's observation of the worst severity they have experienced related to breast area enlargement or tenderness over the past seven days.","Worst Severity Past Seven Days Breast Area Enlargement or Tenderness | In the past 7 days, what was the severity of your breast area enlargement or tenderness at its worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520417","Worst Severity Past Seven Days Body Odor","C132210","A question about an individual's observation of the worst severity they have experienced related to body odor over the past seven days.","Worst Severity Past Seven Days Body Odor | In the past 7 days, what was the severity of your body odor at its worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520405","Past Seven Days How Much Blurry Vision Interfered with Usual or Daily Activities","C132211","A question about how much an individual's blurry vision interfered with their usual or daily activities over the past seven days.","Past Seven Days How Much Blurry Vision Interfered with Usual or Daily Activities | In the past 7 days, how much did blurry vision interfere with your usual or daily activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520409","Past Seven Days How Much Watery Eyes Interfered with Usual or Daily Activities","C132212","A question about how much an individual's watery eyes (tearing) interfered with their usual or daily activities over the past seven days.","Past Seven Days How Much Watery Eyes Interfered with Usual or Daily Activities | In the past 7 days, how much did watery eyes (tearing) interfere with your usual or daily activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520408","Past Seven Days How Much Sudden Urges to Urinate Interfered with Usual or Daily Activities","C132213","A question about how much an individual's sudden urges to urinate interfered with their usual or daily activities over the past seven days.","Past Seven Days How Much Sudden Urges to Urinate Interfered with Usual or Daily Activities | In the past 7 days, how much did sudden urges to urinate interfere with your usual or daily activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520406","Past Seven Days How Much Frequent Urination Interfered with Usual or Daily Activities","C132214","A question about how much an individual's frequent urination interfered with their usual or daily activities over the past seven days.","Past Seven Days How Much Frequent Urination Interfered with Usual or Daily Activities | In the past 7 days, how much did frequent urination interfere with your usual or daily activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520407","Past Seven Days How Much Urinary Incontinence Interfered with Usual or Daily Activities","C132215","A question about how much an individual's loss of control of urine (leakage) interfered with their usual or daily activities over the past seven days.","Past Seven Days How Much Urinary Incontinence Interfered with Usual or Daily Activities | In the past 7 days, how much did loss of control of urine (leakage) interfere with your usual or daily activities | Past Seven Days How Much Loss of Control of Urine Interfered with Usual or Daily Activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520403","Past Seven Days Any Unusual Vaginal Discharge","C132216","A question about whether or not an individual had any unusual vaginal discharge over the past seven days.","Past Seven Days Any Unusual Vaginal Discharge | In the past 7 days, did you have any unusual vaginal discharge",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520402","Past Seven Days Any Irregular Menstrual Period","C132217","A question about whether or not an individual had any irregular menstral periods.","Past Seven Days Any Irregular Menstrual Period | In the past 7 days, did you have any irregular menstrual periods",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520404","Past Seven Days Missed Expected Menstrual Period","C132218","A question about whether or not an individual missed an expected menstrual period.","Past Seven Days Missed Expected Menstrual Period | In the past 7 days, did you miss an expected menstrual period | Past Seven Days Missed Menstrual Period",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520401","Past Seven Days Took Too Long to Have Orgasm","C132219","A question about whether or not an individual felt that it took too long to have an orgasm or climax.","Past Seven Days Took Too Long to Have Orgasm | In the past 7 days, did you feel that it took too long to have an orgasm or climax",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520414","Past Seven Days Unable to Have Orgasm","C132220","A question about whether or not an individual was unable to have an orgasm or climax.","Past Seven Days Unable to Have Orgasm Question | In the past 7 days, were you unable to have an orgasm or climax | Past Seven Days Unable to Have Orgasm | Past Seven Days Unable to Have Orgasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521221","Not Sexually Active","C132221","A response indicating that an individual is not or was not sexually active.","Not Sexually Active | Not sexually active",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520952","Prefer Not to Answer","C132222","A response indicating that an individual prefers or preferred not to answer.","Prefer Not to Answer | Choose Not to Disclose | Prefer not to answer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035164","Request for Proposals","C17088","In a Request for Proposals (RFPs) the Government states work to be undertaken or a problem to be solved.  Respondents compete for a common requirement open to all eligible offerors/bidders. Proposals are evaluated using technical and business evaluation criteria and generally involve negotiations. Bids are awarded to the bidder who is responsible and offers the lowest overall price. (from Acquisition Program)","Request for Proposals | RFP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519755","Cooperative Donor Registry","C132253","A formal business relationship between donor registries allowing for tissue matching against the pool of donors created by all participating registries.","Cooperative Donor Registry | Cooperative Registry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3554390","Transaminitis","C113751","Abnormally high levels of alanine transaminase (ALT) and/or aspartate transaminase (AST) in the blood.","Transaminitis | Elevated Transaminases | Hypertransaminasemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520989","Study Site Dissolved","C132259","An indication that a study site has closed down and is no longer participating in a study.","Study Site Dissolved | Dissolved | Site Dissolved",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520705","General Fatigue Dimension","C132282","A dimension of general fatigue in the Multidimensional Fatigue Inventory.","General Fatigue Dimension | General Fatigue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520493","Physical Fatigue Dimension","C132284","A dimension of physical fatigue in the Multidimensional Fatigue Inventory.","Physical Fatigue Dimension | Physical Fatigue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521337","Mental Fatigue Dimension","C132285","A dimension of mental fatigue in the Multidimensional Fatigue Inventory.","Mental Fatigue Dimension | Mental Fatigue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520231","Reduced Motivation Dimension","C132286","A dimension of reduced motivation in the Multidimensional Fatigue Inventory.","Reduced Motivation Dimension | Reduced Motivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520230","Reduced Activity Dimension","C132287","A dimension of reduced activity in the Multidimensional Fatigue Inventory.","Reduced Activity Dimension | Reduced Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0872173","Functional Disability","C132289","An impairment that causes an individual to require assistance in order to perform an activity.","Functional Disability | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642210","Millimeter Mercury Per Liter Per Minute","C105506","A unit of resistance equal to the number of millimeters of mercury per unit of volume equal to one liter per unit of time equal to one minute.","Millimeter Mercury Per Liter Per Minute | mmHg/L/min | mm[Hg]/L/min | mm[Hg]/l/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705143","BRCA2 wt Allele","C52061","Human BRCA2 wild-type allele is located in the vicinity of 13q12.3 and is approximately 84 kb in length. This allele, which encodes breast cancer type 2 susceptibility protein, is involved in double-stranded DNA break repair, homologous recombination and transcriptional regulation. Certain allelic variants of the BRCA2 gene are associated with early-onset breast cancer, prostate cancer and Fanconi anemia.","BRCA2 wt Allele | BRCA2, DNA Repair Associated wt Allele | BRCC2 | BROVCA2 | Breast Cancer 2 Gene | Breast Cancer 2, Early Onset wt Allele | Breast Cancer Type 2 Susceptibility Gene | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | Hereditary Breast Cancer 2 Gene | PNCA2 | XRCC11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514347","CD276 Antigen Positive","C131770","An indication that CD276 expression has been detected in a sample.","CD276 Antigen Positive | 4Ig-B7-H3 Positive | 8H9 Positive | 8H9 Reactive | Antigen CD276 Positive | B7 Homolog 3 Positive | B7-H3 Positive | B7H3 Positive | B7RP-2 Positive | CD276 Molecule Positive | CD276 Positive | M8H9 Antigen Positive | PSEC0249 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2732301","Oligodendroglioma, Not Otherwise Specified","C129319","A central nervous system tumor with morphological features of oligodendroglioma in which there is insufficient information on the IDH genes and 1p/19q codeletion status.","Oligodendroglioma, Not Otherwise Specified | Oligodendroglioma, NOS","9450/3","Oligodendroglioma, NOS",,,,,,,,,,,,,"608188","Oligodendroglioma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"CL512489","Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted","C129318","An oligodendroglioma carrying IDH gene family mutation and combined whole-arm losses of 1p and 19q (1p/19q codeletion).","Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted | Oligodendroglioma, IDH Mutant and 1p/19q Codeleted | Oligodendroglioma, IDH-mutant and 1p/19q-codeleted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512388","Oligoastrocytoma, Not Otherwise Specified","C129323","A central nervous system tumor with morphological features of oligoastrocytoma in which there is insufficient information on the IDH genes status.","Oligoastrocytoma, Not Otherwise Specified | Oligoastrocytoma, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512283","Glioblastoma, Not Otherwise Specified","C129295","A central nervous system tumor with morphological features of glioblastoma in which there is insufficient information on the IDH genes status.","Glioblastoma, Not Otherwise Specified | Glioblastoma, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514422","Glioblastoma, IDH-Wildtype","C39750","A glioblastoma that arises de novo. It is more commonly seen in older patients. Mutations in IDH1 or IDH2 genes are not present.","Glioblastoma, IDH-Wildtype | Glioblastoma, IDH Wildtype | Glioblastoma, IDH- Wildtype | Glioblastoma, IDH-Wildtype | Primary Glioblastoma | Primary Glioblastoma Multiforme | Primary Glioblastoma, IDH-Wildtype",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519214","Secondary Glioblastoma","C39751","A glioblastoma arising from a lower grade astrocytoma.","Secondary Glioblastoma | Glioblastoma, IDH-Mutant | Secondary Glioblastoma Multiforme",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512354","Gemistocytic Astrocytoma, IDH-Mutant","C129272","Gemistocytic astrocytoma carrying IDH mutations.","Gemistocytic Astrocytoma, IDH-Mutant | Gemistocytic Astrocytoma, IDH Mutant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512400","Epithelioid Glioblastoma","C129293","An IDH-wildtype glioblastoma characterized by the presence of large epithelioid cells with abundant eosinophilic cytoplasm, vesicular chromatin, and prominent nucleoli.","Epithelioid Glioblastoma | E-GB | E-GBM | Epithelioid glioblastoma | e-GB | e-GBM",,,,,,,,,,,,,,,"37116832","Epithelioid glioblastoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512144","Diffuse Midline Glioma, H3 K27M-Mutant","C129309","A diffuse midline glioma characterized by the presence of histone H3 K27M mutation.","Diffuse Midline Glioma, H3 K27M-Mutant | Diffuse Midline Glioma H3 K27M | Diffuse midline glioma, H3 K27M-mutant | Non-DIPG",,,,,,,,,,,,,,,"37116848","Diffuse midline glioma, point mutation K27M in histone H3",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512142","Diffuse Astrocytoma, Not Otherwise Specified","C129277","A central nervous system tumor with morphological features of diffuse astrocytoma in which there is insufficient information on the IDH genes status.","Diffuse Astrocytoma, Not Otherwise Specified | Diffuse Astrocytoma, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512141","Diffuse Astrocytoma, IDH-Wildtype","C129274","Diffuse astrocytoma lacking mutations in IDH1 or IDH2 genes.","Diffuse Astrocytoma, IDH-Wildtype | Diffuse Astrocytoma, IDH Wild Type | Diffuse astrocytoma, IDH-wildtype",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512140","Astrocytoma, IDH-Mutant, Grade 2","C129271","IDH-mutant astrocytoma characterized by the presence of well-differentiated fibrillary glial cells diffusely infiltrating the central nervous system.","Astrocytoma, IDH-Mutant, Grade 2 | Astrocytoma, IDH-Mutant, Grade II | Diffuse Astrocytoma, IDH Mutant | Diffuse Astrocytoma, IDH-Mutant | Diffuse Astrocytoma, IDH-Mutant | Diffuse astrocytoma, IDH-mutant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512338","Anaplastic Oligodendroglioma, Not Otherwise Specified","C129322","A central nervous system tumor with morphological features of anaplastic oligodendroglioma in which there is insufficient information on the IDH genes and 1p/19q codeletion status.","Anaplastic Oligodendroglioma, Not Otherwise Specified | Anaplastic Oligodendroglioma, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512337","Anaplastic Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted","C129321","An anaplastic oligodendroglioma carrying IDH gene family mutation and combined whole-arm losses of 1p and 19q (1p/19q codeletion).","Anaplastic Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted | Anaplastic Oligodendroglioma, IDH mutant and 1p/19q Codeleted | Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512336","Anaplastic Oligoastrocytoma, Not Otherwise Specified","C129324","A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.","Anaplastic Oligoastrocytoma, Not Otherwise Specified | Anaplastic Oligoastrocytoma, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512335","Anaplastic Astrocytoma, Not Otherwise Specified","C129292","A central nervous system tumor with morphological features of anaplastic astrocytoma in which there is insufficient information on the IDH genes status.","Anaplastic Astrocytoma, Not Otherwise Specified | Anaplastic Astrocytoma, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512334","Anaplastic Astrocytoma, IDH-Wildtype","C129291","Anaplastic astrocytoma lacking mutations in IDH1 or IDH2 genes.","Anaplastic Astrocytoma, IDH-Wildtype | Anaplastic Astrocytoma, IDH Wild Type | Anaplastic astrocytoma, IDH-wildtype",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512333","Astrocytoma, IDH-Mutant, Grade 3","C129290","IDH-mutant astrocytoma characterized by the presence of increased mitotic activity and anaplastic features.","Astrocytoma, IDH-Mutant, Grade 3 | Anaplastic Astrocytoma, IDH Mutant | Anaplastic Astrocytoma, IDH-Mutant | Anaplastic Astrocytoma, IDH-Mutant | Anaplastic astrocytoma, IDH-mutant | Astrocytoma, IDH-Mutant, Grade III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349023","Unit Conversion Factor","C70774","An operator used to convert units from one scale to another.","Unit Conversion Factor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006347","Budget","C60757","A summary of intended expenditures along with proposals for how to meet them; a sum of money allocated for a particular purpose.","Budget | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521223","Office of Management and Budget","C132305","The largest office within the Executive Office of the President of the United States. It oversees the performance of federal agencies, and administers the federal budget.","Office of Management and Budget | OMB | Office of Management and Budget (OMB)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1140148","Healthcare Common Procedure Coding System","C132306","A standardized coding system used by Medicare and other health insurance programs to ensure that claims are processed in an orderly and consistent manner. The coding system comprises the procedure codes of the American Medical Association Current Procedural Terminology (CPT) and an additional standardized coding set that is used primarily to identify products, supplies, and services not included in the CPT codes.","Healthcare Financing Administration Common Procedure Coding System | HCPCS | HCPCS | Healthcare Financing Administration Common Procedure Coding System (HCPCS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2499019","ICD-10 Procedure Coding System","C132307","The International Classification of Diseases, 10th Revision, Procedure Coding System, an international system of medical classification used for procedural coding.","ICD-10 Procedure Coding System | ICD-10 Procedure Coding System (ICD-10-PCS) | ICD-10-PCS | ICD-10-PCS | International Classification of Diseases Procedure Coding System, version 10 | International Classification of Diseases, 10th Revision, Procedure Coding System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520914","Plasma Cell Enrichment","C132297","Concentration of plasma cells in a sample for the purpose of the detection of cytogenetic abnormalities.","Plasma Cell Enrichment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221104","Hyperviscosity","C38698","An increase in the viscosity of blood resulting from an increase in the proportion of cellular elements of the blood, a change in the mechanical properties of the cellular elements of the blood, and/or an alteration in plasma viscosity.","Hyperviscosity | Blood Hyperviscosity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897431","Subject Unblinding Event Record","C115572","Documentation describing the actions taken after breaking the blind for the clinical trial.","Clinical Trial Investigational Product Treatment Decoding Documentation | Code Break | IP Treatment Decoding Documentation | Subj Unblind Event | Subject Unblinding Event | Subject Unblinding Event Record | Treatment Decoding Documentation | Unblinding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002456","American Dental Association","C89797","A professional association of dentists, committed to advancing the public's oral health, the ethical and scientific advancement of the field, and the professional advancement of its members.","American Dental Association | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001911","Albendazole","C47384","A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05)","Albendazole | ALBENDAZOLE | Albenza | Bilutac | Carbamic Acid,(5-(Propylthio)-1H-benzimidazol-2-yl)-, Methyl Ester | Proftril | SKF 62979 | Zentel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704743","BRCA1 wt Allele","C52060","Human BRCA1 wild-type allele is located within 17q21 and is approximately 81 kb in length. This allele, which encodes breast cancer type 1 susceptibility protein, plays a role in transcriptional regulation, facilitation of the cellular response to DNA damage, homologous recombination, and cell cycle arrest following radiation exposure. Certain allelic variants of the BRCA1 gene are associated with breast carcinomas and breast/ovarian cancer syndrome.","BRCA1 wt Allele | BRCA1 | BRCA1, DNA Repair Associated wt Allele | BRCAI | BRCC1 | BROVCA1 | Breast Cancer 1 Gene | Breast Cancer 1, Early Onset wt Allele | Breast Cancer Type 1 Susceptibility Gene | FANCS | Hereditary Breast Cancer 1 Gene | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520383","FANCF Gene Mutation","C132003","A change in the nucleotide sequence of the FANCF gene.","FANCF Gene Mutation | FAF Gene Mutation | Fanconi Anemia Complementation Group F Gene Mutation | Fanconi Anemia, Complementation Group F Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520382","FANCM Gene Mutation","C132004","A change in the nucleotide sequence of the FANCM gene.","FANCM Gene Mutation | FAAP250 Gene Mutation | Fanconi Anemia Complementation Group M Gene Mutation | Fanconi Anemia, Complementation Group M Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520204","RAD54L Gene Mutation","C132006","A change in the nucleotide sequence of the RAD54L gene.","RAD54L Gene Mutation | HR54 Gene Mutation | HRAD54 Gene Mutation | RAD54 Homolog Gene Mutation | RAD54-like (S. cerevisiae) Gene Mutation | RAD54A Gene Mutation | hHR54 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520203","RAD51B Gene Mutation","C132005","A change in the nucleotide sequence of the RAD51B gene.","RAD51B Gene Mutation | R51H2 Gene Mutation | RAD51 Paralog B Gene Mutation | RAD51L1 Gene Mutation | REC2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1099412","SLAMF7 protein, human","C95308","SLAM family member 7 (335 aa, ~37 kDa) is encoded by the human SLAMF7 gene. This protein is involved in signal transduction that promotes the activation of natural killer cells.","SLAM Family Member 7 | CD Antigen CD319 | CD2 Subset 1 | CD2-Like Receptor Activating Cytotoxic Cells | CD2-Like Receptor-Activating Cytotoxic Cells | CD319 | CD319 Antigen | CRACC | CS1 | Membrane Protein FOAP-12 | Novel Ly9 | Protein 19A | SLAMF7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348915","HLA-A2 Positive Cells Present","C69408","A laboratory test result indicating the presence of HLA-A*02 positive cells in a tissue sample.","HLA-A2 Positive Cells Present | HLA-A*02 Positive | HLA-A*02 Positive Cells Present | HLA-A*2 Positive | HLA-A02 Allele Positive | HLA-A02 Positive | HLA-A2 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520214","RPA1 Gene Mutation","C132007","A change in the nucleotide sequence of the RPA1 gene.","RPA1 Gene Mutation | RF-A Gene Mutation | RP-A Gene Mutation | RPA70 Gene Mutation | Replication Protein A1 Gene Mutation | Replication Protein A1, 70kDa Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520369","BRIP1 Gene Mutation","C132002","A change in the nucleotide sequence of the BRIP1 gene.","BRIP1 Gene Mutation | BACH1 Gene Mutation | BRCA1 Interacting Protein C-Terminal Helicase 1 Gene Mutation | FANCJ Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525118","Ve","C132332","The ratio of interstitial fluid volume to total body fluid.","Extravascular Extracellular Volume Fraction | ECV | Ve",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1297929","Breast Atypical Hyperplasia","C5195","A general term that refers to atypical hyperplastic proliferations of the epithelial cells in the breast parenchyma.  Examples include atypical ductal hyperplasia, atypical lobular hyperplasia, and columnar cell hyperplasia with atypia.","Breast Atypical Hyperplasia | Atypical Breast Hyperplasia | Atypical Hyperplasia of Breast | Atypical Hyperplasia of the Breast | Atypical Hyperplasia of the Breast",,,,,,,,,,,,,,,"4280896","Atypical hyperplasia of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0393006","Genetic testing for cancer risk","C15638","Analyzing DNA to look for a genetic alteration that may indicate an increased risk for developing a cancer.","Genetic Testing for Cancer Risk | Cancer Risk Assessment with Genetic Testing and Counseling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL358822","t(10;11)(p12;q23)","C132102","A cytogenetic abnormality that refers to the translocation of chromosome 10p12 with chromosome 11q23. It is associated with acute myeloid leukemia in childhood.","t(10;11)(p12;q23) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697642","IDH1 wt Allele","C77216","The IDH1 wt Allele is located in the vicinity of 2q33.3 and is approximately 19 kb in length. This allele, which encodes isocitrate dehydrogenase [NADP] cytoplasmic protein, plays a role in carbohydrate metabolism.","IDH1 wt Allele | HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | Isocitrate Dehydrogenase 1 (NADP+), Soluble wt Allele | PICD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511430","CDKN2A Gene Inactivation","C39629","A mutation in the CDKN2A gene that either inhibits expression of the CDKN2A protein or results in the translation of an inactive CDKN2A protein.","CDKN2A Gene Inactivation | Inactivating CDK4I Gene Mutation | Inactivating CDKN2A Gene Mutation | Inactivating CDKN2A-p16 Gene Mutation | Inactivating p14ARF Gene Mutation | Inactivating p16 Gene Mutation | Inactivating p16-INK4A Gene Mutation | Inactivating p16INK4a Gene Mutation | Inactivating p19ARF Gene Mutation | p16 Gene Inactivation | p16/CMM2 Gene Inactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514641","RB1 Gene Inactivation","C36328","A mutation in the RB1 gene that either inhibits expression of the RB1 protein or results in the translation of an inactive RB1 protein.","RB1 Gene Inactivation | Inactivating RB Gene Mutation | Inactivating RB1 Gene Mutation | Inactivating Retinoblastoma 1 Gene Mutation | Inactivating Retinoblastoma Gene Mutation | Inactivation of Retinoblastoma Tumor-Suppressor Gene | RB1 Tumor-Suppressor Gene Inactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519904","HLA-A11 Positive Cells Present","C131871","A laboratory test result indicating the presence of HLA-A11 positive cells in a tissue sample.","HLA-A11 Positive Cells Present | HLA-A*11 Positive | HLA-A*11 Positive Cells Present | HLA-A11 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348914","HLA-A24 Positive Cells Present","C69410","A laboratory test result indicating the presence of HLA-A*24 positive cells in a tissue sample.","HLA-A24 Positive Cells Present | HLA-A*24 Positive | HLA-A*24 Positive Cells Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520362","Survivin Positive","C131872","An indication that survivin expression has been detected in a sample.","Survivin Positive | BIRC5 Positive | Baculoviral IAP Repeat-Containing 5 Positive | Survivin Antigen Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519702","CD19 Negative","C132245","Indicates that expression of CD19 has not been detected in a sample.","CD19 Negative | B4 Negative | CD19 Antigen Negative | CD19 Molecule Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519705","CD33 Positive","C132228","Indicates that CD33 expression has been detected in a sample.","CD33 Positive | CD33 Antigen Positive | CD33 Molecule Positive | Myeloid Cell Surface Antigen CD33 Positive | SIGLEC-3 Positive | SIGLEC3 Positive | gp67 Positive | p67 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519707","CD70 Positive","C132239","Indicates that CD70 expression has been detected in a sample.","CD70 Positive | CD27 Ligand Positive | CD27L Positive | CD27LG Positive | CD70 Antigen Positive | CD70 Molecule Positive | Ki-24 Antigen Positive | TNFSF7 Positive | Tumor Necrosis Factor Ligand Superfamily, Member 7 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519708","CD79B Positive","C132230","Indicates that CD78B expression has been detected in a sample.","CD79B Positive | AGM6 Positive | B-Cell Antigen Receptor Complex-Associated Protein Beta Chain Positive | B29 Positive | CD79b Antigen Positive | CD79b Molecule Positive | IGB Positive | Ig-Beta Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519740","CDKN2A-p16 Negative","C132226","Indicates that expression of the p16 form of CDKN2A has not been detected in a sample.","CDKN2A-p16 Negative | CDKN2A-p16(INK4a) Negative | Cyclin-Dependent Kinase 4 Inhibitor A Negative | Cyclin-Dependent Kinase Inhibitor 2A Negative | Negative | p16 Negative | p16(INK4a) Negative | p16-INK4 Negative | p16INK4 Negative | p16INK4a Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519750","CREBBP Gene Mutation","C132227","A change in the nucleotide sequence of the CREBBP gene.","CREBBP Gene Mutation | CBP Gene Mutation | CREB Binding Protein Gene Mutation | CREB-Binding Protein Gene Mutation | KAT3A Gene Mutation | RSTS Gene Mutation | Rubinstein-Taybi Syndrome Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520603","Chromosome Arm 3p Loss of Heterozygosity","C132246","A molecular abnormality that results in monoallelic loss of function mutations located within the short arm of chromosome 3 (3p).","Chromosome Arm 3p Loss of Heterozygosity | 3p LOH | 3p Loss of Heterozygosity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520604","Chromosome Arm 9p Loss of Heterozygosity","C132247","A molecular abnormality that results in monoallelic loss of function mutations located  within the short arm of chromosome 9 (9p).","Chromosome Arm 9p Loss of Heterozygosity | 9p LOH | 9p Loss of Heterozygosity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520400","FCER2 Positive","C132231","Indicates that FCER2 expression has been detected in a sample.","FCER2 Positive | Antigen CD23 Positive | CD23 Antigen Positive | CD23 Positive | Fc Fragment of IgE Receptor I Positive | Fc-Epsilon-RII Positive | Immunoglobulin E-Binding Factor Positive | Low Affinity Immunoglobulin Epsilon Fc Receptor Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520388","FGFR Gene Fusion Positive","C132244","Indicates that a fusion containing FGFR family gene sequences has been detected in a sample.","FGFR Gene Fusion Positive | FGF Receptor Gene Family Fusion Positive | FGF Receptor Gene Fusion Positive | FGFR Gene Family Fusion Positive | Fibroblast Growth Factor Receptor Gene Family Fusion Positive | Fibroblast Growth Factor Receptor Gene Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520457","GATA1 Exon 2 Mutation","C132233","A molecular genetic abnormality indicating the presence of a mutation in exon 2 of the GATA1 gene.","GATA1 Exon 2 Mutation | ERYF1 Exon 2 Mutation | GATA Binding Protein 1 Gene Exon 2 Mutation | GATA-1 Exon 2 Mutation | GF-1 Exon 2 Mutation | GF1 Exon 2 Mutation | NF-E1 Exon 2 Mutation | NFE1 Exon 2 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520458","GATA1 Exon 3 Mutation","C132232","A molecular genetic abnormality indicating the presence of a mutation in exon 3 of the GATA1 gene.","GATA1 Exon 3 Mutation | ERYF1 Exon 3 Mutation | GATA Binding Protein 1 Gene Exon 3 Mutation | GATA-1 Exon 3 Mutation | GF-1 Exon 3 Mutation | GF1 Exon 3 Mutation | NF-E1 Exon 3 Mutation | NFE1 Exon 3 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519903","HLA-A*02:01/TP53aa264-272 Complex","C132238","A protein complex comprised of the nine amino acid residues starting at position 264 and ending at position 272 of the wild-type form of cellular tumor antigen p53 bound to the cell surface antigen presenting molecule HLA class I histocompatibility antigen, A*02:01 alpha chain.","HLA-A*02:01/TP53aa264-272 Complex | HLA Class I Histocompatibility Antigen, A*02:01 Alpha Chain/Cellular Tumor Antigen p53 264-272 Peptide Complex | HLA-A2.1/TP53aa264-272 Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521085","LYPD3 Positive","C132243","Indicates that LYPD3 expression has been detected in a sample.","LYPD3 Positive | C4.4a Positive | LY6/PLAUR Domain Containing 3 Positive | LY6/PLAUR Domain-Containing 3 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520091","NR3C1 Positive","C132237","Indicates that NR3C1 expression has been detected in a sample.","NR3C1 Positive | GCR Positive | GR Positive | GRL Positive | Glucocorticoid Receptor Positive | Nuclear Receptor Subfamily 3 Group C Member 1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520113","NTRK2 Fusion Positive","C132235","Indicates that the expression of a NTRK2 fusion has been detected in a sample.","NTRK2 Fusion Positive | BDNF/NT-3 Growth Factors Receptor Fusion Positive | NTRK2 Fusion | NTRK2 fusion | Neurotrophic Receptor Tyrosine Kinase 2 Fusion Positive | TRKB Tyrosine Kinase Fusion Positive | TrkB Fusion Positive | Tropomyosin-Related Kinase B Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520114","NTRK3 Fusion Positive","C132236","Indicates that the expression of a NTRK3 fusion has been detected in a sample.","NTRK3 Fusion Positive | NT-3 Growth Factor Receptor Fusion Positive | NTRK3 Fusion | NTRK3 fusion | Neurotrophic Receptor Tyrosine Kinase 3 Fusion Positive | TRKC Tyrosine Kinase Fusion Positive | TrkC Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520208","RAS Family Gene Mutation","C132229","A change in the nucleotide sequence in a RAS family gene (HRAS, KRAS or NRAS).","RAS Family Gene Mutation | Mutant RAS | Mutant RAS Family Gene | RAS Family Mutation | RAS Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520998","TFE3 Positive","C132234","Indicates that TFE3 expression has been detected in a sample.","TFE3 Positive | RCCP2 Positive | RCCX1 Positive | TFEA Positive | Transcription Factor Binding to IGHM Enhancer 3 Positive | Transcription Factor E3 Positive | bHLHe33 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512417","Herceptin/Paclitaxel","C9759","No Value Exists","Herceptin/Paclitaxel | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520087","NCCN Distress Thermometer and Problem List for Patients Version 2.2016","C132492","A screening tool developed by the National Comprehensive Cancer Network (NCCN) Distress Management Panel used to identify patient distress coming from any source and patient problems in five categories.","NCCN Distress Thermometer and Problem List for Patients Version 2.2016 | Distress Thermometer | Distress Thermometer, 2.2016",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519853","Distress over Physical Problem with Substance Abuse","C132493","A question about an individual's distress related to their physical problems with substance abuse.","Distress over Physical Problem with Substance Abuse | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827068","Seviteronel","C113652","An orally available non-steroidal, lyase-selective inhibitor of the steroid 17-alpha-hydroxylase/C17,20 lyase (CYP17A1 or CYP17), with potential anti-androgenic and antineoplastic activities. Upon oral administration, seviteronel selectively inhibits the enzymatic activity of the cytochrome P450 C17,20 lyase in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells. The cytochrome P450 enzyme CYP17A1, localized to the endoplasmic reticulum, exhibits both 17alpha-hydroxylase and 17,20-lyase activities; it plays a key role in the steroidogenic pathway. The lyase-selective activity of seviteronel prevents the increased synthesis of mineralocorticoids that is normally seen with non-selective CYP17 inhibitors, which also inhibit the 17-alpha-hydroxylase activity of CYP17A1.","Seviteronel | 1H-1,2,3-Triazole-5-methanol, Alpha-(6,7-bis(difluoromethoxy)-2-naphthalenyl)-alpha-(1-methylethyl)-, (AlphaS)- | CYP17 Inhibitor VT-464 | SEVITERONEL | Seviteronel | VT-464",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412347","Multi-epitope TARP-pulsed Autologous Dendritic Cell Vaccine","C85470","A cell-based cancer vaccine comprised of autologous dendritic cells pulsed with multiple antigenic peptides derived from T-cell receptor gamma-chain alternate reading frame protein (TARP), with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, multi-epitope (ME) TARP-pulsed autologous dendritic cell vaccine may stimulate anti-tumor cytotoxic T-lymphocyte (CTL) and antibody responses against TARP-expressing cancer cells, resulting in tumor cell lysis. The highly immunogenic nuclear protein TARP is expressed in a variety of cancer cell types.","Multi-epitope TARP-pulsed Autologous Dendritic Cell Vaccine | Autologous TARP Peptide-Pulsed Dendritic Cell Vaccine | Autologous TARP Peptide-pulsed Dendritic Cell Vaccine | ME T-cell Receptor Gamma Alternate Reading Frame Protein Peptide-pulsed Autologous DC Vaccine | Multi-epitope TARP Peptide-pulsed Autologous Dendritic Cell Vaccine | Multi-epitope TARP-pulsed Autologous DC Vaccine | Multi-epitope TARP-pulsed Autologous Dendritic Cell Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0427540","Blast Cells Present","C35880","A laboratory test result indicating the presence of blast cells in a blood sample.","Blast Cells Present | Circulating Blasts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510745","Absence of Malignant Features","C41429","No Value Exists","Absence of Malignant Features | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055184","Continuation Therapy Epoch","C123452","A period in a clinical study during which subjects receive continuation therapy. This therapy is usually different from the therapy given during the induction phase and administered over a longer period of time.","Continuation Therapy Epoch | CONTINUATION TREATMENT | Continuation | Continuation Phase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507904","Busulfan/Melphalan Regimen","C126792","A regimen composed of busulfan and melphalan used as a conditioning regimen for stem cell transplantation (SCT).","Busulfan/Melphalan Regimen | BuMel | BuMel Regimen | Busulfan and Melphalan | Busulfan-Melphalan Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520086","Myelosuppressive Chemotherapy","C132726","The use of naturally occurring or synthetic chemicals for the purpose of decreasing the rate of blood cell production in the bone marrow.","Myelosuppressive Chemotherapy | Myelosuppression Chemotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519821","Demethylating Agent","C132686","Any agent that inhibits or prevents DNA methylation or agents that promote the removal of methyl groups from DNA.","Demethylating Agent | DNA Methylation Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055025","FDA-Regulated Drug Study Indicator","C123630","An indication as to whether the study involves an FDA-regulated drug.","FDA-Regulated Drug Study Indicator | FDADRIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520380","European Union Drug Regulating Authorities Clinical Trials Database","C132782","The European Union's electronic database of clinical trials. It contains information submitted by sponsors and informs users about ongoing clinical trials in EU Member States and European Economic Area countries.","European Union Drug Regulating Authorities Clinical Trials Database | EudraCT | European Union Drug Regulating Authorities Clinical Trials | European Union Drug Regulating Authorities Clinical Trials (EudraCT)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520271","University Medical Information Network","C132784","A cooperative organization for national medical schools in Japan designed to: provide up-to-date information to healthcare professionals; promote communications between healthcare professionals; support collaborative work among university hospitals; support collaborative medical research; standardize medical data and collect hospital statistics; support education and training at hospitals.","University Medical Information Network | UMIN | University Medical Information Network (UMIN)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897727","Relapse Criteria","C117961","A standard from which a judgment concerning a disease relapse can be established.","Relapse Criteria | RLPSCRIT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520992","Suicide Gene","C132840","A gene which will cause a cell to kill itself, typically through interaction with a prodrug.","Suicide Gene | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504877","Recurrent Glioblastoma","C126306","The reemergence of glioblastoma after a period of remission.","Recurrent Glioblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0349579","Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia","C27789","A neoplastic clonal expansion of endometrial glands characterized by cytologic changes of the epithelium and the presence of an increased number of endometrial glands. The glands form crowded aggregates with tubular or branching patterns which are cytologically distinct from the background architectural and cytological pattern. It is associated with molecular changes seen in endometrioid endometrial carcinoma, including microsatellite instability, PAX2 inactivation, and PTEN, KRAS, and CTNNB1 gene mutations.","Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia | Atypical Endometrial Hyperplasia | Atypical Hyperplasia of Endometrium | Atypical Hyperplasia of the Endometrium | Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasm | Atypical hyperplasia/Endometrial intraepithelial neoplasia (EIN) | EAH/EIN | EIN | EmGD | Endometrial Atypical Hyperplasia /Endometrioid Intraepithelial Neoplasia | Endometrial Glandular Dysplasia | Endometrial Hyperplasia with Atypia | Endometrial Intraepithelial Neoplasia | Endometrial Intraepithelial Neoplasia | Endometrial intraepithelial neoplasia (EIN)",,,,,,,,,,,,,,,"195316|4303970|45766399","Atypical endometrial hyperplasia|Endometrial intraepithelial neoplasia|Endometrioid intraepithelial neoplasia",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C0427780","Negative Pregnancy Test","C35450","A finding which indicates an individual is not pregnant.","Negative Pregnancy Test | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519852","Distress Score Visual Analogue Scale","C132828","A visual analogue scale that ranges from 0: No distress to 10: Extreme distress.","Distress Score Visual Analogue Scale | Distress Score | Distress Score Likert Scale | Distress Thermometer | NCCN Distress Thermometer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519841","Distress Score 0","C132829","A subjective score of 0 on a visual analogue scale that ranges from 0: No distress to 10: Extreme distress.","Distress Score 0 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519843","Distress Score 1","C132830","A subjective score of 1 on a visual analogue scale that ranges from 0: No distress to 10: Extreme distress.","Distress Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519844","Distress Score 2","C132831","A subjective score of 2 on a visual analogue scale that ranges from 0: No distress to 10: Extreme distress.","Distress Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519845","Distress Score 3","C132832","A subjective score of 3 on a visual analogue scale that ranges from 0: No distress to 10: Extreme distress.","Distress Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519846","Distress Score 4","C132833","A subjective score of 4 on a visual analogue scale that ranges from 0: No distress to 10: Extreme distress.","Distress Score 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519847","Distress Score 5","C132834","A subjective score of 5 on a visual analogue scale that ranges from 0: No distress to 10: Extreme distress.","Distress Score 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519848","Distress Score 6","C132835","A subjective score of 6 on a visual analogue scale that ranges from 0: No distress to 10: Extreme distress.","Distress Score 6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519849","Distress Score 7","C132836","A subjective score of 7 on a visual analogue scale that ranges from 0: No distress to 10: Extreme distress.","Distress Score 7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519850","Distress Score 8","C132837","A subjective score of 8 on a visual analogue scale that ranges from 0: No distress to 10: Extreme distress.","Distress Score 8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519851","Distress Score 9","C132838","A subjective score of 9 on a visual analogue scale that ranges from 0: No distress to 10: Extreme distress.","Distress Score 9 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519842","Distress Score 10","C132839","A subjective score of 10 on a visual analogue scale that ranges from 0: No distress to 10: Extreme distress.","Distress Score 10 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2707655","Respiratory Pathogen Panel","C132852","A diagnostic test for respiratory pathogens that uses PCR for differential diagnosis during upper or lower respiratory tract infection.","Respiratory Pathogen Panel | Respiratory Pathogen PCR Panel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521132","PROMIS-29 Adult Profile v1.0","C132903","A 29-item multidimensional and universal measure of health intended for use across a variety of conditions. It measures an adult patient's self-reported health status in seven domains: physical function, anxiety, depression, fatigue, sleep disturbance, pain interference, and participation in social roles. The v1.0 form was copyright in 2009.","PROMIS-29 Adult Profile v1.0 | PROMIS-29",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4034863","Satisfied with How Much Work I Can Do","C132904","A question about an individual's satisfaction with how much work they can do, including work at home.","Satisfied with How Much Work I Can Do | I am satisfied with how much work I can do (include work at home)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512841","Satisfied with Ability to Work","C132905","A question about an individual's satisfaction with their ability to work, including work at home.","Satisfied with Ability to Work Question | I am satisfied with how much work I can do (include work at home) | Satisfied with Ability to Work | Satisfied with Ability to Work",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4034828","Satisfied with Ability to do Regular Personal and Household Responsibilities","C132906","A question about an individual's satisfaction with their ability to do regular personal and household responsibilities.","Satisfied with Ability to do Regular Personal and Household Responsibilities | I am satisfied with my ability to do regular personal and household responsibilities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4034894","Satisfied with Ability to Perform Daily Routine","C132907","A question about an individual's satisfaction with their ability to perform their daily routine.","Satisfied with Ability to Perform Daily Routine | I am satisfied with my ability to perform my daily routine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520322","AKT3 Gene Amplification","C132895","A molecular genetic abnormality indicating the presence of multiple copies of the AKT3 gene.","AKT3 Gene Amplification | AKT Serine/Threonine Kinase 3 Gene Amplification | PKB-GAMMA Gene Amplification | PKBG Gene Amplification | PRKBG Gene Amplification | RAC-Gamma Gene Amplification | RAC-PK-Gamma Gene Amplification | STK-2 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519739","CDK6 Gene Amplification","C132897","A molecular genetic abnormality indicating the presence of multiple copies of the CDK6 gene.","CDK6 Gene Amplification | CDK6 Amplification | CDK6 amplification | Cyclin Dependent Kinase 6 Gene Amplification | Cyclin-Dependent Kinase 6 Gene Amplification | PLSTIRE Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706884","FLCN Gene Mutation","C51150","A change in the nucleotide sequence of the FLCN gene.","FLCN Gene Mutation | BHD Gene Mutation | Birt Hogg Dube Gene Mutation | Birt Hogg Dubé Gene Mutation | Birt-Hogg-Dube Gene Mutation | Birt-Hogg-Dubé Gene Mutation | Folliculin Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520491","PIK3C2B Gene Amplification","C132896","A molecular genetic abnormality indicating the presence of multiple copies of the PIK3C2B gene.","PIK3C2B Gene Amplification | C2-PI3K Gene Amplification | PI3K-C2beta Gene Amplification | Phosphatidylinositol-4-Phosphate 3-Kinase, Catalytic Subunit Type 2 Beta Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520492","PIK3R1 Gene Mutation","C132894","A change in the nucleotide sequence of the PIK3R1 gene.","PIK3R1 Gene Mutation | GRB1 Gene Mutation | PIK3R1 mutation | Phosphoinositide-3-Kinase Regulatory Subunit 1 Gene Mutation | p85-ALPHA Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520292","Unmethylated O-6-Methylguanine-DNA Methyltransferase Gene Promoter","C132892","A genetic finding indicating the absence of DNA methylation in the promoter region of the MGMT gene. This finding is associated with a poor prognosis in patients with glioblastoma.","Unmethylated MGMT Gene Promoter | Absent | MGMT Gene Promoter Methylation Negative | Negative | Unmethylated MGMT Promoter | Unmethylated MGMT Promoter | Unmethylated Methylguanine-DNA Methyltransferase Gene Promoter | Unmethylated O-6-Methylguanine-DNA Methyltransferase Gene Promoter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520047","Immune Cell","C132890","A cell in the immune system that is involved in host defense. This category may include lymphocytes, monocytes, macrophages, neutrophils, eosinophils, basophils, mast cells, and thrombocytes. Precursor cells in these lineages may also be included.","Immune Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826256","Other Medically Important Serious Event","C82521","A serious adverse event that does not meet the criteria for being life threatening, requiring inpatient hospitalization, or causing death, persistent or significant disability or incapacity, cancer, or a congenital anomaly or birth defect, but may require medical or surgical intervention to prevent one or more of those outcomes.","Other Medically Important Serious Event | SMIE | other serious (important medical events)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516231","Cancer Survivor","C18673","An individual who has survived a cancer, and is in a disease free, chronic, or relatively stable stage.","Cancer Survivor | Survivor, Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986419","Good Clinical Practice","C94236","An international set of guidelines that helps make sure that the results of a clinical trial are reliable and that the patients are protected. Good Clinical Practice covers the way a clinical trial is designed, conducted, performed, monitored, audited, recorded, analyzed, and reported.","Good Clinical Practice | GCP | GCRP | Good Clinical Practice (GCP) | good clinical research practice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521325","Decision Regret Scale","C133012","A 5-item Likert scale designed to measure distress or remorse after a health care decision..","Decision Regret Scale | DRS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520441","Made Right Decision","C133013","A question about whether an individual thinks they made the right healthcare decision.","Made Right Decision | It was the right decision",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520233","Regret Choice Made","C133014","A question about whether an individual regrets the healthcare choice that they made.","Regret Choice Made | I regret the choice that was made",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521082","Would Make Same Choice Again","C133015","A question about whether an individual would go for the same healthcare choice if they had to do it over again.","Would Make Same Choice Again | I would go for the same choice if I had to do it over again",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520602","Choice Did Harm","C133016","A question about whether an individual thinks their healthcare choice did them a lot of harm.","Choice Did Harm | The choice did me a lot of harm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519818","Decision was Wise","C133017","A question about whether an individual thinks their healthcare decision was a wise one.","Decision was Wise | The decision was a wise one",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512153","NM_005896.3:c.395_396delGTinsAC","C128900","A complex substitution where the nucleotide sequence at positions 395 and 396 of the coding sequence of the IDH1 gene has changed from thymine-guanine to adenine-cytosine.","IDH1 NM_005896.3:c.395_396inv | IDH c.395_396GT>AC | IDH1 NM_005896.3:c.395_396GT>AC | IDH1 NM_005896.3:c.395_396delGTinsAC | IDH1 NM_005896.3:c.395_396delGTinsAC | IDH1 c.395_396GT>AC | IDH1 c.395_396delGTinsAC | Isocitrate Dehydrogenase 1 (NADP(+)), Cytosolic c.395_396GT>AC | Isocitrate Dehydrogenase 1 (NADP+), Soluble c.395_396GT>AC | NM_005896.3:c.395_396GT>AC | NM_005896.3:c.395_396delGTinsAC | NM_005896.3:c.395_396inv",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508921","PD-L1 Positive","C128554","An immunohistochemical test result that indicates expression of PD-L1 in a tissue sample of a primary or metastatic malignant neoplasm.","PD-L1 Positive | B7 Homolog 1 Positive | B7-H Positive | B7H1 Positive | CD274 Antigen Positive | CD274 Molecule Positive | CD274 Positive | Expression of PD-L1 | PD-L1+ | PDCD1L1 Positive | PDCD1LG1 Positive | PDL1 Positive | Positive | Programmed Cell Death 1 Ligand 1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272693","TEP1 Gene Deletion","C96270","A molecular abnormality referring to the loss of at least one copy of the PTEN gene (10q23).","PTEN Gene Deletion | MMAC1 Gene Deletion | Mutated in Multiple Advanced Cancers 1 Gene Deletion | PTEN Loss | PTEN1 Gene Deletion | Phosphatase and Tensin Homolog Gene Deletion | TEP1 Gene Deletion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704943","ALK wt Allele","C51738","Human ALK wild-type allele is located within 2p23 and is approximately 729 kb in length. This allele, which encodes ALK tyrosine kinase receptor protein, plays a role in brain development and exerts its effects on specific neurons in the nervous system.","ALK wt Allele | ALK | ALK Receptor Tyrosine Kinase wt Allele | Anaplastic Lymphoma Kinase (Ki-1) Gene | Anaplastic Lymphoma Receptor Tyrosine Kinase Gene | CD246 | NBLST3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336763","Toll-Like Receptor Family Gene","C25965","Expressed in a variety of tissues, Toll-Like Receptor Family Genes encode type I transmembrane Toll-Like Receptor proteins, containing a TIR domain and multiple LRR repeats, which respond to various microbial components and mediate pathogen recognition and activation of innate immunity to microbial agents. Sharing structural and functional similarities, highly conserved TLRs recognize pathogen-associated molecular patterns expressed on infectious agents and mediate cytokine production necessary for effective immunity. TLRs typically act via MyD88 (TIR interaction) and TRAF6, activating NF-Kappa-B, cytokine production and secretion, and inflammatory response. (NCI)","Toll-Like Receptor Family Gene | TLR | TLR Gene Family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985207","Oropharyngeal Tissue","C92600","Tissue that occupies the area between the soft palate and upper portion of the epiglottis.","Oropharyngeal Tissue | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551058","are unit of measure","C68869","A unit of area equal to 100 square meters. Are is a non-SI unit accepted for use with SI.","Are | ar | are",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0249529","Febuxostat","C65629","An orally available, non-purine inhibitor of xanthine oxidase with uric acid lowering activity. Upon oral administration, febuxostat selectively and noncompetitively inhibits the activity of xanthine oxidase, an enzyme that converts oxypurines, including hypoxanthine and xanthine, into uric acid. By inhibiting xanthine oxidase, uric acid production is reduced and serum uric acid levels are lowered. Febuxostat may provide protection against acute renal failure caused by the excessive release of uric acid that occurs upon massive tumor cell lysis resulting from the treatment of some malignancies.","Febuxostat | 2-(3-Cyano-4-(2-methylpropoxy)phenyl)-4-methylthiazole-5-carboxylic Acid | Adenuric | FEBUXOSTAT | TMX 67 | Uloric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335920","Sarcoma by FNCLCC Grade","C9023","Grading of sarcomas according to the French Federation of Cancer Centers Sarcoma Group (FNCLCC). This sarcoma grading system is based on three factors: differentiation, mitotic count, and tumor necrosis. The scores for each factor are added to determine the grade (1 to 3) for the sarcoma.","Sarcoma by FNCLCC Grade | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514299","Gross Total Resection","C131672","Surgical removal of an entire visible lesion, with no obvious lesion detected on post-operative evaluation; microscopic residual disease may be present.","Gross Total Resection | Gross Total",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640974","Negation Indicator","C102861","Specifies whether an activity did not occur.","Negation Indicator | negationIndicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640874","Member of High Risk Population","C102666","An indication that a person is part of a population group that has a greater chance of contracting a disease or disorder.","Member of High Risk Population | Member Of High Risk Population | RISKPOP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897834","Procedure Location","C117525","The site in or on the body at which the procedure is performed.","Procedure Location | PRLOC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1171347","Image-Guided Therapy","C16185","The use of imaging techniques to provide the basis for therapy, e.g., enabling surgeons to visualize internal structures through an automated overlay of 3D reconstructions of internal anatomy on top of live video views of a patient. Also used for guidance of biopsy needles.","Image-Guided Therapy | Image Guided Therapy | Imaging Guided Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2748260","Shear Wave Elastography","C116563","An imaging modality that adds the imaging of shear waves to a conventional ultrasound, allowing for a more detailed image, and an accurate measurement of tissue elasticity.","Shear Wave Elastography | SWE | Transient Elastography | US SWE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520704","Gene Rearrangement Abnormality","C133155","A molecular abnormality characterized by rearrangement of a gene sequence that results in either aberrant gene expression or the translation of a novel protein.","Gene Rearrangement Abnormality | Abnormal Gene Rearrangement | Abnormal Rearrangement | Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443977","Polyclonal Gene Rearrangement","C133165","DNA sequence rearrangements that result in the creation of multiple immunoglobulins or T-cell receptors being expressed in a lymphocyte population.","Polyclonal Gene Rearrangement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520644","Clonal Rearrangement, Single Peak","C133166","DNA sequence rearrangements that are detected or characterized by presence of a single type of protein molecule in a cell population.","Clonal Rearrangement, Single Peak | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520643","Clonal Rearrangement, Multiple Peaks","C133167","DNA sequence rearrangements that are detected or characterized by presence of multiple types of protein molecules in a cell population.","Clonal Rearrangement, Multiple Peaks | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521335","Dose Expansion Cohort","C133188","A group of subjects in a phase I trial, usually accrued after the maximum tolerated dose maximum tolerated dose has been established. These subjects, often with additional eligibility criteria, are used to: confirm that a safe level of drug exposure has been established, obtain preliminary evidence of efficacy, and identify specific patient subgroups that might derive particular benefits from the investigational treatment.","Dose Expansion Cohort | DEC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346581","Iobenguane Sulfate I-123","C74049","The neurotransmitter analogue 3-nitrobenzylguanidine conjugated to iodine I 123 and used as a gamma-emitting imaging agent. The adrenergic tissue uptake and storage of I-123 metaiodobenzylguanidine (I-123 MIBG) mimics that of norepinephrine (NE). The distribution of this agent enables the scintigraphic imaging of neural crest tumors, such as neuroblastoma and pheochromocytoma.","Iobenguane Sulfate I-123 | I-123-MIBG | IOBENGUANE SULFATE I-123 | Iodine I 123-Metaiodobenzylguanidine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710383","Therapy Delayed Or Prolonged","C50425","An indication that a therapy was either delayed or prolonged.","Therapy Delayed or Prolonged | Non-Surgical Treatment Delayed Or Prolonged | Non-Surgical Treatment Delayed or Prolonged | Therapy Delayed Or Prolonged",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520809","Mammographically Dense Breast","C132100","A mammographic finding of heterogeneously or extremely dense breast composition, as defined by the visually estimated content of fibroglandular-density tissue within the breast, based on updated editions of the American College of Radiology's Breast Imaging Reporting and Data System (BI-RADS).","Mammographically Dense Breast | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026532","Morals","C94315","Having to do with beliefs about what is right and wrong in terms of how people behave.","Moral | ethical | moral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520321","BTK Gene Mutation","C132254","A change in the nucleotide sequence of the BTK gene.","BTK Gene Mutation | AGMX1 Gene Mutation | AT Gene Mutation | ATK Gene Mutation | BPK Gene Mutation | Bruton Agammaglobulinemia Tyrosine Kinase Gene Mutation | Bruton Tyrosine Kinase Gene Mutation | IMD1 Gene Mutation | MGC126261 Gene Mutation | MGC126262 Gene Mutation | PSCTK1 Gene Mutation | XLA Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520209","RAS Wild Type","C132847","A genetic finding indicating that RAS family gene mutations are absent in a sample.","RAS Wild Type | RAS Family Gene Mutation Negative | RAS Gene Mutation Negative | RAS Mutation Negative | RAS wt Allele | Wild Type RAS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520205","RAF Wild Type","C132848","A genetic finding indicating that RAF family gene mutations are absent in a sample.","RAF Wild Type | RAF Family Gene Mutation Negative | RAF Gene Mutation Negative | RAF Mutation Negative | RAF wt Allele | Rapidly Accelerated Fibrosarcoma Family Gene Mutation Negative | Rapidly Accelerated Fibrosarcoma Family Kinase Gene Mutation Negative | Wild Type RAF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0682323","Significant Other","C119265","A gender-neutral term for a person's partner in an intimate or romantic relationship without disclosing or presuming marital status or sexual orientation.","Significant Other | SIGNIFICANT OTHER | SO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205380","Encase","C133237","To completely and closely surround.","Encase | Enclose",,,,,,,,,,,,,,,"4286330","Walled",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3891067","Laboratory Sample Manual","C115541","Documentation describing work processes and procedures for the collection, handling, and shipping of a sample.","Laboratory Sample Manual | Facility Handbook | Facility Manual | Lab Manl | Lab Manual | Manual | User Manual",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640856","Forgot to Take Medication Dose","C102638","A patient's failure to remember to take a dose of medication.","Forgot to Take Medication Dose | FORGOT TO TAKE MEDICATION DOSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053871","Very Good Partial Response","C123618","Partial response with additional serum and urine M-protein reduction, but not meeting complete response.","Very Good Partial Response | VGPR | VGPR-Very Good Partial Response | Very Good Partial Remission",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050416","Stringent Complete Response","C123614","The confirmed disappearance of all signs of cancer, and absence of molecular or cytogenetic marker of disease, in response to treatment with additional biochemical, immunological and histopathological analyses to verify the CR.","Stringent Complete Response | Stringent Complete Remission | sCR | sCR-Stringent Complete Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006726","Calcium, Dietary","C68241","Forms of the element calcium found in foods.","Dietary Calcium | Calcium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348701","Food Energy","C68544","The amount of energy in food that is available to the body. The values for food energy are expressed in kilocalories (kcal) or kilojoules (kJ).","Food Energy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502663","Undetermined finding","C124294","A term referring to the lack of definitive criteria for classification of a finding.","Undetermined | UNDETERMINED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4018905","Too Early","C133441","At a point before the usual, expected, or specified time.","Too Early | Premature | TE-Too Early | Too Soon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641122","Durvalumab","C103194","A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types.","Durvalumab | DURVALUMAB | Imfinzi | Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer | MEDI 4736 | MEDI-4736 | MEDI4736",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519770","Curie Scoring System","C133462","A semi-quantitative scoring system, developed at the Curie Institute in France, used for staging neuroblastoma patients at diagnosis and for response assessment following induction chemotherapy. Following whole-body 123I-mIBG scanning, osteomedullary involvement is scored for 9 skeletal segments plus a tenth score for soft tissue involvement.","Curie Scoring System | Curie Method | Curie Score | Curie mIBG-Scoring System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519760","Curie Extension Score 0","C133469","No metastatic sites within a segment.","Curie Extension Score 0 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519761","Curie Extension Score 1","C133470","One metastatic site within a segment.","Curie Extension Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519762","Curie Extension Score 2","C133471","More than one metastatic site within a segment.","Curie Extension Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519763","Curie Extension Score 3","C133472","Diffuse involvement within a segment (>50% of the segment).","Curie Extension Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519769","Curie Intensity Score","C133468","A score assigned to a Curie body segment to indicate the strength of 123I-mIBG uptake.","Curie Intensity Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519765","Curie Intensity Score 0","C133473","No uptake within a segment.","Curie Intensity Score 0 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519766","Curie Intensity Score 1","C133474","Doubtful uptake within a segment.","Curie Intensity Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519767","Curie Intensity Score 2","C133475","Definite uptake within a segment, but less uptake than in the liver.","Curie Intensity Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519768","Curie Intensity Score 3","C133477","Intense uptake, greater than in the liver.","Curie Intensity Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520323","ALK NP_004295.2:p.R1275X","C133464","A change in the amino acid residue at position 1170 in the ALK tyrosine kinase receptor protein where arginine has been replaced by another amino acid.","ALK NP_004295.2:p.R1275X | ALK Arg1275Xxx | ALK NP_004295.2:p.Arg1275Xxx | ALK R1275 Mutation | ALK R1275X | ALK Tyrosine Kinase Receptor Arg1275Xxx | ALK Tyrosine Kinase Receptor R1275X | ALK p.Arg1275Xxx | ALK p.R1275X | Anaplastic Lymphoma Kinase Arg1275Xxx | Anaplastic Lymphoma Kinase R1275X | CD246 Antigen Arg1275Xxx | CD246 Antigen R1275X | NP_004295.2:p.Arg1275Xxx | NP_004295.2:p.R1275X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520324","ALK NP_004295.2:p.F1174X","C133465","A change in the amino acid residue at position 1174 in the ALK tyrosine kinase receptor protein where phenylalanine has been replaced by another amino acid.","ALK NP_004295.2:p.F1174X | ALK F1174 Mutation | ALK F1174X | ALK NP_004295.2:p.Phe1174Xxx | ALK Phe1174Xxx | ALK Tyrosine Kinase Receptor F1174X | ALK Tyrosine Kinase Receptor Phe1174Xxx | ALK p.F1174X | ALK p.Phe1174Xxx | Anaplastic Lymphoma Kinase F1174X | Anaplastic Lymphoma Kinase Phe1174Xxx | CD246 Antigen F1174X | CD246 Antigen Phe1174Xxx | NP_004295.2:p.F1174X | NP_004295.2:p.Phe1174Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520325","ALK NP_004295.2:p.F1245X","C133466","A change in the amino acid residue at position 1245 in the ALK tyrosine kinase receptor protein where phenylalanine has been replaced by another amino acid.","ALK NP_004295.2:p.F1245X | ALK F1245 Mutation | ALK F1245X | ALK NP_004295.2:p.Phe1245Xxx | ALK Phe1245Xxx | ALK Tyrosine Kinase Receptor F1245X | ALK Tyrosine Kinase Receptor Phe1245Xxx | ALK p.F1245X | ALK p.Phe1245Xxx | Anaplastic Lymphoma Kinase F1245X | Anaplastic Lymphoma Kinase Phe1245Xxx | CD246 Antigen F1245X | CD246 Antigen Phe1245Xxx | NP_004295.2:p.F1245X | NP_004295.2:p.Phe1245Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520326","ALK NP_004295.2:p.I1170N","C133478","A change in the amino acid residue at position 1170 in the ALK tyrosine kinase receptor protein where isoleucine has been replaced by asparagine.","ALK NP_004295.2:p.I1170N | ALK I1170N | ALK Ile1170Asn | ALK NP_004295.2:p.Ile1170Asn | ALK Tyrosine Kinase Receptor I1170N | ALK Tyrosine Kinase Receptor Ile1170Asn | ALK p.I1170N | ALK p.Ile1170Asn | Anaplastic Lymphoma Kinase I1170N | Anaplastic Lymphoma Kinase Ile1170Asn | CD246 Antigen I1170N | CD246 Antigen Ile1170Asn | NP_004295.2:p.I1170N | NP_004295.2:p.Ile1170Asn",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520327","ALK NP_004295.2:p.I1170S","C133480","A change in the amino acid residue at position 1170 in the ALK tyrosine kinase receptor protein where isoleucine has been replaced by serine.","ALK NP_004295.2:p.I1170S | ALK I1170S | ALK Ile1170Ser | ALK NP_004295.2:p.Ile1170Ser | ALK Tyrosine Kinase Receptor I1170S | ALK Tyrosine Kinase Receptor Ile1170Ser | ALK p.I1170S | ALK p.Ile1170Ser | Anaplastic Lymphoma Kinase I1170S | Anaplastic Lymphoma Kinase Ile1170Ser | CD246 Antigen I1170S | CD246 Antigen Ile1170Ser | NP_004295.2:p.I1170S | NP_004295.2:p.Ile1170Ser",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520328","ALK NP_004295.2:p.I1171N","C133483","A change in the amino acid residue at position 1171 in the ALK tyrosine kinase receptor protein where isoleucine has been replaced by asparagine.","ALK NP_004295.2:p.I1171N | ALK I1171N | ALK Ile1171Asn | ALK NP_004295.2:p.Ile1171Asn | ALK Tyrosine Kinase Receptor I1171N | ALK Tyrosine Kinase Receptor Ile1171Asn | ALK p.I1171N | ALK p.Ile1171Asn | Anaplastic Lymphoma Kinase I1171N | Anaplastic Lymphoma Kinase Ile1171Asn | CD246 Antigen I1171N | CD246 Antigen Ile1171Asn | NP_004295.2:p.I1171N | NP_004295.2:p.Ile1171Asn",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520331","ALK NP_004295.2:p.Y1278S","C133485","A change in the amino acid residue at position 1278 in the ALK tyrosine kinase receptor protein where tyrosine has been replaced by serine.","ALK NP_004295.2:p.Y1278S | ALK NP_004295.2:p.Tyr1278Ser | ALK Tyr1278Ser | ALK Tyrosine Kinase Receptor Tyr1278Ser | ALK Tyrosine Kinase Receptor Y1278S | ALK Y1278S | ALK p.Tyr1278Ser | ALK p.Y1278S | Anaplastic Lymphoma Kinase Tyr1278Ser | Anaplastic Lymphoma Kinase Y1278S | CD246 Antigen Tyr1278Ser | CD246 Antigen Y1278S | NP_004295.2:p.Tyr1278Ser | NP_004295.2:p.Y1278S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521660","ALK NP_004295.2:p.R1192P","C133487","A change in the amino acid residue at position 1192 in the ALK tyrosine kinase receptor protein where arginine has been replaced by proline.","ALK NP_004295.2:p.R1192P | ALK Arg1192Pro | ALK NP_004295.2:p.Arg1192Pro | ALK R1192P | ALK Tyrosine Kinase Receptor Arg1192Pro | ALK Tyrosine Kinase Receptor R1192P | ALK p.Arg1192Pro | ALK p.R1192P | Anaplastic Lymphoma Kinase Arg1192Pro | Anaplastic Lymphoma Kinase R1192P | CD246 Antigen Arg1192Pro | CD246 Antigen R1192P | NP_004295.2:p.Arg1192Pro | NP_004295.2:p.R1192P",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520330","ALK NP_004295.2:p.M1166R","C133489","A change in the amino acid residue at position 1166 in the ALK tyrosine kinase receptor protein where methionine has been replaced by arginine.","ALK NP_004295.2:p.M1166R | ALK M1166R | ALK Met1166Arg | ALK NP_004295.2:p.Met1166Arg | ALK Tyrosine Kinase Receptor M1166R | ALK Tyrosine Kinase Receptor Met1166Arg | ALK p.M1166R | ALK p.Met1166Arg | Anaplastic Lymphoma Kinase M1166R | Anaplastic Lymphoma Kinase Met1166Arg | CD246 Antigen M1166R | CD246 Antigen Met1166Arg | NP_004295.2:p.M1166R | NP_004295.2:p.Met1166Arg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520329","ALK NP_004295.2:p.L1196M","C133491","A change in the amino acid residue at position 1196 in the ALK tyrosine kinase receptor protein where leucine has been replaced by methionine.","ALK NP_004295.2:p.L1196M | ALK L1196M | ALK Leu1196Met | ALK NP_004295.2:p.Leu1196Met | ALK Tyrosine Kinase Receptor L1196M | ALK Tyrosine Kinase Receptor Leu1196Met | ALK p.L1196M | ALK p.Leu1196Met | Anaplastic Lymphoma Kinase Leu1196Met | CD246 Antigen L1196M | CD246 Antigen Leu1196Met | NP_004295.2:p.L1196M | NP_004295.2:p.Leu1196Met",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521659","ALK NP_004295.2:p.G1128A","C133493","A change in the amino acid residue at position 1128 in the ALK tyrosine kinase receptor protein where glycine has been replaced by alanine.","ALK NP_004295.2:p.G1128A | ALK G1128A | ALK Gly1128Ala | ALK NP_004295.2:p.Gly1128Ala | ALK Tyrosine Kinase Receptor G1128A | ALK Tyrosine Kinase Receptor Gly1128Ala | ALK p.G1128A | ALK p.Gly1128Ala | Anaplastic Lymphoma Kinase G1128A | Anaplastic Lymphoma Kinase Gly1128Ala | CD246 Antigen G1128A | CD246 Antigen Gly1128Ala | NP_004295.2:p.G1128A | NP_004295.2:p.Gly1128Ala",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0239941","Hemoglobin F Increased","C36224","A laboratory test result indicating an abnormal amount of fetal hemoglobin in a biological sample.","Hemoglobin F Increased | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513028","Circulating Myeloid Cell","C129907","A myeloid-derived cell found in the peripheral blood.","Circulating Myeloid Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520342","ALK Protein Variant","C133463","A variation in the amino acid sequence for the ALK tyrosine kinase receptor protein.","ALK Protein Variant | ALK Tyrosine Kinase Receptor Protein Variant | Anaplastic Lymphoma Kinase Protein Variant | CD246 Antigen Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0222787","Costal Cartilage","C32391","The cartilage positioned between the anterior end of the rib and the sternum. Its elasticity allows the ribcage to expand while breathing.","Costal Cartilage | COSTAL CARTILAGE",,,,,,,,,,,,,,,"4178112","Structure of costal cartilage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519421","Somatic Cell Genetics","C19037","Various methods for gene function studies that rely on the use of cells in culture.","Somatic Cell Genetics | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510803","Adherent Culture","C20216","A type of culture in which cells grow as a monolayer that is attached to the culture substrate.","Adherent Culture | Monolayer culture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL430252","CCR2 Antagonist PF-04136309","C97507","An orally available human chemokine receptor 2 (CCR2) antagonist with potential immunomodulating and antineoplastic activities. Upon oral administration, CCR2 antagonist PF-04136309 specifically binds to CCR2 and prevents binding of the endothelium-derived chemokine ligand CLL2 (monocyte chemoattractant protein-1 or MCP1) to its receptor CCR2, which may result in inhibition of CCR2 activation and signal transduction. This may inhibit inflammatory processes as well as angiogenesis, tumor cell migration, and tumor cell proliferation. The G-protein coupled receptor CCR2 is expressed on the surface of monocytes and macrophages, stimulates the migration and infiltration of these cell types, and plays an important role in inflammation, angiogenesis, and tumor cell migration and proliferation.","CCR2 Antagonist PF-04136309 | PF-04136309 | PF-4136309",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053635","IDH1(R132) Inhibitor IDH305","C121457","An inhibitor of the citric acid cycle enzyme isocitrate dehydrogenase [NADP] cytoplasmic (isocitrate dehydrogenase 1; IDH1) with mutations at residue R132 (IDH1(R132)), with potential antineoplastic activity. Upon administration, IDH305 specifically inhibits IDH1(R132) mutant forms in the cytoplasm, which inhibits the formation of the oncometabolite 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1(R132)-expressing tumor cells. IDH1(R132) mutations are highly expressed in certain malignancies, including gliomas; they initiate and drive cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.","IDH1(R132) Inhibitor IDH305 | IDH305",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896888","CCR2 Antagonist CCX872-B","C120302","An orally available human C-C chemokine receptor type 2 (CCR2) antagonist, with potential immunomodulating and antineoplastic activities. Upon oral administration, CCR2 antagonist CCX872-B specifically binds to CCR2 and prevents the binding its cognate endothelium-derived chemokine ligand CCL2 (monocyte chemoattractant protein-1 or MCP1). This may result in the inhibition of both CCR2 activation and CCR2-mediated signal transduction, which may inhibit inflammatory processes, angiogenesis, tumor cell migration, and tumor cell proliferation. The G-protein coupled receptor CCR2 is expressed on the surface of monocytes and macrophages, and stimulates their migration and infiltration; it plays a key role in inflammation. CCR2 is overexpressed in certain cancer cell types, where it is involved in angiogenesis, tumor cell migration and proliferation.","CCR2 Antagonist CCX872-B | CCX872-B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519274","Sestamibi Scan","C38091","A nuclear imaging procedure which is performed to identify hyperparathyroidism. Sestamibi is a nuclear radiopharmaceutical which is bound to the radioactive isotope Tc99m. Tc99m-Sestamibi is taken up by both the thyroid gland and the parathyroid gland, and is also used in Nuclear Myocardial Perfusion Imaging.","Sestamibi Scan | sestamibi scan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521084","International Neuroblastoma Risk Group Staging System","C133427","A clinical staging system for neuroblastoma based on preoperative imaging and determined prior to any treatment, including surgery. It includes two stages of localized disease (L1 and L2) and two stages of metastatic disease (M and MS).","International Neuroblastoma Risk Group Staging System | INRGSS | inrg stage | inrg_stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520040","INRG Stage L1","C133428","Locoregional neuroblastoma without image defined risk factors (IDRFs).","INRG Stage L1 | International Neuroblastoma Risk Group Stage L1 | L1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520041","INRG Stage L2","C133429","Locoregional neuroblastoma with one or more image defined risk factors (IDRFs).","INRG Stage L2 | International Neuroblastoma Risk Group Stage L2 | L2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520043","INRG Stage M","C133430","Neuroblastoma with distant metastatic disease (except MS).","INRG Stage M | International Neuroblastoma Risk Group Stage M | M",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520042","INRG Stage MS","C133431","INRG stage L1 or L2 neuroblastoma with metastatic disease confined to the skin and/or liver and/or bone marrow.","INRG Stage MS | International Neuroblastoma Risk Group Stage MS | Ms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880273","Delegate (person)","C54628","A person appointed or elected to represent others.","Delegate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206765","Connective and Soft Tissue Neoplasm","C3810","A benign, intermediate, or malignant neoplasm that affects the connective and soft tissue.","Connective and Soft Tissue Neoplasm | Connective and Soft Tissue Tumor | Musculoskeletal and Soft Tissue Neoplasm | Musculoskeletal and Soft Tissue Tumor | Neoplasm of Skeletal and Soft Tissue | Neoplasm of Soft Tissue and Bone | Neoplasm of Soft Tissue and Skeleton | Skeletal and Soft Tissue Neoplasm | Skeletal and Soft Tissue Tumor | Soft Tissue and Bone Neoplasm | Soft Tissue and Bone Tumor | Tumor of Skeletal and Soft Tissue | Tumor of Soft Tissue and Bone | Tumor of Soft Tissue and Skeleton",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521159","11q Translocation","C133693","A cytogenetic abnormality that refers to any translocation involving the long arm of chromosome 11.","11q Translocation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520332","ALK Negative","C133707","Indicates that expression of ALK has not been detected in a sample.","ALK Negative | ALK Receptor Tyrosine Kinase Negative | ALK Tyrosine Kinase Receptor Negative | Anaplastic Lymphoma Kinase Negative | Anaplastic Lymphoma Kinase Receptor Negative | Anaplastic Lymphoma Receptor Tyrosine Kinase Negative | CD246 Antigen Negative | CD246 Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520359","ATM Gene Deletion","C133680","A molecular abnormality referring to the loss of at least one copy of the ATM gene.","ATM Gene Deletion | A-T Mutated Gene Deletion | AT Mutated Gene Deletion | ATM Serine/Threonine Kinase Gene Deletion | Ataxia Telangiectasia Mutated Gene Deletion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520596","BRAF Gene Amplification","C133674","A molecular genetic abnormality indicating the presence of multiple copies of the BRAF gene.","BRAF Gene Amplification | B-RAF Gene Amplification | B-RAF1 Gene Amplification | v-raf Murine Sarcoma Viral Oncogene Homolog B1 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519710","CDH3 Positive","C133703","Indicates that CDH3 expression has been detected in a sample.","CDH3 Positive | CADP Positive | Cadherin 3 Positive | Cadherin, Placental Positive | Cadherin-3 Positive | P-Cadherin Positive | PCAD Positive | Placental Cadherin Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519751","CSF1R Gene Mutation","C133687","A change in the nucleotide sequence of the CSF1R gene.","CSF1R Gene Mutation | C-FMS Gene Mutation | CD115 Gene Mutation | CSF-1R Gene Mutation | CSFR Gene Mutation | Colony Stimulating Factor 1 Receptor Gene Mutation | FMS Gene Mutation | M-CSF-R Gene Mutation | Macrophage Colony-Stimulating Factor 1 Receptor Gene Mutation | McDonough Feline Sarcoma Viral (V-Fms) Oncogene Homolog Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414075","DLX1 Gene","C133658","This gene may be involved in brain and facial development.","DLX1 Gene | DLX1 | Distal-Less Homeobox 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521036","EPHA2 Gene Mutation","C133683","A change in the nucleotide sequence of the EPHA2 gene.","EPHA2 Gene Mutation | ECK Gene Mutation | EPH Receptor A2 Gene Mutation | Ephrin Receptor A2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520387","FGF Family Alteration Positive","C133704","Indicates that mutation, overexpression or rearrangement of an FGF family member has been detected in a sample.","FGF Family Alteration Positive | FGF Alteration | FGF Alteration Positive | Fibroblast Growth Factor Alteration | Fibroblast Growth Factor Alteration Positive | Fibroblast Growth Factor Family Alteration | Fibroblast Growth Factor Family Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520389","FGFR Family Alteration Positive","C133705","Indicates that mutation, overexpression or rearrangement of an FGFR family member has been detected in a sample.","FGFR Family Alteration Positive | FGFR Alteration | FGFR Alteration Positive | Fibroblast Growth Factor Receptor Alteration | Fibroblast Growth Factor Receptor Alteration Positive | Fibroblast Growth Factor Receptor Family Alteration | Fibroblast Growth Factor Receptor Family Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520646","FYN Gene Mutation","C133684","A change in the nucleotide sequence of the FYN gene.","FYN Gene Mutation | FYN Oncogene Related to SRC, FGR, YES Gene Mutation | FYN Proto-Oncogene, Src Family Tyrosine Kinase Gene Mutation | SLK Gene Mutation | SRC/YES-Related Novel Gene Mutation | SRC/YES-Related Oncogene Gene Mutation | SYN Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348913","HLA-A1 Positive Cells Present","C69407","A laboratory test result indicating the presence of HLA-A*01 positive cells in a tissue sample.","HLA-A1 Positive Cells Present | HLA-A*01 Positive | HLA-A*01 Positive Cells Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519967","Homologous Recombination Repair Gene Mutation","C133695","A change in the nucleotide sequence of a gene involved in homologous recombination-type DNA repair processes.","Homologous Recombination Repair Gene Mutation | HHR Gene Mutation | HRR Gene Mutation | Homologous Recombination Pathway Gene Mutation | Recombination Repair Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521154","KIT Gene Amplification","C133678","A molecular genetic abnormality indicating the presence of multiple copies of the KIT gene.","KIT Gene Amplification | CD117 Gene Amplification | KIT Amplification | KIT Proto-Oncogene Tyrosine Protein Kinase Gene Amplification | c-KIT Gene Amplification | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521121","LCK Gene Mutation","C133689","A change in the nucleotide sequence of the LCK gene.","LCK Gene Mutation | LCK Proto-Oncogene, Src Family Tyrosine Kinase Gene Mutation | LSK Gene Mutation | Lymphocyte-Specific Protein Tyrosine Kinase Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520443","LYN Gene Mutation","C133690","A change in the nucleotide sequence of the LYN gene.","LYN Gene Mutation | JTK8 Gene Mutation | LYN Proto-Oncogene, Src Family Tyrosine Kinase Gene Mutation | v-Yes-1 Yamaguchi Sarcoma Viral Oncogene Homolog Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520064","Mismatch Repair Gene Mutation","C133706","A change in the nucleotide sequence of a gene involved in DNA mismatch repair.","Mismatch Repair Gene Mutation | DNA Mismatch Repair Gene Mutation | MMR Gene Mutation | MMR Mutation | mismatch repair mutation | mismatch_repair_mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520390","MTOR Gene Mutation","C133686","A change in the nucleotide sequence of the MTOR gene.","MTOR Gene Mutation | FK506 Binding Protein 12-Rapamycin Associated Protein 1 Gene Mutation | FRAP Gene Mutation | FRAP1 Gene Mutation | MTOR mutation | Mammalian Target of Rapamycin Gene Mutation | Mechanistic Target of Rapamycin Gene Mutation | Rapamycin and FKBP12 Target 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520451","MYC Protein Overexpression","C133692","A molecular abnormality indicating the presence of an abnormally high level of the Myc proto-oncogene protein.","MYC Protein Overexpression | Class E Basic Helix-Loop-Helix Protein 39 Protein Overexpression | MYC Overexpression | MYC Transcription Factor Protein Overexpression | Myc Proto-Oncogene Protein Overexpression | Proto-Oncogene c-Myc Protein Overexpression | bHLHe39 Protein Overexpression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520471","PTCH1 Gene Deletion","C133679","A molecular abnormality referring to the loss of at least one copy of the PTCH1 gene.","PTCH1 Gene Deletion | PTC Gene Deletion | PTC1 Gene Deletion | PTCH Gene Deletion | Patched 1 Gene Deletion | Patched Homolog (Drosophila) Gene Deletion | Patched Homolog 1 Gene Deletion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520472","PTCH1 Gene Mutation","C133669","A change in the nucleotide sequence of the PTCH1 gene.","PTCH1 Gene Mutation | PTC Gene Mutation | PTC1 Gene Mutation | PTCH Gene Mutation | Patched 1 Gene Mutation | Patched Homolog (Drosophila) Gene Mutation | Patched Homolog 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520206","RAF1 Gene Amplification","C133675","A molecular genetic abnormality indicating the presence of multiple copies of the RAF1 gene.","RAF1 Gene Amplification | CRAF/RAF1 Gene Amplification | NS5 Gene Amplification | RAF Gene Amplification | RAF-1 Gene Amplification | Raf-1 Proto-Oncogene, Serine/Threonine Kinase Gene Amplification | c-Raf Gene Amplification | cRAF Gene Amplification | v-RAF-1 Murine Leukemia Viral Oncogene Homolog 1 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520207","RAF1 Gene Mutation","C133676","A change in the nucleotide sequence of the RAF1 gene.","RAF1 Gene Mutation | NS5 Gene Mutation | RAF Gene Mutation | RAF-1 Gene Mutation | Raf-1 Proto-Oncogene, Serine/Threonine Kinase Gene Mutation | c-Raf Gene Mutation | cRAF Gene Mutation | v-RAF-1 Murine Leukemia Viral Oncogene Homolog 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520210","RB1 Gene Mutation","C133696","A change in the nucleotide sequence of the RB1 gene.","RB1 Gene Mutation | RB Gene Mutation | Retinoblastoma 1 Gene Mutation | Retinoblastoma Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520445","SF3B1 Gene Mutation","C133702","A change in the nucleotide sequence of the SF3B1 gene.","SF3B1 Gene Mutation | Hsh155 Gene Mutation | MDS Gene Mutation | PRP10 Gene Mutation | PRPF10 Gene Mutation | Pre-mRNA Processing 10 Gene Mutation | SAP155 Gene Mutation | SF3B, 155-kD Subunit Gene Mutation | SF3b155 Gene Mutation | Spliceosome-Associated Protein, 155-kD Gene Mutation | Splicing Factor 3b Subunit 1 Gene Mutation | Splicing Factor 3b, Subunit 1 Gene Mutation | Splicing Factor 3b, Subunit 1, 155kDa Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520358","SRC Gene Mutation","C133688","A change in the nucleotide sequence of the SRC gene.","SRC Gene Mutation | ASV Gene Mutation | SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase Gene Mutation | SRC1 Gene Mutation | c-SRC Gene Mutation | v-SRC Avian Sarcoma (Schmidt-Ruppin A-2) Viral Oncogene Homolog Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520498","SRSF2 Gene Deletion","C133699","A molecular abnormality referring to the loss of at least one copy of the SRSF2 gene.","SRSF2 Gene Deletion | SC35 Gene Deletion | SFRS2 Gene Deletion | Serine and Arginine Rich Splicing Factor 2 Gene Deletion | Serine/Arginine-Rich Splicing Factor 2 Gene Deletion | Splicing Factor, Arginine/Serine-Rich 2 Gene Deletion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520499","SRSF2 Gene Mutation","C133698","A change in the nucleotide sequence of the SRSF2 gene.","SRSF2 Gene Mutation | SC35 Gene Mutation | SFRS2 Gene Mutation | Serine and Arginine Rich Splicing Factor 2 Gene Mutation | Serine/Arginine-Rich Splicing Factor 2 Gene Mutation | Splicing Factor, Arginine/Serine-Rich 2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520997","TFE3 Gene Rearrangement","C133697","A molecular abnormality indicating rearrangement of the TFE3 gene.","TFE3 Gene Rearrangement | RCCP2 Gene Rearrangement | RCCX1 Gene Rearrangement | TFEA Gene Rearrangement | Transcription Factor Binding to IGHM Enhancer 3 Gene Rearrangement | Transcription Factor E3 Gene Rearrangement | bHLHe33 Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520565","TP53 Gene Deletion","C133694","A molecular abnormality referring to the loss of at least one copy of the TP53 gene.","TP53 Gene Deletion | TP53 Deletion | Tumor Protein p53 Gene Deletion | p53 Deletion | p53 Gene Deletion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520262","U2AF1 Gene Mutation","C133700","A change in the nucleotide sequence of the U2AF1 gene.","U2AF1 Gene Mutation | FP793 Gene Mutation | RN Gene Mutation | RNU2AF1 Gene Mutation | U2 Small Nuclear RNA Auxiliary Factor 1 Gene Mutation | U2AF35 Gene Mutation | U2AFBP Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521286","YES1 Gene Mutation","C133685","A change in the nucleotide sequence of the YES1 gene.","YES1 Gene Mutation | YES Proto-Oncogene 1, Src Family Tyrosine Kinase Gene Mutation | Yes Gene Mutation | v-Yes-1 Yamaguchi Sarcoma Viral Oncogene Homolog 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520550","ZRSR2 Gene Mutation","C133701","A change in the nucleotide sequence of the ZRSR2 gene.","ZRSR2 Gene Mutation | U2AF1-RS2 Gene Mutation | U2AF1L2 Gene Mutation | U2AF1RS2 Gene Mutation | URP Gene Mutation | ZC3H22 Gene Mutation | Zinc Finger CCCH-type, RNA Binding Motif and Serine/Arginine Rich 2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520585","Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes","C133191","A preparation of a defined ratio of CD4+ and bulk CD8+ autologous T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing a human anti-CD19 single chain variable fragment (scFv) fused to the signaling domain of 4-1BB (CD137), the zeta chain of the TCR/CD3 complex (CD3-zeta), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous human anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes are directed to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a cetuximab-induced antibody dependent cellular cytotoxicity (ADCC) response. The 4-1BB costimulatory signaling domain enhances both proliferation of T-cells and antitumor activity.","Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes | Anti-CD19-CAR Genetically Engineered Autologous T Lymphocytes huJCAR014 | Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes huJCAR014 | Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes | huJCAR014",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896965","Log10 International Units per Milliliter","C116238","A logarithmic-scale (base 10) unit for measuring international units per unit of volume equal to one milliliter.","Log10 International Units per Milliliter | log10 IU/mL | {log10}.[IU]/mL | {log10}.[IU]/ml | {log10}.[iU]/mL | {log10}.[iU]/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523845","Foundation Medicine Inc","C133726","A biotechnology company which develops and manufactures genomic analysis diagnostics based on next-generation sequencing technology for detection of solid and circulating cancers.","Foundation Medicine Inc | FMI | Foundation Medicine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521669","CARIS Life Sciences","C133728","A biotechnology company that specializes in molecular profiling of cancers and identification of targets for treatment.","CARIS Life Sciences | CARIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0243045","Cyclin-Dependent Kinases","C17767","Cyclin-dependent kinases are eukaryotic, phosphoregulated protein kinases that associate with cyclins to control cell cycle progression.","Cyclin-Dependent Kinase | CDK | Cyclin Dependent Kinase | Cyclin Dependent Kinase Family | Cyclin-Dependent Kinase Family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514068","ROS1 Gene Rearrangement","C130236","A molecular abnormality indicating rearrangement of the ROS1 gene.","ROS1 Gene Rearrangement | MCF3 Gene Rearrangement | ROS Gene Rearrangement | ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene Rearrangement | ROS1 Rearrangement | ROS1 rearranged | Rearrangement identified | c-ros-1 Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706902","BRAF wt Allele","C51194","Human BRAF wild-type allele is located within 7q34 and is approximately 190 kb in length. This allele, which encodes B-Raf proto-oncogene serine/threonine-protein kinase protein, plays a role in the transduction of mitogenic signals from the cell membrane to the nucleus. A specific activating somatic mutation in the BRAF gene is associated with several types of cancer such as colorectal and thyroid carcinomas and malignant melanoma.","BRAF wt Allele | B-RAF1 | B-Raf Proto-Oncogene Serine/Threonine-Protein Kinase (P94) Gene | B-Raf Proto-Oncogene, Serine/Threonine Kinase wt Allele | B-raf-1 | BRAF1 | Murine Sarcoma Viral (V-Raf) Oncogene Homolog B1 Gene | NS7 | RAFB1 | v-Raf Murine Sarcoma Viral Oncogene Homolog B Gene | v-raf Murine Sarcoma Viral Oncogene Homolog B1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1365560","Citrus Flavor","C73378","A characteristic of a medicinal product, specifying that its most predominant agreeable savor detected by the unified sensation of taste and olfactory receptors resembles citrus.","Citrus Flavor | CITRUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0805250","BCL2 Gene Rearrangement","C132019","A molecular abnormality indicating rearrangement of the BCL2 gene.","BCL2 Gene Rearrangement | B-Cell CLL-Lymphoma 2 Gene Rearrangement | B-Cell CLL/Lymphoma 2 Gene Rearrangement | BCL2, Apoptosis Regulator Gene Rearrangement | Bcl-2 Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514067","ROS1 Gene Mutation","C130952","A change in the nucleotide sequence of the ROS1 gene.","ROS1 Gene Mutation | MCF3 Gene Mutation | ROS Gene Mutation | ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene Mutation | ROS1 Mutation | c-ros-1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983360","MYD88 wt Allele","C90095","Human MYD88 wild-type allele is located in the vicinity of 3p22 and is approximately 5 kb in length. This allele, which encodes myeloid differentiation primary response protein MyD88, plays a role in both protein-protein interactions and the regulation of the expression of proinflammatory genes. Mutation of the gene is associated with recurrent pyogenic bacterial infections.","MYD88 wt Allele | MYD88D | Myeloid Differentiation Primary Response 88 wt Allele | Myeloid Differentiation Primary Response Gene (88) | Myeloid Differentiation Primary Response Gene 88",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509281","MYD88 Gene Mutation","C128175","A change in the nucleotide sequence of the MYD88 gene.","MYD88 Gene Mutation | Myeloid Differentiation Primary Response 88 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2930913","Chromosome 13q deletion","C36497","A cytogenetic abnormality that refers to the loss of all or part of the long arm of chromosome 13 (13q).","Loss of Chromosome 13q | 13q Deletion | del(13q)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0807034","MYC Gene Rearrangement","C132018","A molecular abnormality indicating rearrangement of the MYC gene.","MYC Gene Rearrangement | C-MYC Gene Rearrangement | MRTL Gene Rearrangement | MYCC Gene Rearrangement | bHLHe39 Gene Rearrangement | c-myc Gene Rearrangement | v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0805251","BCL6 Gene Rearrangement","C132020","A molecular abnormality indicating rearrangement of the BCL6 gene.","BCL6 Gene Rearrangement | B-Cell CLL/Lymphoma 6 Gene Rearrangement | BCL5 Gene Rearrangement | Bcl-6 Gene Rearrangement | LAZ3 Gene Rearrangement | ZBTB27 Gene Rearrangement | ZNF51 Gene Rearrangement | Zinc Finger Protein 51 Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514373","NY-ESO-1 Positive Tumor Cells Present","C131557","An indication that Cancer/Testis Antigen 1 expression has been detected in a sample.","NY-ESO-1 Positive Tumor Cells Present | CT6.1 Positive | CTAG1 Positive | CTAG1A Positive | Cancer/Testis Antigen 1 Positive | LAGE-2 Positive | LAGE2 Positive | NY-ESO-1 Positive | NY-ESO-1 Positive | NY-ESO-1 Positive Tumor Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333923","HOXC6 Gene","C24475","This gene plays a role in transcriptional repression, morphogenesis and differentiation.","HOXC6 Gene | HOXC6 | Homeobox C6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986382","Variant of Unknown Significance","C94187","An indication that there is not enough information to support a more definitive classification of the pathogenicity of a genetic variant.","Variant of Unknown Significance | Uncertain Significance | Unknown Significance | VUS | Variant of Undetermined Significance | unclassified variant | variant of uncertain significance | variant of unknown significance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162860","Inferior Mesenteric Artery","C32780","A blood vessel arising from the aorta that supplies blood to the descending and sigmoid colon as well as the rectum.","Inferior Mesenteric Artery | ",,,,,,,,,,,,,,,"4142926","Structure of inferior mesenteric artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042559","Vertebral Artery","C12819","The first branch of the subclavian artery that ascends both sides of the neck and merges at the middle line to from the basilar artery at the level of the pons.","Vertebral Artery | Structure of vertebral artery (body structure) | VA | VERTEBRAL ARTERY",,,,,,,,,,,,,,,"4310816","Structure of vertebral artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027533","Neck Neoplasm","C3260","A benign or malignant neoplasm that affects the neck region.","Neck Neoplasm | Neck Neoplasms (Including All Pharyngeal Related Neoplasms) | Neck Tumor | Neoplasm of Neck | Neoplasm of the Neck | Tumor of Neck | Tumor of the Neck",,,,,,,,,,,,,,,"4129244","Neoplasm of neck",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504697","Chimeric Antigen Receptor T-Cell Therapy","C126102","Treatment that uses T-cells that have been engineered to contain a chimeric antigen receptor (CAR) that specifically targets a particular antigen.","Chimeric Antigen Receptor T-Cell Therapy | CAR T Infusion | CAR T Therapy | CAR T-cell Therapy | CAR T-cell therapy | Chimeric Antigen Receptor T-cell Infusion | Chimeric Antigen Receptor T-cell Therapy | chimeric antigen receptor T-cell therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053854","WWTR1/CAMTA1 Fusion Gene","C121672","A fusion gene that results from a chromosomal translocation t(1;3)(p36;q23-25) which fuses the first 2, 3 or 4 exons of the WWTR1 gene to the upstream side of either exon 8 or exon 9 of the CAMTA1 gene. This fusion is associated with epithelioid hemangioendothelioma.","WWTR1/CAMTA1 Fusion Gene | TAZ-CAMTA1 Fusion Gene | TAZ/CAMTA1 Fusion Gene | WW Domain Containing Transcription Regulator 1-Calmodulin Binding Transcription Activator 1 Fusion Gene | WW Domain Containing Transcription Regulator 1/Calmodulin Binding Transcription Activator 1 Fusion Gene | WWTR1-CAMTA1 Fusion Gene | WWTR1::CAMTA1 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705526","TP53 wt Allele","C52271","Human TP53 wild-type allele is located in the vicinity of 17p13.1 and is approximately 19 kb in length. This allele, which encodes cellular tumor antigen p53 protein, plays a role in cell cycle regulation during the G0/G1transition. Alterations of the TP53 gene occur as both somatic and germline mutations in human malignancies in select cancer-prone families with Li-Fraumeni syndrome.","TP53 wt Allele | BCC7 | FLJ92943 | LFS1 | P53 | TP53 | TRP53 | Tumor Protein P53 (Li-Fraumeni Syndrome) wt Allele | Tumor Protein p53 Gene | p53 | p53 gene | p53 wild type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596972","Monitoring Device","C41278","A recording device or display that continuously keeps track of the function, condition, or operation of the system or organism and warns of an abnormal or potentially dangerous situation.","Monitoring Device | Monitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706378","Gauges/Meters","C50052","A device designed to give a visual indication of the condition of a system.","Gauge or Meter Device | Gauge or Meter | Gauge or Meter Device Component | Gauges/Meters",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515883","Active Funded Research Project","C39303","A research project that is in an active grant funding cycle.","Active Funded Research Project | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0599395","High School","C89278","A secondary school that usually includes grades 9 through 12.","High School | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055417","Avelumab","C116870","A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T-cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity. PD-L1, a transmembrane protein, is overexpressed on a variety of tumor cell types and is associated with poor prognosis.","Avelumab | AVELUMAB | Bavencio | Immunoglobulin G1-lambda1, Anti-(Homo sapiens CD274 (Programmed Death Ligand 1, PDL1, pd-l1, B7 Homolog 1, B7H1)), Homo sapiens Monoclonal Antibody | MSB 0010718C | MSB-0010718C | MSB0010718C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919268","Recombinant Interleukin-2","C587","Any recombinant analog of endogenous interleukin-2 (IL-2), a cytokine involved in intercellular communication related to cell differentiation, proliferation, inflammation, hematopoiesis, neuronal functions, and release of hormones. IL-2 binds to and activates specific receptors, triggering expression of specific genes, and may induce T cell-mediated tumor regression in some tumor types.","Recombinant Interleukin-2 | HUMAN INTERLEUKIN-2 | IL-2 | Interleukin II | Interleukin-2 | Lymphocyte Mitogenic Factor | Mitogenic Factor | Recombinant interleukin-2 | Ro-236019 | T-Cell Growth Factor | TCGF | TSF | Thymocyte Stimulating Factor | interleukin-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0751297","Leptomeningeal Neoplasm","C4958","A malignant neoplasm that has spread from its original site to the two innermost layers of tissue that cover the brain and spinal cord.","Leptomeningeal Neoplasm | LEPTOMENINGEAL DISEASE | Leptomeningeal Tumor | Neoplasm of Leptomeninges | Neoplasm of the Leptomeninges | Tumor of Leptomeninges | Tumor of the Leptomeninges",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037922","Vertebral Canal","C33869","The space formed by the series of vertebral foramina that courses the length of the vertebral column, and which houses the spinal cord and meninges.","Vertebral Canal | Spinal Canal | Spinal canal structure (body structure)",,,,,,,,,,,,,,,"4268012","Spinal canal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0223602","S5 Vertebra","C33502","The fifth of five sacral vertebrae; it articulates with the coccyx.","S5 Vertebra | Structure of fifth sacral vertebra (body structure)",,,,,,,,,,,,,,,"4061947","Structure of fifth sacral vertebra",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0223601","S4 Vertebra","C33501","The fourth of five sacral vertebrae.","S4 Vertebra | Structure of fourth sacral vertebra (body structure)",,,,,,,,,,,,,,,"4289148","Structure of fourth sacral vertebra",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0223600","S3 Vertebra","C33500","The third of five sacral vertebrae.","S3 Vertebra | Structure of third sacral vertebra (body structure)",,,,,,,,,,,,,,,"4173421","Structure of third sacral vertebra",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0223599","S2 Vertebra","C33499","The second of five sacral vertebrae.","S2 Vertebra | Structure of second sacral vertebra (body structure)",,,,,,,,,,,,,,,"4036687","Structure of second sacral vertebra",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0223598","S1 Vertebra","C33498","The first and largest of five sacral vertebrae, which ultimately fuse into one bone: the sacrum; superiorly, it articulates with the last lumbar vertebra.","S1 Vertebra | Structure of first sacral vertebra (body structure)",,,,,,,,,,,,,,,"4278680","Structure of first sacral vertebra",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0223552","L5 Vertebra","C32903","The fifth lumbar vertebra counting from the top down.","L5 Vertebra | L5 VERTEBRA | Structure of body of fifth lumbar vertebra (body structure)",,,,,,,,,,,,,,,"4175800","Bone structure of L5",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0223537","L4 Vertebra","C32902","The fourth lumbar vertebra counting from the top down.","L4 Vertebra | L4 VERTEBRA | Structure of body of fourth lumbar vertebra (body structure)",,,,,,,,,,,,,,,"4002202","Bone structure of L4",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0223522","L3 Vertebra","C32901","The third lumbar vertebra counting from the top down.","L3 Vertebra | L3 VERTEBRA | Structure of body of third lumbar vertebra (body structure)",,,,,,,,,,,,,,,"4264981","Bone structure of L3",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0223507","L2 Vertebra","C32900","The second lumbar vertebra counting from the top down.","L2 Vertebra | L2 VERTEBRA | Structure of body of second lumbar vertebra (body structure)",,,,,,,,,,,,,,,"4031042","Bone structure of L2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0223492","L1 Vertebra","C32899","The first lumbar vertebra counting from the top down.","L1 Vertebra | L1 VERTEBRA | Structure of body of first lumbar vertebra (body structure)",,,,,,,,,,,,,,,"4281666","Bone structure of L1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0459957","T12 Vertebra","C33723","The twelfth thoracic vertebra counting from the top down.","T12 Vertebra | Structure of body of twelfth thoracic vertebra (body structure) | T12 VERTEBRA",,,,,,,,,,,,,,,"4047482","Bone structure of T12",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0459956","T11 Vertebra","C33722","The eleventh thoracic vertebra counting from the top down.","T11 Vertebra | Structure of body of eleventh thoracic vertebra (body structure) | T11 VERTEBRA",,,,,,,,,,,,,,,"4045242","Bone structure of T11",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0459955","T10 Vertebra","C33721","The tenth thoracic vertebra counting from the top down.","T10 Vertebra | Structure of body of tenth thoracic vertebra (body structure) | T10 VERTEBRA",,,,,,,,,,,,,,,"4295586","Bone structure of T10",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0459954","T9 Vertebra","C33731","The ninth thoracic vertebra counting from the top down.","T9 Vertebra | Structure of body of ninth thoracic vertebra (body structure) | T9 VERTEBRA",,,,,,,,,,,,,,,"4220857","Bone structure of T9",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0459953","T8 Vertebra","C33730","The eighth thoracic vertebra counting from the top down.","T8 Vertebra | Structure of body of eighth thoracic vertebra (body structure) | T8 VERTEBRA",,,,,,,,,,,,,,,"4007625","Bone structure of T8",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0459947","T7 Vertebra","C33729","The seventh thoracic vertebra counting from the top down.","T7 Vertebra | Structure of body of seventh thoracic vertebra (body structure) | T7 VERTEBRA",,,,,,,,,,,,,,,"4268913","Bone structure of T7",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0459949","T6 Vertebra","C33728","The sixth thoracic vertebra counting from the top down.","T6 Vertebra | Structure of body of sixth thoracic vertebra (body structure) | T6 VERTEBRA",,,,,,,,,,,,,,,"4164603","Bone structure of T6",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0459950","T5 Vertebra","C33727","The fifth thoracic vertebra counting from the top down.","T5 Vertebra | Structure of body of fifth thoracic vertebra (body structure) | T5 VERTEBRA",,,,,,,,,,,,,,,"4209448","Bone structure of T5",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0459951","T4 Vertebra","C33726","The fourth thoracic vertebra counting from the top down.","T4 Vertebra | Structure of body of fourth thoracic vertebra (body structure) | T4 VERTEBRA",,,,,,,,,,,,,,,"4249589","Bone structure of T4",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0459952","T3 Vertebra","C33725","The third thoracic vertebra counting from the top down.","T3 Vertebra | Structure of body of third thoracic vertebra (body structure) | T3 VERTEBRA",,,,,,,,,,,,,,,"4038243","Bone structure of T3",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0459936","T2 Vertebra","C33724","The second thoracic vertebra counting from the top down.","T2 Vertebra | Structure of body of secon thoracic vertebra (body structure) | T2 VERTEBRA",,,,,,,,,,,,,,,"4206003","Bone structure of T2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0459933","T1 Vertebra","C33720","The first thoracic vertebra counting from the top down.","T1 Vertebra | Structure of body of first thoracic vertebra (body structure) | T1 VERTEBRA",,,,,,,,,,,,,,,"4277580","Bone structure of T1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0223176","C7 Vertebra","C32245","The seventh of the seven cervical vertebrae.","C7 Vertebra | C7 VERTEBRA | Structure of body of seventh cervical vertebra (body structure)",,,,,,,,,,,,,,,"4337691","Bone structure of C7",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0459944","C6 Vertebra","C32244","The sixth of the seven cervical vertebrae.","C6 Vertebra | C6 VERTEBRA | Structure of body of sixth cervical vertebra (body structure)",,,,,,,,,,,,,,,"4262722","Bone structure of C6",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0459943","C5 Vertebra","C32243","The fifth of the seven cervical vertebrae.","C5 Vertebra | C5 VERTEBRA | Structure of body of fifth cervical vertebra (body structure)",,,,,,,,,,,,,,,"4283894","Bone structure of C5",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0459941","C4 Vertebra","C32242","The fourth of the seven cervical vertebrae.","C4 Vertebra | C4 VERTEBRA | Structure of body of fourth cervical vertebra (body structure)",,,,,,,,,,,,,,,"4183279","Bone structure of C4",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0459939","C3 Vertebra","C32241","The third of the seven cervical vertebrae.","C3 Vertebra | C3 VERTEBRA | Structure of body of third cervical vertebra (body structure)",,,,,,,,,,,,,,,"4014109","Bone structure of C3",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004457","C2 Vertebra","C32240","The second of the seven cervical vertebrae.","C2 Vertebra | Axis of the Vertebra | Bone structure of axis (body structure) | C2 VERTEBRA",,,,,,,,,,,,,,,"4219433","Bone structure of axis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004170","C1 Vertebra","C32239","The first of the seven cervical vertebrae.","C1 Vertebra | Atlas of the Vertebra | Bone structure of atlas (body structure) | C1 VERTEBRA",,,,,,,,,,,,,,,"4033244","Bone structure of atlas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898777","Important","C115916","Of great significance, value, or consequence.","Important | Importance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4048548","Anti-Mullerian Hormone Measurement","C120625","The determination of the anti-Mullerian hormone present in a sample.","Anti-Mullerian Hormone Measurement | AMH | AMH Measurement | Anti-Mullerian Hormone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523868","Consortium for Molecular and Cellular Characterization of Screen-Detected Lesions","C133750","A consortium consisting of independent, multi-disciplinary teams that undertake comprehensive molecular and cellular characterizations of tumor tissue, cell, and microenvironment components to distinguish screen-detected early lesions from interval and symptom-detected cancers.","Consortium for Molecular and Cellular Characterization of Screen-Detected Lesions | MCL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521715","Funded Institution","C133786","The institution where the funded principal investigator is on staff.","Funded Institution | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521706","Anti-CD20 Monoclonal Antibody-FITC","C133777","An immunoconjugate composed of a monoclonal antibody directed against the human antigen CD20 that is conjugated to the fluorescein derivative and fluorochrome fluorescein isothiocyanate (FITC), with potential use for imaging and detection of CD20-expressing cells. Upon application of anti-CD20-FITC to a cell preparation, anti-CD20-FITC targets and binds to CD20-expressing cells. Then, CD20-expressing cells in the sample can be imaged using fluorescence-based imaging techniques or separated from other cells present in the preparation using fluorescence-activated cell sorting (FACS). CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B-cells during most stages of B-cell development; it is involved in the regulation of B-cell differentiation and is overexpressed on certain types of cancer cells.","Anti-CD20 Monoclonal Antibody-FITC | Anti-CD20-FITC | Anti-CD20-Fluorescein Isothiocyanate | CD20-FITC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230245","Hepatoduodenal Ligament","C133752","The portion of the lesser omentum between the liver and the duodenum, containing the hepatic artery, the common bile duct, the portal vein, lymphatic vessels, and the hepatic plexus of nerves.","Hepatoduodenal Ligament | ",,,,,,,,,,,,,,,"4065872","Hepatoduodenal ligament structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521686","Mesenteric Root","C133753","The origin of the mesentery arising from the parietal peritoneum.","Mesenteric Root | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0733948","Renal Pedicle","C133754","The recessed central fissure of the kidney, though which pass the ureter and vessels of the kidney.","Renal Pedicle | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1283683","Sciatic Notch","C133755","Either of the two notches on the dorsal border of each side of the pelvis that when closed off by the sacrospinous and sacrotuberous ligaments form the corresponding sciatic foramina.","Sciatic Notch | ",,,,,,,,,,,,,,,"4236673","Sciatic notch",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0223085","Neural Foramen","C133756","Any of the openings between the vertebrae, through which pass the spinal nerve roots.","Neural Foramen | Intervetebral Foramen",,,,,,,,,,,,,,,"4014430","Structure of intervertebral foramen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0729890","Iliac Vessel","C133757","Any of the branches of the vessels arising from the common iliac artery or vein, located in the pelvis.","Iliac Vessel | ",,,,,,,,,,,,,,,"4193451","Iliac vessel",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521688","Free Radioiodine","C133759","Radioactive iodine that is not attached to another molecule.","Free Radioiodine | Free Radioactive Iodine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1182550","Superior Mesenteric Artery Branch","C33686","Any artery arising from the superior mesenteric artery.","Superior Mesenteric Artery Branch | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1299265","Brachiocephalic Vein","C32816","Either of two veins including the right and left innominate vein.","Brachiocephalic Vein | Innominate Vein | Structure of brachiocephalic vein (body structure)",,,,,,,,,,,,,,,"4229590","Structure of brachiocephalic vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006094","Innominate Artery","C32814","An artery arising from the aortic arch that divides into the right common carotid and right subclavian arteries.","Innominate Artery | ARTERY, BRACHIOCEPHALIC | BRACHIOCEPHALIC ARTERY | Brachiocephalic Artery",,,,,,,,,,,,,,,"4131757","Structure of brachiocephalic artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035065","Renal Artery","C12778","Either of two arteries (right or left) that arise from the aorta to supply the kidneys.","Renal Artery | ARTERY, RENAL | RENAL ARTERY | renal artery",,,,,,,,,,,,,,,"4154880","Structure of renal artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020887","Iliac Artery","C12733","A branch of the abdominal aorta that supplies blood to the lower trunk and the legs.","Iliac Artery | ARTERY, ILIAC",,,,,,,,,,,,,,,"4012567","Structure of iliac artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038969","Suture Device","C50365","A natural (e.g., catgut, silk, or linen) or synthetic, or other (e.g., thin metal wire) monofilament or multifilament material used surgically to close a surgical or accidental wound and to secure apposition of the edges and join tissues.","Suture Device | Suture | Suture Device Component | Suture Material | Suture Thread | Sutured",,,,,,,,,,,,,,,"4097825|4234965","Surgical suture|Suture",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3898897","Helpful","C115927","Serving a useful function or giving help.","Helpful | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706090","Brush Device","C49851","Device consisting of hairs or bristles set into a handle or holder, especially one that conducts current between the rotating and stationary parts of a generator or motor.","Brush Device | Brush | Brush Device Component",,,,,,,,,,,,,,,"4321267","Brush",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1831870","Vintafolide","C62525","A water-soluble, folate-receptor-targeted conjugate of folate and the vinca alkaloid desacetylvinblastine monohydrazide (DAVLBH) with potential antineoplastic activity. The folate moiety of vintafolide binds to folic acid receptors on the tumor cell surface and the agent is internalized via folate receptor-mediated endocytosis, delivering the tubulin-binding DAVLBH moiety directly into the tumor cell; DAVLBH binding to tubulin results in the disruption of microtubule assembly-disassembly dynamics, cell cycle arrest, and tumor cell apoptosis. Folic acid receptors are frequently upregulated on the surfaces of many tumor cell types. DAVLBH is a derivative of the natural product vinblastine.","Vintafolide | EC145 | Folate-Vinca Alkaloid Conjugate EC145 | VINTAFOLIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3490719","3-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene","C84866","An orally bioavailable small-molecule androgen receptor modulator and CYP17 lyase inhibitor with potential antiandrogen activity. Galeterone exhibits three distinct mechanisms of action: 1) as an androgen receptor antagonist, 2) as a CYP17 lyase inhibitor and 3) by decreasing overall androgen receptor levels in prostate cancer tumors, all of which may result in a decrease in androgen-dependent growth signaling. Localized to the endoplasmic reticulum (ER), the cytochrome P450 enzyme CYP17 (P450C17 or CYP17A1) exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens.","Galeterone | Androsta-5,16-dien-3-ol, 17-(1h-benzimidazol-1-yl)-, (3beta)- | GALETERONE | Specific Androgen Receptor Modulator/CYP17 Lyase Inhibitor TOK-001 | TOK 001 | TOK-001 | TOK001 | VN/124 | VN/124-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985183","Apalutamide","C92574","A small molecule and androgen receptor (AR) antagonist with potential antineoplastic activity. Apalutamide binds to AR in target tissues thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes. This ultimately inhibits the expression of genes that regulate prostate cancer cell proliferation and may lead to an inhibition of cell growth in AR-expressing tumor cells.","Apalutamide | 4-(7-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro(3.4)octan-5-yl)-2-fluoro-N-methylbenzamide | APALUTAMIDE | ARN 509 | ARN-509 | ARN509 | Erleada | JNJ 56021927 | JNJ-56021927 | apalutamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897504","Standard Uptake Value Ratio","C116141","An effectively dimensionless measure of regional tracer uptake calculated as the ratio between the uptake or binding of a radiopharmaceutical agent in an anatomical region of interest versus the uptake or binding of a radiopharmaceutical agent in a reference anatomical region.","Standard Uptake Value Ratio | SUVR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897849","Procedure Directionality","C117527","A qualifier for the direction on the body the procedure is performed.","Procedure Directionality | PRDIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1532579","Milliliter per Kilogram per Day","C73758","A dose calculation unit expressed in milliliter(s) per kilogram per period of time equal to twenty-four hours.","Milliliter per Kilogram per Day | (mL/d)/kg | (mL/day)/kg | (ml/d)/kg | Milliliter per Kilogram per 24 Hours | Milliliter/kilogram/day | mL/kg/d | mL/kg/day | ml/kg/d",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439446","Milliliter per 24 Hours","C67410","A metric unit of volumetric flow rate defined as the rate at which one milliliter of matter crosses a given surface during the period of time equal to 24 hours.","Milliliter per 24 Hours | Milliliter per Day | Milliliter/24 Hours | Milliliter/day | mL/24.h | mL/24h | mL/d | mL/day | milliliter per 24 hours | ml/d",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521739","Polyclonality","C133817","Having, or deriving from, two or more progenitors.","Polyclonality | Polyclonal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505125","Not Available","C126101","The desired information is not available.","Not Available | Unavailable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3852521","MDM2 inhibitor AMG 232","C116624","An orally available inhibitor of MDM2 (murine double minute 2), with potential antineoplastic activity. Upon oral administration,navtemadlin binds to the MDM2 protein and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the transcriptional activity of p53 is restored. This leads to p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein and a negative regulator of the p53 pathway, is overexpressed in cancer cells; it plays a key role in cancer cell proliferation and survival.","Navtemadlin | (3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-((1S)-2-methyl-1-(((1-methylethyl)sulfonyl)methyl)propyl)-2-oxo-3-piperidineacetic Acid | AMG 232 | AMG-232 | KRT 232 | KRT-232 | KRT232 | MDM2 Inhibitor AMG-232 | MDM2 Inhibitor KRT-232 | MDM2 Inhibitor KRT-232 | NAVTEMADLIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1451803","trifluridine/tipiracil hydrochloride combination agent TAS-102","C102554","An orally bioavailable combination agent composed of the cytotoxic pyrimidine analog trifluridine (5-trifluoro-2'-deoxythymidine or TFT) and a thymidine phosphorylase inhibitor (TPI) tipiracil hydrochloride, in a molar ratio of 1.0:0.5 (TFT:TPI), with potential antineoplastic activity. After oral administration of TAS-102, TFT is phosphorylated to the active monophosphate form TF-TMP, which binds covalently to the active site of thymidylate synthase, thereby reducing the nucleotide pool levels required for DNA replication. Furthermore, the triphosphate form TF-TTP can be incorporated into DNA, which induces DNA fragmentation and leads to the inhibition of tumor growth. TPI exhibits a dual effect: 1) an anti-angiogenic effect mediated through the inhibition of thymidine phosphorylase, which plays important role in nucleotide metabolism and a variety of development processes, including angiogenesis, 2) increased bioavailability of the normally short-lived antimetabolite TFT by preventing its degradation into the inactive form trifluorothymine (TF-Thy). The synergistic effect of the components in TAS-10 may demonstrate antitumor activity in 5-FU-resistant cancer cells.","Trifluridine and Tipiracil Hydrochloride | FTD-TPI | Lonsurf | TAS 102 | TAS-102 | TAS102 | Thymidine, Alpha,alpha,alpha-trifluoro-, Mixt. with 5-Chloro-6-((2-imino-1-pyrrolidinyl)methyl)-2,4(1H,3H)-pyrimidinedione Monohydrochloride | Tipiracil Hydrochloride Mixture with Trifluridine | Trifluridine and Tipiracil | Trifluridine and tipiracil | Trifluridine/Tipiracil | Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102 | Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4057931","Irinotecan Sucrosofate","C82676","A liposomal dispersion formulated with the semisynthetic camptothecin analogue irinotecan, provided as the hydrochloride trihydrate form, which is encapsulated and entrapped within liposomes in a gelated or precipitated state as the irinotecan sucrose octasulfate (sucrosulfate) salt form, with potential antineoplastic activity. Upon administration of the liposomes containing irinotecan sucrosulfate, irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme. During the S-phase, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing lethal double-strand DNA breaks when complexes are encountered by the DNA replication machinery. Liposome encapsulation of this agent promotes efficient drug delivery into the cytosol from the endosome compartment of the cell, extends the circulation of irinotecan, and prolongs the duration of active therapy at the site of tumor to inhibit tumor growth.","Irinotecan Sucrosofate | IRINOTECAN SUCROSOFATE | Irinotecan Liposome | Irinotecan Sucrosofate Liposome | Irinotecan Sucrosofate-containing Pegylated Liposomal Formulation | Irinotecan liposome | Liposomal Irinotecan | MM 398 | MM-398 | MM398 | Nanoliposomal Irinotecan | Nanoliposomal Irinotecan as Sucrosofate | Nanoparticle Liposome Formulation of Irinotecan | Onivyde | PEP 02 | PEP-02 | PEP02 | inotecan Hydrochloride as Sucrosulfate Salt Form Liposomal Formulation | nal-IRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280611","Cisplatin/Methotrexate","C10285","No Value Exists","Cisplatin/Methotrexate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522035","Mantle Cell Lymphoma International Prognostic Index Combined Biologic Index","C134315","A scoring system designed to classify a patient's risk of mantle cell lymphoma progression or relapse and overall survival following therapy. It uses the criteria of patient's age, ECOG performance status, serum LDH activity, WBC count and Ki-67 index to classify patients into low risk, medium risk or high risk groups. The MIPIb score is calculated using the formula: [0.03535 x age (years)] + 0.6978 (if ECOG > 1) + [1.367 x log10(LDH/ULN)] + [0.9393 x log10(WBC count)] + [0.02142 x Ki-67 (%)]. A score < 5.7 indicates low risk disease, 5.7 - 6.5 indicates intermediate risk, and 6.5 or greater high risk.","Mantle Cell Lymphoma International Prognostic Index Combined Biologic Index | MIPI-c | MIPI-c Score | MIPIb | MIPIb Score | Mantle Cell Lymphoma International Prognostic Index-Combined",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522038","NTRK1 Gene Alteration Positive","C134452","A finding indicating that mutation, overexpression or rearrangement of the NTRK1 gene has been detected in a sample.","NTRK1 Gene Alteration Positive | MTC Gene Alteration Positive | Neurotrophic Tyrosine Kinase Receptor 1 Gene Alteration Positive | Neurotrophic Tyrosine Kinase, Receptor, Type 1 Gene Alteration Positive | TRK Gene Alteration Positive | TRK1 Gene Alteration Positive | TRKA Gene Alteration Positive | Trk-A Gene Alteration Positive | p140-TrkA Gene Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522039","NTRK2 Gene Alteration Positive","C134453","A finding indicating that mutation, overexpression or rearrangement of the NTRK2 gene has been detected in a sample.","NTRK2 Gene Alteration Positive | Neurotrophic Tyrosine Kinase Receptor 2 Gene Alteration Positive | Neurotrophic Tyrosine Kinase Receptor Type 2 Gene Alteration Positive | TRKB Gene Alteration Positive | TRKB Tyrosine Kinase Gene Alteration Positive | Tropomyosin-Related Kinase B Gene Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522040","ROS1 Gene Alteration Positive","C134454","A finding indicating that mutation, overexpression or rearrangement of the ROS1 gene has been detected in a sample.","ROS1 Gene Alteration Positive | Genetic Defect in ROS1 | MCF3 Gene Alteration Positive | ROS Gene Alteration Positive | ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene Alteration Positive | ROS1 Gene Defect | ROS1 Gene Defect Detected | ROS1 Gene Defect Positive | c-ros-1 Gene Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522042","NTRK3 Gene Alteration Positive","C134456","A finding indicating that mutation, overexpression or rearrangement of the NTRK3 gene has been detected in a sample.","NTRK3 Gene Alteration Positive | Neurotrophic Tyrosine Kinase Receptor 3 Gene Alteration Positive | Neurotrophic Tyrosine Kinase Receptor Type 3 Gene Alteration Positive | Neurotrophic Tyrosine Kinase, Receptor, Type 3 Gene Alteration Positive | TRKC Gene Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522044","ALK Gene Alteration Positive","C134458","A finding indicating that mutation, overexpression or rearrangement of the ALK gene has been detected in a sample.","ALK Gene Alteration Positive | ALK Gene Defect | ALK Gene Defect Detected | ALK Gene Defect Positive | Anaplastic Lymphoma Kinase Gene Alteration Positive | Anaplastic Lymphoma Receptor Tyrosine Kinase Gene Alteration Positive | CD246 Gene Alteration Positive | Genetic Defect in ALK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522049","BCL2 Positive","C134463","An indication that BCL2 expression has been detected in a sample.","BCL2 Positive | Apoptosis Regulator Bcl-2 Positive | B-Cell CLL/Lymphoma 2 Positive | B-Cell Leukemia/Lymphoma 2 Positive | BCL-2 Positive | BCL2 Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522051","EGFR Exon 19 Insertion Mutation","C134465","A molecular genetic abnormality indicating the presence of an in-frame insertion mutation occurring within exon 19 of the EGFR gene.","EGFR Exon 19 Insertion Mutation | EGFR Exon 19 Insertion | ERBB Exon 19 Insertion Mutation | ERBB1 Exon 19 Insertion Mutation | Epidermal Growth Factor Receptor Gene Exon 19 Insertion Mutation | HER1 Exon 19 Insertion Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522054","BRAF V600 Wild Type","C134468","A genetic finding indicating that codon 600 of the BRAF gene encodes the wild type amino acid, valine.","BRAF V600 Wild Type | B-RAF V600 Wild Type | B-RAF1 V600 Wild Type | BRAF V600 Mutation Negative | BRAF V600 Wildtype | BRAF V600 wt | BRAF V600V | BRAF p.V600V | Serine/Threonine-Protein Kinase B-raf V600 Wild Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522059","APC Gene Mutation","C134473","A change in the nucleotide sequence of the APC gene.","APC Gene Mutation | APC, WNT Signaling Pathway Regulator Gene Mutation | Adenomatosis Polyposis Gene Mutation | BTPS2 Gene Mutation | FAP Gene Mutation | FPC Gene Mutation | PPP1R46 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513480","Monosomy 17","C36509","A chromosomal abnormality consisting of the absence of one of the copies of chromosome 17.","Monosomy 17 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522071","NECTIN4 Positive","C134486","An indication that NECTIN4 expression has been detected in a sample.","NECTIN4 Positive | Ig Superfamily Receptor LNIR Positive | Nectin 2 Positive | Nectin 4 Positive | Nectin Cell Adhesion Molecule 4 Positive | Nectin-4 Positive | PVRL4 Positive | Poliovirus Receptor-Like 4 Positive | Poliovirus Receptor-Related 4 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522072","ALK Gene Rearrangement Negative","C134487","A genetic finding indicating that rearrangement of the ALK gene has not been detected in a sample.","ALK Gene Rearrangement Negative | ALK Rearrangement Negative | Anaplastic Lymphoma Kinase Gene Rearrangement Negative | Anaplastic Lymphoma Receptor Tyrosine Kinase Gene Rearrangement Negative | CD246 Gene Rearrangement Negative | No rearrangement detected",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522073","ALK Gene Translocation Negative","C134488","A genetic finding indicating that translocations involving the ALK gene have not been detected in a sample.","ALK Gene Translocation Negative | ALK Translocation Negative | Anaplastic Lymphoma Kinase Gene Translocation Negative | Anaplastic Lymphoma Receptor Tyrosine Kinase Gene Translocation Negative | CD246 Gene Translocation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522075","Agammaglobulinaemia Tyrosine Kinase Cys481Xxx","C134490","A change in the cysteine at position 481 of the tyrosine-protein kinase BTK protein to another amino acid.","BTK NP_000052.1:p.C481X | ATK C481X | ATK Cys481Xxx | Agammaglobulinaemia Tyrosine Kinase C481X | Agammaglobulinaemia Tyrosine Kinase Cys481Xxx | B-Cell Progenitor Kinase C481X | B-Cell Progenitor Kinase Cys481Xxx | BPK C481X | BPK Cys481Xxx | BTK C481X | BTK C481X Mutation | BTK Cys481Xxx | BTK NP_000052.1:p.Cys481Xxx | BTK NP_000052.1:pC481X | BTK p.C481X | BTK p.Cys481Xxx | Bruton Tyrosine Kinase C481X | Bruton Tyrosine Kinase Cys481Xxx | Cysteine-481 BTK Mutation | NP_000052.1:p.C481X | NP_000052.1:p.Cys481Xxx | Tyrosine-Protein Kinase BTK C481X | Tyrosine-Protein Kinase BTK Cys481Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522076","MLANA Positive","C134491","An indication that MLANA expression has been detected in a sample.","MLANA Positive | Antigen LB39-AA Positive | Antigen SK29-AA Positive | MART 1 Positive | MART-1 Antigen Positive | MART-1 Positive | MART1 Positive | Melan A Positive | Melan-A Positive | Melanoma Antigen Recognized by T Cells 1 Positive | Melanoma Antigen Recognized by T-Cells 1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522077","GPC3 Positive","C134492","An indication that GPC3 expression has been detected in a sample.","GPC3 Positive | Glypican 3 Positive | Glypican Proteoglycan 3 Positive | Glypican-3 Positive | MXR7 Positive | OCI-5 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522078","Activating EGFR Gene Mutation Negative","C134494","A genetic finding indicating that mutations in the EGFR gene which encode constitutively active forms of the epidermal growth factor receptor protein are not present in a sample.","Activating EGFR Gene Mutation Negative | Activating EGFR Mutation Negative | Activating ERBB Mutation Negative | Activating ERBB1 Mutation Negative | Activating HER1 Mutation Negative | Activating c-erbB1 Mutation Negative | EGFR Activating Mutation Negative | Epidermal Growth Factor Receptor Activating Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522079","KDR Positive","C134495","An indication that KDR expression has been detected in a sample.","KDR Positive | CD309 Antigen Positive | CD309 Positive | FLK-1 Positive | Fetal Liver Kinase 1 Positive | Kinase Insert Domain Receptor Positive | Protein-Tyrosine Kinase Receptor Flk-1 Positive | VEGFR-2 Positive | VEGFR2 Positive | Vascular Endothelial Growth Factor Receptor 2 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522080","IL13RA2 Positive","C134496","An indication that IL13RA2 expression has been detected in a sample.","IL13RA2 Positive | CD213a2 Antigen Positive | CT19 Positive | Cancer/Testis Antigen 19 Positive | IL-13 Receptor Subunit Alpha-2 Positive | IL-13R Subunit Alpha-2 Positive | IL-13R-Alpha-2 Positive | IL-13RA2 Positive | IL13BP Positive | IL13Ralpha2 Positive | Interleukin 13 Binding Protein Positive | Interleukin 13 Receptor Alpha 2 Chain Positive | Interleukin 13 Receptor Subunit Alpha 2 Positive | Interleukin 13 Receptor, Alpha 2 Positive | Interleukin-13 Receptor Subunit Alpha-2 Positive | Interleukin-13-Binding Protein Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522081","FGFR2 Positive","C134497","An indication that FGFR2 expression has been detected in a sample.","FGFR2 Positive | BEK Positive | CD332 Antigen Positive | CD332 Positive | ECT1 Positive | FGFR-2 Positive | Fibroblast Growth Factor Receptor 2 Positive | K-SAM Positive | KGFR Positive | Keratinocyte Growth Factor Receptor Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522082","Activating RAF Mutation","C134499","A mutation in a RAF family gene that encodes a constitutively active serine/threonine-protein kinase and results in aberrant activation of its downstream pathways.","Activating RAF Mutation | Activating RAF Family Gene Mutation | Activating Rapidly Accelerated Fibrosarcoma Family Gene Mutation | Activating Rapidly Accelerated Fibrosarcoma Family Kinase Gene Mutation | RAF Family Activating Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522083","PTPRC Positive","C134500","An indication that PTPRC expression has been detected in a sample.","PTPRC Positive | B220 Positive | CD45 Antigen Positive | CD45 Positive | CD45R Positive | GP180 Positive | L-CA Positive | LCA Positive | LY5 Positive | Leukocyte Common Antigen Positive | Protein Tyrosine Phosphatase, Receptor Type C Positive | Protein Tyrosine Phosphatase, Receptor Type, C Positive | Receptor-Type Tyrosine-Protein Phosphatase C Positive | T200 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710329","NTRK1 Gene Rearrangement","C46006","A molecular abnormality indicating rearrangement of the NTRK1 gene.","NTRK1 Gene Rearrangement | MTC Gene Rearrangement | NTRK1 Rearrangement | Neurotrophic Receptor Tyrosine Kinase 1 Gene Rearrangement | Neurotrophic Tyrosine Kinase, Receptor, Type 1 Gene Rearrangement | TRK Gene Rearrangement | TRK Rearrangement | TRK1 Gene Rearrangement | TRKA Gene Rearrangement | Trk-A Gene Rearrangement | p140-TrkA Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522084","EGFR Positive","C134501","An indication that EGFR expression has been detected in a sample.","EGFR Positive | ERBB Positive | ERBB1 Positive | Epidermal Growth Factor Receptor Positive | HER1 Positive | c-erbB1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522085","NOXA BH3 Priming","C134502","An assay that indirectly quantitates the expression of the antiapoptotic protein, induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1; EAT), in a biological sample. Mitochondria or whole cells are isolated from a patient sample and stained with JC-1. In healthy cells with high mitochondrial membrane potential, JC-1 forms aggregates that emit red fluorescence, while in apoptotic cells with low mitochondrial membrane potential, JC-1 remains a monomer, which emits green fluorescence. The isolate is then exposed to a peptide comprised of the BH3 domain of phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1; NOXA), which specifically binds to and inhibits the antiapoptotic activity of MCL1. Then the mitochondrial outer membrane permeability (MOMP) is assessed by determining the ratio of red and green JC-1 fluorescence.","NOXA BH3 Priming | PMAIP1 BH3 Priming",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522086","Deleterious RAD51B Gene Mutation","C134504","A change in the nucleotide sequence of the RAD51B gene that is associated with increased risk of disease.","Deleterious RAD51B Gene Mutation | Deleterious R51H2 Gene Mutation | Deleterious RAD51 Paralog B Gene Mutation | Deleterious RAD51L1 Gene Mutation | Deleterious REC2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522090","Deleterious PPP2R2A Gene Mutation","C134509","A change in the nucleotide sequence of the PPP2R2A gene that is associated with increased risk of disease.","Deleterious PPP2R2A Gene Mutation | Deleterious B55-Alpha Gene Mutation | Deleterious B55A Gene Mutation | Deleterious B55ALPHA Gene Mutation | Deleterious PR52A Gene Mutation | Deleterious PR55-Alpha Gene Mutation | Deleterious PR55A Gene Mutation | Deleterious PR55alpha Gene Mutation | Deleterious Protein Phosphatase 2 Regulatory Subunit Balpha Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522091","Deleterious FANCL Gene Mutation","C134510","A change in the nucleotide sequence of the FANCL gene that is associated with increased risk of disease.","Deleterious FANCL Gene Mutation | Deleterious FAAP43 Gene Mutation | Deleterious Fanconi Anemia Complementation Group L Gene Mutation | Deleterious Fanconi Anemia, Complementation Group L Gene Mutation | Deleterious PHD Finger Protein 9 Gene Mutation | Deleterious PHF9 Gene Mutation | Deleterious POG Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522092","Deleterious CHEK2 Gene Mutation","C134511","A change in the nucleotide sequence of the CHEK2 gene that is associated with increased risk of disease.","Deleterious CHEK2 Gene Mutation | Deleterious CDS1 Gene Mutation | Deleterious CHK2 Checkpoint Homolog (S. pombe) Gene Mutation | Deleterious CHK2 Gene Mutation | Deleterious Checkpoint Kinase 2 Gene Mutation | Deleterious LFS2 Gene Mutation | Deleterious RAD53 Gene Mutation | Deleterious hCds1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522093","Deleterious CHEK1 Gene Mutation","C134512","A change in the nucleotide sequence of the CHEK1 gene that is associated with increased risk of disease.","Deleterious CHEK1 Gene Mutation | Deleterious CHK1 Checkpoint Homolog (S. pombe) Gene Mutation | Deleterious CHK1 Gene Mutation | Deleterious Checkpoint Kinase 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522094","Deleterious ATM Gene Mutation","C134513","A change in the nucleotide sequence of the ATM gene that is associated with increased risk of disease.","Deleterious ATM Gene Mutation | Deleterious A-T Mutated Gene Mutation | Deleterious AT Mutated Gene Mutation | Deleterious ATM Serine/Threonine Kinase Gene Mutation | Deleterious Ataxia Telangiectasia Mutated Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522176","Human Cancer Models Initiative","C134624","A collaboration between the National Cancer Institute, Cancer Research UK, the Wellcome Trust Sanger Institute, and the foundation Hubrecht Organoid Technology to generate new models of cancer that more accurately represent human tumors than existing cell line models.","Human Cancer Models Initiative | HCMI | Human Cancer Models Initiative (HCMI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522174","Cisplatin-Methotrexate","C134622","A regimen consisting of cisplatin and methotrexate that can be used for the treatment of bladder cancer.","Cisplatin/Methotrexate Regimen | Cisplatin and Methotrexate | Cisplatin-Methotrexate | Cisplatin-Methotrexate Regimen | Cisplatin-Methotrexate Regimen | Cisplatin/Methotrexate | PM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522175","Abraxane-Gemictabine Regimen","C134623","A regimen consisting of gemcitabine and nab-paclitaxel, an albumin-bound formulation of paclitaxel, that can be used for the treatment of ampullary, small bowel and pancreatic adenocarcinomas and biliary tract cancers. A modified version may be used for the treatment of pancreatic adenocarcinoma.","GNP Regimen | Abraxane-Gemictabine Regimen | Abraxane/Gemcitabine Regimen | GEMCNPAC Regimen | GNP | Gemcitabine and nab-Paclitaxel | Gemcitabine-Albumin-bound Paclitaxel Regimen | Gemcitabine-Nab-paclitaxel Regimen | Gemcitabine-Nab-paclitaxel Regimen | Gemcitabine/Nab-paclitaxel | Nab-paclitaxel/Gemcitabine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201452","Circulating Immune Complex Measurement","C127611","The determination of the amount of circulating immune complexes present in a sample.","Circulating Immune Complex Measurement | CIC | Circulating Immune Complexes",,,,,,,,,,,,,,,"4097911","Circulating immune complexes assay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019143","Heparan Sulfate","C540","Heparitin Sulfate.  A glycosaminoglycan, structurally similar to heparin but with more N-acetyl groups and fewer O- and N-sulfate groups. Occurs in the liver, aorta, and lung.  Accumulates in several mucopolysaccharidoses.","Heparan Sulfate | HEPARAN SULFATE (PORCINE 5500 MW)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514287","Folate Receptor Alpha Positive","C131327","An indication that folate receptor alpha has been detected in a sample.","Folate Receptor Alpha Positive | FBP Positive | FOLR Positive | FOLR1 Positive | FR-Alpha Positive | Folate Receptor 1 Positive | Folate-Binding Protein, Adult Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522342","Atara Biotherapeutics","C134822","A privately-held drug development company that is developing cancer treatments based on allogeneic cytotoxic T lymphocyte immunotherapy.","Atara Biotherapeutics | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522343","Bellicum Pharmaceuticals","C134823","A biopharmaceutical company focused on developing cellular immunotherapies for hematological cancers, solid tumors, and orphan inherited blood diseases.","Bellicum Pharmaceuticals | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522344","Mesoblast Limited","C134824","An Australian biotechnology company that is developing a proprietary technology platform based on allogeneic mesenchymal lineage adult stem cells (MLCs) to target inflammatory ailments, cardiovascular disease, and back pain.","Mesoblast Limited | Mesoblast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523846","Geriatric Screening Tool","C134825","A screening tool for geriatric oncology patients consisting of 7 questions from the Mini Nutritional Assessment and one question relative to the age of patient.","Geriatric Screening Tool | G-8 | G8 | Geriatric Screening tool (G-8)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522346","Cancer and Aging Research Group Chemo Toxicity Calculator","C134827","A clinical assessment tool designed to evaluate the risk for chemotherapy toxicity in geriatric cancer patients. The tool captures sociodemographics, tumor and treatment variables, laboratory test results, and geriatric assessment domains.","Cancer and Aging Research Group Chemo Toxicity Calculator | CARG Score | Cancer and Aging Research Group (CARG) Score | Cancer and Aging Research Group Chemo Toxicity Calculator (CARG) | Cancer and Aging Research Group Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050094","Clinical Complete Response","C123574","The disappearance of all signs of cancer based on physical exam, such as palpation.","Clinical Complete Response | Clinical Complete Remission | cCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3858030","Netupitant/Palonosetron Hydrochloride","C121569","An orally available combination formulation containing netupitant, a selective neurokinin 1 (NK1) receptor antagonist, and the hydrochloride salt form of palonosetron, a selective serotonin (5-hydroxytryptamine; 5-HT) receptor subtype 3 (5-HT3) antagonist, with antiemetic activity. Upon oral administration, palonosetron competitively blocks the action of 5-HT at 5-HT3 receptors located on vagal afferent nerves in the chemoreceptor trigger zone (CTZ). This inhibits acute emesis associated with 5-HT secretion and subsequent 5-HT3 activation. Netupitant competitively binds to and blocks the activity of the human NK1 receptors in the central nervous system (CNS), thereby inhibiting NK1 receptor binding of the endogenous tachykinin neuropeptide substance P (SP). This prevents delayed emesis, which is associated with SP secretion. Altogether, this results in the prevention of chemotherapy-induced nausea and vomiting (CINV).","Netupitant/Palonosetron Hydrochloride | Akynzeo | Netupitant and Palonosetron | Netupitant and palonosetron | Netupitant/Palonosetron",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522419","Have Aches in Joints and/or Muscles","C134903","A question about whether an individual has aches in joints and/or muscles.","Have Aches in Joints and/or Muscles | I ache or hurt in my joints and/or muscles | Joints and muscle aches",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522420","Have a Lot of Pain","C134904","A question about whether an individual has a lot of pain.","Have a Lot of Pain | I hurt a lot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522421","Become Nauseated During Medical Treatments","C134905","A question about whether an individual becomes nauseated during medical treatments.","Become Nauseated During Medical Treatments | I become sick to my stomach when I have medical treatments",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522422","Food Does Not Taste Good","C134906","A question about whether food does not taste very good to an individual.","Food Does Not Taste Good | Food does not taste very good to me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522423","Become Nauseated While Thinking About Medical Treatments","C134907","A question about whether an individual becomes nauseated while thinking about medical treatments.","Become Nauseated While Thinking About Medical Treatments | I become sick to my stomach when I think about medical treatments",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522424","Feel Too Nauseated to Eat","C134908","A question about whether an individual feels too nauseous to eat.","Feel Too Nauseated to Eat | I feel too sick to my stomach to eat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522426","Some Foods and Smells Cause Nausea","C134911","A question about whether some foods and smells make an individual nauseous.","Some Foods and Smells Cause Nausea | Some foods and smells make me sick to my stomach",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522427","Needle Sticks Cause Pain","C134912","A question about whether needle sticks cause pain for an individual.","Needle Sticks Cause Pain | Needle sticks hurt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522428","Get Anxious About Having Blood Drawn","C134913","A question about whether an individual gets anxious about having blood drawn.","Get Anxious About Having Blood Drawn | I get scared when I have to have blood tests",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522431","Get Anxious About Having Needle Sticks","C134916","A question about whether an individual gets anxious about having needle sticks.","Get Anxious About Having Needle Sticks | I get scared about having needle sticks",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522433","Get Anxious When Waiting to See Doctor","C134918","A question about whether an individual gets anxious when waiting to see the doctor.","Get Anxious When Waiting to See Doctor | I get scared when I am waiting to see the doctor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522434","Get Anxious About Going to Doctor","C134919","A question about whether an individual gets anxious about going to the doctor.","Get Anxious About Going to Doctor | I get scared when I have to go to the doctor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522437","Get Anxious About Going to Hospital","C134922","A question about whether an individual gets anxious about going to the hospital.","Get Anxious About Going to Hospital | I get scared when I have to go to the hospital",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522438","Worry About Side Effects from Medical Treatments","C134923","A question about whether an individual worries about side effects from medical treatments.","Worry About Side Effects from Medical Treatments | I worry about side effects from medical treatments",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522439","Worry About Whether or not Medical Treatments are Working","C134924","A question about whether an individual worries about whether medical treatments are working.","Worry About Whether or not Medical Treatments are Working | I worry about whether or not my medical treatments are working",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522441","Worry That Cancer Will Reoccur or Relapse","C134926","A question about whether an individual worries that their cancer will reoccur or relapse.","Worry That Cancer Will Reoccur or Relapse | I worry that my cancer will come back or relapse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522444","Difficulty Figuring Out What To Do When Something is Bothersome","C134929","A question about whether an individual has difficulty figuring out what to do when something bothers them.","Difficulty Figuring Out What To Do When Something is Bothersome | It is hard for me to figure out what to do when something bothers me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522446","Difficulty Working with Numbers or Math","C134931","A question about whether an individual has difficulty working with numbers or math.","Difficulty Working with Numbers or Math | I have trouble solving math problems | Trouble solving math problems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522447","Trouble Writing School Papers or Reports","C134932","A question about whether an individual has trouble writing school papers or reports.","Trouble Writing School Papers or Reports | I have trouble writing school papers or reports",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522448","Difficulty Paying Attention To Things","C134933","A question about whether an individual has difficulty paying attention to things.","Difficulty Paying Attention To Things | I have trouble paying attention | It is hard for me to pay attention to things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522449","Difficulty Remembering What is Read","C134934","A question about whether an individual has difficulty remembering what they read.","Difficulty Remembering What is Read | It is hard for me to remember what I read",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522450","Feel Not Good Looking","C134935","A question about whether an individual feels that he/she is not good looking.","Feel Not Good Looking | I feel I am not good looking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522451","Dislike Other People Seeing Scars","C134936","A question about whether an individual does not like other people to see his/her scars.","Dislike Other People Seeing Scars | Dislike Others Seeing Scars | I don't like other people to see my scars",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522452","Embarrassed About Others Seeing Body","C134937","A question about whether an individual is embarrassed about others seeking his/her body.","Embarrassed About Others Seeing Body | Embarrassed About Other People Seeing Body | I am embarrassed when others see my body",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522453","Difficulty Telling Doctors and Nurses About Feelings","C134938","A question about whether an individual has difficulty telling the doctors and nurses how he/she feels.","Difficulty Telling Doctors and Nurses About Feelings | It is hard for me to tell the doctors and nurses how I feel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522454","Difficulty Asking Doctors or Nurses Questions","C134939","A question about whether an individual has difficulty asking the doctors or nurses questions.","Difficulty Asking Doctors or Nurses Questions | It is hard for me to ask the doctors and nurses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522455","Difficulty Explaining Illness to Others","C134940","A question about whether an individual has difficulty explaining his/her illness to others.","Difficulty Explaining Illness to Others | It is hard for me to explain my illness to other people",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522475","Memorial Symptom Assessment Scale (MSAS) 10-18","C134965","A patient-rated questionnaire designed to evaluate the prevalence, characteristics, and distress to children with cancer aged 10-18. This 30-question instrument was adapted from a previously-validated adult version.","Memorial Symptom Assessment Scale (MSAS) 10-18 | MSAS 10-18 | Memorial Symptom Assessment Scale (Pediatrics 10-18) | Memorial Symptom Assessment Scale 10-18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521612","7p12","C13496","A chromosome band present on 7p","7p12 | Memorial Symptom Assessment Scale (MSAS) 10-18 Frequency Score Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522478","Drug Shortage","C134968","A deficit in the availability of a pharmaceutical agent because the supply is insufficient to meet the actual or predicted therapeutic demand.","Drug Shortage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015422","Eyelash","C32576","Anyone of the short hairs that grow on the edge of the eyelid.","Eyelash | EYELASH",,,,,,,,,,,,,,,"4311825","Structure of eyelash",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003151","Anterior Chamber of the Eye","C12667","The space in the eye, filled with aqueous humor, bounded anteriorly by the cornea and a small portion of the sclera and posteriorly by a small portion of the ciliary body, the iris, and that part of the crystalline lens which presents through the pupil. (Cline et al., Dictionary of Visual Science, 4th ed, p109)","Anterior Chamber of the Eye | Anterior Chamber | Anterior Chamber (Eye) | Anterior Chamber of Eye | Chamber, Anterior | EYE, ANTERIOR CHAMBER",,,,,,,,,,,,,,,"4135229","Anterior chamber of eye structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448500","Macula","C26464","A yellowish, highly pigmented, oval shaped area slightly lateral to the center of the retina of the eye which contains the fovea centralis and is mostly comprised of retinal cones, for high-acuity vision, and which if damaged will result in the partial/complete loss of central vision.","Macula | MACULA | Macula Lutea",,,,,,,,,,,,,,,"4220537","Macula lutea structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1948032","Folder (Computer files directory)","C62486","A directory for a collection of computer files.","Folder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040420","Tonometry","C120543","A method in which pressure is applied to the surface of the cornea in order to flatten a prespecified area of the membrane, which is used to calculate intraocular pressure.","Tonometry | Intraocular Pressure Measurement | TONOMETRY",,,,,,,,,,,,,,,"4064074","Tonometry",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029090","Ophthalmoscopy","C120698","A technique used to examine of the back (fundus) and other anatomical structures of the eye with a magnifying instrument.","Ophthalmoscopy | FS | Fundoscopy | OPHTHALMOSCOPY",,,,,,,,,,,,,,,"4201612","Ophthalmoscopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034121","Pupil","C33429","The round, central aperture of the eye, surrounded by the iris, through which light enters.","Pupil | PUPIL | pupil",,,,,,,,,,,,,,,"4213427","Pupil structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1182652","Subcapsular Epithelium of the Lens","C33641","One of the 4 layers of the crystalline lens. It is found between the anterior surface of the capsule and the cortex. It is simple cuboidal epithelium responsible for creating new cells for the lens.","Subcapsular Epithelium of the Lens | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1998280","International Prostate Symptom Score","C113446","A screening tool used to screen for, diagnose, track, and manage the symptoms of benign prostatic hyperplasia.","International Prostate Symptom Score | I-PSS | IPS01 | IPSS",,,,,,,,,,,,,,,"4324046","International prostate symptom score",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514379","CRLF2 Positive","C131217","An indication that CRLF2 expression has been detected in a sample.","CRLF2 Positive | Cytokine Receptor-Like Factor 2 Positive | TSLPR Positive | Thymic Stromal-Derived Lymphopoietin Receptor Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514430","NTRK3 Gene Rearrangement","C131325","A molecular abnormality indicating rearrangement of the NTRK3 gene.","NTRK3 Gene Rearrangement | NTRK3 Rearrangement | Neurotrophic Tyrosine Kinase Receptor 3 Gene Rearrangement | Neurotrophic Tyrosine Kinase Receptor Type 3 Gene Rearrangement | Neurotrophic Tyrosine Kinase, Receptor, Type 3 Gene Rearrangement | TRKC Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514429","NTRK2 Gene Rearrangement","C131321","A molecular abnormality indicating rearrangement of the NTRK2 gene.","NTRK2 Gene Rearrangement | NTRK2 Rearrangement | Neurotrophic Tyrosine Kinase Receptor 2 Gene Rearrangement | Neurotrophic Tyrosine Kinase Receptor Type 2 Gene Rearrangement | TRKB Tyrosine Kinase Gene Rearrangement | Tropomyosin-Related Kinase B Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520370","BCL2 Gene Amplification","C132021","A molecular genetic abnormality indicating the presence of multiple copies of the BCL2 gene.","BCL2 Gene Amplification | B-Cell CLL-Lymphoma 2 Gene Amplification | B-Cell CLL/Lymphoma 2 Gene Amplification | BCL2, Apoptosis Regulator Gene Amplification | Bcl-2 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520371","BCL6 Gene Amplification","C132022","A molecular genetic abnormality indicating the presence of multiple copies of the BCL6 gene.","BCL6 Gene Amplification | B-Cell CLL/Lymphoma 6 Gene Amplification | BCL5 Gene Amplification | Bcl-6 Gene Amplification | LAZ3 Gene Amplification | ZBTB27 Gene Amplification | ZNF51 Gene Amplification | Zinc Finger Protein 51 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522528","Pediatric Quality of Life Inventory Cancer Module","C135089","A complement to the Pediatric Quality of Life generic core scales designed to provide greater measurement sensitivity for patients with cancer. This module has 25 items comprising 8 dimensions for use with children aged 2 to 18 years.","Pediatric Quality of Life Inventory Cancer Module | Pediatric Quality of Life Inventory Cancer-Specific Module | PedsQL Cancer Module | PedsQL-Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335729","Refractory Neoplasm","C7628","A neoplasm that does not respond to treatment.","Refractory Neoplasm | Refractory Tumor | Refractory tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016823","Eye Fundus","C135172","The interior surface of the eye opposite the lens including the retina, optic disc, macula, fovea, and posterior pole.","Eye Fundus | FUNDUS OF THE EYE | Fundus of the Eye | Retinal Fundus",,,,,,,,,,,,,,,"4277904","Structure of fundus of eye",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3808747","Nuclear Cataract","C135176","A type of cataract that forms deep in the central zone (nucleus) of the lens. Nuclear cataracts are usually associated with aging.","Nuclear Cataract | NS | Nuclear Sclerotic Cataract",,,,,,,,,,,,,,,"373769","Nuclear cataract",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL522771","Nuclear Cataract Grade 1","C135193","A stage of nuclear sclerotic cataract marked by mild yellowing and sclerosis of the lens nucleus. (Modified LOCS II)","Nuclear Cataract Grade 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522772","Nuclear Cataract Grade 2","C135194","A stage of nuclear sclerotic cataract marked by moderate yellowing and sclerosis of the lens nucleus. (Modified LOCS II)","Nuclear Cataract Grade 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522773","Nuclear Cataract Grade 3","C135195","A stage of nuclear sclerotic cataract marked by pronounced yellowing and sclerosis of the lens nucleus. (Modified LOCS II)","Nuclear Cataract Grade 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522774","Nuclear Cataract Grade 4","C135196","A stage of nuclear sclerotic cataract marked by severe yellowing and sclerosis of the lens nucleus. (Modified LOCS II)","Nuclear Cataract Grade 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4013328","Cortical Cataract","C135177","A type of cataract that occurs in the lens cortex. It is characterized by white, wedge-like opacities that start in the periphery of the lens and work their way to the center in a spoke-like fashion.","Cortical Cataract | CS | Cortical Spoking Cataract",,,,,,,,,,,,,,,"4103579","Cortical cataract",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL522775","Cortical Cataract Grade 1","C135197","A stage of cortical cataract characterized by 10% of the intrapupillary space obscured by opacity. (Modified LOCS II)","Cortical Cataract Grade 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522777","Cortical Cataract Grade 3","C135199","A stage of cortical cataract characterized by 50-90% of the intrapupillary space obscured by opacity. (Modified LOCS II)","Cortical Cataract Grade 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522778","Cortical Cataract Grade 4","C135200","A stage of cortical cataract characterized by greater than 90% of the intrapupillary space obscured by opacity. (Modified LOCS II)","Cortical Cataract Grade 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3552990","Posterior Subcapsular Cataract","C135180","A type of cataract that forms in the most posterior cortical layer of the lens, directly under the lens capsule. This type of cataract tends to occur in younger patients than cortical or nuclear sclerotic cataracts.","Posterior Subcapsular Cataract | PSC",,,,,,,,,,,,,,,"4197734","Posterior subcapsular cataract",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL522779","Posterior Subcapsular Cataract Grade 1","C135201","A stage of posterior subcapsular cataract characterized by 3% of the posterior capsule obscured by opacity. (Modified LOCS II)","Posterior Subcapsular Cataract Grade 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522780","Posterior Subcapsular Cataract Grade 2","C135202","A stage of posterior subcapsular cataract characterized by 30% of the posterior capsule obscured by opacity. (Modified LOCS II)","Posterior Subcapsular Cataract Grade 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522781","Posterior Subcapsular Cataract Grade 3","C135203","A stage of posterior subcapsular cataract characterized by 50% of the posterior capsule obscured by opacity. (Modified LOCS II)","Posterior Subcapsular Cataract Grade 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522782","Posterior Subcapsular Cataract Grade 4","C135204","A stage of posterior subcapsular cataract characterized by greater than 50% of the posterior capsule obscured by opacity. (Modified LOCS II)","Posterior Subcapsular Cataract Grade 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0065164","Diphenoxylate Hydrochloride/Atropine Sulfate","C135189","A formulation containing the hydrochloride salt form of diphenoxylate, a synthetic opioid of the phenylpiperidine class, and the sulfate salt form of the anticholinergic agent atropine, with antidiarrheal activity. Upon oral administration, diphenoxylate acts on opioid receptors in the gastrointestinal (GI) tract, thereby decreasing GI motility, prolonging transit time, and preventing diarrhea. Through its anticholinergic effects, atropine prevents deliberate over-usage of diphenoxylate by triggering very unpleasant side effects (SEs), such as severe weakness and nausea.","Diphenoxylate Hydrochloride/Atropine Sulfate | Diphenoxylate Hydrochloride and Atropine Sulfate | Lomotil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985796","Measurable Indicator","C93593","Specifies whether an entity is measurable.","Measurable Indicator | measurableIndicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0806487","Image Quality","C84421","A characteristic of an image that measures its perceived quality, especially as compared to an ideal or perfect image.","Image Quality | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053778","Focus of Cellular Alteration","C120882","A group of cell that show altered characteristics in comparison to normal cell types and are confined to a specific area of the sample.","Focus of Cellular Alteration | FOCUS OF CELLULAR ALTERATION | Foci of Cellular Alteration | Focus/foci of Cellular Alteration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054468","Morphologic Complete Remission with Incomplete Blood Count Recovery","C123596","The disappearance of all cells with morphologic characteristics of cancer, accompanied by incomplete bone marrow recovery, as evidenced by persistent anemia, thrombocytopenia or neutropenia.","Morphologic Complete Remission with Incomplete Blood Count Recovery | MORPHOLOGIC CRi | Morphologic CRi | Morphologic Complete Remission with Incomplete Bone Marrow Recovery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522479","AIDS-Related Kaposi Sarcoma Stage","C134969","A term that refers to the staging of AIDS-related Kaposi sarcoma according to the AIDS Clinical Trials Group system. The latter incorporates the extent of tumor (T), the status of the immune system (I), as measured by the number of CD4 cells present in the blood, and the extent of involvement within the body or systemic illness (S). Under each major heading, there are 2 subgroups: either a 0 (good risk) or a 1 (poor risk) group. (American Cancer Society)","AIDS-Related Kaposi Sarcoma Stage | AIDS-Related Kaposi Sarcoma Stage Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522480","AIDS-Related Kaposi Sarcoma T (Tumor) Status","C134970","A term that refers to the tumor status of AIDS-related Kaposi sarcoma according to the AIDS Clinical Trials Group system. (American Cancer Society)","AIDS-Related Kaposi Sarcoma T (Tumor) Status | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522481","AIDS-Related Kaposi Sarcoma T0 (Good Risk): Localized Tumor","C134971","AIDS-related Kaposi sarcoma is only in the skin and/or the lymph nodes, and/or there is only a small amount of disease on the palate. The Kaposi sarcoma lesions in the mouth are flat rather than raised. (American Cancer Society)","AIDS-Related Kaposi Sarcoma T0 (Good Risk): Localized Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522482","AIDS-Related Kaposi Sarcoma T1 (Poor Risk): Widespread Tumor","C134972","AIDS-related Kaposi sarcoma with widespread lesions.","AIDS-Related Kaposi Sarcoma T1 (Poor Risk): Widespread Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522483","AIDS-Related Kaposi Sarcoma T1 (Poor Risk): Edema or Ulceration","C134973","AIDS-related Kaposi sarcoma with edema or ulceration due to the tumor.","AIDS-Related Kaposi Sarcoma T1 (Poor Risk): Edema or Ulceration | AIDS-Related Kaposi Sarcoma T1: Edema or Ulceration | Stage 1 - Edema or Ulceration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522484","AIDS-Related Kaposi Sarcoma T1 (Poor Risk): Extensive Oral Involvement","C134974","AIDS-related Kaposi sarcoma with lesions that are nodular and/or lesions in roof of the mouth.","AIDS-Related Kaposi Sarcoma T1 (Poor Risk): Extensive Oral Involvement | AIDS-Related Kaposi Sarcoma T1: Extensive Oral Involvement | Stage 1 - Extensive Oral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522485","AIDS-Related Kaposi Sarcoma T1 (Poor Risk): Gastrointestinal Tract Involvement","C134975","AIDS-related Kaposi sarcoma involving the esophagus, stomach, or intestines.","AIDS-Related Kaposi Sarcoma T1 (Poor Risk): Gastrointestinal Tract Involvement | AIDS-Related Kaposi Sarcoma T1: Gastrointestinal Tract Involvement | Stage 1 - Gastrointestinal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522486","AIDS-Related Kaposi Sarcoma T1 (Poor Risk): Pulmonary Involvement","C134976","AIDS-related Kaposi sarcoma involving the lungs.","AIDS-Related Kaposi Sarcoma T1 (Poor Risk): Pulmonary Involvement | AIDS-Related Kaposi Sarcoma T1: Pulmonary Involvement | Stage 1 - Pulmonary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522487","AIDS-Related Kaposi Sarcoma T1 (Poor Risk): Other Non-Nodal Viscera Involvement","C134977","AIDS-related Kaposi sarcoma involving organs other than the lungs or gastrointestinal tract. It includes liver, bladder, reproductive tract, heart, and endocrine organs.","AIDS-Related Kaposi Sarcoma T1 (Poor Risk): Other Non-Nodal Viscera Involvement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522488","AIDS-Related Kaposi Sarcoma I (Immune System) Status","C134978","A term that refers to the immune system status of AIDS-related Kaposi sarcoma according to the AIDS Clinical Trials Group system. The immune status is assessed using the CD4 count test. (American Cancer Society)","AIDS-Related Kaposi Sarcoma I (Immune System) Status | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522489","AIDS-Related Kaposi Sarcoma I0 (Good Risk)","C134979","AIDS-related Kaposi sarcoma in which the CD4 cell count is 150 or more cells per cubic mm.","AIDS-Related Kaposi Sarcoma I0 (Good Risk) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522490","AIDS-Related Kaposi Sarcoma I1 (Poor Risk)","C134980","AIDS-related Kaposi sarcoma in which the CD4 cell count is lower than 150 cells per cubic mm.","AIDS-Related Kaposi Sarcoma I1 (Poor Risk) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522491","AIDS-Related Kaposi Sarcoma S (Systemic Illness) Status","C134981","A term that refers to the systemic illness status of AIDS-related Kaposi sarcoma according to the AIDS Clinical Trials Group system. (American Cancer Society)","AIDS-Related Kaposi Sarcoma S (Systemic Illness) Status | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522492","AIDS-Related Kaposi Sarcoma S0 (Good Risk)","C134982","AIDS-related Kaposi sarcoma in which no systemic illness is present; there is no history of opportunistic infections or thrush and no B symptoms lasting more than 2 weeks. The Karnofsky performance status score is 70 or higher. (American Cancer Society)","AIDS-Related Kaposi Sarcoma S0 (Good Risk) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522493","AIDS-Related Kaposi Sarcoma S1 (Poor Risk)","C134983","AIDS-related Kaposi sarcoma in which systemic illness is present; one or more of the following is true: history of opportunistic infections or thrush; one or more B symptoms is present; Karnofsky performance status score is under 70; other HIV-related illness is present, such as neurological disease or lymphoma. (American Cancer Society)","AIDS-Related Kaposi Sarcoma S1 (Poor Risk) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522494","AIDS-Related Kaposi Sarcoma Overall Risk Group","C134984","The overall risk group for AIDS-related Kaposi sarcoma based on the tumor, immune system, and systemic illness status. Since highly active antiretroviral therapy became available to treat HIV, the immune system status has become less important and is often not counted in determining the risk group. (American Cancer Society)","AIDS-Related Kaposi Sarcoma Overall Risk Group | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522495","AIDS-Related Kaposi Sarcoma Good Risk","C134985","The following combinations of tumor and systemic illness status define good risk AIDS-related Kaposi sarcoma: T0 S0, T1 S0, or T0 S1. T0: Localized tumor. T1: Widespread tumor. S0: No systemic illness is present. S1: Systemic illness is present. (American Cancer Society)","AIDS-Related Kaposi Sarcoma Good Risk | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522496","AIDS-Related Kaposi Sarcoma Poor Risk","C134986","The following combination of tumor and systemic illness status define poor risk AIDS-related Kaposi sarcoma: T1 S1. T1: Widespread tumor. S1: Systemic illness is present. (American Cancer Society)","AIDS-Related Kaposi Sarcoma Poor Risk | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050091","Topical Corticosteroid Therapy","C122078","Treatment with a corticosteroid formulation designed for and administered onto a dermal, ocular or mucosal surface.","Topical Corticosteroid Therapy | Topical Corticosteroid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522932","Patient Oriented Prostate Utility Scale","C135576","A 10-item self-report questionnaire that measures quality of life for men with prostate cancer.","Patient Oriented Prostate Utility Scale | PORPUS | Patient Oriented Prostate Utility Scale (PORPUS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522933","Pain and Disturbing Body Sensations","C135577","A question about an individual's level of pain and disturbing body sensations.","Pain and Disturbing Body Sensations | Pain and Disturbing Body Sensations (e.g. hot flashes, painful swelling of breasts, nausea)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522934","Communication with Doctor","C135578","A question about an individual's ability to communicate with their doctor.","Communication with Doctor | Ability to Communicate with Doctor | Communication With Doctor (primary caregiver for prostate cancer, may be specialist or family doctor)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522935","Urinary Frequency and Urgency","C135579","A question about an individual's frequency and urgency of passing urine.","Urinary Frequency and Urgency | Urinary Frequency (need to pass urine frequently during the day or night) and Urgency (difficulty delaying urination after the urge is felt to urinate, ability to 'hold it')",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522936","Bowel Problems Frequency","C135580","A question about the frequency of an individual's bowel problems.","Bowel Problems Frequency | Bowel problems: diarrhea, rectal discomfort (pain, burning or irritation) or constipation | Frequency of Bowel Problems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522937","No Pain and No Disturbing Body Sensations","C135581","A response indicating that an individual has or had no pain and no disturbing body sensations.","No Pain and No Disturbing Body Sensations | No pain and no disturbing body sensations",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522938","Mild Pain or Disturbing Body Sensations Not Limiting Activities","C135582","A response indicating that an individual had mild pain or disturbing body sensations, but  that they do or did not limit activities.","Mild Pain or Disturbing Body Sensations Not Limiting Activities | Mild pain or disturbing body sensations that do not limit any activities (for example: work, social, sexual, sleep)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522939","Moderate Pain or Disturbing Body Sensations that Limit Few Activities","C135583","A response indicating that an individual has or had moderate pain or disturbing body sensations that limited a few activities.","Moderate Pain or Disturbing Body Sensations that Limit Few Activities | Moderate pain or disturbing body sensations that limit a few activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522940","Moderate to Severe Pain or Disturbing Body Sensations that Limit Some Activities","C135584","A response indicating that an individual has or had moderate to severe pain or disturbing body sensations that limited some activities.","Moderate to Severe Pain or Disturbing Body Sensations that Limit Some Activities | Moderate to severe pain or disturbing body sensations that limit some activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522941","Severe Pain or Disturbing Body Sensations that Limit Many Activities","C135585","A response indicating that an individual has or had severe pain or disturbing body sensations that limited many activities.","Severe Pain or Disturbing Body Sensations that Limit Many Activities | Severe pain or disturbing body sensations that limit many activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522942","Very Full of Energy, Lots of Pep","C135586","A response indicating that an individual is or was very full of energy, with lots of pep.","Very Full of Energy, Lots of Pep | Very full of energy, lots of pep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522943","Fairly Energetic, No Limitation of Activities","C135587","A response indicating that an individual is or was fairly energetic, with no limitation of activities.","Fairly Energetic, No Limitation of Activities | Fairly energetic, no limitation of activities (for example: work, social, sexual)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522944","Moderate Reduction in Energy or Pep that Limits a Few Activities","C135588","A response indicating that an individual has or had a moderate reduction in energy or pep that limited a few activities.","Moderate Reduction in Energy or Pep that Limits a Few Activities | Moderate reduction in energy or pep that limits a few activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522945","Generally Low Energy or Pep that Limits Some Activities","C135589","A response indicating that an individual has or had generally low energy or pep that limited some activities.","Generally Low Energy or Pep that Limits Some Activities | Generally low energy or pep that limits some activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522946","No Energy or Pep at All; Feel Drained, Many Activities are Limited","C135590","A response indicating that an individual has or had no energy or pep at all; felt drained, with many activities limited.","No Energy or Pep at All; Feel Drained, Many Activities are Limited | No energy or pep at all. I feel drained, and many activities are limited",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522947","Most Times Feel Supported by Spouse, Family, and Friends","C135591","A response indicating that an individual feels or felt supported by spouse, family, and friends at most times.","Most Times Feel Supported by Spouse, Family, and Friends | Feel Supported by Spouse, Family, and Friends Most Times | Feel Supported by Spouse, Family, and Friends Most of the Time | Most of the time feel supported by my spouse, family and friends",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522948","Fair Amount of Time Feel Supported by Spouse, Family, and Friends","C135592","A response indicating that an individual feels or felt supported by spouse, family, and friends a fair amount of the time.","Fair Amount of Time Feel Supported by Spouse, Family, and Friends | A fair amount of the time feel supported by my spouse, family and friends | Feel Supported by Spouse, Family, and Friends Fair Amount of the Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522949","Occasionally Feel Supported by Spouse, Family and Friends","C135593","A response indicating that an individual feels or felt supported by spouse, family, and friends only occasionally.","Occasionally Feel Supported by Spouse, Family and Friends | Feel Supported by Spouse, Family, and Friends Occasionally | Occasionally feel supported by my spouse, family and friends",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522950","Rarely Feel Supported by Spouse, Family and Friends","C135594","A response indicating that an individual feels or felt supported by spouse, family, and friends only rarely.","Rarely Feel Supported by Spouse, Family and Friends | Feel Supported by Spouse, Family, and Friends Only Rarely | Rarely feel supported by my spouse, family, and friends",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522951","Always Able to Express Concerns to Doctor and Get Needed Information or Advice","C135595","A response indicating that an individual is or was always able to express concerns to their doctor and get the needed information or advice.","Always Able to Express Concerns to Doctor and Get Needed Information or Advice | Always able to express my concerns to my Doctor and get all the information or advice I need",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522952","Most of the Time, Able to Express Concerns to Doctor and Get Needed Information or Advice","C135596","A response indicating that an individual is or was able to express concerns to their doctor and get the needed information or advice most of the time.","Most of the Time, Able to Express Concerns to Doctor and Get Needed Information or Advice | Most of the time, able to express my concerns to my Doctor and get all the information or advice I need",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522953","Some of the Time, Able to Express Concerns to Doctor and Get Needed Information or Advice","C135597","A response indicating that an individual is or was able to express concerns to their doctor and get the needed information or advice some of the time.","Some of the Time, Able to Express Concerns to Doctor and Get Needed Information or Advice | Some of the time, able to express my concerns to my Doctor and get all the information or advice I need",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522954","Rarely Able to Express my Concerns to Doctor and Get Needed Information or Advice","C135598","A response indicating that an individual is or was rarely able to express concerns to their doctor and get the needed information or advice.","Rarely Able to Express my Concerns to Doctor and Get Needed Information or Advice | Rarely able to express my concerns to my Doctor and get all the information or advice I need",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522955","Generally Happy and Free from Worry, Sadness, or Frustration","C135599","A response indicating that an individual is generally happy and free from worry, sadness, or frustration.","Generally Happy and Free from Worry, Sadness, or Frustration | Generally happy and free from worry, sadness, or frustration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522956","Little Worry, Sadness, or Frustration","C135600","A response indicating that an individual has a little worry, sadness, or frustration.","Little Worry, Sadness, or Frustration | A little worry, sadness, or frustration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522957","Moderate Worry, Sadness, or Frustration","C135601","A response indicating that an individual has moderate worry, sadness, or frustration.","Moderate Worry, Sadness, or Frustration | Moderate worry, sadness, or frustration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522958","Quite a bit of Worry, Sadness, or Frustration","C135602","A response indicating that an individual has quite a bit of worry, sadness, and frustration.","Quite a bit of Worry, Sadness, or Frustration | Quite a bit of worry, sadness, or frustration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522959","Extreme Worry, Sadness, or Frustration","C135603","A response indicating that an individual has extreme worry, sadness, or frustration.","Extreme Worry, Sadness, or Frustration | Extreme worry, sadness, or frustration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522960","No Urinary Frequency or Urgency","C135604","A response indicating that an individual feels or felt no urinary frequency or urgency.","No Urinary Frequency or Urgency | No urinary frequency or urgency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522961","Little Urinary Frequency or Urgency; Does not Interfere with Sleep or Other Activities","C135605","A response indicating that an individual feels or felt a little urinary frequency or urgency, but it does not interfere with sleep or other activities.","Little Urinary Frequency or Urgency; Does not Interfere with Sleep or Other Activities | A little urinary frequency or urgency, does not interfere with sleep or other activities (for example: work, social); no need to plan ahead",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522962","Some Urinary Frequency or Urgency that Interferes with Sleep or Other Activities; May Need to Plan Ahead","C135606","A response indicating that an individual feels or felt some urinary frequency or urgency that interferes with sleep or other activities and that may make it necessary to plan ahead.","Some Urinary Frequency or Urgency that Interferes with Sleep or Other Activities; May Need to Plan Ahead | Some urinary frequency or urgency that interferes with sleep or other activities; may need to plan ahead",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522964","Extreme Urinary Frequency or Urgency; Need to be Near a Bathroom Always","C135608","A response indicating that an individual feels or felt extreme urinary frequency or urgency, making it necessary to be near a bathroom always.","Extreme Urinary Frequency or Urgency; Need to be Near a Bathroom Always | Extreme urinary frequency or urgency; need to be near a bathroom always",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522965","Never, Under Any Circumstances Leak Urine or Lose Bladder Control","C135609","A response indicating that an individual never, under any circumstances leaks urine or loses bladder control.","Never, Under Any Circumstances Leak Urine or Lose Bladder Control | Never, under any circumstances leak urine or lose bladder control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522966","On Rare Occasions, Leak Urine or Lose Bladder Control, Does not Interfere with Any Activities","C135610","A response indicating that an individual, on rare occasions, leaks urine or loses bladder control but that it does not interfere with any activities.","On Rare Occasions, Leak Urine or Lose Bladder Control, Does not Interfere with Any Activities | Leak Urine or Lose Bladder Control On Rare Occasions, Does not Interfere with Any Activities | On rare occasions, leak urine or lose bladder control, does not interfere with any activities (for example: work, social, sexual, sleep)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522967","Occasionally Leak Urine or Lose Bladder Control, Interferes with Few Activities","C135611","A response indicating that an individual occasionally leaks urine or loses bladder control and it interferes with a few activities.","Occasionally Leak Urine or Lose Bladder Control, Interferes with Few Activities | Leak Urine or Lose Bladder Control Occasionally, Interferes with Few Activities | Occasionally leak urine or lose bladder control, interferes with a few activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522970","Moderate Amount of the Time, Leak Urine or Lose Bladder Control, Interferes with Some Activities","C135614","A response indicating that an individual leaks urine or loses bladder control a moderate amount of the time and it interferes with some activities.","Moderate Amount of the Time, Leak Urine or Lose Bladder Control, Interferes with Some Activities | A moderate amount of the time, leak urine or lose bladder control, interferes with some activities | Leak Urine or Lose Bladder Control Moderate Amount of the Time, Interferes with Some Activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522973","Most of the Time, Leak Urine or Have Poor Bladder Control, Interferes with Many Activities","C135617","A response indicating that an individual leaks urine or has poor bladder control most of the time and it interferes with many activities.","Most of the Time, Leak Urine or Have Poor Bladder Control, Interferes with Many Activities | Leak Urine or Have Poor Bladder Control Most of the Time, Interferes with Many Activities | Most of the time, leak urine or have poor bladder control, interferes with many activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522974","Require Clamp, Catheter, or Collecting Bag Because of Leaking Urine or Poor Bladder Control","C135618","A response indicating that an individual requires a clamp, catheter, or collecting bag because of leaking urine or poor bladder control.","Require Clamp, Catheter, or Collecting Bag Because of Leaking Urine or Poor Bladder Control | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522976","Full Erections Sufficient for Intercourse","C135620","A response indicating that an individual achieves/maintains full erections sufficient for intercourse.","Full Erections Sufficient for Intercourse | Full erections sufficient for intercourse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522977","Erections Sufficient for Intercourse, but Some Reduction in Firmness","C135621","A response indicating that an individual achieves/maintains erections sufficient for intercourse, but has some reduction in firmness.","Erections Sufficient for Intercourse, but Some Reduction in Firmness | Erections sufficient for intercourse, but some reduction in firmness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522978","Erections Sufficient for Masturbation or Foreplay Only","C135622","A response indicating that an individual achieves/maintains erections sufficient for masturbation or foreplay only.","Erections Sufficient for Masturbation or Foreplay Only | Erections sufficient for masturbation or foreplay only",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522979","Erections, But Not Firm Enough for Any Sexual Activity","C135623","A response indicating that an individual achieves/maintains erections, but not firm enough for any sexual activity.","Erections, But Not Firm Enough for Any Sexual Activity | Erections, but not firm enough for any sexual activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522980","No Erections at All","C135624","A response indicating that an individual achieves no erections at all.","No Erections at All | No erections at all",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522981","Normal Amount of Sexual Drive and Interest","C135625","A response indicating that an individual has or had their normal amount of sexual drive and interest.","Normal Amount of Sexual Drive and Interest | Normal amount of sexual drive and interest for you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522983","Little Decrease of Sexual Drive or Interest","C135628","A response indicating that an individual has or had a little decrease of sexual drive or interest.","Little Decrease of Sexual Drive or Interest | A little decrease of sexual drive or interest for you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522990","Moderate Decrease of Sexual Drive or Interest","C135635","A response indicating that an individual has or had a moderate decrease of sexual drive or interest.","Moderate Decrease of Sexual Drive or Interest | Moderate decrease of sexual drive or interest for you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522991","Substantial Decrease of Sexual Drive or Interest","C135636","A response indicating that an individual has or had a substantial decrease of sexual drive or interest.","Substantial Decrease of Sexual Drive or Interest | Substantial decrease of sexual drive or interest for you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522985","No Sexual Drive or Interest","C135630","A response indicating that an individual has or had no sexual drive or interest.","No Sexual Drive or Interest | No sexual drive or interest",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522992","No Diarrhea, Rectal Discomfort, or Constipation","C135637","A response indicating that an individual has or had no diarrhea, rectal discomfort, or constipation.","No Diarrhea, Rectal Discomfort, or Constipation | No diarrhea, rectal discomfort, or constipation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522993","Have Occasional Diarrhea, Rectal Discomfort, or Constipation","C135638","A response indicating that an individual occasionally has or had diarrhea, rectal discomfort, or constipation.","Have Occasional Diarrhea, Rectal Discomfort, or Constipation | Occasionally have diarrhea, rectal discomfort, or constipation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522994","Have Frequent Diarrhea, Rectal Discomfort, or Constipation","C135639","A response indicating that an individual frequently has or had diarrhea, rectal discomfort, or constipation.","Have Frequent Diarrhea, Rectal Discomfort, or Constipation | Frequently have diarrhea, rectal discomfort, or constipation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522995","Have Nearly Constant Diarrhea, Rectal Discomfort, or Constipation","C135640","A response indicating that an individual nearly always has or had diarrhea, rectal discomfort, or constipation.","Have Nearly Constant Diarrhea, Rectal Discomfort, or Constipation | Nearly always have diarrhea, rectal discomfort, or constipation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523628","Memorial Symptom Assessment Scale (MSAS) 7-12","C136319","A patient-rated questionnaire designed to evaluate the prevalence, characteristics, and distress to young children with cancer aged 7-12. This 8-question instrument was adapted from a previously-validated adult version.","Memorial Symptom Assessment Scale (MSAS) 7-12 | MSAS 7-12 | Memorial Symptom Assessment Scale (Pediatrics 7-12) | Memorial Symptom Assessment Scale 7-12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523630","Yesterday or Today","C136321","The time period consisting of the current day and the preceding day.","Yesterday or Today | Yesterday or today",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523633","Last 2 Days","C136324","The 48 hour period occurring just before the present time.","Last 2 Days | Last 2 days | Last Two Days | Past 2 Days | Past Two Days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523635","Last 2 Nights","C136326","The period of time consisting of the previous night and the night before the previous night.","Last 2 Nights | Last 2 nights | Last Two Nights | Past 2 Nights | Past Two Nights",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523641","A Very Short Time","C136332","A response indicating that something happens or happened for a very short time.","A Very Short Time | A very short time | Very Short",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523866","A Medium Amount of Time","C136333","A response indicating that something happens or happened for a medium amount of time.","A Medium Amount of Time | A Medium Amount | A Medium Amount of the Time | A medium amount | Medium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523865","A Medium Amount","C136334","A response indicating that something is or was of a moderate amount, intensity, or duration.","A Medium Amount | A medium amount | Medium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523642","More Tired Than Usual","C136335","A question about whether an individual feels or felt more tired than usual.","More Tired Than Usual | Did you feel more tired yesterday or today than you usually do",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523644","How Long Feeling Tired Lasted","C136337","A question about how long an individual's tired feeling lasted.","How Long Feeling Tired Lasted | How long did feeling tired last",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523645","How Tired","C136338","A question about how tired an individual felt.","How Tired | How tired did you feel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523646","How Much Bothered by Being Tired","C136339","A question about how much being tired bothered or troubled an individual.","How Much Bothered by Being Tired | How much did being tired bother you or trouble you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523647","How Long Felt Sad","C136340","A question about how long an individual felt sad.","How Long Felt Sad | How Long Feel Sad | How long did you feel sad",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523648","How Sad","C136341","A question about how sad an individual felt.","How Sad | How Sad You Felt | How sad did you feel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523650","How Much Feeling Sad Bothered or Troubled You","C136343","A question about how much an individual was bothered or troubled by feeling sad.","How Much Feeling Sad Bothered or Troubled You | How much did feeling sad bother or trouble you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523654","Were Itchy","C136347","A question about whether an individual feels or felt itchy.","Were Itchy | Were You Itchy | Were you itchy yesterday or today",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523662","How Much Time Itchy","C136355","A question about how much of the time an individual was itchy.","How Much Time Itchy | How much of the time were you itchy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523664","How Itchy","C136357","A question about how itchy an individual was.","How Itchy | How itchy were you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523665","How Much Bothered by Being Itchy","C136358","A question about how much being itchy bothered or troubled an individual.","How Much Bothered by Being Itchy | How Much Bothered or Troubled by Being Itchy | How much did being itchy bother you or trouble you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523666","How Much Time Have Pain","C136359","A question about how much of the time an individual felt pain.","How Much Time Have Pain | How Much Time Felt Pain | How much of the time did you have pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523667","How Much Pain Felt","C136360","A question about how much pain an individual felt.","How Much Pain Felt | How much pain did you feel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523668","How Much Bothered by Pain","C136361","A question about how much pain bothered or troubled an individual.","How Much Bothered by Pain | How Much Bothered or Troubled by Pain | How much did the pain bother you or trouble you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523669","How Much Time Feel Worried","C136362","A question about how much of the time an individual felt worried.","How Much Time Feel Worried | How much of the time did you feel worried",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523670","How Worried","C136363","A question about how worried an individual feels or felt.","How Worried | How Worried You Felt | How worried did you feel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523671","How Much Bothered by Feeling Worried","C136364","A question about how much feeling worried bothered or troubled an individual.","How Much Bothered by Feeling Worried | How Much Bothered by Worry | How Much Bothered or Troubled by Worry | How much did feeling worried bother you or trouble you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523672","Feel Like Eating as Normal","C136365","A question about whether an individual feels or felt like eating as normal.","Feel Like Eating as Normal | Did you feel like eating yesterday or today as you normally do",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523673","How Long Not Feeling Like Eating Lasted","C136366","A question about how long not feeling like eating lasted.","How Long Not Feeling Like Eating Lasted | How long did this last",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523674","How Much Bothered by Not Feeling Like Eating","C136367","A question about how bothered or troubled an individual was by not feeling like eating.","How Much Bothered by Not Feeling Like Eating | How Much Bothered or Troubled by Not Feeling Like Eating | How Much Not Feeling Like Eating Bothered or Troubled You | How much did this bother you or trouble you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523675","Feel Like Going to Vomit","C136368","A question about whether an individual feels or felt like they were going to vomit or throw up.","Feel Like Going to Vomit | Did you feel like you were going to vomit (or going to throw up) yesterday or today | Feel Like Going to Vomit or Throw Up",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523676","How Much of the Time Feel Like Could Vomit","C136369","A question about how much of the time did an individual felt like they could vomit or throw up.","How Much of the Time Feel Like Could Vomit | How Much Time Feeling Like You Could Vomit or Throw Up | How much of the time did you feel like you could vomit (or could throw up)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523677","How Much Bothered by Feeling Like Could Vomit","C136370","A question about how much feeling like vomiting or throwing up bothered or troubled an individual.","How Much Bothered by Feeling Like Could Vomit | How Much Bothered or Troubled by Feeling Like Could Vomit | How much did this feeling bother you or trouble you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523678","Have Trouble Going To Sleep","C136371","A question about whether an individual has or had trouble going to sleep.","Have Trouble Going To Sleep | Did you have trouble going to sleep the last 2 nights | Have Trouble Falling Asleep | I had trouble falling asleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523679","How Much Bothered by Not Being Able to Sleep","C136372","A question about how much not being able to sleep bothered or troubled an individual.","How Much Bothered by Not Being Able to Sleep Question | How Much Bothered by Not Being Able to Sleep | How Much Bothered by Not Being Able to Sleep | How Much Bothered or Troubled by Not Being Able to Sleep | How much did not being able to sleep bother you or trouble you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523680","How Much Bothered by Something Else","C136373","A question about how much anything else bothered or troubled an individual.","How Much Bothered by Something Else | How Much Bothered or Troubled by Something Else | How much did this bother you or trouble you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523684","Anything Else Made You Feel Bad or Sick","C136378","A question about whether an individual has had anything else make them feel bad or sick.","Anything Else Made You Feel Bad or Sick | If you had anything else which made you feel bad or sick yesterday or today, write it here | Something Else Made You Feel Bad or Sick",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0370219","Platelet-poor Plasma","C106556","A plasma sample that is prepared from whole blood, which has undergone a number of centrifugation steps to decrease the amount of platelets.","Platelet-poor Plasma | PLATELET POOR PLASMA | PPP",,,,,,,,,,,,,,,"4021554","Platelet poor plasma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1535946","Beta-2 Globulin Measurement","C119276","The determination of the amount of the beta-2 globulin activity in a biological specimen.","Beta-2 Globulin Measurement | Beta-2 Globulin | GLOBB2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889477","Beta-1 Globulin Measurement","C119274","The determination of the amount of the beta-1 globulin activity in a biological specimen.","Beta-1 Globulin Measurement | Beta-1 Globulin | GLOBB1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334416","Parasympathetic Paraganglioma","C4217","An extra-adrenal paraganglioma that arises from paraganglia located along the parasympathetic nerves.  Representative examples include aorticopulmonary, carotid body, jugulotympanic, and mediastinal paragangliomas.","Parasympathetic Paraganglioma | Parasympathetic Extra-Adrenal Paraganglioma | Parasympathetic Paraganglionic Neoplasm | Parasympathetic paraganglioma",,,,,,,,,,,,,,,"4181435","Parasympathetic paraganglioma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334415","Sympathetic Paraganglioma","C4216","A paraganglioma arising from the chromaffin cells of the paraganglia that are located along the sympathetic nerves.  It includes extra-adrenal paragangliomas and paragangliomas that arise from the adrenal medulla.  The latter are commonly referred to as pheochromocytomas.  Representative examples of extra-adrenal sympathetic paragangliomas include the bladder, and superior and inferior paraaortic paragangliomas.  Clinical signs are related to the secretion of catecholamines resulting in hypertension.","Sympathetic Paraganglioma | Chromaffin Neoplasm | Chromaffin Tumor | Chromaffin tumor | Chromaffinoma | Sympathetic Paraganglionic Neoplasm | Sympathetic paraganglioma",,,,,,,,,,,,,,,"4136519","Sympathetic paraganglioma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1879646","Affected Body Area","C66994","A part of the body showing particular characteristics.","Affected Body Area | Affected Area | Affected Area",,,,,,,,,,,,,,,"37117125","Affected area",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL523790","Last Two Scheduled Appointments","C136487","The two scheduled appointments preceding the present day.","Last Two Scheduled Appointments | Last two scheduled appointments",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1296831","Catahoula Leopard Dog","C53757","A herding dog with a short, single coat, and a deep chest. Some coats can be course, but most are short and tight. The coat is colored in a merle or black/tan pattern. The average height range is 20-26 inches and the average weight range is 55-80 pounds.","Catahoula Leopard Dog | Catahoula Cur | Catahoula Hog Dog | Catahoula Hound | Catahoula Leopard Hound | Louisiana Catahoula Leopard Dog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1453102","Firocoxib","C65686","No Value Exists","Firocoxib | FIROCOXIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2353951","Dapagliflozin","C78126","A selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. Dapagliflozin selectively and potently inhibits SGLT2 compared to SGLT1, which is the cotransporter of glucose in the gut.","Dapagliflozin | BMS-512148-05 | D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, (1S)-, Compd. with (2S)-1,2-propanediol, Hydrate (1:1:1) | DAPAGLIFLOZIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2934281","HDM2-binding Peptide PNC-27","C136515","A human double minute 2 (HDM2)-binding peptide comprised of a carboxy terminal p53 leader sequence (amino acids 12-26) linked to a membrane residency peptide (MRP), which facilitates penetration of the tumor cell plasma membrane, with potential antineoplastic activity. HDM2-binding peptide PNC-27 binds to HDM2, which is expressed in the plasma membrane of certain cancer cells, and induces transmembrane pore formation, resulting in tumor cell necrosis that is independent of p53 activity. HDM2, a zinc finger protein and negative regulator of the p53 pathway, is often overexpressed by cancer cells and has been implicated in cancer cell proliferation and survival.","HDM2-binding Peptide PNC-27 | PNC 27 | PNC-27 | PNC-27 Anti-Cancer Peptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3839741","Core Binding Factor Acute Myeloid Leukemia","C122688","Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis.","Core Binding Factor Acute Myeloid Leukemia | CBF-AML",,,,,,,,,,,,,,,"45765495","Core binding factor acute myeloid leukemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL524360","Swallowing Impairment Scale","C136539","A questionnaire designed to measure symptoms of swallowing dysfunction.","Swallowing Impairment Scale | SIS-6 | Swallowing Impairment Scale (SIS-6)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524365","Requires Great Effort to Swallow","C136540","A question about how often an individual feels or felt that it requires great effort to swallow.","Requires Great Effort to Swallow | It requires great effort to swallow",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524366","Feel a Throat Obstacle During Swallowing","C136541","A question about how often an individual feels or felt a throat obstacle during swallowing.","Feel a Throat Obstacle During Swallowing | I feel a throat obstacle during swallowing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524363","Feel Pharyngeal Annoyance During Bolus Transit","C136542","A question about how often an individual feels or felt pharyngeal annoyance during bolus transit.","Feel Pharyngeal Annoyance During Bolus Transit | I feel pharyngeal annoyance during bolus transit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524364","Cough During Bolus Transit","C136543","A question about how often an individual coughs or coughed during bolus transit.","Cough During Bolus Transit | I cough during bolus transit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524428","Feel Sensation of Foreign Body in Pharynx","C136544","A question about how often an individual feels or felt a sensation of a foreign body in their pharynx.","Feel Sensation of Foreign Body in Pharynx | I feel a sensation of a foreign body in my pharynx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524429","Have Some Difficulties Swallowing Fluids","C136545","A question about how often an individual has or had some difficulties swallowing fluids.","Have Some Difficulties Swallowing Fluids | I have some difficulties swallowing fluids",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524427","Neck Pain Scale","C136546","A visual analogue scale designed to measure neck pain.","Neck Pain Scale | Neck Pain Visual Analog Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4036324","Neck Pain Score 0","C136547","A subjective score of 0 on a visual analogue scale that ranges from 0: No Pain to 10: Excruciating.","Neck Pain Score 0 | 0 = No Pain | No Pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524860","Neck Pain Score 1","C136548","A subjective score of 1 on a visual analogue scale that ranges from 0: No Pain to 10: Excruciating.","Neck Pain Score 1 | 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524430","Neck Pain Score 2","C136549","A subjective score of 2 on a visual analogue scale that ranges from 0: No Pain to 10: Excruciating.","Neck Pain Score 2 | 2= Mild | Mild Pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524858","Neck Pain Score 3","C136550","A subjective score of 3 on a visual analogue scale that ranges from 0: No Pain to 10: Excruciating.","Neck Pain Score 3 | 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524862","Neck Pain Score 4","C136551","A subjective score of 4 on a visual analogue scale that ranges from 0: No Pain to 10: Excruciating.","Neck Pain Score 4 | 4 = Moderate | Moderate Pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524859","Neck Pain Score 5","C136552","A subjective score of 5 on a visual analogue scale that ranges from 0: No Pain to 10: Excruciating.","Neck Pain Score 5 | 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524863","Neck Pain Score 6","C136553","A subjective score of 6 on a visual analogue scale that ranges from 0: No Pain to 10: Excruciating.","Neck Pain Score 6 | 6 = Severe | Severe Pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524857","Neck Pain Score 7","C136554","A subjective score of 7 on a visual analogue scale that ranges from 0: No Pain to 10: Excruciating.","Neck Pain Score 7 | 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524434","Neck Pain Score 8","C136556","A subjective score of 8 on a visual analogue scale that ranges from 0: No Pain to 10: Excruciating.","Neck Pain Score 8 | 8= Very Severe | Very Severe Pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524861","Neck Pain Score 9","C136557","A subjective score of 9 on a visual analogue scale that ranges from 0: No Pain to 10: Excruciating.","Neck Pain Score 9 | 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524432","Neck Pain Score 10","C136558","A subjective score of 10 on a visual analogue scale that ranges from 0: No Pain to 10: Excruciating.","Neck Pain Score 10 | 10 = Excruciating | Excruciating Pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524413","Apparent Sporadic Paraganglioma or Pheochromocytoma","C136560","A paraganglioma-pheochromocytoma that is not associated with a clear genetic mutation.","Apparent Sporadic Paraganglioma or Pheochromocytoma | Apparent Sporadic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709046","SDH Complex Gene Mutation","C48301","A change in the nucleotide sequence of any gene that encodes one of the proteins in the succinate dehydrogenase (SDH) complex.","SDH Complex Gene Mutation | Mitochondrial Complex II Gene Mutation | Mitochondrial Complex II Gene Mutation | Mitochondrial Respiratory Chain Complex II Gene Mutation | SDH Family Gene Mutation | SDH Gene Mutation | SDHA/B/C/D Mutation | SDHx Mutation | Succinate Dehydrogenase Gene Mutation | Succinate-CoQ Reductase Gene Mutation | Succinate-Coenzyme Q Reductase Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523799","Quality of Life Questionnaire - Head & Neck 35","C136497","A questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) consisting of 35 questions designed to assess quality of life in head and neck cancer patients.","Quality of Life Questionnaire - Head & Neck 35 | EOR11 | EORTC QLQ-H&N35 | EORTC QLQ-H&N35 V1 | EORTC QLQ-H&N35 Version 1 | QLQ-H&N35 | Quality of Life Questionnaire-Head & Neck 35 (QLQ-H&N35)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523800","Extent Have Pain in Mouth","C136498","A question about the extent to which an individual has or had pain in their mouth.","Extent Have Pain in Mouth | Extent of Pain in Mouth | Have you had pain in your mouth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523801","Extent Have Pain in Jaw","C136499","A question about the extent to which an individual has or had pain in their jaw.","Extent Have Pain in Jaw | Extent of Pain in Jaw | Have you had pain in your jaw",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523802","Extent Have Soreness in Mouth","C136500","A question about the extent to which an individual has or had soreness in their mouth.","Extent Have Soreness in Mouth | Extent of Soreness in Mouth | Have you had soreness in your mouth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523803","Extent Have Painful Throat","C136501","A question about the extent to which an individual has or had a painful throat.","Extent Have Painful Throat | Extent of Painful Throat | Have you had a painful throat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523804","Extent Have Problems Swallowing Liquids","C136502","A question about the extent to which an individual has or had problems swallowing liquids.","Extent Have Problems Swallowing Liquids | Extent of Problems Swallowing Liquids | Have you had problems swallowing liquids",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523805","Extent Have Problems Swallowing Pureed Food","C136503","A question about the extent to which an individual has or had problems swallowing pureed food.","Extent Have Problems Swallowing Pureed Food | Extent of Problems Swallowing Pureed Food | Have you had problems swallowing pureed food",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523806","Extent Have Problems Swallowing Solid Food","C136504","A question about the extent to which an individual has or had problems swallowing solid food.","Extent Have Problems Swallowing Solid Food | Extent of Problems Swallowing Solid Food | Have you had problems swallowing solid food",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523807","Extent Have Choking when Swallowing","C136505","A question about the extent to which an individual has or had choking when swallowing.","Extent Have Choking when Swallowing | Extent of Choking when Swallowing | Have you choked when swallowing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523808","Extent Have Problems with Teeth","C136506","A question about the extent to which an individual has or had problems with their teeth.","Extent Have Problems with Teeth | Extent of Problems with Teeth | Have you had problems with your teeth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523809","Extent Have Problems Opening Mouth Wide","C136507","A question about the extent to which an individual has or had problems opening their mouth wide.","Extent Have Problems Opening Mouth Wide | Extent of Problems Opening Mouth Wide | Have you had problems opening your mouth wide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523810","Extent Have Dry Mouth","C136508","A question about the extent to which an individual has or had a dry mouth.","Extent Have Dry Mouth | Extent of Dry Mouth | Have you had a dry mouth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523811","Extent Have Sticky Saliva","C136509","A question about the extent to which an individual has or had sticky saliva.","Extent Have Sticky Saliva | Extent of Sticky Saliva | Have you had sticky saliva",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523812","Extent Have Problems with Sense of Smell","C136510","A question about the extent to which an individual has or had problems with their sense of smell.","Extent Have Problems with Sense of Smell | Extent of Problems with Sense of Smell | Have you had problems with your sense of smell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523813","Extent Have Problems with Sense of Taste","C136511","A question about the extent to which an individual has or had problems with their sense of taste.","Extent Have Problems with Sense of Taste | Extent of Problems with Sense of Taste | Have you had problems with your sense of taste",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523814","Extent Have Cough","C136512","A question about the extent to which an individual has or had coughing.","Extent Have Cough | Extent of Cough | Have you coughed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523815","Extent Have Hoarse Voice","C136513","A question about the extent to which an individual has or had a hoarse voice.","Extent Have Hoarse Voice | Extent of Hoarse Voice | Have you been hoarse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524372","Extent Have Felt Ill","C136520","A question about the extent to which an individual feels or felt ill.","Extent Have Felt Ill | Have you felt ill",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524373","Extent Appearance Bothers You","C136521","A question about the extent to which an individual's appearance bothers or bothered them.","Extent Appearance Bothers You | Has your appearance bothered you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524370","Extent Have Trouble Eating","C136522","A question about the extent to which an individual has or had trouble eating.","Extent Have Trouble Eating | Extent of Trouble Eating | Have you had problems eating | Have you had trouble eating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524371","Extent Have Trouble Eating in Front of Family","C136523","A question about the extent to which an individual has or had trouble eating in front of their family.","Extent Have Trouble Eating in Front of Family | Extent of Trouble Eating in Front of Family | Have you had problems eating in front of your family | Have you had trouble eating in front of your family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524376","Extent Have Trouble Eating in Front of Other People","C136524","A question about the extent to which an individual has or had trouble eating in front of other people.","Extent Have Trouble Eating in Front of Other People | Extent of Trouble Eating in Front of Other People | Have you had problems eating in front of other people | Have you had trouble eating in front of other people",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524377","Extent Have Trouble Enjoying Meals","C136525","A question about the extent to which an individual has or had trouble enjoying meals.","Extent Have Trouble Enjoying Meals | Extent of Trouble Enjoying Meals | Have you had problems enjoying your meals | Have you had trouble enjoying your meals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524374","Extent Have Trouble Talking to Other People","C136526","A question about the extent to which an individual has or had trouble talking to other people.","Extent Have Trouble Talking to Other People | Extent of Trouble Talking to Other People | Have you had problems talking to other people | Have you had trouble talking to other people",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524375","Extent Have Trouble Talking on the Telephone","C136527","A question about the extent to which an individual has or had trouble talking on the telephone.","Extent Have Trouble Talking on the Telephone | Extent of Trouble Talking on the Telephone | Have you had problems talking on the telephone | Have you had trouble talking on the telephone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524354","Extent Have Trouble Having Social Contact with Family","C136528","A question about the extent to which an individual has or had trouble having social contact with their family.","Extent Have Trouble Having Social Contact with Family | Extent of Trouble Having Social Contact with Family | Have you had trouble having social contact with your family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524355","Extent Have Trouble Having Social Contact with Friends","C136529","A question about the extent to which an individual has or had trouble having social contact with friends.","Extent Have Trouble Having Social Contact with Friends | Extent of Trouble Having Social Contact with Friends | Have you had trouble having social contact with friends",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524352","Extent Have Trouble Going out in Public","C136530","A question about the extent to which an individual has or had trouble going out in public.","Extent Have Trouble Going out in Public | Extent of Trouble Going out in Public | Have you had problems going out in public | Have you had trouble going out in public",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524353","Extent Have Trouble Having Physical Contact with Family or Friends","C136531","A question about the extent to which an individual has or had having physical contact with family or friends.","Extent Have Trouble Having Physical Contact with Family or Friends | Extent of Trouble Having Physical Contact with Family or Friends | Have you had trouble having physical contact with family or friends",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524358","Extent Feel Less Interest in Sex","C136532","A question about the extent to which an individual feels or felt less interest in sex.","Extent Feel Less Interest in Sex | Have you felt less interest in sex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524359","Extent Feel Less Sexual Enjoyment","C136533","A question about the extent to which an individual feels or felt less sexual enjoyment.","Extent Feel Less Sexual Enjoyment | Have you felt less sexual enjoyment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524357","Have Used Pain-killers","C136535","A question about whether an individual uses or used pain-killers.","Have Used Pain-killers | Have Used Pain Medication | Have you used pain-killers | Taken Pain Medication | Used Pain Medication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524361","Have Taken Nutritional Supplements","C136536","A question about whether an individual has or had taken any nutritional supplements (excluding vitamins).","Have Taken Nutritional Supplements | Have Taken Nutritional Supplements Other Than Vitamins | Have you taken any nutritional supplements (excluding vitamins)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524362","Have Used Feeding Tube","C136537","A question about whether an individual uses or used a feeding tube.","Have Used Feeding Tube | Have you used a feeding tube | Used Feeding Tube",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347449","Participating Clinical Study Organization","C70791","An organization that participates in activities conducted in a framework of a particular clinical trial.","Participating Clinical Study Organization | Clinical Study Participating Organization | Participating Clinical Study Site | Participating Organization | Participating Study Site | Study Participating Organization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447088","ECOG Performance Status","C105721","A performance status scale designed to assess disease progression and its affect on the daily living abilities of the patient.","ECOG Performance Status | ECOG | ECOG Score | Eastern Cooperative Oncology Group Performance Status | ecog performance status | ecog_performance_status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515364","Therapeutic Clinical Trial","C39536","A clinical study that involves administering of exposure to the agent/agents to subjects with particular disease to elucidate the most appropriate treatment for a specific medical condition, or to prolong or improve the patient's life.","Therapeutic Clinical Trial | Clinical Trials, Therapy | Therapeutic Trial | Therapeutic Trials",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523548","MET Fusion Gene Positive","C136235","An indication that a MET fusion gene has been detected in a sample.","MET Fusion Gene Positive | HGFR Fusion Gene Positive | Hepatocyte Growth Factor Receptor Fusion Gene Positive | MET Gene Fusion | MET Proto-Oncogene, Receptor Tyrosine Kinase Fusion Gene Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523598","MET NP_000236.2:p.Y1003X","C136287","A change in the amino acid residue at position 1003 in the hepatocyte growth factor receptor protein where tyrosine has been replaced by another amino acid.","MET NP_000236.2:p.Y1003X | C-MET Tyr1003Xxx | C-MET Y1003X | HGF Receptor Tyr1003Xxx | HGF Receptor Y1003X | HGFR Tyr1003Xxx | HGFR Y1003X | Hepatocyte Growth Factor Receptor Tyr1003Xxx | Hepatocyte Growth Factor Receptor Y1003X | MET NP_000236.2:p.Tyr1003Xxx | NP_000236.2:p.Tyr1003Xxx | NP_000236.2:p.Y1003X | Proto-Oncogene c-Met Tyr1003Xxx | Proto-Oncogene c-Met Y1003X | Scatter Factor Receptor Tyr1003Xxx | Scatter Factor Receptor Y1003X | Tyrosine-Protein Kinase Met Tyr1003Xxx | Tyrosine-Protein Kinase Met Y1003X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523716","Blasts 5 Percent or More of Bone Marrow Nucleated Cells","C136411","A microscopic finding indicating the presence of blasts constituting at least 5% of the nucleated cells in a bone marrow aspirate.","Blasts 5 Percent or More of Bone Marrow Nucleated Cells | Blasts Greater than or Equal to 5 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523857","<2","C136415","An indication that a blood concentration of prostate specific antigen below 2 ng/mL was detected in a sample.","PSA Level Less than Two | <2 | Less than Two | PSA Level Less Than Two | PSA Level Less than 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524356","PSA Level Greater than or Equal to Ten","C136534","A blood concentration of prostate specific antigen greater than or equal to 10 ng/mL.","PSA Level Greater than or Equal to Ten | PSA Level 10 or Greater | PSA Level Greater than or Equal to 10 | PSA Level Ten or Greater",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2742734","Ravtansine","C136538","A tubulin-binding maytansinoid. Ravtansine binds to tubulin at the maytansine-binding site, which disrupts microtubule assembly/disassembly dynamics and inhibits mitosis.","Ravtansine | DM 4 | DM-4 | DM4 | N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)-maytansine | N2'-[4-[(3-carboxypropyl)dithio]-4-methyl-1-oxo-2-sulfopentyl]-N2'-deacetylmaytansine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524416","IDH Family Wildtype","C136567","A genetic finding indicating that no nucleotide sequence change has been detected in any IDH family gene.","IDH Family Wildtype | IDH Family Gene Mutation Negative | IDH Gene Family Wildtype | IDH Gene Mutation Negative | IDH Mutation Negative | IDH Wild Type | IDH Wildtype | IDH wt Allele | IDP Gene Mutation Negative | Isocitrate Dehydrogenase (NADP+) Gene Family Wildtype | Isocitrate Dehydrogenase Gene Family Wild Type | Negative | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524495","SMARCB1 Gene Mutation","C136623","A change in the nucleotide sequence of the SMARCB1 gene.","SMARCB1 Gene Mutation | BAF47 Gene Mutation | Ini1 Gene Mutation | SNF5 Gene Mutation | SNF5L1 Gene Mutation | SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily B, Member 1 Gene Mutation | Snr1 Gene Mutation | hSNFS Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524469","NFKB2 Gene Rearrangement","C136625","A molecular abnormality indicating rearrangement of the NFKB2 gene.","NFKB2 Gene Rearrangement | H2TF1 Gene Rearrangement | LYT-10 Gene Rearrangement | LYT10 Gene Rearrangement | NF-kB2 Gene Rearrangement | Nuclear Factor Kappa B Subunit 2 Gene Rearrangement | p100 Gene Rearrangement | p49/p100 Gene Rearrangement | p52 Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524466","Pyruvate Kinase PKM Isoform M2 Dimer","C136626","A homodimer of the pyruvate kinase PKM isoform M2. This enzyme complex promotes cellular metabolism and is overexpressed in tumors.","Pyruvate Kinase PKM Isoform M2 Dimer | M2-PK | Tumor M2-PK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524467","Blasts 21-30 Percent of Bone Marrow Nucleated Cells","C136627","A semi-quantitative microscopic finding indicating that 21-30 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 21-30 Percent of Bone Marrow Nucleated Cells | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524472","PSA Level Greater than Five","C136628","A blood concentration of prostate specific antigen greater than 5 ng/mL.","PSA Level Greater than Five | PSA Level Greater than 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524473","ESR1 Gene Mutation","C136629","A change in the nucleotide sequence of the ESR1 gene.","ESR1 Gene Mutation | ER Gene Mutation | ERA Gene Mutation | ESR Gene Mutation | ESRA Gene Mutation | Estrogen Receptor 1 Gene Mutation | Estrogen Receptor Gene Mutation | NR3A1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524470","Elevated Alpha-Fetoprotein","C136630","A finding indicating elevated concentrations of alpha-fetoprotein in a sample.","Elevated Alpha-Fetoprotein | Elevated AFP | Elevated Alpha Fetoprotein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524471","Elevated Human Chorionic Gonadotropin","C136631","A finding indicating elevated concentrations of human chorionic gonadotropin in a sample.","Elevated Human Chorionic Gonadotropin | Elevated HCG | Elevated Human Chorionicgonadotropin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524474","Non-synonymous FLT3 Gene Mutation","C136634","A point mutation in the FLT3 gene that encodes an amino acid substitution in the receptor-type tyrosine-protein kinase FLT3 protein.","Non-synonymous FLT3 Gene Mutation | FLT3 Missense Mutation | Non-synonymous CD135 Gene Mutation | Non-synonymous FLK2 Gene Mutation | Non-synonymous FLT3 Gene Mutant | Non-synonymous FMS-Related Tyrosine Kinase 3 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524475","Non-synonymous KIT Gene Mutation","C136635","A point mutation in the KIT gene that encodes an amino acid substitution in the mast/stem cell growth factor receptor Kit protein.","Non-synonymous KIT Gene Mutation | C-KIT Missense Mutation | KIT Missense Mutation | Non-synonymous CD117 Gene Mutation | Non-synonymous KIT Proto-Oncogene Tyrosine Protein Kinase Gene Mutation | Non-synonymous V-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Gene Mutation | Non-synonymous c-KIT Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524480","Non-synonymous RAS Family Gene Mutation","C136636","A point mutation in a gene that is a member of the RAS gene family that encodes an amino acid substitution in a RAS family protein.","Non-synonymous RAS Family Gene Mutation | RAS Family Gene Missense Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524481","Non-synonymous RAF Family Gene Mutation","C136637","A point mutation in a gene that is a member of the RAF gene family that encodes an amino acid substitution in a RAF family protein.","Non-synonymous RAF Family Gene Mutation | Non-Synonymous Rapidly Accelerated Fibrosarcoma Family Gene Mutation | Non-Synonymous Rapidly Accelerated Fibrosarcoma Kinase Family Gene Mutation | RAF Family Gene Missense Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524478","Non-synonymous MAPK Family Gene Mutation","C136638","A point mutation in a gene that is a member of the MAPK gene family that encodes an amino acid substitution in a MAPK family protein.","Non-synonymous MAPK Family Gene Mutation | ERK Family Gene Missense Mutation | MAPK Family Gene Missense Mutation | Non-synonymous ERK Family Gene Mutation | Non-synonymous Extracellular Signal-Regulated Kinase Family Gene Mutation | Non-synonymous Mitogen-Activated Protein Kinase Family Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524479","Non-synonymous MAP2K Family Gene Mutation","C136639","A point mutation in a gene that is a member of the MAP2K gene family that encodes an amino acid substitution in a MAP2K family protein.","Non-synonymous MAP2K Family Gene Mutation | MAP2K Family Gene Missense Mutation | MEK Family Gene Missense Mutation | Non-synonymous MAPKK Family Gene Mutation | Non-synonymous MEK Family Gene Mutation | Non-synonymous Mitogen-Activated Protein Kinase Kinase Family Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524453","Non-synonymous STAT Family Gene Mutation","C136640","A point mutation in a gene that is a member of the STAT gene family that encodes an amino acid substitution in a STAT family protein.","Non-synonymous STAT Family Gene Mutation | Non-synonymous Signal Transducer and Activator of Transcription Family Gene Mutation | STAT Family Gene Missense Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524454","Non-synonymous JAK Family Gene Mutation","C136641","A point mutation in a gene that is a member of the JAK gene family that encodes an amino acid substitution in a JAK family protein.","Non-synonymous JAK Family Gene Mutation | JAK Family Gene Missense Mutation | Non-synonymous Janus Kinase Family Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524451","Non-synonymous VEGFR Family Gene Mutation","C136642","A point mutation in a gene that is a member of the VEGFR gene family that encodes an amino acid substitution in a VEGFR family protein.","Non-synonymous VEGFR Family Gene Mutation | Non-synonymous Vascular Endothelial Growth Factor Receptor Family Gene Mutation | VEGFR Family Gene Missense Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524452","Non-synonymous PDGFR Family Gene Mutation","C136643","A point mutation in a gene that is a member of the PDGFR gene family that encodes an amino acid substitution in a PDGFR family protein.","Non-synonymous PDGFR Family Gene Mutation | Non-synonymous Platelet Derived Growth Factor Receptor Family Gene Mutation | PDGFR Family Gene Missense Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524457","NOTCH Family Gene Mutation","C136644","A change in the nucleotide sequence of a gene that is a member of the NOTCH gene family.","NOTCH Family Gene Mutation | NOTCH Gene Mutation | Notch Receptor Gene Family Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524458","CBL Gene Mutation","C136645","A change in the nucleotide sequence of the CBL gene.","CBL Gene Mutation | C-CBL Gene Mutation | Cas-Br-M Murine Ecotropic Retroviral Transforming Sequence Gene Mutation | Casitas B-Lineage Lymphoma Proto-Oncogene Mutation | Cbl Proto-Oncogene Gene Mutation | RNF55 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524455","PSA Level Greater than Twenty","C136646","A blood concentration of prostate specific antigen greater than 20 ng/mL.","PSA Level Greater than Twenty | PSA Level Greater than 20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524456","JAK3 Gene Mutation","C136647","A change in the nucleotide sequence of the JAK3 gene.","JAK3 Gene Mutation | JAK-3 Gene Mutation | JAK3 | JAKL Gene Mutation | Janus Kinase 3 (A Protein Tyrosine Kinase, Leukocyte) Gene Mutation | Janus Kinase 3 Gene Mutation | Janus Kinase, Leukocyte Gene Mutation | L-JAK Gene Mutation | LJAK Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524461","Blasts 10 Percent or More of Bone Marrow Nucleated Cells","C136648","A semi-quantitative microscopic finding indicating that at least 10 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 10 Percent or More of Bone Marrow Nucleated Cells | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334843","Myeloblasts 5-19 Percent of Bone Marrow Nucleated Cells","C36229","A semi-quantitative microscopic finding indicating that 5-19 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells of myeloid origin.","Myeloblasts 5-19 Percent of Bone Marrow Nucleated Cells | Myeloblasts 5-19% of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514063","Neoplastic Plasma Cells 10 Percent or More of Bone Marrow Nucleated Cells","C41031","A semi-quantitative microscopic finding indicating that at least 10 percent of the nucleated cells in a bone marrow sample are neoplastic plasma cells.","Neoplastic Plasma Cells 10 Percent or More of Bone Marrow Nucleated Cells | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511213","Blasts Under 20 Percent of Bone Marrow Nucleated Cells","C41397","A semi-quantitative microscopic finding indicating that less than 20 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts Under 20 Percent of Bone Marrow Nucleated Cells | Blasts Less than 20 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511210","Blasts 5-19 Percent of Peripheral Blood White Cells","C41400","A semi-quantitative microscopic finding indicating that 5-19 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.","Blasts 5-19 Percent of Peripheral Blood White Cells | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524515","Immune-Modified Response Evaluation Criteria in Solid Tumors","C136711","A modification of the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, for use as a standard approach to solid tumor measurements and definitions for objective change in tumor size in cancer clinical trials in which an immunotherapy is used.","Immune-Modified Response Evaluation Criteria in Solid Tumors | Immune-Modified Response Evaluation Criteria in Solid Tumors (iRECIST) | iRECIST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053901","Unconfirmed Progressive Disease","C123607","A disease process that is increasing in scope or severity but the criteria for progressive disease is not met.","Unconfirmed Progressive Disease | PD Unconfirmed | PDu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0044730","Prostaglandin E2 Metabolite","C129896","Molecules created during the catabolism of prostaglandin E2 (PGE2). The presence of these metabolic products in urine can be correlated with the amount of PGE2 synthesis.","Prostaglandin E2 Metabolite | PGE Metabolite | PGE-M | PGE2 Metabolite | PGE2-M | Prostaglandin E Metabolite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512847","2-Hour Postprandial Glucose","C129778","The amount of glucose present in a sample two hours after a subject has eaten a meal.","2-Hour Postprandial Glucose | 2 Hour Glucose | 2 Hour Postprandial Glucose | 2 hr Glucose | 2 hr Postprandial Glucose | 2-Hour Glucose | 2h Glucose | 2h Postprandial Glucose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512848","2-Hour Postprandial Insulin","C129779","The amount of insulin present in a sample two hours after a subject has eaten a meal.","2-Hour Postprandial Insulin | 2 Hour Postprandial Insulin | 2 hr Postprandial Insulin | 2h Postprandial Insulin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512671","Apoptotic Index","C129675","The percentage or fraction of cells in a biological specimen that are undergoing apoptosis.","Apoptotic Index | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417490","MUC1 Gene","C38939","This gene plays a role in cellular signal transduction and is used as a biomarker for breast cancer.","MUC1 Gene | MUC1 | Mucin 1, Cell Surface Associated Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512719","Phosphorylated Histone H2AX","C129645","A post-translationally modified form of variant histone H2AX where the serine residue at position 139 and/or the tyrosine residue at 142 is phosphorylated. Phosphorylation of serine-139 may be a marker for DNA damage. While phosphorylation or dephosphorylation of tyrosine-142 appears to affect the recruitment of pro-apoptotic factors or DNA repair proteins, respectively.","Phosphorylated Histone H2AX | Gamma H2AX | Gamma-H2AX | Phospho-H2AX | Phosphorylated Histone H2A.X | Phosphorylated Histone H2a/x | Phosphorylated-H2A.X | Phosphorylated-H2a/x",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413366","CGA Gene","C129840","This gene plays a role in protein hormone signaling.","CGA Gene | CGA | Glycoprotein Hormones, Alpha Polypeptide Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538298","ATXN1 Gene","C129915","This gene is involved in both RNA metabolism and chromatin binding.","ATXN1 Gene | ATXN1 | Ataxin 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2350466","Natural Killer T-Cell","C129906","A subset of T-lymphocytes that coexpress an alpha/beta T-cell receptor, and variety of molecular markers that are typically associated with natural killer (NK) cells, which may include CD161, CD16, CD68, and granzyme. NK T-cells recognize glycolipids presented by antigen-presenting glycoprotein CD1d on antigen presenting cells; antigen recognition stimulates a rapid release of various cytokines from the NK T-cells.","Natural Killer T-Cell | NK T-Cell | NKT Cell | Natural Killer T Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513013","TRAF1-C5 Locus","C129881","An intergenic gene locus on the short arm of human chromosome 9 located between the TRAF1 and C5 genes. Polymorphism in this region may be associated with increased susceptibility for rheumatoid arthritis.","TRAF1-C5 Locus | TRAF1-C5 | TRAF1/C5 | TRAF1C5 | Tumor Necrosis Factor-Receptor Associated Factor 1/Complement Component 5 Gene Locus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0369169","Epstein-Barr Virus DNA","C129661","The viral DNA that originates from Epstein-Barr virus.","Epstein-Barr Virus DNA | EBV DNA | HHV-4 DNA | HHV4 DNA | Human Herpesvirus 4 DNA | Human Herpesvirus-4 DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0058990","Eukaryotic Initiation Factor-4G","C129656","A family of proteins that are part of the eukaryotic translation initiation factor 4F complex (eIF4F). The members of the family play a role in recognition of the 5' cap on messenger RNA and the initiation of translation.","Eukaryotic Translation Initiation Factor 4 Gamma Family | Eukaryotic Translation Initiation Factor 4 Gamma | eIF-4-gamma | eIF-4G | eIF4G | eIF4G Family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513004","MicroRNA Expression Profile","C129767","An analysis of all of the microRNA molecules expressed in a biological sample.","MicroRNA Expression Profile | MicroRNA Expression | MicroRNA Profile | miRNA Expression Profile | miRNA Profile | miRNA Profiling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513012","TGF-Beta Responsive Gene Signature","C129769","A data set that determines the expression of genes that are modulated by transforming growth factor beta-dependent signaling pathways.","TGF-Beta Responsive Gene Signature | TGF-Beta Responsive Signature | Transforming Growth Factor Beta Responsive Gene Signature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512556","Human Immunodeficiency Virus RNA","C129663","The viral RNA that originates from a human immunodeficiency virus.","Human Immunodeficiency Virus RNA | HIV RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513050","Hematogenous CSF Blasts","C129905","A morphologic finding indicating the presence of blasts in a sample of cerebrospinal fluid.","Hematogenous CSF Blasts | CSF Blasts | Hematogenous Cerebrospinal Fluid Blasts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428338","INHBE Gene","C129846","This gene plays a role in the regulation of hormone signaling.","INHBE Gene | INHBE | Inhibin Beta E Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519082","Pigment Epithelium","C13177","Tissue consisting of one or more layers of epithelial cells and a basement membrane. The cells contain granules of pigment or melanin, as in the retinal or iris pigment layer.","Pigment Epithelium | Pigmented Epithelium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521310","Sickle Cell-SS Disease","C131682","A variant of sickle cell disease due to homozygosity of the E6V mutation, amino acid substitution of valine for glutamic acid in the sixth position of the beta chain, resulting in the production of hemoglobin S from both alleles.","Sickle Cell-SS Disease | Hb SS | Hemoglobin SS | Hemoglobin SS Disease | Sickle Cell (SS only)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1291743","Catecholamine Metabolite","C129882","Molecules created during the catabolism of catecholamine hormones. Increased concentrations of these metabolic products in plasma and urine may indicate the presence of hormone-producing pheochromocytomas or paragangliomas.","Catecholamine Metabolite | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512653","ERBB2 Antibody","C129670","Any immunoglobulin that recognizes receptor tyrosine-protein kinase erbB-2 protein.","ERBB2 Antibody | Anti-HER-2 Antibody | Anti-HER2 Antibody | Anti-HER2/Neu Antibody | Anti-NEU Antibody | Anti-Proto-Oncogene Neu Antibody | Anti-Receptor Tyrosine-Protein Kinase erbB-2 Antibody | Anti-Tyrosine Kinase-Type Cell Surface Receptor HER2 Antibody | Anti-c-erbB2 Antibody | HER-2 Antibody | HER2 Antibody | HER2/Neu Antibody | NEU Antibody | Receptor Tyrosine-Protein Kinase erbB-2 Antibody | Tyrosine Kinase-Type Cell Surface Receptor HER2 Antibody | c-erbB2 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512648","MUC1 Antibody","C129671","Any immunoglobulin that recognizes mucin-1 protein.","MUC1 Antibody | Anti-CD227 Antibody | Anti-Epithelial Membrane Antigen Antibody | Anti-MUC1 Antibody | Anti-Mucin 1 Antibody | Anti-Mucin-1 Antibody | CD227 Antibody | Epithelial Membrane Antigen Antibody | Mucin 1 Antibody | Mucin-1 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513036","Poly-ADP-Ribosylation","C129759","The transfer of multiple ADP-ribose molecules to amino acids within target proteins.","Poly-ADP-Ribosylation | PARsylation | PARylation | Poly-ADP Ribosylation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512999","Chemokine Expression Profile","C129894","The identification and quantitation of all of the chemokines expressed in a biological sample.","Chemokine Expression Profile | Chemokine Profile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514301","MAGEA10 Positive","C131619","An indication that melanoma-associated antigen 10 expression has been detected in a sample.","MAGEA10 Positive | CT1.10 Positive | Cancer/Testis Antigen 1.10 Positive | MAGE-10 Antigen Positive | Melanoma Antigen 10 Positive | Melanoma-Associated Antigen 10 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416933","LTF Gene","C94663","This gene is involved in both the transport of iron and proteolysis.","LTF Gene | LTF | Lactotransferrin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514487","EGFR T790M Mutation Negative","C131326","Indicates that the T790M mutation of the epidermal growth factor receptor gene has not been detected in a sample.","EGFR T790M Mutation Negative | EGFR NP_005219.2:p.T790M Negative | EGFR NP_005219.2:p.Thr790Met Negative | EGFR Thr790Met Mutation Negative | EGFR p.T790M Mutation Negative | Epidermal Growth Factor Receptor T790M Negative | Proto-Oncogene c-ErbB-1 T790M Negative | Receptor Tyrosine-Protein Kinase erbB-1 T790M Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273083","EGFR-TKI Sensitizing Mutation","C96861","A molecular genetic abnormality indicating the presence of a sensitizing mutation in the epidermal growth factor receptor-tyrosine kinase inhibitor domain.","EGFR-TKI Sensitizing Mutation | EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Sensitivity | EGFR Tyrosine Kinase Inhibitor Sensitizing Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054670","Lack of Expression of PD-L1","C122809","An immunohistochemical test result that indicates lack of expression of PD-L1 in a tissue sample of a primary or metastatic malignant neoplasm.","Lack of Expression of PD-L1 | B7 Homolog 1 Negative | B7-H Negative | B7H1 Negative | CD274 Antigen Negative | CD274 Molecule Negative | CD274 Negative | Negative | PD-L1 Negative | PDCD1L1 Negative | PDCD1LG1 Negative | PDL1 Negative | Programmed Cell Death 1 Ligand 1 Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514655","Human Papillomavirus-18 Positive","C131711","An indication that human papillomavirus-18 has been detected in a sample.","Human Papillomavirus-18 Positive | HPV-18 Positive | HPV18 Positive | Human Papilloma Virus 18 Positive | Human Papilloma Virus-18 Positive | Human Papillomavirus 18 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514637","HLA-A*0206 Positive Cells Present","C131444","An indication that cells expressing HLA-A*0206 have been detected in a sample.","HLA-A*0206 Positive Cells Present | HLA-A*0206 Positive | HLA-A*02:06 Positive | HLA-A*02:06 Positive Cells Present | HLA-A0206 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040139","Thyroid Stimulating Immunoglobulin","C129780","An immunoglobulin that can bind to thyrotropin receptors expressed on thyroid gland cells and stimulates excess secretion of the thyroid hormones thyroxine (T4) and triiodothyronine (T3).","Thyroid Stimulating Immunoglobulin | TSI",,,,,,,,,,,,,,,"4012396|4012853","Thyrotropin receptor antibody|Thyroid stimulating immunoglobulins",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0146462","E2F transcription factors","C129647","A family of transcription factors that bind to the consensus sequence 5'-TTTC[CG]CGC-3' and regulate the transcription of genes involved in cell cycle regulation, DNA repair and DNA replication.","E2F Transcription Factor Family | E2F | E2F Family | E2F Transcription Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514040","Circulating Tumor-Reactive T-Cell","C131128","A population of T-lymphocytes that can mount an immune response against circulating tumor cells. These cells may spontaneously arise as a response to the presence of either endogenous tumor antigens or exogenous tumor antigens administered as a cancer vaccine.","Circulating Tumor-Reactive T-Cell | Circulating Tumor Reactive T Cell | Circulating Tumor Reactive T-Cell | Circulating Tumor-Reactive CD8-Positive T-Cell | Circulating Tumor-Reactive T Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512925","Receptor Tyrosine-Protein Kinase erbB-2 Carboxyl Terminal Fragment","C129898","Receptor tyrosine-protein kinase erbB-2 carboxyl terminal fragment is encoded by the human ERBB2 gene. This protein may be involved in tyrosine kinase activity and may be associated with increased cancer severity.","Receptor Tyrosine-Protein Kinase erbB-2 Carboxyl Terminal Fragment | ERBB2 C-Terminal Fragment | ERBB2 CTF | ERBB2 Carboxyl Terminal Fragment | ERBB2-p95 | HER2 C-Terminal Fragment | HER2 CTF | HER2-p95 | HER2/neu CTF | HER2/neu-p95 | Receptor Tyrosine-Protein Kinase erbB-2 C-Terminal Fragment | Receptor Tyrosine-Protein Kinase erbB-2 CTF | p95 HER2 | p95HER2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512937","Myeloid-Derived Suppressor Cells","C129908","A population of myeloid cells, mainly dendritic cells, macrophages and neutrophils, that have immunosuppressive activity. During inflammation, chronic infection or cancer, these cells may promote angiogenesis or tumor cell invasion.","Myeloid-Derived Suppressor Cell | MDSC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512890","Single Nucleotide Polymorphism Profile","C129888","The analysis of all of the single nucleotide polymorphisms in the genome of a biological sample.","Single Nucleotide Polymorphism Profile | SNP Profile | SNP genotyping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005290","Beta Tubulin","C129655","A family of globular proteins that form dimers with alpha tubulins. The alpha-beta tubulin dimers polymerize in a guanosine triphosphate (GTP)-dependent fashion to form microtubules.","Beta Tubulin | Beta-Tubulin | Tubulin Beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2350479","Natural Cytotoxicity Receptor Family","C129776","A family of receptors belonging to the immunoglobulin superfamily that are mainly expressed on natural killer (NK) cells. Natural cytotoxicity receptors (NCR) bind to a broad range of ligands derived from microbes, tumors, and endogenous sources. Predominantly, ligand binding leads to the activation of NK cells, which stimulates cell-mediated cytotoxic immune responses, but some ligands may inhibit NK cell activation.","Natural Cytotoxicity Receptor Family | NCR | NCR Family | NK Cell-Activating Receptor | Natural Cytotoxicity Receptor | Natural Cytotoxicity Triggering Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0238425","Vaso-Occlusive Crisis","C122412","An exacerbation of sickle cell disease.","Vaso-Occlusive Crisis | Sickle Cell Crisis",,,,,,,,,,,,,,,"26942","Hemoglobin SS disease with crisis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0231225","Pain Crisis","C136820","An event in which the patient reports pain that is severe, uncontrolled, and causing distress for the patient, family members, or both.","Pain Crisis | ",,,,,,,,,,,,,,,"4217581","Pain crisis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512883","PPY Gene Product","C129911","A protein encoded by the PPY gene.","PPY Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513040","Telomere Length","C129765","The number of nucleotide base pairs located in the telomere of a chromosome. Telomere length decreases during each cell division and can be a marker for aging. Additionally, aberrant length can be an indicator of cell transformation.","Telomere Length | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512942","Red Cell Fatty Acid Profile","C129895","The identification and quantitation of all of the fatty acids expressed in the red blood cells isolated from a subject.","Red Cell Fatty Acid Profile | RBC FA Profile | Red Blood Cell Fatty Acid Profile | Red Cell Fatty Acid Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512707","MSLN Antibody","C129681","Any immunoglobulin that recognizes mesothelin protein.","MSLN Antibody | Anti-CAK1 Antibody | Anti-MSLN Antibody | Anti-Mesothelin Antibody | Anti-Pre-Pro-Megakaryocyte-Potentiating Factor Antibody | CAK1 Antibody | Mesothelin Antibody | Pre-Pro-Megakaryocyte-Potentiating Factor Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513029","Global DNA Methylation Profile","C129903","The analysis of all of the methylated nucleotides present in the genome in a biological sample.","Global DNA Methylation Profile | DNA MI | DNA Methylation Index | DNA Methylation Profile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512606","CTAG1 Antibody","C129682","Any immunoglobulin that recognizes cancer/testis antigen 1 protein.","CTAG1 Antibody | Anti-CTAG1 Antibody | Anti-Cancer/Testis Antigen 1 Antibody | Anti-NY-ESO-1 Antibody | Cancer/Testis Antigen 1 Antibody | NY-ESO-1 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513051","Total RNA Expression Profile","C129766","An analysis of all of the RNA molecules expressed in a biological sample.","Total RNA Expression Profile | Total RNA | Total RNA Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513049","Serum-Ascites Albumin Gradient","C129777","A value determined by subtracting the concentration of albumin in ascites fluid from its concentration in the serum where both samples come from one subject. High values indicate portal hypertension and a non-peritoneal cause for ascites; while low values indicate non-portal hypertension and a peritoneal origin of ascites.","Serum-Ascites Albumin Gradient | SAAG | Serum-Ascites Albumin Gap",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512616","Colony Forming Unit-Endothelial Cells","C129679","A population of adherent cells in fibronectin-coated culture that resemble endothelial cells.","Colony Forming Unit-Endothelial Cells | CFU-EC | EC-CFU | Endothelial Cell-Colony Corming Unit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443705","Epstein-Barr Virus Capsid Antigen Antibody","C129678","Any immunoglobulin that recognizes Epstein-Barr virus capsid protein.","Epstein-Barr Virus Capsid Antigen Antibody | Anti-EBV VCA | Anti-EBV VCA-Ig | Anti-Epstein-Barr Virus Capsid Antibody | Anti-Epstein-Barr Virus Capsid Antigen Antibody | EBV VCA Antibody | EBV VCA-Ig | Epstein-Barr Virus Capsid Antibody",,,,,,,,,,,,,,,"4022177","Epstein-Barr virus capsid antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513039","TNF Repeat","C129764","A group of five microsatellite repeats that are either upstream of the LTA gene or downstream of the TNF gene. TNF repeat polymorphism may influence either lymphotoxin-alpha or tumor necrosis factor protein expression, may be associated with certain diseases, or may be used to facilitate population genetics studies.","TNF Repeat | TNF Allele | TNF Haplotype | TNF Microsatellite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826327","PTPN11 Gene Mutation","C82612","Mutation of the protein tyrosine phosphatase, non-receptor type 11 gene. It is seen in cases of juvenile myelomonocytic leukemia.","PTPN11 Gene Mutation | BPTP3 Gene Mutation | PTP-1D Gene Mutation | PTP2C Gene Mutation | PTPN11 | PTPN11 Mutation | Protein Tyrosine Phosphatase Non-Receptor Type 11 Gene Mutation | Protein Tyrosine Phosphatase, Non-Receptor Type 11 Gene Mutation | SH-PTP2 Gene Mutation | SHP-2 Gene Mutation | SHP2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512980","Hypermethylation Profile","C129892","The identification and quantitation of sites for DNA hypermethylation in the genome of a biological sample.","Hypermethylation Profile | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513010","Total Phosphotyrosine","C129770","A data set that quantifies the concentration of all of the tyrosine phosphorylated proteins in a biological sample or specimen.","Total Phosphotyrosine | Total p-Tyr | Total pY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513101","Glucocorticoid Sensitivity","C131125","The ability of a biological specimen to respond to glucocorticoid-glucocorticoid receptor-dependent signaling.","Glucocorticoid Sensitivity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513003","Glioma-Associated Antigen","C129781","A tumor associated antigen derived from the cell surface antigens expressed on glioma cells.","Glioma-Associated Antigen | GAA | Glioma TAA | Glioma-type Tumor Associated Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512993","VLDL-C Oxidation","C129900","The presence of oxidized elements in cholesterol-bearing very low-density lipoprotein (VLDL) particles in the blood. Oxidation may be associated with increased risk for atherosclerosis.","VLDL-C Oxidation | Oxidized VLDL Cholesterol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512874","LDL-C Oxidation","C129899","The presence of oxidized elements in cholesterol-bearing low-density lipoprotein (LDL) particles in the blood. Oxidation may be associated with increased risk for atherosclerosis.","LDL-C Oxidation | Oxidized LDL Cholesterol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010749","Cytochromes c","C129851","Cytochrome c (105 aa, ~12 kDa) is encoded by the human CYCS gene. This protein is involved in the transfer of electrons between complex III and complex IV of the mitochondrial electron transport chain.","Cytochrome C | Cyt C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512632","HPV Transforming Protein E6 Antibody","C129667","Any immunoglobulin that recognizes HPV transforming protein E6.","HPV Transforming Protein E6 Antibody | Anti-HPV E6 Antibody | Anti-HPV Transforming Protein E6 Antibody | Anti-Human Papillomavirus Virus Transforming Protein E6 Antibody | HPV E6 Antibody | Human Papillomavirus Virus Transforming Protein E6 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512633","HPV Transforming Protein E7 Antibody","C129668","Any immunoglobulin that recognizes HPV transforming protein E7.","HPV Transforming Protein E7 Antibody | Anti-HPV E7 Antibody | Anti-HPV Transforming Protein E7 Antibody | Anti-Human Papillomavirus Virus Transforming Protein E7 Antibody | HPV E7 Antibody | Human Papillomavirus Virus Transforming Protein E7 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0136328","Prostaglandin I2 Metabolite","C129897","Molecules created during the catabolism of prostaglandin I2 (PGI2). The presence of these metabolic products in plasma and urine can be correlated with the amount of PGI2 synthesis.","Prostaglandin I2 Metabolite | PGI-M | PGI2 Metabolite | PGI2-M | PGI2-Metabolite | PGIM | Prostacyclin (PGI2)-Metabolite | Prostacyclin Metabolite | Prostaglandin I Metabolite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512672","Asparaginase Antibody","C129659","Any immunoglobulin that recognizes asparaginase.","Asparaginase Antibody | Anti-Asparaginase Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0427460","Erythrocyte Distribution Width Measurement","C64800","An index of the variation in the size of the red cells and can be used to detect subtle degress of anisocytosis. It is computed directly from the RBC histogram and is calculated as a standard statictical value, the coefficient of variation of the red cell volume ditribution (ratio of standard deviation and mean copuscular volume).","Erythrocyte Distribution Width Measurement | Erythrocytes Distribution Width | RDW | RDW-CV | Red Blood Cell Distribution Width | Red Cell Volume Distribution Width",,,,,,,,,,,,,,,"4281085","Red cell distribution width determination",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523509","Apolipoprotein B Measurement","C74734","The determination of the amount of apolipoprotein B present in a sample.","Apolipoprotein B Measurement | APOB | Apolipoprotein B",,,,,,,,,,,,,,,"4017617","Apolipoproteins B measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512597","Phosphorylated UL38 Antibody","C129672","Any immunoglobulin that recognizes phosphorylated forms of CMV apoptosis inhibitor UL38 protein.","ppUL38 Antibody | Anti-Phospho-UL38 Antibody | Anti-Phosphorylated Apoptosis Inhibitor UL38 Antibody | Anti-Phosphorylated UL38 Antibody | Anti-ppUL38 Antibody | Phospho-UL38 Antibody | Phosphorylated Apoptosis Inhibitor UL38 Antibody | Phosphorylated UL38 Antibody | ppUL83 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513035","Phosphoprotein Profile","C129758","A data set that both identifies phosphoproteins and quantifies their concentration in a biological sample or specimen.","Phosphoprotein Profile | Phospho-Protein Profile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512940","Telomeric Allelic Imbalance Region","C129774","A chromosomal aberration where the telomeric and subtelomeric regions of a chromosome does not have the expected 1:1 ratio for the alleles and telomeric sequences inherited from the two parental chromosomes.","Telomeric Allelic Imbalance Region | N(tAI) | NtAI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514234","Nuclear Factor NF-kappa-B p50 Subunit, Human","C131127","Nuclear factor NF-kappa-B p50 subunit (433 aa, ~48 kDa) is encoded by the human NFKB1 gene. This protein is involved in both transcriptional regulation and signal transduction.","Nuclear Factor NF-kappa-B p50 Subunit | NF-Kappa B p50 | NF-kB Subunit 1 p50 | NF-kappaB(p50) | NFKB p50 Subunit | Nuclear Factor Kappa-B Subunit 1 p50",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524737","London Deauville Criteria Point Scale X","C136879","New areas of uptake unlikely to be related to lymphoma.","London Deauville Criteria Point Scale X | London Deauville Criteria PET Point X | PET Score X | X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227875","Ovarian Surface Epithelium","C61518","No Value Exists","Ovarian Surface Epithelium | ",,,,,,,,,,,,,,,"4279458","Structure of germinal epithelium of ovary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152315","Fimbria","C32606","A fringe like structure.","Fimbria | ",,,,,,,,,,,,,,,"4077606","Structure of fimbria of hippocampus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1417602","NAT1 Gene","C129843","This gene is involved in detoxification of arylamine-containing compounds.","NAT1 Gene | N-Acetyltransferase 1 Gene | NAT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512559","IL15 Antibody","C129680","Any immunoglobulin that recognizes interleukin-15 protein.","IL15 Antibody | Anti-IL-15 Antibody | Anti-IL15 Antibody | Anti-Interleukin 15 Antibody | Anti-Interleukin-15 Antibody | IL-15 Antibody | Interleukin 15 Antibody | Interleukin-15 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035342","Retinol Binding Protein Family","C129901","A family of proteins that bind and transport retinol and/or retinoids.","Retinol Binding Protein Family | RBP | RBP Family | Retinol Binding Protein | Retinol-Binding Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512896","Genome-Wide Allelic Status","C129902","The analysis of all of the alleles present in the genome in a biological sample.","Genome-Wide Allelic Status | Allelic Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512887","Persistent Neuroblastic Cells","C129904","A morphologic finding indicating the continuing presence of neuroblastic cells in a set of tissue samples collected over time.","Persistent Neuroblastic Cells | Persistent Neuroblastic Cells Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513008","RAS Family Transcriptional Profile","C129761","A data set that both identifies the RAS family proteins that are present and quantifies their concentration in a biological sample or specimen.","RAS Family Transcriptional Profile | RAS Transcriptional Profile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513032","MYB/NFIB Fusion Gene","C129772","A fusion gene that results from a translocation t(6;9)(q22-23;p23-24) that fuses the first 8, 12 or 14 exons of the MYB gene upstream of exon 8 or 9 of the NFIB gene. This fusion is associated with adenoid cystic carcinomas.","MYB/NFIB Fusion Gene | MYB-NF-IB Fusion Gene | MYB-NF1-B Fusion Gene | MYB-NFI-B Fusion Gene | MYB-NFIB Fusion Gene | MYB/NF-IB Fusion Gene | MYB/NF1-B Fusion Gene | MYB/NFI-B Fusion Gene | MYB::NFIB Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513015","Th1 Cell/Th2 Cell Ratio Measurement","C129775","The determination of the ratio of type 1 T helper cells (Th1) compared to type 2 T helper cells (Th2) present in a sample.","Th1 Cell/Th2 Cell Ratio Measurement | Th1/Th2 | Th1/Th2 Ratio Measurement | Type 1 T Helper Cell/Type 2 T Helper Cell Ratio Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512865","Epigenetic Profile","C129887","The analysis of all of the epigenetic DNA modifications in the genome a biological sample.","Epigenetic Profile | Epigenetic Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516006","Antibody Repertoire","C19587","A data set that both identifies the isotype of antibodies and quantifies their concentration in a biological sample or specimen.","Antibody Repertoire | Antibody Profile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0486959","Human Immunodeficiency Virus DNA","C129662","DNA that is reverse transcribed from human immunodeficiency virus RNA.","Human Immunodeficiency Virus DNA | HIV DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521958","Colorectal Cancer by AJCC v8 Stage","C134180","A term that refers to the staging of colorectal cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to adenocarcinomas, high-grade neuroendocrine carcinomas, and squamous cell carcinomas of the colon and rectum. Appendiceal carcinomas, anal carcinomas, and well-differentiated neuroendocrine tumors (carcinoids) are not covered by this staging system. (from AJCC 8th Ed.)","Colorectal Cancer by AJCC v8 Stage | Colorectal Carcinoma by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0151453","None of the Above","C133298","None of the choices above are suitable.","None of the Above | None of the above",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521967","Stage III Colorectal Cancer AJCC v8","C134191","Stage III includes: IIIA: (T1-T2, N1/N1c, M0); (T1, N2a, M0); IIIB: (T3-T4a, N1/N1c, M0); (T2-T3, N2a, M0); (T1-T2, N2b, M0); IIIC: (T4a, N2a, M0); (T3-T4a, N2b, M0); (T4b, N1-N2, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). T4b: Tumor directly invades or adheres to adjacent organs or structures. N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N1c: No regional lymph nodes are positive, but there are tumor deposits in the subserosa, mesentery, or nonperitonealized pericolic, or perirectal/mesorectal tissues. N2: Four or more regional lymph nodes are positive. N2a: Four to six regional lymph nodes are positive. N2b: Seven or more regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Colorectal Cancer AJCC v8 | Stage III Colorectal (Colon or Rectal) Cancer | Stage III Colorectal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521962","Stage II Colorectal Cancer AJCC v8","C134186","Stage II includes: IIA: T3, N0, M0; IIB: T4a, N0, M0; IIC: T4b, N0, M0. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). T4b: Tumor directly invades or adheres to adjacent organs or structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Colorectal Cancer AJCC v8 | Stage II Colorectal (Colon or Rectal) Cancer | Stage II Colorectal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521961","Stage I Colorectal Cancer AJCC v8","C134185","Stage I includes: (T1, N0, M0); (T2, N0, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Colorectal Cancer AJCC v8 | Stage I Colorectal (Colon or Rectal) Cancer | Stage I Colorectal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4040298","Follicular Lymphoma International Prognostic Index","C136962","A prognostic index designed to be used for patients with follicular lymphoma to stratify them by risk. The index uses 5 parameters: age (greater than or equal to 60 years vs less than 60 years), Ann Arbor stage (III-IV vs I-II), hemoglobin level (less than 120 g/L vs greater than or equal to 120 g/L), number of nodal areas involved (greater than 4 vs less than or equal to 4), serum LDH level (above normal vs normal or below) and divides patients into 3 risk groups: low (0-1 risk factors), intermediate (2 risk factors), high (greater than or equal to 3 risk factors).","Follicular Lymphoma International Prognostic Index | FILIPI | FILIPI Score | Follicular Lymphoma International Prognostic Index (FLIPI Score)",,,,,,,,,,,,,,,"46270770","Follicular Lymphoma International Prognostic Index",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL524788","FLIPI Score 0-1, Low Risk","C136965","A score indicating that a patient has 0 or 1 risk factors associated with follicular lymphoma and is considered in the low risk group.","FLIPI Score 0-1, Low Risk | FLIPI Score 0-1 | Follicular Lymphoma International Prognostic Index Score 0-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524763","FLIPI Score 2, Intermediate Risk","C136967","A score indicating that a patient has 2 risk factors associated with follicular lymphoma and is considered in the intermediate risk group.","FLIPI Score 2, Intermediate Risk | FLIPI Score 2 | Follicular Lymphoma International Prognostic Index Score 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524760","FLIPI Score Greater than or Equal to 3, High Risk","C136968","A score indicating that a patient has 3 or more risk factors associated with follicular lymphoma and is considered in the high risk group.","FLIPI Score Greater than or Equal to 3, High Risk | FLIPI Score Greater than or Equal to 3 | Follicular Lymphoma International Prognostic Index Score Greater than or Equal to 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332614","Breast Angiosarcoma","C5184","A malignant vascular neoplasm arising from the breast.","Breast Angiosarcoma | Angiosarcoma of Breast | Angiosarcoma of the Breast | Breast Hemangiosarcoma | Hemangiosarcoma of Breast | Hemangiosarcoma of the Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332630","Breast Fibrosarcoma","C5185","A usually aggressive malignant neoplasm arising from the breast.  It is characterized by the presence of spindle-shaped fibroblasts and collagenous stroma formation in a herringbone growth pattern.","Breast Fibrosarcoma | Fibrosarcoma of Breast | Fibrosarcoma of the Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511313","Breast Hemangiopericytoma","C40396","A hemangiopericytoma arising from the breast.","Breast Hemangiopericytoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335964","Signet Ring Cell Carcinoma of Breast","C5175","An invasive breast adenocarcinoma characterized by the presence of malignant epithelial cells with signet ring appearance.","Breast Signet Ring Cell Adenocarcinoma | Breast Signet Ring Cell Carcinoma | Breast Signet Ring Cell Carcinoma | Breast Signet-Ring Cell Carcinoma | Mammary Signet Ring Cell Carcinoma | Primary Mammary Signet Ring Cell Carcinoma | Primary SRC Breast Carcinoma | Primary SRC Carcinoma of Breast | Primary SRC Carcinoma of the Breast | Primary Signet Ring Cell Breast Carcinoma | Primary Signet Ring Cell Carcinoma of Breast | Primary Signet Ring Cell Carcinoma of the Breast | SRC Breast Carcinoma | SRC Carcinoma of Breast | SRC Carcinoma of the Breast | Signet Ring Cell Breast Carcinoma | Signet Ring Cell Breast Carcinoma | Signet Ring Cell Carcinoma of Breast | Signet Ring Cell Carcinoma of the Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517894","Lipid Secreting Breast Carcinoma","C40365","An invasive breast carcinoma characterized by the presence of cytoplasmic neutral lipids in the vast majority of the malignant cells.","Breast Lipid-Rich Carcinoma | Lipid Secreting Breast Carcinoma | Lipid-Rich Breast Carcinoma | Lipid-Rich Breast Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332632","Breast Liposarcoma","C5187","A liposarcoma that arises from the breast parenchyma.","Breast Liposarcoma | Liposarcoma of Breast | Liposarcoma of the Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332631","Breast Leiomyosarcoma","C5186","An aggressive malignant smooth muscle neoplasm, arising from the breast.  It is characterized by a proliferation of neoplastic spindle cells.","Breast Leiomyosarcoma | Leiomyosarcoma of Breast | Leiomyosarcoma of the Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334280","Invasive Breast Papillary Carcinoma","C36085","An invasive breast carcinoma characterized by the presence of papillary structures.","Invasive Breast Papillary Carcinoma | Infiltrating Papillary Breast Carcinoma | Invasive Papillary Breast Carcinoma | Invasive Papillary Breast Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0346993","Metastatic Malignant Neoplasm in the Breast","C7511","The spread of a malignant neoplasm to the breast. This may be from a primary breast malignant neoplasm on the opposite side, or from a malignant neoplasm at a distant site.","Metastatic Malignant Neoplasm in the Breast | Breast Metastases | Breast Metastasis | Metastatic Cancer to the Breast | Metastatic Malignant Neoplasm to the Breast | Metastatic Neoplasm to the Breast | Metastatic Tumor to the Breast | Secondary malignant neoplasm of breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336835","Tumor Cell Necrosis","C35957","A morphologic finding that indicates the presence of cells undergoing necrosis within a tumor.","Tumor Cell Necrosis | ",,,,,,,,,,,,,,,"4147451","Tumor necrosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512944","Reovirus Capsid Protein","C129768","A protein encoded by the reoviral genome that forms a three-layered icosahedral protein capsid for the virus.","Reovirus Capsid Protein | Reoviral Capsid Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512800","Immunoglobulin Heavy Chain Variable Domain","C129421","The portion of an antibody molecule that contains the three hypervariable regions in the heavy chains. It is comprised of at most a third of the heavy chains from the amino termini.","Immunoglobulin Heavy Chain Variable Domain | IgH Variable Domain | IgH Variable Region | IgHV | Immunoglobulin Heavy Chain Variable Region",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512674","B-Cell Receptor Complex Profile","C129658","A data set that both identifies the isotype of the immunoglobulin within B-cell receptor complexes and quantifies the level of expression of each isotype-specific complex in a biological sample or specimen.","B-Cell Receptor Complex Profile | B Cell Receptor Complex Profile | B Cell Receptor Profile | B Cell Receptor Repertoire | B-Cell Antigen Receptor Complex Profile | B-Cell Receptor Profile | B-Cell Receptor Repertoire | BCR Profile | BCR Repertoire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0474783","Phytohemagglutinin Skin Test","C129757","A test used to evaluate patient cell-mediated immune responsiveness. A small amount of the purified plant lectin phytohemagglutinin protein is placed under the skin. For subjects with normal immunity, non-specific lymphocyte proliferation and infiltration is induced at the injection site.","Phytohemagglutinin Skin Test | PHA Skin Test | PHA Test",,,,,,,,,,,,,,,"4270686","Delayed hypersensitivity skin test for phytohemagglutinin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513014","Tumor cDNA Expression Profile","C129771","An analysis of all of the complementary DNA molecules expressed in by a tumor.","Tumor cDNA Expression Profile | Tumor cDNA Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512893","NNK Metabolite","C129884","Molecules created during the catabolism of the nitrosamine 4-methylnitrosamino-1,3-pyridyl-1-butanone (nicotine-derived nitrosamine ketone; NNK). The presence of these metabolic products may be correlated with the exposure of the subject to tobacco products.","NNK Metabolite | 4-Methylnitrosamino-1,3-Pyridyl-1-Butanone Metabolite | Nicotine-Derived Nitrosamine Ketone Metabolite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514167","Myelodysplastic Syndrome Clone","C130199","A clonal population of dysplastic hematopoietic cells found in a patient with myelodysplastic syndrome.","Myelodysplastic Syndrome Clone | MDS Clone | MDS Malignant Clone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3872595","Human Papillomavirus DNA","C129664","The viral DNA that originates from a human papillomavirus.","Human Papillomavirus DNA | HPV DNA | Human Papilloma Virus DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201720","Serum Protein Electrophoresis","C129763","An electrophoretic laboratory test performed to determine the concentrations of globulin proteins in the blood.","Serum Protein Electrophoresis | SPE | SPEP",,,,,,,,,,,,,,,"4176702","Serum protein electrophoresis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512575","Reovirus RNA","C129669","The viral RNA that originates from a reovirus.","Reovirus RNA | Reoviral RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335149","Breast Extraskeletal Osteosarcoma","C5189","An osteosarcoma arising from the breast tissue.","Breast Extraskeletal Osteosarcoma | Breast Osteosarcoma | Osteogenic Breast Sarcoma | Osteogenic Sarcoma of Breast | Osteogenic Sarcoma of the Breast | Osteosarcoma of Breast | Osteosarcoma of the Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335489","Non-Hodgkin Breast Lymphoma","C5181","A non-Hodgkin lymphoma that arises from the breast.  There is no history of extramammary breast non-Hodgkin lymphoma and ipsilateral axillary lymph node involvement does not exclude the diagnosis of primary breast non-Hodgkin lymphoma.  Most patients present with a painless breast lump.  The vast majority of cases are B-cell non-Hodgkin lymphomas.  Diffuse large B-cell lymphoma, follicular lymphoma, and extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue are the most common types of primary non-Hodgkin lymphoma of the breast.","Breast Non-Hodgkin Lymphoma | Non-Hodgkin Breast Lymphoma | Non-Hodgkin Breast Lymphoma | Non-Hodgkin's Breast Lymphoma | Primary Non-Hodgkin Breast Lymphoma | Primary Non-Hodgkin Lymphoma of Breast | Primary Non-Hodgkin Lymphoma of the Breast | Primary Non-Hodgkin's Breast Lymphoma | Primary Non-Hodgkin's Lymphoma of Breast | Primary Non-Hodgkin's Lymphoma of the Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334708","Breast Metaplastic Carcinoma","C5164","A group of invasive breast carcinomas characterized by the presence of an adenocarcinomatous component which is admixed with a dominant component that is composed of squamous cells, spindle cells, or mesenchymal cells.","Breast Metaplastic Carcinoma |  MpBC | Metaplastic Breast Carcinoma | Metaplastic Breast Carcinoma | Metaplastic Carcinoma of Breast | Metaplastic Carcinoma of the Breast",,,,,,,,,,,,,,,"35622134","Metaplastic carcinoma of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332592","Borderline Breast Phyllodes Tumor","C5316","A phyllodes tumor of the breast characterized by the presence of intermediate features and a stroma which usually resembles low grade fibrosarcoma.","Borderline Breast Phyllodes Tumor | Borderline Breast Phyllodes Neoplasm | Borderline Phyllodes Neoplasm of Breast | Borderline Phyllodes Neoplasm of the Breast | Borderline Phyllodes Tumor of Breast | Borderline Phyllodes Tumor of the Breast | Low Grade Malignant Breast Phyllodes Tumor",,,,,,,,,,,,,,,"4175847","Phyllodes tumor of breast, borderline",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1336079","Breast Squamous Cell Carcinoma","C5177","A rare carcinoma that arises from the breast parenchyma and is entirely composed of squamous cells.","Breast Squamous Cell Carcinoma | Primary Squamous Cell Breast Carcinoma | Primary Squamous Cell Carcinoma of Breast | Primary Squamous Cell Carcinoma of the Breast | SCC of Breast | SCC of the Breast | Squamous Breast Carcinoma | Squamous Carcinoma of Breast | Squamous Carcinoma of the Breast | Squamous Cell Breast Carcinoma | Squamous Cell Breast Carcinoma | Squamous Cell Carcinoma of Breast | Squamous Cell Carcinoma of the Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0346154","Malignant Breast Phyllodes Tumor","C4504","A phyllodes tumor of the breast characterized by infiltrative margins and a sarcomatous stromal component.  The sarcomatous stroma usually displays features of fibrosarcoma.  Liposarcomatous, osteosarcomatous, or rhabdomyosarcomatous elements may also be present.","Malignant Breast Phyllodes Tumor | Malignant Breast Phyllodes Neoplasm | Malignant Mammary Phyllodes Neoplasm | Malignant Mammary Phyllodes Tumor | Malignant Phyllodes Breast Neoplasm | Malignant Phyllodes Neoplasm of Breast | Malignant Phyllodes Neoplasm of the Breast | Malignant Phyllodes Tumor of Breast | Malignant Phyllodes Tumor of the Breast",,,,,,,,,,,,,,,"4112854","Malignant phyllodes tumor of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0740346","Metastatic Undifferentiated Pleomorphic Sarcoma","C4926","An undifferentiated pleomorphic sarcoma that has spread to other anatomic sites.","Metastatic Undifferentiated Pleomorphic Sarcoma | Malignant Fibrous Histiocytoma Metastatic | Metastatic Malignant Fibrous Histiocytoma | Metastatic Unclassified Pleomorphic Sarcoma | Metastatic Unclassified Pleomorphic Sarcoma (Formerly Metastatic 'MFH') | Metastatic Unclassified Pleomorphic Sarcoma (Formerly Metastatic 'Malignant Fibrous Histiocytoma')",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0349669","Breast Lymphoma","C4671","A lymphoma that arises from the breast.  There is no history of extramammary breast lymphoma and ipsilateral axillary lymph node involvement does not exclude the diagnosis of primary breast lymphoma.  Most patients present with a painless breast lump.  The vast majority of cases are B-cell non-Hodgkin lymphomas.  Diffuse large B-cell lymphoma, follicular lymphoma, and extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue are the most common types of primary non-Hodgkin lymphoma of the breast.  Primary Hodgkin lymphoma of the breast is rare.","Breast Lymphoma | Lymphoma of Breast | Lymphoma of the Breast | PBL | Primary Breast Lymphoma",,,,,,,,,,,,,,,"4080742","Malignant lymphoma of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086681","Overall Survival","C125201","A measure of the time until death from any cause.","Overall Survival | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512992","Short Tandem Repeat Profile","C129889","The analysis of all of the short tandem repeats in the genome of a biological sample.","Short Tandem Repeat Profile | STR Profile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512523","DNA Repair Kinetics","C129677","The rate at which a cell can repair DNA.","DNA Repair Kinetics | Repair Kinetics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512657","Tumor DNA","C129665","DNA that originates from neoplastic cells.","Tumor DNA | Tumor-Derived DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512658","Tumor RNA","C129666","RNA transcribed from tumor DNA.","Tumor RNA | Tumor-Derived RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512981","Hypomethylation Profile","C129893","The identification and quantitation of sites for DNA hypomethylation in the genome of a biological sample.","Hypomethylation Profile | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513043","Tryptophan Metabolite","C129885","Molecules created during the catabolism of the amino acid tryptophan. Increased concentrations of tryptophan metabolites are associated with neurological disease-related cognitive deficits and depressive symptoms and may be used as biomarkers for cancer risk.","Tryptophan Metabolite | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512961","DDRD Signature","C129891","A gene expression profile that indicates that the cells in a sample have decreased ability to respond to and repair DNA damage.","DDRD Signature | DDRD Gene Signature | DNA Damage Response Deficiency Gene Signature | DNA Damage Response Deficiency Signature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898449","Mean Vessel Diameter","C116143","The mean of the inside diameters of the normal blood vessel segments.","Mean Vessel Diameter | MEANVDIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512675","Basement Membrane Thickness","C129676","The dimension between the two surfaces of a basement membrane.","Basement Membrane Thickness | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513027","Choline Metabolite","C129883","Molecules used during the synthesis or created during the catabolism of choline. The presence of these metabolic products in urine can be correlated with the amount of dietary choline or total choline-containing compounds in a subject.","Choline Metabolite | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698507","Nucleated Red Blood Cell to Erythrocyte Ratio Measurement","C74647","The determination of the ratio of nucleated red blood cells compared to erythrocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Nucleated Red Blood Cell to Erythrocyte Ratio Measurement | Nucleated Erythrocytes/Erythrocytes | Nucleated Red Blood Cells/Erythrocytes | RBCNURBC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524773","Tricuspid Valve Regurgitation Velocity","C136979","A measurement of the backward flow of blood through the tricuspid valve during right ventricle contraction. It correlates with pulmonary artery systolic pressure at rest and with exercise. A tricuspid regurgitation velocity greater than or equal to 2.5 m/sec on echocardiography is a surrogate marker for pulmonary hypertension in adults with sickle cell disease.","Tricuspid Valve Regurgitation Velocity | TRJV | TRV | Tricuspid Regurgitant Jet Velocity | Tricuspid Regurgitation Jet Velocity | Tricuspid Regurgitation Velocity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700092","Tumor Flare Reaction","C78655","A side effect of cancer treatment. It has been described in patients with chronic lymphocytic leukemia treated with lenalidomide, breast cancer patients during the initial phase of hormonal treatment, and in prostate cancer patients treated with luteinizing hormone-releasing hormone agonists. Symptoms include a sudden and painful increase in the tumor size, rash, low grade fever, bone pain, hypercalcemia, and an increase in the tumor markers levels.","Tumor Flare Reaction | TFR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983694","Personal Information","C90492","Data, facts or figures about an individual; the set of relevant items would depend on the use case.","Personal Information | PII | Personally Identifiable Information | personally identifiable information (PII)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004704","Balloon Dilatation","C113728","An endoscopic therapeutic procedure in which a balloon device is used to dilate a narrowed lumen.","Balloon Dilation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524813","PSA Level Less than Ten","C137689","A blood concentration of prostate specific antigen less than 10 ng/mL.","PSA Level Less than Ten | PSA Level Less Than Ten | PSA Level Less than 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511214","Blasts Under 5 Percent of Peripheral Blood White Cells","C41399","A semi-quantitative microscopic finding indicating that less than 5 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.","Blasts Under 5 Percent of Peripheral Blood White Cells | Blasts Less Than 5 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524838","PSA Level Greater than Ten","C137686","A blood concentration of prostate specific antigen greater than 10 ng/mL.","PSA Level Greater than Ten | PSA Level Greater than 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524835","PSA Level Ten to Twenty","C137687","A blood concentration of prostate specific antigen between 10 and 20 ng/mL.","PSA Level Ten to Twenty | PSA Level 10 to 20 | PSA Level Between 10 and 20 | PSA Level Between Ten and Twenty | PSA Level Greater than 10 but Less than 20 | PSA Level Greater than Ten but Less than Twenty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524836","PSA Level Less than Twenty","C137688","A blood concentration of prostate specific antigen less than 20 ng/mL.","PSA Level Less than Twenty | PSA Level Less than 20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511211","Blasts Under 10 Percent of Bone Marrow Nucleated Cells","C41398","A semi-quantitative microscopic finding indicating that less than 10 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts Under 10 Percent of Bone Marrow Nucleated Cells | Blasts Less Than 10 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524814","CD20 Negative","C137690","An indication that CD20 expression has not been detected in a sample.","CD20 Negative | CD20 Antigen Negative | Leu-16 Negative | MS4A1 Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524811","DICER1 Gene Mutation","C137691","A change in the nucleotide sequence of the DICER1 gene.","DICER1 Gene Mutation | DCR-1 Gene Mutation | DCR1 Gene Mutation | DICER Gene Mutation | DICER1 Gene Mutation. | DICER1 mutation | Dicer 1, Double-Stranded RNA-Specific Endoribonuclease Gene Mutation | Dicer 1, Ribonuclease III Gene Mutation | Dicer 1, Ribonuclease Type III Gene Mutation | HERNA Gene Mutation | MNG1 Gene Mutation | RMSE2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524812","PSA Level Greater than 2.5","C137692","A blood concentration of prostate specific antigen greater than 2.5 ng/mL.","PSA Level Greater than 2.5 | PSA Levels Greater than 2.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0481430","Human Immunodeficiency Virus Negative","C137693","Indicates that human immunodeficiency virus has not been detected in a sample.","Human Immunodeficiency Virus Negative | HIV Negative | Negative",,,,,,,,,,,,,,,"4013105","HIV not detected",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL524817","Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells","C137694","A semi-quantitative microscopic finding indicating that at least 10 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells of myeloid origin.","Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells | Myeloblasts Greater than or Equal to 10 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524815","Blasts 20 Percent or Less of Bone Marrow Nucleated Cells","C137695","A semi-quantitative microscopic finding indicating that 20 percent or less of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 20 Percent or Less of Bone Marrow Nucleated Cells | Blasts Less than or Equal to 20 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524816","PSA Level Two to Forty","C137696","A blood concentration of prostate specific antigen between 2 and 40 ng/mL.","PSA Level Two to Forty | PSA Level 2 to 40",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524820","PSA Level Greater than or Equal to Two","C137697","A blood concentration of prostate specific antigen greater than or equal to 2 ng/mL.","PSA Level Greater than or Equal to Two | PSA Level 2 or Greater | PSA Level Greater than or Equal to 2 | PSA Level Two or Greater",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524821","Blasts 5 Percent or Less of Bone Marrow Nucleated Cells","C137698","A semi-quantitative microscopic finding indicating that 5 percent or less of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 5 Percent or Less of Bone Marrow Nucleated Cells | Blasts Less than or Equal to 5 Percent of Bone Marrow Nucleated Cells | M1 (less than 5% blasts)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524818","PSA Level Less than Fifteen","C137699","A blood concentration of prostate specific antigen less than 15 ng/mL.","PSA Level Less than Fifteen | PSA Level Less than 15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524824","Blasts Under 25 Percent of Bone Marrow Nucleated Cells","C137701","A semi-quantitative microscopic finding indicating that less than 25 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts Under 25 Percent of Bone Marrow Nucleated Cells | Blasts Less than 25 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332570","Blasts 20 Percent or More of Bone Marrow Nucleated Cells","C36214","A semi-quantitative microscopic finding indicating that 20 percent or more of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 20 Percent or More of Bone Marrow Nucleated Cells | Blasts 20% or More of Bone Marrow Nucleated Cells | Blasts Greater than or Equal to 20 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524825","PSA Level Greater than or Equal to Twenty","C137702","A blood concentration of prostate specific antigen greater than or equal to 20 ng/mL.","PSA Level Greater than or Equal to Twenty | PSA Level 20 or Greater | PSA Level Greater than or Equal to 20 | PSA Level Twenty or Greater",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524822","Blasts 5-10 Percent of Bone Marrow Nucleated Cells","C137703","A semi-quantitative microscopic finding indicating that between 5 and 10 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 5-10 Percent of Bone Marrow Nucleated Cells | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524819","PSA Level Less than or Equal to Eighty","C137700","A blood concentration of prostate specific antigen less than or equal to 80 ng/mL.","PSA Level Less than or Equal to Eighty | PSA Level 80 or Less | PSA Level Eighty or Less | PSA Level Less than or Equal to 80",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524823","Blasts 10-19 Percent of Peripheral Blood White Cells","C137704","A semi-quantitative microscopic finding indicating that between 10 and 19 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.","Blasts 10-19 Percent of Peripheral Blood White Cells | Blasts Between 5 and 19 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524808","PSA Level Greater than or Equal to Four","C137705","A blood concentration of prostate specific antigen greater than or equal to 4 ng/mL.","PSA Level Greater than or Equal to Four | PSA Level 4 or Greater | PSA Level Four or Greater | PSA Level Greater than or Equal to 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511209","Blasts 10-19 Percent of Bone Marrow Nucleated Cells","C41401","A semi-quantitative microscopic finding indicating that between 10 and 19 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 10-19 Percent of Bone Marrow Nucleated Cells | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524809","Blasts 11-20 Percent of Bone Marrow Nucleated Cells","C137706","A semi-quantitative microscopic finding indicating that between 11 and 20 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 11-20 Percent of Bone Marrow Nucleated Cells | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524806","PSA Level 0.5 to 50","C137707","A blood concentration of prostate specific antigen between 0.5 and 50 ng/mL.","PSA Level 0.5 to 50 | PSA Greater than 0.5 but less than 50 | PSA Level 0.5 to Fifty | PSA Level Between 0.5 and 50 | PSA Level Between 0.5 and Fifty | PSA Level Greater than 0.5 but less than 50",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524807","PSA Level Greater than or Equal to Twenty-Five","C137708","A blood concentration of prostate specific antigen greater than or equal to 25 ng/mL.","PSA Level Greater than or Equal to Twenty-Five | PSA Level 25 or Greater | PSA Level Greater than or Equal to 25 | PSA Level Greater than or Equal to Twenty Five | PSA Level Twenty Five or Greater | PSA Level Twenty-Five or Greater",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524840","FLIPI-2 Score 0, Low Risk","C137659","A score indicating that a patient has 0 risk factors associated with follicular lymphoma and is considered in the low risk group.","FLIPI-2 Score 0, Low Risk | FLIPI-2 Score 0 | Follicular Lymphoma International Prognostic Index 2 Score 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524846","FLIPI-2 Score 3-5, High Risk","C137661","A score indicating that a patient has 3-5 risk factors associated with follicular lymphoma and is considered in the high risk group.","FLIPI-2 Score 3-5, High Risk | FLIPI-2 Score 3-5 | Follicular Lymphoma International Prognostic Index 2 Score 3-5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524826","Occult Breast Carcinoma","C137674","Breast carcinoma presenting with isolated axillary lymphadenopathy, without clinical or mammographic evidence of breast tumor.","Occult Breast Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2732830","Intramammary Lymph Node","C137678","Any of the lymph nodes located within the breast parenchyma.","Intramammary Lymph Node | Intramammary Node | Lymph Node(s) Mammary",,,,,,,,,,,,,,,"4075246","Internal mammary lymph node group",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL524830","DPACE Regimen","C137680","A regimen consisting of dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide that may be used as a salvage regimen for aggressive and/or refractory plasma cell myeloma.","DPACE Regimen | Cisplatin/Cyclophosphamide/Dexamethasone/Doxorubicin/Etoposide | Cisplatin/Cyclophosphamide/Dexamethasone/Doxorubicin/Etoposide Regimen | D-PACE | DPACE | Decadron/Platinol/Adriamycin/Cytoxan/Etoposide Regimen | Dexamethasone-Cisplatin-Doxorubicin-Cyclophosphamide-Etoposide Regimen | Dexamethasone/Cisplatin/Doxorubicin/Cyclophosphamide/Etoposide | Dexamethasone/Cisplatin/Doxorubicin/Cyclophosphamide/Etoposide Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524833","DCEP Regimen","C137681","A regimen consisting of dexamethasone, cyclophosphamide, etoposide, and cisplatin that may be used as a salvage regimen for relapsed and/or refractory plasma cell myeloma and/or as a mobilization regimen, followed by granulocyte colony-stimulating factor (G-CSF), for peripheral blood stem cell (PBSC) collection in plasma cell myeloma.","DCEP Regimen | DCEP | Dexamethasone-Cyclophosphamide-Etoposide-Cisplatin | Dexamethasone-Cytoxan-Vepesid-Platinol | Dexamethasone/Cyclophosphamide/Etoposide/Cisplatin | Dexamethasone/Cyclophosphamide/Etoposide/Cisplatin Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524839","Follicular Lymphoma International Prognostic Index 2","C137658","A prognostic index designed to be used for patients with follicular lymphoma to stratify them by risk. The index uses 5 parameters: age (less than 60 years or greater than or equal to 60 years), serum beta 2 microglobulin (normal or elevated), hemoglobin level (less than 12 g/dL or greater than or equal to 12 g/dL), bone marrow involvement (present or absent), longest diameter of largest involved node (less than 6cm or greater than or equal to 6cm) and divides patients into 3 risk groups: low (0 risk factors), intermediate (1-2 risk factors), high (3-5 risk factors).","Follicular Lymphoma International Prognostic Index 2 | Blasts Under 5 Percent of Bone Marrow Nucleated Cells | FLIPI-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524845","FLIPI-2 Score 1-2, Intermediate Risk","C137660","A score indicating that a patient has 1-2 risk factors associated with follicular lymphoma and is considered in the intermediate risk group.","FLIPI-2 Score 1-2, Intermediate Risk | FLIPI-2 Score 1-2 | Follicular Lymphoma International Prognostic Index 2 Score 1-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524764","Intermediate Atypical Prostate Carcinoma","C136972","An aggressive, castration-resistant, histologically distinct, metastatic carcinoma arising from the prostate gland. It is characterized by the presence of a pure population of cytologically bland malignant epithelial cells with moderate to abundant cytoplasm and rare mitotic figures. The prognosis is poor.","Intermediate Atypical Prostate Carcinoma | IAC | Intermediate Atypical Carcinoma | Intermediate Atypical Metastatic Castration-Resistant Prostate Cancer | Intermediate Atypical Metastatic Castration-Resistant Prostate Carcinoma | Intermediate Atypical mCRPC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1300070","Tumor Margin Configuration","C137709","Describes the morphologic appearance where a tumor meets the adjacent tissue.","Tumor Margin Configuration | Margin | Tumor Border Configuration",,,,,,,,,,,,,,,"4154264","Tumor border configuration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL524810","Infiltrative Tumor Margin","C137710","Describes a tumor border that is invading the adjacent tissue.","Infiltrative Tumor Margin | Infiltrative | Infiltrative Tumor Border | Infiltrative Tumor Border Configuration | Infiltrative Tumor Margin Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524865","Generalized Competing Event Model for Cancer Risk","C137799","A stratification method that can be used to identify groups of patients at highest risk for a poor outcome and therefore most likely to benefit from treatment intensification.","Generalized Competing Event Model for Cancer Risk | GCE | Generalized Competing Event Model",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332327","Gleason Score 2","C28095","A low Gleason score that is exceptionally uncommon and indicates a low-grade, non-aggressive prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","Gleason Score 2 | ",,,,,,,,,,,,,,,"4172456","Gleason grade score 2 out of 10",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332330","Gleason Score 5","C28098","An exceptionally uncommon Gleason score that indicates a less aggressive prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","Gleason Score 5 | ",,,,,,,,,,,,,,,"4250166","Gleason grade score 5 out of 10",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL520430","Interleukin-3 Receptor Subunit Alpha Positive","C132655","Indicates that interleukin-3 receptor subunit alpha expression has been detected in a sample.","Interleukin-3 Receptor Subunit Alpha Positive | CD123 Antigen Positive | CD123 Positive | IL-3 Receptor Subunit Alpha Positive | IL-3R Subunit Alpha Positive | IL-3R-Alpha Positive | IL-3RA Positive | IL3R Positive | IL3R-Alpha Positive | IL3RA Positive | IL3RX Positive | Interleukin 3 Receptor Alpha Chain Positive | Interleukin 3 Receptor Alpha Positive | Interleukin 3 Receptor Positive | Low Affinity Interleukin 3 Receptor Alpha Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520595","BCL6 Positive","C132011","An indication that B-cell lymphoma 6 expression has been detected in a sample.","BCL6 Positive | B-Cell CLL/Lymphoma 6 Positive | B-Cell Lymphoma 6 Positive | BCL5 Positive | LAZ-3 Positive | LAZ3 Positive | ZBTB27 Positive | ZNF51 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524902","XM02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524901","Filgrastim-sndz",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524906","Low Risk Mantle Cell Lymphoma International Prognostic Index Combined Biologic Index","C137807","Low risk MIPI score (0-3) and Ki-67 less than 30%. Low risk MIPI-c equals a MIPI-c score of 0.","Low Risk Mantle Cell Lymphoma International Prognostic Index Combined Biologic Index | Low Risk Mantle Cell Lymphoma International Prognostic Index Combined Biologic Index
",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524905","Low-Intermediate Risk Mantle Cell Lymphoma International Prognostic Index Combined Biologic Index","C137808","Low risk MIPI score (0-3) and Ki-67 greater than or equal to 30% or Intermediate risk MIPI score (4-5) and Ki-67 less than 30%. MIPI-c low-intermediate risk equals a MIPI-c score of 1.","Low-Intermediate Risk Mantle Cell Lymphoma International Prognostic Index Combined Biologic Index | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524911","High-Intermediate Risk Mantle Cell Lymphoma International Prognostic Index Combined Biologic Index","C137809","Intermediate risk MIPI score (4-5) and Ki-67 greater than or equal to 30% or High risk MIPI score (6-11) and Ki-67 less than 30%. A MIPI-c high-intermediate risk equals a MIPI-c score of 2.","High-Intermediate Risk Mantle Cell Lymphoma International Prognostic Index Combined Biologic Index | High-Intermediate Risk Mantle Cell Lymphoma International Prognostic Index Combined Biologic Index
",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524910","High Risk Mantle Cell Lymphoma International Prognostic Index Combined Biologic Index","C137810","High risk MIPI score (6-11) and Ki-67 greater than or equal to 30%. A MIPI-c high risk equals a MIPI-c score of 3.","High Risk Mantle Cell Lymphoma International Prognostic Index Combined Biologic Index | High Risk Mantle Cell Lymphoma International Prognostic Index Combined Biologic Index
",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899697","Cells per Kilogram","C116239","A unit of cell concentration expressed as a number of cells per mass unit equal to one kilogram.","Cells per Kilogram | cells/kg | {cells}/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524909","Electronic Patient-reported Outcome System","C137811","Any of various systems designed to collect treatment outcome data directly from patients by electronic means.","Electronic Patient-reported Outcome System | Electronic Patient-reported Outcome | ePRO | ePro",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334971","Nodular Neoplasm","C36012","A benign or malignant neoplasm characterized by the formation of nodules by the proliferating neoplastic cells.","Nodular Neoplasm | Nodular Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525116","Specimen Blood Volume","C137835","The liquid volume of blood in a container or specimen.","Specimen Blood Volume | Blood Volume",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005850","Blood Volume","C137837","The total volume of blood in the circulatory system of an individual.","Blood Volume | Body Blood Volume | Circulating Blood Volume",,,,,,,,,,,,,,,"4053108","Blood volume",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL524837","Blasts Under 5 Percent of Bone Marrow Nucleated Cells","C137685","A semi-quantitative microscopic finding indicating that less than 5 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts Under 5 Percent of Bone Marrow Nucleated Cells | Blasts Less Than 5 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524882","Quality of Life in Neurological Disorders","C137840","A set of self-reported and proxy-reported measures of physical, mental, and social health for adults and children living with a neurological condition.","Quality of Life in Neurological Disorders | Neuro-QoL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524881","Neuro-QoL Adult Self-Reported Mental Health Domain","C137841","A domain of the Quality of Life in Neurological Disorders that assesses the status of an adult individual's mental health.","Neuro-QoL Adult Self-Reported Mental Health Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524887","Neuro QoL Cognitive Function Subdomain","C137842","The collection of Neuro-QoL item scales that assess perceived difficulties in cognitive abilities related to both executive function and general concerns.","Neuro QoL Cognitive Function Subdomain | Cognitive Function Subdomain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3262044","Have to Read Something Several Times to Understand","C137843","A question about whether an individual has or had to read something several times to understand it.","Have to Read Something Several Times to Understand | I had to read something several times to understand it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524886","Current Difficulty Reading and Following Complex Instructions","C137844","A question about how much difficulty an individual currently has reading and following complex instructions.","Current Difficulty Reading and Following Complex Instructions | How much DIFFICULTY do you currently have reading and following complex instructions (e.g., directions for a new medication)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524885","Current Difficulty Planning and Keeping Appointments Not Part of Weekly Routine","C137845","A question about how much difficulty an individual currently has planning for and keeping appointments that are not part of their weekly routine.","Current Difficulty Planning and Keeping Appointments Not Part of Weekly Routine | How much DIFFICULTY do you currently have planning for and keeping appointments that are not part of your weekly routine, (e.g., a therapy or doctor appointment, or a social gathering with friends and family)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3261561","Current Difficulty Managing Time to do Most Daily Activities","C137846","A question about how much difficulty an individual currently has managing their time to do most of their daily activities.","Current Difficulty Managing Time to do Most Daily Activities | How much DIFFICULTY do you currently have managing your time to do most of your daily activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3261567","Current Difficulty Learning New Tasks or Instructions","C137847","A question about how much difficulty an individual currently has learning new tasks or instructions.","Current Difficulty Learning New Tasks or Instructions | How much DIFFICULTY do you currently have learning new tasks or instructions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919292","Strontium Chloride Sr-89","C1238","The chloride salt of a radioactive isotope of strontium. Strontium chloride Sr 89 is taken up and incorporated preferentially in metastatic lesions in bone where it emits cytotoxic beta radiation, resulting in an inhibition and/or reduction of tumor growth and so tumor-related bone pain. (NCI04)","Strontium Chloride Sr-89 | Metastron | STRONTIUM CHLORIDE SR-89 | strontium chloride Sr 89",,,,,,,,,,,,,,,"4053617","Strontium (89-Sr) chloride",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1521752","Sputum Cytology Screening","C16192","An examination of cells obtained from a sample of sputum.","Sputum Cytology | Sputum Cytology Screening | sputum cytology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036085","Hypertonic Saline","C60814","Any solution of sodium chloride (NaCl) in water with a concentration of NaCl higher than that found in physiological saline (0.9% w/v). When administered in vivo, hypertonic saline (HTS) exhibits several physiological effects beneficial to cerebral injury including: 1) osmotic and vasoregulatory - by promoting the flow of excess water from cerebral tissue to the blood via osmosis and decreasing edema in the vascular endothelium of injured tissues, thus lowering vascular resistance and allowing more blood flow; 2) hemodynamic - by effectively expanding plasma volume; 3) immunomodulatory - by preventing leukocytes from becoming activated and adhering to injured neurons and; 4) neurochemical - by counteracting detrimental excitatory amino acids through the normalization of neuronal cell membranes and by restoration of normal electrolyte and neurotransmitter levels in brain cells, and normal cell volumes.","Hypertonic Saline | Hypertonic Saline Solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525117","Foundation for the Accreditation of Cellular Therapy","C137949","A non-profit corporation co-founded by the International Society for Cellular Therapy and the American Society of Blood and Marrow Transplantation for the purposes of voluntary inspection and accreditation in the field of cellular therapy. Founded in 1996, FACT establishes standards for high quality medical and laboratory practice in cellular therapies. FACT Standards are evidence-based requirements set by world-renowned experts vested in the improvement and progress of cellular therapy.","Foundation for the Accreditation of Cellular Therapy | FACT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523554","Capecitabine-Bevacizumab Regimen","C136243","A regimen consisting of bevacizumab and capecitabine that may be used for the treatment of colorectal cancer, small bowel , ampullary and appendiceal adenocarcinoma.","Bevacizumab/Capecitabine Regimen | Avastin-Xeloda | Bevacizumab-Capecitabine | Bevacizumab/Capecitabine | Capecitabine and Bevacizumab | Capecitabine and Bevacizumab-adcd | Capecitabine and Bevacizumab-awwb | Capecitabine and Bevacizumab-aybi | Capecitabine and Bevacizumab-bvzr | Capecitabine and Bevacizumab-equi | Capecitabine and Bevacizumab-maly | Capecitabine and Bevacizumab-onbe | Capecitabine and Bevacizumab-tnjn | Capecitabine-Bevacizumab | Capecitabine-Bevacizumab Regimen | Capecitabine/Bevacizumab | Capecitabine/Bevacizumab Regimen | Capecitabine/Bevacizumab Regimen | Xeloda-Avastin Regimen | Xeloda/Avastin Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523559","FOLFOX-Avastin Regimen","C136248","A regimen consisting of leucovorin, fluorouracil and oxaliplatin (FOLFOX), plus bevacizumab that is used for the treatment of colon cancer and mucinous neoplasms of the ovary.","FOLFOX-Bevacizumab Regimen | FOLFOX Plus Avastin | FOLFOX Plus Bevacizumab | FOLFOX-Avastin Regimen | FOLFOX/Avastin Regimen | FOLFOX/Bevacizumab Regimen | FOLFOX/Bevacizumab Regimen | FOLFOX4 and Bevacizumab | FOLFOX4 and Bevacizumab-adcd | FOLFOX4 and Bevacizumab-awwb | FOLFOX4 and Bevacizumab-aybi | FOLFOX4 and Bevacizumab-bvzr | FOLFOX4 and Bevacizumab-equi | FOLFOX4 and Bevacizumab-maly | FOLFOX4 and Bevacizumab-onbe | FOLFOX4 and Bevacizumab-tnjn | Folfox + Bevacizumab | Folfox + Bevacizumab Regimen | Folinic Acid/Fluorouracil/Oxaliplatin/Bevacizumab Regimen | Leucovorin/Fluorouracil/Oxaliplatin/Bevacizumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0203669","Whole Body Scan","C95004","A series of scans of a subject taken at sequential bed positions as the bed moves through the scanner. The images, each limited by an axial field of view, can then be pieced together to give an extended length image of the subject. A whole body scan contrasts with a single bed position scan in which only a rather limited region within the subject is to be studied.","Whole Body Scan | Whole-Body Imaging | Whole-Body Scan",,,,,,,,,,,,,,,"4038188|4279524","Radioisotope scan of total body|Total body scan",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1336512","Stromal Change","C35996","No Value Exists","Stromal Change | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525030","Gleason Grade Group 1","C137992","Gleason grade defined by Gleason score less than or equal to 6. (ISUP, 2014)","Gleason Grade Group 1 | 1 | Gleason Score Less Than or Equal to 6 | Grade Group 1 | Group 1",,,,,,,,,,,,,,,"3655244","Gleason grade group 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL525029","Gleason Grade Group 2","C137993","Gleason grade defined by Gleason score 3+4=7. (ISUP, 2014)","Gleason Grade Group 2 | 2 | Gleason Score 7: (3 plus 4) | Grade Group 2 | Group 2",,,,,,,,,,,,,,,"3655245","Gleason grade group 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL525028","Gleason Grade Group 3","C137994","Gleason grade defined by Gleason score 4+3=7. (ISUP, 2014)","Gleason Grade Group 3 | 3 | Gleason Score 7: (4 plus 3) | Grade Group 3 | Group 3",,,,,,,,,,,,,,,"3655246","Gleason grade group 3",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL525035","Gleason Grade Group 4","C137995","Gleason grade defined by Gleason score 4+4=8, Gleason score 3+5=8, or Gleason score 5+3=8. (ISUP, 2014)","Gleason Grade Group 4 | 4 | Gleason Score 8: (4 plus 4) or (3 plus 5) or (5 plus 3) | Grade Group 4 | Group 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525034","Gleason Grade Group 5","C137996","Gleason grade defined by Gleason score 9-10. (ISUP, 2014)","Gleason Grade Group 5 | 5 | Gleason Score 9 or 10 | Grade Group 5 | Group 5",,,,,,,,,,,,,,,"3655248","Gleason grade group 5",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL524965","Adnexa","C137974","An appendage or accessory structure of an adjacent or related organ.","Adnexa | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525084","Distal Resection Margin","C138061","The surgical margin resulting from resection of a tumor with respect to the distal border of the specimen, as it was oriented prior to excision.","Distal Resection Margin | Distal | Distal Margin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525115","Deep Resection Margin","C138062","The surgical margin resulting from resection of a tumor with respect to the deep border of the specimen, as it was oriented prior to excision.","Deep Resection Margin | Deep | Deep Margin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525083","Proximal Resection Margin","C138063","The surgical margin resulting from resection of a tumor with respect to the proximal border of the specimen, as it was oriented prior to excision.","Proximal Resection Margin | Proximal | Proximal Margin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525038","How Often Have Sensation of Not Emptying Bladder Completely after Finish Urinating","C138000","A question about how often an individual has or had a sensation of not emptying their bladder completely after they finished urinating.","How Often Have Sensation of Not Emptying Bladder Completely after Finish Urinating | How Often Have Sensation of Not Emptying Bladder Completely after Urinating | How often have you had a sensation of not emptying your bladder completely after you finished urinating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525037","How Often Have to Urinate Again Less Than 2 Hours after Finish Urinating","C138001","A question about how often an individual has or had to urinate again less than 2 hours after they finished urinating.","How Often Have to Urinate Again Less Than 2 Hours after Finish Urinating | How Often Have to Urinate Again Less Than 2 Hours after Urinating | How often have you had to urinate again less than 2 hours after you finished urinating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525036","How Often Have Stopped and Started Again Several Times When Urinating","C138002","A question about how often an individual has or had to stop and start again several times when they urinate.","How Often Have Stopped and Started Again Several Times When Urinating | How often have you found you stopped and started again several times when you urinated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525043","How Often Have Difficulty Postponing Urination","C138003","A question about how often an individual has or had found it difficult to postpone urination.","How Often Have Difficulty Postponing Urination | How often have you found it difficult to postpone urination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525042","How Often Have Weak Urinary Stream","C138004","A question about how often an individual has or had a weak urinary stream.","How Often Have Weak Urinary Stream | How often have you had a weak urinary stream",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525041","How Often Have to Push or Strain to Begin Urination","C138005","A question about how often an individual has or had to push or strain to begin urination.","How Often Have to Push or Strain to Begin Urination | How Often Have to Push or Strain to Begin Urinating | How often have you had to push or strain to begin urination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525040","How Many Times Typically Get Up to Urinate During Nighttime Sleep","C138006","A question about the most typical number of times an individual has or had to get up to urinate from the time they went to bed at night until the time they got up in the morning.","How Many Times Typically Get Up to Urinate During Nighttime Sleep | How Many Times Typically Get Up to Urinate During Nighttime | How many times did you most typically get up to urinate from the time you went to bed at night until the time you got up in the morning",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4263574","Feeling about Current Urinary Condition for Rest of Life","C138007","A question about how an individual feels or felt about spending the rest of their life with their urinary condition just the way it is now.","Feeling about Current Urinary Condition for Rest of Life | If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4264483","Less than One Time in Five","C138008","A response indicating that something happens or happened less than one in five times.","Less than One Time in Five | Less than 1 time in 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4264482","About Half the Time","C138009","A response indicating that something happens or happened about half of the time.","About Half the Time | About half the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4264467","Mostly Satisfied","C138010","A response indicating that an individual is or has been mostly satisfied.","Mostly Satisfied | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4264465","Mostly Dissatisfied","C138011","A response indicating that an individual is or has been mostly dissatisfied.","Mostly Dissatisfied | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525019","Unhappy","C138012","A response indicating that an individual is or has been unhappy.","Unhappy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525069","Candidate","C138079","Someone or something considered as suitable or likely for something.","Candidate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519487","Breast Squamous Cell Carcinoma, Spindle Cell Variant","C40358","A squamous cell carcinoma that arises from the breast parenchyma and is characterized by the presence of spindle-shaped malignant cells.","Breast Squamous Cell Carcinoma, Spindle Cell Variant | Squamous Cell Breast Carcinoma, Spindle Cell Variant | Squamous Cell Breast Carcinoma, Spindle Cell Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525068","Never Have Erection When Want One","C138080","A subjective response indicating that an individual never has or had an erection when they wanted one.","Never Have Erection When Want One | I NEVER had an erection when I wanted one",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525073","Have Erection Less Than Half the Time","C138081","A subjective response indicating that an individual has or had an erection less than half the time when they wanted one.","Have Erection Less Than Half the Time | I had an erection LESS THAN HALF the time I wanted one",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525072","Have Erection About Half the Time","C138083","A subjective response indicating that an individual has or had an erection about half the time when they wanted one.","Have Erection About Half the Time | I had an erection ABOUT HALF the time I wanted one",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525071","Have Erection More Than Half the Time","C138084","A subjective response indicating that an individual has or had an erection more than half the time when they wanted one.","Have Erection More Than Half the Time | I had an erection MORE THAN HALF the time I wanted one",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525077","Have Erection Whenever Want One","C138085","A subjective response indicating that an individual has or had an erection whenever they wanted one.","Have Erection Whenever Want One | I had an erection WHENEVER I wanted one",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525076","No Pads per Day","C138086","A subjective response indicating that an individual did not use any absorbent pads per day.","No Pads per Day | 0 pad per day | Zero Pads per Day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525075","One Pad per Day","C138087","A subjective response indicating that an individual uses or used one absorbent pad per day.","One Pad per Day | 1 pad per day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525074","Two Pads per Day","C138088","A subjective response indicating that an individual uses or used two absorbent pads per day.","Two Pads per Day | 2 pads per day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525058","Three or More Pads per Day","C138089","A subjective response indicating that an individual uses or used three or more absorbent pads per day.","Three or More Pads per Day | 3 or more pads per day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525057","No Urinary Control","C138090","A subjective response indicating that an individual has or had no urinary control.","No Urinary Control | No urinary control whatsoever",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525055","Frequent Dribbling","C138092","A subjective response indicating that an individual frequently dribbles urine.","Frequent Dribbling | Frequent Urinary Dribbling | Frequent dribbling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525060","Occasional Dribbling","C138094","A subjective response indicating that an individual occasionally dribbles urine.","Occasional Dribbling | Occasional Urinary Dribbling | Occasional dribbling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525059","Total Urinary Control","C138095","A subjective response indicating that an individual has or had total urinary control.","Total Urinary Control | Total control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827840","Terrible","C113698","Exceptionally bad or displeasing.","Terrible | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830544","Delight","C113697","A feeling of extreme pleasure or satisfaction.","Delight | Delighted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709982","SDHD Gene Mutation","C48304","A change in the nucleotide sequence of the SDHD gene.","SDHD Gene Mutation | CII-4 Gene Mutation | SDH4 Gene Mutation | Succinate Dehydrogenase Complex Subunit D Gene Mutation | cybS Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709980","SDHB Gene Mutation","C48302","A change in the nucleotide sequence of the SDHB gene.","SDHB Gene Mutation | IP Gene Mutation | SDH Gene Mutation | SDH1 Gene Mutation | SDH2 Gene Mutation | SDHIP Gene Mutation | Succinate Dehydrogenase Complex Iron Sulfur Subunit B Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709981","SDHC Gene Mutation","C48303","A change in the nucleotide sequence of the SDHC gene.","SDHC Gene Mutation | CYB560 Gene Mutation | QPS1 Gene Mutation | SDH3 Gene Mutation | Succinate Dehydrogenase Complex Subunit C Gene Mutation | cybL Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524998","Blasts 10 Percent or More of Peripheral Blood White Cells","C138056","A semi-quantitative microscopic finding indicating that 10 percent or more of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.","Blasts 10 Percent or More of Peripheral Blood White Cells | Blasts Greater than or Equal to 10 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525080","ErbB Family Pathway Deregulation","C138058","Aberrant activation of an ERBB family member-dependent signaling pathway.","ErbB Family Pathway Deregulation | EGFR Family Pathway Deregulation | ErbB Pathway Deregulation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525078","ERBB4 Gene Mutation","C138060","A change in the nucleotide sequence of the ERBB4 gene.","ERBB4 Gene Mutation | ERBB-4 Gene Mutation | Erb-B2 Receptor Tyrosine Kinase 4 Gene Mutation | HER-4 Gene Mutation | HER4 Gene Mutation | V-Erb-A Erythroblastic Leukemia Viral Oncogene Homolog 4 Gene Mutation | V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 4 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525082","ERBB3 Gene Mutation","C138064","A change in the nucleotide sequence of the ERBB3 gene.","ERBB3 Gene Mutation | Erb-B2 Receptor Tyrosine Kinase 3 Gene Mutation | ErbB-3 Gene Mutation | HER-3 Gene Mutation | HER3 Gene Mutation | V-Erb-A Erythroblastic Leukemia Viral Oncogene Homolog 3 Gene Mutation | V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 3 Gene Mutation | c-erbB-3 Gene Mutation | c-erbB3 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525088","Blasts 50 Percent or More of Bone Marrow Nucleated Cells","C138065","A semi-quantitative microscopic finding indicating that greater than or equal to 50 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 50 Percent or More of Bone Marrow Nucleated Cells | Blasts Greater Than 50 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525086","PSA Level Less than or Equal to Twenty","C138067","A blood concentration of prostate specific antigen less than or equal to 20 ng/mL.","PSA Level Less than or Equal to Twenty | PSA Level 20 or Less | PSA Level Less than or Equal to 20 | PSA Level Twenty or Less",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525085","FGFR2 Gene Translocation","C138068","A cytogenetic abnormality that refers to any translocation involving the FGFR2 gene.","FGFR2 Gene Translocation | BEK Gene Translocation | CD332 Gene Translocation | ECT1 Gene Translocation | FGFR-2 Gene Translocation | Fibroblast Growth Factor Receptor 2 Gene Translocation | K-SAM Gene Translocation | KGFR Gene Translocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525092","cfDNA Mutation","C138069","A genetic finding indicating the presence of mutations in the cell-free DNA that is present in a peripheral blood sample.","cfDNA Mutation | Cell-Free DNA Mutation | Circulating Free DNA Mutation | Circulating Free Deoxyribonucleic Acid Mutation | Mutated Cell-Free DNA | Mutated cfDNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525091","Elevated CA19-9","C138070","A laboratory test result indicating the presence of an increased level of the tumor-associated antigen (TAA) CA19-9 in a biological sample.","Elevated CA19-9 | Elevated CA19-9 Antigen | Elevated Cancer Antigen 19-9 | Elevated Carbohydrate Antigen 19-9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525090","PSA Level Less than 0.1","C138071","An indication that a blood concentration of prostate specific antigen below 0.1 ng/mL was detected in a sample.","PSA Level Less than 0.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525089","ASS1 Gene Deficiency","C138072","A genetic finding indicating that low expression of the ASS1 gene has been detected in a sample.","ASS1 Gene Deficiency | ASS1 Low Expression | Argininosuccinate Synthase 1 Gene Deficiency | Argininosuccinate Synthase 1 Low",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525067","Elevated CEA","C138073","A laboratory test result indicating the presence of an increased level of the tumor-associated antigen (TAA) CEA in a biological sample.","Elevated CEA | Elevated Carcinoembryonic Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525066","GPNMB Positive","C138074","An indication that GPNMB expression has been detected in a sample.","GPNMB Positive | Glycoprotein Nmb Positive | Glycoprotein Nonmetastatic Melanoma Protein B Positive | NMB Positive | Transmembrane Glycoprotein Nmb Positive | gpNMB Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3472504","Sexual Health Inventory for Men","C138113","A 5-item questionnaire for screening and diagnosis of erectile dysfunction (ED) and severity of ED in clinical practice and research.","Sexual Health Inventory for Men | SHIM | Sexual Health Inventory for Men (SHIM)",,,,,,,,,,,,,,,"42872757","Sexual health inventory for men",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL525050","Confidence Can Get and Keep Erection","C138114","A question to rate the confidence of an individual with regard to getting and keeping an erection.","Confidence Can Get and Keep Erection | Can Get and Keep Erection Confidence Rating | How do you rate your confidence that you could get and keep an erection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525048","How Often Erection with Sexual Stimulation Hard Enough for Penetration","C138116","A question about how often an individual's erection was hard enough for penetration when the erection was due to sexual stimulation.","How Often Erection with Sexual Stimulation Hard Enough for Penetration | When you had erections with sexual stimulation, how often were your erections hard enough for penetration (entering your partner)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525054","How Often Able to Maintain Erection After Penetration During Sexual Intercourse","C138117","A question about how often an individual is or was able to maintain an erection after they penetrated their partner.","How Often Able to Maintain Erection After Penetration During Sexual Intercourse Question | During sexual intercourse, how often were you able to maintain your erection after you had penetrated (entered) your partner | How Often Able to Maintain Erection After Penetration During Sexual Intercourse | How Often Able to Maintain Erection After Penetration During Sexual Intercourse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525053","How Difficult to Maintain Erection to Complete Sexual Intercourse","C138118","A question about how difficult it is or was for an individual to maintain their erection to completion of intercourse.","How Difficult to Maintain Erection to Complete Sexual Intercourse | During sexual intercourse, how difficult was it to maintain your erection to completion of intercourse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525052","How Often Sexual Intercourse Satisfactory","C138119","A question about how often sexual intercourse is or was satisfactory when attempted by an individual.","How Often Sexual Intercourse Satisfactory | When you attempted sexual intercourse, how often was it satisfactory for you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525051","Erectile Dysfunction Severity Breakpoint","C138120","Scoring groups for the Sexual Health Inventory for Men: 1-7, Severe erectile dysfunction; 8-11, Moderate erectile dysfunction; 12-16, Mild to Moderate erectile dysfunction; 17-21,  Mild erectile dysfunction.","Erectile Dysfunction Severity Breakpoint | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525103","SOX11 Transcription Factor Staining Method","C138121","Any of various immunohistochemical procedures for visualizing and/or quantitating SOX11 transcription factor expression in a sample. Dysregulation of SOX11 is associated with several types of cancer and has diagnostic and prognostic value.","SOX11 Transcription Factor Staining Method | SOX11 Staining | SOX11 Staining Method | SRY-Related HMG-Box Gene 11 Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525102","DUSP22 Gene Rearrangement","C138122","A molecular abnormality indicating rearrangement of the DUSP22 gene.","DUSP22 Gene Rearrangement | DUSP22 Rearrangement | Dual Specificity Protein Phosphatase 22 Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525105","PROMIS Psychosocial Illness Impact-Positive","C138132","PROMIS question items and instruments designed to assess positive psychosocial (emotional and social) outcomes of illness.","PROMIS Psychosocial Illness Impact-Positive | PII | PIIP | PROMIS Bank v1.0 - Psychosocial Illness Impact-Pos | PROMIS PIIP | Positive Illness Impact | Psychosocial Illness Impact-Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525111","Comfortable with Who I Am","C138133","A question about an individual being comfortable with who they are.","Comfortable with Who I Am | I am comfortable with who I am",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525110","Realize Who True Friends Are","C138134","A question about an individual realizing who their true friends are.","Realize Who True Friends Are | I realize who my true friends are",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525109","Can Adjust to Things I Cannot Change","C138135","A question about an individual's adjustment to things they cannot change.","Can Adjust to Things I Cannot Change | I can adjust to things I cannot change",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525108","Life is Meaningful","C138136","A question about an individual's life being meaningful.","Life is Meaningful | My life is meaningful",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525100","How True Before Illness","C138137","A question about how true something was before an individual's illness.","How True Before Illness | How true was this before your illness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511303","Breast Carcinoma with Melanotic Features","C40351","A very rare primary malignant tumor of the breast, characterized by an invasive breast carcinoma that co-exists with a melanoma component.  The vast majority of melanotic tumors that affect the breast are metastatic melanomas that originate in extra-mammary sites.","Breast Carcinoma with Melanotic Features | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511302","Breast Carcinoma with Choriocarcinomatous Features","C40350","An invasive ductal breast carcinoma, not otherwise specified, characterized by increased levels of human beta-chorionic gonadotropin in the serum.  Morphologic evidence of choriocarcinomatous differentiation is rare.","Breast Carcinoma with Choriocarcinomatous Features | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3839546","Malignant Breast Adenomyoepithelioma","C5143","An adenomyoepithelioma of the breast in which the epithelial, myoepithelial, or both components have undergone malignant transformation.  Such cases may follow an aggressive clinical course, including recurrences and local and distant metastases.","Malignant Breast Adenomyoepithelioma | Adenomyoepithelioma with carcinoma | Breast Adenomyoepithelioma with Malignant Change | Malignant Adenomyoepithelioma of Breast | Malignant Adenomyoepithelioma of the Breast",,,,,,,,,,,,,,,"45766479","Adenomyoepithelioma with carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332635","Breast Neuroendocrine Neoplasm","C5169","A neoplasm that arises from the breast and is composed of cells exhibiting neuroendocrine differentiation. It is classified as neuroendocrine carcinoma or neuroendocrine tumor G1 and neuroendocrine tumor G2. Most cases are neuroendocrine carcinomas.  Primary neuroendocrine tumors in the breast are very rare.","Breast Neuroendocrine Neoplasm | Breast Endocrine Neoplasm | Neuroendocrine Neoplasm of Breast | Neuroendocrine Neoplasm of the Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519207","Breast Sebaceous Carcinoma","C40369","A very rare breast adenocarcinoma with sebaceous differentiation.","Breast Sebaceous Carcinoma | Sebaceous Breast Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987603","Mogamulizumab","C62510","A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons. CCR4, also known as CD194, may be overexpressed on adult T-cell lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) cells.","Mogamulizumab | Immunoglobulin G1, Anti-(CC Chemokine Receptor CCR4) (Human-Mouse Monoclonal KW-0761 Heavy Chain), Disulfide With Human-Mouse Monoclonal KW-0761 Kappa-Chain, Dimer | KM8761 | KW 0761 | KW-0761 | KW0761 | MOGAMULIZUMAB | Mogamulizumab-kpkc | Poteligeo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524520","Mismatch Repair Deficiency","C136712","A finding indicating that a cellular sample has high microsatellite instability and/or a functional loss of a protein involved in the DNA mismatch repair process.","Mismatch Repair Deficiency | Deficient DNA Mismatch Repair | MMR Deficiency | MMR Deficient | Mismatch Repair Deficient | dMMR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512285","H3 K28M Mutation","C129310","A change in the amino acid residue at position 27 in histone H3 where lysine has been replaced by methionine.","H3 K27M Variant | H3 K27M | H3 K27M Mutation | H3 K27M Mutation | H3 K28M | H3 K28M Mutation | H3 K28M Variant | H3 Lys27Met | H3 Lys28Met | H3 p.K28M | H3 p.Lys28Met | H3K27M | H3K27M Mutation | Histone 3 K27M Mutation | Histone 3 K28M Mutation | Histone H3 K27M | Histone H3 K28M | Histone H3 Lys27Met | Histone H3 Lys28Met",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2939465","Glucose-6-Phosphate Dehydrogenase Deficiency","C98933","An X-linked recessive inherited disorder caused by mutations in the G6PD gene. It is characterized by the absence or presence of very low levels of glucose-6-phosphate dehydrogenase. Patients develop hemolytic anemia usually in response to infection or exposure to drugs.","Glucose-6-Phosphate Dehydrogenase Deficiency | G-6-PD Variant Enzyme Deficiency Anemia | G6PD | G6PD Deficiency",,,,,,,,,,,,,,,"4269764","Glucose-6-phosphate dehydrogenase deficiency anemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL522931","MAGEA3 Positive","C135575","An indication that melanoma-associated antigen 3 expression has been detected in a sample.","MAGEA3 Positive | HIP8 Positive | HYPD Positive | MAGE-3 Positive | MAGE-A3 Positive | MAGE3 Positive | Melanoma-Associated Antigen 3 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514169","Anaplastic Breast Carcinoma","C5161","A rare, aggressive, high grade invasive ductal carcinoma, not otherwise specified.  It is characterized by the presence of pleomorphic and bizarre malignant cells that constitute more than 50 percent of the malignant cellular infiltrate.","Breast Pleomorphic Carcinoma | Anaplastic Breast Carcinoma | Pleomorphic Breast Carcinoma | Pleomorphic Breast Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825844","ALK Fusion Protein Expression","C81946","Expression of fusion protein transcripts resulting from genetic alterations of the anaplastic lymphoma kinase (ALK) gene.","ALK Fusion Protein Expression | ALK Fusion Protein Positive | ALK Tyrosine Kinase Receptor Fusion Protein Expression | Anaplastic Lymphoma Kinase Fusion Protein Expression | CD246 Antigen Fusion Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031749","Photography","C94527","The process by which an image is acquired by recording light emissions on radiation-sensitive paper.","Photography | PHOTOGRAPHY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825498","Measurement Device","C81182","Any device used to determine the dimension of an object.","Measurement Device | Measuring device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054348","Non Progressive Disease","C123599","Following a previous assessment of progressive disease unconfirmed (PDu) of non-target lesion(s), the subsequent required assessment does not confirm progressive disease.","Non Progressive Disease | NON-PD | Non-PD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272974","Non Complete Response/Non Progressive Disease","C96700","Persistence of one or more non-target lesion(s) and/or maintenance of tumor marker levels above the normal limits. (RECIST)","Non Complete Response/Non Progressive Disease | NON-CR/NON-PD | Non-CR/Non-PD-Non-CR/Non-PD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522545","c-Myc Staining Method","C23035","c-Myc staining is a sensitive immunohistochemical method for studying the tissue localization of c-Myc protein using antibody followed by a microscopic observation of the c-Myc staining distribution. The technique is used to detect overexpression of c-Myc oncogene which leads to cancer.","c-Myc Staining Method | Cmyc Staining Method | MYC Staining Method | Myc Proto-Oncogene Protein Staining Method | Proto-Oncogene c-Myc Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525735","Luminal A Prostate Carcinoma","C138168","Prostate carcinoma associated with increased androgen receptor expression and signaling (androgen activity pathway), increased luminal markers, and a lower proliferation score than the luminal B and basal-like prostate carcinomas.","Luminal A Prostate Carcinoma | Luminal A Prostate Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525734","Luminal B Prostate Carcinoma","C138169","Prostate carcinoma associated with increased androgen receptor expression and signaling (androgen activity pathway), increased luminal markers, and a higher proliferation score than the luminal A prostate carcinoma. Patients with luminal B prostate carcinoma have the poorest prognosis but respond better to postoperative androgen deprivation therapy compared to patients with non-luminal B prostate carcinoma.","Luminal B Prostate Carcinoma | Luminal B Prostate Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525733","Basal-Like Prostate Carcinoma","C138170","Prostate carcinoma in which the CD49f signature is increased, the luminal markers and androgen receptor expression and signaling (androgen activity pathway) are not increased, and the proliferation score is higher than the luminal A prostate carcinoma.","Basal-Like Prostate Carcinoma | Basal-Like Prostate Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525737","t(2;5)","C138175","A cytogenetic abnormality that involves a translocation between chromosomes 2 and 5.","t(2;5) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525739","t(11;18)","C138176","A cytogenetic abnormality that involves a translocation between chromosomes 11 and 18.","t(11;18) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525738","Epstein-Barr Encoding Region in situ Hybridization","C138177","Any of various in situ hybridization methods for the detection of latent Epstein-Barr virus (EBV) in tissue sections or other samples. The two small noncoding RNAs, Epstein-Barr encoding region (EBER)-1 and EBER-2, are ubiquitously expressed in all known EBV latency states.","Epstein-Barr Encoding Region in situ Hybridization | EBER in situ Hybridization | Epstein-Barr Virus Encoding Region in situ Hybridization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0742343","Acute Chest Syndrome","C138179","A vaso-occlusive crisis of the pulmonary vasculature occurring in patients with sickle cell disease. It is characterized by the presence of a new radiodensity on a chest radiograph accompanied by fever, cough, sputum production, dyspnea, or hypoxia.","Acute Chest Syndrome | ACS",,,,,,,,,,,,,,,"254062","Acute chest syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0522637","Ruler","C138178","A device used for measuring, or for drawing straight lines, consisting of an elongated piece of rigid or semi-rigid material marked with units of measurement.","Ruler | Rule",,,,,,,,,,,,,,,"4008014","Measuring ruler",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0860678","Alpha-1 Globulin Measurement","C92252","The determination of the amount of alpha-1 globulin present in a sample.","Alpha-1 Globulin Measurement | A1-Globulin | Alpha-1 Globulin | GLOBA1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201910","Beta-2 Microglobulin Measurement","C81980","The determination of the amount of beta-2 microglobulin present in a sample.","Beta-2 Microglobulin Measurement | B2MICG | Beta 2 Microglobulin | Beta 2 Microglobulin Measurement | Beta-2 Microglobulin",,,,,,,,,,,,,,,"4216186","Beta-2-microglobulin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0855580","Alpha-2 Globulin Measurement","C92254","The determination of the amount of alpha-2 globulin present in a sample.","Alpha-2 Globulin Measurement | A2-Globulin | Alpha-2 Globulin | GLOBA2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1167820","Beta Globulin Measurement","C92256","The determination of the amount of beta globulin present in a sample.","Beta Globulin Measurement | Beta Globulin | GLOBB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0860681","Gamma Globulin Measurement","C92257","The determination of the amount of gamma globulin present in a sample.","Gamma Globulin Measurement | GLOBG | Gamma Globulin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522928","Serum Immunofixation Electrophoresis","C135571","An immunofixation-based laboratory test performed to detect and type monoclonal immunoglobulins present in a serum sample.","Serum Immunofixation Electrophoresis | SIFE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL429575","Correspondence","C97019","Routine: administrative changes, e.g., change of address, authorized official, or meeting requests.  Donor re-entry request: An applicant's request to re-enter a deferred donor when regulations and/or guidance do not provide a qualification method or process for their specific situation. (21 CFR 610.41(b)) License re-issuance: request from applicant to change legal name. Lot distribution report: Postmarketing report required by 21 CFR 600.81 to be submitted every six (6) months upon approval/licensing of vaccine or biologic product. Final printed labeling.","Correspondence | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054125","Radiologic Response","C123627","An evaluation of the radiologic response of the disease to the therapy.","Radiologic Response | RDIORESP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054530","Metabolic Response","C123623","An evaluation of the metabolic response of the disease to the therapy.","Metabolic Response | METBRESP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL518782","Boston Bowel Preparation Scale","C138206","A tool for reporting the quality of bowel preparation that was developed to limit inter-observer variability, while preserving the ability to distinguish various degrees of bowel cleanliness. The the three broad regions of the colon: the right colon, the transverse colon, and the left colon are rated 0-3 and these segment scores are summed for a total BBPS score ranging from 0 to 9.","Boston Bowel Preparation Scale | BBPS",,,,,,,,,,,,,,,"36717586","BBPS - Boston bowel preparation scale",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL525707","Boston Bowel Preparation Segment Score 0","C138207","Unprepared colon segment with mucosa not seen due to solid stool that cannot be cleared.","Boston Bowel Preparation Segment Score 0 | Segment Score 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525713","Boston Bowel Preparation Segment Score 1","C138208","Portion of mucosa of the colon segment seen, but other areas of the colon segment not well seen due to staining, residual stool and/or opaque liquid.","Boston Bowel Preparation Segment Score 1 | Segment Score 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525712","Boston Bowel Preparation Segment Score 2","C138209","Minor amount of residual staining, small fragments of stool and/or opaque liquid, but mucosa of colon segment seen well.","Boston Bowel Preparation Segment Score 2 | Segment Score 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525711","Boston Bowel Preparation Segment Score 3","C138210","Entire mucosa of colon segment seen well with no residual staining, small fragments of stool or opaque liquid.","Boston Bowel Preparation Segment Score 3 | Segment Score 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525727","PDGFRA Gene Mutation Negative","C138193","A genetic finding indicating that PDGFRA gene mutations have not been detected in a sample.","PDGFRA Gene Mutation Negative | CD140A Gene Mutation Negative | No mutation detected | PDGFR-2 Gene Mutation Negative | PDGFR2 Gene Mutation Negative | PDGFRA Mutation Negative | PDGFRA Wild Type | PDGFRA Wildtype | PDGFRA wt | PDGFRalpha Gene Mutation Negative | Platelet-Derived Growth Factor Receptor Alpha Gene Mutation Negative | RHEPDGFRA Gene Mutation Negative | Wild-type PDGFRA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525726","KIT Gene Mutation Negative","C138194","A genetic finding indicating that KIT gene mutations have not been detected in a sample.","KIT Gene Mutation Negative | CD117 Gene Mutation Negative | KIT Mutation Negative | KIT Proto-Oncogene Tyrosine Protein Kinase Gene Mutation Negative | KIT Wild Type | KIT Wildtype | KIT wt | No mutation detected | Wild-type KIT | c-KIT Gene Mutation Negative | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525702","Barely Any","C138196","A response indicating a very small amount.","Barely Any | Barely any | Hardly Any",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525701","Assistance with Registering","C138197","A response indicating that an individual required assistance with registering.","Assistance with Registering | Registering with the application | Registering with the application the first time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525700","Assistance Reading Questions","C138198","A response indicating that an individual required assistance reading questions.","Assistance Reading Questions | Reading Questions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525699","Assistance Entering Answers","C138199","A response indicating that an individual required assistance entering answers.","Assistance Entering Answers | Entering Answers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525706","Assistance Submitting Questionnaire","C138200","A response indicating that an individual required assistance submitting a questionnaire.","Assistance Submitting Questionnaire | Submitting Questionnaires",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525705","Assistance with Password","C138201","A response indicating that an individual required assistance with a password.","Assistance with Password | Password Assistance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525704","Used Personal Smartphone","C138202","A response indicating that an individual used their personal smartphone.","Used Personal Smartphone | My personal smartphone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525703","Used Personal Tablet","C138203","A response indicating that an individual used their personal tablet.","Used Personal Tablet | My personal tablet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525709","Used Clinic's Tablet","C138204","A response indicating that an individual used a tablet belonging to a healthcare clinic.","Used Clinic's Tablet | A health care clinic tablet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525708","Used Family or Friend's Smartphone","C138205","A response indicating that an individual used the smartphone belonging to a friend or family member.","Used Family or Friend's Smartphone | My family or friend's smartphone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525823","Assistance Getting Started with the Application","C138324","A response indicating that an individual required assistance getting started with an application.","Assistance Getting Started with the Application | Help getting started with the application",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525822","Assistance Reading Answers","C138325","A response indicating that an individual required assistance reading answers.","Assistance Reading Answers | Help reading answers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525821","Assistance Reading Questions and Answers","C138326","A response indicating that an individual required assistance reading questions and answers.","Assistance Reading Questions and Answers | Help reading questions and answers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525820","Used Paper Form","C138327","A response indicating that an individual used a paper form.","Used Paper Form | Paper form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520718","Line of Therapy","C133518","The sequence of therapies administered to a patient.","Line of Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525748","Cordonnier Infectious Complications Grading Scale","C138287","A three-level prognostic grading system that describes the severity of infectious complications occurring in allogeneic stem cell transplant (SCT) recipients.","Cordonnier Infectious Complications Grading Scale | Cordonnier Infection Grading Scale | Cordonnier Infection Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525850","Cordonnier Grade 1 Bacterial Complication, Outpatient Treatment Bacterial Focus","C138293","Any bacterially-focused infection treated as an outpatient (e.g., urinary tract infection, angina), excluding any form of bronchopneumonia.","Cordonnier Grade 1 Bacterial Complication, Outpatient Treatment Bacterial Focus | Cordonnier Grade 1 Bacterial Complication | Grade 1 Bacterial Focus Treated in Outpatients Excluding Any Form of Bronchopneumonia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525849","Cordonnier Grade 2 Bacterial Complication, Bacteremia without Severe Sepsis","C138294","Any bacteremia without severe sepsis.","Cordonnier Grade 2 Bacterial Complication, Bacteremia without Severe Sepsis | Grade 2 Bacteremia without Severe Sepsis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525848","Cordonnier Grade 2 Bacterial Complication Requiring Inpatient Management","C138295","Any bacterially-focused infection requiring treated as an inpatient.","Cordonnier Grade 2 Bacterial Complication Requiring Inpatient Management | Grade 2 Bacterial Focus Requiring Inpatient Management",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525855","Cordonnier Grade 3 Bacterial Complication, Bacteremia with Severe Sepsis","C138296","Any bacteremia with severe sepsis.","Cordonnier Grade 3 Bacterial Complication, Bacteremia with Severe Sepsis | Grade 3 Bacterial Infection Bacteremia with Severe Sepsis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525854","Cordonnier Grade 3 Bacterial Complication, Complex Bacteremia","C138297","Any complex bacteremia with deep organ involvement.","Cordonnier Grade 3 Bacterial Complication, Complex Bacteremia | Grade 3 Complex Bacteremia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525853","Cordonnier Grade 1 Fungal Complication, Superficial Candida Infection","C138298","Any superficial Candida infection.","Cordonnier Grade 1 Fungal Complication, Superficial Candida Infection | Cordonnier Grade 1 Fungal Complication | Grade 1 Superficial Candida Infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525852","Cordonnier Grade 2 Fungal Complication, Deep Candida Infection without Candidemia","C138299","Any deep Candida infection without candidemia.","Cordonnier Grade 2 Fungal Complication, Deep Candida Infection without Candidemia | Grade 2 Deep Candida Infection without Candidemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525859","Cordonnier Grade 2 Fungal Complication, Candidemia without Severe Sepsis","C138300","Any candidemia without severe sepsis and without focus.","Cordonnier Grade 2 Fungal Complication, Candidemia without Severe Sepsis | Grade 2 Candidemia without Severe Sepsis and without Focus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525858","Cordonnier Grade 2 Fungal Complication, Aspergillus Sinusitis without Bone Involvement","C138301","Any Aspergillus sinusitis without bone involvement.","Cordonnier Grade 2 Fungal Complication, Aspergillus Sinusitis without Bone Involvement | Grade 2 Aspergillus Sinusitis without Bone Involvement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525857","Cordonnier Grade 3 Fungal Complication, Candidemia with Either Sepsis or Deep Focus","C138302","Any candidemia with either sepsis or deep focus.","Cordonnier Grade 3 Fungal Complication, Candidemia with Either Sepsis or Deep Focus | Grade 3 Candidemia with Either Sepsis or Deep Focus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525856","Cordonnier Grade 3 Fungal Complication, Proven or Probable Aspergillus Pneumonia","C138303","Any proven or probable Aspergillus pneumonia.","Cordonnier Grade 3 Fungal Complication, Proven or Probable Aspergillus Pneumonia | Grade 3 Proven or Probable Aspergillus Pneumonia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525863","Cordonnier Grade 1 Viral Complication, Mucous Herpes Simplex Virus Infection","C138304","Any mucous herpes simplex virus infection.","Cordonnier Grade 1 Viral Complication, Mucous Herpes Simplex Virus Infection | Cordonnier Grade 1 Viral Complication | Grade 1 Mucous HSV Infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525862","Cordonnier Grade 2 Viral Complication, Varicella Zoster Virus Infection","C138305","Any Varicella zoster virus infection.","Cordonnier Grade 2 Viral Complication, Varicella Zoster Virus Infection | Grade 2 VZV Infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525861","Cordonnier Grade 3 Viral Complication, Severe Varicella Zoster Virus Infection","C138306","Any severe Varicella zoster virus infection.","Cordonnier Grade 3 Viral Complication, Severe Varicella Zoster Virus Infection | Grade 3 Severe VZV Infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525860","Cordonnier Grade 3 Viral Complication, Viral Encephalitis","C138307","Any viral encephalitis.","Cordonnier Grade 3 Viral Complication, Viral Encephalitis | Grade 3 Any Viral Encephalitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525835","Cordonnier Grade 1 Viral Complication, Asymptomatic Cytomegalovirus Infection","C138308","Any asymptomatic cytomegalovirus infection.","Cordonnier Grade 1 Viral Complication, Asymptomatic Cytomegalovirus Infection | Grade 1 Asymptomatic CMV Infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525834","Cordonnier Grade 2 Viral Complication, Symptomatic Cytomegalovirus Infection","C138309","Any symptomatic cytomegalovirus infection.","Cordonnier Grade 2 Viral Complication, Symptomatic Cytomegalovirus Infection | Grade 2 Symptomatic CMV Infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525833","Cordonnier Grade 3 Viral Complication, Cytomegalovirus Pneumonia or Gut Disease","C138310","Any cytomegalovirus pneumonia or gut disease.","Cordonnier Grade 3 Viral Complication, Cytomegalovirus Pneumonia or Gut Disease | Grade 3 CMV Pneumonia or Gut Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525832","Cordonnier Grade 2 Parasitic Complication, Toxoplasmosis Infection without Organ Involvement","C138311","Any Toxoplasmosis infection without organ involvement.","Cordonnier Grade 2 Parasitic Complication, Toxoplasmosis Infection without Organ Involvement | Cordonnier Grade 2 Parasitic Complication | Grade 2 Toxoplasmosis Infection without Organ Involvement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525839","Cordonnier Grade 3 Parasitic Complication, Pneumocystis jiroveci Pneumonia","C138312","Any Pneumocystis jiroveci pneumonia.","Cordonnier Grade 3 Parasitic Complication, Pneumocystis jiroveci Pneumonia | Grade 3 Pneumocystis jiroveci Pneumonia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525838","Cordonnier Grade 3 Parasitic Complication, Central Nervous System or Other Organ Toxoplasmosis","C138313","Any Toxoplasmosis infection with central nervous system involvement or other organ involvement.","Cordonnier Grade 3 Parasitic Complication, Central Nervous System or Other Organ Toxoplasmosis | Grade 3 CNS or Other Organ Toxoplasmosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525837","Cordonnier Grade 1 Fever of Unknown Origin in Neutropenic Patient","C138314","Any fever of unknown origin in a neutropenic patient receiving broad spectrum antibiotics.","Cordonnier Grade 1 Fever of Unknown Origin in Neutropenic Patient | Grade 1 Fever of Unknown Origin in Neutropenic Patients Receiving Broad Spectrum Antibiotics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525843","Cordonnier Grade 2 Pneumonia or Bronchopneumonia with PaO2 Greater than 65 mmHg","C138316","Any pneumonia or bronchopneumonia with PaO2 greater than 65 mmHg.","Cordonnier Grade 2 Pneumonia or Bronchopneumonia with PaO2 Greater than 65 mmHg | Grade 2 Pneumonia or Bronchopneumonia with PaO2 Greater than 65 mmHg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525842","Cordonnier Grade 2 Infectious Symptom Requiring Inpatient Management","C138317","Any infectious symptom requiring inpatient management.","Cordonnier Grade 2 Infectious Symptom Requiring Inpatient Management | Grade 2 Infectious Symptoms Requiring Inpatient Management",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525841","Cordonnier Grade 3 Acute Pneumonia with PaO2 Less than or Equal to 65 mmHg","C138318","Any acute pneumonia with PaO2 less than or equal to 65 mmHg.","Cordonnier Grade 3 Acute Pneumonia with PaO2 Less than or Equal to 65 mmHg | Cordonnier Grade 3 Acute Pneumonia with PaO2  Less than or Equal to 65 mmHg | Grade 3 Acute Pneumonia with PaO2  Less than or Equal to 65 mmHg | Grade 3 Acute Pneumonia with PaO2 Less than or Equal to 65 mmHg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525840","Cordonnier Sepsis Syndrome Requiring Transfer to Intensive Care Unit","C138319","Any sepsis syndrome requiring transfer to an intensive care unit.","Cordonnier Sepsis Syndrome Requiring Transfer to Intensive Care Unit | Grade 3 Sepsis Syndrome Requiring Transfer to Intensive Care Unit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525844","Liver Ultrasonographic Elastography","C138323","A noninvasive test that is used to stage fibrosis in the liver. A 50-MHz wave is passed into the liver from a small transducer on the end of an ultrasound probe which measures the velocity of the shear wave (in meters per second) as this wave passes through the liver. The shear wave velocity can then be converted into liver stiffness. This technique is an alternative to liver biopsy.","Liver Ultrasonographic Elastography | Fibroscan | TE | Transient Elastography | VCTE | Vibration-Controlled Transient Elastrography",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086254","EGFR Exon 20 Insertion Mutation","C125605","Mutation located after the C-helix of the tyrosine kinase domain of EGFR.","EGFR Exon 20 Insertion Mutation | Exon 20 Insertion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274366","EGFR NP_005219.2:p.V774_C775insHV","C98695","An insertion of the amino acid sequence histidine-valine between the valine at position 774 and the cysteine at position 775 of the epidermal growth factor receptor protein.","EGFR NP_005219.2:p.V774_C775insHV | EGFR NP_005219.2:p.Val774_Cys775insHisVal | EGFR V774_C775insHV | EGFR p.V774_C775insHV | Epidermal Growth Factor Receptor V774_C775insHV | NP_005219.2:p.H773_V774dup | NP_005219.2:p.His773_Val774dup | NP_005219.2:p.V774_C775insHV | NP_005219.2:p.Val774_Cys775insHisVal | Proto-Oncogene c-ErbB-1 V774_C775insHV | Receptor Tyrosine-Protein Kinase erbB-1 V774_C775insHV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274357","EGFR NP_005219.2:p.H773_V774insGNPH","C98686","An insertion of the amino acid sequence glycine-asparagine-proline-histidine between the histidine at position 773 and the valine at position 774 of the epidermal growth factor receptor protein.","EGFR NP_005219.2:p.H773_V774insGNPH | EGFR H773_V774insGNPH | EGFR NP_005219.2:p.His773_Val774insGlyAsnProHis | EGFR p.H773_V774insGNPH | Epidermal Growth Factor Receptor H773_V774insGNPH | NP_005219.2:p.H773_V774insGNPH | NP_005219.2:p.His773_Val774insGlyAsnProHis | Proto-Oncogene c-ErbB-1 H773_V774insGNPH | Receptor Tyrosine-Protein Kinase erbB-1 H773_V774insGNPH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274363","EGFR NP_005219.2:p.H773_V774insPH","C98692","An insertion of the amino acid sequence proline-histidine between the histidine at position 773 and the valine at position 774 of the epidermal growth factor receptor protein.","EGFR NP_005219.2:p.H773_V774insPH | EGFR H773_V774insPH | EGFR NP_005219.2:p.His773_Val774insProHis | EGFR p.H773_V774insPH | Epidermal Growth Factor Receptor H773_V774insPH | NP_005219.2:p.H773_V774insPH | NP_005219.2:p.P772_H773dup | NP_005219.2:p.Pro772_His773dup | Proto-Oncogene c-ErbB-1 H773_V774insPH | Receptor Tyrosine-Protein Kinase erbB-1 H773_V774insPH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274359","EGFR NP_005219.2:p.H773_V774insH","C98688","An insertion of the amino acid histidine between the histidine at position 773 and the valine at position 774 of the epidermal growth factor receptor protein.","EGFR NP_005219.2:p.H773_V774insH | EGFR H773_V774insH | EGFR NP_005219.2:p.His773_Val774insHis | EGFR p.H773_V774insH | Epidermal Growth Factor Receptor H773_V774insH | NP_005219.2:p.H773_V774insH | NP_005219.2:p.H773dup | NP_005219.2:p.His773_Val774insHis | NP_005219.2:p.His773dup | Proto-Oncogene c-ErbB-1 H773_V774insH | Receptor Tyrosine-Protein Kinase erbB-1 H773_V774insH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274361","EGFR NP_005219.2:p.H773_V774insNPH","C98690","An insertion of the amino acid sequence asparagine-proline-histidine between the histidine at position 773 and the valine at position 774 of the epidermal growth factor receptor protein.","EGFR NP_005219.2:p.H773_V774insNPH | EGFR Asn771_His773dupAsnProHis | EGFR Exon 20 Insertion (N771_H773dupNPH) | EGFR H773_V774insNPH | EGFR N771_H773dupNPH | EGFR NP_005219.2:p.His773_Val774insAsnProHis | EGFR p.Asn771_His773dupAsnProHis | EGFR p.H773_V774insNPH | EGFR p.N771_H773dupNPH | Epidermal Growth Factor Receptor H773_V774insNPH | NP_005219.2:p.Asn771_His773dup | NP_005219.2:p.H773_V774insNPH | NP_005219.2:p.His773_Val774insAsnProHis | NP_005219.2:p.N771_H773dup | Proto-Oncogene c-ErbB-1 H773_V774insNPH | Receptor Tyrosine-Protein Kinase erbB-1 H773_V774insNPH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274352","EGFR NP_005219.2:p.P772_H773insYNP","C98680","An insertion of the amino acid sequence tyrosine-asparagine-proline between the proline at position 772 and the histidine at position 773 of the epidermal growth factor receptor protein.","EGFR NP_005219.2:p.P772_H773insYNP | EGFR NP_005219.2:p.Pro772_His773insTyrAsnPro | EGFR P772_H773insYNP | EGFR p.P772_H773insYNP | Epidermal Growth Factor Receptor P772_H773insYNP | NP_005219.2:p.P772_H773insYNP | NP_005219.2:p.Pro772_His773insTyrAsnPro | Proto-Oncogene c-ErbB-1 P772_H773insYNP | Receptor Tyrosine-Protein Kinase erbB-1 P772_H773insYNP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274349","EGFR NP_005219.2:p.P772_H773insPR","C98676","An insertion of the amino acid sequence proline-arginine between the proline at position 772 and the histidine at position 773 of the epidermal growth factor receptor protein.","EGFR NP_005219.2:p.P772_H773insPR | EGFR NP_005219.2:p.Pro772_His773insProArg | EGFR P772_H773insPR | EGFR p.P772_H773insPR | Epidermal Growth Factor Receptor P772_H773insPR | NP_005219.2:p.P772_H773insPR | Proto-Oncogene c-ErbB-1 P772_H773insPR | Receptor Tyrosine-Protein Kinase erbB-1 P772_H773insPR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274346","EGFR NP_005219.2:p.N771_P772insN","C98672","An insertion of the amino acid asparagine between the asparagine at position 771 and the proline at position 772 of the epidermal growth factor receptor protein.","EGFR NP_005219.2:p.N771_P772insN | EGFR N771_P772insN | EGFR NP_005219.2:p.Asn771_Pro772insAsn | EGFR p.N771_P772insN | Epidermal Growth Factor Receptor N771_P772insN | NP_005219.2:p.Asn771dup | NP_005219.2:p.N771_P772insN | NP_005219.2:p.N771dup | Proto-Oncogene c-ErbB-1 N771_P772insN | Receptor Tyrosine-Protein Kinase erbB-1 N771_P772insN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274345","EGFR NP_005219.2:p.N771_P772insH","C98671","An insertion of the amino acid histidine between the asparagine at position 771 and the proline at position 772 of the epidermal growth factor receptor protein.","EGFR NP_005219.2:p.N771_P772insH | EGFR N771_P772insH | EGFR NP_005219.2:p.Asn771_Pro772insHis | EGFR p.N771_P772insH | Epidermal Growth Factor Receptor N771_P772insH | NP_005219.2:p.N771_P772insH | Proto-Oncogene c-ErbB-1 N771_P772insH | Receptor Tyrosine-Protein Kinase erbB-1 N771_P772insH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274325","EGFR NP_005219.2:p.D770_N771insGL","C98650","An insertion of the amino acid sequence glycine-leucine between the aspartic acid at position 770 and the asparagine at position 771 of the epidermal growth factor receptor protein.","EGFR NP_005219.2:p.D770_N771insGL | EGFR D770_N771insGL | EGFR NP_005219.2:p.Asp770_Asn771insGlyLeu | EGFR p.D770_N771insGL | Epidermal Growth Factor Receptor D770_N771insGL | NP_005219.2:p.Asp770_Asn771insGlyLeu | NP_005219.2:p.D770_N771insGL | Proto-Oncogene c-ErbB-1 D770_N771insGL | Receptor Tyrosine-Protein Kinase erbB-1 D770_N771insGL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274320","EGFR NP_005219.2:p.D770_N771insG","C98644","An insertion of the amino acid glycine between the aspartic acid at position 770 and the asparagine at position 771 of the epidermal growth factor receptor protein.","EGFR NP_005219.2:p.D770_N771insG | EGFR D770_N771insG | EGFR NP_005219.2:p.Asp770_Asn771insGly | EGFR p.D770_N771insG | Epidermal Growth Factor Receptor D770_N771insG | NP_005219.2:p.Asp770_Asn771insGly | NP_005219.2:p.D770_N771insG | Proto-Oncogene c-ErbB-1 D770_N771insG | Receptor Tyrosine-Protein Kinase erbB-1 D770_N771insG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274333","EGFR NP_005219.2:p.D770_N771insSVD","C98658","An insertion of the amino acid sequence serine-valine-aspartic acid between the aspartic acid at position 770 and the asparagine at position 771 of the epidermal growth factor receptor protein.","EGFR NP_005219.2:p.D770_N771insSVD | EGFR Asn771_Pro772>SerValAspAsnPro | EGFR D770_N771insSVD | EGFR Exon 20 Insertion (D770_N771insSVD) | EGFR Exon 20 Insertion (N771_P772>SVDNP) | EGFR Exon 20 Insertion (S768_D770dupSVD) | EGFR N771_P772>SVDNP | EGFR NP_005219.2:p.Asp770_Asn771insSerValAsp | EGFR S768_D770dupSVD | EGFR Ser768_Asp770dupSerValAsp | EGFR p. Asn771_Pro772>SerValAspAsnPro | EGFR p.D770_N771insSVD | EGFR p.N771_P772>SVDNP | EGFR p.S768_D770dupSVD | EGFR p.Ser768_Asp770dupSerValAsp | Epidermal Growth Factor Receptor D770_N771insSVD | NP_005219.2:p.Asp770_Asn771insSerValAsp | NP_005219.2:p.D770_N771insSVD | NP_005219.2:p.S768_D770dup | NP_005219.2:p.Ser768_Asp770dup | Proto-Oncogene c-ErbB-1 D770_N771insSVD | Receptor Tyrosine-Protein Kinase erbB-1 D770_N771insSVD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274311","EGFR NP_005219.2:p.V769_D770insGVV","C98630","An insertion of the amino acid sequence glycine-valine-valine between the valine at position 769 and the aspartic acid at position 770 of the epidermal growth factor receptor protein.","EGFR NP_005219.2:p.V769_D770insGVV | EGFR NP_005219.2:p.Val769_Asp770insGlyValVal | EGFR V769_D770insGVV | EGFR p.V769_D770insGVV | Epidermal Growth Factor Receptor V769_D770insGVV | NP_005219.2:p.V769_D770insGVV | NP_005219.2:p.Val769_Asp770insGlyValVal | Proto-Oncogene c-ErbB-1 V769_D770insGVV | Receptor Tyrosine-Protein Kinase erbB-1 V769_D770insGVV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274298","EGFR NP_005219.2:p.V769_D770insASV","C98616","An insertion of the amino acid sequence alanine-serine-valine between the valine at position 769 and the aspartic acid at position 770 of the epidermal growth factor receptor protein.","EGFR NP_005219.2:p.V769_D770insASV | EGFR A767_V769dupASV | EGFR Ala767_Val769dupAlaSerVal | EGFR Asp770_Asn771>AlaSerValAspAsn | EGFR D770_N771>ASVDN | EGFR Exon 20 Insertion (A767_V769dupASV) | EGFR Exon 20 Insertion (D770_N771>ASVDN) | EGFR Exon 20 Insertion (V769_D770insASV) | EGFR NP_005219.2:p.Val769_Asp770insAlaSerVal | EGFR V769_D770insASV | EGFR p. Asp770_Asn771>AlaSerValAspAsn | EGFR p.A767_V769dupASV | EGFR p.Ala767_Val769dupAlaSerVal | EGFR p.D770_N771>ASVDN | EGFR p.V769_D770insASV | Epidermal Growth Factor Receptor V769_D770insASV | NP_005219.2:p.A767_V769dup | NP_005219.2:p.Ala767_Val769dup | NP_005219.2:p.Val769_Asp770insAlaSerVal | Proto-Oncogene c-ErbB-1 V769_D770insASV | Receptor Tyrosine-Protein Kinase erbB-1 V769_D770insASV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274287","EGFR NP_005219.2:p.Y764_V765insHH","C98604","An insertion of the amino acid sequence histidine-histidine between the tyrosine at position 764 and the valine at position 765 of the epidermal growth factor receptor protein.","EGFR NP_005219.2:p.Y764_V765insHH | EGFR NP_005219.2:p.Tyr764_Val765insHisHis | EGFR Y764_V765insHH | EGFR p.Y764_V765insHH | Epidermal Growth Factor Receptor Y764_V765insHH | NP_005219.2:p.Y764_V765insHH | Proto-Oncogene c-ErbB-1 Y764_V765insHH | Receptor Tyrosine-Protein Kinase erbB-1 Y764_V765insHH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274293","EGFR NP_005219.2:p.A763_Y764insFQEA","C98611","An insertion of the amino acid sequence phenylalanine-glutamine-glutamic acid-alanine between the alanine at position 763 and the tyrosine at position 764 of the epidermal growth factor receptor protein.","EGFR NP_005219.2:p.A763_Y764insFQEA | EGFR A763_Y764insFQEA | EGFR Exon 20 Insertion (A763_Y764insFQEA) | EGFR NP_005219.2:p.Ala763_Tyr764insPheGlnGluAla | EGFR p.A763_Y764insFQEA | Epidermal Growth Factor Receptor A763_Y764insFQEA | NP_005219.2:p.A763_Y764insFQEA | NP_005219.2:p.Ala763_Tyr764insPheGlnGluAla | Proto-Oncogene c-ErbB-1 A763_Y764insFQEA | Receptor Tyrosine-Protein Kinase erbB-1 A763_Y764insFQEA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274284","EGFR NP_005219.2:p.D761_E762insEAFQ","C98601","An insertion of the amino acid sequence glutamic acid-alanine-phenylalanine-glutamine between the aspartic acid at position 761 and the glutamic acid at position 762 of the epidermal growth factor receptor protein.","EGFR NP_005219.2:p.D761_E762insEAFQ | EGFR NP_005219.2:p.Asp761_Glu762insGluAlaPheGln | EGFR p.D761_E762insEAFQ | Epidermal Growth Factor Receptor D761_E762insEAFQ | NP_005219.2:p.A763_Y764insFQEA | NP_005219.2:p.Ala763_Tyr764insPheGlnGluAla | NP_005219.2:p.Asp761_Glu762insGluAlaPheGln | Proto-Oncogene c-ErbB-1 D761_E762insEAFQ | Receptor Tyrosine-Protein Kinase erbB-1 D761_E762insEAFQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526978","G-8 Screening Tool","C138906","A tool for the assessment of geriatric cancer patients. It combines 7 questions from the mini nutritional assessment (MNA) with one question regarding subject age. Items selected from MNA concern nutritional status, weight loss, body mass index, motor skills, psychological status, number of medications, and self-perception of health.","G-8 Screening Tool | G-8 | G8 | G8 Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526395","Decline of Food Intake over Past 3 Months","C138907","A question about whether an individual had a decline in food intake over the past 3 months due to loss of appetite, digestive problems, chewing, or swallowing difficulties.","Decline of Food Intake over Past 3 Months | Has food intake declined over the past 3 months due to loss of appetite, digestive problems, chewing or swallowing difficulties",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526394","Weight Loss over Past 3 Months","C138908","A question about whether an individual had a weight loss over the past 3 months.","Weight Loss over Past 3 Months | Weight Loss over Last 3 Months | Weight loss during the last 3 months",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526400","Had Neuropsychological Problems","C138909","A question about whether an individual has or had a neuropsychological problems.","Had Neuropsychological Problems | Neuropsychological problems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526399","Take More than 3 Medications per Day","C138910","A question about whether an individual takes or took more than three medications per day.","Take More than 3 Medications per Day | Takes more than 3 medications per day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526397","Comparison of Health Status","C138912","A question about how an individual considers their health status in comparison to others of the same age.","Comparison of Health Status | How does the patient consider his/her health status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526403","Severe Decrease in Food Intake","C138914","A response indicating than an individual has or had a severe decrease in their food intake.","Severe Decrease in Food Intake | Severe decrease in food intake",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526402","Moderate Decrease in Food Intake","C138915","A response indicating than an individual has or had a moderate decrease in their food intake.","Moderate Decrease in Food Intake | Moderate decrease in food intake",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526379","No Decrease in Food Intake","C138917","A response indicating than an individual has or had no decrease in their food intake.","No Decrease in Food Intake | No decrease in food intake",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526378","Weight Loss Greater Than Three Kilograms","C138918","A response indicating than an individual has or had weight loss exceeding 3 kilograms.","Weight Loss Greater Than Three Kilograms | Weight Loss Exceeding Three Kilograms | Weight loss > 3 kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526377","Weight Loss between 1 and 3 Kilograms","C138919","A response indicating than an individual has or had weight loss between 1 and 3 kilograms.","Weight Loss between 1 and 3 Kilograms | Weight loss between 1 and 3 kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526383","No Weight Loss","C138921","A response indicating than an individual has or had no weight loss.","No Weight Loss | No weight loss",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526382","Bed or Chair Bound","C138922","A response indicating than an individual is or was bed or chair bound.","Bed or Chair Bound | Bed or chair bound",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526381","Able to Get Out of Bed or Chair but Does Not Go Out","C138923","A response indicating than an individual is or was able to get out of bed or chair, but did or does not go out.","Able to Get Out of Bed or Chair but Does Not Go Out | Able to get out of bed/chair but does not go out",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526387","Goes Out","C138925","A response indicating than an individual is or was able to go out.","Goes Out | Goes out",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526386","Severe Dementia or Depression","C138926","A response indicating than an individual has or had severe dementia or depression.","Severe Dementia or Depression | Severe dementia or depression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526385","Mild Dementia or Depression","C138927","A response indicating than an individual has or had mild dementia or depression.","Mild Dementia or Depression | Mild dementia or depression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526384","No Psychological Problems","C138928","A response indicating than an individual has or had no psychological problems.","No Psychological Problems | No psychological problems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526390","Not as Good as Others","C138929","A response indicating than an individual is not or was not as good as others.","Not as Good as Others | Not as good",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526389","As Good as Others","C138930","A response indicating than an individual is or was as good as others.","As Good as Others | As good",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526977","Better than Others","C138931","A response indicating than an individual is or was better than others.","Better than Others | Better",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526388","Body Mass Index Less Than 19","C138932","Indicates a body mass index measurement less than 19.","Body Mass Index Less Than 19 | BMI < 19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526479","Body Mass Index 19 to Less Than 21","C138933","Indicates a body mass index measurement greater than or equal to 19 but below 21.","Body Mass Index 19 to Less Than 21 | BMI 19 to < 21",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526478","Body Mass Index 21 to Less Than 23","C138934","Indicates a body mass index measurement greater than or equal to 21 but below 23.","Body Mass Index 21 to Less Than 23 | BMI 21 to < 23",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526477","Body Mass Index Greater Than or Equal to 23","C138935","Indicates a body mass index measurement greater than or equal to 23.","Body Mass Index Greater Than or Equal to 23 | BMI > 23",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526476","Age Greater than 85 Years","C138936","An indication that an individual's age is or was greater than 85 years.","Age Greater than 85 Years | Age > 85",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526482","Age Between 80 and 85 Years","C138937","An indication that an individual's age is or was between 80 and 85 years.","Age Between 80 and 85 Years | Age 80-85",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526971","Age Less than 80 Years","C138938","An indication that an individual's age is or less than 80 years.","Age Less than 80 Years | Age < 80",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273999","BRAF NP_004324.2:p.V600M","C98351","A change in the amino acid residue at position 600 in the serine/threonine protein kinase B-raf protein where valine has been replaced by methionine.","BRAF NP_004324.2:p.V600M | BRAF NP_004324.2:p.Val600Met | BRAF V600M | BRAF V600M Mutation | BRAF Val600Met | BRAF p.V600M | BRAF p.Val600Met | NP_004324.2:p.V600M | NP_004324.2:p.Val600Met | Serine/Threonine-Protein Kinase B-raf V600M | Serine/Threonine-Protein Kinase B-raf Val600Met",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526393","EGFR NP_005219.2:p.D770_N771insGV","C138902","An insertion of the amino acid sequence glycine-valine between the aspartic acid at position 770 and the asparagine at position 771 of the epidermal growth factor receptor protein.","EGFR NP_005219.2:p.D770_N771insGV | EGFR Asp770_Asn771insGlyVal | EGFR D770_N771insGV | EGFR NP_005219.2:p.Asp770_Asn771insGlyVal | EGFR p.Asp770_Asn771insGlyVal | EGFR p.D770_N771insGV | Epidermal Growth Factor Receptor Asp770_Asn771insGlyVal | Epidermal Growth Factor Receptor D770_N771insGV | NP_005219.2:p.Asp770_Asn771insGlyVal | NP_005219.2:p.D770_N771insGV | Proto-Oncogene c-ErbB-1 Asp770_Asn771insGlyVal | Proto-Oncogene c-ErbB-1 D770_N771insGV | Receptor Tyrosine-Protein Kinase erbB-1 Asp770_Asn771insGlyVal | Receptor Tyrosine-Protein Kinase erbB-1 D770_N771insGV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526392","EGFR NP_005219.2:p.M766_A767insASV","C138903","An insertion of the amino acid sequence alanine-serine-valine between the methionine at position 766 and the alanine at position 767 of the epidermal growth factor receptor protein.","EGFR NP_005219.2:p.M766_A767insASV | EGFR M766_A767insASV | EGFR Met766_Ala767insAlaSerVal | EGFR NP_005219.2:p.Met766_Ala767insAlaSerVal | EGFR p.M766_A767insASV | EGFR p.Met766_Ala767insAlaSerVal | Epidermal Growth Factor Receptor M766_A767insASV | Epidermal Growth Factor Receptor Met766_Ala767insAlaSerVal | NP_005219.2:p.M766_A767insASV | NP_005219.2:p.Met766_Ala767insAlaSerVal | Proto-Oncogene c-ErbB-1 M766_A767insASV | Proto-Oncogene c-ErbB-1 Met766_Ala767insAlaSerVal | Receptor Tyrosine-Protein Kinase erbB-1 Met766_Ala767insAlaSerVal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526391","EGFR NP_005219.2:p.P772_H773insNP","C138904","An insertion of the amino acid sequence asparagine-proline between the proline at position 772 and the histidine at position 773 of the epidermal growth factor receptor protein.","EGFR NP_005219.2:p.P772_H773insNP | EGFR NP_005219.2:p.Pro772_His773insAsnPro | EGFR P772_H773insNP | EGFR Pro772_His773insAsnPro | EGFR p.P772_H773insNP | EGFR p.Pro772_His773insAsnPro | Epidermal Growth Factor Receptor P772_H773insNP | Epidermal Growth Factor Receptor Pro772_His773insAsnPro | NP_005219.2:p.P772_H773insNP | NP_005219.2:p.Pro772_His773insAsnPro | Proto-Oncogene c-ErbB-1 P772_H773insNP | Proto-Oncogene c-ErbB-1 Pro772_His773insAsnPro | Receptor Tyrosine-Protein Kinase erbB-1 P772_H773insNP | Receptor Tyrosine-Protein Kinase erbB-1 Pro772_His773insAsnPro",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526396","EGFR NP_005219.2:p.P772_V774insPHV","C138905","An insertion of the amino acid sequence proline-histidine-valine between the proline at position 772 and the valine at position 774 of the epidermal growth factor receptor protein.","EGFR NP_005219.2:p.P772_V774insPHV | EGFR NP_005219.2:p.Pro772_Val774insProHisVal | EGFR P772_V774insPHV | EGFR Pro772_Val774insProHisVal | EGFR p.P772_V774insPHV | EGFR p.Pro772_Val774insProHisVal | Epidermal Growth Factor Receptor P772_V774insPHV | Epidermal Growth Factor Receptor Pro772_Val774insProHisVal | NP_005219.2:p.P772_V774insPHV | NP_005219.2:p.Pro772_Val774insProHisVal | Proto-Oncogene c-ErbB-1 P772_V774insPHV | Proto-Oncogene c-ErbB-1 Pro772_Val774insProHisVal | Receptor Tyrosine-Protein Kinase erbB-1 P772_V774insPHV | Receptor Tyrosine-Protein Kinase erbB-1 Pro772_Val774insProHisVal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526398","EGFR NP_005219.2:p.P772_H773insNPH","C138911","An insertion of the amino acid sequence asparagine-proline-histidine between the proline at position 772 and the histidine at position 773 of the epidermal growth factor receptor protein.","EGFR NP_005219.2:p.P772_H773insNPH | EGFR NP_005219.2:p.Pro772_His773insAsnProHis | EGFR P772_H773insNPH | EGFR Pro772_His773insAsnProHis | EGFR p.P772_H773insNPH | EGFR p.Pro772_His773insAsnProHis | Epidermal Growth Factor Receptor P772_H773insNPH | Epidermal Growth Factor Receptor Pro772_His773insAsnProHis | NP_005219.2:p.P772_H773insNPH | NP_005219.2:p.Pro772_His773insAsnProHis | Proto-Oncogene c-ErbB-1 P772_H773insNPH | Proto-Oncogene c-ErbB-1 Pro772_His773insAsnProHis | Receptor Tyrosine-Protein Kinase erbB-1 P772_H773insNPH | Receptor Tyrosine-Protein Kinase erbB-1 Pro772_His773insAsnProHis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526401","EGFR Asp770_Asn771insGlyThr","C138916","An insertion of the amino acid sequence glycine-threonine between the aspartic acid at position 770 and the asparagine at position 771 of the epidermal growth factor receptor protein.","EGFR NP_005219.2:p.D770_N771insGT | EGFR Asp770_Asn771insGlyThr | EGFR D770_N771insGT | EGFR NP_005219.2:D770_N771insGT | EGFR NP_005219.2:p.Asp770_Asn771insGlyThr | EGFR p.Asp770_Asn771insGlyThr | EGFR p.D770_N771insGT | Epidermal Growth Factor Receptor Asp770_Asn771insGlyThr | Epidermal Growth Factor Receptor D770_N771insGT | NP_005219.2:p.Asp770_Asn771insGlyThr | NP_005219.2:p.D770_N771insGT | Proto-Oncogene c-ErbB-1 Asp770_Asn771insGlyThr | Proto-Oncogene c-ErbB-1 D770_N771insGT | Receptor Tyrosine-Protein Kinase erbB-1 Asp770_Asn771insGlyThr | Receptor Tyrosine-Protein Kinase erbB-1 D770_N771insGT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526380","EGFR NP_005219.2:p.H773_V774insAH","C138924","An insertion of the amino acid sequence alanine-histidine between the histidine at position 773 and the valine at position 774 of the epidermal growth factor receptor protein.","EGFR NP_005219.2:p.H773_V774insAH | EGFR H773_V774insAH | EGFR His773_Val774insAlaHis | EGFR NP_005219.2:p.H773_V774insAH  | EGFR NP_005219.2:p.His773_Val774insAlaHis | EGFR p.H773_V774insAH | EGFR p.His773_Val774insAlaHis | Epidermal Growth Factor Receptor H773_V774insAH | Epidermal Growth Factor Receptor His773_Val774insAlaHis | NP_005219.2:p.H773_V774insAH | NP_005219.2:p.His773_Val774insAlaHis | Proto-Oncogene c-ErbB-1 H773_V774insAH | Proto-Oncogene c-ErbB-1 His773_Val774insAlaHis | Receptor Tyrosine-Protein Kinase erbB-1 H773_V774insAH | Receptor Tyrosine-Protein Kinase erbB-1 His773_Val774insAlaHis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825409","SYP Positive Neoplastic Cells Present","C81013","An immunophenotypic test result indicating positive staining of neoplastic cells for synaptophysin.","Synaptophysin-Positive Neoplastic Cells Present | SYP Positive Neoplastic Cells Present | Synaptophysin Positive Neoplastic Cells Present | Synaptophysin Positive Neoplastic Cells Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880078","CHGA Positive Neoplastic Cells Present","C60674","An immunophenotypic test result indicating positive staining of neoplastic cells for chromogranin A.","Chromogranin-A Positive Neoplastic Cells Present | CHGA Positive Neoplastic Cells Present | Chromogranin A Positive Neoplastic Cells Present | Chromogranin A Positive Neoplastic Cells Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526484","ABL Positive","C138943","Indicates that the expression of a member of the ABL family has been detected in a sample.","ABL Positive | ABL Family Positive | ABL Proto-Oncogene, Non-Receptor Tyrosine Kinase Positive | Abelson Murine Leukemia Viral Oncogene Homolog Positive | Abelson Tyrosine-Protein Kinase Positive | Tyrosine-Protein Kinase ABL Positive | v-Abl Abelson Murine Leukemia Viral Oncogene Homolog Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526470","AR Negative","C138953","Indicates that expression of AR has not been detected in a sample.","Androgen Receptor Negative | AR Negative | AR Negative | Androgen Receptor Negative | Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526488","CTAG2 Positive","C138947","Indicates that CTAG2 expression has been detected in a sample.","CTAG2 Positive | Cancer/Testis Antigen 2 Positive | ESO2 Positive | L Antigen Family Member 1 Positive | LAGE 1 Positive | LAGE Positive | LAGE-1 Positive | LAGE1 Positive | NY-ESO-2 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526468","GUCY2C Positive","C138955","Indicates that GUCY2C expression has been detected in a sample.","GUCY2C Positive | GC-C Positive | Guanylate Cyclase 2C Positive | Guanylyl Cyclase C Positive | Heat Stable Enterotoxin Receptor Positive | Heat-Stable Enterotoxin Receptor Positive | Intestinal Guanylate Cyclase Positive | STAR Positive | hSTAR Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526464","Heregulin Positive","C138951","Indicates that heregulin expression has been detected in a sample.","Heregulin Positive | Neuregulin Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526465","IGF1 Positive","C138950","Indicates that IGF1 expression has been detected in a sample.","IGF1 Positive | IGF I Positive | IGF-1 Positive | IGF-I Positive | Insulin-Like Growth Factor 1 Positive | Insulin-Like Growth Factor I Positive | Somatomedin C Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526485","KIT Positive","C138942","Indicates that KIT expression has been detected in a sample.","KIT Positive | CD117 Positive | KIT Proto-Oncogene Tyrosine Protein Kinase Positive | Mast/Stem Cell Growth Factor Receptor Kit Positive | Positive | c-KIT Positive | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525845","Neoplastic Plasma Cells More than 20 Percent of Bone Marrow Nucleated Cells","C138322","A semi-quantitative microscopic finding indicating that more than 20 percent of the nucleated cells in a bone marrow sample are neoplastic plasma cells.","Neoplastic Plasma Cells More than 20 Percent of Bone Marrow Nucleated Cells | Neoplastic Plasma Cells Greater than 20 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526469","NOS2 Positive","C138954","Indicates that NOS2 expression has been detected in a sample.","NOS2 Positive | Inducible NO Synthase Positive | NOS2A Positive | Nitric Oxide Synthase 2 Positive | Nitric Oxide Synthase 2, Inducible Positive | Nitric Oxide Synthase, Inducible Positive | iNOS Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526486","PDGFR Positive","C138941","Indicates that the expression of a member of the PDGFR family has been detected in a sample.","PDGFR Positive | PDGF Receptor Positive | PDGFR Family Positive | Platelet Derived Growth Factor Receptor Positive | Platelet-Derived Growth Factor Receptor Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526483","PDGFRB Positive","C138944","Indicates that PDGFRB expression has been detected in a sample.","PDGFRB Positive | CD140b Positive | JTK12 Positive | PDGFR-1 Positive | PDGFR1 Positive | PDGFRbeta Positive | Platelet Derived Growth Factor Receptor Beta Positive | Platelet-Derived Growth Factor Receptor Beta Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525846","PSA Level 0.1 to 50","C138321","A blood concentration of prostate specific antigen between 0.1 and 50 ng/mL.","PSA Level 0.1 to 50 | PSA Level 0.1 to Fifty | PSA Level Between 0.1 and 50 | PSA Level Between 0.1 and Fifty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526489","PSA Level Greater than 0.2","C138946","A blood concentration of prostate specific antigen greater than 0.2 ng/mL.","PSA Level Greater than 0.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526466","PSA Level Greater than One","C138949","A blood concentration of prostate specific antigen greater than 1 ng/mL.","PSA Level Greater than One | PSA Level Greater than 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526480","PSA Level Greater than or Equal to 0.1","C138940","A blood concentration of prostate specific antigen greater than or equal to 0.1 ng/mL.","PSA Level Greater than or Equal to 0.1 | PSA Level 0.1 or Greater",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526463","PSA Level Greater than or Equal to 0.2","C138952","A blood concentration of prostate specific antigen greater than or equal to 0.2 ng/mL.","PSA Level Greater than or Equal to 0.2 | PSA Level 0.2 or Greater",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526487","PSA Level Greater than Two","C138948","A blood concentration of prostate specific antigen greater than 2 ng/mL.","PSA Level Greater than Two | PSA Level Greater than 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526490","PSA Level 10 or Less","C138945","A blood concentration of prostate specific antigen less than or equal to 10 ng/mL.","PSA Level Less than or Equal to Ten | PSA Level 10 or Less | PSA Level Less than or Equal 10 | PSA Level Less than or Equal Ten | PSA Level Ten or Less",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526481","PSA Level Less than or Equal to Fifteen","C138939","A blood concentration of prostate specific antigen less than or equal to 15 ng/mL.","PSA Level Less than or Equal to Fifteen | PSA Level 15 or Less | PSA Level Fifteen or Less | PSA Level Less than or Equal to 15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4034374","Liver Stiffness","C138328","The modulus of elasticity of the liver, representing the resistance of the liver to deformation. Liver stiffness has been shown to be a surrogate marker of advanced fibrosis and cirrhosis. Liver stiffness, measured by transient elastography, is an independent predictor of liver failure, hepatocellular carcinoma, and mortality in cirrhotic patients coinfected with the human immunodeficiency virus or acquired immune deficiency syndrome, and hepatitis C virus.","Liver Stiffness | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525825","Fibrosis-4 Score","C138330","A noninvasive test to assess hepatic fibrosis that utilizes common laboratory findings according to the formula: age (years) x aspartate aminotransferase (AST) [U/L]/(platelets [10^9/L] x alanine aminotransferase (ALT) [U/L])^1/2).","Fibrosis-4 Score | FIB-4 | FIB-4 Index | FIB-4 Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0472681","Continuous Venovenous Hemodialysis","C138331","A method for hemodialysis that removes blood from a large vein (femoral, subclavian, or internal jugular), pumps it through a dialysis circuit, and returns it into the venous circulation. This method avoids fluid shifts and other complications of conventional dialysis for patients with acute renal failure.","Continuous Venovenous Hemodialysis | CVVHD",,,,,,,,,,,,,,,"4051329","Continuous venovenous hemodialysis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526458","Glandular (Acinar)/Tubular Differentiation Score 1","C138975","Greater than 75% of tumor area shows glandular/tubular structures.","Glandular (Acinar)/Tubular Differentiation Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526457","Glandular (Acinar)/Tubular Differentiation Score 2","C138976","10% to 75% of tumor area shows glandular/tubular structures.","Glandular (Acinar)/Tubular Differentiation Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526456","Glandular (Acinar)/Tubular Differentiation Score 3","C138977","Less than 10% of tumor area shows glandular/tubular structures.","Glandular (Acinar)/Tubular Differentiation Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526462","Nuclear Pleomorphism Score 1","C138979","Nuclei small with little increase in size in comparison with normal breast epithelial cells, regular outlines, uniform nuclear chromatin, little variation in size.","Nuclear Pleomorphism Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526461","Nuclear Pleomorphism Score 2","C138980","Cells larger than normal with open vesicular nuclei, visible nucleoli, and moderate variability in both size and shape.","Nuclear Pleomorphism Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526460","Nuclear Pleomorphism Score 3","C138981","Vesicular nuclei, often with prominent nucleoli, exhibiting marked variation in size and shape, occasionally with very large and highly unusual forms.","Nuclear Pleomorphism Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526439","Mitotic Rate Score 1","C138983","A finding of less than or equal to 3 mitoses per mm2 (less than or equal to 7 per 10 hpf).","Mitotic Rate Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526438","Mitotic Rate Score 2","C138984","A finding of 4-7 mitoses per mm2 (8-14 per 10 hpf).","Mitotic Rate Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526437","Mitotic Rate Score 3","C138985","A finding of greater than or equal to 8 mitoses per mm2 (greater than 15 per 10 hpf).","Mitotic Rate Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526443","Nottingham Grade 1","C138987","Total Nottingham scores of 3, 4, or 5.","Nottingham Grade 1 | Nottingham Overall Grade 1 | Overall Grade 1 | Total Nottingham Score, Grade 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526442","Nottingham Grade 2","C138988","Total Nottingham scores of 6 or 7.","Nottingham Grade 2 | Nottingham Overall Grade 2 | Overall Grade 2 | Total Nottingham Score,  Grade 2 | Total Nottingham Score, Grade 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526441","Nottingham Grade 3","C138989","Total Nottingham scores of 8 or 9.","Nottingham Grade 3 | Nottingham Overall Grade 3 | Overall Grade 3 | Total Nottingham Score,  Grade 3 | Total Nottingham Score, Grade 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526539","G-8 Screening Tool Total Score","C138998","The cumulative score for the G-8 geriatric assessment, summing the individual scores from the 7 nutritional questions and the age question. The score ranges from 17 (not at all impaired) to 0 (heavily impaired). A score lower or equal to 14 requires comprehensive geriatric assessment.","G-8 Screening Tool Total Score | G-8 Total Score | G8 Total Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883685","Tubular Structures Present","C61294","A morphologic finding indicating the presence of an architectural pattern of tubular formations in a tissue sample.","Tubular Structures Present | Tubular | Tubular Structures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526732","Used Family or Friend's Tablet","C139287","A response indicating that an individual used a tablet belonging to a friend or family member.","Used Family or Friend's Tablet | My family or friend's tablet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526706","Glandular (Acinar)/Tubular Differentiation","C139289","A morphologic finding indicating the presence of acinar and tubular differentiation  in a tissue sample of an epithelial neoplasm.","Glandular (Acinar)/Tubular Differentiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3489692","CAPIRI","C11602","A regimen containing capecitabine and irinotecan used in the treatment of colorectal, esophageal and gastric cancer.","XELIRI Regimen | CAPIRI | CapIri | Capecitabine-Irinotecan | Capecitabine/Irinotecan | Capecitabine/Irinotecan Regimen | XelIri | Xeloda/Camptosar Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229783","Pancreatic Lymph Node","C77642","A lymph node of the pancreas.","Pancreatic Lymph Node | LYMPH NODE, PANCREATIC | PERIPANCREATIC LYMPH NODE",,,,,,,,,,,,,,,"4300891","Structure of pancreatic lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706379","Microscope Device","C50069","An optical instrument that uses a combination of lenses to produce magnified images of very small objects","Microscope Device | Microscope | Microscope Device Component | microscope",,,,,,,,,,,,,,,"4279164","Microscope",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526709","IPSS Risk Score","C139295","The total score for myelodysplastic syndrome progression that considers the percentage of blasts in bone marrow (scored on a scale from zero to 2), chromosome abnormalities (scored from zero to 1), and the patient's blood counts (scored as zero or 0.5).","IPSS Risk Score | International Prognostic Scoring System for Myelodysplastic Syndrome Risk Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526715","IPSS Risk Score 0","C139297","An International Prognostic Scoring System for Myelodysplastic Syndrome risk score of 0, corresponding to low risk.","IPSS Risk Score 0 | International Prognostic Scoring System for Myelodysplastic Syndrome Risk Score 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526714","IPSS Risk Score 0.5 to 1.0","C139298","An International Prognostic Scoring System for Myelodysplastic Syndrome risk score of 0.5 to 1.0, corresponding to intermediate-1 risk.","IPSS Risk Score 0.5 to 1.0 | International Prognostic Scoring System for Myelodysplastic Syndrome Risk Score 0.5 to 1.0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526713","IPSS Risk Score 1.5 to 2.0","C139299","An International Prognostic Scoring System for Myelodysplastic Syndrome risk score of 1.5-2.0, corresponding to intermediate-2 risk.","IPSS Risk Score 1.5 to 2.0 | International Prognostic Scoring System for Myelodysplastic Syndrome Risk Score 1.5 to 2.0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526712","IPSS Risk Score Greater than or Equal to 2.5","C139300","An International Prognostic Scoring System for Myelodysplastic Syndrome risk score greater than or equal to 2.5, corresponding to high risk.","IPSS Risk Score Greater than or Equal to 2.5 | International Prognostic Scoring System for Myelodysplastic Syndrome Risk Score Greater than or Equal to 2.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526708","IPSS Risk Category","C139296","The risk category for myelodysplastic syndrome progression that is derived from IPSS risk score.","IPSS Risk Category | International Prognostic Scoring System for Myelodysplastic Syndrome Risk Category",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526719","IPSS Risk Category Low","C139301","An International Prognostic Scoring System for Myelodysplastic Syndrome risk category that predicts a low likelihood for progression.","IPSS Risk Category Low | IPSS Low Risk | International Prognostic Scoring System for Myelodysplastic Syndrome Low Risk Category | Low | Low Risk Myelodysplastic Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526718","IPSS Risk Category Intermediate-1","C139302","An International Prognostic Scoring System for Myelodysplastic Syndrome risk category that predicts a low-intermediate likelihood for progression.","IPSS Risk Category Intermediate-1 | IPSS Intermediate-1 Risk | Intermediate-1 | International Prognostic Scoring System for Myelodysplastic Syndrome Intermediate-1 Risk Category",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526717","IPSS Risk Category Intermediate-2","C139303","An International Prognostic Scoring System for Myelodysplastic Syndrome risk category that predicts a high-interdemiate likelihood for progression.","IPSS Risk Category Intermediate-2 | IPSS Intermediate-2 Risk | Intermediate-2 | International Prognostic Scoring System for Myelodysplastic Syndrome Intermediate-2 Risk Category",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526716","IPSS Risk Category High","C139304","An International Prognostic Scoring System for Myelodysplastic Syndrome risk category that predicts a high likelihood for progression.","IPSS Risk Category High | High | IPSS High Risk | International Prognostic Scoring System for Myelodysplastic Syndrome High Risk Category",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526826","Very Little Assistance","C139528","A response indicating that an individual needed very little assistance.","Very Little Assistance | Very Little",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526921","Used Family or Friend's Smartphone or Tablet","C139529","A response indicating that an individual used a smartphone or tablet belonging to a friend or family member.","Used Family or Friend's Smartphone or Tablet | My family or friend's smartphone or tablet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526920","Assistance Installing the App","C139530","A response indicating that an individual required assistance with installing the app.","Assistance Installing the App | Installing the app",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526919","Assistance with Log-in","C139531","A response indicating that an individual required assistance with logging in.","Assistance with Log-in | Log-In Assistance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3852004","Copanlisib","C96796","A phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","Copanlisib | BAY 80 6946 | BAY 80-6946 | BAY 806946 | BAY-80-6946 | BAY806946 | COPANLISIB | PI3K Inhibitor BAY 80-6946",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273710","Sulfonylurea Antidiabetic Agent","C97936","Sulfonamide urea derivatives with antihyperglycemic activity. Sulphonylurea antidiabetic agents bind to sulfonylurea receptor type 1 (SUR1), the subunit of ATP-sensitive inwardly-rectifier potassium (IKATP) channels on the membranes of pancreatic beta cells, thereby blocking the inward current flow (influx) of positively charged K+ ions into the cell. This results in tonic membrane depolarization, and induces a calcium ion influx through voltage-sensitive calcium channels; increased intracellular calcium ion levels trigger exocytosis of insulin-containing granules. This eventually induces secretion of insulin. The IKATP channels found in pancreatic islets are complexes of four IKATP 6.2 and four SUR1 subunits. In addition, some sulfonylureas of larger molecular size may increase the sensitivity of peripheral tissues to insulin mediated through peroxisome proliferator-activated receptor gamma (PPARgamma).","Sulfonylurea Antidiabetic Agent | Sulfonylurea | Sulphonylurea Antidiabetic Agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273895","Biguanide Antidiabetic Agent","C98234","Any antidiabetic agent with the biguanide base structure or phenformin derivatives with antihyperglycemic activity. Biguanide antidiabetic agents activate AMP-activated protein kinase (AMPK) resulting in decreased glucose production in the liver, increased peripheral glucose uptake and improved utilization of glucose. Biguanide-based antidiabetic agents do not cause hypoglycemia. In addition, biguanide antidiabetics decrease absorption of glucose from the gastrointestinal tract.","Biguanide Antidiabetic Agent | Biguanide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0407722","Maxillectomy","C51656","Surgery to remove part or all of the maxilla.","Maxillectomy | ",,,,,,,,,,,,,,,"4084585","Maxillectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2986565","Lymphatic Basin","C94547","A regional collection of lymph nodes that drains lymph from a specific area of the body.","Lymphatic Basin | Basin | lymphatic basin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3472609","Pancreatic Mixed Acinar-Ductal Carcinoma","C95458","A carcinoma that arises from the pancreas showing either extensive mucin accumulation and acinar neoplastic cells or a mixture of columnar or signet-ring cells and acinar neoplastic cells.","Pancreatic Mixed Acinar-Ductal Carcinoma | Mixed Acinar-Ductal Carcinoma of the Pancreas | Mixed Acinar-Ductal Carcinoma of the Pancreas | Mixed acinar-ductal carcinoma","8552/3","Mixed acinar-ductal carcinoma",,,,,,,,,,,,,"42872902","Mixed acinar-ductal carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1518871","Pancreatic Intraductal Papillary-Mucinous Neoplasm with an Associated Invasive Carcinoma","C5726","A pancreatic intraductal papillary mucinous neoplasm characterized by the presence of a focal or multifocal invasive carcinomatous component.  The invasive carcinoma is either colloid or ductal adenocarcinoma.","Pancreatic Intraductal Papillary-Mucinous Neoplasm with an Associated Invasive Carcinoma | Intraductal papillary mucinous neoplasm with an associated invasive carcinoma | Intraductal papillary-mucinous carcinoma, invasive | Pancreatic Intraductal Papillary Mucinous Neoplasm with an Associated Invasive Carcinoma | Pancreatic Invasive Intraductal Papillary-Mucinous Carcinoma",,,,,,,,,,,,,,,"4028546","Intraductal papillary-mucinous carcinoma, invasive",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL537839","Used Someone Else's Smartphone or Tablet","C139679","A response indicating that an individual used a smartphone or tablet other than their own, a friend or family member's, or the clinic's.","Used Someone Else's Smartphone or Tablet | Someone else's smartphone or tablet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2267008","Alpha-glucosidase Inhibitor","C139651","Any agent that inhibits the enzyme alpha-glucosidase located in the intestines. This prevents the breakdown of complex carbohydrates to glucose and other monosaccharides, which results in decreased intestinal absorption of monosaccharides.","Alpha-glucosidase Inhibitor | AGI | AGIs | Alpha-Glucosidase Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827447","Genetic Study","C84431","An examination of genetic material for the presence or absence of cytogenetic or molecular genetic abnormalities.","Genetic Study | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641200","Mixed Response in Neuroblastoma","C103315","Greater than 50% reduction of any measurable lesion (primary or metastases) with, less than 50% reduction in any other site; no new lesions; less than 25% increase in any existing lesion (exclude bone marrow evaluation).","Mixed Response in Neuroblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230150","Posterior Mediastinum","C33368","The part of the lower portion of the mediastinum that is located behind the pericardium.","Posterior Mediastinum | MEDIASTINUM, POSTERIOR | Posterior mediastinum | posterior mediastinum",,,,,,,,,,,,,,,"4099302","Structure of posterior mediastinum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2987240","Pancreatic Small Cell NEC","C95583","An aggressive high-grade carcinoma with neuroendocrine differentiation that arises from the pancreas and is composed of malignant small cells. The mitotic count is more than 20 per 2 mm2 and/or the Ki-67 index is more than 20%.","Pancreatic Small Cell Neuroendocrine Carcinoma | Pancreatic Small Cell Carcinoma | Pancreatic Small Cell Carcinoma | Pancreatic Small Cell NEC | Pancreatic Small Cell NEC G3 | Pancreatic Small Cell Neuroendocrine Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537914","EWSR1/ZNF444 Fusion Gene","C139731","A fusion gene that results from a chromosomal translocation t(19;22)(q13;q12) which fuses exon 8 of the EWSR1 gene to exon 5 of the ZNF444 gene. This fusion may be associated with myoepithelioma.","EWSR1/ZNF444 Fusion Gene | EWS-ZNF444 Fusion Gene | EWS/ZNF444 Fusion Gene | EWSR1-ZNF444 | EWSR1-ZNF444 Fusion Gene | EWSR1::ZNF444 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537854","CIC/DUX4 Fusion Gene","C139663","A fusion gene that results from a chromosomal translocation t(4;19)(q35;q13) which fuses exon 20 of the CIC gene to exon 1 of the DUX4 gene. This fusion is associated with soft tissue sarcoma.","CIC/DUX4 Fusion Gene | CIC-DUX4 | CIC-DUX4 Fusion Gene | CIC::DUX4 Fusion Gene | Capicua Homolog (Drosophila)/Double Homeobox 4 Fusion Gene | Capicua Transcriptional Repressor/Double Homeobox 4 Fusion Gene | t(4;19)/CIC-DUX4 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537851","BCOR/CCNB3 Fusion Gene","C139666","A fusion gene that results from a paracentric chromosomal inversion inv(X)(p11.4;p11.22) which fuses the stop codon of the BCOR gene to exon 5 of the CCNB3 gene. This fusion is associated with bone sarcomas.","BCOR/CCNB3 Fusion Gene | BCL6 Corepressor/Cyclin B3 Fusion Gene | BCOR-CCNB3 Fusion Gene | BCOR::CCNB3 Fusion Gene | CCNB3-BCOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537849","EWSR1/PBX1 Fusion Gene","C139668","A fusion gene that results from a chromosomal translocation t(1;22)(q23;q12) which fuses exon 8 of the EWSR1 gene to exon 5 of the PBX1 gene. This fusion may be associated with myoepithelioma.","EWSR1/PBX1 Fusion Gene | EWS-PBX1 Fusion Gene | EWS/PBX1 Fusion Gene | EWSR1-PBX1 | EWSR1-PBX1 Fusion Gene | EWSR1::PBX1 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537971","Blasts 50 Percent or Less of Bone Marrow Nucleated Cells","C139786","A semi-quantitative microscopic finding indicating that 50 percent or less of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 50 Percent or Less of Bone Marrow Nucleated Cells | Blasts Less than or Equal to 50 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1697448","Human Anti-Mouse Antibodies Positive","C139787","Indicates that human anti-mouse antibodies have been detected in a sample.","Human Anti-Mouse Antibodies Positive | HAMA Positive | Human Anti-Mouse Antibodies Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537970","IL2RB Positive","C139788","Indicates that IL2RB expression has been detected in a sample.","IL2RB Positive | CD122 Antigen Positive | CD122 Positive | High Affinity IL-2 Receptor Subunit Beta Positive | IL-2 Receptor Subunit Beta Positive | IL-2R Subunit Beta Positive | IL-2RB Positive | IL15RB Positive | IL2 Receptor Beta Positive | Interleukin 15 Receptor Beta Positive | Interleukin 2 Receptor Beta Positive | Interleukin-2 Receptor Beta Chain Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537969","CD8 Positive","C139789","Indicates that expression of the CD8 complex has been detected in a sample.","CD8 Positive | CD8 Antigen Positive | CD8 Co-Receptor Positive | T-Cell Surface Glycoprotein CD8 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537968","CD57 Positive","C139790","Indicates that expression of the tumor antigen CD57 has been detected in a sample.","CD57 Positive | CD57 Antigen Positive | HNK-1 Positive | HNK1 Positive | Human Natural Killer-1 Antigen Positive | L2/HNK-1 Positive | Leu7 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537967","PSA Level Greater than 0.1","C139791","A blood concentration of prostate specific antigen that is greater than 0.1 ng/mL.","PSA Level Greater than 0.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537981","PSA Level Greater than or Equal to Five","C139792","A blood concentration of prostate specific antigen greater than or equal to 5 ng/mL.","PSA Level Greater than or Equal to Five | PSA Level 5 or Greater | PSA Level Five or Greater | PSA Level Greater than or Equal to 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537980","STEAP1 Positive","C139793","Indicates that STEAP1 expression has been detected in a sample.","STEAP1 Positive | Metalloreductase STEAP1 Positive | PRSS24 Positive | STEAP Positive | Six Transmembrane Epithelial Antigen of the Prostate 1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537979","BPTP3 Activating Mutation","C139794","A change in the nucleotide sequence of the PTPN11 gene that that results in constitutive activation of both tyrosine-protein phosphatase non-receptor type 11 and its downstream signaling pathways.","Activating PTPN11 Gene Mutation | Activating PTPN11 Gene Mutation | Activating PTPN11 Mutation | Activating PTPN11 Mutation | BPTP3 Activating Mutation | PTP-1D Activating Mutation | PTP2C Activating Mutation | PTPN11 Activating Gene Mutation | PTPN11 Activating Mutation | Protein Tyrosine Phosphatase, Non-Receptor Type 11 Activating Mutation | SH-PTP2 Activating Mutation | SHP-2 Activating Mutation | SHP2 Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537978","Activating BRAF Mutation","C139795","A change in the nucleotide sequence of the BRAF gene that that results in constitutive activation of both serine/threonine-protein kinase B-raf and its downstream signaling pathways.","Activating BRAF Mutation | Activating BRAF Gene Mutation | Activating BRAF1 Mutation | B-RAF Activating Mutation | B-RAF1 Activating Mutation | B-Raf Proto-Oncogene, Serine/Threonine Kinase Activating Mutation | BRAF Activating Mutation | v-raf Murine Sarcoma Viral Oncogene Homolog B Activating Mutation | v-raf Murine Sarcoma Viral Oncogene Homolog B1 Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537977","Activating NRAS Mutation","C139796","A change in the nucleotide sequence of the NRAS gene that that results in constitutive activation of both oncogene N-Ras protein and its downstream signaling pathways.","Activating NRAS Mutation | N-RAS Activating Mutation | NRAS Activating Mutation | NRAS Proto-Oncogene, GTPase Activating Mutation | NRAS1 Activating Mutation | Neuroblastoma RAS Viral Oncogene Homolog Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537976","Activating HRAS Mutation","C139798","A change in the nucleotide sequence of the HRAS gene that that results in constitutive activation of both oncogene H-Ras protein and its downstream signaling pathways.","Activating HRAS Mutation | C-H-RAS Activating Mutation | C-HA-RAS1 Activating Mutation | H-ras Activating Mutation | HRAS Activating Mutation | HRAS1 Activating Mutation | HRas Proto-Oncogene, GTPase Activating Mutation | Ha-ras Activating Mutation | Harvey Rat Sarcoma Viral Oncogene Homolog Activating Mutation | RASH1 Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0231957","Slow Vital Capacity","C111315","The maximum volume of air that can be exhaled after slow maximum inhalation.","Slow Vital Capacity | SVC",,,,,,,,,,,,,,,"4308122","Slow vital capacity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0231961","Thoracic Gas Volume","C124426","The absolute volume of gas contained in the thoracic cavity at any given point in time and at any level of alveolar pressure.","Thoracic Gas Volume | TGV",,,,,,,,,,,,,,,"4101682","Thoracic gas volume",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015326","Expiratory Reserve Volume","C111200","The maximum volume of air a subject can exhale from the lungs after a tidal exhalation.","Expiratory Reserve Volume | ERV",,,,,,,,,,,,,,,"4207980","Expiratory reserve volume",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2675457","EWSR1/POU5F1 Fusion Gene","C99256","A fusion gene that results from a chromosomal translocation t(6;22)(p21;q12) which fuses the first six exons of the EWSR1 gene to exon 2 of the POU5F1 gene. This rearrangement is associated with hidradenoma and one case of mucoepidermoid carcinoma of the salivary glands.","EWSR1/POU5F1 Fusion Gene | EWS-POU5F1 Fusion Gene | EWS/POU5F1 Fusion Gene | EWSR1-POU5F1 | EWSR1-POU5F1 Fusion Gene | EWSR1::POU5F1 Fusion Gene | POU5F1/EWS Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274636","EWSR1/CREB1 Fusion Gene","C99249","A fusion gene that results from a chromosomal translocation t(2;22)(q34;q12) which fuses the first 7 exons of the EWSR1 gene to the 5' side of exon 7 of the CREB1 gene. This rearrangement is associated with angiomatoid fibrous histiocytoma and rare cases of malignant clear cell sarcoma of the soft tissue.","EWSR1/CREB1 Fusion Gene | EWS-CREB1 Fusion Gene | EWS/CREB1 Fusion Gene | EWSR1-CREB1 | EWSR1-CREB1 Fusion Gene | EWSR1::CREB1 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1852404","EWSR1/ATF1 Fusion Gene","C99216","A fusion gene that results from a chromosomal translocation t(12;22)(q13;q12) which fuses the first 7 or 8 exons of the EWSR1 gene on the 5' side of exon 4 or 5 of the ATF1 gene. This rearrangement is associated with both malignant clear cell sarcoma of the soft tissue and angiomatoid fibrous histiocytoma.","EWSR1/ATF1 Fusion Gene | ATF1-EWSR1 Fusion Gene | ATF1/EWS Fusion Gene | EWS-ATF1 Fusion Gene | EWS/ATF1 Fusion Gene | EWSR1-ATF1 | EWSR1-ATF1 Fusion Gene | EWSR1::ATF1 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1850932","CREB3L2/FUS FUSION GENE","C99283","A fusion gene that results from a chromosomal translocation t(7;16)(q33-34;p11) which fuses the first six or seven exons of the FUS gene on the 5' side of exon 5 of the CREB3L2 gene. This rearrangement is associated with low-grade fibromyxoid sarcoma.","FUS/CREB3L2 Fusion Gene | CREB3L2/FUS Fusion Gene | FUS-BBF2H7 Fusion Gene | FUS-CREB3L2 Fusion Gene | FUS/BBF2H7 Fusion Gene | FUS::CREB3L2 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274643","EWSR1/ETV4 Fusion Gene","C99262","A fusion gene (~2.1 kb) that results from a chromosomal translocation t(17;22)(q21;q12) which fuses the first seven exons of the EWSR1 gene to the last 6 exons of the ETV4 gene. This rearrangement is associated with Ewing sarcoma.","EWSR1/ETV4 Fusion Gene | ETV4/EWS Fusion Gene | ETV4/EWSR1 Fusion Gene | EWS Protein/E1A Enhancer Binding Protein Chimera Gene | EWS-E1AF Fusion Gene | EWS/ETV4 Fusion Gene | EWSR1-ETV4 | EWSR1-ETV4 Fusion Gene | EWSR1::ETV4 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2677452","EWSR1/ETV1 Fusion Gene","C99259","A fusion gene that results from a chromosomal translocation t(7;22)(p22;q12) which fuses exon 7 of the EWSR1 gene to either exon 10 or 11 of the ETV1 gene. This rearrangement is associated with Ewing sarcoma.","EWSR1/ETV1 Fusion Gene | ETV1/EWS Fusion Gene | ETV1/EWSR1 Fusion Gene | EWS-ETV1 Fusion Gene | EWS/ETV1 Fusion Gene | EWSR1-ETV1 | EWSR1-ETV1 Fusion Gene | EWSR1::ETV1 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508673","Carcinoembryonic Antigen Positive","C128808","A laboratory test result indicating the presence of carcinoembryonic antigen in a sample.","Carcinoembryonic Antigen Positive | CEA Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514620","CD3 Positive","C131386","An indication that the CD3 complex has been detected in a sample.","CD3 Positive | CD3 Antigen Positive | CD3 Complex Positive | T-Cell Surface Glycoprotein CD3 Positive | T3 Complex Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0724597","Histrelin Acetate","C77424","The acetate salt form of histrelin, a long-acting, synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH) with potential anti-tumor activity. Upon administration, histrelin binds to and activates GnRH receptors; prolonged administration results in pituitary GnRH receptor desensitization and inhibition of follicle stimulating hormone (FSH) and luteinizing hormone (LH) secretion, leading to a significant decline in testosterone production in males and may inhibit androgen receptor-positive tumor progression; in females, prolonged administration results in decreased estradiol production.","Histrelin Acetate | HISTRELIN ACETATE | Supprelin | Vantas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709656","Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type","C45194","An aggressive primary cutaneous B-cell lymphoma, usually involving the lower leg.  It is composed of a generally monotonous proliferation of immunoblasts, or less frequently centroblasts, with few admixed reactive cells.  This type of lymphoma occurs most often in elderly women who present with rapidly growing tumors, usually on one or both legs.  Dissemination to extracutaneous sites is frequent.  Treatment with combination chemotherapy is usually required.","Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type | Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-Type | Primary cutaneous DLBCL, leg type",,,,,,,,,,,,,,,"37151344","Primary cutaneous diffuse large B-cell lymphoma leg type",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333171","Primary Cutaneous Follicle Center Lymphoma","C7217","A primary lymphoma of the skin composed of various numbers of small and large irregular neoplastic follicle center cells.  Its morphologic pattern can be nodular, diffuse, or nodular and diffuse.  It presents with solitary or grouped plaques and tumors, and it usually involves the scalp, forehead, or trunk.  It rarely involves the legs.  This type of cutaneous lymphoma tends to remain localized to the skin.","Primary Cutaneous Follicle Center Lymphoma | Crosti's Disease | Cutaneous Follicle Center Lymphoma | Cutaneous Follicle Centre Lymphoma | Cutaneous follicle center lymphoma, unspecified site | PCFCL | Reticulohistiocytoma of the Dorsum",,,,,,,,,,,,,,,"4301668|4303111","Primary cutaneous follicular center B-cell lymphoma|Primary cutaneous follicle center cell lymphoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2698751","Pediatric Nodal Marginal Zone Lymphoma","C80299","A nodal marginal zone lymphoma affecting the pediatric population, predominantly males.  It presents with asymptomatic and localized (mainly head and neck) disease in the vast majority of cases.  Morphologically there is often progressive transformation of the germinal centers.  The prognosis is excellent.","Pediatric Nodal Marginal Zone Lymphoma | Childhood Nodal Marginal Zone Lymphoma",,,,,,,,,,,,,,,"37116846","Pediatric nodal marginal zone lymphoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2699508","Splenic Diffuse Red Pulp Small B-Cell Lymphoma","C80309","An uncommon, indolent B-cell non-Hodgkin lymphoma composed of small B-lymphocytes involving the red pulp of the spleen, bone marrow, and peripheral blood.  Patients often have massive splenomegaly.  The peripheral blood examination reveals villous lymphocytes.","Splenic Diffuse Red Pulp Small B-Cell Lymphoma | Splenic diffuse red pulp small B-cell lymphoma",,,,,,,,,,,,,,,"35622400|37116983","Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2699507","Splenic B-Cell Lymphoma/Leukemia, Unclassifiable","C80308","A small B-cell clonal lymphoproliferative disorder of the spleen that does not fall into any of the other categories of mature B-cell neoplasms.","Splenic B-Cell Lymphoma/Leukemia, Unclassifiable | Splenic B-cell lymphoma/leukemia, unclassifiable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520452","Large B-Cell Lymphoma with 11q Aberration","C131911","A molecularly distinct B-cell lymphoma reminiscent of Burkitt lymphoma. It is characterized by the absence of MYC translocation and the presence of chromosome 11q aberrations.","Burkitt-Like Lymphoma with 11q Aberration | MYC-Negative B-Cell Lymphoma with 11q Aberration Resembling Burkitt Lymphoma",,,,,,,,,,,,,,,"37204535","Burkitt-like lymphoma with 11q aberration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2699776","Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation","C80289","A diffuse large B-cell lymphoma arising in body cavities or narrow spaces of long standing chronic inflammation.  The classic example is the pyothorax-associated lymphoma that arises in the pleural cavity of patients with a history of long standing pyothorax.","Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation | DLBCL-CI | Diffuse large B-cell lymphoma associated with chronic inflammation",,,,,,,,,,,,,,,"37116992","Diffuse large B-cell lymphoma associated with chronic inflammation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL519556","EBV-Positive Mucocutaneous Ulcer","C131906","A rare Epstein-Barr virus-positive B-cell lymphoproliferative disorder that affects mucosal sites (including oral mucosa, palate, tonsils, and gastrointestinal tract) and skin. It presents with well-circumscribed, often painful ulcers. It is associated with immune suppression, including age-related and drug-induced immunosuppression. In the majority of cases the lesions regress either spontaneously or following withdrawal of the immunosuppression therapy.","EBV-Positive Mucocutaneous Ulcer | EBVMCU | Epstein-Barr Virus-Positive Mucocutaneous Ulcer | Epstein-Barr Virus-Positive Mucocutaneous Ulcer",,,,,,,,,,,,,,,"37312306","EBV positive mucocutaneous ulcer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1335428","Plasmacytic Hyperplasia Post-Transplant Lymphoproliferative Disorder","C7235","An early post-transplant lymphoproliferative lesion characterized by plasmacytic proliferation and architectural preservation of the involved tissues.  It often regresses either spontaneously or after reduction in immunosuppression.  The immunoglobulin genes are not rearranged.  In some cases, a polymorphic or monomorphic post-transplant lymphoproliferative disorder may follow this early lesion.","Plasmacytic Hyperplasia Post-Transplant Lymphoproliferative Disorder | Plasmacytic Hyperplasia PTLD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524855","Primary Cutaneous CD4-Positive Small/Medium T-Cell Lymphoproliferative Disorder","C45366","A primary cutaneous T-cell lymphoproliferative disorder composed of small to medium-sized CD4-positive, CD8-negative, and CD30-negative pleomorphic T-lymphocytes in the dermis. A small number of large pleomorphic T-lymphocytes, focal epidermotropism, and subcutaneous involvement may be seen. It usually presents with a solitary plaque or tumor on the face, neck, or upper trunk. The clinical behavior is almost always indolent, and most patients present with localized disease.","Primary Cutaneous CD4-Positive Small/Medium T-Cell Lymphoproliferative Disorder | PCSM-LPD | Primary Cutaneous CD4-Positive Small or Medium T-Cell Lymphoproliferative Disorder | Primary Cutaneous CD4-Positive Small/Medium T-Cell Lymphoma | Primary Cutaneous CD4-Positive Small/Medium-Sized  T-Cell Lymphoproliferative Disorder | Primary Cutaneous CD4-Positive Small/Medium-Sized  T-Cell Lymphoproliferative Disorder | Primary Cutaneous CD4-Positive Small/Medium-Sized Pleomorphic T-Cell Lymphoproliferative Disorder | Primary Cutaneous CD4-Positive Small/Medium-Sized T-Cell Lymphoproliferative Disorder | Primary cutaneous CD4-positive small/medium T-cell lymphoma",,,,,,,,,,,,,,,"37312307","Primary cutaneous CD4-positive small/medium T-cell lymphoproliferative disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709653","Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma","C45339","An aggressive, epidermotropic primary cutaneous T-cell lymphoma composed of small to medium-sized, or medium-sized to large, CD8-positive T-lymphocytes with pleomorphic or blastic nuclei. Epidermotropism is often pronounced, and angiocentricity and angioinvasion may be present. It manifests with localized or disseminated eruptive papules and nodules or tumors.","Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma | PCAETL | Primary Cutaneous Aggressive Epidermotropic CD8-Positive T-Cell Lymphoma | Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma | Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma | Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma",,,,,,,,,,,,,,,"35622904|37116874","Primary cutaneous CD8 positive aggressive epidermotropic cytotoxic T-cell lymphoma|Primary cutaneous CD8 positive aggressive epidermotropic cytotoxic T-cell lymphoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1707547","Primary Cutaneous Gamma-Delta T-Cell Lymphoma","C45340","An aggressive cutaneous lymphoma of mature, activated gamma/delta T-lymphocytes.  It usually presents with disseminated plaques and nodules.  Involvement of mucosal sites is frequent.  However, involvement of lymph nodes, spleen, or bone marrow is uncommon.  Morphologically, there are three patterns of cutaneous involvement: epidermotropic, dermal, and subcutaneous.  Often, more than one pattern may co-exist in a single biopsy specimen, or may be present in different biopsy specimens from the same patient.  The lymphocytic infiltrate is composed of medium- to large-sized lymphocytes expressing CD56.  Most cases lack both CD4 and CD8, although CD8 may be present in some cases.  This group of lymphomas includes cases previously known as subcutaneous panniculitis-like T-cell lymphoma with a gamma/delta phenotype.","Primary Cutaneous Gamma-Delta T-Cell Lymphoma | Cutaneous Gamma/Delta T-Cell Lymphoma | PCGD-TCL | Peripheral Gamma-Delta T-Cell Lymphoma | Primary cutaneous gamma-delta T-cell lymphoma","9726/3","Primary cutaneous gamma-delta T-cell lymphoma",,,,,,,,,,,,,"37116745|42872913","Primary cutaneous gamma-delta-positive T-cell lymphoma|Primary cutaneous gamma-delta T-cell lymphoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C2699747","Systemic EBV-Positive T-Cell Lymphoma of Childhood","C80374","An aggressive and life-threatening, EBV-positive T-cell lymphoma affecting children.  It is more prevalent in Taiwan and Japan.  Clinically, it presents with acute onset of fever and generalized malaise, followed by hepatosplenomegaly and liver failure.  Morphologically it is characterized by the presence of infiltrating T-lymphocytes which are usually small and erythrophagocytosis.  Most patients have a fulminant clinical course.","Systemic EBV-Positive T-Cell Lymphoma of Childhood | Systemic EBV-Positive T-Cell Lymphoproliferative Disease of Childhood | Systemic EBV-Positive T-Cell Lymphoproliferative Disease of Childhood | Systemic EBV-Positive T-Cell Lymphoproliferative Disorder of Childhood | Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood","9724/3","Systemic EBV positive T-cell lymphoproliferative disease of childhood",,,,,,,,,,,,,"42872911","Systemic EBV positive T-cell lymphoproliferative disease of childhood",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"CL521195","Large B-Cell Lymphoma with IRF4 Rearrangement","C133494","A large B-cell lymphoma that usually affects the Waldeyer ring and/or cervical lymph nodes and less often the gastrointestinal tract. It occurs most commonly in children and young adults and is low stage. It is characterized by a follicular, follicular and diffuse, or pure diffuse growth pattern resembling follicular lymphoma grade 3B or a diffuse large B-cell lymphoma. Most cases have IG/IRF4 rearrangements. BCL2 rearrangements are not present. Some cases that belong in this category lack an IRF4 rearrangement but have strong IRF4/MUM1 expression. This lymphoma is more aggressive than pediatric-type follicular lymphomas.","Large B-Cell Lymphoma with IRF4 Rearrangement | LBCL with IRF4 Rearrangement",,,,,,,,,,,,,,,"37203995","Large B-cell lymphoma with IRF4 rearrangement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333294","ALK-Positive Large B-Cell Lymphoma","C7225","A usually aggressive large B-cell lymphoma characterized by the presence of monomorphic immunoblast-like neoplastic B-lymphocytes in a sinusoidal growth pattern.  The neoplastic B-lymphocytes express the ALK kinase but they lack the 2;5 translocation.","ALK-Positive Large B-Cell Lymphoma | ALK positive large B-cell lymphoma | ALK-DLBCL | Diffuse Large B-Cell Lymphoma with Expression of Full-Length ALK | Diffuse Large B-Cell Lymphoma with Expression of Full-Length Anaplastic Lymphoma Kinase","9737/3","ALK positive large B-cell lymphoma",,,,,,,,,,,,,"37396219","ALK-positive large B-cell lymphoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0278347","Plasma Transfusion","C140042","The infusion of plasma into the bloodstream.","Plasma Transfusion | Plasma Infusion",,,,,,,,,,,,,,,"4028665","Transfusion of plasma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2700204","Follicular Helper T-Cell Lymphoma, Follicular-Type","C80375","Follicular helper T-cell lymphoma with a predominantly follicular growth pattern.","Follicular Helper T-Cell Lymphoma, Follicular-Type | FTCL | Follicular T-Cell Lymphoma | Follicular T-Cell Lymphoma | Follicular Variant Peripheral T-Cell Lymphoma | Follicular Variant Peripheral T-Cell Lymphoma",,,,,,,,,,,,,,,"37205181","Follicular T-cell lymphoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL524351","High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements","C131913","High-grade B-cell lymphoma characterized by the abnormal rearrangement of MYC gene, BCL2 gene, and BCL6 gene. Patients with this type of lymphoma usually respond poorly to standard treatments and have a poor prognosis.","High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements | HGBCL-TH | High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements | High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements | High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements | Triple Hit Lymphoma | Triple-Hit Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272525","Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma","C96058","A mature T-cell and NK-cell non-Hodgkin lymphoma of intraepithelial T-lymphocytes. It usually arises from the small intestine. A minority of cases arise from the large intestine or the stomach. It is characterized by the presence of a monomorphic cellular infiltrate of small to medium-sized T-lymphocytes that are cytotoxic and express CD56. It is not associated with celiac disease.","Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma | MEITL | Monomorphic CD56+ Intestinal T-Cell Lymphoma | Monomorphic CD56+ Intestinal T-Cell Lymphoma | Type II EATL",,,,,,,,,,,,,,,"37204000","Monomorphic epitheliotropic intestinal T-cell lymphoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512709","Chronic Lymphoproliferative Disorder of NK-Cells","C39591","An Epstein-Barr virus negative disorder with a chronic clinical course affecting predominantly adults and characterized by the proliferation of large granular lymphocytes with natural killer cell immunophenotype.  The T-cell receptor genes are not rearranged.","Chronic Lymphoproliferative Disorder of NK-Cells | CLPD-NK | Chronic NK-Cell Lymphocytosis | Chronic NK-LGL Lymphoproliferative Disorder | Chronic NK-Large Granular Lymphocyte Lymphoproliferative Disorder | Chronic lymphoproliferative disorder of NK cells | Indolent Large Granular NK-Cell Lymphoproliferative Disorder | Indolent NK-Cell Lymphoproliferative Disorder | NK-Cell Large Granular Lymphocyte Lymphocytosis | NK-LGL leukemia | NK-LGLL | NK-Type Lymphoproliferative Disorder of Granular Lymphocytes | natural killer-cell large granular lymphocyte leukemia",,,,,,,,,,,,,,,"36717239","Chronic lymphoproliferative disorder of natural killer cells",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698750","Pediatric-Type Follicular Lymphoma","C80297","A nodal follicular lymphoma with favorable prognosis. It lacks BCL-2 rearrangement and 14;18 translocation. Nearly all cases are localized. It is usually seen in the pediatric population but similar lymphomas may occur in adults.","Pediatric-Type Follicular Lymphoma | Childhood Follicular Lymphoma | PTFL | Pediatric Follicular Lymphoma | Pediatric Follicular Lymphoma",,,,,,,,,,,,,,,"37116892|42537145","Pediatric follicular lymphoma|Pediatric follicular lymphoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL538176","AspaMetDex Regimen","C140092","A regimen consisting of L-asparaginase, methotrexate and dexamethasone that can be used for the treatment of non-Hodgkin lymphoma (NHL).","AspaMetDex Regimen | Aspa-Met-Dex | AspaMetDex | AspaMetDex (Erwinaze) | Asparaginase-Methotrexate-Dexamethasone | L-asparaginase/Methotrexate/Dexamethasone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538175","AVD Regimen","C140093","A regimen consisting of doxorubicin, vinblastine and dacarbazine that can be used for the treatment of Hodgkin lymphoma (HL).","AVD Regimen | AVD | Adriamycin-Vinblastine-Dacarbazine | Dacarbazine/Doxorubicin/Vinblastine | Doxorubicin/Vinblastine/Dacarbazine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1328232","bendamustine/rituximab","C140094","A regimen consisting of bendamustine and rituximab that can be used for the treatment of non-Hodgkin lymphoma (NHL), including chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, Waldenstrom macroglobulinemia and lymphoplasmacytic lymphoma, gastric and nongastric mucosa-associated lymphoid tissue (MALT) lymphoma, and nodal and splenic marginal zone lymphoma, and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL).","BR Regimen | B-R Regimen | BR | Bendamustine Plus Rituximab | Bendamustine and Rituximab (BR) | Bendamustine and Rituximab-abbs (BR) | Bendamustine and Rituximab-arrx (BR) | Bendamustine and Rituximab-blit (BR) | Bendamustine and Rituximab-pvvr (BR) | Bendamustine and Rituximab-rite (BR) | Bendamustine and Rituximab-rixa (BR) | Bendamustine and Rituximab-rixi (BR) | Bendamustine-Rituximab | Bendamustine/Rituximab | R-B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538174","R-DHAP Regimen","C140095","A regimen consisting rituximab, dexamethasone, high dose cytarabine and cisplatin that can be used for the treatment of diffuse large B-cell lymphoma, nodular lymphocyte-predominant Hodgkin lymphoma, and mantle cell lymphoma.","R-DHAP Regimen | R-DHAP | R-DHAP  Regimen | R-DHAP (rituximab-abbs) | R-DHAP (rituximab-arrx) | R-DHAP (rituximab-blit) | R-DHAP (rituximab-pvvr) | R-DHAP (rituximab-rite) | R-DHAP (rituximab-rixa) | R-DHAP (rituximab-rixi) | RDHAP | Rituximab Plus Cisplatin/Cytarabine/Dexamethasone | Rituximab-DHAP | Rituximab-Dexamethasone-High Dose ARA-C-Platinol | Rituximab-Dexamethasone-High Dose Cytarabine-Cisplatin | Rituximab/Dexamethasone/High-dose Ara-C/Platinol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538173","IVAC Regimen","C140096","A regimen consisting of ifosfamide, etoposide and high-dose cytarabine that can be used for the treatment of non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL).","IVAC Regimen | High-dose Cytarabine/Etoposide/Ifosfamide | IVAC | IVAC  Regimen | Ifosfamide/Etoposide/High Dose Cytarabine | Ifosfamide/VP-16/ARA-C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538172","DA-EPOCH-R","C140097","A regimen consisting of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (EPOCH-R) in a dose-adjusted (DA) version that can be used for the treatment of AIDS-related B-cell lymphomas, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma.","Dose-adjusted EPOCH-R Regimen | DA-EPOCH-R | DA-R-EPOCH | DA-R-EPOCH (rituximab-abbs) | DA-R-EPOCH (rituximab-arrx) | DA-R-EPOCH (rituximab-blit) | DA-R-EPOCH (rituximab-pvvr) | DA-R-EPOCH (rituximab-rite) | DA-R-EPOCH (rituximab-rixa) | DA-R-EPOCH (rituximab-rixi) | Dose-adjusted Etoposide/Prednisone/Vincristine/Cyclophosphamide/Doxorubicin/Rituximab | Dose-adjusted R-EPOCH Regimen | Dose-adjusted Rituximab-Etoposide-Prednisone-Oncovin-Cyclophosphamide-Hydroxydaunorubicin Regimen | R-DA-EPOCH | R-DA-EPOCH  Regimen | R-DA-EPOCH  Regimen | R-DA-EPOCH Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538186","DeVIC Regimen","C140098","A regimen consisting of dexamethasone, etoposide, ifosfamide and carboplatin that can be used for the treatment of non-Hodgkin lymphoma (NHL).","DeVIC Regimen | DeVIC | Dexamethasone-Etoposide-Ifosfamide-Carboplatin | Dexamethasone/Etoposide/Ifosfamide/Carboplatin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538185","R-ESHAP Regimen","C140099","A regimen consisting of rituximab, etoposide, methylprednisolone, high-dose cytarabine and cisplatin that can be used in the treatment of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma.","R-ESHAP Regimen | Cytarabine-Cisplatin-Etoposide-Methylprednisolone-Rituximab | Cytarabine/Cisplatin/Etoposide/Methylprednisolone/Rituxan | Cytarabine/Cisplatin/Etoposide/Methylprednisolone/Rituximab | ESHAP Plus Rituximab | ESHAP-R | Etoposide-Solumedrol-High Dose Ara-C-Platinol-Rituximab Regimen | Etoposide/Methylprednisolone/Cytarabine/Cisplatin Plus Rituximab | Etoposide/Methylprednisolone/High-dose Cytarabine/Cisplatin | Etoposide/Solumedrol/High Dose Ara-C/Platinol/Rituximab Regimen | R-ESHAP | R-ESHAP (rituximab-abbs) | R-ESHAP (rituximab-arrx) | R-ESHAP (rituximab-blit) | R-ESHAP (rituximab-pvvr) | R-ESHAP (rituximab-rite) | R-ESHAP (rituximab-rixa) | R-ESHAP (rituximab-rixi) | Rituximab-Etoposide-Methylprednisolone-High-dose Cytarabine-Cisplatin | Rituximab-Etoposide-Solu-Medrol-High-dose Ara-C-Platinol | Rituximab/Etoposide/Solumedrol/High-dose Cytarabine/Cisplatin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538184","GDP Regimen","C140100","A regimen consisting of gemcitabine, dexamethasone and cisplatin that can be used in the treatment of Hodgkin lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), T-cell lymphoma, and mycosis fungoides/Sezary syndrome.","GDP Regimen | Cisplatin-Dexamethasone-Gemcitabine | Cisplatin/Dexamethasone/Gemcitabine | Cisplatin/Dexamethasone/Gemcitabine Regimen | Cisplatin/Gemcitabine/Decadron | GDP | Gemcitabine-Dexamethasone-Platinol | Gemcitabine/Dexamethasone/Cisplatin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538183","R-GDP Regimen","C140101","A regimen consisting of rituximab, gemcitabine, dexamethasone and cisplatin that can be used in the treatment of Hodgkin lymphoma (HL), Burkitt lymphhoma, and diffuse large B-cell lymphoma.","R-GDP Regimen | Cisplatin/Dexamethasone/Gemcitabine/Rituximab | GDP Plus RITU Regimen | GDP-R Regimen | GDP/Rituximab | Gemcitabine-Dexamethasone-Platinol-Rituximab | R-GDP | R-GDP (rituximab-abbs) | R-GDP (rituximab-arrx) | R-GDP (rituximab-blit) | R-GDP (rituximab-pvvr) | R-GDP (rituximab-rite) | R-GDP (rituximab-rixa) | R-GDP (rituximab-rixi) | Rituximab/Gemcitabine/Dexamethasone/Cisplatin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538182","HD MTX Plus HD AraC","C140102","A regimen consisting of high-dose (HD) methotrexate (MTX) plus HD cytarabine (AraC) that can be used in the treatment of central nervous system (CNS) lymphoma and refractory or relapsed (RR) non-Hodgkin lymphoma (NHL).","Cytarabine/High-dose Methotrexate Regimen | HD MTX Plus HD AraC | HD-MTX/ARA-C | HD-MTX/ARA-C Regimen | HD-MTX/ARA-C Regimen | HD-MTX/ARA-C Regimen  | HD-Methotrexate/Cytarabine | High-dose MTX/ARA-C Regimen | High-dose Methotrexate Plus High-dose Cytarabine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538181","R-HD-MTX/ARA-C","C140103","A regimen consisting of rituximab, high-dose (HD) methotrexate (MTX) and HD cytarabine (AraC) that can be used in the treatment of central nervous system (CNS) lymphoma and refractory or relapsed (RR) non-Hodgkin lymphoma (NHL).","Cytarabine/High-dose Methotrexate/Rituximab Regimen | Cytarabine, Methotrexate, Rituximab | Cytarabine, Methotrexate, Rituximab-abbs | Cytarabine, Methotrexate, Rituximab-arrx | Cytarabine, Methotrexate, Rituximab-blit | Cytarabine, Methotrexate, Rituximab-pvvr | Cytarabine, Methotrexate, Rituximab-rite | Cytarabine, Methotrexate, Rituximab-rixa | Cytarabine, Methotrexate, Rituximab-rixi | R-HD-MTX/ARA-C | R-HD-MTX/ARA-C Regimen | R-HD-MTX/ARA-C Regimen | Rituximab Plus HD MTX Plus HD AraC | Rituximab-HD-MTX/ARA-C | Rituximab-High-dose Methotrexate-High-dose Cytarabine | Rituximab/HD-Methotrexate/Cytarabine | Rituximab/High-dose MTX/ARA-C Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538179","IVE Regimen","C140105","A regimen consisting of ifosfamide, epirubicin and etoposide that can be used in the treatment of non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), and as a stem cell mobilization regimen.","IVE Regimen | IVE | Ifosfamide-Epirubicin-Etoposide | Ifosfamide/Epirubicin/Etoposide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538288","MATRix Regimen","C140106","A regimen consisting of high-dose methotrexate, high-dose cytarabine, thiotepa and rituximab that can be used in the treatment of central nervous system (CNS) lymphoma and as a conditioning regimen for autologous stem cell transplantation (ASCT).","MATRix Regimen | HD-MTX/HD-ARAC/Thiotepa/Rituximab | MATRix | MATRix (rituximab-abbs) | MATRix (rituximab-arrx) | MATRix (rituximab-blit) | MATRix (rituximab-pvvr) | MATRix (rituximab-rite) | MATRix (rituximab-rixa) | MATRix (rituximab-rixi) | Methotrexate-Cytarabine-Thiotepa-Rituximab | Methotrexate/Cytarabine/Thiotepa/Rituximab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538287","MRT Regimen","C140107","A regimen consisting of methotrexate, rituximab and temozolomide that can be used in the treatment of central nervous system (CNS) lymphoma.","MRT Regimen | MRT | MT-R | MT-R (rituximab-abbs) | MT-R (rituximab-arrx) | MT-R (rituximab-blit) | MT-R (rituximab-pvvr) | MT-R (rituximab-rite) | MT-R (rituximab-rixa) | MT-R (rituximab-rixi) | MT-R Regimen | Methotrexate-Rituximab-Temozolomide | Methotrexate/Rituximab/Temozolomide | Methotrexate/Temozolomide/Rituximab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538286","MPV Regimen","C140108","A regimen consisting of methotrexate, procarbazine and vincristine that can be used in the treatment of central nervous system (CNS) lymphoma.","MPV Regimen | MPV | Methotrexate-Procarbazine-Vincristine | Methotrexate/Procarbazine/Vincristine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538285","R-MPV Regimen","C140109","A regimen consisting of rituximab, methotrexate, procarbazine and vincristine that can be used in the treatment of central nervous system (CNS) lymphoma.","R-MPV Regimen | R-MPV | R-MPV (rituximab-abbs) | R-MPV (rituximab-arrx) | R-MPV (rituximab-blit) | R-MPV (rituximab-pvvr) | R-MPV (rituximab-rite) | R-MPV (rituximab-rixa) | R-MPV (rituximab-rixi) | Rituximab-Methotrexate-Procarbazine-Vincristine | Rituximab/Methotrexate/Procarbazine/Vincristine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538284","Nordic Regimen","C140110","A regimen consisting of cycles of rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone (Maxi-CHOP), alternating with rituximab with high-dose (HD) cytarabine that can be used in the treatment of mantle cell lymphoma (MCL).","Nordic Regimen | Maxi-R-CHOP/R-HiDAC | Nordic | R-MaxiCHOP Plus R-HDAraC | Rituximab Plus Cyclophosphamide/Hydroxydaunorubicin/Oncovin/Prednisone and R-HD-Ara-C | Rituximab Plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone Alternating with Rituximab Plus High-Dose Cytarabine | Rituximab Plus Maxi-CHOP Alternating with Rituximab Plus HD Ara-C | Rituximab Plus Maxi-CHOP Alternating with Rituximab Plus High-Dose Cytarabine | Rituximab with Alternating Cycles of Maxi-CHOP and High-dose Cytarabine | Rituximab/Maxi-CHOP Alternating with Rituximab/High-Dose Cytarabine | maxi-R-CHOP/R-HiDAC | maxi-R-CHOP/R-HiDAC (rituximab-abbs) | maxi-R-CHOP/R-HiDAC (rituximab-arrx) | maxi-R-CHOP/R-HiDAC (rituximab-blit) | maxi-R-CHOP/R-HiDAC (rituximab-pvvr) | maxi-R-CHOP/R-HiDAC (rituximab-rite) | maxi-R-CHOP/R-HiDAC (rituximab-rixa) | maxi-R-CHOP/R-HiDAC (rituximab-rixi)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538283","R-BAC Regimen","C140111","A regimen consisting of rituximab, bendamustine and cytarabine that can be used in the treatment of mantle cell lymphoma (MCL). RBAC500 regimen, consisting of bendamustine, low-dose cytarabine and rituximab, may be used for the treatment of MCL.","R-BAC Regimen | Bendamustine/Cytarabine/Rituximab | R-BAC | R-BAC (rituximab-abbs) | R-BAC (rituximab-arrx) | R-BAC (rituximab-blit) | R-BAC (rituximab-pvvr) | R-BAC (rituximab-rite) | R-BAC (rituximab-rixa) | R-BAC (rituximab-rixi) | RBAC Regimen | Rituximab-Bendamustine-Cytarabine | Rituximab/Bendamustine/Ara-C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1541375","lenalidomide/rituximab","C140112","A regimen consisting of lenalidomide and rituximab that can be used in the treatment of primary central nervous system (CNS) lymphoma, Castleman disease, and non-Hodgkin lymphoma, including chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, gastric and nongastric mucosa-associated lymphoid tissue (MALT) lymphoma, and nodal and splenic marginal zone lymphoma.","R-Squared Regimen | Lenalidomide and Rituximab (R2) | Lenalidomide and Rituximab-abbs (R2) | Lenalidomide and Rituximab-arrx (R2) | Lenalidomide and Rituximab-blit (R2) | Lenalidomide and Rituximab-pvvr (R2) | Lenalidomide and Rituximab-rite (R2) | Lenalidomide and Rituximab-rixa (R2) | Lenalidomide and Rituximab-rixi (R2) | Lenalidomide-Rituximab | Lenalidomide/Rituximab | Lenalidomide/Rituximab Regimen | R-squared | R2 Regimen | Revlimid/Rituxan | Rituximab/Lenalidomide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538282","SMILE Regimen","C140113","A regimen consisting of dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide that can be used in the treatment of natural killer (NK)/T-cell lymphoma.","SMILE Regimen | Dexamethasone-Methotrexate-Ifosfamide-L-asparaginase-Etoposide | Dexamethasone/Methotrexate/Ifosfamide/L-asparaginase/Etoposide | SMILE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538295","VIPD Regimen","C140114","A regimen consisting of etoposide, ifosfamide, cisplatin and dexamethasone that can be used in the treatment of natural killer (NK)/T-cell lymphoma.","VIPD Regimen | Etoposide-Ifosfamide-Cisplatin-Dexamethasone | Etoposide/Ifosfamide/Cisplatin/Dexamethasone | VIPD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL406896","Human Cytomegalovirus Immune Globulin","C80826","A sterilized solution containing immunoglobulins (IGs) against cytomegalovirus (CMV) that is derived from human plasma of donors infected with CMV and can be used for passive immunization against CMV. Upon administration, human CMVIG is used to help prevent or treat infection by CMV.","Human Cytomegalovirus Immune Globulin | CMV Hyperimmune Gamma Globulin | CMVIG | Cytogam | Cytomegalovirus Immune Globulin | HUMAN CYTOMEGALOVIRUS IMMUNE GLOBULIN | Human CMV-immune Globulin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538294","R-HCVAD Plus Methotrexate/Cytarabine","C140115","A regimen consisting of rituximab, cyclophosphamide, vincristine, doxorubicin and dexamethasone, administered on a hyperfractionated schedule, and alternating with rituximab, and high-dose methotrexate and cytarabine that can be used for the treatment of mantle cell lymphoma (MCL), AIDS-related B-cell lymphomas, Burkitt lymphoma, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), acute lymphoblastic leukemia (ALL), and T-cell lymphoma.","R-HyperCVAD Alternating with High-dose MTX AraC/Rituximab Regimen | R-HCVAD Plus Methotrexate/Cytarabine | R-Hyper-CVAD/R-MA | R-Hyper-CVAD/R-MA (rituximab-abbs) | R-Hyper-CVAD/R-MA (rituximab-arrx) | R-Hyper-CVAD/R-MA (rituximab-blit) | R-Hyper-CVAD/R-MA (rituximab-pvvr) | R-Hyper-CVAD/R-MA (rituximab-rite) | R-Hyper-CVAD/R-MA (rituximab-rixa) | R-Hyper-CVAD/R-MA (rituximab-rixi) | R-HyperCVAD Alternating with High-dose MTX AraC Regimen | R-HyperCVAD Alternating with High-dose MTX AraC Regimen | R-HyperCVAD/HD MTX AraC Regimen | R-HyperCVAD/HD MTX AraC Regimen | R-HyperCVAD/MTX/AraC | R-hyperCVAD Alternating with R-Methotrexate-Cytarabine | Rituximab Plus Hyper-CVAD Alternating with R-Methotrexate/Cytarabine | Rituximab Plus HyperCVAD Alternating with R-Methotrexate/Cytarabine | Rituximab Plus HyperCVAD Alternating with Rituximab Plus High-dose Cytarabine and Methotrexate | Rituximab Plus HyperCVAD Alternating with Rituximab-Methotrexate/Cytarabine | Rituximab-Hyperfractionated Cyclophosphamide-Vincristine-Adriamycin-Dexamethasone Alternating with Rituximab/Cytarabine/Methotrexate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538401","Enneking Low Surgical Grade","C140260","A low-grade lesion, corresponding to Broder's Grades 1 or 2, with a low risk for distant spread (< 25%). These tumors are characterized by low mitotic rates, low nuclear to cytoplasmic ratio, and limited pleomorphism.","Enneking Low Surgical Grade | G1 | Low Grade | Low Grade (G1) | MSTS Low Surgical Grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538400","Enneking High Surgical Grade","C140261","A high-grade lesion, corresponding to Broder's Grades 3 and 4, having a higher incidence of metastasis and characterized histologically by mitotic figures, prominent nucleoli, and pleomorphism.","Enneking High Surgical Grade | G2 | High Grade | High Grade (G2) | MSTS High Surgical Grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541312","Intracompartmental Tumor","C140263","Bone tumors are confined within the cortex of the bone.","Intracompartmental Tumor | Intracompartmental | Intracompartmental (T1) | MSTS Intracompartmental | T1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545898","Extracompartmental Tumor","C140265","Bone tumors extend beyond the bone cortex.","Extracompartmental Tumor | Extracompartmental | Extracompartmental (T2) | MSTS Extracompartmental | T2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526705","TP63 Gene Rearrangement","C139290","A molecular abnormality indicating rearrangement of the TP63 gene.","TP63 Gene Rearrangement | AIS Gene Rearrangement | B(p51A) Gene Rearrangement | B(p51B) Gene Rearrangement | EEC3 Gene Rearrangement | KET Gene Rearrangement | LMS Gene Rearrangement | NBP Gene Rearrangement | OFC8 Gene Rearrangement | P63 Gene Rearrangement | P73H Gene Rearrangement | P73L Gene Rearrangement | RHS Gene Rearrangement | SHFM4 Gene Rearrangement | TP53CP Gene Rearrangement | TP53L Gene Rearrangement | TP73L Gene Rearrangement | Tumor Protein p53-Competing Protein Gene Rearrangement | Tumor Protein p53-Like Gene Rearrangement | Tumor Protein p63 Gene Rearrangement | Tumor Protein p73-Like Gene Rearrangement | p40 Gene Rearrangement | p51 Gene Rearrangement | p53CP Gene Rearrangement | p63 Gene Rearrangement | p73H Gene Rearrangement | p73L Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881082","HyperCVAD Regimen","C63455","A regimen consisting of cyclophosphamide, vincristine, doxorubicin and dexamethasone, administered on a hyperfractionated schedule that is used to treat adult acute lymphoblastic leukemia (ALL) or Burkitt-type ALL and adult small non-cleaved cell (Burkitt) lymphoma, AIDS-related B-cell lymphomas, blastic plasmacytoid dendritic cell neoplasm (BPDCN), diffuse large B-cell lymphoma (DLBCL) and T-cell lymphomas.","HyperCVAD Regimen | Hyper-CVAD | Hyper-CVAD Regimen | HyperCVAD | Hyperfractionated Cyclophosphamide-Vincristine-Adriamycin-Dexamethasone Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985720","Assessment Date","C93511","The date (and time) on which an assessment is completed.","Assessment Date | assessmentDate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538470","SIOP/COG/NWTSG Stage I","C140301","Wilms' tumor is limited to the kidney and completely excised; the tumor was not ruptured before or during removal; the vessels of the renal sinus are not involved beyond 2 mm; there is no residual tumor present beyond the margins of excision.","SIOP/COG/NWTSG Stage I | Stage I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538469","SIOP/COG/NWTSG y-Stage I","C140302","The assessment of stage I Wilms' tumor was performed after neoadjuvant therapy was given.","SIOP/COG/NWTSG y-Stage I | SIOP/COG/NWTSG Stage I-y",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538468","SIOP/COG/NWTSG Stage II","C140303","Wilms' tumor extends beyond the kidney but is completely excised; no residual tumor is apparent at or beyond the margins of the excision; tumor thrombus in vessels outside the kidney is Stage II if the thrombus is removed en bloc with the tumor.","SIOP/COG/NWTSG Stage II | Stage II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538467","SIOP/COG/NWTSG y-Stage II","C140304","The assessment of stage III Wilms' tumor was performed after neoadjuvant therapy was given.","SIOP/COG/NWTSG y-Stage II | SIOP/COG/NWTSG Stage II-y",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538466","SIOP/COG/NWTSG Stage III","C140305","Residual Wilms' tumor confined to the abdomen; Lymph nodes in the renal hilum, the periaortic chains, or beyond are found to contain tumor; diffuse peritoneal contamination by the tumor; implants are found on the peritoneal surfaces; tumor extends beyond the surgical margins either microscopically or grossly; tumor is not completely resectable because of local infiltration into vital structures.","SIOP/COG/NWTSG Stage III | Stage III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538465","SIOP/COG/NWTSG y-Stage III","C140306","The assessment of stage III Wilms' tumor was performed after neoadjuvant therapy was given.","SIOP/COG/NWTSG y-Stage III | SIOP/COG/NWTSG Stage III-y",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538464","SIOP/COG/NWTSG Stage IV","C140307","Presence of hematogenous metastases or metastases to distant lymph nodes.","SIOP/COG/NWTSG Stage IV | Stage IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538381","International Society of Pediatric Oncology Staging System","C140270","A staging system for Wilms' Tumor that is based on the extent of tumor spread at surgery, after the patient has received neo-adjuvant chemotherapy.","International Society of Pediatric Oncology Staging System | SIOP Staging System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538380","Children's Oncology Group/National Wilms' Tumor Study Group Staging System","C140271","A staging system for Wilms' Tumor that is based on the postoperative, pre-chemotherapy pathological features and findings relating to the extent of tumor spread.","Children's Oncology Group/National Wilms' Tumor Study Group Staging System | COG/NWTSG Staging System | Childrens Oncology Group/National Wilms Tumor Study Group Staging System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538379","SIOP/COG/NWTSG Staging System","C140272","A staging system for Wilms' Tumor that combines the International Society of Pediatric Oncology Staging System and the Children's Oncology Group/National Wilms' Tumor Study Group Staging System.","SIOP/COG/NWTSG Staging System | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538474","Immune-related Response Evaluation Criteria In Solid Tumors","C140313","A set of criteria for capturing the unidimensional measurements which are used to assess the effect of immunotherapeutic agents on solid tumors based on elements of Immune-related RECIST (irRECIST).","Immune-related Response Evaluation Criteria In Solid Tumors | irRECIST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538471","irRECIST Complete Response","C140316","A complete disappearance of all measurable and non-measurable lesions. Lymph nodes must decrease to < 10 mm in short axis. Confirmation of response is not mandatory.","irRECIST Complete Response | irCR | irCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538472","irRECIST Partial Response","C140315","A decrease of 30% or more in TMTB relative to baseline, non-target lesions are irNN, and no unequivocal progression of new non-measurable lesions.","irRECIST Partial Response | irPR | irPR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538455","irRECIST Stable Disease","C140317","A failure to meet criteria for irCR or irPR in the absence of irPD.","irRECIST Stable Disease | irSD | irSD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538454","irRECIST No Baseline Disease","C140318","No target disease was identified at baseline and at follow-up the patient fails to meet criteria for irCR or irPD.","irRECIST No Baseline Disease | irNN | irNN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538453","irRECIST Progressive Disease","C140319","A minimum 20% increase and minimum 5 mm absolute increase in total measured tumor burden compared to nadir, or irPD for non-target or new non-measurable lesions. Confirmation of progression is recommended minimum 4 weeks after the first irPD assessment.","irRECIST Progressive Disease | irPD | irPD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538452","irRECIST Non-Evaluable","C140320","Used in exceptional cases where insufficient data exists.","irRECIST Non-Evaluable | irNE | irNE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538451","irRECIST No Disease","C140321","Used in adjuvant setting when no disease is detected.","irRECIST No Disease | irND | irND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522926","Urine Immunofixation Electrophoresis","C135569","An immunofixation-based laboratory test performed to detect and type monoclonal immunoglobulins present in a urine sample.","Urine Immunofixation Electrophoresis | UIFE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334108","Polyposis","C4089","A condition characterized by the presence of numerous polyps.","Polyposis | Multiple Polyps | polyposis",,,,,,,,,,,,,,,"4317675","Multiple polyps",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517491","Gene Mapping, Human","C18804","Determination of the relative positions of human genes on a DNA molecule (chromosome or plasmid) and of the distance, in linkage units or physical units, between them.","Gene Mapping, Human | DNA Sequencing, Gene Mapping, Human | DNA Sequencing, Human Gene Mapping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086412","Histone H3.3","C101445","Histone H3.3 (136 aa, ~15 kDa) is encoded by both the human H3-3A and H3-3B genes. This protein plays a role in chromosomal structure.","Histone H3.3 | H3.3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640207","Histone H3.1","C101734","Histone H3.1 (136 aa, ~15 kDa) is encoded by the human H3C1, H3C2, H3C3, H3C4, H3C6, H3C7, H3C8, H3C10, H3C11 and H3C12 genes. This protein plays a role in the formation of chromatin structures.","Histone H3.1 | H3.1 | Histone H3/a | Histone H3/b | Histone H3/c | Histone H3/d | Histone H3/f | Histone H3/h | Histone H3/i | Histone H3/j | Histone H3/k | Histone H3/l",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513485","IDH1 NP_005887.2:p.R132L","C131101","A change in the amino acid residue at position 132 in the isocitrate dehydrogenase [NADP] cytoplasmic protein where arginine has been replaced by leucine.","IDH1 NP_005887.2:p.R132L | Cytosolic NADP-Isocitrate Dehydrogenase Protein Arg132Leu | Cytosolic NADP-Isocitrate Dehydrogenase Protein R132L | IDH1 Arg132Leu | IDH1 NP_005887.2:p.Arg132Leu | IDH1 R132L | IDH1 R132L Mutation | IDH1 p.Arg132Leu | IDH1 p.R132L | Isocitrate Dehydrogenase [NADP] Cytoplasmic Arg132Leu | Isocitrate Dehydrogenase [NADP] Cytoplasmic R132L | NP_005887.2:p.Arg132Leu | NP_005887.2:p.R132L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513484","IDH1 NP_005887.2:p.R132G","C131097","A change in the amino acid residue at position 132 in the isocitrate dehydrogenase [NADP] cytoplasmic protein where arginine has been replaced by glycine.","IDH1 NP_005887.2:p.R132G | Cytosolic NADP-Isocitrate Dehydrogenase Protein Arg132Gly | Cytosolic NADP-Isocitrate Dehydrogenase Protein R132G | IDH1 Arg132Gly | IDH1 NP_005887.2:p.Arg132Gly | IDH1 R132G | IDH1 R132G Mutation | IDH1 p.Arg132Gly | IDH1 p.R132G | Isocitrate Dehydrogenase [NADP] Cytoplasmic Arg132Gly | Isocitrate Dehydrogenase [NADP] Cytoplasmic R132G | NP_005887.2:p.Arg132Gly | NP_005887.2:p.R132G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513486","IDH1 NP_005887.2:p.R132S","C131095","A change in the amino acid residue at position 132 in the isocitrate dehydrogenase [NADP] cytoplasmic protein where arginine has been replaced by serine.","IDH1 NP_005887.2:p.R132S | Cytosolic NADP-Isocitrate Dehydrogenase Protein Arg132Ser | Cytosolic NADP-Isocitrate Dehydrogenase Protein R132S | IDH1 Arg132Ser | IDH1 NP_005887.2:p.Arg132Ser | IDH1 R132S | IDH1 R132S Mutation | IDH1 p.Arg132Ser | IDH1 p.R132S | Isocitrate Dehydrogenase [NADP] Cytoplasmic Arg132Ser | Isocitrate Dehydrogenase [NADP] Cytoplasmic R132S | NP_005887.2:p.Arg132Ser | NP_005887.2:p.R132S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513483","IDH1 NP_005887.2:p.R132C","C131099","A change in the amino acid residue at position 132 in the isocitrate dehydrogenase [NADP] cytoplasmic protein where arginine has been replaced by cysteine.","IDH1 NP_005887.2:p.R132C | Cytosolic NADP-Isocitrate Dehydrogenase Protein Arg132Cys | Cytosolic NADP-Isocitrate Dehydrogenase Protein R132C | IDH1 Arg132Cys | IDH1 NP_005887.2:p.Arg132Cys | IDH1 R132C | IDH1 R132C Mutation | IDH1 p.Arg132Cys | IDH1 p.R132C | Isocitrate Dehydrogenase [NADP] Cytoplasmic Arg132Cys | Isocitrate Dehydrogenase [NADP] Cytoplasmic R132C | NP_005887.2:p.Arg132Cys | NP_005887.2:p.R132C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523653","Determination of Tumor DNA Mismatch Repair Status","C136346","An assessment of the DNA mismatch repair (MMR) status of a cancerous neoplasm.","Determination of Tumor DNA Mismatch Repair Status | Determination of Tumor MMR Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512582","WNT Pathway Activated","C129437","A finding indicating that the WNT signaling pathway is activated.","WNT Pathway Activated | WNT Pathway Activation Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826095","Sonic Hedgehog/Patch Pathway Activated","C82326","A finding indicating that the sonic hedgehog/patch pathway is activated.","Sonic Hedgehog/Patch Pathway Activated | SHH/PTCH Pathway Activated | SHH/PTCH Pathway Activation Positive | Sonic Hedgehog/Patch Pathway Activation Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0730319","Genetic Finding","C103223","A laboratory test result that indicates the status of a molecular genetic or cytogenetic event in a pathologic process.","Genetic Finding | ",,,,,,,,,,,,,,,"4025367","Genetic finding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0521095","Determine","C136827","The establishment of a state or result.","Determine | Determination | Determined",,,,,,,,,,,,,,,"4185107","Determined by",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265325","Turcot Syndrome","C3938","An autosomal dominant hereditary neoplastic syndrome caused by mutations in the PMS2, MLH1, MSH2, or APC genes. There are two types described, type 1, characterized by the presence of glioblastoma and often associated with hereditary nonpolyposis colorectal carcinoma, and type 2, characterized by the presence of medulloblastoma and familiar adenomatous polyposis.","Turcot Syndrome | ",,,,,,,,,,,,,,,"4266973","Turcot syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2700007","EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","C80281","A diffuse large B-cell lymphoma originally described in patients older than 50 years, but it has been increasingly recognized in younger patients. Epstein-Barr virus is present in all cases. There is no known history of immunodeficiency or prior lymphoma.","EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Age-Related EBV Positive B-Cell Lymphoproliferative Disorder | EBV Positive Diffuse Large B-Cell Lymphoma of the Elderly | EBV positive diffuse large B-cell lymphoma of the elderly | EBV-Positive DLBCL, NOS | EBV-Positive Diffuse Large B-Cell Lymphoma | EBV-Positive Diffuse Large B-Cell Lymphoma, NOS | Epstein-Barr Virus Positive DLBCL, NOS | Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma of the Elderly | Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Senile EBV-Associated B-Cell Lymphoproliferative Disorder",,,,,,,,,,,,,,,"37396838|37399015","Epstein-Barr virus positive diffuse large B-cell lymphoma of elderly|Epstein-Barr virus positive diffuse large B-cell lymphoma of elderly",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL526535","Florid Follicular Hyperplasia Post-Transplant Lymphoproliferative Disorder","C139028","An early lesion of post-transplant lymphoproliferative disorder with the morphologic appearance of florid follicular hyperplasia.","Florid Follicular Hyperplasia Post-Transplant Lymphoproliferative Disorder | Florid Follicular Hyperplasia PTLD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526545","Breast Implant-Associated Anaplastic Large Cell Lymphoma","C139012","A rare anaplastic large cell lymphoma that develops in individuals with breast implants. It usually presents as an accumulation of seroma fluid between the implant and the surrounding fibrous capsule. The median interval from the time of the implant to the development of lymphoma is approximately 10 years.","Breast Implant-Associated Anaplastic Large Cell Lymphoma | BIA-ALCL | Breast Implant Associated Anaplastic Large Cell Lymphoma (BIA ALCL) | Breast Implant-Associated Anaplastic Large Cell Lymphoma, ALK-Negative | Breast implant-associated anaplastic large cell lymphoma",,,,,,,,,,,,,,,"37152118","Breast implant-associated anaplastic large cell lymphoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526546","Follicular Helper T-Cell Lymphoma, Not Otherwise Specified","C139011","Follicular helper T-cell lymphoma that does not meet the criteria for any other specifically defined entity of follicular helper T-cell lymphoma.","Follicular Helper T-Cell Lymphoma, Not Otherwise Specified | Follicular Helper T-Cell Lymphoma, NOS | Nodal PTCL with T Follicular Helper Phenotype | Nodal PTCL with TFH Phenotype | Nodal Peripheral T-Cell Lymphoma with T Follicular Helper Phenotype | Nodal Peripheral T-Cell Lymphoma with TFH Phenotype",,,,,,,,,,,,,,,"37203899","Nodal peripheral T-cell lymphoma with T follicular helper phenotype",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526526","Indolent Clonal T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract","C139021","A clonal T-cell lymphoproliferative disorder that can involve the mucosa in all sites of the gastrointestinal tract, but is most common in the small intestine and colon. The lymphoid cells infiltrate the lamina propria but usually do not show invasion of the epithelium. The clinical course is indolent, but most patients do not respond to conventional chemotherapy. A subset of cases progress to a higher-grade T-cell lymphoma with spread beyond the gastrointestinal tract. (WHO 2017)","Indolent Clonal T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract | ITLPD-GI | Indolent T-Cell Lymphoma of the Gastrointestinal Tract | Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract | Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract | Indolent T-cell lymphoproliferative disorder of gastrointestinal tract",,,,,,,,,,,,,,,"37204696|37312309","Indolent T-cell lymphoproliferative disorder of gastrointestinal tract|Indolent T-cell lymphoproliferative disorder of gastrointestinal tract",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL526531","Primary Cutaneous Acral CD8-Positive T-Cell Lymphoproliferative Disorder","C139023","A primary cutaneous T-cell lymphoproliferative disorder that presents as an acral (peripheral) lesion. It is composed of CD8-positive neoplastic T-lymphocytes. It is usually localized to a single site and has an indolent clinical course. Local or more extensive recurrences have been described in a minority of patients.","Primary Cutaneous Acral CD8-Positive T-Cell Lymphoproliferative Disorder | Primary Cutaneous Acral CD8-Positive T-Cell LPD | Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma | Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma",,,,,,,,,,,,,,,"37204041","Primary cutaneous acral CD8 positive T-cell lymphoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL525847","HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","C138320","A large B-cell lymphoma characterized by the presence of a diffuse proliferation of large, atypical HHV8-positive neoplastic lymphocytes. It usually arises in association with HHV8-positive multicentric Castleman disease.","HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | HHV8-Positive DLBCL, NOS | HHV8-Positive Diffuse Large B-Cell Lymphoma, NOS | Human Herpesvirus 8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | KSHV/HHV8-Positive Diffuse Large B-Cell Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334174","Infectious Mononucleosis Post-Transplant Lymphoproliferative Disorder","C7236","An early post-transplant lymphoproliferative lesion characterized by immunoblastic proliferation and paracortical expansion as seen in infectious mononucleosis.  There is architectural preservation of the involved tissues.  Oligoclonal or monoclonal cellular populations have been detected in a small number of cases.  In some cases, a polymorphic or monomorphic post-transplant lymphoproliferative disorder may follow this early lesion.","Infectious Mononucleosis Post-Transplant Lymphoproliferative Disorder | Infectious Mononucleosis PTLD | Infectious Mononucleosis-Like Post-Transplant Lymphoproliferative Disorder | Infectious Mononucleosis-Like Post-Transplant Lymphoproliferative Disorder | Infectious Mononucleosis-like PTLD",,,,,,,,,,,,,,,"36716778","Infectious mononucleosis-like post-transplant lymphoproliferative disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL525720","Duodenal-Type Follicular Lymphoma","C138185","A localized low-grade follicular lymphoma within the gastrointestinal tract, which is distinct from other gastrointestinal tract follicular lymphomas.  It has features that overlap with in situ follicular neoplasia as well as some features resembling an extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue. The prognosis is excellent.","Duodenal-Type Follicular Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538391","Enneking Staging System","C140258","A staging system for malignant mesenchymal tumors that takes into account the surgical grade, local extent, and presence or absence of metastasis.","Enneking Staging System | Enneking Staging System for Malignant Musculoskeletal Tumors | Enneking Staging for Malignant Musculoskeletal Tumors | MSTS Staging System | MSTS System | enneking msts stage | enneking_msts_stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985647","Performed Specimen Collection","C93435","The completed action of gathering samples that may be used for subsequent analysis.","Performed Specimen Collection | PerformedSpecimenCollection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449076","Microbiome","C68564","A collection or collectivity of microorganisms. This entity is frequently examined to determine how changes to the surrounding environment affects biological processes and the resulting health status of the organism.","Microbiome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882520","R-CVP Regimen","C63473","A regimen consisting of cyclophosphamide, vincristine, prednisone (CVP) and rituximab that may be used in the treatment of some forms of non-Hodgkin's lymphoma (NHL), including follicular lymphoma, gastric and nongastric MALT lymphomas, nodal marginal zone lymphoma (NMZL) and splenic marginal zone lymphoma (SMZL), Castleman disease and post-transplant lymphoproliferative disorders.","R-CVP Regimen | CVP-Rituximab | CVP/Rituximab | Cyclophosphamide/Prednisone/Rituximab/Vincristine | Cyclophosphamide/Vincristine/Prednisone/Rituximab | R-CVP | R-CVP (rituximab-abbs) | R-CVP (rituximab-arrx) | R-CVP (rituximab-blit) | R-CVP (rituximab-pvvr) | R-CVP (rituximab-rite) | R-CVP (rituximab-rixa) | R-CVP (rituximab-rixi) | Rituximab-Cyclophosphamide-Vincristine-Prednisone Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0128318","CODOX-M Regimen","C63447","A regimen consisting of cyclophosphamide, vincristine, doxorubicin and high-dose methotrexate used to treat aggressive forms of non-Hodgkin lymphoma; also used as primary treatment of AIDS-related and low-risk Burkitt's lymphoma. Intrathecal cytarabine and methotrexate are included in this regimen as either prophylaxis or treatment of central nervous system (CNS) disease.","CODOX-M Regimen | CODOX-M | Cyclophosphamide-Oncovin-Doxorubicin-Methotrexate Regimen | Cyclophosphamide/Vincristine/Doxorubicin/Methotrexate | Cyclophosphamide/Vincristine/Doxorubicin/Methotrexate Regimen | MOCA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826232","Dose Adjustment","C82495","An indication or description of a change in dosage.","Dose Adjustment | DOSADJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1699231","gemcitabine-oxaliplatin regimen","C64833","A regimen consisting of gemcitabine and oxaliplatin used for the treatment of biliary adenocarcinoma, pancreatic cancer, hepatocellular cancer, testicular cancer, T-cell lymphomas, diffuse large B-cell lymphoma (DLBCL), classic Hodgkin lymphoma (HL), mycosis fungoides/Sezary syndrome and malignant germ cell tumors.","GemOx Regimen | GEM-OX Regimen | GEMOX Regimen | GemOx | Gemcitabine-Oxaliplatin | Gemcitabine-Oxaliplatin Regimen | Gemcitabine-Oxaliplatin Regimen | Gemcitabine/Oxaliplatin | Gemcitabine/Oxaliplatin Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1871911","R-FCM Regimen","C63463","A regimen consisting of rituximab, fludarabine, cyclophosphamide and mitoxantrone used to treat indolent non-Hodgkin lymphoma and relapsed or refractory mantle cell lymphoma.","R-FCM Regimen | FCMR Regimen | R-FCM | R-FCM (rituximab-abbs) | R-FCM (rituximab-arrx) | R-FCM (rituximab-blit) | R-FCM (rituximab-pvvr) | R-FCM (rituximab-rite) | R-FCM (rituximab-rixa) | R-FCM (rituximab-rixi) | Rituximab-Fludarabine-Cyclophosphamide-Mitoxantrone Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985768","Expected Indicator","C93565","Specifies whether the entity, event or activity is considered probable or likely.","Expected Indicator | expectedIndicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538486","Hypermutation Phenotype","C140413","A genetic marker marked by the presence of mutations in genes that maintain genomic integrity, which leads to greatly increased rates of mutation for the rest of the genome and may induce malignant transformation.","Hypermutation Phenotype | Hypermutator Phenotype",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538485","IDH2 NP_002159.2:p.R172W","C140414","A change in the amino acid residue at position 172 in the isocitrate dehydrogenase [NADP], mitochondrial protein where arginine has been replaced by tryptophan.","IDH2 NP_002159.2:p.R172W | IDH2 Arg172Trp | IDH2 NP_002159.2:p.Arg172Trp | IDH2 R172W | IDH2 R172W Mutation | IDH2 p.Arg172Trp | Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial Arg172Trp | Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial R172W | Isocitrate Dehydrogenase [NADP], Mitochondrial Arg172Trp | Isocitrate Dehydrogenase [NADP], Mitochondrial R172W | NP_002159.2:p.Arg172Trp | NP_002159.2:p.R172W",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3846720","Not Assessed","C139527","Indicates that an assessment was not performed.","Not Assessed | Assessment Not Done | Evaluation Not Done | Not Evaluated | Not examined",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274398","Free Kappa Light Chain to Free Lambda Light Chain Ratio Measurement","C98731","The determination of the ratio of free kappa light chain compared to free lambda light chain present in a sample. The measurement may be expressed as a ratio or percentage.","Free Kappa Light Chain to Free Lambda Light Chain Ratio Measurement | KLCLLCFR | Kappa Lt Chain,Free/Lambda Lt Chain,Free",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0546672","Bence-Jones Protein Measurement","C111136","The determination of the amount of Bence-Jones protein present in a sample.","Bence-Jones Protein Measurement | BJPROT | Bence Jones Protein Measurement | Bence-Jones Protein",,,,,,,,,,,,,,,"40481415","Measurement of Bence Jones protein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1707400","Classic Medulloblastoma","C54039","A medulloblastoma composed of malignant cells with hyperchromatic nucleus and scanty cytoplasm.  Homer Wright rosettes may be present.","Classic Medulloblastoma | Medulloblastoma, classic",,,,,,,,,,,,,,,"44782550|44783592","Classic medulloblastoma|Classic medulloblastoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2986491","Genetic Hotspot","C94367","A genetic sequence at which mutations occur with an unusually high frequency.","Genetic Hotspot | Hotspot | hotspot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1141951","Panel Reactive Antibody Test","C116210","An assessment of the reactivity between host immune cells and donor human leukocyte antigen. This test is most commonly carried out in subjects awaiting transplant. The recipient's blood or serum is mixed with either a panel of lymphocytes from random blood donations or a potential donor's purified human leukocyte antigens (HLA). Host reactivity is scored as a percent.","Panel Reactive Antibody Test | Cross-Matching | Crossmatch | Crossmatching | PRA | PRA Score | PRAB | Panel Reactive Antibody | Percent Panel Reactive Antibody | Percent Reactive Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514064","Next Generation Targeted Sequencing","C130177","A technique that determines the nucleotide sequence of a pre-specified region of DNA or RNA by using primers that are specific for that region.","Next Generation Targeted Sequencing | NEXT GENERATION TARGETED SEQUENCING | Targeted NGS | Targeted NGS (sequencing of selected regions of the genome either via targeted capture or amplification) | Targeted Sequencing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0806492","Free Immunoglobulin Light Chain","C84258","Immunoglobulin kappa and/or lambda light chains that are not bound to immunoglobulin heavy chains. These proteins are produced in vivo by B-cells but can be synthesized ex vivo for use as diagnostic or therapeutic agents.","Free Immunoglobulin Light Chain | FLK | Free Light Chain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889610","Hepatitis C Virus Antigen Measurement","C116196","The determination of the amount of hepatitis C virus antigen present in a sample.","Hepatitis C Virus Antigen Measurement | HCAG | Hepatitis C Virus Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697576","Hepatitis A Surface Antibody Measurement","C74710","The determination of the surface antibody reaction of a sample to the Hepatitis A virus.","Hepatitis A Surface Antibody Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3658787","superagonist interleukin-15:interleukin-15 receptor alphaSu/Fc fusion complex ALT-803","C107503","A mutated form of the cytokine interleukin (IL)-15 (IL-15N72D), with potential immunomodulating and antineoplastic activities. Upon administration, nogapendekin alfa binds to the IL-15 receptor on natural killer (NK) and CD8+ T lymphocytes, which activates and increases the levels of NK cells and memory T-cells. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation.","Nogapendekin Alfa | ALT 803 | ALT-803 | ALT803 | Fusion Protein Consisting of IL-15N72D and IL-15RaSu/FC | IL-15N72D/IL-15Ra-Fc | IL-15N72D:IL-15RaSu/Fc Fusion Complex | N 803 | N-803 | N803 | NOGAPENDEKIN ALFA | Superagonist Interleukin-15:Interleukin-15 Receptor AlphaSu/Fc Fusion Complex Alt-803 | Superagonist Interleukin-15:Interleukin-15 Receptor alphaSu/Fc Fusion Complex ALT-803",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202341","Bromide Measurement","C140512","A quantitative measurement for assessing the amount of bromide present in a sample.","Bromide Measurement | ",,,,,,,,,,,,,,,"4238670","Bromides measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086849","Sex at Birth","C124436","The physical sexual characteristics of the neonate at birth.","Sex at Birth | SEXRBRTH | Sex Reported at Birth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0276623","Chronic Viral Hepatitis","C82979","Chronic hepatitis caused by viruses, most commonly hepatitis viruses B and C.","Chronic Viral Hepatitis | Chronic viral hepatitis, unspecified",,,,,,,,,,,,,,,"4012113","Chronic viral hepatitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641197","Complete Response in Neuroblastoma","C103312","No evidence of primary tumor, no evidence of metastases (chest, abdomen, liver, bone, bone marrow, nodes, etc.), and HVA/VMA normal.","Complete Response in Neuroblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641198","Partial Response in Neuroblastoma","C103313","Fifty to 90% reduction of primary tumor; 50% or greater reduction in measurable sites of metastases; 0-1 bone marrow samples with tumor; number of positive bone sites decreased by greater than 50%.","Partial Response in Neuroblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641196","Very Good Partial Response in Neuroblastoma","C103311","Greater than 90% reduction of primary tumor; no metastatic tumor (as above except bone); no new bone lesions, all pre-existing lesions improved on bone scan; HVA/VMA normal.","Very Good Partial Response in Neuroblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641199","No Response in Neuroblastoma","C103314","No new lesions; less than 50% reduction but less than 25% increase in any existing lesion (exclude bone marrow evaluation).","No Response in Neuroblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524990","TCH + P","C138047","A regimen consisting of docetaxel, carboplatin, trastuzumab and pertuzumab, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.","TCHP Regimen | Docetaxel/Carboplatin/Pertuzumab/Trastuzumab | Docetaxel/Carboplatin/Trastuzumab/Pertuzumab Regimen | Docetaxel/Carboplatin/Trastuzumab/Pertuzumab Regimen | TCH + P | TCH + Pertuzumab | TCH Plus Pertuzumab Regimen | TCHP | TCHP (Docetaxel) | TCHP (Docetaxel) (trastuzumab-anns) | TCHP (Docetaxel) (trastuzumab-dkst) | TCHP (Docetaxel) (trastuzumab-dttb) | TCHP (Docetaxel) (trastuzumab-herw) | TCHP (Docetaxel) (trastuzumab-pkrb) | TCHP (Docetaxel) (trastuzumab-qyyp) | TCHP (Docetaxel) (trastuzumab-strf) | TCHP (Docetaxel) (trastuzumab-zerc) | TCHP (Docetaxel, SC Trastuzumab) | Taxotere-Carboplatin-Herceptin-Perjeta | Taxotere-Carboplatin-Herceptin-Pertuzumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524992","Pertuzumab + Trastuzumab + Paclitaxel","C138045","A regimen consisting of pertuzumab, trastuzumab and paclitaxel, used as a treatment for recurrent and metastatic HER-2/neu-positive breast cancer.","Paclitaxel/Pertuzumab/Trastuzumab Regimen | Pertuzumab + Trastuzumab + Paclitaxel | Pertuzumab-Trastuzumab-Paclitaxel | Pertuzumab-Trastuzumab-Paclitaxel Regimen | Pertuzumab/Trastuzumab/Paclitaxel Regimen | Pertuzumab/Trastuzumab/Paclitaxel Regimen | THP (Paclitaxel) | THP (Paclitaxel) (trastuzumab-anns) | THP (Paclitaxel) (trastuzumab-dkst) | THP (Paclitaxel) (trastuzumab-dttb) | THP (Paclitaxel) (trastuzumab-herw) | THP (Paclitaxel) (trastuzumab-pkrb) | THP (Paclitaxel) (trastuzumab-qyyp) | THP (Paclitaxel) (trastuzumab-strf) | THP (Paclitaxel) (trastuzumab-zerc) | THP (Taxol) Regimen | Taxol/Herceptin/Pertuzumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883258","TCH Regimen","C63424","A regimen consisting of docetaxel, carboplatin and trastuzumab that can be used in the treatment of breast cancer.","TCH Regimen | Carboplatin/Docetaxel/Trastuzumab | Docetaxel-Carboplatin-Trastuzumab Regimen | Docetaxel/Carboplatin + Trastuzumab | Docetaxel/Carboplatin Plus Trastuzumab | Docetaxel/Doxorubicin/Cyclophosphamide | TCH | TCH (Docetaxel, Carboplatin) | TCbH (Docetaxel) (trastuzumab-anns) | TCbH (Docetaxel) (trastuzumab-dkst) | TCbH (Docetaxel) (trastuzumab-dttb) | TCbH (Docetaxel) (trastuzumab-herw) | TCbH (Docetaxel) (trastuzumab-pkrb) | TCbH (Docetaxel) (trastuzumab-qyyp) | TCbH (Docetaxel) (trastuzumab-zerc) | Taxotere-Carboplatin-Herceptin Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524994","Paclitaxel/Trastuzumab Regimen","C138051","A regimen consisting of paclitaxel and trastuzumab that may be used in the treatment of breast, esophageal and esophagogastric junction, and gastric cancers. Paclitaxel weekly plus trastuzumab regimen and dose-dense paclitaxel plus trastuzumab regimen may be used for the treatment of breast cancer.","Paclitaxel/Trastuzumab Regimen | PH Regimen | Paclitaxel and Trastuzumab (TH) | Paclitaxel and Trastuzumab-anns (TH) | Paclitaxel and Trastuzumab-dkst (TH) | Paclitaxel and Trastuzumab-dttb (TH) | Paclitaxel and Trastuzumab-herw (TH) | Paclitaxel and Trastuzumab-pkrb (TH) | Paclitaxel and Trastuzumab-qyyp (TH) | Paclitaxel and Trastuzumab-strf (TH) | Paclitaxel and Trastuzumab-zerc (TH) | Paclitaxel-Trastuzumab | Paclitaxel-Trastuzumab Regimen | Paclitaxel/Herceptin | Paclitaxel/Trastuzumab | T-H (Paclitaxel) | T-H (Paclitaxel) (trastuzumab-anns) | T-H (Paclitaxel) (trastuzumab-dkst) | T-H (Paclitaxel) (trastuzumab-dttb) | T-H (Paclitaxel) (trastuzumab-herw) | T-H (Paclitaxel) (trastuzumab-pkrb) | T-H (Paclitaxel) (trastuzumab-qyyp) | T-H (Paclitaxel) (trastuzumab-strf) | T-H (Paclitaxel) (trastuzumab-zerc) | TH Regimen | Taxol/Herceptin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525016","Dose-dense AC Followed by Paclitaxel/Trastuzumab Regimen","C138036","A regimen consisting of doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.","Dose-dense AC Followed by Paclitaxel/Trastuzumab Regimen | Dose-dense AC Followed by Paclitaxel-Trastuzumab Regimen | Dose-dense AC Followed by Paclitaxel/Trastuzumab | Dose-dense Adriamycin/Cytoxan Followed by Paclitaxel/Trastuzumab | Dose-dense Doxorubicin/Cyclophosphamide Followed by Paclitaxel/Trastuzumab | ddAC-TH (Paclitaxel) | ddAC-TH (Paclitaxel) (trastuzumab-anns) | ddAC-TH (Paclitaxel) (trastuzumab-dkst) | ddAC-TH (Paclitaxel) (trastuzumab-dttb) | ddAC-TH (Paclitaxel) (trastuzumab-herw) | ddAC-TH (Paclitaxel) (trastuzumab-pkrb) | ddAC-TH (Paclitaxel) (trastuzumab-qyyp) | ddAC-TH (Paclitaxel) (trastuzumab-strf) | ddAC-TH (Paclitaxel) (trastuzumab-zerc)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879500","AC-T Regimen","C63427","A regimen consisting of cyclophosphamide and doxorubicin followed by paclitaxel, used as a neoadjuvant or adjuvant treatment for breast cancer.","AC-T Regimen | AC Followed by Paclitaxel | AC Followed by Paclitaxel Regimen | AC-T | AC-T regimen | AC-Taxol Regimen | AC-Taxol regimen | Doxorubicin/Cyclophosphamide Followed by Paclitaxel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525012","AC Followed by Pertuzumab/Trastuzumab/Paclitaxel Regimen","C138032","A regimen consisting of cyclophosphamide and doxorubicin followed by pertuzumab, trastuzumab, and paclitaxel, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.","AC Followed by Pertuzumab/Trastuzumab/Paclitaxel Regimen | AC Followed by Paclitaxel + Pertuzumab + Trastuzumab | AC Followed by Paclitaxel + Trastuzumab + Pertuzumab | AC Followed by Pertuzumab + Trastuzumab + Paclitaxel | AC Followed by Pertuzumab-Trastuzumab-Paclitaxel Regimen | AC-Pertuzumab + Trastuzumab + Paclitaxel | AC-THP (Paclitaxel) (trastuzumab-anns) | AC-THP (Paclitaxel) (trastuzumab-dkst) | AC-THP (Paclitaxel) (trastuzumab-dttb) | AC-THP (Paclitaxel) (trastuzumab-herw) | AC-THP (Paclitaxel) (trastuzumab-pkrb) | AC-THP (Paclitaxel) (trastuzumab-qyyp) | AC-THP (Paclitaxel) (trastuzumab-strf) | AC-THP (Paclitaxel) (trastuzumab-zerc) | Doxorubicin/Cyclophosphamide Followed by Pertuzumab + Trastuzumab + Paclitaxel | Doxorubicin/Cyclophosphamide Followed by Pertuzumab/Trastuzumab/Paclitaxel | ddAC-THP (Paclitaxel)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525007","AC Followed by Docetaxel Regimen","C138030","A regimen consisting of cyclophosphamide and doxorubicin followed by docetaxel, used as a neoadjuvant or adjuvant treatment for breast cancer.","AC Followed by Docetaxel Regimen | AC Followed by Docetaxel | AC-D | AC-Docetaxel | AC-T | AC-Taxotere | Doxorubicin/Cyclophosphamide Followed by Docetaxel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333041","Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Heavy Chain Variable-Region Gene","C37205","Chronic lymphocytic leukemia characterized by the absence of somatic hypermutation within the immunoglobulin heavy chain gene variable region of neoplastic clones. Patients have a significantly worse prognosis as compared to those with mutated immunoglobulin heavy chain gene variable region rearrangements.","Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Heavy Chain Variable-Region Gene | CLL with Unmutated IGVH | Pregerminal Center Chronic Lymphocytic Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1099479","Alloderm","C82364","A human dermis-derived allograft material.  Acellular cadaveric dermal matrix (ACDM) is derived from human cadaveric dermis from which the epidermis, all viable cells and major histocompatibility class (MHC) II antigens have been removed to minimize alloimmunogenicity, while the dermal collagen matrix is preserved. ACDM may placed over wounds to aid as a substitute for skin when necessary such as for surgical reconstruction or for protection against wound exposure and breakdown and wound infection.","Acellular Cadaveric Dermal Matrix | ACDM | AlloDerm | Allograft Dermis | DermaMatrix | Dermis Allograft",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825861","Reverse Triiodothyronine Measurement","C81968","A measurement of the reverse triiodothyronine in a biological specimen.","Reverse Triiodothyronine Measurement | RT3 | Triiodothyronine, Reverse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526694","Breast Cancer TNM Finding v8","C139390","A finding about one or more characteristics of breast cancer, following the rules of the TNM AJCC v8 classification system. This classification system applies to invasive (infiltrating) carcinoma of the breast and ductal carcinoma in situ of the breast. It does not apply to breast sarcoma, phyllodes tumor, and breast lymphoma. (from AJCC 8th Ed.)","Breast Cancer TNM Finding v8 | Breast Carcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526782","Breast Cancer pT1c TNM Finding v8","C139420","Breast cancer with tumor size more than 10 mm, but not more than 20 mm in greatest dimension. (from AJCC 8th Ed.)","Breast Cancer pT1c TNM Finding v8 | Breast Carcinoma pT1c TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526783","Breast Cancer pT1b TNM Finding v8","C139419","Breast cancer with tumor size more than 5 mm, but not more than 10 mm in greatest dimension. (from AJCC 8th Ed.)","Breast Cancer pT1b TNM Finding v8 | Breast Carcinoma pT1b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526784","Breast Cancer pT1a TNM Finding v8","C139418","Breast cancer with tumor size more than 1 mm, but not more than 5 mm in greatest dimension (round any measurement 1.0-1.9 mm to 2 mm). (from AJCC 8th Ed.)","Breast Cancer pT1a TNM Finding v8 | Breast Carcinoma pT1a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526810","Breast Cancer pT1 TNM Finding v8","C139416","Breast cancer with tumor size 20 mm or less in greatest dimension. (from AJCC 8th Ed.)","Breast Cancer pT1 TNM Finding v8 | Breast Carcinoma pT1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526813","Breast Cancer pT0 TNM Finding v8","C139413","Breast cancer with no evidence of primary tumor. (from AJCC 8th Ed.)","Breast Cancer pT0 TNM Finding v8 | Breast Carcinoma pT0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526793","Breast Cancer pT4b TNM Finding v8","C139425","Breast cancer with ulceration and/or ipsilateral macroscopic satellite nodules and/or edema (including peau d'orange) of the skin that does not meet the criteria for inflammatory carcinoma. (from AJCC 8th Ed.)","Breast Cancer pT4b TNM Finding v8 | Breast Carcinoma pT4b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526786","Breast Cancer pT4a TNM Finding v8","C139424","Breast cancer with extension to the chest wall; invasion or adherence to pectoralis muscle in the absence of invasion of chest wall structures does not qualify as T4. (from AJCC 8th Ed.)","Breast Cancer pT4a TNM Finding v8 | Breast Carcinoma pT4a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526787","Breast Cancer pT4 TNM Finding v8","C139423","Breast cancer with tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. (from AJCC 8th Ed.)","Breast Cancer pT4 TNM Finding v8 | Breast Carcinoma pT4 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526788","Breast Cancer pT3 TNM Finding v8","C139422","Breast cancer with tumor size more than 50 mm in greatest dimension. (from AJCC 8th Ed.)","Breast Cancer pT3 TNM Finding v8 | Breast Carcinoma pT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526789","Breast Cancer pT2 TNM Finding v8","C139421","Breast cancer with tumor size more than 20 mm, but not more than 50 mm in greatest dimension. (from AJCC 8th Ed.)","Breast Cancer pT2 TNM Finding v8 | Breast Carcinoma pT2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526785","Breast Cancer pT1mi TNM Finding v8","C139417","Breast cancer with tumor size 1 mm or less in greatest dimension. (from AJCC 8th Ed.)","Breast Cancer pT1mi TNM Finding v8 | Breast Carcinoma pT1mi TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526792","Breast Cancer pT4c TNM Finding v8","C139426","Breast cancer in which both T4a and T4b are present. (from AJCC 8th Ed.)","Breast Cancer pT4c TNM Finding v8 | Breast Carcinoma pT4c TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526806","Breast Cancer pTX TNM Finding v8","C139412","Breast cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Breast Cancer pTX TNM Finding v8 | Breast Carcinoma pTX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526811","Breast Cancer pTis (Paget) TNM Finding v8","C139415","Paget disease of the nipple not associated with invasive carcinoma and/or carcinoma in situ (DCIS) in the underlying breast parenchyma. Carcinomas in the breast parenchyma associated with Paget disease are categorized based on the size and characteristics of the parenchymal disease, although the presence of Paget disease should still be noted. (from AJCC 8th Ed.)","Breast Cancer pTis (Paget) TNM Finding v8 | Breast Carcinoma pTis (Paget) TNM Finding v8 | Tis (Paget's)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526791","Breast Cancer pT4d TNM Finding v8","C139427","Breast cancer meeting the criteria of inflammatory carcinoma. (from AJCC 8th Ed.)","Breast Cancer pT4d TNM Finding v8 | Breast Carcinoma pT4d TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526812","Breast Cancer pTis (DCIS) TNM Finding v8","C139414","Breast cancer with a finding of ductal carcinoma in situ. Lobular carcinoma in situ (LCIS) is a benign entity and is removed from TNM staging in the AJCC Cancer Staging Manual, 8th Edition. (from AJCC 8th Ed.)","Breast Cancer pTis (DCIS) TNM Finding v8 | Breast Carcinoma pTis (DCIS) TNM Finding v8 | Tis (DCIS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526696","Breast Cancer Clinical Regional Lymph Nodes TNM Finding v8","C139396","A clinical finding about one or more characteristics of breast cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Breast Cancer Clinical Regional Lymph Nodes TNM Finding v8 | Breast Carcinoma Clinical Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526701","Breast Cancer cN1 TNM Finding v8","C139399","Breast cancer with metastasis to movable ipsilateral level I, II axillary lymph node(s). (from AJCC 8th Ed.)","Breast Cancer cN1 TNM Finding v8 | Breast Carcinoma cN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526702","Breast Cancer cN0 TNM Finding v8","C139398","Breast cancer with no regional lymph node metastases (by imaging or clinical examination). (from AJCC 8th Ed.)","Breast Cancer cN0 TNM Finding v8 | Breast Carcinoma cN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526703","Breast Cancer cNX TNM Finding v8","C139397","Breast cancer in which regional lymph nodes cannot be assessed (e.g., previously removed). The cNX category is used sparingly in cases where regional lymph nodes have previously been surgically removed or where there is no documentation of physical examination of the axilla. (from AJCC 8th Ed.)","Breast Cancer cNX TNM Finding v8 | Breast Carcinoma cNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538755","Total Measured Tumor Burden","C140670","The sum of the longest diameters of non-nodal target and new measurable lesions, and the short axes of nodal target and new measurable lesions.","Total Measured Tumor Burden | TMTB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538756","Minor Response in Neuroblastoma","C140669","Partial response or complete response in at least one component (i.e., soft tissue, bone, and bone marrow disease) but at least one other component with stable disease; no component with progressive disease. (J Clin Oncol 35: 2580-2587, 2017)","Minor Response in Neuroblastoma | Minimal Response in Neuroblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526803","Breast Cancer cN3c TNM Finding v8","C139407","Breast cancer with metastases in ipsilateral supraclavicular lymph node(s). (from AJCC 8th Ed.)","Breast Cancer cN3c TNM Finding v8 | Breast Carcinoma cN3c TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526804","Breast Cancer cN3b TNM Finding v8","C139406","Breast cancer with metastases in ipsilateral internal mammary lymph node(s) and axillary lymph node(s). (from AJCC 8th Ed.)","Breast Cancer cN3b TNM Finding v8 | Breast Carcinoma cN3b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526805","Breast Cancer cN3a TNM Finding v8","C139405","Breast cancer with metastases in ipsilateral infraclavicular lymph node(s). (from AJCC 8th Ed.)","Breast Cancer cN3a TNM Finding v8 | Breast Carcinoma cN3a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526798","Breast Cancer cN3 TNM Finding v8","C139404","Breast cancer with metastases in ipsilateral infraclavicular (level III axillary) lymph node(s) with or without level I, II axillary lymph node involvement; or in ipsilateral internal mammary lymph node(s) with level I, II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement. (from AJCC 8th Ed.)","Breast Cancer cN3 TNM Finding v8 | Breast Carcinoma cN3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526799","Breast Cancer cN2b TNM Finding v8","C139403","Breast cancer with metastases only in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases. (from AJCC 8th Ed.)","Breast Cancer cN2b TNM Finding v8 | Breast Carcinoma cN2b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526800","Breast Cancer cN2a TNM Finding v8","C139402","Breast cancer with metastases in ipsilateral level I, II axillary lymph nodes fixed to one another (matted) or to other structures. (from AJCC 8th Ed.)","Breast Cancer cN2a TNM Finding v8 | Breast Carcinoma cN2a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526801","Breast Cancer cN2 TNM Finding v8","C139401","Breast cancer with metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases. (from AJCC 8th Ed.)","Breast Cancer cN2 TNM Finding v8 | Breast Carcinoma cN2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526692","Breast Cancer Clinical Distant Metastasis TNM Finding v8","C139392","A clinical finding about one or more characteristics of breast cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Breast Cancer Clinical Distant Metastasis TNM Finding v8 | Breast Carcinoma Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526697","Breast Cancer cM1 TNM Finding v8","C139395","Breast cancer with distant metastases detected by clinical and radiographic means and/or histologically proven metastases larger than 0.2 mm. (from AJCC 8th Ed.)","Breast Cancer cM1 TNM Finding v8 | Breast Carcinoma cM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526698","Breast Cancer cM0(i+) TNM Finding v8","C139394","Breast cancer in which there is no clinical or radiographic evidence of distant metastases in the presence of tumor cells or deposits no larger than 0.2 mm detected microscopically or by molecular techniques in circulating blood, bone marrow, or other nonregional nodal tissue in a patient without symptoms or signs of metastases. (from AJCC 8th Ed.)","Breast Cancer cM0(i+) TNM Finding v8 | Breast Carcinoma cM0(i+) TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526699","Breast Cancer cM0 TNM Finding v8","C139393","Breast cancer without clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the cM0 category. (from AJCC 8th Ed.)","Breast Cancer cM0 TNM Finding v8 | Breast Carcinoma cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526790","Breast Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C139428","A pathologic finding about one or more characteristics of breast cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Breast Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | Breast Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526774","Breast Cancer pN3c TNM Finding v8","C139444","Breast cancer with metastases in ipsilateral supraclavicular lymph nodes. (from AJCC 8th Ed.)","Breast Cancer pN3c TNM Finding v8 | Breast Carcinoma pN3c TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526775","Breast Cancer pN3b TNM Finding v8","C139443","Breast cancer with pN1a or pN2a in the presence of cN2b (positive internal mammary nodes by imaging); or pN2a in the presence of pN1b. (from AJCC 8th Ed.)","Breast Cancer pN3b TNM Finding v8 | Breast Carcinoma pN3b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526776","Breast Cancer pN3a TNM Finding v8","C139442","Breast cancer with metastases in 10 or more axillary lymph nodes (at least one tumor deposit larger than 2.0 mm); or metastases to the infraclavicular (level III axillary) lymph nodes. (from AJCC 8th Ed.)","Breast Cancer pN3a TNM Finding v8 | Breast Carcinoma pN3a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526777","Breast Cancer pN3 TNM Finding v8","C139441","Breast cancer with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. (from AJCC 8th Ed.)","Breast Cancer pN3 TNM Finding v8 | Breast Carcinoma pN3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526770","Breast Cancer pN2b TNM Finding v8","C139440","Breast cancer with metastases in clinically detected internal mammary lymph nodes with or without microscopic confirmation; with pathologically negative axillary nodes. (from AJCC 8th Ed.)","Breast Cancer pN2b TNM Finding v8 | Breast Carcinoma pN2b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526771","Breast Cancer pN2a TNM Finding v8","C139439","Breast cancer with metastasis in 4-9 axillary lymph nodes (at least one tumor deposit larger than 2.0 mm). (from AJCC 8th Ed.)","Breast Cancer pN2a TNM Finding v8 | Breast Carcinoma pN2a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526772","Breast Cancer pN2 TNM Finding v8","C139438","Breast cancer with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. (from AJCC 8th Ed.)","Breast Cancer pN2 TNM Finding v8 | Breast Carcinoma pN2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526768","Breast Cancer pN1mi TNM Finding v8","C139434","Breast cancer with micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). (from AJCC 8th Ed.)","Breast Cancer pN1mi TNM Finding v8 | Breast Carcinoma pN1mi TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526773","Breast Cancer pN1c TNM Finding v8","C139437","Breast cancer with pN1a and pN1b combined. (from AJCC 8th Ed.)","Breast Cancer pN1c TNM Finding v8 | Breast Carcinoma pN1c TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526766","Breast Cancer pN1b TNM Finding v8","C139436","Breast cancer with metastases in ipsilateral internal mammary sentinel nodes, excluding ITCs. (from AJCC 8th Ed.)","Breast Cancer pN1b TNM Finding v8 | Breast Carcinoma pN1b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526767","Breast Cancer pN1a TNM Finding v8","C139435","Breast cancer with metastases in 1-3 axillary lymph nodes, at least one metastasis larger than 2.0 mm. (from AJCC 8th Ed.)","Breast Cancer pN1a TNM Finding v8 | Breast Carcinoma pN1a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526769","Breast Cancer pN1 TNM Finding v8","C139433","Breast cancer with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. (from AJCC 8th Ed.)","Breast Cancer pN1 TNM Finding v8 | Breast Carcinoma pN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526794","Breast Cancer pN0(mol+) TNM Finding v8","C139432","Breast cancer with positive molecular findings by reverse transcriptase polymerase chain reaction (RT-PCR); no ITCs detected. (from AJCC 8th Ed.)","Breast Cancer pN0(mol+) TNM Finding v8 | Breast Carcinoma pN0(mol+) TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526795","Breast Cancer pN0(i+) TNM Finding v8","C139431","Breast cancer with ITCs only (malignant cell clusters no larger than 0.2 mm) in regional lymph node(s). (from AJCC 8th Ed.)","Breast Cancer pN0(i+) TNM Finding v8 | Breast Carcinoma pN0(i+) TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526796","Breast Cancer pN0 TNM Finding v8","C139430","Breast cancer in which no regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. (from AJCC 8th Ed.)","Breast Cancer pN0 TNM Finding v8 | Breast Carcinoma pN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526797","Breast Cancer pNX TNM Finding v8","C139429","Breast cancer in which regional lymph nodes cannot be assessed (e.g., not removed for pathological study or previously removed).  (from AJCC 8th Ed.)","Breast Cancer pNX TNM Finding v8 | Breast Carcinoma pNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526808","Breast Cancer pM1 TNM Finding v8","C139410","Breast cancer with distant metastases detected by clinical and radiographic means and/or histologically proven metastases larger than 0.2 mm. (from AJCC 8th Ed.)","Breast Cancer pM1 TNM Finding v8 | Breast Carcinoma pM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526906","Anatomic Stage IV Breast Cancer AJCC v8","C139545","Stage IV includes: Any T, Any N, M1. M1: Distant metastases detected by clinical and radiographic means and/or histologically proven metastases larger than 0.2 mm. (AJCC 8th ed.)","Anatomic Stage IV Breast Cancer AJCC v8 | Anatomic Stage IV Breast Carcinoma AJCC v8 | Stage IV Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526930","Anatomic Stage IIIC Breast Cancer AJCC v8","C139544","Stage IIIC includes: Any T, N3, M0. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)","Anatomic Stage IIIC Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Carcinoma AJCC v8 | Stage IIIC Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526931","Anatomic Stage IIIB Breast Cancer AJCC v8","C139543","Stage IIIB includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)","Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Carcinoma AJCC v8 | Stage IIIB Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526932","Anatomic Stage IIIA Breast Cancer AJCC v8","C139542","Stage IIIA includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)","Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Carcinoma AJCC v8 | Stage IIIA Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526926","Anatomic Stage IIB Breast Cancer AJCC v8","C139540","Stage IIB includes: (T2, N1, M0); (T3, N0, M0). T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)","Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Carcinoma AJCC v8 | Stage IIB Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526927","Anatomic Stage IIA Breast Cancer AJCC v8","C139539","Stage IIA includes: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)","Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Carcinoma AJCC v8 | Stage IIA Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526929","Anatomic Stage IB Breast Cancer AJCC v8","C139537","Stage IB includes: (T0, N1mi, M0); (T1, N1mi, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. N1mi: Tumor with micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)","Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage IB Breast Carcinoma AJCC v8 | Stage IB Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526922","Anatomic Stage IA Breast Cancer AJCC v8","C139536","Stage IA includes: T1, N0, M0. T1: Tumor measuring 20 mm or less in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)","Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IA Breast Carcinoma AJCC v8 | Stage IA Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526924","Anatomic Stage 0 Breast Cancer AJCC v8","C139534","Stage 0 includes: Tis, N0, M0. Tis: Ductal carcinoma in situ. Lobular carcinoma in situ is a benign entity and is removed from TNM staging in the AJCC Cancer Staging Manual, 8th Edition. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)","Anatomic Stage 0 Breast Cancer AJCC v8 | Anatomic Stage 0 Breast Carcinoma AJCC v8 | Stage 0 Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523733","Lung Cancer TNM Finding v8","C136430","A finding about one or more characteristics of lung cancer, following the rules of the TNM AJCC v8 classification system. This classification system derives from analyses of the new retrospective and prospective databases of the International Association for the Study of Lung Cancer (IASLC). These databases contain information on patients diagnosed with lung cancer from 1999 to 2010 originating from 35 different databases in 16 countries around the world. This classification system applies to carcinomas of the lung, including non-small cell and small cell carcinomas, and bronchopulmonary carcinoid tumors. It does not apply to sarcomas or other rare tumors of the lung. (from AJCC 8th Ed.)","Lung Cancer TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523760","Lung Cancer pT4 TNM Finding v8","C136457","Lung cancer with tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. (from AJCC 8th Ed.)","Lung Cancer pT4 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523759","Lung Cancer pT3 TNM Finding v8","C136456","Lung cancer with tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. (from AJCC 8th Ed.)","Lung Cancer pT3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523758","Lung Cancer pT2b TNM Finding v8","C136455","Lung cancer with tumor measuring more than 4 cm but 5 cm or less in greatest dimension. (from AJCC 8th Ed.)","Lung Cancer pT2b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523757","Lung Cancer pT2a TNM Finding v8","C136454","Lung cancer with tumor measuring more than 3 cm but 4 cm or less in greatest dimension. (from AJCC 8th Ed.)","Lung Cancer pT2a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523756","Lung Cancer pT2 TNM Finding v8","C136453","Lung cancer with tumor measuring more than 3 cm but 5 cm or less in greatest dimension or having any of the following features: involves the main bronchus regardless of distance to the carina, but without involvement of the carina, invades visceral pleura (extends through the elastic layer-PL1 or extends to the surface of the visceral pleura-PL2), or is associated with atelectasis or obstructive pneumonitis that extends to the hilar region, involving part or all of the lung. T2 tumors with these features are classified as T2a if they measure 4 cm or less or if the size cannot be determined and T2b if they measure more than 4 cm but 5 cm or less in greatest dimension. (from AJCC 8th Ed.)","Lung Cancer pT2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523754","Lung Cancer pT1b TNM Finding v8","C136451","Lung cancer with tumor measuring more than 1 cm but 2 cm or less in greatest dimension. (from AJCC 8th Ed.)","Lung Cancer pT1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523753","Lung Cancer pT1a TNM Finding v8","C136450","Lung cancer with tumor 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. (from AJCC 8th Ed.)","Lung Cancer pT1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523751","Lung Cancer pT1 TNM Finding v8","C136448","Lung cancer with tumor 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). (from AJCC 8th Ed.)","Lung Cancer pT1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523749","Lung Cancer pT0 TNM Finding v8","C136446","Lung cancer without evidence of primary tumor. (from AJCC 8th Ed.)","Lung Cancer pT0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523750","Lung Cancer pTis TNM Finding v8","C136447","Lung cancer with a finding of carcinoma in situ. Squamous cell carcinoma in situ (SCIS). Adenocarcinoma in situ (AIS): adenocarcinoma with pure lepidic pattern, 3 cm or less in greatest dimension. (from AJCC 8th Ed.)","Lung Cancer pTis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523748","Lung Cancer pTX TNM Finding v8","C136445","Lung cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Lung Cancer pTX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523761","Lung Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C136458","A pathologic finding about one or more characteristics of lung cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Lung Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523735","Lung Cancer Clinical Distant Metastasis TNM Finding v8","C136432","A clinical finding about one or more characteristics of lung cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Lung Cancer Clinical Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523739","Lung Cancer cM1b TNM Finding v8","C136436","Lung cancer with single extrathoracic metastasis in a single organ (including involvement of a single nonregional node). (from AJCC 8th Ed.)","Lung Cancer cM1b TNM Finding v8 | cM1b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523738","Lung Cancer cM1a TNM Finding v8","C136435","Lung cancer with separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodules or malignant pleural or pericardial effusion. Most pleural (pericardial) effusions with lung cancer are a result of the tumor. In a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumor, and the fluid is nonbloody and not an exudate. If these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging descriptor. (from AJCC 8th Ed.)","Lung Cancer cM1a TNM Finding v8 | cM1a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523737","Lung Cancer cM1 TNM Finding v8","C136434","Lung cancer with distant metastasis. (from AJCC 8th Ed.)","Lung Cancer cM1 TNM Finding v8 | cM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523736","Lung Cancer cM0 TNM Finding v8","C136433","Lung cancer without distant metastasis. (from AJCC 8th Ed.)","Lung Cancer cM0 TNM Finding v8 | cM0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523766","Lung Cancer pN3 TNM Finding v8","C136463","Lung cancer with metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s). (from AJCC 8th Ed.)","Lung Cancer pN3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523765","Lung Cancer pN2 TNM Finding v8","C136462","Lung cancer with metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s). (from AJCC 8th Ed.)","Lung Cancer pN2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523764","Lung Cancer pN1 TNM Finding v8","C136461","Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. (from AJCC 8th Ed.)","Lung Cancer pN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523763","Lung Cancer pN0 TNM Finding v8","C136460","Lung cancer without regional lymph node metastasis. (from AJCC 8th Ed.)","Lung Cancer pN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523762","Lung Cancer pNX TNM Finding v8","C136459","Lung cancer in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)","Lung Cancer pNX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523742","Lung Cancer Pathologic Distant Metastasis TNM Finding v8","C136439","A pathologic finding about one or more characteristics of lung cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Lung Cancer Pathologic Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226401","Inferior Epigastric Artery","C52861","A blood vessel arising from the external iliac artery with many smaller branches that connects to the superior epigastric artery and lower intercostal arteries.","Inferior Epigastric Artery | ",,,,,,,,,,,,,,,"4301873","Structure of inferior epigastric artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL523745","Lung Cancer pM1b TNM Finding v8","C136442","Lung cancer with single extrathoracic metastasis in a single organ (including involvement of a single nonregional node). (from AJCC 8th Ed.)","Lung Cancer pM1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523744","Lung Cancer pM1a TNM Finding v8","C136441","Lung cancer with separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodules or malignant pleural or pericardial effusion. Most pleural (pericardial) effusions with lung cancer are a result of the tumor. In a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumor, and the fluid is nonbloody and not an exudate. If these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging descriptor. (from AJCC 8th Ed.)","Lung Cancer pM1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523743","Lung Cancer pM1 TNM Finding v8","C136440","Lung cancer with distant metastasis. (from AJCC 8th Ed.)","Lung Cancer pM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226371","Superior Gluteal Artery","C32688","Either of two (superior or inferior) arteries branching from the internal iliac artery in the hip joint and gluteal region.","Superior Gluteal Artery | Gluteal Artery",,,,,,,,,,,,,,,"4219254","Structure of superior gluteal artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224439","Gracilis","C52935","The most superficial muscle extending vertically downward along the inner thigh which adducts the thigh, rotates the leg medially and flexes the knee.","Gracilis | GRACILIS MUSCLE | MUSCLE, GRACILIS",,,,,,,,,,,,,,,"4093615","Structure of gracilis muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0226455","Deep Femoral Artery","C32436","An artery arising from the common femoral artery just below the inguinal ligament running close to the femur and ending in the lower third of the thigh with branches supplying the thigh muscles.","Deep Femoral Artery | PROFUNDA FEMORIS ARTERY | Profunda Femoris",,,,,,,,,,,,,,,"4136495","Structure of profunda femoris artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545928","Graded Prognostic Assessment","C140882","A prognostic index for patients with brain metastases. The GPA incorporates age, Karnofsky performance status, number of extracranial metastases, and number of brain metastases.","Graded Prognostic Assessment | GPA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539037","Disease-specific Graded Prognostic Assessment","C140883","A 4-tiered score that stratifies patients with common primary tumours metastasizing to the brain (malignant melanoma, lung, breast, kidney and gastrointestinal cancers) into subgroups with different prognoses. It takes into account that brain metastases from different primary tumor sites respond differently to radiation therapy.","Disease-specific Graded Prognostic Assessment | DS-GPA | Diagnosis-specific Graded Prognostic Assessment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539036","Graded Prognostic Assessment Score","C140884","A 4-tiered score that stratifies patients with common primary tumors metastasizing to the brain (malignant melanoma, lung, breast, kidney and gastrointestinal cancers) into subgroups with different prognoses. The score is based on age, Karnofsky performance status, number of extracranial metastases, number of brain metastases, and site of primary tumor.","Graded Prognostic Assessment Score | DS-GPA Score | Disease-specific Graded Prognostic Assessment Score | GPS Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538802","Satisfaction with How You Look in Mirror Clothed","C140735","A question about how satisfied or dissatisfied an individual is or was about how they look in the mirror clothed.","Satisfaction with How You Look in Mirror Clothed | How you look in the mirror clothed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538801","Satisfaction with How Comfortably Bras Fit","C140736","A question about how satisfied or dissatisfied an individual is or was about how comfortably their bras fit.","Satisfaction with How Comfortably Bras Fit | How comfortably your bras fit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538800","Satisfaction with Being able to Wear Clothing That is Fitted","C140737","A question about how satisfied or dissatisfied an individual is or was about being able to wear clothing that is fitted.","Satisfaction with Being able to Wear Clothing That is Fitted Question | Being able to wear clothing that is more fitted | Satisfaction with Being able to Wear Clothing That is Fitted | Satisfaction with Being able to Wear Clothing That is Fitted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538799","Satisfaction with How You Look in Mirror Unclothed","C140738","A question about how satisfied or dissatisfied an individual is or was about how they look in the mirror unclothed.","Satisfaction with How You Look in Mirror Unclothed | How you look in the mirror unclothed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538798","How Often Felt Confident in Social Setting","C140739","A question about how often an individual feels or felt confident in a social setting","How Often Felt Confident in Social Setting | Confident in a social setting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538797","How Often Felt Emotionally Able to do Things You Want to do","C140740","A question about how often an individual feels or felt emotionally able to do things they want to do.","How Often Felt Emotionally Able to do Things You Want to do | Emotionally able to do the things that you want to do",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538796","How Often Felt Emotionally Healthy","C140741","A question about how often an individual feels or felt emotionally healthy.","How Often Felt Emotionally Healthy | Emotionally healthy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538795","How Often Felt of Equal Worth to Other Women","C140742","A question about how often an individual feels or felt of equal worth to other women.","How Often Felt of Equal Worth to Other Women | Of equal worth to other women",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538809","How Often Felt Self-confident","C140743","A question about how often an individual feels or felt self-confident.","How Often Felt Self-confident | Self-confident",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538808","How Often Felt Feminine in Your Clothes","C140744","A question about how often an individual feels or felt feminine in their clothes.","How Often Felt Feminine in Your Clothes | Feminine in your clothes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538807","How Often Felt Accepting of Your Body","C140745","A question about how often an individual feels or felt accepting of their body.","How Often Felt Accepting of Your Body | Accepting of your body",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524118","How Often Felt Normal","C140746","A question about how often an individual feels or felt normal.","How Often Felt Normal | Normal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538806","How Often Felt Like Other Women","C140748","A question about how often an individual feels or felt like other women.","How Often Felt Like Other Women | Like other women",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538805","How Often Felt Attractive","C140749","A question about how often an individual feels or felt attractive.","How Often Felt Attractive | Attractive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538920","How Often Experienced Pain in Muscles of Your Chest","C140761","A question about how often an individual has experienced pain in the muscles of their chest.","How Often Experienced Pain in Muscles of Your Chest | Pain in the muscles of your chest",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538919","How Often Experienced Difficulty Lifting or Moving Your Arms","C140762","A question about how often an individual has experienced difficulty lifting or moving their arms.","How Often Experienced Difficulty Lifting or Moving Your Arms | Difficulty lifting or moving your arms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538918","How Often Experienced Difficulty Sleeping Because of Discomfort in Breast Area","C140763","A question about how often an individual has experienced difficulty sleeping because of discomfort in their breast area.","How Often Experienced Difficulty Sleeping Because of Discomfort in Breast Area | Difficulty sleeping because of discomfort in your breast area",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538917","How Often Experienced Tightness in Your Breast Area","C140764","A question about how often an individual has experienced tightness in their breast area.","How Often Experienced Tightness in Your Breast Area | Tightness in your breast area",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538915","How Often Experienced Pulling in Your Breast Area","C140767","A question about how often an individual has experienced pulling in their breast area.","How Often Experienced Pulling in Your Breast Area | Pulling in your breast area",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538916","How Often Experienced Nagging Feeling in Your Breast Area","C140765","A question about how often an individual has experienced a nagging feeling in their breast area.","How Often Experienced Nagging Feeling in Your Breast Area | Nagging feeling in your breast area",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538914","How Often Experienced Tenderness in Your Breast Area","C140768","A question about how often an individual has experienced tenderness in their breast area.","How Often Experienced Tenderness in Your Breast Area | Tenderness in your breast area",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538897","How Often Experienced Sharp Pains in Your Breast Area","C140769","A question about how often an individual has experienced sharp pains in their breast area.","How Often Experienced Sharp Pains in Your Breast Area | Sharp pains in your breast area",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538896","How Often Experienced Aching Feeling in Your Breast Area","C140770","A question about how often an individual has experienced an aching feeling in their breast area.","How Often Experienced Aching Feeling in Your Breast Area | Aching feeling in your breast area",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538895","How Often Experienced Throbbing Feeling in Your Breast Area","C140771","A question about how often an individual has experienced a throbbing feeling in their breast area.","How Often Experienced Throbbing Feeling in Your Breast Area | Throbbing feeling in your breast area",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538882","How Often Feel Sexually Attractive in Your Clothes","C140800","A question about how often an individual feels sexually attractive in their clothes.","How Often Feel Sexually Attractive in Your Clothes | Sexually attractive in your clothes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538860","How Often Feel Comfortable or at Ease During Sexual Activity","C140806","A question about how often an individual feels comfortable or at ease during sexual activity.","How Often Feel Comfortable or at Ease During Sexual Activity | Comfortable/at ease during sexual activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538885","How Often Feel Confident Sexually","C140797","A question about how often an individual feels confident sexually.","How Often Feel Confident Sexually | Confident sexually",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538859","How Often Feel Satisfied with Your Sex-Life","C140807","A question about how often an individual feels satisfied with their sex-life.","How Often Feel Satisfied with Your Sex-Life | Satisfied with your sex-life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538858","How Often Feel Confident Sexually About How Your Breast Area Looks When Unclothed","C140808","A question about how often an individual feels confident sexually about how their breast area looks when unclothed.","How Often Feel Confident Sexually About How Your Breast Area Looks When Unclothed | Confident sexually about how your breast area looks when unclothed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538873","How Often Feel Sexually Attractive When Unclothed","C140809","A question about how often an individual feels sexually attractive when unclothed.","How Often Feel Sexually Attractive When Unclothed | Sexually attractive when unclothed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538872","Breast Cancer Surgeon was Professional","C140810","A question about whether an individual's breast cancer surgeon was professional.","Breast Cancer Surgeon was Professional | Was professional",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538871","Breast Cancer Surgeon Gave You Confidence","C140811","A question about whether an individual's breast cancer surgeon gave them confidence.","Breast Cancer Surgeon Gave You Confidence | Gave you confidence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538870","Breast Cancer Surgeon Involved You in Decision Making","C140812","A question about whether an individual's breast cancer surgeon involved them in the decision-making process.","Breast Cancer Surgeon Involved You in Decision Making | Involved you in the decision-making process",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538869","Breast Cancer Surgeon was Reassuring","C140813","A question about whether an individual's breast cancer surgeon was reassuring.","Breast Cancer Surgeon was Reassuring | Was reassuring",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538868","Breast Cancer Surgeon Answered all Questions","C140814","A question about whether an individual's breast cancer surgeon answered all their questions.","Breast Cancer Surgeon Answered all Questions | Answered all your questions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538867","Breast Cancer Surgeon Made You Comfortable","C140815","A question about whether an individual's breast cancer surgeon made them feel comfortable.","Breast Cancer Surgeon Made You Comfortable | Made you feel comfortable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538866","Breast Cancer Surgeon was Thorough","C140816","A question about whether an individual's breast cancer surgeon was thorough.","Breast Cancer Surgeon was Thorough | Was thorough",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538976","Breast Cancer Surgeon Was Easy to Talk to","C140817","A question about whether an individual's breast cancer surgeon was easy to talk to.","Breast Cancer Surgeon Was Easy to Talk to | Was easy to talk to",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538975","Breast Cancer Surgeon Understood what You Wanted","C140818","A question about whether an individual's breast cancer surgeon understood what they wanted.","Breast Cancer Surgeon Understood what You Wanted | Understood what you wanted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545930","Breast Cancer Surgeon was Sensitive","C140819","A question about whether an individual's breast cancer surgeon was sensitive.","Breast Cancer Surgeon was Sensitive | Was sensitive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538974","Breast Cancer Surgeon Made Time for Your Concerns","C140820","A question about whether an individual's breast cancer surgeon made time for their concerns.","Breast Cancer Surgeon Made Time for Your Concerns | Made time for your concerns",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538973","Breast Cancer Surgeon was Available when You had Concerns","C140821","A question about whether an individual's breast cancer surgeon was available when they had concerns.","Breast Cancer Surgeon was Available when You had Concerns | Was available when you had concerns",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538972","Medical Team was Professional","C140822","A question about whether an individual's medical team was professional.","Medical Team was Professional | Were Professional",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538971","Medical Team Treated You with Respect","C140823","A question about whether an individual's medical team treated them with respect.","Medical Team Treated You with Respect | Treated you with respect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538970","Medical Team was Knowledgeable","C140824","A question about whether an individual's medical team was knowledgeable.","Medical Team was Knowledgeable | Were knowledgeable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538984","Medical Team was Friendly and Kind","C140825","A question about whether an individual's medical team was friendly and kind.","Medical Team was Friendly and Kind | Were friendly and kind",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538983","Medical Team Made You Feel Comfortable","C140826","A question about whether an individual's medical team made them feel comfortable.","Medical Team Made You Feel Comfortable | Made you feel comfortable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538982","Medical Team was Thorough","C140827","A question about whether an individual's medical team was thorough.","Medical Team was Thorough | Were Thorough",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538981","Medical Team Made Time for Your Concerns","C140828","A question about whether an individual's medical team made time for their concerns.","Medical Team Made Time for Your Concerns | Made time for your concerns",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538980","Office Staff was Professional","C140829","A question about whether an individual's office staff was professional.","Office Staff was Professional | Were Professional",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538979","Office Staff Treated You with Respect","C140830","A question about whether an individual's office staff treated them with respect.","Office Staff Treated You with Respect | Treated you with respect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538978","Office Staff was Knowledgeable","C140831","A question about whether an individual's office staff was knowledgeable.","Office Staff was Knowledgeable | Were knowledgeable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538932","Office Staff was Friendly and Kind","C140878","A question about whether an individual's office staff was friendly and kind.","Office Staff was Friendly and Kind | Were friendly and kind",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538931","Office Staff Made You Feel Comfortable","C140879","A question about whether an individual's office staff made them feel comfortable.","Office Staff Made You Feel Comfortable | Made you feel comfortable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538930","Office Staff was Thorough","C140880","A question about whether an individual's office staff was thorough.","Office Staff was Thorough | Were Thorough",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539038","Office Staff Made Time for Your Concerns","C140881","A question about whether an individual's office staff made time for their concerns.","Office Staff Made Time for Your Concerns | Made time for your concerns",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050367","Pill Dosing Unit","C122634","A dosing unit equal to the amount of active ingredient(s) contained in a pill.","Pill Dosing Unit | PILL | Pill | {PILL}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538738","Progressive Disease in Neuroblastoma","C140671","A neuroblastoma that is worsening in terms of extent or severity.","Progressive Neuroblastoma | Progressive Disease in Neuroblastoma | Progressive Disease in Neuroblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538991","Satisfaction with Shape of Your Reconstructed Breasts When Wearing Bra","C140930","A question about how satisfied or dissatisfied an individual is or was with the shape of their reconstructed breasts when they are wearing a bra.","Satisfaction with Shape of Your Reconstructed Breasts When Wearing Bra | The shape of your reconstructed breast(s) when you are wearing a bra",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538990","Satisfaction with How Normal You Feel in Your Clothes","C140931","A question about how satisfied or dissatisfied an individual is or was with how normal you feel in your clothes.","Satisfaction with How Normal You Feel in Your Clothes | How normal you feel in your clothes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538988","Satisfaction with Size of Your Reconstructed Breasts","C140933","A question about how satisfied or dissatisfied an individual is or was with the size of their reconstructed breasts.","Satisfaction with Size of Your Reconstructed Breasts | The size of your reconstructed breast(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538987","Satisfaction with How Your Breasts Line up in Relation to Each Other","C140934","A question about how satisfied or dissatisfied an individual is or was with how their breasts are lined up in relation to each other.","Satisfaction with How Your Breasts Line up in Relation to Each Other | How your breasts are lined up in relation to each other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538985","Satisfaction with Softness of Reconstructed Breasts","C140936","A question about how satisfied or dissatisfied an individual is or was with the softness of their reconstructed breasts.","Satisfaction with Softness of Reconstructed Breasts | The softness of your reconstructed breast(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539000","Satisfaction with How Equal in Size Your Breasts are to Each Other","C140937","A question about how satisfied or dissatisfied an individual is or was with how equal in size their breasts are to each other.","Satisfaction with How Equal in Size Your Breasts are to Each Other | How equal in size your breasts are to each other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538999","Satisfaction with How Natural Your Reconstructed Breasts Look","C140938","A question about how satisfied or dissatisfied an individual is or was with how natural their reconstructed breasts look.","Satisfaction with How Natural Your Reconstructed Breasts Look | How natural your reconstructed breast(s) looks",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538998","Satisfaction with How Naturally Your Reconstructed Breasts Sits and Hangs","C140939","A question about how satisfied or dissatisfied an individual is or was with how naturally their reconstructed breasts sits and hangs.","Satisfaction with How Naturally Your Reconstructed Breasts Sits and Hangs | How naturally your reconstructed breast(s) sits/hangs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538997","Satisfaction with How Your Reconstructed Breasts Feel to Touch","C140940","A question about how satisfied or dissatisfied an individual is or was with how their reconstructed breasts feels to touch.","Satisfaction with How Your Reconstructed Breasts Feel to Touch | How your reconstructed breast(s) feels to touch | Satisfaction with  How Your Reconstructed Breasts Feel to Touch",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538996","Satisfaction with How Much Your Reconstructed Breasts Feel Like a Natural Part of Your Body","C140941","A question about how satisfied or dissatisfied an individual is or was with how much their reconstructed breasts feels like a natural part of your body.","Satisfaction with How Much Your Reconstructed Breasts Feel Like a Natural Part of Your Body | How much your reconstructed breast(s) feels like a natural part of your body",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538995","Satisfaction with How Closely Matched Your Breasts are to Each Other","C140942","A question about how satisfied or dissatisfied an individual is or was with how closely matched or similar their breasts are to each other.","Satisfaction with How Closely Matched Your Breasts are to Each Other | How closely matched (similar) your breasts are to each other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538994","Satisfaction with Amount of Rippling of Your Implants That You Can See","C140943","A question about how satisfied or dissatisfied an individual is or was with the amount of rippling or wrinkling of their implants that they can see.","Satisfaction with Amount of Rippling of Your Implants That You Can See | The amount of rippling (wrinkling) of your implant(s) that you can see",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538993","Satisfaction with Amount of Rippling of Your Implants That you Can Feel","C140944","A question about how satisfied or dissatisfied an individual is or was with the amount of rippling or wrinkling of their implants that they can feel.","Satisfaction with Amount of Rippling of Your Implants That you Can Feel | The amount of rippling (wrinkling) of your implant(s) that you can feel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539101","How Often Experienced Difficulty Sitting up Because Abdominal Muscle Weakness","C140945","A question about how often an individual has or had experienced difficulty sitting up because of abdominal muscle weakness (e.g.getting out of bed).","How Often Experienced Difficulty Sitting up Because Abdominal Muscle Weakness | Difficulty sitting up because of abdominal muscle weakness (e.g. getting out of bed)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539100","How Often Experienced Difficulty Doing Everyday Activities Because of Abdominal Muscle Weakness","C140946","A question about how often an individual has or had experienced difficulty doing everyday activities because of abdominal muscle weakness (e.g.making their bed).","How Often Experienced Difficulty Doing Everyday Activities Because of Abdominal Muscle Weakness | Difficulty doing everyday activities because of abdominal muscle weakness (e.g. making your bed)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545936","How Often Experienced Abdominal Discomfort","C140947","A question about how often an individual experienced abdominal discomfort.","How Often Experienced Abdominal Discomfort | Abdominal discomfort",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539099","How Often Experienced Abdominal Bloating","C140948","A question about how often an individual experienced abdominal bloating.","How Often Experienced Abdominal Bloating | Abdominal bloating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539098","How Often Experienced Abdominal Bulging","C140949","A question about how often an individual experienced abdominal bulging.","How Often Experienced Abdominal Bulging | Abdominal bulging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539097","How Often Experienced Tightness in Abdomen","C140950","A question about how often an individual experienced tightness in their abdomen.","How Often Experienced Tightness in Abdomen | Tightness in your abdomen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539096","How Often Experienced Pulling in Abdomen","C140951","A question about how often an individual experienced pulling in their abdomen.","How Often Experienced Pulling in Abdomen | Pulling in your abdomen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539095","Satisfaction with How Your Abdomen Looks When Unclothed","C140952","A question about how satisfied or dissatisfied an individual is or was with how their abdomen (tummy area) looks when unclothed.","Satisfaction with How Your Abdomen Looks When Unclothed | How your abdomen (tummy area) looks when unclothed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539109","Satisfaction with Position of Navel","C140953","A question about how satisfied or dissatisfied an individual is or was with the position of their navel (belly button).","Satisfaction with Position of Navel | The position of your navel (belly button)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539108","Satisfaction with Appearance of Abdominal Scars","C140954","A question about how satisfied or dissatisfied an individual is or was with how their abdominal scars look.","Satisfaction with Appearance of Abdominal Scars | How your abdominal scars look",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333428","Epstein-Barr Virus Related Carcinoma","C27690","Carcinoma that develops in individuals infected with Epstein-Barr virus (EBV), and in which there is a well-documented association between the neoplastic process and EBV.","EBV-Related Carcinoma | EBV Related Carcinoma | Epstein-Barr Virus Related Carcinoma | Epstein-Barr Virus-Related Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539034","Ivor Lewis Esophagectomy","C140886","A type of esophagectomy where an esophageal tumor is removed through an abdominal incision and a right thoracotomy. The esophagogastric anastomosis is located in the upper chest.","Ivor Lewis Esophagectomy | ILE",,,,,,,,,,,,,,,"4128563","Ivor Lewis subtotal esophagectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0472888","McKeown Esophagectomy","C140887","A type of esophagectomy that involves a right thoracotomy, laparotomy, and left neck incision for creation of a cervical anastomosis. It is appropriate in patients with tumors located above the gastro-esophageal junction up to the level of the clavicles and is the preferred approach for locally advanced esophageal carcinomas.","McKeown Esophagectomy | ME | McKeown Procedure | Tri-incisional Esophagectomy",,,,,,,,,,,,,,,"4128562","McKeown esophagectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL539033","Transhiatal Esophagectomy","C140888","A type of esophagectomy where the esophageal tumor is removed through an abdominal incision and a left neck incision, without a thoracotomy. The esophagogastric anastomosis is located in the neck.","Transhiatal Esophagectomy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3850136","Robot-Assisted Surgery","C140885","A surgical technique that uses a specially designed robotic system to aid with the surgical procedure.","Robot-Assisted Surgery | Navigation and Robotics | Robot Assisted | Robotic Surgery",,,,,,,,,,,,,,,"46272913","Robotic assisted surgery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL539046","Mandard Grading System","C140889","A tumor regression grading (TRG) system commonly used for upper gastrointestinal carcinomas.","Mandard Grading System | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539045","Tumor Regression Grade 1","C140890","Complete regression; fibrosis without detectable tumor.","Tumor Regression Grade 1 | TRG 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539044","Tumor Regression Grade 2","C140891","Presence of fibrosis with scattered tumor cells.","Tumor Regression Grade 2 | TRG 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539043","Tumor Regression Grade 3","C140892","Presence of fibrosis and tumor cells with a preponderance of fibrosis.","Tumor Regression Grade 3 | TRG 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539042","Tumor Regression Grade 4","C140893","Presence of fibrosis and tumor cells with preponderance of tumor cells.","Tumor Regression Grade 4 | TRG 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539041","Tumor Regression Grade 5","C140894","Presence of tumor without changes of regression.","Tumor Regression Grade 5 | TRG 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538751","R-ACVBP Regimen","C140658","A regimen consisting of doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone and rituximab that can be used in the treatment of non-Hodgkin lymphoma (NHL).","R-ACVBP Regimen | ACVBP-R | Doxorubicin/Cyclophosphamide/Vindesine/Bleomycin/Prednisone/Rituximab | R-ACVBP | R-ACVBP (rituximab-abbs) | R-ACVBP (rituximab-arrx) | R-ACVBP (rituximab-blit) | R-ACVBP (rituximab-pvvr) | R-ACVBP (rituximab-rite) | R-ACVBP (rituximab-rixa) | R-ACVBP (rituximab-rixi) | Rituximab-Doxorubicin-Cyclophosphamide-Vindesine-Bleomycin-Prednisone | Rituximab/Doxorubicin/Cyclophosphamide/Vindesine/Bleomycin/Prednisone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538752","BAC Regimen","C140657","A regimen consisting of bendamustine and cytarabine that can be used in the treatment of mantle-cell lymphoma (MCL).","BAC Regimen | BAC | Bendamustine-Cytarabine | Bendamustine/Ara-C | Bendamustine/Cytarabine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538736","R-CHOPE Regimen","C140673","A regimen consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone and etoposide that can be used in the treatment of non-Hodgkin lymphomas (NHL). R-CHOPE differs from R-EPOCH in the drug doses and schedule of the administration of the various drugs.","R-CHOPE Regimen | R-CHOEP | R-CHOEP Regimen | R-CHOPE | Rituximab-Cyclophosphamide-Doxorubicin-Etoposide-Prednisone-Vincristine | Rituximab/Cyclophosphamide/Doxorubicin/Etoposide/Prednisone/Vincristine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538822","FCM Regimen","C140730","A regimen consisting of fludarabine, cyclophosphamide and mitoxantrone that can be used in the treatment of non-Hodgkin lymphoma (NHL).","FCM Regimen | FCM | Fludarabine-Cyclophosphamide-Mitoxantrone | Fludarabine-Cyclophosphamide-Mitoxantrone Regimen | Fludarabine/Cyclophosphamide/Mitoxantrone | Fludarabine/Cyclophosphamide/Mitoxantrone Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538821","R-GemOx Regimen","C140731","A regimen consisting of rituximab, gemcitabine and oxaliplatin used in the treatment of diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma.","R-GemOx Regimen | GEMOX-R | R-GemOx | R-GemOx (rituximab-abbs) | R-GemOx (rituximab-arrx) | R-GemOx (rituximab-blit) | R-GemOx (rituximab-pvvr) | R-GemOx (rituximab-rite) | R-GemOx (rituximab-rixa) | R-GemOx (rituximab-rixi) | Rituximab-Gemcitabine-Oxaliplatin | Rituximab/Gemcitabine/Oxaliplatin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538820","GVD Regimen","C140732","A regimen consisting of gemcitabine, vinorelbine and pegylated liposomal doxorubicin used for the treatment of Hodgkin lymphoma (HL), T-cell lymphomas, and mycosis fungoides and Sezary syndrome.","GVD Regimen | GVD | Gemcitabine-Vinorelbine-Pegylated Liposomal Doxorubicin | Gemcitabine/Vinorelbine/Doxil | Gemcitabine/Vinorelbine/Liposomal Doxorubicin Regimen | Gemcitabine/Vinorelbine/Pegylated Liposomal Doxorubicin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538819","R-GVD Regimen","C140733","A regimen consisting of rituximab, gemcitabine, vinorelbine and pegylated liposomal doxorubicin that can be used in the treatment of Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL).","R-GVD Regimen | Gemcitabine-Vinorelbine-Pegylated Liposomal Doxorubicin-Rituximab | Gemcitabine/Vinorelbine/Doxil/Rituximab | Gemcitabine/Vinorelbine/Pegylated Liposomal Doxorubicin/Rituximab | R-GVD | Rituximab/Gemcitabine/Vinorelbine/Pegylated Liposomal Doxorubicin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538818","Cyclophosphamide/Doxorubicin/Prednisone/Rituximab/Vincristine Alternating with Rituximab Plus Cisplatin/Cytarabine/Dexamethasone","C140734","A regimen that alternates rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with rituximab, dexamethasone, high-dose cytarabine and cisplatin (R-DHAP), and can be used in the treatment of mantle cell lymphoma.","R-CHOP Alternating with R-DHAP Regimen | Cyclophosphamide/Doxorubicin/Prednisone/Rituximab/Vincristine Alternating with Rituximab Plus Cisplatin/Cytarabine/Dexamethasone | Cyclophosphamide/Doxorubicin/Prednisone/Rituximab/Vincristine-Rituximab/Cisplatin/Cytarabine/Dexamethasone | R-CHOP Alternating with R-DHAP | R-CHOP/R-DHAP | R-CHOP/R-DHAP (rituximab-abbs) | R-CHOP/R-DHAP (rituximab-arrx) | R-CHOP/R-DHAP (rituximab-blit) | R-CHOP/R-DHAP (rituximab-pvvr) | R-CHOP/R-DHAP (rituximab-rite) | R-CHOP/R-DHAP (rituximab-rixa) | R-CHOP/R-DHAP (rituximab-rixi) | R-CHOP/R-DHAP Regimen | R-CHOP/R-DHAP Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0212922","Cyclophosphamide/Doxorubicin/Etoposide/Prednisone/Vincristine","C9702","A regimen consisting of cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide that may be used to treat primary cutaneous CD30+ T-cell lymphoproliferative disorders, post-transplant lymphoproliferative disorders, T-cell lymphomas, and other forms of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL).","CHOPE Regimen | CHOEP | CHOEP Regimen | CHOPE | CHOPE regimen | Cyclophosphamide-Hydroxydaunorubicin-Oncovin-Prednisone-Etoposide Regimen | Cyclophosphamide/Doxorubicin/Etoposide/Prednisone/Vincristine | VACOP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515576","del(11q23)","C36533","A cytogenetic abnormality that refers to the deletion of the chromosomal band 11q23.","del(11q23) | 11q23 Deletion | del(11)(q23)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2945704","Conventional Treatment","C97149","A currently accepted and widely used treatment for a certain type of disease, based on the results of past research.","Conventional Therapy | conventional therapy | conventional treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010164","Cosmetic","C78523","A substance that is intended to be applied to the body to promote attractiveness without affecting the body's structure or functions.","Cosmetic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2945767","Childhood Malignant Liver Neoplasm","C7708","A malignant neoplasm that affects the liver and occurs during childhood.","Childhood Malignant Liver Neoplasm | Childhood Cancer of Liver | Childhood Cancer of the Liver | Childhood Liver Cancer | Childhood Malignant Liver Tumor | Malignant Liver Neoplasm | Pediatric Cancer of Liver | Pediatric Cancer of the Liver | Pediatric Liver Cancer | Pediatric Malignant Liver Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0314657","Genetic Susceptibility","C17939","An inherited increase in the risk of developing a disease.","Genetic Susceptibility | Inherited Predisposition | Inherited Susceptibility | genetic predisposition | genetic susceptibility",,,,,,,,,,,,,,,"4166231","Genetic predisposition",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0222608","Areola","C12368","The pigmented circle or ring of skin that surrounds the nipple.","Areola | areola",,,,,,,,,,,,,,,"4106882","Areola structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035273","Resuscitation","C50822","The measures applied for the restoration a person to life and/or consciousness. The act of resuscitation includes such components as artificial respiration and cardiac massage.","Resuscitation | ",,,,,,,,,,,,,,,"4205502","Resuscitation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL539173","PRETEXT Staging System","C141133","A staging system designed by the International Childhood Liver Tumor Strategy Group (SIOPEL) for staging and risk stratification of liver tumors. A PRETEXT stage number is based on the number of contiguous liver sections not involved by tumor, corresponding to a rough estimate of the difficulty of the expected surgical procedure. It is used to describe tumor extent before any therapy, thus allowing more effective comparison between studies conducted by different groups.","PRETEXT Staging System | PRETEXT Staging | PRETEXT Staging System

 | Pretreatment Extent of Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539186","ALK Inhibitor","C141136","Any agent that inhibits the activity of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK).","ALK Inhibitor | Anaplastic Lymphoma Kinase Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039286","Tamoxifen","C62078","An antineoplastic nonsteroidal selective estrogen receptor modulator (SERM).  Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA.  The result is a reduction in DNA synthesis and cellular response to estrogen.  In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth.","Tamoxifen | 1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene | TAMOXIFEN | TMX | tamoxifen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539188","BREAST-Q","C141134","A patient-reported outcome measure designed to provide information about the impact and effectiveness of breast surgery. It consists of 5 modules: augmentation, reduction (or mastopexy), breast conserving therapy, mastectomy, and post-mastectomy reconstruction. Each module is divided into multiple scales that can be used independently.","BREAST-Q | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1699634","HER2-Positive Breast Carcinoma","C53556","A biologic subset of breast carcinoma defined by high expression of HER2, GRB7, and TRAP100, and by lack of expression of estrogen receptor (ER).","HER2-Positive Breast Carcinoma | ERBB2 Overexpressing Subtype of Breast Carcinoma | HER2 Overexpressing Breast Carcinoma | HER2 Overexpressing Subtype of Breast Carcinoma | HER2 Positive Breast Cancer | HER2 Positive Breast Carcinoma | HER2 Positive Breast Carcinoma",,,,,,,,,,,,,,,"4142116","HER2-positive carcinoma of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054594","Loss of INI 1 Protein Expression","C121966","An immunohistochemical finding indicating negative staining of tumor cells for INI 1 protein, resulting from the inactivation of the INI 1 tumor suppressor gene.","Loss of INI 1 Protein Expression | Loss of BAF47 Protein Expression | Loss of INI1 Protein Expression | Loss of SMARCB1 Protein Expression | Loss of SNF5 Homolog Protein Expression | Loss of SWI/SNF-Related Matrix-Associated Actin Dependent Regulator of Chromatin Subfamily B Member 1 Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3267001","PTEN Gene Mutation","C121369","A molecular genetic abnormality indicating the presence of a mutation in the PTEN gene on chromosome 10q23.3.","PTEN Gene Mutation | MMAC1 Gene Mutation | Mutated in Multiple Advanced Cancers 1 Gene Mutation | PTEN Mutation | PTEN1 Gene Mutation | Phosphatase and Tensin Homolog Gene Mutation | TEP1 Gene Mutation | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010827","Cytopathic Effect","C141201","Structural changes in host cells that are caused by viral invasion.","Cytopathic Effect | CPE | Cytopathic Effect  | Cytopathogenic Effect | Viral Cytopathic Change",,,,,,,,,,,,,,,"4012793","Cytopathic effect",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL539358","Satisfaction with How Natural Your Reconstructed Nipples Look","C141214","A question about how satisfied or dissatisfied an individual is or was with how natural their reconstructed nipples look.","Satisfaction with How Natural Your Reconstructed Nipples Look | How natural your reconstructed nipple(s) look",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509245","Hypoploidy","C128304","A chromosomal abnormality in which a somatic cell is missing a single member of one or more pairs of homologous chromosomes.","Hypoploidy | Hypoploid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040046","Thrombophlebitis","C3410","Inflammation of the veins associated with the presence of a thrombus.","Thrombophlebitis | thrombophlebitis",,,,,,,,,,,,,,,"320741","Thrombophlebitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008070","Childcare Center","C127785","Daytime supervision, which may include recreational or medical facilities, for infants and children.","Childcare Center | CHILD CARE CENTER | Child Day Care Center",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512150","IDH Gene Family Mutation","C129264","A change in the nucleotide sequence of an IDH family gene.","IDH Gene Family Mutation | IDH Family Mutation | IDH Gene Mutation | IDH Mutation | Positive | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512381","Tyrosinase Positive","C128846","Indicates that tyrosinase expression has been detected in a sample.","Tyrosinase Positive | TYR Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512156","IGF1R Positive","C128840","Indicates that IGF1R expression has been detected in a sample.","IGF1R Positive | CD221 Positive | IGF-1R Positive | IGFR Positive | Insulin Like Growth Factor 1 Receptor Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268483","Tyrosinemia","C98640","An autosomal recessive inherited metabolic disorder caused by mutations in the FAH, HPD, and TAT genes. It is characterized by deficiency of one of the enzymes that are involved in the metabolism of tyrosine. It results in elevated blood tyrosine levels and accumulation of tyrosine and its byproducts in the liver, kidney, nervous system and other organs.","Tyrosinemia | ",,,,,,,,,,,,,,,"4101289","Tyrosinemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514551","Somatostatin Receptor 2 Positive","C131558","An indication that somatostatin receptor type 2 expression has been detected in a sample.","Somatostatin Receptor 2 Positive | SSR2 Positive | SSTR2 Positive | Somatostatin Receptor Type 2 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512644","Loss of BRG1 Protein Expression","C129500","An immunohistochemical finding indicating negative staining of tumor cells for BRG1 protein, resulting from the mutation of the SMARCA4 gene.","Loss of BRG1 Protein Expression | Loss of ATP-Dependent Helicase SMARCA4 Protein Expression | Loss of BAF190A Protein Expression | Loss of BRG-1 Protein Expression | Loss of Brahma Protein Homolog 1 Protein Expression | Loss of Possible Global Transcription Activator SNF2L4 Protein Expression | Loss of Protein Brahma Homolog 1 Protein Expression | Loss of SMARCA4 Protein Expression | Loss of SNF2-Beta Protein Expression | Loss of SWI/SNF-Related Matrix-Associated Actin-Dependent Regulator of Chromatin Subfamily A Member 4 Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521735","IGHV4-34 Positive","C133813","An indication that IGHV4-34 expression has been detected in a sample.","IGHV4-34 Positive | Ig Heavy Chain V-II Region ARH-77 Positive | Immunoglobulin Heavy Variable 4-34 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3806112","Cholelithiasis","C122822","The presence of calculi in the gallbladder.","Cholelithiasis | Gallstones",,,,,,,,,,,,,,,"196456","Gallstone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518817","PRETEXT Stage 4","C28075","PRETEXT (Hepatoblastoma Pretreatment Extent of Tumor) stage in which the tumor involves all four quadrants of the liver.","PRETEXT Stage 4 | PRETEXT Stage IV | Pretreatment Extent of Disease Stage 4 | Pretreatment Extent of Tumor Stage 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518816","PRETEXT Stage 3","C28074","PRETEXT (Hepatoblastoma Pretreatment Extent of Tumor) stage in which the tumor involves three adjoining quadrants or two nonadjoining quadrants, while one quadrant or two nonadjoining liver quadrants are free of tumor.","PRETEXT Stage 3 | PRETEXT Stage III | Pretreatment Extent of Disease Stage 3 | Pretreatment Extent of Tumor Stage 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518815","PRETEXT Stage 2","C28073","PRETEXT (Hepatoblastoma Pretreatment Extent of Tumor) stage in which the tumor involves two adjoining quadrants, while the other two adjoining liver quadrants are free of tumor.","PRETEXT Stage 2 | PRETEXT Stage II | Pretreatment Extent of Disease Stage 2 | Pretreatment Extent of Tumor Stage 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518814","PRETEXT Stage 1","C28072","PRETEXT (Hepatoblastoma Pretreatment Extent of Tumor) stage in which the tumor involves only one quadrant, while the three adjoining liver quadrants are free of tumor.","PRETEXT Stage 1 | PRETEXT Stage I | Pretreatment Extent of Disease Stage 1 | Pretreatment Extent of Tumor Stage 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522417","BCL6 Gene Translocation","C134901","A cytogenetic abnormality that refers to any translocation involving the BCL6 gene.","BCL6 Gene Translocation | B-Cell CLL/Lymphoma 6 Gene Translocation | BCL5 Gene Translocation | BCL6 Translocation | Bcl-6 Gene Translocation | LAZ3 Gene Translocation | ZBTB27 Gene Translocation | ZNF51 Gene Translocation | Zinc Finger Protein 51 Gene Translocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522378","GLI1 Positive","C134862","An indication that GLI1 expression has been detected in a sample.","GLI1 Positive | GLI Family Zinc Finger 1 Positive | GLI Positive | Glioma Associated Oncogene Homolog 1 Positive | Glioma-Associated Oncogene 1 Positive | Glioma-Associated Oncogene Family Zinc Finger 1 Positive | Zinc Finger Protein GLI1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521738","CD103 Negative","C133816","An indication that CD103 expression was not detected in a sample.","CD103 Negative | Alpha Polypeptide Negative | CD103 Antigen Negative | HML-1 Antigen Negative | HUMINAE Negative | Human Mucosal Lymphocyte Antigen 1, Alpha Subunit Negative | ITGAE Negative | Integrin Alpha-E Negative | Integrin, Alpha E (Antigen CD103, Human Mucosal Lymphocyte Antigen 1 Negative | Integrin, Alpha-E Negative | Mucosal Lymphocyte 1 Antigen Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521737","CD25 Negative","C133815","An indication that CD25 expression was not detected in a sample.","CD25 Negative | CD25 Antigen Negative | IDDM10 Negative | IL2R Negative | IL2R, Alpha Chain Negative | IL2RA Negative | Interleukin 2 Receptor, Alpha Negative | Interleukin-2 Receptor Alpha Chain Negative | Interleukin-2 Receptor Subunit Alpha Negative | TCGFR Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521734","CD11c Positive","C133812","An indication that CD11c expression has been detected in a sample.","CD11c Positive | AlphaX Integrin Chain Positive | Antigen Cd11c (P150), Alpha Polypeptide Positive | Axb2 Positive | CD11 Antigen-Like Family Member C Positive | CD11c Antigen Positive | Cr4 Positive | ITGAX Positive | Integrin Alpha X Positive | Integrin Alpha-X Positive | Leu M5 Positive | Leukocyte Adhesion Glycoprotein P150,95, Alpha Chain Positive | Leukocyte Adhesion Receptor P150,95 Positive | Leukocyte Surface Antigen P150, 95 Positive | Myeloid Membrane Antigen, Alpha Subunit Positive | p150 95 Integrin Alpha Chain Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539328","No Dysphagia","C141228","A response indicating that an individual is able to eat a normal diet.","No Dysphagia | Able to eat normal diet (no dysphagia)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539327","Dysphagia to Normal Solids","C141229","A response indicating that an individual is able to eat only some solid food.","Dysphagia to Normal Solids | Able to eat some solid food (dysphagia to normal solids)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539342","Dysphagia to Soft Solids","C141230","A response indicating that an individual is able to eat only some semisolids.","Dysphagia to Soft Solids | Able to eat semisolids only (dysphagia to soft solids)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539341","Dysphagia to Solids and Liquids","C141231","A response indicating that an individual is able to only swallow liquids.","Dysphagia to Solids and Liquids | Able to swallow liquids only (dysphagia to solids and liquids)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539340","Inability to Swallow Saliva","C141232","A response indicating that an individual is unable to swallow.","Inability to Swallow Saliva | Inability to Swallow | Unable to swallow (inability to swallow saliva)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279538","Plastic Surgeon","C17857","A surgeon with advanced training in treating disfiguring conditions. Surgery may also include cosmetic surgery.","Plastic Surgeon | plastic surgeon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272943","Hepatitis D Virus Antibody Measurement","C96664","The determination of the amount of Hepatitis D virus antibody present in a sample.","Hepatitis D Virus Antibody Measurement | HDAB | Hepatitis D Virus Antibody | Hepatitis Delta Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201483","Hepatitis B Virus e Antigen Measurement","C96663","The determination of the amount of Hepatitis B virus e antigen present in a sample.","Hepatitis B Virus e Antigen Measurement | HBEAG | Hepatitis B Virus e Antigen",,,,,,,,,,,,,,,"4209123","Hepatitis B e antigen test",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL522524","PHOX2B Gene Mutation","C135016","A change in the nucleotide sequence of the PHOX2B gene.","PHOX2B Gene Mutation | NBLST2 Gene Mutation | NBPhox Gene Mutation | Neuroblastoma Paired-Type Homeobox Gene Mutation | PMX2B Gene Mutation | Paired Mesoderm Homeobox 2b Gene Mutation | Paired-Like Homeobox 2b Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523034","KRAS Exon 4 Mutation","C135717","A molecular genetic abnormality indicating the presence of a mutation in exon 4 of the KRAS gene.","KRAS Exon 4 Mutation | KRAS Exon 4 Gene Mutation | KRAS-2 Exon 4 Mutation | KRAS2 Exon 4 Mutation | c-K-ras Exon 4 Mutation | v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Exon 4 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523033","KRAS Exon 3 Mutation","C135716","A molecular genetic abnormality indicating the presence of a mutation in exon 3 of the KRAS gene.","KRAS Exon 3 Mutation | KRAS Exon 3 Gene Mutation | KRAS-2 Exon 3 Mutation | KRAS2 Exon 3 Mutation | c-K-ras Exon 3 Mutation | v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Exon 3 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523032","KRAS Exon 2 Mutation","C135715","A molecular genetic abnormality indicating the presence of a mutation in exon 2 of the KRAS gene.","KRAS Exon 2 Mutation | KRAS-2 Exon 2 Mutation | KRAS2 Exon 2 Mutation | c-K-ras Exon 2 Mutation | v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Exon 2 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522930","MAGEA6 Positive","C135574","An indication that melanoma-associated antigen 6 expression has been detected in a sample.","MAGEA6 Positive | MAGE-A6 Positive | MAGE3B Positive | Melanoma-Associated Antigen 6 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523728","RAF Family Gene Mutation","C136425","A change in the nucleotide sequence in a RAF family gene.","RAF Family Gene Mutation | Mutant RAF | Mutant RAF Family Gene | RAF Family Mutation | RAF Mutation | Rapidly Accelerated Fibrosarcoma Family Gene Mutation | Rapidly Accelerated Fibrosarcoma Family Kinase Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523725","MEK Family Gene Mutation","C136422","A change in the nucleotide sequence in a MEK family gene.","MEK Family Gene Mutation | MAP2K Family Gene Mutation | MAPKK Family Gene Mutation | MEK Family Mutation | MEK Mutation | Mitogen-Activated Protein Kinase Kinase Family Gene Mutation | Mutant MEK | Mutant MEK Family Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523036","NRAS Exon 3 Mutation","C135719","A molecular genetic abnormality indicating the presence of a mutation in exon 3 of the NRAS gene.","NRAS Exon 3 Mutation | N-RAS Exon 3 Mutation | NRAS Exon 3 Gene Mutation | Neuroblastoma RAS Viral Oncogene Homolog Exon 3 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523035","NRAS Exon 2 Mutation","C135718","A molecular genetic abnormality indicating the presence of a mutation in exon 2 of the NRAS gene.","NRAS Exon 2 Mutation | N-RAS Exon 2 Mutation | NRAS Exon 2 Gene Mutation | Neuroblastoma RAS Viral Oncogene Homolog Exon 2 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828627","PDGFRA NM_006206.4:c.2525A>T","C107568","A nucleotide substitution at position 2525 of the coding sequence of the PDGFRA gene where adenine has been mutated to thymine.","PDGFRA NM_006206.4:c.2525A>T | CD140A c.2525A>T | NM_006206.4:c.2525A>T | PDGFR-2 c.2525A>T | PDGFR2 c.2525A>T | PDGFRA c.2525A>T | Platelet-Derived Growth Factor Receptor, Alpha Polypeptide c.2525A>T | RHEPDGFRA c.2525A>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677929","Positive Axillary Lymph Node","C8508","A lymph node in the area of the armpit (axilla) to which cancer has spread. This spread is determined by surgically removing some of the lymph nodes and examining them under a microscope to see whether cancer cells are present.","Positive Axillary Lymph Node | positive axillary lymph node",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985167","Hepatitis B Viral Load Measurement","C92542","The determination of the HBV viral load in a specimen.","Hepatitis B Viral Load Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1868902","Hepatitis C Viral Load Measurement","C92543","The determination of the HCV viral load in a specimen.","Hepatitis C Viral Load Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825200","Bare Metal Stent","C80464","A vascular metal mesh tube without a coating.","Bare Metal Stent | Bare-metal",,,,,,,,,,,,,,,"44783817","Bare metal stent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL428189","Anti-CEA BiTE Monoclonal Antibody MEDI-565","C95728","A recombinant, proprietary bispecific T-cell engagers (BiTE) antibody directed against human carcinoembryonic antigen (CEA), with potential immunostimulating and antineoplastic activities. Anti-CEA BiTE monoclonal antibody AMG211 possesses two antigen-recognition sites, one for CEA and one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR). This bispecific monoclonal antibody brings CEA-expressing tumor cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CEA-expressing cells. CEA, a tumor associated antigen, is overexpressed in many cancer types, including gastrointestinal, breast, non-small cell lung, and thyroid cancers.","Anti-CEA BiTE Monoclonal Antibody AMG211 | AMG211 | MEDI-565 | MT111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2830124","Pimasertib","C84864","An orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity. Pimasertib selectively binds to and inhibits the activity of MEK1/2, preventing the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK1/2 (MAP2K1/K2) are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.","Pimasertib | AS703026 | EMD 1036239 | MSC1936369 | N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4- iodophenyl)amino]isonicotinamide Hydrochloride | PIMASERTIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348906","hypoxia-activated prodrug TH-302","C71722","A hypoxia-activated prodrug of the cytotoxin bromo-isophosphoramide mustard (Br-IPM) conjugated with 2-nitroimidazole, with potential antineoplastic activity. When exposed to hypoxic conditions, such as those found in hypoxic tumors, the 2-nitroimidazole moiety of evofosfamide is reduced. This releases the DNA-alkylating Br-IPM moiety, which introduces intra- and inter-strand DNA crosslinks in nearby cells; the crosslinks inhibit both DNA replication and cell division, and may lead to apoptosis of cells in the tumor. The inactive form of the prodrug is stable under normoxic conditions, which may limit systemic toxicity.","Evofosfamide | EVOFOSFAMIDE | HAP TH-302 | Hypoxia-Activated Prodrug TH-302 | Phosphorodiamidic Acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl Ester | TH-302",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0400998","Bile Duct Leakage","C141238","The leakage of bile into the abdominal cavity as a result of injury to the bile duct.","Bile Duct Leakage | ",,,,,,,,,,,,,,,"4340957","Bile duct leakage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL539307","Cardiac Arrest Requiring Cardiopulmonary Resuscitation","C141268","Cardiac arrest that is treated by CPR and/or defibrillation, regardless of outcome.","Cardiac Arrest Requiring Cardiopulmonary Resuscitation | Cardiac arrest requiring CPR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539318","Coma Greater than 24 Hours","C141239","An indication that coma has lasted more than 24 hours.","Coma Greater than 24 Hours | Coma Longer than 24 Hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539316","Death During, or within 90 Days of, Index Hospital Admission","C141241","An indication that death occurred on or within 90 days of a patient's initial admission to a hospital.","Death During, or within 90 Days of, Index Hospital Admission | Death Less than 90 Days or During Index Hospital Admission",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539315","Postoperative Delayed Gastric Emptying","C141242","Delayed stomach emptying as a result of surgery.","Postoperative Delayed Gastric Emptying | Delayed Gastric Emptying After Surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539313","Graft, Prosthesis, or Flap Failure","C141244","A failure of function of a graft, flap, or prosthesis.","Graft, Prosthesis, or Flap Failure | Failure of Graft, Prosthesis, or Flap",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1306571","Liver Insufficiency","C141245","The inability of the liver to perform its normal synthetic and metabolic functions.","Liver Insufficiency | Hepatic Failure | Hepatic Insufficiency | Liver Failure",,,,,,,,,,,,,,,"4245975","Hepatic failure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL539326","Ventilation Greater than 48 Hours","C141246","An indication that respiratory ventilation was in use for more than 48 hours.","Ventilation Greater than 48 Hours | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539306","Unplanned Intubation","C141269","An intubation procedure that was unexpected.","Unplanned Intubation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009487","Commuting","C141285","To travel regularly between locations, especially between home and a work location.","Commute | Commuting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541307","Transportation","C141286","Methods of traveling from one place to another.","Transportation | Mode of Transportation | Transportation Service",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1698974","Public Transportation","C141287","Forms of transportation that run on fixed routes and are available to the public, usually for a set fare.","Public Transportation | Mass Transit | Public Transit | Public Transport",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539392","Shuttle Service","C141288","A transportation service that makes frequent trips between two places.","Shuttle Service | Shuttle | Shuttle Transport",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0336814","Taxi Service","C141289","A transportation service that uses hired cars and drivers.","Taxi Service | Cab | Cab Service | Taxi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541319","Driven","C141290","Transportation in a vehicle as a passenger.","Driven | Got a Ride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541261","Parking","C141291","A designated location where a vehicle may be left.","Parking | Parking Service | Parking Space",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0083220","Deslorelin","C38709","A synthetic nonapeptide analogue of the natural gonadotrophin releasing hormone (GnRH) with potential antineoplastic activity. Deslorelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Continuous, prolonged administration of goserelin in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. (NCI04)","Deslorelin | 6-D-Tryptophan-9-(N-ethyl-L-prolinamide)-1-9-luteinizing Hormone-releasing Factor (Swine) | DESLORELIN | Ovuplant | deslorelin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986475","Antitumor","C94320","Having to do with stopping abnormal cell growth.","Antitumor | antitumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539534","Simplified Preoperative Assessment for Appendix Tumor Score","C141410","A set of imaging criteria, based on preoperative CT scans, used to predict the likelihood for complete cytoreduction in patients with low-grade mucinous adenocarcinoma (LGMA) of the appendix. A score is determined by the presence of scalloping at 4 anatomic sites and the absence or presence of mesenteric foreshortening of the small bowel. A score under 3 is a significant predictor for complete cytoreduction.","Simplified Preoperative Assessment for Appendix Tumor Score | SPAAT | SPAAT Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539533","SPAAT Score 0","C141411","A subjective score of 0 on a prognostic scale that ranges from 0 to 7.","SPAAT Score 0 | SPAAT 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539532","SPAAT Score 1","C141412","A subjective score of 1 on a prognostic scale that ranges from 0 to 7.","SPAAT Score 1 | SPAAT 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539531","SPAAT Score 2","C141413","A subjective score of 2 on a prognostic scale that ranges from 0 to 7.","SPAAT Score 2 | SPAAT 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539530","SPAAT Score 3","C141414","A subjective score of 3 on a prognostic scale that ranges from 0 to 7.","SPAAT Score 3 | SPAAT 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539529","SPAAT Score 4","C141415","A subjective score of 4 on a prognostic scale that ranges from 0 to 7.","SPAAT Score 4 | SPAAT 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539528","SPAAT Score 5","C141416","A subjective score of 5 on a prognostic scale that ranges from 0 to 7.","SPAAT Score 5 | SPAAT 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539527","SPAAT Score 6","C141417","A subjective score of 6 on a prognostic scale that ranges from 0 to 7.","SPAAT Score 6 | SPAAT 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539510","SPAAT Score 7","C141418","A subjective score of 7 on a prognostic scale that ranges from 0 to 7.","SPAAT Score 7 | SPAAT 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897833","Procedure Occurrence","C117516","An indication or description of a procedure occurrence.","Procedure Occurrence | PROCCUR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539408","Albumin to Bilirubin Ratio Measurement","C141270","The determination of the ratio of albumin compared to bilirubin in a biological sample. The measurement may be expressed as a ratio or percentage.","Albumin to Bilirubin Ratio Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539407","Neutrophil to Lymphocyte Ratio Measurement","C141271","The determination of the ratio of neutrophils compared to lymphocytes present in a biological sample. The measurement may be expressed as a ratio or percentage.","Neutrophil to Lymphocyte Ratio Measurement | NEUTLY | NLR | Neutrophils/Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332922","Cervical Squamous Intraepithelial Neoplasia","C7346","A neoplastic process that affects the squamous epithelium of the cervix.  It is classified as cervical squamous intraepithelial neoplasia 1, 2, or 3, according to the degree of squamous cell maturation and cellular atypia, and the number of mitotic figures.","Cervical Squamous Intraepithelial Neoplasia | CIN | Cervical SIL | Cervical Squamous Intraepithelial Lesion | Cervix Squamous Intraepithelial Lesion | Cervix Uteri SIL | Cervix Uteri Squamous Intraepithelial Lesion | Squamous Intraepithelial Lesion of Cervix | Squamous Intraepithelial Lesion of Cervix Uteri | Squamous Intraepithelial Lesion of Uterine Cervix | Squamous Intraepithelial Lesion of the Cervix | Squamous Intraepithelial Lesion of the Cervix Uteri | Squamous Intraepithelial Lesion of the Uterine Cervix | Uterine Cervix SIL | Uterine Cervix Squamous Intraepithelial Lesion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831191","Car Ride","C113418","A journey in an automobile.","Car Ride | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986969","Stage IIIC2","C95180","A stage term that applies to uterine corpus cancer and indicates that the tumor is confined to the corpus uteri, or it invades stromal connective tissue of the cervix but does not extend beyond the uterus, or it involves serosa and/or adnexa, vagina, or parametrial tissue.  There is regional lymph node metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes.","Stage IIIC2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986968","Stage IIIC1","C95179","A stage term that applies to uterine corpus cancer and indicates that the tumor is confined to the corpus uteri, or it invades the stromal connective tissue of the cervix but does not extend beyond the uterus, or it involves serosa and/or adnexa, vagina, or parametrial tissue. There is regional lymph node metastasis to the pelvic lymph nodes.","Stage IIIC1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2924451","Location of Death","C124331","The physical place at which the subject ceased to live.","Location of Death | LOCDTH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0557128","Live with Friends","C113784","An indication that an individual is living in the home of a friend.","Live with Friends | Live with friends | Living with Friends",,,,,,,,,,,,,,,"4072593|4076104","Lives with friend|Lives with friends",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3272942","Hepatitis B Virus e Antibody Measurement","C96662","The determination of the amount of Hepatitis B virus e antibody present in a sample.","Hepatitis B Virus e Antibody Measurement | HBEAB | Hepatitis B Virus e Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205173","Double","C62265","Consisting of or involving two parts or components, often in pairs.","Double | Dual",,,,,,,,,,,,,,,"4045414","Double",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0280332","Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","C68611","A rare, keratinizing or non-keratinizing squamous cell carcinoma arising from the mucosal epithelium of the nasal cavity or the paranasal sinuses.  It affects most often the maxillary sinus.  Less frequently, it arises from the nasal cavity, ethmoid sinus, sphenoid sinus, and frontal sinus.  Symptoms include nasal fullness, epistaxis, rhinorhea, pain, and paresthesia.  Patients with nasal squamous cell carcinoma usually present earlier than patients with maxillary sinus carcinoma and have a better prognosis compared to the latter group.","Sinonasal Squamous Cell Carcinoma | Nasal Cavity and Paranasal Sinus Squamous Cell Cancer | Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma | Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0179740","Peripherally Inserted Central Catheter","C122591","A central venous catheter inserted through a peripheral vein.","Peripherally Inserted Central Catheter | ",,,,,,,,,,,,,,,"4161814","Peripherally inserted central catheter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1142471","Central Line Complication","C121589","A problem with a central venous access catheter or site of insertion.","Central Line Complication | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985459","Human Papillomavirus DNA Test","C93141","A laboratory test in which cells are scraped from the cervix to look for DNA of human papillomaviruses (HPV).","Human Papillomavirus DNA Test | HPV | HPV DNA test | human papillomavirus DNA test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708287","HPV-High Risk","C44391","Any of a number of strains of human papilloma virus (HPV) that have been shown to cause cancer in humans.","HPV-High Risk | HR-HPV | High Risk HPV | High-Risk Subtype (16, 18, 31, 33, 35, etc.) | Human Papillomaviruses, High Risk | hrHPV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412270","Radiation Therapy Treatment Planning and Simulation","C116434","The creation of a strategy, and the rehearsal of that strategy, for the purpose of identifying and eliminating any problems that may present during treatment.","Radiation Therapy Treatment Planning and Simulation | Radiation Therapy Treatment Planning/Simulation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707316","CRT","C50238","An evacuated glass tube designed to accelerate electrons onto a screen to create images.","Cathode Ray Tube Device | CRT | Cathode Ray Tube | Cathode Ray Tube Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539339","Deleterious BRCA Gene Mutation","C141233","A change in the nucleotide sequence of a gene in the BRCA family that is associated with increased risk of disease.","Deleterious BRCA Gene Mutation | Deleterious BRCA Family Mutation | Deleterious BRCA Gene Family Mutation | Deleterious BRCA Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539338","Beta-2-Microglobulin Greater than 3 g/mL","C141234","A laboratory test result indicating that beta-2-microglobulin is present in a sample at concentrations exceeding 3 g/mL.","Beta-2-Microglobulin Greater than 3 g/mL | B2M Greater than 3 g/mL | B2M Greater than Three g/mL | Beta-2 Microglobulin Greater than 3 g/mL | Beta-2 Microglobulin Greater than Three g/mL | Beta-2-Microglobulin Greater than Three g/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539335","Chromosome 13 Abnormality","C141237","An irregularity in the structure of chromosome 13.","Chromosome 13 Abnormality | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539317","Receptor Tyrosine Kinase Gene Mutation","C141240","A change in the nucleotide sequence of a receptor tyrosine kinase family gene.","Receptor Tyrosine Kinase Gene Mutation | RTK Family Gene Mutation | RTK Family Mutation | RTK Gene Mutation | Receptor Tyrosine Kinase Family Gene Mutation | Tyrosine Kinase Receptor Family Mutation | Tyrosine Kinase Receptor Gene Mutation | Tyrosine Kinase Receptor Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539324","Deleterious Homologous Recombination Pathway Gene Mutation","C141248","A change in the nucleotide sequence of a gene involved in homologous recombination-type DNA repair processes that is associated with increased risk of disease.","Deleterious Homologous Recombination Pathway Gene Mutation | Deleterious HHR Gene Mutation | Deleterious Homologous Recombination Pathway Mutation | Deleterious Recombination Repair Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539323","Human Herpesvirus 1 Positive","C141249","An indication that human herpesvirus 1 has been detected in a sample.","Human Herpesvirus 1 Positive | HHV-1 Positive | HHV1 Positive | HSV-1 Positive | HSV1 Positive | Herpes Simplex Virus 1 Positive | Herpes Simplex Virus Type 1 Positive | Human Alphaherpesvirus 1 Positive | Human Herpes Virus 1 Positive | Human Herpes Virus-1 Positive | Human Herpesvirus-1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539321","CCAAT Enhancer Binding Protein Gene Mutation","C141251","A change in the nucleotide sequence of a CCAAT enhancer binding protein family gene.","CCAAT Enhancer Binding Protein Gene Mutation | C/EBP Gene Mutation | C/EBP Mutation | CCAAT Enhancer Binding Protein Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539320","RNF43 Gene Mutation","C141252","A change in the nucleotide sequence of the RNF43 gene.","RNF43 Gene Mutation | RNF124 Gene Mutation | Ring Finger Protein 43 Gene Mutation | URCC Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539311","Phosphorylated Proto-Oncogene Tyrosine-Protein Kinase Src","C141264","A post-translationally modified form of proto-oncogene tyrosine-protein kinase Src where one or more serine, threonine and/or the tyrosine residues are phosphorylated. Phosphorylation of the tyrosine at residue position 530 inhibits Src kinase activity, while phosphorylation of the tyrosine at residue position 419 results in Src activation.","Phosphorylated Proto-Oncogene Tyrosine-Protein Kinase Src | Phospho-Proto-Oncogene Tyrosine-Protein Kinase Src | Phospho-Src | Phosphorylated SRC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539310","Regulatory T-Cell to Effector T-Cell Ratio Measurement","C141265","The determination of the ratio of regulatory T-cells (Tregs) compared to effector T-cells present in a sample.","Regulatory T-Cell to Effector T-Cell Ratio Measurement | Ratio of Regulatory T Cells to T Effector Cells | Regulatory T Cell to Effector T Cell Ratio Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3840403","Soluble Vascular Endothelial Growth Factor Receptor 2","C141267","Soluble vascular endothelial growth factor receptor 2 is encoded by the human KDR gene. This protein may play a role as a decoy receptor for vascular endothelial growth factors (VEGF)-1, 2 and 3.","Soluble Vascular Endothelial Growth Factor Receptor 2 | Soluble CD309 | Soluble Flk-1 | Soluble Fms-Like Tyrosine Kinase-1 | Soluble KDR | Soluble VEGFR2 | sFLK-1 | sKDR | sVEGFR-2 | sVEGFR2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539404","Phosphorylated Signal Transducer and Activator of Transcription 3 Positive","C141274","An indication that phosphorylated forms of the signal transducer and activator of transcription 3 protein have been detected in a sample.","Phosphorylated Signal Transducer and Activator of Transcription 3 Positive | Phospho-STAT3 Positive | Phospho-Signal Transducer and Activator of Transcription 3 Positive | PhosphoSTAT3 | PhosphoSTAT3 Positive | pSTAT3 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539403","AXL Gene Amplification","C141275","A molecular genetic abnormality indicating the presence of multiple copies of the AXL gene.","AXL Gene Amplification | ARK Gene Amplification | AXL Receptor Tyrosine Kinase Gene Amplification | JTK11 Gene Amplification | Tyro7 Gene Amplification | UFO Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539402","AXL Gene Mutation","C141276","A change in the nucleotide sequence of the AXL gene.","AXL Gene Mutation | ARK Gene Mutation | AXL Receptor Tyrosine Kinase Gene Mutation | JTK11 Gene Mutation | Tyro7 Gene Mutation | UFO Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539401","Serum CA125 Measurement","C141277","The determination of the amount of cancer antigen 125 present in a blood serum sample.","Serum CA125 Measurement | Serum CA-125 | Serum CA125 | Serum Cancer Antigen 125 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539415","Adenovirus Positive","C141278","An indication that adenovirus has been detected in a sample.","Adenovirus Positive | AdV Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539413","66 kDa Phosphoprotein Antibody Positive","C141280","An indication that antibodies that recognize the CMV 65 kDa phosphoprotein have been detected in a sample.","66 kDa Phosphoprotein Antibody Positive | Anti-66 kDa Phosphoprotein Antibody Positive | Anti-CMV 66 kDa Phosphoprotein Antibody Positive | Anti-CMV pp65 Antibody Positive | Anti-Phosphoprotein UL83 Antibody Positive | Anti-pp65 Antibody Positive | CMV 66 kDa Phosphoprotein Antibody Positive | CMV pp65 Antibody Positive | Phosphoprotein UL83 Antibody Positive | pp65 Antibody Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539412","SHH Negative","C141281","An indication that SHH expression has not been detected in a sample.","SHH Negative | HHG1 Negative | Sonic Hedgehog Homolog Negative | Sonic Hedgehog Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539411","Wnt Negative","C141282","An indication that the expression of Wnt family members has not been detected in a sample.","Wnt Negative | Wingless-Type MMTV Integration Site Family Negative | Wnt Family Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539395","CCND2 Positive","C141300","An indication that CCND2 expression has been detected in a sample.","CCND2 Positive | Cyclin D2 Positive | Cyclin-D2 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539394","CCND3 Positive","C141301","An indication that CCND3 expression has been detected in a sample.","CCND3 Positive | Cyclin D3 Positive | Cyclin-D3 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539396","Blasts 5 Percent or More of Peripheral Blood White Cells","C141299","A semi-quantitative microscopic finding indicating that 5 percent or more of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.","Blasts 5 Percent or More of Peripheral Blood White Cells | Blasts Greater than or Equal to 5 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539393","ABCB11 Positive","C141302","An indication that ABCB11 expression has been detected in a sample.","ABCB11 Positive | ABC16 Positive | ATP Binding Cassette Subfamily B Member 11 Positive | ATP-Binding Cassette Subfamily B Member 11 Positive | BRIC2 Positive | BSEP Positive | Bile Salt Export Pump Positive | P Glycoprotein 4 Positive | PGY4 Positive | SPGP Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539380","ABCB4 Positive","C141305","An indication that ABCB4 expression has been detected in a sample.","ABCB4 Positive | ABC21 Positive | ATP Binding Cassette Subfamily B Member 4 Positive | ATP-Binding Cassette Subfamily B Member 4 Positive | MDR3 Positive | Multidrug Resistance Protein 3 Positive | P Glycoprotein 3 Positive | PGY3 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0241923","HTLV-1 Antibody Positive","C141313","An indication that antibodies that recognize the human T-cell lymphotropic virus 1 have been detected in a sample.","HTLV-1 Antibody Positive | Anti-HTLV-1 Antibody Positive | Anti-HTLV-I Antibody Positive | Anti-Human T-Cell Lymphotropic Virus 1 Antibody Positive | Anti-Human T-Lymphotropic Virus 1 Antibody Positive | HTLV-I Antibody Positive | Human T-Cell Lymphotropic Virus 1 Antibody Positive | Human T-Lymphotropic Virus 1 Antibody Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539384","RET Positive","C141317","An indication that RET expression has been detected in a sample.","RET Positive | Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret Positive | Proto-Oncogene c-Ret Positive | Ret Proto-Oncogene Positive | Tyrosine-Protein Kinase Receptor RET Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539364","Epstein-Barr Virus Negative","C141321","An indication that Epstein-Barr virus has not been detected in a sample.","Epstein-Barr Virus Negative | EBV Negative | Epstein Barr Virus Negative | HHV-4 Negative | HHV4 Negative | Human Herpesvirus 4 Negative | Human Herpesvirus-4 Negative | Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539465","PIK3CB Gene Amplification","C141339","A molecular genetic abnormality indicating the presence of multiple copies of the PIK3CB gene.","PIK3CB Gene Amplification | P110BETA Gene Amplification | PI3KBETA Gene Amplification | PIK3C1 Gene Amplification | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta Gene Amplification | p110-Beta Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539464","PIK3CB Gene Mutation","C141340","A change in the nucleotide sequence of the PIK3CB gene.","PIK3CB Gene Mutation | P110BETA Gene Mutation | PI3KBETA Gene Mutation | PIK3C1 Gene Mutation | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta Gene Mutation | p110-Beta Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539460","SLC39A6 Positive","C141360","An indication that SLC39A6 expression has been detected in a sample.","SLC39A6 Positive | LIV-1 Positive | LIV1 Positive | Solute Carrier Family 39 Member 6 Positive | ZIP-6 Positive | Zinc Transporter ZIP6 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539459","MAGEC1 Positive","C141361","An indication that MAGEC1 expression has been detected in a sample.","MAGEC1 Positive | CT7 Positive | CT7.1 Positive | Cancer/Testis Antigen 7.1 Positive | MAGE Family Member C1 Positive | MAGE-C1 Positive | Melanoma Antigen Family C1 Positive | Melanoma-Associated Antigen C1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539458","AKT2 Gene Mutation","C141362","A change in the nucleotide sequence of the AKT2 gene.","AKT2 Gene Mutation | AKT Serine/Threonine Kinase 2 Gene Mutation | HIHGHH Gene Mutation | PKBB Gene Mutation | PKBBETA Gene Mutation | PRKBB Gene Mutation | RAC-BETA Gene Mutation | RAC-PK-Beta Gene Mutation | v-akt Murine Thymoma Viral Oncogene Homolog 2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896829","Axicabtagene Ciloleucel","C120309","A preparation of autologous peripheral blood T-lymphocytes (PBTL) that have been transduced with a gammaretoviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv) coupled to the costimulatory signaling domain CD28 and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3 zeta), with potential immunostimulating and antineoplastic activities. Upon intravenous infusion and re-introduction of axicabtagene ciloleucel into the patient, these cells bind to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen that is expressed in all B-cell lineage malignancies. CD3 zeta is one of several membrane-bound polypeptides found in the TCR/CD3 complex; it regulates both the assembly and cell surface expression of TCR complexes. CD28 is essential for CD4+ T-cell proliferation, interleukin-2 production, and T-helper type-2 (Th2) development.","Axicabtagene Ciloleucel | AXICABTAGENE CILOLEUCEL | Axi-cel | Axicabtagene ciloleucel | Axicel | KTE C19 | KTE-C19 | KTE-C19 CAR | KTEC19 | Yescarta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539457","MME Negative","C141363","An indication that MME expression has not been detected in a sample.","MME Negative | CALLA Negative | CD10 Negative | Common ALL Antigen Negative | Common Acute Lymphoblastic Leukemia Antigen Negative | Membrane Metalloendopeptidase Negative | NEP Negative | Neprilysin Negative | SFE Negative | Skin Fibroblast Elastase Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539456","CCND2 Protein Overexpression","C141364","A molecular abnormality indicating the presence of an abnormally high level of the G1/S-specific cyclin-D2 protein.","CCND2 Protein Overexpression | Cyclin D2 Protein Overexpression | Cyclin-D2 Protein Overexpression | G1/S-Specific Cyclin D2 Protein Overexpression | G1/S-Specific Cyclin-D2 Protein Overexpression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539437","CCND3 Protein Overexpression","C141368","A molecular abnormality indicating the presence of an abnormally high level of the G1/S-specific cyclin-D3 protein.","CCND3 Protein Overexpression | Cyclin D3 Protein Overexpression | Cyclin-D3 Protein Overexpression | G1/S-Specific Cyclin D3 Protein Overexpression | G1/S-Specific Cyclin-D3 Protein Overexpression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539435","Activating ERBB3 Mutation","C141370","A change in the nucleotide sequence of the ERBB3 gene that that results in constitutive activation of receptor tyrosine-protein kinase erbB-3 and its downstream signaling pathways.","Activating ERBB3 Mutation | Activating Erb-B2 Receptor Tyrosine Kinase 3 Gene Mutation | Activating ErbB-3 Gene Mutation | Activating HER-3 Gene Mutation | Activating HER3 Gene Mutation | Activating V-Erb-A Erythroblastic Leukemia Viral Oncogene Homolog 3 Gene Mutation | Activating V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 3 Gene Mutation | Activating c-erbB-3 Gene Mutation | Activating c-erbB3 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539426","Epstein-Barr Virus DNA Positive","C141397","An indication that Epstein-Barr virus DNA has been detected in a sample.","Epstein-Barr Virus DNA Positive | EBV DNA Positive | HHV-4 DNA Positive | HHV4 DNA Positive | Human Herpesvirus 4 DNA Positive | Human Herpesvirus-4 DNA Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2931557","Chromosome 4 short arm deletion","C141398","A cytogenetic abnormality that refers to loss of all or part of the short arm of chromosome 4 (4p).","Loss of Chromosome 4p | 4p Deletion | del(4p)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539425","Wnt Family Gene Alteration Positive","C141399","An indication that mutation, overexpression, or rearrangement of an Wnt gene family member has been detected in a sample.","Wnt Family Gene Alteration Positive | Wingless-Type MMTV Integration Site Family Gene Alteration | Wingless-Type MMTV Integration Site Family Gene Alteration Positive | Wnt Gene Alteration | Wnt Gene Alteration Positive | Wnt Signaling Gene Alteration | Wnt Signaling Gene Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539424","BK Virus Positive","C141400","An indication that BK virus has been detected in a sample.","BK Virus Positive | BKV Papovavirus Positive | BKV Positive | Polyomavirus BK Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539526","Human Herpesvirus 6 Positive","C141401","An indication that human herpesvirus 6 has been detected in a sample.","Human Herpesvirus 6 Positive | HHV-6 Positive | HHV6 Positive | Human Herpes Virus 6 Positive | Human Herpes Virus-6 Positive | Human Herpes virus 6 Positive | Human Herpesvirus-6 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539525","JC Virus Positive","C141402","An indication that JC virus has been detected in a sample.","JC Virus Positive | JC Polyomavirus Virus Positive | JCV Positive | Polyomavirus JC Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539524","DDIT3 Gene Rearrangement","C141403","A molecular abnormality indicating rearrangement of the DDIT3 gene.","DDIT3 Gene Rearrangement | C/EBPzeta Gene Rearrangement | CEBPZ Gene Rearrangement | CHOP-10 Gene Rearrangement | CHOP10 Gene Rearrangement | DDIT3 Rearrangement | DNA Damage Inducible Transcript 3 Gene Rearrangement | DNA-Damage-Inducible Transcript 3 Gene Rearrangement | GADD153 Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539523","SLC45A2 Positive","C141404","An indication that SLC45A2 expression has been detected in a sample.","SLC45A2 Positive | AIM-1 Positive | AIM1 Positive | MATP Positive | Melanoma Antigen AIM1 Positive | OCA4 Positive | SHEP5 Positive | Solute Carrier Family 45 Member 2 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539522","Hepatitis B Virus Positive","C141405","An indication that hepatitis virus B has been detected in a sample.","Hepatitis B Virus Positive | HBV Positive | Hep B Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539521","PSA Level Less than Twenty Five","C141406","A blood concentration of prostate specific antigen less than 25 ng/mL.","PSA Level Less than Twenty Five | PSA Level Less than 25 | PSA Level Less than Twenty-Five",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539520","SCGB2A2 Positive","C141407","An indication that SCGB2A2 expression has been detected in a sample.","SCGB2A2 Positive | MGB1 Positive | Mammaglobin 1 Positive | Mammaglobin A Positive | Mammaglobin-1 Positive | Mammaglobin-A Positive | Secretoglobin 2A2 Positive | Secretoglobin Family 2A Member 2 Positive | UGB2 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539519","UGT1A1*28 Allele Negative","C141408","An indication that UGT1A1*28 expression has not been detected in a sample.","UGT1A1*28 Allele Negative | UGT1A1*28 Absent | UGT1A1*28 Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4078312","Acalabrutinib","C113442","An orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, acalabrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.","Acalabrutinib | ACALABRUTINIB | ACP 196 | ACP-196 | ACP196 | Benzamide, 4-(8-Amino-3-((2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl)imidazo(1,5-a)pyrazin-1-yl)-N-2-pyridinyl- | Bruton Tyrosine Kinase Inhibitor ACP-196 | Calquence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512780","Large Cell/Anaplastic Medulloblastoma","C129436","A medulloblastoma composed of sheets of large cells mixed with cells characterized by marked nuclear pleomorphism and high mitotic activity.","Large Cell/Anaplastic Medulloblastoma | ",,,,,,,,,,,,,,,"37152732","Anaplastic large cell medulloblastoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545925","Malignant Bowel Obstruction Color Code Scale","C141509","A scale using colors to describe the severity and level of care required by an individual to manage their malignant bowel obstruction.","Malignant Bowel Obstruction Color Code Scale | MBO | MBO Color Scale | MBO Scale | Malignant Bowel Obstruction Color Code System Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539557","Malignant Bowel Obstruction Resolved, Self Managing","C141510","A response indicating that an individual's malignant bowel obstruction is resolved and they are managing their care without assistance.","Malignant Bowel Obstruction Resolved, Self Managing | Resolved, self managing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539556","No Malignant Bowel Obstruction, Issues with Constipation","C141511","A response indicating that an individual is not experiencing malignant bowel obstruction symptoms but has issues with constipation.","No Malignant Bowel Obstruction, Issues with Constipation | No MBO, but issues with constipation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539555","Malignant Bowel Obstruction, Ambulatory Care Management","C141512","A response indicating that an individual is experiencing malignant bowel obstruction symptoms and is receiving ambulatory care.","Malignant Bowel Obstruction, Ambulatory Care Management | MBO, ambulatory management",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539554","Malignant Bowel Obstruction, Inpatient Care Management","C141513","A response indicating that an individual is experiencing malignant bowel obstruction symptoms and is receiving care while in hospital.","Malignant Bowel Obstruction, Inpatient Care Management | MBO, inpatient management",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539553","Malignant Bowel Obstruction, Best Supportive Care Palliative Team Management","C141514","A response indicating that an individual is experiencing malignant bowel obstruction symptoms and is receiving best supportive care primarily managed by a palliative care team.","Malignant Bowel Obstruction, Best Supportive Care Palliative Team Management | Best supportive care, primarily managed by Palliative Care Team",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539574","Cisplatin/Fluorouracil/Trastuzumab Regimen","C141505","A regimen consisting of cisplatin, fluorouracil and trastuzumab that can be used in the treatment of esophageal and esophagogastric junction, and gastric cancers.","Cisplatin/Fluorouracil/Trastuzumab Regimen | CFT | Cisplatin and Fluorouracil (CF) and Trastuzumab | Cisplatin and Fluorouracil (CF) and Trastuzumab-anns | Cisplatin and Fluorouracil (CF) and Trastuzumab-dkst | Cisplatin and Fluorouracil (CF) and Trastuzumab-dttb | Cisplatin and Fluorouracil (CF) and Trastuzumab-herw | Cisplatin and Fluorouracil (CF) and Trastuzumab-pkrb | Cisplatin and Fluorouracil (CF) and Trastuzumab-qyyp | Cisplatin and Fluorouracil (CF) and Trastuzumab-strf | Cisplatin and Fluorouracil (CF) and Trastuzumab-zerc | Cisplatin-Fluorouracil-Trastuzumab | Cisplatin-Fluorouracil-Trastuzumab Regimen | Cisplatin/5-FU/Trastuzumab | Cisplatin/Fluorouracil/Leucovorin Plus Trastuzumab | Cisplatin/Fluorouracil/Trastuzumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539573","Capecitabine/Cisplatin Regimen","C141506","A regimen consisting of capecitabine and cisplatin that can be used in the treatment of gastric, hepatobiliary, esophageal and esophagogastric junction cancers.","Capecitabine/Cisplatin Regimen | CX | Capecitabine and Cisplatin (CX) | Capecitabine-Cisplatin | Capecitabine-Cisplatin Regimen | Capecitabine/Cisplatin | XP | Xeloda-Platinol | Xeloda/Platinol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539572","ECX Regimen","C141507","A regimen consisting of capecitabine, cisplatin and epirubicin that can be used in the treatment of a variety of cancers, such as gastric, ovarian, pancreatic, and esophageal cancer.","ECX Regimen | Capecitabine-Cisplatin-Epirubicin | Capecitabine-Cisplatin-Epirubicin Regimen | Capecitabine/Cisplatin/Epirubicin | Capecitabine/Cisplatin/Epirubicin Regimen | Cisplatin-Epirubicin-Xeloda | Cisplatin/Epirubicin/Xeloda | ECX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539571","EOX Regimen","C141508","A regimen consisting of capecitabine, epirubicin and oxaliplatin that can be used in the treatment of esophageal and gastric cancer.","EOX Regimen | Capecitabine-Epirubicin-Oxaliplatin | Capecitabine-Epirubicin-Oxaliplatin Regimen | Capecitabine/Epirubicin/Oxaliplatin | Capecitabine/Epirubicin/Oxaliplatin Regimen | EOX | EOX Regimen  | Epirubicin-Oxaliplatin-Xeloda | Epirubicin/Oxaliplatin/Xeloda",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281678","cisplatin/epirubicin/fluorouracil protocol","C10937","No Value Exists","Cisplatin/Epirubicin/Fluorouracil | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0077964","cyclophosphamide/dactinomycin/vincristine protocol","C9642","No Value Exists","Cyclophosphamide/Dactinomycin/Vincristine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0071126","Pirarubicin","C1197","An analogue of the anthracycline antineoplastic antibiotic doxorubicin.  Pirarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent is less cardiotoxic than doxorubicin and exhibits activity against some doxorubicin-resistant cell lines. (NCI04)","Pirarubicin | (2'R)-4'-O-Tetrahydropyranyladriamycin | (8S,10S)-10-[[3-Amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-3-yl)-alpha-L-lyxo-hexopyranosyl]oxy]-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione | 1609-RB | 1609RB | 4'-O-Tetrahydropyranyl Doxorubicin | PIRARUBICIN | Pinorubicin | THP-ADM | THP-Adriamycin | THP-DOX | THP-Doxorubicin | Tepirubicin | Tetrahydropyranyl-Doxorubicin | Theprubicin | Theprubicine | Therarubicin | [8S-[8Alpha,10alpha(S*)]]-10-[[3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023413","Leucovorin","C71631","A derivative of folic acid with chemoprotectant, antidote and synergistic activity. Leucovorin does not require metabolism by dihydrofolate reductase, the molecular target of folate antagonist-type chemotherapeutic drugs, and is converted to a tetrahydrofolate, which is the necessary folate for purine and pyrimidine synthesis. As this agent allows for some purine/pyrimidine synthesis to occur, the toxic effects of folic acid antagonist-type chemotherapeutic drugs are counteracted while still permitting the antitumor activity of the folic acid antagonist through dihydrofolate reductase inhibition. This agent also potentiates the effects of 5-fluorouracil and its derivatives by stabilizing the binding of 5-fluorouracil's converted form fluorodeoxyuridylic acid to its target enzyme thymidylate synthase, thus prolonging drug activity.","Leucovorin | 5-Formyltetrahydrofolate | Folinic acid | LEUCOVORIN | folinic acid | leucovorin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280754","Carboplatin/Cisplatin/Ifosfamide","C10379","No Value Exists","Carboplatin/Cisplatin/Ifosfamide | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280068","Etoposide/Ifosfamide regimen","C10182","No Value Exists","Etoposide/Ifosfamide | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279844","Busulfan/Melphalan","C10133","No Value Exists","Busulfan/Melphalan | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523567","Infusional 5-FU/LV","C136256","A regimen consisting of infusional fluorouracil and leucovorin that is used for the treatment of colon, vaginal, and gastric cancers, ampullary adenocarcinoma, and thymomas and thymic carcinomas.","Fluorouracil Infusional/Leucovorin Regimen | Infusional 5-FU/LV | Infusional 5-FU/LV Regimen | Infusional 5-FU/Leucovorin | Infusional Fluorouracil-Leucovorin Regimen | Infusional Fluorouracil/Folinic Acid | Infusional Fluorouracil/Leucovorin | Infusional Fluorouracil/Leucovorin Regimen | Infusional Fluorouracil/Leucovorin Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526802","Breast Cancer Pathologic TNM Finding v8","C139408","A pathologic finding about one or more characteristics of breast cancer, following the rules of the TNM AJCC v8 classification system.","Breast Cancer Pathologic TNM Finding v8 | Breast Carcinoma Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539561","Atypical Squamous Cell-Favor High-Grade Squamous Intraepithelial Lesion","C141519","An abnormal squamous cell found in a cervical smear with cytologic features suggestive of high-grade squamous intraepithelial lesion.","Atypical Squamous Cell-Favor High-Grade Squamous Intraepithelial Lesion | ASC-Favor HSIL | Atypical Squamous Cell-Favor HSIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1455886","Atypical endocervical cells NOS","C141518","An abnormal endocervical cell found in a cervical smear. It may be related to an inflammatory or neoplastic process.","Atypical Endocervical Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539562","Atypical Glandular Cell-Favor Neoplasia","C141517","An abnormal endocervical or endometrial cell found in a cervical smear with cytologic features suggestive of a neoplastic process.","Atypical Glandular Cell-Favor Neoplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3888580","Malignant Bowel Obstruction","C141551","Obstruction of the bowel by an advanced malignant tumor. It is a complication especially in patients with an advanced abdominal malignant tumor.","Malignant Bowel Obstruction | MBO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539486","Presumed Alive","C141463","The assumption that a person is still living.","Presumed Alive | Presumed Living",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539485","Recode","C141464","To apply a new, corrected, or updated code value.","Recode | Recoding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550743","Occult Stage","C141461","A stage term that refers to a cancer in which the primary site is unknown (not detectable by clinical or radiologic examination). The definition of occult stage depends on the particular type of cancer that it refers to; for example, for breast cancer, occult stage is defined as cancer presenting with axillary lymph node metastasis without a primary in the breast being found; for non-small cell lung carcinoma, occult stage is defined as cancer detectable by sputum cytology only and the primary tumor is undetectable radiographically or during bronchoscopy.","Occult Stage | OC | Occult",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539487","National Program of Cancer Registries","C141462","Established by Congress through the Cancer Registries Amendment Act in 1992, and administered by CDC, the National Program of Cancer Registries (NPCR) collects data on cancer occurrence (including the type, extent, and location of the cancer), the type of initial treatment, and outcomes. It supports central cancer registries in 46 states, the District of Columbia, Puerto Rico, the U.S. Pacific Island Jurisdictions, and the U.S. Virgin Islands.","National Program of Cancer Registries | NPCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3869907","Stage IVA1","C141344","A mycosis fungoides/Sezary syndrome stage defined as follows: T1-4, N0-2, M0, B2. T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. T2: Patches, papules, or plaques covering 10% or more of the skin surface. T3: One or more tumors (equal or greater than 1 cm in diameter). T4: Confluence of erythema covering 80% or more of body surface area. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. M0: No visceral organ involvement. B2: High blood tumor burden: 1,000 per microliter or more Sezary cells with positive clone. (AJCC 8th ed.)","Stage IVA1 | IVA2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3869908","Stage IVA2","C141345","A mycosis fungoides/Sezary syndrome stage defined as follows: T1-4, N3, M0, B0-2. T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. T2: Patches, papules, or plaques covering 10% or more of the skin surface. T3: One or more tumors (equal or greater than 1 cm in diameter). T4: Confluence of erythema covering 80% or more of body surface area. N3: Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3-4 or NCI LN4; clone positive or negative. M0: No visceral organ involvement.  B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. B2: High blood tumor burden: 1,000 per microliter or more Sezary cells with positive clone. (AJCC 8th ed.)","Stage IVA2 | IVA2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526933","Anatomic Stage III Breast Cancer AJCC v8","C139541","Stage III includes: IIIA: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0); IIIB: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0); IIIC: (Any T, N3, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)","Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage III Breast Carcinoma AJCC v8 | Stage III Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526928","Anatomic Stage II Breast Cancer AJCC v8","C139538","Stage II includes: IIA: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0); IIB: (T2, N1, M0); (T3, N0, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)","Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage II Breast Carcinoma AJCC v8 | Stage II Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526923","Anatomic Stage I Breast Cancer AJCC v8","C139535","Stage I includes: IA: (T1, N0, M0); IB: (T0, N1mi, M0); (T1, N1mi, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1mi: Tumor with micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)","Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage I Breast Carcinoma AJCC v8 | Stage I Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526700","Breast Cancer cN1mi TNM Finding v8","C139400","Breast cancer with micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). cN1mi is rarely used but may be appropriate in cases where sentinel node biopsy is performed before tumor resection, most likely to occur in cases treated with neoadjuvant therapy. (from AJCC 8th Ed.)","Breast Cancer cN1mi TNM Finding v8 | Breast Carcinoma cN1mi TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523752","Lung Cancer pT1mi TNM Finding v8","C136449","Lung cancer with minimally invasive adenocarcinoma: adenocarcinoma (3 cm or less in greatest dimension) with a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. (from AJCC 8th Ed.)","Lung Cancer pT1mi TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523755","Lung Cancer pT1c TNM Finding v8","C136452","Lung cancer with tumor measuring more than 2 cm but 3 cm or less in greatest dimension. (from AJCC 8th Ed.)","Lung Cancer pT1c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523740","Lung Cancer cM1c TNM Finding v8","C136437","Lung cancer with multiple extrathoracic metastases in a single organ or in multiple organs. (from AJCC 8th Ed.)","Lung Cancer cM1c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523746","Lung Cancer pM1c TNM Finding v8","C136443","Lung cancer with multiple extrathoracic metastases in a single organ or in multiple organs. (from AJCC 8th Ed.)","Lung Cancer pM1c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541327","Distress Assessment and Response Tool","C141520","A short, self-assessment to measure an individual's physical symptoms, emotional burden and practical concerns that could interfere with their ability to engage in cancer treatment.","Distress Assessment and Response Tool | DART | Distress Assessment and Response Tool (DART)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541310","Feel Pain","C141521","A question about whether an individual feels or felt pain.","Feel Pain | Pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539560","Pain Score 0","C141522","A subjective score of 0 on a pain scale that ranges from 0: No Pain to 10: Worst Possible Pain.","Pain Score 0 | DART Pain Score 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539559","Pain Score 1","C141523","A subjective score of 1 on a pain scale that ranges from 0: No Pain to 10: Worst Possible Pain.","Pain Score 1 | DART Pain Score 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539558","Pain Score 2","C141524","A subjective score of 2 on a pain scale that ranges from 0: No Pain to 10: Worst Possible Pain.","Pain Score 2 | DART Pain Score 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539542","Pain Score 3","C141525","A subjective score of 3 on a pain scale that ranges from 0: No Pain to 10: Worst Possible Pain.","Pain Score 3 | DART Pain Score 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539541","Pain Score 4","C141526","A subjective score of 4 on a pain scale that ranges from 0: No Pain to 10: Worst Possible Pain.","Pain Score 4 | DART Pain Score 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523741","Lung Cancer Pathologic TNM Finding v8","C136438","A pathologic finding about one or more characteristics of lung cancer, following the rules of the TNM AJCC v8 classification system.","Lung Cancer Pathologic TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539540","Pain Score 5","C141527","A subjective score of 5 on a pain scale that ranges from 0: No Pain to 10: Worst Possible Pain.","Pain Score 5 | DART Pain Score 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539539","Pain Score 6","C141528","A subjective score of 6 on a pain scale that ranges from 0: No Pain to 10: Worst Possible Pain.","Pain Score 6 | DART Pain Score 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539538","Pain Score 7","C141529","A subjective score of 7 on a pain scale that ranges from 0: No Pain to 10: Worst Possible Pain.","Pain Score 7 | DART Pain Score 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539537","Pain Score 8","C141530","A subjective score of 8 on a pain scale that ranges from 0: No Pain to 10: Worst Possible Pain.","Pain Score 8 | DART Pain Score 8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539536","Pain Score 9","C141531","A subjective score of 9 on a pain scale that ranges from 0: No Pain to 10: Worst Possible Pain.","Pain Score 9 | DART Pain Score 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539535","Pain Score 10","C141532","A subjective score of 10 on a pain scale that ranges from 0: No Pain to 10: Worst Possible Pain.","Pain Score 10 | DART Pain Score 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539550","Tiredness Visual Analogue Scale","C141533","A scale of tiredness from 0 to 10 on which the patient marks the current level of tiredness experienced.","Tiredness Visual Analogue Scale | Tiredness | Visual Analogue Tiredness Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526918","Breast Cancer by AJCC v8 Stage","C139532","A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. It applies to invasive (infiltrating) carcinoma of the breast and ductal carcinoma in situ of the breast. It does not apply to breast sarcoma, phyllodes tumor, and breast lymphoma. (from AJCC 8th Ed.)","Breast Cancer by AJCC v8 Stage | Breast Carcinoma by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523770","Lung Cancer by AJCC v8 Stage","C136467","A term that refers to the staging of lung cancer, following the rules of the TNM AJCC v8 classification system. This staging system derives from analyses of the new retrospective and prospective databases of the International Association for the Study of Lung Cancer (IASLC). These databases contain information on patients diagnosed with lung cancer from 1999 to 2010 originating from 35 different databases in 16 countries around the world. This staging system applies to carcinomas of the lung, including non-small cell and small cell carcinomas, and bronchopulmonary carcinoid tumors. It does not apply to sarcomas or other rare tumors of the lung. (from AJCC 8th Ed.)","Lung Cancer by AJCC v8 Stage | Tumor Stage (Pathological)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523771","Occult Lung Cancer AJCC v8","C136468","Occult lung cancer includes: TX, N0, M0. TX: Primary tumor cannot be assessed. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Occult Lung Cancer AJCC v8 | Occult Lung Cancer | Occult Lung Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523787","Stage IVB Lung Cancer AJCC v8","C136484","Stage IVB includes: Any T, Any N, M1c. M1c: Tumor with multiple extrathoracic metastases in a single organ or in multiple organs. (AJCC 8th ed.)","Stage IVB Lung Cancer AJCC v8 | Stage IVB Lung Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523786","Stage IVA Lung Cancer AJCC v8","C136483","Stage IVA includes: (Any T, Any N, M1a); (Any T, Any N, M1b). M1a: Tumor with separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodules or malignant pleural or pericardial effusion. Most pleural (pericardial) effusions with lung cancer are a result of the tumor. In a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumor, and the fluid is nonbloody and not an exudate. If these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging descriptor. M1b: Tumor with single extrathoracic metastasis in a single organ (including involvement of a single nonregional node). (AJCC 8th ed.)","Stage IVA Lung Cancer AJCC v8 | Stage IVA Lung Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523785","Stage IV Lung Cancer AJCC v8","C136482","Stage IV includes: IVA: (Any T, Any N, M1a); (Any T, Any N, M1b); IVB: (Any T, Any N, M1c). M1a: Tumor with separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodules or malignant pleural or pericardial effusion. Most pleural (pericardial) effusions with lung cancer are a result of the tumor. In a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumor, and the fluid is nonbloody and not an exudate. If these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging descriptor. M1b: Tumor with single extrathoracic metastasis in a single organ (including involvement of a single nonregional node). M1c: Tumor with multiple extrathoracic metastases in a single organ or in multiple organs. (AJCC 8th ed.)","Stage IV Lung Cancer AJCC v8 | Stage IV | Stage IV Lung Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523784","Stage IIIC Lung Cancer AJCC v8","C136481","Stage IIIC includes: (T3, N3, M0); (T4, N3, M0). T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. T4: Tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. N3: Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIC Lung Cancer AJCC v8 | Stage IIIC Lung Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523783","Stage IIIB Lung Cancer AJCC v8","C136480","Stage IIIB includes: (T1a, N3, M0); (T1b, N3, M0); (T1c, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N2, M0); (T4, N2, M0). T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. T4: Tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. N2: Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s). N3: Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIB Lung Cancer AJCC v8 | Stage IIIB | Stage IIIB Lung Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523782","Stage IIIA Lung Cancer AJCC v8","C136479","Stage IIIA includes: (T1a, N2, M0); (T1b, N2, M0); (T1c, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T4, N0, M0); (T4, N1, M0). T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. T4: Tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. N0: No regional lymph node metastases. N1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. N2: Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIA Lung Cancer AJCC v8 | Stage IIIA | Stage IIIA Lung Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523780","Stage IIB Lung Cancer AJCC v8","C136477","Stage IIB includes: (T1a, N1, M0); (T1b, N1, M0); (T1c, N1, M0); (T2a, N1, M0); (T2b, N1, M0); (T3, N0, M0). T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. N0: No regional lymph node metastases. N1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIB Lung Cancer AJCC v8 | Stage IIB | Stage IIB Lung Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523779","Stage IIA Lung Cancer AJCC v8","C136476","Stage IIA includes: T2b, N0, M0. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension.  N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIA Lung Cancer AJCC v8 | Stage IIA | Stage IIA Lung Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523777","Stage IB Lung Cancer AJCC v8","C136474","Stage IB includes: T2a, N0, M0. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)","Stage IB Lung Cancer AJCC v8 | Stage IB | Stage IB Lung Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523776","Stage IA3 Lung Cancer AJCC v8","C136473","Stage IA3 includes: T1c, N0, M0. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)","Stage IA3 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523775","Stage IA2 Lung Cancer AJCC v8","C136472","Stage IA2 includes: T1b, N0, M0. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)","Stage IA2 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523774","Stage IA1 Lung Cancer AJCC v8","C136471","Stage IA1 includes: IA1: (T1mi, N0, M0); (T1a, N0, M0). T1mi: Minimally invasive adenocarcinoma: adenocarcinoma (3 cm or less in greatest dimension) with a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)","Stage IA1 Lung Cancer AJCC v8 | Stage IA1 Lung Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523781","Stage III Lung Cancer AJCC v8","C136478","Stage III includes: IIIA: (T1a, N2, M0); (T1b, N2, M0); (T1c, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T4, N0, M0); (T4, N1, M0); IIIB: (T1a, N3, M0); (T1b, N3, M0); (T1c, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N2, M0); (T4, N2, M0); IIIC: (T3, N3, M0); (T4, N3, M0). T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. T4: Tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. N0: No regional lymph node metastases. N1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. N2: Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s). N3: Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)","Stage III Lung Cancer AJCC v8 | Stage III | Stage III Lung Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523778","Stage II Lung Cancer AJCC v8","C136475","Stage II includes: IIA: (T2b, N0, M0); IIB: (T1a, N1, M0); (T1b, N1, M0); (T1c, N1, M0); (T2a, N1, M0); (T2b, N1, M0); (T3, N0, M0). T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension.  T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension.  T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. N0: No regional lymph node metastases. N1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Lung Cancer AJCC v8 | Stage II | Stage II Lung Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523773","Stage I Lung Cancer AJCC v8","C136470","Stage I includes: IA1: (T1mi, N0, M0); (T1a, N0, M0); IA2: (T1b, N0, M0); IA3: (T1c, N0, M0); IB: (T2a, N0, M0). T1mi: Minimally invasive adenocarcinoma: adenocarcinoma (3 cm or less in greatest dimension) with a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Lung Cancer AJCC v8 | Stage I | Stage I Lung Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523772","Stage 0 Lung Cancer AJCC v8","C136469","Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. Squamous cell carcinoma in situ (SCIS). Adenocarcinoma in situ (AIS): adenocarcinoma with pure lepidic pattern, 3 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0 Lung Cancer AJCC v8 | Stage 0 Lung Cancer | Stage 0 Lung Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539549","Tiredness Score 0","C141534","A subjective score of 0 on a tiredness scale that ranges from 0: No Tiredness to 10: Worst Possible Tiredness.","Tiredness Score 0 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539548","Tiredness Score 1","C141535","A subjective score of 1 on a tiredness scale that ranges from 0: No Tiredness to 10: Worst Possible Tiredness.","Tiredness Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539547","Tiredness Score 2","C141536","A subjective score of 2 on a tiredness scale that ranges from 0: No Tiredness to 10: Worst Possible Tiredness.","Tiredness Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539546","Tiredness Score 3","C141537","A subjective score of 3 on a tiredness scale that ranges from 0: No Tiredness to 10: Worst Possible Tiredness.","Tiredness Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539545","Tiredness Score 4","C141538","A subjective score of 4 on a tiredness scale that ranges from 0: No Tiredness to 10: Worst Possible Tiredness.","Tiredness Score 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539544","Tiredness Score 5","C141539","A subjective score of 5 on a tiredness scale that ranges from 0: No Tiredness to 10: Worst Possible Tiredness.","Tiredness Score 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539543","Tiredness Score 6","C141540","A subjective score of 6 on a tiredness scale that ranges from 0: No Tiredness to 10: Worst Possible Tiredness.","Tiredness Score 6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539645","Tiredness Score 7","C141541","A subjective score of 7 on a tiredness scale that ranges from 0: No Tiredness to 10: Worst Possible Tiredness.","Tiredness Score 7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539644","Tiredness Score 8","C141542","A subjective score of 8 on a tiredness scale that ranges from 0: No Tiredness to 10: Worst Possible Tiredness.","Tiredness Score 8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539643","Tiredness Score 9","C141543","A subjective score of 9 on a tiredness scale that ranges from 0: No Tiredness to 10: Worst Possible Tiredness.","Tiredness Score 9 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539642","Tiredness Score 10","C141544","A subjective score of 10 on a tiredness scale that ranges from 0: No Tiredness to 10: Worst Possible Tiredness.","Tiredness Score 10 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522398","Exocrine Pancreatic Cancer Pathologic TNM Finding v8","C134882","A pathologic finding about one or more characteristics of pancreatic cancer, following the rules of the TNM AJCC v8 classification system.","Pancreatic Cancer Pathologic TNM Finding v8 | Exocrine Pancreatic Cancer Pathologic TNM Finding v8 | Exocrine Pancreatic Carcinoma Pathologic TNM Finding v8 | Pancreatic Carcinoma Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522411","Exocrine Pancreatic Cancer pT4 TNM Finding v8","C134895","Pancreatic cancer with tumor involving the celiac axis, superior mesenteric artery, and/or common hepatic artery, regardless of size. (from AJCC 8th Ed.)","Pancreatic Cancer pT4 TNM Finding v8 | Exocrine Pancreatic Cancer pT4 TNM Finding v8 | Exocrine Pancreatic Carcinoma pT4 TNM Finding v8 | Pancreatic Carcinoma pT4 TNM Finding v8 | pT4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522410","Exocrine Pancreatic Cancer pT3 TNM Finding v8","C134894","Pancreatic cancer with tumor measuring more than 4 cm in greatest dimension. (from AJCC 8th Ed.)","Pancreatic Cancer pT3 TNM Finding v8 | Exocrine Pancreatic Cancer pT3 TNM Finding v8 | Exocrine Pancreatic Carcinoma pT3 TNM Finding v8 | Pancreatic Carcinoma pT3 TNM Finding v8 | pT3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522409","Exocrine Pancreatic Cancer pT2 TNM Finding v8","C134893","Pancreatic cancer with tumor measuring more than 2 cm and 4 cm or less in greatest dimension. (from AJCC 8th Ed.)","Pancreatic Cancer pT2 TNM Finding v8 | Exocrine Pancreatic Cancer pT2 TNM Finding v8 | Exocrine Pancreatic Carcinoma pT2 TNM Finding v8 | Pancreatic Carcinoma pT2 TNM Finding v8 | pT2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522408","Exocrine Pancreatic Cancer pT1c TNM Finding v8","C134892","Pancreatic cancer with tumor measuring 1-2 cm in greatest dimension. (from AJCC 8th Ed.)","Pancreatic Cancer pT1c TNM Finding v8 | Exocrine Pancreatic Cancer pT1c TNM Finding v8 | Exocrine Pancreatic Carcinoma pT1c TNM Finding v8 | Pancreatic Carcinoma pT1c TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522407","Exocrine Pancreatic Cancer pT1b TNM Finding v8","C134891","Pancreatic cancer with tumor measuring more than 0.5 cm and less than 1 cm in greatest dimension. (from AJCC 8th Ed.)","Pancreatic Cancer pT1b TNM Finding v8 | Exocrine Pancreatic Cancer pT1b TNM Finding v8 | Exocrine Pancreatic Carcinoma pT1b TNM Finding v8 | Pancreatic Carcinoma pT1b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522406","Exocrine Pancreatic Cancer pT1a TNM Finding v8","C134890","Pancreatic cancer with tumor measuring 0.5 cm or less in greatest dimension. (from AJCC 8th Ed.)","Pancreatic Cancer pT1a TNM Finding v8 | Exocrine Pancreatic Cancer pT1a TNM Finding v8 | Exocrine Pancreatic Carcinoma pT1a TNM Finding v8 | Pancreatic Carcinoma pT1a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522405","Exocrine Pancreatic Cancer pT1 TNM Finding v8","C134889","Pancreatic cancer with tumor measuring 2 cm or less in greatest dimension. (from AJCC 8th Ed.)","Pancreatic Cancer pT1 TNM Finding v8 | Exocrine Pancreatic Cancer pT1 TNM Finding v8 | Exocrine Pancreatic Carcinoma pT1 TNM Finding v8 | Pancreatic Carcinoma pT1 TNM Finding v8 | pT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541266","Drowsiness Visual Analogue Scale","C141545","A scale of drowsiness from 0 to 10 on which the patient marks the current level of drowsiness experienced.","Drowsiness Visual Analogue Scale | Drowsiness | Visual Analogue Drowsiness Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522404","Exocrine Pancreatic Cancer pTis TNM Finding v8","C134888","Pancreatic cancer with a finding of carcinoma in situ. This includes high-grade pancreatic intraepithelial neoplasia (PanIn-3), intraductal papillary mucinous neoplasm with high-grade dysplasia, intraductal tubulopapillary neoplasm with high-grade dysplasia, and mucinous cystic neoplasm with high-grade dysplasia. (from AJCC 8th Ed.)","Pancreatic Cancer pTis TNM Finding v8 | Exocrine Pancreatic Cancer pTis TNM Finding v8 | Exocrine Pancreatic Carcinoma pTis TNM Finding v8 | Pancreatic Carcinoma pTis TNM Finding v8 | pTis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522403","Exocrine Pancreatic Cancer pT0 TNM Finding v8","C134887","Pancreatic cancer with no evidence of primary tumor. (from AJCC 8th Ed.)","Pancreatic Cancer pT0 TNM Finding v8 | Exocrine Pancreatic Cancer pT0 TNM Finding v8 | Exocrine Pancreatic Carcinoma pT0 TNM Finding v8 | Pancreatic Carcinoma pT0 TNM Finding v8 | pT0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522402","Exocrine Pancreatic Cancer pTX TNM Finding v8","C134886","Pancreatic cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Pancreatic Cancer pTX TNM Finding v8 | Exocrine Pancreatic Cancer pTX TNM Finding v8 | Exocrine Pancreatic Carcinoma pTX TNM Finding v8 | Pancreatic Carcinoma pTX TNM Finding v8 | pTX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539641","Drowsiness Score 0","C141546","A subjective score of 0 on a drowsiness scale that ranges from 0: No Drowsiness to 10: Worst Possible Drowsiness.","Drowsiness Score 0 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539640","Drowsiness Score 1","C141547","A subjective score of 1 on a drowsiness scale that ranges from 0: No Drowsiness to 10: Worst Possible Drowsiness.","Drowsiness Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539639","Drowsiness Score 2","C141548","A subjective score of 2 on a drowsiness scale that ranges from 0: No Drowsiness to 10: Worst Possible Drowsiness.","Drowsiness Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522412","Exocrine Pancreatic Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C134896","A pathologic finding about one or more characteristics of pancreatic cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Pancreatic Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | Exocrine Pancreatic Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | Exocrine Pancreatic Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8 | Pancreatic Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8 | Pathologic Staging: Regional Lymph Nodes (pN)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522416","Exocrine Pancreatic Cancer pN2 TNM Finding v8","C134900","Pancreatic cancer with metastasis in four or more regional lymph nodes. (from AJCC 8th Ed.)","Pancreatic Cancer pN2 TNM Finding v8 | Exocrine Pancreatic Cancer pN2 TNM Finding v8 | Exocrine Pancreatic Carcinoma pN2 TNM Finding v8 | Pancreatic Carcinoma pN2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522415","Exocrine Pancreatic Cancer pN1 TNM Finding v8","C134899","Pancreatic cancer with metastasis in one to three regional lymph nodes. (from AJCC 8th Ed.)","Pancreatic Cancer pN1 TNM Finding v8 | Exocrine Pancreatic Cancer pN1 TNM Finding v8 | Exocrine Pancreatic Carcinoma pN1 TNM Finding v8 | Pancreatic Carcinoma pN1 TNM Finding v8 | pN1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522414","Exocrine Pancreatic Cancer pN0 TNM Finding v8","C134898","Pancreatic cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","Pancreatic Cancer pN0 TNM Finding v8 | Exocrine Pancreatic Cancer pN0 TNM Finding v8 | Exocrine Pancreatic Carcinoma pN0 TNM Finding v8 | Pancreatic Carcinoma pN0 TNM Finding v8 | pN0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522413","Exocrine Pancreatic Cancer pNX TNM Finding v8","C134897","Pancreatic cancer in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)","Pancreatic Cancer pNX TNM Finding v8 | Exocrine Pancreatic Cancer pNX TNM Finding v8 | Exocrine Pancreatic Carcinoma pNX TNM Finding v8 | Pancreatic Carcinoma pNX TNM Finding v8 | pNX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539652","Drowsiness Score 3","C141549","A subjective score of 3 on a drowsiness scale that ranges from 0: No Drowsiness to 10: Worst Possible Drowsiness.","Drowsiness Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539651","Drowsiness Score 4","C141550","A subjective score of 4 on a drowsiness scale that ranges from 0: No Drowsiness to 10: Worst Possible Drowsiness.","Drowsiness Score 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539650","Drowsiness Score 5","C141552","A subjective score of 5 on a drowsiness scale that ranges from 0: No Drowsiness to 10: Worst Possible Drowsiness.","Drowsiness Score 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539649","Drowsiness Score 6","C141553","A subjective score of 6 on a drowsiness scale that ranges from 0: No Drowsiness to 10: Worst Possible Drowsiness.","Drowsiness Score 6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539648","Drowsiness Score 7","C141554","A subjective score of 7 on a drowsiness scale that ranges from 0: No Drowsiness to 10: Worst Possible Drowsiness.","Drowsiness Score 7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539647","Drowsiness Score 8","C141555","A subjective score of 8 on a drowsiness scale that ranges from 0: No Drowsiness to 10: Worst Possible Drowsiness.","Drowsiness Score 8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539646","Drowsiness Score 9","C141556","A subjective score of 9 on a drowsiness scale that ranges from 0: No Drowsiness to 10: Worst Possible Drowsiness.","Drowsiness Score 9 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522400","Exocrine Pancreatic Cancer pM1 TNM Finding v8","C134884","Pancreatic cancer with distant metastasis. (from AJCC 8th Ed.)","Pancreatic Cancer pM1 TNM Finding v8 | Exocrine Pancreatic Cancer pM1 TNM Finding v8 | Exocrine Pancreatic Carcinoma pM1 TNM Finding v8 | Pancreatic Carcinoma pM1 TNM Finding v8 | pM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539630","Drowsiness Score 10","C141557","A subjective score of 10 on a drowsiness scale that ranges from 0: No Drowsiness to 10: Worst Possible Drowsiness.","Drowsiness Score 10 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541314","Feel Nausea","C141558","A question about whether an individual feels or felt nausea.","Feel Nausea | Nausea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539629","Nausea Visual Analogue Scale","C141559","A nausea scale from 0 to 10 on which the patient marks the current level of nausea experienced.","Nausea Visual Analogue Scale | Nausea | Visual Analogue Nausea Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522395","Exocrine Pancreatic Cancer Clinical Distant Metastasis TNM Finding v8","C134879","A clinical finding about one or more characteristics of pancreatic cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Pancreatic Cancer Clinical Distant Metastasis TNM Finding v8 | Clinical Staging: Distant Metastasis (cM) | Exocrine Pancreatic Cancer Clinical Distant Metastasis TNM Finding v8 | Exocrine Pancreatic Carcinoma Clinical Distant Metastasis TNM Finding v8 | Pancreatic Carcinoma Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522397","Exocrine Pancreatic Cancer cM1 TNM Finding v8","C134881","Pancreatic cancer with distant metastasis. (from AJCC 8th Ed.)","Pancreatic Cancer cM1 TNM Finding v8 | Exocrine Pancreatic Cancer cM1 TNM Finding v8 | Exocrine Pancreatic Carcinoma cM1 TNM Finding v8 | Pancreatic Carcinoma cM1 TNM Finding v8 | cM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522396","Exocrine Pancreatic Cancer cM0 TNM Finding v8","C134880","Pancreatic cancer without evidence of distant metastasis. (from AJCC 8th Ed.)","Pancreatic Cancer cM0 TNM Finding v8 | Exocrine Pancreatic Cancer cM0 TNM Finding v8 | Exocrine Pancreatic Carcinoma cM0 TNM Finding v8 | Pancreatic Carcinoma cM0 TNM Finding v8 | cM0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522425","Pancreatic Cancer by AJCC v8 Stage","C134909","A term that refers to the staging of pancreatic cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to pancreatic ductal adenocarcinoma, acinar cell carcinoma, intraductal papillary mucinous neoplasm with associated invasive carcinoma, intraductal tubulopapillary neoplasm with associated invasive carcinoma, colloid carcinoma, mucinous cystic neoplasm with associated invasive carcinoma, solid pseudopapillary neoplasm, large cell neuroendocrine carcinoma, small cell neuroendocrine carcinoma, and pancreatoblastoma. Well-differentiated neuroendocrine tumors are not staged using this staging system. (from AJCC 8th Ed.)","Pancreatic Cancer by AJCC v8 Stage | Exocrine Pancreatic Cancer by AJCC v8 Stage | Exocrine Pancreatic Carcinoma by AJCC v8 Stage | Pancreatic Carcinoma by AJCC v8 Stage | Tumor Stage (Pathological)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522445","Stage IV Pancreatic Cancer AJCC v8","C134930","Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Pancreatic Cancer AJCC v8 | Stage IV | Stage IV Exocrine Pancreatic Cancer AJCC v8 | Stage IV Exocrine Pancreatic Carcinoma AJCC v8 | Stage IV Pancreatic Cancer | Stage IV Pancreatic Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522443","Stage III Pancreatic Cancer AJCC v8","C134928","Stage III includes: (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4, Any N, M0). T1: Tumor measuring 2 cm or less in greatest dimension. T2: Tumor measuring more than 2 cm and 4 cm or less in greatest dimension. T3: Tumor measuring more than 4 cm in greatest dimension. T4: Tumor involving the celiac axis, superior mesenteric artery, and/or common hepatic artery, regardless of size. N2: Metastasis in four or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Pancreatic Cancer AJCC v8 | Stage III | Stage III Exocrine Pancreatic Cancer AJCC v8 | Stage III Exocrine Pancreatic Carcinoma AJCC v8 | Stage III Pancreatic Cancer | Stage III Pancreatic Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522442","Stage IIB Pancreatic Cancer AJCC v8","C134927","Stage IIB includes: (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T1: Tumor measuring 2 cm or less in greatest dimension. T2: Tumor measuring more than 2 cm and 4 cm or less in greatest dimension. T3: Tumor measuring more than 4 cm in greatest dimension. N1: Metastasis in one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIB Pancreatic Cancer AJCC v8 | Stage IIB | Stage IIB Exocrine Pancreatic Cancer AJCC v8 | Stage IIB Exocrine Pancreatic Carcinoma AJCC v8 | Stage IIB Pancreatic Cancer | Stage IIB Pancreatic Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522440","Stage IIA Pancreatic Cancer AJCC v8","C134925","Stage IIA includes: T3, N0, M0. T3: Tumor measuring more than 4 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIA Pancreatic Cancer AJCC v8 | Stage IIA | Stage IIA Exocrine Pancreatic Cancer AJCC v8 | Stage IIA Exocrine Pancreatic Carcinoma AJCC v8 | Stage IIA Pancreatic Cancer | Stage IIA Pancreatic Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522436","Stage II Pancreatic Cancer AJCC v8","C134921","Stage II includes: IIA: (T3, N0, M0); IIB: (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T1: Tumor measuring 2 cm or less in greatest dimension. T2: Tumor measuring more than 2 cm and 4 cm or less in greatest dimension. T3: Tumor measuring more than 4 cm in greatest dimension. N0: No regional lymph node metastasis. N1: Metastasis in one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Pancreatic Cancer AJCC v8 | Stage II Exocrine Pancreatic Cancer AJCC v8 | Stage II Exocrine Pancreatic Carcinoma AJCC v8 | Stage II Pancreatic Cancer | Stage II Pancreatic Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522435","Stage IB Pancreatic Cancer AJCC v8","C134920","Stage IB includes: T2, N0, M0. T2: Tumor measuring more than 2 cm and 4 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IB Pancreatic Cancer AJCC v8 | Stage IB | Stage IB Exocrine Pancreatic Cancer AJCC v8 | Stage IB Exocrine Pancreatic Carcinoma AJCC v8 | Stage IB Pancreatic Cancer | Stage IB Pancreatic Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522432","Stage IA Pancreatic Cancer AJCC v8","C134917","Stage IA includes: T1, N0, M0. T1: Tumor measuring 2 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IA Pancreatic Cancer AJCC v8 | Stage IA | Stage IA Exocrine Pancreatic Cancer AJCC v8 | Stage IA Exocrine Pancreatic Carcinoma AJCC v8 | Stage IA Pancreatic Cancer | Stage IA Pancreatic Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522430","Stage I Pancreatic Cancer AJCC v8","C134915","Stage I includes: IA: (T1, N0, M0); IB: (T2, N0, M0). T1: Tumor measuring 2 cm or less in greatest dimension. T2: Tumor measuring more than 2 cm and 4 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Pancreatic Cancer AJCC v8 | Stage I Exocrine Pancreatic Cancer AJCC v8 | Stage I Exocrine Pancreatic Carcinoma AJCC v8 | Stage I Pancreatic Cancer | Stage I Pancreatic Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522429","Stage 0 Pancreatic Cancer AJCC v8","C134914","Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. This includes high-grade pancreatic intraepithelial neoplasia (PanIn-3), intraductal papillary mucinous neoplasm with high-grade dysplasia, intraductal tubulopapillary neoplasm with high-grade dysplasia, and mucinous cystic neoplasm with high-grade dysplasia.  N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0 Pancreatic Cancer AJCC v8 | Stage 0 Exocrine Pancreatic Cancer AJCC v8 | Stage 0 Exocrine Pancreatic Carcinoma AJCC v8 | Stage 0 Pancreatic Cancer | Stage 0 Pancreatic Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538289","Prostate Cancer Clinical Distant Metastasis TNM Finding v8","C140121","A clinical finding about one or more characteristics of prostate cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Prostate Cancer Clinical Distant Metastasis TNM Finding v8 | Clinical Distant Metastasis Status (cM) | Prostate Carcinoma Clinical Distant Metastasis TNM Finding v8 | Staging-M",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538252","Prostate Cancer cT4 TNM Finding v8","C140143","Prostate cancer in which the tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall. (from AJCC 8th Ed.)","Prostate Cancer cT4 TNM Finding v8 | Prostate Carcinoma cT4 TNM Finding v8 | T4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538253","Prostate Cancer cT3b TNM Finding v8","C140142","Prostate cancer in which the tumor invades seminal vesicle(s). (from AJCC 8th Ed.)","Prostate Cancer cT3b TNM Finding v8 | Prostate Carcinoma cT3b TNM Finding v8 | T3b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538254","Prostate Cancer cT3a TNM Finding v8","C140141","Prostate cancer with extraprostatic extension (unilateral or bilateral). (from AJCC 8th Ed.)","Prostate Cancer cT3a TNM Finding v8 | Prostate Carcinoma cT3a TNM Finding v8 | T3a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538256","Prostate Cancer cT3 TNM Finding v8","C140139","Prostate cancer with extraprostatic tumor that is not fixed or does not invade adjacent structures. (from AJCC 8th Ed.)","Prostate Cancer cT3 TNM Finding v8 | Prostate Carcinoma cT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538257","Prostate Cancer cT2c TNM Finding v8","C140138","Prostate cancer in which the tumor involves both sides. (from AJCC 8th Ed.)","Prostate Cancer cT2c TNM Finding v8 | Prostate Carcinoma cT2c TNM Finding v8 | T2c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538274","Prostate Cancer cT2b TNM Finding v8","C140137","Prostate cancer in which the tumor involves more than one-half of one side but not both sides. (from AJCC 8th Ed.)","Prostate Cancer cT2b TNM Finding v8 | Prostate Carcinoma cT2b TNM Finding v8 | T2b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538276","Prostate Cancer cT2a TNM Finding v8","C140135","Prostate cancer in which the tumor involves one-half of one side or less. (from AJCC 8th Ed.)","Prostate Cancer cT2a TNM Finding v8 | Prostate Carcinoma cT2a TNM Finding v8 | T2a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538277","Prostate Cancer cT2 TNM Finding v8","C140134","Prostate cancer in which the tumor is palpable and confined within the prostate. (from AJCC 8th Ed.)","Prostate Cancer cT2 TNM Finding v8 | Prostate Carcinoma cT2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538278","Prostate Cancer cT1c TNM Finding v8","C140133","Prostate cancer in which the tumor is identified by needle biopsy found in one or both sides, but not palpable. (from AJCC 8th Ed.)","Prostate Cancer cT1c TNM Finding v8 | Prostate Carcinoma cT1c TNM Finding v8 | T1c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538280","Prostate Cancer cT1a TNM Finding v8","C140131","Prostate cancer in which the tumor is an incidental histologic finding in 5% or less of tissue resected. (from AJCC 8th Ed.)","Prostate Cancer cT1a TNM Finding v8 | Prostate Carcinoma cT1a TNM Finding v8 | T1a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538281","Prostate Cancer cT1 TNM Finding v8","C140130","Prostate cancer with clinically inapparent tumor that is not palpable. (from AJCC 8th Ed.)","Prostate Cancer cT1 TNM Finding v8 | Prostate Carcinoma cT1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538266","Prostate Cancer cT0 TNM Finding v8","C140129","Prostate cancer with no evidence of primary tumor. (from AJCC 8th Ed.)","Prostate Cancer cT0 TNM Finding v8 | Prostate Carcinoma cT0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538267","Prostate Cancer cTX TNM Finding v8","C140128","Prostate cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Prostate Cancer cTX TNM Finding v8 | Prostate Carcinoma cTX TNM Finding v8 | Tx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538269","Prostate Cancer cM1c TNM Finding v8","C140126","Prostate cancer with metastasis to other site(s) with or without bone disease. (from AJCC 8th Ed.)","Prostate Cancer cM1c TNM Finding v8 | M1c | Prostate Carcinoma cM1c TNM Finding v8 | cM1c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538270","Prostate Cancer cM1b TNM Finding v8","C140125","Prostate cancer with metastasis to bone(s). (from AJCC 8th Ed.)","Prostate Cancer cM1b TNM Finding v8 | M1b | Prostate Carcinoma cM1b TNM Finding v8 | cM1b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538271","Prostate Cancer cM1a TNM Finding v8","C140124","Prostate cancer with metastasis to nonregional lymph node(s). (from AJCC 8th Ed.)","Prostate Cancer cM1a TNM Finding v8 | M1a | Prostate Carcinoma cM1a TNM Finding v8 | cM1a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538272","Prostate Cancer cM1 TNM Finding v8","C140123","Prostate cancer with distant metastasis. (from AJCC 8th Ed.)","Prostate Cancer cM1 TNM Finding v8 | Prostate Carcinoma cM1 TNM Finding v8 | cM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538273","Prostate Cancer cM0 TNM Finding v8","C140122","Prostate cancer without evidence of distant metastasis. (from AJCC 8th Ed.)","Prostate Cancer cM0 TNM Finding v8 | M0 | Prostate Carcinoma cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538265","Prostate Cancer Pathologic Distant Metastasis TNM Finding v8","C140146","A pathologic finding about one or more characteristics of prostate cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Prostate Cancer Pathologic Distant Metastasis TNM Finding v8 | Pathologic Distant Metastasis Status (pM) | Prostate Carcinoma Pathologic Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538239","Prostate Cancer pT4 TNM Finding v8","C140156","Prostate cancer in which the tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall. (from AJCC 8th Ed.)","Prostate Cancer pT4 TNM Finding v8 | Prostate Carcinoma pT4 TNM Finding v8 | pT4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538240","Prostate Cancer pT3b TNM Finding v8","C140155","Prostate cancer with tumor invading seminal vesicle(s). (from AJCC 8th Ed.)","Prostate Cancer pT3b TNM Finding v8 | Prostate Carcinoma pT3b TNM Finding v8 | pT3b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538241","Prostate Cancer pT3a TNM Finding v8","C140154","Prostate cancer with extraprostatic extension (unilateral or bilateral) or microscopic invasion of bladder neck. (from AJCC 8th Ed.)","Prostate Cancer pT3a TNM Finding v8 | Prostate Carcinoma pT3a TNM Finding v8 | pT3a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538258","Prostate Cancer pT3 TNM Finding v8","C140153","Prostate cancer with extraprostatic extension. (from AJCC 8th Ed.)","Prostate Cancer pT3 TNM Finding v8 | Prostate Carcinoma pT3 TNM Finding v8 | pT3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538259","Prostate Cancer pT2 TNM Finding v8","C140152","Prostate cancer which is organ confined. (from AJCC 8th Ed.)","Prostate Cancer pT2 TNM Finding v8 | Prostate Carcinoma pT2 TNM Finding v8 | pT2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538238","Prostate Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C140157","A pathologic finding about one or more characteristics of prostate cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Prostate Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | Pathologic Regional Lymph Node Status (pN) | Prostate Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8 | Staging-N",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538261","Prostate Cancer pM1c TNM Finding v8","C140150","Prostate cancer with metastasis to other site(s) with or without bone disease. (from AJCC 8th Ed.)","Prostate Cancer pM1c TNM Finding v8 | Prostate Carcinoma pM1c TNM Finding v8 | pM1c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538262","Prostate Cancer pM1b TNM Finding v8","C140149","Prostate cancer with metastasis to bone(s). (from AJCC 8th Ed.)","Prostate Cancer pM1b TNM Finding v8 | Prostate Carcinoma pM1b TNM Finding v8 | pM1b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538263","Prostate Cancer pM1a TNM Finding v8","C140148","Prostate cancer with metastasis to nonregional lymph node(s). (from AJCC 8th Ed.)","Prostate Cancer pM1a TNM Finding v8 | Prostate Carcinoma pM1a TNM Finding v8 | pM1a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538264","Prostate Cancer pM1 TNM Finding v8","C140147","Prostate cancer with distant metastasis. (from AJCC 8th Ed.)","Prostate Cancer pM1 TNM Finding v8 | Prostate Carcinoma pM1 TNM Finding v8 | pM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538248","Prostate Cancer by AJCC v8 Stage","C140163","A term that refers to the staging of prostate cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to adenocarcinomas and squamous cell carcinomas of the prostate gland. It does not apply to sarcomas, urothelial cell carcinomas, and urothelial carcinoma of bladder involving prostate. (from AJCC 8th Ed.)","Prostate Cancer by AJCC v8 Stage | Prostate Carcinoma by AJCC v8 Stage | Tumor Stage (Pathologic)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538345","Stage IVB Prostate Cancer AJCC v8","C140175","Stage IVB includes: Any T, N0, M1, PSA: Any, Grade Group: Any. N0: Prostate cancer with no positive regional nodes. M1: Prostate cancer with distant metastasis. (AJCC 8th ed.)","Stage IVB Prostate Cancer AJCC v8 | IVB | Stage IVB Prostate Cancer | Stage IVB Prostate Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538346","Stage IVA Prostate Cancer AJCC v8","C140174","Stage IVA includes: Any T, N1, M0, PSA: Any, Grade Group: Any. N1: Prostate cancer with metastases in regional node(s). M0: Prostate cancer without evidence of distant metastasis. (AJCC 8th ed.)","Stage IVA Prostate Cancer AJCC v8 | IVA | Stage IVA Prostate Cancer | Stage IVA Prostate Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538347","Stage IV Prostate Cancer AJCC v8","C140173","Stage IV includes: IVA: Any T, N1, M0, PSA: Any, Grade Group: Any; IVB: Any T, N0, M1, PSA: Any, Grade Group: Any. N0: Prostate cancer with no positive regional nodes. N1: Prostate cancer with metastases in regional node(s). M0: Prostate cancer without evidence of distant metastasis. M1: Prostate cancer with distant metastasis. (AJCC 8th ed.)","Stage IV Prostate Cancer AJCC v8 | Stage IV Prostate Cancer | Stage IV Prostate Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538348","Stage IIIC Prostate Cancer AJCC v8","C140172","Stage IIIC includes: Any T, N0, M0, PSA: Any, Grade Group 5. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 5: Gleason Score 9 or 10, Gleason Pattern 4+5, or 5+4, or 5+5. (AJCC 8th ed.)","Stage IIIC Prostate Cancer AJCC v8 | IIIC | Stage IIIC Prostate Cancer | Stage IIIC Prostate Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538349","Stage IIIB Prostate Cancer AJCC v8","C140171","Stage IIIB includes: T3-4, N0, M0, PSA: Any, Grade Group 1-4; T3: Prostate cancer with extraprostatic tumor that is not fixed or does not invade adjacent structures. T4: Prostate cancer in which the tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 1: Gleason Score 6 or less, Gleason Pattern 3 or less+3. Grade Group 2: Gleason Score 7, Gleason Pattern 3+4. Grade Group 3: Gleason Score 7, Gleason Pattern 4+3. Grade Group 4: Gleason Score 8, Gleason Pattern 4+4. (AJCC 8th ed.)","Stage IIIB Prostate Cancer AJCC v8 | IIIB | Stage IIIB Prostate Cancer | Stage IIIB Prostate Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538350","Stage IIIA Prostate Cancer AJCC v8","C140170","Stage IIIA includes: T1-2, N0, M0, PSA 20 or more, Grade Group 1-4; T1: Prostate cancer with clinically inapparent tumor that is not palpable. T2: Prostate cancer in which the tumor is palpable and confined within the prostate. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 1: Gleason Score 6 or less, Gleason Pattern 3 or less+3. Grade Group 2: Gleason Score 7, Gleason Pattern 3+4. Grade Group 3: Gleason Score 7, Gleason Pattern 4+3. Grade Group 4: Gleason Score 8, Gleason Pattern 4+4. (AJCC 8th ed.)","Stage IIIA Prostate Cancer AJCC v8 | IIIA | Stage IIIA Prostate Cancer | Stage IIIA Prostate Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538242","Stage III Prostate Cancer AJCC v8","C140169","Stage III includes: IIIA: T1-2, N0, M0, PSA 20 or more, Grade Group 1-4; IIIB: T3-4, N0, M0, PSA: Any, Grade Group 1-4; IIIC: Any T, N0, M0, PSA: Any, Grade Group 5. T1: Prostate cancer with clinically inapparent tumor that is not palpable. T2: Prostate cancer in which the tumor is palpable and confined within the prostate. T3: Prostate cancer with extraprostatic tumor that is not fixed or does not invade adjacent structures. T4: Prostate cancer in which the tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 1: Gleason Score 6 or less, Gleason Pattern 3 or less+3. Grade Group 2: Gleason Score 7, Gleason Pattern 3+4. Grade Group 3: Gleason Score 7, Gleason Pattern 4+3. Grade Group 4: Gleason Score 8, Gleason Pattern 4+4. Grade Group 5: Gleason Score 9 or 10, Gleason Pattern 4+5, or 5+4, or 5+5. (AJCC 8th ed.)","Stage III Prostate Cancer AJCC v8 | Stage III Prostate Cancer | Stage III Prostate Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538243","Stage IIC Prostate Cancer AJCC v8","C140168","Stage IIC includes: (T1-2, N0, M0, PSA less than 20, Grade Group 3); (T1-2, N0, M0, PSA less than 20, Grade Group 4). T1: Prostate cancer with clinically inapparent tumor that is not palpable. T2: Prostate cancer in which the tumor is palpable and confined within the prostate. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 3: Gleason Score 7, Gleason Pattern 4+3. Grade Group 4: Gleason Score 8, Gleason Pattern 4+4. (AJCC 8th ed.)","Stage IIC Prostate Cancer AJCC v8 | IIC | Stage IIC Prostate Cancer | Stage IIC Prostate Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538244","Stage IIB Prostate Cancer AJCC v8","C140167","Stage IIB includes: T1-2, N0, M0, PSA less than 20, Grade Group 2. T1: Prostate cancer with clinically inapparent tumor that is not palpable. T2: Prostate cancer in which the tumor is palpable and confined within the prostate. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 2: Gleason Score 7, Gleason Pattern 3+4. (AJCC 8th ed.)","Stage IIB Prostate Cancer AJCC v8 | IIB | Stage IIB Prostate Cancer | Stage IIB Prostate Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538245","Stage IIA Prostate Cancer AJCC v8","C140166","Stage IIA includes: (cT1a-c, cT2a, N0, M0, PSA equal or more than 10 and less than 20, Grade Group 1); (cT2b-c, N0, M0, PSA less than 20, Grade Group 1). cT1a: Prostate cancer in which the tumor is an incidental histologic finding in 5% or less of tissue resected. cT1b: Prostate cancer in which the tumor is an incidental histologic finding in more than 5% of tissue resected. cT1c: Prostate cancer in which the tumor is identified by needle biopsy found in one or both sides, but not palpable. cT2a: Prostate cancer in which the tumor involves one-half of one side or less. cT2b: Prostate cancer in which the tumor involves more than one-half of one side but not both sides. cT2c: Prostate cancer in which the tumor involves both sides. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 1: Gleason Score 6 or less, Gleason Pattern 3 or less+3. (AJCC 8th ed.)","Stage IIA Prostate Cancer AJCC v8 | IIA | Stage IIA Prostate Cancer | Stage IIA Prostate Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538246","Stage II Prostate Cancer AJCC v8","C140165","Stage II includes: IIA: (cT1a-c, cT2a, N0, M0, PSA equal or more than 10 and less than 20, Grade Group 1); (cT2b-c, N0, M0, PSA less than 20, Grade Group 1); IIB: T1-2, N0, M0, PSA less than 20, Grade Group 2; IIC: (T1-2, N0, M0, PSA less than 20, Grade Group 3); (T1-2, N0, M0, PSA less than 20, Grade Group 4). cT1a: Prostate cancer in which the tumor is an incidental histologic finding in 5% or less of tissue resected. cT1b: Prostate cancer in which the tumor is an incidental histologic finding in more than 5% of tissue resected. cT1c: Prostate cancer in which the tumor is identified by needle biopsy found in one or both sides, but not palpable. cT2a: Prostate cancer in which the tumor involves one-half of one side or less. cT2b: Prostate cancer in which the tumor involves more than one-half of one side but not both sides. cT2c: Prostate cancer in which the tumor involves both sides. T1: Prostate cancer with clinically inapparent tumor that is not palpable. T2: Prostate cancer in which the tumor is palpable and confined within the prostate. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 1: Gleason Score 6 or less, Gleason Pattern 3 or less+3. Grade Group 2: Gleason Score 7, Gleason Pattern 3+4. Grade Group 3: Gleason Score 7, Gleason Pattern 4+3. Grade Group 4: Gleason Score 8, Gleason Pattern 4+4. (AJCC 8th ed.)","Stage II Prostate Cancer AJCC v8 | Stage II Prostate Cancer | Stage II Prostate Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538247","Stage I Prostate Cancer AJCC v8","C140164","Stage I includes: (cT1a-c, cT2a, N0, M0, PSA less than 10, Grade Group 1); (pT2, N0, M0, PSA less than 10, Grade Group 1). cT1a: Prostate cancer in which the tumor is an incidental histologic finding in 5% or less of tissue resected. cT1b: Prostate cancer in which the tumor is an incidental histologic finding in more than 5% of tissue resected. cT1c: Prostate cancer in which the tumor is identified by needle biopsy found in one or both sides, but not palpable. cT2a: Prostate cancer in which the tumor involves one-half of one side or less. pT2: Prostate cancer which is organ confined. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 1: Gleason Score 6 or less, Gleason Pattern 3 or less+3. (AJCC 8th ed.)","Stage I Prostate Cancer AJCC v8 | I | Stage I Prostate Cancer | Stage I Prostate Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539628","DART Nausea Score 0","C141560","A subjective score of 0 on a nausea scale that ranges from 0: No Nausea to 10: Worst Possible Nausea.","DART Nausea Score 0 | Nausea Score 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539627","DART Nausea Score 1","C141561","A subjective score of 1 on a nausea scale that ranges from 0: No Nausea to 10: Worst Possible Nausea.","DART Nausea Score 1 | Nausea Score 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539626","DART Nausea Score 2","C141562","A subjective score of 2 on a nausea scale that ranges from 0: No Nausea to 10: Worst Possible Nausea.","DART Nausea Score 2 | Nausea Score 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539625","DART Nausea Score 3","C141563","A subjective score of 3 on a nausea scale that ranges from 0: No Nausea to 10: Worst Possible Nausea.","DART Nausea Score 3 | Nausea Score 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539624","DART Nausea Score 4","C141564","A subjective score of 4 on a nausea scale that ranges from 0: No Nausea to 10: Worst Possible Nausea.","DART Nausea Score 4 | Nausea Score 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539638","DART Nausea Score 5","C141565","A subjective score of 5 on a nausea scale that ranges from 0: No Nausea to 10: Worst Possible Nausea.","DART Nausea Score 5 | Nausea Score 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539637","DART Nausea Score 6","C141566","A subjective score of 6 on a nausea scale that ranges from 0: No Nausea to 10: Worst Possible Nausea.","DART Nausea Score 6 | Nausea Score 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539636","DART Nausea Score 7","C141567","A subjective score of 7 on a nausea scale that ranges from 0: No Nausea to 10: Worst Possible Nausea.","DART Nausea Score 7 | Nausea Score 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539635","DART Nausea Score 8","C141568","A subjective score of 8 on a nausea scale that ranges from 0: No Nausea to 10: Worst Possible Nausea.","DART Nausea Score 8 | Nausea Score 8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539634","DART Nausea Score 9","C141569","A subjective score of 9 on a nausea scale that ranges from 0: No Nausea to 10: Worst Possible Nausea.","DART Nausea Score 9 | Nausea Score 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539633","DART Nausea Score 10","C141570","A subjective score of 10 on a nausea scale that ranges from 0: No Nausea to 10: Worst Possible Nausea.","DART Nausea Score 10 | Nausea Score 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539632","Lack of Appetite Visual Analogue Scale","C141571","A lack of appetite scale from 0 to 10 on which the patient marks the current level of lack of appetite experienced.","Lack of Appetite Visual Analogue Scale | Lack of Appetite | Visual Analogue Lack of Appetite Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539631","Lack of Appetite Score 0","C141572","A subjective score of 0 on an appetite scale that ranges from 0: No Lack of Appetite to 10: Worst Possible Lack of Appetite.","Lack of Appetite Score 0 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539616","Lack of Appetite Score 1","C141573","A subjective score of 1 on an appetite scale that ranges from 0: No Lack of Appetite to 10: Worst Possible Lack of Appetite.","Lack of Appetite Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539615","Lack of Appetite Score 2","C141574","A subjective score of 2 on an appetite scale that ranges from 0: No Lack of Appetite to 10: Worst Possible Lack of Appetite.","Lack of Appetite Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539614","Lack of Appetite Score 3","C141575","A subjective score of 3 on an appetite scale that ranges from 0: No Lack of Appetite to 10: Worst Possible Lack of Appetite.","Lack of Appetite Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539613","Lack of Appetite Score 4","C141576","A subjective score of 4 on an appetite scale that ranges from 0: No Lack of Appetite to 10: Worst Possible Lack of Appetite.","Lack of Appetite Score 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539612","Lack of Appetite Score 5","C141577","A subjective score of 5 on an appetite scale that ranges from 0: No Lack of Appetite to 10: Worst Possible Lack of Appetite.","Lack of Appetite Score 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539611","Lack of Appetite Score 6","C141578","A subjective score of 6 on an appetite scale that ranges from 0: No Lack of Appetite to 10: Worst Possible Lack of Appetite.","Lack of Appetite Score 6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539610","Lack of Appetite Score 7","C141579","A subjective score of 7 on an appetite scale that ranges from 0: No Lack of Appetite to 10: Worst Possible Lack of Appetite.","Lack of Appetite Score 7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539609","Lack of Appetite Score 8","C141580","A subjective score of 8 on an appetite scale that ranges from 0: No Lack of Appetite to 10: Worst Possible Lack of Appetite.","Lack of Appetite Score 8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539623","Lack of Appetite Score 9","C141581","A subjective score of 9 on an appetite scale that ranges from 0: No Lack of Appetite to 10: Worst Possible Lack of Appetite.","Lack of Appetite Score 9 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539622","Lack of Appetite Score 10","C141582","A subjective score of 10 on an appetite scale that ranges from 0: No Lack of Appetite to 10: Worst Possible Lack of Appetite.","Lack of Appetite Score 10 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541317","Shortness of Breath Visual Analogue Scale","C141583","A shortness of breath scale from 0 to 10 on which the patient marks the current level of shortness of breath experienced.","Shortness of Breath Visual Analogue Scale | Shortness of Breath | Visual Analogue Shortness of Breath Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539621","Shortness of Breath Score 0","C141584","A subjective score of 0 on a shortness of breath scale that ranges from 0: No Shortness of Breath to 10: Worst Possible Shortness of Breath.","Shortness of Breath Score 0 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539620","Shortness of Breath Score 1","C141585","A subjective score of 1 on a shortness of breath scale that ranges from 0: No Shortness of Breath to 10: Worst Possible Shortness of Breath.","Shortness of Breath Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539619","Shortness of Breath Score 2","C141586","A subjective score of 2 on a shortness of breath scale that ranges from 0: No Shortness of Breath to 10: Worst Possible Shortness of Breath.","Shortness of Breath Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539618","Shortness of Breath Score 3","C141587","A subjective score of 3 on a shortness of breath scale that ranges from 0: No Shortness of Breath to 10: Worst Possible Shortness of Breath.","Shortness of Breath Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539617","Shortness of Breath Score 4","C141588","A subjective score of 4 on a shortness of breath scale that ranges from 0: No Shortness of Breath to 10: Worst Possible Shortness of Breath.","Shortness of Breath Score 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539600","Shortness of Breath Score 5","C141589","A subjective score of 5 on a shortness of breath scale that ranges from 0: No Shortness of Breath to 10: Worst Possible Shortness of Breath.","Shortness of Breath Score 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539599","Shortness of Breath Score 6","C141590","A subjective score of 6 on a shortness of breath scale that ranges from 0: No Shortness of Breath to 10: Worst Possible Shortness of Breath.","Shortness of Breath Score 6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539598","Shortness of Breath Score 7","C141591","A subjective score of 7 on a shortness of breath scale that ranges from 0: No Shortness of Breath to 10: Worst Possible Shortness of Breath.","Shortness of Breath Score 7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539597","Shortness of Breath Score 8","C141592","A subjective score of 8 on a shortness of breath scale that ranges from 0: No Shortness of Breath to 10: Worst Possible Shortness of Breath.","Shortness of Breath Score 8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539596","Shortness of Breath Score 9","C141593","A subjective score of 9 on a shortness of breath scale that ranges from 0: No Shortness of Breath to 10: Worst Possible Shortness of Breath.","Shortness of Breath Score 9 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539595","Shortness of Breath Score 10","C141594","A subjective score of 10 on a shortness of breath scale that ranges from 0: No Shortness of Breath to 10: Worst Possible Shortness of Breath.","Shortness of Breath Score 10 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541254","Depression Visual Analogue Scale","C141595","A depression scale from 0 to 10 on which the patient marks the current level of depression experienced.","Depression Visual Analogue Scale | Depression | Visual Analogue Depression Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539594","Depression Score 0","C141596","A subjective score of 0 on a depression scale that ranges from 0: No Depression to 10: Worst Possible Depression.","Depression Score 0 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539608","Depression Score 1","C141597","A subjective score of 1 on a depression scale that ranges from 0: No Depression to 10: Worst Possible Depression.","Depression Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539606","Depression Score 3","C141599","A subjective score of 3 on a depression scale that ranges from 0: No Depression to 10: Worst Possible Depression.","Depression Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539605","Depression Score 4","C141600","A subjective score of 4 on a depression scale that ranges from 0: No Depression to 10: Worst Possible Depression.","Depression Score 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539604","Depression Score 5","C141601","A subjective score of 5 on a depression scale that ranges from 0: No Depression to 10: Worst Possible Depression.","Depression Score 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539603","Depression Score 6","C141602","A subjective score of 6 on a depression scale that ranges from 0: No Depression to 10: Worst Possible Depression.","Depression Score 6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539602","Depression Score 7","C141603","A subjective score of 7 on a depression scale that ranges from 0: No Depression to 10: Worst Possible Depression.","Depression Score 7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539601","Depression Score 8","C141604","A subjective score of 8 on a depression scale that ranges from 0: No Depression to 10: Worst Possible Depression.","Depression Score 8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539708","Depression Score 9","C141605","A subjective score of 9 on a depression scale that ranges from 0: No Depression to 10: Worst Possible Depression.","Depression Score 9 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539707","Depression Score 10","C141606","A subjective score of 10 on a depression scale that ranges from 0: No Depression to 10: Worst Possible Depression.","Depression Score 10 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539706","Anxiety Visual Analogue Scale","C141607","An anxiety scale from 0 to 10 on which the patient marks the current level of anxiety experienced.","Anxiety Visual Analogue Scale | Anxiety | Visual Analogue Anxiety Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539705","Anxiety Score 0","C141608","A subjective score of 0 on an anxiety scale that ranges from 0: No Anxiety to 10: Worst Possible Anxiety.","Anxiety Score 0 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539704","Anxiety Score 1","C141609","A subjective score of 1 on an anxiety scale that ranges from 0: No Anxiety to 10: Worst Possible Anxiety.","Anxiety Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539703","Anxiety Score 2","C141610","A subjective score of 2 on an anxiety scale that ranges from 0: No Anxiety to 10: Worst Possible Anxiety.","Anxiety Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539702","Anxiety Score 3","C141611","A subjective score of 3 on an anxiety scale that ranges from 0: No Anxiety to 10: Worst Possible Anxiety.","Anxiety Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539701","Anxiety Score 4","C141612","A subjective score of 4 on an anxiety scale that ranges from 0: No Anxiety to 10: Worst Possible Anxiety.","Anxiety Score 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539716","Anxiety Score 5","C141613","A subjective score of 5 on an anxiety scale that ranges from 0: No Anxiety to 10: Worst Possible Anxiety.","Anxiety Score 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539715","Anxiety Score 6","C141614","A subjective score of 6 on an anxiety scale that ranges from 0: No Anxiety to 10: Worst Possible Anxiety.","Anxiety Score 6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539714","Anxiety Score 7","C141615","A subjective score of 7 on an anxiety scale that ranges from 0: No Anxiety to 10: Worst Possible Anxiety.","Anxiety Score 7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539713","Anxiety Score 8","C141616","A subjective score of 8 on an anxiety scale that ranges from 0: No Anxiety to 10: Worst Possible Anxiety.","Anxiety Score 8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539712","Anxiety Score 9","C141617","A subjective score of 9 on an anxiety scale that ranges from 0: No Anxiety to 10: Worst Possible Anxiety.","Anxiety Score 9 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539711","Anxiety Score 10","C141618","A subjective score of 10 on an anxiety scale that ranges from 0: No Anxiety to 10: Worst Possible Anxiety.","Anxiety Score 10 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539710","Well Being Visual Analogue Scale","C141619","An overall well being scale from 0 to 10 on which the patient marks the current level of well being experienced.","Well Being Visual Analogue Scale | Visual Analogue Well Being Scale | Wellbeing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539709","Well-Being Score 0","C141620","A subjective score of 0 on a well-being scale that ranges from 0: No Well-Being to 10: Worst Possible Well-Being.","Well-Being Score 0 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539692","Well-Being Score 1","C141621","A subjective score of 1 on a well-being scale that ranges from 0: No Well-Being to 10: Worst Possible Well-Being.","Well-Being Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539691","Well-Being Score 2","C141622","A subjective score of 2 on a well-being scale that ranges from 0: No Well-Being to 10: Worst Possible Well-Being.","Well-Being Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539690","Well-Being Score 3","C141623","A subjective score of 3 on a well-being scale that ranges from 0: No Well-Being to 10: Worst Possible Well-Being.","Well-Being Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539689","Well-Being Score 4","C141624","A subjective score of 4 on a well-being scale that ranges from 0: No Well-Being to 10: Worst Possible Well-Being.","Well-Being Score 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539688","Well-Being Score 5","C141625","A subjective score of 5 on a well-being scale that ranges from 0: No Well-Being to 10: Worst Possible Well-Being.","Well-Being Score 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539687","Well-Being Score 6","C141626","A subjective score of 6 on a well-being scale that ranges from 0: No Well-Being to 10: Worst Possible Well-Being.","Well-Being Score 6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539686","Well-Being Score 7","C141627","A subjective score of 7 on a well-being scale that ranges from 0: No Well-Being to 10: Worst Possible Well-Being.","Well-Being Score 7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539685","Well-Being Score 8","C141628","A subjective score of 8 on a well-being scale that ranges from 0: No Well-Being to 10: Worst Possible Well-Being.","Well-Being Score 8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539700","Well-Being Score 9","C141629","A subjective score of 9 on a well-being scale that ranges from 0: No Well-Being to 10: Worst Possible Well-Being.","Well-Being Score 9 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539699","Well-Being Score 10","C141630","A subjective score of 10 on a well-being scale that ranges from 0: No Well-Being to 10: Worst Possible Well-Being.","Well-Being Score 10 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539697","Have Other Problem","C141633","A question about whether an individual has or had another problem not previously mentioned or specified.","Have Other Problem | Other Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539696","Other Problem Visual Analogue Scale","C141634","A scale for reporting another problem, which ranges from 0 to 10, on which the patient marks the current level of the other problem experienced.","Other Problem Visual Analogue Scale | Other Problem | Visual Analogue Other Problem Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539695","Other Problem Score 0","C141635","A subjective score of 0 on a scale that ranges from 0: No Other Problem to 10: Worst Possible Other Problem.","Other Problem Score 0 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539694","Other Problem Score 1","C141636","A subjective score of 1 on a scale that ranges from 0: No Other Problem to 10: Worst Possible Other Problem.","Other Problem Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539693","Other Problem Score 2","C141637","A subjective score of 2 on a scale that ranges from 0: No Other Problem to 10: Worst Possible Other Problem.","Other Problem Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539676","Other Problem Score 3","C141638","A subjective score of 3 on a scale that ranges from 0: No Other Problem to 10: Worst Possible Other Problem.","Other Problem Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539675","Other Problem Score 4","C141639","A subjective score of 4 on a scale that ranges from 0: No Other Problem to 10: Worst Possible Other Problem.","Other Problem Score 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539674","Other Problem Score 5","C141640","A subjective score of 5 on a scale that ranges from 0: No Other Problem to 10: Worst Possible Other Problem.","Other Problem Score 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539673","Other Problem Score 6","C141641","A subjective score of 6 on a scale that ranges from 0: No Other Problem to 10: Worst Possible Other Problem.","Other Problem Score 6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539672","Other Problem Score 7","C141642","A subjective score of 7 on a scale that ranges from 0: No Other Problem to 10: Worst Possible Other Problem.","Other Problem Score 7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539670","Other Problem Score 9","C141644","A subjective score of 9 on a scale that ranges from 0: No Other Problem to 10: Worst Possible Other Problem.","Other Problem Score 9 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539669","Other Problem Score 10","C141645","A subjective score of 10 on a scale that ranges from 0: No Other Problem to 10: Worst Possible Other Problem.","Other Problem Score 10 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539684","Daily Activity Rating Scale","C141646","A scale from 0 to 4 for an individual to rate their perception of their daily activities.","Daily Activity Rating Scale | I would generally rate my activity as (shade one)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539683","Normal Activity with No Limitations","C141647","A response indicating that an individual's activity is normal with no limitations.","Normal Activity with No Limitations | Normal with no limitations | Score 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539682","Not Normal but Fairly Active","C141648","A response indicating that an individual is not their normal self, but able to be up and about with fairly normal activity.","Not Normal but Fairly Active | Not my normal self, but able to be up and about with fairly normal activities | Score 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539681","Not Feeling Well; in Bed or Chair Less than Half Day","C141649","A response indicating that an individual is not feeling up to most things, but in bed or chair less than half the day.","Not Feeling Well; in Bed or Chair Less than Half Day | Not feeling up to most things, but in bed or chair less than half the day | Score 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539680","Little Activity; in Bed or Chair Most of Day","C141650","A response indicating that an individual is able to do little activity and spends most of the day in bed or chair.","Little Activity; in Bed or Chair Most of Day | Able to do little activity and spend most of the day in bed or chair | Score 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539679","Bedridden; Rarely Out of Bed","C141651","A response indicating that an individual is pretty much bedridden, rarely out of bed.","Bedridden; Rarely Out of Bed | Pretty much bedridden, rarely out of bed | Score 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016734","Frontal Sinus","C12277","The paired, mucosal lined air spaces located above the orbit and communicating with the nasal passages.","Frontal Sinus | FRONTAL SINUS | Frontal sinus | Frontal sinus structure (body structure) | Sinus, Frontal | frontal sinus",,,,,,,,,,,,,,,"4204534","Frontal sinus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898635","Laboratory Shipment Record","C115569","Documentation detailing the shipment of a laboratory sample.","Laboratory Shipment Record | Lab Shipmt Record | Laboratory Shipment Records | Shipment Records | Specimen Shipment Records",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522393","Exocrine Pancreatic Cancer TNM Finding v8","C134877","A finding about one or more characteristics of pancreatic cancer, following the rules of the TNM AJCC v8 classification system. This classification applies to pancreatic ductal adenocarcinoma, acinar cell carcinoma, intraductal papillary mucinous neoplasm with associated invasive carcinoma, intraductal tubulopapillary neoplasm with associated invasive carcinoma, colloid carcinoma, mucinous cystic neoplasm with associated invasive carcinoma, solid pseudopapillary neoplasm, large cell neuroendocrine carcinoma, small cell neuroendocrine carcinoma, and pancreatoblastoma. Well-differentiated neuroendocrine tumors are not staged using this staging system. (from AJCC 8th Ed.)","Pancreatic Cancer TNM Finding v8 | Exocrine Pancreatic Cancer TNM Finding v8 | Exocrine Pancreatic Carcinoma TNM Finding v8 | Pancreatic Carcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538291","Prostate Cancer TNM Finding v8","C140119","A finding about one or more characteristics of prostate cancer, following the rules of the TNM AJCC v8 classification system. This classification system applies to adenocarcinomas and squamous cell carcinomas of the prostate gland. It does not apply to sarcomas, urothelial cell carcinomas, and urothelial carcinoma of bladder involving prostate. (from AJCC 8th Ed.)","Prostate Cancer TNM Finding v8 | Prostate Carcinoma TNM Finding v8 | Staging-T Category",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538235","Prostate Cancer pN1 TNM Finding v8","C140160","Prostate cancer with metastases in regional node(s). (from AJCC 8th Ed.)","Prostate Cancer pN1 TNM Finding v8 | N1 | Prostate Carcinoma pN1 TNM Finding v8 | pN1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538236","Prostate Cancer pN0 TNM Finding v8","C140159","Prostate cancer with no positive regional nodes. (from AJCC 8th Ed.)","Prostate Cancer pN0 TNM Finding v8 | N0 | Prostate Carcinoma pN0 TNM Finding v8 | pN0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538237","Prostate Cancer pNX TNM Finding v8","C140158","Prostate cancer in which the regional nodes were not assessed. (from AJCC 8th Ed.)","Prostate Cancer pNX TNM Finding v8 | NX | Prostate Carcinoma pNX TNM Finding v8 | pNX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516604","Clinical Cancer Center","C19725","A cancer center that provides treatment to patients.","Clinical Cancer Center | Clinic/Center Oncology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538517","Bladder Cancer Clinical Distant Metastasis TNM Finding v8","C140382","A clinical finding about one or more characteristics of bladder cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Bladder Cancer Clinical Distant Metastasis TNM Finding v8 | Bladder Carcinoma Clinical Distant Metastasis TNM Finding v8 | Clinical Distant Metastasis Status (cM)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538513","Bladder Cancer cM1b TNM Finding v8","C140386","Bladder cancer with non-lymph node distant metastases. (from AJCC 8th Ed.)","Bladder Cancer cM1b TNM Finding v8 | Bladder Carcinoma cM1b TNM Finding v8 | cM1b (other)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538514","Bladder Cancer cM1a TNM Finding v8","C140385","Bladder cancer with distant metastasis limited to lymph nodes beyond the common iliacs. (from AJCC 8th Ed.)","Bladder Cancer cM1a TNM Finding v8 | Bladder Carcinoma cM1a TNM Finding v8 | cM1a (non-regional lymph nodes)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538515","Bladder Cancer cM1 TNM Finding v8","C140384","Bladder cancer with distant metastasis. (from AJCC 8th Ed.)","Bladder Cancer cM1 TNM Finding v8 | Bladder Carcinoma cM1 TNM Finding v8 | cM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538516","Bladder Cancer cM0 TNM Finding v8","C140383","Bladder cancer without evidence of distant metastasis. (from AJCC 8th Ed.)","Bladder Cancer cM0 TNM Finding v8 | Bladder Carcinoma cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538511","Bladder Cancer Pathologic Distant Metastasis TNM Finding v8","C140388","A pathologic finding about one or more characteristics of bladder cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Bladder Cancer Pathologic Distant Metastasis TNM Finding v8 | Bladder Carcinoma Pathologic Distant Metastasis TNM Finding v8 | Pathologic Distant Metastasis Status (pM)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538524","Bladder Cancer pM1b TNM Finding v8","C140391","Bladder cancer with non-lymph node distant metastases. (from AJCC 8th Ed.)","Bladder Cancer pM1b TNM Finding v8 | Bladder Carcinoma pM1b TNM Finding v8 | pM1b (other)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538525","Bladder Cancer pM1a TNM Finding v8","C140390","Bladder cancer with distant metastasis limited to lymph nodes beyond the common iliacs. (from AJCC 8th Ed.)","Bladder Cancer pM1a TNM Finding v8 | Bladder Carcinoma pM1a TNM Finding v8 | pM1a (non-regional lymph nodes)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538526","Bladder Cancer pM1 TNM Finding v8","C140389","Bladder cancer with distant metastasis. (from AJCC 8th Ed.)","Bladder Cancer pM1 TNM Finding v8 | Bladder Carcinoma pM1 TNM Finding v8 | pM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538483","Bladder Cancer by AJCC v8 Stage","C140416","A term that refers to the staging of bladder cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to carcinomas arising in the bladder. The typical carcinoma of the bladder is urothelial carcinoma. These carcinomas may include other histologic elements, including adenocarcinoma, squamous cell carcinoma, and small cell neuroendocrine carcinoma, but should be classified as urothelial unless the cancer is composed entirely of the alternative histology. All histologic cell types that are derived primarily from the urinary bladder epithelium should follow this staging system. It does not apply to prostatic urothelial carcinomas (are staged according to the classification for urethra), lymphomas (are staged according to the classification for Hodgkin and non-Hodgkin lymphoma), and sarcomas (are staged according to the classification for soft tissue sarcoma of the abdomen and thoracic visceral organs).  (from AJCC 8th Ed.)","Bladder Cancer by AJCC v8 Stage | Bladder Carcinoma by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538489","Stage IVB Bladder Cancer AJCC v8","C140426","Stage IVB includes: Any T, Any N, M1b. M1b: Non-lymph node distant metastases. (AJCC 8th ed.)","Stage IVB Bladder Cancer AJCC v8 | IVB | Stage IVB Bladder Cancer | Stage IVB Bladder Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538490","Stage IVA Bladder Cancer AJCC v8","C140425","Stage IVA includes: (T4b, N0, M0); (Any T, Any N, M1a). T4b: Extravesical tumor invades pelvic wall, abdominal wall. N0: No regional lymph node metastasis. M0: No distant metastasis. M1a: Distant metastasis limited to lymph nodes beyond the common iliacs. (AJCC 8th ed.)","Stage IVA Bladder Cancer AJCC v8 | IVA | Stage IVA Bladder Cancer | Stage IVA Bladder Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538491","Stage IV Bladder Cancer AJCC v8","C140424","Stage IV includes: IVA: (T4b, N0, M0); (Any T, Any N, M1a); IVB: (Any T, Any N, M1b). T4b: Extravesical tumor invades pelvic wall, abdominal wall. N0: No regional lymph node metastasis. M0: No distant metastasis. M1a: Distant metastasis limited to lymph nodes beyond the common iliacs. M1b: Non-lymph node distant metastases. (AJCC 8th ed.)","Stage IV Bladder Cancer AJCC v8 | Stage IV Bladder Cancer | Stage IV Bladder Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538492","Stage IIIB Bladder Cancer AJCC v8","C140423","Stage IIIB includes: T1-T4a, N2, N3, M0. T1: Tumor invades lamina propria (subepithelial connective tissue). T2: Tumor invades muscularis propria. T3: Tumor invades perivesical soft tissue. T4a: Extravesical tumor invades directly into prostatic stroma, uterus, vagina. N2: Multiple regional lymph node metastasis in the true pelvis (perivesical, obturator, internal and external iliac, or sacral lymph node metastasis). N3: Lymph node metastasis to the common iliac lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIB Bladder Cancer AJCC v8 | IIIB | Stage IIIB Bladder Cancer | Stage IIIB Bladder Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538493","Stage IIIA Bladder Cancer AJCC v8","C140422","Stage IIIA includes: (T3a, T3b, T4a, N0, M0); (T1-T4a, N1, M0). T1: Tumor invades lamina propria (subepithelial connective tissue). T2: Tumor invades muscularis propria. T3: Tumor invades perivesical soft tissue. T3a: Tumor invades perivesical soft tissue, microscopically. T3b: Tumor invades perivesical soft tissue, macroscopically (extravesical mass). T4a: Extravesical tumor invades directly into prostatic stroma, uterus, vagina. N0: No regional lymph node metastasis. N1: Single regional lymph node metastasis in the true pelvis (perivesical, obturator, internal and external iliac, or sacral lymph node). M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIA Bladder Cancer AJCC v8 | IIIA | Stage IIIA Bladder Cancer | Stage IIIA Bladder Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538494","Stage III Bladder Cancer AJCC v8","C140421","Stage III includes: IIIA: (T3a, T3b, T4a, N0, M0); (T1-T4a, N1, M0); IIIB: (T1-T4a, N2, N3, M0). T1: Tumor invades lamina propria (subepithelial connective tissue). T2: Tumor invades muscularis propria. T3: Tumor invades perivesical soft tissue. T3a: Tumor invades perivesical soft tissue, microscopically. T3b: Tumor invades perivesical soft tissue, macroscopically (extravesical mass). T4a: Extravesical tumor invades directly into prostatic stroma, uterus, vagina. N0: No regional lymph node metastasis. N1: Single regional lymph node metastasis in the true pelvis (perivesical, obturator, internal and external iliac, or sacral lymph node). N2: Multiple regional lymph node metastasis in the true pelvis (perivesical, obturator, internal and external iliac, or sacral lymph node metastasis). N3: Lymph node metastasis to the common iliac lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Bladder Cancer AJCC v8 | Stage III Bladder Cancer | Stage III Bladder Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538479","Stage II Bladder Cancer AJCC v8","C140420","Stage II includes: (T2a, N0, M0); (T2b, N0, M0). T2a: Tumor invades superficial muscularis propria (inner half). T2b: Tumor invades deep muscularis propria (outer half). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Bladder Cancer AJCC v8 | II | Stage II Bladder Cancer | Stage II Bladder Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538480","Stage I Bladder Cancer AJCC v8","C140419","Stage I includes: T1, N0, M0. T1: Tumor invades lamina propria (subepithelial connective tissue). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Bladder Cancer AJCC v8 | I | Stage I Bladder Cancer | Stage I Bladder Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538481","Stage 0is Bladder Cancer AJCC v8","C140418","Stage 0is includes: Tis, N0, M0. Tis: Urothelial carcinoma in situ: 'flat tumor'. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0is Bladder Cancer AJCC v8 | 0is | Carcinoma in situ of bladder | Stage 0is Bladder Cancer | Stage 0is Bladder Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538482","Stage 0a Bladder Cancer AJCC v8","C140417","Stage 0a includes: Ta, N0, M0. Ta: Non-invasive papillary carcinoma. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0a Bladder Cancer AJCC v8 | 0a | Stage 0a Bladder Cancer | Stage 0a Bladder Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526733","Microsatellite Stability Assessment","C139286","An assessment of the variability in length of an individual's microsatellite sequences; microsatellite length instability may be due to mismatch repair protein mutation.","Microsatellite Stability Assessment | MSI Assessment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0142825","Sodium Citrate","C62075","The sodium salt of citrate with alkalinizing activity. Upon absorption, sodium citrate dissociates into sodium cations and citrate anions; organic citrate ions are metabolized to bicarbonate ions, resulting in an increase in the plasma bicarbonate concentration, the buffering of excess hydrogen ion, the raising of blood pH, and potentially the reversal of acidosis. In addition, increases in free sodium load due to sodium citrate administration may increase intravascular blood volume, facilitating the excretion of bicarbonate compounds and an anti-urolithic effect.","Sodium Citrate | Albright's Solution | Bicitra | Modified Shohl's Solution | Oracit | SODIUM CITRATE, UNSPECIFIED FORM | citric acid/potassium-sodium citrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524889","T-Cell Receptor Gene","C18017","The T-cell antigen receptors consist of a heterodimer of integral membrane glycoproteins. Two distinct receptors exist, alpha/beta and gamma/delta. Alpha/beta receptors are found on helper and cytotoxic T-cells and are specific for antigenic peptides presented in association with MHC gene products. Gamma/delta receptors, found in association with CD3, directly recognize proteins and non-proteinacious phospho-ligands. Alpha/beta and gamma/delta are non-covalently associated with CD3-gamma, -delta, -epsilon, and -zeta proteins, forming the TCR-CD3 complex, which activate MAPKs and JNK1 through the CD3 antigens, the adaptor protein LAT, and tyrosine kinases LCK and ZAP70. The genes for T-cell receptor subunits are encoded by distinct gene elements that are assembled by somatic rearrangement during T-cell development. Translocations and inversions of these loci are observed in human T-cell leukemias and lymphomas.","T-Cell Receptor Gene | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985541","Tumor Board Review","C93304","A treatment planning approach in which a number of doctors who are experts in different specialties (disciplines) review and discuss the medical condition and treatment options of a patient. In cancer treatment, a multidisciplinary opinion may include that of a medical oncologist (who provides cancer treatment with drugs), a surgical oncologist (who provides cancer treatment with surgery), and a radiation oncologist (who provides cancer treatment with radiation).","Tumor Board Review | multidisciplinary opinion | tumor board review",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545917","Aversion","C142158","A strong dislike or disinclination.","Aversion | Averse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540169","Delineate","C142157","To describe something precisely or to indicate the exact position of a boundary or border.","Delineate | Delineated | Delineation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0680240","Concordance","C142156","An agreement of findings.","Concordance | Concordant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1168369","HIV Viral Load Measurement","C92544","The determination of the HIV viral load in a specimen.","HIV Viral Load Measurement | hiv viral load | hiv_viral_load",,,,,,,,,,,,,,,"4201046","HIV viral load",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3272275","Urgent Procedure","C100031","Deferring an urgent procedure increases risk of adverse outcome or clinical deterioration.  Clinical situation warrants performing urgent procedures during the current episode of care to avoid compromising patient safety. (ACC)","Urgent Procedure | URGENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540159","Abscopal Effect","C142169","The ability of localized radiation to trigger systemic antitumor effects.","Abscopal Effect | Abscopal Effect After Radiotherapy | Abscopal Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540162","Transition Point","C142166","The point at which something changes from one form to another.","Transition Point | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227164","Pharyngeal Recess","C142140","A recess located behind the ostium of the eustachian tube. It is the most common site of origin for nasopharyngeal carcinoma.","Pharyngeal Recess | Fossa of Rosenmuller",,,,,,,,,,,,,,,"4083256","Structure of pharyngeal recess",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540188","Neck Lymph Node Boundary Levels I-IV","C142146","A grouping of lymph nodes comprising neck lymph node boundary levels I-IV.","Neck Lymph Node Boundary Levels I-IV | Neck Lymph Node Levels I-IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540187","Neck Lymph Node Boundary Levels II-IV","C142147","A grouping of lymph nodes comprising neck lymph node boundary levels II-IV.","Neck Lymph Node Boundary Levels II-IV | Neck Lymph Node Levels II-IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540186","Serial Transverse Cross-Sectioning","C142148","A histological method used to determine surgical margin for skin tumors. The process involves cutting a specimen into 3 or more sections and examining a thin slice from each cut face.","Serial Transverse Cross-Sectioning | Bread Loafing | Bread-Loafing Technique",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1621966","Tissue Growth","C16648","An increase is the size or mass of a tissue due to an increase in cell number.","Tissue Growth | Growth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513743","Multimodal Imaging","C19341","Simultaneous use of more than one imaging technique.","Multimodal Imaging | Multimodality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891814","Substrate","C120264","Any chemical that can be modified or consumed during a chemical reaction or biological process.","Substrate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL382015","Endorectal Coil","C142180","A thin wire covered with a latex balloon that is inserted into the rectum to enhance the local magnetic field during MRI of the prostate and surrounding tissues.","Endorectal Coil | ERC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540163","8-Core Prostate Biopsy","C142181","A prostate biopsy collection protocol that consists of sextant cores plus 2 lateral peripheral zone cores.","8-Core Prostate Biopsy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540262","12-Core Prostate Biopsy","C142182","A prostate biopsy collection protocol that consists of sextant cores plus 6 lateral peripheral zone cores.","12-Core Prostate Biopsy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540260","4Kscore","C142184","A proprietary blood test for prostate cancer screening that measures four kallikrein markers (total, free, and intact prostate-specific antigen, and human kallikrein-related peptidase 2 [hK2]).","4Kscore | 4K | 4Kscore Blood Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540258","Oncotype DX Genomic Prostate Score","C142186","A proprietary multi-gene assay that analyzes expression of 17 genes across four genetic pathways to predict prostate cancer aggressiveness.","Oncotype DX Genomic Prostate Score | Oncotype DX GPS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517054","Extracutaneous Dissemination of Disease","C39625","A finding indicating the presence of disease beyond the skin.","Extracutaneous Dissemination of Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2717795","Teaching Rounds","C142164","A teaching conference or meeting at which clinical problems are discussed.","Teaching Rounds | Rounds",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3534656","Prostate Cancer Antigen 3 mRNA Measurement","C132379","The determination of the amount of prostate cancer antigen 3 mRNA in a biological sample.","Prostate Cancer Antigen 3 mRNA Measurement | PCA3 | PCA3 Test | PCA3 mRNA Measurement | PCA3MRNA | Prostate Cancer Antigen 3 mRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537828","Oligometastasis","C139674","A disease state that refers to a limited number of clinically detectable metastases, an intermediate state between purely localized disease and widespread metastases.","Oligometastasis | oligometastasis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707441","Large Intestinal Small Cell Neuroendocrine Carcinoma","C43587","An aggressive high-grade carcinoma with neuroendocrine differentiation that arises from the colon or rectum and is composed of malignant small cells. The mitotic count is more than 20 per 2 mm2 and/or the Ki-67 index is more than 20%.","Colorectal Small Cell Neuroendocrine Carcinoma | Colorectal Small Cell Carcinoma | Colorectal Small Cell Carcinoma | Colorectal Small Cell Neuroendocrine Carcinoma | Large Intestinal Small Cell Neuroendocrine Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986669","Clarify","C94778","An act to make understandable and free from confusion.","Clarify | Clarification | Clarified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986586","Median Survival Time","C94594","The time from either diagnosis or treatment at which half of the patients with a given disease are found to be, or expected to be, still alive. In a clinical trial, median survival time is one way to measure how effective a treatment is.","Median Survival Time | median survival time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2919030","Administrative Division","C85531","An administrative unit within a government, academic organization or business.","Division | Administrative Division",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826330","Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified","C82616","A myelodysplastic/myeloproliferative neoplasm characterized by marked thrombocytosis, anemia, erythroid lineage dysplasia, presence or absence of multilineage dysplasia, 15% or more ring sideroblasts, blasts less than 5% in bone marrow and less than 1% in peripheral blood, absence of BCR/ABL fusion, absence of SF3B1 mutation, absence of genetic abnormalities associated with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions, and no history of other myelodysplastic/myeloproliferative neoplasms or myeloproliferative neoplasms and myelodysplastic syndromes.","Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified | Essential Thrombocythemia with Ring Sideroblasts | MDS/MPN with Ring Sideroblasts and Thrombocytosis | MDS/MPN-RS-T | MDS/MPN-RS-T, NOS | Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis | Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis | Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis, NOS | RARS-T | Refractory Anemia with Ring Sideroblasts Associated with Marked Thrombocytosis | Refractory anemia with ring sideroblasts associated with marked thrombocytosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512939","Myeloid/Lymphoid Neoplasms with JAK2 Rearrangement","C129853","Hematologic neoplasms characterized by the presence of t(8;9)(p22;p24.1) that results in PCM1-JAK2 fusion gene expression. It is associated with eosinophilia, bone marrow findings of left-shifted erythroid predominance, lymphoid aggregates, and often myelofibrosis. Rare cases present as T- or B-acute lymphoblastic leukemia.","Myeloid/Lymphoid Neoplasms with JAK2 Rearrangement | M/LN-eo with t(8;9)(p22;p24.1)/PCM1/JAK2 | M/LN-eo with t(8;9)(p22;p24.1)/PCM1::JAK2 | Myeloid and Lymphoid Neoplasms with t(8;9)(p22;p24.1);PCM1-JAK2 | Myeloid and Lymphoid Neoplasms with t(8;9)(p22;p24.1);PCM1-JAK2 | Myeloid and Lymphoid Neoplasms with t(8;9)(p22;p24.1);PCM1::JAK2 | Myeloid/Lymphoid Neoplasm with JAK2 Rearrangement | Myeloid/Lymphoid Neoplasm with JAK2-PCM1 Fusion | Myeloid/Lymphoid Neoplasm with PCM1- JAK2 Fusion | Myeloid/Lymphoid Neoplasms with PCM1-JAK2 | Myeloid/Lymphoid Neoplasms with PCM1-JAK2 | Myeloid/Lymphoid Neoplasms with PCM1::JAK2",,,,,,,,,,,,,,,"37164284|37312736","Myeloid and/or lymphoid neoplasm with PCM1-JAK2|Myeloid/lymphoid neoplasm with JAK2 rearrangement",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL497893","Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement","C84277","Hematologic neoplasms characterized by the rearrangement of the FGFR1 gene, resulting in translocations with an 8p11 breakpoint. Patients present with a myeloproliferative neoplasm, acute myeloid leukemia, lymphoblastic lymphoma/leukemia of T or B-cell lineage, or acute leukemia of mixed phenotype.","Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement | 8p11 Myeloproliferative Syndrome | 8p11 Stem Cell Leukemia/Lymphoma Syndrome | 8p11 Stem Cell Lymphoma/Leukemia Syndrome | 8p11 Stem Cell Syndrome | M/LN-eo with FGFR1 Rearrangement | Myeloid and Lymphoid Neoplasms with FGFR1 Rearrangement | Myeloid and Lymphoid Neoplasms with FGFR1 Rearrangement | Myeloid and lymphoid neoplasms with FGFR1 abnormalities | Myeloid/Lymphoid Neoplasm with FGFR1 Rearrangement",,,,,,,,,,,,,,,"36717160|42872947","Myeloid and lymphoid neoplasm with fibroblast growth factor receptor 1 abnormality|Myeloid/lymphoid neoplasm with FGFR1 rearrangement",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3472621","Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement","C84276","Myeloid and rarely lymphoid neoplasms characterized by the rearrangement of the PDGFRB gene, most often resulting in the formation of ETV6-PDGFRB fusion transcripts. Patients usually present with chronic myelomonocytic leukemia and less often with atypical chronic myeloid leukemia, or chronic eosinophilic leukemia.","Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement | M/LN-eo with PDGFRB Rearrangement | Myeloid Neoplasms with PDGFRB Rearrangement | Myeloid and Lymphoid Neoplasms with PDGFRB Rearrangement | Myeloid and Lymphoid Neoplasms with PDGFRB Rearrangement | Myeloid neoplasms with PDGFRB rearrangement | Myeloid/Lymphoid Neoplasm with PDGFRB Rearrangement",,,,,,,,,,,,,,,"37158026","Myeloid/lymphoid neoplasm with PDGFRB rearrangement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827360","Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement","C84275","Hematologic neoplasms characterized by the rearrangement of the PDGFRA gene, most often resulting in the formation of FIP1L1-PDGFRA fusion transcripts. Patients usually present with chronic eosinophilic leukemia, and less often with acute myeloid leukemia or T-lymphoblastic leukemia.","Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement | M/LN-eo with PDGFRA Rearrangement | Myeloid and Lymphoid Neoplasms with PDGFRA Rearrangement | Myeloid and Lymphoid Neoplasms with PDGFRA Rearrangement | Myeloid and lymphoid neoplasms with PDGFRA rearrangement | Myeloid/Lymphoid Neoplasm with PDGFRA Rearrangement",,,,,,,,,,,,,,,"42872945","Myeloid/lymphoid neoplasm with PDGFRA rearrangement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526807","Breast Cancer Pathologic Primary Tumor TNM Finding v8","C139411","A pathologic finding about one or more characteristics of breast cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor. Lobular carcinoma in situ (LCIS) is a benign entity and is removed from TNM staging in the AJCC Cancer Staging Manual, 8th Edition. (from AJCC 8th Ed.)","Breast Cancer Pathologic Primary Tumor TNM Finding v8 | Breast Carcinoma Pathologic Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523747","Lung Cancer Pathologic Primary Tumor TNM Finding v8","C136444","A pathologic finding about one or more characteristics of lung cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Lung Cancer Pathologic Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511062","Basaloid Cell","C32190","A cell usually of the epidermis that resembles a basal cell.","Basaloid Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1185605","Head and Neck Lymph Node","C12358","Lymph nodes found within the head and neck region of the body, which drain into the deep cervical nodes, either directly or indirectly. These include the occipital, mastoid, parotid, facial, retropharyngeal, submandibular, submental, lingual and cervical lymph nodes. Any lymph node located in the head or neck.","Head and Neck Lymph Node | Lymph Node of Head, Face and Neck | Lymph Nodes of Head, Face and Neck | Lymph nodes of head, face and neck",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704713","Can Dosing Unit","C48479","A dosing unit equal to the amount of active ingredient(s) contained in a can.","Can Dosing Unit | CAN | Can | can | {CAN} | {Can} | {can}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540118","Rous Sarcoma Virus Positive","C142092","An indication that rous sarcoma virus has been detected in a sample.","Rous Sarcoma Virus Positive | RSV Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540119","Elevated Catecholamine Metabolites","C142091","A finding indicating elevated concentrations of catecholamine metabolites in a biological sample.","Elevated Catecholamine Metabolites | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540120","FLT3 NP_004110.2:p.Y842C","C142090","A change in the amino acid residue at position 842 in the receptor-type tyrosine-protein kinase FLT3 protein where tyrosine has been replaced by cysteine.","FLT3 NP_004110.2:p.Y842C | CD135 Antigen Tyr842Cys | CD135 Antigen Y842C | FLT3 NP_004110.2:p.Tyr842Cys | FLT3 Tyr842Cys | FLT3 Y842C | FLT3 Y842C Mutation | FLT3 p.Tyr842Cys | FLT3 p.Y842C | Fetal Liver Kinase-2 Tyr842Cys | Fetal Liver Kinase-2 Y842C | Flt-3 Receptor Tyr842Cys | Flt-3 Receptor Y842C | Fms-Related Tyrosine Kinase 3 Tyr842Cys | Fms-Related Tyrosine Kinase 3 Y842C | NP_004110.2:p.Tyr842Cys | NP_004110.2:p.Y842C | Receptor-Type Tyrosine-Protein Kinase FLT3 Tyr842Cys | Receptor-Type Tyrosine-Protein Kinase FLT3 Y842C | Stem Cell Tyrosine Kinase 1 Tyr842Cys | Stem Cell Tyrosine Kinase 1 Y842C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540122","FGFR3 NP_000133.1:p.K650E","C142088","A change in the amino acid residue at position 250 in the fibroblast growth factor receptor 3 protein where lysine has been replaced by glutamic acid.","FGFR3 NP_000133.1:p.K650E | CD333 Antigen K650E | CD333 Antigen Lys650Glu | FGFR-3 K650E | FGFR-3 Lys650Glu | FGFR-3 p.K650E | FGFR-3 p.Lys650Glu | FGFR3 K650E | FGFR3 K652E Mutation | FGFR3 Lys650Glu | FGFR3 NP_000133.1:p.Lys650Glu | FGFR3 NP_001156685.1:p.K652E | FGFR3 NP_001156685.1:p.Lys652Glu | FGFR3 p.K650E | FGFR3 p.Lys650Glu | Fibroblast Growth Factor Receptor 3 K650E | Fibroblast Growth Factor Receptor 3 Lys650Glu | NP_000133.1:p.K650E | NP_000133.1:p.Lys650Glu | NP_001156685.1:p.K652E | NP_001156685.1:p.Lys652Glu | Tyrosine Kinase JKT4 K650E | Tyrosine Kinase JKT4 Lys650Glu | Tyrosine Kinase JTK4 K650E | Tyrosine Kinase JTK4 Lys650Glu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412084","ABCD1 Gene","C142193","This gene plays a role in the import of fatty acids and acyl-coenzyme A (acylCoA)-conjugated fatty acids into the peroxisome.","ABCD1 Gene | ABCD1 | ATP Binding Cassette Subfamily D Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540266","Globin Gene","C142196","A family of genes whose members encode globin family proteins, which are globular heme-containing proteins and include androglobin, cryoglobin, hemoglobin subunits, myoglobin and neuroglobin.","Globin Gene | Globin Gene Family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704667","WT1 wt Allele","C53122","Human WT1 wild-type allele is located in the vicinity of 11p13 and is approximately 48 kb in length. This allele, which encodes Wilms' tumor protein, plays a role in the modulation of both transcription and urogenital development. Mutations in the gene are linked to Wilms' tumor.","WT1 wt Allele | AWT1 | GUD | NPHS4 | WAGR | WIT-2 | WT-1 | WT1 Transcription Factor wt Allele | WT33 | Wilms Tumor 1 Gene | Wilms Tumor 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0671831","prostate stem cell antigen","C50887","Prostate stem cell antigen (123 aa, ~13 kDa) is encoded by the human PSCA gene. This protein may play a role in the regulation of cell proliferation.","Prostate Stem Cell Antigen | PSCA | PSCA Protein | Prostate Antigen | Prostate Stem Cell Antigen Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508929","PRAME wt Allele","C127929","Human PRAME wild-type allele is located in the vicinity of 22q11.22 and is approximately 12 kb in length. This allele, which encodes melanoma antigen preferentially expressed in tumors protein, is involved in transcriptional repression. Aberrant expression of the gene is associated with melanoma and some acute leukemias.","PRAME wt Allele | CT130 | MAPE | OIP-4 | OIP4 | Preferentially Expressed Antigen in Melanoma wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347296","Mucin-16, Human","C71020","Mucin-16 (22152 aa, ~2353 kDa) is encoded by the human MUC16 gene. This protein may be involved in both cellular adhesion and the lubrication of mucosal surfaces.","Mucin-16 | CA-125 | MUC16 | Mucin 16 | Ovarian Cancer-Related Tumor Marker CA125 | Ovarian Carcinoma Antigen CA125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0767808","MAGEA10 protein, human","C104498","Melanoma-associated antigen 10 (369 aa, ~41 kDa) is encoded by the human MAGEA10 gene. This protein may be involved in tumor progression.","Melanoma-Associated Antigen 10 | CT1.10 | Cancer/Testis Antigen 1.10 | MAGE-10 Antigen | MAGE-A10 | MAGEA10 | Melanoma Antigen 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537350","Melanoma-Associated Antigen 4, Human","C104515","Melanoma-associated antigen 4 (317 aa, ~35 kDa) is encoded by the human MAGEA4 gene. This protein may be involved in embryonal development, tumor transformation, or tumor progression.","Melanoma-Associated Antigen 4 | Cancer/Testis Antigen 1.4 | Cancer/Testis Antigen Family 1, Member 4 | MAGE-4 Antigen | MAGE-41 Antigen | MAGE-A4 | MAGE-X2 Antigen | MAGEA4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987047","SLAMF7 wt Allele","C95307","Human SLAMF7 wild-type allele is located within 1q23.1-q24.1 and is approximately 16 kb in length. This allele, which encodes SLAM family member 7 protein, plays a role in the modulation of natural killer cell activity.","SLAMF7 wt Allele | 19A | 19A24 Protein Gene | CD319 | CRACC | CS1 | Novel LY9 (Lymphocyte Antigen 9) Like Protein Gene | SLAM Family Member 7 wt Allele | UNQ576/PRO1138",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810647","L1CAM wt Allele","C112137","Human L1CAM wild-type allele is located in the vicinity of Xq28 and is approximately 48 kb in length. This allele, which encodes neural cell adhesion molecule L1 protein, is involved in neuron-neuron cell adhesion, axon guidance and bundling of neurons. Mutation of the gene is associated with hydrocephalus due to stenosis of the aqueduct of Sylvius (HSAS), mental retardation, aphasia, shuffling gait, and adducted thumbs syndrome (MASA or CRASH syndrome), spastic paraplegia 1, X-linked and agenesis of the corpus callosum, X-linked, partial and may contribute to intestinal aganglionosis in Hirschsprung disease.","L1CAM wt Allele | Antigen Identified By Monoclonal Antibody R1 Gene | CAML1 | CD171 | HSAS | HSAS1 | L1 Cell Adhesion Molecule wt Allele | L1-CAM | MASA | MIC5 | N-CAM-L1 | N-CAML1 | NCAM-L1 | S10 | SPG1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0758637","Interleukin-3 Receptor Subunit Alpha, Human","C39275","Interleukin-3 receptor subunit alpha (378 aa, ~43 kDa) is encoded by the human IL3RA gene. This protein is involved in interleukin-3 signaling.","Interleukin-3 Receptor Subunit Alpha | CD123 | CD123 Antigen | IL-3 Receptor Subunit Alpha | IL-3R Subunit Alpha | IL-3R-Alpha | IL-3RA | IL3R | IL3R-Alpha | IL3RA | IL3RX | Interleukin 3 Receptor | Interleukin 3 Receptor Alpha | Interleukin 3 Receptor Alpha Chain | Low Affinity Interleukin 3 Receptor Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521680","Gamma-hydroxy-1,N(2)-propanodeoxyguanosine","C133745","A mutagenic and carcinogenic cyclic 1,N2-propanodeoxy (Pd) DNA adduct derived from the reaction of deoxyguanosine (dG) in DNA with the environmentally widely available or endogenously produced mutagenic and carcinogenic unsaturated aldehyde acrolein (Acr) that can potentially be used as a biomarker for exposure to Acr, the formation of certain forms of cancer and the presence of oxidative stress. The formation of gamma-hydroxy-1,N(2)-propanodeoxyguanosine (g-OH-PdG) damages DNA and stimulates the formation of tumors. Also, as Acr is formed due to oxidation of certain polyunsaturated fatty acids (PUFAs), mostly omega-3-PUFA, the lipid peroxidation-derived DNA adduct g-OH-PdG can potentially be used as a biomarker to assess the presence of oxidized PUFAs, the level of oxidative stress and the extent of oxidative DNA damage.","Gamma-hydroxy-1,N(2)-propanodeoxyguanosine | 3-(2'-Deoxy-beta-d-erythro-pentofuranosyl)-5,6,7,8-tetrahydro-8-hydroxypyrimido[1,2-a] Purin-10(3H)-one | Acr-dG3 | Acrolein-dG3 | g-OH-PdG | g-OHPdG | gamma-OH-PdG | gamma-OHPdG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540132","PSA Level Greater than or Equal to 0.01","C142094","A blood concentration of prostate specific antigen greater than or equal to 0.01 ng/mL.","PSA Level Greater than or Equal to 0.01 | PSA Level 0.01 or Greater",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540117","Merkel Cell Polyomavirus T Antigen Positive","C142093","An indication that the expression of the Merkel cell polyomavirus T antigen has been detected in a sample.","Merkel Cell Polyomavirus T Antigen Positive | MCPyV TAg Positive | Merkel Cell Polyomavirus TAg Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512861","Advanced Malignant Solid Neoplasm","C129707","A malignant solid neoplasm that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Malignant Solid Neoplasm | Advanced Malignant Solid Tumor | Advanced Non-Hematologic Malignancy | Advanced Solid Neoplasm | Advanced Solid Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020944","Immobilization","C142778","The application of a restraint to restrict normal movement of an individual's body, limb, or joint.","Immobilization | Immobilization Technique",,,,,,,,,,,,,,,"4120008","Immobilization - action",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545918","Active Breathing Control","C142779","Technique associated with control of breathing used to restrict movement of the body during medical procedures.","Active Breathing Control | ABC | Active Breath Control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1300125","Distance of Closest Surgical Margin","C137815","The distance of the closest surgical margin from tumor after surgical resection of the tumor. The closest distance between a tumor and its resection margin has prognostic significance.","Distance of Closest Surgical Margin | Closest Distance Between Tumor and Resection Margin | Distance of Tumor from Closest Margin | Distance of Tumor from Closest Surgical Margin | Least Distance to Closest Margin | TUMOR_FROM_MARGIN | margin distance | margin_distance",,,,,,,,,,,,,,,"4160346","Distance of neoplasm from closest surgical margin in excised specimen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540129","HLA-A*26 Positive Cells Present","C142097","A laboratory test result indicating the presence of HLA-A*26 positive cells in a tissue sample.","HLA-A*26 Positive Cells Present | HLA-A*26 Positive | HLA-A26 Positive | HLA-A26 Positive Cells Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540130","HLA-DP4 Positive Cells Present","C142096","An indication that the expression of major histocompatibility complex, class II DP protein in which haplotype of the alpha subunit is HLA-DPA1*0103 and haplotype of the beta subunit is either HLA-DPB1*0401 or HLA-DPB1*0402 allele of the HLA-DPB1 gene is present in a cell or tissue sample.","HLA-DP4 Positive Cells Present | HLA-DP*04 Positive | HLA-DP*04 Positive Cells Present | HLA-DP4 Antigen Positive | HLA-DP4 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540127","Trisomy 21 Mosaicism","C142099","The presence of cells with and without three copies of chromosome 21 in either somatic or germinal tissue.","Trisomy 21 Mosaicism | Mosaicism for Trisomy 21",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540128","PSA Level Less than One Hundred Fifty","C142098","A blood concentration of prostate specific antigen less than 150 ng/mL.","PSA Level Less than One Hundred Fifty | PSA Level Less than 150 | PSA Level Less than One Hundred and Fifty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540125","Activating MTOR Gene Mutation","C142101","A change in the nucleotide sequence of the MTOR gene that that results in constitutive activation of serine/threonine-protein kinase mTOR and its downstream signaling pathways.","Activating MTOR Gene Mutation | Activating FK506 Binding Protein 12-Rapamycin Associated Protein 1 Gene Mutation | Activating FRAP Gene Mutation | Activating FRAP1 Gene Mutation | Activating Mammalian Target of Rapamycin Gene Mutation | Activating Mechanistic Target of Rapamycin Gene Mutation | Activating Rapamycin and FKBP12 Target 1 Gene Mutation | MTOR Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540126","PSA Level 0.1 to 0.7","C142100","A blood concentration of prostate specific antigen between 0.1 ng/mL and 0.7 ng/mL.","PSA Level 0.1 to 0.7 | PSA Level Between 0.1 and 0.7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541264","Lugano Lymphoma Response Classification Complete Remission by CT","C142791","Target nodes/nodal masses must regress to less than or equal to 1.5 cm in the longest transverse diameter. Complete disappearance of radiologic evidence of disease. No extralymphatic sites of disease. Organ enlargement regress to normal. Bone marrow normal by morphology; if indeterminate, IHC negative.","Lugano Lymphoma Response Classification Complete Remission by CT | CR | Complete Remission",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541305","Lugano Lymphoma Response Classification Partial Remission by CT","C142792","For multiple lesions, greater than or equal to 50 percent decrease in the sum of the product of the perpendicular diameters of up to six target measurable nodes and extranodal sites. If only a single lesion is present, greater than or equal to 50 percent decrease in the cross product of the longest transverse diameter and perpendicular diameter.. Spleen must have regressed by >50% in length beyond normal' to the definition.","Lugano Lymphoma Response Classification Partial Remission by CT | PR | Partial Remission",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541260","Lugano Lymphoma Response Classification Progressive Disease by CT","C142794","Progressive disease is assigned with at least one of the following: an individual node must be abnormal with the longest transverse diameter greater than 1.5 cm or an increase by greater than or equal to 50 percent from the product of the perpendicular diameter nadir; an increase in the longest transverse diameter or shortest transverse diameter from nadir 0.5 cm for lesions less than or equal to 2 cm or 1.0 cm for lesions greater than 2 cm. New or recurrent splenomegaly; a new node >1.5 cm in any axis; new or recurrent bone marrow involvement.","Lugano Lymphoma Response Classification Progressive Disease by CT | PD | Progressive Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540720","Lugano Lymphoma Response Classification Complete Remission by PET","C142795","A score of 1, 2, or 3 on a 5-point PET scale in nodal or extranodal sites with or without a residual mass. No evidence of FDG-avid disease in the marrow.","Lugano Lymphoma Response Classification Complete Remission by PET | CR | Complete Remission",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541306","Lugano Lymphoma Response Classification Partial Remission by PET","C142796","A score of 4 or 5 on a 5-point PET scale with reduced uptake compared with baseline and residual mass(es) of any size. Residual uptake higher than uptake in normal marrow but reduced compared to baseline.","Lugano Lymphoma Response Classification Partial Remission by PET | PR | Partial Remission",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540719","Lugano Lymphoma Response Classification No Response/Stable Disease by PET","C142797","A score of 4 or 5 on a 5-point PET scale with no significant change in FDG uptake from baseline, at interim or end of treatment. No change in the bone marrow from baseline.","Lugano Lymphoma Response Classification No Response/Stable Disease by PET | NR/SD | No Response/Stable Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541262","Lugano Lymphoma Response Classification Progressive Disease by PET","C142798","A score of 4 or 5 on a 5-point PET scale with an increase in intensity of uptake from baseline and/or new FDG-avid foci consistent with lymphoma at interim or end of treatment assessment.","Lugano Lymphoma Response Classification Progressive Disease by PET | PD | Progressive Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540722","Lugano Lymphoma Response Classification","C142790","A lymphoma response criteria system developed at the 11th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, June 2011.","Lugano Lymphoma Response Classification | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539589","Bevacizumab-Pemetrexed","C141479","A regimen consisting of bevacizumab and pemetrexed that can be used in the treatment of non-small cell lung cancer (NSCLC).","Bevacizumab/Pemetrexed Regimen | Bevacizumab-Pemetrexed | Bevacizumab-Pemetrexed Regimen | Bevacizumab-Pemetrexed Regimen | Bevacizumab/Pemetrexed | Pemetrexed and Bevacizumab | Pemetrexed and Bevacizumab-adcd | Pemetrexed and Bevacizumab-awwb | Pemetrexed and Bevacizumab-aybi | Pemetrexed and Bevacizumab-bvzr | Pemetrexed and Bevacizumab-equi | Pemetrexed and Bevacizumab-maly | Pemetrexed and Bevacizumab-onbe | Pemetrexed and Bevacizumab-tnjn",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986511","Evaluable Patient","C94425","Patients whose response to a treatment can be measured because enough information has been collected.","Evaluable Patient | evaluable patients",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524907","Computed Tomography with Contrast","C137805","Computed tomography that uses a contrast agent to visualize anatomic structures.","Computed Tomography with Contrast | CONTRAST ENHANCED CT SCAN | CT Scan With Contrast | CT Scan with Contrast | CT with Contrast | Contrast Enhanced Computed Tomography | Contrast-enhanced Computed Tomography",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540106","Elevated Serum CA-125 Tumor Antigen","C142104","A finding indicating elevated concentrations of the tumor antigen CA-125 in a blood serum sample.","Elevated Serum CA-125 Tumor Antigen | Elevated Serum CA-125 | Elevated Serum CA-125 Tumor Antigen Levels | Elevated Serum CA125 | Elevated Serum Cancer Antigen 125 | Elevated Serum Carbohydrate Antigen 125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540107","Lymphoblasts 5 Percent or More of Bone Marrow Nucleated Cells","C142103","A semi-quantitative microscopic finding indicating that 5 percent or more of the nucleated cells in a bone marrow sample are immature mononuclear cells of lymphoid origin.","Lymphoblasts 5 Percent or More of Bone Marrow Nucleated Cells | Lymphoblasts Greater than or Equal to 5 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517659","Keratinizing Malignant Squamous Cell","C36791","A malignant squamous cell which produces extracellular keratin.","Keratinizing Malignant Squamous Cell | Well Differentiated Malignant Squamous Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521208","Neck Lymph Node Boundary Level III","C132499","The following anatomical structures define the neck lymph node boundary for level III: Superior: horizontal plane defined by the inferior body of the hyoid; inferior: horizontal plane defined by the inferior border of the cricoid cartilage; anterior (medial): lateral border of the sternohyoid muscle; posterior (lateral): lateral border of the sternocleidomastoid or sensory branches of the cervical plexus. (AJCC 8th ed.)","Neck Lymph Node Boundary Level III | CERVICAL LYMPH NODE LEVEL III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521209","Neck Lymph Node Boundary Level IV","C132500","The following anatomical structures define the neck lymph node boundary for level IV: Superior: horizontal plane defined by the inferior border of the cricoid cartilage; inferior: clavicle; anterior (medial): lateral border of the sternohyoid muscle; posterior (lateral): lateral border of the sternocleidomastoid or sensory branches of the cervical plexus. (AJCC 8th ed.)","Neck Lymph Node Boundary Level IV | CERVICAL LYMPH NODE LEVEL IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521212","Neck Lymph Node Boundary Sublevel IA","C132495","The following anatomical structures define the neck lymph node boundary for sublevel IA: Superior: symphysis of the mandible; inferior: body of the hyoid; anterior (medial): anterior belly of the contralateral digastric muscle; posterior (lateral): anterior belly of the ipsilateral digastric muscle. (AJCC 8th ed.)","Neck Lymph Node Boundary Sublevel IA | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521213","Neck Lymph Node Boundary Sublevel IB","C132496","The following anatomical structures define the neck lymph node boundary for sublevel IB: Superior: body of the mandible; inferior: posterior belly of the digastric muscle; anterior (medial): anterior belly of the digastric muscle; posterior (lateral): stylohyoid muscle. (AJCC 8th ed.)","Neck Lymph Node Boundary Sublevel IB | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521214","Neck Lymph Node Boundary Sublevel IIA","C132497","The following anatomical structures define the neck lymph node boundary for sublevel IIA: Superior: skull base; inferior: horizontal plane defined by the inferior border of the hyoid bone; anterior (medial): stylohyoid muscle; posterior (lateral): vertical plane defined by the spinal accessory nerve. (AJCC 8th ed.)","Neck Lymph Node Boundary Sublevel IIA | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521215","Neck Lymph Node Boundary Sublevel IIB","C132498","The following anatomical structures define the neck lymph node boundary for sublevel IIB: Superior: skull base; inferior: horizontal plane defined by the inferior body of the hyoid bone; anterior (medial): vertical plane defined by the spinal accessory nerve; posterior (lateral): lateral border of the sternocleidomastoid muscle. (AJCC 8th ed.)","Neck Lymph Node Boundary Sublevel IIB | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521216","Neck Lymph Node Boundary Sublevel VA","C132501","The following anatomical structures define the neck lymph node boundary for sublevel VA: Superior: apex of the convergence of the sternocleidomastoid and trapezius muscles; inferior: horizontal plane defined by the lower border of the cricoid cartilage; anterior (medial): posterior border of the sternocleidomastoid muscle or sensory branches of the cervical plexus; posterior (lateral): anterior border of the trapezius muscle. (AJCC 8th ed.)","Neck Lymph Node Boundary Sublevel VA | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521217","Neck Lymph Node Boundary Sublevel VB","C132502","The following anatomical structures define the neck lymph node boundary for sublevel VB: Superior: horizontal plane defined by the lower border of the cricoid cartilage; inferior: clavicle; anterior (medial): posterior border of the sternocleidomastoid muscle; posterior (lateral): anterior border of the trapezius muscle. (AJCC 8th ed.)","Neck Lymph Node Boundary Sublevel VB | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521211","Neck Lymph Node Boundary Level VI","C132503","The following anatomical structures define the neck lymph node boundary for level VI: Superior: hyoid bone; inferior: suprasternal notch; anterior (medial): common carotid artery; posterior (lateral): common carotid artery. (AJCC 8th ed.)","Neck Lymph Node Boundary Level VI | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521210","Neck Lymph Node Boundary Level VII","C132504","The following anatomical structures define the neck lymph node boundary for level VII: Superior: suprasternal notch; inferior: innominate artery; anterior (medial): sternum; posterior (lateral): trachea, esophagus, and prevertebral fascia. (AJCC 8th ed.)","Neck Lymph Node Boundary Level VII | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540102","CTLA4 Positive","C142108","An indication that CTLA4 expression has been detected in a sample.","CTLA4 Positive | CD152 Antigen Positive | CD152 Positive | CTLA-4 Positive | Cytotoxic T Lymphocyte-Associated 4 Positive | Cytotoxic T-Lymphocyte Protein 4 Positive | Cytotoxic T-Lymphocyte-Associated Antigen 4 Positive | Cytotoxic T-Lymphocyte-Associated Protein 4 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540103","Neoplastic Plasma Cells 10 Percent of Bone Marrow Nucleated Cells","C142107","A microscopic finding indicating that 10 percent of the nucleated cells in a bone marrow sample are neoplastic plasma cells.","Neoplastic Plasma Cells 10 Percent of Bone Marrow Nucleated Cells | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540104","PSA Level Ten to Fifteen","C142106","A blood concentration of prostate specific antigen between 10 ng/mL and 15 ng/mL.","PSA Level Ten to Fifteen | PSA Level 10 to 15 | PSA Level Between 10 and 15 | PSA Level Between Ten and Fifteen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540105","FGFR2IIIb Positive","C142105","An indication that FGFR2IIIb expression has been detected in a sample.","FGFR2IIIb Positive | FGFR-2 IIIb Positive | FGFR2 IIIb Positive | FGFR2(IIIb) Positive | FGFR2-IIIb Positive | FGFR2b Positive | Fibroblast Growth Factor Receptor 2 Isoform IIIb Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540115","Neoplastic Plasma Cells More than 5 Percent of Peripheral Blood White Cells","C142111","A microscopic finding indicating that more than 5 percent of the nucleated cells in a peripheral leukocyte sample are neoplastic plasma cells.","Neoplastic Plasma Cells More than 5 Percent of Peripheral Blood White Cells | Neoplastic Plasma Cells Greater than 5 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540116","HLA-A*24:02 Positive Cells Present","C142110","A laboratory test result indicating the presence of HLA-A*24:02 positive cells in a tissue sample.","HLA-A*24:02 Positive Cells Present | HLA-A*2402 Positive | HLA-A*2402 Positive Cells Present | HLA-A*24:02 Positive | HLA-A2402 Positive | HLA-A2402 Positive Cells Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540101","PSA Level Less than 0.2","C142109","A blood concentration of prostate specific antigen less than 0.2 ng/mL.","PSA Level Less than 0.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545915","Viral Transduction","C142787","The transfer of genetic material from one microorganism to another by a viral agent.","Viral Transduction | Transduction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540721","Lugano Lymphoma Response Classification No Response/Stable Disease by CT","C142793","Less than 50 percent decrease from baseline in  the sum of the product of the perpendicular diameters of up to 6 dominant, measurable nodes and extranodal sites; no criteria for progressive disease are met.","Lugano Lymphoma Response Classification No Response/Stable Disease by CT | NR/SD | No Response/Stable Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0445106","Not Performed","C141477","An indicator that specifies that an activity did not occur.","Not Performed | NP | Not performed",,,,,,,,,,,,,,,"4118638","Not performed",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2983747","Sapanisertib","C90548","An orally bioavailable inhibitor of raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR complex 2 or TORC2) with potential antineoplastic activity. Sapanisertib binds to and inhibits both TORC1 and TORC2 complexes of mTOR, which may result in tumor cell apoptosis and a decrease in tumor cell proliferation. TORC1 and 2 are upregulated in some tumors and play an important role in the PI3K/Akt/mTOR signaling pathway, which is frequently dysregulated in human cancers.","Sapanisertib | INK-128 | INK128 | MLN-0128 | MLN0128 | SAPANISERTIB | TAK-228",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334302","Combined Carcinoid and Adenocarcinoma","C4139","A malignant epithelial neoplasm composed of a mixture of neuroendocrine cells with morphologic and immunohistochemical characteristics of carcinoid tumor and malignant glandular cells.","Combined Carcinoid and Adenocarcinoma | Adenocarcinoid Neoplasm | Adenocarcinoid Tumor | Adenocarcinoid tumor | Combined Carcinoid Neoplasm and Adenocarcinoma | Combined Carcinoid Tumor and Adenocarcinoma | Combined carcinoid and adenocarcinoma | Combined/mixed carcinoid and adenocarcinoma | Composite Carcinoid | Composite Carcinoid Neoplasm | Composite Carcinoid Tumor | Composite carcinoid | Mixed Carcinoid Neoplasm | Mixed Carcinoid Tumor",,,,,,,,,,,,,,,"4197443","Mixed adenoneuroendocrine carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519787","Undifferentiated Neuroblastoma","C42046","A neuroblastoma characterized by the absence of differentiating neuroblasts.","Undifferentiated Neuroblastoma | Undifferentiated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514225","Poorly Differentiated Neuroblastoma","C42047","A neuroblastoma in which the differentiating neuroblasts constitute less than five-percent of the tumor cells.","Poorly Differentiated Neuroblastoma | Poorly Differentiated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0397761","Hepatic Artery Embolization","C66902","A therapeutic procedure involving the injection or deployment of blocking agents in the hepatic artery to treat tumors.","Hepatic Artery Embolization | ",,,,,,,,,,,,,,,"4052240","Embolization of hepatic artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526925","Breast Cancer by AJCC v8 Anatomic Stage","C139533","A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should only be used in global regions where biomarker tests are not routinely available. (from AJCC 8th Ed.)","Breast Cancer by AJCC v8 Anatomic Stage | Breast Carcinoma by AJCC v8 Anatomic Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540703","Presumed","C142832","Likely to be true; accepted as true.","Presumed | Presume",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526912","Breast Cancer by AJCC v8 Prognostic Stage","C139554","A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should be used in countries where HER2, ER, and PR biomarker tests are routinely performed for patient care (U.S., Canada, etc.). (from AJCC 8th Ed.)","Breast Cancer by AJCC v8 Prognostic Stage | Breast Cancer by AJCC v8 Prognostic Stage Group | Breast Carcinoma by AJCC v8 Prognostic Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526879","Prognostic Stage IV Breast Cancer AJCC v8","C139587","Stage IV includes: Any T, Any N, M1, G1-3, HER2 Status: Any, ER Status: Any, PR Status: Any. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M1: Distant metastases detected by clinical and radiographic means and/or histologically proven metastases larger than 0.2 mm. (AJCC 8th ed.)","Prognostic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Carcinoma AJCC v8 | Stage IV Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526917","Prognostic Stage IA Breast Cancer AJCC v8","C139557","Stage IA includes: (T1, N0, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T1, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (T0-1, N1mi, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T0-1, N1mi, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (MultiGene Panel-Oncotype Dx Recurrence Score Less Than 11, T1-2, N0, M0, G1-3, HER2 Status: Negative, ER Status: Positive, PR Status: Any). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)","Prognostic Stage IA Breast Cancer AJCC v8 | Prognostic Stage IA Breast Carcinoma AJCC v8 | Stage IA Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526911","Prognostic Stage 0 Breast Cancer AJCC v8","C139555","Stage 0 includes: Tis, N0, M0, G1-3, HER2 Status: Any, ER Status: Any, PR Status: Any. Tis: Ductal carcinoma in situ. Lobular carcinoma in situ is a benign entity and is removed from TNM staging in the AJCC Cancer Staging Manual, 8th Edition. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)","Prognostic Stage 0 Breast Cancer AJCC v8 | Prognostic Stage 0 Breast Carcinoma AJCC v8 | Stage 0 Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514316","Matched Related Donor","C131675","A donor who is related to the transplant recipient, and who is a human leukocyte antigen (HLA) tissue type match.","Matched Related Donor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512360","HLA Mismatch Count","C128933","The determination of the total number of mismatches between the study subject and his or her donor for the human leukocyte antigens (HLA).","HLA Mismatch Count | HLAMSC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540767","Cerebral Adrenoleukodystrophy","C142852","A subtype of adrenoleukodystrophy (ALD) occurring in approximately 40 percent of boys with ALD, primarily affecting the cerebrum, resulting in rapidly declining neurocognitive function and in most patients, premature death.","Cerebral Adrenoleukodystrophy | CALD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041281","Enteral Tube Feeding","C93322","Delivery of enteral nutrition via a tube placed into the stomach, duodenum, or jejunum.","Enteral Tube Feeding | tubefeeding",,,,,,,,,,,,,,,"4263536","Tube feeding of patient",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0184148","Nasojejunal Tube","C122597","A hollow tube that is directed into the jejunum from the nose.","Nasojejunal Tube | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053965","Surgically Placed Gastrostomy Tube","C122622","A hollow tube that is inserted into a surgically created external opening into the stomach.","Surgically Placed Gastrostomy Tube | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507993","Hematopoietic Cell Transplantation Recipient","C126836","An individual receiving a hematopoietic cell transplant.","Hematopoietic Cell Transplant Recipient | Hematopoietic Cell Transplantation Recipient | Hematopoietic Cell Transplantation Recipient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540112","ALK Fusion Gene Positive","C142114","An indication that an ALK fusion gene has been detected in a sample.","ALK Fusion Gene Positive | ALK Fusion Gene Present | ALK Fusion Oncogene Positive | ALK Gene Fusion | Anaplastic Lymphoma Kinase Fusion Gene Positive | Anaplastic Lymphoma Kinase Fusion Oncogene Positive | Anaplastic Lymphoma Receptor Tyrosine Kinase Fusion Gene Alteration Positive | CD246 Fusion Gene Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540113","Blasts 10 Percent or Less of Bone Marrow Nucleated Cells","C142113","A semi-quantitative microscopic finding indicating that at most 10 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 10 Percent or Less of Bone Marrow Nucleated Cells | Blasts Less than or Equal to 10 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540114","Blasts More than 5 Percent of Bone Marrow Nucleated Cells","C142112","A semi-quantitative microscopic finding indicating that more than 5 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts More than 5 Percent of Bone Marrow Nucleated Cells | Blasts Greater than 5 Percent of Bone Marrow Nucleated Cells | Blasts Over 5 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540739","Histone H3 Trimethyl Lys36","C142872","A post-translationally modified form of histone H3 where the lysine residue at position 36 is trimethylated. This modification may be involved in defining exon boundaries; it also may be a marker for genes targeted for transcriptional repression.","Histone H3 Trimethyl Lys36 | H3K36me3 | Histone H3 Trimethyl Lysine 36 | Trimethylated Histone H3 at Lysine 36",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541325","Long Course Chemoradiotherapy","C142874","Chemoradiotherapy generally consisting of 45 Gy given in 25 fractions over 5 weeks with concomitant chemotherapy as a radiosensitizer.","Long Course Chemoradiotherapy | LCCRT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541326","Short Course Chemoradiotherapy","C142875","Chemoradiotherapy generally consisting of 25 Gy in 5 fractions given in 1 week with concomitant chemotherapy as a radiosensitizer.","Short Course Chemoradiotherapy | SCCRT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540753","CB-1158","C142866","An orally available inhibitor of arginase, a manganese-dependent enzyme that hydrolyzes the amino acid arginine to form ornithine and urea, with potential immunomodulating and antineoplastic activities. Upon administration, numidargistat inhibits the breakdown of arginine by arginase, which is produced by myeloid cells, and restores arginine levels. This allows arginine to stimulate the synthesis of nitric oxide and the secretion of pro-inflammatory cytokines and chemokines, which induces the proliferation and activation of T-cells. Therefore, this agent may prevent the immunosuppressive effects of tumor-infiltrating myeloid cells and promote lymphocyte-mediated immune responses against tumor cells. Arginase is produced by neutrophils, macrophages and myeloid-derived suppressor cells (MDSC) and plays a role in inflammation-associated immunosuppression.","Numidargistat | Arginase Inhibitor INCB001158 | Arginase Inhibitor INCB001158 | CB-1158 | CB1158 | INCB001158 | NUMIDARGISTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540748","Real Imager 8","C142871","A proprietary imaging system designed to determine breast health through the acquisition and analysis of 3D imaging biomarkers. It provides a radiation-free complement for mammography particularly suited for women with dense breast tissue.","Real Imager 8 | RI8 | RI8 Imaging Device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540752","Metastatic Microsatellite Stable Colorectal Carcinoma","C142867","A microsatellite stable carcinoma that arises from the colon or rectum and has metastasized to other anatomic sites.","Metastatic Microsatellite Stable Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540751","Advanced Microsatellite Stable Colorectal Carcinoma","C142868","A microsatellite stable carcinoma that arises from the colon or rectum and has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Microsatellite Stable Colorectal Carcinoma | Advanced Microsatellite Stable Colorectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540750","Metastatic Bile Duct Carcinoma","C142869","A carcinoma that arises from the intrahepatic or extrahepatic bile ducts and has metastasized to other anatomic sites.","Metastatic Bile Duct Carcinoma | Metastatic Bile Duct Cancer | Metastatic Biliary Tract Cancer | Metastatic Biliary Tract Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540749","Advanced Bile Duct Carcinoma","C142870","A carcinoma that arises from the intrahepatic or extrahepatic bile ducts and has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Bile Duct Carcinoma | Advanced Bile Duct Cancer | Advanced Biliary Tract Cancer | Advanced Biliary Tract Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540754","Anti-PD-1 Monoclonal Antibody Sym021","C142865","A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1 , PCD-1; PDCD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody Sym021 binds to and inhibits PD-1 activation and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF), is expressed on T-cells and functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death ligand 1 (PD-L1) or 2 (PD-L2). Activated PD-1 plays an important role in tumor evasion from host immunity.","Anti-PD-1 Monoclonal Antibody Sym021 | Anti-PD1 Monoclonal Antibody Sym021 | SYM-021 | Sym021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019342","Genital Herpes","C14364","Herpes simplex infection of the genitals, most commonly caused by the herpes simplex-2 virus.","Genital Herpes | ",,,,,,,,,,,,,,,"74855","Genital herpes simplex",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042998","Vulvovaginitis","C35131","An inflammatory pathologic process that affects the vulva and the vagina.","Vulvovaginitis | ",,,,,,,,,,,,,,,"4180978","Vulvovaginitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0000734","Abdominal Mass","C34333","An abnormal growth in the abdomen.","Abdominal Mass | ",,,,,,,,,,,,,,,"192438","Abdominal mass",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL449210","Submucosal","C96296","Occurring in, or located in the submucosa.","Submucosal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0729264","Preterm Premature Rupture of Membrane","C92862","Spontaneous rupture of fetal membranes that occurs before the onset of labor and before 37 weeks.","Preterm Premature Rupture of Membrane | PPROM | Preterm Premature Rupture of Membranes",,,,,,,,,,,,,,,"4208215","Preterm premature rupture of membranes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014586","Episiotomy","C92774","A surgical widening of the introitus by cutting into the musculature of the maternal perineum with a linear midline or oblique incision so as to facilitate vaginal childbirth.","Episiotomy | ",,,,,,,,,,,,,,,"4311671","Episiotomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0269932","Postpartum Endometritis","C111914","Infection of the endometrium, decidua and/or myometrium occurring at any time between birth and 42 days postpartum.","Postpartum Endometritis | Puerperal Endometritis | Puerperal Endomyometritis",,,,,,,,,,,,,,,"4328870","Puerperal endometritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032797","Postpartum Hemorrhage","C92853","Hemorrhage defined as a blood loss in excess of 500 mL after vaginal delivery or more than 1000 mL after a cesarean delivery.","Postpartum Hemorrhage | ",,,,,,,,,,,,,,,"443929","Postpartum hemorrhage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0156406","Postcoital Bleeding","C35220","Non-menstrual bleeding that occurs during or after sexual intercourse.","Postcoital Bleeding | ",,,,,,,,,,,,,,,"194093","Postcoital bleeding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540715","Perfusion Computed Tomography Target Lesion","C142817","A target lesion that has been identified by computed tomography perfusion imaging.","Perfusion Computed Tomography Target Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540716","Conventional Imaging","C142816","Imaging using computed tomography, magnetic resonance imaging, or ultrasound.","Conventional Imaging | Conventional CT | Conventional MRI | Conventional US",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540717","Imaging Core Lab","C142815","A shared facility for imaging services.","Imaging Core Lab | Core Lab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0233187","Braxton-Hicks Contraction","C113488","Irregular infrequent uterine contractions typically characteristic of the third trimester of pregnancy that do not result in cervical change or labor.","Braxton-Hicks Contraction | Braxton-Hicks Contractions | False Labor | Preterm Contractions",,,,,,,,,,,,,,,"4139126","Braxton Hicks contractions",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004768","Bartholin Gland","C12675","The two mucous secreting glands on either side of the vaginal opening.","Bartholin Gland | Bartholin's Gland",,,,,,,,,,,,,,,"4336841","Bartholin's gland structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227782","Skene Gland","C61122","A gland located in the anterior wall of the vagina that drains into the urethra at the opening.","Skene Gland | Paraurethral Skene Gland | Skene's Gland",,,,,,,,,,,,,,,"4100476","Structure of minor vestibular gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540729","Hyperfractionated Accelerated Radiation Delivered with Integrated Neck Surgery","C142774","The integration of planned neck surgery subsequent to the delivery of hyperfractionated accelerated radiation.","Hyperfractionated Accelerated Radiation Delivered with Integrated Neck Surgery | HARDWINS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540728","The Danish Head and Neck Cancer Group","C142775","A permanent working group under the Danish Society for Head and Neck Oncology with the primary aim to develop national guidelines for the treatment of head and neck cancer in Denmark.","The Danish Head and Neck Cancer Group | DAHANCA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707382","Bavituximab","C49088","A chimeric, IgG1 monoclonal antibody directed against anionic phospholipids with potential antineoplastic activity. Bavituximab binds to anionic phospholipids in a beta 2-glycoprotein I-dependent manner, inhibiting tumor growth by stimulating antibody-dependent cellular cytotoxicity (ADCC) to tumor vessels.","Bavituximab | BAVITUXIMAB | Chimeric Anti-Phosphotidylserine Monoclonal Antibody | PGN 401 | PGN-401 | PGN401 | Tarvacin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983812","Mirabegron","C90633","An orally bioavailable agonist of the human beta-3 adrenergic receptor (ADRB3), with muscle relaxing, neuroprotective and potential antineoplastic activities.  Upon oral administration, mirabegron binds to and activates ADRB3, which leads to smooth muscle relaxation. Mirabegron also restores sympathetic stimulation in mesenchymal stem cell (MSC) niches, inhibits JAK2-mutated hematopoietic stem cell (HSC) expansion and blocks the progression of myeloproliferative neoplasms (MPNs). Lack of sympathetic stimulation of the MSC and HSC niche is associated with the development of MPNs.","Mirabegron | 2-(2-Aminothiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl] Acetamide | 4-Thiazoleacetamide, 2-Amino-N-(4-(2-(((2R)-2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)- | Betanis | MIRABEGRON | Myrbetriq | YM-178 | YM178",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540198","FGF19 Positive","C142119","An indication that FGF19 expression has been detected in a sample.","FGF19 Positive | FGF-19 Positive | Fibroblast Growth Factor 19 Positive | Fibroblast Growth Factor-19 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540199","Activating PIK3R2 Gene Mutation","C142118","A change in the nucleotide sequence of the PIK3R2 gene that that results in constitutive activation of phosphatidylinositol 3-kinase regulatory subunit beta and its downstream signaling pathways.","Activating PIK3R2 Gene Mutation | Activating P85B Gene Mutation | Activating Phosphoinositide-3-Kinase Regulatory Subunit 2 Gene Mutation | Activating p85-BETA Gene Mutation | PIK3R2 Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540109","Activating PIK3R1 Gene Mutation","C142117","A change in the nucleotide sequence of the PIK3R1 gene that that results in constitutive activation of phosphatidylinositol 3-kinase regulatory subunit alpha and its downstream signaling pathways.","Activating PIK3R1 Gene Mutation | Activating GRB1 Gene Mutation | Activating Phosphoinositide-3-Kinase Regulatory Subunit 1 Gene Mutation | Activating p85-ALPHA Gene Mutation | PIK3R1 Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540110","Activating PIK3CA Gene Mutation","C142116","A change in the nucleotide sequence of the PIK3CA gene that that results in constitutive activation of phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform and its downstream signaling pathways.","Activating PIK3CA Gene Mutation | Activating PI3K-Alpha Gene Mutation | Activating PI3KCA Gene Mutation | Activating Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Gene Mutation | Activating p110-alpha Gene Mutation | PIK3CA Activating Mutation | PIK3CA Activation Mutation | PIK3CA Gain of Function Gene Mutation | PIK3CA Gain of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540111","Activating AKT1 Gene Mutation","C142115","A change in the nucleotide sequence of the AKT1 gene that that results in constitutive activation of RAC-alpha serine/threonine-protein kinase and its downstream signaling pathways.","Activating AKT1 Gene Mutation | AKT1 Activating Mutation | Activating AKT Gene Mutation | Activating v-akt Murine Thymoma Viral Oncogene Homolog 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498224","anti-CSF1R monoclonal antibody FPA008","C123831","A humanized monoclonal antibody directed against the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R; CSF-1R), also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), with potential antineoplastic activity. Upon administration, anti-CSF1R monoclonal antibody FPA008 binds to CSF1R expressed on monocytes, macrophages, and osteoclasts and inhibits the binding of the CSF1R ligands colony-stimulating factor-1 (CSF-1) and interleukin-34 (IL-34), to CSF1R. This prevents CSF1R activation and CSF1R-mediated signaling in these cells. This blocks the production of inflammatory mediators by macrophages and monocytes and reduces inflammation. By blocking the recruitment to the tumor microenvironment and activity of CSF1R-dependent tumor-associated macrophages (TAMs), FPA008 enhances T-cell infiltration and antitumor T-cell immune responses, which inhibits the proliferation of tumor cells. Additionally, FPA008 prevents the activation of osteoclasts and blocks bone destruction. TAMs play key roles in immune suppression and promoting inflammation, tumor cell proliferation and survival.","Cabiralizumab | Anti-CSF1R FPA008 | Anti-CSF1R Monoclonal Antibody FPA008 | BMS-986227 | CABIRALIZUMAB | Cabiralizumab | FPA 008 | FPA-008 | FPA008",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540195","BRCA2 Biallelic Inactivation","C142122","The presence of mutations in both alleles of the BRCA2 gene that either lead to loss of expression of the BRCA2 protein or result in the translation of an inactive BRCA2 protein.","BRCA2 Biallelic Inactivation | BRCA2 Biallelic Gene Inactivation | BRCC2 Biallelic Gene Inactivation | BROVCA2 Biallelic Gene Inactivation | Breast Cancer 2 Biallelic Gene Inactivation | Breast Cancer 2, Early Onset Biallelic Gene Inactivation | Breast Cancer Type 2 Susceptibility Biallelic Gene Inactivation | FANCD1 Biallelic Gene Inactivation | XRCC11 Biallelic Gene Inactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540196","BRCA1 Biallelic Inactivation","C142121","The presence of mutations in both alleles of the BRCA1 gene that either lead to loss of expression of the BRCA1 protein or result in the translation of an inactive BRCA1 protein.","BRCA1 Biallelic Inactivation | BRCA1 Biallelic Gene Inactivation | BROVCA1 Biallelic Gene Inactivation | Breast Cancer 1 Biallelic Gene Inactivation | Breast Cancer 1, Early Onset Biallelic Gene Inactivation | Breast Cancer Type 1 Susceptibility Biallelic Gene Inactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540197","ATM Biallelic Inactivation","C142120","The presence of mutations in both alleles of the ATM gene that either lead to loss of expression of the ATM protein or result in the translation of an inactive ATM protein.","ATM Biallelic Inactivation | A-T Mutated Gene Deletion | AT Mutated Biallelic Gene Inactivation | ATM Biallelic Gene Inactivation | ATM Serine/Threonine Kinase Biallelic Gene Inactivation | Ataxia Telangiectasia Mutated Biallelic Gene Inactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540192","ENX-1 Gain of Function Mutation","C142125","A mutation in the EZH2 gene that leads to increased histone-lysine N-methyltransferase EZH2 activity.","Activating EZH2 Gene Mutation | Activating EZH2 Gene Mutation | ENX-1 Gain of Function Mutation | EZH2 Activating Mutation | EZH2 Gain of Function | EZH2 Gain of Function | EZH2 Gain of Function Gene Mutation | EZH2 Gain of Function Mutation | Enhancer of Zeste 2 Polycomb Repressive Complex 2 Subunit Gene Gain of Function Mutation | KMT6A Gain of Function Mutation | KTM6A Gain of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540193","Activated B-Cell Positive","C142124","An indication that actively proliferating and differentiating B-lymphocytes have been detected in a sample.","Activated B-Cell Positive | ABC Positive | Activated B Cell Positive | Activated B Cells Present | Activated B Lymphocyte Positive | Activated B Lymphocytes Present | Activated B-Cells Present | Activated B-Lymphocyte Positive | Activated B-Lymphocytes Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540194","ROR1 Positive","C142123","An indication that ROR1 expression has been detected in a sample.","ROR1 Positive | NTRKR1 Positive | Receptor Tyrosine Kinase-Like Orphan Receptor 1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540206","HTLV-1 Positive","C142127","An indication that HTLV-1 was detected in a sample.","HTLV-1 Positive | HTLV-I Positive | Human T Cell Lymphotropic Virus 1 Positive | Human T-Cell Lymphotropic Virus 1 Positive | Human T-Lymphotropic Virus 1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540207","SMARCA4 Gene Mutation","C142126","A change in the nucleotide sequence of the SMARCA4 gene.","SMARCA4 Gene Mutation | BAF190 Gene Mutation | BAF190A Gene Mutation | BRG-1 Gene Mutation | BRG1 Gene Mutation | BRM/SWI2-Related Gene 1 Mutation | SMARCA4 mutation | SNF2 Gene Mutation | SNF2-Beta Gene Mutation | SNF2L4 Mutation | SNF2LB Gene Mutation | SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily A, Member 4 Gene Mutation | SWI1 Gene Mutation | SWI2 Gene Mutation | hSNF2b Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541410","Anti-LAG-3 Monoclonal Antibody TSR-033","C142978","A humanized, immunoglobulin G4 (IgG4) monoclonal antibody directed against the inhibitory receptor lymphocyte activation gene 3 protein (LAG3; LAG-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration,encelimab binds to LAG3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells, and negatively regulates both proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.","Encelimab | Anti-LAG-3 Monoclonal Antibody TSR-033 | Anti-LAG3 Monoclonal Antibody TSR-033 | Anti-LAG3 Monoclonal Antibody TSR-033 | Anti-Lymphocyte Activation Gene 3 Protein Monoclonal Antibody TSR-033 | ENCELIMAB | TSR 033 | TSR-033 | TSR033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3491971","Insulin Degludec","C142979","A recombinant, long-acting analog of human insulin, with blood glucose-lowering activity. Upon subcutaneous injection, insulin degludec forms a multi-hexameric depot from which insulin monomers are slowly released into the systemic circulation. Insulin regulates glucose metabolism by binding to insulin receptors on muscle and fat cells, which stimulates the cellular uptake of glucose and lowers blood glucose levels. Insulin inhibits the liver's conversion of stored glycogen into glucose, which also contributes to lower blood glucose levels. In addition, insulin inhibits lipolysis in adipose tissue, inhibits proteolysis, and enhances protein synthesis. Insulin degludec doesn't contain the amino acid threonine that is found at position B30 in human insulin; additionally, the lysine at position B29 is conjugated to hexadecanedioic acid, which allows the formation of the multi-hexamers upon subcutaneous injection. The phenol and zinc present in the pharmaceutical formulation promote a di-hexameric state of insulin degludec.","Insulin Degludec | (1A-21A),(1B-29B)-Insulin (human), 29B-(N6-(N-(15-carboxy-1-oxopentadecyl)-L-gamma-glutamyl)-L-lysine)- | INSULIN DEGLUDEC | NN1250 | Tresiba",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540202","Increasing MRD","C142131","A finding indicating an increased presence of residual disease over time.","Increasing Levels of Measurable Residual Disease | Increasing Levels of Minimal Residual Disease | Increasing Levels of Minimal Residual Disease | Increasing MRD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540203","MAPK Gene Alteration Positive","C142130","A finding indicating that mutation, overexpression or rearrangement of a MAPK family gene has been detected in a sample.","MAPK Gene Alteration Positive | ERK Alteration Positive | ERK Family Alteration Positive | ERK Family Gene Alteration Positive | Extracellular Signal-Regulated Kinase Family Gene Alteration Positive | MAPK Family Gene Alteration Positive | Mitogen-Activated Protein Kinase Family Gene Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540204","PSA Level Less than or Equal to Thirty","C142129","A blood concentration of prostate specific antigen less than or equal to 30 ng/mL.","PSA Level Less than or Equal to Thirty | PSA Level 30 or Less | PSA Level Less than or Equal to 30 | PSA Level Thirty or Less",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540205","PSA Level Less than Thirty","C142128","A blood concentration of prostate specific antigen less than 30 ng/mL.","PSA Level Less than Thirty | PSA Level Less than 30",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541412","Selective Estrogen Receptor Covalent Antagonist H3B-6545","C142980","An orally available, selective and covalent antagonist of estrogen receptor alpha (ERalpha; ERa; ESR1; nuclear receptor subfamily 3, group A, member 1; NR3A1), with potential antineoplastic activity. Upon oral administration, selective estrogen receptor covalent antagonist (SERCA) H3B-6545 selectively and covalently binds to a cysteine that is unique to ERalpha and is not present in other nuclear hormone receptors, thereby inhibiting the activity of ERalpha. This inhibits the growth and survival of ERalpha-expressing cancer cells. ERalpha, a nuclear hormone receptor, is often overexpressed and/or mutated in a variety of cancer cell types. It plays a key role in tumor cell proliferation and survival.","Selective Estrogen Receptor Covalent Antagonist H3B-6545 | H3B 6545 | H3B-6545 | H3B6545 | SERCA H3B-6545",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540182","t(11;14) Positive","C142136","A cytogenetic finding indicating that the translocation t(11;14) has been detected in a sample.","t(11;14) Positive | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540183","ALK Fusion Positive","C142135","An indication that ALK fusion expression has been detected in a sample.","ALK Fusion Positive | ALK Tyrosine Kinase Receptor Fusion Positive | Anaplastic Lymphoma Kinase Fusion Positive | CD246 Antigen Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540184","KRAS Positive","C142134","An indication that KRAS expression has been detected in a sample.","KRAS Positive | GTPase Kras Positive | KRAS Proto-Oncogene, GTPase Positive | KRAS-2 Positive | RASK Positive | c-K-ras Positive | p21 K-Ras Positive | v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540200","CTNNB1 Positive","C142133","An indication that CTNNB1 expression has been detected in a sample.","CTNNB1 Positive | Beta Catenin Positive | Beta-Catenin Positive | CTNNB Positive | Catenin Beta-1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540201","Activating FGFR3 Gene Mutation","C142132","A change in the nucleotide sequence of the FGFR3 gene that that results in constitutive activation of fibroblast growth factor 3 and its downstream signaling pathways.","Activating FGFR3 Gene Mutation | Activating CD333 Gene Mutation | Activating FGFR-3 Gene Mutation | Activating FGFR3 Mutation | Activating Fibroblast Growth Factor Receptor 3 Gene Mutation | Activating JKT4 Gene Mutation | Activating JTK4 Gene Mutation | FGFR3 Activating Mutation | FGFR3 Gain of Function Gene Mutation | FGFR3 Gain of Function Mutation | Gain of Function FGFR3 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708050","Fiberoptic","C50358","A device made with thin fibers of glass or plastic as a conduit for the transmission of light.","Fiber Optic Device | Fiber Optic Device | Fiber-optic Device | Fiberoptic | Fiberoptic Device | Fiberoptic Device | Optical Fiber Device | fiberoptic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040736","Autologous Transplantation","C142985","Transplantation in which the patient is their own donor.","Autologous Transplantation | Autologous Transplant",,,,,,,,,,,,,,,"4200535","Autogenous transplantation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2717829","Polychemotherapy","C142984","Chemotherapy involving the simultaneous administration of two or more cytotoxic drugs.","Polychemotherapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546053","Friability","C142884","A finding indicating the tendency of a tissue sample or solid substance to break into small pieces under pressure or contact.","Friability | ",,,,,,,,,,,,,,,"4281912","Friability",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL541377","Post-Abortion Endometritis","C142885","Endometritis that develops following an abortion.","Post-Abortion Endometritis | Postabortal Endometritis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221376","Hydrosalpinx","C142886","Fluid accumulation and dilatation of the fallopian tube due to tubal blockage.","Hydrosalpinx | Hydrosalpinx ",,,,,,,,,,,,,,,"4067971","Hydrosalpinx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540131","CD3 Negative","C142095","An indication that expression of CD3 has not been detected in a sample.","CD3 Negative | CD3 Antigen Negative | CD3 Complex Negative | T-Cell Surface Glycoprotein CD3 Negative | T3 Complex Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540108","CTAG1B Positive","C142102","An indication that CTAG1B expression has been detected in a sample.","CTAG1B Positive | CT6.1B Positive | Cancer/Testis Antigen 1B Positive | ESO1B Positive | LAGE-2B Positive | LAGE2B Positive | NY-ESO-1B Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714906","Tumor Grade GB","C113729","A morphologic qualifier indicating that a neoplasm is of borderline malignancy.","Grade B | Borderline Grade | Borderline Histologic Grade | GB",,,,,,,,,,,,,,,"37164073","GB",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545976","Breath Actuated Nebulizer","C143007","A nebulizer that creates an aerosol in response to the patient's inspiratory flow.","Breath Actuated Nebulizer | BAN | Breath-Actuated Nebulizer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541395","CpG Oligodeoxynucleotide TLR9 Agonist DV281","C143006","A proprietary synthetic, aerosolized C-class CpG oligodeoxynucleotide-based (ODN) agonist of toll-like receptor 9 (TLR9), with potential immunostimulating activity. Upon inhalation, CpG ODN TLR9 agonist DV281 specifically targets, binds to and activates TLR9 expressed by plasmacytoid dendritic cells (pDCs) and B-cells. This initiates immune signaling pathways and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against antigens expressed by lung cancer cells. TLR9, a member of the TLR family, plays a fundamental role in pathogen recognition and activation of the innate immune system.","CpG Oligodeoxynucleotide TLR9 Agonist DV281 | CPG ODN TLR9 Agonist DV281 | DV 281 | DV-281 | DV281 | TLR9 Agonist DV281",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541502","Recurrent Skin Squamous Cell Carcinoma","C143012","The reemergence of squamous cell carcinoma of the skin after a period of remission.","Recurrent Skin Squamous Cell Carcinoma | Recurrent Cutaneous Squamous Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087141","Metastatic Skin Squamous Cell Carcinoma","C143013","Squamous cell carcinoma of the skin which has spread to other anatomic sites.","Metastatic Skin Squamous Cell Carcinoma | Metastatic Cutaneous Squamous Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541503","Neurofibromatosis Type 1 with Inoperable, Progressive, Symptomatic Plexiform Neurofibromas","C143014","Progressive, symptomatic neurofibromatosis type 1 associated with plexiform neurofibromas that cannot be removed surgically without risk of substantial morbidity.","Neurofibromatosis Type 1 with Inoperable, Progressive, Symptomatic Plexiform Neurofibromas | NF Type 1 with Inoperable, Progressive, Symptomatic Plexiform Neurofibromas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541488","Formalin-Fixed Paraffin-Embedded","C143028","Refers to a process where a sample is preserved with formalin and then embedded into a paraffin block for sectioning.","Formalin-Fixed Paraffin-Embedded | FFPE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0680330","Waterpipe","C143029","A device for smoking herbal substances that filters and cools the smoke by passing it through water.","Waterpipe | Bong | Water Pipe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0430853","Intraoperative Nerve Monitoring","C143030","The use of electrophysiological methods to evaluate the functional integrity of neural structures during surgery.","Intraoperative Nerve Monitoring | IONM | Intraoperative Neuromonitoring | Intraoperative Neurophysiological Monitoring",,,,,,,,,,,,,,,"4098799","Intraoperative neurophysiological monitoring",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0373705","Progesterone Measurement","C74791","The determination of the amount of progesterone present in a sample.","Progesterone Measurement | PROGEST | Progesterone",,,,,,,,,,,,,,,"4263754","Progesterone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0851563","Vascular Hemorrhagic Disorder","C35595","A hemorrhagic disorder that is caused by pathologic changes in the vasculature.","Vascular Hemorrhagic Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520951","ypTNM Finding","C133398","Pathologic TNM staging performed with access to postneoadjuvant therapy information only.","Postneoadjuvant Therapy Pathologic TNM Finding | Postneoadjuvant Therapy Pathologic TNM Finding | Postneoadjuvant Therapy TNM Finding | ypTNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541569","Posttherapy Clinical TNM Finding","C143081","Clinical TNM staging performed following systemic therapy or radiation.","Posttherapy Clinical TNM Finding | ycTNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521161","AJCC v8 Stage","C132248","A cancer stage defined according to the AJCC 8th edition criteria.","AJCC v8 Stage | 8th",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524483","PSA Level Less than Fifty","C136611","A blood concentration of prostate specific antigen less than or equal to 50 ng/mL.","PSA Level Less than Fifty | PSA Level Less than 50",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524423","PSA Level Greater than or Equal to One","C136574","A blood concentration of prostate specific antigen greater than or equal to 1 ng/mL.","PSA Level Greater than or Equal to One | PSA Level 1 or Greater | PSA Level 1.0 or Greater | PSA Level Greater than or Equal to 1 | PSA Level One or Greater",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538458","Blasts 25 Percent or More of Bone Marrow Nucleated Cells","C140330","A semi-quantitative microscopic finding indicating that 25 percent or more of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 25 Percent or More of Bone Marrow Nucleated Cells | Blasts 25% or More of Bone Marrow Nucleated Cells | Blasts Greater than or Equal to 25 Percent of Bone Marrow Nucleated Cells | M3 (greater than 25% blasts)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524766","Deleterious EPCAM Gene Mutation","C136970","A change in the nucleotide sequence of the EPCAM gene that is associated with increased risk of disease.","Deleterious EPCAM Gene Mutation | Deleterious Epithelial Cell Adhesion Molecule Gene Mutation | Deleterious TACSTD1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524610","IDH1 R132H Negative","C136746","A finding indicating that a mutation of the IDH1 gene encoding the amino acid substitution Arg132His (R132H) in the isocitrate dehydrogenase [NADP] cytoplasmic protein has not been detected in a sample.","IDH1 R132H Negative | Cytosolic NADP-Isocitrate Dehydrogenase Protein Arg132His Negative | Cytosolic NADP-Isocitrate Dehydrogenase Protein R132H Negative | IDH1 Arg132His Negative | IDH1 NP_005887.2:p.Arg132His Negative | IDH1 NP_005887.2:p.R132H Negative | IDH1 R132H Substitution Negative | IDH1 p.Arg132His Negative | IDH1 p.R132H Negative | Isocitrate Dehydrogenase [NADP] Cytoplasmic Arg132His Negative | Isocitrate Dehydrogenase [NADP] Cytoplasmic R132H Negative | NP_005887.2:p.Arg132His Negative | NP_005887.2:p.R132H Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029295","Oropharyngeal Neoplasm","C3291","A benign or malignant neoplasm that affects the oropharynx.","Oropharyngeal Neoplasm | Neoplasm of Oropharynx | Neoplasm of the Oropharynx | Oropharyngeal Neoplasms | Oropharyngeal Tumor | Tumor of Oropharynx | Tumor of the Oropharynx",,,,,,,,,,,,,,,"4054617","Neoplasm of oropharynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL525674","TRK Receptor Family Alteration Positive","C138155","Indicates that mutation, overexpression, or rearrangement of an TRK receptor family member has been detected in a sample.","TRK Receptor Family Alteration Positive | NTRK Alteration | NTRK Alteration Positive | TRK Alteration | TRK Alteration Positive | TRK Receptor Alteration | TRK Receptor Family Alteration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525673","TRK Receptor Family Fusion Positive","C138156","Indicates that the expression of a fusion involving a TRK receptor family member has been detected in a sample.","TRK Receptor Family Fusion Positive | NTRK Family Fusion Positive | NTRK Fusion | NTRK Fusion Positive | TRK Fusion | TRK Receptor Family Fusion | TRK Receptor Fusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539398","Blasts 30 Percent or Less of Bone Marrow Nucleated Cells","C141297","A semi-quantitative microscopic finding indicating that 30 percent or less of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 30 Percent or Less of Bone Marrow Nucleated Cells | Blasts Less than or Equal to 30 Percent of Bone Marrow Nucleated Cells | Blasts Under 31 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538560","DLL3 Positive","C140465","An indication that DLL3 expression has been detected in a sample.","DLL3 Positive | Delta Like Canonical Notch Ligand 3 Positive | Delta-Like 3 Positive | Delta3 Positive | Drosophila Delta Homolog 3 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538352","HLA-A1101 Positive Cells Present","C140184","A laboratory test result indicating the presence of HLA-A1101 positive cells in a tissue sample.","HLA-A1101 Positive Cells Present | HLA-A*01:01 Positive | HLA-A*01:01 Positive Cells Present | HLA-A*1101 Positive | HLA-A*1101 Positive Cells Present | HLA-A*11:01 Positive | HLA-A*11:01 Positive Cells Present | HLA-A1101 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085358","T-Cell Surface Glycoprotein CD8","C139799","A dimeric protein complex that functions as a co-receptor for the T-cell receptor and is involved with both signal transduction in and antigen interactions with T-lymphocytes. CD8 is commonly composed of a heterodimer of the T-cell surface glycoprotein CD8 alpha and beta chains, but functional homodimers of the alpha chain also exist.","T-Cell Surface Glycoprotein CD8 | CD8 | CD8 Antigen | CD8 Co-Receptor | CD8 Complex",,,,,,,,,,,,,,,"4182363","Lymphocyte antigen CD8",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526886","MGMT Gene Promoter Hypermethylation","C139588","A genetic finding indicating an excess of DNA methylation in the promoter region of the MGMT gene.","MGMT Gene Promoter Hypermethylation | Hypermethylated MGMT Gene Promoter | Methylguanine-DNA Methyltransferase Gene Promoter Hypermethylation | O-6-Methylguanine-DNA Methyltransferase Gene Promoter Hypermethylation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525671","TRK Receptor Family Fusion Negative","C138158","Indicates that the expression of a fusion involving a TRK receptor family member has not been detected in a sample.","TRK Receptor Family Fusion Negative | NTRK Family Fusion Negative | NTRK Fusion Negative | Non-fusion NTRK | Non-fusion TRK | TRK Non-fusion | TRK Receptor Family Non-fusion | TRK Receptor Non-fusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521236","Oropharyngeal (p16-Negative) Cancer TNM Finding v8","C132909","A finding about one or more characteristics of p16-negative oropharyngeal cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to p16-negative squamous cell carcinomas of the oropharynx, oropharyngeal cancers without p16 immunostaining performed, minor salivary gland carcinomas of the oropharynx, and neuroendocrine carcinomas of the oropharynx. Oropharyngeal cancers which are p16-positive are staged according to the classification for p16-positive oropharyngeal cancers. (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521266","Oropharyngeal (p16-Negative) Cancer pTX TNM Finding v8","C132916","Oropharyngeal (p16-negative) cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer pTX TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma pTX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521267","Oropharyngeal (p16-Negative) Cancer pTis TNM Finding v8","C132917","Oropharyngeal (p16-negative) cancer with a finding of carcinoma in situ. (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer pTis TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma pTis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521265","Oropharyngeal (p16-Negative) Cancer pT4b TNM Finding v8","C132925","Oropharyngeal (p16-negative) cancer with very advanced local disease. Tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base or encases carotid artery. (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer pT4b TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma pT4b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521264","Oropharyngeal (p16-Negative) Cancer pT4a TNM Finding v8","C132924","Oropharyngeal (p16-negative) cancer with moderately advanced local disease. Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible. Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of the larynx. (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer pT4a TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma pT4a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521263","Oropharyngeal (p16-Negative) Cancer pT4 TNM Finding v8","C132922","Oropharyngeal (p16-negative) cancer with moderately advanced or very advanced local disease. (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer pT4 TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma pT4 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521262","Oropharyngeal (p16-Negative) Cancer pT3 TNM Finding v8","C132920","Oropharyngeal (p16-negative) cancer with tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis. (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer pT3 TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma pT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521261","Oropharyngeal (p16-Negative) Cancer pT2 TNM Finding v8","C132919","Oropharyngeal (p16-negative) cancer with tumor larger than 2 cm but not larger than 4 cm in greatest dimension. (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer pT2 TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma pT2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521260","Oropharyngeal (p16-Negative) Cancer pT1 TNM Finding v8","C132918","Oropharyngeal (p16-negative) cancer with tumor 2 cm or smaller in greatest dimension. (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer pT1 TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma pT1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521230","Oropharyngeal (p16-Negative) Cancer Clinical Regional Lymph Nodes TNM Finding v8","C132935","A clinical finding about one or more characteristics of oropharyngeal (p16-negative) cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Oropharyngeal (p16-Negative) Cancer Clinical Regional Lymph Nodes TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma Clinical Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521248","Oropharyngeal (p16-Negative) Cancer cNX TNM Finding v8","C132939","Oropharyngeal (p16-negative) cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer cNX TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma cNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521247","Oropharyngeal (p16-Negative) Cancer cN3b TNM Finding v8","C132957","Oropharyngeal (p16-negative) cancer with metastasis in any node(s) and clinically overt ENE(+). (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer cN3b TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma cN3b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521246","Oropharyngeal (p16-Negative) Cancer cN3a TNM Finding v8","C132955","Oropharyngeal (p16-negative) cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer cN3a TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma cN3a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521245","Oropharyngeal (p16-Negative) Cancer cN3 TNM Finding v8","C132953","Oropharyngeal (p16-negative) cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in any node(s) and clinically overt ENE(+). (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer cN3 TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma cN3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521244","Oropharyngeal (p16-Negative) Cancer cN2c TNM Finding v8","C132951","Oropharyngeal (p16-negative) cancer with metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer cN2c TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma cN2c TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521243","Oropharyngeal (p16-Negative) Cancer cN2b TNM Finding v8","C132949","Oropharyngeal (p16-negative) cancer with metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer cN2b TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma cN2b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521242","Oropharyngeal (p16-Negative) Cancer cN2a TNM Finding v8","C132947","Oropharyngeal (p16-negative) cancer with metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer cN2a TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma cN2a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521241","Oropharyngeal (p16-Negative) Cancer cN2 TNM Finding v8","C132945","Oropharyngeal (p16-negative) cancer with metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer cN2 TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma cN2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521240","Oropharyngeal (p16-Negative) Cancer cN1 TNM Finding v8","C132943","Oropharyngeal (p16-negative) cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (-). (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer cN1 TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma cN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521239","Oropharyngeal (p16-Negative) Cancer cN0 TNM Finding v8","C132941","Oropharyngeal (p16-negative) cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer cN0 TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma cN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521249","Oropharyngeal (p16-Negative) Cancer pM1 TNM Finding v8","C132987","Oropharyngeal (p16-negative) cancer with distant metastasis. (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer pM1 TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma pM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521238","Oropharyngeal (p16-Negative) Cancer cM1 TNM Finding v8","C132984","Oropharyngeal (p16-negative) cancer with distant metastasis. (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer cM1 TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma cM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521237","Oropharyngeal (p16-Negative) Cancer cM0 TNM Finding v8","C132983","Oropharyngeal (p16-negative) cancer without evidence of distant metastasis. (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer cM0 TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424333","PDLIM4 Gene","C24740","This gene plays a role in cytoskeletal modeling via regulation of actin fiber turnover.","PDLIM4 Gene | PDLIM4 | PDZ and LIM Domain 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1867391","RRAD Gene","C18523","This gene plays a role in signal transduction and is associated with diabetes mellitus.","RRAD Gene | RRAD | RRAD, Ras Related Glycolysis Inhibitor and Calcium Channel Regulator Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0795806","Chromosome 3, monosomy 3p","C36502","A cytogenetic abnormality that refers to the loss of all or part of the short arm of chromosome 3.","Loss of Chromosome 3p | 3p Deletion | del(3p)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521234","Oropharyngeal (p16-Negative) Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C132937","A pathologic finding about one or more characteristics of oropharyngeal (p16-negative) cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Oropharyngeal (p16-Negative) Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521259","Oropharyngeal (p16-Negative) Cancer pNX TNM Finding v8","C132959","Oropharyngeal (p16-negative) cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer pNX TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma pNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521258","Oropharyngeal (p16-Negative) Cancer pN3b TNM Finding v8","C132977","Oropharyngeal (p16-negative) cancer with metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+). (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer pN3b TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma pN3b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521257","Oropharyngeal (p16-Negative) Cancer pN3a TNM Finding v8","C132975","Oropharyngeal (p16-negative) cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer pN3a TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma pN3a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521256","Oropharyngeal (p16-Negative) Cancer pN3 TNM Finding v8","C132973","Oropharyngeal (p16-negative) cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+). (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer pN3 TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma pN3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521255","Oropharyngeal (p16-Negative) Cancer pN2c TNM Finding v8","C132971","Oropharyngeal (p16-negative) cancer with metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer pN2c TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma pN2c TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521254","Oropharyngeal (p16-Negative) Cancer pN2b TNM Finding v8","C132969","Oropharyngeal (p16-negative) cancer with metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer pN2b TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma pN2b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521253","Oropharyngeal (p16-Negative) Cancer pN2a TNM Finding v8","C132966","Oropharyngeal (p16-negative) cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer pN2a TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma pN2a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521252","Oropharyngeal (p16-Negative) Cancer pN2 TNM Finding v8","C132965","Oropharyngeal (p16-negative) cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer pN2 TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma pN2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521251","Oropharyngeal (p16-Negative) Cancer pN1 TNM Finding v8","C132963","Oropharyngeal (p16-negative) cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (-). (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer pN1 TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma pN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521250","Oropharyngeal (p16-Negative) Cancer pN0 TNM Finding v8","C132961","Oropharyngeal (p16-negative) cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) Cancer pN0 TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma pN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1257806","Chromosomal Instability","C48195","The instability of chromosomes is attributed to the continuous formation of novel chromosome mutations. These mutations form at an elevated rate in comparison to the normal cell population. The increased frequency of structural chromosome aberrations can be caused by an abnormally high incidence of DNA double-strand breaks and translocations. Screening for chromosomal breakage and rearrangement is used as a diagnostic tool in Fanconi anemia.","Chromosomal Instability | Chromosome Instability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517394","Gain of Chromosome 17q","C36484","A cytogenetic abnormality that refers to the duplication of all or part of the long arm of chromosome 17.","Gain of Chromosome 17q | 17q Gain | add(17q)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517408","Gain of Chromosome 2p","C36439","A cytogenetic abnormality that refers to the duplication of all or part of the short arm of chromosome 2.","Gain of Chromosome 2p | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514636","HLA-A*0205 Positive Cells Present","C131443","An indication that cells expressing HLA-A*0205 have been detected in a sample.","HLA-A*0205 Positive Cells Present | HLA-A*0205 Positive | HLA-A*02:05 Positive | HLA-A*02:05 Positive Cells Present | HLA-A0205 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522972","Androgen Receptor Splice Variant 3 Positive","C135616","An indication that androgen receptor splice variant 3 expression has been detected in a sample.","Androgen Receptor Splice Variant 7 Positive | AR-v7 Positive | AR-v7 Positive | AR3 Positive | Androgen Receptor Splice Variant 3 Positive | Androgen Receptor Splice Variant 7 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512308","PML/RARA Fusion Positive","C128836","Indicates that expression of the PML/RARA fusion has been detected in a sample.","PML/RARA Fusion Positive | PML-RAR Alpha Fusion Positive | PML-RAR Alpha Positive | PML-RARA Fusion Positive | PML-RARA Positive | PML/RAR Alpha Fusion Positive | PML/RAR Alpha Positive | PML/RARA Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425224","TRPM7 Gene","C98058","This gene plays a role in both ion transport and protein phosphorylation.","TRPM7 Gene | TRPM7 | Transient Receptor Potential Cation Channel Subfamily M Member 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273351","EZH2 Gene Mutation","C97311","A molecular genetic abnormality that refers to the presence of a mutation in the histone methyltransferase gene EZH2.","EZH2 Gene Mutation | ENX-1 Gene Mutation | ENX1 Gene Mutation | EZH2b Gene Mutation | Enhancer of Zeste 2 Gene Mutation | Enhancer of Zeste 2 Polycomb Repressive Complex 2 Subunit Gene Mutation | KMT6 Gene Mutation | KMT6A Gene Mutation | KTM6A Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273086","AKT Family Gene Mutation","C96865","A molecular genetic abnormality indicating the presence of mutations in the AKT family of genes.  This family includes the AKT1, AKT2, and AKT3 genes that are located on chromosomes 14, 19, and 1, respectively.","AKT Family Gene Mutation | AKT Gene Mutation | AKT Serine/Threonine Kinase Family Gene Mutation | AKT mutation | v-akt Murine Thymoma Viral Oncogene Homolog Gene Family Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983088","GNA11 Gene Mutation","C89714","A somatic mutation of the GNA11 gene which encodes guanine nucleotide-binding protein subunit alpha-11.","GNA11 Gene Mutation | G Protein Subunit Alpha 11 Gene Mutation | GA11 Gene Mutation | GNA-11 Gene Mutation | Guanine Nucleotide Binding Protein (G Protein), Alpha 11 Gene Mutation | Guanine Nucleotide-Binding Protein, Alpha-11 Gene Mutation | Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983087","GNAQ Gene Mutation","C89713","A somatic mutation of the GNAQ gene which encodes guanine nucleotide-binding protein G(q) subunit alpha.","GNAQ Gene Mutation | CMC1 Gene Mutation | G Protein Subunit Alpha q Gene Mutation | G-ALPHA-q Gene Mutation | GAQ Gene Mutation | Guanine Nucleotide Binding Protein (G Protein), Q Polypeptide Gene Mutation | Positive | SWS Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827310","FGFR4 Gene Mutation","C84092","Mutation of the fibroblast growth factor receptor 4 gene which is located on the long arm of chromosome 5. It has been described in patients with childhood rhabdomyosarcoma. Overexpression of this gene in these patients is associated with advanced stage disease and poor survival.","FGFR4 Gene Mutation | CD334 Gene Mutation | FGFR-4 Gene Mutation | FGFR4 mutation | Fibroblast Growth Factor Receptor 4 Gene Mutation | JTK2 Gene Mutation | TKF Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541540","c-Met Inhibitor","C143099","Any small molecule that inhibits the enzymatic activity of the receptor tyrosine kinase c-Met (hepatocyte growth factor receptor; HGFR).","c-Met Inhibitor | HGFR Inhibitor | Hepatocyte Growth Factor Receptor Inhibitor | MET Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519913","HPV-Mediated (p16-Positive) Oropharyngeal Cancer TNM Finding v8","C132858","A finding about one or more characteristics of HPV-mediated (p16-positive) oropharyngeal cancer, following the rules of the TNM AJCC v8 classification system. Oropharyngeal cancers which are p16-negative are staged according to the classification for oropharynx (p16-negative) and hypopharynx cancers. (from AJCC 8th Ed.)","HPV-Mediated (p16-Positive) Oropharyngeal Cancer TNM Finding v8 | HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519928","HPV-Mediated (p16-Positive) Oropharyngeal Cancer pT4 TNM Finding v8","C132866","HPV-mediated (p16-positive) oropharyngeal cancer with moderately advanced local disease. Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible or beyond. Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of the larynx. (from AJCC 8th Ed.)","HPV-Mediated (p16-Positive) Oropharyngeal Cancer pT4 TNM Finding v8 | HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma pT4 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519927","HPV-Mediated (p16-Positive) Oropharyngeal Cancer pT3 TNM Finding v8","C132865","HPV-mediated (p16-positive) oropharyngeal cancer with tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis. (from AJCC 8th Ed.)","HPV-Mediated (p16-Positive) Oropharyngeal Cancer pT3 TNM Finding v8 | HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma pT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519926","HPV-Mediated (p16-Positive) Oropharyngeal Cancer pT2 TNM Finding v8","C132864","HPV-mediated (p16-positive) oropharyngeal cancer with tumor larger than 2 cm but not larger than 4 cm in greatest dimension. (from AJCC 8th Ed.)","HPV-Mediated (p16-Positive) Oropharyngeal Cancer pT2 TNM Finding v8 | HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma pT2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519925","HPV-Mediated (p16-Positive) Oropharyngeal Cancer pT1 TNM Finding v8","C132863","HPV-mediated (p16-positive) oropharyngeal cancer with tumor 2 cm or smaller in greatest dimension. (from AJCC 8th Ed.)","HPV-Mediated (p16-Positive) Oropharyngeal Cancer pT1 TNM Finding v8 | HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma pT1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519924","HPV-Mediated (p16-Positive) Oropharyngeal Cancer pT0 TNM Finding v8","C132862","No primary identified. (from AJCC 8th Ed.)","HPV-Mediated (p16-Positive) Oropharyngeal Cancer pT0 TNM Finding v8 | HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma pT0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519907","HPV-Mediated (p16-Positive) Oropharyngeal Cancer Clinical Regional Lymph Nodes TNM Finding v8","C132872","A clinical finding about one or more characteristics of HPV-mediated (p16-positive) oropharyngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","HPV-Mediated (p16-Positive) Oropharyngeal Cancer Clinical Regional Lymph Nodes TNM Finding v8 | HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma Clinical Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519918","HPV-Mediated (p16-Positive) Oropharyngeal Cancer cN3 TNM Finding v8","C132875","HPV-mediated (p16-positive) oropharyngeal cancer with lymph node(s) metastasis, larger than 6 cm. (from AJCC 8th Ed.)","HPV-Mediated (p16-Positive) Oropharyngeal Cancer cN3 TNM Finding v8 | HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma cN3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519917","HPV-Mediated (p16-Positive) Oropharyngeal Cancer cN2 TNM Finding v8","C132874","HPV-mediated (p16-positive) oropharyngeal cancer with contralateral or bilateral lymph node metastasis, none larger than 6 cm. (from AJCC 8th Ed.)","HPV-Mediated (p16-Positive) Oropharyngeal Cancer cN2 TNM Finding v8 | HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma cN2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519916","HPV-Mediated (p16-Positive) Oropharyngeal Cancer cN1 TNM Finding v8","C132873","HPV-mediated (p16-positive) oropharyngeal cancer with metastasis in one or more ipsilateral lymph nodes, none larger than 6 cm. (from AJCC 8th Ed.)","HPV-Mediated (p16-Positive) Oropharyngeal Cancer cN1 TNM Finding v8 | HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma cN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519923","HPV-Mediated (p16-Positive) Oropharyngeal Cancer pNX TNM Finding v8","C132868","HPV-mediated (p16-positive) oropharyngeal cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","HPV-Mediated (p16-Positive) Oropharyngeal Cancer pNX TNM Finding v8 | HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma pNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519920","HPV-Mediated (p16-Positive) Oropharyngeal Cancer pN0 TNM Finding v8","C132869","HPV-mediated (p16-positive) oropharyngeal cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","HPV-Mediated (p16-Positive) Oropharyngeal Cancer pN0 TNM Finding v8 | HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma pN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519919","HPV-Mediated (p16-Positive) Oropharyngeal Cancer pM1 TNM Finding v8","C132877","HPV-mediated (p16-positive) oropharyngeal cancer with distant metastasis. (from AJCC 8th Ed.)","HPV-Mediated (p16-Positive) Oropharyngeal Cancer pM1 TNM Finding v8 | HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma pM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519915","HPV-Mediated (p16-Positive) Oropharyngeal Cancer cM1 TNM Finding v8","C132880","HPV-mediated (p16-positive) oropharyngeal cancer with distant metastasis. (from AJCC 8th Ed.)","HPV-Mediated (p16-Positive) Oropharyngeal Cancer cM1 TNM Finding v8 | HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma cM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519914","HPV-Mediated (p16-Positive) Oropharyngeal Cancer cM0 TNM Finding v8","C132879","HPV-mediated (p16-positive) oropharyngeal cancer without evidence of distant metastasis. (from AJCC 8th Ed.)","HPV-Mediated (p16-Positive) Oropharyngeal Cancer cM0 TNM Finding v8 | HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519911","HPV-Mediated (p16-Positive) Oropharyngeal Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C132867","A pathologic finding about one or more characteristics of HPV-mediated (p16-positive) oropharyngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","HPV-Mediated (p16-Positive) Oropharyngeal Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519922","HPV-Mediated (p16-Positive) Oropharyngeal Cancer pN2 TNM Finding v8","C132871","HPV-mediated (p16-positive) oropharyngeal cancer with metastasis in more than four lymph nodes. (from AJCC 8th Ed.)","HPV-Mediated (p16-Positive) Oropharyngeal Cancer pN2 TNM Finding v8 | HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma pN2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519921","HPV-Mediated (p16-Positive) Oropharyngeal Cancer pN1 TNM Finding v8","C132870","HPV-mediated (p16-positive) oropharyngeal cancer with metastasis in four or fewer lymph nodes. (from AJCC 8th Ed.)","HPV-Mediated (p16-Positive) Oropharyngeal Cancer pN1 TNM Finding v8 | HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma pN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0375381","iRECIST Stable Disease","C142359","Cancer that is neither decreasing nor increasing in extent or severity based on predetermined boundaries following an initial apparent radiographic progression.","iRECIST Stable Disease | iSD",,,,,,,,,,,,,,,"45757504","Urethral intrinsic sphincter deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540335","iRECIST Partial Response","C142358","A finding indicating that there is a decrease based on a predetermined threshold in the size and the extent of tissue involvement by cancer following an initial apparent radiographic progression.","iRECIST Partial Response | iPR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540348","iRECIST Unconfirmed Progressive Disease","C142360","Apparent radiographic progression which requires confirmation, per criteria, with additional imaging.","iRECIST Unconfirmed Progressive Disease | iUPD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540337","iRECIST Confirmed Progressive Disease","C142356","Radiographic progression which has been confirmed by additional imaging showing worsening of initial progression.","iRECIST Confirmed Progressive Disease | iCPD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540336","iRECIST Complete Response","C142357","The disappearance of all signs of cancer following an initial apparent radiographic progression.","iRECIST Complete Response | iCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0288330","BCL-XL Protein","C17698","Bcl-2-like protein 1 (233 aa, ~26 kDa) is encoded by the human BCL2L1 gene. This protein is involved in the modulation of apoptosis.","Bcl-2-Like Protein 1 | Apoptosis Regulator Bcl-X | B-Cell Lymphoma-Extra Large | BCL-X | BCL-X Long Protein | BCL-X Protein | BCL-X(L) | BCL-XL Protein | BCL2-Like 1, Long Isoform | BCL2-Related Protein 1, Long Isoform | BCL2L1 | Bcl-XL | Bcl2-L-1 | Bcl2-Related Protein, Long Isoform",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700325","Patient observation","C116555","The act, by a healthcare worker, of monitoring an identified subject and recording signs, symptoms, or behavior.","Clinical Observation | observation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521268","Oropharyngeal (p16-Negative) Carcinoma by AJCC v8 Stage","C132994","A term that refers to the staging of p16-negative oropharyngeal carcinoma according to the American Joint Committee on Cancer, 8th edition.","Oropharyngeal (p16-Negative) Carcinoma by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520974","Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8","C133002","Stage IVC includes: Any T, Any N, M1. M1: distant metastasis. (AJCC 8th ed.)","Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Stage IVC Oropharyngeal (p16-Negative) Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520971","Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8","C133001","Stage IVB includes: (Any T, N3, M0); (T4b, Any N, M0). T4b: Very advanced local disease. Tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base or encases carotid artery. N3: Tumor with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+). M0: No distant metastasis. (AJCC 8th ed.)","Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Stage IVB Oropharyngeal (p16-Negative) Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520967","Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8","C133000","Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0). T4a: Moderately advanced local disease. Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible. Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of the larynx. T1: Tumor 2 cm or smaller in greatest dimension. T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension. T3: Tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis. N0: No regional lymph node metastasis. N1: Tumor with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-). N2: Tumor with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). M0: No distant metastasis. (AJCC 8th ed.)","Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Stage IVA Oropharyngeal (p16-Negative) Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520964","Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8","C132999","Stage IV includes: IVA: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB: (Any T, N3, M0); (T4b, Any N, M0); IVC: (Any T, Any N, M1). T4a: Moderately advanced local disease. Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible. Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of the larynx. T1: Tumor 2 cm or smaller in greatest dimension. T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension. T3: Tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis. T4b: Very advanced local disease. Tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base or encases carotid artery. N0: No regional lymph node metastasis. N1: Tumor with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (-). N2: Tumor with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). N3: Tumor with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+). M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Stage IV Oropharyngeal (p16-Negative) Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520959","Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8","C132998","Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T3: Tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis. T1: Tumor 2 cm or smaller in greatest dimension. T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension. N0: No regional lymph node metastasis. N1: Tumor with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (-). M0: No distant metastasis. (AJCC 8th ed.)","Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Stage III Oropharyngeal (p16-Negative) Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521283","Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8","C132997","Stage II includes: T2, N0, M0. T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Stage II Oropharyngeal (p16-Negative) Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521279","Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8","C132996","Stage I includes: T1, N0, M0. T1: Tumor 2 cm or smaller in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Stage I Oropharyngeal (p16-Negative) Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521275","Stage 0 Oropharyngeal (p16-Negative) Carcinoma AJCC v8","C132995","Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0 Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Stage 0 Oropharyngeal (p16-Negative) Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546004","Eosinophilia, CTCAE","C143190","A disorder characterized by laboratory test results that indicate an increased number of eosinophils in the blood.","Eosinophilia, CTCAE | Eosinophilia | Eosinophilia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541576","Methemoglobinemia, CTCAE","C143191","A disorder characterized by laboratory test results that indicate increased methemoglobin in the blood.","Methemoglobinemia, CTCAE | Methemoglobinemia | Methemoglobinemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541577","Cyanosis, CTCAE","C143192","A disorder characterized by a bluish discoloration of the skin and/or mucous membranes.","Cyanosis, CTCAE | Cyanosis | Cyanosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541578","Hypophysitis, CTCAE","C143193","A disorder characterized by inflammation and cellular infiltration of the pituitary gland.","Hypophysitis, CTCAE | Hypophysitis | Hypophysitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541579","Hypopituitarism, CTCAE","C143194","A disorder characterized by a decrease in production of hormones from the pituitary gland.","Hypopituitarism, CTCAE | Hypopituitarism | Hypopituitarism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524163","Testosterone Deficiency, CTCAE","C143195","A disorder characterized by low testosterone.","Testosterone Deficiency, CTCAE | Testosterone Deficiency | Testosterone deficiency | Testosterone deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545992","Vision Decreased, CTCAE","C143196","A disorder characterized by a decrease in visual acuity.","Vision Decreased, CTCAE | Vision decreased | Vision decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541570","Anal Fissure, CTCAE","C143197","A disorder characterized by a tear in the lining of the anus.","Anal Fissure, CTCAE | Anal fissure | Anal fissure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541571","Belching, CTCAE","C143198","To expel gas noisily from the mouth.","Belching, CTCAE | Belching | Belching",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541572","Chylous Ascites, CTCAE","C143199","A disorder characterized by accumulation of milky fluid in the peritoneal cavity.","Chylous Ascites, CTCAE | Chylous ascites | Chylous ascites",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523892","Rectal Fissure, CTCAE","C143200","A disorder characterized by a tear in the lining of the rectum.","Rectal Fissure, CTCAE | Rectal Fissure (Priority 2) | Rectal fissure | Rectal fissure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541573","Disease Progression, CTCAE","C143201","Death due to disease progression that cannot be attributed to a CTCAE term associated with Grade 5.","Disease Progression, CTCAE | Disease progression | Disease progression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545994","Generalized Edema, CTCAE","C143202","A disorder characterized by fluid accumulation in the tissues of the body including the skin.","Generalized Edema, CTCAE | Generalized edema | Generalized edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550426","Vaccination Site Lymphadenopathy, CTCAE","C143203","A disorder characterized by lymph node enlargement after vaccination","Vaccination Site Lymphadenopathy, CTCAE | Vaccination site lymphadenopathy | Vaccination site lymphadenopathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545967","Budd-Chiari Syndrome, CTCAE","C143204","A disorder characterized by occlusion of the hepatic veins and typically presents with abdominal pain, ascites and hepatomegaly.","Budd-Chiari Syndrome, CTCAE | Budd-Chiari syndrome | Budd-Chiari syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541665","Sinusoidal Obstruction Syndrome, CTCAE","C143205","A disorder characterized by severe hepatic injury as a result of the blood vessels of the liver becoming inflamed and/or blocked.","Sinusoidal Obstruction Syndrome, CTCAE | Sinusoidal obstruction syndrome | Sinusoidal obstruction syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541666","Bacteremia, CTCAE","C143206","A disorder characterized by the presence of bacteria in the blood stream.","Bacteremia, CTCAE | Bacteremia | Bacteremia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546049","Cytomegalovirus Infection Reactivation, CTCAE","C143207","A disorder characterized by the reactivation of cytomegalovirus (CMV).","Cytomegalovirus Infection Reactivation, CTCAE | CMV Reactivation | Cytomegalovirus Reactivation | Cytomegalovirus infection reactivation | Cytomegalovirus infection reactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546019","Epstein-Barr Virus Infection Reactivation, CTCAE","C143208","A disorder characterized by the reactivation of Epstein-Barr virus (EBV).","Epstein-Barr Virus Infection Reactivation, CTCAE | Epstein-Barr virus infection reactivation | Epstein-Barr virus infection reactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541667","Folliculitis, CTCAE","C143209","A disorder characterized by inflammation or infection of the hair follicles.","Folliculitis, CTCAE | Folliculitis | Folliculitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541668","Fungemia, CTCAE","C143210","A disorder characterized by the presence of fungus in the blood stream.","Fungemia, CTCAE | Fungemia | Fungemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545957","Hepatitis B Reactivation, CTCAE","C143211","A disorder characterized by the reactivation of hepatitis B virus.","Hepatitis B Reactivation, CTCAE | Hepatitis B reactivation | Hepatitis B reactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525578","Herpes Simplex Reactivation, CTCAE","C143212","A disorder characterized by the reactivation of Herpes simplex virus","Herpes Simplex Reactivation, CTCAE | Herpes simplex reactivation | Herpes simplex reactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541661","Shingles, CTCAE","C143213","A disorder characterized by the reactivation of herpes zoster virus.","Shingles, CTCAE | Shingles | Shingles",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550657","Thrush, CTCAE","C143214","A disorder characterized by a suspected candidal infection involving an oral mucosal surface.","Thrush, CTCAE | Thrush | Thrush",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541662","Viremia, CTCAE","C143215","A disorder characterized by the presence of a virus in the blood stream.","Viremia, CTCAE | Viremia | Viremia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546036","Vaccination Complication, CTCAE","C143216","A disorder that occurs after the injection of a substance with antigenic properties, administered to activate the immune system.","Vaccination Complication, CTCAE | Vaccination complication | Vaccination complication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545966","Blood Bicarbonate Decreased, CTCAE","C143217","A finding based on laboratory test results that indicate a decrease in levels of bicarbonate in a venous blood specimen.","Blood Bicarbonate Decreased, CTCAE | Blood bicarbonate decreased | Blood bicarbonate decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541663","Blood Lactate Dehydrogenase Increased, CTCAE","C143218","A finding based on laboratory test results that indicate increased levels of lactate dehydrogenase in the blood specimen.","Blood Lactate Dehydrogenase Increased, CTCAE | Blood lactate dehydrogenase increased | Blood lactate dehydrogenase increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541664","Electrocardiogram T Wave Abnormal, CTCAE","C143219","A disorder characterized by Electrocardiogram T wave amplitude changes.","Electrocardiogram T Wave Abnormal, CTCAE | Electrocardiogram T wave abnormal | Electrocardiogram T wave abnormal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545998","Thyroid Stimulating Hormone Increased, CTCAE","C143220","A disorder characterized by an increase in thyroid stimulating hormone.","Thyroid Stimulating Hormone Increased, CTCAE | Thyroid stimulating hormone increased | Thyroid stimulating hormone increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541656","Hyperlipidemia, CTCAE","C143221","A disorder characterized by laboratory test results that indicate an elevation in the concentration of lipids in blood.","Hyperlipidemia, CTCAE | Hyperlipidemia | Hyperlipidemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541657","Hyperphosphatemia, CTCAE","C143222","A disorder characterized by laboratory test results that indicate an elevation in the concentration of phosphate in a blood.","Hyperphosphatemia, CTCAE | Hyperphosphatemia | Hyperphosphatemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546055","Chest Wall Necrosis, CTCAE","C143223","A disorder characterized by a necrotic process occurring in the soft tissues of the chest wall including breast.","Chest Wall Necrosis, CTCAE | Chest wall necrosis | Chest wall necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541658","Muscle Cramp, CTCAE","C143224","A disorder characterized by marked cramping sensation originating from a muscle or group of muscles.","Muscle Cramp, CTCAE | Muscle cramp | Muscle cramp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541659","Osteonecrosis, CTCAE","C143225","A disorder characterized by necrotic changes in the bone tissue due to interruption of blood supply. Most often affecting the epiphysis of the long bones, the necrotic changes result in the collapse and the destruction of the bone structure.","Osteonecrosis, CTCAE | Osteonecrosis | Osteonecrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541660","Rhabdomyolysis, CTCAE","C143226","A disorder characterized by the breakdown of muscle tissue resulting in the release of muscle fiber contents into the bloodstream.","Rhabdomyolysis, CTCAE | Rhabdomyolysis | Rhabdomyolysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546039","Rotator Cuff Injury, CTCAE","C143227","A disorder characterized by an injury of the rotator cuff.","Rotator Cuff Injury, CTCAE | Rotator cuff injury | Rotator cuff injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541651","Skin Papilloma, CTCAE","C143228","A disorder characterized by the presence of one or more warts.","Skin Papilloma, CTCAE | Skin papilloma | Skin papilloma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545993","Tumor Hemorrhage, CTCAE","C143229","A disorder characterized by bleeding in a tumor.","Tumor Hemorrhage, CTCAE | Tumor hemorrhage | Tumor hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541652","Anosmia, CTCAE","C143230","A disorder characterized by a change in the sense of smell.","Anosmia, CTCAE | Anosmia | Anosmia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541653","Guillain-Barre Syndrome, CTCAE","C143231","A disorder characterized by the body's immune system attacking the peripheral nervous system causing ascending paralysis.","Guillain-Barre Syndrome, CTCAE | Guillain-Barre syndrome | Guillain-Barre syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541654","Myasthenia Gravis, CTCAE","C143232","A disorder characterized by weakness and rapid fatigue of any of the skeletal muscles.","Myasthenia Gravis, CTCAE | Myasthenia gravis | Myasthenia gravis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541655","Spinal Cord Compression, CTCAE","C143233","A disorder characterized by pressure on the spinal cord.","Spinal Cord Compression, CTCAE | Spinal cord compression | Spinal cord compression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700078","Tendon Reflex Decreased, CTCAE","C143234","A disorder characterized by less than normal deep tendon reflexes.","Tendon Reflex Decreased, CTCAE | Tendon reflex decreased | Tendon reflex decreased",,,,,,,,,,,,,,,"4237167","Decreased tendon reflex",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545921","Trochlear Nerve Disorder, CTCAE","C143235","A disorder characterized by dysfunction of the trochlear nerve (fourth cranial nerve).","Trochlear Nerve Disorder, CTCAE | IVth Nerve Disorder | Trochlear nerve disorder | Trochlear nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541646","Pregnancy Loss, CTCAE","C143236","Death in utero.","Pregnancy Loss, CTCAE | Pregnancy loss | Pregnancy loss",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541647","Dysuria, CTCAE","C143237","A disorder characterized by painful urination.","Dysuria, CTCAE | Dysuria | Dysuria | Dysuria (Priority 1)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546043","Glucosuria, CTCAE","C143238","A disorder characterized by laboratory test results that indicate glucose in the urine.","Glucosuria, CTCAE | Glucosuria | Glucosuria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541648","Nephrotic Syndrome, CTCAE","C143239","A disorder characterized by symptoms that include severe edema, proteinuria, and hypoalbuminemia; it is indicative of renal dysfunction.","Nephrotic Syndrome, CTCAE | Nephrotic syndrome | Nephrotic syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545990","Amenorrhea, CTCAE","C143240","A disorder characterized by the abnormal absence of menses for at least three consecutive menstrual cycles","Amenorrhea, CTCAE | Amenorrhea | Amenorrhea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545968","Oropharyngeal Pain, CTCAE","C143241","A disorder characterized by a sensation of marked discomfort in the oropharynx.","Oropharyngeal Pain, CTCAE | Oropharyngeal pain | Oropharyngeal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541649","Rhinorrhea, CTCAE","C143242","A disorder characterized by excessive mucous secretions draining from the nose.","Rhinorrhea, CTCAE | Rhinorrhea | Rhinorrhea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541650","Eczema, CTCAE","C143243","A disorder characterized by skin which becomes itchy, red, inflamed, crusty, thick, scaly, and/or forms blisters.","Eczema, CTCAE | Eczema | Eczema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545958","Hair Color Changes, CTCAE","C143244","A disorder characterized by change in hair color or loss of normal pigmentation.","Hair Color Changes, CTCAE | Hair color changes | Hair color changes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546027","Hair Texture Abnormal, CTCAE","C143245","A disorder characterized by a change in the way the hair feels.","Hair Texture Abnormal, CTCAE | Hair texture abnormal | Hair texture abnormal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541642","Nail Changes, CTCAE_5","C143247","A disorder characterized by a change in the nails.","Nail Changes, CTCAE 5.0 | Nail changes | Nail changes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541643","Subcutaneous Emphysema, CTCAE","C143248","A disorder characterized by air in the subcutaneous tissue.","Subcutaneous Emphysema, CTCAE | Subcutaneous emphysema | Subcutaneous emphysema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524295","Arterial Thromboembolism, CTCAE","C143249","A disorder characterized by occlusion of an arterial vessel by a blood clot that develops in an artery.","Arterial Thromboembolism, CTCAE | Arterial thromboembolism | Arterial thromboembolism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519929","HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma by AJCC v8 Clinical Stage","C132883","A term that refers to the clinical staging of HPV-mediated (p16-positive) oropharyngeal carcinoma according to the American Joint Committee on Cancer, 8th edition.","HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma by AJCC v8 Clinical Stage | HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma by AJCC v8 cTNM Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520634","Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","C132893","Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520629","Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","C132891","Stage III includes: (T0, N3, M0); (T1, N3, M0); (T2, N3, M0); (T3, N3, M0); (T4, N0, M0); (T4, N1, M0); (T4, N2, M0); (T4, N3, M0). T0: No primary identified. T1: Tumor 2 cm or smaller in greatest dimension. T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension. T3: Tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis. T4: Tumor with moderately advanced local disease. Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible or beyond. Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of the larynx. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or more ipsilateral lymph nodes, none larger than 6 cm. N2: Tumor with contralateral or bilateral lymph nodes metastasis, none larger than 6 cm. N3: Tumor with lymph node(s) metastasis, larger than 6 cm. M0: No distant metastasis. (AJCC 8th ed.)","Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520618","Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","C132886","Stage II includes: (T0, N2, M0); (T1, N2, M0) ;(T2, N2, M0); (T3, N0, M0); (T3, N1, M0); (T3, N2, M0). T0: No primary identified. T1: Tumor 2 cm or smaller in greatest dimension. T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension. T3: Tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or more ipsilateral lymph nodes, none larger than 6 cm. N2: Tumor with contralateral or bilateral lymph nodes metastasis, none larger than 6 cm. M0: No distant metastasis. (AJCC 8th ed.)","Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520613","Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","C132885","Stage I includes: (T0, N0, M0); (T0, N1, M0); (T1, N0, M0); (T1, N1, M0); (T2, N0, M0); (T2, N1, M0). T0: No primary identified. T1: Tumor 2 cm or smaller in greatest dimension. T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or more ipsilateral lymph nodes, none larger than 6 cm. M0: No distant metastasis. (AJCC 8th ed.)","Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348577","Subject Completed Participation in Study","C70735","The case where a subject ceases active participation in a trial because the subject has, or is presumed to have followed all appropriate conditions of a protocol.","Subject Completed Participation in Study | Subject Participation Completed | subject completion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540693","Study Subject Enrolled","C142715","The study subject is/was enrolled.","Study Subject Enrolled | Enrolled | Subject Registered | enrolled",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519930","HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma by AJCC v8 Pathologic Stage","C132884","A term that refers to the pathologic staging of HPV-mediated (p16-positive) oropharyngeal carcinoma according to the American Joint Committee on Cancer, 8th edition.","HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma by AJCC v8 Pathologic Stage | HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma by AJCC v8 pTNM Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520883","Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","C132901","Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520873","Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","C132900","Stage III includes: (T3, N2, M0); (T4, N2, M0). T3: Tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis. T4: Moderately advanced local disease. Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible or beyond. Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of the larynx. N2: Tumor with metastasis in more than four lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520863","Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","C132899","Stage II includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N0, M0); (T3, N1, M0); (T4, N0, M0); (T4, N1, M0). T0: No primary identified. T1: Tumor 2 cm or smaller in greatest dimension. T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension. T3: Tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis. T4: Moderately advanced local disease. Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible or beyond. Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of the larynx. N0: No regional lymph node metastasis. N1: Tumor with metastasis in four or fewer lymph nodes.  N2: Tumor with metastasis in more than four lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520851","Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","C132898","Stage I includes: (T0, N0, M0); (T0, N1, M0); (T1, N0, M0); (T1, N1, M0); (T2, N0, M0); (T2, N1, M0). T0: No primary identified. T1: Tumor 2 cm or smaller in greatest dimension. T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension. N0: No regional lymph node metastasis. N1: Tumor with metastasis in four or fewer lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4255259","Clinical trial protocol","C142451","A document that describes the objective(s), design, methodology, statistical considerations, and organization of a trial. The protocol usually also gives the background and rationale for the trial, but these could be provided in other protocol referenced documents. Throughout the ICH GCP Guideline the term protocol refers to protocol and protocol amendments. NOTE: Present usage can refer to any of three distinct entities: 1) the plan (i.e., content) of a protocol, 2) the protocol document, and 3) a series of tests or treatments (as in oncology). [ICH E6 Glossary]","Clinical Trial Protocol | clinical protocol | protocol | study protocol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541644","Immune Checkpoint Inhibitor","C143250","An agent that inhibits any of the immune checkpoint inhibitory proteins.","Immune Checkpoint Inhibitor | ICI",,,,,,,,,,,,,,,"3661702","Immune checkpoint inhibitor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL542156","Systematic Programmed Illumination","C143954","A type of light therapy that uses ambient exposure to bluish-white light in a programmed schedule for prevention and treatment of cancer-related fatigue.","Systematic Programmed Illumination | sPI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542157","Blood Inflammatory Marker","C143955","A substance detectable in the blood that can be used to assess levels of inflammation in the body.","Blood Inflammatory Marker | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538268","Prostate Cancer Clinical Primary Tumor TNM Finding v8","C140127","A clinical finding about one or more characteristics of prostate cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Prostate Cancer Clinical Primary Tumor TNM Finding v8 | Prostate Carcinoma Clinical Primary Tumor TNM Finding v8 | Staging-T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538260","Prostate Cancer Pathologic Primary Tumor TNM Finding v8","C140151","A pathologic finding about one or more characteristics of prostate cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor. There is no pathologic T1 classification.","Prostate Cancer Pathologic Primary Tumor TNM Finding v8 | Pathologic Primary Tumor Status (pT) | Prostate Carcinoma Pathologic Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086720","PSA Level","C124827","The concentration of prostate specific antigen in a sample.","PSA Level | PSA Value",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540347","Non iRECIST Complete Response-Non iRECIST Unconfirmed Progressive Disease","C142361","Persistence of one or more non-target lesion(s) without unequivocal progression following an initial apparent radiographic progression.","Non iRECIST Complete Response-Non iRECIST Unconfirmed Progressive Disease | NON-iCR/NON-iUPD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540581","Standard Treatment","C142696","A therapy approved by a health regulatory authority and in wide use, which is considered to be the standard of care for the management of a specific disease or condition.","Standard Treatment | standard treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520228","Recurrent Glioma","C132506","The reemergence of a glioma after a period of remission.","Recurrent Glioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538390","Enneking Surgical Grade","C140259","A description of malignant mesenchymal tumors based on cell morphological features.","Enneking Surgical Grade | MSTS Grade | enneking msts grade | enneking_msts_grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544728","Enneking Stage IA","C146701","A stage for malignant musculoskeletal tumors characterized by low grade (G1), intracomparmental site (T1), and no metastasis (M0).","Enneking Stage IA | Stage IA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544729","Enneking Stage IB","C146702","A stage for malignant musculoskeletal tumors characterized by low grade (G1), extracomparmental site (T2), and no metastasis (M0).","Enneking Stage IB | Stage IB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544730","Enneking Stage IIA","C146703","A stage for malignant musculoskeletal tumors characterized by high grade (G2), intracomparmental site (T1), and no metastasis (M0).","Enneking Stage IIA | Stage IIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544731","Enneking Stage IIB","C146704","A stage for malignant musculoskeletal tumors characterized by high grade (G2), intracomparmental site (T2), and no metastasis (M0).","Enneking Stage IIB | Stage IIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544732","Enneking Stage III","C146705","A stage for malignant musculoskeletal tumors characterized by any grade, any site, and regional or distant metastasis (M1).","Enneking Stage III | Stage III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544715","Index Date","C146721","A date used as a reference point for ensuing events, often a diagnosis date, or a first visit date, or the date a patient enrolled in a study.","Index Date | index date | index_date",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642980","DNA Methyltransferase Inhibitor","C2083","Any substance that inhibits DNA methyltransferase, an enzyme required for DNA methylation. Inhibition of DNA methyltransferase results in hypomethylation of genomic DNA and cell cycle arrest at S-phase. Hypomethylation in malignant cells may also restore suppressor gene expression and re-establish controlled growth and differentiation.","DNA Methyltransferase Inhibitor | DNMT Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274067","KRAS NP_004976.2:p.G13V","C98419","A change in the amino acid residue at position 13 in the GTPase KRas protein where glycine has been replaced by valine.","KRAS NP_004976.2:p.G13V | GTPase KRas G13V | K-Ras 2 G13V | KRAS G13V | KRAS Gly13Val | KRAS NP_004976.2:p.Gly13Val | KRAS p.G13V | KRAS p.Gly13Val | Ki-Ras G13V | NP_004976.2:p.Gly13Val | c-K-ras G13V",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274046","KRAS NP_004976.2:p.G13A","C98399","A change in the amino acid residue at position 13 in the GTPase KRas protein where glycine has been replaced by alanine.","KRAS NP_004976.2:p.G13A | GTPase KRas G13A | K-Ras 2 G13A | KRAS G13A | KRAS Gly13Ala | KRAS NP_004976.2:p.Gly13Ala | KRAS p.G13A | KRAS p.Gly13Ala | Ki-Ras G13A | NP_004976.2:p.Gly13Ala | c-K-ras G13A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274062","KRAS NP_004976.2:p.G13R","C98414","A change in the amino acid residue at position 13 in the GTPase KRas protein where glycine has been replaced by arginine.","KRAS NP_004976.2:p.G13R | GTPase KRas G13R | K-Ras 2 G13R | KRAS G13R | KRAS Gly13Arg | KRAS NP_004976.2:p.Gly13Arg | KRAS p.G13R | KRAS p.Gly13Arg | Ki-Ras G13R | NP_004976.2:p.Gly13Arg | c-K-ras G13R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524899","Isocitrate Dehydrogenase Inhibitor","C137826","Any agent that inhibits isocitrate dehydrogenase (IDH).","Isocitrate Dehydrogenase Inhibitor | IDH Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333198","Cytoplasmic Protein","C20033","Protein within the interior of the cell; excludes membrane, mitochondrial, and nuclear proteins.","Cytoplasmic Protein | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544658","3p14 Loss of Heterozygosity","C146641","A molecular abnormality that results in monoallelic loss of function mutations located within 3p14.","3p14 Loss of Heterozygosity | 3p14 LOH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544662","KIR2DL1 Polymorphism Positive","C146646","An indication that polymorphism of the KIR2DL1 gene has been detected in a sample.","KIR2DL1 Polymorphism Positive | CD158A Polymorphism Positive | KIR-K64 Polymorphism Positive | KIR221 Polymorphism Positive | KIR2DL1 Gene Polymorphism Positive | KIR2DL1 Polymorphism Present | KIR2DS5 Polymorphism Positive | Killer Cell Immunoglobulin Like Receptor, Two Ig Domains and Long Cytoplasmic Tail 1 Gene Polymorphism Positive | NKAT Polymorphism Positive | NKAT-1 Polymorphism Positive | NKAT1 Polymorphism Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544663","Helicobacter pylori Negative","C146647","An indication that Helicobacter pylori was not detected in a sample.","Helicobacter pylori Negative | H. pylori Negative | Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544664","BRCA1 Polymorphism Positive","C146648","An indication that polymorphism of the BRCA1 gene has been detected in a sample.","BRCA1 Polymorphism Positive | BRCA1 Gene Polymorphism Present | BRCA1 Polymorphism Present | BROVCA1 Gene Polymorphism Present | Breast Cancer Type 1 Susceptibility Gene Polymorphism Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544650","BRCA2 Polymorphism Positive","C146649","An indication that polymorphism of the BRCA2 gene has been detected in a sample.","BRCA2 Polymorphism Positive | BRCA2 Gene Polymorphism Present | BRCA2 Polymorphism Present | BROVCA2 Gene Polymorphism Present | Breast Cancer Type 2 Susceptibility Gene Polymorphism Present | FANCD1 Gene Polymorphism Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544651","Clostridium difficile Positive","C146650","An indication that Clostridium difficile was detected in a sample.","Clostridium difficile Positive | C. diff. Positive | C. difficile Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544652","AKT1 Gene Alteration Positive","C146651","A finding indicating that mutation, overexpression or rearrangement of the AKT1 gene has been detected in a sample.","AKT1 Gene Alteration Positive | AKT Gene Alteration Positive | PKB Gene Alteration Positive | PRKBA Gene Alteration Positive | RAC Gene Alteration Positive | RAC-ALPHA Gene Alteration Positive | RAC-PK-Alpha Gene Alteration Positive | v-akt Murine Thymoma Viral Oncogene Homolog 1 Gene Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544653","AKT2 Gene Alteration Positive","C146652","A finding indicating that mutation, overexpression or rearrangement of the AKT2 gene has been detected in a sample.","AKT2 Gene Alteration Positive | AKT Serine/Threonine Kinase 2 Gene Alteration Positive | HIHGHH Gene Alteration Positive | PKBB Gene Alteration Positive | PKBBETA Gene Alteration Positive | PRKBB Gene Alteration Positive | RAC-BETA Gene Alteration Positive | RAC-PK-Beta Gene Alteration Positive | v-akt Murine Thymoma Viral Oncogene Homolog 2 Gene Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544654","AKT3 Gene Alteration Positive","C146653","A finding indicating that mutation, overexpression or rearrangement of the AKT3 gene has been detected in a sample.","AKT3 Gene Alteration Positive | AKT Serine/Threonine Kinase 3 Gene Alteration Positive | PKB-GAMMA Alteration Positive | PKBG Gene Alteration Positive | PRKBG Gene Alteration Positive | RAC-GAMMA Gene Alteration Positive | RAC-PK-Gamma Gene Alteration Positive | STK-2 Alteration Positive | v-akt Murine Thymoma Viral Oncogene Homolog 3 Gene Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544655","RB1 Gene Deletion","C146654","A molecular abnormality referring to the loss of at least one copy of the RB1 gene.","RB1 Gene Deletion | RB Gene Deletion | Retinoblastoma 1 Gene Deletion | Retinoblastoma Gene Deletion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544656","RARA Positive","C146655","An indication that RARA expression has been detected in a sample.","RARA Positive | NR1B1 Positive | Nuclear Receptor Subfamily 1 Group B Member 1 Positive | RAR Positive | RARalpha Positive | Retinoic Acid Receptor Alpha Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544657","Blasts More Than 5 Percent of Peripheral Blood White Cells","C146656","A semi-quantitative microscopic finding indicating that more than 5 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.","Blasts More Than 5 Percent of Peripheral Blood White Cells | Blasts Greater than 5 Percent of Peripheral Blood White Cells | Blasts Over 5 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544642","MLL Positive","C146657","An indication that MLL expression has been detected in a sample.","MLL Positive | ALL-1 Positive | Histone-Lysine N-Methyltransferase 2A Positive | Histone-Lysine N-Methyltransferase MLL Positive | KMT2A Positive | Lysine (K)-Specific Methyltransferase 2A Positive | Lysine N-Methyltransferase 2A Positive | Myeloid/Lymphoid or Mixed-Lineage Leukemia Positive | Zinc Finger Protein HRX Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544643","MITF Positive","C146659","An indication that MITF expression has been detected in a sample.","MITF Positive | Class E Basic Helix-Loop-Helix Protein 32 Positive | MI Positive | Microphthalmia-Associated Transcription Factor Positive | bHLHe32 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544645","Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells","C146661","A semi-quantitative microscopic finding indicating that 20 percent or more of the nucleated cells in a bone marrow sample are immature mononuclear cells of lymphoid origin.","Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells | Lymphoblasts 20 Percent or more of Bone Marrow Nucleated Cells | Lymphoblasts Greater than or Equal to 20 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544646","Lymphoblasts 20 Percent or More of Peripheral Blood White Cells","C146662","A semi-quantitative microscopic finding indicating that 20 percent or more of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells of lymphoid origin.","Lymphoblasts 20 Percent or More of Peripheral Blood White Cells | Lymphoblasts Greater than or Equal to 20 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL515828","TP53 Positive","C146668","An indication that TP53 expression has been detected in a sample.","TP53 Positive | Antigen NY-CO-13 Positive | Cellular Tumor Antigen p53 Positive | TRP53 Positive | Transformation-Related Protein 53 Positive | Tumor Protein p53 Positive | Tumor Suppressor p53 Positive | p53 Positive",,,,,,,,,,,,,,,"36713961","Tumor protein p53 detected",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL544637","Myeloblasts 5 Percent or More of Bone Marrow Nucleated Cells","C146669","A semi-quantitative microscopic finding indicating that 5 percent or more of the nucleated cells in a bone marrow sample are immature mononuclear cells of myeloid origin.","Myeloblasts 5 Percent or More of Bone Marrow Nucleated Cells | Myeloblasts Greater than or Equal to 5 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544638","CEACAM5 Positive","C146670","An indication that CEACAM5 expression has been detected in a sample.","CEACAM5 Positive | CD66e Antigen Positive | CD66e Positive | CEA Positive | Carcinoembryonic Antigen CGM2 Positive | Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 Positive | Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 Positive | Meconium Antigen 100 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544639","FLT3 Positive","C146671","An indication that FLT3 expression has been detected in a sample.","FLT3 Positive | CD135 Positive | FLK-2 Positive | FLK2 Positive | FLT-3 Positive | FMS-Related Tyrosine Kinase 3 Positive | Fetal Liver Kinase-2 Positive | Receptor-Type Tyrosine-Protein Kinase FLT3 Positive | Stem Cell Tyrosine Kinase 1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544640","Human Herpesvirus 8 Positive","C146672","An indication that human herpesvirus 8 has been detected in a sample.","Human Herpesvirus 8 Positive | HHV-8 Positive | HHV8 Positive | Human Herpesvirus-8 Positive | KSHV Positive | Kaposi Sarcoma Herpes Virus Positive | Kaposi Sarcoma-Associated Herpes Virus Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544641","Blasts 30 Percent or Less of Peripheral Blood White Cells","C146673","A semi-quantitative microscopic finding indicating that 30 percent or less of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.","Blasts 30 Percent or Less of Peripheral Blood White Cells | Blasts Less than or Equal to 30 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544629","Deleterious PTEN Gene Mutation","C146675","A change in the nucleotide sequence of the PTEN gene that is associated with increased risk of disease.","Deleterious PTEN Gene Mutation | Deleterious MMAC1 Gene Mutation | Deleterious Mutated in Multiple Advanced Cancers 1 Gene Mutation | Deleterious PTEN1 Gene Mutation | Deleterious Phosphatase and Tensin Homolog Gene Mutation | Deleterious TEP1 Gene Mutation | PTEN Deleterious Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544630","Deleterious TP53 Gene Mutation","C146676","A change in the nucleotide sequence of the TP53 gene that is associated with increased risk of disease.","Deleterious TP53 Gene Mutation | Deleterious BCC7 Gene Mutation | Deleterious LFS1 Gene Mutation | Deleterious Li-Fraumeni Syndrome Gene Mutation | Deleterious TRP53 Gene Mutation | Deleterious Tumor Protein p53 Gene Mutation | Deleterious p53 Gene Mutation | TP53 Deleterious Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544632","Disseminated Tumor Cells Positive","C146678","An indication that single tumor cells or small clusters of tumor cells have been detected in a tissue sample.","Disseminated Tumor Cells Positive | DTC Positive | Disseminated Tumor Cells Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544744","MKI67 Positive","C146686","An indication that MKI67 expression has been detected in a sample.","MKI67 Positive | Antigen Ki-67 Positive | KI67 Positive | Ki 67 Positive | Ki-67 Antigen Positive | Ki-67 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544747","Blasts 5-30 Percent of Bone Marrow Nucleated Cells","C146689","A semi-quantitative microscopic finding indicating that between 5 and 30 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 5-30 Percent of Bone Marrow Nucleated Cells | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544733","Circulating Tumor Cells Positive","C146691","An indication that tumor cells have been detected in a peripheral blood sample.","Circulating Tumor Cells Positive | CTC Positive | Circulating Tumor Cells Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544734","BRCA Mutation Analysis","C146692","A procedure to test for the presence of mutations in BRCA family genes.","BRCA Mutation Analysis | BRCA Family Gene Mutation Analysis | BRCA Mutation Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544720","Blasts 5-25 Percent of Bone Marrow Nucleated Cells","C146709","A semi-quantitative microscopic finding indicating that between 5 and 25 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 5-25 Percent of Bone Marrow Nucleated Cells | M2 (5-25% blasts)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544723","Blasts 20-30 Percent of Bone Marrow Nucleated Cells","C146712","A semi-quantitative microscopic finding indicating that between 20 and 30 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 20-30 Percent of Bone Marrow Nucleated Cells | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544724","FGFR Gene Mutation","C146713","A change in the nucleotide sequence of an FGFR family gene.","FGFR Gene Mutation | FGF Receptor Gene Family Mutation | FGF Receptor Gene Mutation | FGFR Family Gene Mutation | FGFR Family Mutation | FGFR Mutation | Fibroblast Growth Factor Receptor Family Gene Mutation | Fibroblast Growth Factor Receptor Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544710","Human Papillomavirus-16 Negative","C146716","An indication that human papillomavirus-16 has not been detected in a sample.","Human Papillomavirus-16 Negative | HPV-16 Negative | HPV16 Negative | Human Papilloma Virus 16 Negative | Human Papilloma Virus-16 Negative | Human Papillomavirus 16 Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544712","PSA-DT Less than or Equal to 6 Months","C146718","An indication that the number of months that a subject's blood concentration of prostate specific antigen took to double was six months or less.","PSA Doubling Time Less than or Equal to 6 Months | PSA Doubling Time Less Than or Equal to 6 Months | PSA Doubling Time Less than or Equal to Six Months | PSA-DT Less than or Equal to 6 Months | PSADT Less than or Equal to 6 Months",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544716","Activating ALK Gene Mutation","C146722","A change in the nucleotide sequence of the ALK gene that that results in constitutive activation of both ALK tyrosine kinase receptor protein and its downstream signaling pathways.","Activating ALK Gene Mutation | Activating ALK Mutation | Activating ALK Receptor Tyrosine Kinase Gene Mutation | Activating Anaplastic Lymphoma Kinase Receptor Gene Mutation | Activating Anaplastic Lymphoma Receptor Tyrosine Kinase Gene Mutation | Activating CD246 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544701","Activating ROS1 Gene Mutation","C146723","A change in the nucleotide sequence of the ROS1 gene that that results in constitutive activation of both proto-oncogene tyrosine-protein kinase ROS and its downstream signaling pathways.","Activating ROS1 Gene Mutation | Activating MCF3 Gene Mutation | Activating ROS Gene Mutation | Activating ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene Mutation | Activating c-ros-1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544702","AG7 Antigen Positive","C146724","An indication that expression of the tumor-associated antigen AG7 has been detected in a sample.","AG7 Antigen Positive | AG7 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544703","HLA-DPB1*0401 Positive Cells Present","C146725","An indication that cells expressing HLA-DPB1*0401 have been detected in a sample.","HLA-DPB1*0401 Positive Cells Present | HLA-DPB1*0401 Positive | HLA-DPB1*04:01 Positive | HLA-DPB1*04:01 Positive Cells Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544704","WT1 Gene Mutation","C146726","A change in the nucleotide sequence of the WT1 gene.","WT1 Gene Mutation | GUD Gene Mutation | WAGR Gene Mutation | WIT-2 Gene Mutation | WT1 mutation | WT33 Gene Mutation | Wilms Tumor 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544705","PIK3CG Gene Mutation","C146727","A change in the nucleotide sequence of the PIK3CG gene.","PIK3CG Gene Mutation | PI3CG Gene Mutation | PI3Kgamma Gene Mutation | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma Gene Mutation | p110gamma Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544706","PIK3R5 Gene Mutation","C146728","A change in the nucleotide sequence of the PIK3R5 gene.","PIK3R5 Gene Mutation | FOAP-2 Gene Mutation | P101-PI3K Gene Mutation | Phosphoinositide-3-Kinase Regulatory Subunit 5 Gene Mutation | Phosphoinositide-3-Kinase, Regulatory Subunit 5 Gene Mutation | p101 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544764","Child-Pugh Class A5","C146790","A total score of 5 for hepatic function, corresponding to class A in the Child-Pugh classification.","Child-Pugh Class A5 | A5 | Child-Pugh Class A5 | Child-Pugh Grade A5 | Child-Pugh Grade A5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544765","Child-Pugh Class A6","C146791","A total score of 6 for hepatic function, corresponding to class A in the Child-Pugh classification.","Child-Pugh Class A6 | A6 | Child-Pugh Class A6 | Child-Pugh Grade A6 | Child-Pugh Grade A6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544766","Child-Pugh Class B7","C146792","A total score of 7 for hepatic function, corresponding to class B in the Child-Pugh classification.","Child-Pugh Class B7 | B7 | Child-Pugh Class B7 | Child-Pugh Grade B7 | Child-Pugh Grade B7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544767","Child-Pugh Class B8","C146793","A total score of 8 for hepatic function, corresponding to class B in the Child-Pugh classification.","Child-Pugh Class B8 | B8 | Child-Pugh Class B8 | Child-Pugh Grade B8 | Child-Pugh Grade B8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544768","Child-Pugh Class B9","C146794","A total score of 9 for hepatic function, corresponding to class B in the Child-Pugh classification.","Child-Pugh Class B9 | B9 | Child-Pugh Class B9 | Child-Pugh Grade B9 | Child-Pugh Grade B9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544769","Child-Pugh Class C10","C146795","A total score of 10 for hepatic function, corresponding to class C in the Child-Pugh classification.","Child-Pugh Class C10 | C10 | Child-Pugh Class C10 | Child-Pugh Grade C10 | Child-Pugh Grade C10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544770","Child-Pugh Class C11","C146796","A total score of 11 for hepatic function, corresponding to class C in the Child-Pugh classification.","Child-Pugh Class C11 | C11 | Child-Pugh Class C11 | Child-Pugh Grade C11 | Child-Pugh Grade C11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544771","Child-Pugh Class C12","C146797","A total score of 12 for hepatic function, corresponding to class C in the Child-Pugh classification.","Child-Pugh Class C12 | C12 | Child-Pugh Class C12 | Child-Pugh Grade C12 | Child-Pugh Grade C12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544756","Child-Pugh Class C13","C146798","A total score of 13 for hepatic function, corresponding to class C in the Child-Pugh classification.","Child-Pugh Class C13 | Child-Pugh Class C13 | Child-Pugh Grade C13 | Child-Pugh Grade C13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544757","Child-Pugh Class C14","C146799","A total score of 14 for hepatic function, corresponding to class C in the Child-Pugh classification.","Child-Pugh Class C14 | Child-Pugh Class C14 | Child-Pugh Grade C14 | Child-Pugh Grade C14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544758","Child-Pugh Class C15","C146801","A total score of 15 for hepatic function, corresponding to class C in the Child-Pugh classification..","Child-Pugh Class C15 | Child-Pugh Class C15 | Child-Pugh Grade C15 | Child-Pugh Grade C15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540701","FOLR2 Positive","C142835","An indication that folate receptor beta has been detected in a sample.","FOLR2 Positive | BETA-HFR Positive | FR-Beta Positive | FRbeta Positive | Folate Receptor 2 Positive | Folate Receptor Beta Positive | Folate Receptor, Fetal/Placental Positive | Placental Folate-Binding Protein Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540714","HLA-A*0207 Positive Cells Present","C142818","An indication that cells expressing HLA-A*0207 have been detected in a sample.","HLA-A*0207 Positive Cells Present | HLA-A*0207 Positive | HLA-A*02:07 Positive | HLA-A*02:07 Positive Cells Present | HLA-A0207 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541619","Blasts Under 30 Percent of Peripheral Blood White Cells","C143154","A semi-quantitative microscopic finding indicating that less than 30 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.","Blasts Under 30 Percent of Peripheral Blood White Cells | Blasts Less than 30 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541617","Blasts Under 15 Percent of Peripheral Blood White Cells","C143152","A semi-quantitative microscopic finding indicating that less than 15 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.","Blasts Under 15 Percent of Peripheral Blood White Cells | Blasts Less than 15 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541618","Blasts Under 15 Percent of Bone Marrow Nucleated Cells","C143153","A semi-quantitative microscopic finding indicating that less than 15 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts Under 15 Percent of Bone Marrow Nucleated Cells | Blasts Less than 15 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540699","NRAS Negative","C142837","An indication that NRAS expression has not been detected in a sample.","NRAS Negative | GTPase Nras Negative | N-Ras Negative | Neuroblastoma RAS Viral Oncogene Homolog Negative | p21 N-Ras Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540700","BRAF Negative","C142836","An indication that BRAF expression has not been detected in a sample.","BRAF Negative | B-RAF Negative | B-RAF1 Negative | KRAB Negative | RAFB1 Negative | Serine/Threonine-Protein Kinase B-Raf Negative | v-raf Murine Sarcoma Viral Oncogene Homolog B Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540763","ROS1 Fusion Negative","C142839","An indication that the expression of a fusion involving ROS1 has not been detected in a sample.","ROS1 Fusion Negative | MCF3 Fusion Negative | Proto-Oncogene Tyrosine-Protein Kinase ROS Fusion Negative | Proto-Oncogene c-Ros Fusion Negative | Proto-Oncogene c-Ros-1 Fusion Negative | ROS Fusion Negative | ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Fusion Negative | Receptor Tyrosine Kinase c-Ros Oncogene 1 Fusion Negative | c-Ros-1 Fusion Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540758","SPANXB1 Positive","C142845","An indication that  SPANXB1 expression has been detected in a sample.","SPANXB1 Positive | CT11.2 Positive | Cancer/Testis Antigen 11.2 Positive | SPAN-Xb Positive | SPANX Family Member B1 Positive | SPANX-B Positive | Sperm Protein Associated With the Nucleus on the X Chromosome B/F Positive | Sperm Protein Associated With the Nucleus on the X Chromosome B1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540762","SPA17 Positive","C142841","An indication that SPA17 expression has been detected in a sample.","SPA17 Positive | CT22 Positive | Cancer/Testis Antigen 22 Positive | SP17 Positive | Sp17-1 Positive | Sperm Autoantigenic Protein 17 Positive | Sperm Protein 17 Positive | Sperm Surface Protein Sp17 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540760","ROPN1 Positive","C142843","An indication that ROPN1 expression has been detected in a sample.","ROPN1 Positive | CT91 Positive | Cancer/Testis Antigen 91 Positive | ROPN1A Positive | Rhophilin Associated Tail Protein Positive | Ropporin Positive | Ropporin-1A Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540759","PTTG1 Positive","C142844","An indication that PTTG1 expression has been detected in a sample.","PTTG1 Positive | PTTG Positive | Pituitary Tumor-Transforming 1 Positive | Securin Positive | TUTR1 Positive | Tumor-Transforming Protein 1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540761","AKAP4 Positive","C142842","An indication that AKAP4 expression has been detected in a sample.","AKAP4 Positive | A-Kinase Anchor Protein 4 Positive | AKAP 82 Positive | AKAP-4 Positive | AKAP82 Positive | CT99 Positive | Cancer/Testis Antigen 99 Positive | HI Positive | Major Sperm Fibrous Sheath Protein Positive | PRKA4 Positive | Protein Kinase A-Anchoring Protein 4 Positive | Testis-Specific Gene HI Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540708","CA19-9 Antigen Positive","C142809","An indication that expression of the carbohydrate antigen CA19-9 has been detected in a sample.","CA19-9 Antigen Positive | CA 19-9 Positive | CA19-9 Positive | Cancer Antigen 19-9 Positive | Carbohydrate Antigen 19-9 Positive | SLeA Positive | Sialyl Le(a) Antigen Positive | Sialyl LeA Positive | Sialyl LewisA Positive | Sialyl-Lewis A Positive | Sialylated Lewis (a) Antigen Positive | Sialylated Lewis a Antigen Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0153661","Malignant Thoracic Neoplasm","C3576","A primary or metastatic malignant neoplasm affecting the tissues of the thorax.","Malignant Thoracic Neoplasm | Malignant Neoplasm of Thorax | Malignant Neoplasm of the Thorax | Malignant Thoracic Tumor | Malignant Tumor of Thorax | Malignant Tumor of the Thorax | Malignant neoplasm of thorax",,,,,,,,,,,,,,,"80665","Malignant neoplasm of thorax",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0238792","Bone Lesion","C43260","A localized pathological or traumatic structural change, damage, deformity, or discontinuity of bone.","Bone Lesion | Skeletal Lesion",,,,,,,,,,,,,,,"618960","Lesion of bone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL544761","Renorrhaphy","C146804","Surgical suturing of a kidney.","Renorrhaphy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544760","Minimally Invasive Interval Debulking Surgery","C146803","Endoscopic or robotic-assisted cytoreductive surgery performed after primary cytoreduction and between courses of chemotherapy.","Minimally Invasive Interval Debulking Surgery | Minimally Invasive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504548","CDK4/6 inhibitor SHR6390","C125899","A cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Upon administration, dalpiciclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6). This inhibits retinoblastoma (Rb) protein phosphorylation early in the G1 phase, which prevents CDK-mediated G1-S phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.","Dalpiciclib | CDK4/6 Inhibitor SHR6390 | CDK4/6 Inhibitor SHR6390 | DALPICICLIB | SHR 6390 | SHR-6390 | SHR6390",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055129","Disease Transformation","C123583","A conversion from one disease diagnosis to another, which may be considered a progression to a worsening state.","Disease Transformation | DISEASE TRANSFORMATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504625","Lugano Classification Oncology Response Criteria","C126025","Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. (Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Espanol de Medula Osea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. J Clin Oncol. 2014 Sep 20;32(27):3059-68.)","Lugano Classification Oncology Response Criteria | LUGANO CLASSIFICATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348747","Genomic Biomarker","C68753","A measurable DNA or RNA characteristic that is an indicator of normal biologic processes, pathogenic processes, and/or response to therapeutic or other intervention. The definition for a genomic biomarker is not limited to human samples. A genomic biomarker could, for example, reflect: the expression of a gene; the function of a gene; the regulation of a gene. A genomic biomarker can consist of one or more deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) characteristics. The definition for a genomic biomarker does not include the measurement and characterisation of proteins or low molecular weight metabolites. DNA characteristics include, but are not limited to: single nucleotide polymorphisms (SNPs); variability of short sequence repeats; DNA modification, e.g., methylation; insertions; deletions; copy number variation; cytogenetic rearrangements, e.g., translocations, duplications, deletions or inversions. RNA characteristics include, but are not limited to: RNA sequence; RNA expression levels; RNA processing, e.g., splicing and editing; microRNA levels (ICH Draft Consensus Guideline E15).","Genomic Biomarker | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879924","CDISC SDTM Action Taken with Study Treatment Terminology","C66767","Terminology associated with the action taken with study treatment codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Action Taken with Study Treatment Terminology | ACN | Action Taken with Study Treatment | SDTM-ACN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544837","Salvage Surgery","C146855","Surgical treatment undertaken after failure of initial surgery or failure of other modalities.","Salvage Surgery | Rescue Surgery | Salvage Resection | Salvage Surgical Resection | Surgical Salvage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544759","Since First Time Questionnaire Was Answered","C146802","A question about the status of an individual since the time when they first answered a questionnaire.","Since First Time Questionnaire Was Answered | Since Questionnaire Was First Answered | Since the first time I answered this questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544920","Metastatic Genitourinary Cancer","C146893","A carcinoma that arises from the genitourinary system and has metastasized to other anatomic sites.","Metastatic Genitourinary System Carcinoma | Metastatic Genitourinary Cancer | Metastatic Genitourinary Carcinoma | Metastatic Genitourinary Carcinoma | Metastatic Urogenital Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541634","Abdominal Distension, CTCAE","C143253","A disorder characterized by swelling of the abdomen.","Abdominal Distension, CTCAE | Abdominal Distension | Abdominal distension | Abdominal distension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541635","Abdominal Infection, CTCAE","C143254","A disorder characterized by an infectious process involving the abdominal cavity.","Abdominal Infection, CTCAE | Abdominal Infection | Abdominal infection | Abdominal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541636","Abdominal Pain, CTCAE","C143255","A disorder characterized by a sensation of marked discomfort in the abdominal region.","Abdominal Pain, CTCAE | Abdominal Pain | Abdominal pain | Abdominal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541637","Abdominal Soft Tissue Necrosis, CTCAE","C143256","A disorder characterized by a necrotic process occurring in the soft tissues of the abdominal wall.","Abdominal Soft Tissue Necrosis, CTCAE | Abdominal Soft Tissue Necrosis | Abdominal soft tissue necrosis | Abdominal soft tissue necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541638","Abducens Nerve Disorder, CTCAE","C143257","A disorder characterized by dysfunction of the abducens nerve (sixth cranial nerve).","Abducens Nerve Disorder, CTCAE | Abducens Nerve Disorder | Abducens nerve disorder | Abducens nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541639","Accessory Nerve Disorder, CTCAE","C143258","A disorder characterized by dysfunction of the accessory nerve (eleventh cranial nerve).","Accessory Nerve Disorder, CTCAE | Accessory Nerve Disorder | Accessory nerve disorder | Accessory nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541640","Acidosis, CTCAE","C143259","A disorder characterized by abnormally high acidity (high hydrogen-ion concentration) of the blood and other body tissues.","Acidosis, CTCAE | Acidosis | Acidosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546042","Acoustic Nerve Disorder NOS, CTCAE","C143260","A disorder characterized by dysfunction of the acoustic nerve (eighth cranial nerve).","Acoustic Nerve Disorder NOS, CTCAE | Acoustic Nerve Disorder NOS | Acoustic nerve disorder NOS | Acoustic nerve disorder NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541628","Activated Partial Thromboplastin Time Prolonged, CTCAE","C143261","A finding based on laboratory test results in which the partial thromboplastin time is found to be greater than the control value. As a possible indicator of coagulopathy, a prolonged partial thromboplastin time (PTT) may occur in a variety of diseases and disorders, both primary and related to treatment.","Activated Partial Thromboplastin Time Prolonged, CTCAE | Activated Partial Thromboplastin Time Prolonged | Activated partial thromboplastin time prolonged | Activated partial thromboplastin time prolonged",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963059","Adrenal Insufficiency, CTCAE","C55748","A disorder characterized by the adrenal cortex not producing enough of the hormone cortisol and in some cases, the hormone aldosterone. It may be due to a disorder of the adrenal cortex as in Addison's disease or primary adrenal insufficiency.","Adrenal Insufficiency, CTCAE | Adrenal Insufficiency | Adrenal insufficiency | Adrenal insufficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963227","Adult Respiratory Distress Syndrome, CTCAE","C58020","A disorder characterized by progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery.","Adult Respiratory Distress Syndrome, CTCAE | Adult Respiratory Distress Syndrome | Adult Respiratory Distress Syndrome (ARDS) | Adult respiratory distress syndrome | Adult respiratory distress syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544784","Agitation, CTCAE_5","C146777","A disorder characterized by a state of restlessness associated with unpleasant feelings of irritability and tension.","Agitation, CTCAE 5.0 | Agitation | Agitation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541629","Akathisia, CTCAE","C143266","A disorder characterized by an uncomfortable feeling of inner restlessness and inability to stay still; this is a side effect of some psychotropic drugs.","Akathisia, CTCAE | Akathisia | Akathisia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541630","Alanine Aminotransferase Increased, CTCAE","C143267","A finding based on laboratory test results that indicate an increase in the level of alanine aminotransferase (ALT or SGPT) in the blood specimen.","Alanine Aminotransferase Increased, CTCAE | Alanine Aminotransferase Increased | Alanine aminotransferase increased | Alanine aminotransferase increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541631","Alcohol Intolerance, CTCAE","C143268","A disorder characterized by an increase in sensitivity to the adverse effects of alcohol, which can include nasal congestion, skin flushes, heart dysrhythmias, nausea, vomiting, indigestion and headaches.","Alcohol Intolerance, CTCAE | Alcohol Intolerance | Alcohol intolerance | Alcohol intolerance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546025","Alkaline Phosphatase Increased, CTCAE","C143269","A finding based on laboratory test results that indicate an increase in the level of alkaline phosphatase in a blood specimen.","Alkaline Phosphatase Increased, CTCAE | Alkaline Phosphatase Increased | Alkaline phosphatase increased | Alkaline phosphatase increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541632","Alkalosis, CTCAE","C143270","A disorder characterized by abnormally high alkalinity (low hydrogen-ion concentration) of the blood and other body tissues.","Alkalosis, CTCAE | Alkalosis | Alkalosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541633","Allergic Reaction, CTCAE","C143271","A disorder characterized by an adverse local or general response from exposure to an allergen.","Allergic Reaction, CTCAE | Allergic Reaction | Allergic reaction | Allergic reaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541718","Allergic Rhinitis, CTCAE","C143272","A disorder characterized by an inflammation of the nasal mucous membranes caused by an IgE-mediated response to external allergens. The inflammation may also involve the mucous membranes of the sinuses, eyes, middle ear, and pharynx. Symptoms include sneezing, nasal congestion, rhinorrhea and itching.","Allergic Rhinitis, CTCAE | Allergic Rhinitis | Allergic rhinitis | Allergic rhinitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1559115","Alopecia, CTCAE","C57898","A disorder characterized by a decrease in density of hair compared to normal for a given individual at a given age and body location.","Alopecia, CTCAE | Alopecia | Alopecia | Hair loss/alopecia (scalp or body)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541719","Amnesia, CTCAE","C143274","A disorder characterized by systematic and extensive loss of memory.","Amnesia, CTCAE | Amnesia | Amnesia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546016","Anal Fistula, CTCAE","C143275","A disorder characterized by an abnormal communication between the opening in the anal canal to the perianal skin.","Anal Fistula, CTCAE | Anal Fistula | Anal fistula | Anal fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541720","Anal Hemorrhage, CTCAE","C143276","A disorder characterized by bleeding from the anal region.","Anal Hemorrhage, CTCAE | Anal Hemorrhage | Anal hemorrhage | Anal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541721","Anal Mucositis, CTCAE","C143277","A disorder characterized by ulceration or inflammation of the mucous membrane of the anus.","Anal Mucositis, CTCAE | Anal Mucositis | Anal mucositis | Anal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541722","Anal Necrosis, CTCAE","C143278","A disorder characterized by a necrotic process occurring in the anal region.","Anal Necrosis, CTCAE | Anal Necrosis | Anal necrosis | Anal necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541723","Anal Pain, CTCAE","C143279","A disorder characterized by a sensation of marked discomfort in the anal region.","Anal Pain, CTCAE | Anal Pain | Anal pain | Anal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541724","Anal Stenosis, CTCAE","C143280","A disorder characterized by a narrowing of the lumen of the anal canal.","Anal Stenosis, CTCAE | Anal Stenosis | Anal stenosis | Anal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541712","Anal Ulcer, CTCAE","C143281","A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the anal canal.","Anal Ulcer, CTCAE | Anal Ulcer | Anal ulcer | Anal ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546000","Anaphylaxis, CTCAE","C143282","A disorder characterized by an acute inflammatory reaction resulting from the release of histamine and histamine-like substances from mast cells, causing a hypersensitivity immune response. Clinically, it presents with breathing difficulty, dizziness, hypotension, cyanosis and loss of consciousness and may lead to death.","Anaphylaxis, CTCAE | Anaphylaxis | Anaphylaxis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545972","Anemia, CTCAE","C143283","A disorder characterized by a reduction in the amount of hemoglobin in 100 ml of blood. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability.","Anemia, CTCAE | Anemia | Anemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541713","Ankle Fracture, CTCAE","C143284","A finding of damage to the ankle joint characterized by a break in the continuity of the ankle bone. Symptoms include marked discomfort, swelling and difficulty moving the affected leg and foot.","Ankle Fracture, CTCAE | Ankle Fracture | Ankle fracture | Ankle fracture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541714","Anorectal Infection, CTCAE","C143285","A disorder characterized by an infectious process involving the anal area and the rectum.","Anorectal Infection, CTCAE | Anorectal Infection | Anorectal infection | Anorectal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963063","Anorexia, CTCAE","C57118","A disorder characterized by a loss of appetite.","Anorexia, CTCAE | Anorexia | Anorexia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541715","Anorgasmia, CTCAE","C143287","A disorder characterized by an inability to achieve orgasm.","Anorgasmia, CTCAE | Anorgasmia | Anorgasmia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544785","Anxiety, CTCAE_5","C146778","A disorder characterized by apprehension of danger and dread accompanied by restlessness, tension, tachycardia, and dyspnea unattached to a clearly identifiable stimulus.","Anxiety, CTCAE 5.0 | Anxiety | Anxiety",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541716","Aortic Injury, CTCAE","C143289","A finding of damage to the aorta.","Aortic Injury, CTCAE | Aortic Injury | Aortic injury | Aortic injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541717","Aortic Valve Disease, CTCAE","C143290","A disorder characterized by a defect in aortic valve function or structure.","Aortic Valve Disease, CTCAE | Aortic Valve Disease | Aortic valve disease | Aortic valve disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541706","Aphonia, CTCAE","C143291","A disorder characterized by the inability to speak. It may result from injuries to the vocal cords or may be functional (psychogenic).","Aphonia, CTCAE | Aphonia | Aphonia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963065","Apnea, CTCAE","C55340","A disorder characterized by cessation of breathing.","Apnea, CTCAE | Apnea | Apnea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545962","Appendicitis, CTCAE","C143294","A disorder characterized by acute inflammation to the vermiform appendix caused by a pathogenic agent.","Appendicitis, CTCAE | Appendicitis | Appendicitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546033","Appendicitis Perforated, CTCAE","C143293","A disorder characterized by acute inflammation to the vermiform appendix caused by a pathogenic agent with gangrenous changes resulting in the rupture of the appendiceal wall. The appendiceal wall rupture causes the release of inflammatory and bacterial contents from the appendiceal lumen into the abdominal cavity.","Appendicitis Perforated, CTCAE | Appendicitis Perforated | Appendicitis perforated | Appendicitis perforated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541707","Arachnoiditis, CTCAE","C143295","A disorder characterized by inflammation of the arachnoid membrane and adjacent subarachnoid space.","Arachnoiditis, CTCAE | Arachnoiditis | Arachnoiditis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541708","Arterial Injury, CTCAE","C143296","A finding of damage to an artery.","Arterial Injury, CTCAE | Arterial Injury | Arterial injury | Arterial injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541709","Arteritis Infective, CTCAE","C143297","A disorder characterized by an infectious process involving an artery.","Arteritis Infective, CTCAE | Arteritis Infective | Arteritis infective | Arteritis infective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541710","Arthralgia, CTCAE","C143298","A disorder characterized by a sensation of marked discomfort in a joint.","Arthralgia, CTCAE | Arthralgia | Arthralgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541711","Arthritis, CTCAE","C143299","A disorder characterized by inflammation involving a joint.","Arthritis, CTCAE | Arthritis | Arthritis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541698","Ascites, CTCAE","C143300","A disorder characterized by accumulation of serous or hemorrhagic fluid in the peritoneal cavity.","Ascites, CTCAE | Ascites | Ascites",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541699","Aspartate Aminotransferase Increased, CTCAE","C143301","A finding based on laboratory test results that indicate an increase in the level of aspartate aminotransferase (AST or SGOT) in a blood specimen.","Aspartate Aminotransferase Increased, CTCAE | Aspartate Aminotransferase Increased | Aspartate aminotransferase increased | Aspartate aminotransferase increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544694","Asystole, CTCAE_5","C146731","A disorder characterized by a dysrhythmia without cardiac electrical activity. Typically, this is accompanied by cessation of the pumping function of the heart.","Asystole, CTCAE 5.0 | Asystole | Asystole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545970","Ataxia, CTCAE_5","C146737","A disorder characterized by lack of coordination of muscle movements resulting in the impairment or inability to perform voluntary activities.","Ataxia, CTCAE 5.0 | Ataxia | Ataxia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1962948","Atelectasis, CTCAE","C58022","A disorder characterized by the collapse of part or the entire lung.","Atelectasis, CTCAE | Atelectasis | Atelectasis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963067","Atrial Fibrillation, CTCAE","C54767","A disorder characterized by a dysrhythmia without discernible P waves and an irregular ventricular response due to multiple reentry circuits. The rhythm disturbance originates above the ventricles.","Atrial Fibrillation, CTCAE | Atrial Fibrillation | Atrial fibrillation | Atrial fibrillation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963068","FLUTTER ATRIAL","C54768","A disorder characterized by a dysrhythmia with organized rhythmic atrial contractions with a rate of 200-300 beats per minute. The rhythm disturbance originates in the atria.","Atrial Flutter, CTCAE | Atrial Flutter | Atrial flutter | Atrial flutter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541700","Atrioventricular Block Complete, CTCAE","C143308","A disorder characterized by a dysrhythmia with complete failure of atrial electrical impulse conduction through the AV node to the ventricles.","Atrioventricular Block Complete, CTCAE | Atrioventricular Block Complete | Atrioventricular block complete | Atrioventricular block complete",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541701","Atrioventricular Block First Degree, CTCAE","C143309","A disorder characterized by a dysrhythmia with a delay in the time required for the conduction of an electrical impulse through the atrioventricular (AV) node beyond 0.2 seconds; prolongation of the PR interval greater than 200 milliseconds.","Atrioventricular Block First Degree, CTCAE | Atrioventricular Block First Degree | Atrioventricular block first degree | Atrioventricular block first degree",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541702","Autoimmune Disorder, CTCAE","C143310","A disorder characterized by loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to his own tissue constituents.","Autoimmune Disorder, CTCAE | Autoimmune Disorder | Autoimmune disorder | Autoimmune disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541703","Avascular Necrosis, CTCAE","C143311","A disorder characterized by necrotic changes in the bone tissue due to interruption of blood supply. Most often affecting the epiphysis of the long bones, the necrotic changes result in the collapse and the destruction of the bone structure.","Avascular Necrosis, CTCAE | Avascular Necrosis | Avascular necrosis | Avascular necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541704","Azoospermia, CTCAE","C143312","A disorder characterized by laboratory test results that indicate complete absence of spermatozoa in the semen.","Azoospermia, CTCAE | Azoospermia | Azoospermia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541705","Bile Duct Stenosis, CTCAE","C143314","A disorder characterized by a narrowing of the lumen of the bile duct.","Bile Duct Stenosis, CTCAE | Bile Duct Stenosis | Bile duct stenosis | Bile duct stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541691","Biliary Anastomotic Leak, CTCAE","C143315","A finding of leakage of bile due to breakdown of a biliary anastomosis (surgical connection of two separate anatomic structures).","Biliary Anastomotic Leak, CTCAE | Biliary Anastomotic Leak | Biliary anastomotic leak | Biliary anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541692","Biliary Fistula, CTCAE","C143316","A disorder characterized by an abnormal communication between the bile ducts and another organ or anatomic site.","Biliary Fistula, CTCAE | Biliary Fistula | Biliary fistula | Biliary fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0920156","Biliary Tract Infection, CTCAE","C143317","A disorder characterized by an infectious process involving the biliary tract.","Biliary Tract Infection, CTCAE | Biliary Tract Infection | Biliary tract infection | Biliary tract infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541693","Bladder Anastomotic Leak, CTCAE","C143318","A finding of leakage of urine due to breakdown of a bladder anastomosis (surgical connection of two separate anatomic structures).","Bladder Anastomotic Leak, CTCAE | Bladder Anastomotic Leak | Bladder anastomotic leak | Bladder anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541694","Bladder Infection, CTCAE","C143319","A disorder characterized by an infectious process involving the bladder.","Bladder Infection, CTCAE | Bladder Infection | Bladder infection | Bladder infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544718","Bladder Perforation, CTCAE_5","C146707","A disorder characterized by a rupture in the bladder wall.","Bladder Perforation, CTCAE 5.0 | Bladder Perforation | Bladder perforation | Bladder perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544725","Bladder Spasm, CTCAE_5","C146698","A disorder characterized by a sudden and involuntary contraction of the bladder wall.","Bladder Spasm, CTCAE 5.0 | Bladder Spasm | Bladder Spasms (Priority 2) | Bladder spasm | Bladder spasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541695","Bloating, CTCAE","C143322","A disorder characterized by subject-reported feeling of uncomfortable fullness of the abdomen.","Bloating, CTCAE | Bloating | Bloating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541696","Blood and Lymphatic System Disorders - Other, Specify, CTCAE","C143323","Blood and lymphatic system disorders - Other, specify","Blood and Lymphatic System Disorders - Other, Specify, CTCAE | Blood and Lymphatic System Disorders - Other | Blood and lymphatic system disorders - Other, specify | Blood and lymphatic system disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541697","Blood Antidiuretic Hormone Abnormal, CTCAE","C143324","A finding based on laboratory test results that indicate abnormal levels of antidiuretic hormone in the blood specimen.","Blood Antidiuretic Hormone Abnormal, CTCAE | Blood Antidiuretic Hormone Abnormal | Blood antidiuretic hormone abnormal | Blood antidiuretic hormone abnormal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541683","Blood Bilirubin Increased, CTCAE","C143325","A finding based on laboratory test results that indicate an abnormally high level of bilirubin in the blood. Excess bilirubin is associated with jaundice.","Blood Bilirubin Increased, CTCAE | Blood Bilirubin Increased | Blood bilirubin increased | Blood bilirubin increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541684","Blood Corticotrophin Decreased, CTCAE","C143326","A finding based on laboratory test results that indicate an decrease in levels of corticotrophin in a blood specimen.","Blood Corticotrophin Decreased, CTCAE | Blood Corticotrophin Decreased | Blood corticotrophin decreased | Blood corticotrophin decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541685","Blood Gonadotrophin Abnormal, CTCAE","C143327","A finding based on laboratory test results that indicate abnormal levels of gonadotrophin hormone in a blood specimen.","Blood Gonadotrophin Abnormal, CTCAE | Blood Gonadotrophin Abnormal | Blood gonadotrophin abnormal | Blood gonadotrophin abnormal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541686","Blood Prolactin Abnormal, CTCAE","C143328","A finding based on laboratory test results that indicate abnormal levels of prolactin hormone in a blood specimen.","Blood Prolactin Abnormal, CTCAE | Blood Prolactin Abnormal | Blood prolactin abnormal | Blood prolactin abnormal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1557375","Blurred Vision, CTCAE","C55906","A disorder characterized by visual perception of unclear or fuzzy images.","Blurred Vision, CTCAE | Blurred Vision | Blurred vision | Blurred vision | Vision-blurred vision",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541687","Body Odor, CTCAE","C143330","A disorder characterized by an abnormal body smell resulting from the growth of bacteria on the body.","Body Odor, CTCAE | Body Odor | Body odor | Body odor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541688","Bone Infection, CTCAE","C143331","A disorder characterized by an infectious process involving the bones.","Bone Infection, CTCAE | Bone Infection | Bone infection | Bone infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541689","Bone Marrow Hypocellular, CTCAE","C143332","A disorder characterized by the inability of the bone marrow to produce hematopoietic elements.","Bone Marrow Hypocellular, CTCAE | Bone Marrow Hypocellular | Bone marrow hypocellular | Bone marrow hypocellular",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544689","Bone Pain, CTCAE_5","C146741","A disorder characterized by a sensation of marked discomfort in the bones.","Bone Pain, CTCAE 5.0 | Bone Pain | Bone pain | Bone pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544805","Brachial Plexopathy, CTCAE_5","C146754","A disorder characterized by regional paresthesia of the brachial plexus, marked discomfort and muscle weakness, and limited movement in the arm or hand.","Brachial Plexopathy, CTCAE 5.0 | Brachial Plexopathy | Brachial plexopathy | Brachial plexopathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541690","Breast Atrophy, CTCAE","C143335","A disorder characterized by underdevelopment of the breast.","Breast Atrophy, CTCAE | Breast Atrophy | Breast atrophy | Breast atrophy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552409","Breast Infection, CTCAE","C143336","A disorder characterized by an infectious process involving the breast.","Breast Infection, CTCAE | Breast Infection | Breast infection | Breast infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545910","Breast Pain, CTCAE_5","C146742","A disorder characterized by a sensation of marked discomfort in the breast region.","Breast Pain, CTCAE 5.0 | Breast Pain | Breast pain | Breast pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541677","Bronchial Fistula, CTCAE","C143338","A disorder characterized by an abnormal communication between the bronchus and another organ or anatomic site.","Bronchial Fistula, CTCAE | Bronchial Fistula | Bronchial fistula | Bronchial fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546040","Bronchial Infection, CTCAE","C143339","A disorder characterized by an infectious process involving the bronchi.","Bronchial Infection, CTCAE | Bronchial Infection | Bronchial infection | Bronchial infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541678","Bronchial Obstruction, CTCAE","C143340","A disorder characterized by blockage of a bronchus passage, most often by bronchial secretions and exudates.","Bronchial Obstruction, CTCAE | Bronchial Obstruction | Bronchial obstruction | Bronchial obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541679","Bronchial Stricture, CTCAE","C143341","A disorder characterized by a narrowing of the bronchial tube.","Bronchial Stricture, CTCAE | Bronchial Stricture | Bronchial stricture | Bronchial stricture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541680","Bronchopleural Fistula, CTCAE","C143342","A disorder characterized by an abnormal communication between a bronchus and the pleural cavity.","Bronchopleural Fistula, CTCAE | Bronchopleural Fistula | Bronchopleural fistula | Bronchopleural fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541681","Bronchopulmonary Hemorrhage, CTCAE","C143343","A disorder characterized by bleeding from the bronchial wall and/or lung parenchyma.","Bronchopulmonary Hemorrhage, CTCAE | Bronchopulmonary Hemorrhage | Bronchopulmonary hemorrhage | Bronchopulmonary hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541682","Bronchospasm, CTCAE","C143344","A disorder characterized by a sudden contraction of the smooth muscles of the bronchial wall.","Bronchospasm, CTCAE | Bronchospasm | Bronchospasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541669","Bruising, CTCAE","C143345","A finding of injury of the soft tissues or bone characterized by leakage of blood into surrounding tissues.","Bruising, CTCAE | Bruising | Bruising",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541670","Bullous Dermatitis, CTCAE","C143346","A disorder characterized by inflammation of the skin characterized by the presence of bullae which are filled with fluid.","Bullous Dermatitis, CTCAE | Bullous Dermatitis | Bullous dermatitis | Bullous dermatitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1962979","Burn, CTCAE","C57900","A finding of impaired integrity to the anatomic site of an adverse thermal reaction. Burns can be caused by exposure to chemicals, direct heat, electricity, flames and radiation. The extent of damage depends on the length and intensity of exposure and time until provision of treatment.","Burn, CTCAE | Burn | Burn",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544691","Buttock Pain, CTCAE_5","C146744","A disorder characterized by a sensation of marked discomfort in the buttocks.","Buttock Pain, CTCAE 5.0 | Buttock Pain | Buttock pain | Buttock pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541777","CD4 Lymphocytes Decreased, CTCAE","C143357","A finding based on laboratory test results that indicate an decrease in levels of CD4 lymphocytes in a blood specimen.","CD4 Lymphocytes Decreased, CTCAE | CD4 Lymphocytes Decreased | CD4 lymphocytes decreased | CD4 lymphocytes decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541755","CPK Increased, CTCAE","C143389","A finding based on laboratory test results that indicate an increase in levels of creatine phosphokinase in a blood specimen.","CPK Increased, CTCAE | CPK Increased | CPK increased | CPK increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541671","Capillary Leak Syndrome, CTCAE","C143349","A disorder characterized by leakage of intravascular fluids into the extravascular space. This syndrome is observed in patients who demonstrate a state of generalized leaky capillaries following shock syndromes, low-flow states, ischemia-reperfusion injuries, toxemias, medications, or poisoning. It can lead to generalized edema and multiple organ failure.","Capillary Leak Syndrome, CTCAE | Capillary Leak Syndrome | Capillary leak syndrome | Capillary leak syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541672","Carbon Monoxide Diffusing Capacity Decreased, CTCAE","C143350","A finding based on lung function test results that indicate a decrease in the lung capacity to absorb carbon monoxide.","Carbon Monoxide Diffusing Capacity Decreased, CTCAE | Carbon Monoxide Diffusing Capacity Decreased | Carbon monoxide diffusing capacity decreased | Carbon monoxide diffusing capacity decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541673","Cardiac Arrest, CTCAE","C143351","A disorder characterized by cessation of the pumping function of the heart.","Cardiac Arrest, CTCAE | Cardiac Arrest | Cardiac arrest | Cardiac arrest",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541674","Cardiac Disorders - Other, Specify, CTCAE","C143352","Cardiac disorders - Other, specify","Cardiac Disorders - Other, Specify, CTCAE | Cardiac Disorders - Other | Cardiac disorders - Other, specify | Cardiac disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541675","Cardiac Troponin I Increased, CTCAE","C143353","A finding based on laboratory test results that indicate increased levels of cardiac troponin I in a biological specimen.","Cardiac Troponin I Increased, CTCAE | Cardiac Troponin I Increased | Cardiac troponin I increased | Cardiac troponin I increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541676","Cardiac Troponin T Increased, CTCAE","C143354","A finding based on laboratory test results that indicate increased levels of cardiac troponin T in a biological specimen.","Cardiac Troponin T Increased, CTCAE | Cardiac Troponin T Increased | Cardiac troponin T increased | Cardiac troponin T increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545895","Cataract, CTCAE_5","C146674","A disorder characterized by partial or complete opacity of the crystalline lens of one or both eyes. This results in a decrease in visual acuity and eventual blindness if untreated.","Cataract, CTCAE 5.0 | Cataract | Cataract",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541776","Catheter Related Infection, CTCAE","C143356","A disorder characterized by an infectious process that arises secondary to catheter use.","Catheter Related Infection, CTCAE | Catheter Related Infection | Catheter related infection | Catheter related infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541778","Cecal Hemorrhage, CTCAE","C143358","A disorder characterized by bleeding from the cecum.","Cecal Hemorrhage, CTCAE | Cecal Hemorrhage | Cecal hemorrhage | Cecal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541779","Cecal Infection, CTCAE","C143359","A disorder characterized by an infectious process involving the cecum.","Cecal Infection, CTCAE | Cecal Infection | Cecal infection | Cecal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541780","Central Nervous System Necrosis, CTCAE","C143360","A disorder characterized by a necrotic process occurring in the brain and/or spinal cord.","Central Nervous System Necrosis, CTCAE | Central Nervous System Necrosis | Central nervous system necrosis | Central nervous system necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541781","Cerebrospinal Fluid Leakage, CTCAE","C143361","A disorder characterized by loss of cerebrospinal fluid into the surrounding tissues.","Cerebrospinal Fluid Leakage, CTCAE | Cerebrospinal Fluid Leakage | Cerebrospinal fluid leakage | Cerebrospinal fluid leakage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545961","Chest Pain - Cardiac, CTCAE","C143364","A disorder characterized by substernal discomfort due to insufficient myocardial oxygenation e.g., angina pectoris.","Chest Pain - Cardiac, CTCAE | Chest Pain - Cardiac | Chest pain - cardiac | Chest pain - cardiac",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544690","Chest Wall Pain, CTCAE_5","C146743","A disorder characterized by a sensation of marked discomfort in the chest wall.","Chest Wall Pain, CTCAE 5.0 | Chest Wall Pain | Chest wall pain | Chest wall pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541769","Chills, CTCAE","C143366","A disorder characterized by a sensation of cold that often marks a physiologic response to sweating after a fever.","Chills, CTCAE | Chills | Chills",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544777","Cholecystitis, CTCAE_5","C146788","A disorder characterized by inflammation involving the gallbladder. It may be associated with the presence of gallstones.","Cholecystitis, CTCAE 5.0 | Cholecystitis | Cholecystitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545969","Cholesterol High, CTCAE","C143368","A finding based on laboratory test results that indicate higher than normal levels of cholesterol in a blood specimen.","Cholesterol High, CTCAE | Cholesterol High | Cholesterol high | Cholesterol high",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541770","Chronic Kidney Disease, CTCAE","C143369","A disorder characterized by gradual and usually permanent loss of kidney function resulting in renal failure.","Chronic Kidney Disease, CTCAE | Chronic Kidney Disease | Chronic kidney disease | Chronic kidney disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544693","Cognitive Disturbance, CTCAE_5","C146746","A disorder characterized by a conspicuous change in cognitive function.","Cognitive Disturbance, CTCAE 5.0 | Cognitive Disturbance | Cognitive disturbance | Cognitive disturbance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963084","Colitis, CTCAE","C57134","A disorder characterized by inflammation of the colon.","Colitis, CTCAE | Colitis | Colitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541771","Colonic Fistula, CTCAE","C143373","A disorder characterized by an abnormal communication between the large intestine and another organ or anatomic site.","Colonic Fistula, CTCAE | Colonic Fistula | Colonic fistula | Colonic fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541772","Colonic Hemorrhage, CTCAE","C143374","A disorder characterized by bleeding from the colon.","Colonic Hemorrhage, CTCAE | Colonic Hemorrhage | Colonic hemorrhage | Colonic hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541773","Colonic Obstruction, CTCAE","C143375","A disorder characterized by blockage of the normal flow of the intestinal contents in the colon.","Colonic Obstruction, CTCAE | Colonic Obstruction | Colonic obstruction | Colonic obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541774","Colonic Perforation, CTCAE","C143376","A disorder characterized by a rupture in the colonic wall.","Colonic Perforation, CTCAE | Colonic Perforation | Colonic perforation | Colonic perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541775","Colonic Stenosis, CTCAE","C143377","A disorder characterized by a narrowing of the lumen of the colon.","Colonic Stenosis, CTCAE | Colonic Stenosis | Colonic stenosis | Colonic stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541761","Colonic Ulcer, CTCAE","C143378","A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the colon.","Colonic Ulcer, CTCAE | Colonic Ulcer | Colonic ulcer | Colonic ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541762","Concentration Impairment, CTCAE","C143379","A disorder characterized by a deterioration in the ability to concentrate.","Concentration Impairment, CTCAE | Concentration Impairment | Concentration impairment | Concentration impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541763","Conduction Disorder, CTCAE","C143380","A disorder characterized by pathological irregularities in the cardiac conduction system.","Conduction Disorder, CTCAE | Conduction Disorder | Conduction disorder | Conduction disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544775","Confusion, CTCAE_5","C146785","A disorder characterized by a lack of clear and orderly thought and behavior.","Confusion, CTCAE 5.0 | Confusion | Confusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541764","Congenital, Familial and Genetic Disorders - Other, Specify, CTCAE","C143382","Congenital, familial and genetic disorders - Other, specify","Congenital, Familial and Genetic Disorders - Other, Specify, CTCAE | Congenital, Familial and Genetic Disorders - Other | Congenital, familial and genetic disorders - Other, specify | Congenital, familial and genetic disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541766","Conjunctivitis, CTCAE","C143384","A disorder characterized by inflammation, swelling and redness to the conjunctiva of the eye.","Conjunctivitis, CTCAE | Conjunctivitis | Conjunctivitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541765","Conjunctivitis Infective, CTCAE","C143383","A disorder characterized by an infectious process involving the conjunctiva. Clinical manifestations include pink or red color in the eyes.","Conjunctivitis Infective, CTCAE | Conjunctivitis Infective | Conjunctivitis infective | Conjunctivitis infective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963087","Constipation, CTCAE","C57141","A disorder characterized by irregular and infrequent or difficult evacuation of the bowels.","Constipation, CTCAE | Constipation | Constipation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541767","Corneal Infection, CTCAE","C143386","A disorder characterized by an infectious process involving the cornea.","Corneal Infection, CTCAE | Corneal Infection | Corneal infection | Corneal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541768","Corneal Ulcer, CTCAE","C143387","A disorder characterized by an area of epithelial tissue loss on the surface of the cornea. It is associated with inflammatory cells in the cornea and anterior chamber.","Corneal Ulcer, CTCAE | Corneal Ulcer | Corneal ulcer | Corneal ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1961131","COUGHING","C58028","A disorder characterized by sudden, often repetitive, spasmodic contraction of the thoracic cavity, resulting in violent release of air from the lungs and usually accompanied by a distinctive sound.","Cough, CTCAE | Cough | Cough",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541756","Cranial Nerve Infection, CTCAE","C143390","A disorder characterized by an infectious process involving a cranial nerve.","Cranial Nerve Infection, CTCAE | Cranial Nerve Infection | Cranial nerve infection | Cranial nerve infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546003","Creatinine Increased, CTCAE","C143391","A finding based on laboratory test results that indicate increased levels of creatinine in a biological specimen.","Creatinine Increased, CTCAE | Creatinine Increased | Creatinine increased | Creatinine increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541757","Cushingoid, CTCAE","C143392","A disorder characterized by signs and symptoms that resemble Cushing's disease or syndrome: buffalo hump obesity, striations, adiposity, hypertension, diabetes, and osteoporosis, usually due to exogenous corticosteroids.","Cushingoid, CTCAE | Cushingoid | Cushingoid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541758","Cystitis Noninfective, CTCAE","C143393","A disorder characterized by inflammation of the bladder which is not caused by an infection of the urinary tract.","Cystitis Noninfective, CTCAE | Cystitis Noninfective | Cystitis Noninfective (Priority 2) | Cystitis noninfective | Cystitis noninfective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541759","Cytokine Release Syndrome, CTCAE","C143394","A disorder characterized by fever, tachypnea, headache, tachycardia, hypotension, rash, and/or hypoxia caused by the release of cytokines.","Cytokine Release Syndrome, CTCAE | Cytokine Release Syndrome | Cytokine release syndrome | Cytokine release syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550658","Death NOS, CTCAE","C143396","Death that cannot be attributed to a CTCAE term associated with Grade 5.","Death NOS, CTCAE | Death NOS | Death NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541760","Death Neonatal, CTCAE","C143395","Newborn death occurring during the first 28 days after birth.","Death Neonatal, CTCAE | Death Neonatal | Death neonatal | Death neonatal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963090","Dehydration, CTCAE","C57787","A disorder characterized by excessive loss of water from the body. It is usually caused by severe diarrhea, vomiting or diaphoresis.","Dehydration, CTCAE | Dehydration | Dehydration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541748","Delayed Orgasm, CTCAE","C143398","A disorder characterized by sexual dysfunction characterized by a delay in climax.","Delayed Orgasm, CTCAE | Delayed Orgasm | Delayed orgasm | Delayed orgasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883716","Delayed Puberty, CTCAE","C55742","A disorder characterized by unusually late sexual maturity.","Delayed Puberty, CTCAE | Delayed Puberty | Delayed puberty | Delayed puberty | Puberty (delayed)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541749","Delirium, CTCAE","C143400","A disorder characterized by the acute and sudden development of confusion, illusions, movement changes, inattentiveness, agitation, and hallucinations. Usually, it is a reversible condition.","Delirium, CTCAE | Delirium | Delirium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541750","Delusions, CTCAE","C143401","A disorder characterized by false personal beliefs held contrary to reality, despite contradictory evidence and common sense.","Delusions, CTCAE | Delusions | Delusions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541751","Dental Caries, CTCAE","C143402","A disorder characterized by the decay of a tooth, in which it becomes softened, discolored and/or porous.","Dental Caries, CTCAE | Dental Caries | Dental caries | Dental caries",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541752","Depressed Level of Consciousness, CTCAE","C143403","A disorder characterized by a decrease in ability to perceive and respond.","Depressed Level of Consciousness, CTCAE | Depressed Level of Consciousness | Depressed level of consciousness | Depressed level of consciousness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1999266","Depression, CTCAE","C55447","A disorder characterized by melancholic feelings of grief or unhappiness.","Depression, CTCAE | Depression | Depression | Depression (Priority 2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541753","Dermatitis Radiation, CTCAE","C143405","A finding of cutaneous inflammatory reaction occurring as a result of exposure to biologically effective levels of ionizing radiation.","Dermatitis Radiation, CTCAE | Dermatitis Radiation | Dermatitis radiation | Dermatitis radiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541754","Device Related Infection, CTCAE","C143406","A disorder characterized by an infectious process involving the use of a medical device.","Device Related Infection, CTCAE | Device Related Infection | Device related infection | Device related infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963091","DIARRHOEA","C57788","A disorder characterized by an increase in frequency and/or loose or watery bowel movements.","Diarrhea, CTCAE | Diarrhea | Diarrhea | Diarrhea (Priority 1)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963092","Disseminated Intravascular Coagulation Adverse Event","C55273","A disorder characterized by systemic pathological activation of blood clotting mechanisms which results in clot formation throughout the body. There is an increase in the risk of hemorrhage as the body is depleted of platelets and coagulation factors.","Disseminated Intravascular Coagulation, CTCAE | DIC (disseminated intravascular coagulation) | Disseminated Intravascular Coagulation | Disseminated intravascular coagulation | Disseminated intravascular coagulation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544801","Dizziness, CTCAE_5","C146747","A disorder characterized by a disturbing sensation of lightheadedness, unsteadiness, giddiness, spinning or rocking.","Dizziness, CTCAE 5.0 | Dizziness | Dizziness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545897","Dry Eye, CTCAE","C143410","A disorder characterized by dryness of the cornea and conjunctiva.","Dry Eye, CTCAE | Dry Eye | Dry eye | Dry eye",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541740","Dry Mouth, CTCAE","C143411","A disorder characterized by reduced salivary flow in the oral cavity.","Dry Mouth, CTCAE | Dry Mouth | Dry mouth | Dry mouth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963094","SKIN DRY","C57996","A disorder characterized by flaky and dull skin; the pores are generally fine, the texture is a papery thin texture.","Dry Skin, CTCAE | Dry Skin | Dry skin | Dry skin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1962984","Duodenal Fistula, CTCAE","C57789","A disorder characterized by an abnormal communication between the duodenum and another organ or anatomic site.","Duodenal Fistula, CTCAE | Duodenal Fistula | Duodenal fistula | Duodenal fistula | Duodenum fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541741","Duodenal Hemorrhage, CTCAE","C143414","A disorder characterized by bleeding from the duodenum.","Duodenal Hemorrhage, CTCAE | Duodenal Hemorrhage | Duodenal hemorrhage | Duodenal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541743","Duodenal Obstruction, CTCAE","C143416","A disorder characterized by blockage of the normal flow of stomach contents through the duodenum.","Duodenal Obstruction, CTCAE | Duodenal Obstruction | Duodenal obstruction | Duodenal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541744","Duodenal Perforation, CTCAE","C143417","A disorder characterized by a rupture in the duodenal wall.","Duodenal Perforation, CTCAE | Duodenal Perforation | Duodenal perforation | Duodenal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541745","Duodenal Stenosis, CTCAE","C143418","A disorder characterized by a narrowing of the lumen of the duodenum.","Duodenal Stenosis, CTCAE | Duodenal Stenosis | Duodenal stenosis | Duodenal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541746","Duodenal Ulcer, CTCAE","C143419","A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the duodenal wall.","Duodenal Ulcer, CTCAE | Duodenal Ulcer | Duodenal ulcer | Duodenal ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541747","Dysarthria, CTCAE","C143420","A disorder characterized by slow and slurred speech resulting from an inability to coordinate the muscles used in speech.","Dysarthria, CTCAE | Dysarthria | Dysarthria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541733","Dysesthesia, CTCAE","C143421","A disorder characterized by distortion of sensory perception, resulting in an abnormal and unpleasant sensation.","Dysesthesia, CTCAE | Dysesthesia | Dysesthesia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541734","Dysgeusia, CTCAE","C143422","A disorder characterized by abnormal sensual experience with the taste of foodstuffs; it can be related to a decrease in the sense of smell.","Dysgeusia, CTCAE | Dysgeusia | Dysgeusia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541735","Dysmenorrhea, CTCAE","C143423","A disorder characterized by abnormally painful abdominal cramps during menses.","Dysmenorrhea, CTCAE | Dysmenorrhea | Dysmenorrhea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545960","Dyspareunia, CTCAE","C143424","A disorder characterized by painful or difficult coitus.","Dyspareunia, CTCAE | Dyspareunia | Dyspareunia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541736","Dyspepsia, CTCAE","C143425","A disorder characterized by an uncomfortable, often painful feeling in the stomach, resulting from impaired digestion. Symptoms include burning stomach, bloating, heartburn, nausea and vomiting.","Dyspepsia, CTCAE | Dyspepsia | Dyspepsia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1560331","Dysphagia, CTCAE","C57795","A disorder characterized by difficulty in swallowing.","Dysphagia, CTCAE | Dysphagia | Dysphagia | Dysphagia (difficulty swallowing)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541737","Dysphasia, CTCAE","C143427","A disorder characterized by impairment of verbal communication skills, often resulting from brain damage.","Dysphasia, CTCAE | Dysphasia | Dysphasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963100","Dyspnea, CTCAE","C58185","A disorder characterized by an uncomfortable sensation of difficulty breathing.","Dyspnea, CTCAE | Dyspnea | Dyspnea | Dyspnea (shortness of breath)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541738","Ear and Labyrinth Disorders - Other, Specify, CTCAE","C143429","Ear and labyrinth disorders - Other, specify","Ear and Labyrinth Disorders - Other, Specify, CTCAE | Ear and Labyrinth Disorders - Other | Ear and labyrinth disorders - Other, specify | Ear and labyrinth disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541739","Ear Pain, CTCAE","C143430","A disorder characterized by a sensation of marked discomfort in the ear.","Ear Pain, CTCAE | Ear Pain | Ear pain | Ear pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541725","Edema Cerebral, CTCAE","C143431","A disorder characterized by swelling due to an excessive accumulation of fluid in the brain.","Edema Cerebral, CTCAE | Edema Cerebral | Edema cerebral | Edema cerebral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541726","Edema Face, CTCAE","C143432","A disorder characterized by swelling due to excessive fluid accumulation in facial tissues.","Edema Face, CTCAE | Edema Face | Edema face | Edema face",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541727","Edema Limbs, CTCAE","C143433","A disorder characterized by swelling due to excessive fluid accumulation in the upper or lower extremities.","Edema Limbs, CTCAE | Edema Limbs | Edema limbs | Edema limbs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541728","Edema Trunk, CTCAE","C143434","A disorder characterized by swelling due to excessive fluid accumulation in the trunk area.","Edema Trunk, CTCAE | Edema Trunk | Edema trunk | Edema trunk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541729","Ejaculation Disorder, CTCAE","C143435","A disorder characterized by problems related to ejaculation. This category includes premature, delayed, retrograde and painful ejaculation.","Ejaculation Disorder, CTCAE | Ejaculation Disorder | Ejaculation Disorder (Priority 2) | Ejaculation disorder | Ejaculation disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541730","Ejection Fraction Decreased, CTCAE","C143436","The percentage computed when the amount of blood ejected during a ventricular contraction of the heart is compared to the amount that was present prior to the contraction.","Ejection Fraction Decreased, CTCAE | Ejection Fraction Decreased | Ejection fraction decreased | Ejection fraction decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541731","Electrocardiogram QT Corrected Interval Prolonged, CTCAE","C143437","A finding of a cardiac dysrhythmia characterized by an abnormally long corrected QT interval.","Electrocardiogram QT Corrected Interval Prolonged, CTCAE | Electrocardiogram QT Corrected Interval Prolonged | Electrocardiogram QT corrected interval prolonged | Electrocardiogram QT corrected interval prolonged",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541732","Encephalitis Infection, CTCAE","C143438","A disorder characterized by an infectious process involving the brain tissue.","Encephalitis Infection, CTCAE | Encephalitis Infection | Encephalitis infection | Encephalitis infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541836","Encephalomyelitis Infection, CTCAE","C143439","A disorder characterized by an infectious process involving the brain and spinal cord tissues.","Encephalomyelitis Infection, CTCAE | Encephalomyelitis Infection | Encephalomyelitis infection | Encephalomyelitis infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544726","Encephalopathy, CTCAE_5","C146699","A disorder characterized by a pathologic process involving the brain.","Encephalopathy, CTCAE 5.0 | Encephalopathy | Encephalopathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541837","Endocarditis Infective, CTCAE","C143441","A disorder characterized by an infectious process involving the endocardial layer of the heart.","Endocarditis Infective, CTCAE | Endocarditis Infective | Endocarditis infective | Endocarditis infective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546037","Endocrine Disorders - Other, Specify, CTCAE","C143442","Endocrine disorders - Other, specify","Endocrine Disorders - Other, Specify, CTCAE | Endocrine Disorders - Other | Endocrine disorders - Other, specify | Endocrine disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541838","Endophthalmitis, CTCAE","C143443","A disorder characterized by an infectious process involving the internal structures of the eye.","Endophthalmitis, CTCAE | Endophthalmitis | Endophthalmitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541840","Enterocolitis, CTCAE","C143445","A disorder characterized by inflammation of the small and large intestines.","Enterocolitis, CTCAE | Enterocolitis | Enterocolitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541839","Enterocolitis Infectious, CTCAE","C143444","A disorder characterized by an infectious process involving the small and large intestines.","Enterocolitis Infectious, CTCAE | Enterocolitis Infectious | Enterocolitis infectious | Enterocolitis infectious",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541841","Enterovesical Fistula, CTCAE","C143446","A disorder characterized by an abnormal communication between the urinary bladder and the intestine.","Enterovesical Fistula, CTCAE | Enterovesical Fistula | Enterovesical fistula | Enterovesical fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541842","Epistaxis, CTCAE","C143447","A disorder characterized by bleeding from the nose.","Epistaxis, CTCAE | Epistaxis | Epistaxis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1961100","Erectile Dysfunction, CTCAE","C55615","A disorder characterized by the persistent or recurrent inability to achieve or to maintain an erection during sexual activity.","Erectile Dysfunction, CTCAE | Erectile Dysfunction | Erectile Dysfunction (Priority 1) | Erectile dysfunction | Erectile dysfunction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541829","Erythema Multiforme, CTCAE","C143449","A disorder characterized by target lesions (a pink-red ring around a pale center).","Erythema Multiforme, CTCAE | Erythema Multiforme | Erythema multiforme | Erythema multiforme",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540990","Erythroderma, CTCAE","C143450","A disorder characterized by generalized inflammatory erythema and exfoliation. The inflammatory process involves > 90% of the body surface area.","Erythroderma, CTCAE | Erythroderma | Erythroderma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541830","Esophageal Anastomotic Leak, CTCAE","C143451","A finding of leakage due to breakdown of an esophageal anastomosis (surgical connection of two separate anatomic structures).","Esophageal Anastomotic Leak, CTCAE | Esophageal Anastomotic Leak | Esophageal anastomotic leak | Esophageal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963104","Esophageal Fistula, CTCAE","C57798","A disorder characterized by an abnormal communication between the esophagus and another organ or anatomic site.","Esophageal Fistula, CTCAE | Esophageal Fistula | Esophageal fistula | Esophageal fistula | Esophagus fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541831","Esophageal Hemorrhage, CTCAE","C143453","A disorder characterized by bleeding from the esophagus.","Esophageal Hemorrhage, CTCAE | Esophageal Hemorrhage | Esophageal hemorrhage | Esophageal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541832","Esophageal Infection, CTCAE","C143454","A disorder characterized by an infectious process involving the esophagus.","Esophageal Infection, CTCAE | Esophageal Infection | Esophageal infection | Esophageal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541833","Esophageal Necrosis, CTCAE","C143455","A disorder characterized by a necrotic process occurring in the esophageal wall.","Esophageal Necrosis, CTCAE | Esophageal Necrosis | Esophageal necrosis | Esophageal necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541834","Esophageal Obstruction, CTCAE","C143456","A disorder characterized by blockage of the normal flow of the contents in the esophagus.","Esophageal Obstruction, CTCAE | Esophageal Obstruction | Esophageal obstruction | Esophageal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541835","Esophageal Pain, CTCAE","C143457","A disorder characterized by a sensation of marked discomfort in the esophageal region.","Esophageal Pain, CTCAE | Esophageal Pain | Esophageal pain | Esophageal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541821","Esophageal Perforation, CTCAE","C143458","A disorder characterized by a rupture in the wall of the esophagus.","Esophageal Perforation, CTCAE | Esophageal Perforation | Esophageal perforation | Esophageal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541822","Esophageal Stenosis, CTCAE","C143459","A disorder characterized by a narrowing of the lumen of the esophagus.","Esophageal Stenosis, CTCAE | Esophageal Stenosis | Esophageal stenosis | Esophageal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541823","Esophageal Ulcer, CTCAE","C143460","A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the esophageal wall.","Esophageal Ulcer, CTCAE | Esophageal Ulcer | Esophageal ulcer | Esophageal ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544721","Esophageal Varices Hemorrhage, CTCAE_5","C146710","A disorder characterized by bleeding from esophageal varices.","Esophageal Varices Hemorrhage, CTCAE 5.0 | Esophageal Varices Hemorrhage | Esophageal varices hemorrhage | Esophageal varices hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963106","OESOPHAGITIS","C57797","A disorder characterized by inflammation of the esophageal wall.","Esophagitis, CTCAE | Esophagitis | Esophagitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550637","Euphoria, CTCAE_5","C146748","A disorder characterized by an exaggerated feeling of well-being which is disproportionate to events and stimuli.","Euphoria, CTCAE 5.0 | Euphoria | Euphoria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544802","Exostosis, CTCAE_5","C146749","A disorder characterized by non-neoplastic overgrowth of bone.","Exostosis, CTCAE 5.0 | Exostosis | Exostosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541824","Extraocular Muscle Paresis, CTCAE","C143466","A disorder characterized by incomplete paralysis of an extraocular muscle.","Extraocular Muscle Paresis, CTCAE | Extraocular Muscle Paresis | Extraocular muscle paresis | Extraocular muscle paresis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541825","Extrapyramidal Disorder, CTCAE","C143467","A disorder characterized by abnormal, repetitive, involuntary muscle movements, frenzied speech and extreme restlessness.","Extrapyramidal Disorder, CTCAE | Extrapyramidal Disorder | Extrapyramidal disorder | Extrapyramidal disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541826","Eye Disorders - Other, Specify, CTCAE","C143468","Eye disorders - Other, specify","Eye Disorders - Other, Specify, CTCAE | Eye Disorders - Other | Eye disorders - Other, specify | Eye disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541827","Eye Infection, CTCAE","C143469","A disorder characterized by an infectious process involving the eye.","Eye Infection, CTCAE | Eye Infection | Eye infection | Eye infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544803","Eye Pain, CTCAE_5","C146751","A disorder characterized by a sensation of marked discomfort in the eye.","Eye Pain, CTCAE 5.0 | Eye Pain | Eye pain | Eye pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541828","Eyelid Function Disorder, CTCAE","C143471","A disorder characterized by impaired eyelid function.","Eyelid Function Disorder, CTCAE | Eyelid Function Disorder | Eyelid function disorder | Eyelid function disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541814","Facial Muscle Weakness, CTCAE","C143472","A disorder characterized by a reduction in the strength of the facial muscles.","Facial Muscle Weakness, CTCAE | Facial Muscle Weakness | Facial muscle weakness | Facial muscle weakness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541815","Facial Nerve Disorder, CTCAE","C143473","A disorder characterized by dysfunction of the facial nerve (seventh cranial nerve).","Facial Nerve Disorder, CTCAE | Facial Nerve Disorder | Facial nerve disorder | Facial nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541816","Facial Pain, CTCAE","C143474","A disorder characterized by a sensation of marked discomfort in the face.","Facial Pain, CTCAE | Facial Pain | Facial pain | Facial pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546052","Fall, CTCAE","C143475","A finding of sudden movement downward, usually resulting in injury.","Fall, CTCAE | Fall | Fall",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541817","Fallopian Tube Anastomotic Leak, CTCAE","C143476","A finding of leakage due to breakdown of a fallopian tube anastomosis (surgical connection of two separate anatomic structures).","Fallopian Tube Anastomotic Leak, CTCAE | Fallopian Tube Anastomotic Leak | Fallopian tube anastomotic leak | Fallopian tube anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544804","Fallopian Tube Obstruction, CTCAE_5","C146752","A disorder characterized by blockage of the normal flow of the contents in the fallopian tube.","Fallopian Tube Obstruction, CTCAE 5.0 | Fallopian Tube Obstruction | Fallopian tube obstruction | Fallopian tube obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544709","Fallopian Tube Perforation, CTCAE_5","C146714","A disorder characterized by a rupture of the fallopian tube wall.","Fallopian Tube Perforation, CTCAE 5.0 | Fallopian Tube Perforation | Fallopian tube perforation | Fallopian tube perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541818","Fat Atrophy, CTCAE","C143479","A disorder characterized by shrinking of adipose tissue.","Fat Atrophy, CTCAE | Fat Atrophy | Fat atrophy | Fat atrophy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550640","Fatigue, CTCAE_5","C146753","A disorder characterized by a state of generalized weakness with a pronounced inability to summon sufficient energy to accomplish daily activities.","Fatigue, CTCAE 5.0 | Fatigue | Fatigue | Fatigue (Priority 2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541819","Febrile Neutropenia, CTCAE","C143481","A disorder characterized by an ANC <1000/mm3 and a single temperature of >38.3 degrees C (101 degrees F) or a sustained temperature of >=38 degrees C (100.4 degrees F) for more than one hour","Febrile Neutropenia, CTCAE | Febrile Neutropenia | Febrile neutropenia | Febrile neutropenia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541820","Fecal Incontinence, CTCAE","C143482","A disorder characterized by inability to control the escape of stool from the rectum.","Fecal Incontinence, CTCAE | Fecal Incontinence | Fecal Incontinence (Priority 1) | Fecal incontinence | Fecal incontinence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541807","Feminization Acquired, CTCAE","C143483","A disorder characterized by the development of secondary female sex characteristics in males due to extrinsic factors.","Feminization Acquired, CTCAE | Feminization Acquired | Feminization acquired | Feminization acquired",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546012","Fetal Growth Retardation, CTCAE","C143484","A disorder characterized by inhibition of fetal growth resulting in the inability of the fetus to achieve its potential weight.","Fetal Growth Retardation, CTCAE | Fetal Growth Retardation | Fetal growth retardation | Fetal growth retardation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541808","Fever, CTCAE","C143485","A disorder characterized by elevation of the body's temperature above the upper limit of normal.","Fever, CTCAE | Fever | Fever",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541809","Fibrinogen Decreased, CTCAE","C143486","A finding based on laboratory test results that indicate an decrease in levels of fibrinogen in a blood specimen.","Fibrinogen Decreased, CTCAE | Fibrinogen Decreased | Fibrinogen decreased | Fibrinogen decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541810","Fibrosis Deep Connective Tissue, CTCAE","C143487","A disorder characterized by fibrotic degeneration of the deep connective tissues.","Fibrosis Deep Connective Tissue, CTCAE | Fibrosis Deep Connective Tissue | Fibrosis deep connective tissue | Fibrosis deep connective tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541811","Flank Pain, CTCAE","C143488","A disorder characterized by a sensation of marked discomfort on the lateral side of the body in the region below the ribs and above the hip.","Flank Pain, CTCAE | Flank Pain | Flank pain | Flank pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541812","Flashing Lights, CTCAE","C143489","A disorder characterized by a sudden or brief burst of light.","Flashing Lights, CTCAE | Flashing Lights | Flashing lights | Flashing lights",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1962956","FLATULENCE","C57807","A disorder characterized by a discharge of excessive gas from the lower GI tract.","Flatulence, CTCAE | Flatulence | Flatulence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541813","Floaters, CTCAE","C143491","A disorder characterized by an individual seeing spots before their eyes. The spots are shadows of opaque cell fragments in the vitreous humor or lens.","Floaters, CTCAE | Floaters | Floaters",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541799","Flu Like Symptoms, CTCAE","C143492","A disorder characterized by a group of symptoms similar to those observed in patients with the flu. It includes fever, chills, body aches, malaise, loss of appetite and dry cough.","Flu Like Symptoms, CTCAE | Flu Like Symptoms | Flu like symptoms | Flu like symptoms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545971","Flushing, CTCAE_5","C146643","A disorder characterized by episodic reddening of the skin, especially face, neck, or chest.","Flushing, CTCAE 5.0 | Flushing | Flushing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541800","Forced Expiratory Volume Decreased, CTCAE","C143494","A finding based on test results that indicate a relative decrease in the fraction of the forced vital capacity that is exhaled in a specific number of seconds.","Forced Expiratory Volume Decreased, CTCAE | Forced Expiratory Volume Decreased | Forced expiratory volume decreased | Forced expiratory volume decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963113","FRACTURE BONE","C58382","A finding of traumatic injury to the bone in which the continuity of the bone is broken.","Fracture, CTCAE | Fracture | Fracture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541787","GGT Increased, CTCAE","C143516","A finding based on laboratory test results that indicate higher than normal levels of the enzyme gamma-glutamyltransferase in the blood specimen. GGT (gamma-glutamyltransferase ) catalyzes the transfer of a gamma glutamyl group from a gamma glutamyl peptide to another peptide, amino acids or water.","GGT Increased, CTCAE | GGT Increased | GGT increased | GGT increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541801","Gait Disturbance, CTCAE","C143496","A disorder characterized by walking difficulties.","Gait Disturbance, CTCAE | Gait Disturbance | Gait disturbance | Gait disturbance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963110","Gallbladder Fistula, CTCAE","C57808","A disorder characterized by an abnormal communication between the gallbladder and another organ or anatomic site.","Gallbladder Fistula, CTCAE | Gallbladder Fistula | Gallbladder fistula | Gallbladder fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541802","Gallbladder Infection, CTCAE","C143497","A disorder characterized by an infectious process involving the gallbladder.","Gallbladder Infection, CTCAE | Gallbladder Infection | Gallbladder infection | Gallbladder infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544698","Gallbladder Necrosis, CTCAE_5","C146735","A disorder characterized by a necrotic process occurring in the gallbladder.","Gallbladder Necrosis, CTCAE 5.0 | Gallbladder Necrosis | Gallbladder necrosis | Gallbladder necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1964021","Gallbladder Obstruction, CTCAE","C57810","A disorder characterized by blockage of the normal flow of the contents of the gallbladder.","Gallbladder Obstruction, CTCAE | Gallbladder Obstruction | Gallbladder obstruction | Gallbladder obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544793","Gallbladder Pain, CTCAE_5","C146755","A disorder characterized by a sensation of marked discomfort in the gallbladder region.","Gallbladder Pain, CTCAE 5.0 | Gallbladder Pain | Gallbladder pain | Gallbladder pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544719","Gallbladder Perforation, CTCAE_5","C146708","A disorder characterized by a rupture in the gallbladder wall.","Gallbladder Perforation, CTCAE 5.0 | Gallbladder Perforation | Gallbladder perforation | Gallbladder perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541803","Gastric Anastomotic Leak, CTCAE","C143498","A finding of leakage due to breakdown of a gastric anastomosis (surgical connection of two separate anatomic structures).","Gastric Anastomotic Leak, CTCAE | Gastric Anastomotic Leak | Gastric anastomotic leak | Gastric anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541804","Gastric Fistula, CTCAE","C143499","A disorder characterized by an abnormal communication between the stomach and another organ or anatomic site.","Gastric Fistula, CTCAE | Gastric Fistula | Gastric fistula | Gastric fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541805","Gastric Hemorrhage, CTCAE","C143500","A disorder characterized by bleeding from the gastric wall.","Gastric Hemorrhage, CTCAE | Gastric Hemorrhage | Gastric hemorrhage | Gastric hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541806","Gastric Necrosis, CTCAE","C143501","A disorder characterized by a necrotic process occurring in the gastric wall.","Gastric Necrosis, CTCAE | Gastric Necrosis | Gastric necrosis | Gastric necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541791","Gastric Perforation, CTCAE","C143502","A disorder characterized by a rupture in the stomach wall.","Gastric Perforation, CTCAE | Gastric Perforation | Gastric perforation | Gastric perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541792","Gastric Stenosis, CTCAE","C143503","A disorder characterized by a narrowing of the lumen of the stomach.","Gastric Stenosis, CTCAE | Gastric Stenosis | Gastric stenosis | Gastric stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541793","Gastric Ulcer, CTCAE","C143504","A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the stomach.","Gastric Ulcer, CTCAE | Gastric Ulcer | Gastric ulcer | Gastric ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1560435","Gastritis, CTCAE","C57812","A disorder characterized by inflammation of the stomach.","Gastritis, CTCAE | Gastritis | Gastritis | Gastritis (including bile reflux gastritis)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541794","Gastroesophageal Reflux Disease, CTCAE","C143506","A disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is chronic in nature and usually caused by incompetence of the lower esophageal sphincter, and may result in injury to the esophageal mucosal. Symptoms include heartburn and acid indigestion.","Gastroesophageal Reflux Disease, CTCAE | Gastroesophageal Reflux Disease | Gastroesophageal reflux disease | Gastroesophageal reflux disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541795","Gastrointestinal Anastomotic Leak, CTCAE","C143507","A finding of leakage due to breakdown of a gastrointestinal anastomosis (surgical connection of two separate anatomic structures).","Gastrointestinal Anastomotic Leak, CTCAE | Gastrointestinal Anastomotic Leak | Gastrointestinal anastomotic leak | Gastrointestinal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541796","Gastrointestinal Disorders - Other, Specify, CTCAE","C143508","Gastrointestinal disorders - Other, specify","Gastrointestinal Disorders - Other, Specify, CTCAE | Gastrointestinal Disorders - Other | Gastrointestinal disorders - Other, specify | Gastrointestinal disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541797","Gastrointestinal Pain, CTCAE","C143510","A disorder characterized by a sensation of marked discomfort in the gastrointestinal region.","Gastrointestinal Pain, CTCAE | Gastrointestinal Pain | Gastrointestinal pain | Gastrointestinal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541798","Gastrointestinal Stoma Necrosis, CTCAE","C143511","A disorder characterized by a necrotic process occurring in the gastrointestinal tract stoma.","Gastrointestinal Stoma Necrosis, CTCAE | Gastrointestinal Stoma Necrosis | Gastrointestinal stoma necrosis | Gastrointestinal stoma necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541783","Gastroparesis, CTCAE","C143512","A disorder characterized by an incomplete paralysis of the muscles of the stomach wall resulting in delayed emptying of the gastric contents into the small intestine.","Gastroparesis, CTCAE | Gastroparesis | Gastroparesis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541784","General Disorders and Administration Site Conditions - Other, Specify, CTCAE","C143513","General disorders and administration site conditions - Other, specify","General Disorders and Administration Site Conditions - Other, Specify, CTCAE | General Disorders and Administration Site Conditions - Other | General disorders and administration site conditions - Other, specify | General disorders and administration site conditions - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541785","Generalized Muscle Weakness, CTCAE","C143514","A disorder characterized by a reduction in the strength of muscles in multiple anatomic sites.","Generalized Muscle Weakness, CTCAE | Generalized Muscle Weakness | Generalized muscle weakness | Generalized muscle weakness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541786","Genital Edema, CTCAE","C143515","A disorder characterized by swelling due to an excessive accumulation of fluid in the genitals.","Genital Edema, CTCAE | Genital Edema | Genital edema | Genital edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544673","Gingival Pain, CTCAE","C146626","A disorder characterized by a sensation of marked discomfort in the gingival region.","Gingival Pain, CTCAE | Gingival Pain | Gingival pain | Gingival pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1962986","GLAUCOMA","C55842","A disorder characterized by an increase in pressure in the eyeball due to obstruction of the aqueous humor outflow.","Glaucoma, CTCAE | Glaucoma | Glaucoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541788","Glossopharyngeal Nerve Disorder, CTCAE","C143518","A disorder characterized by dysfunction of the glossopharyngeal nerve (ninth cranial nerve).","Glossopharyngeal Nerve Disorder, CTCAE | Glossopharyngeal Nerve Disorder | Glossopharyngeal nerve disorder | Glossopharyngeal nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541789","Glucose Intolerance, CTCAE","C143519","A disorder characterized by an inability to properly metabolize glucose.","Glucose Intolerance, CTCAE | Glucose Intolerance | Glucose intolerance | Glucose intolerance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541790","Growth Accelerated, CTCAE","C143520","A disorder characterized by greater growth than expected for age.","Growth Accelerated, CTCAE | Growth Accelerated | Growth accelerated | Growth accelerated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541895","Growth Hormone Abnormal, CTCAE","C143521","A finding based on laboratory test results that indicate abnormal levels of growth hormone in a biological specimen.","Growth Hormone Abnormal, CTCAE | Growth Hormone Abnormal | Growth hormone abnormal | Growth hormone abnormal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541896","Growth Suppression, CTCAE","C143522","A disorder characterized by stature that is smaller than normal as expected for age.","Growth Suppression, CTCAE | Growth Suppression | Growth suppression | Growth suppression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541897","Gum Infection, CTCAE","C143523","A disorder characterized by an infectious process involving the gums.","Gum Infection, CTCAE | Gum Infection | Gum infection | Gum infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544743","Gynecomastia, CTCAE_5","C146685","A disorder characterized by excessive development of the breasts in males.","Gynecomastia, CTCAE 5.0 | Gynecomastia | Gynecomastia | Gynecomastia (Priority 2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541898","Hallucinations, CTCAE","C143525","A disorder characterized by a false sensory perception in the absence of an external stimulus.","Hallucinations, CTCAE | Hallucinations | Hallucinations",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541899","Haptoglobin Decreased, CTCAE","C143526","A finding based on laboratory test results that indicate an decrease in levels of haptoglobin in a blood specimen.","Haptoglobin Decreased, CTCAE | Haptoglobin Decreased | Haptoglobin decreased | Haptoglobin decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963121","Head Soft Tissue Necrosis, CTCAE","C58383","A disorder characterized by a necrotic process occurring in the soft tissues of the head.","Head Soft Tissue Necrosis, CTCAE | Head Soft Tissue Necrosis | Head soft tissue necrosis | Head soft tissue necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541900","Headache, CTCAE","C143527","A disorder characterized by a sensation of marked discomfort in various parts of the head, not confined to the area of distribution of any nerve.","Headache, CTCAE | Headache | Headache",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545983","Hearing Impaired, CTCAE","C143528","A disorder characterized by partial or complete loss of the ability to detect or understand sounds resulting from damage to ear structures.","Hearing Impaired, CTCAE | Hearing Impaired | Hearing impaired | Hearing impaired",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541901","Heart Failure, CTCAE","C143529","A disorder characterized by the inability of the heart to pump blood at an adequate volume to meet tissue metabolic requirements, or, the ability to do so only at an elevation in the filling pressure.","Heart Failure, CTCAE | Heart Failure | Heart failure | Heart failure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1962958","Hematoma, CTCAE","C56539","A disorder characterized by a localized collection of blood, usually clotted, in an organ, space, or tissue, due to a break in the wall of a blood vessel.","Hematoma, CTCAE | Hematoma | Hematoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541887","Hematosalpinx, CTCAE","C143531","A disorder characterized by the presence of blood in a fallopian tube.","Hematosalpinx, CTCAE | Hematosalpinx | Hematosalpinx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541888","Hematuria, CTCAE","C143532","A disorder characterized by laboratory test results that indicate blood in the urine.","Hematuria, CTCAE | Hematuria | Hematuria | Hematuria (Priority 1)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541889","Hemoglobin Increased, CTCAE","C143533","A finding based on laboratory test results that indicate increased levels of hemoglobin above normal.","Hemoglobin Increased, CTCAE | Hemoglobin Increased | Hemoglobin increased | Hemoglobin increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544790","Hemoglobinuria, CTCAE_5","C146768","A disorder characterized by laboratory test results that indicate the presence of free hemoglobin in the urine.","Hemoglobinuria, CTCAE 5.0 | Hemoglobinuria | Hemoglobinuria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1560209","Hemolysis, CTCAE","C55992","A disorder characterized by laboratory test results that indicate widespread erythrocyte cell membrane destruction.","Hemolysis, CTCAE | Hemolysis | Hemolysis | Hemolysis (e.g., immune hemolytic anemia, drug-related hemolysis)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541890","Hemolytic Uremic Syndrome, CTCAE","C143536","A disorder characterized by a form of thrombotic microangiopathy with renal failure, hemolytic anemia, and severe thrombocytopenia.","Hemolytic Uremic Syndrome, CTCAE | Hemolytic Uremic Syndrome | Hemolytic uremic syndrome | Hemolytic uremic syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541891","Hemorrhoidal Hemorrhage, CTCAE","C143537","A disorder characterized by bleeding from the hemorrhoids.","Hemorrhoidal Hemorrhage, CTCAE | Hemorrhoidal Hemorrhage | Hemorrhoidal hemorrhage | Hemorrhoidal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544700","Hemorrhoids, CTCAE_5","C146738","A disorder characterized by the presence of dilated veins in the rectum and surrounding area.","Hemorrhoids, CTCAE 5.0 | Hemorrhoids | Hemorrhoids | Hemorrhoids (Priority 2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541892","Hepatic Failure, CTCAE","C143539","A disorder characterized by the inability of the liver to metabolize chemicals in the body. Laboratory test results reveal abnormal plasma levels of ammonia, bilirubin, lactic dehydrogenase, alkaline phosphatase, aminotransferase, and/or prolongation of prothrombin time (INR.) Drug-induced liever injury (DILI) as defined by Hy's Law.","Hepatic Failure, CTCAE | Hepatic Failure | Hepatic failure | Hepatic failure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541893","Hepatic Hemorrhage, CTCAE","C143540","A disorder characterized by bleeding from the liver.","Hepatic Hemorrhage, CTCAE | Hepatic Hemorrhage | Hepatic hemorrhage | Hepatic hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541894","Hepatic Infection, CTCAE","C143541","A disorder characterized by an infectious process involving the liver.","Hepatic Infection, CTCAE | Hepatic Infection | Hepatic infection | Hepatic infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544699","Hepatic Necrosis, CTCAE_5","C146736","A disorder characterized by a necrotic process occurring in the hepatic parenchyma.","Hepatic Necrosis, CTCAE 5.0 | Hepatic Necrosis | Hepatic necrosis | Hepatic necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541880","Hepatic Pain, CTCAE","C143542","A disorder characterized by a sensation of marked discomfort in the liver region.","Hepatic Pain, CTCAE | Hepatic Pain | Hepatic pain | Hepatic pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541881","Hepatitis Viral, CTCAE","C143543","A disorder characterized by a viral pathologic process involving the liver parenchyma.","Hepatitis Viral, CTCAE | Hepatitis Viral | Hepatitis viral | Hepatitis viral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541882","Hepatobiliary Disorders - Other, Specify, CTCAE","C143544","Hepatobiliary disorders - Other, specify","Hepatobiliary Disorders - Other, Specify, CTCAE | Hepatobiliary Disorders - Other | Hepatobiliary disorders - Other, specify | Hepatobiliary disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541883","Hiccups, CTCAE","C143545","A disorder characterized by repeated gulp sounds that result from an involuntary opening and closing of the glottis. This is attributed to a spasm of the diaphragm.","Hiccups, CTCAE | Hiccups | Hiccups",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541884","Hip Fracture, CTCAE","C143546","A finding of traumatic injury to the hip in which the continuity of either the femoral head, femoral neck, intertrochanteric or subtrochanteric regions is broken.","Hip Fracture, CTCAE | Hip Fracture | Hip fracture | Hip fracture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541885","Hirsutism, CTCAE","C143547","A disorder characterized by the presence of excess hair growth in women in anatomic sites where growth is considered to be a secondary male characteristic and under androgen control (beard, moustache, chest, abdomen).","Hirsutism, CTCAE | Hirsutism | Hirsutism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541886","Hoarseness, CTCAE","C143548","A disorder characterized by harsh and raspy voice arising from or spreading to the larynx.","Hoarseness, CTCAE | Hoarseness | Hoarseness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545907","Hot Flashes, CTCAE","C143549","A disorder characterized by an uncomfortable and temporary sensation of intense body warmth, flushing, sometimes accompanied by sweating upon cooling.","Hot Flashes, CTCAE | Hot Flashes | Hot flashes | Hot flashes | Hot flashes (Priority 2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963137","Hydrocephalus, CTCAE","C55401","A disorder characterized by an abnormal increase of cerebrospinal fluid in the ventricles of the brain.","Hydrocephalus, CTCAE | Hydrocephalus | Hydrocephalus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541874","Hypercalcemia, CTCAE","C143551","A disorder characterized by laboratory test results that indicate an elevation in the concentration of calcium (corrected for albumin) in blood.","Hypercalcemia, CTCAE | Hypercalcemia | Hypercalcemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541875","Hyperglycemia, CTCAE","C143552","A disorder characterized by laboratory test results that indicate an elevation in the concentration of blood sugar. It is usually an indication of diabetes mellitus or glucose intolerance.","Hyperglycemia, CTCAE | Hyperglycemia | Hyperglycemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541876","Hyperhidrosis, CTCAE","C143553","A disorder characterized by excessive sweating.","Hyperhidrosis, CTCAE | Hyperhidrosis | Hyperhidrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541877","Hyperkalemia, CTCAE","C143554","A disorder characterized by laboratory test results that indicate an elevation in the concentration of potassium in the blood; associated with kidney failure or sometimes with the use of diuretic drugs.","Hyperkalemia, CTCAE | Hyperkalemia | Hyperkalemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546021","Hypermagnesemia, CTCAE","C143555","A disorder characterized by laboratory test results that indicate an elevation in the concentration of magnesium in the blood.","Hypermagnesemia, CTCAE | Hypermagnesemia | Hypermagnesemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020488","Hypernatremia, CTCAE","C143556","A disorder characterized by laboratory test results that indicate an elevation in the concentration of sodium in the blood.","Hypernatremia, CTCAE | Hypernatremia | Hypernatremia",,,,,,,,,,,,,,,"36674249|36674250","Sodium retention|Hypernatremia",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL541879","Hypersomnia, CTCAE","C143558","A disorder characterized by characterized by excessive sleepiness during the daytime.","Hypersomnia, CTCAE | Hypersomnia | Hypersomnia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963138","HYPERTENSION ARTERIAL","C55060","A disorder characterized by a pathological increase in blood pressure.","Hypertension, CTCAE | Hypertension | Hypertension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541866","Hyperthyroidism, CTCAE","C143560","A disorder characterized by excessive levels of thyroid hormone in the body. Common causes include an overactive thyroid gland or thyroid hormone overdose.","Hyperthyroidism, CTCAE | Hyperthyroidism | Hyperthyroidism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541867","Hypertrichosis, CTCAE","C143561","A disorder characterized by hair density or length beyond the accepted limits of normal in a particular body region, for a particular age or race.","Hypertrichosis, CTCAE | Hypertrichosis | Hypertrichosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541868","Hypertriglyceridemia, CTCAE","C143562","A disorder characterized by laboratory test results that indicate an elevation in the concentration of triglyceride concentration in the blood.","Hypertriglyceridemia, CTCAE | Hypertriglyceridemia | Hypertriglyceridemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541869","Hyperuricemia, CTCAE","C143563","A disorder characterized by laboratory test results that indicate an elevation in the concentration of uric acid.","Hyperuricemia, CTCAE | Hyperuricemia | Hyperuricemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541870","Hypoalbuminemia, CTCAE","C143564","A disorder characterized by laboratory test results that indicate a low concentration of albumin in the blood.","Hypoalbuminemia, CTCAE | Hypoalbuminemia | Hypoalbuminemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541871","Hypocalcemia, CTCAE","C143565","A disorder characterized by laboratory test results that indicate a low concentration of calcium (corrected for albumin) in the blood.","Hypocalcemia, CTCAE | Hypocalcemia | Hypocalcemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541872","Hypoglossal Nerve Disorder, CTCAE","C143566","A disorder characterized by dysfunction of the hypoglossal nerve (twelfth cranial nerve).","Hypoglossal Nerve Disorder, CTCAE | Hypoglossal Nerve Disorder | Hypoglossal nerve disorder | Hypoglossal nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541873","Hypoglycemia, CTCAE","C143567","A disorder characterized by laboratory test results that indicate a low concentration of glucose in the blood.","Hypoglycemia, CTCAE | Hypoglycemia | Hypoglycemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541859","Hypohidrosis, CTCAE","C143568","A disorder characterized by reduced sweating.","Hypohidrosis, CTCAE | Hypohidrosis | Hypohidrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541860","Hypokalemia, CTCAE","C143569","A disorder characterized by laboratory test results that indicate a low concentration of potassium in the blood.","Hypokalemia, CTCAE | Hypokalemia | Hypokalemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541861","Hypomagnesemia, CTCAE","C143570","A disorder characterized by laboratory test results that indicate a low concentration of magnesium in the blood.","Hypomagnesemia, CTCAE | Hypomagnesemia | Hypomagnesemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541862","Hyponatremia, CTCAE","C143571","A disorder characterized by laboratory test results that indicate a low concentration of sodium in the blood.","Hyponatremia, CTCAE | Hyponatremia | Hyponatremia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541863","Hypoparathyroidism, CTCAE","C143572","A disorder characterized by a decrease in production of parathyroid hormone by the parathyroid glands.","Hypoparathyroidism, CTCAE | Hypoparathyroidism | Hypoparathyroidism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0595888","Hypophosphatemia, CTCAE","C143573","A disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood.","Hypophosphatemia, CTCAE | Hypophosphatemia | Hypophosphatemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3163620","ARTERIAL BLOOD PRESSURE DECREASED","C55061","A disorder characterized by a blood pressure that is below the normal expected for an individual in a given environment.","Hypotension, CTCAE | Hypotension | Hypotension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963170","Hypothermia, CTCAE","C55332","A disorder characterized by an abnormally low body temperature. Treatment is required when the body temperature is 35C (95F) or below.","Hypothermia, CTCAE | Hypothermia | Hypothermia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541864","Hypothyroidism, CTCAE","C143576","A disorder characterized by a decrease in production of thyroid hormone by the thyroid gland.","Hypothyroidism, CTCAE | Hypothyroidism | Hypothyroidism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963140","HYPOXIA","C58188","A disorder characterized by a decrease in the level of oxygen in the body.","Hypoxia, CTCAE | Hypoxia | Hypoxia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541845","INR Increased, CTCAE","C143590","A finding based on laboratory test results that indicate an increase in the ratio of the patient's prothrombin time to a control sample in the blood.","INR Increased, CTCAE | INR Increased | INR increased | INR increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1397399","Ileal Fistula, CTCAE","C57821","A disorder characterized by an abnormal communication between the ileum and another organ or anatomic site.","Ileal Fistula, CTCAE | Ileal Fistula | Ileal Fistula | Ileal fistula | Ileum fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963142","Ileal Hemorrhage, CTCAE","C56542","A disorder characterized by bleeding from the ileal wall.","Ileal Hemorrhage, CTCAE | Ileal Hemorrhage | Ileal hemorrhage | Ileal hemorrhage | Ileum hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1400387","Ileal Obstruction, CTCAE","C57823","A disorder characterized by blockage of the normal flow of the intestinal contents in the ileum.","Ileal Obstruction, CTCAE | Ileal Obstruction | Ileal obstruction | Ileal obstruction | Ileum obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544665","Ileal Perforation, CTCAE_5","C146633","A disorder characterized by a rupture in the ileal wall.","Ileal Perforation, CTCAE 5.0 | Ileal Perforation | Ileal perforation | Ileal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541865","Ileal Stenosis, CTCAE","C143578","A disorder characterized by a narrowing of the lumen of the ileum.","Ileal Stenosis, CTCAE | Ileal Stenosis | Ileal stenosis | Ileal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963143","Ileal Ulcer, CTCAE","C57826","A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the ileum.","Ileal Ulcer, CTCAE | Ileal Ulcer | Ileal ulcer | Ileal ulcer | Ileum ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1560456","Ileus, CTCAE","C57814","A disorder characterized by failure of the ileum to transport intestinal contents.","Ileus, CTCAE | Ileus | Ileus | Ileus, GI (functional obstruction of bowel, i.e., neuroconstipation)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541851","Immune System Disorders - Other, Specify, CTCAE","C143580","Immune system disorders - Other, specify","Immune System Disorders - Other, Specify, CTCAE | Immune System Disorders - Other | Immune system disorders - Other, specify | Immune system disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541852","Infections and Infestations - Other, Specify, CTCAE","C143581","Infections and infestations - Other, specify","Infections and Infestations - Other, Specify, CTCAE | Infections and Infestations - Other | Infections and infestations - Other, specify | Infections and infestations - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541853","Infective Myositis, CTCAE","C143582","A disorder characterized by an infectious process involving the skeletal muscles.","Infective Myositis, CTCAE | Infective Myositis | Infective myositis | Infective myositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541854","Infusion Related Reaction, CTCAE","C143583","A disorder characterized by adverse reaction to the infusion of pharmacological or biological substances.","Infusion Related Reaction, CTCAE | Infusion Related Reaction | Infusion related reaction | Infusion related reaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541855","Infusion Site Extravasation, CTCAE","C143584","A disorder characterized by leakage of the infusion into the surrounding tissue. Signs and symptoms may include induration, erythema, swelling, burning sensation and marked discomfort at the infusion site.","Infusion Site Extravasation, CTCAE | Infusion Site Extravasation | Infusion site extravasation | Infusion site extravasation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541856","Injection Site Reaction, CTCAE","C143585","A disorder characterized by an intense adverse reaction (usually immunologic) developing at the site of an injection.","Injection Site Reaction, CTCAE | Injection Site Reaction | Injection site reaction | Injection site reaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541857","Injury To Carotid Artery, CTCAE","C143586","A finding of damage to the carotid artery.","Injury To Carotid Artery, CTCAE | Injury to Carotid Artery | Injury to carotid artery | Injury to carotid artery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1559031","Injury To Inferior Vena Cava, CTCAE","C56735","A finding of damage to the inferior vena cava.","Injury To Inferior Vena Cava, CTCAE | IVC vein-injury | Injury to Inferior Vena Cava | Injury to inferior vena cava | Injury to inferior vena cava",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541858","Injury To Jugular Vein, CTCAE","C143587","A finding of damage to the jugular vein.","Injury To Jugular Vein, CTCAE | Injury to Jugular Vein | Injury to jugular vein | Injury to jugular vein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541843","Injury To Superior Vena Cava, CTCAE","C143588","A finding of damage to the superior vena cava.","Injury To Superior Vena Cava, CTCAE | Injury to Superior Vena Cava | Injury to superior vena cava | Injury to superior vena cava",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541844","Injury, Poisoning and Procedural Complications - Other, Specify, CTCAE","C143589","Injury, poisoning and procedural complications - Other, specify","Injury, Poisoning and Procedural Complications - Other, Specify, CTCAE | Injury, Poisoning and Procedural Complications - Other | Injury, poisoning and procedural complications - Other, specify | Injury, poisoning and procedural complications - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544779","Insomnia, CTCAE_5","C146771","A disorder characterized by difficulty in falling asleep and/or remaining asleep.","Insomnia, CTCAE 5.0 | Insomnia | Insomnia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541846","Intestinal Stoma Leak, CTCAE","C143592","A finding of leakage of contents from an intestinal stoma (surgically created opening on the surface of the body).","Intestinal Stoma Leak, CTCAE | Intestinal Stoma Leak | Intestinal stoma leak | Intestinal stoma leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541847","Intestinal Stoma Obstruction, CTCAE","C143593","A disorder characterized by blockage of the normal flow of the contents of the intestinal stoma.","Intestinal Stoma Obstruction, CTCAE | Intestinal Stoma Obstruction | Intestinal stoma obstruction | Intestinal stoma obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541848","Intestinal Stoma Site Bleeding, CTCAE","C143594","A disorder characterized by bleeding from the intestinal stoma.","Intestinal Stoma Site Bleeding, CTCAE | Intestinal Stoma Site Bleeding | Intestinal stoma site bleeding | Intestinal stoma site bleeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541849","Intra-Abdominal Hemorrhage, CTCAE","C143595","A disorder characterized by bleeding in the abdominal cavity.","Intra-Abdominal Hemorrhage, CTCAE | Intra-Abdominal Hemorrhage | Intra-abdominal hemorrhage | Intra-abdominal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541850","Intracranial Hemorrhage, CTCAE","C143596","A disorder characterized by bleeding from the cranium.","Intracranial Hemorrhage, CTCAE | Intracranial Hemorrhage | Intracranial hemorrhage | Intracranial hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541956","Intraoperative Arterial Injury, CTCAE","C143597","A finding of damage to an artery during a surgical procedure.","Intraoperative Arterial Injury, CTCAE | Intraoperative Arterial Injury | Intraoperative arterial injury | Intraoperative arterial injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541957","Intraoperative Breast Injury, CTCAE","C143598","A finding of damage to the breast parenchyma during a surgical procedure.","Intraoperative Breast Injury, CTCAE | Intraoperative Breast Injury | Intraoperative breast injury | Intraoperative breast injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541958","Intraoperative Cardiac Injury, CTCAE","C143599","A finding of damage to the heart during a surgical procedure.","Intraoperative Cardiac Injury, CTCAE | Intraoperative Cardiac Injury | Intraoperative cardiac injury | Intraoperative cardiac injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541959","Intraoperative Ear Injury, CTCAE","C143600","A finding of damage to the ear during a surgical procedure.","Intraoperative Ear Injury, CTCAE | Intraoperative Ear Injury | Intraoperative ear injury | Intraoperative ear injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541961","Intraoperative Gastrointestinal Injury, CTCAE","C143602","A finding of damage to the gastrointestinal system during a surgical procedure.","Intraoperative Gastrointestinal Injury, CTCAE | Intraoperative Gastrointestinal Injury | Intraoperative gastrointestinal injury | Intraoperative gastrointestinal injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541962","Intraoperative Head and Neck Injury, CTCAE","C143603","A finding of damage to the head and neck during a surgical procedure.","Intraoperative Head and Neck Injury, CTCAE | Intraoperative Head and Neck Injury | Intraoperative head and neck injury | Intraoperative head and neck injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541963","Intraoperative Hemorrhage, CTCAE","C143604","A finding of uncontrolled bleeding during a surgical procedure.","Intraoperative Hemorrhage, CTCAE | Intraoperative Hemorrhage | Intraoperative hemorrhage | Intraoperative hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541948","Intraoperative Hepatobiliary Injury, CTCAE","C143605","A finding of damage to the hepatic parenchyma and/or biliary tract during a surgical procedure.","Intraoperative Hepatobiliary Injury, CTCAE | Intraoperative Hepatobiliary Injury | Intraoperative hepatobiliary injury | Intraoperative hepatobiliary injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541949","Intraoperative Musculoskeletal Injury, CTCAE","C143606","A finding of damage to the musculoskeletal system during a surgical procedure.","Intraoperative Musculoskeletal Injury, CTCAE | Intraoperative Musculoskeletal Injury | Intraoperative musculoskeletal injury | Intraoperative musculoskeletal injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541950","Intraoperative Neurological Injury, CTCAE","C143607","A finding of damage to the nervous system during a surgical procedure.","Intraoperative Neurological Injury, CTCAE | Intraoperative Neurological Injury | Intraoperative neurological injury | Intraoperative neurological injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541951","Intraoperative Ocular Injury, CTCAE","C143608","A finding of damage to the eye during a surgical procedure.","Intraoperative Ocular Injury, CTCAE | Intraoperative Ocular Injury | Intraoperative ocular injury | Intraoperative ocular injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541952","Intraoperative Renal Injury, CTCAE","C143609","A finding of damage to the kidney during a surgical procedure.","Intraoperative Renal Injury, CTCAE | Intraoperative Renal Injury | Intraoperative renal injury | Intraoperative renal injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541953","Intraoperative Reproductive Tract Injury, CTCAE","C143610","A finding of damage to the reproductive organs during a surgical procedure.","Intraoperative Reproductive Tract Injury, CTCAE | Intraoperative Reproductive Tract Injury | Intraoperative reproductive tract injury | Intraoperative reproductive tract injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541954","Intraoperative Respiratory Injury, CTCAE","C143611","A finding of damage to the respiratory system during a surgical procedure.","Intraoperative Respiratory Injury, CTCAE | Intraoperative Respiratory Injury | Intraoperative respiratory injury | Intraoperative respiratory injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541955","Intraoperative Splenic Injury, CTCAE","C143612","A finding of damage to the spleen during a surgical procedure.","Intraoperative Splenic Injury, CTCAE | Intraoperative Splenic Injury | Intraoperative splenic injury | Intraoperative splenic injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541940","Intraoperative Urinary Injury, CTCAE","C143613","A finding of damage to the urinary system during a surgical procedure.","Intraoperative Urinary Injury, CTCAE | Intraoperative Urinary Injury | Intraoperative urinary injury | Intraoperative urinary injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541941","Intraoperative Venous Injury, CTCAE","C143614","A finding of damage to a vein during a surgical procedure.","Intraoperative Venous Injury, CTCAE | Intraoperative Venous Injury | Intraoperative venous injury | Intraoperative venous injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541942","Investigations - Other, Specify, CTCAE","C143615","Investigations - Other, specify","Investigations - Other, Specify, CTCAE | Investigations - Other | Investigations - Other, specify | Investigations - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541943","Irregular Menstruation, CTCAE","C143617","A disorder characterized by a change in cycle or duration of menses from baseline.","Irregular Menstruation, CTCAE | Irregular Menstruation | Irregular menstruation | Irregular menstruation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541944","Irritability, CTCAE","C143618","A disorder characterized by an abnormal responsiveness to stimuli or physiological arousal; may be in response to pain, fright, a drug, an emotional situation or a medical condition.","Irritability, CTCAE | Irritability | Irritability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541945","Ischemia Cerebrovascular, CTCAE","C143619","A disorder characterized by a decrease or absence of blood supply to the brain caused by obstruction (thrombosis or embolism) of an artery resulting in neurological damage.","Ischemia Cerebrovascular, CTCAE | Ischemia Cerebrovascular | Ischemia cerebrovascular | Ischemia cerebrovascular",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963149","Jejunal Fistula, CTCAE","C57827","A disorder characterized by an abnormal communication between the jejunum and another organ or anatomic site.","Jejunal Fistula, CTCAE | Jejunal Fistula | Jejunal fistula | Jejunal fistula | Jejunum fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963150","Jejunal Hemorrhage, CTCAE","C56543","A disorder characterized by bleeding from the jejunal wall.","Jejunal Hemorrhage, CTCAE | Jejunal Hemorrhage | Jejunal hemorrhage | Jejunal hemorrhage | Jejunum hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1401336","Jejunal Obstruction, CTCAE","C57829","A disorder characterized by blockage of the normal flow of the intestinal contents in the jejunum.","Jejunal Obstruction, CTCAE | Jejunal Obstruction | Jejunal obstruction | Jejunal obstruction | Jejunum obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541946","Jejunal Perforation, CTCAE","C143622","A disorder characterized by a rupture in the jejunal wall.","Jejunal Perforation, CTCAE | Jejunal Perforation | Jejunal perforation | Jejunal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541947","Jejunal Stenosis, CTCAE","C143623","A disorder characterized by a narrowing of the lumen of the jejunum.","Jejunal Stenosis, CTCAE | Jejunal Stenosis | Jejunal stenosis | Jejunal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963151","Jejunal Ulcer, CTCAE","C57832","A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the jejunum.","Jejunal Ulcer, CTCAE | Jejunal Ulcer | Jejunal ulcer | Jejunal ulcer | Jejunum ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544798","Joint Effusion, CTCAE_5","C146760","A disorder characterized by excessive fluid in a joint, usually as a result of joint inflammation.","Joint Effusion, CTCAE 5.0 | Joint Effusion | Joint effusion | Joint effusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541933","Joint Infection, CTCAE","C143626","A disorder characterized by an infectious process involving a joint.","Joint Infection, CTCAE | Joint Infection | Joint infection | Joint infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541936","Joint Range of Motion Decreased, CTCAE","C143629","A disorder characterized by a decrease in joint flexibility of any joint.","Joint Range of Motion Decreased, CTCAE | Joint Range of Motion Decreased | Joint range of motion decreased | Joint range of motion decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541934","Joint Range of Motion Decreased Cervical Spine, CTCAE","C143627","A disorder characterized by a decrease in flexibility of a cervical spine joint.","Joint Range of Motion Decreased Cervical Spine, CTCAE | Joint Range of Motion Decreased Cervical Spine | Joint range of motion decreased cervical spine | Joint range of motion decreased cervical spine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541935","Joint Range of Motion Decreased Lumbar Spine, CTCAE","C143628","A disorder characterized by a decrease in flexibility of a lumbar spine joint.","Joint Range of Motion Decreased Lumbar Spine, CTCAE | Joint Range of Motion Decreased Lumbar Spine | Joint range of motion decreased lumbar spine | Joint range of motion decreased lumbar spine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1557321","Keratitis, CTCAE","C55847","A disorder characterized by inflammation to the cornea of the eye.","Keratitis, CTCAE | Keratitis | Keratitis | Keratitis (corneal inflammation/corneal ulceration)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541937","Kidney Anastomotic Leak, CTCAE","C143631","A finding of leakage of urine due to breakdown of a kidney anastomosis (surgical connection of two separate anatomic structures).","Kidney Anastomotic Leak, CTCAE | Kidney Anastomotic Leak | Kidney anastomotic leak | Kidney anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546047","Kidney Infection, CTCAE","C143632","A disorder characterized by an infectious process involving the kidney.","Kidney Infection, CTCAE | Kidney Infection | Kidney infection | Kidney infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541938","Kyphosis, CTCAE","C143633","A disorder characterized by an abnormal increase in the curvature of the thoracic portion of the spine.","Kyphosis, CTCAE | Kyphosis | Kyphosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541939","Lactation Disorder, CTCAE","C143634","A disorder characterized by disturbances of milk secretion. It is not necessarily related to pregnancy that is observed in females and can be observed in males.","Lactation Disorder, CTCAE | Lactation Disorder | Lactation disorder | Lactation disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541925","Large Intestinal Anastomotic Leak, CTCAE","C143635","A finding of leakage due to breakdown of an anastomosis (surgical connection of two separate anatomic structures) in the large intestine.","Large Intestinal Anastomotic Leak, CTCAE | Large Intestinal Anastomotic Leak | Large intestinal anastomotic leak | Large intestinal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541926","Laryngeal Edema, CTCAE","C143636","A disorder characterized by swelling due to an excessive accumulation of fluid in the larynx.","Laryngeal Edema, CTCAE | Laryngeal Edema | Laryngeal edema | Laryngeal edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1397408","Laryngeal Fistula, CTCAE","C58190","A disorder characterized by an abnormal communication between the larynx and another organ or anatomic site.","Laryngeal Fistula, CTCAE | Laryngeal Fistula | Laryngeal fistula | Laryngeal fistula | Larynx fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881362","Laryngeal Hemorrhage, CTCAE","C56545","A disorder characterized by bleeding from the larynx.","Laryngeal Hemorrhage, CTCAE | Laryngeal Hemorrhage | Laryngeal hemorrhage | Laryngeal hemorrhage | Larynx hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541927","Laryngeal Inflammation, CTCAE","C143637","A disorder characterized by an inflammation involving the larynx.","Laryngeal Inflammation, CTCAE | Laryngeal Inflammation | Laryngeal inflammation | Laryngeal inflammation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541928","Laryngeal Mucositis, CTCAE","C143638","A disorder characterized by ulceration or inflammation involving the mucous membrane of the larynx.","Laryngeal Mucositis, CTCAE | Laryngeal Mucositis | Laryngeal mucositis | Laryngeal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541929","Laryngeal Obstruction, CTCAE","C143639","A disorder characterized by blockage of the laryngeal airway.","Laryngeal Obstruction, CTCAE | Laryngeal Obstruction | Laryngeal obstruction | Laryngeal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541930","Laryngeal Stenosis, CTCAE","C143640","A disorder characterized by a narrowing of the laryngeal airway.","Laryngeal Stenosis, CTCAE | Laryngeal Stenosis | Laryngeal stenosis | Laryngeal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541931","Laryngitis, CTCAE","C143641","A disorder characterized by an inflammatory process involving the larynx.","Laryngitis, CTCAE | Laryngitis | Laryngitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541932","Laryngopharyngeal Dysesthesia, CTCAE","C143642","A disorder characterized by an uncomfortable persistent sensation in the area of the laryngopharynx.","Laryngopharyngeal Dysesthesia, CTCAE | Laryngopharyngeal Dysesthesia | Laryngopharyngeal dysesthesia | Laryngopharyngeal dysesthesia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541917","Laryngospasm, CTCAE","C143643","A disorder characterized by paroxysmal spasmodic muscular contraction of the vocal cords.","Laryngospasm, CTCAE | Laryngospasm | Laryngospasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544713","Left Ventricular Systolic Dysfunction, CTCAE_5","C146719","A disorder characterized by failure of the left ventricle to produce adequate output.","Left Ventricular Systolic Dysfunction, CTCAE 5.0 | Left Ventricular Systolic Dysfunction | Left ventricular systolic dysfunction | Left ventricular systolic dysfunction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541918","Lethargy, CTCAE","C143645","A disorder characterized by a decrease in consciousness characterized by mental and physical inertness.","Lethargy, CTCAE | Lethargy | Lethargy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541919","Leukemia Secondary To Oncology Chemotherapy, CTCAE","C143646","A disorder characterized by leukemia arising as a result of the mutagenic effect of chemotherapy agents.","Leukemia Secondary To Oncology Chemotherapy, CTCAE | Leukemia Secondary to Oncology Chemotherapy | Leukemia secondary to oncology chemotherapy | Leukemia secondary to oncology chemotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541920","Leukocytosis, CTCAE","C143647","A disorder characterized by laboratory test results that indicate an increased number of white blood cells in the blood.","Leukocytosis, CTCAE | Leukocytosis | Leukocytosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541921","Leukoencephalopathy, CTCAE","C143648","A disorder characterized by diffuse reactive astrocytosis with multiple areas of necrotic foci without inflammation.","Leukoencephalopathy, CTCAE | Leukoencephalopathy | Leukoencephalopathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541923","Libido Increased, CTCAE","C143650","A disorder characterized by an increase in sexual desire.","Libido Increased, CTCAE | Libido Increased | Libido increased | Libido increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541924","Lip Infection, CTCAE","C143651","A disorder characterized by an infectious process involving the lips.","Lip Infection, CTCAE | Lip Infection | Lip infection | Lip infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544799","Lip Pain, CTCAE_5","C146761","A disorder characterized by a sensation of marked discomfort of the lip.","Lip Pain, CTCAE 5.0 | Lip Pain | Lip pain | Lip pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541910","Lipase Increased, CTCAE","C143652","A finding based on laboratory test results that indicate an increase in the level of lipase in a biological specimen.","Lipase Increased, CTCAE | Lipase Increased | Lipase increased | Lipase increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541911","Lipohypertrophy, CTCAE","C143653","A disorder characterized by hypertrophy of the subcutaneous adipose tissue at the site of multiple subcutaneous injections of insulin.","Lipohypertrophy, CTCAE | Lipohypertrophy | Lipohypertrophy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541912","Localized Edema, CTCAE","C143654","A disorder characterized by swelling due to excessive fluid accumulation at a specific anatomic site.","Localized Edema, CTCAE | Localized Edema | Localized edema | Localized edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545982","Lordosis, CTCAE","C143655","A disorder characterized by an abnormal increase in the curvature of the lumbar portion of the spine.","Lordosis, CTCAE | Lordosis | Lordosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541913","Lower Gastrointestinal Hemorrhage, CTCAE","C143656","A disorder characterized by bleeding from the lower gastrointestinal tract (small intestine, large intestine, and anus).","Lower Gastrointestinal Hemorrhage, CTCAE | Lower Gastrointestinal Hemorrhage | Lower gastrointestinal hemorrhage | Lower gastrointestinal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541914","Lung Infection, CTCAE","C143657","A disorder characterized by an infectious process involving the lungs, including pneumonia.","Lung Infection, CTCAE | Lung Infection | Lung infection | Lung infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541915","Lymph Gland Infection, CTCAE","C143658","A disorder characterized by an infectious process involving the lymph nodes.","Lymph Gland Infection, CTCAE | Lymph Gland Infection | Lymph gland infection | Lymph gland infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541916","Lymph Leakage, CTCAE","C143659","A disorder characterized by the loss of lymph fluid into the surrounding tissue or body cavity.","Lymph Leakage, CTCAE | Lymph Leakage | Lymph leakage | Lymph leakage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544781","Lymph Node Pain, CTCAE_5","C146773","A disorder characterized by a sensation of marked discomfort in a lymph node.","Lymph Node Pain, CTCAE 5.0 | Lymph Node Pain | Lymph node pain | Lymph node pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541902","Lymphedema, CTCAE","C143660","A disorder characterized by excessive fluid collection in tissues that causes swelling.","Lymphedema, CTCAE | Lymphedema | Lymphedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541903","Lymphocyte Count Decreased, CTCAE","C143662","A finding based on laboratory test results that indicate a decrease in number of lymphocytes in a blood specimen.","Lymphocyte Count Decreased, CTCAE | Lymphocyte Count Decreased | Lymphocyte count decreased | Lymphocyte count decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541904","Lymphocyte Count Increased, CTCAE","C143663","A finding based on laboratory test results that indicate an abnormal increase in the number of lymphocytes in the blood, effusions or bone marrow.","Lymphocyte Count Increased, CTCAE | Lymphocyte Count Increased | Lymphocyte count increased | Lymphocyte count increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963165","Malabsorption, CTCAE","C57838","A disorder characterized by inadequate absorption of nutrients in the small intestine. Symptoms include abdominal marked discomfort, bloating and diarrhea.","Malabsorption, CTCAE | Malabsorption | Malabsorption",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541905","Malaise, CTCAE","C143665","A disorder characterized by a feeling of general discomfort or uneasiness, an out-of-sorts feeling.","Malaise, CTCAE | Malaise | Malaise",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541906","Mania, CTCAE","C143666","A disorder characterized by excitement of psychotic proportions manifested by mental and physical hyperactivity, disorganization of behavior and elevation of mood.","Mania, CTCAE | Mania | Mania",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1560796","Mediastinal Hemorrhage, CTCAE","C56549","A disorder characterized by bleeding from the mediastinum.","Mediastinal Hemorrhage, CTCAE | Mediastinal Hemorrhage | Mediastinal hemorrhage | Mediastinal hemorrhage | Mediastinum hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541907","Mediastinal Infection, CTCAE","C143667","A disorder characterized by an infectious process involving the mediastinum.","Mediastinal Infection, CTCAE | Mediastinal Infection | Mediastinal infection | Mediastinal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544787","Memory Impairment, CTCAE_5","C146763","A disorder characterized by a deterioration in memory function.","Memory Impairment, CTCAE 5.0 | Memory Impairment | Memory impairment | Memory impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541908","Meningismus, CTCAE","C143669","A disorder characterized by neck stiffness, headache, and photophobia resulting from irritation of the cerebral meninges.","Meningismus, CTCAE | Meningismus | Meningismus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541909","Meningitis, CTCAE","C143670","A disorder characterized by acute inflammation of the meninges of the brain and/or spinal cord.","Meningitis, CTCAE | Meningitis | Meningitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542013","Menorrhagia, CTCAE","C143671","A disorder characterized by abnormally heavy vaginal bleeding during menses.","Menorrhagia, CTCAE | Menorrhagia | Menorrhagia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542014","Metabolism and Nutrition Disorders - Other, Specify, CTCAE","C143672","Metabolism and nutrition disorders - Other, specify","Metabolism and Nutrition Disorders - Other, Specify, CTCAE | Metabolism and Nutrition Disorders - Other | Metabolism and nutrition disorders - Other, specify | Metabolism and nutrition disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542015","Middle Ear Inflammation, CTCAE","C143673","A disorder characterized by inflammation (physiologic response to irritation), swelling and redness to the middle ear.","Middle Ear Inflammation, CTCAE | Middle Ear Inflammation | Middle ear inflammation | Middle ear inflammation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542016","Mitral Valve Disease, CTCAE","C143674","A disorder characterized by a defect in mitral valve function or structure.","Mitral Valve Disease, CTCAE | Mitral Valve Disease | Mitral valve disease | Mitral valve disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1964030","Mobitz (Type) II Atrioventricular Block, CTCAE","C54772","A disorder characterized by a dysrhythmia with relatively constant PR interval prior to the block of an atrial impulse. This is the result of intermittent failure of atrial electrical impulse conduction through the atrioventricular (AV) node to the ventricles.","Mobitz (Type) II Atrioventricular Block, CTCAE | AV Block Second Degree Mobitz Type II Adverse Event | AV Block-Second degree Mobitz Type II | Mobitz (Type) II Atrioventricular Block | Mobitz (type) II atrioventricular block | Mobitz (type) II atrioventricular block",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1560266","AV Block Second Degree Möbitz Type I Adverse Event","C54771","A disorder characterized by a dysrhythmia with a progressively lengthening PR interval prior to the blocking of an atrial impulse. This is the result of intermittent failure of atrial electrical impulse conduction through the atrioventricular (AV) node to the ventricles.","Mobitz Type I, CTCAE | AV Block Second Degree Möbitz Type I Adverse Event | AV Block-Second degree Mobitz Type I (Wenckebach) | Mobitz Type I | Mobitz type I | Mobitz type I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545900","Movements Involuntary, CTCAE","C143677","A disorder characterized by uncontrolled and purposeless movements.","Movements Involuntary, CTCAE | Movements Involuntary | Movements involuntary | Movements involuntary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542017","Mucosal Infection, CTCAE","C143678","A disorder characterized by an infectious process involving a mucosal surface.","Mucosal Infection, CTCAE | Mucosal Infection | Mucosal infection | Mucosal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542018","Mucositis Oral, CTCAE","C143679","A disorder characterized by ulceration or inflammation of the oral mucosal.","Mucositis Oral, CTCAE | Mucositis Oral | Mucositis oral | Mucositis oral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542019","Multi-Organ Failure, CTCAE","C143680","A disorder characterized by progressive deterioration of the lungs, liver, kidney and clotting mechanisms.","Multi-Organ Failure, CTCAE | Multi-Organ Failure | Multi-organ failure | Multi-organ failure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542005","Muscle Weakness Left-Sided, CTCAE","C143681","A disorder characterized by a reduction in the strength of the muscles on the left side of the body.","Muscle Weakness Left-Sided, CTCAE | Muscle Weakness Left-Sided | Muscle weakness left-sided | Muscle weakness left-sided",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542006","Muscle Weakness Lower Limb, CTCAE","C143682","A disorder characterized by a reduction in the strength of the lower limb muscles.","Muscle Weakness Lower Limb, CTCAE | Muscle Weakness Lower Limb | Muscle weakness lower limb | Muscle weakness lower limb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542007","Muscle Weakness Right-Sided, CTCAE","C143683","A disorder characterized by a reduction in the strength of the muscles on the right side of the body.","Muscle Weakness Right-Sided, CTCAE | Muscle Weakness Right-Sided | Muscle weakness right-sided | Muscle weakness right-sided",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542008","Muscle Weakness Trunk, CTCAE","C143684","A disorder characterized by a reduction in the strength of the trunk muscles.","Muscle Weakness Trunk, CTCAE | Muscle Weakness Trunk | Muscle weakness trunk | Muscle weakness trunk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542009","Muscle Weakness Upper Limb, CTCAE","C143685","A disorder characterized by a reduction in the strength of the upper limb muscles.","Muscle Weakness Upper Limb, CTCAE | Muscle Weakness Upper Limb | Muscle weakness upper limb | Muscle weakness upper limb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542010","Musculoskeletal and Connective Tissue Disorder - Other, Specify, CTCAE","C143686","Musculoskeletal and connective tissue disorder - Other, specify","Musculoskeletal and Connective Tissue Disorder - Other, Specify, CTCAE | Musculoskeletal and Connective Tissue Disorders - Other | Musculoskeletal and connective tissue disorder - Other, specify | Musculoskeletal and connective tissue disorder - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542011","Musculoskeletal Deformity, CTCAE","C143687","A disorder characterized by a malformation of the musculoskeletal system.","Musculoskeletal Deformity, CTCAE | Musculoskeletal Deformity | Musculoskeletal deformity | Musculoskeletal deformity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542012","Myalgia, CTCAE","C143688","A disorder characterized by marked discomfort sensation originating from a muscle or group of muscles.","Myalgia, CTCAE | Myalgia | Myalgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963178","Myelitis, CTCAE","C55459","A disorder characterized by inflammation involving the spinal cord. Symptoms include weakness, paresthesia, sensory loss, marked discomfort and incontinence.","Myelitis, CTCAE | Myelitis | Myelitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541998","Myelodysplastic Syndrome, CTCAE","C143690","A disorder characterized by insufficiently healthy hematapoietic cell production by the bone marrow.","Myelodysplastic Syndrome, CTCAE | Myelodysplastic Syndrome | Myelodysplastic syndrome | Myelodysplastic syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546005","Myocardial Infarction, CTCAE","C143691","A disorder characterized by gross necrosis of the myocardium; this is due to an interruption of blood supply to the area.","Myocardial Infarction, CTCAE | Myocardial Infarction | Myocardial infarction | Myocardial infarction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544737","Myocarditis, CTCAE_5","C146695","A disorder characterized by inflammation of the muscle tissue of the heart.","Myocarditis, CTCAE 5.0 | Myocarditis | Myocarditis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544776","Myositis, CTCAE_5","C146787","A disorder characterized by inflammation involving the skeletal muscles.","Myositis, CTCAE 5.0 | Myositis | Myositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541999","Nail Discoloration, CTCAE","C143694","A disorder characterized by a change in the color of the nail plate.","Nail Discoloration, CTCAE | Nail Discoloration | Nail discoloration | Nail discoloration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542000","Nail Infection, CTCAE","C143695","A disorder characterized by an infectious process involving the nail.","Nail Infection, CTCAE | Nail Infection | Nail infection | Nail infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542001","Nail Loss, CTCAE","C143696","A disorder characterized by loss of all or a portion of the nail.","Nail Loss, CTCAE | Nail Loss | Nail loss | Nail loss",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542003","Nasal Congestion, CTCAE","C143698","A disorder characterized by obstruction of the nasal passage due to mucosal edema.","Nasal Congestion, CTCAE | Nasal Congestion | Nasal congestion | Nasal congestion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550642","Nausea, CTCAE_5","C146764","A disorder characterized by a queasy sensation and/or the urge to vomit.","Nausea, CTCAE 5.0 | Nausea | Nausea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542004","Neck Edema, CTCAE","C143700","A disorder characterized by swelling due to an accumulation of excessive fluid in the neck.","Neck Edema, CTCAE | Neck Edema | Neck edema | Neck edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544789","Neck Pain, CTCAE_5","C146766","A disorder characterized by a sensation of marked discomfort in the neck area.","Neck Pain, CTCAE 5.0 | Neck Pain | Neck pain | Neck pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963181","Neck Soft Tissue Necrosis, CTCAE","C58394","A disorder characterized by a necrotic process occurring in the soft tissues of the neck.","Neck Soft Tissue Necrosis, CTCAE | Neck Soft Tissue Necrosis | Neck soft tissue necrosis | Neck soft tissue necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541991","Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other, Specify, CTCAE","C143701","Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify","Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other, Specify, CTCAE | Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other | Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify | Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546038","Nervous System Disorders - Other, Specify, CTCAE","C143702","Nervous system disorders - Other, specify","Nervous System Disorders - Other, Specify, CTCAE | Nervous System Disorders - Other | Nervous system disorders - Other, specify | Nervous system disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541992","Neuralgia, CTCAE","C143703","A disorder characterized by intense painful sensation along a nerve or group of nerves.","Neuralgia, CTCAE | Neuralgia | Neuralgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541993","Neutrophil Count Decreased, CTCAE","C143704","A finding based on laboratory test results that indicate a decrease in number of neutrophils in a blood specimen.","Neutrophil Count Decreased, CTCAE | Neutrophil Count Decreased | Neutrophil count decreased | Neutrophil count decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541994","Night Blindness, CTCAE","C143705","A disorder characterized by an inability to see clearly in dim light.","Night Blindness, CTCAE | Night Blindness | Night blindness | Night blindness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541995","Nipple Deformity, CTCAE","C143706","A disorder characterized by a malformation of the nipple.","Nipple Deformity, CTCAE | Nipple Deformity | Nipple deformity | Nipple deformity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541996","Non-Cardiac Chest Pain, CTCAE","C143707","A disorder characterized by a sensation of marked discomfort in the chest unrelated to a heart disorder.","Non-Cardiac Chest Pain, CTCAE | Non-Cardiac Chest Pain | Non-cardiac chest pain | Non-cardiac chest pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544783","Nystagmus, CTCAE_5","C146775","A disorder characterized by involuntary movements of the eyeballs.","Nystagmus, CTCAE 5.0 | Nystagmus | Nystagmus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963185","Obesity, CTCAE","C55334","A disorder characterized by having a high amount of body fat.","Obesity, CTCAE | Obesity | Obesity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541997","Obstruction Gastric, CTCAE","C143710","A disorder characterized by blockage of the normal flow of the contents in the stomach.","Obstruction Gastric, CTCAE | Obstruction Gastric | Obstruction gastric | Obstruction gastric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541984","Oculomotor Nerve Disorder, CTCAE","C143711","A disorder characterized by dysfunction of the oculomotor nerve (third cranial nerve).","Oculomotor Nerve Disorder, CTCAE | Oculomotor Nerve Disorder | Oculomotor nerve disorder | Oculomotor nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541985","Olfactory Nerve Disorder, CTCAE","C143712","A disorder characterized by dysfunction of the olfactory nerve (first cranial nerve).","Olfactory Nerve Disorder, CTCAE | Olfactory Nerve Disorder | Olfactory nerve disorder | Olfactory nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541986","Oligospermia, CTCAE","C143713","A disorder characterized by a decrease in the number of spermatozoa in the semen.","Oligospermia, CTCAE | Oligospermia | Oligospermia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545955","Optic Nerve Disorder, CTCAE","C143714","A disorder characterized by involvement of the optic nerve (second cranial nerve).","Optic Nerve Disorder, CTCAE | Optic Nerve Disorder | Optic nerve disorder | Optic nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541987","Oral Cavity Fistula, CTCAE","C143715","A disorder characterized by an abnormal communication between the oral cavity and another organ or anatomic site.","Oral Cavity Fistula, CTCAE | Oral Cavity Fistula | Oral cavity fistula | Oral cavity fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541988","Oral Dysesthesia, CTCAE","C143716","A disorder characterized by a burning or tingling sensation on the lips, tongue or entire mouth.","Oral Dysesthesia, CTCAE | Oral Dysesthesia | Oral dysesthesia | Oral dysesthesia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1560644","Oral Hemorrhage, CTCAE","C56551","A disorder characterized by bleeding from the mouth.","Oral Hemorrhage, CTCAE | Oral Hemorrhage | Oral cavity hemorrhage | Oral hemorrhage | Oral hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544674","Oral Pain, CTCAE_5","C146627","A disorder characterized by a sensation of marked discomfort in the mouth, tongue or lips.","Oral Pain, CTCAE 5.0 | Oral Pain | Oral pain | Oral pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541989","Osteonecrosis of Jaw, CTCAE","C143717","A disorder characterized by a necrotic process occurring in the bone of the mandible.","Osteonecrosis of Jaw, CTCAE | Osteonecrosis of Jaw | Osteonecrosis of jaw | Osteonecrosis of jaw",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545899","Osteoporosis, CTCAE_5","C146767","A disorder characterized by reduced bone mass, with a decrease in cortical thickness and in the number and size of the trabeculae of cancellous bone (but normal chemical composition), resulting in increased fracture incidence.","Osteoporosis, CTCAE 5.0 | Osteoporosis | Osteoporosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541990","Otitis Externa, CTCAE","C143719","A disorder characterized by an infectious process involving the outer ear and ear canal. Contributory factors include excessive water exposure (swimmer's ear infection) and cuts in the ear canal. Symptoms include fullness, itching, swelling and marked discomfort in the ear and ear drainage.","Otitis Externa, CTCAE | Otitis Externa | Otitis externa | Otitis externa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541977","Otitis Media, CTCAE","C143720","A disorder characterized by an infectious process involving the middle ear.","Otitis Media, CTCAE | Otitis Media | Otitis media | Otitis media",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963125","Ovarian Hemorrhage, CTCAE","C56553","A disorder characterized by bleeding from the ovary.","Ovarian Hemorrhage, CTCAE | Ovarian Hemorrhage | Ovarian hemorrhage | Ovarian hemorrhage | Ovary hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541978","Ovarian Infection, CTCAE","C143721","A disorder characterized by an infectious process involving the ovary.","Ovarian Infection, CTCAE | Ovarian Infection | Ovarian infection | Ovarian infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541979","Ovarian Rupture, CTCAE","C143722","A disorder characterized by tearing or disruption of the ovarian tissue.","Ovarian Rupture, CTCAE | Ovarian Rupture | Ovarian rupture | Ovarian rupture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544791","Ovulation Pain, CTCAE_5","C146769","A disorder characterized by a sensation of marked discomfort in one side of the abdomen between menstrual cycles, around the time of the discharge of the ovum from the ovarian follicle.","Ovulation Pain, CTCAE 5.0 | Ovulation Pain | Ovulation pain | Ovulation pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550641","Pain, CTCAE","C143725","A disorder characterized by the sensation of marked discomfort, distress or agony.","Pain, CTCAE | Pain | Pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541980","Pain In Extremity, CTCAE","C143723","A disorder characterized by a sensation of marked discomfort in the upper or lower extremities.","Pain In Extremity, CTCAE | Pain in Extremity | Pain in extremity | Pain in extremity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541981","Pain of Skin, CTCAE","C143724","A disorder characterized by a sensation of marked discomfort in the skin.","Pain of Skin, CTCAE | Pain of Skin | Pain of skin | Pain of skin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541982","Palmar-Plantar Erythrodysesthesia Syndrome, CTCAE","C143726","A disorder characterized by redness, marked discomfort, swelling, and tingling in the palms of the hands or the soles of the feet. Also known as Hand-Foot Syndrome.","Palmar-Plantar Erythrodysesthesia Syndrome, CTCAE | Palmar-Plantar Erythrodysesthesia Syndrome | Palmar-plantar erythrodysesthesia syndrome | Palmar-plantar erythrodysesthesia syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3160712","Palpitations, CTCAE","C54935","A disorder characterized by an unpleasant sensation of irregular and/or forceful beating of the heart.","Palpitations, CTCAE | Palpitations | Palpitations",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541983","Pancreas Infection, CTCAE","C143728","A disorder characterized by an infectious process involving the pancreas.","Pancreas Infection, CTCAE | Pancreas Infection | Pancreas infection | Pancreas infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541970","Pancreatic Anastomotic Leak, CTCAE","C143729","A finding of leakage due to breakdown of a pancreatic anastomosis (surgical connection of two separate anatomic structures).","Pancreatic Anastomotic Leak, CTCAE | Pancreatic Anastomotic Leak | Pancreatic anastomotic leak | Pancreatic anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541971","Pancreatic Duct Stenosis, CTCAE","C143730","A disorder characterized by a narrowing of the lumen of the pancreatic duct.","Pancreatic Duct Stenosis, CTCAE | Pancreatic Duct Stenosis | Pancreatic duct stenosis | Pancreatic duct stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541972","Pancreatic Enzymes Decreased, CTCAE","C143731","A finding based on laboratory test results that indicate an decrease in levels of pancreatic enzymes in a biological specimen.","Pancreatic Enzymes Decreased, CTCAE | Pancreatic Enzymes Decreased | Pancreatic enzymes decreased | Pancreatic enzymes decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963197","Pancreatic Fistula, CTCAE","C57845","A disorder characterized by an abnormal communication between the pancreas and another organ or anatomic site.","Pancreatic Fistula, CTCAE | Pancreas fistula | Pancreatic Fistula | Pancreatic fistula | Pancreatic fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963128","Pancreatic Hemorrhage, CTCAE","C56554","A disorder characterized by bleeding from the pancreas.","Pancreatic Hemorrhage, CTCAE | Pancreas hemorrhage | Pancreatic Hemorrhage | Pancreatic hemorrhage | Pancreatic hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541973","Pancreatic Necrosis, CTCAE","C143732","A disorder characterized by a necrotic process occurring in the pancreas.","Pancreatic Necrosis, CTCAE | Pancreatic Necrosis | Pancreatic necrosis | Pancreatic necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544778","Pancreatitis, CTCAE_5","C146789","A disorder characterized by inflammation of the pancreas with no documented pancreas infection.","Pancreatitis, CTCAE 5.0 | Pancreatitis | Pancreatitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541974","Papilledema, CTCAE","C143734","A disorder characterized by swelling around the optic disc.","Papilledema, CTCAE | Papilledema | Papilledema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541975","Papulopustular Rash, CTCAE","C143735","A disorder characterized by an eruption consisting of papules (a small, raised pimple) and pustules (a small pus filled blister), typically appearing in face, scalp, and upper chest and back. Unlike acne, this rash does not present with whiteheads or blackheads, and can be symptomatic, with itchy or tender lesions.","Papulopustular Rash, CTCAE | Papulopustular Rash | Papulopustular rash | Papulopustular rash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541976","Paresthesia, CTCAE","C143736","A disorder characterized by functional disturbances of sensory neurons resulting in abnormal cutaneous sensations of tingling, numbness, pressure, cold, and/or warmth.","Paresthesia, CTCAE | Paresthesia | Paresthesia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545950","Paronychia, CTCAE","C143737","A disorder characterized by an infectious process involving the soft tissues around the nail.","Paronychia, CTCAE | Paronychia | Paronychia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541964","Paroxysmal Atrial Tachycardia, CTCAE","C143738","A disorder characterized by a dysrhythmia with abrupt onset and sudden termination of atrial contractions with a rate of 150-250 beats per minute. The rhythm disturbance originates in the atria.","Paroxysmal Atrial Tachycardia, CTCAE | Paroxysmal Atrial Tachycardia | Paroxysmal atrial tachycardia | Paroxysmal atrial tachycardia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546035","Pelvic Infection, CTCAE","C143740","A disorder characterized by an infectious process involving the pelvic cavity.","Pelvic Infection, CTCAE | Pelvic Infection | Pelvic infection | Pelvic infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545999","Pelvic Pain, CTCAE_5","C146679","A disorder characterized by a sensation of marked discomfort in the pelvis.","Pelvic Pain, CTCAE 5.0 | Pelvic Pain | Pelvic pain | Pelvic pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1962964","Pelvic Soft Tissue Necrosis, CTCAE","C58399","A disorder characterized by a necrotic process occurring in the soft tissues of the pelvis.","Pelvic Soft Tissue Necrosis, CTCAE | Pelvic Soft Tissue Necrosis | Pelvic soft tissue necrosis | Pelvic soft tissue necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541966","Penile Infection, CTCAE","C143741","A disorder characterized by an infectious process involving the penis.","Penile Infection, CTCAE | Penile Infection | Penile infection | Penile infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544633","Penile Pain, CTCAE_5","C146680","A disorder characterized by a sensation of marked discomfort in the penis.","Penile Pain, CTCAE 5.0 | Penile Pain | Penile pain | Penile pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541967","Perforation Bile Duct, CTCAE","C143742","A disorder characterized by a rupture in the wall of the extrahepatic or intrahepatic bile duct.","Perforation Bile Duct, CTCAE | Perforation Bile Duct | Perforation bile duct | Perforation bile duct",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545996","Pericardial Effusion, CTCAE","C143743","A disorder characterized by fluid collection within the pericardial sac, usually due to inflammation.","Pericardial Effusion, CTCAE | Pericardial Effusion | Pericardial effusion | Pericardial effusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541968","Pericardial Tamponade, CTCAE","C143744","A disorder characterized by an increase in intrapericardial pressure due to the collection of blood or fluid in the pericardium.","Pericardial Tamponade, CTCAE | Pericardial Tamponade | Pericardial tamponade | Pericardial tamponade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963211","PERICARDITIS","C55067","A disorder characterized by irritation to the layers of the pericardium (the protective sac around the heart).","Pericarditis, CTCAE | Pericarditis | Pericarditis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544634","Perineal Pain, CTCAE_5","C146681","A disorder characterized by a sensation of marked discomfort in the area between the genital organs and the anus.","Perineal Pain, CTCAE 5.0 | Perineal Pain | Perineal pain | Perineal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1559300","Periodontal Disease, CTCAE","C57849","A disorder in the gingival tissue around the teeth.","Periodontal Disease, CTCAE | Dental: periodontal disease | Periodontal Disease | Periodontal disease | Periodontal disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541969","Periorbital Edema, CTCAE","C143747","A disorder characterized by swelling due to an excessive accumulation of fluid around the orbits of the face.","Periorbital Edema, CTCAE | Periorbital Edema | Periorbital edema | Periorbital edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542071","Periorbital Infection, CTCAE","C143748","A disorder characterized by an infectious process involving the orbit of the eye.","Periorbital Infection, CTCAE | Periorbital Infection | Periorbital infection | Periorbital infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542072","Peripheral Ischemia, CTCAE","C143749","A disorder characterized by impaired circulation to an extremity.","Peripheral Ischemia, CTCAE | Peripheral Ischemia | Peripheral ischemia | Peripheral ischemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542073","Peripheral Motor Neuropathy, CTCAE","C143750","A disorder characterized by damage or dysfunction of the peripheral motor nerves.","Peripheral Motor Neuropathy, CTCAE | Peripheral Motor Neuropathy | Peripheral motor neuropathy | Peripheral motor neuropathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542074","Peripheral Nerve Infection, CTCAE","C143751","A disorder characterized by an infectious process involving the peripheral nerves.","Peripheral Nerve Infection, CTCAE | Peripheral Nerve Infection | Peripheral nerve infection | Peripheral nerve infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542075","Peripheral Sensory Neuropathy, CTCAE","C143752","A disorder characterized by damage or dysfunction of the peripheral sensory nerves.","Peripheral Sensory Neuropathy, CTCAE | Peripheral Sensory Neuropathy | Peripheral sensory neuropathy | Peripheral sensory neuropathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542076","Peritoneal Infection, CTCAE","C143753","A disorder characterized by an infectious process involving the peritoneum.","Peritoneal Infection, CTCAE | Peritoneal Infection | Peritoneal infection | Peritoneal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556514","Peritoneal Necrosis, CTCAE","C57850","A disorder characterized by a necrotic process occurring in the peritoneum.","Peritoneal Necrosis, CTCAE | Peritoneal Necrosis | Peritoneal cavity necrosis | Peritoneal necrosis | Peritoneal necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542077","Personality Change, CTCAE","C143754","A disorder characterized by a conspicuous change in a person's behavior and thinking.","Personality Change, CTCAE | Personality Change | Personality change | Personality change",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544740","Phantom Pain, CTCAE_5","C146682","A disorder characterized by a sensation of marked discomfort related to a limb or an organ that is removed from or is not physically part of the body.","Phantom Pain, CTCAE 5.0 | Phantom Pain | Phantom pain | Phantom pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542078","Pharyngeal Anastomotic Leak, CTCAE","C143755","A finding of leakage due to breakdown of a pharyngeal anastomosis (surgical connection of two separate anatomic structures).","Pharyngeal Anastomotic Leak, CTCAE | Pharyngeal Anastomotic Leak | Pharyngeal anastomotic leak | Pharyngeal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1560407","Pharyngeal Fistula, CTCAE","C57851","A disorder characterized by an abnormal communication between the pharynx and another organ or anatomic site.","Pharyngeal Fistula, CTCAE | Pharyngeal Fistula | Pharyngeal fistula | Pharyngeal fistula | Pharynx GI fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1560807","Pharyngeal Hemorrhage, CTCAE","C56557","A disorder characterized by bleeding from the pharynx.","Pharyngeal Hemorrhage, CTCAE | Pharyngeal Hemorrhage | Pharyngeal hemorrhage | Pharyngeal hemorrhage | Pharynx hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542065","Pharyngeal Mucositis, CTCAE","C143756","A disorder characterized by ulceration or inflammation involving the mucous membrane of the pharynx.","Pharyngeal Mucositis, CTCAE | Pharyngeal Mucositis | Pharyngeal mucositis | Pharyngeal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1397204","Pharyngeal Necrosis, CTCAE","C57855","A disorder characterized by a necrotic process occurring in the pharynx.","Pharyngeal Necrosis, CTCAE | Pharyngeal Necrosis | Pharyngeal necrosis | Pharyngeal necrosis | Pharynx necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542066","Pharyngeal Stenosis, CTCAE","C143757","A disorder characterized by a narrowing of the pharyngeal airway.","Pharyngeal Stenosis, CTCAE | Pharyngeal Stenosis | Pharyngeal stenosis | Pharyngeal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542067","Pharyngitis, CTCAE","C143758","A disorder characterized by inflammation of the throat.","Pharyngitis, CTCAE | Pharyngitis | Pharyngitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542068","Pharyngolaryngeal Pain, CTCAE","C143759","A disorder characterized by a sensation of marked discomfort in the pharyngolaryngeal region.","Pharyngolaryngeal Pain, CTCAE | Pharyngolaryngeal Pain | Pharyngolaryngeal pain | Pharyngolaryngeal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542070","Phlebitis, CTCAE","C143761","A disorder characterized by inflammation of the wall of a vein.","Phlebitis, CTCAE | Phlebitis | Phlebitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542069","Phlebitis Infective, CTCAE","C143760","A disorder characterized by an infectious process involving the vein. Clinical manifestations include erythema, marked discomfort, swelling, and induration along the course of the infected vein.","Phlebitis Infective, CTCAE | Phlebitis Infective | Phlebitis infective | Phlebitis infective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544792","Photophobia, CTCAE_5","C146770","A disorder characterized by fear and avoidance of light.","Photophobia, CTCAE 5.0 | Photophobia | Photophobia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2362621","PHOTOSENSITIVITY (NOS)","C58005","A disorder characterized by an increase in sensitivity of the skin to light.","Photosensitivity, CTCAE | Photosensitivity | Photosensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545991","Platelet Count Decreased, CTCAE","C143764","A finding based on laboratory test results that indicate a decrease in number of platelets in a blood specimen.","Platelet Count Decreased, CTCAE | Platelet Count Decreased | Platelet count decreased | Platelet count decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545973","Pleural Effusion, CTCAE","C143765","A disorder characterized by an increase in amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough and marked chest discomfort.","Pleural Effusion, CTCAE | Pleural Effusion | Pleural effusion | Pleural effusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556619","Pleural Hemorrhage, CTCAE","C56558","A disorder characterized by bleeding from the pleural cavity.","Pleural Hemorrhage, CTCAE | Pleura hemorrhage | Pleural Hemorrhage | Pleural hemorrhage | Pleural hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542057","Pleural Infection, CTCAE","C143766","A disorder characterized by an infectious process involving the pleura.","Pleural Infection, CTCAE | Pleural Infection | Pleural infection | Pleural infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544647","Pleuritic Pain, CTCAE_5","C146663","A disorder characterized by a sensation of marked discomfort in the pleura.","Pleuritic Pain, CTCAE 5.0 | Pleuritic Pain | Pleuritic pain | Pleuritic pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542058","Pneumonitis, CTCAE","C143767","A disorder characterized by inflammation focally or diffusely affecting the lung parenchyma.","Pneumonitis, CTCAE | Pneumonitis | Pneumonitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963215","Pneumothorax, CTCAE","C58201","A disorder characterized by abnormal presence of air in the pleural cavity resulting in the collapse of the lung.","Pneumothorax, CTCAE | Pneumothorax | Pneumothorax",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542059","Portal Hypertension, CTCAE","C143769","A disorder characterized by an increase in blood pressure in the portal venous system.","Portal Hypertension, CTCAE | Portal Hypertension | Portal hypertension | Portal hypertension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542060","Portal Vein Thrombosis, CTCAE","C143770","A disorder characterized by the formation of a thrombus (blood clot) in the portal vein.","Portal Vein Thrombosis, CTCAE | Portal Vein Thrombosis | Portal vein thrombosis | Portal vein thrombosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542061","Postnasal Drip, CTCAE","C143771","A disorder characterized by excessive mucous secretion in the back of the nasal cavity or throat, causing sore throat and/or coughing.","Postnasal Drip, CTCAE | Postnasal Drip | Postnasal drip | Postnasal drip",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542062","Postoperative Hemorrhage, CTCAE","C143772","A disorder characterized by bleeding occurring after a surgical procedure.","Postoperative Hemorrhage, CTCAE | Postoperative Hemorrhage | Postoperative hemorrhage | Postoperative hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542063","Postoperative Thoracic Procedure Complication, CTCAE","C143773","A finding of a previously undocumented problem that occurs after a thoracic procedure.","Postoperative Thoracic Procedure Complication, CTCAE | Postoperative Thoracic Procedure Complication | Postoperative thoracic procedure complication | Postoperative thoracic procedure complication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544661","Precocious Puberty, CTCAE_5","C146645","A disorder characterized by unusually early development of secondary sexual features; the onset of sexual maturation begins usually before age 8 for girls and before age 9 for boys.","Precocious Puberty, CTCAE 5.0 | Precocious Puberty | Precocious puberty | Precocious puberty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542064","Pregnancy, Puerperium and Perinatal Conditions - Other, Specify, CTCAE","C143775","Pregnancy, puerperium and perinatal conditions - Other, specify","Pregnancy, Puerperium and Perinatal Conditions - Other, Specify, CTCAE | Pregnancy, Puerperium and Perinatal Conditions - Other | Pregnancy, puerperium and perinatal conditions - Other, specify | Pregnancy, puerperium and perinatal conditions - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542049","Premature Delivery, CTCAE","C143776","A disorder characterized by delivery of a viable infant before the normal end of gestation. Typically, viability is achievable between the twentieth and thirty-seventh week of gestation.","Premature Delivery, CTCAE | Premature Delivery | Premature delivery | Premature delivery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542050","Premature Menopause, CTCAE","C143777","A disorder characterized by premature ovarian failure. Symptoms may include hot flashes, night sweats, mood swings, and a decrease in sex drive. Laboratory findings include elevated luteinizing hormone (LH) and follicle-stimulating hormone (FSH.)","Premature Menopause, CTCAE | Premature Menopause | Premature menopause | Premature menopause",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963216","PROCTITIS","C57857","A disorder characterized by inflammation of the rectum.","Proctitis, CTCAE | Proctitis | Proctitis | Proctitis (Priority 1)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542052","Productive Cough, CTCAE","C143780","A disorder characterized by expectorated secretions upon coughing.","Productive Cough, CTCAE | Productive Cough | Productive cough | Productive cough",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542053","Prolapse of Intestinal Stoma, CTCAE","C143781","A finding of protrusion of the intestinal stoma (surgically created opening on the surface of the body) above the abdominal surface.","Prolapse of Intestinal Stoma, CTCAE | Prolapse of Intestinal Stoma | Prolapse of intestinal stoma | Prolapse of intestinal stoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542054","Prolapse of Urostomy, CTCAE","C143782","A finding of displacement of the urostomy.","Prolapse of Urostomy, CTCAE | Prolapse of Urostomy | Prolapse of urostomy | Prolapse of urostomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542055","Prostate Infection, CTCAE","C143783","A disorder characterized by an infectious process involving the prostate gland.","Prostate Infection, CTCAE | Prostate Infection | Prostate infection | Prostate infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963129","Prostatic Hemorrhage, CTCAE","C56552","A disorder characterized by bleeding from the prostate gland.","Prostatic Hemorrhage, CTCAE | Prostate hemorrhage | Prostatic Hemorrhage | Prostatic hemorrhage | Prostatic hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542056","Prostatic Obstruction, CTCAE","C143784","A disorder characterized by compression of the urethra secondary to enlargement of the prostate gland. This results in voiding difficulties (straining to void, slow urine stream, and incomplete emptying of the bladder).","Prostatic Obstruction, CTCAE | Prostatic Obstruction | Prostatic obstruction | Prostatic obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544648","Prostatic Pain, CTCAE_5","C146664","A disorder characterized by a sensation of marked discomfort in the prostate gland.","Prostatic Pain, CTCAE 5.0 | Prostatic Pain | Prostatic pain | Prostatic pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544796","Proteinuria, CTCAE_5","C146758","A disorder characterized by laboratory test results that indicate the presence of excessive protein in the urine. It is predominantly albumin, but also globulin.","Proteinuria, CTCAE 5.0 | Proteinuria | Proteinuria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1559138","Pruritus, CTCAE","C58006","A disorder characterized by an intense itching sensation.","Pruritus, CTCAE | Pruritus | Pruritus | Pruritus/itching",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542043","Psychiatric Disorders - Other, Specify, CTCAE","C143787","Psychiatric disorders - Other, specify","Psychiatric Disorders - Other, Specify, CTCAE | Psychiatric Disorders - Other | Psychiatric disorders - Other, specify | Psychiatric disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545977","Psychosis, CTCAE","C143788","A disorder characterized by personality change, impaired functioning, and loss of touch with reality. It may be a manifestation of schizophrenia, bipolar disorder or brain tumor.","Psychosis, CTCAE | Psychosis | Psychosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542044","Pulmonary Edema, CTCAE","C143789","A disorder characterized by accumulation of fluid in the lung tissues that causes a disturbance of the gas exchange that may lead to respiratory failure.","Pulmonary Edema, CTCAE | Pulmonary Edema | Pulmonary edema | Pulmonary edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542045","Pulmonary Fibrosis, CTCAE","C143790","A disorder characterized by the replacement of the lung tissue by connective tissue, leading to progressive dyspnea, respiratory failure or right heart failure.","Pulmonary Fibrosis, CTCAE | Pulmonary Fibrosis | Pulmonary fibrosis | Pulmonary fibrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542046","Pulmonary Fistula, CTCAE","C143791","A disorder characterized by an abnormal communication between the lung and another organ or anatomic site.","Pulmonary Fistula, CTCAE | Pulmonary Fistula | Pulmonary fistula | Pulmonary fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963220","Pulmonary Hypertension, CTCAE","C55068","A disorder characterized by an increase in pressure within the pulmonary circulation due to lung or heart disorder.","Pulmonary Hypertension, CTCAE | Pulmonary Hypertension | Pulmonary hypertension | Pulmonary hypertension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542047","Pulmonary Valve Disease, CTCAE","C143793","A disorder characterized by a defect in pulmonary valve function or structure.","Pulmonary Valve Disease, CTCAE | Pulmonary Valve Disease | Pulmonary valve disease | Pulmonary valve disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545981","Purpura, CTCAE","C143794","A disorder characterized by hemorrhagic areas of the skin and mucous membrane. Newer lesions appear reddish in color. Older lesions are usually a darker purple color and eventually become a brownish-yellow color.","Purpura, CTCAE | Purpura | Purpura",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542048","Pyramidal Tract Syndrome, CTCAE","C143795","A disorder characterized by dysfunction of the corticospinal (pyramidal) tracts of the spinal cord. Symptoms include an increase in the muscle tone in the lower extremities, hyperreflexia, positive Babinski and a decrease in fine motor coordination.","Pyramidal Tract Syndrome, CTCAE | Pyramidal Tract Syndrome | Pyramidal tract syndrome | Pyramidal tract syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542036","Radiation Recall Reaction (Dermatologic), CTCAE","C143796","A finding of acute skin inflammatory reaction caused by drugs, especially chemotherapeutic agents, for weeks or months following radiotherapy. The inflammatory reaction is confined to the previously irradiated skin and the symptoms disappear after the removal of the pharmaceutical agent.","Radiation Recall Reaction (Dermatologic), CTCAE | Radiation Recall Reaction (Dermatologic) | Radiation recall reaction (dermatologic) | Radiation recall reaction (dermatologic)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542037","Radiculitis, CTCAE","C143797","A disorder characterized by inflammation involving a nerve root. Patients experience marked discomfort radiating along a nerve path because of spinal pressure on the connecting nerve root.","Radiculitis, CTCAE | Radiculitis | Radiculitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542038","Rash Acneiform, CTCAE","C143798","A disorder characterized by an eruption of papules and pustules, typically appearing in face, scalp, upper chest and back.","Rash Acneiform, CTCAE | Rash Acneiform | Rash acneiform | Rash acneiform",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542039","Rash Maculo-Papular, CTCAE","C143799","A disorder characterized by the presence of macules (flat) and papules (elevated). Also known as morbillform rash, it is one of the most common cutaneous adverse events, frequently affecting the upper trunk, spreading centripetally and associated with pruritis.","Rash Maculo-Papular, CTCAE | Rash Maculo-Papular | Rash maculo-papular | Rash maculo-papular",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542040","Rash Pustular, CTCAE","C143800","A disorder characterized by a circumscribed and elevated skin lesion filled with pus.","Rash Pustular, CTCAE | Rash Pustular | Rash pustular | Rash pustular",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546006","Rectal anastomotic leak","C143801","A finding of leakage due to breakdown of a rectal anastomosis (surgical connection of two separate anatomic structures).","Rectal Anastomotic Leak, CTCAE | Rectal Anastomotic Leak | Rectal anastomotic leak | Rectal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963224","Rectal Fistula, CTCAE","C57859","A disorder characterized by an abnormal communication between the rectum and another organ or anatomic site.","Rectal Fistula, CTCAE | Rectal Fistula | Rectal Fistula (Priority 1) | Rectal fistula | Rectal fistula | Rectum fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1962965","RECTAL BLEEDING","C56560","A disorder characterized by bleeding from the rectal wall and discharged from the anus.","Rectal Hemorrhage, CTCAE | Rectal Hemorrhage | Rectal hemorrhage | Rectal hemorrhage | Rectum hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542041","Rectal Mucositis, CTCAE","C143802","A disorder characterized by ulceration or inflammation of the mucous membrane of the rectum.","Rectal Mucositis, CTCAE | Rectal Mucositis | Rectal Mucositis (Priority 2) | Rectal mucositis | Rectal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556521","Rectal Necrosis, CTCAE","C57863","A disorder characterized by a necrotic process occurring in the rectal wall.","Rectal Necrosis, CTCAE | Rectal Necrosis | Rectal necrosis | Rectal necrosis | Rectum necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1406054","Rectal Obstruction, CTCAE","C57864","A disorder characterized by blockage of the normal flow of the intestinal contents in the rectum.","Rectal Obstruction, CTCAE | Rectal Obstruction | Rectal obstruction | Rectal obstruction | rectum obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544677","Rectal Pain, CTCAE_5","C146631","A disorder characterized by a sensation of marked discomfort in the rectal region.","Rectal Pain, CTCAE 5.0 | Rectal Pain | Rectal Pain (Priority 2) | Rectal pain | Rectal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544666","Rectal Perforation, CTCAE_5","C146634","A disorder characterized by a rupture in the rectal wall.","Rectal Perforation, CTCAE 5.0 | Rectal Perforation | Rectal Perforation (Priority 1) | Rectal perforation | Rectal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542042","Rectal Stenosis, CTCAE","C143803","A disorder characterized by a narrowing of the lumen of the rectum.","Rectal Stenosis, CTCAE | Rectal Stenosis | Rectal Stenosis (Priority 2) | Rectal stenosis | Rectal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963258","Rectal Ulcer, CTCAE","C57867","A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the rectum.","Rectal Ulcer, CTCAE | Rectal Ulcer | Rectal Ulcer (Priority 1) | Rectal ulcer | Rectal ulcer | Rectum ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542028","Recurrent Laryngeal Nerve Palsy, CTCAE","C143804","A disorder characterized by paralysis of the recurrent laryngeal nerve.","Recurrent Laryngeal Nerve Palsy, CTCAE | Recurrent Laryngeal Nerve Palsy | Recurrent laryngeal nerve palsy | Recurrent laryngeal nerve palsy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542029","Renal and Urinary Disorders - Other, Specify, CTCAE","C143805","Renal and urinary disorders - Other, specify","Renal and Urinary Disorders - Other, Specify, CTCAE | Renal and Urinary Disorders - Other | Renal and urinary disorders - Other, specify | Renal and urinary disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542030","Renal Calculi, CTCAE","C143806","A disorder characterized by the formation of crystals/kidney stones in the pelvis of the kidney.","Renal Calculi, CTCAE | Renal Calculi | Renal calculi | Renal calculi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542031","Renal Colic, CTCAE","C143807","A disorder characterized by paroxysmal and severe flank marked discomfort radiating to the inguinal area. Often, the cause is the passage of crystals/kidney stones.","Renal Colic, CTCAE | Renal Colic | Renal colic | Renal colic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963127","Renal Hemorrhage, CTCAE","C56544","A disorder characterized by bleeding from the kidney.","Renal Hemorrhage, CTCAE | Kidney hemorrhage | Renal Hemorrhage | Renal hemorrhage | Renal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542032","Reproductive System and Breast Disorders - Other, Specify, CTCAE","C143808","Reproductive system and breast disorders - Other, specify","Reproductive System and Breast Disorders - Other, Specify, CTCAE | Reproductive System and Breast Disorders - Other | Reproductive system and breast disorders - Other, specify | Reproductive system and breast disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542033","Respiratory Failure, CTCAE","C143809","A disorder characterized by impaired gas exchange by the respiratory system resulting in hypoxia and a decrease in oxygenation of the tissues that may be associated with an increase in arterial levels of carbon dioxide.","Respiratory Failure, CTCAE | Respiratory Failure | Respiratory failure | Respiratory failure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542034","Respiratory, Thoracic and Mediastinal Disorders - Other, Specify, CTCAE","C143810","Respiratory, thoracic and mediastinal disorders - Other, specify","Respiratory, Thoracic and Mediastinal Disorders - Other, Specify, CTCAE | Respiratory, Thoracic and Mediastinal Disorders - Other | Respiratory, thoracic and mediastinal disorders - Other, specify | Respiratory, thoracic and mediastinal disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542035","Restlessness, CTCAE","C143811","A disorder characterized by an inability to rest, relax or be still.","Restlessness, CTCAE | Restlessness | Restlessness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544707","Retinal Detachment, CTCAE_5","C146729","A disorder characterized by the separation of the inner retina layers from the underlying pigment epithelium.","Retinal Detachment, CTCAE 5.0 | Retinal Detachment | Retinal detachment | Retinal detachment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542020","Retinal Tear, CTCAE","C143814","A disorder characterized by a small laceration of the retina, this occurs when the vitreous separates from the retina. Symptoms include flashes and floaters.","Retinal Tear, CTCAE | Retinal Tear | Retinal tear | Retinal tear",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542021","Retinal Vascular Disorder, CTCAE","C143815","A disorder characterized by pathological retinal blood vessels that adversely affects vision.","Retinal Vascular Disorder, CTCAE | Retinal Vascular Disorder | Retinal vascular disorder | Retinal vascular disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1962966","Retinopathy, CTCAE","C55891","A disorder involving the retina.","Retinopathy, CTCAE | Retinopathy | Retinopathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544678","Retroperitoneal Hemorrhage, CTCAE_5","C146632","A disorder characterized by bleeding from the retroperitoneal area.","Retroperitoneal Hemorrhage, CTCAE 5.0 | Retroperitoneal Hemorrhage | Retroperitoneal hemorrhage | Retroperitoneal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542022","Reversible Posterior Leukoencephalopathy Syndrome, CTCAE","C143818","A disorder characterized by headaches, mental status changes, visual disturbances, and/or seizures associated with imaging findings of posterior leukoencephalopathy. It has been observed in association with hypertensive encephalopathy, eclampsia, and immunosuppressive and cytotoxic drug treatment. It is an acute or subacute reversible condition. Also known as posterior reversible encephalopathy syndrome (PRES).","Reversible Posterior Leukoencephalopathy Syndrome, CTCAE | Reversible Posterior Leukoencephalopathy Syndrome | Reversible posterior leukoencephalopathy syndrome | Reversible posterior leukoencephalopathy syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556315","Right Ventricular Dysfunction, CTCAE","C55070","A disorder characterized by impairment of right ventricular function associated with low ejection fraction and a decrease in motility of the right ventricular wall.","Right Ventricular Dysfunction, CTCAE | Right Ventricular Dysfunction | Right ventricular dysfunction | Right ventricular dysfunction | Right ventricular dysfunction (cor pulmonale)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542024","Salivary Duct Inflammation, CTCAE","C143821","A disorder characterized by inflammation of the salivary duct.","Salivary Duct Inflammation, CTCAE | Salivary Duct Inflammation | Salivary duct inflammation | Salivary duct inflammation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700637","Salivary gland fistula","C57868","A disorder characterized by an abnormal communication between a salivary gland and another organ or anatomic site.","Salivary Gland Fistula, CTCAE | Salivary Gland Fistula | Salivary gland fistula | Salivary gland fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542025","Salivary Gland Infection, CTCAE","C143822","A disorder characterized by an infectious process involving the salivary gland.","Salivary Gland Infection, CTCAE | Salivary Gland Infection | Salivary gland infection | Salivary gland infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544780","Scalp Pain, CTCAE_5","C146772","A disorder characterized by a sensation of marked discomfort in the skin covering the top and the back of the head.","Scalp Pain, CTCAE 5.0 | Scalp Pain | Scalp pain | Scalp pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542026","Scleral Disorder, CTCAE","C143823","A disorder characterized by involvement of the sclera of the eye.","Scleral Disorder, CTCAE | Scleral Disorder | Scleral disorder | Scleral disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542027","Scoliosis, CTCAE","C143824","A disorder characterized by a malformed, lateral curvature of the spine.","Scoliosis, CTCAE | Scoliosis | Scoliosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542131","Scrotal Infection, CTCAE","C143825","A disorder characterized by an infectious process involving the scrotum.","Scrotal Infection, CTCAE | Scrotal Infection | Scrotal infection | Scrotal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544649","Scrotal Pain, CTCAE_5","C146665","A disorder characterized by a sensation of marked discomfort in the scrotal area.","Scrotal Pain, CTCAE 5.0 | Scrotal Pain | Scrotal pain | Scrotal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544727","Seizure, CTCAE_5","C146700","A disorder characterized by a sudden, involuntary skeletal muscular contractions of cerebral or brain stem origin.","Seizure, CTCAE 5.0 | Seizure | Seizure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545911","Sepsis, CTCAE","C143827","A disorder characterized by the presence of pathogenic microorganisms in the blood stream that cause a rapidly progressing systemic reaction that may lead to shock.","Sepsis, CTCAE | Sepsis | Sepsis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542132","Serum Amylase Increased, CTCAE","C143829","A finding based on laboratory test results that indicate an increase in the levels of amylase in a serum specimen.","Serum Amylase Increased, CTCAE | Serum Amylase Increased | Serum amylase increased | Serum amylase increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544659","Serum Sickness, CTCAE_5","C146642","A disorder characterized by a delayed-type hypersensitivity reaction to foreign proteins derived from an animal serum. It occurs approximately six to twenty-one days following the administration of the foreign antigen. Symptoms include fever, arthralgias, myalgias, skin eruptions, lymphadenopathy, chest marked discomfort and dyspnea.","Serum Sickness, CTCAE 5.0 | Serum Sickness | Serum sickness | Serum sickness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963235","Sick Sinus Syndrome, CTCAE","C54938","A disorder characterized by a dysrhythmia with alternating periods of bradycardia and atrial tachycardia accompanied by syncope, fatigue and dizziness.","Sick Sinus Syndrome, CTCAE | Sick Sinus Syndrome | Sick sinus syndrome | Sick sinus syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963175","Sinus Bradycardia, CTCAE","C54940","A disorder characterized by a dysrhythmia with a heart rate less than 60 beats per minute that originates in the sinus node.","Sinus Bradycardia, CTCAE | Sinus Bradycardia | Sinus bradycardia | Sinus bradycardia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542133","Sinus Disorder, CTCAE","C143831","A disorder characterized by involvement of the paranasal sinuses.","Sinus Disorder, CTCAE | Sinus Disorder | Sinus disorder | Sinus disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544774","Sinus Pain, CTCAE_5","C146783","A disorder characterized by a sensation of marked discomfort in the face, between the eyes, or upper teeth originating from the sinuses.","Sinus Pain, CTCAE 5.0 | Sinus Pain | Sinus pain | Sinus pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544797","Sinus Tachycardia, CTCAE_5","C146759","A disorder characterized by a dysrhythmia with a heart rate greater than 100 beats per minute that originates in the sinus node.","Sinus Tachycardia, CTCAE 5.0 | Sinus Tachycardia | Sinus tachycardia | Sinus tachycardia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542134","Sinusitis, CTCAE","C143832","A disorder characterized by an infectious process involving the mucous membranes of the paranasal sinuses.","Sinusitis, CTCAE | Sinusitis | Sinusitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546009","Skin and Subcutaneous Tissue Disorders - Other, Specify, CTCAE","C143833","Skin and subcutaneous tissue disorders - Other, specify","Skin and Subcutaneous Tissue Disorders - Other, Specify, CTCAE | Skin and Subcutaneous Tissue Disorders - Other | Skin and subcutaneous tissue disorders - Other, specify | Skin and subcutaneous tissue disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544660","Skin Atrophy, CTCAE_5","C146644","A disorder characterized by the degeneration and thinning of the epidermis and dermis.","Skin Atrophy, CTCAE 5.0 | Skin Atrophy | Skin atrophy | Skin atrophy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542135","Skin Hyperpigmentation, CTCAE","C143835","A disorder characterized by darkening of the skin due to excessive melanin deposition.","Skin Hyperpigmentation, CTCAE | Skin Hyperpigmentation | Skin hyperpigmentation | Skin hyperpigmentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542136","Skin Hypopigmentation, CTCAE","C143836","A disorder characterized by loss of skin pigment (e.g., vitiligo).","Skin Hypopigmentation, CTCAE | Skin Hypopigmentation | Skin hypopigmentation | Skin hypopigmentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542125","Skin Induration, CTCAE","C143837","A disorder characterized by an area of hardness in the skin.","Skin Induration, CTCAE | Skin Induration | Skin induration | Skin induration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545896","Skin Infection, CTCAE","C143838","A disorder characterized by an infectious process involving the skin such as cellulitis.","Skin Infection, CTCAE | Skin Infection | Skin infection | Skin infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542126","Skin Ulceration, CTCAE","C143839","A disorder characterized by a circumscribed, erosive lesion on the skin.","Skin Ulceration, CTCAE | Skin Ulceration | Skin ulceration | Skin ulceration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545901","Sleep Apnea, CTCAE","C143840","A disorder characterized by cessation of breathing for short periods during sleep.","Sleep Apnea, CTCAE | Sleep Apnea | Sleep apnea | Sleep apnea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542127","Small Intestinal Anastomotic Leak, CTCAE","C143841","A finding of leakage due to breakdown of an anastomosis (surgical connection of two separate anatomic structures) in the small bowel.","Small Intestinal Anastomotic Leak, CTCAE | Small Intestinal Anastomotic Leak | Small intestinal anastomotic leak | Small intestinal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542128","Small Intestinal Mucositis, CTCAE","C143842","A disorder characterized by ulceration or inflammation of the mucous membrane of the small intestine.","Small Intestinal Mucositis, CTCAE | Small Intestinal Mucositis | Small intestinal mucositis | Small intestinal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542129","Small Intestinal Obstruction, CTCAE","C143843","A disorder characterized by blockage of the normal flow of the intestinal contents of the small intestine.","Small Intestinal Obstruction, CTCAE | Small Intestinal Obstruction | Small intestinal obstruction | Small intestinal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544667","Small Intestinal Perforation, CTCAE_5","C146635","A disorder characterized by a rupture in the small intestine wall.","Small Intestinal Perforation, CTCAE 5.0 | Small Intestinal Perforation | Small intestinal perforation | Small intestinal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542130","Small Intestinal Stenosis, CTCAE","C143844","A disorder characterized by a narrowing of the lumen of the small intestine.","Small Intestinal Stenosis, CTCAE | Small Intestinal Stenosis | Small intestinal stenosis | Small intestinal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542117","Small Intestine Infection, CTCAE","C143845","A disorder characterized by an infectious process involving the small intestine.","Small Intestine Infection, CTCAE | Small Intestine Infection | Small intestine infection | Small intestine infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542118","Small Intestine Ulcer, CTCAE","C143846","A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the small intestine.","Small Intestine Ulcer, CTCAE | Small Intestine Ulcer | Small intestine ulcer | Small intestine ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542119","Sneezing, CTCAE","C143847","A disorder characterized by the involuntary expulsion of air from the nose.","Sneezing, CTCAE | Sneezing | Sneezing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542120","Social Circumstances - Other, Specify, CTCAE","C143848","Social circumstances - Other, specify","Social Circumstances - Other, Specify, CTCAE | Social Circumstances - Other | Social circumstances - Other, specify | Social circumstances - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542121","Soft Tissue Infection, CTCAE","C143849","A disorder characterized by an infectious process involving soft tissues.","Soft Tissue Infection, CTCAE | Soft Tissue Infection | Soft tissue infection | Soft tissue infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542122","Soft Tissue Necrosis Lower Limb, CTCAE","C143850","A disorder characterized by a necrotic process occurring in the soft tissues of the lower extremity.","Soft Tissue Necrosis Lower Limb, CTCAE | Soft Tissue Necrosis Lower Limb | Soft tissue necrosis lower limb | Soft tissue necrosis lower limb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542123","Soft Tissue Necrosis Upper Limb, CTCAE","C143851","A disorder characterized by a necrotic process occurring in the soft tissues of the upper extremity.","Soft Tissue Necrosis Upper Limb, CTCAE | Soft Tissue Necrosis Upper Limb | Soft tissue necrosis upper limb | Soft tissue necrosis upper limb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542124","Somnolence, CTCAE","C143852","A disorder characterized by characterized by excessive sleepiness and drowsiness.","Somnolence, CTCAE | Somnolence | Somnolence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542109","Sore Throat, CTCAE","C143853","A disorder characterized by marked discomfort in the throat","Sore Throat, CTCAE | Sore Throat | Sore throat | Sore throat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542110","Spasticity, CTCAE","C143854","A disorder characterized by increased involuntary muscle tone that affects the regions interfering with voluntary movement. It results in gait, movement, and speech disturbances.","Spasticity, CTCAE | Spasticity | Spasticity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542111","Spermatic Cord Anastomotic Leak, CTCAE","C143855","A finding of leakage due to breakdown of a spermatic cord anastomosis (surgical connection of two separate anatomic structures).","Spermatic Cord Anastomotic Leak, CTCAE | Spermatic Cord Anastomotic Leak | Spermatic cord anastomotic leak | Spermatic cord anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963130","Spermatic Cord Hemorrhage, CTCAE","C56563","A disorder characterized by bleeding from the spermatic cord.","Spermatic Cord Hemorrhage, CTCAE | Spermatic Cord Hemorrhage | Spermatic cord hemorrhage | Spermatic cord hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544795","Spermatic Cord Obstruction, CTCAE_5","C146757","A disorder characterized by blockage of the normal flow of the contents of the spermatic cord.","Spermatic Cord Obstruction, CTCAE 5.0 | Spermatic Cord Obstruction | Spermatic cord obstruction | Spermatic cord obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542112","Spinal Fracture, CTCAE","C143856","A finding of traumatic injury to the spine in which the continuity of a vertebral bone is broken.","Spinal Fracture, CTCAE | Spinal Fracture | Spinal fracture | Spinal fracture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542113","Splenic Infection, CTCAE","C143857","A disorder characterized by an infectious process involving the spleen.","Splenic Infection, CTCAE | Splenic Infection | Splenic infection | Splenic infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542114","Stenosis of Gastrointestinal Stoma, CTCAE","C143858","A finding of narrowing of the gastrointestinal stoma (surgically created opening on the surface of the body).","Stenosis of Gastrointestinal Stoma, CTCAE | Stenosis of Gastrointestinal Stoma | Stenosis of gastrointestinal stoma | Stenosis of gastrointestinal stoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542115","Stevens-Johnson Syndrome, CTCAE","C143859","A disorder characterized by less than 10% total body skin area separation of dermis. The syndrome is thought to be a hypersensitivity complex affecting the skin and the mucous membranes.","Stevens-Johnson Syndrome, CTCAE | Stevens-Johnson Syndrome | Stevens-Johnson syndrome | Stevens-Johnson syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544782","Stomach Pain, CTCAE_5","C146774","A disorder characterized by a sensation of marked discomfort in the stomach.","Stomach Pain, CTCAE 5.0 | Stomach Pain | Stomach pain | Stomach pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544736","Stomal Ulcer, CTCAE_5","C146694","A disorder characterized by a circumscribed, erosive lesion on the jejunal mucosal surface close to the anastomosis site following a gastroenterostomy procedure.","Stomal Ulcer, CTCAE 5.0 | Stomal Ulcer | Stomal ulcer | Stomal ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542102","Stridor, CTCAE","C143861","A disorder characterized by a high pitched breathing sound due to laryngeal or upper airway obstruction.","Stridor, CTCAE | Stridor | Stridor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542103","Stroke, CTCAE","C143862","A disorder characterized by a decrease or absence of blood supply to the brain caused by obstruction (thrombosis or embolism) of an artery resulting in neurological damage.","Stroke, CTCAE | Stroke | Stroke",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542104","Sudden Death NOS, CTCAE","C143863","An unexpected death that cannot be attributed to a CTCAE term associated with Grade 5.","Sudden Death NOS, CTCAE | Sudden Death NOS | Sudden death NOS | Sudden death NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545963","Suicidal Ideation, CTCAE","C143864","A disorder characterized by thoughts of taking one's own life.","Suicidal Ideation, CTCAE | Suicidal Ideation | Suicidal ideation | Suicidal ideation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542105","Suicide Attempt, CTCAE","C143865","A disorder characterized by self-inflicted harm in an attempt to end one's own life.","Suicide Attempt, CTCAE | Suicide Attempt | Suicide attempt | Suicide attempt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542106","Superficial Soft Tissue Fibrosis, CTCAE","C143866","A disorder characterized by fibrotic degeneration of the superficial soft tissues.","Superficial Soft Tissue Fibrosis, CTCAE | Superficial Soft Tissue Fibrosis | Superficial soft tissue fibrosis | Superficial soft tissue fibrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542107","Superficial Thrombophlebitis, CTCAE","C143867","A disorder characterized by a blood clot and inflammation involving a superficial vein of the extremities.","Superficial Thrombophlebitis, CTCAE | Superficial Thrombophlebitis | Superficial thrombophlebitis | Superficial thrombophlebitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542108","Superior Vena Cava Syndrome, CTCAE","C143868","A disorder characterized by obstruction of the blood flow in the superior vena cava. Signs and symptoms include swelling and cyanosis of the face, neck, and upper arms, cough, orthopnea and headache.","Superior Vena Cava Syndrome, CTCAE | Superior Vena Cava Syndrome | Superior vena cava syndrome | Superior vena cava syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963244","Supraventricular Tachycardia, CTCAE","C54945","A disorder characterized by a dysrhythmia with a heart rate greater than 100 beats per minute that originates above the ventricles.","Supraventricular Tachycardia, CTCAE | Supraventricular Tachycardia | Supraventricular tachycardia | Supraventricular tachycardia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542094","Surgical and Medical Procedures - Other, Specify, CTCAE","C143869","Surgical and medical procedures - Other, specify","Surgical and Medical Procedures - Other, Specify, CTCAE | Surgical and Medical Procedures - Other | Surgical and medical procedures - Other, specify | Surgical and medical procedures - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545953","Syncope, CTCAE_5","C146750","A disorder characterized by spontaneous loss of consciousness caused by insufficient blood supply to the brain.","Syncope, CTCAE 5.0 | Syncope | Syncope",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544688","Telangiectasia, CTCAE_5","C146740","A disorder characterized by local dilatation of small vessels resulting in red discoloration of the skin or mucous membranes.","Telangiectasia, CTCAE 5.0 | Telangiectasia | Telangiectasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542095","Testicular Disorder, CTCAE","C143872","A disorder characterized by abnormal function or appearance of the testis.","Testicular Disorder, CTCAE | Testicular Disorder | Testicular disorder | Testicular disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963131","Testicular Hemorrhage, CTCAE","C56566","A disorder characterized by bleeding from the testis.","Testicular Hemorrhage, CTCAE | Testes hemorrhage | Testicular Hemorrhage | Testicular hemorrhage | Testicular hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544635","Testicular Pain, CTCAE_5","C146666","A disorder characterized by a sensation of marked discomfort in the testis.","Testicular Pain, CTCAE 5.0 | Testicular Pain | Testicular pain | Testicular pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542096","Thromboembolic Event, CTCAE","C143873","A disorder characterized by occlusion of a vessel by a thrombus that has migrated from a distal site via the blood stream.","Thromboembolic Event, CTCAE | Thromboembolic Event | Thromboembolic event | Thromboembolic event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542097","Thrombotic Thrombocytopenic Purpura, CTCAE","C143874","A disorder characterized by the presence of microangiopathic hemolytic anemia, thrombocytopenic purpura, fever, renal abnormalities and neurological abnormalities such as seizures, hemiplegia, and visual disturbances. It is an acute or subacute condition.","Thrombotic Thrombocytopenic Purpura, CTCAE | Thrombotic Thrombocytopenic Purpura | Thrombotic thrombocytopenic purpura | Thrombotic thrombocytopenic purpura",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545922","Tinnitus, CTCAE_5","C146690","A disorder characterized by noise in the ears, such as ringing, buzzing, roaring or clicking.","Tinnitus, CTCAE 5.0 | Tinnitus | Tinnitus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542098","Tooth Development Disorder, CTCAE","C143876","A disorder characterized by a pathological process of the teeth occurring during tooth development.","Tooth Development Disorder, CTCAE | Tooth Development Disorder | Tooth development disorder | Tooth development disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542099","Tooth Discoloration, CTCAE","C143877","A disorder characterized by a change in tooth hue or tint.","Tooth Discoloration, CTCAE | Tooth Discoloration | Tooth discoloration | Tooth discoloration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542100","Tooth Infection, CTCAE","C143878","A disorder characterized by an infectious process involving a tooth.","Tooth Infection, CTCAE | Tooth Infection | Tooth infection | Tooth infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542101","Toothache, CTCAE","C143879","A disorder characterized by a sensation of marked discomfort in the tooth.","Toothache, CTCAE | Toothache | Toothache",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542087","Toxic Epidermal Necrolysis, CTCAE","C143880","A disorder characterized by greater than 30% total body skin area separation of dermis. The syndrome is thought to be a hypersensitivity complex affecting the skin and the mucous membranes.","Toxic Epidermal Necrolysis, CTCAE | Toxic Epidermal Necrolysis | Toxic epidermal necrolysis | Toxic epidermal necrolysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963251","Tracheal Fistula, CTCAE","C58205","A disorder characterized by an abnormal communication between the trachea and another organ or anatomic site.","Tracheal Fistula, CTCAE | Trachea fistula | Tracheal Fistula | Tracheal fistula | Tracheal fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556636","Tracheal Hemorrhage, CTCAE","C56567","A disorder characterized by bleeding from the trachea.","Tracheal Hemorrhage, CTCAE | Trachea hemorrhage | Tracheal Hemorrhage | Tracheal hemorrhage | Tracheal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542088","Tracheal Mucositis, CTCAE","C143881","A disorder characterized by an inflammation or ulceration involving the mucous membrane of the trachea.","Tracheal Mucositis, CTCAE | Tracheal Mucositis | Tracheal mucositis | Tracheal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542089","Tracheal Obstruction, CTCAE","C143882","A disorder characterized by blockage of the lumen of the trachea.","Tracheal Obstruction, CTCAE | Tracheal Obstruction | Tracheal obstruction | Tracheal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542090","Tracheal Stenosis, CTCAE","C143883","A disorder characterized by a narrowing of the trachea.","Tracheal Stenosis, CTCAE | Tracheal Stenosis | Tracheal stenosis | Tracheal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542091","Tracheitis, CTCAE","C143884","A disorder characterized by an infectious process involving the trachea.","Tracheitis, CTCAE | Tracheitis | Tracheitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542092","Tracheostomy Site Bleeding, CTCAE","C143885","A disorder characterized by bleeding from the tracheostomy site.","Tracheostomy Site Bleeding, CTCAE | Tracheostomy Site Bleeding | Tracheostomy site bleeding | Tracheostomy site bleeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545979","Transient Ischemic Attacks, CTCAE","C143886","A disorder characterized by a brief attack (less than 24 hours) of cerebral dysfunction of vascular origin, with no persistent neurological deficit.","Transient Ischemic Attacks, CTCAE | Transient Ischemic Attacks | Transient ischemic attacks | Transient ischemic attacks",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542093","Treatment Related Secondary Malignancy, CTCAE","C143887","A disorder characterized by development of a malignancy most probably as a result of treatment for a previously existing malignancy.","Treatment Related Secondary Malignancy, CTCAE | Treatment Related Secondary Malignancy | Treatment related secondary malignancy | Treatment related secondary malignancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544772","Tremor, CTCAE_5","C146780","A disorder characterized by the uncontrolled shaking movement of the whole body or individual parts.","Tremor, CTCAE 5.0 | Tremor | Tremor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542079","Tricuspid Valve Disease, CTCAE","C143889","A disorder characterized by a defect in tricuspid valve function or structure.","Tricuspid Valve Disease, CTCAE | Tricuspid Valve Disease | Tricuspid valve disease | Tricuspid valve disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542080","Trigeminal Nerve Disorder, CTCAE","C143890","A disorder characterized by dysfunction of the trigeminal nerve (fifth cranial nerve).","Trigeminal Nerve Disorder, CTCAE | Trigeminal Nerve Disorder | Trigeminal nerve disorder | Trigeminal nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1561266","Trismus, CTCAE","C58404","A disorder characterized by lack of ability to open the mouth fully due to a decrease in the range of motion of the muscles of mastication.","Trismus, CTCAE | Trismus | Trismus | Trismus (difficulty, restriction or pain when opening mouth)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544746","Tumor Lysis Syndrome, CTCAE_5","C146688","A disorder characterized by metabolic abnormalities that result from a spontaneous or therapy-related cytolysis of tumor cells.","Tumor Lysis Syndrome, CTCAE 5.0 | Tumor Lysis Syndrome | Tumor lysis syndrome | Tumor lysis syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544773","Tumor Pain, CTCAE_5","C146782","A disorder characterized by a sensation of marked discomfort from a neoplasm that may be pressing on a nerve, blocking blood vessels, inflamed or fractured from metastasis.","Tumor Pain, CTCAE 5.0 | Tumor Pain | Tumor pain | Tumor pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544708","Typhlitis, CTCAE_5","C146730","A disorder characterized by necrotizing enterocolitis in neutropenic patients.","Typhlitis, CTCAE 5.0 | Typhlitis | Typhlitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542081","Unequal Limb Length, CTCAE","C143894","A disorder characterized by a discrepancy between the lengths of the lower or upper extremities.","Unequal Limb Length, CTCAE | Unequal Limb Length | Unequal limb length | Unequal limb length",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542082","Upper Gastrointestinal Hemorrhage, CTCAE","C143895","A disorder characterized by bleeding from the upper gastrointestinal tract (oral cavity, pharynx, esophagus, and stomach).","Upper Gastrointestinal Hemorrhage, CTCAE | Upper Gastrointestinal Hemorrhage | Upper gastrointestinal hemorrhage | Upper gastrointestinal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542083","Upper Respiratory Infection, CTCAE","C143896","A disorder characterized by an infectious process involving the upper respiratory tract (nose, paranasal sinuses, pharynx, larynx, or trachea).","Upper Respiratory Infection, CTCAE | Upper Respiratory Infection | Upper respiratory infection | Upper respiratory infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542084","Ureteric Anastomotic Leak, CTCAE","C143897","A finding of leakage due to breakdown of a ureteral anastomosis (surgical connection of two separate anatomic structures).","Ureteric Anastomotic Leak, CTCAE | Ureteric Anastomotic Leak | Ureteric anastomotic leak | Ureteric anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542085","Urethral Anastomotic Leak, CTCAE","C143898","A finding of leakage due to breakdown of a urethral anastomosis (surgical connection of two separate anatomic structures).","Urethral Anastomotic Leak, CTCAE | Urethral Anastomotic Leak | Urethral anastomotic leak | Urethral anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542086","Urethral Infection, CTCAE","C143899","A disorder characterized by an infectious process involving the urethra.","Urethral Infection, CTCAE | Urethral Infection | Urethral infection | Urethral infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542190","Urinary Fistula, CTCAE","C143900","A disorder characterized by an abnormal communication between any part of the urinary system and another organ or anatomic site.","Urinary Fistula, CTCAE | Urinary Fistula | Urinary Fistula (Priority 1) | Urinary fistula | Urinary fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542191","Urinary Frequency, CTCAE","C143901","A disorder characterized by urination at short intervals.","Urinary Frequency, CTCAE | Urinary Frequency | Urinary Frequency (Priority 1) | Urinary frequency | Urinary frequency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1558141","Urinary Retention, CTCAE","C57097","A disorder characterized by accumulation of urine within the bladder because of the inability to urinate.","Urinary Retention, CTCAE | Urinary Retention | Urinary Retention (Priority 1) | Urinary retention | Urinary retention | Urinary retention (including neurogenic bladder)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545980","Urinary Tract Infection, CTCAE","C143904","A disorder characterized by an infectious process involving the urinary tract, most commonly the bladder and the urethra.","Urinary Tract Infection, CTCAE | Urinary Tract Infection | Urinary tract infection | Urinary tract infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542192","Urinary Tract Obstruction, CTCAE","C143905","A disorder characterized by blockage of the normal flow of contents of the urinary tract.","Urinary Tract Obstruction, CTCAE | Urinary Tract Obstruction | Urinary Tract Obstruction (Priority 2) | Urinary tract obstruction | Urinary tract obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542193","Urinary Tract Pain, CTCAE","C143906","A disorder characterized by a sensation of marked discomfort in the urinary tract.","Urinary Tract Pain, CTCAE | Urinary Tract Pain | Urinary Tract Pain (Priority 2) | Urinary tract pain | Urinary tract pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542194","Urinary Urgency, CTCAE","C143907","A disorder characterized by a sudden compelling urge to urinate.","Urinary Urgency, CTCAE | Urinary Urgency | Urinary Urgency (Priority 1) | Urinary urgency | Urinary urgency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542195","Urine Discoloration, CTCAE","C143908","A disorder characterized by a change in the color of the urine.","Urine Discoloration, CTCAE | Urine Discoloration | Urine discoloration | Urine discoloration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542196","Urine Output Decreased, CTCAE","C143909","A finding based on test results that indicate urine production is less relative to previous output.","Urine Output Decreased, CTCAE | Urine Output Decreased | Urine output decreased | Urine output decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542183","Urostomy Leak, CTCAE","C143910","A finding of leakage of contents from a urostomy.","Urostomy Leak, CTCAE | Urostomy Leak | Urostomy leak | Urostomy leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542184","Urostomy Obstruction, CTCAE","C143911","A disorder characterized by blockage of the urostomy.","Urostomy Obstruction, CTCAE | Urostomy Obstruction | Urostomy obstruction | Urostomy obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542185","Urostomy Site Bleeding, CTCAE","C143912","A disorder characterized by bleeding from the urostomy site.","Urostomy Site Bleeding, CTCAE | Urostomy Site Bleeding | Urostomy site bleeding | Urostomy site bleeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542186","Urostomy Stenosis, CTCAE","C143913","A finding of narrowing of the opening of a urostomy.","Urostomy Stenosis, CTCAE | Urostomy Stenosis | Urostomy stenosis | Urostomy stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1559188","Urticaria, CTCAE","C58019","A disorder characterized by an itchy skin eruption characterized by wheals with pale interiors and well-defined red margins.","Urticaria, CTCAE | Urticaria | Urticaria | Urticaria (hives, welts, wheals)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542187","Uterine Anastomotic Leak, CTCAE","C143915","A finding of leakage due to breakdown of a uterine anastomosis (surgical connection of two separate anatomic structures).","Uterine Anastomotic Leak, CTCAE | Uterine Anastomotic Leak | Uterine anastomotic leak | Uterine anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542188","Uterine Fistula, CTCAE","C143916","A disorder characterized by an abnormal communication between the uterus and another organ or anatomic site.","Uterine Fistula, CTCAE | Uterine Fistula | Uterine fistula | Uterine fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1560757","HEMORRHAGE UTERINE","C56572","A disorder characterized by bleeding from the uterus.","Uterine Hemorrhage, CTCAE | Uterine Hemorrhage | Uterine hemorrhage | Uterine hemorrhage | Uterus hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042136","Uterine Infection, CTCAE","C143917","A disorder characterized by an infectious process involving the endometrium. It may extend to the myometrium and parametrial tissues.","Uterine Infection, CTCAE | Uterine Infection | Uterine infection | Uterine infection",,,,,,,,,,,,,,,"4200518","Infection of uterus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL542189","Uterine Obstruction, CTCAE","C143918","A disorder characterized by blockage of the uterine outlet.","Uterine Obstruction, CTCAE | Uterine Obstruction | Uterine obstruction | Uterine obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544741","Uterine Pain, CTCAE_5","C146683","A disorder characterized by a sensation of marked discomfort in the uterus.","Uterine Pain, CTCAE 5.0 | Uterine Pain | Uterine pain | Uterine pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542175","Uterine Perforation, CTCAE","C143919","A disorder characterized by a rupture in the uterine wall.","Uterine Perforation, CTCAE | Uterine Perforation | Uterine perforation | Uterine perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963266","Uveitis, CTCAE","C55901","A disorder characterized by inflammation to the uvea of the eye.","Uveitis, CTCAE | Uveitis | Uveitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542176","Vaginal Anastomotic Leak, CTCAE","C143921","A finding of leakage due to breakdown of a vaginal anastomosis (surgical connection of two separate anatomic structures).","Vaginal Anastomotic Leak, CTCAE | Vaginal Anastomotic Leak | Vaginal anastomotic leak | Vaginal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542177","Vaginal Discharge, CTCAE","C143922","A disorder characterized by vaginal secretions. Mucus produced by the cervical glands is discharged from the vagina naturally, especially during the childbearing years.","Vaginal Discharge, CTCAE | Vaginal Discharge | Vaginal discharge | Vaginal discharge",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544745","Vaginal Dryness, CTCAE_5","C146687","A disorder characterized by an uncomfortable feeling of itching and burning in the vagina.","Vaginal Dryness, CTCAE 5.0 | Vaginal Dryness | Vaginal dryness | Vaginal dryness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963267","Vaginal Fistula, CTCAE","C57104","A disorder characterized by an abnormal communication between the vagina and another organ or anatomic site.","Vaginal Fistula, CTCAE | Vagina fistula | Vaginal Fistula | Vaginal fistula | Vaginal fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2911646","Vaginal Hemorrhage, CTCAE","C56573","A disorder characterized by bleeding from the vagina.","Vaginal Hemorrhage, CTCAE | Vagina hemorrhage | Vaginal Hemorrhage | Vaginal hemorrhage | Vaginal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542178","Vaginal Infection, CTCAE","C143924","A disorder characterized by an infectious process involving the vagina.","Vaginal Infection, CTCAE | Vaginal Infection | Vaginal infection | Vaginal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542179","Vaginal Inflammation, CTCAE","C143925","A disorder characterized by inflammation involving the vagina. Symptoms may include redness, edema, marked discomfort and an increase in vaginal discharge.","Vaginal Inflammation, CTCAE | Vaginal Inflammation | Vaginal inflammation | Vaginal inflammation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544738","Vaginal Obstruction, CTCAE_5","C146696","A disorder characterized by blockage of vaginal canal.","Vaginal Obstruction, CTCAE 5.0 | Vaginal Obstruction | Vaginal obstruction | Vaginal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544742","Vaginal Pain, CTCAE_5","C146684","A disorder characterized by a sensation of marked discomfort in the vagina.","Vaginal Pain, CTCAE 5.0 | Vaginal Pain | Vaginal pain | Vaginal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544739","Vaginal Perforation, CTCAE_5","C146697","A disorder characterized by a rupture in the vaginal wall.","Vaginal Perforation, CTCAE 5.0 | Vaginal Perforation | Vaginal perforation | Vaginal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542180","Vaginal Stricture, CTCAE","C143926","A disorder characterized by a narrowing of the vaginal canal.","Vaginal Stricture, CTCAE | Vaginal Stricture | Vaginal stricture | Vaginal stricture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542181","Vagus Nerve Disorder, CTCAE","C143927","A disorder characterized by dysfunction of the vagus nerve (tenth cranial nerve).","Vagus Nerve Disorder, CTCAE | Vagus Nerve Disorder | Vagus nerve disorder | Vagus nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542182","Vas Deferens Anastomotic Leak, CTCAE","C143928","A finding of leakage due to breakdown of a vas deferens anastomosis (surgical connection of two separate anatomic structures).","Vas Deferens Anastomotic Leak, CTCAE | Vas Deferens Anastomotic Leak | Vas deferens anastomotic leak | Vas deferens anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542169","Vascular Access Complication, CTCAE","C143929","A finding of a previously undocumented problem related to the vascular access site.","Vascular Access Complication, CTCAE | Vascular Access Complication | Vascular access complication | Vascular access complication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542170","Vascular Disorders - Other, Specify, CTCAE","C143930","Vascular disorders - Other, specify","Vascular Disorders - Other, Specify, CTCAE | Vascular Disorders - Other | Vascular disorders - Other, specify | Vascular disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963274","ANGIITIS","C54741","A disorder characterized by inflammation involving the wall of a vessel.","Vasculitis, CTCAE | Vasculitis | Vasculitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542171","Vasovagal Reaction, CTCAE","C143932","A disorder characterized by a sudden drop of the blood pressure, bradycardia, and peripheral vasodilation that may lead to loss of consciousness. It results from an increase in the stimulation of the vagus nerve.","Vasovagal Reaction, CTCAE | Vasovagal Reaction | Vasovagal reaction | Vasovagal reaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542172","Venous Injury, CTCAE","C143933","A finding of damage to a vein.","Venous Injury, CTCAE | Venous Injury | Venous injury | Venous injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544675","Ventricular Arrhythmia, CTCAE_5","C146629","A disorder characterized by a dysrhythmia that originates in the ventricles.","Ventricular Arrhythmia, CTCAE 5.0 | Ventricular Arrhythmia | Ventricular arrhythmia | Ventricular arrhythmia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544695","Ventricular Fibrillation, CTCAE_5","C146732","A disorder characterized by a dysrhythmia without discernible QRS complexes due to rapid repetitive excitation of myocardial fibers without coordinated contraction of the ventricles.","Ventricular Fibrillation, CTCAE 5.0 | Ventricular Fibrillation | Ventricular fibrillation | Ventricular fibrillation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544696","Ventricular Tachycardia, CTCAE_5","C146733","A disorder characterized by a dysrhythmia with a heart rate greater than 100 beats per minute that originates distal to the bundle of His.","Ventricular Tachycardia, CTCAE 5.0 | Ventricular Tachycardia | Ventricular tachycardia | Ventricular tachycardia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546001","Vertigo, CTCAE","C143935","A disorder characterized by a sensation as if the external world were revolving around the patient (objective vertigo) or as if he himself were revolving in space (subjective vertigo).","Vertigo, CTCAE | Vertigo | Vertigo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545965","Vestibular Disorder, CTCAE","C143936","A disorder characterized by dizziness, imbalance, nausea, and vision problems.","Vestibular Disorder, CTCAE | Vestibular Disorder | Vestibular disorder | Vestibular disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542173","Virilization, CTCAE","C143937","A disorder characterized by inappropriate masculinization occurring in a female or prepubertal male.","Virilization, CTCAE | Virilization | Virilization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542174","Visceral Arterial Ischemia, CTCAE","C143938","A disorder characterized by a decrease in blood supply due to narrowing or blockage of a visceral (mesenteric) artery.","Visceral Arterial Ischemia, CTCAE | Visceral Arterial Ischemia | Visceral arterial ischemia | Visceral arterial ischemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542161","Vital Capacity Abnormal, CTCAE","C143939","A finding based on pulmonary function test results that indicate an abnormal vital capacity (amount of exhaled after a maximum inhalation) when compared to the predicted value.","Vital Capacity Abnormal, CTCAE | Vital Capacity Abnormal | Vital capacity abnormal | Vital capacity abnormal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544631","Vitreous Hemorrhage, CTCAE_5","C146677","A disorder characterized by bleeding into the vitreous humor.","Vitreous Hemorrhage, CTCAE 5.0 | Vitreous Hemorrhage | Vitreous hemorrhage | Vitreous hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542162","Voice Alteration, CTCAE","C143941","A disorder characterized by a change in the sound and/or speed of the voice.","Voice Alteration, CTCAE | Voice Alteration | Voice alteration | Voice alteration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963281","Vomiting, CTCAE","C57896","A disorder characterized by the reflexive act of ejecting the contents of the stomach through the mouth.","Vomiting, CTCAE | Vomiting | Vomiting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542164","Watering Eyes, CTCAE","C143944","A disorder characterized by excessive tearing in the eyes; it can be caused by overproduction of tears or impaired drainage of the tear duct.","Watering Eyes, CTCAE | Watering Eyes | Watering eyes | Watering eyes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2911647","Weight Gain, CTCAE","C55338","A finding characterized by an unexpected or abnormal increase in overall body weight; for pediatrics, greater than the baseline growth curve.","Weight Gain, CTCAE | Weight Gain | Weight gain | Weight gain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2911645","Weight Loss, CTCAE","C55339","A finding characterized by a decrease in overall body weight; for pediatrics, less than the baseline growth curve.","Weight Loss, CTCAE | Weight Loss | Weight loss | Weight loss",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542165","Wheezing, CTCAE","C143947","A disorder characterized by a high-pitched, whistling sound during breathing. It results from the narrowing or obstruction of the respiratory airways.","Wheezing, CTCAE | Wheezing | Wheezing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542166","White Blood Cell Decreased, CTCAE","C143948","A finding based on laboratory test results that indicate an decrease in number of white blood cells in a blood specimen.","White Blood Cell Decreased, CTCAE | White Blood Cell Decreased | White blood cell decreased | White blood cell decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542167","Wound Complication, CTCAE","C143949","A finding of development of a new problem at the site of an existing wound.","Wound Complication, CTCAE | Wound Complication | Wound complication | Wound complication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542168","Wound Dehiscence, CTCAE","C143950","A finding of separation of the approximated margins of a surgical wound.","Wound Dehiscence, CTCAE | Wound Dehiscence | Wound dehiscence | Wound dehiscence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542153","Wound Infection, CTCAE","C143951","A disorder characterized by an infectious process involving the wound.","Wound Infection, CTCAE | Wound Infection | Wound infection | Wound infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542154","Wrist Fracture, CTCAE","C143952","A finding of traumatic injury to the wrist joint in which the continuity of a wrist bone is broken.","Wrist Fracture, CTCAE | Wrist Fracture | Wrist fracture | Wrist fracture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4045494","Ribociclib","C95701","An orally available inhibitor of the cyclin-dependent kinases (CDKs) 4 and 6, with antineoplastic activity. Upon oral administration, ribociclib specifically targets, binds to and inhibits CDK4 and CDK6. This inhibits the cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, which inhibits phosphorylation of the retinoblastoma (Rb) protein. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle dysregulation.","Ribociclib | 7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide | Kisqali | LEE 011 | LEE-011 | LEE011 | RIBOCICLIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544955","AJCC Cancer Staging Manual 8th Edition","C146985","The 8th edition of the criteria developed by the American Joint Committee on Cancer (AJCC), implemented in 2018, used for the classification and staging of neoplastic diseases.","AJCC Cancer Staging Manual 8th Edition | 8th | AJCC Ed. 8 | AJCC Edition 8 | AJCC V8 | AJCC v8 | AJCC2 | AJCC8 | American Joint Committee on Cancer Staging Manual, Edition 8 | Eighth Edition (2017)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544872","NY-ESO-1 TCR/sr39TK Lentiviral Vector-transduced Autologous PBSCs","C146940","Human autologous peripheral blood stem cells (PBSCs) transduced with a lentiviral vector (LV) encoding a T-cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1, and carrying the positron emission tomography (PET) reporter/suicide gene sr39TK, a mutant form of the herpes simplex virus type 1 thymidine kinase gene (HSV-1 TK), with potential immunostimulating and antineoplastic activities. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the NY-ESO-1 TCR/sr39TK LV-transduced autologous PBSCs recognize and bind to NY-ESO-1-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of NY-ESO-1-positive tumor cells. NY-ESO-1, a tumor-associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types. The incorporation of sr39TK allows for the ganciclovir (GCV)-mediated cell killing of the gene-modified PBSCs if serious adverse effects occur. sr39TK converts the nucleoside prodrug GCV into GCV monophosphate (GCV-MP), which is in turn phosphorylated by cellular kinases to the cytotoxic nucleotide GCV-triphosphate (GCV-TP); the TP form competitively inhibits deoxyguanosine triphosphate (dGTP) incorporation into DNA and inhibits DNA synthesis, causing DNA damage and cell death in the sr39TK-expressing PBSCs. In addition, sr39TK allows for PET imaging of the gene-modified PBSCs upon subsequent administration of radio-labeled substrates, such as 9-(4-[18F]-fluoro-3-[hydroxymethyl]butyl)guanine ([18F]-FHBG). The monophosphorylation of [18 F]-FHBG is catalyzed by sr39TK; this promotes triphosphorylation and accumulation of [18F]-FHBG in the PBSCs, which allows in vivo imaging and tracking of the PBSCs upon PET. Compared to wild-type HSV-TK, the mutant form has increased prodrug phosphorylating capacity and enhances the cell killing by GCV.","NY-ESO-1 TCR/sr39TK Lentiviral Vector-transduced Autologous PBSCs | Autologous LV-NY-ESO-1 TCR PBSC | Engineered Autologous PBSC Expressing NY-ESO-1 TCR/sr39TK | LV-NYESO TCR/sr39TK PBSC | NY-ESO-1 Reactive TCR/sr39TK LV-transduced Autologous PBSCs | NY-ESO-1 T-cell Receptor/sr39TK-engineered Peripheral Blood Stem Cells | NY-ESO-1 TCR/HSV-sr39TK LV-modified PBSCs | NY-ESO-1 TCR/sr39TK-modified Autologous PBSC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544871","NY-ESO-1 TCR Retroviral Vector-transduced Autologous PBMCs","C146939","Human autologous peripheral blood mononuclear cells (PBMCs) transduced with a retroviral vector (RV) encoding a T-cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1, with potential immunostimulating and antineoplastic activities. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the NY-ESO-1 TCR RV-transduced autologous PBMCs recognize and bind to NY-ESO-1-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of NY-ESO-1-positive tumor cells. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types.","NY-ESO-1 TCR Retroviral Vector-transduced Autologous PBMCs | Autologous RV-NY-ESO-1 TCR PBMC | Autologous RV-NYESO TCR PBMC | Engineered Autologous PBMC Expressing NY-ESO-1 TCR | NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBMCs | NY-ESO-1 T-cell Receptor-engineered Peripheral Blood Mononuclear Cells | NY-ESO-1 TCR-transduced Autologous PBMCs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544828","ALK NP_004295.2:p.F1174L","C146863","A change in the amino acid residue at position 1174 in the ALK tyrosine kinase receptor protein where phenylalanine has been replaced by leucine.","ALK NP_004295.2:p.F1174L | ALK F1174L | ALK NP_004295.2:p.Phe1174Leu | ALK Phe1174Leu | ALK Tyrosine Kinase Receptor F1174L | ALK Tyrosine Kinase Receptor Phe1174Leu | ALK p.F1174L | ALK p.Phe1174Leu | Anaplastic Lymphoma Kinase F1174L | Anaplastic Lymphoma Kinase Phe1174Leu | CD246 Antigen F1174L | CD246 Antigen Phe1174Leu | NP_004295.2:p.F1174L | NP_004295.2:p.Phe1174Leu | p.F1174L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544821","ALK NP_004295.2:p.K1062M","C146872","A change in the amino acid residue at position 1062 in the ALK tyrosine kinase receptor protein where lysine has been replaced by methionine.","ALK NP_004295.2:p.K1062M | ALK K1062M | ALK Lys1062Met | ALK NP_004295.2:p.Lys1062Met | ALK Tyrosine Kinase Receptor K1062M | ALK Tyrosine Kinase Receptor Lys1062Met | ALK p.K1062M | ALK p.Lys1062Met | Anaplastic Lymphoma Kinase K1062M | Anaplastic Lymphoma Kinase Lys1062Met | CD246 Antigen K1062M | CD246 Antigen Lys1062Met | NP_004295.2:p.K1062M | NP_004295.2:p.Lys1062Met",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544807","ALK NP_004295.2:p.R1275Q","C146874","A change in the amino acid residue at position 1275 in the ALK tyrosine kinase receptor protein where arginine has been replaced by glutamine.","ALK NP_004295.2:p.R1275Q | ALK Arg1275Gln | ALK NP_004295.2:p.Arg1275Gln | ALK R1275Q | ALK Tyrosine Kinase Receptor Arg1275Gln | ALK Tyrosine Kinase Receptor R1275Q | ALK p.Arg1275Gln | ALK p.R1275Q | Anaplastic Lymphoma Kinase Arg1275Gln | Anaplastic Lymphoma Kinase R1275Q | CD246 Antigen Arg1275Gln | CD246 Antigen R1275Q | NP_004295.2:p.Arg1275Gln | NP_004295.2:p.R1275Q",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544808","ALK NP_004295.2:p.T1087I","C146875","A change in the amino acid residue at position 1087 in the ALK tyrosine kinase receptor protein where threonine has been replaced by isoleucine.","ALK NP_004295.2:p.T1087I | ALK NP_004295.2:p.Thr1087Ile | ALK T1087I | ALK Thr1087Ile | ALK Tyrosine Kinase Receptor T1087I | ALK Tyrosine Kinase Receptor Thr1087Ile | ALK p.T1087I | ALK p.Thr1087Ile | Anaplastic Lymphoma Kinase Thr1087Ile | CD246 Antigen T1087I | CD246 Antigen Thr1087Ile | NP_004295.2:p.T1087I | NP_004295.2:p.Thr1087Ile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544816","ALK NP_004295.2:p.F1174C","C146867","A change in the amino acid residue at position 1174 in the ALK tyrosine kinase receptor protein where phenylalanine has been replaced by cysteine.","ALK NP_004295.2:p.F1174C | ALK F1174C | ALK NP_004295.2:p.Phe1174Cy | ALK Phe1174Cys | ALK Tyrosine Kinase Receptor F1174C | ALK Tyrosine Kinase Receptor Phe1174Cys | ALK p.F1174C | ALK p.Phe1174Cys | Anaplastic Lymphoma Kinase F1174C | Anaplastic Lymphoma Kinase Phe1174Cys | CD246 Antigen F1174C | CD246 Antigen Phe1174Cys | NP_004295.2:p.F1174C | NP_004295.2:p.Phe1174Cys",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544818","ALK NP_004295.2:p.F1174V","C146869","A change in the amino acid residue at position 1174 in the ALK tyrosine kinase receptor protein where phenylalanine has been replaced by valine.","ALK NP_004295.2:p.F1174V | ALK F1174V | ALK NP_004295.2:p.Phe1174Val | ALK Phe1174Val | ALK Tyrosine Kinase Receptor F1174V | ALK Tyrosine Kinase Receptor Phe1174Val | ALK p.F1174V | ALK p.Phe1174Val | Anaplastic Lymphoma Kinase F1174V | Anaplastic Lymphoma Kinase Phe1174Val | CD246 Antigen F1174V | CD246 Antigen Phe1174Val | NP_004295.2:p.F1174V | NP_004295.2:p.Phe1174Val",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544924","BRAF NP_004324.2:p.K601E","C146881","A change in the amino acid residue at position 601 in the serine/threonine protein kinase B-raf protein where lysine has been replaced by glutamic acid.","BRAF NP_004324.2:p.K601E | BRAF K601E | BRAF Lys601Glu | BRAF NP_004324.2:p.Lys601Glu | BRAF p.K601E | BRAF p.Lys601Glu | NP_004324.2:p.K601E | NP_004324.2:p.Lys601Glu | Serine/Threonine-Protein Kinase B-raf K601E | Serine/Threonine-Protein Kinase B-raf Lys601Glu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544926","TP53 Protein Variant","C146884","A variation in the amino acid sequence for cellular tumor antigen p53.","TP53 Protein Variant | Antigen NY-CO-13 Protein Variant | Cellular Tumor Antigen p53 Protein Variant | Transformation-Related Protein 53 Protein Variant | Tumor Protein p53 Protein Variant | Tumor Suppressor p53 Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544928","TP53 NP_000537.3:p.R175H","C146886","A change in the amino acid residue at position 175 in the cellular tumor antigen p53 protein where arginine has been replaced by histidine.","TP53 NP_000537.3:p.R175H | Antigen NY-CO-13 Arg175His | Antigen NY-CO-13 R175H | Cellular Tumor Antigen p53 Arg175His | Cellular Tumor Antigen p53 R175H | NP_000537.3:p.Arg175His | NP_000537.3:p.R175H | TP53 Arg175His | TP53 NP_000537.3:p.Arg175His | TP53 R175H | TP53 p.Arg175His | TP53 p.R175H | Transformation-Related Protein 53 Arg175His | Transformation-Related Protein 53 R175H | Tumor Protein p53 Arg175His | Tumor Protein p53 R175H | Tumor Suppressor p53 Arg175His | Tumor Suppressor p53 R175H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544930","TP53 NP_000537.3:p.R213L","C146888","A change in the amino acid residue at position 213 in the cellular tumor antigen p53 protein where arginine has been replaced by leucine.","TP53 NP_000537.3:p.R213L | Antigen NY-CO-13 Arg213Leu | Antigen NY-CO-13 R213L | Cellular Tumor Antigen p53 Arg213Leu | Cellular Tumor Antigen p53 R213L | NP_000537.3:p.Arg213Leu | NP_000537.3:p.R213L | TP53 Arg213Leu | TP53 NP_000537.3:p.Arg213Leu | TP53 R213L | TP53 p.Arg213Leu | TP53 p.R213L | Transformation-Related Protein 53 Arg213Leu | Transformation-Related Protein 53 R213L | Tumor Protein p53 Arg213Leu | Tumor Protein p53 R213L | Tumor Suppressor p53 Arg213Leu | Tumor Suppressor p53 R213L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544917","TP53 NP_000537.3:p.Y220C","C146890","A change in the amino acid residue at position 220 in the cellular tumor antigen p53 protein where tyrosine has been replaced by cysteine.","TP53 NP_000537.3:p.Y220C | Antigen NY-CO-13 Tyr220Cys | Antigen NY-CO-13 Y220C | Cellular Tumor Antigen p53 Tyr220Cys | Cellular Tumor Antigen p53 Y220C | NP_000537.3:p.Tyr220Cys | NP_000537.3:p.Y220C | TP53 NP_000537.3:p.Tyr220Cys | TP53 Tyr220Cys | TP53 Y220C | TP53 p.Tyr220Cys | TP53 p.Y220C | Transformation-Related Protein 53 Tyr220Cys | Transformation-Related Protein 53 Y220C | Tumor Protein p53 Tyr220Cys | Tumor Protein p53 Y220C | Tumor Suppressor p53 Tyr220Cys | Tumor Suppressor p53 Y220C | p53 Y220C Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544919","TP53 NP_000537.3:p.C238Y","C146892","A change in the amino acid residue at position 238 in the cellular tumor antigen p53 protein where cysteine has been replaced by tyrosine.","TP53 NP_000537.3:p.C238Y | Antigen NY-CO-13 C238Y | Antigen NY-CO-13 Cys238Tyr | Cellular Tumor Antigen p53 C238Y | Cellular Tumor Antigen p53 Cys238Tyr | NP_000537.3:p.C238Y | NP_000537.3:p.Cys238Tyr | TP53 C238Y | TP53 Cys238Tyr | TP53 NP_000537.3:p.Cys238Tyr | TP53 p.C238Y | TP53 p.Cys238Tyr | Transformation-Related Protein 53 C238Y | Transformation-Related Protein 53 Cys238Tyr | Tumor Protein p53 C238Y | Tumor Protein p53 Cys238Tyr | Tumor Suppressor p53 C238Y | Tumor Suppressor p53 Cys238Tyr",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544923","TP53 NP_000537.3:p.G245S","C146896","A change in the amino acid residue at position 245 in the cellular tumor antigen p53 protein where glycine has been replaced by serine.","TP53 NP_000537.3:p.G245S | Antigen NY-CO-13 G245S | Antigen NY-CO-13 Gly245Ser | Cellular Tumor Antigen p53 G245S | Cellular Tumor Antigen p53 Gly245Ser | NP_000537.3:p.G245S | NP_000537.3:p.Gly245Ser | TP53 G245S | TP53 Gly245Ser | TP53 NP_000537.3:p.Gly245Ser | TP53 p.G245S | TP53 p.Gly245Ser | Transformation-Related Protein 53 G245S | Transformation-Related Protein 53 Gly245Ser | Tumor Protein p53 G245S | Tumor Protein p53 Gly245Ser | Tumor Suppressor p53 G245S | Tumor Suppressor p53 Gly245Ser",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544911","TP53 NP_000537.3:p.G245D","C146900","A change in the amino acid residue at position 245 in the cellular tumor antigen p53 protein where glycine has been replaced by aspartic acid.","TP53 NP_000537.3:p.G245D | Antigen NY-CO-13 G245D | Antigen NY-CO-13 Gly245Asp | Cellular Tumor Antigen p53 G245D | Cellular Tumor Antigen p53 Gly245Asp | NP_000537.3:p.G245D | NP_000537.3:p.Gly245Asp | TP53 G245D | TP53 Gly245Asp | TP53 NP_000537.3:p.Gly245Asp | TP53 p.G245D | TP53 p.Gly245Asp | Transformation-Related Protein 53 G245D | Transformation-Related Protein 53 Gly245Asp | Tumor Protein p53 G245D | Tumor Protein p53 Gly245Asp | Tumor Suppressor p53 G245D | Tumor Suppressor p53 Gly245Asp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544914","TP53 NP_000537.3:p.R248Q","C146903","A change in the amino acid residue at position 248 in the cellular tumor antigen p53 protein where arginine has been replaced by glutamine.","TP53 NP_000537.3:p.R248Q | Antigen NY-CO-13 Arg248Gln | Antigen NY-CO-13 R248Q | Cellular Tumor Antigen p53 Arg248Gln | Cellular Tumor Antigen p53 R248Q | NP_000537.3:p.Arg248Gln | NP_000537.3:p.R248Q | TP53 Arg248Gln | TP53 NP_000537.3:p.Arg248Gln | TP53 R248Q | TP53 p.Arg248Gln | TP53 p.R248Q | Transformation-Related Protein 53 Arg248Gln | Transformation-Related Protein 53 R248Q | Tumor Protein p53 Arg248Gln | Tumor Protein p53 R248Q | Tumor Suppressor p53 Arg248Gln | Tumor Suppressor p53 R248Q",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544902","TP53 NP_000537.3:p.R248W","C146906","A change in the amino acid residue at position 248 in the cellular tumor antigen p53 protein where arginine has been replaced by tryptophan.","TP53 NP_000537.3:p.R248W | Antigen NY-CO-13 Arg248Trp | Antigen NY-CO-13 R248W | Cellular Tumor Antigen p53 Arg248Trp | Cellular Tumor Antigen p53 R248W | NP_000537.3:p.Arg248Trp | NP_000537.3:p.R248W | TP53 Arg248Trp | TP53 NP_000537.3:p.Arg248Trp | TP53 R248W | TP53 p.Arg248Trp | TP53 p.R248W | Transformation-Related Protein 53 Arg248Trp | Transformation-Related Protein 53 R248W | Tumor Protein p53 Arg248Trp | Tumor Protein p53 R248W | Tumor Suppressor p53 Arg248Trp | Tumor Suppressor p53 R248W",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544904","TP53 NP_000537.3:p.G266V","C146908","A change in the amino acid residue at position 266 in the cellular tumor antigen p53 protein where glycine has been replaced by valine.","TP53 NP_000537.3:p.G266V | Antigen NY-CO-13 G266V | Antigen NY-CO-13 Gly266Val | Cellular Tumor Antigen p53 G266V | Cellular Tumor Antigen p53 Gly266Val | NP_000537.3:p.G266V | NP_000537.3:p.Gly266Val | TP53 G266V | TP53 Gly266Val | TP53 NP_000537.3:p.Gly266Val | TP53 p.G266V | TP53 p.Gly266Val | Transformation-Related Protein 53 G266V | Transformation-Related Protein 53 Gly266Val | Tumor Protein p53 G266V | Tumor Protein p53 Gly266Val | Tumor Suppressor p53 G266V | Tumor Suppressor p53 Gly266Val",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544906","TP53 NP_000537.3:p.G266E","C146910","A change in the amino acid residue at position 266 in the cellular tumor antigen p53 protein where glycine has been replaced by glutamic acid.","TP53 NP_000537.3:p.G266E | Antigen NY-CO-13 G266E | Antigen NY-CO-13 Gly266Glu | Cellular Tumor Antigen p53 G266E | Cellular Tumor Antigen p53 Gly266Glu | NP_000537.3:p.G266E | NP_000537.3:p.Gly266Glu | TP53 G266E | TP53 Gly266Glu | TP53 NP_000537.3:p.Gly266Glu | TP53 p.G266E | TP53 p.Gly266Glu | Transformation-Related Protein 53 G266E | Transformation-Related Protein 53 Gly266Glu | Tumor Protein p53 G266E | Tumor Protein p53 Gly266Glu | Tumor Suppressor p53 G266E | Tumor Suppressor p53 Gly266Glu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544908","TP53 NP_000537.3:p.V272M","C146913","A change in the amino acid residue at position 272 in the cellular tumor antigen p53 protein where valine has been replaced by methionine.","TP53 NP_000537.3:p.V272M | Antigen NY-CO-13 V272M | Antigen NY-CO-13 Val272Met | Cellular Tumor Antigen p53 V272M | Cellular Tumor Antigen p53 Val272Met | NP_000537.3:p.V272M | NP_000537.3:p.Val272Met | TP53 NP_000537.3:p.Val272Met | TP53 V272M | TP53 Val272Met | TP53 p.V272M | TP53 p.Val272Met | Transformation-Related Protein 53 V272M | Transformation-Related Protein 53 Val272Met | Tumor Protein p53 V272M | Tumor Protein p53 Val272Met | Tumor Suppressor p53 V272M | Tumor Suppressor p53 Val272Met",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544895","TP53 NP_000537.3:p.R273H","C146915","A change in the amino acid residue at position 273 in the cellular tumor antigen p53 protein where arginine has been replaced by histidine.","TP53 NP_000537.3:p.R273H | Antigen NY-CO-13 Arg273His | Antigen NY-CO-13 R273H | Cellular Tumor Antigen p53 Arg273His | Cellular Tumor Antigen p53 R273H | NP_000537.3:p.Arg273His | NP_000537.3:p.R273H | TP53 Arg273His | TP53 NP_000537.3:p.Arg273His | TP53 R273H | TP53 p.Arg273His | TP53 p.R273H | Transformation-Related Protein 53 Arg273His | Transformation-Related Protein 53 R273H | Tumor Protein p53 Arg273His | Tumor Protein p53 R273H | Tumor Suppressor p53 Arg273His | Tumor Suppressor p53 R273H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544897","TP53 NP_000537.3:p.R273C","C146917","A change in the amino acid residue at position 273 in the cellular tumor antigen p53 protein where arginine has been replaced by cysteine.","TP53 NP_000537.3:p.R273C | Antigen NY-CO-13 Arg273Cys | Antigen NY-CO-13 R273C | Cellular Tumor Antigen p53 Arg273Cys | Cellular Tumor Antigen p53 R273C | NP_000537.3:p.Arg273Cys | NP_000537.3:p.R273C | TP53 Arg273Cys | TP53 NP_000537.3:p.Arg273Cys | TP53 R273C | TP53 p.Arg273Cys | TP53 p.R273C | Transformation-Related Protein 53 Arg273Cys | Transformation-Related Protein 53 R273C | Tumor Protein p53 Arg273Cys | Tumor Protein p53 R273C | Tumor Suppressor p53 Arg273Cys | Tumor Suppressor p53 R273C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544899","TP53 NP_000537.3:p.R273L","C146920","A change in the amino acid residue at position 273 in the cellular tumor antigen p53 protein where arginine has been replaced by leucine.","TP53 NP_000537.3:p.R273L | Antigen NY-CO-13 Arg273Leu | Antigen NY-CO-13 R273L | Cellular Tumor Antigen p53 Arg273Leu | Cellular Tumor Antigen p53 R273L | NP_000537.3:p.Arg273Leu | NP_000537.3:p.R273L | TP53 Arg273Leu | TP53 NP_000537.3:p.Arg273Leu | TP53 R273L | TP53 p.Arg273Leu | TP53 p.R273L | Transformation-Related Protein 53 Arg273Leu | Transformation-Related Protein 53 R273L | Tumor Protein p53 Arg273Leu | Tumor Protein p53 R273L | Tumor Suppressor p53 Arg273Leu | Tumor Suppressor p53 R273L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544887","TP53 NP_000537.3:p.R282W","C146923","A change in the amino acid residue at position 282 in the cellular tumor antigen p53 protein where arginine has been replaced by tryptophan.","TP53 NP_000537.3:p.R282W | Antigen NY-CO-13 Arg282Trp | Antigen NY-CO-13 R282W | Cellular Tumor Antigen p53 Arg282Trp | Cellular Tumor Antigen p53 R282W | NP_000537.3:p.Arg282Trp | NP_000537.3:p.R282W | TP53 Arg282Trp | TP53 NP_000537.3:p.Arg282Trp | TP53 R282W | TP53 p.Arg282Trp | TP53 p.R282W | Transformation-Related Protein 53 Arg282Trp | Transformation-Related Protein 53 R282W | Tumor Protein p53 Arg282Trp | Tumor Protein p53 R282W | Tumor Suppressor p53 Arg282Trp | Tumor Suppressor p53 R282W",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544889","TP53 NP_000537.3:p.R282G","C146925","A change in the amino acid residue at position 282 in the cellular tumor antigen p53 protein where arginine has been replaced by glycine.","TP53 NP_000537.3:p.R282G | Antigen NY-CO-13 Arg282Gly | Antigen NY-CO-13 R282G | Cellular Tumor Antigen p53 Arg282Gly | Cellular Tumor Antigen p53 R282G | NP_000537.3:p.Arg282Gly | NP_000537.3:p.R282G | TP53 Arg282Gly | TP53 NP_000537.3:p.Arg282Gly | TP53 R282G | TP53 p.Arg282Gly | TP53 p.R282G | Transformation-Related Protein 53 Arg282Gly | Transformation-Related Protein 53 R282G | Tumor Protein p53 Arg282Gly | Tumor Protein p53 R282G | Tumor Suppressor p53 Arg282Gly | Tumor Suppressor p53 R282G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544890","CDKN2A Protein Variant","C146926","A variation in the amino acid sequence for a protein encoded by the CDKN2A gene.","CDKN2A Protein Variant | CDK4I Protein Variant | Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant | Cyclin-Dependent Kinase Inhibitor 2A Protein Variant | Cyclin-Dependent Kinase Inhibitor p16 Protein Variant | p16(INK4a) Protein Variant | p16-INK4 Protein Variant | p16INK4A Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544892","CDKN2A NP_000068.1:p.A30V","C146928","A change in the amino acid residue at position 30 in the cyclin-dependent kinase inhibitor 2 protein where alanine has been replaced by valine.","CDKN2A NP_000068.1:p.A30V | CDK4I Protein Variant A30V | CDK4I Protein Variant Ala30Val | CDKN2A A30V | CDKN2A Ala30Val | CDKN2A NP_000068.1:p.Ala30Val | CDKN2A p.A30V | CDKN2A p.Ala30Val | Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant A30V | Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant Ala30Val | Cyclin-Dependent Kinase Inhibitor 2A Protein Variant A30V | Cyclin-Dependent Kinase Inhibitor 2A Protein Variant Ala30Val | Cyclin-Dependent Kinase Inhibitor p16 Protein Variant A30V | Cyclin-Dependent Kinase Inhibitor p16 Protein Variant Ala30Val | NP_000068.1:p.A30V | NP_000068.1:p.Ala30Val | p16(INK4a) Protein Variant A30V | p16(INK4a) Protein Variant Ala30Val | p16-INK4 Protein Variant A30V | p16-INK4 Protein Variant Ala30Val | p16INK4A Protein Variant A30V | p16INK4A Protein Variant Ala30Val",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544878","CDKN2A NP_000068.1:p.V51D","C146930","A change in the amino acid residue at position 51 in the cyclin-dependent kinase inhibitor 2 protein where valine has been replaced by aspartic acid.","CDKN2A NP_000068.1:p.V51D | CDK4I Protein Variant V51D | CDK4I Protein Variant Val51Asp | CDKN2A NP_000068.1:p.Val51Asp | CDKN2A V51D | CDKN2A Val51Asp | CDKN2A p.V51D | CDKN2A p.Val51Asp | Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant V51D | Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant Val51Asp | Cyclin-Dependent Kinase Inhibitor 2A Protein Variant V51D | Cyclin-Dependent Kinase Inhibitor 2A Protein Variant Val51Asp | Cyclin-Dependent Kinase Inhibitor p16 Protein Variant V51D | Cyclin-Dependent Kinase Inhibitor p16 Protein Variant Val51Asp | NP_000068.1:p.V51D | NP_000068.1:p.Val51Asp | p16(INK4a) Protein Variant V51D | p16(INK4a) Protein Variant Val51Asp | p16-INK4 Protein Variant V51D | p16-INK4 Protein Variant Val51Asp | p16INK4A Protein Variant V51D | p16INK4A Protein Variant Val51Asp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544880","CDKN2A NP_000068.1:p.V51I","C146932","A change in the amino acid residue at position 51 in the cyclin-dependent kinase inhibitor 2 protein where valine has been replaced by isoleucine.","CDKN2A NP_000068.1:p.V51I | CDK4I Protein Variant V51I | CDK4I Protein Variant Val51Ile | CDKN2A NP_000068.1:p.Val51Ile | CDKN2A V51I | CDKN2A Val51Ile | CDKN2A p.V51I | CDKN2A p.Val51Ile | Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant V51I | Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant Val51Ile | Cyclin-Dependent Kinase Inhibitor 2A Protein Variant V51I | Cyclin-Dependent Kinase Inhibitor 2A Protein Variant Val51Ile | Cyclin-Dependent Kinase Inhibitor p16 Protein Variant V51I | Cyclin-Dependent Kinase Inhibitor p16 Protein Variant Val51Ile | NP_000068.1:p.V51I | NP_000068.1:p.Val51Ile | p16(INK4a) Protein Variant V51I | p16(INK4a) Protein Variant Val51Ile | p16-INK4 Protein Variant V51I | p16-INK4 Protein Variant Val51Ile | p16INK4A Protein Variant V51I | p16INK4A Protein Variant Val51Ile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544882","CDKN2A NP_000068.1:p.H83Y","C146934","A change in the amino acid residue at position 83 in the cyclin-dependent kinase inhibitor 2 protein where histidine has been replaced by tyrosine.","CDKN2A NP_000068.1:p.H83Y | CDK4I Protein Variant H83Y | CDK4I Protein Variant His83Tyr | CDKN2A H83Y | CDKN2A His83Tyr | CDKN2A NP_000068.1:p.His83Tyr | CDKN2A p.H83Y | CDKN2A p.His83Tyr | Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant H83Y | Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant His83Tyr | Cyclin-Dependent Kinase Inhibitor 2A Protein Variant H83Y | Cyclin-Dependent Kinase Inhibitor 2A Protein Variant His83Tyr | Cyclin-Dependent Kinase Inhibitor p16 Protein Variant H83Y | Cyclin-Dependent Kinase Inhibitor p16 Protein Variant His83Tyr | NP_000068.1:p.H83Y | NP_000068.1:p.His83Tyr | p16(INK4a) Protein Variant H83Y | p16(INK4a) Protein Variant His83Tyr | p16-INK4 Protein Variant H83Y | p16-INK4 Protein Variant His83Tyr | p16INK4A Protein Variant H83Y | p16INK4A Protein Variant His83Tyr",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544870","CDKN2A NP_000068.1:p.H83P","C146938","A change in the amino acid residue at position 83 in the cyclin-dependent kinase inhibitor 2 protein where histidine has been replaced by proline.","CDKN2A NP_000068.1:p.H83P | CDK4I Protein Variant H83P | CDK4I Protein Variant His83Pro | CDKN2A H83P | CDKN2A His83Pro | CDKN2A NP_000068.1:p.His83Pro | CDKN2A p.H83P | CDKN2A p.His83Pro | Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant H83P | Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant His83Pro | Cyclin-Dependent Kinase Inhibitor 2A Protein Variant H83P | Cyclin-Dependent Kinase Inhibitor 2A Protein Variant His83Pro | Cyclin-Dependent Kinase Inhibitor p16 Protein Variant H83P | Cyclin-Dependent Kinase Inhibitor p16 Protein Variant His83Pro | NP_000068.1:p.H83P | NP_000068.1:p.His83Pro | p16(INK4a) Protein Variant H83P | p16(INK4a) Protein Variant His83Pro | p16-INK4 Protein Variant H83P | p16-INK4 Protein Variant His83Pro | p16INK4A Protein Variant H83P | p16INK4A Protein Variant His83Pro",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544874","CDKN2A NP_000068.1:p.D108H","C146942","A change in the amino acid residue at position 108 in the cyclin-dependent kinase inhibitor 2 protein where aspartic acid has been replaced by histidine.","CDKN2A NP_000068.1:p.D108H | CDK4I Protein Variant Asp108His | CDK4I Protein Variant D108H | CDKN2A Asp108His | CDKN2A D108H | CDKN2A NP_000068.1:p.Asp108His | CDKN2A p.Asp108His | CDKN2A p.D108H | Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant Asp108His | Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant D108H | Cyclin-Dependent Kinase Inhibitor 2A Protein Variant Asp108His | Cyclin-Dependent Kinase Inhibitor 2A Protein Variant D108H | Cyclin-Dependent Kinase Inhibitor p16 Protein Variant Asp108His | Cyclin-Dependent Kinase Inhibitor p16 Protein Variant D108H | NP_000068.1:p.Asp108His | NP_000068.1:p.D108H | p16(INK4a) Protein Variant Asp108His | p16(INK4a) Protein Variant D108H | p16-INK4 Protein Variant Asp108His | p16-INK4 Protein Variant D108H | p16INK4A Protein Variant Asp108His | p16INK4A Protein Variant D108H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544876","CDKN2A NP_000068.1:p.D108Y","C146944","A change in the amino acid residue at position 108 in the cyclin-dependent kinase inhibitor 2 protein where aspartic acid has been replaced by tyrosine.","CDKN2A NP_000068.1:p.D108Y | CDK4I Protein Variant Asp108Tyr | CDK4I Protein Variant D108Y | CDKN2A Asp108Tyr | CDKN2A D108Y | CDKN2A NP_000068.1:p.Asp108Tyr | CDKN2A p.Asp108Tyr | CDKN2A p.D108Y | Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant Asp108Tyr | Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant D108Y | Cyclin-Dependent Kinase Inhibitor 2A Protein Variant Asp108Tyr | Cyclin-Dependent Kinase Inhibitor 2A Protein Variant D108Y | Cyclin-Dependent Kinase Inhibitor p16 Protein Variant Asp108Tyr | Cyclin-Dependent Kinase Inhibitor p16 Protein Variant D108Y | NP_000068.1:p.Asp108Tyr | NP_000068.1:p.D108Y | p16(INK4a) Protein Variant Asp108Tyr | p16(INK4a) Protein Variant D108Y | p16-INK4 Protein Variant Asp108Tyr | p16-INK4 Protein Variant D108Y | p16INK4A Protein Variant Asp108Tyr | p16INK4A Protein Variant D108Y",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544981","CDKN2A NP_000068.1:p.L130Q","C146946","A change in the amino acid residue at position 130 in the cyclin-dependent kinase inhibitor 2 protein where leucine has been replaced by glutamine.","CDKN2A NP_000068.1:p.L130Q | CDK4I Protein Variant L130Q | CDK4I Protein Variant Leu130Gln | CDKN2A L130Q | CDKN2A Leu130Gln | CDKN2A NP_000068.1:p.Leu130Gln | CDKN2A p.L130Q | CDKN2A p.Leu130Gln | Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant L130Q | Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant Leu130Gln | Cyclin-Dependent Kinase Inhibitor 2A Protein Variant L130Q | Cyclin-Dependent Kinase Inhibitor 2A Protein Variant Leu130Gln | Cyclin-Dependent Kinase Inhibitor p16 Protein Variant L130Q | Cyclin-Dependent Kinase Inhibitor p16 Protein Variant Leu130Gln | NP_000068.1:p.L130Q | NP_000068.1:p.Leu130Gln | p16(INK4a) Protein Variant L130Q | p16(INK4a) Protein Variant Leu130Gln | p16-INK4 Protein Variant L130Q | p16-INK4 Protein Variant Leu130Gln | p16INK4A Protein Variant L130Q | p16INK4A Protein Variant Leu130Gln",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544983","CDKN2A NP_000068.1:p.A147T","C146948","A change in the amino acid residue at position 147 in the cyclin-dependent kinase inhibitor 2 protein where alanine has been replaced by threonine.","CDKN2A NP_000068.1:p.A147T | CDK4I Protein Variant A147T | CDK4I Protein Variant Ala147Thr | CDKN2A A147T | CDKN2A Ala147Thr | CDKN2A NP_000068.1:p.Ala147Thr | CDKN2A p.A147T | CDKN2A p.Ala147Thr | Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant A147T | Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant Ala147Thr | Cyclin-Dependent Kinase Inhibitor 2A Protein Variant A147T | Cyclin-Dependent Kinase Inhibitor 2A Protein Variant Ala147Thr | Cyclin-Dependent Kinase Inhibitor p16 Protein Variant A147T | Cyclin-Dependent Kinase Inhibitor p16 Protein Variant Ala147Thr | NP_000068.1:p.A147T | NP_000068.1:p.Ala147Thr | p16(INK4a) Protein Variant A147T | p16(INK4a) Protein Variant Ala147Thr | p16-INK4 Protein Variant A147T | p16-INK4 Protein Variant Ala147Thr | p16INK4A Protein Variant A147T | p16INK4A Protein Variant Ala147Thr",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544985","CDKN2A NP_000068.1:p.A148T","C146950","A change in the amino acid residue at position 148 in the cyclin-dependent kinase inhibitor 2 protein where alanine has been replaced by threonine.","CDKN2A NP_000068.1:p.A148T | CDK4I Protein Variant A148T | CDK4I Protein Variant Ala148Thr | CDKN2A A148T | CDKN2A Ala148Thr | CDKN2A NP_000068.1:p.Ala148Thr | CDKN2A p.A148T | CDKN2A p.Ala148Thr | Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant A148T | Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant Ala148Thr | Cyclin-Dependent Kinase Inhibitor 2A Protein Variant A148T | Cyclin-Dependent Kinase Inhibitor 2A Protein Variant Ala148Thr | Cyclin-Dependent Kinase Inhibitor p16 Protein Variant A148T | Cyclin-Dependent Kinase Inhibitor p16 Protein Variant Ala148Thr | NP_000068.1:p.A148T | NP_000068.1:p.Ala148Thr | p16(INK4a) Protein Variant A148T | p16(INK4a) Protein Variant Ala148Thr | p16-INK4 Protein Variant A148T | p16-INK4 Protein Variant Ala148Thr | p16INK4A Protein Variant A148T | p16INK4A Protein Variant Ala148Thr",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544986","GNAS Protein Variant","C146951","A variation in the amino acid sequence for a protein encoded by the GNAS gene.","GNAS Protein Variant | GNAS Complex Locus Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544973","GNAS NP_000507.1:p.Q125R","C146954","A change in the amino acid residue at position 125 in the guanine nucleotide-binding protein G(s) subunit alpha isoforms short protein where glutamine has been replaced by arginine.","GNAS NP_000507.1:p.Q125R | Adenylate Cyclase-Stimulating G Alpha Protein Gln125Arg | Adenylate Cyclase-Stimulating G Alpha Protein Q125R | GNAS Gln125Arg | GNAS NP_000507.1:p.Gln125Arg | GNAS Q125R | GNAS p.Gln125Arg | GNAS p.Q125R | Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short Gln125Arg | Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short Q125R | NP_000507.1:p.Gln125Arg | NP_000507.1:p.Q125R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544975","GNAS NP_000507.1:p.R160C","C146956","A change in the amino acid residue at position 160 in the guanine nucleotide-binding protein G(s) subunit alpha isoforms short protein where arginine has been replaced by cysteine.","GNAS NP_000507.1:p.R160C | Adenylate Cyclase-Stimulating G Alpha Protein Arg160Cys | Adenylate Cyclase-Stimulating G Alpha Protein R160C | GNAS Arg160Cys | GNAS NP_000507.1:p.Arg160Cys | GNAS R160C | GNAS p.Arg160Cys | GNAS p.R160C | Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short Arg160Cys | Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short R160C | NP_000507.1:p.Arg160Cys | NP_000507.1:p.R160C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544977","GNAS NP_000507.1:p.R201H","C146958","A change in the amino acid residue at position 201 in the guanine nucleotide-binding protein G(s) subunit alpha isoforms short protein where arginine has been replaced by histidine.","GNAS NP_000507.1:p.R201H | Adenylate Cyclase-Stimulating G Alpha Protein Arg201His | Adenylate Cyclase-Stimulating G Alpha Protein R201H | GNAS Arg201His | GNAS NP_000507.1:p.Arg201His | GNAS R201H | GNAS p.Arg201His | GNAS p.R201H | Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short Arg201His | Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short R201H | NP_000507.1:p.Arg201His | NP_000507.1:p.R201H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544979","GNAS NP_000507.1:p.R201C","C146960","A change in the amino acid residue at position 201 in the guanine nucleotide-binding protein G(s) subunit alpha isoforms short protein where arginine has been replaced by cysteine.","GNAS NP_000507.1:p.R201C | Adenylate Cyclase-Stimulating G Alpha Protein Arg201Cys | Adenylate Cyclase-Stimulating G Alpha Protein R201C | GNAS Arg201Cys | GNAS NP_000507.1:p.Arg201Cys | GNAS R201C | GNAS p.Arg201Cys | GNAS p.R201C | Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short Arg201Cys | Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short R201C | NP_000507.1:p.Arg201Cys | NP_000507.1:p.R201C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544965","GNAS NP_000507.1:p.R201S","C146962","A change in the amino acid residue at position 201 in the guanine nucleotide-binding protein G(s) subunit alpha isoforms short protein where arginine has been replaced by serine.","GNAS NP_000507.1:p.R201S | Adenylate Cyclase-Stimulating G Alpha Protein Arg201Ser | Adenylate Cyclase-Stimulating G Alpha Protein R201S | GNAS Arg201Ser | GNAS NP_000507.1:p.Arg201Ser | GNAS R201S | GNAS p.Arg201Ser | GNAS p.R201S | Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short Arg201Ser | Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short R201S | NP_000507.1:p.Arg201Ser | NP_000507.1:p.R201S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544967","GNAS NP_000507.1:p.Q227R","C146964","A change in the amino acid residue at position 227 in the guanine nucleotide-binding protein G(s) subunit alpha isoforms short protein where glutamine has been replaced by arginine.","GNAS NP_000507.1:p.Q227R | Adenylate Cyclase-Stimulating G Alpha Protein Gln227Arg | Adenylate Cyclase-Stimulating G Alpha Protein Q227R | GNAS Gln227Arg | GNAS NP_000507.1:p.Gln227Arg | GNAS Q227R | GNAS p.Gln227Arg | GNAS p.Q227R | Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short Gln227Arg | Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short Q227R | NP_000507.1:p.Gln227Arg | NP_000507.1:p.Q227R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544969","GNAS NP_000507.1:p.Q227L","C146966","A change in the amino acid residue at position 227 in the guanine nucleotide-binding protein G(s) subunit alpha isoforms short protein where glutamine has been replaced by leucine.","GNAS NP_000507.1:p.Q227L | Adenylate Cyclase-Stimulating G Alpha Protein Gln227Leu | Adenylate Cyclase-Stimulating G Alpha Protein Q227L | GNAS Gln227Leu | GNAS NP_000507.1:p.Gln227Leu | GNAS Q227L | GNAS p.Gln227Leu | GNAS p.Q227L | Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short Gln227Leu | Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short Q227L | NP_000507.1:p.Gln227Leu | NP_000507.1:p.Q227L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544970","GNAS NP_000507.1:p.Q227P","C146967","A change in the amino acid residue at position 227 in the guanine nucleotide-binding protein G(s) subunit alpha isoforms short protein where glutamine has been replaced by proline.","GNAS NP_000507.1:p.Q227P | Adenylate Cyclase-Stimulating G Alpha Protein Gln227Pro | Adenylate Cyclase-Stimulating G Alpha Protein Q227P | GNAS Gln227Pro | GNAS NP_000507.1:p.Gln227Pro | GNAS Q227P | GNAS p.Gln227Pro | GNAS p.Q227P | Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short Gln227Pro | Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short Q227P | NP_000507.1:p.Gln227Pro | NP_000507.1:p.Q227P",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544972","GNAS NP_000507.1:p.Q227E","C146969","A change in the amino acid residue at position 227 in the guanine nucleotide-binding protein G(s) subunit alpha isoforms short protein where glutamine has been replaced by glutamic acid.","GNAS NP_000507.1:p.Q227E | Adenylate Cyclase-Stimulating G Alpha Protein Gln227Glu | Adenylate Cyclase-Stimulating G Alpha Protein Q227E | GNAS Gln227Glu | GNAS NP_000507.1:p.Gln227Glu | GNAS Q227E | GNAS p.Gln227Glu | GNAS p.Q227E | Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short Gln227Glu | Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short Q227E | NP_000507.1:p.Gln227Glu | NP_000507.1:p.Q227E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544957","RNF43 Protein Variant","C146971","A variation in the amino acid sequence for E3 ubiquitin-protein ligase RNF43.","RNF43 Protein Variant | E3 Ubiquitin-Protein Ligase RNF43 Protein Variant | RING Finger Protein 124 Protein Variant | RING-Type E3 Ubiquitin Transferase RNF43 Protein Variant | Ring Finger Protein 43 Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544959","RNF43 NP_060233.3:p.R127P","C146973","A change in the amino acid residue at position 127 in the E3 ubiquitin-protein ligase RNF43 protein where arginine has been replaced by proline.","RNF43 NP_060233.3:p.R127P | E3 Ubiquitin-Protein Ligase RNF43 Protein Variant Arg127Pro | E3 Ubiquitin-Protein Ligase RNF43 Protein Variant R127P | NP_060233.3:p.Arg127Pro | NP_060233.3:p.R127P | RING Finger Protein 124 Protein Variant Arg127Pro | RING Finger Protein 124 Protein Variant R127P | RING-Type E3 Ubiquitin Transferase RNF43 Protein Variant Arg127Pro | RING-Type E3 Ubiquitin Transferase RNF43 Protein Variant R127P | RNF43 Arg127Pro | RNF43 NP_060233.3:p.Arg127Pro | RNF43 R127P | RNF43 p.Arg127Pro | RNF43 p.R127P | Ring Finger Protein 43 Protein Variant Arg127Pro | Ring Finger Protein 43 Protein Variant R127P",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544961","RNF43 NP_060233.3:p.D140E","C146975","A change in the amino acid residue at position 140 in the E3 ubiquitin-protein ligase RNF43 protein where aspartic acid has been replaced by glutamic acid.","RNF43 NP_060233.3:p.D140E | E3 Ubiquitin-Protein Ligase RNF43 Protein Variant Asp140Glu | E3 Ubiquitin-Protein Ligase RNF43 Protein Variant D140E | NP_060233.3:p.Asp140Glu | NP_060233.3:p.D140E | RING Finger Protein 124 Protein Variant Asp140Glu | RING Finger Protein 124 Protein Variant D140E | RING-Type E3 Ubiquitin Transferase RNF43 Protein Variant Asp140Glu | RING-Type E3 Ubiquitin Transferase RNF43 Protein Variant D140E | RNF43 Asp140Glu | RNF43 D140E | RNF43 NP_060233.3:p.Asp140Glu | RNF43 p.Asp140Glu | RNF43 p.D140E | Ring Finger Protein 43 Protein Variant Asp140Glu | Ring Finger Protein 43 Protein Variant D140E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544963","RNF43 NP_060233.3:p.P154L","C146977","A change in the amino acid residue at position 154 in the E3 ubiquitin-protein ligase RNF43 protein where proline has been replaced by leucine.","RNF43 NP_060233.3:p.P154L | E3 Ubiquitin-Protein Ligase RNF43 Protein Variant P154L | E3 Ubiquitin-Protein Ligase RNF43 Protein Variant Pro154Leu | NP_060233.3:p.P154L | NP_060233.3:p.Pro154Leu | RING Finger Protein 124 Protein Variant P154L | RING Finger Protein 124 Protein Variant Pro154Leu | RING-Type E3 Ubiquitin Transferase RNF43 Protein Variant P154L | RING-Type E3 Ubiquitin Transferase RNF43 Protein Variant Pro154Leu | RNF43 NP_060233.3:p.Pro154Leu | RNF43 P154L | RNF43 Pro154Leu | RNF43 p.P154L | RNF43 p.Pro154Leu | Ring Finger Protein 43 Protein Variant P154L | Ring Finger Protein 43 Protein Variant Pro154Leu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544949","RNF43 NP_060233.3:p.A169T","C146979","A change in the amino acid residue at position 169 in the E3 ubiquitin-protein ligase RNF43 protein where alanine has been replaced by threonine.","RNF43 NP_060233.3:p.A169T | E3 Ubiquitin-Protein Ligase RNF43 Protein Variant A169T | E3 Ubiquitin-Protein Ligase RNF43 Protein Variant Ala169Thr | NP_060233.3:p.A169T | NP_060233.3:p.Ala169Thr | RING Finger Protein 124 Protein Variant A169T | RING Finger Protein 124 Protein Variant Ala169Thr | RING-Type E3 Ubiquitin Transferase RNF43 Protein Variant A169T | RING-Type E3 Ubiquitin Transferase RNF43 Protein Variant Ala169Thr | RNF43 A169T | RNF43 Ala169Thr | RNF43 NP_060233.3:p.Ala169Thr | RNF43 p.A169T | RNF43 p.Ala169Thr | Ring Finger Protein 43 Protein Variant A169T | Ring Finger Protein 43 Protein Variant Ala169Thr",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544951","RNF43 NP_060233.3:p.E318D","C146981","A change in the amino acid residue at position 318 in the E3 ubiquitin-protein ligase RNF43 protein where glutamic acid has been replaced by aspartic acid.","RNF43 NP_060233.3:p.E318D | E3 Ubiquitin-Protein Ligase RNF43 Protein Variant E318D | E3 Ubiquitin-Protein Ligase RNF43 Protein Variant Glu318Asp | NP_060233.3:p.E318D | NP_060233.3:p.Glu318Asp | RING Finger Protein 124 Protein Variant E318D | RING Finger Protein 124 Protein Variant Glu318Asp | RING-Type E3 Ubiquitin Transferase RNF43 Protein Variant E318D | RING-Type E3 Ubiquitin Transferase RNF43 Protein Variant Glu318Asp | RNF43 E318D | RNF43 Glu318Asp | RNF43 NP_060233.3:p.Glu318Asp | RNF43 p.E318D | RNF43 p.Glu318Asp | Ring Finger Protein 43 Protein Variant E318D | Ring Finger Protein 43 Protein Variant Glu318Asp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544952","PIK3CA Exon 9 Mutation","C146982","A change in the nucleotide sequence of exon 9 of the PIK3CA gene.","PIK3CA Exon 9 Mutation | PI3K-Alpha Exon 9 Mutation | PI3KCA Exon 9 Mutation | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Exon 9 Mutation | p110-alpha Exon 9 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544953","PIK3CA Exon 20 Mutation","C146983","A change in the nucleotide sequence of exon 20 of the PIK3CA gene.","PIK3CA Exon 20 Mutation | PI3K-Alpha Exon 20 Mutation | PI3KCA Exon 20 Mutation | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Exon 20 Mutation | p110-alpha Exon 20 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544956","PTEN Coding Region Mutation Present","C146986","A genetic finding indicating that a sample has one or more exon mutations in the PTEN gene.","PTEN Coding Region Mutation Present | MMAC1 Coding Region Mutation Present | Mutated in Multiple Advanced Cancers 1 Gene Coding Region Mutation Present | PTEN Exon 1-9 Mutation Present | PTEN Exon Mutation Present | PTEN Gene Mutation in Exon | PTEN1 Coding Region Mutation Present | Phosphatase and Tensin Homolog Gene Coding Region Mutation Present | TEP1 Coding Region Mutation Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3850007","Fluorine-19 Magnetic Resonance Imaging","C146991","Magnetic resonance imaging that uses a probe labeled with 19F. MR sensitivity of 19F is relatively high and no fluorine atoms exist in biological tissues, resulting in low endogenous background noise.","Fluorine-19 Magnetic Resonance Imaging | 19F-MRI | Fluorine-19 MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544940","Worst Nausea Past 24 Hours Rating","C147000","A question about the rating of an individual's nausea during the last 24 hours.","Worst Nausea Past 24 Hours Rating | Please rate your worst nausea over the past 24 hours | Worst Nausea Last 24 Hours Rating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544941","Undesirable Sedation Troubles Past 24 Hours Rating","C147001","A question about the rating of an individual's undesirable sedation troubles during the last 24 hours.","Undesirable Sedation Troubles Past 24 Hours Rating | Please rate any undesired sedation trouble that you had over the past 24 hours | Undesirable Sedation Troubles Last 24 Hours Rating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544942","Undesirable Appetite Increase Past 24 Hours Rating","C147002","A question about the rating of an individual's undesirable appetite increase during the last 24 hours.","Undesirable Appetite Increase Past 24 Hours Rating | Please rate any undesired appetite increase that you had over the past 24 hours | Undesirable Appetite Increase Last 24 Hours Rating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273955","BRAF Protein Variant","C98307","A variation in the amino acid sequence for the serine/threonine-protein kinase B-raf protein.","BRAF Protein Variant | Serine/Threonine-Protein Kinase B-raf Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554697","Lung Non-Mucinous Adenocarcinoma In Situ","C136716","Lung adenocarcinoma in situ characterized by the presence of type II pneumocyte and/or Clara cell differentiation. Almost all cases of lung adenocarcinoma in situ are non-mucinous.","Lung Non-Mucinous Adenocarcinoma In Situ | Non-Mucinous Lung Adenocarcinoma In Situ",,,,,,,,,,,,,,,"37312138","Non-mucinous adenocarcinoma in situ of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554698","Lung Mucinous Adenocarcinoma In Situ","C136717","A very rare lung adenocarcinoma in situ variant characterized by the presence of tall columnar cells with basal nuclei and abundant cytoplasmic mucin.","Lung Mucinous Adenocarcinoma In Situ | Mucinous Lung Adenocarcinoma In Situ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524514","Lung Enteric Adenocarcinoma","C136710","A well-differentiated adenocarcinoma located in the lung periphery. It resembles colorectal adenocarcinoma with acinar and/or cribriform architecture and papillotubular structures.","Lung Enteric Adenocarcinoma | Enteric adenocarcinoma | Pulmonary Intestinal-Type Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545032","Baseline Nausea and Vomiting Scale","C147033","A scale for the subjective scoring of nausea that ranges from 0: No nausea at all to 10: Nausea as bad as it can be.","Baseline Nausea and Vomiting Scale | Nausea Scale | Nausea and Vomiting Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545031","Baseline Nausea and Vomiting Score 0","C147032","A subjective score of 0 on a scale that ranges from 0: No nausea at all to 10: Nausea as bad as it can be.","Baseline Nausea and Vomiting Score 0 | Nausea Score 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545033","Baseline Nausea and Vomiting Score 1","C147034","A subjective score of 1 on a scale that ranges from 0: No nausea at all to 10: Nausea as bad as it can be.","Baseline Nausea and Vomiting Score 1 | Nausea Score 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545034","Baseline Nausea and Vomiting Score 2","C147035","A subjective score of 2 on a scale that ranges from 0: No nausea at all to 10: Nausea as bad as it can be.","Baseline Nausea and Vomiting Score 2 | Nausea Score 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545019","Baseline Nausea and Vomiting Score 3","C147036","A subjective score of 3 on a scale that ranges from 0: No nausea at all to 10: Nausea as bad as it can be.","Baseline Nausea and Vomiting Score 3 | Nausea Score 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545020","Baseline Nausea and Vomiting Score 4","C147037","A subjective score of 4 on a scale that ranges from 0: No nausea at all to 10: Nausea as bad as it can be.","Baseline Nausea and Vomiting Score 4 | Nausea Score 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545021","Baseline Nausea and Vomiting Score 5","C147038","A subjective score of 5 on a scale that ranges from 0: No nausea at all to 10: Nausea as bad as it can be.","Baseline Nausea and Vomiting Score 5 | Nausea Score 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545022","Baseline Nausea and Vomiting Score 6","C147039","A subjective score of 6 on a scale that ranges from 0: No nausea at all to 10: Nausea as bad as it can be.","Baseline Nausea and Vomiting Score 6 | Nausea Score 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545023","Baseline Nausea and Vomiting Score 7","C147040","A subjective score of 7 on a scale that ranges from 0: No nausea at all to 10: Nausea as bad as it can be.","Baseline Nausea and Vomiting Score 7 | Nausea Score 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545024","Baseline Nausea and Vomiting Score 8","C147041","A subjective score of 8 on a scale that ranges from 0: No nausea at all to 10: Nausea as bad as it can be.","Baseline Nausea and Vomiting Score 8 | Nausea Score 8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545025","Baseline Nausea and Vomiting Score 9","C147042","A subjective score of 9 on a scale that ranges from 0: No nausea at all to 10: Nausea as bad as it can be.","Baseline Nausea and Vomiting Score 9 | Nausea Score 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545026","Baseline Nausea and Vomiting Score 10","C147043","A subjective score of 10 on a scale that ranges from 0: No nausea at all to 10: Nausea as bad as it can be.","Baseline Nausea and Vomiting Score 10 | Nausea Score 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1524035","Cytology Specimen Collection Procedure","C38113","Procedures for the collection and/or preparation of biological specimens for light microscopy examination.","Cytology Specimen Collection Procedure | Cytologic Sampling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521691","Anal Cancer TNM Finding v8","C133762","A finding about one or more characteristics of anal cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to all carcinomas arising in the anal canal, including carcinomas that arise within anorectal fistulas and those arising in the perianal area (anal margin). High-grade neuroendocrine carcinomas (small cell neuroendocrine carcinoma and large cell neuroendocrine carcinoma) are staged using this system. There is no AJCC staging system for anal mucosal melanomas and anal well-differentiated neuroendocrine tumors. (from AJCC 8th Ed.)","Anal Cancer TNM Finding v8 | Anal Canal and Perianal (Anal Margin) Carcinoma TNM Finding v8 | Anal Carcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521707","Anal Cancer pT4 TNM Finding v8","C133778","Anal cancer with tumor of any size invading adjacent organ(s), such as the vagina, urethra, or bladder. (from AJCC 8th Ed.)","Anal Cancer pT4 TNM Finding v8 | Anal Canal and Perianal (Anal Margin) Carcinoma pT4 TNM Finding v8 | Anal Carcinoma pT4 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521705","Anal Cancer pT3 TNM Finding v8","C133776","Anal cancer with tumor larger than 5 cm. (from AJCC 8th Ed.)","Anal Cancer pT3 TNM Finding v8 | Anal Canal and Perianal (Anal Margin) Carcinoma pT3 TNM Finding v8 | Anal Carcinoma pT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521704","Anal Cancer pT2 TNM Finding v8","C133775","Anal cancer with tumor larger than 2 cm but equal to or smaller than 5 cm. (from AJCC 8th Ed.)","Anal Cancer pT2 TNM Finding v8 | Anal Canal and Perianal (Anal Margin) Carcinoma pT2 TNM Finding v8 | Anal Carcinoma pT2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521703","Anal Cancer pT1 TNM Finding v8","C133774","Anal cancer with tumor 2 cm or smaller. (from AJCC 8th Ed.)","Anal Cancer pT1 TNM Finding v8 | Anal Canal and Perianal (Anal Margin) Carcinoma pT1 TNM Finding v8 | Anal Carcinoma pT1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521702","Anal Cancer pTis TNM Finding v8","C133773","Anal cancer with a finding of high-grade squamous intraepithelial lesion (previously termed carcinoma in situ, Bowen disease, anal intraepithelial neoplasia II-III, high-grade anal intraepithelial neoplasia). (from AJCC 8th Ed.)","Anal Cancer pTis TNM Finding v8 | Anal Canal and Perianal (Anal Margin) Carcinoma pTis TNM Finding v8 | Anal Carcinoma pTis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521701","Anal Cancer pT0 TNM Finding v8","C133772","Anal cancer with no evidence of primary tumor. (from AJCC 8th Ed.)","Anal Cancer pT0 TNM Finding v8 | Anal Canal and Perianal (Anal Margin) Carcinoma pT0 TNM Finding v8 | Anal Carcinoma pT0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521700","Anal Cancer pTX TNM Finding v8","C133771","Anal cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Anal Cancer pTX TNM Finding v8 | Anal Canal and Perianal (Anal Margin) Carcinoma pTX TNM Finding v8 | Anal Carcinoma pTX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521714","Anal Cancer pN1c TNM Finding v8","C133785","Anal cancer with metastasis in external iliac with any N1a nodes. (from AJCC 8th Ed.)","Anal Cancer pN1c TNM Finding v8 | Anal Canal and Perianal (Anal Margin) Carcinoma pN1c TNM Finding v8 | Anal Carcinoma pN1c TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521713","Anal Cancer pN1b TNM Finding v8","C133784","Anal cancer with metastasis in external iliac lymph nodes. (from AJCC 8th Ed.)","Anal Cancer pN1b TNM Finding v8 | Anal Canal and Perianal (Anal Margin) Carcinoma pN1b TNM Finding v8 | Anal Carcinoma pN1b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521712","Anal Cancer pN1a TNM Finding v8","C133783","Anal cancer with metastasis in inguinal, mesorectal, or internal iliac lymph nodes. (from AJCC 8th Ed.)","Anal Cancer pN1a TNM Finding v8 | Anal Canal and Perianal (Anal Margin) Carcinoma pN1a TNM Finding v8 | Anal Carcinoma pN1a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521711","Anal Cancer pN1 TNM Finding v8","C133782","Anal cancer with metastasis in inguinal, mesorectal, internal iliac, or external iliac nodes. (from AJCC 8th Ed.)","Anal Cancer pN1 TNM Finding v8 | Anal Canal and Perianal (Anal Margin) Carcinoma pN1 TNM Finding v8 | Anal Carcinoma pN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521710","Anal Cancer pN0 TNM Finding v8","C133781","Anal cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","Anal Cancer pN0 TNM Finding v8 | Anal Canal and Perianal (Anal Margin) Carcinoma pN0 TNM Finding v8 | Anal Carcinoma pN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521709","Anal Cancer pNX TNM Finding v8","C133780","Anal cancer in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)","Anal Cancer pNX TNM Finding v8 | Anal Canal and Perianal (Anal Margin) Carcinoma pNX TNM Finding v8 | Anal Carcinoma pNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521698","Anal Cancer pM1 TNM Finding v8","C133769","Anal cancer with distant metastasis. (from AJCC 8th Ed.)","Anal Cancer pM1 TNM Finding v8 | Anal Canal and Perianal (Anal Margin) Carcinoma pM1 TNM Finding v8 | Anal Carcinoma pM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521695","Anal Cancer cM1 TNM Finding v8","C133766","Anal cancer with distant metastasis. (from AJCC 8th Ed.)","Anal Cancer cM1 TNM Finding v8 | Anal Canal and Perianal (Anal Margin) Carcinoma cM1 TNM Finding v8 | Anal Carcinoma cM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521694","Anal Cancer cM0 TNM Finding v8","C133765","Anal cancer without evidence of distant metastasis. (from AJCC 8th Ed.)","Anal Cancer cM0 TNM Finding v8 | Anal Canal and Perianal (Anal Margin) Carcinoma cM0 TNM Finding v8 | Anal Carcinoma cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523788","Stage IA3","C136485","A stage term referring to invasive lung cancer. It includes: T1c, N0, M0. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (adapted from AJCC)","Stage IA3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335981","Small Cell Undifferentiated Hepatoblastoma","C7096","A hepatoblastoma composed exclusively of noncohesive sheets of small undifferentiated cells. Cases showing loss of INI1 nuclear staining should be classified as rhabdoid tumors.","Small Cell Undifferentiated Hepatoblastoma | SCUD HBL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896785","EGFR T790M inhibitor PF-06747775","C120307","An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. Mavelertinib specifically binds to and inhibits EGFR T790M, a secondary acquired resistance mutation, which prevents EGFR-mediated signaling and leads to cell death in EGFR/T790M-expressing tumor cells. Compared to some other EGFR inhibitors, PF-06747775 may have therapeutic benefits in tumors with T790M-mediated drug resistance. This agent shows minimal activity against wild-type EGFR (WT EGFR), and does not cause dose-limiting toxicities that occur during the use of non-selective EGFR inhibitors, which can inhibit WT EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","Mavelertinib | 2-Propenamide, N-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)-3-pyrrolidinyl)- | MAVELERTINIB | PF-06747775",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2352806","Necitumumab","C88281","A fully human IgG1 monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Necitumumab binds to and blocks the ligand binding site of EGFR, thereby preventing the activation and subsequent dimerization of the receptor. This may lead to an inhibition of EGFR-dependent downstream pathways and so inhibition of EGFR-dependent tumor cell proliferation and metastasis.  EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surfaces of various tumor cell types.","Necitumumab | Anti-Epidermal Growth Factor Receptor Monoclonal Antibody IMC-11F8 | IMC 11F8 | IMC-11F8 | IMC11F8 | Immunoglobulin G1, Anti-(Human Epidermal Growth Factor Receptor (Receptor Tyrosine-Protein Kinase ErbB-1, EC 2.7.10.1)); Human Monoclonal IMC-11F8 Gamma1 Heavy Chain (224-214')-Disulfide with Human Monoclonal IMC-11F8 Kappa Light Chain, Dimer (230- 230'':233-233'')-Bisdisulfide | NECITUMUMAB | Portrazza",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333717","GTF2A2 Gene","C20598","This gene is involved in transcriptional initiation.","GTF2A2 Gene | GTF2A2 | General Transcription Factor IIA, 2, 12kDa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555038","Abenaki","C43878","A person having origins in the original Abenaki people.","Abenaki | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555039","Algonquian","C43879","A person having origins in the original Algonquian people.","Algonquian | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337855","Apache","C43880","A person having origins in the original Apache people.","Apache | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555040","Chiricahua","C43881","A person having origins in the original Chiricahua people.","Chiricahua | Chiricahua Apache",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555042","Jicarilla Apache","C43883","A person having origins in the original Jicarilla Apache people.","Jicarilla Apache | Jicarilla Apache | Jicarilla Apache | Jicarilla Apache Nation, New Mexico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555043","Lipan Apache","C43884","A person having origins in the original Lipan Apache people.","Lipan Apache | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555044","Mescalero Apache","C43885","A person having origins in the original Mescalero Apache people.","Mescalero Apache | Mescalero Apache | Mescalero Apache | Mescalero Apache Tribe of the Mescalero Reservation, New Mexico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555045","Oklahoma Apache","C43886","A person having origins in the original Oklahoma Apache people.","Oklahoma Apache | Apache Tribe of Oklahoma | Oklahoma Apache | Oklahoma Apache",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0682104","Arapaho","C43890","A person having origins in the original Arapaho people.","Arapaho | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555049","Northern Arapaho","C43891","A person having origins in the original Northern Arapaho people.","Northern Arapaho | Northern Arapaho | Northern Arapaho | Northern Arapaho Tribe of the Wind River Reservation, Wyoming",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555050","Southern Arapaho","C43892","A person having origins in the original Southern Arapaho people.","Southern Arapaho | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555041","Fort Sill Apache Tribe of Oklahoma","C43882","A person having origins in the original Fort Sill Apache people.","Fort Sill Apache | Fort Sill Apache | Fort Sill Apache | Fort Sill Apache Tribe of Oklahoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555046","Payson Apache","C43887","A person having origins in the original Payson Apache people.","Payson Apache | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555047","San Carlos Apache","C43888","A person having origins in the original San Carlos Apache people.","San Carlos Apache | San Carlos Apache | San Carlos Apache | San Carlos Apache Tribe of the San Carlos Reservation, Arizona",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555048","White Mountain Apache","C43889","A person having origins in the original White Mountain Apache people.","White Mountain Apache | White Mountain Apache | White Mountain Apache | White Mountain Apache Tribe of the Fort Apache Reservation, Arizona",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555052","Arikara","C43894","A person having origins in the original Arikara people.","Arikara | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555053","Assiniboine","C43895","A person having origins in the original Assiniboine people.","Assiniboine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555054","Assiniboine Sioux","C43896","A person having origins in the original Assiniboine Sioux people.","Assiniboine Sioux | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555055","Fort Peck Assiniboine Sioux","C43897","A person having origins in the original Fort Peck Assiniboine Sioux people.","Fort Peck Assiniboine Sioux | Assiniboine and Sioux Tribes of the Fort Peck Indian Reservation, Montana | Fort Peck Assiniboine Sioux | Fort Peck Assiniboine Sioux",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555056","Bannock","C43898","A person having origins in the original Bannock people.","Bannock | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337860","Blackfeet","C43899","A person having origins in the original Blackfeet people.","Blackfeet | Blackfeet | Blackfeet | Blackfeet Tribe of the Blackfeet Indian Reservation of Montana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555057","Brotherton","C43900","A person having origins in the original Brotherton people.","Brotherton | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555058","Burt Lake Band","C43901","A person having origins in the original Burt Lake Band people.","Burt Lake Band | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555059","Caddo","C43902","A person having origins in the original Caddo people.","Caddo | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555060","Oklahoma Cado","C43903","A person having origins in the original Oklahoma Cado people.","Oklahoma Cado | Caddo Nation of Oklahoma | Oklahoma Cado | Oklahoma Cado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555061","Cahuilla","C43904","A person having origins in the original Cahuilla people.","Cahuilla | Cahuilla | Cahuilla | Cahuilla Band of Indians",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555062","Agua Caliente Cahuilla","C43905","A person having origins in the original Agua Caliente Cahuilla people.","Agua Caliente Cahuilla | Agua Caliente Band of Cahuilla Indians of the Agua Caliente Indian Reservation, California | Agua Caliente Cahuilla | Agua Caliente Cahuilla",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555063","Augustine","C43909","A person having origins in the original Augustine people.","Augustine | Augustine | Augustine | Augustine Band of Cahuilla Indians, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555064","Cabazon","C43910","A person having origins in the original Cabazon people.","Cabazon | Cabazon | Cabazon | Cabazon Band of Cahuilla Indians | Cabazon Band of Mission Indians, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555065","Los Coyotes","C43911","A person having origins in the original Los Coyotes people.","Los Coyotes | Los Coyotes | Los Coyotes | Los Coyotes Band of Cahuilla and Cupeno Indians, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555066","Morongo","C43912","A person having origins in the original Morongo people.","Morongo | Morongo | Morongo | Morongo Band of Mission Indians, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555067","Santa Rosa Cahuilla","C43913","A person having origins in the original Santa Rosa Cahuilla people.","Santa Rosa Cahuilla | Santa Rosa Band of Cahuilla Indians, California | Santa Rosa Cahuilla | Santa Rosa Cahuilla",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555068","Torres-Martinez","C43914","A person having origins in the original Torres-Martinez people.","Torres-Martinez | Torres Martinez Desert Cahuilla Indians, California | Torres-Martinez | Torres-Martinez",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555069","California Tribes","C43915","A person having origins in the original California Tribes people.","California Tribes | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555070","Cahto","C44506","A person having origins in the original Cahto people.","Cahto | Cahto | Cahto | Cahto Tribe of the Laytonville Rancheria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555071","Chimariko","C44507","A person having origins in the original Chimariko people.","Chimariko | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555072","Coast Miwok","C44508","A person having origins in the original Coast Miwok people.","Coast Miwok | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555073","Digger","C44509","A person having origins in the original Digger people.","Digger | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555074","Kawaiisu","C44510","A person having origins in the original Kawaiisu people.","Kawaiisu | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555075","Kern River","C44511","A person having origins in the original Kern River people.","Kern River | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555076","Mattole","C44512","A person having origins in the original Mattole people.","Mattole | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555077","Red Wood","C44513","A person having origins in the original Red Wood people.","Red Wood | Red Wood | Red Wood | Redwood Valley or Little River Band of Pomo Indians of the Redwood Valley Rancheria California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555078","Santa Rosa","C44514","A person having origins in the original Santa Rosa people.","Santa Rosa | Santa Rosa | Santa Rosa | Santa Rosa Indian Community of the Santa Rosa Rancheria, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555079","Takelma","C44515","A person having origins in the original Takelma people.","Takelma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555080","Wappo","C44516","A person having origins in the original Wappo people.","Wappo | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555081","Yana","C44517","A person having origins in the original Yana people.","Yana | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555082","Yuki","C44518","A person having origins in the original Yuki people.","Yuki | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555083","Canadian and Latin American Indian","C43916","A person having origins in the original Canadian and Latin American Indian people.","Canadian and Latin American Indian | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555084","Canadian Indian","C44949","A person having origins in the original Canadian Indian people.","Canadian Indian | CANADIAN INDIAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021207","Central American Indians","C44950","A person having origins in the original Central American Indian people.","Central American Indian | CENTRAL AMERICAN INDIAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555085","French American Indian","C44951","A person having origins in the original French American Indian people.","French American Indian | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555086","Mexican American Indian","C44952","A person having origins in the original Mexican American Indian people.","Mexican American Indian | Indigenous Mexican American",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1610165","South American Indian (Original peoples of South American)","C44953","A person having origins in the original South American Indian people.","South American Indian | SOUTH AMERICAN INDIAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555087","Spanish American Indian","C44954","A person having origins in the original Spanish American Indian people.","Spanish American Indian | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL334372","Alatna","C44733","A person having origins in the original Alatna people.","Alatna | Alatna | Alatna | Alatna Village",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0682102","Catawba","C43917","A person having origins in the original Catawba people.","Catawba | Catawba | Catawba | Catawba Indian Nation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551702","Alexander","C44734","A person having origins in the original Alexander people.","Alexander | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551703","Allakaket","C44735","A person having origins in the original Allakaket people.","Allakaket | Allakaket | Allakaket | Allakaket Village",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551704","Alanvik","C44736","A person having origins in the original Alanvik people.","Alanvik | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551705","Anvik","C44737","A person having origins in the original Anvik people.","Anvik | Anvik | Anvik | Anvik Village",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL337306","Arctic","C44738","A person having origins in the original Arctic people.","Arctic | Arctic | Arctic | Arctic Village | Artic Village | Native Village of Venetie",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551707","Beaver","C44739","A person having origins in the original Beaver people.","Beaver | Beaver | Beaver | Beaver Village",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551708","Birch Creek","C44740","A person having origins in the original Birch Creek people.","Birch Creek | Birch Creek | Birch Creek | Birch Creek Tribe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551709","Cantwell","C44741","A person having origins in the original Cantwell people.","Cantwell | Cantwell | Cantwell | Native Village of Cantwell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551710","Chalkyitsik","C44742","A person having origins in the original Chalkyitsik people.","Chalkyitsik | Chalkyitsik | Chalkyitsik | Chalkyitsik Village",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551711","Chickaloon","C44743","A person having origins in the original Chickaloon people.","Chickaloon | Chickaloon | Chickaloon | Chickaloon Native Village",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551712","Chistochina","C44744","A person having origins in the original Chistochina people.","Chistochina | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551714","Circle","C44746","A person having origins in the original Circle Tribe people.","Circle Tribe | Circle | Circle | Circle Native Community | Circle Tribe | Circle Tribe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553351","Other Pacific Islander","C107602","A person having origins in the original peoples of the Pacific Islands, but not Guam, Hawaii, the Mariana Islands or Samoa.","Other Pacific Islander | OTHER PACIFIC ISLANDER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL415133","African American","C128937","Denotes a person of African ancestral origins whose family settled in America.","African American | AFRICAN AMERICAN | Afro American | Afro-American",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347612","Child-Pugh Clinical Classification","C121007","A standardized rating scale used to assess the severity of liver cirrhosis and determine the prognosis, the required strength of treatment, and the necessity of liver transplantation. This instrument uses the following clinical and lab criteria: encephalopathy grade, ascites, bilirubin, albumin, and prothrombin index.","Child-Pugh Clinical Classification | CHILD-PUGH CLASSIFICATION | CPS01 | Child-Pugh | Child-Pugh Classification | Child-Pugh Score | child pugh classification | child_pugh_classification",,,,,,,,,,,,,,,"37016292","Child-Pugh score",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521726","Stage IIIA Anal Cancer AJCC v8","C133801","Stage IIIA includes: (T1, N1, M0); (T2, N1, M0). T1: Tumor 2 cm or smaller. T2: Tumor larger than 2 cm but equal to or smaller than 5 cm. N1: Metastasis in inguinal, mesorectal, internal iliac, or external iliac nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIA Anal Cancer AJCC v8 | Stage IIIA Anal Canal and Perianal (Anal Margin) Carcinoma AJCC v8 | Stage IIIA Anal Cancer | Stage IIIA Anal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545081","Mutant Protein","C147118","A protein with an amino acid sequence that differs from the wildtype, canonical sequence.","Mutant Protein | Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1367597","AFP Gene","C21577","This gene plays a role in fetal progression.","AFP Gene | AFP | Alpha-Fetoprotein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1308086","Glypican-3, Human","C88175","Glypican-3 (580 aa, ~66 kDa) is encoded by the human GPC3 gene. This protein is involved in the mediation of proteoglycan binding to the cell surface.","Glypican-3 | GPC3 | GTR2-2 | Glypican 3 | Glypican Proteoglycan 3 | Intestinal Protein OCI-5 | MXR7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334786","Teratoid Hepatoblastoma","C7098","A mixed epithelial and mesenchymal hepatoblastoma characterized by the presence of heterologous elements. The latter include neuroectoderm, endoderm, or melanin-holding cells. Muscle, cartilage and osteoid may or may not be present.","Teratoid Hepatoblastoma | Mixed Hepatoblastoma with Teratoid Features | Mixed Hepatoblastoma with Teratoid Features",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334784","Mixed Epithelial and Mesenchymal Hepatoblastoma","C7097","A subtype of hepatoblastoma characterized by the presence of epithelial and mesenchymal components.","Mixed Epithelial and Mesenchymal Hepatoblastoma | Hepatoblastoma, mixed epithelial-mesenchymal",,,,,,,,,,,,,,,"37116967","Mixed epithelial-mesenchymal hepatoblastoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333981","Hepatoblastoma with Combined Fetal and Embryonal Epithelial Differentiation","C7094","A hepatoblastoma composed of cells resembling fetal epithelial cells and small round cells resembling blastema cells.","Hepatoblastoma with Combined Fetal and Embryonal Epithelial Differentiation | Hepatoblastoma with Mixed Fetal and Embryonal Epithelial Differentiation | Mixed Embryonal/Fetal Hepatoblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1558210","Intraoperative Injury","C78367","Trauma to the body occurring during a surgical intervention.","Intraoperative Injury | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279690","Releasing Hormone Agonist Therapy","C15489","The use of releasing hormone agonists to bind to specific receptors and ultimately downregulate the activity of its specific hormone.","Releasing Hormone Agonist Therapy | Releasing Factor Agonist Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545105","Lymphovascular Invasion 0","C147091","Lymphovascular invasion is not present (absent) or is not identified. (AJCC 8th ed.)","Lymphovascular Invasion 0 | LVI 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545090","Lymphovascular Invasion 1","C147092","Lymphovascular invasion is present or identified. (AJCC 8th ed.)","Lymphovascular Invasion 1 | LVI 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545091","Lymphovascular Invasion 9","C147093","Presence of lymphovascular invasion unknown or indeterminate. (AJCC 8th ed.)","Lymphovascular Invasion 9 | LVI 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545092","Lymphovascular Invasion 2","C147094","Lymphatic and small vessel invasion only. (AJCC 8th ed.)","Lymphovascular Invasion 2 | LVI 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545093","Lymphovascular Invasion 3","C147095","Venous (large vessel) invasion only. (AJCC 8th ed.)","Lymphovascular Invasion 3 | LVI 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545094","Lymphovascular Invasion 4","C147096","Both lymphatic and small vessel and venous (large vessel) invasion. (AJCC 8th ed.)","Lymphovascular Invasion 4 | LVI 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545043","EGFR NP_005219.2:p.C797S","C147011","A change in the amino acid residue at position 797 in the epidermal growth factor receptor protein where cysteine has been replaced by serine.","EGFR NP_005219.2:p.C797S | EGFR C797S | EGFR Cys797Ser | EGFR NP_005219.2:p.Cys797Ser | EGFR p.C797S | EGFR p.Cys797Ser | Epidermal Growth Factor Receptor C797S | Epidermal Growth Factor Receptor Cys797Ser | NP_005219.2:p.C797S | NP_005219.2:p.Cys797Ser | Proto-Oncogene c-ErbB-1 C797S | Proto-Oncogene c-ErbB-1 Cys797Ser | Receptor Tyrosine-Protein Kinase erbB-1 C797S | Receptor Tyrosine-Protein Kinase erbB-1 Cys797Ser",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545044","EGFR NP_005219.2:p.C797A","C147012","A change in the amino acid residue at position 797 in the epidermal growth factor receptor protein where cysteine has been replaced by alanine.","EGFR NP_005219.2:p.C797A | EGFR C797A | EGFR Cys797Ala | EGFR NP_005219.2:p.Cys797Ala | EGFR p.C797A | EGFR p.Cys797Ala | Epidermal Growth Factor Receptor C797A | Epidermal Growth Factor Receptor Cys797Ala | NP_005219.2:p.C797A | NP_005219.2:p.Cys797Ala | Proto-Oncogene c-ErbB-1 C797A | Proto-Oncogene c-ErbB-1 Cys797Ala | Receptor Tyrosine-Protein Kinase erbB-1 C797A | Receptor Tyrosine-Protein Kinase erbB-1 Cys797Ala",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545046","EGFR NP_005219.2:p.L792F","C147014","A change in the amino acid residue at position 792 in the epidermal growth factor receptor protein where leucine has been replaced by phenylalanine.","EGFR NP_005219.2:p.L792F | EGFR L792F | EGFR Leu792Phe | EGFR NP_005219.2:p.Leu792Phe | EGFR p.L792F | EGFR p.Leu792Phe | Epidermal Growth Factor Receptor L792F | Epidermal Growth Factor Receptor Leu792Phe | NP_005219.2:p.L792F | NP_005219.2:p.Leu792Phe | Proto-Oncogene c-ErbB-1 L792F | Proto-Oncogene c-ErbB-1 Leu792Phe | Receptor Tyrosine-Protein Kinase erbB-1 L792F | Receptor Tyrosine-Protein Kinase erbB-1 Leu792Phe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545048","EGFR NP_005219.2:p.L792H","C147016","A change in the amino acid residue at position 792 in the epidermal growth factor receptor protein where leucine has been replaced by histidine.","EGFR NP_005219.2:p.L792H | EGFR L792H | EGFR Leu792His | EGFR NP_005219.2:p.Leu792His | EGFR p.L792H | EGFR p.Leu792His | Epidermal Growth Factor Receptor L792H | Epidermal Growth Factor Receptor Leu792His | NP_005219.2:p.L792H | NP_005219.2:p.Leu792His | Proto-Oncogene c-ErbB-1 L792H | Proto-Oncogene c-ErbB-1 Leu792His | Receptor Tyrosine-Protein Kinase erbB-1 L792H | Receptor Tyrosine-Protein Kinase erbB-1 Leu792His",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545049","EGFR NP_005219.2:p.L792Y","C147017","A change in the amino acid residue at position 792 in the epidermal growth factor receptor protein where leucine has been replaced by tyrosine.","EGFR NP_005219.2:p.L792Y | EGFR L792Y | EGFR Leu792Tyr | EGFR NP_005219.2:p.Leu792Tyr | EGFR p.L792Y | EGFR p.Leu792Tyr | Epidermal Growth Factor Receptor L792Y | Epidermal Growth Factor Receptor Leu792Tyr | NP_005219.2:p.L792Y | NP_005219.2:p.Leu792Tyr | Proto-Oncogene c-ErbB-1 L792Y | Proto-Oncogene c-ErbB-1 Leu792Tyr | Receptor Tyrosine-Protein Kinase erbB-1 L792Y | Receptor Tyrosine-Protein Kinase erbB-1 Leu792Tyr",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545050","EGFR NP_005219.2:p.L718V","C147018","A change in the amino acid residue at position 718 in the epidermal growth factor receptor protein where leucine has been replaced by valine.","EGFR NP_005219.2:p.L718V | EGFR L718V | EGFR Leu718Val | EGFR NP_005219.2:p.Leu718Val | EGFR p.L718V | EGFR p.Leu718Val | Epidermal Growth Factor Receptor L718V | Epidermal Growth Factor Receptor Leu718Val | NP_005219.2:p.L718V | NP_005219.2:p.Leu718Val | Proto-Oncogene c-ErbB-1 L718V | Proto-Oncogene c-ErbB-1 Leu718Val | Receptor Tyrosine-Protein Kinase erbB-1 L718V | Receptor Tyrosine-Protein Kinase erbB-1 Leu718Val",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545036","EGFR NP_005219.2:p.L718Q","C147021","A change in the amino acid residue at position 718 in the epidermal growth factor receptor protein where leucine has been replaced by glutamine.","EGFR NP_005219.2:p.L718Q | EGFR L718Q | EGFR Leu718Gln | EGFR NP_005219.2:p.Leu718Gln | EGFR p.L718Q | EGFR p.Leu718Gln | Epidermal Growth Factor Receptor L718Q | Epidermal Growth Factor Receptor Leu718Gln | NP_005219.2:p.L718Q | NP_005219.2:p.Leu718Gln | Proto-Oncogene c-ErbB-1 L718Q | Proto-Oncogene c-ErbB-1 Leu718Gln | Receptor Tyrosine-Protein Kinase erbB-1 L718Q | Receptor Tyrosine-Protein Kinase erbB-1 Leu718Gln",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545038","EGFR NP_005219.2:p.G796S","C147023","A change in the amino acid residue at position 796 in the epidermal growth factor receptor protein where glycine has been replaced by serine.","EGFR NP_005219.2:p.G796S | EGFR G796S | EGFR Gly796Ser | EGFR NP_005219.2:p.Gly796Ser | EGFR p.G796S | EGFR p.Gly796Ser | Epidermal Growth Factor Receptor G796S | Epidermal Growth Factor Receptor Gly796Ser | NP_005219.2:p.G796S | NP_005219.2:p.Gly796Ser | Proto-Oncogene c-ErbB-1 G796S | Proto-Oncogene c-ErbB-1 Gly796Ser | Receptor Tyrosine-Protein Kinase erbB-1 G796S | Receptor Tyrosine-Protein Kinase erbB-1 Gly796Ser",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545040","EGFR NP_005219.2:p.G796R","C147025","A change in the amino acid residue at position 796 in the epidermal growth factor receptor protein where glycine has been replaced by arginine.","EGFR NP_005219.2:p.G796R | EGFR G796R | EGFR Gly796Arg | EGFR NP_005219.2:p.Gly796Arg | EGFR p.G796R | EGFR p.Gly796Arg | Epidermal Growth Factor Receptor G796R | Epidermal Growth Factor Receptor Gly796Arg | NP_005219.2:p.G796R | NP_005219.2:p.Gly796Arg | Proto-Oncogene c-ErbB-1 G796R | Proto-Oncogene c-ErbB-1 Gly796Arg | Receptor Tyrosine-Protein Kinase erbB-1 G796R | Receptor Tyrosine-Protein Kinase erbB-1 Gly796Arg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545070","MET Codon 963 Splice Mutation","C147123","A change in the nucleotide sequence of MET gene that alters splicing at codon 963.","MET Codon 963 Splice Mutation | HGFR Codon 963 Splice Mutation | MET Asp963 Splice Mutation | MET D963 Splice Mutation | MET D963_splice mutation detected | MET Proto-Oncogene, Receptor Tyrosine Kinase Codon 963 Splice Mutation | Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Codon 963 Splice Mutation | c-Met Codon 963 Splice Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545066","MET NP_000236.2:p.D1010N","C147119","A change in the amino acid residue at position 1010 in the hepatocyte growth factor receptor protein where aspartic acid has been replaced by asparagine.","MET NP_000236.2:p.D1010N | C-MET Asp1010Asn | C-MET D1010N | HGF Receptor Asp1010Asn | HGF Receptor D1010N | HGFR Asp1010Asn | HGFR D1010N | Hepatocyte Growth Factor Receptor Asp1010Asn | Hepatocyte Growth Factor Receptor D1010N | MET Asp1010Asn | MET D1010N | MET D1010N mutation detected | MET NP_000236.2:p.Asp1010Asn | MET NP_001120972.1:p.Asp1028Asn | MET NP_001120972.1:p.D1028N | MET p.Asp1010Asn | MET p.D1010N | NP_000236.2:p.Asp1010Asn | NP_000236.2:p.D1010N | NP_001120972.1:p.Asp1028Asn | NP_001120972.1:p.D1028N | Proto-Oncogene c-Met Asp1010Asn | Proto-Oncogene c-Met D1010N | Scatter Factor Receptor Asp1010Asn | Scatter Factor Receptor D1010N | Tyrosine-Protein Kinase Met Asp1010Asn | Tyrosine-Protein Kinase Met D1010N",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545071","MET Codon 1010 Splice Mutation","C147124","A change in the nucleotide sequence of MET gene that alters splicing at codon 1010.","MET Codon 1010 Splice Mutation | HGFR Codon 1010 Splice Mutation | MET Asp1010 Splice Mutation | MET D1010 Splice Mutation | MET D1010_splice mutation detected | MET Proto-Oncogene, Receptor Tyrosine Kinase Codon 1010 Splice Mutation | Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Codon 1010 Splice Mutation | c-Met Codon 1010 Splice Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545069","MET Intron 14 Mutation","C147122","A molecular genetic abnormality indicating the presence of a mutation in intron 14 of the MET gene.","MET Intron 14 Mutation | HGFR Intron 13 Mutation | HGFR Intron 14 Mutation | MET Proto-Oncogene, Receptor Tyrosine Kinase Intron 14 Mutation | Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Intron 14 Mutation | c-Met Intron 14 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545075","Progressive Medulloblastoma","C147111","A medulloblastoma that is worsening in terms of extent or severity.","Progressive Medulloblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545076","Progressive Ependymoma","C147112","An ependymoma that is worsening in terms of extent or severity.","Progressive Ependymoma | Progressive Ependymoma ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545077","Progressive Central Nervous System Neoplasm","C147113","A central nervous system neoplasm that is worsening in terms of extent or severity.","Progressive Central Nervous System Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545079","Progressive Medulloblastoma, SHH-Activated","C147115","A medulloblastoma, SHH-activated that is worsening in terms of extent or severity.","Progressive Medulloblastoma, SHH-Activated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545088","Refractory Ependymoma","C147108","Ependymoma that does not respond to treatment.","Refractory Ependymoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545089","Recurrent Medulloblastoma, SHH-Activated","C147109","The reemergence of SHH-activated medulloblastoma after a period of remission.","Recurrent Medulloblastoma, SHH-Activated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545074","Refractory Medulloblastoma, SHH-Activated","C147110","SHH-activated medulloblastoma that does not respond to treatment.","Refractory Medulloblastoma, SHH-Activated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545078","Steroid Refractory Graft Versus Host Disease","C147114","Graft versus host disease that does not respond to steroid treatment.","Steroid Refractory Graft Versus Host Disease | Steroid Refractory GVHD | Steroid Refractory cGVHD | Steroid Resistant GVHD | Steroid Resistant Graft Versus Host Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335915","FNCLCC Sarcoma Grade 3","C9029","A sarcoma with a total score of 6 or higher according to the FNCLCC guidelines.","Sarcoma G3 | AJCC G3 Sarcoma | AJCC Grade 3 Sarcoma | FNCLCC Sarcoma Grade 3 | FNCLCC Sarcoma Grade 3 | G3 Grade 3 | Sarcoma Differentiation Score 3 | Sarcoma FNCLCC Grade 3 | Sarcoma Grade 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335914","FNCLCC Sarcoma Grade 2","C9028","A sarcoma with a total score of 4 or 5 according to the FNCLCC guidelines.","Sarcoma G2 | AJCC G2 Sarcoma | AJCC Grade 2 Sarcoma | FNCLCC Sarcoma Grade 2 | FNCLCC Sarcoma Grade 2 | G2 Grade 2 | Moderately Differentiated Sarcoma | Sarcoma Differentiation Score 2 | Sarcoma FNCLCC Grade 2 | Sarcoma Grade 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829229","Macrometastasis","C106296","Metastasis that is clinically obvious.","Macrometastasis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545738","Estrogen Receptor Status 0","C147852","An immunohistochemical result of 0 for estrogen receptor expression that is considered negative for expression.","Estrogen Receptor Status 0 | ER IHC 0 | ER Status 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545739","Estrogen Receptor Status 1+","C147853","An immunohistochemical result of 1 for estrogen receptor expression that is considered weak for expression.","Estrogen Receptor Status 1+ | ER IHC 1+ | ER Status 1+",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829491","Isolated Tumor Cells","C106301","The presence of single tumor cells or tiny clusters of tumor cells in a pathologic specimen.","Isolated Tumor Cells | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545740","Estrogen Receptor Status 2+","C147854","An immunohistochemical result of 2 for estrogen receptor expression that is considered intermediate for expression.","Estrogen Receptor Status 2+ | ER IHC 2+ | ER Status 2+",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545741","Estrogen Receptor Status 3+","C147855","An immunohistochemical result of 3 for estrogen receptor expression that is considered positive for expression.","Estrogen Receptor Status 3+ | ER IHC 3+ | ER Status 3+",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545742","Progesterone Receptor Status 0","C147856","An immunohistochemical result of 0 for progesterone receptor expression that is considered negative for expression.","Progesterone Receptor Status 0 | PgR IHC 0 | PgR Status 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545743","Progesterone Receptor Status 1+","C147857","An immunohistochemical result of 1 for progesterone receptor expression that is considered intermediate for expression.","Progesterone Receptor Status 1+ | PgR IHC 2+ | PgR Status 2+",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545728","Progesterone Receptor Status 2+","C147858","An immunohistochemical result of 2 for progesterone receptor expression that is considered intermediate for expression.","Progesterone Receptor Status 2+ | PgR IHC 2+ | PgR Status 2+",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545729","Progesterone Receptor Status 3+","C147859","An immunohistochemical result of 3 for progesterone receptor expression that is considered positive for expression.","Progesterone Receptor Status 3+ | PgR IHC 3+ | PgR Status 3+",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545334","HER2/Neu Expression by Immunohistochemistry 0","C147524","An immunohistochemical result of 0 for HER2/Neu expression that is considered negative for expression.","HER2/Neu Expression by Immunohistochemistry 0 | HER2/Neu IHC 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545335","HER2/Neu Expression by Immunohistochemistry 1+","C147525","An immunohistochemical result of 1+ for HER2/Neu expression that is considered negative for expression.","HER2/Neu Expression by Immunohistochemistry 1+ | HER2/Neu IHC 1+",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545336","HER2/Neu Expression by Immunohistochemistry 2+","C147526","An immunohistochemical result of 2+ for HER2/Neu expression that is considered equivocal for expression.","HER2/Neu Expression by Immunohistochemistry 2+ | HER2/Neu IHC 2+",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545424","HER2/Neu Expression by Immunohistochemistry 3+","C147527","An immunohistochemical result of 3+ for HER2/Neu expression that is considered positive for expression.","HER2/Neu Expression by Immunohistochemistry 3+ | HER2/Neu IHC 3+",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545396","Synthetic Vaccine Particles-Rapamycin","C147562","A proprietary, biodegradable, poly (lactic-co-glycolic acid) (PLGA) nanoparticle-based formulation composed of synthetic vaccine particles (SVP) encapsulating the macrolide antibiotic rapamycin (SVP-R), with immunosuppressant and drug-protective activities. Upon administration of SVP-R, the SVP moiety is selectively and preferentially taken up through endocytosis by antigen-presenting cells (APCs), located in the spleen and lymph nodes, specifically dendritic cells (DCs). Rapamycin, a mammalian target of rapamycin (mTOR) inhibitor, prevents DC maturation, induces tolerogenic DCs, induces regulatory T-cells (Tregs), blocks activation of effector T-cells, induces B-cell tolerance, reduces B-cell activation, and prevents antibody formation, thereby inducing immune tolerance. When co-administered with a biological immunogenic drug known to induce the production of anti-drug antibodies (ADA), SVP-R is able to prevent ADA formation, which prevents the unwanted neutralizing effects of ADAs, increases efficacy of the biological drug, and permits sustained therapeutic activity and repeated administration of the biological drug. In the presence of a specific target antigen, SVP-R is able to prevent an antigen-specific immune response and induces antigen-specific immune tolerance. Compared to the administration of free rapamycin, SVP-R induces long-lasting immunological tolerance.","Synthetic Vaccine Particles-Rapamycin | SEL 110 | SEL-110 | SEL110 | SVP-R | SVP-Rapa | SVP-Rapamycin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3869912","Enneking Metastasis M0","C147528","No metastasis.","Enneking Metastasis M0 | M0 | No Metastasis (M0)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545425","Enneking Metastasis M1","C147529","Regional or distant metastasis.","Enneking Metastasis M1 | M1 | Regional or Distant Metastasis (M1)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0231052","Midgut","C34210","The middle region (foregut, midgut and hindgut) of the early formation of the digestive tract in the developing embryo, which gives rise to the distal duodenum, jejunum, ileum, cecum, appendix, and colon from the cecum to the distal transverse colon.","Midgut | ",,,,,,,,,,,,,,,"4103454","Primitive midgut structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512323","FGF4 Gene Amplification","C41379","A molecular genetic abnormality indicating the presence of multiple copies of the FGF4 gene.","FGF4 Gene Amplification | FGF-4 Gene Amplification | Fibroblast Growth Factor 4 Gene Amplification | HST Gene Amplification | HST-1 Gene Amplification | HSTF-1 Gene Amplification | HSTF1 Gene Amplification | K-FGF Gene Amplification | KFGF Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545009","HLA-A*0202 Positive Cells Present","C147058","An indication that cells expressing HLA-A*0202 have been detected in a sample.","HLA-A*0202 Positive Cells Present | HLA-A*0202 Positive | HLA-A*02:02 Positive | HLA-A*02:02 Positive Cells Present | HLA-A0202 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0074774","Sodium Thiosulfate","C1230","A water soluble salt and reducing agent that reacts with oxidizing agents.  Although its exact mechanism of action is unknown, thiosulfate likely provides an exogenous source of sulfur, thereby hastening the detoxification of cyanide through the enzyme rhodanese (thiosulfate cyanide sulfurtransferase) which converts cyanide to the relatively nontoxic, excretable thiocyanate ion. In addition, this agent neutralizes the reactive alkylating species of nitrogen mustard, thereby decreasing skin toxicity related to nitrogen mustard extravasation. (NCI04)","Sodium Thiosulfate | Cyanide Antidote Package | Disodium Thiosulfate | Disodium thiosulfate | S-Hydril | SODIUM THIOSULFATE | Sodium Hyposulfate | Sodium Thiosulfate Pentahydrate | Sodium Thiosulphate | Sodium thiosulfate | Sodothiol | Thiosulfate, Sodium, Pentahydrate | Thiosulfuric Acid Disodium Salt | Thiosulfuric acid disodium salt | sodium thiosulfate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545062","EGFR NP_005219.2:p.L792X","C147131","A change in the amino acid residue at position 792 in the epidermal growth factor receptor protein where leucine has been replaced by another amino acid.","EGFR NP_005219.2:p.L792X | EGFR L792X | EGFR Leu792Xxx | EGFR NP_005219.2:p.Leu792Xxx | EGFR p.L792X | EGFR p.Leu792Xxx | Epidermal Growth Factor Receptor L792X | Epidermal Growth Factor Receptor Leu792Xxx | NP_005219.2:p.L792X | NP_005219.2:p.Leu792Xxx | Proto-Oncogene c-ErbB-1 L792X | Proto-Oncogene c-ErbB-1 Leu792Xxx | Receptor Tyrosine-Protein Kinase erbB-1 L792X | Receptor Tyrosine-Protein Kinase erbB-1 Leu792Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545063","EGFR NP_005219.2:p.G796X","C147132","A change in the amino acid residue at position 796 in the epidermal growth factor receptor protein where glycine has been replaced by another amino acid.","EGFR NP_005219.2:p.G796X | EGFR G796X | EGFR Gly796Xxx | EGFR NP_005219.2:p.Gly796Xxx | EGFR p.G796X | EGFR p.Gly796Xxx | Epidermal Growth Factor Receptor G796X | Epidermal Growth Factor Receptor Gly796Xxx | NP_005219.2:p.G796X | NP_005219.2:p.Gly796Xxx | Proto-Oncogene c-ErbB-1 G796X | Proto-Oncogene c-ErbB-1 Gly796Xxx | Receptor Tyrosine-Protein Kinase erbB-1 G796X | Receptor Tyrosine-Protein Kinase erbB-1 Gly796Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545064","EGFR NP_005219.2:p.L718X","C147133","A change in the amino acid residue at position 718 in the epidermal growth factor receptor protein where leucine has been replaced by another amino acid.","EGFR NP_005219.2:p.L718X | EGFR L718X | EGFR Leu718Xxx | EGFR NP_005219.2:p.Leu718Xxx | EGFR p.L718X | EGFR p.Leu718Xxx | Epidermal Growth Factor Receptor L718X | Epidermal Growth Factor Receptor Leu718Xxx | NP_005219.2:p.L718X | NP_005219.2:p.Leu718Xxx | Proto-Oncogene c-ErbB-1 L718X | Proto-Oncogene c-ErbB-1 Leu718Xxx | Receptor Tyrosine-Protein Kinase erbB-1 L718X | Receptor Tyrosine-Protein Kinase erbB-1 Leu718Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545724","Undesired Appetite Increase Scale","C147871","A scale for the subjective scoring of undesired appetite increase that ranges from 0: No undesired appetite increase at all to 10: Undesired appetite increase as bad as it can be.","Undesired Appetite Increase Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545725","Undesired Appetite Increase Score 0","C147872","A subjective score of 0 on a scale that ranges from 0: No undesired appetite increase at all to 10: Undesired appetite increase as bad as it can be.","Undesired Appetite Increase Score 0 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545726","Undesired Appetite Increase Score 1","C147873","A subjective score of 1 on a scale that ranges from 0: No undesired appetite increase at all to 10: Undesired appetite increase as bad as it can be.","Undesired Appetite Increase Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545727","Undesired Appetite Increase Score 2","C147874","A subjective score of 2 on a scale that ranges from 0: No undesired appetite increase at all to 10: Undesired appetite increase as bad as it can be.","Undesired Appetite Increase Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545712","Undesired Appetite Increase Score 3","C147875","A subjective score of 3 on a scale that ranges from 0: No undesired appetite increase at all to 10: Undesired appetite increase as bad as it can be.","Undesired Appetite Increase Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545713","Undesired Appetite Increase Score 4","C147876","A subjective score of 4 on a scale that ranges from 0: No undesired appetite increase at all to 10: Undesired appetite increase as bad as it can be.","Undesired Appetite Increase Score 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545714","Undesired Appetite Increase Score 5","C147877","A subjective score of 5 on a scale that ranges from 0: No undesired appetite increase at all to 10: Undesired appetite increase as bad as it can be.","Undesired Appetite Increase Score 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545716","Undesired Appetite Increase Score 6","C147879","A subjective score of 6 on a scale that ranges from 0: No undesired appetite increase at all to 10: Undesired appetite increase as bad as it can be.","Undesired Appetite Increase Score 6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545717","Undesired Appetite Increase Score 7","C147880","A subjective score of 7 on a scale that ranges from 0: No undesired appetite increase at all to 10: Undesired appetite increase as bad as it can be.","Undesired Appetite Increase Score 7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545718","Undesired Appetite Increase Score 8","C147881","A subjective score of 8 on a scale that ranges from 0: No undesired appetite increase at all to 10: Undesired appetite increase as bad as it can be.","Undesired Appetite Increase Score 8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545719","Undesired Appetite Increase Score 9","C147882","A subjective score of 9 on a scale that ranges from 0: No undesired appetite increase at all to 10: Undesired appetite increase as bad as it can be.","Undesired Appetite Increase Score 9 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545704","Undesired Appetite Increase Score 10","C147883","A subjective score of 10 on a scale that ranges from 0: No undesired appetite increase at all to 10: Undesired appetite increase as bad as it can be.","Undesired Appetite Increase Score 10 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545706","Undesired Sedation Scale","C147885","A scale for the subjective scoring of undesired sedation that ranges from 0: No undesired sedation at all to 10: Undesired sedation as bad as it can be.","Undesired Sedation Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545707","Undesired Sedation Score 0","C147886","A subjective score of 0 on a scale that ranges from 0: No undesired sedation at all to 10: Undesired sedation as bad as it can be.","Undesired Sedation Score 0 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545708","Undesired Sedation Score 1","C147887","A subjective score of 1 on a scale that ranges from 0: No undesired sedation at all to 10: undesired sedation as bad as it can be.","Undesired Sedation Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545709","Undesired Sedation Score 2","C147888","A subjective score of 2 on a scale that ranges from 0: No undesired sedation at all to 10: undesired sedation as bad as it can be.","Undesired Sedation Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545710","Undesired Sedation Score 3","C147889","A subjective score of 3 on a scale that ranges from 0: No undesired sedation at all to 10: undesired sedation as bad as it can be.","Undesired Sedation Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545711","Undesired Sedation Score 4","C147890","A subjective score of 4 on a scale that ranges from 0: No undesired sedation at all to 10: undesired sedation as bad as it can be.","Undesired Sedation Score 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545696","Undesired Sedation Score 5","C147891","A subjective score of 5 on a scale that ranges from 0: No undesired sedation at all to 10: undesired sedation as bad as it can be.","Undesired Sedation Score 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545697","Undesired Sedation Score 6","C147892","A subjective score of 6 on a scale that ranges from 0: No undesired sedation at all to 10: undesired sedation as bad as it can be.","Undesired Sedation Score 6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545699","Undesired Sedation Score 7","C147894","A subjective score of 7 on a scale that ranges from 0: No undesired sedation at all to 10: undesired sedation as bad as it can be.","Undesired Sedation Score 7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545700","Undesired Sedation Score 8","C147895","A subjective score of 8 on a scale that ranges from 0: No undesired sedation at all to 10: undesired sedation as bad as it can be.","Undesired Sedation Score 8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545701","Undesired Sedation Score 9","C147896","A subjective score of 9 on a scale that ranges from 0: No undesired sedation at all to 10: undesired sedation as bad as it can be.","Undesired Sedation Score 9 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545702","Undesired Sedation Score 10","C147897","A subjective score of 10 on a scale that ranges from 0: No undesired sedation at all to 10: undesired sedation as bad as it can be.","Undesired Sedation Score 10 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545072","AC 0010","C147125","An orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. Upon oral administration, abivertinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the drug-resistant T790M EGFR mutant, which prevents signaling mediated by mutant forms of EGFR. This may both induce cell death and inhibit tumor growth in EGFR-mutated tumor cells. EGFR, a receptor tyrosine kinase that is mutated in a variety of cancers, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors, which also inhibit wild-type EGFR.","Abivertinib | ABIVERTINIB | AC 0010 | AC-0010 | AC0010 | Avitinib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441090","Dipstick","C106516","A strip of paper or other composite material that is coated or impregnated with reagents designed to detect the presence of an analyte in a liquid by producing a color change on the strip or is read using an instrument.","Dipstick | ",,,,,,,,,,,,,,,"4159730","Dipstick",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0430370","Urine Dipstick Test","C147905","Use of a test strip designed to detect one or more specific substances in urine. Results are indicated by a color change and may be qualitative or semi-quantitative.","Urine Dipstick Test | Urine Test Strip",,,,,,,,,,,,,,,"4041869","Urine dipstick test",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333843","Grade 3 Invasive Breast Carcinoma","C27832","An invasive breast carcinoma characterized by the presence of poorly differentiated histopathological features.","Poorly Differentiated Invasive Breast Carcinoma | Grade 3 Infiltrating Breast Carcinoma | Grade 3 Invasive Breast Carcinoma | Grade 3 Invasive Breast Carcinoma | High Combined Histologic Grade Infiltrating Breast Carcinoma | Poorly Differentiated Infiltrating Breast Carcinoma | Poorly Differentiated Invasive Breast Carcinoma | Unfavorable Infiltrating Breast Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333838","Grade 2 Invasive Breast Carcinoma","C27831","An invasive breast carcinoma characterized by the presence of histopathological features that are intermediate between well differentiated and poorly differentiated.","Moderately Differentiated Invasive Breast Carcinoma | Grade 2 Infiltrating Breast Carcinoma | Grade 2 Invasive Breast Carcinoma | Grade 2 Invasive Breast Carcinoma | Intermediate Combined Histologic Grade Infiltrating Breast Carcinoma | Moderately Differentiated Infiltrating Breast Carcinoma | Moderately Differentiated Invasive Breast Carcinoma | Moderately Favorable Infiltrating Breast Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333832","Grade 1 Invasive Breast Carcinoma","C27830","An invasive breast carcinoma characterized by the presence of well differentiated histopathological features.","Well Differentiated Invasive Breast Carcinoma | Favorable Infiltrating Breast Carcinoma | Grade 1 Infiltrating Breast Carcinoma | Grade 1 Invasive Breast Carcinoma | Grade 1 Invasive Breast Carcinoma | Low Combined Histologic Grade Infiltrating Breast Carcinoma | Well Differentiated Infiltrating Breast Carcinoma | Well Differentiated Invasive Breast Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022662","Renal Function Test","C74972","A laboratory procedure that evaluates the kidney function.","Renal Function Test | kidney function test | renal function test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985451","Estrogen Receptor Test","C93128","A lab test to find out if cancer cells have estrogen receptors (proteins to which estrogen will bind). If the cells have estrogen receptors, they may need estrogen to grow, and this may affect how the cancer is treated.","Estrogen Receptor Test | estrogen receptor test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274459","Brigatinib","C98831","An orally available inhibitor of receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Brigatinib binds to and inhibits ALK kinase and ALK fusion proteins as well as EGFR and mutant forms. This leads to the inhibition of ALK kinase and EGFR kinase, disrupts their signaling pathways and eventually inhibits tumor cell growth in susceptible tumor cells. In addition, AP26113 appears to overcome mutation-based resistance. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. EGFR is overexpressed in a variety of cancer cell types.","Brigatinib | (2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethyl-,delta5-phosphanone | 5-Chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine | AP 26113 | AP-26113 | AP26113 | Alunbrig | BRIGATINIB | Biganib | Briganix | Trepmac",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3884739","Lorlatinib","C113655","An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, lorlatinib binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK- and ROS1-mediated signaling and eventually inhibits tumor cell growth in ALK- and ROS1-overexpressing tumor cells. In addition, PF-06463922 is able to cross the blood brain barrier. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells.","Lorlatinib | 2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)- | 7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile | LORLATINIB | Lorbrena | Lorviqua | PF 06463922 | PF-06463922 | PF06463922",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0428627","Protein to Creatinine Ratio Measurement","C79463","The determination of the ratio of total protein compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Protein to Creatinine Ratio Measurement | PROTCRT | Protein/Creatinine",,,,,,,,,,,,,,,"4353852","Protein/creatinine ratio measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2586211","Vascular Thrombosis","C114397","The formation of a blood clot in the lumen of a vessel; causes include coagulation disorders, and vascular endothelial injury.","Vascular Thrombosis | thrombosis",,,,,,,,,,,,,,,"4208466","Thrombosis of blood vessel",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL539496","HER2/Neu Negative by FISH","C141435","A laboratory test result indicating the absence of HER2/Neu in a tissue sample using fluorescence in situ hybridization.","HER2/Neu Negative by FISH | ERBB2 Negative by FISH | HER2 Negative by FISH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545692","Breast Carcinoma Grade","C147915","A modification of the Nottingham grading system for use in grading breast carcinoma.","Breast Carcinoma Grade | Breast Cancer Grade | Breast Cancer Modified Nottingham Grade | Modified Nottingham Grade | Modified Nottingham Grade for Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545795","Breast Carcinoma Grade G1","C147916","A low combined histologic grade (favorable), SBR score of 3-5 points.","Breast Carcinoma Grade G1 | Breast Cancer Grade G1 | G1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545796","Breast Carcinoma Grade G2","C147917","An intermediate combined histologic grade (moderately favorable), SBR score of 6-7 points.","Breast Carcinoma Grade G2 | Breast Cancer Grade G2 | G2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545797","Breast Carcinoma Grade G3","C147918","A high combined histologic grade (unfavorable), SBR score of 8-9 points.","Breast Carcinoma Grade G3 | Breast Cancer Grade G3 | G3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544997","MAP2K1 Gene Mutation","C147062","A change in the nucleotide sequence of the MAP2K1 gene.","MAP2K1 Gene Mutation | MAPKK1 Gene Mutation | MEK1 Gene Mutation | MKK1 Gene Mutation | Mitogen-Activated Protein Kinase Kinase 1 Gene Mutation | PRKMK1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544996","ARAF Gene Mutation","C147061","A change in the nucleotide sequence of the ARAF gene.","ARAF Gene Mutation | A-RAF Gene Mutation | A-Raf Proto-Oncogene, Serine/Threonine Kinase Gene Mutation | ARAF1 Gene Mutation | PKS2 Gene Mutation | RAFA1 Gene Mutation | v-Raf Murine Sarcoma 3611 Viral Oncogene Homolog 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544995","HLA-C*0404 Positive Cells Present","C147060","An indication that cells expressing HLA-C*0404 have been detected in a sample.","HLA-C*0404 Positive Cells Present | HLA-C*0404 Positive | HLA-C*04:04 Positive | HLA-C*04:04 Positive Cells Present | HLA-C0404 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545010","HLA-B*5103 Positive Cells Present","C147059","An indication that cells expressing HLA-B*5103 have been detected in a sample.","HLA-B*5103 Positive Cells Present | HLA-B*5103 Positive | HLA-B*51:03 Positive | HLA-B*51:03 Positive Cells Present | HLA-B5103 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545008","CD44 Positive","C147057","An indication that CD44 expression has been detected in a sample.","CD44 Positive | CD44 Antigen Positive | CD44 Molecule Positive | CDw44 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545007","Blasts 6-19 Percent of Bone Marrow Nucleated Cells","C147056","A semi-quantitative microscopic finding indicating that between 6 and 19 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 6-19 Percent of Bone Marrow Nucleated Cells | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545006","Blasts 1 Percent or More of Peripheral Blood White Cells","C147055","A semi-quantitative microscopic finding indicating that 1 percent or more of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.","Blasts 1 Percent or More of Peripheral Blood White Cells | Blasts Greater than or Equal to 1 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545005","ROS1 Gene Rearrangement Negative","C147054","A genetic finding indicating that rearrangement of the ROS1 gene has not been detected in a sample.","ROS1 Gene Rearrangement Negative | MCF3 Gene Rearrangement Negative | No rearrangement detected | ROS Gene Rearrangement Negative | ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene Rearrangement Negative | c-ros-1 Gene Rearrangement Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545004","Soluble Tumor Necrosis Factor Receptor Superfamily Member 1A","C147053","Soluble tumor necrosis factor receptor superfamily member 1A (~18 kDa) is encoded by the human TNFRSF1A gene. This enzymatically processed protein may be involved in the inhibition of binding and downstream signaling associated with binding of either tumor necrosis factor or lymphotoxin-alpha to the membrane-bound form of tumor necrosis factor receptor superfamily member 1A.","Soluble Tumor Necrosis Factor Receptor Superfamily Member 1A | Soluble Tumor Necrosis Factor Receptor Superfamily Member I | sTNF RI | sTNF-RI | sTNFRSF1A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545003","PIK3AP1 Gene Mutation","C147052","A change in the nucleotide sequence of the PIK3AP1 gene.","PIK3AP1 Gene Mutation | BCAP Gene Mutation | Phosphoinositide-3-Kinase Adaptor Protein 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544794","ENPP3 Positive","C146756","An indication that ENPP3 expression has been detected in a sample.","ENPP3 Positive | CD203c Positive | Ectonucleotide Pyrophosphatase/Phosphodiesterase 3 Positive | Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 Positive | PD-Ibeta Positive | PDNP3 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545111","MET Gene Deletion","C147081","A molecular abnormality referring to the loss of at least one copy of the MET gene.","MET Gene Deletion | HGFR Gene Deletion | Hepatocyte Growth Factor Receptor Gene Deletion | MET Proto-Oncogene, Receptor Tyrosine Kinase Gene Deletion | c-MET Gene Deletion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545110","Chromogranin-Positive Neoplastic Cells Present","C147080","An indication that expression of one or more chromogranin family proteins has been detected in a sample of neoplastic cells.","Chromogranin-Positive Neoplastic Cells Present | CHG-Positive Neoplastic Cells Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545109","Chromogranin Positive","C147079","An indication that expression of one or more chromogranin family proteins has been detected in a sample.","Chromogranin Positive | CHG Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545108","MAGEA4 Positive","C147078","An indication that MAGEA4 expression has been detected in a sample.","MAGEA4 Positive | CT1.4 Positive | Cancer/Testis Antigen 1.4 Positive | MAGE A4 Positive | MAGE-41 Positive | MAGE-X2 Positive | MAGE4 Positive | MAGE4A Positive | MAGE4B Positive | Melanoma-Associated Antigen 4 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545107","BRAF Fusion Positive","C147077","An indication that BRAF fusion expression has been detected in a sample.","BRAF Fusion Positive | B-RAF Fusion Positive | BRAF Fusion | BRAF1 Fusion Positive | Serine/Threonine-Protein Kinase B-raf Fusion Positive | v-raf Murine Sarcoma Viral Oncogene Homolog B1 Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545106","KIT Overexpression Positive","C147076","An indication that overexpression of KIT has been detected in a sample.","KIT Overexpression Positive | CD117 Antigen Overexpression Positive | CD117 Antigen Positive | CD117 Overexpression Positive | CD117 Positive | Mast/Stem Cell Growth Factor Receptor Kit Overexpression Positive | Mast/Stem Cell Growth Factor Receptor Kit Positive | Proto-Oncogene c-Kit Overexpression Positive | Proto-Oncogene c-Kit Positive | c-KIT Overexpression Positive | c-KIT Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544994","PRLR Positive","C147075","An indication that PRLR expression has been detected in a sample.","PRLR Positive | PRL-R Positive | Prolactin Receptor Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544993","Sensitizing ALK Gene Mutation","C147074","A molecular genetic abnormality indicating the presence of a sensitizing mutation in the ALK gene.","Sensitizing ALK Gene Mutation | ALK Sensitizing Mutation | Sensitizing Anaplastic Lymphoma Kinase (Ki-1) Gene Mutation | Sensitizing Anaplastic Lymphoma Receptor Tyrosine Kinase Gene Mutation | Sensitizing CD246 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544999","FGF3 Gene Amplification","C147064","A molecular genetic abnormality indicating the presence of multiple copies of the FGF3 gene.","FGF3 Gene Amplification | FGF-3 Gene Amplification | Fibroblast Growth Factor 3 Gene Amplification | HBGF-3 Gene Amplification | HBGF3 Gene Amplification | INT-2 Gene Amplification | INT2 Gene Amplification | Murine Mammary Tumor Virus Integration Site 2 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544998","DLL3 Gene Positive","C147063","An indication that the DLL3 gene has been detected in a sample.","DLL3 Gene Positive | Delta Like Canonical Notch Ligand 3 Gene Positive | Delta, Drosophila, Homolog of, 3 Gene Positive | Delta-Like 3 (Drosophila) Gene Positive | Delta-Like 3 Gene Positive | Delta3 Gene Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332572","Blasts Under 20 Percent of Peripheral Blood White Cells","C36220","A semi-quantitative microscopic finding indicating that less than 20 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.","Blasts Under 20 Percent of Peripheral Blood White Cells | Blasts Less than 20 Percent of Peripheral Blood White Cells | Blasts Less than 20% of Peripheral Blood White Cells | Blasts Under 20% of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332571","Blasts 20 Percent or More of Peripheral Blood White Cells","C36213","A semi-quantitative microscopic finding indicating that 20 percent or more of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.","Blasts 20 Percent or More of Peripheral Blood White Cells | Blasts 20% or More of Peripheral Blood White Cells | Blasts Greater than or Equal to 20 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334851","Myeloblasts Under 5 Percent of Bone Marrow Nucleated Cells","C36209","A semi-quantitative microscopic finding indicating that less than 5 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells of myeloid origin.","Myeloblasts Under 5 Percent of Bone Marrow Nucleated Cells | Myeloblasts Less Than 5 Percent of Bone Marrow Nucleated Cells | Myeloblasts Under 5% of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545104","CD2 Negative","C147090","Indicates that expression of C2 has not been detected in a sample.","CD2 Negative | CD2 Antigen Negative | CD2 Molecule Negative | LFA-2 Negative | T11 Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545103","CCND1 Negative","C147089","Indicates that expression of CCND1 has not been detected in a sample.","CCND1 Negative | BCL-1 Negative | BCL1 Negative | Cyclin D1 Negative | Cyclin-D1 Negative | PRAD1 Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545102","PSA Level Greater than Four","C147088","A blood concentration of prostate specific antigen greater than 4 ng/mL.","PSA Level Greater than Four | PSA Level Greater than 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545101","CD38 Positive","C147087","An indication that CD38 expression has been detected in a sample.","CD38 Positive | ADP-Ribosyl Cyclase 1 Positive | ADPRC1 Positive | CD38 Antigen Positive | CD38 Molecule Positive | T10 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545100","Protein Wnt-10b Activity Measurement","C147086","A measurement of the protein Wnt-10b activity in a sample.","Protein Wnt-10b Activity Measurement | Protein Wnt-12 Activity Measurement | WNT10B Activity Measurement | Wingless-Type MMTV Integration Site Family Member 10B Protein Activity Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545099","Antigen-Presentation Machinery Expression Profile","C147085","The identification and quantitation of all of the antigen-presentation machinery molecules expressed in a biological sample.","Antigen-Presentation Machinery Expression Profile | APM Expression Profile | Antigen-Presentation Machinery Molecules Expression Profile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545112","TRPM6 Gene","C147082","This gene plays a role in both magnesium ion transport and protein phosphorylation.","TRPM6 Gene | TRPM6 | Transient Receptor Potential Cation Channel Subfamily M Member 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348998","HHV-8-Positive Neoplastic Cells Present","C73941","An indication that human herpesvirus 8 has been detected in a sample of neoplastic cells.","Human Herpesvirus 8-Positive Neoplastic Cells Present | HHV-8 Positive Neoplastic Cells Present | HHV-8-Positive Neoplastic Cells Present | HHV8 Positive Neoplastic Cells Present | Human Herpesvirus-8-Positive Neoplastic Cells Present | KSHV Positive Neoplastic Cells Present | Kaposi Sarcoma Herpes Virus Positive Neoplastic Cells Present | Kaposi Sarcoma-Associated Herpes Virus Positive Neoplastic Cells Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708022","FH Gene Mutation","C51305","A change in the nucleotide sequence of the FH gene.","FH Gene Mutation | FMRD Gene Mutation | Fumarase Gene Mutation | Fumarate Hydratase Gene Mutation | Fumarate Hydratase, Mitochondrial Gene Mutation | MCL Gene Mutation | MCUL1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515178","TSC1 Gene Inactivation","C40462","A mutation in the TSC1 gene that either inhibits the expression of or results in the translation of an inactive hamartin protein.","TSC1 Gene Inactivation | Hamartin Gene Inactivation | Inactivating TSC1 Gene Mutation | Inactivating TSC1 Mutation | Loss of Function TSC1 Mutation | TSC Gene Inactivation | TSC1 Inactivating Mutation | TSC1 Loss of Function Gene Mutation | TSC1 Loss of Function Mutation | TSC1 Tumor-Suppressor Gene Inactivation | Tuberous Sclerosis 1 Gene Inactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511355","C-KIT Tyrosine Kinase Protein Overexpression","C39711","A molecular abnormality indicating the presence of an abnormally high level of the mast/stem cell growth factor receptor Kit protein.","C-KIT Tyrosine Kinase Protein Overexpression | CD117 Antigen Protein Overexpression | CD117 Protein Overexpression | CD117 Tyrosine Kinase Protein Overexpression | KIT Protein Overexpression | KIT Tyrosine Kinase Protein Overexpression | Mast/Stem Cell Growth Factor Receptor Kit Protein Overexpression | Proto-Oncogene Tyrosine-Protein Kinase Kit Protein Overexpression | Proto-Oncogene c-Kit Protein Overexpression | Stem Cell Factor Receptor Protein Overexpression | Tyrosine-Protein Kinase Kit Protein Overexpression | c-KIT Protein Overexpression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516130","BCL2 Gene Translocation","C38176","A cytogenetic abnormality that refers to any translocation involving the BCL2 gene.","BCL2 Gene Translocation | B-Cell CLL-Lymphoma 2 Gene Translocation | B-Cell CLL/Lymphoma 2 Gene Translocation | BCL-2 Translocation | BCL2, Apoptosis Regulator Gene Translocation | Bcl-2 Gene Translocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515179","TSC2 Gene Inactivation","C36696","A mutation in the TSC2 gene that either inhibits the expression of or results in the translation of an inactive tuberin protein.","TSC2 Gene Inactivation | Inactivating TSC2 Gene Mutation | TSC2 Tumor-Suppressor Gene Inactivation | Tuberin Gene Inactivation | Tuberous Sclerosis 2 Gene Inactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511111","CTNNB1 Gene Mutation","C36659","A change in the nucleotide sequence of the CTNNB1 gene.","CTNNB1 Gene Mutation | Beta Catenin Gene Mutation | Beta-Catenin Gene Mutation | CTNNB Gene Mutation | CTNNB1 mutation | Cadherin-Associated Protein, Beta 1 (88kD) Gene Mutation | Cadherin-Associated Protein, Beta Gene Mutation | Catenin Beta 1 Gene Mutation | Catenin Beta-1 Gene Mutation | Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515171","TP53 Gene Inactivation","C36329","A mutation in the TP53 gene that either inhibits the expression of or results in the translation of an inactive cellular tumor antigen p53 protein.","TP53 Gene Inactivation | Inactivating TP53 Gene Mutation | Inactivation of p53 Tumor-Suppressor Gene | LFS1 Gene Inactivation | Li-Fraumeni Syndrome Gene Inactivation | P53 Gene Inactivation | P53 Loss of Function Gene Mutation | P53 Tumor-Suppressor Gene Inactivation | TP53 Loss of Function Gene Mutation | TP53 Tumor-Suppressor Gene Inactivation | TRP53 Gene Inactivation | Tumor Protein p53 Gene Inactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545798","Ill-Defined Anatomic Site","C147919","An anatomic site that is not specified or defined well enough to associate with a specific site.","Ill-Defined Anatomic Site | Ill-Defined Site | Other ill-defined sites",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0679199","strategy","C147914","A plan of action intended to accomplish a specific goal.","Strategy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545687","Vascular Thrombosis Response","C147909","Guidelines for monitoring and reporting vascular thrombosis response. These guidelines are consistent with RECIST1.1 and consider thrombosis as a non-measurable disease.","Vascular Thrombosis Response | RECIST Vascular Thrombosis Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545688","irCR Thrombosis","C147910","Complete resolution of thrombosis, with recanalization of vessel.","irCR Thrombosis | irCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545689","irPR Thrombosis","C147911","Any of a) partial recanalization of thrombosis (if prior complete blockage), b) unequivocal reduction in the maximal girth of thrombosis, c) unequivocal reduction in the volume, or elimination, of arterial enhancing portion of thrombosis.","irPR Thrombosis | irPR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545690","irPD Thrombosis","C147912","Any unequivocal, unambiguous increase in the volume of new or existing enhancing thrombosis. Unequivocal progression of thrombosis corresponds to at least 73% increase in volume, which is similar to 20% increase in diameter, and at least a 5 mm absolute increase.","irPD Thrombosis | irPD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545691","irSD Thrombosis","C147913","Any of a) no change or small changes that do not meet the criteria for irPR or irPD, taking as reference the smallest sum diameters while on study, b) increase in the volume of non-enhancing thrombosis, c) new bland non-enhancing thrombosis.","irSD Thrombosis | irSD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085632","Apathy","C117197","An emotional state of indifference characterized by a lack of interest or concern.","Apathy | Emotional Indifference",,,,,,,,,,,,,,,"4071366","Indifference",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514214","Inventory of Depressive Symptomatology Self-Report Version Questionnaire","C130315","A standardized 30-item self-report questionnaire that utilizes a 5-point rating scale for the assessment of the severity of depressive symptoms over the seven day period prior to evaluation. The questionnaire, which was created by Rush, et al. in 1986, originally consisted of 28 items including the nine diagnostic DSM-IV symptom domains used to characterize a major depressive episode, as well as items to address melancholic and atypical features. Two additional items were later added to address leaden paralysis and interpersonal rejection sensitivity.","Inventory of Depressive Symptomatology Self-Report Version Questionnaire | IDS-SR | IDSR1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513352","Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form","C130318","A standardized 16-item self-report questionnaire that utilizes a 5-point rating scale to assess the degree of enjoyment and satisfaction experienced by adults in various areas of daily functioning. The questionnaire was developed by Endicot et al. in 1993 to assess broad functional impairment in research and treatment settings.","Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form | Q-LES-Q-SF | QLES2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513351","Quality Of Life Enjoyment And Satisfaction Questionnaire","C130317","A standardized self-report questionnaire, available as a 16-item short form for adults and 93-item long form for children, adolescents, and adults, that utilizes a 5-point rating scale to assess the degree of enjoyment and satisfaction experienced by individuals in various areas of daily functioning. The questionnaire was developed by Endicot et al. in 1993 to assess broad functional impairment in research and treatment settings.","Quality Of Life Enjoyment And Satisfaction Questionnaire | Q-LES-Q | QLES1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL423897","Capsule (drug packaging type)","C92708","A drug packaging type usually in a cylindrical shape with rounded ends. Capsule shells may be made from gelatin, starch, or cellulose, or other suitable materials, may be soft or hard, and are filled with solid or liquid drug products.","Capsule | CAPSULE | Capsule shell | Capsule-Container",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773665","Telotristat Etiprate","C81941","An orally bioavailable, small-molecule, tryptophan hydroxylase (TPH) inhibitor prodrug, with potential antiserotonergic activity. Upon administration, telotristat etiprate is converted to its active moiety, telotristat (LP-778902), which binds to and blocks the activity of TPH. This may result in a reduction in peripheral serotonin (5-HT) production and improvement of serotonin-mediated gastrointestinal effects such as severe diarrhea. TPH, the rate-limiting enzyme in serotonin biosynthesis, is overexpressed in carcinoid tumor cells.","Telotristat Etiprate | Ethyl 4-(2-amino-6-((1r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pryrimidin-4-yl)-l-phenylalaninate N-benzoylglycinate (1:1) | LX1032 Hippurate | LX1606 | LX1606 Hippurate | TELOTRISTAT ETIPRATE | TPH Inhibitor LX1606 | Tryptophan Hydroxylase Inhibitor LX1032 | Tryptophan Hydroxylase Inhibitor LX1606 | Xermelo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036379","Preschool","C147937","An educational institution for children that precedes kindergarten.","Preschool | Nursery School",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545785","Inventory of Callous-Unemotional Traits","C147938","A 24-item questionnaire designed to provide a comprehensive assessment of callous and unemotional traits. These traits have proven to be important for designating a distinct subgroup of antisocial and aggressive youth.","Inventory of Callous-Unemotional Traits | ICU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889585","Mood (attribute)","C117021","The modes that may be applied to an entity as it passes through various phases of a life cycle or business process.","Mood | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545780","Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire","C147949","A version of the Quality of Life Enjoyment and Satisfaction Questionnaire designed to assess changes in quality of life associated with treatment, as perceived by children and adolescents in the context of life events that are more meaningful in this population.","Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire | PQ-LES-Q",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545760","The Screen for Child Anxiety Related Emotional Disorders","C147958","A 41-item, self- or parent-report questionnaire designed to screen for childhood anxiety disorders, including general anxiety disorder, separation anxiety disorder, panic disorder, social phobia, and symptoms related to school phobias in children aged 8-17.","The Screen for Child Anxiety Related Emotional Disorders | SCARED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545761","Symptom Checklist 90","C147959","A 90-item self-report symptom inventory designed to measure psychological symptoms and psychological distress for individuals 13 years and older. It is intended to measure symptom intensity on nine different subscales.","Symptom Checklist 90 | SCL-90",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545762","The Mood and Feelings Questionnaire","C147960","A 13-item, self-administered questionnaire designed to meassure depressive symptoms. The MFQ consists of a series of descriptive phrases regarding how the subject has been feeling or acting recently and is a screening tool for depression in children and young people aged between 6 and 17 years.","The Mood and Feelings Questionnaire | MFQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520049","Metastatic Disease Indicator","C132456","An indication as to whether a malignancy has appeared at sites distant to the primary site of disease.","Metastatic Disease Indicator | METSIND | Metastatic Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545834","Intergroup Rhabdomyosarcoma Clinical Grouping System","C148010","Staging and grouping for rhabdomyosarcoma that groups patients into low, intermediate, or high clinical risk groups based on: histologic type, tumor site, tumor size, and pathologic TNM. Note: this is not the TNM system described in AJCC.","Intergroup Rhabdomyosarcoma Study Group Clinical Staging and Grouping System | Intergroup Rhabdomyosarcoma Clinical Grouping System | Intergroup Rhabdomyosarcoma Clinical Grouping System | Rhabdomyosarcoma Clinical Group System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546046","Intergroup Rhabdomyosarcoma Clinical Group Extent of Disease","C148011","An indication of whether rhabdomyosarcoma is confined to its primary location or has extended beyond the site of origin.","Intergroup Rhabdomyosarcoma Clinical Group Extent of Disease | Rhabdomyosarcoma Extent of Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546054","Intergroup Rhabdomyosarcoma Group I","C148012","Localized disease, excised.","Intergroup Rhabdomyosarcoma Group I | Group I | Rhabdomyosarcoma Group I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545835","Intergroup Rhabdomyosarcoma Group Ia","C148013","Confined to site of origin.","Intergroup Rhabdomyosarcoma Group Ia | Group Ia | Rhabdomyosarcoma Group Ia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545836","Intergroup Rhabdomyosarcoma Group Ib","C148014","Infiltrative, beyond site of origin; negative lymph nodes.","Intergroup Rhabdomyosarcoma Group Ib | Group Ib | Rhabdomyosarcoma Group Ib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545823","Intergroup Rhabdomyosarcoma Group II","C148015","Total gross resection with regional disease spread.","Intergroup Rhabdomyosarcoma Group II | Group II | Rhabdomyosarcoma Group II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545824","Intergroup Rhabdomyosarcoma Group IIa","C148016","Localized tumor with microscopic residual disease.","Intergroup Rhabdomyosarcoma Group IIa | Group IIa | Rhabdomyosarcoma Group IIa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545825","Intergroup Rhabdomyosarcoma Group IIb","C148017","Regional disease with positive lymph nodes, excised.","Intergroup Rhabdomyosarcoma Group IIb | Group IIb | Rhabdomyosarcoma Group IIb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545826","Intergroup Rhabdomyosarcoma Group IIc","C148018","Regional disease with positive lymph nodes.","Intergroup Rhabdomyosarcoma Group IIc | Group IIc | Rhabdomyosarcoma Group IIc",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545827","Intergroup Rhabdomyosarcoma Group III","C148019","Gross residual disease.","Intergroup Rhabdomyosarcoma Group III | Group III | Rhabdomyosarcoma Group III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545828","Intergroup Rhabdomyosarcoma Group IIIa","C148020","Localized or regional disease; biopsy.","Intergroup Rhabdomyosarcoma Group IIIa | Group IIIa | Rhabdomyosarcoma Group IIIa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545829","Intergroup Rhabdomyosarcoma Group IIIb","C148021","Localized or regional disease; resection (debulking of more than 50% of tumor).","Intergroup Rhabdomyosarcoma Group IIIb | Group IIIb | Rhabdomyosarcoma Group IIIb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545830","Intergroup Rhabdomyosarcoma Group IV","C148022","Distant metastasis.","Intergroup Rhabdomyosarcoma Group IV | Group IV | Rhabdomyosarcoma Group IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1137105","DSM-V","C147964","Published by the American Psychiatric Association, the DSM is a listing of currently recognized mental health disorders and their diagnostic criteria, for children and adults. It includes statistical information on etiology, incidence, prevalence, age of onset and prognosis. The 5th edition was published in 2013. As new information becomes available subsequent editions are published.","Diagnostic and Statistical Manual of Mental Disorders, 5th Edition | DSM-5 | DSM-V",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826604","AFF1 Gene","C24602","This gene is involved in the regulation of transcription elongation.","AFF1 Gene | AF4 | AF4/FMR2 Family Member 1 Gene | AFF1 | MLLT2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706636","ACVR2A Gene","C21271","This gene plays a role in the transforming growth factor-beta signal transduction pathway through constitutive kinase activity.","ACVR2A Gene | ACVR2A | Activin A Receptor, Type II Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424328","ACSL6 Gene","C97519","This gene is involved in the biosynthesis of lipids.","ACSL6 Gene | ACSL6 | Acyl-CoA Synthetase Long-Chain Family Member 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414519","ACSL3 Gene","C97365","This gene is involved in lipid biosynthesis.","ACSL3 Gene | ACSL3 | Acyl-CoA Synthetase Long-Chain Family Member 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335864","ABI1 Gene","C24824","This gene plays a role in signal transduction and negative regulation of cell proliferation.","ABI1 Gene | ABI1 | ABL Interactor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541489","A1CF Gene","C143031","This gene is involved in the deamination of APOB mRNA.","A1CF Gene | A1CF | APOBEC1 Complementation Factor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1540292","CD274 Gene","C96022","This gene is involved in T cell activation and proliferation.","CD274 Gene | CD274 | CD274 Molecule Gene | PD-L1 | PDL1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332697","CCNE1 Gene","C21412","This gene regulates the G1/S phase of the cell cycle by cyclin expression.","CCNE1 Gene | CCNE1 | Cyclin E1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413175","CCND3 Gene","C97381","This gene is involved in cell cycle progression.","CCND3 Gene | CCND3 | Cyclin D3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426243","CCNB1IP1 Gene","C97372","This gene plays a role in both ubiquitination and cell cycle progression.","CCNB1IP1 Gene | CCNB1IP1 | Cyclin B1 Interacting Protein 1, E3 Ubiquitin Protein Ligase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425774","CCDC6 Gene","C18376","This gene may play a role in tumor suppression.","CCDC6 Gene | CCDC6 | Coiled-Coil Domain Containing 6 Gene | H4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423865","CBLC Gene","C97439","This gene is involved in both ubiquitination and signaling.","CBLC Gene | CBLC | Cbl Proto-Oncogene C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332672","CBLB Gene","C21589","This gene plays a role in the regulation of T cell activation.","CBLB Gene | CBLB | Cbl Proto-Oncogene B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332671","CBFB Gene","C18584","This gene is involved in hematopoiesis and osteogenesis.","CBFB Gene | CBFB | Core-Binding Factor Subunit Beta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413149","CBFA2T3 Gene","C97445","This gene plays a role in transcriptional regulation.","CBFA2T3 Gene | CBFA2/RUNX1 Partner Transcriptional Co-Repressor 3 Gene | CBFA2T3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332667","CASP8 Gene","C26623","This gene is involved in apoptosis, immune cell homeostasis, lymphocyte activation and immunoprotection.","CASP8 Gene | CASP8 | Caspase 8 Gene | Caspase 8, Apoptosis-Related Cysteine Protease Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539063","KNL1 Gene","C97378","This gene is involved in both signaling and chromosome alignment in mitosis.","KNL1 Gene | CASC5 | KNL1 | Kinetochore Scaffold 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413126","CARS1 Gene","C97369","This gene is involved in transfer RNA metabolism.","CARS1 Gene | CARS | CARS Gene | CARS Gene | CARS1 | Cysteinyl-tRNA Synthetase 1 Gene | Cysteinyl-tRNA Synthetase Gene 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538435","CANT1 Gene","C97375","This gene plays a role in both nucleotide hydrolysis and signal transduction.","CANT1 Gene | CANT1 | Calcium Activated Nucleotidase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413058","CACNA1D Gene","C113769","This gene is involved in voltage-dependent calcium transport.","CACNA1D Gene | CACNA1D | Calcium Voltage-Gated Channel Subunit Alpha1 D Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824110","WDCP Gene","C101428","This gene plays a role in binding to tyrosine-protein kinase HCK.","WDCP Gene | C2orf44 | WD Repeat and Coiled Coil Containing Gene | WDCP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273816","PIERCE2 Gene","C98096","This gene may play a role in microtubule structure and ciliary motility.","PIERCE2 Gene | C15orf65 | C15orf65 Gene | C15orf65 Gene | Chromosome 15 Open Reading Frame 65 Gene | FLJ27352 | PIERCE2 | Piercer of Microtubule Wall 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422073","BRD4 Gene","C92702","This gene plays a role in mitosis.","BRD4 Gene | BRD4 | Bromodomain Containing 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412821","BRD3 Gene","C97397","This gene may play a role in both histone acetylation and transcriptional regulation.","BRD3 Gene | BRD3 | Bromodomain Containing 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332426","BMP5 Gene","C21353","This gene plays a role in the regulation of mesenchymal differentiation. It is involved in cartilage and bone formation.","BMP5 Gene | BMP5 | Bone Morphogenetic Protein 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332417","BIRC6 Gene","C20352","This gene regulates the apoptotic program via signal transduction in the ubiquitination pathway.","BIRC6 Gene | BIRC6 | Baculoviral IAP Repeat-Containing 6 (Apollon) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332415","BIRC3 Gene","C20356","This anti-apoptotic gene regulates apoptotic activity. BIRC3 gene promotes tumor cell survival.","BIRC3 Gene | BIRC3 | Baculoviral IAP Repeat Containing 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538320","BCORL1 Gene","C131268","This gene plays a role in the inhibition of gene expression.","BCORL1 Gene | BCL6 Corepressor-Like 1 Gene | BCORL1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424602","BCLAF1 Gene","C115994","Human BCLAF1 wild-type allele is located within 6q22-q23 and is approximately 33 kb in length. This allele, which encodes Bcl-2-associated transcription factor 1 protein, plays a role in both apoptosis promotion and the repression of transcription.","BCLAF1 Gene | BCL2-Associated Transcription Factor 1 Gene | BCLAF1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428193","BCL9L Gene","C132328","This gene plays a role in the coactivation of gene transcription.","BCL9L Gene | B-Cell CLL/Lymphoma 9-Like Gene | BCL9L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332402","BCL9 Gene","C24262","This gene plays a role in signal transduction and is involved in development.","BCL9 Gene | BCL9 | BCL9 Transcription Coactivator Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332400","BCL7A Gene","C24261","This gene may play a role in signal transduction.","BCL7A Gene | BAF Chromatin Remodeling Complex Subunit BCL7A Gene | BCL7A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422195","BCL2L12 Gene","C114743","This gene is involved in the regulation of apoptosis.","BCL2L12 Gene | BCL2-Like 12 (Proline Rich) Gene | BCL2L12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421887","BCL11B Gene","C91855","This gene may play a role in tumor suppression, signaling and T cell development.","BCL11B Gene | BAF Chromatin Remodeling Complex Subunit BCL11B Gene | BCL11B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421886","BCL11A Gene","C97394","This gene is involved in both the modulation of cell shape and lymphopoiesis.","BCL11A Gene | BAF Chromatin Remodeling Complex Subunit BCL11A Gene | BCL11A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1367449","BCL10 Gene","C24259","This gene is involved in the promotion of apoptosis.","BCL10 Gene | B-Cell CLL/Lymphoma 10 Gene | BCL10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332381","BARD1 Gene","C20715","This gene plays a role in cellular response and is susceptible to oncogenic mutations in breast and ovarian cancers.","BARD1 Gene | BARD1 | BRCA1 Associated RING Domain 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412709","B2M Gene","C62660","This gene plays a role in immune responses.","B2M Gene | B2M | Beta-2-Microglobulin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412642","ATP2B3 Gene","C113765","This gene plays a role in ATP-dependent calcium transport.","ATP2B3 Gene | ATP2B3 | ATPase Plasma Membrane Ca2+ Transporting 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412625","ATIC Gene","C97400","This gene plays a role in purine biosynthesis.","ATIC Gene | 5-Aminoimidazole-4-Carboxamide Ribonucleotide Formyltransferase/IMP Cyclohydrolase Gene | ATIC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428272","ASXL2 Gene","C116296","This gene plays a role in both chromatin modification and the positive regulation of transcription.","ASXL2 Gene | ASXL2 | Additional Sex Combs Like 2 (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422219","ASPSCR1 Gene","C70991","This gene is involved in the modulation of blood glucose levels.","ASPSCR1 Gene | ASPSCR1 | ASPSCR1 Tether for SLC2A4, UBX Domain Containing Gene | Alveolar Soft Part Sarcoma Chromosome Region, Candidate 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332116","ARNT Gene","C26373","This gene is involved in xenobiotic metabolism and receptor-ligand mediated interactions.","ARNT Gene | ARNT | Aryl Hydrocarbon Receptor Nuclear Translocator Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425257","ARID2 Gene","C101088","This gene is involved in both transcriptional regulation and chromatin remodeling.","ARID2 Gene | ARID2 | AT-Rich Interactive Domain 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425260","ARID1B Gene","C102520","This gene plays a role in both chromatin remodeling and transcriptional regulation.","ARID1B Gene | ARID1B | AT-Rich Interactive Domain 1B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422475","ARHGEF12 Gene","C97436","This gene plays a role in both G-protein coupled receptor- and Rho-mediated signaling.","ARHGEF12 Gene | ARHGEF12 | Rho Guanine Nucleotide Exchange Factor (GEF) 12 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412522","ARHGAP5 Gene","C97279","This gene is involved in the regulation of GTPase activity.","ARHGAP5 Gene | ARHGAP5 | Rho GTPase Activating Protein 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538925","ARHGAP26 Gene","C97504","This gene plays a role in signal transduction.","ARHGAP26 Gene | ARHGAP26 | Rho GTPase Activating Protein 26 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424925","APOBEC3B Gene","C117001","This gene plays a role in viral DNA cytosine deamination.","APOBEC3B Gene | APOBEC3B | Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825263","AMER1 Gene","C68718","This gene may play a role in kidney development.","AMER1 Gene | AMER1 | APC Membrane Recruitment Protein 1 Gene | FAM123B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412335","ALDH2 Gene","C84921","This gene plays a role in intermediary metabolism.","ALDH2 Gene | ALDH2 | Aldehyde Dehydrogenase 2 Family (Mitochondrial) Gene | Aldehyde Dehydrogenase 2 Family Member Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706652","AFF4 Gene","C21385","This gene plays a regulatory role in transcription and is involved in male germ cell differentiation.","AFF4 Gene | AF4/FMR2 Family Member 4 Gene | AFF4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708616","AFF3 Gene","C24538","This gene is involved in transcriptional activation and is purported to play roles in lymphoid development and oncogenesis.","AFF3 Gene | AF4/FMR2 Family, Member 3 Gene | AFF3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333343","EPS15 Gene","C24369","This gene plays a role in signal transduction and cell proliferation.","EPS15 Gene | EPS15 | Epidermal Growth Factor Receptor Pathway Substrate 15 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414382","ELN Gene","C75333","This gene is involved in the structure of the extracellular matrix.","ELN Gene | ELN | Elastin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427925","ELL Gene","C97516","This gene is involved in the modulation of transcription.","ELL Gene | ELL | Elongation Factor RNA Polymerase II Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414381","ELK4 Gene","C97476","This gene is involved in the regulation of transcription.","ELK4 Gene | ELK4 | ELK4, ETS-Domain Protein (SRF Accessory Protein 1) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414377","ELF4 Gene","C97470","This gene plays a role in both DNA binding and transcriptional activation.","ELF4 Gene | E74 Like ETS Transcription Factor 4 Gene | ELF4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366763","ELF3 Gene","C20899","This gene is involved in the regulation of both transcription and epithelial cell differentiation. It also plays a role in angiogenesis.","ELF3 Gene | E74-Like Factor 3 (ETS Domain Transcription Factor, Epithelial-Specific) Gene | ELF3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414349","EIF4A2 Gene","C97467","This gene is involved in translation initiation.","EIF4A2 Gene | EIF4A2 | Eukaryotic Translation Initiation Factor 4A2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812224","EIF3E Gene","C18347","This gene is involved in the initiation and regulation of protein translation.","EIF3E Gene | EIF3E | Eukaryotic Translation Initiation Factor 3, Subunit E Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539339","EIF1AX Gene","C131315","This gene is involved in translation initiation and efficiency.","EIF1AX Gene | EIF1AX | Eukaryotic Translation Initiation Factor 1A X-Linked Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414269","EED Gene","C101721","This gene plays a role in the negative regulation of transcription.","EED Gene | EED | Embryonic Ectoderm Development Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427334","ECT2L Gene","C101452","This gene may be involved in guanine nucleotide exchange.","ECT2L Gene | ECT2L | Epithelial Cell Transforming Sequence 2 Oncogene-Like Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498402","DUX4L1 Gene","C124048","Human DUX4L1 gene is located in the vicinity of 4q35 and is approximately 2 kb in length. The product is a processed pseudogene that produces an RNA transcript, but does not encode a protein product. This gene is within a D4Z4 repeat array; contraction of this macrosatellite repeat is associated with facioscapulohumeral muscular dystrophy (FSHD).","DUX4L1 Gene | DUX10 | DUX4L1 | Double Homeobox 4 Gene | Double Homeobox 4 Like 1 (Pseudogene) Gene | Double Homeobox 4 Like 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709966","DROSHA Gene","C25955","This gene plays a role in the processing of microRNA in the nucleus.","DROSHA Gene | DROSHA | Drosha Ribonuclease III Gene | RNASEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414120","DNM2 Gene","C102796","This gene plays a role in both GTP hydrolysis and microtubule organization.","DNM2 Gene | DNM2 | Dynamin 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415791","DNAJB1 Gene","C122560","This gene plays a role in the regulation of protein folding.","DNAJB1 Gene | DNAJB1 | DnaJ (Hsp40) Homolog, Subfamily B, Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414028","DGCR8 Gene","C92663","This gene plays a role in microRNA processing.","DGCR8 Gene | DGCR8 | DGCR8 Microprocessor Complex Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333214","DEK Gene","C24339","This gene is involved in RNA processing and regulation of chromatin organization.","DEK Gene | DEK | DEK Proto-Oncogene Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812257","DDX6 Gene","C18378","This gene plays a role in the translation of mRNA encoded by genes involved in cell proliferation and malignant transformation.","DDX6 Gene | DDX6 | DEAD-Box Helicase 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413963","DDX5 Gene","C97460","This gene is involved in the mediation of RNA metabolism.","DDX5 Gene | DDX5 | DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 5 Gene | DEAD-Box Helicase 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413952","DDX10 Gene","C97457","This gene plays a role in both RNA metabolism and ATP hydrolysis.","DDX10 Gene | DDX10 | DEAD-Box Helicase 10 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413947","DDIT3 Gene","C92539","This gene plays a role in the modulation of transcription.","DDIT3 Gene | CHOP | DDIT3 | DNA Damage Inducible Transcript 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413935","DCTN1 Gene","C122875","This gene is involved in the modulation of retrograde transport of cytoplasmic organelles and vesicles.","DCTN1 Gene | DCTN1 | Dynactin 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823822","DCAF12L2 Gene","C143036","This gene may play a role in protein complex formation.","DCAF12L2 Gene | DCAF12L2 | DDB1 and CUL4 Associated Factor 12 Like 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541483","CYSLTR2 Gene","C143039","This gene is involved in cysteinyl leukotriene binding and signal transduction.","CYSLTR2 Gene | CYSLTR2 | Cysteinyl Leukotriene Receptor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413827","CUX1 Gene","C95578","This gene is involved in both transcriptional regulation and Golgi vesicle transport.","CUX1 Gene | CUX1 | Cut-Like Homeobox 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332811","CUL3 Gene","C24323","This gene plays a role in protein degradation and cell cycle arrest.","CUL3 Gene | CUL3 | Cullin 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413801","CTNND2 Gene","C82941","This gene is involved in the regulation of both transcription and signal transduction.","CTNND2 Gene | CTNND2 | Catenin (Cadherin-Associated Protein), Delta 2 (Neural Plakophilin-Related Arm-Repeat Protein) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413800","CTNND1 Gene","C79770","This gene plays a role in signal transduction.","CTNND1 Gene | CTNND1 | Catenin (Cadherin-Associated Protein), Delta 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541524","CTNNA2 Gene","C143115","This gene is involved in cell-cell adhesion and cellular differentiation in the nervous system.","CTNNA2 Gene | CTNNA2 | Catenin Alpha 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824800","CRTC3 Gene","C95276","This gene is involved in transcriptional regulation.","CRTC3 Gene | CREB Regulated Transcription Coactivator 3 Gene | CRTC3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541477","CRNKL1 Gene","C143049","This gene is involved in RNA binding and pre-mRNA splicing.","CRNKL1 Gene | CRNKL1 | Crooked Neck Pre-mRNA Splicing Factor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428221","CREB3L2 Gene","C95480","This gene is involved in the response to cellular stress.","CREB3L2 Gene | CREB3L2 | cAMP Responsive Element Binding Protein 3-Like 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425827","CREB3L1 Gene","C95477","This gene plays a role in transcriptional regulation in response to cellular stress.","CREB3L1 Gene | CREB3L1 | cAMP Responsive Element Binding Protein 3-Like 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413702","CREB1 Gene","C38536","This gene is involved in transcriptional regulation and its activity is modulated in response to hormonal stimulation from the cAMP pathway.","CREB1 Gene | CREB1 | cAMP Responsive Element Binding Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332776","COX6C Gene","C24308","This gene is involved in mitochondrial respiration.","COX6C Gene | COX6C | Cytochrome C Oxidase Subunit VIC Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413581","COL3A1 Gene","C143052","This gene plays a role in collagen formation in connective tissues.","COL3A1 Gene | COL3A1 | Collagen Type III Alpha 1 Chain Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413580","COL2A1 Gene","C75315","This gene plays a role in both skeletal development and cartilage structure.","COL2A1 Gene | COL2A1 | Collagen, Type II, Alpha 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332772","COL1A1 Gene","C29949","This gene plays an important structural role in cartilage and mutations in the gene are associated with osteogenesis imperfecta.","COL1A1 Gene | COL1A1 | Collagen Type I Alpha 1 Chain Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824717","CNTRL Gene","C97891","This gene plays a role in cell cycle progression.","CNTRL Gene | CNTRL | Centriolin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422223","CNTNAP2 Gene","C73461","This gene may be involved in axonal structure.","CNTNAP2 Gene | CNTNAP2 | Contactin Associated Protein-Like 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417765","CNOT3 Gene","C107658","This gene is involved in mRNA degradation, miRNA-mediated repression, translational regulation and general transcription regulation.","CNOT3 Gene | CCR4-NOT Transcription Complex, Subunit 3 Gene | CNOT3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824763","CNBP Gene","C97888","This gene is involved in sterol-mediated transcription.","CNBP Gene | CCHC-Type Zinc Finger, Nucleic Acid Binding Protein Gene | CNBP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541468","CNBD1 Gene","C143056","This gene is involved in cyclic nucleotide binding.","CNBD1 Gene | CNBD1 | Cyclic Nucleotide Binding Domain Containing 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413513","CLTCL1 Gene","C97415","This gene is involved in both receptor-mediated endocytosis and vesicle formation.","CLTCL1 Gene | CLTCL1 | Clathrin Heavy Chain Like 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413512","CLTC Gene","C97412","This gene plays a role in both the formation of cellular vesicles and receptor-mediated endocytosis.","CLTC Gene | CLTC | Clathrin Heavy Chain Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824753","CLP1 Gene","C97528","This gene plays a role in RNA processing.","CLP1 Gene | CLP1 | Cleavage Factor Polyadenylation Kinase Subunit 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422489","CIC Gene","C97912","This gene is involved in the modulation of transcription.","CIC Gene | CIC | Capicua Transcriptional Repressor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424960","CHST11 Gene","C143061","This gene plays a role in the metabolism of chondroitin sulfate.","CHST11 Gene | CHST11 | Carbohydrate Sulfotransferase 11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413390","CHIC2 Gene","C97406","This gene may play a role in vesicular transport.","CHIC2 Gene | CHIC2 | Cysteine Rich Hydrophobic Domain 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413383","CHD4 Gene","C128251","This gene is involved in ATP-dependent chromatin remodeling.","CHD4 Gene | CHD4 | Chromodomain Helicase DNA Binding Protein 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413381","CHD2 Gene","C75307","This gene may be involved in the regulation of both gene expression and chromatin modification.","CHD2 Gene | CHD2 | Chromodomain Helicase DNA Binding Protein 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428688","CHCHD7 Gene","C97403","This gene may be involved in stature.","CHCHD7 Gene | CHCHD7 | Coiled-Coil-Helix-Coiled-Coil-Helix Domain Containing 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824650","CEP89 Gene","C122887","This gene is involved in cilia formation.","CEP89 Gene | CEP89 | Centrosomal Protein 89kDa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332737","CDKN1B Gene","C20060","This gene is involved in cell cycle regulation and cyclin regulation.","CDKN1B Gene | CDKN1B | Cyclin Dependent Kinase Inhibitor 1B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0249197","CDKN1A Gene","C17782","This gene is a regulator of cell cycle progression at the G1 phase of the cell cycle.","CDKN1A Gene | CDKN1A | Cyclin Dependent Kinase Inhibitor 1A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541553","CDH17 Gene","C143096","This gene is involved in cell-cell adhesion and intestinal proton-dependent peptide transport.","CDH17 Gene | CDH17 | Cadherin 17 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541550","CDH10 Gene","C143093","This gene plays a role in the modulation of neuronal cell shape and cell-cell adhesion.","CDH10 Gene | CDH10 | Cadherin 10 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708291","CDC73 Gene","C43569","This gene is involved in transcription and may play a role in cell cycle progression.","CDC73 Gene | CDC73 | Cell Division Cycle 73 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413237","CD74 Gene","C97418","This gene plays a role in antigen processing and presentation.","CD74 Gene | CD74 | CD74 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826273","Test Name","C82541","The literal identifier of an examination.","Test Name | TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426030","FIP1L1 Gene","C97454","This gene is involved in mRNA processing.","FIP1L1 Gene | FIP1 Like 1 (S. cerevisiae) Gene | FIP1L1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333544","FGFR4 Gene","C20743","This gene plays a role in mitogenesis and differentiation.","FGFR4 Gene | FGFR4 | Fibroblast Growth Factor Receptor 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333541","CEP43 Gene","C24401","This gene is involved in the regulation of cell shape, polarity and motility.","CEP43 Gene | CEP43 | Centrosomal Protein 43 Gene | FGFR1OP | FGFR1OP Gene | FGFR1OP Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425602","FEV Gene","C97482","This gene may play a role in transcriptional repression.","FEV Gene | FEV | FEV Transcription Factor, ETS Family Member Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414588","FES Gene","C45497","This gene is involved in hematopoiesis and the maintenance of cellular transformation.","FES Gene | FES | Feline Sarcoma Oncogene Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539514","FCRL4 Gene","C97592","This gene may be involved in B cell receptor signaling.","FCRL4 Gene | FCRL4 | Fc Receptor-Like 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422085","FBXO11 Gene","C101104","This gene plays a role in the recognition of proteins to be ubiquitinylated.","FBXO11 Gene | F-Box Protein 11 Gene | FBXO11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541507","FBLN2 Gene","C143130","This gene plays a role in protein-protein interactions in the extracellular matrix.","FBLN2 Gene | FBLN2 | Fibulin 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427920","FAT4 Gene","C128254","This gene plays a role in planar cell polarity.","FAT4 Gene | FAT Atypical Cadherin 4 Gene | FAT4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541510","FAT3 Gene","C143133","This gene is involved in cell adhesion and neurite development.","FAT3 Gene | FAT Atypical Cadherin 3 Gene | FAT3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541534","FAM47C Gene","C143109","This gene has no known function.","FAM47C Gene | FAM47C | Family with Sequence Similarity 47 Member C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539445","TENT5C Gene","C96316","This gene is involved in polyadenylation of RNA and mRNA stability.","TENT5C Gene | FAM46C | FAM46C Gene | TENT5C | Terminal Nucleotidyltransferase 5C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541537","FAM135B Gene","C143112","This gene may play a role in the metabolism of lipids.","FAM135B Gene | FAM135B | Family with Sequence Similarity 135 Member B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2239421","FAM131B Gene","C106340","This gene has not been characterized.","FAM131B Gene | FAM131B | Family with Sequence Similarity 131 Member B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421450","EZR Gene","C68722","This gene plays a role in cellular structure.","EZR Gene | EZR | Ezrin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0694879","EXT2 Gene","C18252","This gene is involved in the heparin/heparin sulfate biosynthesis, cell organization/biogenesis and development of the cytoskeleton in chondrocytes.","EXT2 Gene | EXT2 | Exostosin Glycosyltransferase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0694878","EXT1 Gene","C18251","This gene plays a role in heparin/heparin sulfate biosynthesis, axon guidance and biogenesis/cell organization.","EXT1 Gene | EXT1 | Exostosin Glycosyltransferase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414477","ETV5 Gene","C97479","This gene plays a role in the regulation of gene transcription.","ETV5 Gene | ETV5 | Ets Variant Transcription Factor 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333362","ETV4 Gene","C24378","This gene plays a regulatory role in transcription and in matrix metalloproteinase activity.","ETV4 Gene | E1AF | ETS Variant Transcription Factor 4 Gene | ETV4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539368","ETNK1 Gene","C122823","This gene plays a role in phospholipid biosynthesis.","ETNK1 Gene | ETNK1 | Ethanolamine Kinase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825059","ERC1 Gene","C97499","This gene plays a role in signaling.","ERC1 Gene | ELKS/RAB6-Interacting/CAST Family Member 1 Gene | ERC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882416","Polymorphic Microsatellite Marker Analysis","C63332","Analysis that looks for differences in the lengths of microsatellite repeats between alleles. Polymorphic microsatellites are present in the genome every few thousand base pairs and can function as molecular markers.","Polymorphic Microsatellite Marker Analysis | Microsatellite Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705687","Inversion Mutation Abnormality","C45589","A structural change in genomic DNA where the 5' to 3' order of a nucleotide sequence is completely reversed to the 3' to 5' order relative to its adjacent sequences. This inversion is termed either pericentric, if it includes the centromere of a chromosome, or pancentric, if it excludes the centromere. An inversion mutation abnormality may be heritable or occur somatically.","Inversion Mutation Abnormality | Inversion | Inversion Mutation | Inversion NOS | Inversion, NOS | inv",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705960","Gene Duplication Abnormality","C45582","Generation of an extra copy of a particular gene in the genome. A gene duplication abnormality may occur by gene amplification, random breakage and reunion, retrotransposition or unequal crossing-over at meiosis. A gene duplication abnormality can be either heritable or somatic.","Gene Duplication Abnormality | Duplication | Gene Duplication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334308","KLK2 Gene","C26584","This gene plays a role in proteolysis.","KLK2 Gene | KLK2 | Kallikrein 2, Prostatic Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416639","KIF5B Gene","C101425","This gene is involved in the transport of vesicles along microtubules.","KIF5B Gene | KIF5B | Kinesin Family Member 5B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049723","SHTN1 wt Allele","C122907","Human SHTN1 wild-type allele is located in the vicinity of 10q25.3 and is approximately 242 kb in length. This allele, which encodes shootin-1 protein, plays a role in signaling involved in neuronal polarization.","SHTN1 wt Allele | KIAA1598 | SHOOTIN1 | Shootin 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2681629","KIAA1549 Gene","C98017","This gene may play a role in brain functions.","KIAA1549 Gene | KIAA1549",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419288","KDM5A Gene","C97595","This gene plays a role in transcriptional modulation.","KDM5A Gene | JARID1A | KDM5A | Lysine (K)-Specific Demethylase 5A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416587","KCNJ5 Gene","C95838","This gene is involved in ion transport.","KCNJ5 Gene | KCNJ5 | Potassium Voltage-Gated Channel Subfamily J Member 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424687","KAT7 Gene","C73660","This gene is involved in epigenetic control of gene expression through histone acetylation.","KAT7 Gene | K(Lysine) Acetyltransferase 7 Gene | KAT7 | MYST2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425003","KAT6B Gene","C71431","This gene plays a role in both transcription and histone acetylation.","KAT6B Gene | K(Lysine) Acetyltransferase 6B Gene | KAT6B | MYST4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421709","KAT6A Gene","C71429","This gene is involved in both histone acetylation and transcriptional regulation.","KAT6A Gene | KAT6A | Lysine Acetyltransferase 6A Gene | MOZ | MYST3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825635","JAZF1 Gene","C73542","This gene may be involved in transcriptional repression.","JAZF1 Gene | JAZF Zinc Finger 1 Gene | JAZF1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334290","JAK1 Gene","C24528","This gene plays a role in non-receptor tyrosine protein kinase-mediated signal transduction.","JAK1 Gene | JAK1 | Janus Kinase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416494","ITGAV Gene","C53661","This gene plays a role in cell communication and angiogenesis.","ITGAV Gene | ITGAV | Integrin, Alpha V Gene | VTNR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334142","IRS4 Gene","C24524","This gene plays a role in signal transduction and ligand binding.","IRS4 Gene | IRS4 | Insulin Receptor Substrate 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1442489","IKBKB Gene","C96383","This gene is involved in protein phosphorylation.","IKBKB Gene | IKBKB | Inhibitor of Kappa Light Polypeptide Gene Enhancer in B-Cells, Kinase Beta Gene | Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415856","ID3 Gene","C102968","This gene plays a role in transcriptional repression.","ID3 Gene | ID3 | Inhibitor of DNA Binding 3, Dominant Negative Helix-Loop-Helix Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825540","HSP90AB1 Gene","C97589","This gene plays a role in both interferon signaling and protein folding.","HSP90AB1 Gene | HSP90AB1 | Heat Shock Protein 90kDa Alpha (Cytosolic), Class B Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825534","HSP90AA1 Gene","C97586","This gene is involved in both protein folding and nitric oxide metabolism.","HSP90AA1 Gene | HSP90AA1 | Heat Shock Protein 90 Alpha Family Class A Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415687","HOXD13 Gene","C97583","This gene plays a role in the development of limbs and appendages.","HOXD13 Gene | HOXD13 | Homeobox D13 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415685","HOXD11 Gene","C97580","This gene is involved in limb morphogenesis.","HOXD11 Gene | HOXD11 | Homeobox D11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415677","HOXC13 Gene","C97577","This gene plays a role in the modulation of transcription.","HOXC13 Gene | HOXC13 | Homeobox C13 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415675","HOXC11 Gene","C97574","This gene is involved in embryological development.","HOXC11 Gene | HOXC11 | Homeobox C11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415655","HOXA13 Gene","C97571","This gene plays a role in transcriptional modulation.","HOXA13 Gene | HOXA13 | Homeobox A13 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415654","HOXA11 Gene","C97568","This gene is involved in embryologic pattern formation.","HOXA11 Gene | HOXA11 | Homeobox A11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428139","HOOK3 Gene","C97493","This gene plays a role in endocytosis and Golgi maintenance.","HOOK3 Gene | HOOK3 | Hook Homolog 3 (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428626","HMGN2P46 Gene","C98093","This gene may be involved in prostate functions.","HMGN2P46 Gene | HMGN2P46 | High Mobility Group Nucleosomal Binding Domain 2 Pseudogene 46 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333903","HMGA1 Gene","C20576","This gene plays a role in a number of cellular processes including apoptosis, chromatin organization and transcriptional regulation.","HMGA1 Gene | HMGA1 | High Mobility Group AT-Hook 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415594","HLF Gene","C97556","This gene is involved in both transcriptional regulation and DNA binding.","HLF Gene | HLF | HLF Transcription Factor, PAR BZIP Family Member Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415453","H4C9 Gene","C68734","This gene plays a role in nucleosomal structure.","H4C9 Gene | H4 Clustered Histone 9 Gene | H4C9 | HIST1H4I | HIST1H4I Gene | HIST1H4I Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415439","H3C2 Gene","C101732","This gene is involved in chromatin structure.","H3C2 Gene | H3 Clustered Histone 2 Gene | H3C2 | HIST1H3B | HIST1H3B Gene | HIST1H3B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415546","HIP1 Gene","C97537","This gene plays a role in both vesicle coat formation and endocytosis.","HIP1 Gene | HIP1 | Huntingtin Interacting Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415524","HEY1 Gene","C101107","This gene is involved in both transcription factor binding and transcriptional repression.","HEY1 Gene | HEY1 | Hes Related Family BHLH Transcription Factor With YRPW Motif 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422179","HERPUD1 Gene","C97534","This gene is involved in the response to endoplasmic reticulum stress.","HERPUD1 Gene | HERPUD1 | Homocysteine Inducible ER Protein with Ubiquitin Like Domain 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415428","H3-3B Gene","C113760","This gene plays a role in nucleosome assembly.","H3-3B Gene | H3-3B | H3.3 Histone B Gene | H3F3B | H3F3B Gene | H3F3B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415299","GRIN2A Gene","C98146","This gene is involved in the regulation of ion transport.","GRIN2A Gene | GRIN2A | Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 2A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423507","GPHN Gene","C97525","This gene is involved in vitamin metabolism.","GPHN Gene | GPHN | Gephyrin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415195","GPC3 Gene","C88173","This gene is involved in heparin sulfate binding.","GPC3 Gene | GPC3 | Glypican 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425021","GOPC Gene","C97546","This gene plays a role in protein transport.","GOPC Gene | GOPC | Golgi-Associated PDZ and Coiled-Coil Motif Containing Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415177","GOLGA5 Gene","C97543","This gene is involved in Golgi maintenance.","GOLGA5 Gene | GOLGA5 | Golgin A5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415137","GMPS Gene","C97522","This gene plays a role in nucleotide biosynthesis.","GMPS Gene | GMPS | Guanine Monphosphate Synthetase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414992","GAS7 Gene","C97562","This gene may play a role in neuronal development.","GAS7 Gene | GAS7 | Growth Arrest Specific 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333581","FSTL3 Gene","C24408","This gene plays a role in a variety of processes including transcription.","FSTL3 Gene | FSTL3 | Follistatin-Like 3 (Secreted Glycoprotein) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541517","FOXR1 Gene","C143124","This gene plays a role in DNA binding and transcriptional regulation.","FOXR1 Gene | FOXR1 | Forkhead Box R1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333573","FOXO3 Gene","C28519","This gene is involved in transcriptional regulation and apoptosis.","FOXO3 Gene | FOXO3 | Forkhead Box O3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424722","FNBP1 Gene","C97540","This gene plays a role in endocytosis.","FNBP1 Gene | FNBP1 | Formin Binding Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1860424","FLI1 Gene","C18321","This gene plays a role in transcriptional activation and has been implicated in the pathogenesis of neuroepithelioma.","FLI1 Gene | FLI1 | Friend Leukemia Virus Integration 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541520","FKBP9 Gene","C143127","This gene is involved in chaperone-mediated protein folding.","FKBP9 Gene | FK506 Binding Protein 9 Gene | FKBP9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519328","Regulatory Region SNP","C41010","Single Nucleotide Polymorphism in Regulatory Sequences (Regulatory Region SNP) consists of a variation at an appreciable frequency between individuals of a single interbreeding population of a single nucleotide, due to base substitution, at an equivalent location within a gene region that is involved in the regulation of genetic processes, such as transcription and replication.","Regulatory Region SNP | Single Nucleotide Polymorphism in Regulatory Sequences | rSNP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710092","Intronic SNP","C45387","Single Nucleotide Polymorphism in Intronic Sequences (Intronic SNP) consists of a variation at an appreciable frequency between individuals of a single interbreeding population of a single nucleotide, due to base substitution, at an equivalent location within a transcribed non-coding intervening DNA sequence separating protein-coding sequences (exons) in an eukaryotic nuclear gene. Poorly conserved and of variable length and number, intron sequences are removed from nascent message RNA transcripts in the nucleus after the 5' cap and polyA tail have been added. Self-complementary sequences at exon-intron junctions form a hairpin structure recognized by enzymes that splice exons together into a mature mRNA that is ready for translation in the cytoplasm. When the intron is removed, the donor junction at the 5' end of the intron is spliced to the acceptor junction at the 3' end of the intron.","Intronic SNP | Intronic, Intron SNP | Single Nucleotide Polymorphism in Intronic Sequences",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881249","Intron Splice Region Mutation","C63428","Any intronic mutation that occurs at a distance up to 10 bases from the exon junction.","Intron Splice Region Mutation | Intronic Splice Region Mutation | Splice Region Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706692","Acceptor Splice Site SNP","C45389","A heritable single nucleotide polymorphism located at the acceptor splice site in certain allelic variants of eukaryotic genes. These sites are located in genes at intron to exon junctions at the 3' end of the intron.","Acceptor Splice Site SNP | Intronic, Acceptor Splice Site SNP | Splice Acceptor | Splice Acceptor Point Mutation | Splice Acceptor Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707808","Donor Splice Site SNP","C45390","An inherited single base change at a donor splice site in a genomic DNA sequence that results in an allelic variant of the wild-type gene. Donor splice sites are located at exon to intron junctions at the 5' end of the intron.","Donor Splice Site SNP | Intronic, Donor Splice Site SNP | Splice Donor | Splice Donor Point Mutation | Splice Donor Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710582","Upstream Region SNP","C45575","An inherited single base substitution in a sequence of eukaryotic DNA located within a region 5' to the transcription start site of a gene. This type of single nucleotide polymorphism may affect gene expression if it occurs in the promoter region of a gene and alters the recognition sequence of a specific promoter protein.","Upstream Region SNP | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545808","S-warfarin","C148031","The S-enantiomer of warfarin, an orally available coumarin and a vitamin K antagonist, with anticoagulant activity. Upon administration, S-warfarin inhibits vitamin K epoxide reductase, thereby interfering with the cyclic interconversion of vitamin K epoxide to its reduced form, vitamin K hydroquinone (KH2). Vitamin KH2 is a cofactor for the carboxylation of glutamate residues on the N-terminal regions of vitamin K-dependent proteins, such as the vitamin K-dependent coagulation factors II, VII, IX and X, and the anticoagulant proteins C, S and Z. Therefore, this agent inhibits vitamin KH2 production and prevents blood clot formation. Warfarin is composed of a racemic mixture of R- and S-isomers; S-warfarin is a more potent anticoagulant than the R-form.","S-warfarin | 2H-1-Benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)-, (S)- | WARFARIN, (S)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825506","Derived Flag","C81197","An indication that a data element has been derived from one or more data elements.","Derived Flag | DERIVED | DRVFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418629","PLAG1 Gene","C71423","This gene is involved in cellular proliferation.","PLAG1 Gene | PLAG1 | PLAG1 Zinc Finger Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423544","PICALM Gene","C84434","This gene plays a role in receptor mediated endocytosis.","PICALM Gene | PICALM | Phosphatidylinositol Binding Clathrin Assembly Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418464","PER1 Gene","C97721","This gene is involved in circadian rhythm.","PER1 Gene | PER1 | Period Circadian Regulator 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418374","PCM1 Gene","C97900","This gene is involved in centrosome formation.","PCM1 Gene | PCM1 | Pericentriolar Material 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418297","PCBP1 Gene","C95865","This gene plays a role in RNA splicing.","PCBP1 Gene | PCBP1 | Poly(rC)-Binding Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418277","PAX8 Gene","C97687","This gene is involved in thyroid development and transcriptional regulation.","PAX8 Gene | PAX8 | Paired Box 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418246","PAFAH1B2 Gene","C97894","This gene is involved in lipid metabolism.","PAFAH1B2 Gene | PAFAH1B2 | Platelet Activating Factor Acetylhydrolase 1b Catalytic Subunit 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541452","PABPC1 Gene","C143072","This gene is involved in binding to poly(A)RNA.","PABPC1 Gene | PABPC1 | Poly(A) Binding Protein Cytoplasmic 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423554","P2RY8 Gene","C97683","This gene plays a role in signaling.","P2RY8 Gene | P2RY8 | P2Y Receptor Family Member 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417948","OMD Gene","C97680","This gene is involved in cell adhesion.","OMD Gene | OMD | Osteomodulin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539399","NUTM2B Gene","C101101","The function of this gene is unknown.","NUTM2B Gene | FAM22B | NUT Family Member 2B Gene | NUTM2B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541493","NUTM2A Gene","C101098","This gene has an unknown function.","NUTM2A Gene | FAM22A | NUT Family Member 2A Gene | NUTM2A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1837033","NUTM1 Gene","C92705","This gene may be involved in testicular function.","NUTM1 Gene | C15orf55 | NUT Midline Carcinoma Family Member 1 Gene | NUTM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334913","NUP98 Gene","C20820","This gene plays a role in transport and is frequently overexpressed in prostate cancers.","NUP98 Gene | NUP98 | Nucleoporin 98 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334912","NUP214 Gene","C24649","This gene plays a critical role in nuclear transport and docking regulation. Alterations in the gene have been associated with several cancers and leukemias.","NUP214 Gene | NUP214 | Nucleoporin 214 Gene | Nucleoporin 214kDa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417837","NR4A3 Gene","C96007","This gene is involved in nuclear receptor-dependent modulation of gene transcription.","NR4A3 Gene | NR4A3 | Nuclear Receptor Subfamily 4 Group A Member 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334894","NPM1 Gene","C21185","This gene is involved in the regulation of ribosomal assembly.","NPM1 Gene | NPM1 | Nucleophosmin (Nucleolar Phosphoprotein B23, Numatrin) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417767","NOTCH2 Gene","C97677","This gene plays a role in cell-cell signaling.","NOTCH2 Gene | NOTCH2 | Notch 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417758","NONO Gene","C71419","This gene may play a role in both transcriptional regulation and nuclear RNA processing.","NONO Gene | NONO | Non-POU Domain Containing, Octamer-Binding Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1384616","NKX2-1 Gene","C73443","This gene plays a role in thyroid gene transcription.","NKX2-1 Gene | NK2 Homeobox 1 Gene | NKX2-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505189","GSKIP Gene","C97668","This gene is involved in the localization of the centrosome.","NIN Gene | NIN | Ninein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417710","NFKBIE Gene","C38396","This gene plays a role in signal transduction and regulation of transcription. It is involved in the immune response.","NFKBIE Gene | NFKB Inhibitor Epsilon Gene | NFKBIE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812286","NFKB2 Gene","C18404","This gene plays a role in transcriptional regulation, signal transduction and inflammatory responses.","NFKB2 Gene | NFKB2 | Nuclear Factor Kappa B Subunit 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417695","NFATC2 Gene","C93138","This gene is involved in cytokine gene transcription.","NFATC2 Gene | NFATC2 | Nuclear Factor of Activated T Cells 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334871","NCOR2 Gene","C28633","This gene plays a role in repression of transcription. It is also involved in chromatin remodeling.","NCOR2 Gene | NCOR2 | Nuclear Receptor Co-Repressor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812260","NCOA4 Gene","C18381","This gene is involved in the transcriptional activation of target genes.","NCOA4 Gene | NCOA4 | Nuclear Receptor Coactivator 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334867","NCOA2 Gene","C20697","This gene is involved in regulation of transcription. It also plays a role in myogenic differentiation.","NCOA2 Gene | NCOA2 | Nuclear Receptor Coactivator 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423524","NCKIPSD Gene","C97433","This gene plays a role in stress fiber formation.","NCKIPSD Gene | NCK Interacting Protein with SH3 Domain Gene | NCKIPSD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541563","NBEA Gene","C143075","This gene plays a role in membrane-targeting of protein kinase A.","NBEA Gene | NBEA | Neurobeachin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417590","NACA Gene","C97653","This gene plays a role in protein sorting.","NACA Gene | NACA | Nascent Polypeptide Associated Complex Subunit Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417589","NAB2 Gene","C122903","This gene plays a role in the repression of gene transcription.","NAB2 Gene | NAB2 | NGFI-A Binding Protein 2 (EGR1 Binding Protein 2) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417565","MYO5A Gene","C122881","This gene is involved in vesicle transport along actin filaments.","MYO5A Gene | MYO5A | Myosin VA (Heavy Chain 12, Myoxin) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417544","MYH9 Gene","C97646","This gene is involved in both cytoskeleton modeling and cytokinesis.","MYH9 Gene | MYH9 | Myosin Heavy Chain 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334535","MTCP1 Gene","C24617","This gene plays a role in the proliferation of T cells and is involved in cell cycle regulation.","MTCP1 Gene | MTCP1 | Mature T-Cell Proliferation 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417371","MSN Gene","C97621","This gene plays a role in both cell adhesion and cytoskeleton modeling.","MSN Gene | MSN | Moesin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425623","MSI2 Gene","C91356","This gene is involved in translational regulation.","MSI2 Gene | MSI2 | Musashi RNA Binding Protein 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415596","MNX1 Gene","C97559","This gene plays a role in both the regulation of transcription and DNA binding.","MNX1 Gene | HLXB9 | MNX1 | Motor Neuron and Pancreas Homeobox 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334517","MLLT6 Gene","C24605","This gene is involved in transcriptional regulation and aberrations in the gene are associated with acute leukemias due to chromosomal translocations.","MLLT6 Gene | AF17 | MLLT6 | MLLT6, PHD Finger Containing Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334516","AFDN Gene","C24604","This gene is involved in cell adhesion and cytoskeletal modeling.","AFDN Gene | AF6 | AFDN | Afadin, Adherens Junction Formation Factor Gene | MLLT4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334515","MLLT3 Gene","C24603","This gene plays a role in transcriptional regulation and translocations in the gene are associated with leukemia.","MLLT3 Gene | AF9 | MLLT3 | MLLT3 Super Elongation Complex Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423947","MLLT10 Gene","C84461","This gene may be involved in transcriptional regulation through the modulation of histone methyltransferase activity.","MLLT10 Gene | AF10 | MLLT10 | MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334513","MLLT1 Gene","C24601","This gene is involved in transcriptional regulation as part of the transcription elongation factor complex.","MLLT1 Gene | ENL | MLLT1 | MLLT1, Super Elongation Complex Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417188","MLF1 Gene","C97650","This gene plays a role in both transcriptional regulation and cell cycle arrest.","MLF1 Gene | MLF1 | Myeloid Leukemia Factor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537677","MED12 Gene","C98210","This gene plays a role in the regulation of RNA polymerase II-dependent transcription.","MED12 Gene | MED12 | Mediator Complex Subunit 12 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825956","MDS2 Gene","C97615","This gene plays a role in myelodysplastic syndrome.","MDS2 Gene | MDS2 | Myelodysplastic Syndrome 2 Translocation Associated Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812222","MDM2 Gene","C18345","This gene plays a role in several cellular processes related to cellular viability; including the cell cycle and apoptosis.","MDM2 Gene | MDM2 | MDM2 Proto-Oncogene Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3147784","MB21D2 Gene","C132170","This gene plays a role in protein-protein interactions.","MB21D2 Gene | MB21D2 | Mab-21 Domain Containing 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417012","MAP3K13 Gene","C102523","This gene is involved in both protein phosphorylation and signaling.","MAP3K13 Gene | MAP3K13 | Mitogen-Activated Protein Kinase Kinase Kinase 13 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1367675","MAP3K1 Gene","C24572","This gene plays a role in mediating cellular responses to growth factors, metabolic stimuli and mitogens.","MAP3K1 Gene | MAP3K1 | Mitogen-Activated Protein Kinase Kinase Kinase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417008","MAP2K4 Gene","C97674","This gene is involved in MAPK signaling.","MAP2K4 Gene | MAP2K4 | Mitogen-Activated Protein Kinase Kinase 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537647","MALAT1 Gene","C92696","This gene may play a role in carcinogenesis.","MALAT1 Gene | MALAT1 | Metastasis Associated Lung Adenocarcinoma Transcript 1 (Non-Protein Coding) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416947","LZTR1 Gene","C128257","This gene may be involved in Golgi stabilization, embryogenesis or transcriptional regulation.","LZTR1 Gene | LZTR1 | Leucine Zipper Like Transcription Regulator 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825913","LSM14A Gene","C122884","This gene plays a role in the storage of mRNA.","LSM14A Gene | LSM14A | LSM14A, SCD6 Homolog A (S. cerevisiae) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537590","LRIG3 Gene","C101446","This gene may be involved in signaling.","LRIG3 Gene | LRIG3 | Leucine-Rich Repeats and Immunoglobulin-Like Domains 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416904","LPP Gene","C97610","This gene may be involved in cell shape and cell motility.","LPP Gene | LIM Domain Containing Preferred Translocation Partner in Lipoma Gene | LPP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334339","LIFR Gene","C24552","This gene plays a critical role in cell fate and proliferation in both embryonic and adult cells.","LIFR Gene | LIFR | Leukemia Inhibitory Factor Receptor Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416844","LHFPL6 Gene","C97607","This gene may play a role in cell adhesion or cell proliferation.","LHFPL6 Gene | LHFP | LHFPL Tetraspan Subfamily Member 6 Gene | LHFPL6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334332","LCP1 Gene","C21294","This gene plays a role in cytoskeletal remodeling.","LCP1 Gene | LCP1 | Lymphocyte Cytosolic Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919477","LCK Gene","C18541","This gene is involved in signal transduction and the development/function of T cells.","LCK Gene | LCK | LCK Proto-Oncogene, Src Family Tyrosine Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416800","LASP1 Gene","C97604","This gene is involved in actin-dependent ion transport.","LASP1 Gene | LASP1 | LIM and SH3 Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541460","LARP4B Gene","C143064","This gene is involved in RNA metabolism and translation.","LARP4B Gene | LARP4B | La Ribonucleoprotein Domain Family Member 4B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416766","KTN1 Gene","C97601","This gene plays a role in kinesin function.","KTN1 Gene | KTN1 | Kinectin 1 (Kinesin Receptor) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539051","KNSTRN Gene","C119652","This gene plays a role in both mitotic spindle formation and chromosome segregation.","KNSTRN Gene | KNSTRN | Kinetochore-Localized Astrin/SPAG5 Binding Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419112","PTPRB Gene","C122909","This gene is involved in dephosphorylation of proteins.","PTPRB Gene | PTPRB | Protein Tyrosine Phosphatase, Receptor Type, B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335274","PTK6 Gene","C24701","This gene plays a role in signal transduction.","PTK6 Gene | PTK6 | PTK6 Protein Tyrosine Kinase 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335268","PSIP1 Gene","C20676","This gene is involved in regulation of transcription. It also plays a role in mediation of pre-mRNA splicing.","PSIP1 Gene | PC4 and SFRS1 Interacting Protein 1 Gene | PSIP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541547","PRPF40B Gene","C143090","This gene may be involved in mRNA splicing.","PRPF40B Gene | PRPF40B | Pre-mRNA Processing Factor 40 Homolog B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418907","PRKAR1A Gene","C97742","This gene plays a role in the regulation of protein kinase A.","PRKAR1A Gene | PRKAR1A | Protein Kinase cAMP-Dependent Type I Regulatory Subunit Alpha Gene | Protein Kinase, cAMP-Dependent, Regulatory, Type I, Alpha (Tissue Specific Extinguisher 1) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418901","PRKACA Gene","C38409","This gene is involved in the regulation of diverse cell processes including cell growth, proliferation, differentiation and motility.","PRKACA Gene | PRKACA | Protein Kinase cAMP-Activated Catalytic Subunit Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427805","PREX2 Gene","C102517","This gene is involved in guanine nucleotide exchange activity that regulates the GTPase activity of Rac family proteins.","PREX2 Gene | PREX2 | Phosphatidylinositol-3,4,5-Trisphosphate-Dependent Rac Exchange Factor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418875","PRDM2 Gene","C143121","This gene is involved in both methylation of histone H3 and transcriptional regulation.","PRDM2 Gene | PR/SET Domain 2 Gene | PRDM2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422337","PRDM16 Gene","C97736","This gene plays a role in both transcriptional regulation and adipocyte differentiation.","PRDM16 Gene | PR/SET Domain 16 Gene | PRDM16",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418872","PRCC Gene","C70994","This gene may be involved in transcriptional regulation.","PRCC Gene | PRCC | Papillary Renal Cell Carcinoma (Translocation-Associated) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418853","PPP6C Gene","C102901","This gene plays a role in both protein dephosphorylation and signaling.","PPP6C Gene | PPP6C | Protein Phosphatase 6, Catalytic Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418837","PPP2R1A Gene","C92536","This gene plays a role in the regulation of cell growth and division.","PPP2R1A Gene | PPP2R1A | Protein Phosphatase 2 Scaffold Subunit Aalpha Gene | Protein Phosphatase 2, Regulatory Subunit A, Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418789","PPFIBP1 Gene","C101494","This gene plays a role in protein-protein interactions and cell-matrix adhesion.","PPFIBP1 Gene | PPFIBP1 | PTPRF Interacting Protein, Binding Protein 1 (Liprin Beta 1) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335238","PPARG Gene","C24689","This gene plays a regulatory role in adipocyte differentiation.","PPARG Gene | PPARG | Peroxisome Proliferator-Activated Receptor Gamma Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418768","POU5F1 Gene","C61140","This gene plays a role in early mammalian development.","POU5F1 Gene | POU Class 5 Homeobox 1 Gene | POU5F1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418760","POU2AF1 Gene","C97730","This gene is involved in both humoral immunity and transcriptional regulation.","POU2AF1 Gene | POU Class 2 Associating Factor 1 Gene | POU2AF1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418738","POLQ Gene","C131801","This gene is involved in DNA synthesis and repair.","POLQ Gene | DNA Polymerase Theta Gene | POLQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418731","POLG Gene","C143069","This gene plays a role in the replication of mitochondrial DNA.","POLG Gene | DNA Polymerase Gamma, Catalytic Subunit Gene | POLG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824428","RMI2 Gene","C96027","This gene is involved in DNA replication.","RMI2 Gene | RMI2 | RecQ Mediated Genome Instability 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419377","RGS7 Gene","C143118","This gene plays a role in the inhibition of both G protein-coupled receptor signaling and signal transduction.","RGS7 Gene | RGS7 | Regulator of G Protein Signaling 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541555","RGPD3 Gene","C143082","This gene may play a role in the localization of the GTPase Ran.","RGPD3 Gene | RANBP2-Like and GRIP Domain Containing 3 Gene | RGPD3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335607","RECQL4 Gene","C26492","This gene is involved in the initiation of DNA replication and sister-chromatid cohesion.","RECQL4 Gene | RECQL4 | RecQ Like Helicase 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423088","RBM15 Gene","C97293","This gene plays a role in RNA binding.","RBM15 Gene | RBM15 | RNA Binding Motif Protein 15 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419296","RBM10 Gene","C115382","This gene is involved in RNA binding and processing.","RBM10 Gene | RBM10 | RNA Binding Motif Protein 10 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419268","RAP1GDS1 Gene","C97758","This gene is involved in guanine nucleotide exchange.","RAP1GDS1 Gene | RAP1GDS1 | Rap1 GTPase-GDP Dissociation Stimulator 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419259","RANBP2 Gene","C114452","This gene is involved in both SUMOylation and nuclear transport.","RANBP2 Gene | RAN Binding Protein 2 Gene | RANBP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335588","RALGDS Gene","C24721","This gene plays a role in signal transduction and cytoskeletal remodeling. It is also involved in regulation of cell growth.","RALGDS Gene | RAL Guanine Nucleotide Dissociation Stimulator Gene | RALGDS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425034","RABEP1 Gene","C97751","This gene is involved in the regulation of both GTPase activity and endocytosis.","RABEP1 Gene | RABEP1 | Rabaptin, RAB GTPase Binding Effector Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427319","QKI Gene","C111937","This gene is involved in both the biosynthesis and maintenance of mRNA.","QKI Gene | QKI | QKI, KH Domain Containing, RNA Binding Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2239866","PWWP2A Gene","C122890","This gene may play a role in protein-protein or protein-DNA interactions.","PWWP2A Gene | PWWP Domain Containing 2A Gene | PWWP2A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335289","PTPRT Gene","C24716","This gene plays a role in the control of motor axon guidance.","PTPRT Gene | PTPRT | Protein Tyrosine Phosphatase, Receptor Type, T Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419117","PTPRK Gene","C106113","This gene is involved in receptor signaling, cell-cell contact and cell migration.","PTPRK Gene | PTPRK | Protein Tyrosine Phosphatase, Receptor Type, K Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539835","SPEN Gene","C115310","This gene plays a role in hormone-mediated transcriptional regulation.","SPEN Gene | SPEN | Spen Family Transcriptional Repressor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823096","SPECC1 Gene","C97531","This gene may be involved in nuclear structure.","SPECC1 Gene | SPECC1 | Sperm Antigen with Calponin Homology and Coiled-Coil Domains 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1822796","SND1 Gene","C96331","This gene plays a role in both transcriptional regulation and RNA interference.","SND1 Gene | SND1 | Staphylococcal Nuclease and Tudor Domain Containing 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1822777","SMC1A Gene","C75406","This gene is involved in maintenance of sister chromatid cohesion during mitosis.","SMC1A Gene | SMC1A | Structural Maintenance of Chromosomes 1A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335850","SMARCE1 Gene","C19874","This gene is involved in chromatin remodeling and regulation of transcription.","SMARCE1 Gene | SMARCE1 | SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily E, Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335847","SMARCD1 Gene","C19875","This gene plays a role in chromatin remodeling and regulation of transcription.","SMARCD1 Gene | SMARCD1 | SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily D, Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418294","SLC45A3 Gene","C97791","This gene plays a role in transmembrane transport.","SLC45A3 Gene | SLC45A3 | Solute Carrier Family 45, Member 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420186","SLC34A2 Gene","C101434","This gene plays a role in phosphate transport.","SLC34A2 Gene | SLC34A2 | Solute Carrier Family 34 Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812379","SKI Gene","C69184","This gene is involved in transcriptional regulation and is involved in cellular signal transduction.","SKI Gene | SKI | SKI Proto-Oncogene Gene | V-SKI Sarcoma Viral Oncogene Homolog (Avian) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420025","SH3GL1 Gene","C97788","This gene may be involved in endocytosis.","SH3GL1 Gene | SH3-Domain GRB2-Like 1 Gene | SH3GL1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419984","SFPQ Gene","C71417","This gene may be involved in both transcriptional regulation and nuclear RNA processing.","SFPQ Gene | SFPQ | Splicing Factor Proline/Glutamine-Rich (Polypyrimidine Tract Binding Protein Associated) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366517","SET Gene","C24801","This gene is involved in apoptosis, biogenesis, DNA replication and nuclear organization.","SET Gene | SET | SET Nuclear Proto-Oncogene Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419894","SDC4 Gene","C101431","This gene is involved in cell-matrix interactions.","SDC4 Gene | SDC4 | Syndecan 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426244","SBDS Gene","C97767","This gene plays a role in ribosome formation.","SBDS Gene | SBDS | SBDS Ribosome Maturation Factor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423836","SALL4 Gene","C112905","This gene plays a role in both transcriptional regulation and stem cell maintenance.","SALL4 Gene | SALL4 | Spalt Like Transcription Factor 4 Gene | Spalt-Like Transcription Factor 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541566","S100A7 Gene","C143078","This gene is involved in both calcium binding and antimicrobial activity.","S100A7 Gene | S100 Calcium Binding Protein A7 Gene | S100A7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2680432","SNX29 Gene","C97764","This gene may be involved in signal transduction or lipid binding.","SNX29 Gene | RUNDC2A | SNX29 | Sorting Nexin 29 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704989","RSPO3 Gene","C24397","This gene is thought to be involved in transport; however, a function has yet to be elucidated.","RSPO3 Gene | R-Spondin 3 Gene | RSPO3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826945","RSPO2 Gene","C106067","This gene plays a role in both Wnt signaling and embryonic morphogenesis.","RSPO2 Gene | R-Spondin 2 Gene | RSPO2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419697","RPN1 Gene","C97290","This gene plays a role in post-translational protein modification.","RPN1 Gene | RPN1 | Ribophorin I Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419683","RPL5 Gene","C107652","This gene plays a role in ribosome assembly.","RPL5 Gene | RPL5 | Ribosomal Protein L5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419639","RPL22 Gene","C97761","This gene is involved in translation.","RPL22 Gene | RPL22 | Ribosomal Protein L22 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335635","RPL10 Gene","C24748","This gene plays a role in protein biosynthesis. It is also involved in signal transduction.","RPL10 Gene | RPL10 | Ribosomal Protein L10 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422738","RNF213 Gene","C97390","This gene may be involved in ubiquitination.","RNF213 Gene | RNF213 | Ring Finger Protein 213 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546011","Medical Clearance","C148040","Written permission from a medical professional stating that an individual is healthy enough to participate in a specific activity.","Medical Clearance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036836","Serum Total Protein Measurement","C61033","A quantitative measurement of the total amount of protein present in a sample of serum.","Serum Total Protein Measurement | Serum Protein Total Measurement | Total Serum Protein Measurement",,,,,,,,,,,,,,,"4152983","Serum total protein measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202084","Immunoglobulin M Measurement","C81972","The determination of the amount of immunoglobulin M present in a sample.","Immunoglobulin M Measurement | IGM | IgM | Immunoglobulin M",,,,,,,,,,,,,,,"4164130","Immunoglobulin M measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202087","Immunoglobulin G Measurement","C81971","The determination of the amount of immunoglobulin G present in a sample.","Immunoglobulin G Measurement | IGG | IgG | Immunoglobulin G",,,,,,,,,,,,,,,"4163378","Immunoglobulin G measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202083","Immunoglobulin A Measurement","C81969","The determination of the amount of immunoglobulin A present in a sample.","Immunoglobulin A Measurement | IGA | IgA | Immunoglobulin A",,,,,,,,,,,,,,,"4135810","Immunoglobulin A measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0201657","C-Reactive Protein Measurement","C64548","A quantitative measurement of the amount of C-reactive protein present in a sample.","C-Reactive Protein Measurement | C Reactive Protein | C-Reactive Protein | CRP",,,,,,,,,,,,,,,"4208414","C-reactive protein measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0201933","Carcinoembryonic Antigen Measurement","C81983","The determination of the amount of carcinoembryonic antigen present in a sample.","Carcinoembryonic Antigen Measurement | CEA | Carcinoembryonic Antigen",,,,,,,,,,,,,,,"4244721","Carcinoembryonic antigen measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524893","T-Cell Receptor Delta Locus","C26420","This region represents the germline organization of the T cell receptordelta locus. The delta locus includes V (variable), J (joining), diversity (D), and C (constant) segments. During T cell development, the delta chain is synthesized by a recombination event at the DNA level joining a D segment with a J segment; a V segment is then joined to the D-J gene. The C segment is later joined by splicing at the RNA level. Recombination of many different V segments with several D and J segments provides a wide range of antigen recognition. Additional diversity is attained by junctional diversity, resulting from the random additional of nucleotides by terminal deoxynucleotidyltransferase. (from LocusLink)","T-Cell Receptor Delta Locus | T Cell Receptor Delta Locus | T-Cell Receptor Delta Gene | TCRD | TRD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1540047","TRAF7 Gene","C107646","This gene is involved in both MAPK signaling and protein ubiquitination.","TRAF7 Gene | TNF Receptor-Associated Factor 7, E3 Ubiquitin Protein Ligase Gene | TRAF7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524890","T-Cell Receptor Alpha Locus","C26419","This region represents the germline organization of the T cell receptor alpha locus. The alpha locus includes V (variable), J (joining), and C (constant) segments. During T cell development, the alpha chain is synthesized by a recombination event at the DNA level joining a V segment with a J segment. The C segment is later joined by splicing at the RNA level. Recombination of many different V segments with several J segments provides a wide range of antigen recognition. Additional diversity is attained by junctional diversity, resulting from the random additional of nucleotides by terminal deoxynucleotidyltransferase. (from LocusLink)","T-Cell Receptor Alpha Locus | T-Cell Receptor Alpha Gene | TCRA | TRA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420877","TPR Gene","C97855","This gene plays a role in both nuclear transport and mitosis.","TPR Gene | TPR | Translocated Promoter Region, Nuclear Basket Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420875","TPM4 Gene","C97852","This gene is involved in smooth muscle cell contraction.","TPM4 Gene | TPM4 | Tropomyosin 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420874","TPM3 Gene","C97849","This gene plays a role in muscle contraction.","TPM3 Gene | TPM3 | Tropomyosin 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336656","TOP1 Gene","C26591","This gene is involved in the regulation of both DNA topology and transcription.","TOP1 Gene | DNA Topoisomerase I Gene | TOP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422043","TLX3 Gene","C98099","This gene may be involved in transcriptional regulation.","TLX3 Gene | T Cell Leukemia Homeobox 3 Gene | TLX3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427817","THRAP3 Gene","C97840","This gene is involved in the activation of transcription.","THRAP3 Gene | THRAP3 | Thyroid Hormone Receptor Associated Protein 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422118","TFPT Gene","C97837","This gene plays a role in the regulation of apoptosis.","TFPT Gene | TCF3 Fusion Partner Gene | TFPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420703","TFG Gene","C97834","This gene is involved in signaling.","TFG Gene | TFG | Trafficking from ER to Golgi Regulator Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428863","TET1 Gene","C95423","This gene is involved in the regulation of DNA methylation.","TET1 Gene | TET1 | Tet Methylcytosine Dioxygenase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420644","TCF7L2 Gene","C24847","This gene plays a role in signal transduction and regulation of transcription.","TCF7L2 Gene | TCF7L2 | Transcription Factor 7 Like 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420632","TCF12 Gene","C97828","This gene is involved in both transcriptional regulation and tissue differentiation.","TCF12 Gene | TCF12 | Transcription Factor 12 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420622","TCEA1 Gene","C97822","This gene is involved in transcription.","TCEA1 Gene | TCEA1 | Transcription Elongation Factor A (SII), 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539940","TBL1XR1 Gene","C80116","This gene is involved in transcriptional activation.","TBL1XR1 Gene | TBL1X Receptor 1 Gene | TBL1XR1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336574","TAL2 Gene","C24843","This gene is involved in transcriptional regulation. It plays a role in T-cell acute lymphocytic leukemia.","TAL2 Gene | TAL bHLH Transcription Factor 2 Gene | TAL2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420573","TAF15 Gene","C95994","This gene plays a role in transcriptional initiation.","TAF15 Gene | TAF15 | TATA-Box Binding Protein Associated Factor 15 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335892","SYK Gene","C26536","This gene plays a role in receptor tyrosine phosphorylation signal transduction, phagocytosis, endothelial cell growth and proliferation.","SYK Gene | SYK | Spleen Tyrosine Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420489","STRN Gene","C107661","This gene may play a role in cell scaffolding or calcium signaling.","STRN Gene | STRN | Striatin, Calmodulin Binding Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420065","STIL Gene","C101126","This gene plays a role in both cellular proliferation and embryonic development.","STIL Gene | SCL/TAL1 Interrupting Locus Gene | STIL | STIL Centriolar Assembly Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1832224","STAT6 Gene","C24835","This gene plays a role in signal transduction and activation of transcription.","STAT6 Gene | STAT6 | Signal Transducer and Activator of Transcription 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335876","STAT5B Gene","C28667","This gene is involved in signal transduction and activation of transcription. It plays a role in the immune response via stimulation of T-cell proliferation.","STAT5B Gene | STAT5B | Signal Transducer and Activator of Transcription 5B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1367307","STAT3 Gene","C24833","This gene plays a role in signal transduction and activation of transcription. It is involved in regulation of both apoptosis and cell growth.","STAT3 Gene | STAT3 | Signal Transducer and Activator of Transcription 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420449","STAG2 Gene","C101346","This gene is involved in cell division.","STAG2 Gene | STAG2 | STAG2 Cohesin Complex Component Gene | Stromal Antigen 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420448","STAG1 Gene","C131224","This gene plays a role in sister chromatid binding.","STAG1 Gene | STAG1 | Stromal Antigen 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423601","SS18L1 Gene","C97803","This gene plays a role in the positive regulation of transcription.","SS18L1 Gene | SS18L1 | Synovial Sarcoma Translocation Gene on Chromosome 18-Like 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420439","SS18 Gene","C97800","This gene is involved in transcriptional activation.","SS18 Gene | SS18 | SS18 Subunit of BAF Chromatin Remodeling Complex Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419994","SRSF3 Gene","C97785","This gene plays a role in RNA splicing and export.","SRSF3 Gene | SRSF3 | Serine/Arginine-Rich Splicing Factor 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539848","SRGAP3 Gene","C97797","This gene plays a role in GTPase-mediated signaling.","SRGAP3 Gene | SLIT-ROBO Rho GTPase Activating Protein 3 Gene | SRGAP3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538251","ZNRF3 Gene","C118319","This gene is involved in protein ubiquitination and Wnt pathway inhibition.","ZNRF3 Gene | ZNRF3 | Zinc and Ring Finger 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541544","ZNF479 Gene","C143103","This gene may play a role in the regulation of gene transcription.","ZNF479 Gene | ZNF479 | Zinc Finger Protein 479 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423940","ZNF444 Gene","C106358","This gene is involved in LDL metabolism, transcriptional regulation and DNA binding.","ZNF444 Gene | ZNF444 | Zinc Finger Protein 444 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541541","ZNF429 Gene","C143100","This gene may play a role in the regulation of gene transcription.","ZNF429 Gene | ZNF429 | Zinc Finger Protein 429 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420834","ZNF384 Gene","C97882","This gene is involved in both transcriptional regulation and DNA binding.","ZNF384 Gene | ZNF384 | Zinc Finger Protein 384 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423527","ZNF331 Gene","C97879","This gene plays a role in transcriptional regulation.","ZNF331 Gene | ZNF331 | Zinc Finger Protein 331 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826545","PATZ1 Gene","C97876","This gene is involved in both transcriptional regulation and the modulation of cellular tumor antigen p53-dependent cellular processes.","PATZ1 Gene | PATZ1 | POZ (BTB) and AT Hook Containing Zinc Finger 1 Gene | ZNF278",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823958","ZMYM2 Gene","C97873","This gene plays a role in transcriptional modulation.","ZMYM2 Gene | ZMYM2 | ZNF198 | Zinc Finger MYM-Type Containing 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412611","ZFHX3 Gene","C115424","This gene is involved in myoblast and neuronal differentiation.","ZFHX3 Gene | ZFHX3 | Zinc Finger Homeobox 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428463","ZCCHC8 Gene","C122878","This gene plays a role in RNA binding.","ZCCHC8 Gene | ZCCHC8 | Zinc Finger CCHC-Type Containing 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538149","ZBTB16 Gene","C28635","This gene plays a role in apoptosis and regulation of transcription. It is also involved in cell organization/biogenesis and megakaryocytic development.","ZBTB16 Gene | ZBTB16 | Zinc Finger and BTB Domain Containing 16 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421560","YWHAE Gene","C101116","This gene plays a role in signaling.","YWHAE Gene | Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein, Epsilon Polypeptide Gene | YWHAE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541531","WNK2 Gene","C143106","This gene plays a role in electrolyte homeostasis, cell signaling, cell survival, and cellular proliferation.","WNK2 Gene | WNK Lysine Deficient Protein Kinase 2 Gene | WNK2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425289","WIF1 Gene","C97867","This gene plays a role in Wnt protein-dependent signaling.","WIF1 Gene | WIF1 | WNT Inhibitory Factor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421506","NSD3 Gene","C96341","This gene is involved in histone methylation.","NSD3 Gene | NSD3 | Nuclear Receptor Binding SET Domain Protein 3 Gene | WHSC1L1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421478","WAS Gene","C43236","This gene is involved in signal transduction and plays a role in cell communication and organization.","WAS Gene | WAS | WASP Actin Nucleation Promoting Factor Gene | Wiskott-Aldrich Syndrome (Eczema-Thrombocytopenia) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425079","VTI1A Gene","C99462","This gene is involved in vesicular transport.","VTI1A Gene | VTI1A | Vesicle Transport through Interaction with t-SNAREs Homolog 1A (Yeast) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336926","VAV1 Gene","C18365","This gene plays a role in signal transduction. It is involved in the development and activation of both B cells and T cells.","VAV1 Gene | VAV1 | Vav Guanine Nucleotide Exchange Factor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336848","USP8 Gene","C24893","This gene plays a role in ubiquitin-dependent proteolysis and cell proliferation.","USP8 Gene | USP8 | Ubiquitin Specific Protease 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421407","USP6 Gene","C24892","This gene is involved in the regulation of cellular ubiquitination. It also plays a role in promoting the recycling of endocytic vesicles to the plasma membrane.","USP6 Gene | USP6 | Ubiquitin Specific Peptidase 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825027","UBR5 Gene","C111928","This gene plays a role in protein ubiquitination.","UBR5 Gene | UBR5 | Ubiquitin Protein Ligase E3 Component N-Recognin 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336679","TSHR Gene","C24881","This gene plays an important role in the regulation of thyroid cell metabolism.","TSHR Gene | TSHR | Thyroid Stimulating Hormone Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336677","TRRAP Gene","C24880","This gene is involved in DNA repair and regulation of mitosis.","TRRAP Gene | TRRAP | Transformation/Transcription Domain-Associated Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421146","TRIP11 Gene","C97861","This gene plays a role in thyroid receptor binding.","TRIP11 Gene | TRIP11 | Thyroid Hormone Receptor Interactor 11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424158","TRIM33 Gene","C97858","This gene is involved in the mediation of protein ubiquitination.","TRIM33 Gene | TRIM33 | Tripartite Motif Containing 33 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823489","TRIM27 Gene","C24733","This gene is involved in the differentiation of male germ cells.","TRIM27 Gene | TRIM27 | Tripartite Motif-Containing 27 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823488","TRIM24 Gene","C95280","This gene plays a role in hormone-dependent gene transcription.","TRIM24 Gene | TRIM24 | Tripartite Motif-Containing 24 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3160897","Opioid-Induced Constipation","C148034","Constipation that results from, or follows, treatment with an opioid or opioid-containing medication.","Opioid-Induced Constipation | OIC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545810","PSMA-Positive Tumor","C148035","An indication that prostate-specific membrane antigen (PSMA) expression has been detected in a tumor sample.","PSMA-Positive Tumor | FOLH1-Positive Tumor | Folate Hydrolase 1-Positive Tumor | Glutamate Carboxypeptidase 2-Positive Tumor | Prostate-Specific Membrane Antigen Positive Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026857","Musculoskeletal Disorder","C107377","A non-neoplastic or neoplastic disorder that affects muscles and bones.","Musculoskeletal Disorder | Disorder of Musculoskeletal System | Musculoskeletal System Disorder | Musculoskeletal System Disorder",,,,,,,,,,,,,,,"4244662","Disorder of musculoskeletal system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1428834","SHTN1 Gene","C122906","This gene is involved in neuronal polarization.","SHTN1 Gene | KIAA1598 | SHTN1 | Shootin 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545804","Nullizygosity","C148063","Having no copies, or nonfunctional copies, of a particular gene or genetic region.","Nullizygosity | Homozygous Null | Nullizygous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545807","Histone H3.2","C148067","Histone H3.2 (136 aa, ~15 kDa) is encoded by the human H3C13, H3C14 and H3C15 genes. This protein plays a role in nucleosome remodeling and chromosomal structure.","Histone H3.2 | H3.2 | Histone H3/m | Histone H3/o",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545893","Sequencing Library","C148073","A collection of double stranded DNA fragments flanked by oligonucleotide sequence adapters to enable their analysis by high-throughput sequencing.","Sequencing Library | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1401086","Peripheral Vascular Insufficiency","C148074","A condition in which there is inadequate blood flow through the peripheral blood vessels due to intrinsic disease of the vasculature.","Peripheral Vascular Insufficiency | PVI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545894","Septal Defect Repair","C148075","Any surgical repair of a septal defect.","Septal Defect Repair | Closure of Septal Defect | Repair of Septal Defect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524898","Mismatch Repair Protein Deficiency","C137827","A finding indicating that a cellular sample has a functional loss of a protein involved in the DNA mismatch repair process.","Mismatch Repair Protein Deficiency | MMR Protein Deficiency | MMR Protein Deficient | Mismatch Repair Protein Deficient | Non-Proficient Mismatch Repair | Non-pMMR | dMMR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522614","Lung Non-Squamous Non-Small Cell Carcinoma","C135017","A non-small cell lung carcinoma without evidence of squamous differentiation.","Lung Non-Squamous Non-Small Cell Carcinoma | Non-Squamous Non-Small Cell Lung Cancer | Non-Squamous Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small Cell Lung Carcinoma | Non-squamous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348452","Environmental Particulates","C72674","Problem associated with fine solids or liquid particles such as dust, smoke, fume, and/or mist suspended in the immediate atmosphere in which the device is being used.","Environmental Particulates | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0151942","Arterial Thrombosis","C98826","Formation of a blood clot in the lumen of an artery.","Arterial Thrombosis | Arterial thrombosis",,,,,,,,,,,,,,,"4278217","Arterial thrombosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545876","Sequencing Run","C148088","The valid and completed operation of a high-throughput sequencing instrument for a single sequencing process.","Sequencing Run | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221406","Cushing Disease","C113210","Cushing's syndrome due to abnormally high secretion of adrenocorticotropic hormone (ACTH) from the pituitary gland.","Cushing Disease | ACTH Producing Pituitary Adenoma | Cushing disease | Cushing's Disease",,,,,,,,,,,,,,,"4096185","Pituitary dependent hypercortisolism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0158266","Intervertebral Disc Degenerative Disorder","C26983","Any disease of a degenerative nature that affects the intervertebral disc.","Intervertebral Disc Degenerative Disorder | Intervertebral Disc Degeneration | Intervertebral Disc Degenerative Disease | Vertebral Disc Degenerative Disease | Vertebral Disc Degenerative Disorder",,,,,,,,,,,,,,,"80816","Degeneration of intervertebral disc",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054466","Morphologic Leukemia-Free State","C123597","The disappearance of all cells with morphologic characteristics of leukemia, accompanied by bone marrow recovery, in response to treatment. Hematologic recovery is not required. Leukemia free state can be a hypocellular marrow.","Morphologic Leukemia-Free State | MORPHOLOGIC LEUKEMIA-FREE STATE | Morphologic Leukemia-Free State (MLFS) | NEL | No Evidence of Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3806857","Macular Degeneration","C123330","Loss of vision in the central portion of the retina (macula), secondary to retinal degeneration.","Macular Degeneration | macular degeneration",,,,,,,,,,,,,,,"4224741","Degenerative disorder of macula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4230663","Bilateral Cataracts","C101193","Partial or complete opacity of the crystalline lens of both eyes that decreases visual acuity and eventually results in blindness. Some cataracts appear in infancy or in childhood, but most develop in older individuals. (Sternberg Diagnostic Surgical Pathology, 3rd ed.)","Bilateral Cataracts | ",,,,,,,,,,,,,,,"4317977","Bilateral cataracts",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545730","Computer-Based Cognitive Stimulation Intervention","C147860","Computer-based programs designed to improve thinking, concentration, memory, and communication.","Computer-Based Cognitive Stimulation Intervention | Computer-Based General Cognitive Stimulation Intervention",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL414972","Total Knee Replacement","C51565","Surgical replacement of all parts of a damaged knee joint with an artificial joint.","Total Knee Replacement | Total Arthroplasty of the Knee",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014098","Endarterectomy","C52002","Excision of an atheromatous plaque.","Endarterectomy | ENDARTERECTOMY",,,,,,,,,,,,,,,"4194238","Endarterectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0050565","Acodazole","C988","A synthetic imidazoquinoline with antineoplastic activity. Acodazole intercalates into DNA, resulting in disruption of DNA replication.  Use of this agent has been associated with significant cardiotoxicity. (NCI04)","Acodazole | 1H-imidazo[4,5-f]quinoline, acetamide deriv | ACODAZOLE | acetamide, N-methyl-N-[4-[(7-methyl-1H-imidazo[4, 5-f]quinolin-9-yl)amino]phenyl]-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3852841","Abemaciclib","C97660","An orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.","Abemaciclib | 2-Pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl) | ABEMACICLIB | LY 2835219 | LY-2835219 | LY2835219 | Verzenio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0098361","Eniluracil","C1773","An orally-active fluoropyrimidine analogue. Eniluracil inhibits dihydropyrimidine dehydrogenase, the rate-limiting enzyme that catabolizes and inactivates 5-fluorouracil (5-FU) in the liver. Co-administration of ethynyluracil permits the oral administration of 5-FU.","Eniluracil | 5-Ethynyl-2,4(1H,3H)-pyrimidinedione | 5-Ethynyluracil | 5-Fluorouracil Enhancer | 5-ethynyluracil | 776C85 | ENILURACIL | GW776 | PCS 6422 | PCS-6422 | PCS6422 | eniluracil | ethynyluracil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0044667","Edatrexate","C958","A polyglutamatable folate antagonist analogue of methotrexate with antineoplastic activity. Edatrexate inhibits dihydrofolate reductase, thereby increasing cellular levels of polyglutamates, inhibiting thymidylate synthase and glycinamide ribonucleotide formyl transferase, impairing synthesis of purine nucleotides and amino acids, and resulting in tumor cell death. Edatrexate may overcome tumor resistance to methotrexate, which loses its activity after it is polyglutamated. (NCI04)","Edatrexate | 10-EDAM | 10-EdAM | 10-Ethyl-10-deaza-aminopterin | CGP-30694 | EDAM | EDATREXATE | N-[4-[1-[(2, 4-Diamino-6-pteridinyl)-methyl]propyl]benzoyl]-L-glutamic acid | N-[4-[1-[(2,4-Diamino-6-pteridinyl)-methyl]propyl]benzoyl]-L-glutamic Acid | edatrexate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879697","Xanafide","C61306","The malate salt of amonafide, an imide derivative of naphthalic acid, with potential antineoplastic activity. Amonafide intercalates into DNA and inhibits topoisomerase II, resulting in DNA double-strand breaks (DSB) and inhibition of DNA replication and RNA synthesis.","Amonafide L-Malate | 5-amino-2-[2-(dimethylamino)ethyl]-1H-benz[de]isoquinoline-1,3(2H)-dione (2S)-2-ydroxybutanedioate | AMONAFIDE L-MALATE | AS1413 | Butanedioic Acid, 2-hydroxy-, (2S)-, compd. with 5-amino-2-(2-(dimethylamino)ethyl)-1h-benz[de]isoquinoline-1,3(2h)-dione (1:1) | XAN-02 | Xanafide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347295","motesanib","C71896","An orally bioavailable receptor tyrosine kinase inhibitor with potential antineoplastic activity. AMG 706 selectively targets and inhibits vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGFR), Kit, and Ret receptors, thereby inhibiting angiogenesis and cellular proliferation.","Motesanib | MOTESANIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0051162","Alizapride","C995","A substituted benzamide that acts as a dopamine receptor antagonist with antiemetic properties.","Alizapride | ALIZAPRIDE | N-((1-Allyl-2-Pyrrolidinyl)Methyl)-6-Methoxy-1H-Benzotriazole-5-Carboxamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412460","FGFR Inhibitor AZD4547","C88272","An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. fexagratinib binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways, and, so, the inhibition of tumor cell proliferation and tumor cell death. FGFR, up-regulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cellular proliferation, differentiation and survival.","Fexagratinib | ABSK-091 | ABSK091 | AZD-4547 | AZD4547 | FEXAGRATINIB | FGFR Inhibitor AZD4547 | FGFR Inhibitor AZD4547 | KB-74810",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981846","Vistusertib","C88329","An orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. Vistusertib inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, plays an important role downstream in the PI3K/Akt/mTOR signaling pathway.","Vistusertib | AZD 2014 | AZD-2014 | AZD2014 | Benzamide, 3-(2,4-Bis((3S)-3-methyl-4-morpholinyl)pyrido(2,3-d)pyrimidin-7-yl)-N-methyl- | VISTUSERTIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879521","Multikinase Inhibitor AT9283","C66947","A small synthetic molecule and aurora kinase (AK) inhibitor with potential antineoplastic activity. AT9283 selectively binds to and inhibits AKs A and B, which are serine-threonine kinases that play essential roles in mitotic checkpoint control during mitosis. Inhibition of these kinases results in an inhibition of cellular division and proliferation in tumor cells that overexpress AKs.","Multikinase Inhibitor AT9283 | AT-9283 | AT9283 | Aurora kinase inhibitor AT9283",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879520","CDKI AT7519","C64761","An orally bioavailable small molecule with potential antineoplastic activity. AT7519M selectively binds to and inhibits cyclin dependent kinases (CDKs), which may result in cell cycle arrest, induction of apoptosis, and inhibition of tumor cell proliferation. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some types of cancer cells.","CDK Inhibitor AT7519 | AT-7519 | AT7519 | AT7519M | CDK inhibitor AT7519M | CDKI AT7519 | CDKI AT7519 | Cyclin-Dependent Kinase Inhibitor AT7519M",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0388638","Plitidepsin","C1689","A cyclic depsipeptide isolated from the marine tunicate Aplidium albicans. Plitidepsin displays a broad spectrum of antitumor activities, inducing apoptosis by triggering mitochondrial cytochrome c release, initiating the Fas/DC95, JNK pathway and activating caspase 3 activation. This agent also inhibits elongation factor 1-a, thereby interfering with protein synthesis, and induces G1 arrest and G2 blockade, thereby inhibiting tumor cell growth.","Plitidepsin | APLD | Aplidin | Aplidine | DDB | Dehydrodemnin B | Dehydrodidemnin B | N-[1-(1,2-Dioxopropyl)-L-prolyl]didemnin A | PLITIDEPSIN | aplidine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0068395","Nandrolone Decanoate","C1172","The decanoate salt form of nandrolone, an anabolic steroid analog of testosterone with androgenic, anabolic, and erythropoietin stimulating effects. Nandrolone enters the cell and binds to and activates specific nuclear androgen receptors in responsive tissue, including the prostate, seminal vesicles, scrotum, penis, larynx, hair follicles, muscle, and bone. The resulting activated hormone receptor complex translocates into the nucleus and binds to androgen response elements (ARE) in the promoter region of targeted genes, where the complex promotes gene expression necessary for maintaining male sex characteristics. Mimicking the negative feedback mechanism of testosterone, nandrolone decanoate also suppresses the secretion of luteinizing hormone (LH). Furthermore, this agent also stimulates erythropoietin production by enhancing the production of erythropoietic stimulating factors.","Nandrolone Decanoate | Deca-Durabolin | NANDROLONE DECANOATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0073994","Calcitonin Salmon","C329","No Value Exists","Calcitonin Salmon | CALCITONIN SALMON | Calcimar | Calcitonin | Cibacalcin | Miacalcin | Thyrocalcitonin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054173","Bryostatin 1","C1026","A macrocyclic lactone isolated from the bryozoan Bugula neritina with antineoplastic activity.  Bryostatin 1 binds to and inhibits the cell-signaling enzyme protein kinase C, resulting in the inhibition of tumor cell proliferation, the promotion of tumor cell differentiation, and the induction of tumor cell apoptosis. This agent may act synergistically with other chemotherapeutic agents. (NCI04)","Bryostatin 1 | B705008K112 | BRYOSTATIN 1 | Bryostatin I | bryostatin 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0935902","Rebimastat","C1875","A sulfhydryl-based second-generation matrix metalloproteinase (MMP) inhibitor with potential antineoplastic activity. Rebimastat selectively inhibits several MMPs (MMP 1, 2, 8, 9, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.","Rebimastat | BMS-275291 | D2163 | N-((2S)-2-Mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-L-valinamide | REBIMASTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1098058","BMS-275183","C62639","An orally available, C-4 methyl carbonate analog of paclitaxel with potential antineoplastic activity. Like paclitaxel, BMS-275183 binds to tubulin and stabilizes microtubules, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and an induction of apoptosis.","BMS-275183 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005739","Bleomycin Sulfate","C312","A mixture of the sulfate salts of basic glycopeptide antineoplastic antibiotics isolated from Streptomyces verticillus. Bleomycin sulfate forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation.","Bleomycin Sulfate | BLEOMYCIN SULFATE | Blanoxan | BleMomycine | Blenoxane | Bleo-S | Bleo-cell | Bleocin | Bleolem | Bleomycin Sulfas | Bleomycin Sulphate | Bleomycin sulfate | Bleomycini Sulfas | Blexane | Oil Bleo | bleomycin sulfate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0877874","Troxacitabine","C1438","A dioxolane derivative and a novel L-configuration deoxycytidine analogue with potent antineoplastic activity. When incorporated into growing chain during DNA replication, troxacitabine stops DNA polymerization due to its unnatural L-configuration, in contrast to the normal nucleotides with D-configuration. As a result, this agent terminates DNA synthesis upon incorporated into DNA molecules, and consequently interrupts tumor cell proliferation.","Troxacitabine | 2(1H)-Pyrimidinone, 4-amino-1-((2S,4S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)- | BCH-4556 | L-Oddc | TROXACITABINE | Troxatyl | troxacitabine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL429115","Napabucasin","C96429","An orally available cancer cell stemness inhibitor with potential antineoplastic activity. Even though the exact target has yet to be fully elucidated, napabucasin appears to target and inhibit multiple pathways involved in cancer cell stemness. This may ultimately inhibit cancer stemness cell (CSC) growth as well as heterogeneous cancer cell growth. CSCs, self-replicating cells that are able to differentiate into heterogeneous cancer cells, appear to be responsible for the malignant growth, recurrence and resistance to conventional chemotherapies.","Napabucasin | 2-Acetylnaphtho(2,3-b)furan-4,9-dione | BB608 | BBI-608 | BBI608 | NAPABUCASIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL445816","cancer stemness kinase inhibitor BBI503","C104745","An orally available cancer cell stemness kinase inhibitor with potential antineoplastic activity. Even though the exact target has not been fully elucidated, amcasertib targets and inhibits one or more pathways involved in cancer stem cell survival. As a result, cancer stem cell (CSC) growth as well as heterogeneous cancer cell growth is inhibited. CSCs, self-replicating cells able to differentiate into heterogeneous cancer cells, appear to be responsible for both tumor relapse and metastasis.","Amcasertib | AMCASERTIB | BBI503 | Cancer Stemness Kinase Inhibitor BBI503",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0338344","Marimastat","C1652","An orally-active synthetic hydroxamate with potential antineoplastic activity.  Marimastat covalently binds to the zinc(II) ion in the active site of matrix metalloproteinases (MMPs), thereby inhibiting the action of MMPs, inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.  This agent may also inhibit tumor necrosis factor-alpha converting enzyme (TACE), an enzyme involved in tumor necrosis factor alpha (TNF-alpha) production that may play a role in some malignancies as well as in the development of arthritis and sepsis. (NCI04)","Marimastat | (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic Acid | (2S,3R)-3-{(S)-[2,2-Dimethyl-1-(methylcarbamoyl) propyl]carbamoyl}-2-hydroxy-5-methylhexanohydroxamic acid | BB 2516 | BB-2516 | MARIMASTAT | Marimistat | TA-2516 | marimastat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527103","ortataxel","C1867","A semisynthetic, second-generation taxane derivative with potential antineoplastic activity. Ortataxel binds to and stabilizes tubulin molecules, thereby interfering with the dynamics of microtubule assembly/disassembly. This results in the inhibition of cell division and cellular proliferation. As it represents a poor substrate for P-glycoprotein (P-gp), multi-drug resistance protein (MRP-1) and breast cancer resistance protein (BCRP) mediated efflux, ortataxel modulates multi-drug resistance mechanisms and may be useful for treating multi-drug resistant tumors that express Pgp, MRP-1 and BCRP.","Ortataxel | (3aS,4R,5E,7R,8aS,9S,10aR,12aS,12bR,13S,13aS)-7,12a-Bis(acetyloxy)-13-(benzoyloxy)-9-hydroxy-5,8a,14,14-tetramethyl-2,8-dioxo-3a,4,7,8,8a,9,10,10a,12,12a,12b,13-dodecahydro-6,13a-methano-13aH-oxeto(2',3':5',6')benzo(1',2':4,5)cyclodeca(1,2-d)-1,3-dioxol-4-yl(2R,3S)-3-(((1,1-dimethylethoxy)carbonyl)amino)-2-hydroxy-5-methylhexanoate | BAY 59-8862 | BAY59-8862 | Bay 59-8862 | IDN5109 | ORTATAXEL | SB-T-101131",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1101785","BAY 56-3722","C1886","The hydrochloride salt form of afeletecan, a water-soluble camptothecin derivative conjugated to a carbohydrate moiety exhibiting antineoplastic activity. Afeletecan stabilizes the topoisomerase I-DNA covalent complex and forms an enzyme-drug-DNA ternary complex. As a consequence of the formation of this complex, both the initial cleavage reaction and religation steps are inhibited and subsequent collision of the replication fork with the cleaved strand of DNA results in inhibition of DNA replication, double strand DNA breakage and triggering of apoptosis. The peptide carbohydrate moiety of this agent stabilizes the lactone form of camptothecin in blood.","Afeletecan Hydrochloride | AFELETECAN HYDROCHLORIDE | BAY 38-3441 | BAY 56-3722 | BAY 56-3722 | BAY56-3722 | Camptothecin Glycoconjugate BAY 38-3441 | Camptothecin Glycoconjugate BAY 38-3441",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0393069","Tanomastat","C1705","A biphenyl matrix metalloproteinase (MMP) inhibitor (MMPI) with potential antineoplastic activity. Tanomastat inhibits MMP-2, MMP-3, and MMP-9, inhibiting extracellular matrix degradation and potentially inhibiting angiogenesis, tumor growth and invasion, and metastasis. MMPs consist of at least 18 zinc-containing endo-proteinases that are capable of degrading collagen and proteoglycan.","Tanomastat | (S)-3-[(4'-Chloro-4-biphenylyl)carbonyl]-2-[(phenylthio)methyl]propionic acid | 4-[4-(chlorophenyl)phenyl]-4-oxo-2S-(phenylthiomethyl) butanoic acid | BAY 12-9566 | BAY-12-9566 | TANOMASTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642466","volitinib","C104732","An orally bioavailable inhibitor of the c-Met receptor tyrosine kinase with potential antineoplastic activity. Savolitinib selectively binds to and inhibits the activation of c-Met in an ATP-competitive manner, and disrupts c-Met signal transduction pathways. This may result in cell growth inhibition in tumors that overexpress the c-Met protein. C-Met encodes the hepatocyte growth factor receptor tyrosine kinase and plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis; this protein is overexpressed or mutated in a variety of cancers.","Savolitinib | AZD 6094 | AZD6094 | HMPL-504 | SAVOLITINIB | Volitinib | Volitinib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014938","Conjugated Estrogens","C482","Purified orally bioavailable female sex hormones isolated from pregnant mare urine or synthetically derived from plant materials and primarily conjugated as sulfate esters. Estrogen binds to and activates specific nuclear receptors, which, in turn, bind to estrogen response elements (EREs) in target genes, resulting in histone acetylation, alteration of chromatin conformation, and initiation of transcription. (NCI04)","Estrogens, Conjugated | ATC:G03CA57 | Conestron | Conjugated Estrogens | ESTROGENS, CONJUGATED | Femest | Premarin | Sodestrin | Tag-39",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437136","CYP17 inhibitor CFG920","C102855","An orally bioavailable, non-steroidal, potent, reversible, dual inhibitor of cytochrome P450 17 (CYP17 or CYP17A1) and CYP11B2, with potential antiandrogen and antineoplastic activities. Upon oral administration, LAE001 inhibits the enzymatic activity of CYP17A1 in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells. LAE001 also inhibits the enzymatic activity of CYP11B2, thereby inhibiting aldosterone production. This may reduce the elevated aldosterone levels resulting from CYP17 inhibition and androgen deprivation, leading to a reduction in mineralocorticoid side effects including cardiovascular complications. The cytochrome P450 enzyme CYP17A1, localized to the endoplasmic reticulum, exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces steroidal hormones. The cytochrome P450 enzyme CYP11B2, aldosterone synthase, is an enzyme that plays a key role in aldosterone biosynthesis.","CYP17/CYP11B2 Inhibitor LAE001 | CFG 920 | CFG-920 | CFG920 | CYP17 Inhibitor CFG920 | LAE 001 | LAE-001 | LAE001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0056855","Cyproterone Acetate","C1059","The acetate salt of a synthetic steroidal antiandrogen with weak progestational and antineoplastic activities. Cyproterone binds the androgen receptor (AR), thereby preventing androgen-induced receptor activation in target tissues and inhibiting the growth of testosterone-sensitive tumor cells. This agent also exerts progestational agonist properties at the level of the pituitary that reduce luteinizing hormone (LH), resulting in reductions in testicular androgen secretion and serum testosterone levels. Treatment with cyproterone alone results in incomplete suppression of serum testosterone levels.","Cyproterone Acetate | 3'H-Cyclopropa(1,2)pregna-1,4,6-triene-3,20-dione, 17-(Acetyloxy)-6-chloro-1,2-dihydro-, (1beta,2beta)- | 6-Chloro-1b,2b-dihydro-17a-hydroxy-3'H-cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione Acetate | Andro-Diane | Androcur | CYPROTERONE ACETATE | Chloro-6-hydroxy-17 Alpha Methylene-1 Alpha, 2 Alpha Pregnadiene-4,6 Dione-3, 20 Acetate | CyPat | Cyprone | Cyprostat | Cyproteronazetat | Cyproterone acetate | Cyproteroni Acetas | Diane | Dianette | SH 714 | SH-714 | cyproterone acetate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0970561","Teloxantrone Hydrochloride","C74544","The hydrochloride salt of an anthrapyrazole antineoplastic antibiotic. Teloxantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair, as well as RNA and protein synthesis.","Teloxantrone Hydrochloride | Anthra(1,9-cd)pyrazol-6(2H)-one,7,10-dihydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)-5-((2-(methylamino)ethyl)amino) Dihydrochloride | CI-937 Hydrochloride | DUP 937 | Moxantrazole Hydrochloride | TELOXANTRONE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0060692","Fosfestrol","C1105","The diphosphate ester of a synthetic, nonsteroidal form of estrogen. A well-known teratogen and carcinogen, diethylstilbestrol inhibits the hypothalamic-pituitary-gonadal axis, thereby blocking the testicular synthesis of testosterone, lowering plasma testosterone, and inducing a chemical castration.","Fosfestrol | (E)-4,4'-(1,2-ethenediyl)-bisphenol bis(dihydrogen phosphate) | Alpha,alpha'-diethyl-4,4'-stilbenediol Diphosphoric Acid Ester | DESP | Diethyldihydroxystilbene Diphosphate | Diethylstilbestrol 4,4'-Diphosphoric Ester | Diethylstilbestrol Diphosphate | Diethylstilbestryl Diphosphate | FOSFESTROL | Fosfestrol Sodium Phosphoestrolum | Honvan | Honvol | ST-52 | Stilbestrol Diphosphate | Stilboestrol Diphosphate | Stilphostrol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0113768","Didemnin B","C1364","A cyclic depsipeptide extracted from the Caribbean tunicate Trididemnum cyanophorum.  Didemnin B activates caspase, thereby inducing apoptosis, and prevents eukaryotic elongation factor 2 (eEF-2)-dependent translocation, thereby inhibiting protein synthesis.  This agent also has immunosuppressive and antiviral properties. (NCI04)","Didemnin B | 15H-Pyrrolol[2,1-f][1,15,4,7,10,20]dioxatetraazacyclotri-cosine, Cyclic Peptide Deriv. (9CI) | DIDEMNIN B | Didemnin | L-Tyrosine, N-[1-[N-[4-[[3-Hydroxy-4-[[N-[N-[1-(2-hydroxy-1-oxopropyl)- L-prolyl]-N-methyl-L-leucyl]-L-threonyl]amino]-5-methyl-1-oxoheptyl]oxy]-2,5-dimethyl-1,3-dioxohexyl]-L-leucyl]- L-prolyl]-N,O-dimethyl-, phi-lactone (9CI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545392","KRAS NP_004976.2:p.A59X","C147575","A change in the amino acid residue at position 59 in the GTPase KRas protein where alanine has been replaced by another amino acid.","KRAS NP_004976.2:p.A59X | GTPase KRas A59X | GTPase KRas Ala59Xxx | K-Ras 2 A59X | KRAS A59 Mutation | KRAS A59X | KRAS Ala59Xxx | KRAS NP_004976.2:p.Ala59Xxx | KRAS p.A59X | KRAS p.Ala59Xxx | Ki-Ras A59X | NP_004976.2:p.A59X | NP_004976.2:p.Ala59Xxx | c-K-ras A59X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545393","KRAS NP_004976.2:p.K117X","C147576","A change in the amino acid residue at position 117 in the GTPase KRas protein where lysine has been replaced by another amino acid.","KRAS NP_004976.2:p.K117X | GTPase KRas K117X | GTPase KRas Lys117Xxx | K-Ras 2 K117X | KRAS K117 Mutation | KRAS K117X | KRAS Lys117Xxx | KRAS NP_004976.2:p.Lys117Xxx | KRAS p.K117X | KRAS p.Lys146Xxx | Ki-Ras K117X | NP_004976.2:p.K117X | NP_004976.2:p.Lys117Xxx | c-K-ras K117X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545802","ATRX Gene Mutation","C148041","A change in the nucleotide sequence of the ATRX gene.","ATRX Gene Mutation | ATRX | ATRX, Chromatin Remodeler Gene Mutation | Alpha Thalassemia/Mental Retardation Syndrome X-Linked Gene Mutation | Positive | RAD54 Gene Mutation | RAD54 Homolog Gene Mutation | RAD54L Gene Mutation | XH2 Gene Mutation | XNP Gene Mutation | Yes | ZNF-HX Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545694","ABCD1 Gene Mutation","C147902","A change in the nucleotide sequence of the ABCD1 gene.","ABCD1 Gene Mutation | ABC42 Gene Mutation | ALD Gene Mutation | ALDP Gene Mutation | AMN Gene Mutation | ATP Binding Cassette Subfamily D Member 1 Gene Mutation | ATP-Binding Cassette, Subfamily D, Member 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550819","Esperamicin Antibiotic","C148123","Any agent belonging to the esperamicins, a class of bacterium-derived chromoprotein enediyne antibiotics with antineoplastic activity. Esperamicins bind to the minor groove of DNA, cleave DNA and induce apoptosis of tumor cells.","Esperamicin Antibiotic | Esperamicin | Esperamicin Antineoplastic Antibiotic | Esperamicins | Esperamycin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014922","Estramustine Phosphate Sodium","C480","The orally available disodium salt, monohydrate, of estramustine phosphate, a synthetic molecule that combines estradiol and nornitrogen mustard through a carbamate link. Estramustine and its major metabolite estramustine bind to microtubule-associated proteins (MAPs) and tubulin, thereby inhibiting microtubule dynamics and leading to anaphase arrest in a dose-dependent fashion. This agent also exhibits anti-androgenic effects.","Estramustine Phosphate Sodium | ESTRAMUSTINE PHOSPHATE SODIUM | Emcyt | Estracyt | Estramustine 17-(Dihydrogenphosphate) Disodium Salt | Estramustine Phosphate | Estramustine Sodium Phosphate | Estramustine phosphate | Estramustine sodium phosphate | Leo 299 | Leo-299 | Ro-21-8837/001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524900","Enasidenib Mesylate","C137825","The mesylate salt form of enasidenib, an orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits various mutant forms of IDH2, including the IDH2 variants R140Q, R172S, and R172K, which inhibits the formation of 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH2-expressing tumor cells. IDH2, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by blocking differentiation and the production of the oncometabolite 2HG.","Enasidenib Mesylate | 2-Methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol Methanesulfonate | 2-Propanol, 2-Methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-, Methanesulfonate (1:1) | AG-221 Mesylate | CC 90007 | CC-90007 | CC90007 | ENASIDENIB MESYLATE | Enasidenib Methanesulfonate | Idhifa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0059041","Elsamitrucin","C1080","An heterocyclic antineoplastic antibiotic isolated from the bacterium Actinomycete strain J907-21.  Elsamitrucin intercalates into DNA at guanine-cytosine (G-C)-rich sequences and inhibits topoisomerase I and II, resulting in single-strand breaks and inhibition of DNA replication. (NCI04)","Elsamitrucin | 10-O-Elsaminosylelsarosylchartarin | BBM 2478A | BMY-28090 | BRN 5214813 | Benzo(h)(1)benzopyrano(5,4,3-cde)(1)ebnzopyran-5,12-dione,10((2-O-(2-amino-2,6-dideoxy-3-O-methyl-alpha-D-galactopyranosyl)-6-deoxy-3-C-methyl-beta-D-galactopyranosyl)oxy)-6-hydroxy-1-methyl | ELSAMITRUCIN | Elsamicin A | Elsamitrucina | Elsamitrucine | Elsamitrucinum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279218","Edrecolomab","C1554","A murine monoclonal IgG2a antibody to tumor-associated epithelial cell adhesion molecule (EpCAM, or 17-1A) antigen. Edrecolomab attaches to EpCAM, a human cell surface glycoprotein that is found on normal epithelial cells and some tumor cells, such as those of colon and breast carcinomas. Upon binding, this agent recruits the body's immune effector cells, which may exhibit antitumor cytotoxicity. (NCI04)","Edrecolomab | EDRECOLOMAB | Immunoglobulin G2A (Mouse Monoclonal 17-1A Gamma-Chain Anti-Human Colon Cancer Tumor-Associated Antigen), Disulfide With Mouse Monoclonal 17-1A Light Chain, Dimer | MOAB 17-1A | Monoclonal Antibody 17-1A | Panorex | edrecolomab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1548672","Asked but Unknown","C79729","An indication that a question was asked and the response is unknown.","Asked but Unknown | ASKED BUT UNKNOWN | ASKU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541386","ROS1 Gene Amplification","C142878","A molecular genetic abnormality indicating the presence of multiple copies of the ROS1 gene.","ROS1 Gene Amplification | MCF3 Gene Amplification | ROS Gene Amplification | ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene Amplification | c-ros-1 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544987","TP53 Overexpression Positive","C146952","An indication that overexpression of TP53 has been detected in a sample.","TP53 Overexpression Positive | Antigen NY-CO-13 Overexpression | Cellular Tumor Antigen p53 Overexpression | TP53 Overexpression | TRP53 Overexpression | Transformation-Related Protein 53 Overexpression | Tumor Protein p53 Overexpression | Tumor Suppressor p53 Overexpression | p53 Overexpression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539247","PSA Level Greater than or Equal to 0.05","C141203","A blood concentration of prostate specific antigen greater than or equal to 0.05 ng/mL.","PSA Level Greater than or Equal to 0.05 | PSA Level 0.05 or Greater",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539246","PSA Level Less than 0.7","C141204","A blood concentration of prostate specific antigen less than 0.7 ng/mL.","PSA Level Less than 0.7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539436","PSA Level Greater than 0.03","C141369","A blood concentration of prostate specific antigen greater than 0.03 ng/mL.","PSA Level Greater than 0.03 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538411","NRAS NP_002515.1:p.G12V","C140249","A change in the amino acid residue at position 12 in the GTPase NRas protein where glycine has been replaced by valine.","NRAS NP_002515.1:p.G12V | GTPase NRas G12V | GTPase NRas Gly12Val | NP_002515.1:p.G12V | NP_002515.1:p.Gly12Val | NRAS G12V | NRAS G12V Mutation | NRAS Gly12Val | NRAS NP_002515.1:p.Gly12Val | NRAS p.G12V | NRAS p.Gly12Val | Transforming Protein N-Ras G12V | Transforming Protein N-Ras Gly12Val",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538395","HRAS NP_005334.1:p.G12V","C140253","A change in the amino acid residue at position 12 in the GTPase HRas protein where glycine has been replaced by valine.","HRAS NP_005334.1:p.G12V | GTPase HRas G12V | GTPase HRas Gly12Val | H-Ras G12V | H-Ras Gly12Val | H-Ras-1 G12V | H-Ras-1 Gly12Val | HRAS G12V | HRAS G12V Mutation | HRAS Gly12Val | HRAS NP_005334.1:p.Gly12Val | HRAS p.G12V | HRAS p.Gly12Val | Ha-Ras G12V | Ha-Ras Gly12Val | Ha-Ras1 G12V | Ha-Ras1 Gly12Val | Harvey Rat Sarcoma Viral Oncoprotein G12V | Harvey Rat Sarcoma Viral Oncoprotein Gly12Val | NP_005334.1:p.G12V | NP_005334.1:p.Gly12Val | c-H-ras G12V | c-H-ras Gly12Val",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523726","ERK Family Gene Mutation","C136423","A change in the nucleotide sequence in a ERK family gene.","ERK Family Gene Mutation | ERK Family Mutation | ERK Gene Mutation | ERK Mutation | Extracellular Signal-Regulated Kinase Family Gene Mutation | MAP Kinase Family Gene Mutation | MAPK Family Gene Mutation | MAPK Gene Mutation | Mitogen-Activated Protein Kinase Family Gene Mutation | Mutant ERK | Mutant ERK Family Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517999","Loss of Merlin Expression","C41424","A molecular abnormality indicating the absence of merlin protein.","Loss of Merlin Expression | Loss of NF2 Protein Expression | Loss of Neurofibromin 2 Expression | Loss of Schwannomerlin Expression | Loss of Schwannomin Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540757","CCND1 Gene Mutation","C142846","A change in the nucleotide sequence of the CCND1 gene.","CCND1 Gene Mutation | BCL-1 Gene Mutation | BCL1 Gene Mutation | CCND1 mutation | Cyclin D1 Gene Mutation | PRAD1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525022","SMARCA4 Gene Inactivation","C138016","A mutation in the SMARCA4 gene that either inhibits expression of the SMARCA4 protein or results in the translation of an inactive SMARCA4 protein.","SMARCA4 Gene Inactivation | Inactivating BAF190 Gene Mutation | Inactivating BAF190A Gene Mutation | Inactivating BRG-1 Gene Mutation | Inactivating BRG1 Gene Mutation | Inactivating BRM/SWI2-Related Gene 1 Mutation | Inactivating SMARCA4 Gene Mutation | Inactivating SNF2 Gene Mutation | Inactivating SNF2-Beta Gene Mutation | Inactivating SNF2L4 Mutation | Inactivating SNF2LB Gene Mutation | Inactivating SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily A, Member 4 Gene Mutation | Inactivating SWI1 Gene Mutation | Inactivating SWI2 Gene Mutation | Inactivating hSNF2b Gene Mutation | SMARCA4 Inactivating Gene Mutation | SMARCA4 Loss of Function | SMARCA4 Loss of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515645","SMARCB1 Gene Inactivation","C39813","A mutation in the SMARCB1 gene that either inhibits expression of the SMARCB1 protein or results in the translation of an inactive SMARCB1 protein.","SMARCB1 Gene Inactivation | Inactivating BAF47 Gene Mutation | Inactivating Ini1 Gene Mutation | Inactivating SMARCB1 Gene Mutation | Inactivating SNF5 Gene Mutation | Inactivating SNF5L1 Gene Mutation | Inactivating SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily B, Member 1 Gene Mutation | Inactivating Snr1 Gene Mutation | Inactivating hSNFS Gene Mutation | SMARCB1 Loss of Function | SMARCB1 Loss of Function Mutation | hSNF5/INI1 Gene Inactivation | hSNF5/INI1 Tumor Suppressor Gene Inactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541387","KRAS Gene Mutation Negative","C142879","A genetic finding indicating that KRAS gene mutations have not been detected in a sample.","KRAS Gene Mutation Negative | KRAS Wild-Type | KRAS Wildtype | KRAS wt | KRAS-2 Gene Mutation Negative | KRAS2 Gene Mutation Negative | Negative | No mutation detected | c-K-ras Gene Mutation Negative | v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986417","Unaffected","C94232","An individual who does not manifest symptoms of a condition or disease occurring in his or her family.","Unaffected | unaffected",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0400435","Right Hemihepatectomy","C51569","Surgical removal of the right hemisphere of the liver.","Right Hemihepatectomy | ",,,,,,,,,,,,,,,"4247012","Hepatectomy, total right lobectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0400436","Left Hemihepatectomy","C51571","Surgical removal of the left hemisphere of the liver.","Left Hemihepatectomy | ",,,,,,,,,,,,,,,"4270222","Hepatectomy, total left lobectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031957","Piperazine","C61892","A cyclic organic compound possessing two nitrogen atoms in opposite positions within a 6-member heterocyclic ring that serves as a backbone for piperazine derivatives and acts as a gamma-amino-butyric acid (GABA) receptor agonist in nematodes, with potential anti-helminthic activity. Upon administration, piperazine binds to the GABA inhibitory receptors in susceptible nematodes, thereby inducing chloride channel opening and hyperpolarization. This results in paralysis of the worm musculature and allows normal peristalsis to dislodge the worm from the intestinal lumen, which causes the worm to be expelled from the body. Unlike vertebrates where GABA is restricted to the central nervous system (CNS), the GABA receptors in helminths are also expressed in the peripheral nervous system.","Piperazine | 1,4-Diazacyclohexane | 1,4-Diethylenediamine | 1,4-Piperazine | Dispermine | Entacyl | PIPERAZINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333432","Epstein-Barr Virus-Related Malignancy","C27689","A malignant neoplasm that develops in a patient infected with Epstein-Barr virus (EBV) and in which there is a well-documented association between the malignancy and EBV. Representative examples include EBV-related lymphomas and carcinomas.","EBV-Related Malignant Neoplasm | EBV Related Malignancy | EBV-Related Malignancy | Epstein-Barr Virus Related Malignancy | Epstein-Barr Virus-Related Malignancy | Epstein-Barr Virus-Related Malignant Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025678","Levomepromazine","C66118","A phenothiazine and typical antipsychotic agent, with sedative/hypnotic, anxiolytic, antiemetic, analgesic and antipsychotic activities. Although the exact mechanism of action of levomepromazine is not fully known, upon administration, this agent appears to act as an antagonist for a variety of receptors in the central nervous system (CNS), including adrenergic, dopamine, histamine, cholinergic and serotonin (5-hydroxytryptamine; 5-HT) receptors. Blocking these receptors results in levomepromazine's pharmacologic effects.","Levomepromazine | (-)-10-(3-(Dimethylamino)-2-methylpropyl)-2-methoxyphenothiazine | Arc-VI-C-5 | Bayer 1213 | LEVOMEPROMAZINE | Levoprome | Methotrimeprazine | Neozine | Nirvan | Nozinan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545814","A2AR Antagonist AZD4635","C148039","An orally bioavailable antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, imaradenant selectively binds to and inhibits A2AR expressed on T-lymphocytes. This blocks tumor-released adenosine from interacting with A2AR and prevents the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits T-cell proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression.","Imaradenant | A2AR Antagonist AZD4635 | AZD-4635 | AZD4635 | Adenosine A2A Receptor Antagonist AZD4635 | Adenosine A2A Receptor Antagonist AZD4635 | HTL-1071 | IMARADENANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3852710","Aganirsen","C148131","A 25-mer antisense oligonucleotide (ASO) that targets the mRNA transcript for insulin receptor substrate (IRS-1), a protein required for the formation and growth of new blood vessels, that can be used to reduce corneal angiogenesis and neovascularization. Upon ocular administration, aganirsen binds to IRS-1 mRNA and blocks the synthesis of IRS-1. By blocking the expression of IRS-1 in pro-angiogenic conditions, such as those seen in corneal grafts and other inflammatory-based ocular diseases, aganirsen blocks the corneal neovascularization pathway, inhibits vascular endothelial growth factor (VEGF) production, which is a key component of neovascularization, and prevents the production of various pro-inflammatory cytokines, which together decrease the risk of corneal neovascularization. Additionally, upon corneal transplantation, neovascularization induces an immune response that can lead to immunological corneal graft rejection; therefore, by inhibiting neovascularization this agent can decrease the risk of corneal graft rejection. IRS-1, overexpressed in endothelial cells during corneal neovascularization, plays a key role in the regulation of angiogenesis.","Aganirsen | AGANIRSEN | GS-101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550802","Adenoviral PSA Vaccine ETBX-071","C148142","A cancer vaccine composed of a genetically engineered, replication-deficient adenovirus carrying the gene encoding human prostate-specific antigen (PSA), with potential immunostimulating and antineoplastic activities. Upon vaccination with the adenoviral-PSA vaccine ETBX-071, the adenovirus infects cells and expresses PSA. In turn, PSA activates the immune system and induces a cytotoxic T-lymphocyte (CTL) response against PSA-expressing tumor cells. PSA, a tumor associated antigen (TAA), is expressed by prostate epithelial cells and is overexpressed in prostate cancer.","Adenoviral PSA Vaccine ETBX-071 | Adenoviral PSA Prostate Cancer Vaccine ETBX-071 | ETBX-071",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3661315","Rucaparib","C137800","An orally bioavailable tricyclic indole and inhibitor of poly(ADP-ribose) polymerases (PARPs) 1 (PARP1), 2 (PARP2) and 3 (PARP3), with potential chemo/radiosensitizing and antineoplastic activities. Upon administration, rucaparib selectively binds to PARP1, 2 and 3 and inhibits PARP-mediated DNA repair. This enhances the accumulation of DNA strand breaks, promotes genomic instability and induces cell cycle arrest and apoptosis. This may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy. PARPs are enzymes activated by single-strand DNA breaks that catalyze the post-translational ADP-ribosylation of nuclear proteins, which induces signaling and the recruitment of other proteins to repair damaged DNA. The PARP-mediated repair pathway plays a key role in DNA repair and is dysregulated in a variety of cancer cell types.","Rucaparib | 6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)- | 8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one | AG 14447 | AG-14447 | AG14447 | RUCAPARIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642154","Glossopharyngeal Sulcus","C105407","A groove between the base of the tongue and the palatine tonsil.","Glossopharyngeal Sulcus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473912","Indocyanine Green/Albumin Solution","C116716","A solution containing a non-toxic, fluorescent tricarbocyanine dye with a peak spectral absorption at 790 nm bound to the plasma protein albumin, that may be used in sentinel node mapping using a near infrared (NIR) imaging system. Upon injection of the indocyanine green (ICG)/albumin solution around the tumor, the ICG/albumin complex, travels though the vascular system. Using a NIR imaging system, the ICG, which emits light in the NIR range, permits the visualization of sentinel nodes and may help in cancer staging.","Indocyanine Green/Albumin Solution | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0223084","Vertebral Body","C12852","The largest part of a vertebra, which is the primary weight-bearing component of the vertebrae.","Vertebral Body | Body of Vertebra | Body of the Vertebra | Structure of body of vertebra (body structure)",,,,,,,,,,,,,,,"4149170","Structure of body of vertebra",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545767","Interventional Radiologist","C147951","A radiologist that specializes in the use of minimally invasive image-guided procedures for the diagnosis and treatment of disease.","Interventional Radiologist | Radiology Vascular and Interventional Radiology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714739","Mesothelial Neoplasm","C3786","A neoplasm characterized by the proliferation of neoplastic mesothelial cells. It usually arises from the pleura or peritoneum. This category includes malignant mesothelioma, adenomatoid tumor (benign mesothelioma), well differentiated papillary mesothelial tumor, and multicystic mesothelioma.","Mesothelial Neoplasm | Mesothelial Neoplasms | Mesothelial Tumor | Mesothelioma | Mesothelioma, NOS | mesothelioma",,,,,,,,,,,,,,,"4019489","Mesothelial neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206619","Lymphatic Vessel Neoplasm","C3723","A benign or malignant neoplasm arising from the lymphatic vessels.","Lymphatic Vessel Neoplasm | Lymph Vessel Neoplasm | Lymph Vessel Tumor | Lymphatic Vessel Tumor | Lymphatic Vessel Tumors | Neoplasm of Lymph Vessel | Neoplasm of Lymphatic Vessel | Neoplasm of the Lymph Vessel | Neoplasm of the Lymphatic Vessel | Tumor of Lymph Vessel | Tumor of Lymphatic Vessel | Tumor of the Lymph Vessel | Tumor of the Lymphatic Vessel",,,,,,,,,,,,,,,"4019106","Lymphatic vessel tumor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206631","Lipomatous Neoplasm","C4248","A benign, intermediate, or malignant mesenchymal neoplasm composed of adipose (fatty) tissue.","Lipomatous Neoplasm | Adipose Tissue Neoplasm | Adipose Tissue Tumor | Lipomatous Neoplasms | Lipomatous Tumor | Neoplasm of Adipose Tissue | Neoplasm of the Adipose Tissue | Tumor of Adipose Tissue | Tumor of the Adipose Tissue",,,,,,,,,,,,,,,"4019487","Lipomatous neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021071","Alpha Heavy Chain Disease","C3132","A clonal disorder, also known as immunoproliferative small intestinal disease or Mediterranean lymphoma, characterized by the secretion of a defective alpha heavy chain. It predominantly affects young people in the Mediterranean region. It involves the small intestine, and patients usually present with malabsorption syndrome, abdominal pain, weight loss, and fever. There is extensive villous atrophy of the small intestinal mucosa, which is heavily infiltrated by small lymphocytes and plasma cells. The small intestinal morphologic changes are consistent with a mucosa-associated lymphoid tissue lymphoma (MALT lymphoma).","Alpha Heavy Chain Disease | Alpha heavy chain disease | IPSID | Immunoproliferative Small Intestinal Disease | Immunoproliferative disease, NOS | Immunoproliferative small intestinal disease | Immunoproliferative small intestinal diseases | Mediterranean Abdominal Lymphoma | Mediterranean Lymphoma | Mediterranean lymphoma","9760/3|9764/3","Immunoproliferative disease, NOS|Immunoproliferative small intestinal disease",,,,,,,,,,,,,"4003835|4270220","Alpha heavy chain disease (clinical)|Heavy chain disease",,,,,,,,,,,,,"--","--|--",,,,,,,,"--|--"
"C0206649","Fibroepithelial Neoplasm","C3743","A benign, borderline, or malignant neoplasm characterized by the presence of an epithelial and a fibrous component.  Representative examples are fibroadenoma and phyllodes tumor.","Fibroepithelial Neoplasm | Fibroepithelial Neoplasms | Fibroepithelial Tumor",,,,,,,,,,,,,,,"4019488","Fibroepithelial neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334811","Mucinous Neoplasm","C7070","A benign, borderline, or malignant neoplasm characterized by the proliferation of neoplastic cells that contain intracytoplasmic mucin. It may be associated with the presence of extracellular mucin.","Mucinous Neoplasm | Mucinous Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335951","Serous Neoplasm","C7074","No Value Exists","Serous Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282607","Blood Vessel Neoplasm","C7387","A neoplasm arising from arteries or veins.","Blood Vessel Neoplasm | Blood Vessel Tumor",,,,,,,,,,,,,,,"44783504","Blood vessel neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0345988","Skin Appendage Neoplasm","C4463","A benign or malignant neoplasm that arises from the hair follicles, sebaceous glands, or sweat glands.","Skin Appendage Neoplasm | Adnexal Neoplasm of Skin | Adnexal Neoplasm of the Skin | Adnexal Tumor of Skin | Adnexal Tumor of the Skin | Appendageal Neoplasm | Appendageal Tumor | Cutaneous Adnexal Neoplasm | Epidermal Appendage Neoplasm | Epidermal Appendage Tumor | Neoplasm of Epidermal Appendage | Neoplasm of Skin Appendage | Neoplasm of the Skin Appendage | Skin Appendage Tumor | Skin Appendageal Neoplasm | Skin Appendageal Tumor | Tumor of Epidermal Appendage | Tumor of Skin Appendage | Tumor of the Skin Appendage",,,,,,,,,,,,,,,"4054736","Neoplasm of skin with adnexal differentiation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334390","Acinar Cell Neoplasm","C4197","A benign or malignant glandular epithelial neoplasm consisting of secretory cells forming acinar patterns. It includes the acinar cell adenoma and acinar cell carcinoma.","Acinar Cell Neoplasm | Acinar Cell Neoplasms | Acinar Cell Tumor | Acinar cell tumor | Acinic cell tumor","8550/1","Acinar cell tumor",,,,,,,,,,,,,"4019484","Acinar cell neoplasm",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334266","Transitional Cell Papilloma","C4115","A benign papillary neoplasm composed of transitional cells which show preservation of the nuclear polarity.","Transitional Cell Papilloma | PAPILLOMA, UROTHELIAL CELL, BENIGN | Transitional Papilloma | Transitional cell papilloma, NOS | Transitional papilloma",,,,,,,,,,,,,,,"4260683","Urothelial papilloma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1328043","Combined Thymic Epithelial Neoplasm","C45722","A primary thymus epithelial neoplasm characterized by the presence of at least two distinct areas representing thymoma and carcinoma. The most aggressive component usually determines the clinical outcome.","Combined Thymus Epithelial Neoplasm | Combined Thymic Carcinoma | Combined Thymic Epithelial Neoplasm | Combined Thymic Epithelial Neoplasm | Combined Thymic Epithelial Tumor | Composite Thymoma-Thymic Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0476203","Synovial Neoplasm","C8964","A benign or malignant soft tissue neoplasm arising exclusively from the synovial membrane.  Examples include the diffuse giant cell tumor of tendon sheath, localized giant cell tumor of tendon sheath, and malignant giant cell tumor of tendon sheath.","Synovial Neoplasm | Neoplasm of Synovium | Neoplasm of the Synovium | Synovial Tumor | Tumor of Synovium | Tumor of the Synovium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206720","Squamous Cell Neoplasm","C3792","A neoplasm that is composed of squamous epithelial cells.  Squamous cell carcinoma is a representative example.","Squamous Cell Neoplasm | Epidermoid Cell Neoplasm | Epidermoid Cell Tumor | Squamous Cell Neoplasms | Squamous Cell Tumor",,,,,,,,,,,,,,,"4041443","Squamous cell neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1335146","Osteogenic Neoplasm","C6603","A benign, intermediate, or malignant bone-forming neoplasm. Representative examples include osteoma, osteoblastoma, and osteosarcoma.","Osteogenic Neoplasm | Osseous Neoplasm | Osseous Tumor | Osteogenic Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0476147","Chondrogenic Neoplasm","C4755","A benign, intermediate, or malignant cartilaginous matrix-producing neoplasm.  Representative examples include osteochondroma, chondroblastoma, and chondrosarcoma.","Chondrogenic Neoplasm | Cartilaginous Neoplasm | Cartilaginous Tumor | Chondrogenic Tumor | Chondromatous Neoplasm | Chondromatous Tumor | Neoplasm of Cartilage | Neoplasm of the Cartilage | Tumor of Cartilage | Tumor of the Cartilage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028880","Odontogenic Neoplasm","C3286","A benign or malignant neoplasm arising from tooth-forming tissues. It occurs in the maxillofacial skeleton or the gingiva. Benign neoplasms are slow growing and are not associated with specific clinical symptoms. Pain is absent or slight. Malignant neoplasms are usually associated with rapid swelling and pain.","Odontogenic Neoplasm | Odontogenic Tumor | Odontogenic Tumors | Odontogenic tumor, NOS","9270/1","Odontogenic tumor, NOS",,,,,,,,,,,,,"4133300","Odontogenic neoplasm (morphology)",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0206715","Neuroepithelial Neoplasm","C3787","A neoplasm of the nervous system that arises from the neuroepithelial tissues.  Representative examples include astrocytic tumors, oligodendroglial tumors, ependymal tumors, and primitive neuroectodermal tumors.","Neuroepithelial Neoplasm | Neoplasm of Neuroepithelial Tissue | Neoplasm of Neuroepithelium | Neoplasm of the Neuroepithelium | Neuroepithelial Neoplasms | Neuroepithelial Tissue Neoplasm | Neuroepithelial Tissue Tumor | Neuroepithelial Tumor | Neuroepithelial Tumors | Neuroepitheliomatous Neoplasms | Tumor of Neuroepithelial Tissue | Tumor of Neuroepithelium | Tumor of the Neuroepithelium",,,,,,,,,,,,,,,"4019914","Neuroepitheliomatous neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0282606","Myomatous Neoplasm","C4063","A benign or malignant mesenchymal neoplasm arising from smooth, skeletal, or cardiac muscle.","Myomatous Neoplasm | Muscle Neoplasm | Muscle Tumor | Myomatous Neoplasms | Myomatous Tumor | Neoplasm of Muscle | Neoplasm of the Muscle | Tumor of Muscle | Tumor of the Muscle",,,,,,,,,,,,,,,"4016018","Myomatous neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL550773","MUC1 SP Vaccine","C148171","A therapeutic cancer vaccine comprised of a synthetic, 21-mer long peptide (LP) derived from the entire signal peptide (SP) domain of the tumor-associated antigen (TAA) mucin 1 (MUC1), with potential immunomodulating and antineoplastic activities. Upon intradermal administration, MUC1 SP vaccine may stimulate the host immune system to mount robust cytotoxic T-lymphocyte (CTL) and B-cell responses against MUC1-expressing tumor cells, resulting in tumor cell apoptosis and decreased tumor growth. MUC1 is overexpressed on many tumor cell types.","MUC1 SP Vaccine | IMMUCIN | ImMucin | MUC1-SP-L Vaccine | Mucin 1 Signal Peptide Vaccine | SP MUC1 Vaccine | VXL-100 | VXL100",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0118175","fostriecin","C1372","An anti-tumor antibiotic isolated from the bacterium Streptomyces pulveraceus. Fostriecin inhibits topoisomerase II catalytic activity, resulting in impaired DNA and RNA synthesis in various malignant cell types.  This agent also inhibits serine/threonine protein phosphatase type 2A in some tumor cell types, thereby interfering with cellular proliferation and differentiation. (NCI04)","Fostriecin | 2H-pyran-2-one,5,6-dihydro-6-(3,6,13-trihydroxy-3-methyl-4-(phosphonooxy)-1,7,9,11,-tridecatetraenyl)-,trans | FOSTRIECIN | FST | Phosphotrienin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0060441","Mitoflaxone","C1101","A synthetic flavonoid with vascular targeting properties. Flavone acetic acid exhibits an antiproliferative effect on endothelial cells as a result of a superoxide-dependent mechanism, which induces changes in permeability of the vasculature of the tumor. This agent may stimulate tumor necrosis and promote shunting of blood flow to viable regions of the tumor, increasing their oxygenation and rendering them more susceptible to the antitumor effects of hyperthermia and ionizing radiation.  (NCI04)","Mitoflaxone | 2-Phenyl-8-(carboxymethyl)-benzopyran-4-one | 4H-1-Benzopyran-8-acetic acid, 4-oxo-2-phenyl- | 4H-1-benzopyran-8-acetic Acid, 4-Oxo-2-phenyl | FAA | Flavone Acetic Acid | Flavone acetic acid | Flavone-8-Acetic Acid | LM 975 | MITOFLAXONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981793","PI3K inhibitor GSK2126458","C88270","A small-molecule pyridylsulfonamide inhibitor of phosphatidylinositol 3-kinase (PI3K) with potential antineoplastic activity. Omipalisib binds to and inhibits PI3K in the PI3K/mTOR signaling pathway, which may trigger the translocation of cytosolic Bax to the mitochondrial outer membrane, increasing mitochondrial membrane permeability and inducing apoptotic cell death. Bax is a member of the proapoptotic Bcl2 family of proteins. PI3K, often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.","Omipalisib | Benzenesulfonamide, 2,4-Difluoro-N-(2-methoxy-5-(4-(4-pyridazinyl)-6-quinolinyl)-3-pyridinyl)- | GSK2126458 | OMIPALISIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0915967","Thiarabine","C92589","A analog of antimetabolite cytarabine (ara-C), with potential antineoplastic activity. Upon administration, thiarabine (T-araC) is phosphorylated to the triphosphate form T-araCTP and competes with cytidine for incorporation into DNA. This results in an inhibition of DNA replication and RNA synthesis, chain termination and may eventually decrease tumor cell proliferation. Compared to ara-C, T-araC appears to have a longer half-life and has a higher efficacy.","Thiarabine | 4-thio-araC | GS7836 | OSI-7836 | THIARABINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0338324","GM2-KLH vaccine/QS21","C11571","A cancer vaccine based on the immunogenic ganglioside GM2, The GM2-KLH Vaccine/QS21 vaccine consists of GM2 conjugated with KLH keyhole limpet hemocyanin (KLH), a potent immunostimulant, and is admixed with the adjuvant QS21, a saponin fraction extracted from the bark of the South American tree Quillaja saponaria Molina. GM2 is a cell surface carbohydrate antigen expressed by most melanoma cells and various other tumor cell types. (NCI04)","GM2-KLH Vaccine/QS21 | GM2-KLH/QS-21 | GM2-KLH/QS21 | GMK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015980","Recombinant Interferon Beta","C495","A recombinant protein which is chemically identical to or similar to endogenous interferon beta with antiviral and anti-tumor activities. Endogenous interferons beta are cytokines produced by nucleated cells (predominantly natural killer cells) upon exposure to live or inactivated virus, double-stranded RNA or bacterial products. These agents bind to specific cell-surface receptors, resulting in the transcription and translation of genes with an interferon-specific response element. The proteins so produced mediate many complex effects, including antiviral (the most important being inhibition of viral protein synthesis), antiproliferative and immune modulating effects. The recombinant therapeutic forms of interferon beta are interferon beta 1-a and interferon beta 1-b. (NCI05)","Recombinant Interferon Beta | Beta Interferon | Betantrone | Feron | Human Interferon Beta | INTERFERON BETA | Interferon Beta | Interferon, Beta | Interferon-B | Interferon-beta | Naferon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554643","Recombinant Human Chorionic Gonadotropin","C528","A recombinant therapeutic agent which is chemically identical to or similar to the endogenous glycoprotein hormone human chorionic gonadotropin (HCG).  HCG binds to cells of the corpus luteum, thereby stimulating progesterone production and helping to maintain a secretory endometrium. (NCI04)","Recombinant Human Chorionic Gonadotropin | CHORIONIC GONADOTROPIN | Follutein | Gonadotropin, Chorionic | Human Chorionic Gonadotropin | LDI-200 | Novarel | Pregnyl | Profasi | hCG | rhCG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0065175","Lonidamine","C1146","An indazole carboxylic acid derivative that exhibits radiosensitizing and antiparasitic effects and interferes with the multidrug resistance mechanism.","Lonidamine | AF 1890 | Diclondazolic Acid | Doridamina | LONIDAMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2721771","Levoleucovorin","C1559","The active l-isomer of the racemic mixture of the 5-formyl derivative of tetrahydrofolic acid. Metabolically active, l-leucovorin, also known levoleucovorin, does not require bioactivation by dihydrofolate reductase, an enzyme inhibited by folic acid antagonists. This agent may enhance the effects of fluoropyrimidines by stabilizing their binding to the enzyme thymidylate synthase. (NCI04)","Levoleucovorin | CL-307,782 | Elvorine, Isovorin, Levofolene, Levorin | Isovorin | L-5-Formyltetrahydrofolate | L-Leucovorin | LEVOLEUCOVORIN | Levofolinate | Levofolinic acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0771414","Lanreotide Acetate","C74584","The acetate salt of a synthetic cyclic octapeptide analogue of somatostatin. Lanreotide binds to somatostatin receptors (SSTR), specifically SSTR-2 and also to SSTR-5 with a lesser affinity. However, compare with octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Furthermore, lanreotide has an acute effect on decreasing circulating total and free insulin-like growth factor 1 (IGF-I).  This agent is usually given as a prolonged-release microparticle or Autogel formulation for the treatment of acromegaly and to relieve the symptoms of neuroendocrine tumors.","Lanreotide Acetate | AT-1001 | L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7)-disulfide, acetate | LANREOTIDE ACETATE | Lanreotide LAR | Somatuline Depot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0389883","ISIS 5132","C2721","A synthetic, 20-base antisense oligodeoxynucleotide that hybridizes to c-raf kinase messenger RNA.  ISIS 5132 has been shown to specifically suppress Raf-1 expression both in vitro and in vivo.  Raf-1 serine/threonine kinase functions as a critical effector of Ras-mediated signal transduction; constitutive activation of this pathway directly contributes to malignant transformation. (NCI04)","c-raf Antisense Oligonucleotide ISIS 5132 | CGP 69846A | CGP69846A | ISIS 5132 | ISIS 5132 | ISIS 5132/CGP69846A | ISIS-5132 | RAF-IK Antisense ODN | c-RAF Antisense",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0666551","ISIS 3521","C1788","A synthetic phosphorothioate oligodeoxynucleotide. As an antisense molecule, aprinocarsen hybridizes to the 3-untranslated region of the human protein kinase C (PKC-alpha) mRNA, thereby inhibiting PKC-alpha expression and growth of PKC-alpha-dependent tumor cells. (NCI04)","Aprinocarsen | APRINOCARSEN | Affinitac | Affinitak | CGP 64128A | DNA, d(P-thio)(G-T-T-C-T-C-G-C-T-G-G-T-G-A-G-T-T-T-C-A) | DNA, d(P-thio)(GTTCTCGCTGGTGAGTTTCA) | ISIS 3521 | ISIS 3521 | LY900003 | PKC-alpha Antisense Oligodeoxynucleotide ISIS 3521 | Protein Kinase C-Alpha Antisense",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896730","Monalizumab","C120208","A humanized immunoglobulin G4 (IgG4) monoclonal antibody against the human natural killer (NK) and T-lymphocyte cell checkpoint inhibitor killer cell lectin-like receptor subfamily C member 1 (NKG2A), with potential antineoplastic activity. Upon administration, monalizumab binds to NKG2A and prevents the binding of NKG2A to its ligand human leukocyte antigen-E (HLA-E), which is overexpressed on tumor cells. This blocks the HLA-E-mediated inhibition of NKG2A-positive infiltrating NK and cytotoxic T-lymphocytes (CTLs) and induces a NK and CTL-mediated immune response against the cancer cells leading to their destruction. Human NKG2A, an inhibitory cell surface receptor covalently bound to CD94, is expressed by NK cells and CTLs. Stimulation of the CD94/NKG2A complex inhibits the cytotoxic activity of these cells. HLA-E, a nonclassical HLA class Ib molecule, is often overexpressed on tumor cells and is associated with poor prognosis.","Monalizumab | IPH-2201 | IPH2201 | Immunoglobulin G4-kappa, Anti-(Homo sapiens KLRC1 (Killer Cell Lectin-like Receptor Subfamily C Member 1, NKG2-a, NKG2a, CD159A, CD94)), Humanized Monoclonal Antibody | MONALIZUMAB | NN-8765 | NN8765 | NN8765-3658",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1701589","interleukin-4, human","C20508","Interleukin-4 (153 aa, ~17 kDa) is encoded by the human IL4 gene. This protein is involved in the regulation of the expression of class II MHC molecules, Fc receptors and cell surface-bound immunoglobulins.","Interleukin-4 | B Cell Proliferating Factor | B-Cell Differentiation Factor-1 | B-Cell Growth Factor | B-Cell Growth Factor-1 | B-Cell Stimulating Factor | B-Cell Stimulation Factor-1 | B-Cell Stimulatory Factor 1 | BCDF-1 | BCGF | BCGF-1 | BCSF 1 | BSF-1 | BSF1 | IL-4 | IL4 | IL4 Protein | Interleukin 4 | Interleukin-4 Precursor | Lymphocyte Stimulatory Factor 1 | MCGF 2 | Mast Cell Growth Factor-2 | T-Cell Growth Factor 2 | interleukin-4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0528372","Zosuquidar Trihydrochloride","C2225","A difluorocyclopropyl quinoline. Zosuquidar trihydrochloride binds with high affinity to P-glycoprotein and inhibits P-glycoprotein-mediated multidrug resistance (MDR). P-glycoprotein, encoded by the MDR-1 gene, is a member of the ATP-binding cassette superfamily of transmembrane transporters and prevents the intracellular accumulation of many natural product-derived cytotoxic agents. (NCI04)","Zosuquidar Trihydrochloride | (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, Trihydrochloride | LY335979 | ZOSUQUIDAR TRIHYDROCHLORIDE | zosuquidar trihydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0298619","Etalocib","C1626","A second-generation selective leukotriene B4 receptor (LTB4R) antagonist with potential antineoplastic activity. Although the exact underlying mechanism through which LY293111 exerts its effects has not been fully elucidated, this agent selectively binds to and blocks LTB4Rs, thereby inhibiting the downstream signalling pathway. LY29311 has been shown to induce apoptosis and inhibits cellular proliferation in LTB4R expressing cells, such as pancreatic cancer cells.","Etalocib | 2-[2-Propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]phenoxy]benzoic Acid | 2-[3-[3-[(5-Ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-2-propylphenoxy]benzoic Acid | ETALOCIB | LY293111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0127527","Menogaril","C1389","A semisynthetic derivative of the anthracycline antineoplastic antibiotic nogalamycin.  Menogaril intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent is less cardiotoxic than doxorubicin. (NCI04)","Menogaril | 7(R)-O-Methylnogarol | 7-(R)-O-methylnogarol | 7-OMEN | 7-con-O-Methylnogarol | 7-con-O-methylnogarol | 7-con-O-methylnorgarol | MEN | MENOGARIL | Menogarol | OMEN,7- | TUT-7 | U-52047 | [2R-(2alpha,3beta,4alpha,5beta,6alpha,11alpha,13alpha)]-4-(dimethylamino)-3,4,5,6,11,12,13,14-octahydro-3,5,8,10,13-pentahydroxy-11-methoxy-6,13-dimethyl-2,6-epoxy-2H-naphthaceno[1,2-b]oxocin-9,16-dione",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0761616","Melanoma Theraccine","C1830","A synthetic allogeneic cancer vaccine.  Melanoma theraccine typically consists of lysed melanoma cells obtained from several melanoma cell lines combined with an adjuvant (such as DETOX or RIBI).  This agent may be combined with immunomodulatory cytokines such as interferon alpha.  Melanoma theraccine may induce a rise in the level of cytotoxic T-lymphocyte precursors. (NCI04)","Melanoma Theraccine | Melacine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0591085","Amsacrine","C240","An aminoacridine derivative with potential antineoplastic activity. Although its mechanism of action is incompletely defined, amsacrine may intercalate into DNA and inhibit topoisomerase II, resulting in DNA double-strand breaks, arrest of the S/G2 phase of the cell cycle, and cell death. This agent's cytotoxicity is maximal during the S phase of the cell cycle when topoisomerase levels are greatest. In addition, amsacrine may induce transcription of tumor promoter p53 protein and block p53 ubiquitination and proteasomal degradation, resulting in p53-dependent tumor cell apoptosis.","Amsacrine | 4'-(9-Acridinylamino)methane-sulfon-m-anisidide | AMSA | AMSACRINE | Acridinyl Anisidide | Amekrin | Amsa P-D | Amsidine | Amsidyl | CI 880 | CI-880 | CI880 | Cain's Acridine | Lamasine | N-[4-(9-Acridinylamino)-3-methoxyphenyl]methanesulfonamide | SN 11841 | SN-11841 | SN-21429 | SN11841 | amsacrine | m-AMSA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796640","MG 98","C2530","A second-generation, mixed-backbone, phosphorothioate antisense oligonucleotide (ODN) with potential antitumor activity. MG 98 is a highly specific inhibitor of translation of the mRNA for human DNA (cytosine-5-)-methyltransferase 1 (DNMT1), hybridizing to the 3' un-translated region of DNMT1 mRNA. The silencing of DNMT1 translation by MG 98 may result in the prevention or reversal of abnormal methylation of tumor suppressor genes and ultimately in tumor growth inhibition or tumor regression.","DNMT1 Mixed-Backbone Antisense Oligonucleotide MG 98 | MG 98 | MG 98 | MG-98 | MG-98 oligonucleotide | MG98",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896648","Genetically-modified MAGE-A3-expressing MG1 Maraba Virus Vaccine","C118973","A vaccine consisting of the attenuated, genetically-modified, oncolytic form of the Maraba virus, MG1, which has been engineered to express a gene encoding the cancer testis antigen melanoma antigen family A3 (MAGE-A3), with potential antineoplastic activity. Upon administration of genetically-modified MAGE-A3-expressing MG1 Maraba virus vaccine, the attenuated Maraba virus selectively and rapidly replicates in cancer cells; however, it is unable to replicate in normal, healthy cells. This induces a selective Maraba virus-mediated cytotoxicity in those cancer cells, and leads to cancer cell lysis. In addition, the expression of MAGE-A3 further stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing MAGE-A3. The tumor-associated antigen MAGE-A3 is overexpressed by a variety of cancer cell types. The attenuated virus is a double mutant strain with single amino acid substitutions occurring in both G protein (Q242R) and M protein (L123W).","Genetically-modified MAGE-A3-expressing MG1 Maraba Virus Vaccine | MG1 Maraba/MAGE-A3 | MG1MA3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036637","Semustine","C827","A methylated derivative of carmustine with antineoplastic activity. As an alkylating agent, semustine forms covalent linkages with nucleophilic centers in DNA, causing depurination, base-pair miscoding, strand scission, and DNA-DNA cross-linking, which may result in cytotoxicity. (NCI04)","Semustine | 1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea | 1-(2-Chloroethyl)-3-(Trans-4-Methylcyclohexane)-1-Nitrosourea | 1-(2-Chloroethyl)-3-(trans-4-methylcyclohexane)-1-nitrosourea | 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea | Lomustine, Methyl | Lomustine, methyl | MCCNU | MeCCNU | Methyl CCNU | Methyl Lomustine | SEMUSTINE | Urea, 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitroso-, trans- (8CI) | Urea, N-(2-chloroethyl)-N'-(4-methylcyclohexyl)-N-nitroso-, trans- (9CI) | methyl-CCNU | semustine | trans-Methyl-CCNU | urea, 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitroso-, trans- (8CI) | urea, N-(2-chloroethyl)-N'-(4-methylcyclohexyl)-N-nitroso-, trans- (9CI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447293","Liposome-encapsulated miR-34 Mimic MRX34","C105802","A liposomal formulation containing a nucleotide that mimics the human tumor suppressor microRNA (miRNA) miR-34, with potential antineoplastic activity. Upon administration, liposome-encapsulated MRX34 mimics miR-34 by inhibiting the expression of a variety of oncogenes including MYC, MET, BCL2, and beta-catenin. This induces cell cycle arrest, senescence and apoptosis in susceptible tumor cells. miR-34 is downregulated in most solid and hematologic malignancies and regulates the expression of a variety of genes. This miRNA plays an important role in the inhibition of cancer cell stemness, metastasis and cancer cell survival.","Liposome-encapsulated miR-34 Mimic MRX34 | MRX34",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026088","Mifepristone","C655","A derivative of the synthetic progestin norethindrone with antiprogesterone activity. Mifepristone competitively binds to the progesterone receptor, resulting in inhibition of the effects of endogenous or exogenous progesterone. This agent also exhibits antiglucocorticoid and weak antiandrogenic activities.","Mifepristone | (aa Beta, 17 beta)-11-[4-(dimethylamino)-phenyl]-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one | 11 Beta-[4-(N,N-dimethylamino)phenyl]-17alpha-(propyl-1-ynyl)-delta-4,9-estradiene-17 beta-ol-3-one | 11-((4-dimethylamino) phenyl)-17-Hydroxy-17-(1-propynyl) Estra-4,9- dien-3-one | Korlym | MIFEPRISTONE | Mifegyne | Mifeprex | RU 486 | RU-38486 | RU-486 | mifepristone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641866","Darolutamide","C104748","A formulation containing an androgen receptor (AR) antagonist with potential antineoplastic activity. Darolutamide binds to ARs in target tissues; subsequently, inhibiting androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes that regulate prostate cancer cell proliferation. This ultimately leads to an inhibition of growth in AR-expressing prostate cancer cells.","Darolutamide | AR Antagonist ODM-201 | Antiandrogen ODM-201 | BAY 1841788 | BAY-1841788 | BAY1841788 | DAROLUTAMIDE | Nubeqa | ODM 201 | ODM-201 | ODM201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0935959","Lurtotecan Liposome","C1876","A liposome-encapsulated formulation of lurtotecan with antineoplastic activity. Lurtotecan, a semisynthetic analogue of camptothecin, selectively stabilizes the topoisomerase I-DNA covalent complex and forms an enzyme-drug-DNA ternary complex during S phase of the cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-stranded DNA breaks. This ultimately results in an inhibition of DNA replication, inducing double-stranded DNA breakages, obstruction of RNA and protein synthesis and triggering apoptosis. Furthermore, this agent also stimulates degradation of topoisomerase I, likely mediated through ubiquitin-proteasomal pathway. Liposomal delivery of lurtotecan improves its penetration and delivery into tumors while lowering systemic side effects.","Lurtotecan Liposome | NX211 | OSI-211 | liposomal lurtotecan | liposome, lurtotecan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0066373","N-Methylformamide","C1163","A water-soluble organic solvent.  As an adjuvant antineoplastic agent, N-methylformamide depletes cellular glutathione, a key molecule involved in the antioxidation of reactive oxygen species (ROS) and other free radicals, thereby enhancing ionizing radiation-induced DNA cross-linking in and terminal differentiation of tumor cells. (NCI04)","N-Methylformamide | EK 7011 | Formamide, N-methyl | Monomethylformamide | N-METHYLFORMAMIDE | NMF | X 188 | formylmethylamine | monomethylformamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0664207","Oregovomab","C1784","A murine monoclonal antibody that attaches to the tumor-associated antigen CA125. Vaccination with monoclonal antibody B43.13 may stimulate a host cytotoxic immune response against tumor cells that express CA125. (NCI04)","Oregovomab | B43.13 | MoAb B43.13 | Monoclonal Antibody B43.13 | OREGOVOMAB | OvaRex | OvaRex Monoclonal Antibody B43.13 | oregovomab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348994","Apatorsen","C71740","A second-generation antisense oligonucleotide targeting heat shock protein 27 (Hsp27) with potential antitumor and chemosensitizing activities. Apatorsen suppresses tumor cell expression of Hsp27, which may induce tumor cell apoptosis and enhance tumor cell sensitivity to cytotoxic agents. Hsp27, a chaperone belonging to the small heat shock protein (sHsp) group of proteins, is a cytoprotective protein that supports cell survival under conditions of stress; it has been found to be over-expressed in a variety of human cancers.","Apatorsen | APATORSEN | ISIS 306053 | OGX-427",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1328699","Custirsen Sodium","C1055","The eicosasodium salt of a mixed-backbone antisense oligodeoxynucleotide with chemosensitizing properties. Custirsen inhibits testosterone-repressed prostate message-2 (TRPM-2). Administration of custirsen abrogates the anti-apoptotic effect of TRPM-2, thereby sensitizing cells to chemotherapy and resulting in tumor cell death. TRPM-2 is an anti-apoptotic clusterin that is overexpressed by prostate cancer cells and is associated with chemoresistance.","Custirsen Sodium | (3'-5')d(P-thio)([2'-O-(2-methoxyethyl)]m5rC-[2'-O-(2-methoxyethyl)]rA-[2'-O-(2- methoxyethyl)]rG-[2'-O-(2-methoxyethyl)]m5rC-A-G-C-A-G-A-G-T-C-T-T-C-A-[2'-O-(2- methoxyethyl)]m5rU-[2'-O-(2-methoxyethyl)]m5rC-[2'-O-(2-methoxyethyl)]rA-[2'-O-(2- methoxyethyl)]m5rU), Eicosasodium Salt | Antisense TRPM-2 | Antisense Testosterone-Repressed Prostate Message 2 | CUSTIRSEN SODIUM | Clusterin Antisense Oligonucleotide | ISIS 112989 | OGX 011 | OGX-011 | OGX011 | TRPM-2 Antisense | custirsen sodium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981174","Ponatinib Hydrochloride","C78194","The hydrochloride salt form of an orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.","Ponatinib Hydrochloride | AP24534 HCl | Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)-, Hydrochloride (1:1) | Iclusig | PONATINIB HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346909","Refametinib","C74059","An orally bioavailable selective MEK inhibitor with potential antineoplastic activity. Refametinib specifically inhibits mitogen-activated protein kinase kinase 1 (MAP2K1 or MAPK/ERK kinase 1), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a dual specificity threonine/tyrosine kinase, is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers.","Refametinib | BAY 869766 | BAY-869766 | BAY86-9766 | BAY869766 | MEK Inhibitor RDEA119 | RDEA119 | REFAMETINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700466","Ranitidine Hydrochloride","C66506","A member of the class of histamine H2-receptor antagonists with antacid activity. Ranitidine is a competitive and reversible inhibitor of the action of histamine, released by enterochromaffin-like (ECL) cells, at the histamine H2-receptors on parietal cells in the stomach, thereby inhibiting the normal and meal-stimulated secretion of stomach acid. In addition, other substances that promote acid secretion have a reduced effect on parietal cells when the H2 receptors are blocked.","Ranitidine Hydrochloride | N-(2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine, hydrochloride | RANITIDINE HYDROCHLORIDE | Ranitidine | Ranitidine.HCl | Zantac",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1566038","Sonolisib","C78848","A small-molecule wortmannin analogue inhibitor of the alpha, gamma, and delta isoforms of phosphoinositide 3-kinase (PI3K) with potential antineoplastic activity. Sonolisib inhibits the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K/Akt signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","Sonolisib | (4E)-4-(((Bis(prop-2-en-1-yl)amino)methylidene)-6-hydroxy-1alpha-(methoxymethyl)-3,7,17-trioxo-2-oxaandrosta-5,8-dien-11alpha-yl Acetate | PX 866 | PX-866 | PX866 | SONOLISIB | acetic acid (1S,4E,10R,11R,13S,14R)-4-diallylaminomethylene-6-hydroxy-1-methoxymethyl-10,13-dimethyl-3,7,17-trioxo-1,3,4,7,10,11,12,13,14,15,16,17-dodecahydro-2-oxa-cyclopenta[a]phenanthren-11-yl ester | acetic acid 4-diallylaminomethylene-6-hydroxy-1-alpha 12-methoxymethyl-10beta,13beta-dimethyl-3,7,17-trioxo-1,3,4,7,10,11beta,12,13,14alpha,15,16,17-dodecahydro-2-oxa-cyclopenta[a]phenanthren-11-yl ester",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519903","Rilimogene Galvacirepvec","C38681","A vaccine formulation consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA) and recombinant vaccinia virus encoding three co-stimulatory molecule transgenes B7.1, ICAM-1, and LFA-3 (TRICOM). Vaccination with PSA in combination with TRICOM may enhance antigen presentation, resulting in the augmentation of a cytotoxic T cell (CTL) immune response against tumor cells expressing PSA.","Rilimogene Galvacirepvec | PROSTVAC | Prostvac-V | RILIMOGENE GALVACIREPVEC | Recombinant Vaccinia-PSA(L155)-TRICOM Vaccine | Recombinant Vaccinia-PSA(L155)/TRICOM | Recombinant Vaccinia-PSA(L155)/TRICOM Vaccine | rVaccinia-PSA(L155)-TRICOM Vaccine | rVaccinia-Prostate-Specific Antigen/TRICOM Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033447","Propantheline","C78077","No Value Exists","Propantheline | PROPANTHELINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0591309","Therapeutic Progesterone","C777","The therapeutic form of the naturally occurring hormone progesterone.  Progesterone binds to the progesterone receptor, resulting in dissociation of heat shock proteins, receptor phosphorylation, and transcription activation through direct or indirect interaction with transcription factors.  This agent exerts inhibitory effects on estrogens by decreasing the number of estrogen receptors and increasing its metabolism to inactive metabolites.  Progesterone induces secretory changes in the endometrium, decreases uterine contractility during pregnancy, and maintains pregnancy.","Therapeutic Progesterone | 17alpha-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione | Corlutina | Corluvite | Corpus luteum hormone | Cyclogest | Delta4-pregnene-3,20-dione | Gestiron | Gestone | Lipo-Lutin | Luteohormone | Lutocyclin | Lutocylin M | Lutogyl | Lutromone | PROGESTERONE | Progestasert | Progesterone | Progestin | Progestogel | Progestol | Progeston | Prolidon | Proluton | Syngesterone | Utrogestan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3467801","Pracinostat","C71708","An orally available, small-molecule histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Pracinostat inhibits HDACs, which may result in the accumulation of highly acetylated histones, followed by the induction of chromatin remodeling; the selective transcription of tumor suppressor genes; the tumor suppressor protein-mediated inhibition of tumor cell division; and, finally, the induction of tumor cell apoptosis. This agent may possess improved metabolic, pharmacokinetic and pharmacological properties compared to other HDAC inhibitors.","Pracinostat | 2-propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1h-benzimidazol-5-yl)-N-hydroxy-, (2E)- | HDAC Inhibitor SB939 | PRACINOSTAT | SB 939 | SB-939 | SB939 | kaempferol 3-o-beta-d-(6-E-P-coumaroylglucoside)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0045644","SarCNU","C963","An alkylating chloroethylnitrosourea with antineoplastic activity.  Selectively accumulating in some tumor cells, SarCNU forms covalent linkages with nucleophilic centers in DNA, causing depurination, base pair miscoding, strand scission, and DNA-DNA cross-linking, which may result in cytotoxicity. (NCI04)","SarCNU | 2-CHLOROETHYL-3-SARCOSINAMIDE-1-NITROSOUREA | 2-Chloroethyl-3-Sarcosinamide-1-Nitrosourea | sarCNU | sarcosinamide nitrosourea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348352","Voxtalisib","C71704","An orally bioavailable small molecule targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinases in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Voxtalisib inhibits both PI3K kinase and mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in susceptible tumor cell populations. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated in a PI3K-independent fashion in response to nutrient and energy deprivation. Accordingly, this agent maybe more potent compared to an agent that inhibits either PI3K kinase or mTOR kinase alone.","Voxtalisib | SAR-245409 | SAR245409 | VOXTALISIB | XL-765 | XL765",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347424","XL147","C71705","An orally bioavailable small molecule, targeting the class I phosphatidylinositol 3 kinase (PI3K) family of lipid kinases, with potential antineoplastic activity. Pilaralisib reversibly binds to class 1 PI3Ks in an ATP-competitive manner, inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K signaling pathway; this may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents including genotoxic agents and receptor tyrosine kinase inhibitors.","Pilaralisib | 2-Amino-N-(3-(N-(3-((2-chloro-5-methoxyphenyl)amino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-methylpropanamide | PILARALISIB | SAR245408 | XL 147 | XL-147 | XL147",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3247913","Ruxolitinib Phosphate","C97937","The phosphate salt form of ruxolitinib, an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","Ruxolitinib Phosphate | (3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile Phosphate (1:1) | 1H-Pyrazole-1-propanenitrile, beta-cyclopentyl-4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-,(betaR)-, phosphate (1:1) | INCB-18424 Phosphate | Jakafi | Jakavi | RUXOLITINIB PHOSPHATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513492","Rucaparib Camsylate","C131178","The camsylate salt form of rucaparib, an orally bioavailable tricyclic indole and inhibitor of poly(ADP-ribose) polymerases (PARPs) 1 (PARP1), 2 (PARP2) and 3 (PARP3), with potential chemo/radiosensitizing and antineoplastic activities. Upon administration, rucaparib selectively binds to PARP1, 2 and 3 and inhibits PARP-mediated DNA repair. This enhances the accumulation of DNA strand breaks, promotes genomic instability and induces cell cycle arrest and apoptosis. This may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy. PARPs are enzymes activated by single-strand DNA breaks that catalyze the post-translational ADP-ribosylation of nuclear proteins, which induces signaling and the recruitment of other proteins to repair damaged DNA. The PARP-mediated repair pathway plays a key role in DNA repair and is dysregulated in a variety of cancer cell types.","Rucaparib Camsylate | 8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-pyrrolo(4,3,2-ef)(2)benzazepin-6-one (7,7-dimethyl-2-oxobicyclo(2.2.1)heptan-1-yl)methanesulfonate (1:1) | 8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic Acid Salt | Bicyclo(2.2.1)heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (1S,4R)-, Compound with 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-6H-pyrrolo(4,3,2-ef)(2)benzazepin-6-one (1:1) | C0-338 | CO 338 | CO-338 | CO338 | RUCAPARIB CAMSYLATE | Rubraca | Rucaparib Phosphate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0073688","Zorubicin","C91365","A benzoylhydrazone derivative of the anthracycline antineoplastic antibiotic daunorubicin. Zorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair as well as RNA and protein synthesis.","Zorubicin | (2S-cis)-Benzoic Acid[1-[4-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]ethylidene]hydrazide | Benzoic Acid Hydrazide 3-Hydrazone with Daunorubicin | Benzoylhydrazone Daunorubicin | Daunomycin Benzoylhydrazone | Rubidazon | Rubidazone | ZORUBICIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0392979","Larotaxel","C48427","A semi-synthetic derivative of the taxane 10-deacetylbaccatin III with potential antineoplastic activities. Larotaxel binds to tubulin, promoting microtubule assembly and stabilization and preventing microtubule depolymerization, thereby inhibiting cell proliferation. As it represents poor substrate for P-glycoprotein-related drug resistance mechanisms, this agent may be useful for treating multi-drug resistant tumors. Larotaxel penetrates the blood brain barrier.","Larotaxel | LAROTAXEL | RPR 109881A | RPR-109881 | Taxoid-109881 | XRP9881",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0218068","Relcovaptan","C1497","A substance being studied in the treatment of cancer. It inhibits a hormone growth factor that causes some cancer cells to divide. It is a type of vasopressin receptor antagonist.","Relcovaptan | 1-(5-Chloro-3-(2-chlorophenyl)-1-(3,4-dimethoxybenzenesulfonyl)-3-hydroxy-2,3-dihydro-1H-indole-2-carbonyl)pyrrolidine-2-carboxamide | RELCOVAPTAN | SR-49059 | SR49059",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0075018","Spirogermanium","C1232","A synthetic organometallic compound containing the element germanium with possible antineoplastic activity. Spirogermanium exhibits significant toxicity, particularly neurotoxicity. (NCI04)","Spirogermanium | 2-[3-(Dimethyl-amino)propyl]-8,8-diethyl-2-aza-8-germaspiro[4,5]decane | 8,8-Diethyl-N,N-dimethyl-3-aza-8-germaspiro[4,5]decane-2-propanamine | S 99 A | SPG | SPIROGERMANIUM | Spiro 32 | Spiro-32 | Spirogermanium Compound | Spirogermanium compound",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700546","Methylprednisolone Sodium Succinate","C48004","The sodium succinate salt of a synthetic glucocorticoid receptor agonist with immunosuppressive and anti-inflammatory effects. Methylprednisolone sodium succinate is converted into active prednisolone in the body, which activates glucocorticoid receptor mediated gene expression. This includes inducing synthesis of anti-inflammatory protein IkappaB-alpha and inhibiting synthesis of nuclear factor kappaB (NF-kappaB). As a result, proinflammatory cytokine production such as IL-1, IL-2 and IL-6 is down-regulated and cytotoxic T-lymphocyte activation is inhibited. Therefore, an overall reduction in chronic inflammation and autoimmune reactions may be achieved.","Methylprednisolone Sodium Succinate | A-MethaPred | Asmacortone | Cryosolona | METHYLPREDNISOLONE SODIUM SUCCINATE | Medrate | Metypred | Prednilem | Solu Moderin | Solu-Medrol | Solu-Medrone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0770560","Hydrocortisone Sodium Succinate","C1819","The sodium salt of hydrocortisone succinate with glucocorticoid property. Hydrocortisone sodium succinate is chemically similar to the endogenous hormone that stimulates anti-inflammatory and immunosuppressive activities, in addition to exhibiting minor mineralocorticoid effects. This agent binds to intracellular glucocorticoid receptors and is translocated into the nucleus, where it initiates the transcription of glucocorticoid-responsive genes, such as various cytokines and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both potent mediators of inflammation.","Hydrocortisone Sodium Succinate | (11beta)-21-(3-Carboxy-1-oxopropyl)-11,17-dihydroxypregn-4-ene-3,20-dione, Monosodium Salt | A-Hydrocort | Buccalsone | Corlan | Cortisol Sodium Succinate | Cortisol sodium succinate | Cortop | Efcortelan | Emergent-EZ | Flebocortid | HYDROCORTISONE SODIUM SUCCINATE | Hidroc Clora | Hycorace | Hydro-Adreson | Hydro-adreson | Hydrocort | Hydrocortisone 21-Sodium Succinate | Hydrocortisone Na Succinate | Hydrocortisone sodium succinate | Kinogen | Nordicort | Nositrol | Sinsurrene | Sodium hydrocortisone succinate | Solu-Cortef | Solu-Glyc",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1446539","Tegafur-Uracil","C9506","A formulated therapeutic oral agent consisting of a combination of the 5-fluorouracil (5-FU) congener prodrug tegafur (tetrahydrofuranyl-5-fluorouracil) and uracil (1:4). The high concentration of uracil reversibly inhibits the uracil-reducing enzyme dihydropyrimidine dehydrogenase (DPD), thereby inhibiting first-pass DPD-mediated hepatic metabolism of the uracil analogue 5-FU and permitting administration of 5-FU as the orally bioavailable prodrug tegafur. Tegafur is bioactivated to 5-FU by liver microsomal cytochrome P450 enzymes. 5-FU is subsequently converted into its active metabolites 5-fluoro-deoxyuridine-monophosphate (FdUMP) and 5-fluorouridine-triphosphate (FUTP) intracellularly; these metabolites inhibit the enzyme thymidylate synthase and intercalate into RNA, resulting in decreased thymidine synthesis, reduced DNA synthesis, disrupted RNA function, and tumor cell cytotoxicity.","Tegafur-Uracil | Oral Fluorouracil-Uracil | TEGAFUR-URACIL | Tefudex | Tegafur and Uracil | Tegafur and uracil | UFT | Uftoral | Ufur | Uracil and Ftorafur | Uracil and Tegafur | Uracil and Tetrahydrofuranyl-5-Fluorouracil | Uracil/Tegafur (UFT) | tegafur-uracil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3660928","Taselisib","C116876","An orally bioavailable inhibitor of the class I phosphatidylinositol 3-kinase (PI3K) alpha isoform (PIK3CA), with potential antineoplastic activity. Taselisib selectively inhibits PIK3CA and its mutant forms in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PIK3CA-expressing tumor cells. By specifically targeting class I PI3K alpha, this agent may be more efficacious and less toxic than pan PI3K inhibitors. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and causes increased tumor cell growth, survival, and resistance to both chemotherapy and radiotherapy. PIK3CA, which encodes the p110-alpha catalytic subunit of the class I PI3K, is mutated in a variety of cancer cell types and plays a key role in cancer cell growth and invasion.","Taselisib | GDC-0032 | RO5537381 | TASELISIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0286890","Tallimustine","C1603","A benzoyl mustard derivative of the antiviral agent distamycin A with potential antineoplastic activity. Tallimustine selectively binds to A-T rich regions in the minor groove of DNA and alkylates at the N3 position of adenine in a highly sequence-specific manner. This prevents DNA replication, inhibits cellular proliferation and triggers apoptosis. Moreover, unlike other clinical nitrogen mustards, tallimustine does not carry out guanine-N7 alkylation in the major groove of DNA, which may lead to a high selectivity of action.","Tallimustine | FCE 24517 | PNU-152241 | TALLIMUSTINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4042960","Talazoparib","C95733","An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. Talazoparib selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.","Talazoparib | BMN 673 | BMN-673 | BMN673 | TALAZOPARIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008275","Chlorotrianisene","C65320","An orally bioavailable, highly lipophilic, synthetic triphenylethylene (TPE) derivative and selective estrogen receptor modulator (SERM), with predominantly estrogenic but also antiestrogenic activities. Upon administration, chlorotrianisene binds to estrogen receptors (ER) and, depending on the responsive target cells, either activates or blocks ER activity. This modulates the expression of ER-responsive genes in a tissue-specific manner. This agent may increase bone mineral density, modify the lipid profile and ameliorate vasomotor symptoms. Chlorotrianisene inhibits the pituitary secretion of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH) through a negative feedback mechanism.","Chlorotrianisene | Benzene, 1,1',1''-(1-chloro-1-ethenyl-2-ylidene)tris(4-methoxy- | CHLOROTRIANISENE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1327873","T900607","C26674","A pentafluorophenylsulfonamide compound with potential antineoplastic activity. T900607 inhibits tubulin polymerization by binding irreversibly to colchicine binding sites, resulting in cell cycle arrest and apoptosis. (NCI04)","T900607 | T-900607",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0767921","Batabulin Sodium","C1835","The sodium salt form of batabulin, a synthetic pentafluorophenylsulfonamide with potential antineoplastic activity. Batabulin covalently binds to and selectively modifies the beta 1, beta 2, beta 3, and beta 4 isotypes of beta tubulin at a conserved cysteine residue, resulting in disruption of microtubule polymerization, collapse of the cytoskeleton, an increase in chromosomal ploidy, cell cycle arrest, and tumor cell apoptosis.","Batabulin Sodium | 2-Fluoro-1-methoxy-4-(pentafluorophenyl-sulfonamido)benzene, Sodium Salt | BATABULIN SODIUM | T138067 Sodium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0165187","Sulofenur","C1432","A diarylsulfonylurea with potential antineoplastic activity. Sulofenur's antineoplastic mechanism of action is unknown. (NCI04)","Sulofenur | LY186641 | SULOFENUR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039600","Testolactone","C2301","A progesterone derivative with antineoplastic activity. Testolactone inhibits steroid aromatase, thereby preventing the formation of estrogen from adrenal androstenedione and reducing endogenous estrogen levels. (NCI04)","Testolactone | 1,2,3,4,4a,4b,7,9,10,10a-Decahydro-2-hydroxy-2,4b-dimethyl-7-oxo-1-phenanthrenepropionic Acid Delta-Lactone | 1-Dehydrotestololactone | 13-Hydroxy-3-0x0-13,17-secoandrosta-1,4-dien-17-oic Acid Delta-Lactone | 17Alpha-oxo-D-homo-1,4-androstadiene-3,17-dione | D-Homo-17a-oxaandrosta-1,4-diene-3,17-dione | Delta-1-Testololactone | Fludestrin | SQ 9538 | SQ-9538 | TESTOLACTONE | Teslac | Therapeutic Testolactone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042683","Vindesine Sulfate","C935","The sulfate salt form of Vindesine.  Vindesine binds to and stabilizes tubulin, thereby interrupting tubulin polymerization and preventing the formation of the mitotic spindle and cell division; treated cells are unable to undergo mitosis and are arrested in metaphase. This agent also disrupts macromolecular synthesis. (NCI)","Vindesine Sulfate | Desacetyl Vinblastine Amide Sulfate | Eldesine | Eldisin | Eldisine | Enison | Fildesin | Gesidine | LY 099094 | LY-099094 | LY099094 | VINDESINE SULFATE | Vindesine Sulphate | Vindesine sulfate | Vindesini Sulfas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831819","anti-EpCAM antibody fragment -Pseudomonas exotoxin fusion protein","C61307","A fusion protein immunotoxin consisting of a humanized, single-chain monoclonal antibody fragment specific for the epithelial cell adhesion molecule (EpCAM) conjugated with a truncated form of Pseudomonas exotoxin A with potential antineoplastic activity. Oportuzumab monatox binds to Ep-CAM-positive tumor cells, thereby delivering the Pseudomonas exotoxin A moiety specifically; the Pseudomonas exotoxin A moiety then inactivates elongation factor 2 (EF-2) through ADP ribosylation, resulting in inhibition of protein synthesis in target cells. EpCAM, a cell surface protein, is expressed by a variety of tumor cells and is frequently found in head and neck cancers.","Oportuzumab Monatox | OPORTUZUMAB MONATOX | Proxinium | VB4 845 | VB4-845 | Vicinium | anti-EpCAM-Pseudomonas-exotoxin fusion protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041920","Uracil Mustard","C918","An alkylating derivative of the pyrimidine nucleobase uracil that is bound to nitrogen mustard, with antineoplastic activity. Uramustine alkylates and damages DNA by binding to the guanine and cytosine moieties of DNA. This leads to cross-linking of DNA, which inhibits DNA synthesis and promotes cell death in rapidly metabolizing cells, such as cancer cells.","Uracil Mustard | 5-(bis-(2-Chloroethyl) Amino) Uracil | 5-[Bis(2-chloroethyl)amino]uracil | U 8344 | U-8344 | URACIL MUSTARD | Uracil mustard | Uramustine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0208407","Tirapazamine","C1464","A benzotriazine di-N-oxide with potential antineoplastic activity.  Tirapazamine is selectively activated by multiple reductases to form free radicals in hypoxic cells, thereby inducing single-and double-strand breaks in DNA, base damage, and cell death.  This agent also sensitizes hypoxic cells to ionizing radiation and inhibits the repair of radiation-induced DNA strand breaks via inhibition of topoisomerase II. (NCI04)","Tirapazamine | 3-Amino-1,2,4-benzotriazine-1,4-dioxide | SR 4233 | SR-4233 | SR4233 | TIRAPAZAMINE | Tirazone | WIN 59075 | WIN-59075 | WIN59075 | tirapazamine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0076656","Tiazofurin","C1254","A synthetic nucleoside analogue with antineoplastic activity. Tiazofurin (TR) is anabolized intracellularly to an analogue of NAD, tiazole-4-carboxamide adenine dinucleotide (TAD), a potent inhibitor of IMP dehydrogenase (IMPDH); IMPDH is the rate-limiting enzyme for de novo purine synthesis. Inhibition of IMPDH results in reduced levels of guanylates, resulting in the inhibition tumor cell growth in vitro and in vivo. (NCI04)","Tiazofurin | 2-.beta.-D-Ribofuranosyl-4-thiazolecarboxamide | 2-.beta.-D-Ribofuranosylthiazole-4-carboxamide | 2-Beta-D-ribofuranosyl-4-thiazolecarboxamide | 2-Beta-D-ribofuranosylthiazole-4-carboxamide | 4-Thiazolecarboxamide, 2-.beta.-D-ribofuranosyl- (9CI) | 4-Thiazolecarboxamide, 2-Beta-D-ribofuranosyl- (9CI) | Riboxamide | TCAR | TIAZOFURIN | Tiazofurine | tiazofurin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1328193","Zibotentan","C48430","An orally available selective antagonist of the endothelin-A (ET-A) receptor with potential antineoplastic activity. Zibotentan binds selectively to the ET-A receptor, thereby inhibiting endothelin-mediated mechanisms that promote tumor cell proliferation.","Zibotentan | 3-Pyridinesulfonamide, N-(3-methoxy-5-methylpyrazinyl)-2-(4-(1,3,4-oxadiazol-2-yl)phenyl)- | N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pridine-3- sulfonamide | ZD-4054 | ZD4054 | ZIBOTENTAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0671135","Picoplatin","C48416","A new generation organic platinum analog with an extended spectrum of antineoplastic activity. Designed to overcome platinum drug resistance, picoplatin alkylates DNA, forming both inter- and intra-strand cross-linkages, resulting in inhibition of DNA replication and transcription, and the induction of apoptosis.","Picoplatin | AMD473 | Cis-Amminedichloro (2-Methylpyridine) Platinum (II) | JM473 | NX-473 | PICOPLATIN | Platinum, Amminedichloro(2-methylpyridine)-, (SP-4-3)- | ZD0473",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0286224","Vorozole","C1601","A hormone therapy drug used to decrease the production of estrogen.","Vorozole | (+)-6-((4-Chlorophenyl)-1H-1,2,4-triazol-1-ylmethyl)-1-methyl-1H-benzotriazole | (+)-Vorozole | R 83 842 | R83842 | Rivizor | VOROZOLE | vorozole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700251","Vinflunine Ditartrate","C76266","The ditartrate salt of vinflunine, a bi-fluorinated derivative of the semisynthetic vinca alkaloid vinorelbine with potential antimitotic and antineoplastic activities. Vinflunine binds to tubulin and inhibits tubulin assembly and disrupts microtubule assembly dynamics. This results in cell cycle arrest in mitosis and an induction of apoptosis.","Vinflunine Ditartrate | Javlor | VINFLUNINE DITARTRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504650","Wolchok Solid Tumors 2009 Oncology Response Criteria","C126051","A measure proposed by Wolchok et al. (Clin Cancer Res 2009;15:7412-7420) to determine the extent of an antitumor response to a particular immunotherapeutic agent.","Wolchok Solid Tumors 2009 Oncology Response Criteria | Modified Overall Immune Related Response Criterion | Modified irRC | WOLCHOK SOLID TUMORS 2009 | irRC | irRECIST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0936142","Pemetrexed Disodium","C1533","The disodium salt of a synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS) which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.","Pemetrexed Disodium | Alimta | Almita | LY231514 | N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt | PEMETREXED DISODIUM | pemetrexed disodium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021734","Recombinant Interferon Alfa-2a","C1952","A non-glycosylated recombinant human alpha interferon, subtype 2a, produced in the bacterium E. coli.  Interferon alpha-2a binds to its specific cell-surface receptor, resulting in the transcription and translation of genes whose protein products have antiviral, antiproliferative, anticancer, and immune modulating effects. (NCI04)","Recombinant Interferon Alfa-2a | Alpha 2 Interferon | IFN alpha-2A | IFN-Alpha 2 | INTERFERON ALFA-2A | Interferon alfa 2a | Interferon alfa-2a | Laroferon | Recombinant Interferon Alpha-2a | Roceron-A | Roferon A | Roferon-A | rHuIFN-a 2a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021735","Recombinant Interferon Alfa-2b","C1953","A non-glycosylated recombinant interferon with antiviral and antineoplastic activities. Alfa interferons bind to specific cell-surface receptors, resulting in the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects.","Recombinant Interferon Alfa-2b | Alfatronol | Glucoferon | Heberon Alfa | IFN alpha-2B | INTERFERON ALFA-2B | Interferon Alfa-2B | Interferon Alpha-2b | Interferon alfa 2b | Interferon alfa-2b | Intron A | Sch 30500 | Urifron | Viraferon | interferon alfa-2b | recombinant interferon alfa-2b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3536884","Visual Analog Scale","C121547","A psychometric response scale to assess subjective characteristics or symptoms, which relies upon a continuum of possible result values in between two fixed end-points.","Visual Analog Scale | VAS | VISUAL ANALOG SCALE | Visual Analogue Scale",,,,,,,,,,,,,,,"4158877","Visual analog scale",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162578","Thrombectomy","C52003","Surgery performed with the purpose of removing a thrombus.","Thrombectomy | thrombectomy",,,,,,,,,,,,,,,"4185284","Removal of thrombus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0702221","Touch","C38535","The faculty of touch, the sensation produced by pressure receptors in the skin.","Touch | ",,,,,,,,,,,,,,,"4265871","Touch sensation, function",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035287","Reticuloendothelial System","C12780","A network of phagocytic cells, primarily monocytes and macrophages, located in the connective tissue of the bone marrow, spleen, and liver that are involved in the clearance of bacteria, toxins, exogenous antigens, and immune complexes from the blood and tissues, as well as cytotoxicity against tumor cells.","Reticuloendothelial System | RE System | Reticuloendothelial system, NOS | reticuloendothelial system",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007303","Articular Cartilage","C32144","The cartilage that covers the ends of each bone in a joint.","Articular Cartilage | articular cartilage of joint",,,,,,,,,,,,,,,"4164803","Structure of articular cartilage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1513058","Medical Occupation","C19254","Occupations within the field of medicine.","Medical Occupation | Health Care Occupation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0558355","Tonsillar Carcinoma","C4825","A carcinoma arising from the tonsilar epithelium.","Tonsillar Carcinoma | Cancer of Tonsil | Cancer of the Tonsil | Carcinoma of Tonsil | Carcinoma of the Tonsil | Tonsil Cancer | Tonsil Carcinoma | Tonsillar Cancer",,,,,,,,,,,,,,,"4158909","Tonsil carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0558353","Tongue Carcinoma","C4824","A malignant tumor arising from the epithelium that covers the tongue.  The vast majority of tongue carcinomas are moderately or poorly differentiated squamous cell carcinomas.","Tongue Carcinoma | Cancer of Tongue | Cancer of the Tongue | Carcinoma of Tongue | Carcinoma of the Tongue | Tongue Cancer | tongue cancer",,,,,,,,,,,,,,,"4149844","Tongue carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0740339","Throat Carcinoma","C35506","Carcinoma, predominantly squamous cell, arising from epithelial cells of the larynx or pharynx.","Throat Carcinoma | Throat Cancer | Throat Cancer | throat cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0948627","Malignant Lymph Node Neoplasm","C35812","A primary or metastatic malignant tumor involving the lymph node.  Lymphomas and metastatic carcinomas are representative examples.","Malignant Lymph Node Neoplasm | Lymph Node Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0740277","Bile Duct Carcinoma","C27814","A carcinoma arising from the intrahepatic or extrahepatic bile ducts.","Bile Duct Carcinoma | Bile Duct Cancer | Bile Duct Cancer (including Cholangiocarcinoma) | Bile duct carcinoma | bile duct cancer",,,,,,,,,,,,,,,"4321680","Cholangiocarcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL550844","PI3K/BET Inhibitor LY294002","C148229","A morpholine-based inhibitor of phosphatidylinositol 3-kinase (PI3K) and the bromodomain and extra-terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, the PI3K/BET inhibitor LY294002 specifically targets and binds to both PI3K and the acetylated lysine recognition motifs in the bromodomains of BET proteins. Inhibition of PI3K activity inhibits the PI3K/AKT kinase signaling pathway. This may result in inhibition of growth and survival for tumor cells in which the PI3K-mediated signaling pathway is overactivated. Inhibition of BET proteins prevents their interaction with acetylated histones, disrupts chromatin remodeling and inhibits the expression of oncogenic drivers that are important for cell proliferation and survival, which together may lead to an inhibition of proliferation in BET-overexpressing tumor cells. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators and play an important role during development and cellular growth. In tumor cells, BET proteins play a key role in the regulation of oncogene transcription and tumor cell proliferation.","PI3K/BET Inhibitor LY294002 | 2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | 2-Morpholin-4-yl-8-phenylchromen-4-one | 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl- | LY 294002 | LY-294002 | LY294002",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550757","FGF1 Gene Fusion Positive","C148109","An indication that a FGF1 fusion gene has been detected in a sample.","FGF1 Gene Fusion Positive | AFGF Gene Fusion Positive | ECGF Gene Fusion Positive | ECGF-alpha Gene Fusion Positive | ECGF-beta Gene Fusion Positive | ECGFA Gene Fusion Positive | ECGFB Gene Fusion Positive | FGF-1 Gene Fusion Positive | FGF1 Fusion | FGF1 Fusion Mutation | FGFA Gene Fusion Positive | Fibroblast Growth Factor 1 (Acidic) Gene Fusion Positive | Fibroblast Growth Factor 1 Gene Fusion Positive | Fibroblast Growth Factor 1, Acidic Gene Fusion Positive | HBGF-1 Gene Fusion Positive | HBGF1 Gene Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550752","FGF1 Gene Mutation","C148111","A change in the nucleotide sequence of the FGF1 gene.","FGF1 Gene Mutation | AFGF Gene Mutation | ECGF Gene Mutation | ECGF-alpha Gene Mutation | ECGF-beta Gene Mutation | ECGFA Gene Mutation | ECGFB Gene Mutation | FGF-1 Gene Mutation | FGFA Gene Mutation | Fibroblast Growth Factor 1 (Acidic) Gene Mutation | Fibroblast Growth Factor 1 Gene Mutation | Fibroblast Growth Factor 1, Acidic Gene Mutation | HBGF-1 Gene Mutation | HBGF1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550755","FGF1 Gene Amplification","C148112","A molecular genetic abnormality indicating the presence of multiple copies of the FGF1 gene.","FGF1 Gene Amplification | AFGF Gene Amplification | ECGF Gene Amplification | ECGF-alpha Gene Amplification | ECGF-beta Gene Amplification | ECGFA Gene Amplification | ECGFB Gene Amplification | FGF-1 Gene Amplification | FGFA Gene Amplification | Fibroblast Growth Factor 1 (Acidic) Gene Amplification | Fibroblast Growth Factor 1 Gene Amplification | Fibroblast Growth Factor 1, Acidic Gene Amplification | HBGF-1 Gene Amplification | HBGF1 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550753","FGF3 Gene Fusion Positive","C148110","An indication that a FGF3 fusion gene has been detected in a sample.","FGF3 Gene Fusion Positive | FGF-3 Gene Fusion Positive | FGF3 Fusion | FGF3 Fusion Mutation | FGF3 Fusion Positive | Fibroblast Growth Factor 3 Gene Fusion Positive | HBGF-3 Gene Fusion Positive | HBGF3 Gene Fusion Positive | INT-2 Gene Fusion Positive | INT2 Gene Fusion Positive | Murine Mammary Tumor Virus Integration Site 2 Gene Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550754","FGF3 Gene Mutation","C148113","A change in the nucleotide sequence of the FGF3 gene.","FGF3 Gene Mutation | FGF-3 Gene Mutation | Fibroblast Growth Factor 3 Gene Mutation | HBGF-3 Gene Mutation | HBGF3 Gene Mutation | INT-2 Gene Mutation | INT2 Gene Mutation | Murine Mammary Tumor Virus Integration Site 2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550749","FGFR1 Gene Fusion Positive","C148114","An indication that a FGFR1 fusion gene has been detected in a sample.","FGFR1 Gene Fusion Positive | BFGFR Gene Fusion Positive | CD331 Gene Fusion Positive | CEK Gene Fusion Positive | FGFBR Gene Fusion Positive | FGFR-1 Gene Fusion Positive | FGFR1 Fusion | FGFR1 Fusion Mutation | FLG Gene Fusion Positive | FLT-2 Gene Fusion Positive | FLT2 Gene Fusion Positive | FMS-Like Tyrosine Kinase 2 Gene Fusion Positive | Fibroblast Growth Factor Receptor 1 Gene Fusion Positive | KAL2 Gene Fusion Positive | N-SAM Gene Fusion Positive | OGD Gene Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545871","FGFR3 Gene Fusion Positive","C148097","An indication that a FGFR3 fusion gene has been detected in a sample.","FGFR3 Gene Fusion Positive | CD333 Gene Fusion Positive | FGFR-3 Gene Fusion Positive | FGFR3 Fusion | Fibroblast Growth Factor Receptor 3 Gene Fusion Positive | JKT4 Gene Mutation Fusion Positive | JTK4 Gene Mutation Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550748","PDGFA Gene Fusion Positive","C148115","An indication that a PDGFA fusion gene has been detected in a sample.","PDGFA Gene Fusion Positive | PDGF-A Fusion | PDGF-A Fusion Mutation | PDGF-A Gene Fusion Positive | PDGF1 Gene Fusion Positive | PDGFA Fusion | Platelet Derived Growth Factor Subunit A Gene Fusion Positive | Platelet-Derived Growth Factor Alpha Polypeptide Gene Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550751","PDGFB Gene Fusion Positive","C148116","An indication that a PDGFB fusion gene has been detected in a sample.","PDGFB Gene Fusion Positive | IBGC5 Gene Fusion Positive | PDGF-2 Gene Fusion Positive | PDGF-B Fusion | PDGF-B Fusion Mutation | PDGF2 Gene Fusion Positive | PDGFB Fusion | Platelet Derived Growth Factor Subunit B Gene Fusion Positive | Platelet-Derived Growth Factor Beta Polypeptide Gene Fusion Positive | SIS Gene Fusion Positive | SSV Gene Fusion Positive | c-sis Gene Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550750","PDGFRA Gene Fusion Positive","C148117","An indication that a PDGFRA fusion gene has been detected in a sample.","PDGFRA Gene Fusion Positive | CD140A Gene Fusion Positive | PDGFR-2 Gene Fusion Positive | PDGFR-A Fusion | PDGFR-A Fusion Mutation | PDGFR2 Gene Fusion Positive | PDGFRA Fusion | PDGFRalpha Gene Fusion Positive | Platelet-Derived Growth Factor Receptor Alpha Gene Fusion Positive | RHEPDGFRA Gene Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550745","PDGFRB Gene Fusion Positive","C148118","An indication that a PDGFRB fusion gene has been detected in a sample.","PDGFRB Gene Fusion Positive | CD140b Gene Fusion Positive | JTK12 Gene Fusion Positive | PDGFR-1 Gene Fusion Positive | PDGFR-B Fusion | PDGFR-B Fusion Mutation | PDGFR1 Gene Fusion Positive | PDGFRB Fusion | PDGFRbeta Gene Fusion Positive | Platelet-Derived Growth Factor Receptor Beta Gene Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550744","PDGFA Gene Amplification","C148119","A molecular genetic abnormality indicating the presence of multiple copies of the PDGFA gene.","PDGFA Gene Amplification | PDGF-1 Gene Amplification | PDGF-A Gene Amplification | PDGF1 Gene Amplification | Platelet Derived Growth Factor Subunit A Gene Amplification | Platelet-Derived Growth Factor Alpha Polypeptide Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550747","PDGFB Gene Amplification","C148120","A molecular genetic abnormality indicating the presence of multiple copies of the PDGFB gene.","PDGFB Gene Amplification | IBGC5 Gene Amplification | PDGF-2 Gene Amplification | PDGF-B Gene Amplification | PDGF2 Gene Amplification | Platelet Derived Growth Factor Subunit B Gene Amplification | Platelet-Derived Growth Factor Beta Polypeptide Gene Amplification | SIS Gene Amplification | SSV Gene Amplification | c-sis Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550746","PDGFA Gene Mutation","C148121","A change in the nucleotide sequence of the PDGFA gene.","PDGFA Gene Mutation | PDGF-1 Gene Mutation | PDGF-A Gene Mutation | PDGF1 Gene Mutation | Platelet Derived Growth Factor Subunit A Gene Mutation | Platelet-Derived Growth Factor Alpha Polypeptide Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550820","PDGFB Gene Mutation","C148122","A change in the nucleotide sequence of the PDGFB gene.","PDGFB Gene Mutation | IBGC5 Gene Mutation | PDGF-2 Gene Mutation | PDGF-B Gene Mutation | PDGF2 Gene Mutation | Platelet Derived Growth Factor Subunit B Gene Mutation | Platelet-Derived Growth Factor Beta Polypeptide Gene Mutation | SIS Gene Mutation | SSV Gene Mutation | c-sis Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545885","PIK3CA Gene Mutation Negative","C148081","A genetic finding indicating that PIK3CA gene mutations have not been detected in a sample.","PIK3CA Gene Mutation Negative | PI3KCA Mutation Negative | PIK3CA Mutation Negative | PIK3CA Wildtype | PIK3CA wt | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Gene Mutation Negative | p110-alpha Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545886","FLT3 Gene Mutation Negative","C148082","A genetic finding indicating that FLT3 gene mutations have not been detected in a sample.","FLT3 Gene Mutation Negative | CD135 Gene Mutation Negative | FLK2 Gene Mutation Negative | FLT3 Mutation Negative | FLT3 Wild Type | FLT3 Wildtype | FLT3 wt | FMS-Related Tyrosine Kinase 3 Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545887","CDKN2A Gene Mutation Negative","C148083","A genetic finding indicating that CDKN2A gene mutations have not been detected in a sample.","CDKN2A Gene Mutation Negative | CDK4I Gene Mutation Negative | CDKN2A Mutation Negative | CDKN2A Wildtype | CDKN2A wt | Cyclin-Dependent Kinase Inhibitor 2A Gene Mutation Negative | p14ARF Gene Mutation Negative | p16 Gene Mutation Negative | p16-INK4A Gene Mutation Negative | p16INK4 Gene Mutation Negative | p16INK4a Gene Mutation Negative | p19ARF Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1445907","BRCA1 Gene Mutation Negative","C148084","A genetic finding indicating that BRCA1 gene mutations have not been detected in a sample.","BRCA1 Gene Mutation Negative | BRCA1 Mutation Negative | BRCA1 Wildtype | BRCA1 wt | BROVCA1 Gene Mutation Negative | Breast Cancer 1 Gene Mutation Negative | Breast Cancer 1, Early Onset Gene Mutation Negative | Breast Cancer Type 1 Susceptibility Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1445910","BRCA2 Gene Mutation Negative","C148085","A genetic finding indicating that BRCA2 gene mutations have not been detected in a sample.","BRCA2 Gene Mutation Negative | BRCA2 Mutation Negative | BRCA2 Wildtype | BRCA2 wt | BRCC2 Gene Mutation Negative | BROVCA2 Gene Mutation Negative | Breast Cancer 2 Gene Mutation Negative | Breast Cancer 2, Early Onset Gene Mutation Negative | Breast Cancer Type 2 Susceptibility Gene Mutation Negative | FANCD1 Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545874","IDH1 Gene Mutation Negative","C148086","A genetic finding indicating that IDH1 gene mutations have not been detected in a sample.","IDH1 Gene Mutation Negative | HEL-216 Gene Mutation Negative | HEL-S-26 Gene Mutation Negative | IDCD Gene Mutation Negative | IDH1 Mutation Negative | IDH1 Wild Type | IDH1 Wildtype | IDH1 wt | IDPC Gene Mutation Negative | Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic Gene Mutation Negative | Isocitrate Dehydrogenase 1 (NADP+), Soluble Gene Mutation Negative | PICD Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545875","IDH2 Gene Mutation Negative","C148087","A genetic finding indicating that IDH2 gene mutations have not been detected in a sample.","IDH2 Gene Mutation Negative | D2HGA2 Gene Mutation Negative | ICD-M Gene Mutation Negative | IDH2 Mutation Negative | IDH2 Wildtype | IDH2 wt | IDHM Gene Mutation Negative | IDPM Gene Mutation Negative | Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial Gene Mutation Negative | Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial Gene Mutation Negative | mNADP-IDH Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545877","BRAF Gene Mutation Negative","C148089","A genetic finding indicating that BRAF gene mutations have not been detected in a sample.","BRAF Gene Mutation Negative | B-RAF Gene Mutation Negative | B-RAF1 Gene Mutation Negative | BRAF Mutation Negative | BRAF Wild Type | BRAF Wildtype | BRAF wt | Negative | No mutation detected | v-raf Murine Sarcoma Viral Oncogene Homolog B1 Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545878","ALK Gene Mutation Negative","C148090","A genetic finding indicating that ALK gene mutations have not been detected in a sample.","ALK Gene Mutation Negative | ALK Mutation Negative | ALK Wildtype | ALK wt | Anaplastic Lymphoma Kinase (Ki-1) Gene Mutation  Negative | Anaplastic Lymphoma Kinase (Ki-1) Gene Mutation Negative | Anaplastic Lymphoma Receptor Tyrosine Kinase Gene Mutation Negative | CD246 Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545879","EGFR Gene Mutation Negative","C148091","A genetic finding indicating that EGFR gene mutations have not been detected in a sample.","EGFR Gene Mutation Negative | EGFR Mutation Negative | EGFR Wildtype | EGFR wt | ERBB Gene Mutation Negative | ERBB1 Gene Mutation Negative | Epidermal Growth Factor Receptor Gene Mutation Negative | HER1 Gene Mutation Negative | No mutation detected | c-erbB1 Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545867","TP53 Gene Mutation Negative","C148092","A genetic finding indicating that TP53 gene mutations have not been detected in a sample.","TP53 Gene Mutation Negative | BCC7 Gene Mutation Negative | LFS1 Gene Mutation Negative | Li-Fraumeni Syndrome Gene Mutation Negative | Negative | No | Normal | TP53 Mutation Negative | TP53 Wild Type | TP53 Wildtype | TP53 wt | TRP53 Gene Mutation Negative | Tumor Protein p53 Gene Mutation Negative | p53 Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545868","NRAS Gene Mutation Negative","C148093","A genetic finding indicating that NRAS gene mutations have not been detected in a sample.","NRAS Gene Mutation Negative | N-RAS Gene Mutation Negative | NRAS Mutation Negative | NRAS Wild-Type | NRAS Wildtype | NRAS wt | Negative | Neuroblastoma RAS Viral Oncogene Homolog Gene Mutation Negative | No mutation detected",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545869","MYD88 Gene Mutation Negative","C148094","A genetic finding indicating that MYD88 gene mutations have not been detected in a sample.","MYD88 Gene Mutation Negative | MYD88 Mutation Negative | MYD88 Wildtype | MYD88 wt | Myeloid Differentiation Primary Response 88 Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545870","EGFR Gene Rearrangement","C148095","A molecular abnormality indicating rearrangement of the EGFR gene.","EGFR Gene Rearrangement | ERBB Gene Rearrangement | ERBB1 Gene Rearrangement | Epidermal Growth Factor Receptor Gene Rearrangement | HER1 Gene Rearrangement | c-erbB1 Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552562","H3.3 K28M Mutation","C148096","A change in the amino acid residue at position 27 in histone H3.3 protein where lysine has been replaced by methionine.","H3.3 K27M Variant | H3.3 K27M Mutation | H3.3 K27M Mutation | H3.3 K27M Mutation Positive | H3.3 K28M Mutation | H3.3 Lys27Met Mutation | H3.3 Lys28Met Mutation | H3.3 NP_002098.1:p.K28M | H3.3 NP_002098.1:p.Lys28Met | H3.3 p.K28M | H3.3 p.Lys28Met | H3.3K27M Mutation | Histone H3.3 K27M Mutation | Histone H3.3 K28M Mutation | Histone H3.3 Lys27Met Mutation | Histone H3.3 Lys28Met Mutation | NP_002098.1:p.K28M | NP_002098.1:p.Lys28Met",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545892","Low Density Array Gene Signature","C148072","A gene expression profile determined using quantitative reverse transcriptase-based PCR (QRT-PCR) and low-density array technology.","Low Density Array Gene Signature | LDA Gene Signature | Low-Density Array Gene Signature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545891","Blasts Under 20,000 in Peripheral Blood White Cells","C148071","A quantitative microscopic finding indicating that less than 20,000 of the total number of nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.","Blasts Under 20,000 in Peripheral Blood White Cells | Absolute Blasts in Peripheral Blood Less Than 20,000 | Absolute Blasts in Peripheral Blood Less Than 20000 | Blasts Less than 20,000 of Peripheral Blood White Cells | Blasts Less than 20000 of Peripheral Blood White Cells | Blasts Under 20000 in Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545890","HSATII RNA","C148070","A 30 base to 800 base ribonucleic acid derived from transcription of demethlyated human satellite II (HSATII) DNA sequences. This ribonucleotide may sequester chromatin regulatory proteins and may be a biomarker for various cancers.","HSATII RNA | HSAT-II RNA | Human Satellite II Repeat RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707102","CD4-Positive Neoplastic Cells Present","C45295","An indication that expression of CD4 has been detected in a sample of neoplastic cells.","CD4-Positive Neoplastic Cells Present | CD4 Antigen-Positive Neoplastic Cells Present | CD4 Molecule-Positive Neoplastic Cells Present | OKT4 Antigen-Positive Neoplastic Cells Present | T-Cell Antigen T4/Leu3-Positive Neoplastic Cells Present | T-Cell Surface Glycoprotein CD4-Positive Neoplastic Cells Present | T4/Leu-3-Positive Neoplastic Cells Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545888","CD34 Positive","C148068","An indication that CD34 expression has been detected in a sample.","CD34 Positive | CD34 Antigen Positive | CD34 Molecule Positive | HPCA1 Positive | Hematopoietic Progenitor Cell Antigen CD34 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347260","CD52-Positive Neoplastic Cells Present","C71597","An indication that expression of CD52 has been detected in a sample of neoplastic cells.","CD52-Positive Neoplastic Cells Present | CAMPATH-1 Antigen-Positive Neoplastic Cells Present | CD52 Antigen-Positive Neoplastic Cells Present | CD52 Molecule-Positive Neoplastic Cells Present | CDw52-Positive Neoplastic Cells Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550776","SLCO1B3 Gene Positive","C148172","An indication that the SLCO1B3 gene has been detected in a sample.","SLCO1B3 Gene Positive | LST2 Gene Positive | LST3 Gene Positive | OATP-8 Gene Positive | OATP1B3 Gene Positive | OATP8 Gene Positive | SLC21A8 Gene Positive | Solute Carrier Organic Anion Transporter Family Member 1B3 Gene Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550840","PSA Level Less than or Equal to Two","C148233","A blood concentration of prostate specific antigen less than or equal to 2 ng/mL.","PSA Level Less than or Equal to Two | PSA Level 2 or Less | PSA Level Less than or Equal to 2 | PSA Level Two or Less",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550873","How Difficult to Push or Pull Large Objects with Affected Arm","C148198","A question about how difficult it is for an individual to push or pull large objects with their affected arm.","How Difficult to Push or Pull Large Objects with Affected Arm | Push or pull large objects, like a living room chair, with your affected arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550868","How Difficult to Lift Items over 10 Pounds with Affected Arm","C148199","A question about how difficult it is for an individual to lift items over 10 pounds with their affected arm.","How Difficult to Lift Items over 10 Pounds with Affected Arm | Lift items over 10 pounds, like a heavy bag or groceries with your affected arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550867","How Difficult to Reach or Extend Affected Arm Above Shoulder Level","C148200","A question about how difficult it is for an individual to reach or extend their affected arm above shoulder level.","How Difficult to Reach or Extend Affected Arm Above Shoulder Level | Reach or extend your affected arm above shoulder level",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550870","How Difficult to Wash Back with Affected Arm","C148201","A question about how difficult it is for an individual to wash their back with their affected arm.","How Difficult to Wash Back with Affected Arm | Wash your back with your affected arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550869","How Difficult to Bend and Straighten Affected Arm","C148202","A question about how difficult it is for an individual to bend or straighten their affected arm.","How Difficult to Bend and Straighten Affected Arm | Bend and straighten your affected arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550864","How Much Bothered by Tenderness in Affected Underarm, Arm, or Hand","C148203","A question about how bothered an individual is by tenderness in their affected underarm, arm, or hand.","How Much Bothered by Tenderness in Affected Underarm, Arm, or Hand | Tenderness in the underarm, arm or hand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550863","How Much Bothered by Swelling in Affected Underarm, Arm, or Hand","C148204","A question about how bothered an individual is by swelling in their affected underarm, arm, or hand.","How Much Bothered by Swelling in Affected Underarm, Arm, or Hand | Swelling in the underarm, arm or hand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550866","How Much Bothered by Numbness in Affected Underarm, Arm, or Hand","C148205","A question about how bothered an individual is by numbness in their affected underarm, arm, or hand.","How Much Bothered by Numbness in Affected Underarm, Arm, or Hand | Numbness in the underarm, arm or hand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550865","How Much Bothered by Tingling in Affected Underarm, Arm, or Hand","C148206","A question about how bothered an individual is by tingling sensation in their affected underarm, arm, or hand.","How Much Bothered by Tingling in Affected Underarm, Arm, or Hand | Tingling sensation ('pins and needles') in the underarm, arm or hand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550861","How Much Bothered by Increased Skin Sensitivity in Affected Underarm, Arm, or Hand","C148207","A question about how bothered an individual is by increased skin sensitivity in their affected underarm, arm, or hand.","How Much Bothered by Increased Skin Sensitivity in Affected Underarm, Arm, or Hand | Increased skin sensitivity in the underarm, arm or hand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550860","How Much Bothered by Tightness, Pulling, or Stretching in Affected Underarm, Arm, or Hand","C148208","A question about how bothered an individual is by tenderness in their affected underarm, arm, or hand.","How Much Bothered by Tightness, Pulling, or Stretching in Affected Underarm, Arm, or Hand | Tightness, pulling, or stretching in the underarm, arm or hand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550862","How Much Bothered by Discomfort or Pain in Affected Underarm, Arm, or Hand","C148209","A question about how bothered an individual is by discomfort or pain in their affected underarm, arm, or hand.","How Much Bothered by Discomfort or Pain in Affected Underarm, Arm, or Hand | Discomfort or pain in the underarm, arm or hand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552471","How Much Bothered by Arm Weakness in Affected Arm","C148210","A question about how bothered an individual is by arm weakness in their affected arm.","How Much Bothered by Arm Weakness in Affected Arm | Arm weakness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550857","How Much Bothered by Arm Heaviness in Affected Arm","C148211","A question about how bothered an individual is by arm heaviness in their affected arm.","How Much Bothered by Arm Heaviness in Affected Arm | Arm heaviness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552459","How Much Bothered by Shoulder Stiffness in Affected Arm","C148212","A question about how bothered an individual is by shoulder stiffness in their affected arm.","How Much Bothered by Shoulder Stiffness in Affected Arm | Shoulder stiffness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550856","How Much Bothered by Tenderness in Affected Breast or Chest Area","C148217","A question about how bothered an individual is by tenderness in their breast or chest area.","How Much Bothered by Tenderness in Affected Breast or Chest Area | Tenderness in the breast or chest area",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550855","How Much Bothered by Swelling in Affected Breast or Chest Area","C148218","A question about how bothered an individual is by swelling in their breast or chest area.","How Much Bothered by Swelling in Affected Breast or Chest Area | Swelling in the breast or chest area",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550850","How Much Bothered by Numbness in Affected Breast or Chest Area","C148219","A question about how bothered an individual is by numbness in their breast or chest area .","How Much Bothered by Numbness in Affected Breast or Chest Area | Numbness in the breast or chest area",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550849","How Much Bothered by Tingling in Affected Breast or Chest Area","C148220","A question about how bothered an individual is by tingling sensation in their breast or chest area.","How Much Bothered by Tingling in Affected Breast or Chest Area | Tingling sensation ('pins and needles') in the breast or chest area",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550852","How Much Bothered by Increased Skin Sensitivity in Affected Breast or Chest Area","C148221","A question about how bothered an individual is by increased skin sensitivity in their breast or chest area.","How Much Bothered by Increased Skin Sensitivity in Affected Breast or Chest Area | Increased skin sensitivity in the breast or chest area",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550851","How Much Bothered by Tightness, Pulling, or Stretching in Affected Breast or Chest Area","C148222","A question about how bothered an individual is by tightness, pulling, or stretching in their breast or chest area.","How Much Bothered by Tightness, Pulling, or Stretching in Affected Breast or Chest Area | Tightness, pulling, or stretching in the breast or chest area",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550846","How Much Bothered by Discomfort or Pain in Affected Breast or Chest Area","C148223","A question about how bothered an individual is by discomfort or pain in their breast or chest area.","How Much Bothered by Discomfort or Pain in Affected Breast or Chest Area | Discomfort or pain in the breast or chest area",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550845","Extent Breast Cancer Treatment Disrupted Social Activities with Family and Friends","C148224","A question about to what extent an individual's breast cancer treatment has disrupted their social activities with family and friends.","Extent Breast Cancer Treatment Disrupted Social Activities with Family and Friends | Social activities with family and friends",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550848","Extent Breast Cancer Treatment Disrupted Work","C148225","A question about to what extent an individual's breast cancer treatment has disrupted their work .","Extent Breast Cancer Treatment Disrupted Work | Work (including housework)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550847","Extent Breast Cancer Treatment Disrupted Recreational Activities","C148226","A question about to what extent an individual's breast cancer treatment has disrupted their recreational activities.","Extent Breast Cancer Treatment Disrupted Recreational Activities | Recreational activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550842","Extent Breast Cancer Treatment Disrupted Self-care","C148227","A question about to what extent an individual's breast cancer treatment has disrupted their self-care.","Extent Breast Cancer Treatment Disrupted Self-care | Self-care (bathing, dressing)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550841","Extent Breast Cancer Treatment Disrupted Normal Sleep","C148228","A question about to what extent an individual's breast cancer treatment has disrupted their normal sleep.","Extent Breast Cancer Treatment Disrupted Normal Sleep | Normal sleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526757","Testing of Patient Sample or Reference Material Using Reference Method","C139453","The investigation employed relevant empirical testing of a patient sample or reference material using an appropriate reference method to the device (usually an IVD) involved in the reported adverse event in order to support the identification of possible causes for the adverse event. Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the latest relevant standards.","Testing of Patient Sample or Reference Material Using Reference Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550838","Painful, Irritated, or Watery Eyes","C148237","A question about whether an individual's eyes are or were painful, irritated, or watery.","Painful, Irritated, or Watery Eyes | Painful, Irritated, or Watery Eyes
",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550835","Quality of Life Questionnaire BR-23","C148236","A questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) consisting of 23 questions designed to assess the quality of life of breast cancer patients participating in international clinical trials.","Quality of Life Questionnaire BR-23 | EOR05 | EORTC QLQ-BR23 | EORTC QLQ-BR23 V1.0 | EORTC QLQ-BR23 Version 1.0 | QLQ-BR23 | Quality of Life Questionnaire BR-23
",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550837","Very Much Disrupted","C148238","A response indicating that aspects of an individual's life are or were very much disrupted.","Very Much Disrupted | Disrupted very much | Very Much Disrupted
",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550875","Immune-Related Response Criteria","C148192","A set of response criteria designed to capture additional response patterns observed with immune therapy beyond those described by Response Evaluation Criteria in Solid Tumors (RECIST) or WHO criteria.","Immune-Related Response Criteria | irRC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550878","Complete Response","C148193","Complete disappearance of all lesions (whether measurable or not, and no new lesions); confirmation by a repeat, consecutive assessment no less than 4 weeks from the date first documented.","Immune-Related Response Criteria Complete Response | Complete Response | irCR | irCR (Immune-Related Response Criteria) | irCR (Immune-Related Response Criteria) | irRC Complete Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550877","Partial Response","C148194","Decrease in tumor burden greater than or equal to 50 percent relative to baseline confirmed by a consecutive assessment at least 4 weeks after first documentation.","Immune-Related Response Criteria Partial Response | Partial Response | irPR | irPR (Immune-Related Response Criteria) | irPR (Immune-Related Response Criteria) | irRC Criteria Partial Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550872","Stable Disease","C148195","Not meeting criteria for irCR or irPR, in absence of irPD.","Immune-Related Response Criteria Stable Disease | Stable Disease | irRC Stable Disease | irSD | irSD (Immune-Related Response Criteria) | irSD (Immune-Related Response Criteria) | irSD (Immune-Related Response Criteria)  ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550871","Progressive Disease","C148196","Increase in tumor burden greater than or equal to 25 percent relative to nadir (minimum recorded tumor burden); confirmation by a repeat, consecutive assessment no less than 4 weeks from the date first documented.","Immune-Related Response Criteria Progressive Disease | Progressive Disease | irPD | irPD (Immune-Related Response Criteria) | irPD (Immune-Related Response Criteria) | irRC Progressive Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883514","VAC Regimen (Vincristine-Dactinomycin-Cyclophosphamide)","C67299","A regimen consisting of vincristine, dactinomycin and cyclophosphamide that may be used for the treatment of Ewing sarcoma, mesenchymal chondrosarcoma, rhabdomyosarcoma (RMS), malignant sex cord-stromal tumors and malignant germ cell tumors.","VAC Regimen | VAC | Vincristine/Actinomycin-D/Cyclophosphamide | Vincristine/Dactinomycin/Cyclophosphamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880091","Cisplatin-Doxorubicin-High Dose Methotrexate Regimen","C67339","A regimen consisting of cisplatin, doxorubicin, and methotrexate that can be used in the treatment of osteosarcoma.","MAP Regimen | ADM | Cisplatin-Doxorubicin-High Dose Methotrexate Regimen | Cisplatin-Doxorubicin-Methotrexate Osteosarcoma Regimen | Cisplatin-Doxorubicin-Methotrexate Regimen | Cisplatin-Doxorubicin-Methotrexate Regimen | HD Methotrexate/Doxorubicin/Cisplatin | High-dose Methotrexate/Doxorubicin/Cisplatin | MAP | Methotrexate/Adriamycin/Platinol | Methotrexate/Doxorubicin/Cisplatin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1137102","Triptorelin Pamoate","C29523","The pamoate salt of triptorelin, a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH).  Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion after prolonged administration.  After chronic, continuous administration, a sustained decrease in LH, FSH and testicular and ovarian steroidogenesis is observed.  The serum testosterone concentration may fall to levels typically seen in surgically castrated men. (NCI04)","Triptorelin Pamoate | 6-D-Tryptophan-, 4,4'Mmethylenebis(3-hydroxy-2-naphthalenecarboxylate) (Salt) | Decapeptyl | Diphereline | Pamorelin | TRIPTORELIN PAMOATE | Trelstar | Triptorelin Embonate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520459","Niraparib Tosylate Monohydrate","C133238","An orally bioavailable, hydrated, tosylate salt form of niraparib, an inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2 (PARP-1 and -2), with antineoplastic activity. Upon administration, niraparib binds to and inhibits the activity of PARP-1 and -2, thereby inhibiting PARP-1 and -2-mediated DNA repair, enhancing the accumulation of DNA strand breaks, promoting genomic instability and resulting in apoptosis. The PARP family of proteins catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks.","Niraparib Tosylate Monohydrate | 2H-Indazole-7-carboxamide, 2-(4-(3S)-3-piperidinylphenyl)-, 4-Methylbenzenesulfonate, Hydrate (1:1:1) | NIRAPARIB TOSYLATE | NIRAPARIB TOSYLATE MONOHYDRATE | Niraparib Tosylate Hydrate | Zejula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043843","1,2-dipalmitoyl-3-phosphatidylethanolamine","C75196","No Value Exists","Tesmilifene | DPPE | TESMILIFENE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550829","Primary Industry of Employment","C148246","The main category of employment for an individual.","Primary Industry of Employment | Primary Industry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550824","Natural and Applied Sciences","C148247","A grouping of sciences including those concerned with the description, prediction, and understanding of natural phenomena, based on empirical evidence from observation and experimentation, as well as those focused on the use of scientific processes and knowledge as the means to achieve a particular practical or useful result.","Natural and Applied Sciences | Basic and Applied Science",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550823","Trades, Transport, or Construction","C148248","Occupations that include tradesmen, laborers, or professional employed in the physical construction of the built environment and its infrastructure, as well as professional or vocational positions of employment that involve transportation or material moving.","Trades, Transport, or Construction | Trades/Transport/Construction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550826","Processing, Manufacturing, or Utilities","C148249","Occupations involved in refining of raw materials, creation of finished goods, and distribution of materials or services.","Processing, Manufacturing, or Utilities | Processing/Manufacturing/Utilities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550825","Out of Pocket Payment","C148250","A payment made from personal funds.","Out of Pocket Payment | Out of Pocket | Out-of-Pocket | Out-of-Pocket Payment | Self Pay | Self-pay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242807","Sick Leave","C148251","A leave of absence granted because of illness.","Sick Leave | On sick leave from full- or part-time work",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242805","Disability Leaves","C148252","A leave of absence granted because of physical or mental disability.","Disability Leave | On disability leave from full- or part-time work",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550933","Stay at Home Parent","C148253","A homemaker whose work includes caring for children.","Stay at Home Parent | Stay-at-Home Parent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550932","Working Full Time Hours","C148254","A response indicating that an individual is working full time.","Working Full Time Hours | Yes, started working full time hours (> 30 hours per week)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550929","Working Part Time Hours","C148255","A response indicating that an individual is working part time.","Working Part Time Hours | Yes, started working part time hours (< 30 hours per week)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550928","On Sick or Disability Leave","C148256","A response indicating that an individual is on sick or disability leave from work.","On Sick or Disability Leave | Yes, started sick or disability leave",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550931","Unemployed or Retired","C148257","A response indicating that an individual is unemployed due to quitting, being fired, or retirement.","Unemployed or Retired | Yes, quit work/ became unemployed or retired",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550930","Not Currently Working","C148258","A response indicating that an individual does not currently work.","Not Currently Working | Not applicable - not currently working",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332996","Childhood B Lymphoblastic Lymphoma","C7209","A B lymphoblastic lymphoma that occurs during childhood.","Childhood B Lymphoblastic Lymphoma | B Lymphoblastic Lymphoma | Childhood B-Lymphoblastic Lymphoma | Childhood Precursor B-Lymphoblastic Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879672","Agent Combination","C62633","No Value Exists","Agent Combination | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550918","Have Swollen Arm or Hand","C148269","A question about whether an individual has or had a swollen arm or hand.","Have Swollen Arm or Hand | Arm or Hand is Swollen | Did you have a swollen arm or hand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550921","Have Difficulty Raising Arm or Moving Arm Sideways","C148270","A question about whether an individual had or has difficulty raising their arm or to move it sideways.","Have Difficulty Raising Arm or Moving Arm Sideways | Was it difficult to raise your arm or to move it sideways",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550920","Have Pain in Area of Affected Breast","C148271","A question about whether an individual has or had any pain in the area of their affected breast.","Have Pain in Area of Affected Breast | Have you had any pain in the area of your affected breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550915","Area of Affected Breast Swollen","C148272","A question about whether the area of an individual's affected breast is or was swollen.","Area of Affected Breast Swollen | Was the area of your affected breast swollen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550917","Have Skin Problem On or In Area of Affected Breast","C148274","A question about whether an individual has or had skin problems on or in the area of their affected breast.","Have Skin Problem On or In Area of Affected Breast | Have you had skin problems on or in the area of your affected breast (e.g., itchy, dry, flaky)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550923","Bupropion Hydrochloride Controlled-release","C148267","A controlled-release tablet formulation containing the hydrochloride salt of the aminoketone bupropion, with antidepressant activity and for potential use in promoting smoking cessation, improving sexual desire, and improving cancer-related fatigue. Bupropion is a weak blocker of the neuronal uptake of serotonin, dopamine and norepinephrine and is a central nicotinic acetylcholine receptor antagonist. Bupropion may also reduce circulating levels of tumor necrosis factor (TNF) and normalize hypothalamic-pituitary-adrenal (HPA) axis functioning, which is dysregulated in certain cases of cancer-related fatigue.  The controlled-release formulation results in a higher concentration of the drug in the body over an extended period, thereby permitting a reduction in the frequency of dosing.","Bupropion Hydrochloride Controlled-release | Bupropion HCl Controlled-release | Bupropion HCl Extended Release | Bupropion Hydrochloride Extended-Release | Forfivo XL | Wellbutrin SR | Wellbutrin XL | Zyban",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037434","Social Sciences","C17141","Comprises the scientific study of the human aspects of the world. They are also known as social studies. Psychology studies the human mind, sociology examines human society, political science studies the governing of groups and economics concerns itself with the allocation of wealth in society.","Social Sciences | Social Studies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518288","Neurologic Oncology","C17854","The branch of oncology concerned with the study, diagnosis, and treatment of cancers of the nervous system.","Neurologic Oncology | Neuro-Oncology | oncology, neurologic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883515","VAdriaC-IE","C67232","A regimen consisting of vincristine, doxorubicin and cyclophosphamide, alternating with ifosfamide and etoposide that can be used for the treatment of Ewing sarcoma, nonpleomorphic rhabdomyosarcoma and mesenchymal chondrosarcoma.","Cyclophosphamide/Doxorubicin/Vincristine Alternating with IE Regimen | VAC-IE | VAC/IE | VAdriaC Alternating with IE | VAdriaC Alternating with IE Regimen | VAdriaC Alternating with IE Regimen | VAdriaC-IE | VAdriaC-IE Regimen | VAdriaC-IE Regimen | VDC/IE | VDC/IE Regimen | Vincristine/Adriamycin/Cyclophosphamide-Ifosfamide/Etoposide Regimen | Vincristine/Doxorubicin/Cyclophosphamide Alternating with Ifosfamide/Etoposide Regimen | Vincristine/Doxorubicin/Cyclophosphamide-Ifosfamide/Etoposide Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550904","VAC Alternating with VI","C148284","A regimen consisting of vincristine, dactinomycin and cyclophosphamide, alternating with vincristine and irinotecan that can be used for the treatment of rhabdomyosarcoma.","VAC Alternating with VI Regimen | VAC Alternating with VI | VAC Plus VI | VAC-VI | VAC-VI Regimen | VAC/VI | VAC/VI Regimen | Vincristine/Actinomycin-D/Cyclophosphamide Alternating with Vincristine/Irinotecan | Vincristine/Actinomycin-D/Cyclophosphamide-Vincristine/Irinotecan | Vincristine/Dactinomycin/Cyclophosphamide Alternating With Vincristine/Irinotecan | Vincristine/Dactinomycin/Cyclophosphamide-Vincristine/Irinotecan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831721","irinotecan/temozolomide/vincristine","C148285","A regimen consisting of vincristine, irinotecan and temozolomide that can be used for the treatment of Ewing sarcoma and nonpleomorphic rhabdomyosarcoma.","VIT Regimen | VIT | Vincristine-Irinotecan-Temozolomide | Vincristine/Irinotecan/Temozolomide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201721","Urine Protein Electrophoresis","C135568","An electrophoresis-based laboratory test performed to determine the concentrations of globulin proteins in the urine.","Urine Protein Electrophoresis | UPEP",,,,,,,,,,,,,,,"4251338","Urine protein electrophoresis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3827730","Unable to Draw Blood","C113724","Indicates that a phlebotomist was unable to find or penetrate a blood vessel or was unable to acquire a blood sample following a successful vein stick.","Unable to Draw Blood | Blood draw not successful",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524717","Cutaneous Melanoma TNM Finding v8","C136892","A finding about one or more characteristics of cutaneous melanoma, following the rules of the TNM AJCC v8 classification system. This classification system does not apply to melanoma of the conjunctiva, melanoma of the uvea, mucosal melanoma arising in the head and neck, and mucosal melanoma of the urethra, vagina, rectum, and anus. (from AJCC 8th Ed.)","Cutaneous Melanoma TNM Finding v8 | Melanoma of the Skin TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524775","Cutaneous Melanoma pT4b TNM Finding v8","C136952","Cutaneous melanoma measuring more than 4.0 mm in thickness. Ulceration status: With ulceration. (from AJCC 8th Ed.)","Cutaneous Melanoma pT4b TNM Finding v8 | Melanoma of the Skin pT4b TNM Finding v8 | pT4b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524778","Cutaneous Melanoma pT4a TNM Finding v8","C136951","Cutaneous melanoma measuring more than 4.0 mm in thickness. Ulceration status: Without ulceration. (from AJCC 8th Ed.)","Cutaneous Melanoma pT4a TNM Finding v8 | Melanoma of the Skin pT4a TNM Finding v8 | pT4a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524777","Cutaneous Melanoma pT4 TNM Finding v8","C136950","Cutaneous melanoma measuring more than 4.0 mm in thickness. Ulceration status: Unknown or unspecified. (from AJCC 8th Ed.)","Cutaneous Melanoma pT4 TNM Finding v8 | Melanoma of the Skin pT4 TNM Finding v8 | pT4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524803","Cutaneous Melanoma pT3b TNM Finding v8","C136949","Cutaneous melanoma measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: With ulceration. (from AJCC 8th Ed.)","Cutaneous Melanoma pT3b TNM Finding v8 | Melanoma of the Skin pT3b TNM Finding v8 | pT3b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524802","Cutaneous Melanoma pT3a TNM Finding v8","C136948","Cutaneous melanoma measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: Without ulceration. (from AJCC 8th Ed.)","Cutaneous Melanoma pT3a TNM Finding v8 | Melanoma of the Skin pT3a TNM Finding v8 | pT3a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524805","Cutaneous Melanoma pT3 TNM Finding v8","C136947","Cutaneous melanoma measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: Unknown or unspecified. (from AJCC 8th Ed.)","Cutaneous Melanoma pT3 TNM Finding v8 | Melanoma of the Skin pT3 TNM Finding v8 | pT3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524804","Cutaneous Melanoma pT2b TNM Finding v8","C136946","Cutaneous melanoma measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: With ulceration. (from AJCC 8th Ed.)","Cutaneous Melanoma pT2b TNM Finding v8 | Melanoma of the Skin pT2b TNM Finding v8 | pT2b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524799","Cutaneous Melanoma pT2a TNM Finding v8","C136945","Cutaneous melanoma measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. (from AJCC 8th Ed.)","Cutaneous Melanoma pT2a TNM Finding v8 | Melanoma of the Skin pT2a TNM Finding v8 | pT2a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524798","Cutaneous Melanoma pT2 TNM Finding v8","C136944","Cutaneous melanoma measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Unknown or unspecified. (from AJCC 8th Ed.)","Cutaneous Melanoma pT2 TNM Finding v8 | Melanoma of the Skin pT2 TNM Finding v8 | pT2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524801","Cutaneous Melanoma pT1b TNM Finding v8","C136943","Cutaneous melanoma measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. (from AJCC 8th Ed.)","Cutaneous Melanoma pT1b TNM Finding v8 | Melanoma of the Skin pT1b TNM Finding v8 | pT1b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524800","Cutaneous Melanoma pT1a TNM Finding v8","C136942","Cutaneous melanoma measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. (from AJCC 8th Ed.)","Cutaneous Melanoma pT1a TNM Finding v8 | Melanoma of the Skin pT1a TNM Finding v8 | pT1a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524795","Cutaneous Melanoma pT1 TNM Finding v8","C136941","Cutaneous melanoma measuring 1.0 mm or less in thickness. Ulceration status: Unknown or unspecified. (from AJCC 8th Ed.)","Cutaneous Melanoma pT1 TNM Finding v8 | Melanoma of the Skin pT1 TNM Finding v8 | pT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524794","Cutaneous Melanoma pTis TNM Finding v8","C136940","Cutaneous melanoma with a finding of melanoma in situ. Thickness: Not applicable. Ulceration status: Not applicable. (from AJCC 8th Ed.)","Cutaneous Melanoma pTis TNM Finding v8 | Melanoma of the Skin pTis TNM Finding v8 | pTis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524797","Cutaneous Melanoma pT0 TNM Finding v8","C136939","Cutaneous melanoma with no evidence of primary tumor (e.g., unknown primary or completely regressed melanoma). Thickness: Not applicable. Ulceration status: Not applicable. (from AJCC 8th Ed.)","Cutaneous Melanoma pT0 TNM Finding v8 | Melanoma of the Skin pT0 TNM Finding v8 | pT0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524796","Cutaneous Melanoma pTX TNM Finding v8","C136938","Cutaneous melanoma in which the primary tumor thickness cannot be assessed (e.g., diagnosis by curettage). Thickness: Not applicable. Ulceration status: Not applicable. (from AJCC 8th Ed.)","Cutaneous Melanoma pTX TNM Finding v8 | Melanoma of the Skin pTX TNM Finding v8 | pTX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524706","Cutaneous Melanoma Clinical Regional Lymph Nodes TNM Finding v8","C136909","A clinical finding about one or more characteristics of cutaneous melanoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes. The TNM clinical and pathologic regional lymph nodes classifications of cutaneous melanoma are not the same. TNM clinical regional lymph nodes findings are based on clinical/radiographic examination of the regional lymph nodes (clinically detected regional lymph node metastasis). (from AJCC 8th Ed.)","Cutaneous Melanoma Clinical Regional Lymph Nodes TNM Finding v8 | Melanoma of the Skin Clinical Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524681","Cutaneous Melanoma cN3c TNM Finding v8","C136920","Cutaneous melanoma with two or more clinically detected nodal metastases and/or presence of any number of matted nodes. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. (from AJCC 8th Ed.)","Cutaneous Melanoma cN3c TNM Finding v8 | Melanoma of the Skin cN3c TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524680","Cutaneous Melanoma cN3b TNM Finding v8","C136919","Cutaneous melanoma with four or more nodal metastases, at least one of which was clinically detected, or presence of any number of matted nodes. Presence of in-transit, satellite, and/or microsatellite metastases: No.  (from AJCC 8th Ed.)","Cutaneous Melanoma cN3b TNM Finding v8 | Melanoma of the Skin cN3b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524683","Cutaneous Melanoma cN3 TNM Finding v8","C136918","Cutaneous melanoma with four or more tumor-involved nodes or in-transit satellite, and/or microsatellite metastases with two or more tumor-involved nodes, or any number of matted nodes without or with in-transit, satellite, and/or microsatellite metastases. (from AJCC 8th Ed.)","Cutaneous Melanoma cN3 TNM Finding v8 | Melanoma of the Skin cN3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524682","Cutaneous Melanoma cN2c TNM Finding v8","C136917","Cutaneous melanoma with one clinically detected metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. (from AJCC 8th Ed.)","Cutaneous Melanoma cN2c TNM Finding v8 | Melanoma of the Skin cN2c TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524709","Cutaneous Melanoma cN2b TNM Finding v8","C136916","Cutaneous melanoma with two or three nodal metastases at least one of which was clinically detected. Presence of in-transit, satellite, and/or microsatellite metastases: No.  (from AJCC 8th Ed.)","Cutaneous Melanoma cN2b TNM Finding v8 | Melanoma of the Skin cN2b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524708","Cutaneous Melanoma cN2 TNM Finding v8","C136915","Cutaneous melanoma with two or three tumor-involved nodes or in-transit satellite, and/or microsatellite metastases with one tumor-involved node. (from AJCC 8th Ed.)","Cutaneous Melanoma cN2 TNM Finding v8 | Melanoma of the Skin cN2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524711","Cutaneous Melanoma cN1c TNM Finding v8","C136914","Cutaneous melanoma with no regional lymph node disease. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. (from AJCC 8th Ed.)","Cutaneous Melanoma cN1c TNM Finding v8 | Melanoma of the Skin cN1c TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524710","Cutaneous Melanoma cN1b TNM Finding v8","C136913","Cutaneous melanoma with one clinically detected nodal metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: No.  (from AJCC 8th Ed.)","Cutaneous Melanoma cN1b TNM Finding v8 | Melanoma of the Skin cN1b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524705","Cutaneous Melanoma cN1 TNM Finding v8","C136912","Cutaneous melanoma with one tumor-involved node or in-transit satellite, and/or microsatellite metastases with no tumor-involved nodes. (from AJCC 8th Ed.)","Cutaneous Melanoma cN1 TNM Finding v8 | Melanoma of the Skin cN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524704","Cutaneous Melanoma cN0 TNM Finding v8","C136911","Cutaneous melanoma without regional lymph node metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: No.  (from AJCC 8th Ed.)","Cutaneous Melanoma cN0 TNM Finding v8 | Melanoma of the Skin cN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524707","Cutaneous Melanoma cNX TNM Finding v8","C136910","Cutaneous melanoma in which the regional lymph nodes are not assessed (e.g., sentinel lymph node biopsy is not performed, regional lymph nodes were previously removed for another reason). Exception: pathological N category is not required for T1 melanomas, use cN. Presence of in-transit, satellite, and/or microsatellite metastases: No.  (from AJCC 8th Ed.)","Cutaneous Melanoma cNX TNM Finding v8 | Melanoma of the Skin cNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550898","Statutory Holiday","C148292","Cultural, nationalistic, and religious holidays that are legislated by the government.","Statutory Holiday | Legal Holiday | Public Holiday",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550897","Patient Did Not Keep Appointment","C148293","Failure of a patient to go to a scheduled appointment.","Patient Did Not Keep Appointment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437011","Ensartinib","C102754","An orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with potential antineoplastic activity. Upon oral administration, ensartinib binds to and inhibits ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to the disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors; ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors.","Ensartinib | 6-Amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]- N-{4-[(3R,5S)-3,5-dimethylpiperazine- 1-carbonyl]phenyl}pyridazine-3-carboxamide | ENSARTINIB | Ensacove | X 396 | X-396 | X396",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541513","ARFRP1 Gene","C143137","This gene plays a role in protein sorting and GTPase activity.","ARFRP1 Gene | ADP Ribosylation Factor Related Protein 1 Gene | ARFRP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0855605","Apolipoprotein AII Measurement","C82000","The determination of the amount of apolipoprotein AII present in a sample.","Apolipoprotein AII Measurement | APOA2 | APOA2 Measurement | Apolipoprotein A-II Measurement | Apolipoprotein A2 Measurement | Apolipoprotein AII",,,,,,,,,,,,,,,"40482400","Measurement of apolipoprotein A-II",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332376","ADGRB3 Gene","C24256","This gene is involved in G protein-coupled receptor signaling.","ADGRB3 Gene | ADGRB3 | Adhesion G Protein-Coupled Receptor B3 Gene | BAI3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640818","Mirvetuximab Soravtansine","C102566","An immunoconjugate consisting of the humanized monoclonal antibody M9346A against folate receptor 1 (FOLR1) conjugated, via the disulfide-containing cleavable linker sulfo-SPDB, to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. The anti-FOLR1 monoclonal antibody moiety of mirvetuximab soravtansine targets and binds to the cell surface antigen FOLR1. After antibody-antigen interaction and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, thereby inhibiting cell division and cell growth of FOLR1-expressing tumor cells. FOLR1, a member of the folate receptor family is overexpressed on a variety of epithelial-derived cancer cells. The sulfo-SPDB linker prevents cleavage in the bloodstream and may improve this agent's efficacy in multidrug resistant tumor cells.","Mirvetuximab Soravtansine | Elahere | IMGN 853 | IMGN-853 | IMGN853 | M9346A-sulfo-SPDB-DM4 | MIRVETUXIMAB SORAVTANSINE | Mirvetuximab Soravtansine-gynx | Mirvetuximab soravtansine | mirvetuximab Soravtansine-gynx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL423831","Epacadostat","C92582","An orally available hydroxyamidine and inhibitor of indoleamine 2,3-dioxygenase (IDO1), with potential immunomodulating and antineoplastic activities. Epacadostat targets and binds to IDO1, an enzyme responsible for the oxidation of tryptophan into kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, INCB024360 increases and restores the proliferation and activation of various immune cells, including dendritic cells (DCs), NK cells, and T-lymphocytes, as well as interferon (IFN) production, and a reduction in tumor-associated regulatory T cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may inhibit the growth of IDO1-expressing tumor cells. IDO1 is overexpressed by a variety of tumor cell types and DCs.","Epacadostat | 1,2,5-Oxadiazole-3-carboximidamide, 4-((2-((Aminosulfonyl)amino)ethyl)amino)-N-(3-bromo-4-fluorophenyl)-N'-hydroxy-, (C(Z))- | EPACADOSTAT | INCB 024360 | INCB024360",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1608841","Ustekinumab","C84237","An orally available, human, IgG1kappa, monoclonal antibody directed against the p40 protein subunit of both interleukin-12 (IL-12) and IL-23, with immunomodulating activity. Upon administration, ustekinumab binds to the p40 subunit of IL-12 and IL-23, blocking the binding of IL-12 and IL-23 to their interleukin receptors. This inhibits IL-12- and IL-23-mediated signaling and inhibits differentiation of CD4 positive T-cells into Th1 and Th17 cells. This prevents Th1- and Th17-mediated responses and cytokine production. This may prevent graft versus host disease (GVHD). IL-12 and IL-23, cytokines that play a key role in the regulation of the immune system, are upregulated in immune-mediated inflammatory disorders. Both Th1 and Th17 cells play a crucial role in GVHD.","Ustekinumab | CNTO 1275 | CNTO1275 | Immunoglobulin G1, Anti-(Human Interleukin-12 Subunit beta (IL-12B, CLMF p40, NKSF2)) (Human Monoclonal CNTO 1275 gamma1-chain), Disulfide with Human Monoclonal CNTO 1275 kappa-chain, Dimer | Stelara | USTEKINUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474137","antibody-drug conjugate PF-06647020","C123828","An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against human inactive tyrosine-protein kinase 7 (PTK7) linked, via a cleavable valine-citrulline linker, to an analog of the auristatin microtubule inhibitor dolastatin 10, auristatin-0101, with potential antineoplastic activity. Upon administration, cofetuzumab pelidotin targets and binds to PTK7 expressed on tumor cells. Upon binding, internalization and cleavage, auristatin-0101 binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and apoptosis of PTK7-expressing tumor cells. PTK7, a tumor-associated antigen (TAA), is overexpressed on a variety of cancer cells.","Cofetuzumab Pelidotin | ADC PF-06647020 | ADC PF-7020 | Anti-PTK7/Auristatin-0101 Antibody-drug Conjugate PF-06647020 | Antibody-drug Conjugate PF-06647020 | COFETUZUMAB PELIDOTIN | Immunoglobulin G1, Anti-(human protein tyrosine kinase 7) (humanized Mus musculus clone hu24 gamma-chain), Disulfide with humanized Mus musculus clone hu24 kappa-chain, Dimer, Thioether with N-(((4-((N-(6-(2,5-Dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl)-L-valyl-N5-(aminocarbonyl)-L-ornithyl)amino)phenyl)methoxy)carbonyl)-2-methylalanyl-N-((1S,2R)-2-methoxy-4-((2S)-2-((1R,2R)-1-methoxy-2-methyl-3-oxo-3-(((1S)-2-phenyl-1-(2-thiazolyl)ethyl)amino)propyl)-1-pyrrolidinyl)-1-((1S)-1-methylpropyl)-4-oxobutyl)-N-methyl-L-valinamide | PF 06647020 | PF 7020 | PF-06647020 | PF-7020 | PF06647020 | h6M24-vc0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984213","Prexasertib","C91392","An inhibitor of checkpoint kinase 1 (chk1) with potential antineoplastic activity. Upon administration, prexasertib selectively binds to chk1, thereby preventing activity of chk1 and abrogating the repair of damaged DNA. This may lead to an accumulation of damaged DNA and may promote genomic instability and apoptosis. Prexasertib may potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapeutic agents. Chk1, a serine/threonine kinase, mediates cell cycle checkpoint control and is essential for DNA repair and plays a key role in resistance to chemotherapeutic agents.","Prexasertib | 2-Pyrazinecarbonitrile, 5-((5-(2-(3-Aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)- | ACR 368 | ACR-368 | ACR368 | LY2606368 | PREXASERTIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3253985","Dolutegravir","C121543","An orally bioavailable integrase strand-transfer inhibitor (INSTI), with activity against human immunodeficiency virus type 1 (HIV-1) infection. Upon oral administration, dolutegravir binds to the active site of integrase, an HIV enzyme that catalyzes the transfer of viral genetic material into human chromosomes. This prevents integrase from binding to retroviral deoxyribonucleic acid (DNA), and blocks the strand transfer step, which is essential for the HIV replication cycle. This prevents HIV-1 replication.","Dolutegravir | 2H-Pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9-carboxamide, N-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS) | DOLUTEGRAVIR | DTG | GSK 1349572 | GSK-1349572",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0065023","Fidaxomicin","C66979","A narrow-spectrum, 18-membered macrolide antibiotic isolated from the actinomycete Dactylosporangium aurantiacum subsp. hamdenensis with potential antibacterial activity. Although the exact mechanism of action has yet to be fully elucidated, fidaxomicin may bind to and inhibit bacterial DNA-dependent RNA polymerase, thereby inhibiting the initiation of bacterial RNA synthesis. When orally administered, this agent is minimally absorbed into the systemic circulation, acting locally in the gastrointestinal tract. Fidaxomicin appears to be active against pathogenic Gram-positive bacteria, such as clostridia, enterococci, and staphylococci, but does not appear to be active against other beneficial intestinal bacteria.","Fidaxomicin | Clostomicin B1 | Dificid | Difimicin | FIDAXOMICIN | Lipiarmycin A3 | OPT-80 | PAR-101 | Tiacumicin B | tiacumicin B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2000261","Linaclotide","C81001","A synthetic, fourteen amino acid peptide and agonist of intestinal guanylate cyclase type C (GC-C), which is structurally related to the guanylin peptide family, with secretagogue, analgesic and laxative activities.  Upon oral administration, linaclotide binds to and activates GC-C receptors located on the luminal surface of the intestinal epithelium. This increases the concentration of intracellular cyclic guanosine monophosphate (cGMP), which is derived from guanosine triphosphate (GTP). cGMP activates the cystic fibrosis transmembrane conductance regulator (CFTR) and stimulates the secretion of chloride and bicarbonate into the intestinal lumen. This promotes sodium excretion into the lumen and results in increased intestinal fluid secretion. This ultimately accelerates GI transit of intestinal contents, improves bowel movement and relieves constipation. Increased extracellular cGMP levels may also exert an antinociceptive effect, through an as of yet not fully elucidated mechanism, that may involve modulation of nociceptors found on colonic afferent pain fibers. Linaclotide is minimally absorbed from the GI tract.","Linaclotide | L-Tyrosine, L-cysteinyl-L-cysteinyl-L-alpha-glutamyl-L-tyrosyl-L-cysteinyl-L-cysteinyl-L- asparaginyl-L-prolyl-L-alanyl-L-cysteinyl-L-threonylglycyl-L-cysteinyl-, cyclic (1->6), (2->10), (5->13)-tris(disulfide) | LINACLOTIDE | Linzess | MD-1100 | [9-L-tyrosine]heat-stable enterotoxin (Escherichia coli)-(6-19)-peptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541994","Drug Hypersensitivity Syndrome","C112208","A potentially life-threatening hypersensitivity reaction to a pharmacologic substance that is characterized by rash, lymphadenopathy, fever, hematologic abnormalities and involvement of one or more internal organs.","Drug Hypersensitivity Syndrome | DHS | DRESS | Drug Reaction with Eosinophilia and Systemic Symptoms",,,,,,,,,,,,,,,"45765791","Drug reaction with eosinophilia and systemic symptoms",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1413289","CDK8 Gene","C95297","This gene plays a role in transcriptional regulation.","CDK8 Gene | CDK8 | Cyclin-Dependent Kinase 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422171","CDH23 Gene","C101753","This gene is involved in cell adhesion.","CDH23 Gene | CDH23 | Cadherin-Related 23 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413277","CDH2 Gene","C77157","This gene is involved in cell adhesion.","CDH2 Gene | CDH2 | Cadherin 2, Type 1, N-Cadherin (Neuronal) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273385","Protein CASC5","C97380","Kinetochore scaffold 1 (2342 aa, ~265 kDa) is encoded by the human KNL1 gene. This protein is involved in the attachment of kinetochores to spindle microtubules.","Kinetochore Scaffold 1 | AF15q14 | ALL1-Fused Gene from Chromosome 15q14 Protein | Blinkin | Bub-Linking Kinetochore Protein | CASC5 | CT29 | Cancer Susceptibility Candidate Gene 5 Protein | Cancer/Testis Antigen 29 | KNL1 | Kinetochore Null 1 Homolog | Kinetochore-Null Protein 1 | Protein CASC5 | Protein D40/AF15q14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814865","EMSY wt Allele","C111827","Human EMSY wild-type allele is located in the vicinity of 11q13.5 and is approximately 108 kb in length. This allele, which encodes protein EMSY, plays a role in repression of transcription and may play a role in DNA repair.","EMSY wt Allele | C11orf30 | Chromosome 11 Open Reading Frame 30 Gene | EMSY Transcriptional Repressor, BRCA2 Interacting wt Allele | EMSY, BRCA2 Interacting Transcriptional Repressor Gene | EMSY, BRCA2-Interacting Transcriptional Repressor Gene | GL002",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332416","BIRC5 Gene","C20350","This gene regulates the apoptotic pathway by manipulation of the cell cycle. BIRC5 has been associated with several cancers.","BIRC5 Gene | BIRC5 | Baculoviral IAP Repeat-Containing 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332414","BIRC2 Gene","C20355","This gene is a potent inhibitor of apoptosis and plays an important role in apoptotic signal transduction.","BIRC2 Gene | API1 | BIRC2 | Baculoviral IAP Repeat-Containing 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332398","BCL2L2 Gene","C20411","This gene is involved in the regulation of apoptosis. Expression of BCL2L2 gene inhibits cellular apoptosis under cytotoxic conditions.","BCL2L2 Gene | BCL2 Like 2 Gene | BCL2-Like 2 Gene | BCL2L2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428431","DOT1L Gene","C73677","This gene is involved in epigenetic control of gene expression.","DOT1L Gene | DOT1-like, Histone H3 Methyltransferase (S. cerevisiae) Gene | DOT1L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824940","DIS3 Gene","C96358","This gene is involved in RNA processing.","DIS3 Gene | DIS3 | DIS3 Homolog, Exosome Endoribonuclease and 3'-5' Exoribonuclease Gene | DIS3 Mitotic Control Homolog (S. cerevisiae) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332828","CYP2C19 Gene","C26512","This gene is involved in the metabolism of drugs and xenobiotics.","CYP2C19 Gene | CYP2C19 | Cytochrome P450, Family 2, Subfamily C, Polypeptide 19 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334117","IL3 Gene","C28595","This gene plays a role in hematopoiesis and has neurotrophic activity.","IL3 Gene | IL3 | Interleukin 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422750","IKBKE Gene","C147987","This gene plays a role in the phosphorylation of both interferon regulatory factors-3 and -7 and proteins in the nuclear factor kappa-B signaling pathway.","IKBKE Gene | IKBKE | Inhibitor of Nuclear Factor Kappa B Kinase Subunit Epsilon Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415388","H1-4 Gene","C115353","This gene is involved in chromatin fiber formation.","H1-4 Gene | H1-4 | H1.4 Linker Histone, Cluster Member Gene | HIST1H1E | HIST1H1E Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415359","GUCY1A2 Gene","C38421","This gene plays a role in GTP metabolism and nitric oxide-mediated signal transduction.","GUCY1A2 Gene | GUCY1A2 | Guanylate Cyclase 1, Soluble, Alpha 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333703","GPS2 Gene","C24453","This gene plays a role in suppression of signal transduction.","GPS2 Gene | G Protein Pathway Suppressor 2 Gene | GPS2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415144","GNAI3 Gene","C38381","This gene is involved in signal transduction and neurotransmission.","GNAI3 Gene | G Protein Subunit Alpha I3 Gene | GNAI3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415139","GNA13 Gene","C115328","This gene plays a role in heterotrimeric G protein signaling.","GNA13 Gene | GNA13 | Guanine Nucleotide Binding Protein (G Protein), Alpha 13 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545758","GID4 Gene","C147972","This gene plays a role in the ubiquitination of gluconeogenic enzymes.","GID4 Gene | GID Complex Subunit 4 Homolog Gene | GID4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333669","GDNF Gene","C28465","This gene is involved in neurogenesis. It plays a role in promoting the differential and survival of neurons.","GDNF Gene | GDNF | Glial Cell Derived Neurotrophic Factor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333652","G6PD Gene","C26529","This gene plays a role in carbohydrate metabolism.","G6PD Gene | G6PD | Glucose-6-Phosphate Dehydrogenase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415627","FOXA2 Gene","C73451","This gene plays a role in transcriptional regulation.","FOXA2 Gene | FOXA2 | Forkhead Box A2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1367472","FN1 Gene","C28574","This gene is involved in several important cellular events such as cellular adhesion and migration processes.","FN1 Gene | FN1 | Fibronectin 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812296","FGF6 Gene","C18412","This gene is involved in angiogenesis and cell proliferation.","FGF6 Gene | FGF6 | Fibroblast Growth Factor 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812290","FGF3 Gene","C18408","This gene plays a role in the regulation of cell growth.","FGF3 Gene | FGF3 | Fibroblast Growth Factor 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545845","FGF14 Gene","C147990","This gene is involved in development and maintenance of the central nervous system.","FGF14 Gene | FGF14 | Fibroblast Growth Factor 14 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540333","BRINP3 wt Allele","C142376","Human BRINP3 wild-type allele is located in the vicinity of 1q31.1 and is approximately 381 kb in length. This allele, which encodes BMP/retinoic acid-inducible neural-specific protein 3, is involved in neuronal differentiation and cell cycle arrest. Aberrant expression of the gene may be associated with pituitary tumors, tongue squamous cell carcinomas, ulcerative colitis, and peri-implantitis. Hypermethylation of the gene may be a marker for gastric cancer.","BRINP3 wt Allele | BMP/Retinoic Acid Inducible Neural Specific 3 wt Allele | DBCCR1L | DBCCR1L1 | FAM5C | Family With Sequence Similarity 5, Member C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541221","FLJ13614","C101798","Human ABRAXAS1 wild-type allele is located in the vicinity of 4q21.23 and is approximately 64 kb in length. This allele, which encodes BRCA1-A complex subunit Abraxas 1 protein, plays a role in the mediation of DNA repair and the progression of the cell cycle.","ABRAXAS1 wt Allele | ABRA1 | ABRAXAS | Abraxas 1, BRCA1 A Complex Subunit wt Allele | Abraxas Gene | CCDC98 | Coiled-Coil Domain Containing 98 Gene | FAM175A | FLJ11520 | FLJ12642 | FLJ13614 | Family with Sequence Similarity 175 Member A Gene | Family with Sequence Similarity 175, Member A Gene | UNQ496/PRO1013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1570167","Activating Transcription Factor 7-Interacting Protein 1","C119672","Activating transcription factor 7-interacting protein 1 (1270 aa, ~136 kDa) is encoded by the human ATF7IP gene. This protein is involved in both transcriptional regulation and histone methylation.","Activating Transcription Factor 7-Interacting Protein 1 | ATF-IP | ATF-Interacting Protein | ATF7-Interacting Protein | ATF7IP | ATFa-Associated Modulator | Activating Transcription Factor 7-Interacting Protein | MBD1-Containing Chromatin-Associated Factor 1 | P621 | hAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422048","MARK4 Gene","C114391","This gene plays a role in protein phosphorylation.","MARK4 Gene | MAP/Microtubule Affinity-Regulating Kinase 4 Gene | MARK4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1367731","MAPK8 Gene","C21228","This gene plays a role in signal transduction that affects cell differentiation, growth and proliferation. It is also involved in mediation of both insulin resistance and obesity.","MAPK8 Gene | MAPK8 | Mitogen-Activated Protein Kinase 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334477","MAP3K7 Gene","C24574","This gene plays a role in apoptosis, transcription and the cellular response to stress.","MAP3K7 Gene | MAP3K7 | Mitogen-Activated Protein Kinase Kinase Kinase 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427865","MAGI1 Gene","C24257","This gene is involved in signal transduction and structural remodeling.","MAGI1 Gene | MAGI1 | Membrane Associated Guanylate Kinase, WW and PDZ Domain Containing 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550999","BET Inhibitor ABBV-744","C148415","An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, the BET inhibitor ABBV-744 preferentially binds to the second bromodomain (BD2) of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of proliferation in BET-overexpressing tumor cells. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that contain two homologous bromodomains, the BD1 and BD2 domains. They play an important role during development and cellular growth.","BET Inhibitor ABBV-744 | 1H-Pyrrolo(2,3-C)pyridine-2-carboxamide, N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(1-hydroxy-1-methylethyl)phenyl)-6,7-dihydro-6-methyl-7-oxo- | ABBV 744 | ABBV-744 | ABBV744 | BD2-selective BET Inhibitor ABBV-744",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551002","Dolutegravir Sodium","C148408","The sodium salt form of dolutegravir, an orally bioavailable integrase strand-transfer inhibitor (INSTI), with activity against human immunodeficiency virus type 1 (HIV-1) infection. Upon oral administration, dolutegravir binds to the active site of integrase, an HIV enzyme that catalyzes the transfer of viral genetic material into human chromosomes. This prevents integrase from binding to retroviral deoxyribonucleic acid (DNA), and blocks the strand transfer step, which is essential for the HIV replication cycle. This prevents HIV-1 replication.","Dolutegravir Sodium | DOLUTEGRAVIR SODIUM | Tivicay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420888","TRAF3 Gene","C96377","This gene is involved in both signal transduction and apoptosis regulation.","TRAF3 Gene | TNF Receptor Associated Factor 3 Gene | TNF Receptor-Associated Factor 3 Gene | TRAF3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1540033","TNK2 Gene","C21266","This gene is involved in the negative regulation of cell growth.","TNK2 Gene | TNK2 | Tyrosine Kinase, Non-Receptor, 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2680482","TMEM216 Gene","C101661","This gene is involved in ciliogenesis.","TMEM216 Gene | TMEM216 | Transmembrane Protein 216 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336634","TLR2 Gene","C24863","This gene plays a role in pathogen recognition and mediates the host response to gram-positive bacteria and yeast.","TLR2 Gene | TLR2 | Toll-Like Receptor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336564","TAF1 Gene","C20421","This gene is involved in transcriptional initiation, cell cycle progression and ubiquitination.","TAF1 Gene | TAF1 | TATA-Box Binding Protein Associated Factor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2680433","SNX31 Gene","C102906","This gene is involved in intracellular transport.","SNX31 Gene | SNX31 | Sorting Nexin 31 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1822780","SMC3 Gene","C24317","This gene plays a role in chromosomal segregation during mitosis and is involved in cellular adhesion.","SMC3 Gene | SMC3 | Structural Maintenance of Chromosomes 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420017","SH2D1A Gene","C75393","This gene plays roles in proliferation, differentiation and activation of B and T-cells.","SH2D1A Gene | SH2 Domain Containing 1A Gene | SH2D1A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419413","RNASEL Gene","C101335","This gene plays a role in RNA processing.","RNASEL Gene | RNASEL | Ribonuclease L (2',5'-Oligoisoadenylate Synthetase-Dependent) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1367485","PTGS2 Gene","C26598","This gene is involved in mitogenesis, inflammation and angiogenesis.","PTGS2 Gene | COX2 | PTGS2 | Prostaglandin-Endoperoxide Synthase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418572","PIK3C2B Gene","C102942","This gene is involved in the metabolism of phosphoinositol.","PIK3C2B Gene | PIK3C2B | Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Beta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812223","NOTCH4 Gene","C18346","This gene plays a regulatory role in vascular, renal and hepatic development.","NOTCH4 Gene | NOTCH4 | Notch 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417101","MEF2B Gene","C92157","This gene is involved in transcriptional regulation.","MEF2B Gene | MEF2B | Myocyte Enhancer Factor 2B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824002","ZNF703 Gene","C95868","This gene may play a role in transcriptional regulation.","ZNF703 Gene | ZNF703 | Zinc Finger Protein 703 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421509","CCN6 Gene","C21418","This gene plays a role in mitochondrial function, postnatal skeletal growth and cartilage homeostasis.","CCN6 Gene | CCN6 | Cellular Communication Network Factor 6 Gene | WISP3 | WISP3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524723","Cutaneous Melanoma Clinical Distant Metastasis TNM Finding v8","C136894","A clinical finding about one or more characteristics of cutaneous melanoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Cutaneous Melanoma Clinical Distant Metastasis TNM Finding v8 | Clinical Staging: Distant Metastasis (cM) | Melanoma of the Skin Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524701","Cutaneous Melanoma cM1d(1) TNM Finding v8","C136908","Cutaneous melanoma with distant metastasis to CNS with or without M1a, M1b, or M1c sites of disease.  LDH level elevated. (from AJCC 8th Ed.)","Cutaneous Melanoma cM1d(1) TNM Finding v8 | Melanoma of the Skin cM1d(1) TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524700","Cutaneous Melanoma cM1d(0) TNM Finding v8","C136907","Cutaneous melanoma with distant metastasis to CNS with or without M1a, M1b, or M1c sites of disease.  LDH level normal. (from AJCC 8th Ed.)","Cutaneous Melanoma cM1d(0) TNM Finding v8 | Melanoma of the Skin cM1d(0) TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524703","Cutaneous Melanoma cM1d TNM Finding v8","C136906","Cutaneous melanoma with distant metastasis to CNS with or without M1a, M1b, or M1c sites of disease.  LDH level not recorded or unspecified. (from AJCC 8th Ed.)","Cutaneous Melanoma cM1d TNM Finding v8 | Melanoma of the Skin cM1d TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524702","Cutaneous Melanoma cM1c(1) TNM Finding v8","C136905","Cutaneous melanoma with distant metastasis to non-CNS visceral sites with or without M1a or M1b sites of disease.  LDH level elevated. (from AJCC 8th Ed.)","Cutaneous Melanoma cM1c(1) TNM Finding v8 | Melanoma of the Skin cM1c(1) TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524697","Cutaneous Melanoma cM1c(0) TNM Finding v8","C136904","Cutaneous melanoma with distant metastasis to non-CNS visceral sites with or without M1a or M1b sites of disease.  LDH level not elevated. (from AJCC 8th Ed.)","Cutaneous Melanoma cM1c(0) TNM Finding v8 | Melanoma of the Skin cM1c(0) TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524696","Cutaneous Melanoma cM1c TNM Finding v8","C136903","Cutaneous melanoma with distant metastasis to non-CNS visceral sites with or without M1a or M1b sites of disease.  LDH level not recorded or unspecified. (from AJCC 8th Ed.)","Cutaneous Melanoma cM1c TNM Finding v8 | Melanoma of the Skin cM1c TNM Finding v8 | cM1c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524699","Cutaneous Melanoma cM1b(1) TNM Finding v8","C136902","Cutaneous melanoma with distant metastasis to lung with or without M1a sites of disease. LDH level elevated. (from AJCC 8th Ed.)","Cutaneous Melanoma cM1b(1) TNM Finding v8 | Melanoma of the Skin cM1b(1) TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524698","Cutaneous Melanoma cM1b(0) TNM Finding v8","C136901","Cutaneous melanoma with distant metastasis to lung with or without M1a sites of disease. LDH level not elevated. (from AJCC 8th Ed.)","Cutaneous Melanoma cM1b(0) TNM Finding v8 | Melanoma of the Skin cM1b(0) TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524725","Cutaneous Melanoma cM1b TNM Finding v8","C136900","Cutaneous melanoma with distant metastasis to lung with or without M1a sites of disease. LDH level not recorded or unspecified. (from AJCC 8th Ed.)","Cutaneous Melanoma cM1b TNM Finding v8 | Melanoma of the Skin cM1b TNM Finding v8 | cM1b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524724","Cutaneous Melanoma cM1a(1) TNM Finding v8","C136899","Cutaneous melanoma with distant metastasis to skin, soft tissue including muscle, and/or nonregional lymph node. LDH level elevated. (from AJCC 8th Ed.)","Cutaneous Melanoma cM1a(1) TNM Finding v8 | Melanoma of the Skin cM1a(1) TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524727","Cutaneous Melanoma cM1a(0) TNM Finding v8","C136898","Cutaneous melanoma with distant metastasis to skin, soft tissue including muscle, and/or nonregional lymph node. LDH level not elevated. (from AJCC 8th Ed.)","Cutaneous Melanoma cM1a(0) TNM Finding v8 | Melanoma of the Skin cM1a(0) TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524726","Cutaneous Melanoma cM1a TNM Finding v8","C136897","Cutaneous melanoma with distant metastasis to skin, soft tissue including muscle, and/or nonregional lymph node. LDH level not recorded or unspecified. (from AJCC 8th Ed.)","Cutaneous Melanoma cM1a TNM Finding v8 | Melanoma of the Skin cM1a TNM Finding v8 | cM1a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524721","Cutaneous Melanoma cM1 TNM Finding v8","C136896","Cutaneous melanoma with evidence of distant metastasis. (from AJCC 8th Ed.)","Cutaneous Melanoma cM1 TNM Finding v8 | Melanoma of the Skin cM1 TNM Finding v8 | cM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524720","Cutaneous Melanoma cM0 TNM Finding v8","C136895","Cutaneous melanoma without evidence of distant metastasis. LDH level is not applicable. (from AJCC 8th Ed.)","Cutaneous Melanoma cM0 TNM Finding v8 | Melanoma of the Skin cM0 TNM Finding v8 | cM0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550996","Partially HLA-matched Adenovirus-specific T Lymphocytes","C148419","A population of frozen, off-the-shelf, ready to administer, allogeneic, partially or closely human leukocyte antigen (HLA) matched cytotoxic T-lymphocytes (CTLs) specifically reactive to human adenovirus (Ad; AdV), with potential immunomodulating and anti-adenoviral activities. Ex vivo, Ad-derived peptides were mixed with peripheral blood mononuclear cells (PBMCs) from healthy donors and the Ad-reactive CTLs were selected, grown and frozen. Upon thawing and infusion, the partially HLA-matched Ad-specific CTLs may help reconstitute Ad-specific CTL responses in patients at risk of developing Ad infections after allogeneic stem cell transplant (HSCT) or in Ad-infected immunocompromised hosts. This may induce killing of Ad-infected cells and may prevent or reduce severity of Ad infection.","Partially HLA-matched Adenovirus-specific T Lymphocytes | Partially HLA-matched Ad-specific CTLs | Partially HLA-matched Viralym-A Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550992","Moderate Hepatic Insufficiency","C148420","Findings indicating moderate impairment of liver function.","Moderate Hepatic Insufficiency | Moderate Hepatic Impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2960582","Adult Comorbidity Evaluation-27","C148417","A 27-item comorbidity index for patients with cancer. ACE27 includes comorbid conditions of various organ systems, as well as malignancy, substance abuse, and body weight.","Adult Comorbidity Evaluation-27 | ACE-27 | ACE27",,,,,,,,,,,,,,,"40488785","Adult comorbidity evaluation-27",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL550997","Neuromuscular","C148418","Pertaining to muscles and nerves.","Neuromuscular | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524776","Cutaneous Melanoma Pathologic Regional Lymph Nodes TNM Finding v8","C136953","A pathologic finding about one or more characteristics of cutaneous melanoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes. The TNM pathologic and clinical regional lymph nodes classifications of cutaneous melanoma are not the same. TNM pathologic findings are based on the microscopic examination of the regional lymph nodes, usually detected by lymphatic mapping and sentinel lymph node biopsy (clinically occult regional lymph node metastasis). (from AJCC 8th Ed.)","Cutaneous Melanoma Pathologic Regional Lymph Nodes TNM Finding v8 | Melanoma of the Skin Pathologic Regional Lymph Nodes TNM Finding v8 | Pathologic Staging: Regional Lymph Nodes (pN)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524783","Cutaneous Melanoma pN2a TNM Finding v8","C136960","Cutaneous melanoma with two or three clinically occult nodal metastases (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No.  (from AJCC 8th Ed.)","Cutaneous Melanoma pN2a TNM Finding v8 | Melanoma of the Skin pN2a TNM Finding v8 | pN2a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524786","Cutaneous Melanoma pN2 TNM Finding v8","C136959","Cutaneous melanoma with two or three tumor-involved nodes or in-transit satellite, and/or microsatellite metastases with one tumor-involved node. (from AJCC 8th Ed.)","Cutaneous Melanoma pN2 TNM Finding v8 | Melanoma of the Skin pN2 TNM Finding v8 | pN2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524785","Cutaneous Melanoma pN1c TNM Finding v8","C136958","Cutaneous melanoma with no regional lymph node disease. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. (from AJCC 8th Ed.)","Cutaneous Melanoma pN1c TNM Finding v8 | Melanoma of the Skin pN1c TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524780","Cutaneous Melanoma pN1a TNM Finding v8","C136957","Cutaneous melanoma with one clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No.  (from AJCC 8th Ed.)","Cutaneous Melanoma pN1a TNM Finding v8 | Melanoma of the Skin pN1a TNM Finding v8 | pN1a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524779","Cutaneous Melanoma pN1 TNM Finding v8","C136956","Cutaneous melanoma with one tumor-involved node or in-transit satellite, and/or microsatellite metastases with no tumor-involved nodes. (from AJCC 8th Ed.)","Cutaneous Melanoma pN1 TNM Finding v8 | Melanoma of the Skin pN1 TNM Finding v8 | pN1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524782","Cutaneous Melanoma pN0 TNM Finding v8","C136955","Cutaneous melanoma without regional lymph node metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: No.  (from AJCC 8th Ed.)","Cutaneous Melanoma pN0 TNM Finding v8 | Melanoma of the Skin pN0 TNM Finding v8 | pN0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524781","Cutaneous Melanoma pNX TNM Finding v8","C136954","Cutaneous melanoma in which the regional lymph nodes are not assessed (e.g., sentinel lymph node biopsy is not performed, regional lymph nodes were previously removed for another reason). Exception: pathological N category is not required for T1 melanomas, use cN. Presence of in-transit, satellite, and/or microsatellite metastases: No.  (from AJCC 8th Ed.)","Cutaneous Melanoma pNX TNM Finding v8 | Melanoma of the Skin pNX TNM Finding v8 | pNX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524762","Cutaneous Melanoma pN3c TNM Finding v8","C136966","Cutaneous melanoma with two or more clinically occult nodal metastases. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. (from AJCC 8th Ed.)","Cutaneous Melanoma pN3c TNM Finding v8 | Melanoma of the Skin pN3c TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524787","Cutaneous Melanoma pN3a TNM Finding v8","C136964","Cutaneous melanoma with four or more clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No.  (from AJCC 8th Ed.)","Cutaneous Melanoma pN3a TNM Finding v8 | Melanoma of the Skin pN3a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524789","Cutaneous Melanoma pN3 TNM Finding v8","C136963","Cutaneous melanoma with four or more tumor-involved nodes or in-transit satellite, and/or microsatellite metastases with two or more tumor-involved nodes, or any number of matted nodes without or with in-transit, satellite, and/or microsatellite metastases. (from AJCC 8th Ed.)","Cutaneous Melanoma pN3 TNM Finding v8 | Melanoma of the Skin pN3 TNM Finding v8 | pN3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524784","Cutaneous Melanoma pN2c TNM Finding v8","C136961","Cutaneous melanoma with one clinically occult nodal metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. (from AJCC 8th Ed.)","Cutaneous Melanoma pN2c TNM Finding v8 | Melanoma of the Skin pN2c TNM Finding v8 | pN2c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017195","Gastroscopy","C16604","Endoscopic examination of the stomach.","Gastroscopy | gastroscopy | upper endoscopy",,,,,,,,,,,,,,,"4297516","Endoscopy of stomach",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL524687","Cutaneous Melanoma Pathologic Distant Metastasis TNM Finding v8","C136922","A pathologic finding about one or more characteristics of cutaneous melanoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Cutaneous Melanoma Pathologic Distant Metastasis TNM Finding v8 | Melanoma of the Skin Pathologic Distant Metastasis TNM Finding v8 | Pathologic Staging: Distant Metastasis (pM)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524790","Cutaneous Melanoma pM1d(1) TNM Finding v8","C136936","Cutaneous melanoma with distant metastasis to CNS with or without M1a, M1b, or M1c sites of disease.  LDH level elevated. (from AJCC 8th Ed.)","Cutaneous Melanoma pM1d(1) TNM Finding v8 | Melanoma of the Skin pM1d(1) TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524793","Cutaneous Melanoma pM1d(0) TNM Finding v8","C136935","Cutaneous melanoma with distant metastasis to CNS with or without M1a, M1b, or M1c sites of disease.  LDH level normal. (from AJCC 8th Ed.)","Cutaneous Melanoma pM1d(0) TNM Finding v8 | Melanoma of the Skin pM1d(0) TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524792","Cutaneous Melanoma pM1d TNM Finding v8","C136934","Cutaneous melanoma with distant metastasis to CNS with or without M1a, M1b, or M1c sites of disease.  LDH level not recorded or unspecified. (from AJCC 8th Ed.)","Cutaneous Melanoma pM1d TNM Finding v8 | Melanoma of the Skin pM1d TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524693","Cutaneous Melanoma pM1c(1) TNM Finding v8","C136932","Cutaneous melanoma with distant metastasis to non-CNS visceral sites with or without M1a or M1b sites of disease.  LDH level elevated. (from AJCC 8th Ed.)","Cutaneous Melanoma pM1c(1) TNM Finding v8 | Melanoma of the Skin pM1c(1) TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524692","Cutaneous Melanoma pM1c(0) TNM Finding v8","C136931","Cutaneous melanoma with distant metastasis to non-CNS visceral sites with or without M1a or M1b sites of disease.  LDH level not elevated. (from AJCC 8th Ed.)","Cutaneous Melanoma pM1c(0) TNM Finding v8 | Melanoma of the Skin pM1c(0) TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524695","Cutaneous Melanoma pM1c TNM Finding v8","C136930","Cutaneous melanoma with distant metastasis to non-CNS visceral sites with or without M1a or M1b sites of disease.  LDH level not recorded or unspecified. (from AJCC 8th Ed.)","Cutaneous Melanoma pM1c TNM Finding v8 | Melanoma of the Skin pM1c TNM Finding v8 | pM1c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524694","Cutaneous Melanoma pM1b(1) TNM Finding v8","C136929","Cutaneous melanoma with distant metastasis to lung with or without M1a sites of disease. LDH level elevated. (from AJCC 8th Ed.)","Cutaneous Melanoma pM1b(1) TNM Finding v8 | Melanoma of the Skin pM1b(1) TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524689","Cutaneous Melanoma pM1b(0) TNM Finding v8","C136928","Cutaneous melanoma with distant metastasis to lung with or without M1a sites of disease. LDH level not elevated. (from AJCC 8th Ed.)","Cutaneous Melanoma pM1b(0) TNM Finding v8 | Melanoma of the Skin pM1b(0) TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524688","Cutaneous Melanoma pM1b TNM Finding v8","C136927","Cutaneous melanoma with distant metastasis to lung with or without M1a sites of disease. LDH level not recorded or unspecified. (from AJCC 8th Ed.)","Cutaneous Melanoma pM1b TNM Finding v8 | Melanoma of the Skin pM1b TNM Finding v8 | pM1b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524691","Cutaneous Melanoma pM1a(1) TNM Finding v8","C136926","Cutaneous melanoma with distant metastasis to skin, soft tissue including muscle, and/or nonregional lymph node. LDH level elevated. (from AJCC 8th Ed.)","Cutaneous Melanoma pM1a(1) TNM Finding v8 | Melanoma of the Skin pM1a(1) TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524690","Cutaneous Melanoma pM1a(0) TNM Finding v8","C136925","Cutaneous melanoma with distant metastasis to skin, soft tissue including muscle, and/or nonregional lymph node. LDH level not elevated. (from AJCC 8th Ed.)","Cutaneous Melanoma pM1a(0) TNM Finding v8 | Melanoma of the Skin pM1a(0) TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524685","Cutaneous Melanoma pM1a TNM Finding v8","C136924","Cutaneous melanoma with distant metastasis to skin, soft tissue including muscle, and/or nonregional lymph node. LDH level not recorded or unspecified. (from AJCC 8th Ed.)","Cutaneous Melanoma pM1a TNM Finding v8 | Melanoma of the Skin pM1a TNM Finding v8 | pM1a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524684","Cutaneous Melanoma pM1 TNM Finding v8","C136923","Cutaneous melanoma with evidence of distant metastasis. (from AJCC 8th Ed.)","Cutaneous Melanoma pM1 TNM Finding v8 | Melanoma of the Skin pM1 TNM Finding v8 | pM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0396247","Intranasal Ethmoidectomy","C51898","Surgical removal of part of the ethmoid bone, using an intra-nasl approach.","Intranasal Ethmoidectomy | ",,,,,,,,,,,,,,,"4067358","Intranasal ethmoidectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030600","Subtotal Gastrectomy","C51583","Surgical removal of part of the stomach.","Subtotal Gastrectomy | ",,,,,,,,,,,,,,,"4174035","Subtotal gastrectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL550991","Compartectomy","C148421","A limb-sparing surgical tumor resection procedure in which the entire lesion is removed and the plane of dissection is outside the limiting fascia or bone.","Compartectomy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698017","CDISC SDTM Marital Status Terminology","C76348","Terminology codelist used for Marital Status within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.","CDISC SDTM Marital Status Terminology | MARISTAT | Marital Status Response | SDTM-MARISTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551028","Polygamous","C76242","A type of living arrangement or mating system in which at least one member of a relationship has more than one mate.","Polygamous | POLYGAMOUS | Polygamous Status",,,,,,,,,,,,,,,"4329021","Polygamous",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1549108","Interlocutory Marital Status","C76241","The condition existing when an order or judgement is considered temporary until either a specified period of time has passed or specific information is provided to assist in rendering a permanent decision.","Interlocutory Marital Status | INTERLOCUTORY | Interlocutory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549109","Annulled","C76240","A marital status in which a voidable marriage is legally declared null and void, as though it never existed. Specific grounds for annullment vary within the presiding jurisdiction, whether geographic or religious.","Annulled | ANNULLED | Annulled Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514546","Partial Resection","C131680","Surgical removal of a part of a lesion; some portion of the lesion is detectable on post-operative evaluation.","Partial Resection | Incomplete Resection | Subtotal Resection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0191234","Pericardiocentesis","C52010","The aspiration of excess fluid between the pericardium and the heart. (ACC)","Pericardiocentesis | PERICARDIOCENTESIS",,,,,,,,,,,,,,,"4149930","Pericardiocentesis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0193318","Complete Parotidectomy","C51491","Surgery involving complete excision of the parotid gland.","Complete Parotidectomy | Parotidectomy, total | Total Parotidectomy",,,,,,,,,,,,,,,"4028229","Complete parotidectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0193319","Partial Parotidectomy","C51573","Surgery involving partial excision of the parotid gland.","Partial Parotidectomy | ",,,,,,,,,,,,,,,"4008569","Partial parotidectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0585092","Para-Aortic Lymph Node Biopsy","C136289","A surgical procedure in which a single or multiple para-aortic lymph nodes are removed for microscopic examination.","Para-Aortic Lymph Node Biopsy | Para-Aortic Lymph Node Sampling",,,,,,,,,,,,,,,"4144796","Biopsy of para-aortic lymph nodes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0278314","Nephrostomy","C94443","The surgical creation of an opening between one or both kidneys and the skin, through which a tube is place, thereby allowing for the direct drainage of urine from the kidney.","Nephrostomy | nephrostomy",,,,,,,,,,,,,,,"4220029","Nephrostomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL523599","Radical Trachelectomy","C136288","Surgical removal of the uterine cervix and pelvic lymph nodes.","Radical Trachelectomy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879937","CDISC SDTM Patient Ethnic Group Terminology","C66790","Terminology codelist used with Ethnic Group within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.","CDISC SDTM Ethnic Group Terminology | ETHNIC | Ethnic Group | SDTM-ETHNIC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508061","Observational Medical Outcomes Partnership","C127113","A public-private partnership established to inform the appropriate use of observational healthcare databases for studying the effects of medical products. Its goals were: 1) conduct methodological research to empirically evaluate the performance of various analytical methods on their ability to identify true associations and avoid false findings, 2) develop tools and capabilities for transforming, characterizing, and analyzing disparate data sources across the health care delivery spectrum, and 3) establish a shared resource so that the broader research community can collaboratively advance the science.","Observational Medical Outcomes Partnership | OMOP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0185524","Mandibulotomy","C148438","A surgical incision through the mandible to access the mouth or throat.","Mandibulotomy | ",,,,,,,,,,,,,,,"4209141","Osteotomy of mandible",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL550984","Free Tissue Transfer","C148436","The transplantation of autologous tissue that is completely detached from its original blood supply from one location to another using microvascular reconstruction techniques to reestablish circulation.","Free Tissue Transfer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020710","Hysteroscopy","C148437","Endoscopic examination of the uterine cavity through the vagina and cervix.","Hysteroscopy | ",,,,,,,,,,,,,,,"4052532","Hysteroscopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552447","BRIEF Health Literacy Screening Tool","C148441","A standardized four-item questionnaire developed by Haun et al. in 2009 that utilizes a five-point Likert rating scale to assess the adequacy of an individual's health literacy.","BRIEF Health Literacy Screening Tool | BRIEF | BRIEF Health Literacy Screening Tool (BRIEF)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550977","Require Help to Read Hospital Materials","C148442","A question about whether an individual has or had someone help them read hospital materials.","Require Help to Read Hospital Materials | How often do you have someone help you read hospital materials",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551090","Have Problems Learning About Medical Condition Due to Difficulty Understanding Written Information","C148446","A question about whether an individual has or had problems learning about their medical condition because of difficulty understanding written information.","Have Problems Learning About Medical Condition Due to Difficulty Understanding Written Information | How often do you have problems learning about your medical condition because of difficulty understanding written information",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551089","Have Problem Understanding What is Told About Medical Condition","C148447","A question about whether an individual has or had a problem understanding what is told to them about their medical condition.","Have Problem Understanding What is Told About Medical Condition | How often do you have a problem understanding what is told to you about your medical condition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551086","Confident Filling Out Medical Forms","C148450","A question about how confident an individual is filling out medical forms by themselves.","Confident Filling Out Medical Forms | How confident are you filling out medical forms by yourself",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699817","Drug Product: Manufacturer(s)","C79342","An entity that produces drug products and engages in current Good Manufacturing Practice (cGMP) activities as regulated and enforced by the US Food and Drug Administration (FDA).","Drug Product: Manufacturer(s) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524748","Cutaneous Melanoma by AJCC v8 Clinical Stage","C137646","A term that refers to the clinical staging of cutaneous melanoma, following the rules of the TNM AJCC v8 classification system.","Cutaneous Melanoma by AJCC v8 Clinical Stage | Melanoma of the Skin by AJCC v8 Clinical Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524841","Clinical Stage IV Cutaneous Melanoma AJCC v8","C137656","Stage IV includes: Any T, Any N, M1. M1: Evidence of distant metastasis. (AJCC 8th ed.)","Clinical Stage IV Cutaneous Melanoma AJCC v8 | Clinical Stage IV Melanoma of the Skin AJCC v8 | Stage IV Cutaneous (Skin) Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524757","Clinical Stage III Cutaneous Melanoma AJCC v8","C137655","Stage III includes: Any T, Tis, N1 or More, M0. Tis: Melanoma in situ. Thickness: Not applicable. Ulceration status: Not applicable. N1: One tumor-involved node or in-transit, satellite, and/or microsatellite metastases with no tumor-involved nodes. N2: Two or three tumor-involved nodes or in-transit, satellite, and/or microsatellite metastases with one tumor-involved node. N3: Four or more tumor-involved nodes or in-transit, satellite, and/or microsatellite metastases with two or more tumor-involved nodes, or any number of matted nodes without or with in-transit, satellite, and/or microsatellite metastases. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage III Melanoma of the Skin AJCC v8 | Stage III Cutaneous (Skin) Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524756","Clinical Stage IIC Cutaneous Melanoma AJCC v8","C137654","Stage IIC includes: T4b, N0, M0. T4b: Tumor measuring more than 4.0 mm in thickness. Ulceration status: With ulceration.  N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","Clinical Stage IIC Cutaneous Melanoma AJCC v8 | Clinical Stage IIC Melanoma of the Skin AJCC v8 | Stage IIC Cutaneous (Skin) Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524759","Clinical Stage IIB Cutaneous Melanoma AJCC v8","C137653","Stage IIB includes: (T3b, N0, M0); (T4a, N0, M0). T3b: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: With ulceration. T4a: Tumor measuring more than 4.0 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","Clinical Stage IIB Cutaneous Melanoma AJCC v8 | Clinical Stage IIB Melanoma of the Skin AJCC v8 | Stage IIB Cutaneous (Skin) Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524758","Clinical Stage IIA Cutaneous Melanoma AJCC v8","C137652","Stage IIA includes: (T2b, N0, M0); (T3a, N0, M0). T2b: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: With ulceration. T3a: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","Clinical Stage IIA Cutaneous Melanoma AJCC v8 | Clinical Stage IIA Melanoma of the Skin AJCC v8 | Stage IIA Cutaneous (Skin) Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524753","Clinical Stage II Cutaneous Melanoma AJCC v8","C137651","Stage II includes: IIA: (T2b, N0, M0); (T3a, N0, M0); IIB: (T3b, N0, M0); (T4a, N0, M0); IIC: (T4b, N0, M0). T2b: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: With ulceration. T3a: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: Without ulceration. T3b: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: With ulceration. T4a: Tumor measuring more than 4.0 mm in thickness. Ulceration status: Without ulceration. T4b: Tumor measuring more than 4.0 mm in thickness. Ulceration status: With ulceration.  N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","Clinical Stage II Cutaneous Melanoma AJCC v8 | Clinical Stage II Melanoma of the Skin AJCC v8 | Stage II Cutaneous (Skin) Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524752","Clinical Stage IB Cutaneous Melanoma AJCC v8","C137650","Stage IB includes: (T1b, N0, M0); (T2a, N0, M0). T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","Clinical Stage IB Cutaneous Melanoma AJCC v8 | Clinical Stage IB Melanoma of the Skin AJCC v8 | Stage IB Cutaneous (Skin) Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524755","Clinical Stage IA Cutaneous Melanoma AJCC v8","C137649","Stage IA includes: T1a, N0, M0. T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","Clinical Stage IA Cutaneous Melanoma AJCC v8 | Clinical Stage IA Melanoma of the Skin AJCC v8 | Stage IA Cutaneous (Skin) Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524754","Clinical Stage I Cutaneous Melanoma AJCC v8","C137648","Stage I includes: IA: (T1a, N0, M0); IB: (T1b, N0, M0); (T2a, N0, M0). T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","Clinical Stage I Cutaneous Melanoma AJCC v8 | Clinical Stage I Melanoma of the Skin AJCC v8 | Stage I Cutaneous (Skin) Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524749","Clinical Stage 0 Cutaneous Melanoma AJCC v8","C137647","Stage 0 includes: Tis, N0, M0. Tis: Melanoma in situ. Thickness: Not applicable. Ulceration status: Not applicable. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","Clinical Stage 0 Cutaneous Melanoma AJCC v8 | Clinical Stage 0 Melanoma of the Skin AJCC v8 | Stage 0 Cutaneous (Skin) Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524842","Cutaneous Melanoma by AJCC v8 Pathologic Stage","C137657","A term that refers to the pathologic staging of cutaneous melanoma, following the rules of the TNM AJCC v8 classification system.","Cutaneous Melanoma by AJCC v8 Pathologic Stage | Melanoma of the Skin by AJCC v8 Pathologic Stage | Tumor Stage (Pathological)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524853","Pathologic Stage IIB Cutaneous Melanoma AJCC v8","C137668","Stage IIB includes: (T3b, N0, M0); (T4a, N0, M0). T3b: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: With ulceration. T4a: Tumor measuring more than 4.0 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","Pathologic Stage IIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIB Melanoma of the Skin AJCC v8 | Stage IIB | Stage IIB Cutaneous (Skin) Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524848","Pathologic Stage IIA Cutaneous Melanoma AJCC v8","C137667","Stage IIA includes: (T2b, N0, M0); (T3a, N0, M0). T2b: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: With ulceration. T3a: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","Pathologic Stage IIA Cutaneous Melanoma AJCC v8 | Pathologic Stage IIA Melanoma of the Skin AJCC v8 | Stage IIA | Stage IIA Cutaneous (Skin) Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524847","Pathologic Stage II Cutaneous Melanoma AJCC v8","C137666","Stage II includes: IIA: (T2b, N0, M0); (T3a, N0, M0); IIB: (T3b, N0, M0); (T4a, N0, M0); IIC: (T4b, N0, M0). T2b: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: With ulceration. T3a: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: Without ulceration. T3b: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: With ulceration. T4a: Tumor measuring more than 4.0 mm in thickness. Ulceration status: Without ulceration. T4b: Tumor measuring more than 4.0 mm in thickness. Ulceration status: With ulceration.  N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","Pathologic Stage II Cutaneous Melanoma AJCC v8 | Pathologic Stage II Melanoma of the Skin AJCC v8 | Stage II Cutaneous (Skin) Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524850","Pathologic Stage IB Cutaneous Melanoma AJCC v8","C137665","Stage IB includes: T2a, N0, M0. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","Pathologic Stage IB Cutaneous Melanoma AJCC v8 | Pathologic Stage IB Melanoma of the Skin AJCC v8 | Stage IB | Stage IB Cutaneous (Skin) Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524849","Pathologic Stage IA Cutaneous Melanoma AJCC v8","C137664","Stage IA includes: (T1a, N0, M0); (T1b, N0, M0). T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","Pathologic Stage IA Cutaneous Melanoma AJCC v8 | Pathologic Stage IA Melanoma of the Skin AJCC v8 | Stage IA | Stage IA Cutaneous (Skin) Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524844","Pathologic Stage I Cutaneous Melanoma AJCC v8","C137663","Stage I includes: IA: (T1a, N0, M0); (T1b, N0, M0); IB: (T2a, N0, M0). T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","Pathologic Stage I Cutaneous Melanoma AJCC v8 | Pathologic Stage I Melanoma of the Skin AJCC v8 | Stage I Cutaneous (Skin) Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524843","Pathologic Stage 0 Cutaneous Melanoma AJCC v8","C137662","Stage 0 includes: Tis, N0, M0. Tis: Melanoma in situ. Thickness: Not applicable. Ulceration status: Not applicable. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","Pathologic Stage 0 Cutaneous Melanoma AJCC v8 | Melanoma in situ, unspecified | Pathologic Stage 0 Melanoma of the Skin AJCC v8 | Stage 0 | Stage 0 Cutaneous (Skin) Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524831","Pathologic Stage IV Cutaneous Melanoma AJCC v8","C137677","Stage IV includes: Any T, Tis, Any N, M1. Tis: Melanoma in situ. Thickness: Not applicable. Ulceration status: Not applicable. M1: Evidence of distant metastasis. (AJCC 8th ed.)","Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Melanoma of the Skin AJCC v8 | Stage IV | Stage IV Cutaneous (Skin) Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524827","Pathologic Stage IIID Cutaneous Melanoma AJCC v8","C137675","Stage IIID includes: T4b, N3a/b/c, M0. T4b: Tumor measuring more than 4.0 mm in thickness. Ulceration status: With ulceration.  N3a: Four or more clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. N3b: Four or more nodal metastases, at least one of which was clinically detected, or presence of any number of matted nodes. Presence of in-transit, satellite, and/or microsatellite metastases: No. N3c: Two or more clinically occult nodal metastases. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Melanoma of the Skin AJCC v8 | Stage IIID Cutaneous (Skin) Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524828","Pathologic Stage IIIB Cutaneous Melanoma AJCC v8","C137672","Stage IIIB includes: (T0, N1b, N1c, M0); (T1a/b-T2a, N1b/c or N2b, M0); (T2b/T3a, N1a-N2b, M0). T0: No evidence of primary tumor (e.g., unknown primary or completely regressed melanoma). Thickness: Not applicable. Ulceration status: Not applicable. T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration.  T2b: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: With ulceration. T3a: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: Without ulceration. N1b: One clinically detected nodal metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: No. N1c: No regional lymph node disease. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. N2b: Two or three nodal metastases at least one of which was clinically detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. N1a: One clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. N2a: Two or three clinically occult nodal metastases (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Melanoma of the Skin AJCC v8 | Stage IIIB | Stage IIIB Cutaneous (Skin) Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524852","Pathologic Stage IIIA Cutaneous Melanoma AJCC v8","C137671","Stage IIIA includes: T1a/b-T2a, N1a or N2a, M0. T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. N1a: One clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No.  N2a: Two or three clinically occult nodal metastases (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No.  M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","Pathologic Stage IIIA Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIA Melanoma of the Skin AJCC v8 | Stage IIIA | Stage IIIA Cutaneous (Skin) Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826295","Non-Study Treatment Relationship","C82564","An indication or description of the correlation between a finding or event of interest and a treatment outside the specifications of a study.","Non-Study Treatment Relationship | RELNST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0399839","Bypass Gastrojejunostomy","C51758","Surgical procedure in which the stomach is connected to the jejunum, bypassing the duodenum.","Bypass Gastrojejunostomy | Gastric Bypass | Gastric Bypass Surgery | Roux-en-Y Gastric Bypass",,,,,,,,,,,,,,,"4171187","Bypass gastrojejunostomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0230165","Upper Abdomen","C139562","The superior portion of the abdomen.","Upper Abdomen | ",,,,,,,,,,,,,,,"4149973","Surface region of upper abdomen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1879938","CDISC SDTM Pharmaceutical Dosage Form Terminology","C66726","Terminology codelist used with Pharmaceutical Dosage Form within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.","CDISC SDTM Dosage Form Terminology | CDISC SDTM Pharmaceutical Dosage Form Terminology | Dosage Form | FRM | Pharmaceutical Dosage Form | SDTM-FRM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0193866","Bilateral Modified Radical Neck Dissection","C148527","A surgical procedure in which all the bilateral cervical lymph node groups of the neck are removed but the internal jugular veins, sternocleidomastoid muscles, and/or spinal accessory nerves are preserved.","Bilateral Modified Radical Neck Dissection | Functional (Limited) Neck Dissection | Functional Bilateral Neck Dissection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550981","CD274 Gene Mutation","C148440","A change in the nucleotide sequence of the CD274 gene.","CD274 Gene Mutation | B7-H Gene Mutation | B7H1 Gene Mutation | CD274 Antigen Gene Mutation | CD274 Molecule Gene Mutation | PD-L1 Gene Mutation | PDCD1L1 Gene Mutation | PDCD1LG1 Gene Mutation | PDL1 Gene Mutation | Programmed Cell Death 1 Ligand 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551053","During Hospital or Clinic Visits after Abnormal Screening or Diagnosis","C148492","The time period during a hospital or clinic visit and after when an individual received an abnormal screening or diagnosis.","During Hospital or Clinic Visits after Abnormal Screening or Diagnosis | During All Hospital or Clinic Visits after Abnormal Screening or Diagnosis | Thinking about all the visits you have had to a clinic or hospital, after receiving a diagnosis/abnormal screening",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0189476","Tube Thoracostomy","C148463","A surgical procedure in which a chest tube is inserted between the ribs to drain fluid or air from the pleural cavity.","Tube Thoracostomy | Chest Tube Placement | Chest Tube Thoracostomy",,,,,,,,,,,,,,,"4141919","Insertion of pleural tube drain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL551075","Patient Satisfaction with Cancer Care Questionnaire","C148464","A questionnaire designed measure patient satisfaction with cancer care. It is designed to address: 1) satisfaction with care during screening and treatment, 2) challenges of poor and minority individuals receiving cancer-related care, and 3) relevance for evaluation of care for both navigated and un-navigated patients. The questionnaire is usually administered within 3 months of screening and again 3 months after the initiation of treatment.","Patient Satisfaction with Cancer Care Questionnaire | PSCC | Patient Satisfaction with Cancer Care | Patient Satisfaction with Cancer Care (PSCC) | Patient Satisfaction with Cancer Care Measure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551077","During Most Recent Visit","C148465","Happening during a patient's most recent visit.","During Most Recent Visit | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551072","Health Concerns Were Understood","C148467","A response indicating that an individual feels or felt that their health concerns were understood.","Health Concerns Were Understood | Felt Health Concerns Were Understood | I felt that my health concerns were understood",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551071","Treated with Courtesy and Respect","C148468","A response indicating that an individual feels or felt that they were treated with courtesy and respect.","Treated with Courtesy and Respect | Felt Treated with Courtesy and Respect | I felt that I was treated with courtesy and respect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551074","Included in Decisions About Health","C148469","A response indicating that an individual feels or felt included in decisions about their health.","Included in Decisions About Health | Felt Included in Decisions About Health | I felt included in decisions about my health",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551073","Told How to Take Care of Myself","C148470","A response indicating that an individual was told how to take care of themselves.","Told How to Take Care of Myself | I was told how to take care of myself",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551068","Encouraged to Talk About Personal Health Concerns","C148471","A response indicating that an individual feels or felt encouraged to talk about their personal health concerns.","Encouraged to Talk About Personal Health Concerns | Felt Encouraged to Talk About Personal Health Concerns | I felt encouraged to talk about my personal health concerns",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551067","Had Enough Time With Doctor","C148472","A response indicating that an individual feels or felt that they had enough time with their doctor.","Had Enough Time With Doctor | Felt I Had Enough Time with Doctor | I felt I had enough time with my doctor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551070","My Questions Were Answered to My Satisfaction","C148473","A response indicating that an individual feels or felt that their questions were answered to their satisfaction.","My Questions Were Answered to My Satisfaction | My questions were answered to my satisfaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551069","Making Appointment was Easy","C148474","A response indicating that an individual feels or felt that making an appointment was easy.","Making Appointment was Easy | Making an appointment was easy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551076","After Most Recent Visit","C148466","Happening after a patient's most recent visit.","After Most Recent Visit | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551064","Knew What Next Steps of Care Would Be","C148475","A response indicating that an individual knew what the next steps in their care would be.","Knew What Next Steps of Care Would Be | I knew what the next step in my care would be",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551063","Confident in How I Dealt with Health Care System","C148476","A response indicating that an individual feels or felt confident in how they dealt with the health care system.","Confident in How I Dealt with Health Care System | I felt confident in how I dealt with the health care system",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551066","Able to Get Advice Needed About Health Issues","C148477","A response indicating that an individual was able to get the advice they needed about their health issues.","Able to Get Advice Needed About Health Issues | Able to Get Advice I Needed About My Health Issues | I was able to get the advice I needed about my health issues",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551065","Know Who to Contact for Questions","C148478","A response indicating that an individual knows who to contact when they have a question.","Know Who to Contact for Questions | I knew who to contact when I had a question | Knew Whom to Contact for Questions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551114","Parotid Bed","C148553","The structures that surround and contact the parotid gland, forming the boundaries of the parotid space.","Parotid Bed | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1301931","Time of Death","C99797","The time of day it is determined or presumed that an individual has died.","Time of Death | ",,,,,,,,,,,,,,,"4162388","Time of death",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898900","Healthy","C115935","Having no significant health-related issues.","Healthy | Well",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551109","Components of Primary Care Instrument","C148558","A questionnaire designed to measure key aspects of the delivery of primary care from the perspective of patients visiting their family physician, and to report the association of these aspects with patient satisfaction.","Components of Primary Care Instrument | CPCI | Components of Primary Care Instrument (CPCI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551112","Go to This Doctor for Almost All Medical Care","C148559","A question about whether an individual sees a particular doctor for almost all of their medical care.","Go to This Doctor for Almost All Medical Care | I go to this doctor for almost all of my medical care",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551111","This Doctor Handles Emergencies","C148560","A question about whether an individual's doctor handles emergencies.","This Doctor Handles Emergencies | This doctor handles emergencies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551106","This Doctor Can Take Care of Almost Any Medical Problem I Might Have","C148561","A question about whether an individual's doctor can take care of almost any problem the individual might have.","This Doctor Can Take Care of Almost Any Medical Problem I Might Have | This doctor can take care of almost any medical problem I might have",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551105","I Could Go to This Doctor for Help with Personal or Emotional Problem","C148562","A question about whether an individual could see a particular doctor for help with a personal or emotional problem.","I Could Go to This Doctor for Help with Personal or Emotional Problem | I could go to this doctor for help with a personal or emotional problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551108","I Could Go to This Doctor for Care of Ongoing Problem","C148563","A question about whether an individual could see a particular doctor for an ongoing problem.","I Could Go to This Doctor for Care of Ongoing Problem | I could go to this doctor for care of an ongoing problem such as high blood pressure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551107","This Doctor Knows a Lot About My Family Medical History","C148564","A question about whether an individual's doctor knows a lot about the individual's family medical history.","This Doctor Knows a Lot About My Family Medical History | This doctor knows a lot about my family medical history",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551102","This Doctor Clearly Understands My Health Needs","C148565","A question about whether an individual's doctor understands the individual's health needs.","This Doctor Clearly Understands My Health Needs | This doctor clearly understands my health needs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551101","This Doctor and I Have Been Through a Lot Together","C148566","A question about whether an individual has been through a lot with their doctor.","This Doctor and I Have Been Through a Lot Together | This doctor and I have been through a lot together",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551104","This Doctor Understands What is Important to Me Regarding My Health","C148567","A question about whether an individual's doctor understands what is important to the individual regarding their health.","This Doctor Understands What is Important to Me Regarding My Health | This doctor understands what is important to me regarding my health",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551103","This Doctor Does Not Know My Medical History Very Well","C148568","A question about whether an individual's doctor doesn't know the individual's medical history well.","This Doctor Does Not Know My Medical History Very Well | This doctor does not know my medical history very well",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551098","I Could Go to This Doctor for Check-Up to Prevent Illness","C148569","A question about whether an individual could see a particular doctor for checkups to prevent illness.","I Could Go to This Doctor for Check-Up to Prevent Illness | I could go to this doctor for a check-up to prevent illness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551097","This Doctor Always Takes My Beliefs and Wishes into Account in Caring for Me","C148570","A question about whether an individual's doctor takes the individual's beliefs and wishes into account in caring for them.","This Doctor Always Takes My Beliefs and Wishes into Account in Caring for Me | This doctor always takes my beliefs and wishes into account in caring for me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551100","This Doctor Knows Whether I Exercise, Eat Right, Smoke, or Drink Alcohol","C148571","A question about whether an individual's doctor knows whether the individual exercises, eats right, smokes, or drinks alcohol.","This Doctor Knows Whether I Exercise, Eat Right, Smoke, or Drink Alcohol | This doctor knows whether or not I exercise, eat right, smoke, or drink alcohol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551096","This Doctor Knows Me Well as a Person","C148575","A question about whether an individual's doctor knows the individual well as a person.","This Doctor Knows Me Well as a Person | This doctor knows me well as a person (such as my hobbies, job, etc.)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551095","I Can Easily Talk About Personal Things with This Doctor","C148576","A question about whether an individual could talk about personal things with their doctor.","I Can Easily Talk About Personal Things with This Doctor | I can easily talk about personal things with this doctor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551212","Sometimes This Doctor Does Not Listen to Me","C148577","A question about whether an individual's doctor sometimes does not listen to them.","Sometimes This Doctor Does Not Listen to Me | Sometimes, this doctor does not listen to me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551211","This Doctor Always Explains Things to My Satisfaction","C148578","A question about whether an individual's doctor always explains things to the individual's satisfaction.","This Doctor Always Explains Things to My Satisfaction | This doctor always explains things to my satisfaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551214","Sometimes with This Doctor I Don't Bring Up Things That I'm Worried About","C148579","A question about whether an individual sometimes does not bring up things they are worried about with their doctor.","Sometimes with This Doctor I Don't Bring Up Things That I'm Worried About | Sometimes, with this doctor, I don't bring up things that I'm worried about",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551208","I Don't Always Feel Comfortable Asking Questions of This Doctor","C148581","A question about whether an individual does not always feel comfortable asking questions of their doctor.","I Don't Always Feel Comfortable Asking Questions of This Doctor | I don't always feel comfortable asking questions of this doctor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551210","Sometimes I Feel Like This Doctor Ignores My Concerns","C148583","A question about whether an individual sometimes feels that their doctor ignores the individual's concerns.","Sometimes I Feel Like This Doctor Ignores My Concerns | Sometimes, I feel like this doctor ignores my concerns",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551209","If I am Sick I Would Always Contact a Doctor in This Office First","C148584","A question about whether an individual would contact a doctor in a particular office first when sick.","If I am Sick I Would Always Contact a Doctor in This Office First | If I am sick, I would always contact a doctor in this office first",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551204","My Medical Care Improves When I See the Same Doctor that I Have Seen Before","C148585","A question about whether an individual feels that their medical care improves when they see the same doctor that they have seen before.","My Medical Care Improves When I See the Same Doctor that I Have Seen Before | My medical care improves when I see the same doctor that I have seen before",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551206","It is Very Important to Me to See My Regular Doctor","C148587","A question about whether it is very important for an individual to see the same doctor that they have seen before.","It is Very Important to Me to See My Regular Doctor | It is very important to me to see my regular doctor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551205","I Rarely See the Same Doctor When I Go for Medical Care","C148588","A question about whether an individual rarely sees the same doctor then they go for medical care.","I Rarely See the Same Doctor When I Go for Medical Care | I rarely see the same doctor when I go for medical care",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551200","I Can Call This Doctor if I Have Concern and am Not Sure I Need to See a Doctor","C148589","A question about whether an individual can call a particular doctor if they have a concern and are not sure they need to see a doctor.","I Can Call This Doctor if I Have Concern and am Not Sure I Need to See a Doctor | I can call this doctor if I have a concern and am not sure I need to see a doctor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551199","I Have Tremendous Trust in This Doctor","C148590","A question about whether an individual has tremendous trust in a particular doctor.","I Have Tremendous Trust in This Doctor | I have tremendous trust in this doctor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551202","This Doctor Knows When I'm Due for Checkup","C148591","A question about whether an individual's doctor knows when the individual is due for a checkup.","This Doctor Knows When I'm Due for Checkup | This doctor knows when I'm due for a checkup",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551201","I Want One Doctor to Coordinate All of the Health Care I Receive","C148592","A question about whether an individual wants one doctor to coordinate all of the individual's health care.","I Want One Doctor to Coordinate All of the Health Care I Receive | I want one doctor to coordinate all of the health care I receive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551196","This Doctor Keeps Track of All My Health Care","C148593","A question about whether an individual's doctor tracks all of the individual's health care.","This Doctor Keeps Track of All My Health Care | This doctor keeps track of all my health care",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551195","Follows Up on a Problem I've Had Either at the Next Visit or By Phone","C148594","A question about whether an individual's doctor always follows up on the individual's problem on the phone or at the next visit.","Follows Up on a Problem I've Had Either at the Next Visit or By Phone | This Doctor Always Follows Up on a Problem I've Had Either at the Next Visit or By Phone | This doctor always follows up on a problem I've had, either at the next visit or by phone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551197","I Would Recommend This Doctor to Friends and Family","C148596","A question about whether an individual would recommend their doctor to friends and family.","I Would Recommend This Doctor to Friends and Family | I would recommend this doctor to friends and family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551192","This Doctor Always Has My Best Interests at Heart","C148597","A question about whether an individual's doctor always has the individual's best interests at heart.","This Doctor Always Has My Best Interests at Heart | This doctor always has my best interests at heart",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551191","This Doctor Takes Responsibility for Helping Me Get All the Health Care I Need","C148598","A question about whether an individual's doctor takes responsibility for helping the individual get all the health care they need.","This Doctor Takes Responsibility for Helping Me Get All the Health Care I Need | This doctor takes responsibility for helping me get all the health care I need",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551194","I am Confident This Doctor Will Act as My Advocate","C148599","A question about whether an individual is confident that their doctor will act as the individual's health advocate.","I am Confident This Doctor Will Act as My Advocate | I am confident this doctor will act as my advocate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551188","This Doctor Looks Out for My Interests in Dealing with My Health Insurance","C148601","A question about whether an individual's doctor looks out for the individual's interests in dealing with their health insurer.","This Doctor Looks Out for My Interests in Dealing with My Health Insurance | This doctor looks out for my interests in dealing with my health insurance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551187","I Wonder if This Doctor is Cutting Corners on My Health Care","C148602","A question about whether an individual wonders if their doctor is cutting corners on the individual's health care.","I Wonder if This Doctor is Cutting Corners on My Health Care | I wonder if this doctor is cutting corners on my health care",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551189","This Doctor Helps Me Weigh the Pros and Cons of My Health Care Decisions","C148604","A question about whether an individual's doctor helps the individual to weight the pros and cons of their health care decisions.","This Doctor Helps Me Weigh the Pros and Cons of My Health Care Decisions | This doctor helps me weigh the pros and cons of my health care decisions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551184","This Doctor Guides Me Through the Steps I Need to Deal with My Insurance Plan","C148605","A question about whether an individual's doctor guides the individual through the steps needed to deal with the individual's insurance plan.","This Doctor Guides Me Through the Steps I Need to Deal with My Insurance Plan | This doctor guides me through the steps I need to take to deal with my insurance plan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551183","Other Members of My Family See This Doctor","C148606","A question about whether members of an individual's family see the same doctor.","Other Members of My Family See This Doctor | Other members of my family see this doctor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551186","This Doctor Knows a Lot About My Family","C148607","A question about whether an individual's doctor knows a lot about the individual's family.","This Doctor Knows a Lot About My Family | This doctor knows a lot about my family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551185","This Doctor Understands How My Family Affects My Health","C148608","A question about whether an individual's doctor understands how the individual's family affects the individual's health.","This Doctor Understands How My Family Affects My Health | This doctor understands how my family affects my health",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551180","This Doctor Knows a Lot About My Community","C148609","A question about whether an individual's doctor knows a lot about the individual's community.","This Doctor Knows a Lot About My Community | This doctor knows a lot about my community",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551179","This Doctor Uses Knowledge of My Community to Take Care of Me","C148610","A question about whether an individual's doctor uses their knowledge about the individual's community to take care of the individual..","This Doctor Uses Knowledge of My Community to Take Care of Me | This doctor uses her/his knowledge of my community to take care of me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551182","This Doctor Always Follows Up on My Visits to Other Health Care Providers","C148611","A question about whether an individual's doctor always follows up on the individual's visits to other health care providers.","This Doctor Always Follows Up on My Visits to Other Health Care Providers | This doctor always follows up on my visits to other health care providers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551181","This Doctor Helps Me Interpret My Lab Tests, X-Rays, or Visits to Other Doctors","C148612","A question about whether an individual's doctor helps the individual's to interpret lab results, x-rays, or visits to other health care providers.","This Doctor Helps Me Interpret My Lab Tests, X-Rays, or Visits to Other Doctors | This doctor helps me interpret my lab tests, x-rays or visits to other doctors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551176","This Doctor Communicates with the Other Health Providers I See","C148613","A question about whether an individual's doctor communicates with the individual's other health care providers.","This Doctor Communicates with the Other Health Providers I See | This doctor communicates with the other health providers I see",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551175","This Doctor Does Not Always Know About Care I Have Received at Other Places","C148614","A question about whether an individual's doctor does not always know about the care the individual received from other health care providers.","This Doctor Does Not Always Know About Care I Have Received at Other Places | This doctor does not always know about care I have received at other places",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551178","How Long Been a Patient of This Doctor","C148615","A question about how long an individual has been a patient of a specific doctor.","How Long Been a Patient of This Doctor | Have you been a patient of this doctor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551177","How Long Been a Patient of This Practice","C148616","A question about how long an individual has been a patient of a specific medical practice.","How Long Been a Patient of This Practice | Have you been a patient of this practice | How Long Been Patient of This Practice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551171","Number of Visits to This Doctor","C148618","A question about how many visits an individual has had with a specific doctor.","Number of Visits to This Doctor | Visits have you had to this doctor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551173","Number of Visits to Other Doctors in This Office","C148620","A question about how many visits an individual has had with other doctors at a specific medical office.","Number of Visits to Other Doctors in This Office | Visits have you had to other doctors in this office",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551168","Number of Visits to Doctors Outside of This Office","C148621","A question about how many visits an individual has had with other doctors outside of a specific medical office.","Number of Visits to Doctors Outside of This Office | Visits have you had to doctors outside of this office | Visits to Doctors Outside of This Office | Visits to Doctors Outside of This Office",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551170","Agreement Rating Scale","C148623","A subjective scale for the scoring of agreement that ranges from 1: Strongly Disagree to 6: Strongly Agree.","Agreement Rating Scale | 6 Point Agreement Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551169","Agreement Rating Score 1","C148624","A subjective score of 1 on a scale that ranges from 1: Strongly Disagree to 6: Strongly Agree.","Agreement Rating Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551164","Agreement Rating Score 2","C148625","A subjective score of 2 on a scale that ranges from 1: Strongly Disagree to 6: Strongly Agree.","Agreement Rating Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551166","Agreement Rating Score 3","C148627","A subjective score of 3 on a scale that ranges from 1: Strongly Disagree to 6: Strongly Agree.","Agreement Rating Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551165","Agreement Rating Score 4","C148628","A subjective score of 4 on a scale that ranges from 1: Strongly Disagree to 6: Strongly Agree.","Agreement Rating Score 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551159","Agreement Rating Score 5","C148630","A subjective score of 5 on a scale that ranges from 1: Strongly Disagree to 6: Strongly Agree.","Agreement Rating Score 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551162","Agreement Rating Score 6","C148631","A subjective score of 6 on a scale that ranges from 1: Strongly Disagree to 6: Strongly Agree.","Agreement Rating Score 6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085092","Parenting","C150045","The act or activities involved in being a parent and raising children.","Parenting | ",,,,,,,,,,,,,,,"4224907","Parenting behavior",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL551885","Physical Function","C150046","An individual's capacity to undertake physical activities, such as everyday tasks.","Physical Function | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551881","Overall Comorbidity Score","C150050","Represents the severity grade of organ decompensation for the highest-ranked single comorbid ailment or, in the case in which there are two comorbid ailments in 2 different organ systems each rated as moderate organ decompensation, the overall score is severe.","Overall Comorbidity Score | ACE-27 Overall Comorbidity Score | ACE-27 Overall Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0231187","Decompensation","C150047","The inability of an organ or organ system to maintain homeostasis due to functional overload, often caused by the presence of disease intrinsic to the organ or organ system, or dysfunction in other organ systems.","Decompensation | ",,,,,,,,,,,,,,,"4314553","Decompensation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL551043","MBD1 wt Allele","C148503","Human MBD1 wild-type allele is located in the vicinity of 18q21.1 and is approximately 15 kb in length. This allele, which encodes methyl-CpG-binding domain protein 1, is involved in the inhibition of gene expression.","MBD1 wt Allele | CXXC3 | Methyl-CpG Binding Domain Protein 1 wt Allele | PCM1 | RFT | The Regulator of Fibroblast Growth Factor 2 (FGF-2) Transcription Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551260","Silent Stop Codon Mutation","C148651","A mutation occurring within the stop codon of a gene, which still encodes a stop codon.","Silent Stop Codon Mutation | Stop Retained Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551258","Start Lost Mutation","C148649","A mutation occurring within the start codon of a gene that results in a sequence that no longer encodes a start codon. This can result in a gene deletion or gene transcription may start from an alternative start site.","Start Lost Mutation | Start Lost",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551155","Elongation Mutation","C148640","The mutation of either a splice site or stop codon that leads to an extended transcript.","Elongation Mutation | Feature Elongation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551266","Truncation Mutation","C148641","The mutation of either a splice site or stop codon that leads to a truncated transcript.","Truncation Mutation | Feature Truncation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551265","Intergenic Mutation","C148642","A change in the nucleotide sequence of a region between gene loci.","Intergenic Mutation | Intergenic Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551268","Non-Sense Mediated Decay Mutation","C148643","A mutation occurring in a sequence that regulates non-sense mediated mRNA decay.","Non-Sense Mediated Decay Mutation | NMD Mutation | NMD Transcript Variant | NONSENSE MEDIATED DECAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551267","Non-Coding Gene Mutation","C148644","A change in the nucleotide sequence of a non-coding gene.","Non-Coding Gene Mutation | Non-Coding Gene Exon Mutation | Non-Coding Transcript Variant | Noncoding Gene Mutation | Untranslated Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551262","Non-Coding Gene Exon Mutation","C148645","A change in the nucleotide sequence of an exon in a non-coding gene.","Non-Coding Gene Exon Mutation | Non-Coding Gene Mutation | Non-Coding Transcript Exon Variant | Noncoding Gene Exon Mutation | Untranslated Gene Exon Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551264","Regulatory Region Deletion","C148647","A deletion mutation where the deleted sequence includes a regulatory region for a gene.","Regulatory Region Deletion | Regulatory Region Ablation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551263","Regulatory Region Amplification","C148648","An increase in the copy number of a region containing a regulatory sequence for a gene.","Regulatory Region Amplification | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551261","Regulatory Region Mutation","C148646","A change in the nucleotide sequence of a regulatory region for a gene.","Regulatory Region Mutation | Regulatory Region Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551259","Transcription Factor Binding Site Mutation","C148652","A change in the nucleotide sequence of a transcription factor binding site for a gene.","Transcription Factor Binding Site Mutation | TF Binding Site Variant | TFBS Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551256","Transcription Factor Binding Site Deletion Mutation","C148653","A deletion mutation where the deleted sequence includes a transcription factor binding site for a gene.","Transcription Factor Binding Site Deletion Mutation | TFBS Ablation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551255","Transcription Factor Binding Site Amplification","C148654","An increase in the copy number of a region containing a transcription factor binding site for a gene.","Transcription Factor Binding Site Amplification | TFBS Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551257","Nonstop Mutation","C148650","A mutation occurring within the stop codon of a gene that results in a sequence that no longer encodes a stop codon and results in the transcription of non-coding regions downstream of the gene.","Nonstop Mutation | Read-Through Mutation | Stop Lost",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3843089","Less Than One Year","C148655","An indication that something has lasted, or occurred during, less than one year.","Less Than One Year | Less than 1 Year | Less than one year",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3843646","One to Two Years","C148656","An indication that something has lasted, or occurred during, one to two years.","One to Two Years | 1 to 2 Years | One to two years",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551252","Three to Five Years","C148657","An indication that something has lasted, or occurred during, three to five years.","Three to Five Years | 3 to 5 Years | Three to five years",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551251","Six to Ten Years","C148658","An indication that something has lasted, or occurred during, six to ten years.","Six to Ten Years | 6 to 10 Years | Six to ten years",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551254","Eleven to Fifteen Years","C148659","An indication that something has lasted, or occurred during, 11 to 15 years.","Eleven to Fifteen Years | 11 to 15 Years | Eleven to 15 years",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551253","Sixteen to Twenty Years","C148660","An indication that something has lasted, or occurred during, 16 to 20 years.","Sixteen to Twenty Years | 16 to 20 Years | Sixteen to 20 years",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551248","Twenty Years or More","C148661","An indication that something has lasted, or occurred during, 20 years or more.","Twenty Years or More | Greater than or Equal to 20 Years | Twenty years or more",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1561310","Grade 4 Confusion, CTCAE","C55383","Life-threatening consequences; urgent intervention indicated","Grade 4 Confusion, CTCAE | Grade 4 Confusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1561309","Grade 3 Confusion, CTCAE","C55382","Severe disorientation; limiting self care ADL","Grade 3 Confusion, CTCAE | Grade 3 Confusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1561308","Grade 2 Confusion, CTCAE","C55381","Moderate disorientation; limiting instrumental ADL","Grade 2 Confusion, CTCAE | Grade 2 Confusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1561307","Grade 1 Confusion, CTCAE","C55380","Mild disorientation","Grade 1 Confusion, CTCAE | Grade 1 Confusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543873","Grade 4 Depressed Level of Consciousness, CTCAE","C145816","Life-threatening consequences; coma; urgent intervention indicated","Grade 4 Depressed Level of Consciousness, CTCAE | Grade 4 Depressed level of consciousness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543401","Grade 3 Depressed Level of Consciousness, CTCAE","C145221","Difficult to arouse","Grade 3 Depressed Level of Consciousness, CTCAE | Grade 3 Depressed level of consciousness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542825","Grade 2 Depressed Level of Consciousness, CTCAE","C144604","Sedation; slow response to stimuli; limiting instrumental ADL","Grade 2 Depressed Level of Consciousness, CTCAE | Grade 2 Depressed level of consciousness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542312","Grade 1 Depressed Level of Consciousness, CTCAE","C144051","Decreased level of alertness","Grade 1 Depressed Level of Consciousness, CTCAE | Grade 1 Depressed level of consciousness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551845","Undecided","C150084","A response indicating that a decision has or had not been made.","Undecided | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551848","Received All the Services Needed","C150085","A response indicating that an individual feels or felt that they received all the services they needed.","Received All the Services Needed | I received all the services I needed | Received All the Services I Needed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551847","Satisfied With the Care Received","C150086","A response indicating that an individual feels or felt that they are satisfied with the care they received.","Satisfied With the Care Received | I was satisfied with the care I received | Satisfied With the Care I Received",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551842","Doctors Seemed to Communicate Well About Care","C150087","A response indicating that an individual feels or felt that doctors seemed to communicate well about their care.","Doctors Seemed to Communicate Well About Care | Doctors Seemed to Communicate Well About My Care | The doctors seemed to communicate well about my care",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551841","Received High Quality Care From Regular Doctor","C150088","A response indicating that an individual feels or felt that they received high quality care from their regular doctor.","Received High Quality Care From Regular Doctor | I received high quality care from my regular doctor | Received High Quality Care From My Regular Doctor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551844","Received High Quality Care From Specialists","C150089","A response indicating that an individual feels or felt that they received high quality care from their specialists.","Received High Quality Care From Specialists | I received high quality care from my specialists | Received High Quality Care From My Specialists",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551843","Regular Doctor was Informed About the Results of Test","C150090","A response indicating that an individual feels or felt that their regular doctor was informed about the results of the test they got.","Regular Doctor was Informed About the Results of Test | My Regular Doctor was Informed About the Results of the Test I Got | My regular doctor was informed about the results of the test I got",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272500","CD274 wt Allele","C96023","Human CD274 wild-type allele is located in the vicinity of 9p24 and is approximately 20 kb in length. This allele, which encodes programmed cell death 1 ligand 1 protein, plays a role in the regulation of T cell stimulation and proliferation.","CD274 wt Allele | B7-H | B7H1 | CD274 Antigen Gene | CD274 Molecule wt Allele | MGC142294 | MGC142296 | PD-L1 | PDCD1L1 | PDCD1LG1 | PDL1 | Programmed Cell Death 1 Ligand 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1557289","Grade 5 Seizure, CTCAE","C55582","Death","Grade 5 Seizure, CTCAE | Grade 5 Seizure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1557288","Grade 4 Seizure, CTCAE","C55581","Life-threatening consequences; prolonged repetitive seizures","Grade 4 Seizure, CTCAE | Grade 4 Seizure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1557287","Grade 3 Seizure, CTCAE","C55580","New onset seizures (partial or generalized); multiple seizures despite medical intervention","Grade 3 Seizure, CTCAE | Grade 3 Seizure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1557286","Grade 2 Seizure, CTCAE","C55579","Brief generalized seizure","Grade 2 Seizure, CTCAE | Grade 2 Seizure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542524","Grade 1 Seizure, CTCAE","C144392","Brief partial seizure and no loss of consciousness","Grade 1 Seizure, CTCAE | Grade 1 Seizure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1557304","Grade 3 Tremor, CTCAE","C55599","Severe symptoms; limiting self care ADL","Grade 3 Tremor, CTCAE | Grade 3 Tremor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1557303","Grade 2 Tremor, CTCAE","C55598","Moderate symptoms; limiting instrumental ADL","Grade 2 Tremor, CTCAE | Grade 2 Tremor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1557302","Grade 1 Tremor, CTCAE","C55597","Mild symptoms","Grade 1 Tremor, CTCAE | Grade 1 Tremor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543936","Grade 4 Hallucinations, CTCAE","C145882","Life-threatening consequences, threats of harm to self or others; hospitalization indicated","Grade 4 Hallucinations, CTCAE | Grade 4 Hallucinations",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543436","Grade 3 Hallucinations, CTCAE","C145323","Severe hallucinations; hospitalization not indicated","Grade 3 Hallucinations, CTCAE | Grade 3 Hallucinations",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542858","Grade 2 Hallucinations, CTCAE","C144703","Moderate hallucinations","Grade 2 Hallucinations, CTCAE | Grade 2 Hallucinations",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542352","Grade 1 Hallucinations, CTCAE","C144141","Mild hallucinations (e.g., perceptual distortions)","Grade 1 Hallucinations, CTCAE | Grade 1 Hallucinations",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1558949","Grade 5 Tumor Lysis Syndrome, CTCAE","C56632","Death","Grade 5 Tumor Lysis Syndrome, CTCAE | Grade 5 Tumor lysis syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544210","Grade 4 Tumor Lysis Syndrome, CTCAE","C146159","Life-threatening consequences; urgent intervention indicated","Grade 4 Tumor Lysis Syndrome, CTCAE | Grade 4 Tumor lysis syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1558948","Grade 3 Tumor Lysis Syndrome, CTCAE","C56620","Present","Grade 3 Tumor Lysis Syndrome, CTCAE | Grade 3 Tumor lysis syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551920","Tumor Mutation Burden","C150128","The total number of genomic alterations found in the cells of a cancer.","Tumor Mutation Burden | MUTATED_ALLELE | Mutated Allele | TMB | Tumor Mutational Burden",,,,,,,,,,,,,,,"37161542","Tumor mutational burden",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL551923","Circulating Protein","C150129","Protein found in the peripheral blood.","Circulating Protein | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827964","Specimen Weight Measurement","C106569","A quantitative measurement of the weight of a biological specimen.","Specimen Weight Measurement | SPWEIGHT | Specimen Weight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033613","Protective Agents","C26170","A class of agents used in prophylactic or curative therapy to attenuate the negative side effects of toxins or drugs.  Protective agents belong to various chemical classes, acting through various pharmacological mechanisms.  They may neutralize exogenous poisons, coat mucosa for protection against physical or chemical damage, offer antioxidant protection against free radicals or ionizing radiation, or induce endogenous detoxifying enzymes. (NCI04)","Protective Agent | Protective Drug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543385","Grade 3 Dysphasia, CTCAE","C145238","Severe receptive or expressive characteristics; impairing ability to read, write or communicate intelligibly","Grade 3 Dysphasia, CTCAE | Grade 3 Dysphasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542810","Grade 2 Dysphasia, CTCAE","C144622","Moderate receptive or expressive characteristics; impairing ability to communicate spontaneously","Grade 2 Dysphasia, CTCAE | Grade 2 Dysphasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542294","Grade 1 Dysphasia, CTCAE","C144066","Awareness of receptive or expressive characteristics; not impairing ability to communicate","Grade 1 Dysphasia, CTCAE | Grade 1 Dysphasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1561283","CTCAE Grade 3 Ataxia (incoordination)","C55353","Severe symptoms; limiting self care ADL; mechanical assistance indicated","Grade 3 Ataxia, CTCAE | CTCAE Grade 3 Ataxia (incoordination) | Grade 3 Ataxia | Grade 3 Ataxia (incoordination)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1561282","CTCAE Grade 2 Ataxia (incoordination)","C55352","Moderate symptoms; limiting instrumental ADL","Grade 2 Ataxia, CTCAE | CTCAE Grade 2 Ataxia (incoordination) | Grade 2 Ataxia | Grade 2 Ataxia (incoordination)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1561281","CTCAE Grade 1 Ataxia (incoordination)","C55351","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Ataxia, CTCAE | CTCAE Grade 1 Ataxia (incoordination) | Grade 1 Ataxia | Grade 1 Ataxia (incoordination)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544451","Grade 5 Nervous System Disorders - Other, Specify, CTCAE","C146455","Death","Grade 5 Nervous System Disorders - Other, Specify, CTCAE | Grade 5 Nervous system disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544082","Grade 4 Nervous System Disorders - Other, Specify, CTCAE","C146011","Life-threatening consequences; urgent intervention indicated","Grade 4 Nervous System Disorders - Other, Specify, CTCAE | Grade 4 Nervous system disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543663","Grade 3 Nervous System Disorders - Other, Specify, CTCAE","C145485","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL","Grade 3 Nervous System Disorders - Other, Specify, CTCAE | Grade 3 Nervous system disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542971","Grade 2 Nervous System Disorders - Other, Specify, CTCAE","C144863","Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL","Grade 2 Nervous System Disorders - Other, Specify, CTCAE | Grade 2 Nervous system disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542482","Grade 1 Nervous System Disorders - Other, Specify, CTCAE","C144287","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Nervous System Disorders - Other, Specify, CTCAE | Grade 1 Nervous system disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0857751","Erythema Multiforme Minor","C8924","Self-limiting form of erythema multiforme.","Erythema Multiforme Minor | ",,,,,,,,,,,,,,,"46270026","Erythema multiforme minor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005477","Biochemistry","C16337","The study of the chemical substances and vital processes occurring in living organisms.","Biochemistry | Chemistry, Biological",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985658","Oversight Committee","C93446","An organization that approves, monitors and reviews biomedical research to protect the rights, safety and welfare of the study subjects. This committee performs critical oversight functions for research conducted on human study subjects that are scientific, ethical, and regulatory.Institutional Review Board (IRB), ethics committee, research ethics board, etc.","Oversight Committee | OversightCommittee",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050223","Progressive Metabolic Disease","C123608","An increase of metabolic tumor activity in all relevant lesions, based on pre-defined thresholds, or the development of new lesions.","Progressive Metabolic Disease | PMD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011211","Delivery of Health Care","C15219","The provision of medical care.","Health Care Delivery | Care Delivery | Health Services Delivery, Other | Healthcare Delivery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162648","Telemedicine","C15380","The use of telecommunications technology to provide, enhance, or expedite health care services, as by accessing off-site databases, linking clinics or physicians' offices to central hospitals, or transmitting x-rays or other diagnostic images for examination at another site. (Bartleby.com)","Telemedicine | Telehealth | telemedicine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544355","Grade 5 Depressed Level of Consciousness, CTCAE","C146276","Death","Grade 5 Depressed Level of Consciousness, CTCAE | Grade 5 Depressed level of consciousness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544424","Grade 5 Hallucinations, CTCAE","C146332","Death","Grade 5 Hallucinations, CTCAE | Grade 5 Hallucinations",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025853","Metoclopramide","C62046","A substituted benzamide and a derivative of para-aminobenzoic acid (PABA) that is structurally related to procainamide, with gastroprokinetic and antiemetic effects. Metoclopramide exerts its prokinetic effect by antagonizing dopamine mediated relaxation effect on gastrointestinal smooth muscle. This enhances the response of the gastrointestinal smooth muscle to cholinergic stimulation, thereby leading to an increase of gastric emptying into the intestines. Metoclopramide may also strengthen the lower esophagus sphincter, thereby preventing acid reflux. This agent antagonizes D2 dopamine receptors in chemoreceptive trigger zone (CTZ) of the medulla, thereby preventing nausea and vomiting.","Metoclopramide | METOCLOPRAMIDE | metoclopramide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012522","Diphenhydramine","C61728","A first generation antihistamine and ethanolamine with sedative and anti-allergic properties. Diphenhydramine competitively inhibits the histamine-1 (H1) receptor, thereby alleviating the symptoms caused by endogenous histamine on bronchial, capillary and gastrointestinal smooth muscles. This prevents histamine-induced bronchoconstriction, vasodilation, increased capillary permeability, and GI smooth muscle spasms.","Diphenhydramine | 2-(Diphenylmethoxy)-N,N-dimethylethylamine | DIPHENHYDRAMINE | FAR 90X2 | O-Benzhydryldimethylaminoethanol | PM 255 | Probedryl | Rigidyl | S51 | Syntedril | diphenhydramine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242896","Anticholinergic Agent","C66880","Any agent that binds to and blocks nicotinic and/or muscarinic receptors, thereby preventing the actions of the neurotransmitter acetylcholine (Ach) at these receptors.","Anticholinergic Agent | Cholinergic Antagonist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036442","Scopolamine","C47712","A tropane alkaloid derived from plants of the nightshade family (Solanaceae), specifically Hyoscyamus niger and Atropa belladonna, with anticholinergic, antiemetic and antivertigo properties. Structurally similar to acetylcholine, scopolamine antagonizes acetylcholine activity mediated by muscarinic receptors located on structures innervated by postganglionic cholinergic nerves as well as on smooth muscles that respond to acetylcholine but lack cholinergic innervation. The agent is used to cause mydriasis, cycloplegia, to control the secretion of saliva and gastric acid, to slow gut motility, and prevent vomiting.","Scopolamine | 1alphaH,5alphaH-Tropan-3alpha-ol, 6beta,7beta-epoxy-,(-)-tropate(ester) | 6,7-Epoxytropine Tropate | 6beta,7beta-Epoxy-3alpha-tropanyl S-(-)-tropate | Atrochin | Benzeneacetic Acid, alpha-(hydroxymethyl)-,(1alpha,2beta,4beta,5alpha,7beta)-9-methyl-3-oxa-9-azatricyclo(3.3.1.02,4)non-7-yl ester,(alphaS)- | Epoxytropine Tropate | Hyoscine | SCOPOLAMINE | Scopoderm | Transderm Scop",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0991556","Skin Patch Dosage Form","C28276","A patch intended for administration to the skin.","Skin Patch Dosage Form | Cutaneous patch | Skin Patch | Skin Patch Dose Form | Transdermal Patch | Transepidermal Patch | skin patch",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551910","Clinically Significant Anxiety Symptoms","C150139","An indication that an individual's anxiety symptoms are or were clinically significant.","Clinically Significant Anxiety Symptoms | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551909","Clinically Significant Depressive Symptoms","C150140","An indication that an individual's depressive symptoms are or were clinically significant.","Clinically Significant Depressive Symptoms | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552051","Hepatic Artery Infusion Pump","C150247","A pump designed to adminster chemotherapy directly to the liver via the hepatic artery.","Hepatic Artery Infusion Pump | HAI Pump | HAIP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552052","Perfusion","C150246","The passage of fluid through the vessels of a specific organ or tissue.","Perfusion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552049","Hepatic Perfusion Imaging","C150245","Any imaging procedure designed to assess the state of fluid flow through the liver.","Hepatic Perfusion Imaging | Hepatic Perfusion Scan | Hepatic Perfusion Study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013964","Emergency Medicine","C105685","The medical specialty concerned with the prompt diagnosis and treatment of injuries, trauma, or sudden illness.","Emergency Medicine | ",,,,,,,,,,,,,,,"36674375","Emergency medicine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015607","Family Practice","C89796","A medical specialty that provides comprehensive health care for all members of a family regardless of age or sex.","Family Practice | Family Medicine | General Practice",,,,,,,,,,,,,,,"4304711","Family practice",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL524908","Radiation Boost","C137812","One or more extra radiation treatments targeted at the tumor bed, given after the regular sessions of radiation are complete.","Radiation Boost | BOOST | Boost Radiation | Boost Radiation Therapy | Boost Radiotherapy | Radiation Therapy Boost | Radiotherapy Boost",,,,,,,,,,,,,,,"40482853","Boost radiation therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0857490","Granulocyte Count","C96654","The determination of the amount of granulocytes present in a sample.","Granulocyte Count | GRAN | Granulocytes | Polymorphonuclear Leukocytes",,,,,,,,,,,,,,,"4041973","Granulocyte count",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL551897","ACTG1 Gene","C150159","This gene plays a role in cell motility.","ACTG1 Gene | ACTG1 | Actin Gamma 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551999","ADAMTS20 Gene","C150165","This gene is involved in both tissue-remodeling and proteolysis.","ADAMTS20 Gene | ADAM Metallopeptidase with Thrombospondin Type 1 Motif 20 Gene | ADAMTS20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551995","ANKRD24 Gene","C150169","This gene plays a role in the modulation of protein-protein interactions.","ANKRD24 Gene | ANKRD24 | Ankyrin Repeat Domain 24 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551992","ARFGAP3 Gene","C150172","This gene is involved in the modulation of ADP-ribosylation factor 1-mediated signaling.","ARFGAP3 Gene | ADP Ribosylation Factor GTPase Activating Protein 3 Gene | ARFGAP3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551988","BOD1L1 Gene","C150176","This gene plays a role in the protection of DNA replication forks.","BOD1L1 Gene | BOD1L1 | Biorientation of Chromosomes in Cell Division 1 Like 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551984","CACNA1E Gene","C150180","This gene is involved in depolarization of neuronal membranes.","CACNA1E Gene | CACNA1E | Calcium Voltage-Gated Channel Subunit Alpha1 E Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551974","CACNA1S Gene","C150193","This gene plays a role in muscle cell membrane depolarization.","CACNA1S Gene | CACNA1S | Calcium Voltage-Gated Channel Subunit Alpha1 S Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509813","Nuclear Radiology Imaging Procedure","C127514","Any type of imaging method that uses radioactive materials.","Nuclear Radiology Imaging Procedure | NUCLEAR RADIOLOGY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0750610","Gastric Vein","C32665","Either of two veins (left gastric and right gastric) that drain blood away from the stomach and lesser curvature.","Gastric Vein | ",,,,,,,,,,,,,,,"4005975","Structure of gastric vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0226311","Gastroduodenal Artery","C150362","A small artery located in the abdomen that arises from the common, left, or right hepatic artery, and supplies blood to the pylorus of the stomach, the proximal duodenum, and the head of the pancreas.","Gastroduodenal Artery | ",,,,,,,,,,,,,,,"4291165","Structure of gastroduodenal artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL551968","CDH20 Gene","C150203","This gene is involved in calcium-dependent cell-cell adhesion.","CDH20 Gene | CDH20 | Cadherin 20 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551953","CMPK1 Gene","C150214","This gene plays a role in the synthesis of pyrimidine nucleoside diphosphates.","CMPK1 Gene | CMPK1 | Cytidine/Uridine Monophosphate Kinase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551950","DNAH9 Gene","C150218","This gene is involved in cilium movement.","DNAH9 Gene | DNAH9 | Dynein Axonemal Heavy Chain 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551948","EPHB6 Gene","C150223","This gene plays a role in ephrin-B signal transduction.","EPHB6 Gene | EPH Receptor B6 Gene | EPHB6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551945","FGA Gene","C150227","This gene is involved in fibrin formation.","FGA Gene | FGA | Fibrinogen Alpha Chain Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552061","FOXP4 Gene","C150232","This gene plays a role in the tissue-specific repression of gene transcription.","FOXP4 Gene | FOXP4 | Forkhead Box P4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552057","FZR1 Gene","C150236","This gene is involved in the regulation of protein ubiquitination and the cell cycle.","FZR1 Gene | FZR1 | Fizzy and Cell Division Cycle 20 Related 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552054","ADGRA2 Gene","C150239","This gene plays a role in endothelial cell migration.","ADGRA2 Gene | ADGRA2 | Adhesion G Protein-Coupled Receptor A2 Gene | GPR124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552047","GSN Gene","C150249","This gene is involved in the regulation of actin filament polymerization.","GSN Gene | GSN | Gelsolin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272411","Gastric Mixed Adenoneuroendocrine Carcinoma","C95886","A carcinoma that arises from the stomach and is characterized by the presence of a malignant glandular epithelial component and a malignant neuroendocrine component.  At least 30 percent of either component should be present for the diagnosis to be made.","Gastric Mixed Adenoneuroendocrine Carcinoma | Gastric (Stomach) Mixed Adenoneuroendocrine Cancer | Gastric MANEC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333788","Gastric Small Cell Carcinoma","C6764","An aggressive high-grade carcinoma with neuroendocrine differentiation that arises from the stomach and is composed of malignant small cells. The mitotic count is more than 20 per 2 mm2 and/or the Ki-67 index is more than 20%.","Gastric Small Cell Neuroendocrine Carcinoma | Gastric Oat Cell Carcinoma | Gastric Small Cell Carcinoma | Gastric Small Cell Carcinoma | Gastric Small Cell Neuroendocrine Carcinoma | Oat Cell Carcinoma of Stomach | Oat Cell Carcinoma of the Stomach | Small Cell Carcinoma of Stomach | Small Cell Carcinoma of the Stomach",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987397","Gastric Carcinoma with Lymphoid Stroma","C95748","A rare adenocarcinoma that arises from the gastric mucosa and is characterized by the presence of prominent lymphocytic stromal infiltration and poorly formed tubular structures.","Gastric Carcinoma with Lymphoid Stroma | Gastric Lymphoepithelioma-Like Carcinoma | Gastric Medullary Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0343378","Helicobacter Pylori-Associated Gastritis","C27121","Inflammation of the stomach that is associated with Helicobacter Pylori.","Helicobacter Pylori-Associated Gastritis | Helicobacter Gastritis",,,,,,,,,,,,,,,"45769496","Helicobacter pylori-associated gastritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3274416","Megakaryoblast Cell Count","C98752","The determination of the amount of megakaryoblasts present in a sample.","Megakaryoblast Cell Count | BLSTMGK | Megakaryoblasts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552045","HCAR1 Gene","C150255","This gene plays a role in lactate-dependent signaling.","HCAR1 Gene | HCAR1 | Hydroxycarboxylic Acid Receptor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552042","HNRNPK Gene","C150258","This gene is involved in binding to poly-cytidine sequences in pre-mRNA and single-stranded DNA.","HNRNPK Gene | HNRNPK | Heterogeneous Nuclear Ribonucleoprotein K Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552035","CILK1 Gene","C150261","This gene plays a role in ciliogenesis and intraflagellar transport.","CILK1 Gene | CILK1 | CLIK1 Gene | Ciliogenesis Associated Kinase 1 Gene | Ciliogenesis Associated Kinase 1 Gene Gene | ICK | ICK Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552032","ING4 Gene","C150264","This gene is involved in acetylation of histone H3 and histone H4.","ING4 Gene | ING4 | Inhibitor of Growth Family Member 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552033","ITGA10 Gene","C150267","This gene plays a role in collagen binding.","ITGA10 Gene | ITGA10 | Integrin Subunit Alpha 10 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552030","ITGA9 Gene","C150270","This gene is involved in cell-matrix adhesion-dependent signaling.","ITGA9 Gene | ITGA9 | Integrin Subunit Alpha 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552020","LYZ Gene","C150276","This gene is involved in bacterial cell wall peptidoglycan metabolism.","LYZ Gene | LYZ | Lysozyme Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552021","MARK1 Gene","C150279","This gene plays a role in both cell polarity and microtubule dynamics.","MARK1 Gene | MARK1 | Microtubule Affinity Regulating Kinase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552017","NUP93 Gene","C150284","This gene is involved in both nuclear pore formation and nuclear import.","NUP93 Gene | NUP93 | Nucleoporin 93 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552013","PCDHAC2 Gene","C150288","This gene plays a role in homophilic cell adhesion.","PCDHAC2 Gene | PCDHAC2 | Protocadherin Alpha Subfamily C, 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552010","PGAP3 Gene","C150291","This gene is involved in lipid remodeling of glycophosphoinositol anchors.","PGAP3 Gene | PGAP3 | Post-GPI Attachment to Proteins 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552006","PKD1L2 Gene","C150295","This gene may play a role in calcium channel regulation and G protein-coupled receptor activity.","PKD1L2 Gene | PKD1L2 | Polycystin 1 Like 2 (Gene/Pseudogene) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552124","PKHD1 Gene","C150298","This gene may be involved in signaling and differentiation of the collecting duct and biliary system.","PKHD1 Gene | PKHD1 | PKHD1, Fibrocystin/Polyductin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552121","PLEKHG5 Gene","C150301","This gene plays a role in transforming protein RhoA- and nuclear factor kappa B-dependent signaling.","PLEKHG5 Gene | PLEKHG5 | Pleckstrin Homology and RhoGEF Domain Containing G5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552122","RNF2 Gene","C150304","This gene is involved in monoubiquitination of lysine-119 of histone H2A and transcriptional repression.","RNF2 Gene | RNF2 | Ring Finger Protein 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552119","RPS6KA2 Gene","C150307","This gene plays a role in the regulation of transcription, cellular proliferation, differentiation, and survival.","RPS6KA2 Gene | RPS6KA2 | Ribosomal Protein S6 Kinase A2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552115","RYR1 Gene","C150311","This gene is involved in the release of calcium ions from the sarcoplasmic reticulum and from intracellular stores in neurons.","RYR1 Gene | RYR1 | Ryanodine Receptor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552108","SAMD9 Gene","C150314","This gene may play a role in endosomal vesicle fusion, extra-osseous calcification and inflammatory responses.","SAMD9 Gene | SAMD9 | Sterile Alpha Motif Domain Containing 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539750","SEPTIN9 Gene","C97897","This gene plays a role in actin filament dynamics.","SEPTIN9 Gene | SEPT9 | SEPT9 Gene | SEPT9 Gene | SEPTIN9 | Septin 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552107","SMUG1 Gene","C150319","This gene is involved in the initiation of DNA base excision repair.","SMUG1 Gene | SMUG1 | Single-Strand-Selective Monofunctional Uracil-DNA Glycosylase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552101","SP140 Gene","C150321","This gene may play a role in transcriptional activation in leukocytes.","SP140 Gene | SP140 | SP140 Nuclear Body Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552102","STK36 Gene","C150324","This gene is involved in the regulation of GLI zinc-finger transcription factor family activity.","STK36 Gene | STK36 | Serine/Threonine Kinase 36 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552099","SYNE1 Gene","C150327","This gene plays a role in subcellular spatial organization.","SYNE1 Gene | SYNE1 | Spectrin Repeat Containing Nuclear Envelope Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552092","SYT1 Gene","C150330","This gene is involved in synaptic vesicle trafficking.","SYT1 Gene | SYT1 | Synaptotagmin 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552089","TAF1L Gene","C150333","This gene plays a role in transcription initiation during male meiosis.","TAF1L Gene | TAF1L | TATA-Box Binding Protein Associated Factor 1 Like Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552090","TBX22 Gene","C150336","This gene is involved in transcriptional regulation and development of the palate.","TBX22 Gene | T-Box 22 Gene | TBX22",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552087","TCF7L1 Gene","C150339","This gene plays a role in catenin beta-1-dependent transcriptional regulation.","TCF7L1 Gene | TCF7L1 | Transcription Factor 7 Like 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552080","TGM7 Gene","C150342","This gene is involved in the conjugation of polyamines to and cross-linking of proteins.","TGM7 Gene | TGM7 | Transglutaminase 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552076","UMODL1 Gene","C150346","This gene may play a role in development of visual and olfactory pathways.","UMODL1 Gene | UMODL1 | Uromodulin Like 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552073","VIPR2 Gene","C150349","This gene is involved in the regulation of vasoactive intestinal peptide (VIP)- and pituitary adenylate cyclase-activating peptide (PACAP)-mediated signaling.","VIPR2 Gene | VIPR2 | Vasoactive Intestinal Peptide Receptor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552074","ZBTB7B Gene","C150352","This gene plays a role in the regulation of T-cell lineage commitment and the repression of collagen gene expression.","ZBTB7B Gene | ZBTB7B | Zinc Finger and BTB Domain Containing 7B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552071","ZSWIM4 Gene","C150355","This gene is involved in zinc binding.","ZSWIM4 Gene | ZSWIM4 | Zinc Finger SWIM-Type Containing 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552023","ADGRL3 Gene","C150273","This gene plays a role in cell-cell adhesion, G protein-coupled receptor signaling and neuronal migration.","ADGRL3 Gene | ADGRL3 | Adhesion G Protein-Coupled Receptor L3 Gene | LPHN3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0949266","Therapies, Investigational","C142589","Any agent or product being assessed in a clinical trial.","Investigational Treatment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550924","PSA Level Two to Ten","C148266","A blood concentration of prostate specific antigen between 2 and 10 ng/mL.","PSA Level Two to Ten | PSA Level 2 to 10 | PSA Level Between 2 and 10 | PSA Level Between Two and Ten",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0262506","Hepatitis B Virus Core Antibody Positive","C148282","An indication that antibodies that recognize a hepatitis B virus core protein have been detected in a sample.","Hepatitis B Virus Core Antibody Positive | Anti-HBc Antibody Positive | Anti-HBc Positive | Anti-HBcAb Positive | Anti-Hepatitis B Core Antibody Positive | Anti-Hepatitis B Virus Core Antibody Positive | HBcAb Positive | Hepatitis B Core Antibody Positive | Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550909","TET2 Gene Mutation","C148283","A change in the nucleotide sequence of the TET2 gene.","TET2 Gene Mutation | KIAA1546 Gene Mutation | Tet Methylcytosine Dioxygenase 2 Gene Mutation | Tet Oncogene Family Member 2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550905","Blasts More than 25 Percent of Bone Marrow Nucleated Cells","C148287","A semi-quantitative microscopic finding indicating that more than 25 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts More than 25 Percent of Bone Marrow Nucleated Cells | Blasts Greater than 25 Percent of Bone Marrow Nucleated Cells | Blasts Over 25 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523720","PDGFR Family Gene Mutation","C136417","A change in the nucleotide sequence in a PDGFR family gene.","PDGFR Family Gene Mutation | Mutant PDGFR | Mutant PDGFR Family Gene | PDGFR Family Mutation | PDGFR Mutation | Platelet Derived Growth Factor Receptor Family Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550936","Cytomegalovirus DNA","C148379","The viral DNA that originates from cytomegalovirus.","Cytomegalovirus DNA | CMV DNA | HHV-5 DNA | HHV5 DNA | Human Herpes Virus 5 DNA | Human Herpes Virus-5 DNA | Human Herpesvirus 5 DNA | Human Herpesvirus-5 DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551028","MUC16 Ectodomain Antigen Positive","C148381","An indication that a soluble form of the extracellular domain of the mucin-16 protein has been detected in a sample. This is a marker for intramembrane cleavage of mucin-16.","MUC16 Ectodomain Antigen Positive | MUC16 ecto Antigen Positive | Mucin 16 Ectodomain Antigen Positive | Mucin-16 Ectodomain Antigen Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551120","CMV Reactivation","C148545","A laboratory test result indicating that a previously latent cytomegalovirus infection has become an active infection.","Cytomegalovirus Reactivation Finding | CMV Reactivation | Cytomegalovirus Reactivation | Cytomegalovirus Reactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551010","MET Overexpression Positive","C148403","An indication that overexpression of MET has been detected in a sample.","MET Overexpression Positive | HGFR Overexpression Positive | Hepatocyte Growth Factor Receptor Overexpression Positive | MET Proto-Oncogene, Receptor Tyrosine Kinase Overexpression Positive | Met Proto-Oncogene Overexpression Positive | c-met Overexpression Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551005","PDGFR Gene Amplification","C148404","A molecular genetic abnormality indicating the presence of multiple copies of a PDGFR family gene.","PDGFR Gene Amplification | PDGF Receptor Gene Amplification | PDGFR Family Gene Amplification | Platelet Derived Growth Factor Receptor Gene Amplification | Platelet-Derived Growth Factor Receptor Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551004","PDGFR Protein Overexpression","C148405","A molecular abnormality indicating the presence of an abnormally high level of a platelet-derived growth factor receptor family protein.","PDGFR Protein Overexpression | PDGF Receptor Protein Overexpression | PDGFR Family Protein Overexpression | Platelet Derived Growth Factor Receptor Protein Overexpression | Platelet-Derived Growth Factor Receptor Protein Overexpression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551007","AXL Overexpression Positive","C148406","An indication that overexpression of AXL has been detected in a sample.","AXL Overexpression Positive | ARK Overexpression Positive | AXL Receptor Tyrosine Kinase Overexpression Positive | JTK11 Overexpression Positive | Tyro7 Overexpression Positive | Tyrosine-Protein Kinase Receptor UFO Overexpression Positive | UFO Overexpression Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551006","Unspecified Atypical Cells Present","C148407","A finding indicating that abnormal cells with indeterminate morphological features are present in a sample.","Unspecified Atypical Cells Present | Atypical Cells Present | Indeterminate Abnormal Cells Present | Unspecified Abnormal Cells Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551125","CD5-Positive Blast Cells Greater than 50 Percent","C148544","A semi-quantitative microscopic finding indicating that more than 50% of the immature blood cells in a sample express CD5.","CD5-Positive Blast Cells Greater than 50 Percent | >50% CD5 Positive Blasts | >50% CD5-Positive Blasts | CD5 Positive Blast Cells Greater than 50 Percent | Greater than 50 Percent CD5 Positive Blasts | Greater than 50 Percent CD5-Positive Blasts | Greater than 50% CD5 Positive Blasts | Greater than 50% CD5-Positive Blasts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551941","PSA Level Less than 0.5","C150099","An indication that a blood concentration of prostate specific antigen below 0.5 ng/mL was detected in a sample.","PSA Level Less than 0.5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1168500","Thyroglobulin Antibody Negative","C150125","An indication that antibodies that recognize thyroglobulin have not been detected in a sample.","Thyroglobulin Antibody Negative | Anti-TG Antibody Negative | Anti-Thyroglobulin Antibody Negative | TG Antibody Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551903","Deleterious ATR Gene Mutation","C150148","A change in the nucleotide sequence of the ATR gene that is associated with increased risk of disease.","Deleterious ATR Gene Mutation | Deleterious ATR Serine/Threonine Kinase Gene Mutation | Deleterious Ataxia Telangiectasia and Rad3 Related Gene Mutation | Deleterious FRP1 Gene Mutation | Deleterious MEC1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551906","Deleterious FANCA Gene Mutation","C150149","A change in the nucleotide sequence of the FANCA gene that is associated with increased risk of disease.","Deleterious FANCA Gene Mutation | Deleterious FA Gene Mutation | Deleterious FA-H Gene Mutation | Deleterious FA1 Gene Mutation | Deleterious FAA Gene Mutation | Deleterious FACA Gene Mutation | Deleterious FAH Gene Mutation | Deleterious FANCH Gene Mutation | Deleterious Fanconi Anemia Complementation Group A Gene Mutation | Deleterious Fanconi Anemia, Complementation Group A Gene Mutation | Deleterious Fanconi Anemia, Complementation Group H Gene Mutation | Deleterious Fanconi Anemia, Type 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551905","Deleterious FANCC Gene Mutation","C150150","A change in the nucleotide sequence of the FANCC gene that is associated with increased risk of disease.","Deleterious FANCC Gene Mutation | Deleterious FA3 Gene Mutation | Deleterious FAC Gene Mutation | Deleterious FACC Gene Mutation | Deleterious Fanconi Anemia Complementation Group C Gene Mutation | Deleterious Fanconi Anemia, Complementation Group C Gene Mutation | Deleterious Fanconi Anemia, Type 3 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551900","Deleterious FANCD2 Gene Mutation","C150151","A change in the nucleotide sequence of the FANCD2 gene that is associated with increased risk of disease.","Deleterious FANCD2 Gene Mutation | Deleterious FA-D2 Gene Mutation | Deleterious FA4 Gene Mutation | Deleterious FACD Gene Mutation | Deleterious FAD Gene Mutation | Deleterious FAD2 Gene Mutation | Deleterious FANCD Gene Mutation | Deleterious Fanconi Anemia Complementation Group D2 Gene Mutation | Deleterious Fanconi Anemia, Complementation Group D2 Gene Mutation | Deleterious Fanconi Anemia, Type 4 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551899","Deleterious FANCE Gene Mutation","C150152","A change in the nucleotide sequence of the FANCE gene that is associated with increased risk of disease.","Deleterious FANCE Gene Mutation | Deleterious FACE Gene Mutation | Deleterious FAE Gene Mutation | Deleterious Fanconi Anemia Complementation Group E Gene Mutation | Deleterious Fanconi Anemia, Complementation Group E Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551902","Deleterious FANCF Gene Mutation","C150153","A change in the nucleotide sequence of the FANCF gene that is associated with increased risk of disease.","Deleterious FANCF Gene Mutation | Deleterious FAF Gene Mutation | Deleterious Fanconi Anemia Complementation Group F Gene Mutation | Deleterious Fanconi Anemia, Complementation Group F Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551901","Deleterious FANCM Gene Mutation","C150154","A change in the nucleotide sequence of the FANCM gene that is associated with increased risk of disease.","Deleterious FANCM Gene Mutation | Deleterious FAAP250 Gene Mutation | Deleterious Fanconi Anemia Complementation Group M Gene Mutation | Deleterious Fanconi Anemia, Complementation Group M Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551896","Deleterious MRE11 Gene Mutation","C150155","A change in the nucleotide sequence of the MRE11 gene that is associated with increased risk of disease.","Deleterious MRE11 Gene Mutation | Deleterious ATLD Gene Mutation | Deleterious HNGS1 Gene Mutation | Deleterious MRE11 Homolog A, Double Strand Break Repair Nuclease Gene Mutation | Deleterious MRE11 Homolog, Double Strand Break Repair Nuclease Gene Mutation | Deleterious MRE11 Meiotic Recombination 11 Homolog A (S. cerevisiae) Gene Mutation | Deleterious MRE11A Gene Mutation | Deleterious MRE11B Gene Mutation | Deleterious Meiotic Recombination (S. cerevisiae) 11 Homolog A Gene Mutation | Deleterious Meiotic Recombination 11, S. cerevisiae, Homolog of, A Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551895","Deleterious NBN Gene Mutation","C150157","A change in the nucleotide sequence of the NBN gene that is associated with increased risk of disease.","Deleterious NBN Gene Mutation | Deleterious AT-V1 Gene Mutation | Deleterious AT-V2 Gene Mutation | Deleterious ATV Gene Mutation | Deleterious NBS Gene Mutation | Deleterious NBS1 Gene Mutation | Deleterious Nibrin Gene Mutation | Deleterious Nijmegen Breakage Syndrome 1 Gene Mutation | Deleterious P95 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551898","Deleterious RAD50 Gene Mutation","C150158","A change in the nucleotide sequence of the RAD50 gene that is associated with increased risk of disease.","Deleterious RAD50 Gene Mutation | Deleterious NBSLD Gene Mutation | Deleterious RAD50 (S. cerevisiae) Homolog Gene Mutation | Deleterious RAD50 Double Strand Break Repair Protein Gene Mutation | Deleterious RAD50 Homolog (S. cerevisiae) Gene Mutation | Deleterious RAD50 Homolog, Double Strand Break Repair Protein Gene Mutation | Deleterious RAD50, S. cerevisiae, Homolog of Gene Mutation | Deleterious RAD50-2 Gene Mutation | Deleterious RAD502 Gene Mutation | Deleterious hRad50 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4021848","Abnormal DNA Repair","C36335","A defect in the repair of damaged DNA that results from variations or mutations in one or more genes encoding proteins involved in DNA repair pathways.","Abnormal DNA Repair | DNA Repair Abnormality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551153","SSX2 Positive","C148638","An indication that SSX2 expression has been detected in a sample.","SSX2 Positive | CT5.2 Positive | Cancer/Testis Antigen 5.2 Positive | SSX Family Member 2 Positive | SSX2A Positive | SSX2B Positive | Synovial Sarcoma, X Breakpoint 2 Positive | Tumor Antigen HOM-MEL-40 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0754280","Flibanserin","C80769","An orally bioavailable, non-hormonal, multifunctional serotonin agonist and antagonist (MSAA) that may improve sexual desire and arousal in women. Upon oral administration, flibanserin selectively binds to serotonin receptors in the central nervous system, acting as an agonist on 5-HT1A receptors and an antagonist on 5-HT2A receptors. Agonist activity at 5-HT1A postsynaptic receptors may enhance the release of dopamine and other monoamines. Combined with 5-HT2A antagonism, flibanserin boosts levels of dopamine in the mesocortical area of the prefrontal cortex and produces a net increase of norepinephrine selectively in the prefrontal cortex through disinhibition of locus coeruleus noradrenergic neurons. In addition, flibanserin reduces concentrations of serotonin in the prefrontal cortex with chronic administration. Reducing serotonin, which modulates sexual activity in an inhibitory fashion through downstream decreases in dopamine release, while enhancing the release of norepinephrine and dopamine in the prefrontal cortex may improve sexual desire and interest.","Flibanserin | FLIBANSERIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053752","Indeterminate Response","C123589","A response that is neither favorable nor unfavorable.","Indeterminate Response | INDETERMINATE RESPONSE | Indeterminate (possible pseudo-progression)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552137","Million Tissue Culture Infectious Dose 50%","C150415","A potency unit equal to the potency at which one dose of preparation contains one million (10^6) 50 percent tissue culture infective doses.","Million Tissue Culture Infectious Dose 50% | 10*6.[TCID_50]/{dose} | 10^6 50 Percent Tissue Culture Infective Dose per Dose | 10^6 TCID 50/dose | 10^6.[TCID_50]/{dose} | 10^6{TCID50} | Million Tissue Culture Infectious Dose 50 Percent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552136","Ten Million Tissue Culture Infectious Dose 50%","C150416","A unit of potency equal to ten million tissue culture infectious dose 50% units.","Ten Million Tissue Culture Infectious Dose 50% | 10^7 50 Percent Tissue Culture Infective Dose per Dose | 10^7 TCID 50/dose | 10^7.[TCID50] | 10^7{TCID50} | Ten Million Tissue Culture Infectious Dose 50 Percent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552139","Hundred Million Tissue Culture Infectious Dose 50%","C150417","A potency unit equal to the potency at which one dose of preparation contains one million (10^8) 50 percent tissue culture infective doses.","Hundred Million Tissue Culture Infectious Dose 50% | 10*8.[TCID_50]/{dose} | 10^8 50 Percent Tissue Culture Infective Dose per Dose | 10^8 TCID 50/dose | 10^8.[TCID_50]/{dose} | 10^8{TCID50} | Hundred Million Tissue Culture Infectious Dose 50 Percent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831111","ChIP-Seq","C106049","A molecular genetic technique that combines chromatin immunoprecipitation (ChIP) with massively parallel DNA sequencing to map the binding sites of DNA-associated proteins in a sample of cells. First, crosslinked protein-DNA complexes are isolated using ChIP. Next, the crosslinks are broken, the proteins are removed and the purified DNA is modified with adaptor oligonucleotides to facilitate massively parallel DNA sequencing. Following sequencing, the DNA sequences that are obtained can be mapped to their genomic locations.","ChIP-Seq | ChIP-Seq (chromatin ImmunoPrecipitation) | ChIP-Sequencing | Chromatin Immunoprecipitation Sequencing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830265","FAIRE-Seq","C106051","A molecular genetic technique that depletes a biological sample of nucleosomal DNA and then subjects the non-nucleosome-associated DNA to next-generation sequencing. Since nucleosome disruption of chromatin is indicative of active sites of DNA transcription, this technique can isolate DNA sequences that are involved in transcriptional regulation. First, a sample is treated with formaldehyde to form DNA-protein crosslinks, followed by sample lysis and sonication. The processed sample is subjected to phenol/chloroform extraction and the DNA in the aqueous phase is analyzed using next-generation sequencing techniques.","FAIRE-Seq | Formaldehyde-Assisted Isolation of Regulatory Elements Sequencing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640007","Viral Small RNA","C101143","Small non-coding RNA that is encoded by viral DNA and transcribed by virally-infected cells.","Viral Small RNA | Viral-Derived Short RNA | vsRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272453","Genomic DNA","C95940","The DNA that is part of the normal chromosomal complement of an organism.","Genomic DNA | gDNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542480","Grade 1 Neck Edema, CTCAE","C144285","Asymptomatic localized neck edema","Grade 1 Neck Edema, CTCAE | Grade 1 Neck edema | Grade 1 Neck edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0235522","Vein Disorder","C35279","Any disorder of the veins.","Vein Disorder | Venous Disorder",,,,,,,,,,,,,,,"4234997","Disorder of vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552129","Paired-End Sequencing","C150423","A DNA sequencing strategy where a single read is initiated from each end of a DNA fragment.","Paired-End Sequencing | Paired End | Paired-end Reads",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521719","Anal Cancer by AJCC v8 Stage","C133794","A term that refers to the staging of anal cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to all carcinomas arising in the anal canal, including carcinomas that arise within anorectal fistulas and those arising in the perianal area (anal margin). High-grade neuroendocrine carcinomas (small cell neuroendocrine carcinoma and large cell neuroendocrine carcinoma) are staged using this system. There is no AJCC staging system for anal mucosal melanomas and anal well-differentiated neuroendocrine tumors. (from AJCC 8th Ed.)","Anal Cancer by AJCC v8 Stage | Anal Canal and Perianal (Anal Margin) Carcinoma by AJCC v8 Stage | Anal Carcinoma by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521729","Stage IV Anal Cancer AJCC v8","C133804","Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Anal Cancer AJCC v8 | Stage IV Anal Canal and Perianal (Anal Margin) Carcinoma AJCC v8 | Stage IV Anal Cancer | Stage IV Anal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521728","Stage IIIC Anal Cancer AJCC v8","C133803","Stage IIIC includes: (T3, N1, M0); (T4, N1, M0). T3: Tumor larger than 5 cm. T4: Tumor of any size invading adjacent organ(s), such as the vagina, urethra, or bladder. N1: Metastasis in inguinal, mesorectal, internal iliac, or external iliac nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIC Anal Cancer AJCC v8 | Stage IIIC Anal Canal and Perianal (Anal Margin) Carcinoma AJCC v8 | Stage IIIC Anal Cancer | Stage IIIC Anal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521727","Stage IIIB Anal Cancer AJCC v8","C133802","Stage IIIB includes: T4, N0, M0. T4: Tumor of any size invading adjacent organ(s), such as the vagina, urethra, or bladder. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIB Anal Cancer AJCC v8 | Stage IIIB Anal Canal and Perianal (Anal Margin) Carcinoma AJCC v8 | Stage IIIB Anal Cancer | Stage IIIB Anal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521724","Stage IIB Anal Cancer AJCC v8","C133799","Stage IIB includes: T3, N0, M0. T3: Tumor larger than 5 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIB Anal Cancer AJCC v8 | Stage IIB Anal Canal and Perianal (Anal Margin) Carcinoma AJCC v8 | Stage IIB Anal Cancer | Stage IIB Anal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521723","Stage IIA Anal Cancer AJCC v8","C133798","Stage IIA includes: T2, N0, M0. T2: Tumor larger than 2 cm but equal to or smaller than 5 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIA Anal Cancer AJCC v8 | Stage IIA Anal Canal and Perianal (Anal Margin) Carcinoma AJCC v8 | Stage IIA Anal Cancer | Stage IIA Anal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521721","Stage I Anal Cancer AJCC v8","C133796","Stage I includes: T1, N0, M0. T1: Tumor 2 cm or smaller. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Anal Cancer AJCC v8 | Stage I Anal Canal and Perianal (Anal Margin) Carcinoma AJCC v8 | Stage I Anal Cancer | Stage I Anal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521720","Stage 0 Anal Cancer AJCC v8","C133795","Stage 0 includes: Tis, N0, M0. Tis: High-grade squamous intraepithelial lesion (previously termed carcinoma in situ, Bowen disease, anal intraepithelial neoplasia II-III, high-grade anal intraepithelial neoplasia). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0 Anal Cancer AJCC v8 | Stage 0 Anal Canal and Perianal (Anal Margin) Carcinoma AJCC v8 | Stage 0 Anal Cancer | Stage 0 Anal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030286","Pancreatic Disorder","C26842","A non-neoplastic or neoplastic disorder that affects the pancreas.  Representative examples of non-neoplastic disorders include pancreatitis and pancreatic insufficiency.  Representative examples of neoplastic disorders include cystadenomas, carcinomas, lymphomas, and neuroendocrine neoplasms.","Pancreatic Disorder | ",,,,,,,,,,,,,,,"192963","Disorder of pancreas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552241","Unstranded Library Sequencing","C150427","Non-directional sequencing, where the reads can map from either the transcript strand or its complement.","Unstranded Library Sequencing | Unstranded | Unstranded Library | Unstranded Sequencing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552130","Second-strand Library Sequencing","C150426","Directional sequencing, where the first read of the read pair (or in case of single end reads, the only read) is from the transcript strand.","Second-strand Library Sequencing | Second-strand | Second-strand Library | Second-strand Sequencing | Second_Stranded",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552240","First-strand Library Sequencing","C150428","Directional sequencing, where the first read (or the only read in case of single end reads) is from the complement strand.","First-strand Library Sequencing | First-strand | First-strand Library | First-strand Sequencing | First_Stranded",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274807","Lymphomatous Involvement of Extranodal Site","C99567","A pathologic and/or clinical finding indicating the spread of a lymphomatous process to an anatomic site other than lymph nodes.","Lymphomatous Involvement of Extranodal Site | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544334","Grade 5 Edema Cerebral, CTCAE","C146288","Death","Grade 5 Edema Cerebral, CTCAE | Grade 5 Edema cerebral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543867","Grade 4 Edema Cerebral, CTCAE","C145827","Life-threatening consequences; urgent intervention indicated","Grade 4 Edema Cerebral, CTCAE | Grade 4 Edema cerebral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543373","Grade 3 Edema Cerebral, CTCAE","C145242","New onset; worsening from baseline","Grade 3 Edema Cerebral, CTCAE | Grade 3 Edema cerebral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1328856","chromatin immunoprecipitation","C106048","A technique that utilizes immunoprecipitation to find protein-DNA interactions in a biological sample. First, the sample is treated causing the formation of protein-chromatin crosslinks. Then, the sample is sheared to separate individual protein-DNA complexes. Finally, an antibody directed against a protein of interest is applied and the protein-DNA complexes are immunoprecipitated.","Chromatin Immunoprecipitation | ChIP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552112","Grade 3 or 4 Elevation of AST, ALT, and/or Bilirubin","C150310","A finding of grade 3 or 4 AST, Grade 3 or 4 ALT, and/or grade 3 or 4 bilirubin.","Grade 3 or 4 Elevation of AST, ALT, and/or Bilirubin | Grade 3 or 4 Elevation of Aspartate Aminotransferase, Alanine Aminotransferase, and/or Bilirubin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898219","Multiple Complete Digest Restriction Fragment Mapping","C116160","A DNA mapping technique based on complete restriction enzyme digestion of a set of overlapping clones that provides highly redundant coverage of the mapping target.","Multiple Complete Digest Restriction Fragment Mapping | MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING | Multiple Complete Digestion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828998","MNase Sequencing","C106056","A molecular genetic technique where genome-wide sequencing is performed on chromosomal DNA that is resistant to treatment with micrococcal nuclease. This technique identifies nucleosomal DNA sequences.","MNase Sequencing | MNase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0974143","Aloe Vera Gel","C1565","A preparation of leaf pulp from the parenchymal tissue of the plant Aloe vera (Liliaceae). Aloe vera gel contains carbohydrate polymers, such as glucomannans or pectic acid, and various vitamins and essential amino acids, as well as other organic and inorganic compounds. This agent has been used internally or externally for sunburn, skin problems, insect bites, ulcers, arthritis, constipation, and as an immune system enhancer.","Aloe Vera Gel | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0717368","Oxycodone/Acetaminophen","C29311","A combination preparation of the analgesic and antipyretic acetaminophen and the semisynthetic opioid agonist oxycodone with analgesic and antitussive properties. Acetaminophen exerts its analgesic activity by inhibiting prostaglandin synthesis, while oxycodone exerts its analgesic activity by binding to the mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids.","Oxycodone/Acetaminophen | Percocet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0052593","Atipamezole","C72921","No Value Exists","Atipamezole | 4-(2-Ethyl-2-indanyl)imidazole | ATIPAMEZOLE | Antisedan | Atipamezol | MPV 1248",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711245","Arthro-7","C53685","A dietary supplement to support joint health. Ingredients include ascorbic acid, chicken collagen II, methylsulfonylmethane, cetyl myristoleate 5%, lipase, bromelain, and turmeric extract.","Arthro-7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544750","454 Sequencing","C146809","A proprietary next-generation DNA sequencing system from 454 Life Sciences that used large-scale parallel pyrosequencing. The system relied on fixing nebulized and adapter-ligated DNA fragments to small DNA-capture beads in a water-in-oil emulsion.","454 Sequencing | 454 Sequencing Technology | LS 454 Sequencing | LS454",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273953","AKT1 NM_001014431.1:c.49G>A","C98305","A nucleotide substitution at position 49 of the coding sequence of the AKT1 gene where guanine has been mutated to adenine.","AKT1 NM_001014431.1:c.49G>A | AKT c.49G>A | AKT1 G49A Mutation | AKT1 c.49G>A | NM_001014431.1:c.49G>A | PKB c.49G>A | PRKBA c.49G>A | RAC c.49G>A | RAC-ALPHA c.49G>A | RAC-PK-Alpha c.49G>A | v-akt Murine Thymoma Viral Oncogene Homolog 1 c.49G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273954","AKT1 NP_001014431.1:p.E17K","C98306","A change in the amino acid residue at position 17 in the RAC-alpha serine/threonine-protein kinase protein where glutamic acid has been replaced by lysine.","AKT1 NP_001014431.1:p.E17K | AKT1 E17K | AKT1 E17K (G49A) Mutation | AKT1 E17K Mutation | AKT1 Glu17Lys | AKT1 NP_001014431.1:p.Glu17Lys | AKT1 p.E17K | AKT1 p.Glu17Lys | NP_001014431.1:p.Glu17Lys | RAC-alpha Serine/Threonine-Protein Kinase E17K | RAC-alpha Serine/Threonine-Protein Kinase Glu17Lys | RAC-alpha Serine/Threonine-Protein Kinase p.E17K | RAC-alpha Serine/Threonine-Protein Kinase p.Glu17Lys",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0678584","Salty","C150480","Tasting of or like salt.","Salty | Saltiness | Salty Taste",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0235290","bitter","C150481","Having a sharp, pungent taste.","Bitter | Bitter Taste | Bitterness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538177","Refractory Transformed Non-Hodgkin Lymphoma","C140091","An indolent non-Hodgkin lymphoma which has undergone histologic transformation to an aggressive non-Hodgkin lymphoma and has become resistant to treatment.","Refractory Transformed Non-Hodgkin Lymphoma | Refractory Transformed Indolent Non-Hodgkin Lymphoma | Refractory Transformed Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539305","Diffuse Large B-Cell Lymphoma by Ann Arbor Stage","C141254","An anatomic stage for diffuse large B-cell lymphoma based on the Ann Arbor classification criteria.","Diffuse Large B-Cell Lymphoma by Ann Arbor Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0855116","Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","C8857","Ann Arbor Classification: Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s); or any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid.","Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma Stage IV | Stage IV Diffuse Large B-Cell Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0855115","Ann Arbor Stage III Diffuse Large B-Cell Lymphoma","C8856","Ann Arbor Classification: Stage III: Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S).","Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma Stage III | Stage III Diffuse Large B-Cell Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539184","Ann Arbor Stage","C141138","A lymphoma anatomic stage defined according to the Ann Arbor classification criteria.","Ann Arbor Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0855114","Ann Arbor Stage II Diffuse Large B-Cell Lymphoma","C8855","Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE).","Ann Arbor Stage II Diffuse Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma Stage II | Stage II Diffuse Large B-Cell Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0855113","Ann Arbor Stage I Diffuse Large B-Cell Lymphoma","C8854","Ann Arbor Classification: Stage I: Involvement of a single lymph node region (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE).","Ann Arbor Stage I Diffuse Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma Stage I | Stage I Diffuse Large B-Cell Lymphoma",,,,,,,,,,,,,,,"764839","Diffuse non-Hodgkin's lymphoma Lugano stage I",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883550","Wash Dosage Form","C64903","A solution or suspension composed of active and/or inert ingredient(s) and intended for administration as an irrigant and cleanser.","Wash Dosage Form | Wash | Wash Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335330","Papillomavirus Protein E2","C20053","A viral DNA binding protein involved in viral replication.  It is a transcriptional activator and major regulator of viral DNA replication and gene expression.  May interact with p53 in vivo. (from Oncogene 1999;18:7748-54)","Papillomavirus Protein E2 | HPV E2 | HPV Oncogene Protein E2 | HPV Protein E2 | HPV Regulatory Protein E2 | Oncogene Protein E2 | Regulatory Protein E2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272842","MUTYH Gene Mutation","C96521","A molecular genetic abnormality that refers to the mutation of the MUTYH gene on chromosome 1p34.1.","MUTYH Gene Mutation | MYH Gene Mutation | MutY (E. Coli) Homolog Gene Mutation | MutY DNA Glycosylase Gene Mutation | MutY Homolog (E. coli) Gene Mutation | MutY Homolog Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552254","Ann Arbor Stage IE","C150547","An Ann Arbor classification lymphoma stage term that refers to the involvement of a single extranodal organ or site in the absence of any lymph node involvement.","Ann Arbor Stage IE | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552253","Ann Arbor Stage IIE","C150548","An Ann Arbor classification lymphoma stage term that refers to the involvement of a single extranodal organ or site plus its regional lymph nodes with or without other lymph nodes involvement on the same side of the diaphragm.","Ann Arbor Stage IIE | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552248","Ann Arbor Stage IIIE","C150549","An Ann Arbor classification lymphoma stage term that refers to extralymphatic organ or site involvement plus involvement of lymph nodes on both sides of the diaphragm.","Ann Arbor Stage IIIE | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552247","Ann Arbor Stage IIIS","C150550","An Ann Arbor classification lymphoma stage term that refers to the involvement of lymph nodes on both sides of the diaphragm plus involvement of the spleen.","Ann Arbor Stage IIIS | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552250","Ann Arbor Stage IIIE and IIIS","C150551","An Ann Arbor classification lymphoma stage term that refers to extralymphatic organ or site involvement plus involvement of lymph nodes on both sides of the diaphragm or involvement of lymph nodes on both sides of the diaphragm plus involvement of the spleen.","Ann Arbor Stage IIIE and IIIS | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224419","Psoas Major Muscle","C33420","A striated muscle located in the iliac region that originates both on the transverse processes of the twelfth thoracic through fifth lumbar vertebrae and the lateral aspects of the discs between them, and inserts on the lesser trochanter of the femur; it functions to flex the hip joint.","Psoas Major Muscle | MUSCLE, PSOAS MAJOR | Musculus Psoas Major | Psoas Magnus",,,,,,,,,,,,,,,"4238035","Structure of psoas major muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0933345","Paracaval Lymph Node","C117869","A lymph node located adjacent to the lumbar region of the spine, along the right lateral aspect of the inferior vena cava.","Paracaval Lymph Node | PARACAVAL LYMPH NODE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552356","Incomplete Response/Stable Disease","C150562","Persistence of one or more non-target lesions.","Incomplete Response/Stable Disease | IR/SD | Incomplete Response/Stable Disease (IR/SD)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224234","Deltoid","C32446","The muscle that creates the rounded contour of the shoulder which originates from the lateral third of the clavicle, the superior surface of the acromion process, and the posterior border of the spine of the scapula and inserts on the lateral side of the shaft of the humerus. The deltoid muscle is innervated by the brachial plexus arising from the fifth and sixth cervical nerves and controls abduction, extension, flexion, and rotation of the arm.","Deltoid | DELTOID MUSCLE | MUSCLE, DELTOID",,,,,,,,,,,,,,,"4148083","Structure of deltoid muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552331","Complete Remission with Incomplete Hematological Recovery","C150587","The disappearance of all signs of leukemia in response to treatment with residual neutropenia (less than 1,000 per microliter), with or without complete platelet recovery.","Complete Remission in Leukemia with Incomplete Hematologic Recovery | Complete Remission in Leukemia with Incomplete Hematological Recovery | Complete Remission with Incomplete Hematologic Recovery | Complete Remission with Incomplete Hematological Recovery | Complete Remission with Incomplete Hematological Recovery | Complete Remission with Incomplete Hematological Recovery (CRi)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054795","Hematologic Improvement-Erythroid Response","C123585","An improvement in erythrocyte count as a response to treatment.","Hematologic Improvement-Erythroid Response | HI-E | Hematologic Improvement - Erythroid (HI-E) | Hematological Improvement Erythroid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053780","Hematologic Improvement-Neutrophil Response","C123586","An improvement of neutrophil count as a response to treatment.","Hematologic Improvement-Neutrophil Response | HI-N | Hematologic Improvement - Neutrophil (HI-N)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054794","Hematologic Improvement-Platelet Response","C123587","An improvement of platelet count as a response to treatment.","Hematologic Improvement-Platelet Response | HI-P | Hematologic Improvement - Platelet (HI-P)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049612","Marrow Complete Response","C123591","A decrease in the number of bone marrow plasma cells to protocol-defined level(s).","Marrow Complete Response | Marrow CR | Marrow Complete Remission | mCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2607622","Fosaprepitant Dimeglumine","C72788","The dimeglumine salt form of fosaprepitant, the water-soluble, N-phosphorylated prodrug of aprepitant, with antiemetic activity. Upon intravenous administration and rapid conversion to aprepitant, this agent binds selectively to the human substance P/neurokinin 1 (NK1) receptors in the central nervous system (CNS). This inhibits receptor binding of the endogenous substance P and prevents substance P-induced emesis.","Fosaprepitant Dimeglumine | Emend for Injection | FOSAPREPITANT DIMEGLUMINE | Focinvez | L-785,298 | MK-0517 | Proemend | fosaprepitant dimeglumine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985567","Defined Administrative Activity","C93353","An activity defined at a global library level that is not directly related to hypothesis evaluation or testing, but is typically essential to the efficient and/or effective coordination and execution of a study.","Defined Administrative Activity | DefinedAdministrativeActivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552363","Chemically-Induced Menopause","C150669","Menopause caused by chemotherapy or other chemicals or medications.","Chemically-Induced Menopause | CIM | Chemical Menopause | Chemically Induced Menopause",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511212","Blasts Under 10 Percent of Peripheral Blood White Cells","C41241","A semi-quantitative microscopic finding indicating that less than 10 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.","Blasts Under 10 Percent of Peripheral Blood White Cells | Blasts Less Than 10 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552135","Neoplastic Plasma Cells Under 5 Percent of Bone Marrow Nucleated Cells","C150421","A semi-quantitative microscopic finding indicating that less than 5 percent of the nucleated cells in a bone marrow sample are neoplastic plasma cells.","Neoplastic Plasma Cells Under 5 Percent of Bone Marrow Nucleated Cells | Neoplastic Plasma Cells Less than 5 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711158","CD8-Positive Neoplastic Cells Present","C45324","An indication that expression of CD8 has been detected in a sample of neoplastic cells.","CD8-Positive Neoplastic Cells Present | CD8 Antigen Positive Neoplastic Cells Present | CD8 Co-Receptor Positive Neoplastic Cells Present | T-Cell Surface Glycoprotein CD8 Positive Neoplastic Cells Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL494952","Loss of Chromosome 3q","C45859","A cytogenetic abnormality that refers to the loss of all or part of the long arm of chromosome 3 (3q).","Loss of Chromosome 3q | 3q Deletion | del(3q)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0078944","Intravenous Patient-Controlled Analgesia","C21060","A method of intravenous narcotic analgesic delivery that uses a pump or similar delivery system that allows the patient, or in the absence of the patient's ability to do so the patient's nurse or family members, to administer predetermined doses of analgesic as needed to maintain adequate pain control.  This method allows the patient and/or family to have increased autonomy.  Further, research has shown improved pain control and reductions in narcotics necessary to maintain pain control to be associated with this delivery method.","Intravenous Patient-Controlled Analgesia | IV PCA | PCA | Patient-Controlled Analgesia | patient-controlled analgesia",,,,,,,,,,,,,,,"4086425","Patient controlled analgesia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825737","Elevated CA15-3","C81731","A laboratory test result indicating the presence of an increased level of the tumor-associated antigen (TAA) CA15-3 in a blood or serum sample.","Elevated CA15-3 | Elevated CA 15-3 | Elevated CA15-3 | Elevated CA15-3 Antigen | Elevated Cancer Antigen 15-3 | Elevated MUC-1 Antigen | Elevated MUC1 Antigen | Elevated Mucin 1 Antigen | Elevated Mucin-1 Antigen | Elevated Serum CA 15-3 Tumor Antigen Levels | Elevated Serum CA 15-3 Tumor Antigen Levels | Elevated Sialylated MUC-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3888504","ERBB2 Protein Overexpression","C36639","A molecular abnormality indicating the presence of an abnormally high level of the receptor tyrosine-protein kinase erbB-2 protein.","ERBB2 Protein Overexpression | HER2 Protein Overexpression | Proto-Oncogene Neu Protein Overexpression | Receptor Tyrosine-Protein Kinase erbB-2 Protein Overexpression | Tyrosine Kinase-Type Cell Surface Receptor HER2 Protein Overexpression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334848","Myeloblasts Under 20 Percent of Bone Marrow Nucleated Cells","C36216","A semi-quantitative microscopic finding indicating less than 20 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells of myeloid origin.","Myeloblasts Under 20 Percent of Bone Marrow Nucleated Cells | Myeloblasts Less than 20 Percent of Bone Marrow Nucleated Cells | Myeloblasts Under 20% of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334849","Myeloblasts Under 20 Percent of Peripheral Blood White Cells","C36223","A semi-quantitative microscopic finding indicating less than 20 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells of myeloid origin.","Myeloblasts Under 20 Percent of Peripheral Blood White Cells | Myeloblasts Less than 20 Percent of Peripheral Blood White Cells | Myeloblasts Under 20% of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552237","9p21 Loss of Heterozygosity","C150431","A molecular abnormality that results in monoallelic loss of function mutations located within 9p21.","9p21 Loss of Heterozygosity | 9p21 LOH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552236","ABL2 Gene Mutation","C150432","A change in the nucleotide sequence of the ABL2 gene.","ABL2 Gene Mutation | ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase Gene Mutation | ABLL Gene Mutation | ARG Gene Mutation | Abelson-Related Gene Mutation | v-Abl Abelson Murine Leukemia Viral Oncogene Homolog 2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552238","Activating CD79A Gene Mutation","C150434","A change in the nucleotide sequence of the CD79A gene that that results in constitutive activation of B-cell antigen receptor complex-associated protein alpha chain and its downstream signaling pathways.","Activating CD79A Gene Mutation | Activating CD79A Mutation | Activating CD79a Molecule Gene Mutation | Activating CD79a Molecule, Immunoglobulin-Associated Alpha Gene Mutation | Activating IGA Gene Mutation | Activating MB-1 Gene Mutation | Activating MB1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552233","Activating CD79B Gene Mutation","C150435","A change in the nucleotide sequence of the CD79B gene that that results in constitutive activation of B-cell antigen receptor complex-associated protein beta chain and its downstream signaling pathways.","Activating CD79B Gene Mutation | Activating AGM6 Gene Mutation | Activating B29 Gene Mutation | Activating CD79B Mutation | Activating CD79b Antigen Gene Mutation | Activating CD79b Molecule Gene Mutation | Activating IGB Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552232","Activating EML4/ALK Gene Mutation","C150436","A change in the nucleotide sequence of the ALK portion of the EML4/ALK fusion gene that that results in constitutive activation of the EML4/ALK fusion protein and its downstream signaling pathways. These mutations are associated with increased oncogenic potential.","Activating EML4/ALK Gene Mutation | Activating EML4-ALK Fusion Gene Mutation | Activating EML4-ALK Gene Mutation | Activating EML4-ALK Mutation | Activating EML4/ALK Fusion Gene Mutation | Activating EML4/ALK Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552234","Activating NTRK Family Fusion Gene Mutation","C150438","A fusion mutation involving an NTRK family gene that causes the encoded receptor tyrosine kinase and its downstream pathways to be constitutively activated.","Activating NTRK Family Fusion Gene Mutation | Activating NTRK Fusion Gene Mutation | Activating TRK Family Fusion Gene Mutation | Activating TRK Fusion Gene Mutation | Activating TRK Receptor Family Fusion Gene Mutation | Activating TRK Receptor Fusion Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552229","Activating NTRK Family Point Mutation","C150439","A point mutation in an NTRK family gene that causes the encoded receptor tyrosine kinase and its downstream pathways to be constitutively activated.","Activating NTRK Family Point Mutation | Activating NTRK Point Mutation | Activating TRK Family Gene Point Mutation | Activating TRK Gene Point Mutation | Activating TRK Receptor Family Gene Point Mutation | Activating TRK Receptor Gene Point Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552228","ACVR1B Gene Mutation","C150440","A change in the nucleotide sequence of the ACVR1B gene.","ACVR1B Gene Mutation | ACTRIB Gene Mutation | ACVRLK4 Gene Mutation | ALK4 Gene Mutation | Activin A Receptor, Type IB Gene Mutation | Activin A Receptor, Type II-Like Kinase 4 Gene Mutation | Activin Receptor-Like Kinase 4 Gene Mutation | SKR2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552231","AKT1 Gene Rearrangement","C150441","A molecular abnormality indicating rearrangement of the AKT1 gene.","AKT1 Gene Rearrangement | AKT Gene Rearrangement | PKB Gene Rearrangement | PRKBA Gene Rearrangement | RAC Gene Rearrangement | RAC-ALPHA Gene Rearrangement | RAC-PK-Alpha Gene Rearrangement | v-akt Murine Thymoma Viral Oncogene Homolog 1 Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552230","AKT3 Gene Mutation","C150442","A change in the nucleotide sequence of the AKT3 gene.","AKT3 Gene Mutation | AKT Serine/Threonine Kinase 3 Gene Mutation | PKB-GAMMA Gene Mutation | PKBG Gene Mutation | PRKBG Gene Mutation | RAC-Gamma Gene Mutation | RAC-PK-Gamma Gene Mutation | STK-2 Gene Mutation | v-akt Murine Thymoma Viral Oncogene Homolog 3 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552226","ALKATI Positive","C150446","An indication that expression of ALKATI has been detected in a sample.","ALKATI Positive | ALK ATI Positive | ALK Alternative Transcription Initiation Positive | ALK Intron 19 ATI Isoform Positive | ALK(ATI) Positive | ALK-ATI Positive | ALKATI Alteration Positive | Anaplastic Lymphoma Kinase Alternative Transcription Initiation Positive | Anaplastic Lymphoma Receptor Tyrosine Kinase Alternative Transcription Initiation Positive | CD246 Alternative Transcription Initiation Positive | CD246 Antigen Alternative Transcription Initiation Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552221","ATM Deficient Tumor","C150447","A finding indicating that the expression of ATM in a tumor sample is aberrantly low or undetectable.","ATM Deficient Tumor | A-T Mutated Deficient Tumor | AT Mutated Deficient Tumor | ATM Serine/Threonine Kinase Deficient Tumor | Ataxia Telangiectasia Mutated Deficient Tumor | Serine-Protein Kinase ATM Deficient Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552223","BAP1 Loss of Function Mutation Positive","C150449","An indication that expression of BAP1 with a loss of function mutation has been detected in a sample.","BAP1 Loss of Function Mutation Positive | Inactivating BAP1 Mutation Positive | Inactivating BRCA1 Associated Protein 1 Mutation Positive | Inactivating BRCA1-Associated Protein 1 Mutation Positive | Inactivating UCHL2 Mutation Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0204977","Home Care","C99957","Healthcare administered to an individual in the individual's residence.","Home Care | HOME, SELF CARE",,,,,,,,,,,,,,,"4246074","Home care of patient",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552222","BCL6 Overexpression Positive","C150450","An indication that overexpression of BCL6 has been detected in a sample.","BCL6 Overexpression Positive | B-Cell CLL/Lymphoma 6 Overexpression Positive | B-Cell Lymphoma 6 Overexpression Positive | BCL5 Overexpression Positive | BCL6 Overexpression | LAZ-3 Overexpression Positive | LAZ3 Overexpression Positive | ZBTB27 Overexpression Positive | ZNF51 Overexpression Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0813153","Bence Jones Protein Present","C150451","An indication that Bence Jones protein has been detected in a sample.","Bence Jones Protein Present | Bence Jones Protein Positive | Bence-Jones Protein Positive | Bence-Jones Protein Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552217","Blasts 20-30 Percent of Peripheral Blood White Cells","C150452","A semi-quantitative microscopic finding indicating that between 20 and 30 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.","Blasts 20-30 Percent of Peripheral Blood White Cells | Blasts Between 20 and 30 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552219","Blasts 30 Percent or More of Bone Marrow Nucleated Cells","C150453","A semi-quantitative microscopic finding indicating that 30 percent or more of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 30 Percent or More of Bone Marrow Nucleated Cells | Blasts Greater than or Equal to 30 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552218","Blasts 5 Percent or Less of Peripheral Blood White Cells","C150454","A semi-quantitative microscopic finding indicating that 5 percent or less of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.","Blasts 5 Percent or Less of Peripheral Blood White Cells | Blasts Less than or Equal to 5 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552214","Blasts 5-19 Percent of Bone Marrow Nucleated Cells","C150455","A semi-quantitative microscopic finding indicating that between 5 and 19 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 5-19 Percent of Bone Marrow Nucleated Cells | Blasts Between 5 and 19 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552213","Blasts Less than or Equal to 10000/mm3","C150456","A quantitative microscopic finding indicating that immature mononuclear cells are found at less than or equal to 10000 per cubic millimeter field in a sample.","Blasts Less than or Equal to 10000/mm3 | Blasts Less than or Equal to 10,000 per Cubic Millimeter | Blasts Less than or Equal to 10,000/mm3 | Blasts Less than or Equal to 10000 per Cubic Millimeter | Blasts Less than or Equal to 10000 per Cubic mm | Blasts Less than or Equal to 10000 per Microliter | Blasts Less than or Equal to 10000 per uL | Blasts Less than or Equal to 10000/Cubic mm | Blasts Less than or Equal to 10000/uL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552216","Blasts More than 10 Percent of Bone Marrow Nucleated Cells","C150457","A semi-quantitative microscopic finding indicating that more than 10 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts More than 10 Percent of Bone Marrow Nucleated Cells | Blasts Greater than 10 Percent of Bone Marrow Nucleated Cells | Blasts Over 10 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552215","Blasts More than 10 Percent of Peripheral Blood White Cells","C150458","A semi-quantitative microscopic finding indicating that more than 10 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.","Blasts More than 10 Percent of Peripheral Blood White Cells | Blasts Greater than 10 Percent of Peripheral Blood White Cells | Blasts Over 10 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552210","Blasts More than 10000 of Peripheral Blood White Cells","C150459","A quantitative microscopic finding indicating that more than 10000 of the total number of nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.","Blasts More than 10000 of Peripheral Blood White Cells | Absolute Blasts in Peripheral Blood Greater than 10,000 | Absolute Blasts in Peripheral Blood Greater than 10000 | Absolute Blasts in Peripheral Blood More than 10,000 | Absolute Blasts in Peripheral Blood More than 10000 | Blasts Greater than 10,000 in Peripheral Blood White Cells | Blasts Greater than 10000 in Peripheral Blood White Cells | Blasts More than 10,000 in Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552209","Blasts More than 20 Percent of Bone Marrow Nucleated Cells","C150460","A semi-quantitative microscopic finding indicating that more than 20 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts More than 20 Percent of Bone Marrow Nucleated Cells | Blasts Greater than 20 Percent of Bone Marrow Nucleated Cells | Blasts Over 20 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552212","Blasts More than 20 Percent of Peripheral Blood White Cells","C150461","A semi-quantitative microscopic finding indicating that more than 20 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.","Blasts More than 20 Percent of Peripheral Blood White Cells | Blasts Greater than 20 Percent of Peripheral Blood White Cells | Blasts Over 20 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552211","Blasts More than 60 Percent of Peripheral Blood White Cells","C150462","A semi-quantitative microscopic finding indicating that more than 60 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.","Blasts More than 60 Percent of Peripheral Blood White Cells | Blasts Greater than 60 Percent of Peripheral Blood White Cells | Blasts Over 60 Percent of Bone Marrow Nucleated Cells | Blasts Over 60 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552205","CCND1 Splice Variant Positive","C150464","An indication that expression of a splice variant of CCND1 has been detected in a sample.","CCND1 Splice Variant Positive | BCL-1 Splice Variant Positive | BCL1 Splice Variant Positive | CCND1 Splice Variant | CCND1 Splice Variant Present | Cyclin D1 Splice Variant Positive | Cyclin-D1 Splice Variant Positive | PRAD1 Splice Variant Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552208","CD28 Positive","C150465","An indication that expression of CD28 has been detected in a sample.","CD28 Positive | Antigen CD28 Positive | CD28 Antigen Positive | CD28 Molecule Positive | T-Cell Antigen CD28 Positive | T-Cell Specific Surface Glycoprotein CD28 Positive | T44 Positive | T90/44 Positive | Tp44 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552207","CD34 Negative","C150466","An indication that expression of CD34 has not been detected in a sample.","CD34 Negative | Antigen CD34 Negative | CD34 Antigen Negative | CD34 Molecule Negative | HPCA1 Negative | Hematopoietic Progenitor Cell Antigen CD34 Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552201","SPN Positive","C150468","An indication that expression of SPN has been detected in a sample.","SPN Positive | Antigen CD43 Positive | CD43 Antigen Positive | CD43 Positive | GALGP Positive | LSN Positive | Leukocyte Large Sialoglycoprotein Positive | Leukocyte Sialoglycoprotein Positive | Leukosialin Positive | SPN-Positive | Sialophorin Positive | gpL115 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552204","CD7 Positive","C150469","An indication that expression of CD7 has been detected in a sample.","CD7 Positive | Antigen CD7 Positive | CD7 Antigen Positive | CD7 Molecule Positive | GP40 Positive | LEU9 Positive | Leu-9 Positive | T-Cell Antigen CD7 Positive | T-Cell Leukemia Antigen Positive | TP40 Positive | TP41 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552197","CD86 Positive","C150472","An indication that expression of CD86 has been detected in a sample.","CD86 Positive | Activation B7-2 Antigen Positive | Antigen CD86 Positive | B-Lymphocyte Activation Antigen B7-2 Positive | B-Lymphocyte Antigen B7-2 Positive | B7-2 Positive | B7.2 Positive | CD28LG2 Positive | CD86 Antigen Positive | CD86 Molecule Positive | CTLA-4 Counter-Receptor B7.2 Positive | FUN-1 Positive | LAB7-2 Positive | LAB72 Positive | T-Lymphocyte Activation Antigen CD86 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552200","CDH1 Gene Mutation","C150473","A change in the nucleotide sequence of the CDH1 gene.","CDH1 Gene Mutation | Arc-1 Gene Mutation | CD324 Gene Mutation | CDHE Gene Mutation | Cadherin 1 Gene Mutation | Cadherin 1, Type 1, E-Cadherin (Epithelial) Gene Mutation | Cadherin, Epithelial Gene Mutation | Calcium-Dependent Adhesion Protein, Epithelial Gene Mutation | E-Cadherin Gene Mutation | ECAD Gene Mutation | LCAM Gene Mutation | Positive | UVO Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504654","Calcification Indicator","C126056","A textual indication as to whether calcification is present.","Calcification Indicator | CALCFIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033872","Psychiatrist","C93157","A physician who specializes in the treatment of emotional and mental disorders.","Psychiatrist | Psychiatry & Neurology Psychiatry | psychiatrist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274379","BK Virus Viral Load Measurement","C98710","The determination of the amount of BK virus viral load present in a sample.","BK Virus Viral Load Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031142","Peritoneal Disorder","C26848","A non-neoplastic or neoplastic disorder that affects the peritoneum.  Representative examples of non-neoplastic disorders include peritonitis and panniculitis.  Representative examples of neoplastic disorders include adenomatoid tumor, primary peritoneal carcinoma, metastatic carcinoma to the peritoneum, and malignant mesothelioma.","Peritoneal Disorder | Peritoneal Disease",,,,,,,,,,,,,,,"197324","Disorder of peritoneum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0240611","Ovarian Mass","C3882","An abnormal growth in the ovary.","Ovarian Mass | Mass of Ovary",,,,,,,,,,,,,,,"4129499","Mass of ovary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552199","CDK4 Gene Mutation","C150474","A change in the nucleotide sequence of the CDK4 gene.","CDK4 Gene Mutation | CDK4 mutation | Cell Division Kinase 4 Gene Mutation | Cyclin Dependent Kinase 4 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552194","CDKN1A Gene Mutation","C150475","A change in the nucleotide sequence of the CDKN1A gene.","CDKN1A Gene Mutation | CDKN1 Gene Mutation | CIP1 Gene Mutation | Cyclin Dependent Kinase Inhibitor 1A Gene Mutation | MDA-6 Gene Mutation | MDA6 Gene Mutation | P21 Gene Mutation | PIC1 Gene Mutation | SDI1 Gene Mutation | WAF1 Gene Mutation | p21CIP1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552193","CDKN1B Gene Mutation","C150476","A change in the nucleotide sequence of the CDKN1B gene.","CDKN1B Gene Mutation | CDKN4 Gene Mutation | Cyclin Dependent Kinase Inhibitor 1B Gene Mutation | KIP1 Gene Mutation | p27Kip1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552196","CHD4 Gene Mutation","C150477","A change in the nucleotide sequence of the CHD4 gene.","CHD4 Gene Mutation | CHD-4 Gene Mutation | Chromodomain Helicase DNA Binding Protein 4 Gene Mutation | Mi-2b Gene Mutation | Mi2-BETA Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552195","Chromosome 5 Rearrangement","C150478","A rearrangement of genomic material involving chromosome 5.","Chromosome 5 Rearrangement | Rearrangement of Chromosome 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552192","Chromosome 7 Rearrangement","C150479","A rearrangement of genomic material involving chromosome 7.","Chromosome 7 Rearrangement | Rearrangement of Chromosome 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552190","High CpG Island Methylator Phenotype","C150486","A phenotype characterized by hypermethylation of a high number of promoter-associated CpG islands.","High CpG Island Methylator Phenotype | CIMP High | CIMP-High | CIMP-High Phenotype Positive | CIMP-High Phenotype Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552185","Clostridium difficile Toxin Positive","C150487","An indication that Clostridium difficile toxin was detected in a sample.","Clostridium difficile Toxin Positive | C. diff. Toxin Positive | C. difficile Toxin Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552187","COX2 Positive","C150490","An indication that COX2 expression has been detected in a sample.","COX2 Positive | COX-2 Positive | Cyclo-Oxygenase-2 Positive | Cyclooxygenase 2 Positive | Cyclooxygenase-2 Positive | PTGS2 Positive | Prostaglandin G/H Synthase 2 Positive | Prostaglandin-Endoperoxide Synthase 2 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552186","CRLF2 Gene Mutation","C150491","A change in the nucleotide sequence of the CRLF2 gene.","CRLF2 Gene Mutation | CRLF2 Mutation | Cytokine Receptor Crl2 Gene Mutation | Cytokine Receptor Like Factor 2 Gene Mutation | Cytokine Receptor-Like Factor 2 Gene Mutation | TSLPR Gene Mutation | Thymic Stromal-Derived Lymphopoietin Receptor Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552300","CRP Level Greater than or Equal to 3 mg/L","C150492","A laboratory test result indicating that C-reactive protein is present in a sample at concentrations of 3 mg/L or more.","CRP Level Greater than or Equal to 3 mg/L | C-Reactive Protein Level Greater than or Equal to 3 Milligrams per Liter | C-Reactive Protein Level Greater than or Equal to 3 Milligrams/Liter | CRP Level Greater than or Equal to 3 | CRP Level Greater than or Equal to 3 Milligrams per Liter | CRP Level Greater than or Equal to 3 Milligrams/Liter | CRP Level Greater than or Equal to Three",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552299","CXCR4 Gene Mutation","C150493","A change in the nucleotide sequence of the CXCR4 gene.","CXCR4 Gene Mutation | C-X-C Chemokine Receptor Type 4 Gene Mutation | CD184 Gene Mutation | CXC-R4 Gene Mutation | CXCR-4 Gene Mutation | Chemokine (C-X-C Motif) Receptor 4 Gene Mutation | LAP3 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552302","CYLD Gene Mutation","C150494","A change in the nucleotide sequence of the CYLD gene.","CYLD Gene Mutation | CDMT Gene Mutation | CYLD Lysine 63 Deubiquitinase Gene Mutation | CYLD1 Gene Mutation | CYLDI Gene Mutation | Cylindromatosis (Turban Tumor Syndrome) Gene Mutation | EAC Gene Mutation | USPL2 Gene Mutation | Ubiquitin Specific Peptidase Like 2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552297","Deleterious IKZF1 Gene Mutation","C150496","A change in the nucleotide sequence of the IKZF1 gene that is associated with increased risk of disease.","Deleterious IKZF1 Gene Mutation | Deleterious IK1 Gene Mutation | Deleterious IKAROS Family Zinc Finger 1 Gene Mutation | Deleterious IKAROS Gene Mutation | Deleterious LYF1 Gene Mutation | Deleterious LyF-1 Gene Mutation | Deleterious ZNFN1A1 Gene Mutation | Deleterious hIk-1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552296","DNMT3A Gene Mutation","C150497","A change in the nucleotide sequence of the DNMT3A gene.","DNMT3A Gene Mutation | DNA Methyltransferase 3 Alpha Gene Mutation | DNA Methyltransferase 3A Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552298","DPYD Negative","C150498","An indication that expression of DPYD has not been detected in a sample.","DPYD Negative | DHP Negative | DHPDHASE Negative | DPD Negative | Dihydropyrimidine Dehydrogenase Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0241883","Epstein-Barr Virus Antibody Positive","C150499","An indication that antibodies that recognize the Epstein-Barr virus have been detected in a sample.","Epstein-Barr Virus Antibody Positive | Anti-EBV Antibody Positive | EBV Antibody Positive | Epstein Barr Virus Antibody Positive | HHV-4 Antibody Positive | HHV4 Antibody Positive | Human Herpesvirus 4 Antibody Positive | Human Herpesvirus-4 Antibody Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552293","Deleterious EGFR Gene Mutation","C150500","A change in the nucleotide sequence of the EGFR gene that is associated with increased risk of disease.","Deleterious EGFR Gene Mutation | Deleterious EGFR Mutation | Deleterious ERBB Gene Mutation | Deleterious ERBB1 Gene Mutation | Deleterious Epidermal Growth Factor Receptor Gene Mutation | Deleterious HER1 Gene Mutation | EGFR Driver Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552292","EGFR Negative","C150501","An indication that EGFR expression has not been detected in a sample.","EGFR Negative | ERBB Negative | ERBB1 Negative | Epidermal Growth Factor Receptor Negative | HER1 Negative | c-erbB1 Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552191","EGFRvIII Positive","C150485","An indication that expression of EGFRvIII has been detected in a sample.","EGFRvIII Positive | EGFR Variant III Positive | Epidermal Growth Factor Receptor Class III Variant Positive | Epidermal Growth Factor Receptor Variant III Positive | Epidermal Growth Factor Receptor vIII Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552295","EP300 Gene Mutation","C150502","A change in the nucleotide sequence of the EP300 gene.","EP300 Gene Mutation | E1A Binding Protein p300 Gene Mutation | KAT3B Gene Mutation | p300 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552294","Estrogen Receptor Positive by Immunohistochemistry 1-9 Percent","C150503","An immunohistochemical staining finding indicating that between 1 and 9 percent of the cells in a tissue sample are expressing estrogen receptor.","Estrogen Receptor Positive by Immunohistochemistry 1-9 Percent | ER Positive by Immunohistochemistry 1-9 Percent | ESR1 Positive by Immunohistochemistry 1-9 Percent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552131","HMB-45 Positive","C150425","An immunohistochemical finding that the monoclonal antibody HMB-45 binds to a the cells in a biosample.","HMB45-Positive Cells Present | HMB-45 Positive | HMB-45 Positive Cells Present | HMB-45-Positive Cells Present | HMB45 Positive | HMB45 Positive Cells Present | HMB45 Positive Cells Present | Human Melanoma Black 45 Positive Cells Present | Melanoma (gp100) Antibody (HMB45) Positive Cells Present | Monoclonal Mouse Anti-Human Melanocyte Protein PMEL Positive Cells Present | Monoclonal Mouse Anti-Human Melanosome, Clone HMB-45-Positive Cells Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552203","HLA-A*02:642 Positive Cells Present","C150470","A laboratory test result indicating the presence of HLA-A*02:642 positive cells in a tissue sample.","HLA-A*02:642 Positive Cells Present | HLA-A*02:642 Positive | HLA-A*02:642 Positive Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552280","DNA Damage Response Gene Mutation","C150520","Any change in the nucleotide sequence of a gene involved in DNA damage response pathways.","DNA Damage Response Gene Mutation | DDR Gene Alteration | DDR Gene Mutation | DNA Damage Response Gene Alteration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552336","PALB2 Biallelic Inactivation","C150582","The presence of mutations in both alleles of the PALB2 gene that either lead to loss of expression of the PALB2 protein or result in the translation of an inactive PALB2 protein.","PALB2 Biallelic Inactivation | FANCN Biallelic Gene Inactivation | Fanconi Anemia, Complementation Group N Biallelic Gene Inactivation | PALB2 Biallelic Gene Inactivation | PNCA3 Biallelic Gene Inactivation | Partner and Localizer of BRCA2 Biallelic Gene Inactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552335","FANCA Biallelic Inactivation","C150583","The presence of mutations in both alleles of the FANCA gene that either lead to loss of expression of the FANCA protein or result in the translation of an inactive FANCA protein.","FANCA Biallelic Inactivation | FA Biallelic Gene Inactivation | FA-H Biallelic Gene Inactivation | FA1 Biallelic Gene Inactivation | FAA Biallelic Gene Inactivation | FACA Biallelic Gene Inactivation | FAH Biallelic Gene Inactivation | FANCA Biallelic Gene Inactivation | FANCH Biallelic Gene Inactivation | Fanconi Anemia Complementation Group A Biallelic Gene Inactivation | Fanconi Anemia, Complementation Group A Biallelic Gene Inactivation | Fanconi Anemia, Complementation Group H Biallelic Gene Inactivation | Fanconi Anemia, Type 1 Biallelic Gene Inactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552338","ATM Monoallelic Inactivation","C150584","The presence of mutations in only one allele of the ATM gene that either lead to decreased of expression of the ATM protein or result in the translation of an inactive and potentially dominant-negative form of the ATM protein.","ATM Monoallelic Inactivation | A-T Mutated Monoallelic Gene Inactivation | AT Mutated Monoallelic Gene Inactivation | ATM Gene LOH | ATM Gene Loss of Heterozygosity | ATM LOH | ATM Loss of Heterozygosity | ATM Monoallelic Gene Inactivation | ATM Serine/Threonine Kinase Monoallelic Gene Inactivation | Ataxia Telangiectasia Mutated Monoallelic Gene Inactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552368","COL6A3 Positive","C150668","An indication that expression of COL6A3 has been detected in a sample.","COL6A3 Positive | Collagen Alpha-3(VI) Chain Positive | Collagen Type VI Alpha 3 Chain Positive | Type VI Collagen Alpha 3 Chain Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335038","Non-Neoplastic Respiratory System Disorder","C35755","A non-neoplastic disorder that affects the respiratory system.  Representative examples include pneumonia, chronic obstructive pulmonary disease, pulmonary failure, tracheitis, and tracheal agenesis.","Non-Neoplastic Respiratory System Disorder | Non-Neoplastic Respiratory Disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0949766","Physical Therapy","C15302","The treatment of deformity or disease through mechanical force and movement, including both active and passive exercises, intended to ameliorate injury, increase mobility, and improve overall function.","Physical Therapy | PT | Physiatric Procedure | Physical Medicine Procedure | Physical Therapeutics | Physical Therapy Procedure | Physiotherapy | Physiotherapy Procedure | physical therapy",,,,,,,,,,,,,,,"4238738|4280228","Physical therapy procedure|Physical medicine procedure",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1266824","Total Skin Electron Beam Radiation Therapy","C93341","Electron beam radiation therapy that targets the entire skin.","Total Skin Electron Beam Radiation Therapy | TSE Irradiation | TSEB Radiation Therapy | TSEB Therapy | TSEB radiation therapy | TSEI | Total Skin Electron Irradiation | total skin electron beam radiation therapy",,,,,,,,,,,,,,,"4020923","Total skin electron beam therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043030","General Wards","C150763","The part or unit of a hospital that provides care to adult patients with a variety of general medical needs.","General Medical Unit | General Medical Ward | General Ward",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552623","Oncology Unit","C150764","The part or unit of a hospital that provides specialized care for patients undergoing treatment for cancer.","Oncology Unit | Oncology Department | Oncology Ward",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2136015","Live in Assisted Living Facility","C113781","An indication that an individual is living in an assisted living facility.","Live in Assisted Living Facility | Live in assisted living | Living in Assisted Living Facility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0555024","Eloped","C150719","Married in secret, especially without parental consent.","Eloped | Elope",,,,,,,,,,,,,,,"4116182","Eloped",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0425152","Engaged","C150720","In a formal agreement for marriage.","Engaged | Engaged to be married | Engagement",,,,,,,,,,,,,,,"4204399","Engaged to be married",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037179","Single","C150721","Never married.","Single | Single Person",,,,,,,,,,,,,,,"4053842","Single person",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1510465","Widow","C150722","A woman who has lost her spouse by death and has not remarried.","Widow | ",,,,,,,,,,,,,,,"4149091","Widow",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552519","Widowed or Surviving Civil Partner","C150723","An individual who has lost their spouse by death, has not remarried, and who has legal rights related to the estate of the deceased spouse.","Widowed or Surviving Civil Partner | Widowed/surviving civil partner",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043174","Widower","C150724","A man who has lost his spouse by death and has not remarried.","Widower | ",,,,,,,,,,,,,,,"4302155","Widower",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0337600","Bachelor","C150725","A man who is not, and has never been, married.","Bachelor | ",,,,,,,,,,,,,,,"4185851","Bachelor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0425153","Broken Engagement","C150727","A formal agreement or promise to marry that is ended before the marriage takes place.","Broken Engagement | Broken engagement",,,,,,,,,,,,,,,"4022641","Broken engagement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0425154","Broken with Partner","C150728","The ending of a social partnership.","Broken with Partner | Broken with partner",,,,,,,,,,,,,,,"4145800","Broken with partner",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0555028","Spouse Left Home","C150730","An indication that a married individual who is or was living with another person left their shared home.","Spouse Left Home | Spouse left home",,,,,,,,,,,,,,,"4171752","Spouse left home",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0555049","Husband Left Home","C150731","An indication that a male, married individual who is or was living with another person left their shared home.","Husband Left Home | Husband left home",,,,,,,,,,,,,,,"4079702","Husband left home",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0555050","Wife Left Home","C150732","An indication that a female, married individual who is or was living with another person left their shared home.","Wife Left Home | Wife left home",,,,,,,,,,,,,,,"4172699","Wife left home",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552520","Cohabitating","C150733","Living together as if married, usually without legal or religious sanction.","Cohabitating | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009448","Common Law Partnership","C150735","A legal status where individuals are living in a continuous, conjugal relationship for a period of time defined by law.","Common Law Partnership | Common Law Marriage | Common law partnership",,,,,,,,,,,,,,,"4030401","Common law partnership",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552522","Civil Partnership Dissolved","C150736","Indicates that a civil partnership has been legally dissolved.","Civil Partnership Dissolved | Divorced/person whose civil partnership has been dissolved",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552526","Marital or Civil Status Not Disclosed","C150742","An indication that the marital or civil status of a relationship has not been disclosed.","Marital or Civil Status Not Disclosed | Marital/civil state not disclosed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552527","Married or Civil Partner","C150743","An indication that an individual is in a legally recognized relationship with another person, with the same rights and responsibilities as a marriage.","Married or Civil Partner | Married/civil partner",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0558125","Monogamous","C150744","An indication that an individual is or was married to single individual at a given time.","Monogamous | ",,,,,,,,,,,,,,,"4021661","Monogamous",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0425381","Newly Wed","C150745","An indication that an individual has recently married.","Newly Wed | Newly wed | Newlywed",,,,,,,,,,,,,,,"4132774","Newly wed",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3496283","Purposely Unmarried and Sexually Abstinent","C150746","An indication that an individual is intentionally not married and abstains from engaging in sexual activities.","Purposely Unmarried and Sexually Abstinent | Purposely unmarried and sexually abstinent",,,,,,,,,,,,,,,"43021238","Purposely unmarried and sexually abstinent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0425380","Remarried","C150747","An indication that an individual has married, after already having been married at least once.","Remarried | ",,,,,,,,,,,,,,,"4150598","Remarried",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1553498","home health encounter","C150752","A patient encounter that takes place in a private home.","Home Health Encounter | HH | Home | Home Care Visit | Home Health",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337598","Spinster","C150749","An unmarried, older woman, beyond the usual age for marriage.","Spinster | ",,,,,,,,,,,,,,,"4270893","Spinster",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0234004","Trial Separation","C150750","An indication that a couple has informally separated.","Trial Separation | Trial separation",,,,,,,,,,,,,,,"4322182","Trial separation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0086972","Separated from Cohabitee","C150748","An indication that an individual is separated from the person with whom they were sharing a home.","Separated from Cohabitee | Separated from cohabitee",,,,,,,,,,,,,,,"4172698","Separated from cohabitee",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1555324","inpatient encounter","C150753","A patient encounter where a patient is admitted to a hospital or equivalent facility.","Inpatient Encounter | IMP | In Patient | Inpatient | Inpatient Visit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551345","acute inpatient encounter","C150754","An inpatient encounter for short-term treatment of a severe injury or episode of illness, or other urgent medical condition.","Inpatient Acute Care Encounter | ACUTE | Acute Inpatient Care | Inpatient Acute | Inpatient Acute Care | Inpatient Acute Care Visit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553499","Inpatient Non-acute Care Encounter","C150755","An inpatient encounter for a non-acute condition.","Inpatient Non-acute Care Encounter | Inpatient Non-acute | Inpatient Non-acute Care | Inpatient Non-acute Care Visit | NONAC | Non-Acute Inpatient Care | Non-Acute Institutional Stay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554574","Pre-admission Encounter","C150757","A patient encounter that takes place before the planned date for a medical service.","Pre-admission Encounter | PRENC | Pre-admission",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1698490","short stay encounter","C150758","A patient encounter where the patient is admitted to a health care facility for a predetermined length of time, usually less than 24 hours.","Short Stay | SS | Short Stay Encounter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553497","virtual patient encounter","C150759","A patient encounter where the patient and the practitioner(s) are not in the same physical location and the interaction takes place by electronic means.","Virtual Patient Encounter | VIRTUAL VISIT | VR | Virtual | Virtual Encounter | Virtual Visit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552622","Emergency Department Admit to Inpatient Hospital Stay","C150760","A patient encounter that begins in an emergency department and the patient is subsequently admitted to a hospital as an inpatient.","Emergency Department Admit to Inpatient Hospital Stay | EI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554569","Observation Stay","C150761","A patient encounter where the patient receives short-term treatment in a hospital but is not admitted and remains classified as an outpatient.","Observation Stay | OS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554541","Institutional Professional Consultation","C150762","A patient encounter with a healthcare professional for a medical consultation.","Institutional Professional Consultation | IC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040296","Tissue Procurements","C150718","The removal of tissues from a donor for the purpose of transplantation.","Tissue Procurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0557850","Long Term Care Hospital","C135382","A hospital equipped and staffed to provide prolonged care to patients.","Long Term Care Hospital | LONG TERM CARE HOSPITAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987129","Gastrointestinal Mixed Adenoneuroendocrine Carcinoma","C95406","A carcinoma that arises from the digestive system and is characterized by the presence of a malignant glandular epithelial component and a malignant neuroendocrine component. At least 30% of either component should be present for the diagnosis to be made.","Digestive System Mixed Adenoneuroendocrine Carcinoma | Digestive System Mixed Adenoneuroendocrine Cancer | Gastrointestinal MANEC | Gastrointestinal Mixed Adenoneuroendocrine Carcinoma | MANEC | Mixed Adenoneuroendocrine Carcinoma | Mixed adenoneuroendocrine carcinoma","8244/3","Mixed adenoneuroendocrine carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C1879746","Aspect (characteristic)","C61468","A characteristic to be considered; a distinct feature or element.","Aspect | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882332","Periampullary Region","C60699","The area of the duodenum surrounding the ampulla of Vater.","Periampullary Region | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332243","Ampulla of Vater Adenocarcinoma","C6650","An invasive carcinoma with glandular differentiation arising from the ampulla of Vater.  Signs and symptoms include jaundice, abdominal pain, anorexia, nausea, vomiting, and weight loss.","Ampulla of Vater Adenocarcinoma | Adenocarcinoma of Ampulla of Vater | Ampullary Adenocarcinoma | Invasive Adenocarcinoma of the Ampullary Region",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272480","Ampulla of Vater Neuroendocrine Carcinoma","C95984","An aggressive high-grade carcinoma with neuroendocrine differentiation that arises from the ampulla of Vater. It is composed of malignant small or large cells. The mitotic count is more than 20 per 2 mm2 and/or the Ki-67 index is more than 20%.","Ampulla of Vater Neuroendocrine Carcinoma | Ampulla of Vater High Grade Neuroendocrine Carcinoma | Ampulla of Vater NEC | Ampulla of Vater NEC G3 | Ampulla of Vater Poorly Differentiated Endocrine Carcinoma | Ampulla of Vater Small and Large Cell Endocrine Carcinoma | Neuroendocrine Carcinoma of the Ampullary Region",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0262401","Ampulla of Vater Carcinoma","C3908","A carcinoma arising from the ampulla of Vater.  The vast majority of cases are adenocarcinomas.  Signs and symptoms include jaundice, abdominal pain, anorexia, nausea, vomiting, and weight loss.","Ampulla of Vater Carcinoma | Ampulla of Vater Cancer | Ampullary Carcinoma | ampulla of Vater cancer | ampullary cancer",,,,,,,,,,,,,,,"4115272","Carcinoma of ampulla of Vater",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332247","Ampulla of Vater Invasive Intestinal Type Adenocarcinoma","C27415","An invasive adenocarcinoma arising from the ampulla of Vater. Morphologically, it is characterized by the presence of intestinal-type malignant epithelial cells.","Ampulla of Vater Intestinal-Type Adenocarcinoma | Ampulla of Vater Invasive Intestinal Type Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3472607","Ampulla of Vater Pancreatobiliary Type Adenocarcinoma","C95963","An invasive adenocarcinoma that arises from the ampulla of Vater. It is characterized by the presence of malignant cells that resemble the malignant cells of the pancreatic ductal or extrahepatic bile duct carcinomas.","Ampulla of Vater Pancreatobiliary Type Adenocarcinoma | Pancreatobiliary-type carcinoma",,,,,,,,,,,,,,,"42872899","Pancreatobiliary-type carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332245","Ampulla of Vater Adenosquamous Carcinoma","C27418","A carcinoma with glandular and squamous differentiation arising from the ampulla of Vater. Signs and symptoms include jaundice, abdominal pain, anorexia, nausea, vomiting, and weight loss.","Ampulla of Vater Adenosquamous Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332249","Ampulla of Vater Signet Ring Cell Carcinoma","C6656","An adenocarcinoma arising from the ampulla of Vater.  Morphologically, it is characterized by the presence of mucin-containing signet-ring cells.","Ampulla of Vater Signet Ring Cell Adenocarcinoma | Ampulla of Vater Signet Ring Cell Carcinoma | Ampulla of Vater Signet Ring Cell Carcinoma | Ampulla of Vater Signet-Ring Cell Carcinoma | Ampullary Signet Ring Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332246","Ampulla of Vater Clear Cell Adenocarcinoma","C27414","A carcinoma with glandular differentiation arising from the ampulla of Vater.  Morphologically, it is characterized by the presence of glycogen-rich cells with hyperchromatic nuclei.","Ampulla of Vater Clear Cell Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332248","Ampulla of Vater Mucinous Adenocarcinoma","C27416","A carcinoma with glandular differentiation arising from the ampulla of Vater.  Morphologically, it is characterized by the presence of mucoid stroma formation.","Ampulla of Vater Mucinous Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552586","BRD4 Gene Mutation","C150825","A change in the nucleotide sequence of the BRD4 gene.","BRD4 Gene Mutation | Bromodomain Containing 4 Gene Mutation | Bromodomain-Containing 4 Gene Mutation | CAP Gene Mutation | Chromosome-Associated Protein Gene Mutation | HUNK1 Gene Mutation | HUNKI Gene Mutation | MCAP Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552753","DOT1L Gene Mutation","C150907","A change in the nucleotide sequence of the DOT1L gene.","DOT1L Gene Mutation | DOT1 Gene Mutation | DOT1 Like Histone Lysine Methyltransferase Gene Mutation | DOT1-like, Histone H3 Methyltransferase (S. cerevisiae) Gene Mutation | Histone Methyltransferase DOT1L Gene Mutation | KMT4 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552754","IKBKE Gene Mutation","C150908","A change in the nucleotide sequence of the IKBKE gene.","IKBKE Gene Mutation | IKK-E Gene Mutation | IKK-I Gene Mutation | IKKE Gene Mutation | IKKI Gene Mutation | Inhibitor of Kappa Light Polypeptide Gene Enhancer in B-Cells, Kinase Epsilon Gene Mutation | Inhibitor of Nuclear Factor Kappa B Kinase Subunit Epsilon Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539106","Definable","C151401","Able to concisely explain of the meaning of a word or phrase or symbol.","Definable | Defined",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553235","Tumor Implant","C151403","A nodular tumor that develops at a site in a body cavity or the surface of an organ, at a distance from the primary tumor.","Tumor Implant | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL568584","Septation","C151402","The formation of a division between cavities or parts of an organism.","Septation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230179","Left Upper Quadrant of Abdomen","C151397","The region of the abdomen that extends from the median plane to the left of the patient, and from the umbilical plane to the left ribcage.","Left Upper Quadrant of Abdomen | ABDOMINAL QUADRANT, LEFT UPPER | LUQ | Left Upper Quadrant | left upper quadrant of abdomen",,,,,,,,,,,,,,,"4314121","Structure of left upper quadrant of abdomen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0230177","Right Upper Quadrant of Abdomen","C151398","The region of the abdomen that extends from the median plane to the right of the patient, and from the umbilical plane to the right ribcage.","Right Upper Quadrant of Abdomen | ABDOMINAL QUADRANT, RIGHT UPPER | RUQ | Right Upper Quadrant | right upper quadrant of abdomen",,,,,,,,,,,,,,,"4196689","Structure of right upper quadrant of abdomen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053982","Subsequent Relapse","C123400","The reemergence of a disorder as diagnosed by clinical and/or laboratory evidence following two or more documented periods of remission.","Subsequent Relapse | Subsequent Recurrence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054953","First Relapse","C123399","The reemergence of a disorder as diagnosed by clinical and/or laboratory evidence following a single documented period of remission.","First Relapse | First Recurrence | INITIAL DISEASE RELAPSE | Initial Recurrence | Initial Relapse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449722","Dominant Hand","C114182","The preferred hand of use for controlled and efficient performance of motor tasks.","Dominant Hand | HANDDOM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697501","Giant Platelet Count (procedure)","C74728","The determination of the number of giant platelets present in a sample.","Giant Platelet Count | Giant Platelets | PLATGNT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550651","Agranular Platelets Count","C147415","The determination of the amount of agranular platelets present in a sample.","Agranular Platelets Count | PLATAGRN | Platelets, Agranular",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002890","Leukoerythroblastic Reaction","C36218","A laboratory test result indicating the presence of nucleated red blood cells and immature leukocytes in the peripheral blood. It is observed in disorders causing extramedullary hematopoiesis such as myelofibrosis and metastatic cancer to the bone marrow.","Leukoerythroblastic Reaction | Leukoerythroblastosis",,,,,,,,,,,,,,,"4098131","Myelophthisic anemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0243092","Cellular Structures","C14135","The components of the cell and how they are arranged.","Cell Structure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553178","Supradiaphragmatic","C151950","Located or performed from above the diaphragm.","Supradiaphragmatic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493351","Suprarenal","C151959","Located above the upper pole of the kidney.","Suprarenal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0507880","Axillary Lymph Node Level I","C123461","Axillary lymph nodes located inferolateral to the pectoralis minor.","Axillary Lymph Node Level I | AXILLARY LYMPH NODE LEVEL I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0507881","Axillary Lymph Node Level II","C123462","Axillary lymph nodes located posterior to the pectoralis minor.","Axillary Lymph Node Level II | AXILLARY LYMPH NODE LEVEL II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897601","Single Nucleotide Polymorphism Array","C116151","A genomic microarray-based method able to detect single nucleotide polymorphisms.","Single Nucleotide Polymorphism Array | Genotype Chip | SNP ARRAY | SNP Genotyping | SNP Probe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518053","Lymph Node by Anatomic Site","C33027","A lymph node named according to its location in the body.","Lymph Node by Anatomic Site | Lymph Node Station | Nodal Station | lymph node involved site | lymph_node_involved_site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897880","Porta Hepatis Lymph Node","C117871","A lymph node located in the transverse fissure of the liver.","Porta Hepatis Lymph Node | PORTA HEPATIS LYMPH NODE | Portahepatis lymph node group (body structure)",,,,,,,,,,,,,,,"4081785","Portahepatis lymph node group",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0226025","Infrarenal Aortic Segment","C116179","The portion of the abdominal aorta that lies below the kidneys.","Infrarenal Aortic Segment | INFRARENAL AORTA",,,,,,,,,,,,,,,"4151366","Structure of infrarenal aorta",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554539","Bowl Dosing Unit","C151970","A dosing unit equal to the amount of smokable material in a pipe bowl.","Bowl Dosing Unit | BOWL | Bowl | Bowl Dosage Unit | {BOWL}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0181264","Ice Pack","C151989","A container filled with frozen material that retains its temperature for an extended period.","Ice Pack | ",,,,,,,,,,,,,,,"4244127","Ice bag",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL502778","Fluid Volume","C124480","The amount of three dimensional space occupied by a fluid.","Fluid Volume | FVOLUME",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525715","Neoplastic Plasma Cells 30 Percent or Less of Bone Marrow Nucleated Cells","C138182","A semi-quantitative microscopic finding indicating that 30 percent or less of the nucleated cells in a bone marrow sample are neoplastic plasma cells.","Neoplastic Plasma Cells 30 Percent or Less of Bone Marrow Nucleated Cells | Neoplastic Plasma Cells Less than or Equal to 30 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553369","Intensity-Modulated Radiotherapy Forward Planning","C152034","A procedure that utilizes manual determinations of beam angles and aperture exposure time to optimize radiation dose distributions associated with intensity-modulated radiotherapy (IMRT).","Intensity-Modulated Radiotherapy Forward Planning | Forward-Planned Intensity-Modulated Radiation Therapy | IMRT Forward Planning",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553370","Tangential Fields","C152035","A two-dimensional (2D) array of opposing, oblique beams of external radiation. This approach is most often used in the adjuvant radiotherapy of breast malignancies.","Tangential Fields | Tangential Field | Tangents | TgF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553368","Intensity-Modulated Radiotherapy Inverse Planning","C152033","A procedure that utilizes a computerized algorithm to directly determine aperture intensities for optimal radiation dose distributions associated with intensity-modulated radiotherapy (IMRT).","Intensity-Modulated Radiotherapy Inverse Planning | IMRT Reverse Planned | Inverse-Planned Intensity-Modulated Radiation Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553356","Analgesic Quantification Algorithm","C152021","An algorithm designed to categorize  analgesic medication use, and capture changes in the dosing, frequency, and/or type of analgesic medications administered.","Analgesic Quantification Algorithm | AQA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553357","No Analgesic","C152022","A response that indicates the patient did not use any analgesic.","No Analgesic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553358","Non-Opioid Analgesic","C152023","A response that indicates the patient used a non-opioid analgesic.","Non-Opioid Analgesic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553359","Weak Opioids","C152024","A response that indicates the patient used weak opioids.","Weak Opioids | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553360","Strong Opioids Less than or Equal to 75 mg Oral Morphine Equivalent per Day","C152025","A response that indicates the patient used strong opioids at less than or equal to 75 mg oral morphine equivalents (OME) per day.","Strong Opioids Less than or Equal to 75 mg Oral Morphine Equivalent per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553361","Strong Opioids Greater than 75-150 mg Oral Morphine Equivalent per Day","C152026","A response that indicates the patient used strong opioids at greater than 75 mg to a maximum of 150 mg oral morphine equivalents (OME) per day.","Strong Opioids Greater than 75-150 mg Oral Morphine Equivalent per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553362","Strong Opioids Greater than 150-300 mg Oral Morphine Equivalent per Day","C152027","A response that indicates the patient used strong opioids at greater than 150 mg to a maximum of 300 mg oral morphine equivalents (OME) per day.","Strong Opioids Greater than 150-300 mg Oral Morphine Equivalent per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553363","Strong Opioids Greater than 300-600 mg Oral Morphine Equivalent per Day","C152028","A response that indicates the patient used strong opioids at greater than 300 mg to a maximum of 600 mg oral morphine equivalents (OME) per day.","Strong Opioids Greater than 300-600 mg Oral Morphine Equivalent per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553364","Strong Opioids Greater than 600 mg Oral Morphine Equivalent per Day","C152029","A response that indicates the patient used strong opioids at greater than 600 mg oral morphine equivalents (OME) per day.","Strong Opioids Greater than 600 mg Oral Morphine Equivalent per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0507882","Axillary Lymph Node Level III","C123463","Axillary lymph nodes located superomedial to pectoralis minor.","Axillary Lymph Node Level III | AXILLARY LYMPH NODE LEVEL III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553387","Direct Field","C152052","A radiation therapy technique where treatment is emitted along the central axis of an external radiation beam.","Direct Field | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553388","Modified Wide Tangent Field","C152053","A radiation therapy technique used to treat breast malignancies where the treatment fields are wide superiorly to include the internal mammary nodes, but narrow inferiorly to reduce radiation exposure to the heart and lung.","Modified Wide Tangent Field | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553389","Direct Electron Field","C152054","A radiation therapy technique where external electron beams are used to deliver treatment to superficial malignancies while sparing underlying organs at risk.","Direct Electron Field | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553390","Direct Mixed Photon and Electron Field","C152055","A radiation therapy technique where external photon and electron beams are used to deliver treatment of superficial and deep-seated malignancies, respectively, while sparing underlying organs at risk.","Direct Mixed Photon and Electron Field | Mixed | Radiation, Mixed Photon Beam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0556641","Megavolt","C152056","A SI derived unit of electric potential and electromotive force that is equal to one million volts.","Megavolt | MV | Megavolts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553391","Megaelectronvolt","C152057","A unit of energy that is equal to one million electron volts.","Megaelectronvolt | 10^6 Electronvolts | 10^6 eV | MeV | Megaelectron Volt | Megaelectronvolts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539073","In the Field","C102650","A setting outside the clinic or a comparable health care facility, e.g., a doctor's office, the subject's home or workplace, a school, a public park, or a restaurant.","In the Field | FIELD | FLD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0585339","Every Six Months","C89789","To be done at regular intervals of every six months.","Every Six Months | Every 6 Months | Q6M",,,,,,,,,,,,,,,"4288401","Every six months",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0546547","Bone Marrow Aspiration and Biopsy","C92958","A procedure in which a small sample of bone marrow (soft, sponge-like tissue in the center of most bones) and bone is removed. A small area of skin and the surface of the bone underneath are numbed with an anesthetic. Then a special wide needle is pushed into the bone. A sample of liquid bone marrow is removed with a syringe attached to the needle. The syringe is then removed and the needle is rotated to remove a sample of the bone and the bone marrow. Both the bone marrow and bone samples are sent to a laboratory to be looked at under a microscope.","Bone Marrow Aspiration and Biopsy | bone marrow aspiration and biopsy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553196","Occasionally","C151974","Not frequently or regularly.","Occasionally | From time to time, occasionally | Only occasionally",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553211","Mixed Phenotype Acute Leukemia, NOS, Rare Subtypes","C151990","A very rare mixed phenotype acute leukemia in which the blasts express combinations of B, T, myeloid, and megakaryocytic lineage markers but are negative for KMT2A rearrangement and t(9;22)(q34;q11.2) translocation. The prognosis is usually unfavorable.","Mixed Phenotype Acute Leukemia, Rare Types | Mixed Phenotype Acute Leukemia, NOS, Rare Subtypes | Mixed Phenotype Acute Leukemia, Not Otherwise Specified, Rare Subtypes | Mixed Phenotype Acute Leukemia, Not Otherwise Specified, Rare Subtypes | Mixed Phenotype Acute Leukemia, Rare Subtypes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553212","Mixed Phenotype Acute Leukemia, B/T/Myeloid, NOS","C151991","A very rare mixed phenotype acute leukemia in which the blasts show evidence of B-cell, T-cell, and myeloid lineage but are negative for KMT2A rearrangement and t(9;22)(q34;q11.2) translocation.","Mixed Phenotype Acute Leukemia, B/T/Myeloid | MPAL-B/T/M | Mixed Phenotype Acute Leukemia, B/T/Myeloid, NOS | Mixed Phenotype Acute Leukemia, B/T/Myeloid, Not Otherwise Specified | Mixed Phenotype Acute Leukemia, B/T/Myeloid, Not Otherwise Specified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553213","Mixed Phenotype Acute Leukemia, B/T, NOS","C151992","A very rare mixed phenotype acute leukemia in which the blasts show clear-cut evidence of both B-cell and T-cell lineage but are negative for KMT2A rearrangement and t(9;22)(q34;q11.2) translocation.","Mixed Phenotype Acute Leukemia, B/T | MPAL-B/T | Mixed Phenotype Acute Leukemia, B/T, NOS | Mixed Phenotype Acute Leukemia, B/T, Not Otherwise Specified | Mixed Phenotype Acute Leukemia, B/T, Not Otherwise Specified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553302","Radiation Therapy Beam Energy","C152094","External rays of high energy ionizing radiation that are delivered to precise locations within the body.","Radiation Therapy Beam Energy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553305","Lung Inhomogeneity Correction","C152097","Adjustment of radiation therapy measurements for the effects of increased transmission through lung tissue in the treatment of thoracic malignancies.","Lung Inhomogeneity Correction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0679247","Terminal Disease","C9228","An illness that has a prognosis of death.","Terminal Disease | Terminal Illness | terminal disease",,,,,,,,,,,,,,,"4116982","Terminal illness",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2826786","CDISC CDASH Variable Terminology","C83188","The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) variables used by the Clinical Data Acquisition Standards Harmonization (CDASH) group.","CDISC CDASH Variable Terminology | CDISC-CDASH VARIABLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1541282","Alternative Medical Therapy","C64386","Treatment used instead of, or supplementary to, conventional Western-based practices. Alternative medicine includes treatments and practices such as acupuncture, holistic medicine, homeopathy, ayurveda, Chinese medicine, massage therapy, herbal therapy, and biofeedback.","Alternative Medical Procedure | Alternative Medical Therapy | Alternative Product Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553312","Drug Preload","C152104","The administration of an additional aliquot of an agent ahead of a standard dose, with the intent of raising the concentration of the agent in the compartment to which it is administered.","Drug Preload | Preload",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552322","MECOM Positive","C150599","An indication that expression of MECOM has been detected in a sample.","MECOM Positive | EVI-1 Positive | EVI1 Positive | Ecotropic Virus Integration 1 Site Positive | Ecotropic Virus Integration Site 1 Positive | MDS1 Positive | MDS1 and EVI1 Complex Positive | MDS1-EVI1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552244","F3 Positive","C150554","An indication that expression of F3 has been detected in a sample.","F3 Positive | CD142 Antigen Positive | CD142 Positive | Coagulation Factor III Positive | Factor III Positive | TF Positive | Tissue Factor Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552312","FGF19 Gene Amplification","C150612","A molecular genetic abnormality indicating the presence of multiple copies of the FGF19 gene.","FGF19 Gene Amplification | FGF-19 Gene Amplification | FGF19 Amplification | Fibroblast Growth Factor 19 Gene Amplification | Fibroblast Growth Factor-19 Gene Amplification | HBGF-1 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552311","FGFR Family Alteration Negative","C150613","An indication that mutation, overexpression, fusion or rearrangement of an FGFR family member has not been detected in a sample.","FGFR Family Alteration Negative | FGF Receptor Alteration Negative | FGF Receptor Family Alteration Negative | FGFR Alteration Negative | Fibroblast Growth Factor Receptor Alteration Negative | Fibroblast Growth Factor Receptor Family Alteration Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552314","FGFR1 Gene Alteration Positive","C150614","An indication that mutation, overexpression, fusion or rearrangement involving the FGFR1 gene has been detected in a sample.","FGFR1 Gene Alteration Positive | BFGFR Gene Alteration Positive | CD331 Gene Alteration Positive | CEK Gene Alteration Positive | FGFBR Gene Alteration Positive | FGFR-1 Gene Alteration Positive | FGFR1 Gene Aberration | FGFR1 Gene Aberration Positive | FGFR1 Gene Alteration | FLG Gene Alteration Positive | FLT-2 Gene Alteration Positive | FLT2 Gene Alteration Positive | FMS-Like Tyrosine Kinase 2 Gene Alteration Positive | Fibroblast Growth Factor Receptor 1 Gene Alteration Positive | KAL2 Gene Alteration Positive | N-SAM Gene Alteration Positive | OGD Gene Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552313","FGFR1 Gene Translocation","C150615","A cytogenetic abnormality that refers to any translocation involving the FGFR1 gene.","FGFR1 Gene Translocation | BFGFR Gene Translocation | CD331 Gene Translocation | CEK Gene Translocation | FGFBR Gene Translocation | FGFR-1 Gene Translocation | FLG Gene Translocation | FLT-2 Gene Translocation | FLT2 Gene Translocation | FMS-Like Tyrosine Kinase 2 Gene Translocation | Fibroblast Growth Factor Receptor 1 Gene Translocation | KAL2 Gene Translocation | N-SAM Gene Translocation | OGD Gene Translocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552308","FGFR2 Fusion Positive","C150616","An indication that expression of a fusion containing sequences from FGFR2 has been detected in a sample.","FGFR2 Fusion Positive | BEK Fusion Positive | CD332 Antigen Fusion Positive | CD332 Fusion Positive | ECT1 Fusion Positive | FGFR-2 Fusion Positive | FGFR2 Fusion | Fibroblast Growth Factor Receptor 2 Fusion Positive | K-SAM Fusion Positive | KGFR Fusion Positive | Keratinocyte Growth Factor Receptor Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552307","FGFR2 Gene Alteration Positive","C150617","An indication that mutation, overexpression, fusion or rearrangement involving the FGFR2 gene has been detected in a sample.","FGFR2 Gene Alteration Positive | BEK Gene Alteration Positive | CD332 Gene Alteration Positive | ECT1 Gene Alteration Positive | FGFR-2 Gene Alteration Positive | FGFR2 Alteration Positive | FGFR2 Gene Aberration | FGFR2 Gene Aberration Positive | FGFR2 Gene Alteration | Fibroblast Growth Factor Receptor 2 Gene Alteration Positive | K-SAM Gene Alteration Positive | KGFR Gene Alteration Positive | Keratinocyte Growth Factor Receptor Gene Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552310","FGFR3 Gene Alteration Positive","C150618","An indication that mutation, overexpression, fusion or rearrangement involving the FGFR3 gene has been detected in a sample.","FGFR3 Gene Alteration Positive | CD333 Gene Alteration Positive | FGFR-3 Gene Alteration Positive | FGFR3 Alteration Positive | FGFR3 Gene Aberration | FGFR3 Gene Aberration Positive | FGFR3 Gene Alteration | Fibroblast Growth Factor Receptor 3 Gene Alteration Positive | JKT4 Gene Alteration Positive | JTK4 Gene Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552309","FGFR3 Gene Translocation","C150619","A cytogenetic abnormality that refers to any translocation involving the FGFR3 gene.","FGFR3 Gene Translocation | CD333 Gene Translocation | FGFR-3 Gene Translocation | Fibroblast Growth Factor Receptor 3 Gene Translocation | JKT4 Gene Translocation | JTK4 Gene Translocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552303","FGFR4 Alteration Positive","C150621","An indication that mutation, overexpression, fusion or rearrangement involving FGFR4 has been detected in a sample.","FGFR4 Alteration Positive | CD334 Alteration Positive | FGFR-4 Alteration Positive | Fibroblast Growth Factor Receptor 4 Alteration Positive | JKT2 Alteration Positive | JTK2 Alteration Positive | TKF Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552305","Activating FLT3 Gene Mutation","C150623","A change in the nucleotide sequence of the FLT3 gene that that results in constitutive activation of receptor-type tyrosine-protein kinase FLT3 and its downstream signaling pathways.","Activating FLT3 Gene Mutation | Activating CD135 Gene Mutation | Activating FLK2 Gene Mutation | Activating FLT3 Gene Mutant | Activating FMS-Related Tyrosine Kinase 3 Gene Mutation | FLT3 Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552403","FLT3 Gene Amplification","C150624","A molecular genetic abnormality indicating the presence of multiple copies of the FLT3 gene.","FLT3 Gene Amplification | CD135 Gene Amplification | FLK2 Gene Amplification | FLT3 Amplification | FMS-Related Tyrosine Kinase 3 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552402","FLT3 Internal Tandem Duplication Negative","C150625","An indication that internal tandem duplication within the FLT3 gene has not been detected in a sample.","FLT3 Internal Tandem Duplication Negative | FLT3-ITD Mutation Negative | FLT3-ITD Negative | FLT3/ITD Mutation Negative | FLT3/ITD Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552405","FLT3 Internal Tandem Duplication Positive","C150626","An indication that internal tandem duplication within the FLT3 gene has been detected in a sample.","FLT3 Internal Tandem Duplication Positive | FLT3-ITD Mutation Positive | FLT3-ITD Positive | FLT3/ITD Mutation Positive | FLT3/ITD Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552404","FOXO1 Fusion Positive","C150627","An indication that expression of a fusion containing sequences from FOXO1 has been detected in a sample.","FOXO1 Fusion Positive | FKH1 Fusion Positive | FKHR Fusion Positive | FOXO1 Fusion Mutation | FOXO1A Fusion Positive | Forkhead Box O1 Fusion Positive | Forkhead Box O1A Fusion Positive | Forkhead in Rhabdomyosarcoma Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552399","GATA3 Gene Mutation","C150628","A change in the nucleotide sequence of the GATA3 gene.","GATA3 Gene Mutation | GATA Binding Protein 3 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552398","Germline BRCA1 Gene Mutation","C150629","A change in the nucleotide sequence of the BRCA1 gene that originates in the gametes.","Germline BRCA1 Gene Mutation | Germline BRCA1 Mutation | Germline BROVCA1 Gene Mutation | Germline Breast Cancer Type 1 Susceptibility Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552401","Germline BRCA2 Gene Mutation","C150630","A change in the nucleotide sequence of the BRCA2 gene that originates in the gametes.","Germline BRCA2 Gene Mutation | Germline BRCA2 Mutation | Germline Breast Cancer Type 2 Susceptibility Gene Mutation | Germline FANCD1 Gene Mutation | Germline XRCC11 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552400","Human Anti-Chimeric Antibody Positive","C150631","An indication that antibodies directed against chimeric therapeutic antibodies have been detected in a human sample.","Human Anti-Chimeric Antibody Positive | HACA Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552394","ERBB2 Exon 20 Insertion Mutation","C150633","A molecular genetic abnormality indicating the presence of an in-frame insertion mutation occurring within exon 20 of the ERBB2 gene.","ERBB2 Exon 20 Insertion Mutation | CD340 Exon 20 Insertion Mutation | Erb-B2 Receptor Tyrosine Kinase 2 Exon 20 Insertion Mutation | Erb-B2 Receptor Tyrosine Kinase Exon 20 Insertion Mutation | HER-2 Exon 20 Insertion Mutation | HER2 Exon 20 Insertion Mutation | HER2/Neu Exon 20 Insertion Mutation | Neu Exon 20 Insertion Mutation | c-erbB2 Exon 20 Insertion Mutation | v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 Exon 20 Insertion Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552397","ERBB2 Overexpression","C150634","An indication that overexpression of ERBB2 has been detected in a sample.","ERBB2 Overexpression | Erb-B2 Receptor Tyrosine Kinase Overexpression | HER2 Overexpression | HER2/neu Overexpression | NEU Overexpression | Proto-Oncogene Neu Overexpression | Receptor Tyrosine-Protein Kinase erbB-2 Protein Variant Overexpression | Tyrosine Kinase-Type Cell Surface Receptor HER2 Overexpression | v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 Overexpression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552396","ERBB3 Positive","C150636","An indication that expression of ERBB3 has been detected in a sample.","ERBB3 Positive | ERBB3 Receptor Protein-Tyrosine Kinase Positive | ErbB-3 Positive | HER-3 Positive | HER3 Positive | Receptor Tyrosine-Protein Kinase erbB-3 Positive | Tyrosine Kinase-Type Cell Surface Receptor HER3 Positive | c-erbB-3 Positive | c-erbB3 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552390","HGF Gene Mutation","C150638","A change in the nucleotide sequence of the HGF gene.","HGF Gene Mutation | F-TCF Gene Mutation | HGF/SF Gene Mutation | HPTA Gene Mutation | Hepatocyte Growth Factor Gene Mutation | SF Gene Mutation | Scatter Factor Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552392","HLA-A*0201 Negative","C150640","An indication that cells expressing HLA-A*0201 have not been detected in a tissue sample.","HLA-A*0201 Negative | HLA-A*02:01 Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552387","Homologous Recombination Repair Biallelic Inactivation","C150641","The presence of mutations in both alleles of a gene involved in homologous recombination-type DNA repair that lead to defects in DNA repair pathways.","Homologous Recombination Repair Biallelic Inactivation | HHR Biallelic Inactivation | HRR Biallelic Inactivation | Homologous Recombination Pathway Biallelic Inactivation | Recombination Repair Biallelic Inactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552386","HOXA10 Positive","C150642","An indication that expression of HOXA10 has been detected in a sample.","HOXA10 Positive | HOX1.8 Positive | HOX1H Positive | Homeo Box A10 Positive | Homeobox 1.8 Positive | Homeobox 1H Positive | Homeobox A10 Positive | Hox-1.8 Positive | Hox-1H Positive | Hox-A10 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552389","HOXA9 Positive","C150643","An indication that expression of HOXA9 has been detected in a sample.","HOXA9 Positive | HOX1.7 Positive | HOX1G Positive | Homeo Box A9 Positive | Homeobox 1.7 Positive | Homeobox 1G Positive | Homeobox A9 Positive | Hox-1.7 Positive | Hox-1G Positive | Hox-A9 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552388","IGF1R Negative","C150644","An indication that expression of IGF1R has not been detected in a sample.","IGF1R Negative | CD221 Negative | IGF-1R Negative | IGFR Negative | Insulin Like Growth Factor 1 Receptor Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552383","SMARCB1 Negative","C150645","An indication that expression of SMARCB1 has not been detected in a sample.","SMARCB1 Negative | BAF47 Negative | INI1-Negative | SNF5 Negative | SWI/SNF-Related Matrix-Associated Actin Dependent Regulator of Chromatin Subfamily B Member 1 Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552384","ISG15 Positive","C150648","An indication that expression of ISG15 has been detected in a sample.","ISG15 Positive | G1P2 Positive | IFI15 Positive | IP17 Positive | ISG15 Ubiquitin-Like Modifier Positive | UCRP Positive | Ubiquitin Cross-Reactive Protein Positive | Ubiquitin-Like Protein ISG15 Positive | hUCRP Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552378","KIR Ligand Negative","C150650","An indication that expression of ligands for the killer-cell immunoglobulin-like receptors have not been detected in a sample.","KIR Ligand Negative | Killer-Cell Immunoglobulin-Like Receptor Ligand Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552381","KMT2D Gene Mutation","C150651","A change in the nucleotide sequence of the KMT2D gene.","KMT2D Gene Mutation | ALR Gene Mutation | CAGL114 Gene Mutation | KABUK1 Gene Mutation | KMS Gene Mutation | Lysine (K)-Specific Methyltransferase 2D Gene Mutation | Lysine Methyltransferase 2D Gene Mutation | MLL2 Gene Mutation | MLL4 Gene Mutation | Myeloid/Lymphoid or Mixed-Lineage Leukemia 2 Gene Mutation | TNRC21 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552380","KRT5 Gene Mutation","C150652","A change in the nucleotide sequence of the KRT5 gene.","KRT5 Gene Mutation | CK-5 Gene Mutation | CK5 Gene Mutation | EBS2 Gene Mutation | K5 Gene Mutation | KRT5A Gene Mutation | Keratin 5 Gene Mutation | Keratin 5, Type II Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552375","KRT72 Gene Mutation","C150653","A change in the nucleotide sequence of the KRT72 gene.","KRT72 Gene Mutation | CK6 Gene Mutation | K6IRS2 Gene Mutation | K6irs Gene Mutation | KB35 Gene Mutation | KRT6 Gene Mutation | KRT6IRS2 Gene Mutation | Keratin 72 Gene Mutation | Keratin 72, Type II Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552374","GNRHR Positive","C150654","An indication that expression of GNRHR has been detected in a sample.","GNRHR Positive | GNRHR1 Positive | GRHR Positive | Gonadotropin Releasing Hormone Receptor Positive | Gonadotropin-Releasing Hormone Receptor Positive | LHRH Receptor Positive | LHRHR Positive | LRHR Positive | Luteinizing Releasing Hormone Receptor Positive | Luteinizing-Releasing Hormone (LHRH) Receptor Positive | Luteinizing-Releasing Hormone Receptor Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552377","Cells with Surface Ig","C150655","A microscopic finding indicating that immunoglobulins are bound to or expressed on the surface of cells in a sample.","Surface Immunoglobulin-Positive Cells Present | Cells with Surface Ig | Cells with Surface Immunoglobulins Present | Presence of Surface Immunoglobulin | Surface Ig Present | Surface Immunoglobulin Positive Cells Present | Surface Immunoglobulin Positive Cells Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552376","Lymphoblasts with Surface Immunoglobulin Present","C150656","A microscopic finding indicating that immunoglobulins are bound to or expressed on the surface of the immature lymphoid cells in a sample.","Lymphoblasts with Surface Immunoglobulin Present | Lymphoblasts with Surface Ig | Surface Immunoglobulin Positive Lymphoblasts Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552487","MAGEA12 Positive","C150681","An indication that MAGEA12 expression has been detected in a sample.","MAGEA12 Positive | CT1.12 Positive | Cancer/Testis Antigen 1.12 Positive | MAGE A12 Positive | MAGE-12 Antigen Positive | MAGE12 Positive | MAGE12F Antigen Positive | Melanoma Antigen Family A 12 Positive | Melanoma Antigen Family A, 12 Positive | Melanoma-Associated Antigen 12 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552489","MAGI2 Gene Mutation","C150683","A change in the nucleotide sequence of the MAGI2 gene.","MAGI2 Gene Mutation | ACVRINP1 Gene Mutation | ACVRIP1 Gene Mutation | AIP-1 Gene Mutation | AIP1 Gene Mutation | ARIP1 Gene Mutation | MAGI-2 Gene Mutation | Membrane Associated Guanylate Kinase, WW and PDZ Domain Containing 2 Gene Mutation | SSCAM Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552491","MAP3K1 Gene Mutation","C150685","A change in the nucleotide sequence of the MAP3K1 gene.","MAP3K1 Gene Mutation | MAPKKK1 Gene Mutation | MEKK Gene Mutation | MEKK1 Gene Mutation | Mitogen-Activated Protein Kinase Kinase Kinase 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552515","NF2 Gene Rearrangement","C150714","A molecular abnormality indicating rearrangement of the NF2 gene.","NF2 Gene Rearrangement | ACN Gene Rearrangement | BANF Gene Rearrangement | Merlin Gene Rearrangement | NF-2 Gene Rearrangement | Neurofibromin 2 Gene Rearrangement | SCH Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552492","MED12 Gene Mutation","C150689","A change in the nucleotide sequence of the MED12 gene.","MED12 Gene Mutation | ARC240 Gene Mutation | CAGH45 Gene Mutation | HOPA Gene Mutation | Human Opposite Paired Gene Mutation | Mediator Complex Subunit 12 Gene Mutation | TNRC11 Gene Mutation | TRAP230 Gene Mutation | Trinucleotide Repeat-Containing Gene 11 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552496","MPO Positive","C150694","An indication that expression of MPO has been detected in a sample.","MPO Positive | Myeloperoxidase Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518003","Low-Frequency Microsatellite Instability","C36494","Genomic instability associated with the presence of hypermutation either in one microsatellite instability (MSI) marker or in between 10 and 30 percent of the MSI markers in a tumor sample.","Low-Frequency Microsatellite Instability | MSI low | MSI-L | Microsatellite Instability Low",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552506","MTOR Gene Rearrangement","C150705","A molecular abnormality indicating rearrangement of the MTOR gene.","MTOR Gene Rearrangement | FK506 Binding Protein 12-Rapamycin Associated Protein 1 Gene Rearrangement | FRAP1 Gene Rearrangement | Mammalian Target of Rapamycin Gene Rearrangement | Mechanistic Target of Rapamycin Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552507","MUC1 Positive","C150706","An indication that expression of MUC1 has been detected in a sample.","MUC1 Positive | CD227 Antigen Positive | CD227 Positive | Carcinoma-Associated Mucin Positive | EMA Positive | Epithelial Membrane Antigen Positive | H23 Antigen Positive | H23AG Positive | KL-6 Positive | MAM6 Positive | MCD Positive | MUC-1 Antigen Positive | MUC-1 Positive | Mucin 1 Positive | Mucin-1 Positive | PEM Positive | PEMT Positive | PUM Positive | Peanut-Reactive Urinary Mucin Positive | Polymorphic Epithelial Mucin Positive | Tumor-Associated Epithelial Membrane Antigen Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552509","XK Gene Mutation","C150708","A change in the nucleotide sequence of the XK gene.","XK Gene Mutation | KX Gene Mutation | Kell Blood Group Precursor Gene Mutation | McLeod Syndrome Gene Mutation | NA Gene Mutation | NAC Gene Mutation | Neuroacanthocytosis Gene Mutation | Neurocanthocytosis Gene Mutation | Precursor Substance, Kell Blood Group Gene Mutation | X-Linked Kx Blood Group Gene Mutation | X1k Gene Mutation | XK Locus Gene Mutation | XKR1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552510","Neoplastic Plasma Cells 20 Percent or Less of Bone Marrow Nucleated Cells","C150709","A semi-quantitative microscopic finding indicating that 20 percent or less of the nucleated cells in a bone marrow sample are neoplastic plasma cells.","Neoplastic Plasma Cells 20 Percent or Less of Bone Marrow Nucleated Cells | Neoplastic Plasma Cells Less than or Equal to 20 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552511","Neoplastic Plasma Cells 60 Percent or More of Bone Marrow Nucleated Cells","C150710","A semi-quantitative microscopic finding indicating that 60 percent or more of the nucleated cells in a bone marrow sample are neoplastic plasma cells.","Neoplastic Plasma Cells 60 Percent or More of Bone Marrow Nucleated Cells | Neoplastic Plasma Cells Greater than or Equal to 60 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552512","Neoplastic Plasma Cells 10-60 Percent of Bone Marrow Nucleated Cells","C150711","A semi-quantitative microscopic finding indicating that between 10 and 60 percent of the nucleated cells in a bone marrow sample are neoplastic plasma cells.","Neoplastic Plasma Cells 10-60 Percent of Bone Marrow Nucleated Cells | Neoplastic Plasma Cells Between 10 and 60 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514062","Neoplastic Plasma Cells More than 30 Percent of Bone Marrow Nucleated Cells","C41028","A semi-quantitative microscopic finding indicating that more than 30 percent of the nucleated cells in a bone marrow sample are neoplastic plasma cells.","Neoplastic Plasma Cells More than 30 Percent of Bone Marrow Nucleated Cells | Neoplastic Plasma Cells Greater than 30 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552513","NF1 Gene Rearrangement","C150712","A molecular abnormality indicating rearrangement of the NF1 gene.","NF1 Gene Rearrangement | NF-1 Gene Rearrangement | NFNS Gene Rearrangement | Neurofibromin 1 Gene Rearrangement | Neurofibromin Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552514","NF1 Positive","C150713","An indication that expression of NF1 has been detected in a sample.","NF1 Positive | NF-1 Positive | Neurofibromin 1 Positive | Neurofibromin Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230232","Hepatogastric Ligament","C32737","The portion of the lesser omentum between the liver and the lesser curvature of the stomach.","Hepatogastric Ligament | Gastrohepatic Ligament | Structure of gastrohepatic ligament (body structure)",,,,,,,,,,,,,,,"4278374","Structure of gastrohepatic ligament",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0230230","Gastrosplenic Ligament","C32671","The portion of the greater omentum between the greater curvature of the stomach and the hilum of the spleen.","Gastrosplenic Ligament | ",,,,,,,,,,,,,,,"4324946","Structure of gastrosplenic ligament",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0230229","Gastrocolic Ligament","C32667","A major portion of the greater omentum between the stomach and the transverse colon.","Gastrocolic Ligament | ",,,,,,,,,,,,,,,"4168469","Structure of gastrocolic ligament",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1514801","Recto-Vaginal Pouch","C33447","The peritoneal reflection of the superior part of the posterior wall of the vagina, anterior to the rectum, which is the deepest point of the peritoneal cavity in females.","Recto-Vaginal Pouch | Pouch of Douglas | Pouch of Douglass | RECTO-UTERINE POUCH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879922","CDISC SDTM Laboratory Test Terminology by Name","C67154","A terminology set that includes concepts contained in the CDISC laboratory test codelist.","CDISC SDTM Laboratory Test Name Terminology | LBTEST | Laboratory Test Name | SDTM-LBTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879943","CDISC SDTM Sex of Individual Terminology","C66731","Terminology codelist used with Sex of Individual within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.","CDISC SDTM Sex of Individual Terminology | SDTM-SEX | SEX | Sex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879925","CDISC SDTM Adverse Event Outcome Terminology","C66768","Terminology associated with the adverse event outcome codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Adverse Event Outcome Terminology | OUT | Outcome of Event | SDTM-OUT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554405","Lymphoma Response to Immunomodulatory Therapy Criteria","C153152","A tumor response criteria for immunomodulatory therapies designed to account for tumor flares.","Lymphoma Response to Immunomodulatory Therapy Criteria | LYRIC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554406","Lymphoma Response to Immunomodulatory Therapy Criteria Indeterminate Response 1","C153153","An increase in overall tumor burden of greater than or equal to 50 percent of up to six measurable lesions in the first 12 weeks of therapy, without clinical deterioration.","Lymphoma Response to Immunomodulatory Therapy Criteria Indeterminate Response 1 | IR1 | Indeterminate Response 1 | LYRIC IR1 | LYRIC Indeterminate Response 1 | LYRIC Intermediate Response 1 | LYRIC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554296","Lymphoma Response to Immunomodulatory Therapy Criteria Indeterminate Response 2","C153154","The appearance of new lesions or growth of one or more existing lesions greater than or equal to 50 percent at any time during treatment occurring in the context of lack of overall progression of overall tumor burden.","Lymphoma Response to Immunomodulatory Therapy Criteria Indeterminate Response 2 | IR2 | Indeterminate Response 2 | LYRIC IR2 | LYRIC Indeterminate Response 2 | LYRIC Intermediate Response 2 | LYRIC2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554297","Lymphoma Response to Immunomodulatory Therapy Criteria Indeterminate Response 3","C153155","An increase in F-fluorodeoxyglucose (FDG) uptake of one or more lesions without a concomitant increase in lesion size or number.","Lymphoma Response to Immunomodulatory Therapy Criteria Indeterminate Response 3 | IR3 | Indeterminate Response 3 | LYRIC IR3 | LYRIC Indeterminate Response 3 | LYRIC Intermediate Response 3 | LYRIC3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1644073","LYRIC Indeterminate Response","C153156","A lymphoma response that cannot be distinguished between flare/pseudo-progression and true progressive disease.","LYRIC Indeterminate Response | IR | Indeterminate Lymphoma Response | Indeterminate Response | Intermediate Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3894683","Extracellular Vesicle","C153165","Bilayer membrane fragments present in the blood plasma that are released by different cell types upon activation or death. Extracellular vesicles are usually classified as either exosomes (formed by the membranes of intracellular compartments, 50-100 nm in diameter) and ectosomes (also called microparticles or microvesicles, formed from plasma membrane, 100-1000 nm in diameter).","Extracellular Vesicle | Plasma Extracellular Vesicle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554567","Cell Preparation Tube","C153166","An evacuated blood collection tube that contains sodium heparin, intended for the collection of whole blood and the separation of mononuclear cells.","Cell Preparation Tube | CPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554571","Plasma Preparation Tube","C153167","An evacuated blood collection tube that contains an inert gel and spray-dried K2EDTA anticoagulant, intended for the collection of whole blood and the separation of plasma.","Plasma Preparation Tube | PPT",,,,,,,,,,,,,,,"601562","Evacuated blood collection tube with spray-dried ethylenediaminetetraacetic acid and gel separator",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825504","Imputed Date","C81195","The calendar date of the observation that is imputed.","Imputed Date | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825521","Day Imputed","C81212","An imputed date that includes the day of observation.","Day Imputed | D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825520","Month Day Imputed","C81211","An imputed date that includes the month and day of observation.","Month Day Imputed | M",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512151","IDH Gene Family","C129260","A family of genes that encode enzymes that catalyze the decarboxylation of isocitrate yielding alpha-ketoglutarate and carbon dioxide. Alpha-ketoglutarate is a precursor used in the synthesis of alanine, glutamine and pyruvate, and is an important intermediate in the citric acid cycle, which is an essential metabolic pathway used by cells to produce energy through aerobic respiration. Mutations in the IDH1 and IDH2 genes are associated with several types of brain tumors.","IDH Gene Family | IDH | Isocitrate Dehydrogenase Gene Family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986654","Nodular Parenchymal Tissue","C94757","Normal tissue characterized by the presence of well defined parenchymal nodules.","Nodular Parenchymal Tissue | nodular parenchyma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055453","Antibody MIB-1 Staining Method","C122928","An immunohistochemical technique used to quantify the percent of cells in a tissue sample that can react with the monoclonal antibody MIB-1. Antibody MIB-1 recognizes antigen KI-67 protein, which is a nuclear protein that is exclusively expressed by proliferating cells.","Antibody MIB-1 Staining Method | Antibody MIB1 Staining Method | MIB-1 Antibody Staining Method | MIB-1 Ki67 Assay | MIB-1 Staining Method | MIB1 Antibody Staining Method | MIB1 Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334739","Metastatic/Recurrent Disease","C36163","A disease that reappears at its original location or that newly-occurs at a distant location.","Metastatic/Recurrent Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826807","Planned Arm Code","C83216","A character or string that represents a planned arm of a trial.","Planned Arm Code | ARMCD | Arm Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900117","Actual Arm Code","C117449","A short sequence of characters that represents the arm in which the subject actually participated.","Actual Arm Code | ACTARMCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879957","CDISC SDTM Vital Sign Terminology by Name","C67153","Terminology codelist used with Vital Sign Test Name within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.","CDISC SDTM Vital Sign Test Name Terminology | SDTM-VSTEST | VSTEST | Vital Signs Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511699","DNA Structure","C13404","The structure of a DNA molecule, consisting of its primary nucleotide sequence as well as its secondary and tertiary arrangement in space.","DNA Structure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332300","Other Than","C151896","Distinct from those already mentioned, listed, or considered.","Other Than | Except",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL427838","Obscure","C153207","Make less clear or visible.","Obscure | Obscured",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554332","Coalesce","C153208","Join together or fuse.","Coalesce | Coalesced",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554325","Primary Immune Deficiency Treatment Consortium","C153199","A consortium of 42 centers in North America whose shared goal is to improve the outcome of patients with rare, life threatening, inherited disorders of the immune system.","Primary Immune Deficiency Treatment Consortium | PIDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545354","Maximum Predicted Heart Rate","C147492","The predicted upper limit for an individual's heart rate, which is calculated as 220 minus the subject's age for men, and 210 minus the subject's age for women.","Maximum Predicted Heart Rate | MAXPREHR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545353","Energy Expenditure","C147491","A measurement of the amount of energy used to carry out a physiological or physical function.","Energy Expenditure | ENRGEXP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055375","Body Fat Measurement","C122232","A measurement of the total fat mass within the subject's body.","Body Fat Measurement | BODYFATM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0562351","Mid-Upper Arm Circumference","C124475","A circumferential measurement of the largest part of the upper arm.","Mid-Upper Arm Circumference | MUARMCIR",,,,,,,,,,,,,,,"4111666","Mid upper arm circumference",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0678121","Basal Metabolic Rate","C126083","A patient's energy expenditure at rest.","Basal Metabolic Rate | BMR",,,,,,,,,,,,,,,"4065423","Basal metabolic rate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521346","Estimated Body Weight","C132482","An approximate determination of the weight of a body.","Estimated Body Weight | EWEIGHT | Estimated Weight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0412472","Total Body Water Measurement","C104622","A measurement of the quantity of water within the body, including both the intracellular and extracellular compartments.","Total Body Water Measurement | TBW | Total Body Water",,,,,,,,,,,,,,,"4346957","Total body water measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0562350","Hip Circumference","C100947","A circumferential measurement of the largest part of the hip.","Hip Circumference | HIPCIR",,,,,,,,,,,,,,,"4111665","Hip circumference",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3639880","Forearm Circumference","C100946","A circumferential measurement of the largest part of the forearm.","Forearm Circumference | FARMCIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0455829","Waist Circumference","C100948","A circumferential measurement of the waist, which may be classified as the area immediately below the lowest rib, at the narrowest part of the torso, midpoint between the lowest rib and the iliac crest, or immediately above the iliac crest.","Waist Circumference | WSTCIR",,,,,,,,,,,,,,,"4172830","Waist circumference",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2828149","Sagittal Abdominal Diameter","C87054","A standard measure of visceral obesity, or abdominal fat, which is measured from the patient's back to upper abdomen between the bottom of the rib cage and the top of the pelvic area. This measurement may be taken with the patient standing or in the supine position.","Sagittal Abdominal Diameter | SAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0949236","Pulse Pressure","C100945","The force of a heart contraction measured by the difference between the diastolic and systolic blood pressure measurements.","Pulse Pressure | PULSEPR | Pulse pressure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827417","Knee to Heel Length Measurement","C84372","A measurement of the length of the lower leg from the top of the knee to the bottom of the heel. This measurement may be taken with a knemometer or calipers.","Knee to Heel Length Measurement | KNEEHEEL | Knee Height | Knee to Heel Length | Lower Leg Length",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879948","CDISC SDTM Terminology","C66830","The terminology subset that includes terms pertaining to the CDISC Study Data Tabulation Model (SDTM).","CDISC SDTM Terminology | SDTM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1112682","Retroperitoneal Lymph Node Dissection","C48184","The surgical removal of retroperitoneal lymph nodes from the abdominal cavity. The surgery is a therapeutic treatment for testicular cancer, performed after (orchiectomy) or testicular removal. The surgery is recommended for men who are at an increased risk of metastasis, or who decline other treatment options such as radiation or chemotherapy.","Retroperitoneal Lymph Node Dissection | RPLND",,,,,,,,,,,,,,,"42538967","Retroperitoneal lymph node dissection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1879955","CDISC SDTM Unit for Vital Sign Result Terminology","C66770","Terminology codelist used with Unit for Vital Sign Result within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.","CDISC SDTM Unit for Vital Sign Result Terminology | SDTM-VSRESU | Units for Vital Signs Results | VSRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456649","Kilocalorie per Day","C139135","A unit of energy equal to one kilocalorie per day.","Kilocalorie per Day | kcal/d | kcal/day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545060","Centimeters of Mercury","C147129","A unit of pressure equal to 0.001316 atmosphere and equal to the pressure indicated by one centimeter rise of mercury in a barometer at the Earth's surface.","Centimeters of Mercury | Centimeter of Mercury | cmHg | cm[Hg]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509799","Metabolic Equivalent of Task Unit","C127805","A unit of energy expenditure equal to the ratio of the metabolic rate during physical activity in comparison to a reference metabolic rate.","Metabolic Equivalent of Task Unit | MET | Metabolic Equivalent of Task | [MET]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540608","Raw Data","C142663","The original information, collected from the primary source.","Raw Data | raw data",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554339","Smart Device","C153216","An electronic device that is capable of connecting to a network and can make use of the network for more complex services.","Smart Device | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879939","CDISC SDTM Reason for Non-Completion Terminology","C66727","Terminology codelist used with Reason for Non-Completion within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.","CDISC SDTM Reason for Non-Completion Terminology | Completion/Reason for Non-Completion | NCOMPLT | SDTM-NCOMPLT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526667","Randomized By Mistake With Study Treatment","C139238","An indication that the subject was randomized but should not have been, and was subsequently given study treatment.","Randomized By Mistake With Study Treatment | RANDOMIZED BY MISTAKE WITH STUDY TREATMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526640","Non-Compliance With Study Device","C139241","An indication that a subject has not agreed with, or followed the instructions related to, the study device.","Non-Compliance With Study Device | NON-COMPLIANCE WITH STUDY DEVICE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526669","Failure To Meet Continuation Criteria","C139236","An indication that the subject has not been able to meet protocol-defined continuation criteria and will not continue to participate in the clinical trial.","Failure To Meet Continuation Criteria | FAILURE TO MEET CONTINUATION CRITERIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526666","Randomized By Mistake Without Study Treatment","C139239","An indication that the subject was randomized but should not have been, and was subsequently not given study treatment.","Randomized By Mistake Without Study Treatment | RANDOMIZED BY MISTAKE WITHOUT STUDY TREATMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526668","Randomized By Mistake","C139237","An indication that the subject was randomized but should not have been.","Randomized By Mistake | RANDOMIZED BY MISTAKE | Randomized in Error",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526641","Non-Compliance With Non-Study Device","C139240","An indication that a subject has not agreed with, or followed the instructions related to, the non-study device.","Non-Compliance With Non-Study Device | NON-COMPLIANCE WITH NON-STUDY DEVICE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540355","Protocol-Specified Withdrawal Criterion Met","C142349","An indication that the patient has met one or multiple protocol-specified withdrawal criteria and has been withdrawn from the study.","Protocol-Specified Withdrawal Criterion Met | PROTOCOL-SPECIFIED WITHDRAWAL CRITERION MET",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640719","Study Subject Withdrawal by Parent or Guardian","C102355","An indication that a study participant has been removed from the study by the parent or legal guardian.","Study Subject Withdrawal by Parent or Guardian | WITHDRAWAL BY PARENT/GUARDIAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642162","Failure to Meet Randomization Criteria","C105448","An indication that the subject has been unable to fulfill the criteria required for assignment into a randomized group.","Failure to Meet Randomization Criteria | FAILURE TO MEET RANDOMIZATION CRITERIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827772","Trial Site Terminated by Sponsor","C106576","An indication that a clinical study was stopped at a particular site by its sponsor.","Trial Site Terminated by Sponsor | SITE TERMINATED BY SPONSOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552737","Subject Met Eligibility Criteria But Was Not Needed","C150884","An indication that the individual met inclusion and exclusion criteria but was ultimately not utilized as a trial subject.","Subject Met Eligibility Criteria But Was Not Needed | MET ELIGIBILITY CRITERIA BUT NOT NEEDED | Passed Screening But Not Needed | Qualified But Not Needed | Reserve, Not Used",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540259","Protocol Violation","C142185","A significant departure from processes or procedures that were required by the protocol. Violations often result in data that are not deemed evaluable for a per-protocol analysis, and may require that the subject(s) who violate the protocol be discontinued from the study. Compare to protocol deviation. (CDISC Glossary)","Protocol Violation | PROTOCOL VIOLATION | protocol violation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274529","CDISC SDTM Epoch Terminology","C99079","Terminology associated with the epoch codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Epoch Terminology | EPOCH | Epoch | SDTM-EPOCH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640651","Blinded Treatment Epoch","C102255","A period in a clinical study during which subjects receive blinded therapeutic treatment.","Blinded Treatment Epoch | BLINDED TREATMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640652","Open Label Treatment Epoch","C102256","A period in a clinical study during which subjects receive open label therapeutic treatment.","Open Label Treatment Epoch | OPEN LABEL TREATMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505129","Baseline Epoch","C125938","A period in a clinical study during which a subject's base standard measurements are collected and recorded for use in future comparisons and analyses.","Baseline Epoch | BASELINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049995","Induction Therapy Epoch","C123453","A period in a clinical study during which subjects receive induction therapy.","Induction Therapy Epoch | INDUCTION TREATMENT | Induction Phase | Intensive Phase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698621","CDISC SDTM Category For Disposition Event Terminology","C74558","Terminology codelist used for Disposition Event within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.","CDISC SDTM Category For Disposition Event Terminology | Category of Disposition Event | DSCAT | SDTM-DSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552585","Non-Protocol Disposition Event","C150824","The group of incidents that are not driven by the protocol but that may occur during a clinical trial and describe whether a subject completed the study epoch or the reason this event did not occur.","Non-Protocol Disposition Event | OTHER EVENT | Other Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698907","Protocol Disposition Event","C74590","The group of incidents that occur during a clinical trial and describe whether a subject completed the study epoch or the reason this event did not occur. The subject's disposition is often described for each phase of the study.","Protocol Disposition Event | DISPOSITION EVENT | DSTERM | Disposition Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033607","Protease Inhibitor","C783","Any substance that inhibits a protease, an enzyme that breaks peptide bonds. Proteases are required for many cell processes and inhibition of proteases can inhibit viral replication, inflammatory responses, proliferation, and tumor growth.","Protease Inhibitor | Protease Inhibitors | protease inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554472","International Myeloma Working Group","C153239","A working group established to conduct basic, clinical and translational research in a collaborative manner to improve outcomes in myeloma and to provide scientifically valid and critically appraised consensus opinions on the diagnosis and treatment of myeloma and related disorders.","International Myeloma Working Group | IMWG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540372","Clinical Study Data Element","C142437","A data element associated with a clinical study.","Clinical Study Data Element | clinical study data element",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554564","Sequence Alignment Map","C153248","A tab-delimited, text-based format for storing biological sequences aligned to a reference sequence. A SAM file includes an optional header section and an alignment section. Each alignment line has 11 mandatory fields for essential alignment information, such as mapping position, and a variable number of optional fields.","Sequence Alignment Map | SAM | Sequence Alignment/Map",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554575","Binary Alignment Map","C153249","A binary representation of a sequence alignment map (SAM), a compact and indexable representation of nucleotide sequence alignments, compressed by the BGZF (Blocked GNU Zip Format) library.","Binary Alignment Map | BAM | Binary Alignment/Map | Binary Sequence Alignment Map",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055130","Disease Recurrence Relative Location","C123633","A description of the region or relative location for the disease recurrence.","Disease Recurrence Relative Location | DRCRLTLC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826698","Exposure Location","C83087","The physical portion of the body at which the exposure takes place.","Exposure Location | EXLOC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0346182","Immature Ovarian Teratoma","C8111","An immature teratoma arising from the ovary.  It usually affects females in their first two decades of life.","Immature Ovarian Teratoma | Grade 2 Ovarian Teratoma | Immature Germ Cell Teratoma of Ovary | Immature Germ Cell Teratoma of the Ovary | Immature Teratoma of Ovary | Immature Teratoma of the Ovary | Ovarian Germ Cell Immature Teratoma | Ovarian Immature Germ Cell Teratoma | Ovarian Immature Teratoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986423","Chemoimmunotherapy","C94251","Chemotherapy combined with immunotherapy. Chemotherapy uses different drugs to kill or slow the growth of cancer cells; immunotherapy uses treatments to stimulate or restore the ability of the immune system to fight cancer.","Chemoimmunotherapy | chemoimmunotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554479","FASTQ Format","C153250","A text-based format for storing a biological sequence that encodes the nucleotide calls as well as their quality scores. It is an extension of the FASTA format.","FASTQ Format | FASTQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508040","MPL Gene Mutation","C126821","A change in the nucleotide sequence of the MPL gene.","MPL Gene Mutation | CD110 Gene Mutation | MPL | MPL Proto-Oncogene, Thrombopoietin Receptor Gene Mutation | Myeloproliferative Leukemia Virus Oncogene Gene Mutation | TPOR Gene Mutation | c-MPL Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515353","UC Davis Comprehensive Cancer Center","C39531","The University of California Davis Cancer Center is cancer research and clinical institution with more than 200 scientists in more than a dozen scientific disciplines actively engaged in cancer research. The Center offers 150 adult clinical trials and 50 pediatric clinical trials at any given time. It received its NCI designation in 2002 and comprehensive status in 2011.","UC Davis Comprehensive Cancer Center | The UC Davis Cancer Center | The University of California Davis Clinical Cancer Center",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512327","H Lee Moffitt Cancer Center and Research Institute","C39415","The H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida achieved NCI cancer center designation in 1998 and was awarded NCI comprehensive cancer center designation in 2001.","H Lee Moffitt Cancer Center and Research Institute | H Lee Moffitt Cancer Center & Research Institute | H Lee Moffitt Cancer Center and Research Institute at the University of South Florida | H. Lee Moffitt Cancer Center & Research Institute",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515356","Vanderbilt-Ingram Cancer Center","C39534","The mission of the Vanderbilt-Ingram Cancer Center is to alleviate cancer death and suffering through pioneering research, clinical trials, evidence-based patient-centered care, prevention and education, and community activities. The Center's research programs encompass basic, clinical, and population-based research, interdisciplinary collaboration, and bi-directional translation. It became an NCI-designated cancer center in 1995 and earned its status as a comprehensive cancer center in 2001.","Vanderbilt-Ingram Cancer Center | The Vanderbilt-Ingram Cancer Center at the Vanderbilt University | VICC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642273","Stanford Cancer Institute","C105626","The Stanford Cancer Institute is focused on improving the diagnosis, treatment, and outcomes for cancer patients, understanding cancer etiologies among diverse populations, and reducing the incidence of cancer. It became an NCI-designated cancer center in 2007. It is a Stanford School of Medicine center.","Stanford Cancer Institute | SCI | Stanford Cancer Institute at Stanford University",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512702","Indiana University Melvin and Bren Simon Cancer Center","C39427","The Indiana University Cancer Center's mission is to advance the understanding, prevention, and treatment of cancer with patient-centered care, acceleration of promising science, and collaborative educational programs. It became an NCI-designated cancer center in 1999.","Indiana University Melvin and Bren Simon Cancer Center | Indiana University Cancer Center",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517622","Jonsson Comprehensive Cancer Center","C39438","The Jonsson Comprehensive Cancer Center conducts basic, clinical, and cancer prevention research, while providing the latest treatments to patients, while training the next generation of medical researchers. The Center is developing new technologies for early detection and classification of cancers, combining nanotechnology, systems biology, and molecular imaging. It is affiliated with University of California, Los Angeles and was designated as an NCI comprehensive cancer center in 1974.","Jonsson Comprehensive Cancer Center | JCCC | Jonsson Comprehensive Cancer Center of University of California Los Angeles | The UCLA's Jonsson Comprehensive Cancer Center",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519972","Vermont Cancer Center at the University of Vermont","C39561","The Vermont Cancer Center is committed to innovative cancer research, life-saving prevention and treatment programs, public education and scientific collaboration, and serves to influence standards of cancer prevention, screening, diagnosis and care. It is part of the University of Vermont College of Medicine and has a clinical partnership with Fletcher Allen Health Care.","Vermont Cancer Center at the University of Vermont | VCC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512518","Huntsman Cancer Institute at the University of Utah","C39422","The Huntsman Cancer Institute at the University of Utah has a mission to understand cancer from its beginnings, to use that knowledge in the creation and improvement of new treatments, to relieve the suffering of cancer patients, and to provide education about cancer risk, prevention, and care. It received its NCI designation as a cancer center in 1986.","Huntsman Cancer Institute | HCI | Huntsman Cancer Institute at the University of Utah",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828025","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University","C39514","The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University has a mission to go beyond the cutting edge in science and medicine to perform the most advanced research and offer patients the very best therapies for their disease. Research scientists at the Center work closely with the clinicians to offer the latest diagnostic and therapeutic services to patients. It was designated as an NCI comprehensive cancer center in 1974.","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University | Sidney Kimmel Comprehensive Cancer Center",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554488","Milligram Morphine Equivalent","C153260","A value assigned to opioids to represent their relative potencies. It is determined by using an equivalency factor to calculate a dose of morphine that is equivalent to the ordered opioid.","Milligram Morphine Equivalent | MEU | MME | Morphine Equivalent Units | Morphine Milligram Equivalent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017469","Geriatrics","C16635","The branch of medical science that deals with diseases and problems specific to elderly people.","Geriatrics | Geriatric Health | Gerontological | Gerontology | Gerontology / Geriatrics",,,,,,,,,,,,,,,"4190561","Geriatric medicine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3539727","Neuropsychiatric Inventory - 12 Item Version Questionnaire","C100772","A standardized rating scale originally developed and copyrighted by Jeffrey L. Cummings in 1994 as well as published in the journal Neurology (Cummings J.L., The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients. Neurology May 1997 48:10S-16S) which is used to assess the severity of an individual's neuropathic behaviors based on a observations made by the patient's caregiver. This instrument contains 12 neuropsychiatric areas associated with dementia such as delusions, anxiety, motor disturbances, and appetite. Each behavior is evaluated only if the individual displays the behavior. For these behaviors, the frequency is assessed on a scale of 0-4 with 0 being occasionally and 4 being very frequently, the severity is assessed on a scale of 1-3 with 1 being mild and 3 being marked, and the level of distress each behavior inflicts on the caregiver is assessed on a scale of 0-5 with 0 being not distressing and 5 being extremely distressing.","Neuropsychiatric Inventory - 12 Item Version Questionnaire | NPI | NPI-12 | NPI-Q | NPI1 | Neuropsychiatric Inventory Questionnaire | Neuropsychiatric Inventory-Questionnaire",,,,,,,,,,,,,,,"37157689","Neuropsychiatric Inventory Questionnaire",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL541308","Life","C142142","The biochemical phenomenon that distinguishes organisms from inorganic matter. It is characterized by growth, metabolism, and reproduction.","Life | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552220","BAP1 Loss of Function Gene Mutation","C150448","A change in the nucleotide sequence of the BAP1 gene that either inhibits expression or results in the translation of an inactive ubiquitin carboxyl-terminal hydrolase BAP1 protein.","BAP1 Loss of Function Gene Mutation | Inactivating BAP1 Gene Mutation | Inactivating BAP1 Mutation | Inactivating BRCA1 Associated Protein 1 Gene Mutation | Inactivating BRCA1-Associated Protein 1 Gene Mutation | Inactivating UCHL2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3484216","Knee Injury and Osteoarthritis Outcome Score","C153299","A self-reported instrument to assess a patient's opinion about their knee and associated problems. It consists of 5 subscales: Pain, Function in Daily Living, Function in Sport and Recreation, Other Symptoms, and Knee Related Quality of Life.","Knee Injury and Osteoarthritis Outcome Score | KOOS | Knee Injury and Osteoarthritis Outcome Score (KOOS)",,,,,,,,,,,,,,,"37203804","Knee Injury and Osteoarthritis Outcome Score",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554415","Informant Questionnaire on Cognitive Decline in the Elderly","C153300","A questionnaire designed to assess whether an individual had a decline in cognitive functioning. This questionnaire is answered by a friend or family member of the individual and each situation is rated by the informant for the amount of change over the previous 10 years.","Informant Questionnaire on Cognitive Decline in the Elderly | IQCODE | Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554416","Framingham Foot Assessment Clinical Tool","C153301","A research tool designed to assess foot pain and relate it to footwear.","Framingham Foot Assessment Clinical Tool | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554417","Study of Osteoporotic Fractures Frailty Index","C153302","A frailty index consisting of 3 components: weight loss, the subject's inability to rise from a chair 5 times without using their arms, and reduced energy level.","Study of Osteoporotic Fractures Frailty Index | SOF | Study of Osteoporotic Fractures (SOF) Frailty Index | Study of Osteoporotic Fractures Index | Study of Osteoporotic Fractures [SOF] Index",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554418","Life Space Questionnaire","C153303","A questionnaire instrument designed to assess how much an individual gets out and about and the spatial extent of the person's typical life space, i.e., what is the usual range of places in which the person engages in activities.","Life Space Questionnaire | LSQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554568","Brief Resilience Scale","C153304","A scale developed by Smith, et al, designed to assess an individual's ability to recover from stressful circumstances.","Brief Resilience Scale | BRS | Brief Resilience Scale (BRS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554419","Taste and Smell Questionnaire","C153305","A section of the National Health and Nutrition Examination Survey (NHANES) pertaining to taste and smell ability and related health conditions.","Taste and Smell Questionnaire | NHANES Taste and Smell Questionnaire | NHANES Taste and Smell Section",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554420","Oral Health and Dental History Questions","C153306","The questions in the Health, Aging, and Body Composition Study that assess an individual's oral health and dental history.","Oral Health and Dental History Questions | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554421","Weight History","C153307","A summary of an individual's weight over time.","Weight History | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023980","Longevity","C153298","The length or duration of life or viability.","Longevity | Lifespan",,,,,,,,,,,,,,,"4008739","Longevity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554422","Family History of Dementia and Longevity","C153308","The section and questions of the University of Michigan Health and Retirement Study (HRS) that explores psychosocial and cognitive predictors of an individual's perceived threat of Alzheimer's disease.","Family History of Dementia and Longevity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3280900","Ambiguous Genitalia","C98810","A rare congenital abnormality in which the infant's external genitalia do not have the typical appearance of a male's or female's genitalia.","Ambiguous Genitalia | Atypical Genitalia",,,,,,,,,,,,,,,"4062097","Ambiguous genitalia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205949","Sexual Orientation","C84361","The pattern of a person's emotional, romantic, and/or sexual attractions.","Sexual Orientation | SEXORIE | Sex Orientation | Sexual Preference | Sexuality",,,,,,,,,,,,,,,"4283657","Sexual orientation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3274035","Interventional Study","C98388","Studies in which individuals are assigned by an investigator based on a protocol to receive specific interventions. Subjects may receive diagnostic, therapeutic or other types of interventions. The assignment of the intervention may or may not be random. The individuals are then followed and biomedical and/or health outcomes are assessed.","Interventional Study | INTERVENTIONAL | Interventional Trial | interventional clinical trial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2919670","Left Against Medical Advice","C99969","A designation that a patient has chosen not to heed the directions that medical staff has advised, and has chosen to leave the facility.","Left Against Medical Advice | LEFT AGAINST MEDICAL ADVICE OR DISCONTINUED CARE | Left AMA",,,,,,,,,,,,,,,"40482021","Left against medical advice",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1831828","Talimogene Laherparepvec","C61314","An ICP34.5, ICP47-deleted, oncolytic herpes simplex type-1 virus (HSV-1) based on the JS1 strain, and encoding the immunostimulating factor human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with potential immunostimulating and antineoplastic activities. Upon intratumoral injection, talimogene laherparepvec selectively infects and replicates in tumor cells, thereby inducing tumor cell lysis. In addition, GM-CSF attracts dendritic cells (DCs) and may stimulate a cytotoxic T cell response against tumor cells, which results in immune-mediated tumor cell death. Deletion of the gene encoding for ICP34.5 provides tumor selectivity and prevents replication in healthy cells. As ICP47 blocks antigen presentation in HSV-infected cells, deletion of this gene may induce a more potent antitumor immune response in the tumor cells. Additionally, deletion of ICP47 causes increased expression of the HSV US11 gene and allows US11 to be expressed as an immediate early and not a late gene. This further enhances the degree of viral replication and oncolysis of tumor cells.","Talimogene Laherparepvec | ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene | Imlygic | JS1 34.5-hGMCSF 47- pA- | OncoVEX GM-CSF | T-VEC | TALIMOGENE LAHERPAREPVEC | Talimogene laherparepvec",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552587","Dose Rate Reduced","C150826","An indication that the administration of a medication was modified by reducing the rate at which the dose was given.","Dose Rate Reduced | DOSE RATE REDUCED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826889","CDISC SDTM Device Events Action Taken with Device Terminology","C111110","Terminology associated with the device events action taken with device codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Device Events Action Taken with Device Terminology | DEACNDEV | Device Events Action Taken with Device | SDTM-DEACNDEV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828338","Reprogram","C111306","The act of rewritting program code or application software.","Reprogram | REPROGRAMMING | Reprogrammed | Reprogramming",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555708","electronic health record","C142529","A digital version of a patient's medical history.","Electronic Health Record | EHR | EHR (electronic health record) | From Electronic Health Record",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0238258","Lymphangitic Carcinomatosis","C3870","Extensive infiltration of the lymphatic vessels by cancer cells, resulting in widespread cancer dissemination.  The lymphatic vessels appear as palpable, cord-like structures, especially in skin areas overlying the carcinoma.","Lymphangitic Carcinomatosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1170745","Ertapenem Sodium","C61753","The sodium salt of ertapenem, a 1-beta-methyl carbapenem and a broad-spectrum beta-lactam antibiotic with bactericidal activity. Ertapenem binds to penicillin binding proteins (PBPs) located on the bacterial cell wall, in particular PBPs 2 and 3, thereby inhibiting the final transpeptidation step in the synthesis of peptidoglycan, an essential component of the bacterial cell wall. Inhibition of peptidoglycan synthesis results in weakening and lysis of the cell wall and cell death. In vitro, this agent has shown activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria. Erapenem is resistant to hydrolysis by a variety of beta-lactamases, including penicillinases, cephalosporinases and extended-spectrum beta-lactamases.","Ertapenem Sodium | ERTAPENEM SODIUM | Invanz",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985256","MALAT1 wt Allele","C92697","Human MALAT1 wild-type allele is located in the vicinity of 11q13.1 and is approximately 9 kb in length. This allele, which encodes metastasis-associated lung adenocarcinoma transcript 1 non-coding RNA, may be involved in tumorigenesis. Aberrant expression of the gene is associated with non-small cell lung cancer and the gene may be involved in a translocation t(6;11)(p21.1;q13) with the human TFEB gene that may be associated with renal cell carcinoma.","MALAT1 wt Allele | Alpha Gene | HCN | Hepcarcin Gene | MALAT-1 | Metastasis Associated In Lung Adenocarcinoma Transcript 1 Gene | Metastasis Associated Lung Adenocarcinoma Transcript 1 (Non-Protein Coding) wt Allele | NCRNA00047 | NEAT2 | Non-Protein Coding RNA 47 Gene | Nuclear Enriched Abundant Transcript 2 Gene | Nuclear Paraspeckle Assembly Transcript 2 (Non-Protein Coding) Gene | PRO1073 | PRO2853",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346564","ASPSCR1 wt Allele","C70992","Human ASPSCR1 wild-type allele is located in the vicinity of 17q25.3 and is approximately 40 kb in length. This allele, which encodes tether containing UBX domain for GLUT4 protein, plays a role in the regulation of insulin-mediated glucose transport. A chromosomal translocation t(X;17)(p11;q25) fuses the gene to the TFE3 gene and is associated with alveolar soft part sarcomas.","ASPSCR1 wt Allele | ASPCR1 | ASPL | ASPS | ASPSCR1 Tether for SLC2A4, UBX Domain Containing wt Allele | ASPSCR1 Tether for SLC2A4, UBX Domain-Containing Gene | ASPSCR1, UBX Domain Containing Tether for SLC2A4 Gene | Alveolar Soft Part Sarcoma Chromosome Region, Candidate 1 Gene | Alveolar Soft Part Sarcoma Chromosome Region, Candidate 1 wt Allele | Alveolar Soft Part Sarcoma Locus Gene | RCC17 | Renal Cell Carcinoma Gene On Chromosome 17 | Renal Cell Carcinoma, Papillary, 17 Gene | TUG | Tether, Containing UBX Domain for GLUT4 Gene | UBX Domain Protein 9 Gene | UBXD9 | UBXN9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574175","Arabic Language","C153339","A Central Semitic language native to countries of the Arab League, minorities in neighboring countries, and some parts of Asia, Africa, Europe.","Arabic Language | ARA | Arabic",,,,,,,,,,,,,,,"4181374","Arabic language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554446","Northeastern Asian","C153342","Denotes a person whose ancestry is in any of the Asian countries bordering the Pacific Ocean: China, Japan, Mongolia, North Korea, and South Korea.","Northeastern Asian | Northeastern Asian Ancestry | Northeastern Asian Descent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0238699","ASIAN, WESTERN","C153343","Denotes a person whose ancestry is in any of the Asian countries bordering Africa, such as Afghanistan, Armenia, Azerbaijan, Bahrain, Cyprus, Gaza Strip, Georgia, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Syrian Arab Republic, Turkey, United Arab Emirates, West Bank, and Yemen.","Western Asian | WEST ASIAN | Western Asian Ancestry | Western Asian Descent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554447","Southeastern European","C153344","Denotes a person whose ancestry is in any of the European countries of the Balkan peninsula: Turkey, Albania, Bosnia and Herzegovina, Bulgaria, Republic of Macedonia, Romania, Serbia, Greece, Croatia, Moldova and Montenegro.","Southeastern European | Southeastern European Ancestry | Southeastern European Descent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554448","Sub-Saharan African","C153346","Denotes a person whose ancestral origins are in any of the African countries that are fully or partially located south of the Sahara desert.","Sub-Saharan African | Sub-Saharan African Ancestry | Sub-Saharan African Descent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554563","Nucleotide Sequence Read","C153349","The manual or automated determination of the nucleotide order in a nucleic acid fragment obtained after the completion of a sequencing process.","Nucleotide Sequence Read | Nucleotide Sequencing Read | Read | Sequence Read | Sequencing Read | Sequencing Reads | Sequencing read",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554436","Sequencing Data","C153329","A collection of digital nucleic acid sequences, protein sequences, or other polymer sequences stored on a computer.","Sequencing Data | Sequence Data",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826245","Pre-specified","C82510","An indication or description that something was previously determined, characterized, or detailed.","Pre-specified | PRESP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641101","Portion or Totality","C103166","An anatomical qualifier that describes the arrangement or apportioning of an entity within a body part, region or organ.","Anatomical Portion or Totality | PORTOT | Portion or Totality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826719","Other Actions taken in Response to Adverse Event","C83109","An indication or description of an other action taken in response to an adverse event.","Other Actions taken in Response to Adverse Event | AEACNOTH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900118","Action Taken with Device","C117037","Describes changes made with respect to the device in the study in response to an event or protocol change.","Action Taken with Device | ACNDEV | Action Taken With Device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826802","Adverse Event Involves Cancer","C83211","An indication or description that an adverse event includes cancer.","Adverse Event Involves Cancer | AESCAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697887","Adverse Event Occurrence","C78604","An indication or description of an adverse event occurrence.","Adverse Event Occurrence | AEOCCUR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826803","Adverse Event Subcategory","C83212","A subdivision of adverse event data.","Adverse Event Subcategory | AESCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981424","Adverse Event Pre-specified","C87840","An indication or description that an adverse event was previously determined, characterized, or detailed.","Adverse Event Pre-specified | AEPRESP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826797","Adverse Event Location","C83205","The site of an adverse event.","Adverse Event Location | AELOC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710066","Severity of Adverse Event","C53253","The intensity of a specific adverse event evaluated based on the magnitude of clinical signs, symptoms and findings. Severe adverse event may be of relatively minor medical significance. The term is not synonymous with the term seriousness of adverse event.","Severity of Adverse Event | AESEV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826805","Adverse Event Occurred with Overdose","C83214","An indication or description that an adverse event occurred with an overdose.","Adverse Event Occurred with Overdose | AESOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826626","Adverse Event Action Taken with Study Treatment","C83013","An indication or description of an action taken in response to an adverse event.","Adverse Event Action Taken with Study Treatment | AEACN | AdverseEventActionTakenRelationship",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826233","Adverse Event Caused Study Discontinuation","C82496","An indication or description of whether the adverse event caused the subject to discontinue from the study.","Adverse Event Caused Study Discontinuation Indicator | AEDIS | Adverse Event Caused Study Discontinuation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826801","Adverse Event Relationship to Non Study Treatment","C83210","An indication or description of the relationship of an adverse event to a non-study treatment.","Adverse Event Relationship to Non Study Treatment | AERELNST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826799","Adverse Event Pattern","C83208","The pattern of an adverse event.","Adverse Event Pattern | AEPATT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826791","Adverse Event Concomitant Treatment","C83199","An indication or description of a concomitant treatment for an adverse event.","Adverse Event Concomitant Treatment | AECONTRT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826798","Adverse Event Modified Reported Term","C83206","An indication or description of a change in an adverse event.","Adverse Event Modified Reported Term | AEMODIFY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826934","Adverse Event Dictionary Derived Term","C83344","An adverse event identifier obtained from a dictionary.","Adverse Event Dictionary Derived Term | AEDECOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1140284","RxNorm","C127112","A system that provides normalized names for generic and branded drugs and that functions as a tool to support interoperability between terminologies. RxNorm is produced by the National Library of Medicine.","RxNorm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2964659","Patient Reported Outcomes Measurement Information System","C102988","A project to develop standards for the collection and analysis of patient-reported health status data using a system of highly reliable, precise measures for physical, mental, and social well-being. Patients are asked a series of rigorously reviewed questions covering common domains and metrics across differing conditions and treatments. The questions can be administered in short forms or adaptively through computerized adaptive testing and reports can be generated to allow clinicians to better understand how treatments might affect the quality of life of their patients.","Patient Reported Outcomes Measurement Information System | PROMIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554519","Read Length","C153362","The number of nucleotides successfully ordered from each side of a nucleic acid fragment obtained after the completion of a sequencing process.","Read Length | Sequence Read Length | Sequencing Read Length | read length | read_length",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554573","Sequencing Adapter","C153363","A short single-stranded or double-stranded oligonucleotide that is ligated/added to each fragment of a sequencing library to permit its amplification and subsequent sequencing.","Sequencing Adapter | Adapter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554520","Nucleotide Sequencing Flow Cell","C153364","An optical slide with microliter or picoliter sized wells that each hold a single nucleotide sequencing template. Sequencing reagents flow over the wells and nucleotide incorporation is separately determined for each well after each round of nucleotide elongation.","Nucleotide Sequencing Flow Cell | Flow Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554521","Sequencing Size Selection Range","C153365","The minimum and maximum lengths of the DNA fragments selected for inclusion in a sequencing library.","Sequencing Size Selection Range | Size Selection Range | size selection range | size_selection_range",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554522","Sequencing Target Region","C153366","A specific region in the genome or in a gene of interest that is chosen for sequencing by the use of appropriate primers.","Sequencing Target Region | Target Region",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554523","BED Format","C153367","A tab-delimited text file format that allows the specification of the sequence data that is displayed in an annotation track. The minimum required information is chromosome, start position, and end position.","BED Format | BED File Format | Browser Extensible Data | Browser Extensible Data Format",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554525","Global Registration Identifier for Donors","C153369","A unique identifier assigned to a hematopoietic progenitor cell donor, potential donor, or a cord blood product that is listed in a registry.","Global Registration Identifier for Donors | GRID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826692","Study Site Identifier","C83081","A sequence of characters used to identify, name, or characterize the study site.","Study Site Identifier | SITEID | Site ID | StudySite.identifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826694","Subject Identifier","C83083","A sequence of characters used to identify, name, or characterize a trial or study subject.","Subject Identifier | Research_Participant_ID | SUBJID | Subject ID | Subject_ID | registration id | registration_id",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900084","Adverse Event MedDRA Preferred Term Code","C117384","A coded value specifying the preferred term for the adverse event from the Medical Dictionary for Regulatory Activities (MedDRA).","Adverse Event MedDRA Preferred Term Code | AEPTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900086","Adverse Event MedDRA High Level Term","C117380","A superordinate descriptor for one or more Medical Dictionary for Regulatory Activities (MedDRA) preferred terms (PTs) for the adverse event.","Adverse Event MedDRA High Level Term | AEHLT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900087","Adverse Event MedDRA High Level Term Code","C117381","A coded value specifying the high level term for the adverse event from the Medical Dictionary for Regulatory Activities (MedDRA).","Adverse Event MedDRA High Level Term Code | AEHLTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900088","Adverse Event MedDRA High Level Group Term","C117378","A superordinate descriptor for one or more Medical Dictionary for Regulatory Activities (MedDRA) high level terms (HLT) for the adverse event.","Adverse Event MedDRA High Level Group Term | AEHLGT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900089","Adverse Event MedDRA High Level Group Term Code","C117379","A coded value specifying the high level group term for the adverse event from the Medical Dictionary for Regulatory Activities (MedDRA).","Adverse Event MedDRA High Level Group Term Code | AEHLGTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900082","Adverse Event MedDRA System Organ Class","C117385","Adverse event term related to the highest level of the Medical Dictionary for Regulatory Activities (MedDRA) terminology, and distinguished by anatomical or physiological system, etiology, or purpose.","Adverse Event MedDRA System Organ Class | AESOC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900083","Adverse Event MedDRA Primary System Organ Class Code","C117386","A coded value specifying the primary system organ class for the adverse event from the Medical Dictionary for Regulatory Activities (MedDRA).","Adverse Event MedDRA Primary System Organ Class Code | AESOCCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0724556","Citric Acid Monohydrate","C47452","A tricarboxylic acid found in citrus fruits. Citric acid is used as an excipient in pharmaceutical preparations due to its antioxidant properties.  It maintains stability of active ingredients and is used as a preservative. It is also used as an acidulant to control pH and acts as an anticoagulant by chelating calcium in blood.","Citric Acid Monohydrate | 2-Hydroxy-1,2,3-propanetricarboxylic Acid | 2-Hydroxypropanetricarboxylic Acid | CITRIC ACID MONOHYDRATE | Citric Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274523","CDISC SDTM Laterality Terminology","C99073","Terminology associated with the laterality codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Laterality Terminology | LAT | Laterality | SDTM-LAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274524","CDISC SDTM Directionality Terminology","C99074","Terminology associated with the directionality codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Directionality Terminology | DIR | Directionality | SDTM-DIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3163631","Rostral","C94393","Of or relating to a structure resembling a beak.","Rostral | ROSTRAL | Rostral Experimental Organism Anatomical Concept",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545151","Lower Flexor Surface","C147162","Pertaining to the lower portion of the surface on the same side of the joint when it bends.","Lower Flexor Surface | LOWER FLEXOR SURFACE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545155","Upper Flexor Surface","C147166","Pertaining to the upper portion of the surface on the same side of the joint when it bends.","Upper Flexor Surface | UPPER FLEXOR SURFACE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1179847","Anteromedial","C147159","Denoting the front portion of the body towards the median plane.","Anteromedial | ANTEROMEDIAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443349","Volar","C147167","Pertaining to the palm side of a hand or the sole side of a foot.","Volar | VOLAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545149","Distal Volar","C147160","Pertaining to the farthest portion from the palm side of a hand or the sole side of a foot.","Distal Volar | DISTAL VOLAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545154","Upper Extensor Surface","C147165","Pertaining to the upper portion of the surface on the opposite side of the joint when it bends.","Upper Extensor Surface | UPPER EXTENSOR SURFACE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545150","Lower Extensor Surface","C147161","Pertaining to the lower portion of the surface on the opposite side of the joint when it bends.","Lower Extensor Surface | LOWER EXTENSOR SURFACE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545153","Proximal Volar","C147164","Pertaining to the nearest portion from the palm side of a hand or the sole side of a foot.","Proximal Volar | PROXIMAL VOLAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545152","Lower Medial","C147163","Denoting to the lower portion of the body towards the median plane.","Lower Medial | LOWER MEDIAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3266730","Ventrolateral","C98798","Of or pertaining to the front and side of a main body.","Ventrolateral | VENTROLATERAL",,,,,,,,,,,,,,,"42538937","Ventrolateral",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0442043","Temporal - Regional site descriptor","C117754","Of, or related to, anatomic sites that are located in the cranium, brain, and eye.","Temporal Anatomic Qualifier | TEMPORAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983607","Fore","C90386","Of or involving the front of a main body.","Fore | FORE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983612","Hind","C90393","Of or involving the back of a main body.","Hind | HIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983598","Dorsolateral","C90376","Of or involving the back and side of a main body.","Dorsolateral | DORSOLATERAL",,,,,,,,,,,,,,,"42538329","Dorsolateral",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554351","ERBB2 Gene Mutation Negative","C153091","A genetic finding indicating that ERBB2 gene mutations have not been detected in a sample.","ERBB2 Gene Mutation Negative | ERBB2 Mutation Negative | ERBB2 Wild-Type | ERBB2 Wildtype | ERBB2 wt | Erb-B2 Receptor Tyrosine Kinase 2 Gene Mutation Negative | Erb-B2 Receptor Tyrosine Kinase Gene Mutation Negative | HER-2 Gene Mutation Negative | HER2 Gene Mutation Negative | HER2 Wild-Type | HER2 Wildtype | HER2 wt | HER2/neu Gene Mutation Negative | NEU Gene Mutation Negative | Negative | No mutation detected | v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554384","LAGE-1A Positive","C153126","An indication that expression of the LAGE-1A isoform of the cancer/testis antigen 2 protein has been detected in a sample.","LAGE-1A Positive | CT6.2a Positive | Cancer/Testis Antigen 2 Isoform LAGE-1A Positive | Cancer/Testis Antigen 6.2a Positive | Isoform LAGE-1A Positive | L Antigen Family Member 1 Isoform A Positive | LAGE-1S Positive | LAGE-1a Protein Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274525","CDISC SDTM Portion/Totality Terminology","C99075","Terminology associated with the portion totality codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Portion/Totality Terminology | PORTOT | Portion/Totality | SDTM-PORTOT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554302","BRAF V600E Negative","C153163","An indication that expression of the BRAF V600E mutation has not been detected in a sample.","BRAF V600E Negative | BRAF NP_004324.2:p.V600E Negative | BRAF NP_004324.2:p.Val600Glu Negative | BRAF Non-V600E Gene Mutation | BRAF V600E Mutation Negative | BRAF Val600Glu Negative | BRAF p.V600E Negative | BRAF p.Val600Glu Negative | NP_004324.2:p.V600E Negative | NP_004324.2:p.Val600Glu Negative | Non-BRAF V600E Gene Mutation | Serine/Threonine-Protein Kinase B-raf V600E Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554301","H3 K27M Negative","C153162","An indication that expression of the histone H3 K27M mutation has not been detected in a sample.","H3 K27M Negative | H3 K27M Mutation Negative | H3 K28M Mutation Negative | H3 K28M Negative | H3 Lys27Met Negative | H3 Lys28Met Negative | H3 p.K28M Negative | H3 p.Lys28Met Negative | Histone 3 K27M Mutation Negative | Histone H3 K28M Negative | Histone H3 Lys27Met Negative | Histone H3 Lys28Met Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554403","CLDN18.2 Positive","C153150","An indication that expression of Claudin-18 Isoform A2 has been detected in a sample.","CLDN18.2 Positive | Claudin 18 Isoform A2 Positive | Claudin 18.2 Positive | Claudin-18 Isoform A2 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554500","TFE3 Gene Translocation","C153272","A cytogenetic abnormality that refers to a translocation involving the TFE3 gene.","TFE3 Gene Translocation | RCCP2 Gene Translocation | RCCX1 Gene Translocation | TFE3 Translocation | TFEA Gene Translocation | Transcription Factor Binding to IGHM Enhancer 3 Gene Translocation | Transcription Factor E3 Gene Translocation | bHLHe33 Gene Translocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554501","TFEB Gene Translocation","C153273","A cytogenetic abnormality that refers to a translocation involving the TFEB gene.","TFEB Gene Translocation | BHLHE35 Gene Translocation | TCFEB Gene Translocation | TFEB Translocation | Transcription Factor EB Gene Translocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554347","MUC20 Gene","C153087","This gene is involved in regulation of hepatocyte growth factor (HGF)/HGF receptor (c-Met) signaling.","MUC20 Gene | MUC20 | Mucin 20, Cell Surface Associated Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554357","1p/19q Codeletion Negative","C153099","A finding indicating that concurrent deletion of chromosome arms 1p and 19q is not detected in a sample.","1p/19q Codeletion Negative | 1p/19q Co-deletion Negative | 1p/19q Intact | Negative | del(1p/19q) Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879942","CDISC SDTM Severity Intensity Scale for Adverse Event Terminology","C66769","Terminology codelist used with Severity Intensity Scale for Adverse Event within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.","CDISC SDTM Severity Intensity Scale for Adverse Event Terminology | AESEV | SDTM-AESEV | Severity/Intensity Scale for Adverse Events",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202117","Low Density Lipoprotein Cholesterol Measurement","C105588","The determination of the amount of low-density lipoprotein cholesterol present in a sample.","Low Density Lipoprotein Cholesterol Measurement | LDL | LDL Cholesterol | LDL Cholesterol Measurement | LDL-C Measurement | LDL-Cholesterol Measurement | Low Density Lipoprotein-Cholesterol Measurement | Low-Density Lipoprotein Cholesterol Measurement | Low-Density Lipoprotein-Cholesterol Measurement",,,,,,,,,,,,,,,"4012479","Low density lipoprotein cholesterol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2699467","Creatine Kinase MB to Total Creatine Kinase Ratio Measurement","C79441","The determination of the ratio of creatine kinase MB compared to total creatine kinase present in a sample. The measurement may be expressed as a ratio or percentage.","Creatine Kinase MB to Total Creatine Kinase Ratio Measurement | CKMBCK | Creatine Kinase MB/Total Creatine Kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523584","Creatine Kinase MB Measurement","C64491","A quantitative measurement of the amount of heterozygous MB-type creatine kinase present in a sample.","Creatine Kinase MB Measurement | CKMB | CKMB Measurement | Creatine Kinase MB",,,,,,,,,,,,,,,"4017058","Creatine kinase MB measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554358","ABL1 Gene Mutation","C153100","A change in the nucleotide sequence of the ABL1 gene.","ABL1 Gene Mutation | ABL Gene Mutation | ABL Proto-Oncogene 1, Non-Receptor Tyrosine Kinase Gene Mutation | JTK7 Gene Mutation | c-ABL1 Gene Mutation | v-Abl Abelson Murine Leukemia Viral Oncogene Homolog 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554359","Activated PI3K-Positive Cells Present","C153101","An indication that cells expressing the active form of a phosphatidylinositol 3-kinase (PI3K) family protein has been detected in a sample.","Activated PI3K-Positive Cells Present | Activated PI3K Present | CD43 Antigen Positive Neoplastic Cells Present | Cells with Activated 1-Phosphatidylinositol 3-Kinase Present | Cells with Activated PI3 Kinase Present | Cells with Activated PI3-Kinase Present | Cells with Activated PI3K Family Present | Cells with Activated PI3K Present | Cells with Activated PIK3 Present | Cells with Activated Phosphatidylinositide 3-Kinase Present | Cells with Activated Phosphatidylinositol 3 Kinase Present | Cells with Activated Phosphatidylinositol 3-Kinase Present | Cells with Activated Phosphatidylinositol-3-Kinase Present | Cells with Activated Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826790","Adverse Event Category","C83198","A classification of adverse event data.","Adverse Event Category | AECAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697889","Adverse Event Start Time","C78539","The time at which and adverse event starts.","Adverse Event Start Time | AESTTIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826658","Adverse Event End Time","C83046","The stop time of the adverse event.","Adverse Event End Time | AEENTIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554361","Activating FGFR Gene Mutation","C153103","A change in the nucleotide sequence of an FGFR family gene that that results in constitutive activation the encoded fibroblast growth factor receptor protein and its downstream signaling pathways.","Activating FGFR Gene Mutation | Activating FGF Receptor Gene Family Mutation | Activating FGF Receptor Gene Mutation | Activating FGFR Family Gene Mutation | Activating FGFR Family Mutation | Activating FGFR Mutation | Activating Fibroblast Growth Factor Receptor Family Gene Mutation | Activating Fibroblast Growth Factor Receptor Gene Mutation | Gain-of-Function FGFR Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554362","CD45RO Antibody","C153104","Any immunoglobulin that recognizes CD45RO protein.","CD45RO Antibody | Anti-CD45R0 Antibody | Anti-CD45R0 Antigen Antibody | Anti-CD45RO | Anti-CD45RO Antigen Antibody | Anti-PTPRC Isoform CD45RO | Anti-PTPRC Isoform CD45RO Antibody | Anti-Prostatic Acid Phosphatase Antibodies | Anti-Receptor-Type Tyrosine-Protein Phosphatase C Isoform CD45RO Antibody | CD45R0 Antigen Antibody | CD45RO Antigen Antibody | PTPRC Isoform CD45RO Antibody | Receptor-Type Tyrosine-Protein Phosphatase C Isoform CD45RO Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554367","BCL-2 Family Protein","C153109","A family of proteins that all contain at least one of four Bcl-2 homology domains (BH). These proteins are involved in the regulation of apoptosis.","BCL-2 Family Protein | BCL-2 Family | BCL-2 Family Proteins | BCL2 Family | BCL2 Family Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554369","BCL2 Overexpression Positive","C153111","An indication that overexpression of BCL2 has been detected in a sample.","BCL2 Overexpression Positive | Apoptosis Regulator Bcl-2 Overexpression Positive | B-Cell CLL/Lymphoma 2 Overexpression Positive | B-Cell Leukemia/Lymphoma 2 Overexpression Positive | B-Cell Lymphoma 2 Overexpression Positive | BCL-2 Overexpression | BCL-2 Overexpression Positive | BCL2 Overexpression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554371","BCOR Gene Mutation","C153113","A change in the nucleotide sequence of the BCOR gene.","BCOR Gene Mutation | ANOP2 Gene Mutation | BCL6 Co-Repressor Gene Mutation | BCL6 Corepressor Gene Mutation | BCOR mutation | MAA2 Gene Mutation | MCOPS2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554372","BCORL1 Gene Mutation","C153114","A change in the nucleotide sequence of the BCORL1 gene.","BCORL1 Gene Mutation | BCL6 Corepressor-Like 1 Gene Mutation | BCORL1 mutation | BCoR-L1 Gene Mutation | CXorf10 Gene Mutation | Chromosome X Open Reading Frame 10 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554373","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.T315A","C153115","A fusion protein encoded by the BCR/ABL1 fusion gene with a mutation in codon 315 of the ABL1 gene. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the threonine at position 315 of the ABL1 protein has been replaced by alanine.","BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.T315A | BCR-ABL T315A Mutation | BCR-ABL Thr315Ala Mutation | BCR-ABL1 T315A Mutation | BCR-ABL1 Thr315IAla Mutation | BCR/ABL Fusion Protein with T315A | BCR/ABL Fusion Protein with Thr315Ala | BCR/ABL T315A Mutation | BCR/ABL Thr315Ala Mutation | BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Thr315Ala | BCR/ABL1 Fusion Protein with NP_005148.2:p.T315A | BCR/ABL1 Fusion Protein with NP_005148.2:p.Thr315Ala | BCR/ABL1 T315A Mutation | BCR/ABL1 Thr315Ala Mutation | BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.T315A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554375","Blasts 30,000 or Less of Peripheral Blood White Cells","C153117","A quantitative microscopic finding indicating that 30,000 or fewer nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.","Blasts 30,000 or Less of Peripheral Blood White Cells | Absolute Blasts 30,000 or Less of Peripheral Blood White Cells | Absolute Blasts 30000 or Less of Peripheral Blood White Cells | Absolute Blasts in Peripheral Blood Less Than or Equal to 30,000 | Absolute Blasts in Peripheral Blood Less Than or Equal to 30000 | Blasts 30000 or Less of Peripheral Blood White Cells | Blasts Less than or Equal to 30,000 in Peripheral Blood White Cells | Blasts Less than or Equal to 30000 in Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554377","Blasts 9 Percent or Less of Bone Marrow Nucleated Cells","C153119","A semi-quantitative microscopic finding indicating that 9 percent or less of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 9 Percent or Less of Bone Marrow Nucleated Cells | Blasts Less than or Equal to 9 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554378","Blasts 9 Percent or Less of Peripheral Blood White Cells","C153120","A semi-quantitative microscopic finding indicating that 9 percent or less of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.","Blasts 9 Percent or Less of Peripheral Blood White Cells | Blasts Less than or Equal to 9 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554379","Blasts Increased by Greater than or Equal to 50 Percent","C153121","A semi-quantitative microscopic finding indicating that the amount of immature mononuclear cells in a sample from a certain subject has increased by at least 50 percent over a prior sample from the same subject.","Blasts Increased by Greater than or Equal to 50 Percent | Increase in Blasts by Greater than or Equal to 50",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554341","CBLB Gene Mutation","C153219","A change in the nucleotide sequence of the CBLB gene.","CBLB Gene Mutation | Cas-Br-M Ecotropic Retroviral Transforming Sequence B Gene Mutation | Cbl Proto-Oncogene B Gene Mutation | Cbl-B Gene Mutation | RNF56 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554342","CD4 Positive","C153220","An indication that CD4 expression has been detected in a sample.","CD4 Positive | CD4 Antigen Positive | CD4 Molecule Positive | CD4-Positive | OKT4 Antigen Positive | T-Cell Antigen T4/Leu3 Positive | T-Cell Surface Glycoprotein CD4 Positive | T4/Leu-3 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554343","CD52 Positive","C153221","An indication that CD52 expression has been detected in a sample.","CD52 Positive | CAMPATH-1 Antigen Positive | CD52 Antigen Positive | CD52 Molecule Positive | CD52-Positive | CDw52 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554344","NCAM1 Negative","C153222","Indicates that NCAM1 expression has not been detected in a sample.","NCAM1 Negative | CD56 Antigen Negative | CD56 Negative | Neural Cell Adhesion Molecule 1 Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554345","Chromogranin Negative","C153223","An indication that the expression of chromogranin family proteins have not been detected in a sample,","Chromogranin Negative | CHG Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554460","CSF3R Gene Mutation","C153225","A change in the nucleotide sequence of the CSF3R gene.","CSF3R Gene Mutation | CD114 Gene Mutation | Colony Stimulating Factor 3 Receptor (Granulocyte) Gene Mutation | Colony Stimulating Factor 3 Receptor Gene Mutation | Colony-Stimulating Factor 3 Receptor, Granulocyte Gene Mutation | GCSF-R Gene Mutation | GCSFR Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554463","Decrease in Blasts","C153228","A semi-quantitative microscopic finding indicating that the amount of immature mononuclear cells in a sample from a certain subject has decreased when compared to a prior sample from the same subject.","Decrease in Blasts | Blast Cells Decreased | Blasts Decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1292242","Duffy Null Polymorphism","C153231","A finding indicating that expression of atypical chemokine receptor 1 protein (ACKR1; DARC; Duffy antigen/chemokine receptor) is not detected on a subject's red blood cells. The Duffy null state is associated with leukopenia and neutropenia, decreased rate of HIV disease progression and with resistance to infection by the malarial parasite Plasmodium vivax. (Blood. 2009; 114:2783-2792.)","Duffy Null Polymorphism | ACKR1 Negative | DARC Negative | Duffy Negative | Duffy Null | Duffy-Null State | Fy(a-b-) | Fy(a-b-) Phenotype",,,,,,,,,,,,,,,"4020789","Fy(a-b-) phenotype",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554466","Sensitizing EGFR Gene Mutation","C153232","A change in the sequence of the EGFR gene that results in increased sensitivity to EGFR targeted agents.","Sensitizing EGFR Gene Mutation | EGFR Sensitizing Mutation | ERBB1 Sensitizing Mutation | Epidermal Growth Factor Receptor Sensitizing Gene Mutation | HER1 Sensitizing Mutation | c-erbB1 Sensitizing Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554467","Elevated Alpha-Hydroxyglutarate","C153233","A finding indicating elevated concentrations of alpha-hydroxyglutarate in a sample.","Elevated Alpha-Hydroxyglutarate | Elevated 2-HG | Elevated 2-Hydroxy-Pentanedioic Acid | Elevated 2-Hydroxyglutarate | Elevated 2-Hydroxyglutaric Acid | Elevated 2-Hydroxypentanedioic Acid | Elevated 2HG | Elevated Alpha-Hydroxyglutaric Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554468","Elevated WT1","C153235","A finding indicating elevated concentrations of WT1 in a sample.","Elevated WT1 | Elevated Wilms Tumor 1 | WT1 Elevated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554469","FGF9 Gene Amplification","C153236","A molecular genetic abnormality indicating the presence of multiple copies of the FGF9 gene.","FGF9 Gene Amplification | FGF-9 Gene Amplification | FGF9 Amplification | Fibroblast Growth Factor 9 (Glia-Activating Factor) Gene Amplification | Fibroblast Growth Factor 9 Gene Amplification | Fibroblast Growth Factor-9 Gene Amplification | GAF Gene Amplification | Glia-Activating Factor Gene Amplification | HBFG-9 Gene Amplification | SYNS3 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554470","FGFR2 Gene Fusion Positive","C153237","An indication that a FGFR2 fusion gene has been detected in a sample.","FGFR2 Gene Fusion Positive | BEK Gene Fusion Positive | CD332 Gene Fusion Positive | ECT1 Gene Fusion Positive | FGFR-2 Gene Fusion Positive | FGFR2 Fusion | FGFR2 Fusion Gene | Fibroblast Growth Factor Receptor 2 Gene Fusion Positive | K-SAM Gene Fusion Positive | KGFR Gene Fusion Positive | Keratinocyte Growth Factor Receptor Gene Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554474","FGFR2 Gene Rearrangement","C153241","A molecular abnormality indicating rearrangement of the FGFR2 gene.","FGFR2 Gene Rearrangement | BEK Gene Rearrangement | CD332 Gene Rearrangement | ECT1 Gene Rearrangement | FGFR-2 Gene Rearrangement | Fibroblast Growth Factor Receptor 2 Gene Rearrangement | K-SAM Gene Rearrangement | KGFR Gene Rearrangement | Keratinocyte Growth Factor Receptor Gene Rearrangement | Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554475","Folate Receptor Family Positive","C153242","An indication that expression of a member of the folate receptor family has been detected in a sample.","Folate Receptor Family Positive | Folate Binding Protein Positive | Folate Receptor Positive | Folate-Binding Protein Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0149708","Hepatitis B Surface Antibody Positive","C153243","An indication that antibodies that recognize a hepatitis B virus surface protein have been detected in a sample.","Hepatitis B Surface Antibody Positive | Anti-HBs Antibody Positive | Anti-HBs Positive | Anti-HBsAb Positive | Anti-Hepatitis B Virus Surface Antibody Positive | HBsAb Positive | Hepatitis B Virus Surface Antibody Positive | Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0744842","Hepatitis B Surface Antibody Negative","C153244","An indication that antibodies that recognize a hepatitis B virus surface protein have not been detected in a sample.","Hepatitis B Surface Antibody Negative | Anti-HBs Antibody Negative | Anti-HBs Negative | Anti-HBsAb Negative | Anti-Hepatitis B Virus Surface Antibody Negative | HBsAb Negative | Hepatitis B Virus Surface Antibody Negative | Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554476","Hematopoietic Immune Cell","C153245","A population of cells involved in the formation of blood cells and in host defense.","Hematopoietic Immune Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554477","Homologous Recombination Repair Gene","C153246","A gene involved in homologous recombination repair of DNA double-strand breaks.","Homologous Recombination Repair Gene | HHR Gene | HRR Gene | Recombination Repair Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554478","KDM2B Gene Mutation","C153247","A change in the nucleotide sequence of the KDM2B gene.","KDM2B Gene Mutation | CXXC2 Gene Mutation | F-Box and Leucine-Rich Repeat Protein 10 Gene Mutation | FBXL10 Gene Mutation | Fbl10 Gene Mutation | JEMMA (Jumonji Domain, EMSY-Interactor, Methyltransferase Motif) Protein Gene Mutation | JHDM1B Gene Mutation | Lysine (K)-Specific Demethylase 2B Gene Mutation | Lysine Specific Demethylase 2B Gene Mutation | PCCX2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554480","KIT Exon 18 Mutation","C153251","A change in the nucleotide sequence in exon 18 of the KIT gene.","KIT Exon 18 Mutation | CD117 Exon 18 Mutation | KIT Proto-Oncogene Tyrosine Protein Kinase Gene Exon 18 Mutation | c-KIT Exon 18 Mutation | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Gene Exon 18 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554481","KMT2C Gene Mutation","C153252","A change in the nucleotide sequence of the KMT2C gene.","KMT2C Gene Mutation | HALR Gene Mutation | Lysine (K)-Specific Methyltransferase 2C Gene Mutation | Lysine Methyltransferase 2C Gene Mutation | MLL3 Gene Mutation | Myeloid/Lymphoid or Mixed-Lineage Leukemia 3 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554482","MAP2K1 Gene Amplification","C153253","A molecular genetic abnormality indicating the presence of multiple copies of the MAP2K1 gene.","MAP2K1 Gene Amplification | MAPKK1 Gene Amplification | MEK1 Gene Amplification | MKK1 Gene Amplification | Mitogen-Activated Protein Kinase Kinase 1 Gene Amplification | PRKMK1 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554483","MAP2K1 Gene Rearrangement","C153254","A molecular abnormality indicating rearrangement of the MAP2K1 gene.","MAP2K1 Gene Rearrangement | MAPKK1 Gene Rearrangement | MEK1 Gene Rearrangement | MKK1 Gene Rearrangement | Mitogen-Activated Protein Kinase Kinase 1 Gene Rearrangement | PRKMK1 Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554484","MAP2K2 Gene Amplification","C153255","A molecular genetic abnormality indicating the presence of multiple copies of the MAP2K2 gene.","MAP2K2 Gene Amplification | MAPKK2 Gene Amplification | MEK2 Gene Amplification | MKK2 Gene Amplification | Mitogen-Activated Protein Kinase Kinase 2 Gene Amplification | PRKMK2 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554485","MAP2K2 Gene Mutation","C153256","A change in the nucleotide sequence of the MAP2K2 gene.","MAP2K2 Gene Mutation | MAPKK2 Gene Mutation | MEK2 Gene Mutation | MKK2 Gene Mutation | Mitogen-Activated Protein Kinase Kinase 2 Gene Mutation | PRKMK2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554486","MAP2K2 Gene Rearrangement","C153257","A molecular abnormality indicating rearrangement of the MAP2K2 gene.","MAP2K2 Gene Rearrangement | MAPKK2 Gene Rearrangement | MEK2 Gene Rearrangement | MKK2 Gene Rearrangement | Mitogen-Activated Protein Kinase Kinase 2 Gene Rearrangement | PRKMK2 Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554491","MUC16 Positive","C153263","An indication that MUC16 expression has been detected in a sample.","MUC16 Positive | CA125 Antigen Positive | CA125 Positive | MUC-16 Positive | MUC16 Antigen Positive | Mucin 16 Positive | Mucin-16 Positive | Ovarian Cancer-Related Tumor Marker CA125 Positive | Ovarian Carcinoma Antigen CA125 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554492","NF1 Gene Deletion","C153264","A molecular abnormality referring to the loss of at least one copy of the NF1 gene.","NF1 Gene Deletion | NF1 Deletion | NFNS Gene Deletion | Neurofibromin 1 Gene Deletion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554493","SLC5A5 Positive","C153265","An indication that SLC5A5 expression has been detected in a sample.","SLC5A5 Positive | NIS Positive | Sodium-Iodide Symporter Positive | Sodium/Iodide Cotransporter Positive | Solute Carrier Family 5 Member 5 Positive | TDH1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554494","NLRP1 Gene Mutation","C153266","A change in the nucleotide sequence of the NLRP1 gene.","NLRP1 Gene Mutation | CARD7 Gene Mutation | CIDED Gene Mutation | CLR17.1 Gene Mutation | DEFCAP Gene Mutation | NAC Gene Mutation | NALP1 Gene Mutation | NLR Family Pyrin Domain Containing 1 Gene Mutation | PP1044 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554495","NSD1 Gene Mutation","C153267","A change in the nucleotide sequence of the NSD1 gene.","NSD1 Gene Mutation | ARA267 Gene Mutation | KMT3B Gene Mutation | Nuclear Receptor Binding SET Domain Protein 1 Gene Mutation | Nuclear Receptor-Binding Su-Var, Enhancer of Zeste, and Trithorax Domain Protein 1 Gene Mutation | SOTOS Gene Mutation | SOTOS1 Gene Mutation | STO Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554496","NUP98 Gene Mutation","C153268","A change in the nucleotide sequence of the NUP98 gene.","NUP98 Gene Mutation | ADAR2 Gene Mutation | ADIR2 Gene Mutation | NUP196 Gene Mutation | NUP96 Gene Mutation | Nucleoporin 98 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554497","NUTM1 Gene Rearrangement","C153269","A molecular abnormality indicating rearrangement of the NUTM1 gene.","NUTM1 Gene Rearrangement | C15orf55 Gene Rearrangement | FAM22H Gene Rearrangement | NUT Gene Rearrangement | NUT Midline Carcinoma, Family Member 1 Gene Rearrangement | NUT Rearrangement | Nuclear Protein in Testis Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554498","PHF6 Gene Mutation","C153270","A change in the nucleotide sequence of the PHF6 gene.","PHF6 Gene Mutation | BFLS Gene Mutation | BORJ Gene Mutation | CENP-31 Gene Mutation | CENP31 Gene Mutation | Centromere Protein 31 Gene Mutation | PHD Finger Protein 6 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554499","RSPO Gene Fusion Positive","C153271","Indicates that a fusion containing RSPO family gene sequences has been detected in a sample.","RSPO Gene Fusion Positive | R-Spondin Family Gene Fusion Positive | R-Spondin Gene Fusion Positive | R-Spondin Homolog Gene Fusion Positive | RSPO Family Gene Fusion Positive | RSPO Fusion | RSPO Gene Fusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554503","CRIPTO Gene","C153275","This gene plays a role in the modulation of signaling by the growth factor Nodal homolog.","CRIPTO Gene | CRIPTO | Cripto, EGF-CFC Family Member Gene | TDGF1 | TDGF1 Gene | TDGF1 Gene | Teratocarcinoma-Derived Growth Factor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554508","FCN2 Gene","C153280","This gene is involved in carbohydrate binding and the lectin complement pathway.","FCN2 Gene | FCN2 | Ficolin 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554511","TRPA1 Gene","C153283","This gene plays a role in the perception of pain and cation transport.","TRPA1 Gene | TRPA1 | Transient Receptor Potential Cation Channel Subfamily A Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554945","Physician Listens to How I Would Like to do Things","C153444","A question about whether an individual's physician listens to how they would like to do things.","Physician Listens to How I Would Like to do Things | My physician listens to how I would like to do things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554942","Physician Handles People's Emotions Very Well","C153445","A question about whether an individual's physician handles people's emotions very well.","Physician Handles People's Emotions Very Well | My physician handles people's emotions very well",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554943","Physician Cares about Me as a Person","C153446","A question about whether an individual feels that their physician cares about them as  person.","Physician Cares about Me as a Person | I feel that my physician cares about me as a person",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554948","Don't Feel Very Good About the Way My Physician Talks to Me","C153447","A question about whether an individual doesn't feel very good about the way their physician talks to them.","Don't Feel Very Good About the Way My Physician Talks to Me | I don't feel very good about the way my physician talks to me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554949","Physician Tries to Understand how I See Things before Suggesting New Way to Do Things","C153448","A question about whether an individual's physician tries to understand how they see things before suggesting a new way to do things.","Physician Tries to Understand how I See Things before Suggesting New Way to Do Things | My physician tries to understand how I see things before suggesting a new way to do things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554946","Able to Share My Feelings with My Physician","C153449","A question about whether an individual feels able to share their feelings with their physician.","Able to Share My Feelings with My Physician Question | Able to Share My Feelings with My Physician | Able to Share My Feelings with My Physician | I feel able to share my feelings with my physician",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554947","7 Point Agreement Rating Scale","C153450","A subjective scale for the scoring of agreement that ranges from 1: Strongly Disagree to 7: Strongly Agree, with 4: Neutral.","7 Point Agreement Rating Scale | 7 Point Agreement Scale | Agreement Rating Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554952","Agreement Rating 1","C153451","A subjective score of 1 on a scale that ranges from 1: Strongly Disagree to 7: Strongly Agree, with 4: Neutral.","Agreement Rating 1 | Agreement Rating Score 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554953","Agreement Rating 2","C153452","A subjective score of 2 on a scale that ranges from 1: Strongly Disagree to 7: Strongly Agree, with 4: Neutral.","Agreement Rating 2 | Agreement Rating Score 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554950","Agreement Rating 3","C153453","A subjective score of 3 on a scale that ranges from 1: Strongly Disagree to 7: Strongly Agree, with 4: Neutral.","Agreement Rating 3 | Agreement Rating Score 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554951","Agreement Rating 4","C153454","A subjective score of 4 (neutral) on a scale that ranges from 1: Strongly Disagree to 7: Strongly Agree, with 4: Neutral.","Agreement Rating 4 | Agreement Rating Score 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554956","Agreement Rating 5","C153455","A subjective score of 5 on a scale that ranges from 1: Strongly Disagree to 7: Strongly Agree, with 4: Neutral.","Agreement Rating 5 | Agreement Rating Score 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554957","Agreement Rating 6","C153456","A subjective score of 6 on a scale that ranges from 1: Strongly Disagree to 7: Strongly Agree, with 4: Neutral.","Agreement Rating 6 | Agreement Rating Score 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554954","Agreement Rating 7","C153457","A subjective score of 7 on a scale that ranges from 1: Strongly Disagree to 7: Strongly Agree, with 4: Neutral.","Agreement Rating 7 | Agreement Rating Score 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554931","The Health Care Climate Questionnaire","C153434","A questionnaire designed to assess a patient's perceptions of the degree to which their specific doctor supports the patient's autonomy.","The Health Care Climate Questionnaire | HCCQ | The Health Care Climate Questionnaire (HCCQ)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554936","Feel Physician Provided Choices and Options","C153435","A question about whether an individual feels that their physician has provided choices and options.","Feel Physician Provided Choices and Options | I feel that my physician has provided me choices and options",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554937","Feel Understood by Physician","C153436","A question about whether an individual feels understood by their physician.","Feel Understood by Physician | I feel understood by my physician",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554934","Able to be Open with Physician at Meetings","C153437","A question about whether an individual feels able to be open with their physician at their meetings.","Able to be Open with Physician at Meetings Question | Able to be Open with Physician at Meetings | Able to be Open with Physician at Meetings | I am able to be open with my physician at our meetings",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554935","Physician Conveys Confidence in My Ability to Make Choices","C153438","A question about whether an individual's physician conveys confidence in their ability to make choices.","Physician Conveys Confidence in My Ability to Make Choices | My physician conveys confidence in my ability to make changes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554940","Feel My Physician Accepts Me","C153439","A question about whether an individual feels that their physician accepts them.","Feel My Physician Accepts Me | I feel that my physician accepts me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554941","Physician Made Sure I Understood about My Condition and what I Need to Do","C153440","A question about whether an individual's physician has made sure they really understand about their condition and what they need to do.","Physician Made Sure I Understood about My Condition and what I Need to Do | My physician has made sure I really understand about my condition and what I need to do",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554938","Physician Encourages Me to Ask Questions","C153441","A question about whether an individual's physician encourages them to ask questions.","Physician Encourages Me to Ask Questions | My physician encourages me to ask questions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554939","Feel Lot of Trust in Physician","C153442","A question about whether an individual feels a lot of trust in their physician.","Feel Lot of Trust in Physician | I feel a lot of trust in my physician",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554944","Physician Answers Questions Fully and Carefully","C153443","A question about whether an individual's physician answers their questions fully and carefully.","Physician Answers Questions Fully and Carefully | My physician answers my questions fully and carefully",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554955","Preparation for Decision Making Scale","C153458","A questionnaire designed to assess a patient's perception of how useful a decision aid, or other decision-support intervention, is in preparing them to communicate with their physician to make a healthcare decision.","Preparation for Decision Making Scale | PrepDM | Preparation for Decision Making",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554960","Helped Recognize that Decision Needs to be Made","C153459","A question about whether an individual was helped to recognize that a decision needs to be made.","Helped Recognize that Decision Needs to be Made | Help you recognize that a decision needs to be made",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554961","Prepared to Make Better Decision","C153460","A question about whether an individual was prepared to make a better decision.","Prepared to Make Better Decision | Prepare you to make a better decision",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554958","Helped Think About Pros and Cons of Each Option","C153461","A question about whether an individual was helped to think about the pros and cons of each option.","Helped Think About Pros and Cons of Each Option | Help you think about the pros and cons of each option",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554959","Helped Think About which Pros and Cons are Most Important","C153462","A question about whether an individual was helped to think about which pros and cons are most important.","Helped Think About which Pros and Cons are Most Important | Help you think about which pros and cons are most important",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554964","Helped to Know that Decision Depends on What Matters Most to You","C153463","A question about whether an individual was helped to know that the decision depends on what matters most to them.","Helped to Know that Decision Depends on What Matters Most to You | Help you know that the decision depends on what matters most to you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554969","Helped Organize Your Thoughts About Decision","C153468","A question about whether an individual was helped to organize their own thoughts about their decision.","Helped Organize Your Thoughts About Decision | Help you organize your own thoughts about the decision",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554966","Helped Think About How Involved You Want to be in Decision","C153469","A question about whether an individual was helped to think about how involved they want to be in this decision.","Helped Think About How Involved You Want to be in Decision | Help you think about how involved you want to be in this decision",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554967","Helped Identify Questions You Want to Ask Your Doctor","C153470","A question about whether an individual was helped to identify questions they want to ask their doctor.","Helped Identify Questions You Want to Ask Your Doctor | Help you identify questions you want to ask your doctor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554970","Prepared You to Talk to Your Doctor About What Matters Most to You","C153471","A question about whether an individual was prepared to talk to their doctor about what matters most to them.","Prepared You to Talk to Your Doctor About What Matters Most to You | Prepare you to talk to your doctor about what matters most to you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554971","Prepared You for Follow-up Visit with Your Doctor","C153472","A question about whether an individual was prepared for a follow-up visit with their doctor.","Prepared You for Follow-up Visit with Your Doctor | Prepare you for a follow-up visit with your doctor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554982","Perceived Efficacy in Patient-Physician Interactions","C153484","A 10-item questionnaire, or 5-item subset, designed to assess a patient's confidence in obtaining medical information and attention to their medical concerns from physicians.","Perceived Efficacy in Patient-Physician Interactions | PEPPI | Perceived Efficacy in Patient-Physician Interactions (PEPPI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554980","How Confident in Ability to Know What Questions to Ask Doctor","C153485","A question about how confident an individual is in their ability to know what questions to ask a doctor.","How Confident in Ability to Know What Questions to Ask Doctor | How confident are you in your ability to know what questions to ask a doctor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554981","How Confident in Ability to get Doctor to Answer All Questions","C153486","A question about how confident an individual is in their ability to get a doctor to answer all of their questions.","How Confident in Ability to get Doctor to Answer All Questions | How confident are you in your ability to get a doctor to answer all of your questions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554985","How Confident in Ability to Make Most of Visit with Doctor","C153487","A question about how confident an individual is in their ability to make the most of their visit with a doctor.","How Confident in Ability to Make Most of Visit with Doctor | How confident are you in your ability to make the most of your visit with a doctor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554986","How Confident in Ability to Get Doctor to Take Chief Health Concern Seriously","C153488","A question about how confident an individual is in their ability to get a doctor to take their chief health concern seriously.","How Confident in Ability to Get Doctor to Take Chief Health Concern Seriously | How confident are you in your ability to get a doctor to take your chief health concern seriously",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554983","How Confident in Ability to Get Doctor to do Something About Chief Health Concern","C153489","A question about how confident an individual is in their ability to get a doctor to do something about their chief health concern.","How Confident in Ability to Get Doctor to do Something About Chief Health Concern | How confident are you in your ability to get a doctor to do something about your chief health concern",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554984","5-Point Confidence Scale","C153490","A subjective scale for the scoring of confidence that ranges from 1: Not at all confident 5: Very confident.","5-Point Confidence Scale | Confidence Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554989","Confidence 1","C153491","A subjective score of 1 on a confidence scale that ranges from 1: Not at all confident to 5: Very confident.","Confidence 1 | Confidence Score 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554990","Confidence 2","C153492","A subjective score of 2 on a confidence scale that ranges from 1: Not at all confident to 5: Very confident.","Confidence 2 | Confidence Score 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554987","Confidence 3","C153493","A subjective score of 3 on a confidence scale that ranges from 1: Not at all confident to 5: Very confident.","Confidence 3 | Confidence Score 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554988","Confidence 4","C153494","A subjective score of 4 on a confidence scale that ranges from 1: Not at all confident to 5: Very confident.","Confidence 4 | Confidence Score 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554872","Confidence 5","C153495","A subjective score of 5 on a confidence scale that ranges from 1: Not at all confident to 5: Very confident.","Confidence 5 | Confidence Score 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699044","Adverse Event Verbatim Description","C78541","The verbatim description of the adverse event.","Adverse Event Verbatim Description | AETERM | Adverse Event Reported Term | adverse event description | adverse_event_description",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697888","Adverse Event Start Date","C78536","The calendar date on which an adverse event starts.","Adverse Event Start Date | AESTDAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697886","Adverse Event End Date","C78537","The calendar date on which an adverse event ends.","Adverse Event End Date | AEENDAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697890","Adverse Event Toxicity Grade","C78605","The toxicity grade value of the adverse event.","Adverse Event Toxicity Grade | AETOXGR | Toxicity Value",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1710056","Seriousness of Adverse Event","C53252","Clinical significance of adverse event defined based on the patient and event outcome or action criteria usually associated with events that pose a threat to a patient's life or functioning. Seriousness of adverse event serves as a primary guide for defining regulatory reporting obligations and changes in medicinal product development and usage.","Seriousness of Adverse Event | AESER | AdverseEventSeriousness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830477","Disabling Adverse Event","C113380","An adverse event, and/or its immediate sequelae which is associated with physical or mental disabilities that affect or limit the ability of a person to perform activities of daily living (eating, ambulation, toileting, etc.).","Disabling Adverse Event | AESDISAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826727","Adverse Event Seriousness Due to Congenital Anomaly","C83117","An indication or description that the seriousness of an adverse event was due to a congenital abnormality.","Adverse Event Seriousness Due to Congenital Anomaly | AESCONG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826665","Adverse Event Associated with Serious Medical Event","C83053","An indication or description of an adverse event associated with a critical medical event.","Adverse Event Associated with Serious Medical Event | AESMIE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510821","Adverse Event Attribution to Product or Procedure","C41358","A specific identifiable level (defined qualitatively or quantitatively) of probability of adverse event being caused or associated with the product or procedure administration to a patient.","Adverse Event Attribution to Product or Procedure | AEREL | AE_ATTRIBUTION | Adverse Event Relationship to Study Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900085","Adverse Event MedDRA Low Level Term","C117382","Adverse event term related to the lowest level of the Medical Dictionary for Regulatory Activities (MedDRA) terminology, related to a single PT as a synonym, lexical variant, or quasi-synonym.","Adverse Event MedDRA Low Level Term | AELLT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897027","Adverse Event MedDRA Low Level Term Code","C117383","A coded value specifying the low level term for the adverse event from the Medical Dictionary for Regulatory Activities (MedDRA).","Adverse Event MedDRA Low Level Term Code | AELLTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826937","Occurrence of Adverse Event","C83347","An indication of whether an adverse event has occurred.","Adverse Event Yes No Indicator | AEYN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826685","Adverse Event Sponsor Defined Identifier","C83074","One or more sponsor defined characters used to identify, name, or characterize the adverse event.","Adverse Event Sponsor Defined Identifier | AESPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553294","PARN Gene Mutation","C152086","A change in the nucleotide sequence of the PARN gene.","PARN Gene Mutation | DAN Gene Mutation | DKCB6 Gene Mutation | Deadenylation Nuclease Gene Mutation | Poly(A)-Specific Ribonuclease (Deadenylation Nuclease) Gene Mutation | Poly(A)-Specific Ribonuclease Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553293","CTC1 Gene Mutation","C152085","A change in the nucleotide sequence of the CTC1 gene.","CTC1 Gene Mutation | AAF-132 Gene Mutation | AAF132 Gene Mutation | C17orf68 Gene Mutation | CST Telomere Replication Complex Component 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553292","TINF2 Gene Mutation","C152084","A change in the nucleotide sequence of the TINF2 gene.","TINF2 Gene Mutation | DKCA3 Gene Mutation | TERF1 Interacting Nuclear Factor 2 Gene Mutation | TIN2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553291","WRAP53 Gene Mutation","C152083","A change in the nucleotide sequence of the WRAP53 gene.","WRAP53 Gene Mutation | DKCB3 Gene Mutation | TCAB1 Gene Mutation | Telomerase Cajal Body Protein 1 Gene Mutation | WD Repeat Containing, Antisense to TP53 Gene Mutation | WD Repeat Domain 79 Gene Mutation | WDR79 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553290","NHP2 Gene Mutation","C152082","A change in the nucleotide sequence of the NHP2 gene.","NHP2 Gene Mutation | DKCB2 Gene Mutation | NHP2 Ribonucleoprotein Gene Mutation | NHP2P Gene Mutation | NOLA2 Gene Mutation | Nucleolar Protein Family A, Member 2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553289","NOP10 Gene Mutation","C152081","A change in the nucleotide sequence of the NOP10 gene.","NOP10 Gene Mutation | DKCB1 Gene Mutation | NOLA3 Gene Mutation | NOP10 Ribonucleoprotein Gene Mutation | NOP10P Gene Mutation | Nucleolar Protein Family A, Member 3 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553288","TERC Gene Mutation","C152080","A change in the nucleotide sequence of the TERC gene.","TERC Gene Mutation | DKCA1 Gene Mutation | SCARNA19 Gene Mutation | Small Cajal Body-Specific RNA 19 Gene Mutation | TR Gene Mutation | TRC3 Gene Mutation | Telomerase RNA Component Gene Mutation | hTR Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553287","DKC1 Gene Mutation","C152079","A change in the nucleotide sequence of the DKC1 gene.","DKC1 Gene Mutation | CBF5 Gene Mutation | DKC Gene Mutation | DKCX Gene Mutation | Dyskerin Pseudouridine Synthase 1 Gene Mutation | NAP57 Gene Mutation | NOLA4 Gene Mutation | XAP101 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554878","SURE Test","C153506","A 4-item questionnaire designed to assess the probability that a patient experiences clinically-significant decisional conflict.","SURE Test | SURE | SURE Test for Clinical Practice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554883","Feel Sure About Best Choice","C153507","A question about whether an individual feels sure about the best choice for them.","Feel Sure About Best Choice | Do you feel SURE about the best choice for you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554884","Know Benefits and Risk of Each Option","C153508","A question about whether an individual knows the benefits and risks of each option.","Know Benefits and Risk of Each Option | Do you know the benefits and risks of each option",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554881","Clear About Which Benefits and Risks Matter Most","C153509","A question about whether an individual is clear about which benefits and risks matter most to them.","Clear About Which Benefits and Risks Matter Most | Are you clear about which benefits and risks matter most to you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554882","Have Enough Support and Advice to Make Choice","C153510","A question about whether an individual has enough support and advice to make a choice.","Have Enough Support and Advice to Make Choice | Do you have enough support and advice to make a choice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509318","Review Healthcare Training or Educational Materials","C128499","The healthcare provider or patient must review certain training or educational materials.","Review Healthcare Training or Educational Materials | Review Training or Educational Materials",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553279","Prostaglandin F2alpha","C152070","A naturally occurring prostaglandin that stimulates myometrial activity, relaxes the cervix, inhibits corpus luteal steroidogenesis, and induces luteolysis by direct action on the corpus luteum. Expression of prostaglandin F2alpha (PGF2) is elevated in certain types of cancers.","Prostaglandin F2alpha | (5Z,13E,15S)-9alpha,11alpha,15-trihydroxyprosta-5,13-dien-1-oic acid | PGF2 | PGF2a | PGF2alpha | Prostaglandin F2a | Prostaglandin-F2alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553278","9alpha,11beta-Prostaglandin F2alpha","C152069","A form of prostaglandin F2alpha derived from prostaglandin D2 (PGD2). The concentration of 9alpha,11beta-prostaglandin F2alpha (9a11b-PGF2a) in a sample may be correlated with the levels of PGD2 synthesis. 9a11b-PGF2a levels are elevated in certain types of cancers.","9alpha,11beta-Prostaglandin F2alpha | 9a11b-PGF2a | 9alpha,11beta-PGF2alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0000617","6-Ketoprostaglandin F1alpha","C152068","A form of prostaglandin F1alpha that has been modified with a keto group at position 6. 6-Ketoprostaglandin F1alpha (6-ketoPGF1a) is an inactive metabolite derived from prostaglandin I2 (PGI2). The concentration of 6-ketoPGF1a in a sample may be correlated with the levels of PGI2 synthesis. 6-KetoPGF1a levels are elevated in certain types of cancers.","6-Ketoprostaglandin F1alpha | (13E,15S)-9alpha,11alpha,15-trihydroxy-6-oxoprost-13-en-1-oic acid | 6-Keto-PGF1alpha | 6-Keto-Prostaglandin F1-Alpha | 6-Keto-Prostaglandin F1a | 6-Keto-Prostaglandin F1alpha | 6-KetoPGF1a | 6-Ketoprostaglandin F1-Alpha | 6-Oxo-PGF1a | 6-Oxo-PGF1alpha | 6-Oxoprostaglandin F1a | 6-Oxoprostaglandin F1alpha | Prost-13-en-1-oic acid, 9,11,15-trihydroxy-6-oxo-, (9alpha,11alpha,13E,15S)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553399","Oxylipins","C152067","A family of bioactive lipid metabolites that are produced when polyunsaturated fatty acids (PUFAs) undergo at least one round of dioxygen-dependent oxidation, which is catalyzed by cyclooxygenase (COX), lipoxygenase (LOX) or cytochrome P450 (CYP) epoxygenase family enzymes Oxylipins play an important role in the modulation of the tumor microenvironment (TME) and facilitate tumor cell proliferation, migration and invasion.","Oxylipin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513359","TERT Gene Mutation","C131104","A change in the nucleotide sequence of the TERT gene.","TERT Gene Mutation | DKCA2 Gene Mutation | DKCB4 Gene Mutation | EST2 Gene Mutation | TCS1 Gene Mutation | TERT mutation | TP2 Gene Mutation | TRT Gene Mutation | Telomerase Reverse Transcriptase Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553296","ACD Gene Mutation","C152088","A change in the nucleotide sequence of the ACD gene.","ACD Gene Mutation | ACD, Shelterin Complex Subunit and Telomerase Recruitment Factor Gene Mutation | Adrenocortical Dysplasia Homolog (Mouse) Gene Mutation | PIP1 Gene Mutation | PTOP Gene Mutation | TINT1 Gene Mutation | TPP1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553295","RTEL1 Gene Mutation","C152087","A change in the nucleotide sequence of the RTEL1 gene.","RTEL1 Gene Mutation | C20orf41 Gene Mutation | DKCA4 Gene Mutation | DKCB5 Gene Mutation | NHL Gene Mutation | RTEL Gene Mutation | Regulator of Telomere Elongation Helicase 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554210","NTRK1 Gene Amplification","C153062","A molecular genetic abnormality indicating the presence of multiple copies of the NTRK1 gene.","NTRK1 Gene Amplification | MTC Gene Amplification | NTRK1 Amplification | Neurotrophic Receptor Tyrosine Kinase 1 Gene Amplification | Neurotrophic Tyrosine Kinase, Receptor, Type 1 Gene Amplification | TRK Amplification | TRK Gene Amplification | TRK1 Gene Amplification | TRKA Amplification | TRKA Gene Amplification | Trk-A Gene Amplification | p140-TrkA Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554209","NTRK1 Gene Translocation","C153061","A cytogenetic abnormality that refers to any translocation involving the NTRK1 gene.","NTRK1 Gene Translocation | MTC Gene Translocation | NTRK1 Translocation | Neurotrophic Receptor Tyrosine Kinase 1 Gene Translocation | Neurotrophic Tyrosine Kinase, Receptor, Type 1 Gene Translocation | TRK Gene Translocation | TRK Translocation | TRK1 Gene Translocation | TRKA Gene Translocation | TRKA Translocation | Trk-A Gene Translocation | p140-TrkA Gene Translocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554208","NTRK1 Overexpression Positive","C153060","An indication that overexpression of NTRK1 has been detected in a sample.","NTRK1 Overexpression Positive | High Affinity Nerve Growth Factor Receptor Overexpression Positive | NTRK1 Overexpression | Neurotrophic Receptor Tyrosine Kinase 1 Overexpression Positive | TRK1 Overexpression Positive | TRKA Overexpression Positive | Trk-A Overexpression Positive | Tropomyosin-Related Kinase A Overexpression Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554207","NTRK1 Gene Mutation","C153059","A change in the nucleotide sequence of the NTRK1 gene.","NTRK1 Gene Mutation | MTC Gene Mutation | NTRK1 Mutation | Neurotrophic Receptor Tyrosine Kinase 1 Gene Mutation | Neurotrophic Tyrosine Kinase, Receptor, Type 1 Gene Mutation | TRK Gene Mutation | TRK Mutation | TRK1 Gene Mutation | TRKA Gene Mutation | TRKA Mutation | Trk-A Gene Mutation | TrkA Gene Mutation | p140-TrkA Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021210","Indican","C152073","A toxic metabolite derived from dietary proteins and tryptophan. In the intestine, proteins and tryptophan are converted to indole by tryptophanase-expressing organisms. In the liver, indole is hydroxylated to form indoxyl and indoxyl is sufated to produce indican. Overproduction of indican is associated with glomerular sclerosis, interstitial fibrosis and renal failure.","Indican | 1H-Indol-3-yl Hydrogen Sulfate | 3-Indolyl Hydrogen Sulfate | 3-Indolyl Sulfate | 3-Indoxyl Sulfate | 3-Indoxylsulfuric Acid | INDICAN | Indol-3-yl Hydrogen Sulfate | Indol-3-yl Sulfate | Indoxyl Sulfate | Indoxylsulfuric Acid | Uindoxyl Sulfate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553281","Phthalate","C152072","A family of benzene derivatives that are formed by esterification of phthalic acid. Phthalates are added to increase the flexibility and softness of commercial plastics, which are incorporated into a wide variety of consumer goods. Ingested phthalates may exhibit estrogenic or antiandrogenic effects or they may act as endocrine disruptors. Exposure to phthalate may increase the risk of certain cancers.","Phthalate | Phthalic Acid Ester",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553280","Bisphenol A","C152071","A diphenylmethane derivative with two hydroxyphenyl groups. Bisphenol A (BPA) is a colorless solid that is used in the synthesis of commercial plastics, including polycarbonates and epoxy resins, which are incorporated into a wide variety of consumer goods. Ingested BPA may exhibit estrogenic effects. Exposure to BPA may increase the risk of certain cancers.","Bisphenol A | 2, 2-Bis(4-hydroxyphenyl)propane | 2,2-Bis(4'-hydroxyphenyl)propane | 2,2-Bis(4-Hydroxyphenyl)propane | 2,2-Bis(p-hydroxyphenyl)propane | 2,2-Di(4-hydroxyphenyl)propane | 2,2-Di(4-phenylol)propane | 4,4' Isopropylidinediphenol | 4,4'-(1-Methylethane-1,1-diyl)diphenol | 4,4'-(1-Methylethylidene)bisphenol | 4,4'-(Propane-2,2-diyl)diphenol | 4,4'-Isopropylidenediphenol | BISPHENOL A | BPA | Phenol, 4,4'-(1-methylethylidene)bis- | Phenol, 4,4'-isopropylidenedi-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540385","Clinical Benefit","C142422","An effect of a therapeutic intervention that prolongs life, improves function, and/or improves the way a subject feels.","Clinical Benefit | clinical benefit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054479","Molecular Response","C123624","An evaluation of the molecular response of the disease to the therapy.","Molecular Response | MOLRESP | MR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826838","Disposition Subcategory","C83248","A subdivision of disposition data.","Disposition Subcategory | DSSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826669","Disposition Continuation","C83057","An indication or description that the subject will be continuing on to next phase of the trial.","Disposition Continuation | DSCONT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017398","Science of genetics","C16624","The branch of biology that deals with heredity, especially the mechanisms of hereditary transmission and the variation of inherited characteristics among similar or related organisms","Genetics | genetics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826687","Next Trial Identification","C83076","The identifier of the subsequent trial that the patient is entering.","Next Trial Identification | DSNEXT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826735","Disposition Start Date","C83125","The date on which the disposition event begins.","Disposition Start Date | DSSTDAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556874","Patient Provider Orientation Scale","C153527","A questionnaire designed to assess beliefs that people have concerning doctors, patients, and medical care.","Patient Provider Orientation Scale | PPOS | Patient Provider Orientation Scale (PPOS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554902","Doctor Should Decide What Gets Talked About During Visit","C153528","A question about whether the doctor is the one who should decide what gets talked about during a visit.","Doctor Should Decide What Gets Talked About During Visit | The doctor is the one who should decide what gets talked about during a visit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554900","Health Care is Less Personal but Pays for Medical Advances","C153529","A question about whether health care is less personal these days, but a small price to pay for medical advances.","Health Care is Less Personal but Pays for Medical Advances | Although health care is less personal these days, this is a small price to pay for medical advances",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554901","Most Important Part of Standard Medical Visit is Physical Exam","C153530","A question about whether the most important part of a standard medical visit is the physical exam.","Most Important Part of Standard Medical Visit is Physical Exam | The most important part of the standard medical visit is the physical exam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554905","Often Best for Patients to Not Have Full Explanation of Medical Condition","C153531","A question about whether it is often best for patients if they do not have a full explanation of their medical condition.","Often Best for Patients to Not Have Full Explanation of Medical Condition | It is often best for patients if they do not have a full explanation of their medical condition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554906","Patient Should Rely on Doctor's Knowledge and Not Find Out About Their Conditions","C153532","A question about whether patients should rely on their doctor's knowledge and not try to find out about their conditions on their own.","Patient Should Rely on Doctor's Knowledge and Not Find Out About Their Conditions | Patients should rely on their doctors' knowledge and not try to find out about their conditions on their own",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554903","Doctors Asking Lots of Questions About Patient's Background is Prying into Personal Matters","C153533","A question about whether when doctors ask a lot of questions about patient's background, they are prying too much into personal matters.","Doctors Asking Lots of Questions About Patient's Background is Prying into Personal Matters | When doctors ask a lot of questions about a patient's background, they are prying too much into personal matters",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554904","If Doctors are Good at Diagnosis and Treatment then their Relations with Patients Not Important","C153534","A question about if doctors are truly good at diagnosis and treatment, the way they relate to patients is not that important.","If Doctors are Good at Diagnosis and Treatment then their Relations with Patients Not Important | If doctors are truly good at diagnosis and treatment, the way they relate to patients is not that important",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554909","Many Patients Continue Asking Questions When Not Learning Anything New","C153535","A question about whether many patients continue asking questions even though they are not learning anything new.","Many Patients Continue Asking Questions When Not Learning Anything New | Many patients continue asking questions even though they are not learning anything new",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554910","Patients Should be Treated as Equal Partners with Doctor","C153536","A question about whether patients should be treated as if they were partners with their doctor, equal in power and status.","Patients Should be Treated as Equal Partners with Doctor | Patients should be treated as if they were partners with the doctor, equal in power and status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554907","Patients Generally Want Reassurance Rather than Information about Health","C153537","A question about whether patients generally want reassurance rather than information about their health.","Patients Generally Want Reassurance Rather than Information about Health | Patients generally want reassurance rather than information about their health",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554908","If Doctor's Primary Tools are being Open and Warm, Doctor Will Not Have Success","C153538","A question about if a doctor's primary tools are being open and warm, the doctor will not have a lot of success.","If Doctor's Primary Tools are being Open and Warm, Doctor Will Not Have Success | If a doctor's primary tools are being open and warm, the doctor will not have a lot of success",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554913","Disagreement is Sign that Doctor Does Not Have Patient's Respect and Trust","C153539","A question about whether when patients disagree with their doctor, this is a sign that the doctor does not have the patient's respect and trust.","Disagreement is Sign that Doctor Does Not Have Patient's Respect and Trust | When patients disagree with their doctor, this is a sign that the doctor does not have the patient's respect and trust",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554914","Treatment Plan Cannot Succeed if in Conflict with Patient's Lifestyle or Values","C153540","A question about whether a treatment plan cannot succeed if it is in conflict with a patient's lifestyle or values.","Treatment Plan Cannot Succeed if in Conflict with Patient's Lifestyle or Values | A treatment plan cannot succeed if it is in conflict with a patient's lifestyle or values",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554911","Most Patients Want to Get in and Out of Doctor's Office as Quickly as Possible","C153541","A question about whether most patients want to get in and get out of the doctor's office as quickly as possible.","Most Patients Want to Get in and Out of Doctor's Office as Quickly as Possible | Most patients want to get in and get out of the doctor's office as quickly as possible",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554912","Patient Must Always be Aware that Doctor is in Charge","C153542","A question about whether the patient must always be aware that the doctor is in charge.","Patient Must Always be Aware that Doctor is in Charge | The patient must always be aware that the doctor is in charge",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554917","Not Important to Know Patient's Culture and Background to Treat their Illness","C153543","A question about whether it is not important that a doctor know a patient's culture and background in order to treat the person's illness.","Not Important to Know Patient's Culture and Background to Treat their Illness | It is not that important to know a patient's culture and background in order to treat the person's illness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554915","When Patients Look up Medical Information This Confuses More than Helps","C153545","A question about whether when patients look up medical information on their own, it usually confuses more than it helps.","When Patients Look up Medical Information This Confuses More than Helps | When patients look up medical information on their own, this usually confuses more than it helps.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554916","Moderately Disagree","C153546","A response indicating moderate disagreement.","Moderately Disagree | Moderate Disagreement | Moderately disagree",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554921","Moderately Agree","C153547","A response indicating moderate agreement.","Moderately Agree | Moderate Agreement | Moderately agree",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556374","Control Preference Scale","C153563","A tool designed to assess the degree of control an individual wants to assume when decisions are being made about medical treatment.","Control Preference Scale | CPS | Control Preferences Scale (CPS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555027","Preference for Making Decisions about Health Care","C153564","A question about an individual's preference for making decisions about their healthcare.","Preference for Making Decisions about Health Care | What is your preference for making decisions about your health care",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0373670","Lipase Measurement","C117748","The determination of the amount of lipase present in a sample.","Lipase Measurement | LIPASET | Lipase | Total Lipase | Triacylglycerol Lipase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054720","Influenza B Antigen Measurement","C120679","The determination of the amount of the Influenza B antigen in a sample.","Influenza B Antigen Measurement | INFBAG | Influenza B Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054721","Influenza A/B Antigen Measurement","C120678","The determination of the amount of the Influenza A/B antigen in a sample.","Influenza A/B Antigen Measurement | INFABAG | Influenza A/B Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054722","Influenza A Antigen Measurement","C120677","The determination of the amount of the Influenza A antigen in a sample.","Influenza A Antigen Measurement | INFAAG | Influenza A Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0392885","High Density Lipoprotein Cholesterol Measurement","C105587","The determination of the amount of high-density lipoprotein cholesterol present in a sample.","High Density Lipoprotein Cholesterol Measurement | HDL | HDL Cholesterol | HDL Cholesterol Measurement",,,,,,,,,,,,,,,"4101713","High density lipoprotein cholesterol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1295113","Choriogonadotropin Measurement","C147128","The determination of the amount of choriogonadotropin present in a sample.","Choriogonadotropin Measurement | Choriogonadotropin | HCGND | Human Chorionic Gonadotropin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272930","Fibrinogen Equivalent Unit","C96649","A unit of measure for the concentration of fibrin degradation products in a sample, calculated based upon the mass of fibrinogen contained within that sample.","Fibrinogen Equivalent Unit | FEU | Fibrinogen Equivalent Units | [FEU]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826741","Disposition Start Time","C83131","The time at which the disposition event begins.","Disposition Start Time | DSSTTIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086231","Enzyme Immunoassay","C17455","Any of several immunoassay methods that use an enzyme covalently linked to an antigen or antibody as a label; the most common types are enzyme-linked immunosorbent assay (ELISA) and enzyme-multiplied immunoassay technique (EMIT).","Enzyme Immunoassay | EIA | Immunologic, Enzyme Linked Immunoassay",,,,,,,,,,,,,,,"4189303","Enzyme immunoassay method",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1880076","Choriogonadotropin Beta Measurement","C64851","A determination of the presence of Choriogonadotropin Beta protein.","Choriogonadotropin Beta Measurement | Choriogonadotropin Beta | HCG | Pregnancy Test | beta-hCG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981469","Exposure Yes No Indicator","C87885","An indication of whether an exposure occurrence has taken place.","Exposure Yes No Indicator | EXYN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826866","Exposure Category","C83276","A classification of exposure data.","Exposure Category | EXCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826875","Exposure Subcategory","C83285","A subdivision of exposure data.","Exposure Subcategory | EXSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826702","Exposure Reported Name of Treatment","C83091","The literal identifier of an exposure treatment.","Exposure Reported Name of Treatment | EXTRT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830288","Exposure Reference Identifier","C113358","A character or string used to name, or characterize an exposure reference.","Exposure Reference Identifier | EXREFID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826710","Exposure Lot Number","C83099","The numerical identifier of the medication exposure lot.","Exposure Lot Number | EXLOT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086283","Exposure Fasting Status","C123969","An indication or description of whether an exposure assessment was obtained from a subject that has abstained from food and possibly water for the prescribed amount of time.","Exposure Fasting Status | EXFAST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826721","Exposure Dose Form","C83111","The dosage form of the exposure.","Exposure Dose Form | EXDOSFRM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826743","Exposure Start Time","C83133","The time at which the exposure begins.","Exposure Start Time | EXSTTIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826661","Exposure End Time","C83049","The stop time of the exposure.","Exposure End Time | EXENTIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826647","Exposure Dose Unit","C83035","The unit of measure for the exposure dosage.","Exposure Dose Unit | EXDOSU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826655","Exposure Dose Frequency","C83043","The rate of exposure of a medication, therapy, or environmental state.","Exposure Dose Frequency | EXDOSFRQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826731","Exposure Route of Administration","C83121","Designation of the part of the body through which the exposure is introduced.","Exposure Route of Administration | EXROUTE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826867","Exposure Intended Dose Regimen","C83277","A treatment plan that specifies the amount, schedule and duration of an exposure.","Exposure Intended Dose Regimen | EXDOSRGM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826652","Exposure Dose Adjustment Reason","C83040","The explanation given as to why an exposure was adjusted.","Exposure Dose Adjustment Reason | EXADJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981467","Exposure Treatment Vehicle Amount","C87883","The quantity of exposure to an excipient in a treatment.","Exposure Treatment Vehicle Amount | EXVAMT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981468","Exposure Treatment Vehicle Amount Unit","C87884","The unit of measure for the quantity of exposure to an excipient in a treatment.","Exposure Treatment Vehicle Amount Unit | EXVAMTU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826682","Exposure Flow Rate","C83071","The velocity or speed of an exposure.","Exposure Flow Rate | EXFLRT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826683","Exposure Flow Rate Unit of Measure","C83072","The unit of measure for the velocity or speed of an exposure.","Exposure Flow Rate Unit of Measure | EXFLRTU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826764","Exposure Time Point","C83157","A point in time that the exposure takes place.","Exposure Time Point | EXTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826674","Study Treatment Course Completion Occurrence","C83062","An indication or description that the course of study treatment has been carried out in full.","Study Treatment Course Completion Occurrence | EXMEDCMP | EXTRTCMP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086284","Exposure Laterality","C123973","A qualifier for the side of the body the exposure assessment is performed.","Exposure Laterality | EXLAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086282","Exposure Directionality","C123945","A qualifier for the direction on the body the exposure assessment is performed.","Exposure Directionality | EXDIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1277709","Transferrin Saturation Measurement","C98792","The determination of the iron bound to transferrin in a sample.","Transferrin Saturation Measurement | Iron Binding Capacity Saturation | Iron Saturation | Iron to TIBC | TFRRNSAT | Transferrin Saturation",,,,,,,,,,,,,,,"4306252","Transferrin saturation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334160","Bridging Fibrosis","C153815","A morphologic finding indicating the presence of fibrous bands connecting portal tracts, portal tracts and centrilobular spaces, or centrilobular spaces in a liver tissue sample in a patient with evolving cirrhosis.","Bridging Fibrosis | ",,,,,,,,,,,,,,,"4151430","Bridging fibrosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555042","Decision Quality Instruments - Breast Surgery","C153581","A questionnaire designed to assess what it is like for an individual to make decisions about surgery for early-stage breast cancer.","Decision Quality Instruments - Breast Surgery | DQI-Breast | Decision Quality Instruments (DQI) - Breast Surgery | Decision Quality Instruments - Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555043","How Important to Keep Breast","C153582","A question about how important it is to an individual that they keep their breast.","How Important to Keep Breast | How important is it to you to keep your breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555040","How Important to Remove Entire Breast for Peace of Mind","C153583","A question about how important it is to an individual to have their entire breast removed for peace of mind.","How Important to Remove Entire Breast for Peace of Mind | How important is it to you remove your entire breast to gain peace of mind",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555046","How Important to Avoid Having Radiation","C153585","A question about how important it is to an individual to avoid having radiation therapy.","How Important to Avoid Having Radiation | How important is it to you avoid having radiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555047","Which Treatment Wanted to Treat Early Stage Breast Cancer","C153586","A question about which treatment an individual prefers for treating their early-stage breast cancer.","Which Treatment Wanted to Treat Early Stage Breast Cancer | Which treatment do you want to do to treat your early stage breast cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555050","How Much Does Waiting Few Weeks for Treatment Decision Affects Chances of Survival","C153589","A question about how much waiting a few weeks to make a treatment decision would affect an individual's chances of survival.","How Much Does Waiting Few Weeks for Treatment Decision Affects Chances of Survival | For most women with early breast cancer, how much would waiting a few weeks to make a treatment decision affect their chances of survival",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555048","With Treatment How Many Women Diagnosed with Early Breast Cancer Eventually Die of Breast Cancer","C153591","A question about how many women diagnosed with early breast cancer eventually die of breast cancer following treatment.","With Treatment How Many Women Diagnosed with Early Breast Cancer Eventually Die of Breast Cancer | With treatment, about how many women diagnosed with early breast cancer will eventually die of breast cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555049","Which Treatment More Likely Needs Another Operation to Remove Tumor Cells","C153592","A question about which treatment is more likely to need another operation to remove more tumor cells.","Which Treatment More Likely Needs Another Operation to Remove Tumor Cells | After which treatment is it more likely that women will need to have another operation to remove more tumor cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555053","Which Women with Early Breast Cancer Live Longer on Average","C153593","A question about which women with early breast cancer live longer on average, based on treatment type.","Which Women with Early Breast Cancer Live Longer on Average | On average, which women with early breast cancer live longer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555054","Which Women Have Higher Chance of Cancer Coming Back in Treated Breast on Average","C153594","A question about which women with early breast cancer have a higher chance of cancer returning in the treated breast, on average, based on treatment type.","Which Women Have Higher Chance of Cancer Coming Back in Treated Breast on Average | On average, which women have a higher chance of having cancer come back in the breast that has been treated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555052","10-Point Importance Scale","C153596","A scale for the subjective scoring of importance that ranges from 0: Not at all important to 10: Extremely important.","10-Point Importance Scale | Importance Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555057","Importance Score 0","C153597","A subjective score of 0 on a scale that ranges from 0: Not at all important to 10: Extremely important.","Importance Score 0 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555055","Importance Score 1","C153599","A subjective score of 1 on a scale that ranges from 0: Not at all important to 10: Extremely important.","Importance Score 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555056","Importance Score 2","C153600","A subjective score of 2 on a scale that ranges from 0: Not at all important to 10: Extremely important.","Importance Score 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555060","Importance Score 3","C153601","A subjective score of 3 on a scale that ranges from 0: Not at all important to 10: Extremely important.","Importance Score 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555061","Importance Score 4","C153602","A subjective score of 4 on a scale that ranges from 0: Not at all important to 10: Extremely important.","Importance Score 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555058","Importance Score 5","C153603","A subjective score of 5 on a scale that ranges from 0: Not at all important to 10: Extremely important.","Importance Score 5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555059","Importance Score 6","C153604","A subjective score of 6 on a scale that ranges from 0: Not at all important to 10: Extremely important.","Importance Score 6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555064","Importance Score 7","C153605","A subjective score of 7 on a scale that ranges from 0: Not at all important to 10: Extremely important.","Importance Score 7 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555065","Importance Score 8","C153606","A subjective score of 8 on a scale that ranges from 0: Not at all important to 10: Extremely important.","Importance Score 8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555062","Importance Score 9","C153607","A subjective score of 9 on a scale that ranges from 0: Not at all important to 10: Extremely important.","Importance Score 9 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555063","Importance Score 10","C153608","A subjective score of 10 on a scale that ranges from 0: Not at all important to 10: Extremely important.","Importance Score 10 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555068","Equally Likely for Both","C153609","A response indicating that 2 things are equally likely.","Equally Likely for Both | Equally Likely",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556901","No Difference in Likelihood","C153610","A response indicating no difference in likelihood.","No Difference in Likelihood | No difference",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826732","Disposition Dictionary Derived Term","C83122","The literal identifier of a disposition as determined by a standards organization.","Disposition Dictionary Derived Term | DSDECOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521736","PRAME Positive","C133814","An indication that PRAME expression has been detected in a sample.","PRAME Positive | CT130 Positive | Cancer/Testis Antigen 130 Positive | MAPE Positive | Melanoma Antigen Preferentially Expressed in Tumors Positive | OIP-4 Positive | OIP4 Positive | Opa-Interacting Protein 4 Positive | PRAME Expression Positive | Preferentially Expressed Antigen in Melanoma Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711107","MYC Gene Mutation","C43597","A change in the nucleotide sequence of the MYC gene.","MYC Gene Mutation | MRTL Gene Mutation | MYCC Gene Mutation | bHLHe39 Gene Mutation | c-myc Gene Mutation | v-MYC Myelocytomatosis Viral Oncogene Homolog (Avian) Gene Mutation | v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826673","Exposure Dose Adjustment","C83061","An indication or description that an exposure dosage was adjusted.","Exposure Dose Adjustment | EXDOSADJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826737","Exposure Start Date","C83127","The date on which the exposure begins.","Exposure Start Date | EXSTDAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826746","Exposure End Date","C83138","The stop date of the exposure.","Exposure End Date | EXENDAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826869","Exposure Dose Description","C83279","A characterization of the dose of an exposure to something.","Exposure Dose Description | EXDOSTXT | EXDSTXT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698612","CDISC CDASH Terminology","C77527","The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) Clinical Data Acquisition Standards Harmonization (CDASH) group.","CDISC CDASH Terminology | CDASH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698609","CDISC CDASH Exposure Dose Form Terminology","C78426","A terminology subset of the CDISC Study Data Tabulation Model (SDTM) Pharmaceutical Dosage Form codelist created for Clinical Data Acquisition Standards Harmonization (CDASH) Exposure Dose Form terminology.","CDISC CDASH Exposure Dose Form Terminology | CDASH-EXDOSFRM | EXDOSFRM | Exposure Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347273","CDISC SDTM Frequency Terminology","C71113","The terminology subset that includes terms pertaining to frequency scheduling of interventions and medications within the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Frequency Terminology | FREQ | Frequency | SDTM-FREQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0585298","Five Times Weekly","C85552","Five times per week.","Five Times Weekly | 5 TIMES PER WEEK | 5 Times Per Week | 5 Times per week | Five times a week",,,,,,,,,,,,,,,"4146466","Five times weekly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3274469","Five Times Monthly","C98850","Five times per month.","Five Times Monthly | 5 TIMES PER MONTH | 5 Times Per Month",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274471","Four Times Yearly","C98853","Four times per year.","Four Times Yearly | 4 TIMES PER YEAR | 4 Times Per Year",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0585305","Four Times Monthly","C98852","Four times per month.","Four Times Monthly | 4 TIMES PER MONTH | 4 Times Per Month",,,,,,,,,,,,,,,"4145081","Four times monthly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3274474","Three Times Yearly","C98860","Three times per year.","Three Times Yearly | 3 TIMES PER YEAR | 3 Times Per Year",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0585304","Three Times Monthly","C98859","Three times per month.","Three Times Monthly | 3 TIMES PER MONTH | 3 Times Per Month",,,,,,,,,,,,,,,"4146467","Three times monthly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3274475","Two Times Yearly","C98861","Two times per year.","Two Times Yearly | 2 TIMES PER YEAR | 2 Times Per Year",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526590","Ten Days Per Month","C139179","Ten days per month.","Ten Days Per Month | 10 DAYS PER MONTH | 10 Days Monthly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526593","Eight Times Per Day","C139181","Eight times per day.","Eight Times Per Day | 8 TIMES PER DAY | 8 Times Daily",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0585300","Seven Times Weekly","C98854","Seven times per week.","Seven Times Weekly | 7 TIMES PER WEEK | 7 Times Per Week",,,,,,,,,,,,,,,"4144041","Seven times weekly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526594","Seven Times Per Day","C139180","Seven times per day.","Seven Times Per Day | 7 TIMES PER DAY | 7 Times Daily",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274473","Six Times Yearly","C98858","Six times per year.","Six Times Yearly | 6 TIMES PER YEAR | 6 Times Per Year",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0585299","Six Times Weekly","C98857","Six times per week.","Six Times Weekly | 6 TIMES PER WEEK | 6 Times Per Week",,,,,,,,,,,,,,,"4144040","Six times weekly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3274470","Five Times Yearly","C98851","Five times per year.","Five Times Yearly | 5 TIMES PER YEAR | 5 Times Per Year",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826785","CDISC Variable Terminology","C83187","The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) variables.","CDISC Variable Terminology | CDISC-VARIABLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1310550","Glutamate Carboxypeptidase 2, Human","C17796","Glutamate carboxypeptidase 2 (750 aa, ~84 kDa) is encoded by the human FOLH1 gene. This protein plays a role in the mediation of folate metabolism.","Glutamate Carboxypeptidase 2 | Cell Growth-Inhibiting Gene 27 Protein | EC 3.4.17.21 | FGCP | FOLH1 | Folate Hydrolase 1 | Folylpoly-Gamma-Glutamate Carboxypeptidase | GCP2 | GCPII | Glutamate Carboxypeptidase II | Membrane Glutamate Carboxypeptidase | N-Acetylated-Alpha-Linked Acidic Dipeptidase I | NAALADase I | PSM | PSMA | Prostate-Specific Membrane Antigen | Pteroylpoly-Gamma-Glutamate Carboxypeptidase | mGCP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1311253","Fluciclovine F18","C74002","A radiotracer containing a synthetic amino acid analogue of L-leucine radiolabeled with fluorine F 18 with potential diagnostic imaging use. Similar to most amino acids, fluciclovine F18 appears to enter cells through the energy-independent L-type amino acid transporter (LAT) system. As an amino acid analogue, this agent is preferentially accumulated by tumor cells due to their increased metabolic needs; however, unlike naturally occurring amino acids, this non-natural amino acid-analogue radiotracer is not metabolized. Accordingly, fluciclovine F18 accumulates in tumor cells and can potentially be used to image tumors using positron emission tomography (PET).","Fluciclovine F18 | (18F)Fluciclovine | (18F)GE-148 | (1R,3R)-1-Amino-3(18f)fluorocyclobutane-1-carboxylic Acid | 18F-Fluciclovine | Anti-(18f)FABC | Anti-1-Amino-3-[18F]Fluorocyclobutane-1-Carboxylic Acid | Anti-[18F] FACBC | Axumin | FLUCICLOVINE F-18 | Fluciclovine (18F) | GE-148 (18F) | GE-148 F-18 | [18F]FACBC",,,,,,,,,,,,,,,"43020523","Fluciclovine (18-F)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698614","CDISC CDASH Unit for Duration of Treatment Interruption Terminology","C78427","A terminology subset of the CDISC Study Data Tabulation Model (SDTM) Unit codelist created for Clinical Data Acquisition Standards Harmonization (CDASH) Unit for Duration of Treatment Interruption terminology.","CDISC CDASH Unit for Duration of Treatment Interruption Terminology | CDASH-EXINTPU | EXINTPU | Unit for Duration of Treatment Interruption | Unit for the Duration of Treatment Interruption",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826808","Concomitant Medication Category","C83218","A classification of concomitant medication data.","Concomitant Medication Category | CMCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826822","Concomitant Medication Subcategory","C83232","A subdivision of concomitant medication data.","Concomitant Medication Subcategory | CMSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826668","Concomitant Medication Yes No Indicator","C83056","An indication of whether concomitant medication usage has occurred.","Concomitant Medication Yes No Indicator | CMYN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826686","Concomitant Medication Use Sponsor Defined Identifier","C83075","One or more sponsor-defined characters used to identify, name, or characterize the concomitant medication.","Concomitant Medication Use Sponsor Defined Identifier | CMSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826820","Concomitant Medication Use Occurrence","C83230","An indication or description regarding the use of a concomitant medication.","Concomitant Medication Use Occurrence | CMOCCUR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826627","Concomitant Medication Active Ingredient","C83014","The pharmaceutically active ingredients of the concomitant medication.","Concomitant Medication Active Ingredient | CMINGRD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826696","Concomitant Medication Use Indication","C83085","A signal which serves to indicate or point out the specific use cases for a particular concomitant medication.","Concomitant Medication Use Indication | CMINDC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698617","CDISC CDASH Units for Exposure Terminology","C78423","A terminology subset of the CDISC Study Data Tabulation Model (SDTM) Unit codelist created for Clinical Data Acquisition Standards Harmonization (CDASH) Units for Exposure terminology.","CDISC CDASH Units for Exposure Terminology | CDASH-EXDOSU | EXDOSU | Units for Exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826708","Concomitant Medication Adverse Event Number","C83097","The numerical identifier of the adverse event associated with the concomitant medication.","Concomitant Medication Adverse Event Number | CMAENO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826709","Concomitant Medication Medical History Number","C83098","The numerical identifier of the medical history event associated with the concomitant medication.","Concomitant Medication Medical History Number | CMMHNO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826811","Concomitant Medication Dose","C83221","An amount of concomitant medication.","Concomitant Medication Dose | CMDOSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826767","Concomitant Medication Administration Dose","C83160","The dose of concomitant medication taken per administration.","Concomitant Medication Administration Dose | CMDSTXT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826638","Concomitant Medication Daily Dose","C83025","The gross amount of concomitant medication that the subject is exposed to each day.","Concomitant Medication Daily Dose | CMDOSTOT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826720","Concomitant Medication Dose Form","C83110","The dosage form of the concomitant medication.","Concomitant Medication Dose Form | CMDOSFRM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826730","Concomitant Medication Route of Administration","C83120","The means of entry through which the concomitant medication is taken into the body.","Concomitant Medication Route of Administration | CMROUTE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826734","Concomitant Medication Start Date","C83124","The date on which the concomitant medication usage begins.","Concomitant Medication Start Date | CMSTDAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698611","CDISC CDASH Exposure Route of Administration Terminology","C78425","A terminology subset of the CDISC Study Data Tabulation Model (SDTM) Route codelist created for Clinical Data Acquisition Standards Harmonization (CDASH) Exposure Route of Administration terminology.","CDISC CDASH Exposure Route of Administration Terminology | CDASH-EXROUTE | EXROUTE | Exposure Route of Administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826740","Concomitant Medication Start Time","C83130","The time at which the concomitant medication usage begins.","Concomitant Medication Start Time | CMSTTIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826667","Concomitant Medication Previous Occurrence","C83055","An indication or description that a particular concomitant medication was taken in the past.","Concomitant Medication Previous Occurrence | CMPRIOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826666","Concomitant Medication Ongoing","C83054","An indication or description that the concomitant medication usage is ongoing.","Concomitant Medication Ongoing | CMONGO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826744","Concomitant Medication End Date","C83136","The stop date of the concomitant medication.","Concomitant Medication End Date | CMENDAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826659","Concomitant Medication End Time","C83047","The stop time of the concomitant medication.","Concomitant Medication End Time | CMENTIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826935","Concomitant Medication Dictionary Derived Term","C83345","A concomitant medication identifier obtained from a dictionary.","Concomitant Medication Dictionary Derived Term | CMDECOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826809","Concomitant Medication Class","C83219","The variable assigned to a concomitant medication class.","Concomitant Medication Class | CMCLAS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826810","Concomitant Medication Class Code","C83220","A character or string that represents a concomitant medication class.","Concomitant Medication Class Code | CMCLASCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698616","CDISC CDASH Unit of Measure for Flow Rate Terminology","C78429","A terminology subset of the CDISC Study Data Tabulation Model (SDTM) Unit codelist created for Clinical Data Acquisition Standards Harmonization (CDASH) Unit of Measure for Flow Rate terminology.","CDISC CDASH Unit of Measure for Flow Rate Terminology | CDASH-EXFLRTU | EXFLRTU | Unit of Measure for Flow Rate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439424","Microgram per Minute","C71211","A unit of mass flow rate equivalent to the rate at which one millionth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to one minute. Microgram per minute is also a dose administration rate unit equal to the rate at which one millionth of a gram of a product is administered per unit of time equal to one minute.","Microgram per Minute | Microgram/Minute | mcg/min | ug/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698607","CDISC CDASH Concomitant Medication Dose Units Terminology","C78417","A terminology subset of the CDISC Study Data Tabulation Model (SDTM) Unit codelist created for Clinical Data Acquisition Standards Harmonization (CDASH) Concomitant Medication Dose Units terminology.","CDISC CDASH Concomitant Medication Dose Units Terminology | CDASH-CMDOSU | CMDOSU | Concomitant Medication Dose Units",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698604","CDISC CDASH Concomitant Medication Dose Form Terminology","C78418","A terminology subset of the CDISC Study Data Tabulation Model (SDTM) Pharmaceutical Dosage Form codelist created for Clinical Data Acquisition Standards Harmonization (CDASH) Concomitant Medication Dose Form terminology.","CDISC CDASH Concomitant Medication Dose Form Terminology | CDASH-CMDOSFRM | CMDOSFRM | Concomitant Medication Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698605","CDISC CDASH Concomitant Medication Dosing Frequency per Interval Terminology","C78419","A terminology subset of the CDISC Study Data Tabulation Model (SDTM) Frequency codelist created for Clinical Data Acquisition Standards Harmonization (CDASH) Concomitant Medication Dosing Frequency per Interval Terminology.","CDISC CDASH Concomitant Medication Dosing Frequency per Interval Terminology | CDASH-CMDOSFRQ | CMDOSFRQ | Concomitant Medication Dosing Frequency per Interval",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700038","Female Reproductive System","C12402","The collection of organs and tissues, including the ovaries, genital tract, and breasts, that have several functions, including sexual maturation, pregnancy, and childbirth.","Female Reproductive System | Body System, Gynecologic | Body System, Reproductive, Female | FEMALE REPRODUCTIVE SYSTEM | Female Genital Tract | Female Reproductive Body System | Female Reproductive Organ System | Female Reproductive Tract | Genital System, Female | Gynecologic Body System | Gynecologic Organ System | Organ System, Female Reproductive | Organ System, Gynecologic | Reproductive System, Female | female reproductive system",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698606","CDISC CDASH Concomitant Medication Route of Administration Terminology","C78420","A terminology subset of the CDISC Study Data Tabulation Model (SDTM) Route codelist created for Clinical Data Acquisition Standards Harmonization (CDASH) Concomitant Medication Route of Administration terminology.","CDISC CDASH Concomitant Medication Route of Administration Terminology | CDASH-CMROUTE | CMROUTE | Concomitant Medication Route of Administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002708","Amygdala","C12440","A cluster of nuclei located deep and medially within each temporal lobe of the brain. These limbic system structures serve a role in processing memory, emotional reactions and decision-making.","Amygdala | AMYGDALA | Amygdaloid Body | Amygdaloid Nucleus | BRAIN, AMYGDALOID BODY",,,,,,,,,,,,,,,"4175782","Amygdaloid structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0223792","Hand Phalanx","C52771","A bone of the finger.","Hand Phalanx | Bone of Finger | HAND PHALANX | Hand Phalanges | Phalanges of Hand | Phalanx of Finger | Phalanx of Hand | Phalanx of the Hand",,,,,,,,,,,,,,,"4152304|4251333","Bone structure of phalanx of finger|Bone structure of phalanx of hand",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0022889","Inner Ear","C12499","The portion of the ear located within the temporal bone that is involved in both hearing and balance and includes the semicircular canals, vestibule, and cochlea. (from American Heritage Dictionary online)","Inner Ear | EAR, INNER | INNER EAR | Internal Ear | Labyrinth",,,,,,,,,,,,,,,"4042536","Inner ear structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1879743","As Much as Desired","C64636","As much as desired.","As Much as Desired | AD LIBITUM | Ad Lib | Ad Libitum | As Much as One Desires | Freely | ad libitum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1261082","Left Coronary Artery","C12872","A coronary artery that arises from the aorta and bifurcates into the left anterior descending artery and the left circumflex artery.","Left Coronary Artery | CORONARY ARTERY, LEFT | LM | Left Main Coronary Artery | Left Main Coronary Artery Segment",,,,,,,,,,,,,,,"4173435","Left coronary artery structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0223724","Scaphoid Bone","C12854","A nut-shaped bone of the wrist located in the radial site of the hand. It is one of the eight carpal bones.","Scaphoid Bone | Navicular Bone of Hand | Os Scaphoideum | SCAPHOID BONE | Scaphoid",,,,,,,,,,,,,,,"4147990","Bone structure of scaphoid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3842791","Every Night","C139178","Occurring or done each night.","Every Night | Every Night. | QN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1275569","Every Seven Days","C139177","Every seven days.","Every Seven Days | Every 7 Days | Q7D",,,,,,,,,,,,,,,"4262462","Every seven days",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0585320","Every Forty-Five Minutes","C139183","Every forty-five minutes.","Every Forty-Five Minutes | Every 45 Minutes | Q45MIN",,,,,,,,,,,,,,,"4144045","Every forty-five minutes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1275553","Every Forty-eight Hours","C89790","To be done at regular intervals of every 48 hours.","Every Forty-eight Hours | Every 48 Hours | Q48H",,,,,,,,,,,,,,,"4245250","Every forty eight hours",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1275549","Every Thirty-six Hours","C89791","To be done at regular intervals ofevery 36 hours.","Every Thirty-six Hours | Every 36 Hours | Q36H",,,,,,,,,,,,,,,"4244848","Every thirty six hours",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3274472","Six Times Monthly","C98856","Six times per month.","Six Times Monthly | 6 TIMES PER MONTH | 6 Times Per Month",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0585336","Every Six Weeks","C89788","To be done at regular intervals of every six weeks.","Every Six Weeks | EVERY 6 WEEKS | Every 6 Weeks | Q6S",,,,,,,,,,,,,,,"4145091","Every six weeks",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0585337","Every Eight Weeks","C103389","Every eight weeks.","Every Eight Weeks | EVERY 8 WEEKS | Every 8 weeks | Q8S",,,,,,,,,,,,,,,"4241481","Bimonthly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899254","Every Seven Weeks","C116149","Every seven weeks.","Every Seven Weeks | EVERY 7 WEEKS | Every 7 weeks | Q7S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641240","Every Five Weeks","C103390","Every five weeks.","Every Five Weeks | EVERY 5 WEEKS | Every 5 weeks | Q5S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037197","Sinus of Valsalva","C33557","Any one of the three normal anatomical dilatations of the aortic wall, which are located behind each of the cusps of the aortic valve.","Sinus of Valsalva | ASCENDING AORTA, SINUS OF VALSALVA | Petit's sinus | Pulmonary Sinus | Sinus of Mehta | Sinus of Morgagni | Sinus of Otto",,,,,,,,,,,,,,,"4217776","Structure of sinus of Valsalva",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0223736","Trapezial Bone","C12857","A carpal bone on the thumb side of the hand that articulates with the 1st and 2nd metacarpals.","Trapezial Bone | Greater Multiangular Bone | TRAPEZIAL BONE | Trapezium",,,,,,,,,,,,,,,"4215772","Bone structure of trapezium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698613","CDISC CDASH Total Volume Administration Unit Terminology","C78428","A terminology subset of the CDISC Study Data Tabulation Model (SDTM) Unit codelist created for Clinical Data Acquisition Standards Harmonization (CDASH) Total Volume Administration Unit terminology.","CDISC CDASH Total Volume Administration Unit Terminology | CDASH-EXVOLTU | EXVOLTU | Total Volume Administration Unit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827732","Medical History Yes No Indicator","C85522","An indication of whether a medical history has been taken.","Medical History Yes No Indicator | MHYN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826679","Medical History Occurrence","C83067","An indication or description that a medical history has been taken.","Medical History Occurrence | MHOCCUR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981481","Medical History Pre-specified","C87897","An indication or description that a medical history event was previously determined, characterized, or detailed.","Medical History Pre-specified | MHPRESP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826680","Medical History Ongoing","C83068","An indication or description that an event or occurrence in an individual's medical history is continuing.","Medical History Ongoing | MHONGO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826678","Medical History Controlled","C83066","An indication or description that an event or occurrence in an individual's medical history is being managed.","Medical History Controlled | MHCTRL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1113704","Protein Induced by Vitamin K Absence-II Measurement","C150846","The determination of the amount of protein induced by vitamin K absence-II present in a sample.","Protein Induced by Vitamin K Absence-II Measurement | DCP | DCP Measurement | Des-Gamma Carboxyprothrombin Measurement | Des-Gammacarboxyprothrombin | Des-Gammacarboxyprothrombin Measurement | PIVKA-II | PIVKA-II Measurement | PIVKAII | Protein Induced by Vitamin K Absence-II | Protein Induced by Vitamin K Absence/Antagonist-II | Protein Induced by Vitamin K Absence/Antagonist-II Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811718","Chemokine (C-C Motif) Ligand 18 Measurement","C112237","The determination of the amount of chemokine (C-C Motif) ligand 18 present in a sample.","Chemokine (C-C Motif) Ligand 18 Measurement | AMAC-1 | AMAC1 | CCL18 | CKB7 | Chemokine (C-C Motif) Ligand 18 | DC-CK1 | DCCK1 | MIP4 | Macrophage inflammatory protein-4 | PARC | Pulmonary and Activation-Regulated Chemokine | SCYA18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827714","CDISC SDTM Method Terminology","C85492","Terminology associated with the method codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Method Terminology | METHOD | Method | SDTM-METHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523832","Accelerator Mass Spectrometry","C135452","A type of mass spectrometry in which ions in the sample are accelerated to very high kinetic energies, thus allowing for the separation of rare isotopes from more abundant isotopes.","Accelerator Mass Spectrometry | ACCELERATOR MASS SPECTROMETRY | AMS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698627","CDISC SDTM Reference Range Indicator","C78736","Terminology associated with the reference range indicator codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Reference Range Indicator | NRIND | Reference Range Indicator | SDTM-NRIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700149","Value Above Reference Range","C78800","Reported values above the typical or expected range.","Value Above Reference Range | Elevated | HIGH | High",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699333","Abnormal Reference Range","C78802","Reported values outside the typical or expected range.","Abnormal Reference Range | ABNORMAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700150","Value Below Reference Range","C78801","Reported values below the typical or expected range.","Value Below Reference Range | LOW | Low",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0430862","Applanation Tonometry","C120682","A method in which a constant pressure is applied to the surface of the cornea in order to flatten a prespecified area of the membrane, which is used to calculate intraocular pressure.","Applanation Tonometry | APPLANATION TONOMETRY",,,,,,,,,,,,,,,"4099256","Applanation tonometry",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827753","Antimicrobial Combination Testing Method","C85558","A method to determine the microbial susceptibility to two or more antibiotics. Numerical result translated into indifference, antagonism, synergism, or additive.","Antimicrobial Combination Testing Method | ANTIMICROBIAL COMBINATION TESTING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827752","Antibiotic Agar Screening Method","C85557","A method used to detect organisms that have resistance to a single concentration of antibiotics in an agar matrix.","Antibiotic Agar Screening Method | ANTIBIOTIC AGAR SCREEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596085","Analytical Ultracentrifugation","C120681","An ultracentrifugation based method that uses an optical detection system to monitor and record data during the centrifugation process.","Analytical Ultracentrifugation | ANALYTICAL ULTRACENTRIFUGATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1293946","Alcian Blue Staining Method","C92299","A microscopy staining method that utilizes alcian blue, a cationic, water soluble copper-containing phthalocyanine dye to determine the presence of acid mucopolysaccharides and glycosaminoglycans.","Alcian Blue Staining Method | ALCIAN BLUE STAIN",,,,,,,,,,,,,,,"4036046","Alcian blue stain method",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1293965","Alcian Blue and Periodic Acid Schiff Staining Method","C92304","A microscopy staining method that utilizes periodic acid, an oxoacid of iodine, Schiff reagent, the reaction product of fuchsine and sodium bisulfite, and Alcian blue, a water soluble copper phthalocyanine dye. This staining method is used to differentially stain glycoproteins.","Alcian Blue and Periodic Acid Schiff Staining Method | ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN",,,,,,,,,,,,,,,"4037976","Alcian blue with Periodic acid Schiff stain method",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513769","AHG-enhanced Complement-dependent Lymphocytotoxicity Assay","C130170","A form of complement-dependent lymphocytotoxicity assay with the addition of anti-human globulin (AHG), which is a complement fixing antibody to human immunoglobulin. The AHG binds to both complement proteins and alloantibodies bound to donor lymphocytes, thereby increasing the antibody density and the likelihood of activating complement, resulting in increased sensitivity of the assy.","AHG-enhanced Complement-dependent Lymphocytotoxicity Assay | AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441669","Agar Dilution Method","C85555","A method to determine microbial susceptibility to antibiotics in which test bacteria is inoculated onto agar plates with serial dilutions of know quantities of antibiotics. The minimum inhibitory concentration of antibiotic is assessed.","Agar Dilution Method | AGAR DILUTION",,,,,,,,,,,,,,,"4121025","Agar dilution",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522643","Acid Fast Bacillae Staining Method","C23015","The use of acid-fast stain to examine a specimen for the presence of acid-fast microorganisms, specifically mycobacteria.","Acid Fast Bacillae Staining Method | ACID FAST STAIN | AFB Staining | Acid Fast Bacillae Staining | Acid Fast Staining",,,,,,,,,,,,,,,"4282470|45769410","Acid fast stain method|Acid fast stain",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2698631","CDISC SDTM Specimen Condition Terminology","C78733","Terminology associated with the specimen condition codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Specimen Condition Terminology | SDTM-SPECCOND | SPECCOND | Specimen Condition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512349","Concentrated Specimen","C128999","A specimen that has been concentrated, that is whose volume has decreased and density has increased.","Concentrated Specimen | CONCENTRATED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522868","Specimen with Unexpected Odor","C135505","A specimen that has an odor that is either not anticipated or normal.","Specimen with Unexpected Odor | UNEXPECTED ODOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523874","Gelatinous Specimen","C135503","A specimen that has a gelatinous consistency.","Gelatinous Specimen | GELLED | Gelled Specimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522867","Solidified Specimen","C135504","A specimen that has no tendency to flow under moderate stress, and/or that resists forces (such as compression) that tend to deform it, and/or that retains a definite size and shape.","Solidified Specimen | SOLIDIFIED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698950","Calcified Specimen","C78723","A specimen that has undergone calcification.","Calcified Specimen | CALCIFIED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0460077","Lipemic Specimen","C70715","A specimen that consists of or contains excessive amounts of fat and fatty substances.","Lipemic Specimen | LIPEMIC",,,,,,,,,,,,,,,"4039370","Sample lipemic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0475880","Hemolysis in Specimen","C70720","A specimen that has undergone the destruction of red blood cells followed by the release of the hemoglobin.","Hemolysis in Specimen | HEMOLYZED | Hemolyzed Specimen",,,,,,,,,,,,,,,"4039371","Sample hemolyzed",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552734","Ballpoint Pen Technique","C150875","A technique used to measure the skin induration diameter of intradermal tuberculin tests based on resistance to the movement of a ballpoint pen across the skin.","Ballpoint Pen Technique | BALLPOINT PEN TECHNIQUE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897123","Bacterial Artificial Chromosome Array-based Comparative Genomic Hybridization","C116157","A molecular cytogenetic method combining chromosomal comparative genomic hybridization technique and microarray to detect chromosomal aberrations and changes in DNA copy numbers, using bacterial artificial chromosome clones containing target DNA fragments for hybridization. This method is especially sensitive in detecting single copy changes in the genome.","Bacterial Artificial Chromosome Array-based Comparative Genomic Hybridization | BAC ACGH | BAC Array-based CGH | Bacterial Artificial Chromosome Array-based CGH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1318909","Auramine Staining Method","C102599","A microscopy acid fast staining method that utilizes auramine O, a bright yellow ketonimine dye, which binds to the mycolic acid in the cell walls of acid fast microorganisms.","Auramine Staining Method | AURAMINE STAIN | Auramine O",,,,,,,,,,,,,,,"4232149","Auramine stain method",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037806","Atomic Absorption Spectroscopy","C85574","A spectrometric method that determines the type and concentration of metal elements in a sample, based upon the principle that each elemental metal absorbs a particular wavelength of ultraviolet light when exposed to heat.","Atomic Absorption Spectroscopy | ATOMIC ABSORPTION SPECTROMETRY",,,,,,,,,,,,,,,"4311939","Atomic absorption measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL446664","Arterial Spin Labeling Magnetic Resonance Imaging","C116450","An application of functional MRI used to measure cerebral blood flow. ASL uses magnetically labeled water as the tracer.","Arterial Spin Labeling Magnetic Resonance Imaging | ARTERIAL SPIN LABELING FUNCTIONAL MRI | ASL | ASL fMRI | Arterial Spin Labeling MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513818","Complement-dependent Lymphocytotoxicity Assay","C130171","A method that detects the presence and reaction of alloantibodies to donor lymphocytes in pre-transplant patients via the addition of complement proteins and lysis of the lymphocytes.","Complement-dependent Lymphocytotoxicity Assay | COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009407","Colorimetry","C111096","An assessment used to quantify and describe the colors within the visible spectrum of light.","Colorimetry | COLORIMETRY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827252","Clot Detection","C111095","Any of several methods used to detect the presence of or quantify the formation of a thrombus in a specimen.","Clot Detection | CLOT DETECTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899488","Cross-linking Immunoprecipitation High-throughput Sequencing","C116152","A molecular biology method combining crosslinking-immunoprecipitation and high-throughput sequencing techniques to detect and map RNA-protein interactions. In CLIP, whole tissues, organisms or individual cell types are treated with UV irradiation, which introduces covalent bonds between RNA-protein complexes. This is followed by immunoprecipitation and removal of the protein component of the crosslinked complex. The purified RNAs are then fragmented, reduced in size and subjected to high-throughput sequencing for the identification of RNA binding sites.","Cross-linking Immunoprecipitation High-throughput Sequencing | CLIP SEQUENCING | CLIP Sequencing | CLIP-Seq | HITS-CLIP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812382","Cross-Linking and Immunoprecipitation","C111163","A type of immunoprecipitation protocol that employs UV-light induced covalent cross-linking of molecules (for instance protein and RNA) prior to the immunoprecipitation and purification steps.","Cross-Linking and Immunoprecipitation | CLIP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540354","Clauss Method","C142334","An in vitro method to determine the rate of fibrin clot formation, in which diluted plasma (with thrombin-dependency removed) is mixed with high concentrations of thrombin. This reaction is run in tandem with a control sample and compared.","Clauss Method | CLAUSS METHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008795","Cineangiography","C127679","A type of angiography in which motion picture camera technology is used to record the passage of dye (usually fluorescent) through blood vessels and the heart.","Cineangiography | CINEANGIOGRAPHY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827770","Cellulose Tape Method","C85578","A microbiological technique for specimen collection and mounting for microscopic examination that utilizes a cellulose-based adhesive ribbon.","Cellulose Tape Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552735","Cell Based Bioassay","C150876","An in vitro assay that utilizes live cells to test the biological activity or potency of a drug substance or product.","Cell Based Bioassay | CELL BASED BIOASSAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552617","Cardiac Output Thermodilution Method","C150870","A technique for calculating cardiac output using a Swan-Ganz catheter that is inserted into the pulmonary artery through a peripheral vein to measure the change in right ventricular outflow blood temperature after a cold saline solution is injected into the right atrium from a proximal catheter port.","Cardiac Output Thermodilution Method | CARDIAC THERMODILUTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827769","Beta Lactamase Screening Method","C85576","A test that detects beta lactamase produced by Staphylococcus species, Haemophilus species, Moraxella catarrhalis, and Neisseria gonorrhoeae.","Beta Lactamase Screening Method | BETA LACTAMASE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347274","CDISC SDTM Unit of Measure Terminology","C71620","Terminology codelist used with Units of Measure within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.","CDISC SDTM Unit of Measure Terminology | SDTM-UNIT | UNIT | Unit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545372","Enzyme-Linked Lectin Assay","C147466","An enzyme immunoassay that utilizes enzyme-lectin conjugates to detect specific carbohydrate end groups on immobilized glycoproteins on microtiter plates.","Enzyme-Linked Lectin Assay | ELLA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0430689","Electrogastrography","C150871","A non-invasive technique that utilizes abdominal skin electrodes and computerized spectral analysis to assess gastric myoelectrical activity.","Electrogastrography | ELECTROGASTROGRAPHY",,,,,,,,,,,,,,,"4091889","Electromyography of stomach",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3830325","Electrochemiluminescence Immunoassay","C111194","A method in which electromagnetic radiation, in the form of light emission, is generated from an electrochemical reaction in a solution due to the formation of antigen-antibody complexes.","Electrochemiluminescence Immunoassay | ELECTROCHEMILUMINESCENCE IMMUNOASSAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830326","Electrochemiluminescence","C111193","A method in which electromagnetic radiation, in the form of light emission, is generated from an electrochemical reaction in a solution.","Electrochemiluminescence | ELECTROCHEMILUMINESCENCE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471721","Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging","C116453","A type of magnetic resonance imaging that uses the transient signal reduction induced by the first pass of gadolinium chelate through the brain vessels to calculate cerebral blood flow maps, and to determine the ratio between the cerebral blood volume in the lesion and the cerebral blood volume in normal tissue.","Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging | DSC | DSC-MRI | DYNAMIC SUSCEPTIBILITY-CONTRAST MRI | Dynamic Susceptibility Contrast-Enhanced MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055113","Duke Incision Method","C122163","A method for assessing bleeding time in which a controlled stab incision is made with a lancet on the earlobe or finger and blood is drawn off of the incision site with blotting paper every 30 seconds until bleeding stops.","Duke Incision Method | DUKE INCISION METHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0948161","Ductography","C123465","A type of mammography that uses contrast medium to visualize the ducts of the breast.","Ductography | DUCTOGRAPHY | Galactography",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827787","Disk Diffusion Method","C85595","A method to determine microbial susceptibility to antibiotics in which filter paper disks containing known concentrations of antibiotics are placed on the agar surface that has been previously inoculated with the bacteria of interest. Microbial susceptibility is assessed by measuring the area around the disk that is free of microbial growth.","Disk Diffusion Method | DISK DIFFUSION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899368","Direct Sequencing","C116154","A technique used to identify the sequence of individual nucleobases in a single strand of DNA fragment template, which can be a plasmid insert, genomic DNA or a PCR product. In addition, direct sequencing of genomic DNA or PCR products does not require sub-cloning of the gene of interest into a vector.","Direct Sequencing | DIRECT SEQUENCING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899376","Digital Array","C116158","A technique used to deliver high-throughput digital PCR. The digital array partitions a sample premixed with PCR reagents into hundreds of individual PCR reactions, which allows the absolute quantification of target sequences and rare allele detection, as compared to conventional real-time quantitative PCR.","Digital Array | DIGITAL PCR ARRAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827982","Dark Field Microscopy","C85837","A light microscopic technique in which the light that does not come into contact with the structures or details of interest is subtracted from the ocular image. This yields an image in which the structures or details are alight while the areas where the structures or details are absent are dark.","Dark Field Microscopy | DARK FIELD MICROSCOPY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1275400","Computed Tomography without Contrast","C137806","Computed tomography that does not use a contrast agent to visualize anatomic structures.","Computed Tomography without Contrast | CT SCAN WITHOUT CONTRAST | CT Scan without Contrast | CT without Contrast",,,,,,,,,,,,,,,"4163903","CT without contrast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0259896","Cryoscopy","C122162","A method for measuring the molar concentration of a substance in solution by determining the freezing point of the solution.","Cryoscopy | CRYOSCOPY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085532","Coronary Angiography","C100085","The passage of a catheter into the aortic root or other great vessel for the purpose of angiography of the native coronary arteries or bypass grafts supplying native coronary arteries. (ACC)","Coronary Angiography | CORONARY ANGIOGRAPHY | Coronary angiography",,,,,,,,,,,,,,,"4142645","Angiography of coronary artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545371","Transthoracic Echocardiography With Contrast","C147465","A non-invasive cardiac ultrasound performed by placing the transducer on the chest, with intravenous application of a contrast agent.","Transthoracic Echocardiography With Contrast | CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2585900","Transesophageal Echocardiography With Contrast","C147464","A cardiac ultrasound performed by passing a specialized probe containing a transducer into the patient's esophagus, with intravenous application of a contrast agent.","Transesophageal Echocardiography With Contrast | CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY",,,,,,,,,,,,,,,"4234778","Transesophageal echocardiography with contrast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540353","Contrast Enhanced PET-CT Scan","C142335","A form of PET/CT imaging in which radiopharmaceuticals is either ingested or injected intravenously in an attempt to enhance the collected images for diagnostic purposes.","Contrast Enhanced PET-CT Scan | CONTRAST ENHANCED PET/CT SCAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055186","Contact Specular Microscopy","C120683","A type of specular microscopy in which the specular microscope makes contact with the cornea of the eye.","Contact Specular Microscopy | CONTACT SPECULAR MICROSCOPY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698615","CDISC CDASH Unit of Drug Dispensed or Returned Terminology","C78421","A terminology subset of the CDISC Study Data Tabulation Model (SDTM) Unit codelist created for Clinical Data Acquisition Standards Harmonization (CDASH) Unit of Drug Dispensed or Returned Terminology.","CDISC CDASH Unit of Drug Dispensed or Returned Terminology | CDASH-DAORRESU | DAORRESU | Unit of Drug Dispensed or Returned",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706087","Box Dosing Unit","C48478","A dosing unit equal to the amount of active ingredient(s) contained in a box.","Box Dosing Unit | BOX | BX | Box | {BOX} | {Box}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705370","Disk Dosing Unit","C48490","A dosing unit equal to the amount of active ingredient(s) contained in a disk.","Disk Dosing Unit | DISK | Disc | Disk | {DISK} | {Disk}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704710","Package Dosing Unit","C48520","A dosing unit equal to the amount of active ingredient(s) contained in a package.","Package Dosing Unit | PACKAGE | Pack | Pack Dosing Unit | Package | {PACKAGE} | {Package}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704474","Tube Dosing Unit","C48549","A dosing unit equal to the amount of active ingredient(s) contained in a tube.","Tube Dosing Unit | TB | TUBE | Tube | {TUBE} | {Tube}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706398","Vial Dosing Unit","C48551","A dosing unit equal to the amount of active ingredient(s) contained in a single vial.","Vial Dosing Unit | VI | VIAL | Vial | vial | {VIAL} | {Vial} | {vial}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705563","Container Dosing Unit","C48484","A dosing unit equal to the amount of active ingredient(s) in a container.","Container Dosing Unit | CH | CONTAINER | Container | {CONTAINER} | {Container}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826641","Laboratory Test Date","C83028","The date on which the laboratory test occurred.","Laboratory Test Date | Date Of Record of Lab Result | Date_of_Test | LBDAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010097","Corpus Striatum","C12448","The striped grey and white matter that comprises the caudate and the lentiform nuclei, and is located anterior and lateral to the thalamus in each hemisphere of the brain.","Corpus Striatum | CORPUS STRIATUM | Striate Body | Striate Nucleus | Striatum","C71.0","Corpus striatum",,,,,,,,,,,,,"4151442","Corpus striatum structure",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0446908","Mastoid Process","C12503","A honeycombed section of bone located near the base of the skull, protruding behind the outer ear. It is connected to the middle ear.","Mastoid Process | MASTOID PROCESS | Mastoid | Mastoid structure (body structure) | Process Mastoideus",,,,,,,,,,,,,,,"4240970","Mastoid structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0226927","Mucosa of the Lip","C12226","The lining of the fleshy folds surrounding the mouth. It is comprised of the epithelium, basement membrane, lamina propria mucosae, and lamina muscularis mucosae.","Mucosa of the Lip | Labial Mucosa | MUCOSA OF THE LIP | Mucosa of Lip | Mucosa of lip, NOS | Non-Hair Bearing Lip | labial mucosa",,,,,,,,,,,,,,,"4245168","Structure of mucous membrane of lip",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0560737","Hamate Bone","C12860","The medial bone in the distal row of carpal bones.","Hamate Bone | HAMATE BONE | Hamate | Unciform Bone | Uncinate Bone",,,,,,,,,,,,,,,"4103845","Bone structure of hamate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2826899","Laboratory Test Fasting Status","C83309","An indication or description of whether a laboratory specimen was obtained from a subject that has abstained from food and possibly water for the prescribed amount of time.","Laboratory Test Fasting Status | LBFAST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826750","Laboratory Test Subcategory","C83142","A sub-division of the laboratory test classification.","Laboratory Test Subcategory | LBSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0458450","Prostatic Urethra","C13101","That part of the male urethra that passes through the prostate gland.","Prostatic Urethra | Prostatic Portion of the Male Urethra | Prostatic urethra structure (body structure) | URETHRA, PROSTATIC",,,,,,,,,,,,,,,"4323817","Prostatic urethra structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036624","Lunate Bone","C12786","The bone in the proximal row of carpal bones that lies between the scaphoid and triquetral bones.","Lunate Bone | LUNATE BONE | Lunate | Semilunar Bone",,,,,,,,,,,,,,,"4178722","Structure of lunate bone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0223741","Trapezoid Bone","C12859","A carpal bone located between the trapezium and capitate bones.","Trapezoid Bone | Lesser Multiangular Bone | TRAPEZOID BONE | Trapezoid",,,,,,,,,,,,,,,"4309961","Trapezoid bone structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0201551","Cancer Antigen 19-9 Measurement","C81982","The determination of the amount of cancer antigen 19-9 present in a sample.","Cancer Antigen 19-9 Measurement | CA 19-9 assay | CA-19-9 Measurement | CA19-9 Level | CA19-9 Measurement | CA19_9AG | Cancer Antigen 19-9 | Carbohydrate Antigen 19-9 | Carbohydrate Antigen 19-9 Measurement",,,,,,,,,,,,,,,"4164784","Cancer antigen 19-9 measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0883409","Cardiac troponin I measurement","C135448","The determination of the amount of troponin I type 3 (cardiac muscle) in a biological sample.","Troponin I Type 3 Measurement | Cardiac Troponin I | Cardiac Troponin I Measurement | TNNC1 | TNNI3 Measurement | TROPONI3 | Troponin I Type 3 | cTnI | cTnI Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523847","Growth Differentiation Factor 11 Measurement","C135422","The determination of the amount of growth differentiation factor 11 in a biological sample.","Growth Differentiation Factor 11 Measurement | BMP-11 | BMP11 Measurement | Bone Morphogenetic Protein 11 | Bone Morphogenetic Protein 11 Measurement | GDF11 | GDF11 Measurement | Growth Differentiation Factor 11 | Growth/Differentiation Factor 11 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2732693","Cancer Antigen 72-4 Measurement","C106505","The determination of the amount of the cancer antigen 72-4 present in a sample.","Cancer Antigen 72-4 Measurement | CA 72-4 | CA72_4AG | Cancer Antigen 72-4 | Carbohydrate Antigen 72-4 | TAG-72 | Tumor Associated Antigen 72 Measurement | Tumor-Associated Antigen TAG-72 Measurement | Tumor-Associated Glycoprotein 72 Measurement",,,,,,,,,,,,,,,"40483235","Measurement of cancer antigen 72-4",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825557","Hemoglobin S to Total Hemoglobin Ratio Measurement","C81279","The determination of the ratio of Hemoglobin S compared to total Hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.","Hemoglobin S to Total Hemoglobin Ratio Measurement | HGBSHGB | Hemoglobin S Measurement | Hemoglobin S/Total Hemoglobin | Percent Hemoglobin S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0253309","Sialyl SSEA-1 Antigen Measurement","C114223","The determination of the amount of sialyl SSEA-1 antigen present in a sample.","Sialyl SSEA-1 Antigen Measurement | SLXAG | SLeX | Sialyl Lewis X Antigen | Sialyl Lex | Sialyl SSEA-1 Antigen | Sialyl-CD15 | Sialyl-CD15 Antigen | Sialyl-Lewis X Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1295143","Fetal Fibronectin Test","C92786","A test for the presence of fetal fibronectin in the cervico-vaginal area that is used to predict preterm birth.","Fetal Fibronectin Test | FBNCTFT | FFN | Fetal Fibronectin Measurement | Fibronectin, Fetal",,,,,,,,,,,,,,,"4007658","Fetal fibronectin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL568449","Forebrain","C40185","The largest part of the brain composed of the cerebral hemispheres, thalamus, hypothalamus, and the limbic system.","Forebrain | BRAIN, FOREBRAIN | FOREBRAIN | Fore-Brain | Prosencephalon",,,,,,,,,,,,,,,"4218236","Prosencephalon structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1281902","Total Thyroxine Measurement","C74794","The determination of the amount of free and bound thyroxine present in a sample.","Total Thyroxine Measurement | T4 | Thyroxine | Total T4 | Total Thyroid",,,,,,,,,,,,,,,"4196731","Total thyroxine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL523820","Growth Differentiation Factor 8 Measurement","C135423","The determination of the amount of growth differentiation factor 8 in a biological sample.","Growth Differentiation Factor 8 Measurement | GDF8 | GDF8 Measurement | Growth Differentiation Factor 8 | Growth/Differentiation Factor 8 Measurement | MSTN Measurement | Myostatin | Myostatin Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825554","Hemoglobin A to Total Hemoglobin Ratio Measurement","C81276","The determination of the ratio of Hemoglobin A compared to total Hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.","Hemoglobin A to Total Hemoglobin Ratio Measurement | HGBAHGB | Hemoglobin A/Total Hemoglobin | Percent Hemoglobin A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826630","Laboratory Test Category","C83017","A classification of the laboratory test.","Laboratory Test Category | LAB_CAT | LAB_CATEGORY | LBCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202406","Lysergide Measurement","C75354","The determination of the amount of lysergide (LSD) present in a sample.","Lysergide Measurement | Acid | LSD | LSD Measurement | Lysergate Diethylamide | Lysergic Acid Diethylamide | Lysergic Acid Diethylamide Measurement",,,,,,,,,,,,,,,"4173714","Lysergic acid diethylamide measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL522825","Troponin I Type 1 Measurement","C135447","The determination of the amount of troponin I type 1 (slow twitch skeletal muscle) in a biological sample.","Troponin I Type 1 Measurement | Slow-Twitch Skeletal Muscle Troponin I | Slow-Twitch Skeletal Muscle Troponin I Measurement | TNNI1 Measurement | TROPONI1 | Troponin I Type 1 | ssTnI | ssTnI Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541224","CD11B Expressing Cell Count","C105440","The determination of the amount of the CD11b expressing cells in a sample.","CD11B Expressing Cell Count | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825555","Hemoglobin A2 to Total Hemoglobin Ratio Measurement","C81277","The determination of the ratio of Hemoglobin A2 compared to total Hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.","Hemoglobin A2 to Total Hemoglobin Ratio Measurement | HGBA2HGB | Hemoglobin A2/Total Hemoglobin | Percent Hemoglobin A2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1168443","Butyrylcholinesterase Measurement","C111142","The determination of the amount of total butyrylcholinesterase present in a sample.","Butyrylcholinesterase Measurement | Acylcholine Acylhydrolase | BCHE Measurement | BUCHE | Butyrylcholinesterase | Non-neuronal Cholinesterase | Plasma Cholinesterase | Pseudocholinesterase",,,,,,,,,,,,,,,"4179778","Butyrylcholinesterase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2826633","Laboratory Test Result Clinically Significant","C83020","An indication or description that the outcome of the laboratory assessment was clinically significant.","Laboratory Test Result Clinically Significant | LBCLSIG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811652","A Proliferation-Inducing Ligand Measurement","C111123","The determination of the amount of a proliferation-inducing ligand present in a sample.","A Proliferation-Inducing Ligand Measurement | A Proliferation-Inducing Ligand | APRIL | APRIL Measurement | CD256 | Soluble CD256 | TNFSF13 | TNFSF13 Measurement | Tumor Necrosis Factor Ligand Superfamily Member 13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826676","Laboratory Test Protocol Test Conditions Occurrence","C83064","An indication or description that the laboratory testing conditions laid out in the study protocol have been met.","Laboratory Test Protocol Test Conditions Occurrence | LBCOND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826637","Laboratory Test Specimen Condition","C83024","A characteristic that refers to the physical and organoleptic state of a laboratory specimen.","Laboratory Test Specimen Condition | LBSPCCND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826705","Laboratory Test Reference Range Indicator","C83094","A indication that a laboratory test result lies within normal parameters.","Laboratory Test Reference Range Indicator | LBNRIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266617","3,4-Methylenedioxymethamphetamine Measurement","C75359","The determination of the amount of 3,4-methylenedioxymethamphetamine (MDMA) present in a sample.","3,4-Methylenedioxymethamphetamine Measurement | 3,4-methylenedioxymethamphetamine | Ecstasy | MDMA | MDMA Measurement | Methylenedioxymethamphetamine Measurement",,,,,,,,,,,,,,,"4005832","Methylenedioxymethamphetamine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827504","Beta Amyloid 42 Measurement","C84809","The determination of the amount of the 1-42 amino acid beta amyloid protein isoform present in a sample.","Beta Amyloid 42 Measurement | AMYLB42 | Amyloid Beta 1-42 | Amyloid Beta 1-42 Measurement | Amyloid Beta 42 | Amyloid Beta 42 Protein | Beta Amyloid 1-42 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699318","Smudge Cell Count","C74627","The determination of the number of smudge cells present in a sample.","Smudge Cell Count | Basket Cells | Gumprecht Shadow Cells | SMDGCE | Shadow Cells | Smudge Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1168438","Factor XIV Measurement","C102272","The determination of the amount of factor XIV present in a sample.","Factor XIV Measurement | Autoprothrombin IIA | FACTXIV | Factor XIV | Protein C | Protein C Antigen | Protein C Measurement | Protein C, Inactivator of Coagulation Factors Va and VIIIa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890156","Lysosomal Acid Lipase Measurement","C117842","The determination of the amount of lysosomal acid lipase present in a sample.","Lysosomal Acid Lipase Measurement | Acid Cholesteryl Ester Hydrolase | LAL | LIPA | LIPA Measurement | LIPASLAL | Lipase, Lysosomal Acid | Lysosomal Lipase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023509","Mixed Lymphocyte Reaction Test","C16790","An assay that measures the proliferative response of lymphocytes from one individual when they are exposed to inactivated lymphocytes from another individual. The reaction can be performed on lymphocytes from the same individual (auto-MLR), from different individuals of the same species (allo-MLR), or individuals from different species (xeno-MLR). It is used to evaluate the potential for graft-versus-host or host-versus-graft reactions during transplantation procedures involving mismatched tissue types or individuals.","Mixed Lymphocyte Reaction Test | MLR | Mixed Leukocyte Reaction | Mixed Lymphocyte Culture | Mixed Lymphocyte Reaction | Mixed T Cells, B Cells",,,,,,,,,,,,,,,"4098032|4323698","Mixed lymphocyte reaction|Mixed lymphocyte culture assay",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3814815","Lipocalin-2 Measurement","C106539","The determination of the amount of lipocalin-2 present in a sample.","Lipocalin-2 Measurement | LCN2 | Lipocalin-2 | NGAL | NGAL Measurement | Neutrophil Gelatinase-Associated Lipocalin | Neutrophil Gelatinase-Associated Lipocalin Measurement | Oncogene 24p3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523688","Beta-1B Glycoprotein Measurement","C127607","The determination of the amount of beta-1B glycoprotein present in a sample.","Beta-1B Glycoprotein Measurement | B1BGLP | Beta-1B Glycoprotein | Beta-1B-Glycoprotein Measurement | HPX | Hemopexin | Hemopexin Measurement",,,,,,,,,,,,,,,"4020985","Hemopexin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521326","Lymphotoxin Alpha Measurement","C132375","The determination of the amount of lymphotoxin alpha in a biological sample.","Lymphotoxin Alpha Measurement | LTA | LTA Measurement | Lymphotoxin Alpha | TNF-beta | TNFSF1 Measurement | Tumor Necrosis Factor Beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889640","Progesterone Receptor Measurement","C117846","The determination of the amount of progesterone receptor present in a sample.","Progesterone Receptor Measurement | NR3C3 | PGR | PR | PROGESTR | PgR | Progesterone Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1262886","Osteoprotegerin Measurement","C116206","The determination of the amount of osteoprotegerin present in a sample.","Osteoprotegerin Measurement | OCIF | OPG | Osteoclastogenesis Inhibitory Factor | Osteoprotegerin | TNFRS11B | Tumor Necrosis Factor Receptor Superfamily Member 11b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL480911","Phenylalanine Measurement","C81280","The measurement of the amount of phenylalanine in a biologic specimen.","Phenylalanine Measurement | PHE | Phenylalanine",,,,,,,,,,,,,,,"4296616","Phenylalanine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2826726","Laboratory Test Reference Identifier","C83116","A sequence of characters used to identify, name, or characterize the laboratory test reference.","Laboratory Test Reference Identifier | LBREFID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826760","Laboratory Test Time","C83152","The time that the laboratory test was carried out.","Laboratory Test Time | LBTIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555174","Women who Have Lumpectomy and Radiation Therapy","C154232","The group of women who treat their breast cancer with lumpectomy and radiation therapy.","Women who Have Lumpectomy and Radiation Therapy | Women who have a lumpectomy and radiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555175","Women who Have Mastectomy","C154233","The group women who treat their breast cancer with mastectomy.","Women who Have Mastectomy | Women who have a mastectomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555172","Most Will Die of Something Else","C154234","A response indicating the belief that most breast cancer patients will die of something else.","Most Will Die of Something Else | Most will die of something else",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555173","About Half Will Die of Breast Cancer","C154235","A response indicating the belief that about half of breast cancer patients will die of breast cancer.","About Half Will Die of Breast Cancer | About half will die of breast cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555178","Most Will Die of Breast Cancer","C154236","A response indicating the belief that most breast cancer patients will die of breast cancer.","Most Will Die of Breast Cancer | Most will die of breast cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555179","A Little or Not at All","C154237","A response indicating little to no agreement, interest, or importance.","A Little or Not at All | A little or not at all | Little or None | Little or Not at All",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024868","Gas Chromatography Mass Spectrometry","C111203","An analytical technique wherein gas chromatography is coupled to mass spectrometry in order to separate, identify, and quantify substances in a sample.","Gas Chromatography Mass Spectrometry | GC/MS | Gas Chromatography/Mass Spectrometry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523855","Gas Chromatography and Flame Ionization Detection","C135454","A method that combines a flame ionization detector with a gas chromatograph to identify and quantify organic species within a gas stream.","Gas Chromatography and Flame Ionization Detection | GC/FID | Gas Chromatography/Flame Ionization Detector",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0200189","Eye Fundus Photography","C147467","A method of capturing images of the vitreous, retina, choroid, and optic nerve using a specialized low power microscope with an attached camera.","Eye Fundus Photography | FUNDUS PHOTOGRAPHY",,,,,,,,,,,,,,,"4063911","Ocular fundus photography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0444700","Freezing Point Depression","C135453","The addition of a solute to a solvent that results in a decrease in the temperature at which the solute-solvent mixture freezes.","Freezing Point Depression | FREEZING POINT DEPRESSION",,,,,,,,,,,,,,,"4106632","Freezing point depression",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054934","Forced Oscillation Technique","C122165","A non-invasive method to evaluate respiratory mechanical properties of the lung and airways using small-amplitude pressure oscillations superimposed on the normal, tidal breathing of a subject.","Forced Oscillation Technique | FORCED OSCILLATION TECHNIQUE | FOT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016352","Fluorimetry","C62322","An analytical method that utilizes ultraviolet light to excite the sample and detects the fluorescence emitted during the return of the sample to its ground state.","Fluorimetry | FLUORIMETRY | Fluorometry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520394","Fluorescent Spot Test","C132427","A method to assess enzymatic activity in which a substrate reagent is incubated with a biological specimen and spotted on filter paper. The spots are then examined for fluorescence, which correlates with enzyme activity.","Fluorescent Spot Test | FLUORESCENT SPOT TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026022","Fluorescence Microscopy","C16856","A technique in which samples that either contain fluorescent compounds or are stained with fluorescent dyes are exposed to a wavelength of light that excites the fluorophore, allowing for an image to be captured by a microscope.","Fluorescence Microscopy | FLUORESCENT MICROSCOPY | Fluorescence Light Microscopy | Microscopy, Light, Fluorescence | fluorescence microscopy",,,,,,,,,,,,,,,"4121029","Fluorescence microscopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545902","Fluorescent Enzyme Immunoassay","C142336","An assay technique that uses enzymes, which when bound to the substrate transform into a fluorescent product, to detect the presence of a substance, usually an antigen.","Fluorescent Enzyme Immunoassay | ELFA | Enzyme-linked Fluorescence Assay | Enzyme-linked Fluorescent Immunoassay | FEIA | FLUORESCENT ENZYME IMMUNOASSAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016313","Fluorescence Angiography","C116569","An examination technique that uses fluorescent dye and a specialized camera to inspect blood flow in the retina and choroid.","Fluorescence Angiography | FLUORESCENCE ANGIOGRAPHY",,,,,,,,,,,,,,,"4068181","Angiography of eye using fluorescein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3827370","Flow Microscopy","C112284","A method of measuring the number of cells in a sample by placing the cells in a fluid and passing them, in a stream, through a special light microscope that can record and analyze images of the cells (presence of foreign particles, cell counts, protein aggregates, morphology information).","Flow Microscopy | FLOW MICROSCOPY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0260132","Flame Photometry","C106523","A type of atomic spectroscopy capable of qualitatively or quantitatively determining certain cations (particularly Na, K, Rb, Cs, Ca, Ba, Cu) by utilizing a low temperature flame capable of exciting a valence electron to an upper energy state which emits light at a wavelength unique to each cation as the electron returns to its ground state.","Flame Photometry | FLAME PHOTOMETRY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4068944","Farnsworth-Munsell 100 Hue Test","C130172","A diagrammatic method to test color blindness or deficiencies, which uses 100 colors from the Munsell color system arranged in rows of four color families, containing 25 hues for each color. The subject must put the hues in order based on the anchor colors at the ends of each row.","Farnsworth-Munsell 100 Hue Test | FARNSWORTH-MUNSELL 100 HUE TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899277","Early Treatment of Diabetic Retinopathy Study Eye Chart","C117877","A diagrammatic method to test visual acuity which incorporates the Bailey-Lovie layout in conjunction with Sloan optotypes, which was first used in the Early Treatment of Diabetic Retinopathy Study.","Early Treatment of Diabetic Retinopathy Study Eye Chart | ETDRS EYE CHART",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827788","Epsilometry","C85596","A method to determine microbial susceptibility to antibiotics in which a plastic strip impregnated with the antibiotic of interest is placed on an agar plate that has been inoculated with bacteria. The antibiotic diffuses from the strip producing a concentration gradient of drug on the agar. The point at which the elliptical shaped area of growth inhibition meets the strip is the minimum inhibitory concentration of the drug of interest.","Epsilometry | E-Test | EPSILOMETER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162676","Enzyme Multiplied Immunoassay Technique","C111196","A type of homogenous immunoassay in which sample is applied to a reagent mixture of enzyme-labeled ligand, antibody, and substrate. Substrate binding to enzyme leads to inactivation and unlabeled-ligand in the sample can be quantified by colorimetric analysis.","Enzyme Multiplied Immunoassay Technique | EMIT | ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE",,,,,,,,,,,,,,,"37159723|4010409","Enzyme-multiplied immunoassay technique|Enzyme-multiplied immunoassay technique",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C4055057","Enzymatic Ultracentrifugation","C122164","An ultracentrifugation based method that uses enzymatic catalytic reaction to quantify a substance, which has been separated in solution by an ultracentrifugation process.","Enzymatic Ultracentrifugation | ENZYMATIC ULTRACENTRIFUGATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830313","Enzymatic Colorimetry","C111195","A type of colorimetry that makes use of an enzymatic reaction to induce a color change.","Enzymatic Colorimetry | ENZYMATIC COLORIMETRY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055064","Endpoint Dilution Assay","C120684","An in vitro cell based assay in which plated host cells are inoculated with serial dilutions of an infective agent and observed for cytotoxic effects in order to calculate the titer.","Endpoint Dilution Assay | ENDPOINT DILUTION ASSAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221971","Hair Follicle","C13317","A tube-like invagination of the epidermis from which the hair shaft develops and into which the sebaceous glands open; the follicle is lined by a cellular inner and outer root sheath of epidermal origin and is invested with a fibrous sheath derived from the dermis.","Hair Follicle | Follicles | HAIR FOLLICLE | Hair Follicles | hair follicle",,,,,,,,,,,,,,,"4283235","Hair follicle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0596638","Gut-Associated Lymphoid Tissue","C12936","Non-encapsulated accumulations of lymphoid tissue in the alimentary tract that form a secretory immune system containing cells committed to IgA or IgE synthesis; It includes Peyer's patches and the lymphoid tissue which is present throughout the gastrointestinal mucosa.","Gut-Associated Lymphoid Tissue | GALT | GUT-ASSOCIATED LYMPHOID TISSUE | Gut Associated Lymphoid Tissue",,,,,,,,,,,,,,,"4056928","Structure of lymphoid tissue of gastrointestinal tract",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0223729","Pisiform Bone","C12855","The medial bone of the proximal row of carpal bones.","Pisiform Bone | PISIFORM BONE | Pisiform | Pisiform Bone of Hand",,,,,,,,,,,,,,,"4056181","Structure of pisiform bone of wrist region",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205031","Skin of the Trunk","C12295","The skin or integument surrounding the trunk of the body.","Skin of the Trunk | SKIN OF THE TRUNK | Skin of Trunk | Skin of trunk | Skin, trunk, local | Superficial trunk | skin of trunk",,,,,,,,,,,,,,,"4313445","Skin structure of trunk",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0596458","Dorsal Motor Nucleus","C12934","A brain nucleus located in the medulla oblongata.","Dorsal Motor Nucleus | DMN | DORSAL MOTOR NUCLEUS | Dorsal Motor Nucleus of the Vagus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0223733","Capitate Bone","C12856","The largest of eight carpal bones, located in the center of the hand.","Capitate Bone | CAPITATE BONE | Capitate",,,,,,,,,,,,,,,"4305357","Structure of capitate bone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0222101","Skin of the Lip","C12291","The skin portion of the lip that contains hair.","Skin of the Lip | Hair Bearing Lip | SKIN OF THE LIP | Skin of Lip | Skin of lip, NOS",,,,,,,,,,,,,,,"4338113","Skin structure of lip",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0595944","Nostril","C33178","One of the two channels of the nose, from the point where they divide to the external opening.","Nostril | External Nare | NOSTRIL | Naris",,,,,,,,,,,,,,,"4075758","Structure of anterior naris",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827870","Macro Broth Dilution Method","C85697","A method to determine the minimum inhibitory concentration (MIC) of antibiotics in which growth media is pipetted into a test tube. Each tube contains a known concentration of drug and is inoculated with a known quantity of bacteria. The tubes are incubated for a specified period of time and each is assessed for bacterial cell growth. The drug concentration in the first tube showing no growth is known as the MIC for that antibiotic.","Macro Broth Dilution Method | MACRO BROTH DILUTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1293988","Luxol Fast Blue and Cresyl Violet Staining Method","C92300","A microscopy staining method that utilizes luxol fast blue, an alcohol soluble copper phthalocyanine dye, and cresyl violet, an organic compound that is commonly used as a counter stain, to determine the presence of myelin as well as helicobacter and campylobacter bacterial species.","Luxol Fast Blue and Cresyl Violet Staining Method | LUXOL FAST BLUE AND CRESYL VIOLET STAIN",,,,,,,,,,,,,,,"4038138","Luxol fast blue with cresyl violet stain method",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3539922","Loop-mediated Isothermal Amplification","C102661","A type of nucleic acid amplification test in which sample DNA is exposed to a single temperature in the presence of multiple sets of primers and a polymerase with replication and high strand displacement activity. This test negates the need for thermal cyclers and may be a low cost alternative to PCR.","Loop-mediated Isothermal Amplification | LAMP | LOOP-MEDIATED ISOTHERMAL AMPLIFICATION",,,,,,,,,,,,,,,"37158456","Loop-mediated isothermal amplification technique",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4050253","Liquid Scintillation Counting","C122170","A method for measuring the amount of ionizing radiation in a liquid substance. Samples are mixed with a mixture of solvent, surfactant and scintillators that can convert beta particles into light energy, which can be measured.","Liquid Scintillation Counting | LIQUID SCINTILLATION COUNTING | LSC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539666","Line Probe Assay","C102656","A technique in which polymerase chain reaction is used to amplify specific nucleic acid sequences in a biospecimen. The product of this reaction is then applied to a nitrocellulose test strip containing complementary DNA probes.","Line Probe Assay | LINE PROBE ASSAY | LPA | LiPA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1328171","Light-Scattering Spectroscopy","C20059","The nuclei of precancerous lesions are distinct in that they become enlarged, crowded and hyperchromatic.  Light-scattering spectroscopy can diagnose early epithelial cancers based on the scattering of light through their enlarged nuclei. (from Medscape)","Light-Scattering Spectroscopy | LIGHT SCATTERING SPECTROSCOPY | LiSSP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984970","Lead Citrate Staining Method","C92301","A microscopy staining method that utilizes lead citrate, a mixture of lead nitrate and sodium citrate, and has applications for electron microscopy staining.","Lead Citrate Staining Method | LEAD CITRATE STAIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054644","Liquid Chromatography-Fluorescence","C122169","An analytical technique where liquid chromatography with a fluorescence detector is used to separate, identify, and quantify substances in a sample.","Liquid Chromatography-Fluorescence | LC-FL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049918","Liquid Chromatography/Tandem Mass Spectrometry","C122168","An analytical technique wherein liquid chromatography is coupled to tandem mass spectrometry in order to separate, identify, and quantify substances in a sample.","Liquid Chromatography/Tandem Mass Spectrometry | LC/MS/MS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0872318","Liquid Chromatography Mass Spectrometry","C18475","LC/MS is a hyphenated technique, combining the separation power of liquid chromatography (LC), an analytical chromatographic technique for separating ions or molecules dissolved in a solvent, with the detection power of mass spectrometry(MS), a technique to separate gas phase ions according their m/z (mass to charge ratio) value. Used for drug screening, pharmacology studies, environmental analyses and forensics.","Liquid Chromatography Mass Spectrometry | LC/MS | Liquid Chromatography-Mass Spectrometry | Liquid Chromatography/Mass Spectrometry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1113652","Laser Capture Microdissection","C19263","A high-resolution method used to isolate cells from their surrounding tissues, with the aid of a laser beam, under direct microscopic visualization. Specific cells can be isolated directly by cutting target cells away from unwanted cells, to obtain enriched cell populations.","Laser Capture Microdissection | LASER CAPTURE MICRODISSECTION | LCM | LMD | Laser Capture Micro-dissection | Laser Microdissection | Laser-assisted Microdissection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540350","Landolt Ring","C142340","A standard test of visual acuity, a symbol, in the shape of the letter C, is presented to the patient who must identify on which side of the symbol the gap is present. Both the size of the gap and the size of the symbol are reduced until the subject makes a predetermined rate of errors, thus ending the test.","Landolt Ring | LANDOLT RING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0200976","Kinyoun Staining Method","C85651","A microscopy acid fast staining method that utilizes kinyoun carbol fuchsin, a dye containing basic fuchsin in solution with ethyl alcohol and aqueous phenol. This acid fast staining technique does not require heating during the primary staining step involving the carbol fuchsin.","Kinyoun Staining Method | KINYOUN STAIN",,,,,,,,,,,,,,,"4284903|45769467","Acid fast Kinyoun's cold carbolfuchsin stain method|Acid fast Kinyoun's cold carbolfuchsin stain",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3829386","Kinetic Microparticle Immunoassay","C111240","A type of immunoassay in which the antigen of interest found in a biological specimen competes with a lattice of antigen-antibody complexes. Competing antigen inhibits lattice formation and decreases absorbance in proportion to the amount of antigen present in a biological specimen.","Kinetic Microparticle Immunoassay | KINETIC MICROPARTICLE IMMUNOASSAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540351","Kinetic Chromogenic Assay","C142339","A bioassay in which a biological specimen is incubated with a kinetic substrate, followed by optical analysis of color change.","Kinetic Chromogenic Assay | KINETIC CHROMOGENIC ASSAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054692","Jaffe Reaction","C120694","A colorimetric method used to measure creatinine, in which color change is directly related to the amount of creatinine in an alkaline solution containing picric acid.","Jaffe Reaction | JAFFE REACTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513960","Jaeger Eye Chart","C130175","A diagrammatic method to test visual acuity that uses paragraphs of text in differing font sizes to assess near vision.","Jaeger Eye Chart | JAEGER EYE CHART",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054697","Ishihara Color Plates","C123466","A diagrammatic method to test color blindness of deficiencies, which utilizes a circular form composed of multiple size circles in varying colors. A number or symbol is present in the middle of the circle and is composed of little circles which are a different color from the circles composing the outer circular form.","Ishihara Color Plates | ISHIHARA COLOR PLATES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1293985","Iron Hematoxylin Staining Method","C85650","A microscopy staining method that utilizes a mixture of iron and hematoxylin to visualize intracellular structures in a microscopic sample. In this dye system, iron acts as a mordant to hematoxylin rendering it insoluble, thereby allowing irreversible blue-black colored dyeing to the cell nucleus.","Iron Hematoxylin Staining Method | IRON HEMATOXYLIN STAIN",,,,,,,,,,,,,,,"4037391","Iron hematoxylin stain method",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827828","Iodine Staining Method","C85649","A microscopy staining method that utilizes Iodine, an element belonging to the halogen group, which specifically stains polysaccharides such as cellulose, chitin, glycogen, and starch a blue color.","Iodine Staining Method | IODINE STAIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087042","Interrupter Technique","C124352","A non-invasive method of measuring airway resistance during which the subject breathes normally while airflow is interrupted at a predetermined rate and volume during the early exhalation phase. Airway resistance is calculated as the ratio of alveolar pressure, which is estimated from mouth pressure during occlusion, to airflow before interruption. This method is used most often in children and other subjects unable to comply with instructions for conventional lung function tests.","Interrupter Technique | INTERRUPTER TECHNIQUE | RINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037807","Infrared Spectrometry","C85643","A spectrometric method that determines the type and concentration of elements or chemicals in a sample, based upon the principle that the atoms in a sample will vibrate or rotate at a specific frequency when exposed to infrared light.","Infrared Spectrometry | INFRARED SPECTROMETRY",,,,,,,,,,,,,,,"4058483","Infrared spectrometry",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0200972","India Ink Staining Method","C85642","A microscopy staining method that utilizes India Ink, a water soluble carbon-based black ink, to determine the presence of microorganisms that are surrounded by a gelatinous capsule. This is a negative staining method in which background is stained in black and the microbes and microscopic structures of interest remain white.","India Ink Staining Method | INDIA INK STAIN",,,,,,,,,,,,,,,"4057705","India ink stain method",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054735","Incision-induced Bleeding Method","C122039","Any of multiple methods used to assess bleeding time, in which a controlled incision is made in the dermis and clotting time is measured.","Incision-induced Bleeding Method | INCISION-INDUCED BLEEDING METHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050256","Impulse Oscillometry","C122166","A non-invasive method to measure pulmonary resistance and reactance, and the impedance of the respiratory system, using small pressure oscillation of a regular square wave of pressure 5 times per second.","Impulse Oscillometry | IMPULSE OSCILLOMETRY | IOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL772930","Immunoturbidimetry","C106536","A method that measures the absorbance of light from a sample which is used for quantifying an amount of analyte based on the level of turbidity produced by the formation and precipitation of an immune complex containing the analyte.","Immunoturbidimetry | IMMUNOTURBIDIMETRY | Immunoturbidimetric Assay | Turbidimetric Immunoassay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021073","Immunoradiometric Assay","C111236","A type of antibody-excess, non-competition radioimmunometric assay in which ligand is sandwiched between an immobilized antibody on a solid phase and a radiolabeled antibody raised against a different epitope of the ligand.","Immunoradiometric Assay | IMMUNORADIOMETRIC ASSAY | IRMA",,,,,,,,,,,,,,,"4278971","Radioreceptor assay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540352","Immunomagnetic Fluorescence Microscopy","C142338","An imaging technique in which fluorescently labeled cells are immunomagnetically selected and imaged by a semi-automated fluorescence microscope.","Immunomagnetic Fluorescence Microscopy | IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1318793","Immunofluorescent Staining Method","C142337","A microscopy staining method that utilizes immunofluorescent markers for use with histological applications of preserved cells.","Immunofluorescent Staining Method | IMMUNOFLUORESCENT STAIN | Immunofluorescence",,,,,,,,,,,,,,,"4229247","Immunofluorescent stain method",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1532552","Chemiluminescent Immunoassay","C111235","A type of immunoassay in which the antigen-antibody complex is quantified using light emission, which is generated from a chemical reaction.","Chemiluminescent Immunoassay | CLIA | Chemiluminescence Immunoassay | Chemiluminescent Assay | Chemiluminescent Immunoassay | Chemiluminesence Immunoassay | ICMA | IMMUNOCHEMILUMINOMETRIC ASSAY | Immunochemiluminometric Assay | Immunochemiluminometric Assay",,,,,,,,,,,,,,,"4188178","Immunochemiluminometric assay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020985","Immunoblot Analysis","C17638","A technique for analyzing or identifying proteins immobilized on a filter by complementary reaction with specific antibodies.","Immunoblot Analysis | IMMUNOBLOT | Immunoblot | Immunoblot Assay",,,,,,,,,,,,,,,"4107470|4291344|45766313","Immunoblotting|Immunoblot assay|Immunoblot assay",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C0020980","Immunoenzyme Procedure","C16714","An immunological procedure used for the microscopic examination of tissues.  It involves the usage of enzyme-antibody or enzyme-antigen conjugates, antienzyme antibodies, or enzyme-antienzyme complexes.","Immunoenzyme Procedure | IMMUNOASSAY",,,,,,,,,,,,,,,"4190497","Immunoassay method",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1553183","Inductively-Coupled Plasma Mass Spectrometry","C62328","A mass spectrometry technique that uses inductively-coupled plasma generated from argon gas to atomize and ionize a sample. The resulting ions are separated and analyzed using a mass spectrometer.","Inductively-Coupled Plasma Mass Spectrometry | ICP-MS | ICPMS | Inductively Coupled Plasma Mass Spectrometry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054774","High-performance Liquid Chromatography-UV","C120693","An analytical technique where high performance liquid chromatography with an ultraviolet light detector is used to separate, identify, and quantify substances in a sample.","High-performance Liquid Chromatography-UV | HPLC-UV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054775","High-performance Liquid Chromatography-Fluorescence","C120692","An analytical technique where high performance liquid chromatography with a fluorescence detector is used to separate, identify, and quantify substances in a sample.","High-performance Liquid Chromatography-Fluorescence | HPLC-FL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054772","High-performance Liquid Chromatography/Tandem Mass Spectrometry","C120691","An analytical technique wherein high performance liquid chromatography is coupled to tandem mass spectrometry in order to separate, identify, and quantify substances in a sample.","High-performance Liquid Chromatography/Tandem Mass Spectrometry | HPLC/MS/MS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641325","High Performance Liquid Chromatography Mass Spectrometry","C103513","An analytical technique wherein high performance liquid chromatography is coupled to mass spectrometry in order to separate, identify, and quantify substances in a sample.","High Performance Liquid Chromatography Mass Spectrometry | HPLC/MS | High Performance Liquid Chromatography/Mass Spectrometry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054773","High-performance Liquid Chromatography/Ion-Exchange Chromatography","C120690","A type of high performance liquid chromatography that separates proteins based on net charge.","High-performance Liquid Chromatography/Ion-Exchange Chromatography | HPLC/IEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519965","Hillmen Color Chart","C132428","A visual color scale created by Hillman et al in 2004 to enable standardization of urine color in the assessment of hemoglobinuria. (Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE, Cullen MJ, Richards SJ, Rollins SA, Mojcik CF, Rother RP. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004 Feb 5;350(6):552-9.)","Hillmen Color Chart | HILLMEN COLOR CHART",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514085","High Resolution Melt Analysis","C130174","A reverse, real-time, polymerase chain reaction technique in which fluroescently labeled double-stranded DNA is slowly melted apart by increasing temperature. Genetic mutations and polymorphisms can be detected by analyzing the melt curves, which correspond to the rate at which double-stranded DNA become single-stranded.","High Resolution Melt Analysis | HIGH RESOLUTION MELT ANALYSIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827751","Aminoglycoside Screening Method","C85556","A method to determine microbial susceptibility to high concentrations of aminoglycoside antibiotics.","Aminoglycoside Screening Method | HIGH LEVEL AMINOGLYCOSIDE SCREEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054792","Hemocytometry","C120689","A method that uses a thick glass slide containing a chamber with a defined volume, which is etched with a precisely ruled grid and is used to quantify cells or cell-sized particles in suspension.","Hemocytometry | HEMOCYTOMETRY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018904","Hemagglutination Inhibition Assay","C120688","An in vitro assay that is used to determine whether antibodies present in serum samples will prevent hemagglutination in a cell culture plate containing red blood cells and influenza virus.","Hemagglutination Inhibition Assay | HEMAGGLUTINATION INHIBITION ASSAY",,,,,,,,,,,,,,,"4143027","Hemagglutination inhibition assay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018905","Hemagglutination Assay","C130173","An in vitro assay used to measure the relative concentration of viruses, bacteria, or antibodies in which serial dilutions of solution containing virus, bacteria, or antibody are applied to red blood cells in culture to look for the presence of hemagglutination.","Hemagglutination Assay | HEMAGGLUTINATION ASSAY",,,,,,,,,,,,,,,"4226044","Hemagglutination assay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1293979","Hansel Staining Method","C111205","A microscopy staining method that utilizes Hansel reagent to differentiate eosinophils and neutrophils in a specimen. (NCI)","Hansel Staining Method | HANSEL STAIN",,,,,,,,,,,,,,,"4037227","Hansel stain method",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827789","Gradient Diffusion Method","C85599","A method to determine microbial susceptibility to antibiotics in which an agar plate, which has a concentration gradient of the drug within the agar, is streaked with the microorganism of interest. Microbial susceptibility as well as minimum inhibitory concentration of antibiotic is assessed.","Gradient Diffusion Method | GRADIENT DIFFUSION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054904","Gas Chromatography/Electron Ionization Mass Spectrometry","C120687","An analytical technique where gas chromatography is coupled with electron ionization mass spectrometry in order to separate, identify, and quantify substances in a sample.","Gas Chromatography/Electron Ionization Mass Spectrometry | GC/MS-EI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054905","Gas Chromatography/Chemical Ionization Mass Spectrometry","C120686","An analytical technique where gas chromatography is coupled with chemical ionization mass spectrometry in order to separate, identify, and quantify substances in a sample.","Gas Chromatography/Chemical Ionization Mass Spectrometry | GC/MS-CI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054903","Gas Chromatography/Tandem Mass Spectrometry","C120685","An analytical technique wherein gas chromatography is coupled to tandem mass spectrometry in order to separate, identify, and quantify substances in a sample.","Gas Chromatography/Tandem Mass Spectrometry | GC/MS/MS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225860","Left Atrium","C12869","One of four chambers of the heart, which receives blood from the pulmonary veins and pumps blood through the mitral valve into the left ventricle.","Left Atrium | HEART, LEFT ATRIUM | Left Atrium of Heart",,,,,,,,,,,,,,,"4220705","Left atrial structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227936","Body of the Penis","C12325","The portion of the penis that extends from the site of attachment to the glans, and which is covered by skin. It is formed by the joining of the two proximal free parts of the corpora cavernosa and the related free part of the corpus spongiosum.","Body of the Penis | Body of Penis | Body of penis | PENIS, BODY",,,,,,,,,,,,,,,"4328499","Corpus penis structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038593","Subtalar Joint","C33653","The plane synovial joint between the talus and calcaneus bones of the foot.","Subtalar Joint | SUBTALAR JOINT | Talocalcaneal Joint",,,,,,,,,,,,,,,"4133320","Subtalar joint structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1182883","Appendiceal Tip","C83470","The distal end of the appendix.","Appendiceal Tip | APPENDICEAL TIP | Appendix Tip | Tip of the Appendix",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230041","Cranial Cavity","C77638","The atrium that is formed by the bones of the skull and containing the brain.","Cranial Cavity | BODY CAVITY, CRANIAL | CRANIAL CAVITY | Intracranial Cavity",,,,,,,,,,,,,,,"4003337","Cranial cavity structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227973","Lateral Lobe of the Prostate","C13092","The prostate gland lobe that is located on the lateral side of the organ.","Lateral Lobe of the Prostate | PROSTATE GLAND, LATERAL LOBE",,,,,,,,,,,,,,,"4182997","Structure of lateral lobe of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038590","Substantia Nigra","C12453","A large cell mass extending forward, over the dorsal surface of the crus cerebri, from the rostral border of the pons into the subthalamic region. It is composed of a dorsal stratum of closely spaced pigmented cells, the pars compacta, and a larger ventral region of widely scattered cells, the pars reticulata. The pars compacta includes numerous cells that project forward to the striatum (caudate nucleus and putamen) and contain dopamine, which acts as the primary neurotransmitter at the synaptic endings. Other, apparently non-dopaminergic cells project to portions of the ventral nucleus of thalamus, the superior colliculus and reticular formation. The nigrostriatal projection is reciprocated by a striatonigral fiber system with multiple neurotransmitters, chief among which is gamma-aminobutyric acid (GABA). The substantia nigra is involved in the metabolic disturbances associated with Parkinson's disease and Huntington's disease.","Substantia Nigra | BRAIN, SUBSTANTIA NIGRA | SUBSTANTIA NIGRA",,,,,,,,,,,,,,,"4321537","Substantia nigra structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034169","Putamen","C12452","A structure located in the middle of the brain. The putamen is part of the basal ganglia and together with the caudate forms the striatum that influences motor activity.","Putamen | PUTAMEN","C71.0","Putamen",,,,,,,,,,,,,"4229760","Structure of putamen",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0222166","Abdominal Skin","C52758","The skin or integument surrounding the abdomen.","Abdominal Skin | ABDOMINAL SKIN | Abdomen Skin | Skin structure of anterior abdominal wall (body structure)",,,,,,,,,,,,,,,"4327489","Skin structure of abdomen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0226942","External Lower Lip","C12222","The external surface of the lower lip.","External Lower Lip | External lower lip | LIP, LOWER",,,,,,,,,,,,,,,"4027546","Structure of vermilion border of lower lip",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0447059","Ramus Intermedius Artery","C102338","An artery that arises from the left main coronary artery and is positioned between the left anterior descending coronary artery and the circumflex artery.","Ramus Intermedius Artery | RAMUS | RAMUS ARTERY | RAMUS INTERMEDIUS ARTERY | RAMUS INTERMEDIUS ARTERY SEGMENT",,,,,,,,,,,,,,,"4351873","Structure of coronary intermediate artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640687","Lateral Second Obtuse Marginal Branch Artery","C102311","The lateral branch distal to a bifurcation of the second obtuse marginal artery.","Lateral Second Obtuse Marginal Branch Artery | LAT 2ND OM | LATERAL SECOND OBTUSE MARGINAL BRANCH ARTERY | LATERAL SECOND OBTUSE MARGINAL BRANCH ARTERY SEGMENT | Second Obtuse Marginal Lateral Branch",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640684","Lateral First Obtuse Marginal Branch Artery","C102308","The lateral branch distal to a bifurcation of the first obtuse marginal artery.","Lateral First Obtuse Marginal Branch Artery | First Obtuse Marginal Lateral Branch | LAT 1ST OM | LATERAL FIRST OBTUSE MARGINAL BRANCH ARTERY | LATERAL FIRST OBTUSE MARGINAL BRANCH ARTERY SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226936","External Upper Lip","C12221","The external surface of the upper lip.","External Upper Lip | External upper lip | LIP, UPPER",,,,,,,,,,,,,,,"4134589","Structure of vermilion border of upper lip",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224521","Facet Joint","C32577","A synovial joint between two adjacent vertebrae. The facet joint links the articular process of one vertebra and the inferior articular process of the adjacent vertebra.","Facet Joint | FACET JOINT | Zygapophyseal Joint",,,,,,,,,,,,,,,"4217314","Zygapophyseal joint structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1261316","Right Coronary Artery","C12875","A coronary artery that originates above the right coronary cusp and supplies blood predominantly to the right side of the heart.","Right Coronary Artery | CORONARY ARTERY, RIGHT",,,,,,,,,,,,,,,"4029631","Right coronary artery structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227976","Posterior Lobe of the Prostate","C13093","The prostate gland lobe that is located on the posterior side of the organ.","Posterior Lobe of the Prostate | PROSTATE GLAND, POSTERIOR LOBE",,,,,,,,,,,,,,,"4278084","Posterior lobe of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0226802","Cephalic Vein","C32286","One of five superficial veins of the upper extremity, beginning at the radial aspect of the wrist area, wrapping around the forearm and emptying into the axillary vein.","Cephalic Vein | CEPHALIC VEIN | VEIN, CEPHALIC | Vena Cephalica",,,,,,,,,,,,,,,"4047437","Structure of cephalic vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1282007","Pulmonary Artery Branch","C33427","Any artery arising from the pulmonary artery.","Pulmonary Artery Branch | ",,,,,,,,,,,,,,,"4193064","Pulmonary artery branch",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555176","Brief Appraisal Inventory","C154238","A questionnaire designed to account for quality-of-life issues and assess their impact on responses in patient-reported outcome surveys.","Brief Appraisal Inventory | BAI | Brief Appraisal Inventory (BAI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555177","How Often Did You Think About","C154239","A question about the frequency that a person thought about a particular thing.","How Often Did You Think About | During today's interview, how often did you think about",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555182","Maintain Positive Outlook, Even When Things are Going Badly","C154240","A question about how often a person thought about maintaining a positive outlook, even when things are going badly.","Maintain Positive Outlook, Even When Things are Going Badly | Maintaining a positive outlook, even when things are going badly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555183","Achieve Calmer, More Peaceful, or Healthier Lifestyle","C154241","A question about how often a person thought about achieving a calmer, more peaceful, or healthier lifestyle.","Achieve Calmer, More Peaceful, or Healthier Lifestyle | Achieving a calmer, more peaceful or healthier lifestyle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555180","Solve Problems with Health Care or Health Care System","C154242","A question about how often a person thought about solving problems that they have with health care or the health care system.","Solve Problems with Health Care or Health Care System | Solving problems that you have with health care or the health care system",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555181","Impressions and Assumptions Others Have About You Because of Your Health","C154243","A question about how often a person thought about impressions and assumptions that others have about them because of their health.","Impressions and Assumptions Others Have About You Because of Your Health | Impressions and assumptions that others have about you because of your health",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555186","Comparison to Others Whose Health Does not Limit Them","C154244","A question about how often a person thought about how they compare to others whose health does not limit them.","Comparison to Others Whose Health Does not Limit Them | How you compare to others whose health does not limit them",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555187","Free of Money Problems","C154245","A question about how often a person thought about being free of money problems.","Free of Money Problems | Being free of money problems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555184","Increase Volunteer Work to Help Others in Community","C154246","A question about how often a person thought about increasing their volunteer work to help others in the community.","Increase Volunteer Work to Help Others in Community | Increasing your volunteer work to help others in your community",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555185","Grow Spiritually","C154247","A question about how often a person thought about growing spiritually.","Grow Spiritually | Growing spiritually",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555252","Stay Active and Productive","C154248","A question about how often a person thought about staying active and productive.","Stay Active and Productive | Staying active and productive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555253","Resolve Problems in Living Situation","C154249","A question about how often a person thought about resolving problems in their living situation.","Resolve Problems in Living Situation | Resolving problems in your living situation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555250","Prepare Family for Ups and Downs of Health Condition","C154250","A question about how often a person thought about preparing their family for the ups and downs of the person's health condition.","Prepare Family for Ups and Downs of Health Condition | Preparing your family for the ups and downs of your health condition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555251","Settle Conflicts with People in Life","C154251","A question about how often a person thought about settling conflicts with the people in their life.","Settle Conflicts with People in Life | Settling conflicts with people in your life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555256","Find Romance","C154252","A question about how often a person thought about finding romance.","Find Romance | Finding romance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555257","Learn to Accept Yourself as You Are","C154253","A question about how often a person thought about learning to accept themselves as they are.","Learn to Accept Yourself as You Are | Learning to accept yourself as you are",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555254","Things that Usually Don't Come to Mind, Except Because of Survey","C154254","A question about how often a person thought about things that do not usually come to mind, except because of this survey.","Things that Usually Don't Come to Mind, Except Because of Survey | Things that do not usually come to mind, except because of this survey",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555255","Have Dreams and Goals Different From Most People Own Age","C154255","A question about how often a person thought about having dreams and goals that are different from most people their age.","Have Dreams and Goals Different From Most People Own Age | Having dreams and goals that are different from most people your own age",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555260","Spend More Time with Family Before Health Worsens","C154256","A question about how often a person thought about spending more time with their family before the person's health worsens.","Spend More Time with Family Before Health Worsens | Spending more time with your family before your health worsens",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555261","Remain Independent and Be Able to Get Around on Your Own","C154257","A question about how often a person thought about remaining independent and being able to get around on their own.","Remain Independent and Be Able to Get Around on Your Own Question | Remain Independent and Be Able to Get Around on Your Own | Remain Independent and Be Able to Get Around on Your Own | Remaining independent and being able to get around on your own",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555258","Be Rid of Obligations and Responsibilities","C154258","A question about how often a person thought about being rid of obligations and responsibilities.","Be Rid of Obligations and Responsibilities | Being rid of obligations and responsibilities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555259","Try Not to Complain About Health to Others","C154259","A question about how often a person thought about trying not to complain about their health to others.","Try Not to Complain About Health to Others | Trying not to complain about your health to others",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555264","Comparison to Others Facing Similar Health Issues","C154260","A question about how often a person thought about how they compare to others with similar health issues.","Comparison to Others Facing Similar Health Issues | How you compare to others facing similar health issues",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825854","Antithrombin Activity Measurement","C81958","The determination of the amount of antithrombin activity in a sample.","Antithrombin Activity Measurement | ANTHRMA | Antithrombin Activity | Antithrombin III Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831593","Aggrecan Chondroitin Sulfate Epitope 846 Measurement","C112220","The determination of the amount of aggrecan chondroitin sulfate epitope 846 present in a sample.","Aggrecan Chondroitin Sulfate Epitope 846 Measurement | 846-Epitope | Aggrecan Chondroitin Sulfate Epitope 846 | CS846 | CSEPI846 | Chondroitin Sulfate Epitope 846 | Chondroitin Sulfate Proteoglycan 1 Epitope 846",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825850","Eotaxin-3 measurement","C81954","The determination of the amount of eotaxin-3 present in a sample.","Eotaxin-3 Measurement | CCL26 | Chemokine (C-C Motif) Ligand 26 | Chemokine Ligand 26 | EOTAXIN3 | Eotaxin-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811678","Chemokine (C-C Motif) Ligand 17 Measurement","C112236","The determination of the amount of chemokine (C-C Motif) ligand 17 present in a sample.","Chemokine (C-C Motif) Ligand 17 Measurement | ABCD-2 | CCL17 | Chemokine (C-C Motif) Ligand 17 | SCYA17 | TARC | Thymus and Activation Regulated Chemokine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545236","Chemokine (C-X-C Motif) Ligand 3 Measurement","C147329","The determination of the amount of chemokine (C-X-C motif) ligand 3 present in a sample.","Chemokine (C-X-C Motif) Ligand 3 Measurement | CCL3 Measurement | CXCL3 | Chemokine (C-X-C Motif) Ligand 3 | GRO Gamma | MIP2 Beta | MIP2B | Macrophage Inflammatory Protein 2-Beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890560","Receptor Activator Nuclear KappaB Ligand Measurement","C117852","The determination of the amount of receptor activator nuclear kappaB ligand present in a sample.","Receptor Activator Nuclear KappaB Ligand Measurement | Osteoprotegerin Ligand Measurement | RANKL | Receptor Activator Nuclear KappaB Ligand | Receptor Activator of Nuclear Kappa-B Ligand | TNFSF11 Measurement | Tumor Necrosis Factor Ligand Superfamily Member 11 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522795","Complement Ba Measurement","C135403","The determination of the amount of Ba fragment of complement factor B in a biological sample.","Complement Ba Measurement | Ba Fragment of Complement Factor B | Ba Fragment of Factor B | CBA | Complement Ba",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555265","Increase Travel for Leisure or Visit with People","C154261","A question about how often a person thought about increasing their travel for leisure or for visiting with people.","Increase Travel for Leisure or Visit with People | Increasing your travel for leisure or for visiting with people",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555262","Accomplish New Goals at Work","C154262","A question about how often a person thought about accomplishing new goals at work.","Accomplish New Goals at Work | Accomplishing new goals at work",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514231","Chemokine (C-C Motif) Ligand 7 Measurement","C130158","The determination of the amount of chemokine (C-C Motif) ligand 7 present in a sample.","Chemokine (C-C Motif) Ligand 7 Measurement | CCL7 | CCL7 Measurement | Chemokine (C-C Motif) Ligand 7 | MCP3 | Monocyte Chemotactic Protein 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813179","Ghrelin Measurement","C112286","The determination of the amount of ghrelin present in a sample.","Ghrelin Measurement | GHRELIN | Ghrelin | Growth Hormone Secretagogue Receptor Ligand | Motilin-related Peptide | Total Ghrelin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523530","Bile Acid Measurement","C74800","The determination of the amount of bile acids present in a sample.","Bile Acid Measurement | BILEAC | Bile Acid | Bile Acids | Bile Salt | Bile Salts",,,,,,,,,,,,,,,"4019458","Bile acid measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3890034","Total Reticulocyte Corpuscular Hemoglobin Content Measurement","C98776","The determination of the mean amount of hemoglobin per reticulocyte present in a sample.","Reticulocyte Corpuscular Hemoglobin Content | CHr | RETICH | Ret. Corpuscular Hemoglobin Content | Reticulocyte Cellular Hemoglobin Content | Total Reticulocyte Corpuscular Hemoglobin Content Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523444","Prostatic Acid Phosphatase Measurement","C80204","The determination of the amount of prostatic acid phosphatase present in a sample.","Prostatic Acid Phosphatase Measurement | PAP | Prostatic Acid Phosphatase",,,,,,,,,,,,,,,"4019433","Prostatic acid phosphatase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL522822","Retinyl Palmitate Measurement","C135442","The determination of the amount of endogenous retinyl palmitate in a biological sample.","Retinyl Palmitate Measurement | RETPALM | Retinol Palmitate | Retinyl Palmitate | Vitamin A Palmitate | Vitamin A Palmitate Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526589","Reticulocyte Volume Distribution Width Coefficient of Variation","C139072","A measurement of the volume dispersion within a reticulocyte population, calculated as the standard deviation of the mean reticulocyte volume divided by the mean reticulocyte volume, multiplied by 100 for conversion to a percentage.","Reticulocyte Volume Distribution Width Coefficient of Variation | RDWRCV | RDWr-CV | Red Cell Volume Distribution Width Coefficient of Variation in Reticulocytes | Ret RDW Coefficient of Variation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514229","Chemokine (C-X-C Motif) Ligand 6 Measurement","C130159","The determination of the amount of chemokine (C-X-C Motif) ligand 6 present in a sample.","Chemokine (C-X-C Motif) Ligand 6 Measurement | CXCL6 | CXCL6 Measurement | Chemokine (C-X-C Motif) Ligand 6 | GCP2 | Granulocyte Chemotactic Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825856","Factor VII measurement","C81960","The determination of the amount of factor VII present in a sample.","Factor VII Measurement | FACTVII | Factor VII | Proconvertin | Stable Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984934","Erythrocyte Cell Clumps Measurement","C92245","The determination of the amount of erythrocyte cell clumps present in a sample.","Erythrocyte Cell Clumps Measurement | Erythrocyte Cell Clumps | RBC Aggregates | RBC Clumps | RBCCLMP | Red Blood Cell Clumps",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513174","Macrophage Inflammatory Protein 1 Gamma Measurement","C130164","The determination of the amount of macrophage inflammatory protein 1 gamma present in a sample.","Macrophage Inflammatory Protein 1 Gamma Measurement | C-C Motif Chemokine 9 Measurement | CCL9 Measurement | MIP1G | MIP1G Measurement | Macrophage Inflammatory Protein 1 Gamma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272919","Target Cell Count","C96636","The determination of the amount of target cells present in a sample.","Target Cell Count | Codocytes | TRGTCE | Target Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526582","Corpuscular Hemoglobin Content","C139066","A measurement of the mean red blood cell hemoglobin content within an individual red blood cell, calculated as the product of cell volume and cell hemoglobin concentration.","Corpuscular Hemoglobin Content | CH | CHCNT | Cellular Hemoglobin Content | Erythrocyte Corpuscular Hemoglobin Content",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037842","Spermatozoa Cell Count","C74663","The determination of the number of spermatozoa cells present in a sample.","Spermatozoa Cell Count | SPERM | Spermatozoa | sperm count",,,,,,,,,,,,,,,"4120300|4233230","Spermatozoa count|Semen analysis, count only",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL387033","Portal Lymph Node","C77645","Lymph nodes surrounding the portal vein.","Portal Lymph Node | LYMPH NODE, PORTAL | PORTAL LYMPH NODE | Periportal Lymph Node",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001074","Achilles Tendon","C32043","The tendon that connects the heel bone to the calf muscles at the back of the lower leg.","Achilles Tendon | ACHILLES TENDON | Calcanean Tendon | TENDON, CALCANEAL",,,,,,,,,,,,,,,"4266246","Structure of Achilles tendon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0223739","Triangular Bone","C12858","A carpal bone located between the lunate and pisiform bones.","Triangular Bone | TRIANGULAR BONE | Triquetral Bone",,,,,,,,,,,,,,,"4215431","Structure of triangular bone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0226032","Anterior Descending Coronary Artery","C32089","A left coronary artery branch that descends on the anterior portion of the heart through the anterior interventricular groove.","Anterior Descending Coronary Artery | CORONARY ARTERY, ANTERIOR DESCENDING | Left Anterior Descending Coronary Artery | Structure of anterior descending branch of left coronary artery (body structure)",,,,,,,,,,,,,,,"4245039","Structure of left anterior descending artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007461","Caudate Nucleus","C12451","The grey matter adjacent to each lateral ventricle of the brain that comprises the medial dorsal striatum of the basal ganglia. The caudate nucleus is primarily involved in body and limb posture and movement.","Caudate Nucleus | CAUDATE NUCLEUS | Nucleus Caudatus",,,,,,,,,,,,,,,"4001330","Caudate nucleus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0226276","Internal Mammary Artery","C52941","The blood vessel that supplies the breast and the anterior chest wall with arterial blood. It is located in the chest wall.","Internal Mammary Artery | ARTERY, INTERNAL THORACIC | INTERNAL MAMMARY ARTERY | Internal Thoracic Artery","C49.3","Internal mammary artery",,,,,,,,,,,,,"4239527","Structure of internal thoracic artery",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0227190","Abdominal Esophagus","C12252","Clinical esophageal segment composed of smooth muscle. It corresponds to the inferior part of the lower third topographic segment of the esophagus.","Abdominal Esophagus | Abdominal esophagus | ESOPHAGUS, ABDOMINAL",,,,,,,,,,,,,,,"4264641","Abdominal esophagus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL378820","Third Obtuse Marginal Branch Artery","C102351","The third artery arising from the left circumflex artery that supplies the lateral wall, when counted from proximal to distal.","Third Obtuse Marginal Branch Artery | 3RD OM | THIRD OBTUSE MARGINAL BRANCH ARTERY | THIRD OBTUSE MARGINAL BRANCH ARTERY SEGMENT | Third Left Marginal Artery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640679","First Obtuse Marginal Branch Artery","C102299","The first artery arising from the left circumflex artery that supplies the lateral wall, when counted from proximal to distal.","First Obtuse Marginal Branch Artery | 1ST OM | FIRST OBTUSE MARGINAL BRANCH ARTERY | FIRST OBTUSE MARGINAL BRANCH ARTERY SEGMENT | First Left Marginal Artery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL378818","Second Obtuse Marginal Branch Artery","C102346","The second artery arising from the left circumflex artery that supplies the lateral wall, when counted from proximal to distal.","Second Obtuse Marginal Branch Artery | 2ND OM | SECOND OBTUSE MARGINAL BRANCH ARTERY | SECOND OBTUSE MARGINAL BRANCH ARTERY SEGMENT | Second Left Marginal Artery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640699","Mid-Right Coronary Artery Conduit","C102329","The section of the right coronary artery between the right ventricular artery and the acute marginal artery.","Mid-Right Coronary Artery Conduit | MID-RIGHT CORONARY ARTERY CONDUIT | MID-RIGHT CORONARY ARTERY CONDUIT SEGMENT | MRCA | Mid-right Coronary Artery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227230","Body of Stomach","C12258","The main section of the digestive tube that connects the esophagus to the small intestine. The body proper excludes the upper and lower sections of the fundus and pyloric portion respectively.","Body of Stomach | BODY OF STOMACH | Body | Body of stomach | body of stomach",,,,,,,,,,,,,,,"4286028","Gastric corpus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0225883","Right Ventricle","C12870","The lower chamber of the heart located in the right side. It receives blood from the right atrium that is no longer oxygenated and it pumps it to the pulmonary artery.","Right Ventricle | HEART, RIGHT VENTRICLE",,,,,,,,,,,,,,,"4203162","Right cardiac ventricular structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640782","Lateral Third Obtuse Marginal Branch Artery","C102425","The lateral branch distal to a bifurcation of the third obtuse marginal artery.","Lateral Third Obtuse Marginal Branch Artery | LAT 3RD OM | LATERAL THIRD OBTUSE MARGINAL BRANCH ARTERY | LATERAL THIRD OBTUSE MARGINAL BRANCH ARTERY SEGMENT | Third Obtuse Marginal Lateral Branch",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640689","Left Anterior Descending Septal Perforator Artery","C102313","The arteries that arise from the left anterior descending (LAD) artery that supply the interventricular septum.","Left Anterior Descending Septal Perforator Artery | LAD SEPTAL PERFORATOR ARTERY | LAD SEPTAL PERFORATOR ARTERY SEGMENTS | LAD SP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225811","Apex of the Heart","C32126","The lowest superficial part of the heart which is situated behind the left 5th intercostal space.","Apex of the Heart | HEART, APEX",,,,,,,,,,,,,,,"4028830","Structure of apex of heart",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640690","Left Posterolateral Descending Artery","C102314","In an individual with a left-dominant heart, this branch arises from the circumflex artery atrioventricular groove continuation and supplies the inferior apex of the heart.","Left Posterolateral Descending Artery | LEFT POSTEROLATERAL DESCENDING ARTERY | LEFT POSTEROLATERAL DESCENDING ARTERY SEGMENT | LPDA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0223616","Coccygeal Vertebra","C32334","Four vertebral segments positioned at the base of the spine that are fused.","Coccygeal Vertebra | COCCYGEAL VERTEBRA",,,,,,,,,,,,,,,"4056091","Coccygeal vertebra structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0226801","Basilic Vein","C32197","One of the moderately large superficial veins of the forearm that transports blood from the hand and the medial aspect of the forearm to the axillary vein.","Basilic Vein | BASILIC VEIN",,,,,,,,,,,,,,,"4057834","Structure of basilic vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0086835","Posterior Tibial Artery","C12826","A terminal branch of the popliteal artery that runs along the tibia from the lower portion of the popliteus muscle to the lower ankle with numerous branches supplying the lower leg and foot.","Posterior Tibial Artery | POSTERIOR TIBIAL ARTERY | Posterior tibial",,,,,,,,,,,,,,,"4028232","Structure of posterior tibial artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3541347","Distal Left Anterior Descending Artery","C102295","The segment of the left anterior descending (LAD) artery that is distal to the third diagonal branch.","Distal Left Anterior Descending Artery | DISTAL LAD ARTERY | DISTAL LAD ARTERY SEGMENT | DLAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0223710","Olecranon","C33200","A prominence at the proximal end of the ulna. It forms the tip of the elbow.","Olecranon | OLECRANON",,,,,,,,,,,,,,,"4161175","Structure of olecranon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0447748","Interphalangeal Thumb Joint","C102306","A ginglymoid (hinge) synovial joint within the thumb connecting the proximal and distal phalanges.","Interphalangeal Thumb Joint | INTERPHALANGEAL THUMB JOINT | IP THUMB | IP1 of the Hand | Interphalangeal Joint 1 of the Hand",,,,,,,,,,,,,,,"4020922","Structure of interphalangeal joint of thumb",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162857","Radial Artery","C12838","The branch of the brachial artery that passes down the forearm.","Radial Artery | RADIAL ARTERY | Radial | Radial artery",,,,,,,,,,,,,,,"4164917","Structure of radial artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017071","Sympathetic Ganglion","C12467","A cluster of nerve cell bodies located within one of two paravertebral columns comprised of bundled nerve fibers that extend from the base of the skull to the first coccygeal vertebrae, or in a subsidiary location within the sympathetic nervous system. Sympathetic ganglia play a major role in the fight or flight and other stress-mediated responses.","Sympathetic Ganglion | SYMPATHETIC GANGLIA",,,,,,,,,,,,,,,"4204551","Sympathetic ganglion structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640715","Third Diagonal Branch Artery","C102350","The third artery arising from the left anterior descending (LAD) artery that supplies the anterolateral wall, when counted from proximal to distal.","Third Diagonal Branch Artery | 3RD DIAG | THIRD DIAGONAL BRANCH ARTERY | THIRD DIAGONAL BRANCH ARTERY SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224444","Vastus Lateralis","C53073","The largest muscle in the quadriceps femoris that is responsible for extending and stabilizing the knee.","Vastus Lateralis | MUSCLE, VASTUS LATERALIS | VASTUS LATERALIS MUSCLE",,,,,,,,,,,,,,,"4031702","Structure of vastus lateralis muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640713","Second Right Posterolateral Artery","C102347","In an individual with a right-dominant heart, this is the second branch that arises from the right coronary artery distal to the right posterior descending artery, when counted from proximal to distal.","Second Right Posterolateral Artery | 2ND RPL | SECOND RIGHT POSTEROLATERAL ARTERY | SECOND RIGHT POSTEROLATERAL ARTERY SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162864","Tunica Intima","C33820","The inner most layer of the blood vessel wall. The consistency of the intima will vary depending on the type of blood vessel, but will always have an endothelial layer with a basal lamina. It may contain collagen and elastic fibers.","Tunica Intima | TUNICA INTIMA",,,,,,,,,,,,,,,"4337530","Tunica intima of vessel",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709947","Rib 11","C52768","The eleventh rib counting from the top of the rib cage down.","Rib 11 | Bone structure of eleventh rib (body structure) | RIB 11",,,,,,,,,,,,,,,"4240351","Bone structure of eleventh rib",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640688","Lateral Third Diagonal Branch Artery","C102312","The lateral branch distal to a bifurcation of the third diagonal artery.","Lateral Third Diagonal Branch Artery | LAT 3RD DIAG | LATERAL THIRD DIAGONAL BRANCH ARTERY | LATERAL THIRD DIAGONAL BRANCH ARTERY SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242694","Soleus","C53075","A muscle located in the back of the lower leg beneath the gastrocnemius muscle. Its actions involve the flexion of the ankle joint and standing.","Soleus | MUSCLE, SOLEUS | SOLEUS MUSCLE",,,,,,,,,,,,,,,"4302436","Soleus muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036036","Sacroiliac Joint","C33507","The joint located between the sacrum and the ilium.","Sacroiliac Joint | SACROILIAC JOINT",,,,,,,,,,,,,,,"4219320","Sacroiliac joint structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0585574","Pectoralis Major","C33284","Either of two large, bilateral muscles overlying the upper, anterior chest wall, which has two heads: the clavicular head, which originates on the medial half of the clavicle, and the sternal head, which originates on the sternum and the first six costal cartilages; the muscles insert onto the lateral lip of the intertubercular groove of the humerus and the crest of the greater tubercle of the humerus respectively, and function to flex, adduct, and medially rotate the shoulder joint.","Pectoralis Major | Musculus Pectoralis Major | PECTORALIS MAJOR MUSCLE","C49.3","Pectoralis major muscle",,,,,,,,,,,,,"4243057","Pectoralis major muscle structure",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1709954","Rib 8","C52760","The eighth rib counting from the top of the rib cage down.","Rib 8 | Bone structure of eighth rib (body structure) | RIB 8",,,,,,,,,,,,,,,"4241338","Bone structure of eighth rib",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0226050","Acute Marginal Artery","C102285","The arteries that arise at the junction of the proximal and mid-right coronary artery conduit segments.","Acute Marginal Artery | ACUTE MARGINAL ARTERY | ACUTE MARGINAL ARTERY SEGMENT(S) | AMARG",,,,,,,,,,,,,,,"4332014","Structure of marginal branch of right coronary artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0223683","Head of the Humerus","C32720","The upper rounded part of the humerus that fits into the glenoid cavity of the scapula.","Head of the Humerus | HEAD OF THE HUMERUS",,,,,,,,,,,,,,,"4218255","Structure of head of humerus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523631","Folic Acid Measurement","C74676","The determination of the amount of folic acid present in a sample.","Folic Acid Measurement | Folate | Folic Acid | VITB9 | Vitamin B9",,,,,,,,,,,,,,,"4017648","Folic acid measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709948","Rib 12","C52767","The twelfth rib counting from the top of the rib cage down.","Rib 12 | Bone structure of twelfth rib (body structure) | RIB 12",,,,,,,,,,,,,,,"4185558","Bone structure of twelfth rib",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038291","Sternoclavicular Joint","C33615","The synovial juncture between the medial end of the clavicle and the anterior segment of the sternum.","Sternoclavicular Joint | STERNOCLAVICULAR JOINT",,,,,,,,,,,,,,,"4301231","Sternoclavicular joint structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0223947","Navicular Bone","C33162","An oval-shaped bone of the tarsus found on the medial side of the foot.","Navicular Bone | NAVICULAR BONE",,,,,,,,,,,,,,,"4328070","Bone structure of navicular",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526687","Triangular-Hamate Joint","C139200","The articulation between the hamate and the triquetral bones in the wrist.","Triangular-Hamate Joint | TRIANGULAR-HAMATE JOINT | Triquetral-Hamate Joint | Triquetrum-Hamate Joint",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020417","Hyoid Bone","C32752","A U-shaped bone supporting the tongue. This bone is located at the base of the tongue and is suspended from the tips of the styloid processes of the temporal bones by the stylohyoid ligaments.","Hyoid Bone | HYOID BONE | Hyoid bone structure (body structure)",,,,,,,,,,,,,,,"4058660","Hyoid bone structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709950","Rib 3","C52765","The third rib counting from the top of the rib cage down.","Rib 3 | Bone structure of third rib (body structure) | RIB 3",,,,,,,,,,,,,,,"4093907","Bone structure of third rib",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0500507","Septal Perforator Artery","C102348","The arteries arising from the right posterior descending artery that supply the interventricular septum.","Septal Perforator Artery | PDSP | POSTERIOR DESCENDING SEPTAL PERFORATORS ARTERY | POSTERIOR DESCENDING SEPTAL PERFORATORS ARTERY SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640705","Proximal Left Anterior Descending Artery","C102336","The section of the left anterior descending coronary artery that arises from the left main coronary artery and extends to the first diagonal branch.","Proximal Left Anterior Descending Artery | PLAD | PROXIMAL LAD ARTERY | PROXIMAL LAD ARTERY SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709955","Rib 9","C52759","The ninth rib counting from the top of the rib cage down.","Rib 9 | Bone structure of ninth rib (body structure) | RIB 9",,,,,,,,,,,,,,,"4330862","Bone structure of ninth rib",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640717","Third Posterolateral Descending Artery","C102352","In an individual with a left-dominant heart, this is the third branch that arises from the circumflex artery atrioventricular groove continuation when counted from proximal to distal. It supplies the posterolateral wall.","Third Posterolateral Descending Artery | 3RD LPL | THIRD POSTEROLATERAL DESCENDING ARTERY | THIRD POSTEROLATERAL DESCENDING ARTERY SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0736264","Liver Fissure","C32996","Any of the clefts or grooves on the surface of the liver.","Liver Fissure | LIVER FISSURE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162370","Trochanter","C33814","A bony protrusion on the femoral bone to which muscles are attached.","Trochanter | TROCHANTER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0222734","Palatine Bone","C52745","An irregularly shaped bone positioned at the back part of the nasal cavity between the maxilla and the pterygoid process of the sphenoid. It forms the posterior part of the hard palate and the lateral wall of the nasal fossa and helps to form the floor of the orbit as well as several adjoining parts.","Palatine Bone | PALATINE BONE | Palatine bone structure (body structure)",,,,,,,,,,,,,,,"4198253","Palatine bone structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017651","Globus Pallidus","C12449","A sub-cortical, paired nuclei that, though migrated to the telencephalon, is a critical part of the basal ganglia, along with the caudate nucleus and the putamen, the latter of which it joins to form the lentiform nucleus. Each nucleus is subdivided into internal and external parts, called globus pallidus interna and globus pallidus externa, which are separated by an internal medullary lamina.","Globus Pallidus | GLOBUS PALLIDUS","C71.0","Globus pallidus",,,,,,,,,,,,,"4033553","Globus pallidus structure",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C3640678","First Left Posterolateral Branch Artery","C102298","In an individual with a left-dominant heart, this is the first branch that arises from the circumflex artery atrioventricular groove continuation when counted from proximal to distal. It supplies the posterolateral wall.","First Left Posterolateral Branch Artery | 1ST LPL | FIRST LEFT POSTEROLATERAL BRANCH ARTERY | FIRST LEFT POSTEROLATERAL BRANCH ARTERY SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225930","Posterior Cusp of the Tricuspid Valve","C33055","The cusp of the tricuspid valve that is located posterior and on the margin of the right ventricle.","Posterior Cusp of the Tricuspid Valve | Marginal Cusp | TRICUSPID VALVE, POSTERIOR CUSP",,,,,,,,,,,,,,,"4195395","Structure of posterior leaflet of tricuspid valve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1261046","Glenoid Fossa","C32682","The trough in the head of the scapula that receives the head of the humerus to form the shoulder joint.","Glenoid Fossa | GLENOID FOSSA",,,,,,,,,,,,,,,"4186615","Glenoid structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545912","Meconium Measurement","C147391","The determination of the amount of meconium present in a sample.","Meconium Measurement | MECONIUM | Meconium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545280","Lymphoma Cells to Leukocytes Ratio Measurement","C147389","The determination of the ratio of lymphoma cells compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Lymphoma Cells to Leukocytes Ratio Measurement | LYMMCELE | Lymphoma Cells/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545319","Immature Plasma Cells to Total Cells Ratio Measurement","C147416","The determination of the ratio of immature plasma cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Immature Plasma Cells to Total Cells Ratio Measurement | Immature Plasma Cells/Total Cells | PLSIMCCE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545268","Cladosporium herbarum IgE Antibody Measurement","C147286","The determination of the amount of Cladosporium herbarum IgE antibody present in a sample.","Cladosporium herbarum IgE Antibody Measurement | C147286 | Cladosporium herbarum IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512366","HLA-DR51 Antibody Measurement","C128959","The determination of the amount of HLA-DR51 antibody present in a sample.","HLA-DR51 Antibody Measurement | HLA-DR51 Antibody | HLADR51A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524265","Sertraline Measurement","C147432","The determination of the amount of sertraline present in a sample.","Sertraline Measurement | SERTRAL | Sertraline",,,,,,,,,,,,,,,"4023008","Sertraline measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552581","Potassium Excretion Rate","C150820","A determination of the amount of potassium being excreted in a biological specimen over a defined period of time.","Potassium Excretion Rate | KEXR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545278","Levetiracetam Measurement","C147386","The determination of the amount of levetiracetam present in a sample.","Levetiracetam Measurement | LVTRCTM | Levetiracetam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546013","HDL Cholesterol to Total Cholesterol Ratio Measurement","C147362","The determination of the ratio of HDL cholesterol compared to total cholesterol present in a sample. The measurement may be expressed as a ratio or percentage.","HDL Cholesterol to Total Cholesterol Ratio Measurement | HDL Cholesterol/Total Cholesterol | HDLCCHOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545294","Free Erythrocyte Protoporphyrin Measurement","C147339","The determination of the amount of free erythrocyte protoporphyrin present in a sample.","Free Erythrocyte Protoporphyrin Measurement | Erythrocyte Protoporphyrin, Free | FEP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225630","Left Main Bronchus","C32968","One of the two main bronchi. It is narrower but longer than the right main bronchus and connects to the left lung.","Left Main Bronchus | MAIN BRONCHUS, LEFT",,,,,,,,,,,,,,,"4328491","Left main bronchus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0222204","Arm skin","C52754","The skin or integument covering the arm.","Arm Skin | ARM SKIN",,,,,,,,,,,,,,,"4160210","Skin structure of upper arm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018120","Ovarian Follicle","C33244","A spherical aggregation of cells found in the ovaries that contains a single oocyte.","Ovarian Follicle | Follicle | OVARIAN FOLLICLE",,,,,,,,,,,,,,,"4083229","Ovarian follicle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085816","Anterior Tibial Artery","C12825","An artery of the lower extremity that supplies blood to the anterior part of the leg and the foot.","Anterior Tibial Artery | ANTERIOR TIBIAL ARTERY",,,,,,,,,,,,,,,"4238551","Structure of anterior tibial artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709952","Rib 6","C52762","The sixth rib counting from the top of the rib cage down.","Rib 6 | Bone structure of sixth rib (body structure) | RIB 6",,,,,,,,,,,,,,,"4245149","Bone structure of sixth rib",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640680","First Right Posterolateral Artery","C102300","In an individual with a right-dominant heart, this is the first branch that arises from the right coronary artery distal to the right posterior descending artery, when counted from proximal to distal.","First Right Posterolateral Artery | 1ST RPL | FIRST RIGHT POSTEROLATERAL ARTERY | FIRST RIGHT POSTEROLATERAL ARTERY SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024631","Malleus","C33051","A hammer-shaped bone, part of three interconnected small bones located in the middle ear. It is attached to the inner surface of the tympanic membrane and its function is to transmit sound vibrations.","Malleus | MALLEUS | Malleus structure (body structure)",,,,,,,,,,,,,,,"4143488","Malleus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224361","Trapezius Muscle","C33809","One of a pair of flat, large, triangular muscles that extend from the external occipital protuberance and the medial third of the superior nuchal line of the occipital bone to the middle of the back. The trapezius muscle is involved in moving the shoulder and arm.","Trapezius Muscle | TRAPEZIUS MUSCLE","C49.3","Trapezius muscle",,,,,,,,,,,,,"4136969","Structure of trapezius muscle",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1261103","Foot Digit 5","C52843","The smallest and most lateral toe of the foot.","Foot Digit 5 | FOOT DIGIT 5 | Little Toe",,,,,,,,,,,,,,,"4220655","Fifth toe structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0584894","Rectus Femoris","C53175","One of the four quadriceps muscles, located in the middle of the front of the thigh. Its actions involve the extension of the knee joint and flexion of the hip.","Rectus Femoris | MUSCLE, RECTUS FEMORIS | RECTUS FEMORIS MUSCLE",,,,,,,,,,,,,,,"4216386","Rectus femoris muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242403","Vomer","C33888","A thin, paired or unpaired, trapezoidal bone of the skull located in the floor of the nasal cavity. The vomer forms the posterior and inferior parts of the nasal septum.","Vomer | VOMER | Vomer bone structure (body structure)",,,,,,,,,,,,,,,"4314536","Vomer bone structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1711376","Rib 5","C52763","The fifth rib counting from the top of the rib cage down.","Rib 5 | Bone structure of fifth rib (body structure) | RIB 5",,,,,,,,,,,,,,,"4035001","Bone structure of fifth rib",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021181","Incus","C32770","One of the three bones comprising the middle ear. This anvil-shaped bone is positioned between the malleus and the stapes.","Incus | Bone structure of incus (body structure) | INCUS",,,,,,,,,,,,,,,"4149643","Incus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640669","Circumflex Artery AV Groove Continuation Artery","C102287","The segment of the left circumflex artery that is distal to the third marginal branch, located in the atrioventricular groove.","Circumflex Artery AV Groove Continuation Artery | CIRC AV | CIRCUMFLEX ARTERY AV GROOVE CONTINUATION ARTERY | CIRCUMFLEX ARTERY AV GROOVE CONTINUATION ARTERY SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443737","Monoclonal Protein Measurement","C92291","The determination of the amount of monoclonal protein present in a sample.","Monoclonal Protein Measurement | Abnormal Gamma Protein Band | M Protein | M Protein Measurement | M-Spike Paraprotein | M-Spike Protein | MCPROT | Monoclonal Immunoglobulin Protein | Monoclonal Protein | Monoclonal Protein Spike | Myeloma Protein | Paraprotein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812270","Periostin Measurement","C112395","The determination of the amount of periostin present in a sample.","Periostin Measurement | OSF2 | Osteoblast Specific Factor 2 | PERIOSTN | POSTN | Periostin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202144","Neuron Specific Enolase Measurement","C116205","The determination of the amount of neuron specific enolase present in a sample.","Neuron Specific Enolase Measurement | ENO2 Measurement | Enolase 2 | Enolase 2 Measurement | Gamma-Enolase | Gamma-Enolase Measurement | Gamma-enolase | NSE | NSE Measurement | Neuron Specific Enolase | Neuron-Specific Enolase Measurement",,,,,,,,,,,,,,,"4147623","Measurement of gamma-enolase",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202224","Triiodothyronine Uptake Measurement","C74748","The determination of the binding of triiodothyonine to thyroxine binding globulin protein in a sample.","Triiodothyronine Uptake Measurement | T3RU | T3U | T3UP | Triiodothyronine Uptake",,,,,,,,,,,,,,,"4064495","T3 uptake measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2699417","Complement Bb Measurement","C80172","The determination of the amount of complement Bb present in a sample.","Complement Bb Measurement | Bb Fragment of Complement Factor B | Bb Fragment of Factor B | CBB | Complement Bb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523863","Nerve Growth Factor Measurement","C135439","The determination of the amount of nerve growth factor in a biological sample.","Nerve Growth Factor Measurement | Beta-NGF Measurement | Beta-Nerve Growth Factor Measurement | NGF | NGF Measurement | Nerve Growth Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545242","Blasts to Nucleated Cells Ratio Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1295050","Human leukocyte antigen (HLA) A antigen typing (procedure)","C128955","The determination of the amount of human leukocyte antigen, class I, group A (HLA-A), present in a sample.","HLA-A Antigen Type | HLAAAGT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545267","Common Ragweed Pollen IgE Antibody Measurement","C147285","The determination of the amount of common ragweed pollen IgE antibody present in a sample.","Common Ragweed Pollen IgE Antibody Measurement | C147285 | Common Ragweed Pollen IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545919","Round Cell Count","C142288","The determination of the amount of round shaped cells, mainly comprised of white blood cells and immature spermatogenic cells, present in a sample.","Round Cell Count | ROUNDCE | Round Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512365","HLA-DR Mismatch Count","C128963","The determination of the number of mismatch between the study subject and his or her donor for the human leukocyte antigen, class II, antigen-D-related (HLA-DR).","HLA-DR Mismatch Count | HLADRMSC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552601","Free Estradiol to Estradiol Ratio Measurement","C150843","The determination of the ratio of free estradiol compared to total estradiol present in a sample. The measurement may be expressed as a ratio or percentage.","Free Estradiol to Estradiol Ratio Measurement | ESTFREST | Estradiol, Free/Estradiol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266689","Paroxetine Measurement","C147410","The determination of the amount of paroxetine present in a sample.","Paroxetine Measurement | PAROXET | Paroxetine",,,,,,,,,,,,,,,"4005841","Paroxetine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552579","Glucose Excretion Rate","C150818","A determination of the amount of glucose being excreted in a biological specimen over a defined period of time.","Glucose Excretion Rate | GLUCEXR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545956","Keratocyte Count","C147380","The determination of the amount of keratocytes present in a sample.","Keratocyte Count | KERAT | Keratocyte",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815172","Interleukin 1 Beta Measurement","C112323","The determination of the amount of interleukin 1 beta present in a sample.","Interleukin 1 Beta Measurement | IL-1B | IL1Beta | INTLK1B | Interleukin 1 Beta | Interleukin 1B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526583","Red Cell Volume Distribution Width Standard Deviation","C139071","A measurement of the volume dispersion within a red blood cell population, calculated as the width of the distribution curve at the 20% frequency level.","Red Cell Volume Distribution Width Standard Deviation | Erythrocyte Distribution Width Standard Deviation | RDW Standard Deviation | RDW-SD | RDWSD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3511565","JC Virus Antibody Measurement","C112326","The determination of the amount of JC Virus antibody present in a sample.","JC Virus Antibody Measurement | JC Polyomavirus Antibody | JC Virus Antibody | JCV Antibody | JCVAB | John Cunningham Virus Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526588","Reticulocyte Volume Distribution Width Standard Deviation","C139073","A measurement of the volume dispersion within a reticulocyte population, calculated as the width of the distribution curve at the 20% frequency level.","Reticulocyte Volume Distribution Width Standard Deviation | RDWRSD | RDWr Standard Deviation | RDWr-SD | Red Cell Volume Distribution Width Standard Deviation in Reticulocytes | Ret RDW Standard Deviation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513465","Chemokine (C-C Motif) Ligand 19 Measurement","C130157","The determination of the amount of chemokine (C-C Motif) ligand 19 present in a sample.","Chemokine (C-C Motif) Ligand 19 Measurement | CCL19 | CCL19 Measurement | Chemokine (C-C Motif) Ligand 19 | MIP3B | Macrophage Inflammatory Protein 3 Beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0522872","Chemokine (C-X-C Motif) Ligand 4 Measurement","C147330","The determination of the amount of chemokine (C-X-C mofitf) ligand 4 present in a sample.","Chemokine (C-X-C Motif) Ligand 4 Measurement | CXCL4 | CXCL4 Measurement | Chemokine (C-X-C Motif) Ligand 4 | Oncostatin A | PLF4 | Platelet Factor 4",,,,,,,,,,,,,,,"4015596","Platelet factor 4 assay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825907","ProB-Type Natriuretic Peptide Measurement","C82032","The determination of the amount of proB-type natriuretic peptide present in a sample.","ProB-Type Natriuretic Peptide Measurement | BNPPRO | Pro-Brain Natriuretic Peptide | ProB-type Natriuretic Peptide | proBNP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL480889","Smudge Cells to Leukocytes Ratio Measurement","C119294","The determination of the ratio of smudge cells to leukocytes in a biological specimen.","Smudge Cells to Leukocytes Ratio Measurement | Basket Cells/Leukocytes | Gumprecht Shadow Cells/Leukocytes | SMDGCELE | Shadow Cells/Leukocytes | Smudge Cells/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880245","Dacryocyte Analysis","C64801","The determination of the presence or absence of dacryocytes, abnormal erythrocytes shaped like a teardrop, seen in myelofibrosis and certain other myeloproliferative diseases.","Dacryocyte Analysis | Dacryocytes | TEARDCY | Tear Shaped Erythrocytes | Teardrop Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538722","Amyloid Beta Precursor Protein Measurement","C105438","The determination of the amount of amyloid beta precursor protein present in a sample.","Amyloid Beta Precursor Protein Measurement | APPB | Amyloid Beta Precursor | Amyloid Beta Precursor Protein | Amyloid Precursor Beta | Amyloid Precursor Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521646","Alpha-Methylacyl Coenzyme A Racemase Measurement","C132364","The determination of the amount of alpha-methylacyl coenzyme A racemase in a biological sample.","Alpha-Methylacyl Coenzyme A Racemase Measurement | AMACR | AMACR Measurement | Alpha-Methylacyl Coenzyme A Racemase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811691","Fatty Acid Binding Protein 3 Measurement","C106521","The determination of the amount of the fatty acid binding protein 3 present in a sample.","Fatty Acid Binding Protein 3 Measurement | FABP-11 | FABP3 | FABP3 Measurement | Fatty Acid Binding Protein 3 | Fatty Acid Binding Protein 3, Muscle And Heart | Fatty Acid Binding Protein, Heart | Fatty Acid-Binding Protein 3 Measurement | H-FABP | Heart-Type Fatty Acid-Binding Protein | Heart-type Fatty Acid Binding Protein Measurement | M-FABP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0474543","Hemoglobin A2 Measurement","C92259","The determination of the amount of hemoglobin A2 present in a sample.","Hemoglobin A2 Measurement | HGBA2 | Hemoglobin A2",,,,,,,,,,,,,,,"4155233","Hemoglobin A2 measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL405474","Somatotrophin Measurement","C80360","The determination of the amount of somatotrophin present in a sample.","Somatotrophin Measurement | Growth Hormone | SOMATRO | Somatotrophin | Somatotropin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815866","CD33 Expressing Cell Count","C111150","The determination of the amount of CD33 expressing cells per unit present in a sample.","CD33 Expressing Cell Count | Myeloid Cell Surface Antigen CD33 Expressing Cell Count | SIGLEC3 Expressing Cell Count | Siglec-3 Expressing Cell Count",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812195","Chemokine (C-X-C Motif) Ligand 10 Measurement","C112238","The determination of the amount of chemokine (C-X-C Motif) ligand 10 present in a sample.","Chemokine (C-X-C Motif) Ligand 10 Measurement | CXCL10 | Chemokine (C-X-C Motif) Ligand 10 | IP-10 | Interferon Gamma-induced Protein 10 | Interferon-inducible Protein-10 | Small-inducible Cytokine B10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509807","WD Repeat-Containing Protein 26 Measurement","C127637","The determination of the amount of WD-repeat containing protein 26 present in a sample.","WD Repeat-Containing Protein 26 Measurement | CDW2 | MIP2 | Macrophage Inflammatory Protein-2 | WD Repeat-Containing Protein 26 | WDR26",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0373719","Renin Measurement","C74893","The determination of the amount of renin present in a sample.","Renin Measurement | Active Renin | Angiotensinogenase | Direct Renin | RENIN | Renin",,,,,,,,,,,,,,,"4169577","Renin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545243","Complement C1 Esterase Inhibitor Measurement","C147313","The determination of the amount of complement C1 esterase inhibitor present in a sample.","Complement C1 Esterase Inhibitor Measurement | C1 Esterase Inhibitor Measurement | C1-Inh Measurement | C1-Inhibitor Measurement | C1INH | Complement C1 Esterase Inhibitor | SERPING1 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539070","Chemokine Receptor CXCR3 Measurement","C100431","The determination of the amount of chemokine receptor CXCR3 present in a sample.","Chemokine Receptor CXCR3 Measurement | CD183 | CXCR3 | Chemokine (C-X-C Motif) Receptor 3 | GPR9 | Soluble CD183",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811666","Apolipoprotein J to Creatinine Ratio Measurement","C111130","The determination of the ratio of the apolipoprotein J compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Apolipoprotein J to Creatinine Ratio Measurement | APOJCRT | ApoJ Measurement | Apolipoprotein J/Creatinine | Clusterin Measurement | Clusterin/Creatinine | Clusterin/Creatinine Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698136","Anti-Double Stranded DNA Measurement","C74913","The determination of the amount of anti-double stranded DNA present in a sample.","Anti-Double Stranded DNA Measurement | ADSDNA | Anti-Double Stranded DNA | Anti-Double Stranded DNA Antibody Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274482","Pronormoblast to Total Cell Ratio Measurement","C98870","The determination of the ratio of pronormoblasts compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Pronormoblast to Total Cell Ratio Measurement | BLSTRBCE | Proerythroblast/Total Cells | Pronormoblasts to Total Cells Ratio Measurement | Pronormoblasts/Total Cells | Rubriblast/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825851","Lymphotactin Measurement","C81955","The determination of the amount of lymphotactin present in a sample.","Lymphotactin Measurement | Chemokine Ligand 1 | LYMPHOTC | Lymphotactin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699469","Crenated Cell Measurement","C74703","The determination of the number of crenated red blood cells present in a sample.","Crenated Cell Measurement | CRENCE | Crenated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829535","Intact Glucose-dependent Insulinotropic Peptide Measurement","C106537","The determination of the amount of the intact (containing amino acids 1-42) glucose-dependent insulinotropic peptide present in a sample.","Intact Glucose-dependent Insulinotropic Peptide Measurement | GIPI | Glucose-dep Insulinotropic Pep, Intact | Intact GIP | Intact Gastric Inhibitory Polypeptide | Intact Glucose-dependent Insulinotropic Peptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050424","Tumor Necrosis Factor Receptor 1 Measurement","C120666","The determination of the tumor necrosis factor receptor 1 present in a sample.","Tumor Necrosis Factor Receptor 1 Measurement | CD120a | Soluble CD120a | TNFR1 | TNFR1 Measurement | TNFRSF1A Measurement | Tumor Necrosis Factor Receptor 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1275423","Hemoglobin C Measurement","C92261","The determination of the amount of hemoglobin C present in a sample.","Hemoglobin C Measurement | HGBC | Hemoglobin C | Measurement of Hemoglobin C",,,,,,,,,,,,,,,"4269017","Hemoglobin C measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3274476","Activated PTT/Standard Ratio Measurement","C98862","The determination of the ratio of a subject's partial thromboplastin time to a standard or control partial thromboplastin time. The measurement may be expressed as a ratio or percentage.","Activated PTT/Standard Ratio Measurement | APTTSTND | Activated PTT to Standard PTT Ratio Measurement | Activated PTT/Standard | Activated PTT/Standard PTT | Activated Partial Thromboplastin Time/Standard Thromboplastin Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830307","Epstein-Barr Virus Panel","C106519","An assessment of Epstein-Barr virus infection based on a panel of EBV antigen antibody tests.","Epstein-Barr Virus Infection Status | EBV Profile Interpretation | EBVINTP | Epstein-Barr Virus Antibody Profile | Epstein-Barr Virus Panel | Epstein-Barr Virus Profile Interpretation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0428419","Triiodothyronine Measurement","C74747","The determination of the amount of free and bound triiodothyronine present in a sample.","Triiodothyronine Measurement | T3 | Total T3 | Triiodothyronine",,,,,,,,,,,,,,,"4094598","Triiodothyronine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825857","Factor VIII measurement","C81961","The determination of the amount of factor VIII present in a sample.","Factor VIII Measurement | Anti-hemophilic Factor | FACTVIII | Factor VIII",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697573","Heinz-Ehrlich Body Measurement","C74709","The determination of the amount of Heinz bodies (denatured hemoglobin) present in a sample.","Heinz-Ehrlich Body Measurement | HEINZ | Heinz Bodies | Heinz-Erhlich Bodies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698870","Precursor Plasma Cell Count","C74619","The determination of the number of precursor plasma cells present in a sample.","Precursor Plasma Cell Count | PB | PLSPCE | Plasmablast | Plasmablasts | Precursor Plasma Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700087","Tubular Epithelial Cell Count","C74775","The determination of the number of tubular epithelial cells present in a urine sample.","Tubular Epithelial Cell Count | EPITUCE | Renal Tubular Epithelial Cells | Tubular Epithelial Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641238","Dipeptidyl Peptidase-4 Activity Measurement","C103387","The determination of the amount of the biological activity of dipeptidyl peptidase-4 in a sample.","Dipeptidyl Peptidase-4 Activity Measurement | DPP4 Activity Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1319572","Fractional Excretion of Potassium","C114222","The determination of the fractional excretion of potassium that is computed based upon the concentrations of potassium and creatinine in both blood and urine.","Fractional Excretion of Potassium | FEK | Fractional Excretion of K | Fractional Potassium Excretion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1167755","Parathyroid Hormone-related Protein Measurement","C117851","The determination of the amount of parathyroid hormone-related protein present in a sample.","Parathyroid Hormone-related Protein Measurement | PTHRP | Parathyrin Hormone-related Protein | Parathyroid Hormone-related Peptide | Parathyroid Hormone-related Protein",,,,,,,,,,,,,,,"4044820","Parathyroid related protein measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054057","Ribonucleoprotein-70 Antibody Measurement","C120657","The determination of the ribonucleoprotein-70 antibody present in a sample.","Ribonucleoprotein-70 Antibody Measurement | RNP70AB | Ribonucleoprotein-70 Antibody | SNRNP70 Antibody Measurement | snRNP70 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825892","Glutamic Acid Decarboxylase 1 Measurement","C82015","The determination of the amount of glutamic acid decarboxylase 1 present in a sample.","Glutamic Acid Decarboxylase 1 Measurement | GAD1 | Glutamic Acid Decarboxylase 1 | Glutamic Acid Decarboxylase 67",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825913","Type I Collagen N-Telopeptide Measurement","C82039","The determination of the amount of the type I collagen N-telopeptide present in a sample.","Type I Collagen N-Telopeptide Measurement | NTXI | Type I Collagen N-Telopeptides | Type I Collagen X-Linked N-Telopeptides",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523338","Complement C3a Measurement","C80175","The determination of the amount of complement C3a present in a sample.","Complement C3a Measurement | C3A | Complement C3a",,,,,,,,,,,,,,,"4015466","Complement C3a measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1977907","Fractional Excretion of Phosphate","C114221","The determination of the fractional excretion of hosphate that is computed based upon the concentrations of hosphate and creatinine in both blood and urine.","Fractional Excretion of Phosphate | FEPI | Fractional Excretion of P | Fractional Inorganic Phosphate Excretion | Fractional Phosphorus Excretion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891293","Gastric Lipase Measurement","C117840","The determination of the amount of gastric lipase present in a sample.","Gastric Lipase Measurement | Gastric Triacylglycerol Lipase | Gastric Triacylglycerol Lipase Measurement | LIPASEG | LIPF | LIPF Measurement | Lipase, Gastric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811057","Abnormal Cell Count","C111124","The determination of the amount of abnormal cells present in a sample.","Abnormal Cell Count | ABNCE | Abnormal Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523817","Thymidine Kinase 1 Measurement","C135445","The determination of the amount of thymidine kinase 1 in a biological sample.","Thymidine Kinase 1 Measurement | TK1 | TK1 Measurement | Thymidine Kinase 1 | Thymidine Kinase, Cytosolic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540291","Sperm Aggregation Measurement","C142291","The determination of the amount of immotile spermatozoa aggregation present in a sample.","Sperm Aggregation Measurement | SPMAGGR | Sperm Aggregation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512368","HLA-DR53 Antibody Measurement","C128961","The determination of the amount of HLA-DR53 antibody present in a sample.","HLA-DR53 Antibody Measurement | HLA-DR53 Antibody | HLADR53A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550437","Hemoglobin A1 to Total Hemoglobin Ratio Measurement","C147363","The determination of the ratio of hemoglobin A1 compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.","Hemoglobin A1 to Total Hemoglobin Ratio Measurement | HGBA1HGB | Hemoglobin A1/Total Hemoglobin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698755","Pelger Huet Anomaly Measurement","C74617","The determination of the amount of Pelger Huet anomaly present in a sample.","Pelger Huet Anomaly Measurement | PELGERH | PHA | Pelger Huet Anomaly | Pelger Huët Anomaly Measurement | Pelger-Huet Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509673","Troponin I Type 2 Measurement","C127636","The determination of the amount of toponin I type 2 present in a sample.","Troponin I Type 2 Measurement | Fast-Twitch Skeletal Muscle Troponin I | TROPONI2 | Troponin I Type 2 | fsTnI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700114","Unsaturated Non-esterified Fatty Acids Measurement","C80209","The determination of the amount of unsaturated non-esterified fatty acids present in a sample.","Unsaturated Non-esterified Fatty Acids Measurement | FATACFRU | Free Fatty Acid, Unsaturated | Non-esterified Fatty Acid, Unsaturated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526577","N-Terminal ProA-type Natriuretic Peptide Measurement","C139088","The determination of the amount of N-terminal proA-type natriuretic peptide present in a sample.","N-Terminal ProA-type Natriuretic Peptide Measurement | ANPPRONT | N-Terminal ProA-type Natriuretic Peptide | N-terminal pro-Atrial Natriuretic Peptide | NT proANP II | Pro-NPPA Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697608","Hippuric Acid Crystal Measurement","C74754","The determination of the amount of hippuric acid crystals present in a urine sample.","Hippuric Acid Crystal Measurement | CYHIPPAC | Hippurate Crystals | Hippuric Acid Crystals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201898","Vitamin C Measurement","C74903","The determination of the amount of Vitamin C present in a sample.","Vitamin C Measurement | Ascorbate | Ascorbic Acid | VITC | Vitamin C",,,,,,,,,,,,,,,"4100657","Ascorbic acid measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0580952","Myeloblast Count","C74632","The determination of the number of myeloblast cells present in a sample.","Myeloblast Count | MYBLA | Myeloblasts | Myeloid Blasts",,,,,,,,,,,,,,,"4306419","Myeloblast count procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641244","Factor VII Activity Measurement","C103397","The determination of the amount of the biological activity of factor VII in a sample.","Factor VII Activity Measurement | FACTVIIA | Factor VII Activity | Proconvertin Activity | Stable Factor Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0474676","Free Estriol Measurement","C81963","The determination of the amount of free estriol present in a sample.","Free Estriol Measurement | ESTRIOLF | Estriol, Free | Unconjugated Estriol",,,,,,,,,,,,,,,"4098631","Unconjugated estriol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825888","Extracell Newly Ident RAGE Bind Protein measurement","C82011","The determination of the amount of extracellular newly identified RAGE (receptor for advanced glycation end products) present in a sample.","Extracell Newly Ident RAGE Bind Protein Measurement | ENRAGE | Extracell Newly Ident RAGE Bind Protein | S100 Calcium Binding Protein A12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201532","Perinuclear Neutrophil Cytoplasmic Antibody Measurement","C147302","The determination of the amount of perinuclear neutrophil cytoplasmic antibody present in a sample.","Perinuclear Neutrophil Cytoplasmic Antibody Measurement | ANCPNCAB | Anti-Neutrophil Cytoplasmic Antibody, Perinuclear | Neutrophil Cytoplasmic Ab, Perinuclear | Perinuclear ANCA Measurement | p-ANCA Measurement",,,,,,,,,,,,,,,"4197940","P-ANCA measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3812682","Epidermal Growth Factor Receptor Measurement","C112273","The determination of the amount of epidermal growth factor receptor present in a sample.","Epidermal Growth Factor Receptor Measurement | EGFR | ERBB1 | Epidermal Growth Factor Receptor | HER1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1168445","Ribonucleoprotein Antibody Measurement","C100457","The determination of the amount of ribonucleoprotein antibody present in a sample.","Ribonucleoprotein Antibody Measurement | RNP Antibody | RNPAB | Ribonucleoprotein Antibody | Ribonucleoprotein Extractable Nuclear Antibody",,,,,,,,,,,,,,,"4014131","RNP antibody measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3539928","Beta-2 Glycoprotein 1 IgG Antibody Measurement","C103358","The determination of the amount of the Beta-2 glycoprotein 1 IgG antibodies in a sample.","Beta-2 Glycoprotein 1 IgG Antibody Measurement | APOH IgG Antibody Measurement | Apolipoprotein H IgG Antibody Measurement | B2G1GGAB | Beta-2 Glycoprotein 1 IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828335","Reticulocyte Mean Corpuscular Volume","C114215","The determination of the average reticulocyte volume in a blood sample.","Reticulocyte Mean Corpuscular Volume | MCV Reticulocytes | MCVRETIC | MCVr | Mean Corpuscular Volume Reticulocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973050","Macrophage Inflammatory Protein 1 Alpha Measurement","C82023","The determination of the amount of macrophage inflammatory protein 1 alpha present in a sample.","Macrophage Inflammatory Protein 1 Alpha Measurement | Chemokine Ligand 3 | MIP1A | Macrophage Inflammatory Protein 1 Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714685","Angiopoietin 1 Measurement","C111128","A measurement of angiopoietin 1 present in a sample.","Angiopoietin 1 Measurement | ANG-1 Measurement | ANGPT1 | ANGPT1 Measurement | Angiopoietin 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523737","Lactoferrin Measurement","C82021","The determination of the amount of lactoferrin present in a sample.","Lactoferrin Measurement | LTF | Lactoferrin | Lactotransferrin",,,,,,,,,,,,,,,"4018342","Lactoferrin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3272900","N-Terminal ProB-type Natriuretic Peptide Measurement","C96610","The determination of the amount of N-terminal proB-type natriuretic peptide present in a sample.","N-Terminal ProB-type Natriuretic Peptide Measurement | BNPPRONT | N-Terminal ProB-type Natriuretic Peptide | N-terminal pro-Brain Natriuretic Peptide | NT proBNP II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984960","Acyl Coenzyme A Oxidase Measurement","C92286","The determination of the amount of acyl coenzyme A oxidase present in a sample.","Acyl Coenzyme A Oxidase Measurement | ACYLCAOX | Acyl CoA Oxidase | Acyl Coenzyme A Oxidase | Fatty Acyl Coenzyme A Oxidase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699295","Sezary Cell to Lymphocyte Ratio Measurement","C74655","The determination of the ratio of Sezary cells compared to all lymphocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Sezary Cell to Lymphocyte Ratio Measurement | SEZCELY | Sezary Cells/Lymphocytes | Sézary Cell to Lymphocyte Ratio Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698833","Plasmacytoid Lymphocyte Count","C74618","The determination of the number of plasmacytoid lymphocytes present in a sample.","Plasmacytoid Lymphocyte Count | LYMPL | Plasmacytoid Lymphocytes | Plymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0369320","Free Hemoglobin Measurement","C127617","The determination of the amount of free hemoglobin present in a sample.","Free Hemoglobin Measurement | HGBFR | Hemoglobin, Free",,,,,,,,,,,,,,,"4018324","Hemoglobin, free measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825848","Eotaxin-1 Measurement","C81952","The determination of the amount of eotaxin-1 present in a sample.","Eotaxin-1 Measurement | Chemokine Ligand 11 | EOTAXIN1 | Eotaxin-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984961","Bone Specific Alkaline Phosphatase Measurement","C92287","The determination of the amount of bone specific alkaline phosphatase present in a sample.","Bone Specific Alkaline Phosphatase Measurement | ALPBS | Bone ALP Measurement | Bone Alkaline Phosphatase Measurement | Bone Specific Alkaline Phosphatase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698763","Peptide YY Measurement","C80202","The determination of the amount of peptide YY present in a sample.","Peptide YY Measurement | PYY | Peptide Tyrosine Tyrosine | Peptide YY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523818","Deoxyribonucleic Acid Measurement","C135409","The determination of the amount of deoxyribonucleic acid (DNA) in a biological sample.","Deoxyribonucleic Acid Measurement | DNA | DNA Measurement | Deoxyribonucleic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0428539","IgG IgM IgA Total Measurement","C111233","The determination of the total amount of IgG, IgM, and IgA present in a sample.","IgG IgM IgA Total Measurement | IGAGM | IgG IgM IgA Total | Quantitative Immunoglobulins | Total Ig | Total Immunoglobulins Measurement",,,,,,,,,,,,,,,"4353511","Total immunoglobulin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1551409","Erythrocyte Agglutination Measurement","C111197","The determination of the amount of erythrocyte agglutination present in a sample.","Erythrocyte Agglutination Measurement | Autoagglutination | Erythrocyte Agglutination | RBC Agglutination | RBCAGGLU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697503","Glucagon-like Peptide-1 measurement","C80183","The determination of the amount of glucagon-like peptide-1 present in a sample.","Glucagon-like Peptide-1 Measurement | GLP1 | Glucagon-Like Peptide-1 | Total Glucagon-Like Peptide-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825852","Macrophage-Derived Chemokine measurement","C81956","The determination of the amount of macrophage-derived chemokine present in a sample.","Macrophage-Derived Chemokine Measurement | C-C Motif Chemokine Ligand 22 | CCL22 | Chemokine (C-C Motif) Ligand 22 | Chemokine Ligand 22 | MDC | Macrophage-Derived Chemokine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825893","Glutamic Acid Decarboxylase 2 Measurement","C82016","The determination of the amount of glutamic acid decarboxylase 2 present in a sample.","Glutamic Acid Decarboxylase 2 Measurement | GAD2 | Glutamic Acid Decarboxylase 2 | Glutamic Acid Decarboxylase 65",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641226","Amyloid Beta 1-38 Measurement","C103352","The determination of the amount of amyloid beta protein which is composed of peptides 1 to 38 in a sample.","Amyloid Beta 1-38 Measurement | AMYLB38 | Amyloid Beta 1-38 | Amyloid Beta 38 | Amyloid Beta 38 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL384344","Atypical Lymphocyte Count","C64818","The determination of the number of atypical lymphocytes in a blood sample.","Atypical Lymphocyte Count | LYMAT | Lymphocytes Atypical | Lymphocytes, Variant | Reactive Lymphocytes",,,,,,,,,,,,,,,"4313853","Reactive lymphocyte count",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2939113","Alpha-1 Microglobulin Measurement","C100461","The determination of the amount of alpha-1 microglobulin present in a sample.","Alpha-1 Microglobulin Measurement | A1MICG | Alpha 1 Microglobulin Measurement | Alpha-1 Microglobulin | Protein HC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526585","Corpuscular Hemoglobin Concentration Distribution Width","C139068","A measurement of the standard deviation of hemoglobin concentrations in individual red blood cells, calculated as the standard deviation of hemoglobin content divided by the mean hemoglobin content.","Corpuscular Hemoglobin Concentration Distribution Width | CHDW | Corpuscular HGB Conc Distribution Width | Erythrocyte Corpuscular Hemoglobin Concentration Distribution Width",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699712","Sulfa Crystal Measurement","C74755","The determination of the amount of sulfa crystals present in a urine sample.","Sulfa Crystal Measurement | CYSULFA | Sulfa Crystals | Sulfonamide Crystals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521190","Kallikrein-2 Measurement","C132374","The determination of the amount of kallikrein-2 in a biological sample.","Kallikrein-2 Measurement | KLK-2 Measurement | KLK2 | KLK2 Measurement | Kallikrein-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825915","Type II Collagen N-Telopeptide Measurement","C82041","The determination of the amount of the type II collagen N-telopeptide present in a sample.","Type II Collagen N-Telopeptide Measurement | NTXII | Type II Collagen N-Telopeptides | Type II Collagen X-Linked N-Telopeptides",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825910","Stem Cell Factor Measurement","C82035","The determination of the amount of stem cell factor present in a sample.","Stem Cell Factor Measurement | KIT Ligand | SCF | Stem Cell Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698025","Matrix Metalloproteinase 3 Measurement","C80194","The determination of the amount of matrix metalloproteinase 3 present in a sample.","Matrix Metalloproteinase 3 Measurement | MMP3 | Matrix Metalloproteinase 3 | Stromelysin 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202239","Urate Measurement","C64814","A quantitative measurement of the amount of urate present in a sample.","Urate Measurement | URATE | Urate | Uric Acid",,,,,,,,,,,,,,,"4313992","Uric acid measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523524","Beta-Hydroxybutyrate Measurement","C96568","The determination of the amount of beta-hydroxybutyrate present in a sample.","Beta-Hydroxybutyrate Measurement | 3-Hydroxybutyrate | B-Hydroxybutyrate | BHB | BHYXBTR | Beta-Hydroxybutyrate | Beta-Hydroxybutyric Acid",,,,,,,,,,,,,,,"4006204","3-Hydroxybutyrate measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3830083","Fractional Excretion of Calcium","C114219","The determination of the fractional excretion of calcium that is computed based upon the concentrations of calcium and creatinine in both blood and urine.","Fractional Excretion of Calcium | FECA | FECa | Fractional Calcium Excretion | Fractional Excretion of Ca",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545913","Cocaine Amphetamine-Regulated Transcript Protein Measurement","C142273","The determination of the amount of cocaine amphetamine-regulated transcript protein present in a sample.","Cocaine Amphetamine-Regulated Transcript Protein Measurement | CART | CARTP | CARTPT Protein Measurement | Cocaine Amphetamine-Reg Transcript Prot | Cocaine and Amphetamine-Regulated Transcript Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897558","Soluble Interleukin 6 Receptor Measurement","C117837","The determination of the amount of soluble interleukin 6 Receptor present in a sample.","Soluble Interleukin 6 Receptor Measurement | IL-6 Measurement | IL6SR | Interleukin-6 Measurement | Soluble Interleukin 6 Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0373785","Thrombomodulin Measurement","C135444","The determination of the amount of thrombomodulin in a biological sample.","Thrombomodulin Measurement | BDCA3 | THBD | THBD Measurement | Thrombomodulin",,,,,,,,,,,,,,,"4015600","Thrombomodulin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0455282","Nucleated Red Blood Cell Count","C74705","The determination of the number of nucleated red blood cells present in a sample.","Nucleated Red Blood Cell Count | Nucleated Erythrocytes | Nucleated Red Blood Cells | RBCNUC",,,,,,,,,,,,,,,"4012826","Nucleated red blood cell count procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698026","Matrix Metalloproteinase 7 Measurement","C80195","The determination of the amount of matrix metalloproteinase 7 present in a sample.","Matrix Metalloproteinase 7 Measurement | MMP7 | Matrilysin | Matrix Metalloproteinase 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512303","Metarubricyte to Total Cell Ratio Measurement","C128971","The determination of the ratio of the metarubricytes compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Metarubricyte to Total Cell Ratio Measurement | METARBCE | Metarubricyte/Total Cells | Metarubricytes to Total Cells Ratio Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545244","Calcium Corrected for Total Protein Measurement","C147314","The determination of the amount of calcium, which has been corrected for total protein, present in a sample.","Calcium Corrected for Total Protein Measurement | CACRTP | Calcium Corrected for Total Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545303","Free Testosterone to Testosterone Ratio Measurement","C147439","The determination of the ratio of free testosterone compared to total testosterone present in a sample. The measurement may be expressed as a ratio or percentage.","Free Testosterone to Testosterone Ratio Measurement | TSTFTSTT | Testosterone, Free/Testosterone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552580","Iron Excretion Rate","C150819","A determination of the amount of iron being excreted in a biological specimen over a defined period of time.","Iron Excretion Rate | IRONEXR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540303","Beta-1 Globulin to Total Beta Protein Ratio Measurement","C142277","The determination of the ratio of beta-1 globulin compared to beta protein present in a sample. The measurement may be expressed as a ratio or percentage.","Beta-1 Globulin to Total Beta Protein Ratio Measurement | Beta-1 Globulin/Beta Protein | GLOBB1BP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545306","Tissue Transglutaminase IgM Antibody Measurement","C147442","The determination of the amount of tissue transglutaminase IgM antibody present in a sample.","Tissue Transglutaminase IgM Antibody Measurement | TTGIGMAB | Tissue Transglutaminase IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1294692","Dengue Virus Antibody Measurement","C147332","The determination of the amount of Dengue virus antibody present in a sample.","Dengue Virus Antibody Measurement | DNVAB | Dengue Virus Antibody",,,,,,,,,,,,,,,"4008432","Measurement of Dengue virus antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545281","Immunoglobulin Light Chain Measurement","C147376","The determination of the amount of immunoglobulin light chain present in a sample.","Immunoglobulin Light Chain Measurement | IMMGLC | Immunoglobulin Light Chains | Serum Free Immunoglobulin Light Chain, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202408","Meperidine Measurement","C147392","The determination of the amount of meperidine present in a sample.","Meperidine Measurement | MEPRDN | Meperidine",,,,,,,,,,,,,,,"4181914","Meperidine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL524019","Weakly Bound Testosterone Measurement","C147434","The determination of the amount of weakly bound testosterone present in a sample.","Weakly Bound Testosterone Measurement | TESTOSWB | Testosterone, Weakly Bound",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550650","Liquefaction Time Measurement","C142284","The determination of the amount of the time it takes for a gelatinous or semi-solid substance to change to a liquid.","Liquefaction Time Measurement | LIQUFT | Liquefaction Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540282","Renal Papillary Antigen 1 Measurement","C142289","The determination of the amount of renal papillary antigen 1 present in a sample.","Renal Papillary Antigen 1 Measurement | RPA1 | Renal Papillary Antigen 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552577","Chloride Excretion Rate","C150816","A determination of the amount of chloride being excreted in a biological specimen over a defined period of time.","Chloride Excretion Rate | CLEXR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512361","HLA-A Mismatch Count","C128956","The determination of the number of mismatch between the study subject and his or her donor for the human leukocyte antigen, class I, group A (HLA-A).","HLA-A Mismatch Count | HLAAMSC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545316","Pyridinoline to Creatinine Ratio Measurement","C147426","The determination of the ratio of pyridinoline compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Pyridinoline to Creatinine Ratio Measurement | PYDCREAT | Pyridinoline/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202463","Salicylates Measurement","C147431","The determination of the amount of salicylates present in a sample.","Salicylates Measurement | SALCYLT | Salicylates",,,,,,,,,,,,,,,"4264233","Salicylate measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512359","HLA Class II Panel Reactive Antibody Measurement","C128966","The determination of the amount of human leukocyte antigen (HLA) class II panel reactive antibody present in a sample.","HLA Class II Panel Reactive Antibody Measurement | HLA Class II Panel Reactive Antibody | HLAIIPRA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526574","Carbon Monoxide Measurement","C139084","The determination of the amount of carbon monoxide present in a sample.","Carbon Monoxide Measurement | CMONOX | Carbon Monoxide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545258","Alpha Fetoprotein Adjusted for Body Weight Measurement","C147291","The determination of the amount of alpha fetoprotein, adjusted for body weight, present in a sample.","Alpha Fetoprotein Adjusted for Body Weight Measurement | AFPADJBW | Alpha Fetoprotein Adj for Body Weight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512357","HLA Class I Panel Reactive Antibody Measurement","C128967","The determination of the amount of human leukocyte antigen (HLA) class I panel reactive antibody present in a sample.","HLA Class I Panel Reactive Antibody Measurement | HLA Class I Panel Reactive Antibody | HLAIPRA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545251","Beta-2 Glycoprotein 1 IgA Antibody Measurement","C147308","The determination of the amount of beta-2 glycoprotein 1 IgA antibody present in a sample.","Beta-2 Glycoprotein 1 IgA Antibody Measurement | B2G1GAAB | Beta-2 Glycoprotein 1 IgA Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524136","Fentanyl Measurement","C147338","The determination of the amount of fentanyl present in a sample.","Fentanyl Measurement | FENTANYL | Fentanyl",,,,,,,,,,,,,,,"4020862","Fentanyl measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552575","Albumin Excretion Rate","C150814","A determination of the amount of albumin being excreted in a biological specimen over a defined period of time.","Albumin Excretion Rate | ALBEXR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1295059","HLA-DR Antigen Type","C128962","The determination of the amount of human leukocyte antigen, class II, antigen-D-related (HLA-DR), present in a sample.","HLA-DR Antigen Type | HLADRAGT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540300","Interleukin 1 Receptor-Like 1 Measurement","C142281","The determination of the amount of interleukin 1 receptor-like 1 present in a sample.","Interleukin 1 Receptor-Like 1 Measurement | IL1RL1 | Interleukin 1 Receptor-Like 1 | Protein ST2 | sST2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523365","Gliadin IgG Antibody Measurement","C147349","The determination of the amount of gliadin IgG antibody present in a sample.","Gliadin IgG Antibody Measurement | GLDIGGAB | Gliadin IgG Antibody",,,,,,,,,,,,,,,"4014758","Gliadin antibody, IgG measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552595","Blasts to Total Cells Ratio Measurement","C150836","The determination of the ratio of blasts compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Blasts to Total Cells Ratio Measurement | BLASTCE | Blasts to Nucleated Cells Ratio Measurement | Blasts/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512507","T-lymphocyte Crossmatch Measurement","C128979","The determination of the HLA histocompatibility between the donor and the study subject by examining the presence or absence of the subject's anti-HLA antibody reactivity towards HLA antigens expressed on the donor T-lymphocytes.","T-lymphocyte Crossmatch Measurement | T-lymphocyte Crossmatch | TLYMXM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266682","Oxymorphone Measurement","C147409","The determination of the amount of oxymorphone present in a sample.","Oxymorphone Measurement | OXMORPHN | Oxymorphone",,,,,,,,,,,,,,,"4006363","Oxymorphone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512232","Rubricyte to Total Cell Ratio Measurement","C129006","The determination of the ratio of the rubricytes compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Rubricyte to Total Cell Ratio Measurement | RUBCE | Rubricyte/Total Cells | Rubricytes to Total Cells Ratio Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546032","Clefted Lymphocytes Count","C147387","The determination of the amount of clefted lymphocytes present in a sample.","Clefted Lymphocytes Count | LYMCLF | Lymphocytes, Clefted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546018","Protein Pattern Measurement","C147422","An assessment of the protein band pattern present in a sample.","Protein Pattern Measurement | PROTPATN | Protein Pattern",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545234","Citalopram Measurement","C147327","The determination of the amount of citalopram present in a sample.","Citalopram Measurement | CTLPRM | Citalopram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545305","Tissue Transglutaminase IgA Antibody Measurement","C147441","The determination of the amount of tissue transglutaminase IgA antibody present in a sample.","Tissue Transglutaminase IgA Antibody Measurement | TTGIGAAB | Tissue Transglutaminase IgA Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552582","Phosphorus Excretion Rate","C150821","A determination of the amount of phosphorus being excreted in a biological specimen over a defined period of time.","Phosphorus Excretion Rate | PHOSEXR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545317","Reducing Sugar Measurement","C147429","The determination of the amount of reducing sugars present in a sample.","Reducing Sugar Measurement | RDCSUG | Reducing Sugars",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0302187","Cryofibrinogen Measurement","C147326","The determination of the amount of cryofibrinogen present in a sample.","Cryofibrinogen Measurement | CRYOFBRN | Cryofibrinogen",,,,,,,,,,,,,,,"4017634","Cryofibrinogen measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526586","Functional Fibrinogen Measurement","C139075","The determination of the amount of functional fibrinogen present in a sample.","Functional Fibrinogen Measurement | FIBRINOF | Fibrinogen, Functional",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266197","N-methylhistamine Measurement","C147404","The determination of the amount of N-methylhistamine present in a sample.","N-Methylhistamine Measurement | N-methylhistamine | N-methylhistamine Measurement | NMH",,,,,,,,,,,,,,,"4006194","N-Methylhistamine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552594","Abnormal Cells to Total Cells Ratio Measurement","C150835","The determination of the ratio of abnormal cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Abnormal Cells to Total Cells Ratio Measurement | ABNCECE | Abnormal Cells/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545279","Clefted Lymphocytes to Leukocytes Ratio Measurement","C147388","The determination of the ratio of clefted lymphocytes compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Clefted Lymphocytes to Leukocytes Ratio Measurement | LYMCLFLE | Lymphocytes, Clefted/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546048","IgG Clearance to Albumin Clearance Ratio Measurement","C147374","The determination of the ratio of IgG clearance compared to albumin clearance present in a sample. The measurement may be expressed as a ratio or percentage.","IgG Clearance to Albumin Clearance Ratio Measurement | IGGCALBC | IgG Clearance/Albumin Clearance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526572","HCV Antibody Signal to HCV Antibody Cutoff Ratio Measurement","C139086","The determination of the ratio of the Hepatitis C virus antibody signal in a biological specimen to Hepatitis C virus positive internal control. The measurement may be expressed as a ratio or percentage.","HCV Antibody Signal to HCV Antibody Cutoff Ratio Measurement | HCV Antibody Signal/HCV Antibody Cutoff | HCVSHCVC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545266","Boxelder Pollen IgE Antibody Measurement","C147284","The determination of the amount of boxelder pollen IgE antibody present in a sample.","Boxelder Pollen IgE Antibody Measurement | Boxelder Pollen IgE Antibody | C147284",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523363","Gliadin Antibody Measurement","C147347","The determination of the amount of gliadin antibody present in a sample.","Gliadin Antibody Measurement | GLDAB | Gliadin Antibody",,,,,,,,,,,,,,,"4018604","Gliadin antibody measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0443760","Reducing Substance Measurement","C147428","The determination of the amount of reducing substances present in a sample.","Reducing Substance Measurement | RDCSUB | Reducing Substances",,,,,,,,,,,,,,,"4125076","Reducing substance measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545309","25-Hydroxyvitamin D2 and 25-Hydroxyvitamin D3 Measurement","C147446","The determination of the amount of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 present in a sample.","25-Hydroxyvitamin D2 and 25-Hydroxyvitamin D3 Measurement | 25-Hydroxyvit D2 + 25-Hydroxyvit D3 | VTD2D3IT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201870","Alpha-N-acetylglucosaminidase Measurement","C147299","The determination of the amount of alpha-N-acetylglucosaminidase present in a sample.","Alpha-N-acetylglucosaminidase Measurement | ANAG | Alpha-N-acetylglucosaminidase",,,,,,,,,,,,,,,"4326102","Alpha-n-acetylglucosaminidase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545240","Cryoglobulin Volume to Serum Volume Ratio Measurement","C147325","The determination of the ratio of cryoglobulin volume compared to serum volume present in a sample. The measurement may be expressed as a ratio or percentage.","Cryoglobulin Volume to Serum Volume Ratio Measurement | CRYGLBSR | Cryoglobulin Volume/Serum Volume",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1719908","West Nile Virus Antibody Measurement","C147448","The determination of the amount of West Nile virus antibody present in a sample.","West Nile Virus Antibody Measurement | WNVAB | West Nile Virus Antibody",,,,,,,,,,,,,,,"4226642","West Nile virus antibody measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202431","Nicotine Measurement","C147403","The determination of the amount of nicotine present in a sample.","Nicotine Measurement | NICOTINE | Nicotine",,,,,,,,,,,,,,,"4203316","Nicotine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545250","Adenosine Triphosphate Measurement","C147307","The determination of the amount of adenosine triphosphate present in a sample.","Adenosine Triphosphate Measurement | ATP | Adenosine Triphosphate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1295110","Carnitine Ester Measurement","C147323","The determination of the amount of carnitine ester present in a sample.","Carnitine Ester Measurement | CRNTESTR | Carnitine Esters",,,,,,,,,,,,,,,"4006856","Carnitine ester measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524191","Midazolam Measurement","C139083","The determination of the amount of midazolam present in a sample.","Midazolam Measurement | MDZLM | Midazolam",,,,,,,,,,,,,,,"4022489","Midazolam measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523866","Zinc Protoporphyrin Measurement","C147452","The determination of the amount of zinc protoporphyrin present in a sample.","Zinc Protoporphyrin Measurement | ZPP | Zinc Protoporphyrin",,,,,,,,,,,,,,,"4017334","Zinc protoporphyrin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524083","Clorazepate Measurement","C139077","The determination of the amount of clorazepate present in a sample.","Clorazepate Measurement | CLRZPT | Clorazepate",,,,,,,,,,,,,,,"4020260","Clorazepate measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1294064","Mesothelial Cells Count","C147398","The determination of the amount of mesothelial cells present in a sample.","Mesothelial Cells Count | MSTHCE | Mesothelial Cells",,,,,,,,,,,,,,,"4039857","Mesothelial cell count",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545248","Chromatin Antibody Measurement","C147318","The determination of the amount of chromatin antibody present in a sample.","Chromatin Antibody Measurement | CHRMTNAB | Chromatin Antibodies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545307","Ubiquitin Protein Measurement","C147443","The determination of the amount of ubiquitin present in a sample.","Ubiquitin Protein Measurement | UBQN | Ubiquitin Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552602","Glitter Cell Count","C150844","The determination of the amount of glitter cells present in a sample.","Glitter Cell Count | GLTRCE | Glitter Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545254","Anabasine Measurement","C147298","The determination of the amount of anabasine present in a sample.","Anabasine Measurement | ANABASN | ANABSN | Anabasine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524028","Hemoglobin D to Total Hemoglobin Ratio Measurement","C147364","The determination of the ratio of hemoglobin D compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.","Hemoglobin D to Total Hemoglobin Ratio Measurement | HGBDHGB | Hemoglobin D/Total Hemoglobin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546029","Hemoglobin Lepore to Total Hemoglobin Ratio Measurement","C147357","The determination of the ratio of hemoglobin Lepore compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.","Hemoglobin Lepore to Total Hemoglobin Ratio Measurement | HBLEPRHB | Hemoglobin Lepore/Total Hemoglobin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266545","Halazepam Measurement","C139078","The determination of the amount of halazepam present in a sample.","Halazepam Measurement | HLZPM | Halazepam",,,,,,,,,,,,,,,"4006529","Halazepam measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL546015","Phosphatidylcholine to Albumin Ratio Measurement","C147420","The determination of the ratio of phosphatidylcholine compared to albumin present in a sample. The measurement may be expressed as a ratio or percentage.","Phosphatidylcholine to Albumin Ratio Measurement | PPTDCALB | Phosphatidylcholine/Albumin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545265","White Elm Pollen IgG Antibody Measurement","C147283","The determination of the amount of white elm pollen IgG antibody present in a sample.","White Elm Pollen IgG Antibody Measurement | C147283 | White Elm Pollen IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512162","Interleukin 12+23 p40 Measurement","C128970","The determination of the amount of interleukin 12+23 p40 present in a sample.","Interleukin 12+23 p40 Measurement | IL122340 | Interleukin 12+23 p40",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545256","Acylcarnitine to Free Carnitine Ratio Measurement","C147289","The determination of the ratio of acylcarnitine compared to free carnitine present in a sample. The measurement may be expressed as a ratio or percentage.","Acylcarnitine to Free Carnitine Ratio Measurement | ACRNCRNF | Acylcarnitine/Carnitine, Free",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512367","HLA-DR52 Antibody Measurement","C128960","The determination of the amount of HLA-DR52 antibody present in a sample.","HLA-DR52 Antibody Measurement | HLA-DR52 Antibody | HLADR52A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545289","Filamentous Fungi Count","C147343","The determination of the amount of filamentous fungus present in a sample.","Filamentous Fungi Count | FUNGIFIL | Fungi, Filamentous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202454","Phenytoin Measurement","C147413","The determination of the amount of phenytoin present in a sample.","Phenytoin Measurement | PHENYTN | Phenytoin",,,,,,,,,,,,,,,"4141139","Phenytoin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1295175","Lambda Light Chain Measurement","C147384","The determination of the amount of lambda light chain present in a sample.","Lambda Light Chain Measurement | LMBDLC | Lambda Light Chain",,,,,,,,,,,,,,,"4007662","Lambda light chain measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545264","White Oak Pollen IgE Antibody Measurement","C147282","The determination of the amount of white oak pollen IgE antibody present in a sample.","White Oak Pollen IgE Antibody Measurement | C147282 | White Oak Pollen IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512307","Plasma Cells to Leukocytes Ratio Measurement","C128975","The determination of the ratio of the plasma cells compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Plasma Cells to Leukocytes Ratio Measurement | PLSTCELE | Total Plasma Cells/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552603","Estimated Creatinine Clearance","C150847","An estimate of the clearance of endogenous creatinine, used for evaluating the glomerular filtration rate.","Estimated Creatinine Clearance | CRTCLRE | Creatinine Clearance, Estimated",,,,,,,,,,,,,,,"37205200","Estimated creatinine clearance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545935","Sperm Agglutination Measurement","C142290","The determination of the amount of the motile spermatozoa agglutination present in a sample.","Sperm Agglutination Measurement | SPMAGGLU | Sperm Agglutination",,,,,,,,,,,,,,,"4092662","Spermatozoa agglutination",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512356","HLA Class I Antibody Measurement","C128964","The determination of the amount of HLA class I antibody present in a sample.","HLA Class I Antibody Measurement | HLA Class I Antibody | HLAIAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1294848","Yellow Fever Virus Antibody Measurement","C147450","The determination of the amount of Yellow Fever virus antibody present in a sample.","Yellow Fever Virus Antibody Measurement | YFVAB | Yellow Fever Virus Antibody",,,,,,,,,,,,,,,"4044796","Measurement of Yellow fever virus antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552578","Creatinine Excretion Rate","C150817","A determination of the amount of creatinine being excreted in a biological specimen over a defined period of time.","Creatinine Excretion Rate | CREATEXR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545263","Egg White Antigen IgE Antibody Measurement","C147281","The determination of the amount of egg white antigen IgE antibody present in a sample.","Egg White Antigen IgE Antibody Measurement | C147281 | Egg White Antigen IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545310","Motile Sperm to Total Sperm Ratio Measurement","C147433","The determination of the ratio of motile sperm compared to total sperm present in a sample. The measurement may be expressed as a ratio or percentage.","Motile Sperm to Total Sperm Ratio Measurement | Motile Sperm/Total Sperm | SPMMSPM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540304","Globulin to Creatinine Ratio Measurement","C142276","The determination of the ratio of globulin compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Globulin to Creatinine Ratio Measurement | GLBCREAT | Globulin/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545259","Apolipoprotein A1 to Apolipoprotein B Ratio Measurement","C147292","The determination of the ratio of apolipoprotein A1 compared to apolipoprotein B present in a sample. The measurement may be expressed as a ratio or percentage.","Apolipoprotein A1 to Apolipoprotein B Ratio Measurement | ALA1ALB | Apolipoprotein A1/Apolipoprotein B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545327","Free Metanephrine Measurement","C147400","The determination of the amount of free metanephrine present in a sample.","Free Metanephrine Measurement | MTNEPHFR | Metanephrine, Free",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524027","Hemoglobin E to Total Hemoglobin Ratio Measurement","C147365","The determination of the ratio of hemoglobin E compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.","Hemoglobin E to Total Hemoglobin Ratio Measurement | HGBEHGB | Hemoglobin E/Total Hemoglobin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545321","Polychromatophilic Erythroblast Count","C147418","The determination of the amount of polychromatophilic erythroblasts present in a sample from an experimental organism.","Polychromatophilic Erythroblast Count | POLYERY | Polychromatophilic Erythroblast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545290","Yeast-Like Fungi Count","C147344","The determination of the amount of yeast-like fungus present in a sample.","Yeast-Like Fungi Count | FUNGYLK | Fungi, Yeast-Like",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545328","Nonhematic Cells to Leukocytes Ratio Measurement","C147402","The determination of the ratio of nonhematic cells compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Nonhematic Cells to Leukocytes Ratio Measurement | NHMCELE | Nonhematic Cells/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512364","HLA-B Mismatch Count","C128958","The determination of the number of mismatch between the study subject and his or her donor for the human leukocyte antigen, class I, group B (HLA-B).","HLA-B Mismatch Count | HLABMSC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550420","Mesothelial Cells to Leukocytes Ratio Measurement","C147399","The determination of the ratio of mesothelial cells compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Mesothelial Cells to Leukocytes Ratio Measurement | MSTHCELE | Mesothelial Cells/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0581142","Plasma Cell Count","C128974","The determination of the amount of plasma cells present in a sample.","Plasma Cell Count | PC | PLSTCE | Plasma Cells | Total Plasma Cells",,,,,,,,,,,,,,,"4152974","Plasma cell count",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540292","Cocaine, Benzoylecgonine, and/or Ecgonine Measurement","C142274","The determination of the amount of cocaine, benzoylecgonine, and/or ecgonine present in a sample.","Cocaine, Benzoylecgonine, and/or Ecgonine Measurement | COCBNZEC | Cocaine Benzoylecgonine Ecgonine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550423","Hemoglobin F to Total Hemoglobin Ratio Measurement","C147366","The determination of the ratio of hemoglobin F compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.","Hemoglobin F to Total Hemoglobin Ratio Measurement | HGBFHGB | Hemoglobin F/Total Hemoglobin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512362","HLA-A2 Antibody Measurement","C128954","The determination of the amount of HLA-A2 antibody present in a sample.","HLA-A2 Antibody Measurement | HLA-A2 Antibody | HLAA2AB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545323","Neutral Fats Measurement","C147407","The determination of the amount of neutral fats present in a sample.","Neutral Fats Measurement | NTRLFAT | Neutral Fats",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552599","Eosinophils to Nucleated Cells Ratio Measurement","C150840","The determination of the ratio of eosinophils compared to nucleated cells present in a sample. The measurement may be expressed as a ratio or percentage.","Eosinophils to Nucleated Cells Ratio Measurement | EOSNUCCE | Eosinophils/Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545322","Polychromatophilic Normoblast Count","C147419","The determination of the amount of polychromatophilic normoblasts present in a sample from an experimental organism.","Polychromatophilic Normoblast Count | POLYNORM | Polychromatophilic Normoblast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266786","Venlafaxine Measurement","C147444","The determination of the amount of venlafaxine present in a sample.","Venlafaxine Measurement | VENLAFAX | Venlafaxine",,,,,,,,,,,,,,,"4005368","Venlafaxine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL550421","Monocytes and Macrophages to Leukocytes Ratio Measurement","C147396","The determination of the ratio of monocytes and macrophages compared to total leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Monocytes and Macrophages to Leukocytes Ratio Measurement | MONMPHLE | Monocytes and Macrophages/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545330","Nornicotine Measurement","C147406","The determination of the amount of nornicotine present in a sample.","Nornicotine Measurement | NORNCTN | Nornicotine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540233","Streptococcus pneumoniae IgG Antibody Measurement","C142232","The determination of the amount of Streptococcus pneumoniae IgG antibody present in a sample.","Streptococcus pneumoniae IgG Antibody Measurement | SPNAB | SPNIGGAB | Streptococcus pneumoniae IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0373729","Thyroid Stimulating Immunoglobulin Measurement","C147438","The determination of the amount of thyroid stimulating immunoglobulin present in a sample.","Thyroid Stimulating Immunoglobulin Measurement | TSI | Thyroid Stimulating Immunoglobulin",,,,,,,,,,,,,,,"4020112","Thyroid stimulating immunoglobulins measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545329","Basophilic Normoblast Count","C147405","The determination of the amount of basophilic normoblasts present in a sample from an experimental organism.","Basophilic Normoblast Count | Basophilic Normoblast | NORMBASO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545938","Ovalocyte Count","C142287","The determination of the amount of ovalocytes present in a sample.","Ovalocyte Count | OVALCY | Ovalocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1294823","Japanese Encephalitis Virus Antibody Measurement","C147378","The determination of the amount of Japanese encephalitis virus antibody present in a sample.","Japanese Encephalitis Virus Antibody Measurement | JEVAB | Japanese Encephalitis Virus Antibody",,,,,,,,,,,,,,,"4007504","Measurement of Japanese encephalitis virus antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2591489","Estimated Average Glucose Measurement","C142275","A computed estimate of the blood glucose based on the value of the glycated hemoglobin present in a sample.","Estimated Average Glucose Measurement | EAG | EAGLUC | Estimated Average Glucose | Estimated Average Glucose | Glucose, Estimated | Glucose, Estimated Average",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550428","Methemoglobin to Total Hemoglobin Ratio Measurement","C147367","The determination of the ratio of methemoglobin compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.","Methemoglobin to Total Hemoglobin Ratio Measurement | FMET HB | Fractionated Methemoglobin | HGBMHGB | Methemoglobin/Total Hemoglobin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018819","Heart Septum","C49485","The tissue in the heart that separates the two atria (atrial septum) and the two ventricles (ventricular septum).","Heart Septum | Cardiac Septum | HEART, SEPTUM",,,,,,,,,,,,,,,"4027932","Cardiac septum structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037009","Shoulder Joint","C33548","A ball-and-socket joint at the upper end of the humerus, located at the junction of humerus and scapula.","Shoulder Joint | Glenohumeral joint structure (body structure) | SHOULDER JOINT",,,,,,,,,,,,,,,"4310972","Glenohumeral joint structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0376381","Cuboid Bone","C32414","A bone on the lateral side of the tarsus between the calcaneus and the fourth and fifth metatarsal bones.","Cuboid Bone | CUBOID BONE",,,,,,,,,,,,,,,"4215753","Bone structure of cuboid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001208","Acromioclavicular Joint","C32047","The junction of the upper distal end of the scapula to the distal edge of the collarbone, also known as the acromion and the clavicle.","Acromioclavicular Joint | ACROMIOCLAVICULAR JOINT",,,,,,,,,,,,,,,"4311928","Acromioclavicular joint structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0225701","Hilar Area of the Lung","C49282","The wedge-shaped area at the central portion of the lung through which the bronchi, vessels and nerves enter or exit the organ.","Hilar Area of the Lung | LUNG, HILUM",,,,,,,,,,,,,,,"4263316","Structure of hilum of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0222234","Hand Digit Skin","C52720","The skin covering the fingers or appendages of the hand.","Hand Digit Skin | SKIN OF THE FINGER | Skin of the Finger",,,,,,,,,,,,,,,"4210454","Skin of finger",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640686","Lateral Second Diagonal Branch Artery","C102310","The lateral branch distal to a bifurcation of the second diagonal artery.","Lateral Second Diagonal Branch Artery | LAT 2ND DIAG | LATERAL SECOND DIAGONAL BRANCH ARTERY | LATERAL SECOND DIAGONAL BRANCH ARTERY SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229769","Hepatic Lymph Node","C77640","Any of the lymph nodes adjacent to the stomach and duodenum.","Hepatic Lymph Node | HEPATIC LYMPH NODE | LYMPH NODE, HEPATIC",,,,,,,,,,,,,,,"4265614","Structure of hepatic lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001209","Acromion","C32048","The upper distal process of the scapula.","Acromion | ACROMION",,,,,,,,,,,,,,,"4136802","Structure of acromion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0228176","Left Cerebral Hemisphere","C32955","The left half of the cerebrum that controls the muscles on the right side of the body.","Left Cerebral Hemisphere | CEREBRAL HEMISPHERE, LEFT | Left Brain Hemisphere | Left Hemisphere",,,,,,,,,,,,,,,"4248708","Left cerebral hemisphere structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2985480","Upper Pole of Kidney","C93179","The pole of the kidney located in the uppermost region of the kidney.","Upper Pole of Kidney | KIDNEY, UPPER POLE | Kidney Upper Lobe | Kidney, Upper Pole | Superior Pole of Kidney | Upper Lobe of Kidney | Upper Lobe of Kidney | Upper Pole of the Kidney",,,,,,,,,,,,,,,"4183269","Structure of superior pole of kidney",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028937","Olfactory Mucosa","C33205","The part of the nasal mucosa composed of neuroepithelial tissue and mucus-producing Bowman's glands. The mucus moistens the epithelium and helps dissolve odor-containing gases.","Olfactory Mucosa | MUCOSA, NASAL | OLFACTORY MUCOSA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224622","Carpometacarpal Joint 1","C103912","A saddle-shaped synovial joint between the metacarpal of the thumb and the trapezium.","Carpometacarpal Joint 1 | CARPOMETACARPAL JOINT 1 | CMC1 | Carpometacarpal Joint of the Thumb",,,,,,,,,,,,,,,"4146767","Carpometacarpal joint structure of thumb",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0225608","Right Main Bronchus","C33486","One of the two main bronchi. It is wider but shorter than the left main bronchus and connects to the right lung.","Right Main Bronchus | MAIN BRONCHUS, RIGHT",,,,,,,,,,,,,,,"4321551","Right main bronchus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708083","Foot Digit 3","C52841","The middle or third toe from the medial side of the foot.","Foot Digit 3 | FOOT DIGIT 3 | Middle Toe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640696","Mid-Circumflex Artery","C102326","The segment of the left circumflex artery between the first and second marginal branches.","Mid-Circumflex Artery | MCIRC | MID-CIRCUMFLEX ARTERY | MID-CIRCUMFLEX ARTERY SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1261102","Foot Digit 4","C52842","The fourth toe from the medial side of the foot.","Foot Digit 4 | FOOT DIGIT 4 | Fourth Toe",,,,,,,,,,,,,,,"4197655","Fourth toe structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0230147","Superior Mediastinum","C33684","The part of the mediastinum that is located between the upper part of the sternum in the front and the upper thoracic vertebrae in the back.","Superior Mediastinum | MEDIASTINUM, SUPERIOR",,,,,,,,,,,,,,,"4322819","Superior mediastinum structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512766","Anterior Cusp of the Tricuspid Valve","C32799","The cusp of the tricuspid valve that is located between the atrioventricular orifice and the conus arteriosus.","Anterior Cusp of the Tricuspid Valve | Infundibular Cusp | TRICUSPID VALVE, ANTERIOR CUSP",,,,,,,,,,,,,,,"4105923","Structure of anterior leaflet of tricuspid valve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224453","Semitendinosus","C53176","A muscle located at the posterior and medial aspect of the thigh that extends the hip joint, flexes the knee joint and assists in medially rotating the knee. (CDISC)","Semitendinosus | MUSCLE, SEMITENDINOSUS | SEMITENDINOSUS MUSCLE",,,,,,,,,,,,,,,"4179043","Semitendinosus muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221961","Shaft of the Hair","C33543","The segment of the hair that projects above the skin surface.","Shaft of the Hair | HAIR SHAFT",,,,,,,,,,,,,,,"4285806","Hair shaft structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1527245","Tarsal Joints","C33735","The synovial joints between the tarsal bones of the foot.","Tarsal Joint | JOINT, TARSUS | TARSAL JOINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640708","Right Posterior Atrioventricular Artery","C102341","The arterial branch between the right posterior descending artery segment and the first right posterolateral segment.","Right Posterior Atrioventricular Artery | RIGHT POSTERIOR ATRIOVENTRICULAR ARTERY | RIGHT POSTERIOR ATRIOVENTRICULAR ARTERY SEGMENT | RPAV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640711","Second Left Posterolateral Branch Artery","C102345","In an individual with a left-dominant heart, this is the second branch that arises from the circumflex artery atrioventricular groove continuation when counted from proximal to distal. It supplies the posterolateral wall.","Second Left Posterolateral Branch Artery | 2ND LPL | SECOND LEFT POSTEROLATERAL BRANCH ARTERY | SECOND LEFT POSTEROLATERAL BRANCH ARTERY SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709953","Rib 7","C52761","The seventh rib counting from the top of the rib cage down.","Rib 7 | Bone structure of seventh rib (body structure) | RIB 7",,,,,,,,,,,,,,,"4090726","Bone structure of seventh rib",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640672","Distal Circumflex Artery","C102290","The segment of the left circumflex artery that is between the second and third obtuse marginal branches.","Distal Circumflex Artery | DCIRC | DISTAL CIRCUMFLEX ARTERY | DISTAL CIRCUMFLEX ARTERY SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224449","Biceps Femoris","C53147","A muscle in the back of the thigh. Its action involves the knee flexion and hip extension.","Biceps Femoris | BICEPS FEMORIS MUSCLE | MUSCLE, BICEPS FEMORIS",,,,,,,,,,,,,,,"4231296","Biceps femoris muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640706","Proximal Right Coronary Artery Conduit","C102337","The section of the right coronary artery proximal to the origin of the right ventricular artery.","Proximal Right Coronary Artery Conduit | PRCA | PROXIMAL RIGHT CORONARY ARTERY CONDUIT | PROXIMAL RIGHT CORONARY ARTERY CONDUIT SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640676","Distal Right Coronary Artery Conduit","C102296","The section of the right coronary artery distal to the origin of the acute marginal artery.","Distal Right Coronary Artery Conduit | DISTAL RIGHT CORONARY ARTERY CONDUIT | DISTAL RIGHT CORONARY ARTERY CONDUIT SEGMENT | DRCA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038989","Sweat Gland","C33712","The small coiled tubes in the skin that produce and secrete sweat.","Sweat Gland | SUDORIFEROUS GLAND",,,,,,,,,,,,,,,"4015167","Sweat gland structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709951","Rib 4","C52764","The fourth rib counting from the top of the rib cage down.","Rib 4 | Bone structure of fourth rib (body structure) | RIB 4",,,,,,,,,,,,,,,"4103150","Bone structure of fourth rib",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640685","Lateral Ramus Intermedius Artery","C102309","The lateral branch distal to a bifurcation of the ramus intermedius artery.","Lateral Ramus Intermedius Artery | LAT RAMUS | LATERAL RAMUS INTERMEDIUS ARTERY | LATERAL RAMUS INTERMEDIUS ARTERY SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640718","Third Right Posterolateral Artery","C102353","In an individual with a right-dominant heart, this is the third branch that arises from the right coronary artery distal to the right posterior descending artery, when counted from proximal to distal.","Third Right Posterolateral Artery | 3RD RPL | THIRD RIGHT POSTEROLATERAL ARTERY | THIRD RIGHT POSTEROLATERAL ARTERY SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225931","Septal Cusp of the Tricuspid Valve","C33534","The cusp of the tricuspid valve that is attached to the right and left fibrous trigones and the atrial and ventricular septa.","Septal Cusp of the Tricuspid Valve | Septal Cusp | TRICUSPID VALVE, SEPTAL CUSP",,,,,,,,,,,,,,,"4098271","Structure of septal leaflet of tricuspid valve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640677","First Diagonal Branch Artery","C102297","The first artery arising from the left anterior descending (LAD) artery that supplies the anterolateral wall, when counted from proximal to distal.","First Diagonal Branch Artery | 1ST DIAG | FIRST DIAGONAL BRANCH ARTERY | FIRST DIAGONAL BRANCH ARTERY SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882430","Posterior Portion of the Urethra","C61126","The portion of the urethra that is located on the posterior aspect of the urogenital diaphragm.","Posterior Portion of the Urethra | URETHRA, POSTERIOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640698","Mid-Left Anterior Descending Artery","C102328","The segment of the left anterior descending (LAD) artery between the first and third diagonal branches.","Mid-Left Anterior Descending Artery | MID-LAD ARTERY | MID-LAD ARTERY SEGMENT | MLAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0222224","Hand Skin","C52753","The skin covering the distal portion of the upper extremity.","Hand Skin | SKIN OF THE HAND | Skin Of The Hand",,,,,,,,,,,,,,,"4144227","Skin structure of hand",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0447584","Bladder Fundus","C48939","The portion of the bladder that is formed by the posterior wall and is located opposite to the bladder opening.","Bladder Fundus | BLADDER, FUNDUS | Fundus of the Bladder | Urinary Bladder Fundus | fundus of urinary bladder",,,,,,,,,,,,,,,"4282297","Structure of fundus of urinary bladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0458451","Penile Portion of the Urethra","C61123","The portion of the urethra that spans the corpus spongiosum.","Penile Portion of the Urethra | Penile Urethra | URETHRA, PENILE",,,,,,,,,,,,,,,"4270902","Structure of spongiose portion of urethra",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010271","Dural Venous Sinus","C102627","Venous channels within the dura mater of the brain which receives both blood from blood vessels within the brain as well as cerebrospinal fluid then drains into the internal jugular vein. Unlike other blood vessels, dural venous sinuses lack valves and other vessel associated layers.","Dural Venous Sinus | Cerebral Sinus | Cranial Sinus | DURAL VENOUS SINUS",,,,,,,,,,,,,,,"4204388","Dural sinus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709949","Rib 2","C52766","The second rib counting from the top of the rib cage down.","Rib 2 | Bone structure of second rib (body structure) | RIB 2",,,,,,,,,,,,,,,"4301626","Bone structure of second rib",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027432","Nasal Septum","C33160","The thin wall between the two nasal cavities.","Nasal Septum | NASAL SEPTUM",,,,,,,,,,,,,,,"4287099","Nasal septum structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2985481","Lower Pole of Kidney","C93180","The pole of the kidney located in the lowest region of the kidney.","Lower Pole of Kidney | Inferior Pole of Kidney | KIDNEY, LOWER POLE | Kidney Lower Lobe | Kidney, Lower Pole | Lower Lobe of Kidney | Lower Lobe of Kidney | Lower Pole of the Kidney",,,,,,,,,,,,,,,"4232766","Structure of inferior pole of kidney",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016125","Interphalangeal Joint of the Hand","C32868","The hinge synovial joints between the phalanges of the fingers.","Interphalangeal Joint of the Hand | Hand Phalanges | INTERPHALANGEAL JOINT OF THE HAND | Interphalangeal Joint of Hand",,,,,,,,,,,,,,,"4053843|4118104|4220781","Finger joint structure|Structure of interphalangeal joint of finger|Interphalangeal joint of hand structure",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C3640701","Proximal Circumflex Artery","C102331","The section of the left circumflex coronary artery that arises from the left main coronary artery and extends to the first marginal branch.","Proximal Circumflex Artery | PCIRC | PROXIMAL CIRCUMFLEX ARTERY | PROXIMAL CIRCUMFLEX ARTERY SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708081","Foot Digit 2","C52840","The second toe from the medial side of the foot.","Foot Digit 2 | FOOT DIGIT 2 | Index Toe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709946","Rib 10","C52769","The tenth rib counting from the top of the rib cage down.","Rib 10 | Bone structure of tenth rib (body structure) | RIB 10",,,,,,,,,,,,,,,"4298973","Bone structure of tenth rib",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640710","Second Diagonal Branch Artery","C102344","The second artery arising from the left anterior descending (LAD) artery that supplies the anterolateral wall, when counted from proximal to distal.","Second Diagonal Branch Artery | 2ND DIAG | SECOND DIAGONAL BRANCH ARTERY | SECOND DIAGONAL BRANCH ARTERY SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225972","Pericardial Cavity","C38662","The potential body space formed between the parietal and visceral layers of the pericardial sac.","Pericardial Cavity | BODY CAVITY, PERICARDIAL | PERICARDIAL CAVITY",,,,,,,,,,,,,,,"4104246","Pericardial cavity structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040356","Interphalangeal Joint of the Foot","C32867","The hinge synovial joints between the bones of the toes.","Interphalangeal Joint of the Foot | INTERPHALANGEAL OF THE FOOT | IP of the Foot",,,,,,,,,,,,,,,"4022673|4046736","Interphalangeal toe joint structure|Structure of joint of toe",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1710195","Sternal Manubrium","C52730","The upper segment of the sternum, quadrangular in shape, as well as wider superiorly and narrower inferiorly. The sternal manubrium articulates with the clavicle and first two ribs.","Sternal Manubrium | STERNAL MANUBRIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640709","Right Posterior Descending Artery","C102342","In an individual with a right-dominant heart, the arterial branch that arises from the distal right coronary artery between the acute marginal artery and the first right posterolateral segment. It supplies the inferior apex of the heart.","Right Posterior Descending Artery | RIGHT POSTERIOR DESCENDING ARTERY | RIGHT POSTERIOR DESCENDING ARTERY SEGMENT | RPDA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028936","Olfactory Bulb","C28401","Anatomical structure located in the vertebral forebrain that receives neural input regarding odors that have been detected by cells within the nasal cavity. The axons of olfactory receptor cells extend into the olfactory bulb.","Olfactory Bulb | BRAIN, OLFACTORY BULB | OLFACTORY BULB",,,,,,,,,,,,,,,"4034435","Structure of olfactory bulb",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1709945","Rib 1","C52770","The first rib counting from the top of the rib cage down.","Rib 1 | Bone structure of first rib (body structure) | RIB 1",,,,,,,,,,,,,,,"4171837","Bone structure of first rib",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0222681","Epicondyle","C69300","A bone prominence to which ligaments and tendons of the joints are attached.","Epicondyle | EPICONDYLE",,,,,,,,,,,,,,,"4262445","Structure of epicondyle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205029","Head Skin","C52757","The integument that covers the head, including the face and scalp.","Head Skin | SKIN OF THE HEAD",,,,,,,,,,,,,,,"4321847","Skin structure of head",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3900033","Ankle Mortise","C117868","A rectangular socket or bony arch that connects the ends of the tibia and fibula to the talus.","Ankle Mortise | ANKLE MORTISE | Talar Mortise",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640695","Metatarsophalangeal Joint 5","C102325","A condyloid synovial joint within the fifth digit of the foot connecting metatarsal with the proximal phalanx.","Metatarsophalangeal Joint 5 | METATARSOPHALANGEAL JOINT 5 | MTP5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3495141","Coronary Vein","C12882","A blood vessel in the heart which returns coronary blood to the chambers of the heart, most often the right atrium.","Coronary Vein | CORONARY VEIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227327","Terminal Ileum","C33757","The most distal section of the ileum that is continuous with the cecum.","Terminal Ileum | ILEUM, TERMINAL",,,,,,,,,,,,,,,"4311821","Structure of distal portion of ileum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003489","Aortic Arch","C32123","The curved section of the aorta between the ascending and the descending tracts. The brachiocephalic, left common carotid and left subclavian arteries branch from the aorta at this section.","Aortic Arch | AORTIC ARCH",,,,,,,,,,,,,,,"4211548","Aortic arch structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0225844","Right Atrium","C12868","One of the four chambers of the heart, which is located immediately superior to the right ventricle, and which receives deoxygenated venous blood from the systemic circulation.","Right Atrium | HEART, RIGHT ATRIUM",,,,,,,,,,,,,,,"4250014","Right atrial structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227956","Preputial Gland","C79432","Exocrine glands located at the anterior aspect of the genitals of some mammals, such as mice and rats, that produce and secrete pheromones.","Preputial Gland | GLAND, PREPUTIAL | PREPUTIAL GLAND",,,,,,,,,,,,,,,"4163960","Structure of preputial gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1879708","Anterior Portion of the Urethra","C61125","The portion of the urethra that extends from the meatus to the membranous urethra.","Anterior Portion of the Urethra | URETHRA, ANTERIOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230149","Middle Mediastinum","C33123","The broadest part of the lower portion of the mediastinum. It contains the heart and the great vessels.","Middle Mediastinum | MEDIASTINUM, MIDDLE",,,,,,,,,,,,,,,"4320334","Middle mediastinum structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0222279","Leg Skin","C52749","The skin or integument surrounding the leg.","Leg Skin | LEG SKIN",,,,,,,,,,,,,,,"4327352","Skin structure of lower leg",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018534","Foot Digit 1","C52839","The largest and most medial toe of the foot.","Foot Digit 1 | Big Toe | FOOT DIGIT 1",,,,,,,,,,,,,,,"4193225","Hallux structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0225810","Base of the Heart","C48589","The superior portion of the heart located opposite to the apical portion. It is formed mainly by the left atrium.","Base of the Heart | HEART, BASE",,,,,,,,,,,,,,,"4246289","Structure of base of heart",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640683","Lateral First Diagonal Branch Artery","C102307","The lateral branch distal to a bifurcation of the first diagonal artery.","Lateral First Diagonal Branch Artery | LAT 1ST DIAG | LATERAL FIRST DIAGONAL BRANCH ARTERY | LATERAL FIRST DIAGONAL BRANCH ARTERY SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152281","Frontal Horn of the Lateral Ventricle","C32637","The part of the lateral ventricle located in the frontal lobe, anterior to the interventricular foramen (of Monro), and bounded by the septum pellucidum, fornix, and genu of the corpus callosum.","Frontal Horn of the Lateral Ventricle | ANTERIOR HORN OF THE LATERAL VENTRICLE",,,,,,,,,,,,,,,"4147668","Structure of anterior horn of lateral ventricle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0226492","Dorsalis Pedis Artery","C32478","An artery of the dorsal surface of the foot, originating from the anterior tibial artery of the lower leg. The following arterial branches originate from the dorsalis pedis artery: the arcuate artery of the foot and deep plantar artery.","Dorsalis Pedis Artery | DORSALIS PEDIS ARTERY | Dorsal Pedal Artery | Dorsalis pedis",,,,,,,,,,,,,,,"4312875","Structure of dorsalis pedis artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224422","Obturator Internus Muscle","C33192","A striated muscle covering the majority of the lateral wall of the pelvis, with its origin on the ischiopubic ramus and obturator membrane and insertion on the greater trochanter, which functions to externally rotate the hip.","Obturator Internus Muscle | OBTURATOR INTERNUS MUSCLE",,,,,,,,,,,,,,,"4219459","Internal obturator muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640693","Metatarsophalangeal Joint 3","C102323","A condyloid synovial joint within the third digit of the foot connecting metatarsal with the proximal phalanx.","Metatarsophalangeal Joint 3 | METATARSOPHALANGEAL JOINT 3 | MTP3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829521","Interphalangeal Joint 4 of the Foot","C114203","A ginglymoid (hinge) synovial joint between the phalanges of the fourth digit of the foot.","Interphalangeal Joint 4 of the Foot | INTERPHALANGEAL JOINT 4 OF THE FOOT | IP4 of the Foot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224252","Flexor Carpi Radialis","C53155","A muscle in the forearm running from the head of the humerus to the radial side of the wrist that flexes and radially abducts the hand.","Flexor Carpi Radialis | FLEXOR CARPI RADIALIS MUSCLE",,,,,,,,,,,,,,,"4147547","Flexor carpi radialis muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039482","Temporal Artery","C33741","A terminal branch of the external carotid artery that branches into the anterior and posterior temporal arteries.","Temporal Artery | TEMPORAL ARTERY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224240","Brachialis","C53149","A muscle that originates from the lower two-thirds of the anterior surface of the humerus that flexes the elbow.","Brachialis | BRACHIALIS MUSCLE",,,,,,,,,,,,,,,"4294253","Structure of brachialis muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0230185","Epigastric Region","C32525","The upper central region of the abdomen between the costal margins and the subcostal plane.","Epigastric Region | EPIGASTRIC REGION",,,,,,,,,,,,,,,"4101855","Epigastric region structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640692","Metatarsophalangeal Joint 2","C102322","A condyloid synovial joint within the second digit of the foot connecting metatarsal with the proximal phalanx.","Metatarsophalangeal Joint 2 | METATARSOPHALANGEAL JOINT 2 | MTP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829520","Interphalangeal Joint 4 of the Hand","C114192","A ginglymoid (hinge) synovial joint between the phalanges of the fourth digit of the hand.","Interphalangeal Joint 4 of the Hand | INTERPHALANGEAL JOINT 4 OF THE HAND | IP4 of the Hand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517753","Layer of the Ophthalmic Nerve Fibers","C32953","A retina layer that contains the axons of ganglion cells. It collects the visual impulses.","Layer of the Ophthalmic Nerve Fibers | RETINAL NERVE FIBER LAYER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640682","Interphalangeal Joint 5","C102305","A ginglymoid (hinge) synovial joint between the phalanges of the fifth digit of the hand or foot.","Interphalangeal Joint 5 | INTERPHALANGEAL JOINT 5 | IP5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205030","Neck Skin","C52756","The integumentary covering of the neck.","Neck Skin | SKIN OF THE NECK | skin of neck",,,,,,,,,,,,,,,"4182739","Skin structure of neck",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224249","Pronator Teres Muscle","C53174","A muscle of the superficial flexor compartment of the forearm, which originates on both the humeral and ulnar heads and inserts on the body of the radius, that functions to pronate the arm and flex the elbow.","Pronator Teres Muscle | PRONATOR TERES MUSCLE",,,,,,,,,,,,,,,"4105164","Pronator teres muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221962","Hair Bulb","C32706","The lower segment of the hair that circles the dermal papilla and the hair matrix.","Hair Bulb | HAIR BULB",,,,,,,,,,,,,,,"4236008","Hair bulb structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3540576","Metatarsophalangeal Joint 1","C102321","A condyloid synovial joint within the first digit of the foot connecting metatarsal with the proximal phalanx.","Metatarsophalangeal Joint 1 | METATARSOPHALANGEAL JOINT 1 | MTP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542924","Interphalangeal Joint 3","C102303","A ginglymoid (hinge) synovial joint between the phalanges of the third digit of the hand or foot.","Interphalangeal Joint 3 | INTERPHALANGEAL JOINT 3 | IP3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829524","Interphalangeal Joint 2 of the Hand","C114190","A ginglymoid (hinge) synovial joint between the phalanges of the second digit of the hand.","Interphalangeal Joint 2 of the Hand | INTERPHALANGEAL JOINT 2 OF THE HAND | IP2 of the Hand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640673","Distal Interphalangeal Joint 3","C102292","A ginglymoid (hinge) synovial joint within the third digit of the hand or foot connecting the middle and distal phalanges.","Distal Interphalangeal Joint 3 | DIP3 | DISTAL INTERPHALANGEAL JOINT 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229723","Submental Lymph Node","C142322","The lymph nodes located between the anterior bellies of the digastric muscles.","Submental Lymph Node | SUBMENTAL LYMPH NODE | Suprahyoid Lymph Node | Suprahyoid Lymph Nodes",,,,,,,,,,,,,,,"4263598","Structure of submental lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0226476","Peroneal Artery","C33314","An artery arising from the posterior tibial artery that supplies the muscles on the lateral side of the lower leg.","Peroneal Artery | PERONEAL ARTERY",,,,,,,,,,,,,,,"4339212","Structure of peroneal artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3830462","Distal Interphalangeal Joint 3 of the Foot","C114199","A ginglymoid (hinge) synovial joint within the third digit of the foot connecting the middle and distal phalanges.","Distal Interphalangeal Joint 3 of the Foot | DIP3 of the Foot | DISTAL INTERPHALANGEAL JOINT 3 OF THE FOOT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0222084","Skin of the Face","C33561","The integumentary covering of the face.","Skin of the Face | SKIN OF THE FACE | skin of face",,,,,,,,,,,,,,,"4250773","Skin structure of face",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0228224","Calcarine Sulcus","C32252","A cerebral fissure that originates near the occipital lobe and terminates below the corpus callosum.","Calcarine Sulcus | CALCARINE SULCUS",,,,,,,,,,,,,,,"4078601","Calcarine sulcus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1261080","Non-Coronary Cusp of the Aortic Valve","C127639","The cusp of the aortic valve that is positioned posteriorly relative to the other two aortic cusps.","Non-Coronary Cusp of the Aortic Valve | AORTIC VALVE, NON-CORONARY CUSP | Aortic Valve, Posterior Semilunar Cusp",,,,,,,,,,,,,,,"4290235","Structure of posterior cusp of aortic valve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640694","Metatarsophalangeal Joint 4","C102324","A condyloid synovial joint within the fourth digit of the foot connecting metatarsal with the proximal phalanx.","Metatarsophalangeal Joint 4 | METATARSOPHALANGEAL JOINT 4 | MTP4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017069","Parasympathetic Ganglion","C52557","A usually small autonomic ganglion of the parasympathetic nervous system. The majority are located near or in the organs that they innervate.","Parasympathetic Ganglion | PARASYMPATHETIC GANGLIA",,,,,,,,,,,,,,,"4302163","Structure of parasympathetic ganglion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640691","Metacarpophalangeal Joint 5","C102320","A condyloid synovial joint within the fifth digit of the hand connecting the metacarpal to the proximal phalanx.","Metacarpophalangeal Joint 5 | MCP5 | METACARPOPHALANGEAL JOINT 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642479","Carpometacarpal Joint 5","C103916","A plane joint between the fifth metacarpal and the pisiform.","Carpometacarpal Joint 5 | CARPOMETACARPAL JOINT 5 | CMC5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0598179","Cingulate Cortex","C52713","Part of the medial aspect of the cerebral cortex.","Cingulate Cortex | CINGULATE CORTEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829525","Interphalangeal Joint 2 of the Foot","C114201","A ginglymoid (hinge) synovial joint between the phalanges of the second digit of the foot.","Interphalangeal Joint 2 of the Foot | INTERPHALANGEAL JOINT 2 OF THE FOOT | IP2 of the Foot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640703","Proximal Interphalangeal Joint 4","C102334","A ginglymoid (hinge) synovial joint within the fourth digit of the hand or foot connecting the proximal and middle phalanges.","Proximal Interphalangeal Joint 4 | PIP4 | PROXIMAL INTERPHALANGEAL JOINT 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004455","Axillary Artery","C32169","An artery that originates from the subclavian artery at the lateral margin of the first rib that supplies the brachial artery.","Axillary Artery | AXILLARY ARTERY","C49.3","Axillary artery",,,,,,,,,,,,,"4239013","Structure of axillary artery",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C3829526","Interphalangeal Joint 1 of the Foot","C114200","A ginglymoid (hinge) synovial joint within the first digit of the foot connecting the proximal and distal phalanges.","Interphalangeal Joint 1 of the Foot | INTERPHALANGEAL JOINT 1 OF THE FOOT | IP1 of the Foot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829519","Interphalangeal Joint 5 of the Foot","C114204","A ginglymoid (hinge) synovial joint between the phalanges of the fifth digit of the foot.","Interphalangeal Joint 5 of the Foot | INTERPHALANGEAL JOINT 5 OF THE FOOT | IP5 of the Foot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828452","Proximal Interphalangeal Joint 2 of the Foot","C114205","A ginglymoid (hinge) synovial joint within the second digit of the foot connecting the proximal and middle phalanges.","Proximal Interphalangeal Joint 2 of the Foot | PIP2 of the Foot | PROXIMAL INTERPHALANGEAL JOINT 2 OF THE FOOT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830460","Distal Interphalangeal Joint 4 of the Foot","C114275","A ginglymoid (hinge) synovial joint within the fourth digit of the foot connecting the middle and distal phalanges.","Distal Interphalangeal Joint 4 of the Foot | DIP4 of the Foot | DISTAL INTERPHALANGEAL JOINT 4 OF THE FOOT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224423","Obturator Externus Muscle","C33191","A striated muscle located on the anterior surface of the pelvis, with its origin on the obturator foramen and obturatory membrane and insertion on the trochanteric fossa of the femur, which functions to laterally rotate the femur.","Obturator Externus Muscle | OBTURATOR EXTERNUS MUSCLE",,,,,,,,,,,,,,,"4218790","External obturator muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1185903","Anterior Cusp of the Pulmonary Valve","C127673","The cusp of the pulmonic valve that has no attachment to the cardiac septum.","Anterior Cusp of the Pulmonary Valve | PULMONARY VALVE, ANTERIOR CUSP | Pulmonary Valve, Anterior Semilunar Cusp",,,,,,,,,,,,,,,"4102770","Structure of anterior cusp of pulmonic valve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3830463","Distal Interphalangeal Joint 2 of the Hand","C114188","A ginglymoid (hinge) synovial joint within the second digit of the hand connecting the middle and distal phalanges.","Distal Interphalangeal Joint 2 of the Hand | DIP2 of the Hand | DISTAL INTERPHALANGEAL JOINT 2 OF THE HAND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224278","Abductor Pollicis Longus","C52888","A skeletal muscle of the forearm originating from the posterior surfaces of the ulna and radius and the interosseous membrane.","Abductor Pollicis Longus | ABDUCTOR POLLICIS LONGUS MUSCLE",,,,,,,,,,,,,,,"4103156","Structure of abductor pollicis longus muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1182707","hair root","C32711","The portion of the hair that is enclosed within the hair follicle.","Hair Root | HAIR ROOT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540687","Distal Interphalangeal Joint 2","C102291","A ginglymoid (hinge) synovial joint within the second digit of the hand or foot connecting the middle and distal phalanges.","Distal Interphalangeal Joint 2 | DIP2 | DISTAL INTERPHALANGEAL JOINT 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708989","Metacarpal Bone Digit 3","C52794","The third of five miniature long bones located in the palm of the hand, which articulates proximally with the capitate and second and fourth metacarpals at the carpometacarpal joint and distally with the middle finger phalanx at the metacarpophalangeal joint.","Metacarpal Bone Digit 3 | METACARPAL BONE 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708988","Metacarpal Bone Digit 2","C52795","The second and the longest of five miniature long bones located in the palm of the hand, which articulates proximally with the trapezoid, trapezium, and capitate at the carpometacarpal joint and distally with the index finger phalanx at the metacarpophalangeal joint.","Metacarpal Bone Digit 2 | METACARPAL BONE 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038446","Primary Visual Cortex","C97340","A brain region in the occipital cortex that receives visual stimuli from the retina.","Primary Visual Cortex | BRAIN, VISUAL CORTEX | PRIMARY VISUAL CORTEX",,,,,,,,,,,,,,,"4034278","Area striata structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828447","Proximal Interphalangeal Joint 4 of the Hand","C114196","A ginglymoid (hinge) synovial joint within the fourth digit of the hand connecting the proximal and middle phalanges.","Proximal Interphalangeal Joint 4 of the Hand | PIP4 of the Hand | PROXIMAL INTERPHALANGEAL JOINT 4 OF THE HAND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227481","Right Lobe of the Liver","C33481","The larger lobe of the liver extending into the right side of the body.","Right Lobe of the Liver | LIVER, RIGHT LOBE | Right Lobe",,,,,,,,,,,,,,,"4168794","Structure of right lobe of liver",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2952211","Portacaval Lymph Node","C117872","A lymph node located in the space between the portal vein and inferior vena cava, along the hepatoduodenal ligament.","Portacaval Lymph Node | PORTACAVAL LYMPH NODE | Portocaval Lymph Node",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640704","Proximal Interphalangeal Joint 5","C102335","A ginglymoid (hinge) synovial joint within the fifth digit of the hand or foot connecting the proximal and middle phalanges.","Proximal Interphalangeal Joint 5 | PIP5 | PROXIMAL INTERPHALANGEAL JOINT 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828446","Proximal Interphalangeal Joint 5 of the Hand","C114197","A ginglymoid (hinge) synovial joint within the fifth digit of the hand connecting the proximal and middle phalanges.","Proximal Interphalangeal Joint 5 of the Hand | PIP5 of the Hand | PROXIMAL INTERPHALANGEAL JOINT 5 OF THE HAND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035301","Retinal Artery","C52997","An artery arising from the ophthalmic artery that supplies the retina.","Retinal Artery | RETINAL ARTERY",,,,,,,,,,,,,,,"4101564","Structure of retinal artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1185905","Left Cusp of the Pulmonary Valve","C127674","The cusp of the pulmonic valve attached to the left side of the cardiac septum.","Left Cusp of the Pulmonary Valve | PULMONARY VALVE, LEFT CUSP | Pulmonary Valve, Left Semilunar Cusp",,,,,,,,,,,,,,,"4103305","Structure of left cusp of pulmonic valve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3541901","Metacarpophalangeal Joint 4","C102319","A condyloid synovial joint within the fourth digit of the hand connecting the metacarpal to the proximal phalanx.","Metacarpophalangeal Joint 4 | MCP4 | METACARPOPHALANGEAL JOINT 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708987","Metacarpal Bone Digit 1","C52796","The first and most medial of five miniature long bones located in the palm of the hand, which articulates proximally with the trapezium of the carpus at the carpometacarpal joint and distally with the thumb phalanx at the metacarpophalangeal joint.","Metacarpal Bone Digit 1 | METACARPAL BONE 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1261078","Right Coronary Cusp of the Aortic Valve","C127640","The cusp of the aortic valve that overlies the right coronary ostium.","Right Coronary Cusp of the Aortic Valve | AORTIC VALVE, RIGHT CORONARY CUSP | Aortic Valve, Right Semilunar Cusp",,,,,,,,,,,,,,,"4166076","Structure of right cusp of aortic valve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3830461","Distal Interphalangeal Joint 3 of the Hand","C114189","A ginglymoid (hinge) synovial joint within the third digit of the hand connecting the middle and distal phalanges.","Distal Interphalangeal Joint 3 of the Hand | DIP3 of the Hand | DISTAL INTERPHALANGEAL JOINT 3 OF THE HAND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0458296","Retroauricular Lymph Node","C142313","The lymph nodes located immediately posterior to the ear; also known as the mastoid lymph nodes or the posterior auricular lymph nodes.","Retroauricular Lymph Node | Mastoid Lymph Node | Posterior Auricular Lymph Node | RETROAURICULAR LYMPH NODE",,,,,,,,,,,,,,,"4150890","Mastoid lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038001","Splenic Vein","C33608","A vein arising from the splenic trabecular vein in the hilum of the spleen that drains into the portal vein.","Splenic Vein | SPLENIC VEIN",,,,,,,,,,,,,,,"4147745","Structure of splenic vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829518","Interphalangeal Joint 5 of the Hand","C114193","A ginglymoid (hinge) synovial joint between the phalanges of the fifth digit of the hand.","Interphalangeal Joint 5 of the Hand | INTERPHALANGEAL JOINT 5 OF THE HAND | IP5 of the Hand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640675","Distal Interphalangeal Joint 5","C102294","A ginglymoid (hinge) synovial joint within the fifth digit of the hand or foot connecting the middle and distal phalanges.","Distal Interphalangeal Joint 5 | DIP5 | DISTAL INTERPHALANGEAL JOINT 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225968","Epicardium","C13164","The outer membranous connective tissue layer of the heart tissue.","Epicardium | EPICARDIUM",,,,,,,,,,,,,,,"4287680","Structure of visceral pericardium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1268054","Aortopulmonary Window Lymph Node","C116165","A lymph node located in the aortopulmonary window.","Aortopulmonary Window Lymph Node | AORTOPULMONARY WINDOW LYMPH NODE | AP Window Lymph Node | Lymph node of aortopulmonary window (body structure)",,,,,,,,,,,,,,,"4027263","Lymph node of aortopulmonary window",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522460","Thoracic Aorta","C33766","The section of the aorta between the lower border of the fourth dorsal vertebrae and the aortic opening in the diaphragm.","Thoracic Aorta | THORACIC AORTA",,,,,,,,,,,,,,,"4014548","Thoracic aorta structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023951","Locus Coeruleus","C97333","A brainstem nucleus. It is the major brain site for the synthesis and secretion of norepinephrine.","Locus Coeruleus | LOCUS CERULEUS | Locus Ceruleus",,,,,,,,,,,,,,,"4020188","Structure of locus ceruleus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828450","Proximal Interphalangeal Joint 3 of the Foot","C114206","A ginglymoid (hinge) synovial joint within the third digit of the foot connecting the proximal and middle phalanges.","Proximal Interphalangeal Joint 3 of the Foot | PIP3 of the Foot | PROXIMAL INTERPHALANGEAL JOINT 3 OF THE FOOT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224476","Flexor Digitorum Profundus","C52923","A muscle in the forearm beginning at the head of the ulna and ending with four tendons projecting to the second, third, fourth, and fifth fingers which flexes the midcarpal, metacarpophalangeal and interphalangeal joints.","Flexor Digitorum Profundus | FLEXOR DIGITORUM PROFUNDUS MUSCLE",,,,,,,,,,,,,,,"4311132","Structure of flexor digitorum profundus muscle of hand",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029078","Ophthalmic Artery","C33216","An artery arising from the internal carotid artery that branches into two groups of vessels; the orbital group that supplies the orbit and surrounding parts and the ocular group that supplies the globe and muscles of the eye.","Ophthalmic Artery | OPHTHALMIC ARTERY",,,,,,,,,,,,,,,"4205853","Structure of ophthalmic artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0447105","Common Femoral Artery","C32354","An artery arising from the external iliac artery at the inguinal ligament which bifurcates forming the deep and superficial femoral arteries.","Common Femoral Artery | COMMON FEMORAL ARTERY",,,,,,,,,,,,,,,"4109754","Common femoral artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0223567","Extra Lumbar Vertebra","C120673","A congenital anomaly of the spine, where an extra or supernumerary lumbar vertebra arises from below the 5th lumbar vertebra.","Extra Lumbar Vertebra | L6 VERTEBRA | L6 Vertebra",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152321","Genu of the Corpus Callosum","C32675","The anterior portion of the corpus callosum that bends downward and backward.","Genu of the Corpus Callosum | CORPUS CALLOSUM, GENU",,,,,,,,,,,,,,,"4321688","Structure of genu of corpus callosum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0447106","Superficial Femoral Artery","C33661","The portion of the femoral artery distal to the branching of the deep femoral artery that runs close to the skin.","Superficial Femoral Artery | SUPERFICIAL FEMORAL ARTERY",,,,,,,,,,,,,,,"4111596","Superficial femoral artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708990","Metacarpal Bone Digit 4","C52793","The fourth of five miniature long bones located in the palm of the hand, which articulates proximally with the capitate, hamate, and third and fifth metacarpals at the carpometacarpal joint and distally with the ring finger phalanx at the metacarpophalangeal joint.","Metacarpal Bone Digit 4 | METACARPAL BONE 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225295","Ischiorectal Fossa","C103455","A tetrahedral region of adipose tissue located in the ischiorectal region with its base between the tuberosity of the ischium and the lower end of the rectum and its apex at the point where the obturator fascia and the Levator ani membrane divide.","Ischiorectal Fossa | ISCHIORECTAL FOSSA | Ischioanal Fossa",,,,,,,,,,,,,,,"4138996","Ischiorectal fossa structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3540569","Metacarpophalangeal Joint 3","C102318","A condyloid synovial joint within the third digit of the hand connecting the metacarpal to the proximal phalanx.","Metacarpophalangeal Joint 3 | MCP3 | METACARPOPHALANGEAL JOINT 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0175227","Nucleus of Diagonal Band","C97342","A brain structure that is part of the septal nuclear complex. It is connected with the hippocampus, hypothalamus and amygdala.","Nucleus of Diagonal Band | BASAL NUCLEUS/DIAGONAL BAND | NUCLEUS OF DIAGONAL BAND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224445","Vastus Medialis Muscle","C117736","The portion of the quadriceps femoris muscle group that extends medially from the intertrochanteric line of the femur to the medial aspects of the quadriceps femoris tendon and patella.","Vastus Medialis Muscle | MUSCLE, VASTUS MEDIALIS | VASTUS MEDIALIS MUSCLE",,,,,,,,,,,,,,,"4147439","Structure of vastus medialis muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0226827","Short Saphenous Vein","C33546","A superficial vein originating from the dorsal vein at the fifth toe and the dorsal venous arch of the foot and extends up the back of the leg to empty into the popliteal vein at the knee joint.","Short Saphenous Vein | SMALL SAPHENOUS VEIN",,,,,,,,,,,,,,,"4097371","Structure of small saphenous vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3541339","Metacarpophalangeal Joint 1","C102316","A condyloid synovial joint within the first digit of the hand connecting the metacarpal to the proximal phalanx.","Metacarpophalangeal Joint 1 | MCP1 | METACARPOPHALANGEAL JOINT 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830458","Distal Interphalangeal Joint 5 of the Foot","C114276","A ginglymoid (hinge) synovial joint within the fifth digit of the foot connecting the middle and distal phalanges.","Distal Interphalangeal Joint 5 of the Foot | DIP5 of the Foot | DISTAL INTERPHALANGEAL JOINT 5 OF THE FOOT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224620","Carpometacarpal Joint","C32265","The synovial joints between the carpal and metacarpal bones in the hand.","Carpometacarpal Joint | CARPOMETACARPAL JOINT",,,,,,,,,,,,,,,"4014114","Carpometacarpal joint structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3830457","Distal Interphalangeal Joint 5 of the Hand","C114274","A ginglymoid (hinge) synovial joint within the fifth digit of the hand connecting the middle and distal phalanges.","Distal Interphalangeal Joint 5 of the Hand | DIP5 of the Hand | DISTAL INTERPHALANGEAL JOINT 5 OF THE HAND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641676","Carpometacarpal Joint 2","C103913","A plane joint primarily between the second metacarpal and the trapezoid, which also connects with the trapezium and capitate.","Carpometacarpal Joint 2 | CARPOMETACARPAL JOINT 2 | CMC2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829523","Interphalangeal Joint 3 of the Foot","C114202","A ginglymoid (hinge) synovial joint between the phalanges of the third digit of the foot.","Interphalangeal Joint 3 of the Foot | INTERPHALANGEAL JOINT 3 OF THE FOOT | IP3 of the Foot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224421","Obturator Muscle","C33193","One of two muscles located in the pelvis: the obturator externus muscle or the obturator internus muscle.","Obturator Muscle | OBTURATOR MUSCLE",,,,,,,,,,,,,,,"4098432","Structure of obturator muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0588193","Femoral Shaft","C96209","The cylindrical body of the femur.","Femoral Shaft | Body of Femur | Bone structure of shaft of femur (body structure) | FEMUR SHAFT",,,,,,,,,,,,,,,"4165396","Bone structure of shaft of femur",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3830459","Distal Interphalangeal Joint 4 of the Hand","C114273","A ginglymoid (hinge) synovial joint within the fourth digit of the hand connecting the middle and distal phalanges.","Distal Interphalangeal Joint 4 of the Hand | DIP4 of the Hand | DISTAL INTERPHALANGEAL JOINT 4 OF THE HAND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152320","Body of the Corpus Callosum","C32216","An area within the corpus callosum, a white matter structure within the cleft that separates the left and right cerebral hemispheres in the mammalian brain, between the genu (anterior region) and the splenium (posterior region).","Body of the Corpus Callosum | CORPUS CALLOSUM, BODY",,,,,,,,,,,,,,,"4192116","Structure of body of corpus callosum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3827332","Proximal Interphalangeal Joint 5 of the Foot","C114208","A ginglymoid (hinge) synovial joint within the fifth digit of the foot connecting the proximal and middle phalanges.","Proximal Interphalangeal Joint 5 of the Foot | PIP5 of the Foot | PROXIMAL INTERPHALANGEAL JOINT 5 OF THE FOOT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641677","Carpometacarpal Joint 3","C103914","A plane joint between the third metacarpal and the capitate.","Carpometacarpal Joint 3 | CARPOMETACARPAL JOINT 3 | CMC3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224254","Flexor Carpi Ulnaris","C53156","A muscle in the forearm running from the humeral and ulnar heads to the ulnar side of the wrist that flexes and abducts the hand toward the ulna.","Flexor Carpi Ulnaris | FLEXOR CARPI ULNARIS MUSCLE",,,,,,,,,,,,,,,"4031186","Flexor carpi ulnaris muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL379053","Lunotriquetral Joint","C139203","The articulation between the lunate and the triquetral bones in the wrist.","Lunotriquetral Joint | TRIANGULAR-LUNATE JOINT | Triquetral-Lunate Joint | Triquetrum-Lunate Joint",,,,,,,,,,,,,,,"36695796","Structure of lunate-triquetrum joint",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3830464","Distal Interphalangeal Joint 2 of the Foot","C114198","A ginglymoid (hinge) synovial joint within the second digit of the foot connecting the middle and distal phalanges.","Distal Interphalangeal Joint 2 of the Foot | DIP2 of the Foot | DISTAL INTERPHALANGEAL JOINT 2 OF THE FOOT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456944","Coronary Sinus","C32378","The coronary vein that terminates in the right atrium and transports deoxygenated blood from the coronary circulation.","Coronary Sinus | CORONARY SINUS",,,,,,,,,,,,,,,"4234539","Coronary sinus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152319","Splenium of the Corpus Callosum","C33610","The posterior bulbous part of the corpus callosum situated, which is located anterior to the occipital lobe, and which overhangs the thalamic pulvinars, the pineal gland and tectum of the midbrain; Its fibers connect occipital and parietal cortices, as well as inferior and medial temporal regions.","Splenium of the Corpus Callosum | CORPUS CALLOSUM, SPLENIUM",,,,,,,,,,,,,,,"4051175","Structure of splenium of corpus callosum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828448","Proximal Interphalangeal Joint 4 of the Foot","C114207","A ginglymoid (hinge) synovial joint within the fourth digit of the foot connecting the proximal and middle phalanges.","Proximal Interphalangeal Joint 4 of the Foot | PIP4 of the Foot | PROXIMAL INTERPHALANGEAL JOINT 4 OF THE FOOT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890179","Pulmonary Trunk","C116918","An artery arising from the right ventricle of the heart that bifurcates into the left and right pulmonary arteries.","Pulmonary Trunk | Main Pulmonary Artery | PULMONARY TRUNK",,,,,,,,,,,,,,,"4163839","Structure of trunk of pulmonary artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0230240","Falciform Ligament","C32582","A broad, thin, crescent-shaped fold consisting of two layers of peritoneum extending from the notch of the anterior margin of the liver to the anterior abdominal wall and diaphragm.","Falciform Ligament | FALCIFORM LIGAMENT",,,,,,,,,,,,,,,"4002036","Falciform ligament structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641678","Carpometacarpal Joint 4","C103915","A plane joint between the fourth metacarpal and the hamate.","Carpometacarpal Joint 4 | CARPOMETACARPAL JOINT 4 | CMC4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0815008","Cerebral Subcortex","C98712","The layer located below the cerebral cortex that includes the forebrain, midbrain and hindbrain.","Cerebral Subcortex | CEREBRAL SUBCORTEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0223666","Inferior Pubic Ramus","C132392","The portion of the pubic ramus that lies between the superior pubic ramus and the inferior ramus of the ischium.","Inferior Pubic Ramus | INFERIOR PUBIC RAMUS",,,,,,,,,,,,,,,"4182706","Structure of inferior ramus of pubis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1711224","Metacarpal Bone Digit 5","C52792","The fifth and the most lateral of five miniature long bones located in the palm of the hand, which articulates proximally with the hamate and fourth metacarpal at the carpometacarpal joint and distally with the small finger phalanx at the metacarpophalangeal joint.","Metacarpal Bone Digit 5 | METACARPAL BONE 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542923","Interphalangeal Joint 1","C102301","A ginglymoid (hinge) synovial joint within the first digit of the hand or foot connecting the proximal and distal phalanges.","Interphalangeal Joint 1 | INTERPHALANGEAL JOINT 1 | IP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828451","Proximal Interphalangeal Joint 2 of the Hand","C114194","A ginglymoid (hinge) synovial joint within the second digit of the hand connecting the proximal and middle phalanges.","Proximal Interphalangeal Joint 2 of the Hand | PIP2 of the Hand | PROXIMAL INTERPHALANGEAL JOINT 2 OF THE HAND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640674","Distal Interphalangeal Joint 4","C102293","A ginglymoid (hinge) synovial joint within the fourth digit of the hand or foot connecting the middle and distal phalanges.","Distal Interphalangeal Joint 4 | DIP4 | DISTAL INTERPHALANGEAL JOINT 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224448","Vastus Intermedius Muscle","C117876","The portion of the quadriceps femoris muscle group that is underneath the Rectus Femoris muscle, spans and covers the upper two-thirds of the anterior and lateral surfaces of the femur, and inserts into the lateral border of the patella.","Vastus Intermedius Muscle | MUSCLE, VASTUS INTERMEDIUS | VASTUS INTERMEDIUS MUSCLE",,,,,,,,,,,,,,,"4239958","Structure of vastus intermedius muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3539929","Metacarpophalangeal Joint 2","C102317","A condyloid synovial joint within the second digit of the hand connecting the metacarpal to the proximal phalanx.","Metacarpophalangeal Joint 2 | MCP2 | METACARPOPHALANGEAL JOINT 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509277","Posterior Annulus of the Mitral Valve","C127670","The portion of the mitral valve annulus that attaches to the posterior mitral valve leaflet.","Posterior Annulus of the Mitral Valve | MITRAL VALVE, POSTERIOR ANNULUS | Mitral Valve, Posterolateral Annulus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640702","Proximal Interphalangeal Joint 3","C102333","A ginglymoid (hinge) synovial joint within the third digit of the hand or foot connecting the proximal and middle phalanges.","Proximal Interphalangeal Joint 3 | PIP3 | PROXIMAL INTERPHALANGEAL JOINT 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828449","Proximal Interphalangeal Joint 3 of the Hand","C114195","A ginglymoid (hinge) synovial joint within the third digit of the hand connecting the proximal and middle phalanges.","Proximal Interphalangeal Joint 3 of the Hand | PIP3 of the Hand | PROXIMAL INTERPHALANGEAL JOINT 3 OF THE HAND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539932","Interphalangeal Joint 2","C102302","A ginglymoid (hinge) synovial joint between the phalanges of the second digit of the hand or foot.","Interphalangeal Joint 2 | INTERPHALANGEAL JOINT 2 | IP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829522","Interphalangeal Joint 3 of the Hand","C114191","A ginglymoid (hinge) synovial joint between the phalanges of the third digit of the hand.","Interphalangeal Joint 3 of the Hand | INTERPHALANGEAL JOINT 3 OF THE HAND | IP3 of the Hand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028633","Accumbens Nucleus","C52733","A nucleus composed of neurons in the forebrain.","Accumbens Nucleus | NUCLEUS ACCUMBENS",,,,,,,,,,,,,,,"4142108","Nucleus accumbens",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3538724","Proximal Interphalangeal Joint 2","C102332","A ginglymoid (hinge) synovial joint within the second digit of the hand or foot connecting the proximal and middle phalanges.","Proximal Interphalangeal Joint 2 | PIP2 | PROXIMAL INTERPHALANGEAL JOINT 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1261079","Left Coronary Cusp of the Aortic Valve","C127638","The cusp of the aortic valve that overlies the left coronary ostium.","Left Coronary Cusp of the Aortic Valve | AORTIC VALVE, LEFT CORONARY CUSP | Aortic Valve, Left Semilunar Cusp",,,,,,,,,,,,,,,"4268458","Structure of left cusp of aortic valve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640681","Interphalangeal Joint 4","C102304","A ginglymoid (hinge) synovial joint between the phalanges of the fourth digit of the hand or foot.","Interphalangeal Joint 4 | INTERPHALANGEAL JOINT 4 | IP4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509276","Anterior Annulus of the Mitral Valve","C127668","The portion of the mitral valve annulus that attaches to the anterior mitral valve leaflet, and also forms the mitral portion of the aortic-mitral curtain.","Anterior Annulus of the Mitral Valve | MITRAL VALVE, ANTERIOR ANNULUS | Mitral Valve, Anteroseptal Annulus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003484","Abdominal Aorta","C32038","The portion of the descending aorta that lies within the abdomen, beginning below the diaphragm and ending at its division into the right and left common iliac arteries.","Abdominal Aorta | ABDOMINAL AORTA | Abdominal aorta",,,,,,,,,,,,,,,"4301737","Abdominal aorta structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0458580","Tracheobronchial Tree","C117875","An anatomical structure comprising of trachea, bronchi, and bronchioles that terminate with the alveolar ducts, sacs, and alveoli.","Tracheobronchial Tree | TRACHEOBRONCHIAL TREE",,,,,,,,,,,,,,,"4241273","Tracheobronchial structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513186","Posterior Annulus of the Tricuspid Valve","C130169","The portion of the tricuspid valve annulus that attaches to both the posterior and lateral tricuspid valve leaflets.","Posterior Annulus of the Tricuspid Valve | TRICUSPID VALVE, POSTERIOR ANNULUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225892","Right Ventricular Outflow Tract","C127648","The funnel-shaped structure through which blood flows from the right ventricle into the pulmonary trunk.","Right Ventricular Outflow Tract | HEART, RIGHT VENTRICULAR OUTFLOW TRACT",,,,,,,,,,,,,,,"4259006","Structure of outflow tract of right ventricle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0226024","Suprarenal Aorta","C130168","The portion of the abdominal aorta superior to the renal arteries.","Suprarenal Aorta | SUPRARENAL AORTA",,,,,,,,,,,,,,,"4078917","Structure of suprarenal aorta",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0588196","Fibular Shaft","C120670","The elongated bony body of a fibula compressing of the anterior, posterior, internal and external surfaces separated by the anteroexternal, anterointernal, posteroexternal and posterointernal borders.","Fibular Shaft | FIBULA SHAFT",,,,,,,,,,,,,,,"4014541","Bone structure of shaft of fibula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508897","Left Ventricular Mid Inferolateral Segment","C127665","The inferolateral portion of the mid-cavity division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).","Left Ventricular Mid Inferolateral Segment | LEFT VENTRICULAR MID INFEROLATERAL SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509326","Scaphoid-Lunate-Capitate Joint","C127677","A condyloid synovial joint within the wrist connecting the scaphoid, lunate, and capitate bones.","Scaphoid-Lunate-Capitate Joint | SCAPHOID-LUNATE-CAPITATE JOINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0588199","Tibial Shaft","C120675","The triangular prismoid, elongated bony body of a tibia compressing of the anterior, posterior and external surfaces separated by the anterior, posterior and interosseous borders.","Tibial Shaft | TIBIA SHAFT",,,,,,,,,,,,,,,"4199608","Bone structure of shaft of tibia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521202","Left Lung, Inferior Lobe, Superior Segment","C132397","The superior segment of the inferior lobe of the left lung.","Left Lung, Inferior Lobe, Superior Segment | LUNG, LEFT, INFERIOR LOBE, SUPERIOR SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152306","Precuneus","C112399","The medial aspect of the posterior parietal lobe, which is bounded anteriorly by the marginal branch of the cingulate sulcus, posteriorly by the medial portion of the parieto-occipital fissure and inferiorly by the subparietal sulcus. It is involved in a wide range of higher-order cognitive function, such as episodic memory, visuospatial processing, reflections upon self, and aspects of consciousness.","Precuneus | PRECUNEUS",,,,,,,,,,,,,,,"4066417","Structure of precuneus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0225895","Right Ventricular Endocardium","C102343","The innermost layer of endothelial cells and connective tissue that lines the right ventricle.","Right Ventricular Endocardium | RIGHT VENTRICULAR ENDOCARDIUM",,,,,,,,,,,,,,,"4102981","Structure of endocardium of right ventricle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508888","Left Ventricular Basal Anterolateral Segment","C127656","The anterolateral portion of the basal division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).","Left Ventricular Basal Anterolateral Segment | LEFT VENTRICULAR BASAL ANTEROLATERAL SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL378831","Sinotubular Junction","C127642","The terminus of the aortic root; the point at which the aorta attains a tubular configuration.","Sinotubular Junction | ASCENDING AORTA, SINOTUBULAR JUNCTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026638","Sublingual Region","C102349","The area directly beneath the tongue.","Sublingual Region | SUBLINGUAL REGION",,,,,,,,,,,,,,,"4005977","Sublingual region structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897357","Tibioperoneal Arterial Trunk","C116182","An arterial trunk that contains parts of the posterior tibial artery and fibular artery.","Tibioperoneal Arterial Trunk | TIBIO-PERONEAL TRUNK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226045","Right Coronary Artery Ostium","C116169","The opening of the right coronary artery at its origin.","Right Coronary Artery Ostium | RIGHT CORONARY ARTERY OSTIUM",,,,,,,,,,,,,,,"4209012","Structure of ostium of right coronary artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508894","Left Ventricular Mid Anterolateral Segment","C127662","The anterolateral portion of the mid-cavity division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).","Left Ventricular Mid Anterolateral Segment | LEFT VENTRICULAR MID ANTEROLATERAL SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900019","Aortoiliac Artery Segment","C116166","The segment of the arterial system that includes the iliac artery and its origin from the aorta.","Aortoiliac Artery Segment | AORTO-ILIAC PERIPHERAL ARTERY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229762","Diaphragmatic Lymph Node","C132391","Lymph node located adjacent to the diaphragm.","Diaphragmatic Lymph Node | DIAPHRAGMATIC LYMPH NODE | Structure of diaphragmatic lymph node (body structure)",,,,,,,,,,,,,,,"4024991","Structure of diaphragmatic lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508885","Left Ventricular Apical Lateral Segment","C127653","The lateral portion of the apical division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).","Left Ventricular Apical Lateral Segment | LEFT VENTRICULAR APICAL LATERAL SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898617","Left Anterior Descending Artery Ostium","C116175","The opening of the left anterior descending coronary artery at its origin.","Left Anterior Descending Artery Ostium | LEFT ANTERIOR DESCENDING ARTERY OSTIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898614","Left Main Coronary Artery Bifurcation","C116174","The portion of the distal end of the left main coronary artery that branches into the left anterior descending artery and the left circumflex artery.","Left Main Coronary Artery Bifurcation | LEFT MAIN CORONARY ARTERY BIFURCATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521204","Left Lung, Superior Lobe, Apicoposterior Segment","C132399","The apicoposterior segment of the superior lobe of the left lung.","Left Lung, Superior Lobe, Apicoposterior Segment | LUNG, LEFT, SUPERIOR LOBE, APICOPOSTERIOR SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508889","Left Ventricular Basal Anteroseptal Segment","C127657","The anteroseptal portion of the basal division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).","Left Ventricular Basal Anteroseptal Segment | LEFT VENTRICULAR BASAL ANTEROSEPTAL SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225721","Right Lung, Middle Lobe, Medial Segment","C132408","The medial segment of the middle lobe of the right lung.","Right Lung, Middle Lobe, Medial Segment | LUNG, RIGHT, MIDDLE LOBE, MEDIAL SEGMENT",,,,,,,,,,,,,,,"4144698","Structure of medial segment of middle lobe of right lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897696","Right Ventricular Branch of Right Coronary Artery","C116171","The branch of the right coronary artery that supplies blood to the right ventricular wall.","Right Ventricular Branch of Right Coronary Artery | RIGHT VENTRICULAR BRANCH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521377","Rectosigmoid Colon","C103438","A portion of the large intestine that includes the sigmoid colon and rectum.","Rectosigmoid Colon | COLON, RECTOSIGMOID",,,,,,,,,,,,,,,"4218247","Rectosigmoid structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508884","Left Ventricular Apical Inferior Segment","C127652","The inferior portion of the apical division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).","Left Ventricular Apical Inferior Segment | LEFT VENTRICULAR APICAL INFERIOR SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641267","Upper Cervical Lymph Node","C103447","A lymph node located in the upper region of the neck. (NCI)","Upper Cervical Lymph Node | UPPER CERVICAL LYMPH NODE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508895","Left Ventricular Mid Anteroseptal Segment","C127663","The anteroseptal portion of the mid-cavity division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).","Left Ventricular Mid Anteroseptal Segment | LEFT VENTRICULAR MID ANTEROSEPTAL SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520243","Right Lung, Inferior Lobe, Posterior Basal Segment","C132405","The posterior basal segment of the inferior lobe of the right lung.","Right Lung, Inferior Lobe, Posterior Basal Segment | LUNG, RIGHT, INFERIOR LOBE, POSTERIOR BASAL SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520368","Periventricular Region","C132390","The area surrounding the ventricles of the brain.","Periventricular Region | BRAIN, PERIVENTRICULAR REGION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512363","HLA-A23 Antibody Measurement","C128953","The determination of the amount of HLA-A23 antibody present in a sample.","HLA-A23 Antibody Measurement | HLA-A23 Antibody | HLAA23A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545239","Creatinine Clearance Adjusted for BSA","C147324","The determination of the clearance of creatinine and whose result is adjusted for body surface area.","Creatinine Clearance Adjusted for BSA | CRTCLRBS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545255","Penicillium chrysogenum IgE Antibody Measurement","C147287","The determination of the amount of Penicillium chrysogenum IgE antibody present in a sample.","Penicillium chrysogenum IgE Antibody Measurement | Penicillium chrysogenum IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542405","CD3 Expressing Cell Count","C103809","The determination of the amount of the CD3 expressing cells in a sample.","CD3 Expressing Cell Count | CD3 | CD3 Expressing Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552584","Sodium Excretion Rate","C150823","A determination of the amount of sodium being excreted in a biological specimen over a defined period of time.","Sodium Excretion Rate | SODMEXR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552576","Calcium Excretion Rate","C150815","A determination of the amount of calcium being excreted in a biological specimen over a defined period of time.","Calcium Excretion Rate | CAEXR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512350","Free Testosterone to Total Protein Ratio Measurement","C128980","The determination of the ratio of free testosterone compared to total protein present in a sample. The measurement may be expressed as a ratio or percentage.","Free Testosterone to Total Protein Ratio Measurement | TSTSFRPT | Testosterone, Free/Total Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202361","Clonazepam Measurement","C139082","The determination of the amount of clonazepam present in a sample.","Clonazepam Measurement | CLNZPM | Clonazepam",,,,,,,,,,,,,,,"4195577","Clonazepam measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0391940","Fructose Measurement","C147342","The determination of the amount of fructose present in a sample.","Fructose Measurement | FRUCTOSE | Fructose",,,,,,,,,,,,,,,"4018311","Fructose measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545260","Albumin Clearance","C147293","The determination of the clearance of endogenous albumin, used for evaluating the glomerular filtration rate.","Albumin Clearance | ALBC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524137","Flunitrazepam Measurement","C139081","The determination of the amount of flunitrazepam present in a sample.","Flunitrazepam Measurement | FLNTRZPM | Flunitrazepam",,,,,,,,,,,,,,,"4019675","Flunitrazepam measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1295054","Human leukocyte antigen (HLA) B antigen typing (procedure)","C128957","The determination of the amount of human leukocyte antigen, class I, group B (HLA-B), present in a sample.","HLA-B Antigen Type | HLABAGT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552598","Dysmorphic Erythrocytes to Erythrocytes Ratio Measurement","C150839","The determination of the ratio of dysmorphic erythrocytes compared to total erythrocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Dysmorphic Erythrocytes to Erythrocytes Ratio Measurement | Dysmorphic Erythrocytes/Erythrocytes | RBCDYRBC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202308","Methanol Measurement","C147394","The determination of the amount of methanol present in a sample.","Methanol Measurement | METHANOL | Methanol",,,,,,,,,,,,,,,"4212375","Alcohol, methyl measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3540683","CD19 Expressing Cell Count","C103808","The determination of the amount of the CD19 expressing cells in a sample.","CD19 Expressing Cell Count | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545311","Thyroglobulin Recovery Rate","C147435","The determination of the thyroglobulin recovery rate present in a sample.","Thyroglobulin Recovery Rate | TGLOBRR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545964","Tetrahydrocannabinol Measurement","C147436","The determination of the amount of tetrahydrocannabinol present in a sample.","Tetrahydrocannabinol Measurement | Delta-9-Tetrahydrocannabinol | THC | Tetrahydrocannabinol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546026","Carboxyhemoglobin to Total Hemoglobin Ratio Measurement","C147355","The determination of the ratio of carboxyhemoglobin compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.","Carboxyhemoglobin to Total Hemoglobin Ratio Measurement | Carboxyhemoglobin/Total Hemoglobin | HBCOHGB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0552809","IgG Synthesis Rate","C147375","The determination of the IgG synthesis rate in a biological specimen.","IgG Synthesis Rate | IGGSYNRT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522809","Hemoglobin Tetramer Measurement","C135425","The determination of the amount of hemoglobin tetramer in a biological sample.","Hemoglobin Tetramer Measurement | HGBTET | Hemoglobin Tetramer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698027","Matrix Metalloproteinase 8 Measurement","C80196","The determination of the amount of matrix metalloproteinase 8 present in a sample.","Matrix Metalloproteinase 8 Measurement | MMP8 | Matrix Metalloproteinase 8 | Neutrophil Collagenase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540283","Neurofilament Light Chain Protein Measurement","C142285","The determination of the amount of neurofilament light chain protein present in a sample.","Neurofilament Light Chain Protein Measurement | NEFL | NEFL Protein Measurement | NF-L | NFLP | Neurofilament Light Chain Protein | Neurofilament Light Polypeptide | Protein Phosphatase 1, Regulatory Subunit 110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825865","Aspartate Aminotransferase Antigen Measurement","C81978","The determination of the amount of aspartate aminotransferase antigen present in a sample.","Aspartate Aminotransferase Antigen Measurement | ASTAG | Aspartate Aminotransferase Antigen | SGOT Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897012","Tartrate-Resistant Acid Phosphatase 5b Measurement","C117865","The determination of the amount of tartrate-resistant acid phosphatase 5b present in a sample.","Tartrate-Resistant Acid Phosphatase 5b Measurement | TRACP5B | TRAP5B | Tartrate-Resistant Acid Phosphatase 5b | Tartrate-Resistant Acid Phosphatase Type 5b Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0200655","Erythrocyte Cell Morphology","C92296","An examination or assessment of the form and structure of red blood cells.","Erythrocyte Cell Morphology | RBC Morphology | RBCMORPH | Red Blood Cell Morphology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546007","Nonhematic Cells Count","C147401","The determination of the amount of nonhematic cells present in a sample.","Nonhematic Cells Count | NHMCE | Nonhematic Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006950","Carbamazepine Measurement","C147322","The determination of the amount of carbamazepine present in a sample.","Carbamazepine Measurement | CRBMZPN | Carbamazepine",,,,,,,,,,,,,,,"4336243","Carbamazepine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552593","Abnormal Cells to Leukocytes Ratio Measurement","C150834","The determination of the ratio of abnormal cells compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Abnormal Cells to Leukocytes Ratio Measurement | ABNCELE | Abnormal Cells/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524249","Prazepam Measurement","C139080","The determination of the amount of prazepam present in a sample.","Prazepam Measurement | PRZPM | Prazepam",,,,,,,,,,,,,,,"4019699","Prazepam measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545285","IgG Clearance","C147373","The determination of the clearance of endogenous IgG, used for evaluating the glomerular filtration rate.","IgG Clearance | IGGC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550422","Anion Gap 4 Measurement","C147304","The determination of the amount of unmeasured anions (computed as the difference between the sum of serum sodium and serum potassium, and the sum of the serum bicarbonate and chloride) present in a sample.","Anion Gap 4 Measurement | ANIONG4 | Anion Gap 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033016","Pregnenolone Measurement","C147421","The determination of the amount of pregnenolone present in a sample.","Pregnenolone Measurement | PRGNENLN | Pregnenolone",,,,,,,,,,,,,,,"4019987","Pregnenolone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526575","Toxoplasma gondii IgM Antibody Measurement","C139090","The determination of the amount of Toxoplasma gondii IgM antibody present in a sample.","Toxoplasma gondii IgM Antibody Measurement | TGNIGMAB | Toxoplasma gondii IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545287","Intact Choriogonadotropin Measurement","C147361","The determination of the amount of intact choriogonadotropin present in a sample.","Intact Choriogonadotropin Measurement | Choriogonadotropin, Intact | HCGNDI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524018","Free Protoporphyrin Measurement","C147341","The determination of the amount of free protoporphyrin present in a sample.","Free Protoporphyrin Measurement | FPP | Protoporphyrin, Free",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523590","Cystathionine Measurement","C147331","The determination of the amount of cystathionine present in a sample.","Cystathionine Measurement | CYSTHION | Cystathionine",,,,,,,,,,,,,,,"4019554","Cystathionine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL546045","Xanthochromia Measurement","C147449","The determination of the amount of xanthochromia present in a sample.","Xanthochromia Measurement | XNTHCHR | Xanthochromia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550436","Oxyhemoglobin to Total Hemoglobin Ratio Measurement","C147359","The determination of the ratio of oxyhemoglobin compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.","Oxyhemoglobin to Total Hemoglobin Ratio Measurement | FO2 Hb | Fractioned Oxyhemoglobin | HBOXHGB | Oxyhemoglobin/Total Hemoglobin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526576","Toxoplasma gondii IgG Antibody Measurement","C139089","The determination of the amount of Toxoplasma gondii IgG antibody present in a sample.","Toxoplasma gondii IgG Antibody Measurement | TGNIGGAB | Toxoplasma gondii IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545301","Zika Virus Antibody Measurement","C147451","The determination of the amount of Zika virus antibody present in a sample.","Zika Virus Antibody Measurement | ZKVAB | Zika Virus Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545241","Basophilic Erythroblast Count","C147311","The determination of the amount of basophilic erythroblasts present in a sample from an experimental organism.","Basophilic Erythroblast Count | BLASTERY | Basophilic Erythroblast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524174","Medazepam Measurement","C139079","The determination of the amount of medazepam present in a sample.","Medazepam Measurement | MDZPM | Medazepam",,,,,,,,,,,,,,,"4020386","Medazepam measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL546028","Hemoglobin O-Arab to Total Hemoglobin Ratio Measurement","C147358","The determination of the ratio of hemoglobin O-Arab compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.","Hemoglobin O-Arab to Total Hemoglobin Ratio Measurement | HBOARBHB | Hemoglobin O-Arab/Total Hemoglobin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552600","Free Estradiol Measurement","C150842","The determination of the amount of free estradiol present in a sample.","Free Estradiol Measurement | ESTFR | Estradiol, Free",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526975","Lymphoid Cell Count","C139064","The determination of the amount of lymphoid cells present in a sample.","Lymphoid Cell Count | LYMPHOID | Lymphoid Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829588","Humeral Epicondyle","C114187","A bone prominence at the distal end of the humerus to which ligaments and tendons of the joints are attached.","Humeral Epicondyle | HUMERAL EPICONDYLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2950548","Presacral Space","C132414","The potential body space formed between the rectum and the sacrum.","Presacral Space | PRESACRAL SPACE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225951","Posterior Cusp of the Mitral Valve","C127671","The cusp of the mitral valave that is located posterior to the two commissures, and which has no attachement to the aortic root.","Posterior Cusp of the Mitral Valve | MITRAL VALVE, POSTERIOR CUSP",,,,,,,,,,,,,,,"4212609","Structure of posterior leaflet of mitral valve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509325","Scaphoid-Capitate Joint","C127676","A condyloid synovial joint within the wrist connecting the scaphoid bone to the capitate bone.","Scaphoid-Capitate Joint | SCAPHOID-CAPITATE JOINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0223554","Fifth Lumbar Spinous Process","C116163","The spinous process of the 5th lumbar vertebra.","Fifth Lumbar Spinous Process | 5TH LUMBAR SPINOUS PROCESS",,,,,,,,,,,,,,,"4140359","Structure of spinous process of fifth lumbar vertebra",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227488","Quadrate Lobe of Liver","C112404","An oblong shaped area of the liver that is situated inferior to the right lobe, bounded by the anterior margin of the liver and the porta hepatis.","Quadrate Lobe of Liver | LIVER, QUADRATE LOBE | Quadrate Lobe",,,,,,,,,,,,,,,"4098129","Structure of quadrate lobe of liver",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508883","Left Ventricular Apical Anterior Segment","C127651","The anterior portion of the apical division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).","Left Ventricular Apical Anterior Segment | LEFT VENTRICULAR APICAL ANTERIOR SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226335","Accessory Renal Artery","C116183","An additional renal artery originating from the aorta. Accessory renal arteries are found in 26-30% of humans.","Accessory Renal Artery | ACCESSORY RENAL ARTERY",,,,,,,,,,,,,,,"4310542","Accessory renal artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL520909","Periureteral Region","C132412","The area surrounding the ureter.","Periureteral Region | PERIURETERAL REGION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278463","Iliac Fossa","C103454","The large smooth and concave surface of the ilium.","Iliac Fossa | ILIAC FOSSA",,,,,,,,,,,,,,,"4222476","Iliac fossa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508959","Pericardial Wall","C127672","The wall of the pericardium, comprising the following tissue layers: the fibrous pericardium; the parietal and visceral layers of the serous pericardium.","Pericardial Wall | PERICARDIAL WALL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520246","Right Lung, Superior Lobe, Apical Segment","C132410","The apical segment of the superior lobe of the right lung.","Right Lung, Superior Lobe, Apical Segment | LUNG, RIGHT, SUPERIOR LOBE, APICAL SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898615","Left Circumflex Artery Ostium","C116176","The opening of the left circumflex artery at its origin.","Left Circumflex Artery Ostium | LEFT CIRCUMFLEX ARTERY OSTIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520247","Right Lung, Superior Lobe, Posterior Segment","C132411","The posterior segment of the superior lobe of the right lung.","Right Lung, Superior Lobe, Posterior Segment | LUNG, RIGHT, SUPERIOR LOBE, POSTERIOR SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508896","Left Ventricular Mid Inferior Segment","C127664","The inferior portion of the mid-cavity division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).","Left Ventricular Mid Inferior Segment | LEFT VENTRICULAR MID INFERIOR SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546030","Hemoglobin A2 Prime to Total Hemoglobin Ratio Measurement","C147353","The determination of the ratio of hemoglobin A2 prime compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.","Hemoglobin A2 Prime to Total Hemoglobin Ratio Measurement | HBA2PHB | Hemoglobin A2 Prime/Total Hemoglobin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523997","Acetone Measurement","C147288","The determination of the amount of acetone present in a sample.","Acetone Measurement | ACETONE | Acetone",,,,,,,,,,,,,,,"4021304","Acetone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512310","Prorubricyte to Total Cell Ratio Measurement","C128977","The determination of the ratio of the prorubricytes compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Prorubricyte to Total Cell Ratio Measurement | PRORUBCE | Prorubricyte/Total Cells | Prorubricytes to Total Cells Ratio Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523364","Gliadin IgA Antibody Measurement","C147348","The determination of the amount of gliadin IgA antibody present in a sample.","Gliadin IgA Antibody Measurement | GLDIGAAB | Gliadin IgA Antibody",,,,,,,,,,,,,,,"4014757","Gliadin antibody, IgA measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545238","Endomysial IgA Antibody Measurement","C147334","The determination of the amount of endomysial IgA antibody present in a sample.","Endomysial IgA Antibody Measurement | EDMIGAAB | Endomysial IgA Antibody | Endomysium IgA Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225926","Tricuspid Valve Annulus","C130047","A fibrous membrane that attaches to, and provides support for, the tricuspid valve leaflets.","Tricuspid Valve Annulus | TRICUSPID VALVE ANNULUS",,,,,,,,,,,,,,,"4011864","Structure of annulus fibrosus of tricuspid orifice",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521200","Left Lung, Inferior Lobe, Medial Basal Segment","C132395","The medial basal segment of the inferior lobe of the left lung.","Left Lung, Inferior Lobe, Medial Basal Segment | LUNG, LEFT, INFERIOR LOBE, MEDIAL BASAL SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0175196","Entorhinal Cortex","C97338","A brain region in the medial temporal lobe near the hippocampus.","Entorhinal Cortex | ENTORHINAL CORTEX",,,,,,,,,,,,,,,"4214471","Structure of entorhinal cortex",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL520060","Middle Jugular Lymph Node Group (Level III)","C132511","Lymph nodes located around the middle third of the internal jugular vein, extending from the inferior border of the hyoid bone (above) to the inferior border of the cricoid cartilage (below). The anterior (medial) boundary is the lateral border of the sternohyoid muscle, and the posterior (lateral) boundary is the posterior border of the sternocleidomastoid muscle. These nodes are at greatest risk for harboring metastases from cancers arising from the oral cavity, nasopharynx, oropharynx, hypopharynx, and larynx. (AJCC 8th ed.)","Middle Jugular Lymph Node Group (Level III) | MID-JUGULAR LYMPH NODE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0223613","Sacral Tuberosity","C105447","The prominence on the lateral surface of the sacrum, posterior to the auricular surface of the sacrum.","Sacral Tuberosity | SACRAL TUBEROSITY",,,,,,,,,,,,,,,"4261672","Structure of sacral tuberosity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0229697","Superficial Lymph Node","C102716","A lymph node located in a superficial part of the body.","Superficial Lymph Node | SUPERFICIAL LYMPH NODE",,,,,,,,,,,,,,,"4235872","Structure of superficial lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508887","Left Ventricular Basal Anterior Segment","C127655","The anterior portion of the basal division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).","Left Ventricular Basal Anterior Segment | LEFT VENTRICULAR BASAL ANTERIOR SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0223656","Ischial Tuberosity","C105446","The bony prominence of the lower part of the ischium.","Ischial Tuberosity | ISCHIAL TUBEROSITY",,,,,,,,,,,,,,,"4288849","Ischial tuberosity structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0225957","Aortic Valve Annulus","C130167","A fibrous membrane that attaches to, and provides support for, the aortic valve leaflets.","Aortic Valve Annulus | AORTIC VALVE ANNULUS",,,,,,,,,,,,,,,"4300290","Structure of annulus fibrosus of aorta",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0582800","Femoral Condyle","C114186","A rounded bony projection at the distal end of the femur.","Femoral Condyle | FEMORAL CONDYLE",,,,,,,,,,,,,,,"4121684","Condyle of femur",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1295169","Kappa Light Chain Measurement","C147379","The determination of the amount of kappa light chain present in a sample.","Kappa Light Chain Measurement | KAPPALC | Kappa Light Chain",,,,,,,,,,,,,,,"4005508","Kappa light chain measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL520242","Right Lung, Inferior Lobe, Medial Basal Segment","C132404","The medial basal segment of the inferior lobe of the right lung.","Right Lung, Inferior Lobe, Medial Basal Segment | LUNG, RIGHT, INFERIOR LOBE, MEDIAL BASAL SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545286","Free Choriogonadotropin Beta Measurement","C147360","The determination of the amount of free choriogonadotropin beta present in a sample.","Free Choriogonadotropin Beta Measurement | Choriogonadotropin Beta, Free | HCGFR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0588204","Ulnar Shaft","C120676","The prismatic, elongated bony body of an ulna which curves from behind forwards, and compresses of the anterior, posterior and external surfaces separated by the anterior, posterior and interosseous borders. The distal portion of the shaft is rounded, smooth and bents outward.","Ulnar Shaft | ULNA SHAFT",,,,,,,,,,,,,,,"4055984","Bone structure of shaft of ulna",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0486334","Anion Gap 3 Measurement","C147303","The determination of the amount of unmeasured anions (computed as sodium minus the chloride and bicarbonate) present in a sample.","Anion Gap 3 Measurement | ANIONG3 | Anion Gap 3",,,,,,,,,,,,,,,"45766348","Anion gap based on sodium, chloride and bicarbonate ions",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508901","Left Ventricular Outflow Tract","C127644","The funnel-shaped structure through which blood flows from the left ventricle into the aortic root.","Left Ventricular Outflow Tract | HEART, LEFT VENTRICULAR OUTFLOW TRACT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512341","B-lymphocyte Crossmatch Measurement","C128951","The determination of the HLA histocompatibility between the donor and the study subject by examining the presence or absence of the subject's anti-HLA antibody reactivity towards HLA antigens expressed on the donor B-lymphocytes.","B-lymphocyte Crossmatch Measurement | B-lymphocyte Crossmatch | BLYMXM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640697","Mid-Distal Left Anterior Descending Coronary Artery and All Diagonal Coronary Branches","C102327","All of the arterial branches distal to the proximal left anterior descending coronary artery.","Mid-Distal Left Anterior Descending Coronary Artery and All Diagonal Coronary Branches | MID/DISTAL LEFT ANTERIOR DESCENDING CORONARY ARTERY AND ALL DIAGONAL CORONARY BRANCHES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546056","Hemoglobin Barts to Total Hemoglobin Ratio Measurement","C147354","The determination of the ratio of hemoglobin Barts compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.","Hemoglobin Barts to Total Hemoglobin Ratio Measurement | HBBARTHB | Hemoglobin Barts/Total Hemoglobin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897814","Proximal Urethra","C115335","The part of the urethra that is closer to the bladder.","Proximal Urethra | PROXIMAL URETHRA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640671","Costochondral Joint 7","C102289","The seventh hyaline cartilaginous joint between the ribs and costal cartilage.","Costochondral Joint 7 | COSTOCHONDRAL JOINT 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0588210","Humeral Shaft","C120671","The cylindrical, elongated bony body of a humerus compressing of the anterior, posterior and external surfaces separated by the anterior, posterior and interosseous borders. The distal portion of the shaft becomes more prismatic and flattened.","Humeral Shaft | HUMERUS SHAFT",,,,,,,,,,,,,,,"4049370","Bone structure of shaft of humerus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545262","Cow Milk Protein Antigen IgE Antibody Measurement","C147280","The determination of the amount of cow milk protein antigen IgE antibody present in a sample.","Cow Milk Protein Antigen IgE Antibody Measurement | C147280 | Cow Milk Protein Antigen IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546034","Hemoglobin G Coushatta to Total Hemoglobin Ratio Measurement","C147356","The determination of the ratio of hemoglobin G compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.","Hemoglobin G Coushatta to Total Hemoglobin Ratio Measurement | HBGCHTHB | Hemoglobin G Coushatta/Total Hemoglobin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554576","Nucleated Cell Count","C150841","The determination of the amount of nucleated cells present in a sample.","Nucleated Cell Count | NUCCE | Nucleated Cells | Total Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266533","Fluvoxamine Measurement","C147340","The determination of the amount of fluvoxamine present in a sample.","Fluvoxamine Measurement | FLUVOXAM | Fluvoxamine",,,,,,,,,,,,,,,"4006014","Fluvoxamine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552597","Cylindroid Cast Measurement","C150838","The determination of the amount of cylindroid casts present in a sample.","Cylindroid Cast Measurement | CSCYL | Cylindroid Casts | Cylindroid Pseudocasts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526573","HIV-1/2 Antibody and HIV-1 p24 Antigen Measurement","C139085","The determination of the amount of either the HIV-1 or HIV-2 virus and the determination of HIV-1 p24 antigen present in a sample.","HIV-1/2 Antibody and HIV-1 p24 Antigen Measurement | HIV-1/2 Antibody + HIV-1 p24 Antigen | HIV12P24",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4034373","Liver Fibrosis Score","C147385","The determination of the liver pathology through the assessment of multiple blood test parameters, taking into account the age and gender of the patient.","Liver Fibrosis Score | LVFBRSC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266559","Hydroxyalprazolam Measurement","C147352","The determination of the amount of hydroxyprazolam present in a sample.","Hydroxyalprazolam Measurement | HALPRZLM | Hydroxyalprazolam",,,,,,,,,,,,,,,"4047938","Hydroxyalprazolam measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523720","Free Insulin Measurement","C147377","The determination of the amount of free insulin present in a sample.","Free Insulin Measurement | INSLNFR | Insulin, Free",,,,,,,,,,,,,,,"4020992","Insulin, free measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3274405","Herpes Simplex Virus 1 IgM Antibody Measurement","C98738","The determination of the amount of herpes simplex virus 1 IgM antibody present in a sample.","Herpes Simplex Virus 1 IgM Antibody Measurement | HS1IGMAB | Herpes Simplex Virus 1 IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274406","Herpes Simplex Virus 2 IgM Antibody Measurement","C98739","The determination of the amount of herpes simplex virus 2 IgM antibody present in a sample.","Herpes Simplex Virus 2 IgM Antibody Measurement | HS2IGMAB | Herpes Simplex Virus 2 IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2363836","Natural Killer Cell Count","C98762","The determination of the amount of natural killer cells present in a sample.","Natural Killer Cell Count | NKCE | Natural Killer Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523851","Basophilic Metamyelocyte Count","C135399","The determination of the amount of basophilic metamyelocytes present in a sample.","Basophilic Metamyelocyte Count | BASOMM | Basophilic Metamyelocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512358","HLA Class II Antibody Measurement","C128965","The determination of the amount of HLA class II antibody present in a sample.","HLA Class II Antibody Measurement | HLA Class II Antibody | HLAIIAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899141","Femoropopliteal Artery Segment","C116167","The segment of the arterial system that includes the popliteal artery and its origin from the femoral artery.","Femoropopliteal Artery Segment | FEMORO-POPLITEAL PERIPHERAL ARTERY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521205","Left Lung, Superior Lobe, Inferior Lingular Segment","C132400","The inferior lingual segment of the superior lobe of the left lung.","Left Lung, Superior Lobe, Inferior Lingular Segment | LUNG, LEFT, SUPERIOR LOBE, INFERIOR LINGULAR SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641262","Posterior Cervical Lymph Node","C103428","A lymph node located in the posterior region of the neck. (NCI)","Posterior Cervical Lymph Node | POSTERIOR CERVICAL LYMPH NODE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640707","Right Coronary Artery and its Branches","C102340","The right coronary artery and all of its branches, including the right posterior descending, right posterolateral and acute marginal branches.","Right Coronary Artery and its Branches | RIGHT CORONARY ARTERY, RIGHT POSTERIOR DESCENDING, RIGHT POSTERIOLATERAL AND ACUTE MARGINAL BRANCHES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508882","Left Ventricular Apex Segment","C127650","The apical cap division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).","Left Ventricular Apex Segment | LEFT VENTRICULAR APEX SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897873","Posterolateral Coronary Artery","C116170","In an individual with a right-dominant heart, the arterial branch that arises from the distal right coronary artery in the posterior atrioventricular groove after the origin of the right posterior descending artery.","Posterolateral Coronary Artery | POSTEROLATERAL SEGMENTAL ARTERY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640670","Costochondral Joint 1","C102288","The first hyaline cartilaginous joint between the ribs and costal cartilage.","Costochondral Joint 1 | COSTOCHONDRAL JOINT 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225855","Right Atrial Endocardium","C102339","The innermost layer of endothelial cells and connective tissue that lines the right atrium.","Right Atrial Endocardium | RIGHT ATRIAL ENDOCARDIUM",,,,,,,,,,,,,,,"4136804","Endocardium of right atrium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521198","Left Lung, Inferior Lobe, Anterior Basal Segment","C132393","The anterior basal segment of the inferior lobe of the left lung.","Left Lung, Inferior Lobe, Anterior Basal Segment | LUNG, LEFT, INFERIOR LOBE, ANTERIOR BASAL SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224718","Transverse tarsal joint","C102354","A combination of syndesmosis and synovial joints formed by the articulation of the talus with the navicular and the calcaneus with the cuboid.","Transverse Tarsal Joint | Mid-Tarsal Joint | TRANSVERSE TARSAL JOINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0175412","Pars Compacta","C97341","A part of the substantia nigra. The pars compacta nerve cells contain melanin and are involved in motor control.","Pars Compacta | PARS COMPACTA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697766","Interleukin 18 Measurement","C74814","The determination of the amount of interleukin 18 present in a sample.","Interleukin 18 Measurement | INTLK18 | Interleukin 18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521199","Left Lung, Inferior Lobe, Lateral Basal Segment","C132394","The lateral basal segment of the inferior lobe of the left lung.","Left Lung, Inferior Lobe, Lateral Basal Segment | LUNG, LEFT, INFERIOR LOBE, LATERAL BASAL SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640662","Hematocrit Corrected Reticulocytes to Erythrocytes Ratio Measurement","C102274","A relative measurement (ratio or percentage) of the hematocrit corrected reticulocytes to erythrocytes present in a sample.","Hematocrit Corrected Reticulocytes to Erythrocytes Ratio Measurement | HCT Corrected Reticulocytes/Erythrocytes | RETCRRBC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521203","Left Lung, Superior Lobe, Anterior Segment","C132398","The anterior segment of the superior lobe of the left lung.","Left Lung, Superior Lobe, Anterior Segment | LUNG, LEFT, SUPERIOR LOBE, ANTERIOR SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899633","Cholera Toxin B Subunit IgG Antibody Measurement","C116194","The determination of the amount of cholera toxin B subunit IgG antibody present in a sample.","Cholera Toxin B Subunit IgG Antibody Measurement | CTBIGGAB | Cholera Toxin B Subunit IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242690","Tibialis Anterior Muscle","C117874","A muscle that originates from the lateral condyle of tibia, spans the upper two-thirds of the lateral surface of the tibia, and is attached to the first cuneiform and metatarsal bones of the foot. It is a dorsiflexor of the ankle and invertor of the foot.","Tibialis Anterior Muscle | MUSCLE, TIBIALIS ANTERIOR | TIBIALIS ANTERIOR MUSCLE",,,,,,,,,,,,,,,"4251190","Tibialis anterior muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524150","Hydrocodone Measurement","C74879","The determination of the amount of hydrocodone present in a sample.","Hydrocodone Measurement | HYDCDN | Hydrocodone",,,,,,,,,,,,,,,"4022980","Hydrocodone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828581","Periurethral Region","C111287","The area surrounding the urethra.","Periurethral Region | PERIURETHRAL REGION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697784","Interleukin 3 Measurement","C74827","The determination of the amount of interleukin 3 present in a sample.","Interleukin 3 Measurement | INTLK3 | Interleukin 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897198","Ventricular Wall of the Heart","C119295","The tissue layers that form the cardiac ventricle. They include the endocardium, myocardium and pericardium.","Ventricular Wall of the Heart | HEART, VENTRICULAR WALL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0223077","Spinous Process","C116112","A bony projection arising from the posterior vertebral arch that serves for the attachment of muscles and ligaments.","Spinous Process | SPINOUS PROCESS",,,,,,,,,,,,,,,"4210163","Structure of spinous process of vertebra",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3639413","Glomerular Filtration Rate from B-2 Microglobulin Adjusted for BSA Measurement","C100450","A measurement of the glomerular filtration rate (GFR) based on the clearance of beta-2 microglobulin after adjusting it for the body surface area.","Glomerular Filtration Rate from B-2 Microglobulin Adjusted for BSA Measurement | GFR from B-2 Microglobulin Adj for BSA | GFRBSB2M",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697774","Interleukin 25 Measurement","C74822","The determination of the amount of interleukin 25 present in a sample.","Interleukin 25 Measurement | INTLK25 | Interleukin 25",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698457","Neuropeptide Y Measurement","C74892","The determination of the amount of neuropeptide Y present in a sample.","Neuropeptide Y Measurement | NPY | Neuropeptide Y",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1295184","Melatonin Measurement","C74867","The determination of the amount of melatonin hormone present in a sample.","Melatonin Measurement | MLATONIN | Melatonin",,,,,,,,,,,,,,,"4004854","Melatonin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3890713","Inclusion Body Measurement","C116184","A measurement of the protein, lipid or small molecule aggregates located within the cytoplasm.","Inclusion Body Measurement | INCLBOD | Inclusion Bodies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699796","Dohle Body Measurement","C74610","The determination of the number of Dohle bodies present in a sample.","Dohle Body Measurement | DOHLE | Dohle Bodies | Döhle Body Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538955","Factor IX Activity Measurement","C103395","The determination of the amount of the biological activity of factor IX in a sample.","Factor IX Activity Measurement | Christmas Factor Activity | Christmas Factor Activity Measurement | FACTIXA | Factor IX Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201514","Thyroid Stimulating Hormone Receptor Antibody Measurement","C122158","The determination of the amount of thyroid stimulating hormone receptor antibody present in a sample.","Thyroid Stimulating Hormone Receptor Antibody Measurement | TSHRAB | Thyroid Stimulating Hormone Receptor Antibody | Thyrotropin Receptor Antibody | Thyrotropin Receptor Measurement",,,,,,,,,,,,,,,"4181904","Antibody to TSH receptor measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029330","Orthochromic Erythroblast","C128972","The determination of the amount of metarubricytes present in a sample.","Metarubricyte Count | Acidophilic Erythroblast | METARUB | Metarubricyte | Orthochromatophilic Normoblast | Orthochromic Erythroblast | Orthochromic Normoblast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514232","Fibroblast Growth Factor 9 Measurement","C130162","The determination of the amount of fibroblast growth factor 9 present in a sample.","Fibroblast Growth Factor 9 Measurement | FGF 9 | FGF9 | FGF9 Measurement | Fibroblast Growth Factor 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698097","Amorphous Sediment Measurement","C74666","The determination of the amount of amorphous sediment present in a sample.","Amorphous Sediment Measurement | AMORPHSD | Amorphous Debris | Amorphous Sediment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825859","Mid-Molecule Parathyroid Hormone Measurement","C81965","The determination of the amount of mid-molecule parathyroid hormone present in a sample.","Mid-Molecule Parathyroid Hormone Measurement | PTHMM | Parathyrin Hormone, Mid-Molecule | Parathyroid Hormone, Mid-Molecule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826765","Laboratory Test Time Point","C83158","A point in time that the laboratory test takes place.","Laboratory Test Time Point | LBTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0236389","Macroamylase Measurement","C111243","A measurement of macroamylase present in a sample.","Macroamylase Measurement | AMYLASEM | Macroamylase",,,,,,,,,,,,,,,"4020536","Macroamylase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545325","Partial Pressure of Carbon Dioxide Adjusted for Body Temperature Measurement","C147411","The determination of the partial pressure of carbon dioxide, adjusted for body temperature, present in a sample.","Partial Pressure of Carbon Dioxide Adjusted for Body Temperature Measurement | PCO2 Adjusted for Body Temperature | PCO2ADJT | Partial Pressure Carbon Dioxide Adj Temp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272906","Parvovirus B19 IgM Antibody Measurement","C96618","The determination of the amount of parvovirus B19 IgM antibody present in a sample.","Parvovirus B19 IgM Antibody Measurement | PB19GMAB | Parvovirus B19 IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085981","Anti-Phospholipid IgG Antibody Measurement","C124335","The determination of the amount of anti-phospholipid IgG antibody present in a sample.","Anti-Phospholipid IgG Antibody Measurement | APLIGGAB | Anti-Phospholipid IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201837","Albumin to Globulin Ratio Measurement","C74894","The determination of the ratio of albumin compared to globulin in a blood sample. The measurement may be expressed as a ratio or percentage.","Albumin to Globulin Ratio Measurement | ALBGLOB | Albumin/Globulin",,,,,,,,,,,,,,,"4288601","Albumin/Globulin ratio",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3830082","Fractional Excretion of Chloride","C114220","The determination of the fractional excretion of chloride that is computed based upon the concentrations of chloride and creatinine in both blood and urine.","Fractional Excretion of Chloride | FECL | FECl | Fractional Chloride Excretion | Fractional Excretion of Cl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049699","Proliferating Cell Nuclear Antigen Measurement","C120646","The determination of the proliferating cell nuclear antigen present in a sample.","Proliferating Cell Nuclear Antigen Measurement | Cyclin | PCNA Measurement | PCNAG | Proliferating Cell Nuclear Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697755","Intact Parathyroid Hormone Measurement","C74789","The determination of the amount of intact parathyroid hormone (consisting of amino acids 1-84 or 7-84) present in a sample.","Intact Parathyroid Hormone Measurement | PTHI | Parathyrin, Intact | Parathyroid Hormone, Intact",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522824","Thymidine Kinase 2 Measurement","C135446","The determination of the amount of thymidine kinase 2 in a biological sample.","Thymidine Kinase 2 Measurement | TK2 | TK2 Measurement | Thymidine Kinase 2 | Thymidine Kinase, Mitochondrial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1142102","Monoblast Count","C74631","The determination of the number of monoblast cells present in a sample.","Monoblast Count | MONOBL | Monoblasts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513763","Alternaria tenuis alternata Antigen IgE Antibody Measurement","C130150","A measurement of the Alternaria tenuis alternata antigen IgE antibody in a biological specimen.","Alternaria tenuis alternata Antigen IgE Antibody Measurement | Alternaria alternata IgE Antibody | Alternaria tenuis IgE Antibody | C130150",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825855","Factor III measurement","C81959","The determination of the amount of factor III present in a sample.","Factor III Measurement | FACTIII | Factor III | Soluble CD142 | Tissue Factor, CD142",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509354","Vacuolated Lymphocyte to Leukocyte Ratio Measurement","C127627","The determination of the ratio of vacuolated lymphocytes compared to total leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Vacuolated Lymphocyte to Leukocyte Ratio Measurement | LYMVACLE | Vacuolated Lymphocytes/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700211","Fragmented Parathyroid Hormone Measurement","C74784","The determination of the amount of fragmented parathyroid hormone present in a sample.","Fragmented Parathyroid Hormone Measurement | PTHFG | Parathyrin Hormone, Fragmented | Parathyroid Hormone, Fragmented",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054450","Myelin Basic Protein Measurement","C122135","The determination of the amount of myelin basic protein present in a sample.","Myelin Basic Protein Measurement | MBP | Myelin Basic Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202059","Bicarbonate Measurement","C74667","The determination of the amount of bicarbonate present in a sample.","Bicarbonate Measurement | BICARB | Bicarbonate | HCO3",,,,,,,,,,,,,,,"4227915","Bicarbonate measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2826914","Laboratory Test Toxicity Grade","C83324","A ranking of the poisonous nature of an object as determined by a laboratory test.","Laboratory Test Toxicity Grade | LBTOXGR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826913","Laboratory Test Toxicity","C83323","A laboratory test designed to quantify or qualify the poisonous nature of a sample.","Laboratory Test Toxicity | LBTOX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050387","Remnant Lipoprotein Measurement","C120656","The determination of the remnant lipoprotein present in a sample.","Remnant Lipoprotein Measurement | RMNTLP | Remnant Lipoprotein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201494","Hepatitis E Virus Antibody Measurement","C119283","The determination of the amount of hepatitis E virus antibody in a biological specimen.","Hepatitis E Virus Antibody Measurement | HEAB | Hepatitis E Virus Antibody",,,,,,,,,,,,,,,"4062328","Hepatitis E antibody measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4050244","Apolipoprotein CI Measurement","C120630","The determination of the apolipoprotein CI present in a sample.","Apolipoprotein CI Measurement | APOC1 | APOC1 Measurement | Apolipoprotein C-I Measurement | Apolipoprotein C1 Measurement | Apolipoprotein CI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1141990","Hyaluronic Acid Measurement","C112319","The determination of the amount of hyaluronic acid present in a sample.","Hyaluronic Acid Measurement | HYALUAC | Hyaluronic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272863","Alpha Fetoprotein L2 Measurement","C96563","The determination of the amount of alpha fetoprotein L2 present in a sample.","Alpha Fetoprotein L2 Measurement | AFPL2 | Alpha Fetoprotein L2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828199","Sediment Analysis","C105744","An observation, assessment or examination of the sediment in a sample.","Sediment Analysis | Microscopic Sediment Analysis | SEDEXAM | Sediment Examination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699115","Round Epithelial Cell Count","C74698","The determination of the number of round epithelial cells present in a urine sample.","Round Epithelial Cell Count | EPIROCE | Round Epithelial Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825914","Type II Collagen C-Telopeptide Measurement","C82040","The determination of the amount of the type II collagen C-telopeptide present in a sample.","Type II Collagen C-Telopeptide Measurement | CTXII | Type II Collagen C-Telopeptides | Type II Collagen X-Linked C-Telopeptides",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825899","Macrophage Inflammatory Protein 1 Beta measurement","C82024","The determination of the amount of macrophage inflammatory protein 1 beta present in a sample.","Macrophage Inflammatory Protein 1 Beta Measurement | Chemokine Ligand 4 | MIP1B | Macrophage Inflammatory Protein 1 Beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1443561","Large Unstained Cell Count","C74659","The determination of the number of large unstained cells present in a sample.","Large Unstained Cell Count | LGUNSCE | Large Unstained Cells",,,,,,,,,,,,,,,"4254487","Large unstained cell count",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0201549","CA-125 Measurement","C79089","The determination of the amount of cancer antigen 125 present in a sample.","CA-125 Measurement | CA125 | CA125AG | Cancer Antigen 125 | Cancer Antigen 125 Measurement | Carbohydrate Antigen 125 | MUC16 | Mucin-16 | Mucin-16, Cell Surface Associated",,,,,,,,,,,,,,,"4197913","CA 125 measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0373917","HIV-2 Antibody Measurement","C74715","The determination of the antibody reaction of a sample to the HIV-2 virus.","HIV-2 Antibody Measurement | HIV-2 Antibody | HIV2AB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201856","Alpha-1 Antitrypsin Measurement","C80167","The determination of the amount of alpha-1 antitrypsin present in a sample.","Alpha-1 Antitrypsin Measurement | A1ANTRYP | Alpha-1 Antitrypsin | Serum Trypsin Inhibitor",,,,,,,,,,,,,,,"4324147","Alpha-1-antitrypsin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2699294","Sezary Cell Count","C74625","The determination of the number of Sezary cells present in a sample.","Sezary Cell Count | SEZCE | Sezary Cells | Sézary Cell Count",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054879","HTLV-I HTLV-II Antibody Measurement","C122125","The determination of the amount of human T-cell lymphotropic virus I and II antibodies present in a sample.","HTLV-I HTLV-II Antibody Measurement | HTLV-1/2 Antibody | HTLV-I/II Antibody | HTLV12AB | Human T-cell Lymphotropic Virus 1/2 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831196","Cardiolipin IgG Antibody Measurement","C111144","The determination of the amount of cardiolipin IgG antibody present in a sample.","Cardiolipin IgG Antibody Measurement | Anitcardiolipin IgG Antibody Measurement | Anti-Cardiolipin IgG Antibody | CRDIGGAB | Cardiolipin IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825849","Eotaxin-2 measurement","C81953","The determination of the amount of eotaxin-2 present in a sample.","Eotaxin-2 Measurement | Chemokine Ligand 24 | EOTAXIN2 | Eotaxin-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1446135","Beta-2 Glycoprotein 1 IgM Antibody Measurement","C103359","The determination of the amount of the Beta-2 glycoprotein 1 IgM antibodies in a sample.","Beta-2 Glycoprotein 1 IgM Antibody Measurement | APOH IgM Antibody Measurement | Apolipoprotein H IgM Antibody Measurement | B2G1GMAB | Beta-2 Glycoprotein 1 IgM Antibody",,,,,,,,,,,,,,,"4135562","Anti B2 glycoprotein 1 IgM antibody measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2697522","Granular Fine Cast Measurement","C74769","The determination of the amount of fine granular casts present in a urine sample.","Granular Fine Cast Measurement | CSGRANF | Fine Granular Cast Measurement | Granular Fine Casts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526587","Reticulocyte Volume Distribution Width","C139074","A measurement of the volume dispersion within a reticulocyte population in a biological specimen, derived from flow cytometric pulse-height analysis and expressed as either coefficient of variation or standard deviation.","Reticulocyte Volume Distribution Width | RDWR | RDWr | Ret Volume Distribution Width",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539771","Vitamin K1 Measurement","C103449","The determination of the amount of the Vitamin K1 in a sample.","Vitamin K1 Measurement | Phylloquinone | Phytomenadione | VITK1 | Vitamin K1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889165","Pancreatic Lipase Measurement","C117841","The determination of the amount of pancreatic lipase present in a sample.","Pancreatic Lipase Measurement | LIPASEP | Lipase, Pancreatic | PNLIP | PNLIP Measurement | Pancreatic Triacylglycerol Lipase | Pancreatic Triacylglycerol Lipase Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054016","Sjogrens SS-A52 Antibody Measurement","C120661","The determination of the Sjogrens SS-A52 antibody present in a sample.","Sjogrens SS-A52 Antibody Measurement | 52 kDa Ribonucleoprotein Autoantigen Ro/SS-A Antibody Measurement | E3 Ubiquitin-Protein Ligase TRIM21 Antibody Measurement | SJSA52AB | Sjogrens SS-A52 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202161","C-Terminal Parathyroid Hormone Measurement","C81964","The determination of the amount of C-terminal parathyroid hormone present in a sample.","C-Terminal Parathyroid Hormone Measurement | PTHCT | Parathyrin Hormone, C-Terminal | Parathyroid Hormone, C-Terminal",,,,,,,,,,,,,,,"4320801","Parathyroid hormone measurement, C-terminal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514039","Chemokine (C-C Motif) Ligand 12 Measurement","C130156","The determination of the amount of chemokine (C-C Motif) ligand 12 present in a sample.","Chemokine (C-C Motif) Ligand 12 Measurement | CCL12 | CCL12 Measurement | Chemokine (C-C Motif) Ligand 12 | Monocyte Chemotactic Protein 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698028","Matrix Metalloproteinase 9 measurement","C80197","The determination of the amount of matrix metalloproteinase 9 present in a sample.","Matrix Metalloproteinase 9 Measurement | Gelatinase B | MMP9 | Matrix Metalloproteinase 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545245","Chemokine (C-C Motif) Ligand 21 Measurement","C147315","The determination of the amount of chemokine (C-C motif) ligand 21 present in a sample.","Chemokine (C-C Motif) Ligand 21 Measurement | 6Ckine | CCL21 | CCL21 Measurement | Chemokine (C-C Motif) Ligand 21 | Secondary Lymphoid Tissue Chemokine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897886","Platelet Derived Growth Factor Isoform AB Measurement","C116208","The determination of the amount of platelet-derived growth factor isoform AB present in a sample.","Platelet Derived Growth Factor Isoform AB Measurement | PDGF Isoform AB | PDGFAB | Platelet Derived Growth Factor IsoformAB | Platelet Derived Growth Factor-AB Isoform",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539780","Proerythroblast Measurement","C100446","The determination of the amount of proerythroblasts present in a sample.","Proerythroblast Measurement | BLASTRUB | Proerythroblast | Pronormoblast | Rubriblast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698029","Mature Plasma Cell Count","C74661","The determination of the number of mature plasma cells present in a sample.","Mature Plasma Cell Count | Mature Plasma Cells | PLSMCE | Plasmacytes | Plasmocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502703","Intercellular Adhesion Molecule 1 Measurement","C124345","The determination of the amount of intercellular adhesion molecule 1 present in a sample.","Intercellular Adhesion Molecule 1 Measurement | CD54 | ICAM1 | ICAM1 Measurement | Intercellular Adhesion Molecule 1 | Soluble CD54",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984935","Leukocyte Cell Clumps Measurement","C92246","The determination of the amount of leukocyte cell clumps present in a sample.","Leukocyte Cell Clumps Measurement | Leukocyte Cell Clumps | WBC Clumps | WBCCLMP | White Blood Cell Clumps",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545257","ADAM Metallopeptidase Domain 8 Measurement","C147290","The determination of the amount of ADAM metallopeptidase domain 8 present in a sample.","ADAM Metallopeptidase Domain 8 Measurement | A Disintegrin And Metalloproteinase Domain 8 | ADAM Metallopeptidase Domain 8 | ADAM8 | ADAM8 Measurement | CD156a Antigen | Soluble CD156a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642159","Factor XIV Activity Measurement","C105442","The determination of the amount of Factor XIV activity present in a sample.","Factor XIV Activity Measurement | FACTXIVA | Factor XIV Activity | Protein C Activity | Protein C Function",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825894","Glutamic Acid Decarboxylase 2 Antibody Measurement","C82017","The determination of the amount of glutamic acid decarboxylase 2 antibody present in a sample.","Glutamic Acid Decarboxylase 2 Antibody Measurement | GAD2AB | Glutamic Acid Decarboxylase 2 Antibody | Glutamic Acid Decarboxylase 65 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825853","Reg upon Act Normal T-cell Exprd Secrtd Measurement","C81957","The determination of the amount of the RANTES (regulated on activation, normally, T-cell expressed, and secreted) chemokine present in a sample.","Reg upon Act Normal T-cell Exprd Secrtd Measurement | Chemokine Ligand 5 | RANTES | Reg upon Act Normal T-cell Exprd Secrtd",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520566","Soluble Intercellular Adhesion Molecule 1 Measurement","C132386","The determination of the amount of soluble intercellular adhesion molecule 1 in a biological sample.","Soluble Intercellular Adhesion Molecule 1 Measurement | SICAM1 | Soluble Intercell Adhesion Molecule 1 | sICAM-1 Measurement | sICAM1 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0696105","Beta Carotene Measurement","C100472","The determination of the amount of beta-carotene present in a sample.","Beta Carotene Measurement | BETACRTN | Beta Carotene | Beta Carotin | b-Carotene",,,,,,,,,,,,,,,"4187876","Beta carotene level",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0236300","Anti-DNA Antibody Measurement","C81973","The determination of the amount of anti-DNA antibodies present in a sample.","Anti-DNA Antibody Measurement | Anti-DNA Antibodies | Anti-ds-DNA Antibodies | DNAAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829228","Macrophage to Total Cell Ratio Measurement","C111244","The determination of the ratio of the macrophages compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Macrophage to Total Cell Ratio Measurement | MCPHGCE | Macrophages to Total Cells Ratio Measurement | Macrophages/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642161","Lymphoblast to Leukocyte Ratio Measurement","C105444","The determination of the ratio of lymphoblasts compared to total leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Lymphoblast to Leukocyte Ratio Measurement | BLSTLYLE | Lymphoblasts/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0200664","Platelet Morphology Measurement","C111296","An examination or assessment of the form and structure of platelets.","Platelet Morphology Measurement | PLTMORPH | Platelet Morphology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523998","Lecithin to Sphingomyelin Ratio Measurement","C147381","The determination of the ratio of lecithin compared to sphingomyelin present in a sample. The measurement may be expressed as a ratio or percentage.","Lecithin to Sphingomyelin Ratio Measurement | LCTHSPGM | LS Ratio | Lecithin/Sphingomyelin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897926","Pi-GST Excretion Rate","C119279","A determination of the amount of pi glutathione-s-transferase being excreted over a defined period of time.","Pi-GST Excretion Rate | GSTPIEXR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825862","Antimitochondrial Antibody Measurement","C81975","The determination of the amount of antimitochondrial antibodies present in a sample.","Antimitochondrial Antibody Measurement | AMA | Antimitochondrial Antibodies | Mitochondrial Antibody",,,,,,,,,,,,,,,"4015457","Antibody to mitochondria measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698117","Anisocyte Measurement","C74797","The determination of the number of anisocytes present in a sample.","Anisocyte Measurement | ANISO | Anisocytes | Anisocytosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524029","Benzoylecgonine Measurement","C75350","The determination of the amount of benzoylecgonine, the primary metabolite of cocaine, present in a sample.","Benzoylecgonine Measurement | BNZLCGN | Benzoylecgonine",,,,,,,,,,,,,,,"4020243","Benzoylecgonine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825860","N-Terminal Parathyroid Hormone Measurement","C81966","The determination of the amount of N-terminal parathyroid hormone present in a sample.","N-Terminal Parathyroid Hormone Measurement | PTHNT | Parathyrin Hormone, N-Terminal | Parathyroid Hormone, N-Terminal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272910","Procollagen 1 N-Terminal Propeptide Measurement","C96625","The determination of the amount of procollagen 1 N-terminal propeptide present in a sample.","Procollagen 1 N-Terminal Propeptide Measurement | Amino-terminal propeptide of type 1 procollagen | P1NP | P1NP Aminoterm Type 1 | Procollagen 1 N-Terminal Propeptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1171405","Leukocyte Cell Morphology","C92297","An examination or assessment of the form and structure of white blood cells.","Leukocyte Cell Morphology | WBC Morphology | WBCMORPH | White Blood Cell Morphology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698023","Matrix Metalloproteinase 1 Measurement","C80192","The determination of the amount of matrix metalloproteinase 1 present in a sample.","Matrix Metalloproteinase 1 Measurement | Interstitial Collagenase | MMP1 | Matrix Metalloproteinase 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639414","Ova and Parasite Measurement","C100452","The determination of the amount of ova and parasites present in a sample.","Ova and Parasite Measurement | OVAPARS | Ova and Parasite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697781","Interleukin 31 Measurement","C74829","The determination of the amount of interleukin 31 present in a sample.","Interleukin 31 Measurement | INTLK31 | Interleukin 31",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810574","Potassium Clearance Measurement","C106560","The determination of the amount of the potassium clearance in a sample.","Potassium Clearance Measurement | KCLR | Potassium Clearance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274394","Factor X Measurement","C98727","The determination of the amount of factor X present in a sample.","Factor X Measurement | FACTX | Factor X | Factor X Antigen Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274450","Varicella Zoster Virus IgA Antibody Measurement","C98795","The determination of the amount of varicella zoster virus IgA antibody present in a sample.","Varicella Zoster Virus IgA Antibody Measurement | VZVIGAAB | Varicella Zoster Virus IgA Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641227","Amyloid Beta 1-40 Measurement","C103353","The determination of the amount of amyloid beta protein which is composed of peptides 1 to 40 in a sample.","Amyloid Beta 1-40 Measurement | AMYLB40 | Amyloid Beta 1-40 | Amyloid Beta 40 | Amyloid Beta 40 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050409","Beta-defensin 2 Measurement","C122102","The determination of the amount of beta-defensin 2 in a biological specimen.","Beta-defensin 2 Measurement | BD2 | Beta-defensin 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825864","Antithrombin Antigen Measurement","C81977","The determination of the amount of antithrombin antigen present in a sample.","Antithrombin Antigen Measurement | ANTHRMAG | Antithrombin | Antithrombin Antigen | Antithrombin III | Antithrombin III Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699272","Saturated Non-esterified Fatty Acids Measurement","C80206","The determination of the amount of saturated non-esterified fatty acids present in a sample.","Saturated Non-esterified Fatty Acids Measurement | FATACFRS | Free Fatty Acid, Saturated | Non-esterified Fatty Acid, Saturated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815570","Myosin Light Chain 3 Measurement","C106547","The determination of the amount of myosin light chain 3 present in a sample.","Myosin Light Chain 3 Measurement | Cardiac myosin light chain 1 | MYL3 | Myosin Light Chain 3 | Myosin light chain 1, slow-twitch muscle B/ventricular isoform",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830546","Degenerated Leukocyte Count","C111190","The determination of the amount of degenerated leukocytes (leukocytes that show deterioration in form or function) present in a sample.","Degenerated Leukocyte Count | DGNWBC | Degenerated Leukocytes | Degenerated WBC | Degenerated White Blood Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642160","FibroTest Score Measurement","C105443","A patented biomarker test (APHP, 2001) that measures liver pathology through the assessment of a six-parameter blood test (for alpha-2-macroglobulin, haptoglobin, apolipoprotein A1, gamma-glutamyl transpeptidase, total bilirubin, and alanine aminotransferase), taking into account the age and gender of the patient.","FibroTest Score Measurement | FBRTST | FibroSURE Score | FibroSure Score Measurement | FibroTest Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202445","Phencyclidine Measurement","C74694","The determination of the amount of phencyclidine present in a sample.","Phencyclidine Measurement | PCP | PCP Measurement | Phencyclidine | Phenylcyclohexylpiperidine",,,,,,,,,,,,,,,"4049508","Phencyclidine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2681921","Kidney Injury Molecule-1 Measurement","C100433","The determination of the amount of kidney injury molecule-1 present in a sample.","Kidney Injury Molecule-1 Measurement | HAVCR1 Measurement | HAVcr-1 Measurement | Hepatitis A Virus Cellular Receptor 1 | Hepatitis A Virus Cellular Receptor 1 Measurement | KIM-1 | KIM-1 Measurement | KIM1 | KIM1 Measurement | Kidney Injury Molecule 1 Measurement | Kidney Injury Molecule-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3516405","Alpha-2 Antiplasmin Measurement","C103351","The determination of the amount of the alpha-2 antiplasmin in a sample.","Alpha-2 Antiplasmin Measurement | APLSMA2 | Alpha-2 Antiplasmin | Alpha-2 Plasmin Inhibitor | Serpin F2 Measurement",,,,,,,,,,,,,,,"4194500","Alpha-2 antiplasmin assay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL522800","Ebola Virus IgM Antibody Measurement","C135410","The determination of the amount of the Ebola virus IgM antibodies in a biological sample.","Ebola Virus IgM Antibody Measurement | EBOIGMAB | Ebola Virus IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522823","Skeletal Troponin I Measurement","C135443","The determination of the amount of total skeletal troponin I in a biological sample.","Skeletal Troponin I Measurement | STROPONI | Skeletal Troponin I | sTnl | sTnl Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831150","Centromere B Antibody Measurement","C111154","A measurement of centromere B antibodies present in a sample.","Centromere B Antibody Measurement | CENPB Antibody Measurement | CENTROAB | Centromere B Antibodies | Centromere Protein B Antibody Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512519","Chemokine (C-X-C Motif) Ligand 1 Measurement","C128952","The determination of the amount of chemokine (C-X-C motif) ligand 1 present in a sample.","Chemokine (C-X-C Motif) Ligand 1 Measurement | CXCL1 | Chemokine (C-X-C Motif) Ligand 1 | GRO Alpha | GRO/KC | GRO1 | GROA | Growth-Regulated Alpha Protein | Melanoma Growth Stimulating Activity, Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337441","Prealbumin Measurement","C100435","The determination of the amount of prealbumin present in a sample.","Prealbumin Measurement | PREALB | Prealbumin | TTR Measurement | Thyroxine-binding Prealbumin | Thyroxine-binding Prealbumin Measurement | Transthyretin | Transthyretin Measurement",,,,,,,,,,,,,,,"4020695","Transthyretin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0201998","Epinephrine Measurement","C79445","The determination of the amount of epinephrine present in a sample.","Epinephrine Measurement | Adrenaline | Adrenaline Measurement | EPIN | Epinephrine",,,,,,,,,,,,,,,"4274176","Epinephrine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3538998","Pepsinogen C Measurement","C100470","The determination of the amount of pepsinogen C present in a sample.","Pepsinogen C Measurement | PEPSNGC | PGC | Pepsinogen C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825867","Islet Cell 512 Antibody Measurement","C81985","The determination of the amount of islet cell 512 antibody present in a sample.","Islet Cell 512 Antibody Measurement | IA-2 Antibody | IC512AB | ICA-512 Antibody | Islet Antigen 2 Autoantibody | Islet Antigen 2 Autoantibody Measurement | Islet Cell 512 Antibody | Islet Cell Antigen 512 Autoantibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699519","Acanthocyte Count (procedure)","C74699","The determination of the number of acanthocytes present in a sample.","Acanthocyte Count | ACANT | Acanthocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816169","B-Cell Activating Factor Measurement","C111135","The determination of the amount of B-cell activating factor present in a sample.","B-Cell Activating Factor Measurement | B-Cell Activating Factor | BAFF | TNFSF13B Measurement | Tumor Necrosis Factor Ligand Superfamily Member 13B Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266387","6 Beta-Hydroxycortisol Measurement","C150833","The determination of the amount of 6 beta-hydroxycortisol present in a sample.","6 Beta-Hydroxycortisol Measurement | 6 Beta-Hydrocortisol | 6 Beta-Hydroxycortisol | 6 beta-OHF | 6-Beta-Hydrocortisol Measurement | OHF6B",,,,,,,,,,,,,,,"4004872","6-beta-Hydroxycortisol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL520396","Folate Hydrolase mRNA Measurement","C132367","The determination of the amount of folate hydrolase mRNA in a biological sample.","Folate Hydrolase mRNA Measurement | FOLH1 mRNA Measurement | FOLHMRNA | Folate Hydrolase 1 mRNA Measurement | Folate Hydrolase mRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513762","Alternaria tenuis alternata Antigen IgA Antibody Measurement","C130151","A measurement of the Alternaria tenuis alternata antigen IgA antibody in a biological specimen.","Alternaria tenuis alternata Antigen IgA Antibody Measurement | Alternaria alternata IgA Antibody | Alternaria tenuis IgA Antibody | C130151",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274407","Human Anti-Sheep IgE Antibody Measurement","C98740","The determination of the amount of human anti-sheep IgE antibody present in a sample.","Human Anti-Sheep IgE Antibody Measurement | HASIGEAB | Human Anti-Sheep IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085918","1,5-Anhydroglucitol Measurement","C124334","The determination of the amount of 1,5-anhydroglucitol present in a sample.","1,5-Anhydroglucitol Measurement | 1,5-Anhydroglucitol | AG1_5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697770","Interleukin 21 Measurement","C74818","The determination of the amount of interleukin 21 present in a sample.","Interleukin 21 Measurement | INTLK21 | Interleukin 21",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698951","Calcitriol Measurement","C74849","The determination of the amount of calcitriol hormone present in a sample.","Calcitriol Measurement | CLCTRIOL | Calcitriol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272926","Urea to Creatinine Ratio Measurement","C96645","The determination of the ratio of urea to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Urea to Creatinine Ratio Measurement | UREACRT | Urea/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514026","Bee Mix Antigen IgG Antibody Measurement","C130117","A measurement of the bee mix antigen IgG antibody in a biological specimen.","Bee Mix Antigen IgG Antibody Measurement | Bee Mix Antigen IgG Antibody | C130117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520193","Prostate Specific Antigen mRNA Measurement","C132385","The determination of the amount of prostate specific antigen mRNA in a biological sample.","Prostate Specific Antigen mRNA Measurement | PSAMRNA | Prostate Specific Antigen mRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829690","Histone 2A Antibody Measurement","C112294","The determination of the amount of histone 2a antibody present in a sample.","Histone 2A Antibody Measurement | HIST2AAB | Histone 2A Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642199","Hundred Million Per Liter","C105489","A concentration unit expressed as a number or quantity of objects in hundred millions per unit of volume equal to one liter.","Hundred Million Per Liter | 10*8/L | 10*8/l | 10^2/mm3 | 10^2/uL | 10^5/mL | 10^8/L | 10^8/l",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642198","Hundred Billion Per Liter","C105488","A concentration unit expressed as a number or quantity of objects in hundred billions per unit of volume equal to one liter.","Hundred Billion Per Liter | 10*11/L | 10*11/l | 10^11/L | 10^11/l | 10^5/mm3 | 10^5/uL | 10^8/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539841","Hectopascal","C105487","A SI derived unit of pressure equivalent to one hundred pascals, 1 millibar or 0.0145 pounds per square inch.","Hectopascal | hPa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642197","Fraction of 1","C105484","A unit for expressing a percentage as a decimal whereby the total value is measured as a fraction of the numeric 1.","Fraction of 1 | Proportion of 1 | fraction of 1 | {fraction of 1}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642196","Decamole Per Liter","C105483","A unit of concentration (molarity unit) equal to one decamole of solute in one liter of solution.","Decamole Per Liter | Decamole per Liter | Moles per Deciliter | damol/L | damol/l | mol/dL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540510","Centisecond","C105482","A unit of time equal to one hundredth of a second (10E-2 seconds).","Centisecond | 10^-2 sec | cs | csec",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642195","Centimeter Per Minute","C105481","A unit of both speed (scalar) and velocity (vector), defined as the distance of one centimeter traveled per unit time equal to one minute.","Centimeter Per Minute | Centimeters per Minute | cm/min | cm/minute",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640891","Per 100 High Powered Fields","C102695","A unit of measurement of the number of entities per unit of area equal to one hundred high powered fields.","Per 100 High Powered Fields | /10*2.[HPF] | /100 HPFs | /10^2.[HPF] | Per 100HPF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640868","Log10 Colony Forming Units per Milliliter","C102659","A logarithmic-scale (base 10) unit for measuring colony forming units per unit of volume equal to one milliliter.","Log10 Colony Forming Units per Milliliter | log10 CFU/mL | {log10}.[CFU]/mL | {log10}.[CFU]/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640867","Log10 Colony Forming Units per Gram","C102658","A logarithmic-scale (base 10) unit for measuring colony forming units per unit of mass equal to one gram.","Log10 Colony Forming Units per Gram | log10 CFU/g | {log10}.[CFU]/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439497","Decibel","C102407","A unit of measure representing the intensity of an electrical signal or sound which is equal to ten times the logarithm of the ratio of two signals.","Decibel | dB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439392","Centimeter per Second","C102406","A unit of both speed (scalar) and velocity (vector), defined as the distance of one centimeter travelled per unit time equal to one second.","Centimeter per Second | cm/s | cm/sec",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640765","Capful Dosing Unit","C102405","A dosing measurement based on the capful unit.","Capful Dosing Unit | CAPFUL | Capful | {CAPFUL} | {Capful}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439484","Diopter","C100899","A unit of measurement of the optical power of a curved mirror or lens represented by the inverse of the focal length in meters.","Diopter | DIOPTER | [diop]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639835","Million Copies per Milliliter","C100898","The unit of concentration expressed as the number of 10 to the sixth power copies in unit volume equal to one milliliter.","Million Copies per Milliliter | 10*6.{copies}/mL | 10*6.{copies}/ml | 10^6 copies/mL | 10^6.{copies}/mL | 10^6.{copies}/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639834","Thousand Copies per Milliliter","C100897","The unit of concentration expressed as the number of 10 to the third power copies in unit volume equal to one milliliter.","Thousand Copies per Milliliter | 10*3.{copies}/mL | 10*3.{copies}/ml | 10^3 copies/mL | 10^3.{copies}/mL | 10^3.{copies}/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053883","VLDL Cholesterol Subtype 2 Measurement","C120668","The determination of the very low density lipoprotein cholesterol subtype 2 present in a sample.","VLDL Cholesterol Subtype 2 Measurement | VLDL Cholesterol Subtype 2 | VLDL2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697789","Interleukin 9 Measurement","C74837","The determination of the amount of interleukin 9 present in a sample.","Interleukin 9 Measurement | INTLK9 | Interleukin 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697765","Interleukin 17 Measurement","C74813","The determination of the amount of interleukin 17 present in a sample.","Interleukin 17 Measurement | IL-17A | INTLK17 | Interleukin 17 | Interleukin 17A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509808","Murinoglobulin Measurement","C127630","The determination of the amount of murinoglobulin present in a sample.","Murinoglobulin Measurement | MUG | Murinoglobulin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272944","Hepatitis E Virus IgM Antibody Measurement","C96665","The determination of the amount of Hepatitis E virus IgM antibody present in a sample.","Hepatitis E Virus IgM Antibody Measurement | HEIGMAB | Hepatitis E Virus IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545326","Platelet Factor 4-Heparin Complex Induced Antibody Measurement","C147412","The determination of the amount of platelet factor-4 heparin complex induced antibody present in a sample.","Platelet Factor 4-Heparin Complex Induced Antibody Measurement | PF4HCIAB | Platelet Factor 4 Heparin Complex Induced Antibody | Platelet Fctr 4 Heparin Cmplx Induced Ab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2732404","Calcium Corrected Measurement","C119272","The determination of the amount of the calcium corrected in a biological specimen.","Calcium Corrected Measurement | CACR | Calcium Corrected",,,,,,,,,,,,,,,"40483260","Corrected measurement of calcium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4085982","Anti-Phospholipid IgM Antibody Measurement","C124336","The determination of the amount of anti-phospholipid IgM antibody present in a sample.","Anti-Phospholipid IgM Antibody Measurement | APLIGMAB | Anti-Phospholipid IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522561","ABO A1 Subtype Determination","C135397","The characterization of the ABO blood group A1 subtype in an individual.","ABO A1 Subtype Determination | ABO A1 Subtype | ABOA1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898432","Medium Absorption Reticulocytes to Total Reticulocytes Ratio Measurement","C116193","The determination of the ratio of medium absorption reticulocytes compared to total reticulocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Medium Absorption Reticulocytes to Total Reticulocytes Ratio Measurement | Medium Absorption Retic/Reticulocytes | RETIMRTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829565","Immature Cell to Total Cell Ratio Measurement","C111234","The determination of the ratio of the immature hematopoietic cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Immature Cell to Total Cell Ratio Measurement | CEIMCE | Immature Cells to Total Cells Ratio Measurement | Immature Cells/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898571","Low Absorption Reticulocytes to Total Reticulocytes Ratio Measurement","C116191","The determination of the ratio of low absorption reticulocytes compared to total reticulocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Low Absorption Reticulocytes to Total Reticulocytes Ratio Measurement | Low Absorption Retic/Reticulocytes | RETILRTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984951","Legionella pneumophila Antigen Measurement","C92275","The determination of the amount of Legionella pneumophila antigen present in a sample.","Legionella pneumophila Antigen Measurement | LPNAG | Legionella pneumophila Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523852","Basophilic Myelocyte Count","C135400","The determination of the amount of basophilic myelocytes present in a sample.","Basophilic Myelocyte Count | BASOMYL | Basophilic Myelocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272955","Immature Monocyte to Leukocyte Ratio Measurement","C96677","The determination of the ratio of immature monocytes compared to total leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Immature Monocyte to Leukocyte Ratio Measurement | Immature Monocytes/Leukocytes | MONOIMLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522819","Myeloid Proliferation Index","C135436","The determination of the ratio of the sum of myeloid proliferative phase cells (pool) to the sum of myeloid maturation phase cells (pool) present in a sample.","Myeloid Proliferation Index | MYCEPIDX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984927","Trichomonas Screening","C92238","Examination of a biological specimen to detect the presence of any protozoan belonging to the Trichomonas genus.","Trichomonas Screening | TRICH | Trichomonas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640656","Endogenous Thrombin Potential Measurement","C102266","The determination of the total concentration of thrombin generated in the presence of a substrate in a plasma or blood sample.","Endogenous Thrombin Potential Measurement | ETP | Endogenous Thrombin Potential",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522806","Erythroid Proliferation Index","C135417","The determination of the ratio of the sum of erythroid proliferative phase cells (pool) to the sum of erythroid maturation phase cells (pool) present in a sample.","Erythroid Proliferation Index | ERCEPIDX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523452","Adenosine Diphosphate Measurement","C102257","The determination of the amount of adenosine diphosphate present in a sample.","Adenosine Diphosphate Measurement | ADP | Adenosine Diphosphate",,,,,,,,,,,,,,,"4019436","Adenosine diphosphate measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514056","Mold Mix Antigen IgE Antibody Measurement","C130109","A measurement of the mold mix antigen IgE antibody in a biological specimen.","Mold Mix Antigen IgE Antibody Measurement | C130109 | Mold Mix Antigen IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524151","Hydromorphone Measurement","C74880","The determination of the amount of hydromorphone present in a sample.","Hydromorphone Measurement | HYDMRPHN | Hydromorphone",,,,,,,,,,,,,,,"4022981","Hydromorphone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3639408","Immature Lymphocytes to Leukocytes Ratio Measurement","C100443","The determination of the ratio of immature lymphocytes compared to total leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Immature Lymphocytes to Leukocytes Ratio Measurement | Immature Lymphocytes/Leukocytes | LYMIMLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984942","HIV-1 p24 Antigen Measurement","C92265","The determination of the amount of HIV-1 p24 antigen present in a sample.","HIV-1 p24 Antigen Measurement | HIV-1 p24 Antigen | HIV124AG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504572","CDISC SDTM BRIDG Activity Mood Terminology","C125923","Terminology associated with the biomedical research integrated domain group (BRIDG) activity mood codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM BRIDG Activity Mood Terminology | BRDGMOOD | BRIDG Activity Mood | SDTM-BRDGMOOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642200","Hundred Thousand Per Liter","C105490","A concentration unit expressed as a number or quantity of objects in hundred thousands per unit of volume equal to one liter.","Hundred Thousand Per Liter | 10*5/L | 10*5/l | 10^2/mL | 10^5/L | 10^5/l",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1532717","Kilodalton","C105491","A unit of atomic mass equal to one thousand daltons.","Kilodalton | Kilounified Atomic Mass Unit | kDa | kiloDalton | ku | {kDa}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439515","Kilopascal Per Liter Per Second","C105492","A unit of resistance equal to the number of kilopascals per unit of volume equal to one liter per unit of time equal to one second.","Kilopascal Per Liter Per Second | Pa/mL/sec | kPa/L/s | kPa/L/sec | kPa/l/s",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541894","Kilosecond","C105493","A unit of time equal to one thousand seconds (10E3 seconds).","Kilosecond | 10^3 sec | ks | ksec",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642202","Liter Per Hour Per Square Meter","C105494","A unit expressed as one liter of volume per unit of time equal to one hour per square meter of area.","Liter Per Hour Per Square Meter | (L/h)/m2 | (l/h)/m2 | L/h/m2 | Liters per Hour per Square Meter | l/h/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1623737","Liter Per Liter","C105495","A measure of volume concentration expressed as the number of liters of a dissolved substance per liter of solution.","Liter Per Liter | L/L | Liter per Liter | dL/dL | l/l | mL/mL | uL/uL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642203","Liter Per Minute Per Square Meter","C105496","A unit expressed as one liter of volume per unit of time equal to one minute per square meter of area. (NCI)","Liter Per Minute Per Square Meter | (L/min)/m2 | (l/min)/m2 | L/min/m2 | Liters per Minute per Square Meter | l/min/m2 | liters/min/m^2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642204","Microgram Equivalent","C105497","A unit of relative amount of substance concentration equal to one millionth of a gram of an equivalent weight.","Microgram Equivalent | ug.eq | ugEq",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642205","Micromole Per Liter Per Second","C105498","A concentration unit equal to one micromole of solute in one liter of solution per unit of time equal to one second.","Micromole Per Liter Per Second | Micromoles per Liter per Second | umol/(L*s) | umol/(s*L) | umol/L/s | umol/L/sec | umol/l/s | umol/s/L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698623","CDISC SDTM Drug Accountability Test Terminology by Name","C78731","Terminology associated with the drug accountability test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Drug Accountability Test Name Terminology | DATEST | Drug Accountability Test Name | SDTM-DATEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642206","Microvolt Second","C105499","A SI derived unit of magnetic flux, equal to the flux that produces in a circuit of one turn an electromotive force of one microvolt, when the flux is uniformly reduced to zero within one second.","Microvolt Second | Microvolt * Seconds | Microvolt Seconds | uV*s | uV*sec | uV.s",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439495","Mile Per Hour","C105500","A unit of both speed (scalar) and velocity (vector), defined as the distance of one mile traveled per unit time equal to one hour.","Mile Per Hour | Miles Per Hour | Miles per Hour | [mi_i]/h | mph",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642208","Milliliter per Centimeter","C105503","A unit of measure equal to the number of milliliters per unit of length equal to one centimeter.","Milliliter per Centimeter | dL/m | mL/cm | ml/cm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439374","Milliliter per Deciliter","C105504","A measure of volume concentration expressed as the number of milliters of a dissolved substance per deciliter of solution.","Milliliter per Deciliter | Milliliters per Deciliter | mL/dL | ml/dl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642209","Milliliter Per Second Per 1.73 Meter Squared","C105505","A metric unit of volumetric flow rate defined as the rate at which one milliliter of matter travels during the period of time equal to one second per 1.73 meters squared of body surface area.","Milliliter Per Second Per 1.73 Meter Squared | mL/s/1.73 m2 | mL/s/173/100.m2 | mL/sec/1.73m2 | ml/s/173/100.m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642211","Millimeter Per Minute","C105507","A unit of both speed (scalar) and velocity (vector), defined as the distance of one millimeter traveled per unit time equal to one minute.","Millimeter Per Minute | Millimeters per Minute | mm/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456681","Millimeter Per Second","C105508","A unit of both speed (scalar) and velocity (vector), defined as the distance of one millimeter traveled per unit time equal to one second.","Millimeter Per Second | Millimeters per Second | mm/s | mm/sec",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642212","Millimeter per Two Hours","C105509","A unit of both speed (scalar) and velocity (vector), defined as the distance of one centimeter traveled per unit time equal to two hours.","Millimeter per Two Hours | Millimeters per Two Hours | mm/2.h | mm/2h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642214","Millivolt Minute","C105512","A SI derived unit of magnetic flux, equal to the flux that produces in a circuit of one turn an electromotive force of one millivolt, when the flux is uniformly reduced to zero within one minute.","Millivolt Minute | Millivolt * Minutes | mV*min | mV.min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642215","Nanounit Per Centiliter","C105513","An arbitrary unit of substance content expressed in nanounit(s) per centiliter.","Nanounit Per Centiliter | Nanounit per Centiliter | nU/cL | {nUnit}/cL | {nUnit}/cl | {nU}/cL | {nU}/cl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642218","Per Visual Field","C105516","A unit of measure equal to the instances of an entity per visual field of a microscope.","Per Visual Field | /VF | /{VF}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642219","Ten Billion Per Liter","C105517","A concentration unit expressed as a number or quantity of objects in ten billions per unit of volume equal to one liter.","Ten Billion Per Liter | 10*10/L | 10*10/l | 10^10/L | 10^10/l | 10^4/mm3 | 10^4/uL | 10^7/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642220","Tera International Unit Per Liter","C105518","Unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of 10^12 international unit per one liter of system volume.","Tera International Unit Per Liter | 10*12.[IU]/L | 10*12.[IU]/l | 10*12.[iU]/L | 10*12.[iU]/l | 10^12 IU/L | 10^12.[IU]/L | 10^12.[IU]/l | 10^12.[iU]/L | 10^12.[iU]/l | TIU/L | Tera International Unit per Liter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642221","Thousand Per Liter","C105519","A concentration unit expressed as a number or quantity of objects in thousands per unit of volume equal to one liter.","Thousand Per Liter | /mL | 1/mL | 10*3/L | 10*3/l | 10^3/L | 10^3/l",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642222","Unit Per Centiliter","C105520","An arbitrary unit of substance concentration expressed in unit(s) per centiliter.","Unit Per Centiliter | U/cL | Unit per Centiliter | {Unit}/cL | {Unit}/cl | {U}/cL | {U}/cl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1532632","Unit Per Deciliter","C105521","An arbitrary unit of substance concentration expressed in unit(s) per deciliter.","Unit Per Deciliter | U/dL | Unit per Deciliter | {Unit}/dL | {Unit}/dl | {U}/dL | {U}/dl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642223","Unit Per Gram Hemoglobin","C105522","Unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one unit per gram of hemoglobin.","Unit Per Gram Hemoglobin | U/g HGB | U/g Hb | U/g Hemoglobin | U/g{HGB}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642225","Volt Per Second","C105524","A SI derived rate unit equal to one volt per unit of time equal to one second.","Volt Per Second | V/s | V/sec | Volt per Second",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714799","Frames Per Second","C106524","A unit of measure equal to the number of visual frames per unit of time equal to one second.","Frames Per Second | F/s | FPS | Frames per Second | Frames/s | Frames/sec | {Frames}/s",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829067","Milliliters Per Millimeter of Mercury","C106542","A unit equal to the volume in milliliters per one millimeter rise of mercury in a barometer at the Earth's surface.","Milliliters Per Millimeter of Mercury | Milliliters per Millimeter of Mercury | mL/mmHg | mL/mm[Hg] | ml/mm[Hg]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831523","Antibody Unit","C111129","A unit of antibody concentration measured by comparison against a known concentration of antibodies in a standard reference specimen.","Antibody Unit | AU | Antibody Concentration Unit | Standardized Antibody Concentration Unit | {Antibody Unit}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699114","Rouleaux Formation Count","C74624","The determination of the number of stacking red blood cells present in a blood sample.","Rouleaux Formation Count | ROULEAUX | Rouleaux Formation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879927","CDISC SDTM Age Unit Terminology","C66781","Terminology codelist used with Age Unit within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.","CDISC SDTM Age Unit Terminology | AGEU | Age Unit | SDTM-AGEU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454471","Biscuit Dosing Unit","C111139","A dosing unit equal to the amount of ingredient(s) in a biscuit.","Biscuit Dosing Unit | BISCUIT | {BISCUIT} | {Biscuit}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829066","Millimole per Mole","C111253","A unit of fraction expressed as the ratio of the amount of substance of solute in millimoles to the amount of substance of the mixture in moles.","Millimole per Mole | mmol/mol | umol/mmol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814463","Step Unit of Distance","C111318","A unit of measure to quantify the number of strides taken during a normal walking gait.","Step Unit of Distance | STEPS | {STEP} | {Step}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439475","Torr","C112423","A non-SI unit of pressure equal to 1/760 of a standard atmosphere (a standard atmosphere being defined as equal to 101 325 pascals). One Torr is equal to 133.3223684 pascals.","Torr | {Torr}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828029","Shockwave Dosing Unit","C112433","A dosing measurement based on the shock wave unit.","Shockwave Dosing Unit | Shock Wave | {SHOCK WAVE} | {Shock Wave}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828544","Pixels per Centimeter","C114238","A unit of image resolution expressed in the numbers of pixels per centimeter in the horizontal or vertical direction.","Pixels per Centimeter | PIXELS/cm | PPCM | {PIXELS}/cm | {Pixel}/cm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811894","Pixels per Inch","C114239","A unit of image resolution expressed in the numbers of pixels per inch in the horizontal or vertical direction.","Pixels per Inch | PIXELS/in | PPI | {PIXELS}/[in_i] | {Pixel}/[in_i]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813700","Percent per Minute","C114240","A unit of frequency expressed as the percentage of entities or events per minute.","Percent per Minute | %/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829065","Millivolt Squared per Hertz","C114241","A unit equal to one thousandth of a volt squared per unit of frequency equal to one Hertz.","Millivolt Squared per Hertz | Millivolt^2/Hertz | mV2/Hz",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829948","Grating Cycles per Centimeter","C114242","A unit of measure for the number of repeating vertical or horizontal bars per unit of length equal to one centimeter on a visual acuity testing card.","Grating Cycles per Centimeter | cpcm | cy/cm | {cy}/cm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899941","Biological Allergy Unit per Milliliter","C116231","A unit of allergenic product potency expressed as a number of biological units per one milliliter of formulation.","Biological Allergy Unit per Milliliter | BE/mL | Biological Unit per Milliliter | {BE}/mL | {BE}/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891156","Histamine Equivalent Prick Unit","C116232","A unit of allergenic product potency expressed as the number of histamine equivalent prick units.","Histamine Equivalent Prick Unit | HEP | {HEP}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897503","Standardized Allergy Biological Unit per Milliliter","C116233","A unit of allergenic product potency expressed as the number of standardized biological units per one milliliter of formulation.","Standardized Allergy Biological Unit per Milliliter | SBE/mL | Standardized Biological Unit per Milliliter | {SBE}/mL | {SBE}/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897502","Standardized Allergy Quality Unit per Milliliter","C116234","A unit of allergenic product potency expressed as the number of standardized quality units per one milliliter of formulation.","Standardized Allergy Quality Unit per Milliliter | SQ-u/mL | SQU/mL | Standardized Quality Unit per Milliliter | Standardized Quality Unit/mL | {SQU}/mL | {SQU}/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899942","Bioequivalent Allergy Unit per Milliliter","C116235","A unit of allergenic product potency expressed as the number of bioequivalent allergy units per one milliliter of formulation.","Bioequivalent Allergy Unit per Milliliter | BAU/mL | [BAU]/mL | [BAU]/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889285","Allergenic Protein Nitrogen Unit per Milliliter","C116236","A unit of allergenic product potency expressed as the number of protein nitrogen units per one milliliter of formulation.","Allergenic Protein Nitrogen Unit per Milliliter | PNU/mL | Protein Nitrogen Unit per Milliliter | [PNU]/mL | [PNU]/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899499","Copies per Microliter","C116237","A unit of concentration expressed as a number of copies per unit volume equal to one microliter.","Copies per Microliter | copies/uL | {copies}/ul",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898327","Millijoules per Square Centimeter","C116241","A unit of radiant exposure defined as a unit of energy equal to one millijoule applied to a unit of area equal to one square centimeter.","Millijoules per Square Centimeter | mJ/cm2 | mJoule/cm2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889739","Cigar Dosing Unit","C116244","A dosing unit equal to the amount of ingredient(s) in a cigar.","Cigar Dosing Unit | CIGAR | {CIGAR} | {Cigar}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890423","Cigarette Dosing Unit","C116245","A dosing unit equal to the amount of ingredient(s) in a cigarette.","Cigarette Dosing Unit | CIGARETTE | {CIGARETTE} | {Cigarette}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3892047","Pipe Dosing Unit","C116246","A dosing unit equal to the amount of ingredient(s) in a pipe.","Pipe Dosing Unit | PIPE | {PIPE} | {Pipe}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1628982","Percent Inhibition","C117963","The rate of measured normal activity minus inhibited activity, divided by the rate of normal activity of a given object. It is expressed as a percentage.","Percent Inhibition | % INHIBITION | %{INHIBITION} | %{inhibition}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898784","Immunoglobin A Phospholipid Unit per Milliliter","C117965","A unit for semiquantitative measurement of IgA autoantibodies to proteins associated with negatively charged phospholipids evaluated in ELISA serum anticardiolipin or anionic phospholipid assay against an established reference standard, per unit of volume equal to one milliliter.","Immunoglobin A Phospholipid Unit per Milliliter | APL U/mL | IgA Phospholipid Unit per Milliliter | Immunoglobin A Phospholipid Units per Milliliter | [APL'U]/mL | [APL'U]/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439151","Bethesda Unit","C117966","A unit of measurement for blood coagulation inhibitor activity, expressed in the amount of an inhibitor neutralizing 50% of a coagulant during the incubation period per unit of volume equal to one milliliter.","Bethesda Unit | BU | [beth'U]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899949","Bethesda Unit per Milliliter","C117967","A unit of measurement for blood coagulation inhibitor activity, expressed as a Bethesda Unit per unit of volume equal to one milliliter.","Bethesda Unit per Milliliter | BU/mL | [beth'U]/mL | [beth'U]/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899353","Disintegration per Minute per 100 milligrams","C117968","A unit of radioactive decay expressed in atoms of radioactive material that decay over a period of time equal to sixty seconds in a mass unit equal to one centigram.","Disintegration per Minute per 100 milligrams | Disintegrations per Minute per 100 milligrams | dpm/100 mg | dpm/100mg | dpm/cg | {disintegrations}/min/10*2.mg | {disintegrations}/min/10^2.mg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899352","Disintegration per Minute per Milligram","C117969","A unit of radioactive decay expressed in atoms of radioactive material that decay over a period of time equal to sixty seconds in a mass unit equal to one milligram.","Disintegration per Minute per Milligram | Disintegrations per Minute per Milligram | dpm/mg | {disintegrations}/min/mg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899351","Disintegration per Minute per Milliliter","C117970","A unit of radioactive decay expressed in atoms of radioactive material that decay over a period of time equal to sixty seconds in a volume unit equal to one milliliter.","Disintegration per Minute per Milliliter | Disintegrations per Minute per Milliliter | dpm/mL | {disintegrations}/min/mL | {disintegrations}/min/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898783","Immunoglobin G Phospholipid Unit per Milliliter","C117971","A unit for semiquantitative measurement of IgG autoantibodies to proteins associated with negatively charged phospholipids evaluated in ELISA serum anticardiolipin or anionic phospholipid assay against an established reference standard, per unit of volume equal to one milliliter.","Immunoglobin G Phospholipid Unit per Milliliter | GPL U/mL | IgG Phospholipid Units per Milliliter | Immunoglobin G Phospholipid Units per Milliliter | [GPL'U]/mL | [GPL'U]/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898578","Log10 Copies per Milliliter","C117972","A logarithmic-scale (base 10) unit for measuring copies per unit of volume equal to one milliliter.","Log10 Copies per Milliliter | log10 copies/mL | {Log10 copies}/mL | {Log10 copies}/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898782","Immunoglobin M Phospholipid Unit per Milliliter","C117973","A unit for semiquantitative measurement of IgM autoantibodies to proteins associated with negatively charged phospholipids evaluated in ELISA serum anticardiolipin or anionic phospholipid assay against an established reference standard, per unit of volume equal to one milliliter.","Immunoglobin M Phospholipid Unit per Milliliter | IgM Phospholipid Units per Milliliter | Immunoglobin M Phospholipid Units per Milliliter | MPL U/mL | [MPL'U]/mL | [MPL'U]/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898175","Nanomole Bone Collagen Equivalent per Liter","C117974","A unit of relative amount of substance concentration equal to nanomoles of bone collagen equivalent weight per unit of volume equal to one liter.","Nanomole Bone Collagen Equivalent per Liter | Nanomoles Bone Collagen Equivalents per Liter | nmol BCE/L | {nmolBCE}/L | {nmolBCE}/l",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898409","Microequivalent per Liter","C117975","A unit of relative amount of substance concentration equal to one billionth of a gram of an equivalent weight per unit of volume equal to one milliliter.","Microequivalent per Liter | Nanoequivalent per Milliliter | nEq/mL | uEq/L | ueq/L | ueq/l",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897010","Nanomole Bone Collagen Equivalent per Millimole","C118137","A unit of relative amount of substance concentration equal to nanomoles of bone collagen equivalent weight per unit of substance concentration equal to one millimole.","Nanomole Bone Collagen Equivalent per Millimole | Nanomoles Bone Collagen Equivalents per Millimole | nmol BCE/mmol | umol BCE/mol | {nmolBCE}/mmol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050590","Milligram per Mole","C120843","A unit of mass commonly used to express the molar mass of a substance in milligram(s) per mole.","Milligram per Mole | mg/mol | ug/mmol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054209","Per Kilogram","C120844","A mass unit equal to one kilogram used as a denominator to build a derived unit expressed as a ratio.","Per Kilogram | /kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055626","50 Percent Cell Culture Infective Dose per Milliliter","C120845","A potency unit equal to the potency at which one milliliter of preparation contains one 50 percent cell culture infective dose.","50 Percent Cell Culture Infective Dose per Milliliter | CCID 50/mL | [CCID_50]/mL | [CCID_50]/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055128","Disintegrations per Minute per 0.5 Milliliter","C120846","A unit of radioactive decay expressed in atoms of radioactive material that decay over a period of time equal to sixty seconds in a volume unit equal to a half milliliter.","Disintegrations per Minute per 0.5 Milliliter | dpm/0.5 mL | {Disintegrations}/min/(1/2).mL | {Disintegrations}/min/(1/2).ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055625","50 Percent Embryo Infective Dose per Milliliter","C120847","A potency unit for measuring infectious activity of a biologic product or an infectious agent preparation equal to the potency at which one milliliter of infectious material contains one 50 percent embryo infective dose.","50 Percent Embryo Infective Dose per Milliliter | EID 50/mL | [EID_50]/mL | [EID_50]/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1960947","International Unit per Deciliter","C120848","Unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one international unit per one deciliter of system volume.","International Unit per Deciliter | 10 IU/L | IU/dL | International Units per Deciliter | [IU]/dL | [IU]/dl | [iU]/dL | [iU]/dl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054689","Kilogram per Centimeter","C120849","A unit of measure equal to kilograms per length unit equal to one centimeter.","Kilogram per Centimeter | kg/cm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053998","Spot Forming Units Per Million Peripheral Blood Mononuclear Cells","C120850","A unit of measure equal to the spot forming units per million cells.","Spot Forming Units Per Million Peripheral Blood Mononuclear Cells | SFC/10^6 PBMC | SFU/10^6 PBMC | Spots/10^6 PBMC | {SFC}/10*6{PBMC} | {SFC}/10^6{PBMC}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055268","Carratelli Unit","C120851","An arbitrary unit of substance concentration expressed in milligrams per a volume of hydrogen peroxide. One Carratelli unit is equal to 0.8mg substance per liter of hydrogen peroxide.","Carratelli Unit | CARR U | U.CARR | {U.CARR}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050589","Micromole per Liter per Minute","C120852","A concentration unit equal to one micromole of solute in one liter of solution per unit of time equal to one minute.","Micromole per Liter per Minute | umol/L/min | umol/l/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053821","per 4.0 Milliliters","C122197","A volume unit equal to 4.0 milliliters used as a denominator to build a derived unit expressed as a ratio.","per 4.0 Milliliters | /4.0 mL | /4.mL | /4.ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0470397","per 7.5 Milliliters","C122198","A volume unit equal to 7.5 milliliters used as a denominator to build a derived unit expressed as a ratio.","per 7.5 Milliliters | /(75/10).mL | /(75/10).ml | /7.5 mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418712","/mm2","C122199","An area unit equal to one millimeter squared used as a denominator to build a derived unit expressed as a ratio.","per Square Millimeter | /mm2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055382","Billion per Gram","C122200","A unit of measurement equal to 10 to the ninth power of the number of entities per unit of mass equal to one gram.","Billion per Gram | /ng | 1/ng | 10*9/g | 10^12/kg | 10^3/ug | 10^6/mg | 10^9/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055464","Anson Unit","C122201","A unit of enzyme concentration which is defined as the amount of enzyme that can digest urea-denatured hemoglobin at the same initial rate as one milliequivalent of tyrosine at standard conditions (25C and pH 7.50).","Anson Unit | AU | Anson U | {Anson U}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054744","IgA Phospholipid Unit","C122202","A unit for semiquantitative measurement of IgA autoantibodies to proteins associated with negatively charged phospholipids evaluated against an established reference standard.","IgA Phospholipid Unit | APL U | Immunoglobin A Phospholipid Units | [APL'U]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055281","Candela Second per Square Meter","C122203","A unit of luminous intensity expressed as one candela in one second of light emittance per square meter of area.","Candela Second per Square Meter | cd*s/m2 | cd.s/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055280","Candela per Square Meter","C122204","A unit of luminous intensity expressed as one candela per square meter of area.","Candela per Square Meter | cd/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1532313","Enzyme Immunoassay Unit","C122205","A unit for measuring concentration or/and reactivity of a test substance (an antigen or antibody of interest) as defined in the literature reference standard for the particular quantitative enzyme immunoassay method.","Enzyme Immunoassay Unit | EIA unit | EIA value | {EIA unit}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054959","Femtomole per Liter per Second","C122206","A concentration unit equal to one femtomole of solute in one liter of solution per unit of time equal to one second. (NCI)","Femtomole per Liter per Second | Femtomoles per Liter per Second | fmol/L/s | fmol/L/sec | fmol/l/s",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439371","International Unit per Gram Hemoglobin","C122207","A unit of concentration (biologic activity) equal to one international unit of substance per gram of hemoglobin.","International Unit per Gram Hemoglobin | IU/g Hb | [IU]/g{HGB}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054702","International Unit per Millimole","C122208","A unit of concentration (biologic activity) equal to one international unit of substance per millimole of substance.","International Unit per Millimole | IU/mmol | [IU]/mmol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054688","King-Armstrong Unit per Deciliter","C122209","A unit of phosphatase concentration that can free one milligram of phenol from disodium phenylphosphate at standard conditions, per unit volume of the mixture equal to one deciliter.","King-Armstrong Unit per Deciliter | [ka'U]/dL | [ka'U]/dl | ka_u/dL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697914","Leukemic Blast to Lymphocyte Ratio Measurement","C74641","The determination of the ratio of leukemic blasts compared to lymphocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Leukemic Blast to Lymphocyte Ratio Measurement | BLSTLMLY | Leukemic Blasts/Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541350","Factor V Activity Measurement","C103396","The determination of the amount of the biological activity of factor V in a sample.","Factor V Activity Measurement | FACTVA | Factor V Activity | Labile Factor Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698519","Bite Cell to Erythrocyte Ratio Measurement","C74634","The determination of the ratio of bite cells compared to erythrocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Bite Cell to Erythrocyte Ratio Measurement | BTECERBC | Bite Cells/Erythrocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0200638","Eosinophil Count","C64550","The determination of the number of eosinophils in a blood sample.","Eosinophil Count | EOS | Eosinophil | Eosinophils",,,,,,,,,,,,,,,"4216098","Eosinophil count",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0201956","Citrate Measurement","C92248","The determination of the amount of citrate present in a sample.","Citrate Measurement | CITRATE | Citrate | Citric Acid",,,,,,,,,,,,,,,"4220804","Citrate measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1295138","Epidermal Growth Factor Measurement","C82009","The determination of the amount of epidermal growth factor present in a sample.","Epidermal Growth Factor Measurement | EGF | EGF Measurement | Epidermal Growth Factor",,,,,,,,,,,,,,,"4005379","Epidermal growth factor measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3810607","Nitric Oxide Measurement","C112360","The determination of the amount of nitric oxide present in a sample.","Nitric Oxide Measurement | NITRICOX | NO | Nitric Oxide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1168341","Segmented Neutrophil Count","C81997","The determination of the amount of segmented neutrophils present in a sample.","Segmented Neutrophil Count | NEUTSG | Neutrophils, Segmented | Segmented Neutrophil | Segs (Neutrophils)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541223","CD11A Expressing Cell Count","C105439","The determination of the amount of the CD11a expressing cells in a sample.","CD11A Expressing Cell Count | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524280","von Willebrand Factor Activity Actual to Control Ratio Measurement","C147447","The determination of the ratio of the biological activity of von Willebrand factor dependent coagulation in a subject's specimen when compared to the same activity in a control specimen. The measurement may be expressed as a ratio or percentage.","von Willebrand Factor Activity Actual to Control Ratio Measurement | VWFAAC | von Will Factor Act Actual/Control | von Willebrand Factor Activity Actual/Normal | von Willebrand Factor Activity Actual/von Willebrand Factor Activity Control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640655","Endogenous Thrombin Potential Lag Time Relative Measurement","C102265","A relative measurement (ratio or percentage) of time from the start of the thrombin generation test to the point where a predetermined amount of thrombin is generated.","Endogenous Thrombin Potential Lag Time Relative Measurement | ETP Lag Time Relative | ETPLTR | Endogenous Thrombin Potential Lag Time Relative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202086","Immunoglobulin E Measurement","C81970","The determination of the amount of immunoglobulin E present in a sample.","Immunoglobulin E Measurement | IGE | Immunoglobulin E",,,,,,,,,,,,,,,"4220748","Immunoglobulin E measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698390","Bilirubin Crystal Measurement","C74668","The determination of the amount of bilirubin crystals present in a sample.","Bilirubin Crystal Measurement | Bilirubin Crystals | CYBILI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882077","Neutrophil Band Form to Leukocyte Ratio","C64831","The determination of the ratio of band neutrophils compared to leukocytes in a blood sample. The measurement may be expressed as a ratio or percentage.","Neutrophil Band Form to Leukocyte Ratio | NEUTBLE | Neutrophils Band Form/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266744","Temazepam Measurement","C75376","The determination of the amount of temazepam present in a sample.","Temazepam Measurement | TMZPM | Temazepam",,,,,,,,,,,,,,,"4005361","Temazepam measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825885","CD40 Ligand Measurement","C82007","The determination of the amount of CD40 ligand present in a sample.","CD40 Ligand Measurement | TNFSF5 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055336","CD45 to Lymphocyte Ratio Measurement","C122106","The determination of the ratio of CD45 expressing cells to total lymphocytes present in a sample. The measurement by be expressed as a ratio or percentage.","CD45 to Lymphocyte Ratio Measurement | PTPRC to Lymphocyte Ratio Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700289","Yeast Cell Measurement","C74664","The determination of the number of yeast cells present in a sample.","Yeast Cell Measurement | YEAST | Yeast Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1446042","Pemphigoid Antibody Measurement","C81988","The determination of the amount of pemphigoid antibodies present in a sample.","Pemphigoid Antibody Measurement | PEMAB | Pemphigoid Antibodies",,,,,,,,,,,,,,,"4133664","Pemphigoid antibody measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545959","Base Deficit","C147309","The determination of the amount of alkali required to return a biological specimen to a normal pH under standard conditions.","Base Deficit | BASEDEF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201851","Alkaline Phosphatase Isoenzyme Measurement","C139091","The determination of the amount of alkaline phosphatase isoenzyme present in a sample.","Alkaline Phosphatase Isoenzyme Measurement | ALPISOE | Alkaline Phosphatase Isoenzyme",,,,,,,,,,,,,,,"4220699","Alkaline phosphatase isoenzymes measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4050586","Kilogram per Mole","C122210","A unit of mass commonly used to express the molar mass of a substance in kilogram(s) per mole.","Kilogram per Mole | g/mmol | kg/mol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054519","Milli-Anson Unit per Milliliter","C122211","A unit of enzymatic activity defined a one milli-Anson unit per unit volume equal to one milliliter.","Milli-Anson Unit per Milliliter | mAnson U/mL | {mAnson U}/mL | {mAnson U}/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053997","Square Milligram per Square Deciliter","C122212","A unit of mass concentration defined as one square milligram of a substance in unit volume of the mixture equal to one square deciliter.","Square Milligram per Square Deciliter | mg2/dL2 | mg2/dl2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053996","Square Millimole per Square Liter","C122213","A unit of concentration (molarity unit) equal to one square millimole of solute per square liter of solution.","Square Millimole per Square Liter | mmol2/L2 | mmol2/l2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054495","Milliosmole per Liter","C122214","A unit of osmotic pressure equal to one thousandth of an osmole per unit of volume equal to one Liter.","Milliosmole per Liter | mOsm/L | mosm/L | mosm/l",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1532982","Milliunit per Gram","C122215","An arbitrary unit of substance content expressed in milliunit(s) per gram.","Milliunit per Gram | mU/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054494","Millivolt per Second","C122216","A SI derived rate unit equal to one millivolt per unit of time equal to one second.","Millivolt per Second | mV/s | mV/sec | uV/msec",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1533636","Inulin Clearance","C98748","The rate at which inulin is removed or cleared from the whole or part of the body.","Inulin Clearance | INLCLR",,,,,,,,,,,,,,,"4092952","Inulin renal clearance measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2985358","Rh Factor Measurement","C92948","An immunology test to measure for the presence of the Rh factor antigen in blood.","Rh Factor Measurement | RH | Rh Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514046","English Plantain Pollen IgE Measurement","C130084","A measurement of the English plantain (Plantago lanceolata) pollen IgE in a biological specimen.","English Plantain Pollen IgE Measurement | C130084 | English Plantain Pollen IgE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274483","Monocytes to Total Cell Ratio Measurement","C98872","The determination of the ratio of monocytes compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Monocytes to Total Cell Ratio Measurement | MONOCE | Monocytes to Total Cells Ratio Measurement | Monocytes/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274387","Eosinophils to Total Cell Ratio Measurement","C98720","The determination of the ratio of eosinophils compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Eosinophils to Total Cell Ratio Measurement | EOSCE | Eosinophils to Total Cells Ratio Measurement | Eosinophils/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539060","Activated Protein C Resistance Measurement","C100471","A measurement of the resistance in the anticoagulation response to activated protein C in a biological specimen.","Activated Protein C Resistance Measurement | APROTCRS | Activated Protein C Resistance | Factor V Leiden Screen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0236379","Estrone Measurement","C74857","The determination of the amount of estrone hormone present in a sample.","Estrone Measurement | ESTRONE | Estrone | Oestrone",,,,,,,,,,,,,,,"4017646","Estrone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202233","Thyroxine Binding Globulin Protein Measurement","C74746","The determination of the amount of thyroxine binding globulin protein present in a sample.","Thyroxine Binding Globulin Protein Measurement | TBG | Thyroxine Binding Globulin",,,,,,,,,,,,,,,"4190692","Thyroxine binding globulin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0201889","Anion Gap Measurement","C74685","The determination of the unmeasured anions (those other than the chloride and bicarbonate anions) present in a sample.","Anion Gap Measurement | ANIONG | Anion Gap",,,,,,,,,,,,,,,"4103762","Anion gap measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3272895","Erythrocyte Ghost Count","C96605","The determination of the amount of erythrocyte ghosts (erythrocytes in which hemoglobin has been removed through hemolysis) present in a sample.","Erythrocyte Ghost Count | Erythrocyte Ghosts | RBC Ghosts | RBCGHOST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984925","Sjogren's SS-A Antibody Measurement","C92236","The determination of the amount of Sjogren's SS-A antibody present in a sample.","Sjogren's SS-A Antibody Measurement | Ro Antibody | SJSSAAB | Sjogrens SS-A Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699539","Cystine Crystal Measurement","C74674","The determination of the amount of cystine crystals present in a sample.","Cystine Crystal Measurement | CYCYSTIN | Cystine Crystals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698962","Calcium Phosphate Crystal Measurement","C74671","The determination of the amount of calcium phosphate crystals present in a sample.","Calcium Phosphate Crystal Measurement | CYCAPHOS | Calcium Phosphate Crystals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697783","Interleukin 33 Measurement","C74831","The determination of the amount of interleukin 33 present in a sample.","Interleukin 33 Measurement | INTLK33 | Interleukin 33",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514035","Cat Dander Antigen IgG Antibody Measurement","C130125","A measurement of the cat dander antigen IgG antibody in a biological specimen.","Cat Dander Antigen IgG Antibody Measurement | C130125 | Cat Dander Antigen IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274425","Neutrophil to Total Cell Ratio Measurement","C98763","The determination of the ratio of neutrophils compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Neutrophil to Total Cell Ratio Measurement | NEUTCE | Neutrophils to Total Cells Ratio Measurement | Neutrophils/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521192","Keyhole Limpet Hemocyanin IgG Antibody Measurement","C132372","The determination of the amount of keyhole limpet hemocyanin IgG antibody in a biological sample.","Keyhole Limpet Hemocyanin IgG Antibody Measurement | KLHIGGAB | Keyhole Limpet Hemocyanin IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513379","Tree Mix Pollen Antigen IgE Antibody Measurement","C130101","A measurement of the tree mix pollen antigen IgE antibody in a biological specimen.","Tree Mix Pollen Antigen IgE Antibody Measurement | C130101 | Tree Mix Pollen Antigen IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202368","Diazepam Measurement","C75372","The determination of the amount of diazepam present in a sample.","Diazepam Measurement | DZPM | Diazepam",,,,,,,,,,,,,,,"4242527","Diazepam measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202105","Transferrin Measurement","C82037","The determination of the amount of transferrin present in a sample.","Transferrin Measurement | Beta-1 Metal-Binding Globulin | Serotransferrin | Siderophilin | TFERRIN | Transferrin",,,,,,,,,,,,,,,"4235029","Transferrin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825918","Segmented Neutrophil to Leukocyte Ratio Measurement","C82045","The determination of the ratio of segmented neutrophils compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Segmented Neutrophil to Leukocyte Ratio Measurement | NEUTSGLE | Neutrophils, Segmented/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523559","Intermediate Density Lipoprotein Cholesterol Measurement","C112325","The determination of the amount of intermediate density lipoprotein present in a sample.","Intermediate Density Lipoprotein Cholesterol Measurement | IDL | IDL Cholesterol | Intermediate Density Lipoprotein",,,,,,,,,,,,,,,"4019544","IDL cholesterol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202081","Immunoglobulin Measurement","C81869","The determination of the amount of immunoglobulin present in a sample.","Immunoglobulin Measurement | IMMGLB | Immunoglobulin",,,,,,,,,,,,,,,"4174402","Immunoglobulin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698955","Calcium Oxalate Crystal Measurement","C74670","The determination of the amount of calcium oxalate crystals present in a sample.","Calcium Oxalate Crystal Measurement | CYCAOXA | Calcium Oxalate Crystals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0302276","Metanephrine Measurement","C116198","The determination of the amount of metanephrine present in a sample.","Metanephrine Measurement | METANEPH | Metadrenaline | Metanephrine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0392886","Acetoacetic Acid Measurement","C92247","The determination of the amount of acetoacetic acid present in a sample.","Acetoacetic Acid Measurement | ACETOAC | Acetoacetate | Acetoacetic Acid",,,,,,,,,,,,,,,"4019558","Diacetate measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3820394","Thrombin to Antithrombin Ratio Measurement","C106574","The determination of the ratio of thrombin compared to antithrombin present in a sample. The measurement may be expressed as a ratio or percentage.","Thrombin to Antithrombin Ratio Measurement | TAT | Thrombin/Antithrombin | Thrombin/Antithrombin III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054424","Nanomole Bone Collagen Equivalents per Nanomole","C122217","A unit of relative amount of substance concentration equal to nanomoles of bone collagen equivalent weight per unit of substance concentration equal to one nanomole.","Nanomole Bone Collagen Equivalents per Nanomole | Nanomoles Bone Collagen Equivalents per Nanomole | nmol BCE/nmol | {nmolBCE}/nmol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054423","Nanomole per Liter per Hour","C122218","A rate unit expressed in nanomole(s) per liter of solution per period of time equal to sixty minutes.","Nanomole per Liter per Hour | nmol/L/h | nmol/l/h | pmol/mL/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050151","Nanomole per Liter per Minute","C122219","A rate unit equal to the number of nanomoles per unit of volume equal to one liter per unit of time equal to one minute.","Nanomole per Liter per Minute | nmol*min/L | nmol/L/min | nmol/l/min | pmol/mL/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054422","Nanomole per Mole","C122220","A unit of fraction expressed as the ratio of the amount of a substance in solution, in nanomoles, to the amount of a different substance in the mixture, in moles.","Nanomole per Mole | nmol/mol | pmol/mmol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054173","Plaque Forming Units per Animal","C122221","A unit of measure expressed in plaque forming unit(s) per animal.","Plaque Forming Units per Animal | PFU/animal | [PFU]/{animal}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054183","Picokatal per Liter","C122222","A unit of catalytic activity concentration defined as activity equal to a picokatal per one liter of the system volume.","Picokatal per Liter | pkat/L | pkat/l",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054179","Picomole per Ten Billion Cells","C122223","A unit of concentration (molarity unit) equal to one picomole of substance per ten to the tenth power cells.","Picomole per Ten Billion Cells | pmol/10*10{cells} | pmol/10^10 cells | pmol/10^10{cells}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054182","Picomole per Billion Cells","C122224","A unit of concentration (molarity unit) equal to one picomole of substance per ten to the ninth power cells.","Picomole per Billion Cells | pmol/10*9{cells} | pmol/10^9 cells | pmol/10^9{cells}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054181","Picomole per Day","C122225","A unit of amount of substance flow rate equivalent to the rate at which one picomole of substance travels to a given object or space over a period of time equal to 24 hours.","Picomole per Day | pmol/d | pmol/day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054180","Picomole per Deciliter","C122226","A unit of concentration (molarity unit) equal to one picomole of solute per deciliter of solution.","Picomole per Deciliter | Picomoles per Deciliter | pmol/dL | pmol/dl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050622","Picomole per Liter per Hour","C122227","A rate unit expressed in picomole(s) per liter of solution per period of time equal to sixty minutes.","Picomole per Liter per Hour | Picomoles per Liter per Hour | pmol/L/h | pmol/l/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053893","Unit per Trillion Red Blood Cells","C122228","An arbitrary unit of substance content expressed in units of biological activity per ten to the twelfth power red blood cells.","Unit per Trillion Red Blood Cells | /10*12{RBCs} | U/10*12{RBC} | U/10^12 RBC | U/10^12{RBC} | per trillion red blood cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050009","Microgram per Liter per Hour","C122229","A rate unit equal to the number of micrograms per unit of volume equal to one liter per unit of time equal to one hour.","Microgram per Liter per Hour | ng/mL/h | ug/L/h | ug/l/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054525","Microgram Equivalent per Liter","C122230","A concentration unit measured as a number of microgram equivalent of solute per liter of solution.","Microgram Equivalent per Liter | ng.eq/mL | ng.eq/ml | ngEq/mL | ug.eq/L | ug.eq/l | ugEq/L | ugeq/L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1532564","Micromole per Mole","C122231","A unit of fraction expressed as the ratio of the amount of a substance in solution, in micromoles, to the amount of a different substance in the mixture, in moles.","Micromole per Mole | nmol/mmol | umol/mol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050554","Per Thousand","C123634","A unit equal to one thousand entities used as a denominator to build a derived unit expressed as a ratio.","Per Thousand | /10*3 | /10^3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1688650","Milligram per Squared Centimeter","C124456","A unit of area density defined as a spread rate at which one milligram of a substance is spread over the area of one square centimeter. The unit is also used as a dose calculation unit.","Milligram per Squared Centimeter | mg/cm2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086581","Milligram per Dose","C124457","A unit of measure expressed in milligram(s) per dose.","Milligram per Dose | mg/dose | mg/{dose}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086582","Milligram per Kilogram per Dose","C124458","A dose calculation unit expressed in milligram(s) per kilogram per single dose.","Milligram per Kilogram per Dose | mg/kg/dose | mg/kg/{dose}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086583","Milliliter per Dose","C124459","A unit of measure expressed in milliliter(s) per dose.","Milliliter per Dose | mL/dose | mL/{dose} | ml/{dose}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086912","Transducing Unit","C124460","A unit of biological activity described as the number of viral particles in solution that are capable of infecting a cell and stimulating expression of a transgene.","Transducing Unit | TRANSDUCING UNIT | {TRANSDUCING UNIT}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086911","Transducing Unit per Milliliter","C124461","Unit of measure of potency expressed as a number of transducing units per one milliliter of solution.","Transducing Unit per Milliliter | TRANSDUCING UNIT/mL | Transducing Unit/mL | {TRANSDUCING UNIT}/mL | {TRANSDUCING UNIT}/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086574","Microgram per Dose","C124462","A unit of measure expressed in microgram(s) per dose.","Microgram per Dose | ug/dose | ug/{dose}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086571","Micro-International Unit per Deciliter","C124463","A unit of concentration (biologic activity) equal to one micro-international unit of substance per deciliter of solution.","Micro-International Unit per Deciliter | uIU/dL | u[IU]/dL | u[IU]/dl | u[iU]/dL | u[iU]/dl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086572","Micro-International Unit per Liter","C124464","A unit of concentration (biologic activity) equal to one micro-international unit of substance per liter of solution.","Micro-International Unit per Liter | uIU/L | u[IU]/L | u[IU]/l | u[iU]/L | u[iU]/l",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086575","Microkatal per Trillion Erythrocytes","C124465","Unit of catalytic activity concentration defined as activity equal to one millionth of a katal per 10^12 erythrocytes.","Microkatal per Trillion Erythrocytes | mckat/10^12 RBC | ukat/10*12{RBC} | ukat/10^12 RBC | ukat/10^12{RBC}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086576","Microliter per Dose","C124466","A unit of measure expressed in microliter(s) per dose.","Microliter per Dose | uL/dose | uL/{dose} | ul/{dose}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697775","Interleukin 26 Measurement","C74823","The determination of the amount of interleukin 26 present in a sample.","Interleukin 26 Measurement | INTLK26 | Interleukin 26",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0373535","Aldosterone Measurement","C74841","The determination of the amount of aldosterone hormone present in a sample.","Aldosterone Measurement | ALDSTRN | Aldosterone",,,,,,,,,,,,,,,"4308581","Aldosterone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3639410","Immature Granulocytes to Leukocytes Ratio Measurement","C100445","The determination of the ratio of immature granulocytes compared to total leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Immature Granulocytes to Leukocytes Ratio Measurement | GRANIMLE | Immature Granulocytes/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827997","Sodium Clearance Measurement","C106568","The determination of the amount of the sodium clearance in a sample.","Sodium Clearance Measurement | NACLR | Sodium Clearance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272948","Immature Basophil Count","C96670","The determination of the amount of immature basophils present in a sample.","Immature Basophil Count | BASOIM | Immature Basophils",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272958","Immature Plasma Cell to Lymphocyte Ratio Measurement","C96680","The determination of the ratio of immature plasma cells compared to total lymphocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Immature Plasma Cell to Lymphocyte Ratio Measurement | Immature Plasma Cells/Lymphocytes | PLSIMCLY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0428629","Free Androgen Index","C124341","A measurement of androgen status in a biological specimen, which is calculated by dividing total testosterone by sex hormone binding globulin and multiplying by a constant (usually 100).","Free Androgen Index | FAI",,,,,,,,,,,,,,,"4154486","Free androgen index measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1305955","Megakaryocyte Count","C96688","The determination of the amount of megakaryocytes present in a sample.","Megakaryocyte Count | KRCYMG | Megakaryocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0302278","Pyruvate Measurement","C147427","The determination of the amount of pyruvate present in a sample.","Pyruvate Measurement | PYRUVATE | Pyruvate | Pyruvic Acid",,,,,,,,,,,,,,,"4017336","Pyruvate measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640665","Soluble Interleukin 2 Receptor Activity Measurement","C102280","The determination of the amount of soluble interleukin 2 receptor activity present in a sample.","Soluble Interleukin 2 Receptor Activity Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898572","Low Absorption Reticulocyte Measurement","C116190","The determination of the amount of low absorption reticulocytes present in a sample.","Low Absorption Reticulocyte Measurement | Low Absorption Reticulocytes | RETIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828974","Monocytoid Cell to Total Cell Ratio Measurement","C111277","The determination of the ratio of the monocytoid cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Monocytoid Cell to Total Cell Ratio Measurement | MOCYCECE | Monocytoid Cells to Total Cells Ratio Measurement | Monocytoid Cells/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086577","Micromole per Hour per Millimole","C124467","A unit of fraction expressed as the ratio of the number of micromoles of substance per unit of time equal to one hour, to the amount of a different substance, in millimoles.","Micromole per Hour per Millimole | umol/h/mmol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085227","Micromole per Liter per Hour","C124468","A concentration unit equal to one micromole of solute in one liter of solution per unit of time equal to one hour.","Micromole per Liter per Hour | umol/L/h | umol/l/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086573","Micro-Unit per Deciliter","C124469","An arbitrary unit of substance content expressed in microunit(s) per deciliter.","Micro-Unit per Deciliter | uU/dL | u{Unit}/dL | u{Unit}/dl | u{U}/dL | u{U}/dl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085871","Micro-Unit per Liter","C124470","An arbitrary unit of substance content expressed in microunit(s) per liter.","Micro-Unit per Liter | uU/L | u{Unit}/L | u{Unit}/l | u{U}/L | u{U}/l",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086943","Vector Genomes per Dose","C124471","A unit for cloning vector amounts expressed as the number of vector genomes per dose.","Vector Genomes per Dose | VGC/dose | Vector Genomes/dose | Vector Genomic Copies/dose | vg/dose | {vg}/{dose}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086944","Vector Genomes per Milliliter","C124472","A unit for cloning vector amounts expressed as the number of vector genomes per milliliter.","Vector Genomes per Milliliter | VGC/mL | Vector Genomes/mL | Vector Genomic Copies/mL | vg/mL | {vg}/mL | {vg}/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086952","Viral Particles per Dose","C124473","A unit for virus amount expressed as the number of viral particles per dose.","Viral Particles per Dose | Viral Particles/dose | vp/dose | {vp}/{dose}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086953","Viral Particles per Milliliter","C124474","A unit for virus amount expressed as the number of viral particles per milliliter.","Viral Particles per Milliliter | Viral Particles/mL | vp/mL | {vp}/mL | {vp}/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504676","Absorbance Unit per Milliliter","C126078","A unit of optical density expressed as the absorbance of light transmitted through the medium on the logarithmic scale per unit of volume equal to one milliliter.","Absorbance Unit per Milliliter | AU/mL | Absorbance U/mL | {Absorbance U}/mL | {Absorbance U}/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698949","Cabot Ring Count (lab procedure)","C74702","The determination of the number of Cabot rings present in a sample.","Cabot Ring Count | CABOT | Cabot Rings",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504677","Copies per Microgram","C126079","A unit of concentration expressed as a number of copies per unit mass equal to one microgram.","Copies per Microgram | copies/ug | {copies}/ug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1318462","Streptolysin O Antibody Measurement","C92282","The determination of the amount of streptolysin O antibody present in a sample.","Streptolysin O Antibody Measurement | Antistreptolysin O | STRPLOAB | Streptolysin O Antibody",,,,,,,,,,,,,,,"4190509|4220858","ASO test|Antistreptolysin O titer",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL504678","Cubic Millimeter per Square Millimeter per Year","C126080","A rate unit defined as the number of cubic millimeters of substance per area equal to one square millimeter per unit of time equal to one year.","Cubic Millimeter per Square Millimeter per Year | mm3/mm2/a | mm3/mm2/year",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825900","Monocyte Chemotactic Protein 1 Measurement","C82025","The determination of the amount of monocyte chemotactic protein 1 present in a sample.","Monocyte Chemotactic Protein 1 Measurement | CCL2 | Chemokine (C-C Motif) Ligand 2 | MCP1 | Monocyte Chemoattractant Protein-1 | Monocyte Chemotactic Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504679","Micrometer per Day","C126081","A unit of volumetric flow rate defined as the rate at which one micrometer of matter crosses a given surface during the period of time equal to one day.","Micrometer per Day | um/d | um/day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049862","Immunoglobulin G Subclass 4 Measurement","C122130","The determination of the amount of immunoglobulin G subclass 4 present in a sample.","Immunoglobulin G Subclass 4 Measurement | IGG4 | IgG4 Measurement | Immunoglobulin G Subclass 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504680","Micromole per Kilogram per Minute","C126082","A unit of concentration (molarity unit) equal to one millionth of a mole (10E-6 mole) per kilogram of a substance per period of time equal to sixty seconds.","Micromole per Kilogram per Minute | umol/kg/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699418","Complement C1q Antibody Measurement","C80173","The determination of the amount of complement C1q antibody present in a sample.","Complement C1q Antibody Measurement | C1QAB | Complement C1q Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508910","One per Second Times Kilopascal","C127804","A unit of resistance equal to the inverse of one kilopascal multiplied by a unit of time equal to one second.","One per Second Times Kilopascal | /(s*kPa) | 1/(s*kPa) | 1/(s.kPa)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526581","Corpuscular Hemoglobin Concentration Mean","C139067","A measurement of the average concentration of hemoglobin per erythrocyte in a biological specimen, derived from flow cytometric light scatter analysis of intact cells.","Corpuscular Hemoglobin Concentration Mean | CHCM | Corpuscular HGB Concentration Mean | Erythrocyte Corpuscular Hemoglobin Concentration Mean",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509269","Metabolic Equivalent of Task Hours","C127806","A unit of energy expenditure equal to the number of metabolic equivalent of task units multiplied by the number of hours of performed activity.","Metabolic Equivalent of Task Hours | MET*h | [MET].h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699391","Coarse Granular Cast Measurement","C74765","The determination of the amount of coarse granular casts present in a urine sample.","Coarse Granular Cast Measurement | CSGRANC | Granular Coarse Casts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509270","Metabolic Equivalent of Task Minute","C127807","A unit of energy expenditure equal to the number of metabolic equivalent units multiplied by the number of minutes of performed activity.","Metabolic Equivalent of Task Minute | MET*min | [MET].min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698260","Monosodium Urate Crystal Measurement","C74681","The determination of the amount of monosodium urate crystals present in a sample.","Monosodium Urate Crystal Measurement | CYMSU | Monosodium Urate Crystals | Sodium Urate Crystals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456718","Milliliter per Heartbeat","C127808","A unit of measure expressed as the number of milliliter(s) per heart beat.","Milliliter per Heartbeat | mL/beat | mL/{beat} | ml/{beat}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509800","Millinewton","C127809","An SI derived unit of force equal to one thousandth of a Newton.","Millinewton | mN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508971","Pheresis Unit","C127810","An arbitrary unit of substance concentration equal to the yield from a blood pheresis procedure.","Pheresis Unit | PHERESIS UNIT | {PHERESIS UNIT}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512332","Beam Break Unit","C129002","The unit of measure for the number of times in which light paths are interrupted by movement.","Beam Break Unit | BEAM BREAKS | {BEAM BREAKS}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513758","Ejaculate Unit","C130046","A unit of volume equal to the amount of seminal fluid produced by a single ejaculation event.","Ejaculate Unit | Ejaculate U | {Ejaculate U}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513983","Per Large Square Neubauer Chamber","C130187","A unit of measure equal to the instances of an entity per large square (with a 1mm x 1mm area) in a Neubauer chamber.","Per Large Square Neubauer Chamber | /LSQN | /Large Square Neubauer | /{LSQN}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514207","Per Millimeter","C130188","A unit of length equal to one millimeter that is used as a denominator to build a derived unit expressed as a ratio.","Per Millimeter | /mm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513177","Million Per Ejaculate Unit","C130189","A unit of measurement equal to 10 to the sixth power of entities per unit equal to one ejaculation.","Million Per Ejaculate Unit | 10*6/{Ejaculate U} | 10^6/Ejaculate U | 10^6/{Ejaculate U}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274375","Anti-Factor Xa Activity Measurement","C98706","The determination of the amount of anti-activated Factor X present in a sample. This test is used to monitor low molecular weight or unfractionated heparin levels in a biological specimen.","Anti-Factor Xa Activity Measurement | AFACTXAA | Anti-Factor Xa Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545247","Complement CH100 Measurement","C147317","The determination of the amount of complement required to lyse 100 percent of red blood cells in a biological specimen.","Complement CH100 Measurement | CH100 | Complement CH100 | Total Hemolytic Complement CH100",,,,,,,,,,,,,,,"42536357","CH100 (hundred percent hemolytic complement) technique",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509252","Immature Leukocyte Count","C127625","The determination of the number of immature leukocytes in a biological sample.","Immature Leukocyte Count | Immature Leukocytes | LEIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202386","Fluoride Measurement","C122120","The determination of the amount of fluoride present in a sample.","Fluoride Measurement | FLUORIDE | Fluoride",,,,,,,,,,,,,,,"4168768","Fluoride measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898610","Left Shift Neutrophil Measurement","C116202","The determination of the presence of left shift neutrophils in a sample.","Left Shift Neutrophil Measurement | Left Shift Neutrophils | NEUTLS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513747","Weed Mix Pollen Antigen IgA Antibody Measurement","C130108","A measurement of the weed mix pollen antigen IgA antibody in a biological specimen.","Weed Mix Pollen Antigen IgA Antibody Measurement | C130108 | Weed Mix Pollen Antigen IgA Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891545","Amyloid Alpha Precursor Protein Measurement","C119268","The determination of the amount of the amyloid alpha precursor protein in a biological specimen.","Amyloid Alpha Precursor Protein Measurement | APPA | Amyloid Alpha Precursor Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054448","N-telopeptide to Creatinine Ratio Measurement","C120645","The determination of the ratio of N-telopeptide compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","N-telopeptide to Creatinine Ratio Measurement | N-telopeptide/Creatinine | NTELOCRT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513372","Timothy Grass Pollen IgG Measurement","C130090","A measurement of the Timothy grass (Phleum pretense) pollen IgG in a biological specimen.","Timothy Grass Pollen IgG Measurement | C130090 | Timothy Grass Pollen IgG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514010","American Cockroach Antigen IgA Antibody Measurement","C130137","A measurement of the American cockroach (Periplaneta americana) antigen IgA antibody in a biological specimen.","American Cockroach Antigen IgA Antibody Measurement | American Cockroach Antigen IgA Antibody | C130137",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL496387","Alpha-2 Antiplasmin Activity Measurement","C122094","The determination of the amount of the biological activity of alpha-2 antiplasmin in a sample.","Alpha-2 Antiplasmin Activity Measurement | APLSMA2A | Alpha-2 Antiplasmin Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984928","Yeast Hyphae Screening","C92239","Examination of a biological specimen to detect the presence of any yeast cells that are in the long, filamentous and branching phase of growth.","Yeast Hyphae Screening | YEASTHYP | Yeast Hyphae",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541908","Sperm Motility Measurement","C102281","The determination of the amount of sperm capable of forward, progressive movement present in a semen sample.","Sperm Motility Measurement | SPERMMTL | Sperm Motility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522813","Lymphocytes to Non-Squamous Epithelial Cells Ratio Measurement","C135430","The determination of the ratio of lymphocytes compared to non-squamous epithelial cells present in a sample. The measurement may be expressed as a ratio or percentage.","Lymphocytes to Non-Squamous Epithelial Cells Ratio Measurement | LYMNSQE | Lymphocytes/Non-Squam Epi Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639407","Immature Neutrophils to Leukocytes Ratio Measurement","C100442","The determination of the ratio of immature neutrophils compared to total leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Immature Neutrophils to Leukocytes Ratio Measurement | Immature Neutrophils/Leukocytes | NEUTIMLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049919","Insulin Sensitivity Measurement","C123459","The determination of the insulin sensitivity (cells are stimulated by lower than normal insulin levels) in a biological specimen.","Insulin Sensitivity Measurement | INSULINS | Insulin Sensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984933","Amorphous Urate Crystals Measurement","C92244","The determination of the amount of amorphous urate crystals present in a sample.","Amorphous Urate Crystals Measurement | Amorphous Urate Crystals | CYAMPURT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898828","Hypogranular Neutrophil Measurement","C116201","The determination of the amount of hypogranular neutrophils present in a sample.","Hypogranular Neutrophil Measurement | Hypogranular Neutrophils | NEUTHYGR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523954","Trypsin and Trypsinogen Measurement","C135450","The determination of the amount of the total trypsin and total trypsinogen in a biological specimen.","Trypsin and Trypsinogen Measurement | TRPTRG | Trypsin and Trypsinogen",,,,,,,,,,,,,,,"4017358","Trypsin and trypsinogen measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1168442","Proteinase 3 Antibody Measurement","C120649","The determination of the proteinase 3 antibody present in a sample.","Proteinase 3 Antibody Measurement | Myeloblastin Antibody Measurement | Myeloblastin Measurement | PRTN3AB | Proteinase 3 Antibody",,,,,,,,,,,,,,,"4304816","Measurement of proteinase 3 antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698258","Monoblast to Leukocyte Ratio Measurement","C74646","The determination of the ratio of monoblast cells compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Monoblast to Leukocyte Ratio Measurement | MONOBLLE | Monoblasts/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639419","DNase-B Antibody Measurement","C100463","The determination of the amount of Dnase-B antibody present in a sample.","DNase-B Antibody Measurement | Anti-Dnase B | DNASEBAB | DNase-B Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545320","Partial Pressure of Oxygen Adjusted for Body Temperature Measurement","C147417","The determination of the partial pressure of oxygen, adjusted for body temperature, present in a sample.","Partial Pressure of Oxygen Adjusted for Body Temperature Measurement | PO2 Adjusted for Body Temperature | PO2ADJT | Partial Pressure Oxygen Adj for Temp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514054","Mixed Antigen IgE Antibody Measurement","C130100","A measurement of the mixed antigen IgE antibody in a biological specimen.","Mixed Antigen IgE Antibody Measurement | C130100 | Mixed Antigen IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545261","Zea mays Antigen IgE Antibody Measurement","C147279","The determination of the amount of Zea mays antigen IgE antibody present in a sample.","Zea mays Antigen IgE Antibody Measurement | C147279 | Corn Antigen IgE Antibody | Zea mays Antigen IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830309","Epstein-Barr Nuclear Antigen 1 IgG Ab Measurement","C106518","The determination of the amount of the Epstein-Barr nuclear antigen 1 IgG antibody present in a sample.","Epstein-Barr Nuclear Antigen 1 IgG Ab Measurement | EBN1IGAB | Epstein-Barr Nuclear Antigen 1 IgG Ab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697759","Interleukin 11 Measurement","C74807","The determination of the amount of interleukin 11 present in a sample.","Interleukin 11 Measurement | INTLK11 | Interleukin 11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505135","Amyloid A Measurement","C125940","The determination of the amount of amyloid A present in a sample.","Amyloid A Measurement | AMYLOIDA | Amyloid A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272921","Thyroperoxidase Measurement","C96639","The determination of the amount of thyroperoxidase present in a sample.","Thyroperoxidase Measurement | THYPXD | Thyroid Peroxidase | Thyroperoxidase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880522","Eosinophil to Leukocyte Ratio","C64604","The determination of the ratio of eosinophils compared to leukocytes in a blood sample. The measurement may be expressed as a ratio or percentage.","Eosinophil to Leukocyte Ratio | EOSLE | Eosinophils/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698838","Poikilocyte to Erythrocyte Ratio Measurement","C74649","The determination of the ratio of poikilocytes compared to all erythrocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Poikilocyte to Erythrocyte Ratio Measurement | POIKRBC | Poikilocytes/Erythrocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700094","Turbidity Measurement","C74723","The determination of the opacity of a sample.","Turbidity Measurement | TURB | Turbidity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333942","Polychromasia","C64803","The reaction of red cells to stain as indicated by the appearance of bluish or grayish colored erythrocytes.","Polychromasia | POLYCHR",,,,,,,,,,,,,,,"4182050","Polychromatophilic stain reaction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2700107","Unclassified Crystal Measurement","C74757","The determination of the amount of unclassified crystals present in a urine sample.","Unclassified Crystal Measurement | CYUNCLA | Unclassified Crystals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524013","Amobarbital Measurement","C75363","The determination of the amount of amobarbital present in a sample.","Amobarbital Measurement | AMBRBTL | Amobarbital",,,,,,,,,,,,,,,"4017473","Amobarbital measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545292","Factor XIV Activity Actual to Control Ratio Measurement","C147346","The determination of the ratio of the biological activity of factor XIV dependent coagulation in a subject's specimen when compared to the same activity in a control specimen. The measurement may be expressed as a ratio or percentage.","Factor XIV Activity Actual to Control Ratio Measurement | FXIVAAC | Factor XIV Activity Actual/Control | Factor XIV Activity Actual/Factor XIV Activity Control | Factor XIV Activity Actual/Normal | Protein C Activity Actual/Control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523708","5-Hydroxyindoleacetic Acid Measurement","C112217","The determination of the amount of 5-hydroxyindoleacetic acid present in a sample.","5-Hydroxyindoleacetic Acid Measurement | 5-Hydroxyindoleacetate | 5-Hydroxyindoleacetic Acid | IAA5OH",,,,,,,,,,,,,,,"4018333","5-Hydroxyindoleacetic acid measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825881","Apolipoprotein CIII Measurement","C82001","The determination of the amount of apolipoprotein CIII present in a sample.","Apolipoprotein CIII Measurement | APOC3 | APOC3 Measurement | Apolipoprotein C-III Measurement | Apolipoprotein C3 Measurement | Apolipoprotein CIII",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541880","3,4-Dihydroxyphenylglycol Measurement","C101017","The determination of the amount of 3,4-Dihydroxyphenylglycol present in a sample.","3,4-Dihydroxyphenylglycol Measurement | 3,4-Dihydroxyphenylglycol | 3.4 Dihydroxyphenylglycol | DHPG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513759","Opsonization Index 50%","C130193","A potency unit equal to the dilution of serum that causes opsonization and phagocytosis of 50% of the bacteria in a sample.","Opsonization Index 50% | OI50 | {OI50}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514075","Nanogram Equivalents Per Liter","C130192","A concentration unit measured as a number of nanogram equivalent of solute per liter of solution.","Nanogram Equivalents Per Liter | ng.eq/L | ng.eq/l | ngEq/L | pgEq/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513176","Milliliter Per Minute Times One Hundred Milliliters","C130191","A unit of flow rate expressed as the number of milliliters per number of minutes times a unit of volume equal to 100 milliliters.","Milliliter Per Minute Times One Hundred Milliliters | mL/(min*100mL) | mL/min.10*2.mL | mL/min.10*2.ml | ml/min.10*2.mL | ml/min.10*2.ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513102","Glycoprotein-ELISA Unit Per Milliliter","C130190","A unit for measuring potency of immunologically active substance in a product determined as reactivity in a glycoprotein enzyme-linked immunosorbent assay for particular antigen or antibody and expressed per unit volume equal to one milliliter.","Glycoprotein-ELISA Unit Per Milliliter | gpELISA unit/mL | {gpELISA unit}/mL | {gpELISA unit}/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698235","Mixed Cast Count","C74771","The determination of the number of mixed casts present in a urine sample.","Mixed Cast Count | CSMIX | Mixed Casts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899372","Dimorphic Erythrocyte Population","C117853","The determination of the amount of dimorphic erythrocyes present in a sample.","Dimorphic Erythrocyte Population | Dimorphic RBC Population | RBCDIPOP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698800","Pi Glutathione S-Transferase Measurement","C80203","The determination of the amount of Pi glutathione-s-transferase present in a sample.","Pi Glutathione S-Transferase Measurement | GSTPI | Glutathione S-Transferase, Pi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272934","Glutamic Acid Decarboxylase Antibody Measurement","C96653","The determination of the amount of glutamic acid decarboxylase antibody present in a sample.","Glutamic Acid Decarboxylase Antibody Measurement | GAD Antibody | GADAB | Glutamic Acid Decarboxylase Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898820","IDL Particles Measurement","C116197","The determination of the amount of intermediate density lipoprotein particles present in a sample.","IDL Particles Measurement | IDL Particles | IDLP | Intermediate Density Lipoproteins Particles",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523850","Hepatitis C Virus Core Antigen Measurement","C135424","The determination of the amount of hepatitis C virus core antigen in a biological sample.","Hepatitis C Virus Core Antigen Measurement | HCCAG | HCV Core Antigen Measurement | Hepatitis C Virus Core Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700267","Waxy Cell Cast Measurement","C74777","The determination of the number of waxy cell casts present in a urine sample.","Waxy Cell Cast Measurement | CSWAX | Waxy Casts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513757","Reciprocal of Seconds Times Percent O2 Concentration","C130194","A unit of oxygen transfer function expressed as the reciprocal of time in seconds divided by the oxygen concentration.","Reciprocal of Seconds Times Percent O2 Concentration | s-1.(%{O2})-1 | s^-1(%O2)^-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899259","Erythrocyte Fragment Measurement","C116212","The determination of the amount of red blood cell fragments present in a sample.","Erythrocyte Fragment Measurement | Erythrocyte Fragment | RBC Fragment | RBCFRAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4048238","Aspartic Acid Measurement","C122097","The determination of the amount of aspartic acid present in a sample.","Aspartic Acid Measurement | ASP | Aspartate | Aspartic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984926","Sjogren's SS-B Antibody Measurement","C92237","The determination of the amount of Sjogren's SS-B antibody present in a sample.","Sjogren's SS-B Antibody Measurement | La Antibody | SJSSBAB | Sjogrens SS-B Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828529","Platelet Function Closure Time Measurement","C111295","The determination of the collagen closure time, as a surrogate of platelet function, present in a sample.","Platelet Function Closure Time Measurement | PFCT | Platelet Function Closure Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699511","Squamous Epithelial Cell Count","C74773","The determination of the number of squamous epithelial cells present in a urine sample.","Squamous Epithelial Cell Count | EPISQCE | Squamous Cells | Squamous Epithelial Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641252","Immunoblast Count","C103407","The determination of the amount of the immunoblasts in a sample.","Immunoblast Count | BLASTIMM | Immunoblastic Lymphocytes | Immunoblasts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699420","Complement Measurement","C80160","The determination of the amount of complement present in a sample.","Complement Measurement | CTOT | Complement Total | Total Hemolytic Complement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880491","Elliptocyte Count","C64549","The determination of the number of elliptocytes in a blood sample.","Elliptocyte Count | ELLIPCY | Elliptocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814394","HER2 Antigen Measurement","C112291","The determination of the amount of soluble HER2 antigen, including peptides, epitopes, and receptor, present in a sample.","Soluble HER2 Antigen Measurement | HER2 Antigen | HER2 Antigen Measurement | HER2/NEU Antigen | HER2/NEU Shed Antigen | HER2S | Soluble HER2 | Soluble HER2/NEU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825847","Starch Crystal Measurement","C81951","The determination of the amount of starch crystals present in a sample.","Starch Crystal Measurement | CYSTARCH | Starch Crystals | Starch Granules",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698518","Bite Cell Count (procedure)","C74700","The determination of the number of bite cells present in a sample.","Bite Cell Count | BITECE | Bite Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201979","Urine cyclic adenosine monophosphate measurement","C124339","The determination of the amount of cyclic adenosine 3,5-monophosphate present in a sample.","Cyclic Adenosine 3,5-Monophosphate Measurement | CAMP | Cyclic AMP Measurement | Cyclic Adenosine 3,5-Monophosphate | cAMP Measurement",,,,,,,,,,,,,,,"4200828","Cyclic adenosine monophosphate measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3272945","Herpes Simplex Virus 1 IgG Antibody Measurement","C96666","The determination of the amount of Herpes Simplex virus 1 IgG antibody present in a sample.","Herpes Simplex Virus 1 IgG Antibody Measurement | HS1IGGAB | HSV-1 IgG Antibody | Herpes Simplex Virus 1 IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545235","Chemokine (C-X-C Motif) Ligand 13 Measurement","C147328","The determination of the amount of chemokine (C-X-C motif) ligand 13 present in a sample.","Chemokine (C-X-C Motif) Ligand 13 Measurement | B Lymphocyte Chemoattractant | CCL13 Measurement | CXCL13 | CXCL13 Measurement | Chemokine (C-X-C Motif) Ligand 13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879882","Blast to Leukocyte Ratio","C64487","The determination of the ratio of blasts compared to leukocytes in a blood sample. The result may be expressed as either a ratio or a percentage.","Blast to Leukocyte Ratio | BLASTLE | Blasts/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1328418","Hydroxyproline Measurement","C80190","The determination of the amount of hydroxyproline present in a sample.","Hydroxyproline Measurement | HYPRLN | Hydroxyproline",,,,,,,,,,,,,,,"4204713","Hydroxyproline measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL522827","Leukocytes to Total Cells Ratio Measurement","C135451","The determination of the ratio of leukocytes compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Leukocytes to Total Cells Ratio Measurement | Leukocytes/Total Cells | WBC/Total Cells | WBCCE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700083","Triple Phosphate Crystal Measurement","C74756","The determination of the amount of triple phosphate crystals present in a urine sample.","Triple Phosphate Crystal Measurement | Ammonium Magnesium Phosphate Crystals | CYTRPHOS | Struvite Crystals | Triple Phosphate Crystals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0373916","HIV-1 Antibody Measurement","C74713","The determination of the antibody reaction of a sample to the HIV-1 virus.","HIV-1 Antibody Measurement | HIV-1 Antibody | HIV1AB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640657","Endogenous Thrombin Potential Peak Height Measurement","C102267","The determination of the amount of maximum concentration of thrombin generated during a thrombin generation test.","Endogenous Thrombin Potential Peak Height Measurement | ETP Peak Height | ETPPH | Endogenous Thrombin Potential Peak Height",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0427611","Activated Coagulation Time","C103348","The determination of the amount of the inhibition of blood coagulation in response to anticoagulant therapies.","Activated Coagulation Time | ACT | Activated Clotting Time",,,,,,,,,,,,,,,"4288447","Coagulation time, activated",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1881506","Macrocyte Count procedure","C64821","The determination of the number of macrocytes in a blood sample.","Macrocyte Count | MACROCY | Macrocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524040","Buprenorphine Measurement","C75352","The determination of the amount of buprenorphine present in a sample.","Buprenorphine Measurement | BUPREN | Buprenorphine",,,,,,,,,,,,,,,"4021442","Buprenorphine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2697559","Hairy Cell Count","C74604","The determination of the number of hairy cells present in a sample.","Hairy Cell Count | HAIRYCE | Hairy Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337451","Gold Measurement","C80186","The determination of the amount of gold present in a sample.","Gold Measurement | GOLD | Gold",,,,,,,,,,,,,,,"4099467","Gold measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242401","Opiate Measurement","C74796","The determination of the amount of any opiate present in a sample.","Opiate Measurement | OPIATE | Opiate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699192","Cholesterol Crystal Measurement","C74672","The determination of the amount of cholesterol crystals present in a sample.","Cholesterol Crystal Measurement | CYCHOL | Cholesterol Crystals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201927","Ionized Calcium Measurement","C81948","The determination of the amount of ionized calcium present in a sample.","Ionized Calcium Measurement | CAION | Calcium, Ionized",,,,,,,,,,,,,,,"4307178","Measurement of serum ionized calcium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545315","Free Protein S Activity Actual to Control Ratio Measurement","C147425","The determination of the ratio of the biological activity of free protein S in a subject's specimen when compared to the same activity in a control specimen. The measurement may be expressed as a ratio or percentage.","Free Protein S Activity Actual to Control Ratio Measurement | PTSFAAC | Protein S Free Activity Actual/Control | Protein S Free Activity Actual/Normal | Protein S Free Activity Actual/Protein S Free Activity Control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202311","Aluminum Measurement","C111127","A measurement of aluminum present in a sample.","Aluminum Measurement | ALUMINUM | Al | Aluminum",,,,,,,,,,,,,,,"4297322","Aluminum measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2609437","Apolipoprotein J Measurement","C100428","The determination of the amount of apolipoprotein J present in a sample.","Apolipoprotein J Measurement | APOJ | APOJ Measurement | Apolipoprotein J | Clusterin | Clusterin Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520762","Log10 50 Percent Tissue Culture Infective Dose per Milliliter","C132478","A logarithmic-scale (base 10) potency unit for measuring infectious activity of a biologic product or infectious agent preparation equal to the potency at which one milliliter of infectious material contains one 50 percent tissue culture infective dose.","Log10 50 Percent Tissue Culture Infective Dose per Milliliter | log10 TCID 50/mL | {log}.[TCID_50]/mL | {log}.[TCID_50]/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521327","Base Pair Unit","C132477","The unit of measure for the number of paired nucleotides in a DNA or RNA sequence.","Base Pair Unit | BASE PAIRS | BP | {BP}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520896","Per 500 White Blood Cells","C132476","Natural number unit of measurement for a portion of a particular type of cell (excluding white blood cell subtypes) per 500 white blood cells.","Per 500 White Blood Cells | /500 WBC | /500{WBC}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520895","Per 40 High Powered Fields","C132475","A unit of measurement of the number of entities per unit of area equal to 40 high powered fields.","Per 40 High Powered Fields | /40 HPFs | /40.[HPF] | Per 40HPF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520894","Per 2500 White Blood Cells","C132474","Natural number unit of measurement for a portion of a particular type of cell (excluding white blood cell subtypes) per 2500 white blood cells.","Per 2500 White Blood Cells | /2500 WBC | /2500{WBC}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520893","Per 2000 Red Blood Cells","C132473","Natural number unit of measurement for a portion of a particular type of cell (excluding red blood cell subtypes) per 2000 red blood cells.","Per 2000 Red Blood Cells | /2000 RBC | /2000{RBC} | /2x10^3 RBC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520892","Per 200 High Powered Fields","C132472","A unit of measurement of the number of entities per unit of area equal to 200 high powered fields.","Per 200 High Powered Fields | /200 HPFs | /200.[HPF] | Per 200HPF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0427760","Leukocyte Esterase Measurement","C64856","A quantitative measurement of the amount of leukocyte esterase present in a sample.","Leukocyte Esterase Measurement | LEUKASE | Leukocyte Esterase",,,,,,,,,,,,,,,"4017784","Leukocyte esterase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1535899","Non-high-density lipoprotein cholesterol measurement","C116204","The determination of the amount of non-high density lipoprotein cholesterol present in a sample.","Non-High Density Lipoprotein Cholesterol Measurement | NONHDL | Non-HDL Cholesterol | Non-High Density Lipoprotein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053905","Type II Collagen C-Telopeptides to Creatinine Ratio Measurement","C122113","The determination of the ratio of type II collagen C-telopeptides to creatinine present in a sample. The measurement by be expressed as a ratio or percentage.","Type II Collagen C-Telopeptides to Creatinine Ratio Measurement | CTXIICRT | Type II Collagen C-Telopeptides/Creat | Type II Collagen X-Linked C-Telopeptides/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699520","Acanthocyte to Erythrocyte Ratio Measurement","C74633","The determination of the ratio of acanthocytes compared to erythrocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Acanthocyte to Erythrocyte Ratio Measurement | ACANTRBC | Acanthocytes/Erythrocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439517","Liter per Second per Kilopascal","C139133","A unit of conductance equal to the number of liters per unit of time equal to one second per unit of pressure equal to one kilopascal.","Liter per Second per Kilopascal | L/s/kPa | l/s/kPa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526632","Second Times Kilopascal","C139132","A unit of resistance equal to one second times one kilopascal.","Second Times Kilopascal | Kilopascal Second | kPa*s | kPa.s | s*kPa | s.kPa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526968","Hour Times Percent","C139131","A unit of measure for the area under an effect curve (AUEC), defined as hours times percent.","Hour Times Percent | h*% | h.%",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526628","Minimum Alveolar Concentration 50 Percent","C139130","A unit of potency for inhalational gases, defined as the concentration of gas in the lung required to immobilize 50% of individuals in response to a stimulus, such as pain.","Minimum Alveolar Concentration 50 Percent | MAC50 | Minimum Alveolar Concentration 50% | {MAC50}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522883","Milliliter Times Centimeter of Water","C135521","A unit of measure for volume change calculation expressed by multiplying the volume of air flow in mL by the air pressure in cmH2O.","Milliliter Times Centimeter of Water | mL*cmH2O | mL.cm[H2O] | ml.cm[H2O]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522882","Centimeter of Water per Milliliter","C135520","A unit of measure for pressure change that is expressed in cmH2O per milliliter.","Centimeter of Water per Milliliter | cmH2O/mL | cm[H2O]/mL | cm[H2O]/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522881","Centimeter of Water Times Second Squared per Milliliter","C135519","A unit of measure for pressure change that is expressed by multiplying cmH2O by seconds, multiplying that product by seconds, then dividing that subsequent product by the volume of air flow in milliliters","Centimeter of Water Times Second Squared per Milliliter | cmH2O*s2/mL | cm[H2O].s2/mL | cm[H2O].s2/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522880","Centimeter of Water Times Second per Milliliter","C135518","A unit of measure for pressure change that is expressed by multiplying cmH2O by seconds, and then dividing that product by the volume of air flow in milliliters","Centimeter of Water Times Second per Milliliter | cmH2O*s/mL | cm[H2O].s/mL | cm[H2O].s/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522879","Per Centimeter of Water","C135517","A unit of pressure equal to one centimeter of water used as a denominator to build a derived unit expressed as a ratio.","Per Centimeter of Water | /cmH2O | /cm[H2O]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522878","Per Hundred Thousand","C135516","A unit, equal to one hundred thousand entities, is used as a denominator to build a derived unit expressed as a ratio.","Per Hundred Thousand | /10*5 | /10^5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522877","Per Ten Thousand","C135515","A unit, equal to ten thousand entities, is used as a denominator to build a derived unit expressed as a ratio.","Per Ten Thousand | /10*4 | /10^4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520054","Microliter per Kilogram per Day","C132481","A unit of volume expressed as a number of microliters of the constituent per kilogram of weight per day.","Microliter per Kilogram per Day | (uL/day)/kg | nL/g/day | uL/kg/d | uL/kg/day | ul/kg/d",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520061","MilliMerck Unit per Milliliter","C132480","A unit of concentration based on the vaccine specific number of titers that are the geometric mean titer at which an individual is considered to convert from a seronegative to a seropositive response due to the vaccine.","MilliMerck Unit per Milliliter | mMU/mL | {mMU}/mL | {mMU}/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520761","Log10 50 Percent Tissue Culture Infective Dose per Microliter","C132479","A logarithmic-scale (base 10) potency unit for measuring infectious activity of a biologic product or infectious agent preparation equal to the potency at which one microliter of infectious material contains one 50 percent tissue culture infective dose.","Log10 50 Percent Tissue Culture Infective Dose per Microliter | log10 TCID 50/uL | {log}.[TCID_50]/uL | {log}.[TCID_50]/ul",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697999","Macrophage Colony Stimulating Factor Measurement","C80191","The determination of the amount of macrophage colony stimulating factor present in a sample.","Macrophage Colony Stimulating Factor Measurement | MCSF | Macrophage Colony Stimulating Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054280","P100 Polymyositis-scleroderma Autoantigen Antibody Measurement","C120651","The determination of the P100 polymyositis-scleroderma autoantigen antibody present in a sample.","P100 Polymyositis-scleroderma Autoantigen Antibody Measurement | Exosome Component 10 Antibody Measurement | P100 Polymyositis-scleroderma Autoag Ab | PSP100AB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881487","Lymphocyte to Leukocyte Ratio","C64820","The determination of the ratio of lymphocytes compared to leukocytes in a blood sample. The measurement may be expressed as a ratio or percentage.","Lymphocyte to Leukocyte Ratio | LYMLE | Lymphocytes/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700212","Free Carnitine Measurement","C74677","The determination of the amount of free carnitine present in a sample.","Free Carnitine Measurement | CARNITF | Carnitine, Free",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640653","Endogenous Thrombin Potential Area Under Curve Measurement","C102263","The measurement of the area under the thrombin generation curve.","Endogenous Thrombin Potential Area Under Curve Measurement | ETP Area Under Curve | ETPAUC | Endogenous Thrombin Potential Area Under Curve",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522815","Megakaryocyte and Megakaryoblast Morphology Assessment","C135432","An examination or assessment of the form and structure of megakaryocytes and megakaryoblasts present in a sample.","Megakaryocyte and Megakaryoblast Morphology Assessment | MKCMKBMP | Megakaryocyte and Megakaryoblast Morph | Megakaryocyte and Megakaryoblast Morphology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513976","Orchard Grass Pollen IgG4 Measurement","C130083","A measurement of the orchard grass (Dactylis glomerata) pollen IgG4 in a biological specimen.","Orchard Grass Pollen IgG4 Measurement | C130083 | Cocksfoot Grass Pollen IgG4 | Orchard Grass Pollen IgG4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697527","Growth Hormone Releasing Hormone Measurement","C74862","The determination of the amount of growth hormone releasing hormone present in a sample.","Growth Hormone Releasing Hormone Measurement | GRWHRH | Growth Hormone Releasing Hormone | Somatocrinin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202241","Urobilinogen Measurement","C64816","A quantitative measurement of the amount of urobilinogen present in a sample.","Urobilinogen Measurement | UROBIL | Urobilinogen",,,,,,,,,,,,,,,"4327657","Urobilinogen measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4085310","Calcium Sulfate Crystals Measurement","C124340","The determination of the amount of calcium sulphate crystals present in a sample.","Calcium Sulfate Crystals Measurement | CYCASULF | Calcium Sulfate Crystals | Calcium Sulphate Crystals Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202001","Erythropoietin Measurement","C74855","The determination of the amount of erythropoietin hormone present in a sample.","Erythropoietin Measurement | EPO | Erythropoietin | Hematopoietin",,,,,,,,,,,,,,,"4185265","Erythropoietin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1295117","Corticotropin Releasing Hormone Measurement","C74851","The determination of the amount of corticotropin releasing hormone present in a sample.","Corticotropin Releasing Hormone Measurement | CRH | Corticotropin Releasing Factor | Corticotropin Releasing Hormone",,,,,,,,,,,,,,,"4007649","Corticotropin releasing hormone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202098","Insulin Measurement","C74788","The determination of the amount of insulin present in a sample.","Insulin Measurement | INSULIN | Insulin",,,,,,,,,,,,,,,"4060873","Insulin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554558","Event Unit","C150901","A unit of measure for the number of happenings at a given place or time.","Event Unit | EVENTS | {EVENTS}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439525","Hybrid Resistance Units","C150900","A unit of resistance equal to the number of millimeters of mercury times minutes, per unit of volume equal to one liter.","Hybrid Resistance Units | Wood Unit | Wood Units | Wood units | mmHg*min/L | mm[Hg].min/L | mm[Hg].min/l",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552749","Seconds Per Hour","C150899","A rate unit expressed in seconds per period of time equal to sixty minutes.","Seconds Per Hour | Seconds per Hour | s/h | sec/hr",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552748","Millimeters of Aluminum Equivalents","C150898","A unit defined as the thickness, in millimeters, of aluminum that has the equivalent degree of attenuation, under specified conditions, as the actual material in use within the procedure.","Millimeters of Aluminum Equivalents | mmAI | mmAL | {mmAL}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545061","Enzyme Unit per Liter","C147130","Unit of catalytic activity concentration defined as activity equal to one enzyme unit per one liter of system volume.","Enzyme Unit per Liter | Enzyme U/L | Enzyme Unit/L | {Enzyme}.U/L | {Enzyme}.U/l",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698401","N-Acetyl Glucosamide Measurement","C79459","The determination of the amount of N-acetyl glucosamide present in a sample.","N-Acetyl Glucosamide Measurement | N-Acetyl Glucosamide | N-Acetyl Glucosamine | NAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2208854","Borrelia burgdorferi IgM Antibody Measurement","C122101","The determination of the amount of Borrelia burgdorferi IgM antibody present in a sample.","Borrelia burgdorferi IgM Antibody Measurement | BBRIGMAB | Borrelia Burgdorferi IgM Antibody Measurement | Borrelia burgdorferi IgM Antibody | Lyme IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201379","Heterophile Antibody Measurement","C81984","The determination of the amount of heterophile antibodies present in a sample.","Heterophile Antibody Measurement | HTPHAB | Heterophile Antibodies",,,,,,,,,,,,,,,"4040445","Heterophile antibody measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825919","Nucleated Erythrocyte to Leukocyte Ratio Measurement","C82046","The determination of the ratio of nucleated erythrocytes compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Nucleated Erythrocyte to Leukocyte Ratio Measurement | Nucleated Erythrocytes/Leukocytes | RBCNUCLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201883","Amylase Measurement","C64434","A quantitative measurement of amylase present in a sample.","Amylase Measurement | AMYLASE | Amylase",,,,,,,,,,,,,,,"4276028","Amylase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897988","Partial Pressure Arterial Oxygen to Fraction Inspired Oxygen Ratio Measurement","C119293","The determination of the ratio of the pressure of oxygen dissolved in arterial blood to the percentage oxygen of an inhaled mixture of gasses in a biological specimen.","Partial Pressure Arterial Oxygen to Fraction Inspired Oxygen Ratio Measurement | PAO2/FIO2 | PO2FIO2 | PP Arterial O2/Fraction Inspired O2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700256","Vitamin B7 Measurement","C74902","The determination of the amount of Vitamin B7 present in a sample.","Vitamin B7 Measurement | Biotin | VITB7 | Vitamin B7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539065","Dextroamphetamine Measurement","C102262","The determination of the amount of dextroamphetamine present in a sample.","Dextroamphetamine Measurement | AMPHETD | Dextroamphetamine | d-amphetamine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0582515","Farad","C42552","A SI unit of capacitance equal to the capacitance of a capacitor having an equal and opposite charge of one coulomb on each plate and a potential difference of one volt between the plates.","Farad | F | farad",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0562424","Coulomb","C42550","A SI derived unit of quantity of electricity, equal to the quantity of charge transferred in one second across a conductor in which there is a constant current of one ampere.","Coulomb | Amp-second | Ampere second | C | coulomb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0542569","Newton","C42546","A SI derived unit of force. The force which, when applied in a vacuum to a body having a mass of one kilogram, causes an acceleration of one meter per second squared. It is equal to 10E5 dynes.","Newton | N | newton",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700300","Candela","C42538","A unit of luminous intensity, one of the seven base units of the International System of Units (Systeme International d'Unites, SI). It is the luminous intensity in a given direction of a small monochromatic light source at 540 terahertz emitting 1/683 watt per steradian in that direction. This is dependent upon the definitions of the meter, kilogram, and second.","Candela | candela | cd",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706498","Ampule Dosing Unit","C48473","A dosing unit equal to the amount of active ingredient(s) contained in an ampule.","Ampule Dosing Unit | AMPULE | Amp | Ampoule | Ampule | {AMPULE} | {Ampule}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0560915","Meter per Second Squared","C42572","Meter per second squared is a SI unit of acceleration.","Meter per Second Squared | Meter per Second per Second | m/s/s | m/s2 | m/sec2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439493","Meter per Second","C42571","A SI derived unit of both speed (scalar) and velocity (vector), defined as the distance of one meter travelled per unit time equal to one second.","Meter per Second | Meter Per Second | m/s | m/sec",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439245","Katal","C42566","A unit for measuring catalytic (e.g. enzymatic) activity, the ability of the compound to accelerate the chemical reaction by providing a lower energy pathway between the reactants and the products. One katal is that catalytic activity which will raise the rate of reaction by one mole per second in a specified assay system. When the katal is used, the measurand should be specified by reference to the measurement procedure; the measurement procedure must identify the indicator reaction. The katal is not used to express a rate of reaction itself, which should be expressed in moles per second. Katal is coherent with the SI.","Katal | kat | katal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0560038","Becquerel","C42562","A SI derived unit of activity of a radionuclide, equal to one nuclear disintegration or other nuclear transition from a particular energy state occurring in an amount of a radionuclide during one second-long time interval.","Becquerel | Bq | becquerel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0560137","Lux","C42561","A SI derived unit of illuminance equal to the direct illumination on a surface that is everywhere one meter from a uniform point source of one candela; a unit of illuminance that is equal to one lumen per square meter.","Lux | lux | lx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551056","Units Of Measure - lumen","C42560","A SI derived unit of luminous flux. It is the amount of light that falls on a unit area at unit distance from a source of one candela.","Lumen | lm | lumen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0582517","Henry","C42558","A SI derived unit of electric inductance. A coil with an inductance of one henry requires a flux of one weber for each ampere of induced current. If it is the current which changes, then the induced field will generate a potential difference within the coil: if the inductance is one henry a current change of one ampere per second generates a potential difference of one volt. The henry is a large unit; inductances in practical circuits are measured in millihenrys or microhenrys.","Henry | H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0582525","Weber (magnetic flux unit)","C42556","A SI derived unit of magnetic flux, equal to the flux that produces in a circuit of one turn an electromotive force of one volt, when the flux is uniformly reduced to zero within one second.","Weber | V*s | V*sec | V.s | Volt Second | Volt-second | Wb | weber",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551054","Units Of Measure - Siemens","C42555","A unit of electrical conductance, admittance, and susceptance. A conductor has a conductance of one siemens if an electrical potential difference of one volt produces a one ampere current in it. The conductance in siemens is the reciprocal of its resistance in ohms.","Siemens | Reciprocal ohm | S | mho | siemens",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705958","Drum Dosing Unit","C48492","A dosing unit equal to the amount of active ingredient(s) contained in a drum.","Drum Dosing Unit | DRUM | Drum | {DRUM} | {Drum}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704654","Cylinder Dosing Unit","C48489","A dosing unit equal to the amount of active ingredient(s) contained in a cylinder.","Cylinder Dosing Unit | CYLINDER | Cylinder | {CYLINDER} | {Cylinder}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705944","Coat Dosing Unit","C48483","A dosing measurement based on the coat unit.","Coat Dosing Unit | COAT | Coat | {COAT} | {Coat}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705509","Bolus Dosing Unit","C48476","A dosing unit equal to the amount of active ingredient(s) contained in a bolus.","Bolus Dosing Unit | BOLUS | Bolus | {BOLUS} | {Bolus}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704759","Bar Dosing Unit","C48475","A dosing unit equal to the amount of active ingredient(s) contained in a bar.","Bar Dosing Unit | BAR | Bar | {BAR} | {Bar}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705993","Lozenge Dosing Unit","C48506","A dosing unit equal to the amount of active ingredient(s) contained in a lozenge.","Lozenge Dosing Unit | LOZENGE | Lozenge | {LOZENGE} | {Lozenge}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1690540","Kit Dosing Unit","C48504","A dosing unit equal to the amount of active ingredient(s) contained in a kit.","Kit Dosing Unit | KIT | KT | Kit | {KIT} | {Kit}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1445118","Kallikrein Inhibitor Unit","C48503","One Kallikrein Inhibitor Unit is identical to the quantity of protease inhibitor (eg, aprotinin) that has the ability to inhibit two kallikrein units by 50% under optimal conditions. One Kallikrein Inhibitor Unit is equal to 0.025 antiplasmin units or 0.0031 trypsin inhibitor units.","Kallikrein Inhibitor Unit | KALLIKREIN INHIBITOR UNIT | KIU | Kallikrein Inactivator Unit | {KALLIKREIN INHIBITOR} | {Kallikrein Inhibitor}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706196","Jar Dosing Unit","C48502","A dosing unit equal to the amount of active ingredient(s) contained in a jar.","Jar Dosing Unit | JAR | Jar | {JAR} | {Jar}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705604","Implant Dosing Unit","C48499","A dosing unit equal to the amount of active ingredient(s) contained in an implant.","Implant Dosing Unit | IMPLANT | Implant | {IMPLANT} | {Implant}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705107","Homeopathic Dilution Unit","C48498","A dosing unit that is based on homeopathic dilution.","Homeopathic Dilution Unit | HOMEOPATHIC DILUTION | Homeopathic Dilution | {HOMEOPATHIC DILUTION} | {Homeopathic Dilution}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1552950","grain unit of measure","C48497","The traditional unit of mass derived from the weight of a grain and equal to one seven-thousandth of a pound, or 1/480 troy ounce, or 64.79891 milligrams. The original English grain unit based on the mass of a ripe grain barleycorn was larger the corresponding grain units of France and other European nations which were based on the weight of the smaller wheat grain.","Grain | GRAIN | [gr] | gr | grain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706425","Wafer Dosing Unit","C48552","A dosing unit equal to the amount of active ingredient(s) contained in a wafer.","Wafer Dosing Unit | WAFER | Wafer | {WAFER} | {Wafer}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705161","Trace Dosing Unit","C48547","An extremely small amount.","Trace Dosing Unit | TRACE | Trace | {TRACE} | {trace}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704611","Tampon Dosing Unit","C48543","A dosing unit equal to the amount of active ingredient(s) contained in a tampon.","Tampon Dosing Unit | TAMPON | Tampon | {TAMPON} | {Tampon}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706071","Syringe Dosing Unit","C48540","A dosing unit equal to the amount of active ingredient(s) contained in a single syringe.","Syringe Dosing Unit | SYRINGE | SZ | Syringe | {SYRINGE} | {Syringe}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705490","Strip Dosing Unit","C48538","A dosing unit equal to the amount of active ingredient(s) contained in a strip.","Strip Dosing Unit | STRIP | Strip | {STRIP} | {Strip}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706491","Scoopful Dosing Unit","C48536","A dosing unit equal to the amount of active ingredient(s) contained typically in a spoon-shaped object.","Scoopful Dosing Unit | SCOOPFUL | Scoopful | {SCOOPFUL} | {Scoopful}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709645","Pressor Unit","C48532","The activity of a pressor agent expressed as one pressor unit being equal to the activity of 0.5 milligram of the USP Standard Powdered Pituitary U.S.P., a USP posterior pituitary reference standard.","Pressor Unit | PRESSOR UNITS | {PRESSOR} | {Pressor}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706200","Pouch Dosing Unit","C48530","A dosing unit equal to the amount of active ingredient(s) contained in a pouch.","Pouch Dosing Unit | POUCH | Pouch | {POUCH} | {Pouch}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706128","Pellet Dosing Unit","C48525","A dosing unit equal to the amount of active ingredient(s) contained in a pellet.","Pellet Dosing Unit | PELLET | Pellet | {PELLET} | {Pellet}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1300565","Kilogram per Liter","C64566","A unit of mass concentration defined as the concentration of one kilogram of a substance in unit volume of the mixture equal to one liter. The concept also refers to the unit of mass density (volumic mass) defined as the density of substance which mass equal to one kilogram occupies the volume one liter.","Kilogram per Liter | Gram per Cubic Centimeter | Gram per Milliliter | Kilogram/Liter | Microgram per Nanoliter | Milligram per Microliter | g/cm3 | g/mL | g/ml | gram(s)/millilitre | gram/mL | kg/L | kg/l | kilogram(s)/litre | mg/uL | ug/nL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880406","Dram Mass Unit","C64564","The non-SI unit of mass equal to 1/16 Avoirdupois ounce or 1/256 Avoirdupois pound. One dram equals approximately 1.7718451953125 grams.","Dram Mass Unit | 1 [oz_av]/16 | Avoirdupois Dram | Dram | [dr_av] | [fdr_us] | dram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1532624","Atomic Mass Unit","C64559","A small unit of mass used to express atomic and molecular masses.","Atomic Mass Unit | amu | atomic mass unit | u",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1275572","Centigram","C64554","The metric unit of mass equal to one hundredth of a gram.","Centigram | cg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879754","Attogram","C64553","The metric unit of mass equal to one a quintillionth of a gram (10E-18 gram).","Attogram | ag",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882954","Ring Dosing Unit","C62609","A dosing unit equal to the amount of active ingredient(s) contained in a ring.","Ring Dosing Unit | RING | Ring | {RING} | {Ring}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0678214","Atmosphere","C54711","Non-SI unit of pressure equal to 101 325 Pa.","Atmosphere | Standard Atmosphere | atm | atmos | atmosphere (standard)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711366","Fluid Ounce British","C48577","A traditional unit of liquid volume equal in the British Imperial system to 1/20 pint, or 1.733 871 cubic inches or 28.413 063 milliliters.","Fluid Ounce British | Fluid Ounce Imperial | Imperial Fluid Ounce | [foz_br] | foz_br",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887614","Percent Volume per Volume","C48571","A unit of percentage concentration expressed as a fraction of a component by volume s in the entire volume of a resulting mixture. The unit denotes a number of milliliters of a solute per 100 milliliters of solution. The standard conditions for temperature and pressure apply.","Percent Volume per Volume | % (V/V) | %(v/v) | %V/V | %{VolumeToVolume} | %{v/v} | Milliliter per 100 Milliliters | PERCENT VOLUME/VOLUME | Percent Volume/Volume | Percent by Volume | Volume Percent | Volume Percentage | Volume-Volume Percentage | mL/100 mL | mL/100 mL/AB | percent volume per volume | percent volume/volume | vol%",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1319633","Million International Units","C67335","A unit of biological activity equal to one million international units.","Million International Units | 10*6.[IU] | 10*6.[iU] | 10E6 IU | 10^6 IU | 10^6.[iU] | 10^6[iU] | MIU | M[iU] | Mega International Unit | Mega-International Unit | Megainternational Unit | Million IU | million IU | million international units",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439259","Calorie","C67194","A non-SI unit of energy defined as the amount of heat required to raise the temperature of one kilogram of pure water by one degree Centigrade under standard conditions (the specific heat of the water at 15 degrees Celsius and the constant pressure of 101.325 kPa or one atm being defined as unity), equal to approximately 4.1855 kJ. It is also is used by nutritionists in measuring the energy-producing potential of food as a unit of potential energy contained by a substance, which can be liberated when the material is oxidized, usually by combustion in the presence of oxygen. According to the current national standard in the United States (IEEE/ASTM SI 10 TM-2002. American National Standard for Use of the International System of Units (SI): The Modern Metric System, New York: IEEE, 2002) the calorie in any form is not to be used. Joules should be used instead.","Calorie | C | Cal | Calorie (nutrition) | Dietician's Calorie | Food Calorie | Kcal | Kilocalorie | Kilogram Calorie | Kilogram-Calorie | Large Calorie | Nutritionist's Calorie | [Cal] | kcal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435395","calorie","C67193","A non-SI unit of energy defined as the amount of heat required to raise the temperature of one gram of pure water by one degree Centigrade under standard conditions (the specific heat of the water at 3.98, 14.5, or 19.5 degrees Celcius and the constant pressure of 101.325 kPa or one atm being defined as unity), equal to approximately 4.184 J. According to the current national standard in the United States (IEEE/ASTM SI 10 TM-2002. American National Standard for Use of the International System of Units (SI): The Modern Metric System, New York: IEEE, 2002) the calorie in any form is not to be used. Joules should be used instead.","calorie | Calorie | Gram Calorie | Small Calorie | cal | calorie (usual)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1961135","Milliliter per Square Meter per Day","C66977","A dose calculation unit expressed in milliliter(s) per square meter per period of time equal to twenty-four hours.","Milliliter per Square Meter per Day | Milliliter per Square Meter per 24 Hours | Milliliter/Square Meter/Day | Milliliter/meter2/day | mL/m2/d | mL/m2/day | ml/m2/d",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1532536","Gram per Kilogram per Day","C66975","A dose administration rate unit equal to the rate at which one gram of a product per kilogram of body mass is delivered or administered over the period of one day.","Gram per Kilogram per Day | Gram per Kilogram per 24 Hours | Gram/kilogram/day | Microgram per Milligram per Day | Milligram per Gram per Day | Milligram/gram/day | g/kg/d | g/kg/day | mcg/mg/d | mg/g/d | mg/g/day | ug/mg/d",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0564385","Per Hour","C66966","A frequency rate of occurrences of something within a period of time equal to sixty minutes.","Per Hour | /h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1532464","Tuberculin Unit","C65132","An arbitrary unit of tuberculin dosage defined by comparison of clinical response to a preparation of the purified protein derivative standardized for use in humans for tuberculin skin test reaction.","Tuberculin Unit | Tuberculin | [tb'U] | tuberculin unit | tuberculin unit(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347013","Billion Colony Forming Units per Gram","C68901","A derived unit of viable cell concentration defined as the number of billion colony forming units (10E9 CFU) in one gram of substance.","Billion Colony Forming Units per Gram | 10*9.[CFU]/g | 10E9 CFU | 10^9 CFU/g | 10^9.[CFU]/g | Billion CFU per Gram | Billion CFU/Gram | Billion CFU/g | billion CFU/g | billion colony forming units/gram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347157","Million Colony Forming Units per Gram","C68900","A derived unit of viable cell concentration defined as the number of million colony forming units (10E6 CFU) in one gram of substance.","Million Colony Forming Units per Gram | 10*6.[CFU]/g | 10E6 CFU/g | 10^6 CFU per Gram | 10^6 CFU/Gram | 10^6 CFU/g | 10^6.[CFU]/g | Million CFU per Gram | Million CFU/g | million CFU/g | million colony forming units/gram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348774","Thousand Colony Forming Units per Gram","C68899","A derived unit of viable cell concentration defined as the number of thousand colony forming units (10E3 CFU) in one gram of substance.","Thousand Colony Forming Units per Gram | 10*3.[CFU]/g | 10E3CFU/g | 10^3 CFU per Gram | 10^3 CFU/g | 10^3 Colony Forming Units per Gram | 10^3.[CFU]/g | Thousand CFU per Gram | Thousand CFU/g | thousand CFU/g | thousand colony forming units/gram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439362","Colony Forming Unit per Gram","C68898","A derived unit of viable cell concentration defined as the number of colony forming units in one gram of substance.","Colony Forming Unit per Gram | CFU per Gram | CFU/g | Colony Forming Unit/Gram | [CFU]/g | colony forming unit(s)/gram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347012","Billion Colony Forming Units","C68897","A unit of viable cell quantity equal to 10E9 colony forming units (10E9 CFU).","Billion Colony Forming Units | 10*9.[CFU] | 10E9 CFU | 10^9 CFU | 10^9.[CFU] | Billion CFU | billion CFU | billion colony forming units",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347156","Million Colony Forming Units","C68896","A unit of measurement of viable cell quantity equal to 10E6 colony forming units (10E6 CFU).","Million Colony Forming Units | 10*6.[CFU] | 10E6 CFU | 10^6 CFU | 10^6 Colony Forming Units | 10^6.[CFU] | Million CFU | million CFU | million colony forming units",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348773","Thousand Colony Forming Units","C68895","A unit of viable cell quantity equal to 10E3 colony forming units (10E3 CFU).","Thousand Colony Forming Units | 10*3.[CFU] | 10E3CFU | 10^3 CFU | 10^3 Colony Forming Units | 10^3.[CFU] | Thousand CFU | thousand CFU | thousand colony forming units",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347287","Mole per Milligram","C68894","A unit of amount of substance content (molality unit) defined as one mole of solute per one milligram of solvent.","Mole per Milligram | Attomole per Zeptogram | Femtomole per Attogram | Micromole per Nanogram | Millimole per Microgram | Mole(s)/milligram | Mole/Milligram | Nanomole per Picogram | Picomole per Femtogram | Zeptomole per Yoctogram | amol/zg | fmol/ag | mmol/mcg | mmol/ug | mol/mg | nmol/pg | pmol/fg | umol/ng | zmol/yg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347285","Mole per Gram (mol/g)","C68893","A unit of amount of substance content (molality unit) defined as one mole of solute per one gram of solvent.","Mole per Gram | Attomole per Attogram | Femtomole per Femtogram | Micromole per Microgram | Millimole per Milligram | Mole(s)/gram | Mole/Gram | Nanomole per Nanogram | Picomole per Picogram | Yoctomole per Yoctogram | Zeptomole per Zeptogram | amol/ag | fmol/fg | mmol/mg | mol/g | nmol/ng | pmol/pg | umol/ug | ymol/yg | zmol/zg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439291","Millimole per Kilogram","C68892","A unit of amount of substance content (molality unit) defined as one thousandth of mole (10E-3 mole) of solute per one kilogram of solvent.","Millimole per Kilogram | Attomole per Picogram | Femtomole per Nanogram | Micromole per Gram | Millimole/Kilogram | Nanomole per Milligram | Picomole per Microgram | Yoctomole per Attogram | Zeptomole per Femtogram | amol/pg | fmol/ng | millimole(s)/kilogram | mmol/kg | nmol/mg | pmol/mcg | pmol/ug | umol/g | ymol/ag",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347288","Mole per Milliliter","C68891","A unit of concentration (molarity unit) equal to one mole of solute in one milliliter of solution.","Mole per Milliliter | Attomole per Zeptoliter | Femtomole per Attoliter | Micromole per Nanoliter | Millimole per Microliter | Mole/Milliliter | Nanomole per Picoliter | Picomole per Femtoliter | Zeptomole per Yoctoliter | amol/zL | fmol/aL | mmol/uL | mol/mL | mol/ml | mole(s)/millilitre | nmol/pL | pmol/fL | umol/nL | zmol/yL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1532980","Centimole per Liter","C68886","A unit of concentration (molarity unit) equal to one hundredth of a mole (10E-2 mole) of solute in one liter of solution.","Centimole per Liter | Centimole/Liter | Millimoles per Deciliter | cmol/L | cmol/l | millimole per deciliter | mmol/dL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346698","Log10 Enzyme-Linked Immunosorbent Assay Unit per Dose","C68879","A logarithmic-scale (base 10) unit for measuring potency of immunologically active substance in a product determined as reactivity in a quantitative immunoassay for particular antigen or antibody and expressed per quantity of preparation used as a single dose.","Log10 Enzyme-Linked Immunosorbent Assay Unit per Dose | Log10 ELISA unit/dose | log10 EL. U/dose | log10 ELISA unit per Dose | log10 ELISA unit/Dose | log10 ELISA unit/dose | log10 enzyme-linked immunosorbent assay unit/dose | {Log10}.[ELU]/{dose}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346697","Log10 Enzyme-Linked Immunosorbent Assay Unit","C68878","A logarithmic-scale (base 10) unit for measuring concentration and/or reactivity of a test substance (an antigen or antibody of interest) as defined in the literature reference for the particular quantitative enzyme-linked immunosorbent assay method.","Log10 Enzyme-Linked Immunosorbent Assay Unit | Log10 ELISA unit | log10 EL. U | log10 ELISA unit | log10 enzyme-linked immunosorbent assay unit | {Log10}.[ELU]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348455","Enzyme-Linked Immunosorbent Assay Unit per Milliliter","C68877","A unit for measuring potency of immunologically active substance in a product determined as reactivity in a quantitative immunoassay for particular antigen or antibody and expressed per unit volume equal to one milliliter.","Enzyme-Linked Immunosorbent Assay Unit per Milliliter | ELISA Unit per Milliliter | ELISA Unit per mL | ELISA Unit/mL | ELISA unit/mL | ELISA unit/ml | Enzyme-Linked Immunosorbent Assay Unit/Milliliter | [ELU]/mL | [ELU]/ml | enzyme-linked immunosorbent assay unit/millilitre",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348454","Enzyme-Linked Immunosorbent Assay Unit per Dose","C68876","A unit for measuring potency of immunologically active substance in a product determined as reactivity in a quantitative immunoassay for particular antigen or antibody and expressed per quantity of preparation used as a single dose.","Enzyme-Linked Immunosorbent Assay Unit per Dose | EL. U/dose | ELISA Unit per Dose | ELISA Unit/dose | ELISA unit/dose | Enzyme-Linked Immunosorbent Assay Unit/Dose | [ELU]/{dose} | enzyme-linked immunosorbent assay unit/dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348453","Enzyme-Linked Immunosorbent Assay Unit","C68875","A unit for measuring concentration or/and reactivity of a test substance (an antigen or antibody of interest) as defined in the literature reference standard for the particular quantitative enzyme-linked immunosorbent assay method. The enzyme-linked immunosorbent assay unit is used to express potency of immunologically active substances and products, e.g. vaccines.","Enzyme-Linked Immunosorbent Assay Unit | EL. U | ELISA Unit | ELISA unit | [ELU] | enzyme-linked immunosorbent assay unit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348522","Standard Cubic Foot","C68859","A unit used in physical chemistry to express the amount of substance of an ideal gas in one cubic foot at 60 degrees Fahrenheit and pressure of one atmosphere.","Standard Cubic Foot | [ft_i]3 | ft3 | scf",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348523","Standard Cubic Meter","C68858","A unit used in physical chemistry to express the amount of substance of an ideal gas in one cubic meter at standard (according to DIN 1343 standard) conditions: temperature 273.15 K and pressure of one atmosphere (101.325 kPa).","Standard Cubic Meter | scm | {scm}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347286","Mole per Kilogram","C68740","A unit amount of substance content (molality unit) defined as one mole of solute per one kilogram of solvent.","Mole per Kilogram | Attomole per Femtogram | Femtomole per Picogram | Micromole per Milligram | Millimole per Gram | Mole(s)/kilogram | Mole/Kilogram | Nanomole per Microgram | Picomole per Nanogram | Yoctomole per Zeptogram | Zeptomole per Attogram | amol/fg | fmol/pg | millimole(s)/gram | mmol/g | mol/kg | nmol/mcg | nmol/ug | pmol/ng | umol/mg | ymol/zg | zmol/ag",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347582","Centimole","C68687","A unit of amount of substance equal to one hundredth of a mole (10E-2 mole).","Centimole | cmol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348083","Decimole","C68685","A unit of amount of substance equal to one tenth of a mole (10E-1 mole).","Decimole | dmol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456616","Thousand per Milliliter","C67452","A concentration unit expressed as a number or quantity of objects in thousands per unit of volume equal to one milliliter.","Thousand per Milliliter | /mm3 | /uL | 1/mm3 | 1/uL | 10*6/L | 10*6/l | 10E3/mL | 10E6/L | 10^3 per Milliliter | 10^3/mL | 10^6/L | 10^6/l | M/L | Mega/L | Million per Liter | thousand per milliliter",,,,,,,,,,,,,,,"4079422","10*6/L",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2346696","Log10 50 Percent Tissue Culture Infective Dose per Dose","C70489","A logarithmic-scale (base 10) potency unit for measuring infectious activity of a biologic product or infectious agent preparation equal to the potency at which one dose of infectious material contains one 50 percent tissue culture infective dose.","Log10 50 Percent Tissue Culture Infective Dose per Dose | Log10 50% Tissue Culture Infective Dose per Dose | log10 TCID 50/dose | log10 TCID50/dose | log10 tissue culture infective dose 50/dose | {log10}.[TCID_50]/{dose}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346692","Log10 50 Percent Cell Culture Infective Dose per Dose","C70485","A logarithmic-scale (base 10) potency unit for measuring infectious activity of a biologic product or infectious agent preparation equal to the potency at which one dose of infectious material contains one 50 percent cell culture infective dose.","Log10 50 Percent Cell Culture Infective Dose per Dose | Log10 50% Cell Culture Infective Dose per Dose | log10 CCID 50/dose | log10 CCID50/dose | log10 cell culture infective dose 50/dose | {log10}.[CCID_50]/{dose}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346694","Log10 50 Percent Embryo Infective Dose per Dose","C70480","A logarithmic-scale (base 10) potency unit for measuring infectious activity of a biologic product or infectious agent preparation equal to the potency at which one dose of infectious material contains one 50 percent embryo infective dose.","Log10 50 Percent Embryo Infective Dose per Dose | Log10 50% Embryo Infective Dose per Dose | log 10 50% embryo infective dose/dose (ICH) | log EID 50/dose | log10 EID 50/dose | log10 EID50/dose | {log10}.[EID_50]/{dose} | {log}.[EID_50]/{dose}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600130","Dyne","C70470","A unit of force in the CGS system defined as the force that accelerates a mass of one gram at the rate of one centimeter per second squared. One dyne is equal to 10E-5 newton and 2.248E-6 pound of force.","Dyne | dyn | dyne",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0582523","Revolution per Minute","C70469","A unit of frequency equal to one revolution per unit of time equal to one minute.","Revolution per Minute | r/min | revolution/minute | rpm | {Revolution}/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347289","Mole per Mole","C70455","A unit of fraction expressed as the ratio of the amount of substance of solute in moles to the amount of substance of the mixture in moles.","Mole per Mole | Mole/Mole | mmol/mmol | mol/mol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1319635","Gram per Gram","C70453","A unit of a mass fraction expressed as a number of grams of substance per gram of mixture. The unit is also used as a dose calculation unit.","Gram per Gram | Gram/Gram | Kilogram per Kilogram | Microgram per Microgram | Milligram per Milligram | g/g | kg/kg | mcg/mcg | mg/mg | ug/ug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4048603","Drop - Unit of Volume","C69441","A unit of measure of volume defined as the amount of liquid dispensed as one drop from a dropper dispenser. The volume of a drop depends on the physical properties of the liquid dispensed, the dispenser device, and the technique used to produce the drop.","Drop | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346686","Liter per Hour","C69160","A non-SI unit of volumetric flow rate defined as the rate at which one liter of matter crosses a given surface during the period of time equal to one hour.","Liter per Hour | L/h | Liter/Hour | l/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347519","Pint British","C69114","A traditional unit of volume equal to 20 British fluid ounces, 34.678 cubic inches or approximately 568.261 milliliters.","Pint British | British Pint | Imperial Pint | [pt_br] | pt_br",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551050","Part per Thousand","C69112","A unit of proportion equal to 10E-3.","Part per Thousand | [ppth] | parts per thousand | per mil | per mille | permil | ppt | ppth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475219","Liter per Day","C69110","A metric unit of volumetric flow rate defined as the rate at which one liter of matter crosses a given surface during the period of time equal to one day.","Liter per Day | L/d | L/day | Liter per 24 Hours | Liter/Day | l/d",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346616","Kilogram per Square Centimeter","C69094","A SI derived unit of spread rate of a substance by mass expressed in kilograms per area unit equal to one square centimeter, used also as a measure of area density and as a dose calculation unit.","Kilogram per Square Centimeter | Kilogram per Centimeter Squared | Kilogram/Square Centimeter | kg/cm2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551088","Gauss","C68915","A CGS unit of magnetic flux density. A field of one gauss exerts a force on a conductor, placed in the field of 0.1 dyne per ampere of current per centimetre of conductor. One gauss represents a magnetic flux of one maxwell per square centimetre of cross-section perpendicular to the field. In SI units, one gauss equals 10-4 tesla.","Gauss | G | Gs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347014","Billion Colony Forming Units per Milliliter","C68905","A derived unit of viable cell concentration defined as the number of billion colony forming units (10E9 CFU) in one milliliter of substance.","Billion Colony Forming Units per Milliliter | 10*9.[CFU]/mL | 10*9.[CFU]/ml | 10E9 CFU/mL | 10^9 CFU/mL | 10^9.[CFU]/mL | 10^9.[CFU]/ml | Billion CFU per Milliliter | Billion CFU/Milliliter | Billion CFU/mL | billion CFU/ml | billion colony forming units/millilitre",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347158","Million Colony Forming Units per Milliliter","C68904","A derived unit of viable cell concentration defined as the number of million colony forming units (10E6 CFU) in one milliliter of substance.","Million Colony Forming Units per Milliliter | 10*6.[CFU]/mL | 10E6 CFU/mL | 10^6 CFU per Milliliter | 10^6 CFU/Milliliter | 10^6 CFU/mL | 10^6.[CFU]/mL | Million CFU per Milliliter | Million CFU/mL | million CFU/ml | million colony forming units/millilitre",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348775","Thousand Colony Forming Units per Milliliter","C68903","A derived unit of viable cell concentration defined as the number of thousand colony forming units (10E3 CFU) in one milliliter of substance.","Thousand Colony Forming Units per Milliliter | 10*3.[CFU]/mL | 10*3.[CFU]/ml | 10E3CFU/mL | 10^3 CFU per Milliliter | 10^3 CFU/mL | 10^3 Colony Forming Units per Milliliter | 10^3.[CFU]/mL | 10^3.[CFU]/ml | Thousand CFU per Milliliter | Thousand CFU/mL | thousand CFU/mL | thousand colony forming units/milliliter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439361","Colony Forming Unit per Milliliter","C68902","A derived unit of viable cell concentration defined as the number of colony forming units in one milliliter of substance.","Colony Forming Unit per Milliliter | CFU per Milliliter | CFU/mL | CFU/ml | Colony Forming Unit/Milliliter | [CFU]/mL | [CFU]/ml | colony forming unit(s)/millilitre",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346984","Becquerel per Milliliter","C71167","A metric unit of volumetric radioactivity concentration defined as a concentration of a radionuclide with an activity equal to one becquerel per unit volume equal to one milliliter or one kilobecquerel per liter.","Becquerel per Milliliter | Becquerel/Milliliter | Bq/mL | Bq/ml | Kilobecquerel per Liter | Kilobecquerel/Microliter | becquerel(s)/millilitre | kBq/L | kBq/l | kilobecquerel(s)/litre",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1690011","Becquerel per Microliter","C71166","A metric unit of volumetric radioactivity concentration defined as a concentration of a radionuclide with an activity equal to one becquerel per unit volume equal to one millionth of a liter.","Becquerel per Microliter | Becquerel/Microliter | Bq/uL | Bq/ul | Kilobecquerel per Milliliter | MBq/L | MBq/l | Megabecquerel per Liter | becquerel(s)/microlitre | kBq/mL | kBq/ml | kilobecquerel(s)/millilitre | megabecquerel(s)/litre",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346981","Becquerel per Liter","C71165","A metric unit of volumetric radioactivity concentration defined as a concentration of a radionuclide with an activity equal to one becquerel per unit volume equal to one liter.","Becquerel per Liter | Becquerel/Liter | Bq/L | Bq/l | becquerel(s)/litre",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347133","Milliequivalent per Microgram","C70581","A unit of relative amount of substance content equivalent to the content at which one millionth of a gram of mixture contains one thousandth of an equivalent of a component. The unit is also used as a dose calculation unit.","Milliequivalent per Microgram | Milliequivalent Per Microgram | Milliequivalent/Microgram | mEq/mcg | mEq/ug | meq/ug | milliequivalent(s)/microgram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347132","Milliequivalent per Gram","C70580","A unit of relative amount of substance content equivalent to the content at which one gram of mixture contains one thousandth of an equivalent of a component. The unit is also used as a dose calculation unit.","Milliequivalent per Gram | Milliequivalent Per Gram | Milliequivalent/Gram | mEq/g | meq/g | milliequivalent(s)/gram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347134","Milliequivalent per Microliter","C70578","A concentration unit measured as a number of milliequivalents of solute per microliter of solution.","Milliequivalent per Microliter | Milliequivalent Per Microliter | Milliequivalent/Microliter | mEq/uL | mEq/ul | meq/uL | meq/ul | milliequivalent(s)/microlitre",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0560562","Roentgen","C70575","A unit of exposure to ionizing radiation in CGS system. One roentgen is the amount of gamma or x-rays required to produce ions resulting in a charge of 2.58E-4 coulombs/kilogram of air under standard conditions.","Roentgen | R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551051","Parts per Trillion","C70566","A unit of proportion equal to 10E-12.","Part Per Trillion | Parts per Trillion | [pptr] | parts per trillion | pptr",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0560002","Part Per Billion","C70565","A unit of proportion equal to 10E-9.","Part Per Billion | /10*10 | Part per Billion | Per 10 Billion | [ppb] | parts per billion | ppb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439250","Microkatal","C70562","A unit of catalytic activity measurement equal to one millionth of katal (10E-6 katal).","Microkatal | mckat | microkatal | microkatal(s) | ukat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346551","50 Percent Tissue Culture Infective Dose per Dose","C70537","A potency unit equal to the potency at which one dose of preparation contains one 50 percent tissue culture infective dose.","50 Percent Tissue Culture Infective Dose per Dose | 50% Tissue Culture Infective Dose per Dose | 50% Tissue Culture Infective Dose/Dose | TCID 50/dose | TCID50/dose | [TCID_50]/{dose} | tissue culture infective dose 50/dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346548","50 Percent Cell Culture Infective Dose per Dose","C70535","A potency unit equal to the potency at which one dose of preparation contains one 50 percent cell culture infective dose.","50 Percent Cell Culture Infective Dose per Dose | 50% Cell Culture Infective Dose per Dose | 50% Cell Culture Infective Dose/Dose | CCID 50/dose | CCID50/dose | [CCID_50]/{dose} | cell culture infective dose 50/dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346550","50 Percent Embryo Infective Dose per Dose","C70533","A potency unit for measuring infectious activity of a biologic product or an infectious agent preparation equal to the potency at which one dose of infectious material contains one 50 percent embryo infective dose.","50 Percent Embryo Infective Dose per Dose | 50% Embryo Infective Dose per Dose | 50% embryo infective dose/dose | EID 50/dose | EID50/dose | [EID_50]/{dose}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1688582","Gigabecquerel","C70513","A unit of radioactivity equal to 10E9 nuclear disintegrations or other nuclear transformations per second, or to 10E9 becquerels.","Gigabecquerel | GBq | gigabecquerel(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0560040","Kilobecquerel","C70511","A unit of radioactivity equal to 10E3 nuclear disintegrations or other nuclear transformations per second, or to 10E3 becquerels.","Kilobecquerel | kBq | kilobecquerel | kilobecquerel(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347326","Nanokatal per Liter","C70510","A unit of catalytic activity concentration defined as the catalytic activity of the component equal to one billionth of katal (10E-9 katal) in the unit volume of the system equal to one liter.","Nanokatal per Liter | Nanokatal/Liter | nkat/L | nkat/l",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439248","Picokatal","C70509","A unit of catalytic activity measurement equal to trillionth of katal (10E-12 katal).","Picokatal | picokatal | pkat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439247","Nanokatal","C70508","A unit of catalytic activity measurement equal to one billionth of katal (10E-9 katal).","Nanokatal | nanokatal | nkat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439246","Millikatal","C70507","A unit of catalytic activity measurement equal to one thousandth of katal (10E-3 katal).","Millikatal | millikatal | mkat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348823","Tuberculin Unit per Milliliter","C70506","A unit of biologic activity of tuberculin expressed as a number of arbitrary units of tuberculin in one milliliter of preparation.","Tuberculin Unit per Milliliter | Tuberculin Unit/Milliliter | Tuberculin Unit/mL | [tb'U]/mL | [tb'U]/ml | tuberculin unit(s)/millilitre | tuberculin unit/mL | tuberculin unit/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347022","Bioequivalent Allergy Unit","C70505","A unit used for standardization of an allergenic product based on evaluation of product potency against reference standard in combined in vivo (skin test) and in vitro (IgE-based ELISA) testing.","Bioequivalent Allergy Unit | BAU | BIOEQUIVALENT ALLERGY UNITS | [BAU]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348421","Allergy Unit per Milliliter","C70504","Unit of measure of potency of allergenic product expressed as a number of allergy units per one milliliter of formulation.","Allergy Unit per Milliliter | AU/mL | AU/ml | UA/mL | allergy unit(s)/millilitre | kAU/L | kUA/L | {AU}/mL | {AU}/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348053","D Antigen Unit per Milliliter","C70502","A unit of potency of poliovirus vaccine expressed as a number of D antigen units per one milliliter of vaccine formulation.","D Antigen Unit per Milliliter | D Antigen Unit/Milliliter | D antigen unit(s)/millilitre | DAgU/mL | DAgU/ml | [D'ag'U]/mL | [D'ag'U]/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348052","D Antigen Unit","C70501","A unit of potency of poliovirus vaccine used for poliomyelitis prevention. The unit is poliovirus type-specific.","D Antigen Unit | D antigen unit(s) | D-ANTIGEN UNITS | DAgU | [D'ag'U]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346833","Antigen Unit per Milliliter","C70500","A measure of an antigen potency defined as a number of antigen units per one milliliter of product.","Antigen Unit per Milliliter | AgU/mL | AgU/ml | Antigen Unit/Milliliter | antigen unit(s)/millilitre | {AgU}/mL | {AgU}/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346826","Anti-Xa Activity International Unit per Milliliter","C70498","A specific anticoagulation activity of unfractionated or low molecular weight heparin on factor Xa, expressed as a number of international anti-Xa heparin units per one milliliter of plasma.","Anti-Xa Activity International Unit per Milliliter | Anti-Xa Activity International Unit/Milliliter | anti-Xa IU/mL | anti-Xa IU/ml | anti-Xa activity international unit(s)/millilitre | {anti-Xa IU}/mL | {anti-Xa IU}/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346825","Anti-Xa Activity International Unit","C70497","A unit of unfractionated or low molecular weight heparin anticoagulation potency determined as the amount that neutralizes one unit of coagulation factor Xa preparation defined as an international biological standard by WHO First International Low Molecular Weight Heparin Reference Standard.","Anti-Xa Activity International Unit | anti-Xa IU | anti-Xa activity international unit(s) | {anti-Xa IU}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1319631","International Unit per Gram","C70493","A unit of measure of a quantity of substance per unit mass, expressed as the quantity of substance in International Units, divided by the mass of the substance in grams. It is also used as a dose calculation unit expressed in International Units of biological activity per one gram of body mass.","International Unit per Gram | IU/g | International Unit/Gram | Kilointernational Unit per Kilogram | [IU]/g | [iU]/g | international unit(s)/gram | kIU/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439454","Kilointernational Unit","C70492","A unit equal to one thousand international units.","Kilointernational Unit | Kilo International Unit | Thousand International Units | kIU | k[IU] | k[iU] | kilo international units",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346713","Absorbance Unit per Minute","C73687","A unit of a speed of optical density change expressed as a logarithm of absorbance of light transmitted through a partially absorbing substance per minute.","Absorbance Unit per Minute | AU/min | Absorbance U/min | Absorbance Units per Minute | {Absorbance U}/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346712","Absorbance Unit","C73686","A unit of optical density expressed as the absorbance of light transmitted through the medium on the logarithmic scale.","Absorbance Unit | AU | Absorbance U | {Absorbance U}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1320755","Milligram per Kilogram per Hour","C71362","A dose calculation unit equal to one thousandth of a gram of a preparation per one kilogram of body mass administered per unit of time equal to one hour.","Milligram per Kilogram per Hour | Milligram/Kilogram/Hour | mg/kg/h | mg/kg/hr",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348675","Fingertip Dosing Unit","C71321","An arbitrary dosing unit used predominantly for semisolid topical formulations such as cream, ointment, paste, etc. One fingertip unit is the amount of a product that is squeezed out from a standard tube with 5-millimeter diameter nozzle along an adult's fingertip. A fingertip length is defined from the tip of the index finger to the first finger crease. A fingertip dosing unit varies with age and size of the body. The average fingertip unit is equal to approximately 0.5 gram for an adult male and 0.4 gram for an adult female.","Fingertip Dosing Unit | FINGERTIP UNIT | FTU | Fingertip | Fingertip Unit | {FINGERTIP} | {Fingertip}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1300567","Microgram per Kilogram per Minute","C71210","A dose calculation unit equal to one millionth of a gram of a preparation per one kilogram of body mass administered per unit of time equal to one minute.","Microgram per Kilogram per Minute | Gamma per Kilogram per Minute | Gamma/kg/min | Microgram/Kilogram/Minute | gamma/kg/min | mcg/kg/min | ug/kg/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1532975","International Unit per Kilogram per Hour","C71209","A dose calculation unit equal to one international unit (an arbitrary unit of biological activity) of a product per one kilogram of body mass administered per unit of time equal to one hour.","International Unit per Kilogram per Hour | IU/kg/h | International Unit/Kilogram/Hour | International units per Kilogram per Hour | [IU]/kg/h | [iU]/kg/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1320756","Milligram per Kilogram per Minute","C71207","A dose calculation unit equal to one thousandth of a gram of a preparation per one kilogram of body mass administered per unit of time equal to one minute.","Milligram per Kilogram per Minute | Milligram/Kilogram/Minute | mg/kg/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347333","Nebule Dosing Unit","C71204","A dosing unit equal to the amount of active ingredient(s) contained in a nebule.","Nebule Dosing Unit | NEBULE | Nebule | {NEBULE} | {Nebule}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346614","Kilo United States Pharmacopeia Unit","C71202","A unit of potency equal to one thousand US Pharmacopoeia Units.","Kilo United States Pharmacopeia Unit | 10*3.[USP'U] | 10^3.[USP'U] | KUSP unit | KUSP'U | Kilo US Pharmacopeia Unit | Thousand United States Pharmacopeia Unit | kUSP | kUSP units | kilo United States pharmacopoeia units",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348886","Gram per Square Centimeter","C71201","A metric unit of areal density defined as a spread rate at which one gram of a substance is spread over the area of one square centimeter. The unit is also used as a dose calculation unit.","Gram per Square Centimeter | Gram/Square Centimeter | g/cm2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553005","Bel (unit of measure)","C71200","A logarithmic ratio unit (base-10 logarithms) used to express relative magnitude of a physical quantity (usually power or intensity) in comparison with a specified or implied reference level. Particularly, Bel is used as a unit of relative sound intensity. In the latter context it is equal to ten decibels or to approximately 1.151293 nepers.","Bel | B | bel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347532","Plaque Forming Unit per Milliliter","C71199","A unit of potency of a biological product expressed as a quantity of viable infectious entities capable to produce a cytopathic effect in the appropriate cell culture per one milliliter of the preparation.","Plaque Forming Unit per Milliliter | PFU/Milliliter | PFU/mL | PFU/ml | [PFU]/mL | [PFU]/ml | plaque forming unit(s)/millilitre",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347531","Plaque Forming Unit per Dose","C71198","A unit of potency of a biological product expressed as a quantity of viable infectious entities capable to produce a cytopathic effect in the appropriate cell culture per a single dose of the preparation.","Plaque Forming Unit per Dose | PFU/Dose | PFU/dose | Plaque Forming Unit/Dose | [PFU]/{dose} | plaque forming unit(s)/dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347018","Billion Organisms per Milliliter","C71197","A unit of measure of organism concentration expressed in billions of organisms per unit of volume equal to one milliliter.","Billion Organisms per Milliliter | 10*9.{organisms}/mL | 10*9.{organisms}/ml | 10E9 Organisms/mL | 10^9 Organisms/Milliliter | 10^9 Organisms/mL | 10^9 organisms/mL | 10^9.{organisms}/mL | 10^9.{organisms}/ml | Billion Organisms/mL | billion organisms/millilitre | billion organisms/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347162","Million Organisms per Milliliter","C71196","A unit of measure of organism concentration expressed in millions of organisms per unit of volume equal to one milliliter.","Million Organisms per Milliliter | 10*6.{organisms}/mL | 10*6.{organisms}/ml | 10E6 Organisms/mL | 10^6 Organisms per Milliliter | 10^6 Organisms/mL | 10^6 organisms/mL | 10^6.{organisms}/mL | 10^6.{organisms}/ml | Million Organisms/mL | million organisms/millilitre | million organisms/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348778","Thousand Organisms per Milliliter","C71195","A unit of measure of organism concentration expressed in thousands of organisms per unit of volume equal to one milliliter.","Thousand Organisms per Milliliter | 10*3.{organisms}/mL | 10*3.{organisms}/ml | 10E3 Organisms/mL | 10^3 Organisms per Milliliter | 10^3 Organisms/mL | 10^3 organisms/mL | 10^3.{organisms}/mL | 10^3.{organisms}/ml | Thousand Organisms/mL | thousand organisms/millilitre | thousand organisms/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347017","Billion Organisms per Milligram","C71194","A unit of measure of organism content expressed in billions of organisms per unit of mass equal to one milligram.","Billion Organisms per Milligram | 10*9.{organisms}/mg | 10E9 Organisms/mg | 10^9 Organisms/mg | 10^9 organisms/mg | 10^9.{organisms}/mg | Billion Organisms/mg | billion organisms/mg | billion organisms/milligram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347161","Million Organisms per Milligram","C71193","A unit of measure of organism content expressed in millions of organisms per unit of mass equal to one milligram.","Million Organisms per Milligram | 10*6.{organisms}/mg | 10E6 Organisms/mg | 10^6 Organisms per Milligram | 10^6 Organisms/mg | 10^6 organisms/mg | 10^6.{organisms}/mg | Million Organisms/mg | million organisms/mg | million organisms/milligram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347016","Billion Organisms per Gram","C71192","A unit of measure of organism content expressed in billions of organisms per unit of mass equal to one gram.","Billion Organisms per Gram | 10*9.{organisms}/g | 10E9 Organisms/g | 10^9 Organisms/g | 10^9 organisms/g | 10^9.{organisms}/g | Billion Organisms/g | billion organisms/g | billion organisms/gram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347160","Million Organisms per Gram","C71191","A unit of measure of organism content expressed in millions of organisms per unit of mass equal to one gram.","Million Organisms per Gram | 10*6.{organisms}/g | 10E6 Organisms/g | 10^6 Organisms per Gram | 10^6 Organisms/g | 10^6 organisms/g | 10^6.{organisms}/g | Million Organisms/g | million organisms/g | million organisms/gram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348777","Thousand Organisms per Gram","C71190","A unit of measure of organism content expressed in thousands of organisms per unit of mass equal to one gram.","Thousand Organisms per Gram | 10*3.{organisms}/g | 10E3 Organisms/g | 10^3 Organisms per Gram | 10^3 Organisms/g | 10^3 organisms/g | 10^3.{organisms}/g | Thousand Organisms/g | thousand organisms/g | thousand organisms/gram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347015","Billion Organisms","C71189","A unit of measure of quantity of organisms expressed in billions.","Billion Organisms | 10*9{organisms} | 10E9 Organisms | 10^9 Organisms | 10^9 organisms | 10^9{organisms} | billion organisms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347159","Million Organisms","C71188","A unit of measure of quantity of organisms expressed in millions.","Million Organisms | 10*6{organisms} | 10E6 Organisms | 10^6 Organisms | 10^6 organisms | 10^6{organisms} | million organisms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348776","Thousand Organisms","C71187","A unit of measure of quantity of organisms expressed in thousands.","Thousand Organisms | 10*3{organisms} | 10E3 Organisms | 10^3 Organisms | 10^3 organisms | 10^3{organisms} | thousand organisms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348028","Cycle per Minute","C71176","A unit of frequency equal to the frequency at which one complete execution of a periodically repeated phenomenon, alternation, event, or sequence of events occurs per unit of time equal to one minute.","Cycle per Minute | Cycle/min | cpm | cycle/min | {cycle}/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347131","Millicurie per Liter","C71174","A unit of volumetric radioactivity concentration defined as a concentration of a radionuclide with an activity equal to one thousandth of a curie per unit volume equal to one liter.","Millicurie per Liter | Microcurie per Milliliter | Millicurie/Liter | mCi/L | mCi/l | microcurie(s)/millilitre | millicurie(s)/litre | uCi/mL | uCi/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347115","Microcurie per Liter","C71173","A unit of volumetric radioactivity concentration defined as a concentration of a radionuclide with an activity equal to one millionth of a curie per unit volume equal to one liter.","Microcurie per Liter | mcCi/L | microcurie(s)/litre | uCi/L | uCi/l",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348025","Curie per Milliliter","C71172","A unit of volumetric radioactivity concentration defined as a concentration of a radionuclide with an activity equal to one curie per unit volume equal to one milliliter.","Curie per Milliliter | Ci/mL | Ci/ml | Curie/Milliliter | Millicurie per Microliter | curie(s)/millilitre | mCi/uL | mCi/ul | millicurie(s)/microlitre",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348023","Curie per Microliter","C71171","A unit of volumetric radioactivity concentration defined as a concentration of a radionuclide with an activity equal to one curie per unit volume equal to one millionth of a liter.","Curie per Microliter | Ci/mcL | Ci/uL | Ci/ul | curie(s)/microlitre",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348021","Curie per Liter","C71170","A unit of volumetric radioactivity concentration defined as a concentration of a radionuclide with an activity equal to one curie per unit volume equal to one liter.","Curie per Liter | Ci/L | Ci/l | Curie/Liter | Microcurie per Microliter | Millicurie per Milliliter | curie(s)/litre | mCi/mL | mCi/ml | microcurie(s)/microlitre | millicurie(s)/millilitre | uCi/uL | uCi/ul",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1690481","Megabecquerel per Microliter","C71169","A metric unit of volumetric radioactivity concentration defined as a concentration of a radionuclide with an activity equal to one million becquerels per unit volume equal to one millionth of a liter.","Megabecquerel per Microliter | GBq/mL | GBq/ml | Gigabecquerel per Milliliter | MBq/uL | MBq/ul | gigabecquerel/millilitre | megabecquerel(s)/microlitre",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1639216","Kilobecquerel per Microliter","C71168","A metric unit of volumetric radioactivity concentration defined as a concentration of a radionuclide with an activity equal to one thousand becquerels per unit volume equal to one millionth of a liter.","Kilobecquerel per Microliter | GBq/L | GBq/l | Gigabecquerel per Liter | MBq/mL | MBq/ml | Megabecquerel per Milliliter | gigabecquerel/litre | kBq/uL | kBq/ul | kilobecquerel(s)/microlitre | megabecquerel(s)/millilitre",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348879","Gram per Animal per Week","C73715","A dose calculation unit expressed in gram(s) per animal per period of time equal to seven days.","Gram per Animal per Week | g/anim/week | g/animal/wk | g/{animal}/wk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348878","Gram per Animal per Day","C73714","A dose calculation unit expressed in gram(s) per animal per period of time equal to twenty-four hours.","Gram per Animal per Day | Gram per Animal per 24 Hours | g/anim/d | g/animal/day | g/{animal}/d",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348877","Gram per Animal","C73713","A dose calculation unit expressed in gram(s) per animal.","Gram per Animal | g/anim | g/animal | g/{animal}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348668","Femtomole per Gram","C73711","A molality unit that describes the amount of substance, expressed in femtomole(s) per gram.","Femtomole per Gram | Femtomole/Gram | fmol/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1634619","Disintegration per Minute","C73710","A unit of radioactive decay expressed in atoms of radioactive material that decay over a period of time equal to sixty seconds.","Disintegration per Minute | DPM | Disintegration/Minute | Disintegrations per Minute | dpm | {Disintegrations}/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274447","Thousand RNA Copies per Milliliter","C98790","A unit of measurement equal to one thousand ribonucleic acid (RNA) copies per unit of volume equal to one milliliter.","Thousand RNA Copies per Milliliter | 10*3.{RNA copies}/mL | 10*3.{RNA copies}/ml | 10^3 RNA copies/mL | 10^3.{RNA copies}/mL | 10^3.{RNA copies}/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274446","Thousand per High Powered Field","C98789","A unit of measurement equal to one thousand entities per unit of area equal to one high powered field.","Thousand per High Powered Field | 10*3/[HPF] | 10^3/[HPF] | 10^3/hpf",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274445","Thousand DNA Copies per Milliliter","C98788","A unit of measurement equal to one thousand deoxyribonucleic acid (DNA) copies per unit of volume equal to one milliliter.","Thousand DNA Copies per Milliliter | 10*3.{DNA copies}/mL | 10*3.{DNA copies}/ml | 10^3 DNA copies/mL | 10^3.{DNA copies}/mL | 10^3.{DNA copies}/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274444","Ten Thousand per High Powered Field","C98787","A unit of measurement equal to ten thousand entities per unit of area equal to one high powered field.","Ten Thousand per High Powered Field | 10*4/[HPF] | 10^4/[HPF] | 10^4/hpf",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274443","Ten Million per Liter","C98786","A unit of measurement equal to ten million entities per unit of volume equal to one liter.","Ten Million per Liter | 10*7/L | 10*7/l | 10^6/dL | 10^7/L | 10^7/l",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274423","Million RNA Copies per Milliliter","C98760","A unit of measurement equal to one million ribonucleic acid (RNA) copies per unit of volume equal to one milliliter.","Million RNA Copies per Milliliter | 10*6.{RNA copies}/mL | 10*6.{RNA copies}/ml | 10^6 RNA copies/mL | 10^6.{RNA copies}/mL | 10^6.{RNA copies}/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274422","Million per High Powered Field","C98759","A unit of measurement equal to one million entities per unit of area equal to one high powered field.","Million per High Powered Field | 10*6/[HPF] | 10^6/[HPF] | 10^6/hpf",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274421","Million per Gram","C98758","A unit of measurement equal to one million entities per unit of mass equal to one gram.","Million per Gram | /ug | 1/ug | 10*6/g | 10^3/mg | 10^6/g | 10^9/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274420","Million International Units per Milliliter","C98757","A unit of measurement equal to 10 to one million international units of an entity per unit of volume equal to one milliliter.","Million International Units per Milliliter | 10*6.[IU]/mL | 10*6.[IU]/ml | 10*6.[iU]/mL | 10*6.[iU]/ml | 10^6 IU/mL | 10^6.[IU]/mL | 10^6.[IU]/ml | 10^6.[iU]/mL | 10^6.[iU]/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274419","Million DNA Copies per Milliliter","C98756","A unit of measurement equal to one million deoxyribonucleic acid (DNA) copies per unit of volume equal to one milliliter.","Million DNA Copies per Milliliter | 10*6.{DNA copies}/mL | 10*6.{DNA copies}/ml | 10^6 DNA copies/mL | 10^6.{DNA copies}/mL | 10^6.{DNA copies}/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1532578","Milliliter per Centimeter of Water","C98755","A unit of pressure expressed in milliliter(s) per centimeter of water.","Milliliter per Centimeter of Water | mL/cm H2O | mL/cm[H2O] | ml/cm[H2O]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274410","Hundred Thousand per High Powered Field","C98743","A unit of measurement equal to one hundred thousand entities per unit of area equal to one high powered field.","Hundred Thousand per High Powered Field | 10*5.[HPF] | 10^5.[HPF] | 10^5/hpf",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274386","DNA Copies per Milliliter","C98719","A unit of measure of the concentration of deoxyribonucleic acid (DNA) copies per unit of volume equal to one milliliter.","DNA Copies per Milliliter | DNA copies/mL | {DNA copies}/mL | {DNA copies}/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272967","Molecule of Equivalent Soluble Fluorochrome","C96691","A unit of measure of the fluorescence intensity of a fluorochrome-labeled sample, which is equivalent to the fluorescence intensity of a solution containing an equivalent number of molecules of free fluorochrome in solution, under identical experimental conditions.","Molecule of Equivalent Soluble Fluorochrome | MESF | Molecules of Equivalent Soluble Fluorochromes | {MESF}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1532175","Per Low Powered Field","C96620","A unit of measure equal to the instances of an entity per visual field of a microscope set to its minimum magnification power.","Per Low Powered Field | /LPF | /[LPF]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439530","Per High Powered Field","C96619","A unit of measure equal to the instances of an entity per visual field of a microscope set to its maximum magnification power.","Per High Powered Field | /HPF | /[HPF] | Per HPF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1532290","Ehrlich Unit","C96599","A unit of measure equal to one milligram of urobilinogen per deciliter.","Ehrlich Unit | EU | EU/dL | Ehrlich Units | Ehrlich unit | [EU] | {mg urobilinogen}/dL | {mg urobilinogen}/dl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1552985","Hounsfield Unit","C94908","Term given to the dimensions of the quantifier of x-ray attenuation, CT number.","Hounsfield Unit | HU | [hnsf'U]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985216","Unit per Millimole","C92618","An arbitrary unit of substance concentration equal to the concentration at which one millimole of a mixture contains one unit of a substance.","Unit per Millimole | U/mmol | {Unit}/mmol | {U}/mmol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985214","mEq/mmol","C92616","A concentration unit measured as a number of one thousandth of an equivalent weight per millimole of substance.","Milliequivalent per Millimole | Milliequivalent per Milliimole | mEq/mmol | meq/mmol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985213","Kilonewton per Centimeter Squared","C92615","The kilonewton per centimeter squared is an SI derived unit of pressure; one newton is computed as the force necessary to accelerate a mass of one gram at the rate of one centimeter per second squared. One kilonewton per centimeter squared is descriptive of the amount of force exerted in a particular area. This measurement is frequently used when describing conditions of cellular movement.","Kilonewton per Centimeter Squared | Kdyn/cm2 | Kilodyne per centimeter squared | kN/cm2 | kdyn/cm2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439409","Nanomole per Minute per Milliliter","C92613","A unit of concentration (molarity unit) equal to one billionth of a mole (10E-9 mole) of solute per minute per milliliter.","Nanomole per Minute per Milliliter | Nanomole per Milliliter per Minute | nmol/mL/min | nmol/min/mL | nmol/ml/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984568","Globule Unit","C91803","An unit of small globular masses of various sizes. Medications are compounded with globular shaped sucrose, lactose, or other polysaccharides and dried before administered.","Globule Unit | GLOBULE | {GLOBULE}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439283","Nanomole per Kilogram","C85754","Nanomoles per kilogram.","Nanomole per Kilogram | nmol/kg | pmol/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439292","Nanomole per Gram","C85752","Nanomoles per gram.","Nanomole per Gram | nmol/g | pmol/mg | umol/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439438","Nanomole per Day","C85751","Nanomoles per day.","Nanomole per Day | Nanomole per 24 Hours | nmol/d | nmol/day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439428","Mole per Day","C85737","Moles per day.","Mole per Day | Mole per 24 Hours | mol/d | mol/day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827891","Millimole per Second","C85723","Millimoles per second.","Millimole per Second | Millimoles per Second | mmol/s | mmol/sec",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827879","Micromole per Minute","C85708","Micromoles per minute.","Micromole per Minute | mcmol/min | umol/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439465","International Unit per Day","C85645","International units per day.","International Unit per Day | IU/d | IU/day | International Unit per 24 Hours | [IU]/d | [iU]/d",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439278","Femtogram per Milliliter","C85597","Femtograms per milliliter.","Femtogram per Milliliter | fg/mL | fg/ml | pg/L | pg/l",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2608091","Unit per Gram","C77606","An arbitrary unit of substance content expressed in unit(s) per gram.","Unit per Gram | U/g | Unit/Gram | {Unit}/g | {U}/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699026","Relative Fluorescence Unit","C77535","A unit of measurement that estimates the size or amount of material in a sample by normalizing its luminescence to that of a reference standard.","Relative Fluorescence Intensity Unit | RFIU | RFU | RIU | Relative Fluorescence Unit | Relative Fluorescence Unit | Relative Intensity Unit | {RFU}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698180","Arbitrary Fluorescence Units","C77534","Arbitrary unit(s) of fluorescent luminescence.","Arbitrary Fluorescence Units | AFU | Arbitrary Fluorescence Unit | {AFU}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698213","Microgram per Milliliter per Hour","C75905","A dose calculation unit expressed in microgram(s) per milliliter of solution per period of time equal to sixty minutes.","Microgram per Milliliter per Hour | Microgram/Milliliter/Hour | mcg/mL/h | ug/mL/h | ug/ml/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439183","Arbitrary Unit","C75765","A single undivided thing (unit) based on or subject to individual judgment or preference, and not by necessity, reason, or principle.","Arbitrary Unit | ARBITRARY UNITS | AU | Arbitrary U | [arb'U] | arbitary unit | unit, arbitary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698212","Microgram per Gram per Minute","C74923","A dose calculation unit expressed in microgram(s) per gram per period of time equal to sixty seconds.","Microgram per Gram per Minute | Microgram/Gram/Minute | mcg/g/min | ug/g/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698211","Microgram per Gram per Hour","C74922","A dose calculation unit expressed in microgram(s) per gram per period of time equal to sixty minutes.","Microgram per Gram per Hour | Microgram/Gram/Hour | mcg/g/h | ug/g/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698210","Microgram per Gram per Day","C74921","A dose calculation unit expressed in microgram(s) per gram per period of time equal to twenty-four hours.","Microgram per Gram per Day | Microgram per Gram per 24 Hours | Microgram/Gram/Day | mcg/g/d | ug/g/d | ug/g/day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347119","Microgram per Square Meter per Day","C73787","A dose calculation unit expressed in microgram(s) per square meter per period of time equal to twenty-four hours.","Microgram per Square Meter per Day | Microgram per Square Meter per 24 Hours | mcg/m2/d | ug/m2/d | ug/m2/day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349079","Unit per Square Meter per Minute","C73785","An arbitrary unit of substance rate expressed in unit(s) per square meter per period of time equal to sixty seconds.","Unit per Square Meter per Minute | U/m2/min | Unit/Square Meter/Minute | {Unit}/m2/min | {U}/m2/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349078","Unit per Square Meter per Hour","C73784","An arbitrary unit of substance rate expressed in unit(s) per square meter per period of time equal to sixty minutes.","Unit per Square Meter per Hour | U/m2/h | Unit/Square Meter/Hour | {Unit}/m2/h | {U}/m2/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349077","Unit per Square Meter per Day","C73783","An arbitrary unit of substance rate expressed in unit(s) per square meter per period of time equal to twenty-four hours.","Unit per Square Meter per Day | (m2.d) | U/m2/d | U/m2/day | Unit per Square Meter per 24 Hours | Unit/meter2/day | meter squared in 24 hours | {Unit}/m2/d | {U}/m2/d",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1638407","Unit per Milligram","C73780","An arbitrary unit of substance content expressed in unit(s) per milligram.","Unit per Milligram | U/mg | Unit/Milligram | {Unit}/mg | {U}/mg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1532636","Unit per Kilogram per Minute","C73779","An arbitrary unit of substance rate expressed in unit(s) per kilogram per period of time equal to sixty seconds.","Unit per Kilogram per Minute | U/kg/min | Unit/Kilogram/Minute | {Unit}/kg/min | {U}/kg/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1532635","Unit per Kilogram per Hour","C73778","An arbitrary unit of substance rate expressed in unit(s) per kilogram per period of time equal to sixty minutes.","Unit per Kilogram per Hour | U/kg/h | Unit/Kilogram/Hour | {Unit}/kg/h | {U}/kg/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1532634","Unit per Kilogram per Day","C73777","An arbitrary unit of substance rate expressed in unit(s) per kilogram per period of time equal to twenty-four hours.","Unit per Kilogram per Day | U/kg/d | U/kg/day | Unit per Kilogram per 24 Hours | Unit/kilogram/day | {Unit}/kg/d | {U}/kg/d",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349074","Unit per Gram per Minute","C73776","An arbitrary unit of substance rate expressed in unit(s) per gram per period of time equal to sixty seconds.","Unit per Gram per Minute | U/g/min | Unit/Gram/Minute | {Unit}/g/min | {U}/g/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349073","Unit per Gram per Hour","C73775","An arbitrary unit of substance rate expressed in unit(s) per gram per period of time equal to sixty minutes.","Unit per Gram per Hour | U/g/h | Unit/Gram/Hour | {Unit}/g/h | {U}/g/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349072","Unit per Gram per Day","C73774","An arbitrary unit of substance rate expressed in unit(s) per gram per period of time equal to twenty-four hours.","Unit per Gram per Day | U/g/d | U/g/day | Unit per Gram per 24 Hours | Unit/gram/day | {Unit}/g/d | {U}/g/d",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349071","Unit per Animal","C73773","An arbitrary dosing unit expressed in unit(s) per animal.","Unit per Animal | U/anim | U/animal | {Unit}/{animal} | {U}/{animal}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349046","Unit of Gravity","C73772","A unit of gravity expressed as a multiple of the force of gravity.","Unit of Gravity | Gravitational Unit | g | {Gravitational Unit}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348779","Thousand per Deciliter","C73771","A unit of concentration measurement expressed in thousand(s) per deciliter.","Thousand per Deciliter | 10*4/L | 10*4/l | 10E3/dL | 10^3/dL | 10^4/L | 10^4/l | Thousand/Deciliter | thous/dL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347517","Picosecond","C73768","A unit of time equal to one trillionth of a second.","Picosecond | ps | psec",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439225","Nanosecond","C73767","A unit of time equal to one billionth of a second.","Nanosecond | ns | nsec",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347163","Millipascal","C73765","A SI derived unit of pressure equivalent to one thousandth of one pascal.","Millipascal | mPa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347155","Millimeter of Mercury per Second","C73764","A rate of inflation or deflation of a manometric device based on the unit of pressure equal to 133,332 Pa or 1.316E10-3 standard atmosphere during period of time equal to one sixtieth of a minute.","Millimeter of Mercury per Second | Millimeter of Mercury/Second | mmHg/s | mmHg/sec | mm[Hg]/s",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347154","Milliliter per Square Meter per Minute","C73763","A dose calculation unit expressed in milliliter(s) per square meter per period of time equal to sixty seconds.","Milliliter per Square Meter per Minute | Milliliter/Square Meter/Minute | mL/m2/min | mL/min/m2 | ml/m2/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1960954","Milliliter per Square Meter per Hour","C73762","A dose calculation unit expressed in milliliter(s) per square meter per period of time equal to sixty minutes.","Milliliter per Square Meter per Hour | Milliliter/Square Meter/Hour | mL/m2/h | ml/m2/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1532780","Milliliter per Square Meter","C73761","A dose calculation unit expressed in milliliter(s) per square meter.","Milliliter per Square Meter | Milliliter/Square Meter | mL/m2 | ml/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1532580","Milliliter per Kilogram per Hour","C73759","A dose calculation unit expressed in milliliter(s) per kilogram per period of time equal to sixty minutes.","Milliliter per Kilogram per Hour | (mL/h)/kg | (ml/h)/kg | Milliliter/Kilogram/Hour | mL/kg/h | ml/kg/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347152","Milliliter per Gram per Minute","C73757","A dose calculation unit expressed in milliliter(s) per gram per period of time equal to sixty seconds.","Milliliter per Gram per Minute | (L/min)/kg | (l/min)/kg | (mL/min)/g | (ml/min)/g | Milliliter per Minute per Gram | Milliliter/Gram/Minute | mL/g/min | ml/g/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347151","Milliliter per Gram per Hour","C73756","A dose calculation unit expressed in milliliter(s) per gram per period of time equal to sixty minutes.","Milliliter per Gram per Hour | (L/h)/kg | (l/h)/kg | (mL/h)/g | (ml/h)/g | Milliliter per Hour per Gram | Milliliter/Gram/Hour | mL/g/h | ml/g/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347150","Milliliter per Gram per Day","C73755","A dose calculation unit expressed in milliliter(s) per gram per period of time equal to twenty-four hours.","Milliliter per Gram per Day | (L/d)/kg | (L/day)/kg | (l/d)/kg | (mL/d)/g | (mL/day)/g | (ml/d)/g | Liter per Kilogram per Day | Milliliter per Day per Gram | Milliliter per Gram per 24 Hours | Milliliter/gram/day | mL/g/d | mL/g/day | ml/g/d",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347149","Milliliter per Cage per Week","C73752","A dose calculation unit expressed in milliliter(s) per cage expressed per period of time equal to seven days.","Milliliter per Cage per Week | mL/cage/wk | mL/{cage}/wk | ml/{cage}/wk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347148","Milliliter per Cage per Day","C73751","A dose calculation unit expressed in milliliter(s) per cage per period of time equal to twenty-four hours.","Milliliter per Cage per Day | Milliliter per Cage per 24 Hours | mL/cage/d | mL/cage/day | mL/{cage}/d | ml/{cage}/d",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347147","Milliliter per Cage","C73750","A dose calculation unit expressed in milliliter(s) per cage.","Milliliter per Cage | mL/cage | mL/{cage} | ml/{cage}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347146","Milliliter per Breath","C73749","A dose calculation unit expressed in milliliter(s) per inspiration or expiration of breath.","Milliliter per Breath | Milliliter/Breath | mL/breath | mL/{breath} | ml/{breath}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347145","Milliliter per Animal per Week","C73748","A dose calculation unit expressed in milliliter(s) per animal per period of time equal to seven days.","Milliliter per Animal per Week | mL/anim/wk | mL/animal/wk | mL/{animal}/wk | ml/{animal}/wk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347144","Milliliter per Animal per Day","C73747","A dose calculation unit expressed in milliliter(s) per animal per period of time equal to twenty-four hours.","Milliliter per Animal per Day | Milliliter per Animal per 24 Hours | mL/anim/d | mL/animal/day | mL/{animal}/d | ml/{animal}/d",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347143","Milliliter per Animal","C73746","A dose calculation unit expressed in milliliter(s) per animal.","Milliliter per Animal | mL/anim | mL/animal | mL/{animal} | ml/{animal}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347141","Milligram per Square Meter per Minute","C73744","A dose calculation unit expressed in milligram(s) per square meter per period of time equal to sixty seconds.","Milligram per Square Meter per Minute | Milligram/Square Meter/Minute | mg/m2/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1532576","Milligram per Square Meter per Hour","C73743","A dose calculation unit expressed in milligram(s) per square meter per period of time equal to sixty minutes.","Milligram per Square Meter per Hour | Milligram/Square Meter/Hour | mg/m2/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439420","Milligram per Minute","C73742","A dose calculation expressed in milligram(s) period of time equal to sixty seconds.","Milligram per Minute | Milligram/Minute | mg/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347140","Milligram per Gram per Minute","C73741","A dose calculation unit expressed in milligram(s) per gram per period of time equal to sixty seconds.","Milligram per Gram per Minute | Milligram/Gram/Minute | mg/g/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347139","Milligram per Gram per Hour","C73740","A dose calculation unit expressed in milligram(s) per gram per period of time equal to sixty minutes.","Milligram per Gram per Hour | Milligram/Gram/Hour | mg/g/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347137","Milligram per Animal","C73738","A dose calculation unit expressed in milligram(s) per animal.","Milligram per Animal | mg/anim | mg/animal | mg/{animal}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1532574","Milliequivalent per Milliliter","C73737","A concentration unit expressed in milliequivalent(s) of solute per milliliter of solution.","Milliequivalent per Milliliter | Milliequivalent/Milliliter | mEq/mL | mEq/ml | meq/mL | meq/ml | milliequivalent(s)/millilitre",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347125","Microosmole","C73736","A unit of osmotic pressure equal to one millionth of an osmole or the osmotic pressure of a 10E-6 molar solution of a substance that does not dissociate.","Microosmole | uOsm | uosm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347123","Micromole per Milligram per Minute","C73735","A unit of concentration (molarity unit) equal to one millionth of a mole (10E-6 mole) per milligram of a substance per period of time equal to sixty seconds.","Micromole per Milligram per Minute | Micromole/Milligram/Minute | umol/mg/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347121","Microgram per Square Meter per Minute","C73733","A dose calculation unit expressed in microgram(s) per square meter per period of time equal to sixty seconds.","Microgram per Square Meter per Minute | Microgram/Square Meter/Minute | mcg/m2/min | ug/m2/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1320752","Microgram per Kilogram per Hour","C73730","A dose calculation unit expressed in microgram(s) per kilogram per period of time equal to sixty minutes.","Microgram per Kilogram per Hour | Microgram/Kilogram/Hour | mcg/kg/h | ug/kg/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347116","Microgram per Animal","C73728","A dose calculation unit expressed in microgram(s) per animal.","Microgram per Animal | ug/anim | ug/animal | ug/{animal}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439153","Microequivalent","C73726","A unit of relative amount of a substance equal to one millionth of an equivalent weight.","Microequivalent | uEq | ueq",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL428003","Liter per Kilogram","C73725","A dose calculation unit expressed in liter(s) per kilogram.","Liter per Kilogram | L/kg | Liter/Kilogram | Milliliter per Gram | Milliliter/Gram | l/kg | mL/g | ml/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0567349","Gram per Mole","C73721","A unit of mass commonly used to express the molar mass of a substance in gram(s) per mole.","Gram per Mole | Gram/Mole | g/mol | mg/mmol | microgram per micromole | milligram per millimole | ug/umol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348884","Gram per Gram per Day","C73720","A dose calculation unit expressed in gram(s) per gram per period of time equal to twenty-four hours.","Gram per Gram per Day | Gram per Gram per 24 Hours | Kilogram per Kilogram per Day | Microgram per Microgram per Day | Milligram per Milligram per Day | g/g/d | g/g/day | kg/kg/d | mcg/mcg/d | mg/mg/d | ug/ug/d",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348882","Gram per Cage per Week","C73718","A dose calculation unit expressed in gram(s) per cage per period of time equal to seven days.","Gram per Cage per Week | g/cage/wk | g/{cage}/wk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348881","Gram per Cage per Day","C73717","A dose calculation unit expressed in gram(s) per cage per period of time equal to twenty-four hours.","Gram per Cage per Day | Gram per Cage per 24 Hours | g/cage/d | g/cage/day | g/{cage}/d",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348880","Gram per Cage","C73716","A dose calculation unit expressed in gram(s) per cage.","Gram per Cage | g/cage | g/{cage}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698624","CDISC SDTM Evaluator Terminology","C78735","Terminology associated with the evaluator codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Evaluator Terminology | EVAL | Evaluator | SDTM-EVAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697672","Independent Rater","C78720","An individual qualified to perform an evaluation who is masked from a subject's data in order to minimize bias or maximize consistency and quality.","Independent Rater | INDEPENDENT ASSESSOR | Independent Assessor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554545","Child Relation","C150886","An individual's biological or non-biological first generation offspring, including but not limited to biological children (including those born outside of marriage), adopted children, step children, and foster children.","Child Relation | CHILD | Child",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897813","proxy (advance directive)","C119264","A type of advance directive that gives a person the authority to make decisions for another individual. It becomes active when that person loses the ability to make decisions for him- or herself.","Proxy | PROXY | proxy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347270","CDISC SDTM ECG Test Method Terminology","C71151","Terminology codelist used with ECG Test Methods within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.","CDISC SDTM ECG Test Method Terminology | ECG Test Method | EGMETHOD | SDTM-EGMETHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013801","Holter Monitoring","C38064","An ambulatory electrocardiography technique that records a continuous electrocardiographic rhythm pattern for 24 hours or more to detect heart arrhythmias.","Holter Monitoring | HOLTER CONTINUOUS ECG RECORDING | Holter Electrocardiography | Holter Monitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346537","12 Lead Placement Standard Extended Right","C71130","An electrocardiogram (ECG) lead placement whereby the rightward oriented V leads progress from V1R, placed instead of the standard V2, to V6R. The V3 lead in the standard placement is replaced by V4R.","12 Lead Placement Standard Extended Right | 12-LEAD EXTENDED RIGHT | 12-lead extended to the right by V5R, V4R, V3R | STANDARD 12-LEAD EXTENDED RIGHT | Standard 12-lead extended to the right by V5R, V4R, V3R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346536","12 Lead Placement Standard Extended Left","C71131","An electrocardiogram (ECG) lead placement whereby the standard lead placement is modified by having leads V7, V8 and V9.","12 Lead Placement Standard Extended Left | STANDARD 12-LEAD EXTENDED LEFT | Standard 12-lead extended to the left by V7, V8, V9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346659","Lead Placement Pseudo Orthogonal XYZ","C71122","An electrocardiogram (ECG) lead placement that allows monitoring and recording of cardiac electrical activity. A V1-type lead is used whose positive electrode is localized in the 4th intercostal space, 2.5cm from the sternum. Its negative electrode is placed below the left clavicle. An addition of lead V5 and aVF can be made to facilitate interpretation.","Lead Placement Pseudo Orthogonal XYZ | PSEUDO-ORTHOGONAL XYZ LEAD SYSTEM | Pseudo-orthogonal XYZ lead system",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346527","12 Lead Placement 1 Lead Missing","C71125","An electrocardiogram (ECG) lead placement whereby 12 leadpoints are recorded but one standard lead position is missing therefore requiring a Mortara source consistency filter.","12 Lead Placement 1 Lead Missing | 12 LEAD 1 LEAD MISSING | 12 Lead 1 Lead Missing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346656","Lead Placement EASI Dower Transformation","C71123","An electrocardiogram (ECG) lead placement whereby 4 chest electrodes and 1 reference electrode are used to allow for continuous monitoring at the clinical level. This placement creates a 12 lead ECG that allows the acquisition of simultaneous events in the frontal, horizontral and sagittal heart planes with the linear transformation of vectors. This system provides a three-dimensional portrayal of the heart and uses mathematical and fixed coefficients for each lead.","Lead Placement EASI Dower Transformation | 12 LEAD EASI DOWER TRANSFORMATION | 12 Lead EASI Dower Transformation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346654","Lead Placement Bipolar Uncorrected XYZ","C71121","An electrocardiogram (ECG) lead placement whereby the X+ lead is placed at the right mid-axillary line at the 4th intercostal space, X- at the left mid-axillary line at the 4th intercostal space, Y+ at the proximal left leg, Y- at the superior aspect of the manubrium, Z+ at the direct posterior to Z- and Z- at the 4th intercostal space at the left sternal margin.","Lead Placement Bipolar Uncorrected XYZ | BIPOLAR UNCORRECTED XYZ LEAD SYSTEM | Bipolar uncorrected XYZ lead system",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346535","12 Lead Placement Standard And CC5-CM5-ML","C71128","An electrocardiogram (ECG) lead placement whereby 12 leadpoints are recorded but the standard lead positions have been modified so that the negative reference is at CM5 and the active electrode is at the left leg position.","12 Lead Placement Standard And CC5-CM5-ML | STANDARD 12-LEAD AND CC5-CM5-ML | Standard 12-lead and CC5-CM5-ML",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346534","12 Lead Placement Standard And CC5-CM5-CH5","C71126","An electrocardiogram (ECG) lead placement whereby 12 leadpoints are recorded but the standard lead positions have been modified so that the bipolar lead groups place the negative of the reference electrode over the manubrium (CM5), the right scapula (CB5), V5R (CC5) or on the forehead (CH5) and the active electrode at V5.","12 Lead Placement Standard And CC5-CM5-CH5 | STANDARD 12-LEAD AND CM5-CC5-CH5 | Standard 12-lead and CM5-CC5-CH5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346655","Lead Placement Cube","C71120","An electrocardiogram (ECG) lead placement that is a type of uncorrected vectorcardiograph. This lead system is based on a rectangular body axis. It uses an extra number of electrodes to make it three-dimensional.","Lead Placement Cube | CUBE LEAD SYSTEM | Cube lead system",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346532","12 Lead Placement Non-Standard","C71114","An electrocardiogram (ECG) lead placement whereby the limb leads are placed on the torso for easier and faster application in emergency situations.","12 Lead Placement Non-Standard | 12 LEAD NON-STANDARD | 12 Lead Non-Standard",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346529","12 Lead Placement Chest","C71112","An electrocardiogram (ECG) lead placement whereby 12 leadpoints are recorded but the standard lead positions have been modified so that all leads on the chest are part of a single electrode pad.","12 Lead Placement Chest | 12 LEAD SINGLE PAD | 12 Lead Single Pad",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346658","Lead Placement McFee-Parungao","C71119","An electrocardiogram (ECG) lead placement for determining 3 orthogonal components X (back to front), Y (right to left) and Z (foot to head) of the heart. This system places the electrodes closer to the heart to achieve better orthogonality and a homogeneous lead field.","Lead Placement McFee-Parungao | MCFEE-PARUNGAO LEAD SYSTEM | McFee-Parungao lead system",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346530","12 Lead Placement Mason Likar","C71103","An electrocardiogram (ECG) lead placement whereby 12 leadpoints are recorded but the standard lead positions have been modified for ECG recording during exercise. Exercise stress testing requires moving the limb electrodes to more central positions on the thorax. The electrodes are placed in bony prominences close to the bases of the respective limbs in order to avoid skeletal muscle artifact, provide stability for recording electrodes and to record waveforms similar to the standard limb sites.","12 Lead Placement Mason Likar | 12 LEAD MASON LIKAR | 12 Lead Mason Likar",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346657","Lead Placement Frank","C71118","An electrocardiogram (ECG) lead placement for determining 3 orthogonal components X (right to left direction), Y (foot to head direction) and Z (back to front direction) of the heart. For this method a minimum of 4 electrodes are needed that represent the right arm, left arm, left leg and back. However, ususally 7 electrodes are used to avoid dependence on the dipole location and facilitate interpretation.","Lead Placement Frank | FRANK LEAD SYSTEM | Frank lead system",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346660","Lead Placement Standard Intercostal Space Higher","C71117","An electrocardiographic lead placement schema in which the 'V' leads are placed one intercostal space cephalad to the position they would have in the standard lead placement schema.","Lead Placement Standard Intercostal Space Higher | STANDARD LEADS ONE INTERCOSTAL SPACE HIGHER | Standard leads one intercostal space higher",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346531","12 Lead Placement Mason Likar Modified","C71110","An electrocardiogram (ECG) lead placement whereby 12 leadpoints are recorded but the Mason Likar lead positions have been modified so that V1 to V6 on the chest are part of a single electrode pad. In addition, lead CM5 is substituted for lead aVR.","12 Lead Placement Mason Likar Modified | 12 LEAD MODIFIED MASON LIKAR | 12 Lead Modified Mason Likar",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346528","12 Lead Placement Cabrera","C71116","An electrocardiogram (ECG) lead placement whereby the display of the 12 standard ECG leads is in an 'orderly' sequence in a single horizontal display of: aVL, I, -aVR, II, aVF, III, V1 to V6. In the Cabrera display the limb lead aVR is inverted (-aVR) to obtain the same positive leftward orientation as the other 5 limbs.","12 Lead Placement Cabrera | 12 LEAD CABRERA | 12 Lead Cabrera",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349112","Vectorcardiograph Corrected","C71092","This is a measurement of electric heart vectors whereby this type of measurement aims to create an orthonormal measurement of the electric cardiac vector.","Vectorcardiograph Corrected | VECTORCARDIOGRAPH CORRECTED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900207","12 Lead Placement Right-sided Precordial Leads","C116139","An electrocardiogram (ECG) lead placement whereby the precordial leads are intentionally placed on the right side of the chest. (CDISC)","12 Lead Placement Right-sided Precordial Leads | 12 LEAD RIGHT-SIDED PRECORDIAL LEADS | 12 Lead Right-sided Precordial Leads | Right-sided Chest Leads",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983575","6 Lead Standard","C90350","An electrocardiogram lead placement on the patient using a six electrode lead set with three standard leads and three augmented derived leads to elicit an electrical view of the heart.","6 Lead Standard | 6 LEAD STANDARD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983574","10 Lead Standard","C90349","An electrocardiogram lead placement on the patient using a ten electrode lead set to synthesize standard 12 lead electrocardiograph data to elicit an electrical view of the heart.","10 Lead Standard | 10 LEAD STANDARD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346653","Lead Placement Bicycle","C71115","Limb leads on the back (shoulder and on the hips).","Lead Placement Bicycle | STANDARD LEADS FOR BICYCLE EXERCISE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053761","Continuous Ambulatory ECG","C123446","A continuous electrocardiographic (ECG) recording that utilizes one or more leads that both records and stores data directly to a device worn by the subject, such that the subject need not be restricted to a medical facility, and may be able to participate in their customary activities of daily living.","Continuous Ambulatory ECG | CONTINUOUS AMBULATORY ECG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055629","12 Lead ECG Extracted From 12 Lead Continuous ECG Recording","C123445","Any electrocardiogram (ECG) reading excerpted from a continuous, 12 Lead ECG.","12 Lead ECG Extracted From 12 Lead Continuous ECG Recording | 12 LEAD ECG EXTRACTED FROM 12 LEAD CONTINUOUS ECG RECORDING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055630","12 Lead Continuous ECG","C123444","A continuous electrocardiographic (ECG) recording that utilizes twelve leads, though the lead placement may vary from the standard 12 Lead ECG placement. Examples include, but are not limited to, 12 lead Holter with modified Mason-Likar lead placements, 12 lead exercise ECGs, and 12 lead telemetry systems.","12 Lead Continuous ECG | 12 LEAD CONTINUOUS ECG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521017","6 Lead NEHB-SPORI","C132355","An electrocardiogram (ECG) lead configuration that is primarily used to record ECGs in non-human animals, and which uses six (6) electrodes to generate eight (8) ECG leads (ECG wave forms). The six electrode configuration includes the following: four (4) limb electrodes, which are placed analogous to an Einthoven configuration in humans, and two (2) chest electrodes. The eight (8) ECG leads recorded comprise three standard limb leads (leads I, II, and III), three augmented leads (Leads aVr, aVF, and aVL), and two chest leads, which are generated using two unipolar chest leads, typically CV5RL [rV2] and CV6LL [V2] for canines, or MV1 and MV2 for primates. (CDISC)","6 Lead NEHB-SPORI | 6 LEAD NEHB-SPORI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521019","8 Lead Standard","C132356","An electrocardiogram (ECG) recorded using 6 electrodes to generate 8 ECG leads (ECG wave forms). The 6 electrode configuration includes 4 limb electrodes in an Einthoven configuration and two chest electrodes. The 8 ECG leads recorded comprise three standard limb leads (leads I, II, and III), three augmented leads (leads aVR, aVF, and aVL), and two chest leads, which are generated using two unipolar chest leads, typically CV5RL [rV2] and CV6LL [V2] for canines, or MV1 and MV2 for non-human primates. This lead configuration is typically used to record ECGs in non-human animals. (CDISC)","8 Lead Standard | 8 LEAD STANDARD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347271","CDISC SDTM ECG Test Name Terminology","C71152","Terminology codelist used with ECG Test Names within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.","CDISC SDTM ECG Test Name Terminology | ECG Test Name | EGTEST | SDTM-EGTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897403","T Wave Amplitude Single Beat","C117815","An electrocardiographic measurement of the mean amplitude (usually measured in mV) of the T wave measured from the isoelectric baseline to the peak of the T wave of a single beat utilizing one or more leads. Based on the recording gain, this measurement may also be reported in mm. (CDISC)","T Wave Amplitude Single Beat | T Wave Amplitude, Single Beat | TWHSB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897402","T Wave Area Single Beat","C117811","An electrocardiographic measurement of the area of the T wave of a single beat utilizing one or more leads. (CDISC)","T Wave Area Single Beat | T Wave Area, Single Beat | TWARSB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897404","T Wave Amplitude Aggregate","C117814","An aggregate T wave amplitude value based on the measurement of T wave amplitudes from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)","T Wave Amplitude Aggregate | T Wave Amplitude, Aggregate | TWHAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897051","T Wave Area Aggregate","C117810","An aggregate T wave area value based on the measurement of T wave areas from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)","T Wave Area Aggregate | T Wave Area, Aggregate | TWARAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897401","T Wave Duration Aggregate","C117812","An aggregate T wave duration value based on the measurement of T wave duration intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)","T Wave Duration Aggregate | T Wave Duration, Aggregate | TWDURAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900108","Acute Myocardial Ischemia by ECG Assessment","C116140","An electrocardiographic finding assessment of new or presumed new significant ST-segment-T wave (ST-T) changes or new left bundle branch block consistent with acute myocardial ischemia. (Thygesen K, Alpert JS, Jaffe AS, et al.: the Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. J Am Coll Cardiol 60(16):1-18, 2012)","Acute Myocardial Ischemia by ECG Assessment | AMIEGCHG | Acute Myocardial Ischemia ECG Change",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880469","Minimum ST Segment Depression by ECG Finding","C62162","An electrocardiographic finding of the minimum depression of the ST segment, obtained from a set of measurements of the depression of the ST segment.","Minimum ST Segment Depression by ECG Finding | Minimum ST Segment Depression | Minimum ST Segment Depression by EKG Finding | STDPMIN | Summary (Min) ST Depression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880442","Maximum ST Segment Depression by ECG Finding","C62163","An electrocardiographic finding of the maximum depression of the ST segment, obtained from a set of measurements of the depression of the ST segment.","Maximum ST Segment Depression by ECG Finding | Maximum ST Segment Depression | Maximum ST Segment Depression by EKG Finding | STDPMAX | Summary (Max) ST Depression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812282","Ventricular Arrhythmia ECG Assessment","C111330","An electrocardiographic assessment of the atypical cardiac rhythms originating in the ventricle.","Ventricular Arrhythmia ECG Assessment | VTARRY | Ventricular Arrhythmias",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827656","Ventricular Tachyarrhythmia ECG Assessment","C111331","An electrocardiographic assessment of the abnormally fast cardiac rhythms originating within the ventricles.","Ventricular Tachyarrhythmia ECG Assessment | VTTARRY | Ventricular Tachyarrhythmias",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810814","Myocardial Infarction ECG Assessment","C111280","An electrocardiographic assessment of findings that suggest the occurrence of a myocardial infarction.","Myocardial Infarction ECG Assessment | MI | Myocardial Infarction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814839","Supraventricular Arrhythmia ECG Assessment","C111320","An electrocardiographic assessment of the atypical cardiac rhythms originating in the atrium, AV node or AV junction.","Supraventricular Arrhythmia ECG Assessment | SPRARRY | Supraventricular Arrhythmias",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828016","Sinus Node Rhythm and Arrhythmia ECG Assessment","C111312","An electrocardiographic assessment of the typical and atypical cardiac rhythms originating from the sinoatrial node.","Sinus Node Rhythm and Arrhythmia ECG Assessment | SNRARRY | Sinus Node Rhythms and Arrhythmias",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3853833","Supraventricular Tachyarrhythmia ECG Assessment","C111321","An electrocardiographic assessment of the abnormally fast cardiac rhythms originating above the ventricles.","Supraventricular Tachyarrhythmia ECG Assessment | SPRTARRY | Supraventricular Tachyarrhythmias",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827906","ST Segment, T wave, and U wave ECG Assessment","C111363","An electrocardiographic assessment of the characteristics of the ST segment, T wave, and U wave.","ST Segment, T wave, and U wave ECG Assessment | ST Segment, T wave, and U wave | STSTWUW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828331","Rhythm Not Otherwise Specified ECG Assessment","C111307","An electrocardiographic assessment of a cardiac rhythm that is not specified in a particular list.","Rhythm Not Otherwise Specified ECG Assessment | RHYNOS | Rhythm Not Otherwise Specified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3853703","Pacemaker ECG Assessment","C111285","An electrocardiographic assessment of the rate of firing of a an artificial, mechanical pacemaker.","Pacemaker ECG Assessment | PACEMAKR | Pacemaker",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831145","Chamber Hypertrophy or Enlargement ECG Assessment","C111155","An electrocardiographic assessment of chamber hypertrophy or enlargement.","Chamber Hypertrophy or Enlargement ECG Assessment | CHYPTENL | Chamber Hypertrophy or Enlargement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829509","Intraventricular and Intraatrial Conduction ECG Assessment","C111238","An electrocardiographic assessment of the transmission of electrical impulses through the cardiac atria and ventricles.","Intraventricular and Intraatrial Conduction ECG Assessment | IVTIACD | Intraventricular-Intraatrial Conduction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827378","Axis and Voltage ECG Assessment","C111132","An electrocardiographic assessment of the mean cardiac electrical vector and ECG voltage.","Axis and Voltage ECG Assessment | AXISVOLT | Axis and Voltage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831454","Atrioventricular Conduction ECG Assessment","C111131","An electrocardiographic assessment of the transmission of electrical impulses between the atria and ventricles.","Atrioventricular Conduction ECG Assessment | AVCOND | Atrioventricular Conduction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880467","Minimum QT Duration","C62133","The minimum duration (time) of the QT interval, obtained from a set of measurements of the QT interval. The QT interval is defined as the time from the beginning of the QRS complex to the end of the T wave, representing the time it takes for the ventricles to depolarize and subsequently repolarize. In some cases, the Q wave will be absent, in which case the QT interval is measured from the beginning of the R wave to the end of the T wave.","Minimum QT Duration | QTMIN | Summary (Min) QT Duration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880441","Maximum RR Duration","C62094","The maximum duration (time) between successive peaks of R waves in a particular set of RR intervals.","Maximum RR Duration | RRMAX | Summary (Max) RR Duration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880438","Maximum JT Duration","C62117","The maximum duration (time) of the JT interval, obtained from a set of measurements of the JT interval. The JT interval is defined as the time from the J point (end of ventricular depolarization, the point at which the QRS meets the ST segment) to the end of the T wave (representing the end of ventricular repolarization).","Maximum JT Duration | JTMAX | Summary (Max) JT Interval",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880470","Minimum ST Deviation","C62156","The minimum deviation (distance from baseline, positive or negative, usually measured in mm) of the ST segment, obtained from a set of measurements of the deviation of the ST segment.","Minimum ST Deviation | STDVMIN | Summary (Min) ST Deviation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880471","Minimum ST Segment Elevation","C62159","The minimum elevation of the ST segment, obtained from a set of measurements of the elevation of the ST segment.","Minimum ST Segment Elevation | STELMIN | Summary (Min) ST Elevation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880439","Maximum PR Duration","C62131","The maximum duration (time) of the PR interval, obtained from a set of measurements of the PR interval. The PR interval is defined as the time from the beginning of the P wave (representing the onset of atrial depolarization) to the beginning of the R wave (representing the onset of ventricular depolarization). In some cases, a Q wave will precede the R wave, in which case the PR interval is measured from the beginning of the P wave to the beginning of the Q wave.","Maximum PR Duration | PRMAX | Summary (Max) PR Duration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880468","Minimum RR Duration","C62093","The minimum duration (time) between successive peaks of R waves in a particular set of RR intervals.","Minimum RR Duration | RRMIN | Summary (Min) RR Duration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880465","Minimum JT Duration","C62116","The minimum duration (time) of the JT interval, obtained from a set of measurements of the JT interval. The JT interval is defined as the time from the J point (end of ventricular depolarization, the point at which the QRS meets the ST segment) to the end of the T wave (representing the end of ventricular repolarization).","Minimum JT Duration | JTMIN | Summary (Min) JT Interval",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880440","Maximum QT Duration","C62135","The maximum duration (time) of the QT interval, obtained from a set of measurements of the QT interval. The QT interval is defined as the time from the beginning of the QRS complex to the end of the T wave, representing the time it takes for the ventricles to depolarize and subsequently repolarize. In some cases, the Q wave will be absent, in which case the QT interval is measured from the beginning of the R wave to the end of the T wave.","Maximum QT Duration | QTMAX | Summary (Max) QT Duration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880444","Maximum ST Segment Elevation","C62160","The maximum elevation of the ST segment, obtained from a set of measurements of the elevation of the ST segment.","Maximum ST Segment Elevation | STELMAX | Summary (Max) ST Elevation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880466","Minimum PR Duration","C62125","The minimum duration (time) of the PR interval, obtained from a set of measurements of the PR interval. The PR interval is defined as the time from the beginning of the P wave (representing the onset of atrial depolarization) to the beginning of the R wave (representing the onset of ventricular depolarization). In some cases, a Q wave will precede the R wave, in which case the PR interval is measured from the beginning of the P wave to the beginning of the Q wave.","Minimum PR Duration | PRMIN | Summary (Min) PR Duration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880443","Maximum ST Deviation","C62157","The maximum deviation (distance from baseline, positive or negative, usually measured in mm) of the ST segment, obtained from a set of measurements of the deviation of the ST segment.","Maximum ST Deviation | STDVMAX | Summary (Max) ST Deviation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055106","ECG Median Heart Rate","C123447","An electrocardiographic measurement of the median rate of depolarization of a specific region of the heart during an interval of time, usually expressed in beats per minute. Unless otherwise specified, this is usually the median ventricular rate.","ECG Median Heart Rate | EGHRMED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055484","Aggregate QTcV Interval","C123450","The correction of the aggregate of QT intervals using the Van der Water's formula, which allows for the comparison of QT intervals across a range of heart rates.","Aggregate QTcV Interval | QTCVAG | QTcV Interval, Aggregate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054020","Single Beat QTcL Interval","C123449","The correction of the QT interval within a single beat using a linear correction formula.","Single Beat QTcL Interval | QTCLSB | QTcL Interval, Single Beat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055485","Aggregate QTcL Interval","C123448","The correction of the aggregate of QT intervals using a linear correction formula, which allows for the comparison of QT intervals across a range of heart rates.","Aggregate QTcL Interval | QTCLAG | QTcL Interval, Aggregate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054019","Single Beat QTcV Interval","C123451","The correction of the QT interval within a single beat using the Van der Water's formula.","Single Beat QTcV Interval | QTCVSB | QTcV Interval, Single Beat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0429012","QRS Axis","C118165","A numerical representation of the electrocardiographic vector assessed at maximum deviation of the QRS complex from the isoelectric baseline, usually reported for the frontal plane. (CDISC)","QRS Axis | QRS axis | QRS_AXIS",,,,,,,,,,,,,,,"4089466","QRS Axis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0489659","T Wave Axis","C118166","A numerical representation of the electrocardiographic vector assessed at maximum deviation of the T wave from the isoelectric baseline, usually reported for the frontal plane. (CDISC)","T Wave Axis | T_AXIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0429008","P Wave Axis","C118164","A numerical representation of the electrocardiographic vector assessed at maximum deviation of the P wave from the isoelectric baseline, usually reported for the frontal plane. (CDISC)","P Wave Axis | P_AXIS",,,,,,,,,,,,,,,"4092015","P wave axis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054018","Single Beat RR Extrapolated Heart Rate by ECG Assessment","C120608","The extrapolation of an individual's heart rate as estimated from a single R-R interval as measured by an electrocardiographic machine.","Single Beat RR Extrapolated Heart Rate by ECG Assessment | EGHRSI | Single RR Heart Rate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898309","Minimum Atrial Rate by Electrocardiogram","C119255","An electrocardiographic measurement of the minimum rate of atrial depolarizations (P waves) recorded during a specified period of time, and usually expressed in beats per minute.","Minimum Atrial Rate by Electrocardiogram | ECG Minimum Atrial Rate | EGARMIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898308","Minimum Heart Rate by Electrocardiogram","C119258","An electrocardiographic measurement of the minimum number of depolarisations of a specific region of the heart, most often the ventricles, recorded during a specified, extended period of time, and usually expressed in beats per minute.","Minimum Heart Rate by Electrocardiogram | ECG Minimum Heart Rate | EGHRMIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898440","Median Atrial Rate by Electrocardiogram","C119254","An assessment of the median atrial depolarization rate as measured and recorded by an electrocardiograph during a specified period of time, and which is usually expressed in beats per minute.","Median Atrial Rate by Electrocardiogram | ECG Median Atrial Rate | EGARMED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898454","Maximum Ventricular Rate by Electrocardiogram","C119260","An electrocardiographic measurement of the maximum number of ventricular depolarizations (QRS complexes) recorded during a specified, extended period of time, usually expressed in beats per minute.","Maximum Ventricular Rate by Electrocardiogram | ECG Maximum Ventricular Rate | EGVRMAX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898450","Mean Heart Rate by Electrocardiogram","C119259","The calculated average rate of depolarisation of a specific region of the heart, most often the ventricles, as measured and recorded by an electrocardiograph during a specified, extended period of time, and which is usually expressed in beats per minute.","Mean Heart Rate by Electrocardiogram | ECG Mean Heart Rate | EGHRMN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898451","Mean Atrial Rate by Electrocardiogram","C119256","The calculated average rate of atrial depolarization (P waves) as measured and recorded by an electrocardiograph during a specified period of time, and which is usually expressed in beats per minute.","Mean Atrial Rate by Electrocardiogram | ECG Mean Atrial Rate | EGARMN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898306","Minimum Ventricular Rate by Electrocardiogram","C119262","An electrocardiographic measurement of the minimum number of ventricular depolarizations (QRS complexes) recorded during a specified, extended period of time, and usually expressed in beats per minute.","Minimum Ventricular Rate by Electrocardiogram | ECG Minimum Ventricular Rate | EGVRMIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898439","Median Ventricular Rate by Electrocardiogram","C119261","An assessment of the median ventricular depolarization rate as measured and recorded by an electrocardiograph during a specified period of time, and which is usually expressed in beats per minute.","Median Ventricular Rate by Electrocardiogram | ECG Median Ventricular Rate | EGVRMED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898457","Maximum Heart Rate by Electrocardiogram","C119257","An electrocardiographic measurement of the maximum number of depolarisations of a specific region of the heart, most often the ventricles, recorded during a specified, extended period of time, and usually expressed in beats per minute.","Maximum Heart Rate by Electrocardiogram | ECG Maximum Heart Rate | EGHRMAX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896978","Mean Ventricular Rate by Electrocardiogram","C119263","The calculated average rate of ventricular depolarisation as measured and recorded by an electrocardiograph during a specified, extended period of time, and which is usually expressed in beats per minute.","Mean Ventricular Rate by Electrocardiogram | ECG Mean Ventricular Rate | EGVRMN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898458","Maximum Atrial Rate by Electrocardiogram","C119253","An electrocardiographic measurement of the maximum number of atrial depolarizations (P waves) recorded during a specified period of time, and usually expressed in beats per minute.","Maximum Atrial Rate by Electrocardiogram | ECG Maximum Atrial Rate | EGARMAX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086853","Single Beat QTca Interval","C124333","The correction of the QT interval within a single beat using individual probabilistic QT/RR slopes for each subject based on a single beat-QT interval from one or more EKG leads.","Single Beat QTca Interval | QTCASB | QTca Interval, Single Beat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085943","Aggregate QTca Interval","C124332","The correction on the aggregate of QT intervals using individual probabilistic QT/RR slopes for each subject based on the measurement of QT intervals from multiple beats within a single ECG or from a defined time period within a continuous ECG. The method of aggregation, which can vary, is typically a measure of central tendency, such as mean.","Aggregate QTca Interval | QTCAAG | QTca Interval, Aggregate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899323","ECG Technical Quality","C117807","A statement about an electrocardiographic recording describing technical issues or interference during the recording, processing, or transmission of the data. This does not represent an electrocardiographic diagnosis. (CDISC)","ECG Technical Quality | TECHQUAL | Technical Quality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899521","Comparison to a Prior ECG","C117761","A comparative interpretation of an ECG relative to a previous (comparator) ECG. The definition of the comparator ECG may be specified elsewhere. Common comparator result values include improved, no change, deteriorated. (CDISC)","Comparison to a Prior ECG | EGCOMP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897668","ST Segment Elevation Single Beat","C117802","An electrocardiographic measurement of the mean amplitude (usually measured in mV) of the ST segment elevation above the isoelectric baseline measured from the baseline to the ST segment of a single beat utilizing one or more leads. Based on the recording gain, this measurement may also be reported in mm. (CDISC)","ST Segment Elevation Single Beat | ST Segment Elevation, Single Beat | STESB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897691","S Wave Amplitude Single Beat","C117806","An electrocardiographic measurement of the mean amplitude (usually measured in mV) of the S wave measured from the isoelectric baseline to the peak of the S wave of a single beat utilizing one or more leads. Based on the recording gain, this measurement may also be reported in mm. (CDISC)","S Wave Amplitude Single Beat | S Wave Amplitude, Single Beat | SWASB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897096","ST Segment Elevation Aggregate","C117801","An aggregate ST segment elevation value based on the measurement of ST segment elevation from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)","ST Segment Elevation Aggregate | ST Segment Elevation, Aggregate | STEAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897671","ST Segment Deviation Single Beat","C117800","An electrocardiographic measurement of the mean amplitude (usually measured in mV) of the ST segment deviation above or below the isoelectric baseline measured from the baseline to the ST segment of a single beat utilizing one or more leads. Based on the recording gain, this measurement may also be reported in mm. (CDISC)","ST Segment Deviation Single Beat | ST Segment Deviation, Single Beat | STDVSB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897669","ST Segment Duration Single Beat","C117804","An electrocardiographic interval measured from the J point to the onset of the T wave of a single beat utilizing one or more leads. (CDISC)","ST Segment Duration Single Beat | ST Segment Duration, Single Beat | STSDURSB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897692","S Wave Amplitude Aggregate","C117805","An aggregate S wave amplitude value based on the measurement of S wave amplitudes from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)","S Wave Amplitude Aggregate | S Wave Amplitude, Aggregate | SWAAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897405","T Peak-T End Interval Single Beat","C117809","An electrocardiographic interval measured from the peak of the T wave to the offset of the T wave of a single beat utilizing one or more leads. (CDISC)","T Peak-T End Interval Single Beat | TPTESB | Tpeak-Tend Interval, Single Beat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897406","T Peak-T End Interval Aggregate","C117808","An aggregate Tpeak-Tend value based on the measurement of Tpeak-Tend from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)","T Peak-T End Interval Aggregate | TPTEAG | Tpeak-Tend Interval, Aggregate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897670","ST Segment Duration Aggregate","C117803","An aggregate ST segment duration value based on the measurement of ST segment duration intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)","ST Segment Duration Aggregate | ST Segment Duration, Aggregate | STSDURAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897673","ST Segment Depression Single Beat","C117798","An electrocardiographic measurement of the mean amplitude (usually measured in mV) of the ST segment depression below the isoelectric baseline measured from the baseline to the ST segment of a single beat utilizing one or more leads. Based on the recording gain, this measurement may also be reported in mm. (CDISC)","ST Segment Depression Single Beat | ST Segment Depression, Single Beat | STDSB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898141","New Q Wave","C117770","An electrocardiographic finding assessment of new or presumed new pathologic Q waves suggestive of myocardial infarction. (Thygesen K, Alpert JS, Jaffe AS, et al.: the Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. J Am Coll Cardiol 60(16):1-18, 2012). (CDISC)","New Q Wave | NEWQWAVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900076","Aggregate JTCB Interval","C117763","A JTAG interval corrected for heart rate using Bazett's formula. (CDISC)","Aggregate JTCB Interval | JTCBAG | JTcB Interval, Aggregate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897606","Single Beat QRS Duration","C117780","An electrocardiographic interval measured from the onset of the QRS complex to the offset of the QRS complex of a single beat utilizing one or more leads. (CDISC)","Single Beat QRS Duration | QRS Duration, Single Beat | QRSSB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897605","Single Beat QT Interval","C117788","An electrocardiographic interval measured from the onset of the QRS complex to the offset of the T wave of a single beat utilizing one or more leads. (CDISC)","Single Beat QT Interval | QT Interval, Single Beat | QTSB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900069","Aggregate QRS Duration","C117779","An aggregate QRS value based on the measurement of QRS intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)","Aggregate QRS Duration | QRS Duration, Aggregate | QRSAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897612","Single Beat JTCB Interval","C117764","A JTSB interval corrected for heart rate using Bazett's formula. (CDISC)","Single Beat JTCB Interval | JTCBSB | JTcB Interval, Single Beat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889973","RS Wave Amplitude Aggregate","C117793","An aggregate RS wave amplitude value based on measurements from multiple beats from a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)","RS Wave Amplitude Aggregate | RS Wave Amplitude, Aggregate | RSAAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900073","Aggregate P Wave Duration","C117775","An aggregate P wave duration value based on the measurement of P wave duration intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)","Aggregate P Wave Duration | P Wave Duration, Aggregate | PWDURAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897604","Single Beat QTCB Interval","C117785","A QT single beat interval corrected for heart rate using Bazett's formula.","Single Beat QTCB Interval | QTCBSB | QTcB Interval, Single Beat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897608","Single Beat PR Interval","C117774","An electrocardiographic interval measured from the onset of the P wave to the onset of the QRS complex of a single beat utilizing one or more leads. (CDISC)","Single Beat PR Interval | PQ Interval, Single Beat | PQSB | PR Interval, Single Beat | PRSB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900077","Aggregate JT Interval","C117762","An aggregate JT value based on the measurement of JT intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)","Aggregate JT Interval | JT Interval, Aggregate | JTAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897609","Single Beat P Wave Duration","C117776","An electrocardiographic interval measured from the onset of the P wave to the offset of the P wave of a single beat utilizing one or more leads. (CDISC)","Single Beat P Wave Duration | P Wave Duration, Single Beat | PWDURSB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900065","Aggregate RR Interval","C117791","An aggregate RR value based on the measurement of RR intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)","Aggregate RR Interval | RR Interval, Aggregate | RRAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897782","RR Interval Single Measurement","C117792","An electrocardiographic measurement of the interval between two consecutive R waves. If R waves are not present, this measurement may utilize the interval between the most easily identified components of the QRS complex within two consecutive beats. (CDISC)","RR Interval Single Measurement | RR Interval, Single Measurement | RRSM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897613","Single Beat JT Interval","C117769","An electrocardiographic interval measured from the J point to the offset of the T wave of a single beat utilizing one or more leads. (CDISC)","Single Beat JT Interval | JT Interval, Single Beat | JTSB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900067","Aggregate QTCB Interval","C117784","A QT aggregate interval corrected for heart rate using Bazett's formula.","Aggregate QTCB Interval | QTCBAG | QTcB Interval, Aggregate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900074","Aggregate P Wave Amplitude","C117777","An aggregate P wave amplitude value based on the measurement of P wave amplitudes from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)","Aggregate P Wave Amplitude | P Wave Amplitude, Aggregate | PWHTAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897674","ST Segment Depression Aggregate","C117797","An aggregate ST segment depression value based on the measurement of ST segment depression from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)","ST Segment Depression Aggregate | ST Segment Depression, Aggregate | STDAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897607","Single Beat Q Wave Amplitude","C117790","An electrocardiographic measurement of the mean amplitude (usually measured in mV) of the Q wave measured from the isoelectric baseline to the peak of the Q wave of a single beat utilizing one or more leads. Based on the recording gain, this measurement may also be reported in mm. (CDISC)","Single Beat Q Wave Amplitude | Q Wave Amplitude, Single Beat | QWASB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897610","Single Beat P Wave Amplitude","C117778","An electrocardiographic measurement of the mean amplitude (usually measured in mV) of the P wave measured from the isoelectric baseline to the peak of the P wave of a single beat utilizing one or more leads. Based on the recording gain, this measurement may also be reported in mm. (CDISC)","Single Beat P Wave Amplitude | P Wave Amplitude, Single Beat | PWHTSB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890895","R Wave Amplitude Single Beat","C117796","An electrocardiographic measurement of the mean amplitude (usually measured in mV) of the R wave measured from the isoelectric baseline to the peak of the R wave of a single beat utilizing one or more leads. Based on the recording gain, this measurement may also be reported in mm. (CDISC)","R Wave Amplitude Single Beat | R Wave Amplitude, Single Beat | RWASB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900071","Aggregate PR Interval","C117773","An aggregate PR value based on the measurement of PR intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)","Aggregate PR Interval | PQ Interval, Aggregate | PQAG | PR Interval, Aggregate | PRAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897603","Single Beat QTCF Interval","C117787","A QT single beat interval corrected for heart rate using Fridericia's formula.","Single Beat QTCF Interval | QTCFSB | QTcF Interval, Single Beat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898034","Paced Ventricular Single Beat QRS Duration","C117782","An electrocardiographic interval measured from the onset of the paced QRS complex to the offset of the QRS complex of a single beat utilizing one or more leads. (CDISC)","Paced Ventricular Single Beat QRS Duration | QRS Duration, Ventr. Paced, Single Beat | QRVDVPSB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900072","Aggregate PP Interval","C117771","An aggregate PP value based on the measurement of PP intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)","Aggregate PP Interval | PP Interval, Aggregate | PPAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900078","Aggregate J-T Peak Interval","C117767","An aggregate J-Tpeak value based on the measurement of J-Tpeak intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)","Aggregate J-T Peak Interval | J-Tpeak Interval, Aggregate | JTPAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900068","Aggregate QT Interval","C117783","An aggregate QT value based on the measurement of QT intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)","Aggregate QT Interval | QT Interval, Aggregate | QTAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900075","Aggregate JTCF Interval","C117765","A JTAG interval corrected for heart rate using Fridericia's formula. (CDISC)","Aggregate JTCF Interval | JTCFAG | JTcF Interval, Aggregate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900070","Aggregate Q Wave Amplitude","C117789","An aggregate Q wave amplitude value based on the measurement of Q wave amplitudes from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)","Aggregate Q Wave Amplitude | Q Wave Amplitude, Aggregate | QWAAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897602","Single Measurement PP Interval","C117772","An electrocardiographic measurement of the interval between the onsets of two consecutive P waves. (CDISC)","Single Measurement PP Interval | PP Interval, Single Measurement | PPSM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897614","Single Beat J-T Peak Interval","C117768","An electrocardiographic interval measured from the J point to the peak of the T wave of a single beat utilizing one or more leads. (CDISC)","Single Beat J-T Peak Interval | J-Tpeak Interval, Single Beat | JTPSB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897611","Single Beat JTCF Interval","C117766","A JTSB interval corrected for heart rate using Fridericia's formula. (CDISC)","Single Beat JTCF Interval | JTCFSB | JTcF Interval, Single Beat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898035","Paced Ventricular Aggregate QRS Duration","C117781","An aggregate paced QRS duration value based on the measurement of paced QRS duration intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)","Paced Ventricular Aggregate QRS Duration | QRS Duration, Ventr. Paced, Aggregate | QRVDVPAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900066","Aggregate QTCF Interval","C117786","A QT aggregate interval corrected for heart rate using Fridericia's formula.","Aggregate QTCF Interval | QTCFAG | QTcF Interval, Aggregate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889984","R Wave Amplitude Aggregate","C117795","An aggregate R wave amplitude value based on the measurement of R wave amplitudes from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)","R Wave Amplitude Aggregate | R Wave Amplitude, Aggregate | RWAAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889665","RS Wave Amplitude Single Beat","C117794","An electrocardiographic measurement of the sum of the amplitudes of the R and S waves, obtained from a single beat in one particular lead or set of leads. (CDISC)","RS Wave Amplitude Single Beat | RS Wave Amplitude, Single Beat | RSASB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013557","Economic","C117466","This interventions domain model reflects protocol-specified study treatment administrations, as collected.","Exposure as Collected Domain | EC | Exposure as Collected",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899210","Exposure as Collected Occurrence","C117478","An indication or description of a collected exposure occurrence.","Exposure as Collected Occurrence | ECOCCUR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513451","Dermatophagoides farinae Antigen IgE Antibody Measurement","C130132","A measurement of the Dermatophagoides farinae antigen IgE antibody in a biological specimen.","Dermatophagoides farinae Antigen IgE Antibody Measurement | American House Dust Mite IgE Antibody | C130132 | D. farinae Antigen IgE Antibody | Dermatophagoides farinae IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084804","Galactose Elimination Capacity","C124342","A liver function test that measures galactose elimination capacity in a biological specimen.","Galactose Elimination Capacity | GEC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520661","G6PD-Deficient Erythrocytes to Erythrocytes Ratio Measurement","C132369","The determination of the ratio of the G6PD-deficient erythrocytes as compared to the total erythrocytes present in a sample. The measurement may be expressed as a ratio or percentage.","G6PD-Deficient Erythrocytes to Erythrocytes Ratio Measurement | G6PD-Deficient Erythrocytes/Erythrocytes | G6PDRBRB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545252","Borrelia burgdorferi IgG and IgM Antibody Measurement","C147310","The determination of the amount of Borrelia burgdorferi IgG and IgM antibody present in a sample.","Borrelia burgdorferi IgG and IgM Antibody Measurement | B. burgdorferi IgG and IgM Antibody | BBIGGMAB | Borrelia burgdorferi IgG and IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513467","Myeloid Progenitor Cell Count","C130165","The determination of the number of myeloid progenitor cells in a sample.","Myeloid Progenitor Cell Count | MYPC | Myeloid Progenitor Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899219","Exposure as Collected Fasting Status","C117492","An indication or description of whether a collected exposure specimen was obtained from a subject that has abstained from food and possibly water for the prescribed amount of time.","Exposure as Collected Fasting Status | ECFAST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272953","Immature Granulocyte Count","C96675","The determination of the amount of immature granulocytes present in a sample.","Immature Granulocyte Count | GRANIM | Immature Granulocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522794","Segmented Basophil Count","C135401","The determination of the amount of segmented basophils present in a sample.","Segmented Basophil Count | BASOSG | Basophils, Segmented",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520469","Free PSA to Total PSA Ratio Measurement","C132384","The determination of the ratio of free prostate specific antigen as compared to the total prostate specific antigen present in a sample. The measurement may be expressed as a ratio or percentage.","Free PSA to Total PSA Ratio Measurement | PSA, Free/PSA | PSAFPSAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697788","Interleukin 8 Measurement","C74836","The determination of the amount of interleukin 8 present in a sample.","Interleukin 8 Measurement | INTLK8 | Interleukin 8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699301","Sickle Cell to Erythrocyte Ratio Measurement","C74656","The determination of the ratio of sickle cells compared to all erythrocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Sickle Cell to Erythrocyte Ratio Measurement | SCKCERBC | Sickle Cells/Erythrocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272959","Inhibin B Measurement","C96681","The determination of the amount of inhibin B present in a sample.","Inhibin B Measurement | INHIBINB | Inhibin B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202070","Histamine Measurement","C80189","The determination of the amount of histamine present in a sample.","Histamine Measurement | HISTAMIN | Histamine",,,,,,,,,,,,,,,"4103391","Histamine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0373727","Vitamin B1 Measurement","C74896","The determination of the amount of Vitamin B1 present in a sample.","Vitamin B1 Measurement | Thiamine | VITB1 | Vitamin B1",,,,,,,,,,,,,,,"4021280","Thiamine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1880185","Creatine Kinase BB Measurement","C64490","A quantitative measurement of the amount of homozygous B-type creatine kinase present in a sample.","Creatine Kinase BB Measurement | CKBB | CKBB Measurement | Creatine Kinase BB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538935","Procedure Domain","C102700","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to procedure.","Procedure Domain | PR | Procedures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897830","Procedure Pre-specified","C117515","An indication or description that the procedure was previously determined, characterized, or detailed.","Procedure Pre-specified | PRPRESP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274415","Lymphocyte to Total Cell Ratio Measurement","C98751","The determination of the ratio of lymphocytes compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Lymphocyte to Total Cell Ratio Measurement | LYMCE | Lymphocytes to Total Cells Ratio Measurement | Lymphocytes/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887695","Total Amyloid Precursor Protein Measurement","C119269","The determination of the amount of the total amyloid precursor protein in a biological specimen.","Total Amyloid Precursor Protein Measurement | APPT | Total Amyloid Precursor Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202419","Methamphetamine Measurement","C75348","The determination of the amount of methamphetamine present in a sample.","Methamphetamine Measurement | METHAMPH | Methamphetamine",,,,,,,,,,,,,,,"4101536","Methamphetamine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545313","Phosphatidylglycerol to Lung Surfactant Ratio Measurement","C147423","The determination of the ratio of phosphatidylglycerol compared to lung surfactant present in a sample. The measurement may be expressed as a ratio or percentage.","Phosphatidylglycerol to Lung Surfactant Ratio Measurement | PSDGLSRF | Phosphatidylglycerol/Lung Surfactant | Phosphatidylglycerol/Pulmonary Surfactant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202251","Vitamin B6 Measurement","C74901","The determination of the amount of Vitamin B6 present in a sample.","Vitamin B6 Measurement | Pyridoxine | VITB6 | Vitamin B6",,,,,,,,,,,,,,,"4038509","Vitamin B6 measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL505093","Calbindin Measurement","C125942","The determination of the amount of calbindin present in a sample.","Calbindin Measurement | CALB | Calbindin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513449","Cytokeratin 18 Fragment Measurement","C130160","The determination of the amount of cytokeratin 18 fragment present in a sample.","Cytokeratin 18 Fragment Measurement | CYFRA18 | Cytokeratin 18 Fragment | KRT18 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054059","Rheumatoid Factor Antibody IgM Measurement","C120654","The determination of the rheumatoid factor antibody IgM present in a sample.","Rheumatoid Factor Antibody IgM Measurement | RFIGMAB | Rheumatoid Factor IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699419","Complement C3 Measurement","C80174","The determination of the amount of complement C3 present in a sample.","Complement C3 Measurement | C3 | Complement C3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697574","Helmet Cell Count","C74658","The determination of the number of helmet cells present in a sample.","Helmet Cell Count | HELMETCE | Helmet Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641237","Dilute Russell's Viper Venom Time to Control Ratio Measurement","C103386","The determination of the ratio of the dilute Russell's viper venom time in a subject sample to a control sample. The measurement may be expressed as a ratio or percentage.","Dilute Russell's Viper Venom Time to Control Ratio Measurement | DRVVTRT | Dilute Russell's Viper Venom Time Ratio | Lupus Anticoagulant Ratio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540691","CH50 Measurement","C100423","A measurement of the complement required to lyse 50 percent of red blood cells in a biological specimen.","CH50 Measurement | CH50 | CH50 Assay | Complement CH50 | Total Hemolytic Complement CH50",,,,,,,,,,,,,,,"42536356","CH50 (fifty percent hemolytic complement) technique",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0863184","Parietal Cell Antibody Measurement","C116207","The determination of the amount of parietal cell antibody present in a sample.","Parietal Cell Antibody Measurement | Anti-Parietal Cell Antibody | PARICEAB | Parietal Cell Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881936","Myelocyte to Leukocyte Ratio","C64826","The determination of the ratio of myelocytes compared to leukocytes in a blood sample. The measurement may be expressed as a ratio or percentage.","Myelocyte to Leukocyte Ratio | MYCYLE | Myelocytes/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545249","Antithrombin Activity Actual to Control Ratio Measurement","C147306","The determination of the ratio of the biological activity of antithrombin in a subject's specimen when compared to the same activity in a control specimen. The measurement may be expressed as a ratio or percentage.","Antithrombin Activity Actual to Control Ratio Measurement | ATHMBAAC | Antithrombin Activity Actual/Antithrombin Activity Control | Antithrombin Activity Actual/Control | Antithrombin Activity Actual/Normal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523560","Very Low Density Lipoprotein Cholesterol Measurement","C105589","The determination of the amount of very low-density lipoprotein cholesterol present in a sample.","Very Low Density Lipoprotein Cholesterol Measurement | VLDL | VLDL Cholesterol | VLDL Cholesterol Measurement",,,,,,,,,,,,,,,"4016949","VLDL cholesterol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513980","Penicillium notatum Antigen IgE Antibody Measurement","C130146","A measurement of the Penicillium notatum antigen IgE antibody in a biological specimen.","Penicillium notatum Antigen IgE Antibody Measurement | C130146 | Penicillium chrysogenum IgE Antibody | Penicillium notatum IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513098","German Cockroach Antigen IgG4 Antibody Measurement","C130143","A measurement of the German cockroach (Blattella germanica) antigen IgG4 antibody in a biological specimen.","German Cockroach Antigen IgG4 Antibody Measurement | C130143 | German Cockroach Antigen IgG4 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520917","Platelet Mass Distribution Width","C132380","The determination of the variation defined by two standard deviations of the platelet dry mass distribution in a biological sample.","Platelet Mass Distribution Width | PMDW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825902","Polymorphonuclear Neutrophil Elastase Measurement","C82027","The determination of the amount of polymorphonuclear neutrophil elastase present in a sample.","Polymorphonuclear Neutrophil Elastase Measurement | ELA2PMN | Neutrophil Elastase, Polymorphonuclear",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520345","Alpha-Methylacyl Coenzyme A Racemase mRNA Measurement","C132365","The determination of the amount of alpha-methylacyl coenzyme A racemase mRNA in a biological sample.","Alpha-Methylacyl Coenzyme A Racemase mRNA Measurement | AMACR mRNA | AMACR mRNA Measurement | AMCRMRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0373745","Vitamin A Measurement","C74895","The determination of the amount of Vitamin A present in a sample.","Vitamin A Measurement | Retinol | VITA | Vitamin A",,,,,,,,,,,,,,,"4297178","Vitamin A measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698890","Promyelocyte to Lymphocyte Ratio Measurement","C74653","The determination of the ratio of promyelocytes compared to all lymphocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Promyelocyte to Lymphocyte Ratio Measurement | PROMYLE | Promyelocytes/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641225","Alpha Tocopherol to Vitamin E Ratio Measurement","C103350","The determination of the ratio of alpha-tocopherol compared with the total vitamin E in a sample. The measurement may be expressed as a ratio or percentage.","Alpha Tocopherol to Vitamin E Ratio Measurement | ATPVITE | Alpha Tocopherol to Total Vitamin E Ratio Measurement | Alpha Tocopherol/Vitamin E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640654","Endogenous Thrombin Potential Lag Time Measurement","C102264","A measurement of time from the start of the thrombin generation test to the point where a predetermined amount of thrombin is generated.","Endogenous Thrombin Potential Lag Time Measurement | ETP Lag Time | ETPLT | Endogenous Thrombin Potential Lag Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698008","Malignant Cell to Blood Cell Ratio Measurement","C74643","The determination of the ratio of malignant cells compared to blood cells present in a sample. The measurement may be expressed as a ratio or percentage.","Malignant Cell to Blood Cell Ratio Measurement | MLIGCEBC | Malignant Cells, NOS/Blood Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202106","Unsaturated Iron Binding Capacity Measurement","C74719","The determination of the binding capacity of unsaturated iron in a sample.","Unsaturated Iron Binding Capacity Measurement | IBCU | UIBC | Unsaturated Iron Binding Capacity",,,,,,,,,,,,,,,"4218675","Unsaturated iron binding capacity measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827664","Clinical Events Domain","C85441","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to clinical events.","Clinical Events Domain | CE | Clinical Events",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981435","Clinical Events Occurrence","C87851","An indication or description of a clinical event occurrence.","Clinical Events Occurrence | CEOCCUR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513760","Aspergillus fumigatus Antigen IgE Antibody Measurement","C130144","A measurement of the Aspergillus fumigatus antigen IgE antibody in a biological specimen.","Aspergillus fumigatus Antigen IgE Antibody Measurement | Aspergillus fumigatus IgE Antibody | C130144",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521354","Free Prostate Specific Antigen Measurement","C132383","The determination of the amount of free prostate specific antigen in a biological sample.","Free Prostate Specific Antigen Measurement | PSAF | Prostate Specific Antigen, Free",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049937","Anti-Neutrophil Cytoplasmic Antibody Measurement","C120626","The determination of the anti-neutrophil cytoplasmic antibody present in a sample.","Anti-Neutrophil Cytoplasmic Antibody Measurement | ANCAB | Anti-Neutrophil Cytoplasmic Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513395","Birch Pollen IgE Measurement","C130072","A measurement of the birch pollen IgE in a biological specimen.","Birch Pollen IgE Measurement | Birch Pollen IgE | C130072",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514230","Leukemia Inhibitory Factor Measurement","C130163","The determination of the amount of leukemia inhibitory factor present in a sample.","Leukemia Inhibitory Factor Measurement | LIF | LIF Measurement | Leukemia Inhibitory Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699974","Total Radical-Trap Antioxidant Potential measurement","C80208","The determination of the potential for the antioxidants contained in a biological specimen to buffer free radicals in a solution.","Total Radical-Trap Antioxidant Potential Measurement | TRAP | Total Radical-Trap Antioxidant Potential",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882480","Prolymphocyte to Leukocyte Ratio","C64829","The determination of the ratio of prolymphocytes compared to leukocytes in a blood sample. The measurement may be expressed as a ratio or percentage.","Prolymphocyte to Leukocyte Ratio | PRLYMLE | Prolymphocytes/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202388","Flurazepam Measurement","C75373","The determination of the amount of flurazepam present in a sample.","Flurazepam Measurement | FLRZPM | Flurazepam",,,,,,,,,,,,,,,"4262244","Flurazepam measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3539062","Apolipoprotein C2 Measurement","C100427","The determination of the amount of apolipoprotein C2 present in a sample.","Apolipoprotein C2 Measurement | APOC2 | APOC2 Measurement | Apolipoprotein C-II Measurement | Apolipoprotein C2 | Apolipoprotein CII | Apolipoprotein CII Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524170","Lorazepam Measurement","C75374","The determination of the amount of lorazepam present in a sample.","Lorazepam Measurement | LRZPM | Lorazepam",,,,,,,,,,,,,,,"4022986","Lorazepam measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705947","Interleukin-17A","C20519","Interleukin-17A (155 aa, ~18 kDa) is encoded by the human IL17A gene. This protein is involved in the positive regulation of cytokine production.","Interleukin-17A | CTLA-8 | CTLA8 | Cytotoxic T-Lymphocyte-Associated Antigen 8 | Cytotoxic T-Lymphocyte-Associated Serine Esterase 8 | IL-17 | IL-17A | IL17 | IL17 Protein | IL17A | Interleukin 17 | Interleukin 17 Precursor | Interleukin-17",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825876","Interferon Beta Measurement","C81995","The determination of the amount of interferon beta present in a sample.","Interferon Beta Measurement | IFNB | Interferon Beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0373601","Dihydrotestosterone Measurement","C74853","The determination of the amount of dihydrotestosterone hormone present in a sample.","Dihydrotestosterone Measurement | Androstanalone | Androstanolone | DHT | Dihydrotestosterone",,,,,,,,,,,,,,,"4212875","Dihydrotestosterone level",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545253","Acetylcholine Receptor Modulation Antibody to Acetylcholine Receptor Antibody Ratio Measurement","C147297","The determination of the ratio of acetylcholine receptor modulation antibody compared to acetylcholine receptor antibody present in a sample. The measurement may be expressed as a ratio or percentage.","Acetylcholine Receptor Modulation Antibody to Acetylcholine Receptor Antibody Ratio Measurement | ACH Receptor Modulation Antibody to ACH Receptor Antibody Ratio Measurement | ACH Receptor Modulation Antibody/ACH Receptor Antibody | ACH Receptor Modulatn Ab/ACH Receptor Ab | AMABARAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890402","Soluble E-Selectin Measurement","C119273","The determination of the amount of the soluble E-selectin activity in a biological specimen.","Soluble E-Selectin Measurement | ESELS | Soluble E-Selectin | sE-selectin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981436","Clinical Events Pre-specified","C87852","An indication or description that a clinical event was previously determined, characterized, or detailed.","Clinical Events Pre-specified | CEPRESP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509268","Maturing Erythroid Cell to Total Cell Ratio Measurement","C127628","The determination of the ratio of maturing erythroid cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Maturing Erythroid Cell to Total Cell Ratio Measurement | Erythroid Precursors/Total Cells | MERCECE | Maturing Erythroid Cells to Total Cells Ratio Measurement | Maturing Erythroid Cells/Total Cells | Maturing Erythroid/Total Cells | Total Erythroid Precursors/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1868706","N-Telopeptide Measurement","C74743","The determination of the amount of N-telopeptide present in a sample.","N-Telopeptide Measurement | N-telopeptide | NTELOP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0428209","Leucine Measurement","C122133","The determination of the amount of leucine present in a sample.","Leucine Measurement | LEU | Leucine",,,,,,,,,,,,,,,"4020999","Leucine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0337435","Estriol Measurement","C74856","The determination of the amount of estriol hormone present in a sample.","Estriol Measurement | ESTRIOL | Estriol | Oestriol",,,,,,,,,,,,,,,"4147892","Estriol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448198","Cystatin C to Creatinine Ratio Measurement","C106513","The determination of the ratio of cystatin C compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Cystatin C to Creatinine Ratio Measurement | CYSCREAT | Cystatin C/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699928","Theta Glutathione S-Transferase Measurement","C80207","The determination of the amount of Theta glutathione-s-transferase present in a sample.","Theta Glutathione S-Transferase Measurement | GSTTH | Glutathione S-Transferase, Theta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513986","Shellfish Mix Antigen IgG Antibody Measurement","C130121","A measurement of the shellfish mix antigen IgG antibody in a biological specimen.","Shellfish Mix Antigen IgG Antibody Measurement | C130121 | Shellfish Mix Antigen IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054008","Soluble Liver Antigen IgG Antibody Measurement","C122150","The determination of the amount of soluble liver antigen IgG antibody present in a sample.","Soluble Liver Antigen IgG Antibody Measurement | SLAIGGAB | Soluble Liver Antigen IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697617","Howell-Jolly Body Measurement","C74704","The determination of the number of Howell-Jolly bodies present in a sample.","Howell-Jolly Body Measurement | HOWJOL | Howell-Jolly Bodies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813545","CD79A Expressing Cell Count","C111152","The determination of the amount of CD79A expressing cells per unit present in a sample.","CD79A Expressing Cell Count | B-Cell Antigen Receptor Complex-Associated Protein Alpha Chain Expressing Cell Count",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698740","Pappenheimer Body Count (lab procedure)","C74616","The determination of the number of Pappenheimer bodies in a sample.","Pappenheimer Body Count | PAPPEN | Pappenheimer Bodies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523816","Pepsinogen I Measurement","C100467","The determination of the amount of pepsinogen I present in a sample.","Pepsinogen I Measurement | PEPSNGI | PGI | Pepsinogen I",,,,,,,,,,,,,,,"4017223","Pepsinogen I measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899227","Exposure as Collected Dose Form","C117482","The form in which active and/or inert ingredient(s) of the collected exposure are physically presented.","Exposure as Collected Dose Form | ECDOSFRM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201879","Ammonia Measurement","C74799","The determination of the amount of ammonia present in a sample.","Ammonia Measurement | AMMONIA | Ammonia | NH3",,,,,,,,,,,,,,,"4245982","Ammonia measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0455279","Promyelocyte Count","C74622","The determination of the number of promyelocytes present in a sample.","Promyelocyte Count | PROMY | Promyelocytes",,,,,,,,,,,,,,,"4306234","Promyelocyte count procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202464","Secobarbital Measurement","C75369","The determination of the amount of secobarbital present in a sample.","Secobarbital Measurement | SCBRBTL | Secobarbital",,,,,,,,,,,,,,,"4215159","Secobarbital measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2697521","Granular Cast Measurement","C74768","The determination of the amount of granular casts present in a urine sample.","Granular Cast Measurement | CSGRAN | Granular Casts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005729","Bleeding Time","C89775","The amount of time it take for a cessation of bleeding. It is a measurement of the ability of capillaries and platelets to interact to form a blood clot.","Bleeding Time | BLEEDT | Clotting Time Homeostasis",,,,,,,,,,,,,,,"4219104","Bleeding time",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2697516","Gonadotropin Releasing Hormone Measurement","C74860","The determination of the amount of gonadotropin releasing hormone present in a sample.","Gonadotropin Releasing Hormone Measurement | GNRH | Gonadotropin Releasing Hormone | Luteinising Hormone Releasing Hormone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0373587","Copper Measurement","C111161","The determination of the amount of copper present in a sample.","Copper Measurement | COPPER | Copper | Cu",,,,,,,,,,,,,,,"4218387","Copper measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2700357","5 Prime Nucleotidase Measurement","C79437","The determination of the amount of 5 prime nucleotidase present in a sample.","5 Prime Nucleotidase Measurement | 5 Prime Nucleotidase | 5'-Ribonucleotide Phosphohydrolase | 5'Nucleotidase | NCTD5P",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0474702","Sulfate Measurement","C122153","The determination of the amount of sulfate present in a sample.","Sulfate Measurement | SULFATE | Sulfate | Sulphate",,,,,,,,,,,,,,,"4020104","Sulfate measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829704","Herpes Simplex Virus 6 Antibody Measurement","C112292","The determination of the amount of herpes simplex virus 6 antibody present in a sample.","Herpes Simplex Virus 6 Antibody Measurement | HHV6AB | HS6AB | Herpes Simplex Virus 6 Antibody | Human Herpesvirus 6 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984941","HIV-1 Group O Antibody Measurement","C92264","The determination of the amount of HIV-1 group O antibody present in a sample.","HIV-1 Group O Antibody Measurement | HIV-1 Group O Antibody | HIV1OAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970075","Neisseria gonorrhoeae Measurement","C92298","The determination of the amount of Neisseria gonorrhoeae present in a sample.","Neisseria gonorrhoeae Measurement | NGO | Neisseria gonorrhoeae | Neisseria gonorrhoeae Screening",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1619716","Cystatin C Measurement","C92290","The determination of the amount of cystatin C present in a sample.","Cystatin C Measurement | CYSTATC | Cystatin C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522816","Monocytes to Non-Squamous Epithelial Cells Ratio Measurement","C135433","The determination of the ratio of monocytes compared to non-squamous epithelial cells present in a sample. The measurement may be expressed as a ratio or percentage.","Monocytes to Non-Squamous Epithelial Cells Ratio Measurement | MONONSQE | Monocytes/Non-Squam Epi Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049832","Desmoglein 3 Antibody Measurement","C122115","The determination of the amount of desmoglein 3 antibody in a biological specimen.","Desmoglein 3 Antibody Measurement | DSG3AB | Desmoglein 3 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0546660","Methemoglobin Measurement","C96689","The determination of the amount of methemoglobin present in a sample.","Methemoglobin Measurement | HGBMET | Methemoglobin",,,,,,,,,,,,,,,"40481360","Measurement of methemoglobin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2984959","Type III Myeloblasts Measurement","C92285","The determination of the amount of type III myeloblasts present in a sample.","Type III Myeloblasts Measurement | MYBLAT3 | Type III Myeloblasts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522818","Myeloid Maturation Pool Count","C135435","The determination of the amount of myeloid maturation phase cells (metamyelocytes, band neutrophils, and segmented neutrophils) present in a sample.","Myeloid Maturation Pool Count | MYCEMPOL | Myeloid Maturation Pool",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899212","Exposure as Collected Mood","C117474","A description of the mood of the collected exposure record.","Exposure as Collected Mood | ECMOOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826753","Drug Accountability Assessment Test","C83145","A character or string that represents the full name of the drug accountability assessment.","Drug Accountability Assessment Test | DATEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697537","HDL-Cholesterol Subclass 3 Measurement","C80188","The determination of the amount of HDL-cholesterol subclass 3 present in a sample.","HDL-Cholesterol Subclass 3 Measurement | HDL-Cholesterol Subclass 3 | HDL3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700255","Vitamin B5 Measurement","C74900","The determination of the amount of Vitamin B5 present in a sample.","Vitamin B5 Measurement | Pantothenic Acid | VITB5 | Vitamin B5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1829782","Icteric Index","C111232","The determination of the amount of yellow color of a biological specimen, due to the presence of bile pigments.","Icteric Index | ICTERUSI | Icterus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697912","Leucine Crystal Measurement","C74680","The determination of the amount of leucine crystals present in a sample.","Leucine Crystal Measurement | CYLEUC | Leucine Crystals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697560","Hairy Cell to Lymphocyte Ratio Measurement","C74640","The determination of the ratio of hairy cells compared to lymphocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Hairy Cell to Lymphocyte Ratio Measurement | HRYCELY | Hairy Cells/Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641235","Cholesteryl Ester Transfer Protein Activity Measurement","C103380","The determination of the amount of the biological activity of cholesteryl ester transfer protein in a sample.","Cholesteryl Ester Transfer Protein Activity Measurement | CETP Activity Measurement | CETPA | Cholesteryl Ester Transfer Protein Act",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1271664","Apolipoprotein H Measurement","C82003","The determination of the amount of apolipoprotein H present in a sample.","Apolipoprotein H Measurement | APOH | APOH Measurement | Apolipoprotein H | Beta-2-Glycoprotein 1 Measurement",,,,,,,,,,,,,,,"4212820","Beta 2 glycoprotein 1 level",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698067","Alpha Glutathione-S-Transferase to Creatinine Ratio Measurement","C80166","The determination of the ratio of alpha glutathione-s-transferase compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Alpha Glutathione-S-Transferase to Creatinine Ratio Measurement | GSTALCRT | Glutathione S-Transferase, Alpha/Creat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4035027","Reticulocyte Corpuscular Hemoglobin Concentration Mean","C138970","An indirect measurement of the average concentration of hemoglobin per reticulocyte in a biological specimen, calculated as the ratio of hemoglobin to hematocrit.","Reticulocyte Corpuscular Hemoglobin Concentration Mean | CHCMR | CHCMr | Ret. Corpuscular HGB Concentration Mean",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550424","Classic Neutrophil Cytoplasmic Antibody Measurement","C147301","The determination of the amount of classic neutrophil cytoplasmic antibody present in a sample.","Classic Neutrophil Cytoplasmic Antibody Measurement | ANCCLSAB | Anti-Neutrophil Cytoplasmic Antibody, Classic | Classical ANCA Measurement | Neutrophil Cytoplasmic Ab, Classic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520455","Neutrophilic Toxic Change Assessment","C132376","The determination of any type of toxic change in the neutrophilic cells within a sample.","Neutrophilic Toxic Change Assessment | NEUTTOXC | Neutrophilic Toxic Change",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513453","Dermatophagoides pteronyssinus Antigen IgE Antibody Measurement","C130134","A measurement of the Dermatophagoides pteronyssinus antigen IgE antibody in a biological specimen.","Dermatophagoides pteronyssinus Antigen IgE Antibody Measurement | C130134 | D. pteronyssinus Antigen IgE Antibody | Dermatophagoides pteronyssinus IgE Antibody | European House Dust Mite IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272947","Hyperchromia Measurement","C96669","The determination of the prevalence of erthrocytes with an elevated hemoglobin concentration.","Hyperchromia Measurement | HYPERCHR | Hyperchromia | Hyperchromic Erythrocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522805","Erythroid Maturation Pool Count","C135416","The determination of the amount of erythroid maturation phase cells (polychromatic rubricytes, normochromic rubricytes, and metarubricytes) present in a sample.","Erythroid Maturation Pool Count | ERCEMPOL | Erythroid Maturation Pool",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1295164","Insulin-Like Growth Factor Binding Protein 1 Measurement","C128968","The determination of the amount of insulin-like growth factor binding protein 1 present in a sample.","Insulin-Like Growth Factor Binding Protein 1 Measurement | IGFBP1 | IGFBP1 Measurement | Insulin-Like Growth Factor Binding Prot1 | Insulin-Like Growth Factor Binding Protein 1",,,,,,,,,,,,,,,"4004859","Insulin-like growth factor binding protein 1 measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641246","Factor VIII Activity Measurement","C103399","The determination of the amount of the biological activity of factor VIII in a sample.","Factor VIII Activity Measurement | Anti-hemophilic Factor Activity | FCTVIIIA | Factor VIII Activity | Factor VIII:C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700127","Urine Ammonium Oxalate Crystal Measurement","C74759","The determination of the amount of ammonium oxalate crystals present in a urine sample.","Urine Ammonium Oxalate Crystal Measurement | Ammonium Oxalate Crystals | CYAMMOX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542547","Free Glycerol Measurement","C100448","The determination of the amount of free glycerol present in a sample.","Free Glycerol Measurement | Free Glycerin | Free Glycerol | GLYCRLFR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1532316","Smooth Muscle IgG Antibody Measurement","C122151","The determination of the amount of smooth muscle IgG antibody present in a sample.","Smooth Muscle IgG Antibody Measurement | Actin IgG Antibody | SMUSCGAB | Smooth Muscle IgG Antibody",,,,,,,,,,,,,,,"4217559","Anti smooth muscle antibody IgG level",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882943","Reticulocyte to Erythrocyte Ratio","C64828","The determination of the ratio of reticulocytes compared to erythrocytes in a blood sample. The measurement may be expressed as a ratio or percentage.","Reticulocyte to Erythrocyte Ratio | RETIRBC | Reticulocytes/Erythrocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2361850","Amorphous Crystal Measurement","C74665","The determination of the amount of amorphous crystals present in a sample.","Amorphous Crystal Measurement | Amorphous Crystals | CYAMORPH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521125","PCA3 mRNA to PSA mRNA Ratio Measurement","C132378","The determination of the ratio of prostate cancer antigen 3 mRNA as compared to the total prostate specific antigen mRNA present in a sample. The measurement may be expressed as a ratio or percentage.","PCA3 mRNA to PSA mRNA Ratio Measurement | PC3MPSAM | PCA3 mRNA/PSA mRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0200453","Fibrin Degradation Products Measurement","C82013","The determination of the amount of fibrin degradation products present in a sample.","Fibrin Degradation Products Measurement | FDP | Fibrin Degradation Products",,,,,,,,,,,,,,,"4282610","Fibrin-fibrinogen split products assay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513971","Nut Mix Antigen IgE Antibody Measurement","C130122","A measurement of the nut mix antigen IgE antibody in a biological specimen.","Nut Mix Antigen IgE Antibody Measurement | C130122 | Nut Mix Antigen IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513773","Basophil Band Form to Leukocytes Ratio Measurement","C130155","The determination of the ratio of band basophils compared to leukocytes in a sample. The measurement may be expressed as a ratio or percentage.","Basophil Band Form to Leukocytes Ratio Measurement | BASOBLE | Basophils Band Form/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274477","Basophil to Total Cell Ratio Measurement","C98865","The determination of the ratio of basophils compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Basophil to Total Cell Ratio Measurement | BASOCE | Basophils to Total Cells Ratio Measurement | Basophils/Total Cells | Blasts to Nucleated Cells Ratio Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274414","Iothalamate Clearance Adjusted for BSA","C98750","The determination of the clearance of iothalamate and whose result is adjusted for body surface area.","Iothalamate Clearance Adjusted for BSA | IOTCLRBS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899229","Exposure as Collected Directionality","C117490","A qualifier for the direction on the body the collected exposure assessment is performed.","Exposure as Collected Directionality | ECDIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039773","Theophylline Measurement","C105445","The determination of the amount of theophylline present in a sample.","Theophylline Measurement | THEOPHYL | Theophylline",,,,,,,,,,,,,,,"4231178","Theophylline measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829689","Histone 2B Antibody Measurement","C112295","The determination of the amount of histone 2b antibody present in a sample.","Histone 2B Antibody Measurement | HIST2BAB | Histone 2B Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514012","American Cockroach Antigen IgG Antibody Measurement","C130138","A measurement of the American cockroach (Periplaneta americana) antigen IgG antibody in a biological specimen.","American Cockroach Antigen IgG Antibody Measurement | American Cockroach Antigen IgG Antibody | C130138",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505124","Lipoarabinomannan Measurement","C125947","The determination of the amount of lipoarabinomannan present in a sample.","Lipoarabinomannan Measurement | LAM | Lipoarabinomannan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514030","Bermuda Grass Pollen IgG Measurement","C130070","A measurement of the Bermuda grass (Cynodon dactylon) pollen IgG in a biological specimen.","Bermuda Grass Pollen IgG Measurement | Bermuda Grass Pollen IgG | C130070",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4048362","Immunoglobulin G Subclass 3 Measurement","C122129","The determination of the amount of immunoglobulin G subclass 3 present in a sample.","Immunoglobulin G Subclass 3 Measurement | IGG3 | IgG3 Measurement | Immunoglobulin G Subclass 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825901","Neutrophil Elastase Measurement","C82026","The determination of the amount of neutrophil elastase present in a sample.","Neutrophil Elastase Measurement | ELA2 | Neutrophil Elastase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698837","Poikilocyte Measurement","C79602","The determination of the number of poikilocytes present in a sample.","Poikilocyte Measurement | POIKILO | Poikilocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830623","Cytokeratin 19 Fragment 21-1 Measurement","C106514","The determination of the amount of the cytokeratin 19 fragment 21-1 present in a sample.","Cytokeratin 19 Fragment 21-1 Measurement | CYFRA21-1 | CYFRA211 | Cytokeratin 19 Fragment 21-1",,,,,,,,,,,,,,,"4040056","Measurement of keratin, type I cytoskeletal 19 fragment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0201804","Osmolarity Measurement","C74802","The determination of the osmoles of solute per liter of solution present in a sample.","Osmolarity Measurement | OSMRTY | Osmolarity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521664","Calculated Panel Reactive Antibody Measurement","C132381","The determination of the calculated panel reactive antibody (CPRA), which is based on the number/type of unacceptable HLA antigens to which an organ recipient has been sensitized, and which algorithmically estimates the level of sensitization in the recipient. The CPRA is computed from HLA antigen frequencies in a given donor population using both anti-HLA class I and class II antibody specificities; it also represents the percentage of actual organ donors that express one or more unacceptable HLA antigens to which a recipient may react adversely.","Calculated Panel Reactive Antibody Measurement | CPRA Measurement | Calculated Panel Reactive Antibody | PRABC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698030","Mature Plasma Cell to Lymphocyte Ratio Measurement","C74911","The determination of the ratio of mature plasma cells compared to lymphocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Mature Plasma Cell to Lymphocyte Ratio Measurement | Mature Plasma Cells/Lymphocytes | PLSMCELY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700004","Epithelial-Cast Measurement","C74779","The determination of the number of epithelial casts present in a urine sample.","Epithelial-Cast Measurement | CSEPI | Epithelial Casts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0391941","Glucose-6-Phosphate Dehydrogenase Measurement","C80184","The determination of the amount of glucose-6-phosphate dehydrogenase present in a sample.","Glucose-6-Phosphate Dehydrogenase Measurement | G6PD | Glucose-6-Phosphate Dehydrogenase",,,,,,,,,,,,,,,"4018318","Glucose-6-phosphate dehydrogenase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202145","Noradrenaline Measurement","C74868","The determination of the amount of noradrenaline hormone present in a sample.","Noradrenaline Measurement | NOREPIN | Noradrenaline | Norepinephrine",,,,,,,,,,,,,,,"4148073","Norepinephrine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509250","Interleukin 12 Beta Measurement","C127623","The determination of the amount of interleukin 12 beta present in a sample.","Interleukin 12 Beta Measurement | INTLK12B | Interleukin 12 Beta | Interleukin 12 Beta Subunit | Interleukin 12 p40 | Interleukin 12 p40 Subunit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698267","Mucous Thread Measurement","C74721","The determination of the number of mucous threads present in a sample.","Mucous Thread Measurement | MUCTHR | Mucous Threads",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333912","Hypochromia","C64802","An anemic condition which results from a lack hemoglobin within erythrocytes.","Hypochromia | HPOCROM | Hypochromic Erythrocytes",,,,,,,,,,,,,,,"4194991","Hypochromatism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698885","Prolymphocyte Count","C74620","The determination of the number of prolymphocytes in a blood sample.","Prolymphocyte Count | PROLYM | Prolymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4035029","Reticulocyte Hemoglobin Distribution Width","C139070","A measurement of the distribution of the hemoglobin concentration in reticulocytes.","Reticulocyte Hemoglobin Distribution Width | HDWR | Ret Hemoglobin Distribution Width | Reticulocyte Hemoglobin Concentration Distribution Width",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698168","Apolipoprotein A1 Measurement","C74733","The determination of the amount of apolipoprotein A1 present in a sample.","Apolipoprotein A1 Measurement | APOA1 | APOA1 Measurement | Apolipoprotein A1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0200484","Dilute Russell's Viper Venom Time Measurement","C96696","A measurement of the time it takes a plasma sample to clot after adding dilute Russell's viper venom.","Dilute Russell's Viper Venom Time Measurement | DRVVT | Dilute Russell's Viper Venom Time | Lupus Anticoagulant Test",,,,,,,,,,,,,,,"4289228","Dilute Russell viper venom time",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0373527","Acetaminophen Measurement","C135398","The determination of the amount of acetaminophen in a biological sample.","Acetaminophen Measurement | ACETAMIN | Acetaminophen | Paracetamol",,,,,,,,,,,,,,,"4187794","Acetaminophen measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2697951","Lymphoma Cell Count","C74613","The determination of the number of lymphoma cells present in a sample.","Lymphoma Cell Count | LYMMCE | Lymphoma Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512509","Rubricyte Count","C128978","The determination of the amount of rubricytes present in a sample.","Rubricyte Count | Polychromatophilic Erythroblast | Polychromatophilic Normoblast | RUB | Rubricyte",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0368786","Borrelia Burgdorferi Antibody Measurement","C122098","The determination of the amount of Borrelia burgdorferi antibody present in a sample.","Borrelia burgdorferi Antibody Measurement | BBRAB | Borrelia Burgdorferi Antibody Measurement | Borrelia burgdorferi Antibody | Lyme Antibody",,,,,,,,,,,,,,,"4025985","Borrelia burgdorferi antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1167878","Histone Antibody Measurement","C111209","A measurement of histone antibodies present in a sample.","Histone Antibody Measurement | Anti-Histone Antibodies | HISTAB | Histone Antibodies",,,,,,,,,,,,,,,"35624341|4235282","Histone Ab|Antibody to histone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0202356","Chlordiazepoxide Measurement","C75371","The determination of the amount of chlordiazepoxide present in a sample.","Chlordiazepoxide Measurement | CLRDZPXD | Chlordiazepoxide",,,,,,,,,,,,,,,"4270638","Chlordiazepoxide measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2046362","human leukocyte antigen B27 (lab test)","C100460","The determination of the amount of HLA-B27 antigen present in a sample.","HLA-B27 Antigen Measurement | HLA-B27 Antigen | HLAB27AG | Human Leukocyte Antigen B27",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1295018","Human Anti-Mouse Antibody Measurement","C103406","The determination of the amount of the human anti-mouse antibody in a sample.","Human Anti-Mouse Antibody Measurement | HAMA | HAMAB | Human Anti-Mouse Antibody",,,,,,,,,,,,,,,"4044798","Measurement of human anti-mouse antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2984930","Mycobacterium tuberculosis Interferon Gamma Response","C92241","A measurement of the amount of interferon gamma that is released when Mycobacterium tuberculosis antigen is incubated with a biological specimen, usually blood. Increased amount of interferon gamma suggests a prior or existing M. tuberculosis infection.","Mycobacterium tuberculosis Interferon Gamma Response Measurement | M. tuberculosis IFN Gamma Response | MYTBGIR | Mycobacterium tuberculosis IFN Gamma Response | Mycobacterium tuberculosis Interferon Gamma Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697898","Large Platelet Count","C74729","The determination of the number of large platelets present in a sample.","Large Platelet Count | Large Platelets | PLATLRG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523506","Apolipoprotein A Measurement","C124337","The determination of the amount of apolipoprotein A present in a sample.","Apolipoprotein A Measurement | APOA | APOA Measurement | Apo A Measurement | Apolipoprotein A",,,,,,,,,,,,,,,"4014902|4017616","Apolipoproteins A measurement|Apolipoprotein(a) measurement",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0206161","Reticulocyte Count","C51947","The determination of the number of reticulocytes in a blood sample.","Reticulocyte Count | RETI | Reticulocytes",,,,,,,,,,,,,,,"4263581","Reticulocyte count",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825896","Granulocyte Macrophage Colony Stimulating Factor Measurement","C82019","The determination of the amount of granulocyte macrophage colony stimulating factor present in a sample.","Granulocyte Macrophage Colony Stm Factor Measurement | GMCSF | Granulocyte Macrophage Colony Stm Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202304","Ethanol Measurement","C74693","The determination of the amount of ethanol present in a sample.","Ethanol Measurement | Alcohol | ETHANOL | Ethanol",,,,,,,,,,,,,,,"4326820","Ethanol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698871","Precursor Plasma Cell to Lymphocyte Ratio Measurement","C74650","The determination of the ratio of precursor plasma cells compared to all lymphocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Precursor Plasma Cell to Lymphocyte Ratio Measurement | PLSPCELY | Precursor Plasma Cells/Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814777","Hemoglobin Distribution Width Measurement","C106525","A quantitative measurement of the distribution of the hemoglobin concentration in red blood cells.","Hemoglobin Distribution Width Measurement | HDW | Hemoglobin Concentration Distribution Width | Hemoglobin Distribution Width",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699504","Spherocyte Count","C74707","The determination of the number of spherocytes present in a sample.","Spherocyte Count | SPHERO | Spherocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523714","Indican Measurement","C82044","The determination of the amount of indican present in a sample.","Indican Measurement | INDICAN | Indican",,,,,,,,,,,,,,,"4020991","Indicans measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3274435","Prothrombin Activity Measurement","C98774","The determination of the biological activity of prothrombin in a sample.","Prothrombin Activity Measurement | Factor II Activity | PTA | Prothrombin Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1254960","Borrelia burgdorferi IgG antibody test","C122100","The determination of the amount of Borrelia burgdorferi IgG antibody present in a sample.","Borrelia burgdorferi IgG Antibody Measurement | BBRIGGAB | Borrelia Burgdorferi IgG Antibody Measurement | Borrelia burgdorferi IgG Antibody | Lyme IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825882","Brain-Derived Neurotrophic Factor Measurement","C82004","The determination of the amount of brain-derived neurotrophic factor present in a sample.","Brain-Derived Neurotrophic Factor Measurement | BDNF | Brain-Derived Neurotrophic Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698100","Amphetamine Drug Class Measurement","C74687","The determination of the amount of amphetamine present in a sample.","Amphetamine Drug Class Measurement | AMPHET | Amphetamine | Amphetamines",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986901","Microscopic Findings Domain","C95095","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to microscopic findings.","Microscopic Findings Domain | MI | Microscopic Findings",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898374","Microscopic Findings Directionality","C117595","A qualifier for the direction on the body the microscopic findings assessment is performed.","Microscopic Findings Directionality | MIDIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0200637","Monocyte Count","C64823","The determination of the number of monocytes in a blood sample.","Monocyte Count | MONO | Monocytes",,,,,,,,,,,,,,,"4194332","Monocyte count",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1294065","Macrophage Count","C74798","The determination of the number of macrophages present in a sample.","Macrophage Count | MCPHG | Macrophages",,,,,,,,,,,,,,,"4041974","Macrophage count",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524207","Nordazepam Measurement","C139076","The determination of the amount of nordazepam present in a sample.","Nordazepam Measurement | Desmethyldiazepam | N-Desmethyldiazepam | NRDZPM | Nordazepam | Nordiazepam | Nordiazepam Measurement",,,,,,,,,,,,,,,"4020398","Nordazepam measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0201511","Smooth Muscle Antibody Measurement","C111317","The determination of the amount of smooth muscle antibody present in a sample.","Smooth Muscle Antibody Measurement | Anti-Smooth Muscle Antibody | SMUSCAB | Smooth Muscle Antibody",,,,,,,,,,,,,,,"4179789","Smooth muscle antibody measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523722","Insulin-Like Growth Factor Binding Protein 3 Measurement","C112322","The determination of the amount of insulin-like growth factor binding protein 3 present in a sample.","Insulin-Like Growth Factor Binding Protein 3 Measurement | IGFBP3 | Insulin-Like Growth Factor Binding Prot3 | Insulin-Like Growth Factor Binding Protein 3",,,,,,,,,,,,,,,"4188290","Insulin-like growth factor binding protein 3 level",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0587381","Extractable Nuclear Antigen Antibody Measurement","C92270","The determination of the amount of extractable nuclear antigen antibody present in a sample.","Extractable Nuclear Antigen Antibody Measurement | Anti-ENA | ENAAB | Extractable Nuclear Antigen Antibody",,,,,,,,,,,,,,,"4187815","Antibody to extractable nuclear antigen measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0201534","Antiphospholipid Antibody Measurement","C102258","The determination of the amount of antiphospholipid antibodies present in a sample.","Antiphospholipid Antibody Measurement | APLAB | Anti-Phospholipid Antibody Measurement | Antiphospholipid Antibodies",,,,,,,,,,,,,,,"4221127","Antiphospholipid antibody measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827505","Tau Protein Measurement","C84810","The determination of the amount of Tau protein present in a sample.","Tau Protein Measurement | TPROT | Tau Protein | Total Tau Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813610","Skin Response Domain","C112420","A findings domain for assessments that determine whether a therapy induced an immune response.","Skin Response Domain | SR | Skin Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202348","Caffeine Measurement","C75346","The determination of the amount of caffeine present in a sample.","Caffeine Measurement | CAFFEINE | Caffeine",,,,,,,,,,,,,,,"4243613","Caffeine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545314","Protein S Activity Actual to Control Ratio Measurement","C147424","The determination of the ratio of the biological activity of protein S in a subject's specimen when compared to the same activity in a control specimen. The measurement may be expressed as a ratio or percentage.","Protein S Activity Actual to Control Ratio Measurement | PTSAAC | Protein S Activity Actual/Control | Protein S Activity Actual/Normal | Protein S Activity Actual/Protein S Activity Control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272931","Fibroblast Growth Factor 23 Measurement","C96650","The determination of the amount of fibroblast growth factor 23 present in a sample.","Fibroblast Growth Factor 23 Measurement | FGF23 | Fibroblast Growth Factor 23 | Phosphatonin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1096202","Lipoprotein a Measurement","C82022","The determination of the amount of lipoprotein a present in a sample.","Lipoprotein a Measurement | LPA | Lipoprotein-a",,,,,,,,,,,,,,,"4007663","Lipoprotein (a) measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202153","Oxalate Measurement","C92250","The determination of the amount of oxalate present in a sample.","Oxalate Measurement | Ethanedioate | OXALATE | Oxalate",,,,,,,,,,,,,,,"4230514","Oxalate measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1735602","Beta-2 Glycoprotein Antibody Measurement","C81979","The determination of the amount of beta-2 glycoprotein antibody present in a sample.","Beta-2 Glycoprotein Antibody Measurement | B2GLYAB | Beta-2 Glycoprotein Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697637","Hypersegmented Neutrophil Measurement","C74612","The determination of the number of hypersegmented neutrophils present in a sample.","Hypersegmented Neutrophil Measurement | HYPSEGCE | Hypersegmented Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0200408","Factor IX Measurement","C98725","The determination of the amount of factor IX present in a sample.","Factor IX Measurement | Christmas Factor | FACTIX | Factor IX",,,,,,,,,,,,,,,"4193241","Clotting factor IX assay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202449","Phenothiazine Measurement","C74695","The determination of the amount of phenothiazine present in a sample.","Phenothiazine Measurement | Dibenzothiazine | PHENTHZ | Phenothiazine",,,,,,,,,,,,,,,"4253034","Phenothiazine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4050386","Immunoglobulin G Subclass 2 Measurement","C122128","The determination of the amount of immunoglobulin G subclass 2 present in a sample.","Immunoglobulin G Subclass 2 Measurement | IGG2 | IgG2 Measurement | Immunoglobulin G Subclass 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984932","Amorphous Phosphate Crystals Measurement","C92243","The determination of the amount of amorphous phosphate crystals present in a sample.","Amorphous Phosphate Crystals Measurement | Amorphous Phosphate Crystals | CYAMPPH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522796","Columnar Epithelial Cells to Non-Squamous Epithelial Cells Ratio Measurement","C135405","The determination of the ratio of columnar epithelial cells compared to non-squamous epithelial cells present in a sample. The measurement may be expressed as a ratio or percentage.","Columnar Epithelial Cells to Non-Squamous Epithelial Cells Ratio Measurement | CLEPNSQE | Columnar Epi Cells/Non-Squam Epi Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900061","Agranular Neutrophils Measurement","C116200","The determination of the amount of agranular neutrophils present in a sample.","Agranular Neutrophils Measurement | Agranular Neutrophils | NEUTAGR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202118","Leucine Aminopeptidase Measurement","C122132","The determination of the amount of leucine aminopeptidase related peptide present in a biological specimen.","Leucine Aminopeptidase Measurement | Cytosol Aminopeptidase | LAP | LAP3 | Leucine Aminopeptidase | Leucine Aminopeptidase 3 | Leucyl Aminopeptidase",,,,,,,,,,,,,,,"4267427","Leucine aminopeptidase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523975","Valine Measurement","C122160","The determination of the amount of valine present in a sample.","Valine Measurement | VAL | Valine",,,,,,,,,,,,,,,"4020707","Valine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL522807","Erythroid Proliferation Pool Count","C135418","The determination of the amount of erythroid proliferative phase cells (rubriblasts, prorubricytes, and basophilic rubricytes) present in a sample.","Erythroid Proliferation Pool Count | ERCEPPOL | Erythroid Proliferation Pool",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984952","Legionella pneumophila IgG Antibody Measurement","C92276","The determination of the amount of Legionella pneumophila IgG antibody present in a sample.","Legionella pneumophila IgG Antibody Measurement | LPNIGGAB | Legionella pneumophila IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2368068","Chlamydia pneumoniae IgM Antibody Measurement","C92433","The determination of the amount of Chlamydia pneumoniae IgM antibody present in a sample.","Chlamydia pneumoniae IgM Antibody Measurement | CPNIGMAB | Chlamydia pneumoniae IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522799","DNA Fragmentation Index","C135408","The determination of the amount of the deoxyribonucleic acid fragmentation within the nucleated cells in a biological sample.","DNA Fragmentation Index | DFI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523801","Ornithine Measurement","C122140","The determination of the amount of ornithine present in a sample.","Ornithine Measurement | ORNITHIN | Ornithine",,,,,,,,,,,,,,,"4021124","Ornithine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0373573","Ceruloplasmin Measurement","C100432","The determination of the amount of ceruloplasmin present in a sample.","Ceruloplasmin Measurement | CRLPLSMN | Caeruloplasmin | Ceruloplasmin",,,,,,,,,,,,,,,"4337961","Ceruloplasmin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698032","May-Hegglin Anomaly Measurement","C74614","The determination of the amount of May-Hegglin anomaly present in a blood sample.","May-Hegglin Anomaly Measurement | MAYHEG | May-Hegglin Anomaly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2239219","von Willebrand's factor (lab test)","C98799","The determination of the amount of von Willebrand factor present in a sample.","von Willebrand Factor Measurement | FACTVW | von Willebrand Factor | von Willebrand Factor Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1531635","Citrate to Creatinine Ratio Measurement","C122110","The determination of the ratio of citrate to creatinine present in a sample. The measurement by be expressed as a ratio or percentage.","Citrate to Creatinine Ratio Measurement | CITCREAT | Citrate/Creatinine | Citric Acid/Creatinine",,,,,,,,,,,,,,,"4186903","Measurement of ratio of citrate to creatinine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523345","Complement C4a Measurement","C80178","The determination of the amount of complement C4a present in a sample.","Complement C4a Measurement | C4A | Complement C4a",,,,,,,,,,,,,,,"4014748","Complement C4a measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1273342","Epithelial Cell Count","C64605","The determination of the number of epithelial cells in a sample.","Epithelial Cell Count | EPIC | Epithelial Cells",,,,,,,,,,,,,,,"4215717","Epithelial cell count",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825870","Plasminogen Activator Inhibitor-1 Antigen Measurement","C81989","The determination of the amount of plasminogen activator inhibitor-1 antigen present in a sample.","Plasminogen Activator Inhibitor-1 Antigen Measurement | PAI1AG | Plasminogen Activator Inhibitor-1 AG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699513","Squamous Transitional Epithelial Cell Count","C74774","The determination of the number of squamous transitional epithelial cells present in a urine sample.","Squamous Transitional Epithelial Cell Count | EPISQTCE | Squamous Transitional Epithelial Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697631","Hyaline Cast Measurement","C74770","The determination of the amount of hyaline casts present in a urine sample.","Hyaline Cast Measurement | CSHYAL | Hyaline Casts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522826","Trypsin 1 and Trypsinogen 1 Measurement","C135449","The determination of the amount of the trypsin 1 and trypsinogen 1 in a biological specimen.","Trypsin 1 and Trypsinogen 1 Measurement | TRP1TRG1 | Trypsin 1 and Trypsinogen 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055055","Epstein-Barr Early D Antigen IgG Antibody Measurement","C122116","The determination of the amount of Epstein-Barr early D antigen IgG antibody in a biological specimen.","Epstein-Barr Early D Antigen IgG Antibody Measurement | EBEDIGAB | Epstein-Barr Early D Antigen IgG Ab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697786","Interleukin 5 Measurement","C74833","The determination of the amount of interleukin 5 present in a sample.","Interleukin 5 Measurement | INTLK5 | Interleukin 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086617","Mycobacterium tuberculosis IgG Antibody Measurement","C124348","The determination of the amount of Mycobacterium tuberculosis IgG antibody present in a sample.","Mycobacterium tuberculosis IgG Antibody Measurement | MTBIGGAB | Mycobacterium tuberculosis IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984954","Legionella pneumophila IgM Antibody Measurement","C92278","The determination of the amount of Legionella pneumophila IgM antibody present in a sample.","Legionella pneumophila IgM Antibody Measurement | LPNIGMAB | Legionella pneumophila IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513979","Penicillium notatum Antigen IgA Antibody Measurement","C130147","A measurement of the Penicillium notatum antigen IgA antibody in a biological specimen.","Penicillium notatum Antigen IgA Antibody Measurement | C130147 | Penicillium chrysogenum IgA Antibody | Penicillium notatum IgA Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL480890","Immunoglobulin G to Creatinine Ratio Measurement","C119285","The determination of the ratio of immunoglobulin G to creatinine in a biological specimen.","Immunoglobulin G to Creatinine Ratio Measurement | IGGCREAT | Immunoglobulin G/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054732","Indirect Free Thyroxine Measurement","C120664","The determination of the free thyroxine present in a sample by indirect measure.","Indirect Free Thyroxine Measurement | T4FRIND | Thyroxine, Free, Indirect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0373548","Arsenic Measurement","C147305","The determination of the amount of arsenic present in a sample.","Arsenic Measurement | ARSENIC | Arsenic | As",,,,,,,,,,,,,,,"4244200","Arsenic measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523697","Histidine Measurement","C122124","The determination of the amount of histidine present in a sample.","Histidine Measurement | HIS | Histidine",,,,,,,,,,,,,,,"4017768","Histidine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3889983","Skin Response Test Code","C117674","A character or string that represents the short code name of the skin response assessment.","Skin Response Test Code | SRTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0522824","Prothrombin Fragments 1 and 2 Measurement","C82034","The determination of the amount of prothrombin fragments 1 and 2 present in a sample.","Prothrombin Fragments 1 and 2 Measurement | PTF1_2 | Prothrombin Fragments 1 + 2",,,,,,,,,,,,,,,"4013018","Prothrombin fragment 1.2 assay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3812687","Fibroblast Growth Factor 21 Measurement","C112280","The determination of the amount of fibroblast growth factor 21 present in a sample.","Fibroblast Growth Factor 21 Measurement | FGF 21 | FGF21 | Fibroblast Growth Factor 21",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540568","Ammonium Biurate Crystals Measurement","C105590","The determination of the amount of ammonium biurate crystals present in a sample.","Ammonium Biurate Crystals Measurement | Acid Ammonium Urate Crystals | Ammonium Biurate Crystals | Ammonium Urate Crystals | CYAMMBIU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700271","White Blood Cell Cast Measurement","C74778","The determination of the number of white blood cell casts present in a sample.","White Blood Cell Cast Measurement | CSWBC | WBC Casts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829561","Immunoblasts to Lymphocytes Ratio Measurement","C106535","The determination of the ratio of immunoblasts compared to all lymphocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Immunoblasts to Lymphocytes Ratio Measurement | BLSTIMLY | Immunoblasts/Lymphocytes | Lymphocytes, Immunoblastic/Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889126","Azurophilic Granule Measurement","C116185","The determination of the amount of azurophilic granules present in a sample.","Azurophilic Granule Measurement | AZURGRAN | Azurophilic Granulation | Azurophilic Granules",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337445","Thyroglobulin Measurement","C103446","The determination of the amount of the thyroglobulin in a sample.","Thyroglobulin Measurement | TG | TGLOB | Thyroglobulin",,,,,,,,,,,,,,,"4219426","Thyroglobulin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2984929","Protein to Osmolality Ratio Measurement","C92240","The determination of the ratio of total protein compared to the osmolality a sample. The measurement may be expressed as a ratio or percentage.","Protein to Osmolality Ratio Measurement | PROTOSML | Protein/Osmolality | Protein/Osmolality Ratio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700143","Vacuolated Neutrophil Count","C74628","The determination of the number of neutrophils containing small vacuoles present in a sample.","Vacuolated Neutrophil Count | NEUTVAC | Vacuolated Neutrophils",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514033","Cat Dander Antigen IgA Antibody Measurement","C130126","A measurement of the cat dander antigen IgA antibody in a biological specimen.","Cat Dander Antigen IgA Antibody Measurement | C130126 | Cat Dander Antigen IgA Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919751","Alpha Hydroxybutyrate Dehydrogenase Measurement","C111126","The determination of the amount of alpha-hydroxybutyrate dehydrogenase present in a sample.","Alpha Hydroxybutyrate Dehydrogenase Measurement | AHBDH | Alpha Hydroxybutyrate Dehydrogenase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513371","Timothy Grass Pollen IgE Measurement","C130088","A measurement of the Timothy grass (Phleum pretense) pollen IgE in a biological specimen.","Timothy Grass Pollen IgE Measurement | C130088 | Timothy Grass Pollen IgE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0200499","ABO Blood Group Determination","C125939","The determination of the blood type of an individual by testing for the presence or absence of A antigen and/or B antigen on the surface of red blood cells.","ABO Blood Group Determination | ABO | ABO Blood Group",,,,,,,,,,,,,,,"4152673|4238568","ABO blood grouping|ABO typing",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C4054284","Oxidized LDL Cholesterol Measurement","C120635","The determination of the oxidized LDL cholesterol present in a sample.","Oxidized LDL Cholesterol Measurement | LDLOXI | Oxidized LDL Cholesterol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827665","Findings About Events or Interventions Domain","C85442","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to findings about events or interventions.","Findings About Events or Interventions Domain | FA | Findings About Events or Interventions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513990","Silver Birch Pollen IgG4 Measurement","C130079","A measurement of the silver birch pollen IgG4 in a biological specimen.","Silver Birch Pollen IgG4 Measurement | C130079 | Silver Birch Pollen IgG4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509251","Immature Leukocyte to Leukocytes Ratio Measurement","C127626","The determination of the ratio of immature leukocytes compared to total leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Immature Leukocyte to Leukocytes Ratio Measurement | Immature Leukocytes/Leukocytes | LEIMLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513972","Nut Mix Antigen IgG Antibody Measurement","C130123","A measurement of the nut mix antigen IgG antibody in a biological specimen.","Nut Mix Antigen IgG Antibody Measurement | C130123 | Nut Mix Antigen IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272890","Eccentrocyte Count","C96598","The determination of the amount of eccentrocytes present in a sample.","Eccentrocyte Count | ECCENTCY | Eccentrocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0428210","Methionine Measurement","C122238","The determination of the amount of methionine present in a sample.","Methionine Measurement | MET | Methionine",,,,,,,,,,,,,,,"4017210","Methionine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3830120","Findings About Events or Interventions Evaluator","C113362","A person who determines the significance of a finding about an event or intervention.","Findings About Events or Interventions Evaluator | FAEVAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201888","Angiotensin Converting Enzyme Measurement","C80169","The determination of the amount of angiotensin converting enzyme present in a sample.","Angiotensin Converting Enzyme Measurement | ACE | Angiotensin Converting Enzyme",,,,,,,,,,,,,,,"4234494","Angiotensin converting enzyme measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3272909","Platelet Clumps Count","C96624","The determination of the amount of platelet clumps present in a sample.","Platelet Clumps Count | PLATCLMP | PLT Clumps | Platelet Clumps",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881935","Myeloblast to Leukocyte Ratio","C64825","The determination of the ratio of myeloblasts compared to leukocytes in a blood sample. The measurement may be expressed as a ratio or percentage.","Myeloblast to Leukocyte Ratio | MYBLALE | Myeloblasts/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055353","Borrelia Burgdorferi IgA Antibody Measurement","C122099","The determination of the amount of Borrelia burgdorferi IgA antibody present in a sample.","Borrelia burgdorferi IgA Antibody Measurement | BBRIGAAB | Borrelia Burgdorferi IgA Antibody Measurement | Borrelia burgdorferi IgA Antibody | Lyme IgA Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545318","Reptilase Activity Actual to Control Ratio Measurement","C147430","The determination of the ratio of the biological activity of reptilase dependent coagulation in a subject's specimen when compared to the same activity in a control specimen. The measurement may be expressed as a ratio or percentage.","Reptilase Activity Actual to Control Ratio Measurement | RPTLAAC | Reptilase Activity Actual/Control | Reptilase Activity Actual/Normal | Reptilase Activity Actual/Reptilase Activity Control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699157","Cellular Cast Measurement","C74764","The determination of the amount of cellular casts present in a urine sample.","Cellular Cast Measurement | CSCELL | Cellular Casts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812686","Interleukin 1 Receptor Antagonist Measurement","C112324","The determination of the amount of interleukin 1 receptor antagonist present in a sample.","Interleukin 1 Receptor Antagonist Measurement | IL-1RA | INTLK1RA | Interleukin 1 Receptor Antagonist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825884","CD40 Measurement","C82006","The determination of the amount of cellular CD40 expression present in a sample.","CD40 Expression Measurement | CD40 Cell Surface Measurement | CD40 Expression | CD40 Measurement | CD40X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524030","Cocaine Measurement","C74690","The determination of the amount of cocaine present in a sample.","Cocaine Measurement | COCAINE | Cocaine",,,,,,,,,,,,,,,"4104671","Cocaine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524002","Alprazolam Measurement","C75370","The determination of the amount of alprazolam present in a sample.","Alprazolam Measurement | ALPRZLM | Alprazolam",,,,,,,,,,,,,,,"4020132","Alprazolam measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897845","Procedure Dosing Frequency per Interval","C117522","The number of doses administered for the procedure per a specific interval.","Procedure Dosing Frequency per Interval | PRDOSFRQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816193","Nucleated Thrombocyte Count","C111283","The determination of the amount of nucleated thrombocytes present in a sample. This is typically measured in birds and other non-mammalian vertebrates.","Nucleated Thrombocyte Count | Nucleated Thrombocytes | THROMNUC | Thrombocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274393","Factor V Measurement","C98726","The determination of the amount of factor V present in a sample.","Factor V Measurement | FACTV | Factor V | Labile Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0920267","Platelet Aggregation Measurement","C103427","The determination of the amount of the association of platelets to one another via adhesion molecules in a biological sample.","Platelet Aggregation Measurement | PLATAGGR | Platelet Aggregation | Platelet Function",,,,,,,,,,,,,,,"4055338|45769804","Platelet aggregation test|Platelet aggregation technique",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2210362","blood protein studies pregnancy-associated plasma protein-a (lab test)","C82031","The determination of the amount of pregnancy-associated plasma protein-A present in a sample.","Pregnancy-Associated Plasma Protein-A Measurement | PAPPA | Pregnancy-Associated Plasma Protein-A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054015","Sjogrens SS-A60 Antibody Measurement","C120662","The determination of the Sjogrens SS-A60 antibody present in a sample.","Sjogrens SS-A60 Antibody Measurement | 60 kDa SS-A/Ro Ribonucleoprotein Antibody Measurement | SJSA60AB | Sjogrens SS-A60 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825868","Islet Cell 512 Antigen Measurement","C81986","The determination of the amount of islet cell 512 antigen present in a sample.","Islet Cell 512 Antigen Measurement | IC512AG | Islet Cell 512 Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698048","Metamyelocyte to Leukocyte Ratio Measurement","C74645","The determination of the ratio of metamyelocytes compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Metamyelocyte to Leukocyte Ratio Measurement | METAMYLE | Metamyelocytes/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523317","Scl-70 Antibody Measurement","C100458","The determination of the amount of Scl-70 antibody present in a sample.","Scl-70 Antibody Measurement | SCL70AB | Scl-70 Antibody | Scleroderma-70 Antibody",,,,,,,,,,,,,,,"4147759","Antibody to Scl-70 measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL523867","Hepatocyte Growth Factor Measurement","C135426","The determination of the amount of hepatocyte growth factor in a biological sample.","Hepatocyte Growth Factor Measurement | HGF | HGF Measurement | Hepatocyte Growth Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698610","CDISC CDASH Exposure Dosing Frequency per Interval Terminology","C78745","A terminology subset of the CDISC Study Data Tabulation Model (SDTM) Frequency codelist created for Clinical Data Acquisition Standards Harmonization (CDASH) Exposure Dosing Frequency per Interval terminology.","CDISC CDASH Exposure Dosing Frequency per Interval Terminology | CDASH-EXDOSFRQ | EXDOSFRQ | Exposure Dosing Frequency per Interval",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899224","Exposure as Collected Dosing Frequency per Interval","C117483","The number of doses administered for the collected exposure per a specific interval.","Exposure as Collected Dosing Frequency per Interval | ECDOSFRQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826700","Electrocardiogram Method","C83089","The mechanism by which the electrocardiogram assessment is carried out.","Electrocardiogram Method | EGMETHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546057","Macromolecular Type 2 Creatine Kinase to Total Creatine Kinase Ratio Measurement","C147320","The determination of the ratio of macromolecular type 2 creatine kinase compared to total creatine kinase present in a sample. The measurement may be expressed as a ratio or percentage.","Macromolecular Type 2 Creatine Kinase to Total Creatine Kinase Ratio Measurement | CK, Macromolecular Type 2/Total CK | CKMT2CK | Creatine Kinase, Macromolecular Type 2/Total Creatine Kinase | Macro-CK Type 2 to Total Creatine Kinase Ratio Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890352","P-Selectin Measurement","C117850","The determination of the amount of P-selectin present in a sample.","P-Selectin Measurement | GMP-140 | P-Selectin | PSELECT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825905","Plasminogen Activator Inhibitor-1 Measurement","C82030","The determination of the amount of plasminogen activator inhibitor-1 present in a sample.","Plasminogen Activator Inhibitor-1 Measurement | PAI1 | Plasminogen Activator Inhibitor-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2317942","Rubeola IgM Antibody Measurement","C112413","The determination of the amount of Rubeola IgM antibody present in a sample.","Rubeola IgM Antibody Measurement | Measles IgM Antibody | RBOIGMAB | Rubeola IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202349","Cannabinoid Drug Class Measurement","C74689","The determination of the amount of cannabinoid class agents present in a sample.","Cannabinoid Drug Class Measurement | CANNAB | Cannabinoids",,,,,,,,,,,,,,,"4280954","Cannabinoids measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0427565","Platelet Distribution Width","C81962","A measurement of the range of platelet sizes in a blood specimen.","Platelet Distribution Width | PDW",,,,,,,,,,,,,,,"4097620","Platelet distribution width measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698007","Malignant Cell Count","C74660","The determination of the number of malignant cells present in a sample.","Malignant Cell Count | MLIGCE | Malignant Cells, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826714","Electrocardiogram Original Result","C83104","The outcome of the electrocardiogram assessment.","Electrocardiogram Original Result | EGORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826754","Electrocardiogram Test","C83146","A character or string that represents the full name of the ECG assessment.","Electrocardiogram Test | EGTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898353","Mid Cell Fraction Measurement","C116199","The determination of the amount of mid cell fraction (including eosinophils, basophils, monocytes and other precursor white blood cells) present in a sample.","Mid Cell Fraction Measurement | MIDCEF | Mid Cell Fraction | Mid Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700106","Unclassified Cast Measurement","C74776","The determination of the number of unclassified casts present in a urine sample.","Unclassified Cast Measurement | CSUNCLA | Unclassified Casts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541266","Pepsinogen A Measurement","C100469","The determination of the amount of pepsinogen A present in a sample.","Pepsinogen A Measurement | PEPSNGA | PGA | Pepsinogen A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879788","Basophil to Leukocyte Ratio","C64471","The determination of the ratio of basophils to leukocytes in a blood sample. The measurement may be expressed as a ratio or percentage.","Basophil to Leukocyte Ratio | BASOLE | Basophils/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700254","Vitamin B17 Measurement","C74897","The determination of the amount of Vitamin B17 present in a sample.","Vitamin B17 Measurement | Amygdalin | VITB17 | Vitamin B17",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050218","C-C Chemokine Receptor Type 5 Measurement","C122103","The determination of the amount of C-C chemokine receptor type 5 in a biological specimen.","C-C Chemokine Receptor Type 5 Measurement | C-C Chemokine Receptor Type 5 | CCR5 | CD195 | Soluble CD195",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0877347","Globulin Protein Measurement","C74738","The determination of the amount of globulin protein present in a sample.","Globulin Protein Measurement | GLOBUL | Globulin",,,,,,,,,,,,,,,"4353510","Globulin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2984944","1, 25-Dihydroxyvitamin D Measurement","C92267","The determination of the amount of 1, 25-Dihydroxyvitamin D present in a sample.","1, 25-Dihydroxyvitamin D Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201834","Acid Phosphatase Measurement","C80163","The determination of the amount of acid phosphatase present in a sample.","Acid Phosphatase Measurement | ACPHOS | Acid Phosphatase",,,,,,,,,,,,,,,"4245738","Acid phosphatase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640660","Endogenous Thrombin Potential Time to Peak Relative Measurement","C102270","A relative (ratio or percentage) measurement of the time it takes to generate the maximum concentration of thrombin.","Endogenous Thrombin Potential Time to Peak Relative Measurement | ETP Time to Peak Relative | ETPTPR | Endogenous Thrombin Potential Time to Peak Relative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828289","Rubeola IgG Antibody Measurement","C112412","The determination of the amount of Rubeola IgG antibody present in a sample.","Rubeola IgG Antibody Measurement | Measles IgG Antibody | RBOIGGAB | Rubeola IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523339","Complement C3b Measurement","C80176","The determination of the amount of complement C3b present in a sample.","Complement C3b Measurement | C3B | Complement C3b",,,,,,,,,,,,,,,"4014746","Complement C3b measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523683","Guanine Deaminase Measurement","C150845","The determination of the amount of guanine deaminase present in a sample.","Guanine Deaminase Measurement | GDA | Guanase | Guanine Aminohydrolase | Guanine Deaminase",,,,,,,,,,,,,,,"4018323","Guanine deaminase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0391936","Barbiturate Drug Class Measurement","C74688","The determination of the amount of barbiturate class agents present in a sample.","Barbiturate Drug Class Measurement | BARB | Barbiturates",,,,,,,,,,,,,,,"4021313","Barbiturates measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825874","Tissue Plasminogen Activator Antigen Measurement","C81993","The determination of the amount of tissue plasminogen activator antigen present in a sample.","Tissue Plasminogen Activator Antigen Measurement | TPAAG | Tissue Plasminogen Activator Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986553","Vulvovaginal Region","C94529","The body region composed of the vulva and vagina.","Vulvovaginal Region | VULVOVAGINAL REGION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225861","Left Atrial Appendage","C127643","The ear-shaped, muscular pouch of the left atrium.","Left Atrial Appendage | HEART, LEFT ATRIAL APPENDAGE",,,,,,,,,,,,,,,"35632168|4143309","Structure of left pinna|Structure of left auricular appendage",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3897358","Tibialcrural Artery","C116168","The blood vessel segment that includes the crural artery and the tibial artery.","Tibialcrural Artery | TIBIAL-CRURAL PERIPHERAL ARTERY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898611","Left Posterior Descending Artery","C116178","The second posterolateral branch originating from the posterior atrioventricular left circumflex artery in left dominant and mixed circulations.","Left Posterior Descending Artery | LEFT POSTERIOR DESCENDING ARTERY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897951","Pericardial Lymph Node","C117870","A lymph node located anterior to the pericardium, posterior to the xiphoid process, and in the right and left cardiophrenic fat.","Pericardial Lymph Node | PERICARDIAL LYMPH NODE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509319","Right Ventricular Free Wall","C127647","The lateral segment of the right ventricular wall, excluding the anterior and inferior right ventricular wall.","Right Ventricular Free Wall | HEART, RIGHT VENTRICULAR FREE WALL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL497335","Skin Of The Axilla","C116164","The skin or integument surrounding the axilla, or underarm.","Skin of the Axilla | SKIN OF THE AXILLA | Skin Of The Axilla",,,,,,,,,,,,,,,"4294992","Skin structure of axilla",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL520241","Right Lung, Inferior Lobe, Lateral Basal Segment","C132403","The lateral basal segment of the inferior lobe of the right lung.","Right Lung, Inferior Lobe, Lateral Basal Segment | LUNG, RIGHT, INFERIOR LOBE, LATERAL BASAL SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508892","Left Ventricular Basal Inferoseptal Segment","C127660","The inferoseptal portion of the basal division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).","Left Ventricular Basal Inferoseptal Segment | LEFT VENTRICULAR BASAL INFEROSEPTAL SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225720","Right Lung, Middle Lobe, Lateral Segment","C132407","The lateral segment of the middle lobe of the right lung.","Right Lung, Middle Lobe, Lateral Segment | LUNG, RIGHT, MIDDLE LOBE, LATERAL SEGMENT",,,,,,,,,,,,,,,"4168969","Structure of lateral segment of middle lobe of right lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897882","Popliteal Artery Above the Knee","C116180","The segment of the popliteal artery that is located above the knee.","Popliteal Artery Above the Knee | POPLITEAL ARTERY ABOVE KNEE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0549113","Aortic Root","C127641","The portion of the ascending aorta between the aortic annulus and the sinotubular junction.","Aortic Root | ASCENDING AORTA, AORTIC ROOT",,,,,,,,,,,,,,,"4217447","Supraaortic valve area structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898616","Left Atrioventricular Artery","C116177","The first posterolateral branch originating from the posterior atrioventricular left circumflex artery in left dominant and mixed circulations.","Left Atrioventricular Artery | LEFT ATRIOVENTRICULAR ARTERY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508893","Left Ventricular Mid Anterior Segment","C127661","The anterior portion of the mid-cavity division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).","Left Ventricular Mid Anterior Segment | LEFT VENTRICULAR MID ANTERIOR SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509649","Proliferating Myeloid Cell to Total Cell Ratio Measurement","C127634","The determination of the ratio of proliferating myeloid cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Proliferating Myeloid Cell to Total Cell Ratio Measurement | PMYCECE | Proliferating Myeloid Cells to Total Cells Ratio Measurement | Proliferating Myeloid Cells/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513450","Dairy Mix Antigen IgG Antibody Measurement","C130119","A measurement of the dairy mix antigen IgG antibody in a biological specimen.","Dairy Mix Antigen IgG Antibody Measurement | C130119 | Dairy Mix Antigen IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4048784","Reactive Oxygen Metabolite Measurement","C122146","The determination of the amount of reactive oxygen metabolite present in a sample.","Reactive Oxygen Metabolite Measurement | ROM | Reactive Oxygen Metabolite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0546634","Cystine Measurement","C105441","The determination of the amount of cystine present in a sample.","Cystine Measurement | CYSTINE | Cystine",,,,,,,,,,,,,,,"4008122","Cystine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641257","Median Or Lower Cervical Lymph Node","C103417","A lymph node located in the median or lower region of the neck. (NCI)","Median Or Lower Cervical Lymph Node | MEDIAN OR LOWER CERVICAL LYMPH NODE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520919","Portal Vein Bifurcation","C132413","The portion of the distal end of the main portal vein that branches into the left and right portal veins.","Portal Vein Bifurcation | PORTAL VEIN BIFURCATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225845","Right Atrial Appendage","C127646","The ear-shaped, muscular pouch of the right atrium.","Right Atrial Appendage | HEART, RIGHT ATRIAL APPENDAGE",,,,,,,,,,,,,,,"35632169|4286484","Structure of right pinna|Structure of right auricular appendage",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL509271","Metacarpal 1 Base","C127667","The proximal end of the first metacarpal bone.","Metacarpal 1 Base | METACARPAL 1 BASE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0447166","Lower Jugular Lymph Node Group (Level IV)","C132512","Lymph nodes located around the lower third of the internal jugular vein, extending from the inferior border of the cricoid cartilage (above) to the clavicle below. The anterior (medial) boundary is the lateral border of the sternohyoid muscle and the posterior (lateral) boundary is the posterior border of the sternocleidomastoid muscle. These nodes are at greatest risk for harboring metastases from cancers arising from the hypopharynx, thyroid, cervical esophagus, and larynx. (AJCC 8th ed.)","Lower Jugular Lymph Node Group (Level IV) | LOWER JUGULAR LYMPH NODE",,,,,,,,,,,,,,,"4075262|4075853","Lower jugular lymph node|Lower jugular lymph node group",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2699193","Cholesterol to HDL-Cholesterol Ratio Measurement","C80171","The determination of the ratio of total cholesterol compared to high-density lipoprotein type cholesterol present in a sample. The measurement may be expressed as a ratio or percentage.","Cholesterol to HDL-Cholesterol Ratio Measurement | CHOLHDL | Cholesterol/HDL-Cholesterol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880186","Creatine Kinase MM Measurement","C64494","A quantitative measurement of the amount of homozygous M-type creatine kinase present in a sample.","Creatine Kinase MM Measurement | CKMM | CKMM Measurement | Creatine Kinase MM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0948093","Hemoglobin S Measurement","C122123","The determination of the amount of hemoglobin S present in a sample.","Hemoglobin S Measurement | HGBS | Hemoglobin S | Sickle Hemoglobin",,,,,,,,,,,,,,,"4154636","Hemoglobin S measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0455284","Myelocyte Count","C74662","The determination of the number of myelocyte cells present in a sample.","Myelocyte Count | MYCY | Myelocytes",,,,,,,,,,,,,,,"4306263","Myelocyte count procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0201660","Rheumatoid Factor Measurement","C74717","The determination of the amount of rheumatoid factor antibody present in a sample.","Rheumatoid Factor Antibody Measurement | RF | Rheumatoid Factor | Rheumatoid Factor Measurement | Rheumatoid Factor Measurement",,,,,,,,,,,,,,,"4204380","Rheumatoid factor measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0577608","Complement C4 Measurement","C80177","The determination of the amount of complement C4 present in a sample.","Complement C4 Measurement | C4 | Complement C4",,,,,,,,,,,,,,,"4135587","C4 complement assay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4049934","Squamous Cell Carcinoma Antigen Measurement","C120660","The determination of the squamous cell carcinoma antigen present in a sample.","Squamous Cell Carcinoma Antigen Measurement | SCCAG | Serpin B3/B4 Measurement | Squamous Cell Carcinoma Antigen | Squamous Cell Carcinoma Antigen (SCCA)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825903","Pancreatic Elastase Measurement","C82028","The determination of the amount of pancreatic elastase present in a sample.","Pancreatic Elastase Measurement | ELA1 | Pancreatic Elastase 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546014","Macromolecular Type 1 Creatine Kinase to Total Creatine Kinase Ratio Measurement","C147319","The determination of the ratio of macromolecular type 1 creatine kinase compared to total creatine kinase present in a sample. The measurement may be expressed as a ratio or percentage.","Macromolecular Type 1 Creatine Kinase to Total Creatine Kinase Ratio Measurement | CK, Macromolecular Type 1/Total CK | CKMT1CK | Creatine Kinase, Macromolecular Type 1/Total Creatine Kinase | Macro-CK Type 1 to Total Creatine Kinase Ratio Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523676","Glycerol Measurement","C132371","The determination of the amount of glycerol in a biological sample.","Glycerol Measurement | GLYCRL | Glycerol",,,,,,,,,,,,,,,"4018321","Glycerol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL505120","RhD Factor Measurement","C125948","The determination of the amount of Rhesus factor type D present in a sample.","RhD Factor Measurement | RHD | RhD Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829691","Histone 1 Antibody Measurement","C112293","The determination of the amount of histone 1 antibody present in a sample.","Histone 1 Antibody Measurement | HIST1AB | Histone 1 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514055","Mold Mix Antigen IgA Antibody Measurement","C130111","A measurement of the mold mix antigen IgA antibody in a biological specimen.","Mold Mix Antigen IgA Antibody Measurement | C130111 | Mold Mix Antigen IgA Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2732429","Monoclonal Protein to Total Protein Ratio Measurement","C147397","The determination of the ratio of monoclonal protein compared to total protein present in a sample. The measurement may be expressed as a ratio or percentage.","Monoclonal Protein to Total Protein Ratio Measurement | M Protein to Total Protein Ratio Measurement | M Protein/Total Protein | M-Spike Protein/Total Protein | MONOPTPT | Monoclonal Protein Spike/Total Protein | Monoclonal Protein/Total Protein | Myeloma Protein/Total Protein",,,,,,,,,,,,,,,"40481020","Measurement of monoclonal protein/total protein ratio",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL522797","Clostridium tetani Toxoid IgG Antibody Measurement","C135406","The determination of the amount of the Clostridium tetani toxoid IgG antibody in a biological sample.","Clostridium tetani Toxoid IgG Antibody Measurement | CTXIGGAB | Clostridium tetani Toxoid IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984947","Hepatitis A Virus Antibody IgM Measurement","C92271","The determination of the amount of Hepatitis A virus antibody IgM present in a sample.","Hepatitis A Virus Antibody IgM Measurement | HAIGMAB | Hepatitis A Virus IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1328729","Tryptase Measurement","C92292","The determination of the amount of tryptase present in a sample.","Tryptase Measurement | TRYPTASE | Tryptase",,,,,,,,,,,,,,,"4007807","Tryptase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL523853","Dysmorphic Erythrocyte Count","C135441","The determination of the amount of dysmorphic erythrocytes present in a sample.","Dysmorphic Erythrocyte Count | Dysmorphic Erythrocytes | RBCDYSM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986893","Death Diagnosis Domain","C95087","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to death diagnosis.","Death Diagnosis Domain | DD | Death Details | Death Diagnosis and Details",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899409","Death Diagnosis Evaluator","C117548","A person who determines the significance of a death diagnosis assessment.","Death Diagnosis Evaluator | DDEVAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523301","Adenovirus Antibody Measurement","C111125","The determination of the amount of adenovirus antibody present in a sample.","Adenovirus Antibody Measurement | ADENOVAB | Adenovirus Antibody",,,,,,,,,,,,,,,"4017925","Measurement of adenovirus antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4050627","Soluble P-Selectin Measurement","C120650","The determination of the soluble P-selectin present in a sample.","Soluble P-Selectin Measurement | PSELECTS | Soluble P-Selectin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498426","Macrophage to Leukocyte Ratio","C123460","The determination of the ratio of macrophages compared to leukocytes in a sample. The measurement may be expressed as a ratio or percentage.","Macrophage to Leukocyte Ratio | MCPHGLE | Macrophages/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714540","HIV Antibody Measurement","C106527","A quantitative measurement of the antibody reaction of a biological specimen to the HIV virus.","HIV Antibody Measurement | HIV Antibody | HIVAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502707","Osteopontin Measurement","C124349","The determination of the amount of osteopontin present in a sample.","Osteopontin Measurement | OPN | Osteopontin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826849","Electrocardiogram Evaluator","C83259","A person who determines the significance of an electrocardiogram assessment.","Electrocardiogram Evaluator | EGEVAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700257","Vitamin D2 Measurement","C74904","The determination of the amount of Vitamin D2 present in a sample.","Vitamin D2 Measurement | Calciferol | Ergocalciferol | VITD2 | Viosterol | Vitamin D2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825889","Fatty Acid Binding Protein 1 Measurement","C82012","The determination of the amount of fatty acid binding protein-1 present in a sample.","Fatty Acid Binding Protein 1 Measurement | FABP1 | FABP1 Measurement | Fatty Acid Binding Protein 1 | Fatty Acid-Binding Protein, Liver Measurement | L-FABP | L-FABP Measurement | L-Type Fatty Acid-Binding Protein | Liver Fatty Acid-Binding Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882079","Neutrophil to Leukocyte Ratio Measurement","C64827","The determination of the ratio of neutrophils compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Neutrophil to Leukocyte Ratio Measurement | NEUTLE | Neutrophil to Leukocyte Ratio | Neutrophils/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513973","Orchard Grass Pollen IgA Measurement","C130081","A measurement of the orchard grass (Dactylis glomerata) pollen IgA in a biological specimen.","Orchard Grass Pollen IgA Measurement | C130081 | Cocksfoot Grass Pollen IgA | Orchard Grass Pollen IgA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919758","Vitamin D Measurement","C84818","The determination of the amount of vitamin D present in a sample.","Vitamin D Measurement | ",,,,,,,,,,,,,,,"4308739","Vitamin D measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825863","Anti-Saccharomyces cerevisiae Antibody Measurement","C81976","The determination of the amount of anti-Saccharomyces cerevisiae antibody present in a sample.","Anti-Saccharomyces cerevisiae Antibody Measurement | ASCAB | Anti-Saccharomyces cerevisiae Antibody | Baker's Yeast Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890400","Leukemic Cells Measurement","C116195","The determination of the amount of leukemic cells present in a sample.","Leukemic Cells Measurement | LEUKCE | Leukemic Cells | Residual Leukemic Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201985","Base Excess Measurement","C119270","The determination of the amount of the base excess in a biological specimen.","Base Excess Measurement | Actual Base Excess | BASEEXCS | Base Excess",,,,,,,,,,,,,,,"4284393","Delta base, blood",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055266","Cathepsin Antibody Measurement","C120634","The determination of the cathepsin antibody present in a sample.","Cathepsin Antibody Measurement | CSAB | Cathepsin Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514048","English Plantain Pollen IgG4 Measurement","C130087","A measurement of the English plantain (Plantago lanceolata) pollen IgG4 in a biological specimen.","English Plantain Pollen IgG4 Measurement | C130087 | English Plantain Pollen IgG4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509753","Maturing Myeloid Cell to Total Cell Ratio Measurement","C127629","The determination of the ratio of maturing myeloid cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Maturing Myeloid Cell to Total Cell Ratio Measurement | MMYCECE | Maturing Myeloid Cells to Total Cells Ratio Measurement | Maturing Myeloid Cells/Total Cells | Maturing Myeloid/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898373","Microscopic Findings Evaluator","C117598","A person who determines the significance of a microscopic findings assessment.","Microscopic Findings Evaluator | MIEVAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202436","Oxazepam Measurement","C75375","The determination of the amount of oxazepam present in a sample.","Oxazepam Measurement | OXZPM | Oxazepam",,,,,,,,,,,,,,,"4023844","Oxazepam measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1531512","Bactericidal/Permeability-Increasing Protein Antibody Measurement","C120631","The determination of the bactericidal/permeability-increasing protein antibody present in a sample.","Bactericidal/Permeability-Increasing Protein Antibody Measurement | BPI Auto-antibody | BPIAB | Bactericidal/Permeability-Inc Protein Ab",,,,,,,,,,,,,,,"4211473","Anti BPI antibody level",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523961","Urea Measurement","C64815","A quantitative measurement of the amount of urea present in a sample.","Urea Measurement | UREA | Urea",,,,,,,,,,,,,,,"4020121","Urea measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3536958","Surfactant Protein D Measurement","C111322","The determination of the amount of surfactant protein D present in a sample.","Surfactant Protein D Measurement | SFTPD | SP-D | Surfactant Protein D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523483","Alpha-2 Macroglobulin Measurement","C80168","The determination of the amount of alpha-2 macroglobulin present in a sample.","Alpha-2 Macroglobulin Measurement | A2MACG | Alpha-2 Macroglobulin",,,,,,,,,,,,,,,"4019444","Alpha-2-macroglobulin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825904","Polymorphonuclear Pancreatic Elastase Measurement","C82029","The determination of the amount of polymorphonuclear pancreatic elastase present in a sample.","Polymorphonuclear Pancreatic Elastase Measurement | ELA1PMN | Pancreatic Elastase 1, Polymorphonuclear",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3259781","Coagulation Index Measurement","C112239","A measurement of the efficiency of coagulation of a biological specimen. This is calculated by a mathematical formula that takes into account the R value, K value, angle and maximum amplitude of clot formation.","Coagulation Index Measurement | CI | COAGIDX | Coagulation Index",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698834","Plasmacytoid Lymphocyte to Lymphocyte Ratio Measurement","C74648","The determination of the ratio of plasmacytoid lymphocytes compared to all lymphocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Plasmacytoid Lymphocyte to Lymphocyte Ratio Measurement | LYMPLLY | Plasmacytoid Lymphocytes/Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699973","Total Carnitine Measurement","C74682","The determination of the amount of total carnitine present in a sample.","Total Carnitine Measurement | CARNIT | Carnitine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890220","Platelet Satellitism Assessment","C116209","The determination of the presence of platelet satellitism in a sample.","Platelet Satellitism Assessment | PLATSAT | Platelet Satellitism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984940","HIV-1 Group M and O Nucleic Acid Measurement","C92263","The determination of the amount of HIV-1 group M and O nucleic acid present in a sample.","HIV-1 Group M and O Nucleic Acid Measurement | HIV-1 Group M and O Nucleic Acid | HIV1MONA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522804","Erythroid Maturation Index","C135415","The determination of the ratio of the sum of erythroid maturation phase cells (pool) to the sum of erythroid proliferative phase cells (pool) present in a sample.","Erythroid Maturation Index | ERCEMIDX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055338","CD161a to Lymphocyte Ratio Measurement","C122104","The determination of the ratio of CD161a expressing cells to total lymphocytes present in a sample. The measurement by be expressed as a ratio or percentage.","CD161a to Lymphocyte Ratio Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050551","Streptococcus pneumoniae Antigen Measurement","C122152","The determination of the amount of Streptococcus pneumoniae antigen present in a sample.","Streptococcus pneumoniae Antigen Measurement | SPNAG | Streptococcus pneumoniae Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826662","Physical Examination Evaluator","C83050","A person who determines the significance of a physical examination assessment.","Physical Examination Evaluator | PEEVAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897592","Skin Response Evaluator","C117691","A person who determines the significance of a skin response assessment.","Skin Response Evaluator | SREVAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0455285","Metamyelocyte Count","C74615","The determination of the number of metamyelocytes present in a sample.","Metamyelocyte Count | METAMY | Metamyelocytes",,,,,,,,,,,,,,,"4306264","Metamyelocyte count procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0201900","Atrial Natriuretic Peptide Measurement","C74886","The determination of the amount of atrial-natriuretic peptide present in a sample.","Atrial Natriuretic Peptide Measurement | ANP | Atrial Natriuretic Peptide | Atriopeptin",,,,,,,,,,,,,,,"4197113","Atrial natriuretic factor (ANF) measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0201907","Beta Glucuronidase Measurement","C80170","The determination of the amount of beta glucuronidase present in a sample.","Beta Glucuronidase Measurement | GUSB | Glucuronidase, Beta",,,,,,,,,,,,,,,"4288291","Beta-glucuronidase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1881820","Microcyte Count procedure","C64822","The determination of the number of microcytes in a blood sample.","Microcyte Count | MICROCY | Microcytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545291","Factor VIII Activity Actual to Control Ratio Measurement","C147345","The determination of the ratio of the biological activity of factor VIII dependent coagulation in a subject's specimen when compared to the same activity in a control specimen. The measurement may be expressed as a ratio or percentage.","Factor VIII Activity Actual to Control Ratio Measurement | FVIIIAAC | Factor VIII Activity Actual/Control | Factor VIII Activity Actual/Factor VIII Activity Control | Factor VIII Activity Actual/Normal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0200641","Absolute Basophil Count","C64470","The total number of white blood cells that are basophils. It is calculated by multiplying the white blood cell count by the percent of basophils in the differential white blood cell count.","Absolute Basophil Count | BASO | Basophil | Basophils | Total Basophil Count | Total Basophil Count",,,,,,,,,,,,,,,"4172647","Basophil count",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698888","Promonocyte to Lymphocyte Ratio Measurement","C74652","The determination of the ratio of promonocytes compared to all lymphocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Promonocyte to Lymphocyte Ratio Measurement | PROMONLE | Promonocytes/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699127","Cast Present Or Absent (lab procedure)","C74763","The determination of the presence or absence of casts in a sample.","Cast Present Or Absent | CASTS | Casts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699645","Stomatocyte Count","C74708","The determination of the number of stomatocytes present in a sample.","Stomatocyte Count | STOMCY | Stomatocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829688","Histone 4 Antibody Measurement","C112297","The determination of the amount of histone 4 antibody present in a sample.","Histone 4 Antibody Measurement | HIST4AB | Histone 4 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697873","Lactate Dehydrogenase Isoenzyme 2 Measurement","C74888","The determination of the lactate dehydrogenase isoenzyme 2 present in a sample.","Lactate Dehydrogenase Isoenzyme 2 Measurement | LDH Isoenzyme 2 | LDH2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202458","Propoxyphene measurement","C74885","The determination of the amount of propoxyphene present in a sample.","Propoxyphene Measurement | PROPOX | Propoxyphene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522821","Neutrophils to Non-Squamous Epithelial Cells Ratio Measurement","C135438","The determination of the ratio of neutrophils compared to non-squamous epithelial cells present in a sample. The measurement may be expressed as a ratio or percentage.","Neutrophils to Non-Squamous Epithelial Cells Ratio Measurement | NEUTNSQE | Neutrophils/Non-Squam Epi Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL494717","LDL Cholesterol to HDL Cholesterol Ratio Measurement","C121182","The determination of the ratio of LDL cholesterol compared to HDL cholesterol present in a sample. The measurement may be expressed as a ratio or percentage.","LDL Cholesterol to HDL Cholesterol Ratio Measurement | LDL Cholesterol/HDL Cholesterol | LDLHDL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899216","Exposure as Collected Laterality","C117489","A qualifier for the side of the body the collected exposure assessment is performed.","Exposure as Collected Laterality | ECLAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898613","Left Main Coronary Artery Body","C116173","The segment of the left main coronary artery that is bounded by its ostium and bifurcation.","Left Main Coronary Artery Body | LEFT MAIN CORONARY ARTERY BODY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018427","Cingulate Gyrus","C96217","A long curved fold located in the medial surface of the cerebral hemisphere.","Cingulate Gyrus | ANTERIOR CINGULATE GYRUS",,,,,,,,,,,,,,,"4098059","Structure of cingulate gyrus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0748512","Occipital Scalp","C103456","The occipital region of the skin that covers the top of the head.","Occipital Scalp | OCCIPITAL SCALP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034671","Raphe Nuclei","C97335","A group of nuclei that are located in the midline of the brainstem and release serotonin.","Raphe Nuclei | RAPHE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508890","Left Ventricular Basal Inferior Segment","C127658","The inferior portion of the basal division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).","Left Ventricular Basal Inferior Segment | LEFT VENTRICULAR BASAL INFERIOR SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520244","Right Lung, Inferior Lobe, Superior Segment","C132406","The superior segment of the inferior lobe of the right lung.","Right Lung, Inferior Lobe, Superior Segment | LUNG, RIGHT, INFERIOR LOBE, SUPERIOR SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053852","Ward's Triangle","C122161","A radiolucent and fracture-prone triangular zone in the proximal femur.","Ward's Triangle | WARDS TRIANGLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521206","Left Lung, Superior Lobe, Superior Lingular Segment","C132401","The superior inguinal segment of the superior lobe of the left lung.","Left Lung, Superior Lobe, Superior Lingular Segment | LUNG, LEFT, SUPERIOR LOBE, SUPERIOR LINGULAR SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897881","Popliteal Artery Below the Knee","C116181","The segment of the popliteal artery that is located below the knee.","Popliteal Artery Below the Knee | POPLITEAL ARTERY BELOW KNEE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898612","Left Main Coronary Artery Ostium","C116172","The opening of the left coronary artery at its origin.","Left Main Coronary Artery Ostium | LEFT MAIN CORONARY ARTERY OSTIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225947","Mitral Valve Annulus","C127306","A saddle-shaped, fibrous structure that provides support to the mitral valve leaflets, and functions to contract during ventricular systole, thereby providing complete closure of the mitral valve and preventing regurgitant blood flow into the left atrium.","Mitral Valve Annulus | MITRAL VALVE ANNULUS",,,,,,,,,,,,,,,"4278992","Structure of annulus fibrosus of mitral orifice",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3495441","Primary Motor Cortex","C97339","A brain region that is located in the dorsal part of the precentral gyrus.","Primary Motor Cortex | MOTOR CORTEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508898","Left Ventricular Mid Inferoseptal Segment","C127666","The inferoseptal portion of the mid-cavity division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).","Left Ventricular Mid Inferoseptal Segment | LEFT VENTRICULAR MID INFEROSEPTAL SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897837","Procedure Laterality","C117526","A qualifier for the side of the body the procedure is performed.","Procedure Laterality | PRLAT | PROCEDURE_LATERALITY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898371","Microscopic Findings Laterality","C117594","A qualifier for the side of the body the microscopic findings assessment is performed.","Microscopic Findings Laterality | MILAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540271","Hand Digit 2 Proximal Phalanx","C142304","A long bone in the second finger, as counted from the thenar side of the hand; it is located between, and articulates with, the second metacarpal and the middle phalanx.","Hand Digit 2 Proximal Phalanx | PROXIMAL PHALANX 2 OF THE HAND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526683","Hand Digit 5 Distal Phalanx","C139193","The bone that forms the tip of the fifth finger, as counted from the thenar side of the hand.","Hand Digit 5 Distal Phalanx | DISTAL PHALANX 5 OF THE HAND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829361","L2-L3 Intervertebral Space","C112327","The space between the L2 and L3 vertebrae.","L2-L3 Intervertebral Space | L2-L3 INTERVERTEBRAL SPACE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0504035","Right Ventricular Wall","C127649","The wall of the right ventricle, comprising anterior, inferior, and lateral walls; and excluding the interventricular septum.","Right Ventricular Wall | HEART, RIGHT VENTRICULAR WALL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL494689","Intertrochanteric Region","C120672","The bony region in the proximal portion of the femur between the greater, lesser and sub- (also called the third) trochanters.","Intertrochanteric Region | INTERTROCHANTERIC REGION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0504054","Left Ventricular Epicardium","C102315","The outermost layer of cardiac tissue lining of the left ventricle.","Left Ventricular Epicardium | LEFT VENTRICULAR EPICARDIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0223667","Superior Pubic Ramus","C132415","The portion of the pubic ramus that lies between the body of the ilium and the inferior pubic ramus.","Superior Pubic Ramus | SUPERIOR PUBIC RAMUS",,,,,,,,,,,,,,,"4230038","Structure of superior ramus of pubis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508891","Left Ventricular Basal Inferolateral Segment","C127659","The inferolateral portion of the basal division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).","Left Ventricular Basal Inferolateral Segment | LEFT VENTRICULAR BASAL INFEROLATERAL SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640668","Circumflex Artery and its Branches","C102286","The left circumflex coronary artery and all of its branches, including the obtuse marginals, left posterolateral and left posterior descending artery branches.","Circumflex Artery and its Branches | CIRCUMFLEX, OBTUSE MARGINALS, LEFT POSTEROLATERAL AND LEFT POSTERIOR DESCENDING ARTERY BRANCHES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225950","Anterior Cusp of the Mitral Valve","C127669","The cusp of the mitral valve that is anchored to the aortic-mitral curtain.","Anterior Cusp of the Mitral Valve | MITRAL VALVE, ANTERIOR CUSP",,,,,,,,,,,,,,,"4062660","Structure of anterior leaflet of mitral valve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL520240","Right Lung, Inferior Lobe, Anterior Basal Segment","C132402","The anterior basal segment of the inferior lobe of the right lung.","Right Lung, Inferior Lobe, Anterior Basal Segment | LUNG, RIGHT, INFERIOR LOBE, ANTERIOR BASAL SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227931","Radix Penis","C124350","The most proximal portion of the penis located between the descending portion of the pubic bone and the body of the penis.","Radix Penis | PENIS, RADIX",,,,,,,,,,,,,,,"4219096","Radix penis structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829360","L3-L4 Intervertebral Space","C112328","The space between the L3 and L4 vertebrae.","L3-L4 Intervertebral Space | L3-L4 INTERVERTEBRAL SPACE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0588208","Radius Shaft","C120674","The slightly curved, prismoid, elongated bony body of a radius compressing of the anterior, posterior and external surfaces separated by the anterior, posterior and interosseous borders.","Radius Shaft | RADIUS SHAFT",,,,,,,,,,,,,,,"4172771","Bone structure of shaft of radius",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0504053","Left Ventricular Wall","C127645","The wall of the left ventricle, comprising anterior, inferior, lateral, apical, basal wall; and excluding the interventricular septum.","Left Ventricular Wall | HEART, LEFT VENTRICULAR WALL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520245","Right Lung, Superior Lobe, Anterior Segment","C132409","The anterior segment of the superior lobe of the right lung.","Right Lung, Superior Lobe, Anterior Segment | LUNG, RIGHT, SUPERIOR LOBE, ANTERIOR SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897590","Skin Response Laterality","C117689","A qualifier for the side of the body the skin response assessment is performed.","Skin Response Laterality | SRLAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0222269","Skin of the Thigh","C150856","The skin or integument covering the thigh.","Skin of the Thigh | SKIN OF THE THIGH",,,,,,,,,,,,,,,"4160209","Skin structure of thigh",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540285","Hand Digit 4 Middle Phalanx","C142299","A long bone in the fourth finger, as counted from the thenar side of the hand; it is located between, and articulates with, the proximal and distal phalanges.","Hand Digit 4 Middle Phalanx | MIDDLE PHALANX 4 OF THE HAND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224262","Flexor Pollicis Longus Muscle","C150851","A muscle that originates on the anterior surface of the radius and interosseous membrane and inserts into the palmar aspect of the base of the distal phalanx of the thumb; It is involved in flexion of the thumb and is supplied by the anterior interosseous branch of the median nerve and the radial and anterior interosseous arteries.","Flexor Pollicis Longus Muscle | FLEXOR POLLICIS LONGUS MUSCLE",,,,,,,,,,,,,,,"4220703","Flexor pollicis longus muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540286","Hand Digit 3 Middle Phalanx","C142298","A long bone in the third finger, as counted from the thenar side of the hand; it is located between, and articulates with, the proximal and distal phalanges.","Hand Digit 3 Middle Phalanx | MIDDLE PHALANX 3 OF THE HAND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229742","Pretracheal Lymph Node","C147455","A lymph node located anterior to the trachea, between the isthmus of the thyroid gland and the innominate vein.","Pretracheal Lymph Node | PRETRACHEAL LYMPH NODE",,,,,,,,,,,,,,,"4058760","Structure of pretracheal lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540277","Renal Fossa","C142312","The usual retroperitoneal location of the kidney in the dorsolumbar region of the body.","Renal Fossa | RENAL FOSSA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545302","Paralaryngeal Lymph Node","C147453","A lymph node located adjacent to the larynx, in the parapharyngeal space.","Paralaryngeal Lymph Node | PARALARYNGEAL LYMPH NODE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226378","Uterine Artery","C142329","An artery that arises most often as a branch of the anterior division of the internal iliac artery; it continues medially in the pelvis within the base of the broad ligament, to the exterior surface of the uterus where it branches into the descending, transverse, and ascending divisions, which further branch into the following: the helicine branches that supply the uterus; the vaginal branch, which anastomoses with the vaginal artery to supply vagina; the ovarian branch, which anastomoses with ovarian artery to supply the ovaries; and the tubal branch that supplies the fallopian tubes.","Uterine Artery | UTERINE ARTERY",,,,,,,,,,,,,,,"4237052","Structure of uterine artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540274","Hand Digit 5 Middle Phalanx","C142300","A long bone in the fifth finger, as counted from the thenar side of the hand; it is located between, and articulates with, the proximal and distal phalanges.","Hand Digit 5 Middle Phalanx | MIDDLE PHALANX 5 OF THE HAND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1720043","Abdominal Region","C139186","Any portion of the body that lies within the boundary, either internally or externally, of the abdomen: superior margin, the thorax; inferior margin the pelvis; lateral margins, the ribs.","Abdominal Region | ABDOMINAL REGION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229092","Posterior Pole of the Eye","C142303","The scleral curvature of the eye comprising the retina, inclusive of the macula and optic disc.","Posterior Pole of the Eye | POSTERIOR POLE OF THE EYE",,,,,,,,,,,,,,,"4050632","Structure of posterior pole of eye",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540273","Nuchal Lymph Node","C142301","Any lymph node located in the posterior of the neck, including the postauricular, superficial occipital, middle posterior cervical chain, and lower posterior cervical chain.","Nuchal Lymph Node | NUCHAL LYMPH NODE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0448458","First Dorsal Interosseous Muscle of the Hand","C139198","A dorsal interosseous muscle of the hand that originates on the proximal half of the lateral border of the index metacarpal and the full length of the medial border of the thumb metacarpal, and inserts into the lateral side of the index finger.","First Dorsal Interosseous Muscle of the Hand | FIRST DORSAL INTEROSSEOUS MUSCLE OF THE HAND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540325","Striatum Nuclei","C142370","A group of subcortical nuclei of the basal ganglia comprising the caudate and putamen dorsally, and the nucleus accumbens as well as the olfactory tubercle ventrally.","Striatum Nuclei | STRIATUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540280","Internal Capsule of the Pyramidal Tracts","C142309","The segments of the corticospinal and corticobulbar tracts that traverse the internal capsule.","Internal Capsule of the Pyramidal Tracts | PYRAMIDAL TRACTS, INTERNAL CAPSULE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227124","Gingival Mucosa","C139199","The portion of the oral mucosa that surrounds the cervical aspect of teeth and the alveolar process of the jaw.","Gingival Mucosa | GINGIVAL MUCOSA",,,,,,,,,,,,,,,"4010667","Structure of gingival mucous membrane",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086955","Vital Signs Laterality","C123975","A qualifier for the side of the body vital signs test is performed.","Vital Signs Laterality | VSLAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526684","Hand Digit 4 Distal Phalanx","C139192","The bone that forms the tip of the fourth finger, as counted from the thenar side of the hand.","Hand Digit 4 Distal Phalanx | DISTAL PHALANX 4 OF THE HAND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540368","Trapezoid-Capitate Joint","C142327","The articulation of the trapezoid and capitate bones in the wrist.","Trapezoid-Capitate Joint | TRAPEZOID-CAPITATE JOINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526596","Hand Digit 3 Distal Phalanx","C139191","The bone that forms the tip of the third finger, as counted from the thenar side of the hand.","Hand Digit 3 Distal Phalanx | DISTAL PHALANX 3 OF THE HAND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0175190","Anterior Cingulate Cortex","C139185","The front region of the cingulate cortex that is located in the medial frontal lobe, adjacent to the corpus callosum. The anterior cingulate functions in decision making and in the regulation of emotions and physiological processes like blood pressure and heart rate.","Anterior Cingulate Cortex | ANTERIOR CINGULATE CORTEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540268","Hand Digit 5 Proximal Phalanx","C142307","A long bone in the fifth finger, as counted from the thenar side of the hand; it is located between, and articulates with, the fifth metacarpal and the middle phalanx.","Hand Digit 5 Proximal Phalanx | PROXIMAL PHALANX 5 OF THE HAND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3472474","Temple","C142369","The flat area on either side of the head that is located posterior to the eye and forehead, anterior to the ear, and superior to the cheek bone.","Temple | TEMPLE",,,,,,,,,,,,,,,"42872729","Structure of temporal region",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0222106","Skin Of The Chin","C142319","The integumentary covering of the chin.","Skin Of The Chin | SKIN OF THE CHIN",,,,,,,,,,,,,,,"4129348","Skin structure of chin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0582484","Upper Urinary System","C142328","The division of the urinary tract comprising the kidney and the ureters.","Upper Urinary System | UPPER URINARY SYSTEM | Upper Urinary Tract",,,,,,,,,,,,,,,"4119966","Structure of upper urinary system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0222155","Skin Of The Back","C142318","The integumentary covering of the back.","Skin Of The Back | SKIN OF THE BACK",,,,,,,,,,,,,,,"4280364","Skin structure of back",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540363","Skin Between the Eyebrows","C142317","The integumentary covering located medial to the orbital ridges and superior to the nose.","Skin Between the Eyebrows | SKIN BETWEEN EYEBROWS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0448196","Medial Femoral Condyle","C139204","A rounded bony projection on the inner side of the distal end of the femur to which the medial collateral and the posterior cruciate ligaments are attached.","Medial Femoral Condyle | MEDIAL FEMORAL CONDYLE",,,,,,,,,,,,,,,"4046734","Structure of medial condyle of femur",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526671","Distal Femur R1","C139208","The portion of the distal femur, identified during a DXA scan, that contains primarily metaphyseal or trabecular bone.","Distal Femur R1 | DISTAL FEMUR R1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552604","Hand Digit 1 Proximal Phalanx","C150848","The long bone in the first finger, as counted from the thenar side of the hand; it is located between, and articulates with, the first metacarpal and the distal phalanx.","Hand Digit 1 Proximal Phalanx | PROXIMAL PHALANX 1 OF THE HAND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540279","Radius-Lunate Joint","C142310","The articulation of the radius and the lunate bone in the wrist.","Radius-Lunate Joint | RADIUS-LUNATE JOINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225266","Iliotibial Band","C139207","A dense band of avascular, regular connective tissue, it is formed as the union of the superficial and deep layers of the tensor fascia latae, creating a thick band that extends inferiorly, taking its origins from the iliac crest, the tensor fascia latae, and the gluteus maximus, travelling inferiolaterally along the thigh, and inserting on Gerdy's tubercle on the lateral aspect of the tibia. Functionally, the iliotibial band helps to flex, abduct, and medially rotate the femur at the hip joint, and it also helps to stabilize the knee laterally.","Iliotibial Band | ILIOTIBIAL BAND",,,,,,,,,,,,,,,"4253042","Structure of iliotibial tract",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224294","Lumbrical Muscle","C150852","One of a group of four short muscles in the hand that originate on the radial and ulnar sides of the tendons of the flexor digitorum profundus and insert in the radial lateral band of the extensor expansion tendon; they are involved in the extension of the proximal and distal interphalangeal joints, and are supplied by the median and ulnar nerves and the palmar metacarpal arteries.","Lumbrical Muscle | LUMBRICAL MUSCLES OF THE HAND",,,,,,,,,,,,,,,"4339384","Structure of lumbrical muscle of hand",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526686","Lateral Humeral Epicondyle","C139202","A bone prominence at the distal end of the humerus to which the radial collateral ligament of the elbow joint, the anconeus and supinator muscles, and the common extensor tendon are attached.","Lateral Humeral Epicondyle | LATERAL HUMERAL EPICONDYLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826671","Protocol Deviation Yes No Indicator","C83059","An indication of whether protocol deviation has occurred.","Protocol Deviation Yes No Indicator | DVYN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889614","Healthcare Encounters Domain","C117757","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to a subject's healthcare encounter.","Healthcare Encounters Domain | HO | Healthcare Encounters",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086429","Healthcare Encounters Occurrence","C123982","An indication or description of a healthcare encounter occurrence.","Healthcare Encounters Occurrence | HOOCCUR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981457","Drug Accountability Performed","C87873","An indication or description that a drug accountability test has occurred.","Drug Accountability Performed | DAPERF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826832","Drug Accountability Assessment Test Code","C83242","A character or string that represents the short code name of the drug accountability assessment.","Drug Accountability Assessment Test Code | DATESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826672","Electrocardiogram Performed","C83060","An indication or description that an electrocardiogram assessment has occurred.","Electrocardiogram Performed | EGPERF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826632","Electrocardiogram Results Clinically Significant Occurrence","C83019","An indication or description that the outcome of the electrocardiogram was clinically significant.","Electrocardiogram Results Clinically Significant Occurrence | EGCLSIG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826675","Inclusion Exclusion Criteria Yes No Indicator","C83063","An indication of whether inclusion or exclusion criteria has been met.","Inclusion Exclusion Criteria Yes No Indicator | IEYN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981540","Pharmacokinetic Concentration Fasting Status","C87957","Indicates whether a specimen that had undergone a pharmacokinetic concentration assessment was obtained from a subject that had abstained from food and possibly water for the prescribed amount of time.","Pharmacokinetic Concentration Fasting Status | PCFAST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0514231","Physical Exam Performed","C113376","An indication or description that a subject physical examination test has occurred.","Physical Exam Performed | PEPERF | physical exam performed | physical_exam_performed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826634","Physical Examination Clinically Significant","C83021","An indication or description that the outcome of the physical examination was clinically significant.","Physical Examination Clinically Significant | PECLSIG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826998","Subject Characteristics Test Code","C83409","A character or string that represents the short code name of the subject characteristics test.","Subject Characteristics Test Code | SCTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827274","Subject Characteristic Performed","C113379","An indication or description that a subject characteristics test has occurred.","Subject Characteristic Performed | SCPERF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827054","Vital Signs Test Code","C83466","A character or string that represents the short code name of the vital signs test.","Vital Signs Test Code | VSTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981594","Vital Signs Performed","C88012","An indication or description that a vital signs test has occurred.","Vital Signs Performed | VSPERF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540679","Study Start","C142714","The official beginning of a clinical study, as specified in the clinical study report.","Study Start | study start",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1976106","Fasting Status","C120460","The state of a subject that represents to what extent they have abstained from consuming food or liquid.","Fasting Status | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541325","Reproductive System Findings Domain","C102707","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to reproductive system findings.","Reproductive System Findings Domain | RP | Reproductive System Findings",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335757","Reproductive System Finding","C36284","Symptoms, physical examination results, and/or laboratory test results related to the reproductive system.","Reproductive System Finding | REPRODUCTIVE SYSTEM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889822","Skin Response Test","C117675","A character or string that represents the long name of the skin response assessment.","Skin Response Test | SRTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087024","Findings About Laterality","C123974","A qualifier for the side of the body the findings about test is performed.","Findings About Laterality | FALAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347848","Data Disc","C72073","A flat rotating disk designed for data storage. Data is stored on either or both surfaces of disks in concentric rings called tracks.","Computer Disk | Computer Disc | Data Disc | Data Disk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019149","Common Hepatic Duct","C32356","A component of the biliary duct system created by the convergence of the left and right hepatic ducts.","Common Hepatic Duct | DUCT, COMMON HEPATIC | common hepatic duct",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898370","Microscopic Findings Location","C117593","The site in or on the body at which the microscopic assessment test or result is performed or collected.","Microscopic Findings Location | MILOC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826940","Physical Examination Location","C83350","The site of a physical examination.","Physical Examination Location | PELOC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897589","Skin Response Location","C117688","The site in or on the body at which the skin response test or result is performed or collected.","Skin Response Location | SRLOC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826699","Vital Signs Location","C83088","The physical portion of the body at which the vital signs assessment takes place.","Vital Signs Location | VSLOC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229829","Epigastric Lymph Node","C139195","A parietal lymph node located along the inferior epigastric vessels.","Epigastric Lymph Node | EPIGASTRIC LYMPH NODE",,,,,,,,,,,,,,,"4264725","Structure of epigastric lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0730169","Distal Radioulnar Joint","C139194","The articulation of the head of the ulna bone and the ulnar notch of the radius; the distal radioulnar joint is a pivot joint that functions in pronation and supination of the forearm.","Distal Radioulnar Joint | DISTAL RADIOULNAR JOINT",,,,,,,,,,,,,,,"4276343","Inferior radioulnar joint structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0223921","Calcaneal Tuberosity","C142295","A roughened surface on the superior portion of the posterior half of the calcaneus, where the calcaneal (Achilles) tendon inserts.","Calcaneal Tuberosity | CALCANEAL TUBEROSITY",,,,,,,,,,,,,,,"4219073","Calcaneal tubercle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540361","Supraclavicular Fossa","C142323","A depression found at the base of the neck that is bounded thusly: superiorly by the posterior belly of the omohyoid muscle; inferiorly by the clavicle; and medially by the sternocleidomastoid muscle.","Supraclavicular Fossa | SUPRACLAVICULAR FOSSA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526685","First Dorsal Interosseous Muscle of the Foot","C139197","A dorsal interosseous muscle of the foot that originates on the lateral side of the first metatarsal and the medial side of the second metatarsal, and inserts into the medial side of the base of the proximal phalanx of the second toe.","First Dorsal Interosseous Muscle of the Foot | FIRST DORSAL INTEROSSEOUS MUSCLE OF THE FOOT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0223644","Anterior Superior Iliac Spine","C139187","A bony projection from the anterior region of the iliac crest that functions as the site of attachment for the sartorius and tensor fascia latae muscles and the inguinal ligament.","Anterior Superior Iliac Spine | ANTERIOR SUPERIOR ILIAC SPINE",,,,,,,,,,,,,,,"4216942","Structure of anterior superior iliac spine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540272","Parapharyngeal Lymph Node","C142302","Any lymph node located in the potential space of the neck, which is bounded superiorly by the base of the skull, inferiorly by the greater cornu of the hyoid bone, anteriorly by the investing fascia of the deep cervical fascia covering the medial pterygoid muscle, posteriorly by the prevertebral layer of the deep cervical fascia, medially by the middle (pretracheal) layer of the deep cervical fascia, and laterally by the investing fascia of the deep cervical fascia covering the deep lobe of the parotid.","Parapharyngeal Lymph Node | PARAPHARYNGEAL LYMPH NODE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830119","Findings About Events or Interventions Location","C113363","The physical portion of the body at which the findings about the event or intervention assessment takes place.","Findings About Events or Interventions Location | FALOC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273126","Extrahepatic Bile Duct Adenocarcinoma, Biliary Type","C96936","A well or moderately differentiated adenocarcinoma that arises from the extrahepatic bile ducts.  It is characterized by the presence of malignant tubular glands.","Extrahepatic Bile Duct Adenocarcinoma, Biliary Type | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334279","Intestinal-Type Adenocarcinoma","C4126","An adenocarcinoma arising from epithelium which has undergone intestinal metaplasia. Representative examples include gastric, gallbladder, and ampulla of Vater intestinal type adenocarcinomas.","Intestinal-Type Adenocarcinoma | Adenocarcinoma, Intestinal Type | Adenocarcinoma, intestinal type | Carcinoma, intestinal type | Intestinal Type Carcinoma | Intestinal-type adenocarcinoma","8144/3","Adenocarcinoma, intestinal type",,,,,,,,,,,,,"4097305","Adenocarcinoma, intestinal type",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C3273052","Bile Duct Intraductal Papillary Neoplasm with an Associated Invasive Carcinoma","C96810","An intraductal papillary neoplasm that arises from the epithelium of the intrahepatic or extrahepatic bile ducts and it is associated with an invasive carcinomatous component.","Bile Duct Intraductal Papillary Neoplasm with an Associated Invasive Carcinoma | Bile Duct IPN with an Associated Invasive Carcinoma | Bile Duct Papillary Adenocarcinoma | Bile Duct Papillary Neoplasm with an Associated Invasive Carcinoma | Bile Duct Papillary Neoplasm with an Associated Invasive Carcinoma | Intraductal Papillary Neoplasm with Associated Invasive Carcinoma | Intraductal Papillary Neoplasm with an Associated Invasive Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882081","Nevoid Melanoma","C54662","A rare variant of cutaneous melanoma occurring mostly in adults in their fifth decade. Morphologically it resembles an ordinary compound or dermal nevus.","Nevoid Melanoma | Nevoid Cutaneous (Skin) Melanoma",,,,,,,,,,,,,,,"37159033|37168635","Nevoid melanoma|Nevoid melanoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1842036","Giant Congenital Melanocytic Nevus","C4234","A congenital melanocytic nevus that measures more than 200 mm or is unresectable. It usually presents as a dark brown to black hairy lesion. Morphologically, it is characterized by the presence of a compound or intradermal nevus. There is an increased risk of malignant transformation to melanoma, rhabdomyosarcoma, and poorly differentiated malignant tumors.","Giant Congenital Melanocytic Nevus | Bathing Trunk Nevus | GCN | Giant Congenital Nevus | Giant Congenital Nevus | Giant Pigmented Nevus of Skin | Giant Pigmented Nevus of the Skin | Giant pigmented nevus, NOS","8761/1","Giant pigmented nevus, NOS",,,,,,,,,,,,,"37162272|37166962|4012099","Giant pigmented nevus of skin|Large congenital pigmented melanocytic nevus of skin|Giant pigmented nevus",,,,,,,,,,,,,"--","--",,,,,,,,"--|--|--"
"CL540281","Brainstem Portion of the Pyramidal Tracts","C142308","The segments of the corticospinal and corticobulbar tracts that either traverse or terminate in the brainstem.","Brainstem Portion of the Pyramidal Tracts | PYRAMIDAL TRACTS, BRAINSTEM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0446495","Periumbilical Region","C139205","The region of the body that surrounds the umbilicus.","Periumbilical Region | PERIUMBILICAL REGION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224287","Opponens Pollicis Muscle","C150853","A muscle that originates on the distal border of the flexor retinaculum and the tubercles of the scaphoid and trapezium, and inserts into the lateral aspect of the first metacarpal; it is involved in the rotation and flexion of the thumb and is supplied by the recurrent branch of the medial nerve and the superficial palmar branch of the radial artery.","Opponens Pollicis Muscle | OPPONENS POLLICIS MUSCLE",,,,,,,,,,,,,,,"4194364","Structure of opponens pollicis muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540275","Scaphoid-Radius Joint","C142315","The articulation of the radius and the scaphoid bone in the wrist.","Scaphoid-Radius Joint | SCAPHOID-RADIUS JOINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224264","Brachioradialis Muscle","C150849","A muscle that originates from the proximal two-thirds of the lateral supracondylar ridge of the humerus and inserts into the styloid process of the radius; it enables flexion of the elbow and assists with pronation and supination of the forearm.","Brachioradialis Muscle | BRACHIORADIALIS MUSCLE",,,,,,,,,,,,,,,"4215940","Structure of brachioradialis muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540287","Hand Digit 2 Middle Phalanx","C142297","A long bone in the second finger, as counted from the thenar side of the hand; it is located between, and articulates with, the proximal and distal phalanges.","Hand Digit 2 Middle Phalanx | MIDDLE PHALANX 2 OF THE HAND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540369","Trapezium-Trapezoid Joint","C142326","The articulation of the trapezium and trapezoid bones in the wrist.","Trapezium-Trapezoid Joint | TRAPEZIUM-TRAPEZOID JOINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540288","L4-L5 Intervertebral Space","C142296","The space between the L4 and L5 vertebrae.","L4-L5 Intervertebral Space | L4-L5 INTERVERTEBRAL SPACE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540278","Rectovaginal Space","C142311","The anatomical space located between the vagina and rectum, extending from the superior border of the perineal body to the underside of the rectouterine Douglas pouch, which has its formal borders noted thusly: anteriorly by the rectovaginal septum; posteriorly by the anterior rectal wall; and laterally by the descending rectal septa that separate the rectovaginal space from the pararectal space on each side. - Abby is this different to C33447?","Rectovaginal Space | RECTOVAGINAL SPACE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898368","Microscopic Findings Method","C117596","The technique used to administer the microscopic assessment.","Microscopic Findings Method | MIMETHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540276","Scaphoid-Lunate Joint","C142314","The articulation of the scaphoid and lunate bones in the wrist.","Scaphoid-Lunate Joint | SCAPHOID-LUNATE JOINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526598","Capitate-Lunate Joint","C139189","The articulation of the capitate and lunate bones in the wrist.","Capitate-Lunate Joint | CAPITATE-LUNATE JOINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540269","Hand Digit 4 Proximal Phalanx","C142306","A long bone in the fourth finger, as counted from the thenar side of the hand; it is located between, and articulates with, the fourth metacarpal and the middle phalanx.","Hand Digit 4 Proximal Phalanx | PROXIMAL PHALANX 4 OF THE HAND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039976","Thoracic Artery","C142325","An artery that branches from the axillary artery or one of its branches, and which supplies the muscles and organs of the thorax.","Thoracic Artery | THORACIC ARTERY",,,,,,,,,,,,,,,"4043008","Artery of thorax",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0229760","Esophageal Lymph Node","C139196","Any lymph node located near the esophagus, including cervical, and upper, middle, and lower thoracic lymph nodes.","Esophageal Lymph Node | ESOPHAGEAL LYMPH NODE",,,,,,,,,,,,,,,"4043359","Structure of esophageal lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224258","Flexor Digitorum Superficialis Muscle","C150850","A muscle that originates in the humeroulnar and radial heads of the forearm and inserts in the middle phalanges of the second through fifth digits of the hand; it is primarily involved in the flexion of the fingers at the proximal interphalangeal joints and is supplied by the median nerve and the ulnar artery.","Flexor Digitorum Superficialis Muscle | FLEXOR DIGITORUM SUPERFICIALIS MUSCLE",,,,,,,,,,,,,,,"4231715","Structure of flexor digitorum superficialis muscle of hand",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526599","Capitate-Hamate Joint","C139188","The articulation of the capitate and hamate bones in the wrist.","Capitate-Hamate Joint | CAPITATE-HAMATE JOINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224263","Pronator Quadratus Muscle","C150854","A muscle that originates on the distal anteriomedial surface of the ulna and inserts in the distal anteriolateral surface of the radius; it is involved in the pronation of the forearm and is supplied by the anterior interosseous nerve and artery.","Pronator Quadratus Muscle | PRONATOR QUADRATUS MUSCLE",,,,,,,,,,,,,,,"4029139","Structure of pronator quadratus muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540270","Hand Digit 3 Proximal Phalanx","C142305","A long bone in the third finger, as counted from the thenar side of the hand; it is located between, and articulates with, the third metacarpal and the middle phalanx.","Hand Digit 3 Proximal Phalanx | PROXIMAL PHALANX 3 OF THE HAND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526597","Hand Digit 2 Distal Phalanx","C139190","The bone that forms the tip of the second finger, as counted from the thenar side of the hand.","Hand Digit 2 Distal Phalanx | DISTAL PHALANX 2 OF THE HAND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0223646","Posterior Superior Iliac Spine","C139206","A bony projection from the posterior region of the iliac crest that lies over the sacroiliac joint and functions as the site of attachment for the thoracolumbar fascia and the posterior sacroiliac and sacrotuberous ligaments.","Posterior Superior Iliac Spine | POSTERIOR SUPERIOR ILIAC SPINE",,,,,,,,,,,,,,,"4029791","Structure of posterior superior iliac spine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0229740","Prelaryngeal Lymph Node","C147454","A lymph node located anterior to the larynx.","Prelaryngeal Lymph Node | PRELARYNGEAL LYMPH NODE",,,,,,,,,,,,,,,"4253663","Structure of prelaryngeal lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540362","Splenic Lymph Node","C142320","Any lymph node located along the splenic artery that receives afferent drainage from the pancreas, spleen, and stomach, and which generally has their efferents join the celiac group of preaortic lymph nodes.","Splenic Lymph Node | Lymph Node(s) Splenic | SPLENIC LYMPH NODE | Splenic lymph nodes | splenic lymph node",,,,,,,,,,,,,"UBERON:0015469","splenic lymph node",,,,,,,,,,,,,,,"--"
"C0446987","Cardiac Wall","C139201","All of the tissue that comprises the solid, outer structure of the heart, including the epicardium, the myocardium, and the endocardium.","Cardiac Wall | CARDIAC WALL",,,,,,,,,,,,,,,"4157865","Cardiac wall structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0222165","Skin of the Buttock","C150855","The skin or integument covering the buttocks.","Skin of the Buttock | SKIN OF THE BUTTOCK",,,,,,,,,,,,,,,"4318817","Skin structure of buttock",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897365","Terminal Deoxynucleotidyl Transferase Antigen Measurement","C117859","The determination of the amount of terminal deoxynucleotidyl transferase antigen present in a sample.","Terminal Deoxynucleotidyl Transferase Antigen Measurement | TDTAG | Terminal Deoxynucleotidyl Transferase Ag | Terminal Deoxynucleotidyl Transferase Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049928","Immunoglobulin G Subclass 1 Measurement","C122127","The determination of the amount of immunoglobulin G subclass 1 present in a sample.","Immunoglobulin G Subclass 1 Measurement | IGG1 | IgG1 Measurement | Immunoglobulin G Subclass 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825845","Oval Fat Body Measurement","C81947","The determination of the amount of oval-shaped fat bodies present in a sample.","Oval Fat Body Measurement | FATBODOV | Fat Bodies, Oval",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0474566","Platelet Hematocrit Measurement","C100424","The determination of the amount of platelet hematocrit present in a sample.","Platelet Hematocrit Measurement | PLATHCT | Platelet Hematocrit | Thrombocytocrit",,,,,,,,,,,,,,,"4097621","Platelet hematocrit measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523565","Cholecystokinin Measurement","C74850","The determination of the amount of cholecystokinin hormone present in a sample.","Cholecystokinin Measurement | CCK | Cholecystokinin | Pancreozymin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550481","Anti-Neutrophil Cytoplasmic Antibody, Atypical","C147300","The determination of the amount of atypical neutrophil cytoplasmic antibody present in a sample.","Atypical Neutrophil Cytoplasmic Antibody Measurement | ANCATYAB | Anti-Neutrophil Cytoplasmic Antibody, Atypical | Atypical ANCA Measurement | Neutrophil Cytoplasmic Ab, Atypical",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523979","Vitamin D3 Measurement","C74905","The determination of the amount of Vitamin D3 present in a sample.","Vitamin D3 Measurement | Calciol | Calciol Measurement | Cholecalciferol | Colecalciferol | Colecalciferol Measurement | VITD3 | Vitamin D | Vitamin D Measurement | Vitamin D3",,,,,,,,,,,,,,,"4020710","Vitamin D3 measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523348","Complement C5a Measurement","C80179","The determination of the amount of complement C5a present in a sample.","Complement C5a Measurement | C5A | Complement C5a",,,,,,,,,,,,,,,"4015469","Complement C5a measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202444","Pentobarbital Measurement","C75367","The determination of the amount of pentobarbital present in a sample.","Pentobarbital Measurement | PNTBRBTL | Pentobarbital",,,,,,,,,,,,,,,"4176873","Pentobarbital measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202345","Butalbital Measurement","C75365","The determination of the amount of butalbital present in a sample.","Butalbital Measurement | BTLBTL | Butalbital",,,,,,,,,,,,,,,"4040993","Butalbital measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512311","Prorubricyte Count","C128976","The determination of the amount of prorubricytes present in a sample.","Prorubricyte Count | Basophilic Erythroblast | Basophilic Normoblast | PRORUB | Prorubricyte",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640663","Lupus Anticoagulant Sensitive APTT Measurement","C102277","The determination of the amount of time that it takes for clotting to occur when a lupus sensitive reagent is added to a plasma specimen.","Lupus Anticoagulant Sensitive APTT Measurement | APTT-LA | APTTLA | APTTLAS | Lupus Anticoagulant Sensitive APTT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825869","Islet Neogenesis Associated Protein Antibody Measurement","C81987","The determination of the amount of islet neogenesis associated protein antibody present in a sample.","Islet Neogenesis Associated Protein Antibody Measurement | INGAPAB | Islet Neogenesis Assoc Protein Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698324","Bacterial Cast Measurement","C74762","The determination of the amount of bacterial casts present in a urine sample.","Bacterial Cast Measurement | Bacterial Casts | CSBACT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266245","Pyridinoline Measurement","C80211","The determination of the amount of pyridinoline present in a sample.","Pyridinoline Measurement | PYRIDNLN | Pyridinoline",,,,,,,,,,,,,,,"4005522","Pyridinoline measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513975","Orchard Grass Pollen IgG Measurement","C130082","A measurement of the orchard grass (Dactylis glomerata) pollen IgG in a biological specimen.","Orchard Grass Pollen IgG Measurement | C130082 | Cocksfoot Grass Pollen IgG | Orchard Grass Pollen IgG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697952","Lymphoma Cell to Lymphocyte Ratio Measurement","C74910","The determination of the ratio of lymphoma cells compared to lymphocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Lymphoma Cell to Lymphocyte Ratio Measurement | LYMMCELY | Lymphoma Cells/Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828564","Physical Exam Method","C113375","A systematic course of action that is performed in order to complete a physical examination.","Physical Exam Method | PEMETHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889969","Transforming Growth Factor Beta 1 Measurement","C117861","The determination of the amount of transforming growth factor Beta 1 present in a sample.","Transforming Growth Factor Beta 1 Measurement | TGFB1 | Transforming Growth Factor Beta 1 | Transforming Growth Factor Beta-1 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523671","Glutathione-S-Transferase Measurement","C80185","The determination of the amount of glutathione-s-transferase present in a sample.","Glutathione-S-Transferase Measurement | GST | Glutathione S-Transferase, Total",,,,,,,,,,,,,,,"4017086","Glutathione S-transferase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540289","YKL-40 Protein Measurement","C142294","The determination of the amount of YKL-40 protein present in a sample.","YKL-40 Protein Measurement | CHI3L1 Protein Measurement | Chitinase-3-Like Protein 1 | YKL-40 Protein | YKL40P",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699477","Crystal Present Or Absent (lab procedure)","C74673","The determination of the presence or absence of crystals in a sample.","Crystal Present Or Absent | CRYSTALS | Crystals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700097","Tyrosine Crystal Measurement","C74683","The determination of the amount of tyrosine crystals present in a sample.","Tyrosine Crystal Measurement | CYTYRO | Tyrosine Crystals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699764","Active Glucagon-like Peptide-1 Measurement","C80164","The determination of the amount of active glucagon-like peptide-1 present in a sample.","Active Glucagon-like Peptide-1 Measurement | GLP1AC | Glucagon-Like Peptide-1, Active Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523792","Nitrite Measurement","C64810","A quantitative measurement of the amount of nitrite present in a sample.","Nitrite Measurement | NITRITE | Nitrite",,,,,,,,,,,,,,,"4017899","Nitrite measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521350","Vascular Endothelial Growth Factor A Measurement","C132389","The determination of the amount of vascular endothelial growth factor A in a biological sample.","Vascular Endothelial Growth Factor A Measurement | VEGFA | VEGFA Measurement | Vascular Endothelial Growth Factor A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523809","Oxytocin Measurement","C74869","The determination of the amount of oxytocin hormone present in a sample.","Oxytocin Measurement | OXYTOCIN | Oxytocin | Oxytoxin",,,,,,,,,,,,,,,"4020555","Oxytocin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523500","Angiotensinogen Measurement","C74846","The determination of the amount of angiotensinogen hormone present in a sample.","Angiotensinogen Measurement | ANGTNSGN | Angiotensin Precursor | Angiotensinogen",,,,,,,,,,,,,,,"4019451","Angiotensinogen measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2699063","Resistin Measurement","C80205","The determination of the amount of resistin present in a sample.","Resistin Measurement | RESISTIN | Resistin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508857","Islet Amyloid Polypeptide Measurement","C127622","The determination of the amount of islet amyloid polypeptide present in a sample.","Islet Amyloid Polypeptide Measurement | Amylin | IAPP | Islet Amyloid Polypeptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825875","Interferon Alpha Measurement","C81994","The determination of the amount of interferon alpha present in a sample.","Interferon Alpha Measurement | IFNA | Interferon Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513974","Orchard Grass Pollen IgE Measurement","C130080","A measurement of the orchard grass (Dactylis glomerata) pollen IgE in a biological specimen.","Orchard Grass Pollen IgE Measurement | C130080 | Cocksfoot Grass Pollen IgE | Orchard Grass Pollen IgE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700229","Galanin measurement","C80182","The determination of the amount of galanin present in a sample.","Galanin Measurement | GALANIN | Galanin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2041383","Thyrotropin Releasing Hormone Measurement","C74874","The determination of the amount of thyrotropin releasing hormone present in a sample.","Thyrotropin Releasing Hormone Measurement | TRH | Thyrotropin Releasing Factor | Thyrotropin Releasing Hormone",,,,,,,,,,,,,,,"4021284","Thyrotropin releasing factor measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825878","Amyloid P Measurement","C81998","The determination of the amount of amyloid P present in a sample.","Amyloid P Measurement | AMYLOIDP | Amyloid P | Amyloid P Component | SAP | Serum Amyloid P Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1829759","Hemolysis","C111208","The determination of the amount of destruction of red blood cells present in a sample.","Hemolytic Index | HEMOLYSI | Hemolysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879934","CDISC SDTM Not Done Terminology","C66789","Terminology codelist used with Not Done within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.","CDISC SDTM Not Done Terminology | ND | Not Done | SDTM-ND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004618","Bacterial Count","C64469","The quantitative determination of bacterial populations. The two most widely used methods for determining bacterial numbers are: 1) the standard, or viable, plate count method and 2) spectrophotometric (turbidimetric) analysis.","Bacterial Count | BACT | Bacteria",,,,,,,,,,,,,,,"4017280","Bacterial count",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698065","Alpha Glucuronidase Measurement","C80165","The determination of the amount of alpha glucuronidase present in a sample.","Alpha Glucuronidase Measurement | GUSA | Glucuronidase, Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272946","Herpes Simplex Virus 2 IgG Antibody Measurement","C96667","The determination of the amount of Herpes Simplex virus 2 IgG antibody present in a sample.","Herpes Simplex Virus 2 IgG Antibody Measurement | HS2IGGAB | HSV-2 IgG Antibody | Herpes Simplex Virus 2 IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524238","Phenobarbital Measurement","C75368","The determination of the amount of phenobarbital present in a sample.","Phenobarbital Measurement | PHNBRBTL | Phenobarbital",,,,,,,,,,,,,,,"4022502","Phenobarbital measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825871","Thyroid Antibody Measurement","C81990","The determination of the amount of thyroid antibodies present in a sample.","Thyroid Antibody Measurement | THYAB | Thyroid Antibodies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1829809","Lipemic Index","C111242","The determination of the amount of abnormally high concentration of lipid present in a sample.","Lipemic Index | LIPEMIAI | Lipemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698200","Auer Rod Measurement","C74657","The determination of the number of Auer rods present in a biospecimen.","Auer Rod Measurement | AUERRODS | Auer Rods",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881895","Monocyte to Leukocyte Ratio","C64824","The determination of the ratio of monocytes compared to leukocytes in a blood sample. The measurement may be expressed as a ratio or percentage.","Monocyte to Leukocyte Ratio | MONOLE | Monocytes/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521648","Ribonucleic Acid Measurement","C132301","The determination of the amount of ribonucleic acids in a biological sample.","Ribonucleic Acid Measurement | RNA | RNA Measurement | Ribonucleic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0518829","Vital Signs Completion Status","C83134","A term used to describe the state or condition of the completeness of the vital signs data.","Vital Signs Completion Status | VSSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273047","Large Duct Intrahepatic Cholangiocarcinoma","C96804","An intrahepatic cholangiocarcinoma that arises from the intrahepatic large bile ducts.","Large Duct Intrahepatic Cholangiocarcinoma | Perihilar Intrahepatic Cholangiocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697536","HDL-Cholesterol Subclass 2 Measurement","C80187","The determination of the amount of HDL-cholesterol subclass 2 present in a sample.","HDL-Cholesterol Subclass 2 Measurement | HDL-Cholesterol Subclass 2 | HDL2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1142562","Vitamin B3 Measurement","C74899","The determination of the amount of Vitamin B3 present in a sample.","Vitamin B3 Measurement | Niacin | VITB3 | Vitamin B3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811745","Mast Cell Count","C111246","The determination of the amount of mast cells present in a sample.","Mast Cell Count | MASTCE | Mast Cells | Mastocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272966","Methylmalonic Acid Measurement","C96690","The determination of the amount of methylmalonic acid present in a sample.","Methylmalonic Acid Measurement | MMA | Methylmalonate | Methylmalonic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL429632","Vitamin B2 Measurement","C74898","The determination of the amount of Vitamin B2 present in a sample.","Vitamin B2 Measurement | Riboflavin | VITB2 | Vitamin B2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700165","Fatty Cast Measurement","C74766","The determination of the amount of fatty casts present in a urine sample.","Fatty Cast Measurement | CSFAT | Fatty Casts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641270","Whole Parathyroid Hormone Measurement","C103451","The determination of the amount of the whole parathyroid hormone (consisting of amino acids 1-84) in a sample.","Whole Parathyroid Hormone Measurement | PTHW | Parathyrin Hormone, Whole | Parathyroid Hormone, Whole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272972","Herpes Simplex Virus 1/2 IgM Antibody Measurement","C96698","The determination of the amount of Herpes Simplex virus 1/2 IgM antibody present in a sample.","Herpes Simplex Virus 1/2 IgM Antibody Measurement | HS12GMAB | HSV-1/2 IgM Ab | Herpes Simplex Virus 1/2 IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524222","Oxycodone Measurement","C74884","The determination of the amount of oxycodone present in a sample.","Oxycodone Measurement | OXYCDN | Oxycodone | Oxycontin",,,,,,,,,,,,,,,"4022499","Oxycodone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202228","Free Testosterone Measurement","C74785","The determination of the amount of free testosterone present in a sample.","Free Testosterone Measurement | Free Testosterone | TESTOSFR | Testosterone, Free",,,,,,,,,,,,,,,"4068735","Testosterone measurement, unbound",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640659","Endogenous Thrombin Potential Time to Peak Measurement","C102269","The determination of the amount of time it takes to generate the maximum concentration of thrombin.","Endogenous Thrombin Potential Time to Peak Measurement | ETP Time to Peak | ETPTP | Endogenous Thrombin Potential Time to Peak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0855592","N-acetyl-beta-D-glucosaminidase Measurement","C103419","The determination of the amount of the N-acetyl-beta-D-glucosaminidase in a sample.","N-acetyl-beta-D-glucosaminidase Measurement | Beta-N-acetyl-D-glucosaminidase | N-acetyl-beta-D-glucosaminidase | NAGASE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028792","Occult Blood Measurement","C74686","A measurement of the blood in body products such as a urine or stool sample, not detectable on gross examination.","Occult Blood Measurement | OCCBLD | Occult Blood",,,,,,,,,,,,,,,"4091292","Occult blood screening",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3541306","Plasmodium Measurement","C100453","The determination of the amount of Plasmodium present in a sample.","Plasmodium Measurement | Malaria | PLSMDM | Plasmodium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202158","Pancreatic Polypeptide Measurement","C80201","The determination of the amount of pancreatic polypeptide present in a sample.","Pancreatic Polypeptide Measurement | PNCTPP | Pancreatic Polypeptide",,,,,,,,,,,,,,,"4204548","Pancreatic polypeptide measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509612","Type I Collagen C-Telopeptide to Creatinine Ratio Measurement","C127613","The determination of the ratio of type I collagen c-telopeptides compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Type I Collagen C-Telopeptide to Creatinine Ratio Measurement | CTXICRT | Type I Collagen C-Telopeptides/Creat | Type I Collagen X-Linked C-Telopeptides/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919773","Haptoglobin Protein Measurement","C74740","The determination of the amount of haptoglobin protein present in a sample.","Haptoglobin Protein Measurement | HAPTOG | Haptoglobin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814776","Budding Yeast Measurement","C106504","Examination of a biological specimen to detect the presence of any yeast cells that are in the budding phase of asexual reproduction.","Budding Yeast Measurement | Budding Yeast | YEASTBUD | Yeast Budding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523909","Taurine Measurement","C122154","The determination of the amount of taurine present in a sample.","Taurine Measurement | TAURINE | Tauric Acid | Taurine",,,,,,,,,,,,,,,"4017348","Taurine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825887","Epithelial Neutrophil-Activating Peptide 78 measurement","C82010","The determination of the amount of epithelial neutrophil-activating peptide 78 present in a sample.","Epithelial Neutrophil-Activating Peptide 78 Measurement | ENA78 | Epith Neutrophil-Activating Peptide 78",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825908","Procollagen Type I Carboxy Terminal Peptide Measurement","C82033","The determination of the amount of procollagen type I carboxy terminal peptide present in a sample.","Procollagen Type I Carboxy Terminal Peptide Measurement | PICP | Procollagen Type I Carboxy Term Peptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337432","Androstenedione Measurement","C74843","The determination of the amount of androstenedione hormone present in a sample.","Androstenedione Measurement | 4-Androstenedione | ANDSTNDN | Androstenedione",,,,,,,,,,,,,,,"4221394","Androstenedione measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2699010","Reactive Lymphocyte to Lymphocyte Ratio Measurement","C74654","The determination of the ratio of reactive lymphocytes compared to all lymphocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Reactive Lymphocyte to Lymphocyte Ratio Measurement | Atypical Lymphocytes/Lymphocytes | LYMATLY | Lymphocytes Atypical/Lymphocytes | Reactive Lymphocytes/Lymphocytes | Variant Lymphocytes/Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698953","Calcium Carbonate Crystal Measurement","C74669","The determination of the amount of calcium carbonate crystals present in a sample.","Calcium Carbonate Crystal Measurement | CYCACAR | Calcium Carbonate Crystals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3715143","Cartilage Oligomeric Matrix Protein Measurement","C111145","The determination of the amount of cartilage oligomeric matrix protein present in a sample.","Cartilage Oligomeric Matrix Protein Measurement | COMP | COMP Measurement | Cartilage Oligomeric Matrix Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521331","Oncostatin M Measurement","C132377","The determination of the amount of oncostatin M in a biological sample.","Oncostatin M Measurement | OSM | OSM Measurement | Oncostatin M",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503120","Intercellular Adhesion Molecule Measurement","C124344","The determination of the amount of intercellular adhesion molecule present in a sample.","Intercellular Adhesion Molecule Measurement | ICAM | ICAM Measurement | Intercellular Adhesion Molecule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698572","Burr Cell Count (procedure)","C74701","The determination of the number of Burr cells present in a sample.","Burr Cell Count | BURRCE | Burr Cells | Echinocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984956","Smith Antibody Measurement","C92281","The determination of the amount of Smith antibody present in a sample.","Smith Antibody Measurement | SMTHAB | Smith Antibody | Smith Extractable Nuclear Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698886","Prolymphocyte to Lymphocyte Ratio Measurement","C74651","The determination of the ratio of prolymphocytes compared to all lymphocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Prolymphocyte to Lymphocyte Ratio Measurement | PROLYMLY | Prolymphocytes/Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826716","Laboratory Test Original Result Unit","C83106","The unit of measure for the original laboratory test result.","Laboratory Test Original Result Unit | LAB_RESULT_UNIT | LBORRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699300","Sickle Cell Count","C74626","The determination of the number of sickle cells present in a sample.","Sickle Cell Count | Drepanocytes | SCKLCE | Sickle Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697526","Growth Hormone Inhibiting Hormone Measurement","C74861","The determination of the amount of growth hormone inhibiting hormone present in a sample.","Growth Hormone Inhibiting Hormone Measurement | GRWHIH | Growth Hormone Inhibiting Hormone | Somatostatin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526584","Reticulocyte Corpuscular Hemoglobin Distribution Width","C139069","A measurement of the standard deviation of hemoglobin concentrations in reticulocytes, calculated as the standard deviation of hemoglobin content divided by the mean hemoglobin content.","Reticulocyte Corpuscular Hemoglobin Distribution Width | CHDWR | Ret Corpuscular HGB Conc Distr Width",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049833","Centromere IgG Antibody Measurement","C122111","The determination of the amount of centromere IgG antibody present in a biological specimen.","Centromere IgG Antibody Measurement | CNTIGGAB | Centromere IgG Antibody | Centromere Protein B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523817","Pepsinogen II Measurement","C100468","The determination of the amount of pepsinogen II present in a sample.","Pepsinogen II Measurement | PEPSNGII | PGII | Pepsinogen II",,,,,,,,,,,,,,,"4020557","Pepsinogen II measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897556","Soluble Tumor Necrosis Factor Receptor Measurement","C117749","The determination of the amount of soluble tumor necrosis factor receptor present in a sample.","Soluble Tumor Necrosis Factor Receptor Measurement | Soluble Tumor Necrosis Factor Receptor | TNFR Measurement | TNFSR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545312","Thrombin Activity Actual to Control Ratio Measurement","C147437","The determination of the ratio of the biological activity of thrombin dependent coagulation in a subject's specimen when compared to the same activity in a control specimen. The measurement may be expressed as a ratio or percentage.","Thrombin Activity Actual to Control Ratio Measurement | THMBAAC | Thrombin Activity Actual/Control | Thrombin Activity Actual/Normal | Thrombin Activity Actual/Thrombin Activity Control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272971","Herpes Simplex Virus 1/2 IgG Antibody Measurement","C96697","The determination of the amount of Herpes Simplex virus 1/2 IgG antibody present in a sample.","Herpes Simplex Virus 1/2 IgG Antibody Measurement | HS12GGAB | HSV-1/2 IgG Ab | Herpes Simplex Virus 1/2 IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640658","Endogenous Thrombin Potential Peak Height Relative Measurement","C102268","A relative (ratio or percentage) of the maximum concentration of thrombin generated during a thrombin generation test.","Endogenous Thrombin Potential Peak Height Relative Measurement | ETP Peak Height Relative | ETPPHR | Endogenous Thrombin Potential Peak Height Relative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825897","Inhibin A Measurement","C82020","The determination of the amount of inhibin A present in a sample.","Inhibin A Measurement | INHIBINA | Inhibin A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1295163","Insulin-Like Growth Factor Binding Protein 2 Measurement","C128969","The determination of the amount of insulin-like growth factor binding protein 2 present in a sample.","Insulin-Like Growth Factor Binding Protein 2 Measurement | IGFBP2 | IGFBP2 Measurement | Insulin-Like Growth Factor Binding Prot2 | Insulin-Like Growth Factor Binding Protein 2",,,,,,,,,,,,,,,"4005183","Insulin-like growth factor binding protein 2 measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3827822","Tissue Inhibitor of Metalloproteinase 1 to Creatinine Ratio Measurement","C106575","The determination of the ratio of tissue inhibitor of metalloproteinase 1 compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Tissue Inhibitor of Metalloproteinase 1 to Creatinine Ratio Measurement | TIMP1/Creatinine | TIMP1CRE | Tissue Inhibitor of Metalloproteinase 1/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0373691","Osteocalcin Measurement","C74744","The determination of the amount of osteocalcin present in a sample.","Osteocalcin Measurement | OSTEOC | Osteocalcin",,,,,,,,,,,,,,,"4020552","Osteocalcin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825886","Endothelin-1 measurement","C82008","The determination of the amount of endothelin-1 present in a sample.","Endothelin-1 Measurement | ENDOTH1 | Endothelin-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054049","Scl-70 IgG Antibody Measurement","C122148","The determination of the amount of Scl-70 IgG antibody in a biological specimen.","Scl-70 IgG Antibody Measurement | SCL70GAB | Scl-70 IgG Antibody | Scleroderma-70 IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826639","Demographics Date of Collection","C83026","The date on which the subject demographics are taken.","Demographics Date of Collection | DMDAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897555","Soluble Tumor Necrosis Factor Receptor Type I Measurement","C117863","The determination of the amount of soluble TNF receptor type I present in a sample.","Soluble Tumor Necrosis Factor Receptor Type I Measurement | Soluble TNF Receptor Type I | TNFSR1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697854","LDH Isoenzyme 3 to LDH Ratio Measurement","C79453","The determination of the ratio of LDH isoenzyme 3 compared to total LDH present in a sample. The measurement may be expressed as a ratio or percentage.","LDH Isoenzyme 3 to LDH Ratio Measurement | LDH Isoenzyme 3/LDH | LDH3LDH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641617","CD8 Cell to Lymphocyte Ratio Measurement","C103816","The determination of the ratio of CD8 cells compared to lymphocytes present in a sample. The measurement may be expressed as a ratio or percentage.","CD8 Cell to Lymphocyte Ratio Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538779","Leukotriene D4 Measurement","C103414","The determination of the amount of the leukotriene D4 in a sample.","Leukotriene D4 Measurement | LTD4 | Leukotriene D4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512375","Procollagen 3 N-Terminal Propeptide Measurement","C128973","The determination of the amount of procollagen 3 N-terminal propeptide present in a sample.","Procollagen 3 N-Terminal Propeptide Measurement | P3NP | P3NP Measurement | Procollagen 3 N-Terminal Propeptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540310","Streptococcus pneumoniae Serotype 5 IgG Antibody Measurement","C142253","The determination of the amount of Streptococcus pneumoniae serotype 5 IgG antibody present in a sample.","Streptococcus pneumoniae Serotype 5 IgG Antibody Measurement | C142253 | S. pneumonia Sero 5 IgG AB | S. pneumoniae Sero 5 IgG AB | Streptococcus pneumoniae Serotype 5 IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697760","Interleukin 12 Measurement","C74808","The determination of the amount of interleukin 12 present in a sample.","Interleukin 12 Measurement | INTLK12 | Interleukin 12 | Interleukin 12 p70",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0200396","Prothrombin Measurement","C96626","The determination of the amount of prothrombin present in a sample.","Prothrombin Measurement | FACTII | Factor II | Prothrombin",,,,,,,,,,,,,,,"4173906","Clotting factor II assay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2097230","Cyclic Guanosine Monophosphate Measurement","C111165","The determination of the amount of cyclic guanosine 3,5-monophosphate present in a sample.","Cyclic Guanosine Monophosphate Measurement | CGMP | Cyclic Guanosine Monophosphate | cGMP Measurement",,,,,,,,,,,,,,,"4017060","Cyclic guanosine monophosphate measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523387","Myelin Antibodies Measurement","C103418","The determination of the amount of the myelin antibodies in a sample.","Myelin Antibodies Measurement | MYELINAB | Myelin Antibodies",,,,,,,,,,,,,,,"4018609","Antibody to myelin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641254","Influenza B IgG Antibody Measurement","C103409","The determination of the amount of the Influenza B IgG antibody in a sample.","Influenza B IgG Antibody Measurement | IBIGGAB | Influenza B IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438177","Alpha Tocopherol Measurement","C103349","The determination of the amount of the alpha tocopherol in a sample.","Alpha Tocopherol Measurement | ALTCPHRL | Alpha Tocopherol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827898","Sulfur Dioxide Measurement","C114224","The determination of the amount of sulfur dioxide present in a sample.","Sulfur Dioxide Measurement | SO2 | Sulfur Dioxide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890370","Microfilaria Measurement","C117843","The determination of the amount of microfilaria present in a sample.","Microfilaria Measurement | MFILARIA | Microfilaria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641253","Influenza A IgG Antibody Measurement","C103408","The determination of the amount of the Influenza A IgG antibody in a sample.","Influenza A IgG Antibody Measurement | IAIGGAB | Influenza A IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266240","Prostaglandin Measurement","C103343","The determination of the amount of the total prostaglandin in a sample.","Prostaglandin Measurement | PG | Prostaglandin",,,,,,,,,,,,,,,"4007671","Prostaglandin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1979695","Eosinophil Band Form Count","C114216","The determination of the number of band eosinophils in a blood sample.","Eosinophil Band Form Count | EOSB | Eosinophils Band Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641229","Calcium and Phosphorus Product Measurement","C103360","The determination of the amount of the product of the calcium and phosphate measurements in a sample.","Calcium and Phosphorus Product Measurement | CAPHOSPD | Calcium - Phosphorus Product",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540438","Data Message","C142486","The atomic unit of data transferred between systems. It comprises a group of segments in a defined sequence, each message has a message type that defines its purpose. (HL7)","Data Message | message (HL7)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273157","Direct Mail","C96978","Direct Mail (CDM/CLT/PLT)","Direct Mail | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897016","Procedure Portion or Totality","C117528","A qualifier for the arrangement or apportioning of an entity within a body part, region or organ for the procedure.","Procedure Portion or Totality | PRPORTOT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508886","Left Ventricular Apical Septal Segment","C127654","The septal portion of the apical division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).","Left Ventricular Apical Septal Segment | LEFT VENTRICULAR APICAL SEPTAL SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826739","Substance Usage Start Date","C83129","The date on which the substance usage begins.","Substance Usage Start Date | SUSTDAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826748","Substance Use End Date","C83140","The stop date of the substance usage.","Substance Use End Date | SUENDAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826736","Protocol Deviation Start Date","C83126","The date on which the protocol deviation begins.","Protocol Deviation Start Date | DVSTDAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826745","Protocol Deviation End Date","C83137","The stop date of the protocol deviation.","Protocol Deviation End Date | DVENDAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826642","Medical History Completion Date","C83029","The date on which the recording of the patient medical history was finished.","Medical History Completion Date | MHDAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826738","Medical History Start Date","C83128","The date on which the medical history event begins.","Medical History Start Date | MHSTDAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826747","Medical History End Date","C83139","The stop date of the medical history item.","Medical History End Date | MHENDAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1320303","Visit Date","C83031","The date on which a visit occurred.","Visit Date | VISDAT | visit date | visit_date",,,,,,,,,,,,,,,"4231970","Date of visit",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698619","CDISC CDASH Vital Signs Position of Subject Terminology","C78431","A terminology subset of the CDISC Study Data Tabulation Model (SDTM) Position codelist created for Clinical Data Acquisition Standards Harmonization (CDASH) Vital Signs Position of Subject terminology.","CDISC CDASH Vital Signs Position of Subject Terminology | CDASH-VSPOS | VSPOS | Vital Signs Position of Subject",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826640","Electrocardiogram Date","C83027","The date on which the electrocardiogram assessment was taken.","Electrocardiogram Date | EGDAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2199618","Ecarin Clotting Time Measurement","C100422","The determination of the activity of thrombin inhibitors in a biological specimen based on the generation of meizothrombin.","Ecarin Clotting Time Measurement | ECT | Ecarin Clotting Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0430087","Tricyclic Antidepressant Measurement","C100420","The determination of the amount of tricyclic antidepressants present in a sample.","Tricyclic Antidepressant Measurement | TRCYANDP | Tricyclic Antidepressants",,,,,,,,,,,,,,,"4260399","Tricyclic antidepressant measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3538913","Ringed Sideroblast Measurement","C100419","The determination of the amount of ringed sideroblasts present in a sample.","Ring Sideroblast Measurement | BLSTRSID | Ringed Sideroblasts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538861","Sideroblast Measurement","C100418","The determination of the amount of sideroblasts present in a sample.","Sideroblast Measurement | BLSTSID | Sideroblast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0391945","Pepsinogen Measurement","C100122","The determination of the amount of pepsinogen present in a sample.","Pepsinogen Measurement | PEPSNG | Pepsinogen",,,,,,,,,,,,,,,"4021127","Pepsinogen measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2826643","Physical Examination Date","C83030","The date that the physical examination occurred on.","Physical Examination Date | PEDAT | date of examination | date_of_examination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986139","Performed Observation Result Reported Date","C93941","The date (and time) on which the result is reported.","Performed Observation Result Reported Date | PerformedObservationResult.reportedDate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639402","HDL Cholesterol to LDL Cholesterol Ratio Measurement","C100425","The determination of the ratio of HDL cholesterol compared to LDL cholesterol present in a sample. The measurement may be expressed as a ratio or percentage.","HDL Cholesterol to LDL Cholesterol Ratio Measurement | HDL Cholesterol/LDL Cholesterol | HDLCLDLC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919678","Protein S Measurement","C100436","The determination of the amount of protein S present in a sample.","Protein S Measurement | PROTS | Protein S",,,,,,,,,,,,,,,"4070937","Protein S assay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0552299","Non-Prostatic Acid Phosphatase Measurement","C100434","The determination of the amount of non-prostatic acid phosphatase present in a sample.","Non-Prostatic Acid Phosphatase Measurement | NPAP | Non-Prostatic Acid Phosphatase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523481","Alpha-1 Acid Glycoprotein Measurement","C100429","The determination of the amount of alpha-1 acid glycoprotein present in a sample.","Alpha-1 Acid Glycoprotein Measurement | A1AGLP | Alpha-1 Acid Glycoprotein",,,,,,,,,,,,,,,"4014894","Alpha-1-acid glycoprotein measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2826644","Vital Signs Date","C83032","The date on which a vital signs assessment is carried out.","Vital Signs Date | Date of Vital Signs | VSDAT | date of vital signs | date_of_vital_signs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL407200","Birth Time","C81296","The hour, minute, and/or second at which birth occurs.","Birth Time | BRTHTIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826742","Protocol Deviation Start Time","C83132","The time at which the protocol deviation begins.","Protocol Deviation Start Time | DVSTTIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0442681","Correctional Institution","C85862","An institution where persons are confined for punishment and to protect the public.","Correctional Institution | Correctional Facility | Correctional Institute | Jail | PRISON | Penal Institution | Penitentiary | Prison",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826660","Protocol Deviation End Time","C83048","The stop time of the protocol deviation.","Protocol Deviation End Time | DVENTIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826761","Physical Examination Time","C83153","The time that the physical examination took place.","Physical Examination Time | PETIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826762","Vital Signs Time","C83155","The time at which a vital signs assessment is carried out.","Vital Signs Time | VSTIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641115","CDISC Domain","C103182","A collection of data variables or metadata for use with a Clinical Data Interchange Standards Consortium (CDISC) data submission. Representative examples include Laboratory (LB), Subject Characteristics (SC), and Trial Summary (TS).","CDISC Domain | Clinical Data Interchange Standards Consortium Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826724","Vital Signs Position","C83114","The physical bearing of the body during a vital signs assessment.","Vital Signs Position | VSPOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899202","Exposure as Collected Route of Administration","C117486","The means of entry through which the exposure is taken into the body.","Exposure as Collected Route of Administration | ECROUTE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898359","Microscopic Findings Specimen Condition","C117592","A characteristic that refers to the physical and organoleptic state of a biospecimen used for a microscopic assessment.","Microscopic Findings Specimen Condition | MISPCCND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347028","Biospecimen Condition","C70714","A characteristic that refers to the physical and organoleptic state of a biospecimen.","Biospecimen Condition | SPCCND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698632","CDISC SDTM Specimen Type Terminology","C78734","Terminology associated with the specimen type codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Specimen Type Terminology | SDTM-SPECTYPE | SPECTYPE | Specimen Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552741","Abscess Fluid","C150890","The fluid that is abnormally collected in localized areas of damaged tissue within the body, usually composed of living and dead white blood cells, bacteria, and dead tissue.","Abscess Fluid | ABSCESS FLUID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898358","Microscopic Findings Specimen Type","C117591","The type of a material sample taken from a biological entity for microscopic testing.","Microscopic Findings Specimen Type | MISPEC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981550","Pharmacokinetic Concentration Specimen Type","C87967","The type of a material sample taken from a biological entity for pharmacokinetic concentration testing.","Pharmacokinetic Concentration Specimen Type | PCSPEC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826875","CDISC SDTM Skin Response Test Name Terminology","C112023","Terminology associated with the skin response test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Skin Response Test Name Terminology | SDTM-SRTEST | SRTEST | Skin Response Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831566","Allergen Skin Response Index","C112221","The ratio measurement of the allergen wheal size to the positive control wheal size in an allergen skin test.","Allergen Skin Response Index | ASRINDEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509344","CDISC SDTM Collected Race Terminology","C128689","Terminology associated with the race collected codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Collected Race Terminology | RACEC | Race As Collected | SDTM-RACEC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274479","Megakaryocyte to Total Cell Ratio Measurement","C98867","The determination of the ratio of megakaryocytes compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Megakaryocyte to Total Cell Ratio Measurement | KRCYMGCE | Megakaryocytes to Total Cells Ratio Measurement | Megakaryocytes/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274480","Myelocyte to Total Cell Ratio Measurement","C98868","The determination of the ratio of myelocytes compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Myelocyte to Total Cell Ratio Measurement | MYCYCE | Myelocytes to Total Cells Ratio Measurement | Myelocytes/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274481","PLSMCECE","C98869","The determination of the ratio of mature plasma cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Mature Plasma Cell to Total Cell Ratio Measurement | Mature Plasma Cells to Total Cells Ratio Measurement | Mature Plasma Cells/Total Cells | PLSMCECE | PLSTCECE | Plasma Cell to Total Cell Ratio Measurement | Total Plasma Cells/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826311","Treatment Vehicle Amount Unit","C82583","The unit of measure for a treatment vehicle.","Treatment Vehicle Amount Unit | VAMTU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897846","Procedure Dose Units","C117520","The unit of measure for the dosage form of the procedure.","Procedure Dose Units | PRDOSU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826313","Interruption Duration Unit","C82585","The unit of measure for the duration of an interruption in treatment.","Interruption Duration Unit | INTRPU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826769","Substance Use Duration Units","C83162","The unit of measure for the period of time over which substance usage occurs.","Substance Use Duration Units | SUCDURU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826312","Use Duration Unit","C82584","The unit of measure for the duration of substance usage.","Use Duration Unit | CDURU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898366","Microscopic Findings Original Result Unit","C117583","The unit of measure for the result of the microscopic test or finding as originally received or collected.","Microscopic Findings Original Result Unit | MIORRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897708","Reproductive System Findings Original Result Unit","C117645","The unit of measure for the result of the reproductive system findings test or finding as originally received or collected.","Reproductive System Findings Original Result Unit | RPORRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274417","Megakaryoblast to Total Cell Ratio Measurement","C98753","The determination of the ratio of megakaryoblasts compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Megakaryoblast to Total Cell Ratio Measurement | BLSTMKCE | Megakaryoblasts to Total Cells Ratio Measurement | Megakaryoblasts/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274418","Metamyelocyte to Total Cell Ratio Measurement","C98754","The determination of the ratio of metamyelocytes compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Metamyelocyte to Total Cell Ratio Measurement | METAMYCE | Metamyelocytes to Total Cells Ratio Measurement | Metamyelocytes/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274424","Myeloblast to Total Cell Ratio Measurement","C98761","The determination of the ratio of myeloblasts compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Myeloblast to Total Cell Ratio Measurement | BLSTMBCE | Myeloblasts to Total Cells Ratio Measurement | Myeloblasts/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274434","Promyelocyte to Total Cell Ratio Measurement","C98773","The determination of the ratio of promyelocytes compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Promyelocyte to Total Cell Ratio Measurement | PROMYCE | Promyelocytes to Total Cells Ratio Measurement | Promyelocytes/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830106","Flare Size","C112283","The size of the area of redness that forms around the site of an antigenic challenge to the skin.","Antigenic Skin Flare Size | FLARESZ | Flare Size | Flare Size",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897586","Skin Response Original Result Unit","C117680","The unit of measure for the result of the skin response test or finding as originally received or collected.","Skin Response Original Result Unit | SRORRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830108","Flare Longest Diameter","C112281","The longest diameter of the area of redness that forms around the site of an antigenic challenge to the skin.","Antigenic Skin Flare Longest Diameter | FLRLDIAM | Flare Longest Diameter | Flare Longest Diameter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830107","Flare Mean Diameter","C112282","The mean diameter of the area of redness that forms around the site of an antigenic challenge to the skin.","Antigenic Skin Flare Mean Diameter | FLRMDIAM | Flare Mean Diameter | Flare Mean Diameter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274408","Human Anti-Sheep IgG Antibody Measurement","C98741","The determination of the amount of human anti-sheep IgG antibody present in a sample.","Human Anti-Sheep IgG Antibody Measurement | HASIGGAB | Human Anti-Sheep IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274409","Human Anti-Sheep IgM Antibody Measurement","C98742","The determination of the amount of human anti-sheep IgM antibody present in a sample.","Human Anti-Sheep IgM Antibody Measurement | HASIGMAB | Human Anti-Sheep IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0577612","Immunoglobulin D Measurement","C98745","The determination of the amount of immunoglobulin D present in a sample.","Immunoglobulin D Measurement | IGD | Immunoglobulin D",,,,,,,,,,,,,,,"4286509","Immunoglobulin D measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3274413","Iothalamate Clearance","C98749","The rate at which iothalamate is removed or cleared from the whole or part of the body.","Iothalamate Clearance | IOTCLR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054730","Induration Longest Diameter","C122196","The longest diameter of an area of hardness in the skin.","Induration Longest Diameter | IDRLDIAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827475","Wheal Size","C112429","The size of the flat, circular, slightly raised area that forms around the site of an antigenic challenge to the skin.","Wheal Size | WHEALSZ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827477","Wheal Longest Diameter","C112427","The longest diameter of the flat, circular, slightly raised area that forms around the site of an antigenic challenge to the skin.","Wheal Longest Diameter | WHLLDIAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827476","Wheal Mean Diameter","C112428","The mean diameter of the flat, circular, slightly raised area that forms around the site of an antigenic challenge to the skin.","Wheal Mean Diameter | WHLMDIAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826768","Vital Signs Original Result Unit","C83161","The unit of measure for the original vital signs test result.","Vital Signs Original Result Unit | VITALS_RESULT_UNIT | VSORRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274395","Fat Droplet Measurement","C98728","The determination of the amount of triglyceride aggregates present in a sample.","Fat Droplet Measurement | FATDROP | Fat Droplet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274401","Glomerular Filtration Rate Adjusted for BSA","C98734","The determination of the glomerular filtration rate whose result is adjusted for body surface area.","Glomerular Filtration Rate Adjusted for BSA | GFRBSA | Glomerular Filtration Rate Adj for BSA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274402","Glomerular Filtration Rate from Creatinine Adjusted for BSA","C98735","The determination of the glomerular filtration rate by measurement of creatinine clearance and whose result is adjusted for body surface area.","Glomerular Filtration Rate from Creatinine Adjusted for BSA | GFR from Creatinine Adjusted for BSA | GFRBSCRT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274403","Glomerular Filtration Rate from Cystatin C Adjusted for BSA","C98736","The determination of the glomerular filtration rate by measurement of cystatin c clearance and whose result is adjusted for body surface area.","Glomerular Filtration Rate from Cystatin C Adjusted for BSA | GFR from Cystatin C Adjusted for BSA | GFRBSCYC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830116","Findings About Events or Interventions Original Result Unit","C113365","The unit of measure for the original findings about events or interventions result.","Findings About Events or Interventions Original Result Unit | FAORRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272963","Mean Platelet Component Measurement","C96686","The determination of the amount of mean platelet component present in a sample.","Mean Platelet Component Measurement | MPC | Mean Platelet Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272954","Immature Monocyte Count","C96676","The determination of the amount of immature monocytes present in a sample.","Immature Monocyte Count | Immature Monocytes | MONOIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272956","Immature Neutrophil Count","C96678","The determination of the amount of immature neutrophils present in a sample.","Immature Neutrophil Count | Immature Neutrophils | NEUTIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272957","Immature Plasma Cell Count","C96679","The determination of the amount of immature plasma cells present in a sample.","Immature Plasma Cell Count | Immature Plasma Cells | PLSIMCE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272949","Immature Basophil to Leukocyte Ratio Measurement","C96671","The determination of the ratio of immature basophils compared to total leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Immature Basophil to Leukocyte Ratio Measurement | BASOIMLE | Immature Basophils/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272951","Immature Eosinophil Count","C96673","The determination of the amount of immature eosinophils present in a sample.","Immature Eosinophil Count | EOSIM | Immature Eosinophils",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272952","Immature Eosinophil to Leukocyte Ratio Measurement","C96674","The determination of the ratio of immature eosinophils compared to total leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Immature Eosinophil to Leukocyte Ratio Measurement | EOSIMLE | Immature Eosinophils/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337894","Bhutanese","C43673","Denotes the inhabitants of Bhutan, a person from there, or their descendants elsewhere.","Bhutanese | BHUTANESE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553337","Barbadian","C43823","Denotes the inhabitants of Barbados, a person from there, or their descendants elsewhere.","Barbadian | BARBADIAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553336","Bahamian","C67271","Denotes the inhabitants of the Bahamas, a person from there, or their descendants elsewhere.","Bahamian | BAHAMIAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282540","Arab","C43876","Denotes a person with ethnic origins in the Semitic people originally from the Arabian peninsula and surrounding territories in the Middle East and northern Africa.","Arab | ARAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553328","Iwo Jiman","C43718","Denotes the inhabitants of Iwo Jima, a person from there, or their descendants elsewhere.","Iwo Jiman | IWO JIMAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551795","Inupiat Eskimos","C44268","A person having origins in the original Inupiat Eskimo people.","Inupiat Eskimo | INUPIAT INUIT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337900","Indonesian","C43715","Denotes the inhabitants of Indonesia, a person from there, or their descendants elsewhere.","Indonesian | INDONESIAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0239806","Haitian","C43825","Denotes the inhabitants of Haiti, a person from there, or their descendants elsewhere.","Haitian | HAITIAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551794","Greenland Eskimo","C44265","A person having origins in the original Greenland Eskimo people.","Greenland Eskimo | GREENLAND INUIT | Greenland Inuit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0239304","Ethiopian","C43831","Denotes the inhabitants of Ethiopia, a person from there, or their descendants elsewhere.","Ethiopian | ETHIOPIAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553322","Burmese","C43674","Denotes the inhabitants of Myanmar (formerly Burma), a person from there, or their descendants elsewhere.","Burmese | BURMESE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553333","Botswanan","C43830","Denotes the inhabitants of Botswana, a person from there, or their descendants elsewhere.","Botswanan | BOTSWANAN | Motswana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512098","Black South American","C128992","Denotes a person of African ancestral origins whose family settled in South America.","Black South American | BLACK SOUTH AMERICAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512097","Black Central American","C128991","Denotes a person of African ancestral origins whose family settled in Central America.","Black Central American | BLACK CENTRAL AMERICAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553331","Singaporean","C43721","Denotes the inhabitants of Singapore, a person from there, or their descendants elsewhere.","Singaporean | SINGAPOREAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551841","Siberian Eskimo","C44269","A person having origins in the original Siberian Eskimo people.","Siberian Eskimo | SIBERIAN ESKIMO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337816","Russian","C43860","Denotes the inhabitants of Russia, a person from there, or their descendants elsewhere.","Russian | RUSSIAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553326","Okinawan","C43717","Denotes the inhabitants of the japanese island of Okinawa, a person from there, or their descendants elsewhere.","Okinawan | OKINAWAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556089","Nigerian","C43834","Denotes the inhabitants of Nigeria, a person from there, or their descendants elsewhere.","Nigerian | NIGERIAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553330","Nepalese","C43720","Denotes the inhabitants of Nepal, a person from there, or their descendants elsewhere.","Nepalese | NEPALESE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553334","Namibian","C43833","Denotes the inhabitants of Namibia, a person from there, or their descendants elsewhere.","Namibian | NAMIBIAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709065","Mongolian (race)","C43864","Denotes the inhabitants of Mongolia, a person from there, or their descendants elsewhere.","Mongolian | MONGOLIAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553329","Maldivian","C43719","Denotes the inhabitants of the Maldives, a person from there, or their descendants elsewhere.","Maldivian | MALDIVIAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0240293","Malaysian","C43716","Denotes the inhabitants of Malaysia, a person from there, or their descendants elsewhere.","Malaysian | MALAYSIAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553332","Madagascar","C43722","Denotes the inhabitants of Madagascar, a person from there, or their descendants elsewhere.","Malagasy | MALAGASY | Madagascar",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556088","Liberian","C43832","Denotes the inhabitants of Liberia, a person from there, or their descendants elsewhere.","Liberian | LIBERIAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0240072","Jamaican","C43826","Denotes the inhabitants of Jamaica, a person from there, or their descendants elsewhere.","Jamaican | JAMAICAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553335","Zairean","C43835","Denotes the inhabitants of the Democratic Republic of the Congo (formerly Zaire), a person from there, or their descendants elsewhere.","Zairean | ZAIREAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551845","Yupik Eskimo","C44270","A person having origins in the original Yupik Eskimo people.","Yupik Eskimo | YUPIK ESKIMO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512247","White South American","C128994","A person having origins in the any of the countries of South America who identifies as white.","White South American | WHITE SOUTH AMERICAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512246","White Central American","C128993","A person having origins in the any of the countries of Central America who identifies as white.","White Central American | WHITE CENTRAL AMERICAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0425373","West Indian","C43829","Denotes the inhabitants of the West Indies, a person from there, or their descendants elsewhere.","West Indian | WEST INDIAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553340","Trinidadian","C43828","Denotes the inhabitants of Trinidad, a person from there, or their descendants elsewhere.","Trinidadian | TRINIDADIAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553339","Tobagoan","C43827","Denotes the inhabitants of Tobago, a person from there, or their descendants elsewhere.","Tobagoan | TOBAGOAN | Tabagonian",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556096","Taiwanese","C43675","Denotes the inhabitants of Taiwan, a person from there, or their descendants elsewhere.","Taiwanese | TAIWANESE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553327","Sri Lankan","C43672","Denotes the inhabitants of Sri Lanka, a person from there, or their descendants elsewhere.","Sri Lankan | SRI LANKAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826704","Visit Name","C83093","The literal identifier of a visit.","Visit Name | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272939","Hemosiderin Measurement","C96659","The determination of the amount of hemosiderin present in a sample.","Hemosiderin Measurement | HMOSIDRN | Hemosiderin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049590","Hepatitis B Virus Core IgM Antibody Measurement","C96661","The determination of the amount of Hepatitis B virus core IgM antibody present in a sample.","Hepatitis B Virus Core IgM Antibody Measurement | HBCIGMAB | Hepatitis B Virus Core IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523692","Hexokinase Measurement","C96668","The determination of the amount of hexokinase present in a sample.","Hexokinase Measurement | HEXK | Hexokinase",,,,,,,,,,,,,,,"4018328","Hexokinase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521175","Capillary Plasma","C132461","Plasma that has been isolated from capillary blood.","Capillary Plasma | CAPILLARY PLASMA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229666","Capillary Blood","C112235","A mixture of arterial blood, venous blood and interstitial fluid, which is found in the capillaries.","Capillary Blood | CAPILLARY BLOOD",,,,,,,,,,,,,,,"4135328","Capillary blood",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2936350","Atherosclerotic Plaque","C78739","Fatty tissue which is deposited in the inner lining of the arterial wall.","Atherosclerotic Plaque | ATHEROSCLEROTIC PLAQUE | Atherosclerotic plaque",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055440","Arterial Cord Blood","C120838","Blood present in the umbilical arteries at the time of delivery.","Arterial Cord Blood | ARTERIAL CORD BLOOD",,,,,,,,,,,,,,,"37157241","Arterial cord blood",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0225389","Alveolar Air","C150891","The gas located in the alveolus of the lungs, which takes part in gas exchange with the blood in the pulmonary capillaries.","Alveolar Air | ALVEOLAR AIR",,,,,,,,,,,,,,,"4218774","Alveolar air",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0225387","Expired Air","C78741","The air that moves out of the chest during expiration. It contains a higher percentage of carbon dioxide and a lower percentage of oxygen compared to the inhaled air.","Expired Air | EXPIRED AIR | Exhaled Air | Exhaled Breath | Expired Breath",,,,,,,,,,,,,,,"4275732","Exhaled air",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1629517","Exhaled Breath Condensate","C126053","Expired air that has been condensed.","Exhaled Breath Condensate | EXHALED BREATH CONDENSATE",,,,,,,,,,,,,,,"4302057","Exhaled breath condensate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042965","Vomitus","C77666","Gastrointestinal contents that have returned to the mouth or are ejected beyond the mouth.","Vomitus | EMESIS | Emesis | VOMITUS | Vomit",,,,,,,,,,,,,,,"4057954","Vomitus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0600083","Discharge specimen","C142366","Normal or abnormal secretions expelled from a body location.","Discharge Body Fluid | DISCHARGE | Discharge | Discharge Fluid",,,,,,,,,,,,,,,"4124256","Discharge specimen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011646","Dermis","C12701","The lower layer of the skin containing connective tissue, blood vessels, oil and sweat glands, nerves, hair follicles and other structures.","Dermis | Corium | Cutis | DERMAL TISSUE | dermis | vertebrate dermis",,,,,,,,,,,,,"UBERON:0002067","dermis","4202346","Dermis structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897249","Umbilical Cord Serum","C119550","The clear portion of the blood that remains after the removal of the blood cells and the clotting proteins from umbilical cord blood.","Umbilical Cord Serum | CORD SERUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552742","Cervicovaginal Secretion","C150892","The watery fluid, consisting of vulvar gland, endometrium, and oviduct secretions, cervical mucus, vaginal wall plasma transudate, exfoliated cells, and bacterial and immune cell products, that hydrates and forms an antimicrobial barrier for the mucosa of the lower female genital tract.","Cervicovaginal Secretion | CERVICOVAGINAL SECRETION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0740486","Cerumen","C32293","A soft yellow wax secreted by glands in the ear canal.","Cerumen | CERUMEN | Earwax",,,,,,,,,,,,,,,"4187204","Cerumen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034085","Lung Surfactant","C13273","Pulmonary surfactant lines the lung epithelium and lowers surface tension to prevent collapse at end-expiration. Deficiency of pulmonary surfactant results in respiratory distress syndrome (RDS) in premature infants. Lung surfactant is synthesized in alveolar type II cells, stored in lamellar bodies and secreted via exocytosis.","Lung Surfactant | LUNG SURFACTANT | Surfactant | Surfactant, Lung",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227855","Lochia","C78742","Vaginal discharge occurring during the post-partum period. It consists of a mixture of blood, mucus, and placental remnants.","Lochia | LOCHIA",,,,,,,,,,,,,,,"4175793","Lochia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022567","Keratinocyte","C12589","The keratin-producing cells of the epidermis.  They are the predominant cells of the epidermis that form in the deep basal layer of the stratified epithelium of the epidermis.  They gradually migrate upward to the cornified layer of the epidermis undergoing characteristic changes.","Keratinocyte | KERATINOCYTE | Keratinocytes",,,,,,,,,,,,,,,"4253926","Keratinocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162367","Interstitial Fluid","C120839","The extracellular fluid component found in the spaces between tissues. This excludes plasma and transcellular fluid.","Interstitial Fluid | INTERSTITIAL FLUID",,,,,,,,,,,,,,,"37154086","Interstitial fluid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828187","Serum Infranatant","C106565","The liquid, solid or semi-solid lying below a liquid residue, which is separated by crystallization, precipitation or centrifugation of a serum sample.","Serum Infranatant | INFRANATANT, SERUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828526","Pleural Fluid Infranatant","C106558","The liquid, solid or semi-solid lying below a liquid residue, which is separated by crystallization, precipitation or centrifugation of a pleural fluid sample.","Pleural Fluid Infranatant | INFRANATANT, PLEURAL FLUID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828539","Plasma Infranatant","C106554","The liquid, solid or semi-solid lying below a liquid residue, which is separated by crystallization, precipitation or centrifugation of a plasma sample.","Plasma Infranatant | INFRANATANT, PLASMA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828094","Gastric Fluid","C86998","The fluid produced by the stomach glands, composed of gastric acids and enzymes.","Gastric Fluid | GASTRIC FLUID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034161","Pus","C50718","A yellowish substance produced during bacterial inflammation. It contains necrotic cells and cells fighting the infection.","Pus | PUS",,,,,,,,,,,,,,,"4014083|4275663","Pus|Pus",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0227977","Prostatic Fluid","C100896","A slightly alkaline fluid produced by the prostate gland. It contributes 20-30% of the total volume of seminal fluid.","Prostatic Fluid | PROSTATIC FLUID",,,,,,,,,,,,,,,"4305325","Prostatic fluid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0370220","Platelet-rich Plasma","C106557","A plasma sample that is prepared from whole blood, which has undergone a number of centrifugation steps to concentrate the amount of platelets.","Platelet-rich Plasma | PLATELET RICH PLASMA | PRP | Platelet Rich Plasma",,,,,,,,,,,,,,,"4021555","Platelet rich plasma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0694689","Menstrual Blood","C78740","The discharged blood from the uterus during the reproductive years. The discharge occurs approximately once a month.","Menstrual Blood | Human Menstrual Blood | MENSTRUAL BLOOD",,,,,,,,,,,,,,,"4208941","Menstrual blood",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025047","Meconium","C78743","The newborn's first intestinal discharge. It is a dark-green, thick substance composed of mucus, intestinal secretions, hair, and intestinal mucosa cells.","Meconium | MECONIUM",,,,,,,,,,,,,,,"4101702","Meconium stool",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037359","Smegma","C33574","A white secretion of the sebaceous glands of the foreskin.","Smegma | SMEGMA",,,,,,,,,,,,,,,"4264622","Smegma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828186","Serum or Plasma","C105706","The non-cellular portion of the circulating blood, with or without the clotting proteins present.","Serum or Plasma | SERUM OR PLASMA | Ser/Plas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036511","Sebum","C13276","A thick, oily substance produced by the sebaceous glands located in the dermis.","Sebum | SEBUM | sebum",,,,,,,,,,,,,,,"4198250","Sebum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1879941","CDISC SDTM Route of Administration Terminology","C66729","Terminology codelist used with Route of Administration within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.","CDISC SDTM Route of Administration Terminology | ROUTE | Route of Administration Response | SDTM-ROUTE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897829","Procedure Route of Administration","C117524","The means of entry through which the procedure is taken into the body.","Procedure Route of Administration | PRROUTE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3838734","Venous Plasma","C132462","Plasma that has been isolated from venous blood.","Venous Plasma | VENOUS PLASMA",,,,,,,,,,,,,,,"45766643","Venous plasma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053879","Venous Cord Blood","C120840","Blood present in the umbilical vein at the time of delivery.","Venous Cord Blood | VENOUS CORD BLOOD",,,,,,,,,,,,,,,"37157240","Venous cord blood",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040767","Transudate","C78744","The fluid that passes through the wall of the veins and capillaries to the surrounding tissues because of increased intravascular pressure. It has low protein content.","Transudate | TRANSUDATE",,,,,,,,,,,,,,,"4066156|4327742","Transudate|Transudate",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL552745","Swabbed Material","C150895","A heterogeneous and variable aggregate of body fluids, tissues, cells, microorganisms, and other materials that are collected from a swab biospecimen collection procedure.","Swabbed Material | SWABBED MATERIAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552743","Serum or Plasma Supernatant","C150893","The liquid lying above a liquid, solid or semi-solid residue, which is separated by crystallization, precipitation or centrifugation of a serum or plasma sample.","Serum or Plasma Supernatant | SUPERNATANT, SERUM OR PLASMA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828185","Serum Supernatant","C106566","The liquid lying above a liquid, solid or semi-solid residue, which is separated by crystallization, precipitation or centrifugation of a serum sample.","Serum Supernatant | SUPERNATANT, SERUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828525","Pleural Fluid Supernatant","C106559","The liquid lying above a liquid, solid or semi-solid residue, which is separated by crystallization, precipitation or centrifugation of a pleural fluid sample.","Pleural Fluid Supernatant | SUPERNATANT, PLEURAL FLUID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552744","Cerebrospinal Fluid Supernatant","C150894","The liquid lying above a liquid, solid or semi-solid residue, which is separated by crystallization, precipitation or centrifugation of a cerebrospinal fluid sample.","Cerebrospinal Fluid Supernatant | SUPERNATANT, CEREBROSPINAL FLUID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828535","Plasma Supernatant","C106555","The liquid lying above a liquid, solid or semi-solid residue, which is separated by crystallization, precipitation or centrifugation of a plasma sample.","Plasma Supernatant | SUPERNATANT, PLASMA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347268","CDISC SDTM Body Position Terminology","C71148","Terminology codelist used with Body Position within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.","CDISC SDTM Body Position Terminology | POSITION | Position | SDTM-POSITION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983687","Unconstrained Body Movement","C90480","The ability to move body parts and limbs without physical restriction.","Unconstrained Body Movement | UNCONSTRAINED | Unconstrained",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883387","Trendelenburg","C62168","A supine position with the person inclined at an angle of 45 degrees so that the pelvis is higher than the head.","Trendelenburg | TRENDELENBURG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985208","Patient in Body Sling","C92604","A position in which the subject's body is supported by a sling.","Patient in Body Sling | SLING | Sling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552738","Sitting With Legs Dependent","C150885","A dependent position where the legs of a subject dangle or hang down while sitting.","Sitting With Legs Dependent | SITTING, LEGS DEPENDENT | Sitting With Legs Dangling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828195","Semi-Recumbent","C111310","A semi-sitting or semi-reclined body position in which the head is elevated to some degree above horizontal.","Semi-Recumbent | Inclined | SEMI-RECUMBENT | Semi-Supine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882998","Semi-Fowler's Position","C62174","A semi-sitting or semi-reclined body position whereby the head is elevated on an angle of approximately 30 degrees.","Semi-Fowler's Position | SEMI-FOWLERS | Semi-Fowlers",,,,,,,,,,,,,,,"4140023","Semi-Fowler's position",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1882949","Reverse Trendelenburg","C62169","A supine position with the person inclined at an angle of 45 degrees so that the head is higher than the pelvis.","Reverse Trendelenburg | REVERSE TRENDELENBURG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0444379","Lateral Decubitus Position","C100758","Lying down or reclining with one side of the body in a downward direction.","Lateral Decubitus Position | Decubitus | LATERAL DECUBITUS | Lateral Decubitus",,,,,,,,,,,,,,,"4136831","Lateral decubitus position",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0277811","Fowler's Position","C62173","A semi-sitting position whereby the head of an adjustable bed is elevated to the desired height, about 60-90 cm, to produce angulation of the body, usually 45 to 60 degrees. Knees may or may not be bent.","Fowler's Position | FOWLERS | Fowlers",,,,,,,,,,,,,,,"4147052","Fowler's position",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2826723","Electrocardiogram Position","C83113","The physical bearing of the body during an electrocardiogram assessment.","Electrocardiogram Position | EGPOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639406","Diethylene Triamine Pentaacetic Acid Clearance","C100441","A measurement of the volume of serum or plasma that would be cleared of Diethylenetriamine pentaacetate (DTPA) through its excretion for a specified unit of time.","Diethylene Triamine Pentaacetic Acid Clearance | DTPA Clearance | DTPACLR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639405","EDTA Clearance","C100440","A measurement of the volume of serum or plasma that would be cleared of Ethylenediamine tetraacetic acid (EDTA) through its excretion for a specified unit of time.","EDTA Clearance | EDTACLR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639404","Iohexol Clearance","C100439","A measurement of the volume of serum or plasma that would be cleared of Iohexol through excretion for a specified unit of time.","Iohexol Clearance | IOHEXCLR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879928","CDISC SDTM Category for Inclusion And Or Exclusion Terminology","C66797","Terminology codelist used with Category for Inclusion And Or Exclusion within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.","CDISC SDTM Category for Inclusion And Or Exclusion Terminology | Category of Inclusion/Exclusion | IECAT | SDTM-IECAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826629","Inclusion Exclusion Criterion Category","C83016","A classification of the inclusion exclusion criterion.","Inclusion Exclusion Criterion Category | IECAT | Study Eligibility Criteria Category",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639409","Immature Lymphocytes Measurement","C100444","The determination of the amount of immature lymphocytes present in a sample.","Immature Lymphocytes Measurement | Immature Lymphocytes | LYMIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272923","Toxic Granulation Measurement","C96641","The determination of the toxic granulation in neutrophilic blood cells.","Toxic Granulation Measurement | TOXGRAN | Toxic Granulation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272932","Giant Neutrophil Count","C96651","The determination of the amount of giant neutrophils present in a sample.","Giant Neutrophil Count | Giant Neutrophils | NEUTGT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272933","Glucose Clearance Measurement","C96652","A measurement of the glucose clearance in a sample.","Glucose Clearance Measurement | GLUCCLR | Glucose Clearance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201365","Jo-1 Antibody Measurement","C100459","The determination of the amount of Jo-1 antibody present in a sample.","Jo-1 Antibody Measurement | JO1AB | Jo-1 Antibody",,,,,,,,,,,,,,,"4144232","Antibody to JO-1 measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3639417","Liver Kidney Microsomal Type 1 IgA Antibody Measurement","C100456","The determination of the amount of liver kidney microsomal type 1 IgA antibody present in a sample.","Liver Kidney Microsomal Type 1 IgA Antibody Measurement | LKM1IAAB | Liver Kidney Microsomal Type 1 IgA Ab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639416","Liver Kidney Microsomal Type 1 IgM Antibody Measurement","C100455","The determination of the amount of liver kidney microsomal type 1 IgM antibody present in a sample.","Liver Kidney Microsomal Type 1 IgM Antibody Measurement | LKM1IMAB | Liver Kidney Microsomal Type 1 IgM Ab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639415","Liver Kidney Microsomal Type 1 IgG Antibody Measurement","C100454","The determination of the amount of liver kidney microsomal type 1 IgG antibody present in a sample.","Liver Kidney Microsomal Type 1 IgG Antibody Measurement | LKM1IGAB | Liver Kidney Microsomal Type 1 IgG Ab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639412","Glomerular Filtration Rate from Beta-Trace Protein Adjusted for BSA Measurement","C100449","A measurement of the glomerular filtration rate (GFR) based on the clearance of beta-trace protein after adjusting it for the body surface area.","Glomerular Filtration Rate from Beta-Trace Protein Adjusted for BSA Measurement | GFR from Beta-Trace Protein Adj for BSA | GFRBSBTP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830123","Findings About Events or Interventions Completion Status","C113367","A term used to describe the state or condition of the completeness of the findings about events or interventions data.","Findings About Events or Interventions Completion Status | FASTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272904","Oxygen Capacity Measurement","C96614","The determination of the maximum amount of oxygen that can be combined chemically with hemoglobin in a volume of blood.","Oxygen Capacity Measurement | OXYCAP | Oxygen Capacity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1168591","Oxyhemoglobin Measurement","C96616","The determination of the amount of oxyhemoglobin present in a sample.","Oxyhemoglobin Measurement | HGBOXY | Oxyhemoglobin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272905","Parvovirus B19 IgG Antibody Measurement","C96617","The determination of the amount of parvovirus B19 IgG antibody present in a sample.","Parvovirus B19 IgG Antibody Measurement | PB19GGAB | Parvovirus B19 IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202177","Phospholipid Measurement","C96623","The determination of the amount of phospholipid present in a sample.","Phospholipid Measurement | PHOSLPD | Phospholipid",,,,,,,,,,,,,,,"4056952","Phospholipid measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555304","Do Not Process","C154309","An indication that a biospecimen should not be subjected to any treatment.","Do Not Process | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555303","en Masse","C154308","As a group; all together.","en Masse | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555306","Enrichment","C154307","Any of various techniques designed to select or increase a target item in a mixed sample.","Enrichment | Enrich",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037369","Smoking","C154329","The act of puffing and/or inhaling the combustion products of a substance so as to be tasted and absorbed into the bloodstream.","Smoking | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898442","MedDRA Low Level Term Code","C117048","A coded value specifying the low level term from the Medical Dictionary for Regulatory Activities (MedDRA).","MedDRA Low Level Term Code | LLTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890177","MedDRA Preferred Term Code","C117056","A coded value specifying the preferred term from the Medical Dictionary for Regulatory Activities (MedDRA).","MedDRA Preferred Term Code | PTCD | meddra code | meddra_code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898443","MedDRA High Level Term Code","C117047","A coded value specifying the high level term from the Medical Dictionary for Regulatory Activities (MedDRA).","MedDRA High Level Term Code | HLTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898444","MedDRA High Level Group Term Code","C117046","A coded value specifying the high level group term from the Medical Dictionary for Regulatory Activities (MedDRA).","MedDRA High Level Group Term Code | HLGTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898441","MedDRA Primary System Organ Class Code","C117059","A coded value specifying the primary system organ class from the Medical Dictionary for Regulatory Activities (MedDRA).","MedDRA Primary System Organ Class Code | SOCCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272888","Clarity Measurement","C96594","The determination of the transparency of a sample.","Clarity Measurement | CLARITY | Clarity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1610653","Cyclic Citrullinated Peptide Antibody Measurement","C96595","The determination of the amount of cyclic citrullinated peptide antibody present in a sample.","Cyclic Citrullinated Peptide Antibody Measurement | CCPAB | Cyclic Citrullinated Peptide Antibody",,,,,,,,,,,,,,,"4255168","Cyclic citrullinated peptide antibody measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899211","Exposure as Collected Name of Treatment","C117473","The literal identifier of the exposure as collected.","Exposure as Collected Name of Treatment | ECTRT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899207","Exposure as Collected Planned Time Point Name","C117501","The literal identifier of a planned point in time for exposure collection.","Exposure as Collected Planned Time Point Name | ECTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272883","Broad Casts Measurement","C96588","The determination of the amount of urinary broad (waxy) casts present in a sample.","Broad Casts Measurement | Broad Casts | CSBROAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272884","Calcium Clearance Measurement","C96589","A measurement of the calcium clearance in a sample.","Calcium Clearance Measurement | CACLR | Calcium Clearance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272885","Calcium Sulfate Measurement","C96590","The determination of the amount of calcium sulphate present in a sample.","Calcium Sulphate Measurement | CASULPH | Calcium Sulphate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201932","Carboxyhemoglobin Measurement","C96591","The determination of the amount of carboxyhemoglobin present in a sample.","Carboxyhemoglobin Measurement | CARBXHGB | Carboxyhemoglobin",,,,,,,,,,,,,,,"4056787","Carboxyhemoglobin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897717","Reported Name of Procedure","C117511","The literal identifier of the procedure.","Reported Name of Procedure | PRTRT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985804","Name Code Modified Text","C93601","A character string that is a revision of the original text to enable the coding of the text.","Name Code Modified Text | nameCodeModifiedText",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272867","Basophilic Stippling Measurement","C96567","The determination of the amount of basophilic stippling present in a sample.","Basophilic Stippling Measurement | Basophilic Stippling | STIPBASO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826703","Substance Use Reported Name","C83092","The literal identifier of the substance in use.","Substance Use Reported Name | SUTRT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827012","Substance Use Modified Reported Term","C83423","An indication or description of a change in substance usage.","Substance Use Modified Reported Term | SUMODIFY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826763","Electrocardiogram Time Point","C83156","The planned time point at which the electrocardiogram assessment took place.","Electrocardiogram Time Point | EGTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826269","Laboratory Vendor Name","C82537","The literal identifier of the laboratory that performs an assessment or examination.","Laboratory Vendor Name | LBNAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898355","Microscopic Findings Vendor Name","C117590","The literal identifier of the vendor or laboratory that performs a microscopic assessment.","Microscopic Findings Vendor Name | MINAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981557","Pharmacokinetic Concentration Timepoint","C87974","A point in time referring to pharmacokinetic concentration data.","Pharmacokinetic Concentration Timepoint | PCTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1277725","Acetylcholine Receptor Antibody Measurement","C96559","The determination of the amount of acetylcholine receptor antibody present in a sample.","Acetylcholine Receptor Antibody Measurement | ACHRAB | Acetylcholine Receptor Antibody",,,,,,,,,,,,,,,"4044814","Measurement of acetylcholine receptor antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0201832","Acetylcholinesterase Measurement","C96560","The determination of the amount of acetylcholinesterase present in a sample.","Acetylcholinesterase Measurement | ACHE | Acetylcholinesterase",,,,,,,,,,,,,,,"4336534","Acetylcholinesterase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3272862","Alpha Fetoprotein L1 Measurement","C96562","The determination of the amount of alpha fetoprotein L1 present in a sample.","Alpha Fetoprotein L1 Measurement | AFPL1 | Alpha Fetoprotein L1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272865","Alpha Fetoprotein L3 to Total Alpha Fetoprotein Ratio Measurement","C96565","The determination of the ratio of alpha fetoprotein L3 compared to total alpha fetoprotein present in a sample. The measurement may be expressed as a ratio or percentage.","Alpha Fetoprotein L3 to Total Alpha Fetoprotein Ratio Measurement | A Fetoprotein L3/A Fetoprotein | AFPL3AFP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981555","Pharmacokinetic Concentration Test","C87972","A character or string that represents a pharmacokinetic concentration examination.","Pharmacokinetic Concentration Test | PCTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897584","Skin Response Planned Time Point Name","C117694","The literal identifier of a planned point in time for a skin response assessment.","Skin Response Planned Time Point Name | SRTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826766","Vital Signs Time Point","C83159","A point in time that the vital signs assessment takes place.","Vital Signs Time Point | VSTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985099","Chlamydia pneumoniae IgA Antibody Measurement","C92432","The determination of the amount of Chlamydia pneumoniae IgA antibody present in a sample.","Chlamydia pneumoniae IgA Antibody Measurement | CPNIGAAB | Chlamydia pneumoniae IgA Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2239222","Vascular Endothelial Growth Factor Measurement","C92514","The determination of the amount of vascular epithelial growth factor present in a sample.","Vascular Endothelial Growth Factor Measurement | VEGF | Vascular Endothelial Growth Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985161","Soluble Vascular Cell Adhesion Molecule 1","C92533","The determination of the amount of soluble vascular cell adhesion molecule 1 present in a sample.","Soluble Vascular Cell Adhesion Molecule 1 | SVCAM1 | Soluble Vasc Cell Adhesion Molecule 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985162","Hepatitis A Antibody Measurement","C92534","A quantitative measurement of the antibody reaction of a biological specimen to the Hepatitis A virus.","Hepatitis A Antibody Measurement | HAAB | Hepatitis A Virus Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984962","Carnitine Acetyl Transferase Measurement","C92288","The determination of the amount of carnitine Acetyl transferase present in a sample.","Carnitine Acetyl Transferase Measurement | CARNITAT | Carnitine Acetyl Transferase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202207","Cholinesterase Measurement","C92289","The determination of the amount of cholinesterase present in a sample.","Cholinesterase Measurement | CHOLINES | Cholinesterase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984964","Apolipoprotein E4 Measurement","C92293","The determination of the amount of apolipoprotein E4 present in a sample.","Apolipoprotein E4 Measurement | APOE4 | APOE4 Measurement | Apolipoprotein E4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984965","Beta Globulin to Total Protein Ratio Measurement","C92294","The determination of the ratio of beta globulin compared to total protein present in a sample. The measurement may be expressed as a ratio or percentage.","Beta Globulin to Total Protein Ratio Measurement | Beta Globulin/Total Protein | GLOBBPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984966","Gamma Globulin to Total Protein Ratio Measurement","C92295","The determination of the ratio of gamma globulin compared to total protein present in a sample. The measurement may be expressed as a ratio or percentage.","Gamma Globulin to Total Protein Ratio Measurement | GLOBGPT | Gamma Globulin/Total Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984953","Legionella pneumophila IgG IgM Antibody Measurement","C92277","The determination of the amount of Legionella pneumophila IgG and IgM antibody present in a sample.","Legionella pneumophila IgG IgM Antibody Measurement | LPNGMAB | Legionella pneumophila IgG IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984955","Mycobacterium tuberculosis Nucleic Acid Measurement","C92279","The determination of the amount of Mycobacterium tuberculosis nucleic acid present in a sample.","Mycobacterium tuberculosis Nucleic Acid Measurement | MYTBNUAC | Mycobacterium tuberculosis Nucleic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1277814","Myeloperoxidase Antibody Measurement","C92280","The determination of the amount of myeloperoxidase antibody present in a sample.","Myeloperoxidase Antibody Measurement | MPOAB | Myeloperoxidase Antibody",,,,,,,,,,,,,,,"4036693","Measurement of myeloperoxidase antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2984957","Type I Myeloblasts Measurement","C92283","The determination of the amount of type I myeloblasts present in a sample.","Type I Myeloblasts Measurement | MYBLAT1 | Type I Myeloblasts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984958","Type II Myeloblasts Measurement","C92284","The determination of the amount of type II myeloblasts present in a sample.","Type II Myeloblasts Measurement | MYBLAT2 | Type II Myeloblasts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984946","Anti-Single Stranded DNA IgG Measurement","C92269","The determination of the amount of anti-single stranded DNA IgG present in a sample.","Anti-Single Stranded DNA IgG Measurement | ASSDNA | Anti-Single Stranded DNA IgG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984939","Hemoglobin B measurement","C92260","The determination of the amount of hemoglobin B present in a sample.","Hemoglobin B Measurement | HGBB | Hemoglobin B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984943","HIV-2 Nucleic Acid Measurement","C92266","The determination of the amount of HIV-2 nucleic acid present in a sample.","HIV-2 Nucleic Acid Measurement | HIV-2 Nucleic Acid | HIV2NUAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984936","Transitional Epithelial Cells Measurement","C92251","The determination of the amount of transitional epithelial cells present in a urine sample.","Transitional Epithelial Cells Measurement | EPITCE | Transitional Epithelial Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984937","Alpha-1 Globulin to Total Protein Ratio Measurement","C92253","The determination of the ratio of alpha-1 globulin compared to total protein present in a sample. The measurement may be expressed as a ratio or percentage.","Alpha-1 Globulin to Total Protein Ratio Measurement | Alpha-1 Globulin/Total Protein | GLOBA1PT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984938","Alpha-2 Globulin to Total Protein Ratio Measurement","C92255","The determination of the ratio of alpha-2 globulin compared to total protein present in a sample. The measurement may be expressed as a ratio or percentage.","Alpha-2 Globulin to Total Protein Ratio Measurement | Alpha-2 Globulin/Total Protein | GLOBA2PT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984931","Myeloid to Erythroid Ratio Measurement","C92242","The determination of the ratio of myeloid cells compared to erythroid cells present in a sample. The measurement may be expressed as a ratio or percentage.","Myeloid to Erythroid Ratio Measurement | MYPCERPC | Myeloid Erythroid Ratio | Myeloid/Erythroid Ratio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827506","Nonphosphorylated Tau Protein Measurement","C84811","The determination of the amount of nonphosphorylated Tau protein present in a sample.","Nonphosphorylated Tau Protein Measurement | Non-Phosphorylated Tau Protein | TPRONP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827507","Phosphorylated Tau Protein Measurement","C84812","The determination of the amount of phosphorylated Tau protein present in a sample.","Phosphorylated Tau Protein Measurement | Phosphorylated Tau Protein | TPROTP | Tau (pT181) | pTau",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827509","Eosinophilic Metamyelocyte Count","C84819","The determination of the number of eosinophilic metamyelocytes in a blood sample.","Eosinophilic Metamyelocyte Count | EOSMM | Eosinophilic Metamyelocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827510","Eosinophilic Myelocyte Count","C84821","The determination of the number of eosinophilic myelocytes in a blood sample.","Eosinophilic Myelocyte Count | EOSMYL | Eosinophilic Myelocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827511","Neutrophilic Metamyelocyte Count","C84822","The determination of the number of neutrophilic metamyelocytes in a blood sample.","Neutrophilic Metamyelocyte Count | NEUTMM | Neutrophilic Metamyelocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0236401","Free Cortisol Measurement","C88113","The determination of the amount of free, unbound cortisol present in a sample.","Free Cortisol Measurement | CORTFR | Cortisol, Free",,,,,,,,,,,,,,,"4017631","Cortisol, free measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641239","Diphtheria IgG Antibody Measurement","C103388","The determination of the amount of the Diphtheria IgG antibodies in a sample.","Diphtheria IgG Antibody Measurement | Corynebacterium diphtheriae IgG Antibody | DPTIGGAB | Diphtheria IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641236","Clostridium tetani IgG Antibody Measurement","C103382","The determination of the amount of the Clostridium tetani IgG antibody in a sample.","Clostridium tetani IgG Antibody Measurement | CTTIGGAB | Clostridium tetani IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540684","CD20 Expressing Cell Measurement","C103368","A count of the CD20 expressing cells per unit of a biological specimen.","CD20 Expressing Cell Measurement | CD20 | CD20 Expressing Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641231","CD2 Expressing Cell to Lymphocyte Ratio Measurement","C103367","The determination of the ratio of CD2 expressing cells compared with the total number of lymphocytes in a sample. The measurement may be expressed as a ratio or percentage.","CD2 Expressing Cell to Lymphocyte Ratio Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539069","CD2 Expressing Cell Measurement","C103366","A count of the CD2 expressing cells per unit of a biological specimen.","CD2 Expressing Cell Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538991","CD14 Expressing Cell Measurement","C103365","A count of the CD14 expressing cells per unit of a biological specimen.","CD14 Expressing Cell Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541222","CD1 Expressing Cell Measurement","C103364","A count of the CD1 expressing cells per unit of a biological specimen.","CD1 Expressing Cell Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539000","Apolipoprotein A5 Measurement","C103355","The determination of the amount of the apolipoprotein A5 in a sample.","Apolipoprotein A5 Measurement | APOA5 | APOA5 Measurement | Apolipoprotein A5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523702","Hydrogen Measurement","C102275","The determination of the amount of hydrogen present in a sample.","Hydrogen Measurement | HYDROGEN | Hydrogen",,,,,,,,,,,,,,,"4017092","Hydrogen measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640661","Hematocrit Corrected Reticulocyte Count","C102273","The determination of the amount of hematocrit corrected reticulocytes present in a sample.","Hematocrit Corrected Reticulocyte Count | Hematocrit Corrected Reticulocytes | RETIHCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919242","Carbohydrate-Deficient Transferrin Measurement","C101016","The determination of the amount of transferrin with a reduced number of carbohydrate moieties present in a biological sample.","Carbohydrate-Deficient Transferrin Measurement | CDT | Carbohydrate-Deficient Transferrin",,,,,,,,,,,,,,,"4004235","Carbohydrate deficient transferrin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2368071","Chlamydia trachomatis IgG Antibody Measurement","C100466","The determination of the amount of Chlamydia trachomatis IgG antibody present in a sample.","Chlamydia trachomatis IgG Antibody Measurement | CTRIGGAB | Chlamydia trachomatis IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541267","3,4-Dihydroxyphenylacetic Acid Measurement","C103345","The determination of the amount of the 3,4-dihydroxyphenylacetic acid in a sample.","3,4-Dihydroxyphenylacetic Acid Measurement | 3,4-Dihydroxyphenylacetic Acid | DOPAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640666","Urine Conductivity","C102282","The determination of the ability of urine to conduct an electrical current. This test is a non-linear function of the electrolyte concentration in the urine.","Urine Conductivity | CONDUCTU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640664","P50 Oxygen Measurement","C102279","The determination of the amount of partial pressure of oxygen when hemoglobin is half saturated that is present in a sample.","P50 Oxygen Measurement | P50 Oxygen | P50OXYGN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1167770","Lymphoblast Count","C102278","The determination of the amount of lymphoblasts (immature cells that differentiate to form lymphocytes) present in a sample.","Lymphoblast Count | BLSTLY | Lymphoblasts | Lymphoid Blasts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1446165","Immature Reticulocyte Fraction Measurement","C102276","The determination of the ratio of immature reticulocytes to total reticulocytes present in a sample.","Immature Reticulocyte Fraction Measurement | IRF | Immature Reticulocyte Fraction",,,,,,,,,,,,,,,"4135655","Immature reticulocyte fraction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3542419","Factor V Leiden Measurement","C102271","The determination of the amount of Factor V Leiden present in a sample.","Factor V Leiden Measurement | FACTVL | Factor V Leiden",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539880","Clue Cell Count","C102261","The determination of the amount of clue cells present in a sample.","Clue Cell Count | CLUECE | Clue Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2316832","Arachidonic Acid Measurement","C102259","The determination of the amount of arachidonic acid present in a sample.","Arachidonic Acid Measurement | ARA | Arachidonic Acid",,,,,,,,,,,,,,,"4334474","Arachidonic acid measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2368072","Chlamydia trachomatis IgM Antibody Measurement","C100465","The determination of the amount of Chlamydia trachomatis IgM antibody present in a sample.","Chlamydia trachomatis IgM Antibody Measurement | CTRIGMAB | Chlamydia trachomatis IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639420","Chlamydia trachomatis IgA Antibody Measurement","C100464","The determination of the amount of Chlamydia trachomatis IgA antibody present in a sample.","Chlamydia trachomatis IgA Antibody Measurement | CTRIGAAB | Chlamydia trachomatis IgA Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639418","Alpha-1 Microglobulin to Creatinine Ratio Measurement","C100462","The determination of the ratio of alpha-1 microglobulin compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Alpha-1 Microglobulin to Creatinine Ratio Measurement | A1MCREAT | Alpha-1 Microglobulin/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542403","Apolipoprotein A4 Measurement","C103354","The determination of the amount of the apolipoprotein A4 in a sample.","Apolipoprotein A4 Measurement | APOA4 | APOA4 Measurement | Apolipoprotein A4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3543835","Beta Catenin Measurement","C103357","The determination of the amount of the beta catenin in a sample.","Beta Catenin Measurement | Beta Catenin | CATNINB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641228","Apolipoprotein B to Apolipoprotein A1 Ratio Measurement","C103356","The determination of the ratio of the Apolipoprotein B compared with Apolipoprotein A1 in a sample. The measurement may be expressed as a ratio or percentage.","Apolipoprotein B to Apolipoprotein A1 Ratio Measurement | APOBAPA1 | Apolipoprotein B/Apolipoprotein A1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826622","CDISC CDASH Substance Usage Never Current Former Terminology","C83004","A terminology subset of the CDISC Study Data Tabulation Model (SDTM) Never Current Former codelist created for Clinical Data Acquisition Standards Harmonization (CDASH) Substance Usage Never Current Former terminology.","CDISC CDASH Substance Use Never/Current/Former Classification Terminology | CDASH-SUNCF | SUNCF | Substance Usage Never Current Former Classification | Substance Use Never/Current/Former Classification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826621","Substance Use Never Current Former","C83003","An indication or description that an individual's substance usage status is never, current, or former.","Substance Use Never Current Former | SUNCF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698608","CDISC CDASH ECG Original Units Terminology","C78422","A terminology subset of the CDISC Study Data Tabulation Model (SDTM) Unit codelist created for Clinical Data Acquisition Standards Harmonization (CDASH) ECG Original Units terminology.","CDISC CDASH ECG Original Units Terminology | CDASH-EGORRESU | ECG Original Units | EGORRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826715","Electrocardiogram Original Result Unit of Measure","C83105","The unit of measure for the original ECG result.","Electrocardiogram Original Result Unit of Measure | EGORRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541948","CDISC SDTM Subject Characteristic Test Name Terminology","C103330","The terminology that includes concepts relevant to the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM) subject characteristics test names.","CDISC SDTM Subject Characteristic Test Name Terminology | SCTEST | SDTM-SCTEST | Subject Characteristic Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640906","Type of Contagion Contact","C102723","Identification and clinical investigation of disease contacts.","Type of Contagion Contact | TYPCON | Type of Contact",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827743","Twin Type","C112424","The classification of the two offspring born from the same pregnancy.","Twin Type | TWINTYP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545362","Student Indicator","C147485","An indication as to whether the subject or associated person is enrolled in school.","Student Indicator | STDNTIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538984","Social Risk Factor","C102711","Social factors such as personal behavior, lifestyle, or environment belonging to the subject which are known to increase the likelihood of infection and disease.","Social Risk Factor | RISKSOC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640901","Source Case Investigation","C102713","A public health activity for the determination of who transmitted a disease to another subject and whether this person: is still infectious; was reported to the health department as a disease case or suspect; or has infected others.","Source Case Investigation | SRCCSINV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699308","Skin Type","C74580","A distinctive characteristic of the skin marked by the amount of sebum secreted by sebaceous glands.","Skin Type | SKINTYP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700191","Fitzpatrick Classification Scale","C74563","A classification system used by dermatologists to determine a person's risk for sunburn. The classification is based on the skin complexion and the degree of tolerance to sun exposure and it relates to the amount of melanin pigment in the skin. It was developed by Dr. Thomas Fitzpatrick in 1975 to determine patient's skin reaction to laser and light therapy treatments. According to this system, there are six skin varieties classified from I to VI.","Fitzpatrick Classification Scale | Fitzpatrick Skin Classification | Fitzpatrick Skin Phototype | Fitzpatrick Skin Type System | SKINCLAS | Skin Classification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539810","Setting of Disease Contact","C102708","The environment within which the person may have come into contact with a disease carrier, or played the role of a disease carrier.","Setting of Disease Contact | SETCON | Setting of Contact",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521272","Secondary Language Spoken","C132460","Additional language(s) that is spoken by the subject but which is not considered the primary language.","Secondary Language Spoken | LNGSPS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640895","Priority of Disease Contact","C102699","The categorization of individuals with or without the potential for having tuberculosis.","Priority of Disease Contact | PRICON",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520954","Primary Language Spoken","C132459","The main language that is spoken by the subject most frequently or dominantly.","Primary Language Spoken | LNGSPP | Primary Language Spoken at Home",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828489","Premature Birth Indicator","C112400","An indication as to whether the subject was born prior to 38 weeks gestation.","Premature Birth Indicator | PREMBRTH | premature at birth | premature_at_birth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054327","Number of Years of Education","C122393","The number of education years that a subject has competed.","Number of Years of Education | EDUYRNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522865","Number of Biological Sisters","C135501","The number of sisters that are biologically related to the subject.","Number of Biological Sisters | BIOSISN | Number of Sisters, Biological",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522864","Number of Biological Brothers","C135500","The number of brothers that are biologically related to the subject.","Number of Biological Brothers | BIOBRON | Number of Brothers, Biological",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522866","Living with Subject Indicator","C135502","An indication as to whether the associated person is living with the subject.","Living with Subject Indicator | LVSBJIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456129","Gestational Age at Birth","C124435","The gestational age of the subject at birth.","Gestational Age at Birth | GSTABRTH | weeks gestation at birth | weeks_gestation_at_birth",,,,,,,,,,,,,,,"4260747","Length of gestation at birth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640851","Entry Date from Country of Potential Disease Exposure","C102631","The date on which the subject arrived in the reporting country from the country of potential disease exposure.","Entry Date from Country of Potential Disease Exposure | CTRYDDTC | Entry Date from Ptntl Cntry Disease Exp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699870","Employee Salary Type","C74566","A coding scheme used to describe the possible methods of compensation in an occupation.","Employee Salary Type | SALTYP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699869","Employee Job Class","C74565","A coding system used to specify attributes of an occupation.","Employee Job Class | Employment Status | JOBCLAS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526749","Donor Status at Time of Organ Donation","C139269","The donor's state or condition of being either living or brain dead at the time of organ harvesting.","Donor Status at Time of Organ Donation | DSTATTOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526748","Deceased Donor Donation Condition","C139270","The conditions under which an organ is harvested from a dead donor, including the condition of the donor and the environment.","Deceased Donor Donation Condition | DDDTYPE | Deceased Donor Donation Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640845","Country of Potential Disease Exposure","C102612","System of classification based on the nation in which an individual was exposed to a disease, regardless of the nation in which he/she currently resides.","Country of Potential Disease Exposure | CTRYDEXP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640849","Disease Contact Investigation","C102625","A public health activity whereby individuals who have been exposed to a person with a suspected or confirmed contagious illness are identified, usually for the purpose of identifying additional cases of the illness, or to offer some form of prophylactic intervention to either prevent or ameliorate disease in the exposed individual.","Disease Contact Investigation | CNTCINV | Contact Investigation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526747","CDC HIV High Risk Donor Indicator","C139271","An indication as to whether an organ donor may fall into one or more behavioral categories associated with increased risk of human immunodeficiency virus (HIV) infection, as defined by the 1994 Centers for Disease Control (CDC) Public Health Service Criteria for High Risk Behavior (Guidelines for preventing transmission of human immunodeficiency virus through transplantation of human tissue and organs. Centers for Disease Control and Prevention. MMWR Recomm Rep 1994; 43: 1-17).","CDC HIV High Risk Donor Indicator | HIVHRIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831272","Breast Fed Indicator","C112233","An indication as to whether the subject was breast fed (received mother's milk) as an infant.","Breast Fed Indicator | BRFEDIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826757","Subject Characteristics Test","C83149","A character or string that represents the full name of the subject characteristics assessment.","Subject Characteristics Test | SCTEST | Subject Characteristics Assessment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826831","Comment Value","C83241","The importance assigned to a particular remark.","Comment Value | COVAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437400","Thromboxane B2 Measurement","C103445","The determination of the amount of the thromboxane B2 in a sample.","Thromboxane B2 Measurement | TXB2 | Thromboxane B2",,,,,,,,,,,,,,,"4017350","Thromboxane B-2 measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3541327","Rubella IgG Antibody Measurement","C103440","The determination of the amount of the Rubella IgG antibody in a sample.","Rubella IgG Antibody Measurement | RUBIGGAB | Rubella IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539077","Prostaglandin F2 Alpha Measurement","C103437","The determination of the amount of the prostaglandin F2 alpha in a sample.","Prostaglandin F2 Alpha Measurement | PGF2A | Prostaglandin F2 Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539840","Prostaglandin F1 Alpha Measurement","C103436","The determination of the amount of the prostaglandin F1 alpha in a sample.","Prostaglandin F1 Alpha Measurement | PGF1A | Prostaglandin F1 Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538990","Prostaglandin E2 Measurement","C103435","The determination of the amount of the prostaglandin E2 in a sample.","Prostaglandin E2 Measurement | PGE2 | Prostaglandin E2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541346","Prostaglandin E Synthase Measurement","C103433","The determination of the amount of the prostaglandin E synthase in a sample.","Prostaglandin E Synthase Measurement | PGES | Prostaglandin E Synthase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541873","Prostaglandin D2 Synthase Measurement","C103432","The determination of the amount of the prostaglandin D2 synthase in a sample.","Prostaglandin D2 Synthase Measurement | Beta-Trace Protein | Beta-Trace Protein Measurement | PGD2S | Prostaglandin D2 Synthase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541268","Prostaglandin D2 Measurement","C103431","The determination of the amount of the prostaglandin D2 in a sample.","Prostaglandin D2 Measurement | PGD2 | Prostaglandin D2",,,,,,,,,,,,,,,"4005521","Prostaglandin D2 measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1535922","Procalcitonin Measurement","C103430","The determination of the amount of the procalcitonin in a sample.","Procalcitonin Measurement | PCT | Procalcitonin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538780","Leukotriene E4 Measurement","C103415","The determination of the amount of the leukotriene E4 in a sample.","Leukotriene E4 Measurement | LTE4 | Leukotriene E4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538778","Leukotriene B4 Measurement","C103413","The determination of the amount of the leukotriene B4 in a sample.","Leukotriene B4 Measurement | LTB4 | Leukotriene B4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641256","LDL Particle Size Measurement","C103412","The determination of the amount of the average particle size of low-density lipoprotein in a sample.","LDL Particle Size Measurement | LDL Particle Size | LDLPSZ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523728","Isoleucine Measurement","C103410","The determination of the amount of the isoleucine in a sample.","Isoleucine Measurement | ILE | Isoleucine",,,,,,,,,,,,,,,"4017198","Isoleucine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641251","Human Albumin Antibody Measurement","C103405","The determination of the amount of the human albumin antibody in a sample.","Human Albumin Antibody Measurement | HALBAB | Human Albumin Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1277797","Helicobacter pylori IgG Antibody Measurement","C103403","The determination of the amount of the Helicobacter pylori IgG antibody in a sample.","Helicobacter pylori IgG Antibody Measurement | HPLIGGAB | Helicobacter pylori IgG Antibody",,,,,,,,,,,,,,,"4210859","Helicobacter pylori IgG antibody measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641249","HDL Particle Size Measurement","C103402","The determination of the amount of the average particle size of high-density lipoprotein in a sample.","HDL Particle Size Measurement | HDL Particle Size | HDLPSZ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641245","Factor VIIa Activity Measurement","C103398","The determination of the amount of the biological activity of factor VIIa in a sample.","Factor VIIa Activity Measurement | FCTVIIAA | Factor VIIa Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539839","Collagen Type IV Measurement","C103383","The determination of the amount of the collagen type IV in a sample.","Collagen Type IV Measurement | COL4 | Collagen Type IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540570","Clostridium difficile Toxin Measurement","C103381","The determination of the amount of the Clostridium difficile toxin in a sample.","Clostridium difficile Toxin Measurement | CDFTXN | Clostridium difficile Toxin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641230","Cardiolipin IgM Antibody Measurement","C103363","The determination of the amount of the cardiolipin IgM antibodies in a sample.","Cardiolipin IgM Antibody Measurement | CRDIGMAB | Cardiolipin IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201547","Cancer Antigen 15-3 Measurement","C103362","The determination of the amount of the cancer antigen 15-3 in a sample.","Cancer Antigen 15-3 Measurement | CA15_3AG | Cancer Antigen 15-3 | Carbohydrate Antigen 15-3",,,,,,,,,,,,,,,"4013180","Cancer antigen 15-3 measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3539074","Cancer Antigen 1 Measurement","C103361","The determination of the amount of the cancer antigen 1 in a sample.","Cancer Antigen 1 Measurement | CA1AG | Cancer Antigen 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556411","Anatomical Therapeutic Chemical Classification System","C154331","A World Health Organization (WHO) classification system for medicinal substances where active substances are divided into different groups according to the organ or system on which they act and their therapeutic, pharmacological, and chemical properties. Drugs are classified in groups at five different levels.","Anatomical Therapeutic Chemical Classification System | ATC | ATC System | WHO ATC CLASSIFICATION SYSTEM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448197","Cortisol to Creatinine Ratio Measurement","C106512","The determination of the ratio of cortisol compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Cortisol to Creatinine Ratio Measurement | CORCREAT | Cortisol/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831004","Corticosterone to Creatinine Ratio Measurement","C106511","The determination of the ratio of corticosterone compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Corticosterone to Creatinine Ratio Measurement | CRTCREAT | Corticosterone/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831109","Chloride Clearance Measurement","C106509","The determination of the amount of the chloride clearance in a sample.","Chloride Clearance Measurement | CLCLR | Chloride Clearance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831556","Alpha Fetoprotein Activity Measurement","C106499","The determination of the amount of the alpha fetoprotein activity present in a sample.","Alpha Fetoprotein Activity Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831581","Alanine Aminotransferase to Aspartate Aminotransferase Ratio Measurement","C106498","The determination of the ratio of alanine aminotransferase (ALT) compared to aspartate aminotransferase (AST) present in a sample. The measurement may be expressed as a ratio or percentage.","Alanine Aminotransferase to Aspartate Aminotransferase Ratio Measurement | ALT/AST | ALTAST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473823","Total Cholesterol Measurement","C105586","The determination of the amount of total cholesterol present in a sample.","Cholesterol Measurement | CHOL | Cholesterol | Total Cholesterol",,,,,,,,,,,,,,,"4008265","Total cholesterol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641616","CD4 Cell to Lymphocyte Ratio Measurement","C103815","The determination of the ratio of CD4 cells compared to lymphocytes present in a sample. The measurement may be expressed as a ratio or percentage.","CD4 Cell to Lymphocyte Ratio Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641615","CD4 Cell to CD8 Cell Ratio Measurement","C103814","The determination of the ratio of CD4 cells compared to CD8 cells present in a sample. The measurement may be expressed as a ratio or percentage.","CD4 Cell to CD8 Cell Ratio Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641614","CD3 Cell to Lymphocyte Ratio Measurement","C103813","The determination of the ratio of CD3 cells compared to lymphocytes present in a sample. The measurement may be expressed as a ratio or percentage.","CD3 Cell to Lymphocyte Ratio Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641613","CD19 Cell to Lymphocyte Ratio Measurement","C103812","The determination of the ratio of CD19 cells compared to lymphocytes present in a sample. The measurement may be expressed as a ratio or percentage.","CD19 Cell to Lymphocyte Ratio Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641271","Albumin to Total Protein Ratio Measurement","C103453","The determination of the ratio of the albumin compared with total protein in a biological sample. The measurement may be expressed as a ratio or percentage.","Albumin to Total Protein Ratio Measurement | ALBPROT | Albumin/Total Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641269","VLDL Particle Size Measurement","C103450","The determination of the amount of the average particle size of very-low-density lipoprotein in a sample.","VLDL Particle Size Measurement | VLDL Particle Size | VLDLPSZ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641268","Vitamin E to Cholesterol Ratio Measurement","C103448","The determination of the ratio of vitamin E compared with the total cholesterol in a sample. The measurement may be expressed as a ratio or percentage.","Vitamin E to Cholesterol Ratio Measurement | VITECHOL | Vitamin E/Cholesterol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830620","Cytoplasmic Basophilia Neutrophil Count","C111166","The determination of the amount of neutrophils in a biological specimen showing a dark staining pattern in the cytoplasm due to increased acidic content.","Cytoplasmic Basophilia Neutrophil Count | Cytoplasmic Basophilia Neutrophil | NEUTCYBS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202093","Cryoglobulin Measurement","C111164","The determination of the amount of cryoglobulin present in a sample.","Cryoglobulin Measurement | CRYOGLBN | Cryoglobulin",,,,,,,,,,,,,,,"4150668","Cryoglobulin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0373889","Coccidioides Antibody Measurement","C111160","The determination of the amount of coccidioides antibody present in a sample.","Coccidioides Antibody Measurement | COCCAB | Coccidioides Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0391939","Chymotrypsin Measurement","C111159","The determination of the amount of chymotrypsin present in a sample.","Chymotrypsin Measurement | CHYTRYP | Chymotrypsin",,,,,,,,,,,,,,,"4016954","Chymotrypsin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0877174","Cancer Antigen 27-29 Measurement","C111143","The determination of the amount of cancer antigen 27-29 present in a sample.","Cancer Antigen 27-29 Measurement | CA2729AG | Cancer Antigen 27-29",,,,,,,,,,,,,,,"40483741","Measurement of cancer antigen 27-29",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828568","Phosphate Clearance Measurement","C106553","The determination of the amount of the phosphate clearance in a sample.","Phosphate Clearance Measurement | PHOSCLR | Phosphate Clearance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448196","Myoglobin to Creatinine Ratio Measurement","C106546","The determination of the ratio of myoglobin compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Myoglobin to Creatinine Ratio Measurement | MGBCREAT | Myoglobin/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828975","Monocytes to Macrocytes Ratio Measurement","C106544","The determination of the ratio of monocytes compared to macrocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Monocytes to Macrocytes Ratio Measurement | MONOMA | Monocytes/Macrocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829275","Lipocalin-2 to Creatinine Ratio Measurement","C106540","The determination of the ratio of lipocalin-2 compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Lipocalin-2 to Creatinine Ratio Measurement | LCN2CREA | Lipocalin-2/Creatinine | NGAL/Creatinine | Neutrophil Gelatinase-Associated Lipocalin/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829709","Hepatitis E Virus IgG Antibody Measurement","C106526","The determination of the amount of IgG antibody to the hepatitis E virus in a biological specimen","Hepatitis E Virus IgG Antibody Measurement | HEIGGAB | Hepatitis E Virus IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1135976","Umbilical Cord Blood Transplantation","C15640","A therapeutic procedure that involves the transplantation of hematopoietic stem cells collected from the umbilical cord.","Umbilical Cord Blood Transplantation | Cord Blood | Cord Blood Transplantation | UCB transplantation | UMBILICAL CORD BLOOD TRANSPLANT | umbilical cord blood transplantation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1370231","Count of Unspecified Cells","C112241","The determination of the amount of unspecified cells, those not otherwise identified, present in a sample.","Count of Unspecified Cells | UNSPCE | Unspecified Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813324","Active Ghrelin Measurement","C112219","The determination of the amount of active ghrelin present in a sample.","Active Ghrelin Measurement | Active Ghrelin | GHRELINA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL455346","Vacuolated Lymphocyte Count","C111329","The determination of the amount of vacuolated lymphocytes present in a sample.","Vacuolated Lymphocyte Count | LYMVAC | Vacuolated Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828466","Proinsulin to Insulin Ratio Measurement","C111299","The determination of the ratio of the proinsulin compared to insulin present in a sample. The measurement may be expressed as a ratio or percentage.","Proinsulin to Insulin Ratio Measurement | PRINSINS | Proinsulin/Insulin Ratio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828530","Platelet Component Distribution Width Measurement","C111294","The determination of the amount of platelet shape changes present in a sample.","Platelet Component Distribution Width Measurement | PCDW | Platelet Component Distribution Width",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828534","Platelet Aggregation Amplitude Measurement","C111293","The determination of the amount or magnitude of the platelet aggregation present in a sample.","Platelet Aggregation Amplitude Measurement | PLTAGAMP | Platelet Aggregation Amplitude",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL455345","Monocytoid Cell Count","C111276","The determination of the amount of monocytoid cells present in a sample.","Monocytoid Cell Count | MOCYCE | Monocytoid Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829128","Meningeal Cell to Total Cell Ratio Measurement","C111251","The determination of the ratio of the meningeal cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Meningeal Cell to Total Cell Ratio Measurement | MENGLCE | Meningeal Cells to Total Cells Ratio Measurement | Meningeal Cells/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829129","Meningeal Cell Count","C111250","The determination of the amount of meningeal cells present in a sample.","Meningeal Cell Count | MENGL | Meningeal Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829179","Mast Cell to Total Cell Ratio Measurement","C111247","The determination of the ratio of the mast cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Mast Cell to Total Cell Ratio Measurement | MASTCECE | Mast Cells to Total Cells Ratio Measurement | Mast Cells/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202110","Ketone Body Measurement","C111239","The determination of the amount of ketone bodies (acetone, acetoacetic acid, beta-hydroxybutyric acid, beta-ketopentanoate and beta-hydroxypentanoate) present in a sample.","Ketone Body Measurement | KETONEBD | Ketone Bodies",,,,,,,,,,,,,,,"4097313","Ketone bodies measurement, quantitative",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829721","Heinz Body to Erythrocyte Ratio Measurement","C111206","The determination of the ratio of the erythrocytes that contain heinz bodies compared to total erythrocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Heinz Body to Erythrocyte Ratio Measurement | HEINZRBC | Heinz Bodies/Erythrocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827338","Histone 3 Antibody Measurement","C112296","The determination of the amount of histone 3 antibody present in a sample.","Histone 3 Antibody Measurement | HIST3AB | Histone 3 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814775","Hemoglobin C Crystals Measurement","C112288","The determination of the amount of hemoglobin c crystals present in a sample.","Hemoglobin C Crystals Measurement | CYHGBC | Hemoglobin C Crystals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811895","Renin Activity Measurement","C111305","The determination of the amount of renin activity present in a sample.","Renin Activity Measurement | RENINA | Renin Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811388","Platelet Activating Factor Measurement","C111292","The determination of the amount of platelet activating factor present in a sample.","Platelet Activating Factor Measurement | PAF | Platelet Activating Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699466","Creatine Kinase BB to Total Creatine Kinase Ratio Measurement","C79466","The determination of the ratio of creatine kinase BB compared to total creatine kinase present in a sample. The measurement may be expressed as a ratio or percentage.","Creatine Kinase BB to Total Creatine Kinase Ratio Measurement | CKBBCK | Creatine Kinase BB/Total Creatine Kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697899","Large Unstained Cells to Leukocytes Ratio Measurement","C79467","The determination of the ratio of large unstained cells compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Large Unstained Cells to Leukocytes Ratio Measurement | LGLUCLE | Large Unstained Cells/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698402","N-Acetyl Glucosamide to Creatinine Ratio Measurement","C79460","The determination of the ratio of N-acetyl glucosamide compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","N-Acetyl Glucosamide to Creatinine Ratio Measurement | N-Acetyl Glucosamide/Creatinine | NAGCREAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698797","Phosphate to Creatinine Ratio Measurement","C79461","The determination of the ratio of phosphate compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Phosphate to Creatinine Ratio Measurement | PHOSCRT | Phosphate/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698861","Potassium to Creatinine Ratio Measurement","C79462","The determination of the ratio of potassium compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Potassium to Creatinine Ratio Measurement | KCREAT | Potassium/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697856","LDH Isoenzyme 5 to LDH Ratio Measurement","C79455","The determination of the ratio of LDH isoenzyme 5 compared to total LDH present in a sample. The measurement may be expressed as a ratio or percentage.","LDH Isoenzyme 5 to LDH Ratio Measurement | LDH Isoenzyme 5/LDH | LDH5LDH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1446080","Magnesium to Creatinine Ratio Measurement","C79456","The determination of the ratio of magnesium compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Magnesium to Creatinine Ratio Measurement | MGCREAT | Magnesium/Creatinine",,,,,,,,,,,,,,,"4136600","Magnesium / creatinine ratio measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698265","Mu Glutathione-S-Transferase Measurement","C79457","The determination of the amount of mu glutathione-s-transferase present in a sample.","Mu Glutathione-S-Transferase Measurement | GSTMU | Mu Glutathione-S-Transferase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698266","Mu Glutathione-S-Transferase to Creatinine Ratio Measurement","C79458","The determination of the ratio of mu glutathione-s-transferase compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Mu Glutathione-S-Transferase to Creatinine Ratio Measurement | GSTMUCRT | Mu Glutathione-S-Transferase/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898433","Medium Absorption Reticulocyte Measurement","C116192","The determination of the amount of medium absorption reticulocytes present in a sample.","Medium Absorption Reticulocyte Measurement | Medium Absorption Reticulocytes | RETIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898886","High Absorption Reticulocyte Measurement","C116188","The determination of the amount of high absorption reticulocytes present in a sample.","High Absorption Reticulocyte Measurement | High Absorption Reticulocytes | RETIH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898887","Heterophils to Leukocytes Ratio Measurement","C116187","The determination of the ratio of heterophils compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Heterophils to Leukocytes Ratio Measurement | HETRPHLE | Heterophils/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890712","Heterophil Measurement","C116186","The determination of the amount of heterophils present in a sample.","Heterophil Measurement | HETRPH | Heterophils",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827722","Unspecified Cells to Total Cell Ratio Measurement","C114225","The determination of the ratio of the cells not otherwise identified or specified compared to total cells in a sample. The measurement may be expressed as a ratio or percentage.","Unspecified Cells to Total Cell Ratio Measurement | UNSPCECE | Unspecified Cells to Total Cells Ratio Measurement | Unspecified Cells/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830312","Eosinophil Band Form to Leukocyte Ratio","C114217","The determination of the ratio of band eosinophils compared to leukocytes in a blood sample. The measurement may be expressed as a ratio or percentage.","Eosinophil Band Form to Leukocyte Ratio | EOSBLE | Eosinophils Band Form/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887699","Mean Platelet Dry Mass Measurement","C114214","The determination of the amount of mean platelet dry mass present in a sample.","Mean Platelet Dry Mass | MPM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828748","Nuclear Swelling Measurement","C114213","The determination of the expansion of the nucleus of the cells in a sample.","Nuclear Swelling Measurement | NUCSWELL | Nuclear Swelling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828531","Platelet Aggregometry Mean Curve Type","C114212","The average curve type resulting from platelet aggregometry.","Platelet Aggregometry Mean Curve Type | PLAGMCVT | Platelet Aggregation Mean Curve Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828532","Platelet Aggregometry Mean Amplitude","C114211","An average of the measurements of the magnitude of the platelet aggregation in a sample.","Platelet Aggregometry Mean Amplitude | PLAGMAMP | Platelet Aggregation Mean Amplitude",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828533","Platelet Aggregometry Curve Type","C114210","The classification of the curve pattern that is formed as a result of platelet aggregation.","Platelet Aggregometry Curve Type | PLAGGCVT | Platelet Aggregation Curve Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889289","Protozoa Measurement","C117849","The determination of the amount of protozoa present in a sample.","Protozoa Measurement | PROTOZOA | Protozoa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897557","Soluble Interleukin-1 Receptor Type I Measurement","C117836","The determination of the amount of soluble interleukin-1 receptor type I present in a sample.","Soluble Interleukin-1 Receptor Type I Measurement | IL1SR1 | Soluble Interleukin-1 Receptor Type I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897559","Soluble Immunoglobulin Measurement","C117835","The determination of the amount of soluble immunoglobulin present in a sample.","Soluble Immunoglobulin Measurement | IGSOL | Soluble Immunoglobulin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900012","Aspartate Aminotransferase to Creatinine Ratio Measurement","C117830","The determination of the ratio of aspartate aminotransferase compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Aspartate Aminotransferase to Creatinine Ratio Measurement | ASTCREAT | Aspartate Aminotransferase/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891161","Gamma Tocopherol Measurement","C116211","The determination of the amount of gamma tocopherol present in a sample.","Gamma Tocopherol Measurement | GATCPHRL | Gamma Tocopherol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699635","Dietary Route of Administration","C78373","Administration by way of food stuff.","Dietary Route of Administration | DIETARY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898585","Liver Specific Alkaline Phosphatase Measurement","C119267","The determination of the amount of the liver specific alkaline phosphatase in a biological specimen.","Liver Specific Alkaline Phosphatase Measurement | ALPLS | Liver Specific Alkaline Phosphatase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898710","Intestinal Specific Alkaline Phosphatase Measurement","C119266","The determination of the amount of the intestinal specific alkaline phosphatase in a biological specimen.","Intestinal Specific Alkaline Phosphatase Measurement | ALPIS | Intestinal Specific Alkaline Phosphatase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0552562","Oxalate to Creatinine Ratio Measurement","C117983","The determination of the ratio of oxalate compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Oxalate to Creatinine Ratio Measurement | OXACREAT | Oxalate/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523316","Varicella Zoster Virus Antibody Measurement","C117867","The determination of the amount of total Varicella Zoster virus antibody present in a sample.","Varicella Zoster Virus Antibody Measurement | VZVAB | Varicella Zoster Virus Antibody",,,,,,,,,,,,,,,"4018595|4191701","Measurement of Varicella-zoster virus antibody|Serologic test for Varicella-zoster virus",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0370118","Urate to Creatinine Ratio Measurement","C117866","The determination of the ratio of urate compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Urate to Creatinine Ratio Measurement | URATECRT | Urate/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897554","Soluble Tumor Necrosis Factor Receptor Type II Measurement","C117864","The determination of the amount of soluble TNF receptor type II present in a sample.","Soluble Tumor Necrosis Factor Receptor Type II Measurement | Soluble CD120b | Soluble CD120b Antigen Measurement | Soluble TNF Receptor 1B | Soluble TNF Receptor Type II | Soluble TNF Receptor Type II Measurement | Soluble TNF-R-II Measurement | Soluble TNF-R2 Measurement | Soluble TNF-RII Measurement | Soluble TNFBR Measurement | Soluble TNFR-II Measurement | Soluble TNFR1B | Soluble TNFR1B Measurement | Soluble TNFR2 Measurement | Soluble TNFRSF1B Measurement | Soluble Tumor Necrosis Factor Receptor 2 Measurement | Soluble Tumor Necrosis Factor Receptor Superfamily Member 1B Measurement | TNFSR2 | sTNFaRII Measurement | sTNFαRII Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897382","TNF-a Production Inhibitory Activity Measurement","C117862","The determination of the amount of TNF-alpha production inhibitory activity present in a sample.","TNF-a Production Inhibitory Activity Measurement | TNF-a Production Inhibition | TNF-a Production Inhibitory Activity | TNFAPI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL497349","Bioavailable Testosterone Measurement","C117860","The determination of the amount of bioavailable testosterone present in a sample.","Bioavailable Testosterone Measurement | Bioavailable Testosterone | TESTOSBA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897485","Strongyloides IgG Antibody Measurement","C117858","The determination of the amount of strongyloides IgG antibody present in a sample.","Strongyloides IgG Antibody Measurement | STRIGGAB | Strongyloides IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887493","Sclerostin Measurement","C117857","The determination of the amount of sclerostin present in a sample.","Sclerostin Measurement | SOST | Sclerostin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826701","Birth Month","C83090","The month in which a person was born.","Birth Month | BRTHMO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899951","Beta-1 Globulin to Total Protein Ratio Measurement","C119275","The determination of the ratio of the beta-1 globulin to albumin in a biological specimen.","Beta-1 Globulin to Total Protein Ratio Measurement | Beta-1 Globulin/Total Protein | GLOBB1PT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899520","Complement C3d Antibody Measurement","C119271","The determination of the amount of the complement C3d antibody in a biological specimen.","Complement C3d Antibody Measurement | C3DAB | Complement C3d Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0425379","Other Race","C104495","Individuals who do not necessarily identify with any particular race or others who do not wish to self select into a racial category(ies).","Other Race | OTHER RACE | Other | RACEOTH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881239","Intracameral Route of Administration","C64984","Administration of a medicinal product directly into the anterior chamber of the eye.","Intracameral Route of Administration | INTRACAMERAL | Intracameral | Intracameral use",,,,,,,,,,,,,,,"4303409","Intracameral",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2697853","LDH Isoenzyme 2 to LDH Ratio Measurement","C79452","The determination of the ratio of LDH isoenzyme 2 compared to total LDH present in a sample. The measurement may be expressed as a ratio or percentage.","LDH Isoenzyme 2 to LDH Ratio Measurement | LDH Isoenzyme 2/LDH | LDH2LDH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697855","LDH Isoenzyme 4 to LDH Ratio Measurement","C79454","The determination of the ratio of LDH isoenzyme 4 compared to total LDH present in a sample. The measurement may be expressed as a ratio or percentage.","LDH Isoenzyme 4 to LDH Ratio Measurement | LDH Isoenzyme 4/LDH | LDH4LDH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898889","Hepatitis D Virus IgM Antibody Measurement","C119282","The determination of the amount of hepatitis D virus IgM antibody in a biological specimen.","Hepatitis D Virus IgM Antibody Measurement | HDIGMAB | Hepatitis D Virus IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898890","Hepatitis D Virus IgG Antibody Measurement","C119281","The determination of the amount of hepatitis D virus IgG antibody in a biological specimen.","Hepatitis D Virus IgG Antibody Measurement | HDIGGAB | Hepatitis D Virus IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898891","Hepatitis B Virus Core IgG Antibody Measurement","C119280","The determination of the amount of hepatitis B virus core IgG antibody in a biological specimen.","Hepatitis B Virus Core IgG Antibody Measurement | HBCIGGAB | Hepatitis B Virus Core IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900056","Alpha-GST Excretion Rate","C119278","A determination of the amount of alpha glutathione-s-transferase being excreted over a defined period of time.","Alpha-GST Excretion Rate | Alpha Glutathione-S-Transferase Excretion Rate | GSTALEXR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899950","Beta-2 Globulin to Total Protein Ratio Measurement","C119277","The determination of the ratio of the beta-2 globulin to total protein in a biological specimen.","Beta-2 Globulin to Total Protein Ratio Measurement | Beta-2 Globulin/Total Protein | GLOBB2PT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826771","Birth Year","C83164","The year in which a person was born.","Birth Year | BRTHYR | BRTHYY | Year of Birth | year of birth | year_of_birth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898701","Intraparenchymal Route of Administration","C119548","Administration into the parenchyma of an organ.","Intraparenchymal Route of Administration | INTRAPARENCHYMAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640763","Intrapalatal Route of Administration","C102400","Administration into the palate.","Intrapalatal Route of Administration | INTRAPALATAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0595613","Intraosseous Route of Administration","C64987","Administration within the marrow of the bone.","Intraosseous Route of Administration | INTRAOSSEOUS | Intraosseous | Intraosseous use",,,,,,,,,,,,,,,"4213522","Intraosseous",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2697802","Intranodal Route of Administration","C79141","Administration within a lymph node.","Intranodal Route of Administration | INTRANODAL | Intranodal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640762","Intrajejunal Route of Administration","C102399","Administration into the jejunum.","Intrajejunal Route of Administration | INTRAJEJUNAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049930","Apolipoprotein B100 Measurement","C120628","The determination of the apolipoprotein B100 present in a sample.","Apolipoprotein B100 Measurement | APOB100 | APOB100 Measurement | Apolipoprotein B100",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055457","Anti-Nucleosome Antibody Measurement","C120627","The determination of the anti-nucleosome antibody present in a sample.","Anti-Nucleosome Antibody Measurement | ANUAB | Anti-Nucleosome Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900187","8-Iso-Prostaglandin F2 Alpha Measurement","C119292","The determination of the amount of 8-iso-prostaglandin F2 alpha in a biological specimen.","8-Iso-Prostaglandin F2 Alpha Measurement | 8-Iso-Prostaglandin F2 Alpha | PGF2AI8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900186","8-Iso-Prostaglandin F2 Alpha to Creatinine Ratio Measurement","C119291","The determination of the ratio of the 8-iso-prostaglandin F2 alpha to creatinine in a biological specimen.","8-Iso-Prostaglandin F2 Alpha to Creatinine Ratio Measurement | 8-Iso-PGF2alpha/Creatinine | PF2AI8CR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898143","Neutrophil Myeloperoxidase Index","C119290","The mean myeloperoxidase staining intensity of the neutrophil population relative to the archetype.","Neutrophil Myeloperoxidase Index | MPXI | Myeloperoxidase Index",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889996","Activated Lymphocytes Measurement","C119289","The determination of the amount of activated lymphocytes in a biological specimen.","Activated Lymphocytes Measurement | LYMA | Lymphocytes Activated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898063","Oxidized LDL Cholesterol Antibody Measurement","C119288","The determination of the amount of oxidized low density lipoprotein cholesterol antibody in a biological specimen.","Oxidized LDL Cholesterol Antibody Measurement | LDLOXAB | Oxidized LDL Cholesterol Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337430","Insulin Antibody Measurement","C119287","The determination of the amount of insulin antibody in a biological specimen.","Insulin Antibody Measurement | INSAB | Insulin Antibody",,,,,,,,,,,,,,,"4290342","Insulin antibody measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2243092","Insulin Autoantibody Measurement","C119286","The determination of the amount of insulin autoantibody in a biological specimen.","Insulin Autoantibody Measurement | INS Autoantibody Measurement | INSAAB | Insulin Autoantibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898746","Insulinoma-Associated Protein 2 Antibody Measurement","C119284","The determination of the amount of insulinoma-associated protein 2 antibody in a biological specimen.","Insulinoma-Associated Protein 2 Antibody Measurement | IA2AB | Insulinoma-Associated Protein 2 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899197","Exposure as Collected Subcategory","C117476","A subdivision of collected exposure data.","Exposure as Collected Subcategory | ECSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897823","Procedure Subcategory","C117514","A subdivision of a procedure event.","Procedure Subcategory | PRSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827016","Substance Use Subcategory","C83427","Classification of substance use data.","Substance Use Subcategory | SUSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981445","Clinical Events Subcategory","C87861","A subdivision of adverse event data.","Clinical Events Subcategory | CESCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981579","Protocol Deviation Subcategory","C87996","A subdivision of protocol deviation data.","Protocol Deviation Subcategory | DVSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086439","Healthcare Encounters Subcategory","C123999","A subdivision of healthcare encounters data.","Healthcare Encounters Subcategory | HOSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826751","Medical History Subcategory","C83143","A sub-division of the medical history classification.","Medical History Subcategory | MHSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826749","Drug Accountability Record Subcategorization","C83141","A sub-division of the drug accountability classification.","Drug Accountability Record Subcategorization | DASCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890903","Death Diagnosis Assessment Test","C117545","A character or string that represents the long name of the death diagnosis assessment.","Death Diagnosis Assessment Test | DDTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826855","Electrocardiogram Subcategory","C83265","A subdivision of electrocardiographic data.","Electrocardiogram Subcategory | EGSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826888","Inclusion Exclusion Criterion Subcategory","C83298","A subdivision of inclusion exclusion criterion.","Inclusion Exclusion Criterion Subcategory | IESCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898356","Microscopic Findings Subcategory","C117581","A subdivision of microscopic findings data.","Microscopic Findings Subcategory | MISCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826945","Physical Examination Subcategory","C83355","A subdivision of physical examination data.","Physical Examination Subcategory | PESCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826991","Subject Characteristics Subcategory","C83402","A subdivision of subject characteristics data.","Subject Characteristics Subcategory | SCSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897701","Reproductive System Findings Subcategory","C117643","A subdivision of reproductive system findings data.","Reproductive System Findings Subcategory | RPSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897576","Skin Response Subcategory","C117678","A subdivision of skin response data.","Skin Response Subcategory | SRSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827049","Vital Signs Subcategory","C83461","A subdivision of vital signs data.","Vital Signs Subcategory | VSSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981475","Findings About Events or Interventions Subcategory","C87891","A subdivision of findings data.","Findings About Events or Interventions Subcategory | FASCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897103","Exposure as Collected Category","C117475","A classification of collected exposure data.","Exposure as Collected Category | ECCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897851","Procedure Category","C117513","A classification of a procedure event.","Procedure Category | PRCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826236","Substance Use Category","C82499","A classification scheme based on the use of a particular material or product.","Substance Use Category | SUCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981428","Clinical Events Category","C87844","A classification of clinical event data.","Clinical Events Category | CECAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981573","Protocol Deviation Category","C87990","A classification of protocol deviation data.","Protocol Deviation Category | DVCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086420","Healthcare Encounters Category","C123940","A classification of healthcare encounters data.","Healthcare Encounters Category | HOCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826631","Medical History Category","C83018","A classification of the medical history.","Medical History Category | MEDICAL_HISTORY_CATEGORY | MHCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826628","Drug Accountability Record Categorization","C83015","A classification of the drug accountability.","Drug Accountability Record Categorization | DACAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826844","Electrocardiogram Category","C83254","A classification of electrocardiogram data.","Electrocardiogram Category | EGCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898379","Microscopic Findings Category","C117580","A classification of microscopic findings data.","Microscopic Findings Category | MICAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890399","Microscopic Findings Result Category","C117587","A classification of a microscopic findings result.","Microscopic Findings Result Category | MIRESCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826931","Physical Examination Category","C83341","A classification of physical examination data.","Physical Examination Category | PECAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826985","Subject Characteristics Category","C83396","A classification of subject characteristics data.","Subject Characteristics Category | SCCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897715","Reproductive System Findings Category","C117642","A classification of reproductive system findings data.","Reproductive System Findings Category | RPCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897598","Skin Response Category","C117677","A classification of skin response data.","Skin Response Category | SRCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827040","Vital Signs Category","C83452","A classification of vital signs data.","Vital Signs Category | VSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981470","Findings About Events or Interventions Category","C87886","A classification of findings about events or interventions data.","Findings About Events or Interventions Category | FACAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889668","Death Diagnosis Assessment Test Code","C117544","A character or string that represents the short code name of the death diagnosis assessment.","Death Diagnosis Assessment Test Code | DDTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985663","Study Reference","C93452","A citation to a publication related to the protocol's background.","Study Reference | StudyReference",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054342","Non-HDL Cholesterol to HDL Cholesterol Ratio Measurement","C120644","The determination of the ratio of non-HDL cholesterol compared to HDL cholesterol present in a sample. The measurement may be expressed as a ratio or percentage.","Non-HDL Cholesterol to HDL Cholesterol Ratio Measurement | NOHDLHDL | Non-HDL Cholesterol/HDL Cholesterol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054040","Segmented Neutrophils to Neutrophils Ratio Measurement","C120643","The determination of the ratio of segmented neutrophils compared to neutrophils present in a sample. The measurement may be expressed as a ratio or percentage.","Segmented Neutrophils to Neutrophils Ratio Measurement | NEUTSGNE | Neutrophils, Segmented/Neutrophils",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054355","Neutrophils Band Form to Neutrophils Ratio Measurement","C120642","The determination of the ratio of neutrophil band form compared to neutrophils present in a sample. The measurement may be expressed as a ratio or percentage.","Neutrophils Band Form to Neutrophils Ratio Measurement | NEUTBNE | Neutrophils Band Form/ Neutrophils",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054477","Monocytoid Cells to Leukocytes Ratio Measurement","C120641","The determination of the ratio of monocytoid cells compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Monocytoid Cells to Leukocytes Ratio Measurement | MOCYCELE | Monocytoid Cells/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2587208","Lysozyme Measurement","C120640","The determination of the lysozyme present in a sample.","Lysozyme Measurement | LYSOZYME | Lysozyme",,,,,,,,,,,,,,,"4020535","Lysozyme measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1532761","Lactoferrin Antibody Measurement","C120639","The determination of the lactoferrin antibody present in a sample.","Lactoferrin Antibody Measurement | LTFAB | Lactoferrin Antibody",,,,,,,,,,,,,,,"4190522","Anti lactoferrin antibody level",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2584948","Lipoprotein Associated Phospholipase A2 Measurement","C120638","The determination of the lipoprotein associated phospholipase A2 present in a sample.","Lipoprotein Associated Phospholipase A2 Measurement | LPPLA2 | Lipoprotein Associated Phospholipase A2",,,,,,,,,,,,,,,"4229193","Lipoprotein associated phospholipase A₂ measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054684","LDL Subtype Pattern","C120637","A description of the low density lipoprotein particle pattern (an interpretation of the amounts of LDL particles based on size and density) in a sample.","LDL Subtype Pattern | LDLPATT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050214","Cholesteryl Ester Transfer Protein Measurement","C120632","The determination of the cholesteryl ester transfer protein present in a sample.","Cholesteryl Ester Transfer Protein Measurement | CETP | Cholesteryl Ester Transfer Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054685","LDL Particles Measurement","C120636","The determination of the LDL particles present in a sample.","LDL Particles Measurement | LDL Particles | LDLP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523571","Chylomicrons Measurement","C120633","The determination of the chylomicrons present in a sample.","Chylomicrons Measurement | CHLMCRN | Chylomicrons",,,,,,,,,,,,,,,"4019548","Chylomicrons measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4050330","Apolipoprotein B48 Measurement","C120629","The determination of the apolipoprotein B48 present in a sample.","Apolipoprotein B48 Measurement | APOB48 | APOB48 Measurement | Apolipoprotein B48",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055451","Antinuclear IgG Antibody Measurement","C122093","The determination of the amount of antinuclear IgG antibody present in a sample.","Antinuclear IgG Antibody Measurement | ANAIGGAB | Antinuclear IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523674","Glycated Albumin Measurement","C122092","The determination of the amount of glycated albumin related peptide present in a biological specimen.","Glycated Albumin Measurement | ALBGLYCA | Glycated Albumin",,,,,,,,,,,,,,,"4018320","Glycated albumin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523459","Alanine Measurement","C122091","The determination of the amount of alanine present in a sample.","Alanine Measurement | ALA | Alanine",,,,,,,,,,,,,,,"4017496","Alanine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL494719","Triglycerides to HDL Cholesterol Ratio Measurement","C121183","The determination of the ratio of triglycerides compared to HDL cholesterol present in a sample. The measurement may be expressed as a ratio or percentage.","Triglycerides to HDL Cholesterol Ratio Measurement | TRIGHDL | Triglycerides/HDL Cholesterol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053882","VLDL Cholesterol Subtype 3 Measurement","C120669","The determination of the very low density lipoprotein cholesterol subtype 3 present in a sample.","VLDL Cholesterol Subtype 3 Measurement | VLDL Cholesterol Subtype 3 | VLDL3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053884","VLDL Cholesterol Subtype 1 Measurement","C120667","The determination of the very low density lipoprotein cholesterol subtype 1 present in a sample.","VLDL Cholesterol Subtype 1 Measurement | VLDL Cholesterol Subtype 1 | VLDL1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050092","Thymidine Kinase Measurement","C120665","The determination of the thymidine kinase present in a sample.","Thymidine Kinase Measurement | TK | Thymidine Kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053904","Type II Secretory Phospholipase A2 Measurement","C120663","The determination of the type II secretory phospholipase A2 present in a sample.","Type II Secretory Phospholipase A2 Measurement | SPLA2II | Type II Secretory Phospholipase A2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1294732","Ribosomal P Protein Antibody Measurement","C120659","The determination of the ribosomal P protein antibody present in a sample.","Ribosomal P Protein Antibody Measurement | RPPAB | Ribosomal P Protein Antibody",,,,,,,,,,,,,,,"4039698","Measurement of ribosomal P protein antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054058","Ribonucleoprotein Smith Complex Antibody Measurement","C120658","The determination of the ribonucleoprotein Smith complex antibody present in a sample.","Ribonucleoprotein Smith Complex Antibody Measurement | RNPSMAB | Ribonucleoprotein Smith Complex Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054077","Remnant-like Particle Cholesterol Measurement","C120655","The determination of the RLP cholesterol present in a sample.","Remnant-like Particle Cholesterol Measurement | RLP | RLP Cholesterol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054060","Rheumatoid Factor Antibody IgG Measurement","C120653","The determination of the rheumatoid factor antibody IgG present in a sample.","Rheumatoid Factor Antibody IgG Measurement | RFIGGAB | Rheumatoid Factor IgG Antibody",,,,,,,,,,,,,,,"4187459","Rheumatoid factor IgG level",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054061","Rheumatoid Factor Antibody IgA Measurement","C120652","The determination of the rheumatoid factor antibody IgA present in a sample.","Rheumatoid Factor Antibody IgA Measurement | RFIGAAB | Rheumatoid Factor IgA Antibody",,,,,,,,,,,,,,,"4185915","IgA rheumatoid factor level",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523843","Porphyrin Measurement","C120648","The determination of the porphyrin present in a sample.","Porphyrin Measurement | PORPH | Porphyrin",,,,,,,,,,,,,,,"4019985","Porphyrin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4050316","Proprotein Convertase Subtilisin/Kexin Type 9 Measurement","C120647","The determination of the proprotein convertase subtilisin/kexin type 9 present in a sample.","Proprotein Convertase Subtilisin/Kexin Type 9 Measurement | PCSK9 | Proprotein Convertase Subtilisin/Kexin 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0302274","Glutamine measurement","C122121","The determination of the amount of glutamine present in a sample.","Glutamine Measurement | GLN | Glutamine",,,,,,,,,,,,,,,"4017081","Glutamine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053755","Fractional Excretion of Magnesium Measurement","C122119","The percentage of the total magnesium filtered by the kidney that is excreted in the urine. The fractional excretion is calculated by multiplying urinary magnesium concentration by the plasma creatinine concentration, then dividing by the urinary creatinine concentration multiplied by the plasma magnesium concentration. The resulting ratio is multiplied by 100.","Fractional Excretion of Magnesium | FEMG | Fractional Magnesium Excretion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053801","Factor X Activity Measurement","C122118","The determination of the amount of the biological activity of factor X in a sample.","Factor X Activity Measurement | FACTXA | Factor X Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1271799","von Willebrand Factor Activity Measurement","C122117","The determination of the amount of the biological activity of von Willebrand factor in a sample.","von Willebrand Factor Activity Measurement | FACTVWA | von Willebrand Factor Activity",,,,,,,,,,,,,,,"4287766","Von Willebrand factor activity measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4050093","Desmoglein 1 Antibody Measurement","C122114","The determination of the amount of desmoglein 1 antibody in a biological specimen.","Desmoglein 1 Antibody Measurement | DSG1AB | Desmoglein 1 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053738","Cardiolipin IgA Antibody Measurement","C122112","The determination of the amount of cardiolipin IgA antibody in a biological specimen.","Cardiolipin IgA Antibody Measurement | CRDIGAAB | Cardiolipin IgA Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523573","Citrulline Measurement","C122109","The determination of the amount of citrulline present in a sample.","Citrulline Measurement | CIT | Citrulline",,,,,,,,,,,,,,,"4016955","Citrulline measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1295114","Chromogranin A Measurement","C122108","The determination of the amount of chromogranin A present in a sample.","Chromogranin A Measurement | CGA | CHGA Measurement | CgA Measurement | Chromogranin A | Chromogranin-A Measurement | Parathyroid Secretory Protein 1 Measurement | Pituitary Secretory Protein I Measurement | SP-I Measurement",,,,,,,,,,,,,,,"4006180","Chromogranin A measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055335","CD45RA to Lymphocyte Ratio Measurement","C122107","The determination of the ratio of CD45RA expressing cells to total lymphocytes present in a sample. The measurement by be expressed as a ratio or percentage.","CD45RA to Lymphocyte Ratio Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055339","CD161 to Lymphocyte Ratio Measurement","C122105","The determination of the ratio of CD161 expressing cells to total lymphocytes present in a sample. The measurement by be expressed as a ratio or percentage.","CD161 to Lymphocyte Ratio Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523516","Asparagine Measurement","C122096","The determination of the amount of asparagine present in a sample.","Asparagine Measurement | ASN | Asparagine",,,,,,,,,,,,,,,"4019455","Asparagine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523503","Arginine Measurement","C122095","The determination of the amount of arginine present in a sample.","Arginine Measurement | ARG | Arginine",,,,,,,,,,,,,,,"4014900","Arginine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2699468","Creatine Kinase MM to Total Creatine Kinase Ratio Measurement","C79442","The determination of the ratio of creatine kinase MM compared to total creatine kinase present in a sample. The measurement may be expressed as a ratio or percentage.","Creatine Kinase MM to Total Creatine Kinase Ratio Measurement | CKMMCK | Creatine Kinase MM/Total Creatine Kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523601","Deoxypyridinoline Measurement","C79443","The determination of the amount of deoxypyridinoline present in a sample.","Deoxypyridinoline Measurement | DPD | Deoxypyridinoline",,,,,,,,,,,,,,,"4018199","Deoxypyridinoline measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0805873","Deoxypyridinoline to Creatinine Ratio Measurement","C79444","The determination of the ratio of deoxypyridinoline compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Deoxypyridinoline to Creatinine Ratio Measurement | DPDCREAT | Deoxypyridinoline/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700237","Gamma Glutamyl Transferase to Creatinine Ratio Measurement","C79446","The determination of the ratio of gamma glutamyl transferase compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Gamma Glutamyl Transferase to Creatinine Ratio Measurement | GGTCREAT | Gamma Glutamyl Transferase/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697505","Glucose to Creatinine Ratio Measurement","C79447","The determination of the ratio of glucose compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Glucose to Creatinine Ratio Measurement | GLUCCRT | Glucose/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0302273","Glutamate Dehydrogenase Measurement","C79448","The determination of the amount of glutamate dehydrogenase present in a sample.","Glutamate Dehydrogenase Measurement | GLDH | Glutamate Dehydrogenase",,,,,,,,,,,,,,,"4018319","Glutamate dehydrogenase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2697877","Lactate Dehydrogenase to Creatinine Ratio Measurement","C79449","The determination of the ratio of lactate dehydrogenase compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Lactate Dehydrogenase to Creatinine Ratio Measurement | LDHCREAT | Lactate Dehydrogenase/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697852","LDH Isoenzyme 1 to LDH Ratio Measurement","C79451","The determination of the ratio of LDH isoenzyme 1 compared to total LDH present in a sample. The measurement may be expressed as a ratio or percentage.","LDH Isoenzyme 1 to LDH Ratio Measurement | LDH Isoenzyme 1/LDH | LDH1LDH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698066","Alpha Glutathione-S-Transferase Measurement","C79433","The determination of the amount of alpha glutathione-s-transferase present in a sample.","Alpha Glutathione-S-Transferase Measurement | Alpha Glutathione-S-Transferase | GSTAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0373588","Corticosterone Measurement","C79434","The determination of the amount of corticosterone present in a sample.","Corticosterone Measurement | CRTRONE | Corticosterone",,,,,,,,,,,,,,,"4017630","Corticosterone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2697506","Glutathione-S-Transferase to Creatinine Ratio Measurement","C79435","The determination of the ratio of glutathione-s-transferase compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Glutathione-S-Transferase to Creatinine Ratio Measurement | GSTCREAT | Glutathione-S-Transferase/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697990","Alkaline Phosphatase to Creatinine Ratio Measurement","C79438","The determination of the ratio of alkaline phosphatase compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Alkaline Phosphatase to Creatinine Ratio Measurement | ALPCREAT | Alkaline Phosphatase/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0428613","Calcium to Creatinine Ratio Measurement","C79439","The determination of the ratio of calcium compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Calcium to Creatinine Ratio Measurement | CACREAT | Calcium/Creatinine",,,,,,,,,,,,,,,"4354261","Calcium/creatinine ratio measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0805628","Chloride to Creatinine Ratio Measurement","C79440","The determination of the ratio of chloride compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Chloride to Creatinine Ratio Measurement | CLCREAT | Chloride/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512300","Intravaginal Route of Administration","C128996","Administration within the vagina.","Intravaginal Route of Administration | INTRAVAGINAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512299","Intrathalamic Route of Administration","C128995","Administration within the thalamus.","Intrathalamic Route of Administration | INTRATHALAMIC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540343","Intrasurgical Site Route of Administration","C142365","Administration within the site of surgery.","Intrasurgical Site Route of Administration | INTRASURGICAL SITE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879636","Administration via Stoma","C65138","Administration into a stoma.","Administration via Stoma | INTRASTOMAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552740","Microdialysis Route of Administration","C150889","Administration through perfusion liquid.","Microdialysis Route of Administration | MICRODIALYSIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1299004","Oromucosal Route of Administration","C64906","Administration of a medicinal product to the oral cavity to obtain either a systemic or a local effect.","Oromucosal Route of Administration | OROMUCOSAL | Oromucosal use",,,,,,,,,,,,,,,"4186839","Oromucosal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698653","Oral Gavage Route of Administration","C78374","Administration through the mouth and into the stomach, usually by means of a tube.","Oral Gavage Route of Administration | ORAL GAVAGE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828580","Perivenous Route of Administration","C112396","Administration into the area surrounding a vein. (NCI)","Perivenous Route of Administration | PERIVENOUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512494","Suprachoroidal Route of Administration","C128997","Administration above the choroid.","Suprachoroidal Route of Administration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986610","Subtenon Route of Administration","C94636","Administration by injection through the membrane covering the muscles and nerves at the back of the eyeball.","Subtenon Route of Administration | SUBTENON | subtenon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699708","Subretinal Route of Administration","C79143","Administration beneath the retina.","Subretinal Route of Administration | SUBRETINAL | Subretinal | Subretinal use",,,,,,,,,,,,,,,"37207465","Subretinal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2826725","Electrocardiogram Reference Identifier","C83115","A reference identifier for the electrocardiogram assessment.","Electrocardiogram Reference Identifier | EGREFID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826276","Medical History Line Number","C82544","The line number of the medical history.","Medical History Line Number | MHNO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826275","Adverse Event Line Number","C82543","The line number of the adverse event.","Adverse Event Line Number | AENO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899203","Exposure as Collected Reference Identifier","C117469","A sequence of characters used to identify, name, or characterize the collected exposure reference.","Exposure as Collected Reference Identifier | ECREFID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899213","Exposure as Collected Lot Number","C117487","A distinctive alpha-numeric identification code assigned by the manufacturer or distributor to a specific quantity of manufactured material or product within a batch that the subject was exposed to.","Exposure as Collected Lot Number | ECLOT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899217","Exposure as Collected Intended Dose Regimen","C117485","A treatment plan that specifies the amount, schedule, and the duration of the collected exposure.","Exposure as Collected Intended Dose Regimen | ECDOSRGM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826657","Exposure Interruption Duration","C83045","The time span of a disruption in the exposure.","Exposure Interruption Duration | EXINTRP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826284","Treatment Vehicle Amount","C82553","The quantity of a treatment vehicle.","Treatment Vehicle Amount | VAMT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826733","Protocol Deviation Dictionary Derived Term","C83123","The literal identifier of a protocol deviation as determined by a standards organization.","Protocol Deviation Dictionary Derived Term | DVDECOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697872","Lactate Dehydrogenase Isoenzyme 1 Measurement","C74887","The determination of the lactate dehydrogenase isoenzyme 1 present in a sample.","Lactate Dehydrogenase Isoenzyme 1 Measurement | LDH Isoenzyme 1 | LDH1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697874","Lactate Dehydrogenase Isoenzyme 3 Measurement","C74889","The determination of the lactate dehydrogenase isoenzyme 3 present in a sample.","Lactate Dehydrogenase Isoenzyme 3 Measurement | LDH Isoenzyme 3 | LDH3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697875","Lactate Dehydrogenase Isoenzyme 4 Measurement","C74890","The determination of the lactate dehydrogenase isoenzyme 4 present in a sample.","Lactate Dehydrogenase Isoenzyme 4 Measurement | LDH Isoenzyme 4 | LDH4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697876","Lactate Dehydrogenase Isoenzyme 5 Measurement","C74891","The determination of the lactate dehydrogenase isoenzyme 5 present in a sample.","Lactate Dehydrogenase Isoenzyme 5 Measurement | LDH Isoenzyme 5 | LDH5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826688","Protocol Deviation Sponsor Defined Identifier","C83077","One or more sponsor-defined characters used to identify, name, or characterize the protocol deviations.","Protocol Deviation Sponsor Defined Identifier | DVSPID | Sponsor Defined Deviation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830393","Drug Accountability Date","C113356","The date that the drug accountability assessments occurred on.","Drug Accountability Date | DADAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981458","Drug Accountability Reference Identifier","C87874","A character or string used to name, or characterize a drug accountability reference.","Drug Accountability Reference Identifier | DAREFID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826712","Drug Accountability Assessment Original Result","C83102","The outcome of the drug accountability examination.","Drug Accountability Assessment Original Result | DAORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981455","Drug Accountability Group Identifier","C87871","A character or string that represents a drug accountability group.","Drug Accountability Group Identifier | DAGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981440","Clinical Events Sponsor Defined Identifier","C87856","One or more sponsor defined characters used to identify, name, or characterize the clinical event.","Clinical Events Sponsor Defined Identifier | CESPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981603","Clinical Events Reported Term","C88021","An account or report of a clinical event.","Clinical Events Reported Term | CETERM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981439","Clinical Events Severity","C87855","The degree of gravity of a clinical event.","Clinical Events Severity | CESEV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826262","Toxicity Grade","C82528","A ranking of the poisonous nature of an object.","Toxicity Grade | TOXGR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981430","Clinical Events Dictionary Derived Term","C87846","The name of a clinical event as described in a dictionary.","Clinical Events Dictionary Derived Term | CEDECOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337446","Tyrosine Measurement","C122159","The determination of the amount of tyrosine present in a sample.","Tyrosine Measurement | TYR | Tyrosine",,,,,,,,,,,,,,,"4225595","Tyrosine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1167909","T-Lymphocyte Count","C122157","The determination of the amount of T-lymphocytes in a biological specimen.","T-Lymphocyte Count | T-Cell Count | T-Cell Lymphocytes | T-Cells | T-Lymphocytes | TLYCE",,,,,,,,,,,,,,,"4039856","T lymphocyte count",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523920","Threonine Measurement","C122156","The determination of the amount of threonine present in a sample.","Threonine Measurement | THR | Threonine",,,,,,,,,,,,,,,"4021281","Threonine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL497226","Transforming Growth Factor Beta Measurement","C122155","The determination of the amount of total transforming growth factor beta in a biological specimen.","Transforming Growth Factor Beta Measurement | TGFB | Transforming Growth Factor Beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523888","Serine Measurement","C122149","The determination of the amount of serine present in a sample.","Serine Measurement | SER | Serine",,,,,,,,,,,,,,,"4017341","Serine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054132","RNA Polymerase III IgG Antibody Measurement","C122147","The determination of the amount of RNA polymerase III IgG antibody present in a sample.","RNA Polymerase III IgG Antibody Measurement | RNA Polymerase III IgG Antibody | RP3IGGAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054184","Phosphatidylserine Antibody IgM Measurement","C122145","The determination of the amount of phosphatidylserine antibody IgM present in a sample.","Phosphatidylserine Antibody IgM Measurement | PSIGMAB | Phosphatidylserine IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054185","Phosphatidylserine Antibody IgG Measurement","C122144","The determination of the amount of phosphatidylserine antibody IgG present in a sample.","Phosphatidylserine Antibody IgG Measurement | PSIGGAB | Phosphatidylserine IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054186","Phosphatidylserine Antibody IgA Measurement","C122143","The determination of the amount of phosphatidylserine antibody IgA present in a sample.","Phosphatidylserine Antibody IgA Measurement | PSIGAAB | Phosphatidylserine IgA Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1168440","Free Protein S Measurement","C122142","The determination of the amount of unbound protein S in a biological specimen.","Free Protein S Measurement | PROTSFR | Protein S, Free",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202205","Oligoclonal Bands Measurement","C122139","The determination of the amount of oligoclonal bands in a biological specimen.","Oligoclonal Bands Measurement | OLIGBAND | Oligoclonal Bands",,,,,,,,,,,,,,,"4212433","Oligoclonal protein measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523795","Normetanephrine Measurement","C122138","The determination of the amount of normetanephrine present in a sample.","Normetanephrine Measurement | NORMETA | Normetanephrine",,,,,,,,,,,,,,,"4017218","Normetanephrine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3536769","Sodium to Potassium Ratio Measurement","C122137","The determination of the ratio of sodium to potassium present in a sample. The measurement by be expressed as a ratio or percentage.","Sodium to Potassium Ratio Measurement | NAK | Sodium/Potassium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054453","Mumps Virus IgG Antibody Measurement","C122136","The determination of the amount of mumps virus IgG antibody present in a sample.","Mumps Virus IgG Antibody Measurement | MMPIGGAB | Mumps Virus IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523760","Lysine Measurement","C122134","The determination of the amount of lysine present in a sample.","Lysine Measurement | LYS | Lysine",,,,,,,,,,,,,,,"4017789","Lysine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4050157","Interleukin 1 Alpha Measurement","C122131","The determination of the amount of interleukin-1 alpha present in a sample.","Interleukin 1 Alpha Measurement | INTLK1A | Interleukin 1 Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523677","Glycine Measurement","C122122","The determination of the amount of glycine present in a sample.","Glycine Measurement | GLY | Glycine",,,,,,,,,,,,,,,"4020983","Glycine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2170357","Aldosterone to Renin Activity Ratio Measurement","C124338","The determination of the ratio of the aldosterone compared to renin activity present in a sample. The measurement may be expressed as a ratio or percentage.","Aldosterone to Renin Activity Ratio Measurement | ARR | Aldosterone/Renin Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049994","Insulin Resistance Measurement","C123458","The determination of the insulin resistance (cells inability to respond to insulin) in a biological specimen.","Insulin Resistance Measurement | INSULINR | Insulin Resistance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055385","Beta-Cell Function Measurement","C123455","The determination of the beta cell function (insulin production and secretion) in a biological specimen.","Beta-Cell Function Measurement | BCEFNCTN | Beta-cell Function",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509064","Segmented Granulocyte to Total Cell Ratio Measurement","C127616","The determination of the ratio of segmented granulocytes compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Segmented Granulocyte to Total Cell Ratio Measurement | GRANSGCE | Granulocytes Segmented/Total Cells | Segmented Granulocytes to Total Cells Ratio Measurement | Segmented Granulocytes/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509063","Band Form Granulocyte to Total Cell Ratio Measurement","C127615","The determination of the ratio of band form granulocytes compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Band Form Granulocyte to Total Cell Ratio Measurement | Band Form Granulocytes to Total Cells Ratio Measurement | GRANBCE | Granulocytes Band Form/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509614","Glomeluar Filtration Rate from Cystatin C and Creatinine Adjusted for BSA","C127614","The determination of the glomerular filtration rate by measurement of creatinine and cystatin C clearance and whose result is adjusted for body surface area.","Glomerular Filtration Rate from Cystatin C and Creatinine Adjusted for BSA | GFR from Cystatin C and Creat Adj BSA | GFRBSCCC | Glomeluar Filtration Rate from Cystatin C and Creatinine Adjusted for BSA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512522","Copeptin Measurement","C127612","The determination of the amount of copeptin present in a sample.","Copeptin Measurement | COPEP | Copeptin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523347","Complement C4d Measurement","C127610","The determination of the amount of complement C4d present in a sample.","Complement C4d Measurement | C4D | Complement C4d",,,,,,,,,,,,,,,"4015468","Complement C4d measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509814","Blister Cell Count","C127609","The determination of the number of blister cells in a biological sample.","Blister Cell Count | BLISTCE | Blister Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0552328","Beta-2 Microglobulin to Creatinine Ratio Measurement","C127608","The determination of the ratio of beta-2 microglobulin compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Beta-2 Microglobulin to Creatinine Ratio Measurement | B2MCREAT | Beta-2 Microglobulin/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505161","Urea Nitrogen to Creatinine Ratio Measurement","C125950","The determination of the ratio of urea-nitrogen to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Urea Nitrogen to Creatinine Ratio Measurement | UREANCRT | Urea Nitrogen/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202238","Urea Nitrogen Measurement","C125949","The determination of the amount of urea nitrogen present in a sample.","Urea Nitrogen Measurement | UREAN | Urea Nitrogen",,,,,,,,,,,,,,,"4074649","Urea nitrogen measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504581","Iohexol Measurement","C125946","The determination of the amount of iohexol present in a sample.","Iohexol Measurement | IOHEXOL | Iohexol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523725","Inulin Measurement","C125945","The determination of the amount of inulin present in a sample.","Inulin Measurement | INULIN | Inulin",,,,,,,,,,,,,,,"4018337","Inulin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504580","Hepatitis B Virus Antibody Measurement","C125944","The determination of the amount of hepatitis B virus antibody present in a sample.","Hepatitis B Virus Antibody Measurement | HBAB | Hepatitis B Virus Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504579","Carbohydrate-Deficient Transferrin to Transferrin Ratio Measurement","C125943","The determination of the ratio of carbohydrate-deficient transferrin to total transferrin present in a sample. The measurement may be expressed as a ratio or percentage.","Carbohydrate-Deficient Transferrin to Transferrin Ratio Measurement | CDTTFRN | Carb-Deficient Transferrin/Transferrin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086616","Mycobacterium tuberculosis IgE Antibody Measurement","C124347","The determination of the amount of Mycobacterium tuberculosis IgE antibody present in a sample.","Mycobacterium tuberculosis IgE Antibody Measurement | MTBIGEAB | Mycobacterium tuberculosis IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504578","Ionized pH Adjusted Calcium Measurement","C125941","The determination of the amount of ionized pH adjusted calcium present in a sample.","Ionized pH Adjusted Calcium Measurement | CAIONPH | Calcium, Ionized pH Adjusted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086615","Mycobacterium tuberculosis IgA Antibody Measurement","C124346","The determination of the amount of Mycobacterium tuberculosis IgA antibody present in a sample.","Mycobacterium tuberculosis IgA Antibody Measurement | MTBIGAAB | Mycobacterium tuberculosis IgA Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523600","Deoxyhemoglobin Measurement","C124343","The determination of the amount of deoxyhemoglobin present in a sample.","Deoxyhemoglobin Measurement | Deoxyhemoglobin | HGBDOXY",,,,,,,,,,,,,,,"4018198","Deoxyhemoglobin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1262735","Plasminogen Measurement","C127633","The determination of the amount of plasminogen present in a sample.","Plasminogen Measurement | PLG | Plasminogen",,,,,,,,,,,,,,,"4238994","Plasminogen assay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509645","Proliferating Erythroid Cell to Total Cell Ratio Measurement","C127632","The determination of the ratio of proliferating erythroid cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Proliferating Erythroid Cell to Total Cell Ratio Measurement | PERCECE | Proliferating Erythroid Cells to Total Cells Ratio Measurement | Proliferating Erythroid/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509804","Para-Aminohippurate Sodium Measurement","C127631","The determination of the amount of para-aminohippurate sodium present in a sample.","Para-Aminohippurate Sodium Measurement | P-Aminohippurate Sodium | PAH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508860","Klotho Protein Measurement","C127624","The determination of the amount of klotho protein present in a sample.","Klotho Protein Measurement | KLOTHO | Klotho",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509459","Human Papillomavirus 6 Antibody Measurement","C127621","The determination of the amount of human papillomavirus 6 antiboy present in a sample.","Human Papillomavirus 6 Antibody Measurement | HPV6AB | Human Papillomavirus 6 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509458","Human Papillomavirus 18 Antibody Measurement","C127620","The determination of the amount of human papillomavirus 18 antiboy present in a sample.","Human Papillomavirus 18 Antibody Measurement | HPV18AB | Human Papillomavirus 18 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509457","Human Papillomavirus 16 Antibody Measurement","C127619","The determination of the amount of human papillomavirus 16 antiboy present in a sample.","Human Papillomavirus 16 Antibody Measurement | HPV16AB | Human Papillomavirus 16 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509456","Human Papillomavirus 11 Antibody Measurement","C127618","The determination of the amount of human papillomavirus 11 antiboy present in a sample.","Human Papillomavirus 11 Antibody Measurement | HPV11AB | Human Papillomavirus 11 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0373706","Prolactin Measurement","C74870","The determination of the amount of prolactin hormone present in a sample.","Prolactin Measurement | PROLCTN | Prolactin",,,,,,,,,,,,,,,"4010412","Prolactin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523887","Secretin Measurement","C74871","The determination of the amount of secretin hormone present in a sample.","Secretin Measurement | SECRETIN | Secretin",,,,,,,,,,,,,,,"4017340","Secretin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202217","Serotonin Measurement","C74872","The determination of the amount of serotonin hormone present in a sample.","Serotonin Measurement | SRTONIN | Serotonin",,,,,,,,,,,,,,,"4176275","Serotonin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2699935","Thrombopoietin Measurement","C74873","The determination of the amount of thrombopoietin hormone present in a sample.","Thrombopoietin Measurement | THRMPTN | Thrombopoietin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266389","6-Monoacetylmorphine Measurement","C74876","The determination of the amount of 6-monoacetylmorphine present in a sample.","6-Monoacetylmorphine Measurement | 6-Monoacetylmorphine | SIXMAM",,,,,,,,,,,,,,,"4006333","6-Monoacetylmorphine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524087","Codeine Measurement","C74877","The determination of the amount of codeine present in a sample.","Codeine Measurement | CODEINE | Codeine",,,,,,,,,,,,,,,"4022838","Codeine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266501","Dihydrocodeine Measurement","C74878","The determination of the amount of dihydrocodeine present in a sample.","Dihydrocodeine Measurement | DIHYDCDN | Dihydrocodeine",,,,,,,,,,,,,,,"4006517","Dihydrocodeine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202418","Methadone Measurement","C74881","The determination of the amount of methadone present in a sample.","Methadone Measurement | METHDN | Methadone",,,,,,,,,,,,,,,"4150223","Methadone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025628","Methaqualone Measurement","C74882","The determination of the amount of methaqualone present in a sample.","Methaqualone Measurement | METHQLDN | Methaqualone",,,,,,,,,,,,,,,"4184156","Methaqualone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698261","Morphine Measurement","C74883","The determination of the amount of morphine present in a sample.","Morphine Measurement | MORPHINE | Morphine",,,,,,,,,,,,,,,"40484938","Measurement of morphine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514028","Bermuda Grass Pollen IgA Measurement","C130069","A measurement of the Bermuda grass (Cynodon dactylon) pollen IgA in a biological specimen.","Bermuda Grass Pollen IgA Measurement | Bermuda Grass Pollen IgA | C130069",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514029","Bermuda Grass Pollen IgE Measurement","C130068","A measurement of the Bermuda grass (Cynodon dactylon) pollen IgE in a biological specimen.","Bermuda Grass Pollen IgE Measurement | Bermuda Grass Pollen IgE | C130068",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509780","Toxic Vacuolation Assessment","C127813","An evaluation of the presence or degree of toxic vacuolation present in a sample.","Toxic Vacuolation Assessment | TOXVAC | Toxic Vacuolation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509806","S100 Calcium-Binding Protein B Measurement","C127635","The determination of the amount of S100 calcium-binding protein B present in a sample.","S100 Calcium-Binding Protein B Measurement | S100 Calcium-Binding Protein B | S100B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337437","Glucagon Measurement","C74859","The determination of the amount of glucagon hormone present in a sample.","Glucagon Measurement | GLUCAGON | Glucagon",,,,,,,,,,,,,,,"4322453","Glucagon measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202220","Insulin Like Growth Factor-1 Measurement","C74864","The determination of the amount of insulin-like growth factor-1 present in a sample.","Insulin Like Growth Factor-1 Measurement | IGF1 | Insulin-like Growth Factor-1",,,,,,,,,,,,,,,"4195408","Somatomedin-C measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2697754","Insulin Like Growth Factor-2 Measurement","C74865","The determination of the amount of insulin-like growth factor-2 present in a sample.","Insulin Like Growth Factor-2 Measurement | IGF2 | Insulin-like Growth Factor-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1295176","Leptin Measurement","C74866","The determination of the amount of leptin hormone present in a sample.","Leptin Measurement | LEPTIN | Leptin",,,,,,,,,,,,,,,"4039384","Leptin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523498","Angiotensin I Measurement","C74844","The determination of the amount of angiotensin I hormone present in a sample.","Angiotensin I Measurement | ANGTNS1 | Angiotensin I",,,,,,,,,,,,,,,"4019450","Angiotensin I measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0373546","Angiotensin II Measurement","C74845","The determination of the amount of angiotensin II hormone present in a sample.","Angiotensin II Measurement | ANGTNS2 | Angiotensin II",,,,,,,,,,,,,,,"4014899","Angiotensin II measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0201989","Dopamine Measurement","C74854","The determination of the amount of dopamine hormone present in a sample.","Dopamine Measurement | DOPAMINE | Dopamine",,,,,,,,,,,,,,,"4139269","Dopamine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513373","Timothy Grass Pollen IgG4 Measurement","C130091","A measurement of the Timothy grass (Phleum pretense) pollen IgG4 in a biological specimen.","Timothy Grass Pollen IgG4 Measurement | C130091 | Timothy Grass Pollen IgG4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513370","Timothy Grass Pollen IgA Measurement","C130089","A measurement of the Timothy grass (Phleum pretense) pollen IgA in a biological specimen.","Timothy Grass Pollen IgA Measurement | C130089 | Timothy Grass Pollen IgA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514047","English Plantain Pollen IgG Measurement","C130086","A measurement of the English plantain (Plantago lanceolata) pollen IgG in a biological specimen.","English Plantain Pollen IgG Measurement | C130086 | English Plantain Pollen IgG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514045","English Plantain Pollen IgA Measurement","C130085","A measurement of the English plantain (Plantago lanceolata) pollen IgA in a biological specimen.","English Plantain Pollen IgA Measurement | C130085 | English Plantain Pollen IgA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513989","Silver Birch Pollen IgG Measurement","C130078","A measurement of the silver birch pollen IgG in a biological specimen.","Silver Birch Pollen IgG Measurement | C130078 | Silver Birch Pollen IgG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513987","Silver Birch Pollen IgA Measurement","C130077","A measurement of the silver birch pollen IgA in a biological specimen.","Silver Birch Pollen IgA Measurement | C130077 | Silver Birch Pollen IgA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513988","Silver Birch Pollen IgE Measurement","C130076","A measurement of the silver birch pollen IgE in a biological specimen.","Silver Birch Pollen IgE Measurement | C130076 | Silver Birch Pollen IgE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513397","Birch Pollen IgG4 Measurement","C130075","A measurement of the birch pollen IgG4 in a biological specimen.","Birch Pollen IgG4 Measurement | Birch Pollen IgG4 | C130075",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513396","Birch Pollen IgG Measurement","C130074","A measurement of the birch pollen IgG in a biological specimen.","Birch Pollen IgG Measurement | Birch Pollen IgG | C130074",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513394","Birch Pollen IgA Measurement","C130073","A measurement of the birch pollen IgA in a biological specimen.","Birch Pollen IgA Measurement | Birch Pollen IgA | C130073",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514031","Bermuda Grass Pollen IgG4 Measurement","C130071","A measurement of the Bermuda grass (Cynodon dactylon) pollen IgG4 in a biological specimen.","Bermuda Grass Pollen IgG4 Measurement | Bermuda Grass Pollen IgG4 | C130071",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700366","Adiponectin Measurement","C74839","The determination of the amount of adiponectin hormone present in a sample.","Adiponectin Measurement | ADPNCTN | Adiponectin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698113","Androstenediol Metabolite Measurement","C74842","The determination of the amount of androstenediol metabolite present in a sample.","Androstenediol Metabolite Measurement | ANDSTNDL | Androstenediol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697782","Interleukin 32 Measurement","C74830","The determination of the amount of interleukin 32 present in a sample.","Interleukin 32 Measurement | INTLK32 | Interleukin 32",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697785","Interleukin 4 Measurement","C74832","The determination of the amount of interleukin 4 present in a sample.","Interleukin 4 Measurement | INTLK4 | Interleukin 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL384316","Interleukin 6 Measurement","C74834","The determination of the amount of interleukin 6 present in a sample.","Interleukin 6 Measurement | INTLK6 | Interleukin 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697787","Interleukin 7 Measurement","C74835","The determination of the amount of interleukin 7 present in a sample.","Interleukin 7 Measurement | INTLK7 | Interleukin 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523441","Acetylcholine Measurement","C74838","The determination of the amount of acetylcholine hormone present in a sample.","Acetylcholine Measurement | ACH | Acetylcholine",,,,,,,,,,,,,,,"4017491","Acetylcholine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2697767","Interleukin 19 Measurement","C74815","The determination of the amount of interleukin 19 present in a sample.","Interleukin 19 Measurement | INTLK19 | Interleukin 19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697779","Interleukin 2 Measurement","C74816","The determination of the amount of interleukin 2 present in a sample.","Interleukin 2 Measurement | INTLK2 | Interleukin 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697769","Interleukin 20 Measurement","C74817","The determination of the amount of interleukin 20 present in a sample.","Interleukin 20 Measurement | INTLK20 | Interleukin 20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697771","Interleukin 22 Measurement","C74819","The determination of the amount of interleukin 22 present in a sample.","Interleukin 22 Measurement | INTLK22 | Interleukin 22",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697772","Interleukin 23 Measurement","C74820","The determination of the amount of interleukin 23 present in a sample.","Interleukin 23 Measurement | INTLK23 | Interleukin 23 | Interleukin 23 p59",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697773","Interleukin 24 Measurement","C74821","The determination of the amount of interleukin 24 present in a sample.","Interleukin 24 Measurement | INTLK24 | Interleukin 24",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697776","Interleukin 27 Measurement","C74824","The determination of the amount of interleukin 27 present in a sample.","Interleukin 27 Measurement | INTLK27 | Interleukin 27",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697777","Interleukin 28 Measurement","C74825","The determination of the amount of interleukin 28 present in a sample.","Interleukin 28 Measurement | INTLK28 | Interleukin 28",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697778","Interleukin 29 Measurement","C74826","The determination of the amount of interleukin 29 present in a sample.","Interleukin 29 Measurement | INTLK29 | Interleukin 29",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513461","Dog Dander Antigen IgG4 Antibody Measurement","C130131","A measurement of the dog dander antigen IgG4 antibody in a biological specimen.","Dog Dander Antigen IgG4 Antibody Measurement | C130131 | Dog Dander Antigen IgG4 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513458","Dog Dander Antigen IgA Antibody Measurement","C130130","A measurement of the dog dander antigen IgA antibody in a biological specimen.","Dog Dander Antigen IgA Antibody Measurement | C130130 | Dog Dander Antigen IgA Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513460","Dog Dander Antigen IgG Antibody Measurement","C130129","A measurement of the dog dander antigen IgG antibody in a biological specimen.","Dog Dander Antigen IgG Antibody Measurement | C130129 | Dog Dander Antigen IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513459","Dog Dander Antigen IgE Antibody Measurement","C130128","A measurement of the dog dander antigen IgE antibody in a biological specimen.","Dog Dander Antigen IgE Antibody Measurement | C130128 | Dog Dander Antigen IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514036","Cat Dander Antigen IgG4 Antibody Measurement","C130127","A measurement of the cat dander antigen IgG4 antibody in a biological specimen.","Cat Dander Antigen IgG4 Antibody Measurement | C130127 | Cat Dander Antigen IgG4 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514034","Cat Dander Antigen IgE Antibody Measurement","C130124","A measurement of the cat dander antigen IgE antibody in a biological specimen.","Cat Dander Antigen IgE Antibody Measurement | C130124 | Cat Dander Antigen IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513985","Shellfish Mix Antigen IgE Antibody Measurement","C130120","A measurement of the shellfish mix antigen IgE antibody in a biological specimen.","Shellfish Mix Antigen IgE Antibody Measurement | C130120 | Shellfish Mix Antigen IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514027","Bee Mix Antigen IgG4 Antibody Measurement","C130118","A measurement of the bee mix antigen IgG4 antibody in a biological specimen.","Bee Mix Antigen IgG4 Antibody Measurement | Bee Mix Antigen IgG4 Antibody | C130118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514025","Bee Mix Antigen IgE Antibody Measurement","C130116","A measurement of the bee mix antigen IgE antibody in a biological specimen.","Bee Mix Antigen IgE Antibody Measurement | Bee Mix Antigen IgE Antibody | C130116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514080","Industrial Mix Antigen IgG Antibody Measurement","C130115","A measurement of the industrial mix antigen IgG antibody in a biological specimen.","Industrial Mix Antigen IgG Antibody Measurement | C130115 | Industrial Mix Antigen IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514079","Industrial Mix Antigen IgE Antibody Measurement","C130114","A measurement of the industrial mix antigen IgE antibody in a biological specimen.","Industrial Mix Antigen IgE Antibody Measurement | C130114 | Industrial Mix Antigen IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514015","Animal Mix Antigen IgG Antibody Measurement","C130113","A measurement of the animal mix antigen IgG antibody in a biological specimen.","Animal Mix Antigen IgG Antibody Measurement | Animal Mix Antigen IgG Antibody | C130113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514014","Animal Mix Antigen IgE Antibody Measurement","C130112","A measurement of the animal mix antigen IgE antibody in a biological specimen.","Animal Mix Antigen IgE Antibody Measurement | Animal Mix Antigen IgE Antibody | C130112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514057","Mold Mix Antigen IgG Antibody Measurement","C130110","A measurement of the mold mix antigen IgG antibody in a biological specimen.","Mold Mix Antigen IgG Antibody Measurement | C130110 | Mold Mix Antigen IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513748","Weed Mix Pollen Antigen IgE Antibody Measurement","C130106","A measurement of the weed mix pollen antigen IgE antibody in a biological specimen.","Weed Mix Pollen Antigen IgE Antibody Measurement | C130106 | Weed Mix Pollen Antigen IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513103","Grass Mix Pollen Antigen IgA Antibody Measurement","C130105","A measurement of the grass mix pollen antigen IgA antibody in a biological specimen.","Grass Mix Pollen Antigen IgA Antibody Measurement | C130105 | Grass Mix Pollen Antigen IgA Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513105","Grass Mix Pollen Antigen IgG Antibody Measurement","C130104","A measurement of the grass mix pollen antigen IgG antibody in a biological specimen.","Grass Mix Pollen Antigen IgG Antibody Measurement | C130104 | Grass Mix Pollen Antigen IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513104","Grass Mix Pollen Antigen IgE Antibody Measurement","C130103","A measurement of the grass mix pollen antigen IgE antibody in a biological specimen.","Grass Mix Pollen Antigen IgE Antibody Measurement | C130103 | Grass Mix Pollen Antigen IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513380","Tree Mix Pollen Antigen IgG Antibody Measurement","C130102","A measurement of the tree mix pollen antigen IgG antibody in a biological specimen.","Tree Mix Pollen Antigen IgG Antibody Measurement | C130102 | Tree Mix Pollen Antigen IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514060","Mucor racemosus IgG4 Measurement","C130099","A measurement of the Mucor racemosus IgG4 in a biological specimen.","Mucor racemosus IgG4 Measurement | C130099 | Mucor racemosus IgG4 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514061","Mucor racemosus IgG Measurement","C130098","A measurement of the Mucor racemosus IgG in a biological specimen.","Mucor racemosus IgG Measurement | C130098 | Mucor racemosus IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514058","Mucor racemosus IgA Measurement","C130097","A measurement of the Mucor racemosus IgA in a biological specimen.","Mucor racemosus IgA Measurement | C130097 | Mucor racemosus IgA Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514059","Mucor racemosus IgE Measurement","C130096","A measurement of the Mucor racemosus IgE in a biological specimen.","Mucor racemosus IgE Measurement | C130096 | Mucor racemosus IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513752","Western Ragweed Pollen IgG4 Measurement","C130095","A measurement of the western ragweed (Ambrosia psilostachya) pollen IgG4 in a biological specimen.","Western Ragweed Pollen IgG4 Measurement | C130095 | Western Ragweed Pollen IgG4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513753","Western Ragweed Pollen IgG Measurement","C130094","A measurement of the western ragweed (Ambrosia psilostachya) pollen IgG in a biological specimen.","Western Ragweed Pollen IgG Measurement | C130094 | Western Ragweed Pollen IgG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513750","Western Ragweed Pollen IgA Measurement","C130093","A measurement of the western ragweed (Ambrosia psilostachya) pollen IgA in a biological specimen.","Western Ragweed Pollen IgA Measurement | C130093 | Western Ragweed Pollen IgA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513751","Western Ragweed Pollen IgE Measurement","C130092","A measurement of the western ragweed (Ambrosia psilostachya) pollen IgE in a biological specimen.","Western Ragweed Pollen IgE Measurement | C130092 | Western Ragweed Pollen IgE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697761","Interleukin 13 Measurement","C74809","The determination of the amount of interleukin 13 present in a sample.","Interleukin 13 Measurement | INTLK13 | Interleukin 13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697762","Interleukin 14 Measurement","C74810","The determination of the amount of interleukin 14 present in a sample.","Interleukin 14 Measurement | INTLK14 | Interleukin 14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697763","Interleukin 15 Measurement","C74811","The determination of the amount of interleukin 15 present in a sample.","Interleukin 15 Measurement | INTLK15 | Interleukin 15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697764","Interleukin 16 Measurement","C74812","The determination of the amount of interleukin 16 present in a sample.","Interleukin 16 Measurement | INTLK16 | Interleukin 16",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201803","Osmolality Measurement","C74801","The determination of the osmoles of solute per kilogram of solvent present in a sample.","Osmolality Measurement | OSMLTY | Osmolality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697768","Interleukin 1 Measurement","C74805","The determination of the amount of interleukin 1 present in a sample.","Interleukin 1 Measurement | INTLK1 | Interleukin 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697758","Interleukin 10 Measurement","C74806","The determination of the amount of interleukin 10 present in a sample.","Interleukin 10 Measurement | INTLK10 | Interleukin 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513774","Basophil Band Form Count","C130154","The determination of the number of band basophils in a sample.","Basophil Band Form Count | BASOB | Basophils Band Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513765","Alternaria tenuis alternata Antigen IgG4 Antibody Measurement","C130153","A measurement of the Alternaria tenuis alternata antigen IgG4 antibody in a biological specimen.","Alternaria tenuis alternata Antigen IgG4 Antibody Measurement | Alternaria alternata IgG4 Antibody | Alternaria tenuis IgG4 Antibody | C130153",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513764","Alternaria tenuis alternata Antigen IgG Antibody Measurement","C130152","A measurement of the Alternaria tenuis alternata antigen IgG antibody in a biological specimen.","Alternaria tenuis alternata Antigen IgG Antibody Measurement | Alternaria alternata IgG Antibody | Alternaria tenuis IgG Antibody | C130152",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513982","Penicillium notatum Antigen IgG4 Antibody Measurement","C130149","A measurement of the Penicillium notatum antigen IgG4 antibody in a biological specimen.","Penicillium notatum Antigen IgG4 Antibody Measurement | C130149 | Penicillium chrysogenum IgG4 Antibody | Penicillium notatum IgG4 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513981","Penicillium notatum Antigen IgG Antibody Measurement","C130148","A measurement of the Penicillium notatum antigen IgG antibody in a biological specimen.","Penicillium notatum Antigen IgG Antibody Measurement | C130148 | Penicillium chrysogenum IgG Antibody | Penicillium notatum IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513761","Aspergillus fumigatus Antigen IgG Antibody Measurement","C130145","A measurement of the Aspergillus fumigatus antigen IgG antibody in a biological specimen.","Aspergillus fumigatus Antigen IgG Antibody Measurement | Aspergillus fumigatus IgG Antibody | C130145",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513097","German Cockroach Antigen IgG Antibody Measurement","C130142","A measurement of the German cockroach (Blattella germanica) antigen IgG antibody in a biological specimen.","German Cockroach Antigen IgG Antibody Measurement | C130142 | German Cockroach Antigen IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513095","German Cockroach Antigen IgA Antibody Measurement","C130141","A measurement of the German cockroach (Blattella germanica) antigen IgA antibody in a biological specimen.","German Cockroach Antigen IgA Antibody Measurement | C130141 | German Cockroach Antigen IgA Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513096","German Cockroach Antigen IgE Antibody Measurement","C130140","A measurement of the German cockroach (Blattella germanica) antigen IgE antibody in a biological specimen.","German Cockroach Antigen IgE Antibody Measurement | C130140 | German Cockroach Antigen IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514013","American Cockroach Antigen IgG4 Antibody Measurement","C130139","A measurement of the American cockroach (Periplaneta americana) antigen IgG4 antibody in a biological specimen.","American Cockroach Antigen IgG4 Antibody Measurement | American Cockroach Antigen IgG4 Antibody | C130139",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514011","American Cockroach Antigen IgE Antibody Measurement","C130136","A measurement of the American cockroach (Periplaneta americana) antigen IgE antibody in a biological specimen.","American Cockroach Antigen IgE Antibody Measurement | American Cockroach Antigen IgE Antibody | C130136",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513454","Dermatophagoides pteronyssinus Antigen IgG Antibody Measurement","C130135","A measurement of the Dermatophagoides pteronyssinus antigen IgG antibody in a biological specimen.","Dermatophagoides pteronyssinus Antigen IgG Antibody Measurement | C130135 | D. pteronyssinus Antigen IgG Antibody | Dermatophagoides pteronyssinus IgG Antibody | European House Dust Mite IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513452","Dermatophagoides farinae Antigen IgG Antibody Measurement","C130133","A measurement of the Dermatophagoides farinae antigen IgG antibody in a biological specimen.","Dermatophagoides farinae Antigen IgG Antibody Measurement | American House Dust Mite IgG Antibody | C130133 | D. farinae Antigen IgG Antibody | Dermatophagoides farinae IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698157","Antidepressant Measurement","C74691","The determination of the amount of antidepressant class drug present in a sample.","Antidepressant Measurement | ANTIDPRS | Antidepressants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0373486","Benzodiazepine Measurement","C74692","The determination of the amount of benzodiazepine class drug present in a sample.","Benzodiazepine Measurement | BNZDZPN | Benzodiazepine",,,,,,,,,,,,,,,"4211848","Benzodiazepine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524257","Pseudoephedrine Measurement","C74696","The determination of the amount of pseudoephedrine present in a sample","Pseudoephedrine Measurement | PSDEPHD | Pseudoephedrine",,,,,,,,,,,,,,,"4023005","Pseudoephedrine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0919842","Syphilis Serodiagnosis","C132388","The determination of the amount of Treponema pallidum antibody in a biological sample.","Treponema pallidum Antibody Measurement | TPLAB | Treponema pallidum Antibody",,,,,,,,,,,,,,,"4151408|4229096","Syphilis infectious titer test|Serologic test for syphilis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL521662","T-Kininogen Measurement","C132387","The determination of the amount of T-kininogen in a biological sample.","T-Kininogen Measurement | T-Kininogen | TKG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512835","Circulating Prostate Tumor Cell Count","C132382","The determination of the amount of circulating prostate tumor cells present in a sample.","Circulating Prostate Tumor Cell Count | PRCTC | Prostate Circulating Tumor Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521193","Keyhole Limpet Hemocyanin IgM Antibody Measurement","C132373","The determination of the amount of keyhole limpet hemocyanin IgM antibody in a biological sample.","Keyhole Limpet Hemocyanin IgM Antibody Measurement | KLHIGMAB | Keyhole Limpet Hemocyanin IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521663","1,3-Beta-D-Glucan Measurement","C132370","The determination of the amount of 1,3-beta-D-glucan in a biological sample.","1,3-Beta-D-Glucan Measurement | 1,3-Beta-D-Glucan | GLUBD13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520660","G6PD-Deficient Erythrocytes Count","C132368","The determination of the amount of G6PD-deficient erythrocytes in a biological sample.","G6PD-Deficient Erythrocytes Count | G6PD-Deficient Erythrocytes | G6PDRBC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521037","Squamous Epithelial Cells to Total Cells Ratio Measurement","C132366","The determination of the ratio of the squamous epithelial cells compared to the total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Squamous Epithelial Cells to Total Cells Ratio Measurement | EPISCECE | Squamous Cells/Total Cells | Squamous Epithelial Cells/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521661","High Molecular Weight Adiponectin Measurement","C132363","The determination of the amount of high molecular weight adiponectin in a biological sample.","High Molecular Weight Adiponectin Measurement | ADPNHMW | Adiponectin, High Molecular Weight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513822","Epithelial Cells to Total Cells Ratio Measurement","C130161","The determination of the ratio of epithelial cells compared to total cells in a sample. The measurement may be expressed as a ratio or percentage.","Epithelial Cells to Total Cells Ratio Measurement | EPICCE | Epithelial Cells/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540293","Alpha Synuclein Protein Measurement","C142272","The determination of the amount of alpha synuclein protein present in a sample.","Alpha Synuclein Protein Measurement | ASYNP | Alpha Synuclein Protein | SCNA Protein Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540294","Streptococcus pneumoniae Serotype 33F IgG Antibody Measurement","C142271","The determination of the amount of Streptococcus pneumoniae serotype 33F IgG antibody present in a sample.","Streptococcus pneumoniae Serotype 33F IgG Antibody Measurement | C142271 | S. pneumonia Sero 33F IgG AB | S. pneumoniae Sero 33F IgG AB | Streptococcus pneumoniae Serotype 33F IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540295","Streptococcus pneumoniae Serotype 23F IgG Antibody Measurement","C142270","The determination of the amount of Streptococcus pneumoniae serotype 23F IgG antibody present in a sample.","Streptococcus pneumoniae Serotype 23F IgG Antibody Measurement | C142270 | S. pneumonia Sero 23F IgG AB | S. pneumoniae Sero 23F IgG AB | Streptococcus pneumoniae Serotype 23F IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540296","Streptococcus pneumoniae Serotype 22F IgG Antibody Measurement","C142269","The determination of the amount of Streptococcus pneumoniae serotype 22F IgG antibody present in a sample.","Streptococcus pneumoniae Serotype 22F IgG Antibody Measurement | C142269 | S. pneumonia Sero 22F IgG AB | S. pneumoniae Sero 22F IgG AB | Streptococcus pneumoniae Serotype 22F IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540298","Streptococcus pneumoniae Serotype 19A IgG Antibody Measurement","C142267","The determination of the amount of Streptococcus pneumoniae serotype 19A IgG antibody present in a sample.","Streptococcus pneumoniae Serotype 19A IgG Antibody Measurement | C142267 | S. pneumonia Sero 19A IgG AB | S. pneumoniae Sero 19A IgG AB | Streptococcus pneumoniae Serotype 19A IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540313","Streptococcus pneumoniae Serotype 19F IgG Antibody Measurement","C142266","The determination of the amount of Streptococcus pneumoniae serotype 19F IgG antibody present in a sample.","Streptococcus pneumoniae Serotype 19F IgG Antibody Measurement | C142266 | S. pneumonia Sero 19F IgG AB | S. pneumoniae Sero 19F IgG AB | Streptococcus pneumoniae Serotype 19F IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540314","Streptococcus pneumoniae Serotype 18C IgG Antibody Measurement","C142265","The determination of the amount of Streptococcus pneumoniae serotype 18C IgG antibody present in a sample.","Streptococcus pneumoniae Serotype 18C IgG Antibody Measurement | C142265 | S. pneumonia Sero 18C IgG AB | S. pneumoniae Sero 18C IgG AB | Streptococcus pneumoniae Serotype 18C IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540315","Streptococcus pneumoniae Serotype 17F IgG Antibody Measurement","C142264","The determination of the amount of Streptococcus pneumoniae serotype 17F IgG antibody present in a sample.","Streptococcus pneumoniae Serotype 17F IgG Antibody Measurement | C142264 | S. pneumonia Sero 17F IgG AB | S. pneumoniae Sero 17F IgG AB | Streptococcus pneumoniae Serotype 17F IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540316","Streptococcus pneumoniae Serotype 15B IgG Antibody Measurement","C142263","The determination of the amount of Streptococcus pneumoniae serotype 15B IgG antibody present in a sample.","Streptococcus pneumoniae Serotype 15B IgG Antibody Measurement | C142263 | S. pneumonia Sero 15B IgG AB | S. pneumoniae Sero 15B IgG AB | Streptococcus pneumoniae Serotype 15B IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540317","Streptococcus pneumoniae Serotype 14 IgG Antibody Measurement","C142262","The determination of the amount of Streptococcus pneumoniae serotype 14 IgG antibody present in a sample.","Streptococcus pneumoniae Serotype 14 IgG Antibody Measurement | C142262 | S. pneumonia Sero 14 IgG AB | S. pneumoniae Sero 14 IgG AB | Streptococcus pneumoniae Serotype 14 IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540318","Streptococcus pneumoniae Serotype 12F IgG Antibody Measurement","C142261","The determination of the amount of Streptococcus pneumoniae serotype 12F IgG antibody present in a sample.","Streptococcus pneumoniae Serotype 12F IgG Antibody Measurement | C142261 | S. pneumonia Sero 12F IgG AB | S. pneumoniae Sero 12F IgG AB | Streptococcus pneumoniae Serotype 12F IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540319","Streptococcus pneumoniae Serotype 11A IgG Antibody Measurement","C142260","The determination of the amount of Streptococcus pneumoniae serotype 11A IgG antibody present in a sample.","Streptococcus pneumoniae Serotype 11A IgG Antibody Measurement | C142260 | S. pneumonia Sero 11A IgG AB | S. pneumoniae Sero 11A IgG AB | Streptococcus pneumoniae Serotype 11A IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540320","Streptococcus pneumoniae Serotype 10A IgG Antibody Measurement","C142259","The determination of the amount of Streptococcus pneumoniae serotype 10A IgG antibody present in a sample.","Streptococcus pneumoniae Serotype 10A IgG Antibody Measurement | C142259 | S. pneumonia Sero 10A IgG AB | S. pneumoniae Sero 10A IgG AB | Streptococcus pneumoniae Serotype 10A IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540305","Streptococcus pneumoniae Serotype 9V IgG Antibody Measurement","C142258","The determination of the amount of Streptococcus pneumoniae serotype 9V IgG antibody present in a sample.","Streptococcus pneumoniae Serotype 9V IgG Antibody Measurement | C142258 | S. pneumonia Sero 9V IgG AB | S. pneumoniae Sero 9V IgG AB | Streptococcus pneumoniae Serotype 9V IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540306","Streptococcus pneumoniae Serotype 9N IgG Antibody Measurement","C142257","The determination of the amount of Streptococcus pneumoniae serotype 9N IgG antibody present in a sample.","Streptococcus pneumoniae Serotype 9N IgG Antibody Measurement | C142257 | S. pneumonia Sero 9N IgG AB | S. pneumoniae Sero 9N IgG AB | Streptococcus pneumoniae Serotype 9N IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540307","Streptococcus pneumoniae Serotype 8 IgG Antibody Measurement","C142256","The determination of the amount of Streptococcus pneumoniae serotype 8 IgG antibody present in a sample.","Streptococcus pneumoniae Serotype 8 IgG Antibody Measurement | C142256 | S. pneumonia Sero 8 IgG AB | S. pneumoniae Sero 8 IgG AB | Streptococcus pneumoniae Serotype 8 IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540308","Streptococcus pneumoniae Serotype 7F IgG Antibody Measurement","C142255","The determination of the amount of Streptococcus pneumoniae serotype 7F IgG antibody present in a sample.","Streptococcus pneumoniae Serotype 7F IgG Antibody Measurement | C142255 | S. pneumonia Sero 7F IgG AB | S. pneumoniae Sero 7F IgG AB | Streptococcus pneumoniae Serotype 7F IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540309","Streptococcus pneumoniae Serotype 6B IgG Antibody Measurement","C142254","The determination of the amount of Streptococcus pneumoniae serotype 6B IgG antibody present in a sample.","Streptococcus pneumoniae Serotype 6B IgG Antibody Measurement | C142254 | S. pneumonia Sero 6B IgG AB | S. pneumoniae Sero 6B IgG AB | Streptococcus pneumoniae Serotype 6B IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540311","Streptococcus pneumoniae Serotype 4 IgG Antibody Measurement","C142252","The determination of the amount of Streptococcus pneumoniae serotype 4 IgG antibody present in a sample.","Streptococcus pneumoniae Serotype 4 IgG Antibody Measurement | C142252 | S. pneumonia Sero 4 IgG AB | S. pneumoniae Sero 4 IgG AB | Streptococcus pneumoniae Serotype 4 IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540312","Streptococcus pneumoniae Serotype 3 IgG Antibody Measurement","C142251","The determination of the amount of Streptococcus pneumoniae serotype 3 IgG antibody present in a sample.","Streptococcus pneumoniae Serotype 3 IgG Antibody Measurement | C142251 | S. pneumonia Sero 3 IgG AB | S. pneumoniae Sero 3 IgG AB | Streptococcus pneumoniae Serotype 3 IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540215","Streptococcus pneumoniae Serotype 2 IgG Antibody Measurement","C142250","The determination of the amount of Streptococcus pneumoniae serotype 2 IgG antibody present in a sample.","Streptococcus pneumoniae Serotype 2 IgG Antibody Measurement | C142250 | S. pneumonia Sero 2 IgG AB | S. pneumoniae Sero 2 IgG AB | Streptococcus pneumoniae Serotype 2 IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540216","Streptococcus pneumoniae Serotype 1 IgG Antibody Measurement","C142249","The determination of the amount of Streptococcus pneumoniae serotype 1 IgG antibody present in a sample.","Streptococcus pneumoniae Serotype 1 IgG Antibody Measurement | C142249 | S. pneumonia Sero 1 IgG AB | S. pneumoniae Sero 1 IgG AB | Streptococcus pneumoniae Serotype 1 IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526571","Calcium to Phosphorus Ratio Measurement","C139087","The determination of the ratio of calcium to phosphorus in a sample. The measurement may be expressed as a ratio or percentage.","Calcium to Phosphorus Ratio Measurement | CAPHOS | Calcium/Phosphate | Calcium/Phosphorus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0427508","Glucose-6-Phosphate Dehydrogenase Activity","C139065","The determination of the amount of glucose-6-phosphate dehydrogenase activity present in a sample.","Glucose-6-Phosphate Dehydrogenase Activity | G6PD Activity | G6PDA | Glucose-6-Phosphate Dehydrogenase Act",,,,,,,,,,,,,,,"4017083","Glucose-6-phosphate dehydrogenase measurement, quantitative",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0200642","Estimated Platelets Measurement","C135440","The estimated amount of platelets in a biological sample.","Estimated Platelets Measurement | PLATEST | Platelets, Estimated",,,,,,,,,,,,,,,"4310103","Platelet estimate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL522820","Myeloid Proliferation Pool Count","C135437","The determination of the amount of myeloid proliferative phase cells (myeloblasts, promyelocytes, and myelocytes) present in a sample.","Myeloid Proliferation Pool Count | MYCEPPOL | Myeloid Proliferation Pool",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522817","Myeloid Maturation Index","C135434","The determination of the ratio of the sum of myeloid maturation phase cells (pool) to the sum of myeloid proliferative phase cells (pool) present in a sample.","Myeloid Maturation Index | MYCEMIDX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522814","Macrophages to Non-Squamous Epithelial Cells Ratio Measurement","C135431","The determination of the ratio of macrophages compared to non-squamous epithelial cells present in a sample. The measurement may be expressed as a ratio or percentage.","Macrophages to Non-Squamous Epithelial Cells Ratio Measurement | MCPHNSQE | Macrophages/Non-Squam Epi Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522811","Hairy Cells to Leukocytes Ratio Measurement","C135428","The determination of the ratio of hairy cells (B-cell lymphocytes with hairy projections from the cytoplasm) compared to all leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Hairy Cells to Leukocytes Ratio Measurement | HRYCELE | Hairy Cells/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522810","Hairy Cells to Total Cells Ratio Measurement","C135427","The determination of the ratio of hairy cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Hairy Cells to Total Cells Ratio Measurement | HRYCECE | Hairy Cells/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523854","Flagellates Measurement","C135421","Examination of a biological specimen to detect the presence of any flagellates or protozoans that possess flagella.","Flagellates Measurement | FLAGEL | Flagellates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523848","Intact Fibroblast Growth Factor 23 Measurement","C135420","The determination of the amount of the intact fibroblast growth factor 23 in a biological sample.","Intact Fibroblast Growth Factor 23 Measurement | FGF23I | Fibroblast Growth Factor 23, Intact",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522808","C-Terminal Fibroblast Growth Factor 23 Measurement","C135419","The determination of the amount of the C-terminal fibroblast growth factor 23 in a biological sample.","C-Terminal Fibroblast Growth Factor 23 Measurement | FGF23C | Fibroblast Growth Factor 23, C-Terminal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522803","Epithelial Cells to Non-Squamous Epithelial Cells Ratio Measurement","C135414","The determination of the ratio of epithelial cells compared to non-squamous epithelial cells present in a sample. The measurement may be expressed as a ratio or percentage.","Epithelial Cells to Non-Squamous Epithelial Cells Ratio Measurement | EPINSQE | Epi Cells/Non-Squam Epi Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523842","Non-Squamous Epithelial Cell Count","C135413","The determination of the amount of non-squamous epithelial cells present in a sample.","Non-Squamous Epithelial Cell Count | EPINSQCE | Non-Squamous Epithelial Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522802","Segmented Eosinophil Count","C135412","The determination of the amount of segmented eosinophils present in a sample.","Segmented Eosinophil Count | EOSSG | Eosinophils, Segmented",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522801","Eosinophils to Non-Squamous Epithelial Cells Ratio Measurement","C135411","The determination of the ratio of eosinophils compared to non-squamous epithelial cells present in a sample. The measurement may be expressed as a ratio or percentage.","Eosinophils to Non-Squamous Epithelial Cells Ratio Measurement | EOSNSQE | Eosinophils/Non-Squam Epi Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522798","Dicalcium Phosphate Crystals Measurement","C135407","The determination of the amount of dicalcium phosphate crystals in a biological sample.","Dicalcium Phosphate Crystals Measurement | CYDCPHOS | Dicalcium Phosphate Crystals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2733077","Chikungunya Virus Antibody Measurement","C135404","The determination of the amount of the Chikungunya virus antibodies in a biological sample.","Chikungunya Virus Antibody Measurement | CHKAB | Chikungunya Virus Antibody",,,,,,,,,,,,,,,"40481045","Measurement of Chikungunya virus antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL523849","Synthetic Cannabinoid Measurement","C135402","The determination of the amount of synthetic cannabinoids present in a biological sample.","Synthetic Cannabinoid Measurement | CANNABS | Cannabinoids, Synthetic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546022","Liver Alkaline Phosphatase to Total Alkaline Phosphatase Ratio Measurement","C147296","The determination of the ratio of liver-specific alkaline phosphatase compared to total alkaline phosphatase present in a sample. The measurement may be expressed as a ratio or percentage.","Liver Alkaline Phosphatase to Total Alkaline Phosphatase Ratio Measurement | ALPLALP | Alk Phos, Liver/Total Alk Phos | Alkaline Phosphatase, Liver/Total Alkaline Phosphatase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546023","Intestinal Alkaline Phosphatase to Total Alkaline Phosphatase Ratio Measurement","C147295","The determination of the ratio of intestinal-specific alkaline phosphatase compared to total alkaline phosphatase present in a sample. The measurement may be expressed as a ratio or percentage.","Intestinal Alkaline Phosphatase to Total Alkaline Phosphatase Ratio Measurement | ALPIALP | Alk Phos, Intestinal/Total Alk Phos | Alkaline Phosphatase, Intestinal/Total Alkaline Phosphatase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546024","Bone Alkaline Phosphatase to Total Alkaline Phosphatase Ratio Measurement","C147294","The determination of the ratio of bone-specific alkaline phosphatase compared to total alkaline phosphatase present in a sample. The measurement may be expressed as a ratio or percentage.","Bone Alkaline Phosphatase to Total Alkaline Phosphatase Ratio Measurement | ALPBALP | Alk Phos, Bone/Total Alk Phos | Alkaline Phosphatase, Bone/Total Alkaline Phosphatase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545276","Glycine max Antigen IgE Antibody Measurement","C147278","The determination of the amount of Glycine max antigen IgE antibody present in a sample.","Glycine max Antigen IgE Antibody Measurement | C147278 | Glycine max Antigen IgE Antibody | Soybean Antigen IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545275","Triticum aestivum Antigen IgE Antibody Measurement","C147277","The determination of the amount of Triticum aestivum antigen IgE antibody present in a sample.","Triticum aestivum Antigen IgE Antibody Measurement | Bread Wheat Antigen IgE Antibody | C147277 | Triticum aestivum Antigen IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545274","Arachis hypogaea Antigen IgE Antibody Measurement","C147276","The determination of the amount of Arachis hypogaea antigen IgE antibody present in a sample.","Arachis hypogaea Antigen IgE Antibody Measurement | Arachis hypogaea Antigen IgE Antibody | C147276 | Peanut Antigen IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545908","Normal Sperm to Total Sperm Ratio Measurement","C142286","The determination of the ratio of normal sperm compared to total sperm present in a sample. The measurement may be expressed as a ratio or percentage.","Normal Sperm to Total Sperm Ratio Measurement | NSPMTSPM | Normal Sperm/Total Sperm | Sperm Morphology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540284","Interleukin 2 Receptor Subunit Beta Measurement","C142283","The determination of the amount of interleukin 2 receptor subunit beta present in a sample.","Interleukin 2 Receptor Subunit Beta Measurement | IL-2Rb | IL2RB | Interleukin 2 Receptor Subunit Beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540299","Interleukin 2 Receptor Subunit Alpha Measurement","C142282","The determination of the amount of interleukin 2 receptor subunit alpha present in a sample.","Interleukin 2 Receptor Subunit Alpha Measurement | CD25 | IL-2Ra | IL2RA | Interleukin 2 Receptor Subunit Alpha | Soluble CD25",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540301","Mutant Huntingtin Protein Measurement","C142280","The determination of the amount of mutant huntingtin protein present in a sample.","Mutant Huntingtin Protein Measurement | HTTPM | Huntingtin Protein, Mutant | Mutant HTT Protein Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545934","Huntingtin Protein Measurement","C142279","The determination of the amount of huntingtin protein present in a sample.","Huntingtin Protein Measurement | HTT Protein Measurement | HTTP | Huntingtin Protein | Total Huntingtin Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540290","11-Nor-Delta9-THC-9-Carboxylic Acid Measurement","C142293","The determination of the amount of 11-nor-delta-9-THC-9-carboxylic acid present in a sample.","11-Nor-Delta9-THC-9-Carboxylic Acid Measurement | 11-Nor-Delta9-THC-9-Carboxylic Acid | THC-COOH | THCCOOH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545277","Mitochondrial M2 Antibody Measurement","C147395","The determination of the amount of mitochondrial M2 antibody present in a sample.","Mitochondrial M2 Antibody Measurement | AMA-M2 Measurement | MITOM2AB | Mitochondrial M2 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0428257","Mercury Measurement","C147393","The determination of the amount of mercury present in a sample.","Mercury Measurement | Hg | MERCURY | Mercury",,,,,,,,,,,,,,,"4066418","Mercury measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL546051","Macroscopic Blood Measurement","C147390","The determination of the amount or presence of macroscopic blood present in a sample.","Macroscopic Blood Measurement | MACROBLD | Macroscopic Blood | Visible Blood",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1294061","Leukocytes Corrected for Nucleated Erythrocytes Count","C147383","The determination of the amount of leukocytes, which has been corrected for nucleated erythrocytes, present in a sample.","Leukocytes Corrected for Nucleated Erythrocytes Count | LEUKCRBC | Leukocytes Corrected for Nucleated Erythrocytes | Leuks Corrected for Nucl Erythrocytes",,,,,,,,,,,,,,,"4022146","Leukocyte count corrected for nucleated erythrocytes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524167","Lead Measurement","C147382","The determination of the amount of lead present in a sample.","Lead Measurement | LEAD | Lead | Pb",,,,,,,,,,,,,,,"4022985","Lead measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545284","IDL Cholesterol and VLDL Cholesterol Subtype 3 Measurement","C147371","The determination of the amount of IDL cholesterol and VLDLD cholesterol subtype 3 present in a sample.","IDL Cholesterol and VLDL Cholesterol Subtype 3 Measurement | IDL Cholesterol and VLDL Cholesterol Subtype 3 | IDL+VLDL Cholesterol Subtype 3 | IDLVLDL3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202075","17-Hydroxyprogesterone Measurement","C147370","The determination of the amount of 17-hydroxyprogesterone present in a sample.","17-Hydroxyprogesterone Measurement | 17-Hydroxyprogesterone | 17-OHP | HYPGST17",,,,,,,,,,,,,,,"4216716","17 Hydroxyprogesterone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545283","Heat Shock Protein 90 Alpha Measurement","C147369","The determination of the amount of heat shock protein 90 present in a sample.","Heat Shock Protein 90 Alpha Measurement | HSP90 Measurement | HSP90A | Heat Shock Protein 90 Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545282","Heat Shock Protein 70 Measurement","C147368","The determination of the amount of heat shock protein 70 present in a sample.","Heat Shock Protein 70 Measurement | HSP70 | HSP70 Measurement | Heat Shock Protein 70",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545288","Granulocytes to Leukocytes Ratio Measurement","C147351","The determination of the ratio of granulocytes compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Granulocytes to Leukocytes Ratio Measurement | GRANLE | Granulocytes/Leukocytes | Polymorphonuclear Leukocytes/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443566","Very Long Chain Fatty Acids Measurement","C147337","The determination of the amount of very long chain fatty acids present in a sample.","Very Long Chain Fatty Acids Measurement | FATACVLC | Fatty Acids, Very Long Chain | VLCFA Measurement",,,,,,,,,,,,,,,"4264096","Very long chain fatty acids measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545293","von Willebrand Factor Multimers Measurement","C147336","The determination of the amount of von Willebrand factor multimers present in a sample.","von Willebrand Factor Multimers Measurement | FACTVWMU | vWF Multimers Measurement | von Willebrand Factor Multimers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202006","Estrogen Measurement","C147335","The determination of the amount of estrogen present in a sample.","Estrogen Measurement | ESTROGEN | Estrogen | Oestrogen",,,,,,,,,,,,,,,"4228843","Estrogen measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545237","Desvenlafaxine Measurement","C147333","The determination of the amount of desvenlafaxine present in a sample.","Desvenlafaxine Measurement | DSVLFXN | Desvenlafaxine | O-Desmethylvenlafaxine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266273","Ubiquinone 10 Measurement","C147321","The determination of the amount of ubiquinone 10 present in a sample.","Ubiquinone 10 Measurement | COQ10 | Coenzyme Q10 | Ubiquinone 10",,,,,,,,,,,,,,,"4036226","Ubiquinone 10 measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545246","Cyclic Citrullinated Peptide IgG Antibody Measurement","C147316","The determination of the amount of cyclic citrullinated peptide IgG antibody present in a sample.","Cyclic Citrullinated Peptide IgG Antibody Measurement | CCPIGGAB | Cyclic Citrullinated Peptide IgG Ab | Cyclic Citrullinated Peptide IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552596","C-peptide to Creatinine Ratio Measurement","C150837","The determination of the ratio of C-peptide compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","C-peptide to Creatinine Ratio Measurement | C Peptide to Creatinine Ratio Measurement | C-peptide/Creatinine | CPEPCRT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523823","Phenylketone Measurement","C147414","The determination of the amount of phenylketone present in a sample.","Phenylketone Measurement | PHNKET | Phenyl Ketones | Phenylketones",,,,,,,,,,,,,,,"4020558","Phenylketones measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545324","Type 1 Collagen X-link N-Telopeptides to Creatinine Ratio Measurement","C147408","The determination of the ratio of the type 1 collagen X-link N-telopeptides compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Type 1 Collagen X-link N-Telopeptides to Creatinine Ratio Measurement | NTXICRT | T1 Collagen X-link N-Telopeptides/Creat | Type I Collagen X-linked N-Telopeptides/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898218","Multiplex Amplifiable Probe Hybridization","C116159","A screening method used to determine abnormal DNA copy number changes in complex genomes. This method uses unique short probes which can be quantitatively recovered and amplified after hybridization to genomic DNA. In addition, the probes can be specifically designed for any genomic region of interest (such as locus, telomere, chromosomal segment, whole chromosome or total genome) with high hybridization specificity.","Multiplex Amplifiable Probe Hybridization | MAPH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829206","Manual Clot Detection","C111245","A clot detection method that uses a manual means (visual discernment) to detect the presence and/or quantify the formation of a thrombus in a specimen.","Manual Clot Detection | MANUAL CLOT DETECTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640875","Microbial Liquid Culture","C102668","A method for growing microorganisms in liquid culture media.","Microbial Liquid Culture | MICROBIAL CULTURE, LIQUID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827875","Microbial Concentration Method","C85702","Any technique in which a sample is condensed in order to afford greater sensitivity for the detection of microorganisms.","Microbial Concentration Method | MICROBIAL CONCENTRATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0087124","Bacterial Typing Procedure","C51955","A procedure for identifying types and strains of bacteria. The most frequently used typing systems are bacteriophage typing, serotyping, bacteriocin typing, and biotyping.","Bacterial Typing Procedure | MICROBIAL BIOCHEMICAL IDENTIFICATION",,,,,,,,,,,,,,,"4030178","Bacterial typing procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827874","Micro Broth Dilution Method","C85701","A method to determine the minimum inhibitory concentration (MIC) of antibiotics in which growth media is pipetted into a multi-well plate. Each well contains a known concentration of drug which is inoculated with a known quantity of bacteria. The plate is incubated for a specified period of time and each well is assessed for bacterial cell growth. The drug concentration in the first well showing no growth is known as the MIC for that antibiotic.","Micro Broth Dilution Method | MICRO BROTH DILUTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829143","Mechanical Clot Detection","C111249","A clot detection method that uses a mechanical means (electromagnetic mechanical or electromechanical) to detect the presence and/or quantify the formation of a thrombus in a specimen.","Mechanical Clot Detection | MECHANICAL CLOT DETECTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545373","Multiplexed Opsonophagocytic Killing Assay","C147468","An assay technique that measures the opsonophagocytic killing activity of antibodies against multiple serotypes in a single serum assay.","Multiplexed Opsonophagocytic Killing Assay | MOPA | MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522828","Multiplexed Bead Based Immunoassay","C135455","A type of solid-phase immunoassay that uses distinctly colored microbeads coated with one or more reagents, which may be antigens, antibodies, oligonucleotides, enzyme substrates, or receptors, for the simultaneous detection and measurement of one or many analytes within a single sample.","Multiplexed Bead Based Immunoassay | FMIA | Fluorescent Microsphere Immunoassay | MULTIPLEXED BEAD BASED IMMUNOASSAY | Multiplex Bead Array Assay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3494189","Multiplex Ligation-dependent Probe Amplification","C116161","A type of high-throughput, multiplex PCR method used to determine abnormal DNA copy number changes of up to 50 genomic DNA or RNA sequences with a single pair of PCR primers. It is frequently used in the detection of genetic aberrations in tumors, and can distinguish sequences differing in only a single nucleotide.","Multiplex Ligation-dependent Probe Amplification | MLPA | MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513466","Multiple Breath Washout","C130176","A test of lung function in which changes in exhaled tracer gas concentration is analyzed for a specified number of tidal expirations, a defined period of time, or a defined index of expired gas volume.","Multiple Breath Washout | MULTIPLE BREATH WASHOUT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828881","Multi-slice Spiral Computed Tomography","C106545","A type of spiral computed tomography that employs multiple rows of detectors, each capable of producing a simultaneous image (slice).","Multi-slice Spiral Computed Tomography | MULTI-SLICE SPIRAL CT | Multi-Slice Spiral Computed Tomography | Multi-slice Spiral CT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827904","Modified Acid Fast Staining Method","C85736","A microscopy staining method, that does not utilize heat in the slide preparation, used to examine a specimen for the presence of acid-fast microorganisms, specifically nocardia.","Modified Acid Fast Staining Method | MODIFIED ACID FAST STAIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3655762","Microparticle Enzyme Immunoassay","C111252","A type of enzyme immunoassay that uses antigen-coated microparticles as a substrate for antibody binding.","Microparticle Enzyme Immunoassay | MEIA | MICROPARTICLE ENZYME IMMUNOASSAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054524","MICRONEUTRALIZATION ASSAY","C120695","An in vitro assay that is used to determine whether antibodies that can block viral infection are present in a biological specimen. Virus is mixed with serum taken from the subject and is incubated in culture with laboratory cells, which are monitored over time for cytotoxicity.","Virus Neutralization Assay | MICRONEUTRALIZATION ASSAY | Microneutralization Assay | VNA | Virus Neutralization Assay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552618","Microdensitometry","C150872","A technique for measuring microscopic optical density on exposed film or photographic images through the detection of faint spectral lines.","Microdensitometry | MICRODENSITOMETRY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640876","Microbial Solid Culture","C102669","A method for growing microorganisms in solid culture media.","Microbial Solid Culture | MICROBIAL CULTURE, SOLID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828566","Photometric Clot Detection","C111291","A clot detection method that uses a photometric means (measuring the absorbancy of monochromatic light) to detect the presence and/or quantify the formation of a thrombus in a specimen.","Photometric Clot Detection | PHOTOMETRIC CLOT DETECTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0182250","Phoropter","C120699","An instrument composed of multiple lenses that refract the light going into the subject's eye, allowing the examiner to determine the refractive error of the eye.","Phoropter | PHOROPTER",,,,,,,,,,,,,,,"4264869","Phoropter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513178","Phenotypic Multiple Antigen Bead-based Multiplex Assay","C130178","A type of solid-phase multiplex assay that uses microbeads coated with recombinant or infinity purified antigens from multiple alleles for the detection and identification of antibodies that would bind and react to these antigens.","Phenotypic Multiple Antigen Bead-based Multiplex Assay | PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522829","Phase-Contrast Magnetic Resonance Imaging","C135456","A form of MRI in which a phase shift between flowing tissue and static tissue is generated in order to determine the quantity and velocity of blood flow.","Phase-Contrast Magnetic Resonance Imaging | PCMR | PHASE-CONTRAST MRI | Phase-Contrast MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026024","Phase-Contrast Microscopy","C16857","A simple non-quantitative form of interference microscopy of great utility in visualising live cells. Small differences in optical path length due to differences in refractive index and thickness of structures are visualised as differences in light intensity.","Phase-Contrast Microscopy | Microscopy, Phase-Contrast | PHASE CONTRAST MICROSCOPY",,,,,,,,,,,,,,,"4123000","Phase contrast microscopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0182229","pH Meter","C122172","An electronic device used to measure the alkalinity or acidity of a liquid or semi-solid substance.","pH Meter | ",,,,,,,,,,,,,,,"45765320","pH meter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540360","PET-CT Scan Without Contrast","C142342","A form of PET/CT imaging in which radiopharmaceuticals is not used.","PET-CT Scan Without Contrast | PET/CT SCAN WITHOUT CONTRAST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0412290","Peripheral Angiography","C117879","A procedure in which the catheter is passed into a peripheral vessel (usually in the groin) for the purpose of angiography of the abdomen, hands, arms, feet and legs.","Peripheral Angiography | PERIPHERAL ANGIOGRAPHY",,,,,,,,,,,,,,,"4156054","Peripheral angiography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523213","Periodic Acid Schiff Staining Method","C23019","This is an all-round useful stain for many things, including glycogen, mucin, mucoprotein, glycoprotein, as well as fungi. The reaction is based on the oxidation of glycol group to aldehydes by periodate. The schiff's reagent selectively stains the aldehydes to a rose pink color. PAS is useful for outlining tissue structures--basement membranes, capsules, blood vessels, etc.","Periodic Acid Schiff Staining Method | PAS | PAS Staining Method | PERIODIC ACID SCHIFF STAIN | Periodic Acid-Schiff Staining",,,,,,,,,,,,,,,"4015319","Periodic acid Schiff stain method",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897970","Pelli-Robson Contrast Sensitivity Eye Chart","C117878","A diagrammatic method to test visual acuity and contrast sensitivity, which utilizes large letters (at a 20/60 acuity) that decrease in contrast from right to left and top to bottom.","Pelli-Robson Contrast Sensitivity Eye Chart | PELLI-ROBSON EYE CHART",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054223","Peak Flowmetry","C122171","A method for measuring the flow of air through the bronchi upon expiration.","Peak Flowmetry | PEAK FLOWMETRY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086729","Pathologic Examination","C125006","An assessment of disease process to include cause, development, and/or structural and functional changes associated with the disease.","Pathologic Examination | PATHOLOGICAL EVALUATION | Pathologic Review | Pathology Examination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504582","Particle-Enhanced Turbidimetric Immunoassay","C125953","A method to quantify the opaqueness of a liquid using a turbidimeter, by measuring the decrease in light intensity due to the scattering effect of suspended immunoaggregates in a liquid sample. The immunoaggregates are target antigens agglutinated to antigen-specific antibody-coated polystyrene latex-enhanced particles.","Particle-Enhanced Turbidimetric Immunoassay | PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY | PETIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505162","Particle-Enhanced Nephelometric Immunoassay","C125952","A method to quantify the concentration of immunoaggregates suspended in a liquid or gas using a nephelometer. The immunoaggregates are target antigens agglutinated to antigen-specific antibody-coated polystyrene latex-enhanced particles.","Particle-Enhanced Nephelometric Immunoassay | PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY | PENIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512520","Papanicolaou Staining Method","C128984","A microscopy staining method that utilizes a mixture of dyes including hematoxylin, orange G (OG), and eosin azure, which contains variable portions of Eosin Y, light green SF yellowish, and Bismarck brown Y. This multichromatic staining method is used to differentially stain samples containing mixed cell populations.","Papanicolaou Staining Method | PAP STAIN | PAP Stain | Papanicolau Stain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898095","Optical Mapping","C116162","A technique used for constructing the ordered and high-resolution genome or chromosome sized restriction enzyme map of an organism from a single, stained DNA molecule, digested by the restriction enzyme and imaged by an optical microscope.","Optical Mapping | OPTICAL MAPPING | Optical Map",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266211","Optical Density Measurement","C85776","A quantification of the amount of light that is absorbed by or transmitted through a substance.","Optical Density Measurement | OPTICAL DENSITY MEASUREMENT",,,,,,,,,,,,,,,"4007334","Optical density measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898104","Oligonucleotide Array-based Comparative Genomic Hybridization","C116156","A molecular cytogenetic method combining chromosomal comparative genomic hybridization technique and microarray to detect chromosomal aberrations and changes in DNA copy numbers in the genome, using oligonucleotides immobilized on a solid support as targets for hybridization.","Oligonucleotide Array-based Comparative Genomic Hybridization | OLIGO ACGH | Oligonucleotide Array-based CGH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054346","Non-Contact Specular Microscopy","C120697","A type of specular microscopy in which the specular microscope does not make contact with the cornea of the eye.","Non-Contact Specular Microscopy | NON-CONTACT SPECULAR MICROSCOPY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054359","Neuraminidase Inhibition Assay","C120696","A type of enzyme-based assay that assesses neuraminidase activity in the presence of an enzyme inhibitor.","Neuraminidase Inhibition Assay | NEURAMINIDASE INHIBITION ASSAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027692","Nephelometry","C111281","A method to quantify the concentration of particulate matter suspended in a liquid or gas using a nephelometer.","Nephelometry | NEPHELOMETRY",,,,,,,,,,,,,,,"4234277","Nephelometry",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827951","Ryan Blue Staining Method","C85801","A microscopy staining method that utilizes a modified trichrome stain to determine the presence of microsporidial species. This staining technique substitutes aniline blue for the fast green counterstain of the original trichrome staining method and decreased levels of phosphotungstic acid in the reagent.","Ryan Blue Staining Method | RYAN BLUE STAIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034580","Radioimmunoassay","C17057","Radioimmunoassay (RIA) is an immunological technique, which quantitatively determines antigen and antibody concentrations, using a radioactively labeled substance (radioligand), either directly or indirectly.","Radioimmunoassay | Immunologic, Radioimmunoassay | RIA",,,,,,,,,,,,,,,"4187803|45773086","Radioimmunoassay|Radioimmunoassay",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1514862","Representational Oligonucleotide Microarray Analysis","C40211","A genomic microarray-based method able to identify regions in the cancer genome that have undergone copy number fluctuation. This method is reported to be highly sensitive and quantitative, able to detect loss of a single allele. See: Genome Res. 2003 Oct;13(10):2291-305. Epub 2003 Sep 15.","Representational Oligonucleotide Microarray Analysis | REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS | ROMA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034953","Refractometry","C111304","A method to measure the refractive index (propensity for light to bend) of a sample.","Refractometry | REFRACTOMETRY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514813","Reflectance or Transmission Spectroscopy","C19340","The spectroscopic analysis of light reflected from a polished sample.  The peaks of reflectance/transmittance occur in the same spectral region where the sample absorbs light.  In near infrared (IR) reflectance/transmission spectroscopy (NIRS), the reflectance signals result from bending and stretching vibrations in molecular bonds between carbon, nitrogen, hydrogen, and oxygen. (from FRTR Field Sampling and Analysis Technologies Reference Guide (online))","Reflectance or Transmission Spectroscopy | REFLECTANCE SPECTROSCOPY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054118","Rebound Tonometry","C120703","A method in which a probe is bounced off of the surface of the cornea, creating an induction current that is used to calculate intraocular pressure.","Rebound Tonometry | REBOUND TONOMETRY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522832","Raji Cell Radioimmunoassay","C135459","A type of complement receptor-dependent immune complex assay that uses radiolabeled anti-IgA, anti-IgG, or anti-IgM Raji cells to detect the presence of soluble immune complexes in biologic fluids.","Raji Cell Radioimmunoassay | RAJI CELL RIA | Raji Cell RIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522831","Raji Cell Enzyme Immunoassay","C135458","A type of complement receptor-dependent immune complex assay that uses Raji cells washed with anti-IgA, anti-IgG, anti-IgM, and anti-Ig (A+G+M) conjugated with an enzyme to detect the presence of circulating immune complexes in biologic fluids.","Raji Cell Enzyme Immunoassay | RAJI CELL EIA | Raji Cell EIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201717","Radial Immunodiffusion","C119296","A quantitative technique used to detect and estimate the concentration of an antigen by measuring the diameter of the ring of precipitation (precipitin ring), which is formed as a result of the interaction of the antigen and an antibody at optimal concentration.","Radial Immunodiffusion | RADIAL IMMUNODIFFUSION",,,,,,,,,,,,,,,"4065221","Radial immunodiffusion measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552619","Quantitative Ultrasound","C150873","A method of empirically measuring the velocity and attenuation of ultrasonic sound waves as they pass through tissue.","Quantitative Ultrasound | QUANTITATIVE ULTRASOUND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054138","Quantitative Peripheral Angiography","C120702","A type of angiographic procedure that allows for direct quantitative assessment of the vessels of the hands, arms, feet and legs.","Quantitative Peripheral Angiography | QUANTITATIVE PERIPHERAL ANGIOGRAPHY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054139","Quantitative Coronary Angiography","C120701","A type of angiographic procedure that allows for direct quantitative assessment of the native coronary arteries or bypass grafts supplying native coronary arteries.","Quantitative Coronary Angiography | QUANTITATIVE CORONARY ANGIOGRAPHY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050238","Monocular Pupillometry","C120700","A technique used to measure the diameter of a single pupil in response to stimuli.","Monocular Pupillometry | PUPILLOMETRY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032847","Potentiometry","C142343","An electroanalytical technique in which the electrical potential of a solution is measured to determine the composition of the sample, by comparing the constant potential of the reference electrode with the actual potential of the indicator electrode.","Potentiometry | ISE Method | Ion Selective Electrode Method | POTENTIOMETRY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522830","Population Sequencing","C135457","A process by which the individual genomes of most or all of an entire population of a species undergoes a large-scale comparison of the DNA sequences within that population, using probabilistic matching tools. Such comparison allows for the study of microevolution within a population.","Population Sequencing | POPULATION SEQUENCING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162701","Polysomnography","C114185","A group of tests taken during sleep to capture and record brain wave changes, eye movements, breathing rate, blood pressure, heart rate, and the electrical activity of the heart and other muscles.","Polysomnography | POLYSOMNOGRAPHY | PSG",,,,,,,,,,,,,,,"4189015","Polysomnography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032221","Plethysmography","C122173","A method used to measure changes in volume, pressure and resistance within an organ or whole body by means of a plethysmograph.","Plethysmography | Body Box | PLETHYSMOGRAPHY",,,,,,,,,,,,,,,"4070662","Plethysmography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2702546","Exposure Method","C119826","The technique used to administer the exposure treatment.","Exposure Method | EXMETHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897101","Exposure as Collected Reason for Dose Adjustment","C117495","The explanation given as to why the collected exposure was adjusted.","Exposure as Collected Reason for Dose Adjustment | ECADJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2228040","Annular Lesion","C111971","A ring-shaped skin finding with clear central area.","Annular Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272304","Coronary Vessel Lesion","C100063","Pathologic material in a vessel that obstructs myocardial perfusion. (ACC)","Coronary Vessel Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332573","Macular Lesion","C43278","A flat lesion characterized by change in the skin color.","Macular Lesion | Macule",,,,,,,,,,,,,,,"4010895","Macule",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334988","Non-Measurable Lesion","C36110","A neoplasm for which no exact measurement may be obtained. This may be due to a size below detection, an invasive presentation, or pertain to an effusion or ascites.","Non-Measurable Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897895","Placental Lesion","C117372","Macroscopically identifiable placental parenchymal abnormality.","Placental Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272645","Serosal Lesion","C96211","A lesion that is located in the serosa surface of an organ.","Serosal Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827857","Targetoid Lesion","C111972","A red, edematous ring skin finding that may have a central dusky disk and an erythematous halo.","Targetoid Lesion | Iris Lesion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272960","Kurloff Cells Measurement","C96682","The determination of the amount of large secretory granule-containing immune cells in a biological specimen taken from members of certain genera of the Caviidae family.","Kurloff Cells Measurement | KURLOFCE | Kurloff Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0430462","Transthoracic Echocardiography","C80404","A non-invasive cardiac ultrasound performed by placing the transducer on the chest.","Transthoracic Echocardiography | TRANSTHORACIC ECHOCARDIOGRAPHY | TTE",,,,,,,,,,,,,,,"4335825","Transthoracic echocardiography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206054","Transesophageal Echocardiography","C80405","A cardiac ultrasound performed by passing a specialized probe containing a transducer into the patient's esophagus.","Transesophageal Echocardiography | TEE | TRANSESOPHAGEAL ECHOCARDIOGRAPHY",,,,,,,,,,,,,,,"4019824","Transesophageal echocardiography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1553166","Transcription-mediated Amplification","C122175","A technique used to selectively replicate nucleic acid sequences from RNA templates using reverse transcriptase and RNA polymerase. Reverse transcriptase generates cDNA from the region of interest using primers and then RNA polymerase generates copies of the original RNA template.","Transcription-mediated Amplification | TRANSCRIPTION-MEDIATED AMPLIFICATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272922","Total Body Radiography","C96640","A diagnostic radiologic test that involves the examination of the entire body in a single procedure.","Total Body Radiography | TOTAL BODY RADIOGRAPHY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523203","Toluidine Blue Staining Method","C92302","A microscopy staining method that utilizes toluidine blue, a solution composed of tolonium chloride, to determine the presence of mast cells, lignin, proteoglycans and glycosaminoglycans.","Toluidine Blue Staining Method | TOLUIDINE BLUE STAIN",,,,,,,,,,,,,,,"4015317","Toluidine blue stain method",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2827970","Thin Smear Technique","C85820","A blood smear technique used to make a thin blood smear on a microscope slide which is generally used to look for blood parasites such as those causing malaria.","Thin Smear Technique | THIN SMEAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827969","Thick Smear Technique","C85819","A blood smear technique used to make a thick blood smear on a microscope slide which is generally used to look for blood parasites such as those causing malaria.","Thick Smear Technique | THICK SMEAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705054","Test Strip Device","C50322","A piece of chemically treated medium designed to react in the presence of specific amounts of a trigger substance.","Test Strip Device | TEST STRIP | Test Strip",,,,,,,,,,,,,,,"45773575","Test strip",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053946","Template Incision Method","C122174","A modification of the Ivy method for assessing bleeding time in which the individual wears a blood pressure cuff inflated to 40mmHg, a controlled incision is made using an automatic blade on the volar surface of the arm (thus standardizing the incision size), and blood is drawn off of the incision site with blotting paper every 30 seconds until bleeding stops.","Template Incision Method | TEMPLATE INCISION METHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0563666","Teller Acuity Cards","C142345","A diagrammatic method to test visual acuity that uses a set of cards with parallel lines, used for those individuals who are unable to provide a verbal response to questions, including infants, toddlers, and other non verbal individuals.","Teller Acuity Cards | TELLER ACUITY CARDS",,,,,,,,,,,,,,,"4112888","Teller acuity cards",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552733","Single Energy X-Ray Absorptiometry","C150874","A technique for measuring anatomical densities in which a single X-ray beam, whose low and high energy is separated, is aimed at the bone or tissue of interest and x-ray absorption is assessed. This technique has multiple applications including the measurement of bone mineral density and bone mineral content and more novel applications such as breast density.","Single Energy X-Ray Absorptiometry | SXA | SXA SCAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0920208","Stress Echocardiography","C80407","An image of the heart produced by ultrasonography under conditions intended to elicit signs and symptoms of myocardial ischemia. Conditions often include exercise, pharmacologic agents or pacing.","Stress Echocardiography | STRESS ECHOCARDIOGRAPHY | Stress Echo",,,,,,,,,,,,,,,"37311810","Stress echocardiography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054002","Specular Microscopy","C120542","A noninvasive photographic technique used to visualize and examine the corneal endothelium, in which a source of light is projected onto the cornea and the subsequent image reflected from the optical interface between the corneal endothelium and the aqueous humor is captured.","Specular Microscopy | SPECULAR MICROSCOPY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037805","Spectrophotometry","C116701","A laboratory test that produces a quantitative measurement of the reflection or transmission properties of a material as a function of wavelength.","Spectrophotometry | SPECTROPHOTOMETRY | spectrophotometer method | spectrophotometer_method",,,,,,,,,,,,,,,"4141429","Spectrophotometric measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0183370","Snellen Eye Chart","C123467","A diagrammatic method to test visual acuity, which utilizes a chart containing 11 lines of Sloan optotypes in varying sizes, the largest located at the top of the chart and decreasing in size toward the bottom of the chart.","Snellen Eye Chart | SNELLEN EYE CHART",,,,,,,,,,,,,,,"4268146","Snellen chart",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897567","Sloan Letter Eye Chart 2.5 Percent","C117881","A diagrammatic method to test visual acuity that utilizes the Sloan optotypes and a 2.5% contrast level.","Sloan Letter Eye Chart 2.5 Percent | SLOAN LETTER EYE CHART 2.5%",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897568","Sloan Letter Eye Chart 1.25 Percent","C117880","A diagrammatic method to test visual acuity that utilizes the Sloan optotypes and a 1.25% contrast level.","Sloan Letter Eye Chart 1.25 Percent | SLOAN LETTER EYE CHART 1.25%",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540359","Silver-Enhanced in Situ Hybridization","C142344","A type of in situ hybridization that uses a hybridization probe linked to an enzyme that elicits neutralization and deposition of silver onto the probe target site.","Silver-Enhanced in Situ Hybridization | SISH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513497","Single-strand Conformation Polymerase Chain Reaction","C130183","A modified polymerase chain reaction (PCR) technique that uses differences in molecular weights and three-dimensional structures to identify mutations in DNA configurations.","Single-strand Conformation Polymerase Chain Reaction | PCR-SSCP | SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828017","Single-slice Spiral Computed Tomography","C106567","A type of spiral computed tomography that employs only one detector that produces one image (slice).","Single-slice Spiral Computed Tomography | SINGLE-SLICE SPIRAL CT | Single-Slice Spiral Computed Tomography | Single-slice Spiral CT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513496","Single Antigen Bead-based Multiplex Assay","C130182","A type of solid-phase multiplex assay that uses microbeads coated with recombinant or infinity purified antigens from a single allele for the detection and identification of an antibody that would bind and react to this antigen.","Single Antigen Bead-based Multiplex Assay | SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889830","Biopolymer Sequencing","C116155","A process to identify and determine the primary structure of, and the order of constituents in a biopolymer.","Biopolymer Sequencing | SEQUENCING | Sequencing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513494","Sequence-specific Oligonucleotide Probe Polymerase Chain Reaction","C130181","A modified polymerase chain reaction (PCR) technique that uses distinct probes, specifically synthesized according to the polymorphic region sequence of the gene of interest, to detect nucleotide differences during genotype testing.","Sequence-specific Oligonucleotide Probe Polymerase Chain Reaction | PCR-SSOP | SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514215","Sequence-based Typing","C130180","A method that provides the entirety of the nucleotide sequence of a specific DNA strand, allowing for reliable and thorough genotyping of the allele in question.","Sequence-based Typing | SBT | SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513493","Allele Specific Primer Polymerase Chain Reaction","C130179","A modified polymerase chain reaction (PCR) technique in which a specific primer can amplify its corresponding allele only; this allows for the determination of the presence or absence of a single, specific allele during genotype testing.","Allele Specific Primer Polymerase Chain Reaction | PCR-SSP | SEQUENCE SPECIFIC PRIMER POLYMERASE CHAIN REACTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0546674","Sorbitol dehydrogenase measurement","C79465","The determination of the amount of sorbitol dehydrogenase present in a sample.","Sorbitol Dehydrogenase Measurement | SDH | Sorbitol Dehydrogenase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699329","Sodium to Creatinine Ratio Measurement","C79464","The determination of the ratio of sodium compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Sodium to Creatinine Ratio Measurement | NACREAT | Sodium/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041394","Turbidimetry","C111328","A method to quantify the opaqueness of a liquid using a turbidimeter, by measuring the decrease in light intensity due to the scattering effect of suspended particles in the liquid sample.","Turbidimetry | TURBIDIMETRY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519650","Triple-Phase Spiral CT","C19907","A form of computed tomography (CT) in which images are taken during three distinct timing points (phases) following the injection of contrast material: arterial, venous, and delayed. This form of CT imaging is most commonly used to image hepatic lesions.","Triple-Phase Spiral CT | TRIPLE-PHASE SPIRAL CT SCAN | Triphasic Spiral CT | Triple-Phase Spiral Computed Tomography",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513382","Triple Phase MRI","C130184","A form of magnetic resonance imaging (MRI) in which images are taken during three distinct timing points (phases) following the injection of contrast material: arterial, venous, and delayed.","Triple Phase MRI | TRIPLE-PHASE MRI SCAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1318721","Ziehl Neelsen Acid Fast Staining Method","C85831","A microscopy acid fast staining method that utilizes Ziehl-Neelsen carbol fuchsin, acid alcohol and methylene blue, to determine the presence of acid fast microorganisms. This acid fast staining technique requires heating during the primary staining step involving the carbol fuchsin.","Ziehl Neelsen Acid Fast Staining Method | ZIEHL NEELSEN ACID FAST STAIN | Ziehl-Neelsen Acid-fast Staining | Ziehl-Neelsen Acid-fast Staining Method",,,,,,,,,,,,,,,"4249538","Ziehl-Neelsen stain method",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037804","X-Ray Fluorescence Spectrometry","C85830","A spectrometric method that determines the type and concentration of elements or chemicals in a sample, based upon the principle that each element emits fluorescent light of a particular wavelength when exposed to an X-ray.","X-Ray Fluorescence Spectrometry | X-RAY FLUORESCENCE SPECTROMETRY",,,,,,,,,,,,,,,"4060637","X-ray fluorescence spectrometry",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0770761","Wright Staining Method","C85829","A microscopy staining method that utilizes the Romanowsky stains, eosin and methylene blue, solubilized in methanol. In this staining protocol, methanol is also utilized as a fixative agent prior to staining.","Wright Staining Method | WRIGHT STAIN",,,,,,,,,,,,,,,"4018453|45773085","Wright stain method|Wright stain method",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2827978","Weber Green Staining Method","C85828","A microscopy staining method that utilizes a modified trichrome stain to determine the presence of microspordial, sporulating species. The staining method utilizes chromotrope 2R, a red acidic dye, the counterstain fast green, and phosphotungstic acid.","Weber Green Staining Method | WEBER GREEN STAIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0560738","Ventilation Perfusion Scanning","C38100","A nuclear imaging test that uses radiopharmaceuticals to produce an image of the blood flow to the lungs, that measures the ability of the lungs to inhale gas, and that assesses the gas distribution within the lungs.","Ventilation Perfusion Scanning | VENTILATION PERFUSION LUNG SCAN | VQ SCAN | Ventilation-Perfusion Scan",,,,,,,,,,,,,,,"4242700","Pulmonary ventilation perfusion study",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2984971","Uranyl Acetate Staining Method","C92303","A microscopy staining method that utilizes uranyl acetate, a water insoluble yellow crystalline solid, which is used as a negative stain in electron microscopy.","Uranyl Acetate Staining Method | URANYL ACETATE STAIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053724","Ultra High-performance Liquid Chromatography/Tandem Mass Spectrometry","C122176","An analytical technique wherein ultra-high performance liquid chromatography is coupled to tandem mass spectrometry in order to separate, identify, and quantify substances in a sample.","Ultra High-performance Liquid Chromatography/Tandem Mass Spectrometry | U-HPLC/MS/MS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897264","Two Color Microarray","C116153","A genomic microarray-based method using cDNA from two samples, labeled with two separate fluorophores/dyes at different emission wavelengths, and hybridized to a single microarray for laser excitation in a microarray scanner. Relative fluorescence intensity of each dye can be measured and used in log- or intensity- ratio based comparative analysis for gene expression between the two experimental conditions.","Two Color Microarray | Dual-channel Microarray | TWO-COLOR MICROARRAY | Two-channel Expression Array | Two-channel Microarray | Two-color Microarray-based Gene Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0743284","Drug Exposure","C41362","Contact with drug.","Drug Exposure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545308","VITD23OH","C147445","The determination of the amount of vitamin D2, vitamin D3, and 25-hydroxyvitamin D present in a sample.","Vitamin D2 and Vitamin D3 and 25-Hydroxy Vitamin D2 and 25-Hydroxy Vitamin D3 Measurement | VITD23OH | Vitamin D + Metabolites | Vitamin D2 + Vitamin D3 + 25-Hydroxy Vitamin D2 + 25-Hydroxy Vitamin D3 | Vitamin D2 D3 25-OH | Vitamin D2 and Vitamin D3 and 25-Hydroxyvitamin D Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1277750","Varicella Zoster Virus IgG Antibody Measurement","C98796","The determination of the amount of varicella zoster virus IgG antibody present in a sample.","Varicella Zoster Virus IgG Antibody Measurement | VZVIGGAB | Varicella Zoster Virus IgG Antibody",,,,,,,,,,,,,,,"4209241","Varicella-zoster virus antibody IgG measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899226","Exposure as Collected Dose Units","C117481","The unit of measure for the dosage form of the collected exposure.","Exposure as Collected Dose Units | ECDOSU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0678587","steady state","C151966","Having reached equilibrium for the measurement or phenomenon concerned.","Steady-State | Steady State",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826697","Exposure Interruption Duration Unit","C83086","The unit of measure for the time span of a disruption in the exposure.","Exposure Interruption Duration Unit | EXINTRPU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554365","Priority at Discharge Code","C153107","A coded value specifying the degree to which a condition is established to be chiefly responsible for occasioning the admission of the patient.","Priority at Discharge Code | PriorityAtDischargeCode | priorityAtDischargeCode",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439609","Urgency","C153140","The pressing importance of something.","Urgency | Immediacy | Urgent",,,,,,,,,,,,,,,"4014167","Urgent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2981472","Findings About Events or Interventions Observation Object","C87888","The name of the object that is being assessed in order to determine the finding of the event or intervention.","Findings About Events or Interventions Observation Object | FAOBJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898447","Measurement, Test or Examination Detail","C117062","Particulars considered individually and in relation to a measurement, test or examination.","Measurement, Test or Examination Detail | TSTDTL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830117","Findings About Events or Interventions Original Result","C113364","The outcome of the findings about events or interventions assessment.","Findings About Events or Interventions Original Result | FAORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826308","Normal Range Lower Limit Original Unit","C82580","The lowest number in a previously accepted range of values as originally received or collected.","Normal Range Lower Limit Original Unit | ORNRLO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830115","Findings About Events or Interventions Reason Not Done","C113366","The explanation given as to why findings about events or interventions were not collected.","Findings About Events or Interventions Reason Not Done | FAREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826775","Duration of Use","C83168","The amount of time that a thing is consumed or employed.","Duration of Use | CDUR | medication duration | medication_duration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086431","Healthcare Encounters Reason Not Done","C123993","The explanation given as to why the healthcare encounter was not assessed.","Healthcare Encounters Reason Not Done | HOREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086435","Healthcare Encounters Sponsor Defined Identifier","C124004","One or more sponsor defined characters used to identify, name, or characterize the healthcare encounters.","Healthcare Encounters Sponsor Defined Identifier | HOSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086440","Healthcare Encounters Verbatim Description","C124023","The verbatim description of the healthcare encounter being reported.","Healthcare Encounters Verbatim Description | HOTERM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086423","Healthcare Encounters Dictionary-derived Term","C123944","A healthcare encounter identifier obtained from a dictionary.","Healthcare Encounters Dictionary-derived Term | HODECOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826887","Inclusion Exclusion Criterion Original Result","C83297","The first outcome of the inclusion exclusion criterion.","Inclusion Exclusion Criterion Original Result | IEORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826247","Test Date","C82512","The date that the test was performed.","Test Date | DAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826752","Inclusion Exclusion Criterion Test Code","C83144","A character or string that represents the short code name of the inclusion exclusion criterion test.","Inclusion Exclusion Criterion Test Code | IETESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826755","Inclusion Exclusion Criterion Test","C83147","A character or string that represents the full name of the inclusion exclusion criterion assessment.","Inclusion Exclusion Criterion Test | IETEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826706","Laboratory Test Reference Range Lower Limit Original Unit","C83095","The lower limit of the laboratory test reference range, as reported in original units.","Laboratory Test Reference Range Lower Limit Original Unit | LBORNRLO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826684","Laboratory Test Reference Range Upper Limit Original Unit","C83073","The upper limit of the laboratory test reference range, as reported in original units.","Laboratory Test Reference Range Upper Limit Original Unit | LBORNRHI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826772","Laboratory Test Original Result","C83165","The outcome of the laboratory test assessment.","Laboratory Test Original Result | LBORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826690","Medical History Sponsor Defined Identifier","C83079","One or more sponsor-defined characters used to identify, name, or characterize the medical history items.","Medical History Sponsor Defined Identifier | MHSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826728","Medical History Reported Term","C83118","The verbatim description of the medical history being reported.","Medical History Reported Term | MEDICAL_HISTORY | MHTERM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826713","Drug Accountability Assessment Result Original Units","C83103","The unit of measure for the original drug accountability result.","Drug Accountability Assessment Result Original Units | DAORRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826923","Medical History Modified Reported Term","C83333","An indication or description of a change in medical history.","Medical History Modified Reported Term | MHMODIFY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826936","Medical History Dictionary Derived Term","C83346","A medical history identifier obtained from a dictionary.","Medical History Dictionary Derived Term | MHDECOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898363","Microscopic Findings Reference Identifier","C117575","A character or string used to name, or characterize a microscopic findings reference.","Microscopic Findings Reference Identifier | MIREFID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898357","Microscopic Findings Sponsor Defined Identifier","C117576","One or more sponsor defined characters used to identify, name, or characterize the microscopic findings.","Microscopic Findings Sponsor Defined Identifier | MISPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898369","Microscopic Findings Measurement, Test or Examination Detail","C117579","Particulars considered individually and in relation to a microscopic findings measurement, test or examination.","Microscopic Findings Measurement, Test or Examination Detail | MITSTDTL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898365","Microscopic Findings Original Result","C117582","The outcome of the microscopic assessment as originally received or collected.","Microscopic Findings Original Result | MIORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828572","Pharmacokinetic Concentration Completion Status","C113374","A term used to describe the state or condition of the completeness of the pharmacokinetic concentration data.","Pharmacokinetic Concentration Completion Status | PCSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981545","Pharmacokinetic Concentration Original Result Unit","C87962","The unit of measure first specified in the pharmacokinetic concentration assessment.","Pharmacokinetic Concentration Original Result Unit | PCORRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981546","Pharmacokinetic Concentration Reason Not Done","C87963","The explanation given as to why pharmacokinetic concentration was not assessed.","Pharmacokinetic Concentration Reason Not Done | PCREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981547","Pharmacokinetic Concentration Reference Identifier","C87964","A character or string used to name, or characterize a pharmacokinetic concentration reference.","Pharmacokinetic Concentration Reference Identifier | PCREFID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981544","Pharmacokinetic Concentration Original Result","C87961","The value in which the outcome of the pharmacokinetic concentration assessment observation was originally reported.","Pharmacokinetic Concentration Original Result | PCORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826729","Physical Exam Result","C83119","The result of an evaluation of the body and its functions using visual inspection, palpation, percussion, or auscultation that is performed to determine the presence, absence, or degree of a condition.","Physical Examination Finding | PERES | Physical Exam Finding | Physical Exam Result | Physical Exam Result | Physical Examination | Physical Examination Result | pe finding | pe_finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826930","Physical Examination Body System or Organ Class","C83340","The body system or organ class that pertains to a physical examination.","Physical Examination Body System or Organ Class | PEBODSYS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826877","CDISC SDTM Reproductive System Findings Test Name Terminology","C106478","Terminology associated with the reproductive system findings test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Reproductive System Findings Test Name Terminology | RPTEST | Reproductive System Findings Test Name | SDTM-RPTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3840302","Stillbirth Indicator","C122194","Specifies whether any pregnancies resulted in stillbirths.","Stillbirth Indicator | STILBIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526746","Pregnancy Indicator","C139264","An indication as to whether the individual is pregnant.","Pregnancy Indicator | PREGIND | Pregnant Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828490","Pregnant During the Study","C106561","An indicator as to whether the female subject is pregnant during the study period.","Pregnant During the Study | PREGST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054158","Pregnancy Confirmed Indicator","C122192","Specifies whether the subject's pregnancy has been confirmed.","Pregnancy Confirmed Indicator | PCONFIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0429913","Number of Stillbirths","C139267","A measurement of the total number of birth events at which the fetus is of at least 20 weeks gestation, or of a birth weight of at least 350 grams if the gestational age is unknown, which is born without signs of life at the time of delivery, and with an Apgar score of zero at both one and five minutes.","Number of Stillbirths | BRTHSTN",,,,,,,,,,,,,,,"4092786","Number of stillbirths",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0429916","Number of Spontaneous Abortions","C120837","A measurement of the total number of spontaneous abortions (in which the fetus is less than 20 weeks gestational age) experienced by a female subject.","Number of Spontaneous Abortions | Number of Miscarriages | SPABORTN",,,,,,,,,,,,,,,"4095945","Number of miscarriages",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0422807","Number of Previous Pregnancies","C120836","A measurement of the total number of pregnancy events experienced by the female subject prior to the current pregnancy.","Number of Previous Pregnancies | PRVPREGN",,,,,,,,,,,,,,,"4078008","Number of previous pregnancies",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2826691","Physical Examination Sponsor Defined Identifier","C83080","One or more sponsor-defined characters used to identify, name, or characterize the physical examination.","Physical Examination Sponsor Defined Identifier | PESPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526744","Number of Premature Live Births","C139266","A measurement of the total number of live birth events at which the gestational age of the neonate is less than 37 weeks and 0 days.","Number of Premature Live Births | BRTHPRN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054328","Number of Premature Births","C122193","A measurement of the total number of birth events at which the gestational age of the neonate is less than 37 weeks and 0 days.","Number of Premature Births | PREMBTHN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812254","Number of Pregnancies","C106551","A measurement of the total number of pregnancy events experienced by the female subject.","Number of Pregnancies | Maternal Gravity | PREGNN | Total Number of Pregnancies | number of pregnancies | number_of_pregnancies | pregnancy count | pregnancy_count",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054329","Number of Late Fetal Deaths","C120834","A measurement of the total number of fetal deaths (in which the fetus is greater than or equal to 20 weeks gestational age) experienced by a female subject.","Number of Late Fetal Deaths | FETLDTHN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0429915","Number of Induced Abortions","C120835","A measurement of the total number of induced abortions experienced by a female subject.","Number of Induced Abortions | INABORTN",,,,,,,,,,,,,,,"4091280","Number of induced terminations of pregnancy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054330","Number of Full Term Births","C122190","A measurement of the total number of birth events at which the gestational age of the neonate is 39 weeks and 0 days through 40 weeks and 6 days.","Number of Full Term Births | FULLTRMN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2584889","Number of Ectopic Pregnancies","C120832","A measurement of the total number of ectopic pregnancies experienced by a female subject.","Number of Ectopic Pregnancies | ECTPREGN",,,,,,,,,,,,,,,"4209345","Number of ectopic pregnancies",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054331","Number of Early Term Births","C122189","A measurement of the total number of birth events at which the gestational age of the neonate is 37 weeks and 0 days through 38 weeks and 6 days.","Number of Early Term Births | ERLYTRMN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448200","Number of Abortions","C106550","A measurement of the total number of instances in which there has been a termination of pregnancy happening before the fetus is able to sustain independent life.","Number of Abortions | ABORTN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526745","Number of Full Term Live Births","C139265","A measurement of the total number of live birth events at which the gestational age of the neonate is 39 weeks and 0 days through 40 weeks and 6 days.","Number of Full Term Live Births | BRTHFTN | Number Full Term Live Births",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054485","Miscarriage Indicator","C122191","Specifies whether any pregnancies resulted in miscarriages.","Miscarriage Indicator | MSCRGIND | Spontaneous Abortion Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0425934","Menstrual Cycle Duration","C119549","The length of time of the menses cycle, measured from the beginning of one menstrual period to the beginning of the next.","Menstrual Cycle Duration | MENSDUR",,,,,,,,,,,,,,,"4089551|4270151","Measure of duration of menstrual cycle|Duration of menstrual cycle",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2826756","Physical Examination Test","C83148","A character or string that represents the full name of the physical examination assessment.","Physical Examination Test | PETEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513126","Menopause Status","C106541","An indicator as to whether the female subject is in menopause.","Menopause Status | MENOSTAT | Menopausal Status | menopause status | menopause_status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1629609","Age at Menopause","C106497","The age at which permanent cessation of menses occurs.","Age at Menopause | MENOAGE | Menopause Age",,,,,,,,,,,,,,,"36676381","Age at menopause",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1314691","Age at Menarche","C19666","Age of first menstruation.  A risk factor for breast cancer","Age at Menarche | MENARAGE | Menarche Age",,,,,,,,,,,,,,,"4162552","Age at menarche",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0262472","ESTIMATED GESTATIONAL AGE","C122188","An approximate calculation of the gestational age of the fetus.","Estimated Gestational Age | EGESTAGE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825543","Expected Date of Confinement","C81247","The best estimated due date is determined by: last menstrual period (LMP) if confirmed by early ultrasound or no ultrasound performed, or early ultrasound if no known LMP or the ultrasound is not consistent with LMP, or known date of fertilization (e.g. Assisted Reproductive Technology (ART), Intrauterine Insemination (IUI)). Notes: 1. Ultrasound margin of error and 'early' to be defined by SMFM/ACOG/NICHD workshop. 2. Pregnancy should not be re-dated by a later ultrasound after a best obstetrical estimate of EDD has been established. (adapted from reVITALize)","Expected Date of Confinement | Due Date | EDC | EDD | EDLVRDTC | Estimated Date of Confinement | Estimated Date of Delivery | Estimated Due Date",,,,,,,,,,,,,,,"4059478","Estimated date of delivery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0425966","Estimated Date of Conception","C120833","An approximate calculated date at which the conception event took place.","Estimated Date of Conception | EDCDTC",,,,,,,,,,,,,,,"4089559","Estimated date of conception",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055197","Congenital Abnormality Indicator","C122187","Specifies whether any abnormality was present at birth or during the neonatal period.","Congenital Abnormality Indicator | CABNIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2004464","birth control method (history)","C106501","The method by which conception or impregnation is prevented. This may be achieved through the use of devices, drugs or surgery.","Birth Control Method | BCMETHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826636","Physical Examination Abnormal Finding","C83023","An indication or description of any abnormal findings as a result of a physical examination.","Physical Examination Abnormal Finding | PEDESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826944","Physical Examination Reason Not Done","C83354","The rationale why a physical examination was not performed.","Physical Examination Reason Not Done | PEREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826941","Physical Examination Modified Reported Term","C83351","An indication or description of a change in a physical examination.","Physical Examination Modified Reported Term | PEMODIFY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889266","Reproductive System Finding Test","C117641","A character or string that represents the long name of the reproductive system finding assessment.","Reproductive System Finding Test | RPTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545304","Free Testosterone and Weakly Bound to Total Testosterone Ratio Measurement","C147440","The determination of the ratio of free and weakly bound testosterone compared to total testosterone present in a sample. The measurement may be expressed as a ratio or percentage.","Free Testosterone and Weakly Bound to Total Testosterone Ratio Measurement | TSTFWTST | Testosterone Free+Weakly Bound/Testost | Testosterone, Free and Weakly Bound/Testosterone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897827","Procedure Sponsor Defined Identifier","C117508","One or more sponsor defined characters used to identify, name, or characterize the procedure.","Procedure Sponsor Defined Identifier | PRSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897501","Standardized Name of Procedure","C117512","A procedure identifier obtained from a dictionary.","Standardized Name of Procedure | PRDECOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826287","Not-Done Reason","C82556","The explanation given as to why an action was not completed.","Not-Done Reason | Reason Not Done | negationReason",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897838","Procedure Intended Dose Regimen","C117523","A treatment plan that specifies the amount, schedule, and the duration of the procedure.","Procedure Intended Dose Regimen | PRDOSRGM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826286","Dose Adjustment Reason","C82555","The explanation given as to why a dosage was adjusted.","Dose Adjustment Reason | ADJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538832","Reason for Treatment Interruption","C102703","The reason the drug or therapy was temporarily ceased.","Reason for Treatment Interruption | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897702","Reproductive System Findings Sponsor Defined Identifier","C117639","One or more sponsor defined characters used to identify, name, or characterize the reproductive system finding.","Reproductive System Findings Sponsor Defined Identifier | RPSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897707","Reproductive System Findings Original Result","C117644","The outcome of the reproductive system findings assessment as originally received or collected.","Reproductive System Findings Original Result | RPORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897706","Reproductive System Findings Reason Not Done","C117650","The rationale why a reproductive system finding was not obtained.","Reproductive System Findings Reason Not Done | RPREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826717","Subject Characteristics Original Result","C83107","The earliest outcome of the subject characteristics assessment.","Subject Characteristics Original Result | SCORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826988","Subject Characteristics Group Identifier","C83399","A character or string that represents a subject characteristics group.","Subject Characteristics Group Identifier | SCGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826993","Subject Characteristics Sponsor Defined Identifier","C83404","One or more sponsor defined characters used to name subject characteristics data.","Subject Characteristics Sponsor Defined Identifier | SCSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897585","Skin Response Original Result","C117679","The outcome of the skin response assessment as originally received or collected.","Skin Response Original Result | SRORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897582","Skin Response Reason Not Done","C117685","The rationale why a skin response test was not performed.","Skin Response Reason Not Done | SRREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897577","Skin Response Sponsor Defined Identifier","C117673","One or more sponsor defined characters used to identify, name, or characterize the skin response.","Skin Response Sponsor Defined Identifier | SRSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897044","Skin Response Observation Object","C117676","The name of the entity that is being assessed in a skin response examination.","Skin Response Observation Object | SROBJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897591","Skin Response Group Identifier","C117671","A character or string that represents a skin response findings about group.","Skin Response Group Identifier | SRGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826255","Substance Use Duration","C82520","The length of time that substance usage occurs.","Substance Use Duration | SUCDUR | SUDUR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827018","Substance Use Sponsor Defined Identifier","C83429","One or more sponsor defined characters used to name substance usage data.","Substance Use Sponsor Defined Identifier | SUSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827014","Substance Use Reason Not Collected","C83425","The rationale why substance use data was not obtained.","Substance Use Reason Not Collected | SUREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826653","Substance Use Dose Description","C83041","A characterization of the dose of substance that has been used.","Substance Use Dose Description | SUDOSTXT | SUDSTXT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826656","Substance Use Dose Frequency","C83044","The rate of substance usage.","Substance Use Dose Frequency | SUDOSFRQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827004","Substance Usage Dictionary Derived Substance Term","C83415","A substance usage identifier obtained from a dictionary.","Substance Usage Dictionary Derived Substance Term | SUDECOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826635","Vital Signs Clinical Significance","C83022","An indication or description that the outcome of the vital signs assessment was clinically significant.","Vital Signs Clinical Significance | VSCLSIG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826718","Vital Signs Original Result","C83108","The outcome of the vital signs assessment.","Vital Signs Original Result | VITALS_RESULT | VSORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827045","Vital Signs Group Identifier","C83457","A character or string that represents a vital signs group.","Vital Signs Group Identifier | VSGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826695","Vital Signs Sponsor Defined Identifier","C83084","One or more sponsor-defined characters used to identify, name, or characterize the vital signs test.","Vital Signs Sponsor Defined Identifier | VSSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3262229","Primary Cause of Death","C99531","The first significant event which ultimately led to death.","Primary Cause of Death | PRCDTH | Primary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899408","Death Diagnosis Original Result","C117546","The outcome of the death diagnosis assessment as originally received or collected.","Death Diagnosis Original Result | DDORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3262233","Secondary Cause of Death","C116142","The second significant event which ultimately led to death.","Secondary Cause of Death | SECDTH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826264","Sponsor ID","C82530","A sponsor-defined sequence of characters used to identify, name, or characterize an entity such as an event, intervention or finding.","Sponsor ID | SPID | Sponsor Defined Identifier | Sponsor-Defined Identifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273021","MEDEVAL","C96777","Terminology associated with the medical evaluator identifier codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Medical Evaluator Identifier Terminology | CDISC SDTM Medical Evaluator Terminology | MEDEVAL | Medical Evaluator | Medical Evaluator Identifier | SDTM-MEDEVAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552614","Adjudicator 1","C150867","An adjudicator performing the assessment that is given the designation of one.","Adjudicator 1 | ADJUDICATOR 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526670","Reader 3","C139209","A reader performing the assessment that is given the designation of three.","Reader 3 | READER 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520217","Rater 2","C132426","The second in a series of raters that are performing an assessment.","Rater 2 | RATER 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520216","Rater 1","C132425","The first in a series of raters that are performing an assessment.","Rater 1 | RATER 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520218","Rater","C132304","Any individual qualified to perform an evaluation.","Rater | RATER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986555","Radiologist 2","C94531","The second in a series of radiologists that are performing an assessment.","Radiologist 2 | RADIOLOGIST 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986554","Radiologist 1","C94530","The first in a series of radiologists that are performing an assessment.","Radiologist 1 | RADIOLOGIST 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0586846","Pediatric Neurologist","C147463","A neurologist with additional training/certification in child neurology.","Pediatric Neurologist | PEDIATRIC NEUROLOGIST | Psychiatry and Neurology Neurology with Special Qualifications in Child Neurology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029146","Optometrist","C132424","A physician with a Doctor of Optometry degree (or analogous) that specializes in the diagnosis and treatment of eye disorders.","Optometrist | OPTOMETRIST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272902","Oncologist 2","C96612","The second in a series of oncologists that are performing an assessment.","Oncologist 2 | ONCOLOGIST 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272901","Oncologist 1","C96611","The first in a series of oncologists that are performing an assessment.","Oncologist 1 | ONCOLOGIST 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272896","Neurologist 2","C96606","The second in a series of neurologists that are performing an assessment.","Neurologist 2 | NEUROLOGIST 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272968","Neurologist 1","C96692","The first in a series of neurologists that are performing an assessment.","Neurologist 1 | NEUROLOGIST 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0237426","Neurologist","C17721","A doctor who specializes in diagnosing and treating diseases and disorders of the nervous system.","Neurologist | NEUROLOGIST | neurologist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520058","Microscopist 3","C132423","The third in a series of microscopists that are performing an assessment.","Microscopist 3 | MICROSCOPIST 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520057","Microscopist 2","C132422","The second in a series of microscopists that are performing an assessment.","Microscopist 2 | MICROSCOPIST 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520056","Microscopist 1","C132421","The first in a series of microscopists that are performing an assessment.","Microscopist 1 | MICROSCOPIST 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520059","Microscopist","C132303","A health care professional trained in the visualization of structures too small to be seen by the naked eye, using various microscopic techniques.","Microscopist | MICROSCOPIST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540365","Forensic Pathologist","C142333","A physician specializing in the diagnosis of both the cause of death and the manner of death of another human being.","Forensic Pathologist | FORENSIC PATHOLOGIST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545300","Developmental Psychologist","C147462","A psychologist who specializes in diagnosing and treating emotional and behavioral problems associated with developmental delay or disability.","Developmental Psychologist | DEVELOPMENTAL PSYCHOLOGIST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545299","Developmental Behavioral Pediatrician","C147461","A pediatrician who specializes in diagnosing and treating developmental and behavioral disorders in children.","Developmental Behavioral Pediatrician | DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN | Pediatrics Developmental -Behavioral Pediatrics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0259831","Dermatologist","C17816","A doctor concerned with the diagnosis and treatment of skin conditions.","Dermatologist | DERMATOLOGIST | dermatologist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334901","Clinical Pathologist","C142332","A physician specializing in medical diagnosis based on both the macroscopic and the microscopic changes to tissues and organs caused by a disease.","Clinical Pathologist | CLINICAL PATHOLOGIST | Pathology Clinical Pathology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0175906","Cardiologist","C125951","A physician who specializes in the diagnosis and treatment of heart disorders.","Cardiologist | CARDIOLOGIST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552616","Adjudicator 3","C150869","An adjudicator performing the assessment that is given the designation of three.","Adjudicator 3 | ADJUDICATOR 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552615","Adjudicator 2","C150868","An adjudicator performing the assessment that is given the designation of two.","Adjudicator 2 | ADJUDICATOR 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899257","Evaluator Identifier","C117043","A sequence of characters used to identify, name, or characterize the evaluator.","Evaluator Identifier | EVALID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985643","Performed Procedure","C93431","The completed activity whose immediate and primary intention is the alteration of the physical or mental condition of the subject, study subject or experimental unit.","Performed Procedure | PerformedProcedure | procedures performed | procedures_performed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205233","Firm","C154336","Having a structure or consistency that strongly resists stress or pressure.","Firm | ",,,,,,,,,,,,,,,"4070308","Firm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554397","Result Classification","C153143","A category describing the result as distinguished by anatomical or physiological system, etiology, or purpose.","Result Classification | ResultClassification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889689","CDISC SDTM Death Diagnosis Test Name Terminology","C116107","Terminology associated with the death detail test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Death Diagnosis Test Name Terminology | DTHDX | SDTM Death Diagnosis and Details Test Name | SDTM-DTHDX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522550","Hospital Medical Record Indicator","C135386","An indication as to whether medical records were obtained from the hospital.","Hospital Medical Record Indicator | HMROIND | Hospital Medical Record Obtained Ind | Hospital Medical Record Obtained Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522549","Death Certification Indicator","C135385","An indication as to whether a death certificate was obtained.","Death Certification Indicator | DTHCOIND | Death Certificate Obtained Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522548","Autopsy Indicator","C135384","An indication as to whether an autopsy was performed.","Autopsy Indicator | AUTOPIND | Was Autopsy Performed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1546180","Age at Death","C135383","The age at which death occurred.","Age at Death | AGEDTH | Age At Date of Death",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519737","CDISC SDTM Microscopic Findings Test Name Terminology","C132262","Terminology associated with the SDTM microscopic findings test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Microscopic Findings Test Name Terminology | MITS | SDTM Microscopic Findings Test Name | SDTM-MITS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509264","Dendritic Cell Lysosomal-Associated Membrane Protein Measurement","C127764","The determination of the amount of dendritic cell lysosomal-associated membrane protein present in a sample.","Dendritic Cell Lysosomal-Associated Membrane Protein Measurement | DC LAMP Protein Measurement | DCLAMP | DCLAMP Protein Measurement | Dendritic Cell-Lysosomal-Assoc Memb Prot | LAMP3 Protein Measurement | Lysosome-Associated Membrane Glycoprotein 3 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509811","Cytokeratin 16 Measurement","C127763","The determination of the amount of cytokeratin 16 present in a sample.","Cytokeratin 16 Measurement | CY16 | Cytokeratin 16",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520598","Cellular Differentiation Assessment","C132430","The determination of the amount of cellular differentiation in a biological sample.","Cellular Differentiation Assessment | CELLDIFF | Cellular Differentiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526562","CDX2 Antigen Measurement","C139098","The determination of the amount of CDX2 antigen present in a sample.","CDX2 Antigen Measurement | CDK-2 Antigen Measurement | CDX2 Antigen | CDX2AG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055283","Cancer Cellularity Measurement","C123556","The determination of the ratio of neoplastic cells compared to total cells in a sample. The measurement may be expressed as a ratio or percentage.","Cancer Cellularity Measurement | Cancer Cellularity | NEOCECE | Neoplastic Cells/Total Cells | TUMCECE | Tumor Cells to Total Cells Ratio Measurement | Tumor Cells/Total Cells | Tumor Purity | Tumor_Purity | cellularity | tumor purity | tumor_purity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050215","Breast Cancer Type 1 Susceptibility Protein Measurement","C123555","The determination of the amount of breast cancer type 1 susceptibility protein present in a sample.","Breast Cancer Type 1 Susceptibility Protein Measurement | BRCA1 | BRCA1 Measurement | Breast Cancer Type 1 Susceptibility Prot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526976","Bradykinin Receptor B1 Measurement","C139099","The determination of the amount of bradykinin receptor B1 present in a sample.","Bradykinin Receptor B1 Measurement | BDKRB1 | BDKRB1 Measurement | BK-1 Receptor | Bradykinin Receptor B1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522836","Banff Renal Diagnostic Category Assessment","C135464","The histologic evaluation and diagnosis of the type of renal allograft rejection based on kidney biopsies and the Banff Working Classification from the Banff Foundation for Allograft Pathology.","Banff Renal Diagnostic Category Assessment | BANFRDX | Banff Diagnostic Category Renal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522835","Arteriolar Hyaline Thickening Assessment","C135463","An evaluation of the presence or degree of arteriolar hyaline thickening present in a sample.","Arteriolar Hyaline Thickening Assessment | ARTLRHYT | Arteriolar Hyaline Thickening",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2919051","Ischemic Myocardium","C80424","Myocardial tissue which exhibits characteristics of inadequate blood flow.","Ischemic Myocardium | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522839","Mononuclear Cell Interstitial Inflammation Assessment","C135469","An evaluation of the presence or degree of mononuclear cell interstitial inflammation present in a sample.","Mononuclear Cell Interstitial Inflammation Assessment | MCINTINF | Mononuc Cell Interstitial Inflammation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522840","Mitotic Figure Assessment","C135470","An evaluation of the presence or degree of mitotic figures present in a sample.","Mitotic Figure Assessment | MITOFIG | Mitotic Figure | Mitotic Figures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526579","Mismatch Repair Proteins Interpretation","C139093","The determination of the meaning of multiple mismatch repair protein assessments.","Mismatch Repair Proteins Interpretation | MMRPINTP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523838","Mesangial Matrix Assessment","C135471","An evaluation of the presence or degree of mesangial matrix present in a sample.","Mesangial Matrix Assessment | MSNGMTRX | Mesangial Matrix",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508907","Lymphatic Invasion Assessment","C127766","An evaluation of the presence or degree of lymphatic invasion present in a sample.","Lymphatic Invasion Assessment | LYMPHINV | Lymphatic Invasion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049944","Ki67 Measurement","C123557","The determination of the amount of Ki-67 protein present in a sample.","Ki67 Measurement | Antigen KI-67 Measurement | KI67 | Ki-67 | MKI67 | pKi-67",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540357","Intraepidermal Nerve Fiber Density","C142347","An evaluation of intraepidermal nerve fiber density present in a specimen.","Intraepidermal Nerve Fiber Density | IENFDEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522838","Intimal Arteritis Assessment","C135467","An evaluation of the presence or degree of intimal arteritis present in a sample.","Intimal Arteritis Assessment | INTMART | Intimal Arteritis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523840","Interstitial Fibrosis Assessment","C135468","An evaluation of the presence or degree of interstitial fibrosis present in a sample.","Interstitial Fibrosis Assessment | INTSFBRO | Interstitial Fibrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522837","Glomerulopathy Assessment","C135466","An evaluation of the presence or degree of glomerulopathy present in a sample.","Glomerulopathy Assessment | GLOMPATH | Glomerulopathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523839","Glomerulitis Assessment","C135465","An evaluation of the presence or degree of glomerulitis present in a sample.","Glomerulitis Assessment | GLOMLTIS | Glomerulitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520395","Folate Hydrolase 1 Measurement","C132431","The determination of the amount of folate hydrolase 1 in a biological sample.","Folate Hydrolase 1 Measurement | FOLH1 | FOLH1 Measurement | Folate Hydrolase 1 | Folate Hydrolase Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512084","Fibrosis Assessment","C127765","An evaluation of the presence or degree of fibrosis present in a sample.","Fibrosis Assessment | FIBROSIS | Fibrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509359","Vascular Invasion Assessment","C127772","An evaluation of the presence or degree of vascular invasion present in a sample.","Vascular Invasion Assessment | VASINV | Vascular Invasion | vascular invasion present | vascular_invasion_present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522843","Vascular Fibrous Intimal Thickening Assessment","C135476","An evaluation of the presence or degree of vascular fibrous intimal thickening present in a sample.","Vascular Fibrous Intimal Thickening Assessment | VFBINTMT | Vascular Fibrous Intimal Thickening",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522842","Tubulitis Assessment","C135475","An evaluation of the presence or degree of tubulitis present in a sample.","Tubulitis Assessment | TUBULTIS | Tubulitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523837","Tubular Atrophy Assessment","C135474","An evaluation of the presence or degree of tubular atrophy present in a sample.","Tubular Atrophy Assessment | TUBATRO | Tubular Atrophy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053732","Surgical Margins Status","C123560","The determination of the presence of actual or potential neoplastic tissue which has been left outside the boundary of a resected specimen within the patient.","Surgical Margins Status | MARGINS | Margin Status | SGMGSTAT | margin status | margin_status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508977","Stromal Cell to Total Cell Ratio Measurement","C127770","The determination of the ratio of stromal cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Stromal Cell to Total Cell Ratio Measurement | STRMCECE | Stromal Cells to Total Cells Ratio Measurement | Stromal Cells/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512521","S100 Calcium Binding Protein A7 Measurement","C127769","The determination of the amount of S100 calcium binding protein A7 protein present in a sample.","S100 Calcium Binding Protein A7 Measurement | S100 Calcium Binding Protein A7 | S100-A7 Protein Measurement | S100A7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526563","PMS1 Homolog 2 Measurement","C139097","The determination of the amount of PMS1 homolog 2 present in a sample.","PMS1 Homolog 2 Measurement | PMS1 Homolog 2 | PMS2 | PMS2 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523859","Platelet Endothelial Cell Adhesion Molecule 1 Measurement","C135472","The determination of the amount of platelet endothelial cell adhesion molecule 1 in a biological sample.","Platelet Endothelial Cell Adhesion Molecule 1 Measurement | CD31 | CD31 Antigen | CD31 Measurement | PECAM | PECAM Measurement | PECAM-1 | PECAM1 | PECAM1 Measurement | Platelet And Endothelial Cell Adhesion Molecule 1 | Platelet Endo Cell Adhesion Molecule 1 | Platelet Endothelial Adhesion Molecule | Platelet Endothelial Adhesion Molecule 1 | Platelet Endothelial Cell Adhesion Molecule Measurement | Soluble CD31",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550425","Phosphatase and Tensin Homolog Measurement","C147470","The determination of the amount of phosphatase and tensin homolog protein in a biological sample.","Phosphatase and Tensin Homolog Measurement | PTEN | PTEN Measurement | Phosphatase and Tensin Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522841","Peritubular Capillaritis Assessment","C135473","An evaluation of the presence or degree of peritubular capillaritis present in a sample.","Peritubular Capillaritis Assessment | PTBCPLTS | Peritubular Capillaritis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508960","Perineural Invasion Assessment","C127768","An evaluation of the presence or degree of perineural invasion present in a sample.","Perineural Invasion Assessment | PNLINV | Perineural Invasion | perineural invasion present | perineural_invasion_present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054195","Percentage of in situ Carcinoma","C123559","A relative measurement (percentage) of in situ component present in a carcinoma compared to the entire malignant cellular proliferation.","Percentage of in situ Carcinoma | PCTISCA | Percentage of In situ Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540356","PAX3-FKHR Fusion Protein Measurement","C142348","The determination of the amount of PAX3-FKHR fusion protein present in a sample.","PAX3-FKHR Fusion Protein Measurement | PAX3-FKHR Fusion Protein | PAX3FKHR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526580","Number of Malignant Biopsy Cores","C139092","A measurement of the total number of core biopsies that contain malignant tissue.","Number of Malignant Biopsy Cores | CORBIOMN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509287","Normal Cell to Total Cell Ratio Measurement","C127767","The determination of the ratio of normal cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Normal Cell to Total Cell Ratio Measurement | NORMCECE | Normal Cells to Total Cells Ratio Measurement | Normal Cells/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050011","NK2 Homeobox 1 Measurement","C123558","The determination of the amount of the NKX2.1 transcription factor present in a sample.","NK2 Homeobox 1 Measurement | NK2 Homeobox 1 | NKX2.1 Measurement | NKX2_1 | TEBP | TTF1 | Thyroid Transcription Factor 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526564","MutS Homolog 6 Measurement","C139096","The determination of the amount of MutS homolog 6 present in a sample.","MutS Homolog 6 Measurement | MSH6 | MSH6 Measurement | MutS Homolog 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526578","MutS Homolog 2 Measurement","C139095","The determination of the amount of MutS homolog 2 present in a sample.","MutS Homolog 2 Measurement | MSH2 | MSH2 Measurement | MutS Homolog 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526969","MutL Homolog 1 Measurement","C139094","The determination of the amount of MutL homolog 1 present in a sample.","MutL Homolog 1 Measurement | MLH1 | MLH1 Measurement | MutL Homolog 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890734","Microscopic Findings Test","C117578","A character or string that represents the long name of the microscopic findings assessment.","Microscopic Findings Test | MITEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035239","Respiratory Therapy","C15322","Any form of treatment that acts to improve or assist with respiratory function.","Respiratory Therapy | respiratory therapy",,,,,,,,,,,,,,,"4203780","Respiratory therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554396","Order Care Setting Type Code","C153139","A coded value specifying the level of healthcare (care setting) the patient was in when the order was given.","Order Care Setting Type Code | OrderCareSettingTypeCode | orderCareSettingTypeCode",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981476","Finding About Event or Intervention Test","C87892","A character or string that represents a finding of the event or intervention.","Finding About Event or Intervention Test | FATEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554832","Neoplastic Plasma Cells Under 50 Percent of Bone Marrow Nucleated Cells","C153386","A semi-quantitative microscopic finding indicating that less than 50 percent of the nucleated cells in a bone marrow sample are neoplastic plasma cells.","Neoplastic Plasma Cells Under 50 Percent of Bone Marrow Nucleated Cells | Neoplastic Plasma Cells Less than 50 Percent of Bone Marrow Nucleated Cells | Neoplastic Plasma Cells Under ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554838","H3.1 K27M Mutation","C153401","A change in the amino acid residue at position 27 in histone H3.1 protein where lysine has been replaced by methionine.","H3.1 K27M Variant | H3.1 K27M Mutation | H3.1 K27M Mutation | H3.1 K28M Mutation | H3.1 Lys27Met Mutation | H3.1 Lys28Met Mutation | H3.1 NP_003521.2:p.K28M | H3.1 NP_003521.2:p.Lys28Met | H3.1 NP_003522.1:p.K28M | H3.1 NP_003522.1:p.Lys28Met | H3.1 NP_003528.1:p.K28M | H3.1 NP_003528.1:p.Lys28Met | H3.1 p.K28M | H3.1 p.Lys28Met | Histone H3.1 K27M Mutation | Histone H3.1 K28M Mutation | Histone H3.1 Lys27Met Mutation | Histone H3.1 Lys28Met Mutation | NP_003521.2:p.K28M | NP_003521.2:p.Lys28Met | NP_003522.1:p.K28M | NP_003522.1:p.Lys28Met | NP_003528.1:p.K28M | NP_003528.1:p.Lys28Met",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554930","SLC6A8 Positive","C153433","An indication that expression of SLC6A8 has been detected in a sample.","SLC6A8 Positive | CRTR Positive | CT1 Positive | Creatine Transporter Positive | Solute Carrier Family 6 Member 8 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554828","Phosphorylated EIF4E","C153382","A post-translationally modified form of eukaryotic translation initiation factor 4E where either the threonine at residue 22 or the serine at residue 209 are phosphorylated. Phosphorylation of eukaryotic translation initiation factor 4E increases its binding to 7-methylguanosine-containing mRNA caps and may promote the translation of mRNAs involved in epithelial mesenchymal transition (EMT), tumorigenesis and metastasis.","Phosphorylated EIF4E | Phospho-EIF4E | Phosphorylated Eukaryotic Initiation Factor 4E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554829","PI3K Alteration Positive","C153383","An indication that mutation, overexpression, fusion or rearrangement of a PI3K family member has been detected in a sample.","PI3K Alteration Positive | 1-Phosphatidylinositol 3-Kinase Alteration Positive | PI3 Kinase Alteration Positive | PI3-Kinase Alteration Positive | Phosphatidylinositide 3-Kinase Alteration Positive | Phosphatidylinositol 3 Kinase Alteration Positive | Phosphatidylinositol 3-Kinase Alteration Positive | Phosphatidylinositol-3-Kinase Alteration Positive | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554826","PIGA Gene Mutation","C153384","A change in the nucleotide sequence of the PIGA gene.","PIGA Gene Mutation | GPI3 Gene Mutation | MCAHS2 Gene Mutation | PIG-A Gene Mutation | PNH1 Gene Mutation | Paroxysmal Nocturnal Hemoglobinuria Gene Mutation | Phosphatidylinositol Glycan Anchor Biosynthesis Class A Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554827","PIK3C2B Gene Mutation","C153385","A change in the nucleotide sequence of the PIK3C2B gene.","PIK3C2B Gene Mutation | C2-PI3K Gene Mutation | PI3K-C2beta Gene Mutation | Phosphatidylinositol-4-Phosphate 3-Kinase, Catalytic Subunit Type 2 Beta Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554837","PIK3CA Gene Alteration Positive","C153393","An indication that mutation, overexpression, fusion or rearrangement involving the PIK3CA gene has been detected in a sample.","PIK3CA Gene Alteration Positive | PI3K-Alpha Gene Alteration | PI3KCA Gene Alteration | PIK3-Alpha Gene Alteration | PIK3CA Gene Alteration | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Gene Alteration | p110-alpha Gene Alteration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554834","PIK3CA Gene Rearrangement","C153394","A molecular abnormality indicating rearrangement of the PIK3CA gene.","PIK3CA Gene Rearrangement | PI3K-Alpha Gene Rearrangement | PI3KCA Gene Rearrangement | PIK3-Alpha Gene Rearrangement | Phosphatidylinositol 3-Kinase, Catalytic Subunit Gene Rearrangement | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Gene Rearrangement | Phosphoinositide-3-Kinase, Catalytic, Alpha Polypeptide Gene Rearrangement | p110-Alpha Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554835","Activating PIK3CB Gene Mutation","C153395","A change in the nucleotide sequence of the PIK3CB gene that results in constitutive activation of phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform and its downstream signaling pathways.","Activating PIK3CB Gene Mutation | P110BETA Activating Gene Mutation | PI3KBETA Activating Gene Mutation | PIK3C1 Activating Gene Mutation | PIK3CB Activating Gene Mutation | PIK3CB Activating Mutation | PIK3CB Gain | PIK3CB Gain of Function | PIK3CB Gain of Function Mutation | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta Activating Gene Mutation | p110-Beta Activating Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554839","PLCG2 Gene Mutation","C153396","A change in the nucleotide sequence of the PLCG2 gene.","PLCG2 Gene Mutation | APLAID Gene Mutation | FCAS3 Gene Mutation | PLC-IV Gene Mutation | PLC-gamma-2 Gene Mutation | PLCgamma2 Gene Mutation | Phospholipase C Gamma 2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554841","PMEL Positive","C153405","An indication that expression of PMEL has been detected in a sample.","PMEL Positive | ME20 Positive | ME20-M Positive | ME20M Positive | Melanocyte Protein PMEL Positive | P1 Positive | PMEL17 Positive | Premelanosome Protein Positive | SIL Positive | SILV Positive | Silver Homolog Positive | gp100 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554842","Presence of ERBB2 Overexpressing Disseminated Tumor Cells","C153406","An indication that single tumor cells or small clusters of tumor cells that are overexpressing ERBB2 are present in a tissue sample.","Presence of ERBB2 Overexpressing Disseminated Tumor Cells | ERBB2 Overexpressing DTCs Positive | ERBB2 Overexpressing DTCs Present | ERBB2 Overexpressing Disseminated Tumor Cells Positive | ERBB2 Overexpressing Disseminated Tumor Cells Present | Erb-B2 Receptor Tyrosine Kinase 2 Overexpressing Disseminated Tumor Cells Present | Erb-B2 Receptor Tyrosine Kinase Overexpressing Disseminated Tumor Cells Present | HER2 Overexpressing Disseminated Tumor Cells Present | HER2/neu Overexpressing Disseminated Tumor Cells Positive | HER2/neu Overexpressing Disseminated Tumor Cells Present | NEU Overexpressing Disseminated Tumor Cells Present | Presence of ERBB2 Overexpressing DTCs | Proto-Oncogene Neu Overexpressing Disseminated Tumor Cells Present | Receptor Tyrosine-Protein Kinase erbB-2 Protein Variant Overexpressing Disseminated Tumor Cells Present | Tyrosine Kinase-Type Cell Surface Receptor HER2 Overexpressing Disseminated Tumor Cells Present | v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 Overexpressing Disseminated Tumor Cells Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554847","Progesterone Receptor Positive by Immunohistochemistry 1-9 Percent","C153407","An immunohistochemical staining finding indicating that between 1 and 9 percent of the cells in a tissue sample are expressing progesterone receptor.","Progesterone Receptor Positive by Immunohistochemistry 1-9 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554848","PSA 50 Percent or Greater than Nadir","C153408","A finding indicating that the blood concentration of prostate specific antigen in a subject's sample has increased by 50 percent or more over the lowest value recorded for a sample from that subject.","PSA 50 Percent or Greater than Nadir | PSA 50% or Greater than Nadir | PSA Fifty Percent or Greater than Nadir",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554845","PSA Decline Greater than 75 Percent","C153409","A finding indicating that the blood concentration of prostate specific antigen in a subject's sample has decreased by more than 75 percent compared to the value recorded for a previous sample from that subject.","PSA Decline Greater than 75 Percent | PSA Decline Greater than Seventy Five Percent | PSA Decline Greater than Seventy-Five Percent | PSA Decline More than 75 Percent | PSA Decreased Greater than 75 Percent | PSA Decreased Greater than Seventy Five Percent | PSA Decreased Greater than Seventy-Five Percent | PSA Decreased More than 75 Percent | PSA Decreased More than Seventy Five Percent | PSA Decreased More than Seventy-Five Percent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554846","PSA Level Zero to Two","C153410","A blood concentration of prostate specific antigen between 0 ng/mL and 2 ng/mL.","PSA Level Zero to Two | PSA Level 0 to 2 | PSA Level Between 0 and 2 | PSA Level Between Zero and Two",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554851","PSA Level 0.2 to Four","C153411","A blood concentration of prostate specific antigen between 0.2 ng/mL and 4 ng/mL.","PSA Level 0.2 to Four | PSA Level 0.2 to 4 | PSA Level 0.2 to 4.0 | PSA Level Between 0.2 and 4 | PSA Level Between 0.2 and 4.0 | PSA Level Between 0.2 and Four",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554852","PSA Level Greater than or Equal to 0.4","C153412","A blood concentration of prostate specific antigen greater than or equal to 0.4 ng/mL.","PSA Level Greater than or Equal to 0.4 | PSA Level 0.4 or Greater",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554849","PSA Level Less than or Equal to Eleven","C153413","A blood concentration of prostate specific antigen less than or equal to 11 ng/mL.","PSA Level Less than or Equal to Eleven | PSA Level 11 or Less | PSA Level Eleven or Less | PSA Level Less than or Equal to 11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554850","PSA Level Four to Ten","C153414","A blood concentration of prostate specific antigen between 4 ng/mL and 10 ng/mL.","PSA Level Four to Ten | PSA Level 4 to 10 | PSA Level Between 4 and 10 | PSA Level Between Four and Ten",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554855","PSA Level Greater than 0.4","C153415","A blood concentration of prostate specific antigen greater than 0.4 ng/mL.","PSA Level Greater than 0.4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554856","PSA Level Greater than or Equal to Fifteen","C153416","A blood concentration of prostate specific antigen greater than or equal to 15 ng/mL.","PSA Level Greater than or Equal to Fifteen | PSA Level 15 or Greater | PSA Level Fifteen or Greater | PSA Level Greater than or Equal to 15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554854","PSA Level Greater than or Equal to Three","C153418","A blood concentration of prostate specific antigen greater than or equal to 3 ng/mL.","PSA Level Greater than or Equal to Three | PSA Level 3 or Greater | PSA Level Greater than or Equal to 3 | PSA Level Three or Greater",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554860","PSA Level Less than Four","C153420","A blood concentration of prostate specific antigen less than 4 ng/mL.","PSA Level Less than Four | PSA Level Less than 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554857","PSA Level Less than One","C153421","A blood concentration of prostate specific antigen less than 1 ng/mL.","PSA Level Less than One | PSA Level Less than 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554858","PSA Level Less than One Hundred","C153422","A blood concentration of prostate specific antigen less than 100 ng/mL.","PSA Level Less than One Hundred | PSA Level Less than 100",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554863","PSA Level Less than or Equal to One Hundred Fifty","C153423","A blood concentration of prostate specific antigen less than or equal to 150 ng/mL.","PSA Level Less than or Equal to One Hundred Fifty | PSA Level 150 or Less | PSA Level Less than or Equal to 150 | PSA Level One Hundred Fifty or Less",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554965","FOLH1 Positive","C153464","An indication that FOLH1 expression has been detected in a sample.","FOLH1 Positive | FGCP Positive | FOLH Positive | Folate Hydrolase 1 Positive | Folylpoly-Gamma-Glutamate Carboxypeptidase Positive | GCP2 Positive | GCPII Positive | Glutamate Carboxypeptidase 2 Positive | NAALAD1 Positive | NAALAdase Positive | PSM Positive | PSMA Positive | Prostate-Specific Membrane Antigen Positive | mGCP Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983643","Percentage Body Weight Gain","C90434","The amount of weight gained over a period of time in relation to the total weight.","Percentage Body Weight Gain | BWGAINP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554962","PTEN Alteration Positive","C153465","An indication that mutation, overexpression, fusion or rearrangement involving PTEN has been detected in a sample.","PTEN Alteration Positive | MMAC1 Alteration Positive | Mutated in Multiple Advanced Cancers 1 Alteration Positive | PTEN Alteration | PTEN Tyrosine Phosphatase Alteration Positive | PTEN1 Alteration Positive | Phosphatase and Tensin Homolog Alteration Positive | Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN Alteration Positive | TEP1 Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554963","PTEN Gene Alteration Positive","C153466","An indication that mutation, overexpression, fusion or rearrangement involving the PTEN gene has been detected in a sample.","PTEN Gene Alteration Positive | MMAC1 Gene Alteration Positive | Mutated in Multiple Advanced Cancers 1 Gene Alteration Positive | PTEN Gene Alteration | PTEN1 Gene Alteration Positive | Phosphatase and Tensin Homolog Gene Alteration Positive | TEP1 Gene Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554968","PTEN Deficiency","C153467","A condition of decreased or absent presence or activity of phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN, which is associated with multiple hamartoma syndrome (Cowden syndrome) and increased risk for development of several types of malignant cancers, including head and neck, breast, lung and prostate cancer and glioblastoma.","PTEN Deficiency | MMAC1 Deficiency | Mutated in Multiple Advanced Cancers 1 Deficiency | PTEN Tyrosine Phosphatase Deficiency | PTEN1 Deficiency | Phosphatase and Tensin Homolog Deficiency | Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN Deficiency | TEP1 Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554873","RB1 Gene Mutation Negative","C153496","A genetic finding indicating that RB1 gene mutations have not been detected in a sample.","RB1 Gene Mutation Negative | RB Gene Mutation Negative | RB Mutation Negative | RB1 Mutation Negative | RB1 Wildtype | RB1 wt | Retinoblastoma 1 Gene Mutation Negative | Retinoblastoma Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554870","RHEB Gene Rearrangement","C153497","A molecular abnormality indicating rearrangement of the RHEB gene.","RHEB Gene Rearrangement | RHEB Rearrangement | RHEB2 Gene Rearrangement | Ras Homolog Enriched In Brain 2 Gene Rearrangement | Ras Homolog Enriched In Brain Gene Rearrangement | Ras Homolog, mTORC1 Binding Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554871","ROS1 Negative","C153498","An indication that expression of ROS1 has not been detected in a sample.","ROS1 Negative | MCF3 Negative | Proto-Oncogene Tyrosine-Protein Kinase ROS Negative | Proto-Oncogene c-Ros Negative | Proto-Oncogene c-Ros-1 Negative | ROS Negative | ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Negative | Receptor Tyrosine Kinase c-Ros Oncogene 1 Negative | c-Ros-1 Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554875","S100B Positive","C153499","An indication that expression of S100B has been detected in a sample.","S100B Positive | NEF Positive | Protein S100-B Positive | S-100 Protein Beta Chain Positive | S-100 Protein Subunit Beta Positive | S100 Calcium Binding Protein B Positive | S100 Calcium-Binding Protein B Positive | S100-B Positive | S100beta Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556864","Soluble Tumor Necrosis Factor Receptor Superfamily Member 9","C153501","Soluble tumor necrosis factor receptor superfamily member 9 is encoded by the human TNFRSF9 gene. This protein plays a role in both activation-induced cell death (AICD) of T-lymphocytes and negative feedback control of inflammation.","Soluble Tumor Necrosis Factor Receptor Superfamily Member 9 | Soluble 4-1BB | Soluble 4-1BB Ligand Receptor | Soluble CD137 | Soluble CD137 Antigen | Soluble Receptor Protein 4-1BB | Soluble T-Cell Antigen 4-1BB Homolog | Soluble T-Cell Antigen ILA | Soluble TNFRSF9 | s4-1BB | sCD137 | sILA | sTNFRSF9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554874","Sensitizing ROS1 Fusion Positive","C153502","An indication that expression of ROS1 fusion containing a ROS1 alteration that causes increased sensitivity to ROS1 inhibitory agents has been detected in a sample.","Sensitizing ROS1 Fusion Positive | Sensitizing MCF3 Fusion Positive | Sensitizing Proto-Oncogene Tyrosine-Protein Kinase ROS Fusion Positive | Sensitizing Proto-Oncogene c-Ros Fusion Positive | Sensitizing Proto-Oncogene c-Ros-1 Fusion Positive | Sensitizing ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Fusion Positive | Sensitizing ROS-1 Fusion | Sensitizing ROS1 Fusion | Sensitizing Receptor Tyrosine Kinase c-Ros Oncogene 1 Fusion Positive | Sensitizing c-Ros-1 Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554879","SETBP1 Gene Mutation","C153503","A change in the nucleotide sequence of the SETBP1 gene.","SETBP1 Gene Mutation | SEB Gene Mutation | SET Binding Protein 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554880","SETD2 Gene Mutation","C153504","A change in the nucleotide sequence of the SETD2 gene.","SETD2 Gene Mutation | HBP231 Gene Mutation | HIF-1 Gene Mutation | HIP-1 Gene Mutation | HYPB Gene Mutation | KMT3A Gene Mutation | LLS Gene Mutation | SET Domain Containing 2 Gene Mutation | SET2 Gene Mutation | p231HBP Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554877","SH2D1A Gene Mutation","C153505","A change in the nucleotide sequence of the SH2D1A gene.","SH2D1A Gene Mutation | DSHP Gene Mutation | EBVS Gene Mutation | IMD5 Gene Mutation | LYP Gene Mutation | MTCP1 Gene Mutation | SAP Gene Mutation | SH2 Domain Containing 1A Gene Mutation | XLP Gene Mutation | XLPD Gene Mutation | XLPD1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554888","SOX9 Gene Mutation","C153512","A change in the nucleotide sequence of the SOX9 gene.","SOX9 Gene Mutation | CMD1 Gene Mutation | CMPD1 Gene Mutation | SRA1 Gene Mutation | SRY (Sex Determining Region Y)-Box 9 (Campomelic Dysplasia, Autosomal Sex-Reversal) Gene Mutation | SRY-Box 9 Gene Mutation | SRY-Related HMG-Box Gene 9 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554885","STAG2 Gene Mutation","C153513","A change in the nucleotide sequence of the STAG2 gene.","STAG2 Gene Mutation | SA-2 Gene Mutation | SA2 Gene Mutation | SCC3B Gene Mutation | STAG2 | Stromal Antigen 2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554886","STAT3 Gene Mutation","C153514","A change in the nucleotide sequence of the STAT3 gene.","STAT3 Gene Mutation | ADMIO Gene Mutation | ADMIO1 Gene Mutation | APRF Gene Mutation | HIES Gene Mutation | Signal Transducer and Activator of Transcription 3 (Acute-Phase Response Factor) Gene Mutation | Signal Transducer and Activator of Transcription 3 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554891","STK11 Gene Rearrangement","C153516","A molecular abnormality indicating rearrangement of the STK11 gene.","STK11 Gene Rearrangement | LKB1 Gene Rearrangement | Liver Kinase B1 Gene Rearrangement | STK11 Rearrangement | Serine/Threonine Kinase 11 Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556831","T-Cell Receptor Gene Rearrangement","C153517","A molecular abnormality indicating rearrangement of a T-cell receptor (TCR) family gene.","T-Cell Receptor Gene Rearrangement | T Cell Receptor Family Gene Rearrangement | T Cell Receptor Gene Rearrangement | T-Cell Receptor Family Gene Rearrangement | T-Cell Receptor Rearrangement | TCR Family Gene Rearrangement | TCR Gene Rearrangement | TCR Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554889","t(15;17) Positive","C153518","A cytogenetic finding indicating that the translocation t(15;17) has been detected in a sample.","t(15;17) Positive | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554894","TAF1 Gene Mutation","C153519","A change in the nucleotide sequence of the TAF1 gene.","TAF1 Gene Mutation | BA2R Gene Mutation | CCG1 Gene Mutation | CCGS Gene Mutation | Cell Cycle Gene 1 Mutation | DYT3 Gene Mutation | KAT4 Gene Mutation | N-TAF1 Gene Mutation | NSCL2 Gene Mutation | OF Gene Mutation | P250 Gene Mutation | TAF2A Gene Mutation | TAFII250 Gene Mutation | TATA-Box Binding Protein Associated Factor 1 Gene Mutation | XDP Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554895","TBX3 Gene Mutation","C153520","A change in the nucleotide sequence of the TBX3 gene.","TBX3 Gene Mutation | T-Box 3 Gene Mutation | TBX3-ISO Gene Mutation | UMS Gene Mutation | XHL Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554892","Testosterone Greater than or Equal to 100 ng/dL","C153521","A semiquantitative finding indicating that the concentration of testosterone in a sample is greater than or equal to 100 ng/dL.","Testosterone Greater than or Equal to 100 ng/dL | Testosterone Greater or Equal to 100 | Testosterone Greater than or Equal to 100 | Testosterone Greater than or Equal to 100 Nanograms per Deciliter | Testosterone Greater than or Equal to 100 Nanograms/Deciliter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554893","Testosterone Greater than 100 ng/dL","C153522","A semiquantitative finding indicating that the concentration of testosterone in a sample is greater than 100 ng/dL.","Testosterone Greater than 100 ng/dL | Testosterone Greater than 100 | Testosterone Greater than 100 Nanograms per Deciliter | Testosterone Greater than 100 Nanograms/Deciliter | Testosterone Level Greater than 100",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554898","TNFSF9 Gene Mutation Negative","C153523","A genetic finding indicating that TNFSF9 gene mutations have not been detected in a sample.","TNFSF9 Gene Mutation Negative | 4-1BB-L Gene Mutation Negative | 4-1BB-L Wildtype | 4-1BB-L wt | CD137L Gene Mutation Negative | CD137L Wildtype | CD137L wt | TNFSF9 Wildtype | TNFSF9 wt | TNLG5A Gene Mutation Negative | Tumor Necrosis Factor Ligand Superfamily, Member 9 Gene Mutation Negative | Tumor Necrosis Factor Superfamily Member 9 Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554899","TTR Gene Mutation","C153524","A change in the nucleotide sequence of the TTR gene.","TTR Gene Mutation | ATTR Gene Mutation | PALB Gene Mutation | Prealbumin, Thyroxine-Binding Gene Mutation | TBPA Gene Mutation | TTR Mutation | Transthyretin Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554887","SMARCB1 Positive","C153511","An indication that expression of SMARCB1 has been detected in a sample.","SMARCB1 Positive | BAF47 Positive | INI1 Positive | SMARCB Positive | SNF5 Positive | SWI/SNF-Related Matrix-Associated Actin Dependent Regulator of Chromatin Subfamily B Member 1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554896","TSC1 Gene Rearrangement","C153525","A molecular abnormality indicating rearrangement of the TSC1 gene.","TSC1 Gene Rearrangement | Hamartin Gene Rearrangement | TSC Gene Rearrangement | TSC1 Rearrangement | Tuberous Sclerosis 1 Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554897","TSC2 Gene Rearrangement","C153526","A molecular abnormality indicating rearrangement of the TSC2 gene.","TSC2 Gene Rearrangement | TSC2 Rearrangement | Tuberin Gene Rearrangement | Tuberous Sclerosis 2 Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554922","Tumor-Infiltrating Immune Cell","C153548","Immune cells that have left the bloodstream and migrated into a tumor.","Tumor-Infiltrating Immune Cell | Tumor-Infiltrating Immune Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554919","Ultra High Sensitivity C-Reactive Protein Measurement","C153549","The determination of the amount of C-reactive protein (CRP) present in a sample, usually serum from a blood draw from a subject that does not have a chronic inflammatory condition, through the use of an enhanced particle-enhanced immunoturbidimetric assay. This test is optimized to measure lower concentrations of CRP than a conventional CRP test. Accuracy is enhanced to ultra high levels through the use of a proprietary set of calibrated CRP samples.","Ultra High Sensitivity C-Reactive Protein Measurement | Ultra High Sensitivity CRP Measurement | uhs-CRP | uhsCRP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554920","Urinary Microbiome","C153550","The collection of microorganisms existing in the urinary tract and/or urine of an organism.","Urinary Microbiome | Urinary Microbiome Profile | Urinary Microbiota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554924","25-Hydroxyvitamin D Less than 66 ng/ml","C153551","A semiquantitative finding indicating that the concentration of 25-hydroxyvitamin D2 plus 25-hydroxyvitamin D3 is less than 66 ng/mL.","25-Hydroxyvitamin D Less than 66 ng/ml | 25(OH)D Less than 66 Nanograms per Milliliter | 25(OH)D Less than 66 Nanograms/Milliliter | 25(OH)D Less than 66 ng/mL | 25-Hydroxyvitamin D Less than 66 Nanograms per Milliliter | 25-Hydroxyvitamin D Less than 66 Nanograms/Milliliter | 25-OH-VitD Less than 66 Nanograms per Milliliter | 25-OH-VitD Less than 66 Nanograms/Milliliter | 25-OH-VitD Less than 66 ng/mL | 25-OH-Vitamin D Less than 66 Nanograms per Milliliter | 25-OH-Vitamin D Less than 66 Nanograms/Milliliter | 25-OH-Vitamin D Less than 66 ng/mL | Calcidiol Less than 66 Nanograms per Milliliter | Calcidiol Less than 66 Nanograms/Milliliter | Calcidiol Less than 66 ng/mL | Calcifediol Less than 66 Nanograms per Milliliter | Calcifediol Less than 66 ng/mL | Vitamin D Less than 66 ng/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554925","25-Hydroxyvitamin D Less than 30 ng/ml","C153552","A semiquantitative finding indicating that the concentration of 25-hydroxyvitamin D2 plus 25-hydroxyvitamin D3 is less than 30 ng/mL.","25-Hydroxyvitamin D Less than 30 ng/ml | 25(OH)D Less than 30 Nanograms per Milliliter | 25(OH)D Less than 30 Nanograms/Milliliter | 25(OH)D Less than 30 ng/mL | 25-Hydroxyvitamin D Less than 30 Nanograms per Milliliter | 25-Hydroxyvitamin D Less than 30 Nanograms/Milliliter | 25-OH-VitD Less than 30 Nanograms per Milliliter | 25-OH-VitD Less than 30 Nanograms/Milliliter | 25-OH-VitD Less than 30 ng/mL | 25-OH-Vitamin D Less than 30 Nanograms per Milliliter | 25-OH-Vitamin D Less than 30 Nanograms/Milliliter | 25-OH-Vitamin D Less than 30 ng/mL | Calcidiol Less than 30 Nanograms per Milliliter | Calcidiol Less than 30 Nanograms/Milliliter | Calcidiol Less than 30 ng/mL | Calcifediol Less than 30 Nanograms per Milliliter | Calcifediol Less than 30 Nanograms/Milliliter | Calcifediol Less than 30 ng/mL | Vitamin D Less than 30 ng/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554923","Peak Oxygen Consumption","C153553","The highest rate of oxygen consumption a subject reaches during an aerobic capacity test.","Peak Oxygen Consumption | Oxygen Consumption Peak | V'O2 Peak | VO2 Peak | VO2peak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554928","WT1 Negative","C153555","Indicates that expression of WT1 has not been detected in a sample.","WT1 Negative | Wilms Tumor 1 Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554929","XPO1 Gene Mutation","C153556","A change in the nucleotide sequence of the XPO1 gene.","XPO1 Gene Mutation | CRM1 Gene Mutation | Exportin 1 Gene Mutation | Exportin-1 Gene Mutation | Required For Chromosome Region Maintenance Gene Mutation | emb Gene Mutation | exp1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554926","Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level","C153557","A semiquantitative finding indicating that the amount of immature mononuclear cells in a subject's sample of nucleated cells from bone marrow has decreased by 50 percent or more over the value recorded for a pretreatment sample from that subject.","Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level | Decrease of Pretreatment Bone Marrow Blast Percentage by at Least 50 | Decrease of Pretreatment Bone Marrow Blast Percentage by at Least 50 Percent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554927","Phosphorylated-FAK Y397","C153558","A post-translationally modified form of focal adhesion kinase 1 (FAK; FAK1; PTK2) where the tyrosine (Y; Tyr) at residue 397 is phosphorylated. Cell adhesion-signaling promotes the association of FAK with Src family kinases, which stimulates autophosphorylation of FAK Y397 and creates a SH2-binding site on FAK to promote Src family kinase- and integrin-mediated signaling.","Phosphorylated-FAK Y397 | FAK (Phospho Tyr397) | FAK (Phospho Y397) | FAK (pY397) | Focal Adhesion Kinase 1 Y397 Phosphorylated | Phospho-FAK (Y397) | Phospho-PTK2 (Tyr397) | Phospho-PTK2 (Y397) | Phosphorylated FAK Y397 | Phosphorylated-Focal Adhesion Kinase 1 Y397",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555024","Xp11.2 Translocation","C153560","A cytogenetic abnormality that refers to any translocation involving Xp11.2 on the short arm of the X chromosome.","Xp11.2 Translocation | t(V;X)(v;p11.2) | t(X;V)(p11.2;v) | t(v;Xp11.2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555022","EGFR Gene Amplification Negative","C153561","An indication that amplification of the EGFR gene was not detected in a sample.","EGFR Gene Amplification Negative | EGFR Amplification Negative | EGFR Non-Amplification | ERBB1 Gene Amplification Negative | Epidermal Growth Factor Receptor Gene Amplification Negative | HER1 Gene Amplification Negative | No | Unamplified | c-erbB1 Gene Amplification Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2964214","MGMT Gene Promoter Methylation","C153562","A genetic finding indicating that DNA methylation in the promoter region of the MGMT gene has been detected in a sample.","MGMT Gene Promoter Methylation | MGMT Gene Methylation | MGMT Methylation | Methylated MGMT | Methylated MGMT Gene Promoter | Methylated MGMT Promoter | Methylguanine-DNA Methyltransferase Gene Promoter Methylation | O-6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation | Positive | Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0917792","Sequence Determinations, DNA","C153598","The determination of the sequence of purines and pyrimidines in deoxyribonucleic acid (DNA).","DNA Sequencing | DNA Sequence Analysis | DNA-Seq | Deoxyribonucleic Acid Sequencing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555477","Adherence Starts With Knowledge 12 Questionnaire","C154571","A 12 question patient-report measure designed to identify factors that influence medication adherence and adherence-related behavior. It was derived from the ASK-20 questionnaire.","Adherence Starts With Knowledge 12 Questionnaire | ASK-12 | Adherence Starts With Knowledge 12 Questionnaire ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555476","Forgot to Take Medicines Some of the Time","C154574","A question about whether a person sometimes just forgets to take their medicines.","Forgot to Take Medicines Some of the Time | I just forget to take my medicines some of the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555481","Run Out of Medicine Because Do Not Get Refills on Time","C154575","A question about whether a person runs out of medicine because they do not get refills in time.","Run Out of Medicine Because Do Not Get Refills on Time | I run out of my medicine because I don't get refills on time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555482","Taking Medicines More than Once a Day is Inconvenient","C154576","A question about whether a person feels that taking medicines more than once a day is inconvenient.","Taking Medicines More than Once a Day is Inconvenient | Taking medicines more than once a day is inconvenient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555479","Feel Confident Each Medicine Will Help","C154577","A question about whether a person feels confident that each of their medicines will help them.","Feel Confident Each Medicine Will Help | I feel confident that each one of my medicines will help me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555480","Know if Reaching Health Goals","C154578","A question about whether a person knows if they are reaching their health goals.","Know if Reaching Health Goals | I know if I am reaching my health goals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1320928","Resident","C54624","A physician who has completed medical school and an internship and is in the process of receiving specialized training.","Resident | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555485","Have Someone to Call with Questions about Medicines","C154579","A question about whether a person has someone to call with questions about their medicines.","Have Someone to Call with Questions about Medicines | I have someone I can call with questions about my medicines",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555486","Work Together with Doctor or Nurse to Make Decisions","C154580","A question about whether a person works together with their doctor or nurse to make decisions.","Work Together with Doctor or Nurse to Make Decisions | My doctor/nurse and I work together to make decisions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555483","Have Taken a Medicine More or Less Often than Prescribed","C154581","A question about whether a person has taken a medicine more or less often than prescribed.","Have Taken a Medicine More or Less Often than Prescribed | Have you taken a medicine more or less often than prescribed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555484","Have Skipped or Stopped Medicine Because Didn't Think it was Working","C154582","A question about whether a person has skipped or stopped taking a medicine because they didn't think it was working.","Have Skipped or Stopped Medicine Because Didn't Think it was Working | Have you skipped or stopped taking a medicine because you didn't think it was working",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555488","Have Skipped or Stopped Medicine Because it Made You Feel Bad","C154583","A question about whether a person has skipped or stopped taking a medicine because it made them feel bad.","Have Skipped or Stopped Medicine Because it Made You Feel Bad | Have you skipped or stopped taking a medicine because it made you feel bad",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555489","Have Skipped, Stopped, Not Refilled, or Taken Less Medicine Because of Cost","C154584","A question about whether a person has skipped, stopped, took less, or did not refill a medicine because of the cost.","Have Skipped, Stopped, Not Refilled, or Taken Less Medicine Because of Cost | Have you skipped, stopped, not refilled, or taken less medicine because of the cost",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555487","Did not Have Medicine When Time to Take it","C154585","A question about whether a person did not have their medicine with them when it was time to take it.","Did not Have Medicine When Time to Take it | Have you not had medicine with you when it was time to take it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555478","More than 3 Months Ago","C154572","A period of time more than 3 months before the present.","More than 3 Months Ago | More than 3 months ago",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3833401","Neutral","C154573","A response indicating that a person has a neutral opinion.","Neutral | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555503","Siewert Classification","C154609","A system of anatomical classification used for adenocarcinomas of the esophagogastric junction.","Siewert Classification | Siewert Classification of Adenocarcinoma of the Esophagogastric Junction | Siewert-Stein Classification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555500","Siewert Type I","C154610","An adenocarcinoma of the lower esophagus with the center located 1 cm to 5 cm above the esophagogastric junction.","Siewert Type I | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555501","Siewert Type II","C154611","A true carcinoma of the cardia with the tumor center within 1 cm above and 2 cm below the esophagogastric junction.","Siewert Type II | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555505","Siewert Type III","C154612","A subcardial carcinoma with the tumor center between 2 and 5 cm below the esophagogastric junction, with infiltration of the esophagogastric junction and lower esophagus from below.","Siewert Type III | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509737","Flap Surgical Reconstruction","C127812","The surgical transfer of tissue from one site to another while maintaining its own blood supply.","Flap Surgical Reconstruction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050171","Sustained Virologic Response","C120598","A finding of aviremia at a predetermined time point after the end of planned or actual treatment.","Sustained Virologic Response | SUSTAINED VIROLOGIC RESPONSE | SVR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4048786","RG-3635","C71759","An orally bioavailable receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Linifanib inhibits members of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor families; it exhibits much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. This agent does not have a general antiproliferative effect due to its high dose requirement. However, linifanib may exhibit potent antiproliferative and apoptotic effects on tumor cells whose proliferation is dependent on mutant kinases, such as FMS-related tyrosine kinase receptor-3 (FLT3).","Linifanib | ABT-869 | LINIFANIB | multitargeted receptor tyrosine kinase inhibitor ABT-869",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700604","Brivanib","C67040","A pyrrolotriazine-based compound and an inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) with potential antineoplastic activity. BMS-540215 specifically targets and binds strongly to human VEGFR-2, a tyrosine kinase receptor and pro-angiogenic growth factor expressed almost exclusively on vascular endothelial cells. Blockade of VEGFR-2 by this agent may lead to an inhibition of VEGF-stimulated endothelial cell migration and proliferation, thereby inhibiting tumor angiogenesis.","Brivanib | (R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol | BMS-540215 | BRIVANIB | VEGFR2 Inhibitor BMS-540215 | brivanib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019189","Chronic Hepatitis","C82978","An active inflammatory process affecting the liver for more than six months. Causes include viral infections, autoimmune disorders, drugs, and metabolic disorders.","Chronic Hepatitis | Chronic hepatitis, unspecified | Hepatitis, Chronic",,,,,,,,,,,,,,,"200763","Chronic hepatitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3273016","High Grade Liver Dysplastic Nodule","C96768","A hepatic dysplastic nodule characterized by the presence of high grade atypical cellular changes.","High Grade Liver Dysplastic Nodule | HGDN | High Grade Hepatic Dysplastic Nodule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273018","Low Grade Liver Dysplastic Nodule","C96770","A hepatic dysplastic nodule characterized by the presence of low grade atypical cellular changes.","Low Grade Liver Dysplastic Nodule | LGDN | Low Grade Hepatic Dysplastic Nodule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555238","Healthcare Problem List","C154403","A list of health problems or conditions compiled through healthcare encounters.","Healthcare Problem List | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555236","PCORnet-defined Condition Algorithm","C154404","An algorithm designed to identify health conditions as defined by the National Patient-Centered Clinical Research Network.","PCORnet-defined Condition Algorithm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0679217","active state","C154405","Being in a state of progress or motion.","Active State | Active",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556394","Inactive","C154407","Not progressing or moving.","Inactive | Inactive State",,,,,,,,,,,,,,,"9173","Inactive",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555239","ICD-9-CM/PCS","C154408","The International Classification of Diseases, Ninth Revision, Clinical Modification/Procedure Coding System is the U.S. health system's adaptation of international ICD-9 standard list of six-character alphanumeric codes used in hospital inpatient settings for inpatient procedure coding.","ICD-9-CM/PCS | ICD-9-PCS | International Classification of Diseases, Ninth Revision, Clinical Modification/Procedure Coding System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556517","ICD-10-CM/PCS","C154410","The International Classification of Diseases, Tenth Revision, Clinical Modification/Procedure Coding System is the U.S. health system's adaptation of international ICD-10 standard list of six-character alphanumeric codes used in hospital inpatient settings for inpatient procedure coding.","ICD-10-CM/PCS | ICD-10-PCS | International Classification of Diseases, Tenth Revision, Clinical Modification/Procedure Coding System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555240","ICD-11-CM/PCS","C154412","The International Classification of Diseases, Eleventh Revision, Clinical Modification/Procedure Coding System is the U.S. health system's adaptation of international ICD11 standard list of six-character alphanumeric codes used in hospital inpatient settings for inpatient procedure coding.","ICD-11-CM/PCS | ICD-11-PCS | International Classification of Diseases, Eleventh Revision, Clinical Modification/Procedure Coding System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555241","International Classification of Diseases, Eleventh Revision, Clinical Modification","C154413","An extension of the ICD-11 created by the U.S. National Center for Health Statistics so that the system could be used to capture more morbidity data.","International Classification of Diseases, Eleventh Revision, Clinical Modification | ICD-11-CM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937340","Human Phenotype Ontology","C154414","A standardized vocabulary of phenotypic abnormalities encountered in human disease.","Human Phenotype Ontology | HPO | HPO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0681042","revenue","C154415","The income that a government or company receives regularly.","Revenue | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0444455","Underlying","C154417","Situated beneath, or the basic or root cause of something.","Underlying | ",,,,,,,,,,,,,,,"4114673","Underlay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555242","Month Imputed","C154418","An imputed date that includes the month of observation.","Month Imputed | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556381","Genderqueer","C154419","An individual who does not subscribe to conventional gender distinctions but identifies with neither, both, or a combination of male and female genders.","Genderqueer | GENDER QUEER | Gender Expansive | Gender Non-conforming | Non-binary Gender | Queer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556896","Other Gender","C154420","A response indicating that an individual identifies with a gender category not included in the existing list of values.","Other Gender | Gender Something Else | Other | Other gender | Something Else | Something else",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3266856","Transgender Identity","C154421","A person whose gender identity differs from their sex assigned at birth.","Transgender Identity | Transgender | Transgender",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555243","Insurance Claim","C154422","Notification to an insurance company requesting payment of an amount due under the terms of the policy.","Insurance Claim | Claim",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555244","Unable to Classify","C154423","An inability to assign something to the existing classifications or categories.","Unable to Classify | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4035871","Adult Foster Home","C154424","A private home or other facility that provides care to persons of adult age in a home-like environment.","Adult Foster Home | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0872103","Assisted Living Facility","C154425","A residence facility for individuals who are able to attend to most of their personal and medical care, but who need oversight and support services, including some on-sight medical services.","Assisted Living Facility | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4035868","Other Acute Inpatient Hospital","C154426","An inpatient acute-care hospital not elsewhere specified.","Other Acute Inpatient Hospital | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0237680","Residential Care Facility","C154427","A residential group facility for individuals who are able to attend to most of their personal and medical care. Generally, residents receive personal care and meals and have staff available around the clock, but nursing and medical care usually are not provided on site.","Residential Care Facility | Board and Care Home | Residential Facility | Residential Institution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037265","Skilled Nursing Facility","C154428","A specialized, short-term care facility, that offers care (often including rehab) for a previously hospitalized patient as they transition back to their home or maybe eventually a nursing home.","Skilled Nursing Facility | Nursing Facility | Nursing Home",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4035875","Ambulatory Visit","C154474","A visit to an ambulatory care facility.","Ambulatory Visit | Ambulatory Care Clinic Visit | Ambulatory Care Facility Visit | Ambulatory Center Visit | OUTPATIENT CLINIC VISIT | Outpatient Visit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4035872","Discharged Alive","C154475","An indication that a patient left an in-patient facility while alive.","Discharged Alive | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4035176","Absent without Leave","C154476","An indication that a patient is missing from an in-patient facility.","Absent without Leave | AW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4035866","Still in Hospital","C154477","An indication that a patient remains in an in-patient hospital.","Still in Hospital | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555396","No Higher Limit","C154478","A higher limit of the normal range does not exist.","No Higher Limit | No Higher Limit of Normal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282664","Point-of-Care Systems","C154479","Services designed to be administered at the patient's bedside or other patient location.","Point-of-Care | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555399","Adult Sickle Cell Quality of Life Measurement Information System","C154481","A patient-reported outcome measurement system designed to evaluate and monitor the physical, mental, and social well-being of adults with sickle cell disease.","Adult Sickle Cell Quality of Life Measurement Information System | ASCQ-Me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555397","NIH Toolbox","C154482","A comprehensive set of neuro-behavioral measures that assess cognitive, emotional, sensory, and motor functions, designed to be run on an iPad.","NIH Toolbox | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555398","Hospital Consumer Assessment of Healthcare Providers and Systems","C154483","A national, standardized, publicly reported satisfaction survey of a patients' perspectives of their hospital experience. It is required by the Centers for Medicare and Medicaid Services for all hospitals in the United States.","Hospital Consumer Assessment of Healthcare Providers and Systems | CAHPS Hospital Survey | HCAHPS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555402","Every Afternoon","C154484","Scheduled or occurring each afternoon.","Every Afternoon | EVERY AFTERNOON",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555403","Paper Form","C154485","A questionnaire or measure that is printed on a paper medium and filled out with a writing device.","Paper Form | Paper Format",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555400","Electronic Form","C154486","A questionnaire or measure that is administered on an electronic device, such as a computer, tablet, or smartphone.","Electronic Form | Electronic Administration | Electronic Format",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555413","Telephonic Format","C154498","A questionnaire or measure that is administered via telephone.","Telephonic Format | Telephone Administration | Telephonic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555314","Self Without Assistance","C154506","An indication that an individual completed a questionnaire or measure by themselves, without assistance.","Self Without Assistance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555311","Self With Assistance","C154507","An indication that an individual completed a questionnaire or measure by themselves, but required some assistance.","Self With Assistance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555312","Proxy Without Assistance","C154508","An indication that a questionnaire or measure was completed by someone on behalf of an individual, without input from the individual.","Proxy Without Assistance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555316","Proxy With Assistance","C154509","An indication that a questionnaire or measure was completed by someone on behalf of an individual, with input from the individual.","Proxy With Assistance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0857118","Heavy Smoker","C154510","A smoker who smokes more than 10 cigarettes per day, or an equivalent quantity of cigar or pipe smoke.","Heavy Smoker | Heavy Tobacco Smoker | Heavy tobacco smoker",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3494624","Light Smoker","C154511","A smoker who smokes less than 10 cigarettes per day, or an equivalent quantity of cigar or pipe smoke.","Light Smoker | Light Tobacco Smoker | Light tobacco smoker",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555319","Smoked Tobacco Only","C154513","An indication that individual used only tobacco products that are smoked.","Smoked Tobacco Only | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555320","Non-Smoked Tobacco Only","C154514","An indication that individual used only smokeless tobacco products.","Non-Smoked Tobacco Only | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555317","Use of both Smoked and Non-smoked Tobacco Products","C154515","An indication that individual only used both smoked and smokeless tobacco products.","Use of both Smoked and Non-smoked Tobacco Products | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555323","Use of Smoked Tobacco but no Information about Non-smoked Tobacco Use","C154517","An indication that it is known that an individual used smoked tobacco products, but it is unknown if they also used smokeless tobacco products.","Use of Smoked Tobacco but no Information about Non-smoked Tobacco Use | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0747307","Patient-Reported","C154523","An indication that the patient provides information about their vital signs, status, or subjective feelings. Some systems also consider information reported by the patient's family or guardian as patient-reported.","Patient-Reported | Patient Reporting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555324","Patient Device Direct Feed Reporting","C154524","An indication that vital sign data came from a device in direct contact with the patient.","Patient Device Direct Feed Reporting | Patient device direct feed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556871","Healthcare Delivery Setting Reporting","C154525","An indication that vital sign data came from an individual or record within a healthcare delivery setting.","Healthcare Delivery Setting Reporting | Healthcare delivery setting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555329","Centers for Medicare and Medicaid Services System for Diagnosis-Related Groups","C154526","A system developed by the Centers for Medicare and Medicaid Services to classify hospital cases into diagnosis-related groups to facilitate Medicare reimbursement. This system was used until 2007.","Centers for Medicare and Medicaid Services System for Diagnosis-Related Groups | CMS-DRG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555327","Medicare Severity Diagnosis-Related Groups","C154527","A system developed by the Centers for Medicare and Medicaid Services to classify hospital cases into diagnosis-related groups to facilitate Medicare reimbursement. Compared to the CMS-DRG, the MS-DRG adds 300 diagnosis-related groups and factors in the severity of illness for establishing reimbursement levels.","Medicare Severity Diagnosis-Related Groups | MS-DRG | Medicare Severity-Diagnosis Related Group",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555328","Period of Medical Insurance Coverage for Enrollment Basis","C154528","A time period of care where the start and stop dates are based on when the patient's costs are covered by their personal medical insurance plan.","Period of Medical Insurance Coverage for Enrollment Basis | Medical insurance coverage | Period of Medical Insurance Coverage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555332","Period of Outpatient Prescription Drug Coverage for Enrollment Basis","C154529","A time period of care where the start and stop dates are based on when the patient's outpatient drug costs are covered by their personal medical insurance plan.","Period of Outpatient Prescription Drug Coverage for Enrollment Basis | Outpatient prescription drug coverage | Period of Outpatient Prescription Drug Coverage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555331","Geography-Based Enrollment","C154532","An assertion of complete data capture between the start and end dates based upon geographic characteristics, such as regional isolation.","Geography-Based Enrollment | Enrollment Basis Geography | Geography",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4035864","Algorithm-Based Enrollment","C154533","An assertion of complete data capture between the start and end dates, based on a locally developed or applied algorithm, often using multiple criteria.","Algorithm-Based Enrollment | Algorithmic | Algorithmic Enrollment Basis | Enrollment Basis Algorithmic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4035863","Period of Care, Encounter-Based","C154530","A time period of care where the start and stop dates are populated from the earliest observed encounter and latest observed encounter.","Period of Care, Encounter-Based | Encounter-Based Enrollment Period | Encounter-based | Period of Care,  Encounter-Based",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555335","Order to Dispense","C154534","A prescription drug order that specifies outpatient dispensing of the drug.","Order to Dispense | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555333","Order to Administer","C154535","A prescription drug order that orders administration of the drug by a healthcare professional.","Order to Administer | Medication Order",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556393","Enrollment Period","C154623","A period of time during which a person is expected to have complete data capture. This concept is often insurance-based, but other methods of defining enrollment are possible.","Enrollment Period | ENROLLMENT | Enrollment Table",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555510","Healthcare Encounter","C154624","Interactions between patients and providers within the context of healthcare delivery.","Healthcare Encounter | ENCOUNTER | Encounter Table",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556387","Diagnosis Code","C154625","Diagnosis codes indicate the results of diagnostic processes and medical coding within healthcare delivery. Data in this table are expected to be from healthcare-mediated processes and reimbursement drivers.","Diagnosis Code | DIAGNOSIS | Diagnosis Table",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556366","Procedure Code","C154626","Procedure codes indicate the discrete medical interventions and diagnostic testing, such as surgical procedures and lab orders, delivered within a healthcare context.","Procedure Code | PROCEDURES | Procedure Table",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0518766","Vital Signs","C154628","Vital signs (such as height, weight, and blood pressure) directly measure an individual's current state of attributes.","Vital Signs | AGE_AT_VITALS | VITAL | Vital Sign | vital signs | vital_signs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555514","Dispensing","C154629","Prescriptions filled through a community, mail-order or hospital pharmacy. Outpatient dispensing may not be directly captured within healthcare systems.","Dispensing | DISPENSING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555515","Lab Result CM Domain","C154630","This table is used to store quantitative and qualitative measurements from blood and other body specimens.","Lab Result CM Domain | LAB_RESULT_CM | LAB_RESULT_CM Table",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556386","Condition Domain","C154631","A condition represents a patient's diagnosed and self-reported health conditions and diseases. The patient's medical history and current state may both be represented.","Condition Domain | CONDITION | Condition Table",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555513","Patient-Reported Outcomes CM Domain","C154632","This table is used to store responses to patient-reported outcome measures (PROs) or questionnaires. This table can be used to store item-level responses as well as the overall score for each measure.","Patient-Reported Outcomes CM Domain | PRO_CM | PRO_CM Table",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555518","PCORNet Trial Domain","C154634","Patients who are enrolled in PCORnet clinical trials and PCORnet studies.","PCORNet Trial Domain | PCORNET_TRIAL | PCORnet Trial Table",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555516","Death Domain","C154635","Reported mortality information for patients.","Death Domain | DEATH | Death Table",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556406","Death Cause Domain","C154636","The individual causes associated with a reported death.","Death Cause Domain | DEATH_CAUSE | Death Cause Table",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555420","Medication Administered Domain","C154637","Records of medications administered to patients by healthcare providers. These administrations may take place in any setting, including inpatient, outpatient or home health encounters.","Medication Administered Domain | MED_ADMIN | MED_ADMIN Table",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556404","Provider Domain","C154638","Data about the providers who are involved in the care processes documented in the CDM.","Provider Domain | PROVIDER | Provider Table",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555419","Clin Obs Domain","C154640","A subject domain that is used for storing standardized qualitative and quantitative clinical observations about a patient, including vital signs.","Clinical Observation Domain | Clin Obs Domain | Clin Obs Domain | OBS_CLIN | OBS_CLIN Table | OC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555418","General Observation Domain","C154639","A subject domain that is used for storing standardized qualitative and quantitative general observations that are not stored elsewhere.","General Observation Domain | OB | OBS_GEN | OBS_GEN Table",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443343","Unstable","C154660","Subject to change; variable.","Unstable | Unstable Condition | Unstable Status",,,,,,,,,,,,,,,"4137184","Unstable status",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555441","Impossible","C154661","Not able to occur, exist, or be done.","Impossible | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555442","Off Observation","C154662","No longer subject to surveillance.","Off Observation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555445","Variant Allele Frequency","C154665","The relative rate of occurrence of a specific variant allele within a population.","Variant Allele Frequency | VAF | allele frequency | allele_frequency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1277855","Varicella Zoster Virus IgM Antibody Measurement","C98797","The determination of the amount of varicella zoster virus IgM antibody present in a sample.","Varicella Zoster Virus IgM Antibody Measurement | VZVIGMAB | Varicella Zoster Virus IgM Antibody",,,,,,,,,,,,,,,"4196426","Varicella-zoster virus antibody IgM measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1456025","Intravascular ultrasound","C99535","A method for assessing vessel wall morphology and other associated blood vessel properties by cannulating a miniature ultrasound transducer-mounted catheter into an artery.","Intravascular Ultrasound | INTRAVASCULAR ULTRASOUND | IVUS | Intravascular Transducer Ultrasound",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537007","Diffusion Tensor Imaging","C64862","A type of diffusion-weighted magnetic resonance imaging (DW-MRI) that maps the diffusion of water in three dimensions, the principal purpose of which is to image the white matter of the brain, specifically measuring the anisotropy, location, and orientation of the neural tracts, which can demonstrate microstructural changes or differences with neuropathology and treatment.","Diffusion Tensor Imaging | DIFFUSION TENSOR MRI | DT-MRI | DTI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005680","Black","C128938","A person having origins in the original peoples of sub-Saharan Africa or the Caribbean.","Black | BLACK | Black Populations",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513746","Wheal Diameter Interpretation","C130186","A further, qualitative assessment based on the diameter of a wheal on the skin.","Wheal Diameter Interpretation | WHLINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055376","Blistering Indicator","C122195","Specifies whether blistering occurred.","Blistering Indicator | BLISTIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831565","Allergen Skin Response Intensity","C112222","The semiquantitative assessment of the wheal-and-flare index that measures the intensity of the reaction.","Allergen Skin Response Intensity | ASRINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555610","Targeted Imaging","C154910","Imaging that uses tagged molecules that are specific for a target molecule or biomarker.","Targeted Imaging | Targeted Molecular Imaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698301","BRAF V600E Mutation Analysis","C80273","A molecular diagnostic test performed to determine the presence or absence of a BRAF V600E mutation in a tissue sample.","BRAF V600E Mutation Analysis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556900","Robot-Assisted Esophagectomy","C155289","A minimally-invasive surgical technique that uses a robot is aid in the partial or complete removal of the esophagus.","Robot-Assisted Esophagectomy | RAMIE | Robotic Assisted Minimally Invasive Esophagectomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827168","Enasidenib","C111573","An orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits various mutant forms of IDH2, including the IDH2 variants R140Q, R172S, and R172K, which inhibits the formation of 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH2-expressing tumor cells. IDH2, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by blocking differentiation and the production of the oncometabolite 2HG.","Enasidenib | AG 221 | AG-221 | AG221 | CC-90007 Free Base | ENASIDENIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2703133","Pacritinib","C78837","An orally bioavailable inhibitor of Janus kinase 2 (JAK2), the JAK2 mutant JAK2V617F and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration, pacritinib competes with JAK2 and the JAK2 mutant JAK2V617F for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-signal transducer and activator of transcription (STAT) signaling pathway, and the induction of apoptosis. In addition, pacritinib targets, binds to and inhibits the activity of FLT3. This inhibits FLT3-mediated signaling and the proliferation of FLT3-expressing cancer cells. JAK2, often upregulated or mutated in a variety of cancer cells, plays a key role in tumor cell proliferation and survival. The JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617. The JAK-STAT signaling pathway is a major mediator of cytokine activity. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias. In addition, JAK2 and FLT3 play a key role in the regulation of the inflammatory response and dendritic cell (DC) proliferation, differentiation and function. Inhibition of JAK2- and FLT3-mediated signaling may suppress the generation and differentiation of DCs, and may regulate inflammatory and immune responses.","Pacritinib | Oral JAK2 Inhibitor SB1518 | PACRITINIB | SB 1518 | SB-1518 | SB1518",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471818","Ivosidenib","C114383","An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Upon administration, AG-120 specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhibits the formation of the oncometabolite, 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1-expressing tumor cells. IDH1, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.","Ivosidenib | AG 120 | AG-120 | AG120 | IVOSIDENIB | Tibsovo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1667052","Maraviroc","C73144","A C-C Chemokine Receptor Type 5 (CCR5) antagonist with activity against human immunodeficiency virus (HIV). Maraviroc inhibits HIV-1 entry via CCR5 coreceptor interaction.","Maraviroc | Celsentri | MARAVIROC | Selzentry | UK 427,857",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1619966","Abatacept","C28898","A soluble fusion protein consisting of the extracellular domain of human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) linked to a modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1) with immunosuppressive activity. Abatacept binds CD80 and CD86 on antigen presenting cells (APCs), blocking interaction with CD28 on T lymphocytes, which initiates a co-stimulatory signal required for full activation of T lymphocytes.","Abatacept | ABATACEPT | BMS-188667 | CTL A4-Ig B7 Inhibitor | CTLA4-Ig | Orencia | RG2077 | cytotoxic T lymphocyte-associated antigen-4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555946","How Recently","C155315","A question about how recently an individual did or experienced something.","How Recently | How recently have you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555947","Read Depth","C155320","The number of times a particular locus (site, nucleotide, amplicon, region) was sequenced.","Read Depth | Depth of Coverage | READ DEPTH | Sequence Coverage | Sequence Read Coverage | Sequencing Coverage | Sequencing Depth | Total Mapped Reads | Total Read Depth | mean coverage | mean_coverage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555930","CARTOX 10 Point Neurological Assessment","C155295","A test to monitor for neurotoxicity related to CAR T therapy: orientation to year, month, city, hospital, and President; ability to name 3 specified objects; ability to write a standard sentence; ability to count backwards from 100 by 10.","CARTOX 10 Point Neurological Assessment | CARTOX-10 | CARTOX-10 Neurological Assessment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555927","CARTOX Grade 1","C155296","A score of 7-9 on the CARTOX-10 assessment, indicating mild neurotoxicity.","CARTOX Grade 1 | CARTOX Mild Neurological Impairment | CARTOX Score 7-9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555928","CARTOX Grade 2","C155297","A score of 3-6 on the CARTOX-10 assessment, indicating moderate neurotoxicity.","CARTOX Grade 2 | CARTOX Moderate Neurological Impairment | CARTOX Score 3-6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555933","CARTOX Grade 3","C155298","A score of 0-2 on the CARTOX-10 assessment, indicating severe neurotoxicity.","CARTOX Grade 3 | CARTOX Score 0-2 | CARTOX Severe Neurological Impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3553160","Complex Partial Seizure","C155290","A seizure that originates in one area of the brain that affects consciousness.","Complex Partial Seizure | Focal Impaired Awareness Seizure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0751523","Non-Convulsive Status Epilepticus","C155291","Status epilepticus without prominent motor symptoms, the duration of which is at least ten minutes.","Non-Convulsive Status Epilepticus | ",,,,,,,,,,,,,,,"40483620","Nonconvulsive status epilepticus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0864494","Cytoreductive effect","C155678","Any therapy designed to reduce the number of cells of a particular type or in a particular location.","Cytoreduction Treatment | Cytoreduction | Cytoreductive Effect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556285","Cytoreductive Chemotherapy","C155679","Drug therapy designed to reduce the number of target cells.","Cytoreductive Chemotherapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019898","Queer","C155691","Used to describe a sexual orientation that is not exclusively homosexual or heterosexual.","Queer | QUEER",,,,,,,,,,,,,,,"763767","Identifies as non-conforming gender",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556296","Questioning","C155692","Used to describe an individual who is unsure of their sexual orientation.","Questioning | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242659","Lesbian","C155694","A woman whose physical, emotional, or romantic attraction is to other women.","Lesbian | Female Homosexual | Female homosexual | LESBIAN",,,,,,,,,,,,,,,"4230492","Female homosexual",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0599655","asexual","C155696","Used to describe an individual who does not experience sexual attraction.","Asexual | ASEXUAL | Asexuality | Sexually attracted to neither male nor female sex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1571885","Counselor","C155697","A person with training to provide advice or instruction.","Counselor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983596","Clinical Trial Agent","C90373","The pharmacological substance that is being administered in the study.","Clinical Trial Agent | Clinical Trial-Study Agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0184781","Evaluation of Response to Treatment","C140466","An assessment of the effectiveness of therapeutic intervention.","Evaluation of Response to Treatment | Evaluating Response to Treatment | Evaluation of Treatment Response",,,,,,,,,,,,,,,"4021972","Evaluating response to treatment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556279","NRAS NP_002515.1:p.G12C","C155669","A change in the amino acid residue at position 12 in the GTPase NRas protein where glycine has been replaced by cysteine.","NRAS NP_002515.1:p.G12C | GTPase NRas G12C | GTPase NRas Gly12Cys | NP_002515.1:p.G12C | NP_002515.1:p.Gly12Cys | NRAS G12C | NRAS Gly12Cys | NRAS NP_002515.1:p.Gly12Cys | NRAS p.G12C | NRAS p.Gly12Cys | Transforming Protein N-Ras G12C | Transforming Protein N-Ras Gly12Cys",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556277","NRAS NP_002515.1:p.G12D","C155671","A change in the amino acid residue at position 12 in the GTPase NRas protein where glycine has been replaced by aspartic acid.","NRAS NP_002515.1:p.G12D | GTPase NRas G12D | GTPase NRas Gly12Asp | NP_002515.1:p.G12D | NP_002515.1:p.Gly12Asp | NRAS G12D | NRAS Gly12Asp | NRAS NP_002515.1:p.Gly12Asp | NRAS p.G12D | NRAS p.Gly12Asp | Transforming Protein N-Ras G12D | Transforming Protein N-Ras Gly12Asp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556283","NRAS NP_002515.1:p.G12S","C155673","A change in the amino acid residue at position 12 in the GTPase NRas protein where glycine has been replaced by serine.","NRAS NP_002515.1:p.G12S | GTPase NRas G12S | GTPase NRas Gly12Ser | NP_002515.1:p.G12S | NP_002515.1:p.Gly12Ser | NRAS G12S | NRAS G12S Mutation | NRAS Gly12Ser | NRAS NP_002515.1:p.Gly12Ser | NRAS p.G12S | NRAS p.Gly12Ser | Transforming Protein N-Ras G12S | Transforming Protein N-Ras Gly12Ser",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556281","COLORECTAL CANCER, GLY13ARG","C155675","A change in the amino acid residue at position 13 in the GTPase NRas protein where glycine has been replaced by arginine.","NRAS NP_002515.1:p.G13R | GTPase NRas G13R | GTPase NRas Gly13Arg | NP_002515.1:p.G13R | NP_002515.1:p.Gly13Arg | NRAS G13R | NRAS Gly13Arg | NRAS NP_002515.1:p.Gly13Arg | NRAS p.G13R | NRAS p.Gly13Arg | Transforming Protein N-Ras G13R | Transforming Protein N-Ras Gly13Arg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556287","NRAS NP_002515.1:p.G13V","C155677","A change in the amino acid residue at position 13 in the GTPase NRas protein where glycine has been replaced by valine.","NRAS NP_002515.1:p.G13V | GTPase NRas G13V | GTPase NRas Gly13Val | NP_002515.1:p.G13V | NP_002515.1:p.Gly13Val | NRAS G13V | NRAS Gly13Val | NRAS NP_002515.1:p.Gly13Val | NRAS p.G13V | NRAS p.Gly13Val | Transforming Protein N-Ras G13V | Transforming Protein N-Ras Gly13Val",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274088","NRAS NP_002515.1:p.Q61E","C98440","A change in the amino acid residue at position 61 in the GTPase NRas protein where glutamine has been replaced by glutamic acid.","NRAS NP_002515.1:p.Q61E | GTPase NRas Q61E | NP_002515.1:p.Gln61Glu | NP_002515.1:p.Q61E | NRAS Gln61Glu | NRAS NP_002515.1:p.Gln61Glu | NRAS Q61E | NRAS p.Gln61Glu | NRAS p.Q61E | Transforming Protein N-Ras Gln61Glu | Transforming Protein N-Ras Q61E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274090","NRAS NP_002515.1:p.Q61H","C98442","A change in the amino acid residue at position 61 in the GTPase NRas protein where glutamine has been replaced by histidine.","NRAS NP_002515.1:p.Q61H | GTPase NRas Gln61His | GTPase NRas Q61H | NP_002515.1:p.Gln61His | NP_002515.1:p.Q61H | NRAS Gln61His | NRAS NP_002515.1:p.Gln61His | NRAS Q61H | NRAS p.Gln61His | NRAS p.Q61H | Transforming Protein N-Ras Gln61His | Transforming Protein N-Ras Q61H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274093","NRAS NP_002515.1:p.Q61K","C98445","A change in the amino acid residue at position 61 in the GTPase NRas protein where glutamine has been replaced by lysine.","NRAS NP_002515.1:p.Q61K | GTPase NRas Gln61Lys | GTPase NRas Q61K | NP_002515.1:p.Gln61Lys | NP_002515.1:p.Q61K | NRAS Gln61Lys | NRAS NP_002515.1:p.Gln61Lys | NRAS Q61K | NRAS p.Gln61Lys | NRAS p.Q61K | Transforming Protein N-Ras Gln61Lys | Transforming Protein N-Ras Q61K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274097","NRAS NP_002515.1:p.Q61L","C98449","A change in the amino acid residue at position 61 in the GTPase NRas protein where glutamine has been replaced by leucine.","NRAS NP_002515.1:p.Q61L | GTPase NRas Gln61Leu | GTPase NRas Q61L | NP_002515.1:p.Gln61Leu | NP_002515.1:p.Q61L | NRAS Gln61Leu | NRAS NP_002515.1:p.Gln61Leu | NRAS Q61L | NRAS p.Gln61Leu | NRAS p.Q61L | Transforming Protein N-Ras Gln61Leu | Transforming Protein N-Ras Q61L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274101","NRAS NP_002515.1:p.Q61P","C98453","A change in the amino acid residue at position 61 in the GTPase NRas protein where glutamine has been replaced by proline.","NRAS NP_002515.1:p.Q61P | GTPase NRas Q61P | NP_002515.1:p.Gln61Pro | NP_002515.1:p.Q61P | NRAS Gln61Pro | NRAS NP_002515.1:p.Gln61Pro | NRAS Q61P | NRAS p.Q61P | Transforming Protein N-Ras Gln61Pro | Transforming Protein N-Ras Q61P",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274104","NRAS NP_002515.1:p.Q61R","C98456","A change in the amino acid residue at position 61 in the GTPase NRas protein where glutamine has been replaced by arginine.","NRAS NP_002515.1:p.Q61R | GTPase NRas Gln61Arg | GTPase NRas Q61R | NP_002515.1:p.Gln61Arg | NP_002515.1:p.Q61R | NRAS Gln61Arg | NRAS NP_002515.1:p.Gln61Arg | NRAS Q61R | NRAS p.Gln61Arg | NRAS p.Q61R | Transforming Protein N-Ras Gln61Arg | Transforming Protein N-Ras Q61R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556290","KIT NP_000213.1:p.K642E","C155681","A change in the amino acid residue at position 642 in the mast/stem cell growth factor receptor Kit protein where lysine has been replaced by glutamic acid.","KIT NP_000213.1:p.K642E | CD117 Antigen K642E | CD117 Antigen Lys642Glu | KIT K642E | KIT Lys642Glu | KIT NP_000213.1:p.Lys642Glu | KIT p.K642E | KIT p.Lys642Glu | Mast/Stem Cell Growth Factor Receptor Kit K642E | Mast/Stem Cell Growth Factor Receptor Kit Lys642Glu | NP_000213.1:p.K642E | NP_000213.1:p.Lys642Glu | Proto-Oncogene Tyrosine-Protein Kinase Kit K642E | Proto-Oncogene Tyrosine-Protein Kinase Kit Lys642Glu | Proto-Oncogene c-Kit K642E | Proto-Oncogene c-Kit Lys642Glu | Stem Cell Factor Receptor K642E | Stem Cell Factor Receptor Lys642Glu | Tyrosine-Protein Kinase Kit K642E | Tyrosine-Protein Kinase Kit Lys642Glu | c-KIT K642E | c-KIT Lys642Glu | c-KIT p.K642E | c-KIT p.Lys642Glu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556288","KIT NP_000213.1:p.L647F","C155683","A change in the amino acid residue at position 647 in the mast/stem cell growth factor receptor Kit protein where leucine has been replaced by phenylalanine.","KIT NP_000213.1:p.L647F | CD117 Antigen L647F | CD117 Antigen Leu647Phe | KIT L647F | KIT Leu647Phe | KIT NP_000213.1:p.Leu647Phe | KIT p.L647F | KIT p.Leu647Phe | Mast/Stem Cell Growth Factor Receptor Kit L647F | Mast/Stem Cell Growth Factor Receptor Kit Leu647Phe | NP_000213.1:p.L647F | NP_000213.1:p.Leu647Phe | Proto-Oncogene Tyrosine-Protein Kinase Kit L647F | Proto-Oncogene Tyrosine-Protein Kinase Kit Leu647Phe | Proto-Oncogene c-Kit L647F | Proto-Oncogene c-Kit Leu647Phe | Stem Cell Factor Receptor L647F | Stem Cell Factor Receptor Leu647Phe | Tyrosine-Protein Kinase Kit L647F | Tyrosine-Protein Kinase Kit Leu647Phe | c-KIT L647F | c-KIT Leu647Phe | c-KIT p.L647F | c-KIT p.Leu647Phe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556289","KIT NP_000213.1:p.G648D","C155684","A change in the amino acid residue at position 648 in the mast/stem cell growth factor receptor Kit protein where glycine has been replaced by aspartic acid.","KIT NP_000213.1:p.G648D | CD117 Antigen G648D | CD117 Antigen Gly648Asp | KIT G648D | KIT Gly648Asp | KIT NP_000213.1:p.Gly648Asp | KIT p.G648D | KIT p.Gly648Asp | Mast/Stem Cell Growth Factor Receptor Kit G648D | Mast/Stem Cell Growth Factor Receptor Kit Gly648Asp | NP_000213.1:p.G648D | NP_000213.1:p.Gly648Asp | Proto-Oncogene Tyrosine-Protein Kinase Kit G648D | Proto-Oncogene Tyrosine-Protein Kinase Kit Gly648Asp | Proto-Oncogene c-Kit G648D | Proto-Oncogene c-Kit Gly648Asp | Stem Cell Factor Receptor G648D | Stem Cell Factor Receptor Gly648Asp | Tyrosine-Protein Kinase Kit G648D | Tyrosine-Protein Kinase Kit Gly648Asp | c-KIT G648D | c-KIT Gly648Asp | c-KIT p.G648D | c-KIT p.Gly648Asp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556295","KIT NP_000213.1:p.I653T","C155686","A change in the amino acid residue at position 653 in the mast/stem cell growth factor receptor Kit protein where isoleucine has been replaced by threonine.","KIT NP_000213.1:p.I653T | CD117 Antigen I653T | CD117 Antigen Ile653Thr | KIT I653T | KIT Ile653Thr | KIT NP_000213.1:p.Ile653Thr | KIT p.I653T | KIT p.Ile653Thr | Mast/Stem Cell Growth Factor Receptor Kit I653T | Mast/Stem Cell Growth Factor Receptor Kit Ile653Thr | NP_000213.1:p.I653T | NP_000213.1:p.Ile653Thr | Proto-Oncogene Tyrosine-Protein Kinase Kit I653T | Proto-Oncogene Tyrosine-Protein Kinase Kit Ile653Thr | Proto-Oncogene c-Kit I653T | Proto-Oncogene c-Kit Ile653Thr | Stem Cell Factor Receptor I653T | Stem Cell Factor Receptor Ile653Thr | Tyrosine-Protein Kinase Kit I653T | Tyrosine-Protein Kinase Kit Ile653Thr | c-KIT I653T | c-KIT Ile653Thr | c-KIT p.I653T | c-KIT p.Ile653Thr",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556293","KIT NP_000213.1:p.V654A","C155688","A change in the amino acid residue at position 654 in the mast/stem cell growth factor receptor Kit protein where valine has been replaced by alanine.","KIT NP_000213.1:p.V654A | CD117 Antigen V654A | CD117 Antigen Val654Ala | KIT NP_000213.1:p.Val654Ala | KIT V654A | KIT Val654Ala | KIT p.V654A | KIT p.Val654Ala | Mast/Stem Cell Growth Factor Receptor Kit V654A | Mast/Stem Cell Growth Factor Receptor Kit Val654Ala | NP_000213.1:p.V654A | NP_000213.1:p.Val654Ala | Proto-Oncogene Tyrosine-Protein Kinase Kit V654A | Proto-Oncogene Tyrosine-Protein Kinase Kit Val654Ala | Proto-Oncogene c-Kit V654A | Proto-Oncogene c-Kit Val654Ala | Stem Cell Factor Receptor V654A | Stem Cell Factor Receptor Val654Ala | Tyrosine-Protein Kinase Kit V654A | Tyrosine-Protein Kinase Kit Val654Ala | c-KIT V654A | c-KIT Val654Ala | c-KIT p.V654A | c-KIT p.Val654Ala",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556298","KIT NP_000213.1:p.L813P","C155690","A change in the amino acid residue at position 813 in the mast/stem cell growth factor receptor Kit protein where leucine has been replaced by proline.","KIT NP_000213.1:p.L813P | CD117 Antigen L813P | CD117 Antigen Leu813Pro | KIT L813P | KIT Leu813Pro | KIT NP_000213.1:p.Leu813Pro | KIT p.L813P | KIT p.Leu813Pro | Mast/Stem Cell Growth Factor Receptor Kit L813P | Mast/Stem Cell Growth Factor Receptor Kit Leu813Pro | NP_000213.1:p.L813P | NP_000213.1:p.Leu813Pro | Proto-Oncogene Tyrosine-Protein Kinase Kit L813P | Proto-Oncogene Tyrosine-Protein Kinase Kit Leu813Pro | Proto-Oncogene c-Kit L813P | Proto-Oncogene c-Kit Leu813Pro | Stem Cell Factor Receptor L813P | Stem Cell Factor Receptor Leu813Pro | Tyrosine-Protein Kinase Kit L813P | Tyrosine-Protein Kinase Kit Leu813Pro | c-KIT L813P | c-KIT Leu813Pro | c-KIT p.L813P | c-KIT p.Leu813Pro",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556297","KIT NP_000213.1:p.K818Q","C155693","A change in the amino acid residue at position 818 in the mast/stem cell growth factor receptor Kit protein where lysine has been replaced by glutamine.","KIT NP_000213.1:p.K818Q | CD117 Antigen K818Q | CD117 Antigen Lys818Gln | KIT K818Q | KIT Lys818Gln | KIT NP_000213.1:p.Lys818Gln | KIT p.K818Q | KIT p.Lys818Gln | Mast/Stem Cell Growth Factor Receptor Kit K818Q | Mast/Stem Cell Growth Factor Receptor Kit Lys818Gln | NP_000213.1:p.K818Q | NP_000213.1:p.Lys818Gln | Proto-Oncogene Tyrosine-Protein Kinase Kit K818Q | Proto-Oncogene Tyrosine-Protein Kinase Kit Lys818Gln | Proto-Oncogene c-Kit K818Q | Proto-Oncogene c-Kit Lys818Gln | Stem Cell Factor Receptor K818Q | Stem Cell Factor Receptor Lys818Gln | Tyrosine-Protein Kinase Kit K818Q | Tyrosine-Protein Kinase Kit Lys818Gln | c-KIT K818Q | c-KIT Lys818Gln | c-KIT p.K818Q | c-KIT p.Lys818Gln",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556301","KIT NP_000213.1:p.D820Y","C155702","A change in the amino acid residue at position 820 in the mast/stem cell growth factor receptor Kit protein where aspartic acid has been replaced by tyrosine.","KIT NP_000213.1:p.D820Y | CD117 Antigen Asp820Tyr | CD117 Antigen D820Y | KIT Asp820Tyr | KIT D820Y | KIT NP_000213.1:p.Asp820Tyr | KIT p.Asp820Tyr | KIT p.D820Y | Mast/Stem Cell Growth Factor Receptor Kit Asp820Tyr | Mast/Stem Cell Growth Factor Receptor Kit D820Y | NP_000213.1:p.Asp820Tyr | NP_000213.1:p.D820Y | Proto-Oncogene Tyrosine-Protein Kinase Kit Asp820Tyr | Proto-Oncogene Tyrosine-Protein Kinase Kit D820Y | Proto-Oncogene c-Kit Asp820Tyr | Proto-Oncogene c-Kit D820Y | Stem Cell Factor Receptor Asp820Tyr | Stem Cell Factor Receptor D820Y | Tyrosine-Protein Kinase Kit Asp820Tyr | Tyrosine-Protein Kinase Kit D820Y | c-KIT Asp820Tyr | c-KIT D820Y | c-KIT p.Asp820Tyr | c-KIT p.D820Y",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556306","KIT NP_000213.1:p.N822K","C155704","A change in the amino acid residue at position 822 in the mast/stem cell growth factor receptor Kit protein where asparagine has been replaced by lysine.","KIT NP_000213.1:p.N822K | CD117 Antigen Asn822Lys | CD117 Antigen N822K | KIT Asn822Lys | KIT N822K | KIT NP_000213.1:p.Asn822Lys | KIT p.Asn822Lys | KIT p.N822K | Mast/Stem Cell Growth Factor Receptor Kit Asn822Lys | Mast/Stem Cell Growth Factor Receptor Kit N822K | NP_000213.1:p.Asn822Lys | NP_000213.1:p.N822K | Proto-Oncogene Tyrosine-Protein Kinase Kit Asn822Lys | Proto-Oncogene Tyrosine-Protein Kinase Kit N822K | Proto-Oncogene c-Kit Asn822Lys | Proto-Oncogene c-Kit N822K | Stem Cell Factor Receptor Asn822Lys | Stem Cell Factor Receptor N822K | Tyrosine-Protein Kinase Kit Asn822Lys | Tyrosine-Protein Kinase Kit N822K | c-KIT Asn822Lys | c-KIT N822K | c-KIT p.Asn822Lys | c-KIT p.N822K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556310","KIT NP_000213.1:p.N822Y","C155708","A change in the amino acid residue at position 822 in the mast/stem cell growth factor receptor Kit protein where asparagine has been replaced by tyrosine.","KIT NP_000213.1:p.N822Y | CD117 Antigen Asn822Tyr | CD117 Antigen N822Y | KIT Asn822Tyr | KIT N822Y | KIT NP_000213.1:p.Asn822Tyr | KIT p.Asn822Tyr | KIT p.N822Y | Mast/Stem Cell Growth Factor Receptor Kit Asn822Tyr | Mast/Stem Cell Growth Factor Receptor Kit N822Y | NP_000213.1:p.Asn822Tyr | NP_000213.1:p.N822Y | Proto-Oncogene Tyrosine-Protein Kinase Kit Asn822Tyr | Proto-Oncogene Tyrosine-Protein Kinase Kit N822Y | Proto-Oncogene c-Kit Asn822Tyr | Proto-Oncogene c-Kit N822Y | Stem Cell Factor Receptor Asn822Tyr | Stem Cell Factor Receptor N822Y | Tyrosine-Protein Kinase Kit Asn822Tyr | Tyrosine-Protein Kinase Kit N822Y | c-KIT Asn822Tyr | c-KIT N822Y | c-KIT p.Asn822Tyr | c-KIT p.N822Y",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556308","KIT NP_000213.1:p.A829P","C155710","A change in the amino acid residue at position 829 in the mast/stem cell growth factor receptor Kit protein where alanine has been replaced by proline.","KIT NP_000213.1:p.A829P | CD117 Antigen A829P | CD117 Antigen Ala829Pro | KIT A829P | KIT Ala829Pro | KIT NP_000213.1:p.Ala829Pro | KIT p.A829P | KIT p.Ala829Pro | Mast/Stem Cell Growth Factor Receptor Kit A829P | Mast/Stem Cell Growth Factor Receptor Kit Ala829Pro | NP_000213.1:p.A829P | NP_000213.1:p.Ala829Pro | Proto-Oncogene Tyrosine-Protein Kinase Kit A829P | Proto-Oncogene Tyrosine-Protein Kinase Kit Ala829Pro | Proto-Oncogene c-Kit A829P | Proto-Oncogene c-Kit Ala829Pro | Stem Cell Factor Receptor A829P | Stem Cell Factor Receptor Ala829Pro | Tyrosine-Protein Kinase Kit A829P | Tyrosine-Protein Kinase Kit Ala829Pro | c-KIT A829P | c-KIT Ala829Pro | c-KIT p.A829P | c-KIT p.Ala829Pro",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556317","KIT NP_000213.1:p.L831P","C155715","A change in the amino acid residue at position 831 in the mast/stem cell growth factor receptor Kit protein where leucine has been replaced by proline.","KIT NP_000213.1:p.L831P | CD117 Antigen L831P | CD117 Antigen Leu831Pro | KIT L831P | KIT Leu831Pro | KIT NP_000213.1:p.Leu831Pro | KIT p.L831P | KIT p.Leu831Pro | Mast/Stem Cell Growth Factor Receptor Kit L831P | Mast/Stem Cell Growth Factor Receptor Kit Leu831Pro | NP_000213.1:p.L831P | NP_000213.1:p.Leu831Pro | Proto-Oncogene Tyrosine-Protein Kinase Kit L831P | Proto-Oncogene Tyrosine-Protein Kinase Kit Leu831Pro | Proto-Oncogene c-Kit L831P | Proto-Oncogene c-Kit Leu831Pro | Stem Cell Factor Receptor L831P | Stem Cell Factor Receptor Leu831Pro | Tyrosine-Protein Kinase Kit L831P | Tyrosine-Protein Kinase Kit Leu831Pro | c-KIT L831P | c-KIT Leu831Pro | c-KIT p.L831P | c-KIT p.Leu831Pro",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556318","KIT NP_000213.1:p.S840I","C155716","A change in the amino acid residue at position 840 in the mast/stem cell growth factor receptor Kit protein where serine has been replaced by isoleucine.","KIT NP_000213.1:p.S840I | CD117 Antigen S840I | CD117 Antigen Ser840Ile | KIT NP_000213.1:p.Ser840Ile | KIT S840I | KIT Ser840Ile | KIT p.S840I | KIT p.Ser840Ile | Mast/Stem Cell Growth Factor Receptor Kit S840I | Mast/Stem Cell Growth Factor Receptor Kit Ser840Ile | NP_000213.1:p.S840I | NP_000213.1:p.Ser840Ile | Proto-Oncogene Tyrosine-Protein Kinase Kit S840I | Proto-Oncogene Tyrosine-Protein Kinase Kit Ser840Ile | Proto-Oncogene c-Kit S840I | Proto-Oncogene c-Kit Ser840Ile | Stem Cell Factor Receptor S840I | Stem Cell Factor Receptor Ser840Ile | Tyrosine-Protein Kinase Kit S840I | Tyrosine-Protein Kinase Kit Ser840Ile | c-KIT S840I | c-KIT Ser840Ile | c-KIT p.S840I | c-KIT p.Ser840Ile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556316","KIT NP_000213.1:p.Y846C","C155718","A change in the amino acid residue at position 846 in the mast/stem cell growth factor receptor Kit protein where tyrosine has been replaced by cysteine.","KIT NP_000213.1:p.Y846C | CD117 Antigen Tyr846Cys | CD117 Antigen Y846C | KIT NP_000213.1:p.Tyr846Cys | KIT Tyr846Cys | KIT Y846C | KIT p.Tyr846Cys | KIT p.Y846C | Mast/Stem Cell Growth Factor Receptor Kit Tyr846Cys | Mast/Stem Cell Growth Factor Receptor Kit Y846C | NP_000213.1:p.Tyr846Cys | NP_000213.1:p.Y846C | Proto-Oncogene Tyrosine-Protein Kinase Kit Tyr846Cys | Proto-Oncogene Tyrosine-Protein Kinase Kit Y846C | Proto-Oncogene c-Kit Tyr846Cys | Proto-Oncogene c-Kit Y846C | Stem Cell Factor Receptor Tyr846Cys | Stem Cell Factor Receptor Y846C | Tyrosine-Protein Kinase Kit Tyr846Cys | Tyrosine-Protein Kinase Kit Y846C | c-KIT Tyr846Cys | c-KIT Y846C | c-KIT p.Tyr846Cys | c-KIT p.Y846C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556321","KIT NP_000213.1:p.S850G","C155719","A change in the amino acid residue at position 850 in the mast/stem cell growth factor receptor Kit protein where serine has been replaced by glycine.","KIT NP_000213.1:p.S850G | CD117 Antigen S850G | CD117 Antigen Ser850Gly | KIT NP_000213.1:p.Ser850Gly | KIT S850G | KIT Ser850Gly | KIT p.S850G | KIT p.Ser850Gly | Mast/Stem Cell Growth Factor Receptor Kit S850G | Mast/Stem Cell Growth Factor Receptor Kit Ser850Gly | NP_000213.1:p.S850G | NP_000213.1:p.Ser850Gly | Proto-Oncogene Tyrosine-Protein Kinase Kit S850G | Proto-Oncogene Tyrosine-Protein Kinase Kit Ser850Gly | Proto-Oncogene c-Kit S850G | Proto-Oncogene c-Kit Ser850Gly | Stem Cell Factor Receptor S850G | Stem Cell Factor Receptor Ser850Gly | Tyrosine-Protein Kinase Kit S850G | Tyrosine-Protein Kinase Kit Ser850Gly | c-KIT S850G | c-KIT Ser850Gly | c-KIT p.S850G | c-KIT p.Ser850Gly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556319","KIT NP_000213.1:p.V852I","C155721","A change in the amino acid residue at position 852 in the mast/stem cell growth factor receptor Kit protein where valine has been replaced by isoleucine.","KIT NP_000213.1:p.V852I | CD117 Antigen V852I | CD117 Antigen Val852Ile | KIT NP_000213.1:p.Val852Ile | KIT V852I | KIT Val852Ile | KIT p.V852I | KIT p.Val852Ile | Mast/Stem Cell Growth Factor Receptor Kit V852I | Mast/Stem Cell Growth Factor Receptor Kit Val852Ile | NP_000213.1:p.V852I | NP_000213.1:p.Val852Ile | Proto-Oncogene Tyrosine-Protein Kinase Kit V852I | Proto-Oncogene Tyrosine-Protein Kinase Kit Val852Ile | Proto-Oncogene c-Kit V852I | Proto-Oncogene c-Kit Val852Ile | Stem Cell Factor Receptor V852I | Stem Cell Factor Receptor Val852Ile | Tyrosine-Protein Kinase Kit V852I | Tyrosine-Protein Kinase Kit Val852Ile | c-KIT V852I | c-KIT Val852Ile | c-KIT p.V852I | c-KIT p.Val852Ile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556214","KIT NP_000213.1:p.L859P","C155723","A change in the amino acid residue at position 859 in the mast/stem cell growth factor receptor Kit protein where leucine has been replaced by proline.","KIT NP_000213.1:p.L859P | CD117 Antigen L859P | CD117 Antigen Leu859Pro | KIT L859P | KIT Leu859Pro | KIT NP_000213.1:p.Leu859Pro | KIT p.L859P | KIT p.Leu859Pro | Mast/Stem Cell Growth Factor Receptor Kit L859P | Mast/Stem Cell Growth Factor Receptor Kit Leu859Pro | NP_000213.1:p.L859P | NP_000213.1:p.Leu859Pro | Proto-Oncogene Tyrosine-Protein Kinase Kit L859P | Proto-Oncogene Tyrosine-Protein Kinase Kit Leu859Pro | Proto-Oncogene c-Kit L859P | Proto-Oncogene c-Kit Leu859Pro | Stem Cell Factor Receptor L859P | Stem Cell Factor Receptor Leu859Pro | Tyrosine-Protein Kinase Kit L859P | Tyrosine-Protein Kinase Kit Leu859Pro | c-KIT L831P | c-KIT L859P | c-KIT Leu859Pro | c-KIT p.L859P | c-KIT p.Leu859Pro",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556215","KIT NP_000213.1:p.L862P","C155724","A change in the amino acid residue at position 862 in the mast/stem cell growth factor receptor Kit protein where leucine has been replaced by proline.","KIT NP_000213.1:p.L862P | CD117 Antigen L862P | CD117 Antigen Leu862Pro | KIT L862P | KIT Leu862Pro | KIT NP_000213.1:p.Leu862Pro | KIT p.L862P | KIT p.Leu862Pro | Mast/Stem Cell Growth Factor Receptor Kit L862P | Mast/Stem Cell Growth Factor Receptor Kit Leu862Pro | NP_000213.1:p.L862P | NP_000213.1:p.Leu862Pro | Proto-Oncogene Tyrosine-Protein Kinase Kit L862P | Proto-Oncogene Tyrosine-Protein Kinase Kit Leu862Pro | Proto-Oncogene c-Kit L862P | Proto-Oncogene c-Kit Leu862Pro | Stem Cell Factor Receptor L862P | Stem Cell Factor Receptor Leu862Pro | Tyrosine-Protein Kinase Kit L862P | Tyrosine-Protein Kinase Kit Leu862Pro | c-KIT L862P | c-KIT Leu862Pro | c-KIT p.L862P | c-KIT p.Leu862Pro",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242488","Acute Lung Injury","C155766","A finding of acute onset of bilateral pulmonary infiltrates by chest radiograph and a PaO2/FiO2 of less than or equal to 300, in the absence of heart failure. The infiltrate may be rich in neutrophils. This syndrome represents a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).","Acute Lung Injury | ALI",,,,,,,,,,,,,,,"4199961","Acute lung injury",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555273","Ipilimumab/Nivolumab Regimen","C154272","A regimen consisting of ipilimumab and nivolumab that can be used for the treatment of bone, kidney, colorectal, esophageal and esophagogastric junction, head and neck, hepatocellular, and biliary tract cancers, melanoma, non-small cell lung cancer (NSCLC), malignant pleural/peritoneal mesothelioma, soft tissue sarcoma, pancreatic adenocarcinoma, Kaposi sarcoma, and angiosarcoma.","Ipilimumab/Nivolumab Regimen | Ipilimumab + Nivolumab | Ipilimumab Plus Nivolumab | Ipilimumab and Nivolumab | Ipilimumab-Nivolumab | Ipilimumab-Nivolumab Regimen | Ipilimumab/Nivolumab | Nivolumab/Ipilimumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555221","Cobimetinib/Vemurafenib","C154327","A regimen consisting of vemurafenib and cobimetinib that can be used for the treatment of melanoma and central nervous system (CNS) cancers.","Cobimetinib/Vemurafenib Regimen | Cobimetinib and Vemurafenib | Cobimetinib/Vemurafenib | Vemurafenib + Cobimetinib | Vemurafenib Plus Cobimetinib | Vemurafenib-Cobimetinib | Vemurafenib-Cobimetinib Regimen | Vemurafenib/Cobimetinib Regimen | Vemurafenib/Cobimetinib Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555216","Dabrafenib/Trametinib Regimen","C154325","A regimen consisting of dabrafenib and trametinib that can be used in the treatment of cutaneous melanomas, non-small cell lung cancers (NSCLCs), anaplastic carcinoma, central nervous system (CNS), esophageal and esophagogastric junction and gastric cancers, ovarian, fallopian tube and primary peritoneal cancers, follicular, papillary and Hurthle cell thyroid carcinomas, and gallbladder or cholangiocarcinoma, ampullary, small bowel, and pancreatic adenocarcinomas, occult primary adenocarcinoma and squamous cell carcinoma, extrapulmonary poorly differentiated neuroendocrine carcinoma/large or small cell carcinoma/mixed neuroendocrine-non-neuroendocrine neoplasm, salivary gland tumors, gastrintestinal stromal tumors (GIST), and hairy cell leukemia.","Dabrafenib/Trametinib Regimen | Dabrafenib + Trametinib | Dabrafenib Plus Trametinib | Dabrafenib and Trametinib | Dabrafenib-Trametinib Regimen | Dabrafenib/Trametinib | Tafinlar-Mekinist | Tafinlar/Mekinist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555217","Binimetinib/Encorafenib","C154326","A regimen consisting of binimetinib and encorafenib that can be used for the treatment of melanoma and non-small cell lung cancer (NSCLC).","Binimetinib/Encorafenib Regimen | Binimetinib and Encorafenib | Binimetinib/Encorafenib | Braftovi/Mektovi | Encorafenib + Binimetinib | Encorafenib Plus Binimetinib | Encorafenib-Binimetinib | Encorafenib-Binimetinib Regimen | Encorafenib/Binimetinib | Encorafenib/Binimetinib Regimen | Encorafenib/Binimetinib Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556246","Fibroadipose Tissue","C155770","Soft tissue composed of fibrous tissue admixed with adipose tissue.","Fibroadipose Tissue | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555609","Deleterious DNA Damage Response Gene Mutation","C154915","A change in the nucleotide sequence of a gene involved in any DNA damage response pathway that is associated with increased risk of disease.","Deleterious DNA Damage Response Gene Mutation | DDR Deleterious Gene Alteration | DDR Gene Deleterious Alteration | Deleterious DDR Gene Mutation | Deleterious DNA Damage Response (DDR) Gene Alteration | Deleterious DNA Damage Response Gene Alteration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555614","C5 Gene Mutation","C154916","A change in the nucleotide sequence of the C5 gene.","C5 Gene Mutation | CPAMD4 Gene Mutation | Complement Component 5 Gene Mutation | Component 5 Gene Mutation | ECLZB Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555612","ARID1A Negative","C154918","An indication that ARID1A expression has not been detected in a sample.","ARID1A Negative | ARID Domain-Containing Protein 1A Negative | AT Rich Interactive Domain 1A Negative | AT-Rich Interactive Domain-Containing Protein 1A Negative | B120 Negative | BAF250a Negative | BM029 Negative | BRG1-Associated Factor 250a Negative | Brain Protein 120 Negative | ELD Negative | OSA1 Negative | Osa Homolog 1 Negative | SMARCF1 Negative | SWI/SNF-Related, Matrix-Associated, Actin-Dependent Regulator of Chromatin Subfamily F Member 1 Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555638","ARID1A Positive","C154954","An indication that ARID1A expression has been detected in a sample.","ARID1A Positive | ARID Domain-Containing Protein 1A Positive | AT Rich Interactive Domain 1A Positive | AT-Rich Interactive Domain-Containing Protein 1A Positive | B120 Positive | BAF250a Positive | BM029 Positive | BRG1-Associated Factor 250a Positive | Brain Protein 120 Positive | ELD Positive | OSA1 Positive | Osa Homolog 1 Positive | SMARCF1 Positive | SWI/SNF-Related, Matrix-Associated, Actin-Dependent Regulator of Chromatin Subfamily F Member 1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555924","Blasts 5-9 Percent of Bone Marrow Nucleated Cells","C155287","A semi-quantitative microscopic finding indicating that between 5 and 9 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 5-9 Percent of Bone Marrow Nucleated Cells | Blasts Between 5 and 9 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555922","Blasts 2-4 Percent of Peripheral Blood White Cells","C155288","A semi-quantitative microscopic finding indicating that between 2 and 4 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.","Blasts 2-4 Percent of Peripheral Blood White Cells | Blasts Between 2 and 4 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556272","Diagnostic DNA Methylation Signature","C155656","A DNA methylation profile that indicates that the subject has a neoplastic disease. The profile also serves to identify the type and predict the severity of the disease.","Diagnostic DNA Methylation Signature | DDMS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898751","Institutional Review Board Independent Ethics Committee Informed Consent Document","C115697","Records approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC), explaining study information to assist study volunteers in understanding the expectations and requirements of trial participation.","Institutional Review Board Independent Ethics Committee Informed Consent Document | Assent Template | IRB-IEC Approved Informed Consent | IRB-IEC IC | Informed Consent Template | Institutional Review Board Independent Ethics Committee Approved Informed Consent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556903","Pure","C155789","Involving or containing nothing else.","Pure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0178702","Desensitization","C155788","Any of various methods to reduce or eliminate an organism's negative reaction to a substance or stimulus.","Desensitization | ",,,,,,,,,,,,,,,"4279532","Desensitization therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334441","Melanoma Arising in Giant Congenital Nevus","C4235","A melanoma arising in a giant congenital melanocytic nevus. The risk of developing a melanoma in a giant congenital melanocytic nevus has been reported to be between 5% and 50%. The incidence of developing melanoma is higher before the age of 10 and in adult life.","Melanoma Arising in Giant Congenital Nevus | Malignant melanoma in congenital melanocytic nevus | Malignant melanoma in giant pigmented nevus",,,,,,,,,,,,,,,"4294258","Malignant melanoma in giant pigmented nevus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0267924","Suppurative Cholangitis","C35336","Cholangitis that is characterized by pyogenic organisms.","Suppurative Cholangitis | Pyogenic Cholangitis",,,,,,,,,,,,,,,"4289018","Suppurative cholangitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556229","CPT Category III Codes","C155740","Codes for tracking the use of emerging technology, services, and procedures provided by the American Medical Association as part of their Current Procedural Terminology.","CPT Category III Codes | CPT Category III | Temporary Current Procedural Terminology Codes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556230","Codabar","C155741","A linear barcode symbology developed in 1972 by Pitney Bowes Corp.","Codabar | Code-a-bar",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556232","Range Start-End Unit Format","C155744","A format for representation of a range of values along with their associated units where start is the low value of the range and end is the high value, delimited by a vertical bar.","Range Start-End Unit Format | Range Start End Unit | Range Start-End Unit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556225","No Lower Limit","C155739","A lower limit of the normal range does not exist.","No Lower Limit | No Lower Limit of Normal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556326","Ex-vivo T-Cell Depletion","C155795","Treatment that reduces or removes T cells from a graft before administration to the recipient.","Ex-vivo T-Cell Depletion | Ex vivo TCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556330","Filgotinib","C155799","An orally bioavailable inhibitor of the tyrosine kinase Janus kinase 1 (JAK1), with potential anti-inflammatory and immunomodulating activities. Upon oral administration, filgotinib specifically targets, binds to, and inhibits the phosphorylation of JAK1, which interferes with JAK/STAT (signal transducer and activator of transcription)-dependent signaling. As JAK1 mediates signaling of many pro-inflammatory cytokines, JAK1 inhibition prevents cytokine signaling and activity in many inflammatory and immune-mediated processes and leads to a decrease in inflammation and activation of certain immune cells. JAK1 plays a key role in the signaling and activity of many cytokines and growth factors and is often dysregulated in a variety of autoimmune and inflammatory diseases, as well as some malignancies.","Filgotinib | FILGOTINIB | GLPG 0634 | GLPG0634 | GS-6034",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514668","Mismatched Unrelated Donor","C131678","A donor who is not related to the transplant recipient, and who is not a human leukocyte antigen (HLA) tissue type match at one or more of the following loci: HLA-A, HLA-B, HLA-C, and HLA-DRB1.","Mismatched Unrelated Donor | MMUD | Mismatched Non-Related Donor, Mismatched Donor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521647","Matched Unrelated Donor","C131676","A donor who is not related to the transplant recipient, but who is a human leukocyte antigen (HLA) tissue type match.","Matched Unrelated Donor | MUD | Matched Non-Related Donor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556347","PCORnet Reserved","C155814","A code used for PCORNet network-wide activities related to general observation data.","PCORnet Reserved | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554642","Influenza Virus-Specific Culture","C155815","Cell culture conditions that are specific for the growth and identification of influenza virus.","Influenza Virus-Specific Culture | Influenza-Specific Culture | Organism-specific Culture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003015","ACE Inhibitor","C247","Any substance that inhibits angiotensin-converting enzyme (ACE), an enzyme that catalyzes the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in a reduction in angiotensin II and angiotensin II-induced aldosterone secretion, causing vasodilation and natriuresis.","ACE Inhibitor | ACE inhibitor | ACE-inhibitor | Angiotensin-Converting Enzyme Inhibitor | Angiotensin-converting enzyme (ACE) inhibitor medication | angiotensin-converting enzyme inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035067","Renal Artery Stenosis","C123221","Narrowing of a main artery in the kidney.","Renal Artery Stenosis | ",,,,,,,,,,,,,,,"4118795","Renal artery stenosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0521942","Angiotensin II Receptor Antagonist","C66930","A class of agents that act by selectively inhibiting angiotensin II receptor activation in the renin-angiotensin-aldosterone system. Angiotensin II receptor antagonists bind to and block the activation of angiotensin II type 1 (AT1) receptors, thereby reducing production and secretion of aldosterone, amongst other actions. The combined effects result in reduction of blood pressure. Although this class of agents is also used in diabetic nephropathy (kidney damage due to diabetes) and congestive heart failure, it is primarily used for the treatment of hypertension in cases where the patient is intolerant of ACE inhibitor therapy.","Angiotensin II Receptor Antagonist | ARB | Angiotensin II Receptor Antagonists | Angiotensin II Receptor Blocker | Angiotensin II receptor blocker (ARB) medication | Angiotensin Receptor Blockers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448790","Influenzavirus","C53469","A non-taxonomic grouping of orthomyxoviruses capable of causing the respiratory tract infection commonly called the flu.","Influenzavirus | ",,,,,,,,,,,,,,,"37111241","Influenza virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556354","Age-Related Clonal Hematopoiesis","C155821","The gradual, clonal expansion of hematopoietic stem and progenitor cells carrying specific, disruptive, and recurrent genetic variants, in individuals without clear diagnosis of hematological malignancies. It is associated with an increased risk of developing hematologic cancers.","Age-Related Clonal Hematopoiesis | ARCH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555120","TTR Gene Mutation Negative","C154092","A genetic finding indicating that TTR gene mutations have not been detected in a sample.","TTR Gene Mutation Negative | ATTR Gene Mutation Negative | ATTR Wild Type | ATTR Wildtype | ATTR wt | PALB Gene Mutation Negative | Prealbumin, Thyroxine-Binding Gene Mutation Negative | TBPA Gene Mutation Negative | TTR Wild Type | TTR Wildtype | TTR wt | Transthyretin Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987684","Simple nephrectomy","C94460","Surgery to remove one kidney.","Simple Nephrectomy | simple nephrectomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556353","CPT Category II Codes","C155824","A set of supplemental tracking codes that can be used for performance measurement provided by the American Medical Association as part of their Current Procedural Terminology.","CPT Category II Codes | CPT Category II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556509","HCPCS Level I","C155825","Codes used to report medical procedures and professional services provided by the American Medical Association as part of their Current Procedural Terminology.","HCPCS Level I | CPT-4 | Healthcare Financing Administration Common Procedure Coding System Level I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556358","HCPCS Level II","C155826","Codes used to report products, supplies, and services not described by CPT-4 codes.","HCPCS Level II | Healthcare Financing Administration Common Procedure Coding System Level II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556356","HCPCS Level III","C155827","Codes developed by state Medicaid agencies, contractors and private insurers for use in specific programs and jurisdictions.","HCPCS Level III | HCPCS Local Codes | Healthcare Financing Administration Common Procedure Coding System Level III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556357","Rooming","C155828","Placing a patient in a room.","Rooming | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555124","Blasts Under 10,000 of Peripheral Blood White Cells","C154096","A quantitative microscopic finding indicating that less than 10,000 of the total number of nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.","Blasts Under 10,000 of Peripheral Blood White Cells | Absolute Blasts in Peripheral Blood Less Than 10,000 | Absolute Blasts in Peripheral Blood Less Than 10000 | Blasts Less than 10,000 of Peripheral Blood White Cells | Blasts Less than 10000 of Peripheral Blood White Cells | Blasts Under 10,000 in Peripheral Blood White Cells | Blasts Under 10000 in Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555123","Blasts 6-25 Percent of Bone Marrow Nucleated Cells","C154095","A semi-quantitative microscopic finding indicating that between 6 and 25 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 6-25 Percent of Bone Marrow Nucleated Cells | Blasts Between 6 and 25 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555119","Blasts 20 Percent or Less of Peripheral Blood White Cells","C154094","A semi-quantitative microscopic finding indicating that 20 percent or less of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.","Blasts 20 Percent or Less of Peripheral Blood White Cells | Blasts Less than or Equal to 20 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555118","Blasts 0 Percent of Peripheral Blood White Cells","C154093","A semi-quantitative microscopic finding indicating that immature mononuclear cells are not detected when the nucleated cells in a peripheral leukocyte sample were examined.","Blasts 0 Percent of Peripheral Blood White Cells | Blast Cells Not Detected in Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556360","Bronchoalveolar Biopsy Specimen","C155830","Tissue removed from the bronchi and alveoli for microscopic examination.","Bronchoalveolar Biopsy Specimen | BALBX | Bronchoalveolar Biopsy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0444192","Nasopharyngeal Swab Specimen","C155831","A biospecimen collected from the back of the throat by swabbing.","Nasopharyngeal Swab Specimen | NPH | Nasopharyngeal Swab",,,,,,,,,,,,,,,"4122259","Nasopharyngeal swab",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0444146","Nasopharyngeal Wash Specimen","C155832","A biospecimen collected from the back of the throat by washing.","Nasopharyngeal Wash Specimen | NPWASH | Nasopharyngeal Wash",,,,,,,,,,,,,,,"4120338","Nasopharyngeal washings",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556895","Nasal Swab or Nose Specimen","C155833","A biospecimen collected from the nasal passages by swabbing.","Nasal Swab or Nose Specimen | NSWAB | Nasal Swab | Nasal swab | Nose Swab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206289","Nasal Wash Specimen","C155834","A biospecimen collected from the nasal passages by washing.","Nasal Wash Specimen | NWASH | Nasal Wash",,,,,,,,,,,,,,,"762931","Nasal washings",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0439056","Oropharyngeal Swab Specimen","C155835","A biospecimen collected from the oropharynx by swabbing.","Oropharyngeal Swab Specimen | Oropharyngeal Swab | THRT | Throat Swab",,,,,,,,,,,,,,,"37303840|4119519","Oropharyngeal swab|Throat swab",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1707094","CD1a-Positive Neoplastic Cells Present","C43267","An indication that expression of CD1A has been detected in a sample of neoplastic cells.","CD1a-Positive Neoplastic Cells Present | Antigen CD1a-Positive Neoplastic Cells Present | CD1a Antigen-Positive Neoplastic Cells Present | CD1a Molecule-Positive Neoplastic Cells Present | T-Cell Surface Glycoprotein CD1a-Positive Neoplastic Cells Present | T6/Leu-6-Positive Neoplastic Cells Present | Thymocyte Antigen CD1A-Positive Neoplastic Cells Present | hTa1 Thymocyte Antigen-Positive Neoplastic Cells Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555145","CD1A Positive","C154049","An indication that CD1A expression has been detected in a sample.","CD1A Positive | Antigen CD1a Positive | CD1a Antigen Positive | CD1a Molecule Positive | T-Cell Surface Glycoprotein CD1a Positive | T6/Leu-6 Positive | Thymocyte Antigen CD1A Positive | hTa1 Thymocyte Antigen Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555127","C3d Positive","C154106","An indication that C3d expression has been detected in a sample.","C3d Positive | Complement C3d Fragment Positive | Complement C3d Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521186","Esophagus and Esophagogastric Junction Cancer TNM Finding v8","C133365","A finding about one or more characteristics of esophagus and esophagogastric junction cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to carcinomas including squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, undifferentiated carcinoma, neuroendocrine cancers, and adenocarcinoma with neuroendocrine features. Sarcomas, nonepithelial cancers, and gastrointestinal stromal tumors are not staged using this staging system. (from AJCC 8th Ed.)","Esophagus and Esophagogastric Junction Cancer TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521076","Esophagus and Esophagogastric Junction Cancer pT4b TNM Finding v8","C133384","Esophagus and esophagogastric junction cancer with tumor invading other adjacent structures, such as the aorta, vertebral body, or airway. (from AJCC 8th Ed.)","Esophagus and Esophagogastric Junction Cancer pT4b TNM Finding v8 | Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pT4b TNM Finding v8 | pT4b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521075","Esophagus and Esophagogastric Junction Cancer pT4a TNM Finding v8","C133383","Esophagus and esophagogastric junction cancer with tumor invading the pleura, pericardium, azygos vein, diaphragm, or peritoneum. (from AJCC 8th Ed.)","Esophagus and Esophagogastric Junction Cancer pT4a TNM Finding v8 | Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pT4a TNM Finding v8 | pT4a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521074","Esophagus and Esophagogastric Junction Cancer pT4 TNM Finding v8","C133382","Esophagus and esophagogastric junction cancer with tumor invading adjacent structures. (from AJCC 8th Ed.)","Esophagus and Esophagogastric Junction Cancer pT4 TNM Finding v8 | Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pT4 TNM Finding v8 | pT4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521073","Esophagus and Esophagogastric Junction Cancer pT3 TNM Finding v8","C133381","Esophagus and esophagogastric junction cancer with tumor invading adventitia. (from AJCC 8th Ed.)","Esophagus and Esophagogastric Junction Cancer pT3 TNM Finding v8 | Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pT3 TNM Finding v8 | pT3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521072","Esophagus and Esophagogastric Junction Cancer pT2 TNM Finding v8","C133380","Esophagus and esophagogastric junction cancer with tumor invading the muscularis propria. (from AJCC 8th Ed.)","Esophagus and Esophagogastric Junction Cancer pT2 TNM Finding v8 | Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pT2 TNM Finding v8 | pT2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521071","Esophagus and Esophagogastric Junction Cancer pT1b TNM Finding v8","C133379","Esophagus and esophagogastric junction cancer with tumor invading the submucosa. (from AJCC 8th Ed.)","Esophagus and Esophagogastric Junction Cancer pT1b TNM Finding v8 | Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pT1b TNM Finding v8 | pT1b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521070","Esophagus and Esophagogastric Junction Cancer pT1a TNM Finding v8","C133378","Esophagus and esophagogastric junction cancer with tumor invading the lamina propria or muscularis mucosae. (from AJCC 8th Ed.)","Esophagus and Esophagogastric Junction Cancer pT1a TNM Finding v8 | Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pT1a TNM Finding v8 | pT1a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521069","Esophagus and Esophagogastric Junction Cancer pT1 TNM Finding v8","C133377","Esophagus and esophagogastric junction cancer with tumor invading the lamina propria, muscularis mucosae, or submucosa. (from AJCC 8th Ed.)","Esophagus and Esophagogastric Junction Cancer pT1 TNM Finding v8 | Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pT1 TNM Finding v8 | pT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521078","Esophagus and Esophagogastric Junction Cancer pTis TNM Finding v8","C133376","Esophagus and esophagogastric junction cancer with a finding of high-grade dysplasia, defined as malignant cells confined to the epithelium by the basement membrane. (from AJCC 8th Ed.)","Esophagus and Esophagogastric Junction Cancer pTis TNM Finding v8 | Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pTis TNM Finding v8 | pTis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521068","Esophagus and Esophagogastric Junction Cancer pT0 TNM Finding v8","C133375","Esophagus and esophagogastric junction cancer with no evidence of primary tumor. (from AJCC 8th Ed.)","Esophagus and Esophagogastric Junction Cancer pT0 TNM Finding v8 | Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pT0 TNM Finding v8 | pT0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521077","Esophagus and Esophagogastric Junction Cancer pTX TNM Finding v8","C133374","Esophagus and esophagogastric junction cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Esophagus and Esophagogastric Junction Cancer pTX TNM Finding v8 | Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pTX TNM Finding v8 | pTX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555197","Myeloblasts 5 Percent or Less of Bone Marrow Nucleated Cells","C154140","A semi-quantitative microscopic finding indicating that 5 percent or less of the nucleated cells in a bone marrow sample are immature mononuclear cells of myeloid origin.","Myeloblasts 5 Percent or Less of Bone Marrow Nucleated Cells | Myeloblasts Less than or Equal to 5 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555196","CCND1/IGHG1 Fusion Negative","C154139","An indication that CCND1/IGHG1 fusion expression has not been detected in a sample.","CCND1/IGHG1 Fusion Negative | BCL1-IGHG1 Fusion Negative | BCL1-IgH Fusion Negative | BCL1/IGHG1 Fusion Negative | BCL1/IgH Fusion Negative | CCND1-IGH Fusion Negative | CCND1-IGHG1 Fusion Negative | CCND1/IGH Fusion Negative | IGH-CCND1 Fusion Negative | IGH/CCND1 Fusion Negative | IGHG1-CCND1 Fusion Negative | IGHG1/CCND1 Fusion Negative | t(11;14)(IgH/CCND1) Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555193","Type-Specific HPV Antibody","C154138","Any immunoglobulin that recognizes the human papillomavirus serotype(s) in a vaccine following inoculation.","Type-Specific HPV Antibody | HPV Type-Specific Antibody | HPV Type-Specific IgG Antibody | HPV Vaccine-Type-Specific Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555192","BST2 Positive","C154137","An indication that BST2 expression has been detected in a sample.","BST2 Positive | BST-2 Positive | Bone Marrow Stromal Antigen 2 Positive | Bone Marrow Stromal Cell Antigen 2 Positive | CD317 Antigen Positive | CD317 Positive | HM1.24 Antigen Positive | HM1.24 Positive | Tetherin Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555131","HLA-B*1501 Positive Cells Present","C154112","An indication that cells expressing HLA-B*1501 have been detected in a sample.","HLA-B*1501 Positive Cells Present | HLA-B*1501 Positive | HLA-B*15:01 Positive | HLA-B*15:01 Positive Cells Present | HLA-B1501 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517417","Gain of Chromosome 7","C36454","A cytogenetic abnormality that refers to the allelic gain of all or part of chromosome 7.","Gain of Chromosome 7 | Chromosome 7 Gain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521066","Esophagus and Esophagogastric Junction Cancer pN3 TNM Finding v8","C133390","Esophagus and esophagogastric junction cancer with metastasis in seven or more regional lymph nodes. (from AJCC 8th Ed.)","Esophagus and Esophagogastric Junction Cancer pN3 TNM Finding v8 | Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pN3 TNM Finding v8 | pN3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521065","Esophagus and Esophagogastric Junction Cancer pN2 TNM Finding v8","C133389","Esophagus and esophagogastric junction cancer with metastasis in three to six regional lymph nodes. (from AJCC 8th Ed.)","Esophagus and Esophagogastric Junction Cancer pN2 TNM Finding v8 | Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pN2 TNM Finding v8 | pN2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521064","Esophagus and Esophagogastric Junction Cancer pN1 TNM Finding v8","C133388","Esophagus and esophagogastric junction cancer with metastasis in one or two regional lymph nodes. (from AJCC 8th Ed.)","Esophagus and Esophagogastric Junction Cancer pN1 TNM Finding v8 | Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pN1 TNM Finding v8 | pN1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521063","Esophagus and Esophagogastric Junction Cancer pN0 TNM Finding v8","C133387","Esophagus and esophagogastric junction cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","Esophagus and Esophagogastric Junction Cancer pN0 TNM Finding v8 | Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pN0 TNM Finding v8 | pN0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521067","Esophagus and Esophagogastric Junction Cancer pNX TNM Finding v8","C133386","Esophagus and esophagogastric junction cancer in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)","Esophagus and Esophagogastric Junction Cancer pNX TNM Finding v8 | Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pNX TNM Finding v8 | pNX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521062","Esophagus and Esophagogastric Junction Cancer pM1 TNM Finding v8","C133372","Esophagus and esophagogastric junction cancer with distant metastasis. (from AJCC 8th Ed.)","Esophagus and Esophagogastric Junction Cancer pM1 TNM Finding v8 | Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pM1 TNM Finding v8 | pM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521061","Esophagus and Esophagogastric Junction Cancer cM1 TNM Finding v8","C133368","Esophagus and esophagogastric junction cancer with distant metastasis. (from AJCC 8th Ed.)","Esophagus and Esophagogastric Junction Cancer cM1 TNM Finding v8 | Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) cM1 TNM Finding v8 | cM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521060","Esophagus and Esophagogastric Junction Cancer cM0 TNM Finding v8","C133367","Esophagus and esophagogastric junction cancer without evidence of distant metastasis. (from AJCC 8th Ed.)","Esophagus and Esophagogastric Junction Cancer cM0 TNM Finding v8 | Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521043","Esophageal Adenocarcinoma by AJCC v8 Clinical Stage","C133401","A term that refers to the clinical staging of esophageal adenocarcinoma according to the American Joint Committee on Cancer, 8th edition.","Esophageal Adenocarcinoma by AJCC v8 Clinical Stage | Esophageal Adenocarcinoma by AJCC v8 cTNM Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520639","Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8","C133410","Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8 | Stage IVB Esophageal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520635","Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8","C133409","Stage IVA includes: (T1-4a, N2, M0); (T4b, N0-2, M0); (Any T, N3, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8 | Stage IVA Esophageal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520625","Clinical Stage III Esophageal Adenocarcinoma AJCC v8","C133407","Stage III includes: (T2, N1, M0); (T3, N0-1, M0); (T4a, N0-1, M0). T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Stage III Esophageal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520622","Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8","C133406","Stage IIB includes: T2, N0, M0. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8 | Stage IIB Esophageal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520619","Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8","C133405","Stage IIA includes: T1, N1, M0. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8 | Stage IIA Esophageal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520609","Clinical Stage I Esophageal Adenocarcinoma AJCC v8","C133403","Stage I includes: T1, N0, M0. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Clinical Stage I Esophageal Adenocarcinoma AJCC v8 | Stage I Esophageal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520614","Clinical Stage II Esophageal Adenocarcinoma AJCC v8","C133404","Stage II includes: IIA: T1, N1, M0; IIB: T2, N0, M0. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Clinical Stage II Esophageal Adenocarcinoma AJCC v8 | Stage II Esophageal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520605","Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8","C133402","Stage 0 includes: Tis, N0, M0. Tis: High-grade dysplasia, defined as malignant cells confined to the epithelium by the basement membrane. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8 | Stage 0 Esophageal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521044","Esophageal Adenocarcinoma by AJCC v8 Pathologic Stage","C133412","A term that refers to the pathologic staging of esophageal adenocarcinoma according to the American Joint Committee on Cancer, 8th edition.","Esophageal Adenocarcinoma by AJCC v8 Pathologic Stage | Esophageal Adenocarcinoma Tumor Stage Pathologic | Esophageal Adenocarcinoma by AJCC v8 pTNM Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520855","Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8","C133416","Stage IB includes: (T1a, N0, M0, G2); (T1b, N0, M0, G1-2); (T1b, N0, M0, GX). T1a: Tumor invades the lamina propria or muscularis mucosae. T1b: Tumor invades the submucosa. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well-differentiated. GX: Grade cannot be assessed. G2: Moderately differentiated. (AJCC 8th ed.)","Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8 | IB | Stage IB Esophageal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520845","Pathologic Stage 0 Esophageal Adenocarcinoma AJCC v8","C133413","Stage 0 includes: Tis, N0, M0, GN/A. Tis: High-grade dysplasia, defined as malignant cells confined to the epithelium by the basement membrane. N0: No regional lymph node metastasis. M0: No distant metastasis. GN/A: Grade non-applicable. (AJCC 8th ed.)","Pathologic Stage 0 Esophageal Adenocarcinoma AJCC v8 | 0 | Stage 0 Esophageal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562667","Hematopoietic Cell Transplantation-Comorbidity Index","C155842","A tool that predicts overall mortality risk, as well as non-relapse mortality risk, for patients with hematologic malignancies following hematopoietic stem cell transplantation. The index considers 17 categories of organ dysfunction.","Hematopoietic Cell Transplantation-Comorbidity Index | HCT-CI | Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520887","Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8","C133426","Stage IVB includes: Any T, Any N, M1, Any G. M1: Distant metastasis. (AJCC 8th ed.)","Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8 | IVB | Stage IVB Esophageal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520884","Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8","C133425","Stage IVA includes: (T4a, N2, M0, Any G); (T4b, N0-2, M0, Any G); (Any T, N3, M0, Any G). T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8 | IVA | Stage IVA Esophageal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520877","Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8","C133423","Stage IIIB includes: (T2, N2, M0, Any G); (T3, N1-2, M0, Any G); (T4a, N0-1, M0, Any G). T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8 | IIIB | Stage IIIB Esophageal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520874","Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8","C133422","Stage IIIA includes: (T1, N2, M0, Any G); (T2, N1, M0, Any G). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8 | IIIA | Stage IIIA Esophageal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520867","Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8","C133420","Stage IIB includes: (T1, N1, M0, Any G); (T3, N0, M0, Any G). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T3: Tumor invades adventitia. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8 | IIB | Stage IIB Esophageal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520864","Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8","C133419","Stage IIA includes: (T2, N0, M0, G3); (T2, N0, M0, GX). T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. GX: Grade cannot be assessed. G3: Poorly differentiated, undifferentiated. (AJCC 8th ed.)","Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8 | IIA | Stage IIA Esophageal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520858","Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8","C133417","Stage IC includes: (T1, N0, M0, G3); (T2, N0, M0, G1-2). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well-differentiated. G2: Moderately differentiated. G3: Poorly differentiated, undifferentiated. (AJCC 8th ed.)","Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8 | IC | Stage IC Esophageal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017279","GAG Protein","C20588","A protein that is a component of the retroviral core structure.","GAG Protein | Group-Specific Antigen Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521050","Esophageal Squamous Cell Carcinoma by AJCC v8 Clinical Stage","C133444","A term that refers to the clinical staging of esophageal squamous cell carcinoma according to the American Joint Committee on Cancer, 8th edition.","Esophageal Squamous Cell Carcinoma by AJCC v8 Clinical Stage | Esophageal Squamous Cell Carcinoma by AJCC v8 cTNM Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520640","Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8","C133453","Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8 | Stage IVB Esophageal Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520636","Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8","C133452","Stage IVA includes: (T4, N0-2, M0); (Any T, N3, M0). T4: Tumor invades adjacent structures. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8 | Stage IVA Esophageal Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520626","Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8","C133450","Stage III includes: (T3, N1, M0); (T1-3, N2, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8 | Stage III Esophageal Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520615","Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8","C133449","Stage II includes: (T2, N0-1, M0); (T3, N0, M0). T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8 | Stage II Esophageal Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520610","Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8","C133448","Stage I includes: T1, N0-1, M0. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8 | Stage I Esophageal Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520606","Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8","C133447","Stage 0 includes: Tis, N0, M0. Tis: High-grade dysplasia, defined as malignant cells confined to the epithelium by the basement membrane. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8 | Stage 0 Esophageal Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521051","Esophageal Squamous Cell Carcinoma by AJCC v8 Pathologic Stage","C133445","A term that refers to the pathologic staging of esophageal squamous cell carcinoma according to the American Joint Committee on Cancer, 8th edition.","Esophageal Squamous Cell Carcinoma by AJCC v8 Pathologic Stage | Esophageal Squamous Cell Carcinoma Tumor Stage Pathologic | Esophageal Squamous Cell Carcinoma by AJCC v8 pTNM Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520888","Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8","C133542","Stage IVB includes: Any T, Any N, M1, Any G, Tumor location: Any. M1: Distant metastasis. (AJCC 8th ed.)","Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8 | IVB | Stage IVB Esophageal Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520885","Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8","C133541","Stage IVA includes: (T4a, N2, M0, Any G, Tumor location: Any); (T4b, N0-2, M0, Any G, Tumor location: Any); (Any T, N3, M0, Any G, Tumor location: Any). T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8 | IVA | Stage IVA Esophageal Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520878","Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8","C133538","Stage IIIB includes: (T2, N2, M0, Any G, Tumor location: Any); (T3, N1-2, M0, Any G, Tumor location: Any); (T4a, N0-1, M0, Any G, Tumor location: Any). T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8 | IIIB | Stage IIIB Esophageal Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520875","Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8","C133537","Stage IIIA includes: (T1, N2, M0, Any G, Tumor location: Any); (T2, N1, M0, Any G, Tumor location: Any). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8 | IIIA | Stage IIIA Esophageal Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520868","Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8","C133535","Stage IIB includes: (T3, N0, M0, G2-3, Tumor location: Upper/middle); (T3, N0, M0, GX, Tumor location: Any); (T3, N0, M0, Any G, Tumor location: Unknown); (T1, N1, M0, Any G, Tumor location: Any). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T3: Tumor invades adventitia. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. GX: Grade cannot be assessed. G2: Moderately differentiated. G3: Poorly differentiated, undifferentiated (AJCC 8th ed.)","Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8 | IIB | Stage IIB Esophageal Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520865","Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8","C133534","Stage IIA includes: (T2, N0, M0, G2-3, Tumor location: Any); (T2, N0, M0, GX, Tumor location: Any); (T3, N0, M0, Any G, Tumor location: Lower); (T3, N0, M0, G1, Tumor location: Upper/middle). T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. N0: No regional lymph node metastasis. M0: No distant metastasis. GX: Grade cannot be assessed. G1: Well-differentiated. G2: Moderately differentiated. G3: Poorly differentiated, undifferentiated. (AJCC 8th ed.)","Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8 | IIA | Stage IIA Esophageal Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520856","Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC v8","C133530","Stage IB includes: (T1a, N0, M0, G2-3, Tumor location: Any); (T1b, N0, M0, G1-3, Tumor location: Any); (T1b, N0, M0, GX, Tumor location: Any); (T2, N0, M0, G1, Tumor location: Any). T1a: Tumor invades the lamina propria or muscularis mucosae. T1b: Tumor invades the submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well-differentiated. GX: Grade cannot be assessed. G2: Moderately differentiated. G3: Poorly differentiated, undifferentiated. (AJCC 8th ed.)","Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC v8 | IB | Stage IB Esophageal Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520853","Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC v8","C133525","Stage IA includes: (T1a, N0, M0, G1, Tumor location: Any); (T1a, N0, M0, GX, Tumor location: Any). T1a: Tumor invades the lamina propria or muscularis mucosae. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well-differentiated. GX: Grade cannot be assessed. (AJCC 8th ed.)","Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC v8 | IA | Stage IA Esophageal Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520846","Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8","C133519","Stage 0 includes: Tis, N0, M0, GN/A, Tumor location: Any. Tis: High-grade dysplasia, defined as malignant cells confined to the epithelium by the basement membrane. N0: No regional lymph node metastasis. M0: No distant metastasis. GN/A: Grade non-applicable. (AJCC 8th ed.)","Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8 | 0 | Stage 0 Esophageal Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555200","PTEN Negative","C154154","An indication that PTEN expression or activity has not been detected in a sample.","PTEN Negative | MMAC1 Negative | Mutated in Multiple Advanced Cancers 1 Negative | PTEN Loss | PTEN Tyrosine Phosphatase Negative | PTEN1 Negative | Phosphatase and Tensin Homolog Negative | Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555201","PTEN Positive","C154152","An indication that PTEN expression has been detected in a sample.","PTEN Positive | MMAC1 Positive | Mutated in Multiple Advanced Cancers 1 Positive | PTEN Tyrosine Phosphatase Positive | PTEN1 Positive | Phosphatase and Tensin Homolog Positive | Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555199","PARP2 Gene Mutation","C154148","A change in the nucleotide sequence of the PARP2 gene.","PARP2 Gene Mutation | ADPRT 2 Gene Mutation | ADPRT2 Gene Mutation | ADPRTL2 Gene Mutation | ADPRTL3 Gene Mutation | ARTD2 Gene Mutation | PARP-2 Gene Mutation | Poly (ADP Ribose) Polymerase 2 Gene Mutation | Poly (ADP-Ribose) Polymerase 2 Gene Mutation | Poly(ADP-Ribose) Polymerase 2 Gene Mutation | pADPRT-2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555198","PARP1 Gene Mutation","C154144","A change in the nucleotide sequence of the PARP1 gene.","PARP1 Gene Mutation | ADPRT 1 Gene Mutation | ADPRT Gene Mutation | ADPRT1 Gene Mutation | ARTD1 Gene Mutation | PARP Gene Mutation | PARP-1 Gene Mutation | PPOL Gene Mutation | Poly (ADP Ribose) Polymerase 1 Gene Mutation | Poly (ADP-Ribose) Polymerase 1 Gene Mutation | Poly (ADP-Ribose) Polymerase Gene Mutation | Poly(ADP-Ribose) Polymerase 1 Gene Mutation | Poly(ADP-Ribose) Polymerase Gene Mutation | pADPRT-1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711250","NOTCH1 Gene Mutation","C45403","A change in the nucleotide sequence of the NOTCH1 gene.","NOTCH1 Gene Mutation | Notch 1 Gene Mutation | Notch Homolog 1 Gene Mutation | Notch, Drosophila, Homolog of, 1 Gene Mutation | TAN1 Gene Mutation | hN1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4068450","Able to Run 5 Miles","C155853","A question about whether an individual is or was able to run 5 miles (8km).","Able to Run 5 Miles Question | 'Able to Run 5 Miles' | Able to Run 5 Miles | Are you able to run five miles (8 km)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562674","Able to Remove a Heavy Suitcase","C155854","A question about whether an individual is or was able to remove a heavy suitcase from an overhead location.","Able to Remove a Heavy Suitcase Question | Able to Remove a Heavy Suitcase | Able to Remove a Heavy Suitcase | Are you able to remove a heavy suitcase (50 lbs/25 kg) from an overhead bin on an airplane or bus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562675","Have Trouble Multitasking","C155855","A question about whether an individual has or had trouble multitasking.","Have Trouble Multitasking | Have Difficulty Multitasking | I have had difficulty multi-tasking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984277","Chronic Myeloid Leukemia Pathway","C91465","Chronic myelogenous leukaemia (CML) is a biphasic disease, initiated by expression of the BCR/ABL fusion gene product in self-renewing, haematopoietic stem cells (HSCs). HSCs can differentiate into common myeloid progenitors (CMPs), which then differentiate into granulocyte/macrophage progenitors (GMPs). HSCs can also differentiate into common lymphoid progenitors (CLPs), which are the progenitors of lymphocytes such as T cells and B cells. The initial chronic phase of CML (CML-CP) is characterized by a massive expansion of the granulocytic-cell series. Acquisition of additional genetic mutations beyond expression of BCR/ABL causes the progression of CML from chronic phase to blast phase (CML-BP), characterized by an accumulation of myeloid or lymphoid blast cells.","Chronic Myeloid Leukemia Pathway | CML Pathway | Chronic myeloid leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515845","ALK Kinase Overexpression","C38656","A molecular abnormality indicating that the tyrosine kinase activity of the ALK tyrosine kinase receptor protein is expressed at abnormally high levels.","ALK Kinase Overexpression | ALK Kinase Upregulation | Anaplastic Lymphoma Kinase Overexpression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555202","HLA Phenotype Positive","C154157","An indication that a subject's human leukocyte antigen (HLA) complex expression profile is appropriate for inclusion in a study.","HLA Phenotype Positive | HLA Positive | Human Leukocyte Antigen Phenotype Positive | Human Leukocyte Antigen Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555205","Testosterone Greater than 150 ng/dL","C154156","A semiquantitative finding indicating that the concentration of testosterone in a sample is greater than 150 ng/dL.","Testosterone Greater than 150 ng/dL | Testosterone Greater than 150 | Testosterone Greater than 150 Nanograms per Deciliter | Testosterone Greater than 150 Nanograms/Deciliter | Testosterone Level Greater than 150",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555204","Tumor-Associated Peptide Antigens Present","C154155","An indication that expression of part or all of a study-specific panel of tumor-associated peptide antigens has been detected in a sample.","Tumor-Associated Peptide Antigens Present | TAPA Positive | Tumor Associated Peptide Antigens Positive | Tumor Associated Peptide Antigens Present | Tumor-Associated Peptide Antigens Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515852","RUNX1 Gene Mutation","C38362","A change in the nucleotide sequence of the RUNX1 gene.","RUNX1 Gene Mutation | AML1 Gene Mutation | AML1 Mutation | AMLCR1 Gene Mutation | Acute Myeloid Leukemia 1 Gene Mutation | CBFA2 Gene Mutation | CBFalpha2 Mutation | RUNX1 | RUNX1 Mutation | Runt-Related Transcription Factor 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709812","RECQL4 Gene Mutation","C53977","A change in the nucleotide sequence of the RECQL4 gene.","RECQL4 Gene Mutation | RECQ4 Gene Mutation | RecQ Helicase-Like 4 Gene Mutation | RecQ Like Helicase 4 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229657","Plasmablast","C37082","A population of antibody-secreting cells in the blood that are highly proliferative and may act as precursors for plasma cells.","Plasmablast | ",,,,,,,,,,,,,,,"4093269","Plasmablast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2826246","Subsequent Trial Activity","C82511","An indication or description of the next trial activity.","Subsequent Trial Activity | NEXT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555171","GEN1 Gene Mutation","C154229","A change in the nucleotide sequence of the GEN1 gene.","GEN1 Gene Mutation | GEN1 Holliday Junction 5' Flap Endonuclease Gene Mutation | Gen Gene Mutation | Gen Homolog 1, Endonuclease Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555170","ABRAXAS1 Gene Mutation","C154228","A change in the nucleotide sequence of the ABRAXAS1 gene.","ABRAXAS1 Gene Mutation | ABRA1 Gene Mutation | ABRAXAS Gene Mutation | Abraxas 1, BRCA1 A Complex Subunit Gene Mutation | CCDC98 Gene Mutation | FAM175A Gene Mutation | Family with Sequence Similarity 175 Member A Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555166","ERCC3 Gene Mutation","C154227","A change in the nucleotide sequence of the ERCC3 gene.","ERCC3 Gene Mutation | BTF2 Gene Mutation | ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit Gene Mutation | Excision Repair Cross-Complementation Group 3 Gene Mutation | Excision Repair Cross-Complementing Rodent Repair Deficiency, Complementation Group 3 Gene Mutation | Excision-Repair, Complementing Defective, in Chinese Hamster, 3 Gene Mutation | GTF2H Gene Mutation | RAD25 Gene Mutation | TTD2 Gene Mutation | XPB Gene Mutation | Xeroderma Pigmentosum Group B Complementing Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555206","BRAF Gene Rearrangement","C154159","A molecular abnormality indicating rearrangement of the BRAF gene.","BRAF Gene Rearrangement | B-RAF Gene Rearrangement | B-RAF1 Gene Rearrangement | BRAF Rearrangement | Positive | Rearrangement identified | v-raf Murine Sarcoma Viral Oncogene Homolog B1 Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555203","FGFR1 Positive","C154158","An indication that FGFR1 expression has been detected in a sample.","FGFR1 Positive | BFGFR Positive | CD331 Positive | CEK Positive | FGFBR Positive | FGFR-1 Positive | FLG Positive | FLT-2 Positive | FLT2 Positive | FMS-Like Tyrosine Kinase 2 Positive | Fibroblast Growth Factor Receptor 1 Positive | KAL2 Positive | N-SAM Positive | OGD Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511012","BH3 Domain","C13914","The alpha-helical BH3 domain (9 amino acids) represents a minimal death domain and is essential for the activity of pro-apoptotic members of the bcl-2 family. Some of these proteins only contain a BH3 domain.","BH3 Domain | BH-3 | BH3 | Bcl-2 Homology Domain 3 | Bcl-2 Homology Domain-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273353","ASXL1 Gene Mutation","C97313","A molecular genetic abnormality that refers to the presence of a mutation in the ASXL1 gene.","ASXL1 Gene Mutation | ASXL Transcriptional Regulator 1 Gene Mutation | Additional Sex Combs Like 1 Gene Mutation | Additional Sex Combs Like 1, Transcriptional Regulator 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555168","HDAC2 Gene Mutation","C154230","A change in the nucleotide sequence of the HDAC2 gene.","HDAC2 Gene Mutation | HD2 Gene Mutation | Histone Deacetylase 2 Gene Mutation | RPD3 Gene Mutation | YAF1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273352","ETV6 Gene Mutation","C97312","A molecular genetic abnormality that refers to the presence of a mutation in the ETV6 gene (ETS variant gene 6).","ETV6 Gene Mutation | ETS Variant 6 Gene Mutation | ETS Variant Gene 6 Mutation | TEL Gene Mutation | TEL Oncogene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523046","EGFR NP_005219.2:p.S492R","C135731","A change in the amino acid residue at position 492 in the epidermal growth factor receptor protein where serine has been replaced by arginine.","EGFR NP_005219.2:p.S492R | EGFR NP_005219.2:p.Ser492Arg | EGFR S492R | EGFR S492R Mutation | EGFR Ser492Arg | EGFR p.S492R | EGFR p.Ser492Arg | Epidermal Growth Factor Receptor S492R | Epidermal Growth Factor Receptor Ser492Arg | NP_005219.2:p.Ser492Arg | Proto-Oncogene c-ErbB-1 S492R | Proto-Oncogene c-ErbB-1 Ser492Arg | Receptor Tyrosine-Protein Kinase erbB-1 S492R | Receptor Tyrosine-Protein Kinase erbB-1 Ser492Arg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522233","CD2 Positive","C134701","An indication that CD2 expression has been detected in a sample.","CD2 Positive | CD2 Molecule Positive | LFA-2 Positive | T11 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512104","CALR Gene Mutation","C128816","A change in the nucleotide sequence of the CALR gene.","CALR Gene Mutation | Autoantigen Ro Gene Mutation | CALR Mutation | CRT Gene Mutation | Calreticulin Gene Mutation | RO Gene Mutation | cC1qR Gene Mutation | mutCALR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514260","BRCA2 Protein Variant","C131468","A variation in the amino acid sequence for breast cancer type 2 susceptibility protein.","BRCA2 Protein Variant | BRCA1/BRCA2-Containing Complex, Subunit 2 Protein Variant | Breast Cancer 2 Tumor Suppressor Protein Variant | Breast Cancer 2, Early Onset Protein Variant | Breast Cancer Type 2 Susceptibility Protein Variant | Breast and Ovarian Cancer Susceptibility Protein 2 Protein Variant | Fanconi Anemia Group D1 Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514258","BRCA1 Protein Variant","C131467","A variation in the amino acid sequence for breast cancer type 1 susceptibility protein.","BRCA1 Protein Variant | BRCA1/BRCA2-Containing Complex, Subunit 1 Protein Variant | Breast Cancer Type 1 Susceptibility Protein Variant | Breast and Ovarian Cancer Susceptibility Protein 1 Protein Variant | Breast-Ovarian Cancer Protein Variant | Fanconi Anemia, Complementation Group S Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706890","BLM Gene Mutation","C43287","A change in the nucleotide sequence of the BLM gene.","BLM Gene Mutation | BS Gene Mutation | Bloom Syndrome Gene Mutation | RECQ2 Gene Mutation | RECQL2 Gene Mutation | RECQL3 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562691","MD Anderson Symptom Inventory - Gastrointestinal","C155889","A site-specific MDASI module that assesses 5 symptoms specific to gastrointestinal cancer: constipation, diarrhea or watery stools, difficulty swallowing, change in taste, and feeling bloated.","MD Anderson Symptom Inventory - Gastrointestinal | MD Anderson Symptom Inventory - GI | MD Anderson Symptom Inventory Gastrointestinal Cancer Module | MDASI-GI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562692","Diarrhea or Watery Stools via Stoma at its Worst","C155890","A question about an individual's diarrhea, or watery stools, via stoma at its worst.","Diarrhea or Watery Stools via Stoma at its Worst | Your diarrhea, or watery stools via stoma (abdominal opening) at its worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562693","Change in Taste at its Worst","C155891","A question about an individual's change in taste at its worst.","Change in Taste at its Worst | Your change in taste at its worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562694","Feeling Bloated at its Worst","C155892","A question about an individual's bloated feeling at its worst.","Feeling Bloated at its Worst | Your feeling bloated at its worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562777","Inability to Eat at its Worst","C155893","A question about an individual's inability to eat at its worst.","Inability to Eat at its Worst | Your inability to eat at its worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562778","Sore Mouth or Throat at its Worst","C155894","A question about an individual's sore mouth or throat at its worst.","Sore Mouth or Throat at its Worst | Your sore mouth or throat at its worst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697646","IKZF1 Gene Mutation","C79425","A change in the nucleotide sequence of the IKZF1 gene.","IKZF1 Gene Mutation | IK1 Gene Mutation | IKAROS Family Zinc Finger 1 Gene Mutation | IKAROS Gene Mutation | LYF1 Gene Mutation | LyF-1 Gene Mutation | ZNFN1A1 Gene Mutation | hIk-1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019588","Histamine","C73238","A substance that has many effects in the body. It is released from some types of white blood cells during allergic reactions. It causes small blood vessels to dilate (widen) and become leaky, which can cause tissues to swell. It also causes smooth muscles to contract, gastric acid to be made, and the heart rate to increase. Histamine is used in tests for allergies, asthma, and gastric acid secretion. It is a type of neurotransmitter.","Histamine | 1H-Imidazole-4-ethanamine | 2-(4-Imidazolyl)ethylamine | 4-(2-Aminoethyl)-1H-imidazole | 5-Imidazoleethylamine | HISTAMINE | histamine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708260","GNAS Gene Mutation","C45930","A change in the nucleotide sequence of the GNAS gene.","GNAS Gene Mutation | GNAS Complex Locus Gene Mutation | GNAS1 Gene Mutation | Gsalpha Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826105","GATA1 Gene Mutation","C82340","A change in the nucleotide sequence of the GATA1 gene.","GATA1 Gene Mutation | ERYF1 Gene Mutation | GATA Binding Protein 1 Gene Mutation | GATA-1 | GATA-1 Gene Mutation | GATA1 Mutation | GF-1 Gene Mutation | GF1 Gene Mutation | NF-E1 Gene Mutation | NFE1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268689","Vitamin D 1 Alpha-Hydroxylase Deficiency","C131073","An autosomal recessive form of rickets caused by inactivating mutation(s) in the CYP27B1 gene, encoding 25-hydroxyvitamin D-1 alpha hydroxylase, the renal enzyme that converts 25-hydroxyvitamin D to 1 alpha,25-dihydroxyvitamin D (calcitriol), the active metabolite of vitamin D (cholecalciferol). The condition is characterized by reduced serum concentrations of 1 alpha,25-hydroxyvitamin D, normal concentrations of 25-hydroxyvitamin D, increased serum alkaline phosphatase, hypocalcemia due to reduced intestinal calcium absorption, hypophosphatemia due to renal phosphate wasting, secondary hyperparathyroidism, rickets, seizures, muscle weakness and failure to thrive.","Vitamin D 1 Alpha-Hydroxylase Deficiency | 1 Alpha-hydroxylase Deficiency | Pseudo Vitamin-D Deficient Rickets | Selective 1-alpha, 25-hydroxyvitamin D3 deficiency | VDDR1 | Vitamin D Hydroxylation-deficient Rickets type 1a | Vitamin D-Dependent Rickets Type 1 | Vitamin D-dependent Rickets Type 1",,,,,,,,,,,,,,,"4282453","Vitamin D-dependent rickets, type 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2697603","t(14;18) Positive","C80161","A cytogenetic finding indicating that the translocation (14;18) is present in cells.","t(14;18) Positive | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086760","Quantifiable MRD Positivity","C124432","Presence of quantifiable residual disease based on laboratory techniques.","Quantifiable Measurable Residual Disease Positivity | QUANTIFIABLE MRD POSITIVITY | Quantifiable MRD Positivity | Quantifiable Minimal Residual Disease Positivity | Quantifiable Minimal Residual Disease Positivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551020","NOTCH2 Gene Mutation","C148389","A change in the nucleotide sequence of the NOTCH2 gene.","NOTCH2 Gene Mutation | AGS2 Gene Mutation | HJCYS Gene Mutation | Notch 2 Gene Mutation | Notch Homolog 2 Gene Mutation | hN2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417061","MC1R Gene","C48825","This gene plays a role in epidermal development and regulation of melanogenesis.","MC1R Gene | MC1R | Melanocortin 1 Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539349","Rai Stage","C141207","A stage term that refers to the modified Rai staging system which is used for the staging of chronic lymphocytic leukemia.","Rai Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563228","CYP3A5 Inducer","C155913","Any substance capable of increasing the activity of cytochrome P450 3A5.","CYP3A5 Inducer | Cytochrome P450 3A5 Inducer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3850054","Cytochrome P 450 CYP3A5 Inhibitors","C155914","Any substance capable of decreasing the activity of cytochrome P450 3A5.","CYP3A5 Inhibitor | Cytochrome P450 3A5 Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562786","CYP3A4 Substrate","C155915","Any substance that is metabolized by cytochrome P450 3A4.","CYP3A4 Substrate | CYP3A4 Sensitive Substrate | Cytochrome P450 3A4 Substrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562787","CYP3A5 Substrate","C155916","Any substance that is metabolized by cytochrome P450 3A5.","CYP3A5 Substrate | Cytochrome P450 3A5 Substrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811746","SLC47A1 wt Allele","C113565","Human SLC47A1 wild-type allele is located in the vicinity of 17p11.2 and is approximately 84 kb in length. This allele, which encodes multidrug and toxin extrusion protein 1, is involved in solute transport of cationic drugs across brush border membranes. Mutations in this gene are associated with Smith-Magenis syndrome and lactic acidosis.","SLC47A1 wt Allele | FLJ10847 | MATE-1 | MATE1 | Solute Carrier Family 47 (Multidrug and Toxin Extrusion), Member 1 wt Allele | hMATE-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811747","SLC47A2 wt Allele","C113568","Human SLC47A2 wild-type allele is located in the vicinity of 17p11.2 and is approximately 41 kb in length. This allele, which encodes multidrug and toxin extrusion protein 2, plays a role in both secretion of cationic drugs across brush border membranes and excretion of toxic electrolytes through urine and bile.","SLC47A2 wt Allele | FLJ31196 | MATE-2 | MATE2 | MATE2-B | MATE2-K | MATE2K | Solute Carrier Family 47 (Multidrug and Toxin Extrusion), Member 2 wt Allele | hMATE-2 | hMATE2-K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0451184","Geriatric Depression Scale Questionnaire","C106697","A standardized rating scale developed by Yesavage et al in 1983, which is a self-report assessment used to identify depression in older adults. The questionnaire contains 30 items. All questions are answered 'yes' or 'no'.","Geriatric Depression Scale Questionnaire | GDS | GDS01",,,,,,,,,,,,,,,"4159706","Geriatric depression scale",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555130","HLA-B*4601 Positive Cells Present","C154113","An indication that cells expressing HLA-B*4601 have been detected in a sample.","HLA-B*4601 Positive Cells Present | HLA-B*4601 Positive | HLA-B*46:01 Positive | HLA-B*46:01 Positive Cells Present | HLA-B4601 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555121","Blasts More than 60 Percent of Bone Marrow Nucleated Cells","C154097","A semi-quantitative microscopic finding indicating that more than 60 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts More than 60 Percent of Bone Marrow Nucleated Cells | Blasts Greater than 60 Percent of Bone Marrow Nucleated Cells | Blasts Over 60 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086747","Positive and Negative Syndrome Scale Clinical Classification","C124712","A standardized rating scale developed by Kay et al in 1987, which is a classification system used to measure severity of patients with schizophrenia. This instrument rates a patient on a scale of 1 (absent) to 7 (extreme) on 30 different symptoms.","Positive and Negative Syndrome Scale Clinical Classification | PANSS | PANSS1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562781","Suppressive Antiviral Therapy","C155924","Ongoing antiviral therapy to reduce the frequency of recurrence or prevent transmission.","Suppressive Antiviral Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562782","Upfront Treatment","C155925","The initial treatment for a disease.","Upfront Treatment | Up-front Setting | Up-front Treatment | Up-front Treatment Setting | Upfront Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562803","Sleep Disturbance Scale for Children","C155928","A 27-item parent-administered instrument, developed by Bruni et al. in 1996, that utilizes a 5-point Likert rating scale to assess sleep disorders in children.","Sleep Disturbance Scale for Children | SDSC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562804","Cornell Scale for Depression in Dementia","C155929","A 19-item clinician-administered instrument, developed by Alexopoulos et al. in 1986, that utilizes a three-point rating scale to assess signs and symptoms of major depression in patients with dementia, based on interviews with both the patient and a caregiver.","Cornell Scale for Depression in Dementia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562805","Myeloid Mutation Panel","C155930","An assay based on next-generation sequencing techniques designed to detect one or more genetic abnormalities in a set of genes that may have diagnostic, prognostic or therapeutic significance in acute myeloid leukemia, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN) or MDS/MPN overlap disorders.","Myeloid Mutation Panel | Myeloid Molecular Profile | Myeloid Molecular Profiling | Myeloid Panel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514062","Hematologic Neoplasm with Germline Predisposition","C130038","A term that refers to myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms, and acute myeloid leukemias that are associated with germline mutations and are familial.","Hematologic Neoplasm with Germline Predisposition | Myeloid Neoplasm with Germline Predisposition | Myeloid Neoplasms with Germline Predisposition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447291","Sixty Nine","C105793","A natural number greater than sixty-eight and less than seventy and the quantity that it denotes.","Sixty Nine | 69 | Sixty-Nine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562799","Modified Ryan Scheme for Tumor Regression","C155939","A four-point tumor regression grading system that is used to measure therapeutic response of primary tumors and to predict patient outcomes.","Modified Ryan Scheme for Tumor Regression | Ryan TRG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562793","Tumor Regression Score 0","C155941","A score on the Modified Ryan Scheme for Tumor Regression that indicates a complete response, defined as having no viable cancer cells.","Tumor Regression Score 0 | 0 | Complete Response Score 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562794","Tumor Regression Score 1","C155942","A score on the Modified Ryan Scheme for Tumor Regression that indicates a near complete response, defined as the presence of single cells or rare small groups of cancer cells.","Tumor Regression Score 1 | 1 | Near Complete Response Score 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562795","Tumor Regression Score 2","C155943","A score on the Modified Ryan Scheme for Tumor Regression that indicates a partial response, defined as the presence of residual cancer with evident tumor regression but more than single cells or rare small groups of cancer cells.","Tumor Regression Score 2 | 2 | Partial Response Score 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562817","Tumor Regression Score 3","C155944","A score on the Modified Ryan Scheme for Tumor Regression that indicates poor or no response, defined as extensive residual cancer with no evident tumor regression.","Tumor Regression Score 3 | 3 | Poor or No Response Score 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3472495","Children's Global Assessment Scale","C155932","A clinician-assessed rating of psychological and social functioning in children ages six to seventeen that was developed by Shaffer et al. in 1983. The numerical scale, which is an adaptation of the adult Global Assessment Scale (GAS) developed by Endicott et al in 1976, is scored from 0 to 100 based on behaviors and life situations that are applicable to children.","Children's Global Assessment Scale | CGAS | Cildren's Global Assessment Scale",,,,,,,,,,,,,,,"42872748","Children's global assessment scale",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3539655","CDISC Findings Class","C103373","This SDTM class captures the observations resulting from planned evaluations to address specific tests or questions such as laboratory tests, ECG testing, and questions listed on questionnaires.","CDISC Findings Class | FINDINGS | Findings",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0450254","Pathogen","C80324","An agent of disease; a disease producer.","Pathogen | Pathogenic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899938","Blastic Phase","C115160","Sudden increase of the number of blasts in the bone marrow and/or peripheral blood in a patient with a history of chronic leukemia.","Blastic Phase | Blast Crisis | Blast Phase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0549414","Blast Cell Proliferation","C18061","Multiplication or reproduction by cell division of immature precursor cells that have not achieved a fully differentiated state. (NCI)","Blast Cell Proliferation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036776","Serum Alkaline Phosphatase Measurement","C61016","A quantitative measurement of the amount of alkaline phosphatase present in a sample of serum.","Serum Alkaline Phosphatase Measurement | ",,,,,,,,,,,,,,,"4156813","Serum alkaline phosphatase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205832","Merkel Cell","C12592","An epidermal cell, primarily located in the basal layer, that is thought to function in tactile sensory perception.","Merkel Cell | Merkel Cells | Merkel cell",,,,,,,,,,,,,,,"4007384","Merkel's cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL524663","Merkel Cell Carcinoma TNM Finding v8","C136832","A finding about one or more characteristics of Merkel cell carcinoma (primary cutaneous neuroendocrine carcinoma), following the rules of the TNM AJCC v8 classification system. (from AJCC 8th Ed.)","Merkel Cell Carcinoma TNM Finding v8 | Neuroendocrine Carcinoma of the Skin TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524642","Merkel Cell Carcinoma Tis TNM Finding v8","C136843","Merkel cell carcinoma with a finding of in situ primary tumor. (from AJCC 8th Ed.)","Merkel Cell Carcinoma Tis TNM Finding v8 | Neuroendocrine Carcinoma of the Skin Tis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524646","Merkel Cell Carcinoma cT4 TNM Finding v8","C136847","Merkel cell carcinoma with primary tumor invading fascia, muscle, cartilage, or bone. (from AJCC 8th Ed.)","Merkel Cell Carcinoma cT4 TNM Finding v8 | Neuroendocrine Carcinoma of the Skin cT4 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524645","Merkel Cell Carcinoma cT3 TNM Finding v8","C136846","Merkel cell carcinoma with maximum clinical tumor diameter more than 5 cm. (from AJCC 8th Ed.)","Merkel Cell Carcinoma cT3 TNM Finding v8 | Neuroendocrine Carcinoma of the Skin cT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524648","Merkel Cell Carcinoma cT2 TNM Finding v8","C136845","Merkel cell carcinoma with maximum clinical tumor diameter more than 2 cm but equal to or less than 5 cm. (from AJCC 8th Ed.)","Merkel Cell Carcinoma cT2 TNM Finding v8 | Neuroendocrine Carcinoma of the Skin cT2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524647","Merkel Cell Carcinoma cT1 TNM Finding v8","C136844","Merkel cell carcinoma with maximum clinical tumor diameter equal to or less than 2 cm. (from AJCC 8th Ed.)","Merkel Cell Carcinoma cT1 TNM Finding v8 | Neuroendocrine Carcinoma of the Skin cT1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524641","Merkel Cell Carcinoma cT0 TNM Finding v8","C136842","Merkel cell carcinoma with no evidence of primary tumor. (from AJCC 8th Ed.)","Merkel Cell Carcinoma cT0 TNM Finding v8 | Neuroendocrine Carcinoma of the Skin cT0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524644","Merkel Cell Carcinoma cTX TNM Finding v8","C136841","Merkel cell carcinoma in which the primary tumor cannot be assessed (e.g., curetted). (from AJCC 8th Ed.)","Merkel Cell Carcinoma cTX TNM Finding v8 | Neuroendocrine Carcinoma of the Skin cTX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524624","Merkel Cell Carcinoma cN3 TNM Finding v8","C136853","Merkel cell carcinoma with in-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) with lymph node metastasis. (from AJCC 8th Ed.)","Merkel Cell Carcinoma cN3 TNM Finding v8 | Neuroendocrine Carcinoma of the Skin cN3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524623","Merkel Cell Carcinoma cN2 TNM Finding v8","C136852","Merkel cell carcinoma with in-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) without lymph node metastasis. (from AJCC 8th Ed.)","Merkel Cell Carcinoma cN2 TNM Finding v8 | Neuroendocrine Carcinoma of the Skin cN2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524650","Merkel Cell Carcinoma cN1 TNM Finding v8","C136851","Merkel cell carcinoma with metastasis in regional lymph node(s). (from AJCC 8th Ed.)","Merkel Cell Carcinoma cN1 TNM Finding v8 | Neuroendocrine Carcinoma of the Skin cN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524649","Merkel Cell Carcinoma cN0 TNM Finding v8","C136850","Merkel cell carcinoma without regional lymph node metastasis detected on clinical and/or radiologic examination. (from AJCC 8th Ed.)","Merkel Cell Carcinoma cN0 TNM Finding v8 | Neuroendocrine Carcinoma of the Skin cN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524652","Merkel Cell Carcinoma cNX TNM Finding v8","C136849","Merkel cell carcinoma in which the regional lymph nodes cannot be clinically assessed (e.g., previously removed for another reason, or because of body habitus). (from AJCC 8th Ed.)","Merkel Cell Carcinoma cNX TNM Finding v8 | Neuroendocrine Carcinoma of the Skin cNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524651","Merkel Cell Carcinoma Clinical Regional Lymph Nodes TNM Finding v8","C136848","A clinical finding about one or more characteristics of Merkel cell carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Merkel Cell Carcinoma Clinical Regional Lymph Nodes TNM Finding v8 | Neuroendocrine Carcinoma of the Skin Clinical Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524661","Merkel Cell Carcinoma Clinical Distant Metastasis TNM Finding v8","C136834","A clinical finding about one or more characteristics of Merkel cell carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Merkel Cell Carcinoma Clinical Distant Metastasis TNM Finding v8 | Neuroendocrine Carcinoma of the Skin Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524627","Merkel Cell Carcinoma pM1 TNM Finding v8","C136856","Merkel cell carcinoma with distant metastasis microscopically confirmed. (from AJCC 8th Ed.)","Merkel Cell Carcinoma pM1 TNM Finding v8 | Neuroendocrine Carcinoma of the Skin pM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524638","Merkel Cell Carcinoma cM1c TNM Finding v8","C136839","Merkel cell carcinoma with metastasis to all other visceral sites. (from AJCC 8th Ed.)","Merkel Cell Carcinoma cM1c TNM Finding v8 | Neuroendocrine Carcinoma of the Skin cM1c TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524637","Merkel Cell Carcinoma cM1b TNM Finding v8","C136838","Merkel cell carcinoma with metastasis to lung. (from AJCC 8th Ed.)","Merkel Cell Carcinoma cM1b TNM Finding v8 | Neuroendocrine Carcinoma of the Skin cM1b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524640","Merkel Cell Carcinoma cM1a TNM Finding v8","C136837","Merkel cell carcinoma with metastasis to distant skin, distant subcutaneous tissue, or distant lymph node(s). (from AJCC 8th Ed.)","Merkel Cell Carcinoma cM1a TNM Finding v8 | Neuroendocrine Carcinoma of the Skin cM1a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524639","Merkel Cell Carcinoma cM1 TNM Finding v8","C136836","Merkel cell carcinoma with distant metastasis detected on clinical and/or radiologic examination. (from AJCC 8th Ed.)","Merkel Cell Carcinoma cM1 TNM Finding v8 | Neuroendocrine Carcinoma of the Skin cM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524662","Merkel Cell Carcinoma cM0 TNM Finding v8","C136835","Merkel cell carcinoma without distant metastasis detected on clinical and/or radiologic examination. (from AJCC 8th Ed.)","Merkel Cell Carcinoma cM0 TNM Finding v8 | Neuroendocrine Carcinoma of the Skin cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524631","Merkel Cell Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8","C136860","A pathologic finding about one or more characteristics of Merkel cell carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Merkel Cell Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8 | Neuroendocrine Carcinoma of the Skin Pathologic Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524730","Merkel Cell Carcinoma pN3 TNM Finding v8","C136868","Merkel cell carcinoma with in-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) with lymph node metastasis. (from AJCC 8th Ed.)","Merkel Cell Carcinoma pN3 TNM Finding v8 | Neuroendocrine Carcinoma of the Skin pN3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524634","Merkel Cell Carcinoma pN2 TNM Finding v8","C136867","Merkel cell carcinoma with in-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) without lymph node metastasis. (from AJCC 8th Ed.)","Merkel Cell Carcinoma pN2 TNM Finding v8 | Neuroendocrine Carcinoma of the Skin pN2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524633","Merkel Cell Carcinoma pN1b TNM Finding v8","C136866","Merkel cell carcinoma with clinically and/or radiologically detected regional lymph node metastasis, microscopically confirmed. (from AJCC 8th Ed.)","Merkel Cell Carcinoma pN1b TNM Finding v8 | Neuroendocrine Carcinoma of the Skin pN1b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524635","Merkel Cell Carcinoma pN1a(sn) TNM Finding v8","C136864","Merkel cell carcinoma with clinically occult regional lymph node metastasis identified only by sentinel lymph node biopsy. (from AJCC 8th Ed.)","Merkel Cell Carcinoma pN1a(sn) TNM Finding v8 | Neuroendocrine Carcinoma of the Skin pN1a(sn) TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524636","Merkel Cell Carcinoma pN1a TNM Finding v8","C136865","Merkel cell carcinoma with clinically occult regional lymph node metastasis following lymph node dissection. (from AJCC 8th Ed.)","Merkel Cell Carcinoma pN1a TNM Finding v8 | Neuroendocrine Carcinoma of the Skin pN1a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524630","Merkel Cell Carcinoma pN1 TNM Finding v8","C136863","Merkel cell carcinoma with metastasis in regional lymph node(s). (from AJCC 8th Ed.)","Merkel Cell Carcinoma pN1 TNM Finding v8 | Neuroendocrine Carcinoma of the Skin pN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524629","Merkel Cell Carcinoma pN0 TNM Finding v8","C136862","Merkel cell carcinoma without regional lymph node metastasis detected on pathologic examination. (from AJCC 8th Ed.)","Merkel Cell Carcinoma pN0 TNM Finding v8 | Neuroendocrine Carcinoma of the Skin pN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524632","Merkel Cell Carcinoma pNX TNM Finding v8","C136861","Merkel cell carcinoma in which the regional lymph nodes cannot be assessed (e.g., previously removed for another reason or not removed for pathologic evaluation). (from AJCC 8th Ed.)","Merkel Cell Carcinoma pNX TNM Finding v8 | Neuroendocrine Carcinoma of the Skin pNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524622","Merkel Cell Carcinoma Pathologic Distant Metastasis TNM Finding v8","C136855","A pathologic finding about one or more characteristics of Merkel cell carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Merkel Cell Carcinoma Pathologic Distant Metastasis TNM Finding v8 | Neuroendocrine Carcinoma of the Skin Pathologic Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524626","Merkel Cell Carcinoma pM1c TNM Finding v8","C136859","Merkel cell carcinoma with metastasis to all other distant sites, microscopically confirmed. (from AJCC 8th Ed.)","Merkel Cell Carcinoma pM1c TNM Finding v8 | Neuroendocrine Carcinoma of the Skin pM1c TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524625","Merkel Cell Carcinoma pM1b TNM Finding v8","C136858","Merkel cell carcinoma with metastasis to lung, microscopically confirmed. (from AJCC 8th Ed.)","Merkel Cell Carcinoma pM1b TNM Finding v8 | Neuroendocrine Carcinoma of the Skin pM1b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524628","Merkel Cell Carcinoma pM1a TNM Finding v8","C136857","Merkel cell carcinoma with metastasis to distant skin, distant subcutaneous tissue, or distant lymph node(s), microscopically confirmed. (from AJCC 8th Ed.)","Merkel Cell Carcinoma pM1a TNM Finding v8 | Neuroendocrine Carcinoma of the Skin pM1a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524729","Merkel Cell Carcinoma by AJCC v8 Clinical Stage","C136871","A term that refers to the clinical staging of Merkel cell carcinoma (primary cutaneous neuroendocrine carcinoma), following the rules of the TNM AJCC v8 classification system.","Cutaneous Merkel Cell Carcinoma by AJCC v8 Clinical Stage | Merkel Cell Carcinoma by AJCC v8 Clinical Stage | Neuroendocrine Carcinoma of the Skin by AJCC v8 Clinical Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524736","Clinical Stage IV Merkel Cell Carcinoma AJCC v8","C136878","Stage IV includes: T0-4, Any N, M1. T0: No evidence of primary tumor. T1: Maximum clinical tumor diameter equal to or less than 2 cm. T2: Maximum clinical tumor diameter more than 2 cm but equal to or less than 5 cm. T3: Maximum clinical tumor diameter more than 5 cm. T4: Primary tumor invades fascia, muscle, cartilage, or bone. M1: Distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)","Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage IV Merkel Cell Carcinoma AJCC v8 | Clinical Stage IV Neuroendocrine Carcinoma of the Skin AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524739","Clinical Stage III Merkel Cell Carcinoma AJCC v8","C136877","Stage III includes: T0-4, N1-3, M0. T0: No evidence of primary tumor. T1: Maximum clinical tumor diameter equal to or less than 2 cm. T2: Maximum clinical tumor diameter more than 2 cm but equal to or less than 5 cm. T3: Maximum clinical tumor diameter more than 5 cm. T4: Primary tumor invades fascia, muscle, cartilage, or bone. N1: Metastasis in regional lymph node(s). N2: In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) without lymph node metastasis. N3: In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) with lymph node metastasis. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)","Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage III Merkel Cell Carcinoma AJCC v8 | Clinical Stage III Neuroendocrine Carcinoma of the Skin AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524738","Clinical Stage IIB Merkel Cell Carcinoma AJCC v8","C136876","Stage IIB includes: T4, N0, M0. T4: Primary tumor invades fascia, muscle, cartilage, or bone. N0: No regional lymph node metastasis detected on clinical and/or radiologic examination. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)","Clinical Stage IIB Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage IIB Merkel Cell Carcinoma AJCC v8 | Clinical Stage IIB Neuroendocrine Carcinoma of the Skin AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524733","Clinical Stage IIA Merkel Cell Carcinoma AJCC v8","C136875","Stage IIA includes: T2-3, N0, M0. T2: Maximum clinical tumor diameter more than 2 cm but equal to or less than 5 cm. T3: Maximum clinical tumor diameter more than 5 cm. N0: No regional lymph node metastasis detected on clinical and/or radiologic examination. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)","Clinical Stage IIA Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage IIA Merkel Cell Carcinoma AJCC v8 | Clinical Stage IIA Neuroendocrine Carcinoma of the Skin AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524735","Clinical Stage I Merkel Cell Carcinoma AJCC v8","C136873","Stage I includes: T1, N0, M0. T1: Maximum clinical tumor diameter equal to or less than 2 cm. N0: No regional lymph node metastasis detected on clinical and/or radiologic examination. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)","Clinical Stage I Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage I Merkel Cell Carcinoma AJCC v8 | Clinical Stage I Neuroendocrine Carcinoma of the Skin AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524734","Clinical Stage 0 Merkel Cell Carcinoma AJCC v8","C136872","Stage 0 includes: Tis, N0, M0. Tis: In situ primary tumor. N0: No regional lymph node metastasis detected on clinical and/or radiologic examination. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)","Clinical Stage 0 Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage 0 Merkel Cell Carcinoma AJCC v8 | Clinical Stage 0 Neuroendocrine Carcinoma of the Skin AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524742","Merkel Cell Carcinoma by AJCC v8 Pathologic Stage","C136880","A term that refers to the pathologic staging of Merkel cell carcinoma (primary cutaneous neuroendocrine carcinoma), following the rules of the TNM AJCC v8 classification system.","Cutaneous Merkel Cell Carcinoma by AJCC v8 Pathologic Stage | Merkel Cell Carcinoma by AJCC v8 Pathologic Stage | Neuroendocrine Carcinoma of the Skin by AJCC v8 Pathologic Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524719","Pathologic Stage IV Merkel Cell Carcinoma AJCC v8","C136889","Stage IV includes: T0-4, Any N, M1. T0: No evidence of primary tumor. T1: Maximum clinical tumor diameter equal to or less than 2 cm. T2: Maximum clinical tumor diameter more than 2 cm but equal to or less than 5 cm. T3: Maximum clinical tumor diameter more than 5 cm. T4: Primary tumor invades fascia, muscle, cartilage, or bone. M1: Distant metastasis microscopically confirmed. (AJCC 8th ed.)","Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage IV Merkel Cell Carcinoma AJCC v8 | Pathologic Stage IV Neuroendocrine Carcinoma of the Skin AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524713","Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8","C136887","Stage IIIA includes: (T1-4, N1a(sn) or N1a, M0); (T0, N1b, M0). T0: No evidence of primary tumor. T1: Maximum clinical tumor diameter equal to or less than 2 cm. T2: Maximum clinical tumor diameter more than 2 cm but equal to or less than 5 cm. T3: Maximum clinical tumor diameter more than 5 cm. T4: Primary tumor invades fascia, muscle, cartilage, or bone. N1a(sn): Clinically occult regional lymph node metastasis identified only by sentinel lymph node biopsy. N1a: Clinically occult regional lymph node metastasis following lymph node dissection. N1b: Clinically and/or radiologically detected regional lymph node metastasis, microscopically confirmed. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)","Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8 | Pathologic Stage IIIA Neuroendocrine Carcinoma of the Skin AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524715","Pathologic Stage IIB Merkel Cell Carcinoma AJCC v8","C136885","Stage IIB includes: T4, N0, M0. T4: Primary tumor invades fascia, muscle, cartilage, or bone. N0: No regional lymph node metastasis detected on pathologic examination. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)","Pathologic Stage IIB Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage IIB Merkel Cell Carcinoma AJCC v8 | Pathologic Stage IIB Neuroendocrine Carcinoma of the Skin AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524714","Pathologic Stage IIA Merkel Cell Carcinoma AJCC v8","C136884","Stage IIA includes: T2-3, N0, M0. T2: Maximum clinical tumor diameter more than 2 cm but equal to or less than 5 cm. T3: Maximum clinical tumor diameter more than 5 cm. N0: No regional lymph node metastasis detected on pathologic examination. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)","Pathologic Stage IIA Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage IIA Merkel Cell Carcinoma AJCC v8 | Pathologic Stage IIA Neuroendocrine Carcinoma of the Skin AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524740","Pathologic Stage I Merkel Cell Carcinoma AJCC v8","C136882","Stage I includes: T1, N0, M0. T1: Maximum clinical tumor diameter equal to or less than 2 cm. N0: No regional lymph node metastasis detected on pathologic examination. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)","Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage I Merkel Cell Carcinoma AJCC v8 | Pathologic Stage I Neuroendocrine Carcinoma of the Skin AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524743","Pathologic Stage 0 Merkel Cell Carcinoma AJCC v8","C136881","Stage 0 includes: Tis, N0, M0. Tis: In situ primary tumor. N0: No regional lymph node metastasis detected on pathologic examination. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)","Pathologic Stage 0 Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage 0 Merkel Cell Carcinoma AJCC v8 | Pathologic Stage 0 Neuroendocrine Carcinoma of the Skin AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003738","archive","C156018","A place or collection containing records, documents, or other materials, especially those of historical interest.","Archive | Archival",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563218","Archived","C156019","Collected and stored for long-term retrieval.","Archived | Archival",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0680854","Charitable contribution","C156020","The act of giving money or materials or other items of worth.","Donation | Donated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0236048","Gastric Polyp","C3954","A polyp that arises from the stomach.  This category includes neoplastic polyps (intestinal-type adenomatous polyps, gastric-type adenomas, and fundic gland polyps), and non-neoplastic polyps (hyperplastic polyps and hamartomatous polyps).","Gastric Polyp | Gastric Polyp(s) | Gastric Polyposa | Gastric Polyposis | Polyps of Stomach | Polyps of the Stomach",,,,,,,,,,,,,,,"4303233","Gastric polyp",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1260194","PGAP3 protein, human","C150293","Post-GPI attachment to proteins factor 3 (320 aa, ~36 kDa) is encoded by the human PGAP3 gene. This protein is involved in the maturation of glycophosphoinositol anchoring lipids.","Post-GPI Attachment to Proteins Factor 3 | COS16 Homolog | Gene Coamplified with ERBB2 Protein | PGAP3 | Per1-Like Domain Containing 1 | hCOS16",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0855775","Pulmonary Function Test Decreased","C121577","A decrease in any of the parameters used to measure the mechanical function of the lungs and upper airway.","Pulmonary Function Test Decreased | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562726","ROS1 Positive","C155991","An indication that expression of ROS1 has been detected in a sample.","ROS1 Positive | MCF3 Positive | Proto-Oncogene Tyrosine-Protein Kinase ROS Positive | Proto-Oncogene c-Ros Positive | Proto-Oncogene c-Ros-1 Positive | ROS Positive | ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Positive | Receptor Tyrosine Kinase c-Ros Oncogene 1 Positive | c-Ros Positive | c-Ros-1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334844","Myeloblasts 5-19 Percent of Peripheral Blood White Cells","C36222","A semi-quantitative microscopic finding indicating that 5-19 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells of myeloid origin.","Myeloblasts 5-19 Percent of Peripheral Blood White Cells | Myeloblasts 5-19% of Peripheral Blood White Cells | Myeloblasts Between 5 and 19 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562727","ETV6 Gene Rearrangement","C155992","A molecular abnormality indicating rearrangement of the ETV6 gene.","ETV6 Gene Rearrangement | ETS Variant 6 Gene Rearrangement | ETS Variant Gene 6 Rearrangement | ETV6 Rearrangement | ETV6 rearranged | TEL Gene Rearrangement | TEL Oncogene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562728","Blasts 2 Percent or More of Peripheral Blood White Cells","C155993","A semi-quantitative microscopic finding indicating that 2 percent or more of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.","Blasts 2 Percent or More of Peripheral Blood White Cells | Blasts Greater than or Equal to 2 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562750","Folate Receptor Alpha Negative","C155994","An indication that folate receptor alpha has not been detected in a sample.","Folate Receptor Alpha Negative | FBP Negative | FOLR Negative | FOLR1 Negative | FR-Alpha Negative | Folate Receptor 1 Negative | Folate-Binding Protein, Adult Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508318","Myeloblasts Present","C155995","A microscopic finding indicating the presence of immature mononuclear cells of myeloid origin in a sample.","Myeloblasts Present | Myeloblasts Positive | Myeloid Blast Cells Positive | Myeloid Blast Cells Present | Myeloid Blast Positive | Myeloid Blasts Positive | Myeloid Blasts Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562748","Myeloblasts More than 5 Percent of Bone Marrow Nucleated Cells","C156000","A semi-quantitative microscopic finding indicating that more than 5 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells of myeloid origin.","Myeloblasts More than 5 Percent of Bone Marrow Nucleated Cells | Myeloblasts Greater than 5 Percent of Bone Marrow Nucleated Cells | Myeloblasts Over 5 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562744","Soluble Interleukin-6 Receptor Subunit Alpha","C156002","Soluble interleukin-6 receptor subunit alpha is encoded by the human IL6R gene. This protein, which is produced by metalloproteinase-mediated cleavage of the membrane-bound form, is involved in the modulation of interleukin-6-mediated signaling by CD4-positive T-lymphocytes.","Soluble Interleukin-6 Receptor Subunit Alpha | Soluble CD126 | Soluble CD126 Antigen | Soluble IL-6 Receptor | Soluble IL-6 Receptor Alpha | Soluble IL-6R | Soluble IL-6R Subunit Alpha | Soluble IL-6R-Alpha | Soluble IL-6RA | Soluble IL6R | Soluble IL6RA | Soluble Interleukin 6 Receptor | Soluble Interleukin 6 Receptor Subunit Alpha | Soluble Interleukin-6 Receptor | Soluble gp80 | sIL-6R | sIL-6RA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562745","Testosterone Less than or Equal to 100 ng/dL","C156003","A semiquantitative finding indicating that the concentration of testosterone in a sample is less than or equal to 100 ng/dL.","Testosterone Less than or Equal to 100 ng/dL | Testosterone Less than or Equal to 100 Nanograms per Deciliter | Testosterone Less than or Equal to 100 Nanograms/Deciliter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562747","M1 Macrophage to M2 Macrophage Ratio Measurement","C156005","The determination of the ratio of M1 macrophages to M2 macrophages present in a sample.","M1 Macrophage to M2 Macrophage Ratio Measurement | M1 to M2 Macrophage Ratio | M1 to M2 Macrophage Ratio Measurement | M1 to M2 Ratio Measurement | M1/M2 Macrophage Ratio | M1/M2 Macrophage Ratio Measurement | M1/M2 Ratio | M1/M2 Ratio Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562740","Absolute Neutrophil Count Greater than or Equal to 500/mm3","C156006","A quantitative microscopic finding indicating that neutrophils are found at greater than or equal to 500 per cubic millimeter field in a sample.","Absolute Neutrophil Count Greater than or Equal to 500/mm3 | ANC Greater than or Equal to 500 per Cubic Millimeter | ANC Greater than or Equal to 500 per Microliter | ANC Greater than or Equal to 500/mm3 | ANC Greater than or Equal to 500/uL | Absolute Neutrophil Count Greater than or Equal to 500 per Cubic Millimeter | Absolute Neutrophil Count Greater than or Equal to 500 per Microliter | Absolute Neutrophil Count Greater than or Equal to 500/ul | Neutrophil Count 500 | Neutrophil Count 500 per cubic millimeter | Neutrophil Count Greater than or Equal to 500 | Neutrophil Count Greater than or Equal to 500 per cubic millimeter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562741","PSA Level Less than or Equal to Four","C156007","A blood concentration of prostate specific antigen less than or equal to 4 ng/mL.","PSA Level Less than or Equal to Four | PSA Level 4 or Less | PSA Level Four or Less | PSA Level Less than or Equal to 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562742","Deleterious HDAC2 Gene Mutation","C156008","A change in the nucleotide sequence of the HDAC2 gene that is associated with increased risk of disease.","Deleterious HDAC2 Gene Mutation | Deleterious HD2 Gene Mutation | Deleterious Histone Deacetylase 2 Gene Mutation | Deleterious RPD3 Gene Mutation | Deleterious YAF1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562743","Deleterious RAD54L Gene Mutation","C156009","A change in the nucleotide sequence of the RAD54L gene that is associated with increased risk of disease.","Deleterious RAD54L Gene Mutation | Deleterious HR54 Gene Mutation | Deleterious HRAD54 Gene Mutation | Deleterious RAD54 Homolog Gene Mutation | Deleterious RAD54-like (S. cerevisiae) Gene Mutation | Deleterious RAD54A Gene Mutation | Deleterious hHR54 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562761","Deleterious GEN1 Gene Mutation","C156010","A change in the nucleotide sequence of the GEN1 gene that is associated with increased risk of disease.","Deleterious GEN1 Gene Mutation | Deleterious GEN1 Holliday Junction 5' Flap Endonuclease Gene Mutation | Deleterious Gen Gene Mutation | Deleterious Gen Homolog 1, Endonuclease Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562762","Deleterious RAD51 Gene Mutation","C156011","A change in the nucleotide sequence of the RAD51 gene that is associated with increased risk of disease.","Deleterious RAD51 Gene Mutation | Deleterious BRCC5 Gene Mutation | Deleterious FANCR Gene Mutation | Deleterious HRAD51 Gene Mutation | Deleterious HsRad51 Gene Mutation | Deleterious RAD51 Homolog (S. cerevisiae) Gene Mutation | Deleterious RAD51 Recombinase Gene Mutation | Deleterious RAD51, S. cerevisiae, Homolog of A Gene Mutation | Deleterious RAD51A Gene Mutation | Deleterious RECA Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562763","Deleterious ERCC3 Gene Mutation","C156012","A change in the nucleotide sequence of the ERCC3 gene that is associated with increased risk of disease.","Deleterious ERCC3 Gene Mutation | Deleterious BTF2 Gene Mutation | Deleterious ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit Gene Mutation | Deleterious Excision Repair Cross-Complementation Group 3 Gene Mutation | Deleterious Excision Repair Cross-Complementing Rodent Repair Deficiency, Complementation Group 3 Gene Mutation | Deleterious Excision-Repair, Complementing Defective, in Chinese Hamster, 3 Gene Mutation | Deleterious GTF2H Gene Mutation | Deleterious RAD25 Gene Mutation | Deleterious TTD2 Gene Mutation | Deleterious XPB Gene Mutation | Deleterious Xeroderma Pigmentosum Group B Complementing Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562764","Deleterious ABRAXAS1 Gene Mutation","C156013","A change in the nucleotide sequence of the ABRAXAS1 gene that is associated with increased risk of disease.","Deleterious ABRAXAS1 Gene Mutation | Deleterious ABRA1 Gene Mutation | Deleterious ABRAXAS Gene Mutation | Deleterious Abraxas 1, BRCA1 A Complex Subunit Gene Mutation | Deleterious CCDC98 Gene Mutation | Deleterious FAM175A Gene Mutation | Deleterious Family with Sequence Similarity 175 Member A Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562757","UGT1A1 Polymorphism Positive","C156014","An indication that polymorphism of the UGT1A1 gene has been detected in a sample.","UGT1A1 Polymorphism Positive | GNT1 Polymorphism Positive | UDP Glucuronosyltransferase Family 1 Member A1 Polymorphism Positive | UDPGT 1-1 Polymorphism Positive | UDPGT Polymorphism Positive | UGT1 Polymorphism Positive | UGT1A Polymorphism Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562759","FANCG Gene Mutation","C156016","A change in the nucleotide sequence of the FANCG gene.","FANCG Gene Mutation | FA Complementation Group G Gene Mutation | FACG Gene Mutation | FAG Gene Mutation | Fanconi Anemia Complementation Group G Gene Mutation | Fanconi Anemia, Complementation Group G Gene Mutation | X-Ray Repair Complementing Defective Repair In Chinese Hamster Cells 9 Gene Mutation | X-Ray Repair, Complementing Defective, In Chinese Hamster, 9 Gene Mutation | XRCC9 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562752","FANCB Gene Mutation","C156022","A change in the nucleotide sequence of the FANCB gene.","FANCB Gene Mutation | FA Complementation Group B Gene Mutation | FA2 Gene Mutation | FAAP90 Gene Mutation | FAAP95 Gene Mutation | FAB Gene Mutation | FACB Gene Mutation | Fanconi Anemia Complementation Group B Gene Mutation | Fanconi Anemia, Complementation Group B Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562753","FANCI Gene Mutation","C156023","A change in the nucleotide sequence of the FANCI gene.","FANCI Gene Mutation | FA Complementation Group I Gene Mutation | FACI Gene Mutation | Fanconi Anemia Complementation Group I Gene Mutation | Fanconi Anemia, Complementation Group I Gene Mutation | KIAA1794 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562754","FANCL Gene Mutation","C156024","A change in the nucleotide sequence of the FANCL gene.","FANCL Gene Mutation | FA Complementation Group L Gene Mutation | FAAP43 Gene Mutation | FACL Gene Mutation | Fanconi Anemia Complementation Group L Gene Mutation | Fanconi Anemia, Complementation Group L Gene Mutation | PHD Finger Protein 9 Gene Mutation | PHF9 Gene Mutation | POG Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562755","High Tumor Mutation Burden","C156025","An indication that a tumor sample has a high number of genetic mutations per megabase (mb) of sequenced DNA.","High Tumor Mutation Burden | High TMB | High Tumor Mutational Burden | TMB Positive | TMB-H | Tumor Mutational Burden Positive",,,,,,,,,,,,,,,"37163625","High tumor mutational burden",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL562890","Human Papillomavirus-6 Positive","C156027","Indicates that human papillomavirus-6 has been detected in a sample.","Human Papillomavirus-6 Positive | HPV-6 Positive | HPV6 Positive | Human Papilloma Virus 6 Positive | Human Papilloma Virus-6 Positive | Human Papillomavirus 6 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562891","Receptor Tyrosine Kinase Gene Rearrangement","C156028","A molecular abnormality indicating rearrangement of a receptor tyrosine kinase family gene.","Receptor Tyrosine Kinase Gene Rearrangement | RTK Family Gene Rearrangement | RTK Family Rearrangement | RTK Gene Rearrangement | RTK Rearrangement | Receptor Tyrosine Kinase Family Gene Rearrangement | Receptor Tyrosine Kinase Rearrangement | Tyrosine Kinase Receptor Family Rearrangement | Tyrosine Kinase Receptor Gene Rearrangement | Tyrosine Kinase Receptor Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562892","Receptor Tyrosine Kinase Gene Amplification","C156029","A molecular abnormality indicating the presence of multiple copies of a receptor tyrosine kinase family gene.","Receptor Tyrosine Kinase Gene Amplification | RTK Amplification | RTK Family Amplification | RTK Family Gene Amplification | RTK Gene Amplification | Receptor Tyrosine Kinase Amplification | Receptor Tyrosine Kinase Family Gene Amplification | Tyrosine Kinase Receptor Amplification | Tyrosine Kinase Receptor Family Amplification | Tyrosine Kinase Receptor Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562906","Inactivating BRAF Gene Mutation","C156046","A change in the nucleotide sequence of the BRAF gene that inhibits expression or results in the translation of either low-activity or inactive forms of the serine/threonine-protein kinase B-raf protein.","Inactivating BRAF Gene Mutation | BRAF Class 3 Gene Mutation | BRAF Class 3 Mutation | BRAF Class III Alteration | BRAF Class III Gene Mutation | BRAF Gene Inactivation | BRAF Inactivation | Class 3 BRAF Gene Mutation | Class 3 BRAF Mutation | Class III BRAF Gene Mutation | Inactivating B-RAF Gene Mutation | Inactivating B-RAF1 Gene Mutation | Inactivating BRAF Mutation | Inactivating BRAF1 Gene Mutation | Inactivating v-raf Murine Sarcoma Viral Oncogene Homolog B1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562907","ATRX Negative","C156047","An indication that ATRX expression has not been detected in a sample.","ATRX Negative | ATP-Dependent Helicase ATRX Loss | ATP-Dependent Helicase ATRX Negative | ATRX Loss | Loss of ATRX Expression | Loss of Transcriptional Regulator ATRX Expression | RAD54 Negative | RAD54L Negative | Transcriptional Regulator ATRX Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562900","Inactivating SETD2 Gene Mutation","C156048","A change in the nucleotide sequence of the SETD2 gene that inhibits expression or results in the translation of either low-activity or inactive forms of the histone-lysine methyltransferase SETD2 protein.","Inactivating SETD2 Gene Mutation | Inactivating HBP231 Gene Mutation | Inactivating HIF-1 Gene Mutation | Inactivating HIP-1 Gene Mutation | Inactivating HYPB Gene Mutation | Inactivating KMT3A Gene Mutation | Inactivating LLS Gene Mutation | Inactivating SET Domain Containing 2 Gene Mutation | Inactivating SET2 Gene Mutation | Inactivating p231HBP Gene Mutation | SETD2 Deficiency | SETD2 Deficient | SETD2 Inactivating Gene Mutation | SETD2 Loss | SETD2 Loss of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562901","TP53 Negative","C156049","An indication that TP53 expression or activity has not been detected in a sample.","TP53 Negative | Antigen NY-CO-13 Negative | Cellular Tumor Antigen p53 Negative | TP53 Loss | TRP53 Negative | Transformation-Related Protein 53 Negative | Tumor Protein p53 Negative | Tumor Suppressor p53 Negative | p53 Loss | p53 Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562903","MTAP Negative","C156051","An indication that MTAP expression or activity has not been detected in a sample.","MTAP Negative | 5'-Methylthioadenosine Phosphorylase Negative | MTA Phosphorylase Negative | MTAP Deficiency | MTAP Deficient | MTAP Loss | MTAP Null | MTAPase Negative | Methylthioadenosine Phosphorylase Loss | Methylthioadenosine Phosphorylase Negative | Methylthioadenosine Phosphorylase Null | S-Methyl-5'-Thioadenosine Phosphorylase Loss | S-Methyl-5'-Thioadenosine Phosphorylase Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562788","MAPK1 Gene Mutation","C155917","A change in the nucleotide sequence of the MAPK1 gene.","MAPK1 Gene Mutation | ERK Gene Mutation | ERK-2 Gene Mutation | ERK2 Gene Mutation | ERT1 Gene Mutation | MAPK2 Gene Mutation | Mitogen-Activated Protein Kinase 1 Gene Mutation | P42MAPK Gene Mutation | PRKM1 Gene Mutation | PRKM2 Gene Mutation | p38 Gene Mutation | p40 Gene Mutation | p41 Gene Mutation | p41mapk Gene Mutation | p42-MAPK Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562738","PSA Level Greater than or Equal to 0.8","C155980","A blood concentration of prostate specific antigen greater than or equal to 0.8 ng/mL.","PSA Level Greater than or Equal to 0.8 | PSA Level 0.8 or Greater",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562896","FLT3 Tyrosine Kinase Domain Mutation Negative","C156059","An indication that FLT3 gene mutations in the region encoding the tyrosine kinase domain have not been detected in a sample.","FLT3 Tyrosine Kinase Domain Mutation Negative | FLT3-TKD Mutation Negative | FLT3-TKD Negative | FLT3/TKD Mutation Negative | FLT3/TKD Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020964","Immunity","C16710","The protection against infectious disease conferred by the immune response. It encompasses the capacity to distinguish foreign material from self, and to neutralize, eliminate, or metabolize that which is foreign.","Immunity | immunity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562846","Cell-Free DNA Blood Collection Tube","C156117","A blood collection tube with a formaldehyde-free preservative which stabilizes nucleated blood cells, preventing the release of genomic DNA, and allowing isolation of high-quality cell-free DNA.","Cell-Free DNA Blood Collection Tube | Cell-Free DNA BCT | Streck BCT | Streck Blood Collection Tube | Streck Cell-Free DNA BCT | Streck Cell-Free DNA Tube | Streck tube | cfDNA Blood Collection Tube",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562827","Symptom Screening in Pediatrics","C156105","A self-report screening tool, originally developed by Tomlinson et al. in 2013, that is used for symptom assessment in children with cancer and pediatric hematopoietic stem cell transplantation recipients.","Symptom Screening in Pediatrics | SSPedi | SSPedi - Symptom Screening in Pediatrics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562821","Feel Disappointed or Sad","C156106","A question about whether an individual feels or felt disappointed or sad.","Feel Disappointed or Sad | Feeling disappointed or sad",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562822","Feel Scared or Worried","C156107","A question about whether an individual feels or felt scared or worried.","Feel Scared or Worried | Feeling scared or worried",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562823","Feel Cranky or Angry","C156108","A question about whether an individual feels or felt cranky or angry.","Feel Cranky or Angry | Feeling cranky or angry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562824","Problems With Thinking or Remembering Things","C156109","A question about whether an individual has or had problems with thinking or remembering things.","Problems With Thinking or Remembering Things | Problems with thinking or remembering things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562847","Changes in How Body or Face Looks","C156110","A question about whether there are changes in how an individual's body or face looks.","Changes in How Body or Face Looks | Changes in how your body or face look",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562848","Hurt or Pain Other Than Headache","C156111","A question about whether an individual has or had pain other than headache.","Hurt or Pain Other Than Headache | Hurt or pain (other than headache)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562849","Tingly or Numb Hands or Feet","C156112","A question about whether an individual has or had tingly or numb hands or feet.","Tingly or Numb Hands or Feet | Tingly or numb hands or feet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562850","Throwing Up or Feeling Like May Throw Up","C156113","A question about whether an individual vomited or feels or felt like vomiting.","Throwing Up or Feeling Like May Throw Up | Throwing up or feeling like you may throw up",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562844","Feeling More or Less Hungry Than Usual","C156114","A question about whether an individual feels or felt more or less hungry than usual.","Feeling More or Less Hungry Than Usual | Feeling more or less hungry than you usually do",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562845","Other Things That Have Bothered Lately","C156115","A question about other things that have bothered an individual lately.","Other Things That Have Bothered Lately | Please tell us about other things that have bothered you lately by writing them out here",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563222","Moderately Bothered","C156116","A response indicating that an individual is or was moderately bothered.","Moderately Bothered | Medium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562841","Hundred Million International Units","C156119","A unit of biological activity equal to one hundred million international units.","Hundred Million International Units | 10*8.[IU] | 10*8.[iU] | 10^8 IU | 10^8.[IU] | 10^8.[iU] | 10^8[iU] | Hundred Million International Units

 | One Hundred Million IU | One Hundred Million International Units",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335737","Recurrent Hematologic Malignancy","C27358","The reemergence of a hematologic malignancy after a period of remission.","Recurrent Hematologic Malignancy | Recurrent Hematologic Cancer | Recurrent Hematopoietic and Lymphoid Cell Neoplasm | Relapsed Hematologic Cancer | Relapsed Hematologic Malignancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225489","Anterior Wall of the Nasopharynx","C12245","The anterior aspect of the nasopharynx.","Anterior Wall of the Nasopharynx | Anterior Wall of Nasopharynx | Anterior wall of nasopharynx",,,,,,,,,,,,,,,"4220236","Structure of anterior wall of nasopharynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL562935","Low Grade Dysplasia","C156084","A subjective characterization of the phenomenon of dysplasia, based on microscopic examination of the architectural and/or cytological changes in a tissue sample, that is determined to be low.","Low Grade Dysplasia | Dysplasia; low grade | Low Grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562934","High Grade Dysplasia","C156083","A subjective characterization of the phenomenon of dysplasia, based on microscopic examination of the architectural and/or cytological changes in a tissue sample, that is determined to be high.","High Grade Dysplasia | Dysplasia; high grade | High Grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562911","Autoimmune Atrophic Chronic Gastritis","C156076","Chronic atrophic gastritis that is caused by autoimmune destruction of parietal cells in the stomach resulting in hypochlorhydria and decreased production of intrinsic factor.","Autoimmune Atrophic Chronic Gastritis | Autoimmune atrophic chronic gastritis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519627","Transport Models / Radionuclides","C19087","The use of labelled tracers for the elucidation of transport pathways.","Transport Models / Radionuclides | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562838","Health Utilities Index","C156124","A family of generic health profiles and preference-based systems for measuring health status, reporting health-related quality of life, and producing utility scores.","Health Utilities Index | HUI | Health Utilities Index (HUI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562839","Ability to See Well Enough to Read Ordinary Newsprint","C156125","A question about an individual's ability to see well enough to read ordinary newsprint.","Ability to See Well Enough to Read Ordinary Newsprint Question | Ability to See Well Enough to Read Ordinary Newsprint | Ability to See Well Enough to Read Ordinary Newsprint | Subject's ability to see well enough to read ordinary newsprint",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562861","Ability to See Well Enough to Recognize Friend on Other Side of Street","C156126","A question about an individual's ability to see well enough to recognize a friend on the other side of the street.","Ability to See Well Enough to Recognize Friend on Other Side of Street Question | Ability to See Well Enough to Recognize Friend on Other Side of Street | Ability to See Well Enough to Recognize Friend on Other Side of Street | Subject's ability to see well enough to recognize a friend on the other side of the street",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562862","Ability to Hear What Was Said in Group Conversation with at Least Three Other People","C156127","A question about an individual's ability to hear what was said in a group conversation with at least 3 other people.","Ability to Hear What Was Said in Group Conversation with at Least Three Other People Question | Ability to Hear What Was Said in Group Conversation with at Least Three Other People | Ability to Hear What Was Said in Group Conversation with at Least Three Other People | Subject's ability to hear what was said in a group conversation with at least three other people",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562863","Ability to Hear What Was Said in Conversation with One Other Person in Quiet Room","C156128","A question about an individual's ability to hear what was said with one other person in a quiet room.","Ability to Hear What Was Said in Conversation with One Other Person in Quiet Room Question | Ability to Hear What Was Said in Conversation with One Other Person in Quiet Room | Ability to Hear What Was Said in Conversation with One Other Person in Quiet Room | Subject's ability to hear what was said in a conversation with one other person in a quiet room",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562864","Ability to be Understood When Speaking Own Language with People Who do not Know the Subject","C156129","A question about an individual's ability to be understood when speaking their own language with people who do not know them.","Ability to be Understood When Speaking Own Language with People Who do not Know the Subject Question | Ability to be Understood When Speaking Own Language with People Who do not Know the Subject | Ability to be Understood When Speaking Own Language with People Who do not Know the Subject | Subject's ability to be understood when speaking his/her own language with people who do not know the subject",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562858","Ability to be Understood When Speaking with People Who Know the Subject Well","C156130","A question about an individual's ability to be understood when speaking with people who know them well.","Ability to be Understood When Speaking with People Who Know the Subject Well Question | Ability to be Understood When Speaking with People Who Know the Subject Well | Ability to be Understood When Speaking with People Who Know the Subject Well | Subject's ability to be understood when speaking with people who know the subject well",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562859","Subject's Feelings","C156131","A question about an individual's feelings.","Subject's Feelings | Feelings | Individual's Feelings | Subject's feelings",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562860","Pain and Discomfort","C156132","A question about an individual's pain and discomfort.","Pain and Discomfort | The pain and discomfort the subject has experienced",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563221","Ability to Walk","C156133","A question about an individual's ability to walk.","Ability to Walk Question | Ability to Walk | Ability to Walk | Able to Walk | Subject's ability to walk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562854","Ability to Use Hands and Fingers","C156134","A question about an individual's ability to use their hands and fingers.","Ability to Use Hands and Fingers Question | Ability to Use Hands and Fingers | Ability to Use Hands and Fingers | Able to Use Hands and Fingers | Subject's ability  to use his/her hands and fingers | Subject's ability to use his/her hands and fingers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562855","Ability to Remember Things","C156135","A question about an individual's ability to remember things.","Ability to Remember Things Question | Ability to Remember Things | Ability to Remember Things | Able to Remember Things | Subject's ability to remember things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562857","Ability to Think and Solve Day-to-day Problems","C156137","A question about an individual's ability to think and solve day-to-day problems.","Ability to Think and Solve Day-to-day Problems Question | Ability to Think and Solve Day-to-day Problems | Ability to Think and Solve Day-to-day Problems | Able to Think and Solve Day-to-day Problems | Subject's ability to think and solve day to day problems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562851","Ability to Perform Basic Activities","C156138","A question about an individual's ability to perform basic activities.","Ability to Perform Basic Activities Question | Ability to Perform Basic Activities | Ability to Perform Basic Activities | Able to Perform Basic Activities | Subject's ability to perform basic activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563208","Pain or Discomfort","C156140","A question about an individual's pain or discomfort.","Pain or Discomfort | Pain or Discomfort Experienced | Pain or discomfort the subject has experienced",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562878","Able to See Well Enough without Correction","C156144","A response indicating that an individual is or was able to see well enough without glasses or contact lenses.","Able to See Well Enough without Correction | Able to see well enough without glasses or contact lenses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562879","Able to See Well Enough with Correction","C156145","A response indicating that an individual is able to see well enough with glasses or contact lenses.","Able to See Well Enough with Correction | Able to see well enough with glasses or contact lenses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562873","Unable to See Well Enough even with Correction","C156146","A response indicating that an individual is or was unable to see well enough even with glasses or contact lenses.","Unable to See Well Enough even with Correction | Unable to see well enough even with glasses or contact lenses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562874","Unable to See at All","C156147","A response indicating that an individual is or was unable to see at all.","Unable to See at All | Unable to See | Unable to see at all",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563206","Able to Hear without Hearing Aids","C156148","A response indicating that an individual is or was able to hear what was said without hearing aids.","Able to Hear without Hearing Aids | Able to Hear | Able to hear what was said without a hearing aid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562875","Able to Hear with Hearing Aids","C156149","A response indicating that an individual is or was able to hear what was said with hearing aids.","Able to Hear with Hearing Aids | Able to hear what was said with a hearing aid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562869","Unable to Hear even with Hearing Aids","C156150","A response indicating that an individual is or was unable to hear what was said even with hearing aids.","Unable to Hear even with Hearing Aids | Unable to hear what was said even with a hearing aid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562870","Unable to Hear, but did not Wear Hearing Aids","C156151","A response indicating that an individual is or was unable to hear what was said, but was not wearing their hearing aids.","Unable to Hear, but did not Wear Hearing Aids | Unable to hear what was said, but did not wear a hearing aid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562871","Unable to Hear at All","C156152","A response indicating that an individual is or was unable to hear at all.","Unable to Hear at All | Unable to Hear | Unable to hear at all",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562868","Able to be Understood Completely","C156157","A response indicating that an individual is or was able to be understood completely.","Able to be Understood Completely | Able to be understood completely",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563011","Able to be Understood Partially","C156158","A response indicating that an individual is or was able to be understood partially.","Able to be Understood Partially | Able to be understood partially",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563012","Unable to be Understood","C156159","A response indicating that an individual is or was unable to be understood.","Unable to be Understood | Unable to be understood",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278249","Unable to Speak at All","C156160","A response indicating that an individual is or was unable to speak at all.","Unable to Speak at All | Unable to Speak | Unable to speak at all",,,,,,,,,,,,,,,"4115799","Unable to speak",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL563013","Happy and Interested in Life","C156161","A response indicating that an individual is or was happy and interested in life.","Happy and Interested in Life | Happy and interested in life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563007","Somewhat Happy","C156162","A response indicating that an individual is or was somewhat happy.","Somewhat Happy | Somewhat happy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563008","Somewhat Unhappy","C156163","A response indicating that an individual is or was somewhat unhappy.","Somewhat Unhappy | Somewhat unhappy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563009","Very Unhappy","C156164","A response indicating that an individual is or was very unhappy.","Very Unhappy | Very unhappy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563010","So Unhappy that Life was not Worthwhile","C156165","A response indicating that an individual is or was so unhappy that life was not worthwhile.","So Unhappy that Life was not Worthwhile | So unhappy that life was not worthwhile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563022","Free of Pain and Discomfort","C156178","A response indicating that an individual is or was free of pain or discomfort.","Free of Pain and Discomfort | Free of pain and discomfort",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563023","Mild to Moderate Pain or Discomfort that Did Not Prevent Activities","C156179","A response indicating that an individual has or had mild to moderate pain or discomfort, but it did not prevent activities.","Mild to Moderate Pain or Discomfort that Did Not Prevent Activities | Mild to moderate pain or discomfort that prevented no activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563024","Moderate Pain or Discomfort that Prevented Some Activities","C156180","A response indicating that an individual has or had moderate pain or discomfort that prevented some activities.","Moderate Pain or Discomfort that Prevented Some Activities | Moderate pain or discomfort that prevented some activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563018","Severe Pain or Discomfort that Prevented Most Activities","C156182","A response indicating that an individual has or had severe pain or discomfort that prevented most activities.","Severe Pain or Discomfort that Prevented Most Activities | Severe pain or discomfort that prevented most activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563019","Able to Walk Around Neighborhood Without Difficulty; No Walking Equipment Needed","C156183","A response indicating that an individual is or was able to walk around the neighborhood without difficulty and without walking equipment.","Able to Walk Around Neighborhood Without Difficulty; No Walking Equipment Needed | Able to walk around the neighborhood without difficulty, and without walking equipment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563020","Able to Walk Around Neighborhood with Difficulty; No Walking Equipment or Help Required","C156184","A response indicating that an individual is or was able to walk around the neighborhood with difficulty, but did not require walking equipment or the help of another person.","Able to Walk Around Neighborhood with Difficulty; No Walking Equipment or Help Required | Able to walk around the neighborhood with difficulty; but did not require walking equipment or the help of another person",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563021","Able to Walk Around Neighborhood with Walking Equipment; No Help Required","C156185","A response indicating that an individual is or was able to walk around the neighborhood with walking equipment, but without the help of another person.","Able to Walk Around Neighborhood with Walking Equipment; No Help Required | Able to walk around the neighborhood with walking equipment, but without the help of another person",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563014","Able to Walk Only Short Distances with Walking Equipment; Required a Wheelchair to Get Around the Neighborhood","C156186","A response indicating that an individual is or was able to walk only short distances with walking equipment and required a wheelchair to get around the neighborhood.","Able to Walk Only Short Distances with Walking Equipment; Required a Wheelchair to Get Around the Neighborhood | Able to walk only short distances with walking equipment, and required a wheelchair to get around the neighborhood",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563015","Unable to Walk Alone, Even with Walking Equipment; Able to Walk Short Distances with Help; Require Wheelchair to Get Around the Neighborhood","C156187","A response indicating that an individual is or was unable to walk alone, even with walking equipment, but was able to walk short distances with the help of another person and required a wheelchair to get around the neighborhood.","Unable to Walk Alone, Even with Walking Equipment; Able to Walk Short Distances with Help; Require Wheelchair to Get Around the Neighborhood | Unable to walk alone, even with walking equipment. Able to walk short distances with the help of another person, and required a wheelchair to get around the neighborhood",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563016","Unable to Walk at All","C156188","A response indicating that an individual is or was unable to walk at all.","Unable to Walk at All | Unable to Walk | Unable to walk at all",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563043","Full Use of Hands and Fingers","C156191","A response indicating that an individual has full use of both hands and all 10 fingers.","Full Use of Hands and Fingers | Full use of two hands and ten fingers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563042","Limitations in Use of Hands or Fingers","C156190","A response indicating that an individual has limitations in the use of their hands or fingers, but does not require special tools or the help of another person.","Limitations in Use of Hands or Fingers | Limitations in the use of hands or fingers, but did not require special tools or the help of another person",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563044","Limitations in Use of Hands or Fingers; Requires Special Tools for Independence","C156192","A response indicating that an individual has limitations in the use of their hands or fingers, but remains independent through the use of special tools.","Limitations in Use of Hands or Fingers; Requires Special Tools for Independence | Limitations in the use of hands or fingers, independent with use of special tools (did not require the help of another person)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563045","Limitations in Use of Hands or Fingers; Requires Help for Some Tasks","C156193","A response indicating that an individual has limitations in the use of their hands or fingers that requires the help of another person for some tasks, even with use of special tools.","Limitations in Use of Hands or Fingers; Requires Help for Some Tasks | Limitations in the use of hands or fingers, required the help of another person for some tasks (not independent even with use of special tools)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563039","Limitations in Use of Hands or Fingers; Requires Help for All Tasks","C156195","A response indicating that an individual has limitations in the use of their hands or fingers that requires the help of another person for all tasks, even with use of special tools.","Limitations in Use of Hands or Fingers; Requires Help for All Tasks | Limitations in the use of hands or fingers, required the help of another person for all tasks (not independent even with use of special tools)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563040","Able to Remember Most Things","C156196","A response indicating that an individual is or was able to remember most things.","Able to Remember Most Things | Able to remember most things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563041","Somewhat Forgetful","C156197","A response indicating that an individual is or was somewhat forgetful.","Somewhat Forgetful | Somewhat forgetful",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563034","Very Forgetful","C156198","A response indicating that an individual is or was very forgetful.","Very Forgetful | Very forgetful",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563035","Unable to Remember Anything","C156199","A response indicating that an individual is or was unable to remember anything.","Unable to Remember Anything | Unable to Remember | Unable to remember anything at all",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563036","Able to Think Clearly and Solve Day-to-day Problems","C156200","A response indicating that an individual is or was able to think clearly and solve day to day problems.","Able to Think Clearly and Solve Day-to-day Problems | Able to think clearly and solve day to day problems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563037","Had a Little Difficulty When Trying to Think and Solve Day-to-day Problems","C156201","A response indicating that an individual has or had a little difficulty when trying to think and solve day to day problems.","Had a Little Difficulty When Trying to Think and Solve Day-to-day Problems | Had a little difficulty when trying to think and solve day to day problems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563030","Had Some Difficulty When Trying to Think and Solve Day-to-day Problems","C156202","A response indicating that an individual has or had some difficulty when trying to think and solve day to day problems.","Had Some Difficulty When Trying to Think and Solve Day-to-day Problems | Had some difficulty when trying to think and solve day to day problems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563031","Had Great Difficulty When Trying to Think and Solve Day-to-day Problems","C156203","A response indicating that an individual has or had great difficulty when trying to think and solve day to day problems.","Had Great Difficulty When Trying to Think and Solve Day-to-day Problems | Had great difficulty when trying to think and solve day to day problems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563032","Unable to Think or Solve Day-to-day Problems","C156204","A response indicating that an individual is or was unable to think or solve day-to-day problems.","Unable to Think or Solve Day-to-day Problems | Unable to think or solve day to day problems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563033","Eat, Bathe, Dress, and Use Toilet Normally","C156205","A response indicating that an individual is or was able to eat, bathe, dress, and use the toilet normally.","Eat, Bathe, Dress, and Use Toilet Normally | Eat, bathe, dress and use the toilet normally",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563058","Eat, Bathe, Dress, and Use Toilet with Difficulty","C156206","A response indicating that an individual is or was able to eat, bathe, dress, and use the toilet independently, but with difficulty.","Eat, Bathe, Dress, and Use Toilet with Difficulty | Eat, bathe, dress or use the toilet independently with difficulty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563059","Required Mechanical Equipment to Eat, Bathe, Dress, or Use Toilet Independently","C156207","A response indicating that an individual is or was able to eat, bathe, dress, and use the toilet independently, but required mechanical equipment.","Required Mechanical Equipment to Eat, Bathe, Dress, or Use Toilet Independently | Required mechanical equipment to eat, bathe, dress or use the toilet independently",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563060","Required Help to Eat, Bathe, Dress, or Use Toilet","C156208","A response indicating that an individual required help from another person to eat, bathe, dress, or use the toilet.","Required Help to Eat, Bathe, Dress, or Use Toilet | Required the help of another person to eat, bathe, dress or use the toilet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563061","Generally Happy and Free from Worry","C156209","A response indicating that an individual is or was generally happy and free from worry.","Generally Happy and Free from Worry | Generally happy and free from worry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563054","Occasionally Fretful, Angry, Irritable, Anxious, or Depressed","C156210","A response indicating that an individual is or was occasionally fretful, angry, irritable, anxious, or depressed.","Occasionally Fretful, Angry, Irritable, Anxious, or Depressed | Occasionally fretful, angry, irritable, anxious or depressed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563056","Often Fretful, Angry, Irritable, Anxious, or Depressed","C156212","A response indicating that an individual is or was often fretful, angry, irritable, anxious, or depressed.","Often Fretful, Angry, Irritable, Anxious, or Depressed | Often fretful, angry, irritable, anxious or depressed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563057","Almost Always Fretful, Angry, Irritable, Anxious, or Depressed","C156213","A response indicating that an individual is or was almost always fretful, angry, irritable, anxious, or depressed.","Almost Always Fretful, Angry, Irritable, Anxious, or Depressed | Almost always fretful, angry, irritable, anxious or depressed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563050","Extremely Fretful, Angry, Irritable, Anxious, or Depressed; Needing Professional Help","C156214","A response indicating that an individual is or was extremely fretful, angry, irritable, anxious, or depressed, to the point of needing professional help.","Extremely Fretful, Angry, Irritable, Anxious, or Depressed; Needing Professional Help | Extremely fretful, angry, irritable, anxious or depressed; to the point of needing professional help",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563051","Occasional Pain or Discomfort; Relief from Non-prescription Drugs or Activity; No Disruption of Normal Activities","C156215","A response indicating that an individual has or had occasional pain or discomfort that was relieved by non-prescription drugs or self-control activities, without disruption of normal activities.","Occasional Pain or Discomfort; Relief from Non-prescription Drugs or Activity; No Disruption of Normal Activities | Occasional pain or discomfort.  Discomfort relieved by non-prescription drugs or self-control activity without disruption of normal activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563052","Frequent Pain or Discomfort; Relief from Oral Medicines; Occasional Disruption of Normal Activities","C156216","A response indicating that an individual has or had frequent pain or discomfort that was relieved by oral medicines, with occasional disruption of normal activities.","Frequent Pain or Discomfort; Relief from Oral Medicines; Occasional Disruption of Normal Activities | Frequent pain or discomfort.  Discomfort relieved by oral medicines with occasional disruption of normal activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563053","Frequent Pain or Discomfort; Relief Requires Prescription Narcotics; Frequent Disruption of Normal Activities","C156217","A response indicating that an individual has or had frequent pain or discomfort that required prescription narcotics for relief, with frequent disruption of normal activities.","Frequent Pain or Discomfort; Relief Requires Prescription Narcotics; Frequent Disruption of Normal Activities | Frequent pain or discomfort; frequent disruption of normal activities. Discomfort required prescription narcotics for relief",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563046","Severe Pain or Discomfort; Pain not Relieved by Drugs; Constant Disruption of Normal Activities","C156218","A response indicating that an individual has or had severe pain or discomfort that was not relieved by drugs and constantly disrupted normal activities.","Severe Pain or Discomfort; Pain not Relieved by Drugs; Constant Disruption of Normal Activities | Severe pain or discomfort.  Pain not relieved by drugs and constantly disrupted normal activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563047","PROMIS Pediatric and Parent Proxy Physical Health Domain","C156219","The set of PROMIS measures that assess the physical health of pediatric subjects through self-report or parent proxy report.","PROMIS Pediatric and Parent Proxy Physical Health Domain | PROMIS Ped Fatigue | Ped Fatigue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563048","Being Tired Made it Hard to Keep up with Schoolwork","C156220","A question about whether an individual feels or felt that being tired made it hard for them to keep up with their schoolwork.","Being Tired Made it Hard to Keep up with Schoolwork | Being tired made it hard for me to keep up with my schoolwork",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563049","Being Tired Made it Hard to Play or Go Out with Friends as Much as Would Like","C156221","A question about whether an individual feels or felt that being tired made it hard for them to play or go out with friends as much as they would like.","Being Tired Made it Hard to Play or Go Out with Friends as Much as Would Like Question | Being Tired Made it Hard to Play or Go Out with Friends as Much as Would Like | Being Tired Made it Hard to Play or Go Out with Friends as Much as Would Like | Being tired made it hard for me to play or go out with my friends as much as I'd like",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562950","Hard to Pay Attention Because of Tiredness","C156222","A question about whether an individual has or had trouble paying attention because they are tired.","Hard to Pay Attention Because of Tiredness | I was so tired it was hard for me to pay attention",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562951","Too Tired for Sports or Exercise","C156223","A question about whether an individual is or was too tired to do sports or exercise.","Too Tired for Sports or Exercise Question | I was too tired to do sports or exercise | Too Tired for Sports or Exercise | Too Tired for Sports or Exercise",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562952","Too Tired to Do Things Outside","C156224","A question about whether an individual is or was too tired to do things outside.","Too Tired to Do Things Outside | I was too tired to do things outside",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562953","Too Tired to Enjoy the Things I Like to Do","C156225","A question about whether an individual is or was too tired to enjoy the things they like to do.","Too Tired to Enjoy the Things I Like to Do | I was too tired to enjoy the things I like to do",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562940","Complete Tumor Cell Necrosis","C156234","A morphologic finding indicating the presence of tumor cell necrosis involving the entire neoplastic cellular infiltrate in a tissue sample. Viable tumor cells are absent.","Complete Tumor Cell Necrosis | Complete Necrosis (No Viable Tumor)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562941","Incomplete Tumor Cell Necrosis","C156235","A morphologic finding indicating the presence of focal or diffuse tumor cell necrosis involving part of the neoplastic cellular infiltrate in a tissue sample. Viable tumor cells are still present.","Incomplete Tumor Cell Necrosis | Incomplete Necrosis (Viable Tumor Present)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562942","No Evidence of Tumor Cell Necrosis Present","C156236","A morphologic finding indicating the absence of focal or diffuse tumor cell necrosis in a tissue sample.","No Evidence of Tumor Cell Necrosis Present | Not identified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562967","Hallucination Severity","C156239","An indication of the type of a hallucination and its impact on a subject.","Hallucination Severity | Hallucination Severity Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563215","Very Mild Hallucination","C156241","While resting or going to sleep, sees visions, smells odors or hears voices, sounds, or whispers in the absence of external stimulation, but no impairment in functioning.","Very Mild Hallucination | Very mild",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562962","Mild Hallucination","C156242","While in a clear state of consciousness, hears a voice calling the individual's name, experiences non-verbal auditory hallucinations (e.g., sounds or whispers), formless visual hallucinations or has sensory experiences in the presence of a modality relevant stimulus (e.g., visual illusions) infrequently (e.g., 1-2 times per week) and with no functional impairment.","Mild Hallucination | Mild",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562963","Moderate Hallucination","C156243","Occasional verbal, visual, gustatory, olfactory or tactile hallucinations with no functional impairment; or non-verbal auditory hallucinations/visual illusions more than infrequently or with impairment.","Moderate Hallucination | Moderate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562956","Moderately Severe Hallucination","C156252","Experiences daily hallucinations, or some areas of functioning are disrupted by hallucinations.","Moderately Severe Hallucination | Moderately severe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562964","Severe Hallucination","C156244","Experiences verbal or visual hallucinations several times a day, or many areas of functioning are disrupted by these hallucinations.","Severe Hallucination | Severe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562965","Extremely Severe Hallucination","C156245","Persistent verbal or visual hallucinations throughout the day, or most area of functioning are disrupted by these hallucinations.","Extremely Severe Hallucination | Extremely severe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033157","Prince Edward Island","C89813","A maritime province of eastern Canada consisting of the island of Prince Edward Island and other nearby islands. Its capital is Charlottetown.","Prince Edward Island | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028441","Nova Scotia","C89817","A Canadian province located on Canada's southeastern coast. Its capital is Halifax.","Nova Scotia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027963","New Brunswick","C89814","A maritime province of eastern Canada. Its capital is Fredericton.","New Brunswick | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006193","British Columbia","C89812","The westernmost Canadian province. Its capital is Victoria.","British Columbia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043438","Yukon","C89818","A territory in northwest Canada bordering Alaska to the west and the Northwest Territories to the east. Its capital is Whitehorse.","Yukon | Yukon Territory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028417","Northwest Territories","C89816","A province in northwest Canada bordering Yukon to the west and Nunavut to the east. Its capital is Yellowknife.","Northwest Territories | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828023","Signal Frequency","C112417","A measurement of the number of cycles of a periodic wave or pulse per unit of time.","Signal Frequency | Frequency | SIGFREQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563127","CARTOX Grade 0","C156291","A score of 10 on the CARTOX-10 assessment, indicating no neurotoxicity.","CARTOX Grade 0 | CARTOX No Neurological Impairment | CARTOX Score 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563135","Brazilian State","C156312","Any of the 27 federal units of Brazil, which include the 26 federal states of Brazil, plus the Federal District which contains the capital city, Brasilia.","Brazilian State | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL441259","Acre","C156313","A state in the westernmost part of the North Region of Brazil. Its capital is Rio Branco.","Acre | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL441260","Alagoas","C156314","A state in the eastern part of the Northeast Region of Brazil. Its capital is Maceio.","Alagoas | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL441262","Amapá","C156315","A state in the North Region of Brazil. Its capital is Macapa.","Amapa | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL441261","Amazonas","C156316","A state in the North Region of Brazil. Its capital is Manaus.","Amazonas | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL441263","Bahia","C156317","A state in the Northeast Region of Brazil. Its capital is Salvador.","Bahia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL441264","Ceará","C156318","A state in the Northeast Region of Brazil. Its capital is Fortaleza.","Ceara | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL441258","Distrito Federal","C156319","A state in the Central-West Region of Brazil. It contains the Brazilian capital city, Brasilia.","Distrito Federal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL441265","Espírito Santo","C156320","A state in the Southeast Region of Brazil. Its capital is Vitoria.","Espirito Santo | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL441266","Goiás","C156321","A state in the Central-West Region of Brazil. Its capital is Goiania","Goias | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL441267","Maranhão","C156322","A state in the Northeast Region of Brazil. Its capital is Sao Luis.","Maranhao | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL441270","Mato Grosso","C156323","A state in the Central-West Region of Brazil. Its capital is Cuiaba.","Mato Grosso | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL441269","Mato Grosso do Sul","C156324","A state in the Central-West Region of Brazil. Its capital is Campo Grande.","Mato Grosso do Sul | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL441268","Minas Gerais","C156325","A state in the Southeast Region of Brazil. Its capital is Belo Horizonte.","Minas Gerais | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL441275","Paraná","C156326","A state in the South Region of Brazil. Its capital is Curitiba.","Parana | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL441271","Pará","C156328","A state in the North Region of Brazil. Its capital is Belem.","Para | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL441273","Pernambuco","C156329","A state in the Northeast Region of Brazil. Its capital is Recife.","Pernambuco | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL441274","Piauí","C156330","A state in the Northeast Region of Brazil. Its capital is Teresina.","Piaui | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL441276","Rio de Janeiro","C156331","A state in the Southeast Region of Brazil. Its capital is Rio de Janeiro.","Rio de Janeiro | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL441277","Rio Grande do Norte","C156332","A state in the Northeast Region of Brazil. Its capital is Natal.","Rio Grande do Norte | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL441280","Rio Grande do Sul","C156333","A state in the South Region of Brazil. Its capital is Porto Alegre.","Rio Grande do Sul | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL441278","Rondonia","C156334","A state in the North Region of Brazil. Its capital is Porto Velho.","Rondonia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL441279","Roraima","C156335","A state in the North Region of Brazil. Its capital is Boa Vista.","Roraima | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL441281","Santa Catarina","C156336","A state in the South Region of Brazil. Its capital is Florianopolis.","Santa Catarina | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL441282","Sergipe","C156337","A state in the Northeast Region of Brazil. Its capital is Aracaju.","Sergipe | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL441283","São Paulo","C156338","A state in the Southeast Region of Brazil. Its capital is Sao Paulo.","Sao Paulo | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL441284","Tocantins","C156339","A state in the North Region of Brazil. Its capital is Palmas.","Tocantins | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086317","Fluid-Filled","C124535","Containing fluid.","Fluid-Filled | FLUID FILLED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563216","Emotion Regulation Index","C156356","A component of the Behavior Rating Inventory of Executive Function (BRIEF). The Emotion Regulation Index (ERI) represents the child's ability to regulate emotional responses and to shift set or adjust to changes in environment, people, plans, or demands. It is composed of the Shift and Emotional Control scales.","Emotion Regulation Index | ERI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563203","Cognitive Regulation Index","C156359","A component of the Behavior Rating Inventory of Executive Function (BRIEF). The Cognitive Regulation Index (CRI) reflects the child's ability to control and manage cognitive processes and to problem solve effectively. It is composed of the Initiate, Working Memory, Plan/Organize, Task-Monitor, and Organization of Materials scales and relates directly to the ability to actively problem solve in a variety of contexts and to complete tasks such as schoolwork.","Cognitive Regulation Index | CRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563079","del11q22.3/ATM Locus","C156383","A cytogenetic abnormality that refers to the deletion of the chromosomal band 11q22.3, which also results in the deletion of the ATM gene.","del11q22.3/ATM Locus | del11q22.3 (ATM) | del11q22.3/ATM | del11q22.3/Ataxia Telangiectasia Mutated Gene Locus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0398738","Leukocyte Adhesion Deficiency Type 1","C4689","A rare immunodeficiency with an autosomal recessive pattern of inheritance. It is caused by mutation in the ITGB2 gene on chromosome 21 which codes for the beta subunit of beta-2 integrin (CD18). The mutation results in significantly reduced or absent expression of CD18 on the surface of leukocytes which impairs their ability to migrate and interact with antigens. Initial clinical signs include omphalitis and delayed separation of the umbilical cord. The clinical course is marked by recurrent bacterial and fungal infection without pus formation. In instances where there is < 1% expression of CD18, prognosis is dismal with a high likelihood for life-threatening infection within the first year of life.","Leukocyte Adhesion Deficiency Type 1 | LAD-1 | LAD-1 Deficiency | LAD-Type I | LAD1 | LFA-I Deficiency | LFA1 Immunodeficiency",,,,,,,,,,,,,,,"4123096","Leukocyte adhesion deficiency - type 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1415357","GUCA2A Gene","C126515","This gene plays a role in the positive regulation of intestinal guanylate cyclase.","GUCA2A Gene | GUCA2A | Guanylate Cyclase Activator 2A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512343","BCR/ABL1 Fusion Negative","C128834","Indicates that expression of the BCR/ABL1 fusion has not been detected in a sample.","BCR/ABL1 Fusion Negative | BCR-ABL Fusion Negative | BCR-ABL Negative | BCR-ABL1 Fusion Negative | BCR-ABL1 Negative | BCR/ABL Fusion Negative | BCR/ABL Negative | BCR/ABL1 Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0694666","Right Deltoid","C105635","The muscle that creates the rounded contour of the shoulder which originates from the lateral third of the clavicle, the superior surface of the acromion process, and the posterior border of the spine of the scapula and inserts on the lateral side of the shaft of the humerus. The deltoid muscle is innervated by the brachial plexus arising from the fifth and sixth cervical nerves and controls abduction, extension, flexion, and rotation of the arm. This is the deltoid on the right side of the body.","Right Deltoid | RD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563075","Lymphoblasts More Than 50 Percent of Bone Marrow Nucleated Cells","C156386","A semi-quantitative microscopic finding indicating that more than 50 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells of lymphoid origin.","Lymphoblasts More Than 50 Percent of Bone Marrow Nucleated Cells | Lymphoblasts Greater than 50 Percent of Bone Marrow Nucleated Cells | Lymphoblasts Over 50 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563076","Alpha/Beta T-Lymphocyte","C156387","A mature T-cell that expresses a T-cell receptor complex comprised of the highly variable alpha and beta chains complexed with the invariant CD3 antigen complex and plays a primary role in adaptive immunity.","Alpha/Beta T-Lymphocyte | Alpha Beta T Cell | Alpha Beta T Lymphocyte | Alpha Beta T-Cell | Alpha Beta T-Lymphocyte | Alpha/Beta T Cell | Alpha/Beta T Lymphocyte | Alpha/Beta T-Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563077","Histone H3 Lysine 79","C156388","The lysine residue found at amino acid position 79 in the histone H3 protein. Methylation of this residue by DOT1L protein disrupts telomeric silencing and may be a marker for cellular transformation and disease progression in patients with leukemia.","Histone H3 Lysine 79 | H3K79 | Histone H3 Lys79 | Lysine 79 of Histone H3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563100","Neoplastic Plasma Cells 5 Percent or Less of Bone Marrow Nucleated Cells","C156389","A semi-quantitative microscopic finding indicating that 5 percent or less of the nucleated cells in a bone marrow sample are neoplastic plasma cells.","Neoplastic Plasma Cells 5 Percent or Less of Bone Marrow Nucleated Cells | Neoplastic Plasma Cells Less than or Equal to 5 Percent of Bone Marrow Nucleated Cells | Neoplastic Plasma Cells Under or Equal to 5 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563103","HHLA2 Gene","C156392","This gene plays a role in the modulation of T-cell activation.","HHLA2 Gene | HERV-H LTR-Associating 2 Gene | HHLA2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563101","Lymphoblasts 5 Percent or More of Peripheral Blood White Cells","C156390","A semi-quantitative microscopic finding indicating that 5 percent or more of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells of lymphoid origin.","Lymphoblasts 5 Percent or More of Peripheral Blood White Cells | Lymphoblasts Greater than or Equal to 5 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563102","PSA Level Equal to Nadir Plus 2 ng/mL","C156391","A finding indicating that the blood concentration of prostate specific antigen in a subject's sample has increased by 2 ng/mL over the lowest value recorded for a sample from that subject.","PSA Level Equal to Nadir Plus 2 ng/mL | PSA Level Equal to Nadir Plus 2 | PSA Level Equal to Nadir Plus Two ng/mL | PSA Nadir Plus 2 | PSA Nadir Plus 2 ng/mL | PSA Nadir Plus Two ng/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563140","RARA Gene Translocation","C156350","A cytogenetic abnormality that refers to any translocation involving the RARA gene.","RARA Gene Translocation | NR1B1 Gene Translocation | RARA Translocation | RARalpha Gene Translocation | Retinoic Acid Receptor Alpha Gene Translocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563170","T2 (Observed)-Weighted Imaging","C156447","MRI imaging based on the observed T2 relaxation time of tissues.","T2 (Observed)-Weighted Imaging | T2*-Weighted Imaging | T2*MRI | T2*WI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563172","Loes Score","C156449","A rating of the severity of abnormalities in the brain found on MRI. It ranges from 0 to 34, based on a point system derived from the location and extent of disease and the presence of atrophy in the brain, either localized to specific points or globally throughout the brain.","Loes Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563173","International System for Human Cytogenetic Nomenclature","C156450","An international standard for human chromosome nomenclature, which includes band names, symbols and abbreviated terms used in the description of human chromosome and chromosome abnormalities.","International System for Human Cytogenetic Nomenclature | ISCN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079474","Epidermolysis Bullosa Dystrophica, Autosomal Recessive","C156446","An autosomal recessive allelic variant of epidermolysis bullosa dystrophica caused by mutation(s) in the COL7A1 gene, encoding collagen alpha-1(VII) chain.","Epidermolysis Bullosa Dystrophica, Autosomal Recessive | Autosomal Recessive Generalized Dystrophic Epidermolysis Bullosa | RDEB | Recessive Dystrophic Epidermolysis Bullosa",,,,,,,,,,,,,,,"4174972","Recessive dystrophic epidermolysis bullosa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL563166","Tolerance Induction in Solid Organ Transplantation","C156451","An immunological environment, mediated by T-regulatory cells, favoring regulation, supporting graft survival, without interfering with crucial immune surveillance mechanisms and, concurrently, abolishing immunosuppressant-related toxicity.","Tolerance Induction in Solid Organ Transplantation | Tolerance induction associated with solid organ transplant | Transplantation Tolerance Induction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0680536","commercial","C96109","Stability data for a commercial lot.","Commercial Lot | Commercial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545165","Stratified Randomization","C147145","A type of block randomization in which subjects are stratified into groups based on prognostic variables and then randomized into balanced treatment groups.","Stratified Randomization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562948","IL7R Gene Mutation","C156228","A change in the nucleotide sequence of the IL7R gene.","IL7R Gene Mutation | CD127 Gene Mutation | CDW127 Gene Mutation | IL-7R-Alpha Gene Mutation | IL7RA Gene Mutation | Interleukin 7 Receptor Gene Mutation | Interleukin-7 Receptor Subunit Alpha Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562947","SH2B3 Gene Deletion","C156227","A molecular abnormality referring to the loss of at least one copy of the SH2B3 gene.","SH2B3 Gene Deletion | LNK Gene Deletion | SH2B Adaptor Protein 3 Gene Deletion | SH2B3 Deletion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562946","EPOR Fusion Positive","C156226","An indication that expression of a fusion containing sequences from EPOR has been detected in a sample.","EPOR Fusion Positive | EPO-R Fusion Positive | Erythropoietin Receptor Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539764","Reason Treatment Not Administered","C102704","The reason the treatment was not administered.","Reason Treatment Not Administered | reason treatment not given | reason_treatment_not_given",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538535","Bladder Cancer TNM Finding v8","C140380","A finding about one or more characteristics of bladder cancer, following the rules of the TNM AJCC v8 classification system. This classification system applies to carcinomas arising in the bladder. The typical carcinoma of the bladder is urothelial carcinoma. These carcinomas may include other histologic elements, including adenocarcinoma, squamous cell carcinoma, and small cell neuroendocrine carcinoma, but should be classified as urothelial unless the cancer is composed entirely of the alternative histology. All histologic cell types that are derived primarily from the urinary bladder epithelium should follow this classification system. It does not apply to prostatic urothelial carcinomas (are staged according to the classification for urethra), lymphomas (are staged according to the classification for Hodgkin and non-Hodgkin lymphoma), and sarcomas (are staged according to the classification for soft tissue sarcoma of the abdomen and thoracic visceral organs).  (from AJCC 8th Ed.)","Bladder Cancer TNM Finding v8 | Bladder Carcinoma TNM Finding v8 | Tumor Stage (Pathologic)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538509","Bladder Cancer pT4b TNM Finding v8","C140406","Bladder cancer with extravesical tumor invading pelvic wall, abdominal wall. (from AJCC 8th Ed.)","Bladder Cancer pT4b TNM Finding v8 | Bladder Carcinoma pT4b TNM Finding v8 | pT4b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538510","Bladder Cancer pT4a TNM Finding v8","C140405","Bladder cancer with extravesical tumor invading directly into prostatic stroma, uterus, vagina. (from AJCC 8th Ed.)","Bladder Cancer pT4a TNM Finding v8 | Bladder Carcinoma pT4a TNM Finding v8 | pT4a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538495","Bladder Cancer pT4 TNM Finding v8","C140404","Bladder cancer with extravesical tumor directly invading any of the following: prostatic stroma, seminal vesicles, uterus, vagina, pelvic wall, abdominal wall. (from AJCC 8th Ed.)","Bladder Cancer pT4 TNM Finding v8 | Bladder Carcinoma pT4 TNM Finding v8 | pT4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538496","Bladder Cancer pT3b TNM Finding v8","C140403","Bladder cancer with tumor invading perivesical soft tissue, macroscopically (extravesical mass). (from AJCC 8th Ed.)","Bladder Cancer pT3b TNM Finding v8 | Bladder Carcinoma pT3b TNM Finding v8 | pT3b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538497","Bladder Cancer pT3a TNM Finding v8","C140402","Bladder cancer with tumor invading perivesical soft tissue, microscopically. (from AJCC 8th Ed.)","Bladder Cancer pT3a TNM Finding v8 | Bladder Carcinoma pT3a TNM Finding v8 | pT3a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538498","Bladder Cancer pT3 TNM Finding v8","C140401","Bladder cancer with tumor invading perivesical soft tissue. (from AJCC 8th Ed.)","Bladder Cancer pT3 TNM Finding v8 | Bladder Carcinoma pT3 TNM Finding v8 | pT3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538499","Bladder Cancer pT2b TNM Finding v8","C140400","Bladder cancer with tumor invading deep muscularis propria (outer half). (from AJCC 8th Ed.)","Bladder Cancer pT2b TNM Finding v8 | Bladder Carcinoma pT2b TNM Finding v8 | pT2b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538500","Bladder Cancer pT2a TNM Finding v8","C140399","Bladder cancer with tumor invading superficial muscularis propria (inner half). (from AJCC 8th Ed.)","Bladder Cancer pT2a TNM Finding v8 | Bladder Carcinoma pT2a TNM Finding v8 | pT2a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538501","Bladder Cancer pT2 TNM Finding v8","C140398","Bladder cancer with tumor invading muscularis propria. (from AJCC 8th Ed.)","Bladder Cancer pT2 TNM Finding v8 | Bladder Carcinoma pT2 TNM Finding v8 | pT2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538502","Bladder Cancer pT1 TNM Finding v8","C140397","Bladder cancer with tumor invading lamina propria (subepithelial connective tissue). (from AJCC 8th Ed.)","Bladder Cancer pT1 TNM Finding v8 | Bladder Carcinoma pT1 TNM Finding v8 | pT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538519","Bladder Cancer pTis TNM Finding v8","C140396","Bladder cancer with a finding of urothelial carcinoma in situ: 'flat tumor'. (from AJCC 8th Ed.)","Bladder Cancer pTis TNM Finding v8 | Bladder Carcinoma pTis TNM Finding v8 | pTis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538520","Bladder Cancer pTa TNM Finding v8","C140395","Bladder cancer with a finding of non-invasive papillary carcinoma. (from AJCC 8th Ed.)","Bladder Cancer pTa TNM Finding v8 | Bladder Carcinoma pTa TNM Finding v8 | pTa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538521","Bladder Cancer pT0 TNM Finding v8","C140394","Bladder cancer with no evidence of primary tumor. (from AJCC 8th Ed.)","Bladder Cancer pT0 TNM Finding v8 | Bladder Carcinoma pT0 TNM Finding v8 | pT0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538522","Bladder Cancer pTX TNM Finding v8","C140393","Bladder cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Bladder Cancer pTX TNM Finding v8 | Bladder Carcinoma pTX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538503","Bladder Cancer pN3 TNM Finding v8","C140412","Bladder cancer with lymph node metastasis to the common iliac lymph nodes. (from AJCC 8th Ed.)","Bladder Cancer pN3 TNM Finding v8 | Bladder Carcinoma pN3 TNM Finding v8 | pN3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538504","Bladder Cancer pN2 TNM Finding v8","C140411","Bladder cancer with multiple regional lymph node metastasis in the true pelvis (perivesical, obturator, internal and external iliac, or sacral lymph node metastasis). (from AJCC 8th Ed.)","Bladder Cancer pN2 TNM Finding v8 | Bladder Carcinoma pN2 TNM Finding v8 | pN2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538505","Bladder Cancer pN1 TNM Finding v8","C140410","Bladder cancer with single regional lymph node metastasis in the true pelvis (perivesical, obturator, internal and external iliac, or sacral lymph node). (from AJCC 8th Ed.)","Bladder Cancer pN1 TNM Finding v8 | Bladder Carcinoma pN1 TNM Finding v8 | pN1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538506","Bladder Cancer pN0 TNM Finding v8","C140409","Bladder cancer with no lymph node metastasis. (from AJCC 8th Ed.)","Bladder Cancer pN0 TNM Finding v8 | Bladder Carcinoma pN0 TNM Finding v8 | pN0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538507","Bladder Cancer pNX TNM Finding v8","C140408","Bladder cancer in which the lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Bladder Cancer pNX TNM Finding v8 | Bladder Carcinoma pNX TNM Finding v8 | pNX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL929283","Unplanned","C151899","Not expected or scheduled.","Unplanned | ",,,,,,,,,,,,,,,"37158358","Unplanned",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0678857","fine motor skills","C156703","The ability to control the movement of the small muscles of the fingers and hands.","Fine Motor Skills | Dexterity | Fine motor skills | Manual Dexterity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539039","Thyroid Carcinoma TNM Finding v8","C140896","A finding about one or more characteristics of thyroid carcinoma, following the rules of the TNM AJCC v8 classification system.","Thyroid Carcinoma TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539013","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT4b TNM Finding v8","C140924","Gross extrathyroidal extension invading prevertebral fascia or encasing the carotid artery or mediastinal vessels from a tumor of any size. (from AJCC 8th Ed.)","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT4b TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma pT4b TNM Finding v8 | pT4b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539014","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT4a TNM Finding v8","C140923","Gross extrathyroidal extension invading subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve from a tumor of any size. (from AJCC 8th Ed.)","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT4a TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma pT4a TNM Finding v8 | pT4a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539015","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT4 TNM Finding v8","C140922","Tumor of any size with gross extrathyroidal extension. (from AJCC 8th Ed.)","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT4 TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma pT4 TNM Finding v8 | pT4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539016","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT3b TNM Finding v8","C140921","Gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles) from a tumor of any size. (from AJCC 8th Ed.)","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT3b TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma pT3b TNM Finding v8 | pT3b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539001","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT3a TNM Finding v8","C140920","Tumor measuring more than 4 cm in greatest dimension limited to the thyroid. (from AJCC 8th Ed.)","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT3a TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma pT3a TNM Finding v8 | pT3a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539002","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT3 TNM Finding v8","C140919","Tumor measuring more than 4 cm in greatest dimension limited to the thyroid, or gross extrathyroidal extension invading only strap muscles. (from AJCC 8th Ed.)","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT3 TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma pT3 TNM Finding v8 | pT3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539003","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT2 TNM Finding v8","C140918","Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. (from AJCC 8th Ed.)","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT2 TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma pT2 TNM Finding v8 | pT2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539004","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT1b TNM Finding v8","C140917","Tumor measuring more than 1 cm but 2 cm or less in greatest dimension limited to the thyroid. (from AJCC 8th Ed.)","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT1b TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma pT1b TNM Finding v8 | pT1b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539005","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT1a TNM Finding v8","C140916","Tumor measuring 1 cm or less in greatest dimension limited to the thyroid. (from AJCC 8th Ed.)","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT1a TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma pT1a TNM Finding v8 | pT1a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539006","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT1 TNM Finding v8","C140915","Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. (from AJCC 8th Ed.)","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT1 TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma pT1 TNM Finding v8 | pT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539007","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT0 TNM Finding v8","C140914","No evidence of primary tumor. (from AJCC 8th Ed.)","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT0 TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma pT0 TNM Finding v8 | pT0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539008","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pTX TNM Finding v8","C140913","Primary tumor cannot be assessed. (from AJCC 8th Ed.)","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pTX TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma pTX TNM Finding v8 | pTX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539029","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma cN1b TNM Finding v8","C140908","Metastasis to unilateral, bilateral, or contralateral lateral neck lymph nodes (levels I, II, III, IV, or V) or retropharyngeal lymph nodes. (from AJCC 8th Ed.)","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma cN1b TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma cN1b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539030","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma cN1a TNM Finding v8","C140907","Metastasis to level VI or VII (pretracheal, paratracheal, or prelaryngeal /Delphian, or upper mediastinal) lymph nodes. This can be unilateral or bilateral disease. (from AJCC 8th Ed.)","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma cN1a TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma cN1a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539031","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma cN1 TNM Finding v8","C140906","Metastasis to regional nodes. (from AJCC 8th Ed.)","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma cN1 TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma cN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539032","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma cN0b TNM Finding v8","C140905","No radiologic or clinical evidence of locoregional lymph node metastasis. (from AJCC 8th Ed.)","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma cN0b TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma cN0b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539009","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pN0a TNM Finding v8","C140928","One or more cytologically or histologically confirmed benign lymph nodes. (from AJCC 8th Ed.)","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pN0a TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma pN0a TNM Finding v8 | pN0a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539017","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma cN0 TNM Finding v8","C140904","No evidence of locoregional lymph node metastasis. (from AJCC 8th Ed.)","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma cN0 TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma cN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539018","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma cNX TNM Finding v8","C140903","Regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma cNX TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma cNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539026","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pM1 TNM Finding v8","C140911","Distant metastasis. (from AJCC 8th Ed.)","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pM1 TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma pM1 TNM Finding v8 | pM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539020","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma cM1 TNM Finding v8","C140901","Distant metastasis. (from AJCC 8th Ed.)","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma cM1 TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma cM1 TNM Finding v8 | cM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539021","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma cM0 TNM Finding v8","C140900","No distant metastasis. (from AJCC 8th Ed.)","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma cM0 TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538986","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pN1b TNM Finding v8","C140935","Metastasis to unilateral, bilateral, or contralateral lateral neck lymph nodes (levels I, II, III, IV, or V) or retropharyngeal lymph nodes. (from AJCC 8th Ed.)","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pN1b TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma pN1b TNM Finding v8 | pN1b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538989","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pN1a TNM Finding v8","C140932","Metastasis to level VI or VII (pretracheal, paratracheal, or prelaryngeal/Delphian, or upper mediastinal) lymph nodes. This can be unilateral or bilateral disease. (from AJCC 8th Ed.)","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pN1a TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma pN1a TNM Finding v8 | pN1a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538992","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pN1 TNM Finding v8","C140929","Metastasis to regional nodes. (from AJCC 8th Ed.)","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pN1 TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma pN1 TNM Finding v8 | pN1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539010","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pN0 TNM Finding v8","C140927","No evidence of locoregional lymph node metastasis. (from AJCC 8th Ed.)","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pN0 TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma pN0 TNM Finding v8 | pN0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539011","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pNX TNM Finding v8","C140926","Regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pNX TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma pNX TNM Finding v8 | pNX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539103","Differentiated Thyroid Gland Carcinoma Under 55 Years AJCC v8 Stage","C140962","A differentiated thyroid gland carcinoma stage for patients under 55 years of age defined according to the AJCC 8th edition criteria.","Differentiated Thyroid Gland Carcinoma Under 55 Years AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539080","Stage II Differentiated Thyroid Gland Carcinoma Under 55 Years AJCC v8","C140970","Stage II includes: Any T, Any N, M1. M1: Distant metastasis. (from AJCC 8th Ed.)","Stage II Differentiated Thyroid Gland Carcinoma Under 55 Years AJCC v8 | Stage II Differentiated Thyroid Gland Cancer Under 55 Years",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539083","Stage I Differentiated Thyroid Gland Carcinoma Under 55 Years AJCC v8","C140967","Stage I includes: Any T, Any N, M0. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage I Differentiated Thyroid Gland Carcinoma Under 55 Years AJCC v8 | Stage I Differentiated Thyroid Gland Cancer Under 55 Years",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539086","Differentiated Thyroid Gland Carcinoma 55 Years and Older AJCC v8 Stage","C140964","A differentiated thyroid gland carcinoma stage for patients 55 years and older defined according to the AJCC 8th edition criteria.","Differentiated Thyroid Gland Carcinoma 55 Years and Older AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539091","Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8","C140975","Stage IVB includes: 55 years and older: Any T, Any N, M1. M1: Distant metastasis. (from AJCC 8th Ed.)","Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8 | Stage IVB Differentiated Thyroid Gland Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539092","Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8","C140974","Stage IVA includes: 55 years and older: T4b, Any N, M0. T4b: Gross extrathyroidal extension invading prevertebral fascia or encasing the carotid artery or mediastinal vessels from a tumor of any size. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8 | Stage IVA Differentiated Thyroid Gland Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539094","Stage III Differentiated Thyroid Gland Carcinoma AJCC v8","C140972","Stage III includes: 55 years and older: T4a, Any N, M0. T4a: Gross extrathyroidal extension invading subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve from a tumor of any size. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage III Differentiated Thyroid Gland Carcinoma AJCC v8 | Stage III Differentiated Thyroid Gland Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539079","Stage II Differentiated Thyroid Gland Carcinoma 55 Years and Older AJCC v8","C140971","Stage II includes: (T1, N1, M0); (T2, N1, M0); (T3a/T3b, Any N, M0). T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. T3a: Tumor measuring more than 4 cm in greatest dimension limited to the thyroid. T3b: Gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles) from a tumor of any size. N1: Metastasis to regional nodes. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage II Differentiated Thyroid Gland Carcinoma 55 Years and Older AJCC v8 | Stage II Differentiated Thyroid Gland Cancer 55 Years and Older",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539082","Stage I Differentiated Thyroid Gland Carcinoma 55 Years and Older AJCC v8","C140968","Stage I includes: (T1, N0/NX, M0); (T2, N0/NX, M0).  T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. N0: No evidence of locoregional lymph node metastasis. NX: Regional lymph nodes cannot be assessed. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage I Differentiated Thyroid Gland Carcinoma 55 Years and Older AJCC v8 | Stage I Differentiated Thyroid Gland Cancer 55 Years and Older",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986744","Dynamic Scan","C94890","A scan having a number of sequential frames.","Dynamic Scan | Dynamic Acquisition | Dynamic Imaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935880","Static Imaging","C156765","Imaging data acquired over a single time frame. The result is a single frame that represents the average amount of radioactivity during the scan period. Only semi-quantitative information can be derived from static acquisitions (e.g., relative tracer uptake).","Static Imaging | Static Acquisition | Static Scan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520673","Gastric Cancer TNM Finding v8","C133595","A finding about one or more characteristics of gastric cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to all carcinomas that arise in the stomach. Gastrointestinal stromal tumors, sarcomas, lymphomas and well-differentiated neuroendocrine tumors (G1 and G2) are not staged using this staging system. (from AJCC 8th Ed.)","Gastric Cancer TNM Finding v8 | Gastric Carcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520696","Gastric Cancer pT4b TNM Finding v8","C133616","Gastric cancer with tumor invading adjacent structures/organs. (from AJCC 8th Ed.)","Gastric Cancer pT4b TNM Finding v8 | Gastric Carcinoma pT4b TNM Finding v8 | pT4b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520695","Gastric Cancer pT4a TNM Finding v8","C133615","Gastric cancer with tumor invading the serosa (visceral peritoneum). (from AJCC 8th Ed.)","Gastric Cancer pT4a TNM Finding v8 | Gastric Carcinoma pT4a TNM Finding v8 | pT4a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520694","Gastric Cancer pT4 TNM Finding v8","C133614","Gastric cancer with tumor invading the serosa (visceral peritoneum) or adjacent structures. The adjacent structures of the stomach include the spleen, transverse colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small intestine, and retroperitoneum. Intramural extension to the duodenum or esophagus is not considered invasion of an adjacent structure, but is classified using the depth of the greatest invasion in any of these sites. (from AJCC 8th Ed.)","Gastric Cancer pT4 TNM Finding v8 | Gastric Carcinoma pT4 TNM Finding v8 | pT4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520693","Gastric Cancer pT3 TNM Finding v8","C133613","Gastric cancer with tumor penetrating the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. The adjacent structures of the stomach include the spleen, transverse colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small intestine, and retroperitoneum. Intramural extension to the duodenum or esophagus is not considered invasion of an adjacent structure, but is classified using the depth of the greatest invasion in any of these sites. (from AJCC 8th Ed.)","Gastric Cancer pT3 TNM Finding v8 | Gastric Carcinoma pT3 TNM Finding v8 | pT3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520692","Gastric Cancer pT2 TNM Finding v8","C133612","Gastric cancer with tumor invading the muscularis propria. A tumor may penetrate the muscularis propria with extension into the gastrocolic or gastrohepatic ligaments, or into the greater or lesser omentum, without perforation of the visceral peritoneum covering these structures. In this case, the tumor is classified as T3. If there is perforation of the visceral peritoneum covering the gastric ligaments or the omentum, the tumor should be classified as T4. (from AJCC 8th Ed.)","Gastric Cancer pT2 TNM Finding v8 | Gastric Carcinoma pT2 TNM Finding v8 | pT2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520691","Gastric Cancer pT1b TNM Finding v8","C133611","Gastric cancer with tumor invading the submucosa. (from AJCC 8th Ed.)","Gastric Cancer pT1b TNM Finding v8 | Gastric Carcinoma pT1b TNM Finding v8 | pT1b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520690","Gastric Cancer pT1a TNM Finding v8","C133610","Gastric cancer with tumor invading the lamina propria or muscularis mucosae. (from AJCC 8th Ed.)","Gastric Cancer pT1a TNM Finding v8 | Gastric Carcinoma pT1a TNM Finding v8 | pT1a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520689","Gastric Cancer pT1 TNM Finding v8","C133609","Gastric cancer with tumor invading the lamina propria, muscularis mucosae, or submucosa. (from AJCC 8th Ed.)","Gastric Cancer pT1 TNM Finding v8 | Gastric Carcinoma pT1 TNM Finding v8 | pT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520698","Gastric Cancer pTis TNM Finding v8","C133608","Gastric cancer with a finding of carcinoma in situ: intraepithelial tumor without invasion of the lamina propria, high grade dysplasia. (from AJCC 8th Ed.)","Gastric Cancer pTis TNM Finding v8 | Gastric Carcinoma pTis TNM Finding v8 | pTis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520697","Gastric Cancer pTX TNM Finding v8","C133606","Gastric cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Gastric Cancer pTX TNM Finding v8 | Gastric Carcinoma pTX TNM Finding v8 | pTX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520688","Gastric Cancer pT0 TNM Finding v8","C133607","Gastric cancer with no evidence of primary tumor. (from AJCC 8th Ed.)","Gastric Cancer pT0 TNM Finding v8 | Gastric Carcinoma pT0 TNM Finding v8 | pT0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520686","Gastric Cancer pN3b TNM Finding v8","C133624","Gastric cancer with metastasis in sixteen or more regional lymph nodes. (from AJCC 8th Ed.)","Gastric Cancer pN3b TNM Finding v8 | Gastric Carcinoma pN3b TNM Finding v8 | pN3b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520685","Gastric Cancer pN3a TNM Finding v8","C133623","Gastric cancer with metastasis in seven to fifteen regional lymph nodes. (from AJCC 8th Ed.)","Gastric Cancer pN3a TNM Finding v8 | Gastric Carcinoma pN3a TNM Finding v8 | pN3a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520684","Gastric Cancer pN3 TNM Finding v8","C133622","Gastric cancer with metastasis in seven or more regional lymph nodes. (from AJCC 8th Ed.)","Gastric Cancer pN3 TNM Finding v8 | Gastric Carcinoma pN3 TNM Finding v8 | pN3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520683","Gastric Cancer pN2 TNM Finding v8","C133621","Gastric cancer with metastasis in three to six regional lymph nodes. (from AJCC 8th Ed.)","Gastric Cancer pN2 TNM Finding v8 | Gastric Carcinoma pN2 TNM Finding v8 | pN2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520682","Gastric Cancer pN1 TNM Finding v8","C133620","Gastric cancer with metastasis in one or two regional lymph nodes. (from AJCC 8th Ed.)","Gastric Cancer pN1 TNM Finding v8 | Gastric Carcinoma pN1 TNM Finding v8 | pN1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520681","Gastric Cancer pN0 TNM Finding v8","C133619","Gastric cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","Gastric Cancer pN0 TNM Finding v8 | Gastric Carcinoma pN0 TNM Finding v8 | pN0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520687","Gastric Cancer pNX TNM Finding v8","C133618","Gastric cancer in which the regional lymph node(s) cannot be assessed.  (from AJCC 8th Ed.)","Gastric Cancer pNX TNM Finding v8 | Gastric Carcinoma pNX TNM Finding v8 | pNX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520680","Gastric Cancer pM1 TNM Finding v8","C133604","Gastric cancer with distant metastasis. (from AJCC 8th Ed.)","Gastric Cancer pM1 TNM Finding v8 | Gastric Carcinoma pM1 TNM Finding v8 | pM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520679","Gastric Cancer cM1 TNM Finding v8","C133600","Gastric cancer with distant metastasis. (from AJCC 8th Ed.)","Gastric Cancer cM1 TNM Finding v8 | Gastric Carcinoma cM1 TNM Finding v8 | cM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520678","Gastric Cancer cM0 TNM Finding v8","C133598","Gastric cancer without evidence of distant metastasis. (from AJCC 8th Ed.)","Gastric Cancer cM0 TNM Finding v8 | Gastric Carcinoma cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520674","Gastric Cancer by AJCC v8 Clinical Stage","C133639","A term that refers to the clinical staging of gastric cancer according to the American Joint Committee on Cancer, 8th edition.","Gastric Cancer by AJCC v8 Clinical Stage | Gastric Cancer by AJCC v8 cTNM Stage | Gastric Carcinoma by AJCC v8 Clinical Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520641","Clinical Stage IVB Gastric Cancer AJCC v8","C133653","Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","Clinical Stage IVB Gastric Cancer AJCC v8 | Clinical Stage IVB Gastric Carcinoma AJCC v8 | Stage IVB Gastric (Stomach) Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520637","Clinical Stage IVA Gastric Cancer AJCC v8","C133652","Stage IVA includes: (T4b, Any N, M0): T4b: Tumor invades adjacent structures/organs. M0: No distant metastasis. (AJCC 8th ed.)","Clinical Stage IVA Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Carcinoma AJCC v8 | Stage IVA Gastric (Stomach) Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520627","Clinical Stage III Gastric Cancer AJCC v8","C133650","Stage III includes: (T3, N1, N2, or N3, M0); (T4a, N1, N2, or N3, M0). T3: Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. T4a: Tumor invades the serosa (visceral peritoneum). N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastric Carcinoma AJCC v8 | Stage III Gastric (Stomach) Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520623","Clinical Stage IIB Gastric Cancer AJCC v8","C133682","Stage IIB includes: (T3, N0, M0); (T4a, N0, M0). T3: Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. T4a: Tumor invades the serosa (visceral peritoneum). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Clinical Stage IIB Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Carcinoma AJCC v8 | Stage IIB Gastric (Stomach) Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520620","Clinical Stage IIA Gastric Cancer AJCC v8","C133681","Stage IIA includes: (T1, N1, N2, or N3, M0); (T2, N1, N2, or N3, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Carcinoma AJCC v8 | Stage IIA Gastric (Stomach) Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520611","Clinical Stage I Gastric Cancer AJCC v8","C133648","Stage I includes: (T1, N0, M0); (T2, N0, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage I Gastric Carcinoma AJCC v8 | Stage I Gastric (Stomach) Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520607","Clinical Stage 0 Gastric Cancer AJCC v8","C133647","Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ: intraepithelial tumor without invasion of the lamina propria, high grade dysplasia. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Carcinoma AJCC v8 | Stage 0 Gastric (Stomach) Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520675","Gastric Cancer by AJCC v8 Pathologic Stage","C133640","A term that refers to the pathologic staging of gastric cancer according to the American Joint Committee on Cancer, 8th edition.","Gastric Cancer by AJCC v8 Pathologic Stage | Gastric Cancer by AJCC v8 pTNM Stage | Gastric Carcinoma by AJCC v8 Pathologic Stage | Tumor Stage (Pathologic)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520484","Pathologic Stage IV Gastric Cancer AJCC v8","C133668","Stage IV includes: Any T, Any N. M1: Distant metastasis. (AJCC 8th ed.)","Pathologic Stage IV Gastric Cancer AJCC v8 | IV | Pathologic Stage IV Gastric Carcinoma AJCC v8 | Stage IV Gastric (Stomach) Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520482","Pathologic Stage IIIB Gastric Cancer AJCC v8","C133666","Stage IIIB includes: (T1, N3b, M0); (T2, N3b, M0); (T3, N3a, M0); (T4a, N3a, M0); (T4b, N1, M0); (T4b, N2, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. T4a: Tumor invades the serosa (visceral peritoneum). T4b: Tumor invades adjacent structures/organs. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3a: Tumor with metastasis in seven to fifteen regional lymph nodes. N3b: Tumor with metastasis in sixteen or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Pathologic Stage IIIB Gastric Cancer AJCC v8 | IIIB | Pathologic Stage IIIB Gastric Carcinoma AJCC v8 | Stage IIIB Gastric (Stomach) Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520481","Pathologic Stage IIIA Gastric Cancer AJCC v8","C133665","Stage IIIA includes: (T2, N3a, M0); (T3, N2, M0); (T4a, N1, M0); (T4a, N2, M0); (T4b, N0, M0). T2: Tumor invades the muscularis propria. T3: Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. T4a: Tumor invades the serosa (visceral peritoneum). T4b: Tumor invades adjacent structures/organs.  N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3a: Tumor with metastasis in seven to fifteen regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Pathologic Stage IIIA Gastric Cancer AJCC v8 | IIIA | Pathologic Stage IIIA Gastric Carcinoma AJCC v8 | Stage IIIA Gastric (Stomach) Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520479","Pathologic Stage IIB Gastric Cancer AJCC v8","C133662","Stage IIB includes: (T1, N3a, M0); (T2, N2, M0); (T3, N1, M0); (T4a, N0, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. T4a: Tumor invades the serosa (visceral peritoneum). N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3a: Tumor with metastasis in seven to fifteen regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Pathologic Stage IIB Gastric Cancer AJCC v8 | IIB | Pathologic Stage IIB Gastric Carcinoma AJCC v8 | Stage IIB Gastric (Stomach) Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520478","Pathologic Stage IIA Gastric Cancer AJCC v8","C133660","Stage IIA includes: (T1, N2, M0); (T2, N1, M0); (T3, N0, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Pathologic Stage IIA Gastric Cancer AJCC v8 | IIA | Pathologic Stage IIA Gastric Carcinoma AJCC v8 | Stage IIA Gastric (Stomach) Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520476","Pathologic Stage IB Gastric Cancer AJCC v8","C133657","Stage IB includes: (T1, N1, M0); (T2, N0, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Pathologic Stage IB Gastric Cancer AJCC v8 | IB | Pathologic Stage IB Gastric Carcinoma AJCC v8 | Stage IB Gastric (Stomach) Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520475","Pathologic Stage IA Gastric Cancer AJCC v8","C133656","Stage IA includes: (T1, N0, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Pathologic Stage IA Gastric Cancer AJCC v8 | IA | Pathologic Stage IA Gastric Carcinoma AJCC v8 | Stage IA Gastric (Stomach) Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520473","Pathologic Stage 0 Gastric Cancer AJCC v8","C133654","Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ: intraepithelial tumor without invasion of the lamina propria, high grade dysplasia. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Pathologic Stage 0 Gastric Cancer AJCC v8 | 0 | Pathologic Stage 0 Gastric Carcinoma AJCC v8 | Stage 0 Gastric (Stomach) Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520676","Gastric Cancer by AJCC v8 Postneoadjuvant Therapy Stage","C133641","A term that refers to the postneoadjuvant therapy staging of gastric cancer according to the American Joint Committee on Cancer, 8th edition.","Gastric Cancer by AJCC v8 Postneoadjuvant Therapy Stage | Gastric Cancer by AJCC v8 ypTNM Stage | Gastric Carcinoma by AJCC v8 Postneoadjuvant Therapy Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520943","Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8","C133673","Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8 | Postneoadjuvant Therapy Stage IV Gastric Carcinoma AJCC v8 | Stage IV Gastric (Stomach) Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520933","Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8","C133672","Stage III includes: (T4a, N1, M0); (T3, N2, M0); (T2, N3, M0); (T4b, N0, M0); (T4b, N1, M0); (T4a, N2, M0); (T3, N3, M0); (T4b, N2, M0); (T4b, N3, M0); (T4a, N3, M0). T2: Tumor invades the muscularis propria. T3: Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. T4a: Tumor invades the serosa (visceral peritoneum). T4b: Tumor invades adjacent structures/organs. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8 | Postneoadjuvant Therapy Stage III Gastric Carcinoma AJCC v8 | Stage III Gastric (Stomach) Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520929","Postneoadjuvant Therapy Stage II Gastric Cancer AJCC v8","C133671","Stage II includes: (T3, N0, M0); (T2, N1, M0); (T1, N2, M0); (T4a, N0, M0); (T3, N1, M0); (T2, N2, M0); (T1, N3, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. T4a: Tumor invades the serosa (visceral peritoneum). N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Postneoadjuvant Therapy Stage II Gastric Cancer AJCC v8 | Postneoadjuvant Therapy Stage II Gastric Carcinoma AJCC v8 | Stage II Gastric (Stomach) Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520925","Postneoadjuvant Therapy Stage I Gastric Cancer AJCC v8","C133670","Stage I includes: (T1, N0, M0); (T2, N0, M0); (T1, N1, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Postneoadjuvant Therapy Stage I Gastric Cancer AJCC v8 | Postneoadjuvant Therapy Stage I Gastric Carcinoma AJCC v8 | Stage I Gastric (Stomach) Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009201","Cochlear Nerve","C12697","The cochlear portion of cranial nerve VIII (the vestibulocochlear nerve), which transmits auditory sensory impulses to the cochlear nucleus in the brainstem.","Cochlear Nerve | Acoustic Nerve | Acoustic nerve | Auditory Nerve | Cochlear Root of Acoustic Nerve | Cochlear Root of Eighth Cranial Nerve | NERVE, COCHLEAR",,,,,,,,,,,,,,,"4034438","Structure of cochlear nerve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL537836","Cervical Cancer TNM Finding v8","C139682","A finding about one or more characteristics of cervical cancer, following the rules of the TNM AJCC v8 classification system.","Cervical Cancer TNM Finding v8 | Cervical Carcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537814","Cervical Cancer cTX TNM Finding v8","C139688","Cervical cancer in which primary tumor cannot be assessed. (from AJCC 8th Ed.)","Cervical Cancer cTX TNM Finding v8 | Cervical Carcinoma cTX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537816","Cervical Cancer cT4 TNM Finding v8","C139702","Cervical cancer invading the mucosa of the bladder or rectum, and/or extending beyond the true pelvis (bullous edema is not sufficient to classify a tumor as T4). (from AJCC 8th Ed.)","Cervical Cancer cT4 TNM Finding v8 | Cervical Cancer FIGO Stage IVA | Cervical Carcinoma FIGO Stage IVA | Cervical Carcinoma cT4 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537817","Cervical Cancer cT3b TNM Finding v8","C139701","Cervical cancer extending to pelvic wall and/or causing hydronephrosis or nonfunctioning kidney. (from AJCC 8th Ed.)","Cervical Cancer cT3b TNM Finding v8 | Cervical Cancer FIGO Stage IIIB | Cervical Carcinoma FIGO Stage IIIB | Cervical Carcinoma cT3b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537818","Cervical Cancer cT3a TNM Finding v8","C139700","Cervical cancer involving the lower third of vagina but not extending to pelvic wall. (from AJCC 8th Ed.)","Cervical Cancer cT3a TNM Finding v8 | Cervical Cancer FIGO Stage IIIA | Cervical Carcinoma FIGO Stage IIIA | Cervical Carcinoma cT3a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537819","Cervical Cancer cT3 TNM Finding v8","C139699","Cervical cancer extending to pelvic sidewall and/or involving the lower third of vagina, and/or causing hydronephrosis or nonfunctioning kidney. The pelvic sidewall is defined as the muscle, fascia, neurovascular structures, and skeletal portions of the bony pelvis. (from AJCC 8th Ed.)","Cervical Cancer cT3 TNM Finding v8 | Cervical Cancer FIGO Stage III | Cervical Carcinoma FIGO Stage III | Cervical Carcinoma cT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537820","Cervical Cancer cT2b TNM Finding v8","C139698","Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina with parametrial invasion. (from AJCC 8th Ed.)","Cervical Cancer cT2b TNM Finding v8 | Cervical Cancer FIGO Stage IIB | Cervical Carcinoma FIGO Stage IIB | Cervical Carcinoma cT2b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537821","Cervical Cancer cT2a2 TNM Finding v8","C139697","Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina without parametrial invasion. Clinically visible lesion more than 4.0 cm in greatest dimension. (from AJCC 8th Ed.)","Cervical Cancer cT2a2 TNM Finding v8 | Cervical Cancer FIGO Stage IIA2 | Cervical Carcinoma FIGO Stage IIA2 | Cervical Carcinoma cT2a2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537822","Cervical Cancer cT2a1 TNM Finding v8","C139696","Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina without parametrial invasion. Clinically visible lesion 4.0 cm or less in greatest dimension. (from AJCC 8th Ed.)","Cervical Cancer cT2a1 TNM Finding v8 | Cervical Cancer FIGO Stage IIA1 | Cervical Carcinoma FIGO Stage IIA1 | Cervical Carcinoma cT2a1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537823","Cervical Cancer cT2a TNM Finding v8","C139695","Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina without parametrial invasion. (from AJCC 8th Ed.)","Cervical Cancer cT2a TNM Finding v8 | Cervical Cancer FIGO Stage IIA | Cervical Carcinoma FIGO Stage IIA | Cervical Carcinoma cT2a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537808","Cervical Cancer cT2 TNM Finding v8","C139694","Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina. (from AJCC 8th Ed.)","Cervical Cancer cT2 TNM Finding v8 | Cervical Cancer FIGO Stage II | Cervical Carcinoma FIGO Stage II | Cervical Carcinoma cT2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537809","Cervical Cancer cT1b2 TNM Finding v8","C139693","Cervical cancer with clinically visible lesion more than 4.0 cm in greatest dimension. (from AJCC 8th Ed.)","Cervical Cancer cT1b2 TNM Finding v8 | Cervical Cancer FIGO Stage IB2 | Cervical Carcinoma FIGO Stage IB2 | Cervical Carcinoma cT1b2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537810","Cervical Cancer cT1b1 TNM Finding v8","C139692","Cervical cancer with clinically visible lesion 4.0 cm or less in greatest dimension. (from AJCC 8th Ed.)","Cervical Cancer cT1b1 TNM Finding v8 | Cervical Cancer FIGO Stage IB1 | Cervical Carcinoma FIGO Stage IB1 | Cervical Carcinoma cT1b1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537811","Cervical Cancer cT1b TNM Finding v8","C139691","Cervical cancer with clinically visible lesion confined to the cervix. (from AJCC 8th Ed.)","Cervical Cancer cT1b TNM Finding v8 | Cervical Cancer FIGO Stage IB | Cervical Carcinoma FIGO Stage IB | Cervical Carcinoma cT1b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537806","Cervical Cancer pT1a2 TNM Finding v8","C139712","Invasive cervical carcinoma with measured stromal invasion of more than 3.0 mm and not more than 5.0 mm, with a horizontal spread of 7.0 mm or less. (from AJCC 8th Ed.)","Cervical Cancer pT1a2 TNM Finding v8 | Cervical Cancer FIGO Stage IA2 | Cervical Carcinoma FIGO Stage IA2 | Cervical Carcinoma pT1a2 TNM Finding v8 | pT1a2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537807","Cervical Cancer pT1a1 TNM Finding v8","C139711","Invasive cervical carcinoma with measured stromal invasion of 3.0 mm or less in depth and 7.0 mm or less in horizontal spread. (from AJCC 8th Ed.)","Cervical Cancer pT1a1 TNM Finding v8 | Cervical Cancer FIGO Stage IA1 | Cervical Carcinoma FIGO Stage IA1 | Cervical Carcinoma pT1a1 TNM Finding v8 | pT1a1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537792","Cervical Cancer pT1a TNM Finding v8","C139710","Invasive cervical carcinoma diagnosed only by microscopy. Stromal invasion with a maximum depth of 5.0 mm measured from the base of the epithelium and a horizontal spread of 7.0 mm or less. Vascular space involvement, venous or lymphatic, does not affect classification. (from AJCC 8th Ed.)","Cervical Cancer pT1a TNM Finding v8 | Cervical Cancer FIGO Stage IA | Cervical Carcinoma FIGO Stage IA | Cervical Carcinoma pT1a TNM Finding v8 | pT1a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537812","Cervical Cancer cT1 TNM Finding v8","C139690","Cervical carcinoma confined to uterus (extension to corpus should be disregarded). (from AJCC 8th Ed.)","Cervical Cancer cT1 TNM Finding v8 | Cervical Cancer FIGO Stage I | Cervical Carcinoma FIGO Stage I | Cervical Carcinoma cT1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537813","Cervical Cancer cT0 TNM Finding v8","C139689","Cervical cancer with no evidence of primary tumor. (from AJCC 8th Ed.)","Cervical Cancer cT0 TNM Finding v8 | Cervical Carcinoma cT0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537916","Cervical Cancer pN1 TNM Finding v8","C139729","Cervical cancer with regional lymph node metastasis. (from AJCC 8th Ed.)","Cervical Cancer pN1 TNM Finding v8 | Cervical Carcinoma pN1 TNM Finding v8 | pN1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537917","Cervical Cancer pN0(i+) TNM Finding v8","C139728","Cervical cancer with isolated tumor cells in regional lymph node(s) no greater than 0.2 mm. (from AJCC 8th Ed.)","Cervical Cancer pN0(i+) TNM Finding v8 | Cervical Carcinoma pN0(i+) TNM Finding v8 | pN0(i+)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537918","Cervical Cancer pN0 TNM Finding v8","C139727","Cervical cancer with no regional lymph node metastasis. (from AJCC 8th Ed.)","Cervical Cancer pN0 TNM Finding v8 | Cervical Carcinoma pN0 TNM Finding v8 | pN0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537903","Cervical Cancer pNX TNM Finding v8","C139726","Cervical cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Cervical Cancer pNX TNM Finding v8 | Cervical Carcinoma pNX TNM Finding v8 | pNX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537797","Cervical Cancer pM1 TNM Finding v8","C139705","Cervical cancer with distant metastasis (including peritoneal spread or involvement of the supraclavicular, mediastinal, or distant lymph nodes; lung; liver; or bone). (from AJCC 8th Ed.)","Cervical Cancer pM1 TNM Finding v8 | Cervical Cancer FIGO Stage IVB | Cervical Carcinoma FIGO Stage IVB | Cervical Carcinoma pM1 TNM Finding v8 | pM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537832","Cervical Cancer cM1 TNM Finding v8","C139686","Cervical cancer with distant metastasis (including peritoneal spread or involvement of the supraclavicular, mediastinal, or distant lymph nodes; lung; liver; or bone). (from AJCC 8th Ed.)","Cervical Cancer cM1 TNM Finding v8 | Cervical Cancer FIGO Stage IVB | Cervical Carcinoma FIGO Stage IVB | Cervical Carcinoma cM1 TNM Finding v8 | cM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537833","Cervical Cancer cM0 TNM Finding v8","C139685","Cervical cancer in which there is no evidence of distant metastasis. (from AJCC 8th Ed.)","Cervical Cancer cM0 TNM Finding v8 | Cervical Carcinoma cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537793","Cervical Cancer pT1 TNM Finding v8","C139709","Cervical carcinoma confined to uterus (extension to corpus should be disregarded). (from AJCC 8th Ed.)","Cervical Cancer pT1 TNM Finding v8 | Cervical Cancer FIGO Stage I | Cervical Carcinoma FIGO Stage I | Cervical Carcinoma pT1 TNM Finding v8 | pT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537794","Cervical Cancer pT0 TNM Finding v8","C139708","Cervical cancer with no evidence of primary tumor. (from AJCC 8th Ed.)","Cervical Cancer pT0 TNM Finding v8 | Cervical Carcinoma pT0 TNM Finding v8 | pT0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537795","Cervical Cancer pTX TNM Finding v8","C139707","Cervical cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Cervical Cancer pTX TNM Finding v8 | Cervical Carcinoma pTX TNM Finding v8 | pTX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537905","Cervical Cancer pT4 TNM Finding v8","C139724","Cervical cancer invading the mucosa of the bladder or rectum, and/or extending beyond the true pelvis (bullous edema is not sufficient to classify a tumor as T4). (from AJCC 8th Ed.)","Cervical Cancer pT4 TNM Finding v8 | Cervical Cancer FIGO Stage IVA | Cervical Carcinoma FIGO Stage IVA | Cervical Carcinoma pT4 TNM Finding v8 | pT4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537906","Cervical Cancer pT3b TNM Finding v8","C139723","Cervical cancer extending to pelvic wall and/or causing hydronephrosis or nonfunctioning kidney. (from AJCC 8th Ed.)","Cervical Cancer pT3b TNM Finding v8 | Cervical Cancer FIGO Stage IIIB | Cervical Carcinoma FIGO Stage IIIB | Cervical Carcinoma pT3b TNM Finding v8 | pT3b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537907","Cervical Cancer pT3a TNM Finding v8","C139722","Cervical cancer involving the lower third of vagina but not extending to pelvic wall. (from AJCC 8th Ed.)","Cervical Cancer pT3a TNM Finding v8 | Cervical Cancer FIGO Stage IIIA | Cervical Carcinoma FIGO Stage IIIA | Cervical Carcinoma pT3a TNM Finding v8 | pT3a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537908","Cervical Cancer pT3 TNM Finding v8","C139721","Cervical cancer extending to pelvic sidewall and/or involving the lower third of vagina, and/or causing hydronephrosis or nonfunctioning kidney. The pelvic sidewall is defined as the muscle, fascia, neurovascular structures, and skeletal portions of the bony pelvis. (from AJCC 8th Ed.)","Cervical Cancer pT3 TNM Finding v8 | Cervical Cancer FIGO Stage III | Cervical Carcinoma FIGO Stage III | Cervical Carcinoma pT3 TNM Finding v8 | pT3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537909","Cervical Cancer pT2b TNM Finding v8","C139720","Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina with parametrial invasion. (from AJCC 8th Ed.)","Cervical Cancer pT2b TNM Finding v8 | Cervical Cancer FIGO Stage IIB | Cervical Carcinoma FIGO Stage IIB | Cervical Carcinoma pT2b TNM Finding v8 | pT2b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537910","Cervical Cancer pT2a2 TNM Finding v8","C139719","Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina without parametrial invasion. Clinically visible lesion more than 4.0 cm in greatest dimension. (from AJCC 8th Ed.)","Cervical Cancer pT2a2 TNM Finding v8 | Cervical Cancer FIGO Stage IIA2 | Cervical Carcinoma FIGO Stage IIA2 | Cervical Carcinoma pT2a2 TNM Finding v8 | pT2a2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537800","Cervical Cancer pT2a1 TNM Finding v8","C139718","Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina without parametrial invasion. Clinically visible lesion 4.0 cm or less in greatest dimension. (from AJCC 8th Ed.)","Cervical Cancer pT2a1 TNM Finding v8 | Cervical Cancer FIGO Stage IIA1 | Cervical Carcinoma FIGO Stage IIA1 | Cervical Carcinoma pT2a1 TNM Finding v8 | pT2a1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537801","Cervical Cancer pT2a TNM Finding v8","C139717","Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina without parametrial invasion. (from AJCC 8th Ed.)","Cervical Cancer pT2a TNM Finding v8 | Cervical Cancer FIGO Stage IIA | Cervical Carcinoma FIGO Stage IIA | Cervical Carcinoma pT2a TNM Finding v8 | pT2a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537802","Cervical Cancer pT2 TNM Finding v8","C139716","Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina. (from AJCC 8th Ed.)","Cervical Cancer pT2 TNM Finding v8 | Cervical Cancer FIGO Stage II | Cervical Carcinoma FIGO Stage II | Cervical Carcinoma pT2 TNM Finding v8 | pT2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537803","Cervical Cancer pT1b2 TNM Finding v8","C139715","Cervical cancer with clinically visible lesion more than 4.0 cm in greatest dimension. (from AJCC 8th Ed.)","Cervical Cancer pT1b2 TNM Finding v8 | Cervical Cancer FIGO Stage IB2 | Cervical Carcinoma FIGO Stage IB2 | Cervical Carcinoma pT1b2 TNM Finding v8 | pT1b2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537804","Cervical Cancer pT1b1 TNM Finding v8","C139714","Cervical cancer with clinically visible lesion 4.0 cm or less in greatest dimension. (from AJCC 8th Ed.)","Cervical Cancer pT1b1 TNM Finding v8 | Cervical Cancer FIGO Stage IB1 | Cervical Carcinoma FIGO Stage IB1 | Cervical Carcinoma pT1b1 TNM Finding v8 | pT1b1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537805","Cervical Cancer pT1b TNM Finding v8","C139713","Cervical cancer with clinically visible lesion confined to the cervix or microscopic lesion greater than T1a/IA2. It includes all macroscopically visible lesions, even those with superficial invasion. (from AJCC 8th Ed.)","Cervical Cancer pT1b TNM Finding v8 | Cervical Cancer FIGO Stage IB | Cervical Carcinoma FIGO Stage IB | Cervical Carcinoma pT1b TNM Finding v8 | pT1b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537912","Cervical Cancer by AJCC v8 Stage","C139733","A term that refers to the staging of cervical cancer according to the American Joint Committee on Cancer, 8th edition.","Cervical Cancer by AJCC v8 Stage | Cervical Carcinoma by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537911","Stage I Cervical Cancer AJCC v8","C139734","Stage I includes: T1, Any N, M0. T1: Tumor confined to uterus (extension to corpus should be disregarded). M0: No distant metastasis. (AJCC 8th Ed.)","Stage I Cervical Cancer AJCC v8 | I | Stage I Cervical Cancer | Stage I Cervical Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537876","Stage IVB Cervical Cancer AJCC v8","C139755","Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis (including peritoneal spread or involvement of the supraclavicular, mediastinal, or distant lymph nodes; lung; liver; or bone). (from AJCC 8th Ed.)","Stage IVB Cervical Cancer AJCC v8 | IVB | Stage IVB Cervical Cancer | Stage IVB Cervical Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537877","Stage IVA Cervical Cancer AJCC v8","C139754","Stage IVA includes: T4, Any N, M0. T4: Tumor invading the mucosa of the bladder or rectum, and/or extending beyond the true pelvis (bullous edema is not sufficient to classify a tumor as T4). M0: No distant metastasis. (from AJCC 8th Ed.)","Stage IVA Cervical Cancer AJCC v8 | IVA | Stage IVA Cervical Cancer | Stage IVA Cervical Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537879","Stage IIIB Cervical Cancer AJCC v8","C139752","Stage IIIB includes: T3b, Any N, M0. T3b: extending to pelvic wall and/or causing hydronephrosis or nonfunctioning kidney. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIIB Cervical Cancer AJCC v8 | IIIB | Stage IIIB Cervical Cancer | Stage IIIB Cervical Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537896","Stage IIIA Cervical Cancer AJCC v8","C139750","Stage IIIA includes: T3a, Any N, M0. T3a: Tumor involving the lower third of vagina but not extending to pelvic wall. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIIA Cervical Cancer AJCC v8 | IIIA | Stage IIIA Cervical Cancer | Stage IIIA Cervical Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537897","Stage III Cervical Cancer AJCC v8","C139749","Stage III includes: T3, Any N, M0. T3: Tumor extending to pelvic sidewall and/or involving the lower third of vagina, and/or causing hydronephrosis or nonfunctioning kidney. M0: No distant metastasis. (AJCC 8th Ed.)","Stage III Cervical Cancer AJCC v8 | III | Stage III Cervical Cancer | Stage III Cervical Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537898","Stage IIB Cervical Cancer AJCC v8","C139748","Stage IIB includes: T2b, Any N, M0. T2b: Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina with parametrial invasion. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIB Cervical Cancer AJCC v8 | IIB | Stage IIB Cervical Cancer | Stage IIB Cervical Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537900","Stage IIA2 Cervical Cancer AJCC v8","C139746","Stage IIA2 includes: T2a2, Any N, M0. T2a2: Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina without parametrial invasion. Clinically visible lesion more than 4.0 cm in greatest dimension. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIA2 Cervical Cancer AJCC v8 | IIA2 | Stage IIA2 Cervical Cancer | Stage IIA2 Cervical Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537901","Stage IIA1 Cervical Cancer AJCC v8","C139745","Stage IIA1 includes: T2a1, Any N, M0. T2a1: Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina without parametrial invasion. Clinically visible lesion 4.0 cm or less in greatest dimension. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIA1 Cervical Cancer AJCC v8 | IIA1 | Stage IIA1 Cervical Cancer | Stage IIA1 Cervical Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537902","Stage IIA Cervical Cancer AJCC v8","C139744","Stage IIA includes: T2a, Any N, M0. T2a: Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina without parametrial invasion. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIA Cervical Cancer AJCC v8 | IIA | Stage IIA Cervical Cancer | Stage IIA Cervical Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537888","Stage II Cervical Cancer AJCC v8","C139743","Stage II includes: T2, Any N, M0. T2: Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina. M0: No distant metastasis. (AJCC 8th Ed.)","Stage II Cervical Cancer AJCC v8 | II | Stage II Cervical Cancer | Stage II Cervical Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537890","Stage IB2 Cervical Cancer AJCC v8","C139740","Stage IB2 includes: T1b2, Any N, M0. T1b2: Tumor with clinically visible lesion more than 4.0 cm in greatest dimension. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IB2 Cervical Cancer AJCC v8 | IB2 | Stage IB2 Cervical Cancer | Stage IB2 Cervical Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537891","Stage IB1 Cervical Cancer AJCC v8","C139739","Stage IB1 includes: T1b1, Any N, M0. T1b1: Tumor with clinically visible lesion 4.0 cm or less in greatest dimension. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IB1 Cervical Cancer AJCC v8 | IB1 | Stage IB1 Cervical Cancer | Stage IB1 Cervical Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537892","Stage IB Cervical Cancer AJCC v8","C139738","Stage IB includes: T1b, Any N, M0. T1b: Tumor with clinically visible lesion confined to the cervix or microscopic lesion greater than T1a/IA2. It includes all macroscopically visible lesions, even those with superficial invasion. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IB Cervical Cancer AJCC v8 | IB | Stage IB Cervical Cancer | Stage IB Cervical Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537893","Stage IA2 Cervical Cancer AJCC v8","C139737","Stage IA2 includes: T1a2, Any N, M0. T1a2: Invasive cervical carcinoma with measured stromal invasion of more than 3.0 mm and not more than 5.0 mm, with a horizontal spread of 7.0 mm or less. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IA2 Cervical Cancer AJCC v8 | IA2 | Stage IA2 Cervical Cancer | Stage IA2 Cervical Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537894","Stage IA1 Cervical Cancer AJCC v8","C139736","Stage IA1 includes: T1a1, Any N, M0. T1a1: Invasive cervical carcinoma with measured stromal invasion of 3.0 mm or less in depth and 7.0 mm or less in horizontal spread. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IA1 Cervical Cancer AJCC v8 | IA1 | Stage IA1 Cervical Cancer | Stage IA1 Cervical Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537895","Stage IA Cervical Cancer AJCC v8","C139735","Stage IA includes: T1a, Any N, M0. T1a: Tumor diagnosed only by microscopy. Stromal invasion with a maximum depth of 5.0 mm measured from the base of the epithelium and a horizontal spread of 7.0 mm or less. Vascular space involvement, venous or lymphatic, does not affect classification. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IA Cervical Cancer AJCC v8 | IA | Stage IA Cervical Cancer | Stage IA Cervical Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205286","Mature","C156784","Having reached a completed state of growth and development.","Mature | MATURE | Maturity",,,,,,,,,,,,,,,"4145121","Mature",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL935803","Skeletally Mature","C156785","An indication that an individual's growth plates are fused and that bone growth has ceased.","Skeletally Mature | Skeletal Maturity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935804","Skeletally Immature","C156786","An indication that an individual's growth plates are open and that bone growth is likely to continue.","Skeletally Immature | Skeletal Immaturity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522043","Hepatocellular Carcinoma TNM Finding v8","C134457","A finding about one or more characteristics of hepatocellular carcinoma, following the rules of the TNM AJCC v8 classification system. This staging system applies to hepatocellular carcinomas and fibrolamellar carcinomas (fibrolamellar variant of hepatocellular carcinoma). Intrahepatic cholangiocarcinomas, combined hepatocellular-cholangiocarcinomas, and sarcomas of the liver are not staged using this staging system. (from AJCC 8th Ed.)","Hepatocellular Carcinoma TNM Finding v8 | Liver Cell Carcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522064","Hepatocellular Carcinoma pT4 TNM Finding v8","C134479","Hepatocellular carcinoma with single tumor or multiple tumors of any size involving a major branch of the portal vein or hepatic vein, or tumor(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of visceral peritoneum. (from AJCC 8th Ed.)","Hepatocellular Carcinoma pT4 TNM Finding v8 | Liver Cell Carcinoma pT4 TNM Finding v8 | pT4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522063","Hepatocellular Carcinoma pT3 TNM Finding v8","C134477","Hepatocellular carcinoma with multiple tumors, at least one of which is larger than 5 cm. (from AJCC 8th Ed.)","Hepatocellular Carcinoma pT3 TNM Finding v8 | Liver Cell Carcinoma pT3 TNM Finding v8 | pT3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522062","Hepatocellular Carcinoma pT2 TNM Finding v8","C134476","Hepatocellular carcinoma with solitary tumor larger than 2 cm with vascular invasion, or multiple tumors, none larger than 5 cm. (from AJCC 8th Ed.)","Hepatocellular Carcinoma pT2 TNM Finding v8 | Liver Cell Carcinoma pT2 TNM Finding v8 | pT2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522060","Hepatocellular Carcinoma pT1a TNM Finding v8","C134474","Hepatocellular carcinoma with solitary tumor equal to or less than 2 cm. (from AJCC 8th Ed.)","Hepatocellular Carcinoma pT1a TNM Finding v8 | Liver Cell Carcinoma pT1a TNM Finding v8 | pT1a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522058","Hepatocellular Carcinoma pT1 TNM Finding v8","C134472","Hepatocellular carcinoma with solitary tumor equal to or less than 2 cm, or larger than 2 cm without vascular invasion. (from AJCC 8th Ed.)","Hepatocellular Carcinoma pT1 TNM Finding v8 | Liver Cell Carcinoma pT1 TNM Finding v8 | pT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522057","Hepatocellular Carcinoma pT0 TNM Finding v8","C134471","Hepatocellular carcinoma with no evidence of primary tumor. (from AJCC 8th Ed.)","Hepatocellular Carcinoma pT0 TNM Finding v8 | Liver Cell Carcinoma pT0 TNM Finding v8 | pT0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522056","Hepatocellular Carcinoma pTX TNM Finding v8","C134470","Hepatocellular carcinoma in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Hepatocellular Carcinoma pTX TNM Finding v8 | Liver Cell Carcinoma pTX TNM Finding v8 | pTX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522070","Hepatocellular Carcinoma pN1 TNM Finding v8","C134485","Hepatocellular carcinoma with regional lymph node metastasis. (from AJCC 8th Ed.)","Hepatocellular Carcinoma pN1 TNM Finding v8 | Liver Cell Carcinoma pN1 TNM Finding v8 | pN1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522069","Hepatocellular Carcinoma pN0 TNM Finding v8","C134484","Hepatocellular carcinoma with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","Hepatocellular Carcinoma pN0 TNM Finding v8 | Liver Cell Carcinoma pN0 TNM Finding v8 | pN0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522067","Hepatocellular Carcinoma pNX TNM Finding v8","C134482","Hepatocellular carcinoma in which the regional lymph node(s) cannot be assessed.  (from AJCC 8th Ed.)","Hepatocellular Carcinoma pNX TNM Finding v8 | Liver Cell Carcinoma pNX TNM Finding v8 | pNX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522053","Hepatocellular Carcinoma pM1 TNM Finding v8","C134467","Hepatocellular carcinoma with distant metastasis. (from AJCC 8th Ed.)","Hepatocellular Carcinoma pM1 TNM Finding v8 | Liver Cell Carcinoma pM1 TNM Finding v8 | pM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522048","Hepatocellular Carcinoma cM1 TNM Finding v8","C134462","Hepatocellular carcinoma with distant metastasis. (from AJCC 8th Ed.)","Hepatocellular Carcinoma cM1 TNM Finding v8 | Liver Cell Carcinoma cM1 TNM Finding v8 | cM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522047","Hepatocellular Carcinoma cM0 TNM Finding v8","C134461","Hepatocellular carcinoma without evidence of distant metastasis. (from AJCC 8th Ed.)","Hepatocellular Carcinoma cM0 TNM Finding v8 | Liver Cell Carcinoma cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522096","Hepatocellular Carcinoma by AJCC v8 Stage","C134515","A term that refers to the staging of hepatocellular carcinoma according to the American Joint Committee on Cancer, 8th edition. This staging system applies to hepatocellular carcinomas and fibrolamellar carcinomas (fibrolamellar variant of hepatocellular carcinoma). Intrahepatic cholangiocarcinomas, combined hepatocellular-cholangiocarcinomas, and sarcomas of the liver are not staged using this staging system. (from AJCC 8th Ed.)","Hepatocellular Carcinoma by AJCC v8 Stage | Liver Cell Carcinoma by AJCC v8 Stage | Tumor Stage (Pathologic)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522106","Stage IVB Hepatocellular Carcinoma AJCC v8","C134525","Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","Stage IVB Hepatocellular Carcinoma AJCC v8 | IVB | Stage IVB Hepatocellular Cancer | Stage IVB Liver Cell Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522105","Stage IVA Hepatocellular Carcinoma AJCC v8","C134524","Stage IVA includes: Any T, N1, M0. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IVA Hepatocellular Carcinoma AJCC v8 | IVA | Stage IVA Hepatocellular Cancer | Stage IVA Liver Cell Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522103","Stage IIIB Hepatocellular Carcinoma AJCC v8","C134522","Stage IIIB includes: T4, N0, M0. T4: Single tumor or multiple tumors of any size involving a major branch of the portal vein or hepatic vein, or tumor(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of visceral peritoneum. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIB Hepatocellular Carcinoma AJCC v8 | IIIB | Stage IIIB Hepatocellular Cancer | Stage IIIB Liver Cell Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522102","Stage IIIA Hepatocellular Carcinoma AJCC v8","C134521","Stage IIIA includes: T3, N0, M0. T3: Multiple tumors, at least one of which is larger than 5 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIA Hepatocellular Carcinoma AJCC v8 | IIIA | Stage IIIA Hepatocellular Cancer | Stage IIIA Liver Cell Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522100","Stage II Hepatocellular Carcinoma AJCC v8","C134519","Stage II includes: T2, N0, M0. T2: Solitary tumor larger than 2 cm with vascular invasion, or multiple tumors, none larger than 5 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Hepatocellular Carcinoma AJCC v8 | II | Stage II Hepatocellular Cancer | Stage II Liver Cell Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522099","Stage IB Hepatocellular Carcinoma AJCC v8","C134518","Stage IB includes: T1b, N0, M0. T1b: Solitary tumor larger than 2 cm without vascular invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IB Hepatocellular Carcinoma AJCC v8 | IB | Stage IB Hepatocellular Cancer | Stage IB Liver Cell Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518116","MDM2 Gene Amplification","C36681","A molecular genetic abnormality indicating the presence of multiple copies of the MDM2 gene.","MDM2 Gene Amplification | ACTFS Gene Amplification | Double Minute 2 Homolog Gene Amplification | HDMX Gene Amplification | MDM2 Proto-Oncogene Gene Amplification | MDM2 Proto-Oncogene, E3 Ubiquitin Protein Ligase Gene Amplification | Mouse Double Minute 2 Gene Amplification | Mouse Double Minute 2 Homolog Gene Amplification | hdm2 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520044","IRF4 Gene Rearrangement","C133495","A molecular abnormality indicating rearrangement of the IRF4 gene.","IRF4 Gene Rearrangement | Interferon Regulatory Factor 4 Gene Rearrangement | LSIRF Gene Rearrangement | MUM1 Gene Rearrangement | Multiple Myeloma Oncogene 1 Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517097","FIP1L1-PDGFRalpha Fusion Protein Expression","C37217","Expression of a fusion protein involving the human genes FIP1L1 and PDGFRA. It results from an inversion or translocation and is associated with hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL) and systemic mast cell disease.","FIP1L1-PDGFRalpha Fusion Protein Expression | FIP1L1-PDGFRA Fusion Protein Expression | FIP1L1-PDGFRalpha Fusion Protein Positive | FIP1L1/PDGFRA Fusion Protein Expression | FIP1L1/PDGFRA Fusion Protein Positive | FIP1L1/PDGFRalpha Fusion Protein Expression | Pre-mRNA 3'-End-Processing Factor FIP1/Alpha-Type Platelet-Derived Growth Factor Receptor Fusion Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553236","PTP4A3 Gene","C151404","This gene plays a role in cell cycle progression, cell proliferation, cell motility and cellular invasiveness.","PTP4A3 Gene | PTP4A3 | Protein Tyrosine Phosphatase Type IVA, Member 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551023","CD79B Gene Mutation","C148390","A change in the nucleotide sequence of the CD79B gene.","CD79B Gene Mutation | AGM6 Gene Mutation | B29 Gene Mutation | CD79b Antigen Gene Mutation | CD79b Molecule Gene Mutation | IGB Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334852","Myeloblasts Under 5 Percent of Peripheral Blood White Cells","C36221","A semi-quantitative microscopic finding indicating that less than 5 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells of myeloid origin.","Myeloblasts Under 5 Percent of Peripheral Blood White Cells | Myeloblasts Less Than 5 Percent of Peripheral Blood White Cells | Myeloblasts Under 5% of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333321","Duodenal Gastrin-Producing Neuroendocrine Tumor","C5731","A gastrin-producing neuroendocrine tumor that arises from the duodenum.  It is characterized by the presence of uniform cells that form pseudorosettes.  The neoplastic cells have uniform nuclei and small amount of eosinophilic cytoplasm.","Duodenal Gastrin-Producing Neuroendocrine Tumor | Duodenal G-Cell Gastrin Producing Tumor | Duodenal Gastrin-Producing NET | Duodenal Gastrinoma | Gastrin Producing Tumor of Duodenum | Gastrin Producing Tumor of the Duodenum | Gastrinoma of Duodenum | Gastrinoma of the Duodenum",,,,,,,,,,,,,,,"618963","Gastrinoma of duodenum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL935885","PPP2R2A Gene Mutation","C156750","A change in the nucleotide sequence of the PPP2R2A gene.","PPP2R2A Gene Mutation | B55-Alpha Gene Mutation | B55A Gene Mutation | B55ALPHA Gene Mutation | PR52A Gene Mutation | PR55-Alpha Gene Mutation | PR55A Gene Mutation | PR55alpha Gene Mutation | Protein Phosphatase 2 Regulatory Subunit Balpha Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935886","TNFAIP3 Gene Mutation","C156751","A change in the nucleotide sequence of the TNFAIP3 gene.","TNFAIP3 Gene Mutation | A20 Gene Mutation | OTUD7C Gene Mutation | TNF Alpha Induced Protein 3 Gene Mutation | TNFA1P2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935883","SDHB Negative","C156752","An indication that SDHB expression or activity has not been detected in a sample.","SDHB Negative | IP Negative | Negative | SDH1 Negative | SDH2 Negative | SDHB Deficiency | SDHB Deficient | SDHB Loss | SDHIP Negative | Succinate Dehydrogenase Complex Iron Sulfur Subunit B Negative | Succinate Dehydrogenase [Ubiquinone] Iron-Sulfur Subunit, Mitochondrial Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935884","Neoplastic Plasma Cells 10-59 Percent of Bone Marrow Nucleated Cells","C156753","A semi-quantitative microscopic finding indicating that between 10 and 59 percent of the nucleated cells in a bone marrow sample are neoplastic plasma cells.","Neoplastic Plasma Cells 10-59 Percent of Bone Marrow Nucleated Cells | Neoplastic Plasma Cells Between 10 and 59 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935890","Raf/KSR/Mek1 Trimer","C156755","An indication that trimeric protein complexes containing a RAF family protein, a kinase suppressor of Ras (KSR) family protein and MAP2K1 have been detected after subjecting a sample to a proximity ligation assay.","Raf/KSR/Mek1 Trimer | RAF/KSR/MAP2K1 Trimer | Raf/KSR/MAPKK1 Trimer | Raf/KSR/MKK1 Trimer | Raf/KSR/Mek1 Trimers | Raf/KSR/PRKMK1 Trimer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935887","bRaf/cRaf Dimer","C156756","An indication that dimeric protein complexes containing BRAF and RAF1 have been detected after subjecting a sample to a proximity ligation assay.","bRaf/cRaf Dimer | BRAF/RAF1 Dimer | bRaf/cRaf Dimers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935877","RELA Fusion Positive","C156758","An indication that expression of a fusion containing sequences from RELA has been detected in a sample.","RELA Fusion Positive | NF-Kappa B p65 Fusion Positive | NF-Kappa-B Transcription Factor p65 Fusion Positive | NFKB3 Fusion Positive | NFkB p65 Fusion Positive | Nuclear Factor Kappa-B Subunit 3 Fusion Positive | Nuclear Factor of Kappa Light Chain Gene Enhancer in B Cells 3 Fusion Positive | Nuclear Factor of Kappa Light Polypeptide Gene Enhancer in B-Cells 3 Fusion Positive | Transcription Factor p65 Fusion Positive | p65 Fusion Positive | v-REL Avian Reticuloendotheliosis Viral Oncogene Homolog A Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935881","PPM1D Gene Amplification","C156762","A molecular genetic abnormality indicating the presence of multiple copies of the PPM1D gene.","PPM1D Gene Amplification | IDDGIP Gene Amplification | PP2C-DELTA Gene Amplification | Protein Phosphatase 1D Gene Amplification | Protein Phosphatase 1D Magnesium-Dependent, Delta Isoform Gene Amplification | Protein Phosphatase 2C, Delta Isoform Gene Amplification | Protein Phosphatase, Mg2+/Mn2+ Dependent 1D Gene Amplification | WIP1 Gene Amplification | Wild-Type p53-Induced Phosphatase 1 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935882","MDM4 Gene Amplification","C156763","A molecular genetic abnormality indicating the presence of multiple copies of the MDM4 gene.","MDM4 Gene Amplification | HDMX Gene Amplification | MDM4, p53 Regulator Gene Amplification | MDMX Gene Amplification | Mouse Double Minute 4 Homolog Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935879","HER2/Neu Low Expression","C156764","An immunohistochemical result indicating that HER2/Neu (ERBB2) is expressed at low levels in a sample.","HER2/Neu Low Expression | ERBB2 Low Expressing | ERBB2 Low Expression | HER-2 Low Expression | HER2 Low Expressing | HER2 Low Expression | HER2/Neu Low Expressing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935721","Blasts 25 Percent or Less of Bone Marrow Nucleated Cells","C156690","A semi-quantitative microscopic finding indicating that 25 percent or less of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 25 Percent or Less of Bone Marrow Nucleated Cells | Blasts Less than or Equal to 25 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935733","Blasts More than 15 Percent of Bone Marrow Nucleated Cells","C156670","A semi-quantitative microscopic finding indicating that more than 15 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts More than 15 Percent of Bone Marrow Nucleated Cells | Blasts Greater than 15 Percent of Bone Marrow Nucleated Cells | Blasts Over 15 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936005","Cancer Model Development Center","C156876","National Cancer Institute-funded contributors to the Human Cancer Genome Initiative that are tasked with producing next-generation cancer models from clinical samples.","Cancer Model Development Center | CMDC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538693","Uveal Melanoma TNM Finding v8","C140603","A finding about one or more characteristics of uveal melanoma, following the rules of the TNM AJCC v8 classification system. This classification system applies to malignant melanoma of the iris, ciliary body, and choroid. Cutaneous melanoma metastatic to the iris, ciliary body, and choroid is staged according to the classification for melanoma of the skin and secondary intraocular extension of conjunctival melanoma is staged according to the classification for conjunctival melanoma. (from AJCC 8th Ed.)","Uveal Melanoma TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538779","Iris Melanoma pT4b TNM Finding v8","C140629","Iris melanoma with extrascleral extension more than 5 mm in largest diameter. (from AJCC 8th Ed.)","Iris Melanoma pT4b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538780","Iris Melanoma pT4a TNM Finding v8","C140628","Iris melanoma with extrascleral extension 5 mm or less in largest diameter. (from AJCC 8th Ed.)","Iris Melanoma pT4a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538781","Iris Melanoma pT4 TNM Finding v8","C140627","Iris melanoma with extrascleral extension. (from AJCC 8th Ed.)","Iris Melanoma pT4 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538782","Iris Melanoma pT3 TNM Finding v8","C140626","Iris melanoma with tumor confluent with or extending into the ciliary body, choroid, or both, with scleral extension. (from AJCC 8th Ed.)","Iris Melanoma pT3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538783","Iris Melanoma pT2c TNM Finding v8","C140625","Iris melanoma with tumor confluent with or extending into the ciliary body, choroid, or both, with secondary glaucoma. (from AJCC 8th Ed.)","Iris Melanoma pT2c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538784","Iris Melanoma pT2b TNM Finding v8","C140624","Iris melanoma with tumor confluent with or extending into the ciliary body and choroid, without secondary glaucoma. (from AJCC 8th Ed.)","Iris Melanoma pT2b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538785","Iris Melanoma pT2a TNM Finding v8","C140623","Iris melanoma with tumor confluent with or extending into the ciliary body, without secondary glaucoma. (from AJCC 8th Ed.)","Iris Melanoma pT2a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538786","Iris Melanoma pT2 TNM Finding v8","C140622","Iris melanoma with tumor confluent with or extending into the ciliary body, choroid, or both. (from AJCC 8th Ed.)","Iris Melanoma pT2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538675","Iris Melanoma pT1c TNM Finding v8","C140621","Iris melanoma with tumor limited to the iris with secondary glaucoma. (from AJCC 8th Ed.)","Iris Melanoma pT1c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538676","Iris Melanoma pT1b TNM Finding v8","C140620","Iris melanoma with tumor limited to the iris, more than 3 clock hours in size. (from AJCC 8th Ed.)","Iris Melanoma pT1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538677","Iris Melanoma pT1a TNM Finding v8","C140619","Iris melanoma with tumor limited to the iris, not more than 3 clock hours in size. (from AJCC 8th Ed.)","Iris Melanoma pT1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538678","Iris Melanoma pT1 TNM Finding v8","C140618","Iris melanoma with tumor limited to the iris. (from AJCC 8th Ed.)","Iris Melanoma pT1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538754","Uveal Melanoma pN1a TNM Finding v8","C140654","Uveal melanoma with metastasis in one or more regional lymph node(s). (from AJCC 8th Ed.)","Uveal Melanoma pN1a TNM Finding v8 | pN1a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538771","Uveal Melanoma pN1 TNM Finding v8","C140653","Uveal melanoma with regional lymph node metastasis or discrete tumor deposits in the orbit. (from AJCC 8th Ed.)","Uveal Melanoma pN1 TNM Finding v8 | pN1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538667","Uveal Melanoma pM1 TNM Finding v8","C140613","Uveal melanoma with distant metastasis. (from AJCC 8th Ed.)","Uveal Melanoma pM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538670","Uveal Melanoma cM1c TNM Finding v8","C140610","Uveal melanoma with largest diameter of the largest metastasis 8.1 cm or more. (from AJCC 8th Ed.)","Uveal Melanoma cM1c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538671","Uveal Melanoma cM1b TNM Finding v8","C140609","Uveal melanoma with largest diameter of the largest metastasis 3.1-8.0 cm. (from AJCC 8th Ed.)","Uveal Melanoma cM1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538672","Uveal Melanoma cM1a TNM Finding v8","C140608","Uveal melanoma with largest diameter of the largest metastasis 3.0 cm or less. (from AJCC 8th Ed.)","Uveal Melanoma cM1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538673","Uveal Melanoma cM1 TNM Finding v8","C140607","Uveal melanoma with distant metastasis. (from AJCC 8th Ed.)","Uveal Melanoma cM1 TNM Finding v8 | cM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538674","Uveal Melanoma cM0 TNM Finding v8","C140606","Uveal melanoma with no distant metastasis by clinical classification. (from AJCC 8th Ed.)","Uveal Melanoma cM0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538691","Uveal Melanoma Clinical Distant Metastasis TNM Finding v8","C140605","A clinical finding about one or more characteristics of uveal melanoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Uveal Melanoma Clinical Distant Metastasis TNM Finding v8 | Clinical Distant Metastasis Status (cM)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538668","Uveal Melanoma Pathologic Distant Metastasis TNM Finding v8","C140612","A pathologic finding about one or more characteristics of uveal melanoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Uveal Melanoma Pathologic Distant Metastasis TNM Finding v8 | Pathologic Distant Metastasis Status (pM)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538680","Uveal Melanoma pM1c TNM Finding v8","C140616","Uveal melanoma with largest diameter of the largest metastasis 8.1 cm or more. (from AJCC 8th Ed.)","Uveal Melanoma pM1c TNM Finding v8 | pTM1c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538681","Uveal Melanoma pM1b TNM Finding v8","C140615","Uveal melanoma with largest diameter of the largest metastasis 3.1-8.0 cm. (from AJCC 8th Ed.)","Uveal Melanoma pM1b TNM Finding v8 | pTM1b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538682","Uveal Melanoma pM1a TNM Finding v8","C140614","Uveal melanoma with largest diameter of the largest metastasis 3.0 cm or less. (from AJCC 8th Ed.)","Uveal Melanoma pM1a TNM Finding v8 | pTM1a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538773","Choroidal and Ciliary Body Melanoma pT4e TNM Finding v8","C140651","Choroidal and ciliary body melanoma, any tumor size category with extraocular extension more than 5 mm in largest diameter. (from AJCC 8th Ed.)","Choroidal and Ciliary Body Melanoma pT4e TNM Finding v8 | pT4e",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538774","Choroidal and Ciliary Body Melanoma pT4d TNM Finding v8","C140650","Choroidal and ciliary body melanoma, tumor size category 4 with ciliary body involvement and extraocular extension 5 mm or less in largest diameter. (from AJCC 8th Ed.)","Choroidal and Ciliary Body Melanoma pT4d TNM Finding v8 | pT4d",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538775","Choroidal and Ciliary Body Melanoma pT4c TNM Finding v8","C140649","Choroidal and ciliary body melanoma, tumor size category 4 without ciliary body involvement but with extraocular extension 5 mm or less in largest diameter. (from AJCC 8th Ed.)","Choroidal and Ciliary Body Melanoma pT4c TNM Finding v8 | pT4c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538776","Choroidal and Ciliary Body Melanoma pT4b TNM Finding v8","C140648","Choroidal and ciliary body melanoma, tumor size category 4 with ciliary body involvement. (from AJCC 8th Ed.)","Choroidal and Ciliary Body Melanoma pT4b TNM Finding v8 | pT4b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538777","Choroidal and Ciliary Body Melanoma pT4a TNM Finding v8","C140647","Choroidal and ciliary body melanoma, tumor size category 4 without ciliary body involvement and extraocular extension. (from AJCC 8th Ed.)","Choroidal and Ciliary Body Melanoma pT4a TNM Finding v8 | pT4a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538778","Choroidal and Ciliary Body Melanoma pT4 TNM Finding v8","C140646","Choroidal and ciliary body melanoma, tumor size category 4. (from AJCC 8th Ed.)","Choroidal and Ciliary Body Melanoma pT4 TNM Finding v8 | pT4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538764","Choroidal and Ciliary Body Melanoma pT3c TNM Finding v8","C140644","Choroidal and ciliary body melanoma, tumor size category 3 without ciliary body involvement but with extraocular extension 5 mm or less in largest diameter. (from AJCC 8th Ed.)","Choroidal and Ciliary Body Melanoma pT3c TNM Finding v8 | pT3c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538765","Choroidal and Ciliary Body Melanoma pT3b TNM Finding v8","C140643","Choroidal and ciliary body melanoma, tumor size category 3 with ciliary body involvement. (from AJCC 8th Ed.)","Choroidal and Ciliary Body Melanoma pT3b TNM Finding v8 | pT3b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538766","Choroidal and Ciliary Body Melanoma pT3a TNM Finding v8","C140642","Choroidal and ciliary body melanoma, tumor size category 3 without ciliary body involvement and extraocular extension. (from AJCC 8th Ed.)","Choroidal and Ciliary Body Melanoma pT3a TNM Finding v8 | pT3a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538767","Choroidal and Ciliary Body Melanoma pT3 TNM Finding v8","C140641","Choroidal and ciliary body melanoma, tumor size category 3. (from AJCC 8th Ed.)","Choroidal and Ciliary Body Melanoma pT3 TNM Finding v8 | pT3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538768","Choroidal and Ciliary Body Melanoma pT2d TNM Finding v8","C140640","Choroidal and ciliary body melanoma, tumor size category 2 with ciliary body involvement and extraocular extension 5 mm or less in largest diameter. (from AJCC 8th Ed.)","Choroidal and Ciliary Body Melanoma pT2d TNM Finding v8 | pT2d",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538769","Choroidal and Ciliary Body Melanoma pT2c TNM Finding v8","C140639","Choroidal and ciliary body melanoma, tumor size category 2 without ciliary body involvement but with extraocular extension 5 mm or less in largest diameter. (from AJCC 8th Ed.)","Choroidal and Ciliary Body Melanoma pT2c TNM Finding v8 | pT2c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538770","Choroidal and Ciliary Body Melanoma pT2b TNM Finding v8","C140638","Choroidal and ciliary body melanoma, tumor size category 2 with ciliary body involvement. (from AJCC 8th Ed.)","Choroidal and Ciliary Body Melanoma pT2b TNM Finding v8 | pT2b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538787","Choroidal and Ciliary Body Melanoma pT2a TNM Finding v8","C140637","Choroidal and ciliary body melanoma, tumor size category 2 without ciliary body involvement and extraocular extension. (from AJCC 8th Ed.)","Choroidal and Ciliary Body Melanoma pT2a TNM Finding v8 | pT2a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538788","Choroidal and Ciliary Body Melanoma pT2 TNM Finding v8","C140636","Choroidal and ciliary body melanoma, tumor size category 2. (from AJCC 8th Ed.)","Choroidal and Ciliary Body Melanoma pT2 TNM Finding v8 | pT2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538789","Choroidal and Ciliary Body Melanoma pT1d TNM Finding v8","C140635","Choroidal and ciliary body melanoma, tumor size category 1 with ciliary body involvement and extraocular extension 5 mm or less in largest diameter. (from AJCC 8th Ed.)","Choroidal and Ciliary Body Melanoma pT1d TNM Finding v8 | pT1d",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538790","Choroidal and Ciliary Body Melanoma pT1c TNM Finding v8","C140634","Choroidal and ciliary body melanoma, tumor size category 1 without ciliary body involvement but with extraocular extension 5 mm or less in largest diameter. (from AJCC 8th Ed.)","Choroidal and Ciliary Body Melanoma pT1c TNM Finding v8 | pT1c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538791","Choroidal and Ciliary Body Melanoma pT1b TNM Finding v8","C140633","Choroidal and ciliary body melanoma, tumor size category 1 with ciliary body involvement. (from AJCC 8th Ed.)","Choroidal and Ciliary Body Melanoma pT1b TNM Finding v8 | pT1b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538792","Choroidal and Ciliary Body Melanoma pT1a TNM Finding v8","C140632","Choroidal and ciliary body melanoma, tumor size category 1 without ciliary body involvement and extraocular extension. (from AJCC 8th Ed.)","Choroidal and Ciliary Body Melanoma pT1a TNM Finding v8 | pT1a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538793","Choroidal and Ciliary Body Melanoma pT1 TNM Finding v8","C140631","Choroidal and ciliary body melanoma, tumor size category 1. (from AJCC 8th Ed.)","Choroidal and Ciliary Body Melanoma pT1 TNM Finding v8 | pT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538753","Uveal Melanoma pN1b TNM Finding v8","C140655","Uveal melanoma in which no regional lymph nodes are positive, but there are discrete tumor deposits in the orbit that are not contiguous to the eye. (from AJCC 8th Ed.)","Uveal Melanoma pN1b TNM Finding v8 | pN1b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538750","Choroidal and Ciliary Body Melanoma by AJCC v8 Stage","C140659","A term that refers to the staging of choroidal and ciliary body melanoma, following the rules of the TNM AJCC v8 classification system.","Choroidal and Ciliary Body Melanoma by AJCC v8 Stage | Posterior Uveal Melanoma by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538757","Stage IV Choroidal and Ciliary Body Melanoma AJCC v8","C140668","Stage IV includes: (Any T, N1, M0); (Any T, Any N, M1a-c). N1: Regional lymph node metastasis or discrete tumor deposits in the orbit. M0: No distant metastasis. M1a: Distant metastasis, with the largest diameter of the largest metastasis measuring 3 cm or less. M1b: Distant metastasis, with the largest diameter of the largest metastasis measuring 3.1-8.0 cm. M1c: Distant metastasis, with the largest diameter of the largest metastasis measuring 8.1 cm or more.  (AJCC 8th ed.)","Stage IV Choroidal and Ciliary Body Melanoma AJCC v8 | Stage IV Choroidal and Ciliary Body Melanoma | Stage IV Posterior Uveal Melanoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538759","Stage IIIB Choroidal and Ciliary Body Melanoma AJCC v8","C140666","Stage IIIB includes: (T3d, N0, M0); (T4b-c, N0, M0). T3d: Tumor size category 3 with ciliary body involvement and extraocular extension less than or equal to 5 mm in largest diameter.  T4b: Tumor size category 4 with ciliary body involvement. T4c: Tumor size category 4 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in largest diameter. N0: No regional lymph node metastasis. M0: No distant metastasis.  (AJCC 8th ed.)","Stage IIIB Choroidal and Ciliary Body Melanoma AJCC v8 | Stage IIIB Choroidal and Ciliary Body Melanoma | Stage IIIB Posterior Uveal Melanoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538760","Stage IIIA Choroidal and Ciliary Body Melanoma AJCC v8","C140665","Stage IIIA includes: (T2c-d, N0, M0); (T3b-c, N0, M0); (T4a, N0, M0). T2c: Tumor size category 2 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in largest diameter. T2d: Tumor size category 2 with ciliary body involvement and extraocular extension less than or equal to 5 mm in largest diameter. T3b: Tumor size category 3 with ciliary body involvement. T3c: Tumor size category 3 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in largest diameter. T4a: Tumor size category 4 without ciliary body involvement and extraocular extension. N0: No regional lymph node metastasis. M0: No distant metastasis.  (AJCC 8th ed.)","Stage IIIA Choroidal and Ciliary Body Melanoma AJCC v8 | Stage IIIA Choroidal and Ciliary Body Melanoma | Stage IIIA Posterior Uveal Melanoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538762","Stage IIB Choroidal and Ciliary Body Melanoma AJCC v8","C140663","Stage IIB includes: (T2b, N0, M0); (T3a, N0, M0).  T2b: Tumor size category 2 with ciliary body involvement. T3a: Tumor size category 3 without ciliary body involvement and extraocular extension. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 8th ed.)","Stage IIB Choroidal and Ciliary Body Melanoma AJCC v8 | Stage IIB Choroidal and Ciliary Body Melanoma | Stage IIB Posterior Uveal Melanoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538747","Stage IIA Choroidal and Ciliary Body Melanoma AJCC v8","C140662","Stage IIA includes: (T1b-d, N0, M0); (T2a, N0, M0).  T1b: Tumor size category 1 with ciliary body involvement.  T1c: Tumor size category 1 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in largest diameter.  T1d: Tumor size category 1 with ciliary body involvement and extraocular extension less than or equal to 5 mm in largest diameter. T2a: Tumor size category 2 without ciliary body involvement and extraocular extension. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 8th ed.)","Stage IIA Choroidal and Ciliary Body Melanoma AJCC v8 | Stage IIA Choroidal and Ciliary Body Melanoma | Stage IIA Posterior Uveal Melanoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538749","Stage I Choroidal and Ciliary Body Melanoma AJCC v8","C140660","Stage I includes: T1a, N0, M0. T1a: Tumor size category 1 without ciliary body involvement and extraocular extension.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 8th ed.)","Stage I Choroidal and Ciliary Body Melanoma AJCC v8 | Stage I Choroidal and Ciliary Body Melanoma | Stage I Posterior Uveal Melanoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273046","Intrahepatic Large Bile Duct","C96803","The larger bile ducts which are located within the liver and drain bile from the smaller peripheral intrahepatic bile ducts into the right and left hepatic ducts.","Intrahepatic Large Bile Duct | INTRAHEPATIC LARGE BILE DUCT | Perihilar Bile Duct | Periphilar Bile Duct",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880363","Distal Common Bile Duct","C60801","The section of the tube-like structure carrying bile that is closest to the intestine and furthest from the hepatic and cystic ducts.","Distal Common Bile Duct | DISTAL COMMON BILE DUCT | Distal Bile Duct",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522136","Intrahepatic Bile Duct Cancer TNM Finding v8","C134577","A finding about one or more characteristics of intrahepatic bile duct cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to intrahepatic cholangiocarcinomas, combined hepatocellular-cholangiocarcinomas (mixed hepatocholangiocarcinomas), and primary neuroendocrine tumors of the liver. Primary sarcomas of the liver, pure hepatocellular carcinomas, hilar cholangiocarcinomas, and gallbladder carcinomas are not staged using this staging system. (from AJCC 8th Ed.)","Intrahepatic Bile Duct Cancer TNM Finding v8 | Intrahepatic Bile Duct Carcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522154","Intrahepatic Bile Duct Cancer pT4 TNM Finding v8","C134598","Intrahepatic bile duct cancer with tumor involving local extrahepatic structures by direct invasion. (from AJCC 8th Ed.)","Intrahepatic Bile Duct Cancer pT4 TNM Finding v8 | Intrahepatic Bile Duct Carcinoma pT4 TNM Finding v8 | pT4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522153","Intrahepatic Bile Duct Cancer pT3 TNM Finding v8","C134597","Intrahepatic bile duct cancer with tumor perforating the visceral peritoneum. (from AJCC 8th Ed.)","Intrahepatic Bile Duct Cancer pT3 TNM Finding v8 | Intrahepatic Bile Duct Carcinoma pT3 TNM Finding v8 | pT3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522152","Intrahepatic Bile Duct Cancer pT2 TNM Finding v8","C134596","Intrahepatic bile duct cancer with solitary tumor with intrahepatic vascular invasion, or multiple tumors, with or without vascular invasion. (from AJCC 8th Ed.)","Intrahepatic Bile Duct Cancer pT2 TNM Finding v8 | Intrahepatic Bile Duct Carcinoma pT2 TNM Finding v8 | pT2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522151","Intrahepatic Bile Duct Cancer pT1b TNM Finding v8","C134595","Intrahepatic bile duct cancer with solitary tumor larger than 5 cm without vascular invasion. (from AJCC 8th Ed.)","Intrahepatic Bile Duct Cancer pT1b TNM Finding v8 | Intrahepatic Bile Duct Carcinoma pT1b TNM Finding v8 | pT1b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522150","Intrahepatic Bile Duct Cancer pT1a TNM Finding v8","C134594","Intrahepatic bile duct cancer with solitary tumor equal to or less than 5 cm without vascular invasion. (from AJCC 8th Ed.)","Intrahepatic Bile Duct Cancer pT1a TNM Finding v8 | Intrahepatic Bile Duct Carcinoma pT1a TNM Finding v8 | pT1a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522149","Intrahepatic Bile Duct Cancer pT1 TNM Finding v8","C134593","Intrahepatic bile duct cancer with solitary tumor equal to or less than 5 cm, or larger than 5 cm without vascular invasion. (from AJCC 8th Ed.)","Intrahepatic Bile Duct Cancer pT1 TNM Finding v8 | Intrahepatic Bile Duct Carcinoma pT1 TNM Finding v8 | pT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522148","Intrahepatic Bile Duct Cancer pTis TNM Finding v8","C134591","Intrahepatic bile duct cancer with a finding of carcinoma in situ (intraductal tumor). (from AJCC 8th Ed.)","Intrahepatic Bile Duct Cancer pTis TNM Finding v8 | Intrahepatic Bile Duct Carcinoma pTis TNM Finding v8 | pTis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522147","Intrahepatic Bile Duct Cancer pT0 TNM Finding v8","C134590","Intrahepatic bile duct cancer with no evidence of primary tumor. (from AJCC 8th Ed.)","Intrahepatic Bile Duct Cancer pT0 TNM Finding v8 | Intrahepatic Bile Duct Carcinoma pT0 TNM Finding v8 | pT0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522145","Intrahepatic Bile Duct Cancer pTX TNM Finding v8","C134588","Intrahepatic bile duct cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Intrahepatic Bile Duct Cancer pTX TNM Finding v8 | Intrahepatic Bile Duct Carcinoma pTX TNM Finding v8 | pTX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522158","Intrahepatic Bile Duct Cancer pN1 TNM Finding v8","C134603","Intrahepatic bile duct cancer with regional lymph node metastasis. (from AJCC 8th Ed.)","Intrahepatic Bile Duct Cancer pN1 TNM Finding v8 | Intrahepatic Bile Duct Carcinoma pN1 TNM Finding v8 | pN1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522157","Intrahepatic Bile Duct Cancer pN0 TNM Finding v8","C134601","Intrahepatic bile duct cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","Intrahepatic Bile Duct Cancer pN0 TNM Finding v8 | Intrahepatic Bile Duct Carcinoma pN0 TNM Finding v8 | pN0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522156","Intrahepatic Bile Duct Cancer pNX TNM Finding v8","C134600","Intrahepatic bile duct cancer in which the regional lymph node(s) cannot be assessed.  (from AJCC 8th Ed.)","Intrahepatic Bile Duct Cancer pNX TNM Finding v8 | Intrahepatic Bile Duct Carcinoma pNX TNM Finding v8 | pNX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522143","Intrahepatic Bile Duct Cancer pM1 TNM Finding v8","C134585","Intrahepatic bile duct cancer with distant metastasis. (from AJCC 8th Ed.)","Intrahepatic Bile Duct Cancer pM1 TNM Finding v8 | Intrahepatic Bile Duct Carcinoma pM1 TNM Finding v8 | pM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522140","Intrahepatic Bile Duct Cancer cM1 TNM Finding v8","C134581","Intrahepatic bile duct cancer with distant metastasis. (from AJCC 8th Ed.)","Intrahepatic Bile Duct Cancer cM1 TNM Finding v8 | Intrahepatic Bile Duct Carcinoma cM1 TNM Finding v8 | cM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522139","Intrahepatic Bile Duct Cancer cM0 TNM Finding v8","C134580","Intrahepatic bile duct cancer without evidence of distant metastasis. (from AJCC 8th Ed.)","Intrahepatic Bile Duct Cancer cM0 TNM Finding v8 | Intrahepatic Bile Duct Carcinoma cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522171","Stage IV Intrahepatic Bile Duct Cancer AJCC v8","C134619","Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Intrahepatic Bile Duct Cancer AJCC v8 | Stage IV Intrahepatic Bile Duct Cancer | Stage IV Intrahepatic Bile Duct Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522170","Stage IIIB Intrahepatic Bile Duct Cancer AJCC v8","C134618","Stage IIIB includes: (T4, N0, M0); (Any T, N1, M0). T4: Tumor involving local extrahepatic structures by direct invasion. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIB Intrahepatic Bile Duct Cancer AJCC v8 | Stage IIIB Intrahepatic Bile Duct Cancer | Stage IIIB Intrahepatic Bile Duct Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522168","Stage IIIA Intrahepatic Bile Duct Cancer AJCC v8","C134616","Stage IIIA includes: T3, N0, M0. T3: Tumor perforating the visceral peritoneum. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIA Intrahepatic Bile Duct Cancer AJCC v8 | Stage IIIA Intrahepatic Bile Duct Cancer | Stage IIIA Intrahepatic Bile Duct Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522166","Stage II Intrahepatic Bile Duct Cancer AJCC v8","C134614","Stage II includes: T2, N0, M0. T2: Solitary tumor with intrahepatic vascular invasion, or multiple tumors, with or without vascular invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Intrahepatic Bile Duct Cancer AJCC v8 | Stage II Intrahepatic Bile Duct Cancer | Stage II Intrahepatic Bile Duct Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522165","Stage IB Intrahepatic Bile Duct Cancer AJCC v8","C134612","Stage IB includes: T1b, N0, M0. T1b: Solitary tumor larger than 5 cm without vascular invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IB Intrahepatic Bile Duct Cancer AJCC v8 | Stage IB Intrahepatic Bile Duct Cancer | Stage IB Intrahepatic Bile Duct Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522164","Stage IA Intrahepatic Bile Duct Cancer AJCC v8","C134611","Stage IA includes: T1a, N0, M0. T1a: Solitary tumor equal to or less than 5 cm without vascular invasion.  N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IA Intrahepatic Bile Duct Cancer AJCC v8 | Stage IA Intrahepatic Bile Duct Cancer | Stage IA Intrahepatic Bile Duct Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522162","Stage 0 Intrahepatic Bile Duct Cancer AJCC v8","C134609","Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ (intraductal tumor). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0 Intrahepatic Bile Duct Cancer AJCC v8 | Stage 0 Intrahepatic Bile Duct Cancer | Stage 0 Intrahepatic Bile Duct Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522240","Perihilar Bile Duct Cancer TNM Finding v8","C134712","A finding about one or more characteristics of perihilar bile duct cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to perihilar cholangiocarcinomas. Well-differentiated neuroendocrine tumors and sarcomas are not staged using this staging system. (from AJCC 8th Ed.)","Perihilar Bile Duct Cancer TNM Finding v8 | Hilar Cholangiocarcinoma TNM Finding v8 | Perihilar Cholangiocarcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522257","Perihilar Bile Duct Cancer pT4 TNM Finding v8","C134730","Perihilar bile duct cancer with tumor invading the main portal vein or its branches bilaterally, or the common hepatic artery; or unilateral second-order biliary radicals with contralateral portal vein or hepatic artery involvement. (from AJCC 8th Ed.)","Perihilar Bile Duct Cancer pT4 TNM Finding v8 | Hilar Cholangiocarcinoma pT4 TNM Finding v8 | Perihilar Cholangiocarcinoma pT4 TNM Finding v8 | pT4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522256","Perihilar Bile Duct Cancer pT3 TNM Finding v8","C134729","Perihilar bile duct cancer with tumor invading unilateral branches of the portal vein or hepatic artery. (from AJCC 8th Ed.)","Perihilar Bile Duct Cancer pT3 TNM Finding v8 | Hilar Cholangiocarcinoma pT3 TNM Finding v8 | Perihilar Cholangiocarcinoma pT3 TNM Finding v8 | pT3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522255","Perihilar Bile Duct Cancer pT2b TNM Finding v8","C134728","Perihilar bile duct cancer with tumor invading adjacent hepatic parenchyma. (from AJCC 8th Ed.)","Perihilar Bile Duct Cancer pT2b TNM Finding v8 | Hilar Cholangiocarcinoma pT2b TNM Finding v8 | Perihilar Cholangiocarcinoma pT2b TNM Finding v8 | pT2b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522254","Perihilar Bile Duct Cancer pT2a TNM Finding v8","C134727","Perihilar bile duct cancer with tumor invading beyond the wall of the bile duct to surrounding adipose tissue. (from AJCC 8th Ed.)","Perihilar Bile Duct Cancer pT2a TNM Finding v8 | Hilar Cholangiocarcinoma pT2a TNM Finding v8 | Perihilar Cholangiocarcinoma pT2a TNM Finding v8 | pT2a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522253","Perihilar Bile Duct Cancer pT2 TNM Finding v8","C134726","Perihilar bile duct cancer with tumor invading beyond the wall of the bile duct to surrounding adipose tissue, or tumor invading adjacent hepatic parenchyma. (from AJCC 8th Ed.)","Perihilar Bile Duct Cancer pT2 TNM Finding v8 | Hilar Cholangiocarcinoma pT2 TNM Finding v8 | Perihilar Cholangiocarcinoma pT2 TNM Finding v8 | pT2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522252","Perihilar Bile Duct Cancer pT1 TNM Finding v8","C134725","Perihilar bile duct cancer with tumor confined to the bile duct, with extension up to the muscle layer or fibrous tissue. (from AJCC 8th Ed.)","Perihilar Bile Duct Cancer pT1 TNM Finding v8 | Hilar Cholangiocarcinoma pT1 TNM Finding v8 | Perihilar Cholangiocarcinoma pT1 TNM Finding v8 | pT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522251","Perihilar Bile Duct Cancer pTis TNM Finding v8","C134724","Perihilar bile duct cancer with a finding of carcinoma in situ/high grade dysplasia. (from AJCC 8th Ed.)","Perihilar Bile Duct Cancer pTis TNM Finding v8 | Hilar Cholangiocarcinoma pTis TNM Finding v8 | Perihilar Cholangiocarcinoma pTis TNM Finding v8 | pTis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522250","Perihilar Bile Duct Cancer pT0 TNM Finding v8","C134723","Perihilar bile duct cancer with no evidence of primary tumor. (from AJCC 8th Ed.)","Perihilar Bile Duct Cancer pT0 TNM Finding v8 | Hilar Cholangiocarcinoma pT0 TNM Finding v8 | Perihilar Cholangiocarcinoma pT0 TNM Finding v8 | pT0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522249","Perihilar Bile Duct Cancer pTX TNM Finding v8","C134722","Perihilar bile duct cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Perihilar Bile Duct Cancer pTX TNM Finding v8 | Hilar Cholangiocarcinoma pTX TNM Finding v8 | Perihilar Cholangiocarcinoma pTX TNM Finding v8 | pTX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522247","Perihilar Bile Duct Cancer pM1 TNM Finding v8","C134720","Perihilar bile duct cancer with distant metastasis. (from AJCC 8th Ed.)","Perihilar Bile Duct Cancer pM1 TNM Finding v8 | Hilar Cholangiocarcinoma pM1 TNM Finding v8 | Perihilar Cholangiocarcinoma pM1 TNM Finding v8 | pM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522244","Perihilar Bile Duct Cancer cM1 TNM Finding v8","C134717","Perihilar bile duct cancer with distant metastasis. (from AJCC 8th Ed.)","Perihilar Bile Duct Cancer cM1 TNM Finding v8 | Hilar Cholangiocarcinoma cM1 TNM Finding v8 | Perihilar Cholangiocarcinoma cM1 TNM Finding v8 | cM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522243","Perihilar Bile Duct Cancer cM0 TNM Finding v8","C134716","Perihilar bile duct cancer without evidence of distant metastasis. (from AJCC 8th Ed.)","Perihilar Bile Duct Cancer cM0 TNM Finding v8 | Hilar Cholangiocarcinoma cM0 TNM Finding v8 | Perihilar Cholangiocarcinoma cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522262","Perihilar Bile Duct Cancer pN2 TNM Finding v8","C134735","Perihilar bile duct cancer with four or more positive lymph nodes involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes. (from AJCC 8th Ed.)","Perihilar Bile Duct Cancer pN2 TNM Finding v8 | Hilar Cholangiocarcinoma pN2 TNM Finding v8 | Perihilar Cholangiocarcinoma pN2 TNM Finding v8 | pN2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522261","Perihilar Bile Duct Cancer pN1 TNM Finding v8","C134734","Perihilar bile duct cancer with one to three positive lymph nodes typically involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes. (from AJCC 8th Ed.)","Perihilar Bile Duct Cancer pN1 TNM Finding v8 | Hilar Cholangiocarcinoma pN1 TNM Finding v8 | Perihilar Cholangiocarcinoma pN1 TNM Finding v8 | pN1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522260","Perihilar Bile Duct Cancer pN0 TNM Finding v8","C134733","Perihilar bile duct cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","Perihilar Bile Duct Cancer pN0 TNM Finding v8 | Hilar Cholangiocarcinoma pN0 TNM Finding v8 | Perihilar Cholangiocarcinoma pN0 TNM Finding v8 | pN0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522259","Perihilar Bile Duct Cancer pNX TNM Finding v8","C134732","Perihilar bile duct cancer in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)","Perihilar Bile Duct Cancer pNX TNM Finding v8 | Hilar Cholangiocarcinoma pNX TNM Finding v8 | Perihilar Cholangiocarcinoma pNX TNM Finding v8 | pNX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522270","Hilar Cholangiocarcinoma by AJCC v8 Stage","C134743","A term that refers to the staging of hilar cholangiocarcinoma according to the American Joint Committee on Cancer, 8th edition. Hilar well-differentiated neuroendocrine tumors and sarcomas are not staged using this staging system. (from AJCC 8th Ed.)","Hilar Cholangiocarcinoma by AJCC v8 Stage | Hilar Cholangiocarcinoma Tumor Stage (Pathologic) | Perihilar Cholangiocarcinoma by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522280","Stage IVB Hilar Cholangiocarcinoma AJCC v8","C134753","Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","Stage IVB Hilar Cholangiocarcinoma AJCC v8 | IVB | Stage IVB Hilar Cholangiocarcinoma | Stage IVB Perihilar Cholangiocarcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522279","Stage IVA Hilar Cholangiocarcinoma AJCC v8","C134752","Stage IVA includes: Any T, N2, M0. N2: Four or more positive lymph nodes involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage IVA Hilar Cholangiocarcinoma AJCC v8 | IVA | Stage IVA Hilar Cholangiocarcinoma | Stage IVA Perihilar Cholangiocarcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522277","Stage IIIC Hilar Cholangiocarcinoma AJCC v8","C134750","Stage IIIC includes: Any T, N1, M0. N1: One to three positive lymph nodes typically involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIC Hilar Cholangiocarcinoma AJCC v8 | IIIC | Stage IIIC Hilar Cholangiocarcinoma | Stage IIIC Perihilar Cholangiocarcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522276","Stage IIIB Hilar Cholangiocarcinoma AJCC v8","C134749","Stage IIIB includes: T4, N0, M0. T4: Tumor invading the main portal vein or its branches bilaterally, or the common hepatic artery; or unilateral second-order biliary radicals with contralateral portal vein or hepatic artery involvement. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIB Hilar Cholangiocarcinoma AJCC v8 | IIIB | Stage IIIB Hilar Cholangiocarcinoma | Stage IIIB Perihilar Cholangiocarcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522275","Stage IIIA Hilar Cholangiocarcinoma AJCC v8","C134748","Stage IIIA includes: T3, N0, M0. T3: Tumor invading unilateral branches of the portal vein or hepatic artery. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIA Hilar Cholangiocarcinoma AJCC v8 | IIIA | Stage IIIA Hilar Cholangiocarcinoma | Stage IIIA Perihilar Cholangiocarcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522273","Stage II Hilar Cholangiocarcinoma AJCC v8","C134746","Stage II includes: T2a-b, N0, M0. T2a: Tumor invading beyond the wall of the bile duct to surrounding adipose tissue. T2b: Tumor invading adjacent hepatic parenchyma. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Hilar Cholangiocarcinoma AJCC v8 | II | Stage II Hilar Cholangiocarcinoma | Stage II Perihilar Cholangiocarcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522272","Stage I Hilar Cholangiocarcinoma AJCC v8","C134745","Stage I includes: T1, N0, M0. T1: Tumor confined to the bile duct, with extension up to the muscle layer or fibrous tissue. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Hilar Cholangiocarcinoma AJCC v8 | I | Stage I Hilar Cholangiocarcinoma | Stage I Perihilar Cholangiocarcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522271","Stage 0 Hilar Cholangiocarcinoma AJCC v8","C134744","Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ/high grade dysplasia. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0 Hilar Cholangiocarcinoma AJCC v8 | 0 | Stage 0 Hilar Cholangiocarcinoma | Stage 0 Perihilar Cholangiocarcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522311","Distal Bile Duct Cancer TNM Finding v8","C134788","A finding about one or more characteristics of distal bile duct cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to bile duct adenocarcinomas, biliary intraepithelial neoplasia, high-grade neuroendocrine carcinomas, and papillary carcinomas. Tumors arising in the ampulla of Vater, sarcomas, and well-differentiated neuroendocrine tumors (carcinoids) are not staged using this staging system. (from AJCC 8th Ed.)","Distal Bile Duct Cancer TNM Finding v8 | Distal Bile Duct Carcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522325","Distal Bile Duct Cancer pT4 TNM Finding v8","C134803","Distal bile duct cancer with tumor involving the celiac axis, superior mesenteric artery, and/or common hepatic artery. (from AJCC 8th Ed.)","Distal Bile Duct Cancer pT4 TNM Finding v8 | Distal Bile Duct Carcinoma pT4 TNM Finding v8 | pT4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522324","Distal Bile Duct Cancer pT3 TNM Finding v8","C134802","Distal bile duct cancer with tumor invading the bile duct wall with a depth greater than 12 mm. (from AJCC 8th Ed.)","Distal Bile Duct Cancer pT3 TNM Finding v8 | Distal Bile Duct Carcinoma pT3 TNM Finding v8 | pT3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522323","Distal Bile Duct Cancer pT2 TNM Finding v8","C134801","Distal bile duct cancer with tumor invading the bile duct wall with a depth of 5-12 mm. (from AJCC 8th Ed.)","Distal Bile Duct Cancer pT2 TNM Finding v8 | Distal Bile Duct Carcinoma pT2 TNM Finding v8 | pT2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522322","Distal Bile Duct Cancer pT1 TNM Finding v8","C134800","Distal bile duct cancer with tumor invading the bile duct wall with a depth less than 5 mm. (from AJCC 8th Ed.)","Distal Bile Duct Cancer pT1 TNM Finding v8 | Distal Bile Duct Carcinoma pT1 TNM Finding v8 | pT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522321","Distal Bile Duct Cancer pTis TNM Finding v8","C134799","Distal bile duct cancer with a finding of carcinoma in situ/high-grade dysplasia. (from AJCC 8th Ed.)","Distal Bile Duct Cancer pTis TNM Finding v8 | Distal Bile Duct Carcinoma pTis TNM Finding v8 | pTis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522320","Distal Bile Duct Cancer pTX TNM Finding v8","C134798","Distal bile duct cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Distal Bile Duct Cancer pTX TNM Finding v8 | Distal Bile Duct Carcinoma pTX TNM Finding v8 | pTX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0749192","Surgery Declined","C148232","An indication that an individual was offered surgical intervention but decline to undergo surgery.","Surgery Declined | Declined Surgery | Refused Surgery | Surgery Refused",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522330","Distal Bile Duct Cancer pN2 TNM Finding v8","C134809","Distal bile duct cancer with metastasis in four or more regional lymph nodes. (from AJCC 8th Ed.)","Distal Bile Duct Cancer pN2 TNM Finding v8 | Distal Bile Duct Carcinoma pN2 TNM Finding v8 | pN2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522329","Distal Bile Duct Cancer pN1 TNM Finding v8","C134808","Distal bile duct cancer with metastasis in one to three regional lymph nodes. (from AJCC 8th Ed.)","Distal Bile Duct Cancer pN1 TNM Finding v8 | Distal Bile Duct Carcinoma pN1 TNM Finding v8 | pN1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522328","Distal Bile Duct Cancer pN0 TNM Finding v8","C134806","Distal bile duct cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","Distal Bile Duct Cancer pN0 TNM Finding v8 | Distal Bile Duct Carcinoma pN0 TNM Finding v8 | pN0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522327","Distal Bile Duct Cancer pNX TNM Finding v8","C134805","Distal bile duct cancer in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)","Distal Bile Duct Cancer pNX TNM Finding v8 | Distal Bile Duct Carcinoma pNX TNM Finding v8 | pNX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522318","Distal Bile Duct Cancer pM1 TNM Finding v8","C134796","Distal bile duct cancer with distant metastasis. (from AJCC 8th Ed.)","Distal Bile Duct Cancer pM1 TNM Finding v8 | Distal Bile Duct Carcinoma pM1 TNM Finding v8 | pM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522315","Distal Bile Duct Cancer cM1 TNM Finding v8","C134793","Distal bile duct cancer with distant metastasis. (from AJCC 8th Ed.)","Distal Bile Duct Cancer cM1 TNM Finding v8 | Distal Bile Duct Carcinoma cM1 TNM Finding v8 | cM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522314","Distal Bile Duct Cancer cM0 TNM Finding v8","C134791","Distal bile duct cancer without evidence of distant metastasis. (from AJCC 8th Ed.)","Distal Bile Duct Cancer cM0 TNM Finding v8 | Distal Bile Duct Carcinoma cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522332","Distal Bile Duct Cancer by AJCC v8 Stage","C134811","A term that refers to the staging of distal bile duct cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to bile duct adenocarcinomas, biliary intraepithelial neoplasia, high-grade neuroendocrine carcinomas, and papillary carcinomas that arise from the distal bile duct. Tumors arising in the ampulla of Vater, sarcomas, and well-differentiated neuroendocrine tumors (carcinoids) are not staged using this staging system. (from AJCC 8th Ed.)","Distal Bile Duct Cancer by AJCC v8 Stage | Distal Bile Duct Cancer Tumor Stage (Pathologic) | Distal Bile Duct Carcinoma by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522341","Stage IV Distal Bile Duct Cancer AJCC v8","C134820","Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Distal Bile Duct Cancer AJCC v8 | IV | Stage IV Distal Bile Duct Carcinoma AJCC v8 | Stage IV Extrahepatic (Distal) Bile Duct Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522340","Stage IIIB Distal Bile Duct Cancer AJCC v8","C134819","Stage IIIB includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Tumor involving the celiac axis, superior mesenteric artery, and/or common hepatic artery. N0: No regional lymph node metastasis. N1: Metastasis in one to three regional lymph nodes. N2: Metastasis in four or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIB Distal Bile Duct Cancer AJCC v8 | IIIB | Stage IIIB Distal Bile Duct Carcinoma AJCC v8 | Stage IIIB Extrahepatic (Distal) Bile Duct Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522337","Stage IIB Distal Bile Duct Cancer AJCC v8","C134816","Stage IIB includes: (T2, N1, M0); (T3, N0, M0); (T3, N1, M0). T2: Tumor invading the bile duct wall with a depth of 5-12 mm. T3: Tumor invading the bile duct wall with a depth greater than 12 mm. N0: No regional lymph node metastasis. N1: Metastasis in one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIB Distal Bile Duct Cancer AJCC v8 | IIB | Stage IIB Distal Bile Duct Carcinoma AJCC v8 | Stage IIB Extrahepatic (Distal) Bile Duct Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522339","Stage IIIA Distal Bile Duct Cancer AJCC v8","C134818","Stage IIIA includes: (T1, N2, M0); (T2, N2, M0); (T3, N2, M0). T1: Tumor invading the bile duct wall with a depth less than 5 mm. T2: Tumor invading the bile duct wall with a depth of 5-12 mm. T3: Tumor invading the bile duct wall with a depth greater than 12 mm. N2: Metastasis in four or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIA Distal Bile Duct Cancer AJCC v8 | IIIA | Stage IIIA Distal Bile Duct Carcinoma AJCC v8 | Stage IIIA Extrahepatic (Distal) Bile Duct Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522336","Stage IIA Distal Bile Duct Cancer AJCC v8","C134815","Stage IIA includes: (T1, N1, M0); (T2, N0, M0). T1: Tumor invading the bile duct wall with a depth less than 5 mm. T2: Tumor invading the bile duct wall with a depth of 5-12 mm. N0: No regional lymph node metastasis. N1: Metastasis in one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIA Distal Bile Duct Cancer AJCC v8 | IIA | Stage IIA Distal Bile Duct Carcinoma AJCC v8 | Stage IIA Extrahepatic (Distal) Bile Duct Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522334","Stage I Distal Bile Duct Cancer AJCC v8","C134813","Stage I includes: T1, N0, M0. T1: Tumor invading the bile duct wall with a depth less than 5 mm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Distal Bile Duct Cancer AJCC v8 | I | Stage I Distal Bile Duct Carcinoma AJCC v8 | Stage I Extrahepatic (Distal) Bile Duct Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522333","Stage 0 Distal Bile Duct Cancer AJCC v8","C134812","Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ/high-grade dysplasia. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0 Distal Bile Duct Cancer AJCC v8 | 0 | Stage 0 Distal Bile Duct Carcinoma AJCC v8 | Stage 0 Extrahepatic (Distal) Bile Duct Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562731","Synchronous Resection","C155989","A surgical procedure for the removal of multiple tumors within a single operative procedure.","Synchronous Resection | Synchronous Excision | Synchronous Tumor Resection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433777","Multiparametric Magnetic Resonance Imaging","C116458","The combination of multiple magnetic resonance techniques, including diffusion weighted imaging, dynamic contrast-enhanced imaging, and spectroscopy, to achieve an image that will allow for better identification of tumor size and location, as well as possibly identifying cancer spread and aggressiveness.","Multiparametric Magnetic Resonance Imaging | MP-MRI | Multi-parametric MRI | Multiparametric MRI | mpMRI",,,,,,,,,,,,,,,"37205363","Multiparametric magnetic resonance elastography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL537835","Cervical Cancer Clinical TNM Finding v8","C139683","A clinical finding about one or more characteristics of cervical cancer, following the rules of the TNM AJCC v8 classification system.","Cervical Cancer Clinical TNM Finding v8 | Cervical Carcinoma Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537799","Cervical Cancer Pathologic TNM Finding v8","C139703","A pathologic finding about one or more characteristics of cervical cancer, following the rules of the TNM AJCC v8 classification system.","Cervical Cancer Pathologic TNM Finding v8 | Cervical Carcinoma Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898066","Otolaryngologic Disorder","C118420","A non-neoplastic or neoplastic disorder that affects the ears, nose, paranasal sinuses, oral cavity, or throat.","Otolaryngologic Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514044","Early T Precursor Acute Lymphoblastic Leukemia","C130043","T acute lymphoblastic leukemia in which the blasts have unique immunophenotypic and genetic characteristics suggesting only limited early T-cell differentiation.","Early T Precursor Acute Lymphoblastic Leukemia | ETP ALL | ETP-ALL | Early T Acute Lymphoblastic Leukemia | Early T Acute Lymphoblastic Leukemia | Early T-Acute Lymphoblastic Leukemia | Early T-Cell Precursor Acute Lymphoblastic Leukemia | Early T-Cell Precursor Lymphoblastic Leukemia | Early T-Precursor Acute Lymphoblastic Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1720035","Recombinant Human Hyaluronidase","C61504","A human recombinant form of the naturally occurring human enzyme hyaluronidase with potential chemoadjuvant activity. Upon local administration, recombinant human hyaluronidase hydrolyzes hyaluronic acid, a glucosaminoglycan responsible for the viscosity of the interstitial barrier. The digestion of hyaluronic acid lowers the viscosity in the interstitial space, thereby increasing permeability and facilitating local penetration of chemotherapeutic agents into cancer cells.","Recombinant Human Hyaluronidase | Chemophase | HYALURONIDASE (HUMAN RECOMBINANT) | Hyaluronidase Recombinant Human | Hyaluronidase-oysk | Hylenex | rHuPH20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935942","Interfant-06 Protocol","C156939","A clinical study protocol initiated in 2006 designed to improve the treatment for infant acute lymphoblastic leukemia.","Interfant-06 Protocol | Interfant-06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935931","CHAMPS Activities Questionnaire for Older Adults","C156957","A self-report physical activity questionnaire for older men and women, developed to evaluate the outcomes of the Community Healthy Activities Model Program for Seniors (CHAMPS), an intervention to increase physical activity.","CHAMPS Activities Questionnaire for Older Adults | CHAMPS | Community Healthy Activities Model Program for Seniors Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936107","Visit with Friends or Family","C156958","A question about whether an individual visited with friends or family.","Visit with Friends or Family | Did you visit with friends or family (other than those you live with)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936120","Go to Senior Center","C156959","A question about whether an individual went to the senior center.","Go to Senior Center | Did you go to the senior center",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936106","Do Volunteer Work","C156960","A question about whether an individual did or does volunteer work.","Do Volunteer Work | Did you do volunteer work",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936127","Attend Church or Take Part in Church Activities","C156961","A question about whether an individual attended church or participated in church activities.","Attend Church or Take Part in Church Activities | Did you attend church or take part in church activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936057","Attend Other Club or Group Meetings","C156962","A question about whether an individual attended other club or group meetings.","Attend Other Club or Group Meetings | Did you attend other club or group meetings",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936108","Use a Computer","C156963","A question about whether an individual used a computer.","Use a Computer | Did you use a computer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936098","Do You Dance","C156964","A question about whether an individual dances.","Do You Dance Question | Dance | Did you dance (such as square, folk, line, ballroom) (do not count aerobic dance here) | Do You Dance | Do You Dance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936056","Do Artwork or Crafts","C156965","A question about whether an individual does artwork or crafts.","Do Artwork or Crafts Question | Did you do woodworking, needlework, drawing, or other arts or crafts | Do Arts or Crafts | Do Artwork or Crafts | Do Artwork or Crafts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936051","Play Golf and Carry Own Equipment","C156973","A question about whether an individual plays golf and carries or pulls their equipment.","Play Golf and Carry Own Equipment Question | Did you play golf, carrying or pulling your equipment (count walking time only) | Play Golf and Carry Own Equipment | Play Golf and Carry Own Equipment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936054","Play Golf, Riding Cart","C156974","A question about whether an individual plays golf, while riding a golf cart.","Play Golf, Riding Cart Question | Did you play golf, riding a cart (count walking time only) | Play Golf, Riding Cart | Play Golf, Riding Cart",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936055","Attend Concert, Movie, Lecture or Sport Event","C156975","A question about whether an individual attended a concert, movie, lecture, or sports event.","Attend Concert, Movie, Lecture or Sport Event | Did you attend a concert, movie, lecture, or sport event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936130","Play Cards, Bingo, or Board Games with Other People","C156976","A question about whether an individual played cards, bingo, or board games with other people.","Play Cards, Bingo, or Board Games with Other People Question | Did you play cards, bingo, or board games with other people | Play Basketball, Soccer, or Racquetball | Play Cards, Bingo, or Board Games with Other People",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936129","Shoot Pool or Billiards","C156977","A question about whether an individual played pool or billiards.","Shoot Pool or Billiards Question | Did you shoot pool or billiards | Shoot Pool or Billiards | Shoot Pool or Billiards",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936131","Play Singles Tennis","C156978","A question about whether an individual played single tennis.","Play Singles Tennis Question | Did you play singles tennis (do not count doubles) | Play Singles Tennis | Play Singles Tennis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936134","Play Doubles Tennis","C156979","A question about whether an individual played doubles tennis.","Play Doubles Tennis Question | Did you play doubles tennis (do not count singles) | Play Doubles Tennis | Play Doubles Tennis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936101","Go Skating","C156980","A question about whether an individual skated.","Go Skating | Did you skate (ice, roller, in-line) | Skate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936100","Play a Musical Instrument","C156981","A question about whether an individual played a musical instrument.","Play a Musical Instrument Question | Did you play a musical instrument | Play a Musical Instrument | Play a Musical Instrument",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936097","Do Reading","C156982","A question about whether an individual did any reading.","Do Reading Question | Did you read | Do Reading | Do Reading | Read",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936049","Do Heavy Work Around the House","C156983","A question about whether an individual did any heavy work around the house.","Do Heavy Work Around the House Question | Did you do heavy work around the house (such as washing windows, cleaning gutters) | Do Heavy Work Around the House | Do Heavy Work Around the House | Do Heavy household Chores",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936047","Do Light Work Around the House","C156984","A question about whether an individual did any light work around the house.","Do Light Work Around the House Question | Did you do light work around the house (such as sweeping or vacuuming) | Do Light Work Around the House | Do Light Work Around the House | Do Light household Chores",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936048","Do Heavy Gardening","C156985","A question about whether an individual did any heavy gardening.","Do Heavy Gardening Question | Did you do heavy gardening (such as spading, raking) | Do Heavy Gardening | Do Heavy Gardening",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936044","Do Light Gardening","C156986","A question about whether an individual did any light gardening.","Do Light Gardening Question | Did you do light gardening (such as watering plants) | Do Light Gardening | Do Light Gardening",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936133","Work on Car, Truck, Lawn Mower, or Other Machinery","C156987","A question about whether an individual worked on a car, truck, lawn mower, or other machinery.","Work on Car, Truck, Lawn Mower, or Other Machinery Question | Did you work on your car, truck, lawn mower, or other machinery | Work on Car, Truck, Lawn Mower, or Other Machinery | Work on Car, Truck, Lawn Mower, or Other Machinery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936093","Go Jogging or Running","C156988","A question about whether an individual jogged or ran.","Go Jogging or Running Question | Did you jog or run | Go Jogging or Running | Go Jogging or Running | Jog | Jogging | Jogging or Running | Run | Running",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936128","Walk or Hike Uphill","C156989","A question about whether an individual walked or hiked uphill.","Walk or Hike Uphill Question | Did you walk uphill or hike uphill (count only uphill part) | Hike Uphill | Walk Uphill | Walk or Hike Uphill | Walk or Hike Uphill",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936119","Walk Fast or Briskly for Exercise","C156990","A question about whether an individual walked fast or briskly for exercise.","Walk Fast or Briskly for Exercise Question | Did you walk fast or briskly for exercise (do not count walking leisurely or uphill) | Walk Fast or Briskly | Walk Fast or Briskly for Exercise | Walk Fast or Briskly for Exercise",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936046","Walk to Do Errands","C156991","A question about whether an individual walked to do errands.","Walk to Do Errands Question | Did you walk to do errands (such as to/from a store or to take children to school (count walk time only) | Walk to Do Errands | Walk to Do Errands",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936125","Walk Leisurely for Exercise or Pleasure","C156992","A question about whether an individual walked leisurely for exercise or pleasure.","Walk Leisurely for Exercise or Pleasure Question | Did you walk leisurely for exercise or pleasure | Walk Leisurely | Walk Leisurely for Exercise or Pleasure | Walk Leisurely for Exercise or Pleasure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936045","Ride a Bicycle or Stationary Bike","C156993","A question about whether an individual rode a bicycle or a stationary bike.","Ride a Bicycle or Stationary Bike Question | Did you ride a bicycle or stationary cycle | Ride Bicycle | Ride a Bicycle or Stationary Bike | Ride a Bicycle or Stationary Bike",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936083","Use Other Aerobic Equipment","C156994","A question about whether an individual used aerobic equipment such as rowing or step machines.","Use Other Aerobic Equipment | Did you do other aerobic machines such as rowing, or step machines (do not count treadmill or stationary cycle)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936084","Do Water Exercises Other than Swimming","C156995","A question about whether an individual did water exercises other than swimming.","Do Water Exercises Other than Swimming Question | Did you do water exercises (do not count other swimming) | Do Water Exercises Other than Swimming | Do Water Exercises Other than Swimming",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936122","Swim Moderately or Fast","C156996","A question about whether an individual did any moderate or fast swimming.","Swim Moderately or Fast Question | Did you swim moderately or fast | Swim Moderately or Fast | Swim Moderately or Fast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936121","Swim Gently","C156997","A question about whether an individual did any gentle swimming.","Swim Gently Question | Did you swim gently | Swim Gently | Swim Gently",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936087","Do Stretching or Flexibility Exercises","C156998","A question about whether an individual did stretching or flexibility exercises.","Do Stretching or Flexibility Exercises Question | Did you do stretching or flexibility exercises (do not count yoga or Tai-chi) | Do Stretching or Flexibility Exercises | Do Stretching or Flexibility Exercises",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936088","Do Yoga or Tai-chi","C156999","A question about whether an individual did yoga or tai-chi.","Do Yoga or Tai-chi Question | Did you do yoga or Tai-chi | Do Yoga or Tai-chi | Do Yoga or Tai-chi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936085","Do Aerobics or Aerobic Dancing","C157000","A question about whether an individual did aerobics or aerobic dancing.","Do Aerobics or Aerobic Dancing Question | Did you do aerobics or aerobic dancing | Do Aerobics or Aerobic Dancing | Do Aerobics or Aerobic Dancing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936086","Do Moderate to Heavy Strength Training","C157001","A question about whether an individual did moderate to heavy strength training.","Do Moderate to Heavy Strength Training Question | Did you do moderate to heavy strength training (such as hand-held weights of more than 5 lbs., weight machines, or push-ups) | Do Moderate to Heavy Strength Training | Do Moderate to Heavy Strength Training",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936078","Do Light Strength Training","C157002","A question about whether an individual did light strength training.","Do Light Strength Training Question | Did you do light strength training (such as hand-held weights of 5 lbs. or less or elastic bands) | Do Light Strength Training | Do Light Strength Training",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936079","Do General Conditioning Exercises","C157003","A question about whether an individual did general conditioning exercises, like  light calisthenics or chair exercises.","Do General Conditioning Exercises Question | Did you do general conditioning exercises, such as light calisthenics or chair exercises (do not count strength training) | Do General Conditioning Exercises | Do General Conditioning Exercises",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936076","Play Basketball, Soccer, or Racquetball","C157004","A question about whether an individual played basketball, soccer, or racquetball.","Play Basketball, Soccer, or Racquetball Question | Did you play basketball, soccer, or racquetball (do not count time on sidelines) | Play Basketball, Soccer, or Racquetball | Play Basketball, Soccer, or Racquetball",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936077","Do Other Physical Activity","C157005","A question about whether an individual did a physical activity not listed.","Do Other Physical Activity Question | Do Other Physical Activity | Do Other Physical Activity | Do other types of physical activity not previously mentioned (please specify)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL106821","Other (Physical Activity)","C157006","A physical activity not elsewhere listed or specified.","Other Physical Activity | Other physical activity, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936082","Activity Hours per Week","C157007","A question about the total number of hours that an individual spent at a particular activity.","Activity Hours per Week Question | Activity Hours per Week | Activity Hours per Week | Total hours a week did you usually do it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3844316","Less than 1 hour","C156946","An indication that something has lasted, occurred during, or totalled less than one hour.","Less than 1 hour | Less than 1 Hour",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935935","Between 1 and 2.5 Hours","C156947","An indication that something has lasted, occurred during, or totalled between 1 and 2.5 hours.","Between 1 and 2.5 Hours | 1-2 1/2 hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935933","Between 3 and 4.5 Hours","C156948","An indication that something has lasted, occurred during, or totalled between 3 and 4.5 hours.","Between 3 and 4.5 Hours | 3-4 1/2 hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935934","Between 5 and 6.5 Hours","C156949","An indication that something has lasted, occurred during, or totalled between 5 and 6.5 hours.","Between 5 and 6.5 Hours | 5-6 1/2 hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935938","Between 7 and 8.5 Hours","C156950","An indication that something has lasted, occurred during, or totalled between 7 and 8.5 hours.","Between 7 and 8.5 Hours | 7-8 1/2 hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3842635","More than 9 Hours","C156951","An indication that something has lasted, occurred during, or totalled more than 9 hours.","More than 9 Hours | 9 or more hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936071","Edmonton Frail Scale","C157011","An assessment tool designed to be used by clinicians to assess the frailty of older patients. It assesses 10 domains including cognitive impairment and balance and mobility.","Edmonton Frail Scale | EFS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936069","Cognition Clock Test","C157012","A test of the ability of an individual to accurately place the numbers and hands of a clock in their usual and specified positions.","Cognition Clock Test | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936070","Times Admitted to a Hospital","C157013","A question about the number of times an individual has or had been admitted to a hospital.","Times Admitted to a Hospital | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936074","Activities that Require Help","C157014","A question about the activities that an individual did or does require help to do.","Activities that Require Help Question | Activities that Require Help | Activities that Require Help | With how many of the following activities do you require help",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936075","When Help is Needed Can Count on Someone Willing and Able to Meet Needs","C157015","A question about whether someone who is willing and able is or was available when an individual needed help.","When Help is Needed Can Count on Someone Willing and Able to Meet Needs | When you need help, can you count on someone who is willing and able to meet your needs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936072","Use Five or More Different Prescription Medications Regularly","C157016","A question about whether an individual did or does use five or more different prescription medications regularly.","Use Five or More Different Prescription Medications Regularly | Do you use five or more different prescription medications on a regular basis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936073","Sometimes Forget to Take Prescription Medications","C157017","A question about whether an individual sometimes forgets to take their prescription medications.","Sometimes Forget to Take Prescription Medications | At Times Forget to Take Prescription Medication | At times, do you forget to take your prescription medications | Forget to Take Prescription Medications Some of the Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936063","Have Recently Lost Weight and Clothing Has Become Looser","C157018","A question about whether an individual has or had recent weight loss so that their clothing has become looser.","Have Recently Lost Weight and Clothing Has Become Looser | Have you recently lost weight such that your clothing has become looser",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936064","Often Feel Sad or Depressed","C157019","A question about whether an individual often feels or felt sad or depressed.","Often Feel Sad or Depressed | Do you often feel sad or depressed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936061","Have Urinary Incontinence","C157020","A question about whether an individual has or had urinary incontinence.","Have Urinary Incontinence | Do you have a problem with losing control of urine when you don't want to",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936062","Timed Get Up and Go Test","C157021","A test that measures the amount of time it takes a person to rise from a chair, walk to a designated point, and return to sitting.","Timed Get Up and Go Test | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086104","Decision Aid","C155961","Printed or electronic materials designed to provide evidence-based information about the harms and benefits of reasonable healthcare options to help individuals deliberate about their preferences and be meaningfully involved in treatment decisions. Patients who are informed and involved in their healthcare decisions have lower anxiety, experience less decision regret, and achieve higher quality of life.","Decision Aid | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936067","Final Score Equals Sum of Column Totals","C157022","A final test score, as summed from individual column totals.","Final Score Equals Sum of Column Totals | Final score is the sum of column totals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936068","No Spacing Errors","C157023","A response indicating that an individual made no spacing errors.","No Spacing Errors | No errors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936066","Other Errors","C157026","A response indicating that an individual made errors not listed or elsewhere specified.","Other Errors | Other errors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936037","No Hospital Admission","C157027","A response indicating that an individual had no hospital admissions.","No Hospital Admission | 0 Hospital Admission",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936038","One or Two Hospital Admissions","C157028","A response indicating that an individual had 1 or 2 hospital admissions.","One or Two Hospital Admissions | 1-2 Hospital Admissions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936035","Two or More Hospital Admissions","C157029","A response indicating that an individual had 2 or more hospital admissions.","Two or More Hospital Admissions | Greater than or Equal to 2 Hospital Admissions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936036","Excellent, Very Good, or Good Health","C157030","A response indicating that an individual was in excellent, very good, or good health.","Excellent, Very Good, or Good Health | Excellent, Very Good, Good Health",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018715","Health Fairs","C157031","A response indicating that an individual was in fair health.","Fair Health | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0683321","poor health","C157032","A response indicating that an individual was in poor health.","Poor Health | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936039","Zero or One Activity Required Help","C157033","A response indicating that an individual has or had 0 or 1 activities that required help.","Zero or One Activity Required Help | 0-1 Activities required help | None or One Activity Required Help",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936040","Two to Four Activities Required Help","C157034","A response indicating that an individual has or had 2-4 activities that required help.","Two to Four Activities Required Help | 2 to 4 Activities Required Help | 2-4 Activities required help",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936031","Five to Eight Activities Required Help","C157035","A response indicating that an individual has or had 5-8 activities that required help.","Five to Eight Activities Required Help | 5 to 8 Activities Required Help | 5-8 Activities required help",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936032","Zero to Ten Seconds Walking","C157036","A response indicating that an individual can perform a walking exercise in 0-10 seconds.","Zero to Ten Seconds Walking | 0-10 s walking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936029","Eleven to Twenty Seconds Walking","C157037","A response indicating that an individual can perform a walking exercise in 11-20 seconds.","Eleven to Twenty Seconds Walking | 11-20 s walking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936030","Greater Than Twenty Seconds Walking, or Patient Unwilling, or Requires Assistance Walking","C157038","A response indicating that an individual can perform a walking exercise in greater than 20 seconds, or patient was unwilling, or required assistance to perform a walking exercise.","Greater Than Twenty Seconds Walking, or Patient Unwilling, or Requires Assistance Walking | Greater than 20 s, or patient unwilling, or requires assistance walking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556265","Anti-GD2 Monoclonal Antibody","C155653","Any monoclonal antibody that is directed against the GD2 (GD-2) antigen.","Anti-GD2 Monoclonal Antibody | Anti-GD-2 Monoclonal Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415326","GSR Gene","C157040","This gene plays a role in glutathione metabolism.","GSR Gene | GSR | Glutathione-Disulfide Reductase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936028","Glycerol-3-Phosphate Acyltransferase 3","C157048","Glycerol-3-phosphate acyltransferase 3 (434 aa, ~49 kDa) is encoded by the human GPAT3 gene. This protein is involved in the acylation of lysophosphatidic acid to form phosphatidic acid.","Glycerol-3-Phosphate Acyltransferase 3 | 1-AGP Acyltransferase 9 | 1-AGPAT 9 | 1-Acyl-Sn-Glycerol-3-Phosphate O-Acyltransferase 10 | 1-Acyl-Sn-Glycerol-3-Phosphate O-Acyltransferase 9 | 1-Acylglycerol-3-Phosphate O-Acyltransferase 9 | AGPAT 10 | Acyl-CoA:Glycerol-3-Phosphate Acyltransferase 3 | EC 2.3.1.51 | Endoplasmic Reticulum Associated GPAT | GPAT-3 | GPAT3 | LPAAT-Theta | Lung Cancer Metastasis-Associated Protein 1 | Lysophosphatidic Acid Acyltransferase Theta | MAG-1 | MAG1 Protein | hGPAT3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936024","SRXN1 Gene","C157043","This gene plays a role in the cellular response to oxidative stress.","SRXN1 Gene | SRXN1 | Sulfiredoxin 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4017521","Hemoglobin S/O-Arab Heterozygote","C156899","A laboratory finding indicating that the subject expresses abnormal hemoglobin containing 2 variant forms of the hemoglobin subunit beta protein (HBB). One HBB protein variant has the amino acid substitution glutamic acid to valine at residue 6, which is associated with the formation of hemoglobin S (HbS), while the other variant has a glutamic acid to lysine substitution at residue 121, which is associated with the formation of hemoglobin O-Arab (HbO(Arab)). Subjects expressing this compound heterozygous HBB genotype may have severe sickling hemoglobinopathy with clinical manifestations similar to those of homozygous sickle cell anemia.","Hemoglobin S/O-Arab Heterozygote | BS/BO-Arab | HBB Heterozygous Hemoglobin S with O-Arab | Hb S/O Arab | Hb S/O(Arab) | Hb S/O-Arab | HbS/O Arab | HbS/O-Arab | HbSO Arab | HbSO-Arab | Hemoglobin Beta Heterozygous Hemoglobin S Plus O-Arab Genotype | Hemoglobin S/Hemoglobin O-Arab Double Heterozygote | Hemoglobin S/O(Arab) | Hemoglobin S/O-Arab | Hemoglobin S/O-Arab Double Heterozygote",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935997","HRAS NP_005334.1:p.G12D","C156888","A change in the amino acid residue at position 12 in the GTPase HRas protein where glycine has been replaced by aspartic acid.","HRAS NP_005334.1:p.G12D | G12D Mutated HRAS | GTPase HRas G12D | GTPase HRas Gly12Asp | H-Ras G12D | H-Ras Gly12Asp | H-Ras-1 G12D | H-Ras-1 Gly12Asp | HRAS G12D | HRAS G12D Mutation | HRAS Gly12Asp | HRAS NP_005334.1:p.Gly12Asp | HRAS p.G12D | HRAS p.Gly12Asp | Ha-Ras G12D | Ha-Ras Gly12Asp | Ha-Ras1 G12D | Ha-Ras1 Gly12Asp | Harvey Rat Sarcoma Viral Oncoprotein G12D | Harvey Rat Sarcoma Viral Oncoprotein Gly12Asp | NP_005334.1:p.G12D | NP_005334.1:p.Gly12Asp | c-H-ras G12D | c-H-ras Gly12Asp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935959","Human Papillomavirus mRNA","C156861","Any RNA molecule that is the product of transcription of a human papillomavirus gene and contains coding information that can be translated into the amino acid sequence of a protein.","Human Papillomavirus mRNA | HPV Messenger RNA | HPV Messenger Ribonucleic Acid | HPV mRNA | Human Papilloma Virus mRNA | Human Papillomavirus Messenger RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936019","Germline APC Gene Mutation","C157059","A change in the nucleotide sequence of the APC gene that originates in the gametes.","Germline APC Gene Mutation | APC Gene Germline Mutation | Adenomatous Polyposis Coli Germline Mutation | Germline APC, WNT Signaling Pathway Regulator Gene Mutation | Germline Adenomatous Polyposis Coli Mutation | Germline BTPS2 Gene Mutation | Germline FAP Gene Mutation | Germline FPC Gene Mutation | Germline PPP1R46 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4228434","Malabsorption","C113483","Inadequate absorption of nutrients in the small intestine.","Malabsorption | ",,,,,,,,,,,,,,,"194993","Intestinal malabsorption",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1421267","UBC Gene","C38433","This gene plays a role in ubiquitin-dependent proteolysis.","UBC Gene | UBC | Ubiquitin C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545831","RPLP0 Gene","C148007","This gene plays a role in the structure of the 60S ribosome subunit.","RPLP0 Gene | RPLP0 | Ribosomal Protein Lateral Stalk Subunit P0 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511880","Diagnostic Radiology Specialty","C19187","The branch of radiology concerned with the use of ionizing or nonionizing radiation for diagnostic purposes.","Diagnostic Radiology | Diagnostic Radiology (Ionizing and Nonionizing) | Radiology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826905","Laboratory Specimen Type","C83315","The type of a material sample taken from a biological entity for laboratory testing.","Laboratory Specimen Type | LAB_SPEC_TYPE | LBSPEC | biospecimen type | biospecimen_type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826812","Concomitant Medication Dose Regimen","C83222","The dose regimen of a concomitant medication.","Concomitant Medication Dose Regimen | CMDOSRGM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016529","Forced Expiratory Volume Measurement","C120933","The volume of gas an individual can forcible exhale from the lungs in one breath.","Forced Expiratory Volume | FEV",,,,,,,,,,,,,,,"4065409","Forced expired volume",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0600901","Methylprednisolone Acetate","C48003","The acetate salt of a synthetic glucocorticoid receptor agonist with immunosuppressive and antiinflammatory effects. Methylprednisolone acetate is converted into active prednisolone in the body, which activates glucocorticoid receptor mediated gene expression. This includes inducing synthesis of anti-inflammatory protein IkappaB-alpha and inhibiting synthesis of nuclear factor kappaB (NF-kappaB). As a result, proinflammatory cytokine production such as IL-1, IL-2 and IL-6 is down-regulated and cytotoxic T-lymphocyte activation is inhibited. Therefore, an overall reduction in chronic inflammation and autoimmune reactions may be achieved.","Methylprednisolone Acetate | 11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione 21-Acetate | D-Med | Depo-Medrate | Depo-Medrol | Depo-Medrone | METHYLPREDNISOLONE ACETATE | Methylprednisolone acetate | ReadySharp MethylPrednisolone 80",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3808760","Obstructive Sleep Apnea","C116337","Cessation of air flow during sleep due to upper airway obstruction.","Obstructive Sleep Apnea | Obstructive Apnea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509758","Metastatic Malignant Solid Neoplasm","C127155","A malignant solid neoplasm that has spread from its original site of growth to another anatomic site.","Metastatic Malignant Solid Neoplasm | Metastatic Malignant Solid Tumor | Metastatic Solid Neoplasm | Metastatic Solid Tumor | Metastatic Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510472","Drug Dependence","C3894","Drug dependence - replaced the term 'drug addiction' and is defined as a state, psychic and sometimes also physical, resulting from the interaction between a living organism and a drug, characterized by behavioral and other responses that always include a compulsion to take the drug on a continuous or periodic basis in order to experience its psychic effects, and sometimes to avoid the discomfort of its absence. Tolerance may or may not be present. A person may be dependent on more than one drug.","Drug Dependence | Chemical Dependence",,,,,,,,,,,,,,,"4275756","Dependent drug abuse",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1883266","Tank Dosing Unit","C62422","A dosing measurement based on a tank.","Tank Dosing Unit | TANK | Tank",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272919","Oral Dosage Form","C42744","A substance intended for administration through the mouth.","Oral Dosage Form | Oral | Oral Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936823","Acetaminophen-Cysteine Protein Adduct","C157112","A modified protein, usually glutathione, where oxidized acetaminophen is bound to the sulfhydryl group of cysteine residues. The presence of acetaminophen-cysteine or its proteolyzed product 3-para cysteinyl acetaminophen in a sample is a specific biomarker for acetaminophen exposure and increased concentrations of these adducts may be associated with acetaminophen toxicity.","Acetaminophen-Cysteine Protein Adduct | APAP-CYS | Acetaminophen Protein Adduct | Acetaminophen-Cysteine | PPA | Paracetamol Protein Adduct | Paracetamol-Cysteine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936816","TET2 Negative","C157113","An indication that TET2 expression or activity has not been detected in a sample.","TET2 Negative | Methylcytosine Dioxygenase TET2 Loss | Methylcytosine Dioxygenase TET2 Negative | TET2 Deficiency | TET2 Deficient | TET2 Loss | Tet Methylcytosine Dioxygenase 2 Loss | Tet Methylcytosine Dioxygenase 2 Negative | Tet Oncogene Family Member 2 Loss | Tet Oncogene Family Member 2 Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936817","High Sensitivity C-Reactive Protein Measurement","C157114","The determination of the amount of C-reactive protein (CRP) present in a sample through the use of immunonephelometry, immunoturbidimetry, high-sensitivity enzyme-linked immunosorbent assay (ELISA) and/or resonant acoustic profiling (RAP). This test is optimized to measure lower concentrations of CRP than a conventional CRP test.","High Sensitivity C-Reactive Protein Measurement | High Sensitivity CRP Measurement | High-Sensitivity C-Reactive Protein Measurement | High-Sensitivity CRP | hs-CRP | hsCRP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936800","deoxyaminopteroic acid","C157133","A metabolite resulting from the carboxypeptidase-mediated cleavage of methotrexate. Deoxyaminopteroic acid can be used a marker for methotrexate exposure.","Deoxyaminopteroic Acid | 2,4-Apa | 2,4-Diamino-N(10)-methylpteroic Acid | 4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzoic Acid | 4-Amino-4-deoxy-N-10-methylpteroic Acid | 4-Amino-4-deoxy-N-10-methylpteroic Acid Hydrochloride (2:1) | 4-Deoxy-4-amino-N(10)-methylpteroic Acid | DAMPA | N-10-methyl-4-deoxy-4-aminopteroate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936818","Anti-Poliovirus Antibody Positive","C157115","An indication that antibodies that recognize poliovirus have been detected in a sample.","Anti-Poliovirus Antibody Positive | Anti-Poliovirus Positive | Poliovirus Antibody Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936819","PSA Level Less than or Equal to Fifty","C157116","A blood concentration of prostate specific antigen less than or equal to 50 ng/mL.","PSA Level Less than or Equal to Fifty | PSA Level 50 or Less | PSA Level Fifty or Less | PSA Level Less than or Equal to 50",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936815","Truncated Glioma-Associated Oncogene Homolog 1 Protein","C157119","Truncated glioma-associated oncogene homolog 1 protein (1065 aa, ~114 kDa) is encoded by the human GLI1 gene. This protein is involved in transcriptional regulation, tumorigenesis, cell motility and cellular invasiveness.","Truncated Glioma-Associated Oncogene Homolog 1 Protein | TGLI1 | Truncated GLI-Kruppel Family Member GLI1 | Truncated GLI1 | Truncated GLI1 Protein | Truncated Glioma Associated Oncogene Homolog 1 Protein | Truncated Glioma-Associated Oncogene Family Zinc Finger 1 | Truncated Zinc Finger Protein GLI1 | tGLI1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936807","Phosphorylated-STAT3 Y705","C157132","A post-translationally modified form of signal transducer and activator of transcription 3 (STAT3) where the tyrosine (Y; Tyr) at residue 705 is phosphorylated. Janus kinase (JAK)-mediated phosphorylation of Y705 activates STAT3 and promotes the formation of STAT3-containing dimers, which translocate into the nucleus and induce STAT3-dependent gene expression.","Phosphorylated-STAT3 Y705 | Phospho-STAT3 Y705 | Phosphorylated STAT3 Y705 | Phosphorylated-Signal Transducer and Activator of Transcription 3 Y705 | STAT3 (Phospho-Tyr705) | STAT3 (pY705) | STAT3 Phosphorylated on Tyr705 | STAT3 pY705 | pY-STAT3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033559","Prostaglandin E","C157134","A family comprised of three naturally occurring prostaglandins that are involved in the regulation of many biological functions including vasodilation, inflammation and smooth muscle cell contractility.","Prostaglandin E | PGE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936909","Non-synonymous PKLR Gene Mutation","C157142","A point mutation in the PKLR gene that encodes an amino acid substitution in the pyruvate kinase PKLR protein.","Non-synonymous PKLR Gene Mutation | Non-synonymous PK1 Gene Mutation | Non-synonymous PKL Gene Mutation | Non-synonymous PKR Gene Mutation | Non-synonymous PKRL Gene Mutation | Non-synonymous Pyruvate Kinase L/R Gene Mutation | Non-synonymous Pyruvate Kinase, Liver and RBC Gene Mutation | Non-synonymous RPK Gene Mutation | PKLR Missense Gene Mutation | PKLR Missense Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900116","Actual Arm Name","C117448","The name of the arm in which the subject actually participated.","Actual Arm Name | ACTARM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417663","NEDD8 Gene","C95847","This gene plays a role in protein post-translational modification.","NEDD8 Gene | NEDD8 | Neural Precursor Cell Expressed, Developmentally Down-Regulated 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935679","Clinical Proteomic Tumor Analysis Consortium","C157175","A national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics.","Clinical Proteomic Tumor Analysis Consortium | CPTAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879931","CDISC SDTM Country Terminology","C66786","Terminology codelist used with Country within the Clinical Data Interchange Standards Consortium Standard for the Exchange of Non-clinical Data.","CDISC SEND Country Terminology | COUNTRY | Country | SEND-COUNTRY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826834","Demographics Data Collection Day","C83244","The actual study day that demographics data was collected.","Demographics Data Collection Day | DMDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897054","Subject Death Flag","C117451","An indication of whether the subject has died.","Subject Death Flag | DTHFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826689","Investigator Identifier","C83078","A sequence of characters used to identify, name, or characterize the study investigator.","Investigator Identifier | INVID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826892","Investigator Name","C83302","The literal identifier of an investigator.","Investigator Name | INVNAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879940","CDISC SDTM Relation to Reference Period Terminology","C66728","Terminology codelist used with Relation to Reference Period within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.","CDISC SDTM Relation to Reference Period Terminology | Relation to Reference Period | SDTM-STENRF | STENRF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936941","Reimbursement","C157173","A payback for out-of-pocket expenses.","Reimbursement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936942","Busy","C157174","Actively or fully engaged or occupied.","Busy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1546805","Generic - RelationalOperator","C151960","General; lacking specificity.","Generic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981459","Drug Accountability Result Standard Unit","C87875","The standard unit of measure for drug accountability results.","Drug Accountability Result Standard Unit | DASTRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826860","Electrocardiogram Standard Unit","C83270","The standard unit of measure for electrocardiogram results.","Electrocardiogram Standard Unit | EGSTRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827371","Findings About Events or Interventions Result Standard Unit","C113370","The standard unit of measure for findings about events or interventions results.","Findings About Events or Interventions Result Standard Unit | FASTRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812801","Immunogenicity Specimen Assessments Domain","C112320","A findings about domain for submitting dermal responses to antigens.","Immunogenicity Specimen Assessments Domain | IS | Immunogenicity Specimen Assessments",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898795","Immunogenicity Specimen Assessments Original Result Unit","C117560","The unit of measure for the result of the immunogenicity specimen assessment as originally received or collected.","Immunogenicity Specimen Assessments Original Result Unit | ISORRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898791","Immunogenicity Specimen Assessments Result Standard Unit","C117563","The standard unit of measure for the immunogenicity specimen assessment results.","Immunogenicity Specimen Assessments Result Standard Unit | ISSTRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826911","Laboratory Test Result Standard Unit","C83321","The standard unit of measure for laboratory test results.","Laboratory Test Result Standard Unit | LBSTRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981492","Microbiology Specimen Examination Original Result Unit","C87908","The unit of measure first specified in the microbiology specimen examination.","Microbiology Specimen Examination Original Result Unit | MBORRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981500","Microbiology Specimen Result Standard Unit","C87916","The standard unit of measure for microbiology specimen results.","Microbiology Specimen Result Standard Unit | MBSTRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898362","Microscopic Findings Result Standard Unit","C117586","The standard unit of measure for microscopic findings results.","Microscopic Findings Result Standard Unit | MISTRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538743","Morphology Findings Domain","C102671","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to morphology findings.","Morphology Findings Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898242","Morphology Original Result Unit","C117612","The unit of measure for the result of the morphology test or finding as originally received or collected.","Morphology Original Result Unit | MOORRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897075","Morphology Result Standard Unit","C117615","The standard unit of measure for morphology results.","Morphology Result Standard Unit | MOSTRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936009","Steel Milling and Casting","C156864","An occupation involving the processing or shaping of steel either by pouring liquid metal into molds or by shaping it on a rotating cutter.","Steel Milling and Casting | Foundry or Steel Milling | Steel Miller | Steel Milling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936012","Flour, Feed, or Grain Milling","C156867","An occupation involving the grinding of raw agricultural materials into products for farming or industrial applications.","Flour, Feed, or Grain Milling | Feed or Grain Miller | Feed or Grain Milling | Flour, Feed or Grain Milling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981520","Microbiology Susceptibility Original Result Unit","C87936","The unit of measure first specified in the microbiology susceptibility assessment.","Microbiology Susceptibility Original Result Unit | MSORRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981524","Microbiology Susceptibility Result Standard Unit","C87940","The standard unit of measure for microbiology susceptibility results.","Microbiology Susceptibility Result Standard Unit | MSSTRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981553","Pharmacokinetic Concentration Standard Result Unit","C87970","The standard unit of measure for pharmacokinetic concentration results.","Pharmacokinetic Concentration Standard Result Unit | PCSTRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826943","Physical Examination Original Result Unit","C83353","The unit of measure for an original physical examination result.","Physical Examination Original Result Unit | PEORRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826965","Questionnaire Original Result Unit","C83376","The unit of measure for a original questionnaire result.","Questionnaire Original Result Unit | QSORRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826973","Questionnaire Result Standard Unit","C83384","The standard unit of measure for questionnaire results.","Questionnaire Result Standard Unit | QSSTRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897704","Reproductive System Findings Result Standard Unit","C117648","The standard unit of measure for reproductive system findings results.","Reproductive System Findings Result Standard Unit | RPSTRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826989","Subject Characteristics Original Result Unit","C83400","The unit of measure for an original subject characteristics result.","Subject Characteristics Original Result Unit | SCORRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826997","Subject Characteristics Result Standard Unit","C83408","The standard unit of measure for subject characteristics results.","Subject Characteristics Result Standard Unit | SCSTRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897580","Skin Response Result Standard Unit","C117683","The standard unit of measure for skin response results.","Skin Response Result Standard Unit | SRSTRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814152","Tumor Results Domain","C106578","A findings domain that represents quantitative measurements and/or qualitative assessments of the tumors identified in the TU domain.","Tumor Results Domain | TR | Tumor/Lesion Results",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897272","Tumor Results Original Result Unit","C117417","The unit of measure for the result of the tumor results assessment as originally received or collected.","Tumor Results Original Result Unit | TRORRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042684","Vinyl Chloride","C936","A chlorinated hydrocarbon occurring as a colorless, highly flammable gas with a mild, sweet odor that may emit toxic fumes of carbon dioxide, carbon monoxide, hydrogen chloride and phosgene when heated to decomposition. Vinyl chloride is primarily used to make polyvinyl chloride to manufacture plastics. Exposure to this substance affects the central and peripheral nervous system and causes liver damage. Prolonged exposure to vinyl chloride can cause a set of symptoms that is characterized by Raynaud's phenomenon, joint and muscle pain and scleroderma-like skin changes. Vinyl chloride is a known human carcinogen and is associated with an increased risk of developing liver cancer, predominantly angiosarcoma of the liver, but is also linked to brain and lung cancer as well as cancer of the lymphatic and hematopoietic system. (NCI05)","Vinyl Chloride | Chloroethene | Choroethylene | VINYL CHLORIDE | vinyl chloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897266","Tumor Results Standard Unit","C117425","The standard unit of measure for the tumor results.","Tumor Results Standard Unit | TRSTRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897076","Morphology Directionality","C117622","A qualifier for the direction on the body the morphology assessment is performed.","Morphology Directionality | MODIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811255","Tumor Identifier Domain","C106577","A domain that represents the data that uniquely identifies tumors.","Tumor Identifier Domain | TU | Tumor/Lesion Identification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897298","Tumor Identifier Directionality","C117429","A qualifier for the direction on the body the tumor identification is performed.","Tumor Identifier Directionality | TUDIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890732","CDISC SDTM Death Diagnosis Test Code Terminology","C116108","Terminology associated with the death detail test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Death Diagnosis Test Code Terminology | DTHDXCD | SDTM Death Diagnosis and Details Test Code | SDTM-DTHDXCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0303131","Beryllium Compound","C45558","An inorganic substance that contains the metallic element beryllium with excellent thermal and electrical conductivity and is corrosion resistant. Beryllium compounds are used in the electronics, automotive, aerospace, defense and nuclear industries. Inhalation exposure to beryllium compounds can cause pneumonitis, and prolonged exposure can result in berylliosis, characterized by occurrence of granulomatous fibrosis in the lungs. Beryllium compounds are known human carcinogens and are associated with an increased risk of developing lung cancer. (NCI05)","Beryllium Compound | Beryllium | Beryllium compound",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009133","Coal Mining","C156865","An occupation involving the extraction of coal or coal ores from the ground.","Coal Mining | Coal Miner | Coal mining",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347272","CDISC SDTM ECG Test Terminology by Code","C71153","Terminology codelist used with ECG Tests within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.","CDISC SDTM ECG Test Code Terminology | ECG Test Code | EGTESTCD | SDTM-EGTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003948","Asbestos Exposure","C55816","Inhalation of asbestos fibers.","Asbestos Exposure | Asbestos | asbestos exposure | asbestos_exposure",,,,,,,,,,,,,,,"44783302","Exposure to asbestos",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0238760","Benzene Exposure","C36251","Environmental, occupational or consumer-based exposure to benzene, benzene-containing compounds or benzene derivatives.","Benzene Exposure | Benzene | Benzene and/or derivatives | Benzene derivatives",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034538","Ionizing Radiation","C17052","High-energy radiation capable of producing ionization in substances through which it passes.","Ionizing Radiation | Radiation Energy | Radiation, Ionizing | Radiation-Ionizing Total | ionizing radiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205643","Cribriform Carcinoma","C3680","A carcinoma characterized by the presence of a cribriform architectural pattern. Representative examples include the intraductal cribriform breast carcinoma and invasive cribriform breast carcinoma.","Cribriform Carcinoma | Cribriform carcinoma, NOS","8201/3","Cribriform carcinoma, NOS",,,,,,,,,,,,,"4147041","Cribriform carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1518013","Infiltrating Breast Syringomatous Adenoma","C40362","A low grade metaplastic carcinoma of the breast with morphologic features similar to the adenosquamous carcinoma of the skin.  In the majority of cases the prognosis is excellent.","Low Grade Breast Adenosquamous Carcinoma | Infiltrating Breast Syringomatous Adenoma | Low Grade Adenosquamous Breast Carcinoma | Low Grade Adenosquamous Breast Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388377","Anti-GD2 Monoclonal Antibody hu14.18K322A","C80042","A monoclonal antibody directed against human glycosphingolipid GD2 with potential antineoplastic activity. Upon binding to the GD2 antigen, anti-GD2 monoclonal antibody hu14.18K322A triggers a host immune response against GD2-expressing tumor cells, which may result in tumor cell death. GD2, an O-acetylated disialoganglioside with expression in normal tissues restricted primarily to the cerebellum and peripheral nerves, is commonly expressed at high levels on tumors of neuroectodermal origins such as melanomas and neuroblastomas.","Anti-GD2 Monoclonal Antibody hu14.18K322A | hu14.18K322A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512900","GD2 Antibody","C129921","Any immunoglobulin that recognizes ganglioside GD2.","GD2 Antibody | Anti-GD2 Antibody | Anti-Ganglioside GD2 Antibody | Ganglioside GD2 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936843","Welding Exposure","C157234","Environmental, occupational, or consumer-based exposure to vaporized materials or dusts created during the welding process.","Welding Exposure | Welding dust and fumes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936850","Problems Paying Medical Bills","C157226","A question about whether an individual has or had problems paying any medical bills.","Problems Paying Medical Bills Question | Did you have problems paying or were unable to pay any medical bills | Problems Paying Medical Bills | Problems Paying Medical Bills",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936844","Unable to Pay Medical Bills","C157227","A question about whether an individual, or anyone in individual's family, currently has medical bills they are unable to pay at all.","Unable to Pay Medical Bills Question | Do you or anyone in your family currently have medical bills that you are unable to pay at all | Unable to Pay Medical Bills | Unable to Pay Medical Bills",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936845","Paying Medical Bills Over Time","C157228","A question about whether an individual, or anyone in individual's family, currently has medical bills that are being paid off over time.","Paying Medical Bills Over Time | Do you or anyone in your family currently have medical bills that are being paid off over time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936846","Referral Made Based on This Score","C157229","A question about whether a referral was made based on this score.","Referral Made Based on This Score | Was a referral made based on this score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936847","Referral Made Based on Final Score","C157230","A question about whether a referral was made based on the final score.","Referral Made Based on Final Score | Was a referral made based on the final score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936888","HBC","C157235","A rare variant of invasive lobular breast carcinoma characterized by the presence of histiocyte-like malignant cells with pale cytoplasm forming sheets or linear patterns. Apocrine differentiation may be present. It usually has an aggressive clinical course.","Breast Histiocytoid Carcinoma | HBC | Histiocytoid Breast Carcinoma | Histiocytoid Breast Carcinoma | Histiocytoid Lobular Breast Carcinoma | Infiltrating Histiocytoid Breast Carcinoma | Infiltrating Histiocytoid Lobular Breast Carcinoma | Invasive Histiocytoid Breast Carcinoma | Invasive Histiocytoid Lobular Breast Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388335","Refractory Multiple Myeloma","C7024","Multiple myeloma that is resistant to treatment.","Refractory Multiple Myeloma | Refractory Multiple Myeloma | Refractory Multiple Myeloma/Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Refractory Plasma Cell Myeloma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002792","Anaphylaxis","C107101","An acute hypersensitive immune response that occurs from exposure to an allergen. It results from the release of histamine and histamine-like substances from mast cells, and can present with breathing difficulty due to narrowed airways, dizziness and hypotension, skin rash, weak pulse, nausea and vomiting.","Anaphylaxis | ",,,,,,,,,,,,,,,"441202","Anaphylaxis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3553780","Abnormal Liver Function Test","C122516","Atypical results found on serum liver enzyme testing, which may indicate significant disease and/or disease progression.","Abnormal Liver Function Test | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898249","Morphology Evaluator","C117628","A person who determines the significance of a morphology assessment.","Morphology Evaluator | MOEVAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054137","Questionnaire Evaluator","C121940","A person who determines the significance of a questionnaire assessment.","Questionnaire Evaluator | QSEVAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813325","Disease Response Domain","C107097","A domain for disease response evaluations.","Disease Response Domain | Disease Response and Clin Classification | RS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899363","Disease Response Evaluator","C117391","A person who determines the significance of a disease response assessment.","Disease Response Evaluator | RSEVAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891295","Subject Status Domain","C117655","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to subject status.","Subject Status Domain | SS | Subject Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897440","Subject Status Evaluator","C117667","A person who determines the significance of a subject status assessment.","Subject Status Evaluator | SSEVAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897278","Tumor Results Evaluator","C117409","A person who determines the significance of a tumor results assessment.","Tumor Results Evaluator | TREVAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897296","Tumor Identifier Evaluator","C117432","A person who determines the significance of a tumor identification assessment.","Tumor Identifier Evaluator | TUEVAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897847","Procedure Dose Form","C117521","The form in which active and/or inert ingredient(s) of the procedure are physically presented.","Procedure Dose Form | PRDOSFRM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898246","Morphology Laterality","C117621","A qualifier for the side of the body the morphology assessment is performed.","Morphology Laterality | MOLAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897294","Tumor Identifier Laterality","C117435","A qualifier for the side of the body the tumor identification assessment is performed.","Tumor Identifier Laterality | TULAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539092","CDISC SDTM Laboratory Test Standard Character Result Terminology","C102580","Terminology associated with the laboratory test standard character result codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Laboratory Test Standard Character Result Terminology | LBSTRESC | Laboratory Test Standard Character Result | SDTM-LBSTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826909","Laboratory Test Character Result Standard Unit","C83319","The standard character or string for representation and reporting of laboratory test data.","Laboratory Test Character Result in Standard Unit | LBSTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556890","Inhibitor","C154898","A class of substances that binds to and inhibits the function or activity of a target.","Inhibitor | INHIBITOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935818","Basal Cell Carcinoma","C156767","A carcinoma involving the basal cells.","Basal Cell Carcinoma | Malignant Basal Cell Neoplasm","8090/3","Basal cell carcinoma, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C1880805","Fluid/Blood Leak","C63137","Escape (Release, Discharge) of fluid (including blood or bodily fluid) through an unintended location; often accompanied by a loss of pressure and/or output. This includes both external and internal fluid leak. This does not include fluidized powder leak.","Fluid/Blood Leak | Fluid Leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0146226","Ketorolac Tromethamine","C61798","The tromethamine salt of ketorolac, a synthetic pyrrolizine carboxylic acid derivative with anti-inflammatory, analgesic and antipyretic properties. Ketorolac tromethamine, a non-selective inhibitor of the cyclooxygenases (COX), inhibits both COX-1 and COX-2 enzymes. This agent exerts its anti-inflammatory effect by preventing conversion of arachidonic acid to prostaglandins at inflammation site mediated through inhibition of COX-2, which is undetectable in most tissues but is up-regulated at the inflammation sites. Since COX-1 is expressed virtually in all tissues, inhibition of COX-1 enzyme by this agent prevents normal state production of prostaglandins, which plays housekeeping roles in the protection of the gastrointestinal tract, regulating renal blood flow, and functioning in platelet aggregation. As a result, inhibition of COX-1 is usually associated with adverse effects such as gastrointestinal toxicity and nephrotoxicity.","Ketorolac Tromethamine | KETOROLAC TROMETHAMINE | Toradol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704683","Screw","C50161","A fastener device with a tapered threaded shaft and a head designed to engage a drive device.","Screw Device | Screw",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0451212","Hearing Handicap Inventory for the Elderly","C157291","A self-assessment tool designed to assess the effects of hearing impairment on the emotional and social adjustment of elderly people. The inventory is comprised of two subscales: a 13-item subscale that explores the emotional consequences of hearing impairment, and a 12-item subscale that explores both social and situational effects.","Hearing Handicap Inventory for the Elderly | HHIE | Hearing Handicap Inventory for the Elderly (HHIE)",,,,,,,,,,,,,,,"4169148","Hearing handicap inventory for the elderly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937009","Use Phone Less Often than Would Like Due to Hearing Problem","C157292","A question about whether hearing problems cause an individual to use the phone less often than they would like.","Use Phone Less Often than Would Like Due to Hearing Problem | Does a hearing problem cause you to use the phone less often than you would like",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937003","Avoid Groups of People Due to Hearing Problem","C157294","A question about whether hearing problems cause an individual to avoid groups of people.","Avoid Groups of People Due to Hearing Problem | Does a hearing problem cause you to avoid groups of people",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937004","Irritable Due to Hearing Problem","C157295","A question about whether a hearing problem makes an individual irritable.","Irritable Due to Hearing Problem | Does a hearing problem make you irritable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937005","Difficulty Attending Party Due to Hearing Problem","C157297","A question about whether a hearing problem causes an individual difficulty when attending a party.","Difficulty Attending Party Due to Hearing Problem | Does a hearing problem cause you difficulty when attending a party",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937006","Feel Stupid or Dumb Due to Hearing Problem","C157298","A question about whether a hearing problem causes an individual to feel stupid or dumb.","Feel Stupid or Dumb Due to Hearing Problem | Does a hearing problem cause you to feel 'stupid' or 'dumb'",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937049","Nervous Due to Hearing Problem","C157313","A question about whether having a hearing problem causes an individual to be nervous.","Nervous Due to Hearing Problem | Does a hearing problem cause you to be nervous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937050","Visit People Less Often than Like Due to Hearing Problem","C157314","A question about whether having a hearing problem causes an individual to visit friends, relatives, or neighbors less often than they would like.","Visit People Less Often than Like Due to Hearing Problem | Does a hearing problem cause you to visit friends, relatives, or neighbors less often than you would like",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937051","Go Shopping Less Often than Like Due to Hearing Problem","C157315","A question about whether having a hearing problem causes an individual to go shopping less often than they would like.","Go Shopping Less Often than Like Due to Hearing Problem | Does a hearing problem cause you to go shopping less often than you would like",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937052","Upset by Problem or Difficulty with Hearing","C157316","A question about whether any problem or difficulty with an individual's hearing upsets them at all.","Upset by Problem or Difficulty with Hearing | Does any problem or difficulty with your hearing upset you at all",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937045","Want to be Alone Due to Hearing Problem","C157317","A question about whether a hearing problem causes an individual to want to be by themself.","Want to be Alone Due to Hearing Problem | Does a hearing problem cause you to want to be by yourself",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937046","Talk to Family Members Less Often than Like Due to Hearing Problem","C157318","A question about whether having a hearing problem causes an individual to talk to family members less often than they would like.","Talk to Family Members Less Often than Like Due to Hearing Problem | Does a hearing problem cause you to talk to family members less often than you would like",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937047","Feel Depressed Due to Hearing Problem","C157319","A question about whether having a hearing problem causes an individual to feel depressed.","Feel Depressed Due to Hearing Problem | Does a hearing problem cause you to feel depressed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937041","Listen to TV or Radio Less Often than Like Due to Hearing Problem","C157321","A question about whether having a hearing problem causes an individual to listen to TV or radio less often than they would like.","Listen to TV or Radio Less Often than Like Due to Hearing Problem | Does a hearing problem cause you to listen to TV or radio less often than you would like",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937042","Feel Uncomfortable when Talking with Friends Due to Hearing Problem","C157322","A question about whether having a hearing problem causes an individual to feel uncomfortable when talking to friends.","Feel Uncomfortable when Talking with Friends Due to Hearing Problem | Does a hearing problem cause you to feel uncomfortable when talking to friends",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937044","Feel Left Out When with a Group of Friends Due to Hearing Problem","C157325","A question about whether having a hearing problem causes an individual to feel left out when they are with a group of people.","Feel Left Out When with a Group of Friends Due to Hearing Problem | Does a hearing problem cause you to feel left out when you are with a group of people",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937037","Difficulty Hearing or Understanding Co-workers, Clients, or Customers Due to Hearing Problem","C157326","A question about whether an individual has or had difficulty hearing or understanding co-workers, clients or customers.","Difficulty Hearing or Understanding Co-workers, Clients, or Customers Due to Hearing Problem | Do you have difficulty hearing / understanding co-workers, clients or customers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937038","Difficulty in Movies or Theater Due to Hearing Problem","C157327","A question about whether a hearing problem causes an individual difficulty in the movies or in the theater.","Difficulty in Movies or Theater Due to Hearing Problem | Does a hearing problem cause you difficulty in the movies or in the theater",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446606","PI3K inhibitor GDC-0084","C116877","A phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. paxalisib specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in the inhibition of both cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","Paxalisib | GDC-0084 | GDC0084 | PAXALISIB | PI3K Inhibitor GDC-0084 | PI3K Inhibitor GDC-0084",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896774","Entrectinib","C114984","An orally bioavailable inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon administration, entrectinib binds to and inhibits TrkA, TrkB, TrkC, ROS1 and ALK. Inhibition of these kinases may result in a disruption of TrkA-, TrkB-, TrkC-, ROS1-, and ALK-mediated signaling. This leads to an induction of apoptosis and an inhibition of tumor cell proliferation in tumor cells that express these kinases. TrkA, TrkB, TrkC, ROS1 and ALK are overexpressed in a variety of cancer cell types.","Entrectinib | ENTRECTINIB | N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide | RXDX 101 | RXDX-101 | RXDX101 | Rozlytrek",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518666","Other Prior Therapy","C16172","No Value Exists","Other Prior Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898808","Image-Guided Local Therapy","C118619","The use of imaging techniques to target treatment to a specific anatomic location or region.","Image-Guided Local Therapy | Image Directed Local Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333181","Cyclin-Dependent Kinase Gene","C25839","Cyclin-Dependent Kinase Genes encode Cyclin-Dependent Kinases, eukaryotic phosphoregulated protein kinases that physically associate with cyclins to achieve full enzymatic activity and control cell cycle progression. (NCI)","Cyclin-Dependent Kinase Gene | CDK Encoding Gene | CDK Gene | Cyclin Dependent Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640806","Selinexor","C102546","An orally available, small molecule inhibitor of CRM1 (chromosome region maintenance 1 protein, exportin 1 or XPO1), with potential antineoplastic activity. Selinexor modifies the essential CRM1-cargo binding residue cysteine-528, thereby irreversibly inactivates CRM1-mediated nuclear export of cargo proteins such as tumor suppressor proteins (TSPs), including p53, p21, BRCA1/2, pRB, FOXO, and other growth regulatory proteins. As a result, this agent, via the approach of selective inhibition of nuclear export (SINE), restores endogenous tumor suppressing processes to selectively eliminate tumor cells while sparing normal cells. CRM1, the major export factor for proteins from the nucleus to the cytoplasm, is overexpressed in a variety of cancer cell types.","Selinexor | 2-Propenoic Acid, 3-(3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-, 2-(2-Pyrazinyl)hydrazide, (2Z)- | ATG-010 | CRM1 Nuclear Export Inhibitor KPT-330 | KPT 330 | KPT-330 | KPT330 | Nexpovio | SELINEXOR | SINE KPT-330 | Selective Inhibitor of Nuclear Export KPT-330 | Xpovio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983777","Isatuximab","C90578","A humanized IgG1 monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Isatuximab specifically binds to CD38 on CD38-positive tumor cells. This may trigger antitumoral antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and apoptosis eventually leading to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.","Isatuximab | Hu 38SB19 | ISATUXIMAB | Immunoglobulin G1, Anti-(Human CD38 Antigen) (Human-mus musculus Monoclonal HU38SB19 Heavy Chain), Disulfide with Human-mus musculus Monoclonal HU38SB19 Light Chain, Dimer | Isatuximab-irfc | SAR 650984 | SAR-650984 | SAR650984 | Sarclisa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983699","Risk Factor Assessment","C90498","A systematic gathering of information regarding the variables associated with an individual's increased risk of disease or infection.","Risk Factor Assessment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936968","Monoclonal Gammopathy of Renal Significance","C157343","A condition caused by a B-cell or plasma cell clone resulting in the deposition of the secreted monoclonal immunoglobulin, without evidence for overt lymphoma or myeloma. This category includes a wide spectrum of renal pathology and include such lesions as immunoglobulin-associated amyloidosis, the monoclonal immunoglobulin deposition diseases (MIDDs; light chain deposition disease, heavy chain deposition disease, and light and heavy chain deposition disease), proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID), C3 glomerulopathy with monoclonal gammopathy, light chain proximal tubulopathy (Fanconi syndrome), and several others.","Monoclonal Gammopathy of Renal Significance | MGRS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935629","Thrice","C156502","Three times.","Thrice | THRICE | Three Times",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935640","No Longer Clinically Benefiting","C156551","An indication that a treatment or therapy was changed or discontinued because it is no longer clinically beneficial to the subject or patient, based on the primary therapeutic objective for which it is being administered and assessed. (Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Scher HI, Morris MJ, Stadler WM, et al.; Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016 Apr 20;34(12):1402-18.)","No Longer Clinically Benefiting | NLCB | NO LONGER CLINICALLY BENEFITING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935680","Small for Gestational Age Indicator","C156662","An indication as to whether the fetus or infant is small for the gestational age.","Small for Gestational Age Indicator | SMGAIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555700","Income Level","C154890","An indication of the position on a scale measuring compensation or monetary support.","Income Level | INCMLVL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555687","Ulcer Indicator","C154881","An indication as to whether an ulcer is present.","Ulcer Indicator | ULCERIND | ulceration indicator | ulceration_indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509775","Tenderness Indicator","C127775","An indicator as to whether the subject has symptoms of tenderness.","Tenderness Indicator | TNDRIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555689","Skene's Gland Abnormality Indicator","C154879","An indication as to whether the Skene's gland is abnormal.","Skene's Gland Abnormality Indicator | SKGLAIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555688","Rash Indicator","C154878","An indication as to whether rash is present.","Rash Indicator | RASHIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555692","Pustule Indicator","C154882","An indication as to whether a pustule is present.","Pustule Indicator | PUSTIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555693","Peeling Indicator","C154883","An indication as to whether there is the presence of peeling.","Peeling Indicator | PEELIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555697","Motion Tenderness Indicator","C154887","An indication as to whether there are symptoms of motion tenderness.","Motion Tenderness Indicator | MTENDIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0425941","Menstrual Cycle Regularity","C156587","A description of how an individual's menstrual cycle conforms to a consistent temporal pattern.","Menstrual Cycle Regularity | MENREG",,,,,,,,,,,,,,,"4095939","Finding of regularity of menstrual cycle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL935751","Menses Flow Rate Description","C156585","A subjective description of the menstrual flow rate during a menstrual cycle.","Menses Flow Rate Description | MENFRD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555696","Mass Indicator","C154886","An indication as to whether a mass is present.","Mass Indicator | MASSIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935743","Live Birth Indicator","C156589","An indication as to whether the subject has delivered live-born offspring.","Live Birth Indicator | BRTLVIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935750","Induced Abortion Indicator","C156588","An indication as to whether the female subject has had an induced abortion procedure.","Induced Abortion Indicator | INABOIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0426012","Fundal Height","C154876","A measurement of the distance between the pubic symphysis and the top of the palpable uterus.","Fundal Height | FUNDHT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555683","Erythema Indicator","C154877","An indication as to whether erythema is present.","Erythema Indicator | ERYTHIND | Redness Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555691","Edema Indicator","C154885","An indication as to whether edema is present.","Edema Indicator | EDEMAIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555690","Ecchymosis Indicator","C154884","An indication as to whether ecchymosis is present.","Ecchymosis Indicator | ECCHYIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555694","Discharge Indicator","C154888","An indication as to whether there is the presence of discharge.","Discharge Indicator | DSCHGIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555686","Bartholin's Gland Abnormality Indicator","C154880","An indication as to whether the Bartholin's gland is abnormal.","Bartholin's Gland Abnormality Indicator | BTHGLIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555695","Abnormal Bleeding Indicator","C154889","An indication as to whether there is the presence of abnormal bleeding.","Abnormal Bleeding Indicator | BLEEDIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1630403","Neck Circumference","C154891","A circumferential measurement of the neck, just below the larynx.","Neck Circumference | NECKCIR",,,,,,,,,,,,,,,"4171375","Neck circumference",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0424683","Chest Circumference","C156606","A circumferential measurement of the chest.","Chest Circumference | CHESTCIR",,,,,,,,,,,,,,,"4087500","Chest circumference",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL935960","Fractionated Stereotactic Radiation Therapy","C156862","Stereotactic radiation therapy that uses multiple doses of radiation spread over several treatment session.","Fractionated Stereotactic Radiation Therapy | Fractionated Stereotactic Radiotherapy",,,,,,,,,,,,,,,"37158181","Fractionated dose stereotactic radiation therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL935747","Southern African Coloured","C156583","A person of mixed race, whose ancestry is from one or more of the naturalized racial groups of Southern Africa (typically Western European, South Asian, or Southeastern Asian) and one or more of the indigenous Southern African peoples.","Southern African Coloured | SOUTHERN AFRICAN COLOURED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555684","Khoisan","C154874","A name used for the non-Bantu indigenous peoples of Southern Africa.","Khoisan | KHOISAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337948","Aboriginal Australian","C154875","The native people of Australia.","Aboriginal Australian | ABORIGINAL AUSTRALIAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935744","Intramandibular Route of Administration","C156590","Administration within the mandible.","Intramandibular Route of Administration | INTRAMANDIBULAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555665","Peritoneal Dialysis Fluid","C154852","The dialysis fluid which is collected from the peritoneal space and captures, for discard or analysis, the excess water and waste from the blood stream through diffusion and ultrafiltration. (NCI)","Peritoneal Dialysis Fluid | DIALYSIS FLUID, PERITONEAL | PD Fluid | Peritoneal Dialysate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935741","Bone Marrow Mononuclear Cell","C156591","Any cell with a single nucleus found in the bone marrow, for example lymphocytes, monocytes, mesenchymal stem cells and hematopoietic progenitor cells.","Bone Marrow Mononuclear Cell | BMMC | BONE MARROW MONONUCLEAR CELL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519736","CDISC SDTM Microscopic Findings Test Code Terminology","C132263","Terminology associated with the SDTM microscopic findings test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Microscopic Findings Test Code Terminology | MITSCD | SDTM Microscopic Findings Test Code | SDTM-MITSCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555535","EGFR Variant Protein Measurement","C154806","The determination of the amount of EGFR variant protein present in a sample.","EGFR Variant Protein Measurement | EGFR Variant Protein | EGFRVP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935648","CD68 Expressing Cell Count","C156544","The determination of the amount of the CD68 expressing cells in a sample.","CD68 Expressing Cell Count | CD68 | CD68 Expressing Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935653","Blood Vessel Density","C156545","An evaluation of the degree of blood vessel density present in a sample.","Blood Vessel Density | BLDVESD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935654","Beta-defensin 1 Measurement","C156546","The determination of the amount of beta-defensin 1 in a biological specimen.","Beta-defensin 1 Measurement | BD1 | Beta-defensin 1 | DEFB1 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555530","ALK Protein Measurement","C154805","The determination of the amount of ALK protein present in a sample.","ALK Protein Measurement | ALK | ALK Protein | ALK Tyrosine Kinase Receptor Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555527","Transitional Cell to Tumor Cell Ratio Measurement","C154800","The determination of the ratio of transitional cells compared to tumor cells present in a sample. The measurement may be expressed as a ratio or percentage.","Transitional Cell to Tumor Cell Ratio Measurement | TRCETMCE | Transitional Cells/Tumor Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555528","Tumor Cell Count","C154801","The determination of the amount of tumor cells present in a sample.","Tumor Cell Count | NEOCE | Neoplastic Cells | TMCE | Tumor Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555529","ROS1 Protein Measurement","C154804","The determination of the amount of ROS1 protein present in a sample.","ROS1 Protein Measurement | Proto-Oncogene Tyrosine-Protein Kinase ROS Measurement | ROS Proto-oncogene 1 Protein | ROS1 | ROS1 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935652","Positive Cell Count","C156548","A measurement of the number of cells that stain positively in a sample.","Positive Cell Count | POSITIVE CELL COUNT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555536","Programmed Death Ligand 1 Measurement","C154807","The determination of the amount of PD-L1 protein present in a sample.","Programmed Death Ligand 1 Measurement | CD274 | CD274 Measurement | PD-L1 | PD-L1 Measurement | PDL1 | Programmed Cell Death 1 Ligand 1 | Programmed Death Ligand 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555532","Myelofibrosis Assessment","C154803","An evaluation of myelofibrosis in a sample.","Myelofibrosis Assessment | MYFIBROS | Myelofibrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555531","Histologic Type of Cancer","C154802","The determination of the histologic type of cancer in a sample.","Histologic Type of Cancer | HISTTYPC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935651","Intact Epithelial Reticular Basement Membrane Length to Total Epithelial Reticular Basement Membrane Length Ratio Measurement","C156547","The determination of the ratio of intact epithelial reticular basement membrane length compared to total epithelial reticular basement membrane length present in a sample. The measurement may be expressed as a ratio or percentage.","Intact Epithelial Reticular Basement Membrane Length to Total Epithelial Reticular Basement Membrane Length Ratio Measurement | ERLIERLT | Epi RBM Lngth, Intact/Epi RBM Lngth, Tot | Epithelial RBM Length, Intact/Epithelial RBM Length, Total",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556383","Microsiemens","C154859","A unit of electrical conductance, admittance, and susceptance equal to one millionth of a Siemens (10E-6 Siemens).","Microsiemens | micromho | micromhos | uS | uSiemens | umho",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555673","Micrometer per Second","C154858","A unit of both speed (scalar) and velocity (vector), defined as the distance of one micrometer travelled per unit time equal to one second.","Micrometer per Second | Micrometers per Second | micron/sec | um/s | um/sec",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551084","Poise","C154857","A unit of dynamic viscosity equal to one pascal-second.","Poise | P",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439164","Unit of Optical Density","C73681","An indication of the type of unit of measure being used to express an optical density of a substance.","Unit of Optical Density | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1636666","Nanogram per Day","C85741","Nanograms per day.","Nanogram per Day | Nanogram per 24 Hours | ng/d | ng/day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555670","Milliliter per 100 Grams per Minute","C154855","A unit of flow rate expressed as the number of milliliters per 100g of material per minute.","Milliliter per 100 Grams per Minute | mL/10*2.g/min | mL/100g/min | ml/10*2.g/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563181","Milligram Equivalent","C156468","A unit of relative amount of substance concentration equal to one thousandth of a gram of an equivalent weight.","Milligram Equivalent | mg.eq | mgEq",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555669","Hertz Per Second","C154854","A unit of frequency rate change defined as the number of Hertz per unit of time equal to one second.","Hertz Per Second | Hz/s | Hz/sec",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563187","Enzyme Unit per Meter Squared","C156467","A unit of concentration (catalytic activity) equal to one enzyme unit of substance per one square meter of surface area.","Enzyme Unit per Meter Squared | Enzyme U/m2 | Enzyme Unit per Square Meter | {Enzyme}.U/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555668","Enzyme Unit per Gram Hemoglobin","C154856","A unit of concentration (biologic activity) equal to one enzyme unit of substance per gram of hemoglobin.","Enzyme Unit per Gram Hemoglobin | Enzyme U/g Hb | Enzyme Unit per Gram of Hemoglobin | {Enzyme}.U/g{HGB}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439514","Centipoise","C69092","A CGS unit of dynamic viscosity equal to 10E-3 pascal second.","Centipoise | CPS | Millipascal Second | cP | cPo | centipoise | mPa.s | s*mPa | s.mPa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827717","CDISC SDTM Microbiology Susceptibility Testing Result Category Terminology","C85495","Terminology associated with the microorganism result category codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Microbiology Susceptibility Testing Result Category Terminology | MSRESCAT | Microbiology Susceptibility Testing Result Category | SDTM-MSRESCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827754","Antimicrobial Dose Dependent Susceptibility Result","C85559","A microbial susceptibility test result in which the growth of microorganisms may be inhibited when higher than normal dosages of an antimicrobial agent are used and maximal possible blood concentration of the antimicrobial agent is achieved.","Antimicrobial Dose Dependent Susceptibility Result | SUSCEPTIBLE-DOSE DEPENDENT | Susceptible-Dose Dependent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827758","Antimicrobial Susceptibility Result","C85563","A microbial susceptibility test result in which the growth of microorganisms is inhibited by the usually achievable concentrations of antimicrobial agent when the recommended dosage is used for the site of infection.","Antimicrobial Susceptibility Result | SUSCEPTIBLE | Susceptible",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827757","Antimicrobial Resistance Result","C85562","A microbial susceptibility test result in which the growth of microorganisms is not inhibited by the usually achievable concentrations of antimicrobial agent with normal dosage, or microorganisms demonstrate minimum inhibitory concentrations (MIC) or zone diameters that fall in the range where specific microbial resistance mechanisms are likely in effect, or clinical efficacy of the agent against the microorganism has not been reliably shown in treatment studies.","Antimicrobial Resistance Result | RESISTANT | Resistant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827756","Antimicrobial Nonsusceptibility Result","C85561","A microbial susceptibility test result in which the growth of microorganisms is not inhibited by the usually achievable concentrations of antimicrobial agent when the recommended dosage is used for the site of infection. This category may be applied to new antimicrobial agents for which no resistant microorganisms have been encountered at the time the initial interpretive criteria are determined. Microorganisms that test with an MIC above or a zone measurement below the susceptible interpretive criteria may be designated as nonsusceptible. A designation of nonsusceptible does not necessarily mean that a resistance mechanism(s) exists in the microorganism.","Antimicrobial Nonsusceptibility Result | NONSUSCEPTIBLE | Non Susceptible",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827755","Antimicrobial Intermediate Susceptibility Result","C85560","A microbial susceptibility test result in which the growth of microorganisms may be inhibited by the usually achievable concentrations of antimicrobial agent when the recommended dosage is used for the site of infection. The response rates may be lower than for susceptible isolates.","Antimicrobial Intermediate Susceptibility Result | INTERMEDIATE | Intermediate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029375","Oscillometry","C154788","A technique to measure a motion that repeats itself in a regular cycle around an equilibrium point or mean value.","Oscillometry | OSCILLOMETRY",,,,,,,,,,,,,,,"4135361","Vascular oscillometry",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555525","Westergren Tube Method","C154796","A method that measures the sedimentation rate of an entity in an aqueous solution using a Westergren tube.","Westergren Tube Method | WESTERGREN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3472245","Single Photon Tomography and Computed Tomography Scan","C154791","A dual-modality imaging technique that merges data from single-photon emission computed tomography (SPECT) and computed tomography (CT) to provide structural and functional information.","Single Photon Tomography and Computed Tomography Scan | SPECT/CT | SPECT/CT SCAN",,,,,,,,,,,,,,,"42872447","Single photon emission computed tomography with computed tomography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242851","Spectrometry, Mass, Secondary Ion","C154790","An analytical technique in which a mass spectrometer is used to detect sputtered ionized atoms (secondary ions) that are ejected from a solid surface after application of a beam of high energy primary ions.","Secondary Ion Mass Spectrometry | SECONDARY ION MASS SPECTROMETRY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202910","Pulmonary Angiography","C154789","An x-ray imaging technique that involves visualization of the pulmonary vasculature after fluoroscopy-guided catheter placement and injection of an iodinated contrast medium into the pulmonary circulation.","Pulmonary Angiography | PULMONARY ANGIOGRAPHY",,,,,,,,,,,,,,,"4224157","Angiography of pulmonary arteries",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555524","Palm Method","C154793","A method for estimating body surface area, in which the individual's palm, excluding fingers and wrist, accounts for about 0.5% of the total body surface area of that individual. The entire palmar surface (including fingers) accounts for about 1% of the individuals total body surface area.","Palm Method | PALM METHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1441639","Manual Count","C154795","A technique to determine the number of entities, which is performed by visual inspection.","Manual Count | MANUAL COUNT",,,,,,,,,,,,,,,"45773531","Manual count",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555523","Knemometry","C154787","A technique which measures lower limb length using a knemometer, for the assessment of short-term growth and development in childhood.","Knemometry | KNEMOMETRY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555526","Impedance Conductivity","C154797","A method that measures impedance of conductivity which corrects for the concentrations of conducting ions in the sample.","Impedance Conductivity | IMPEDANCE CONDUCTIVITY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3178849","Immunochromatography","C154792","A type of chromatography assay in which an antibody-conjugate is passed over an immobilized antigen, giving a visual indication of positive or negative result.","Immunochromatography | ICA | IMMUNOCHROMATOGRAPHY | Immunochromatography Assay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555522","Fluorescence Lifetime Imaging Microscopy","C154786","An imaging technique that produces spatially resolved images based on the differences in the excited state decay rates of fluorescent compounds in a sample.","Fluorescence Lifetime Imaging Microscopy | FLUORESCENT LIFETIME IMAGING MICROSCOPY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1553167","Flocculation","C154798","A process in which microscopic particles in suspension aggregate to form loosely clumped masses that are often macroscopically observable.","Flocculation Assay | FLOCCULATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555520","Enzymatic Spectrophotometry","C154785","A spectrophotometry technique that measures the changes in the intensity of the light absorbed or scattered in response to an enzymatic reaction.","Enzymatic Spectrophotometry | ENZYMATIC SPECTROPHOTOMETRY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919612","Electroneurography","C154784","A nerve conduction study technique where a brief electrical stimulation is delivered under the skin, and the resulting electrical activity is recorded to assess the conductivity of peripheral nerve impulses.","Electroneurography | ELECTRONEUROGRAPHY",,,,,,,,,,,,,,,"4198105","Nerve conduction study",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555521","Contrast Enhanced X-ray","C154783","An x-ray technique that incorporates the administration of an iodinated contrast agent to enhance lesions that are not visible on standard x-rays.","Contrast Enhanced X-ray | CONTRAST ENHANCED X-RAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1293958","Congo Red Staining Method","C154782","A microscopy staining method that utilizes the Congo Red stain, a benzidine derivative dye that has applications in staining biological structures, such as amyloid, as well as a pH indicator.","Congo Red Staining Method | CONGO RED STAIN",,,,,,,,,,,,,,,"4036047","Congo red stain method",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1551400","Complement Fixation Assay","C154799","An in vitro immunoassay that measures the binding of complement to antigen-antibody complexes in serum, leading to the depletion of free complement and the reduction of hemolytic activity.","Complement Fixation Assay | COMPLEMENT FIXATION",,,,,,,,,,,,,,,"45769470","Complement fixation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1441489","Automated Count","C154794","A technique to determine the number of entities, that employs a machine or device to automatically detect cells as they pass through the instrument's light path.","Automated Count | AUTOMATED COUNT",,,,,,,,,,,,,,,"45765667","Automated count",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027452","Insurance, National Health","C157357","A system of health insurance benefits designed to cover a national population against the costs of health care. It may be administered by the public sector, the private sector, or a combination of both.","National Health Insurance | NHI | SHI | Statutory Health Insurance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085558","Insurance, Medigap","C157358","Various private health insurance plans designed to supplement the coverage of Medicare to help pay out-of-pocket costs.","Medigap | Medigap Insurance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4042889","Children's Health Insurance Program","C157359","A state-run insurance program that provides low-cost health coverage to children in families that earn too much money to qualify for Medicaid but not enough to buy private insurance.","Children's Health Insurance Program | CHIP | Childrens Health Insurance Program",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936955","State-sponsored Health Plan","C157360","Health insurance programs that are run and funded at the state level.","State-sponsored Health Plan | State-sponsored Health Insurance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936951","CHAMPUS","C157361","A federal health care program for uniformed service members, retirees, and their families around the world. The government administers Tricare by contracting with private entities","Tricare | CHAMPUS | Civilian Health and Medical Program of the Uniformed Services | Private Insurance TRICARE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936952","Civilian Health and Medical Program of the Department of Veterans Affairs","C157362","A comprehensive health care program, administered by the Department of Veterans Affairs, designed to provide health care services for military veterans.","Civilian Health and Medical Program of the Department of Veterans Affairs | CHAMPVA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936953","Veterans Health Administration","C157363","The largest integrated health care system in the United States, providing health care services to over 9 million veterans enrolled in the VA health care program. The VHA manages 1,250 health care facilities, including 172 VA Medical Centers and 1,069 outpatient sites and clinics.","Veterans Health Administration | Public Health Insurance VA care | VHA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021682","Health Insurance","C157356","A type of insurance designed to cover some of or all the cost of treating an insured person's illnesses or injuries. In some cases, it pays for preventive care, such as annual physicals and diagnostic tests.","Health Insurance | Health Benefit Plan | Health Insurance Coverage | Insurance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0586872","Geriatric Physician","C157373","A medical doctor who specializes in the diagnosis, treatment, and prevention of disease and disability in older adults.","Geriatric Physician | Geriatric Medicine Doctor | Geriatric Medicine Specialist | Geriatric Specialist | Geriatrician",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936997","Primary Care Nurse Navigator","C157375","A nurse with special training to guide individuals to primary care services, or to services in the primary care system.","Primary Care Nurse Navigator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936996","Did Patient Follow Through with Referral","C157374","A question about whether an individual followed through with a referral.","Did Patient Follow Through with Referral | (If yes), did the patient follow through with the referral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273025","CDISC SDTM Tumor Response Assessment Test Name Terminology","C96781","Terminology associated with the tumor response assessment test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Tumor Response Assessment Test Name Terminology | ONCRTS | Oncology Response Assessment Test Name | SDTM-RSTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520256","Tumor Marker Response","C132458","An evaluation of the tumor marker response of the disease to the therapy.","Tumor Marker Response | TMRESP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086879","Symptomatic Deterioration","C124434","A global deterioration of health status providing evidence of disease progression not covered by disease response criteria (eg. RECIST).","Symptomatic Deterioration | SYMPTDTR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522850","Steroid Use Status","C135483","An assessment of steroid usage as a condition of disease response to therapy.","Steroid Use Status | STRUSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522849","Disease Response in Spleen","C135482","An assessment of the disease response to therapy within the involved spleen.","Disease Response in Spleen | SPLNRESP | Spleen Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521143","Soft Tissue Response","C132457","An evaluation of the soft tissue response of the disease to the therapy.","Soft Tissue Response | SFTSRESP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054230","Pathologic Response","C123626","An evaluation of the pathologic response of the disease to the therapy.","Pathologic Response | PATHRESP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986559","Response in Non-Target Lesion","C94535","A qualitative or quantitative measurement of the response of a non-target lesion(s) to the therapy.","Response in Non-Target Lesion | NTRGRESP | Non-Target Lesions | Non-Target Response | Non-target Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522848","Non-Target Non-Enhancing Lesion Response","C135481","An assessment of the response to the therapy of the non-target non-enhancing lesion.","Non-Target Non-Enhancing Lesion Response | NTNERESP | Non-Target Non-Enhancing Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522847","Non-Target Enhancing Lesion Response","C135480","An assessment of the response to the therapy of the non-target enhancing lesion.","Non-Target Enhancing Lesion Response | NTERESP | Non-Target Enhancing Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540345","New Lesion Worsening Indicator","C142363","An indication as to whether a previously identified new lesion(s) is showing signs of worsening.","New Lesion Worsening Indicator | NEWLWIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641258","New Lesion Progression","C103420","An assessment of the equivocality of disease progression based on a newly identified lesion.","New Lesion Progression | NEWLPROG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540346","New Lesion Indicator","C142362","An indication as to whether a lesion is newly identified, in comparison to a previous timepoint.","New Lesion Indicator | NEWLIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054465","Morphologic Response","C123625","An evaluation of the morphologic response of the disease to the therapy.","Morphologic Response | MRPHRESP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522846","Disease Response in Liver","C135479","An assessment of the disease response to therapy within the involved liver.","Disease Response in Liver | LIVRRESP | Liver Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055131","Disease Recurrence Indicator","C123621","An indication as to whether disease recurrence occurred.","Disease Recurrence Indicator | DRCRIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522845","Clinical Performance Status","C135478","An assessment of the clinical performance, as measured by a rating or scale, as a condition of disease response to therapy.","Clinical Performance Status | CPRFSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519695","Bone Response","C132455","An assessment of the bone response of a disease to a therapy.","Bone Response | BONERESP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522844","Bone Marrow Disease Involvement Indicator","C135477","An indication as to whether disease is present in the bone marrow.","Bone Marrow Disease Involvement Indicator | BMIVLIND | Bone Marrow Involvement Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935638","Anatomic Response","C156564","An assessment of the anatomic response (based on changes in size of anatomic structures) of the disease to the therapy.","Anatomic Response | ANATRESP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034051","Alveolus","C12986","Any of the terminal sacs in the lungs through which gas exchange takes place with the pulmonary capillary blood.","Alveolus | ALVEOLUS | Alveoli | Bronchial Alveolus | Pulmonary Alveolus | alveoli",,,,,,,,,,,,,,,"4011863","Pulmonary alveolar structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1318464","Occupational Therapy","C121351","Interventions and exercises intended to develop, recover, or maintain the ability of an individual to accomplish their activities of daily living.","Occupational Therapy | OT",,,,,,,,,,,,,,,"4309371","Occupational therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL935632","Tibiotarsal Joint","C156506","The joint connecting the lower part of the tibia with the upper part of the tarsus bones, specifically articulating with the talus bone.","Tibiotarsal Joint | TIBIOTARSAL JOINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273026","CDISC SDTM Tumor Response Assessment Test Code Terminology","C96782","Terminology associated with the tumor response assessment test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Tumor Response Assessment Test Code Terminology | ONCRTSCD | Oncology Response Assessment Test Code | SDTM-RSTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226504","Venous Sinus","C12877","A large vein or channel for the circulation of venous blood, such as one of the sinuses of the dura mater.","Venous Sinus | VENOUS SINUS",,,,,,,,,,,,,,,"4197650","Structure of venous sinus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0559502","Triceps Brachii","C90604","The muscle of the upper arm that extends the forearm.","Triceps Brachii | MUSCLE, TRICEPS BRACHII | TRICEPS BRACHII MUSCLE",,,,,,,,,,,,,,,"4222118","Triceps brachii muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0230444","Shin","C154780","The front part of the leg from below the knee to the ankle.","Shin | SHIN",,,,,,,,,,,,,,,"4300070","Shin structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3499125","Sensorimotor Cortex","C154777","The region of the brain that consists of the precentral and postcentral gyri and is involved in somatosensory and motor functions.","Sensorimotor Cortex | SENSORIMOTOR CORTEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226841","Deep Femoral Vein","C154776","A vein located in the upper thigh that connects, through tributaries, to the popliteal and inferior gluteal veins, and joins the superficial femoral vein at the groin to form the common femoral vein.","Deep Femoral Vein | PROFUNDA FEMORIS VEIN",,,,,,,,,,,,,,,"4052085","Structure of profunda femoris vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555603","Presacral Lymph Node","C154775","A lymph node that is located in the mesorectum, between the rectum and the sacrum.","Presacral Lymph Node | PRESACRAL LYMPH NODE | Presacral lymph node group (body structure)",,,,,,,,,,,,,,,"37152528","Presacral lymph node group",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162783","Prefrontal Cortex","C154779","The grey matter on the medial, lateral, and orbital surfaces of the anterior part of the frontal cortex, which play a role in complex cognitive control, emotion, and social behavior.","Prefrontal Cortex | PREFRONTAL CORTEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226832","Posterior Tibial Vein","C33386","A vein in the foot that is formed by the union of the external and internal plantar veins and which becomes the popliteal vein.","Posterior Tibial Vein | POSTERIOR TIBIAL VEIN",,,,,,,,,,,,,,,"4174393","Structure of posterior tibial vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1378605","Posterior Cingulate Cortex","C154778","The caudal region of the cingulate cortex, located within the medial part of the inferior parietal lobule, that is thought to function as an interface between emotion and cognition.","Posterior Cingulate Cortex | POSTERIOR CINGULATE CORTEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032652","Popliteal Vein","C33339","A vein originating from the anterior and posterior tibial veins that ascends the popliteal space to drain blood from the calf, knee joint, and thigh. The popliteal vein ultimately becomes the femoral vein.","Popliteal Vein | POPLITEAL VEIN",,,,,,,,,,,,,,,"4211384","Structure of popliteal vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0229837","Perirectal Lymph Node","C154774","A lymph node that is located in the connective tissue adjacent to the rectum.","Perirectal Lymph Node | PERIRECTAL LYMPH NODE",,,,,,,,,,,,,,,"4074029|4075862","Structure of pararectal lymph node|Pararectal lymph node group",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0229274","Palpebral Conjunctiva","C12901","The part of the conjunctiva, a thin transparent mucous membrane, that covers the posterior surface of the eyelids.","Palpebral Conjunctiva | CONJUNCTIVA, PALPEBRAL | PALPEBRAL CONJUNCTIVA",,,,,,,,,,,,,,,"4048703","Structure of palpebral conjunctiva",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224122","Orbicularis Oculi Muscle","C52886","A ring-like band of skeletal muscle on the palpebrae, temple, cheeks, and surrounding the orbit, which originates on the frontal bone, medial palpebral ligament, and lacrimal bone with insertion on the lateral palpebral raphe, that functions to close the eyelid.","Orbicularis Oculi Muscle | ORBICULARIS OCULI MUSCLE",,,,,,,,,,,,,,,"4209000","Orbicularis oculi muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025473","Mesenteric Vein","C53055","One of two veins (inferior or superior) that returns deoxygenated blood from the intestines.","Mesenteric Vein | MESENTERIC VEIN | VEIN, MESENTERIC",,,,,,,,,,,,,,,"4029960","Structure of mesenteric vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555519","L5-S1 Intervertebral Space","C154781","The space between the L5 and S1 vertebrae.","L5-S1 Intervertebral Space | L5-S1 INTERVERTEBRAL SPACE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224417","Iliopsoas Muscle","C32764","A combination of two muscles found in the thigh, the iliacus and the psoas major, which have different sites of origin but a common insertion on the lesser trochanter of the femur.","Iliopsoas Muscle | ILIOPSOAS MUSCLE",,,,,,,,,,,,,,,"4287107","Structure of iliopsoas muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0392907","Long Saphenous Vein","C33004","A long superficial vein originating from the dorsal vein at the big toe and the dorsal venous arch of the foot and extending up the inner leg to empty into the femoral artery in the groin area.","Long Saphenous Vein | GREAT SAPHENOUS VEIN | Great Saphenous Vein",,,,,,,,,,,,,,,"4245620","Great saphenous vein structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555602","Gastric Curvature Lymph Node","C154773","A lymph node that is located between the two layers of the greater omentum, either superiorly along the cardiac half of the lesser curvature of the stomach or inferiorly along the pyloric half of the greater curvature of the stomach.","Gastric Curvature Lymph Node | GASTRIC CURVATURE LYMPH NODE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226836","Fibular Vein","C154772","A vein that arises from the plantar veins of the foot, accompanies the peroneal artery, and travels up the back of the leg to join the anterior and posterior tibial veins in forming the popliteal vein on the posterior surface of the knee.","Fibular Vein | FIBULAR VEIN",,,,,,,,,,,,,,,"4216082","Structure of peroneal vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028863","Extraocular Muscle","C33199","A group of extrinsic muscles that are responsible for moving the eye and lifting the eyelid. These include: superior rectus, inferior rectus, medial rectus, inferior oblique, and levator palpebrae superioris, all innervated by CN III (oculomotor nerve), superior oblique, innervated by CN IV (trochlear nerve), lateral rectus, innervated by CN VI (abducens nerve).","Extraocular Muscle | EOM | EXTRAOCULAR MUSCLE | MUSCLE, EXTRAOCULAR | Oculomotor Muscle | Oculomotor Muscle",,,,,,,,,,,,,,,"4285885","Structure of extraocular muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010040","Corneal Stroma","C12699","The thickest layer of corneal tissue, composed of collagen fibrils, that is located between the epithelium and the inner endothelium, and extends from behind Bowman's layer to in front of Descement's membrane.","Corneal Stroma | CORNEAL STROMA",,,,,,,,,,,,,,,"4198544","Structure of substantia propria of cornea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0459875","Corneal Epithelium","C12928","Stratified squamous cell tissue that covers the outer surface of the cornea.","Corneal Epithelium | CORNEAL EPITHELIUM",,,,,,,,,,,,,,,"4048705","Structure of corneal epithelium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014259","Corneal Endothelium","C12707","A single layer of specialized, flat, mitochondria-rich cells that line the posterior surface of the cornea, which govern fluid and solute transport across the posterior surface of the cornea.","Corneal Endothelium | CORNEAL ENDOTHELIUM",,,,,,,,,,,,,,,"4278372","Structure of corneal endothelium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1275667","Common Femoral Vein","C154771","A vein that accompanies the common femoral artery and is formed by the confluence of the femoral vein and the deep femoral vein.","Common Femoral Vein | COMMON FEMORAL VEIN",,,,,,,,,,,,,,,"4288094","Common femoral vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555472","Calf Muscular Vein","C154703","Any of the superficial veins located within the muscles of the posterior lower leg, including the gastrocnemial and soleal veins.","Calf Muscular Vein | CALF MUSCULAR VEIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229275","Bulbar Conjunctiva","C12902","The part of the conjunctiva, a thin transparent mucous membrane, that is loosely attached the orbital septum and covers the anterior surface of the sclera.","Bulbar Conjunctiva | BULBAR CONJUNCTIVA | CONJUNCTIVA, BULBAR | Ocular Conjunctiva",,,,,,,,,,,,,,,"4082574","Structure of bulbar conjunctiva",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0229719","Buccal Lymph Node","C154770","A lymph node that is located superficial to the buccinator muscle.","Buccal Lymph Node | BUCCAL LYMPH NODE | Buccinator Lymph Node",,,,,,,,,,,,,,,"4172149","Structure of facial lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0226833","Anterior Tibial Vein","C32115","The vein that runs parallel to the anterior tibial artery and empties into the popliteal vein.","Anterior Tibial Vein | ANTERIOR TIBIAL VEIN",,,,,,,,,,,,,,,"4097545","Structure of anterior tibial vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0304292","Caplet dose form","C97197","A solid dosage form in which a tablet has been compacted into capsule shape.","Caplet Dosage Form | CAPLET | Caplet | Caplet Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540218","Immediate Release Capsule Dosage Form","C142247","A capsule dosage form that is designed to release its active and/or inert ingredient(s) upon administration with no enhanced, delayed or extended release effect.","Immediate Release Capsule Dosage Form | CAPSULE, IMMEDIATE RELEASE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522392","Chewable Gel Dosage Form","C134876","A formed or molded oral gel dosage form that maintains its shape, is elastic, and yields to mastication.","Chewable Gel Dosage Form | Chewable Gel | GEL, CHEWABLE | Gummie | Gummy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540217","Immediate Release Tablet Dosage Form","C142248","A tablet dosage form that is designed to release its active and/or inert ingredient(s) upon administration with no enhanced, delayed or extended release effect.","Immediate Release Tablet Dosage Form | TABLET, IMMEDIATE RELEASE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827715","CDISC SDTM Pharmacokinetic Parameter Long Name Terminology","C85493","Terminology associated with the pharmacokinetic parameter test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Pharmacokinetic Parameter Long Name Terminology | PK Parameters | PKPARM | SDTM-PKPARM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555559","Absolute Bioavailability","C154838","The fraction of the treatment dose that reaches the systemic circulation; this is the ratio of the amount of drug in the system after administration of a test formulation divided by the drug in the system after IV administration.","Absolute Bioavailability | FABS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556364","Atherogenic Index of Plasma","C154726","The determination of the base 10 logarithm of the ratio of molar concentration of plasma triglyceride to high density lipoprotein cholesterol present in a sample","Atherogenic Index of Plasma | AIP | ATHPIDX | Atherogenic Index",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936111","Aspartate Aminotransferase to Platelet Ratio Index","C156512","A calculation that indicates the likely presence of liver cirrhosis and fibrosis, measured as the relative measurement of aspartate aminotransferase (AST) to AST upper limit of normal, divided by the platelet count, and multiplied by 100.","Aspartate Aminotransferase to Platelet Ratio Index | APRI | APRI Score | AST to Platelet Ratio Index",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555598","Argininosuccinic Acid Measurement","C154763","The determination of the amount of argininosuccinic acid present in a sample.","Argininosuccinic Acid Measurement | ARGSAC | Argininosuccinate | Argininosuccinic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555600","Anti-Double Stranded DNA IgG Measurement","C154769","The determination of the amount of anti-double stranded DNA IgG antibodies present in a sample.","Anti-Double Stranded DNA IgG Measurement | Anti-Double Stranded DNA IgG | DDNAIGAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201874","Amino Acid Measurement","C81183","The measurement of the amount of amino acids in a biologic specimen.","Amino Acid Measurement | AA | AA Measurement | AMNOACID | Amino Acid Content | Amino Acids | Measurement of Amino Acid",,,,,,,,,,,,,,,"40479591","Measurement of amino acid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555596","Alpha-Aminobutyric Acid Measurement","C154759","The determination of the amount of alpha-aminobutyric acid present in a sample.","Alpha-Aminobutyric Acid Measurement | AAMBTAC | Alpha-Aminobutyric Acid | Alpha-aminobutyrate | Homoalanine | Homoalanine Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555595","Alpha-Aminoadipic Acid Measurement","C154761","The determination of the amount of alpha-aminoadipic acid present in a sample.","Alpha-Aminoadipic Acid Measurement | AAMAPAC | Alpha-Aminoadipate | Alpha-Aminoadipic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2732892","Alloisoleucine Measurement","C154762","The determination of the amount of alloisoleucine present in a sample.","Alloisoleucine Measurement | ALLOILE | Alloisoleucine",,,,,,,,,,,,,,,"40481937","Measurement of alloisoleucine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555581","Aldrin Epoxidase Measurement","C154743","The determination of the amount of aldrin epoxidase present in a sample.","Aldrin Epoxidase Measurement | ALDEPX | Aldrin Epoxidase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555577","Albumin Index","C154734","A relative measurement (ratio) of the albumin in cerebrospinal fluid to albumin in serum in a sample.","Albumin Index | ALBIDX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935655","Acylglycine Measurement","C156534","The determination of the amount of acylglycine present in a sample.","Acylglycine Measurement | ACYGLYCN | Acylglycine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523446","Acylcarnitine Measurement","C156535","The determination of the amount of acylcarnitine present in a sample.","Acylcarnitine Measurement | ACYCRNTN | Acylcarnitine",,,,,,,,,,,,,,,"4014886","Acylcarnitine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555573","4-Hydroxymidazolam Measurement","C154731","The determination of the amount of 4-hydroxymidazolam present in a sample.","4-Hydroxymidazolam Measurement | 4-Hydroxymidazolam | HYDMDZ4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935625","4-Beta-Hydroxycholesterol Measurement","C156514","The determination of the amount of 4-beta-hydroxycholesterol present in a sample.","4-Beta-Hydroxycholesterol Measurement | 4-Beta-Hydroxy Cholesterol Measurement | 4-Beta-Hydroxycholesterol | 4-Beta-OHC Measurement | CHOLOH4B | Cholest-5-ene-3beta,4beta-diol Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935611","25-Hydroxyvitamin D3 Measurement","C156529","The determination of the amount of 25-hydroxyvitamin D3 present in a sample.","25-Hydroxyvitamin D3 Measurement | 25-Hydroxycholcalciferol | 25-Hydroxycholecalciferol | 25-Hydroxyvitamin D | 25-Hydroxyvitamin D3 | Calcidiol | Calcifediol | Inactive Vitamin D | V25HD3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3164018","25-Hydroxyvitamin D2 Measurement","C156528","The determination of the amount of 25-hydroxyvitamin D2 present in a sample.","25-Hydroxyvitamin D2 Measurement | 25-Hydroxycalciferol | 25-Hydroxyergocalciferol | 25-Hydroxyvitamin D2 | Ercalcidiol | V25HD2",,,,,,,,,,,,,,,"40486051","Measurement of 25-hydroxyergocalciferol",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL935621","24,25-Dihydroxycholecalciferol","C156511","The determination of the amount of 24,25-dihydroxyvitamin D present in a sample.","24,25-Dihydroxyvitamin D3 Measurement | 24,25-Dihydroxycholecalciferol | 24,25-Dihydroxyvitamin D | 24,25-Dihydroxyvitamin D Measurement | 24,25-Dihydroxyvitamin D3 | VTD32425",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555574","1-Hydroxymidazolam Measurement","C154732","The determination of the amount of 1-hydroxymidazolam present in a sample.","1-Hydroxymidazolam Measurement | 1'-Hydroxymidazolam | 1-Hydroxymidazolam | Alpha-Hydroxymidazolam | HYDMDZ1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640721","Accumulation Ratio Cmax","C102357","The maximum concentration at steady state divided by the maximum concentration during the initial dosing interval.","Accumulation Ratio Cmax | ARCMAX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640720","Accumulation Ratio Area Under the Curve","C102356","The area under the curve (AUCTAU) at steady state divided by the area under the curve over the initial dosing interval.","Accumulation Ratio Area Under the Curve | ARAUC | Accumulation Ratio AUCTAU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055507","Accumulation Ratio Area Under the Curve from T1 to T2","C122329","The area under the curve from T1 to T2 at steady state divided by the area under the curve from T1 to T2 during the initial dosing interval.","Accumulation Ratio Area Under the Curve from T1 to T2 | ARAUCINT | Accumulation Ratio AUC from T1 to T2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831743","Accumulation Index using Lambda z","C114234","The predicted accumulation ratio for area under the curve (AUC) calculated using the Lambda z estimated from single dose data.","Accumulation Index using Lambda z | AILAMZ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520355","Accumulation Ratio Ctrough Normalized by Dose","C132439","The trough concentration at steady state divided by the trough concentration during the initial dosing interval, each divided by the associated dose. (CDISC)","Accumulation Ratio Ctrough Normalized by Dose | ARCTROUD | Accum Ratio Ctrough norm by dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520354","Accumulation Ratio Cmin Normalized by Dose","C132438","The minimum concentration at steady state divided by the minimum concentration during the initial dosing interval, each divided by the associated dose. (CDISC)","Accumulation Ratio Cmin Normalized by Dose | ARCMIND | Accum Ratio Cmin norm by dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520353","Accumulation Ratio Cmax Normalized by Dose","C132437","The maximum concentration at steady state divided by the maximum concentration during the initial dosing interval, each divided by the associated dose. (CDISC)","Accumulation Ratio Cmax Normalized by Dose | ARCMAXD | Accum Ratio Cmax norm by dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520351","Accumulation Ratio AUC Over Dosing Interval Normalized by Dose","C132435","The area under the curve (AUCtau) at steady state divided by the area under the curve (AUCtau) over the initial dosing interval, each divided by the associated dose.","Accumulation Ratio AUC Over Dosing Interval Normalized by Dose | ARAUCD | Accum Ratio AUCTAU norm by dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526629","Accumulation Ratio AUC to Last Nonzero Concentration","C139129","The area under the curve (AUC) from the time of dosing to the last measurable concentration divided by the area under the curve from the time of dosing to the last measurable concentration during the initial dosing interval.","Accumulation Ratio AUC to Last Nonzero Concentration | ARAUCLST | Accum Ratio AUC to Last Nonzero Conc",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520352","Accumulation Ratio AUC T1 to T2 Normalized by Dose","C132436","The area under the curve from T1 to T2 at steady state divided by the area under the curve from T1 to T2 during the initial dosing interval, each divided by the associated dose. (CDISC)","Accumulation Ratio AUC T1 to T2 Normalized by Dose | ARAUCIND | Accum Ratio AUC T1 to T2 norm by dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812320","Amount Recovered Infinity Predicted","C112033","The cumulative amount recovered extrapolated to infinity, calculated using the predicted value of the last non-zero concentration.","Amount Recovered Infinity Predicted | Amt Rec Infinity Pred | RCAMIFP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831546","Amount Recovered Infinity Observed Normalized by Weight","C112225","The cumulative amount recovered extrapolated to infinity, calculated using the observed value of the last non-zero concentration, divided by the weight.","Amount Recovered Infinity Observed Normalized by Weight | Amt Rec Infinity Obs Norm by WT | RCAMIFOW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812319","Amount Recovered Infinity Observed Normalized by Surface Area","C112224","The cumulative amount recovered extrapolated to infinity, calculated using the observed value of the last non-zero concentration, divided by the surface area.","Amount Recovered Infinity Observed Normalized by Surface Area | Amt Rec Infinity Obs Norm by SA | RCAMIFOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831547","Amount Recovered Infinity Observed Normalized by Body Mass Index","C112223","The cumulative amount recovered extrapolated to infinity, calculated using the observed value of the last non-zero concentration, divided by the body mass index.","Amount Recovered Infinity Observed Normalized by Body Mass Index | Amt Rec Infinity Obs Norm by BMI | RCAMIFOB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812318","Amount Recovered Infinity Observed","C112032","The cumulative amount recovered extrapolated to infinity, calculated using the observed value of the last non-zero concentration.","Amount Recovered Infinity Observed | Amt Rec Infinity Obs | RCAMIFO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640726","Amount Recovered from T1 to T2 Normalized by Weight","C102362","The cumulative amount recovered from the specimen type specified in PPSPEC over the interval from T1 to T2 divided by weight.","Amount Recovered from T1 to T2 Normalized by Weight | Amt Rec from T1 to T2 Norm by WT | RCAMINTW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640725","Amount Recovered from T1 to T2 Normalized by Surface Area","C102361","The cumulative amount recovered from the specimen type specified in PPSPEC over the interval from T1 to T2 divided by surface area.","Amount Recovered from T1 to T2 Normalized by Surface Area | Amt Rec from T1 to T2 Norm by SA | RCAMINTS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640724","Amount Recovered from T1 to T2 Normalized by Body Mass Index","C102360","The cumulative amount recovered from the specimen type specified in PPSPEC over the interval from T1 to T2 divided by body mass index.","Amount Recovered from T1 to T2 Normalized by Body Mass Index | Amt Rec from T1 to T2 Norm by BMI | RCAMINTB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640723","Amount Recovered from T1 to T2","C102359","The cumulative amount recovered from the specimen type over the interval from T1 to T2.","Amount Recovered from T1 to T2 | Amt Rec from T1 to T2 | RCAMINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640783","Accumulation Ratio Ctrough","C102426","The trough concentration at steady state divided by the trough concentration during the initial dosing interval.","Accumulation Ratio Ctrough | ARCTROUG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640722","Accumulation Ratio Cmin","C102358","The minimum concentration at steady state divided by the minimum concentration during the initial dosing interval.","Accumulation Ratio Cmin | ARCMIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935624","HDL Phospholipid Measurement","C156513","The determination of the amount of high-density lipoprotein phospholipid present in a sample.","HDL Phospholipid Measurement | HDL Phospholipid | HDL-PL | HDLPL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555599","Inactive Glucagon-Like Peptide-1 Measurement","C154768","The determination of the amount of inactive glucagon-like peptide-1 present in a sample.","Inactive Glucagon-Like Peptide-1 Measurement | GLP1IAC | Glucagon-Like Peptide-1, Inactive Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555601","Gamma-Aminobutyric Acid Measurement","C154766","The determination of the amount of gamma-aminobutyric acid present in a sample.","Gamma-Aminobutyric Acid Measurement | GABA | GAMBTAC | Gamma-Aminobutyric Acid | Gamma-aminobutyrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512797","FIO2","C38082","The molar fraction of oxygen in an inhaled gas.","Fraction of Inspired Oxygen | FIO2 | FiO2 | Inspired Oxygen Fraction Test | Maximum fraction of inspired oxygen (FiO2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555571","Fibroblast Growth Factor 19 Measurement","C154727","The determination of the amount of fibroblast growth factor 19 present in a sample.","Fibroblast Growth Factor 19 Measurement | FGF 19 | FGF19 | FGF19 Measurement | Fibroblast Growth Factor 19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935623","Fatty Liver Index","C156516","A calculation that indicates the likely presence of fatty liver disease, taking into account waist circumference, body mass index, triglyceride concentrations, and gamma-glutamyltransferase activity. (Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006 Nov 2;6:33.)","Fatty Liver Index | FATLVIDX | FLI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555589","Factor VIII Inhibitor Measurement","C154752","The determination of the amount of factor VIII inhibitor present in a sample.","Factor VIII Inhibitor Measurement | Alloantibody, Factor VIII Inhibitor | FCT8INH | Factor VIII Antibody | Factor VIII Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555576","E-selectin Measurement","C154736","The determination of the amount of E-selectin present in a sample.","E-selectin Measurement | E-Selectin | ESELECT | SELE Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555565","Erythroid Cells to Total Cells Ratio Measurement","C154719","The determination of the ratio of erythroid cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Erythroid Cells to Total Cells Ratio Measurement | ERCECE | Erythroid Cells/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555566","Erythroid Cells to Nucleated Cells Ratio Measurement","C154720","The determination of the ratio of erythroid cells compared to nucleated cells present in a sample. The measurement may be expressed as a ratio or percentage.","Erythroid Cells to Nucleated Cells Ratio Measurement | ERCENC | Erythroid Cells/Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936123","Drug Crystal Measurement","C156533","The determination of the amount of drug crystals present in a sample.","Drug Crystal Measurement | CYDRUG | Drug Crystals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935657","Delta Aminolevulinate to Creatinine Ratio Measurement","C156538","The determination of the ratio of delta aminolevulinate compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Delta Aminolevulinate to Creatinine Ratio Measurement | DALACRT | Delta Aminolevulinate/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935656","Delta Aminolevulinate Measurement","C156537","The determination of the amount of delta aminolevulinate present in a sample.","Delta Aminolevulinate Measurement | 5-Aminolevulinic Acid | 5ALA | DALA | Delta Aminolevulinate | Delta Aminolevulinic Acid | dALA",,,,,,,,,,,,,,,"4310329","Urine delta aminolevulinic acid measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1295128","Decanoylcarnitine Measurement","C156536","The determination of the amount of decanoylcarnitine present in a sample.","Decanoylcarnitine Measurement | C10 | DCCARNIT | Decanoylcarnitine",,,,,,,,,,,,,,,"4007651","Decanoylcarnitine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1446147","IgG Index","C154735","A relative measurement (ratio) of the IgG in cerebrospinal fluid to IgG in serum in a sample.","IgG Index | CSF IgG Index | CSF Index | CSFIGIDX",,,,,,,,,,,,,,,"4136730","Cerebrospinal fluid index",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266457","Cocaethylene Measurement","C156510","The determination of the amount of cocaethylene present in a sample.","Cocaethylene Measurement | COCAETH | Cocaethylene | Cocaine Ethyl | Ethyl Cocaine Measurement | Ethylbenzoylecgonine Measurement",,,,,,,,,,,,,,,"4007164","Cocaethylene measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL935614","Chemokine (C-C Motif) Ligand 2 Excretion Rate","C156520","The determination of the amount of chemokine (C-C Motif) ligand 2 being excreted in a biological specimen over a defined period of time.","Chemokine (C-C Motif) Ligand 2 Excretion Rate | C-C Motif Chemokine 2 Excretion Rate | CCL2 Excretion Rate | CCL2EXR | Chemokine (C-C Motif) Ligand 2 Excr Rate | MCP1 Excretion Rate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555593","Albumin Corrected Calcium Measurement","C154753","The determination of the amount of calcium in a sample, which has been corrected for albumin.","Albumin Corrected Calcium Measurement | CACRALB | Calcium Corrected for Albumin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556904","Bizarre Platelet Count","C154733","The determination of the amount of bizarre platelets present in a sample.","Bizarre Platelet Count | Bizarre Platelets | PLATBIZ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555597","Beta-Aminobutyric Acid Measurement","C154765","The determination of the amount of beta-aminobutyric acid present in a sample.","Beta-Aminobutyric Acid Measurement | BABA | BAMBTAC | Beta-Aminobutyric Acid | Beta-aminobutyrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523520","Beta Alanine Measurement","C154764","The determination of the amount of beta alanine present in a sample.","Beta Alanine Measurement | BALA | Beta Alanine",,,,,,,,,,,,,,,"4018177","beta-Alanine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523709","Hydroxylysine Measurement","C154767","The determination of the amount of hydroxylysine present in a sample.","Hydroxylysine Measurement | HYXLYS | Hydroxylysine",,,,,,,,,,,,,,,"4017193","Hydroxylysine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523699","Homocitrulline Measurement","C154758","The determination of the amount of homocitrulline present in a sample.","Homocitrulline Measurement | HOMOCIT | Homocitrulline",,,,,,,,,,,,,,,"4017091","Homocitrulline measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555590","HLA DR Beta1 Histocompatibility Antigen Measurement","C154749","The determination of the amount of HLA DR beta1 histocompatibility antigen present in a sample.","HLA DR Beta1 Histocompatibility Antigen Measurement | HLA DR Beta1 Antigen | HLA-DRB1 Antigen Measurement | HLADRB1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555591","HLA DQ Beta1 Histocompatibility Antigen Measurement","C154750","The determination of the amount of HLA DQ beta1 histocompatibility antigen present in a sample.","HLA DQ Beta1 Histocompatibility Antigen Measurement | HLA DQ Beta1 Antigen | HLA-DQB1 Antigen Measurement | HLADQB1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555588","HLA DP Beta1 Histocompatibility Antigen Measurement","C154751","The determination of the amount of HLA DP beta1 histocompatibility antigen present in a sample.","HLA DP Beta1 Histocompatibility Antigen Measurement | HLA DP Beta1 Antigen | HLA-DPB1 Antigen Measurement | HLADPB1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555586","HLA Class IC Histocompatibility Antigen Measurement","C154748","The determination of the amount of HLA class IC histocompatibility antigen present in a sample.","HLA Class IC Histocompatibility Antigen Measurement | HLA Class IC Antigen | HLA-C Antigen Measurement | HLAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555585","HLA Class IB Histocompatibility Antigen Measurement","C154747","The determination of the amount of HLA class IB histocompatibility antigen present in a sample.","HLA Class IB Histocompatibility Antigen Measurement | HLA Class IB Antigen | HLA-B Antigen Measurement | HLAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555587","HLA Class IA Histocompatibility Antigen Measurement","C154746","The determination of the amount of HLA class IA histocompatibility antigen present in a sample.","HLA Class IA Histocompatibility Antigen Measurement | HLA Class IA Antigen | HLA-A Antigen Measurement | HLAA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936126","Hemoglobin Cast Measurement","C156515","The determination of the amount of hemoglobin casts present in a sample.","Hemoglobin Cast Measurement | HGBCS | Hemoglobin Casts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826795","Adverse Event End Relative to Reference Period","C83203","A characterization of the relationship of an adverse event conclusion point in time to a reference point in time.","Adverse Event End Relative to Reference Period | AEENRF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981422","Adverse Event End Relative to Reference Time Point","C87838","An indicator of the conclusion of the adverse event in relation to a specific point in time.","Adverse Event End Relative to Reference Time Point | AEENRTPT | Adverse Events End Relative to Reference Time Point",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981431","Clinical Events End Relative to Reference Period","C87847","A characterization of the relationship of a clinical event point in time to a reference point in time.","Clinical Events End Relative to Reference Period | CEENRF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981432","Clinical Events End Relative to Reference Time Point","C87848","An indicator of the conclusion of a clinical event in relation to a specific point in time.","Clinical Events End Relative to Reference Time Point | CEENRTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981442","Clinical Events Start Relative to Reference Period","C87858","An indication or description that the start of the clinical event is before, during or after a reference time interval.","Clinical Events Start Relative to Reference Period | CESTRF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826817","Concomitant Medication Use End Relative to Reference Period","C83227","A characterization of the relationship of an concomitant medication use conclusion point in time to a reference point in time.","Concomitant Medication Use End Relative to Reference Period | CMENRF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981446","Concomitant Medication End Relative to Reference Time Point","C87862","An indicator of the conclusion of concomitant medication usage in relation to a specific point in time.","Concomitant Medication End Relative to Reference Time Point | CMENRTPT | Concomitant/Prior Medications End Relative to Reference Time Point",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826827","Concomitant Medication Use Start Relative to Reference Period","C83237","A characterization of the relationship of an concomitant medication use beginning point in time to a reference point in time.","Concomitant Medication Use Start Relative to Reference Period | CMSTRF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981448","Concomitant Medication Start Relative to Reference Timepoint","C87864","An indication or description of the start of concomitant medication usage in relation to a specific point in time.","Concomitant Medication Start Relative to Reference Timepoint | CMSTRTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086427","Healthcare Encounters End Relative to Reference Time Point","C123965","An indication or description that the end of the healthcare encounter is before, during or after a reference moment in time.","Healthcare Encounters End Relative to Reference Time Point | HOENRTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086437","Healthcare Encounters Start Relative to Reference Timepoint","C124021","An indication or description of the start of a healthcare encounter in relation to a specific point in time.","Healthcare Encounters Start Relative to Reference Timepoint | HOSTRTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826921","Medical History End Relative to Reference Period","C83331","A characterization of the relationship of an medical history conclusion point in time to a reference point in time.","Medical History End Relative to Reference Period | MHENRF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897840","Procedure End Relative to Reference Time Point","C117541","An indication or description that the end of the procedure is before, during or after a reference moment in time.","Procedure End Relative to Reference Time Point | PRENRTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897824","Procedure Start Relative to Reference Time Point","C117539","An indication or description of the start of a procedure in relation to a specific point in time.","Procedure Start Relative to Reference Time Point | PRSTRTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523841","Porphobilinogen Measurement","C156539","The determination of the amount of porphobilinogen present in a sample.","Porphobilinogen Measurement | PBG | Porphobilinogen",,,,,,,,,,,,,,,"4019983","Porphobilinogen measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL935620","Phosphorylated STAT3 to STAT3 Ratio Measurement","C156522","The determination of the ratio of phosphorylated STAT3 compared to STAT3 present in a sample. The measurement may be expressed as a ratio or percentage.","Phosphorylated STAT3 to STAT3 Ratio Measurement | Phosphorylated STAT3/STAT3 | STAT3PS3 | pSTAT3/STAT3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935619","Phosphorylated STAT3 Measurement","C156521","The determination of the amount of phosphorylated STAT3 present in a sample.","Phosphorylated STAT3 Measurement | Phospho-STAT3 Measurement | Phosphorylated STAT3 | Phosphorylated Signal Transducer and Activator of Transcription 3 Measurement | Phosphorylated-Signal Transducer and Activator of Transcription 3 Measurement | STAT3P | pSTAT3 | pSTAT3 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935622","Nuclear Matrix Protein 22 Measurement","C156509","The determination of the amount of nuclear matrix protein 22 present in a sample.","Nuclear Matrix Protein 22 Measurement | NMP22 | NUMA1 | Nuclear Matrix Protein 22 | Nuclear Mitotic Apparatus Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555582","Nociceptin Measurement","C154744","The determination of the amount of nociceptin present in a sample.","Nociceptin Measurement | NCCPTN | Nociceptin | Orphanin FQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555594","Segmented and Band Form Neutrophils Measurement","C154755","The determination of the amount of segmented and band form neutrophils present in a sample.","Segmented and Band Form Neutrophils Measurement | NEUTSGB | Neutrophils, Segmented + Band Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555592","Segmented, Band Form and Precursor Neutrophils Measurement","C154756","The determination of the amount of segmented, band form, and precursor neutrophils present in a sample.","Segmented, Band Form and Precursor Neutrophils Measurement | NEUTSGBP | Neutrophils, Seg + Band Form + Precursor | Neutrophils, Segmented + Band Form + Precursors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1294062","Mononuclear Cell Count","C154757","The determination of the amount of mononuclear cells present in a sample.","Mononuclear Cell Count | MNC | Mononuclear Cells | Mononucleated Cells",,,,,,,,,,,,,,,"4022016","Mononuclear cell count",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555570","Megakaryocytes to Leukocytes Ratio Measurement","C154722","The determination of the ratio of megakaryocytes compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Megakaryocytes to Leukocytes Ratio Measurement | KRCYMGLE | Megakaryocytes/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555583","Lactulose Measurement","C154741","The determination of the amount of lactulose present in a sample.","Lactulose Measurement | LACTULOS | Lactulose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555578","Kynurenine Measurement","C154740","The determination of the amount of kynurenine present in a sample.","Kynurenine Measurement | KYNURNN | Kynurenine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1611729","KL-6 Cell Marker Analysis","C154724","The determination of the amount of Krebs von den Lungen-6 present in a sample.","Krebs von den Lungen-6 Measurement | KL-6 | KL-6 Measurement | KL6 | Krebs von den Lungen-6 | Krebs von den Lungen-6 Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201519","Islet Cell Antibody Measurement","C154725","The determination of the amount of islet cell antibody present in a sample.","Islet Cell Antibody Measurement | ICAB | Islet Cell Antibody",,,,,,,,,,,,,,,"4273883","Islet cell antibody measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL935613","Interleukin 18 Excretion Rate","C156519","The determination of the amount of interleukin 18 being excreted in a biological specimen over a defined period of time.","Interleukin 18 Excretion Rate | IL18EXR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935616","Interleukin 1 Excretion Rate","C156518","The determination of the amount of interleukin 1 being excreted in a biological specimen over a defined period of time.","Interleukin 1 Excretion Rate | IL1EXR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935615","Free Immunoglobulin Light Chain Measurement","C156517","The determination of the amount of free immunoglobulin light chains present in a sample.","Free Immunoglobulin Light Chain Measurement | IMMGLCFR | Immunoglobulin Light Chains, Free",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555580","Immunoglobulin Heavy Constant Gamma 4 Measurement","C154738","The determination of the amount of immunoglobulin heavy constant gamma 4 present in a sample.","Immunoglobulin Heavy Constant Gamma 4 Measurement | IGHG4 | Immunoglobulin Heavy Constant Gamma 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555579","Immunoglobulin Heavy Constant Gamma 2 Measurement","C154737","The determination of the amount of immunoglobulin heavy constant gamma 2 present in a sample.","Immunoglobulin Heavy Constant Gamma 2 Measurement | IGHG2 | Immunoglobulin Heavy Constant Gamma 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556888","Immature Platelet Count","C154723","The determination of the amount of immature platelets present in a sample.","Immature Platelet Count | Immature Platelets | PLATIM | Reticulated Platelets",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827038","Visit Day","C83450","The day of the week of a visit.","Visit Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549755","Visit Number","C83101","The numerical identifier of the visit.","Visit Number | visit number | visit_number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831029","Concomitant Medication Pre-specified","C113355","An indication or description that concomitant medication was previously determined, characterized, or detailed.","Concomitant Medication Pre-specified | CMPRESP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899204","Exposure as Collected Pre-specified","C117477","An indication or description that the collected exposure was previously determined, characterized, or detailed.","Exposure as Collected Pre-specified | ECPRESP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826843","Electrocardiogram Baseline Flag","C83253","An indication or description that electrocardiogram data is a baseline value.","Electrocardiogram Baseline Flag | EGBLFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826845","Electrocardiogram Derived Flag","C83255","An indication or description that electrocardiogram data is a derived value.","Electrocardiogram Derived Flag | EGDRVFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086430","Healthcare Encounters Pre-specified","C123989","An indication or description that a healthcare encounter was previously determined, characterized, or detailed.","Healthcare Encounters Pre-specified | HOPRESP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826891","Inclusion Exclusion Criterion Character Result in Standard Format","C83301","The standard character or string for representation and reporting of inclusion exclusion criterion data.","Inclusion Exclusion Criterion Character Result in Standard Format | IESTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898804","Immunogenicity Specimen Assessments Baseline Flag","C117569","An indication or description that immunogenicity specimen assessment data is a baseline value.","Immunogenicity Specimen Assessments Baseline Flag | ISBLFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826893","Laboratory Test Baseline Flag","C83303","An indication or description that laboratory test data is a baseline value.","Laboratory Test Baseline Flag | LBBLFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826894","Laboratory Test Derived Flag","C83304","An indication or description that laboratory test data is a derived value.","Laboratory Test Derived Flag | LBDRVFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981490","Microbiology Specimen Examination Baseline Flag","C87906","An indication or description of a baseline value within a microbiology specimen examination.","Microbiology Specimen Examination Baseline Flag | MBBLFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981488","Microbiology Specimen Derived Flag","C87904","An indication that a data element corresponding to a microbiology specimen has been derived from one or more data elements.","Microbiology Specimen Derived Flag | MBDRVFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898257","Morphology Baseline Flag","C117626","An indication or description that morphology data is a baseline value.","Morphology Baseline Flag | MOBLFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898251","Morphology Derived Flag","C117627","An indication or description that morphology assessment data is a derived value.","Morphology Derived Flag | MODRVFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981510","Microbiology Susceptibility Baseline Flag","C87926","An indication or description of a baseline value within a microbiology susceptibility assessment.","Microbiology Susceptibility Baseline Flag | MSBLFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981514","Microbiology Susceptibility Derived Flag","C87930","An indication that a data element corresponding to a microbiology susceptibility assessment has been derived from one or more data elements.","Microbiology Susceptibility Derived Flag | MSDRVFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981536","Pharmacokinetic Concentration Derived Flag","C87953","An indication that a data element corresponding to a pharmacokinetic concentration has been derived from one or more data elements.","Pharmacokinetic Concentration Derived Flag | PCDRVFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935606","Vascular Endothelial Growth Factor Receptor 2 Measurement","C156527","The determination of the amount of vascular endothelial growth factor receptor 2 present in a sample.","Vascular Endothelial Growth Factor Receptor 2 Measurement | KDR Measurement | VEGFR2 | VEGFR2 Measurement | Vasc Endothelial Growth Factor Rec 2 | Vascular Endothelial Growth Factor Receptor 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523957","Tryptophan Measurement","C154739","The determination of the amount of tryptophan present in a sample.","Tryptophan Measurement | TRP | Tryptophan",,,,,,,,,,,,,,,"4021293","Tryptophan measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL935607","TNF Superfamily Member 12 Excretion Rate","C156525","The determination of the amount of TNF superfamily member 12 being excreted in a biological specimen over a defined period of time.","TNF Superfamily Member 12 Excretion Rate | TNF12EXR | TNFSF12 Excretion Rate | TWEAK Excretion Rate | Tumor Necrosis Factor Ligand Superfamily Member 12 Excretion Rate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0302279","Thiocyanate Measurement","C154745","The determination of the amount of thiocyanate present in a sample.","Thiocyanate Measurement | SCN | Thiocyanate",,,,,,,,,,,,,,,"4022512","Thiocyanate measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL563182","STAT3 Measurement","C156469","The determination of the amount of STAT3 present in a sample.","STAT3 Measurement | STAT3 | Signal Transducer and Activator of Transcription 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555569","Standard Base Excess Measurement","C154721","A calculated measurement of the amount of acid required to return blood with hemoglobin at 5g/dL, which is used as a surrogate for extracellular fluid, to a normal pH under standard conditions.","Standard Base Excess Measurement | STBSEXCS | Standard Base Excess",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935608","Soluble TNF Superfamily Member 12 Measurement","C156526","The determination of the amount of soluble TNF superfamily member 12 present in a sample.","Soluble TNF Superfamily Member 12 Measurement | Soluble TNF Superfamily Member 12 | Soluble TNFSF12 | Soluble TNFSF12 Measurement | Soluble TWEAK Measurement | Soluble Tumor Necrosis Factor Ligand Superfamily Member 12 Measurement | TNF12S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555572","Soluble CD163","C154728","The determination of the amount of scavenger receptor cysteine-rich type 1 protein M130 present in a sample.","Scavenger Receptor Cysteine-Rich Type 1 Protein M130 Measurement | CD163S | M130 | Scavenger Rcpt Cys-Rich Type1 Prot M130 | Scavenger Receptor Cysteine-Rich Type 1 Protein M130 | Soluble CD163 | Soluble CD163 Measurement | Soluble CD163a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523886","Sarcosine Measurement","C154760","The determination of the amount of sarcosine present in a sample.","Sarcosine Measurement | N-Methylglycine | SARCOSIN | Sarcosine",,,,,,,,,,,,,,,"4017339","Sarcosine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555575","S100 Calcium Binding Protein A8 Measurement","C154730","The determination of the amount of S100 calcium binding protein A8 present in a sample.","S100 Calcium Binding Protein A8 Measurement | S100 Calcium Binding Protein A8 | S100A8 | S100A8 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1446178","Retinol Binding Protein to Creatinine Ratio Measurement","C154729","The determination of the ratio of retinol binding protein compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Retinol Binding Protein to Creatinine Ratio Measurement | RBPCREAT | Retinol Binding Protein/Creatinine",,,,,,,,,,,,,,,"4131375","Retinol binding protein / creatinine ratio measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL935612","Pyruvate Kinase Muscle Isozyme Measurement","C156530","The determination of the amount of pyruvate kinase muscle isozyme present in a sample.","Pyruvate Kinase Muscle Isozyme Measurement | PKM | PKM Measurement | Pyruvate Kinase Muscle Isozyme",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935609","Pyruvate Kinase Isozyme M2 Measurement","C156531","The determination of the amount of pyruvate kinase isozyme M2 present in a sample.","Pyruvate Kinase Isozyme M2 Measurement | PKM2 | PKM2 Measurement | Pyruvate Kinase Isozyme M2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935610","Pyruvate Kinase Isozyme M1 Measurement","C156532","The determination of the amount of pyruvate kinase isozyme M1 present in a sample.","Pyruvate Kinase Isozyme M1 Measurement | PKM1 | PKM1 Measurement | Pyruvate Kinase Isozyme M1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0373716","Pyruvate Kinase Measurement","C156470","The determination of the amount of pyruvate kinase present in a sample.","Pyruvate Kinase Measurement | PK | PK Measurement | PYK | Phosphoenol Transphosphorylase Measurement | Phosphoenolpyruvate Kinase Measurement | Pyruvate Kinase",,,,,,,,,,,,,,,"4147976","Pyruvate kinase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL935618","Pyocytes Measurement","C156524","The determination of the amount of pyocytes present in a sample.","Pyocytes Measurement | PYOCYTES | Pyocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935617","Pro-gastrin Releasing Peptide Measurement","C156523","The determination of the amount of pro-gastrin releasing peptide present in a sample.","Pro-gastrin Releasing Peptide Measurement | PROGRP | Pro-GRP Measurement | Pro-gastrin Releasing Peptide | proGRP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1278186","Porphobilinogen to Creatinine Ratio Measurement","C156540","The determination of the ratio of porphobilinogen compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Porphobilinogen to Creatinine Ratio Measurement | PBGCREAT | Porphobilinogen/Creatinine",,,,,,,,,,,,,,,"4198873","Porphobilinogen/creatinine ratio measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2826956","Questionnaire Baseline Flag","C83367","An indication or description that questionnaire data is a baseline value.","Questionnaire Baseline Flag | QSBLFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826958","Questionnaire Derived Flag","C83369","An indication or description that questionnaire data is a derived value.","Questionnaire Derived Flag | QSDRVFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897716","Reproductive System Findings Baseline Flag","C117651","An indication or description that reproductive system findings data is a baseline value.","Reproductive System Findings Baseline Flag | RPBLFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897711","Reproductive System Findings Derived Flag","C117652","An indication or description that reproductive system findings data is a derived value.","Reproductive System Findings Derived Flag | RPDRVFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899367","Disease Response Accepted Record Flag","C117387","An indication or description of a record that is considered to be the accepted and final evaluation for the disease response.","Disease Response Accepted Record Flag | RSACPTFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897282","Tumor Results Accepted Record Flag","C117406","An indication or description of a record that is considered to be the accepted and final evaluation for the tumor result.","Tumor Results Accepted Record Flag | TRACPTFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897300","Tumor Identifier Accepted Record Flag","C117428","An indication or description of a record that is considered to be the accepted and final evaluation for the tumor identification.","Tumor Identifier Accepted Record Flag | TUACPTFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827039","Vital Signs Baseline Flag","C83451","An indication or description that reported vital signs data is a baseline value.","Vital Signs Baseline Flag | VSBLFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827041","Vital Signs Derived Flag","C83453","An indication or description that reported vital signs data is a derived value.","Vital Signs Derived Flag | VSDRVFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879923","CDISC SDTM Laboratory Test Terminology by Code","C65047","A terminology set that includes concepts contained in the CDISC laboratory test codelist.","CDISC SDTM Laboratory Test Code Terminology | LBTESTCD | Laboratory Test Code | SDTM-LBTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826861","Electrocardiogram Test Code","C83271","A character or string that represents the short code name of the electrocardiogram test.","Electrocardiogram Test Code | EGTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889424","Microscopic Findings Test Code","C117577","A character or string that represents the short code name of the microscopic findings assessment.","Microscopic Findings Test Code | MITESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981605","Microbiology Susceptibility Result Category","C88023","A classification of a microbiology susceptibility result.","Microbiology Susceptibility Result Category | MSRESCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889270","Disease Response Assessment Test Code","C117405","A character or string that represents the short code name of the disease response assessment.","Disease Response Assessment Test Code | RSTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272335","CDISC SDTM Electrocardiogram Lead Terminology","C90013","The terminology that includes concepts relevant to the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND) electrocardiogram leads.","CDISC SDTM Electrocardiogram Lead Terminology | ECG Lead | EGLEAD | SDTM-EGLEAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449217","Augmented Vector Right","C90362","An augmented unipolar electrocardiogram limb lead in which the positive (white) electrode is situated on the right thoracic limb and the negative electrode is a combination of the left thoracic limb (black) electrode and the left pelvic limb (red) electrode. Measures the electrical activity of the electrode on the right thoracic limb.","Augmented Vector Right | LEAD aVR",,,,,,,,,,,,,,,"4121562","aVR",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL522552","Lead Site aVL-Axial","C135388","An augmented unipolar electrocardiogram limb lead in which the positive electrode is near the apex of the heart (located in the ICS of left 5-6 rib close to the sternum) and the negative electrode is a combination of the electrode behind the right ear near the right mastoid process and the electrode on hindquarters proximal to the sacrum. (CDISC)","Lead Site aVL-Axial | LEAD aVL-AXIAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449216","Augmented Vector Left","C90361","An augmented unipolar electrocardiogram limb lead in which the positive (black) electrode is situated on the left thoracic limb and the negative electrode is a combination of the right thoracic limb (white) electrode and the left pelvic limb (red) electrode. Measures the electrical activity of the electrode on the left thoracic limb.","Augmented Vector Left | LEAD aVL",,,,,,,,,,,,,,,"4107144","aVL",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL522551","Lead Site aVF-Ventral","C135387","An augmented unipolar electrocardiogram limb lead in which the positive electrode is situated at the hindquarters proximal to the sacrum and the negative electrode is a combination of the electrode behind the right ear near the right mastoid process and the electrode near the apex of the heart (located in the ICS of left 5-6 rib close to the sternum). (CDISC)","Lead Site aVF-Ventral | LEAD aVF-VENTRAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449215","Augmented Vector Foot","C90360","An augmented unipolar electrocardiogram limb lead in which the positive (red) electrode is situated on the left pelvic limb and the negative electrode is a combination of the right thoracic limb (white) electrode and the left thoracic limb (black) electrode. Measures the electrical activity of the electrode on the left pelvic limb.","Augmented Vector Foot | LEAD aVF",,,,,,,,,,,,,,,"4107143","aVF",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2983622","Lead Site aV6","C90403","An augmented unipolar lead placed at the sixth intercostal space on the midaxillary line.","Lead Site aV6 | LEAD aV6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891284","Superimposition of Multiple Leads","C117760","Measurement methodology using multiple leads for the determination of an ECG parameter. This is often visually represented as a superimposition of the median beats from multiple leads. (CDISC)","Superimposition of Multiple Leads | Global Median Beat | SML",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522556","Lead Site Ventral","C135392","A bipolar electrocardiogram limb lead which records the voltage with the positive electrode on the hindquarters proximal to the sacrum and the negative electrode near the apex of the heart (located in the ICS of left 5-6 rib close to the sternum). (CDISC)","Lead Site Ventral | LEAD VENTRAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449220","Lead Site V6","C90418","A unipolar electrocardiogram lead site at which the electrode is placed on the anterior chest wall level with lead V5 at the left midaxillary line.","Lead Site V6 | LEAD V6 | Lead C6",,,,,,,,,,,,,,,"4119701","Lead site V6",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0449219","Lead Site V5","C90417","A unipolar electrocardiogram lead site; the electrode is placed on the anterior chest wall level with lead V4 at the left anterior axillary line. In large animals it is placed on the sixth ICS on the right side of the thorax along a line parallel to the level of the point of the shoulder corresponding to the electrical center of the heart (central terminal).","Lead Site V5 | LEAD V5 | Lead C5",,,,,,,,,,,,,,,"4107146","Lead site V5",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0449221","Lead Site V4","C90416","A unipolar electrocardiogram lead site; the electrode is placed at the fifth intercostal space on the anterior chest wall (between ribs 5 and 6) at the left midclavicular line. In small animals it corresponds to V4-V6 where it is placed at the 6th left intercostal space near the costochondral junction. In large animals it is placed over the 6th rib at the level of a horizontal line drawn through the scapulohumeral articulation on the left side of the thorax.","Lead Site V4 | LEAD V4 | Lead C4",,,,,,,,,,,,,,,"4121564","Lead site V4",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0449218","Lead Site V3","C90415","A unipolar electrocardiogram lead site; the electrode is placed on the anterior chest wall midway between leads V2 and V4. In large and small animals, it is placed over the dorsal spinous process of the 7th thoracic vertebra.","Lead Site V3 | LEAD V3 | Lead C3",,,,,,,,,,,,,,,"4107145","Lead site V3",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0441908","Lead Site V2","C90414","A unipolar electrocardiogram lead site; the electrode is placed on the anterior chest wall at the fourth intercostal space (between ribs 4 and 5) to the left of the sternal border.  In small animals it corresponds to V2-V3 where it is placed at the 6th left intercostal space near the sternum.  In large animals it is placed over the 6th rib at the level of the costochondral junction on the left side of the thorax.","Lead Site V2 | LEAD V2 | Lead C2",,,,,,,,,,,,,,,"4105372","Lead site V2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2983631","Lead Site V10","C90413","A unipolar chest lead at which the electrode is placed over the dorsal spinous process of 7th thoracic vertebra.","Lead Site V10 | LEAD V10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441907","Lead Site V1","C90412","A unipolar electrocardiogram lead site; the electrode is placed at the fourth intercostal space on the anterior chest wall (between ribs 4 and 5) to the right of the sternal border. In small animals, it is placed at the right fifth intercostal space near the sternum.","Lead Site V1 | LEAD V1 | Lead C1",,,,,,,,,,,,,,,"4121563","Lead site V1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2983630","Lead Site rV2","C90411","A unipolar precordial lead placed at the second intercostal space to the left of the sternum.","Lead Site rV2 | LEAD rV2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449214","Lead Site III","C90410","A bipolar electrocardiogram limb lead which records the voltage between the negative electrode on the left thoracic limb and the positive electrode on the left pelvic limb.","Lead Site III | LEAD III",,,,,,,,,,,,,,,"4157986","Lead III",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0449213","Lead Site II","C90409","A bipolar electrocardiogram limb lead which records the voltage between the negative electrode on the right thoracic limb and the positive electrode on the left pelvic limb.","Lead Site II | LEAD II",,,,,,,,,,,,,,,"4165927","Lead II",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0449212","Lead Site I","C90408","A bipolar electrocardiogram limb lead which records the voltage between the negative electrode on the right thoracic limb and the positive electrode on the left thoracic limb.","Lead Site I | LEAD I",,,,,,,,,,,,,,,"4157985","Lead I",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL522555","Lead Site Dorsal","C135391","A bipolar electrocardiogram limb lead which records the voltage between the negative electrode behind the right ear near the right mastoid process and the positive electrode on the hindquarters proximal to the sacrum. (CDISC)","Lead Site Dorsal | LEAD DORSAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983626","Lead Site CV6LU","C90407","V2 electrode (+) placed in the 6th intercostal space on the left side of the thorax along a line parallel to the level of the point of the shoulder.","Lead Site CV6LU | LEAD CV6LU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983625","Lead Site CV6LL","C90406","V1 electrode (+) placed in the 6th intercostal space on the left side of the thorax along a line parallel to the level of the point of the elbow.","Lead Site CV6LL | LEAD CV6LL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983624","Lead Site CV5RL","C90405","A unipolar chest lead used mostly in large animals. Placed on the sixth ICS on the right side of the thorax along a line parallel to the level of the point of the elbow.","Lead Site CV5RL | LEAD CV5RL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983623","Lead Site CM5","C90404","A bipolar EKG lead with the right thoracic limb electrode placed on the manubrium and left thoracic limb electrode placed at the surface marking of the V5 position (just above the 5th interspace in the anterior axillary line). The left pelvic limb lead acts as a neutral and may be placed anywhere. The C refers to 'clavicle' where it is often placed.","Lead Site CM5 | LEAD CM5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522554","Lead Site Axial","C135390","A bipolar electrocardiogram limb lead which records the voltage between the positive electrode near the apex of the heart (located in the ICS of left 5-6 rib close to the sternum) and the negative electrode behind the right ear near the right mastoid process. (CDISC)","Lead Site Axial | LEAD AXIAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522553","Lead Site aVR-Dorsal","C135389","An augmented unipolar electrocardiogram limb lead in which the positive electrode is behind the right ear near the right mastoid process and the negative electrode is a combination of the electrode at the hindquarters proximal to the sacrum and the electrode near the apex of the heart (located in the ICS of left 5-6 rib close to the sternum). (CDISC)","Lead Site aVR-Dorsal | LEAD aVR-DORSAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3877952","Electrocardiogram Lead","C123976","An insulated electrical conductor designed to connect to an electrocardiogram machine.","Electrocardiogram Lead | EGLEAD",,,,,,,,,,,,,,,"4121561","ECG lead",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2981497","Microbiology Specimen Origin","C87913","A site where a microbiology specimen is collected.","Microbiology Specimen Origin | MBLOC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898245","Morphology Location","C117620","The site in or on the body at which the morphology test or result is performed or collected.","Morphology Location | MOLOC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897292","Tumor Identifier Location","C117437","The site in or on the body at which the tumor identification test or result is performed or collected.","Tumor Identifier Location | TULOC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899364","Disease Response Evaluator Identifier","C117392","A sequence of characters used to identify, name, or characterize the evaluator of the disease response.","Disease Response Evaluator Identifier | RSEVALID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897279","Tumor Results Evaluator Identifier","C117410","A sequence of characters used to identify, name, or characterize the evaluator of the tumor results.","Tumor Results Evaluator Identifier | TREVALID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897297","Tumor Identifier Evaluator Identifier","C117433","A sequence of characters used to identify, name, or characterize the evaluator of the tumor identification.","Tumor Identifier Evaluator Identifier | TUEVALID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981496","Microbiology Specimen Method","C87912","The technique used to administer an examination of a microbiology specimen.","Microbiology Specimen Method | MBMETHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898244","Morphology Method","C117624","The technique used to administer the morphologic assessment.","Morphology Method | MOMETHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981518","Microbiology Susceptibility Method","C87934","The technique used to administer a microbiology susceptibility assessment.","Microbiology Susceptibility Method | MSMETHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981543","Pharmacokinetic Concentration Method","C87960","The technique used to administer an examination or assessment of pharmacokinetic concentration.","Pharmacokinetic Concentration Method | PCMETHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897588","Skin Response Method","C117690","The technique used to administer the skin response assessment.","Skin Response Method | SRMETHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897274","Tumor Results Method","C117414","The technique used to administer the tumor results assessment.","Tumor Results Method | TRMETHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897291","Tumor Identifier Method","C117438","The technique used to administer the tumor identification assessment.","Tumor Identifier Method | TUMETHOD | TUMOR_DETECTION_METHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831075","Clinical Events Completion Status","C113354","A term used to describe the state or condition of the completeness of the clinical events data.","Clinical Events Completion Status | CESTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826824","Concomitant Medication Use Completion Status","C83234","A term used to describe the state or condition of the completeness of the concomitant medication usage data.","Concomitant Medication Use Completion Status | CMSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830394","Drug Accountability Completion Status","C113357","A term used to describe the state or condition of the completeness of the drug accountability data.","Drug Accountability Completion Status | DASTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826857","Electrocardiogram Completion Status","C83267","A term used to describe the state or condition of the completeness of the electrocardiogram data.","Electrocardiogram Completion Status | EGSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086421","Healthcare Encounters Completion Status","C124007","A term used to describe the state or condition of the completeness of the healthcare encounters data.","Healthcare Encounters Completion Status | HOSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898801","Immunogenicity Specimen Assessments Completion Status","C117564","A term used to describe the state or condition of the completeness of the immunogenicity specimen assessment data.","Immunogenicity Specimen Assessments Completion Status | ISSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829354","Laboratory Data Completion Status","C113371","A term used to describe the state or condition of the completeness of the laboratory data.","Laboratory Data Completion Status | LBSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826927","Medical History Completion Status","C83337","A term used to describe the state or condition of the completeness of the medical history data.","Medical History Completion Status | MHSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829076","Microbiology Completion Status","C113372","A term used to describe the state or condition of the completeness of the microbiology data.","Microbiology Completion Status | MBSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898377","Microscopic Findings Completion Status","C117588","A term used to describe the state or condition of the completeness of the microscopic findings data.","Microscopic Findings Completion Status | MISTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898254","Morphology Completion Status","C117616","A term used to describe the state or condition of the completeness of the morphology data.","Morphology Completion Status | MOSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829075","Microbiology Susceptibility Completion Status","C113373","A term used to describe the state or condition of the completeness of the microbiology susceptibility data.","Microbiology Susceptibility Completion Status | MSSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1444665","Physical Examination Completion Status","C83358","A term used to describe the state or condition of the completeness of the physical examination data.","Physical Examination Completion Status | PESTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828571","Pharmacokinetic Parameters Completion Status","C113377","A term used to describe the state or condition of the completeness of the pharmacokinetic parameters data.","Pharmacokinetic Parameters Completion Status | PPSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826970","Questionnaire Completion Status","C83381","A term used to describe the state or condition of the completeness of the questionnaire data.","Questionnaire Completion Status | QSSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897713","Reproductive System Findings Completion Status","C117649","A term used to describe the state or condition of the completeness of the reproductive system findings data.","Reproductive System Findings Completion Status | RPSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899365","Disease Response Completion Status","C117402","A term used to describe the state or condition of the completeness of the disease response data.","Disease Response Completion Status | RSSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826994","Subject Characteristics Status","C83405","A term used to describe the state or condition of subject characteristics data.","Subject Characteristics Status | SCSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897596","Skin Response Completion Status","C117684","A term used to describe the state or condition of the completeness of the skin response data.","Skin Response Completion Status | SRSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897442","Subject Status Completion Status","C117665","A term used to describe the state or condition of the completeness of the subject status data.","Subject Status Completion Status | SSSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897125","Tumor Results Completion Status","C117422","A term used to describe the state or condition of the completeness of the tumor results data.","Tumor Results Completion Status | TRSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086083","CDISC SDTM Subject Status Response Terminology","C124304","Terminology associated with the subject status response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Subject Status Response Terminology | SDTM-SSTATRS | SSTATRS | Subject Status Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899205","Exposure as Collected Portion or Totality","C117491","A qualifier for the arrangement or apportioning of an entity within a body part, region or organ for the collected exposure assessment.","Exposure as Collected Portion or Totality | ECPORTOT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898238","Morphology Portion or Totality","C117623","A qualifier for the arrangement or apportioning of an entity within a body part, region or organ for a morphology assessment.","Morphology Portion or Totality | MOPORTOT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897289","Tumor Identifier Portion or Totality","C117441","A qualifier for the arrangement or apportioning of an entity within a body part, region or organ for the tumor identification.","Tumor Identifier Portion or Totality | TUPORTOT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898789","Immunogenicity Specimen Assessments Specimen Type","C117567","The type of a material sample taken from a biological entity for immunogenicity specimen assessment testing.","Immunogenicity Specimen Assessments Specimen Type | ISSPEC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981509","Microbiology Specimen Type","C87925","The type of a material sample taken from a biological entity for microbiological testing.","Microbiology Specimen Type | MBSPEC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981569","Pharmacokinetic Parameter Specimen Type","C87986","The type of a material sample taken from a biological entity for pharmacokinetic parameter testing.","Pharmacokinetic Parameter Specimen Type | PPSPEC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897578","Skin Response Specimen Type","C117687","The type of a material sample taken from a biological entity for skin response testing.","Skin Response Specimen Type | SRSPEC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981485","Microbiology Specimen Condition","C87901","A characteristic that refers to the physical and organoleptic state of a microbiology specimen.","Microbiology Specimen Condition | MBSPCCND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981551","Pharmacokinetic Concentration Specimen Condition","C87968","A characteristic that refers to the physical and organoleptic state of a biospecimen used for a pharmacokinetic concentration assessment.","Pharmacokinetic Concentration Specimen Condition | PCSPCCND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898382","Microscopic Findings Baseline Flag","C117597","An indication or description that microscopic findings data is a baseline value.","Microscopic Findings Baseline Flag | MIBLFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827716","CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology","C85494","Terminology associated with the pharmacokinetic parameter unit of measure codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology | PK Units of Measure | PKUNIT | SDTM-PKUNIT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827834","Liter per Gram per Day","C85657","Liters per gram per day.","Liter per Gram per Day | (L/d)/g | (L/day)/g | (l/d)/g | (mL/d)/mg | (mL/day)/mg | (ml/d)/mg | L/day/g | L/g/d | Liter per Gram per 24 Hours | Milliliter per Day per Milligram | mL/mg/day | uL/ug/day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054633","Liter per Day per Microgram per Meter Squared per Day","C120737","A unit of concentration equal to liter per day divided by microgram per meter squared per day.","Liter per Day per Microgram per Meter Squared per Day | (L/d)/(ug/m2/d) | (L/day)/(ug/m2/day) | (l/d)/(ug/m2/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050588","Liter per Day per Microgram per Meter Squared","C120736","A unit of concentration equal to liter per day divided by microgram per meter squared.","Liter per Day per Microgram per Meter Squared | (L/d)/(ug/m2) | (L/day)/(ug/m2) | (l/d)/(ug/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054634","Liter per Day per Microgram per Kilogram per Day","C120735","A unit of concentration equal to liter per day divided by microgram per kilogram per day.","Liter per Day per Microgram per Kilogram per Day | (L/d)/(ug/kg/d) | (L/day)/(ug/kg/day) | (l/d)/(ug/kg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050630","Liter per Day per Microgram per Kilogram","C120734","A unit of concentration equal to liter per day divided by microgram per kilogram.","Liter per Day per Microgram per Kilogram | (L/d)/(ug/kg) | (L/day)/(ug/kg) | (l/d)/(ug/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054635","Liter per Day per Microgram per Day","C120733","A unit of concentration equal to liter per day divided by microgram per day.","Liter per Day per Microgram per Day | (L/d)/(ug/d) | (L/day)/(ug/day) | (l/d)/(ug/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054630","Liter per Day per Milligram per Meter Squared per Day","C120732","A unit of concentration equal to liter per day divided by milligram per meter squared per day.","Liter per Day per Milligram per Meter Squared per Day | (L/d)/(mg/m2/d) | (L/day)/(mg/m2/day) | (l/d)/(mg/m2/d) | (mL/d)/(ug/m2/d) | (mL/day)/(ug/m2/day) | (ml/d)/(ug/m2/d) | Milliliter per Day per Microgram per Meter Squared per Day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050564","Liter per Day per Milligram per Meter Squared","C120731","A unit of concentration equal to liter per day divided by milligram per meter squared.","Liter per Day per Milligram per Meter Squared | (L/d)/(mg/m2) | (L/day)/(mg/m2) | (l/d)/(mg/m2) | (mL/d)/(ug/m2) | (mL/day)/(ug/m2) | (ml/d)/(ug/m2) | Milliliter per Day per Microgram per Meter Squared",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054631","Liter per Day per Milligram per Kilogram per Day","C120730","A unit of concentration equal to liter per day divided by milligram per kilogram per day.","Liter per Day per Milligram per Kilogram per Day | (L/d)/(mg/kg/d) | (L/day)/(mg/kg/day) | (l/d)/(mg/kg/d) | (mL/d)/(ug/kg/d) | (mL/day)/(ug/kg/day) | (ml/d)/(ug/kg/d) | Milliliter per Day per Microgram per Kilogram per Day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050612","Liter per Day per Milligram per Kilogram","C120729","A unit of concentration equal to liter per day divided by milligram per kilogram.","Liter per Day per Milligram per Kilogram | (L/d)/(mg/kg) | (L/day)/(mg/kg) | (l/d)/(mg/kg) | (mL/d)/(ug/kg) | (mL/day)/(ug/kg) | (ml/d)/(ug/kg) | Milliliter per Day per Microgram per Kilogram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054632","Liter per Day per Milligram per Day","C120728","A unit of concentration equal to liter per day divided by milligram per day.","Liter per Day per Milligram per Day | (L/d)/(mg/d) | (L/day)/(mg/day) | (l/d)/(mg/d) | (mL/d)/(ug/d) | (mL/day)/(ug/day) | (ml/d)/(ug/d) | Milliliter per Day per Microgram per Day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054637","Liter per Day per Kilogram per Meter Squared","C120727","A unit of concentration equal to liter per day divided by kilogram per meter squared.","Liter per Day per Kilogram per Meter Squared | (L/d)/(kg/m2) | (L/day)/(kg/m2) | (l/d)/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514755","UC San Diego Moores Cancer Center","C39504","The mission of the UC San Diego Moores Cancer Center is saving lives by transforming cancer prevention, detection and care, and making personalized cancer medicine a reality by creating, translating and disseminating exceptional cancer science and medicine. The Center's major research focus is on the discovery and testing of new agents for cancer prevention, diagnosis, and treatment with a strong emphasis on translational oncology and drug development through relationships with local and regional biotechnology and pharmaceutical companies. It was designated as an NCI cancer center in 1978 and as a comprehensive cancer center in 2001.","UC San Diego Moores Cancer Center | Moores Cancer Center | Rebecca and John Moores UCSD Cancer Center | Rebecca and John Moores University of California at San Diego Cancer Center | The UCSD Cancer Center",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054622","Liter per Hour per Milligram per Kilogram per Day","C120742","A unit of concentration equal to liter per hour divided by milligram per kilogram per day.","Liter per Hour per Milligram per Kilogram per Day | (L/h)/(mg/kg/d) | (L/h)/(mg/kg/day) | (l/h)/(mg/kg/d) | (mL/h)/(ug/kg/d) | (mL/h)/(ug/kg/day) | (ml/h)/(ug/kg/d) | Milliliter per Hour per Microgram per Kilogram per Day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054621","Liter per Hour per Milligram per Kilogram","C120741","A unit of concentration equal to liter per hour divided by milligram per kilogram.","Liter per Hour per Milligram per Kilogram | (L/h)/(mg/kg) | (l/h)/(mg/kg) | (mL/h)/(ug/kg) | (ml/h)/(ug/kg) | Milliliter per Hour per Microgram per Kilogram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054623","Liter per Hour per Milligram per Day","C120740","A unit of concentration equal to liter per hour divided by milligram per day.","Liter per Hour per Milligram per Day | (L/h)/(mg/d) | (L/h)/(mg/day) | (l/h)/(mg/d) | (mL/h)/(ug/d) | (mL/h)/(ug/day) | (ml/h)/(ug/d) | Milliliter per Hour per Microgram per Day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054629","Liter per Hour per Kilogram per Meter Squared","C120739","A unit of concentration equal to liter per hour divided by kilogram per meter squared.","Liter per Hour per Kilogram per Meter Squared | (L/h)/(kg/m2) | (l/h)/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827839","Liter per Microgram per Day","C85665","Liters per microgram per day.","Liter per Microgram per Day | (L/d)/ug | (L/day)/ug | (l/d)/ug | L/day/mcg | L/day/ug | L/mcg/day | L/ug/d | Liter per Microgram per 24 Hours | mL/day/ng | mL/ng/day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827846","Liter per Milligram per Day","C85672","Liters per milligram per day.","Liter per Milligram per Day | (L/d)/mg | (L/day)/mg | (l/d)/mg | (mL/d)/ug | (mL/day)/ug | (ml/d)/ug | L/day/mg | L/mg/d | Liter per Milligram per 24 Hours | Milliliter per Day per Microgram | mL/day/ug | mL/ug/day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054636","Liter per Day per Meter Squared","C120738","A unit of concentration equal to liter per day divided by meter squared.","Liter per Day per Meter Squared | (L/d)/m2 | (L/day)/m2 | (l/d)/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538815","CDISC Questionnaire Category Terminology","C100129","Terminology associated with the questionnaire domain categories of the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire Category Terminology | Category of Questionnaire | QS-QSCAT | QSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2919686","Asthma Control Questionnaire","C122370","A standardized rating scale developed by Juniper et al in 1999, which is used to assess both the adequacy of and change in asthma control. This questionnaire contains 7 items using a 7-point scale.","Asthma Control Questionnaire | ACQ | ACQ01",,,,,,,,,,,,,,,"40483854","Asthma control questionnaire",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937164","Boston University-Boston Medical Center Cancer Center","C157454","A cancer center with the mission of providing a bridge between the clinical oncology and biomedical research communities at the Boston University Medical and Charles River campuses and the Boston Medical Center.","Boston University-Boston Medical Center Cancer Center | BU-BMC | BU-BMC Cancer Center",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937158","Brown University Oncology Research Group","C157456","A cancer research group created in 1994 to coordinate clinical cancer research for Brown University affiliated hospitals, including Rhode Island Hospital, the Miriam Hospital, Roger Williams Medical Center, Memorial Hospital of Rhode Island, and Women & Infants Hospital of Rhode Island, and the Alpert Medical School faculty, with the mission of improving cancer care through the implementation of innovative, multidisciplinary cancer clinical trials.","Brown University Oncology Research Group | BrUOG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937159","NASA Jet Propulsion Laboratory","C157457","A federally funded research facility managed by the California Institute of Technology (Caltech) for the National Aeronautics and Space Administration (NASA) with the primary function of constructing and operating planetary robotic spacecraft.","NASA Jet Propulsion Laboratory | JPL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937154","Tisch Cancer Institute at Mount Sinai","C157459","An NCI-Designated Cancer Center that was established in 2008 as part of the Icahn School of Medicine at Mount Sinai with the mission of advancing the field of cancer research, treatment, and prevention; it employs scientists and physicians with expertise in basic, clinical, and population science research to develop innovative and translational research programs.","Tisch Cancer Institute at Mount Sinai | TCI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937155","Mays Cancer Center","C157460","A cancer center established by UT Health San Antonio in the 1970s that achieved NCI-Designated Cancer Center status in 1991 and is affiliated with MD Anderson Cancer Center.","Mays Cancer Center | Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053498","CDISC SDTM Tumor and Lesion Identification Test Result Terminology","C123650","Terminology associated with the tumor and lesion identification test result codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Tumor and Lesion Identification Test Result Terminology | SDTM-TUIDRS | TUIDRS | Tumor or Lesion Identification Test Results",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641266","Target Nodule Tumor Identification","C103444","The identification of a target tumor located within the liver or spleen, as defined by the International Working Group (IWG) guidelines for lymphoma.","Target Nodule Tumor Identification | TARGET NODULE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641265","Target Nodal Tumor Identification","C103443","The identification of a target tumor located at or near the lymph node.","Target Nodal Tumor Identification | TARGET NODAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641264","Target Extra Nodal Tumor Identification","C103442","The identification of a target tumor located outside of or independent of the lymph node.","Target Extra Nodal Tumor Identification | TARGET EXTRA NODAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552747","Organ of Interest","C150897","The identification of an organ that may contain a tumor, lesion or site of disease, and may be part of the objective assessment of the response to the therapeutic intervention.","Organ of Interest | OOI | Organ Under Study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520465","Non-target Non-enhancing Lesion Identification","C132471","The identification of a tumor or lesion without a well-defined area of unequivocally increased signal intensity on MRI or CT scan images compared with the normal-appearing surrounding tissues, and is not the target of the therapeutic intervention.","Non-target Non-enhancing Lesion Identification | NON-TARGET NON-ENHANCING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520464","Non-Target Nodal Lesion Identification","C132470","The identification of a tumor or lesion located at or near the lymph node that is present at baseline, and is not the target of the therapeutic intervention.","Non-Target Nodal Lesion Identification | NON-TARGET NODAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520463","Non-Target Extra Nodal Lesion Identification","C132469","The identification of a tumor or lesion that is present at baseline, located outside of or independent of any lymph nodes, and is not the target of the therapeutic intervention.","Non-Target Extra Nodal Lesion Identification | NON-TARGET EXTRA NODAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520462","Non-target Enhancing Lesion Identification","C132468","The identification of a tumor or lesion that has a well-defined area of unequivocally increased signal intensity on MRI or CT scan images compared with the normal-appearing surrounding tissues, and is not the target of the therapeutic intervention.","Non-target Enhancing Lesion Identification | NON-TARGET ENHANCING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538912","Non-Measurable Tumor Identification","C103423","The identification of a tumor that is incapable of being measured at baseline.","Non-Measurable Tumor Identification | NON-MEASURABLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526558","New Target Lesion Identification","C139127","The identification of a target tumor, lesion, or site of disease that will be assessed quantitatively over time, and which was not detected at baseline.","New Target Lesion Identification | NEW TARGET | New Index",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526559","New Non-Target Lesion Identification","C139126","The identification of a non-target tumor, lesion, or site of disease that will be assessed qualitatively over time, and which was not detected at baseline.","New Non-Target Lesion Identification | NEW NON-TARGET | New Non-Index",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520456","New Bone Lesion Lesion Identification","C132467","A localized, pathological, or traumatic structural change, damage, deformity, or discontinuity of the bone that has not been previously seen or characterized.","New Bone Lesion Lesion Identification | NEW BONE LESION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541902","Measured Tumor Identification","C103416","The identification of a tumor that is present at baseline and will be quantifiably measured over the course of the study.","Measured Tumor Identification | MEASURED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514895","Resource Informatics","C19268","The field of information science concerned with the analysis and dissemination of medical data through the application of computers to various resource aspects of health care and medicine.  Resources may include databases (drug structures, gene sequences, genealogical data, insurance records, tumor registries), software, cell or tissue banks, or other collections available for use in research.","Resource Informatics | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826800","Adverse Event Reference Identifier","C83209","A character or string used to name, or characterize an adverse event reference.","Adverse Event Reference Identifier | AEREFID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826874","CDISC SDTM Skin Response Test Code Terminology","C112024","Terminology associated with the skin response test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Skin Response Test Code Terminology | SDTM-SRTESTCD | SRTESTCD | Skin Response Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826876","CDISC SDTM Reproductive System Findings Test Code Terminology","C106479","Terminology associated with the reproductive system findings test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Reproductive System Findings Test Code Terminology | RPTESTCD | Reproductive System Findings Test Code | SDTM-RPTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935752","Menses Duration","C156586","The number of days during which menses is expelled from the uterus.","Menses Duration | MENFDUR | Menses Flow Duration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831544","Amount Recovered Infinity Predicted Normalized by Weight","C112228","The cumulative amount recovered extrapolated to infinity, calculated using the predicted value of the last non-zero concentration, divided by the weight.","Amount Recovered Infinity Predicted Normalized by Weight | Amt Rec Infinity Pred Norm by WT | RCAMIFPW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812321","Amount Recovered Infinity Predicted Normalized by Surface Area","C112227","The cumulative amount recovered extrapolated to infinity, calculated using the predicted value of the last non-zero concentration, divided by the surface area.","Amount Recovered Infinity Predicted Normalized by Surface Area | Amt Rec Infinity Pred Norm by SA | RCAMIFPS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831545","Amount Recovered Infinity Predicted Normalized by Body Mass Index","C112226","The cumulative amount recovered extrapolated to infinity, calculated using the predicted value of the last non-zero concentration, divided by the body mass index.","Amount Recovered Infinity Predicted Normalized by Body Mass Index | Amt Rec Infinity Pred Norm by BMI | RCAMIFPB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640729","Amount Recovered Over Dosing Interval Normalized by Surface Area","C102365","The cumulative amount recovered from the specimen type specified in PPSPEC between doses (TAU) divided by surface area.","Amount Recovered Over Dosing Interval Normalized by Surface Area | Amt Rec Over Dosing Interval Norm by SA | RCAMTAUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640728","Amount Recovered Over Dosing Interval Normalized by Body Mass Index","C102364","The cumulative amount recovered from the specimen type specified in PPSPEC between doses (TAU) divided by body mass index.","Amount Recovered Over Dosing Interval Normalized by Body Mass Index | Amt Rec Over Dosing Interval Norm by BMI | RCAMTAUB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640727","Amount Recovered Over Dosing Interval","C102363","The cumulative amount recovered from the specimen type between doses (TAU).","Amount Recovered Over Dosing Interval | Amt Rec Over Dosing Interval | RCAMTAU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827915","Observed Area Under the Curve Percent Extrapolation","C85764","The percentage of the area under the curve (AUC) extrapolated to infinity observed from Tlast to infinity.","Observed Area Under the Curve Percent Extrapolation | AUC %Extrapolation Obs | AUCPEO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827937","Predicted Area Under the Curve Percent Back Extrapolation","C85787","The percentage of the area under the curve (AUC) extrapolated to infinity that was due to back extrapolation to estimate concentration at time zero, based upon predicted values.","Predicted Area Under the Curve Percent Back Extrapolation | AUC %Back Extrapolation Pred | AUCPBEP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827914","Observed Area Under the Curve Percent Back Extrapolation","C85763","The percentage of the area under the curve (AUC) extrapolated to infinity that was due to back extrapolation to estimate concentration at time zero, based upon observed values.","Observed Area Under the Curve Percent Back Extrapolation | AUC %Back Extrapolation Obs | AUCPBEO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555657","Apparent Clearance for Unbound Drug","C154844","The total apparent clearance of the unbound fraction of drug, adjusted for bioavailability.","Apparent Clearance for Unbound Drug | Apparent CL for Unbound Drug | CLFUB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640730","Amount Recovered Over Dosing Interval Normalized by Weight","C102366","The cumulative amount recovered from the specimen type specified in PPSPEC between doses (TAU) divided by weight.","Amount Recovered Over Dosing Interval Normalized by Weight | Amt Rec Over Dosing Interval Norm by WT | RCAMTAUW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984981","AUC from T1 to T2 Normalized by Surface Area","C92314","The area under the curve (AUC) over the interval from T1 to T2 divided by the surface area.","AUC from T1 to T2 Normalized by Surface Area | AUC from T1 to T2 Norm by SA | AUCINTS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984980","AUC from T1 to T2 Normalized by Dose","C92313","The area under the curve (AUC) over the interval from T1 to T2 divided by the dose.","AUC from T1 to T2 Normalized by Dose | AUC from T1 to T2 Norm by Dose | AUCINTD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984979","AUC from T1 to T2 Normalized by Body Mass Index","C92312","The area under the curve (AUC) over the interval from T1 to T2 divided by the body mass index.","AUC from T1 to T2 Normalized by Body Mass Index | AUC from T1 to T2 Norm by BMI | AUCINTB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827761","Area Under the Curve from T1 to T2","C85566","The area under the curve (AUC) from T1 to T2.","Area Under the Curve from T1 to T2 | AUC from T1 to T2 | AUCINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984975","AUC All Normalized by Weight","C92308","The area under the curve (AUC) from the time of dosing to the time of the last observation divided by the weight, regardless of whether the last concentration is measurable or not.","AUC All Normalized by Weight | AUC All Norm by WT | AUCALLW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984974","AUC All Normalized by Surface Area","C92307","The area under the curve (AUC) from the time of dosing to the time of the last observation divided by the surface area, regardless of whether the last concentration is measurable or not.","AUC All Normalized by Surface Area | AUC All Norm by SA | AUCALLS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984973","AUC All Normalized by Dose","C92306","The area under the curve (AUC) from the time of dosing to the time of the last observation divided by the dose, regardless of whether the last concentration is measurable or not.","AUC All Normalized by Dose | AUC All Norm by Dose | AUCALLD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985029","AUC All Normalized by Body Mass Index","C92362","The area under the curve (AUC) from the time of dosing to the time of the last observation divided by the body mass index, regardless of whether the last concentration is measurable or not.","AUC All Normalized by Body Mass Index | AUC All Norm by BMI | AUCALLB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827759","Area Under the Curve All","C85564","The area under the curve (AUC) from the time of dosing to the time of the last observation, regardless of whether the last concentration is measureable or not.","Area Under the Curve All | AUC All | AUCALL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827938","Predicted Area Under the Curve Percent Extrapolation","C85788","The percentage of the area under the curve (AUC) extrapolated to infinity from Tlast based on the predicted value for concentration at Tlast.","Predicted Area Under the Curve Percent Extrapolation | AUC %Extrapolation Pred | AUCPEP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827835","Liter per Gram per Hour","C85658","Liters per gram per hour.","Liter per Gram per Hour | (L/h)/g | (l/h)/g | (mL/h)/mg | (ml/h)/mg | L/g/h | L/h/g | Milliliter per Hour per Milligram | mL/h/mg | mL/mg/h | uL/h/ug | uL/ug/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054625","Liter per Hour per Microgram per Meter Squared per Day","C120749","A unit of concentration equal to liter per hour divided by microgram per meter squared per day.","Liter per Hour per Microgram per Meter Squared per Day | (L/h)/(ug/m2/d) | (L/h)/(ug/m2/day) | (l/h)/(ug/m2/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054624","Liter per Hour per Microgram per Meter Squared","C120748","A unit of concentration equal to liter per hour divided by microgram per meter squared.","Liter per Hour per Microgram per Meter Squared | (L/h)/(ug/m2) | (l/h)/(ug/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054627","Liter per Hour per Microgram per Kilogram per Day","C120747","A unit of concentration equal to liter per hour divided by microgram per kilogram per day.","Liter per Hour per Microgram per Kilogram per Day | (L/h)/(ug/kg/d) | (L/h)/(ug/kg/day) | (l/h)/(ug/kg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054626","Liter per Hour per Microgram per Kilogram","C120746","A unit of concentration equal to liter per hour divided by microgram per kilogram.","Liter per Hour per Microgram per Kilogram | (L/h)/(ug/kg) | (l/h)/(ug/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054628","Liter per Hour per Microgram per Day","C120745","A unit of concentration equal to liter per hour divided by microgram per day.","Liter per Hour per Microgram per Day | (L/h)/(ug/d) | (L/h)/(ug/day) | (l/h)/(ug/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054620","Liter per Hour per Milligram per Meter Squared per Day","C120744","A unit of concentration equal to liter per hour divided by milligram per meter squared per day.","Liter per Hour per Milligram per Meter Squared per Day | (L/h)/(mg/m2/d) | (L/h)/(mg/m2/day) | (l/h)/(mg/m2/d) | (mL/h)/(ug/m2/d) | (mL/h)/(ug/m2/day) | (ml/h)/(ug/m2/d) | Milliliter per Hour per Microgram per Meter Squared per Day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054619","Liter per Hour per Milligram per Meter Squared","C120743","A unit of concentration equal to liter per hour divided by milligram per meter squared.","Liter per Hour per Milligram per Meter Squared | (L/h)/(mg/m2) | (l/h)/(mg/m2) | (mL/h)/(ug/m2) | (ml/h)/(ug/m2) | Milliliter per Hour per Microgram per Meter Squared",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827840","Liter per Microgram per Minute","C85666","Liters per microgram per minute.","Liter per Microgram per Minute | (L/min)/ug | (l/min)/ug | L/mcg/min | L/min/mcg | L/min/ug | L/ug/min | mL/min/ng | mL/ng/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827848","Liter per Milligram per Minute","C85674","Liters per milligram per minute.","Liter per Milligram per Minute | (L/min)/mg | (l/min)/mg | (mL/min)/ug | (ml/min)/ug | L/mg/min | L/min/mg | Milliliter per Minute per Microgram | mL/min/ug | mL/ug/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827836","Liter per Gram per Minute","C85659","Liters per gram per minute.","Liter per Gram per Minute | (L/min)/g | (l/min)/g | (mL/min)/mg | (ml/min)/mg | L/g/min | L/min/g | Milliliter per Minute per Milligram | mL/mg/min | uL/min/ug | uL/ug/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054609","Liter per Minute per Microgram per Meter Squared per Day","C120760","A unit of concentration equal to liter per minute divided by microgram per meter squared per day.","Liter per Minute per Microgram per Meter Squared per Day | (L/min)/(ug/m2/d) | (L/min)/(ug/m2/day) | (l/min)/(ug/m2/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054608","Liter per Minute per Microgram per Meter Squared","C120759","A unit of concentration equal to liter per minute divided by microgram per meter squared.","Liter per Minute per Microgram per Meter Squared | (L/min)/(ug/m2) | (l/min)/(ug/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053751","Liter per Minute per Microgram per Kilogram per Day","C120758","A unit of concentration equal to liter per minute divided by microgram per kilogram per day.","Liter per Minute per Microgram per Kilogram per Day | (L/min)/(ug/kg/d) | (L/min)/(ug/kg/day) | (l/min)/(ug/kg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054610","Liter per Minute per Microgram per Kilogram","C120757","A unit of concentration equal to liter per minute divided by microgram per kilogram.","Liter per Minute per Microgram per Kilogram | (L/min)/(ug/kg) | (l/min)/(ug/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054611","Liter per Minute per Microgram per Day","C120756","A unit of concentration equal to liter per minute divided by microgram per day.","Liter per Minute per Microgram per Day | (L/min)/(ug/d) | (L/min)/(ug/day) | (l/min)/(ug/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054604","Liter per Minute per Milligram per Meter Squared per Day","C120755","A unit of concentration equal to liter per minute divided by milligram per meter squared per day.","Liter per Minute per Milligram per Meter Squared per Day | (L/min)/(mg/m2/d) | (L/min)/(mg/m2/day) | (l/min)/(mg/m2/d) | (mL/min)/(ug/m2/d) | (mL/min)/(ug/m2/day) | (ml/min)/(ug/m2/d) | Milliliter per Minute per Microgram per Meter Squared per Day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054603","Liter per Minute per Milligram per Meter Squared","C120754","A unit of concentration equal to liter per minute divided by milligram per meter squared.","Liter per Minute per Milligram per Meter Squared | (L/min)/(mg/m2) | (l/min)/(mg/m2) | (mL/min)/(ug/m2) | (ml/min)/(ug/m2) | Milliliter per Minute per Microgram per Meter Squared",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054606","Liter per Minute per Milligram per Kilogram per Day","C120753","A unit of concentration equal to liter per minute divided by milligram per kilogram per day.","Liter per Minute per Milligram per Kilogram per Day | (L/min)/(mg/kg/d) | (L/min)/(mg/kg/day) | (l/min)/(mg/kg/d) | (mL/min)/(ug/kg/d) | (mL/min)/(ug/kg/day) | (ml/min)/(ug/kg/d) | Milliliter per Minute per Microgram per Kilogram per Day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054605","Liter per Minute per Milligram per Kilogram","C120752","A unit of concentration equal to liter per minute divided by milligram per kilogram.","Liter per Minute per Milligram per Kilogram | (L/min)/(mg/kg) | (l/min)/(mg/kg) | (mL/min)/(ug/kg) | (ml/min)/(ug/kg) | Milliliter per Minute per Microgram per Kilogram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054607","Liter per Minute per Milligram per Day","C120751","A unit of concentration equal to liter per minute divided by milligram per day.","Liter per Minute per Milligram per Day | (L/min)/(mg/d) | (L/min)/(mg/day) | (l/min)/(mg/d) | (mL/min)/(ug/d) | (mL/min)/(ug/day) | (ml/min)/(ug/d) | Milliliter per Minute per Microgram per Day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054612","Liter per Minute per Kilogram per Meter Squared","C120750","A unit of concentration equal to liter per minute divided by kilogram per meter squared.","Liter per Minute per Kilogram per Meter Squared | (L/min)/(kg/m2) | (l/min)/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827838","Liter per Microgram per Hour","C85662","Liters per microgram per hour.","Liter per Microgram per Hour | (L/h)/ug | (l/h)/ug | L/h/mcg | L/h/ug | L/mcg/h | L/ug/h | mL/h/ng | mL/ng/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827847","Liter per Milligram per Hour","C85673","Liters per milligram per hour.","Liter per Milligram per Hour | (L/h)/mg | (l/h)/mg | (mL/h)/ug | (ml/h)/ug | L/h/mg | L/mg/h | Milliliter per Hour per Microgram | mL/h/ug | mL/ug/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053786","Milliliter per Minute per Meter Squared","C120803","A unit of concentration equal to milliliter per minute divided by meter squared.","Milliliter per Minute per Meter Squared | (mL/min)/m2 | (ml/min)/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054496","Milliliter per Minute per Milligram per Meter Squared per Day","C120796","A unit of concentration equal to milliliter per minute divided by milligram per meter squared per day.","Milliliter per Minute per Milligram per Meter Squared per Day | (mL/min)/(mg/m2/d) | (mL/min)/(mg/m2/day) | (ml/min)/(mg/m2/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050555","Milliliter per Minute per Milligram per Meter Squared","C120795","A unit of concentration equal to milliliter per minute divided by milligram per meter squared.","Milliliter per Minute per Milligram per Meter Squared | (mL/min)/(mg/m2) | (ml/min)/(mg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054497","Milliliter per Minute per Milligram per Kilogram per Day","C120794","A unit of concentration equal to milliliter per minute divided by milligram per kilogram per day.","Milliliter per Minute per Milligram per Kilogram per Day | (mL/min)/(mg/kg/d) | (mL/min)/(mg/kg/day) | (ml/min)/(mg/kg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049709","Milliliter per Minute per Milligram per Kilogram","C120793","A unit of concentration equal to milliliter per minute divided by milligram per kilogram.","Milliliter per Minute per Milligram per Kilogram | (mL/min)/(mg/kg) | (ml/min)/(mg/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054498","Milliliter per Minute per Milligram per Day","C120792","A unit of concentration equal to milliliter per minute divided by milligram per day.","Milliliter per Minute per Milligram per Day | (mL/min)/(mg/d) | (mL/min)/(mg/day) | (ml/min)/(mg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054502","Milliliter per Minute per Kilogram per Meter Squared","C120791","A unit of concentration equal to milliliter per minute divided by kilogram per meter squared.","Milliliter per Minute per Kilogram per Meter Squared | (mL/min)/(kg/m2) | (ml/min)/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054510","Milliliter per Hour per Meter Squared","C120788","A unit of concentration equal to milliliter per hour divided by meter squared.","Milliliter per Hour per Meter Squared | (mL/h)/m2 | (ml/h)/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054504","Milliliter per Hour per Milligram per Meter Squared per Day","C120781","A unit of concentration equal to milliliter per hour divided by milligram per meter squared per day.","Milliliter per Hour per Milligram per Meter Squared per Day | (mL/h)/(mg/m2/d) | (mL/h)/(mg/m2/day) | (ml/h)/(mg/m2/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050603","Milliliter per Hour per Milligram per Meter Squared","C120780","A unit of concentration equal to milliliter per hour divided by milligram per meter squared.","Milliliter per Hour per Milligram per Meter Squared | (mL/h)/(mg/m2) | (ml/h)/(mg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054505","Milliliter per Hour per Milligram per Kilogram per Day","C120779","A unit of concentration equal to milliliter per hour divided by milligram per kilogram per day.","Milliliter per Hour per Milligram per Kilogram per Day | (mL/h)/(mg/kg/d) | (mL/h)/(mg/kg/day) | (ml/h)/(mg/kg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049633","Milliliter per Hour per Milligram per Kilogram","C120778","A unit of concentration equal to milliliter per hour divided by milligram per kilogram.","Milliliter per Hour per Milligram per Kilogram | (mL/h)/(mg/kg) | (ml/h)/(mg/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054506","Milliliter per Hour per Milligram per Day","C120777","A unit of concentration equal to milliliter per hour divided by milligram per day.","Milliliter per Hour per Milligram per Day | (mL/h)/(mg/d) | (mL/h)/(mg/day) | (ml/h)/(mg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054511","Milliliter per Hour per Kilogram per Meter Squared","C120776","A unit of concentration equal to milliliter per hour divided by kilogram per meter squared.","Milliliter per Hour per Kilogram per Meter Squared | (mL/h)/(kg/m2) | (ml/h)/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054517","Milliliter per Day per Meter Squared","C120773","A unit of concentration equal to milliliter per day divided by meter squared.","Milliliter per Day per Meter Squared | (mL/d)/m2 | (mL/day)/m2 | (ml/d)/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054512","Milliliter per Day per Milligram per Meter Squared per Day","C120766","A unit of concentration equal to milliliter per day divided by milligram per meter squared per day.","Milliliter per Day per Milligram per Meter Squared per Day | (mL/d)/(mg/m2/d) | (mL/day)/(mg/m2/day) | (ml/d)/(mg/m2/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050560","Milliliter per Day per Milligram per Meter Squared","C120765","A unit of concentration equal to milliliter per day divided by milligram per meter squared.","Milliliter per Day per Milligram per Meter Squared | (mL/d)/(mg/m2) | (mL/day)/(mg/m2) | (ml/d)/(mg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054513","Milliliter per Day per Milligram per Kilogram per Day","C120764","A unit of concentration equal to milliliter per day divided by milligram per kilogram per day.","Milliliter per Day per Milligram per Kilogram per Day | (mL/d)/(mg/kg/d) | (mL/day)/(mg/kg/day) | (ml/d)/(mg/kg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050587","Milliliter per Day per Milligram per Kilogram","C120763","A unit of concentration equal to milliliter per day divided by milligram per kilogram.","Milliliter per Day per Milligram per Kilogram | (mL/d)/(mg/kg) | (mL/day)/(mg/kg) | (ml/d)/(mg/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054514","Milliliter per Day per Milligram per Day","C120762","A unit of concentration equal to milliliter per day divided by milligram per day.","Milliliter per Day per Milligram per Day | (mL/d)/(mg/d) | (mL/day)/(mg/day) | (ml/d)/(mg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054518","Milliliter per Day per Kilogram per Meter Squared","C120761","A unit of concentration equal to milliliter per day divided by kilogram per meter squared.","Milliliter per Day per Kilogram per Meter Squared | (mL/d)/(kg/m2) | (mL/day)/(kg/m2) | (ml/d)/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899424","Day Times Millimole Per Liter Per Milligram Per Gram Per Day","C117901","Day times millimole per liter, divided by milligram per gram per day.","Day Times Millimole Per Liter Per Milligram Per Gram Per Day | d.mmol/L/(mg/g/d) | d.mmol/l/(mg/g/d) | day*mmol/L/(mg/g/day)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899423","Day Times Millimole Per Liter Per Milligram Per Gram","C117900","Day times millimole per liter, divided by milligram per gram.","Day Times Millimole Per Liter Per Milligram Per Gram | d.mmol/L/(mg/g) | d.mmol/l/(mg/g) | day*mmol/L/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827328","Day Times Millimole per Liter per Kilogram per Meter Squared","C111177","Days times millimoles per liter, divided by kilograms per meter squared.","Day Times Millimole per Liter per Kilogram per Meter Squared | d.mmol/L/(kg/m2) | d.mmol/l/(kg/m2) | day*mmol/L/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827779","Day Times Micromole per Milliliter","C85587","Days times micromoles per milliliter.","Day Times Micromole per Milliliter | d*umol/mL | d.mmol/L | d.mmol/l | day*mcmol/mL | day*mmol/L | mcmol*day/mL | mmol*day/L | umol*day/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830577","Day Times Milligram per Milliliter per Meter Squared","C111176","Days times milligrams per milliliter, divided by meters squared.","Day Times Milligram per Milliliter per Meter Squared | d.mg/mL/m2 | d.mg/ml/m2 | day*mg/mL/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899426","Day Times Milligram Per Milliliter Per Milligram Per Gram Per Day","C117899","Day times milligram per milliliter, divided by milligram per gram per day.","Day Times Milligram Per Milliliter Per Milligram Per Gram Per Day | d.mg/mL/(mg/g/d) | d.mg/ml/(mg/g/d) | day*mg/mL/(mg/g/day)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899425","Day Times Milligram Per Milliliter Per Milligram Per Gram","C117898","Day times milligram per milliliter, divided by milligram per gram.","Day Times Milligram Per Milliliter Per Milligram Per Gram | d.mg/mL/(mg/g) | d.mg/ml/(mg/g) | day*mg/mL/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830578","Day Times Milligram per Milliliter per Kilogram per Meter Squared","C111175","Days times milligrams per milliliter, divided by kilograms per meter squared.","Day Times Milligram per Milliliter per Kilogram per Meter Squared | d.mg/mL/(kg/m2) | d.mg/ml/(kg/m2) | day*mg/mL/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827780","Day Times Milligram per Milliliter","C85588","Days times milligrams per milliliter.","Day Times Milligram per Milliliter | d*mg/mL | d.mg/mL | d.mg/ml | day*g/L | day*mg/mL | day*ug/uL | g*day/L | mg*day/mL | ug*day/uL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830589","Day Times Gram per Milliliter per Meter Squared","C111170","Days times grams per milliliter, divided by meters squared.","Day Times Gram per Milliliter per Meter Squared | d.g/mL/m2 | d.g/ml/m2 | day*g/mL/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830580","Day Times Milligram Per Milliliter Per Gram","C112247","Days times grams per milliliter, divided by kilograms.","Day Times Gram Per Milliliter Per Kilogram | Day Times Milligram Per Milliliter Per Gram | d.g/mL/kg | d.g/ml/kg | d.mg/mL/g | d.mg/ml/g | d.ng/mL/ug | d.ng/ml/ug | d.ug/mL/mg | d.ug/ml/mg | day*g/mL/kg | day*mg/mL/g | day*ng/mL/ug | day*ug/mL/mg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830592","Day Times Gram Per Milliliter Per Gram","C112246","Days times grams per milliliter, divided by grams.","Day Times Gram Per Milliliter Per Gram | d.g/mL/g | d.g/ml/g | day*g/mL/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899415","Day Times gram Per Milliliter Per Milligram Per Gram Per Day","C117897","Day times gram per milliliter, divided by milligram per gram per day.","Day Times gram Per Milliliter Per Milligram Per Gram Per Day | d.g/mL/(mg/g/d) | d.g/ml/(mg/g/d) | day*g/mL/(mg/g/day)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899414","Day Times gram Per Milliliter Per Milligram Per Gram","C117896","Day times gram per milliliter, divided by milligram per gram.","Day Times gram Per Milliliter Per Milligram Per Gram | d.g/mL/(mg/g) | d.g/ml/(mg/g) | day*g/mL/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830590","Day Times Gram per Milliliter per Kilogram per Meter Squared","C111169","Days times grams per milliliter, divided by kilograms per meter squared.","Day Times Gram per Milliliter per Kilogram per Meter Squared | d.g/mL/(kg/m2) | d.g/ml/(kg/m2) | day*g/mL/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827776","Day Times Gram per Milliliter","C85584","Days times grams per milliliter.","Day Times Gram per Milliliter | d*g/mL | d.g/mL | d.g/ml | day*g/mL | day*kg/L | g*day/mL | kg*day/L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830593","Day Times Femtogram per Milliliter per Meter Squared","C111168","Days times femtograms per milliliter, divided by meters squared.","Day Times Femtogram per Milliliter per Meter Squared | d.fg/mL/m2 | d.fg/ml/m2 | day*fg/mL/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830595","Day Times Femtogram Per Milliliter Per Kilogram","C112245","Days times femtograms per milliliter, divided by kilograms.","Day Times Femtogram Per Milliliter Per Kilogram | d.fg/mL/kg | d.fg/ml/kg | day*fg/mL/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830596","Day Times Femtogram Per Milliliter Per Gram","C112244","Days times femtograms per milliliter, divided by grams.","Day Times Femtogram Per Milliliter Per Gram | Day Times Picogram Per Milliliter Per Kilogram | d.fg/mL/g | d.fg/ml/g | d.pg/mL/kg | d.pg/ml/kg | day*fg/mL/g | day*pg/mL/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899432","Day Times Femtogram Per Milliliter Per Milligram Per Gram Per Day","C117895","Day times femtogram per milliliter, divided by milligram per gram per day.","Day Times Femtogram Per Milliliter Per Milligram Per Gram Per Day | d.fg/mL/(mg/g/d) | d.fg/ml/(mg/g/d) | day*fg/mL/(mg/g/day)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899431","Day Times Femtogram Per Milliliter Per Milligram Per Gram","C117894","Day times femtogram per milliliter, divided by milligrams per gram.","Day Times Femtogram Per Milliliter Per Milligram Per Gram | d.fg/mL/(mg/g) | d.fg/ml/(mg/g) | day*fg/mL/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830594","Day Times Femtogram per Milliliter per Kilogram per Meter Squared","C111167","Days times femtograms per milliliter, divided by kilograms per meter squared.","Day Times Femtogram per Milliliter per Kilogram per Meter Squared | d.fg/mL/(kg/m2) | d.fg/ml/(kg/m2) | day*fg/mL/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827775","Day Times Femtogram per Milliliter","C85583","Days times femtograms per milliliter.","Day Times Femtogram per Milliliter | d*fg/mL | d.fg/mL | d.fg/ml | day*fg/mL | day*pg/L | fg*day/mL | pg*day/L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984997","AUMC Infinity Observed Normalized by Body Mass Index","C92330","The area under the first moment curve (AUMC) extrapolated to infinity, based on the last observed concentration divided by the body mass index.","AUMC Infinity Observed Normalized by Body Mass Index | AUMC Infinity Obs Norm by BMI | AUMCIFOB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827916","Observed Area Under the First Moment Curve Infinity","C85765","The area under the first moment curve (AUMC) extrapolated to infinity, based on the last observed concentration.","Observed Area Under the First Moment Curve Infinity | AUMC Infinity Obs | AUMCIFO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827940","Predicted Area Under the First Moment Curve Percent Extrapolation","C85790","The percent of the predicted area under the first moment curve (AUMC) that is extrapolated to infinity.","Predicted Area Under the First Moment Curve Percent Extrapolation | AUMC % Extrapolation Pred | AUMCPEP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827917","Observed Area Under the First Moment Curve Percent Extrapolation","C85766","The percent of the observed area under the first moment curve (AUMC) that is extrapolated to infinity.","Observed Area Under the First Moment Curve Percent Extrapolation | AUMC % Extrapolation Obs | AUMCPEO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555664","Area Under the Curve From Dosing to Last Concentration of Unbound Drug","C154847","The portion of the area under the curve (AUC) from the time of dosing to the last measurable concentration, represented by the unbound fraction of drug. (CDISC)","Area Under the Curve From Dosing to Last Concentration of Unbound Drug | AUC to Last Nonzero Conc, Unbound Drug | AUCLSTUB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984972","AUC Dosing to Last Concentration Normalized by Weight","C92305","The area under the curve (AUC) from the time of dosing to the last measurable concentration divided by the weight.","AUC Dosing to Last Concentration Normalized by Weight | AUC to Last Nonzero Conc Norm by WT | AUCLSTW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984978","AUC Dosing to Last Concentration Normalized by Surface Area","C92311","The area under the curve (AUC) from the time of dosing to the last measurable concentration divided by the surface area.","AUC Dosing to Last Concentration Normalized by Surface Area | AUC to Last Nonzero Conc Norm by SA | AUCLSTS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984977","AUC Dosing to Last Concentration Normalized by Dose","C92310","The area under the curve (AUC) from the time of dosing to the last measurable concentration divided by the dose.","AUC Dosing to Last Concentration Normalized by Dose | AUC to Last Nonzero Conc Norm by Dose | AUCLSTD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984976","AUC Dosing to Last Concentration Normalized by Body Mass Index","C92309","The area under the curve (AUC) from the time of dosing to the last measurable concentration divided by the body mass index.","AUC Dosing to Last Concentration Normalized by Body Mass Index | AUC to Last Nonzero Conc Norm by BMI | AUCLSTB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827760","Area Under the Curve From Dosing to Last Concentration","C85565","The area under the curve (AUC) from the time of dosing to the last measurable concentration.","Area Under the Curve From Dosing to Last Concentration | AUC to Last Nonzero Conc | AUCLST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984992","AUC Over Dosing Interval Normalized by Weight","C92325","The area under the curve (AUC) for the defined interval between doses (TAU) divided by the weight.","AUC Over Dosing Interval Normalized by Weight | AUC Over Dosing Interval Norm by WT | AUCTAUW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984991","AUC Over Dosing Interval Normalized by Surface Area","C92324","The area under the curve (AUC) for the defined interval between doses (TAU) divided by the surface area.","AUC Over Dosing Interval Normalized by Surface Area | AUC Over Dosing Interval Norm by SA | AUCTAUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984990","AUC Over Dosing Interval Normalized by Dose","C92323","The area under the curve (AUC) for the defined interval between doses (TAU) divided by the dose.","AUC Over Dosing Interval Normalized by Dose | AUC Over Dosing Interval Norm by Dose | AUCTAUD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984989","AUC Over Dosing Interval Normalized by Body Mass Index","C92322","The area under the curve (AUC) for the defined interval between doses (TAU) divided by the body mass index.","AUC Over Dosing Interval Normalized by Body Mass Index | AUC Over Dosing Interval Norm by BMI | AUCTAUB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827762","Area Under the Curve Over Dosing Interval","C85567","The area under the curve (AUC) for the defined interval between doses (TAU).","Area Under the Curve Over Dosing Interval | AUC Over Dosing Interval | AUCTAU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555663","Predicted Area Under the Curve Infinity of Unbound Drug","C154846","The portion of predicted AUC to infinity, represented by the unbound fraction of drug. (CDISC)","Predicted Area Under the Curve Infinity of Unbound Drug | AUC Infinity Pred, Unbound Drug | AUCIFPUB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984988","AUC Infinity Predicted Normalized by Weight","C92321","The area under the curve (AUC) extrapolated to infinity from dosing time, based on the predicted last concentration, divided by the weight.","AUC Infinity Predicted Normalized by Weight | AUC Infinity Pred Norm by WT | AUCIFPW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984987","AUC Infinity Predicted Normalized by Surface Area","C92320","The area under the curve (AUC) extrapolated to infinity from dosing time, based on the predicted last concentration, divided by the surface area.","AUC Infinity Predicted Normalized by Surface Area | AUC Infinity Pred Norm by SA | AUCIFPS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827936","Predicted Area Under the Curve Infinity by Dose","C85786","The area under the curve (AUC) extrapolated to infinity from dosing time, based on the predicted last concentration, divided by the dose.","Predicted Area Under the Curve Infinity by Dose | AUC Infinity Pred Norm by Dose | AUCIFPD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984986","AUC Infinity Predicted Normalized by Body Mass Index","C92319","The area under the curve (AUC) extrapolated to infinity from dosing time, based on the predicted last concentration, divided by the body mass index.","AUC Infinity Predicted Normalized by Body Mass Index | AUC Infinity Pred Norm by BMI | AUCIFPB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827935","Predicted Area Under the Curve Infinity","C85785","The area under the curve (AUC) extrapolated to infinity from dosing time, based on the predicted last concentration.","Predicted Area Under the Curve Infinity | AUC Infinity Pred | AUCIFP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555658","Observed Area Under the Curve Infinity of Unbound Drug","C154845","The portion of observed AUC to infinity, represented by the unbound fraction of drug. (CDISC)","Observed Area Under the Curve Infinity of Unbound Drug | AUC Infinity Obs, Unbound Drug | AUCIFOUB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984985","AUC Infinity Observed Normalized by Weight","C92318","The observed area under the curve (AUC) extrapolated to infinity divided by the weight.","AUC Infinity Observed Normalized by Weight | AUC Infinity Obs Norm by WT | AUCIFOW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984984","AUC Infinity Observed Normalized by Surface Area","C92317","The observed area under the curve (AUC) extrapolated to infinity divided by the surface area.","AUC Infinity Observed Normalized by Surface Area | AUC Infinity Obs Norm by SA | AUCIFOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272970","AUC Infinity Observed Normalized by Dose","C96695","The observed area under the curve (AUC) extrapolated to infinity divided by the dose.","AUC Infinity Observed Normalized by Dose | AUC Infinity Obs Norm by Dose | AUCIFOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984983","AUC Infinity Observed Normalized by Body Mass Index","C92316","The observed area under the curve (AUC) extrapolated to infinity divided by the body mass index.","AUC Infinity Observed Normalized by Body Mass Index | AUC Infinity Obs Norm by BMI | AUCIFOB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827912","Observed Area Under the Curve Infinity","C85761","The area under the curve (AUC) extrapolated to infinity from dosing time, based on the last observed concentration.","Observed Area Under the Curve Infinity | AUC Infinity Obs | AUCIFO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984982","AUC from T1 to T2 Normalized by Weight","C92315","The area under the curve (AUC) over the interval from T1 to T2 divided by the weight.","AUC from T1 to T2 Normalized by Weight | AUC from T1 to T2 Norm by WT | AUCINTW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985016","AURC Dosing to Last Concentration Normalized by Weight","C92349","The area under the excretion rate curve (AURC) from time zero to the last measurable rate, divided by the weight.","AURC Dosing to Last Concentration Normalized by Weight | AURC Dosing to Last Conc Norm by WT | AURC to Last Nonzero Rate Norm by WT | AURCLSTW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985015","AURC Dosing to Last Concentration Normalized by Surface Area","C92348","The area under the excretion rate curve (AURC) from time zero to the last measurable rate, divided by the surface area.","AURC Dosing to Last Concentration Normalized by Surface Area | AURC Dosing to Last Conc Norm by SA | AURC to Last Nonzero Rate Norm by SA | AURCLSTS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985014","AURC Dosing to Last Concentration Normalized by Dose","C92347","The area under the excretion rate curve (AURC) from time zero to the last measurable rate, divided by the dose.","AURC Dosing to Last Concentration Normalized by Dose | AURC Dosing to Last Conc Norm by Dose | AURC to Last Nonzero Rate Norm by Dose | AURCLSTD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985013","AURC Dosing to Last Concentration Normalized by Body Mass Index","C92346","The area under the excretion rate curve (AURC) from time zero to the last measurable rate, divided by the body mass index.","AURC Dosing to Last Concentration Normalized by Body Mass Index | AURC Dosing to Last Conc Norm by BMI | AURC to Last Nonzero Rate Norm by BMI | AURCLSTB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985012","AURC All Normalized by Weight","C92345","The area under the excretion rate curve (AURC) from time zero to the last measurable rate divided by the weight.","AURC All Normalized by Weight | AURC All Norm by WT | AURCALLW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985011","AURC All Normalized by Surface Area","C92344","The area under the excretion rate curve (AURC) from time zero to the last measurable rate divided by the surface area.","AURC All Normalized by Surface Area | AURC All Norm by SA | AURCALLS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985010","AURC All Normalized by Dose","C92343","The area under the excretion rate curve (AURC) from time zero to the last measurable rate divided by the dose.","AURC All Normalized by Dose | AURC All Norm by Dose | AURCALLD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985009","AURC All Normalized by Body Mass Index","C92342","The area under the excretion rate curve (AURC) from time zero to the last measurable rate divided by the body mass index.","AURC All Normalized by Body Mass Index | AURC All Norm by BMI | AURCALLB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827985","AURCALL","C85841","The area under the excretion rate curve (AURC) from time zero to the time of the last observation, regardless of whether the last observation is a measurable concentration or not.","Area Under Excretion Rate Curve All | AURC All | AURCALL | Area Under Urinary Excretion Rate Curve All",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827942","AURCPEP","C85792","The area under the excretion rate curve (AURC) from the last predicted non-zero rate value to infinity as a percentage of the area under the excretion rate curve extrapolated to infinity.","Predicted Area Under the Excretion Rate Curve Percent Extrapolation | AURC % Extrapolation Pred | AURCPEP | Predicted Area Under the Urinary Excretion Rate Curve Percent Extrapolation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827919","AURCPEO","C85768","The area under the excretion rate curve (AURC) from the last observed non-zero rate value to infinity as a percentage of the area under the excretion rate curve extrapolated to infinity.","Observed Area Under the Excretion Rate Curve Percent Extrapolation | AURC % Extrapolation Obs | AURCPEO | Observed Area Under the Urinary Excretion Rate Curve Percent Extrapolation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984996","AUMC Dosing to Last Concentration Normalized by Weight","C92329","The area under the moment curve (AUMC) from the time of dosing to the last measurable concentration divided by the weight.","AUMC Dosing to Last Concentration Normalized by Weight | AUMC to Last Nonzero Conc Norm by WT | AUMCLSTW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984995","AUMC Dosing to Last Concentration Normalized by Surface Area","C92328","The area under the moment curve (AUMC) from the time of dosing to the last measurable concentration divided by the surface area.","AUMC Dosing to Last Concentration Normalized by Surface Area | AUMC to Last Nonzero Conc Norm by SA | AUMCLSTS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984994","AUMC Dosing to Last Concentration Normalized by Dose","C92327","The area under the moment curve (AUMC) from the time of dosing to the last measurable concentration divided by the dose.","AUMC Dosing to Last Concentration Normalized by Dose | AUMC to Last Nonzero Conc Norm by Dose | AUMCLSTD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984993","AUMC Dosing to Last Concentration Normalized by Body Mass Index","C92326","The area under the moment curve (AUMC) from the time of dosing to the last measurable concentration divided by the body mass index.","AUMC Dosing to Last Concentration Normalized by Body Mass Index | AUMC to Last Nonzero Conc Norm by BMI | AUMCLSTB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827764","Area Under the First Moment Curve From Dosing to Last Concentration","C85569","The area under the moment curve (AUMC) from the time of dosing to the last measurable concentration.","Area Under the First Moment Curve From Dosing to Last Concentration | AUMC to Last Nonzero Conc | AUMCLST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985008","AUMC Over Dosing Interval Normalized by Weight","C92341","The area under the first moment curve (AUMC) for the defined interval between doses (TAU) divided by the weight.","AUMC Over Dosing Interval Normalized by Weight | AUMC Over Dosing Interval Norm by WT | AUMCTAUW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985007","AUMC Over Dosing Interval Normalized by Surface Area","C92340","The area under the first moment curve (AUMC) for the defined interval between doses (TAU) divided by the surface area.","AUMC Over Dosing Interval Normalized by Surface Area | AUMC Over Dosing Interval Norm by SA | AUMCTAUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985006","AUMC Over Dosing Interval Normalized by Dose","C92339","The area under the first moment curve (AUMC) for the defined interval between doses (TAU) divided by the dose.","AUMC Over Dosing Interval Normalized by Dose | AUMC Over Dosing Interval Norm by Dose | AUMCTAUD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985005","AUMC Over Dosing Interval Normalized by Body Mass Index","C92338","The area under the first moment curve (AUMC) for the defined interval between doses (TAU) divided by the body mass index.","AUMC Over Dosing Interval Normalized by Body Mass Index | AUMC Over Dosing Interval Norm by BMI | AUMCTAUB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827765","Area Under the First Moment Curve Over Dosing Interval","C85570","The area under the first moment curve (AUMC) for the defined interval between doses (TAU).","Area Under the First Moment Curve Over Dosing Interval | AUMC Over Dosing Interval | AUMCTAU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985004","AUMC Infinity Predicted Normalized by Weight","C92337","The area under the first moment curve (AUMC) extrapolated to infinity, based on the last predicted concentration divided by the weight.","AUMC Infinity Predicted Normalized by Weight | AUMC Infinity Pred Norm by WT | AUMCIFPW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985003","AUMC Infinity Predicted Normalized by Surface Area","C92336","The area under the first moment curve (AUMC) extrapolated to infinity, based on the last predicted concentration divided by the surface area.","AUMC Infinity Predicted Normalized by Surface Area | AUMC Infinity Pred Norm by SA | AUMCIFPS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985002","AUMC Infinity Predicted Normalized by Dose","C92335","The area under the first moment curve (AUMC) extrapolated to infinity, based on the last predicted concentration divided by the dose.","AUMC Infinity Predicted Normalized by Dose | AUMC Infinity Pred Norm by Dose | AUMCIFPD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985001","AUMC Infinity Predicted Normalized by Body Mass Index","C92334","The area under the first moment curve (AUMC) extrapolated to infinity, based on the last predicted concentration divided by the body mass index.","AUMC Infinity Predicted Normalized by Body Mass Index | AUMC Infinity Pred Norm by BMI | AUMCIFPB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827939","Predicted Area Under the First Moment Curve Infinity","C85789","The area under the first moment curve (AUMC) extrapolated to infinity, based on the last predicted concentration.","Predicted Area Under the First Moment Curve Infinity | AUMC Infinity Pred | AUMCIFP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985000","AUMC Infinity Observed Normalized by Weight","C92333","The area under the first moment curve (AUMC) extrapolated to infinity, based on the last observed concentration divided by the weight.","AUMC Infinity Observed Normalized by Weight | AUMC Infinity Obs Norm by WT | AUMCIFOW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984999","AUMC Infinity Observed Normalized by Surface Area","C92332","The area under the first moment curve (AUMC) extrapolated to infinity, based on the last observed concentration divided by the surface area.","AUMC Infinity Observed Normalized by Surface Area | AUMC Infinity Obs Norm by SA | AUMCIFOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984998","AUMC Infinity Observed Normalized by Dose","C92331","The area under the first moment curve (AUMC) extrapolated to infinity, based on the last observed concentration divided by the dose.","AUMC Infinity Observed Normalized by Dose | AUMC Infinity Obs Norm by Dose | AUMCIFOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830559","Day Times Picogram per Milliliter per Meter Squared","C111186","Days times picograms per milliliter, divided by meters squared.","Day Times Picogram per Milliliter per Meter Squared | d.pg/mL/m2 | d.pg/ml/m2 | day*pg/mL/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897019","Day Times Picogram Per Milliliter Per Milligram Per Gram Per Day","C117909","Day times picogram per milliliter, divided by milligram per gram per day.","Day Times Picogram Per Milliliter Per Milligram Per Gram Per Day | d.pg/mL/(mg/g/d) | d.pg/ml/(mg/g/d) | day*pg/mL/(mg/g/day)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899418","Day Times Picogram Per Milliliter Per Milligram Per Gram","C117908","Day times picogram per milliliter, divided by milligram per gram.","Day Times Picogram Per Milliliter Per Milligram Per Gram | d.pg/mL/(mg/g) | d.pg/ml/(mg/g) | day*pg/mL/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830560","Day Times Picogram per Milliliter per Kilogram per Meter Squared","C111185","Days times picograms per milliliter, divided by kilograms per meter squared.","Day Times Picogram per Milliliter per Kilogram per Meter Squared | d.pg/mL/(kg/m2) | d.pg/ml/(kg/m2) | day*pg/mL/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827785","Day Times Picogram per Milliliter","C85593","Days times picograms per milliliter.","Day Times Picogram per Milliliter | d*pg/mL | d.pg/mL | d.pg/ml | day*ng/L | day*pg/mL | ng*day/L | pg*day/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830562","Day Times Nanomole per Liter per Meter Squared","C111184","Days times nanomoles per liter, divided by meters squared.","Day Times Nanomole per Liter per Meter Squared | d.nmol/L/m2 | d.nmol/l/m2 | day*nmol/L/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830564","Day Times Nanomole Per Liter Per Kilogram","C112261","Days times nanomoles per liter, divided by kilograms.","Day Times Nanomole Per Liter Per Kilogram | Day Times Picomole Per Liter Per Gram | d.nmol/L/kg | d.nmol/l/kg | d.pmol/L/g | d.pmol/l/g | day*nmol/L/kg | day*pmol/L/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899420","Day Times Nanomole Per Liter Per Milligram Per Gram Per Day","C117907","Day times nanomole per liter, divided by milligram per gram per day.","Day Times Nanomole Per Liter Per Milligram Per Gram Per Day | d.nmol/L/(mg/g/d) | d.nmol/l/(mg/g/d) | day*nmol/L/(mg/g/day)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899419","Day Times Nanomole Per Liter Per Milligram Per Gram","C117906","Day times nanomole per liter, divided by milligram per gram.","Day Times Nanomole Per Liter Per Milligram Per Gram | d.nmol/L/(mg/g) | d.nmol/l/(mg/g) | day*nmol/L/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830563","Day Times Nanomole per Liter per Kilogram per Meter Squared","C111183","Days times nanomoles per liter, divided by kilograms per meter squared.","Day Times Nanomole per Liter per Kilogram per Meter Squared | d.nmol/L/(kg/m2) | d.nmol/l/(kg/m2) | day*nmol/L/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827786","Day Times Picomole per Milliliter","C85594","Days times picomoles per milliliter.","Day Times Picomole per Milliliter | d*pmol/mL | d.nmol/L | d.nmol/l | day*nmol/L | nmol*day/L | pmol*day/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830566","Day Times Nanogram per Milliliter per Meter Squared","C111182","Days times nanograms per milliliter, divided by meters squared.","Day Times Nanogram per Milliliter per Meter Squared | d.ng/mL/m2 | d.ng/ml/m2 | day*ng/mL/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830568","Day Times Nanogram Per Milliliter Per Kilogram","C112259","Days times nanograms per milliliter, divided by kilograms.","Day Times Nanogram Per Milliliter Per Kilogram | Day Times Picogram Per Milliliter Per Gram | d.ng/mL/kg | d.ng/ml/kg | d.pg/mL/g | d.pg/ml/g | day*ng/mL/kg | day*pg/mL/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899422","Day Times Nanogram Per Milliliter Per Milligram Per Gram Per Day","C117905","Day times nanogram per milliliter, divided by milligram per gram per day.","Day Times Nanogram Per Milliliter Per Milligram Per Gram Per Day | d.ng/mL/(mg/g/d) | d.ng/ml/(mg/g/d) | day*ng/mL/(mg/g/day)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899421","Day Times Nanogram Per Milliliter Per Milligram Per Gram","C117904","Day times nanogram per milliliter, divided by milligram per gram.","Day Times Nanogram Per Milliliter Per Milligram Per Gram | d.ng/mL/(mg/g) | d.ng/ml/(mg/g) | day*ng/mL/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830567","Day Times Nanogram per Milliliter per Kilogram per Meter Squared","C111181","Days times nanograms per milliliter, divided by kilograms per meter squared.","Day Times Nanogram per Milliliter per Kilogram per Meter Squared | d.ng/mL/(kg/m2) | d.ng/ml/(kg/m2) | day*ng/mL/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827783","Day Times Nanogram per Milliliter","C85591","Days times nanograms per milliliter.","Day Times Nanogram per Milliliter | d*ng/mL | d.ng/mL | d.ng/ml | day*ng/mL | day*ug/L | ng*day/mL | ug*day/L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830570","Day Times Mole per Liter per Meter Squared","C111180","Days times moles per liter, divided by meters squared.","Day Times Mole per Liter per Meter Squared | d.mol/L/m2 | d.mol/l/m2 | day*mol/L/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830573","Day Times Mole Per Liter Per Gram","C112256","Days times moles per liter, divided by grams.","Day Times Mole Per Liter Per Gram | d.mol/L/g | d.mol/l/g | day*mol/L/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899413","Day Times mole Per Liter Per Milligram Per Gram Per Day","C117903","Day times mole per liter, divided by milligram per gram per day.","Day Times mole Per Liter Per Milligram Per Gram Per Day | d.mol/L/(mg/g/d) | d.mol/l/(mg/g/d) | day*mol/L/(mg/g/day)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899412","Day Times mole Per Liter Per Milligram Per Gram","C117902","Day times mole per liter, divided by milligram per gram.","Day Times mole Per Liter Per Milligram Per Gram | d.mol/L/(mg/g) | d.mol/l/(mg/g) | day*mol/L/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830571","Day Times Mole per Liter per Kilogram per Meter Squared","C111179","Days times moles per liter, divided by kilograms per meter squared.","Day Times Mole per Liter per Kilogram per Meter Squared | d.mol/L/(kg/m2) | d.mol/l/(kg/m2) | day*mol/L/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827781","Day Times Millimole per Milliliter","C85589","Days times millimoles per milliliter.","Day Times Millimole per Milliliter | d*mmol*mL | d.mol/L | d.mol/l | day*mol/L | day*umol/uL | mmol*day/mL | mol*day/L | umol*day/uL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830574","Day Times Millimole per Liter per Meter Squared","C111178","Days times millimoles per liter, divided by meters squared.","Day Times Millimole per Liter per Meter Squared | d.mmol/L/m2 | d.mmol/l/m2 | day*mmol/L/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830576","Day Times Millimole Per Liter Per Gram","C112254","Days times millimoles per liter, divided by grams.","Day Times Millimole Per Liter Per Gram | Day Times Mole Per Liter Per Kilogram | d.mmol/L/g | d.mmol/l/g | d.mol/L/kg | d.mol/l/kg | day*mmol/L/g | day*mol/L/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830556","Day Times Picomole Per Liter Per Kilogram","C112265","Days times picomoles per liter, divided by kilograms.","Day Times Picomole Per Liter Per Kilogram | d.pmol/L/kg | d.pmol/l/kg | day*pmol/L/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899417","Day Times Picomole Per Liter Per Milligram Per Gram Per Day","C117911","Day times picomole per liter, divided by milligram per gram per day.","Day Times Picomole Per Liter Per Milligram Per Gram Per Day | d.pmol/L/(mg/g/d) | d.pmol/l/(mg/g/d) | day*pmol/L/(mg/g/day)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899416","Day Times Picomole Per Liter Per Milligram Per Gram","C117910","Day times picomole per liter, divided by milligram per gram.","Day Times Picomole Per Liter Per Milligram Per Gram | d.pmol/L/(mg/g) | d.pmol/l/(mg/g) | day*pmol/L/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830555","Day Times Picomole per Liter per Kilogram per Meter Squared","C111188","Days times picomoles per liter, divided by kilograms per meter squared.","Day Times Picomole per Liter per Kilogram per Meter Squared | d.pmol/L/(kg/m2) | d.pmol/l/(kg/m2) | day*pmol/L/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830558","Day Times Picomole per Liter","C111187","Days times picomoles per liter.","Day Times Picomole per Liter | d.pmol/L | d.pmol/l | day*pmol/L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830581","Day Times Micromole per Liter per Meter Squared","C111174","Days times micromoles per liter, divided by meters squared.","Day Times Micromole per Liter per Meter Squared | d.umol/L/m2 | d.umol/l/m2 | day*umol/L/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830583","Day Times Micromole Per Liter Per Kilogram","C112251","Days times micromoles per liter, divided by kilograms.","Day Times Micromole Per Liter Per Kilogram | Day Times Nanomole Per Liter Per Gram | d.nmol/L/g | d.nmol/l/g | d.umol/L/kg | d.umol/l/kg | day*nmol/L/g | day*umol/L/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830584","Day Times Micromole Per Liter Per Gram","C112250","Days times micromoles per liter, divided by grams.","Day Times Micromole Per Liter Per Gram | Day Times Millimole Per Liter Per Kilogram | d.mmol/L/kg | d.mmol/l/kg | d.umol/L/g | d.umol/l/g | day*mmol/L/kg | day*umol/L/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899428","Day Times Micromole Per Liter Per Milligram Per Gram Per Day","C117915","Day times micromole per liter, divided by milligram per gram per day.","Day Times Micromole Per Liter Per Milligram Per Gram Per Day | d.umol/L/(mg/g/d) | d.umol/l/(mg/g/d) | day*umol/L/(mg/g/day)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899427","Day Times Micromole Per Liter Per Milligram Per Gram","C117914","Day times micromole per liter, divided by milligram per gram.","Day Times Micromole Per Liter Per Milligram Per Gram | d.umol/L/(mg/g) | d.umol/l/(mg/g) | day*umol/L/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830582","Day Times Micromole per Liter per Kilogram per Meter Squared","C111173","Days times micromoles per liter, divided by kilograms per meter squared.","Day Times Micromole per Liter per Kilogram per Meter Squared | d.umol/L/(kg/m2) | d.umol/l/(kg/m2) | day*umol/L/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827784","Day Times Nanomole per Milliliter","C85592","Days times nanomoles per milliliter.","Day Times Nanomole per Milliliter | d*nmol/mL | d.umol/L | d.umol/l | day*umol/L | nmol*day/mL | umol*day/L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830585","Day Times Microgram per Milliliter per Meter Squared","C111172","Days times micrograms per milliliter, divided by meters squared.","Day Times Microgram per Milliliter per Meter Squared | d.ug/mL/m2 | d.ug/ml/m2 | day*ug/mL/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830587","Day Times Microgram Per Milliliter Per Kilogram","C112249","Days times micrograms per milliliter, divided by kilograms.","Day Times Microgram Per Milliliter Per Kilogram | Day Times Nanogram Per Milliliter Per Gram | d.ng/mL/g | d.ng/ml/g | d.ug/mL/kg | d.ug/ml/kg | day*ng/mL/g | day*ug/mL/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830588","Day Times Microgram Per Milliliter Per Gram","C112248","Days times micrograms per milliliter, divided by grams.","Day Times Microgram Per Milliliter Per Gram | Day Times Milligram Per Milliliter Per Kilogram | d.mg/mL/kg | d.mg/ml/kg | d.ug/mL/g | d.ug/ml/g | day*mg/mL/kg | day*ug/mL/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899430","Day Times Microgram Per Milliliter Per Milligram Per Gram Per Day","C117913","Day times microgram per milliliter, divided by milligram per gram per day.","Day Times Microgram Per Milliliter Per Milligram Per Gram Per Day | d.ug/mL/(mg/g/d) | d.ug/ml/(mg/g/d) | day*ug/mL/(mg/g/day)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899429","Day Times Microgram Per Milliliter Per Milligram Per Gram","C117912","Day times microgram per milliliter, divided by milligram per gram.","Day Times Microgram Per Milliliter Per Milligram Per Gram | d.ug/mL/(mg/g) | d.ug/ml/(mg/g) | day*ug/mL/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830586","Day Times Microgram per Milliliter per Kilogram per Meter Squared","C111171","Days times micrograms per milliliter, divided by kilograms per meter squared.","Day Times Microgram per Milliliter per Kilogram per Meter Squared | d.ug/mL/(kg/m2) | d.ug/ml/(kg/m2) | day*ug/mL/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827778","Day Times Microgram per Milliliter","C85586","Days times micrograms per milliliter.","Day Times Microgram per Milliliter | d.ug/mL | d.ug/ml | day*mcg/mL | day*mg/L | day*ug/mL | mcg*day/mL | mg*day/L | ug*day/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830554","Day Times Picomole per Liter per Meter Squared","C111189","Days times picomoles per liter, divided by meters squared.","Day Times Picomole per Liter per Meter Squared | d.pmol/L/m2 | d.pmol/l/m2 | day*pmol/L/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826307","Serious Event","C82578","An indication or description of a critical circumstance.","Serious Event | SER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021767","Intermediate Care Facility","C99912","A medical center that provides care 24 hours per day. (ACC)","Intermediate Care Facility | INTERMEDIATE CARE FACILITY | Intermediate care | Non-Hospital Intermediate Care Facility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520590","Average Concentration from T1 to T2 Normalized by Surface Area","C132442","The area under the curve over the interval from T1 to T2 divided by the length of the interval and then divided by the surface area. (CDISC)","Average Concentration from T1 to T2 Normalized by Surface Area | Average Conc from T1 to T2 Norm by SA | CAVGINTS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520589","Average Concentration from T1 to T2 Normalized by Dose","C132441","The area under the curve over the interval from T1 to T2 divided by the length of the interval and then divided by the dose. (CDISC)","Average Concentration from T1 to T2 Normalized by Dose | Average Conc from T1 to T2 Norm by Dose | CAVGINTD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520588","Average Concentration from T1 to T2 Normalized by Body Mass Index","C132440","The area under the curve over the interval from T1 to T2 divided by the length of the interval and then divided by the body mass index. (CDISC)","Average Concentration from T1 to T2 Normalized by Body Mass Index | Average Conc from T1 to T2 Norm by BMI | CAVGINTB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520592","Average Concentration from T1 to T2","C132302","The area under the curve over the interval from T1 to T2 divided by the length of the interval.","Average Concentration from T1 to T2 | Average Conc from T1 to T2 | CAVGINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827766","AURCLST","C85571","The area under the excretion rate curve (AURC) from time zero to the time of the last measurable concentration","Area Under the Excretion Rate Curve From Dosing to Last Concentration | AURC to Last Nonzero Rate | AURCLST | Area Under the Urinary Excretion Rate Curve From Dosing to Last Concentration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985028","AURC Infinity Predicted Normalized by Weight","C92361","The area under the excretion rate curve (AURC) extrapolated to infinity, calculated using the predicted value of the last non-zero excretion rate, divided by the weight.","AURC Infinity Predicted Normalized by Weight | AURC Infinity Pred Norm by WT | AURCIFPW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985027","AURC Infinity Predicted Normalized by Surface Area","C92360","The area under the excretion rate curve (AURC) extrapolated to infinity, calculated using the predicted value of the last non-zero excretion rate, divided by the surface area.","AURC Infinity Predicted Normalized by Surface Area | AURC Infinity Pred Norm by SA | AURCIFPS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985026","AURC Infinity Predicted Normalized by Dose","C92359","The area under the excretion rate curve (AURC) extrapolated to infinity, calculated using the predicted value of the last non-zero excretion rate, divided by the dose.","AURC Infinity Predicted Normalized by Dose | AURC Infinity Pred Norm by Dose | AURCIFPD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985025","AURC Infinity Predicted Normalized by Body Mass Index","C92358","The area under the excretion rate curve (AURC) extrapolated to infinity, calculated using the predicted value of the last non-zero excretion rate, divided by the body mass index.","AURC Infinity Predicted Normalized by Body Mass Index | AURC Infinity Pred Norm by BMI | AURCIFPB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827941","AURCIFP","C85791","The area under the urinary excretion rate curve (AURC) extrapolated to infinity, based on the last predicted excretion rate.","Predicted Area Under the Excretion Rate Curve Infinity | AURC Infinity Pred | AURCIFP | Predicted Area Under the Urinary Excretion Rate Curve Infinity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985024","AURC Infinity Observed Normalized by Weight","C92357","The area under the excretion rate curve (AURC) extrapolated to infinity, calculated using the observed value of the last excretion rate, divided by the weight.","AURC Infinity Observed Normalized by Weight | AURC Infinity Obs Norm by WT | AURCIFOW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985023","AURC Infinity Observed Normalized by Surface Area","C92356","The area under the excretion rate curve (AURC) extrapolated to infinity, calculated using the observed value of the last excretion rate, divided by the surface area.","AURC Infinity Observed Normalized by Surface Area | AURC Infinity Obs Norm by SA | AURCIFOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985022","AURC Infinity Observed Normalized by Dose","C92355","The area under the excretion rate curve (AURC) extrapolated to infinity, calculated using the observed value of the last excretion rate, divided by the dose.","AURC Infinity Observed Normalized by Dose | AURC Infinity Obs Norm by Dose | AURCIFOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985021","AURC Infinity Observed Normalized by Body Mass Index","C92354","The area under the excretion rate curve (AURC) extrapolated to infinity, calculated using the observed value of the last excretion rate, divided by the body mass index.","AURC Infinity Observed Normalized by Body Mass Index | AURC Infinity Obs Norm by BMI | AURCIFOB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827918","AURC Infinity Obs","C85767","The area under the excretion rate curve (AURC) extrapolated to infinity, calculated using the observed value of the last excretion rate.","Observed Area Under the Excretion Rate Curve infinity | AURC Infinity Obs | AURCIFO | Observed Area Under the Urinary Excretion Rate Curve infinity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985020","AURC from T1 to T2 Normalized by Weight","C92353","The area under the excretion rate curve (AURC) over the interval from T1 to T2 divided by the weight.","AURC from T1 to T2 Normalized by Weight | AURC from T1 to T2 Norm by WT | AURCINTW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985019","AURC from T1 to T2 Normalized by Surface Area","C92352","The area under the excretion rate curve (AURC) over the interval from T1 to T2 divided by the surface area.","AURC from T1 to T2 Normalized by Surface Area | AURC from T1 to T2 Norm by SA | AURCINTS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985018","AURC from T1 to T2 Normalized by Dose","C92351","The area under the excretion rate curve (AURC) over the interval from T1 to T2 divided by the dose.","AURC from T1 to T2 Normalized by Dose | AURC from T1 to T2 Norm by Dose | AURCINTD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985017","AURC from T1 to T2 Normalized by Body Mass Index","C92350","The area under the excretion rate curve (AURC) over the interval from T1 to T2 divided by the body mass index.","AURC from T1 to T2 Normalized by Body Mass Index | AURC from T1 to T2 Norm by BMI | AURCINTB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827767","AURC from T1 to T2","C85572","The area under the excretion rate curve (AURC) over the interval from T1 to T2.","Area Under the Excretion Rate Curve from T1 to T2 | AURC from T1 to T2 | AURCINT | Area Under the Urinary Excretion Rate Curve from T1 to T2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640759","Trough Concentration Divided by Dose","C102396","The trough concentration divided by dose.","Trough Concentration Divided by Dose | CTROUGHD | Conc Trough by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640758","Trough Concentration Divided by Body Mass Index","C102395","The trough concentration divided by body mass index.","Trough Concentration Divided by Body Mass Index | CTROUGHB | Conc Trough by BMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640757","Trough Concentration","C102394","Concentration at end of dosing interval.","Trough Concentration | CTROUGH | Conc Trough | Concentration Trough | Ctrough | Trough Level",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640734","Concentration Divided by Weight","C102370","The concentration divided by weight.","Concentration Divided by Weight | CONCW | Conc by WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640733","Concentration Divided by Surface Area","C102369","The concentration divided by surface area.","Concentration Divided by Surface Area | CONCS | Conc by SA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640732","Concentration Divided by Dose","C102368","The concentration divided by dose.","Concentration Divided by Dose | CONCD | Conc by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640731","Concentration Divided by Body Mass Index","C102367","The concentration divided by body mass index.","Concentration Divided by Body Mass Index | CONCB | Conc by BMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827768","Average Concentration","C85575","The average measured concentration of a compound in a substance over time.","Average Concentration | CAVG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985037","Average Concentration Normalized by Weight","C92370","AUCTAU divided by TAU and then divided by the weight.","Average Concentration Normalized by Weight | Average Conc Norm by WT | CAVGW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985036","Average Concentration Normalized by Surface Area","C92369","AUCTAU divided by TAU and then divided by the surface area.","Average Concentration Normalized by Surface Area | Average Conc Norm by SA | CAVGS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985035","Average Concentration Normalized by Dose","C92368","AUCTAU divided by TAU and then divided by the dose.","Average Concentration Normalized by Dose | Average Conc Norm by Dose | CAVGD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985034","Average Concentration Normalized by Body Mass Index","C92367","AUCTAU divided by TAU and then divided by the body mass index.","Average Concentration Normalized by Body Mass Index | Average Conc Norm by BMI | CAVGB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520591","Average Concentration from T1 to T2 Normalized by Weight","C132443","The area under the curve over the interval from T1 to T2 divided by the length of the interval and then divided by the weight. (CDISC)","Average Concentration from T1 to T2 Normalized by Weight | Average Conc from T1 to T2 Norm by WT | CAVGINTW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439801","Limited","C142988","Restricted or in amount, size, or extent.","Limited | Limit",,,,,,,,,,,,,,,"4112285","Limited",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937082","OPTI-Surg Toolkit","C157482","A set of pre-surgical questionnaires, including a frailty assessment, designed to provide resource-customized recommendations to address identified vulnerabilities in individual patients.","OPTI-Surg Toolkit | OPTI-Surg | OPTI-Surg Pre-Surgical Frailty Assessment with Resource Recommendations",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937343","Coach","C157483","Someone who teaches a special skill (e.g., how to implement a treatment or intervention).","Coach | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937151","Questionnaire Not Completed Due to Patient Illness","C157464","A response indicating that a questionnaire was not completed due to patient illness.","Questionnaire Not Completed Due to Patient Illness | Patient Illness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937152","Questionnaire Not Completed Due to Institutional Error","C157465","A response indicating that a questionnaire was not completed due to institutional error.","Questionnaire Not Completed Due to Institutional Error | Administrative Error",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826792","Adverse Event Duration","C83200","The period of time from start to finish of an adverse event.","Adverse Event Duration | AEDUR | AdverseEvent.duration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826814","Concomitant Medication Use Duration","C83224","The period of time from start to finish of concomitant medication usage.","Concomitant Medication Use Duration | CMDUR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899223","Exposure as Collected Duration of Treatment","C117500","The period of time from start to finish of the collected exposure.","Exposure as Collected Duration of Treatment | ECDUR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826870","Exposure Duration","C83280","The period of time from start to finish of an exposure.","Exposure Duration | EXDUR | exposure duration | exposure_duration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640760","Trough Concentration Divided by Surface Area","C102397","The trough concentration divided by surface area.","Trough Concentration Divided by Surface Area | CTROUGHS | Conc Trough by SA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086424","Healthcare Encounters Duration","C123949","The period of time from start to finish of a healthcare encounter.","Healthcare Encounters Duration | HODUR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897844","Procedure Duration of Procedure","C117533","The period of time from start to finish of the procedure.","Procedure Duration of Procedure | PRDUR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2703093","Pevonedistat","C77906","A small molecule inhibitor of Nedd8 activating enzyme (NAE) with potential antineoplastic activity. Pevonedistat binds to and inhibits NAE, which may result in the inhibition of tumor cell proliferation and survival. NAE activates Nedd8 (Neural precursor cell expressed, developmentally down-regulated 8), an ubiquitin-like (UBL) protein that modifies cellular targets in a pathway that is parallel to but distinct from the ubiquitin-proteasome pathway (UPP). Functioning in diverse regulatory activities, proteins conjugated to UBLs like Nedd8 typically are not targeted for proteasomal degradation.","Pevonedistat | ((1S,2S,4R)-4-(4-((1S)-2,3-Dihydro-1H-inden-1-ylamino)-7H-pyrrolo(2,3-d)pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl Sulphamate | MLN4924 | Nedd8-Activating Enzyme Inhibitor MLN4924 | PEVONEDISTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704927","ABCG2 wt Allele","C52276","Human ABCG2 wild-type allele is located within 4q22 and is approximately 67 kb in length. This allele, which encodesbroad substrate specificity ATP-binding cassette transporter ABCG2 protein, plays a role in transmembrane transport and transcriptional regulation. The allele is thought to play a role in cellular defense and aberrations are thought to play a role in tumor multidrug resistance.","ABCG2 wt Allele | ABC15 | ABCG2 | ABCP | ATP-Binding Cassette Transporter, Placenta-Specific Gene | ATP-Binding Cassette, Sub-Family G (WHITE), Member 2 (Junior Blood Group) wt Allele | ATP-Binding Cassette, Sub-Family G (WHITE), Member 2 Gene | ATP-Binding Cassette, Subfamily G, Member 2 Gene | BCRP | BCRP1 | BMDP | CD338 | CDw338 | EST157481 | GOUT1 | MRX | MXR | MXR1 | UAQTL1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981433","Clinical Events End Timepoint","C87849","A point in time that indicates the conclusion of a clinical event.","Clinical Events End Timepoint | CEENTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981444","Clinical Events Start Timepoint","C87860","A point in time that indicates the beginning of a clinical event.","Clinical Events Start Timepoint | CESTTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981449","Concomitant Medication Start Timepoint","C87865","A point in time that indicates the beginning of concomitant medication usage.","Concomitant Medication Start Timepoint | CMSTTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899228","Exposure as Collected Dose Description","C117480","A textual description of the agent dose level(s) or range(s) of the collected exposure for a subject, according to the study protocol.","Exposure as Collected Dose Description | ECDOSTXT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826813","Concomitant Medication Dose Description","C83223","A characterization of a dose of concomitant medication.","Concomitant Medication Dose Description | CMDOSTXT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981447","Concomitant Medication End Timepoint","C87863","A point in time that indicates the conclusion of concomitant medication usage.","Concomitant Medication End Timepoint | CMENTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086432","Healthcare Encounters Reference End Time Point End","C123966","A point in time that indicates the conclusion of a healthcare encounter.","Healthcare Encounters Reference End Time Point End | HOENTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086438","Healthcare Encounters Start Timepoint","C124022","A point in time that indicates the beginning of a healthcare encounter.","Healthcare Encounters Start Timepoint | HOSTTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981479","Medical History End Relative to Reference Time Point","C87895","An indicator of the end of the medical history event in relation to a specific point in time.","Medical History End Relative to Reference Time Point | MHENRTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981480","Medical History End Timepoint","C87896","A point in time that indicates the conclusion of a medical history event.","Medical History End Timepoint | MHENTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897848","Procedure Dose Description","C117519","A textual description of the agent dose level(s) or range(s) for the procedure per subject, according to the study protocol.","Procedure Dose Description | PRDOSTXT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897841","Procedure End Reference Time Point","C117542","A point in time that indicates the conclusion of a procedure.","Procedure End Reference Time Point | PRENTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897825","Procedure Start Reference Time Point","C117540","A point in time that indicates the beginning of a procedure.","Procedure Start Reference Time Point | PRSTTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826976","Questionnaire Time Point","C83387","A point in time that questionnaire data is obtained.","Questionnaire Time Point | QSTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981423","Adverse Event End Timepoint","C87839","A point in time that indicates the conclusion of an adverse event.","Adverse Event End Timepoint | AEENTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827773","Concentration Variability Between Dose Time and Tau","C85581","A measurement of variability of concentration for Cmin and Cmax between dose time and Tau.","Concentration Variability Between Dose Time and Tau | FLUCP | Fluctuation%",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642167","Excretion Rate From T1 to T2 Normalized by WT","C105453","The excretion rate over the interval from T1 to T2 divided by the weight.","Excretion Rate From T1 to T2 Normalized by WT | ERINTW | Excret Rate from T1 to T2 Norm by WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642166","Excretion Rate From T1 to T2 Normalized by SA","C105452","The excretion rate over the interval from T1 to T2 divided by the surface area.","Excretion Rate From T1 to T2 Normalized by SA | ERINTS | Excret Rate from T1 to T2 Norm by SA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642165","Excretion Rate From T1 to T2 Normalized by Dose","C105451","The excretion rate over the interval from T1 to T2 divided by the dose.","Excretion Rate From T1 to T2 Normalized by Dose | ERINTD | Excret Rate from T1 to T2 Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642164","Excretion Rate From T1 to T2 Normalized by BMI","C105450","The excretion rate over the interval from T1 to T2 divided by the body mass index.","Excretion Rate From T1 to T2 Normalized by BMI | ERINTB | Excret Rate from T1 to T2 Norm by BMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642163","Excretion Rate From T1 to T2","C105449","The excretion rate over the interval from T1 to T2.","Excretion Rate From T1 to T2 | ERINT | Excret Rate from T1 to T2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986842","Effective Half-life","C95007","Time for the amount of a radionuclide in a living organism to be reduced to half of its value at a given initial time. The amount diminishes due to 2 concurrent processes: radioactive decay, and clearance from the system.","Effective Half-life | EFFHL | Effective Half-Life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827971","Time and Log Concentration Correlation","C85821","The correlation between time (X) and log concentration (Y) for the points used in the estimation of lambda z.","Time and Log Concentration Correlation | CORRXY | Correlation Between TimeX and Log ConcY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522856","Concentration at Half Tmax","C135489","The concentration that occurs at the midpoint time between dosing time and Tmax. (CDISC)","Concentration at Half Tmax | CHTMAX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640761","Trough Concentration Divided by Weight","C102398","The trough concentration divided by weight.","Trough Concentration Divided by Weight | CTROUGHW | Conc Trough by WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827829","Lambda Z","C85652","The first order rate constant associated with the terminal (log-linear) portion of the curve.","Lambda Z | LAMZ | Lambda z",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985053","Initial Concentration Normalized by Weight","C92386","Initial concentration divided by the weight. Given only for bolus IV models.","Initial Concentration Normalized by Weight | C0W | Initial Conc Norm by WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985052","Initial Concentration Normalized by Surface Area","C92385","Initial concentration divided by the surface area. Given only for bolus IV models.","Initial Concentration Normalized by Surface Area | C0S | Initial Conc Norm by SA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985051","Initial Concentration Normalized by Dose","C92384","Initial concentration divided by the dose. Given only for bolus IV models.","Initial Concentration Normalized by Dose | C0D | Initial Conc Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985050","Initial Concentration Normalized by Body Mass Index","C92383","Initial concentration divided by the body mass index. Given only for bolus IV models.","Initial Concentration Normalized by Body Mass Index | C0B | Initial Conc Norm by BMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827826","Initial Concentration","C85644","The first measured concentration of a compound in a substance. In pharmacology, the initial concentration is given only for bolus IV models.","Initial Concentration | C0 | Initial Conc",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898895","Hemodialysis Extraction Ratio","C116213","The determination of the fractional content of a substance removed from the blood during a hemodialysis session.","Hemodialysis Extraction Ratio | HDER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810558","Hemodialysis Clearance","C112287","The rate at which a substance is removed from the blood via hemodialysis.","Hemodialysis Clearance | HDCL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545361","Half-Life TAU","C147483","Half-life calculated within a dosing interval.","Half-Life TAU | TAUHL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827968","Terminal Half Life","C85818","The time required for 50% of a drug to be excreted from a body tissue.","Terminal Half Life | Half-Life Lambda z | LAMZHL | ln2/Lambda z",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522857","Half Tmax","C135491","The midpoint time between dosing time and Tmax. (CDISC)","Half Tmax | HTMAX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523873","Fraction Unbound","C135490","The ratio of free drug concentration to the total concentration.","Fraction Unbound | FU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556362","Fraction Bound","C154840","The ratio of bound drug concentration to the total concentration.","Fraction Bound | FB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935754","Fractional Excretion from T1 to T2","C156576","The fraction of the administered dose that is recovered from the specimen type, over the interval between T1 and T2.","Fractional Excretion from T1 to T2 | FREXINT | Fract Excr from T1 to T2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827831","Lambda Z Time Upper Limit","C85654","The upper limit on timing values to be included in the calculation of Lambda z.","Lambda Z Time Upper Limit | LAMZUL | Lambda z Upper Limit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545359","Lambda z TAU","C147481","The first order rate constant associated with the terminal (log-linear) portion of the curve, calculated within a dosing interval.","Lambda z TAU | LAMZTAU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522858","Lambda Z Span","C135492","The interval of time covered by the data points used in the terminal disposition phase regression analysis, divided by half life; this yields the terminal disposition phase duration expressed as the number of half lives. (CDISC)","Lambda Z Span | LAMZSPN | Lambda z Span",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545357","Lambda z Lower Limit TAU","C147479","The lower limit on time for values to be included in the calculation of Lambda z, calculated within a dosing interval.","Lambda z Lower Limit TAU | LAMZLTAU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827830","Lambda Z Time Lower Limit","C85653","The lower limit on timing values to be included in the calculation of Lambda z.","Lambda Z Time Lower Limit | LAMZLL | Lambda z Lower Limit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347813","Cmax","C70918","This is a measurement that quantifies the maximum concentration of an experimental substance or drug in the plasma or a target organ after dose administration.","Cmax | CMAX | Concentration Maximum | Max Conc | Maximum Concentration | Peak Concentration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985057","Last Concentration Normalized by Weight","C92390","The concentration corresponding to Tlast divided by the weight.","Last Concentration Normalized by Weight | CLSTW | Last Nonzero Conc Norm by WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985056","Last Concentration Normalized by Surface Area","C92389","The concentration corresponding to Tlast divided by the surface area.","Last Concentration Normalized by Surface Area | CLSTS | Last Nonzero Conc Norm by SA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985055","Last Concentration Normalized by Dose","C92388","The concentration corresponding to Tlast divided by the dose.","Last Concentration Normalized by Dose | CLSTD | Last Nonzero Conc Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985054","Last Concentration Normalized by Body Mass Index","C92387","The concentration corresponding to Tlast divided by the body mass index.","Last Concentration Normalized by Body Mass Index | CLSTB | Last Nonzero Conc Norm by BMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827832","Last Concentration","C85655","The final measured concentration of a compound in a substance. In pharmacokinetics, it is the concentration corresponding to Tlast.","Last Concentration | CLST | Last Nonzero Conc",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985061","Last Measurable Excretion Rate Normalized by Weight","C92394","The last measurable (positive) excretion rate divided by the weight.","Last Measurable Excretion Rate Normalized by Weight | ERLSTW | Last Meas Excretion Rate Norm by WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985060","Last Measurable Excretion Rate Normalized by Surface Area","C92393","The last measurable (positive) excretion rate divided by the surface area.","Last Measurable Excretion Rate Normalized by Surface Area | ERLSTS | Last Meas Excretion Rate Norm by SA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985059","Last Measurable Excretion Rate Normalized by Dose","C92392","The last measurable (positive) excretion rate divided by the dose.","Last Measurable Excretion Rate Normalized by Dose | ERLSTD | Last Meas Excretion Rate Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985058","Last Measurable Excretion Rate Normalized by Body Mass Index","C92391","The last measurable (positive) excretion rate divided by the body mass index.","Last Measurable Excretion Rate Normalized by Body Mass Index | ERLSTB | Last Meas Excretion Rate Norm by BMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827833","Last Measurable Observed Excretion Rate","C85656","The last measurable (positive) rate.","Last Measurable Observed Excretion Rate | ERLST | Last Meas Excretion Rate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545360","Lambda z Upper Limit TAU","C147482","The upper limit on time for values to be included in the calculation of Lambda z, calculated within a dosing interval.","Lambda z Upper Limit TAU | LAMZUTAU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985064","Maximum Observed Excretion Rate Normalized by Surface Area","C92397","The maximum observed excretion rate divided by the surface area.","Maximum Observed Excretion Rate Normalized by Surface Area | ERMAXS | Max Excretion Rate Norm by SA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985063","Maximum Observed Excretion Rate Normalized by Dose","C92396","The maximum observed excretion rate divided by the dose.","Maximum Observed Excretion Rate Normalized by Dose | ERMAXD | Max Excretion Rate Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985062","Maximum Observed Excretion Rate Normalized by Body Mass Index","C92395","The maximum observed excretion rate divided by the body mass index.","Maximum Observed Excretion Rate Normalized by Body Mass Index | ERMAXB | Max Excretion Rate Norm by BMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827872","Maximum Observed Excretion Rate","C85699","The maximum observed excretion rate.","Maximum Observed Excretion Rate | ERMAX | Max Excretion Rate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555661","Maximum Concentration of Unbound Drug","C154848","The maximum concentration represented by the unbound fraction of drug, occurring at Tmax. (CDISC)","Maximum Concentration of Unbound Drug | CMAXUB | Max Conc, Unbound Drug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985040","Maximum Concentration Normalized by Weight","C92373","The maximum concentration occurring at Tmax, divided by the weight.","Maximum Concentration Normalized by Weight | CMAXW | Max Conc Norm by WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985039","Maximum Concentration Normalized by Surface Area","C92372","The maximum concentration occurring at Tmax, divided by the surface area.","Maximum Concentration Normalized by Surface Area | CMAXS | Max Conc Norm by SA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827871","Maximum Concentration Dose Normalized","C85698","The maximum observed concentration divided by dose.","Maximum Concentration Dose Normalized | CMAXD | Max Conc Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985038","Maximum Concentration Normalized by Body Mass Index","C92371","The maximum concentration occurring at Tmax, divided by the body mass index.","Maximum Concentration Normalized by Body Mass Index | CMAXB | Max Conc Norm by BMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054561","Mean Residence Time Infinity Predicted by Extravascular Dose","C120725","The mean residence time (MRT) extrapolated to infinity for a substance administered by extravascular dosing, calculated using the predicted value of the last non-zero concentration. Extravascular MRT includes Mean Absorption Time (MAT). (CDISC)","Mean Residence Time Infinity Predicted by Extravascular Dose | MRT Extravasc Infinity Pred | MRTEVIFP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054563","Mean Residence Time Infinity Observed by Extravascular Dose","C120724","The mean residence time (MRT) extrapolated to infinity for a substance administered by extravascular dosing, calculated using the observed value of the last non-zero concentration. Extravascular MRT includes Mean Absorption Time (MAT). (CDISC)","Mean Residence Time Infinity Observed by Extravascular Dose | MRT Extravasc Infinity Obs | MRTEVIFO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985044","Minimum Concentration Normalized by Weight","C92377","The minimum concentration between dose time and dose time plus Tau (at Tmin) divided by the weight.","Minimum Concentration Normalized by Weight | CMINW | Min Conc Norm by WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985043","Minimum Concentration Normalized by Surface Area","C92376","The minimum concentration between dose time and dose time plus Tau (at Tmin) divided by the surface area.","Minimum Concentration Normalized by Surface Area | CMINS | Min Conc Norm by SA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985042","Minimum Concentration Normalized by Dose","C92375","The minimum concentration between dose time and dose time plus Tau (at Tmin) divided by the dose.","Minimum Concentration Normalized by Dose | CMIND | Min Conc Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985041","Minimum Concentration Normalized by Body Mass Index","C92374","The minimum concentration between dose time and dose time plus Tau (at Tmin) divided by the body mass index.","Minimum Concentration Normalized by Body Mass Index | CMINB | Min Conc Norm by BMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827771","Cmin","C85579","The minimum concentration between dose time and dose time plus Tau (at Tmin).","Cmin | CMIN | Min Conc | Minimum Concentration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827973","Time of Maximum Observed Excretion Rate","C85823","TThe midpoint of a collection interval associated with the maximum observed excretion rate.","Time of Maximum Observed Excretion Rate | ERTMAX | Midpoint of Interval of Maximum ER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827772","Collection Interval Midpoint","C85580","The midpoint of collection interval, which is associated with last measureable rate.","Collection Interval Midpoint | ERTLST | Midpoint of Interval of Last Nonzero ER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935764","Metabolite Ratio for AUC Infinity Predicted","C156566","The ratio of AUC infinity predicted for the metabolite to the AUC infinity predicted for the parent analyte.","Metabolite Ratio for AUC Infinity Predicted | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935763","Metabolite Ratio for AUC Infinity Observed","C156565","The ratio of AUC infinity observed for the metabolite to the AUC infinity observed for the parent analyte.","Metabolite Ratio for AUC Infinity Observed | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935762","Metabolite Ratio for AUC Dosing Interval","C156568","The ratio of AUC over dosing interval (TAU) for the metabolite to the AUC over dosing interval (TAU) for the parent analyte.","Metabolite Ratio for AUC Dosing Interval | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935761","Metabolite Ratio AUC Last Nonzero Concentration","C156567","The ratio of AUC to last nonzero concentration for the metabolite to the AUC to last nonzero concentration for the parent analyte.","Metabolite Ratio AUC Last Nonzero Concentration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050090","Mean Absorption Time","C120723","The average time that it takes an exogenous compound to enter the circulation.","Mean Absorption Time | MAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985065","Maximum Observed Excretion Rate Normalized by Weight","C92398","The maximum observed excretion rate divided by the weight.","Maximum Observed Excretion Rate Normalized by Weight | ERMAXW | Max Excretion Rate Norm by WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640747","Percent Recovered from T1 to T2 Normalized by Surface Area","C102384","The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, over the interval between T1 and T2 divided by surface area.","Percent Recovered from T1 to T2 Normalized by Surface Area | Pct Rec from T1 to T2 Norm by SA | RCPCINTS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640746","Percent Recovered from T1 to T2 Normalized by Body Mass Index","C102383","The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, over the interval between T1 and T2 divided by body mass index.","Percent Recovered from T1 to T2 Normalized by Body Mass Index | Pct Rec from T1 to T2 Norm by BMI | RCPCINTB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640745","Percent Recovered from T1 to T2","C102382","The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, over the interval between T1 and T2.","Percent Recovered from T1 to T2 | Pct Rec from T1 to T2 | RCPCINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545358","Number of Points for Lambda z TAU","C147480","The number of time points used in computing Lambda z determined in a dosing interval.","Number of Points for Lambda z TAU | LAMZNTAU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827966","Sum of Lambda Z Timepoints","C85816","The number of time points used in computing Lambda z.","Sum of Lambda Z Timepoints | LAMZNPT | Number of Points for Lambda z",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642171","Nonrenal Clearance Normalized by WT","C105457","The total clearance of a substance from the blood minus the renal clearance divided by the weight.","Nonrenal Clearance Normalized by WT | NRENLCLW | Nonrenal CL Norm by WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642170","Nonrenal Clearance Normalized by SA","C105456","The total clearance of a substance from the blood minus the renal clearance divided by the surface area.","Nonrenal Clearance Normalized by SA | NRENLCLS | Nonrenal CL Norm by SA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642169","Nonrenal Clearance Normalized by Dose","C105455","The total clearance of a substance from the blood minus the renal clearance divided by the dose.","Nonrenal Clearance Normalized by Dose | NRENLCLD | Nonrenal CL Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642168","Nonrenal Clearance Normalized by BMI","C105454","The total clearance of a substance from the blood minus the renal clearance divided by the body mass index.","Nonrenal Clearance Normalized by BMI | NRENLCLB | Nonrenal CL Norm by BMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640739","Nonrenal Clearance","C102376","A measurement of the total clearance rate of a substance from the blood minus the renal clearance rate of that substance.","Nonrenal Clearance | NRENALCL | Nonrenal CL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054558","Mean Residence Time to Last Nonzero Concentration by Intravascular Bolus Dose","C121137","Mean residence time (MRT) from the time of dosing to the time of the last measurable concentration, for a substance administered by intravascular dosing. (CDISC)","Mean Residence Time to Last Nonzero Concentration by Intravascular Bolus Dose | MRT IV Bolus to Last Nonzero Conc | MRTIBLST | Mean Residence Time to Last Nonzero Concentration by Intravascular Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054560","Mean Residence Time Infinity Predicted by Intravascular Bolus Dose","C121136","The mean residence time (MRT) extrapolated to infinity for a substance administered by intravascular dosing, calculated using the predicted value of the last non-zero concentration. (CDISC)","Mean Residence Time Infinity Predicted by Intravascular Bolus Dose | MRT IV Bolus Infinity Pred | MRTIBIFP | Mean Residence Time Infinity Predicted by Intravascular Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054562","Mean Residence Time Infinity Observed by Intravascular Bolus Dose","C121134","The mean residence time (MRT) extrapolated to infinity for a substance administered by intravascular dosing, calculated using the observed value of the last non-zero concentration. (CDISC)","Mean Residence Time Infinity Observed by Intravascular Bolus Dose | MRT IV Bolus Infinity Obs | MRTIBIFO | Mean Residence Time Infinity Observed by Intravascular Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054559","Mean Residence Time to Last Nonzero Concentration by Extravascular Dose","C120726","Mean residence time (MRT) from the time of dosing to the time of the last measurable concentration for a substance administered by extravascular dosing. Extravascular MRT includes Mean Absorption Time (MAT). (CDISC)","Mean Residence Time to Last Nonzero Concentration by Extravascular Dose | MRT Extravasc to Last Nonzero Conc | MRTEVLST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935759","Area Under the Curve Ratio Infinity Predicted","C156577","The ratio of two AUC infinity predicted values.","Area Under the Curve Ratio Infinity Predicted | RAAUCIFP | Ratio AUC Infinity Pred",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935760","Area Under the Curve Ratio Infinity Observed","C156578","The ratio of two AUC infinity observed values.","Area Under the Curve Ratio Infinity Observed | RAAUCIFO | Ratio AUC Infinity Obs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563183","Area Under the Curve Ratio","C156471","The determination of the ratio of one AUC value compared to another AUC value. The measurement may be expressed as a ratio or percentage.","Area Under the Curve Ratio | AUC Ratio | RAAUC | Ratio AUC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827750","Adjusted R Squared","C85553","The goodness of fit statistic for the terminal elimination phase, adjusted for the number of time points used in the estimation of Lambda z.","Adjusted R Squared | R Squared Adjusted | R2ADJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827748","R Squared","C85542","The goodness of fit statistic for the terminal elimination phase.","R Squared | Coefficient of Determination | R2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640744","Peak Trough Ratio","C102381","The ratio of Cmax to Ctrough during a dosing interval.","Peak Trough Ratio | PTROUGHR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640752","Percent Recovered Over Dosing Interval Normalized by Weight","C102389","The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, between doses (TAU) divided by weight.","Percent Recovered Over Dosing Interval Normalized by Weight | Pct Rec Over Dosing Interval Norm by WT | RCPCTAUW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640751","Percent Recovered Over Dosing Interval Normalized by Surface Area","C102388","The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, between doses (TAU) divided by surface area.","Percent Recovered Over Dosing Interval Normalized by Surface Area | Pct Rec Over Dosing Interval Norm by SA | RCPCTAUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640750","Percent Recovered Over Dosing Interval Normalized by Body Mass Index","C102387","The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, between doses (TAU) divided by the body mass index.","Percent Recovered Over Dosing Interval Normalized by Body Mass Index | Pct Rec Over Dosing Interval Norm by BMI | RCPCTAUB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640749","Percent Recovered Over Dosing Interval","C102386","The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, between doses (TAU).","Percent Recovered Over Dosing Interval | Pct Rec Over Dosing Interval | RCPCTAU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828585","Percent Recovered Infinity Predicted Normalized by Weight","C112394","The percentage of the recovered administered dose extrapolated to infinity, calculated using the predicted value of the last non-zero concentration, divided by the weight.","Percent Recovered Infinity Predicted Normalized by Weight | Pct Rec Infinity Pred Norm by WT | RCPCIFPW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812325","Percent Recovered Infinity Predicted Normalized by Surface Area","C112393","The percentage of the recovered administered dose extrapolated to infinity, calculated using the predicted value of the last non-zero concentration, divided by the surface area.","Percent Recovered Infinity Predicted Normalized by Surface Area | Pct Rec Infinity Pred Norm by SA | RCPCIFPS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828586","Percent Recovered Infinity Predicted Normalized by Body Mass Index","C112392","The percentage of the recovered administered dose extrapolated to infinity, calculated using the predicted value of the last non-zero concentration, divided by the body mass index.","Percent Recovered Infinity Predicted Normalized by Body Mass Index | Pct Rec Infinity Pred Norm by BMI | RCPCIFPB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812324","Percent Recovered Infinity Predicted","C112035","The percentage of the recovered administered dose extrapolated to infinity, calculated using the predicted value of the last non-zero concentration.","Percent Recovered Infinity Predicted | Pct Rec Infinity Pred | RCPCIFP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828587","Percent Recovered Infinity Observed Normalized by Weight","C112391","The percentage of the recovered administered dose extrapolated to infinity, calculated using the observed value of the last non-zero concentration, divided by the weight.","Percent Recovered Infinity Observed Normalized by Weight | Pct Rec Infinity Obs Norm by WT | RCPCIFOW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812323","Percent Recovered Infinity Observed Normalized by Surface Area","C112390","The percentage of the recovered administered dose extrapolated to infinity, calculated using the observed value of the last non-zero concentration, divided by the surface area.","Percent Recovered Infinity Observed Normalized by Surface Area | Pct Rec Infinity Obs Norm by SA | RCPCIFOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828588","Percent Recovered Infinity Observed Normalized by Body Mass Index","C112389","The percentage of the recovered administered dose extrapolated to infinity, calculated using the observed value of the last non-zero concentration, divided by the body mass index.","Percent Recovered Infinity Observed Normalized by Body Mass Index | Pct Rec Infinity Obs Norm by BMI | RCPCIFOB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899014","Gram per Milliliter per Microgram per Meter Squared per Day","C119360","A unit of concentration equal to grams per milliliter, divided by micrograms per meter squared per day.","Gram per Milliliter per Microgram per Meter Squared per Day | g/mL/(ug/m2/d) | g/mL/(ug/m2/day) | g/ml/(ug/m2/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812322","Percent Recovered Infinity Observed","C112034","The percentage of the recovered administered dose extrapolated to infinity, calculated using the observed value of the last non-zero concentration.","Percent Recovered Infinity Observed | Pct Rec Infinity Obs | RCPCIFO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899013","Gram per Milliliter per Microgram per Meter Squared","C119359","A unit of concentration equal to grams per milliliter, divided by micrograms per meter squared.","Gram per Milliliter per Microgram per Meter Squared | g/mL/(ug/m2) | g/ml/(ug/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640748","Percent Recovered from T1 to T2 Normalized by Weight","C102385","The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, over the interval between T1 and T2 divided by weight.","Percent Recovered from T1 to T2 Normalized by Weight | Pct Rec from T1 to T2 Norm by WT | RCPCINTW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899016","Gram per Milliliter per Microgram per Kilogram per Day","C119358","A unit of concentration equal to grams per milliliter, divided by micrograms per kilogram per day.","Gram per Milliliter per Microgram per Kilogram per Day | g/mL/(ug/kg/d) | g/mL/(ug/kg/day) | g/ml/(ug/kg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899015","Gram per Milliliter per Microgram per Kilogram","C119357","A unit of concentration equal to grams per milliliter, divided by micrograms per kilogram.","Gram per Milliliter per Microgram per Kilogram | g/mL/(ug/kg) | g/ml/(ug/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890577","Gram per Milliliter per Microgram per Day","C119356","A unit of concentration equal to grams per milliliter, divided by micrograms per day.","Gram per Milliliter per Microgram per Day | g/mL/(ug/d) | g/mL/(ug/day) | g/ml/(ug/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899012","Gram per Milliliter per Milligram per Meter Squared per Day","C119355","A unit of concentration equal to grams per milliliter, divided by milligrams per meter squared per day.","Gram per Milliliter per Milligram per Meter Squared per Day | Milligram per Milliliter per Microgram per Meter Squared per Day | g/mL/(mg/m2/d) | g/mL/(mg/m2/day) | g/ml/(mg/m2/d) | mg/mL/(ug/m2/d) | mg/mL/(ug/m2/day) | mg/ml/(ug/m2/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890589","Milligram per Milliliter per Microgram per Meter Squared","C119354","A unit of concentration equal to grams per milliliter, divided by milligrams per meter squared.","Gram per Milliliter per Milligram per Meter Squared | Milligram per Milliliter per Microgram per Meter Squared | g/mL/(mg/m2) | g/ml/(mg/m2) | mg/mL/(ug/m2) | mg/ml/(ug/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642177","Gram Per Milliliter Per Milligram Per Kilogram Per Day","C105463","A dose calculation unit expressed in grams per milliliter, divided by milligram per kilogram per day.","Gram Per Milliliter Per Milligram Per Kilogram Per Day | Milligram per Milliliter per Microgram per Kilogram per Day | g/mL/(mg/kg/d) | g/mL/(mg/kg/day) | g/ml/(mg/kg/d) | mg/mL/(ug/kg/d) | mg/mL/(ug/kg/day) | mg/ml/(ug/kg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642176","Gram Per Milliliter Per Milligram Per Kilogram","C105462","A dose calculation unit expressed in grams per milliliter, divided by milligram per kilogram.","Gram Per Milliliter Per Milligram Per Kilogram | Milligram per Milliliter per Microgram per Kilogram | g/mL/(mg/kg) | g/ml/(mg/kg) | mg/mL/(ug/kg) | mg/ml/(ug/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890576","Gram per Milliliter per Milligram per Day","C119353","A unit of concentration equal to grams per milliliter, divided by milligrams per day.","Gram per Milliliter per Milligram per Day | Milligram per Milliliter per Microgram per Day | g/mL/(mg/d) | g/mL/(mg/day) | g/ml/(mg/d) | mg/mL/(ug/d) | mg/mL/(ug/day) | mg/ml/(ug/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899019","Gram per Milliliter per Kilogram per Meter Squared","C119352","A unit of concentration equal to grams per milliliter, divided by kilograms per meter squared.","Gram per Milliliter per Kilogram per Meter Squared | g/mL/(kg/m2) | g/ml/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0560021","Gram per Minute","C85602","Grams per minute.","Gram per Minute | g/min | gram/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0560020","Gram per Hour","C85601","Grams per hour.","Gram per Hour | g/h | gram/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899132","Femtogram per Milliliter per Microgram","C119351","A unit of concentration equal to femtogram per milliliter, divided by micrograms.","Femtogram per Milliliter per Microgram | Microgram per Milliliter per Kilogram | Nanogram per Milliliter per Gram | Picogram per Milliliter per Milligram | fg/mL/ug | fg/ml/ug | ng/mL/g | ng/ml/g | pg/mL/mg | pg/ml/mg | ug/mL/kg | ug/ml/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897064","Femtogram per Milliliter per Meter Squared","C119349","A unit of concentration equal to femtogram per milliliter, divided by meters squared.","Femtogram per Milliliter per Meter Squared | fg/mL/m2 | fg/ml/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899138","Femtogram per Milliliter per Kilogram","C119348","A unit of concentration equal to femtogram per milliliter, divided by kilograms.","Femtogram per Milliliter per Kilogram | fg/mL/kg | fg/ml/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899140","Femtogram per Milliliter per Gram","C119347","A unit of concentration equal to femtogram per milliliter, divided by grams.","Femtogram per Milliliter per Gram | Picogram per Milliliter per Kilogram | fg/mL/g | fg/ml/g | pg/mL/kg | pg/ml/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899134","Femtogram per Milliliter per Microgram per Meter Squared per Day","C119346","A unit of concentration equal to femtogram per milliliter, divided by micrograms per meter squared per day.","Femtogram per Milliliter per Microgram per Meter Squared per Day | Picogram per Milliliter per Milligram per Meter Squared per Day | fg/mL/(ug/m2/d) | fg/mL/(ug/m2/day) | fg/ml/(ug/m2/d) | pg/mL/(mg/m2/d) | pg/mL/(mg/m2/day) | pg/ml/(mg/m2/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899133","Femtogram per Milliliter per Microgram per Meter Squared","C119345","A unit of concentration equal to femtogram per milliliter, divided by micrograms per meter squared.","Femtogram per Milliliter per Microgram per Meter Squared | Picogram per Milliliter per Milligram per Meter Squared | fg/mL/(ug/m2) | fg/ml/(ug/m2) | pg/mL/(mg/m2) | pg/ml/(mg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899137","Femtogram per Milliliter per Microgram per Day","C119342","A unit of concentration equal to femtogram per milliliter, divided by micrograms per day.","Femtogram per Milliliter per Microgram per Day | Picogram per Milliliter per Milligram per Day | fg/mL/(ug/d) | fg/mL/(ug/day) | fg/ml/(ug/d) | pg/mL/(mg/d) | pg/mL/(mg/day) | pg/ml/(mg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899128","Femtogram per Milliliter per Milligram per Meter Squared per Day","C119341","A unit of concentration equal to femtogram per milliliter, divided by milligrams per meter squared per day.","Femtogram per Milliliter per Milligram per Meter Squared per Day | fg/mL/(mg/m2/d) | fg/mL/(mg/m2/day) | fg/ml/(mg/m2/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899127","Femtogram per Milliliter per Milligram per Meter Squared","C119340","A unit of concentration equal to femtogram per milliliter, divided by milligrams per meter squared.","Femtogram per Milliliter per Milligram per Meter Squared | fg/mL/(mg/m2) | fg/ml/(mg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899130","Femtogram per Milliliter per Milligram per Kilogram per Day","C119339","A unit of concentration equal to femtogram per milliliter, divided by milligrams per kilogram per day.","Femtogram per Milliliter per Milligram per Kilogram per Day | fg/mL/(mg/kg/d) | fg/mL/(mg/kg/day) | fg/ml/(mg/kg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899129","Femtogram per Milliliter per Milligram per Kilogram","C119338","A unit of concentration equal to femtogram per milliliter, divided by milligrams per kilogram.","Femtogram per Milliliter per Milligram per Kilogram | fg/mL/(mg/kg) | fg/ml/(mg/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899131","Femtogram per Milliliter per Milligram per Day","C119337","A unit of concentration equal to femtogram per milliliter, divided by milligrams per day.","Femtogram per Milliliter per Milligram per Day | fg/mL/(mg/d) | fg/mL/(mg/day) | fg/ml/(mg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899139","Femtogram per Milliliter per Kilogram per Meter Squared","C119336","A unit of concentration equal to femtogram per milliliter, divided by kilograms per meter squared.","Femtogram per Milliliter per Kilogram per Meter Squared | fg/mL/(kg/m2) | fg/ml/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555560","Relative Bioavailability","C154839","The ratio of the amount of drug in the system after administration of a test formulation divided by the drug in the system after reference formulation.","Relative Bioavailability | FREL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935758","Cmax to Cmin Ratio Measurement","C156580","The determination of the ratio of one Cmax value compared to a Cmin value. The measurement may be expressed as a ratio or percentage.","Cmax to Cmin Ratio Measurement | RAMAXMIN | Ratio of CMAX to CMIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935757","Cmax to Cmax Ratio Measurement","C156579","The determination of the ratio of one Cmax value compared to another Cmax value. The measurement may be expressed as a ratio or percentage.","Cmax to Cmax Ratio Measurement | RACMAX | Ratio CMAX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826796","Adverse Event Group Identifier","C83204","A character or string that represents an adverse event group.","Adverse Event Group Identifier | AEGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555660","Renal Clearance for Unbound Drug","C154843","The unbound fraction of drug within the portion of total clearance attributed to the kidneys.","Renal Clearance for Unbound Drug | RNCLUB | Renal CL for Unbound Drug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054072","Renal Clearance for Dose Interval Normalized by Weight","C122337","The clearance of a substance from the blood by the kidneys, calculated using the area under the curve over the dosing interval, divided by the weight.","Renal Clearance for Dose Interval Normalized by Weight | RNCLTAUW | Renal CL for Dose Int Norm by WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054073","Renal Clearance for Dose Interval Normalized by Surface Area","C122336","The clearance of a substance from the blood by the kidneys, calculated using the area under the curve over the dosing interval, divided by the surface area.","Renal Clearance for Dose Interval Normalized by Surface Area | RNCLTAUS | Renal CL for Dose Int Norm by SA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054074","Renal Clearance for Dose Interval Normalized by Dose","C122335","The clearance of a substance from the blood by the kidneys, calculated using the area under the curve over the dosing interval, divided by the dose.","Renal Clearance for Dose Interval Normalized by Dose | RNCLTAUD | Renal CL for Dose Int Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054075","Renal Clearance for Dose Interval Normalized by Body Mass Index","C122334","The clearance of a substance from the blood by the kidneys, calculated using the area under the curve over the dosing interval, divided by the body mass index.","Renal Clearance for Dose Interval Normalized by Body Mass Index | RNCLTAUB | Renal CL for Dose Int Norm by BMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054071","Renal Clearance for Dose Interval","C122050","The clearance of a substance from the blood by the kidneys, calculated using the area under the curve over the dosing interval.","Renal Clearance for Dose Interval | RENCLTAU | Renal CL for Dose Int",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555667","Renal Clearance to Total Clearance Ratio Measurement After Intravenous Dosing","C154850","The portion of total clearance attributed to the kidneys expressed as a percentage, following an intravenous dosing.","Renal Clearance to Total Clearance Ratio Measurement After Intravenous Dosing | CLRPCLIV | Renal CL as Pct CL IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555662","Renal Clearance to Total Clearance Ratio Measurement After Oral Dosing","C154849","The portion of total clearance attributed to the kidneys expressed as a percentage, following an oral dosing.","Renal Clearance to Total Clearance Ratio Measurement After Oral Dosing | CLRPCLEV | Renal CL as Pct CL EV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981434","Clinical Events Group Identifier","C87850","A character or string that represents a clinical event group.","Clinical Events Group Identifier | CEGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826818","Concomitant Medication Group Identifier","C83228","A character or string that represents a concomitant medication group.","Concomitant Medication Group Identifier | CMGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826837","Disposition Group Identifier","C83247","A character or string that represents a disposition event group.","Disposition Group Identifier | DSGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829634","Hour Times Millimole per Liter per Meter Squared","C111221","Hours times millimoles per liter, divided by meters squared.","Hour Times Millimole per Liter per Meter Squared | h*mmol/L/m2 | h.mmol/L/m2 | h.mmol/l/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829636","Hour Times Millimole Per Liter Per Kilogram","C112307","Hours times millimoles per liter, divided by kilograms.","Hour Times Millimole Per Liter Per Kilogram | Hour Times Micromole per liter per Gram | h*mmol/L/kg | h*nmol/L/mg | h*pmol/L/ug | h*umol/L/g | h.mmol/L/kg | h.mmol/l/kg | h.nmol/L/mg | h.nmol/l/mg | h.pmol/L/ug | h.pmol/l/ug | h.umol/L/g | h.umol/l/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829637","Hour times Millimole Per Liter Per Gram","C106530","Hours times millimoles per liter divided by grams.","Hour times Millimole Per Liter Per Gram | Hour Times Mole Per Liter Per Kilogram | h*mmol/L/g | h*mol/L/kg | h.mmol/L/g | h.mmol/l/g | h.mol/L/kg | h.mol/l/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898869","Hour Times Millimole Per Liter Per Milligram Per Gram Per Day","C117923","Hour times millimole per liter, divided by milligram per gram per day.","Hour Times Millimole Per Liter Per Milligram Per Gram Per Day | h*mmol/L/(mg/g/day) | h.mmol/L/(mg/g/d) | h.mmol/l/(mg/g/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898868","Hour Times Millimole Per Liter Per Milligram Per Gram","C117922","Hour times millimole per liter, divided by milligram per gram.","Hour Times Millimole Per Liter Per Milligram Per Gram | h*mmol/L/(mg/g) | h.mmol/L/(mg/g) | h.mmol/l/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829635","Hour Times Millimole per Liter per Kilogram per Meter Squared","C111220","Hours times millimoles per liter, divided by kilograms per meter squared.","Hour Times Millimole per Liter per Kilogram per Meter Squared | h*mmol/L/(kg/m2) | h.mmol/L/(kg/m2) | h.mmol/l/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899218","Exposure as Collected Group Identifier","C117468","A character or string that represents a collected exposure group.","Exposure as Collected Group Identifier | ECGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439397","Hour Times Micromole per Milliliter","C85618","Hours times micromoles per milliliter.","Hour Times Micromole per Milliliter | h*mcmol/mL | h*mmol/L | h*umol/mL | h.mmol/L | h.mmol/l | mcmol*h/mL | mmol*h/L | umol*h/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829638","Hour Times Milligram per Milliliter per Meter Squared","C111219","Hours times milligrams per milliliter, divided by meters squared.","Hour Times Milligram per Milliliter per Meter Squared | h*mg/mL/m2 | h.mg/mL/m2 | h.mg/ml/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642183","Hour Times Milligram Per Milliliter Per Milligram Per Kilogram Per Day","C105469","A dose calculation unit expressed in hours times milligrams per milliliter, divided by milligram per kilogram per day.","Hour Times Milligram Per Milliliter Per Milligram Per Kilogram Per Day | h*mg/mL/(mg/kg/day) | h.mg/mL/(mg/kg/d) | h.mg/ml/(mg/kg/d) | mg*h/mL/(mg/kg/day)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642182","Hour Times Milligram Per Milliliter Per Milligram Per Kilogram","C105468","A dose calculation unit expressed in hours times milligrams per milliliter, divided by milligram per kilogram.","Hour Times Milligram Per Milliliter Per Milligram Per Kilogram | h*mg/mL/(mg/kg) | h.mg/mL/(mg/kg) | h.mg/ml/(mg/kg) | mg*h/mL/(mg/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898870","Hour Times Milligram Per Milliliter Per Milligram Per Gram","C117920","Hour times milligram per milliliter, divided by milligram per gram.","Hour Times Milligram Per Milliliter Per Milligram Per Gram | h*mg/mL/(mg/g) | h.mg/mL/(mg/g) | h.mg/ml/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829639","Hour Times Milligram per Milliliter per Kilogram per Meter Squared","C111218","Hours times milligrams per milliliter, divided by kilograms per meter squared.","Hour Times Milligram per Milliliter per Kilogram per Meter Squared | h*mg/mL/(kg/m2) | h.mg/mL/(kg/m2) | h.mg/ml/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827806","Hour Times Milligram per Milliliter","C85621","Hours times milligrams per milliliter.","Hour Times Milligram per Milliliter | g*h/L | h*g/L | h*mg/mL | h*ug/uL | h.mg/mL | h.mg/ml | mg*h/mL | ug*h/uL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829649","Hour Times Gram per Milliliter per Meter Squared","C111213","Hours times grams per milliliter, divided by meters squared.","Hour Times Gram per Milliliter per Meter Squared | h*g/mL/m2 | h.g/mL/m2 | h.g/ml/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829652","Hour Times Gram Per Milliliter Per Gram","C112300","Hours times grams per milliliter, divided by grams.","Hour Times Gram Per Milliliter Per Gram | h*g/mL/g | h.g/mL/g | h.g/ml/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642179","Hour Times Gram Per Milliliter Per Milligram Per Kilogram Per Day","C105465","A dose calculation unit expressed in hours times grams per milliliter, divided by milligram per kilogram per day.","Hour Times Gram Per Milliliter Per Milligram Per Kilogram Per Day | g*h/mL/(mg/kg/day) | h*g/mL/(mg/kg/day) | h.g/mL/(mg/kg/d) | h.g/ml/(mg/kg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642178","Hour Times Gram Per Milliliter Per Milligram Per Kilogram","C105464","A dose calculation unit expressed in hours times grams per milliliter, divided by milligram per kilogram.","Hour Times Gram Per Milliliter Per Milligram Per Kilogram | g*h/mL/(mg/kg) | h*g/mL/(mg/kg) | h.g/mL/(mg/kg) | h.g/ml/(mg/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896984","Hour Times gram Per Milliliter Per Milligram Per Gram Per Day","C117919","Hour times gram per milliliter, divided by milligram per gram per day.","Hour Times gram Per Milliliter Per Milligram Per Gram Per Day | h*g/mL/(mg/g/day) | h.g/mL/(mg/g/d) | h.g/ml/(mg/g/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898858","Hour Times gram Per Milliliter Per Milligram Per Gram","C117918","Hour times gram per milliliter, divided by milligram per gram.","Hour Times gram Per Milliliter Per Milligram Per Gram | h*g/mL/(mg/g) | h.g/mL/(mg/g) | h.g/ml/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829650","Hour Times Gram per Milliliter per Kilogram per Meter Squared","C111212","Hours times grams per milliliter, divided by kilograms per meter squared.","Hour Times Gram per Milliliter per Kilogram per Meter Squared | h*g/mL/(kg/m2) | h.g/mL/(kg/m2) | h.g/ml/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827800","Hour Times Gram per Milliliter","C85613","Hours times grams per milliliter.","Hour Times Gram per Milliliter | g*h/mL | h*g/mL | h*kg/L | h*mg/uL | h.g/mL | h.g/ml | kg*h/L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829653","Hour Times Femtogram per Milliliter per Meter Squared","C111211","Hours times femtograms per milliliter, divided by meters squared.","Hour Times Femtogram per Milliliter per Meter Squared | h*fg/mL/m2 | h.fg/mL/m2 | h.fg/ml/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829655","Hour Times Femtogram Per Milliliter Per Kilogram","C112299","Hours times femtograms per milliliter, divided by kilograms.","Hour Times Femtogram Per Milliliter Per Kilogram | h*fg/mL/kg | h.fg/mL/kg | h.fg/ml/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898875","Hour Times Femtogram Per Milliliter Per Milligram Per Gram Per Day","C117917","Hour times femtogram per milliliter, divided by milligram per gram per day.","Hour Times Femtogram Per Milliliter Per Milligram Per Gram Per Day | h*fg/mL/(mg/g/day) | h.fg/mL/(mg/g/d) | h.fg/ml/(mg/g/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896985","Hour Times Femtogram Per Milliliter Per Milligram Per Gram","C117916","Hour times femtogram per milliliter, divided by milligram per gram.","Hour Times Femtogram Per Milliliter Per Milligram Per Gram | h*fg/mL/(mg/g) | h.fg/mL/(mg/g) | h.fg/ml/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829654","Hour Times Femtogram per Milliliter per Kilogram per Meter Squared","C111210","Hours times femtograms per milliliter, divided by kilograms per meter squared.","Hour Times Femtogram per Milliliter per Kilogram per Meter Squared | h*fg/mL/(kg/m2) | h.fg/mL/(kg/m2) | h.fg/ml/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826850","Electrocardiogram Group Identifier","C83260","A character or string that represents a electrocardiogram group.","Electrocardiogram Group Identifier | EGGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827798","Hour Times Femtogram per Milliliter","C85611","Hours times femtograms per milliliter.","Hour Times Femtogram per Milliliter | fg*h/mL | h*fg/mL | h*pg/L | h.fg/mL | h.fg/ml | pg*h/L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890578","Gram per Milliliter per Microgram","C119365","A unit of concentration equal to grams per milliliter, divided by micrograms.","Gram per Milliliter per Microgram | g/mL/ug | g/ml/ug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890575","Gram per Milliliter per Milligram","C119364","A unit of concentration equal to grams per milliliter, divided by milligrams.","Gram per Milliliter per Milligram | Milligram per Milliliter per Microgram | g/mL/mg | g/ml/mg | mg/mL/ug | mg/ml/ug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899017","Gram per Milliliter per Meter Squared","C119363","A unit of concentration equal to grams per milliliter, divided by meters squared.","Gram per Milliliter per Meter Squared | g/mL/m2 | g/ml/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899020","Gram per Milliliter per Gram","C119361","A unit of concentration equal to grams per milliliter, divided by grams.","Gram per Milliliter per Gram | Microgram per Milliliter per Microgram | Milligram per Milliliter per Milligram | g/mL/g | g/ml/g | mg/mL/mg | mg/ml/mg | ug/mL/ug | ug/ml/ug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826874","Exposure Group Identifier","C83284","A character or string that represents an exposure group.","Exposure Group Identifier | EXGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981471","Findings About Events or Interventions Group Identifier","C87887","A character or string that represents a findings group.","Findings About Events or Interventions Group Identifier | FAGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086428","Healthcare Encounters Group Identifier","C123971","A character or string that represents a healthcare encounters group.","Healthcare Encounters Group Identifier | HOGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898799","Immunogenicity Specimen Assessments Group Identifier","C117552","A character or string that represents an immunogenicity specimen assessments group.","Immunogenicity Specimen Assessments Group Identifier | ISGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981493","Microbiology Specimen Group Identifier","C87909","A character or string that represents a microbiology specimen group.","Microbiology Specimen Group Identifier | MBGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826922","Medical History Group Identifier","C83332","A character or string that represents a medical history event group.","Medical History Group Identifier | MHGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898372","Microscopic Findings Group Identifier","C117574","A character or string that represents a microscopic findings group.","Microscopic Findings Group Identifier | MIGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898247","Morphology Group Identifier","C117602","A character or string that represents a morphology findings group.","Morphology Group Identifier | MOGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981516","Microbiology Susceptibility Group Identifier","C87932","A character or string that represents a microbiology susceptibility group.","Microbiology Susceptibility Group Identifier | MSGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981541","Pharmacokinetic Concentration Group Identifier","C87958","A character or string that represents a pharmacokinetic concentration group.","Pharmacokinetic Concentration Group Identifier | PCGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826939","Physical Examination Group Identifier","C83349","A character or string that represents a physical examination group.","Physical Examination Group Identifier | PEGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981563","Pharmacokinetic Parameter Group Identifier","C87980","A character or string that represents a pharmacokinetic parameter group.","Pharmacokinetic Parameter Group Identifier | PPGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897839","Procedure Group Identifier","C117507","A character or string that represents a procedure group.","Procedure Group Identifier | PRGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826963","Questionnaire Group Identifier","C83374","A character or string that represents a questionnaire group.","Questionnaire Group Identifier | QSGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897710","Reproductive System Findings Group Identifier","C117637","A character or string that represents a reproductive system findings group.","Reproductive System Findings Group Identifier | RPGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899362","Disease Response Group Identifier","C117393","A character or string that represents a disease response group.","Disease Response Group Identifier | RSGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897439","Subject Status Group Identifier","C117657","A character or string that represents a subject status findings group.","Subject Status Group Identifier | SSGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897277","Tumor Results Group Identifier","C117411","A character or string that represents a tumor results group.","Tumor Results Group Identifier | TRGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897295","Tumor Identifier Group Identifier","C117434","A character or string that represents a tumor identifier group.","Tumor Identifier Group Identifier | TUGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829619","Hour Times Picomole per Liter per Kilogram per Meter Squared","C111230","Hours times picomoles per liter, divided by kilograms per meter squared.","Hour Times Picomole per Liter per Kilogram per Meter Squared | h*pmol/L/(kg/m2) | h.pmol/L/(kg/m2) | h.pmol/l/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827799","Hour Times Femtomole per Milliliter","C85612","Hours times femtomoles per milliliter.","Hour Times Femtomole per Milliliter | fmol*h/mL | h*fmol/mL | h*pmol/L | h.pmol/L | h.pmol/l | pmol*h/L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829622","Hour Times Picogram per Milliliter per Meter Squared","C111229","Hours times picograms per milliliter, divided by meters squared.","Hour Times Picogram per Milliliter per Meter Squared | h*pg/mL/m2 | h.pg/mL/m2 | h.pg/ml/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827820","Hour Times Picogram per Milliliter per Kilogram","C85636","Hours times picograms per milliliter per kilogram.","Hour Times Picogram per Milliliter per Kilogram | Hour Times Femtogram Per Milliliter Per Gram | h*fg/mL/g | h*pg/kg/mL | h*pg/mL/kg | h.fg/mL/g | h.fg/ml/g | h.pg/mL/kg | h.pg/ml/kg | pg*h/kg/mL | pg*h/mL/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642186","Hour Times Picogram Per Milliliter Per Milligram Per Kilogram Per Day","C105472","A dose calculation unit expressed in hours times picograms per milliliter, divided by milligram per kilogram per day.","Hour Times Picogram Per Milliliter Per Milligram Per Kilogram Per Day | h*pg/mL/(mg/kg/day) | h.pg/mL/(mg/kg/d) | h.pg/ml/(mg/kg/d) | pg*h/mL/(mg/kg/day)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642185","Hour Times Picogram Per Milliliter Per Milligram Per Kilogram","C105471","A dose calculation unit expressed in hours times picograms per milliliter, divided by milligram per kilogram.","Hour Times Picogram Per Milliliter Per Milligram Per Kilogram | h*pg/mL/(mg/kg) | h.pg/mL/(mg/kg) | h.pg/ml/(mg/kg) | pg*h/mL/(mg/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898862","Hour Times Picogram Per Milliliter Per Milligram Per Gram Per Day","C117931","Hour times picogram per milliliter, divided by milligram per gram per day.","Hour Times Picogram Per Milliliter Per Milligram Per Gram Per Day | h*pg/mL/(mg/g/day) | h.pg/mL/(mg/g/d) | h.pg/ml/(mg/g/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898861","Hour Times Picogram Per Milliliter Per Milligram Per Gram","C117930","Hour times picogram per milliliter, divided by milligram per gram.","Hour Times Picogram Per Milliliter Per Milligram Per Gram | h*pg/mL/(mg/g) | h.pg/mL/(mg/g) | h.pg/ml/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829623","Hour Times Picogram per Milliliter per Kilogram per Meter Squared","C111228","Hours times picograms per milliliter, divided by kilograms per meter squared.","Hour Times Picogram per Milliliter per Kilogram per Meter Squared | h*pg/mL/(kg/m2) | h.pg/mL/(kg/m2) | h.pg/ml/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827819","Hour Times Picogram per Milliliter","C85635","Hours times picograms per milliliter.","Hour Times Picogram per Milliliter | h*ng/L | h*pg/mL | h.pg/mL | h.pg/ml | ng*h/L | pg*h/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829625","Hour Times Nanomole per Liter per Meter Squared","C111227","Hours times nanomoles per liter, divided by meters squared.","Hour Times Nanomole per Liter per Meter Squared | h*nmol/L/m2 | h.nmol/L/m2 | h.nmol/l/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898865","Hour Times Nanomole Per Liter Per Milligram Per Gram Per Day","C117929","Hour times nanomole per liter, divided by milligram per gram per day.","Hour Times Nanomole Per Liter Per Milligram Per Gram Per Day | h*nmol/L/(mg/g/day) | h.nmol/L/(mg/g/d) | h.nmol/l/(mg/g/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898864","Hour Times Nanomole Per Liter Per Milligram Per Gram","C117928","Hour times nanomole per liter, divided by milligram per gram.","Hour Times Nanomole Per Liter Per Milligram Per Gram | h*nmol/L/(mg/g) | h.nmol/L/(mg/g) | h.nmol/l/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829626","Hour Times Nanomole per Liter per Kilogram per Meter Squared","C111226","Hours times nanomoles per liter, divided by kilograms per meter squared.","Hour Times Nanomole per Liter per Kilogram per Meter Squared | h*nmol/L/(kg/m2) | h.nmol/L/(kg/m2) | h.nmol/l/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439395","Hour Times Picomole per Milliliter","C85640","Hours times picomoles per milliliter.","Hour Times Picomole per Milliliter | h*nmol/L | h*pmol/mL | h.nmol/L | h.nmol/l | nmol*h/L | pmol*h/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827812","Hour Times Nanogram per Milliliter per Milligram","C85627","Hours times nanograms per milliliter per milligram.","Hour Times Nanogram per Milliliter per Milligram | Hour Times Microgram Per Milliliter Per Gram | Hour Times Milligram Per Milliliter Per Kilogram | h*mg/mL/kg | h*ng/mL/mg | h*ng/mg/mL | h*ug/mL/g | h.mg/mL/kg | h.mg/ml/kg | h.ng/mL/mg | h.ng/ml/mg | h.ug/mL/g | h.ug/ml/g | ng*h/mL/mg | ng*h/mg/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829628","Hour Times Nanogram per Milliliter per Meter Squared","C111225","Hours times nanograms per milliliter, divided by meters squared.","Hour Times Nanogram per Milliliter per Meter Squared | h*ng/mL/m2 | h.ng/mL/m2 | h.ng/ml/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827811","Hour Times Nanogram per Milliliter per Kilogram","C85626","Hours times nanograms per milliliter per kilogram.","Hour Times Nanogram per Milliliter per Kilogram | Hour Times Picogram Per Milliliter Per Gram | h*ng/kg/mL | h*ng/mL/kg | h*pg/mL/g | h.ng/mL/kg | h.ng/ml/kg | h.pg/mL/g | h.pg/ml/g | ng*h/kg/mL | ng*h/mL/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829647","Hour Times Microgram Per Milliliter Per Kilogram","C85625","Hours times nanograms per milliliter per gram.","Hour Times Nanogram per Milliliter per Gram | Hour Times Microgram Per Milliliter Per Kilogram | Hour Times Picogram per Milliliter per Milligram | h*ng/g/mL | h*ng/mL/g | h*pg/mL/mg | h*pg/mg/mL | h*ug/mL/kg | h.ng/mL/g | h.ng/ml/g | h.pg/mL/mg | h.pg/ml/mg | h.ug/mL/kg | h.ug/ml/kg | ng*h/g/mL | ng*h/mL/g | pg*h/mL/mg | pg*h/mg/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827814","Hour Times Nanogram per Milliliter per Milligram per Meter Squared","C85629","Hours times nanograms per milliliter per milligram per meter squared.","Hour Times Nanogram per Milliliter per Milligram per Meter Squared | h*ng/mL/(mg/m2) | h*ng/mL/mg/m*m | h*ng/mL/mg/m^2 | h.ng/mL/(mg/m2) | h.ng/ml/(mg/m2) | ng*h/mL/mg/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642184","Hour Times Nanogram Per Milliliter Per Milligram Per Kilogram Per Day","C105470","A dose calculation unit expressed in hours times nanograms per milliliter, divided by milligram per kilogram per day.","Hour Times Nanogram Per Milliliter Per Milligram Per Kilogram Per Day | h*ng/mL/(mg/kg/day) | h.ng/mL/(mg/kg/d) | h.ng/ml/(mg/kg/d) | ng*h/mL/(mg/kg/day)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827813","Hour Times Nanogram per Milliliter per Milligram per Kilogram","C85628","Hours times nanograms per milliliter per milligram per kilogram.","Hour Times Nanogram per Milliliter per Milligram per Kilogram | h*ng/mL/(mg/kg) | h.ng/mL/(mg/kg) | h.ng/ml/(mg/kg) | ng*h/mL/mg/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898867","Hour Times Nanogram Per Milliliter Per Milligram Per Gram Per Day","C117927","Hour times nanogram per milliliter, divided by milligram per gram per day.","Hour Times Nanogram Per Milliliter Per Milligram Per Gram Per Day | h*ng/mL/(mg/g/day) | h.ng/mL/(mg/g/d) | h.ng/ml/(mg/g/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898866","Hour Times Nanogram Per Milliliter Per Milligram Per Gram","C117926","Hour times nanogram per milliliter, divided by milligram per gram.","Hour Times Nanogram Per Milliliter Per Milligram Per Gram | h*ng/mL/(mg/g) | h.ng/mL/(mg/g) | h.ng/ml/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829629","Hour Times Nanogram per Milliliter per Kilogram per Meter Squared","C111224","Hours times nanograms per milliliter, divided by kilograms per meter squared.","Hour Times Nanogram per Milliliter per Kilogram per Meter Squared | h*ng/mL/(kg/m2) | h.ng/mL/(kg/m2) | h.ng/ml/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827809","Hour Times Nanogram per Milliliter","C85624","Hours times nanograms per milliliter.","Hour Times Nanogram per Milliliter | h*ng/mL | h*ug/L | h.ng/mL | h.ng/ml | ng*h/mL | ug*h/L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829630","Hour Times Mole per Liter per Meter Squared","C111223","Hours times moles per liter, divided by meters squared.","Hour Times Mole per Liter per Meter Squared | h*mol/L/m2 | h.mol/L/m2 | h.mol/l/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829633","Hour times Mole Per Liter Per Gram","C106531","Hours times moles per liter divided by grams.","Hour times Mole Per Liter Per Gram | h*mmol/L/mg | h*mol/L/g | h*umol/L/ug | h.mmol/L/mg | h.mmol/l/mg | h.mol/L/g | h.mol/l/g | h.umol/L/ug | h.umol/l/ug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898857","Hour Times mole Per Liter Per Milligram Per Gram Per Day","C117925","Hour times mole per liter, divided by milligram per gram per day.","Hour Times mole Per Liter Per Milligram Per Gram Per Day | h*mol/L/(mg/g/day) | h.mol/L/(mg/g/d) | h.mol/l/(mg/g/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898856","Hour Times mole Per Liter Per Milligram Per Gram","C117924","Hour times mole per liter, divided by milligram per gram.","Hour Times mole Per Liter Per Milligram Per Gram | h*mol/L/(mg/g) | h.mol/L/(mg/g) | h.mol/l/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829631","Hour Times Mole per Liter per Kilogram per Meter Squared","C111222","Hours times moles per liter, divided by kilograms per meter squared.","Hour Times Mole per Liter per Kilogram per Meter Squared | h*mol/L/(kg/m2) | h.mol/L/(kg/m2) | h.mol/l/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827807","Hour Times Millimole per Milliliter","C85622","Hours times millimoles per milliliter.","Hour Times Millimole per Milliliter | h*mmol/mL | h*mol/L | h*umol/uL | h.mol/L | h.mol/l | mmol*h/mL | mol*h/L | umol*h/uL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829658","Hour Squared Times Micromole Per Liter","C106528","Hours squared times micromoles per liter.","Hour Squared Times Micromole Per Liter | h2*umol/L | h2.umol/L | h2.umol/l",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827791","Hour Squared Times Microgram per Milliliter","C85604","Hours squared times micrograms per milliliter.","Hour Squared Times Microgram per Milliliter | h*h*ug/mL | h2*mcg/mL | h2*mg/L | h2*ug/mL | h2.ug/mL | h2.ug/ml | h^2*ug/mL | ug*h2/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829657","Hour Squared Times Picomole Per Liter","C106529","Hours squared times picomoles per liter.","Hour Squared Times Picomole Per Liter | h2*pmol/L | h2.pmol/L | h2.pmol/l",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827796","Hour Squared Times Picogram per Milliliter","C85609","Hours squared times picogram per milliliter.","Hour Squared Times Picogram per Milliliter | h*h*pg/mL | h2*ng/L | h2*pg/mL | h2.pg/mL | h2.pg/ml | h^2*pg/mL | pg*h2/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827797","Hour Squared Times Picomole per Milliliter","C85610","Hours squared times picomoles per milliliter.","Hour Squared Times Picomole per Milliliter | h*h*pmol/mL | h2*nmol/L | h2.nmol/L | h2.nmol/l | h^2*pmol/mL | pmol*h2/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827795","Hour Squared Times Nanogram per Milliliter","C85608","Hours squared times nanograms per milliliter.","Hour Squared Times Nanogram per Milliliter | h*h*ng/mL | h2*ng/mL | h2*ug/L | h2.ng/mL | h2.ng/ml | h^2*ng/mL | ng*h2/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827794","Hour Squared Times Millimole per Milliliter","C85607","Hours squared times millimoles per milliliter.","Hour Squared Times Millimole per Milliliter | h*h*mmol/mL | h2*mol/L | h2*umol/uL | h2.mol/L | h2.mol/l | h^2*mmol/mL | mmol*h2/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827792","Hour Squared Times Micromole per Milliliter","C85605","Hours squared times micromoles per milliliter.","Hour Squared Times Micromole per Milliliter | h*h*umol/mL | h2*mcmol/mL | h2*mmol/L | h2.mmol/L | h2.mmol/l | h^2*umol/mL | umol*h2/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827793","Hour Squared Times Milligram per Milliliter","C85606","Hours squared times milligrams per milliliter.","Hour Squared Times Milligram per Milliliter | h*h*mg/mL | h2*g/L | h2*mg/mL | h2*ug/uL | h2.mg/mL | h2.mg/ml | h^2*mg/mL | mg*h2/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829642","Hour Times Micromole per Liter per Meter Squared","C111217","Hours times micromoles per liter, divided by meters squared.","Hour Times Micromole per Liter per Meter Squared | h*umol/L/m2 | h.umol/L/m2 | h.umol/l/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829644","Hour Times Micromole Per Liter Per Kilogram","C112304","Hours times micromoles per liter, divided by kilograms.","Hour Times Micromole Per Liter Per Kilogram | Hour Times Nanomole per Liter per Gram | h*nmol/L/g | h*umol/L/kg | h.nmol/L/g | h.nmol/l/g | h.umol/L/kg | h.umol/l/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898874","Hour Times Micromole Per Liter Per Milligram Per Gram Per Day","C117937","Hour times micromole per liter, divided by milligram per gram per day.","Hour Times Micromole Per Liter Per Milligram Per Gram Per Day | h*umol/L/(mg/g/day) | h.umol/L/(mg/g/d) | h.umol/l/(mg/g/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898873","Hour Times Micromole Per Liter Per Milligram Per Gram","C117936","Hour times micromole per liter, divided by milligram per gram.","Hour Times Micromole Per Liter Per Milligram Per Gram | h*umol/L/(mg/g) | h.umol/L/(mg/g) | h.umol/l/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829643","Hour Times Micromole per Liter per Kilogram per Meter Squared","C111216","Hours times micromoles per liter, divided by kilograms per meter squared.","Hour Times Micromole per Liter per Kilogram per Meter Squared | h*umol/L/(kg/m2) | h.umol/L/(kg/m2) | h.umol/l/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827817","Hour Times Nanomole per Milliliter","C85632","Hours times nanomoles per milliliter.","Hour Times Nanomole per Milliliter | h*nmol/mL | h*umol/L | h.umol/L | h.umol/l | nmol*h/mL | umol*h/L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827803","Hour Times Microgram per Milliliter per Milligram","C85617","Hours times micrograms per milliliter, divided by milligram.","Hour Times Microgram per Milliliter per Milligram | Hour Times Gram Per Milliliter Per Kilogram | Hour Times Milligram Per Milliliter Per Gram | h*g/mL/kg | h*mcg/mL/mg | h*mg/mL/g | h*ug/mL/mg | h*ug/mg/mL | h.g/mL/kg | h.g/ml/kg | h.mg/mL/g | h.mg/ml/g | h.ug/mL/mg | h.ug/ml/mg | ug*h/mL/mg | ug*h/mg/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829645","Hour Times Microgram per Milliliter per Meter Squared","C111215","Hours times micrograms per milliliter, divided by meters squared.","Hour Times Microgram per Milliliter per Meter Squared | h*ug/mL/m2 | h.ug/mL/m2 | h.ug/ml/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642181","Hour Times Microgram Per Milliliter Per Milligram Per Kilogram Per Day","C105467","A dose calculation unit expressed in hours times micrograms per milliliter, divided by milligram per kilogram per day.","Hour Times Microgram Per Milliliter Per Milligram Per Kilogram Per Day | h*ng/mL/(ug/kg/day) | h*ug/mL/(mg/kg/day) | h.ug/mL/(mg/kg/d) | h.ug/ml/(mg/kg/d) | ug*h/mL/(mg/kg/day)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642180","Hour Times Microgram Per Milliliter Per Milligram Per Kilogram","C105466","A dose calculation unit expressed in hours times micrograms per milliliter, divided by milligram per kilogram.","Hour Times Microgram Per Milliliter Per Milligram Per Kilogram | h*ug/mL/(mg/kg) | h.ug/mL/(mg/kg) | h.ug/ml/(mg/kg) | ug*h/mL/(mg/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890573","Hour Times Microgram Per Milliliter Per Milligram Per Gram Per Day","C117935","Hour times microgram per milliliter, divided by milligram per gram per day.","Hour Times Microgram Per Milliliter Per Milligram Per Gram Per Day | h*ug/mL/(mg/g/day) | h.ug/mL/(mg/g/d) | h.ug/ml/(mg/g/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890574","Hour Times Microgram Per Milliliter Per Milligram Per Gram","C117934","Hour times microgram per milliliter, divided by milligram per gram.","Hour Times Microgram Per Milliliter Per Milligram Per Gram | h*ug/mL/(mg/g) | h.ug/mL/(mg/g) | h.ug/ml/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829646","Hour Times Microgram per Milliliter per Kilogram per Meter Squared","C111214","Hours times micrograms per milliliter, divided by kilograms per meter squared.","Hour Times Microgram per Milliliter per Kilogram per Meter Squared | h*ug/mL/(kg/m2) | h.ug/mL/(kg/m2) | h.ug/ml/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827802","Hour Times Microgram per Milliliter","C85615","Hours times micrograms per milliliter.","Hour Times Microgram per Milliliter | h*mcg/mL | h*mg/L | h*ng/uL | h*ug/mL | h.ug/mL | h.ug/ml | mcg*h/mL | mg*h/L | ng*h/uL | ug*h/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829618","Hour Times Picomole per Liter per Meter Squared","C111231","Hours times picomoles per liter, divided by meters squared.","Hour Times Picomole per Liter per Meter Squared | h*pmol/L/m2 | h.pmol/L/m2 | h.pmol/l/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829620","Hour Times Picomole Per Liter Per Kilogram","C112311","Hours times picomoles per liter, divided by kilograms.","Hour Times Picomole Per Liter Per Kilogram | h*pmol/L/kg | h.pmol/L/kg | h.pmol/l/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829621","Hour times Picomole Per Liter Per Gram","C106532","Hours times picomoles per liter divided by grams.","Hour times Picomole Per Liter Per Gram | Hour Times Nanomole Per Liter Per Kilogram | h*nmol/L/kg | h*pmol/L/g | h.nmol/L/kg | h.nmol/l/kg | h.pmol/L/g | h.pmol/l/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898860","Hour Times Picomole Per Liter Per Milligram Per Gram Per Day","C117933","Hour times picomole per liter, divided by milligram per gram per day.","Hour Times Picomole Per Liter Per Milligram Per Gram Per Day | h*pmol/L/(mg/g/day) | h.pmol/L/(mg/g/d) | h.pmol/l/(mg/g/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898859","Hour Times Picomole Per Liter Per Milligram Per Gram","C117932","Hour times picomole per liter, divided by milligram per gram.","Hour Times Picomole Per Liter Per Milligram Per Gram | h*pmol/L/(mg/g) | h.pmol/L/(mg/g) | h.pmol/l/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827803","Total Body Clearance by Fraction of Dose for Dose Interval Normalized by Dose","C114226","The total body clearance for extravascular administration for dose interval based on the fraction of dose absorbed and divided by the dose.","Total Body Clearance by Fraction of Dose for Dose Interval Normalized by Dose | CLFTAUD | Total CL by F for Dose Int Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827804","Total Body Clearance by Fraction of Dose for Dose Interval Normalized by Body Mass Index","C114227","The total body clearance for extravascular administration for dose interval based on the fraction of dose absorbed and divided by the body mass index.","Total Body Clearance by Fraction of Dose for Dose Interval Normalized by Body Mass Index | CLFTAUB | Total CL by F for Dose Int Norm by BMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815228","Total Body Clearance by Fraction of Dose for Dose Interval","C114121","The total body clearance for extravascular administration for dose interval, where F is the fraction of dose absorbed.","Total Body Clearance by Fraction of Dose for Dose Interval | CLFTAU | Total CL by F for Dose Int",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827974","Time until First Nonzero Concentration","C85824","The time prior to the first measurable (non-zero) concentration.","Time until First Nonzero Concentration | TLAG | Time Until First Nonzero Conc",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827972","Time of Last Nonzero Concentration","C85822","The time of the last measurable (positive) concentration.","Time of Last Nonzero Concentration | TLST | Time of Last Nonzero Conc",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827975","Tmin","C85825","The time of minimum concentration sampled during a dosing interval.","Tmin | TMIN | Time of CMIN | Time of CMIN Observation | Time of Minimum Concentration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348796","Tmax","C70919","The time it takes to reach the maximum concentration (Cmax) of an exogenous compound or drug in the plasma or a tissue after a dose is administered.","Tmax | TMAX | Time of CMAX | Time of CMAX Observation | Time of Maximum Concentration | Time to Maximum Concentration | Time to Peak Concentration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827967","Sum Urine Volume","C85817","The sum of urine volumes that are collected over time.","Sum Urine Volume | Sum of Urine Vol | VOLPK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053989","Stationarity Ratio Area Under the Curve","C122338","The area under the curve (AUCTAU) at steady state divided by the area under the curve extrapolated to infinity for the initial dosing interval.","Stationarity Ratio Area Under the Curve | SRAUC | Stationarity Ratio AUC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642175","Renal Clearance Normalized by WT","C105461","The rate at which a substance is removed from the blood via the kidneys, divided by the weight.","Renal Clearance Normalized by WT | RENALCLW | Renal CL Norm by WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642174","Renal Clearance Normalized by SA","C105460","The rate at which a substance is removed from the blood via the kidneys, divided by the surface area.","Renal Clearance Normalized by SA | RENALCLS | Renal CL Norm by SA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642173","Renal Clearance Normalized by Dose","C105459","The rate at which a substance is removed from the blood via the kidneys, divided by the dose.","Renal Clearance Normalized by Dose | RENALCLD | Renal CL Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642172","Renal Clearance Normalized by BMI","C105458","The rate at which a substance is removed from the blood via the kidneys, divided by the body mass index.","Renal Clearance Normalized by BMI | RENALCLB | Renal CL Norm by BMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054068","Renal Clearance from T1 to T2 Normalized by Weight","C122333","The clearance of a substance from the blood by the kidneys over the interval from T1 to T2 divided by the weight.","Renal Clearance from T1 to T2 Normalized by Weight | RNCLINTW | Renal CL from T1 to T2 Norm by WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050553","Renal Clearance from T1 to T2 Normalized by Surface Area","C122332","The clearance of a substance from the blood by the kidneys over the interval from T1 to T2 divided by the surface area.","Renal Clearance from T1 to T2 Normalized by Surface Area | RNCLINTS | Renal CL from T1 to T2 Norm by SA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054069","Renal Clearance from T1 to T2 Normalized by Dose","C122331","The clearance of a substance from the blood by the kidneys over the interval from T1 to T2 divided by the dose.","Renal Clearance from T1 to T2 Normalized by Dose | RNCLINTD | Renal CL from T1 to T2 Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054070","Renal Clearance from T1 to T2 Normalized by Body Mass Index","C122330","The clearance of a substance from the blood by the kidneys over the interval from T1 to T2 divided by the body mass index.","Renal Clearance from T1 to T2 Normalized by Body Mass Index | RNCLINTB | Renal CL from T1 to T2 Norm by BMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050631","Renal Clearance from T1 to T2","C122049","The clearance of a substance from the blood by the kidneys over the interval from T1 to T2.","Renal Clearance from T1 to T2 | RNCLINT | Renal CL from T1 to T2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827924","Total Clearance Observed","C85773","The observed total body clearance for intravascular administration.","Observed Total Body Clearance Rate | CLO | Total CL Obs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827799","Total Body Clearance for Dose Interval Normalized by Weight","C114233","The total body clearance for intravascular administration for dose interval divided by the weight.","Total Body Clearance for Dose Interval Normalized by Weight | CLTAUW | Total CL for Dose Int Norm by WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815231","Total Body Clearance for Dose Interval Normalized by Surface Area","C114232","The total body clearance for intravascular administration for dose interval divided by the surface area.","Total Body Clearance for Dose Interval Normalized by Surface Area | CLTAUS | Total CL for Dose Int Norm by SA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827800","Total Body Clearance for Dose Interval Normalized by Dose","C114230","The total body clearance for intravascular administration for dose interval divided by the dose.","Total Body Clearance for Dose Interval Normalized by Dose | CLTAUD | Total CL for Dose Int Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827801","Total Body Clearance for Dose Interval Normalized by Body Mass Index","C114231","The total body clearance for intravascular administration for dose interval divided by the body mass index.","Total Body Clearance for Dose Interval Normalized by Body Mass Index | CLTAUB | Total CL for Dose Int Norm by BMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815230","Total Body Clearance for Dose Interval","C114122","The total body clearance for intravascular administration for dose interval.","Total Body Clearance for Dose Interval | CLTAU | Total CL for Dose Int",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827802","Total Body Clearance by Fraction of Dose for Dose Interval Normalized by Weight","C114229","The total body clearance for extravascular administration for dose interval based on the fraction of dose absorbed and divided by the weight.","Total Body Clearance by Fraction of Dose for Dose Interval Normalized by Weight | CLFTAUW | Total CL by F for Dose Int Norm by WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815229","Total Body Clearance by Fraction of Dose for Dose Interval Normalized by Surface Area","C114228","The total body clearance for extravascular administration for dose interval based on the fraction of dose absorbed and divided by the surface area.","Total Body Clearance by Fraction of Dose for Dose Interval Normalized by Surface Area | CLFTAUS | Total CL by F for Dose Int Norm by SA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985087","Total Clearance Predicted by Fraction Dose Normalized by Weight","C92420","The predicted total body clearance for extravascular administration based on the fraction of dose absorbed and divided by the weight.","Total Clearance Predicted by Fraction Dose Normalized by Weight | CLFPW | Total CL Pred by F Norm by WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985086","Total Clearance Predicted by Fraction Dose Normalized by Surface Area","C92419","The predicted total body clearance for extravascular administration based on the fraction of dose absorbed and divided by the surface area.","Total Clearance Predicted by Fraction Dose Normalized by Surface Area | CLFPS | Total CL Pred by F Norm by SA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985085","Total Clearance Predicted by Fraction Dose Normalized by Dose","C92418","The predicted total body clearance for extravascular administration based on the fraction of dose absorbed and divided by the dose.","Total Clearance Predicted by Fraction Dose Normalized by Dose | CLFPD | Total CL Pred by F Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985084","Total Clearance Predicted by Fraction Dose Normalized by Body Mass Index","C92417","The predicted total body clearance for extravascular administration based on the fraction of dose absorbed and divided by the body mass index.","Total Clearance Predicted by Fraction Dose Normalized by Body Mass Index | CLFPB | Total CL Pred by F Norm by BMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827946","Predicted Total Body Clearance by Fraction of Dose Absorbed","C85796","The predicted total body clearance for extravascular administration, where F is the fraction of dose absorbed.","Predicted Total Body Clearance by Fraction of Dose Absorbed | CLFP | Total CL Pred by F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827947","Predicted Total Body Clearance Rate","C85797","The predicted total body clearance for intravascular administration.","Predicted Total Body Clearance Rate | CLP | Total CL Pred",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985073","Total Clearance Observed Normalized by Weight","C92406","The observed total body clearance for intravascular administration divided by the weight.","Total Clearance Observed Normalized by Weight | CLOW | Total CL Obs Norm by WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985072","Total Clearance Observed Normalized by Surface Area","C92405","The observed total body clearance for intravascular administration divided by the surface area.","Total Clearance Observed Normalized by Surface Area | CLOS | Total CL Obs Norm by SA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985071","Total Clearance Observed Normalized by Dose","C92404","The observed total body clearance for intravascular administration divided by the dose.","Total Clearance Observed Normalized by Dose | CLOD | Total CL Obs Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985070","Total Clearance Observed Normalized by Body Mass Index","C92403","The observed total body clearance for intravascular administration divided by the body mass index.","Total Clearance Observed Normalized by Body Mass Index | CLOB | Total CL Obs Norm by BMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555659","Total Clearance Observed for Unbound Drug","C154842","The total body clearance for extravascular administration divided by the fraction of drug unbound, calculated using the observed value of the last non-zero concentration.","Total Clearance Observed for Unbound Drug | CLOUB | Total CL Obs for Unbound Drug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985069","Total Clearance Observed by Fraction Dose Normalized by Weight","C92402","The observed total body clearance for extravascular administration based on the fraction of dose absorbed and divided by the weight.","Total Clearance Observed by Fraction Dose Normalized by Weight | CLFOW | Total CL Obs by F Norm by WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985068","Total Clearance Observed by Fraction Dose Normalized by Surface Area","C92401","The observed total body clearance for extravascular administration based on the fraction of dose absorbed and divided by the surface area.","Total Clearance Observed by Fraction Dose Normalized by Surface Area | CLFOS | Total CL Obs by F Norm by SA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985067","Total Clearance Observed by Fraction Dose Normalized by Dose","C92400","The observed total body clearance for extravascular administration based on the fraction of dose absorbed and divided by the dose.","Total Clearance Observed by Fraction Dose Normalized by Dose | CLFOD | Total CL Obs by F Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985066","Total Clearance Observed by Fraction Dose Normalized by Body Mass Index","C92399","The observed total body clearance for extravascular administration based on the fraction of dose absorbed and divided by the body mass index.","Total Clearance Observed by Fraction Dose Normalized by Body Mass Index | CLFOB | Total CL Obs by F Norm by BMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827923","Observed Total Body Clearance by Fraction of Dose Absorbed","C85772","The observed total body clearance for extravascular administration, where F is the fraction of dose absorbed.","Observed Total Body Clearance by Fraction of Dose Absorbed | CLFO | Total CL Obs by F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826804","Adverse Event Sequence Number","C83213","An identifier that describes the relative position of adverse event data within a series.","Adverse Event Sequence Number | AESEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826823","Concomitant Medication Sequence Number","C83233","An identifier that describes the relative position of concomitant medication data within a series.","Concomitant Medication Sequence Number | CMSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826830","Comment Sequence Number","C83240","An identifier that describes the relative position of comment data within a series.","Comment Sequence Number | COSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981461","Drug Accountability Sequence Number","C87877","A number that identifies the ordering relations (in time, space, etc.) in a set of drug accountability data.","Drug Accountability Sequence Number | DASEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899407","Death Diagnosis Sequence Number","C117543","An identifier that describes the relative position of death diagnoses data within a series.","Death Diagnosis Sequence Number | DDSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826839","Disposition Sequence Number","C83249","An identifier that describes the relative position of a disposition data within a series.","Disposition Sequence Number | DSSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981577","Protocol Deviation Sequence Number","C87994","A number that identifies the ordering relations (in time, space, etc.) in a set of protocol deviations.","Protocol Deviation Sequence Number | DVSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899201","Exposure as Collected Sequence Number","C117467","An identifier that describes the relative position of collected exposure data within a series.","Exposure as Collected Sequence Number | ECSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826856","Electrocardiogram Sequence","C83266","An identifier that describes the relative position of electrocardiogram data within a series.","Electrocardiogram Sequence | EGSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826876","Exposure Sequence Number","C83286","An identifier that describes the relative position of an exposure data within a series.","Exposure Sequence Number | EXSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981473","Findings About Events or Interventions Sequence Number","C87889","A number that identifies the ordering relations (in time, space, etc.) in a set of findings.","Findings About Events or Interventions Sequence Number | FASEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086434","Healthcare Encounters Sequence Number","C124001","An identifier that describes the relative position of healthcare encounters data within a series.","Healthcare Encounters Sequence Number | HOSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826889","Inclusion Exclusion Criterion Sequence Number","C83299","An identifier that describes the relative position of inclusion and exclusion criteria data within a series.","Inclusion Exclusion Criterion Sequence Number | IESEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898790","Immunogenicity Specimen Assessments Sequence Number","C117551","An identifier that describes the relative position of immunogenicity specimen assessments data within a series.","Immunogenicity Specimen Assessments Sequence Number | ISSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826904","Laboratory Test Sequence Number","C83314","An identifier that describes the relative position of laboratory test data within a series.","Laboratory Test Sequence Number | LBSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555558","Total Clearance Predicted for Unbound Drug","C154841","The total body clearance for extravascular administration divided by the fraction of drug unbound, calculated using the predicted value of the last non-zero concentration.","Total Clearance Predicted for Unbound Drug | CLPUB | Total CL Pred for Unbound Drug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981501","Microbiology Specimen Sequence Number","C87917","A number that identifies the ordering relations (in time, space, etc.) in a set of microbiology specimens.","Microbiology Specimen Sequence Number | MBSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826926","Medical History Sequence Number","C83336","An identifier that describes the relative position of medical history data within a series.","Medical History Sequence Number | MHSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898361","Microscopic Findings Sequence Number","C117573","An identifier that describes the relative position of microscopic findings data within a series.","Microscopic Findings Sequence Number | MISEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898233","Morphology Sequence Number","C117601","An identifier that describes the relative position of morphology data within a series.","Morphology Sequence Number | MOSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981525","Microbiology Susceptibility Sequence Number","C87941","A number that identifies the ordering relations (in time, space, etc.) in a set of microbiology susceptibility data.","Microbiology Susceptibility Sequence Number | MSSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981549","Pharmacokinetic Concentration Sequence Number","C87966","A number that identifies the ordering relations (in time, space, etc.) in a set of pharmacokinetic concentration data.","Pharmacokinetic Concentration Sequence Number | PCSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826946","Physical Examination Sequence Number","C83356","An identifier that describes the relative position of physical examination data within a series.","Physical Examination Sequence Number | PESEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981568","Pharmacokinetic Parameter Sequence Number","C87985","A number that identifies the ordering relations (in time, space, etc.) in a set of pharmacokinetic parameters.","Pharmacokinetic Parameter Sequence Number | PPSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897828","Procedure Sequence Number","C117506","An identifier that describes the relative position of procedures within a series.","Procedure Sequence Number | PRSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826968","Questionnaire Sequence Number","C83379","An identifier that describes the relative position of questionnaire data within a series.","Questionnaire Sequence Number | QSSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897703","Reproductive System Findings Sequence Number","C117636","An identifier that describes the relative position of reproductive system findings data within a series.","Reproductive System Findings Sequence Number | RPSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899356","Disease Response Sequence Number","C117400","An identifier that describes the relative position of disease response data within a series.","Disease Response Sequence Number | RSSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826992","Subject Characteristics Sequence Number","C83403","An identifier that describes the relative position of subject characteristics data within a series.","Subject Characteristics Sequence Number | SCSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897579","Skin Response Sequence Number","C117670","An identifier that describes the relative position of skin response data within a series.","Skin Response Sequence Number | SRSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897436","Subject Status Sequence Number","C117656","An identifier that describes the relative position of subject status data within a series.","Subject Status Sequence Number | SSSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897268","Tumor Results Sequence Number","C117420","An identifier that describes the relative position of tumor results data within a series.","Tumor Results Sequence Number | TRSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897126","Tumor Identifier Sequence Number","C117443","An identifier that describes the relative position of tumor identifier data within a series.","Tumor Identifier Sequence Number | TUSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827050","Vital Signs Sequence Number","C83462","An identifier that describes the relative position of vital signs data within a series.","Vital Signs Sequence Number | VSSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273727","Breast Solid Neuroendocrine Carcinoma","C97965","A neuroendocrine carcinoma that arises from the breast.  It is characterized by the presence of cellular solid nests and trabeculae that contain spindle-shaped, plasmacytoid, and large neuroendocrine cells.","Breast Solid Neuroendocrine Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511316","Breast Large Cell Neuroendocrine Carcinoma","C40356","A poorly differentiated neuroendocrine carcinoma that arises from the breast.  It is characterized by the presence of large neuroendocrine cells and high mitotic activity.","Breast Large Cell Neuroendocrine Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981462","Drug Accountability Sponsor Defined Identifier","C87878","One or more sponsor defined characters used to identify, name, or characterize the drug accountability assessment.","Drug Accountability Sponsor Defined Identifier | DASPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826840","Disposition Sponsor Defined Identifier","C83250","One or more sponsor defined characters used to name a disposition event.","Disposition Sponsor Defined Identifier | DSSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899200","Exposure as Collected Sponsor Defined Identifier","C117470","One or more sponsor defined characters used to identify, name, or characterize the collected exposure.","Exposure as Collected Sponsor Defined Identifier | ECSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981464","Electrocardiogram Sponsor Defined Identifier","C87880","One or more sponsor defined characters used to identify, name, or characterize the electrocardiogram assessment.","Electrocardiogram Sponsor Defined Identifier | EGSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826877","Exposure Sponsor Defined Identifier","C83287","One or more sponsor defined characters used to name an exposure.","Exposure Sponsor Defined Identifier | EXSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981474","Findings About Events or Interventions Sponsor Defined Identifier","C87890","One or more sponsor defined characters used to identify, name, or characterize the finding.","Findings About Events or Interventions Sponsor Defined Identifier | FASPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826890","Inclusion Exclusion Criterion Sponsor Defined Identifier","C83300","One or more sponsor defined characters used to name inclusion exclusion criteria.","Inclusion Exclusion Criterion Sponsor Defined Identifier | IESPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897092","Immunogenicity Specimen Assessments Sponsor Defined Identifier","C117554","One or more sponsor defined characters used to identify, name, or characterize the immunogenicity specimen assessment.","Immunogenicity Specimen Assessments Sponsor Defined Identifier | ISSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826906","Laboratory Test Sponsor Defined Identifier","C83316","One or more sponsor defined characters used to name a laboratory test.","Laboratory Test Sponsor Defined Identifier | LBSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981502","Microbiology Specimen Sponsor Defined Identifier","C87918","One or more sponsor defined characters used to identify, name, or characterize the microbiology specimen.","Microbiology Specimen Sponsor Defined Identifier | MBSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898232","Morphology Sponsor Defined Identifier","C117604","One or more sponsor defined characters used to identify, name, or characterize the morphology finding.","Morphology Sponsor Defined Identifier | MOSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981526","Microbiology Susceptibility Sponsor Defined Identifier","C87942","One or more sponsor defined characters used to identify, name, or characterize the microbiology susceptibility assessment.","Microbiology Susceptibility Sponsor Defined Identifier | MSSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826969","Questionnaire Sponsor Defined Identifier","C83380","One or more sponsor defined characters used to name questionnaire data.","Questionnaire Sponsor Defined Identifier | QSSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899355","Disease Response Sponsor Defined Identifier","C117401","One or more sponsor defined characters used to identify, name, or characterize the disease response assessment.","Disease Response Sponsor Defined Identifier | RSSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981552","Pharmacokinetic Concentration Sponsor Defined Identifier","C87969","One or more sponsor defined characters used to identify, name, or characterize the pharmacokinetic concentration assessment.","Pharmacokinetic Concentration Sponsor Defined Identifier | PCSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897435","Subject Status Sponsor Defined Identifier","C117658","One or more sponsor defined characters used to identify, name, or characterize the subject status.","Subject Status Sponsor Defined Identifier | SSSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897267","Tumor Results Sponsor Defined Identifier","C117421","One or more sponsor defined characters used to identify, name, or characterize the tumor results assessment.","Tumor Results Sponsor Defined Identifier | TRSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897287","Tumor Identifier Sponsor Defined Identifier","C117444","One or more sponsor defined characters used to identify, name, or characterize the tumor identification assessment.","Tumor Identifier Sponsor Defined Identifier | TUSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899214","Exposure as Collected Link Identifier","C117471","A sequence of characters used as a linkage between related collected exposure records.","Exposure as Collected Link Identifier | ECLNKID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086286","Exposure Record Link Identifier","C123978","A sequence of characters used as a linkage between related exposure records.","Exposure Record Link Identifier | EXLNKID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898235","Morphology Record Link Identifier","C117605","A sequence of characters used as a linkage between related records of a morphology assessment.","Morphology Record Link Identifier | MOLNKID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897835","Procedure Link Identifier","C117509","A sequence of characters used as a linkage between related procedure records.","Procedure Link Identifier | PRLNKID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899360","Disease Response Link Identifier","C117395","A sequence of characters used as a linkage between related disease response records.","Disease Response Link Identifier | RSLNKID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897275","Tumor Results Link Identifier","C117413","A sequence of characters used as a linkage between related tumor results records.","Tumor Results Link Identifier | TRLNKID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897293","Tumor Identifier Link Identifier","C117436","A sequence of characters used as a linkage between related tumor identifier records.","Tumor Identifier Link Identifier | TULNKID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826852","Electrocardiogram Vendor Name","C83262","The literal identifier of the vendor or laboratory that performs an electrocardiogram examination.","Electrocardiogram Vendor Name | EGNAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898785","Immunogenicity Specimen Assessments Vendor Name","C117566","The literal identifier of the vendor or laboratory that performs a immunogenicity specimen assessment.","Immunogenicity Specimen Assessments Vendor Name | ISNAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981494","Microbiology Specimen Vendor Name","C87910","The literal identifier of the vendor or laboratory that performs a microbiology specimen examination.","Microbiology Specimen Vendor Name | MBNAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898229","Morphology Vendor Name","C117619","The literal identifier of the vendor or laboratory that performs a morphology examination.","Morphology Vendor Name | MONAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981601","Microbiology Susceptibility Vendor Name","C88019","The literal identifier of the vendor or laboratory that performs a microbiology susceptibility assessment.","Microbiology Susceptibility Vendor Name | MSNAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981602","Pharmacokinetic Concentration Vendor Name","C88020","The literal identifier of the vendor or laboratory that performs a pharmacokinetic concentration assessment.","Pharmacokinetic Concentration Vendor Name | PCNAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899354","Disease Response Vendor Name","C117396","The literal identifier of the vendor or laboratory that performs a disease response assessment.","Disease Response Vendor Name | RSNAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897574","Skin Response Vendor Name","C117686","The literal identifier of the vendor or laboratory that performs a skin response assessment.","Skin Response Vendor Name | SRNAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897265","Tumor Results Vendor Name","C117415","The literal identifier of the vendor or laboratory that performs a tumor results assessment.","Tumor Results Vendor Name | TRNAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897286","Tumor Identifier Vendor Name","C117439","The literal identifier of the vendor or laboratory that performs a tumor identification assessment.","Tumor Identifier Vendor Name | TUNAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981437","Clinical Events Reference Identifier","C87853","A character or string used to name, or characterize a clinical events reference.","Clinical Events Reference Identifier | CEREFID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981450","Disposition Reference Identifier","C87866","A character or string used to name, or characterize a disposition reference.","Disposition Reference Identifier | DSREFID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981576","Protocol Deviation Reference Identifier","C87993","A character or string used to name, or characterize a protocol deviation reference.","Protocol Deviation Reference Identifier | DVREFID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086433","Healthcare Encounters Reference Identifier","C123995","A sequence of characters used to identify, name, or characterize the healthcare encounters reference.","Healthcare Encounters Reference Identifier | HOREFID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898792","Immunogenicity Specimen Assessments Reference Identifier","C117553","A sequence of characters used to identify, name, or characterize the immunogenicity specimen assessments reference.","Immunogenicity Specimen Assessments Reference Identifier | ISREFID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826925","Medical History Reference Identifier","C83335","A character or string that represents a medical history event reference.","Medical History Reference Identifier | MHREFID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898234","Morphology Reference Identifier","C117603","A character or string used to name, or characterize a morphology reference.","Morphology Reference Identifier | MOREFID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981522","Microbiology Susceptibility Reference Identifier","C87938","A character or string used to name, or characterize a microbiology susceptibility reference.","Microbiology Susceptibility Reference Identifier | MSREFID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897705","Reproductive System Findings Reference Identifier","C117638","A character or string used to name, or characterize a reproductive system findings reference.","Reproductive System Findings Reference Identifier | RPREFID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899357","Disease Response Reference Identifier","C117399","A sequence of characters used to identify, name, or characterize the disease response reference.","Disease Response Reference Identifier | RSREFID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897581","Skin Response Reference Identifier","C117672","A character or string used to name, or characterize a Skin Response reference.","Skin Response Reference Identifier | SRREFID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897269","Tumor Results Reference Identifier","C117419","A sequence of characters used to identify, name, or characterize the tumor results reference.","Tumor Results Reference Identifier | TRREFID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897288","Tumor Identifier Reference Identifier","C117442","A sequence of characters used to identify, name, or characterize the tumor identifier reference.","Tumor Identifier Reference Identifier | TUREFID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899196","Exposure as Collected Time Point Reference","C117504","The point in time that acts as a fixed reference point to an exposure collection.","Exposure as Collected Time Point Reference | ECTPTREF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826863","Electrocardiogram Time Point Reference","C83273","The point in time that acts as a fixed reference point to an electrocardiogram assessment.","Electrocardiogram Time Point Reference | EGTPTREF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826881","Exposure Time Point Reference","C83291","The point in time that acts as a fixed reference point to an exposure assessment.","Exposure Time Point Reference | EXTPTREF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826916","Laboratory Test Time Point Reference","C83326","The point in time that acts as a fixed reference point to a laboratory assessment.","Laboratory Test Time Point Reference | LBTPTREF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981508","Microbiology Specimen Time Point Reference","C87924","The point in time that acts as a fixed reference point to a microbiology specimen collection.","Microbiology Specimen Time Point Reference | MBTPTREF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898230","Morphology Time Point Reference","C117634","The point in time that acts as a fixed reference point to a morphology finding.","Morphology Time Point Reference | MOTPTREF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981531","Microbiology Susceptibility Time Point Reference","C87948","The point in time that acts as a fixed reference point to a microbiology susceptibility assessment.","Microbiology Susceptibility Time Point Reference | MSTPTREF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981559","Pharmacokinetic Concentration Time Point Reference","C87976","The point in time that acts as a fixed reference point to a pharmacokinetic concentration assessment.","Pharmacokinetic Concentration Time Point Reference | PCTPTREF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897821","Procedure Time Point Reference","C117537","The point in time that acts as a fixed reference point to a procedure.","Procedure Time Point Reference | PRTPTREF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826978","Questionnaire Time Point Reference","C83389","The point in time that acts as a fixed reference point to a questionnaire assessment.","Questionnaire Time Point Reference | QSTPTREF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897575","Skin Response Time Point Reference","C117697","The point in time that acts as a fixed reference point to a skin response.","Skin Response Time Point Reference | SRTPTREF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827056","Vital Signs Time Point Reference","C83468","The point in time that acts as a fixed reference point to a vital signs assessment.","Vital Signs Time Point Reference | VSTPTREF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899206","Exposure as Collected Planned Time Point Number","C117502","The numerical identifier of a collected exposure point in time.","Exposure as Collected Planned Time Point Number | ECTPTNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826862","Electrocardiogram Planned Time Point Number","C83272","The numerical identifier of an electrocardiogram point in time.","Electrocardiogram Planned Time Point Number | EGTPTNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826880","Exposure Planned Time Point Number","C83290","The numerical identifier of an exposure point in time.","Exposure Planned Time Point Number | EXTPTNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826915","Laboratory Test Planned Time Point Number","C83325","The numerical identifier of a laboratory test point in time.","Laboratory Test Planned Time Point Number | LBTPTNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981507","Microbiology Specimen Planned Time Point Number","C87923","The numerical identifier of a microbiology specimen point in time.","Microbiology Specimen Planned Time Point Number | MBTPTNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898239","Morphology Planned Time Point Number","C117632","The numerical identifier of a morphology point in time.","Morphology Planned Time Point Number | MOTPTNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981530","Microbiology Susceptibility Planned Time Point Number","C87947","The numerical identifier of a microbiology susceptibility point in time.","Microbiology Susceptibility Planned Time Point Number | MSTPTNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981558","Pharmacokinetic Concentration Planned Time Point Number","C87975","The numerical identifier of a pharmacokinetic concentration point in time.","Pharmacokinetic Concentration Planned Time Point Number | PCTPTNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897831","Procedure Planned Time Point Number","C117535","The numerical identifier of a planned procedure point in time.","Procedure Planned Time Point Number | PRTPTNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826977","Questionnaire Planned Time Point Number","C83388","The numerical identifier of a questionnaire point in time.","Questionnaire Planned Time Point Number | QSTPTNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897583","Skin Response Planned Time Point Number","C117695","The numerical identifier of a skin response point in time.","Skin Response Planned Time Point Number | SRTPTNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827055","Vital Signs Planned Time Point Number","C83467","The numerical identifier of a vital signs point in time.","Vital Signs Planned Time Point Number | VSTPTNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897476","Study Day of Death Diagnosis","C117550","The study day that a death diagnosis assessment is performed.","Study Day of Death Diagnosis | DDDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830122","Findings About Events or Interventions Data Collection Day","C113361","The day of the week the findings about an event or intervention was collected.","Findings About Events or Interventions Data Collection Day | FADY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826886","Inclusion Exclusion Criterion Data Collection Day","C83296","The day of the week inclusion exclusion criterion data was collected.","Inclusion Exclusion Criterion Data Collection Day | IEDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936110","36 Months","C156844","A period of time of thirty-six months.","36 Months | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935975","24 Months","C156843","A period of time of twenty-four months.","24 Months | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936116","Induction Clinical Trial Setting","C156595","A clinical trial or treatment setting in which the therapy of interest is considered induction therapy.","Induction Clinical Trial Setting | INDUCTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555555","Pathologist 2","C154837","A pathologist performing the assessment that is given the designation of two.","Pathologist 2 | PATHOLOGIST 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555554","Pathologist 1","C154836","A pathologist performing the assessment that is given the designation of one.","Pathologist 1 | PATHOLOGIST 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826794","Adverse Event End Day","C83202","The day of the week that an adverse event concluded.","Adverse Event End Day | AEENDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826933","Adverse Event Start Day","C83343","The day of the week an adverse event began.","Adverse Event Start Day | AESTDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826301","Observation Start Day","C82570","The first day of an observation.","Observation Start Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826816","Concomitant Medication Use End Day","C83226","The day of the week that concomitant medication usage ended.","Concomitant Medication Use End Day | CMENDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826826","Concomitant Medication Start Day","C83236","The day of the week that concomitant medication usage began.","Concomitant Medication Start Day | CMSTDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981453","Study Day of Drug Accountability","C87869","The day that a drug accountability assessment is performed.","Study Day of Drug Accountability | DADY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826842","Disposition Event Start Day","C83252","The day of the week a disposition event began.","Disposition Event Start Day | DSSTDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899198","Exposure as Collected Start Day","C117498","The first day of the exposure collection period.","Exposure as Collected Start Day | ECSTDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826847","Study Day of Electrocardiogram","C83257","The day of the week for an electrocardiogram.","Study Day of Electrocardiogram | EGDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826873","Exposure End Day","C83283","The day of the week an exposure concluded.","Exposure End Day | EXENDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826879","Exposure Start Day","C83289","The day of the week an exposure began.","Exposure Start Day | EXSTDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086872","Study Day of Healthcare Encounters","C123951","The study day that a healthcare encounters assessment is performed.","Study Day of Healthcare Encounters | HODY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086426","Healthcare Encounters End Day","C123959","The final day of the healthcare encounter assessment.","Healthcare Encounters End Day | HOENDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087035","Healthcare Encounters Start Day","C124010","The day of the week a healthcare encounter began.","Healthcare Encounters Start Day | HOSTDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897474","Study Day of Immunogenicity Specimen Assessment","C117572","The study day that an immunogenicity specimen assessment is performed.","Study Day of Immunogenicity Specimen Assessment | ISDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826896","Laboratory Test Data Collection Day","C83306","The day of the week a laboratory test data was collected.","Laboratory Test Data Collection Day | LBDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981487","Study Day of Microbiology Specimen","C87903","The day that a microbiology specimen is collected.","Study Day of Microbiology Specimen | MBDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981506","Microbiology Specimen Timepoint","C87922","A point in time referring to microbiology specimen data.","Microbiology Specimen Timepoint | MBTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826919","Medical History Collection Day","C83329","The day of the week a medical history data was collected.","Medical History Collection Day | MHDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897472","Study Day of Microscopic Findings","C117600","The day that a microscopic findings assessment is performed.","Study Day of Microscopic Findings | MIDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826182","Study Day","C82437","The day that an examination, assessment, or treatment associated with the study is performed.","Study Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898240","Morphology Planned Time Point Name","C117631","The literal identifier of a planned point in time for a morphological assessment.","Morphology Planned Time Point Name | MOTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981513","Study Day of Microbiology Susceptibility","C87929","The day that a microbiology susceptibility assessment is performed.","Study Day of Microbiology Susceptibility | MSDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981529","Microbiology Susceptibility Timepoint","C87946","A point in time referring to microbiology susceptibility data.","Microbiology Susceptibility Timepoint | MSTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981535","Study Day of Pharmacokinetic Concentration","C87952","The day that an pharmacokinetic concentration assessment is performed.","Study Day of Pharmacokinetic Concentration | PCDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826938","Physical Examination Data Collection Day","C83348","The day of the week physical examination data was collected.","Physical Examination Data Collection Day | PEDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086741","Pharmacokinetic Parameters Planned End of Assessment Interval","C123963","The period of time that the pharmacokinetic parameter assessment, done over an interval of time, is intended to finish.","Pharmacokinetic Parameters Planned End of Assessment Interval | PPENINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086742","Pharmacokinetic Parameters Planned Start of Assessment Interval","C124013","The period of time that the pharmacokinetic parameters assessment, done over an interval of time, is intended to begin.","Pharmacokinetic Parameters Planned Start of Assessment Interval | PPSTINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897842","Procedure End Day","C117532","The final day of the procedure.","Procedure End Day | PRENDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897826","Procedure Start Day","C117531","The first day of the procedure.","Procedure Start Day | PRSTDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897832","Procedure Planned Time Point Name","C117534","The literal identifier of a planned point in time for a procedure.","Procedure Planned Time Point Name | PRTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049648","Liter per Microgram per Meter Squared per Day","C120813","A unit of concentration equal to liter divided by microgram per meter squared per day.","Liter per Microgram per Meter Squared per Day | L/(ug/m2/d) | L/(ug/m2/day) | l/(ug/m2/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054615","Liter per Microgram per Meter Squared","C120812","A unit of concentration equal to liter divided by microgram per meter squared.","Liter per Microgram per Meter Squared | L/(ug/m2) | l/(ug/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050629","Liter per Microgram per Kilogram per Day","C120811","A unit of concentration equal to liter divided by microgram per kilogram per day.","Liter per Microgram per Kilogram per Day | L/(ug/kg/d) | L/(ug/kg/day) | l/(ug/kg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054616","Liter per Microgram per Kilogram","C120810","A unit of concentration equal to liter divided by microgram per kilogram.","Liter per Microgram per Kilogram | L/(ug/kg) | l/(ug/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050567","Liter Divided by Microgram per Day","C123563","A unit of concentration equal to one liter divided by the derived denominator microgram per day.","Liter Divided by Microgram per Day | L/(ug/d) | L/(ug/day) | l/(ug/d) | mL/(ng/day)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050608","Liter per Milligram per Meter Squared per Day","C120809","A unit of concentration equal to liter divided by milligram per meter squared per day.","Liter per Milligram per Meter Squared per Day | L/(mg/m2/d) | L/(mg/m2/day) | Milliliter per Microgram per Meter Squared per Day | l/(mg/m2/d) | mL/(ug/m2/d) | mL/(ug/m2/day) | ml/(ug/m2/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050565","Liter Divided by Milligram per Meter Squared","C123562","A unit of concentration equal to one liter divided by the derived denominator milligram per square meter.","Liter Divided by Milligram per Meter Squared | L/(mg/m2) | l/(mg/m2) | mL/(ug/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050563","Liter per Milligram per Kilogram per Day","C120808","A unit of concentration equal to liter divided by milligram per kilogram per day.","Liter per Milligram per Kilogram per Day | L/(mg/kg/d) | L/(mg/kg/day) | Milliliter per Microgram per Kilogram per Day | l/(mg/kg/d) | mL/(ug/kg/d) | mL/(ug/kg/day) | ml/(ug/kg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054613","Liter per Milligram per Kilogram","C120807","A unit of concentration equal to liter divided by milligram per kilogram.","Liter per Milligram per Kilogram | L/(mg/kg) | l/(mg/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050566","Liter Divided by Milligram Per Day","C123561","A unit of concentration equal to liter per milligram per day.","Liter Divided by Milligram Per Day | L/(mg/d) | L/(mg/day) | l/(mg/d) | mL/(ug/day)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054618","Liter per Kilogram per Meter Squared","C120806","A unit of concentration equal to liter divided by kilogram per meter squared.","Liter per Kilogram per Meter Squared | L/(kg/m2) | l/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898721","International Unit per Milliliter per Microgram","C119381","A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by micrograms.","International Unit per Milliliter per Microgram | IU/mL/ug | [IU]/mL/ug | [IU]/ml/ug | [iU]/mL/ug | [iU]/ml/ug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898715","International Unit per Milliliter per Milligram","C119380","A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by milligrams.","International Unit per Milliliter per Milligram | IU/mL/mg | Milli-International Unit per Milliliter per Microgram | [IU]/mL/mg | [IU]/ml/mg | [iU]/mL/mg | [iU]/ml/mg | mIU/mL/ug | m[IU]/mL/ug | m[IU]/ml/ug | m[iU]/mL/ug | m[iU]/ml/ug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898727","International Unit per Milliliter per Meter Squared","C119379","A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by meters squared.","International Unit per Milliliter per Meter Squared | IU/mL/m2 | [IU]/mL/m2 | [IU]/ml/m2 | [iU]/mL/m2 | [iU]/ml/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898728","International Unit per Milliliter per Kilogram","C119378","A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by kilograms.","International Unit per Milliliter per Kilogram | IU/mL/kg | Micro-International Units per Milliliter per Milligram | Milli-International Unit per Milliliter per Gram | [IU]/mL/kg | [IU]/ml/kg | [iU]/mL/kg | [iU]/ml/kg | mIU/mL/g | m[IU]/mL/g | m[IU]/ml/g | m[iU]/mL/g | m[iU]/ml/g | uIU/mL/mg | u[IU]/mL/mg | u[IU]/ml/mg | u[iU]/mL/mg | u[iU]/ml/mg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898730","International Unit per Milliliter per Gram","C119377","A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by grams.","International Unit per Milliliter per Gram | IU/mL/g | Micro-International Units per Milliliter per Microgram | Milli-International Unit per Milliliter per Milligram | [IU]/mL/g | [IU]/ml/g | [iU]/mL/g | [iU]/ml/g | mIU/mL/mg | m[IU]/mL/mg | m[IU]/ml/mg | m[iU]/mL/mg | m[iU]/ml/mg | uIU/mL/ug | u[IU]/mL/ug | u[IU]/ml/ug | u[iU]/mL/ug | u[iU]/ml/ug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898723","International Unit per Milliliter per Microgram per Meter Squared per Day","C119376","A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by micrograms per meter squared per day.","International Unit per Milliliter per Microgram per Meter Squared per Day | IU/mL/(ug/m2/day) | [IU]/mL/(ug/m2/d) | [IU]/ml/(ug/m2/d) | [iU]/mL/(ug/m2/d) | [iU]/ml/(ug/m2/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898722","International Unit per Milliliter per Microgram per Meter Squared","C119375","A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by micrograms per meter squared.","International Unit per Milliliter per Microgram per Meter Squared | IU/mL/(ug/m2) | [IU]/mL/(ug/m2) | [IU]/ml/(ug/m2) | [iU]/mL/(ug/m2) | [iU]/ml/(ug/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898725","International Unit per Milliliter per Microgram per Kilogram per Day","C119374","A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by micrograms per kilogram per day.","International Unit per Milliliter per Microgram per Kilogram per Day | IU/mL/(ug/kg/day) | [IU]/mL/(ug/kg/d) | [IU]/ml/(ug/kg/d) | [iU]/mL/(ug/kg/d) | [iU]/ml/(ug/kg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898724","International Unit per Milliliter per Microgram per Kilogram","C119373","A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by micrograms per kilogram.","International Unit per Milliliter per Microgram per Kilogram | IU/mL/(ug/kg) | [IU]/mL/(ug/kg) | [IU]/ml/(ug/kg) | [iU]/mL/(ug/kg) | [iU]/ml/(ug/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898726","International Unit per Milliliter per Microgram per Day","C119372","A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by micrograms per day.","International Unit per Milliliter per Microgram per Day | IU/mL/(ug/day) | [IU]/mL/(ug/d) | [IU]/ml/(ug/d) | [iU]/mL/(ug/d) | [iU]/ml/(ug/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898717","International Unit per Milliliter per Milligram per Meter Squared per Day","C119371","A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by milligrams per meter squared per day.","International Unit per Milliliter per Milligram per Meter Squared per Day | IU/mL/(mg/m2/day) | Milli-International Unit per Milliliter per Microgram per Meter Squared per Day | [IU]/mL/(mg/m2/d) | [IU]/ml/(mg/m2/d) | [iU]/mL/(mg/m2/d) | [iU]/ml/(mg/m2/d) | mIU/mL/(ug/m2/day) | m[IU]/mL/(ug/m2/d) | m[IU]/ml/(ug/m2/d) | m[iU]/mL/(ug/m2/d) | m[iU]/ml/(ug/m2/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898716","International Unit per Milliliter per Milligram per Meter Squared","C119370","A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by milligrams per meter squared.","International Unit per Milliliter per Milligram per Meter Squared | IU/mL/(mg/m2) | Milli-International Unit per Milliliter per Microgram per Meter Squared | [IU]/mL/(mg/m2) | [IU]/ml/(mg/m2) | [iU]/mL/(mg/m2) | [iU]/ml/(mg/m2) | mIU/mL/(ug/m2) | m[IU]/mL/(ug/m2) | m[IU]/ml/(ug/m2) | m[iU]/mL/(ug/m2) | m[iU]/ml/(ug/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898719","International Unit per Milliliter per Milligram per Kilogram per Day","C119369","A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by milligrams per kilogram per day.","International Unit per Milliliter per Milligram per Kilogram per Day | IU/mL/(mg/kg/day) | Milli-International Unit per Milliliter per Microgram per Kilogram per Day | [IU]/mL/(mg/kg/d) | [IU]/ml/(mg/kg/d) | [iU]/mL/(mg/kg/d) | [iU]/ml/(mg/kg/d) | mIU/mL/(ug/kg/day) | m[IU]/mL/(ug/kg/d) | m[IU]/ml/(ug/kg/d) | m[iU]/mL/(ug/kg/d) | m[iU]/ml/(ug/kg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898718","International Unit per Milliliter per Milligram per Kilogram","C119368","A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by milligrams per kilogram.","International Unit per Milliliter per Milligram per Kilogram | IU/mL/(mg/kg) | Milli-International Unit per Milliliter per Microgram per Kilogram | [IU]/mL/(mg/kg) | [IU]/ml/(mg/kg) | [iU]/mL/(mg/kg) | [iU]/ml/(mg/kg) | mIU/mL/(ug/kg) | m[IU]/mL/(ug/kg) | m[IU]/ml/(ug/kg) | m[iU]/mL/(ug/kg) | m[iU]/ml/(ug/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898720","International Unit per Milliliter per Milligram per Day","C119367","A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by milligrams per day.","International Unit per Milliliter per Milligram per Day | IU/mL/(mg/day) | Milli-International Unit per Milliliter per Microgram per Day | [IU]/mL/(mg/d) | [IU]/ml/(mg/d) | [iU]/mL/(mg/d) | [iU]/ml/(mg/d) | mIU/mL/(ug/day) | m[IU]/mL/(ug/d) | m[IU]/ml/(ug/d) | m[iU]/mL/(ug/d) | m[iU]/ml/(ug/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898729","International Unit per Milliliter per Kilogram per Meter Squared","C119366","A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by kilograms per meter squared.","International Unit per Milliliter per Kilogram per Meter Squared | IU/mL/(kg/m2) | [IU]/mL/(kg/m2) | [IU]/ml/(kg/m2) | [iU]/mL/(kg/m2) | [iU]/ml/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1533023","International Unit per Minute","C85647","International units per minute.","International Unit per Minute | IU/min | [IU]/min | [iU]/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439464","International Unit per Hour","C85646","International units per hour.","International Unit per Hour | IU/h | [IU]/h | [iU]/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897469","Study Day of Reproductive System Findings","C117654","The day that a reproductive system findings assessment is performed.","Study Day of Reproductive System Findings | RPDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826960","Questionnaire Data Collection Day","C83371","The day of the week questionnaire data was collected.","Questionnaire Data Collection Day | QSDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897066","Study Day of Disease Response","C117390","The study day that a disease response assessment is performed.","Study Day of Disease Response | RSDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826987","Subject Characteristics Data Collection Day","C83398","The day of the week the subject characteristics data was collected.","Subject Characteristics Data Collection Day | SCDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897468","Study Day of Skin Response Assessment","C117693","The day that a skin response assessment is performed.","Study Day of Skin Response Assessment | SRDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897467","Study Day of Subject Status","C117669","The day that a subject status assessment is performed.","Study Day of Subject Status | SSDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981583","Subject Visit End Day","C88000","The day of the week a subject visit has concluded.","Subject Visit End Day | SVENDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935790","Maintenance Clinical Trial Setting","C156598","A clinical trial or treatment setting in which the therapy of interest is considered maintenance therapy.","Maintenance Clinical Trial Setting | MAINTENANCE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981584","Subject Visit Start Day","C88001","The day of the week a subject visit began.","Subject Visit Start Day | SVSTDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897464","Study Day of Tumor Results","C117408","The study day that a tumor results assessment is performed.","Study Day of Tumor Results | TRDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897465","Study Day of Tumor Identification","C117431","The study day that a tumor identification assessment is performed.","Study Day of Tumor Identification | TUDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827043","Vital Signs Data Collection Day","C83455","The day of the week vital signs data was collected.","Vital Signs Data Collection Day | VSDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898302","Minute Times Femtogram Per Milliliter Per Milligram Per Gram Per Day","C117939","Minute times femtogram per milliliter, divided by milligram per gram per day.","Minute Times Femtogram Per Milliliter Per Milligram Per Gram Per Day | min*fg/mL/(mg/g/day) | min.fg/mL/(mg/g/d) | min.fg/ml/(mg/g/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898301","Minute Times Femtogram Per Milliliter Per Milligram Per Gram","C117938","Minute times femtogram per milliliter, divided by milligram per gram.","Minute Times Femtogram Per Milliliter Per Milligram Per Gram | min*fg/mL/(mg/g) | min.fg/mL/(mg/g) | min.fg/ml/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829053","Minute Times Femtogram per Milliliter per Kilogram per Meter Squared","C111254","Minutes times femtograms per milliliter, divided by kilograms per meter squared.","Minute Times Femtogram per Milliliter per Kilogram per Meter Squared | min*fg/mL/(kg/m2) | min.fg/mL/(kg/m2) | min.fg/ml/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827892","Minute Times Femtogram per Milliliter","C85724","Minutes times femtograms per milliliter.","Minute Times Femtogram per Milliliter | fg*min/mL | min*fg/mL | min*pg/L | min.fg/mL | min.fg/ml | pg*min/L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898333","Milligram per Milliliter per Meter Squared","C119393","A unit of concentration equal to milligrams per milliliter, divided by meters squared.","Milligram per Milliliter per Meter Squared | mg/mL/m2 | mg/ml/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898330","Milligram per Milliliter per Milligram per Meter Squared per Day","C119385","A unit of concentration equal to milligrams per milliliter, divided by milligrams per meter squared per day.","Milligram per Milliliter per Milligram per Meter Squared per Day | Microgram per Milliliter per Microgram per Meter Squared per Day | mg/mL/(mg/m2/d) | mg/mL/(mg/m2/day) | mg/ml/(mg/m2/d) | ug/mL/(ug/m2/d) | ug/mL/(ug/m2/day) | ug/ml/(ug/m2/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898329","Milligram per Milliliter per Milligram per Meter Squared","C119384","A unit of concentration equal to milligrams per milliliter, divided by milligrams per meter squared.","Milligram per Milliliter per Milligram per Meter Squared | Microgram per Milliliter per Microgram per Meter Squared | mg/mL/(mg/m2) | mg/ml/(mg/m2) | ug/mL/(ug/m2) | ug/ml/(ug/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642190","Milligram Per Milliliter Per Milligram Per Kilogram Per Day","C105476","A dose calculation unit expressed in milligrams per milliliter, divided by milligram per kilogram per day.","Milligram Per Milliliter Per Milligram Per Kilogram Per Day | Microgram per Milliliter per Microgram per Kilogram per Day | g/L/mg/kg/day | mg/mL/(mg/kg/d) | mg/mL/(mg/kg/day) | mg/ml/(mg/kg/d) | ug/mL/(ug/kg/d) | ug/mL/(ug/kg/day) | ug/ml/(ug/kg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642189","Milligram Per Milliliter Per Milligram Per Kilogram","C105475","A dose calculation unit expressed in milligrams per milliliter, divided by milligram per kilogram.","Milligram Per Milliliter Per Milligram Per Kilogram | Microgram per Milliliter per Microgram per Kilogram | g/L/mg/kg | mg/mL/(mg/kg) | mg/ml/(mg/kg) | ug/mL/(ug/kg) | ug/ml/(ug/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898331","Milligram per Milliliter per Milligram per Day","C119383","A unit of concentration equal to milligrams per milliliter, divided by milligrams per day.","Milligram per Milliliter per Milligram per Day | Microgram per Milliliter per Microgram per Day | mg/mL/(mg/d) | mg/mL/(mg/day) | mg/ml/(mg/d) | ug/mL/(ug/d) | ug/mL/(ug/day) | ug/ml/(ug/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898335","Milligram per Milliliter per Kilogram per Meter Squared","C119382","A unit of concentration equal to milligrams per milliliter, divided by kilograms per meter squared.","Milligram per Milliliter per Kilogram per Meter Squared | mg/mL/(kg/m2) | mg/ml/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054614","Liter per Microgram","C120815","A unit of concentration equal to liter per microgram.","Liter per Microgram | L/ug | l/ug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086548","Liter per Milligram","C124417","A dose calculation unit expressed in liter(s) per milligram.","Liter per Milligram | L/mg | l/mg | mL/ug | nL/pg | uL/ng",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054617","Liter per Meter Squared","C120814","A unit of concentration equal to liter per meter squared.","Liter per Meter Squared | L/m2 | l/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898289","Minute Times Nanomole Per Liter Per Milligram Per Gram","C117950","Minute times nanomole per liter, divided by milligram per gram.","Minute Times Nanomole Per Liter Per Milligram Per Gram | min*nmol/L/(mg/g) | min.nmol/L/(mg/g) | min.nmol/l/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829021","Minute Times Nanomole per Liter per Kilogram per Meter Squared","C111270","Minutes times nanomoles per liter, divided by kilograms per meter squared.","Minute Times Nanomole per Liter per Kilogram per Meter Squared | min*nmol/L/(kg/m2) | min.nmol/L/(kg/m2) | min.nmol/l/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827903","Minute Times Picomole per Milliliter","C85735","Minutes times picomoles per milliliter.","Minute Times Picomole per Milliliter | min*nmol/L | min*pmol/mL | min.nmol/L | min.nmol/l | nmol*min/L | pmol*min/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829024","Minute Times Nanogram per Milliliter per Meter Squared","C111269","Minutes times nanograms per milliliter, divided by meters squared.","Minute Times Nanogram per Milliliter per Meter Squared | min*ng/mL/m2 | min.ng/mL/m2 | min.ng/ml/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829026","Minute Times Nanogram Per Milliliter Per Kilogram","C112349","Minutes times nanograms per milliliter, divided by kilograms.","Minute Times Nanogram Per Milliliter Per Kilogram | Minute Times Picogram Per Milliliter Per Gram | min*ng/mL/kg | min*pg/mL/g | min.ng/mL/kg | min.ng/ml/kg | min.pg/mL/g | min.pg/ml/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898292","Minute Times Nanogram Per Milliliter Per Milligram Per Gram Per Day","C117949","Minute times nanogram per milliliter, divided by milligram per gram per day.","Minute Times Nanogram Per Milliliter Per Milligram Per Gram Per Day | min*ng/mL/(mg/g/day) | min.ng/mL/(mg/g/d) | min.ng/ml/(mg/g/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898291","Minute Times Nanogram Per Milliliter Per Milligram Per Gram","C117948","Minute times nanogram per milliliter, divided by milligram per gram.","Minute Times Nanogram Per Milliliter Per Milligram Per Gram | min*ng/mL/(mg/g) | min.ng/mL/(mg/g) | min.ng/ml/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829025","Minute Times Nanogram per Milliliter per Kilogram per Meter Squared","C111268","Minutes times nanograms per milliliter, divided by kilograms per meter squared.","Minute Times Nanogram per Milliliter per Kilogram per Meter Squared | min*ng/mL/(kg/m2) | min.ng/mL/(kg/m2) | min.ng/ml/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827900","Minute Times Nanogram per Milliliter","C85732","Minutes times nanograms per milliliter.","Minute Times Nanogram per Milliliter | min*ng/mL | min*ug/L | min.ng/mL | min.ng/ml | ng*min/mL | ug*min/L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829028","Minute Times Mole per Liter per Meter Squared","C111267","Minutes times moles per liter, divided by meters squared.","Minute Times Mole per Liter per Meter Squared | min*mol/L/m2 | min.mol/L/m2 | min.mol/l/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898282","Minute Times mole Per Liter Per Milligram Per Gram Per Day","C117947","Minute times mole per liter, divided by milligram per gram per day.","Minute Times mole Per Liter Per Milligram Per Gram Per Day | min*mol/L/(mg/g/day) | min.mol/L/(mg/g/d) | min.mol/l/(mg/g/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898281","Minute Times mole Per Liter Per Milligram Per Gram","C117946","Minute times mole per liter, divided by milligram per gram.","Minute Times mole Per Liter Per Milligram Per Gram | min*mol/L/(mg/g) | min.mol/L/(mg/g) | min.mol/l/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829029","Minute Times Mole per Liter per Kilogram per Meter Squared","C111266","Minutes times moles per liter, divided by kilograms per meter squared.","Minute Times Mole per Liter per Kilogram per Meter Squared | min*mol/L/(kg/m2) | min.mol/L/(kg/m2) | min.mol/l/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827898","Minute Times Millimole per Milliliter","C85730","Minutes times millimoles per milliliter.","Minute Times Millimole per Milliliter | min*mmol/mL | min*mol/L | min*umol/uL | min.mol/L | min.mol/l | mmol*min/mL | mol*min/L | umol*min/uL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829032","Minute Times Millimole per Liter per Meter Squared","C111265","Minutes times millimoles per liter, divided by meters squared.","Minute Times Millimole per Liter per Meter Squared | min*mmol/L/m2 | min.mmol/L/m2 | min.mmol/l/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829035","Minute Times Millimole Per Liter Per Gram","C112344","Minutes times millimoles per liter, divided by grams.","Minute Times Millimole Per Liter Per Gram | Minute Times Mole Per Liter Per Kilogram | min*mmol/L/g | min*mol/L/kg | min.mmol/L/g | min.mmol/l/g | min.mol/L/kg | min.mol/l/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898294","Minute Times Millimole Per Liter Per Milligram Per Gram Per Day","C117945","Minute times millimole per liter, divided by milligram per gram per day.","Minute Times Millimole Per Liter Per Milligram Per Gram Per Day | min*mmol/L/(mg/g/day) | min.mmol/L/(mg/g/d) | min.mmol/l/(mg/g/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898293","Minute Times Millimole Per Liter Per Milligram Per Gram","C117944","Minute times millimole per liter, divided by milligram per gram.","Minute Times Millimole Per Liter Per Milligram Per Gram | min*mmol/L/(mg/g) | min.mmol/L/(mg/g) | min.mmol/l/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829033","Minute Times Millimole per Liter per Kilogram per Meter Squared","C111264","Minutes times millimoles per liter, divided by kilograms per meter squared.","Minute Times Millimole per Liter per Kilogram per Meter Squared | min*mmol/L/(kg/m2) | min.mmol/L/(kg/m2) | min.mmol/l/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439413","Minute Times Micromole per Milliliter","C85728","Minutes times micromoles per milliliter.","Minute Times Micromole per Milliliter | min*mcmol/mL | min*mmol/L | min*umol/mL | min.mmol/L | min.mmol/l | mmol*min/L | umol*min/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829036","Minute Times Milligram per Milliliter per Meter Squared","C111263","Minutes times milligrams per milliliter, divided by meters squared.","Minute Times Milligram per Milliliter per Meter Squared | min*mg/mL/m2 | min.mg/mL/m2 | min.mg/ml/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898296","Minute Times Milligram Per Milliliter Per Milligram Per Gram Per Day","C117943","Minute times milligram per milliliter, divided by milligram per gram per day.","Minute Times Milligram Per Milliliter Per Milligram Per Gram Per Day | min*mg/mL/(mg/g/day) | min.mg/mL/(mg/g/d) | min.mg/ml/(mg/g/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898295","Minute Times Milligram Per Milliliter Per Milligram Per Gram","C117942","Minute times milligram per milliliter, divided by milligram per gram.","Minute Times Milligram Per Milliliter Per Milligram Per Gram | min*mg/mL/(mg/g) | min.mg/mL/(mg/g) | min.mg/ml/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829037","Minute Times Milligram per Milliliter per Kilogram per Meter Squared","C111262","Minutes times milligrams per milliliter, divided by kilograms per meter squared.","Minute Times Milligram per Milliliter per Kilogram per Meter Squared | min*mg/mL/(kg/m2) | min.mg/mL/(kg/m2) | min.mg/ml/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827897","Minute Times Milligram per Milliliter","C85729","Minutes times milligrams per milliliter.","Minute Times Milligram per Milliliter | g*min/L | mg*min/mL | min*g/L | min*mg/mL | min*ug/uL | min.mg/mL | min.mg/ml | ug*min/uL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829048","Minute Times Gram per Milliliter per Meter Squared","C111257","Minutes times grams per milliliter, divided by meters squared.","Minute Times Gram per Milliliter per Meter Squared | min*g/mL/m2 | min.g/mL/m2 | min.g/ml/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829050","Minute Times Gram Per Milliliter Per Kilogram","C112337","Minutes times grams per milliliter, divided by kilograms.","Minute Times Gram Per Milliliter Per Kilogram | Minute Times Milligram Per Milliliter Per Gram | min*g/mL/kg | min*mg/mL/g | min.g/mL/kg | min.g/ml/kg | min.mg/mL/g | min.mg/ml/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829051","Minute Times Gram Per Milliliter Per Gram","C112336","Minutes times grams per milliliter, divided by grams.","Minute Times Gram Per Milliliter Per Gram | min*g/mL/g | min.g/mL/g | min.g/ml/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898284","Minute Times gram Per Milliliter Per Milligram Per Gram Per Day","C117941","Minute times gram per milliliter, divided by milligram per gram per day.","Minute Times gram Per Milliliter Per Milligram Per Gram Per Day | min*g/mL/(mg/g/day) | min.g/mL/(mg/g/d) | min.g/ml/(mg/g/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898283","Minute Times gram Per Milliliter Per Milligram Per Gram","C117940","Minute times gram per milliliter, divided by milligram per gram.","Minute Times gram Per Milliliter Per Milligram Per Gram | min*g/mL/(mg/g) | min.g/mL/(mg/g) | min.g/ml/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829049","Minute Times Gram per Milliliter per Kilogram per Meter Squared","C111256","Minutes times grams per milliliter, divided by kilograms per meter squared.","Minute Times Gram per Milliliter per Kilogram per Meter Squared | min*g/mL/(kg/m2) | min.g/mL/(kg/m2) | min.g/ml/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439410","Minute Times Gram per Milliliter","C85725","Minutes times grams per milliliter.","Minute Times Gram per Milliliter | g*min/mL | kg*min/L | min*g/mL | min*kg/L | min.g/mL | min.g/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829052","Minute Times Femtogram per Milliliter per Meter Squared","C111255","Minutes times femtograms per milliliter, divided by meters squared.","Minute Times Femtogram per Milliliter per Meter Squared | min*fg/mL/m2 | min.fg/mL/m2 | min.fg/ml/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829054","Minute Times Femtogram Per Milliliter Per Kilogram","C112335","Minutes times femtograms per milliliter, divided by kilograms.","Minute Times Femtogram Per Milliliter Per Kilogram | min*fg/mL/kg | min.fg/mL/kg | min.fg/ml/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829055","Minute Times Femtogram Per Milliliter Per Gram","C112334","Minutes times femtograms per milliliter, divided by grams.","Minute Times Femtogram Per Milliliter Per Gram | Minute Times Picogram Per Milliliter Per Kilogram | min*fg/mL/g | min*pg/mL/kg | min.fg/mL/g | min.fg/ml/g | min.pg/mL/kg | min.pg/ml/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050607","Milliliter per Milligram per Day","C120817","A unit of concentration equal to milliliter divided by milligram per day.","Milliliter per Milligram per Day | mL/(mg/d) | mL/(mg/day) | ml/(mg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054503","Milliliter per Kilogram per Meter Squared","C120816","A unit of concentration equal to milliliter divided by kilogram per meter squared.","Milliliter per Kilogram per Meter Squared | mL/(kg/m2) | ml/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898347","Milli-International Unit per Milliliter per Meter Squared","C119409","A unit of concentration (biologic activity) equal to one milli-international unit per milliliter, divided by meters squared.","Milli-International Unit per Milliliter per Meter Squared | mIU/mL/m2 | m[IU]/mL/m2 | m[IU]/ml/m2 | m[iU]/mL/m2 | m[iU]/ml/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898348","Milli-International Unit per Milliliter per Kilogram","C119408","A unit of concentration (biologic activity) equal to one milli-international unit per milliliter, divided by kilograms.","Milli-International Unit per Milliliter per Kilogram | Micro-International Units per Milliliter per Gram | mIU/mL/kg | m[IU]/mL/kg | m[IU]/ml/kg | m[iU]/mL/kg | m[iU]/ml/kg | uIU/mL/g | u[IU]/mL/g | u[IU]/ml/g | u[iU]/mL/g | u[iU]/ml/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898338","Milli-International Unit per Milliliter per Milligram per Meter Squared per Day","C119401","A unit of concentration (biologic activity) equal to one milli-international unit per milliliter, divided by milligrams per meter squared per day.","Milli-International Unit per Milliliter per Milligram per Meter Squared per Day | Micro-International Units per Milliliter per Microgram per Meter Squared per Day | mIU/mL/(mg/m2/day) | m[IU]/mL/(mg/m2/d) | m[IU]/ml/(mg/m2/d) | m[iU]/mL/(mg/m2/d) | m[iU]/ml/(mg/m2/d) | uIU/mL/(ug/m2/day) | u[IU]/mL/(ug/m2/d) | u[IU]/ml/(ug/m2/d) | u[iU]/mL/(ug/m2/d) | u[iU]/ml/(ug/m2/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898337","Milli-International Unit per Milliliter per Milligram per Meter Squared","C119400","A unit of concentration (biologic activity) equal to one milli-international unit per milliliter, divided by milligrams per meter squared.","Milli-International Unit per Milliliter per Milligram per Meter Squared | Micro-International Units per Milliliter per Microgram per Meter Squared | mIU/mL/(mg/m2) | m[IU]/mL/(mg/m2) | m[IU]/ml/(mg/m2) | m[iU]/mL/(mg/m2) | m[iU]/ml/(mg/m2) | uIU/mL/(ug/m2) | u[IU]/mL/(ug/m2) | u[IU]/ml/(ug/m2) | u[iU]/mL/(ug/m2) | u[iU]/ml/(ug/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898340","Milli-International Unit per Milliliter per Milligram per Kilogram per Day","C119399","A unit of concentration (biologic activity) equal to one milli-international unit per milliliter, divided by milligrams per kilogram per day.","Milli-International Unit per Milliliter per Milligram per Kilogram per Day | Micro-International Units per Milliliter per Microgram per Kilogram per Day | mIU/mL/(mg/kg/day) | m[IU]/mL/(mg/kg/d) | m[IU]/ml/(mg/kg/d) | m[iU]/mL/(mg/kg/d) | m[iU]/ml/(mg/kg/d) | uIU/mL/(ug/kg/day) | u[IU]/mL/(ug/kg/d) | u[IU]/ml/(ug/kg/d) | u[iU]/mL/(ug/kg/d) | u[iU]/ml/(ug/kg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898339","Milli-International Unit per Milliliter per Milligram per Kilogram","C119398","A unit of concentration (biologic activity) equal to one milli-international unit per milliliter, divided by milligrams per kilogram.","Milli-International Unit per Milliliter per Milligram per Kilogram | Micro-International Units per Milliliter per Microgram per Kilogram | mIU/mL/(mg/kg) | m[IU]/mL/(mg/kg) | m[IU]/ml/(mg/kg) | m[iU]/mL/(mg/kg) | m[iU]/ml/(mg/kg) | uIU/mL/(ug/kg) | u[IU]/mL/(ug/kg) | u[IU]/ml/(ug/kg) | u[iU]/mL/(ug/kg) | u[iU]/ml/(ug/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898341","Milli-International Unit per Milliliter per Milligram per Day","C119397","A unit of concentration (biologic activity) equal to one milli-international unit per milliliter, divided by milligrams per day.","Milli-International Unit per Milliliter per Milligram per Day | Micro-International Units per Milliliter per Microgram per Day | mIU/mL/(mg/day) | m[IU]/mL/(mg/d) | m[IU]/ml/(mg/d) | m[iU]/mL/(mg/d) | m[iU]/ml/(mg/d) | uIU/mL/(ug/day) | u[IU]/mL/(ug/d) | u[IU]/ml/(ug/d) | u[iU]/mL/(ug/d) | u[iU]/ml/(ug/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898349","Milli-International Unit per Milliliter per Kilogram per Meter Squared","C119396","A unit of concentration (biologic activity) equal to one milli-international unit per milliliter, divided by kilograms per meter squared.","Milli-International Unit per Milliliter per Kilogram per Meter Squared | mIU/mL/(kg/m2) | m[IU]/mL/(kg/m2) | m[IU]/ml/(kg/m2) | m[iU]/mL/(kg/m2) | m[iU]/ml/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829040","Minute Times Micromole per Liter per Meter Squared","C111261","Minutes times micromoles per liter, divided by meters squared.","Minute Times Micromole per Liter per Meter Squared | min*umol/L/m2 | min.umol/L/m2 | min.umol/l/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829042","Minute Times Micromole Per Liter Per Kilogram","C112341","Minutes times micromoles per liter, divided by kilograms.","Minute Times Micromole Per Liter Per Kilogram | Minute Times Nanomole Per Liter Per Gram | min*nmol/L/g | min*umol/L/kg | min.nmol/L/g | min.nmol/l/g | min.umol/L/kg | min.umol/l/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829043","Minute Times Micromole Per Liter Per Gram","C112340","Minutes times micromoles per liter, divided by grams.","Minute Times Micromole Per Liter Per Gram | Minute Times Millimole Per Liter Per Kilogram | min*mmol/L/kg | min*umol/L/g | min.mmol/L/kg | min.mmol/l/kg | min.umol/L/g | min.umol/l/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898298","Minute Times Micromole Per Liter Per Milligram Per Gram Per Day","C117959","Minute times micromole per liter, divided by milligram per gram per day.","Minute Times Micromole Per Liter Per Milligram Per Gram Per Day | min*umol/L/(mg/g/day) | min.umol/L/(mg/g/d) | min.umol/l/(mg/g/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898297","Minute Times Micromole Per Liter Per Milligram Per Gram","C117958","Minute times micromole per liter, divided by milligram per gram.","Minute Times Micromole Per Liter Per Milligram Per Gram | min*umol/L/(mg/g) | min.umol/L/(mg/g) | min.umol/l/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829041","Minute Times Micromole per Liter per Kilogram per Meter Squared","C111260","Minutes times micromoles per liter, divided by kilograms per meter squared.","Minute Times Micromole per Liter per Kilogram per Meter Squared | min*umol/L/(kg/m2) | min.umol/L/(kg/m2) | min.umol/l/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829044","Minute Times Microgram per Milliliter per Meter Squared","C111259","Minutes times micrograms per milliliter, divided by meters squared.","Minute Times Microgram per Milliliter per Meter Squared | min*ug/mL/m2 | min.ug/mL/m2 | min.ug/ml/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829046","Minute Times Microgram Per Milliliter Per Kilogram","C112339","Minutes times micrograms per milliliter, divided by kilograms.","Minute Times Microgram Per Milliliter Per Kilogram | Minute Times Nanogram Per Milliliter Per Gram | min*ng/mL/g | min*ug/mL/kg | min.ng/mL/g | min.ng/ml/g | min.ug/mL/kg | min.ug/ml/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829047","Minute Times Microgram Per Milliliter Per Gram","C112338","Minutes times micrograms per milliliter, divided by grams.","Minute Times Microgram Per Milliliter Per Gram | Minute Times Milligram Per Milliliter Per Kilogram | min*mg/mL/kg | min*ug/mL/g | min.mg/mL/kg | min.mg/ml/kg | min.ug/mL/g | min.ug/ml/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898300","Minute Times Microgram Per Milliliter Per Milligram Per Gram Per Day","C117957","Minute times microgram per milliliter, divided by milligram per gram per day.","Minute Times Microgram Per Milliliter Per Milligram Per Gram Per Day | min*ug/mL/(mg/g/day) | min.ug/mL/(mg/g/d) | min.ug/ml/(mg/g/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898299","Minute Times Microgram Per Milliliter Per Milligram Per Gram","C117956","Minute times microgram per milliliter, divided by milligram per gram.","Minute Times Microgram Per Milliliter Per Milligram Per Gram | min*ug/mL/(mg/g) | min.ug/mL/(mg/g) | min.ug/ml/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829045","Minute Times Microgram per Milliliter per Kilogram per Meter Squared","C111258","Minutes times micrograms per milliliter, divided by kilograms per meter squared.","Minute Times Microgram per Milliliter per Kilogram per Meter Squared | min*ug/mL/(kg/m2) | min.ug/mL/(kg/m2) | min.ug/ml/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827895","Minute Times Microgram per Milliliter","C85727","Minutes times micrograms per milliliter.","Minute Times Microgram per Milliliter | mcg*min/mL | mg*min/L | min*mcg/mL | min*mg/L | min*ug/mL | min.ug/mL | min.ug/ml | ug*min/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829011","Minute Times Picomole per Liter per Meter Squared","C111275","Minutes times picomoles per liter, divided by meters squared.","Minute Times Picomole per Liter per Meter Squared | min*pmol/L/m2 | min.pmol/L/m2 | min.pmol/l/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829013","Minute Times Picomole Per Liter Per Kilogram","C112355","Minutes times picomoles per liter, divided by kilograms.","Minute Times Picomole Per Liter Per Kilogram | min*pmol/L/kg | min.pmol/L/kg | min.pmol/l/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898286","Minute Times Picomole Per Liter Per Milligram Per Gram Per Day","C117955","Minute times picomole per liter, divided by milligram per gram per day.","Minute Times Picomole Per Liter Per Milligram Per Gram Per Day | min*pmol/L/(mg/g/day) | min.pmol/L/(mg/g/d) | min.pmol/l/(mg/g/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898285","Minute Times Picomole Per Liter Per Milligram Per Gram","C117954","Minute times picomole per liter, divided by milligram per gram.","Minute Times Picomole Per Liter Per Milligram Per Gram | min*pmol/L/(mg/g) | min.pmol/L/(mg/g) | min.pmol/l/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829012","Minute Times Picomole per Liter per Kilogram per Meter Squared","C111274","Minutes times picomoles per liter, divided by kilograms per meter squared.","Minute Times Picomole per Liter per Kilogram per Meter Squared | min*pmol/L/(kg/m2) | min.pmol/L/(kg/m2) | min.pmol/l/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829015","Minute Times Picomole Per Liter","C106543","Minutes times picomoles per liter.","Minute Times Picomole Per Liter | min*pmol/L | min.pmol/L | min.pmol/l",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829016","Minute Times Picogram per Milliliter per Meter Squared","C111273","Minutes times picograms per milliliter, divided by meters squared.","Minute Times Picogram per Milliliter per Meter Squared | min*pg/mL/m2 | min.pg/mL/m2 | min.pg/ml/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898288","Minute Times Picogram Per Milliliter Per Milligram Per Gram Per Day","C117953","Minute times picogram per milliliter, divided by milligram per gram per day.","Minute Times Picogram Per Milliliter Per Milligram Per Gram Per Day | min*pg/mL/(mg/g/day) | min.pg/mL/(mg/g/d) | min.pg/ml/(mg/g/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898287","Minute Times Picogram Per Milliliter Per Milligram Per Gram","C117952","Minute times picogram per milliliter, divided by milligram per gram.","Minute Times Picogram Per Milliliter Per Milligram Per Gram | min*pg/mL/(mg/g) | min.pg/mL/(mg/g) | min.pg/ml/(mg/g)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829017","Minute Times Picogram per Milliliter per Kilogram per Meter Squared","C111272","Minutes times picograms per milliliter, divided by kilograms per meter squared.","Minute Times Picogram per Milliliter per Kilogram per Meter Squared | min*pg/mL/(kg/m2) | min.pg/mL/(kg/m2) | min.pg/ml/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827902","Minute Times Picogram per Milliliter","C85734","Minutes times picograms per milliliter.","Minute Times Picogram per Milliliter | min*ng/L | min*pg/mL | min.pg/mL | min.pg/ml | ng*min/L | pg*min/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829020","Minute Times Nanomole per Liter per Meter Squared","C111271","Minutes times nanomoles per liter, divided by meters squared.","Minute Times Nanomole per Liter per Meter Squared | min*nmol/L/m2 | min.nmol/L/m2 | min.nmol/l/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829022","Minute Times Nanomole Per Liter Per Kilogram","C112351","Minutes times nanomoles per liter, divided by kilograms.","Minute Times Nanomole Per Liter Per Kilogram | Minute Times Picomole Per Liter Per Gram | min*nmol/L/kg | min*pmol/L/g | min.nmol/L/kg | min.nmol/l/kg | min.pmol/L/g | min.pmol/l/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898290","Minute Times Nanomole Per Liter Per Milligram Per Gram Per Day","C117951","Minute times nanomole per liter, divided by milligram per gram per day.","Minute Times Nanomole Per Liter Per Milligram Per Gram Per Day | min*nmol/L/(mg/g/day) | min.nmol/L/(mg/g/d) | min.nmol/l/(mg/g/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898326","Millimole per Liter per Gram","C119423","A unit of concentration equal to millimoles per liter, divided by grams.","Millimole per Liter per Gram | Micromole per Liter per Milligram | Mole per Liter per Kilogram | Nanomole per Liter per Microgram | mmol/L/g | mmol/l/g | mol/L/kg | mol/l/kg | nmol/L/ug | nmol/l/ug | umol/L/mg | umol/l/mg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898319","Millimole per Liter per Microgram per Meter Squared per Day","C119422","A unit of concentration equal to millimoles per liter, divided by micrograms per meter squared per day.","Millimole per Liter per Microgram per Meter Squared per Day | Mole per Liter per Milligram per Meter Squared per Day | mmol/L/(ug/m2/d) | mmol/L/(ug/m2/day) | mmol/l/(ug/m2/d) | mol/L/(mg/m2/d) | mol/L/(mg/m2/day) | mol/l/(mg/m2/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898318","Millimole per Liter per Microgram per Meter Squared","C119421","A unit of concentration equal to millimoles per liter, divided by micrograms per meter squared.","Millimole per Liter per Microgram per Meter Squared | Mole per Liter per Milligram per Meter Squared | mmol/L/(ug/m2) | mmol/l/(ug/m2) | mol/L/(mg/m2) | mol/l/(mg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898321","Millimole per Liter per Microgram per Kilogram per Day","C119420","A unit of concentration equal to millimoles per liter, divided by micrograms per kilogram per day.","Millimole per Liter per Microgram per Kilogram per Day | Mole per Liter per Milligram per Kilogram per Day | mmol/L/(ug/kg/d) | mmol/L/(ug/kg/day) | mmol/l/(ug/kg/d) | mol/L/(mg/kg/d) | mol/L/(mg/kg/day) | mol/l/(mg/kg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898320","Millimole per Liter per Microgram per Kilogram","C119419","A unit of concentration equal to millimoles per liter, divided by micrograms per kilogram.","Millimole per Liter per Microgram per Kilogram | Mole per Liter per Milligram per Kilogram | mmol/L/(ug/kg) | mmol/l/(ug/kg) | mol/L/(mg/kg) | mol/l/(mg/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898322","Millimole per Liter per Microgram per Day","C119418","A unit of concentration equal to millimoles per liter, divided by micrograms per day.","Millimole per Liter per Microgram per Day | Mole per Liter per Milligram per Day | mmol/L/(ug/d) | mmol/L/(ug/day) | mmol/l/(ug/d) | mol/L/(mg/d) | mol/L/(mg/day) | mol/l/(mg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897079","Millimole per Liter per Milligram per Meter Squared per Day","C119417","A unit of concentration equal to millimoles per liter, divided by milligrams per meter squared per day.","Millimole per Liter per Milligram per Meter Squared per Day | Micromole per Liter per Microgram per Meter Squared per Day | mmol/L/(mg/m2/d) | mmol/L/(mg/m2/day) | mmol/l/(mg/m2/d) | umol/L/(ug/m2/d) | umol/L/(ug/m2/day) | umol/l/(ug/m2/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898313","Millimole per Liter per Milligram per Meter Squared","C119416","A unit of concentration equal to millimoles per liter, divided by milligrams per meter squared.","Millimole per Liter per Milligram per Meter Squared | Micromole per Liter per Microgram per Meter Squared | mmol/L/(mg/m2) | mmol/l/(mg/m2) | umol/L/(ug/m2) | umol/l/(ug/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898315","Millimole per Liter per Milligram per Kilogram per Day","C119415","A unit of concentration equal to millimoles per liter, divided by milligrams per kilogram per day.","Millimole per Liter per Milligram per Kilogram per Day | Micromole per Liter per Microgram per Kilogram per Day | mmol/L/(mg/kg/d) | mmol/L/(mg/kg/day) | mmol/l/(mg/kg/d) | umol/L/(ug/kg/d) | umol/L/(ug/kg/day) | umol/l/(ug/kg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898314","Millimole per Liter per Milligram per Kilogram","C119414","A unit of concentration equal to millimoles per liter, divided by milligrams per kilogram.","Millimole per Liter per Milligram per Kilogram | Micromole per Liter per Microgram per Kilogram | mmol/L/(mg/kg) | mmol/l/(mg/kg) | umol/L/(ug/kg) | umol/l/(ug/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898316","Millimole per Liter per Milligram per Day","C119413","A unit of concentration equal to millimoles per liter, divided by milligrams per day.","Millimole per Liter per Milligram per Day | Micromole per Liter per Microgram per Day | mmol/L/(mg/d) | mmol/L/(mg/day) | mmol/l/(mg/d) | umol/L/(ug/d) | umol/L/(ug/day) | umol/l/(ug/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898325","Millimole per Liter per Kilogram per Meter Squared","C119412","A unit of concentration equal to millimoles per liter, divided by kilograms per meter squared.","Millimole per Liter per Kilogram per Meter Squared | mmol/L/(kg/m2) | mmol/l/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439431","Millimole per Hour","C85720","Millimoles per hour.","Millimole per Hour | mmol/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050628","Milliliter per Microgram per Kilogram","C120822","A unit of concentration equal to milliliter divided by microgram per kilogram.","Milliliter per Microgram per Kilogram | mL/(ug/kg) | ml/(ug/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050557","Milliliter per Milligram per Meter Squared per Day","C120821","A unit of concentration equal to milliliter divided by milligram per meter squared per day.","Milliliter per Milligram per Meter Squared per Day | mL/(mg/m2/d) | mL/(mg/m2/day) | ml/(mg/m2/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050623","Milliliter per Milligram per Meter Squared","C120820","A unit of concentration equal to milliliter divided by milligram per meter squared.","Milliliter per Milligram per Meter Squared | mL/(mg/m2) | ml/(mg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050602","Milliliter per Milligram per Kilogram per Day","C120819","A unit of concentration equal to milliliter divided by milligram per kilogram per day.","Milliliter per Milligram per Kilogram per Day | mL/(mg/kg/d) | mL/(mg/kg/day) | ml/(mg/kg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050552","Milliliter per Milligram per Kilogram","C120818","A unit of concentration equal to milliliter divided by milligram per kilogram.","Milliliter per Milligram per Kilogram | mL/(mg/kg) | ml/(mg/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448380","Recurrent Carcinoma","C7619","The reemergence of a carcinoma after a period of remission.","Recurrent Carcinoma | Recurrent Cancer | Relapsed Cancer | Relapsed Carcinoma",,,,,,,,,,,,,,,"764225","Recurrent malignant neoplastic disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3900090","Adverse Event MedDRA Body System or Organ Class Code","C117377","A coded value specifying the type of body system or organ class related to the adverse event from the Medical Dictionary for Regulatory Activities (MedDRA).","Adverse Event MedDRA Body System or Organ Class Code | AEBDSYCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826789","Adverse Event Body System or Organ Class","C83197","The body system or organ class affected by an adverse event.","Adverse Event Body System or Organ Class | AEBODSYS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981427","Clinical Events Body System or Organ Class","C87843","The body system or organ class affected by a clinical event.","Clinical Events Body System or Organ Class | CEBODSYS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981426","Clinical Events Assessment Reason Not Done","C87842","The explanation given as to why a clinical event was not assessed.","Clinical Events Assessment Reason Not Done | CEREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826819","Concomitant Medication Modified Reported Term","C83229","An indication or description of a change in concomitant medication.","Concomitant Medication Modified Reported Term | CMMODIFY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826821","Concomitant Medication Reason Not Collected","C83231","The rationale why concomitant medication data was not obtained.","Concomitant Medication Reason Not Collected | CMREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826829","Comment Evaluator","C83239","A person who determines the significance of a comment.","Comment Evaluator | COEVAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826240","Reference Comment","C82504","A reference associated with a particular comment.","Reference Comment | COREF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981451","Drug Accountability Assessment Reason Not Done","C87867","The explanation given as to why drug accountability was not assessed.","Drug Accountability Assessment Reason Not Done | DAREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981452","Drug Accountability Character Result in Standard Format","C87868","The standard character or string for representation and reporting of drug accountability data.","Drug Accountability Character Result in Standard Format | DASTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981456","Drug Accountability Numeric Result in Standard Unit","C87872","The numerical identifier of a drug accountability assessment result in standard units.","Drug Accountability Numeric Result in Standard Unit | DASTRESN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640922","Death Diagnosis Result Category","C102742","A classification of a death diagnosis result.","Death Diagnosis Result Category | DDRESCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899411","Death Diagnosis Character Result in Standard Format","C117547","The standard character or string for representation and reporting of death diagnosis data.","Death Diagnosis Character Result in Standard Format | DDSTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899225","Exposure as Collected Dose","C117479","The amount of substance that the patient or test subject was exposed to at one time, or the total quantity administered.","Exposure as Collected Dose | ECDOSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899222","Exposure as Collected Elapsed Time","C117503","The interval between two collected exposure reference time points.","Exposure as Collected Elapsed Time | ECELTM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899215","Exposure as Collected Link Group","C117472","A sequence of characters used to link multiple collected exposure records to a single finding.","Exposure as Collected Link Group | ECLNKGRP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899208","Exposure as Collected Pharmaceutical Strength","C117493","The content of an active ingredient in the exposure expressed quantitatively per dosage unit, per unit of volume, or per unit of weight, according to the pharmaceutical dose form.","Exposure as Collected Pharmaceutical Strength | ECPSTRG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899209","Exposure as Collected Pharmaceutical Strength Units","C117494","The unit of measure for the content of an active ingredient in the exposure, expressed quantitatively per dosage unit.","Exposure as Collected Pharmaceutical Strength Units | ECPSTRGU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562719","Survey of Autonomic Symptoms","C155966","A questionnaire developed by Zilliox et al. in 2011 that consists of 11 items for women and 12 items for men, and utilizes a five-point rating scale to assess the severity of autonomic symptoms in patients with neuropathy.","Survey of Autonomic Symptoms | SAS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826848","Electrocardiogram Elapsed Time","C83258","The interval between two electrocardiogram reference time points.","Electrocardiogram Elapsed Time | EGELTM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826854","Electrocardiogram Reason Not Done","C83264","The rationale why an electrocardiogram was not obtained.","Electrocardiogram Reason Not Done | EGREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937200","Short Somatic Mutation","C157604","Single nucleotide polymorphisms (SNPs) or short nucleotide insertions (ins), deletions (del) or indels that originate in cells that are not destined to become gametes and are not passed on to progeny.","Short Somatic Mutation | Short Somatic Variant | Short Somatic Variation | Somatic Short-Variants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3809621","Pulmonary Arterial Hypertension","C157552","Increased pressure within the pulmonary arterial circulation.","Pulmonary Arterial Hypertension | PAH",,,,,,,,,,,,,,,"4013643","Pulmonary arterial hypertension",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2826858","Electrocardiogram Character Result in Standard Format","C83268","The standard character or string for representation and reporting of electrocardiogram data.","Electrocardiogram Character Result in Standard Format | EGSTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826859","Electrocardiogram Numeric Result in Standard Unit","C83269","The numerical identifier of an electrocardiogram result in standard units.","Electrocardiogram Numeric Result in Standard Unit | EGSTRESN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826864","Electrocardiogram External File Name","C83274","The literal identifier of an external file name.","Electrocardiogram External File Name | EGXFN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826871","Exposure Elapsed Time","C83281","The interval between two exposure reference time points.","Exposure Elapsed Time | EXELTM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086285","Exposure Link Group Identifier","C123977","A sequence of characters used to link multiple exposure assessment records to a single finding.","Exposure Link Group Identifier | EXLNKGRP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830125","Findings About Events or Interventions Baseline Flag","C113359","An indication or description that a finding about an event or intervention is a baseline value.","Findings About Events or Interventions Baseline Flag | FABLFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830124","Findings About Events or Interventions Character Result in Standard Format","C113368","The standard character or string for representation and reporting of findings about events or interventions data.","Findings About Events or Interventions Character Result in Standard Format | FASTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830118","Findings About Events or Interventions Numeric Result in Standard Unit","C113369","The numerical identifier of findings about events or interventions result in standard units.","Findings About Events or Interventions Numeric Result in Standard Unit | FASTRESN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981477","Findings About Events or Interventions Test Code","C87893","A character or string that represents the short code name of the finding of the event or intervention.","Findings About Events or Interventions Test Code | FATESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826883","Identifying Variable","C83293","The variable that identifies a particular data element.","Identifying Variable | IDVAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826884","Identifying Variable Value","C83294","The appraisal of the variable that identifies a particular data element.","Identifying Variable Value | IDVARVAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898803","Immunogenicity Specimen Assessments Category","C117557","Classification of immunogenicity specimen assessments data.","Immunogenicity Specimen Assessments Category | ISCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898800","Immunogenicity Specimen Assessments Data Collection Date Time","C117571","The date and time of immunogenicity specimen assessment data collection.","Immunogenicity Specimen Assessments Data Collection Date Time | ISDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898798","Immunogenicity Specimen Assessments Lower Limit of Quantitation","C117570","The lowest value in a possible range of values for the immunogenicity specimen assessment.","Immunogenicity Specimen Assessments Lower Limit of Quantitation | ISLLOQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898797","Immunogenicity Specimen Assessments Method","C117568","The technique used to administer the immunogenicity specimen assessment.","Immunogenicity Specimen Assessments Method | ISMETHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898793","Immunogenicity Specimen Assessments Reason Not Done","C117565","The rationale why an immunogenicity specimen assessment was not performed.","Immunogenicity Specimen Assessments Reason Not Done | ISREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898788","Immunogenicity Specimen Assessments Subcategory","C117558","A subdivision of immunogenicity specimen assessments.","Immunogenicity Specimen Assessments Subcategory | ISSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898802","Immunogenicity Specimen Assessments Character Result in Standard Format","C117561","The standard character or string for representation and reporting of immunogenicity specimen assessment data.","Immunogenicity Specimen Assessments Character Result in Standard Format | ISSTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898796","Immunogenicity Specimen Assessments Numeric Result in Standard Unit","C117562","The numerical identifier of an immunogenicity specimen assessment result in standard units.","Immunogenicity Specimen Assessments Numeric Result in Standard Unit | ISSTRESN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898786","Immunogenicity Specimen Assessments Test","C117556","A character or string that represents the long name of the immunogenicity specimen assessment.","Immunogenicity Specimen Assessments Test | ISTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898787","Immunogenicity Specimen Assessments Test Code","C117555","A character or string that represents the short code name of the immunogenicity specimen assessment.","Immunogenicity Specimen Assessments Test Code | ISTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826897","Laboratory Test Elapsed Time","C83307","The interval between two laboratory test reference time points.","Laboratory Test Elapsed Time | LBELTM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826901","Laboratory Test LOINC Code","C83311","The LOINC code of a laboratory test.","Laboratory Test LOINC Code | LBLOINC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826903","Laboratory Test Reason Not Done","C83313","The rationale why a laboratory test was not performed.","Laboratory Test Reason Not Done | LBREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826707","Laboratory Test Reference Range for Character Results Standard Unit","C83096","The reference range of a laboratory test outcome, as reported in standard units.","Laboratory Test Reference Range for Character Results Standard Unit | LBSTNRC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826907","Laboratory Test Reference Range Upper Limit Standard Unit","C83317","The greatest value in a range of expected results for a particular laboratory test in standard units.","Laboratory Test Reference Range Upper Limit Standard Unit | LBSTNRHI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826908","Laboratory Test Reference Range Lower Limit Standard Unit","C83318","The least value in a range of expected results for a particular laboratory test in standard units.","Laboratory Test Reference Range Lower Limit Standard Unit | LBSTNRLO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828386","Pass","C81275","One of two possible results of a pass/fail assessment; when the result satisfies a condition.","Pass | PASS | Passed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826910","Laboratory Test Numeric Result in Standard Unit","C83320","The numerical identifier of the laboratory test result in standard units.","Laboratory Test Numeric Result in Standard Unit | LAB_RESULT_NUMERIC | LBSTRESN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826912","Laboratory Test Code","C83322","A character or string that represents the short code name of the laboratory test.","Laboratory Test Code | LBTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981483","Microbiology Specimen Category","C87899","A classification of microbiology specimen data.","Microbiology Specimen Category | MBCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981597","Microbiology Specimen Date Time","C88015","The date and time of the microbiology specimen data.","Microbiology Specimen Date Time | MBDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981489","Microbiology Specimen Elapsed Time","C87905","The interval between two microbiology specimen reference time points.","Microbiology Specimen Elapsed Time | MBELTM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981495","Microbiology Specimen LOINC Code","C87911","A sequence of characters that identifies microbiology specimen data within the Logical Observation Identifiers Names and Codes (LOINC) database.","Microbiology Specimen LOINC Code | MBLOINC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981491","Microbiology Specimen Examination Original Result","C87907","The value in which the outcome of the microbiology specimen examination observation was originally reported.","Microbiology Specimen Examination Original Result | MBORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981482","Microbiology Specimen Assessment Reason Not Done","C87898","The explanation given as to why microbiology specimen was not assessed.","Microbiology Specimen Assessment Reason Not Done | MBREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981604","Microbiology Specimen Result Category","C88022","A classification of a microbiology specimen result.","Microbiology Specimen Result Category | MBRESCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981486","Microbiology Specimen Date Time of Reference Timepoint","C87902","The date and time of a microbiology specimen data reference point.","Microbiology Specimen Date Time of Reference Timepoint | MBRFTDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981503","Microbiology Specimen Subcategory","C87919","A subdivision of microbiology specimen data.","Microbiology Specimen Subcategory | MBSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981484","Microbiology Specimen Character Result in Standard Format","C87900","The standard character or string for representation and reporting of microbiology specimen data.","Microbiology Specimen Character Result in Standard Format | MBSTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981499","Microbiology Specimen Numeric Result in Standard Unit","C87915","The numerical identifier of a microbiology specimen result in standard units.","Microbiology Specimen Numeric Result in Standard Unit | MBSTRESN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981504","Microbiology Specimen Test","C87920","A character or string that represents a microbiology specimen examination.","Microbiology Specimen Test | MBTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981505","Microbiology Specimen Test Code","C87921","A character or string that represents the short code name of the microbiology specimen examination.","Microbiology Specimen Test Code | MBTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826924","Medical History Reason Not Done","C83334","The rationale why a medical history was not obtained.","Medical History Reason Not Done | MHREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898364","Microscopic Findings Reason Not Done","C117589","The rationale why a microscopic finding was not obtained.","Microscopic Findings Reason Not Done | MIREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898378","Microscopic Findings Character Result in Standard Format","C117584","The standard character or string for representation and reporting of microscopic findings data.","Microscopic Findings Character Result in Standard Format | MISTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898367","Microscopic Findings Numeric Result in Standard Unit","C117585","The numerical identifier of microscopic findings result in standard units.","Microscopic Findings Numeric Result in Standard Unit | MISTRESN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898258","Morphology Analysis Method","C117625","A means, manner of procedure, or systematic course of actions that are performed in order to examine and interpret a morphology assessment.","Morphology Analysis Method | MOANMETH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898256","Morphology Category","C117608","A classification of morphology data.","Morphology Category | MOCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898253","Morphology Data Collection Date Time","C117629","The date and time morphology data was collected.","Morphology Data Collection Date Time | MODTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898250","Morphology Elapsed Time","C117633","The interval between two morphology reference time points.","Morphology Elapsed Time | MOELTM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898241","Morphology Original Result","C117611","The outcome of the morphology assessment as originally received or collected.","Morphology Original Result | MOORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898237","Morphology Position","C117610","The physical bearing of the body during a morphology assessment.","Morphology Position | MOPOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1997217","Low Grade Glioma","C132067","A grade I or grade II glioma arising from the central nervous system. This category includes pilocytic astrocytoma, diffuse astrocytoma, subependymal giant cell astrocytoma, ependymoma, oligodendroglioma, oligoastrocytoma, and angiocentric glioma.","Low Grade Glioma | CNS, low grade glioma (LGG) | LGG | Low Grade Glial Neoplasm | Low-Grade Glioma",,,,,,,,,,,,,,,"4327877","Low grade glioma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898236","Morphology Reason Not Done","C117617","The rationale why a morphology test was not performed.","Morphology Reason Not Done | MOREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898252","Morphology Date Time of Reference Timepoint","C117635","The date and time of a specific reference point for the morphology assessment.","Morphology Date Time of Reference Timepoint | MORFTDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898231","Morphology Subcategory","C117609","A subdivision of morphology data.","Morphology Subcategory | MOSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898255","Morphology Character Result in Standard Format","C117613","The standard character or string for representation and reporting of morphology data.","Morphology Character Result in Standard Format | MOSTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898243","Morphology Numeric Result in Standard Unit","C117614","The numerical identifier of morphology result in standard units.","Morphology Numeric Result in Standard Unit | MOSTRESN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889985","Morphology Test","C117607","A character or string that represents the long name of the morphology assessment.","Morphology Test | MOTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889986","Morphology Test Code","C117606","A character or string that represents the short code name of the morphology assessment.","Morphology Test Code | MOTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898248","Morphology External Filename","C117618","The literal identifier of an morphology external file name.","Morphology External Filename | MOXFN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981511","Microbiology Susceptibility Category","C87927","A classification of microbiology susceptibility data.","Microbiology Susceptibility Category | MSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981598","Microbiology Susceptibility Date Time","C88016","The date and time of the microbiology susceptibility data.","Microbiology Susceptibility Date Time | MSDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981515","Microbiology Susceptibility Elapsed Time","C87931","The interval between two microbiology susceptibility reference time points.","Microbiology Susceptibility Elapsed Time | MSELTM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981517","Microbiology Susceptibility LOINC Code","C87933","A sequence of characters that identifies microbiology susceptibility data within the Logical Observation Identifiers Names and Codes (LOINC) database.","Microbiology Susceptibility LOINC Code | MSLOINC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981519","Microbiology Susceptibility Original Result","C87935","The value in which the outcome of the microbiology susceptibility assessment observation was originally reported.","Microbiology Susceptibility Original Result | MSORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981521","Microbiology Susceptibility Reason Not Done","C87937","The explanation given as to why microbiology susceptibility was not assessed.","Microbiology Susceptibility Reason Not Done | MSREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981527","Microbiology Susceptibility Subcategory","C87943","A subdivision of microbiology susceptibility data.","Microbiology Susceptibility Subcategory | MSSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981512","Microbiology Susceptibility Character Result in Standard Format","C87928","The standard character or string for representation and reporting of microbiology susceptibility data.","Microbiology Susceptibility Character Result in Standard Format | MSSTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981523","Microbiology Susceptibility Numeric Result in Standard Unit","C87939","The numerical identifier of a microbiology susceptibility assessment result in standard units.","Microbiology Susceptibility Numeric Result in Standard Unit | MSSTRESN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0806957","Microbial Susceptibility Test","C85540","A method to determine whether microbial growth is affected by an antimicrobial compound.","Microbial Susceptibility Test | MICROSUS | MSTEST | Microbial Susceptibility | Microbiology Susceptibility Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981528","Microbiology Susceptibility Test Code","C87945","A character or string that represents the short code name of the microbiology susceptibility assessment.","Microbiology Susceptibility Test Code | MSTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981532","Pharmacokinetic Concentration Category","C87949","A classification of pharmacokinetic concentration data.","Pharmacokinetic Concentration Category | PCCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981537","Pharmacokinetic Concentration Elapsed Time","C87954","The interval between two pharmacokinetic concentration reference time points.","Pharmacokinetic Concentration Elapsed Time | PCELTM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981539","Pharmacokinetic Concentration Evaluation Interval","C87956","The period of time during which a pharmacokinetic concentration evaluation was performed.","Pharmacokinetic Concentration Evaluation Interval | PCEVLINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981542","Pharmacokinetic Concentration Lower Limit of Quantitation","C87959","The lowest value in a possible range of values for a pharmacokinetic concentration assessment.","Pharmacokinetic Concentration Lower Limit of Quantitation | PCLLOQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981554","Pharmacokinetic Concentration Subcategory","C87971","A subdivision of pharmacokinetic concentration data.","Pharmacokinetic Concentration Subcategory | PCSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981533","Pharmacokinetic Concentration Character Result in Standard Format","C87950","The standard character or string for representation and reporting of pharmacokinetic concentration data.","Pharmacokinetic Concentration Character Result in Standard Format | PCSTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981548","Pharmacokinetic Concentration Numeric Result in Standard Unit","C87965","The numerical identifier of a pharmacokinetic concentration result in standard units.","Pharmacokinetic Concentration Numeric Result in Standard Unit | PCSTRESN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981556","Pharmacokinetic Concentration Test Code","C87973","A character or string that represents the short code name of the pharmacokinetic concentration assessment.","Pharmacokinetic Concentration Test Code | PCTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086740","Pharmacokinetic Concentration Upper Limit Value","C124034","The highest value in a standard range of pharmacokinetic concentration values.","Pharmacokinetic Concentration Upper Limit Value | PCULOQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826942","Physical Examination Original Result","C83352","The earliest outcome of the study questionnaire assessment.","Physical Examination Original Result | PEORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826948","Physical Examination Character Result in Standard Unit","C83359","The standard character or string for representation and reporting of pharmacokinetic parameter data.","Physical Examination Character Result in Standard Unit | PESTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826951","Physical Examination Test Code","C83362","A character or string that represents the short code name of the physical examination test.","Physical Examination Test Code | PETESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981560","Pharmacokinetic Parameter Category","C87977","A classification of pharmacokinetic parameter data.","Pharmacokinetic Parameter Category | PPCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981600","Pharmacokinetic Parameter Date Time","C88018","The date and time of the pharmacokinetic parameter data.","Pharmacokinetic Parameter Date Time | PPDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981564","Pharmacokinetic Parameter Original Result","C87981","The value in which the outcome of the pharmacokinetic parameter was originally reported.","Pharmacokinetic Parameter Original Result | PPORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981565","Pharmacokinetic Parameter Original Result Unit","C87982","The unit of measure first specified in a pharmacokinetic parameter assessment.","Pharmacokinetic Parameter Original Result Unit | PPORRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981566","Pharmacokinetic Parameter Reason Not Done","C87983","The explanation given as to why pharmacokinetic parameter was not assessed.","Pharmacokinetic Parameter Reason Not Done | PPREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981562","Pharmacokinetic Parameter Date Time of Reference Timepoint","C87979","The date and time of a pharmacokinetic parameter reference point.","Pharmacokinetic Parameter Date Time of Reference Timepoint | PPRFTDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981570","Pharmacokinetic Parameter Subcategory","C87987","A subdivision of pharmacokinetic parameter data.","Pharmacokinetic Parameter Subcategory | PPSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981561","Pharmacokinetic Parameter Character Result in Standard Format","C87978","The standard character or string for representation and reporting of pharmacokinetic parameter data.","Pharmacokinetic Parameter Character Result in Standard Format | PPSTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL497439","Pharmacokinetic Parameter Numeric Result in Standard Unit","C87984","The numerical identifier of a pharmacokinetic parameter result in standard units.","Pharmacokinetic Parameter Numeric Result in Standard Unit | PPSTRESN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981567","Pharmacokinetic Parameters Result Standard Unit","C113378","The standard unit of measure for pharmacokinetic parameters results.","Pharmacokinetic Parameters Result Standard Unit | PPSTRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981571","Pharmacokinetic Parameter Test","C87988","A character or string that represents a pharmacokinetic parameter examination.","Pharmacokinetic Parameter Test | PPTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981572","Pharmacokinetic Parameter Test Code","C87989","A character or string that represents the short code name of the pharmacokinetic parameter assessment.","Pharmacokinetic Parameter Test Code | PPTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897017","Procedure Dose","C117518","The amount of substance that the patient or test subject was administered during the procedure, or the total quantity administered.","Procedure Dose | PRDOSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897843","Procedure Elapsed Time","C117536","The interval between two procedure reference time points.","Procedure Elapsed Time | PRELTM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897836","Procedure Link Group","C117510","A sequence of characters used to link multiple procedures to a single finding.","Procedure Link Group | PRLNKGRP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826957","Questionnaire Category","C83368","A classification of questionnaire data.","Questionnaire Category | QSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826961","Questionnaire Elapsed Time","C83372","The interval between two questionnaire reference time points.","Questionnaire Elapsed Time | QSELTM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826962","Questionnaire Evaluation Interval","C83373","A period of time during a questionnaire evaluation.","Questionnaire Evaluation Interval | QSEVLINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826964","Questionnaire Original Result","C83375","The first outcome of a study questionnaire assessment.","Questionnaire Original Result | QSORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826966","Questionnaire Reason Not Done","C83377","The rationale why questionnaire data was not obtained.","Questionnaire Reason Not Done | QSREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981580","Questionnaire Date Time of Reference Timepoint","C87997","The date and time of a questionnaire reference point.","Questionnaire Date Time of Reference Timepoint | QSRFTDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826967","Questionnaire Subcategory","C83378","A subdivision of questionnaire data.","Questionnaire Subcategory | QSSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826971","Questionnaire Character Result in Standard Unit","C83382","The standard character or string for representation and reporting of questionnaire data.","Questionnaire Character Result in Standard Unit | QSSTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826972","Questionnaire Numeric Result in Standard Unit","C83383","The numerical identifier of a questionnaire result in standard unit.","Questionnaire Numeric Result in Standard Unit | QSSTRESN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826974","Questionnaire Test","C83385","A character or string that represents the full name of the questionnaire assessment.","Questionnaire Test | QSTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826975","Questionnaire Test Code","C83386","A character or string that represents the short code name of the questionnaire test.","Questionnaire Test Code | QSTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897714","Reproductive System Findings Character Result in Standard Format","C117646","The standard character or string for representation and reporting of reproductive system findings data.","Reproductive System Findings Character Result in Standard Format | RPSTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897709","Reproductive System Findings Numeric Result in Standard Unit","C117647","The numerical identifier of reproductive system findings result in standard units.","Reproductive System Findings Numeric Result in Standard Unit | RPSTRESN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889267","Reproductive System Finding Test Code","C117640","A character or string that represents the short code name of the reproductive system finding assessment.","Reproductive System Finding Test Code | RPTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899366","Disease Response Category","C117388","A classification of disease response data.","Disease Response Category | RSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899438","Date and Time of Disease Response Assessment","C117389","The date and time of disease response data collection.","Date and Time of Disease Response Assessment | RSDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899361","Disease Response Link Group","C117394","A sequence of characters used to link multiple disease response records to a single finding.","Disease Response Link Group | RSLNKGRP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899359","Disease Response Original Result","C117397","The outcome of the disease response assessment as originally received or collected.","Disease Response Original Result | RSORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899358","Disease Response Reason Not Done","C117398","The rationale why a disease response assessment was not performed.","Disease Response Reason Not Done | RSREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889268","Disease Response Assessment Character Result in Standard Format","C117403","The standard character or string for representation and reporting of disease response data.","Disease Response Assessment Character Result in Standard Format | RSSTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796418","Visual Pathway Glioma","C8567","A glioma that arises from the visual pathway. This condition can be seen in association with neurofibromatosis 1. It is most commonly seen in the pediatric age group.","Visual Pathway Glioma | Glioma of Visual Pathway | Glioma of the Visual Pathway | Optic Pathway Glioma | optic pathway glioma | visual pathway glioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826990","Subject Characteristics Reason Not Done","C83401","The rationale why subject characteristic data was not obtained.","Subject Characteristics Reason Not Done | SCREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826995","Subject Characteristics Character Result in Standard Unit","C83406","The standard character or string for representation and reporting of subject characteristics data.","Subject Characteristics Character Result in Standard Unit | SCSTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826996","Subject Characteristics Numeric Result in Standard Unit","C83407","The numerical identifier of subject characteristics result data in standard units.","Subject Characteristics Numeric Result in Standard Unit | SCSTRESN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897593","Skin Response Elapsed Time","C117696","The interval between two skin response reference time points.","Skin Response Elapsed Time | SRELTM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897597","Skin Response Character Result in Standard Format","C117681","The standard character or string for representation and reporting of skin response data.","Skin Response Character Result in Standard Format | SRSTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897587","Skin Response Numeric Result in Standard Unit","C117682","The numerical identifier of skin response result in standard units.","Skin Response Numeric Result in Standard Unit | SRSTRESN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897444","Subject Status Category","C117661","A classification of subject status data.","Subject Status Category | SSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897441","Subject Status Data Collection Date Time","C117668","The date and time subject status data was collected.","Subject Status Data Collection Date Time | SSDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897438","Subject Status Original Result","C117663","The outcome of the subject status assessment as originally received or collected.","Subject Status Original Result | SSORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897437","Subject Status Reason Not Done","C117666","The rationale why a subject status assessment was not performed.","Subject Status Reason Not Done | SSREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897434","Subject Status Subcategory","C117662","A subdivision of subject status data.","Subject Status Subcategory | SSSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897443","Subject Status Character Result in Standard Format","C117664","The standard character or string for representation and reporting of subject status data.","Subject Status Character Result in Standard Format | SSSTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897432","Subject Status Test","C117660","A character or string that represents the long name of the subject status assessment.","Subject Status Test | SSTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897433","Subject Status Test Code","C117659","A character or string that represents the short code name of the subject status assessment.","Subject Status Test Code | SSTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827023","Subject Visit End Date Time","C83435","The date and time a subject visit has concluded.","Subject Visit End Date Time | SVENDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827024","Subject Visit Start Date Time","C83436","The date and time a subject visit began.","Subject Visit Start Date Time | SVSTDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897280","Tumor Results Date and Time of Assessment","C117407","The date and time of tumor results data collection.","Tumor Results Date and Time of Assessment | TRDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897276","Tumor Results Link Group","C117412","A sequence of characters used to link multiple tumor results records to a single finding.","Tumor Results Link Group | TRLNKGRP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897271","Tumor Results Original Result","C117416","The outcome of the tumor results assessment as originally received or collected.","Tumor Results Original Result | TRORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897270","Tumor Results Reason Not Done","C117418","The rationale why a tumor measurement was not performed.","Tumor Results Reason Not Done | TRREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897281","Tumor Results Character Result in Standard Format","C117423","The standard character or string for representation and reporting of tumor results data.","Tumor Results Character Result in Standard Format | TRSTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897273","Tumor Results Numeric Result in Standard Unit","C117424","The numerical identifier of a tumor result in standard units.","Tumor Results Numeric Result in Standard Unit | TRSTRESN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889740","Tumor Results Assessment Test","C117426","A character or string that represents the long name of the tumor assessment.","Tumor Results Assessment Test | TRTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890728","Tumor Results Assessment Test Code","C117427","A character or string that represents the short code name of the tumor assessment.","Tumor Results Assessment Test Code | TRTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899433","Date and Time of Tumor Identification","C117430","The date and time of tumor identification data collection.","Date and Time of Tumor Identification | TUDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897290","Tumor Identifier Original Result","C117440","The outcome of the tumor identification assessment as originally received or collected.","Tumor Identifier Original Result | TUORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897299","Tumor Identifier Character Result in Standard Format","C117445","The standard character or string for representation and reporting of tumor identification data.","Tumor Identifier Character Result in Standard Format | TUSTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889963","Tumor Identifier Test","C117446","A character or string that represents the long name of the tumor identification assessment.","Tumor Identifier Test | TUTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889964","Tumor Identifier Test Code","C117447","A character or string that represents the short code name of the tumor identification assessment.","Tumor Identifier Test Code | TUTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827044","Vital Signs Elapsed Time","C83456","The interval between two vital signs reference time points.","Vital Signs Elapsed Time | VSELTM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827048","Vital Signs Reason Not Done","C83460","The rationale why vital signs data was not obtained.","Vital Signs Reason Not Done | VSREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827051","Vital Signs Character Result in Standard Unit","C83463","The standard character or string for representation and reporting of vital signs data.","Vital Signs Character Result in Standard Unit | VSSTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827052","Vital Signs Numeric Result in Standard Unit","C83464","The numerical identifier of vital signs result data in standard units.","Vital Signs Numeric Result in Standard Unit | VSSTRESN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827053","Vital Signs Result Standard Unit","C83465","The standard unit of measure for vital signs results.","Vital Signs Result Standard Unit | VSSTRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937235","HA-1(H) Genotype Positive","C157564","A genetic finding indicating that a subject expresses the HA-1(H) genotype and has a homozygous or heterozygous nucleotide substitution at position 416 of the ARHGAP45 gene where the guanine has been mutated to adenine, which encodes a variant of Rho GTPase-activating protein 45 where the arginine at position 139 has been replaced by histidine. The HA-1(H) form of ARHGAP45 protein can be processed into a nonapeptide that can be presented by HLA-A*0201 and other HLA-A isoforms, while the peptide produced by processing the protein resulting from transcription of the ARHGAP45 gene with guanine at position 416, which will have arginine at amino acid residue 139 (HA-1(R)) cannot bind HLA-A.","HA-1(H) Genotype Positive | HA-1(H) Genotype (rs1801284 A/G, A/A) Positive | HA-1(H) Positive | HA-1(H/H) or HA-1(H/R) Positive | rs1801284 A/G or A/A Positive | rs1801284 A/G or A/A Present | rs1801284 A/G, A/A Positive | rs1801284 A/G, A/A Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937228","TP53 Gene Alteration Positive","C157565","A finding indicating that mutation, overexpression or rearrangement of the TP53 gene has been detected in a sample.","TP53 Gene Alteration Positive | P53 Gene Alteration Positive | Tumor Protein p53 Gene Alteration Positive | p53 Gene Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937229","RB1 Gene Alteration Positive","C157566","A finding indicating that mutation, overexpression or rearrangement of the RB1 gene has been detected in a sample.","RB1 Gene Alteration Positive | RB Gene Alteration Positive | Retinoblastoma 1 Gene Alteration Positive | Retinoblastoma Gene Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937230","MicroRNA 1290","C157567","A 19 ribonucleotide sequence that is a final product of the processing of MIR1290 pre-miRNA. This oligonucleotide may be involved in the regulation of gene expression in various cancers.","MicroRNA 1290 | MIR1290 | MIRN1290 | hsa-miR-1290 | miR-1290",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937231","MicroRNA 1246","C157568","A 19 ribonucleotide sequence that is a final product of the processing of MIR1246 pre-miRNA. This oligonucleotide may be involved in transcriptional silencing and tumorigenesis.","MicroRNA 1246 | MIR1246 | MIRN1246 | hsa-miR-1246 | miR-1246",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937284","Biallelic CEBPA Gene Mutation","C157569","The presence of mutations in both alleles of the CEBPA gene.","Biallelic CEBPA Gene Mutation | C/EBP-Alpha Biallelic Gene Mutation | C/EBPalpha Biallelic Gene Mutation | CCAAT Enhancer Binding Protein Alpha Biallelic Gene Mutation | CCAAT/Enhancer Binding Protein Alpha Biallelic Gene Mutation | CCAAT/Enhancer Binding Protein, Alpha Biallelic Gene Mutation | CEBP Biallelic Gene Mutation | CEBPA Biallelic Gene Mutation | CEBPA Biallelic Mutation | biCEBPA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937285","Adenovirus DNA Viremia","C157570","A laboratory test result indicating the presence of adenovirus DNA in the blood.","Adenovirus DNA Viremia | AdV DNA Viremia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937286","PCM1-JAK2 Fusion Protein Expression","C157571","Expression of a fusion protein involving the human genes PCM1 and JAK2. It results from a translocation and is associated with myeloid and lymphoid cancers.","PCM1-JAK2 Fusion Protein Expression | PCM-1/JAK-2 Fusion Protein Expression | PCM1-JAK2 Fusion Protein Positive | PCM1/JAK2 Fusion Protein Expression | Pericentriolar Material 1 Protein/Tyrosine-Protein Kinase JAK2 Fusion Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515156","TEL/JAK2 Fusion Protein Expression","C37886","Expression of a fusion protein involving the human genes ETV6 and JAK2. It results from a translocation and is associated with early B acute lymphoid leukemia, atypical chronic myelogenous leukemia and T-cell acute lymphoid leukemia.","ETV6-JAK2 Fusion Protein Expression | ETV6-JAK2 Fusion Protein Expression | ETV6-JAK2 Fusion Protein Positive | ETV6/JAK2 Fusion Protein Expression | TEL-JAK2 Fusion Protein Expression | TEL-JAK2 Fusion Protein Expression | TEL/JAK2 Fusion Protein Expression | Transcription Factor ETV6/Tyrosine-Protein Kinase JAK2 Fusion Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937287","JAK2 Gene Rearrangement","C157572","A molecular abnormality indicating rearrangement of the JAK2 gene.","JAK2 Gene Rearrangement | JAK-2 Gene Rearrangement | JAK2 Rearrangement | JTK10 Gene Rearrangement | Janus Kinase 2 Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516134","BCR-JAK2 Fusion Protein Expression","C37888","Expression of a fusion protein involving the human genes BCR and JAK2. It results from a translocation and is associated with atypical chronic myeloid leukemia, myleoproliferative neoplasms, acute myeloid leukemia, B lymphoblastic leukemia/lymphoma and Burkitt lymphoma.","BCR-JAK2 Fusion Protein Expression | BCR-JAK2 Fusion Protein Positive | BCR/JAK2 Fusion Protein Expression | Breakpoint Cluster Region Protein/Tyrosine-Protein Kinase JAK2 Fusion Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937280","MAGT1 Gene Mutation","C157579","A change in the nucleotide sequence of the MAGT1 gene.","MAGT1 Gene Mutation | IAP Gene Mutation | MagT1 Mutation | Magnesium Transporter 1 Gene Mutation | OST3B Gene Mutation | XMEN Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937281","Activating PTEN Gene Mutation","C157580","A change in the nucleotide sequence of the PTEN gene that that results in constitutive activation of both phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN and its downstream signaling pathways.","Activating PTEN Gene Mutation | Activating MMAC1 Gene Mutation | Activating Mutated in Multiple Advanced Cancers 1 Gene Mutation | Activating PTEN1 Gene Mutation | Activating Phosphatase and Tensin Homolog Gene Mutation | Activating TEP1 Gene Mutation | PTEN Activating Gene Mutation | PTEN Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937275","GGAA Microsatellite Repeat","C157581","A microsatellite containing 18-26 repeats of the tetranucleotide sequence, GGAA. EWSR1/FLI1 and EWSR1/ETS family fusion proteins bind to GGAA microsatellite sequences in certain gene promoters, which aberrantly upregulates transcription of those genes and is associated with Ewing Sarcoma.","GGAA Microsatellite Repeat | GGAA Microsatellite | GGAA-Microsatellite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937276","SHH Positive","C157582","An indication that SHH expression has been detected in a sample.","SHH Positive | HHG1 Positive | Sonic Hedgehog Homolog Positive | Sonic Hedgehog Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937278","Elevated DKK1","C157584","A finding indicating elevated concentrations of DKK1 in a sample.","Elevated DKK1 | Elevated DKK-1 | Elevated Dickkopf Homolog 1 | Elevated Dickkopf-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937271","EGFR Gene Alteration Positive","C157585","A finding indicating that mutation, overexpression or rearrangement of the EGFR gene has been detected in a sample.","EGFR Gene Alteration Positive | ERBB Gene Alteration Positive | ERBB1 Gene Alteration Positive | Epidermal Growth Factor Receptor Gene Alteration Positive | HER1 Gene Alteration Positive | c-erbB-1 Gene Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937272","IRAK1 Gene Mutation","C157586","A change in the nucleotide sequence of the IRAK1 gene.","IRAK1 Gene Mutation | IRAK Gene Mutation | Interleukin 1 Receptor Associated Kinase 1 Gene Mutation | Interleukin-1 Receptor-Associated Kinase 1 Gene Mutation | pelle Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937273","MYD88 Fusion Positive","C157587","Indicates that expression of a fusion containing sequences from MYD88 has been detected in a sample.","MYD88 Fusion Positive | Myeloid Differentiation Primary Response 88 Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937274","IRAK1 Fusion Positive","C157588","Indicates that expression of a fusion containing sequences from IRAK1 has been detected in a sample.","IRAK1 Fusion Positive | IRAK Fusion Positive | IRAK-1 Fusion Positive | Interleukin 1 Receptor Associated Kinase 1 Fusion Positive | Interleukin-1 Receptor-Associated Kinase 1 Fusion Positive | pelle Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937267","JAK3 Fusion Positive","C157589","Indicates that expression of a fusion containing sequences from JAK3 has been detected in a sample.","JAK3 Fusion Positive | JAK-3 Fusion Positive | JAKL Fusion Positive | Janus Kinase 3 Fusion Positive | L-JAK Fusion Positive | LJAK Fusion Positive | Tyrosine-Protein Kinase JAK3 Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937268","TYK2 Fusion Positive","C157590","An indication that expression of a fusion containing sequences from TYK2 has been detected in a sample.","TYK2 Fusion Positive | JTK1 Fusion Positive | Non-Receptor Tyrosine-Protein Kinase TYK2 Fusion Positive | Tyrosine Kinase 2 Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937269","TYK2 Gene Mutation","C157591","A change in the nucleotide sequence of the TYK2 gene.","TYK2 Gene Mutation | JTK1 Gene Mutation | TYK2 Mutation | Tyrosine Kinase 2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937270","Activating JAK2 Gene Mutation","C157592","A change in the nucleotide sequence of the JAK2 gene that that results in constitutive activation of both tyrosine-protein kinase JAK2 and its downstream signaling pathways.","Activating JAK2 Gene Mutation | Activating JAK-2 Gene Mutation | Activating JAK2 Mutation | Activating JTK10 Gene Mutation | Activating Janus Kinase 2 Gene Mutation | JAK2 Activating Gene Mutation | JAK2 Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937263","Activating JAK3 Gene Mutation","C157593","A change in the nucleotide sequence of the JAK3 gene that that results in constitutive activation of both tyrosine-protein kinase JAK3 and its downstream signaling pathways.","Activating JAK3 Gene Mutation | Activating JAK-3 Gene Mutation | Activating JAK3 Mutation | Activating JAKL Gene Mutation | Activating Janus Kinase 3 Gene Mutation | Activating L-JAK Gene Mutation | Activating LJAK Gene Mutation | JAK3 Activating Gene Mutation | JAK3 Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937264","Activating MYD88 Gene Mutation","C157594","A change in the nucleotide sequence of the MYD88 gene that that results in constitutive activation of both myeloid differentiation primary response protein MyD88 and its downstream signaling pathways.","Activating MYD88 Gene Mutation | Activating MYD88 Mutation | Activating Myeloid Differentiation Primary Response 88 Gene Mutation | MYD88 Activating Gene Mutation | MYD88 Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937265","Activating IRAK1 Gene Mutation","C157595","A change in the nucleotide sequence of the IRAK1 gene that that results in constitutive activation of both interleukin-1 receptor-associated kinase 1 protein and its downstream signaling pathways.","Activating IRAK1 Gene Mutation | Activating IRAK Gene Mutation | Activating IRAK1 Mutation | Activating Interleukin 1 Receptor Associated Kinase 1 Gene Mutation | Activating Interleukin-1 Receptor-Associated Kinase 1 Gene Mutation | Activating pelle Gene Mutation | IRAK1 Activating Gene Mutation | IRAK1 Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937266","Activating TYK2 Gene Mutation","C157596","A change in the nucleotide sequence of the TYK2 gene that that results in constitutive activation of both non-receptor tyrosine-protein kinase TYK2 protein and its downstream signaling pathways.","Activating TYK2 Gene Mutation | Activating JTK1 Gene Mutation | Activating TYK2 Mutation | Activating Tyrosine Kinase 2 Gene Mutation | TKY2 Activating Gene Mutation | TYK2 Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937012","Blasts 0.1 Percent or More of Bone Marrow Nucleated Cells","C157287","A semi-quantitative microscopic finding indicating that at least 0.1 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 0.1 Percent or More of Bone Marrow Nucleated Cells | Blasts Greater than or Equal to 0.1 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936949","Neoplastic Plasma Cells 30 Percent or More of Bone Marrow Nucleated Cells","C157367","A semi-quantitative microscopic finding indicating that at least 30 percent of the nucleated cells in a bone marrow sample are neoplastic plasma cells.","Neoplastic Plasma Cells 30 Percent or More of Bone Marrow Nucleated Cells | Neoplastic Plasma Cells Greater than or Equal to 30 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936990","CCNE1 Gene Mutation","C157382","A change in the nucleotide sequence of the CCNE1 gene.","CCNE1 Gene Mutation | CCNE Gene Mutation | CCNE1 Mutation | Cyclin E1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936995","CDK6 Gene Mutation","C157380","A change in the nucleotide sequence of the CDK6 gene.","CDK6 Gene Mutation | CDK6 Mutation | Cyclin Dependent Kinase 6 Gene Mutation | Cyclin-Dependent Kinase 6 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936989","CCND3 Gene Mutation","C157381","A change in the nucleotide sequence of the CCND3 gene.","CCND3 Gene Mutation | CCND3 Mutation | Cyclin D3 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936994","CCND2 Gene Mutation","C157379","A change in the nucleotide sequence of the CCND2 gene.","CCND2 Gene Mutation | CCND2 Mutation | Cyclin D2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936993","Testosterone Less than 50 ng/dL","C157378","A semiquantitative finding indicating that the concentration of testosterone in a sample is less than 50 ng/dL.","Testosterone Less than 50 ng/dL | Testosterone Less than 50 Nanograms per Deciliter | Testosterone Less than 50 Nanograms/Deciliter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936970","Testosterone Greater than or Equal to 200 ng/dL","C157402","A semiquantitative finding indicating that the concentration of testosterone in a sample is greater than or equal to 200 ng/dL.","Testosterone Greater than or Equal to 200 ng/dL | Testosterone Greater than or Equal to 200 Nanograms per Deciliter | Testosterone Greater than or Equal to 200 Nanograms/Deciliter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937156","ARID1A Gene Mutation","C157462","A change in the nucleotide sequence of the ARID1A gene.","ARID1A Gene Mutation | ARID1A mutation | AT Rich Interactive Domain 1A Gene Mutation | B120 Gene Mutation | BAF250 Gene Mutation | BAF250a Gene Mutation | BRG1-Associated Factor 250a Gene Mutation | SMARCF1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937150","XRCC2 Gene Mutation","C157463","A change in the nucleotide sequence of the XRCC2 gene.","XRCC2 Gene Mutation | DNA Repair Protein XRCC2 Gene Mutation | FANCU Gene Mutation | X-Ray Repair Complementing Defective Repair in Chinese Hamster Cells 2 Gene Mutation | X-Ray Repair Cross Complementing 2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937103","MSI-H Negative","C157521","An indication either that low-frequency microsatellite instability (MSI-L) is present or that genomic instability has not been detected in a sample.","MSI-H Negative | High-Frequency Microsatellite Instability Negative | Microsatellite Instability High Negative | Microsatellite Instability-High Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937240","CDK Gene Mutation","C157553","A change in the nucleotide sequence in a CDK family gene.","CDK Gene Mutation | CDK Family Gene Mutation | CDKx Gene Mutation | Cyclin Dependent Kinase Family Gene Mutation | Cyclin Dependent Kinase Gene Mutation | Cyclin-Dependent Kinase Family Gene Mutation | Cyclin-Dependent Kinase Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937241","PI3K Gene Mutation","C157554","A change in the nucleotide sequence in a PI3K family gene.","PI3K Gene Mutation | 1-Phosphatidylinositol 3-Kinase Gene Mutation | PI3 Kinase Gene Mutation | PI3-Kinase Gene Mutation | PI3K Family Gene Mutation | PI3K Mutation | PIK3 Gene Mutation | Phosphatidylinositide 3-Kinase Gene Mutation | Phosphatidylinositol 3 Kinase Gene Mutation | Phosphatidylinositol 3-Kinase Gene Mutation | Phosphatidylinositol-3-Kinase Gene Mutation | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985094","Volume of Distribution Predicted Normalized by Weight","C92427","The predicted volume of distribution associated with the terminal slope following intravascular administration divided by the weight.","Volume of Distribution Predicted Normalized by Weight | VZPW | Vz Pred Norm by WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985093","Volume of Distribution Predicted Normalized by Surface Area","C92426","The predicted volume of distribution associated with the terminal slope following intravascular administration divided by the surface area.","Volume of Distribution Predicted Normalized by Surface Area | VZPS | Vz Pred Norm by SA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640892","Predicted Volume of Distribution Normalized by Dose","C102696","The volume of distribution associated with the terminal slope following intravascular administration, calculated using the predicted value of the last non-zero concentration, divided by the dose.","Predicted Volume of Distribution Normalized by Dose | VZPD | Vz Pred Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985092","Volume of Distribution Predicted Normalized by Body Mass Index","C92425","The predicted volume of distribution associated with the terminal slope following intravascular administration divided by the body mass index.","Volume of Distribution Predicted Normalized by Body Mass Index | VZPB | Vz Pred Norm by BMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985097","Volume of Distribution of Fraction Dose Predicted Normalized by Weight","C92430","The predicted volume of distribution of the absorbed fraction associated with the terminal slope following extravascular administration, where F equals the fraction of dose absorbed, divided by the weight.","Volume of Distribution of Fraction Dose Predicted Normalized by Weight | VZFPW | Vz Pred by F Norm by WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985096","Volume of Distribution of Fraction Dose Predicted Normalized by Surface Area","C92429","The predicted volume of distribution of the absorbed fraction associated with the terminal slope following extravascular administration, where F equals the fraction of dose absorbed, divided by the surface area.","Volume of Distribution of Fraction Dose Predicted Normalized by Surface Area | VZFPS | Vz Pred by F Norm by SA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640910","Volume of Distribution of Fraction Dose Predicted Normalized by Dose","C102730","The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using the predicted value of the last non-zero concentration, divided by the dose.","Volume of Distribution of Fraction Dose Predicted Normalized by Dose | VZFPD | Vz Pred by F Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985095","Volume of Distribution of Fraction Dose Predicted Normalized by Body Mass Index","C92428","The predicted volume of distribution of the absorbed fraction associated with the terminal slope following extravascular administration, where F equals the fraction of dose absorbed, divided by the body mass index.","Volume of Distribution of Fraction Dose Predicted Normalized by Body Mass Index | VZFPB | Vz Pred by F Norm by BMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827949","Predicted Volume of Distribution of Absorbed Fraction","C85799","The predicted volume of distribution of the absorbed fraction based on the terminal phase, where F equals the fraction of dose absorbed.","Predicted Volume of Distribution of Absorbed Fraction | VZFP | Vz Pred by F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827948","Predicted Volume of Distribution","C85798","The predicted volume of distribution based on the terminal phase.","Predicted Volume of Distribution | VZP | Vz Pred",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985076","Volume of Distribution Observed Normalized by Weight","C92409","The observed volume of distribution associated with the terminal slope following intravascular administration divided by the weight.","Volume of Distribution Observed Normalized by Weight | VZOW | Vz Obs Norm by WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985075","Volume of Distribution Observed Normalized by Surface Area","C92408","The observed volume of distribution associated with the terminal slope following intravascular administration divided by the surface area.","Volume of Distribution Observed Normalized by Surface Area | VZOS | Vz Obs Norm by SA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640880","Observed Volume of Distribution Normalized by Dose","C102683","The volume of distribution associated with the terminal slope following intravascular administration, calculated using the observed value of the last non-zero concentration, divided by the dose.","Observed Volume of Distribution Normalized by Dose | VZOD | Vz Obs Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985074","Volume of Distribution Observed Normalized by Body Mass Index","C92407","The observed volume of distribution associated with the terminal slope following intravascular administration divided by the body mass index.","Volume of Distribution Observed Normalized by Body Mass Index | VZOB | Vz Obs Norm by BMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985079","Volume of Distribution of Fraction Dose Observed Normalized by Weight","C92412","The observed volume of distribution of the absorbed fraction associated with the terminal slope following extravascular administration, where F equals the fraction of dose absorbed, divided by the weight.","Volume of Distribution of Fraction Dose Observed Normalized by Weight | VZFOW | Vz Obs by F Norm by WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985078","Volume of Distribution of Fraction Dose Observed Normalized by Surface Area","C92411","The observed volume of distribution of the absorbed fraction associated with the terminal slope following extravascular administration, where F equals the fraction of dose absorbed, divided by the surface area.","Volume of Distribution of Fraction Dose Observed Normalized by Surface Area | VZFOS | Vz Obs by F Norm by SA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640909","Volume of Distribution of Fraction Dose Observed Normalized by Dose","C102729","The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using the observed value of the last non-zero concentration, divided by the dose.","Volume of Distribution of Fraction Dose Observed Normalized by Dose | VZFOD | Vz Obs by F Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985077","Volume of Distribution of Fraction Dose Observed Normalized by Body Mass Index","C92410","The observed volume of distribution of the absorbed fraction associated with the terminal slope following extravascular administration, where F equals the fraction of dose absorbed, divided by the body mass index.","Volume of Distribution of Fraction Dose Observed Normalized by Body Mass Index | VZFOB | Vz Obs by F Norm by BMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935748","Observed Volume of Distribution of Absorbed Fraction for Unbound Drug","C156581","The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using the observed value of the last non-zero concentration and corrected for unbound drug.","Observed Volume of Distribution of Absorbed Fraction for Unbound Drug | VZFOUB | Vz Obs by F for UB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827926","Observed Volume of Distribution of Absorbed Fraction","C85775","The observed volume of distribution of the absorbed fraction based on the terminal phase, where F equals the fraction of dose absorbed.","Observed Volume of Distribution of Absorbed Fraction | VZFO | Vz Obs by F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827925","Observed Volume of Distribution","C85774","The observed volume of distribution based on the terminal phase.","Observed Volume of Distribution | VZO | Vz Obs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827543","Volume of Distribution for Dosing Interval Normalized by Weight","C111372","The volume of distribution associated with the terminal slope following intravascular administration, calculated using AUCTAU, divided by the weight.","Volume of Distribution for Dosing Interval Normalized by Weight | VZTAUW | Vz for Dose Int Norm by WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816487","Volume of Distribution for Dosing Interval Normalized by Surface Area","C111371","The volume of distribution associated with the terminal slope following intravascular administration, calculated using AUCTAU, divided by the surface area.","Volume of Distribution for Dosing Interval Normalized by Surface Area | VZTAUS | Vz for Dose Int Norm by SA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827544","Volume of Distribution for Dosing Interval Normalized by Dose","C111370","The volume of distribution associated with the terminal slope following intravascular administration, calculated using AUCTAU, divided by the dose.","Volume of Distribution for Dosing Interval Normalized by Dose | VZTAUD | Vz for Dose Int Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827545","Volume of Distribution for Dosing Interval Normalized by Body Mass Index","C111369","The volume of distribution associated with the terminal slope following intravascular administration, calculated using AUCTAU, divided by the body mass index.","Volume of Distribution for Dosing Interval Normalized by Body Mass Index | VZTAUB | Vz for Dose Int Norm by BMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827546","Volume of Distribution for Dosing Interval by Fraction Normalized by Weight","C111368","The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using AUCTAU, divided by the weight.","Volume of Distribution for Dosing Interval by Fraction Normalized by Weight | VZFTAUW | Vz for Dose Int by F Norm by WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816485","Volume of Distribution for Dosing Interval by Fraction Normalized by Surface Area","C111367","The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using AUCTAU, divided by the surface area.","Volume of Distribution for Dosing Interval by Fraction Normalized by Surface Area | VZFTAUS | Vz for Dose Int by F Norm by SA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827547","Volume of Distribution for Dosing Interval by Fraction Normalized by Dose","C111366","The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using AUCTAU, divided by the dose.","Volume of Distribution for Dosing Interval by Fraction Normalized by Dose | VZFTAUD | Vz for Dose Int by F Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827548","Volume of Distribution for Dosing Interval by Fraction Normalized by Body Mass Index","C111365","The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using AUCTAU, divided by the body mass index.","Volume of Distribution for Dosing Interval by Fraction Normalized by Body Mass Index | VZFTAUB | Vz for Dose Int by F Norm by BMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816484","Volume of Distribution for Dosing Interval by Fraction","C111364","The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using AUCTAU.","Volume of Distribution for Dosing Interval by Fraction | VZFTAU | Vz for Dose Int by F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816486","Volume of Distribution for Dosing Interval","C111333","The volume of distribution associated with the terminal slope following intravascular administration, calculated using AUCTAU.","Volume of Distribution for Dosing Interval | VZTAU | Vz for Dose Int",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640756","Predicted Steady State Volume of Distribution Normalized by Weight","C102393","The volume of distribution at steady state based on the predicted CLST for a substance administered by intravascular dosing divided by the weight.","Predicted Steady State Volume of Distribution Normalized by Weight | VSSPW | Vol Dist Steady State Pred Norm by WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640755","Predicted Steady State Volume of Distribution Normalized by Surface Area","C102392","The volume of distribution at steady state based on the predicted CLST for a substance administered by intravascular dosing divided by the surface area.","Predicted Steady State Volume of Distribution Normalized by Surface Area | VSSPS | Vol Dist Steady State Pred Norm by SA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640754","Predicted Steady State Volume of Distribution Normalized by Dose","C102391","The volume of distribution at steady state based on the predicted CLST for a substance administered by intravascular dosing divided by the dose.","Predicted Steady State Volume of Distribution Normalized by Dose | VSSPD | Vol Dist Steady State Pred Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640753","Predicted Steady State Volume of Distribution Normalized by Body Mass Index","C102390","The volume of distribution at steady state based on the predicted CLST for a substance administered by intravascular dosing divided by the body mass index.","Predicted Steady State Volume of Distribution Normalized by Body Mass Index | VSSPB | Vol Dist Steady State Pred Norm by BMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935755","Volume of Distribution Steady State Predicted by Unbound Drug","C156573","The volume of distribution at steady state based on the predicted CLST for a substance administered by extravascular dosing, divided by the fraction of unbound drug.","Volume of Distribution Steady State Predicted by Unbound Drug | VSSPUB | Vol Dist Steady State Pred by UB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935765","Volume of Distribution Steady State Predicted by Fraction of Dose Absorbed","C156571","The volume of distribution at steady state based on the predicted CLST for a substance administered by extravascular dosing, divided by the fraction of dose absorbed.","Volume of Distribution Steady State Predicted by Fraction of Dose Absorbed | VSSPF | Vol Dist Steady State Pred by F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935753","Volume of Distribution Steady State Predicted by Bound Drug","C156575","The volume of distribution at steady state based on the predicted CLST for a substance administered by extravascular dosing, divided by the fraction of bound drug.","Volume of Distribution Steady State Predicted by Bound Drug | VSSPBD | Vol Dist Steady State Pred by B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827944","Predicted Steady State Volume of Distribution","C85794","An estimate of the volume of distribution at steady state, which is the mean residence time (MRT) extrapolated to infinity times steady state clearance (MRTINF*Clss), based on the predicted last concentration.","Predicted Steady State Volume of Distribution | VSSP | Vol Dist Steady State Pred",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640743","Observed Steady State Volume of Distribution Normalized by Weight","C102380","The volume of distribution at steady state based on the observed CLST for a substance administered by intravascular dosing divided by the weight.","Observed Steady State Volume of Distribution Normalized by Weight | VSSOW | Vol Dist Steady State Obs Norm by WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640742","Observed Steady State Volume of Distribution Normalized by Surface Area","C102379","The volume of distribution at steady state based on the observed CLST for a substance administered by intravascular dosing divided by the surface area.","Observed Steady State Volume of Distribution Normalized by Surface Area | VSSOS | Vol Dist Steady State Obs Norm by SA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640741","Observed Steady State Volume of Distribution Normalized by Dose","C102378","The volume of distribution at steady state based on the observed CLST for a substance administered by intravascular dosing divided by the dose.","Observed Steady State Volume of Distribution Normalized by Dose | VSSOD | Vol Dist Steady State Obs Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640740","Observed Steady State Volume of Distribution Normalized by Body Mass Index","C102377","The volume of distribution at steady state based on the observed CLST for a substance administered by intravascular dosing divided by the body mass index.","Observed Steady State Volume of Distribution Normalized by Body Mass Index | VSSOB | Vol Dist Steady State Obs Norm by BMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935766","Volume of Distribution Steady State Observed by Unbound Drug","C156572","The volume of distribution at steady state based on the observed CLST for a substance administered by extravascular dosing, divided by the fraction of unbound drug.","Volume of Distribution Steady State Observed by Unbound Drug | VSSOUB | Vol Dist Steady State Obs by UB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935768","Volume of Distribution Steady State Observed by Fraction of Dose Absorbed","C156570","The volume of distribution at steady state based on the observed CLST for a substance administered by extravascular dosing, divided by the fraction of dose absorbed.","Volume of Distribution Steady State Observed by Fraction of Dose Absorbed | VSSOF | Vol Dist Steady State Obs by F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935756","Volume of Distribution Steady State Observed by Bound Drug","C156574","The volume of distribution at steady state based on the observed CLST for a substance administered by extravascular dosing, divided by the fraction of bound drug.","Volume of Distribution Steady State Observed by Bound Drug | VSSOBD | Vol Dist Steady State Obs by B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827921","Observed Steady State Volume of Distribution","C85770","An estimate of the volume of distribution at steady state, which is the mean residence time (MRT) extrapolated to infinity times steady state clearance (MRTINF*Clss), based on the last observed concentration.","Observed Steady State Volume of Distribution | VSSO | Vol Dist Steady State Obs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640738","Initial Volume of Distribution Normalized by Weight","C102375","The initial volume of distribution for a substance administered by bolus intravascular dosing divided by the weight.","Initial Volume of Distribution Normalized by Weight | V0W | Vol Dist Initial Norm by WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640737","Initial Volume of Distribution Normalized by Surface Area","C102374","The initial volume of distribution for a substance administered by bolus intravascular dosing divided by the surface area.","Initial Volume of Distribution Normalized by Surface Area | V0S | Vol Dist Initial Norm by SA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640736","Initial Volume of Distribution Normalized by Dose","C102373","The initial volume of distribution for a substance administered by bolus intravascular dosing divided by the dose.","Initial Volume of Distribution Normalized by Dose | V0D | Vol Dist Initial Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640735","Initial Volume of Distribution Normalized by Body Mass Index","C102372","The initial volume of distribution for a substance administered by bolus intravascular dosing divided by the body mass index.","Initial Volume of Distribution Normalized by Body Mass Index | V0B | Vol Dist Initial Norm by BMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540692","Initial Volume of Distribution","C102371","The initial volume of distribution for a substance administered by bolus intravascular dosing.","Initial Volume of Distribution | V0 | Vol Dist Initial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049630","Trough Peak Ratio","C122339","The concentration at the start of a dosing interval divided by the maximum concentration during the dosing interval.","Trough Peak Ratio | TROUGHPR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985091","Total Clearance Predicted Normalized by Weight","C92424","The predicted total body clearance for intravascular administration divided by the weight.","Total Clearance Predicted Normalized by Weight | CLPW | Total CL Pred Norm by WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985090","Total Clearance Predicted Normalized by Surface Area","C92423","The predicted total body clearance for intravascular administration divided by the surface area.","Total Clearance Predicted Normalized by Surface Area | CLPS | Total CL Pred Norm by SA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985089","Total Clearance Predicted Normalized by Dose","C92422","The predicted total body clearance for intravascular administration divided by the dose.","Total Clearance Predicted Normalized by Dose | CLPD | Total CL Pred Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985088","Total Clearance Predicted Normalized by Body Mass Index","C92421","The predicted total body clearance for intravascular administration divided by the body mass index.","Total Clearance Predicted Normalized by Body Mass Index | CLPB | Total CL Pred Norm by BMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552762","Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms Version 4 Questionnaire","C150917","A standardized 9-item self-report rating scale developed by Cella, et al. in 2007 to assess disease-related symptoms in patients with kidney cancer.","Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms Version 4 Questionnaire | FAC041 | FKSI-DRS V4 | FKSI-DRS Version 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827034","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory Severe Dementia Questionnaire","C106889","A standardized questionnaire developed by Galasko et al in 1997 as part of the Alzheimer's disease cooperative study, which is used to measure the performance of activities of daily living by patients diagnosed with advanced stage or severe Alzheimer's disease. The questionnaire contains 19 items (and a number of sub-items within the 19 main items) with a range of preset answers that are assigned points based on performance.","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory Severe Dementia Questionnaire | ADCS-ADL SEVERE DEMENTIA | ADCS-ADL Severe Dementia | ADL02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827035","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory Mild Cognitive Impairment Questionnaire","C106888","A standardized questionnaire developed by Galasko et al in 1997 as part of the Alzheimer's disease cooperative study, which is used to measure the performance of activities of daily living by patients diagnosed with Alzheimer's disease, exhibiting evidence of mild cognitive impairment (MCI). The questionnaire contains 24 items (and a number of sub-items within the 24 main items) with a range of preset answers that are assigned points based on performance.","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory Mild Cognitive Impairment Questionnaire | ADCS-ADL MCI | ADL03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641947","Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory Questionnaire","C105166","A standardized questionnaire developed by Galasko et al in 1997 as part of the Alzheimer's disease cooperative study, which is used to measure the performance of activities of daily living by patients diagnosed with Alzheimer's disease. The questionnaire contains 23 items (and a number of sub-items within the 23 main items) with a range of preset answers that are assigned points based on performance.","Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory Questionnaire | ADCS-ADL | ADL01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539026","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version Questionnaire","C100762","The CDISC version of the Alzheimer's Disease Assessment Scale-Cognitive (CDISC ADAS-Cog) containing 15 summary-level tests. This version is based on combining the total pool of ADAS-Cog tests that were observed during a review of multiple case report forms administered in clinical trials of Alzheimer's disease, as well as the CRF administered in the Alzheimer's Disease Neuroimaging Initiative (ADNI) observational study.  (Modified from Mohs RC, Rosen WG, Davis KL. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull 1983;19(3):448-450. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141(11):1356-1364. Mohs RC, Knopman D, Petersen RC et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11 Suppl 2:S13-S21. Wouters H, van Gool WA, Schmand B, Lindeboom R. Revising the ADAS-cog for a more accurate assessment of cognitive impairment. Alzheimer Dis Assoc Disord 2008;22(3):236-244.).","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version Functional Test | ADAS-COG | ADC | Alzheimer's Disease Assessment Scale-Cognitive CDISC Version Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4048375","Asthma Control Test Questionnaire","C123658","A standardized rating scale developed by Nathan et al in 2004, which is used to identify patients with poorly controlled asthma. This questionnaire contains 5 items.","Asthma Control Test Questionnaire | ACT | ACT01",,,,,,,,,,,,,,,"40481511","Asthma control test",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641327","Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change Questionnaire","C103515","A standardized rating scale developed by Lon S. Schneider in 1997 to evaluate a clinically relevant change in an individual's Alzheimer's Disease symptoms. This instrument consists of an interview that is given to both the patient and their caregiver by a clinician at a baseline visit and then is repeated at the 2, 6, and 12 month visits. Based on the information gather at the 2, 6, and 12 month visits, the clinician rates the patients change from baseline on a 7 increment scale ranging from 'Marked Improvement' to 'Marked Worsening.'","Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change Questionnaire | ACGC01 | ADCS-CGIC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055620","ADHD Rating Scale-IV Home Version Questionnaire","C122371","A standardized rating scale developed by DuPaul et al in 1998 based on the DSM-IV criteria, which is used for the diagnosis of ADHD in children and adolescents, and for the assessment of treatment response. This questionnaire requires a subject to rate the frequency and severity of inattentive and hyperactive-impulsive symptoms on a scale of 0 to 3: never or rarely (0), sometimes (1), often (2), or very often (3).","ADHD Rating Scale-IV Home Version Questionnaire | ADHD-RS-IV HOME VERSION | ADHD-RS-IV Home Version | ADHD01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540473","Abnormal Involuntary Movement Scale Questionnaire","C102111","A standardized rating scale developed by William Guy in 1976 which is used to evaluate the severity of tardive dyskinesia in individuals taking neuroleptic agents. This instrument contains 5 sections with a total of 12 items pertaining to facial and oral movements, global judgments, trunk movements, dental status, and extremity movements. Each item is rated on either a 0 to 4 scale with 0 being none and 4 being severe, or as 'yes' or 'no.'","Abnormal Involuntary Movement Scale Clinical Classification | AIMS | AIMS01 | Abnormal Involuntary Movement Scale Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827030","Airway Questionnaire 20","C112518","A standardized rating scale developed by Barley et al in 1988 to measure health status and detect changes in quality of life in asthmatic patients. The questionnaire contains 20 questions and each can be answered with Yes, No, or N/A (Not Applicable).","Airway Questionnaire 20 | AQ01 | AQ20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055434","Asthma Quality of Life Questionnaire","C122372","A standardized rating scale developed by Juniper et al in 1992, which is used to measure the physical and emotional impacts on quality of life in patients with asthma. This questionnaire contains 32 items using a 7-point scale, and the items are grouped into four domains: activity limitations, symptoms, emotional function, and exposure to environmental stimuli.","Asthma Quality of Life Questionnaire | AQLQ | AQLQ01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504411","Arizona Sexual Experiences Scale-Female Version Questionnaire","C125757","A standardized rating scale developed by McGahuey et al in 2000, which is used to measure sexual dysfunction. The female version of the instrument contains 5 items and quantifies sex drive, arousal, vaginal lubrication, ability to reach orgasm, and satisfaction from orgasm.","Arizona Sexual Experiences Scale-Female Version Questionnaire | ASEX-FEMALE | ASEX-Female Version | ASEX01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504412","Arizona Sexual Experiences Scale-Male Version Questionnaire","C125758","A standardized rating scale developed by McGahuey et al in 2000, which is used to measure sexual dysfunction. The male version of the instrument contains 5 items and quantifies sex drive, arousal, penile erection, ability to reach orgasm, and satisfaction from orgasm.","Arizona Sexual Experiences Scale-Male Version Questionnaire | ASEX-MALE | ASEX-Male Version | ASEX02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3871151","Alcohol Use Disorder Identification Test Alcohol Consumption Questions Questionnaire","C119098","A standardized rating scale developed by the World Health Organization (WHO), which is a modified version of the original Alcohol Use Disorder Identification Test (ADUIT). The questionnaire contains 3 questions, and is used to identify patients who are hazardous drinkers or have active alcohol use disorders.","Alcohol Use Disorder Identification Test Alcohol Consumption Questions Questionnaire | ADTC01 | AUDIT-C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0450985","Alcohol Use Disorder Identification Test Self-Report Version Questionnaire","C119097","A standardized rating scale developed by the World Health Organization (WHO) to screen for excessive, hazardous or harmful alcohol consumption. The questionnaire contains 10 questions and evaluates the frequency and amount of alcohol use, alcohol-dependence symptoms and alcohol-related problems.","Alcohol Use Disorder Identification Test Self-Report Version Questionnaire | ADT01 | AUDIT | AUDIT-SR",,,,,,,,,,,,,,,"4157230","Alcohol use disorders identification test",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3541345","Barnes Akathisia Rating Scale Questionnaire","C102113","A standardized rating scale developed by Thomas R. E. Barnes in 1989 to diagnose akathisia associated with use of antipsychotic agents. This instrument contains objective and subjective sections, as well as a global clinical assessment of akathisia. The first two sections contain a total of 3 items which are rated on a scale of 0 to 3 with 0 being none or normal and 3 being severe. The third section is rated on a 0 to 5 scale with 0 being none and 5 being severe.","Barnes Akathisia Rating Scale Clinical Classification | BARS | BARS01 | Barnes Akathisia Rating Scale Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714938","Baseline Dyspnea Index Questionnaire","C106693","A standardized rating scale developed by Mahler et al in 1984, which is a general scale used to measure the rating of severity of dyspnea at a single state (as baseline). The questionnaire contains 3 categories of 24 items; functional impairment, magnitude of task and magnitude of effort. The instrument is scored on a five-grade scale for each category, where grade 0 represents very severe impairment and grade 4 represents no impairment.","Baseline Dyspnea Index Clinical Classification | BDI | BDI01 | Baseline Dyspnea Index Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523050","Baby Eating Behaviour Questionnaire Concurrent Version","C135735","A standardized 18-item concurrent parent-report questionnaire developed by Llewellyn et al in 2010 as a psychometric measure of infant appetite during the 0-3-month period of exclusive milk-feeding. The instrument, which is derived from the Children's Eating Behaviour Questionnaire, was designed to characterize appetite traits that might confer susceptibility to gain weight.","Baby Eating Behaviour Questionnaire Concurrent Version | BEBQ CONCURRENT | BEBQ Concurrent Version | BEBQ01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523051","Baby Eating Behaviour Questionnaire Retrospective Version","C135736","A standardized 18-item retrospective parent-report questionnaire developed by Llewellyn et al in 2010 as a psychometric measure of infant appetite during the 0-3-month period of exclusive milk-feeding. The instrument, which is derived from the Children's Eating Behaviour Questionnaire, was designed to characterize appetite traits that might confer susceptibility to gain weight.","Baby Eating Behaviour Questionnaire Retrospective Version | BEBQ RETROSPECTIVE | BEBQ Retrospective Version | BEBQ02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811877","Bladder Control Scale Questionnaire","C113874","A standardized rating scale developed by Turnbull et al in 1992, which measures the level of bladder function and control, as well as the extent to which bladder problems have an impact on everyday activities. The questionnaire contains 4 questions which are scored ranging from 0 (not at all) to 4 (daily).","Bladder Control Scale Questionnaire | BLCS | BLCS01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639707","BPRS-A","C100761","A standardized rating scale originally developed by Margaret G. Woerner, Salvatore Mannuzza and John M. Kane in 1988 which is used to evaluate the severity of an individual's psychiatric symptoms. This version consists of 18 questions or types of psychiatric symptoms such as depression, anxiety, hallucinations, motor skills, or other unusual behaviors and is completed during a semi-structured interview. Each symptom is rated on a scale of 1-7 or 1-9 with 1 being non-existent and 7 being very severe; 9 represents 'can not be assessed'.","Brief Psychiatric Rating Scale A Clinical Classification | BPRS-A | BPRSA1 | Brief Psychiatric Rating Scale - Anchored | Brief Psychiatric Rating Scale A Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827027","Bowel Control Scale Questionnaire","C113875","A standardized rating scale developed by Turnbull et al in 1992, which measures the level of bowel function and control, as well as the extent to which bowel problems have an impact on everyday activities. The questionnaire contains 5 questions which are scored ranging from 0 (not at all) to 4 (daily).","Bowel Control Scale Questionnaire | BWCS | BWCS01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827021","Columbia-Suicide Severity Rating Scale Already Enrolled Subjects Questionnaire","C106695","A standardized rating scale developed by Posner et al (version 1/14/09), which is used to determine the presence of suicidal ideation or behavior. The already enrolled subjects version questionnaire contains 24 items across 4 domains; suicidal ideation, intensity of ideation, suicidal behavior and actual attempts.","Columbia-Suicide Severity Rating Scale Already Enrolled Subjects Questionnaire | C-SSRS ALREADY ENROLLED SUBJECTS | C-SSRS Already Enrolled Subjects | CSS05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639710","Columbia-Suicide Severity Rating Scale Baseline Questionnaire","C100765","A standardized survey developed and copyrighted by Kelly Posner and colleagues with The Research Foundation for Mental Hygiene in 2008 which is used to evaluate a patient's suicidal tendencies. The baseline version questionnaire contains four sections with approximately 40 questions and is administered in an interview format. The first three sections pertain to the patient's suicidal ideations and behaviors while the fourth section assess any actual suicide attempts.","Columbia-Suicide Severity Rating Scale Baseline Questionnaire | C-SSRS BASELINE | C-SSRS Baseline | CSS01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827020","Columbia-Suicide Severity Rating Scale Baseline/Screening Version Questionnaire","C106696","A standardized rating scale developed by Posner et al (version 1/14/09), which is used to determine the presence of suicidal ideation or behavior. The baseline/screening version questionnaire contains 23 items across 4 domains; suicidal ideation, intensity of ideation, suicidal behavior and actual attempts.","Columbia-Suicide Severity Rating Scale Baseline/Screening Version Questionnaire | C-SSRS BASELINE/SCREENING VERSION | C-SSRS Baseline/Screening Version | CSS04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641945","Columbia-Suicide Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 Questionnaire","C105164","A standardized rating scale developed by Posner et al (version 1/14/09), which is used to determine the presence of suicidal ideation or behavior. The baseline/screening version phase 1 study questionnaire contains 23 items across 4 domains; suicidal ideation, intensity of ideation, suicidal behavior and actual attempts.","Columbia-Suicide Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 Questionnaire | C-SSRS BASELINE/SCREENING VERSION PHASE 1 STUDY | C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09 | CSS03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827019","Columbia-Suicide Severity Rating Scale Children's Baseline Questionnaire","C111377","A standardized rating scale developed by Posner et al (version 6/23/10), which is used to determine the presence of suicidal ideation or behavior. The children's baseline version questionnaire contains 20 items across 4 domains; suicidal ideation, intensity of ideation, suicidal behavior and actual attempts.","Columbia-Suicide Severity Rating Scale Children's Baseline Questionnaire | C-SSRS CHILDREN'S BASELINE | C-SSRS Children's Baseline | CSS06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827018","Columbia-Suicide Severity Rating Scale Children's Baseline/Screening Questionnaire","C111378","A standardized rating scale developed by Posner et al (version 6/23/10), which is used to determine the presence of suicidal ideation or behavior. The children's baseline/screening version questionnaire contains 20 items across 4 domains; suicidal ideation (lifetime and past 6 months), intensity of ideation (lifetime and past 6 months), suicidal behavior and actual attempts.","Columbia-Suicide Severity Rating Scale Children's Baseline/Screening Questionnaire | C-SSRS CHILDREN'S BASELINE/SCREENING | C-SSRS Children's Baseline/Screening | CSS07",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827017","Columbia-Suicide Severity Rating Scale Children's Since Last Visit Questionnaire","C111379","A standardized rating scale developed by Posner et al (version 6/23/10), which is used to determine the presence of suicidal ideation or behavior. The children's since last visit version questionnaire contains 19 items across 4 domains; suicidal ideation, intensity of ideation, suicidal behavior and actual attempts.","Columbia-Suicide Severity Rating Scale Children's Since Last Visit Questionnaire | C-SSRS CHILDREN'S SINCE LAST VISIT | C-SSRS Children's Since Last Visit | CSS08",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896692","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version Questionnaire","C117996","A standardized rating scale developed by Posner et al (version 1/14/2009), which is used to determine the presence of suicidal ideation or behavior. The lifetime/recent version questionnaire contains 23 items across 4 domains; suicidal ideation (lifetime and past 1 month), intensity of ideation (lifetime and past 1 month), suicidal behavior (lifetime and past 3 months) and actual attempts.","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version Questionnaire | C-SSRS LIFETIME/RECENT VERSION | C-SSRS Lifetime/Recent Version | CSS11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827016","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent Questionnaire","C113873","A standardized rating scale developed by Posner et al (version 6/23/10), which is used to determine the presence of suicidal ideation or behavior in pediatric patients. The pediatric/cognitively impaired lifetime/recent version questionnaire contains 20 items across 4 domains; suicidal ideation, intensity of ideation, suicidal behavior and actual attempts.","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent Questionnaire | C-SSRS PEDIATRIC/COGNITIVELY IMPAIRED LIFETIME/RECENT | C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent | CSS10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055216","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired - Lifetime Recent - Clinical Questionnaire","C123661","A standardized rating scale developed by Posner et al (version 6/23/2010), which is used to determine the presence of suicidal ideation or behavior. The pediatric/cognitively impaired - lifetime recent - clinical version questionnaire contains 4 domains; suicidal ideation, intensity of ideation, suicidal behavior and actual attempts.","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired - Lifetime Recent - Clinical Questionnaire | C-SSRS PEDIATRIC/COGNITIVELY IMPAIRED-LIFETIME RECENT-CLINICAL | C-SSRS Pediatric/Cognitively Impaired - Lifetime Recent - Clinical | CSS12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055215","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired - Since Last Visit - Clinical Questionnaire","C123662","A standardized rating scale developed by Posner et al (version 6/23/2010), which is used to determine the presence of suicidal ideation or behavior. The pediatric/cognitively impaired - since last visit - clinical version questionnaire contains 4 domains; suicidal ideation, intensity of ideation, suicidal behavior and actual attempts.","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired - Since Last Visit - Clinical Questionnaire | C-SSRS PEDIATRIC/COGNITIVELY IMPAIRED-SINCE LAST VISIT-CLINICAL | C-SSRS Pediatric/Cognitively Impaired - Since Last Visit - Clinical | CSS13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827015","Columbia-Suicide Severity Rating Scale Screening Questionnaire","C111380","A standardized rating scale developed by Posner et al (version 1/14/09), which is used to determine the presence of suicidal ideation or behavior. The screening version questionnaire contains 23 items across 4 domains; suicidal ideation, intensity of ideation, suicidal behavior and actual attempts.","Columbia-Suicide Severity Rating Scale Screening Questionnaire | C-SSRS SCREENING | C-SSRS Screening | CSS09",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641328","Columbia-Suicide Severity Rating Scale Since Last Visit Questionnaire","C103516","A standardized survey developed and copyrighted by Kelly Posner and colleagues with The Research Foundation for Mental Hygiene in 2008 which is used to evaluate a patient's suicidal tendencies at a subsequent visit. The since last visit version questionnaire contains four sections with approximately 40 questions and is administered in an interview format. The first three sections pertain to the patient's suicidal ideations and behaviors while the fourth section assess any actual suicide attempts.","Columbia-Suicide Severity Rating Scale Since Last Visit Questionnaire | C-SSRS SINCE LAST VISIT | C-SSRS Since Last Visit | CSS02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899619","Clinical COPD Questionnaire 1 Week Version","C119100","A standardized rating scale originally developed by Thys van der Molen et al in 2003, which is a self-administered instrument used to measure clinical status of the airways and health-related quality of life in subjects with COPD. The 1 week version questionnaire contains 10 questions which are divided into 3 areas or domains: symptoms, mental state and functional state.","Clinical COPD Questionnaire 1 Week Version | CCQ 1 WEEK VERSION | CCQ 1 Week Version | CCQ02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899618","Clinical COPD Questionnaire 24 Hour Version","C119099","A standardized rating scale originally developed by Thys van der Molen et al in 2003, which is a self-administered instrument used to measure clinical status of the airways and health-related quality of life in subjects with COPD. The 24 hour version questionnaire contains 10 questions which are divided into 3 areas or domains: symptoms, mental state and functional state.","Clinical COPD Questionnaire 24 Hour Version | CCQ 24 HOUR VERSION | CCQ 24 Hour Version | CCQ01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899636","Children's Dermatology Life Quality Index Questionnaire","C119092","A standardized rating scale originally developed by Lewis-Jones and Finlay in 1995. This instrument is used to make quality of life assessment in children with skin conditions.","Children's Dermatology Life Quality Index Questionnaire | CDLQ | CDLQ1 | CDLQI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0451074","Clinical Dementia Rating Questionnaire","C102114","A standardized rating scale developed by John C. Morris in 1997 to evaluate the severity of an individual's cognitive impairment. This instrument contains 6 areas which include memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Each item is rated on a scale from 0 to 3 with 0 being none and 3 being severe.","Clinical Dementia Rating Clinical Classification | CDR | CDR01 | Clinical Dementia Rating Questionnaire",,,,,,,,,,,,,,,"4164818","Clinical dementia rating scale",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521352","Combat Exposure Scale Questionnaire","C132532","A standardized 7-item self-report scale that was developed by Keane et al in 1989 to measure combat exposure. The instrument is derived from Figley's combat scale (1980), with additional items included by consensus of a group of clinical psychologists with experience in the assessment and treatment of combat-related PTSD. The items are weighted according to the severity of the combat experience.","Combat Exposure Scale Questionnaire | CES | CES01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523052","Clinical Global Impression Generic Modification Version Questionnaire","C135738","A modified version of a standardized questionnaire published in 1976 by Guy et al. that was initially created to provide a clinician-determined summary measure of a patient's global functioning prior to and after initiating a study medication. It has been modified for use in any disease/condition concept use case.","Clinical Global Impression Generic Modification Version Questionnaire | CGI | CGI Generic Modification Version | CGI02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896682","Craig Handicap Assessment and Reporting Technique-Short Form Interview Version Questionnaire","C117995","A standardized rating scale originally developed by Whiteneck et al in 1992 and modified in 2000, which is used to measure the degree to which impairments and disabilities result in handicaps in the years after initial rehabilitation. The questionnaire contains 19 questions and generates 6 subscales: physical independence, cognitive independence, mobility, occupation, social integration and economic self-sufficiency.","Craig Handicap Assessment and Reporting Technique-Short Form Interview Version Questionnaire | CHART-SF | CHART-SF INTERVIEW VERSION | CHSF1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899491","Craig Handicap Assessment and Reporting Technique - Short Form Paper Version Questionnaire","C119101","A standardized rating scale originally developed by Whiteneck et al in 1992 and modified in 2000, which is used to measure the degree to which impairments and disabilities result in handicaps in the years after initial rehabilitation. The paper version questionnaire contains 19 questions and generates 6 subscales: physical independence, cognitive independence, mobility, occupation, social integration and economic self-sufficiency.","Craig Handicap Assessment and Reporting Technique - Short Form Paper Version Questionnaire | CHART-SF PAPER VERSION | CHART-SF Paper Version | CHSF2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505080","COPD Assessment Test Questionnaire","C125756","A standardized rating scale developed by Jones et al in 2009, which is a self-administered instrument used to measure the health status of patients with COPD. This instrument contains 8 items; each item is scored on a scale from 0 to 5.","COPD Assessment Test Questionnaire | CAT | CAT01 | COPD ASSESSMENT TEST",,,,,,,,,,,,,,,"36684442","Chronic Obstructive Pulmonary Disease Assessment Test scale",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3539595","Clinical Opiate Withdrawal Scale Questionnaire","C102115","A standardized rating scale developed by Wesson and Ling in 2003 to evaluate the severity of an individual's opiate withdrawal symptoms. This instrument consists of 11 signs or symptoms which are assessed and rated by a clinician. The severity of each sign or symptom correlates with a numerical value. A total score of 5-12 is 'mild'; 13-24 is 'moderate'; 25-36 is 'moderately severe'; and greater than 36 is 'severe withdrawal.'","Clinical Opiate Withdrawal Scale Questionnaire | COWS | COWS1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053810","Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire","C121002","A standardized rating scale developed by Schunemann et al in 2003, which is a self-administered instrument used to measure the health-related quality of life (HRQL) in patients with chronic airflow limitation. The first administration version contains 20 items and four domains: dyspnea, fatigue, emotional functioning and mastery.","Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire | CRQ-SAS FIRST ADMINISTRATION VERSION | CRQ-SAS First Administration Version | CRQ01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055236","Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire","C121003","A standardized rating scale developed by Schunemann et al in 2003, which is a self-administered instrument used to measure the health-related quality of life (HRQL) in patients with chronic airflow limitation. The follow-up administration version contains 20 items and four domains: dyspnea, fatigue, emotional functioning and mastery.","Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire | CRQ-SAS FOLLOW-UP ADMINISTRATION VERSION | CRQ-SAS Follow-Up Administration Version | CRQ02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641946","Disability Assessment for Dementia Questionnaire","C105165","A standardized questionnaire developed by Gelinas et al in 1998, which is used to measure the changes in functional activities in patients with Alzheimer's disease. The questionnaire contains 40 items across 3 domains; basic activities of daily living, instrumental activities of daily living and leisure activities.","Disability Assessment for Dementia Questionnaire | DAD | DAD01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714751","Disease Steps Questionnaire","C112519","A standardized rating scale developed by Hohol et al in 1995, which is a self-assessment scale of functional disability in multiple sclerosis patients primarily based on ambulation. The questionnaire contains 1 question which is scored ranging from 0 (normal) to 6 (confined to wheelchair). There is an additional score for 'U' (unclassifiable) for patients who do not fit into the 0 to 6 classification categories.","Disease Steps Clinical Classification | DISEASE STEPS | DS | DS01 | Disease Steps Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899393","Dermatology Life Quality Index Questionnaire","C119102","A standardized rating scale originally developed by Finlay and Khan in 1994, which is a dermatology-specific health-related quality of life instrument. This questionnaire contains 10 questions concerning symptoms and feelings, daily activities, leisure, work, and school, personal relationships and treatment. Each question can be answered with: very much, a lot, a little or not at all.","Dermatology Life Quality Index Questionnaire | DLQI | DLQI1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539764","Deployment Risk and Resilience Inventory-2 Questionnaire","C141694","A revision of the Deployment Risk and Resilience Inventory instrument, originally developed by King et al. in 2003, that utilizes 17 distinct scales to assess predeployment, deployment, and postdeployment psychosocial risk and resilience factors in returning war veterans.","Deployment Risk and Resilience Inventory-2 Questionnaire | DRRI-2 | DRRI1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887968","Disability Rating Scale Questionnaire","C115796","A standardized rating scale developed by Rappaport et al in 1982, which is used to measure general functional changes over the course of recovery in patients with moderate and severe traumatic brain injury (TBI). The questionnaire contains 8 questions and generates 4 subscales: arousability awareness and responsivity, cognitive ability for self-care activities, dependence on others and psychosocial adaptability.","Disability Rating Scale Clinical Classification | DRS | DRS01 | Disability Rating Scale Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887783","Kurtzke Expanded Disability Status Scale Questionnaire","C112520","A standardized rating scale developed by John F. Kurtzke in 1983 to measure the disability status and level of functioning in people with multiple sclerosis primarily based on ambulation. The questionnaire contains 1 question which is scored in half point scores ranging from 0 (Normal neurological exam) to 10 (Death due to MS). A score of 0 to 4.5 refers to people with a high degree of ambulatory ability; a score of 5 to 9.5 indicates the loss of ambulatory ability.","Kurtzke Expanded Disability Status Scale Clinical Classification | EDSS | EDSS01 | Kurtzke Expanded Disability Status Scale Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521652","Edinburgh Postnatal Depression Scale Questionnaire","C132533","A standardized 10-item self-report scale that was developed by Cox et al 1987 to assist health professionals in identifying possible symptoms of depression in the postnatal period. The instrument utilizes a 4-point symptom rating scale to allow women to grade their experiences over the past seven days.","Edinburgh Postnatal Depression Scale Questionnaire | EPDS | EPDS01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509053","The Expanded Prostate Cancer Index Composite Short Form Questionnaire","C127367","A standardized rating scale developed by Szymanski et al in 2010, which is used to monitor health-related quality of life outcomes in patients with prostate cancer. This instrument contains five symptom domains (urinary incontinence, urinary irritative/obstructive, sexual, bowel, hormonal) and 26 items, scored from 0 (worst) to 100 (best).","The Expanded Prostate Cancer Index Composite Short Form Questionnaire | EPIC-26 | EPIC-26 (Priority 1) | EPIC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508757","Expanded Prostate Cancer Index Composite for Clinical Practice Questionnaire","C127368","A standardized rating scale developed by Chang et al in 2011, which is used to measure urinary incontinence, urinary irritation, and the bowel, sexual and hormonal health related quality of life in patients with prostate cancer. This instrument contains 16 items.","Expanded Prostate Cancer Index Composite for Clinical Practice Questionnaire | EPIC-CP | EPIC2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050514","Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome Questionnaire","C123666","A standardized rating scale developed by Nancy Leidy and Lindsey Murray under the EXACT-PRO Initiative in 2013, which is used to make symptomatic assessment of chronic obstructive pulmonary disease (COPD) exacerbations. The questionnaire contains 14 items and evaluate the frequency, severity, and duration of COPD exacerbations.","Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome Questionnaire | EXACT | EXACT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505163","Expanded Disability Rating Scale - Postacute Interview Caregiver Version Questionnaire","C125759","A standardized rating scale developed by Rappaport et al in 1982, which is used to track recovery of an individual from coma to community and to capture functional changes over the course of recovery for individuals with moderate to severe TBI. The caregiver version of this instrument has 30 items.","Expanded Disability Rating Scale - Postacute Interview Caregiver Version Questionnaire | ED1 | EXPANDED DRS-PI CAREGIVER VERSION | Expanded DRS-PI Caregiver Version",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505164","Expanded Disability Rating Scale - Postacute Interview Survivor Version Questionnaire","C125760","A standardized rating scale developed by Rappaport et al in 1982, which is used to track recovery of an individual from coma to community and to capture functional changes over the course of recovery for individuals with moderate to severe TBI. The survivor version of this instrument has 26 items.","Expanded Disability Rating Scale - Postacute Interview Survivor Version Questionnaire | ED2 | EXPANDED DRS-PI SURVIVOR VERSION | Expanded DRS-PI Survivor Version",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555952","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank Questionnaire","C155325","A standardized 33-item repository of test questions developed by Choi et al. in 2011 as part of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System developed by Cella et al. in 1987, from which a subset may be administered to evaluate dyspnea severity and limitations in function caused by dyspnea in people with COPD.","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank Questionnaire | FAC100 | FACIT-DYSPNEA 33 ITEM BANK | FACIT-Dyspnea Scale 33 Item Bank Version",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3482891","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 Questionnaire","C129105","A standardized rating scale originally developed by Yellen et al in 1997 and modified by Cella et al in 2002, which includes a 13-item fatigue scale, as well as 13 items from the original FACT-G of the emotional and functional well-being sections. This instrument measures fatigue/tiredness and its impact on daily activities and functioning in a number of chronic diseases.","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 Questionnaire | FAC071 | FACIT-F V4 | FACIT-F Version 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545386","FAC070","C147585","A standardized 10-item self-report, interviewer, or telephone administered questionnaire, part of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System developed by Cella et al. in 1987, that utilizes a five-point Likert rating scale to evaluate shortness of breath across a range of functional activities over the past 7 days in individuals with chronic obstructive pulmonary disease.","Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 Questionnaire | FAC070 | FACIT-FATIGUE 13-ITEM V4 | FACIT-Fatigue 13-Item Version 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512352","Functional Assessment of Cancer Therapy-Breast Version 4 Questionnaire","C129108","A standardized 37-item self-report rating scale to measure quality of life in patients with breast cancer that is divided into five subscales: physical, social/family, emotional, and functional well-being, as well as additional concerns for breast cancer. Originally developed by Cella, et al. in 1997, it combines the Functional Assessment of Cancer Therapy - General (FACT-G) and the Breast Cancer Subscale (BCS).","Functional Assessment of Cancer Therapy-Breast Version 4 Questionnaire | FAC005 | FACT-B V4 | FACT-B Version 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555956","Functional Assessment of Cancer Therapy-Bladder Version 4 Questionnaire","C155326","A standardized 39-item self-report rating scale to measure quality of life in patients with bladder cancer that is divided into five subscales: physical, social/family, emotional, and functional well-being, as well as a bladder cancer subscale to assess urinary tract, intestinal and sexual symptoms. Originally developed by Cella, et al. in 1997, it combines the Functional Assessment of Cancer Therapy - General (FACT-G), and the Bladder Cancer Subscale (BICS).","Functional Assessment of Cancer Therapy-Bladder Version 4 Questionnaire | FAC006 | FACT-BL V4 | FACT-BL Version 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545385","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 Questionnaire","C147583","A standardized, self-administered 12-item subscale, validated by McQuellen et al. in 1997 that, in combination with the general Functional Assessment of Cancer Therapy (FACT) instrument, utilizes a five-point Likert scale and covers four specific domains of well-being to measure quality of life in bone marrow transplantation patients.","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 Questionnaire | FAC061 | FACT-BMT V4 | FACT-BMT Version 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552759","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 Questionnaire","C150914","A standardized 40-item self-report rating scale to measure quality of life in cancer patients receiving treatment with biologic response modifiers that is divided into six subscales: physical, social/family, emotional, and functional well-being, as well as two subscales related to physical and mental symptoms common to treatment with biologic response modifiers. Originally developed by Cella, et al. in 1997, it combines the Functional Assessment of Cancer Therapy - General (FACT-G), and two Biologic Response Modifier (BRM) subscales.","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 Questionnaire | FAC062 | FACT-BRM V4 | FACT-BRM Version 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552758","Functional Assessment of Cancer Therapy-Colorectal Version 4 Questionnaire","C150912","A standardized 36-item self-report rating scale to measure quality of life in patients with colorectal cancer that is divided into five subscales: physical, social/family, emotional, and functional well-being, as well as a colorectal cancer specific subscale. Originally developed by Cella, et al. in 1997, it combines the Functional Assessment of Cancer Therapy - General (FACT-G), and the Colorectal Cancer Subscale (CCS).","Functional Assessment of Cancer Therapy-Colorectal Version 4 Questionnaire | FAC008 | FACT-C V4 | FACT-C Version 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3533310","Functional Assessment of Cancer Therapy-General Version 4 Questionnaire","C127369","A standardized rating scale originally developed by Cella et al in 1993, which is used for general measurements of quality of life in patients with any form of cancer, or other chronic illness condition. The version 4 of this instrument contains 27 items which are divided into four domains: physical well-being, social/family well-being, emotional well-being, and functional well-being.","Functional Assessment of Cancer Therapy-General Version 4 Questionnaire | FAC001 | FACT-G V4 | FACT-G Version 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513091","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 Questionnaire","C130312","A standardized 45-item self-report questionnaire that utilizes a 5-point rating scale to evaluate quality of life in patients with hepatobiliary cancers. The questionnaire, composed of the 27-item Functional Assessment of Cancer Therapy-General (FACT-G) and 18 additional hepatobiliary specific items, was developed by Heffernan and Cella et al. in 2002 and is divided into five subscales: physical well-being, social/family well-being, emotional well-being, functional well-being, and additional concerns.","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 Questionnaire | FAC015 | FACT-HEP V4 | FACT-HEP Version 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552761","Functional Assessment of Cancer Therapy-Lung Version 4 Questionnaire","C150916","A standardized 34-item self-report rating scale to measure quality of life in patients with lung cancer that is divided into five subscales: physical, social/family, emotional, and functional well-being, as well as a subscale that is specific to issues faced by lung cancer patients. Originally developed by Cella, et al. in 1997, it combines the Functional Assessment of Cancer Therapy - General (FACT-G), and the Lung Cancer Subscale (LCS).","Functional Assessment of Cancer Therapy-Lung Version 4 Questionnaire | FAC016 | FACT-L V4 | FACT-L Version 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513092","Functional Assessment of Cancer Therapy-Leukemia Version 4 Questionnaire","C130311","A standardized 44-item self-report questionnaire that utilizes a 5-point rating scale to evaluate quality of life in patients with acute and chronic leukemia. The questionnaire, composed of the 27-item Functional Assessment of Cancer Therapy-General (FACT-G) and 17 additional leukemia specific items, was developed by Cella et al. in 2012 and is divided into five subscales: physical well-being, social/family well-being, emotional well-being, functional well-being, and additional concerns.","Functional Assessment of Cancer Therapy-Leukemia Version 4 Questionnaire | FAC017 | FACT-LEU V4 | FACT-LEU Version 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513093","Functional Assessment of Cancer Therapy-Lymphoma Version 4 Questionnaire","C130313","A standardized 49-item self-report questionnaire that utilizes a 5-point rating scale to evaluate quality of life in patients with Non-Hodgkin lymphoma. The questionnaire, composed of the 27-item Functional Assessment of Cancer Therapy-General (FACT-G) and 22 additional Non-Hodgkin lymphoma specific items, was developed by Cella et al. in 2005 and is divided into five subscales: physical well-being, social/family well-being, emotional well-being, functional well-being, and additional concerns.","Functional Assessment of Cancer Therapy-Lymphoma Version 4 Questionnaire | FAC018 | FACT-LYM V4 | FACT-LYM Version 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509738","Functional Assessment of Cancer Therapy-Prostate Version 4 Questionnaire","C127371","A standardized rating scale originally developed by Cella et al in 1993 and modified by Esper et al in 1997, which includes a 12-item prostate cancer subscale (PCS) in addition to the original 27 items from FACT-G. FACT-P contains 39 items and measures both general health-related quality of life as well as prostate cancer-specific quality of life; the total score is based on both FACT-G and PCS.","Functional Assessment of Cancer Therapy-Prostate Version 4 Questionnaire | FAC023 | FACT-P V4 | FACT-P Version 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3533275","Functional Assessment of Cancer Therapy-Taxane Version 4 Questionnaire","C150913","A standardized 43-item self-report rating scale to measure the health related quality of life in patients receiving taxane containing chemotherapy. Originally developed by Cella, et al. in 1997, it combines the 27-item Functional Assessment of Cancer Therapy - General (FACT-G), which is divided into five subscales: physical, social/family, emotional, and functional well-being, with a Taxane subscale that combines the 11-item Neurotoxicity subscale and 5 additional questions assessing symptoms related to arthralgia, myalgia, and skin discoloration.","Functional Assessment of Cancer Therapy-Taxane Version 4 Questionnaire | FAC063 | FACT-TAXANE V4 | FACT-Taxane Version 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552760","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 Questionnaire","C150915","A standardized 38-item self-report rating scale to measure the effects of chemotherapy-induced neuropathy on the quality of life of cancer patients that is divided into five subscales: physical, social/family, emotional, and functional well-being, as well as a subscale to evaluate symptoms and concerns associated with chemotherapy-induced neuropathy. Originally developed by Cella, et al. in 1997, it combines the Functional Assessment of Cancer Therapy - General (FACT-G), and the Gynecologic Oncology Group - Neurotoxicity (GOG-Ntx) subscale.","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 Questionnaire | FAC057 | FACT/GOG-NTX V4 | FACT/GOG-NTX Version 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827008","Functional Assessment of Multiple Sclerosis Questionnaire","C112521","A standardized, disease-specific rating scale developed by Cella et al in 1996 to assess quality of life and functional status of individuals with multiple sclerosis. The questionnaire contains 58 items across 7 categories; mobility, symptoms, emotional well-being, general contentment, thinking and fatigue, family/social well-being, and additional concerns. The scoring algorithm for this questionnaire assigns a value from 0 (not at all) to 4 (very much) to each item in the response categories, and the total score ranges between 0 and 176.","Functional Assessment of Multiple Sclerosis Questionnaire | FAMS | FAMS Questionnaire | FAMS01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827007","FAQ","C111381","A standardized questionnaire developed by Pfeiffer et al in 1982, which is used to measure instrumental activities of daily living such as preparing meals and managing personal finances in older adults with dementia. The questionnaire contains 11 items. For each activity, six levels of scores are specified: 'dependent' (scored 3), 'requires assistance' (scored 2), 'has difficulty but does by self' (scored 1), 'normal' (scored 0), 'never did but could do now' (scored 0), and 'never did and would have difficulty now' (scored 1).","Functional Activities Questionnaire Clinical Classification | FAQ | FAQ01 | Functional Activities Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827006","FAQ-NACC UDS V2.0","C111382","A standardized questionnaire developed by Pfeiffer et al in 1982 and adapted by National Alzheimer's Coordinating Center (NACC), which is used to measure instrumental activities of daily living such as preparing meals and managing personal finances in older adults with dementia. The questionnaire contains 10 items. For each activity, five levels of scores are specified: 'not applicable' (scored 8), 'normal' (scored 0), 'has difficulty, but does by self' (scored 1), 'requires assistance' (scored 2), and 'dependent' (scored 3).","Functional Assessment Questionnaire-NACC UDS Version 2.0 Clinical Classification | FAQ-NACC UDS V2.0 | FAQ-NACC UDS Version 2.0 | FAQNA1 | Functional Activities Questionnaire-NACC Version | Functional Assessment Questionnaire-NACC UDS Version 2.0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525826","Functional Assessment of Cancer Therapy-Brain Symptom Index Questionnaire","C138336","A 24-item complement to the Functional Assessment of Cancer Therapy-Brain (FACT-Br) questionnaire, developed by Cella et al. in 2010, that is used to assess brain tumor symptoms.","Functional Assessment of Cancer Therapy-Brain Symptom Index Questionnaire | FAC029 | FBRSI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641329","Revised Fibromyalgia Impact Questionnaire","C103518","A standardized survey originally developed in the late 1980s and subsequently copyrighted by Robert M Bennett and Ronald Friend and published in the Arthritis Research and Therapy journal (Bennett RM, Friend R, Jones KD, Ward R, Han BK, and Ross RL. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Research and Therapy 2009, 11:R120) which is used to evaluate an individual's fibromyalgia symptoms and the extent they interfere with daily living. This instrument is a self-administered questionnaire with 3 sections with a total of 21 items pertaining to the difficulty of performing an activity, the overall impact of fibromyalgia, and the intensity of common fibromyalgia symptoms all within the past 7 days. Each item is ranked on a scale from 0-10.","Revised Fibromyalgia Impact Questionnaire | FIQR | FIQR01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525831","Functional Assessment of Cancer Therapy-Lung Symptom Index Questionnaire","C138338","A brief subscale complement of the Functional Assessment of Cancer Therapy General Questionnaire, developed by Cella et al. in 2007, that is utilized to assess the major symptoms related to lung cancer, including dyspnea, pain, fatigue, cough, and weight loss.","Functional Assessment of Cancer Therapy-Lung Symptom Index Questionnaire | FAC043 | FLSI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898763","Influenza Intensity and Impact Questionnaire Once Daily Version","C119093","A standardized rating scale developed by Measured Solutions for Health (MESH) Pty Ltd. This instrument is the once daily version and is used to measure symptoms severity and the impact of influenza.","Influenza Intensity and Impact Questionnaire Once Daily Version | FLU-IIQ ONCE DAILY | FLUIQ1 | Flu-iiQ Once Daily",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898762","Influenza Intensity and Impact Questionnaire Twice Daily Version","C119094","A standardized rating scale developed by Measured Solutions for Health (MESH) Pty Ltd. This instrument is the twice daily version and is used to measure symptoms severity and the impact of influenza.","Influenza Intensity and Impact Questionnaire Twice Daily Version | FLU-IIQ TWICE DAILY | FLUIQ2 | Flu-iiQ Twice Daily",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512353","Functional Assessment of Cancer Therapy-Ovarian Symptom Index Questionnaire","C129109","A standardized 8-item rating scale for the assessment of symptom response to treatment for advanced ovarian cancer that was originally developed by Cella, et al. in 1997 and derived from the ovarian cancer-specific subscale of the Functional Assessment of Cancer Therapy (FACT-O).","Functional Assessment of Cancer Therapy-Ovarian Symptom Index Questionnaire | FAC049 | FOSI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639711","Faces Pain Scale Revised Questionnaire","C100766","A standardized rating scale developed and copyrighted by the International Association for the Study of Pain (IASP) in 2001 but is available for non-commercial clinical, educational and research use in the journal Pain (Hicks CL, von Baeyer CL, Spafford P, van Korlaar I, Goodenough B. The Faces Pain Scale - Revised: Toward a common metric in pediatric pain measurement. Pain 2001;93:173-183). This instrument is used to evaluate the severity of pain in an individual who is unable to use a numerical scale alone such as a child. The scale consists of six facial expression representing varying levels of pain which correspond to a number between 0 and 10 where the 0 face represents 'no pain' and the 10 face represents 'very much pain'.","Faces Pain Scale Revised Questionnaire | FPSR | FPSR1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641948","STANDARDS General Clinical Global Impressions Questionnaire","C105169","Version 1 (2012-08-07) of the general clinical global impression of pain questionnaire created by the STANDARDS (Standardized Analgesic Database for Research, Discovery, and Submissions) committee and sponsored by ACTTION (Analgesic Clinical Trial Translations, Innovations, Opportunities, and Networks).","STANDARDS General Clinical Global Impressions Questionnaire | GCGI | GCGI01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827003","Geriatric Depression Scale Short Form Questionnaire","C106698","A standardized rating scale developed by Sheikh et al in 1986, which is a shorter version derived from the original GDS and used to identify depression in older adults. The questionnaire contains 15 items. All questions are answered 'yes' or 'no'.","Geriatric Depression Scale Short Form Questionnaire | GDS SHORT FORM | GDS-SF | GDS02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899193","Extended Glasgow Outcome Scale Questionnaire","C115797","A standardized rating scale originally developed by Jennett and Bondin in 1975 and later modified by Wilson et al in 1998, which is used to assess outcome after, and level of function in major life areas with head injury and non-traumatic acute brain insults. The questionnaire contains 23 items and generates 7 subscales: consciousness, independence in the home, independence outside the home, work, social and leisure activities, family and friendships, and epilepsy.","Extended Glasgow Outcome Scale Questionnaire | GOS-E | GOSE | GOSE1 | Glasgow Outcome Scale (Extended)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951396","Hemophilia Quality of Life Questionnaire Adult Version","C122381","A standardized rating scale developed by Mackensen et al in 2005, which is used to measure the physical and emotional impacts on quality of life in adults with hemophilia. The questionnaire contains 46 items which are divided into 10 dimensions: physical health, feelings, self-perception, sports and leisure, work and school, coping, treatment, future, family planning and relationships/partners.","Hemophilia Quality of Life Questionnaire Adult Version | HAEM-A-QOL | HAEM09 | HM09 | Haem-A-QoL | Haemophilia Quality of Life Questionnaire for Adults | Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054786","Hemophilia Quality of Life Questionnaire Children's Long Version Age Group I","C122373","A standardized rating scale developed by the Haemo-QoL Study Group in 2002, which is used to measure the physical and emotional impacts on quality of life in children and adolescents with hemophilia. The children's long version age group I questionnaire contains 21 items for children 4 to 7 years of age.","Hemophilia Quality of Life Questionnaire Children's Long Version Age Group I | HAEM01 | HAEMO-QOL CHILDREN'S LONG VERSION AGE GROUP I | HAEMO-QOL Children's Long Version Age Group I | HM01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054787","Hemophilia Quality of Life Questionnaire Children's Long Version Age Group II","C122374","A standardized rating scale developed by the Haemo-QoL Study Group in 2002, which is used to measure the physical and emotional impacts on quality of life in children and adolescents with hemophilia. The children's long version age group II questionnaire contains 64 items for children 8 to 12 years of age.","Hemophilia Quality of Life Questionnaire Children's Long Version Age Group II | HAEM02 | HAEMO-QOL CHILDREN'S LONG VERSION AGE GROUP II | HAEMO-QOL Children's Long Version Age Group II | HM02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054788","Hemophilia Quality of Life Questionnaire Children's Long Version Age Group III","C122375","A standardized rating scale developed by the Haemo-QoL Study Group in 2002, which is used to measure the physical and emotional impacts on quality of life in children and adolescents with hemophilia. The children's long version age group III questionnaire contains 77 items for adolescents 13 to 16 years of age.","Hemophilia Quality of Life Questionnaire Children's Long Version Age Group III | HAEM03 | HAEMO-QOL CHILDREN'S LONG VERSION AGE GROUP III | HAEMO-QOL Children's Long Version Age Group III | HM03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054784","Hemophilia Quality of Life Questionnaire Children's Short Version Age Group I","C122376","A standardized rating scale developed by the Haemo-QoL Study Group in 2002, which is used to measure the physical and emotional impacts on quality of life in children and adolescents with hemophilia. The children's short version age group I questionnaire contains 16 items for children 4 to 7 years of age.","Hemophilia Quality of Life Questionnaire Children's Short Version Age Group I | HAEM04 | HAEMO-QOL CHILDREN'S SHORT VERSION AGE GROUP I | HAEMO-QOL Children's Short Version Age Group I | HM04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054785","Hemophilia Quality of Life Questionnaire Children's Short Version Age Group II/III","C122377","A standardized rating scale developed by the Haemo-QoL Study Group in 2002, which is used to measure the physical and emotional impacts on quality of life in children and adolescents with hemophilia. The children's short version age group II/III questionnaire contains 35 items, which can be used for both children 8 to 12 years of age and adolescents 13 to 16 years of age.","Hemophilia Quality of Life Questionnaire Children's Short Version Age Group II/III | HAEM05 | HAEMO-QOL CHILDREN'S SHORT VERSION AGE GROUP II/III | HAEMO-QOL Children's Short Version Age Group II/III | HM05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054781","Hemophilia Quality of Life Questionnaire Parent's Long Version Age Group I","C122378","A standardized rating scale developed by the Haemo-QoL Study Group in 2002, which is used to measure the physical and emotional impacts on quality of life in children and adolescents with hemophilia. The parent's long version age group I questionnaire contains 21 items and corresponds to age group I of children 4 to 7 years of age.","Hemophilia Quality of Life Questionnaire Parent's Long Version Age Group I | HAEM06 | HAEMO-QOL PARENT'S LONG VERSION AGE GROUP I | HAEMO-QOL Parent's Long Version Age Group I | HM06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054782","Hemophilia Quality of Life Questionnaire Parent's Long Version Age Group II","C122379","A standardized rating scale developed by the Haemo-QoL Study Group in 2002, which is used to measure the physical and emotional impacts on quality of life in children and adolescents with hemophilia. The parent's long version age group II questionnaire contains 64 items and corresponds to age group II of children 8 to 12 years of age.","Hemophilia Quality of Life Questionnaire Parent's Long Version Age Group II | HAEM07 | HAEMO-QOL PARENT'S LONG VERSION AGE GROUP II | HAEMO-QOL Parent's Long Version Age Group II | HM07",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054783","Hemophilia Quality of Life Questionnaire Parent's Long Version Age Group III","C122380","A standardized rating scale developed by the Haemo-QoL Study Group in 2002, which is used to measure the physical and emotional impacts on quality of life in children and adolescents with hemophilia. The parent's long version age group III questionnaire contains 77 items and corresponds to age group III of adolescents 13 to 16 years of age.","Hemophilia Quality of Life Questionnaire Parent's Long Version Age Group III | HAEM08 | HAEMO-QOL PARENT'S LONG VERSION AGE GROUP III | HAEMO-QOL Parent's Long Version Age Group III | HM08",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513956","Hamilton Depression Rating Scale 6 Self-Report Version Questionnaire","C130314","A standardized 6-item self-report rating scale for the assessment of symptoms in patients diagnosed with depression. The original 17-item Hamilton Depression Scale, developed by Max Hamilton at the University of Leeds in 1960, was independently modified by Bech et al in 1975, using Rasch models, to create a melancholia subscale that contains six variables.","Hamilton Depression Rating Scale 6 Self-Report Version Questionnaire | HAM-D6 Self-Report Version | HAMD 6 SELF-REPORT VERSION | HAMDS1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519956","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale","C132534","A standardized 20-item self-report component of the Health Assessment Questionnaire, developed by Fries et al 1978, that assesses a patient's level of functional ability. The disability index utilizes a 4-point symptom rating scale to allow patients to grade eight categories of ability, including dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities.","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale | HAQ-DI WITHOUT VAS | HAQ-DI Without VAS | HAQ02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641331","International Index of Erectile Function Questionnaire","C103521","A standardized survey developed and published by Raymond C. Rosen and colleagues in 1997 which is used to assess erectile function. This instrument is a self-administered questionnaire with 15 items each with as set of 5 or 6 response options associated with a score of 1-5 or 1-6.","International Index of Erectile Function Questionnaire | IIEF | IIEF01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539750","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format","C141692","A standardized 31-item questionnaire, developed by Booth et al. in 2000, that is administered over the telephone and assesses physical activity lasting at least 10 minutes during the past seven days.","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format | IPAQ Long Last 7 Days Telephone Format Version | IPAQ-LF PHONE VERSION | IPAQ02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539751","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format","C141691","A standardized self-administered 31-item questionnaire, developed by Booth et al. in 2000, that assesses physical activity lasting at least 10 minutes during the past seven days.","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format | IPAQ Long Last 7 Days Self-Administered Format Version | IPAQ-LF SELF-ADMINISTERED VERSION | IPAQ03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539749","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format","C141693","A standardized 9-item questionnaire, developed by Booth et al. in 2000, that is administered over the telephone and assesses physical activity lasting at least 10 minutes during the past seven days.","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format | IPAQ Short Last 7 Days Telephone Format Version | IPAQ-SF PHONE VERSION | IPAQ01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539752","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format","C141690","A standardized self-administered 9-item questionnaire, developed by Booth et al. in 2000, that assesses physical activity lasting at least 10 minutes during the past seven days.","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format | IPAQ Short Last 7 Days Self-administered Format Version | IPAQ-SF SELF-ADMINISTERED VERSION | IPAQ04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826990","Impact of Visual Impairment Scale Questionnaire","C113876","A standardized rating scale developed by the National Multiple Sclerosis Society in 1997, which was based on items derived from the Functional Capacities Assessment developed by the Michigan Commission for the Blind. This questionnaire measures the level of visual function and difficulties with simple visual tasks such as reading and watching television. The questionnaire contains 5 questions which are scored ranging from 0 (not at all difficult) to 3 (could not do due to visual problems).","Impact of Visual Impairment Scale Questionnaire | IVIS | IVIS01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826987","KFSS1","C112522","A standardized rating scale developed by John F. Kurtzke in 1983 to measure the level of functioning in people with multiple sclerosis based on a standard neurological examination. The questionnaire contains 7 functional system; pyramidal functions, cerebellar functions, brainstem functions, sensory function, bowel and bladder function, visual function, and cerebral (or mental) functions. The functional system (FS) scores collected from this questionnaire are used in conjunction with observations and information regarding ambulation and the use of assistive devices to rate the EDSS.","Kurtzke Functional Systems Scores Clinical Classification | KFSS | KFSS1 | Kurtzke Functional Systems Scores Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523053","Life Events Checklist for DSM-5 Standard Version Questionnaire","C135740","A standardized 17-item self-report measure, published in 2013, that is used to investigate exposure to potentially traumatic events that meet diagnostic criterion A for post-traumatic stress disorder (PTSD) according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). The instrument is used to assess exposure to 16 event categories known to potentially result in PTSD or distress, as well as an additional item addressing any other extraordinarily stressful events not captured by the 16 categories, in adults 18 years of age and older.","Life Events Checklist for DSM-5 Standard Version Questionnaire | LEC-5 STANDARD VERSION | LEC-5 Standard Version | LEC01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054475","Montgomery-Asberg Depression Rating Scale Questionnaire","C122382","A standardized rating scale developed by Montgomery and Asberg in in 1978, which is used to measure the severity of depressive symptoms in patients with depression. The questionnaire contains 10 items on a scale of 0 to 6.","Montgomery-Asberg Depression Rating Scale Clinical Classification | MADRS | MADRS1 | Montgomery-Asberg Depression Rating Scale Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054532","Menstrual Distress Questionnaire Form-T (Today)","C123660","A standardized rating scale developed by Rudolf H. Moos in 1968, which is used to measure cyclical perimenstrual symptoms. The form-T version of this questionnaire allows an individual to describe her experiences on a specific day. This questionnaire contains 47 items","Menstrual Distress Questionnaire Form-T (Today) | MDQ-T | MDQ01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937185","Illness is Financial Hardship for My Family and Me","C157620","A question about whether an individual's illness is or was a financial hardship for them and their family.","Illness is Financial Hardship for My Family and Me | My illness has been a financial hardship to my family and me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816450","Forty Nine","C105796","A natural number greater than forty-eight and less than fifty and the quantity that it denotes.","Forty Nine | 49 | Forty-Nine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698622","CDISC SDTM Drug Accountability Test Terminology by Code","C78732","Terminology associated with the drug accountability test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Drug Accountability Test Code Terminology | DATESTCD | Drug Accountability Test Code | SDTM-DATESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050148","CDISC SDTM Immunogenicity Specimen Assessments Test Name Terminology","C120526","Terminology associated with the immunogenicity specimen assessments test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Immunogenicity Specimen Assessments Test Name Terminology | ISTEST | Immunogenicity Specimen Assessments Test Name | SDTM-ISTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053925","Total IgG Antibody Secreting Cell Count","C120624","The determination of the number of IgG antibody secreting cells present in a sample.","Total IgG Antibody Secreting Cell Count | TIGGASC | Total IgG ASCs | Total IgG Antibody Secreting Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545271","Neutralizing Binding Antidrug Antibody Measurement","C147273","The determination of the neutralizing binding antidrug antibody in a biological sample.","Neutralizing Binding Antidrug Antibody Measurement | ADA_NAB | NADA Measurement | Neutralizing ADA Measurement | Neutralizing Binding Antidrug Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545272","Neutralizing Cross-Reacting Binding Antidrug Antibody Measurement","C147274","The determination of the neutralizing cross-reactive binding antidrug antibody in a biological sample.","Neutralizing Cross-Reacting Binding Antidrug Antibody Measurement | ADA_NX | Cross-Reactive NADA Measurement | Neutraliz Cross-React Bind Antidrug AB | Neutralizing Cross-Reactive ADA Measurement | Neutralizing Cross-Reactive Binding Antidrug Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520046","IgM Antibody Secreting Cell Count","C132362","The determination of the number of IgM antibody-secreting cells in a biological sample.","IgM Antibody Secreting Cell Count | IGMABSC | IgM Antibody Secreting Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054718","Influenza Hemagglutinin 3 Specific IgG Antibody Secreting Cell Count","C120623","The determination of the number of influenza hemagglutinin 3 specific IgG antibody secreting cells present in a sample.","Influenza Hemagglutinin 3 Specific IgG Antibody Secreting Cell Count | H3 Specific IgG ASCs | H3 Specific IgG Antibody Secreting Cells | H3IGGASC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521039","Ebola Virus Specific IgM Antibody Secreting Cell Count","C132361","The determination of the number of Ebola virus-specific IgM antibody secreting cells in a biological sample.","Ebola Virus Specific IgM Antibody Secreting Cell Count | EBOV Specific IgM AB Secreting Cells | EVIGMASC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521038","Ebola Virus Specific IgG Antibody Secreting Cell Count","C132360","The determination of the number of Ebola virus-specific IgG antibody secreting cells in a biological sample.","Ebola Virus Specific IgG Antibody Secreting Cell Count | EBOV Specific IgG AB Secreting Cells | EVIGGASC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545273","Cross-Reactive Binding Antidrug Antibody Measurement","C147275","The determination of the cross-reactive binding antidrug antibody in a biological sample.","Cross-Reactive Binding Antidrug Antibody Measurement | ADA_X | Cross-Reactive Binding ADA Measurement | Cross-Reactive Binding Antidrug Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545270","Binding Antidrug Antibody Measurement","C147272","The determination of the binding antidrug antibody in a biological sample.","Binding Antidrug Antibody Measurement | ADA_BAB | Binding ADA Measurement | Binding Antidrug Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049861","CDISC SDTM Immunogenicity Specimen Assessments Test Code Terminology","C120525","Terminology associated with the immunogenicity specimen assessments test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Immunogenicity Specimen Assessments Test Code Terminology | ISTESTCD | Immunogenicity Specimen Assessments Test Code | SDTM-ISTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639722","Work Productivity and Activity Impairment Specific Health Problems Version 2.0 Questionnaire","C100779","The second version of a standardized survey originally developed by Margaret C. Reilly in 1993 which is used to evaluate the extent to which a patient's specific health problems effect their ability to work and perform daily activities. This instrument consist of 6 questions which can be completed by the patient or in an interview format.","Work Productivity and Activity Impairment Specific Health Problems Version 2.0 Questionnaire | WPAI-SHP V2.0 | WPAI01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053846","Western Ontario and McMaster Universities Osteoarthritis Index Version 3.1 Visual Analog Scale Format Questionnaire","C122386","A standardized rating scale developed by Nicholas Bellamy with the Western Ontario and McMaster Universities in 1982, which is used to assess pain, stiffness, and physical function in patients with hip and/or knee osteoarthritis. The questionnaire contains 24 items which are divided into 3 subscales: pain, stiffness and physical function. This version of the questionnaire uses the 100mm visual analog scaling format.","Western Ontario and McMaster Universities Osteoarthritis Index Version 3.1 Visual Analog Scale Format Questionnaire | WOMAC Index Version 3.1 Visual Analog Scale Format | WOMAC VA 3.1 INDEX | WOMAC3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053847","Western Ontario and McMaster Universities Osteoarthritis Index Version 3.1 Numerical Rating Scale Format Questionnaire","C122385","A standardized rating scale developed by Nicholas Bellamy with the Western Ontario and McMaster Universities in 1982, which is used to assess pain, stiffness, and physical function in patients with hip and/or knee osteoarthritis. The questionnaire contains 24 items which are divided into 3 subscales: pain, stiffness and physical function. This version of the questionnaire uses the 11-point numerical rating scaling format.","Western Ontario and McMaster Universities Osteoarthritis Index Version 3.1 Numerical Rating Scale Format Questionnaire | WOMAC Index Version 3.1 Numerical Rating Scale Format | WOMAC NRS 3.1 INDEX | WOMAC2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053848","Western Ontario and McMaster Universities Osteoarthritis Index Version 3.1 Likert Scale Format Questionnaire","C122384","A standardized rating scale developed by Nicholas Bellamy with the Western Ontario and McMaster Universities in 1982, which is used to assess pain, stiffness, and physical function in patients with hip and/or knee osteoarthritis. The questionnaire contains 24 items which are divided into 3 subscales: pain, stiffness and physical function. This version of the questionnaire uses the 5-point Likert scaling format.","Western Ontario and McMaster Universities Osteoarthritis Index Version 3.1 Likert Scale Format Questionnaire | WOMAC Index Version 3.1 Likert Scale Format | WOMAC LK 3.1 INDEX | WOMAC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897161","Work Limitations Questionnaire","C119096","A standardized rating scale originally developed by Lerner et al in 1998. This instrument is used to measure the degree to which health problems interfere with specific aspects of job performance and health-related productivity loss in employed individuals.","Work Limitations Questionnaire | WLQ | WLQ01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513745","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered Questionnaire","C130321","A standardized 36-item self-report questionnaire that utilizes a 5-point rating scale to assess an individual's ability to perform activities in six domains of functioning over the 30 days prior to evaluation in order to calculate a global disability score. The questionnaire was developed in 2010 by the World Health Organization (WHO) Classification, Terminology and Standards team, within the framework of the WHO/National Institutes of Health (NIH) Joint Project on Assessment and Classification of Disability.","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered Questionnaire | WD7 | WHODAS 2.0 - 36-ITEM SELF | WHODAS 2.0 36-item Version Self-administered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513705","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered Questionnaire","C130320","A standardized 36-item questionnaire, administered by a friend, relative, or caretaker, that utilizes a 5-point rating scale to assess an individual's ability to perform activities in six domains of functioning over the 30 days prior to evaluation in order to calculate a global disability score. The questionnaire was developed in 2010 by the World Health Organization (WHO) Classification, Terminology and Standards team, within the framework of the WHO/National Institutes of Health (NIH) Joint Project on Assessment and Classification of Disability.","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered Questionnaire | WD6 | WHODAS 2.0 - 36-ITEM PROXY | WHODAS 2.0 36-item Version Proxy-administered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513664","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered Questionnaire","C130319","A standardized 36-item interviewer-administered questionnaire that utilizes a 5-point rating scale to assess an individual's ability to perform activities in six domains of functioning over the 30 days prior to evaluation in order to calculate a global disability score. The questionnaire was developed in 2010 by the World Health Organization (WHO) Classification, Terminology and Standards team, within the framework of the WHO/National Institutes of Health (NIH) Joint Project on Assessment and Classification of Disability.","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered Questionnaire | WD5 | WHODAS 2.0 - 36-ITEM INTERVIEWER | WHODAS 2.0 36-item Version Interviewer-administered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513564","World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered Questionnaire","C130324","A standardized 12-item self-report questionnaire that utilizes a 5-point rating scale to provide a brief assessment of an individual's ability to perform activities in six domains of functioning over the 30 days prior to evaluation in order to calculate a global disability score. The questionnaire was developed in 2010 by the World Health Organization (WHO) Classification, Terminology and Standards team, within the framework of the WHO/National Institutes of Health (NIH) Joint Project on Assessment and Classification of Disability.","World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered Questionnaire | WD3 | WHODAS 2.0 - 12-ITEM SELF | WHODAS 2.0 12-item Version Self-administered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513548","World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered Questionnaire","C130323","A standardized 12-item questionnaire, administered by a friend, relative, or caretaker, that utilizes a 5-point rating scale to provide a brief assessment of an individual's ability to perform activities in six domains of functioning over the 30 days prior to evaluation in order to calculate a global disability score. The questionnaire was developed in 2010 by the World Health Organization (WHO) Classification, Terminology and Standards team, within the framework of the WHO/National Institutes of Health (NIH) Joint Project on Assessment and Classification of Disability.","World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered Questionnaire | WD2 | WHODAS 2.0 - 12-ITEM PROXY | WHODAS 2.0 12-item Version Proxy-administered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513531","World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered Questionnaire","C130322","A standardized 12-item interviewer-administered questionnaire that utilizes a 5-point rating scale to provide a brief assessment of an individual's ability to perform activities in six domains of functioning over the 30 days prior to evaluation in order to calculate a global disability score. The questionnaire was developed in 2010 by the World Health Organization (WHO) Classification, Terminology and Standards team, within the framework of the WHO/National Institutes of Health (NIH) Joint Project on Assessment and Classification of Disability.","World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered Questionnaire | WD1 | WHODAS 2.0 - 12-ITEM INTERVIEWER | WHODAS 2.0 12-item Version Interviewer-administered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513614","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered Questionnaire","C130325","A standardized interviewer-administered or computer-adaptive testing (CAT) questionnaire that utilizes a 5-point rating scale to assess an individual's ability to perform activities in six domains of functioning over the 30 days prior to evaluation in order to calculate a global disability score. The questionnaire is initially administered as 12 items to screen for problematic domains of functioning. Up to 24 items are then added based on the initial responses. The questionnaire was developed in 2010 by the World Health Organization (WHO) Classification, Terminology and Standards team, within the framework of the WHO/National Institutes of Health (NIH) Joint Project on Assessment and Classification of Disability.","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered Questionnaire | WD4 | WHODAS 2.0 - 12 + 24-ITEM INTERVIEWER | WHODAS 2.0 12+24-item Version Interviewer-administered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826863","Visual Functioning Questionnaire 25-Self Administered Format Version 2000","C112528","A standardized rating scale developed by RAND and sponsored by the National Eye Institute (NEI) to assess the dimensions of self-reported vision-targeted health status that are most important for individuals with chronic eye disease. It also measures the influence of visual disability and symptoms on emotional well-being, mental health, social and daily visual functioning. This questionnaire is in the Self or Patient Administered Format and contains 25 multiple choice questions across 3 domains; general health and vision, difficulty with activates, and response to vision problems. It also includes an appendix of additional 13 questions researchers can use to expand the scales up to 38 total items.","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 | VFQ-25 SELF ADMINISTERED | VFQ2 | VFQ25-Self Administered Format",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826864","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000","C112527","A standardized rating scale developed by RAND and sponsored by the National Eye Institute (NEI) to assess the dimensions of self-reported vision-targeted health status that are most important for individuals with chronic eye disease. It also measures the influence of visual disability and symptoms on emotional well-being, mental health, social and daily visual functioning. This questionnaire is in the Interviewer Administered Format and contains 25 multiple choice questions across 3 domains; general health and vision, difficulty with activates, and response to vision problems. It also includes an appendix of additional 13 questions researchers can use to expand the scales up to 38 total items.","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 | VFQ-25 INTERVIEWER ADMINISTERED | VFQ1 | VFQ25-Interviewer Administered Format",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542434","Urgency Perception Scale Questionnaire","C103530","A standardized rating scale developed and published by Linda Cardozo, Karin Coyne and Eboo Versi in 2004 and copyrighted by Pfizer which is used to assess an individual's sense of urinary urgency. This instrument consists of one item in which the individual rates their experience when they have the desire to urinate. The item has three responses that receive a score of 0, 1, or 2.","Urgency Perception Scale Questionnaire | UPS | UPS01 | USP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639721","Unified Parkinson's Disease Rating Scale Clinical Classification","C100778","A standardized rating scale originally developed by S. Fahn, R. Elton, and other members of the UPDRS Development Committee in 1987 which is used to evaluate the status of a patient's Parkinson's disease. This instrument is made up of 6 parts consisting of a mental, behavior and mood section, an activities of daily living section, a motor examination, and questions concerning any complications with the patient's current therapy as well as modified versions of the Hoehn and Yahr Staging assessment and the Schwab and England Activities of Daily Living Scale. Each question is either scored with a 0 for a 'no' response and 1 for a 'yes' response or with a 0-4 point scale.","Unified Parkinson's Disease Rating Scale Clinical Classification | UPD1 | UPDRS | Unified Parkinson's Disease Rating Scale Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520255","Treatment Satisfaction Questionnaire for Medication Version 1.4","C132535","A standardized 14-item self-report scale developed by Atkinson et al in 2004 to assess the major dimensions of patients' satisfaction with medication. The instrument, which permits comparisons across medication types and patient conditions, provides scores on four scales: side effects, effectiveness, convenience, and global satisfaction.","Treatment Satisfaction Questionnaire for Medication Version 1.4 | TSQM V1.4 | TSQM Version 1.4 | TSQM01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545375","Trauma Symptom Checklist for Young Children Questionnaire","C147588","A standardized 90-item caretaker-report questionnaire developed by Briere et al. in 1999, that utilizes a four-point Likert rating scale to evaluate severity of posttraumatic stress and related symptoms in children ages 3-12 years who have experienced traumatic events.","Trauma Symptom Checklist for Young Children Questionnaire | TSCYC | TSCYC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545374","Trauma Symptom Checklist for Children Questionnaire","C147587","A standardized 54-item self-report questionnaire developed by Briere et al. in 1996, that utilizes a four-point Likert rating scale to evaluate severity of posttraumatic stress and related symptoms in children ages 10-17 years who have experienced traumatic events.","Trauma Symptom Checklist for Children Questionnaire | TSCC | TSCC01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714807","Transition Dyspnea Index Questionnaire","C106694","A standardized rating scale developed by Mahler et al in 1984, which is a general scale used to measure the changes in dyspnea severity from the baseline as established by the Baseline Dyspnea Index (BDI). The questionnaire contains 3 categories of 24 items change in functional impairment, change in magnitude of task, change in magnitude of effort. The instrument is scored on a seven-grade scale for each category, where grade -3 represents major deterioration and grade +3 represents major improvement.","Transition Dyspnea Index Clinical Classification | TDI | TDI01 | Transition Dyspnea Index Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897656","Satisfaction With Life Scale Questionnaire","C115799","A standardized rating scale developed by Diener et al in 1985, which is used to measure global cognitive judgments of satisfaction with one's life. The questionnaire contains 5 questions and is scored ranging from 1 (Strongly disagree) to 7 (Strongly agree).","Satisfaction With Life Scale Questionnaire | SWLS | SWLS01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640522","Subjective Opiate Withdrawal Scale Questionnaire","C102123","A standardized rating scale developed by Leonard Handelsman and colleagues in 1987 to evaluate the severity of an individual's opiate withdrawal signs and symptoms. This instrument contains 16 items or symptoms that pertain to opiate withdrawal, which are completed by the individual. Each item is rated on a scale of 0 to 4 with 0 being not at all and 4 being extremely.","Subjective Opiate Withdrawal Scale Questionnaire | SOWS SUBJECTIVE | SOWS Subjective | SOWSA1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639714","Movement Disorder Society Unified Parkinson's Disease Rating Scale Questionnaire","C100769","A standardized rating scale developed and copyrighted by the Movement Disorders Society in 2008 and published in the journal Movement Disorders (C.G. Goetz et al. Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale Presentation and Clinimetric Testing Results. Movement Disorders, 23(15):2129-2170.) which is used to evaluate the severity of an individual's Parkinson's disease symptoms. This instrument contains four parts consisting of non-motor and motor experiences in daily living, a motor examination and an assessment of motor complications which is completed during an interview and physical examination. Each symptom is rated on a scale of 0-4 with 0 being normal and 4 being severe.","Movement Disorder Society Unified Parkinson's Disease Rating Scale Questionnaire | MDS-UPDRS | UPD2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639715","Michigan Neuropathy Screening Instrument Questionnaire","C100771","A standardized survey developed and copyrighted by the University of Michigan's Diabetes Research and Training Center and is based on Peter Dyck's Neuropathy Screening Profile (Dyck PJ, Karnes J, O'Brien PC, Swanson CJ, Neuropathy Symptom Profile in health, motor neuron disease, diabetic neuropathy, and amyloidosis. Neurology, 1986, 36:1300-1308) which is used to screen for neuropathy particularly in individuals with diabetes. This instrument consists of two parts, the first part is a patient history and can be completed by the patient while the second part is physical exam completed by a health professional.","Michigan Neuropathy Screening Instrument Questionnaire | MNSI | MNSI1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639716","Parkinson's Disease Quality of Life Scale Questionnaire","C100773","A standardized rating scale originally developed and copyrighted by Mickie Welsh and The Parkinson Study Group in 1996 then released for publication in the journal Movement Disorders in 2003 which is used to assist the clinician in evaluating the degree to which the patient's Parkinson's disease symptoms interfere with their quality of life. This instrument contains 33 questions covering 7 areas including social/role function, self-image/sexuality, sleep, outlook on life, physical function, independence, and urinary function and can be completed by the patient. For each question, the patient must choose from five different responses.","Parkinson's Disease Quality of Life Scale Questionnaire | PDQ01 | PDQUALIF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639717","Roland Morris Disability Questionnaire","C100774","A standardized survey developed by M.O. Roland and R.W. Morris in 1983 used to assess the level of disability experienced by a patient with back pain. This original version consists of 24 statements and can be completed by the patient. Each statement receives either a 0 if it is not applicable to patient on the day the questionnaire is administered or a 1 if it is applicable.","Roland Morris Disability Questionnaire | RDQ | RDQ01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639718","Short Form 36 Health Survey Standard, US Version 1.0 Questionnaire","C100775","A standardized, multipurpose, general health survey developed by John E. Ware and copyrighted by Medical Outcomes Trust and Quality Metric Inc. in 1988 and 2002 which is used to assess the patient's functional health and overall well-being. This instrument contains 36 questions to be completed by the patient. For each question the patient must choose from five different responses.","Short Form 36 Health Survey Standard, US Version 1.0 Questionnaire | SF36 V1.0 STANDARD | SF36 v1.0 Standard | SF361",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639719","Short-Form McGill Pain Questionnaire-2","C100776","A standardized rating scale developed to evaluate the type and severity of a patients neuropathic or non-neuropathic pain. This revised version contains 22 symptoms associated with neuropathic and non-neuropathic pain which can be completed by the patient. Each symptom is rated on a scale of 0-10 with 0 being no pain and 10 being the worst possible pain. This questionnaire was copyrighted by Ronald Melzack and the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) in 2009 as well as published in the journal pain (Dworkin R.H., Development and initial validation of an expanded and revised version of the Short-form McGill Pain Questionnaire-2 (SF-MPQ-2). Pain, 2009 Jul;144(1-2):35-42).","Short-Form McGill Pain Questionnaire-2 | SFMP2 | SHORT-FORM MPQ-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639720","Screener and Opioid Assessment for Patients with Pain Revised Questionnaire","C100777","A standardized rating scale developed and copyrighted by Inflexxicon, Inc. which is used to aid clinicians in screening a patient's potential for long-term opioid use in the treatment of pain. This revised version consists of 24 questions which can be completed by the patient. Each question is rated on a scale of 0-4 with 0 being 'never' and 4 being 'very often'. A score equal to or greater than 18 indicates that the patient has a high risk of misusing opioids.","Screener and Opioid Assessment for Patients with Pain Revised Questionnaire | SOAPP-R | SOAPR1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640519","Short Form 36 Health Survey Acute, US Version 1.0 Questionnaire","C102120","A standardized, multipurpose, general health survey developed by John E. Ware and copyrighted by the Medical Outcomes Trust and Quality Metric Inc. in 1988 and 2002, which is used to assess the patient's functional health and overall well-being. This first version contains 36 questions that refer to the patient's symptoms or status within the past week and can be completed by the patient. For each question the patient must choose from five different responses.","Short Form 36 Health Survey Acute, US Version 1.0 Questionnaire | SF36 V1.0 ACUTE | SF36 v1.0 Acute | SF362",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640520","Short Form 36 Health Survey Acute, US Version 2.0 Questionnaire","C102121","A standardized, multipurpose, general health survey developed by John E. Ware and copyrighted by Quality Metric Inc. and the Medical Outcomes Trust in 1996 and 2000, which is used to assess the patient's functional health and overall well-being. This second version contains 36 questions that refer to the patient's symptoms or status within the past week and can be completed by the patient. For each question the patient must choose from five different responses.","Short Form 36 Health Survey Acute, US Version 2.0 Questionnaire | SF36 V2.0 ACUTE | SF36 v2.0 Acute | SF364",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087288","Young Mania Rating Scale Questionnaire","C102124","A standardized rating scale developed by R. C. Young and colleagues in 1978 to assess the severity of an individual's mania. This instrument contains 11 items or symptoms associated with mania which is administered by a clinician. Each item has 5 response options but the weight of each response differs with each item.","Young Mania Rating Scale Clinical Classification | YMRS | YMRS01 | Young Mania Rating Scale Questionnaire",,,,,,,,,,,,,,,"36684931","Young mania rating scale",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641332","The Overactive Bladder Questionnaire","C103523","A standardized survey developed and published by K. Coyne and colleagues in 2002 in the journal Quality of Life Research which is used to evaluate the all symptoms associated with overactive bladder. This instrument contains 33 items pertaining to bladder symptoms occurring during the past week that can be self-administered. Each item is rated on a scale of 1-6 with 1 representing none or not at all and 6 representing a great deal or all the time.","The Overactive Bladder Questionnaire | OAB-Q | OAB-q | OABQ01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525816","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report Questionnaire","C138356","A 17-item disease specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure one dimension of patient reported health related quality of life over the past month in children ages 5 to 7 years with neuromuscular disorders.","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report Questionnaire | PEDSQL NEUROMUSCULAR MODULE V3 YOUNG CHILD | PQL07 | PedsQL Neuromuscular Module Version 3.0 Young Child Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525817","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report Questionnaire","C138355","A 25-item disease specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of patient reported health related quality of life over the past month in patients ages 18 to 25 years with neuromuscular disorders.","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report Questionnaire | PEDSQL NEUROMUSCULAR MODULE V3 YOUNG ADULT | PQL01 | PedsQL Neuromuscular Module Version 3.0 Young Adult Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525818","Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report Questionnaire","C138354","A 25-item disease specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of patient reported health related quality of life over the past month in children ages 13 to 18 years with neuromuscular disorders.","Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report Questionnaire | PEDSQL NEUROMUSCULAR MODULE V3 TEEN | PQL03 | PedsQL Neuromuscular Module Version 3.0 Teen Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525819","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child Questionnaire","C138353","A 25-item disease specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of parent reported health related quality of life over the past month in children ages 5 to 7 years with neuromuscular disorders.","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child Questionnaire | PEDSQL NEUROMUSCULAR MODULE V3 YOUNG CHILD PARENT REPORT | PQL08 | PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525812","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Questionnaire","C138352","A 25-item disease specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of parent reported health related quality of life over the past month in individuals ages 18 to 25 years with neuromuscular disorders.","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Questionnaire | PEDSQL NEUROMUSCULAR MODULE V3 YOUNG ADULT PARENT REPORT | PQL02 | PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525813","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen Questionnaire","C138351","A 25-item disease specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of parent reported health related quality of life over the past month in children ages 13 to 18 years with neuromuscular disorders.","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen Questionnaire | PEDSQL NEUROMUSCULAR MODULE V3 TEEN PARENT REPORT | PQL04 | PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525814","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child Questionnaire","C138350","A 25-item disease specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of parent reported health related quality of life over the past month in children ages 8 to 12 years with neuromuscular disorders.","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child Questionnaire | PEDSQL NEUROMUSCULAR MODULE V3 CHILD PARENT REPORT | PQL06 | PedsQL Neuromuscular Module Version 3.0 Parent Report for Child",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525815","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler Questionnaire","C138349","A 25-item disease specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of parent reported health related quality of life over the past month in children ages 2 to 4 years with neuromuscular disorders.","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler Questionnaire | PEDSQL NEUROMUSCULAR MODULE V3 TODDLER PARENT REPORT | PQL09 | PedsQL Neuromuscular Module Version 3.0 Parent of Toddler",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525808","Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report Questionnaire","C138348","A 25-item disease specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of patient reported health related quality of life over the past month in children ages 8 to 12 years with neuromuscular disorders.","Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report Questionnaire | PEDSQL NEUROMUSCULAR MODULE V3 CHILD | PQL05 | PedsQL Neuromuscular Module Version 3.0 Child Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525809","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report Questionnaire","C138347","A 17-item disease specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure one dimension of patient reported health related quality of life over the past seven days in children ages 5 to 7 years with neuromuscular disorders.","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report Questionnaire | PEDSQL NEUROMUSCULAR MODULE ACUTE V3 YOUNG CHILD | PQL16 | PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525810","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report Questionnaire","C138346","A 25-item disease specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of patient reported health related quality of life over the past seven days in individuals ages 18 to 25 years with neuromuscular disorders.","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report Questionnaire | PEDSQL NEUROMUSCULAR MODULE ACUTE V3 YOUNG ADULT | PQL10 | PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525811","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report Questionnaire","C138345","A 25-item disease-specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of patient reported health related quality of life over the past seven days in children ages 13 to 18 years with neuromuscular disorders.","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report Questionnaire | PEDSQL NEUROMUSCULAR MODULE ACUTE V3 TEEN | PQL12 | PedsQL Neuromuscular Module Acute Version 3.0 Teen Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525804","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Questionnaire","C138344","A 25-item disease specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of parent reported health related quality of life over the past seven days in children ages 5 to 7 years with neuromuscular disorders.","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Questionnaire | PEDSQL NEUROMUSCULAR MODULE ACUTE V3 YOUNG CHILD PARENT REPORT | PQL17 | PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525805","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Questionnaire","C138343","A 25-item disease-specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of parent reported health related quality of life over the past seven days in individuals ages 18 to 25 years with neuromuscular disorders.","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Questionnaire | PEDSQL NEUROMUSCULAR MODULE ACUTE V3 YOUNG ADULT PARENT REPORT | PQL11 | PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525806","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen Questionnaire","C138342","A 25-item disease-specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of parent reported health related quality of life over the past seven days in children ages 13 to 18 years with neuromuscular disorders.","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen Questionnaire | PEDSQL NEUROMUSCULAR MODULE ACUTE V3 TEEN PARENT REPORT | PQL13 | PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525807","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child Questionnaire","C138341","A 25-item disease-specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of parent reported health related quality of life over the past seven days in children ages 8 to 12 years with neuromuscular disorders.","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child Questionnaire | PEDSQL NEUROMUSCULAR MODULE ACUTE V3 CHILD PARENT REPORT | PQL15 | PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525830","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report Questionnaire","C138339","A 25-item disease specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of patient reported health related quality of life over the past seven days in children ages 8 to 12 years with neuromuscular disorders.","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report Questionnaire | PEDSQL NEUROMUSCULAR MODULE ACUTE V3 CHILD | PQL14 | PedsQL Neuromuscular Module Acute Version 3.0 Child Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523058","RAND Social Support Survey Instrument Questionnaire","C135745","A standardized 19-item survey developed by Cathy Donalds Helbourne and Anita L. Stewart in 1991 for the assessment of recent thinking about the various dimensions of social support in patients with chronic conditions in the Medical Outcomes Study (MOS). The instrument measures five dimensions of social support: emotional support, informational support, tangible support, positive social interaction, and affectionate support.","RAND Social Support Survey Instrument Questionnaire | RAND SOCIAL SUPPORT SURVEY INSTRUMENT | RAND Social Support Survey | RSSS01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523057","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version Questionnaire","C135744","A standardized 83-item self-report questionnaire, developed by the American Academy of Orthopaedic Surgeons and the Pediatric Orthopaedic Society of North America (POSNA) in 1998 to assess the overall health, pain, and ability to participate in normal daily activities in patients 11 to 18 years of age. The instrument includes five scales: upper extremity and physical function, transfer and mobility tasks, sports/physical functioning, pain/comfort, treatment expectations, happiness, and satisfaction with symptoms, as well as a Global Functioning scale that consists of the mean of the values for the first four scales.","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version Questionnaire | PODCI - ADOLESCENT SELF REPORTED | PODCI Adolescent Self-Reported Version | PODCI3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523056","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version Questionnaire","C135743","A standardized 86-item parent-report questionnaire, developed by the American Academy of Orthopaedic Surgeons and the Pediatric Orthopaedic Society of North America (POSNA) in 1998 to assess the overall health, pain, and ability to participate in normal daily activities in patients 11 to 18 years of age. The instrument includes five scales: upper extremity and physical function, transfer and mobility tasks, sports/physical functioning, pain/comfort, treatment expectations, happiness, and satisfaction with symptoms, as well as a Global Functioning scale that consists of the mean of the values for the first four scales.","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version Questionnaire | PODCI - ADOLESCENT PARENT REPORTED | PODCI Adolescent Parent-Reported Version | PODCI2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523055","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version Questionnaire","C135742","A standardized 86-item parent-report questionnaire, developed by the American Academy of Orthopaedic Surgeons and the Pediatric Orthopaedic Society of North America (POSNA) in 1998 to assess the overall health, pain, and ability to participate in normal daily activities in patients 10 years of age or younger. The instrument includes five scales: upper extremity and physical function, transfer and mobility tasks, sports/physical functioning, pain/comfort, treatment expectations, happiness, and satisfaction with symptoms, as well as a Global Functioning scale that consists of the mean of the values for the first four scales.","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version Questionnaire | PODCI - PEDIATRIC PARENT REPORTED | PODCI Pediatric Parent-Reported Version | PODCI1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523054","The PTSD Checklist for DSM-5 Questionnaire","C135741","A standardized 20-item self-report measure, published in 2013, that is used to assess the 20 Diagnostic and Statistical Manual of Mental Disorders (DSM-5) symptoms of post-traumatic stress disorder (PTSD), using a 5-point Likert-type intensity scale, ranging from zero (not at all) to four (extremely).","The PTSD Checklist for DSM-5 Questionnaire | PCL-5 | PCL01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523872","Patient Global Impression Generic Modification Version Questionnaire","C135739","Patient Global Impression (PGI) generic modification for any disease/condition concept use case (Modified from Guy W: ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: U.S. Department of Health, Education, and Welfare; 1976).","Patient Global Impression Generic Modification Version Questionnaire | PGI | PGI Generic Modification Version | PGI01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513354","Quick Inventory of Depressive Symptomatology Self-Report Version Questionnaire","C130316","A standardized 16-item self-report questionnaire, derived from the 30-item Inventory of Depressive Symptomatology (IDS), that utilizes a 5-point rating scale for the assessment of the severity of depressive symptoms over the seven day period prior to evaluation. The original questionnaire, created by Rush et al. in 1986, includes the nine diagnostic DSM-IV symptom domains that are used to characterize a major depressive episode, as well as items to address melancholic and atypical features. The shortened, 16-item version was initially developed by Rush et al. in 2000 by selecting only items from the original scale that assessed DSM-IV criterion diagnostic symptoms.","Quick Inventory of Depressive Symptomatology Self-Report Version Questionnaire | QIDS-SR | QIDSR1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512230","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 Questionnaire","C129110","A standardized 18-item rating scale for the assessment of symptom response to treatment for advanced ovarian cancer, including subscales that are specific for disease-related symptoms, treatment-related symptoms, and general function/well-being. Originally developed by Cella, et al. in 1997, it is derived from the ovarian cancer-specific subscale of the Functional Assessment of Cancer Therapy (FACT-O).","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 Questionnaire | FAC050 | NCCN-FACT FOSI-18 V2 | NCCN-FACT FOSI-18 Version 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512228","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 Questionnaire","C129107","A standardized 18-item rating scale that assesses the symptoms of bladder cancer that are perceived as most important by patients and clinicians. Originally developed by Cella et al. in 2004, it is a modified version of the Functional Assessment of Cancer Therapy for patients with Bladder cancer (FACT-Bl), incorporating two additional items: 'I feel weak all over,' and 'I feel light-headed (dizzy)'.","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 Questionnaire | FAC028 | NCCN-FACT FBLSI-18 V2 | NCCN-FACT FBLSI-18 Version 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512229","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 Questionnaire","C129106","A standardized 19-item rating scale for symptoms of advanced kidney cancer that is comprised of disease-related, treatment side effects, and general function and well-being subscales. Originally developed by Rao et al. in 2006, it is a modified version of the National Comprehensive Cancer Network (NCCN) 15-item Functional Assessment of Cancer Therapy - Kidney Symptom Index (FKSI-15) that incorporates additional symptoms rated as highest priority by patients and clinicians from the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms (FKSI-DRS).","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 Questionnaire | FAC042 | NCCN-FACT FKSI-19 V2 | NCCN-FACT FKSI-19 Version 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509295","Prostate Cancer Specific Quality of Life Instrument Questionnaire","C127372","A standardized rating scale developed by Stockler et al in 1999 which is used to assess health-related quality of life in patients with advanced hormone-resistant prostate cancer. The instrument contains 9 linear analogue self-assessment scales measuring symptoms, function, and overall well-being, and a six-point ordinal adjectival scale of present pain intensity from the McGill Pain Questionnaire.","Prostate Cancer Specific Quality of Life Instrument Questionnaire | PROS01 | PROSQOLI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509284","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 Questionnaire","C127370","A standardized rating scale modified from FACT-G and FACT-P and developed by Victorson et al in 2011, based on the recommendations of the National Comprehensive Cancer Network (NCCN). This instrument contains 17 items, and is used to examine the effectiveness of noncurative treatments in patients with advanced prostate cancer.","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 Questionnaire | FAC052 | NCCN-FACT FPSI-17 V2 | NCCN-FACT-FPSI 17 Version 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504413","Patient Health Questionnaire Screener Version","C125761","A standardized rating scale developed by Spitzer et al in 1999, which is used to screen and diagnose mental health disorders of depression, anxiety, alcohol, eating, and somatoform. The screener version of this instrument contains 59 items.","Patient Health Questionnaire Screener Version | PHQ SCREENER VERSION | PHQ Screener Version | PHQ03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053777","Multiple Sclerosis Impact Scale Version 2 Questionnaire","C123665","A standardized rating scale developed by Hobart et al in 2001, which is used to assess the physical and psychological impact of multiple sclerosis (MS) on an individual's quality of life. The version 2 questionnaire contains 29 questions on a scale from 1 (not at all) to 4 (extremely).","Multiple Sclerosis Impact Scale Version 2 Questionnaire | MSIS-29 V2 | MSIS-29v2 | MSIS02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054454","Multiple Sclerosis Impact Scale Version 1 Questionnaire","C123664","A standardized rating scale developed by Hobart et al in 2001, which is used to assess the physical and psychological impact of multiple sclerosis (MS) on an individual's quality of life. The version 1 questionnaire contains 29 questions on a scale from 1 (not at all) to 5 (extremely).","Multiple Sclerosis Impact Scale Version 1 Questionnaire | MSIS-29 V1 | MSIS-29v1 | MSIS01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055628","12-Item Multiple Sclerosis Walking Scale Questionnaire","C123663","A standardized rating scale developed by Hobart et al in 2003, which is used to measure the impact of multiple sclerosis (MS) on an individual's walking ability. The questionnaire contains 12 items on a scale from 1 (not at all) to 5 (extremely).","12-Item Multiple Sclerosis Walking Scale Questionnaire | MSWS-12 | MSWS01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054028","Shortness of Breath with Daily Activities Questionnaire","C123659","A standardized rating scale developed by Wilcox et al in 2013, which is used to evaluate the impact of treatment on shortness of breath (SOB) in patients with COPD and to assess how SOB affects daily activities. This questionnaire contains 13 items.","Shortness of Breath with Daily Activities Questionnaire | SOBDA | SOBDA1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897695","Rivermead Post-Concussion Symptoms Questionnaire","C119103","A standardized rating scale originally developed by King et al in 1995, which is used to measure the severity of symptoms following a mild or moderate traumatic brain injury (TBI). The questionnaire requires a subject to rate the severity of 16 different cognitive, somatic, and emotional symptoms after a TBI on a scale of 0 to 4: not experienced at all (0), no more of a problem (1), a mild problem (2), a moderate problem (3), or a severe problem (4).","Rivermead Post-Concussion Symptoms Questionnaire | RPQ | RPQ01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898109","Ocular Comfort Index Questionnaire","C119095","A standardized rating scale originally developed by Johnson and Murphy in 2007. This instrument is used to assess ocular surface irritation and grade the severity of dry eye syndrome.","Ocular Comfort Index Questionnaire | OCI | OCI01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898452","Mayo-Portland Adaptability Inventory-4 Questionnaire","C115798","A standardized rating scale modified and revised by Muriel et al in 2005, which is used to measure global brain injury outcome and functional status of subjects in the post-acute period following acquired brain injury (ABI)/traumatic brain injury (TBI), as well as to evaluate rehabilitation programs providing services to people with brain injuries. The questionnaire contains 35 questions and generates 3 subscales: ability index, adjustment index, and participation index. This instrument is scored on a 5-point Likert scale.","Mayo-Portland Adaptability Inventory-4 Questionnaire | MPAI-4 | MPAI1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826892","RAND 36-Item Health Survey 1.0 Questionnaire","C113879","A standardized rating scale developed by Hays et al in 1993 and the RAND corporation as part of the Medical Outcome Study, which is a generic measurement of health-related quality of life. This questionnaire contains 36 questions and generates 8 subscales: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, general mental health, social functioning, energy/fatigue, and general health perceptions.","RAND 36-Item Health Survey 1.0 Questionnaire | R3601 | RAND-36 V1 | RAND-36 V1.0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826975","Multiple Sclerosis Quality of Life-54 Instrument Questionnaire","C113878","A standardized rating scale developed by Vickrey et al in 1995 and 1997, which combines items that are generic and disease-specific to assess quality of life and the level of physical, emotional, and cognitive functions in patients with multiple sclerosis. The questionnaire contains 54 questions and generates 12 subscales: physical function, role limitations due to physical problems, role limitations due to emotional problems, pain, emotional well-being, energy, health perceptions, social function, cognitive function, health distress, sexual function and overall quality of life.","Multiple Sclerosis Quality of Life-54 Instrument Questionnaire | MSQL1 | MSQOL-54",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810705","Modified Fatigue Impact Scale Questionnaire","C113877","A standardized rating scale developed by Fisk et al in 1994, which assesses how fatigue may affect a person and the impact of fatigue on quality of life. The questionnaire contains 21 questions which are scored ranging from 0 (never) to 4 (almost always).","Modified Fatigue Impact Scale Questionnaire | MFIS | MFIS01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826870","St. George's Respiratory Questionnaire Past 4 Weeks Version","C112526","A standardized, disease-specific rating scale developed by Jones et al in 1992, which is used to determine the impact on overall health, daily life and perceived well-being in patients with obstructive airway disease. The questionnaire contains 51 items across 2 parts; Symptoms component (frequency and severity with a 4-week performance recall); Impact component (activities that are causes to, or limited by breathlessness).","St. George's Respiratory Questionnaire Past 4 Weeks Version | SGRQ PAST 4 WEEKS VERSION | SGRQ Past 4 Weeks Version | SGRQ02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826871","St. George's Respiratory Questionnaire Past 3 Months Version","C112525","A standardized, disease-specific rating scale developed by Jones et al in 1992, which is used to determine the impact on overall health, daily life and perceived well-being in patients with obstructive airway disease. The questionnaire contains 51 items across 2 parts; Symptoms component (frequency and severity with a 3-month performance recall); Impact component (activities that are causes to, or limited by breathlessness).","St. George's Respiratory Questionnaire Past 3 Months Version | SGRQ PAST 3 MONTHS VERSION | SGRQ Past 3 Months Version | SGRQ01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826971","Patient Determined Disease Steps Questionnaire","C112524","A standardized rating scale developed by Hohol et al in 1995, which is a self-assessment scale of functional disability in multiple sclerosis patients primarily based on ambulation. The questionnaire contains 1 question which is scored ranging from 0 (normal) to 8 (bedridden). A score of 0 to 2 indicates mild disability; a score of 3 to 5 indicates moderate disability; a score of 6 to 8 indicates severe disability.","Patient Determined Disease Steps Questionnaire | PDDS | PDDS01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826978","Modified Hachinski Ischemic Scale-NACC Version Questionnaire","C112523","A standardized rating scale originally developed by Hachinski et al in 1975 and later modified by Rosen et al in 1980 to clinically differentiate two most common types of dementia: senile dementia of the Alzheimer type (SDAT), a primary degenerative disease, and primary degenerative disease (MID), a vascular disorder. The modified version of the questionnaire contains 8 features for more accurate diagnosis of MID, the vascular dementia type. This questionnaire can be scored between 0 and 18, where a score greater than 7 suggests vascular involvement.","Modified Hachinski Ischemic Scale-NACC Version Questionnaire | MHIS-NACC | MHIS01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813719","Sheehan Disability Scale Questionnaire","C111384","A standardized questionnaire developed by David Sheehan in 1983, which is used to measure functional impairments caused by panic, anxiety, phobic, or depressive symptoms in three inter-related domains; work/school, social and family life. It is also used in many other chronic medical illnesses due to its generic design. The Sheehan Disability Scale generates 4 scores: a work disability score, a social life disability score, a family life disability score and a total score. This questionnaire contains 6 items, with which patients can rate the extent of their functional impairments on a 10-point visual analog scale.","Sheehan Disability Scale Questionnaire | SDS | SDS01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714939","Modified Rankin Scale Questionnaire","C111383","A standardized clinical classification originally developed by John Rankin in 1957, and later modified by Van Swieten et al in 1988, which is used to assess the degree of disability or dependence in the daily activities of individuals who have suffered a stroke. It also allows comparison between subjects with different kinds of neurologic deficits. The questionnaire contains a '0 to 6' scale, ranging from 'no symptoms at all' (scored 0) to 'dead' (scored 6).","Modified Rankin Scale Clinical Classification | MRS | MRS01 | Modified Rankin Scale | Modified Rankin Scale Questionnaire",,,,,,,,,,,,,,,"3654838","Modified Rankin Scale",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3826872","St. George's Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease Patients","C106890","A standardized rating scale developed by Jones et al in 1992, which is a shorter version derived from the original SGRQ, and used to measure health impairment and perceived well-being (quality of life) in patients with asthma and chronic obstructive pulmonary disease (COPD). It has also been used in patients with bronchiectasis, post tuberculosis, kyphoscoliosis and sarcoidosis. The questionnaire contains 2 parts of 14 questions. Part 1 comprises questions 1 to 7 and addresses the frequency of a subject's respiratory symptoms. Part 2 has questions 8 to 14 and addresses the patient's current state.","St. George's Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease Patients | SGRQ-C | SGRQC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826977","Modified Medical Research Council Dyspnea Scale Questionnaire","C106700","A standardized rating scale developed by Mahler and Wells in 1988, which is a general scale used to measure the rating of dyspnea or breathlessness. The questionnaire contains 1 question and a 0-4 grade answer scale, where grade 0 represents the lowest level of dyspnea impairment perceived, and level 4 represents the greatest dyspnea impairment.","Modified Medical Research Council Dyspnea Scale Questionnaire | MMRC | MMRC01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538934","STANDARDS Pain Relief Questionnaire","C105168","Version 1 (2012-08-07) of the pain relief questionnaire created by the STANDARDS (Standardized Analgesic Database for Research, Discovery, and Submissions) committee and sponsored by ACTTION (Analgesic Clinical Trial Translations, Innovations, Opportunities, and Networks).","STANDARDS Pain Relief Questionnaire | PR | PR01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539772","STANDARDS Pain Intensity Questionnaire","C105167","Version 1 (2012-08-07) of the pain intensity questionnaire created by the STANDARDS (Standardized Analgesic Database for Research, Discovery, and Submissions) committee and sponsored by ACTTION (Analgesic Clinical Trial Translations, Innovations, Opportunities, and Networks).","STANDARDS Pain Intensity Questionnaire | PI | PI01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641336","Short Opiate Withdrawal Scale Questionnaire","C103529","A standardized survey developed and published by Michael Gossop in the journal Addictive Behaviors which is used to assess the signs and symptoms associated with opiate withdrawal. This instrument is a shorter version of the Opiate Withdrawal Scale (OWS) containing 10 items related to symptoms such as stomach cramps, heart pounding and runny eyes. Each item is rated as none, mild, moderate or severe.","Short Opiate Withdrawal Scale Questionnaire | SOWS SHORT | SOWS Short | SOWSB1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641335","Symptom Impact Questionnaire","C103528","A standardized survey developed and copyrighted by Ronald Friend and Robert Bennett that is published in the journal Arthritis Research and Therapy. This instrument was developed along with the Revised Fibromyalgia Questionnaire (FIQR) and was intended for use in assessing symptoms associated with rheumatoid arthritis and systemic lupus erythematous. There are three sections including function, overall impact and symptoms with a total of 21 items. Each item is rated on a 0-10 scale with 0 being none and 10 being the most severe.","Symptom Impact Questionnaire | SIQR | SIQR01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3258005","Patient Health Questionnaire - 15 Item","C103527","A standardized survey developed and published by Kurt Kroenke, Robert Spitzer and Janet Williams in 2002 in the journal Psychosomatic Medicine which is used to assess the severity of an individual's somatic symptoms. This self-administered instrument contains 15 items pertaining to topics such as stomach pain, headaches, dizziness, and trouble sleeping. Each item is rated on a scale of 0-2 with 0 being 'not bothered at all' and 2 being 'bothered a lot.'","Patient Health Questionnaire - 15 Item | PHQ-15 | PHQ02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641334","The Oswestry Disability Index Version 2.1a Questionnaire","C103525","A standardized survey initially developed by John O'Brien in 1976 then published in 1980 by Jeremy Fairbank. This version (2.1a) is copyrighted by Jeremy Fairbank and is used in the assessment and management of spinal disorders. There are 10 items pertaining to a variety of topics including personal care, walking, standing, sleeping and traveling. Each item has six responses.","The Oswestry Disability Index Version 2.1a Questionnaire | ODI V2.1A | ODI v2.1a | ODI01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641333","The Overactive Bladder Questionnaire Short Form","C103524","A standardized survey developed by K. Coyne and colleagues in 2004 and presented at the Joint Meeting of the International Continence Society and the International Urogynecological Association which is used to evaluate the symptoms associated with overactive bladder. This self-administered, shorter version of the Overactive Bladder Questionnaire (OAB-q) contains 19 items pertaining to bladder symptoms occurring during the past four weeks. Each item is rated on a scale of 1-6 with 1 representing none or not at all and 6 representing a great deal or all the time.","The Overactive Bladder Questionnaire Short Form | OAB-Q SHORT FORM | OAB-q Short Form | OABQ02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538803","Neuropathic Pain Scale Questionnaire","C103522","A standardized survey developed and copyrighted by Brad Galer and Mark Jensen in 1997 and published in the journal Neurology (BS Galer and MP Jensen. Development and preliminary validation of a pain measure specific to neuropathic pain: The Neuropathic Pain Scale. Neurology. 1997, 48:332-338.) which is used to assess specific pain qualities associated with neuropathic pain. This instrument consists of 10 items that can be completed by the patient. Each item is rated on a scale of 0-10 with 0 representing none and 10 representing the worst. However, one item is multi-level with open ended responses.","Neuropathic Pain Scale Questionnaire | NPS | NPS01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053500","CDISC SDTM Holter ECG Test Code Terminology","C120523","Terminology associated with the Holter ECG test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Holter ECG Test Code Terminology | HETESTCD | Holter ECG Test Code | SDTM-HETESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555954","Symptoms of Major Depressive Disorder Scale v1.0 Questionnaire","C155328","A standardized 35-item patient-reported outcome instrument, created by McCarrier et al. in 2015, that utilizes a 7-day recall period and a five-point verbal rating scale to assess symptoms of major depressive disorder.","Symptoms of Major Depressive Disorder Scale v1.0 Questionnaire | SMDDS V1.0 | SMDDS Version 1.0 | SMDDS1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555957","Non-Small Cell Lung Cancer Symptom Assessment Questionnaire v1.0","C155327","A standardized 7-item patient-reported outcome instrument, created by McCarrier et al. in 2016, that utilizes a 7-day recall period and a five-point verbal rating scale to assess symptoms of non-small cell lung cancer.","Non-Small Cell Lung Cancer Symptom Assessment Questionnaire v1.0 | NSCLC-SAQ V1.0 | NSCLC-SAQ Version 1.0 | NSCLC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552766","Suicidal Ideation Questionnaire-Junior","C150921","A standardized 15-item self-report questionnaire developed by William M. Reynolds in 1987 that utilizes a seven-point rating scale to assess the frequency of suicidal thoughts in adolescents grades 7 to 9.","Suicidal Ideation Questionnaire-Junior | SIQ-JR | SIQ02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552765","Suicidal Ideation Questionnaire","C150920","A standardized 30-item self-report questionnaire developed by William M. Reynolds in 1987 that utilizes a seven-point rating scale to assess the frequency of suicidal thoughts in adolescents grades 10 to 12.","Suicidal Ideation Questionnaire | SIQ | SIQ01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552764","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 Questionnaire","C150919","A standardized 22-item self-report rating scale to assess quality of life for patients diagnosed with head and neck cancers. Originally developed by Cella et al. in 2013, it is a modified version of the Functional Assessment of Cancer Therapy-Head and Neck questionnaire (FACT-HN) and is broken down into disease-related symptoms, treatment side effects, and general function and well-being.","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 Questionnaire | FAC036 | NCCN-FACT FHNSI-22 V2 | NCCN-FACT FHNSI-22 Version 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552763","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 Questionnaire","C150918","A standardized 24-item self-report rating scale that utilizes a five-point rating scale and a seven-day time frame to assess the symptoms in advanced brain tumors perceived as most important by patients and clinicians. Originally developed by Cella et al. in 2014, it is a modified version of the Functional Assessment of Cancer Therapy-Brain questionnaire (FACT-Br).","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 Questionnaire | FAC030 | NCCN-FACT FBRSI-24 V2 | NCCN-FACT FBRSI-24 Version 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3476334","Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue Questionnaire","C147586","A standardized 11-item self-report questionnaire, part of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System developed by Cella et al. in 1987, that utilizes a five-point Likert rating scale to evaluate fatigue over the past 7 days in children.","Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue Questionnaire | FAC099 | PEDS-FACIT-F | Peds-FACIT-F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525829","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler Questionnaire","C138340","A 25-item disease specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of parent reported health related quality of life over the past seven days in children ages 2 to 4 years with neuromuscular disorders.","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler Questionnaire | PEDSQL NEUROMUSCULAR MODULE ACUTE V3 TODDLER PARENT REPORT | PQL18 | PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2742136","E-Selectin, Human","C17491","E-selectin (610 aa, ~67 kDa) is encoded by the human SELE gene. This protein is involved in leukocyte adhesion, migration and rolling.","E-Selectin | CD62 Antigen-Like Family Member E | CD62E | Cell Adhesion Molecule E-Selectin | ELAM | ELAM-1 | ELAM1 | ESEL | Endothelial Adhesion Molecule 1 | Endothelial Leukocyte Adhesion Molecule 1 | LECAM2 | Leukocyte Endothelial Cell Adhesion Molecule 2 | Leukocyte-Endothelial Cell Adhesion Molecule 2 | SELE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0182060","Orchidometer","C157647","A medical instrument used to measure the volume of the testicles. It consists of a string of twelve numbered wooden or plastic beads of increasing size from about 1 to 25 milliliters. The beads are compared with the testicles of the patient, and the volume is read off the bead which matches most closely in size.","Orchidometer | Orchidometer Bead | Orchidometer Beads | Orchiometer",,,,,,,,,,,,,,,"45758499","Orchidometer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037862","Spermicide","C92886","A chemical product that is deleterious to sperms and can be in the form of either a jelly, foam, or cream.","Spermicide | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898323","Millimole per Liter per Meter Squared","C119425","A unit of concentration equal to millimoles per liter, divided by meters squared.","Millimole per Liter per Meter Squared | mmol/L/m2 | mmol/l/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898312","Millimole per Liter per Milligram","C119426","A unit of concentration equal to millimoles per liter, divided by milligrams.","Millimole per Liter per Milligram | Micromole per Liter per Microgram | Mole per Liter per Gram | mmol/L/mg | mmol/l/mg | mol/L/g | mol/l/g | umol/L/ug | umol/l/ug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898317","Millimole per Liter per Microgram","C119427","A unit of concentration equal to millimoles per liter, divided by micrograms.","Millimole per Liter per Microgram | Mole per Liter per Milligram | mmol/L/ug | mmol/l/ug | mol/L/mg | mol/l/mg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439430","Millimole per Minute","C85722","Millimoles per minute.","Millimole per Minute | mmol/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0560019","Mole per Hour","C85738","Moles per hour.","Mole per Hour | mol/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898272","Mole per Liter per Microgram per Day","C119434","A unit of concentration equal to moles per liter, divided by micrograms per day.","Mole per Liter per Microgram per Day | mol/L/(ug/d) | mol/L/(ug/day) | mol/l/(ug/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898270","Mole per Liter per Microgram per Kilogram","C119435","A unit of concentration equal to moles per liter, divided by micrograms per kilogram.","Mole per Liter per Microgram per Kilogram | mol/L/(ug/kg) | mol/l/(ug/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898271","Mole per Liter per Microgram per Kilogram per Day","C119436","A unit of concentration equal to moles per liter, divided by micrograms per kilogram per day.","Mole per Liter per Microgram per Kilogram per Day | mol/L/(ug/kg/d) | mol/L/(ug/kg/day) | mol/l/(ug/kg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898268","Mole per Liter per Microgram per Meter Squared","C119437","A unit of concentration equal to moles per liter, divided by micrograms per meter squared.","Mole per Liter per Microgram per Meter Squared | mol/L/(ug/m2) | mol/l/(ug/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898269","Mole per Liter per Microgram per Meter Squared per Day","C119438","A unit of concentration equal to moles per liter, divided by micrograms per meter squared per day.","Mole per Liter per Microgram per Meter Squared per Day | mol/L/(ug/m2/d) | mol/L/(ug/m2/day) | mol/l/(ug/m2/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897078","Mole per Liter per Meter Squared","C119441","A unit of concentration equal to moles per liter, divided by meters squared.","Mole per Liter per Meter Squared | mol/L/m2 | mol/l/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898267","Mole per Liter per Microgram","C119443","A unit of concentration equal to moles per liter, divided by micrograms.","Mole per Liter per Microgram | mol/L/ug | mol/l/ug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0560025","Mole per Minute","C85739","Moles per minute.","Mole per Minute | mol/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1827103","Nanogram per Hour","C85742","Nanograms per hour.","Nanogram per Hour | ng/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1827823","Nanogram per Minute","C85749","Nanograms per minute.","Nanogram per Minute | ng/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897011","Nanogram per Milliliter per Kilogram per Meter Squared","C119444","A unit of concentration equal to nanograms per milliliter, divided by kilograms per meter squared.","Nanogram per Milliliter per Kilogram per Meter Squared | ng/mL/(kg/m2) | ng/ml/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898178","Nanogram per Milliliter per Milligram per Day","C119445","A unit of concentration equal to nanograms per milliliter, divided by milligrams per day.","Nanogram per Milliliter per Milligram per Day | Picogram per Milliliter per Microgram per Day | ng/mL/(mg/d) | ng/mL/(mg/day) | ng/ml/(mg/d) | pg/mL/(ug/d) | pg/mL/(ug/day) | pg/ml/(ug/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642191","Nanogram Per Milliliter Per Milligram Per Kilogram","C105477","A dose calculation unit expressed in manograms per milliliter, divided by milligram per kilogram.","Nanogram Per Milliliter Per Milligram Per Kilogram | Picogram per Milliliter per Microgram per Kilogram | ng/mL/(mg/kg) | ng/ml/(mg/kg) | pg/mL/(ug/kg) | pg/ml/(ug/kg) | ug/L/mg/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642192","Nanogram Per Milliliter Per Milligram Per Kilogram Per Day","C105478","A dose calculation unit expressed in nanograms per milliliter, divided by milligram per kilogram per day.","Nanogram Per Milliliter Per Milligram Per Kilogram Per Day | Picogram per Milliliter per Microgram per Kilogram per Day | ng/mL/(mg/kg/d) | ng/mL/(mg/kg/day) | ng/ml/(mg/kg/d) | pg/mL/(ug/kg/d) | pg/mL/(ug/kg/day) | pg/ml/(ug/kg/d) | ug/L/mg/kg/day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898176","Nanogram per Milliliter per Milligram per Meter Squared","C119446","A unit of concentration equal to nanograms per milliliter, divided by milligrams per meter squared.","Nanogram per Milliliter per Milligram per Meter Squared | Picogram per Milliliter per Microgram per Meter Squared | ng/mL/(mg/m2) | ng/ml/(mg/m2) | pg/mL/(ug/m2) | pg/ml/(ug/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898177","Nanogram per Milliliter per Milligram per Meter Squared per Day","C119447","A unit of concentration equal to nanograms per milliliter, divided by milligrams per meter squared per day.","Nanogram per Milliliter per Milligram per Meter Squared per Day | Picogram per Milliliter per Microgram per Meter Squared per Day | ng/mL/(mg/m2/d) | ng/mL/(mg/m2/day) | ng/ml/(mg/m2/d) | pg/mL/(ug/m2/d) | pg/mL/(ug/m2/day) | pg/ml/(ug/m2/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890571","Microgram per Milliliter per Milligram per Day","C119448","A unit of concentration equal to nanograms per milliliter, divided by micrograms per day.","Nanogram per Milliliter per Microgram per Day | Microgram per Milliliter per Milligram per Day | ng/mL/(ug/d) | ng/mL/(ug/day) | ng/ml/(ug/d) | ug/mL/(mg/d) | ug/mL/(mg/day) | ug/ml/(mg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890570","Microgram per Milliliter per Milligram per Meter Squared","C119451","A unit of concentration equal to nanograms per milliliter, divided by micrograms per meter squared.","Nanogram per Milliliter per Microgram per Meter Squared | Microgram per Milliliter per Milligram per Meter Squared | ng/mL/(ug/m2) | ng/ml/(ug/m2) | ug/mL/(mg/m2) | ug/ml/(mg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898181","Nanogram per Milliliter per Microgram per Meter Squared per Day","C119452","A unit of concentration equal to nanograms per milliliter, divided by micrograms per meter squared per day.","Nanogram per Milliliter per Microgram per Meter Squared per Day | Microgram per Milliliter per Milligram per Meter Squared per Day | ng/mL/(ug/m2/d) | ng/mL/(ug/m2/day) | ng/ml/(ug/m2/d) | ug/mL/(mg/m2/d) | ug/mL/(mg/m2/day) | ug/ml/(mg/m2/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827907","Nanogram per Milliliter per Kilogram","C85746","Nanograms per milliliter per kilogram.","Nanogram per Milliliter per Kilogram | Femtogram per Milliliter per Milligram | Picogram per Milliliter per Gram | fg/mL/mg | fg/ml/mg | ng/kg/mL | ng/mL/kg | ng/ml/kg | pg/mL/g | pg/ml/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642188","Microgram Per Milliliter Per Milligram Per Kilogram Per Day","C105474","A dose calculation unit expressed in micrograms per milliliter, divided by milligram per kilogram per day.","Microgram Per Milliliter Per Milligram Per Kilogram Per Day | Nanogram per Milliliter per Microgram per Kilogram per Day | mg/L/mg/kg/day | ng/mL/(ug/kg/d) | ng/mL/(ug/kg/day) | ng/ml/(ug/kg/d) | ug/mL/(mg/kg/d) | ug/mL/(mg/kg/day) | ug/ml/(mg/kg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642187","Microgram Per Milliliter Per Milligram Per Kilogram","C105473","A dose calculation unit expressed in micrograms per milliliter, divided by milligram per kilogram.","Microgram Per Milliliter Per Milligram Per Kilogram | Nanogram per Milliliter per Microgram per Kilogram | mg/L/mg/kg | ng/mL/(ug/kg) | ng/ml/(ug/kg) | ug/mL/(mg/kg) | ug/ml/(mg/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898408","Microgram per Milliliter per Kilogram per Meter Squared","C119500","A unit of concentration equal to micrograms per milliliter, divided by kilograms per meter squared.","Microgram per Milliliter per Kilogram per Meter Squared | ug/mL/(kg/m2) | ug/ml/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827934","Picomole per Liter per Microgram","C85784","Picomoles per liters per microgram.","Picomole per Liter per Microgram | Micromole per Liter per Gram | Millimole per Liter per Kilogram | Nanomole per Liter per Milligram | mmol/L/kg | mmol/l/kg | nmol/L/mg | nmol/l/mg | pmol/L/mcg | pmol/L/ug | pmol/l/ug | pmol/mcg/L | pmol/ug/L | umol/L/g | umol/l/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897909","Picomole per Liter per Meter Squared","C119498","A unit of concentration equal to picomoles per liter, divided by meters squared.","Picomole per Liter per Meter Squared | pmol/L/m2 | pmol/l/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897910","Picomole per Liter per Kilogram","C119497","A unit of concentration equal to picomoles per liter, divided by kilograms.","Picomole per Liter per Kilogram | pmol/L/kg | pmol/l/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897901","Picomole per Liter per Milligram per Meter Squared per Day","C119490","A unit of concentration equal to picomoles per liter, divided by milligrams per meter squared per day.","Picomole per Liter per Milligram per Meter Squared per Day | pmol/L/(mg/m2/d) | pmol/L/(mg/m2/day) | pmol/l/(mg/m2/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897900","Picomole per Liter per Milligram per Meter Squared","C119489","A unit of concentration equal to picomoles per liter, divided by milligrams per meter squared.","Picomole per Liter per Milligram per Meter Squared | pmol/L/(mg/m2) | pmol/l/(mg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897903","Picomole per Liter per Milligram per Kilogram per Day","C119488","A unit of concentration equal to picomoles per liter, divided by milligrams per kilogram per day.","Picomole per Liter per Milligram per Kilogram per Day | pmol/L/(mg/kg/d) | pmol/L/(mg/kg/day) | pmol/l/(mg/kg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897902","Picomole per Liter per Milligram per Kilogram","C119487","A unit of concentration equal to picomoles per liter, divided by milligrams per kilogram.","Picomole per Liter per Milligram per Kilogram | pmol/L/(mg/kg) | pmol/l/(mg/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897904","Picomole per Liter per Milligram per Day","C119486","A unit of concentration equal to picomoles per liter, divided by milligrams per day.","Picomole per Liter per Milligram per Day | pmol/L/(mg/d) | pmol/L/(mg/day) | pmol/l/(mg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897911","Picomole per Liter per Kilogram per Meter Squared","C119485","A unit of concentration equal to picomoles per liter, divided by kilograms per meter squared.","Picomole per Liter per Kilogram per Meter Squared | pmol/L/(kg/m2) | pmol/l/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897922","Picogram per Milliliter per Meter Squared","C119483","A unit of concentration equal to picograms per milliliter, divided by meters squared.","Picogram per Milliliter per Meter Squared | pg/mL/m2 | pg/ml/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642194","Picogram Per Milliliter Per Milligram Per Kilogram Per Day","C105480","A dose calculation unit expressed in picograms per milliliter, divided by milligram per kilogram per day.","Picogram Per Milliliter Per Milligram Per Kilogram Per Day | Femtogram per Milliliter per Microgram per Kilogram per Day | fg/mL/(ug/kg/d) | fg/mL/(ug/kg/day) | fg/ml/(ug/kg/d) | ng/L/mg/kg/day | pg/mL/(mg/kg/d) | pg/mL/(mg/kg/day) | pg/ml/(mg/kg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642193","Picogram Per Milliliter Per Milligram Per Kilogram","C105479","A dose calculation unit expressed in picograms per milliliter, divided by milligram per kilogram.","Picogram Per Milliliter Per Milligram Per Kilogram | Femtogram per Milliliter per Microgram per Kilogram | fg/mL/(ug/kg) | fg/ml/(ug/kg) | ng/L/mg/kg | pg/mL/(mg/kg) | pg/ml/(mg/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897924","Picogram per Milliliter per Kilogram per Meter Squared","C119472","A unit of concentration equal to picograms per milliliter, divided by kilograms per meter squared.","Picogram per Milliliter per Kilogram per Meter Squared | pg/mL/(kg/m2) | pg/ml/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827932","Picogram per Minute","C85782","Picograms per minute.","Picogram per Minute | pg/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827929","Picogram per Hour","C85779","Picograms per hour.","Picogram per Hour | pg/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827928","Picogram per Day","C85778","Picograms per day.","Picogram per Day | Picogram per 24 Hours | pg/d | pg/day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827910","Nanomole per Minute","C85758","Nanomoles per minute.","Nanomole per Minute | nmol/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898171","Nanomole per Liter per Meter Squared","C119469","A unit of concentration equal to nanomoles per liter, divided by meters squared.","Nanomole per Liter per Meter Squared | nmol/L/m2 | nmol/l/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898172","Nanomole per Liter per Kilogram","C119468","A unit of concentration equal to nanomoles per liter, divided by kilograms.","Nanomole per Liter per Kilogram | Picomole per Liter per Gram | nmol/L/kg | nmol/l/kg | pmol/L/g | pmol/l/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898174","Nanomole per Liter per Gram","C119467","A unit of concentration equal to nanomoles per liter, divided by grams.","Nanomole per Liter per Gram | Micromole per Liter per Kilogram | Picomole per Liter per Milligram | nmol/L/g | nmol/l/g | pmol/L/mg | pmol/l/mg | umol/L/kg | umol/l/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898167","Nanomole per Liter per Microgram per Meter Squared per Day","C119466","A unit of concentration equal to nanomoles per liter, divided by micrograms per meter squared per day.","Nanomole per Liter per Microgram per Meter Squared per Day | Micromole per Liter per Milligram per Meter Squared per Day | nmol/L/(ug/m2/d) | nmol/L/(ug/m2/day) | nmol/l/(ug/m2/d) | umol/L/(mg/m2/d) | umol/L/(mg/m2/day) | umol/l/(mg/m2/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898166","Nanomole per Liter per Microgram per Meter Squared","C119465","A unit of concentration equal to nanomoles per liter, divided by micrograms per meter squared.","Nanomole per Liter per Microgram per Meter Squared | Micromole per Liter per Milligram per Meter Squared | nmol/L/(ug/m2) | nmol/l/(ug/m2) | umol/L/(mg/m2) | umol/l/(mg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898168","Nanomole per Liter per Microgram per Kilogram","C119463","A unit of concentration equal to nanomoles per liter, divided by micrograms per kilogram.","Nanomole per Liter per Microgram per Kilogram | Micromole per Liter per Milligram per Kilogram | nmol/L/(ug/kg) | nmol/l/(ug/kg) | umol/L/(mg/kg) | umol/l/(mg/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898170","Nanomole per Liter per Microgram per Day","C119462","A unit of concentration equal to nanomoles per liter, divided by micrograms per day.","Nanomole per Liter per Microgram per Day | Micromole per Liter per Milligram per Day | nmol/L/(ug/d) | nmol/L/(ug/day) | nmol/l/(ug/d) | umol/L/(mg/d) | umol/L/(mg/day) | umol/l/(mg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898161","Nanomole per Liter per Milligram per Meter Squared per Day","C119461","A unit of concentration equal to nanomoles per liter, divided by milligrams per meter squared per day.","Nanomole per Liter per Milligram per Meter Squared per Day | Picomole per Liter per Microgram per Meter Squared per Day | nmol/L/(mg/m2/d) | nmol/L/(mg/m2/day) | nmol/l/(mg/m2/d) | pmol/L/(ug/m2/d) | pmol/L/(ug/m2/day) | pmol/l/(ug/m2/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898160","Nanomole per Liter per Milligram per Meter Squared","C119460","A unit of concentration equal to nanomoles per liter, divided by milligrams per meter squared.","Nanomole per Liter per Milligram per Meter Squared | Picomole per Liter per Microgram per Meter Squared | nmol/L/(mg/m2) | nmol/l/(mg/m2) | pmol/L/(ug/m2) | pmol/l/(ug/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898163","Nanomole per Liter per Milligram per Kilogram per Day","C119459","A unit of concentration equal to nanomoles per liter, divided by milligrams per kilogram per day.","Nanomole per Liter per Milligram per Kilogram per Day | Picomole per Liter per Microgram per Kilogram per Day | nmol/L/(mg/kg/d) | nmol/L/(mg/kg/day) | nmol/l/(mg/kg/d) | pmol/L/(ug/kg/d) | pmol/L/(ug/kg/day) | pmol/l/(ug/kg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898162","Nanomole per Liter per Milligram per Kilogram","C119458","A unit of concentration equal to nanomoles per liter, divided by milligrams per kilogram.","Nanomole per Liter per Milligram per Kilogram | Picomole per Liter per Microgram per Kilogram | nmol/L/(mg/kg) | nmol/l/(mg/kg) | pmol/L/(ug/kg) | pmol/l/(ug/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898164","Nanomole per Liter per Milligram per Day","C119457","A unit of concentration equal to nanomoles per liter, divided by milligrams per day.","Nanomole per Liter per Milligram per Day | Picomole per Liter per Microgram per Day | nmol/L/(mg/d) | nmol/L/(mg/day) | nmol/l/(mg/d) | pmol/L/(ug/d) | pmol/L/(ug/day) | pmol/l/(ug/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898173","Nanomole per Liter per Kilogram per Meter Squared","C119456","A unit of concentration equal to nanomoles per liter, divided by kilograms per meter squared.","Nanomole per Liter per Kilogram per Meter Squared | nmol/L/(kg/m2) | nmol/l/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439437","Nanomole per Hour","C85753","Nanomoles per hour.","Nanomole per Hour | nmol/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889981","Microgram per Milliliter per Gram","C85747","Nanograms per milliliter per milligram.","Nanogram per Milliliter per Milligram | Microgram per Milliliter per Gram | Milligram per Milliliter per Kilogram | Picogram per Milliliter per Microgram | mg/mL/kg | mg/ml/kg | ng/mL/mg | ng/mg/mL | ng/ml/mg | pg/mL/mcg | pg/mL/ug | pg/mcg/mL | pg/ml/ug | pg/ug/mL | ug/mL/g | ug/ml/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898185","Nanogram per Milliliter per Meter Squared","C119454","A unit of concentration equal to nanograms per milliliter, divided by meters squared.","Nanogram per Milliliter per Meter Squared | ng/mL/m2 | ng/ml/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827881","Milligram per Liter per Milligram","C85710","Milligrams per liter per milligram.","Milligram per Liter per Milligram | Gram per Milliliter per Kilogram | Milligram per Milliliter per Gram | Nanogram per Milliliter per Microgram | g/mL/kg | g/ml/kg | mg/L/mg | mg/mL/g | mg/mg/L | mg/ml/g | ng/mL/ug | ng/ml/ug | ug/mL/mg | ug/ml/mg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898406","Microgram per Milliliter per Meter Squared","C119511","A unit of concentration equal to micrograms per milliliter, divided by meters squared.","Microgram per Milliliter per Meter Squared | ug/mL/m2 | ug/ml/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898396","Micromole per Liter per Meter Squared","C119542","A unit of concentration equal to micromoles per liter, divided by meters squared.","Micromole per Liter per Meter Squared | umol/L/m2 | umol/l/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898398","Micromole per Liter per Kilogram per Meter Squared","C119529","A unit of concentration equal to micromoles per liter, divided by kilograms per meter squared.","Micromole per Liter per Kilogram per Meter Squared | umol/L/(kg/m2) | umol/l/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439434","Micromole per Hour","C85707","Micromoles per hour.","Micromole per Hour | mcmol/h | umol/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898424","Micro-International Units per Milliliter per Meter Squared","C119526","A unit of concentration (biologic activity) equal to one micro-international unit per milliliter, divided by meters squared.","Micro-International Units per Milliliter per Meter Squared | uIU/mL/m2 | u[IU]/mL/m2 | u[IU]/ml/m2 | u[iU]/mL/m2 | u[iU]/ml/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898425","Micro-International Units per Milliliter per Kilogram","C119525","A unit of concentration (biologic activity) equal to one micro-international unit per milliliter, divided by kilograms.","Micro-International Units per Milliliter per Kilogram | uIU/mL/kg | u[IU]/mL/kg | u[IU]/ml/kg | u[iU]/mL/kg | u[iU]/ml/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898415","Micro-International Units per Milliliter per Milligram per Meter Squared per Day","C119518","A unit of concentration (biologic activity) equal to one micro-international unit per milliliter, divided by milligrams per meter squared per day.","Micro-International Units per Milliliter per Milligram per Meter Squared per Day | uIU/mL/(mg/m2/day) | u[IU]/mL/(mg/m2/d) | u[IU]/ml/(mg/m2/d) | u[iU]/mL/(mg/m2/d) | u[iU]/ml/(mg/m2/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898414","Micro-International Units per Milliliter per Milligram per Meter Squared","C119517","A unit of concentration (biologic activity) equal to one micro-international unit per milliliter, divided by milligrams per meter squared.","Micro-International Units per Milliliter per Milligram per Meter Squared | uIU/mL/(mg/m2) | u[IU]/mL/(mg/m2) | u[IU]/ml/(mg/m2) | u[iU]/mL/(mg/m2) | u[iU]/ml/(mg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896967","Micro-International Units per Milliliter per Milligram per Kilogram per Day","C119516","A unit of concentration (biologic activity) equal to one micro-international unit per milliliter, divided by milligrams per kilogram per day.","Micro-International Units per Milliliter per Milligram per Kilogram per Day | uIU/mL/(mg/kg/day) | u[IU]/mL/(mg/kg/d) | u[IU]/ml/(mg/kg/d) | u[iU]/mL/(mg/kg/d) | u[iU]/ml/(mg/kg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898416","Micro-International Units per Milliliter per Milligram per Kilogram","C119515","A unit of concentration (biologic activity) equal to one micro-international unit per milliliter, divided by milligrams per kilogram.","Micro-International Units per Milliliter per Milligram per Kilogram | uIU/mL/(mg/kg) | u[IU]/mL/(mg/kg) | u[IU]/ml/(mg/kg) | u[iU]/mL/(mg/kg) | u[iU]/ml/(mg/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898417","Micro-International Units per Milliliter per Milligram per Day","C119514","A unit of concentration (biologic activity) equal to one micro-international unit per milliliter, divided by milligrams per day.","Micro-International Units per Milliliter per Milligram per Day | uIU/mL/(mg/day) | u[IU]/mL/(mg/d) | u[IU]/ml/(mg/d) | u[iU]/mL/(mg/d) | u[iU]/ml/(mg/d)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898426","Micro-International Units per Milliliter per Kilogram per Meter Squared","C119513","A unit of concentration (biologic activity) equal to one micro-international unit per milliliter, divided by kilograms per meter squared.","Micro-International Units per Milliliter per Kilogram per Meter Squared | uIU/mL/(kg/m2) | u[IU]/mL/(kg/m2) | u[IU]/ml/(kg/m2) | u[iU]/mL/(kg/m2) | u[iU]/ml/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1320753","Nanogram per Kilogram per Minute","C85743","Nanograms per kilogram per minute.","Nanogram per Kilogram per Minute | ng/kg/min | ng/min/kg | pg/g/min | pg/min/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898274","Mole per Liter per Kilogram per Meter Squared","C119428","A unit of concentration equal to moles per liter, divided by kilograms per meter squared.","Mole per Liter per Kilogram per Meter Squared | mol/L/(kg/m2) | mol/l/(kg/m2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537924","MLKL Gene","C134709","This gene is involved in cell death activation.","MLKL Gene | MLKL | Mixed Lineage Kinase Domain Like Pseudokinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054275","PD-L1 Overexpression","C122808","An immunohistochemical test result that indicates overexpression of PD-L1 in a tissue sample of a primary or metastatic malignant neoplasm.","PD-L1 Overexpression | CD274 Overexpression | PD-L1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935837","Medical Condition","C156809","Any kind of illness or circumstance which requires medical monitoring.","Medical Condition | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0855333","Corrected Prolonged QT Interval by ECG Finding","C83817","An electrocardiographic finding in which the QTc interval corrected for heart rate is prolonged. Thresholds for different age, gender, and patient populations exist. (CDISC)","Corrected Prolonged QT Interval by ECG Finding | Corrected Prolonged QT Interval | Corrected Prolonged QT Interval by EKG Finding | Electrocardiogram QT corrected interval prolonged | QTC PROLONGATION | QTc Prolongation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935811","Neurocognitive Assessment","C156775","Tests to assess aspects of cognition, including attention, memory, language, reaction time, and perception.","Neurocognitive Assessment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509342","CDISC SDTM PK Unit of Measure Gram Weight Terminology","C128684","Terminology associated with the PK unit of measure gram weight codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM PK Unit of Measure Gram Weight Terminology | PK Units of Measure - Weight g | PKUWG | SDTM-PKUWG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509343","CDISC SDTM PK Unit of Measure Kilogram Weight Terminology","C128683","Terminology associated with the PK unit of measure kilogram weight codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM PK Unit of Measure Kilogram Weight Terminology | PK Units of Measure - Weight kg | PKUWKG | SDTM-PKUWKG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509340","CDISC SDTM PK Unit of Measure Milligram Dose Terminology","C128685","Terminology associated with the PK unit of measure milligram dose codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM PK Unit of Measure Milligram Dose Terminology | PK Units of Measure - Dose mg | PKUDMG | SDTM-PKUDMG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509341","CDISC SDTM PK Unit of Measure Microgram Dose Terminology","C128686","Terminology associated with the PK unit of measure microgram dose codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM PK Unit of Measure Microgram Dose Terminology | PK Units of Measure - Dose ug | PKUDUG | SDTM-PKUDUG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550634","Endocervical","C149484","Relating to the cervix uteri as the intended site of administration.","Endocervical | ",,,,,,,,,,,,,,,"42538085","Endocervical",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937308","Female Genital Grading Table","C157688","A table within the standard terminology developed by the NIH Division of AIDS (DAIDS) to report expedited adverse events (EAEs) reported by Clinical Research Sites (CRSs) participating in DAIDS-supported studies. This table contains specific adverse event grading terminology for Female Genital Microbicide Studies.","Female Genital Grading Table | FGGT | Female Genital Grading Table for Use in Microbicide Studies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976401","Magnetic Resonance Imaging of the Brain with and without Contrast","C137913","Magnetic resonance imaging of the brain with and without the use of a contrast agent to enhance the image.","Magnetic Resonance Imaging of the Brain with and without Contrast | Brain MRI | Brain MRI with and without Contrast | Brain Magnetic Resonance Imaging with and without Contrast | Head MRI with and without Contrast",,,,,,,,,,,,,,,"37311324","MRI of brain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2987512","Mosaic Organism Attribute","C88144","An individual containing two or more populations of genetically different cells that arose from a single zygote.","Mosaic | mosaicism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937295","Pediatric Quality of Life Brain Tumor Module Version 1.0","C157698","A quality of life questionnaire designed to measure health-related quality of life in a pediatric brain tumor patient. It is derived from the Pediatric Quality of Life Inventory Generic Core Scales.","Pediatric Quality of Life Brain Tumor Module Version 1.0 | PedsQL 1.0 Brain Tumor | PedsQL-Brain Tumor Module v1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937357","Cognitive Problems Subscale","C157699","A subscale of the Pediatric Quality of Life Brain Tumor Module designed to assess cognitive problems.","Cognitive Problems Subscale | Cognitive Problems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937296","Pain and Hurt Subscale","C157700","A subscale of the Pediatric Quality of Life Brain Tumor Module designed to assess issues associated with pain and hurting.","Pain and Hurt Subscale | Pain and Hurt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937297","Movement and Balance Subscale","C157701","A subscale of the Pediatric Quality of Life Brain Tumor Module designed to assess issues associated with movement and balance.","Movement and Balance Subscale | Movement and Balance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937348","Procedural Anxiety Subscale","C157702","A subscale of the Pediatric Quality of Life Brain Tumor Module designed to assess issues associated with procedural anxiety.","Procedural Anxiety Subscale | Procedural Anxiety",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937341","Nausea Subscale","C157703","A subscale of the Pediatric Quality of Life Brain Tumor Module designed to assess issues associated with nausea.","Nausea Subscale | Nausea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937354","Worry Subscale","C157704","A subscale of the Pediatric Quality of Life Brain Tumor Module designed to assess issues associated with worry.","Worry Subscale | Worry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883035","Single Cell Necrosis","C60880","A morphologic finding indicating the presence of individual necrotic cells surrounded by viable cells in a tissue sample.","Single Cell Necrosis | SINGLE CELL NECROSIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706207","Bullet (shape)","C48335","A cylindrical shape that is flat at one end and rounded at the other.","Bullet | BULLET",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521993","Conductivity","C134263","A measure of the ion-facilitated electron current through a material.","Conductivity Measurement | Conductivity | Conductivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889667","Study Day of Morphology Assessment","C117630","The day that a morphology assessment is performed.","Study Day of Morphology Assessment | MODY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049631","CDISC SDTM Microbiology Test Name Terminology","C120528","Terminology associated with the microbiology test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Microbiology Test Name Terminology | MBTEST | Microbiology Test Name | SDTM-MBTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512513","Acid-Fast Bacilli Measurement","C128981","The determination of the amount of acid-fast bacilli present in a sample.","Acid-Fast Bacilli Measurement | AFB | Acid-Fast Bacilli",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555552","Adenovirus Antigen Measurement","C154830","The determination of the adenovirus antigen present in a sample.","Adenovirus Antigen Measurement | ADENOVAG | Adenovirus Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555540","Bacterial Sialidase Measurement","C154820","The determination of the bacterial sialidase present in a sample.","Bacterial Sialidase Measurement | BCTSILDS | Bacterial Sialidase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555550","Bordetella pertussis Antigen Measurement","C154832","The determination of the Bordetella pertussis antigen present in a sample.","Bordetella pertussis Antigen Measurement | BPEAG | Bordetella pertussis Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526549","Burkholderia Measurement","C139113","The determination of the amount of Burkholderia genus microorganisms present in a sample.","Burkholderia Measurement | BURKHOLD | Burkholderia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545295","Burkholderia cepacia Measurement","C147456","The determination of the amount of the organism assigned to the Burkholderia cepacia species in a biological sample.","Burkholderia cepacia Measurement | B. cepacia | BCEPACIA | Burkholderia cepacia | Pseudomonas cepacia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552605","C. difficile Glutamate Dehydrogenase Measurement","C150857","The determination of the amount of glutamate dehydrogenase produced by Clostridium difficile present in a sample.","C. difficile Glutamate Dehydrogenase Measurement | C. difficile Glutamate Dehydrogenase | CDFGDH | Clostridium difficile Glutamate Dehydrogenase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555557","Chlamydia trachomatis Antigen Measurement","C154835","The determination of the Chlamydia trachomatis antigen present in a sample.","Chlamydia Trachomatis Antigen Measurement | CTRAG | Chlamydia trachomatis Antigen | Chlamydia trachomatis Antigen Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552391","Clostridium difficile Measurement","C150637","The determination of the amount of Clostridium difficile species in a biological sample.","Clostridium difficile Measurement | CDF | Clostridium difficile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552393","Clostridium difficile 027/NAP1/BI Measurement","C150639","The determination of the amount of the 027/NAP1/BI strain of Clostridium difficile species in a biological specimen.","Clostridium difficile 027/NAP1/BI Measurement | C150639 | Clostridium difficile 027/NAP1/BI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552610","Clostridium difficile A Toxin Measurement","C150863","The determination of the amount of A toxin produced by Clostridium difficile present in a sample.","Clostridium difficile A Toxin Measurement | CDFATOX | Clostridium difficile A Toxin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552606","Clostridium difficile A and/or B Toxin Measurement","C150858","The determination of the amount of A and/or B toxin produced by Clostridium difficile present in a sample.","Clostridium difficile A and/or B Toxin Measurement | CDFABTOX | Clostridium difficile A/B Toxin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552611","Clostridium difficile B Toxin Measurement","C150864","The determination of the amount of B toxin produced by Clostridium difficile present in a sample.","Clostridium difficile B Toxin Measurement | CDFBTOX | Clostridium difficile B Toxin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552613","Clostridium difficile cdt DNA Measurement","C150866","The determination of the amount of cdt DNA produced by Clostridium difficile present in a sample.","Clostridium difficile cdt DNA Measurement | CDFCDTD | Clostridium difficile Binary Toxin DNA Measurement | Clostridium difficile cdt DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552608","Clostridium difficile tcdB DNA Measurement","C150860","The determination of the amount of tcdB DNA produced by Clostridium difficile present in a sample.","Clostridium difficile tcdB DNA Measurement | CDFTCDBD | Clostridium difficile Toxin B DNA Measurement | Clostridium difficile tcdB DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552609","Clostridium difficile tcdC DNA Measurement","C150861","The determination of the amount of tcdC DNA produced by Clostridium difficile present in a sample.","Clostridium difficile tcdC DNA Measurement | CDFTCDCD | Clostridium difficile Regulatory Protein DNA Measurement | Clostridium difficile tcdC DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1277905","Cryptococcus antigen level","C154829","The determination of the Cryptococcus antigen present in a sample.","Cryptococcus Antigen Measurement | CRYPTCAG | Cryptococcus Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555553","Cryptosporidium parvum Antigen Measurement","C154831","The determination of the Cryptosporidium parvum antigen present in a sample.","Cryptosporidium parvum Antigen Measurement | CPAAG | Cryptosporidium parvum Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919707","Cytomegalovirus Antigen Measurement","C154828","The determination of the cytomegalovirus antigen present in a sample.","Cytomegalovirus Antigen Measurement | CMVAG | Cytomegalovirus Antigen",,,,,,,,,,,,,,,"4005681","Cytomegalovirus antigen assay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555542","Escherichia coli Shiga-like Toxin Measurement","C154818","The determination of the Escherichia coli shiga-like toxin present in a sample.","Escherichia coli Shiga-like Toxin Measurement | ECLSLTXN | Escherichia coli Shiga-like Toxin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938105","Fungi Measurement","C154813","The determination of the fungi present in a sample.","Fungi Measurement | FUNGI | Fungi | Fungus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3854008","Galactomannan Antigen Measurement","C154817","The determination of the galactomannan antigen present in a sample.","Galactomannan Antigen Measurement | GLTAG | Galactomannan Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555546","Giardia lamblia Antigen Measurement","C154822","The determination of the Giardia lamblia antigen present in a sample.","Giardia lamblia Antigen Measurement | GLAAG | Giardia lamblia Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556875","Gram Negative Bacteria Measurement","C154812","The determination of the gram-negative bacteria present in a sample.","Gram Negative Bacteria Measurement | GMNBAC | Gram Negative Bacteria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556873","Gram Positive Bacteria Measurement","C154811","The determination of the gram-positive bacteria present in a sample.","Gram Positive Bacteria Measurement | GMPBAC | Gram Positive Bacteria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545297","Haemophilus Measurement","C147458","The determination of the amount of the organism assigned to the Haemophilus genus in a biological sample.","Haemophilus Measurement | HAEMOPH | Haemophilus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545296","Haemophilus influenzae Measurement","C147457","The determination of the amount of the organism assigned to the Haemophilus influenzae species in a biological sample.","Haemophilus influenzae Measurement | H. influenzae | HAEMINF | Haemophilus influenzae",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555543","Helicobacter pylori Antigen Measurement","C154819","The determination of the Helicobacter pylori antigen present in a sample.","Helicobacter pylori Antigen Measurement | HPYAG | Helicobacter pylori Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540367","Hepatitis C Virus RNA Measurement","C142330","The determination of the amount of hepatitis C virus RNA present in a sample.","Hepatitis C Virus RNA Measurement | HCRNA | Hepatitis C RNA | Hepatitis C RNA Measurement | Hepatitis C Virus RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540366","Hepatitis E Virus RNA Measurement","C142331","The determination of the amount of hepatitis E virus RNA present in a sample.","Hepatitis E Virus RNA Measurement | HERNA | Hepatitis E Virus RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555538","Histoplasma capsulatum Antigen Measurement","C154816","The determination of the Histoplasma capsulatum antigen present in a sample.","Histoplasma capsulatum Antigen Measurement | HCPAG | Histoplasma capsulatum Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555541","HIV-1 Antigen Measurement","C154821","The determination of the HIV-1 antigen present in a sample.","HIV-1 Antigen Measurement | HIV-1 Antigen | HIV1AG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555551","Human Parainfluenza Antigen Measurement","C154833","The determination of the human parainfluenza antigen present in a sample.","Human Parainfluenza Antigen Measurement | HPIVAG | Human Parainfluenza Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555556","Human Parainfluenza Type 1 Antigen Measurement","C154834","The determination of the human parainfluenza type 1 antigen present in a sample.","Human Parainfluenza Type 1 Antigen Measurement | HPIV1AG | Human Parainfluenza Virus 1 Antigen | Human Respirovirus 1 Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935650","Human Parvovirus B19 Measurement","C156542","The determination of the amount of the organism assigned to the human parvovirus B19 species in a biological sample.","Human Parvovirus B19 Measurement | B19V | Human Parvovirus B19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555548","Legionella pneumophila Serogroup 1 Antigen Measurement","C154826","The determination of the Legionella pneumophila serogroup 1 antigen present in a sample.","Legionella pneumophila Serogroup 1 Antigen Measurement | LPNS1AG | Legionella pneumophila Serogroup 1 Antigen | Legionella pneumophila Sg 1 Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520055","Microoganism Identification","C132416","The determination of the type of microorganism in a biological sample.","Microoganism Identification | MCORGIDN | Microbial Organism Identification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512514","Mycobacterium Tuberculosis Measurement","C128982","The determination of the amount of mycobacterium tuberculosis present in a sample.","Mycobacterium Tuberculosis Measurement | MTB | Mycobacterium tuberculosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512165","Mycobacterium Tuberculosis Complex Measurement","C128983","The determination of the amount of mycobacterium tuberculosis complex present in a sample.","Mycobacterium tuberculosis Complex Measurement | MTBCMPLX | Mycobacterium tuberculosis Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935647","Mycoplasma pneumoniae Measurement","C156543","The determination of the amount of the organism assigned to the Mycoplasma pneumoniae species in a biological sample.","Mycoplasma pneumoniae Measurement | MPN | Mycoplasma pneumoniae",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546044","Nontuberculous Mycobacteria Measurement","C147459","The determination of the amount of organisms that are assigned to the Mycobacterium genus but are not tuberculosis or leprosy-causing in a biological sample.","Nontuberculous Mycobacteria Measurement | NTBMYCO | NTM | Non-tuberculous mycobacteria | Nontuberculous Mycobacteria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526570","Mucoid Pseudomonas aeruginosa Measurement","C139108","The determination of the amount of mucoid Pseudomonas aeruginosa present in a sample.","Mucoid Pseudomonas aeruginosa Measurement | P. aeruginosa, Mucoid | PAERGMUC | Pseudomonas aeruginosa, Mucoid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526565","Non-Mucoid Pseudomonas aeruginosa Measurement","C139107","The determination of the amount of non-mucoid Pseudomonas aeruginosa present in a sample.","Non-Mucoid Pseudomonas aeruginosa Measurement | P. aeruginosa, Non-Mucoid | P. aeruginosa, Non-mucoid | PAERGNMC | Pseudomonas aeruginosa, Non-Mucoid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526569","Small-Colony Variant Pseudomonas aeruginosa Measurement","C139109","The determination of the amount of small-colony variant Pseudomonas aeruginosa present in a sample.","Small-Colony Variant Pseudomonas aeruginosa Measurement | P. aeruginosa, Small-colony Variant | PAERGSCV | Pseudomonas aeruginosa, SCV | Pseudomonas aeruginosa, Small-colony Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520580","Asexual Plasmodium knowlesi Measurement","C132417","The determination of the amount of the organism assigned to the Plasmodium knowlesi species in the asexual phase in a biological sample.","Asexual Plasmodium knowlesi Measurement | PKNOWLA | Plasmodium knowlesi, Asexual",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521131","Sexual Plasmodium knowlesi Measurement","C132418","The determination of the amount of the organism assigned to the Plasmodium knowlesi species in the sexual phase in a biological sample.","Sexual Plasmodium knowlesi Measurement | PKNOWLS | Plasmodium knowlesi, Sexual",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555547","Respiratory Syncytial Virus Antigen Measurement","C154823","The determination of the Respiratory Syncytial Virus antigen present in a sample.","Respiratory Syncytial Virus Antigen Measurement | RSV Antigen | RSVAG | Respiratory Syncytial Virus Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555549","Rotavirus Antigen Measurement","C154827","The determination of the rotavirus antigen present in a sample.","Rotavirus Antigen Measurement | ROTAG | Rotavirus Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554662","Rubeola Antigen Measurement","C154815","The determination of the Rubeola antigen present in a sample.","Rubeola Antigen Measurement | Measles Virus Antigen | RBOAG | Rubeola Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526568","Methicillin-resistant Staphylococcus aureus Measurement","C139110","The determination of the amount of methicillin-resistant Staphylococcus aureus present in a sample.","Methicillin-resistant Staphylococcus aureus Measurement | MRSA | S. aureus, Methicillin-Resistant | S. aureus, Methicillin-resistant | Staphylococcus aureus, Methicillin-Resistant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526567","Methicillin-susceptible Staphylococcus aureus Measurement","C139111","The determination of the amount of methicillin-susceptible Staphylococcus aureus present in a sample.","Methicillin-susceptible Staphylococcus aureus Measurement | MSSA | S. aureus, Methicillin-Susceptible | S. aureus, Methicillin-susceptible | Staphylococcus aureus, Methicillin-Susceptible",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545298","Staphylococcus aureus Measurement","C147460","The determination of the amount of the organism assigned to the Staphylococcus aureus species in a biological sample.","Staphylococcus aureus Measurement | S. aureus | SAUREUS | Staphylococcus aureus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526979","Stenotrophomonas maltophilia Measurement","C139112","The determination of the amount of Stenotrophomonas maltophilia present in a sample.","Stenotrophomonas maltophilia Measurement | STENMALT | Stenotrophomonas maltophilia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555544","Streptococcus agalactiae Antigen Measurement","C154824","The determination of the Streptococcus agalactiae antigen present in a sample.","Streptococcus agalactiae Antigen Measurement | SAGAG | Streptococcus Group B Antigen | Streptococcus agalactiae Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555539","Streptococcus pyogenes Antigen Measurement","C154814","The determination of the Streptococcus pyogenes antigen present in a sample.","Streptococcus pyogenes Antigen Measurement | SPYAG | Streptococcus pyogenes Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554572","Toxigenic Clostridium difficile Measurement","C150862","The determination of the amount of the Clostridium difficile species that is considered toxigenic in a biological sample.","Toxigenic Clostridium difficile Measurement | TOXCDF | Toxigenic Clostridium difficile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555545","Urease Measurement","C154825","The determination of the urease present in a sample.","Urease Measurement | UREASE | Urease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521324","Zaire Ebolavirus Measurement","C132420","The determination of the amount of the organism assigned to the Zaire ebola virus species in a biological sample.","Zaire Ebolavirus Measurement | ZEBOV | Zaire Ebola Virus Measurement | Zaire Ebolavirus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552612","Toxin B-Producing Clostridium difficile Measurement","C150865","The determination of the amount of the strain of Clostridium difficile species that produces Toxin B in a biological sample.","Toxin B-Producing Clostridium difficile Measurement | TOXBPCDF | Toxin B-Producing Clostridium difficile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827984","CDISC SDTM Pharmacokinetic Parameter Short Name Terminology","C85839","Terminology associated with the pharmacokinetic parameter test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Pharmacokinetic Parameter Short Name Terminology | PK Parameters Code | PKPARMCD | SDTM-PKPARMCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085203","CDISC SDTM Subject Status Test Name Terminology","C124306","Terminology associated with the subject status test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Subject Status Test Name Terminology | SDTM-SSTEST | SSTEST | Subject Status Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084922","CDISC SDTM Subject Status Test Code Terminology","C124305","Terminology associated with the subject status test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Subject Status Test Code Terminology | SDTM-SSTESTCD | SSTESTCD | Subject Status Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509333","CDISC SDTM Microbiology Susceptibility Test Name Terminology","C128687","Terminology associated with the microbiology susceptibility test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Microbiology Susceptibility Test Name Terminology | MSTEST | Microbiology Susceptibility Test Name | SDTM-MSTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935643","Susceptibility Score Mutations Indicator","C156550","An indication as to whether one or more scored mutations of interest that may confer susceptibility in the microorganism is present.","Susceptibility Score Mutations Indicator | SUSMUIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0427978","Minimum Inhibitory Concentration Test","C128985","A laboratory test to determine the lowest concentration of a substance that will inhibit a biological or biochemical function, such as microorganism growth or enzymatic activity.","Minimum Inhibitory Concentration Test | MIC | Minimum Inhibitory Concentration",,,,,,,,,,,,,,,"4190299|45769424","Broth microdilution susceptibility test|MIC",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL526560","Microbial IC95 Subject Result","C139125","A measurement of the biological or biochemical reaction of a microbial organism that has been exposed to the concentration of a specific drug expected to produce 95 percent inhibition on the enzymatic activity of a microbial organism.","Microbial IC95 Subject Result | IC95 Subject Result | MIC95S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526561","Microbial IC95 Reference Control Result","C139124","A reference control sample response based on the concentration of a specific drug expected to produce 95 percent inhibition on the enzymatic activity of a microbial organism.","Microbial IC95 Reference Control Result | IC95 Reference Control Result | MIC95R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526554","Microbial IC95 Fold Change from Ref","C139123","A fold change based on the concentration of a specific drug expected to produce 95 percent inhibition on the enzymatic activity of a microbial organism; it is a ratio calculated by the IC95 Subject Result divided by the IC95 Reference Control Result.","Microbial IC95 Fold Change from Ref | IC95 Fold Change from Reference | MIC95FCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526555","Microbial IC95 Fold Change from Baseline","C139122","A fold change based on the concentration of a specific drug expected to produce 95 percent inhibition on the enzymatic activity of a microbial organism; it is a ratio calculated by the current IC95 Subject Result divided by the IC95 Subject Result from the baseline visit.","Microbial IC95 Fold Change from Baseline | IC95 Fold Change from Baseline | MIC95FCB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526556","Microbial IC50 Subject Result","C139121","A measurement of the biological or biochemical reaction of a microbial organism that has been exposed to the concentration of a specific drug expected to produce 50 percent inhibition on the enzymatic activity of a microbial organism.","Microbial IC50 Subject Result | MIC50S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526557","Microbial IC50 Reference Control Result","C139120","A reference control sample response based on the concentration of a specific drug expected to produce 50 percent inhibition on the enzymatic activity of a microbial organism.","Microbial IC50 Reference Control Result | MIC50R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526550","Microbial IC50 Fold Change from Reference","C139119","A fold change based on the concentration of a specific drug expected to produce 50 percent inhibition on the enzymatic activity of a microbial organism; it is a ratio calculated by the IC50 Subject Result divided by the IC50 Reference Control Result.","Microbial IC50 Fold Change from Reference | MIC50FCR | Microbial IC50 Fold Change from Ref",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526551","Microbial IC50 Fold Change from Baseline","C139118","A fold change based on the concentration of a specific drug expected to produce 50 percent inhibition on the enzymatic activity of a microbial organism; it is a ratio calculated by the current IC50 Subject Result divided by the IC50 Subject Result from the baseline visit.","Microbial IC50 Fold Change from Baseline | MIC50FCB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526552","Microbial EC50 Subject Result","C139117","A measurement of titer of a microbial organism that has been exposed to the concentration of a specific drug expected to produce 50 percent inhibition of the population growth or replication of a microbial organism.","Microbial EC50 Subject Result | MEC50S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526553","Microbial EC50 Reference Control Result","C139116","A reference control sample response based on the concentration of a specific drug expected to produce 50 percent inhibition of the population growth or replication of a microbial organism.","Microbial EC50 Reference Control Result | MEC50R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526547","Microbial EC50 Fold Change from Reference","C139115","A fold change based on the concentration of a specific drug expected to produce 50 percent inhibition of the population growth or replication of a microbial organism; it is a ratio calculated by the EC50 Subject Result divided by the EC50 Reference Control Result.","Microbial EC50 Fold Change from Reference | MEC50FCR | Microbial EC50 Fold Change from Ref",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526548","Microbial EC50 Fold Change from Baseline","C139114","A fold change based on the concentration of a specific drug expected to produce 50 percent inhibition of population growth or replication of a microbial organism.","Microbial EC50 Fold Change from Baseline | MEC50FCB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898760","Inhibitory Concentration Net Assessment Measurement","C116255","An indication of reduced or increased susceptibility of a viral organism, or activity of a biological/biochemical reaction in response to the inhibitory concentration (IC50 and/or IC95) of a specific drug.","Inhibitory Concentration Net Assessment Measurement | ICNETAS | Inhibitory Concentration Net Assessment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545364","Antibiotic Susceptibility Zone Diameter","C147471","The determination of the diameter of the circular region of bacteria growth inhibition that surrounds an antibiotic source on the surface of a cultured plate.","Antibiotic Susceptibility Zone Diameter | DIAZOINH | Diameter of the Kill Zone | Diameter of the Zone of Inhibition | Zone of Inhibition Diameter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509332","CDISC SDTM Microbiology Susceptibility Test Code Terminology","C128688","Terminology associated with the microbiology susceptibility test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Microbiology Susceptibility Test Code Terminology | MSTESTCD | Microbiology Susceptibility Test Code | SDTM-MSTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273022","CDISC SDTM Tumor or Lesion Properties Test Name Terminology","C96778","Terminology associated with the oncology tumor properties test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Tumor or Lesion Properties Test Name Terminology | SDTM-TRTEST | TRTEST | Tumor or Lesion Properties Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641224","Absolute Change From Nadir","C103347","The value of the current measurement minus the lowest value previously recorded.","Absolute Change From Nadir | ACHNAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545350","Absolute Change in Longest Diameter From Nadir Product of Perpendicular Diameters Timepoint","C147488","The absolute change in the longest diameter of the lesion from the timepoint at which the product of perpendicular diameters of the lesion is the smallest.","Absolute Change in Longest Diameter From Nadir Product of Perpendicular Diameters Timepoint | ACPPDNLD | Absolute Change From PPD Nadir in LDIAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545351","Absolute Change in Longest Perpendicular from Nadir Product of Perpendicular Diameters Timepoint","C147489","The absolute change in the longest perpendicular of the lesion from the timepoint at which the product of perpendicular diameters of the lesion is the smallest.","Absolute Change in Longest Perpendicular from Nadir Product of Perpendicular Diameters Timepoint | ACPPDNLP | Absolute Change From PPD Nadir in LPERP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831747","Absolute Change From Nadir in Sum of Diameter","C112218","The most recently recorded sum of diameters minus the lowest sum of diameters previously recorded.","Absolute Change From Nadir in Sum of Diameter | ACNSD | Absolute Change Nadir in Sum of Diam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545352","Bone Marrow Tracer Uptake","C147490","A visually assessed combination of extent and intensity of tracer uptake within the bone marrow.","Bone Marrow Tracer Uptake | BMUPTAKE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522869","Absolute Change from Nadir in Organ Enlargement","C135506","The current organ enlargement minus the lowest organ enlargement previously recorded.","Absolute Change from Nadir in Organ Enlargement | ACNDOREN | Absolute Change Nadir in Organ Enlarge | Absolute Change Nadir in Organ Enlargement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898609","Lesion Failure Indicator","C119551","An indication as to whether lesion failure occurred.","Lesion Failure Indicator | LESFLIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898607","Lesion Revascularization Clinical Indicator","C119556","An indication as to whether an appropriate clinical context was present before lesion revascularization occurred.","Lesion Revascularization Clinical Indicator | LRVCLIND | Lesion Revas Clinical Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898606","Lesion Revascularization Ischemia Indicator","C119555","An indication as to whether clinical or functional ischemia is present before lesion revascularization occurred.","Lesion Revascularization Ischemia Indicator | LRISCIND | Lesion Revas Ischemia Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896972","Lesion Revascularization Indicator","C119552","An indication as to whether repeat revascularization of a lesion occurred.","Lesion Revascularization Indicator | LESRVIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898605","Lesion Success Indicator","C119553","An indication as to whether a performed procedure of a target lesion is considered successful.","Lesion Success Indicator | LESSCIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898595","Limb Failure Indicator","C119554","An indication as to whether limb failure occurred.","Limb Failure Indicator | LMBFLIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0552406","Longest Diameter","C96684","The longest possible length of a straight line passing through the center of a circular or spheroid object that connects two points on the circumference.","Longest Diameter | Greatest Diameter | LDIAM | LONGEST_DIAM_DIM1 | longest dimension | longest measurement | longest_dimension | longest_measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272962","Longest Perpendicular","C96685","The longest possible straight line or plane through a body or figure that is at a right angle to a given line or plane.","Longest Perpendicular | LPERP | Short Axis Diameter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086554","Lymph Node State","C124448","A condition or state of a lymph node at a particular time.","Lymph Node State | LNSTATE | Lymph Node Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641259","New Tumor Confirmation","C103421","The confirmation (by other methods or modalities) that a tumor, which has not been previously seen or characterized, is present in the subject.","New Tumor Confirmation | NEWCONF | New Tumor Confirmed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520365","Number of Bone Lesions","C132463","A measurement of the total number of bone tumors.","Number of Bone Lesions | BNLNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503133","Number of Lymph Nodes Examined","C124446","The number of lymph nodes that were examined.","Number of Lymph Nodes Examined | LMNDEXAM | NUMBER_NODES_NUMERIC | Number of Lymph Nodes Tested | lymph nodes tested | lymph_nodes_tested",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086646","Number of Lymph Nodes Positive","C124447","The number of subject lymph nodes that were positive for presence of disease.","Number of Lymph Nodes Positive | LMNDPNUM | lymph nodes positive | lymph_nodes_positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521123","Number of New Bone Lesions","C132464","A measurement of the total number of bone tumors that have not been previously seen or characterized.","Number of New Bone Lesions | NBNLNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522870","Quantitative Organ Enlargement Assessment","C135507","A quantitative assessment of an increase in organ size or dimension.","Quantitative Organ Enlargement Assessment | ORENLQN | Organ Enlargement, Quantitative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522871","Organ State","C135508","A condition or state of an organ at a particular time.","Organ State | ORSTATE | Organ Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522872","Organ Craniocaudal Length Measurement","C135509","The linear extent along the craniocaudal axis from one end of an organ to the other end.","Organ Craniocaudal Length Measurement | ORVERLN | Organ Vertical Length",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526630","Overall Tracer Uptake Compared to Baseline","C139128","A visually assessed combination of extent and intensity of tracer uptake, as compared to baseline.","Overall Tracer Uptake Compared to Baseline | OTRCUPCB | Overall Tracer Uptake Compared to BL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522873","Percent Change from Baseline in Organ Enlargement","C135510","The current organ enlargement minus the baseline organ enlargement, divided by the baseline organ enlargement, multiplied by 100.","Percent Change from Baseline in Organ Enlargement | PCBSOREN | Percent Change Baseline in Organ Enlarge | Percent Change Baseline in Organ Enlargement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828606","Percent Change From Baseline in Sum of Diameter","C112370","The most recently recorded sum of diameters minus the baseline sum of diameters divided by the baseline sum of diameters, multiplied by 100.","Percent Change From Baseline in Sum of Diameter | PCBSD | Percent Change Baseline in Sum of Diam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520487","Percent Change From Baseline in Sum of Products of Perpendicular Diameter","C132264","The most recently recorded sum of products of perpendicular diameters minus the baseline sum of products of perpendicular diameters divided by the baseline sum of products of perpendicular diameters, multiplied by 100.","Percent Change From Baseline in Sum of Products of Perpendicular Diameter | PCBSPPD | Percent Change Baseline in Sum of PPD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828604","Percent Change From Baseline in Sum of Volume","C112372","The most recently recorded sum of volumes minus the baseline sum of volumes divided by the baseline sum of volumes, multiplied by 100.","Percent Change From Baseline in Sum of Volume | PCBSV | Percent Change Baseline in Sum of Volume",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828605","Percent Change From Baseline in Sum of Longest Diameter","C112371","The most recently recorded sum of longest diameters minus the baseline sum of longest diameters divided by the baseline sum of longest diameters, multiplied by 100.","Percent Change From Baseline in Sum of Longest Diameter | PCBSLD | Percent Change Baseline Sum Longest Diam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272907","Percent Change From Baseline","C96621","The value of the last measurement taken divided by the initial value taken at some baseline event or timepoint.","Percent Change From Baseline | PCHGBL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272908","Percent Change From Nadir","C96622","The value of the last measurement taken divided by the lowest value recorded.","Percent Change From Nadir | PCHGNAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522874","Percent Change from Nadir in Organ Enlargement","C135511","The current organ enlargement minus the lowest organ enlargement previously recorded, divided by the lowest organ enlargement previously recorded, multiplied by 100.","Percent Change from Nadir in Organ Enlargement | PCNDOREN | Percent Change Nadir in Organ Enlarge | Percent Change Nadir in Organ Enlargement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522875","Percent Change from Nadir in Product of Perpendicular Diameters","C135512","The current area minus the lowest area previously recorded, divided by the lowest area previously recorded, multiplied by 100.","Percent Change from Nadir in Product of Perpendicular Diameters | PCNPPD | Percent Change Nadir in PPD | Percent Change from Nadir in PPD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828602","Percent Change From Nadir in Sum of Longest Diameter","C112374","The most recently recorded sum of longest diameters minus the lowest sum of longest diameters previously recorded divided by the lowest sum of longest diameters previously recorded, multiplied by 100.","Percent Change From Nadir in Sum of Longest Diameter | PCNSLD | Percent Change Nadir in Sum Longest Diam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828603","Percent Change From Nadir in Sum of Diameter","C112373","The most recently recorded sum of diameters minus the lowest sum of diameters previously recorded divided by the lowest sum of diameters previously recorded, multiplied by 100.","Percent Change From Nadir in Sum of Diameter | PCNSD | Percent Change Nadir in Sum of Diam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520488","Percent Change From Nadir in Sum of Products of Perpendicular Diameters","C132265","The most recently recorded sum of products of perpendicular diameters minus the lowest sum of diameters previously recorded divided by the lowest sum of products of perpendicular diameters previously recorded, multiplied by 100.","Percent Change From Nadir in Sum of Products of Perpendicular Diameters | PCNSPPD | Percent Change From Nadir in Sum of Area | Percent Change Nadir in Sum of PPD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523841","Product of Perpendicular Diameters","C135513","The diameter multiplied by its perpendicular diameter.","Product of Perpendicular Diameters | PPD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086079","CDISC SDTM Category of Oncology Response Assessment Terminology","C124298","Terminology associated with the category of oncology response assessment codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Category of Oncology Response Assessment Terminology | Category of Oncology Response Assessment | ONCRSCAT | SDTM-ONCRSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899811","CDISC Clinical Classification Category Terminology","C118971","Terminology associated with the clinical classification domain categories of the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification Category Terminology | CC-CCCAT | CCCAT | Category of Clinical Classification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504593","Burcombe Breast Cancer 2005 Oncology Response Criteria","C125993","Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. (Burcombe RJ, Makris A, Richman PI, Daley FM, Noble S, Pittam M, Wright D, Allen SA, Dove J, Wilson GD. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer. 2005 Jan 17;92(1):147-55.)","Burcombe Breast Cancer 2005 Oncology Response Criteria | BURCOMBE BREAST CANCER 2005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504592","Bruggemann MRD 2010 Oncology Response Criteria","C125992","Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. (Bruggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG, Asnafi V, Baruchel A, Bassan R, Benoit Y, Biondi A, Cave H, Dombret H, Fielding AK, Foa R, Gokbuget N, Goldstone AH, Goulden N, Henze G, Hoelzer D, Janka-Schaub GE, Macintyre EA, Pieters R, Rambaldi A, Ribera JM, Schmiegelow K, Spinelli O, Stary J, von Stackelberg A, Kneba M, Schrappe M, van Dongen JJ; European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL); International Berlin-Frankfurt-Munster Study Group (I-BFM-SG). Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia. 2010 Mar;24(3):521-35.)","Bruggemann MRD 2010 Oncology Response Criteria | BRUGGEMANN MRD 2010",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504591","Boonsirikamchai Colorectal Cancer 2011 Oncology Response Criteria","C125991","CT findings of response and recurrence, independent of change in tumor size, in colorectal liver metastasis treated with bevacizumab. (Boonsirikamchai P, Asran MA, Maru DM, Vauthey JN, Kaur H, Kopetz S, Loyer EM. CT findings of response and recurrence, independent of change in tumor size, in colorectal liver metastasis treated with bevacizumab. AJR Am J Roentgenol. 2011 Dec;197(6):W1060-6.)","Boonsirikamchai Colorectal Cancer 2011 Oncology Response Criteria | BOONSIRIKAMCHAI COLORECTAL CANCER 2011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504590","Blazer Colorectal Cancer 2008 Oncology Response Criteria","C125990","Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases. (Blazer DG 3rd, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover KY, Wolff RA, Curley SA, Abdalla EK, Vauthey JN. Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases. J Clin Oncol. 2008 Nov 20;26(33):5344-51.)","Blazer Colorectal Cancer 2008 Oncology Response Criteria | BLAZER COLORECTAL CANCER 2008",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937350","College of American Pathologists","C157719","A member-based physician that serves patients, pathologists, and the public by fostering and advocating best practices in pathology and laboratory medicine.","College of American Pathologists | CAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272911","Radiodensity","C96627","The transparency of a material to the passage of X-rays and other forms of radiation.","Radiodensity | RADIODEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641263","Sum of Diameters of Non Lymph Node Tumors","C103441","A calculation of the aggregated diameter values for tumors other than the lymph nodes.","Sum of Diameters of Non Lymph Node Tumors | SUMNLNLD | Sum Diameters of Non Lymph Node Tumors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272914","Sum of Diameters","C96631","A calculation of the aggregated diameter values.","Sum of Diameters | SUMDIAM | Sum of Diameter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272915","Sum of Longest Diameters","C96632","A calculation of the aggregated longest diameter values.","Sum of Longest Diameters | SUMLDIAM | Sum of Longest Diameter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272916","Sum of Longest Perpendiculars","C96633","A calculation of the aggregated longest perpendicular values.","Sum of Longest Perpendiculars | SUMLPERP | Sum of Longest Perpendicular",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272917","Sum of Viable Diameters","C96634","A calculation of the aggregated diameter values taken from the viable portion of the tumor mass.","Sum of Viable Diameters | SUMVDIAM | Sum of Viable Diameter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272918","Sum of Volumes","C96635","A calculation of the aggregated volume values.","Sum of Volumes | SUMVOL | Sum of Volume",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475752","Tumor Status","C96643","The condition or state of the tumor at a particular time.","Tumor Status | TUMSTATE | Tumor State",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520259","Two or More New Bone Lesions Indicator","C132490","An indication as to whether there are two or more bone tumors that have not been previously seen or characterized.","Two or More New Bone Lesions Indicator | NBNL2IND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520260","Two or More Persisting New Bone Lesions Indicator","C132465","An indication as to whether there are two or more bone tumors that have been previously seen or characterized.","Two or More Persisting New Bone Lesions Indicator | PBNL2IND | Two or More Persist New Bone Lesions Ind",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897191","Vessel Failure Indicator","C119557","An indication as to whether vessel failure occurred.","Vessel Failure Indicator | VSLFLIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897189","Vessel Patency Indicator","C119558","An indication as to whether an artery is patent (free of TLR or restenosis) following intervention.","Vessel Patency Indicator | VSLPIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897188","Vessel Revascularization Indicator","C119559","An indication as to whether repeat revascularization of an artery containing a lesion occurred.","Vessel Revascularization Indicator | VSLRVIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272927","Viable Tumor Diameter","C96646","The diameter of the portion of the tumor mass that is capable of growth, proliferation and metastasis.","Viable Tumor Diameter | VDIAM | Viable Diameter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552746","Overall Tracer Uptake Compared to Nadir","C150896","A visually assessed combination of extent and intensity of tracer uptake, as compared to nadir.","Overall Tracer Uptake Compared to Nadir | OTRCUPCN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520538","Sum of Products of Perpendicular Diameters","C132261","A calculation of the aggregated products of perpendicular diameter values.","Sum of Products of Perpendicular Diameters | SPD | SUMPPD | Sum of Products of Perpendicular Diam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273023","CDISC SDTM Tumor or Lesion Properties Test Code Terminology","C96779","Terminology associated with the oncology tumor properties test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Tumor or Lesion Properties Test Code Terminology | SDTM-TRTESTCD | TRTESTCD | Tumor or Lesion Properties Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273027","CDISC SDTM Tumor Identification Test Name Terminology","C96783","Terminology associated with the tumor identification test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Tumor Identification Test Name Terminology | SDTM-TUTEST | TUTEST | Tumor or Lesion Identification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986549","Tumor Identification","C94523","A diagnostic procedure to localize and characterize a tumor.","Tumor Identification | TUMIDENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896973","Vessel Lesion Identification","C119569","The identification of a non-neoplastic or neoplastic pathologic process taking place within a vessel.","Vessel Lesion Identification | VSLIDENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272924","Tumor Split","C96642","A finding indicating that a tumor mass has been divided into two or more tumors.","Tumor Fragmentation | TUSPLIT | Tumor Mass Fragmentation | Tumor Split | Tumor Split",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986551","Matted Tumor Mass Present","C94525","A finding indicating that two or more tumors have merged to create a single cancerous mass.","Matted Tumor Mass Present | TUMERGE | TUMOR MERGED | Tumor Merged",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555666","Metastatic Tumor Site Indicator","C154853","An indication as to whether an anatomical location contains metastases.","Metastatic Tumor Site Indicator | METIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898596","Limb Associated Lesion Identification","C119568","The identification of the limb that contains a non-neoplastic or neoplastic pathologic process.","Limb Associated Lesion Identification | LMLIDENT | Limb Lesion Identification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899021","Graft Lesion Identification","C119567","The identification of a non-neoplastic or neoplastic pathologic process taking place within a graft.","Graft Lesion Identification | GRLIDENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273028","CDISC SDTM Tumor Identification Test Code Terminology","C96784","Terminology associated with the tumor identification test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Tumor Identification Test Code Terminology | SDTM-TUTESTCD | TUTESTCD | Tumor or Lesion Identification Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0191322","Excision of Lesion of Skin","C51892","The surgical removal of a skin lesion.","Excision of Lesion of Skin | ",,,,,,,,,,,,,,,"4147588","Excision of lesion of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504594","Cheson CLL 2006 Oncology Response Criteria","C125994","CLL response criteria. (Cheson BD. CLL response criteria.Clin Adv Hematol Oncol. 2006 May;4(5):4-5; discussion 10; suppl 12.)","Cheson CLL 2006 Oncology Response Criteria | CHESON CLL 2006",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504595","Cheson CLL 2012 Oncology Response Criteria","C125995","Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. (Cheson BD, Byrd JC, Rai KR, Kay NE, O'Brien SM, Flinn IW, Wiestner A, Kipps TJ. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol. 2012 Aug 10;30(23):2820-2.)","Cheson CLL 2012 Oncology Response Criteria | CHESON CLL 2012",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504596","Cheson Hodgkins Non-Hodgkins Lymphoma 2008 Oncology Response Criteria","C125996","New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma. (Cheson BD. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma. Radiol Clin North Am. 2008 Mar;46(2):213-23, vii.)","Cheson Hodgkins Non-Hodgkins Lymphoma 2008 Oncology Response Criteria | CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504597","Cheson Lymphoma 2008 Oncology Response Criteria","C125997","New response criteria for lymphomas in clinical trials. (Cheson BD. New response criteria for lymphomas in clinical trials. Ann Oncol. 2008 Jun;19 Suppl 4:iv35-8.)","Cheson Lymphoma 2008 Oncology Response Criteria | CHESON LYMPHOMA 2008",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504598","Cheson Malignant Lymphoma 2007 Oncology Response Criteria","C125998","Revised response criteria for malignant lymphoma. (Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007 Feb 10;25(5):579-86. Epub 2007 Jan 22.)","Cheson Malignant Lymphoma 2007 Oncology Response Criteria | CHESON MALIGNANT LYMPHOMA 2007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504599","Cheson Non-Hodgkins Hodgkins Lymphoma 1993 Oncology Response Criteria","C125999","Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. (Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol. 1993 Jun;16(3):223-8.)","Cheson Non-Hodgkins Hodgkins Lymphoma 1993 Oncology Response Criteria | CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504600","Cheson Non-Hodgkins Lymphoma 1999 Oncology Response Criteria","C126000","Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. (Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. J Clin Oncol. 1999 Apr;17(4):1244.)","Cheson Non-Hodgkins Lymphoma 1999 Oncology Response Criteria | CHESON NON-HODGKINS LYMPHOMA 1999",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504602","Dohner AML 2010 Oncology Response Criteria","C126002","Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. (Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Lowenberg B, Bloomfield CD; European LeukemiaNet Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010 Jan 21;115(3):453-74.)","Dohner AML 2010 Oncology Response Criteria | DOHNER AML 2010",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504603","Durie Multiple Myeloma 2006 Oncology Response Criteria","C126003","International uniform response criteria for multiple myeloma. (Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006 Sep;20(9):1467-73. Epub 2006 Jul 20.)","Durie Multiple Myeloma 2006 Oncology Response Criteria | DURIE MULTIPLE MYELOMA 2006",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504604","EASL Bruix Liver Cancer 2001 Oncology Response Criteria","C126004","Clinical management, of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference-European Association for the Study of the Liver. (Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J; EASL Panel of Experts on HCC. Clinical management, of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference-European Association for the Study of the Liver. J Hepatol. 2001 Sep;35(3):421-30.)","EASL Bruix Liver Cancer 2001 Oncology Response Criteria | EASL BRUIX LIVER CANCER 2001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504605","EBMT Blade Myeloma 1998 Oncology Response Criteria","C126005","Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. (Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998 Sep;102(5):1115-23.)","EBMT Blade Myeloma 1998 Oncology Response Criteria | EBMT BLADE MYELOMA 1998",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504606","EORTC Olsen Mycosis Fungoides And Sezary Syndrome 2011 Oncology Response Criteria","C126006","Clinical End Points and Response Criteria in Mycosis Fungoides and Sezary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. (Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, Wood GS, Willemze R, Demierre MF, Pimpinelli N, Bernengo MG, Ortiz-Romero PL, Bagot M, Estrach T, Guitart J, Knobler R, Sanches JA, Iwatsuki K, Sugaya M, Dummer R, Pittelkow M, Hoppe R, Parker S, Geskin L, Pinter-Brown L, Girardi M, Burg G, Ranki A, Vermeer M, Horwitz S, Heald P, Rosen S, Cerroni L, Dreno B, Vonderheid EC; International Society for Cutaneous Lymphomas; United States Cutaneous Lymphoma Consortium; Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Clinical End Points and Response Criteria in Mycosis Fungoides and Sezary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011 Jun 20;29(18):2598-607.)","EORTC Olsen Mycosis Fungoides And Sezary Syndrome 2011 Oncology Response Criteria | EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512493","Supplement to Farooqui CLL 2014 Oncology Response Criteria","C128990","Supplement to: Farooqui MZH, Valdez J, Martyr S, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol 2014; published online Dec 31. http://dx.doi.org/10.1016/S1470-2045(14)71182-9. (Available at http://www.thelancet.com/cms/attachment/2026086364/2045255220/mmc1.pdf. Accessed April 27, 2016)","Supplement to Farooqui CLL 2014 Oncology Response Criteria | FAROOQUI SUPP CLL 2014",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504608","GCIG Rustin Ovarian Cancer 2011 Oncology Response Criteria","C126008","Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). (Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A, Kristensen G, Jakobsen A, Sagae S, Greven K, Parmar M, Friedlander M, Cervantes A, Vermorken J; Gynecological Cancer Intergroup. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011 Feb;21(2):419-23.)","GCIG Rustin Ovarian Cancer 2011 Oncology Response Criteria | GCIG RUSTIN OVARIAN CANCER 2011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504609","Guilhot CML 2007 Oncology Response Criteria","C126009","Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. (Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, Amadori S, de Souza CA, Lipton JH, Hochhaus A, Heim D, Larson RA, Branford S, Muller MC, Agarwal P, Gollerkeri A, Talpaz M. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007 May 15;109(10):4143-50. Epub 2007 Jan 30.)","Guilhot CML 2007 Oncology Response Criteria | GUILHOT CML 2007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504610","Guppy Ovarian Cancer 2002 Oncology Response Criteria","C126010","CA125 Response: Can it Replace the Traditional Response Criteria in Ovarian Cancer? (Guppy AE, Rustin GJS. CA125 Response: Can it Replace the Traditional Response Criteria in Ovarian Cancer? Oncologist. 2002;7(5):437-43.)","Guppy Ovarian Cancer 2002 Oncology Response Criteria | GUPPY OVARIAN CANCER 2002",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504611","Hamaoka Breast Cancer 2010 Oncology Response Criteria","C126011","Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. (Hamaoka T, Costelloe CM, Madewell JE, Liu P, Berry DA, Islam R, Theriault RL, Hortobagyi GN, Ueno NT. Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer. 2010 Feb 16;102(4):651-7.)","Hamaoka Breast Cancer 2010 Oncology Response Criteria | HAMAOKA BREAST CANCER 2010",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504613","Hartman Pancreatic Cancer 2012 Oncology Response Criteria","C126013","Assessing treatment effect in pancreatic cancer. (Hartman DJ, Krasinskas AM. Assessing treatment effect in pancreatic cancer. Arch Pathol Lab Med. 2012 Jan;136(1):100-9.)","Hartman Pancreatic Cancer 2012 Oncology Response Criteria | HARTMAN PANCREATIC CANCER 2012",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504612","Hartmann Germ Cell Cancer 2002 Oncology Response Criteria","C126012","Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. (Hartmann JT, Nichols CR, Droz JP, Horwich A, Gerl A, Fossa SD, Beyer J, Pont J, Kanz L, Einhorn L, Bokemeyer C. Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. Ann Oncol. 2002 Jul;13(7):1017-28.)","Hartmann Germ Cell Cancer 2002 Oncology Response Criteria | HARTMANN GERM CELL CANCER 2002",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504614","IWC Hallek CLL 2008 Oncology Response Criteria","C126014","Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. (Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ. International Workshop on Chronic Lymphocytic Leukemia.Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008 Jun 15;111(12):5446-56.)","IWC Hallek CLL 2008 Oncology Response Criteria | IWC HALLEK CLL 2008",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504615","IWG Cheson AML 2003 Oncology Response Criteria","C126015","Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. (Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD; International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003 Dec 15;21(24):4642-9.)","IWG Cheson AML 2003 Oncology Response Criteria | IWG CHESON AML 2003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504616","IWG Cheson MDS 2000 Oncology Response Criteria","C126016","Report of an international working group to standardize response criteria for myelodysplastic syndromes. (Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Lowenberg B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg PL; World Health Organization(WHO) international working group. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000 Dec 1;96(12):3671-4.)","IWG Cheson MDS 2000 Oncology Response Criteria | IWG CHESON MDS 2000",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504617","IWG Cheson MDS 2006 Oncology Response Criteria","C126017","Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. (Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006 Jul 15;108(2):419-25. Epub 2006 Apr 11.)","IWG Cheson MDS 2006 Oncology Response Criteria | IWG CHESON MDS 2006",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504618","Jacinto Cervical Cancer 2007 Oncology Response Criteria","C126018","Preoperative external beam radiotherapy and reduced dose brachytherapy for carcinoma of the cervix: survival and pathological response. (Jacinto AA, Castilho MS, Novaes PE, Novick PR, Viani GA, Salvajoli JV, Ferrigno R, Pellizzon AC, Lima SS, Maia MA, Fogaroli RC. Preoperative external beam radiotherapy and reduced dose brachytherapy for carcinoma of the cervix: survival and pathological response. Radiat Oncol. 2007 Feb 22;2:9.)","Jacinto Cervical Cancer 2007 Oncology Response Criteria | JACINTO CERVICAL CANCER 2007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504619","Japanese Classification Gastric Cancer 2011 Oncology Response Criteria","C126019","Japanese classification of gastric carcinoma: 3rd English edition. ([No authors listed]. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011 Jun;14(2):101-12.)","Japanese Classification Gastric Cancer 2011 Oncology Response Criteria | JAPANESE CLASSIFICATION GASTRIC CANCER 2011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504620","Juweid Non-Hodgkins Lymphoma 2005 Oncology Response Criteria","C126020","Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. (Juweid ME, Wiseman GA, Vose JM, Ritchie JM, Menda Y, Wooldridge JE, Mottaghy FM, Rohren EM, Blumstein NM, Stolpen A, Link BK, Reske SN, Graham MM, Cheson BD. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.J Clin Oncol. 2005 Jul 20;23(21):4652-61.)","Juweid Non-Hodgkins Lymphoma 2005 Oncology Response Criteria | JUWEID NON-HODGKINS LYMPHOMA 2005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504621","Keam Breast Cancer 2013 Oncology Response Criteria","C126021","Clinical usefulness of AJCC response criteria for neoadjuvant chemotherapy in breast cancer. (Keam B, Im SA, Lim Y, Han SW, Moon HG, Oh DY, Cho N, Lee SH, Han W, Moon WK, Kim DW, Kim TY, Park IA, Noh DY. Clinical usefulness of AJCC response criteria for neoadjuvant chemotherapy in breast cancer. Ann Surg Oncol. 2013 Jul;20(7):2242-9.)","Keam Breast Cancer 2013 Oncology Response Criteria | KEAM BREAST CANCER 2013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504622","Kimby Waldenstroms Macroglobulinemia 2006 Oncology Response Criteria","C126022","Update on Recommendations for Assessing Response from the Third International Workshop on Waldenstrom's Macroglobulinemia. (Kimby E, Treon SP, Anagnostopoulos A, Dimopoulos M, Garcia-Sanz R, Gertz MA, Johnson S, LeBlond V, Fermand JP, Maloney DG, Merlini G, Morel P, Morra E, Nichols G, Ocio EM, Owen R, Stone M, Blade J. Update on Recommendations for Assessing Response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma. 2006 Mar;6(5):380-3.)","Kimby Waldenstroms Macroglobulinemia 2006 Oncology Response Criteria | KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504623","Kuker Lymphoma 2005 Oncology Response Criteria","C126023","Primary central nervous system lymphomas (PCNSL): MRI response criteria revised. (Kuker W, Nagele T, Thiel E, Weller M, Herrlinger U. Primary central nervous system lymphomas (PCNSL): MRI response criteria revised. Neurology. 2005 Oct 11;65(7):1129-31.)","Kuker Lymphoma 2005 Oncology Response Criteria | KUKER LYMPHOMA 2005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545370","Kumar IMWG 2016 Oncology Response Criteria","C147478","A tumor response criterion published in 2016 by Kumar et al. entitled International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. (Kumar S, Paiva B, Anderson KC, Durie B, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016 Aug;17(8):e328-46.)","Kumar IMWG 2016 Oncology Response Criteria | KUMAR IMWG 2016",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504624","Lee Lung Cancer 2011 Oncology Response Criteria","C126024","New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy. (Lee HY, Lee KS, Ahn MJ, Hwang HS, Lee JW, Park K, Ahn JS, Kim TS, Yi CA, Chung MJ. New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy. Lung Cancer. 2011 Jul;73(1):63-9.)","Lee Lung Cancer 2011 Oncology Response Criteria | LEE LUNG CANCER 2011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504626","Macdonald Glioma 1990 Oncology Response Criteria","C126026","Response criteria for phase II studies of supratentorial malignant glioma. (Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990 Jul;8(7):1277-80.)","Macdonald Glioma 1990 Oncology Response Criteria | MACDONALD GLIOMA 1990",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505078","Morphology, Attenuation, Size, and Structure Criteria","C126027","Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. (Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol. 2010 Jun;194(6):1470-8.)","Morphology, Attenuation, Size, and Structure Criteria | MASS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504627","Minkov Langerhans Cell Histiocytosis 2009 Oncology Response Criteria","C126028","Langerhans Cell Histiocytosis: Histiocyte Society Evaluation and Treatment Guidelines April 2009. (Minkov, M., Grois, N., McClain, K., Nanduri, V., Rodriguez-Galindo, C., Simonitsch-Klupp, I., Visser, J., Weitzman, S., Whitlock, J., Windebank, K. (April 2009). Langerhans Cell Histiocytosis: Histiocyte Society Evaluation and Treatment Guidelines April 2009 [pdf]. Retrieved from https://www.histiocytesociety.org/document.doc?id=290)","Minkov Langerhans Cell Histiocytosis 2009 Oncology Response Criteria | MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504628","Montserrat CLL 1989 Oncology Response Criteria","C126029","Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. International Workshop on Chronic Lymphocytic Leukemia. ([No authors listed]. Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. International Workshop on Chronic Lymphocytic Leukemia. Ann Intern Med. 1989 Feb 1;110(3):236-8.)","Montserrat CLL 1989 Oncology Response Criteria | MONTSERRAT CLL 1989",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504629","Modified RANO Van Den Bent Glioma 2011 Oncology Response Criteria","C126030","Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. (van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, Armstrong T, Choucair A, Waldman AD, Gorlia T, Chamberlain M, Baumert BG, Vogelbaum MA, Macdonald DR, Reardon DA, Wen PY, Chang SM, Jacobs AH. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011 Jun;12(6):583-93.)","Modified RANO Van Den Bent Glioma 2011 Oncology Response Criteria | MRANO VAN DEN BENT GLIOMA 2011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504630","Modified RECIST Byrne Mesothelioma 2004 Oncology Response Criteria","C126031","Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. (Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004 Feb;15(2):257-60.)","Modified RECIST Byrne Mesothelioma 2004 Oncology Response Criteria | MRECIST BYRNE MESOTHELIOMA 2004 | mRECIST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504631","Modified RECIST Lencioni Liver Cancer 2010 Oncology Response Criteria","C126032","Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma. (Lencioni R, Llovet JM. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma. Semin Liver Dis. 2010 Feb;30(1):52-60.)","Modified RECIST Lencioni Liver Cancer 2010 Oncology Response Criteria | MRECIST LENCIONI LIVER CANCER 2010",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504632","Murphy Prostate Cancer 1980 Oncology Response Criteria","C126033","Response criteria for the prostate of the USA National Prostatic Cancer Project. (Murphy GP, Slack NH. Response criteria for the prostate of the USA National Prostatic Cancer Project. Prostate. 1980;1(3):375-82.)","Murphy Prostate Cancer 1980 Oncology Response Criteria | MURPHY PROSTATE CANCER 1980",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504633","NCCN ALL MRD 2014 Oncology Response Criteria","C126034","NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Acute Lymphoblastic Leukemia Version 1.2014 06/06/14 (NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Acute Lymphoblastic Leukemia Version 1.2014 06/06/14)","NCCN ALL MRD 2014 Oncology Response Criteria | NCCN ALL MRD 2014",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504634","NCIWG Cheson CLL 1996 Oncology Response Criteria","C126035","National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. (Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996 Jun 15;87(12):4990-7.)","NCIWG Cheson CLL 1996 Oncology Response Criteria | NCIWG CHESON CLL 1996",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504635","Palumbo Multiple Myeloma 2009 Oncology Response Criteria","C126036","International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. (Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, Niesvizky R, Morgan G, Comenzo R, Sonneveld P, Kumar S, Hajek R, Giralt S, Bringhen S, Anderson KC, Richardson PG, Cavo M, Davies F, Blade J, Einsele H, Dimopoulos MA, Spencer A, Dispenzieri A, Reiman T, Shimizu K, Lee JH, Attal M, Boccadoro M, Mateos M, Chen W, Ludwig H, Joshua D, Chim J, Hungria V, Turesson I, Durie BG, Lonial S; IMWG. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia. 2009 Oct;23(10):1716-30.)","Palumbo Multiple Myeloma 2009 Oncology Response Criteria | PALUMBO MULTIPLE MYELOMA 2009 | Palumbo IMWG 2009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504636","PCWG Bubley Prostate Cancer 1999 Oncology Response Criteria","C126037","Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. (Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999 Nov;17(11):3461-7.)","PCWG Bubley Prostate Cancer 1999 Oncology Response Criteria | PCWG BUBLEY PROSTATE CANCER 1999 | PCWG1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504637","PCWG Scher Prostate Cancer 2008 Oncology Response Criteria","C126038","Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. (Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M; Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008 Mar 1;26(7):1148-59.)","PCWG Scher Prostate Cancer 2008 Oncology Response Criteria | PCWG SCHER PROSTATE CANCER 2008 | PCWG2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521127","PCWG Scher Prostate Cancer 2016 Oncology Response Criteria","C132454","Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. (Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016 Apr 20;34(12):1402-18.)","PCWG Scher Prostate Cancer 2016 Oncology Response Criteria | PCWG SCHER PROSTATE CANCER 2016 | PCWG3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504638","PET Response Criteria in Solid Tumors","C126039","A set of rules that define when tumors in cancer patients respond, stabilize, or progress during treatment with respect to positron emission tomography.","PET Response Criteria in Solid Tumors | PERCIST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504639","Petit Breast Cancer 2001 Oncology Response Criteria","C126040","Chemotherapy Response of Breast Cancer Depends on HER-2 Status and Anthracycline Dose Intensity in the Neoadjuvant Setting. (Petit T, Borel C, Ghnassia JP, Rodier JF, Escande A, Mors R, Haegele P. Chemotherapy Response of Breast Cancer Depends on HER-2 Status and Anthracycline Dose Intensity in the Neoadjuvant Setting. Clin Cancer Res. 2001 Jun;7(6):1577-81.)","Petit Breast Cancer 2001 Oncology Response Criteria | PETIT BREAST CANCER 2001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504640","Prince T Cell Lymphoma 2010 Oncology Response Criteria","C126041","Phase III Placebo-Controlled Trial of Denileukin Diftitox for Patients with Cutaneous T-cell Lymphoma. (Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, Straus D, Acosta M, Negro-Vilar A. Phase III Placebo-Controlled Trial of Denileukin Diftitox for Patients with Cutaneous T-cell Lymphoma. J Clin Oncol. 2010 Apr 10;28(11):1870-7.)","Prince T Cell Lymphoma 2010 Oncology Response Criteria | PRINCE TCELL LYMPHOMA 2010",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504641","Protocol Defined Response Criteria","C126042","A description of the disease response to treatment as characterized by the clinical trial protocol.","Protocol Defined Response Criteria | PROTOCOL DEFINED RESPONSE CRITERIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504642","Rajkumar Myeloma 2011 Oncology Response Criteria","C126043","Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. (Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, Zonder J, Ludwig H, Vesole D, Sezer O, Munshi NC, San Miguel J; International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011 May 5;117(18):4691-5.)","Rajkumar Myeloma 2011 Oncology Response Criteria | RAJKUMAR MYELOMA 2011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504643","Response Evaluation Criteria in Cancer of the Liver","C126044","Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 revised version). (Kudo M, Kubo S, Takayasu K, Sakamoto M, Tanaka M, Ikai I, Furuse J, Nakamura K, Makuuchi M; Liver Cancer Study Group of Japan (Committee for Response Evaluation Criteria in Cancer of the Liver, Liver Cancer Study Group of Japan). Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 revised version). Hepatol Res. 2010 Jul;40(7):686-92.)","Response Evaluation Criteria in Cancer of the Liver | RECICL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086826","Response Evaluation Criteria in Solid Tumors Version 1.0","C124414","A standardized guideline developed by the Response Evaluation Criteria in Solid Tumors (RECIST) Working Group in 2000, which is an objective response criteria used to assess solid tumor response and to measure change in tumor size for use in adult and pediatric cancer clinical trials. RECIST version 1.0 contains the following key features: definitions of minimum size of measurable lesions, instructions on how many lesions to follow, and the use of uni-dimensional rather than bi-dimensional measures for evaluation of tumor burden.","Response Evaluation Criteria in Solid Tumors Version 1.0 | RECIST 1.0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504644","Size and Attenuation CT Criteria","C126045","Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. (Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol. 2010 Jan;194(1):157-65.)","Size and Attenuation CT Criteria | SACT | SACT Criteria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504645","Scher Prostate Cancer 2011 Oncology Response Criteria","C126046","End Points and Outcomes in Castration-Resistant Prostate Cancer: From Clinical Trials to Clinical Practice. (Scher HI, Morris MJ, Basch E, Heller G. End Points and Outcomes in Castration-Resistant Prostate Cancer: From Clinical Trials to Clinical Practice. J Clin Oncol. 2011 Sep 20;29(27):3695-704.)","Scher Prostate Cancer 2011 Oncology Response Criteria | SCHER PROSTATE CANCER 2011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504646","Schwarz Cervical Cancer 2009 Oncology Response Criteria","C126047","The Role of 18F-FDG PET in Assessing Therapy Response in Cancer of the Cervix and Ovaries. (Schwarz JK, Grigsby PW, Dehdashti F, Delbeke D. The Role of 18F-FDG PET in Assessing Therapy Response in Cancer of the Cervix and Ovaries. J Nucl Med. 2009 May;50 Suppl 1:64S-73S.)","Schwarz Cervical Cancer 2009 Oncology Response Criteria | SCHWARZ CERVICAL CANCER 2009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504647","Shindoh Colorectal Cancer 2013 Oncology Response Criteria","C126048","Non-Size-Based Response Criteria to Preoperative Chemotherapy in Patients With Colorectal Liver Metastases: The Morphologic Response Criteria. (Shindoh J, Chun YS, Loyer EM, Vauthey JN. Non-Size-Based Response Criteria to Preoperative Chemotherapy in Patients With Colorectal Liver Metastases: The Morphologic Response Criteria. Curr Colorectal Cancer Rep. 2013 Jun 1;9(2):198-202.)","Shindoh Colorectal Cancer 2013 Oncology Response Criteria | SHINDOH COLORECTAL CANCER 2013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504648","Tsukasaki Leukemia Lymphoma 2009 Oncology Response Criteria","C126049","Definition, Prognostic Factors, Treatment, and Response Criteria of Adult T-Cell Leukemia-Lymphoma: A Proposal From an International Consensus Meeting. (Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, Harrington W Jr, O'Mahony D, Janik JE, Bittencourt AL, Taylor GP, Yamaguchi K, Utsunomiya A, Tobinai K, Watanabe T. Definition, Prognostic Factors, Treatment, and Response Criteria of Adult T-Cell Leukemia-Lymphoma: A Proposal From an International Consensus Meeting. J Clin Oncol. 2009 Jan 20;27(3):453-9.)","Tsukasaki Leukemia Lymphoma 2009 Oncology Response Criteria | TSUKASAKI LEUKEMIA LYMPHOMA 2009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504649","Guidelines for Management of Breast Cancer WHO 2006","C126050","Guidelines for Management of Breast Cancer. (WHO (2006). Guidelines for Management of Breast Cancer. Retrieved from http://applications.emro.who.int/dsaf/dsa697.pdf)","Guidelines for Management of Breast Cancer WHO 2006 | WHO BREAST CANCER 2006",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086827","Response Evaluation Criteria in Solid Tumors Version 1.1","C124415","A standardized guideline developed by the Response Evaluation Criteria in Solid Tumors (RECIST) Working Group in 2000 and revised in 2009, which is an objective response criteria used to assess solid tumor response and to measure change in tumor size for use in adult and pediatric cancer clinical trials. Major revisions in RECIST version 1.1 includes lymph node (LN) measurement, the maximum number of target lesions, the definition of disease progression, as well as the inclusion of and guidance on the use of MRI and FDG PET in the detection of new lesions.","Response Evaluation Criteria in Solid Tumors Version 1.1 | RECIST 1.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504601","Chollet Breast Cancer 2002 Oncology Response Criteria","C126001","Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. (Chollet P, Amat S, Cure H, de Latour M, Le Bouedec G, Mouret-Reynier MA, Ferriere JP, Achard JL, Dauplat J, Penault-Llorca F. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer. 2002 Apr 8;86(7):1041-6.)","Chollet Breast Cancer 2002 Oncology Response Criteria | CHOLLET BREAST CANCER 2002",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504607","European Leukemianet Baccarani CML 2006 Oncology Response Criteria","C126007","Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R; European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006 Sep 15;108(6):1809-20. Epub 2006 May 18.)","European Leukemianet Baccarani CML 2006 Oncology Response Criteria | EUROPEAN LEUKEMIANET BACCARANI CML 2006",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0243028","Acute Physiology and Chronic Health Evaluation II Clinical Classification","C121005","A standardized rating scale developed by Knaus et al in 1985, which is a classification system used to measure severity of disease. This instrument uses a point score system based on physiological measurements, age and previous health status.","Acute Physiology and Chronic Health Evaluation II Clinical Classification | APACHE II | APCH1",,,,,,,,,,,,,,,"4159406","Acute physiology and chronic health evaluation II",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897495","Stent Thrombosis Coronary ARC Grade Clinical Classification","C119107","A standardized grading system developed by the Academic Research Consortium (ARC) to describe coronary stent thrombosis based on the evidence (angiographic or pathological confirmation of thrombus, or unexplained sudden death within 30 days) of the event. This grading system includes 3 classifications: definite, probable and possible stent thrombosis.","Stent Thrombosis Coronary ARC Grade Clinical Classification | ARC STC GRADE | ARC STC Grade | STCG01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085998","Atherosclerotic Cardiovascular Disease 10-Year Risk Estimator Clinical Classification","C124705","A standardized rating scale developed by Goff et al in 2013, which is a classification system used to estimate 10-year and lifetime risks for atherosclerotic cardiovascular disease (ASCVD). This estimation takes into consideration of an individual's gender, age, race, diabetes and smoking histories, treatment for hypertension, as well as systolic blood pressure, total cholesterol and high-density lipoprotein (HDL) cholesterol levels.","Atherosclerotic Cardiovascular Disease 10-Year Risk Estimator Clinical Classification | ASCVD 10-YEAR RISK | ASCVD 10-Year Risk Estimator | ASCVD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085922","ASSIGN Cardiovascular Disease 10-Year Risk Score Clinical Classification","C124706","A standardized rating scale developed by Woodward et al and the Scottish Intercollegiate Guidelines Network (SIGN) in 2007, which is a classification system used to predict 10-year risk of cardiovascular disease.","ASSIGN Cardiovascular Disease 10-Year Risk Score Clinical Classification | ASSG01 | ASSIGN CVD 10-YEAR RISK | ASSIGN Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550656","ATLAS Score Clinical Classification","C147589","A standardized scoring system created by Miller et al. in 2013 that assesses age, treatment with systemic antibiotics, leukocyte count, albumin and serum creatinine to predict treatment response or mortality from Clostridium difficile infection.","ATLAS Score Clinical Classification | ATLAS | ATLAS1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053940","The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index Clinical Classification","C121006","A standardized rating scale developed by Celli et al in 2004, which is a multidimensional grading system used to assess the respiratory and systemic expressions of COPD, and to predict the risk of death among patients with COPD. This instrument has a total possible values range from 0 to 10, based on FEV1, body-mass index, the distance walked in six minutes, and the modified MRC dyspnea scale.","The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index Clinical Classification | BODE INDEX | BODE Index | BODE01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513399","Brooke Upper Extremity Rating Scale Clinical Classification","C130304","A standardized 6-item clinician rating scale for the assessment of upper extremity function in patients diagnosed with neuromuscular disease. The scale was developed by Brooke, et al. in 1981 to evaluate disease severity in patients with Duchenne muscular dystrophy.","Brooke Upper Extremity Rating Scale Clinical Classification | BUERS | BUERS1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086148","Center for Disease Control and Prevention Classification System for HIV-Infected Adults and Adolescents Clinical Classification","C124715","A standardized rating scale developed and revised by the Centers for Disease Control and Prevention (CDC) in 1993, which is a classification system used to assess the severity of HIV disease based on CD4 cell counts and the presence of specific HIV-related conditions.","Center for Disease Control and Prevention Classification System for HIV-Infected Adults and Adolescents Clinical Classification | CDC Classification System for HIV-Infected Adults and Adolescents | CDC HIV CLASSIFICATION FOR ADULTS AND ADOLESCENTS | CHIVC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555953","Children's Depression Rating Scale, Revised Clinical Classification","C155323","A standardized 17-item clinician rating scale for the assessment of depressive symptomology in children and adolescents. The instrument, which is based on the adult Hamilton Depression Rating Scale developed by Max Hamilton at the University of Leeds in 1960, was published by Poznanski and Mokros in 1996 as a rating scale for children 6 - 12 years of age. In 2010, Mayes et al. demonstrated its use in adolescents.","Children's Depression Rating Scale, Revised Clinical Classification | CDRS-R | CDRS1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935738","Covi Anxiety Scale Clinical Classification","C156675","A standardized three-item clinician-administered questionnaire published in 1982 by Lipman et al. that utilizes a five-point response scale to assess the severity of anxiety in adults based on patient verbal report, behavior, and somatic symptoms.","Covi Anxiety Scale Clinical Classification | COVI | COVI01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086531","JFK Coma Recovery Scale-Revised Clinical Classification","C124711","A standardized rating scale developed by Giacino et al in 1991, and modified and further characterized by Giacino et al in 2004, which is a classification system used to assist with differential diagnosis, prognostic assessment and treatment planning in patients with disorders of consciousness. This instrument contains 6 subscales addressing auditory, visual, motor, oromotor, communication, and arousal processes.","JFK Coma Recovery Scale-Revised Clinical Classification | CRS-R | CRSR01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086329","Framingham Heart Study Cardiovascular Disease 10-Year Risk Score Clinical Classification","C124707","A standardized rating scale developed by D'Agostino et al in 2008, which is a gender-specific classification system used to estimate the 10-year risk of cardiovascular disease (CVD). This estimation takes into consideration of an individual's gender, age, smoking history, treatment for blood pressure, as well as systolic blood pressure, total cholesterol and high-density lipoprotein (HDL) cholesterol levels.","Framingham Heart Study Cardiovascular Disease 10-Year Risk Score Clinical Classification | FCVD1 | FHS CVD 10-YEAR RISK | FHS CVD 10-Year Risk Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086362","GCS01","C124710","A standardized rating scale developed by Teasdale and Jennett in 1974, which is a classification system used to assess the level of consciousness. The NINDS version measures eye opening, motor and verbal responses.","Glasgow Coma Scale-NINDS Version 1.0 Clinical Classification | GCS NINDS V1.0 | GCS NINDS VERSION | GCS NINDS Version | GCS NINDS Version 1.0 | GCS01 | Glasgow Coma Scale-NINDS Version Clinical Classification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541258","Hamilton Anxiety Rating Scale Questionnaire","C102118","A standardized rating scale developed by M. Hamilton in 1959 which is used to evaluate the severity of an individual's state of neurotic anxiety. This instrument contains 14 questions or types of symptoms associated with anxiety such as fear, mood, insomnia, and somatic symptoms, which is completed during a semi-structured interview. Each symptom is rated on a scale of 0-4 with 0 being none and 4 being the most severe. A score of 0-17 is considered 'mild', while a score of 18-24 is 'mild to moderate' and a score greater than 24 is 'moderate to severe.'","Hamilton Anxiety Rating Scale Clinical Classification | HAM-A | HAMA | HAMA1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639712","Hamilton Depression Rating Scale 17 Item Clinical Classification","C100767","A standardized rating scale developed by M. Hamilton in 1960 which is used to evaluate the severity of an individual's depression. This instrument contains 17 questions or types of symptoms associated with depression such as anxiety, mood, insomnia, and somatic symptoms experienced within the past week and is completed during a semi-structured interview. Each symptom is rated on a scale of 0-2, 0-3, or 0-4 with 0 being absent and 2, 3, or 4 being the most severe. A score of 0-7 is considered normal while a score equal to or greater than 20 qualifies an individual for a clinical trial.","Hamilton Depression Rating Scale 17 Item Clinical Classification | HAMD 17 | HAMD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640518","Hamilton Depression Rating Scale 21-Item Clinical Classification","C102119","A standardized rating scale developed by M. Hamilton in 1960 which is used to evaluate the severity of an individual's depression. This version of the instrument contains all 21 questions or types of symptoms associated with depression such as anxiety, mood, insomnia, and somatic symptoms experienced within the past week and is completed during a semi-structured interview. Each symptom is rated on a scale of 0-2, 0-3, or 0-4 with 0 being absent and 2, 3, or 4 being the most severe.","Hamilton Depression Rating Scale 21-Item Clinical Classification | HAMD 21 | HAMD-21 | HAMD2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513957","Hamilton Depression Rating Scale-24 Item Clinical Classification","C130307","A standardized 24-item rating scale for the assessment of symptoms in patients diagnosed with depression. The original 17-item Hamilton Depression Scale, developed by Max Hamilton at the University of Leeds in 1960, was later modified to include 24 variables.","Hamilton Depression Rating Scale-24 Item Clinical Classification | HAMD 24 | HAMD3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513955","Hamilton Depression Rating Scale 6 Clinician Version Clinical Classification","C130306","A standardized 6-item clinician rating scale for the assessment of symptoms in patients diagnosed with depression. The original 17-item Hamilton Depression Scale, developed by Max Hamilton at the University of Leeds in 1960, was independently modified by Bech, et al. in 1975, using Rasch models, to create a subscale that contains six variables.","Hamilton Depression Rating Scale 6 Clinician Version Clinical Classification | HAM-D6 Clinician Version | HAMD 6 CLINICIAN VERSION | HAMD4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525824","HAS-BLED Bleeding Risk Score Clinical Classification","C138332","A scoring system developed by Ron Pisters et al. in 2010 to assess the risk of bleeding in patients with atrial fibrillation. The calculated score is determined based on the presence of the following risk factors: hypertension, abnormal kidney or liver function, previous history of stroke, a history of or predisposition to bleeding, labile INR, age over 65 years, and concomitant drug and alcohol use; and ranges from 1 to 9 points.","HAS-BLED Bleeding Risk Score Clinical Classification | HAS-BLED | HSB01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513959","Inventory of Depressive Symptomatology Clinician-Rated Version Clinical Classification","C130308","A standardized 30-item clinician-scored questionnaire that utilizes a 5-point rating scale for the assessment of the severity of depressive symptoms over the seven day period prior to evaluation. The questionnaire, which was created by Rush, et al. in 1986, originally consisted of 28 items including the nine diagnostic DSM-IV symptom domains used to characterize a major depressive episode, as well as items to address melancholic and atypical features. Two additional items were later added to address leaden paralysis and interpersonal rejection sensitivity.","Inventory of Depressive Symptomatology Clinician-Rated Version Clinical Classification | IDS-C | IDSC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513963","Kidney Donor Profile Index Clinical Classification","C130310","A standardized clinician scored index created by Rao et al. in 2009 that combines ten donor factors, including demographics and medical history, to calculate the likelihood of graft failure after deceased donor kidney transplant.","Kidney Donor Profile Index Clinical Classification | KDPI | KDPI01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526970","The Lansky Play-Performance Status Scale Clinical Classification","C138333","A parent-rated questionnaire created by Lansky et al. in 1985 to assess play activity over the past week in children ages 1 to 16 with cancer as an indicator of level of performance. Level of performance is scored from 0 to 100 based on active play, quiet play, degree of physical limitation, and degree of independence; with the interpretation ranging from fully active, normal performance (100), to moderately restricted (50 to 60), to completely disabled (10 or less).","The Lansky Play-Performance Status Scale Clinical Classification | LPPS SCALE | LPPSS1 | LPSS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899496","Coronary Artery Dissection NHLBI Grade Clinical Classification","C119105","A standardized grading system developed by the American College of Cardiology American Heart Association to describe coronary artery dissection. This grading system includes 6 classifications of dissection types A through F based on angiographic appearances.","Coronary Artery Dissection NHLBI Grade Clinical Classification | CADG01 | NHLBI CAD GRADE | NHLBI CAD Grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054416","Negative Symptom Assessment-16 Clinical Classification","C121009","A standardized rating scale developed by Axelrod et al in 1993, which is a classification system used to assess the presence, severity, and various negative symptoms associated with schizophrenia. This instrument contains 16 items and the characterization of negative symptoms is based on a 5-factor model: communication, emotion/affect, social involvement, motivation, and retardation.","Negative Symptom Assessment-16 Clinical Classification | NSA-16 | NSA01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520466","North Star Ambulatory Assessment Clinical Classification","C132531","A standardized 17-item scale that was developed by Elaine Scott and Michelle Eagle in 2011 to measure functional motor ability in ambulant children and adolescents with Duchenne muscular dystrophy. The instrument, which is partly based on the Hammersmith Motor Ability Scale (2003), utilizes a 3-point rating scale to grade activities ranging from standing to running, as well as abilities that are necessary for a patient to remain functionally ambulant and that are known to progressively deteriorate in untreated DMD.","North Star Ambulatory Assessment Clinical Classification | NSAA | NSAA1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523049","Psoriasis Area and Severity Index Clinical Classification","C135734","A standardized survey developed by Fredriksson and Pettersson in 1978 to calculate the intensity and extent of psoriatic plaques before, during, and after retinoid treatment in chronic plaquetype psoriasis. The instrument utilizes a 5-point rating scale to measure intensity and assigns a numerical score for the percentage of anatomical involvement.","Psoriasis Area and Severity Index Clinical Classification | PASI | PASI01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513353","Quick Inventory of Depressive Symptomatology Clinician-Rated Version Clinical Classification","C130309","A standardized 16-item clinician-scored questionnaire, derived from the 30-item Inventory of Depressive Symptomatology (IDS), that utilizes a 5-point rating scale for the assessment of the severity of depressive symptoms over the seven day period prior to evaluation. The original questionnaire, created by Rush et al. in 1986, includes the nine diagnostic DSM-IV symptom domains that are used to characterize a major depressive episode, as well as items to address melancholic and atypical features. The shortened, 16-item version was initially developed by Rush et al. in 2000 by selecting only items from the original scale that assessed DSM-IV criterion diagnostic symptoms.","Quick Inventory of Depressive Symptomatology Clinician-Rated Version Clinical Classification | QIDS-C | QIDSC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086832","Reynolds Cardiovascular Disease 10-Year Risk Score Clinical Classification","C124708","A standardized rating scale developed and modified by Ridker et al in 2007 and 2008, which is a classification system used to estimate the 10-year risk of cardiovascular disease (CVD). This estimation takes into consideration of an individual's gender, age, smoking and CVD family histories, as well as systolic blood pressure, high sensitivity C-reactive protein (hsCRP), total cholesterol and high-density lipoprotein (HDL) cholesterol levels.","Reynolds Cardiovascular Disease 10-Year Risk Score Clinical Classification | RCVD01 | REYNOLDS CVD 10-YEAR RISK | Reynolds CVD 10-Year Risk Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086888","Tanner Scale-Boy","C124703","A standardized rating scale developed by Marshal and Tanner in 1970, which is a classification system used to measure physical development in children, adolescents and adults. The boy version of the tanner scale assesses the different stages of physical maturity based on testicular volume, genitalia growth and the development of pubic hair. This instrument has 5 stages.","Tanner Scale Boy Version | TANN02 | TANNER SCALE BOY | Tanner Scale Boy Version Clinical Classification | Tanner Scale-Boy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086889","Tanner Scale-Girl","C124704","A standardized rating scale developed by Marshal and Tanner in 1969, which is a classification system used to measure physical development in children, adolescents and adults. The girl version of the tanner scale assesses the different stages of physical maturity based on breast development and the growth of pubic hair. This instrument has 5 stages.","Tanner Scale Girl Version | TANN01 | TANNER SCALE GIRL | Tanner Scale Girl Version Clinical Classification | Tanner Scale-Girl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899492","Coronary Thrombus TIMI Grade Clinical Classification","C119104","A standardized grading system developed by the Thrombolysis in Myocardial Infarction (TIMI) Study Group to detect the presence of, and to describe the relative size of coronary thrombus via angiographic assessments.","Coronary Thrombus TIMI Grade Clinical Classification | TIMG01 | TIMI THROMBUS GRADE | TIMI Thrombus Grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555951","Unified Huntington's Disease Rating Scale 1999 Version Clinical Classification","C155324","An updated and expanded version of the standardized clinician rating scale developed by the Huntington Study Group in 1996 for the assessment of motor function, cognitive function, behavioral abnormalities, and functional capacity in Huntington's Disease.","Unified Huntington's Disease Rating Scale 1999 Version Clinical Classification | UHDR1 | UHDRS 1999 | UHDRS 1999 Version",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539773","Veterans Administration Lung Study Group Clinical Classification","C141685","A standardized two-stage classification system that was developed by the Veterans Administration Lung Study Group (VALG) in 1957 for the clinical staging of lung cancer as limited or extensive based on the anatomical scope of the disease.","Veterans Administration Lung Study Group Clinical Classification | VALG | VALG01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513507","Vignos Lower Extremity Rating Scale Clinical Classification","C130305","A standardized 10-item clinician rating scale for the assessment of lower extremity function in patients diagnosed with neuromuscular disease. The scale was developed by Vignos, et al. in 1963 to evaluate ability and methods used for elevation and ambulation in patients with childhood progressive muscular dystrophy.","Vignos Lower Extremity Rating Scale Clinical Classification | VLERS | VLERS1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890564","West Haven Hepatic Encephalopathy Grade Clinical Classification","C124709","A standardized rating scale developed by Blei and Cordoba in 2001, which is a classification system used to describe the severity of hepatic encephalopathy based on the level of mental status and intellectual function. This instrument has 4 grades.","West Haven Hepatic Encephalopathy Grade Clinical Classification | WEST HAVEN HEPATIC ENCEPHALOPATHY GRADE | WHEG01 | West Haven Criteria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086966","World Health Organization Clinical Staging of HIV/AIDS for Adults and Adolescents Clinical Classification","C124713","A standardized rating scale developed by the World Health Organization (WHO) in 2007, which is a classification system used for immunological staging of HIV/AIDS in adults and adolescents with established HIV infection. This instrument classifies HIV disease on the basis of clinical manifestations.","World Health Organization Clinical Staging of HIV/AIDS for Adults and Adolescents Clinical Classification | WHIVS1 | WHO Clinical Staging of HIV/AIDS for Adults and Adolescents | WHO HIV STAGING FOR ADULTS AND ADOLESCENTS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086967","World Health Organization Clinical Staging of HIV/AIDS for Children Clinical Classification","C124714","A standardized rating scale developed by the World Health Organization (WHO) in 2007, which is a classification system used for immunological staging of HIV/AIDS in children with established HIV infection. This instrument classifies HIV disease on the basis of clinical manifestations.","World Health Organization Clinical Staging of HIV/AIDS for Children Clinical Classification | WHIVS2 | WHO Clinical Staging of HIV/AIDS for Children | WHO HIV STAGING FOR CHILDREN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049616","Model for End Stage Liver Disease Clinical Classification","C121008","A standardized rating scale developed by Malinchoc et al in 2000, which is a classification system used to assess severity of chronic liver disease and to determine the urgency of a subject needing a liver transplant within the next three months. This instrument uses the values of serum bilirubin and creatinine, and the international normalized ratio for prothrombin time (INR) to predict survival for patients with advanced liver disease.","Model for End Stage Liver Disease Clinical Classification | MELD | MELD01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879956","CDISC SDTM Vital Sign Terminology by Code","C66741","Terminology codelist used with Vital Sign within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.","CDISC SDTM Vital Sign Test Code Terminology | SDTM-VSTESTCD | VSTESTCD | Vital Signs Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347269","CDISC SDTM ECG Finding Terminology","C71150","Terminology codelist used with ECG Findings and Abnormalities within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.","CDISC SDTM ECG Finding Terminology | ECG Result | EGSTRESC | SDTM-EGSTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053501","CDISC SDTM Holter ECG Results Terminology","C120522","Terminology associated with the Holter ECG results codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Holter ECG Results Terminology | HESTRESC | Holter ECG Results | SDTM-HESTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346542","2:1 Atrioventricular Block by ECG Finding","C71044","An electrocardiographic finding of a supraventricular rhythm where the ratio of impulses generated above the atrioventricular node to the number of impulses conducted through to the ventricles is 2:1. This is manifested on the ECG as 2 P waves per QRS complex. (CDISC)","2:1 Atrioventricular Block by ECG Finding | 2:1 AV BLOCK | 2:1 AV block | 2:1 Atrioventricular Block | 2:1 Atrioventricular Block by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831768","50 Hertz Noise by ECG Finding","C114165","An electrocardiographic recording showing power line interference with the electrocardiographic signal. The artifact amplitude modulation has the same frequency as the AC power system present (50 Hz). (CDISC)","50 Hertz Noise by ECG Finding | 50 Hz Artifact | 50 Hz NOISE | 50 Hz Noise",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831766","60 Hertz Noise by ECG Finding","C114164","An electrocardiographic recording showing power line interference with the electrocardiographic signal. The artifact amplitude modulation has the same frequency as the AC power system present (60 Hz). (CDISC)","60 Hertz Noise by ECG Finding | 60 Hz Artifact | 60 Hz NOISE | 60 Hz Noise",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900135","Aberrantly Conducted Complexes by ECG Finding","C116132","An electrocardiographic finding of abnormal QRS complex(es) that are supraventricular in origin, and that are wide secondary to aberrant AV conduction. (CDISC)","Aberrantly Conducted Complexes by ECG Finding | ABERRANTLY CONDUCTED COMPLEXES | Aberrantly Conducted Beats",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900169","CV ENDPOINTS ISCHEMIC ECG CHANGES","C116138","An electrocardiographic finding, in the absence of left ventricular hypertrophy (LVH) and left bundle branch block pattern on ECG, of either a) new (or presumed new) ST elevation at the J point in two contiguous leads with the following cut-points: greater than or equal to 0.1 mV in all leads other than leads V2-V3 where the following cut points apply: greater than or equal to 0.2 mV in men age greater than or equal to 40 years, greater than or equal to 0.25 mV in men age greater than 40 years, or greater than or equal to 0.15 mV in women; or b) new (or presumed new) horizontal or down-sloping ST depression greater than or equal to 0.05 mV in two contiguous leads, and/or T wave inversion greater than or equal to 0.1 mV in two contiguous leads with a prominent R wave, or R/S ratio greater than 1. (Thygesen K, Alpert JS, Jaffe AS, et al.: the Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. J Am Coll Cardiol 60(16):1-18, 2012)","ACC/AHA Ischemic ECG Changes | CV ENDPOINTS ISCHEMIC ECG CHANGES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0078888","Accelerated Idioventricular Rhythm by ECG Finding","C62266","An electrocardiographic finding of idioventricular rhythm with a rate greater than 50 beats per minute. (CDISC)","Accelerated Idioventricular Rhythm by ECG Finding | ACCELERATED IDIOVENTRICULAR RHYTHM | AIVR | Accelerated Idioventricular Rhythm | Accelerated Idioventricular Rhythm by EKG Finding | Accelerated idioventricular rhythm",,,,,,,,,,,,,,,"4247537","Accelerated idioventricular rhythm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2349195","Acute Anterior Wall Myocardial Infarction","C71065","An electrocardiographic finding of pathologic Q waves with accompanying ST elevation in leads V3 and V4, which is suggestive of acute myocardial infarction of the anterior wall of the left ventricle. (CDISC)","Acute Anterior Myocardial Infarction by ECG Finding | ACUTE ANTERIOR WALL MYOCARDIAL INFARCTION | Acute Anterior MI | Acute Anterior Myocardial Infarction by EKG Finding | Acute Anterior Wall Myocardial Infarction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0155627","Acute Anterolateral Myocardial Infarction by ECG Finding","C102591","An electrocardiographic finding of pathologic Q waves with accompanying ST elevation in leads V3 through V6, which is suggestive of acute myocardial infarction of the anterolateral wall of the left ventricle. (CDISC)","Acute Anterolateral Myocardial Infarction by ECG Finding | ACUTE ANTEROLATERAL WALL MYOCARDIAL INFARCTION | Acute Anterolateral Myocardial Infarction by EKG Finding | Acute Anterolateral Wall Myocardial Infarction",,,,,,,,,,,,,,,"438438","Acute myocardial infarction of anterolateral wall",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640830","Acute Anteroseptal Myocardial Infarction by ECG Finding","C102592","An electrocardiographic finding of pathologic Q waves with accompanying ST elevation in leads V1 through V4, which is suggestive of acute myocardial infarction of the anteroseptal wall of the left ventricle. (CDISC)","Acute Anteroseptal Myocardial Infarction by ECG Finding | ACUTE ANTEROSEPTAL WALL MYOCARDIAL INFARCTION | Acute Anteroseptal Myocardial Infarction by EKG Finding | Acute Anteroseptal Wall Myocardial Infarction | Acute anteroseptal MI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831739","Acute Extensive Anterior Wall Myocardial Infarction by ECG Finding","C106496","An electrocardiographic finding of pathologic Q waves with accompanying ST elevation in leads V1 to V6, I and aVL, which is suggestive of acute myocardial infarction involving the anterior and anterolateral walls of the left ventricle. (CDISC)","Acute Extensive Anterior Wall Myocardial Infarction by ECG Finding | ACUTE EXTENSIVE ANTERIOR WALL MYOCARDIAL INFARCTION | Acute Extensive Anterior Wall Myocardial Infarction by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0264704","Acute High Lateral Myocardial Infarction by ECG Finding","C102593","An electrocardiographic finding of pathologic Q waves with accompanying ST elevation in leads I and aVL, which is suggestive of acute myocardial infarction of the high lateral wall of the left ventricle. (CDISC)","Acute High Lateral Myocardial Infarction by ECG Finding | ACUTE HIGH LATERAL WALL MYOCARDIAL INFARCTION | Acute High Lateral Myocardial Infarction by EKG Finding | Acute High Lateral Wall Myocardial Infarction",,,,,,,,,,,,,,,"4275436","Acute myocardial infarction of high lateral wall",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3536991","Acute Inferior Myocardial Infarction by ECG Finding","C71066","An electrocardiographic finding of pathologic Q waves with accompanying ST elevation in leads III, aVF and often II, which is suggestive of acute myocardial infarction of the inferior wall of the left ventricle. (CDISC)","Acute Inferior Myocardial Infarction by ECG Finding | ACUTE INFERIOR WALL MYOCARDIAL INFARCTION | Acute Inferior MI | Acute Inferior Myocardial Infarction by EKG Finding | Acute Inferior Wall Myocardial Infarction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0340311","Acute Lateral Myocardial Infarction by ECG Finding","C71067","An electrocardiographic finding of pathologic Q waves with accompanying ST elevation in leads V5, V6, I and aVL, which is suggestive of acute myocardial infarction of the lateral wall of the left ventricle. (CDISC)","Acute Lateral Myocardial Infarction by ECG Finding | ACUTE LATERAL WALL MYOCARDIAL INFARCTION | Acute Lateral MI | Acute Lateral Myocardial Infarction by EKG Finding | Acute Lateral Wall Myocardial Infarction",,,,,,,,,,,,,,,"436706","Acute myocardial infarction of lateral wall",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3541950","Acute Myocardial Infarction by ECG Finding","C101596","An electrocardiographic finding showing a current of injury with ST elevation. No specification is provided for localization. (CDISC)","Acute Myocardial Infarction by ECG Finding | ACUTE MYOCARDIAL INFARCTION | Acute Myocardial Infarction | Acute Myocardial Infarction by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537180","Acute Posterior Myocardial Infarction by ECG Finding","C71068","An electrocardiographic finding in leads V1 or V2 of an initial R wave duration greater than or equal to 40 ms, R wave greater than S wave, upright T wave, with accompanying ST elevation, which is suggestive of acute myocardial infarction of the posterior wall of the left ventricle. Evidence of inferior or lateral myocardial infarction is usually also present. (CDISC)","Acute Posterior Myocardial Infarction by ECG Finding | ACUTE POSTERIOR WALL MYOCARDIAL INFARCTION | Acute Posterior MI | Acute Posterior Myocardial Infarction by EKG Finding | Acute Posterior Wall Myocardial Infarction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640832","Acute Right Ventricular Myocardial Infarction by ECG Finding","C102594","An electrocardiographic finding in leads V1 or V2 of an initial R wave duration greater than or equal to 40 ms, R wave greater than S wave, upright T wave, with accompanying ST elevation, which is suggestive of acute myocardial infarction of the ventricular wall of the left ventricle. Evidence of inferior or lateral myocardial infarction is usually also present. (CDISC)","Acute Right Ventricular Myocardial Infarction by ECG Finding | ACUTE RIGHT VENTRICULAR WALL MYOCARDIAL INFARCTION | Acute Right Ventricular Myocardial Infarction by EKG Finding | Acute Right Ventricular Wall Myocardial Infarction | Acute Right ventricular MI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640833","Acute Septal Myocardial Infarction by ECG Finding","C102595","An electrocardiographic finding of pathologic Q waves with accompanying ST elevation in leads V1, V2 and often V3, which is suggestive of acute myocardial infarction of the intraventricular septum. (CDISC)","Acute Septal Myocardial Infarction by ECG Finding | ACUTE SEPTAL WALL MYOCARDIAL INFARCTION | Acute Septal Myocardial Infarction by EKG Finding | Acute Septal Wall Myocardial Infarction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831560","All Precordial Electrodes Are Disconnected by ECG Finding","C114159","An electrocardiographic recording in which all precordial electrodes are disconnected resulting in missing waveforms (flat line) of all leads V1 - V6. (CDISC)","All Precordial Electrodes Are Disconnected by ECG Finding | ALL PRECORDIAL ELECTRODES DISCONNECTED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827201","Alternating Current Noise by ECG Finding","C114149","An electrocardiographic recording showing power line interference with the electrocardiographic signal. The artifact amplitude modulation has the same frequency as the AC power system present (usually 50 Hz or 60 Hz). (CDISC)","Alternating Current Noise by ECG Finding | AC NOISE | AC Noise",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0340293","Anterior Myocardial Infarction by ECG Finding","C71069","An electrocardiographic finding of pathologic Q waves in leads V3 and V4, which is suggestive of myocardial infarction of the anterior wall of the left ventricle. (CDISC)","Anterior Myocardial Infarction by ECG Finding | ANTERIOR WALL MYOCARDIAL INFARCTION | Anterior MI | Anterior Myocardial Infarction by EKG Finding | Anterior Wall Myocardial Infarction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642314","Anterolateral Myocardial Infarction by ECG Finding","C35303","An electrocardiographic finding of pathologic Q waves in leads V3 through V6, which is suggestive of myocardial infarction of the anterolateral wall of the left ventricle. (CDISC)","Anterolateral Myocardial Infarction by ECG Finding | ANTEROLATERAL WALL MYOCARDIAL INFARCTION | Anterolateral Myocardial Infarction by EKG Finding | Anterolateral Wall Myocardial Infarction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642315","Anteroseptal Myocardial Infarction by ECG Finding","C35304","An electrocardiographic finding of pathologic Q waves in leads V1 through V4, which is suggestive of myocardial infarction of the anteroseptal wall of the left ventricle. (CDISC)","Anteroseptal Myocardial Infarction by ECG Finding | ANTEROSEPTAL WALL MYOCARDIAL INFARCTION | Anteroseptal MI | Anteroseptal Myocardial Infarction by EKG Finding | Anteroseptal Wall Myocardial Infarction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3715087","Artifact Lead Signal by ECG Finding","C114162","An electrocardiographic recording in which one or more leads display extraneous signals which do not represent cardiac electrical activity. (CDISC)","Artifact Lead Signal by ECG Finding | ARTIFACT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1960143","Asystole by ECG Finding","C116130","An electrocardiographic finding showing no cardiac electrical activity on the monitor or printed strip for the entire duration of the recording. (CDISC)","Asystole by ECG Finding | ASYSTOLE | Asystole",,,,,,,,,,,,,,,"4146418","EKG: asystole",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0262382","Atrial Bigeminy by ECG Finding","C102596","An electrocardiographic finding of a sinus beat followed by a premature atrial complexes for three or more consecutive cycles; a regularly irregular rhythm of normal and abnormal P waves in a 1-1 ratio. (CDISC)","Atrial Bigeminy by ECG Finding | ATRIAL BIGEMINY | Atrial Bigeminy | Atrial Bigeminy by EKG Finding",,,,,,,,,,,,,,,"4088504","Atrial bigeminy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640834","Atrial Couplet by ECG Finding","C102597","An electrocardiographic finding in which two premature atrial complexes occur sequentially. (CDISC)","Atrial Couplet by ECG Finding | ATRIAL COUPLETS | Atrial Couplet | Atrial Couplet by EKG Finding | Atrial Couplets",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348360","EKG Finding Atrial Enlargement","C71039","An electrocardiographic finding which comprises left, right or bilateral atrial enlargement. This is may be characterized by prolonged P wave duration, increased P wave amplitude, or multi-component P waves. (CDISC)","Atrial Enlargement by ECG Finding | ATRIAL ENLARGEMENT | Atrial Enlargement | Atrial Enlargement by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0344434","Atrial Fibrillation by ECG Finding","C111092","An electrocardiographic finding of a supraventricular arrhythmia characterized by the replacement of consistent P waves by rapid oscillations or fibrillatory waves that vary in size, shape and timing and are accompanied by an irregularly irregular ventricular response. (CDISC)","Atrial Fibrillation by ECG Finding | AF | AFib | ATRIAL FIBRILLATION | Atrial Fibrillation | Atrial Fibrillation by EKG Finding | Atrial fibrillation",,,,,,,,,,,,,,,"4064452","ECG: atrial fibrillation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0344423","Atrial Flutter by ECG Finding","C111094","An electrocardiographic finding of an organized, regular atrial rhythm with atrial rate of 240-340 beats per minute. Multiple P waves typically appear in the inferior leads in a saw tooth like pattern between the QRS complexes. (CDISC)","Atrial Flutter by ECG Finding | ATRIAL FLUTTER | Atrial Flutter | Atrial Flutter by EKG Finding | Atrial flutter",,,,,,,,,,,,,,,"4065288","EKG: atrial flutter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033036","Atrial Premature Complex by ECG Finding","C62257","An electrocardiographic finding of an ectopic impulse originating in the atria and not specifically in the sinus node. The P wave morphology of these complexes is often different from a sinus P wave and the RR intervals preceding these complexes is also shorter than those of the regular beats. (CDISC)","Atrial Premature Complex by ECG Finding | APC | Atrial Premature Complex | Atrial Premature Complex by EKG Finding | Atrial premature complex(es) | PAC | PREMATURE ATRIAL COMPLEXES | Premature Atrial Complex | Premature atrial complex | Premature atrial complexes | SVE | Supraventricular Extra Beat | Supraventricular Premature Beat",,,,,,,,,,,,,,,"4065285|4109365|4115173|4144613|4236004|441872","EKG: atrial ectopics|Premature atrial contraction|Atrial premature complex|ECG: ectopic beats - premature atrial contraction|Ectopic atrial beats|Supraventricular premature beats",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--|--|--|--"
"C2059391","Atrial Tachycardia by ECG Finding","C111105","An electrocardiographic finding of an organized, regular atrial rhythm with atrial rate between 101 and 240 beats per minute. The P wave morphology must be distinct from the sinus P wave morphology. (CDISC)","Atrial Tachycardia by ECG Finding | ATRIAL TACHYCARDIA | Atrial Tachycardia | Atrial Tachycardia by EKG Finding | Atrial tachycardia",,,,,,,,,,,,,,,"37017190","EKG: atrial tachycardia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3900008","Atrial Tachycardia With AV Block by ECG Finding","C119249","An electrocardiographic recording that demonstrates atrial tachycardia without 1:1 atrioventricular conduction.","Atrial Tachycardia With AV Block by ECG Finding | ATRIAL TACHYCARDIA WITH AV BLOCK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0428993","Atrial Trigeminy by ECG Finding","C102598","An electrocardiographic finding of two sinus beats followed by a premature atrial complex for 3 or more consecutive cycles; a regularly irregular rhythm of normal and abnormal P waves in a 2-1 ratio. (CDISC)","Atrial Trigeminy by ECG Finding | ATRIAL TRIGEMINY | Atrial Trigeminy | Atrial Trigeminy by EKG Finding",,,,,,,,,,,,,,,"4091903","Atrial trigeminy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL479805","Atrioventricular Dissociation by ECG Finding","C71045","An electrocardiographic finding in which the electrical activity of the atria and ventricles are independent of one another. (CDISC)","Atrioventricular Dissociation by ECG Finding | ATRIOVENTRICULAR DISSOCIATION | AV Dissociation | Atrioventricular Dissociation | Atrioventricular Dissociation by EKG Finding | Atrioventricular dissociation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039232","Atrioventricular Nodal Reentry Tachycardia by ECG Finding","C35058","An electrocardiographic finding of a regular supraventricular tachycardia due to reentry within the AV node. It is characterized by P waves which typically occur nearly simultaneously with the QRS complex, resulting in a P wave which is obscured by the QRS, merged with the QRS or which may follow the QRS. (CDISC)","Atrioventricular Nodal Reentry Tachycardia by ECG Finding | AV NODE RE-ENTRY | AV Node Reentrant Supraventricular Tachycardia | Atrioventricular Nodal Reentrant Tachycardia | Atrioventricular Nodal Reentry Tachycardia | Atrioventricular Nodal Reentry Tachycardia by EKG Finding",,,,,,,,,,,,,,,"4124698","Re-entrant atrioventricular node tachycardia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4023220","Atrioventricular Reentrant Tachycardia by ECG Finding","C62261","An electrocardiographic finding of a regular supraventricular tachycardia which utilizes an atrioventricular bypass tract as its retrograde limb (orthodromic tachycardia) or as its antegrade limb (antidromic tachycardia). QRS complexes during sinus rhythm may show preexcitation. During orthodromic tachycardia the preexcitation is not present and a retrograde P wave may appear after the QRS complex. During antidromic tachycardia the QRS complex is preexcited. (CDISC)","Atrioventricular Reentrant Tachycardia by ECG Finding | AV RE-ENTRANT TACHYCARDIA | AV Reentrant Supraventricular Tachycardia | AV Reentrant Tachycardia | Atrioventricular Reentrant Tachycardia | Atrioventricular Reentrant Tachycardia by EKG Finding",,,,,,,,,,,,,,,"4124699","Re-entrant atrioventricular tachycardia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3715208","AV Block First Degree by ECG Finding","C111088","An electrocardiographic finding of prolonged PR interval for a specific population. For adults one common threshold is a PR interval greater than 0.20 seconds. Note that other thresholds may be applicable. (CDISC)","AV Block First Degree by ECG Finding | 1ST DEGREE AV BLOCK | 1st degree AV block | AV Block First Degree | AV Block First Degree by EKG Finding | First Degree AV Block | First Degree Atrioventricular Block | PR Prolongation | Prolonged AV Conduction | Prolonged PR Interval | Prolonged PR interval",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714697","AV Block Second Degree by ECG Finding","C62016","An electrocardiographic finding of intermittent failure of atrial electrical impulse conduction to the ventricles. This is manifest on the ECG by regular P waves which intermittently are not followed by QRS complexes. (CDISC)","AV Block Second Degree by ECG Finding | 2ND DEGREE AV BLOCK | AV Block Second Degree | AV Block Second Degree by EKG Finding | Intermittent AV Block | Second Degree AV Block | Second Degree Atrioventricular Block",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811814","AV Block Second Degree Mobitz Type I by ECG Finding","C111089","An electrocardiographic finding of intermittent failure of atrial electrical impulse conduction to the ventricles, characterized by a progressively lengthening PR interval prior to the block of an atrial impulse. (CDISC)","AV Block Second Degree Mobitz Type I by ECG Finding | AV Block Second Degree Mobitz Type I | AV Block Second Degree Mobitz Type I by EKG Finding | AV Block Second Degree Möbitz Type I | AV Block Second Degree Möbitz Type I by ECG Finding | AV Block Second Degree Möbitz Type I by EKG Finding | AV MOBITZ I | AV Mobitz I | Mobitz I | Mobitz I Second Degree AV Block | Mobitz Type I Second Degree AV Block | Möbitz I | Möbitz Type I Second Degree AV Block | Second Degree Atrioventricular Block Mobitz Type I | Second Degree Atrioventricular Block Möbitz Type I | Second degree AV block- Mobitz type I | Second-degree AV block, Mobitz type I (Wenckebach) | Type 1 2nd degree AV Block | Type 1 Second Degree AV Block | Type 1 Second Degree Atrioventricular Block | Wenckebach | Wenckebach Block",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811815","AV Block Second Degree Mobitz Type II by ECG Finding","C111090","An electrocardiographic finding of intermittent failure of atrial electrical impulse conduction to the ventricles, characterized by a relatively constant PR interval prior to the block of an atrial impulse.","AV Block Second Degree Mobitz Type II by ECG Finding | AV Block Second Degree Mobitz Type II | AV Block Second Degree Mobitz Type II by EKG Finding | AV Block Second Degree Möbitz Type II | AV Block Second Degree Möbitz Type II by ECG Finding | AV Block Second Degree Möbitz Type II by EKG Finding | AV MOBITZ II | Mobitz II | Mobitz II AV Block | Mobitz II Second Degree AV Block | Mobitz Type II Second Degree AV Block | Möbitz II | Möbitz Type II Second Degree AV Block | Second Degree Atrioventricular Block Mobitz Type II | Second Degree Atrioventricular Block Möbitz Type II | Type 2 2nd degree AV Block | Type 2 Second Degree AV Block | Type II Second Degree AV Block | Type II Second Degree Atrioventricular Block",,,,,,,,,,,,,,,"4138921","EKG: Mobitz type II atrioventricular block",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3831400","Baseline Wander by ECG Finding","C114147","An electrocardiographic recording in which the isoelectric line in one or more leads is vertically displaced resulting in low frequency upward and downward movements of the signal with varying amplitudes. (CDISC)","Baseline Wander by ECG Finding | BASELINE WANDER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3809617","Biventricular Hypertrophy by ECG Finding","C106502","An electrocardiographic finding suggestive of enlargement or thickening of both ventricles, with a combination of findings which are related to LVH and RVH, such as voltage criteria for LVH in the presence of marked right axis deviation. (CDISC)","Biventricular Hypertrophy by ECG Finding | BIVENTRICULAR HYPERTROPHY | Biventricular Hypertrophy by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL436902","Blocked Atrial Premature Complex by ECG Finding","C102603","An electrocardiographic finding of premature atrial complexes which are not conducted to the ventricle, and which are not followed by a QRS complex. (CDISC)","Blocked Atrial Premature Complex by ECG Finding | Atrial premature complexes, nonconducted | Blocked Atrial Premature Complex | Blocked Atrial Premature Complex by EKG Finding | Non-conducted SVE | PREMATURE ATRIAL COMPLEXES BLOCKED | Premature Atrial Complex Blocked | Premature Atrial Complexes Non-conducted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984919","Borderline QTcB","C92228","An electrocardiographic finding in which the QT interval corrected for heart rate using Bazett's formula is slightly prolonged. Thresholds for different age, gender, and patient populations exist. (CDISC)","Borderline QTcB | BORDERLINE QTCB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984920","Borderline QTcF","C92229","An electrocardiographic finding in which the QT interval corrected for heart rate using Fridericia's formula is slightly prolonged. Thresholds for different age, gender, and patient populations exist. (CDISC)","Borderline QTcF | BORDERLINE QTCF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812171","Bradycardia by ECG Finding","C111120","An electrocardiographic finding of abnormally slow heart rate. Thresholds for different age, gender, and patient populations exist.","Bradycardia by ECG Finding | BRADYCARDIA | Bradycardia | Bradycardia by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831255","Brugada Syndrome Pattern by ECG Finding","C106503","An electrocardiographic finding of complete or incomplete right bundle branch block accompanied by ST elevation in leads V1-V3. This may be noted at rest or can be provoked by medication challenge. (CDISC)","Brugada Syndrome Pattern by ECG Finding | BRUGADA SYNDROME PATTERN | Brugada Syndrome Pattern by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055159","Defibrillator Discharge by ECG Finding","C120609","An electrocardiographic tracing that is generated by cardioversion or defibrillation.","Defibrillator Discharge by ECG Finding | DEFIBRILLATOR DISCHARGE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880434","Delta Wave by ECG Finding","C62258","An electrocardiographic finding of initial slurring (delta wave) of the QRS complex due to the presence of an accessory pathway. This characteristic ECG pattern is typically seen in Wolff-Parkinson-White syndrome. (CDISC)","Delta Wave by ECG Finding | DELTA WAVE | Delta Wave | Delta Wave by EKG Finding | Delta wave",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541877","Dextrocardia by ECG Finding","C102623","An electrocardiographic finding suggestive of dextrocardia with situs inversus, characterized by reversal of normal anterior R wave progression and the appearance of reversal of the right and left arm electrodes. (CDISC)","Dextrocardia by ECG Finding | DEXTROCARDIA | Dextrocardia | Dextrocardia by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830475","Disconnected Limb Electrodes by ECG Finding","C114151","An electrocardiographic recording in which one or more of the limb electrodes are disconnected resulting in missing waveforms (often flat lines) of the respective leads. (CDISC)","Disconnected Limb Electrodes by ECG Finding | LIMB ELECTRODE(S) DISCONNECTED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830474","Disconnected Precordial Electrode V1 by ECG Finding","C114153","An electrocardiographic recording in which the electrode for lead V1 is disconnected resulting in missing waveforms (flat line) for lead V1. (CDISC)","Disconnected Precordial Electrode V1 by ECG Finding | PRECORDIAL ELECTRODE V1 DISCONNECTED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827360","Disconnected Precordial Electrode V2 by ECG Finding","C114154","An electrocardiographic recording in which the electrode for lead V2 is disconnected resulting in missing waveforms (flat line) for lead V2. (CDISC)","Disconnected Precordial Electrode V2 by ECG Finding | PRECORDIAL ELECTRODE V2 DISCONNECTED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830473","Disconnected Precordial Electrode V3 by ECG Finding","C114155","An electrocardiographic recording in which the electrode for lead V3 is disconnected resulting in missing waveforms (flat line) for lead V3. (CDISC)","Disconnected Precordial Electrode V3 by ECG Finding | PRECORDIAL ELECTRODE V3 DISCONNECTED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830472","Disconnected Precordial Electrode V4 by ECG Finding","C114156","An electrocardiographic recording in which the electrode for lead V4 is disconnected resulting in missing waveforms (flat line) for lead V4. (CDISC)","Disconnected Precordial Electrode V4 by ECG Finding | PRECORDIAL ELECTRODE V4 DISCONNECTED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830471","Disconnected Precordial Electrode V5 by ECG Finding","C114157","An electrocardiographic recording in which the electrode for lead V5 is disconnected resulting in missing waveforms (flat line) for lead V5. (CDISC)","Disconnected Precordial Electrode V5 by ECG Finding | PRECORDIAL ELECTRODE V5 DISCONNECTED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830470","Disconnected Precordial Electrode V6 by ECG Finding","C114158","An electrocardiographic recording in which the electrode for lead V6 is disconnected resulting in missing waveforms (flat line) for lead V6. (CDISC)","Disconnected Precordial Electrode V6 by ECG Finding | PRECORDIAL ELECTRODE V6 DISCONNECTED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640850","Early R Wave Transition by ECG Finding","C102628","An electrocardiographic finding where the amplitude of the R wave becomes greater than the amplitude of the S wave in the QRS complex at an unusually early point in the precordial leads, usually in leads V1 or V2. (CDISC)","Early R Wave Transition by ECG Finding | EARLY R WAVE TRANSITION | Early R Wave Progression | Early R Wave Transition | Early R Wave Transition by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1997354","Early Repolarization","C102629","An electrocardiographic finding of J point and ST segment elevation in the absence of other signs of acute ischemia or pericarditis. (CDISC)","Early Repolarization | EARLY REPOLARIZATION | ERP | Early Repolarization Pattern | Early Ventricular Repolarization",,,,,,,,,,,,,,,"4326509","Early repolarization",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3830352","ECG Acquired with Precordial Electrodes Placed on the Right Chest","C114175","An electrocardiographic recording in which the precordial electrodes have been placed over the right chest and record a right sided ECG. (CDISC)","ECG Acquired with Precordial Electrodes Placed on the Right Chest | ECG ACQUIRED WITH PRECORDIAL ELECTRODES PLACED ON RIGHT CHEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830351","ECG Evaluation Not Performed Due to Corrupted Digital ECG File","C114181","A digital electrocardiographic recording which is corrupted (i.e. ECG signal cannot be restored) such that measurements and/or interpretation cannot be performed. (CDISC)","ECG Evaluation Not Performed Due to Corrupted Digital ECG File | ECG EVALUATION NOT PERFORMED DUE TO CORRUPTED DIGITAL ECG FILE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830350","ECG Evaluation Not Performed Due to Poor Quality of Printed ECG","C114180","A printed electrocardiographic recording with poor printout quality (e.g. a faded paper ECG tracing or ECG with inconsistent printing speed) such that measurements and/or interpretation cannot be performed. (CDISC)","ECG Evaluation Not Performed Due to Poor Quality of Printed ECG | ECG EVALUATION NOT PERFORMED DUE TO POOR QUALITY OF PRINTED ECG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830349","ECG Evaluation Not Performed Due to Unknown ECG Amplitude Gain or Recording Speed","C114178","An electrocardiographic recording in which measurements and/or interpretation are not performed because the ECG amplitude gain and/or recording speed are not known. (CDISC)","ECG Evaluation Not Performed Due to Unknown ECG Amplitude Gain or Recording Speed | ECG EVALUATION NOT PERFORMED DUE TO UNKNOWN ECG AMPLITUDE GAIN OR RECORDING SPEED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830347","ECG Waveforms Not Present","C114163","An electrocardiographic recording that displays flat lines (no waveforms are visible) in all leads present. (CDISC)","ECG Waveforms Not Present | NO ECG WAVEFORMS PRESENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880480","Ectopic Atrial Rhythm by ECG Finding","C62245","An electrocardiographic finding of a regular atrial rhythm with atrial rate of less than 101 beats per minute which does not originate in the sinus node, and which is characterized by P waves whose morphology differs from the P wave morphology during sinus rhythm. (CDISC)","Ectopic Atrial Rhythm by ECG Finding | ECTOPIC ATRIAL RHYTHM | Ectopic Atrial Rhythm | Ectopic Atrial Rhythm by EKG Finding | Ectopic Supraventricular Rhythm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348377","Ectopic Ventricular Rhythm by ECG Finding","C71042","An electrocardiographic finding of three or more consecutive complexes of ventricular origin. The QRS complexes are wide and have an abnormal morphology. (CDISC)","Ectopic Ventricular Rhythm by ECG Finding | ECTOPIC VENTRICULAR RHYTHM | Ectopic Ventricular Rhythm | Ectopic Ventricular Rhythm by EKG Finding | Ectopic ventricular rhythm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1142551","Electrical Alternans by ECG Finding","C71035","An electrocardiographic finding in which there is an alternating pattern of any of the waveform components.","Electrical Alternans by ECG Finding | ELECTRICAL ALTERNANS | Electrical Alternans | Electrical Alternans by EKG Finding | Electrical alternans",,,,,,,,,,,,,,,"4311428","Electrical alternation of heart",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3830283","Extensive Anterior Wall Myocardial Infarction by ECG Finding","C106520","An electrocardiographic finding of pathologic Q waves in leads V1 to V6, I and aVL, which is suggestive of myocardial infarction involving the anterior and anterolateral walls of the left ventricle. (CDISC)","Extensive Anterior Wall Myocardial Infarction by ECG Finding | EXTENSIVE ANTERIOR WALL MYOCARDIAL INFARCTION | Extensive Anterior Wall Myocardial Infarction by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640853","Extreme Right Axis Deviation","C102634","An electrocardiographic finding of a frontal plane QRS axis from -90 to +180 degrees. (CDISC)","Extreme Right Axis Deviation | NORTHWEST AXIS | Northwest Axis | Right superior axis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054925","Frequent Premature Atrial Complexes by ECG Finding","C120610","An electrocardiographic tracing demonstrating frequent premature atrial contractions that exceed an acceptable, predetermined threshold. Different thresholds may apply to different patient populations.","Frequent Premature Atrial Complexes by ECG Finding | FREQUENT PREMATURE ATRIAL COMPLEXES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0747933","Frequent Premature Ventricular Complexes by ECG Finding","C120611","An electrocardiographic tracing demonstrating frequent premature ventricular contractions that exceed an acceptable, predetermined threshold. Different thresholds may apply to different patient populations.","Frequent Premature Ventricular Complexes by ECG Finding | FREQUENT PREMATURE VENTRICULAR COMPLEXES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640857","Fusion Complex","C102639","An electrocardiographic finding that occurs when electrical activation of the atria or ventricles occurs from two separate sites. This results in a P wave or QRS complex that displays merged characteristics of beats originating from the two different sites. (CDISC)","Fusion Complex | FUSION COMPLEX | Fusion Beat | Fusion Complexes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2363939","High Grade Atrioventricular Block by ECG Finding","C102642","An electrocardiographic finding of intermittent failure of atrial electrical impulse conduction to the ventricles, characterized by two or more consecutive non-conducted P waves. (CDISC)","High Grade Atrioventricular Block by ECG Finding | ADVANCED/HIGH GRADE AV BLOCK | Advanced Atrioventricular Block | Advanced/High Grade AV Block | High Grade Atrioventricular Block | High Grade Atrioventricular Block by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640858","High Lateral Myocardial Infarction by ECG Finding","C102643","An electrocardiographic finding of pathologic Q waves in leads I and aVL, which is suggestive of myocardial infarction of the high lateral wall of the left ventricle. (CDISC)","High Lateral Myocardial Infarction by ECG Finding | HIGH LATERAL WALL MYOCARDIAL INFARCTION | High Lateral Myocardial Infarction by EKG Finding | High Lateral Wall Myocardial Infarction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054771","Holter Lead Fail by ECG Finding","C120612","A continuous, ambulatory electrocardiographic recording during which one or more electrodes are disconnected, at least temporarily, resulting in one or more invalid ECG waveforms.","Holter Lead Fail by ECG Finding | HOLTER LEAD FAIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829556","Inability to Digitize ECG Leads","C114170","A statement indicating the inability to digitize a paper ECG. (CDISC)","Inability to Digitize ECG Leads | UNABLE TO DIGITIZE ECG LEADS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829555","Incomplete ECG","C114167","An electrocardiographic recording which is limited in duration or which does not display all of the expected leads. (CDISC)","Incomplete ECG | INCOMPLETE ECG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829554","Incomplete ECG Measurements Due to Truncation of QRS Complexes","C114179","An electrocardiographic recording in which measurements (particularly of QRS amplitudes) and/or interpretations are not performed because QRS complexes have been truncated. (CDISC)","Incomplete ECG Measurements Due to Truncation of QRS Complexes | INCOMPLETE MEASUREMENTS DUE TO TRUNCATION OF QRS COMPLEXES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281878","Incomplete left bundle branch block","C71047","An electrocardiographic finding of a wide QRS complex with evidence of delayed conduction to the left ventricle, manifest as a widened initial portion of the QRS complex in leads V5, V6, I and aVL and with QRS duration less than 120 ms. (CDISC)","Incomplete Left Bundle Branch Block by ECG Finding | INCOMPLETE LEFT BUNDLE BRANCH BLOCK | Incomplete Left Bundle Branch Block | Incomplete Left Bundle Branch Block by EKG Finding | Incomplete left bundle branch block",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4013607","Incomplete Right Bundle Branch Block by ECG Finding","C71048","An electrocardiographic finding of a wide QRS complex with evidence of delayed conduction to the right ventricle, manifested by a widened initial portion of the QRS in V1 and V2, a widened S wave in V5, V6, I and aVL, and with QRS duration less than 120 ms. (CDISC)","Incomplete Right Bundle Branch Block by ECG Finding | INCOMPLETE RIGHT BUNDLE BRANCH BLOCK | Incomplete Right Bundle Branch Block | Incomplete Right Bundle Branch Block by EKG Finding | Incomplete right bundle branch block | Incomplete right bundle-branch block",,,,,,,,,,,,,,,"37017193|4088338","EKG: Incomplete right bundle branch block|Incomplete right bundle branch block",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3829553","Incompletely Digitized ECG Leads","C114169","A digital electrocardiographic recording which was digitized from paper ECG tracings and which does not contain all leads present on the original paper printout. (CDISC)","Incompletely Digitized ECG Leads | INCOMPLETELY DIGITIZED ECG LEAD(S)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829551","Incorrectly Positioned Precordial Electrodes by ECG Finding","C114160","An electrocardiographic recording in which one or more precordial electrodes are placed incorrectly with respect to the standard chest electrode positions resulting in improper representation of the affected leads. (CDISC)","Incorrectly Positioned Precordial Electrodes by ECG Finding | PRECORDIAL ELECTRODE(S) POSITIONED INCORRECTLY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829550","Incorrectly Scaled ECG","C114168","An electrocardiographic recording in which the ECG signal is not displayed at the indicated recording speed and/or amplitude resolution. (CDISC)","Incorrectly Scaled ECG | INCORRECTLY SCALED ECG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0340305","Inferior Myocardial Infarction by ECG Finding","C35398","An electrocardiographic finding of pathologic Q waves in leads III, aVF and often II, which is suggestive of myocardial infarction of the inferior wall of the left ventricle. (CDISC)","Inferior Myocardial Infarction by ECG Finding | INFERIOR WALL MYOCARDIAL INFARCTION | Inferior MI | Inferior Myocardial Infarction by EKG Finding | Inferior Wall Myocardial Infarction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829536","Insufficient Number of Beats for Complete ECG Evaluation","C114177","An electrocardiographic recording in which fewer than the required number of cardiac complexes are available for measurement and/or interpretation due to a shorter than planned recording or due to cardiac complexes which are present but are not suitable for measurement and/or interpretation. (CDISC)","Insufficient Number of Beats for Complete ECG Evaluation | INSUFFICIENT NUMBER OF BEATS TO COMPLETELY EVALUATE ECG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829533","Interchanged Limb Electrodes by ECG Finding","C114150","An electrocardiographic recording in which two or more of the limb electrodes are switched resulting in improper representation of the affected leads. (CDISC)","Interchanged Limb Electrodes by ECG Finding | LIMB ELECTRODES INTERCHANGED | Limb Lead Reversal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829532","Interchanged Precordial Electrodes by ECG Finding","C114152","An electrocardiographic recording in which two or more of the precordial electrodes are switched resulting in improper representation of the affected leads. (CDISC)","Interchanged Precordial Electrodes by ECG Finding | PRECORDIAL ELECTRODES INTERCHANGED | Precordial Lead Reversal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829517","Interpolated Premature Ventricular Complex by ECG Finding","C107100","An electrocardiographic finding of a premature ventricular complex which occurs between two normal QRS complexes which have normal timing. (CDISC)","Interpolated Premature Ventricular Complex by ECG Finding | Interpolated PVC | Interpolated Premature Ventricular Complex | Interpolated Premature Ventricular Complex by EKG Finding | Interpolated VE | Interpolated VES | Interpolated VPC | Interpolated Ventricular Extra Beat | Interpolated Ventricular Premature Complex | PREMATURE VENTRICULAR COMPLEX INTERPOLATED | Premature Ventricular Complexes Interpolated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346510","Intra-Atrial Conduction Delay by ECG Finding","C71073","An electrocardiographic finding of a delay in impulse propagation through the atria. This is characterized by broad P waves which are often biphasic in V1. (CDISC)","Intra-Atrial Conduction Delay by ECG Finding | INTRAATRIAL CONDUCTION DELAY | Intra-Atrial Conduction Delay | Intra-Atrial Conduction Delay by EKG Finding | Intraatrial Conduction Delay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829507","Invalid ECG Waveforms","C114171","An electrocardiographic recording for which the displayed leads do not represent the individual's true ECG lead information. (CDISC)","Invalid ECG Waveforms | INVALID ECG WAVEFORMS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881279","Isorhythmic Atrioventricular Dissociation","C62248","An electrocardiographic finding of a type of atrioventricular dissociation characterized by the atria (P waves) and ventricles (QRS complexes) beating at similar rates, although independently. (CDISC)","Isorhythmic Atrioventricular Dissociation | ISORHYTHMIC DISSOCIATION | Isorhythmic dissociation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0745499","Junctional Bradycardia by ECG Finding","C71074","An electrocardiographic finding of a junctional rhythm with a heat rate which is abnormally low. (CDISC)","Junctional Bradycardia by ECG Finding | JUNCTIONAL BRADYCARDIA | Junctional Bradycardia | Junctional Bradycardia by EKG Finding | Junctional bradycardia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1960136","Junctional Escape Complexes by ECG Finding","C116129","An electrocardiographic finding of an escape beat following a pause that originates at the AV junction; this manifests as a QRS complex of supraventricular origin not immediately preceded by a P wave. (CDISC)","Junctional Escape Complexes by ECG Finding | JUNCTIONAL ESCAPE COMPLEXES | Junctional Escape Beat | Junctional Escape Complex",,,,,,,,,,,,,,,"4141663","EKG: junctional escape rhythm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4015485","Junctional Escape Rhythm by ECG Finding","C135393","An electrocardiographic finding of a junctional rhythm that arises as a physiologic response to extreme slowing or arrest of sinus node activity. In this setting, a faster junctional rhythm may be a normal response to a very slow or absent sinus rate. (CDISC)","Junctional Escape Rhythm by ECG Finding | JUNCTIONAL ESCAPE RHYTHM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0428981","Junctional Premature Complex by ECG Finding","C102652","An electrocardiographic finding of an ectopic impulse originating in the AV junction presenting as a QRS complex of supraventricular origin which is not preceded by a P wave. (CDISC)","Junctional Premature Complex by ECG Finding | JUNCTIONAL PREMATURE COMPLEX | Junctional Extra Beat | Junctional Premature Complex | Junctional Premature Complex by EKG Finding | Junctional Premature Complexes",,,,,,,,,,,,,,,"4088351","Junctional premature complex",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0232208","Junctional Rhythm by ECG Finding","C71051","An electrocardiographic finding of a rhythm which originates in the AV junction and results in a normal heart rate. It is characterized by retrograde P waves which may be obscured by or may follow the QRS complexes. The QRS complexes may be narrow or may demonstrate aberration. (CDISC)","Junctional Rhythm by ECG Finding | JUNCTIONAL RHYTHM | Junctional Rhythm | Junctional Rhythm by EKG Finding | Junctional rhythm",,,,,,,,,,,,,,,"4038688|4140001","AV junctional rhythm|ECG: junctional rhythm",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1960137","Junctional Tachycardia by ECG Finding","C35059","An electrocardiographic finding of a junctional rhythm with a heart rate which is abnormally elevated. (CDISC)","Junctional Tachycardia by ECG Finding | JUNCTIONAL TACHYCARDIA | Junctional Tachycardia | Junctional Tachycardia by EKG Finding | Junctional tachycardia",,,,,,,,,,,,,,,"4142573","ECG: junctional tachycardia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640864","Late R Wave Transition by ECG Finding","C102653","An electrocardiographic finding where the amplitude of the R wave does not become greater than the amplitude of the S wave until an unusually late point in the precordial leads, usually in leads V4 to V6. (CDISC)","Late R Wave Transition by ECG Finding | LATE R WAVE TRANSITION | Late R Wave Transition | Late R Wave Transition by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281915","Lateral Myocardial Infarction by ECG Finding","C35586","An electrocardiographic finding of pathologic Q waves in leads V5, V6, I and aVL, which is suggestive of myocardial infarction of the lateral wall of the left ventricle. (CDISC)","Lateral Myocardial Infarction by ECG Finding | LATERAL WALL MYOCARDIAL INFARCTION | Lateral MI | Lateral Myocardial Infarction by EKG Finding | Lateral Wall Myocardial Infarction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0264912","Left Anterior Fascicular Block by ECG Finding","C62267","An electrocardiographic finding of a slightly widened QRS duration (typically less than 120 ms) with leftward frontal plane QRS axis and typically small Q waves in leads I and aVL. (CDISC)","Left Anterior Fascicular Block by ECG Finding | LAFB | LEFT ANTERIOR FASCICULAR BLOCK | Left Anterior Fascicular Block | Left Anterior Fascicular Block by EKG Finding | Left Anterior Hemiblock | Left anterior fascicular block",,,,,,,,,,,,,,,"4295336","Left anterior fascicular block",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0264913","Left Posterior Fascicular Block by ECG Finding","C62268","An electrocardiographic finding of an S1Q3 pattern and QRS axis greater than or equal to 120 degrees. It is usually seen in association with other abnormalities (e.g. RBBB or RVH). (CDISC)","Left Posterior Fascicular Block by ECG Finding | LEFT POSTERIOR FASCICULAR BLOCK | LPFB | Left Posterior Fascicular Block | Left Posterior Fascicular Block by EKG Finding | Left Posterior Hemiblock | Left posterior fascicular block",,,,,,,,,,,,,,,"4268046","Left posterior fascicular block",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2984922","Left Ventricular Conduction Delay by ECG Finding","C92231","An electrocardiographic finding in which there is evidence that electrical transmission through the left ventricle is impaired. (CDISC)","Left Ventricular Conduction Delay by ECG Finding | LEFT VENTRICULAR CONDUCTION DELAY | Left Ventricular Conduction Delay | Left Ventricular Conduction Delay by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640865","Left Ventricular Hypertrophy with Strain by ECG Finding","C102655","An electrocardiographic finding suggestive of a hypertrophied left ventricle, characterized by large QRS amplitudes, ST depression and T wave inversion. (CDISC)","Left Ventricular Hypertrophy with Strain by ECG Finding | LEFT VENTRICULAR HYPERTROPHY WITH STRAIN | Left Ventricular Hypertrophy With Strain | Left Ventricular Hypertrophy with Strain by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829250","Low Amplitude QRS Complex by ECG Finding","C114166","An electrocardiographic recording showing smaller than usual QRS complexes in one or more leads. This may represent a technical issue with the ECG acquisition or characteristics of the individual. (CDISC)","Low Amplitude QRS Complex by ECG Finding | LOW AMPLITUDE SIGNAL | Low Amplitude QRS Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349945","Low QRS Voltage by ECG Finding","C71078","An electrocardiographic finding of a QRS amplitude less than or equal to 0.5 mV in the limb leads or QRS amplitude less than or equal to 1 mV in the precordial leads. (CDISC)","Low QRS Voltage by ECG Finding | LOW QRS VOLTAGE | Low QRS Voltage | Low QRS Voltage by EKG Finding | Low QRS voltage",,,,,,,,,,,,,,,"4088499","Low QRS voltages",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898567","Low Voltage in Limb Leads Only by ECG Finding","C116133","An electrocardiographic finding of small QRS amplitudes (less than 500 microvolts) in all limb leads. (CDISC)","Low Voltage in Limb Leads Only by ECG Finding | LOW VOLTAGE - LIMB LEADS ONLY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054574","Marked Sinus Bradycardia by ECG Finding","C120613","An electrocardiographic tracing demonstrating sinus bradycardia, with a heart rate lower than an acceptable, predetermined threshold.  Different thresholds, for rate and/or duration, may apply to different patient populations.","Marked Sinus Bradycardia by ECG Finding | MARKED SINUS BRADYCARDIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4075144","Monomorphic Ventricular Tachycardia by ECG Finding","C62234","An electrocardiographic finding of a ventricular tachycardia in which the QRS complexes have a uniform morphology. (CDISC)","Monomorphic Ventricular Tachycardia by ECG Finding | Monomorphic Ventricular Tachycardia | Monomorphic Ventricular Tachycardia by EKG Finding | VENTRICULAR TACHYCARDIA, MONOMORPHIC | Ventricular Tachycardia, Monomorphic | Ventricular tachycardia, monomorphic",,,,,,,,,,,,,,,"37017189|4091900","EKG ventricular tachycardia monomorphic|Ventricular tachycardia, monomorphic",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3640877","Multifocal Atrial Premature Complex by ECG Finding","C102672","An electrocardiographic finding of premature atrial complexes which have 2 or more distinct morphologies, suggesting origin at more than one atrial site. (CDISC)","Multifocal Atrial Premature Complex by ECG Finding | Multifocal Atrial Premature Complex | Multifocal Atrial Premature Complex by EKG Finding | Multifocal SVE | Multifocal Supraventricular Extra Beats | PREMATURE ATRIAL COMPLEXES MULTIFOCAL | Premature Atrial Complex Multifocal | Premature Atrial Complexes Multiform",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221158","Multifocal Atrial Tachycardia by ECG Finding","C71050","An electrocardiographic finding of a supraventricular arrhythmia characterized by 3 or more distinct P wave morphologies with an isoelectric baseline, variable PR intervals and no predominant atrial rhythm. The ventricular rate is typically 100-150 beats per minute. (CDISC)","Multifocal Atrial Tachycardia by ECG Finding | MULTIFOCAL ATRIAL TACHYCARDIA | Multifocal Atrial Tachycardia | Multifocal Atrial Tachycardia by EKG Finding | Multifocal atrial tachycardia",,,,,,,,,,,,,,,"37017191|4176112","EKG: multifocal atrial tachycardia|Multifocal atrial tachycardia",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0747936","Multifocal Ventricular Premature Complex by ECG Finding","C102673","An electrocardiographic finding of premature ventricular complexes which have two or more distinct morphologies, suggesting origin at more than one ventricular site. (CDISC)","Multifocal Ventricular Premature Complex by ECG Finding | Multifocal VES | Multifocal VPCS | Multifocal Ventricular Extra Beats | Multifocal Ventricular Premature Complex | Multifocal Ventricular Premature Complex by EKG Finding | PREMATURE VENTRICULAR COMPLEXES MULTIFOCAL | Premature Ventricular Complex Multifocal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473427","Muscle Tremor Artifact","C114148","An electrocardiographic recording with intermittent mid to high frequency artifact in one or more leads due to muscular tremor or movement rather than cardiac activity. (CDISC)","Muscle Tremor Artifact | MUSCLE TREMOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0428953","Myocardial Infarction by ECG Finding","C101589","An electrocardiographic finding of pathologic Q waves, which is suggestive of myocardial infarction of one or more regions of the heart. No specification is provided for localization. (CDISC)","Myocardial Infarction by ECG Finding | MYOCARDIAL INFARCTION | Myocardial Infarction | Myocardial Infarction by EKG Finding",,,,,,,,,,,,,,,"4064609","EKG: myocardial infarction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640912","New Anterior Myocardial Infarction by ECG Finding","C102732","An electrocardiographic finding of pathologic Q waves in leads V3 and V4, which is suggestive of myocardial infarction of the anterior wall of the left ventricle and which is new compared to prior ECGs. (CDISC)","New Anterior Myocardial Infarction by ECG Finding | NEW ANTERIOR WALL MYOCARDIAL INFARCTION | New Anterior MI | New Anterior Myocardial Infarction by EKG Finding | New Anterior Wall Myocardial Infarction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640913","New Anterolateral Myocardial Infarction by ECG Finding","C102733","An electrocardiographic finding of pathologic Q waves in leads V3 through V6, which is suggestive of myocardial infarction of the anterolateral wall of the left ventricle and which is new compared to prior ECGs. (CDISC)","New Anterolateral Myocardial Infarction by ECG Finding | NEW ANTEROLATERAL WALL MYOCARDIAL INFARCTION | New Anterolateral Myocardial Infarction by EKG Finding | New Anterolateral Wall Myocardial Infarction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640914","New Anteroseptal Myocardial Infarction by ECG Finding","C102734","An electrocardiographic finding of pathologic Q waves in leads V1 through V4, which is suggestive of myocardial infarction of the anteroseptal wall of the left ventricle and which is new compared to prior ECGs. (CDISC)","New Anteroseptal Myocardial Infarction by ECG Finding | NEW ANTEROSEPTAL WALL MYOCARDIAL INFARCTION | New Anteroseptal Myocardial Infarction by EKG Finding | New Anteroseptal Wall Myocardial Infarction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640915","New Extensive Anterior Myocardial Infarction by ECG Finding","C102735","An electrocardiographic finding of pathologic Q waves in leads V1 to V6, I and aVL, which is suggestive of myocardial infarction involving the anterior and anterolateral walls of the left ventricle and which is new compared to prior ECGs. (CDISC)","New Extensive Anterior Myocardial Infarction by ECG Finding | NEW EXTENSIVE ANTERIOR WALL MYOCARDIAL INFARCTION | New Extensive Anterior Myocardial Infarction by EKG Finding | New Extensive Anterior Wall Myocardial Infarction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640916","New High Lateral Myocardial Infarction by ECG Finding","C102736","An electrocardiographic finding of pathologic Q waves in leads I and aVL, which is suggestive of myocardial infarction of the high lateral wall of the left ventricle and which is new compared to prior ECGs. (CDISC)","New High Lateral Myocardial Infarction by ECG Finding | NEW HIGH LATERAL WALL MYOCARDIAL INFARCTION | New High Lateral Myocardial Infarction by EKG Finding | New High Lateral Wall Myocardial Infarction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640917","New Inferior Myocardial Infarction by ECG Finding","C102737","An electrocardiographic finding of pathologic Q waves in leads III, aVF and often II, which is suggestive of myocardial infarction of the inferior wall of the left ventricle and which is new compared to prior ECGs. (CDISC)","New Inferior Myocardial Infarction by ECG Finding | NEW INFERIOR WALL MYOCARDIAL INFARCTION | New Inferior Myocardial Infarction by EKG Finding | New Inferior Wall Myocardial Infarction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640918","New Lateral Myocardial Infarction by ECG Finding","C102738","An electrocardiographic finding of pathologic Q waves in leads V5, V6, I and aVL, which is suggestive of myocardial infarction of the lateral wall of the left ventricle and which is new compared to prior ECGs. (CDISC)","New Lateral Myocardial Infarction by ECG Finding | NEW LATERAL WALL MYOCARDIAL INFARCTION | New Lateral Myocardial Infarction by EKG Finding | New Lateral Wall Myocardial Infarction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640911","New Myocardial Infarction by ECG Finding","C102731","An electrocardiographic finding of pathologic Q waves, which is suggestive of myocardial infarction of one or more regions of the heart and which is new compared to prior ECGs. No specification is provided for localization. (CDISC)","New Myocardial Infarction by ECG Finding | NEW MYOCARDIAL INFARCTION | New Myocardial Infarction | New Myocardial Infarction by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828822","New Posterior Wall Myocardial Infarction by ECG Finding","C106548","An electrocardiographic finding in leads V1 or V2 of an initial R wave duration greater than or equal to 40 ms, R wave greater than S wave, and upright T wave, which is suggestive of myocardial infarction of the posterior wall of the left ventricle, and which is new compared to prior ECGs. Evidence of inferior or lateral myocardial infarction is usually also present. (CDISC)","New Posterior Wall Myocardial Infarction by ECG Finding | NEW POSTERIOR WALL MYOCARDIAL INFARCTION | New Posterior Wall Myocardial Infarction by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640919","New Septal Myocardial Infarction by ECG Finding","C102739","An electrocardiographic finding of pathologic Q waves in leads V1, V2 and often V3, which is suggestive of myocardial infarction of the intraventricular septum and which is new compared to prior ECGs. (CDISC)","New Septal Myocardial Infarction by ECG Finding | NEW SEPTAL WALL MYOCARDIAL INFARCTION | New Septal Myocardial Infarction by EKG Finding | New Septal Wall Myocardial Infarction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0542269","Non Q Wave Myocardial Infarction by ECG Finding","C71080","An electrocardiographic finding of ST and T wave abnormalities in the absence of pathologic Q waves, which is suggestive of myocardial infarction in one or more regions of the heart. (CDISC)","Non Q Wave Myocardial Infarction by ECG Finding | NON Q WAVE MYOCARDIAL INFARCTION | Non Q Wave Myocardial Infarction | Non Q Wave Myocardial Infarction by EKG Finding",,,,,,,,,,,,,,,"4200113","Non-Q wave myocardial infarction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL522558","Nonconducted P Wave Physiology Not Defined by ECG Finding","C135394","An electrocardiographic finding of a P wave that either does not conduct to the ventricle or that does not result in ventricular activation.","Nonconducted P Wave Physiology Not Defined by ECG Finding | NONCONDUCTED P WAVE PHYSIOLOGY NOT DEFINED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898130","Non-Diagnostic Q Waves by ECG Finding","C116134","An electrocardiographic finding of Q waves that are insufficient for the diagnosis of myocardial infarction. In such cases, a myocardial infarction may be suspected even though ECG diagnostic criteria are absent. (CDISC)","Non-Diagnostic Q Waves by ECG Finding | NON-DIAGNOSTIC Q WAVES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882112","Nonspecific Intraventricular Conduction Delay by ECG Finding","C62271","An electrocardiographic finding of a widened QRS duration typically greater than 110 ms which does not meet the morphologic criteria for any of the standard bundle branch or fascicular block patterns. (CDISC)","Nonspecific Intraventricular Conduction Delay by ECG Finding | INTRAVENTRICULAR CONDUCTION DELAY, NONSPECIFIC | IVCD | Intraventricular Conduction Defect | Intraventricular conduction delay | Nonspecific Intraventricular Conduction Delay | Nonspecific Intraventricular Conduction Delay by EKG Finding | Nonspecific intraventricular conduction delay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347361","Non-Specific ST-T Changes by ECG Finding","C71031","An electrocardiographic finding of changes in the ST segment and T wave that do not meet criteria for ischemia or infarction.","Non-Specific ST-T Changes by ECG Finding | NON-SPECIFIC ST-T CHANGES | Non-Specific ST-T Changes | Non-Specific ST-T Changes by EKG Finding | Non-specific ST-T changes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640879","Non-Sustained Atrial Tachycardia by ECG Finding","C102680","An electrocardiographic finding of an atrial tachycardia which terminates in less than 30 seconds. (CDISC)","Non-Sustained Atrial Tachycardia by ECG Finding | NON-SUSTAINED ATRIAL TACHYCARDIA | Non-Sustained Atrial Tachycardia | Non-Sustained Atrial Tachycardia by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054337","Nonsustained Supraventricular Tachycardia by ECG Finding","C120614","An electrocardiographic tracing demonstrating supraventricular tachycardia of less than thirty seconds duration. Different thresholds, for rate and/or duration, may apply to different patient populations.","Nonsustained Supraventricular Tachycardia by ECG Finding | NONSUSTAINED SUPRAVENTRICULAR TACHYCARDIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0750194","Non-Sustained Ventricular Tachycardia by ECG Finding","C71053","An electrocardiographic finding of ventricular tachycardia less than 30 seconds in duration.","Non-Sustained Ventricular Tachycardia by ECG Finding | NON-SUSTAINED VENTRICULAR TACHYCARDIA | Non-Sustained VT | Non-Sustained Ventricular Tachycardia | Non-Sustained Ventricular Tachycardia by EKG Finding | Non-sustained ventricular tachycardia | Ventricular Tachycardia, Non-Sustained | Ventricular tachycardia, unsustained",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4048179","Old Myocardial Infarction by ECG Finding","C101597","An electrocardiographic finding of pathologic Q waves, which is suggestive of myocardial infarction of one or more regions of the heart, without evidence of current or ongoing acute infarction. No specification is provided for localization. (CDISC)","Old Myocardial Infarction by ECG Finding | OLD OR AGE INDETERMINATE WALL MYOCARDIAL INFARCTION | Old Myocardial Infarction by EKG Finding | Old Or Age Indeterminate Wall Myocardial Infarction",,,,,,,,,,,,,,,"4064348","EKG: old myocardial infarction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640881","Old or Age Indeterminate Anterior Myocardial Infarction by ECG Finding","C102684","An electrocardiographic finding of pathologic Q waves in leads V3 and V4, which is suggestive of myocardial infarction of the anterior wall of the left ventricle, without evidence of current or ongoing acute infarction. (CDISC)","Old or Age Indeterminate Anterior Myocardial Infarction by ECG Finding | OLD OR AGE INDETERMINATE ANTERIOR WALL MYOCARDIAL INFARCTION | Old Or Age Indeterminate Anterior Wall Myocardial Infarction | Old or Age Indeterminate Anterior Myocardial Infarction by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640882","Old or Age Indeterminate Anterolateral Myocardial Infarction by ECG Finding","C102685","An electrocardiographic finding of pathologic Q waves in leads V3 through V6, which is suggestive of myocardial infarction of the anterolateral wall of the left ventricle, without evidence of current or ongoing acute infarction. (CDISC)","Old or Age Indeterminate Anterolateral Myocardial Infarction by ECG Finding | OLD OR AGE INDETERMINATE ANTEROLATERAL WALL MYOCARDIAL INFARCTION | Old Or Age Indeterminate Anterolateral Wall Myocardial Infarction | Old or Age Indeterminate Anterolateral Myocardial Infarction by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640883","Old or Age Indeterminate Anteroseptal Myocardial Infarction by ECG Finding","C102686","An electrocardiographic finding of pathologic Q waves in leads V1 through V4, which is suggestive of myocardial infarction of the anteroseptal wall of the left ventricle, without evidence of current or ongoing acute infarction. (CDISC)","Old or Age Indeterminate Anteroseptal Myocardial Infarction by ECG Finding | OLD OR AGE INDETERMINATE ANTEROSEPTAL WALL MYOCARDIAL INFARCTION | Old Or Age Indeterminate Anteroseptal Wall Myocardial Infarction | Old or Age Indeterminate Anteroseptal Myocardial Infarction by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640884","Old or Age Indeterminate Extensive Anterior Myocardial Infarction by ECG Finding","C102687","An electrocardiographic finding of pathologic Q waves in leads V1 to V6, I and aVL, which is suggestive of myocardial infarction involving the anterior and anterolateral walls of the left ventricle, without evidence of current or ongoing acute infarction. (CDISC)","Old or Age Indeterminate Extensive Anterior Myocardial Infarction by ECG Finding | OLD OR AGE INDETERMINATE EXTENSIVE ANTERIOR WALL MYOCARDIAL INFARCTION | Old Or Age Indeterminate Extensive Anterior Wall Myocardial Infarction | Old or Age Indeterminate Extensive Anterior Myocardial Infarction by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640885","Old or Age Indeterminate High Lateral Myocardial Infarction by ECG Finding","C102688","An electrocardiographic finding of pathologic Q waves in leads I and aVL, which is suggestive of myocardial infarction of the high lateral wall of the left ventricle, without evidence of current or ongoing acute infarction. (CDISC)","Old or Age Indeterminate High Lateral Myocardial Infarction by ECG Finding | OLD OR AGE INDETERMINATE HIGH LATERAL WALL MYOCARDIAL INFARCTION | Old Or Age Indeterminate High Lateral Wall Myocardial Infarction | Old or Age Indeterminate High Lateral Myocardial Infarction by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640886","Old or Age Indeterminate Inferior Myocardial Infarction by ECG Finding","C102689","An electrocardiographic finding of pathologic Q waves in leads III, aVF and often II, which is suggestive of myocardial infarction of the inferior wall of the left ventricle, without evidence of current or ongoing acute infarction. (CDISC)","Old or Age Indeterminate Inferior Myocardial Infarction by ECG Finding | OLD OR AGE INDETERMINATE INFERIOR WALL MYOCARDIAL INFARCTION | Old Or Age Indeterminate Inferior Wall Myocardial Infarction | Old or Age Indeterminate Inferior Myocardial Infarction by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640887","Old or Age Indeterminate Lateral Myocardial Infarction by ECG Finding","C102690","An electrocardiographic finding of pathologic Q waves in leads V5, V6, I and aVL, which is suggestive of myocardial infarction of the lateral wall of the left ventricle, without evidence of current or ongoing acute infarction. (CDISC)","Old or Age Indeterminate Lateral Myocardial Infarction by ECG Finding | OLD OR AGE INDETERMINATE LATERAL WALL MYOCARDIAL INFARCTION | Old Or Age Indeterminate Lateral Wall Myocardial Infarction | Old or Age Indeterminate Lateral Myocardial Infarction by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640889","Old or Age Indeterminate Right Ventricular Myocardial Infarction by ECG Finding","C102692","An electrocardiographic finding, in the presence of an old or age indeterminate inferior wall myocardial infarction, of Q waves greater than or equal to 40 ms in duration in the right ventricular leads V4R through V6R. (CDISC)","Old or Age Indeterminate Right Ventricular Myocardial Infarction by ECG Finding | OLD OR AGE UNDETERMINED RIGHT VENTRICULAR MYOCARDIAL INFARCTION | Old or Age Indeterminate Right Ventricular Myocardial Infarction by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640890","Old or Age Indeterminate Septal Myocardial Infarction by ECG Finding","C102693","An electrocardiographic finding of pathologic Q waves in leads V1, V2 and often V3, which is suggestive of myocardial infarction of the intraventricular septum, without evidence of current or ongoing acute infarction. (CDISC)","Old or Age Indeterminate Septal Myocardial Infarction by ECG Finding | OLD OR AGE INDETERMINATE SEPTAL WALL MYOCARDIAL INFARCTION | Old Or Age Indeterminate Septal Wall Myocardial Infarction | Old or Age Indeterminate Septal Myocardial Infarction by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828690","Other Incorrect Electrode Placement","C114176","An electrocardiographic recording in which one or more electrodes are incorrectly placed but further details are not provided. (CDISC)","Other Incorrect Electrode Placement | OTHER INCORRECT ELECTRODE PLACEMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0438157","P Wave Abnormality by ECG Finding","C90430","An electrocardiographic finding for the P wave that is atypical either for the shape, duration, amplitude, axis or polarity. Abnormality of the P wave signifies aberrant propagation of the electrical impulse through the atria.","P Wave Abnormality by ECG Finding | P WAVE ABNORMALITY | P Wave Abnormality | P Wave Abnormality by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983640","P Wave Notched by ECG Finding","C90431","An electrocardiographic finding of P waves with two peaks longer in duration than normal and amplitude greater than normal. (CDISC)","P Wave Notched by ECG Finding | Notched P Wave | P WAVE NOTCHED | P Wave Notched | P Wave Notched by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984923","Paced Atrial And Ventricular Rhythm","C92232","An electrocardiographic finding in which both the atrial and ventricular rhythm are controlled by an electrical impulse from an artificial cardiac pacemaker. (CDISC)","Paced Atrial And Ventricular Rhythm | AV dual-paced complex(es) or rhythm | PACED ATRIAL AND VENTRICULAR RHYTHM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL423763","Paced Atrial Rhythm","C92233","An electrocardiographic finding in which the atrial rhythm is controlled by an electrical impulse from an artificial cardiac pacemaker. (CDISC)","Paced Atrial Rhythm | Atrial-paced complex(es) or rhythm | PACED ATRIAL RHYTHM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL423762","Paced Ventricular Rhythm","C92234","An electrocardiographic finding in which the ventricular rhythm is controlled by an electrical impulse from an artificial cardiac pacemaker. (CDISC)","Paced Ventricular Rhythm | PACED VENTRICULAR RHYTHM | Ventricular-paced complex(es) or rhythm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050122","Paroxysmal Atrial Fibrillation by ECG Finding","C120615","An electrocardiographic tracing demonstrating intermittent atrial fibrillation in the presence of sinus rhythm, junctional rhythm, or an atrial paced rhythm.","Paroxysmal Atrial Fibrillation by ECG Finding | PAROXYSMAL ATRIAL FIBRILLATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882293","Paroxysmal Atrioventricular Block by ECG Finding","C62250","An electrocardiographic finding of the sudden onset of transient AV block, which is often associated with preexisting conduction disorders. (CDISC)","Paroxysmal Atrioventricular Block by ECG Finding | PAROXYSMAL AV BLOCK | Paroxysmal AV Block | Paroxysmal AV block | Paroxysmal Atrioventricular Block | Paroxysmal Atrioventricular Block by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1832602","Paroxysmal Ventricular Tachycardia by ECG Finding","C34902","An episodic form of ventricular tachycardia, with abrupt onset and termination.","Paroxysmal Ventricular Tachycardia by ECG Finding | PAROXYSMAL VENTRICULAR TACHYCARDIA | Paroxysmal Ventricular Tachycardia | Paroxysmal Ventricular Tachycardia by EKG Finding",,,,,,,,,,,,,,,"4143407|437579","ECG: paroxysmal ventricular tachycardia|Paroxysmal ventricular tachycardia",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3890719","Pause by ECG Finding","C119250","An electrocardiographic recording that demonstrates an R-R interval that exceeds a predefined duration threshold, irrespective of the underlying rhythm.","Pause by ECG Finding | PAUSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897975","Pause Greater Than Three Seconds by ECG Finding","C119251","An electrocardiographic recording that demonstrates an R-R interval that exceeds three seconds, irrespective of the underlying rhythm.","Pause Greater Than Three Seconds by ECG Finding | PAUSE GREATER THAN 3.0 SECONDS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049799","Persistent Atrial Fibrillation by ECG Finding","C120616","An electrocardiographic tracing demonstrating atrial fibrillation that is present during the entire recording.","Persistent Atrial Fibrillation by ECG Finding | PERSISTENT ATRIAL FIBRILLATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0232309","P-mitrale by ECG Finding","C71040","An electrocardiographic finding suggesting underlying hypertrophy or dilatation of the left atrium. Electrocardiographic criteria used for the diagnosis of left atrial abnormality may include a bifid p wave, a biphasic p wave and/or a p wave duration of greater than 0.12 seconds.","P-mitrale by ECG Finding | LEFT ATRIAL ABNORMALITY | Left Atrial Enlargement | Left Atrial Enlargement by ECG Finding | P-mitrale | P-mitrale by EKG Finding",,,,,,,,,,,,,,,"4064616|4337811","P mitrale|Left atrial hypertrophy by EKG",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C4075145","Polymorphic Ventricular Tachycardia by ECG Finding","C62236","An electrocardiographic finding of a ventricular tachycardia in which the QRS complexes have a variable morphology and often rate. (CDISC)","Polymorphic Ventricular Tachycardia by ECG Finding | Polymorphic Ventricular Tachycardia | Polymorphic Ventricular Tachycardia by EKG Finding | VENTRICULAR TACHYCARDIA, POLYMORPHIC | Ventricular Tachycardia, Polymorphic | Ventricular tachycardia, polymorphic | Ventricular tachycardia, polymorphous",,,,,,,,,,,,,,,"37017188","EKG ventricular tachycardia polymorphic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0428962","Poor Quality ECG","C114172","An electrocardiographic recording that does not show proper quality for reasons that are not otherwise described. (CDISC)","Poor Quality ECG | POOR QUALITY ECG",,,,,,,,,,,,,,,"4088345","Poor ECG quality",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0877038","Poor R Wave Progression by ECG Finding","C71033","An electrocardiographic finding of a lack of progression of R wave height across precordial leads. (CDISC)","Poor R Wave Progression by ECG Finding | POOR R WAVE PROGRESSION | Poor R Wave Progression | Poor R Wave Progression by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642316","Posterior Myocardial Infarction by ECG Finding","C35399","An electrocardiographic finding in leads V1 or V2 of an initial R wave duration greater than or equal to 40 ms, R wave greater than S wave, and upright T wave, which is suggestive of myocardial infarction of the posterior wall of the left ventricle. Evidence of inferior or lateral myocardial infarction is usually also present. (CDISC)","Posterior Myocardial Infarction by ECG Finding | POSTERIOR WALL MYOCARDIAL INFARCTION | Posterior MI | Posterior Myocardial Infarction by EKG Finding | Posterior Wall Myocardial Infarction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0232308","P-pulmonale by ECG Finding","C71041","An electrocardiographic finding suggesting underlying hypertrophy or dilatation of the right atrium. Electrocardiographic criteria used for the diagnosis of right atrial abnormality may include a peaked p wave greater than 2.5 millimeters in amplitude in the inferior leads.","P-pulmonale by ECG Finding | P-pulmonale | P-pulmonale by EKG Finding | RIGHT ATRIAL ABNORMALITY | Right Atrial Enlargement | Right Atrial Enlargement by ECG Finding",,,,,,,,,,,,,,,"4065384","P pulmonale",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0429068","PR Segment Depression by ECG Finding","C116135","An electrocardiographic finding of PR segment depression below the iso-electric line in multiple precordial and/or limb leads. (CDISC)","PR Segment Depression by ECG Finding | PR Depression | PR SEGMENT DEPRESSION",,,,,,,,,,,,,,,"4089481","PR depression",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0429030","Prolonged ST Segment by ECG Finding","C116137","An electrocardiographic finding of a prolonged ST segment, resulting in an increased QT interval, without lengthening of the T wave duration; this may be observed in hypocalcemia. (CDISC)","Prolonged ST Segment by ECG Finding | PROLONGED ST SEGMENT",,,,,,,,,,,,,,,"4206924","Prolonged ST segment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0860813","Q Axis Left Axis Deviation","C71094","An electrocardiographic finding of the Q axis from -30 to -90 degrees.","Q Axis Left Axis Deviation | Left-axis deviation | Q AXIS, LEFT AXIS DEVIATION | Q Axis, Left axis deviation | QRS axis, left axis deviation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0232296","Q Axis Right Axis Deviation","C71095","An electrocardiographic finding of the Q axis from +90 to +180 degrees.","Q Axis Right Axis Deviation | Q AXIS, RIGHT AXIS DEVIATION | Q Axis, Right axis deviation | QRS axis, right axis deviation | Right-axis deviation",,,,,,,,,,,,,,,"4166218","Right axis deviation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640896","QRS Axis Indeterminate","C102701","An electrocardiographic finding in which the frontal plane QRS axis cannot be calculated.","QRS Axis Indeterminate | INDETERMINATE QRS AXIS | Indeterminate Axis | Indeterminate QRS Axis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0438173","QRS Complex Abnormality by ECG Finding","C90440","An electrocardiographic finding of a non-specific abnormality of the QRS complex, which is atypical in shape, duration, amplitude, axis or polarity. (CDISC)","QRS Complex Abnormality by ECG Finding | QRS COMPLEX ABNORMALITY | QRS Complex Abnormality | QRS Complex Abnormality by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828432","QTcB Shortened","C112402","An electrocardiographic finding in which the QT interval corrected for heart rate using Bazett's formula is shortened. Thresholds for different age, gender, and patient populations exist. (CDISC)","QTcB Shortened | SHORT QTCB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828430","QTcF Shortened","C112403","An electrocardiographic finding in which the QT interval corrected for heart rate using Fridericia's formula is shortened. Thresholds for different age, gender, and patient populations exist. (CDISC)","QTcF Shortened | SHORT QTCF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828429","Quality Problem Not Otherwise Specified by ECG Finding","C114161","An electrocardiographic artifact or recording error with unknown origin or which is not described otherwise. (CDISC)","Quality Problem Not Otherwise Specified by ECG Finding | QUALITY PROBLEM NOT OTHERWISE SPECIFIED | Unknown Quality Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983653","R Wave Notched by ECG Finding","C90444","An electrocardiographic finding of an R wave variant in which there is a small deflection of the R wave, with changing polarity, within the QRS complex.","R Wave Notched by ECG Finding | Notched R Wave | R WAVE NOTCHED | R Wave Notched | R Wave Notched by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640898","Repolarization Abnormality Secondary To Ventricular Hypertrophy","C102706","An electrocardiographic finding of ST depression and T wave inversion in the presence of increased QRS amplitude which are thought to be due to left ventricular hypertrophy.","Repolarization Abnormality Secondary To Ventricular Hypertrophy | REPOLARIZATION ABNORMALITY SECONDARY TO VENTRICULAR HYPERTROPHY | ST-T change due to ventricular hypertrophy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984924","Right Ventricular Conduction Delay by ECG Finding","C92235","An electrocardiographic finding in which there is evidence that electrical transmission through the right ventricle is impaired with a maximal QRS duration of 110 ms and which does not meet the criteria for Incomplete Right Bundle Branch Block. (CDISC)","Right Ventricular Conduction Delay by ECG Finding | RIGHT VENTRICULAR CONDUCTION DELAY | Right Ventricular Conduction Delay | Right Ventricular Conduction Delay by EKG Finding | Right Ventricular Delay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984918","RSR' by ECG Finding","C92227","An electrocardiographic finding in which there are two R waves, which are two deflections above the baseline resulting from a single ventricular depolarization. The first upward deflection in the complex is the R wave. The S is the first downward deflection. A second upward deflection is called the R-prime wave.","RSR' by ECG Finding | RSR PRIME | RSR' | RSR' by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0746727","Septal Myocardial Infarction by ECG Finding","C35519","An electrocardiographic finding suggesting an infarction in the anatomic location of the cardiac septum.","Septal Myocardial Infarction by ECG Finding | SEPTAL MYOCARDIAL INFARCTION | Septal Myocardial Infarction | Septal Myocardial Infarction by EKG Finding | Septal myocardial infarction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640899","Short QTc Interval","C102709","An electrocardiographic finding of a QT interval corrected for heart rate that is shorter than the lower limit of normal. Thresholds for different age, gender, and patient populations exist. (CDISC)","Short QTc Interval | SHORT QTC INTERVAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897619","Short ST Segment by ECG Finding","C116136","An electrocardiographic finding of a short or absent ST segment, resulting in a decreased QT interval, without changes in T wave morphology; this may be observed in hypercalcemia. (CDISC)","Short ST Segment by ECG Finding | SHORT ST SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3276315","Sinus Arrest by ECG Finding","C62242","An electrocardiographic finding in which a failure of impulse formation or conduction in the sinus node produces prolongation of the P-P interval or dropped P waves. The threshold for the prolongation of the P-P interval is not well defined. (CDISC)","Sinus Arrest by ECG Finding | SINUS ARREST/PAUSE | Sinus Arrest | Sinus Arrest by EKG Finding | Sinus Arrest/Pause | Sinus Pause | Sinus arrest/pause | Sinus pause or arrest",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003813","Sinus Arrhythmia by ECG Finding","C62239","An electrocardiographic finding in which the sinus rate fluctuates with the respiratory cycle. (CDISC)","Sinus Arrhythmia by ECG Finding | Respiratory Sinus Arrhythmia | SINUS ARRHYTHMIA | Sinus Arrhythmia | Sinus Arrhythmia by EKG Finding | Sinus arrhythmia",,,,,,,,,,,,,,,"4217221","Nodal rhythm disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2108107","Sinus Bradycardia","C111097","An electrocardiographic finding of abnormally slow heart rate with its origin in the sinus node. Thresholds for different age, gender, and patient populations exist. (CDISC)","Sinus Bradycardia by ECG Finding | SINUS BRADYCARDIA | Sinus Bradycardia | Sinus Bradycardia by EKG Finding | Sinus bradycardia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0232201","Sinus Rhythm","C100076","An electrocardiographic finding of an atrial rhythm which originates from the sinoatrial node that is considered normal for the population. (CDISC)","Sinus Rhythm | SINUS RHYTHM",,,,,,,,,,,,,,,"4091898","Sinus rhythm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054017","Sinus Slowing With AV Block by ECG Finding","C120617","An electrocardiographic tracing demonstrating the simultaneous occurrence of a slowing sinus rate and AV block.","Sinus Slowing With AV Block by ECG Finding | SINUS SLOWING WITH AV BLOCK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2108109","continuous electrocardiogram sinus tachycardia","C111104","An electrocardiographic finding of abnormally rapid heart rate with its origin in the sinus node. Thresholds for different age, gender, and patient populations exist. (CDISC)","Sinus Tachycardia by ECG Finding | SINUS TACHYCARDIA | Sinus Tachycardia | Sinus Tachycardia by EKG Finding | Sinus tachycardia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348119","ST Elevation Pericarditis by ECG Finding","C71029","An electrocardiographic finding of ST elevation which is concave upwards, and which is often accompanied by PR segment depression. (CDISC)","ST Elevation Pericarditis by ECG Finding | ST ELEVATION PERICARDITIS | ST Elevation Pericarditis | ST Elevation Pericarditis by EKG Finding | ST elevation pericarditis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897423","Supraventricular Couplet by ECG Finding","C119252","An electrocardiographic recording that demonstrates two sequential premature atrial complexes.","Supraventricular Couplet by ECG Finding | SUPRAVENTRICULAR COUPLET",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522559","Supraventricular Escape Beat by ECG Finding","C135395","An electrocardiographic finding of a compensatory supraventricular complex that occurs following a prolonged RR interval. (CDISC)","Supraventricular Escape Beat by ECG Finding | SUPRAVENTRICULAR ESCAPE BEAT | Supraventricular Escape Complex | Supraventricular Escape Complexes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540219","Supraventricular Premature Complex With Unknown Origin by ECG Finding","C142246","An electrocardiographic finding of an ectopic impulse originating from the atria or atrioventricular junction for which the site of origin cannot be determined from the surface electrocardiographic recording; there may be one or more occurrences during an electrocardiographic recording.","Supraventricular Premature Complex With Unknown Origin by ECG Finding | SUPRAVENTRICULAR PREMATURE COMPLEX, ORIGIN UNKNOWN | Supraventricular Premature Complexes, Origin Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053967","Supraventricular Run by ECG Finding","C120618","An electrocardiographic tracing demonstrating three or more consecutive QRS complexes of supraventricular origin, irrespective of rate.","Supraventricular Run by ECG Finding | SUPRAVENTRICULAR RUN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1960155","Supraventricular Tachycardia by ECG Finding","C111100","An electrocardiographic finding of a tachycardia which does not originate in the ventricles or His Purkinje system. There is an abnormally high heart rate and QRS complexes are typically narrow, but aberration or preexcitation may be present. (CDISC)","Supraventricular Tachycardia by ECG Finding | SUPRAVENTRICULAR TACHYCARDIA | SVT | Supraventricular Tachycardia | Supraventricular Tachycardia by EKG Finding | Supraventricular tachycardia",,,,,,,,,,,,,,,"4145510","EKG: supraventricular tachycardia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3827889","Suspicion of Limb Electrodes Reversal But Interpretation Assumes No Reversal by ECG Finding","C114173","An electrocardiographic recording in which an interchange of one or more limb lead electrodes is suspected, but for which an interpretation is performed as though the lead placement is correct. (CDISC)","Suspicion of Limb Electrodes Reversal But Interpretation Assumes No Reversal by ECG Finding | SUSPECT LIMB ELECTRODES REVERSED, INTERPRETATION ASSUMES NO REVERSAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827888","Suspicion of Limb Electrodes Reversal But Interpretation Assumes Reversal by ECG Finding","C114174","An electrocardiographic recording in which an interchange of one or more limb lead electrodes is suspected, and for which an interpretation is performed as though the leads have in fact been interchanged. (CDISC)","Suspicion of Limb Electrodes Reversal But Interpretation Assumes Reversal by ECG Finding | SUSPECT LIMB ELECTRODES REVERSED, INTERPRETATION ASSUMES REVERSAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053964","Sustained Supraventricular Tachycardia by ECG Finding","C120619","An electrocardiographic tracing demonstrating supraventricular tachycardia of greater than thirty seconds duration. Different thresholds, for rate and/or duration, may apply to different patient populations.","Sustained Supraventricular Tachycardia by ECG Finding | SUSTAINED SUPRAVENTRICULAR TACHYCARDIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1998313","T Wave Alternans by ECG Finding","C102718","An electrocardiographic finding in which there are variations in the shape, amplitude, or direction of the T wave from one beat to the next.","T Wave Alternans by ECG Finding | T WAVE ALTERNANS | T Wave Alternans | T Wave Alternans by EKG Finding",,,,,,,,,,,,,,,"4178308","T wave alternans",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0520888","T Wave Inversion by ECG Finding","C71085","An electrocardiographic finding of an inversion of the T wave from the expected axis.","T Wave Inversion by ECG Finding | T WAVE INVERSION | T Wave Inversion | T Wave Inversion by EKG Finding",,,,,,,,,,,,,,,"4245977","Inverted T wave",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347367","T Wave Notched by ECG Finding","C71032","An electrocardiographic finding of an irregular, u or v shaped deflection within the contour of the T wave. (CDISC)","T Wave Notched by ECG Finding | NOTCHED T WAVES | Notched T Wave | Notched T Waves | T Wave Notched | T Wave Notched by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0239242","T Wave Peaked by ECG Finding","C71086","An electrocardiographic finding in which the T wave appears increased in amplitude and cresting at a point.","T Wave Peaked by ECG Finding | T WAVE PEAKED | T Wave Peaked | T Wave Peaked by EKG Finding | T wave peaked",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348639","T Waves Biphasic by ECG Finding","C71087","An electrocardiographic finding of a T wave with both positive and negative components. (CDISC)","T Waves Biphasic by ECG Finding | T WAVES BIPHASIC | T Waves Biphasic | T Waves Biphasic by EKG Finding | T waves biphasic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348640","T Waves Flat by ECG Finding","C71088","An electrocardiographic finding in which the T wave appears decreased in amplitude.","T Waves Flat by ECG Finding | T WAVES FLAT | T Waves Flat | T Waves Flat by EKG Finding | T waves flat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827868","Tachycardia by ECG Finding","C111121","An electrocardiographic finding of abnormally rapid heart rate. Thresholds for different age, gender, and patient populations exist.","Tachycardia by ECG Finding | TACHYCARDIA | Tachycardia | Tachycardia by EKG Finding | tachycardia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0438169","U Wave Abnormality by ECG Finding","C106579","An electrocardiographic finding of U waves which have increased amplitude, are inverted, or merged with the preceding T wave.","U Wave Abnormality by ECG Finding | Abnormal U Wave | U WAVE ABNORMALITY | U Wave Abnormality | U Wave Abnormality by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897246","Undetermined Rhythm by ECG Finding","C116131","An electrocardiographic finding of a cardiac rhythm whose mechanism cannot be determined from the ECG. (CDISC)","Undetermined Rhythm by ECG Finding | UNDETERMINED RHYTHM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053899","Undetermined Supraventricular Rhythm by ECG Finding","C120607","An electrocardiographic finding of a rhythm that cannot be determined from the EKG, but that clearly does not originate in the ventricles or His Purkinje system. Typically, the QRS complexes are narrow, but aberration or preexcitation may be present.","Undetermined Supraventricular Rhythm by ECG Finding | UNDETERMINED SUPRAVENTRICULAR RHYTHM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640907","Unifocal Atrial Premature Complex by ECG Finding","C102724","An electrocardiographic finding of premature atrial complexes which have a single distinct morphology, suggesting origin at one atrial site.","Unifocal Atrial Premature Complex by ECG Finding | PREMATURE ATRIAL COMPLEXES UNIFOCAL | Premature Atrial Complex Unifocal | Unifocal Atrial Premature Complex | Unifocal Atrial Premature Complex by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL436985","Unifocal Ventricular Premature Complex by ECG Finding","C102725","An electrocardiographic finding of premature ventricular complexes which have a single distinct morphology, suggesting origin at one ventricular site.","Unifocal Ventricular Premature Complex by ECG Finding | PREMATURE VENTRICULAR COMPLEXES UNIFOCAL | Premature Ventricular Complex Unifocal | Unifocal VES | Unifocal VPCS | Unifocal Ventricular Extra Beats | Unifocal Ventricular Premature Complex | Unifocal Ventricular Premature Complex by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0429001","Ventricular Couplet by ECG Finding","C62259","An electrocardiographic finding in which two premature ventricular complexes occur sequentially. (CDISC)","Ventricular Couplet by ECG Finding | Couplet | VENTRICULAR COUPLET | Ventricular Couplet | Ventricular Couplet by EKG Finding | Ventricular Couplets | Ventricular Pair",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0232214","Ventricular Escape Beat by ECG Finding","C90483","An electrocardiographic finding of a compensatory ventricular complex that occurs following a prolonged RR interval. (CDISC)","Ventricular Escape Beat by ECG Finding | VENTRICULAR ESCAPE BEAT | Ventricular Escape Beat | Ventricular Escape Beat by EKG Finding | Ventricular Escape Beats | Ventricular Escape Complex | Ventricular Escape Complexes",,,,,,,,,,,,,,,"4327066","Ventricular escape beat",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3812283","Ventricular Flutter by ECG Finding","C111115","A ventricular tachyarrhythmia characterized by a high ventricular rate (180 and 250 beats per minute) with a regular rhythm. The electrocardiogram shows large oscillating sine wave-like complexes occurring as a result of QRS complexes and T waves being merged. The P wave is not visible.","Ventricular Flutter by ECG Finding | VENTRICULAR FLUTTER | VFl | Ventricular Flutter | Ventricular Flutter by EKG Finding | Ventricular flutter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0232215","Ventricular Parasystole by ECG Finding","C102728","An electrocardiographic finding of normal sinus rhythm coexisting with a regular ectopic ventricular rhythm.","Ventricular Parasystole by ECG Finding | Parasystole | VENTRICULAR PARASYSTOLE | Ventricular Parasystole | Ventricular Parasystole by EKG Finding",,,,,,,,,,,,,,,"4244893","Ventricular parasystole",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4049940","Ventricular Quadrigeminy by ECG Finding","C120620","An electrocardiographic tracing demonstrating three normal QRS complexes followed by a premature ventricular contraction over the course of three or more consecutive cycles; a regularly irregular rhythm of normal to abnormal QRS complexes in a 3-1 ratio.","Ventricular Quadrigeminy by ECG Finding | VENTRICULAR QUADRIGEMINY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4230510","Ventricular Repolarization Abnormality","C102574","An electrocardiographic finding of an abnormality of T wave duration or morphology or of early repolarization. (CDISC)","Ventricular Repolarization Abnormality | REPOLARIZATION ABNORMALITY | Repolarization Abnormality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053878","Ventricular Run by ECG Finding","C120621","An electrocardiographic tracing demonstrating three or more consecutive QRS complexes of ventricular origin, irrespective of rate.","Ventricular Run by ECG Finding | VENTRICULAR RUN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0344428","Ventricular Tachycardia by ECG Finding","C111103","An electrocardiographic finding of three or more consecutive complexes of ventricular organ with a rate greater than a certain threshold (100 or 120 beats per minute are commonly used). The QRS complexes are wide and have an abnormal morphology. (CDISC)","Ventricular Tachycardia by ECG Finding | VENTRICULAR TACHYCARDIA | Ventricular Tachycardia | Ventricular Tachycardia by EKG Finding | Ventricular tachycardia",,,,,,,,,,,,,,,"4064871","EKG: ventricular tachycardia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513508","Voltage Criteria Suggesting Left Ventricular Hypertrophy, Without Secondary ECG Findings","C130067","An electrocardiographic finding of large QRS amplitudes that may indicate left ventricular hypertrophy, but is without any of the secondary findings that are typically seen with this diagnosis: left atrial enlargement, left axis deviation, or typical pattern of ST depression and T wave inversion.","Voltage Criteria Suggesting Left Ventricular Hypertrophy, Without Secondary ECG Findings | VOLTAGE CRITERIA SUGGESTING LEFT VENTRICULAR HYPERTROPHY, WITHOUT SECONDARY ECG FINDINGS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1321523","Wandering Atrial Pacemaker by ECG Finding","C62240","An electrocardiographic finding of a supraventricular arrhythmia characterized by 3 or more distinct P wave morphologies with an isoelectric baseline, variable PR intervals and no predominant atrial rhythm. The ventricular rate is typically below 100 beats per minute. (CDISC)","Wandering Atrial Pacemaker by ECG Finding | WANDERING ATRIAL PACEMAKER | Wandering Atrial Pacemaker | Wandering Atrial Pacemaker by EKG Finding | Wandering atrial pacemaker",,,,,,,,,,,,,,,"4111551","Wandering atrial pacemaker",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2349152","Wide QRS Tachycardia by ECG Finding","C71090","An electrocardiographic finding of three or more consecutive wide QRS complexes of uncertain origin with a rate greater than a certain threshold (100 or 120 beats per minute are commonly used). (CDISC)","Wide QRS Tachycardia by ECG Finding | WIDE QRS TACHYCARDIA | Wide QRS Tachycardia | Wide QRS Tachycardia by EKG Finding | Wide QRS tachycardia | Wide-QRS tachycardia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936105","12 Months","C156842","A period of time of twelve months.","12 Months | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050306","CDISC SDTM Microbiology Test Code Terminology","C120527","Terminology associated with the microbiology test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Microbiology Test Code Terminology | MBTESTCD | Microbiology Test Code | SDTM-MBTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540676","Trial Compliance","C142734","Adherence to clinical trial-related requirements, good clinical practice (GCP) requirements, and the applicable regulatory requirements. (ICH)","Trial Compliance | compliance (in relation to trials)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026193","Minor Person","C156663","A subject who, according to the law of the applicable jurisdiction concerned, is under the age of legal competence to give informed consent. [after EU CTR]","Minor Person | Minor | minor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698769","Peritoneal Lymph Node","C77644","A lymph node located in the peritoneum.","Peritoneal Lymph Node | PERITONEAL LYMPH NODE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937460","Axillary Reverse Mapping","C157738","A technique used to identify the lymph nodes that drain the upper arm. Like axillary or sentinel lymph node mapping a blue dye is injected into the upper volar subcutaneous tissue of the upper arm to map the lymphatic drainage of the area. The goal of ARM, however, is to preserve these nodes and the existing lymphatic drainage field.","Axillary Reverse Mapping | ARM | ARM Procedure | ARM Technique",,,,,,,,,,,,,,,"601863","Axillary reverse mapping",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526444","Nottingham Grade","C138986","A histologic grading system developed by Elston and Ellis as a modification of the Scarff-Bloom-Richardson grading system, based on tubule formation, nuclear pleomorphism, and mitotic counts of invasive adenocarcinomas. (CW Ellston, O Ellis. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991 Nov;19(5):403-10.)","Nottingham Grade | Elston-Ellis Modification of Scarff-Bloom-Richardson Grading System | Elston-Ellis modification of Scarff-Bloom-Richardson Grading System | NOTTINGHAM HISTOLOGIC GRADE | Nottingham Histologic Grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937596","4/8 HLA Match","C158038","Degree of HLA match is 4/8 alleles with fewer than 2 mismatches per locus at HLA-A, -B, -C and -DRB1.","4/8 HLA Match | HLA Match 4/8 | Match 4/8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937597","5/8 HLA Match","C158039","Degree of HLA match is 5/8 alleles with fewer than 2 mismatches per locus at HLA-A, -B, -C and -DRB1.","5/8 HLA Match | 5/8 HLA Match  | HLA Match 5/8 | Match 5/8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937594","6/8 HLA Match","C158040","Degree of HLA match is 6/8 alleles with fewer than 2 mismatches per locus at HLA-A, -B, -C and -DRB1.","6/8 HLA Match | 6/8 HLA Match  | HLA Match 6/8 | Match 6/8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937595","7/8 HLA Match","C158041","Degree of HLA Match is 7/8 alleles with a single HLA locus mismatch at HLA-A, -B, -C or DRB1.","7/8 HLA Match | 7/8 HLA Match  | HLA Match 7/8 | Match 7/8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937592","8/8 HLA Match","C158042","Complete HLA matching for HLA-A, -B, -C, and -DRB1 loci.","8/8 HLA Match | 8/8 HLA Match  | HLA Match 8/8 | Match 8/8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0852949","Arterial Disorder","C35317","An impairment of the structure or function of the blood vessels which carry blood away from the heart.","Arterial Disorder | Arterial Disease | Arteriopathy | Disease of Arteries, Arterioles and Capillaries | Disorder of arteries and arterioles, unspecified",,,,,,,,,,,,,,,"321887","Disorder of artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0151736","Accidental Injury","C35165","Unintentional trauma to the body.","Accidental Injury | Unintentional Injury",,,,,,,,,,,,,,,"4053720","Accidental injury",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937198","Complication due to Medical/Surgical Care","C157609","An untoward event that can be attributed to care received during a medical/surgical event.","Complication due to Medical/Surgical Care | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937196","Chronic Lower Respiratory System Disorder","C157607","A non-neoplastic longstanding disorder of the lower respiratory system.","Non-Neoplastic Chronic Lower Respiratory System Disorder | Chronic Lower Respiratory System Disorder | Chronic Lower Respiratory System Disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0000932","Automobile Accident","C34344","An accident occurring while aboard, or involving, an automobile.","Automobile Accident | Motor Vehicle Accident",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937193","Firearm Injury","C157612","An injury sustained by a gun.","Firearm Injury | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985265","Finding During Childbirth Labor","C92718","Symptom, signs, test results in a pregnant mother childbirth.","Finding During Childbirth Labor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085580","Essential Hypertension","C3478","Hypertension that presents without an identifiable cause.","Essential Hypertension | Essential (primary) hypertension | Primary Hypertension",,,,,,,,,,,,,,,"320128","Essential hypertension",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0012736","Dissecting Aortic Aneurysm","C26751","A dissecting aneurysm formed between the intimal and medial layers of the aortic wall due to a tear in the tunica intima.","Dissecting Aortic Aneurysm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937199","Death by Overdose","C157610","A death that is attributed to an excessive amount of a substance.","Death by Overdose | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937192","Death by Alcohol Ingestion","C157611","A death that is attributed to excessive alcohol ingestion.","Death by Alcohol Ingestion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937197","Homicide by Assault","C157608","Death of an individual by physical violence from another.","Homicide by Assault | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162665","Terminal Sedation","C21115","The purposeful use of morphine, other opiates, or other pharmaceuticals at doses adequate to end life functions.","Terminal Sedation | Assisted Suicide | Euthanasia | Euthanized | Mercy Killing | euthanasia | mercy killing",,,,,,,,,,,,,,,"4198985","Assisted suicide",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937190","Symptoms, Signs and Abnormal Clinical and Laboratory Findings, NEC","C157617","A header term for symptoms, signs and abnormal clinical and laboratory findings that is not elsewhere classified.","Symptoms, Signs and Abnormal Clinical and Laboratory Findings, NEC | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020544","Renal Hypertension","C3121","Hypertension caused by narrowing or occlusion of the renal arteries.","Renal Hypertension | ",,,,,,,,,,,,,,,"443771","Renal hypertension",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0747772","Postpartum Complication","C116323","Any adverse event that arises in the six week period immediately following the delivery of a fetus.","Postpartum Complication | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0270075","Perinatal Disorder","C35095","A non-neoplastic or neoplastic disorder occurring during the period from about five months before birth to one month after birth.","Perinatal Disorder | ",,,,,,,,,,,,,,,"4187201","Perinatal disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937189","Other and Unspecified Infectious and Parasitic Diseases and their Sequelae","C157616","Unspecified infectious and parasitic diseases and their sequelae other than those otherwise specified.","Other and Unspecified Infectious and Parasitic Diseases and their Sequelae | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937188","Other and Unspecified Events of Undetermined Intent and their Sequelae","C157615","Events of undetermined intent and their sequelae other than those otherwise specified.","Other and Unspecified Events of Undetermined Intent and their Sequelae | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714509","Nutritional Disorder","C26836","Any condition related to a disturbance between proper intake and utilization of nourishment.","Nutritional Disorder | ",,,,,,,,,,,,,,,"4090739","Nutritional disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0677041","Neoplasm, Uncertain Whether Benign or Malignant","C65157","A neoplasm which, on morphologic grounds, can not be classified with certainty as benign or malignant.","Neoplasm, Uncertain Whether Benign or Malignant | Neoplasm, uncertain whether benign or malignant | Neoplasms of Uncertain and Unknown Behavior","8000/1","Neoplasm, uncertain whether benign or malignant",,,,,,,,,,,,,"4313421","Neoplasm of uncertain behavior",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C2919581","Bosnian Language","C153863","An Indo-European, Balto-Slavic variety of Serbo-Croatian spoken mainly by the Bosniak ethnic group of Bosnia and Herzegovina.","Bosnian Language | BOS | Bosnian",,,,,,,,,,,,,,,"40481563","Bosnian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004981","Bengali Language","C153856","An Indo-Aryan language spoken in South Asia. It is the official and most widely spoken language of Bangladesh.","Bengali Language | BEN | Bangla | Bengali",,,,,,,,,,,,,,,"4052786","Bengali language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003799","Armenian Language","C153953","An Indo-European language spoken as the official language of Armenia.","Armenian Language | Armenian | HYE",,,,,,,,,,,,,,,"4180063","Armenian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574292","Aleut Language","C153831","The sole language in the Aleut branch of the Eskimo-Aleut language family. It is spoken by the Aleut people living in the Aleutian Islands, Pribilof Islands, Commander Islands, and the Alaskan Peninsula.","Aleut Language | ALE | Aleut",,,,,,,,,,,,,,,"4175768","Aleut language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001757","Afrikaans Language","C153828","A West Germanic language, evolved from Dutch, spoken in South Africa, Namibia and, to a lesser extent, Botswana and Zimbabwe.","Afrikaans Language | AFR | Afrikaans",,,,,,,,,,,,,,,"4180185","Afrikaans language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556396","Haitian Creole Language","C153942","A French-based creole language native to Haiti.","Haitian Creole Language | HAT | Haitian | Haitian Creole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2585445","Galician Language","C153932","An Indo-European language of the Western Ibero-Romance branch spoken in the Galicia community of northwestern Spain.","Galician Language | GLG | Galician",,,,,,,,,,,,,,,"4261080","Galician language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574307","Scottish Gaelic Language","C153930","An Indo-European Celtic language native to the Gaels of Scotland.","Scottish Gaelic Language | GLA | Gaelic | Scots Gaelic | Scottish Gaelic",,,,,,,,,,,,,,,"4181529","Scottish Gaelic language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016134","Finnish Language","C153919","A Finnic language spoken by a majority of the population in Finland and by ethnic Finns outside Finland.","Finnish Language | FIN | Finnish",,,,,,,,,,,,,,,"4181730","Finnish language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014909","Estonian Language","C153910","A Uralic language of the Finnic branch, spoken as the official language of Estonia.","Estonian Language | EST | Estonian",,,,,,,,,,,,,,,"4183943","Estonian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010871","Czech Language","C153875","A West Slavic language that serves as the official language of the Czech Republic.","Czech Language | CES | Czech",,,,,,,,,,,,,,,"4180197","Czech language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0684046","Croatian Language","C153950","The standardized variety of the Serbo-Croatian language used by Croats, principally in Croatia, Bosnia and Herzegovina.","Croatian Language | Croatian | HRV",,,,,,,,,,,,,,,"40481973","Croatian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574373","Javanese Language","C153962","An Austronesian language spoken by the Javanese people from the central and eastern parts of the island of Java, Indonesia.","Javanese Language | JAV | Javanese",,,,,,,,,,,,,,,"4175914","Javanese language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1553352","Irish Language","C153931","An Indo-European Celtic language originating in Ireland and historically spoken by the Irish people.","Irish Language | GLE | Irish",,,,,,,,,,,,,,,"4180182","Irish Gaelic language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021248","Indonesian Language","C153959","An Austronesian language that is a standardized register of Malay and the official language of Indonesia.","Indonesian Language | IND | Indonesian",,,,,,,,,,,,,,,"4183663","Indonesian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019547","Hindi Language","C153948","A standardized and Sanskritized register of the Hindustani language.","Hindi Language | HIN | Hindi",,,,,,,,,,,,,,,"4052346","Hindi language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018863","Hebrew Language","C153945","A Northwest Semitic language native to Israel.","Hebrew Language | HEB | Hebrew",,,,,,,,,,,,,,,"4180047","Hebrew language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162878","Hawaiian Language","C153944","A Polynesian language native to the Hawaiian islands of the United States.","Hawaiian Language | HAW | Hawaiian",,,,,,,,,,,,,,,"4181557","Hawaiian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574154","Hausa Language","C153943","An Afro-Asiatic Chadic language native to Niger, Nigeria, Ghana, Benin, Cameroon, Ivory Coast, Togo and Sudan.","Hausa Language | HAU | Hausa",,,,,,,,,,,,,,,"4178556","Hausa language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032376","Polish Language","C154079","An Indo-European West Slavic language spoken primarily in Poland as the native language of the Poles.","Polish Language | POL | Polish",,,,,,,,,,,,,,,"4182515","Polish language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031188","Persian Language","C153916","A Western Iranian language within the Indo-Iranian branch of the Indo-European language family primarily spoken in Iran, Afghanistan, and Tajikistan.","Persian Language | FAS | Persian",,,,,,,,,,,,,,,"4183659","Persian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028424","Norwegian Language","C154059","A North Germanic language that is the official language of Norway.","Norwegian Language | NOR | Norwegian",,,,,,,,,,,,,,,"4181530","Norwegian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027690","Nepali Language","C154051","An Indo-Aryan language that is the official language of Nepal.","Nepali Language | NEP | Nepali",,,,,,,,,,,,,,,"4175908","Nepali language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024782","Marathi Language","C154021","An Indo-Aryan language spoken predominantly by the Marathi people of Maharashtra, India.","Marathi Language | MAR | Marathi",,,,,,,,,,,,,,,"4182519","Marathi language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024549","Malay Language","C154037","An Austronesian language spoken in Brunei, Indonesia, Malaysia and Singapore.","Malay Language | MSA | Malay",,,,,,,,,,,,,,,"4183666","Malay language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024407","Macedonian Language","C154028","A South Slavic language spoken principally in the Republic of Macedonia and by the Macedonian diaspora.","Macedonian Language | MKD | Macedonian",,,,,,,,,,,,,,,"4175905","Macedonian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556409","Lahnda Language","C153995","A group of north-western Indo-Aryan language varieties spoken in Pakistani Punjab and in parts of the neighboring Azad Kashmir and Khyber Pakhtunkhwa.","Lahnda Language | LAH | Lahnda | Lahndi | Western Punjabi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555102","Modern Greek Language","C153909","Refers to the dialects and varieties of the Greek language spoken in the modern era.","Modern Greek Language | ELL | Modern Greek",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574528","Wolof Language","C154198","A Niger-Congo language spoken by the Wolof people of Senegal, the Gambia, and Mauritania.","Wolof Language | WOL | Wolof",,,,,,,,,,,,,,,"4177312","Wolof language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0376253","Welsh Language","C153892","A member of the Brittonic branch of the Celtic languages spoken natively in Wales.","Welsh Language | CYM | Welsh",,,,,,,,,,,,,,,"4175774","Welsh language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041941","Urdu Language","C154188","A Persianized standard register of the Hindustani language that is the official national language of Pakistan.","Urdu Language | URD | Urdu",,,,,,,,,,,,,,,"4059788","Urdu language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041402","Turkish Language","C154180","The most widely spoken of the Turkic languages, spoken as an official language in Turkey, Northern Cyprus, and Cyprus.","Turkish Language | Istanbul Turkish | TUR | Turkish",,,,,,,,,,,,,,,"4175744","Turkish language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555021","Standard Tibetan Language","C153862","A Sino-Tibetan language that is an official language of the Tibet Autonomous Region of the People's Republic of China.","Standard Tibetan Language | BOD | Standard Tibetan | Tibetan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039466","Telugu Language","C154153","A South-central Dravidian language native to India, where it is the primary language in the states of Andhra Pradesh, Telangana, and the union territory of Puducherry.","Telugu Language | TEL | Telugu",,,,,,,,,,,,,,,"4175767","Telugu language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038977","Swahili Language","C154145","A Niger-Congo Bantu language spoken by the Swahili people throughout eastern and south-eastern Africa.","Swahili Language | SWA | Swahili",,,,,,,,,,,,,,,"4181698","Swahili language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037332","Slovak Language","C154116","An Indo-European West Slavic language that is the official language of Slovakia.","Slovak Language | SLK | Slovak",,,,,,,,,,,,,,,"4181540","Slovak language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0424925","Punjabi Language","C154075","An Indo-Aryan language spoken by the Punjabi people of northwest India and eastern Pakistan.","Punjabi Language | PAN | Panjabi | Punjabi",,,,,,,,,,,,,,,"4059175","Punjabi language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0000778","ABO Blood Group","C76245","A blood group system based on recognition of inherited differences in the H antigen as expressed on erythrocytes.","ABO Blood Group | ABO Blood Type | ABO blood group system | ABO_Type",,,,,,,,,,,,,,,"4271584","ABO blood group system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2347797","Clinical Study Status","C70703","A business process state of a clinical study in relation to its approval status, authorization for patient enrollment, and protocol-specific activities.","Clinical Study Status | Clinical Study Protocol Status | Protocol Status | StudyOverallStatus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937582","PKLR NP_000289.1:p.R479H","C158053","A change in the amino acid residue at position 479 in the pyruvate kinase PKLR protein where arginine has been replaced by histidine.","PKLR NP_000289.1:p.R479H | NP_000289.1:p.Arg479His | NP_000289.1:p.R479H | PKLR Arg479His | PKLR NP_000289.1:p.Arg479His | PKLR R479H | PKLR R479H Mutation | PKLR p.Arg479His | PKLR p.R479H | Pyruvate Kinase 1 Arg479His | Pyruvate Kinase 1 R479H | Pyruvate Kinase Isozyme R/L Arg479His | Pyruvate Kinase Isozyme R/L R479H | Pyruvate Kinase Isozymes L/R Arg479His | Pyruvate Kinase Isozymes L/R R479H | Pyruvate Kinase Isozymes R/L Arg479His | Pyruvate Kinase Isozymes R/L R479H | Pyruvate Kinase L/R Arg479His | Pyruvate Kinase L/R R479H | Pyruvate Kinase PKLR Arg479His | Pyruvate Kinase PKLR R479H | R-Type/L-Type Pyruvate Kinase Arg479His | R-Type/L-Type Pyruvate Kinase R479H | Red Cell/Liver Pyruvate Kinase Arg479His | Red Cell/Liver Pyruvate Kinase R479H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511432","CDKN2C Gene Mutation","C41613","A change in the nucleotide sequence of the CDKN2C gene.","CDKN2C Gene Mutation | CDKN6 Gene Mutation | Cyclin Dependent Kinase Inhibitor 2C Gene Mutation | Cyclin-Dependent Kinase Inhibitor 2C Gene Mutation | INK4C Gene Mutation | p18 Gene Mutation | p18(INK4C) Gene Mutation | p18-INK4C Gene Mutation | p18-INK6 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937583","NTRK2 Gene Mutation","C158054","A change in the nucleotide sequence of the NTRK2 gene.","NTRK2 Gene Mutation | NTRK2 Mutation | Neurotrophic Tyrosine Kinase Receptor 2 Gene Mutation | Neurotrophic Tyrosine Kinase Receptor Type 2 Gene Mutation | TRKB Gene Mutation | TRKB Tyrosine Kinase Gene Mutation | Tropomyosin-Related Kinase B Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937580","NTRK3 Gene Mutation","C158055","A change in the nucleotide sequence of the NTRK3 gene.","NTRK3 Gene Mutation | NTRK3 Mutation | Neurotrophic Tyrosine Kinase Receptor 3 Gene Mutation | Neurotrophic Tyrosine Kinase Receptor Type 3 Gene Mutation | Neurotrophic Tyrosine Kinase, Receptor, Type 3 Gene Mutation | TRKC Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937581","Neoplastic Plasma Cells 20 Percent or More of Peripheral Blood White Cells","C158056","A semi-quantitative microscopic finding indicating that at least 20 percent of the nucleated cells in a peripheral leukocyte sample are neoplastic plasma cells.","Neoplastic Plasma Cells 20 Percent or More of Peripheral Blood White Cells | Neoplastic Plasma Cells Greater than or Equal to 20 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937578","NOTCH3 Gene Mutation","C158057","A change in the nucleotide sequence of the NOTCH3 gene.","NOTCH3 Gene Mutation | CADASIL Gene Mutation | CASIL Gene Mutation | IMF2 Gene Mutation | Notch (Drosophila) Homolog 3 Gene Mutation | Notch 3 Gene Mutation | Notch Homolog 3 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937576","Activating NOTCH2 Mutation","C158059","A change in the nucleotide sequence of the NOTCH2 gene that that results in constitutive activation of both neurogenic locus notch homolog protein 2 and its downstream signaling pathways.","Activating NOTCH2 Mutation | Activating AGS2 Gene Mutation | Activating HJCYS Gene Mutation | Activating NOTCH2 Gene Mutation | Activating Notch (Drosophila) Homolog 2 Gene Mutation | Activating Notch 2 Gene Mutation | Activating Notch Homolog 2 Gene Mutation | Activating hN2 Gene Mutation | NOTCH2 Activating Gene Mutation | NOTCH2 Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937574","NOTCH4 Gene Mutation","C158061","A change in the nucleotide sequence of the NOTCH4 gene.","NOTCH4 Gene Mutation | INT2 Gene Mutation | INT3 Gene Mutation | Notch 4 Gene Mutation | Notch Homolog 4 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937575","Activating NOTCH4 Mutation","C158062","A change in the nucleotide sequence of the NOTCH4 gene that that results in constitutive activation of both neurogenic locus notch homolog protein 4 and its downstream signaling pathways.","Activating NOTCH4 Mutation | Activating INT3 Gene Mutation | Activating NOTCH4 Gene Mutation | Activating Notch 4 Gene Mutation | Activating Notch Homolog 4 Gene Mutation | NOTCH4 Activating Gene Mutation | NOTCH4 Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937572","Activating NOTCH1 Mutation","C158063","A change in the nucleotide sequence of the NOTCH1 gene that that results in constitutive activation of both neurogenic locus notch homolog protein 1 and its downstream signaling pathways.","Activating NOTCH1 Mutation | Activating NOTCH1 Gene Mutation | Activating Notch 1 Gene Mutation | Activating Notch Homolog 1 Gene Mutation | Activating TAN1 Gene Mutation | Activating hN1 Gene Mutation | NOTCH1 Activating Gene Mutation | NOTCH1 Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935977","Number of Pack Years Smoked","C156834","A measurement of the amount of smoking exposure an individual has had over time, which is calculated by multiplying the number of cigarettes smoked per day by the number of years smoked, and dividing the product by the number of cigarettes in a pack.","Number of Pack Years Smoked | Number of pack years smoked",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937573","CTNNA1 Gene Mutation","C158064","A change in the nucleotide sequence of the CTNNA1 gene.","CTNNA1 Gene Mutation | CAP102 Gene Mutation | Catenin Alpha 1 Gene Mutation | Catenin Alpha-1 Gene Mutation | Catenin, Alpha-1 Gene Mutation | MDPT2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937709","Lymphoma Cells More than 25 Percent of Bone Marrow Nucleated Cells","C158065","A semi-quantitative microscopic finding indicating that more than 25 percent of the nucleated cells in a bone marrow sample are lymphoma-derived cells.","Lymphoma Cells More than 25 Percent of Bone Marrow Nucleated Cells | Lymphoma Cells Greater than 25 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937397","HOXB13 Gene Mutation","C157753","A change in the nucleotide sequence of the HOXB13 gene.","HOXB13 Gene Mutation | HOXB13 | HPC9 Gene Mutation | Homeo Box B13 Gene Mutation | Homeobox B13 Gene Mutation | Hox-B13 Gene Mutation | PSGD Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937396","Germline HOXB13 Gene Mutation","C157756","A change in the nucleotide sequence of the HOXB13 gene that originates in the gametes.","Germline HOXB13 Gene Mutation | Germline HPC9 Gene Mutation | Germline Homeo Box B13 Gene Mutation | Germline Homeobox B13 Gene Mutation | Germline Hox-B13 Gene Mutation | Germline PSGD Gene Mutation | HOXB13 Germline Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935823","Smoking History","C156825","The history of when and what an individual smoke(s) or smoked.","Smoking History | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937218","Mismatch Repair Proficient","C157646","A finding indicating that a sample has normal concentrations of unmutated mismatch repair proteins and is either microsatellite stable or has low microsatellite instability.","Mismatch Repair Proficient | MSI-H/dMMR Negative | Mismatch Repair Deficiency Negative | Mismatch Repair Proficiency | Mismatch Repair-Proficient | No dMMR or MSI-H | Non-MSI-H/dMMR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936908","PKLR Gene Mutation","C157141","A change in the nucleotide sequence of the PKLR gene.","PKLR Gene Mutation | PK1 Gene Mutation | PKL Gene Mutation | PKR Gene Mutation | PKRL Gene Mutation | Pyruvate Kinase L/R Gene Mutation | Pyruvate Kinase, Liver and RBC Gene Mutation | RPK Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937210","Blasts 0.01 Percent or More of Bone Marrow Nucleated Cells","C157653","A semi-quantitative microscopic finding indicating that at least 0.01 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 0.01 Percent or More of Bone Marrow Nucleated Cells | Blasts Greater than or Equal to 0.01 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937707","Activating ALK Gene Mutation Negative","C158068","A genetic finding indicating that mutations in the ALK gene which encode constitutively active forms of the ALK tyrosine kinase receptor protein are not present in a sample.","Activating ALK Gene Mutation Negative | ALK Activating Gene Mutation Negative | ALK Activating Mutation Negative | Activating ALK Mutation Negative | Activating ALK Receptor Tyrosine Kinase Gene Mutation Negative | Activating Anaplastic Lymphoma Kinase Receptor Gene Mutation Negative | Activating Anaplastic Lymphoma Receptor Tyrosine Kinase Gene Mutation Negative | Activating CD246 Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937708","Activating ROS1 Gene Mutation Negative","C158069","A genetic finding indicating that mutations in the ROS1 gene which encode constitutively active forms of the proto-oncogene tyrosine-protein kinase ROS protein are not present in a sample.","Activating ROS1 Gene Mutation Negative | Activating MCF3 Gene Mutation Negative | Activating ROS Gene Mutation Negative | Activating ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene Mutation Negative | Activating ROS1 Mutation Negative | Activating c-ros-1 Gene Mutation Negative | ROS Activating Gene Mutation Negative | ROS1 Activating Gene Mutation Negative | ROS1 Activating Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937705","FGFR3 Gene Rearrangement","C158072","A molecular abnormality indicating rearrangement of the FGFR3 gene.","FGFR3 Gene Rearrangement | CD333 Gene Rearrangement | FGFR-3 Gene Rearrangement | Fibroblast Growth Factor Receptor 3 Gene Rearrangement | JKT4 Gene Rearrangement | JTK4 Gene Rearrangement | Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827026","Trial Arm Order","C83438","The order in which elements are organized within the trial arm of a study.","Trial Arm Order | TAETORD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL376219","recombinant adenovirus-interferon SCH 721015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3892974","Ceftazidime/Avibactam Sodium","C127836","A combination preparation containing the third-generation cephalosporin ceftazidime and the sodium salt form of avibactam, a non-beta-lactam beta-lactamase inhibitor, with antibiotic and beta-lactamase inhibiting activity, respectively. Upon administration, ceftazidime binds to essential penicillin-binding proteins (PBPs) and inhibits cell wall synthesis in certain bacteria. Avibactam binds to and inactivates beta-lactamases, thereby protecting ceftazidime from degradation and increasing ceftazidime's efficacy.","Ceftazidime/Avibactam Sodium | Avycaz | CAZ-AVI | Ceftazidime-Avibactam Sodium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1135662","Dornase Alfa","C81664","A recombinant human deoxyribonuclease I (rhDNAse) with selective DNA cleaving activity. Upon intrapleural administration, dornase alfa catalyzes the degradation of extracellular DNA in airway secretions, which can reduce their viscosity. Thus, dornase alfa may both promote the clearing of airway mucus and improve pulmonary function.","Dornase Alfa | DORNASE ALFA | Pulmozyme | Recombinant Human Deoxyribonuclease I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3700399","Naloxegol","C97506","A pegylated form of naloxone, a peripherally-acting mu-opioid receptor antagonist, that can be used to reduce opioid-induced symptoms. Upon administration, naloxegol binds to and blocks mu-opioid receptors in the peripheral nervous system. This prevents peripheral opioid receptor activation and abrogates opioid-induced side effects, such as opioid-induced constipation (OIC). Pegylation of naloxone reduces permeability across the blood-brain barrier (BBB) and prevents this agent from interfering with the analgesic activity of opioid receptor agonists.","Naloxegol | AZ13337019 | Morphinan-3,14-diol, 4,5-Epoxy-6-(3,6,9,12,15,18,21-heptaoxadocos-1-yloxy)- 17-(2-propenyl)-, (5alpha,6alpha)- | Movantik | NALOXEGOL | NKTR-118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937352","Solid Nodule","C157658","Fully opaque attenuation through which no normally arborizing structures are visible.","Solid Nodule | Solid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937207","Pure Ground Glass Nodule","C157659","Focal increased opacity through which normal parenchymal structures (airways and vessels) can be seen. If, on lung windows, there is a solid component of greater than or equal to 2 mm that is not vascular or airway, the nodule is not pure ground glass.  Visibility of normal underlying interstitium is acceptable.","Pure Ground Glass Nodule | Pure GGN | Pure Ground Glass",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937208","Part-Solid Nodule","C157660","Nodule with both ground-glass and solid components. The solid component corresponds to NO underlying normal anatomy, obscures the underlying lung structures and should measure at least 2 mm. The solid component should be measured in longest dimension.","Part-Solid Nodule | PSN | Part-solid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937209","Semiconsolidation Nodule","C157661","Nodule with dense (high) attenuation through which some normal underlying structures are visible. Semiconsolidation may appear as subsolid lung attenuation with thickened underlying reticulation or bronchovascular anatomy. In some instances, it may be challenging to distinguish the nodule from pGGNs or PSNs. The nodule is PSN if there is any solid component greater than 2 mm that is not underlying lung.","Semiconsolidation Nodule | Semiconsolidation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937342","Well Marginated Nodule","C157663","The nodule margin can be outlined with your pencil. Spiculated margins are not necessarily poorly marginated; ground glass nodules may be well marginated.","Well Marginated Nodule | Well | Well marginated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937206","Poorly Marginated Nodule","C157664","The nodule margin blends into adjacent lung without clear demarcation between nodule edge and normal lung (i.e., the entire circumference of the nodule can't be drawn with confidence). This is to be distinguished from faint (but definable) margination, as with subsolid nodules.","Poorly Marginated Nodule | Poorly | Poorly marginated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937353","Smooth Nodule","C157666","Featureless margin that cleanly demarcates the nodule from surrounding lung with no undulations or irregularities.","Smooth Nodule | Smooth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937203","Lobulated Nodule","C157667","Smooth or roughly undulating margin in which two or more regions of the nodule extend out from the adjacent surface but having a broader base and smoother convexity than serrations. Lobulations may be subtle. If the nodule has lobulations that are serrated or spiculated, it should be classified as serrated/spiculated.","Lobulated Nodule | Lobulated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205316","Notched Nodule","C157668","Single clear indentation of the nodule surface, resulting in a smooth or sharp concavity along the nodule margin (usually distinguished from lobulated by the fact there is one predominant indentation and the concavity is greater than or equal to 3 mm.","Notched Nodule | Notched | Notched (Concavity)",,,,,,,,,,,,,,,"4299246","Notched",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937204","Spiculated or Serrated Nodule","C157669","A nodule having either spiculated or serrated margin characteristics.","Spiculated or Serrated Nodule | Spiculated or Serrated | Spiculated/Serrated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937356","Spiculated Nodule","C157670","The presence of two or more linear opacities extending from the nodule margin that taper as their distance from the nodule increases. Use tapering to distinguish from external septal stretching.","Spiculated Nodule | Micro-spiculations | Spiculated | Spiculation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937347","Serrated Nodule","C157671","A jagged, ragged, saw-tooth appearance in which individual extensions extend less than 3 mm from adjacent margins. Do NOT include subtle tenting if only observed at the site of external septal stretching.","Serrated Nodule | Micro-serrations | Serrated | Serration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937320","Indeterminate Nodule Type","C157672","The margin satisfies none of the other categories or cannot be determined with confidence.","Indeterminate Nodule Type | Indeterminate | Indeterminate Nodule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937318","Round Nodule","C157674","Nodule shape conforming to a roughly spherical shape, independent of spiculations.","Round Nodule | Round",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL564619","Ovoid Nodule","C157675","Nodule shape conforming to a roughly ovoid shape, in which the perpendicular diameters are dissimilar (there being a long diameter and a short diameter that differ by at least 30 percent).","Ovoid Nodule | Ovoid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937351","Polygonal Nodule","C157676","A nodule shape that is a two dimensional with 3 or more straight sides that do not cross and is a closed shape. Examples of polygons would include triangles, squares, rectangles, hexagons, and octagons. Polygonal nodules are commonly delimited by interlobular septal margins and are a feature of intrapulmonary lymph nodes or possibly bronchiolar/arteriolar disease.","Polygonal Nodule | Polygonal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937319","Complex Nodule Shape","C157677","A complex shape has no normally geometric shape and combines multiple more simple shapes. If no classically defined shape applies, the lesion is likely complex.","Complex Nodule Shape | Complex | Complex Nodule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539590","Not Allowed To Collect","C141478","An indicator that specifies that a collection event was not permitted.","Not Allowed To Collect | not allowed to collect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826306","Reference Time Point","C82576","The point in time that acts as a fixed reference point to an event.","Reference Time Point | TIME_POINT | TPTREF | Time Point Reference",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332564","Bladder Small Cell Neuroendocrine Carcinoma","C9461","A small cell neuroendocrine carcinoma arising from the bladder.","Bladder Small Cell Neuroendocrine Carcinoma | Bladder Small Cell Carcinoma | Bladder Small Cell Carcinoma | Bladder Small Cell Neuroendocrine Cancer | Small Cell Neuroendocrine Carcinoma of Urinary Bladder | Small Cell Neuroendocrine Carcinoma of the Urinary Bladder",,,,,,,,,,,,,,,"36713671","Small cell neuroendocrine carcinoma of bladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0279682","Bladder Adenocarcinoma","C4032","A rare adenocarcinoma arising from metaplastic bladder epithelium. It is frequently associated with long-standing local irritation. The majority of cases originate from the trigone and the posterior wall of the bladder. This group does not include clear cell and endometrioid adenocarcinomas.","Bladder Adenocarcinoma | Adenocarcinoma of Bladder | Adenocarcinoma of Urinary Bladder | Adenocarcinoma of the Bladder | Adenocarcinoma of the Urinary Bladder | Bladder Adenocarcinoma Excluding Clear Cell Adenocarcinoma and Endometrioid Adenocarcinoma | Urinary Bladder Adenocarcinoma",,,,,,,,,,,,,,,"4111028","Adenocarcinoma of bladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0279681","Bladder Squamous Cell Carcinoma","C4031","A squamous cell carcinoma of the bladder arising from metaplastic epithelium.  It represents less than 10% of bladder carcinomas.  The exception is the Middle East along the Nile Valley, where it represents the most common form of carcinoma because of the endemic nature of schistosomiasis.  Bladder squamous cell carcinoma is often associated with long-standing chronic inflammation of the bladder and usually has a poor prognosis.  The diagnosis of squamous cell carcinoma of the bladder should be reserved for those tumors that are predominantly keratin forming.","Bladder Squamous Cell Carcinoma | Bladder Epidermoid Carcinoma | Bladder Squamous Cell Cancer | Epidermoid Carcinoma of Bladder | Epidermoid Carcinoma of Urinary Bladder | Epidermoid Carcinoma of the Bladder | Epidermoid Carcinoma of the Urinary Bladder | Squamous Cell Carcinoma of Bladder | Squamous Cell Carcinoma of Urinary Bladder | Squamous Cell Carcinoma of the Bladder | Squamous Cell Carcinoma of the Urinary Bladder | Urinary Bladder Epidermoid Carcinoma | Urinary Bladder Squamous Cell Carcinoma",,,,,,,,,,,,,,,"4113112","Squamous cell carcinoma of bladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512739","Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant","C39823","Invasive bladder urothelial carcinoma characterized by the presence of malignant cells with plasmacytoid features.","Invasive Bladder Plasmacytoid Urothelial Carcinoma | Bladder Plasmacytoid Urothelial Carcinoma | Infiltrating Bladder Urothelial Carcinoma, Lymphoma-Like/Plasmacytoid Variant | Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant | Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant | Invasive Bladder Lymphoma-Like/Plasmacytoid Urothelial Carcinoma | Invasive Bladder Urothelial Carcinoma, Lymphoma-Like/Plasmacytoid Variant | Invasive Bladder Urothelial Carcinoma, Plasmacytoid Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519972","Household Member","C132449","An individual who is considered part of the social unit comprising one or more individuals living together (all of whom need not be related) in the same dwelling, who aggregate and share their incomes.","Household Member | HOUSEHOLD MEMBER | Household Resident",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3888235","Procedure Agents Domain","C117755","A domain utilized for the submission of information encompassing and representing data, vocabulary or records related to agents used as part of a procedure.","Procedure Agents Domain | AG | Procedure Agents",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640261","CDISC SDTM Cardiovascular Test Name Terminology","C101846","Terminology associated with the cardiovascular test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Cardiovascular Test Name Terminology | CVTEST | Cardiovascular Test Name | SDTM-CVTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526511","Aneurysm Indicator","C139038","An indication as to whether there is the presence of an aneurysm.","Aneurysm Indicator | ANEURIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539109","Cardiac Valvular Regurgitation Severity","C102244","The qualitative measurement of the severity of cardiac valvular regurgitation.","Cardiac Valvular Regurgitation Severity | CVLREGTS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526495","Cardiac Valvular Regurgitation Indicator","C139055","An indication as to whether a specific cardiac valve is regurgitant.","Cardiac Valvular Regurgitation Indicator | CVRGIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526501","Cardiac Valvular Regurgitation Likely Etiology","C139056","An estimation as to the cause of the pathology responsible for the cardiac valve regurgitation.","Cardiac Valvular Regurgitation Likely Etiology | CVRGLE | Cardiac Valvular Regur Likely Etiology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540220","Cardiac Valve Stenosis Likely Etiology","C142245","A description of the likely cause of the pathology responsible for the cardiac valve stenosis.","Cardiac Valve Stenosis Likely Etiology | VLSTNSLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508674","Cardiac Valve Regurgitant Jet Direction","C127563","The anatomic trajectory of the retrograde blood flow from a cardiac valve.","Cardiac Valve Regurgitant Jet Direction | CVRGJDR | Cardiac Valve Regur Jet Direction | Cardiac Valve Regurgitation Jet Direction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007165","Cardiac Output","C119246","The total volume of blood pumped by the heart over a set period of time, conventionally one minute; it is calculated as heart rate times stroke volume (CO= HR x SV), and is additionally dependent on preload and afterload for functional output.","Cardiac Output | CARDOUT | Cardiac output",,,,,,,,,,,,,,,"4221102","Cardiac output",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526502","Heart Chamber Hypertrophy Indicator","C139063","An indication as to whether there is a hypertrophied heart chamber.","Heart Chamber Hypertrophy Indicator | CMHYIND | Cardiac Muscle Hypertrophy Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0428776","Cardiac Index","C119245","The measure of an individual's cardiac output as divided by their body surface area (CI= CO/BSA). This calculation is a useful function to determine an individual's cardiac performance in relation to their body size, providing an overview of global cardiovascular function.","Cardiac Index | CARDIDX | Cardiac index",,,,,,,,,,,,,,,"4208254","Cardiac index",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1999075","Blood Flow Rate","C94866","The volume of blood per unit time passing through a specified location, such as a point in a blood vessel or an entire organ. Units are ml/sec.","Blood Flow Rate | BLDFLRT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509603","Area at End Ventricular Systole","C127538","The 2-dimensional surface enclosed within a boundary and measured at end ventricular systole.","Area at End Ventricular Systole | AREAEVS | Area, End Ventricular Systole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509602","Area at End Ventricular Diastole","C127537","The 2-dimensional surface enclosed within a boundary and measured at end ventricular diastole.","Area at End Ventricular Diastole | AREAEVD | Area, End Ventricular Diastole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509009","Aortic Valve Vena Contracta Width","C127544","The width of the vena contracta of the aortic valve.","Aortic Valve Vena Contracta Width | AVVCW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509008","Aortic Valve Vena Contracta Area","C127543","The area of the vena contracta of the aortic valve.","Aortic Valve Vena Contracta Area | AVVCA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509007","Aortic Valve Regurgitant Volume","C127542","A quantitative measurement of the amount of retrograde blood flow across the orifice of the aortic valve.","Aortic Valve Regurgitant Volume | AVRGVOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509006","Aortic Valve Regurgitant Jet Width","C127541","The measured width of the backflow of blood into the left ventricular outflow tract.","Aortic Valve Regurgitant Jet Width | AVRGJW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509005","Aortic Valve Regurgitant Fraction","C127540","A quantitative measurement of the amount of retrograde blood flow across the orifice of the aortic valve expressed as a percentage of the anterograde flow.","Aortic Valve Regurgitant Fraction | AVRGF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509604","Aortic Regurgitant Jet Width to Left Ventricular Outflow Tract Diameter Ratio","C127539","A relative measurement (ratio or percentage) of the aortic regurgitant jet width to left ventricular outflow tract diameter.","Aortic Regurgitant Jet Width to Left Ventricular Outflow Tract Diameter Ratio | ARGJWLVD | Aortic Regur Jet Width LVOT Diam Rt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526507","Aortic Preductal Coarctation Severity","C139034","The assessment of the severity of preductal aortic coarctation.","Aortic Preductal Coarctation Severity | APRECSEV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526513","Aortic Postductal Coarctation Severity","C139036","The assessment of the severity of postductal aortic coarctation.","Aortic Postductal Coarctation Severity | APOSCSEV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526506","Aortic Juxta-ductal Coarctation Severity","C139035","The assessment of the severity of juxta-ductal aortic coarctation.","Aortic Juxta-ductal Coarctation Severity | ADUCSEV | Aortic Ductal Coarctation Severity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526512","Aortic Coarctation Severity","C139037","The qualitative measurement of the severity of the aortic coarctation.","Aortic Coarctation Severity | ACRCTSEV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526508","Aortic Coarctation Indicator","C139033","An indication as to whether there is coarctation of the aorta.","Aortic Coarctation Indicator | ACRCTIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055427","Augmentation Pressure Point P2","C122086","The second aortic systolic pressure peak, also referred to as a returning pressure wave, used to calculate the aortic augmentation index.","Augmentation Pressure Point P2 | AAUGPRP2 | Aortic Augmentation Pressure Peak P2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055428","Augmentation Pressure Point P1","C122085","The first aortic systolic pressure peak, also referred to as a forward wave, used to calculate the aortic augmentation index.","Augmentation Pressure Point P1 | AAUGPRP1 | Aortic Augmentation Pressure Peak P1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055448","Aortic Augmentation Pressure","C122084","The calculated difference between the second and first aortic systolic peaks, which is an indirect measure of arterial stiffness.","Aortic Augmentation Pressure | AAUGPR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055450","Aortic Augmentation Index at 75bpm","C122083","The normalization of aortic augmentation index for heart rate, using a standard rate of seventy five beats per minute.","Aortic Augmentation Index at 75bpm | AAUGIX75",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055449","Aortic Augmentation Index","C122038","A complex measure of wave reflection calculated as the ratio of aortic augmentation pressure to pulse pressure, and used as an indirect measure of arterial stiffness.","Aortic Augmentation Index | AAUGIX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526519","Annular S' Velocity","C139045","The peak velocity of the annular motion during ventricular systole.","Annular S' Velocity | ANNSVEL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526514","Annular Plane Systolic Excursion","C139042","The longitudinal displacement of a cardiac valve annulus toward the apex of the heart.","Annular Plane Systolic Excursion | APSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509600","Annular e' Velocity","C127536","The maximum rate of the annular motion during early diastole (passive ventricular filling).","Annular e' Velocity | ANNEVEL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509599","Annular a' Velocity","C127535","The maximum rate of the annular motion during late diastole (active ventricular filling).","Annular a' Velocity | ANNAVEL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509432","Cusp Thickening Severity","C127561","The qualitative measurement of the severity of a thickening cardiac valve cusp.","Cusp Thickening Severity | CSPTSEV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509431","Cusp Thickening Indicator","C127560","An indication as to whether there is a thickened cardiac valve cusp.","Cusp Thickening Indicator | CSPTIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509430","Cusp Tethering Severity","C127559","The qualitative measurement of the severity of tethering of a cardiac valve cusp.","Cusp Tethering Severity | CSPTESEV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509429","Cusp Tethering Indicator","C127558","An indication as to whether there is tethering of a cardiac valve cusp.","Cusp Tethering Indicator | CSPTEIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509428","Cusp Restricted Motion Severity","C127557","The qualitative measurement of the severity of restricted motion of a cardiac valve cusp.","Cusp Restricted Motion Severity | CSPRMSEV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509427","Cusp Restricted Motion Indicator","C127556","An indication as to whether there is restricted motion of a cardiac valve cusp.","Cusp Restricted Motion Indicator | CSPRMIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509426","Cusp Prolapse Timing","C127555","The time point during the cardiac cycle when the prolapse of of one or more cusps occurs.","Cusp Prolapse Timing | CSPPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509425","Cusp Prolapse Severity","C127554","The qualitative measurement of the severity of a prolapsing cardiac valve cusp.","Cusp Prolapse Severity | CSPPSEV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509424","Cusp Prolapse Indicator","C127553","An indication as to whether there is a prolapsed cardiac valve cusp.","Cusp Prolapse Indicator | CSPPIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509423","Cusp Flail Timing","C127552","The time point during the cardiac cycle when the flail of one or more cusps occurs.","Cusp Flail Timing | CSPFT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509422","Cusp Flail Severity","C127551","The qualitative measurement of the severity of a flailing cardiac valve cusp.","Cusp Flail Severity | CSPFSEV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509421","Cusp Flail Indicator","C127550","An indication as to whether there is a flailing cardiac valve cusp.","Cusp Flail Indicator | CSPFIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509420","Cusp Doming Severity","C127549","The qualitative measurement of the severity of doming of a cardiac cusp.","Cusp Doming Severity | CSPDSEV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509419","Cusp Doming Indicator","C127548","An indication as to whether there is doming of a cardiac cusp.","Cusp Doming Indicator | CSPDIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526509","Cross-sectional Diameter","C139032","A measurement of a structure taken along the plane that is perpendicular to the long axis.","Cross-sectional Diameter | CSDIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509352","Cross-sectional Thickness at End Ventricular Systole","C127596","The cross-sectional thickness of a tissue measured at end ventricular systole.","Cross-sectional Thickness at End Ventricular Systole | Cross-sec Thickness, EVS | Cross-sectional Thickness, End Ventricular Systole | THCKEVS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509351","Cross-sectional Thickness at End Ventricular Diastole","C127595","The cross-sectional thickness of a tissue measured at end ventricular diastole.","Cross-sectional Thickness at End Ventricular Diastole | Cross-sec Thickness, EVD | Cross-sectional Thickness, End Ventricular Diastole | THCKEVD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509735","Cross-sectional Diameter at Mid Ventricular Systole","C127547","The cross sectional diameter measured at mid ventricular systole.","Cross-sectional Diameter at Mid Ventricular Systole | CSDIAMVS | Cross-sec Diameter, MVS | Cross-sectional Diameter, Mid Ventricular Systole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509733","Cross-sectional Diameter at End Ventricular Diastole","C127545","The cross sectional diameter measured at end ventricular diastole.","Cross-sectional Diameter at End Ventricular Diastole | CSDIAEVD | Cross-sec Diameter, EVD | Cross-sectional Diameter, End Ventricular Diastole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899493","Coronary No Reflow at PCI Site Indicator","C119331","An indication as to whether there is a new acute reduction in flow at the original percutaneous coronary intervention site in the coronary vessel.","Coronary No Reflow at PCI Site Indicator | CANRFIND | Coronary Artery No Reflow Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272320","Coronary Artery Dominance","C100086","The contribution of blood supply from the right or left vessel system to the posterior descending artery. (ACC)","Coronary Artery Dominance | COARTDOM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509039","Chordae Tendineae Prolapse Indicator","C127562","An indication as to whether there is a prolapsed cardiac valve chordae tendineae.","Chordae Tendineae Prolapse Indicator | CTPIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508675","Cardiac Wall Motion Type","C127564","A qualitative assesment of the movement of the cardiac muscle, either as a whole or at one or more specific anatomical locations.","Cardiac Wall Motion Type | CWMTYP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538921","Cardiac Valvular Stenosis Severity","C102245","The qualitative measurement of the severity of cardiac valvular stenosis.","Cardiac Valvular Stenosis Severity | CVLSTNS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540221","Cardiac Valvular Stenosis Indicator","C142244","An indication as to whether the cardiac valve in question has stenosis.","Cardiac Valvular Stenosis Indicator | VLSTNIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509745","Major Axis Cross-sectional Diameter at End Ventricular Diastole","C127573","The cross sectional diameter of a cardiovascular structure measured along the major axis at end ventricular diastole.","Major Axis Cross-sectional Diameter at End Ventricular Diastole | MJDIAEVD | Major Axis Cross-sec Diameter, EVD | Major Axis Cross-sectional Diameter, End Ventricular Diastole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508900","Left Ventricular Outflow Tract Velocity Time Integral","C127569","The integral of all of the flow velocities within the left ventricular outflow tract during ventricular systole.","Left Ventricular Outflow Tract Velocity Time Integral | LVOT Velocity Time Integral | LVOTVTI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508899","Left Ventricular Outflow Tract Peak Velocity","C127568","The measurement of the maximum rate of blood flow measured in the left ventricular outflow tract during systole.","Left Ventricular Outflow Tract Peak Velocity | LVOT Peak Velocity | LVOTPVEL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898608","Lesion Restenosis Indicator","C116147","An indication as to whether there is re-narrowing of a lesion site following treatment of a prior stenosis, to a diameter stenosis of greater than 50% at the previously treated lesion site.","Lesion Restenosis Indicator | LRSTIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540208","Estimated Mass of Left Ventricle","C142242","The weight of the left ventricle in grams as estimated by a formula that uses estimated measurements from echocardiographic exams, as well as constants like the specific gravity of the myocardium. Left ventricular mass is estimated using the following equation, LV Mass (g) = 0.8 {1.04[([LVEDD + IVSd + PWd]^3 - LVEDD^3)]} + 0.6, where LVEDD is LV end-diastolic dimension, IVSd is interventricular septal thickness at end-diastole, and PWd is posterior wall thickness at end-diastole.","Estimated Mass of Left Ventricle | LVMAS_E | Left Ventricular Mass, Estimated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540222","Left Ventricular Mass Index","C142243","The left ventricular mass divided by the subject's body surface area.","Left Ventricular Mass Index | LVMASIDX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522541","Estimated Left Ventricular Ejection Fraction","C135375","A visual estimation of the volume of blood ejected from the left ventricle during ventricular systole.","Estimated Left Ventricular Ejection Fraction | LVEF_E | Left Ventricular Ejection Fraction, Est | Left Ventricular Ejection Fraction, Estimated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522540","Calculated Left Ventricular Ejection Fraction","C135374","The percent or fraction of the left ventricular end diastolic volume ejected in systole, which is calculated as the left ventricular stroke volume divided by the left ventricular end diastolic volume.","Calculated Left Ventricular Ejection Fraction | LVEF_C | Left Ventricular Ejection Fraction, Cal | Left Ventricular Ejection Fraction, Calculated | Left ventriculography EF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898622","Late Lumen Loss Measurement","C116146","The difference between the mean minimum lumen diameter (MLD) assessed immediately after an index procedure and the MLD assessed at follow-up angiography.","Late Lumen Loss Measurement | LLMLOSS | Late Lumen Loss",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508863","Largest Cross-sectional Thickness","C127567","The assessment of the largest cross-sectional thickness of a tissue.","Largest Cross-sectional Thickness | LGTHCK | Largest Cross-sec Thickness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508862","Largest Cross-sectional Diameter at End Ventricular Diastole","C127566","The largest cross sectional diameter measured at end ventricular diastole.","Largest Cross-sectional Diameter at End Ventricular Diastole | LCDIAEVD | Largest Cross-sec Diameter, EVD | Largest Cross-sectional Diameter, End Ventricular Diastole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825223","Ischemic Myocardium Percentage","C80494","Percent of the myocardial tissue estimated to exhibit characteristics of inadequate blood flow (ischemia). This is usually determined using a functional study (e.g. MRI, SPECT or PET).","Ischemic Myocardium Percentage | ISHMYOP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514163","Inferior Vena Cava Collapse Due to Sniff Test Indicator","C130055","An indication as to whether resting inferior vena cava diameter is reduced with sniff, which is defined as a sharp inhalation.","Inferior Vena Cava Collapse Due to Sniff Test Indicator | IVCCSIND | Inferior Vena Cava Collapse Indicator | Inferior Vena Cava Collapse Sniff Ind",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898775","In-Stent Restenosis Indicator","C116148","An indication as to whether there is re-narrowing of a stent implanted at a lesion site to treat a prior stenosis, to a diameter stenosis of greater than 50% within the stent.","In-Stent Restenosis Indicator | INRSTIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522539","Heart Chamber Volume at End Ventricular Systole","C135373","The volume of blood remaining in a heart chamber at end ventricular systole.","End Systolic Volume | End Systolic Blood Volume | HCVOLEVS | Heart Chamber Volume at End Ventricular Systole | Heart Chamber Volume at End Ventricular Systole | Heart Chamber Volume, EVS | Heart Chamber Volume, End Ventricular Systole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522538","Heart Chamber Volume at End Ventricular Diastole","C135372","The volume of blood remaining in a heart chamber at end ventricular diastole.","End Diastolic Volume | EDV | End Diastolic Blood Volume | HCVOLEVD | Heart Chamber Volume at End Ventricular Diastole | Heart Chamber Volume at End Ventricular Diastole | Heart Chamber Volume, EVD | Heart Chamber Volume, End Ventricular Diastole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526503","Heart Chamber Enlargement Indicator","C139062","An indication as to whether there is an enlarged heart chamber.","Heart Chamber Enlargement Indicator | HCENLIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4068466","Fractional Area Change","C142241","The percent reduction in the area of a given structure with the following formula: (EDA-ESA)/EDA times 100, where EDA is end diastolic area and ESA is end systolic area.","Fractional Area Change | FAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055073","Ejection Wave Amplitude","C122088","The magnitude of the ejection wave that occurs during ventricular contraction.","Ejection Wave Amplitude | EJWAMP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508736","Effective Regurgitant Orifice Area","C127565","The quantitative measurement of the effective regurgitant orifice area of a cardiac valve.","Effective Regurgitant Orifice Area | EFFRGOA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545170","Effective Orifice Area Index","C147150","The ratio of the effective orifice area (EOA) to the body surface area (BSA).","Effective Orifice Area Index | EOAINDEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545169","Effective Orifice Area","C147149","The minimal cross-sectional area of the flow jet downstream of a cardiac valve.","Effective Orifice Area | EOA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526500","Eccentric Regurgitant Jet Indicator","C139057","An indication as to whether an eccentric regurgitant jet direction is present.","Eccentric Regurgitant Jet Indicator | ERGJIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526510","Dissection Indicator","C139039","An indication as to whether a blood vessel has dissected.","Dissection Indicator | DISECIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545168","Dimensionless Index","C147148","The ratio of the left ventricular outflow tract (LVOT) velocity to the maximum velocity of the aortic valve.","Dimensionless Index | DIMSSNDX | Dimensionless Velocity Index",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526515","DeBakey Aortic Dissection Classification","C139041","The type of aortic dissection present as defined by the DeBakey Classification System (DeBakey ME, Henly WS, Cooley DA, Morris GC Jr, Crawford ES, Beall AC Jr. Surgical management of dissecting aneurysms of the aorta. J Thorac Cardiovasc Surg 1965;49:130-149).","DeBakey Aortic Dissection Classification | DEBAKADC | DeBakey AoD Classification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509304","Pulmonary Valve Vena Contracta Width","C127592","The width of the vena contracta of the pulmonic valve.","Pulmonary Valve Vena Contracta Width | PVVCW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509303","Pulmonary Valve Vena Contracta Area","C127591","The area of the vena contracta of the pulmonic valve.","Pulmonary Valve Vena Contracta Area | PVVCA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509302","Pulmonary Valve Regurgitant Volume","C127590","A quantitative measurement of the amount of retrograde blood flow across the orifice of the pulmonic valve.","Pulmonary Valve Regurgitant Volume | PVRGVOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509300","Pulmonary Valve Regurgitant Fraction","C127588","A quantitative measurement of the amount of retrograde blood flow across the orifice of the pulmonic valve expressed as a percentage of the anterograde flow.","Pulmonary Valve Regurgitant Fraction | PVRGF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522545","Pulmonary Arterial Hypertension Indicator","C135379","An indication as to whether there is hypertension in the pulmonary artery.","Pulmonary Arterial Hypertension Indicator | PAHTNIND | Pulmonary Arterial Hypertension Ind",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526491","Prosthetic Cardiac Valve Type","C139051","A description of the type of artificial cardiac valve in use.","Prosthetic Cardiac Valve Type | PCVALTYP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526517","Pericardial Effusion Size","C139047","The size of a pericardial effusion as assessed at the point of greatest separation between the parietal and visceral pericardia.","Pericardial Effusion Size | PEFFSIZE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526518","Pericardial Effusion Indicator","C139046","An indication as to whether there is effusion between the parietal and visceral pericardia.","Pericardial Effusion Indicator | PEFFIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897965","PCTDIAST","C116145","The value calculated as 100 x (1 - MLD/RVD), using the mean quantitative values for minimum lumen diameter (MLD) and reference vessel diameter (RVD).","Percent Diameter Stenosis | PCTDIAST | Percent Diameter Stenosis | Percent Diameter Stenosis Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526520","Peak Pressure Rise Rate","C139044","The greatest rate of increase in peak pressure during muscle contraction.","Peak Pressure Rise Rate | PPRR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545160","Peak Pressure Gradient","C147155","The quantitative measurement of the largest pressure gradient across a predetermined point.","Peak Pressure Gradient | PGPRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508957","Peak E Velocity","C127585","The maximum rate of blood flow across a cardiac valve during early diastole (passive ventricular filling).","Peak E Velocity | PKEVEL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508956","Peak Blood Flow Velocity","C127583","The measurement of the maximum rate of blood flow across an area or tissue.","Peak Blood Flow Velocity | PBFVEL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508955","Peak A Velocity","C127584","The maximum rate of blood flow across a cardiac valve during late diastole (active ventricular filling).","Peak A Velocity | PKAVEL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545159","Observed Non-Medical Foreign Body Type","C147154","A description of the type of non-medical foreign body that is present in the body.","Observed Non-Medical Foreign Body Type | OBNMFBT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545156","Observed Foreign Body Indicator","C147151","An indication as to whether a foreign body is present in the body.","Observed Foreign Body Indicator | FBODYIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545158","Observed Medical Device Type Not Present In Intended Location Type","C147153","A description of the type of medical device that is found in a subject but is not present in its intended location within the body.","Observed Medical Device Type Not Present In Intended Location Type | OBMDNLOC | Obs Med Device Type Not In Intended Loc",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544948","Observed Medical Device Type In Intended Location","C146994","A description of the type of medical device that is found in a subject and is present in its intended location within the body.","Observed Medical Device Type In Intended Location | OBMDILOC | Obs Med Device Type In Intended Loc | Observed Medical Device In The Intended Location",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3275120","Number of Diseased Coronary Artery Vessels","C99996","Number of major epicardial vessels with greater than or equal to 70% reduction in diameter or greater than or equal to 50% reduction in cross-sectional area. (ACC)","Number of Diseased Coronary Artery Vessels | NUMDCAV | Number of Diseased Coronary Vessels",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449812","Number of Cardiac Valve Cusps","C139054","A quantitative determination of the number of cusps composing a given cardiac valve.","Number of Cardiac Valve Cusps | NUMCUSPS | Number of Cusps",,,,,,,,,,,,,,,"4137655","Number of cusps",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526492","Native Cardiac Valve Intervention Type","C139050","A description of what, if any, kind of intervention has been performed on a native cardiac valve.","Native Cardiac Valve Intervention Type | NCVALTYP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2923434","Myocardial Performance Index","C139043","A calculated result that uses the following formula to quantify both systolic and diastolic ventricular function: MPI = IVCT + IVRT) / V ET, in which IVCT is isovolumetric contraction time, IVRT is isovolumetric relaxation time, and V ET is ventricular ejection time.","Myocardial Performance Index | MPI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509641","Mitral Valve Vena Contracta Width","C127582","The width of the vena contracta of the mitral valve.","Mitral Valve Vena Contracta Width | MVVCW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509640","Mitral Valve Vena Contracta Area","C127581","The area of the vena contracta of the mitral valve.","Mitral Valve Vena Contracta Area | MVVCA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509639","Mitral Valve Regurgitant Volume","C127580","A quantitative measurement of the amount of retrograde blood flow across the orifice of the mitral valve.","Mitral Valve Regurgitant Volume | MVRGVOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509638","Mitral Valve Regurgitant Jet Area","C127579","The measured area of the backflow of blood into the left atrium.","Mitral Valve Regurgitant Jet Area | MVRGJA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509637","Mitral Valve Regurgitant Fraction","C127578","A quantitative measurement of the amount of retrograde blood flow across the orifice of the mitral valve expressed as a percentage of the anterograde flow.","Mitral Valve Regurgitant Fraction | MVRGF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509636","Mitral Regurgitant Jet Area to Left Atrial Area Ratio","C127577","A relative measurement (ratio or percentage) of the mitral regurgitant jet area to left atrial area.","Mitral Regurgitant Jet Area to Left Atrial Area Ratio | MRGJALA | Mitral Regur Jet Area L Atrial Area Rt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509279","Mitral E/e' Ratio","C127572","The ratio of the peak early diastolic transmitral velocity to the peak mitral annular motion velocity.","Mitral E/e' Ratio | MITRALEE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509278","Mitral E/A Ratio","C127571","The ratio of the rate of blood flow during early diastole to the rate of blood flow during late diastole.","Mitral E/A Ratio | MITRALEA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526505","Minor Axis Internal Diameter at End Ventricular Systole","C139060","The internal diameter of a cardiovascular structure measured along its minor axis at end ventricular systole.","Minor Axis Internal Diameter at End Ventricular Systole | MNIDEVS | Minor Axis Internal Diameter at EVS | Minor Axis Internal Diameter, EVS | Minor Axis Internal Diameter, End Ventricular Systole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526504","Minor Axis Internal Diameter at End Ventricular Diastole","C139061","The internal diameter of a cardiovascular structure measured along its minor axis at end ventricular diastole.","Minor Axis Internal Diameter at End Ventricular Diastole | MNIDEVD | Minor Axis Internal Diameter at EVD | Minor Axis Internal Diameter, EVD | Minor Axis Internal Diameter, End Ventricular Diastole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526497","Minor Axis Cross-sectional Diameter at Mid Ventricular Systole","C139052","The cross-sectional diameter of a cardiovascular structure measured along its minor axis at mid ventricular systole.","Minor Axis Cross-sectional Diameter at Mid Ventricular Systole | MNDIAMVS | Minor Axis Cross-sec. Diameter, MVS | Minor Axis Cross-sectional Diameter, Mid Ventricular Systole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522544","Minor Axis Cross-sectional Diameter","C135378","The cross sectional diameter of a tissue, organ, or structure measured along its minor axis.","Minor Axis Cross-sectional Diameter | MNDIA | Minor Axis Cross-sec. Diameter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509760","Minor Axis Cross-sectional Diameter at End Ventricular Systole","C127576","The cross sectional diameter a cardiovascular structure measured in the minor axis at end ventricular systole.","Minor Axis Cross-sectional Diameter at End Ventricular Systole | MNDIAEVS | Minor Axis Cross-sec Diameter, EVS | Minor Axis Cross-sectional Diameter, End Ventricular Systole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509759","Minor Axis Cross-sectional Diameter at End Ventricular Diastole","C127575","The cross sectional diameter a cardiovascular structure measured in the minor axis at end ventricular diastole.","Minor Axis Cross-sectional Diameter at End Ventricular Diastole | MNDIAEVD | Minor Axis Cross-sec Diameter, EVD | Minor Axis Cross-sectional Diameter, End Ventricular Diastole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898305","Minimum Vessel Lumen Diameter","C116144","The minimum diameter of the inside of a blood vessel (lumen) derived quantitatively in a single view.","Minimum Vessel Lumen Diameter | MINLDIAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545157","Mean Pressure Gradient","C147152","The arithmetic average of the quantitative measurement of the pressure gradient across a predetermined point.","Mean Pressure Gradient | MGPRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522542","Estimated Mean Blood Pressure","C135376","The estimated average blood pressure.","Estimated Mean Blood Pressure | MEANBP_E | Mean Blood Pressure, Estimated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509265","Mean Blood Flow Velocity","C127570","The measurement of the average rate of blood flow across an area or tissue.","Mean Blood Flow Velocity | MBFVEL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526494","Maximal Pericardial Effusion Width","C139048","The measurement of the maximum separation between the parietal and visceral pericardia.","Maximal Pericardial Effusion Width | MAXPEFFW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526499","Major Axis Internal Diameter at End Ventricular Systole","C139058","The internal diameter of a cardiovascular structure measured along its major axis at end ventricular systole.","Major Axis Internal Diameter at End Ventricular Systole | MJIDEVS | Major Axis Internal Diameter at EVS | Major Axis Internal Diameter, EVS | Major Axis Internal Diameter, End Ventricular Systole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526498","Major Axis Internal Diameter at End Ventricular Diastole","C139059","The internal diameter of a cardiovascular structure measured along its major axis at end ventricular diastole.","Major Axis Internal Diameter at End Ventricular Diastole | MJIDEVD | Major Axis Internal Diameter at EVD | Major Axis Internal Diameter, EVD | Major Axis Internal Diameter, End Ventricular Diastole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526496","Major Axis Cross-sectional Diameter at Mid Ventricular Systole","C139053","The cross sectional diameter of a cardiovascular structure measured along its major axis at mid ventricular systole.","Major Axis Cross-sectional Diameter at Mid Ventricular Systole | MJDIAMVS | Major Axis Cross-sec. Diameter, MVS | Major Axis Cross-sectional Diameter, Mid Ventricular Systole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522543","Major Axis Cross-sectional Diameter","C135377","The cross sectional diameter of a tissue, organ, or structure measured along its major axis.","Major Axis Cross-sectional Diameter | MJDIA | Major Axis Cross-sec. Diameter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509746","Major Axis Cross-sectional Diameter at End Ventricular Systole","C127574","The cross sectional diameter of a cardiovascular structure measured along the major axis at end ventricular systole.","Major Axis Cross-sectional Diameter at End Ventricular Systole | MJDIAEVS | Major Axis Cross-sec Diameter, EVS | Major Axis Cross-sectional Diameter, End Ventricular Systole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509353","Blood Flow Velocity Time Integral","C127603","The integral of all of the flow velocities during the time of blood flow across or within a specified area.","Blood Flow Velocity Time Integral | VELTI | Velocity Time Integral, Blood Flow",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545161","Valve Area Index","C147157","The ratio of the valve area to the body surface area.","Valve Area Index | VAREANDX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509672","Tricuspid Valve Vena Contracta Width","C127602","The width of the vena contracta of the tricuspid valve.","Tricuspid Valve Vena Contracta Width | TVVCW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509671","Tricuspid Valve Vena Contracta Area","C127601","The area of the vena contracta of the tricuspid valve.","Tricuspid Valve Vena Contracta Area | TVVCA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509670","Tricuspid Valve Regurgitant Volume","C127600","A quantitative measurement of the amount of retrograde blood flow across the orifice of the tricuspid valve.","Tricuspid Valve Regurgitant Volume | TVRGVOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509669","Tricuspid Valve Regurgitant Jet Area","C127599","The measured area of the backflow of blood into the right atrium.","Tricuspid Valve Regurgitant Jet Area | TVRGJA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509668","Tricuspid Valve Regurgitant Fraction","C127598","A quantitative measurement of the amount of retrograde blood flow across the orifice of the tricuspid valve expressed as a percentage of the anterograde flow.","Tricuspid Valve Regurgitant Fraction | TVRGF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509667","Tricuspid Regurgitant Jet Area to Right Atrial Area Ratio","C127597","A relative measurement (ratio or percentage) the tricuspid regurgitant jet area to the right atrial area.","Tricuspid Regurgitant Jet Area to Right Atrial Area Ratio | TRGJARA | Tricus Regur Jet Area R Atrial Area Rt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526532","Estimated Systolic Blood Pressure","C139031","A quantitative estimate of the pressure in a given cardiovascular structure during ventricular systole.","Estimated Systolic Blood Pressure | SYSPRS_E | Systolic Pressure, Estimated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508991","Systolic Anterior Motion Severity","C127594","The qualitative measurement of the severity of the systolic anterior motion of a cardiac cusp.","Systolic Anterior Motion Severity | SAM Severity | SAMSEV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508990","Systolic Anterior Motion Indicator","C127593","An indication as to whether there is systolic anterior motion of a cardiac cusp.","Systolic Anterior Motion Indicator | SAM Indicator | SAMIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1258192","Systemic Vascular Resistance","C119248","The resistance to blood flow offered by all systemic vasculature, excluding pulmonary vasculature. The major determinant of SVR is arteriolar tone, but blood viscosity and vascular capacitance are also contributing factors.","Systemic Vascular Resistance | SVR | Systemic vascular resistance | TPR | Total Peripheral Resistance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038455","Stroke Volume","C94989","The difference in a cardiac ventricle's blood capacity taken at times of minimum and maximum blood content. This is end diastolic volume less end systolic volume.","Stroke Volume | STROKVOL",,,,,,,,,,,,,,,"4231869","Stroke volume",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526516","Stanford Aortic Dissection Classification","C139040","The type of aortic dissection present as defined by the Stanford Classification System (Daily PO, Trueblood HW, Stinson EB, Wuerflein RD, Shumway NE. Management of acute aortic dissections. Ann Thorac Surg 1970;10(3):237-247).","Stanford Aortic Dissection Classification | STANFADC | Stanford AoD Classification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522547","Estimated Right Ventricular Ejection Fraction","C135381","A visual estimation of the volume of blood ejected from the right ventricle during ventricular systole.","Estimated Right Ventricular Ejection Fraction | RVEF_E | Right Ventricular Ejection Fraction, Est | Right Ventricular Ejection Fraction, Estimated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522546","Calculated Right Ventricular Ejection Fraction","C135380","The percent or fraction of the right ventricular end diastolic volume ejected in systole, which is calculated as the right ventricular stroke volume divided by the right ventricular end diastolic volume.","Calculated Right Ventricular Ejection Fraction | RVEF_C | Right Ventricular Ejection Fraction, Cal | Right Ventricular Ejection Fraction, Calculated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054088","Reflection Wave Amplitude","C122090","The magnitude of the reflected pulse wave that is created when forward blood flow reaches vascular branching points and points of impedance mismatch.","Reflection Wave Amplitude | RFLWAMP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054089","Reflection Magnitude","C122089","The reflected-to-forward pressure wave amplitude ratio. (Hashimoto J et al, J Hypertens. 2008 May;26(5):1017-24)","Reflection Magnitude | RFLMAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3494431","Pulse Wave Velocity","C122087","The rate at which a pressure wave moves distally through an artery, which is a direct measure of arterial stiffness. Clinically, this value is calculated by placing two pressure catheters a known distance apart (pulse wave distance), measuring the pressure wave's travel time between sensors (pulse transit time), and then dividing the distance by the transit time.","Pulse Wave Velocity | PWV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509301","Pulmonic Valve Regurgitant Jet Width","C127589","The measured width of the backflow of blood into the right ventricular outflow tract.","Pulmonic Valve Regurgitant Jet Width | PVRGJW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509291","Pulmonic Regurgitant Jet Width to Right Ventricular Outflow Tract Diameter Ratio","C127586","A relative measurement (ratio or percentage) of the pulmonic regurgitant jet width to the right ventricular outflow tract diameter.","Pulmonic Regurgitant Jet Width to Right Ventricular Outflow Tract Diameter Ratio | PRGJWRVD | Pulmonic Regur Jet Width RVOT Diam Rt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509299","Pulmonary Vein Dominance","C127587","The determination of whether blood flow in the pulmonary veins is greater during ventricular systole or diastole.","Pulmonary Vein Dominance | PVEINDOM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640262","CDISC SDTM Cardiovascular Test Code Terminology","C101847","Terminology associated with the cardiovascular test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Cardiovascular Test Code Terminology | CVTESTCD | Cardiovascular Test Code | SDTM-CVTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937706","Central American Indian Language","C158071","Any of the languages indigenous to the Mesoamerican cultural area, which covers southern Mexico, all of Guatemala and Belize, and parts of Honduras, El Salvador, and Nicaragua.","Central American Indian Language | Central American Indigenous Language",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574712","North American Indian Language","C158073","Any of the languages indigenous to Alaska, Nunavut, Greenland, the United States, and the northern areas of Mexico.","North American Indigenous Language | North American Indian Language | North American Indian Language",,,,,,,,,,,,,,,"4177313","Native North American language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937729","Date of Reference Time Point","C158111","The date for a fixed reference time point.","Date of Reference Time Point | RFTDAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937726","Time of Reference Time Point","C158112","The time for a fixed reference time point.","Time of Reference Time Point | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937736","Cadastro de Pessoas Fisicas","C158102","A unique federal tax identification number that is assigned by the Brazilian Federal Internal Revenue Department (Receita Federal do Brasil) to citizens and non-citizens entering into financial transactions that result in taxable income.","Cadastro de Pessoas Fisicas | CPF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2242570","Human Leukocyte Antigen Sensitization","C114847","Presence of preformed antibodies to donor human leukocyte antigen (HLA).","Human Leukocyte Antigen Sensitization | HLA Sensitization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937668","Empagliflozin","C158136","An orally available competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2; SLC5A2) with antihyperglycemic activity. Upon oral administration, empagliflozin selectively and potently inhibits SGLT2 in the kidneys, thereby suppressing the reabsorption of glucose in the proximal tubule. Inhibition of SGLT2 increases urinary glucose excretion by the kidneys, resulting in a reduction of plasma glucose levels in an insulin-independent manner. Inhibition of SGLT2 in the kidneys also suppresses the renal reabsorption of 1,5-anhydroglucitol (1,5AG). This lowers serum 1,5AG and neutrophil 1,5-anhydroglucitol-6-phosphate (1,5AG6P) levels, which may improve neutropenia and neutrophil dysfunction in patients with glycogen storage disease type Ib (GSD Ib). SGLT2, a transport protein exclusively expressed in the proximal renal tubules, mediates approximately 90% of renal glucose reabsorption from tubular fluid.","Empagliflozin | 1-Chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene | BI 10773 | BI-10773 | BI10773 | EMPAGLIFLOZIN | Jardiance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519694","Bone Lesion Identification","C132466","The identification of a localized, pathological, or traumatic structural change, damage, deformity, or discontinuity of the bone.","Bone Lesion Identification | BONE LESION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563156","REPLI-g Pooled DNA","C156437","A genomic DNA sample produced from a pool of samples from several subjects that is amplified using REPLI-g technology.","REPLI-g Pooled DNA | Repli-G Pooled (Qiagen) DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563155","Formalin-Fixed Paraffin-Embedded RNA","C156436","An RNA sample derived from a formalin-fixed paraffin-embedded tissue sample.","Formalin-Fixed Paraffin-Embedded RNA | FFPE RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563154","Formalin-Fixed Paraffin-Embedded DNA","C156435","A DNA sample derived from a formalin-fixed paraffin-embedded tissue sample.","Formalin-Fixed Paraffin-Embedded DNA | FFPE DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514469","16S Mitochondrial Ribosomal RNA","C131261","16S mitochondrial ribosomal RNA is encoded by the human MT-RNR2 gene. This ribonucleotide is involved in mitochondrial protein translation.","16S Mitochondrial Ribosomal RNA | 16S Mitochondrial rRNA | l-rRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086084","CDISC SDTM Tumor or Lesion Properties Test Result Terminology","C124309","Terminology associated with the tumor or lesion properties test result codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Tumor or Lesion Properties Test Result Terminology | SDTM-TRPROPRS | TRPROPRS | Tumor or Lesion Properties Test Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504653","Present Without Unequivocal Progression","C126055","There is evidence of disease without evidence of unequivocal progression.","Present Without Unequivocal Progression | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086626","Non-Palpable","C124445","Incapable of being handled, touched or felt through palpation.","Non-Palpable | NONPALPABLE | Nonpalpable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504652","Non-Pathological","C126054","The absence of disease or pathology.","Non-Pathological | NON-PATHOLOGICAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935746","Further Enlargement from Nadir","C156594","An increase in size, volume, or quantity in comparison to a previous state that was enlarged from nadir.","Further Enlargement from Nadir | FURTHER ENLARGEMENT FROM NADIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540327","Further Enlargement","C142367","An increase in size, volume, quantity or scope in comparison to a previous enlarged state.","Further Enlargement | FURTHER ENLARGEMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545349","Focally Increased","C147487","An indication that the increase is limited to a specific area.","Focally Increased | FOCALLY INCREASED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935745","Enlargement from Nadir","C156593","An increase in size, volume, or quantity in comparison to nadir.","Enlargement from Nadir | ENLARGEMENT FROM NADIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545363","Diffusely Increased","C147486","An indication that the increase is widespread.","Diffusely Increased | DIFFUSELY INCREASED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517131","Family Sociology","C18791","The study of individual and group behavior with respect to family interactions.","Family Sociology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017447","Geography","C16633","The science that deals with the world and its inhabitants; a description of the earth, or a portion of the earth, including its structure, features, products, political divisions, and the people by whom it is inhabited.","Geography | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273029","CDISC SDTM Tumor Response Result Terminology","C96785","Terminology associated with the tumor response result codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Tumor Response Result Terminology | ONCRSR | Oncology Response Assessment Result | SDTM-RSSTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054987","Favorable Response","C123584","No new lesions(s) and a decrease in tumor size, or a reduction in central necrosis or attenuation in one or more enhancing lesions, based on pre-defined thresholds.","Favorable Response | FAVORABLE RESPONSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055212","Complete Response by Computed Tomography","C123577","The disappearance of all signs of cancer, based on CT scan and criteria-defined assessments.","Complete Response by Computed Tomography | CR-CT | Complete Remission, CT-Based | Complete Response, CT-Based",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050019","Clinical Partial Response","C123576","A decrease in the size and the extent of tissue involvement by cancer, based on physical exam, such as palpation.","Clinical Partial Response | Clinical Partial Remission | Partial | cPR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086208","Complete MRD Response","C124427","Absence of residual disease based on pre-defined thresholds and MRD negativity by laboratory techniques.","Complete Measurable Residual Disease Response | COMPLETE MRD RESPONSE | Complete MRD Response | Complete Minimal Residual Disease Response | Complete Minimal Residual Disease Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050307","Tumor Complete Metabolic Response","C123407","A finding of disappearance of metabolic tumor activity in target and non-target lesions, marked by a decrease in tumor standardized uptake value to the level of surrounding normal tissue.","Tumor Complete Metabolic Response | CMR | Complete Metabolic Response | Definite Tumor Complete Metabolic Response | Definite complete metabolic response | Tumor CMR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055340","CA125 75% Response","C123573","The amount of cancer antigen 125 is reduced by 75% from protocol-defined baseline value(s).","CA125 75% Response | CA125 75% RESPONSE | Cancer Antigen 125 75% Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055341","CA125 50% Response","C123572","The amount of cancer antigen 125 is reduced by 50% from protocol-defined baseline value(s).","CA125 50% Response | CA125 50% RESPONSE | Cancer Antigen 125 50% Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055510","Absent Morphologic Response","C123571","The absence of change in the overall attenuation of the metastasis and in the peripheral rim, suggesting a lack of response to treatment.","Absent Morphologic Response | ABSENT MORPHOLOGIC RESPONSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050242","Pathologic Complete Response","C123603","The disappearance of all signs of cancer, supported by pathological examination.","Pathologic Complete Response | Complete Pathological Response | Pathologic Complete Remission | Pathological Complete Remission | pCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054245","Partial Morphologic Response","C123602","Mixed attenuation and some homogeneity of the metastases with a partially resolved peripheral rim.","Partial Morphologic Response | PARTIAL MORPHOLOGIC RESPONSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054318","Optimal Morphologic Response","C123601","Hypo-attenuation of the metastases which may appear pseudocystic, perfectly homogeneous, and devoid of a recognizable peripheral rim.","Optimal Morphologic Response | OPTIMAL MORPHOLOGIC RESPONSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086587","MRD Reappearance","C124430","Presence of residual disease based on pre-defined thresholds and return of quantifiable MRD positivity after a period of MRD negativity.","Measurable Residual Disease Relapse | MRD RELAPSE | MRD Reappearance | MRD Relapse | Minimal Residual Disease Relapse | Minimal Residual Disease Relapse | Relapse from MRD Negative | Relapsed Disease From Minimal Residual Disease Negativity | Relapsed Disease from MRD Negativity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086586","MRD Persistence","C124429","Presence of residual disease based on pre-defined thresholds and quantifiable MRD positivity by laboratory techniques.","Measurable Residual Disease Persistence | MRD PERSISTENCE | MRD Persistence | Minimal Residual Disease Persistence | Minimal Residual Disease Persistence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054486","Minor Pathologic Response","C123592","A minor decrease in signs of cancer, supported by pathological examination and based on pre-defined thresholds.","Minor Pathologic Response | MINOR PATHOLOGIC RESPONSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054580","Major Pathologic Response","C123590","A major decrease in signs of cancer, supported by pathological examination and based on pre-defined thresholds.","Major Pathologic Response | MAJOR PATHOLOGIC RESPONSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054737","Immunophenotypic Complete Response","C123588","The disappearance of all signs of cancer, supported by the absence of phenotypically aberrant plasma cells (clonal) in bone marrow. (Rajkumar SV, Harousseau J, Durie B et al, Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011; 117(18):4691-4695)","Immunophenotypic Complete Response | IMMUNOPHENOTYPIC CR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053895","Unfavorable Response","C123617","An increase in tumor size, based on a pre-defined threshold, or the development of new lesion(s), marked central fill-in of a lesion, or new enhancement of a previously homogeneously hypoattenuating nonenhancing mass.","Unfavorable Response | UNFAVORABLE RESPONSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049822","Stable Metabolic Disease","C123616","The absence of change or mild changes of metabolic tumor activity in all relevant lesions based on a pre-defined threshold.","Stable Metabolic Disease | NMR | No Metabolic Response | SMD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053995","Stable Disease by Computed Tomography","C123615","The size and extent of tissue involvement by cancer is neither decreasing nor increasing, based on CT scan and criteria-defined assessments.","Stable Disease by Computed Tomography | SD-CT | Stable Disease, CT-Based",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054078","Relapsed Disease From Complete or Partial Response","C123613","The return of a disease after a period of complete remission or partial remission.","Relapsed Disease From Complete or Partial Response | RELAPSED DISEASE FROM CR OR PR | Relapsed Disease From Complete Response or Partial Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054079","Relapsed Disease From Complete Response","C123612","The return of a disease after a period of complete remission.","Relapsed Disease From Complete Response | RELAPSED DISEASE FROM CR | Relapse from CR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054244","Partial Response by Computed Tomography","C123610","A decrease in the size and extent of tissue involvement by cancer, based on CT scan and criteria-defined assessments.","Partial Response by Computed Tomography | PR-CT | Partial Remission, CT-Based | Partial Response, CT-Based",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512309","Partial Response with Lymphocytosis","C128998","A decrease in the size and extent of tissue involvement by cancer, accompanied by an increase in blood lymphocyte count above a predetermined threshold.","Partial Response with Lymphocytosis | PR WITH LYMPHOCYTOSIS | PR-L | PRL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050178","Partial Metabolic Response","C123609","A decrease of metabolic tumor activity in all relevant lesions, based on a pre-defined threshold.","Partial Metabolic Response | PMR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054149","Progression or Relapse After Hematologic Improvement","C123605","Disease progression or the return of a disease after a period of remission, occurring after a hematologic improvement.","Progression or Relapse After Hematologic Improvement | PD/RELAPSE AFTER HI | PD/Relapse After HI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054148","Progressive Disease by Computed Tomography","C123606","There is an increase in the size and extent of tissue involvement by cancer, based on CT scan and criteria-defined assessments.","Progressive Disease by Computed Tomography | PD-CT | Progressive Disease, CT-Based",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053769","Progression from Partial Response","C123604","Disease progression occurring after a partial response.","Progression from Partial Response | PD FROM PR | PD From PR | Progression from PR | Progressive Disease from Partial Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552235","NTRK Family Gene Mutation","C150437","A change in the nucleotide sequence of an NTRK family gene.","NTRK Family Gene Mutation | NTRK Gene Mutation | TRK Family Gene Mutation | TRK Gene Mutation | TRK Receptor Family Gene Mutation | TRK Receptor Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937652","Transplant Registry Unified Management Program","C158154","A Japanese centralized, computer-based software suite developed to manage hematopoietic stem cell transplant outcome data offline in transplant centers. The system emphasizes convenience to institutes, safety of patient information, quality of data management, and outcomes of transplantations.","Transplant Registry Unified Management Program | TRUMP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2316368","Tissue Section","C158415","A thin slice of tissue, usually for examination by microscopy.","Tissue Section | Tissue Slice",,,,,,,,,,,,,,,"4334503","Tissue section",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937838","Blood DNA","C158416","DNA extracted from nucleated cell from the peripheral blood.","Blood DNA | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937836","Frozen Tissue","C158417","A tissue sample that has been frozen prior to analysis.","Frozen Tissue | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937837","Stained Specimen","C158418","A biospecimen that has been prepared using dyes, reagents, or other materials to produce coloration of structures.","Stained Specimen | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205463","Physiologic","C17650","Pertaining to functions of the body.","Physiologic | physiologic",,,,,,,,,,,,,,,"4028825","Physiologic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937886","PicoGreen Dye","C158432","A proprietary dye for staining and quantitation of double-stranded DNA. It can selectively detect as little as 25 pg/ml of dsDNA in the presence of ssDNA, RNA, and free nucleotides. The assay is linear over three orders of magnitude and has little sequence dependence.","PicoGreen Dye | PicoGreen | PicoGreen Fluorescent Nucleic Acid Dye",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937883","RiboGreen Dye","C158433","A proprietary dye for staining and quantitation of RNA in solution. It has linear fluorescence detection in the range of 1-200 ng of RNA.","RiboGreen Dye | RiboGreen | RiboGreen Fluorescent Nucleic Acid Dye",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937884","OliGreen Dye","C158434","A proprietary green-fluorescent nucleic acid stain for quantitating oligonucleotides and single-stranded DNA (ssDNA) in solution.","OliGreen Dye | OliGreen | OliGreen Fluorescent Nucleic Acid Dye",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540342","Log10 Minimum Angle of Resolution","C142351","The base-10 logarithm of the minimum angle of resolution achieved by an individual during testing.","Log10 Minimum Angle of Resolution | MNARSLOG | Minimum Angle of Resolution, Log10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1562036","Calcineurin Inhibitor","C146638","Any agent that inhibits calcineurin (protein phosphatase 3; PPP3), a serine/threonine protein phosphatase dependent on calcium and calmodulin, with immunosuppressant activity. Inhibition of calcineurin prevents dephosphorylation of the transcription factor nuclear factor of activated T-cells, cytoplasmic (NFATc), which prevents its translocation to the nucleus and the subsequent induction of the expression of interleukin-2 (IL-2). This prevents IL-2-mediated proliferation and activation of T-cells, and T-lymphocyte-mediated immune responses.","Calcineurin Inhibitor | CNI Inhibitor | Calcineurin inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938033","Citrate Blood Cell Fraction","C158461","The blood cells that are harvested from a cell collection tube containing sodium citrate.","Citrate Blood Cell Fraction | Citrate Cellular Fraction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938034","EDTA Blood Cell Fraction","C158462","The blood cells that are harvested from a cell collection tube containing EDTA.","EDTA Blood Cell Fraction | EDTA Cellular Fraction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512252","FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma","C40147","Endometrial endometrioid adenocarcinoma exhibiting 6-50% solid non-glandular, non-squamous growth.","FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma | Grade 2 Endometrial Endometrioid Adenocarcinoma | Grade 2 Endometrial Endometrioid Adenocarcinoma | Grade 2 Endometrial Endometrioid Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830395","Dried Blood Spot","C113746","Capillary blood collected on blotting paper, typically from heel or finger stick.","Dried Blood Spot | Blood Spot Card",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040577","Trace Elements","C896","Trace elements or dietary minerals are any of various chemical elements that occur in very small amounts in organisms and are essential for many physiological and biochemical processes. The term is also used to designate these elements and compounds containing them. (NCI)","Trace Element | Micronutrient | Trace Mineral | Trace Nutrient | micronutrient | trace element",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL376219","recombinant adenovirus-interferon SCH 721015","C71011","A replication-deficient recombinant adenovirus encoding human interferon alpha-2b with potential antineoplastic activity. Upon intravesical administration, nadofaragene firadenovec infects nearby tumor cells and expresses INF alpha-2b intracellularly which activates the transcription and translation of genes whose products mediate antiviral, antiproliferative, antitumor, and immune-modulating effects.","Nadofaragene Firadenovec | Adstiladrin | Instiladrin | NADOFARAGENE FIRADENOVEC | Nadofaragene Firadenovec | Nadofaragene Firadenovec-vncg | Nadofaragene Firadenovec/Syn3 | Nadofaragene firadenovec | Recombinant Adenovirus-Interferon SCH 721015 | Recombinant Adenovirus-Interferon SCH 721015 | Recombinant Adenovirus-Interferon With Syn3 | Recombinant Adenovirus-Interferon/Syn3 | SCH 721015 | SCH-721015 | SCH721015 | rAd-IFN | rAd-IFN-2b | rAd-IFN/Syn3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937977","Broad Institute","C158521","A joint research venture of MIT and Harvard, established in 2004 to improve human health by using genomics to advance an understanding of the biology and treatment of human disease, and to help lay the groundwork for a new generation of therapies.","Broad Institute | Broad Institute of MIT and Harvard | Eli and Edythe Broad Institute",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509335","CDISC SDTM Musculoskeletal System Finding Test Name Terminology","C127270","Terminology associated with the musculoskeletal system finding test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Musculoskeletal System Finding Test Name Terminology | MUSCTS | Musculoskeletal System Finding Test Name | SDTM-MUSCTS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508989","Swollen Indicator","C127774","An indicator as to whether the subject has symptoms of swelling.","Swollen Indicator | SWLLIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512245","Sharp van der Heijde Joint Space Narrowing Score","C128989","The numerical value that represents the result of a clinical assessment of joint space narrowing based on the Van der Heijde modification of the Sharp Joint Space Narrowing Assessment (Van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, van de Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;1:1036-8).","Sharp van der Heijde Joint Space Narrowing Score | SVJSNSCR | Sharp/Van der Heijde JSN Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512244","Sharp van der Heijde Bone Erosion Score","C128988","The numerical value that represents the result of a clinical assessment of bone erosion based on the Van der Heijde modification of the Sharp Joint Erosion Assessment (Van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, van de Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;1:1036-8).","Sharp van der Heijde Bone Erosion Score | SVBESCR | Sharp/Van der Heijde Bone Erosion Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512243","Sharp Genant Joint Space Narrowing Score","C128987","The numerical value that represents the result of a clinical assessment of joint space narrowing based on the Genant modification of the Sharp Joint Space Narrowing Assessment (Genant HK. Methods of assessing radiographic change in rheumatoid arthritis. Am J Med. 1983 Dec 30;75(6A):35-47).","Sharp Genant Joint Space Narrowing Score | SGJSNSCR | Sharp/Genant JSN Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512242","Sharp Genant Bone Erosion Score","C128986","The numerical value that represents the result of a clinical assessment of bone erosion based on the Genant modification of the Sharp Joint Erosion Assessment (Genant HK. Methods of assessing radiographic change in rheumatoid arthritis. Am J Med. 1983 Dec 30;75(6A):35-47).","Sharp Genant Bone Erosion Score | SGBESCR | Sharp/Genant Bone Erosion Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526674","Range of Motion, Extension","C139213","An assessment of joint flexibility that measures the straightening (unbending) movement between body parts, in number of degrees.","Range of Motion, Extension | ROMEXT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526673","Range of Motion, Dorsiflexion","C139214","An assessment of joint flexibility that measures the movement of a body part bending towards its dorsal surface, in number of degrees.","Range of Motion, Dorsiflexion | ROMDORFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526675","Range of Motion, Abduction","C139212","An assessment of joint flexibility that measures the movement of a body part pulling away from the midline of the body, in number of degrees.","Range of Motion, Abduction | ROMABDT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1720876","Pinch Strength","C139211","An assessment of hand muscle strength that measures that force with which one squeezes or compresses an object using one's thumb and one or multiple fingers.","Pinch Strength | PINCHSTR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526660","Medical Research Council Manual Muscle Test Score, Plantar Flexion","C139229","The numerical value that represents the result of a clinical assessment of muscle strength and function during plantar flexion that is based on the Medical Research Council Manual Muscle Test. (Medical Research Council. Aids to examination of the peripheral nervous system. Memorandum no. 45, superseding War Memorandum No. 7. London: Her Majesty's Stationary Office; 1976. doi:10.1016/0022-510X(77)90205-2).","Medical Research Council Manual Muscle Test Score, Plantar Flexion | MMTPF | MRC MMT Score, Plantar Flex | MRC MMT Score, Plantar Flexion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526665","Medical Research Council Manual Muscle Test Score, Lateral Rotation","C139232","The numerical value that represents the result of a clinical assessment of muscle strength and function during lateral rotation that is based on the Medical Research Council Manual Muscle Test. (Medical Research Council. Aids to examination of the peripheral nervous system. Memorandum no. 45, superseding War Memorandum No. 7. London: Her Majesty's Stationary Office; 1976. doi:10.1016/0022-510X(77)90205-2).","Medical Research Council Manual Muscle Test Score, Lateral Rotation | MMTLR | MRC MMT Score, Lat. Rotat. | MRC MMT Score, Lateral Rotation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526663","Medical Research Council Manual Muscle Test Score, Inversion","C139234","The numerical value that represents the result of a clinical assessment of muscle strength and function during inversion that is based on the Medical Research Council Manual Muscle Test. (Medical Research Council. Aids to examination of the peripheral nervous system. Memorandum no. 45, superseding War Memorandum No. 7. London: Her Majesty's Stationary Office; 1976. doi:10.1016/0022-510X(77)90205-2).","Medical Research Council Manual Muscle Test Score, Inversion | MMTINV | MRC MMT Score, Inversion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526659","Medical Research Council Manual Muscle Test Score, Flexion","C139230","The numerical value that represents the result of a clinical assessment of muscle strength and function during flexion that is based on the Medical Research Council Manual Muscle. (Medical Research Council. Aids to examination of the peripheral nervous system. Memorandum no. 45, superseding War Memorandum No. 7. London: Her Majesty's Stationary Office; 1976. doi:10.1016/0022-510X(77)90205-2).","Medical Research Council Manual Muscle Test Score, Flexion | MMTFLX | MRC MMT Score, Flexion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526661","Medical Research Council Manual Muscle Test Score, Extension","C139228","The numerical value that represents the result of a clinical assessment of muscle strength and function during extension that is based on the Medical Research Council Manual Muscle Test. (Medical Research Council. Aids to examination of the peripheral nervous system. Memorandum no. 45, superseding War Memorandum No. 7. London: Her Majesty's Stationary Office; 1976. doi:10.1016/0022-510X(77)90205-2).","Medical Research Council Manual Muscle Test Score, Extension | MMTEXT | MRC MMT Score, Extension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526662","Medical Research Council Manual Muscle Test Score, Eversion","C139235","The numerical value that represents the result of a clinical assessment of muscle strength and function during eversion that is based on the Medical Research Council Manual Muscle Test. (Medical Research Council. Aids to examination of the peripheral nervous system. Memorandum no. 45, superseding War Memorandum No. 7. London: Her Majesty's Stationary Office; 1976. doi:10.1016/0022-510X(77)90205-2).","Medical Research Council Manual Muscle Test Score, Eversion | MMTEVE | MRC MMT Score, Eversion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526664","Medical Research Council Manual Muscle Test Score, Dorsiflexion","C139233","The numerical value that represents the result of a clinical assessment of muscle strength and function during dorsiflexion that is based on the Medical Research Council Manual Muscle Test. (Medical Research Council. Aids to examination of the peripheral nervous system. Memorandum no. 45, superseding War Memorandum No. 7. London: Her Majesty's Stationary Office; 1976. doi:10.1016/0022-510X(77)90205-2).","Medical Research Council Manual Muscle Test Score, Dorsiflexion | MMTDORS | MRC MMT Score, Dorsiflexion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526658","Medical Research Council Manual Muscle Test Score, Abduction","C139231","The numerical value that represents the result of a clinical assessment of muscle strength and function during abduction that is based on the Medical Research Council Manual Muscle Test. (Medical Research Council. Aids to examination of the peripheral nervous system. Memorandum no. 45, superseding War Memorandum No. 7. London: Her Majesty's Stationary Office; 1976. doi:10.1016/0022-510X(77)90205-2).","Medical Research Council Manual Muscle Test Score, Abduction | MMTABDT | MRC MMT Score, Abduction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526676","Lean Body Mass to Total Body Mass Ratio","C139219","The proportion of an individual's lean body mass to his total body weight; lean body mass is calculated by subtracting body fat from total body weight.","Lean Body Mass to Total Body Mass Ratio | LBMTBMR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526678","Isometric Muscle Strength, Flexion","C139216","An assessment of muscle strength that measures the force produced by static muscle contraction during the bending movement between body parts.","Isometric Muscle Strength, Flexion | ISOMSFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526672","Isometric Muscle Strength, Extension","C139215","An assessment of muscle strength that measures the force produced by static muscle contraction during the straightening (unbending) movement between body parts.","Isometric Muscle Strength, Extension | ISOMSEXT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0429271","Grip Strength","C139210","An assessment of hand muscle strength that measures that force with which one holds or grasps.","Grip Strength | GRIPSTR",,,,,,,,,,,,,,,"4089159","Grip strength",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555605","Fontanelle Closure Indicator","C154909","An indication as to whether the fontanelle is closed.","Fontanelle Closure Indicator | FOCLOIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526681","Brooke Modified Medical Research Council Manual Muscle Test Score, Plantar Flexion","C139221","The numerical value that represents the result of a clinical assessment of muscle strength and function during plantar flexion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).","Brooke Modified Medical Research Council Manual Muscle Test Score, Plantar Flexion | BMMTPF | Brooke mMRC MMT Score, Plantar Flex | Brooke mMRC MMT Score, Plantar Flexion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526657","Brooke Modified Medical Research Council Manual Muscle Test Score, Lateral Rotation","C139224","The numerical value that represents the result of a clinical assessment of muscle strength and function during lateral rotation that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).","Brooke Modified Medical Research Council Manual Muscle Test Score, Lateral Rotation | BMMTLR | Brooke mMRC MMT Score, Lat. Rotat. | Brooke mMRC MMT Score, Lateral Rotation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526655","Brooke Modified Medical Research Council Manual Muscle Test Score, Inversion","C139226","The numerical value that represents the result of a clinical assessment of muscle strength and function during inversion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).","Brooke Modified Medical Research Council Manual Muscle Test Score, Inversion | BMMTINV | Brooke mMRC MMT Score, Inversion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526680","Brooke Modified Medical Research Council Manual Muscle Test Score, Flexion","C139222","The numerical value that represents the result of a clinical assessment of muscle strength and function during flexion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).","Brooke Modified Medical Research Council Manual Muscle Test Score, Flexion | BMMTFLX | Brooke mMRC MMT Score, Flexion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526682","Brooke Modified Medical Research Council Manual Muscle Test Score, Extension","C139220","The numerical value that represents the result of a clinical assessment of muscle strength and function during extension that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).","Brooke Modified Medical Research Council Manual Muscle Test Score, Extension | BMMTEXT | Brooke mMRC MMT Score, Extension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526654","Brooke Modified Medical Research Council Manual Muscle Test Score, Eversion","C139227","The numerical value that represents the result of a clinical assessment of muscle strength and function during eversion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).","Brooke Modified Medical Research Council Manual Muscle Test Score, Eversion | BMMTEVE | Brooke mMRC MMT Score, Eversion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526656","Brooke Modified Medical Research Council Manual Muscle Test Score, Dorsiflexion","C139225","The numerical value that represents the result of a clinical assessment of muscle strength and function during dorsiflexion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).","Brooke Modified Medical Research Council Manual Muscle Test Score, Dorsiflexion | BMMTDORS | Brooke mMRC MMT Score, Dorsiflexion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526679","Brooke Modified Medical Research Council Manual Muscle Test Score, Abduction","C139223","The numerical value that represents the result of a clinical assessment of muscle strength and function during abduction that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).","Brooke Modified Medical Research Council Manual Muscle Test Score, Abduction | BMMTABDT | Brooke mMRC MMT Score, Abduction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526677","Bone Mineral Density Z-Score","C139217","A statistical score representing the number of standard deviations above or below what is expected for an individual's bone density based on his age, sex, weight, and race. Z-scores are most useful in evaluating low bone density in children, premenopausal women, and men younger than age fifty.","Bone Mineral Density Z-Score | BMDZ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545365","Bone Mineral Density T-Score","C147473","The standard deviation of the subject's bone mineral density score in comparison to the expected normal bone mineral density of a healthy 30-year old adult.","Bone Mineral Density T-Score | BMDT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005963","Bone Mineral Contents","C147472","An assessment of the quantity of minerals within a specific bone.","Bone Mineral Content | BMC | Bone Mass | Bone Mineral Mass",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0518026","Body Fat Percentage","C139218","The amount of an individual's total body mass that is fat, expressed as a percent.","Body Fat Percentage | BODYFATP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524888","F-18 Sodium Fluoride Positron Emission Tomography and Computed Tomography Scan","C137816","An imaging procedure that combines F-18 sodium fluoride PET with a CT scan to overlay activity data onto detailed anatomic images.","F-18 Sodium Fluoride Positron Emission Tomography and Computed Tomography Scan | F-18 Sodium Fluoride PET/CT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509334","CDISC SDTM Musculoskeletal System Finding Test Code Terminology","C127269","Terminology associated with the musculoskeletal system finding test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Musculoskeletal System Finding Test Code Terminology | MUSCTSCD | Musculoskeletal System Finding Test Code | SDTM-MUSCTSCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896596","CDISC SDTM Ophthalmic Focus of Study Specific Interest Terminology","C119013","Terminology associated with the ophthalmic focus of study specific interest codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Ophthalmic Focus of Study Specific Interest Terminology | OEFOCUS | Ophthalmic Focus of Study Specific Interest | SDTM-OEFOCUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229118","Both Eyes","C119335","Of or pertaining to both the left and right eyes,","Both Eyes | OU | Oculus Uterque | Oculus Uterque (Both Eyes)",,,,,,,,,,,,,,,"4230443","Structure of both eyes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3896594","CDISC SDTM Ophthalmic Exam Test Name Terminology","C117742","Terminology associated with the ophthalmic exam test names codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Ophthalmic Exam Test Name Terminology | OETEST | Ophthalmic Exam Test Name | SDTM-OETEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900010","Astigmatism Axis","C117889","A measurement of the location, in degrees, of the flatter principal meridian on a 180-degree scale, where 90 degrees designates the vertical meridian and 180 degrees designates the horizontal meridian.","Astigmatism Axis | ASTAXIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545369","Acuity Card Grating Frequency","C147477","A measurement of the number of horizontal or vertical lines within a pre-determined unit of length on a visual acuity card.","Acuity Card Grating Frequency | VACGRFRQ | Visual Acuity Card Grating Frequency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053992","Standard Deviation of Thickness","C120722","A measure of the range of values in a set of values that describe the thickness of an entity.","Standard Deviation of Thickness | THICKSD | Thickness, Standard Deviation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054488","Minimum Thickness","C120720","The minimum value in a range of values that describe the thickness of an entity.","Minimum Thickness | THICKMIN | Thickness, Minimum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054557","Mean Thickness","C120721","The arithmetic mean of a range of values that describe the thickness of an entity.","Mean Thickness | THCKNMN | THICKMN | Thickness, Mean",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054567","Maximum Thickness","C120719","The maximum value in a range of values that describe the thickness of an entity.","Maximum Thickness | THICKMAX | Thickness, Maximum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545368","Planned Subject to Eye Chart Distance","C147476","The planned distance between the subject and the eye chart during an eye assessment.","Planned Subject to Eye Chart Distance | SUBECPDT | Subject to Eye Chart Planned Distance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545367","Actual Subject to Eye Chart Distance","C147475","The actual distance between the subject and the eye chart during an eye assessment.","Actual Subject to Eye Chart Distance | SUBECADT | Subject to Eye Chart Actual Distance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897546","Spherical Refractive Error","C117893","A measurement of the extent of defect in vision caused by a mismatch of optimal power between the cornea and/or lens and the length of the eyeball, resulting in sub-optimal reflection of light onto the retina.","Spherical Refractive Error | RESPHERE | Spherical Refraction Error",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540338","Number of Lines Unread","C142355","The number of lines not able to be read by the subject during an eye chart assessment.","Number of Lines Unread | NUMLINUR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526639","Number of Eye Chart Lines Read","C139242","The number of lines read by the subject during an eye chart assessment.","Number of Eye Chart Lines Read | NUMLINRD | Number of Lines Read",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898118","Number of Correct Eye Chart Letters","C117891","The integer that describes the number of letters correctly identified by the subject during an eye chart assessment.","Number of Correct Eye Chart Letters | NUMLCOR | Number of Letters Correct",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540339","Number of Characters Unread","C142354","The number of letters not able to be read by the subject during an eye chart assessment.","Number of Characters Unread | NUMCHRUR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540340","Number of Characters Read","C142353","The number of letters read by the subject during an eye chart assessment.","Number of Characters Read | NUMCHRRD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540341","Near-Point Accommodation","C142352","The minimum distance from the retina that an object remains in clear focus.","Near-Point Accommodation | NRPNTACC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540232","Minimum Angle of Resolution","C142233","The smallest angle of separation that allows an image-forming device to distinguish two objects as distinct entities.","Minimum Angle of Resolution | MNARS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054652","Lens Status","C120718","The condition or state of the lens of the eye.","Lens Status | LENSSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519999","Hyperemia Grade","C132432","An evaluation of the presence and extent of hyperemia.","Hyperemia Grade | HYPERGR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545366","Eye Drop Comfort Grade","C147474","The position on a scale of intensity, amount or quality of eye drop comfort.","Eye Drop Comfort Grade | EYDCOMGR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053993","Standard Deviation of Diameter","C120717","A measure of the range of values in a set of values that describe the diameter of an entity.","Standard Deviation of Diameter | DIAMSD | Diameter, Standard Deviation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054490","Minimum Diameter","C120715","The minimum value in a range of values that describe the diameter of an entity.","Minimum Diameter | DIAMMIN | Diameter, Minimum | shortest dimension | shortest_dimension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0552409","Mean Diameter","C120716","The arithmetic mean of a range of values that describe the diameter of an entity.","Mean Diameter | DIAMMN | Diameter, Mean",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899481","Cylindrical Refractive Error","C117892","A measurement of the extent of defect in vision caused by a mismatch of optical power between the cylindrical and horizontal meridians, resulting in sub-optimal reflection of light onto the retina.","Cylindrical Refractive Error | Cylindrical Refraction Error | RECYLDR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0423471","Optic Cup to Disc Ratio","C120714","The ratio of the diameter of the optic cup compared to the diameter of the optic disc.","Optic Cup to Disc Ratio | CUPDISC | Cup to Disc Ratio",,,,,,,,,,,,,,,"4082773","Optic cup/disc ratio",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053994","Standard Deviation of Cell Density","C120713","A measure of the range of values in a set of values that describe the cell density.","Standard Deviation of Cell Density | CELLDSD | Cell Density, Standard Deviation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054565","Mean Cell Density","C120712","The arithmetic mean of a range of values that describe the cell density of an entity.","Mean Cell Density | CELLDMN | Cell Density, Mean",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054569","Maximum Cell Density","C120710","The maximum value in a range of values that describe cell density.","Maximum Cell Density | CELLDMAX | Cell Density, Maximum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162339","Cell Density","C120538","A measurement of the number of cells per unit volume or area.","Cell Density | CELLDENS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053785","Minimum Cell Density","C120711","The minimum value in a range of values that describe cell density.","Minimum Cell Density | CELLDMIN | Cell Density, Minimum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896595","CDISC SDTM Ophthalmic Exam Test Code Terminology","C117743","Terminology associated with the ophthalmic exam test codes codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Ophthalmic Exam Test Code Terminology | OETESTCD | Ophthalmic Exam Test Code | SDTM-OETESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086080","CDISC SDTM Medical History Event Date Type Terminology","C124301","Terminology associated with the medical history event date type codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Medical History Event Date Type Terminology | MHEDTTYP | Medical History Event Date Type | SDTM-MHEDTTYP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086878","Symptom Onset","C124353","The point at which the symptoms began or were first noted.","Symptom Onset | SYMPTOM ONSET",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504571","CDISC SDTM Microscopic Findings Test Detail Terminology","C125922","Terminology associated with the microscopic findings test detail codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Microscopic Findings Test Detail Terminology | MIFTSDTL | Microscopic Findings Test Details | SDTM-MIFTSDTL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522833","AJCC Tumor Grade","C135461","An assessment of the cellular differentiation of a tumor as per the American Joint Committee on Cancer (AJCC) tumor grading scale.","AJCC Tumor Grade | AJCC TUMOR GRADE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555537","Tumor Proportion Score","C154810","The percentage of viable tumor cells with partial or complete cell membrane staining.","Tumor Proportion Score | TPS | TUMOR PROPORTION SCORE | Tumor Proportional Scope | Tumor Proportional Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897651","Scheuer Fibrosis Score","C119573","A scoring system for liver fibrosis developed by Scheuer (Scheuer PJ. Classification of viral hepatitis: a need for reassessment. J Hepatol 1991;13:372-374), based on a 5 category scale.","Scheuer Fibrosis Score | SCHEUER FIBROSIS SCORE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504589","Receptor Overall Status","C125989","A qualitative assessment of the status of a biological specimen with regards to a cellular receptor.","Receptor Overall Status | RECEPTOR OVERALL STATUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897040","METAVIR Fibrosis Score","C119572","A scoring system for liver fibrosis developed by Bedossa and Poynard (Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996 Aug; 24(2):289-93.), based on a 5 category scale.","METAVIR Fibrosis Score | METAVIR FIBROSIS SCORE | Metavir Fibrosis Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898641","Knodell Fibrosis Score","C119571","A scoring system for liver fibrosis developed by Knodell et al (Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431), based on a 4 category scale.","Knodell Fibrosis Score | KNODELL FIBROSIS SCORE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540358","International Society of Urological Pathology Gleason Grade Group","C142346","A grading system for prostatic adenocarcinoma based on modified Gleason cellular differentiation patterns and Gleason primary and secondary scores (Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA; Grading Committee. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016 Feb;40(2):244-52.)","International Society of Urological Pathology Gleason Grade Group | Epstein ISUP Grade Group | ISUP | ISUP GLEASON GRADE GROUP | gleason grade group | gleason_grade_group",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504588","H Score Total Score","C125988","The histopathological evaluation of staining in tissue based on the H Score scoring system (McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716-721).","H Score Total Score | H SCORE TOTAL SCORE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555534","European Consensus Score For Bone Marrow Fibrosis","C154809","A score based on the European Consensus scale, a grading system for the qualitative and quantitative evaluation of bone marrow fibrosis with a score ranging from zero (normal bone marrow) to three (coarse bundles of collagen fibrosis, usually associated with significant osteosclerosis). (Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005 Aug;90(8):1128-32.)","European Consensus Score For Bone Marrow Fibrosis | EUROPEAN CONSENSUS SCORE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521024","Enhanced Liver Fibrosis Score","C132429","A scoring system for liver fibrosis developed by Lichtinghagen et al, based on an algorithm that takes into account tissue inhibitor of metalloproteinases 1 (TIMP-1), amino-terminal propeptide of type III procollagen (PIIINP) and hyaluronic acid (HA) levels. (Lichtinghagen R, Pietsch D, Bantel H, Manns MP, Brand K, Bahr MJ. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. J Hepatol. 2013 Aug;59(2):236-42.)","Enhanced Liver Fibrosis Score | ELF | ENHANCED LIVER FIBROSIS SCORE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555533","Bauermeister Score","C154808","A score based on the Bauermeister scale, a 5-point grading system used to rate the extent of myelofibrosis in potential myeloproliferative neoplasms, based on the amount of reticulin and collagen fibers present in the bone marrow. (Bauermeister DE. Quantitation of bone marrow reticulin-a normal range. Am J Clin Pathol. 1971 Jul;56(1):24-31.)","Bauermeister Score | BAUERMEISTER SCORE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899954","Batts-Ludwig Fibrosis Score","C119570","A scoring system for liver fibrosis developed by Batts and Ludwig (Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995;19:1409), based on a four category scale.","Batts-Ludwig Fibrosis Score | BATTS-LUDWIG FIBROSIS SCORE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522834","Banff Renal Quantitative Criteria Score","C135462","A score originally developed by Solez et al. (1993), and assigned based on the histologic evaluation of kidney allograft biopsies and the Banff Working Classification from the Banff Foundation for Allograft Pathology.","Banff Renal Quantitative Criteria Score | BANFF QUANTITATIVE CRITERIA SCORE RENAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504587","Allred Total Score","C125987","A score for the semi-quantitative staining of estrogen-positive (ER+) or progesterone-positive (PR+) cells in breast cancer tissue samples. It combines a score of 0 through 5 for percentage of stained cells and a score of 0-3 for the intensity of staining. A score of 0-2 is considered negative and 3-8 qualify as positive.","Allred Total Score | ALLRED TOTAL SCORE | Allred Score",,,,,,,,,,,,,,,"40482071","Allred score for neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504586","Allred Average Staining Intensity Score","C125986","A score developed by Allred et al. (1998) for the average staining intensity for all stained protein-positive cells.","Allred Average Staining Intensity Score | ALLRED STAINING INTENSITY SCORE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504585","Allred Proportion Positive Score","C125985","A score developed by Allred et al. (1998) for the proportion of tumor cells that are positive for a given biomarker. The proportion score is assigned based on the biomarker positivity measurement.","Allred Proportion Positive Score | ALLRED PROPORTION POSITIVE SCORE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556869","BRAF Inhibitor","C155322","Any agent that inhibits the serine/threonine-protein kinase BRAF(B-RAF).","BRAF Inhibitor | B-RAF Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896597","CDISC SDTM Nervous System Physiology Test Name Terminology","C116103","Terminology associated with the nervous system physiology test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Nervous System Physiology Test Name Terminology | NVTEST | Nervous System Findings Test Name | SDTM-NVTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831288","Boundary Shift Integral","C114183","A measurement of change in volume of an organ or anatomical feature as determined by a shift in tissue boundary over time.","Boundary Shift Integral | BSI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935646","Wake After Sleep Onset","C156554","A measurement of the sum of durations of wakefulness episodes throughout the night, not including the wakefulness before sleep onset.","Wake After Sleep Onset | Awake After Sleep Onset | WASO | Wake Time After Sleep Onset",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935641","Total Sleep Time","C156552","The total amount of sleep time from sleep onset to sleep offset, determined by summing the N1 sleep, N2 sleep, N3 sleep, and REM sleep durations.","Total Sleep Time | TST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555679","Sleep Onset Latency","C154867","The duration of time between when the lights are turned off and when the individual falls asleep.","Sleep Onset Latency | SOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332138","Sleep Efficiency","C156553","A relative measurement (percentage) of the time spent asleep (N1 sleep + N2 sleep + N3 sleep + REM sleep) to the total time spent in bed.","Sleep Efficiency | SE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0814024","skin conductance","C154866","The degree to which the skin can conduct electricity.","Skin Conductance | SKNCUDNC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935636","REM to Total Sleep Time Ratio Measurement","C156558","The determination of the ratio of REM sleep time compared to total sleep time. The measurement may be expressed as a ratio or percentage.","REM to Total Sleep Time Ratio Measurement | REM/Total Sleep Time | REMTST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555680","Rapid Eye Movement Sleep Phase Latency","C154872","The time between the onset of sleep and the onset of the first rapid eye movement (REM) cycle.","Rapid Eye Movement Sleep Phase Latency | REM Latency | REMLAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555682","Rapid Eye Movement Sleep Phase Duration","C154871","The total amount of time an individual spends in rapid eye movement (REM) sleep.","Rapid Eye Movement Sleep Phase Duration | REM Duration | REMDUR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935634","Peak Response Amplitude Latency","C156560","The time duration between the stimulus and the maximum response.","Peak Response Amplitude Latency | PEAKRAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935633","Peak Response Amplitude","C156559","The maximum height change between the wave and the equilibrium point of a stimulus-response waveform.","Peak Response Amplitude | PEAKRA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898061","P100 Latency","C117888","An assessment of the latency of the P100 or P1 wave of the visual evoked potential assessment waveform.","P100 Latency | P1 Latency | P100LAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898213","N75 to P100 Peak to Peak Amplitude","C117887","The magnitude, or height, of the P100 wave of the visual evoked potential assessment waveform. This assessment calculates the height from the N75 negative peak to the P100 positive peak.","N75 to P100 Peak to Peak Amplitude | N1 to P1 Peak to Peak Amplitude | P100 Amplitude | P100AMP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514063","N75 Latency","C130185","An assessment of the latency of the N75 or N1 wave of the visual evoked potential assessment waveform.","N75 Latency | N1 Latency | N75LAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935635","N3 Sleep to Total Sleep Time Ratio Measurement","C156557","The determination of the ratio of N3 sleep time compared to total sleep time. The measurement may be expressed as a ratio or percentage.","N3 Sleep to Total Sleep Time Ratio Measurement | N3 Sleep/Total Sleep Time | N3SLPTST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555681","N3 Sleep Phase Duration","C154870","The length of time of N3 sleep.","N3 Sleep Phase Duration | N3 Sleep Duration | N3SLPDUR | Stage 3 Sleep Duration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935645","N2 Sleep to Total Sleep Time Ratio Measurement","C156556","The determination of the ratio of N2 sleep time compared to total sleep time. The measurement may be expressed as a ratio or percentage.","N2 Sleep to Total Sleep Time Ratio Measurement | N2 Sleep/Total Sleep Time | N2SLPTST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555678","N2 Sleep Phase Duration","C154869","The length of time of N2 sleep.","N2 Sleep Phase Duration | N2 Sleep Duration | N2SLPDUR | Stage 2 Sleep Duration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827678","Uterine Carcinosarcoma, Heterologous Type","C113239","A carcinosarcoma of the uterus characterized by the presence of sarcomatous elements composed of tissues that are not found in the uterus (e.g., bone, cartilage, skeletal muscle).","Uterine Carcinosarcoma, Heterologous Type | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897035","N145 Latency","C117886","An assessment of the latency of the N145 or N2 wave of the visual evoked potential assessment waveform.","N145 Latency | N145LAT | N2 Latency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935644","N1 Sleep to Total Sleep Time Ratio Measurement","C156555","The determination of the ratio of N1 sleep time compared to total sleep time. The measurement may be expressed as a ratio or percentage.","N1 Sleep to Total Sleep Time Ratio Measurement | N1 Sleep/Total Sleep Time | N1SLPTST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555677","N1 Sleep Phase Duration","C154868","The length of time of N1 sleep.","N1 Sleep Phase Duration | N1 Sleep Duration | N1SLPDUR | Stage 1 Sleep Duration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935639","N-Acetyl Aspartate Measurement","C156561","The determination of the amount of N-acetyl aspartate in a biological specimen.","N-Acetyl Aspartate Measurement | N-Acetyl Aspartate | NAA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936089","Myo-Inositol Measurement","C156562","The determination of the amount of myo-inositol in a biological specimen.","Myo-Inositol Measurement | INOSM | Myo-Inositol | mI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935637","Glutamate and Glutamine Measurement","C156563","The determination of the amount of glutamate and glutamine in a biological specimen.","Glutamate and Glutamine Measurement | GLX | Glutamate Plus Glutamine | Glutamate and Glutamine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556906","Cerebral Blood Flow Assessment","C154865","An evaluation of the perfusion of blood through the brain.","Cerebral Blood Flow Assessment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896598","CDISC SDTM Nervous System Physiology Test Code Terminology","C116104","Terminology associated with the nervous system physiology test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Nervous System Physiology Test Code Terminology | NVTESTCD | Nervous System Findings Test Code | SDTM-NVTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987193","Pancreatic Intraductal Papillary Mucinous Neoplasm, Intestinal-Type","C95510","A pancreatic intraductal papillary mucinous neoplasm characterized by the presence of neoplastic epithelial cells that form tall papillae, similar to those that are present in colonic villous adenomas.","Pancreatic Intraductal Papillary Mucinous Neoplasm, Intestinal-Type | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0586364","Pancreatic Intraepithelial Neoplasia-2","C4846","A pancreatic mucinous intraepithelial neoplasia characterized by the presence of papillary and less often flat architectural patterns.  Moderate cytological atypia is present with some loss of nuclear polarity, nuclear crowding or hyperchromatism.","Pancreatic Intraepithelial Neoplasia-2 | Grade 2 Pancreatic Intraepithelial Neoplasia | Grade II Pancreatic Intraepithelial Neoplasia | PanIN-2",,,,,,,,,,,,,,,"4204029","Moderate pancreatic duct dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3532881","Pancreatic Intraductal Papillary-Mucinous Neoplasm, High Grade","C41251","A non-invasive pancreatic intraductal papillary mucinous neoplasm characterized by the presence of neoplastic epithelial cells that exhibit loss of polarity, nuclear stratification, hyperchromasia, and pleomorphism.  There is severe architectural atypia and frequent mitotic figures present.","Pancreatic Intraductal Papillary-Mucinous Neoplasm, High Grade | Pancreatic Intraductal Papillary Mucinous Neoplasm with High Grade Dysplasia | Pancreatic Intraductal Papillary-Mucinous Neoplasm with High Grade Dysplasia | Pancreatic Intraductal Papillary-Mucinous Neoplasm with High Grade Dysplasia | Pancreatic Intraductal Papillary-Mucinous Neoplasm, High-Grade | Pancreatic Non-Invasive Intraductal Papillary-Mucinous Carcinoma",,,,,,,,,,,,,,,"4030115|43021774","Intraductal papillary-mucinous carcinoma, non-invasive|Intraductal papillary mucinous carcinoma in situ of pancreas",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1335305","Pancreatic Intraductal Papillary-Mucinous Neoplasm with Intermediate Grade Dysplasia","C5719","A non-invasive pancreatic intraductal papillary mucinous neoplasm characterized by the presence of neoplastic epithelial cells that exhibit nuclear stratification, loss of polarity, and crowding.  There is moderate nuclear hyperchromasia.","Pancreatic Intraductal Papillary-Mucinous Neoplasm with Intermediate Grade Dysplasia | Pancreatic Borderline Intraductal Papillary-Mucinous Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987145","Grade 3 Pancreatic Intraepithelial Neoplasia","C95432","A pancreatic epithelial neoplasia characterized by the presence of papillary and rarely flat architectural patterns with formation of cribriform patterns and luminal necrosis.  Severe dysplasia is present.","High Grade Pancreatic Intraepithelial Neoplasia | Grade 3 Pancreatic Intraepithelial Neoplasia | Grade III Pancreatic Intraepithelial Neoplasia | High Grade PanIN | High-Grade PanIN | High-Grade Pancreatic Intraepithelial Neoplasia | PanIN-3 | Pancreatic Intraepithelial Neoplasia-3 | Pancreatic Intraepithelial Neoplasia-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987142","Pancreatic Intraepithelial Neoplasia-1A","C95429","A pancreatic intraepithelial neoplasia characterized by the presence of tall columnar cells that form flat architectural patterns.  Mild cytological atypia is present.","Pancreatic Intraepithelial Neoplasia-1A | PanIN-1A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829003","Mixed Type Pancreatic Intraductal Papillary-Mucinous Neoplasm","C113667","An intraductal papillary-mucinous neoplasm of the pancreas that arises primarily from the main pancreatic duct and extends to the branch ducts.","Mixed Type Pancreatic Intraductal Papillary-Mucinous Neoplasm | Mixed Type Pancreatic IPMN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0535350","MUC5AC protein, human","C90334","Mucin-5AC (5030 aa, ~527 kDa) is encoded by the human MUC5AC gene. This protein plays a role in the defense of the gastrointestinal and respiratory tracts from microorganism infection.","Mucin-5AC | Gastric Mucin | LeB | Lewis B Blood Group Antigen | MUC-5AC | MUC5AC | Major Airway Glycoprotein | Mucin-5 Subtype AC, Tracheobronchial | TBM | Tracheobronchial Mucin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1744064","Mucin-4, Human","C128856","Mucin-4 (2169 aa, ~232 kDa) is encoded by the human MUC4 gene. This protein is involved in receptor signaling, the modulation of cell-matrix adhesion, and in tumor progression.","Mucin-4 | Ascites Sialoglycoprotein | MUC-4 | MUC4 | Pancreatic Adenocarcinoma Mucin | Testis Mucin | Tracheobronchial Mucin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1528289","Mucin-2, Human","C115187","Mucin-2 (5179 aa, ~540 kDa) is encoded by the human MUC2 gene. This protein plays a role in coating the intestinal epithelium.","Mucin-2 | Intestinal Mucin-2 | MUC-2 | MUC2 | Mucin 2 | Mucin-Like Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522897","Pancreatic Neuroendocrine Tumor TNM Finding v8","C135536","A finding about one or more characteristics of a pancreatic neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system. This classification system applies to well-differentiated neuroendocrine tumors arising in the pancreas. It does not apply to carcinomas of the pancreas, including high-grade (grade 3), poorly differentiated neuroendocrine carcinomas. (from AJCC 8th Ed.)","Pancreatic Neuroendocrine Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522916","Pancreatic Neuroendocrine Tumor pT4 TNM Finding v8","C135555","Pancreatic neuroendocrine tumor invading adjacent organs (stomach, spleen, colon, adrenal gland) or the wall of large vessels (celiac axis or the superior mesenteric artery). (from AJCC 8th Ed.)","Pancreatic Neuroendocrine Tumor pT4 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522915","Pancreatic Neuroendocrine Tumor pT3 TNM Finding v8","C135554","Pancreatic neuroendocrine tumor limited to the pancreas and measuring more than 4 cm; or tumor invading the duodenum or bile duct. (from AJCC 8th Ed.)","Pancreatic Neuroendocrine Tumor pT3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522914","Pancreatic Neuroendocrine Tumor pT2 TNM Finding v8","C135553","Pancreatic neuroendocrine tumor limited to the pancreas and measuring 2-4 cm. (from AJCC 8th Ed.)","Pancreatic Neuroendocrine Tumor pT2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522913","Pancreatic Neuroendocrine Tumor pT1 TNM Finding v8","C135552","Pancreatic neuroendocrine tumor limited to the pancreas and measuring less than 2 cm. Limited to the pancreas means there is no invasion of adjacent organs (stomach, spleen, colon, adrenal gland) or the wall of large vessels (celiac axis or the superior mesenteric artery). Extension of tumor into peripancreatic adipose tissue is not a basis for staging. (from AJCC 8th Ed.)","Pancreatic Neuroendocrine Tumor pT1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522912","Pancreatic Neuroendocrine Tumor pTX TNM Finding v8","C135551","Pancreatic neuroendocrine tumor in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Pancreatic Neuroendocrine Tumor pTX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512736","Invasive Bladder Lymphoepithelioma-Like Carcinoma","C39821","Invasive bladder urothelial carcinoma with lymphoepithelioma-like features.","Invasive Bladder Lymphoepithelioma-Like Carcinoma | Bladder Lymphoepithelioma-Like Carcinoma | Infiltrating Bladder Lymphoepithelioma-Like Carcinoma | Infiltrating Bladder Lymphoepithelioma-Like Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511204","Urachal Adenocarcinoma","C39843","A rare bladder adenocarcinoma that develops from the urachal remnant.","Urachal Adenocarcinoma | Bladder Urachal Adenocarcinoma | Bladder Urachal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522920","Pancreatic Neuroendocrine Tumor pN1 TNM Finding v8","C135559","Pancreatic neuroendocrine tumor with regional lymph node involvement. (from AJCC 8th Ed.)","Pancreatic Neuroendocrine Tumor pN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522919","Pancreatic Neuroendocrine Tumor pN0 TNM Finding v8","C135558","Pancreatic neuroendocrine tumor without regional lymph node involvement. (from AJCC 8th Ed.)","Pancreatic Neuroendocrine Tumor pN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522918","Pancreatic Neuroendocrine Tumor pNX TNM Finding v8","C135557","Pancreatic neuroendocrine tumor in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)","Pancreatic Neuroendocrine Tumor pNX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522899","Pancreatic Neuroendocrine Tumor Clinical Distant Metastasis TNM Finding v8","C135538","A clinical finding about one or more characteristics of a pancreatic neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Pancreatic Neuroendocrine Tumor Clinical Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522907","Pancreatic Neuroendocrine Tumor pM1 TNM Finding v8","C135546","Pancreatic neuroendocrine tumor with distant metastasis. (from AJCC 8th Ed.)","Pancreatic Neuroendocrine Tumor pM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522904","Pancreatic Neuroendocrine Tumor cM1c TNM Finding v8","C135543","Pancreatic neuroendocrine tumor with both hepatic and extrahepatic metastases. (from AJCC 8th Ed.)","Pancreatic Neuroendocrine Tumor cM1c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522903","Pancreatic Neuroendocrine Tumor cM1b TNM Finding v8","C135542","Pancreatic neuroendocrine tumor with metastasis in at least one extrahepatic site (e.g., lung, ovary, nonregional lymph node, peritoneum, bone). (from AJCC 8th Ed.)","Pancreatic Neuroendocrine Tumor cM1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522902","Pancreatic Neuroendocrine Tumor cM1a TNM Finding v8","C135541","Pancreatic neuroendocrine tumor with metastasis confined to liver. (from AJCC 8th Ed.)","Pancreatic Neuroendocrine Tumor cM1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522901","Pancreatic Neuroendocrine Tumor cM1 TNM Finding v8","C135540","Pancreatic neuroendocrine tumor with distant metastasis. (from AJCC 8th Ed.)","Pancreatic Neuroendocrine Tumor cM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522900","Pancreatic Neuroendocrine Tumor cM0 TNM Finding v8","C135539","Pancreatic neuroendocrine tumor without evidence of distant metastasis. (from AJCC 8th Ed.)","Pancreatic Neuroendocrine Tumor cM0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522906","Pancreatic Neuroendocrine Tumor Pathologic Distant Metastasis TNM Finding v8","C135545","A pathologic finding about one or more characteristics of a pancreatic neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Pancreatic Neuroendocrine Tumor Pathologic Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522910","Pancreatic Neuroendocrine Tumor pM1c TNM Finding v8","C135549","Pancreatic neuroendocrine tumor with both hepatic and extrahepatic metastases. (from AJCC 8th Ed.)","Pancreatic Neuroendocrine Tumor pM1c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522909","Pancreatic Neuroendocrine Tumor pM1b TNM Finding v8","C135548","Pancreatic neuroendocrine tumor with metastasis in at least one extrahepatic site (e.g., lung, ovary, nonregional lymph node, peritoneum, bone). (from AJCC 8th Ed.)","Pancreatic Neuroendocrine Tumor pM1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522908","Pancreatic Neuroendocrine Tumor pM1a TNM Finding v8","C135547","Pancreatic neuroendocrine tumor with metastasis confined to liver. (from AJCC 8th Ed.)","Pancreatic Neuroendocrine Tumor pM1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522921","Pancreatic Neuroendocrine Tumor by AJCC v8 Stage","C135560","A term that refers to the staging of a pancreatic neuroendocrine tumor, following the American Joint Committee on Cancer (AJCC) v8 staging guidelines. This staging system applies to well-differentiated neuroendocrine tumors arising in the pancreas. Carcinomas of the pancreas, including high-grade (grade 3), poorly differentiated neuroendocrine carcinomas are not staged using this staging system. (from AJCC 8th Ed.)","Pancreatic Neuroendocrine Tumor by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522925","Stage IV Pancreatic Neuroendocrine Tumor AJCC v8","C135564","Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Pancreatic Neuroendocrine Tumor AJCC v8 | Stage IV Pancreatic Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522924","Stage III Pancreatic Neuroendocrine Tumor AJCC v8","C135563","Stage III includes: (T4, N0, M0); (Any T, N1, M0). T4: Tumor invading adjacent organs (stomach, spleen, colon, adrenal gland) or the wall of large vessels (celiac axis or the superior mesenteric artery). N0: No regional lymph node involvement. N1: Regional lymph node involvement. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Pancreatic Neuroendocrine Tumor AJCC v8 | Stage III Pancreatic Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522923","Stage II Pancreatic Neuroendocrine Tumor AJCC v8","C135562","Stage II includes: (T2, N0, M0); (T3, N0, M0). T2: Tumor limited to the pancreas and measuring 2-4 cm. T3: Tumor limited to the pancreas and measuring more than 4 cm; or tumor invading the duodenum or bile duct. N0: No regional lymph node involvement. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Pancreatic Neuroendocrine Tumor AJCC v8 | Stage II Pancreatic Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522922","Stage I Pancreatic Neuroendocrine Tumor AJCC v8","C135561","Stage I includes: T1, N0, M0. T1: Tumor limited to the pancreas and measuring less than 2 cm. N0: No regional lymph node involvement. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Pancreatic Neuroendocrine Tumor AJCC v8 | Stage I Pancreatic Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937953","Clonal Hematopoiesis of Indeterminate Potential","C158547","A term that refers to the presence of somatic mutations in bone marrow or peripheral blood cells in individuals who may be cytopenic but do not have morphologic evidence of hematologic neoplasia. Its prevalence rises with age and is found in approximately 10% of individuals aged 70 to 80. It is associated with an increased risk of hematologic neoplasia. Mutations in the DNMT3A, TET2, or ASXL1 genes are usually identified. Approximately 10%-40% of individuals with age-related clonal hematopoiesis will progress to meet the diagnostic criteria for clonal hematopoiesis of indeterminate potential.","Clonal Hematopoiesis of Indeterminate Potential | CHIP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0447556","Neck of the Pancreas","C158551","The portion of the pancreas that is the junction of the head and body of the pancreas; the portion of the pancreas that lies anterior to the aorta.","Neck of the Pancreas | Neck | PANCREAS, NECK | Pancreas Neck | Pancreatic Neck | Pancreatic neck",,,,,,,,,,,,,,,"4081810","Neck of pancreas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055371","Borderline Ovarian Serous Tumor-Micropapillary Variant/Non-Invasive Low Grade Ovarian Serous Carcinoma","C122585","A non-invasive serous neoplasm that arises from the ovary and shows micropapillary and/or cribriform architectural patterns.  It is composed of round epithelial cells with scant cytoplasm and moderate nuclear atypia.","Borderline Ovarian Serous Tumor-Micropapillary Variant/Non-Invasive Low Grade Ovarian Serous Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055047","Extramedullary Involvement","C122601","A finding indicating the involvement of sites other than the bone marrow by a hematopoietic neoplasm.","Extramedullary Involvement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538340","Testicular Cancer cT4 TNM Finding v8","C140197","Testicular cancer in which the tumor invades scrotum with or without vascular/lymphatic invasion. (from AJCC 8th Ed.)","Testicular Cancer cT4 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538341","Testicular Cancer cTis TNM Finding v8","C140196","Testicular cancer with a finding of germ cell neoplasia in situ. (from AJCC 8th Ed.)","Testicular Cancer cTis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538342","Testicular Cancer cT0 TNM Finding v8","C140195","Testicular cancer with no evidence of primary tumor. (from AJCC 8th Ed.)","Testicular Cancer cT0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538343","Testicular Cancer cTX TNM Finding v8","C140194","Testicular cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Testicular Cancer cTX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538318","Testicular Cancer cN3 TNM Finding v8","C140203","Testicular cancer with metastasis with a lymph node mass larger than 5 cm in greatest dimensi. (from AJCC 8th Ed.)","Testicular Cancer cN3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538319","Testicular Cancer cN2 TNM Finding v8","C140202","Testicular cancer with metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension or multiple lymph nodes, any one mass larger than 2 cm but not larger than 5 cm in greatest dimension. (from AJCC 8th Ed.)","Testicular Cancer cN2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538336","Testicular Cancer cN1 TNM Finding v8","C140201","Testicular cancer with metastases in a lymph node mass 2 cm or smaller in greatest dimension or multiple lymph nodes, none larger than 2 cm in greatest dimension. (from AJCC 8th Ed.)","Testicular Cancer cN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538337","Testicular Cancer cN0 TNM Finding v8","C140200","Testicular cancer with no regional lymph node metastasis. (from AJCC 8th Ed.)","Testicular Cancer cN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538338","Testicular Cancer cNX TNM Finding v8","C140199","Testicular cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Testicular Cancer cNX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538315","Testicular Cancer pM1 TNM Finding v8","C140206","Testicular cancer with distant metastasis. (from AJCC 8th Ed.)","Testicular Cancer pM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538329","Testicular Cancer cM1b TNM Finding v8","C140192","Testicular cancer with non-pulmonary visceral metastases. (from AJCC 8th Ed.)","Testicular Cancer cM1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538330","Testicular Cancer cM1a TNM Finding v8","C140191","Testicular cancer with non-retroperitoneal nodal or pulmonary metastases. (from AJCC 8th Ed.)","Testicular Cancer cM1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538331","Testicular Cancer cM1 TNM Finding v8","C140190","Testicular cancer with distant metastasis. (from AJCC 8th Ed.)","Testicular Cancer cM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538332","Testicular Cancer cM0 TNM Finding v8","C140189","Testicular cancer without evidence of distant metastasis. (from AJCC 8th Ed.)","Testicular Cancer cM0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538317","Testicular Cancer Pathologic TNM Finding v8","C140204","A pathologic finding about one or more characteristics of testicular cancer, following the rules of the TNM AJCC v8 classification system.","Testicular Cancer Pathologic TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538303","Testicular Cancer pT4 TNM Finding v8","C140218","Testicular cancer in which the tumor invades scrotum with or without lymphovascular invasion. (from AJCC 8th Ed.)","Testicular Cancer pT4 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538320","Testicular Cancer pT3 TNM Finding v8","C140217","Testicular cancer in which the tumor invades spermatic cord with or without lymphovascular invasion. (from AJCC 8th Ed.)","Testicular Cancer pT3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538321","Testicular Cancer pT2 TNM Finding v8","C140216","Testicular cancer which is limited to testis (including rete testis invasion) with lymphovascular invasion or invades hilar soft tissue or epididymis or penetrates visceral mesothelial layer covering the external surface of tunica albuginea with or without lymphovascular invasion. (from AJCC 8th Ed.)","Testicular Cancer pT2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538322","Testicular Cancer pT1b TNM Finding v8","C140215","Testicular cancer which is limited to testis (including rete testis invasion) without lymphovascular invasion and is 3 cm or larger in size. This pT1 subclassification applies only to pure seminomas. (from AJCC 8th Ed.)","Testicular Cancer pT1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538323","Testicular Cancer pT1a TNM Finding v8","C140214","Testicular cancer which is limited to testis (including rete testis invasion) without lymphovascular invasion and is smaller than 3 cm in size. This pT1 subclassification applies only to pure seminomas. (from AJCC 8th Ed.)","Testicular Cancer pT1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538324","Testicular Cancer pT1 TNM Finding v8","C140213","Testicular cancer which is limited to testis (including rete testis invasion) without lymphovascular invasion. (from AJCC 8th Ed.)","Testicular Cancer pT1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538325","Testicular Cancer pTis TNM Finding v8","C140212","Testicular cancer with a finding of germ cell neoplasia in situ. (from AJCC 8th Ed.)","Testicular Cancer pTis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538326","Testicular Cancer pT0 TNM Finding v8","C140211","Testicular cancer with no evidence of primary tumor. (from AJCC 8th Ed.)","Testicular Cancer pT0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538327","Testicular Cancer pTX TNM Finding v8","C140210","Testicular cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Testicular Cancer pTX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538297","Testicular Cancer pN3 TNM Finding v8","C140224","Testicular cancer with metastasis with a lymph node mass larger than 5 cm in greatest dimension. (from AJCC 8th Ed.)","Testicular Cancer pN3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538298","Testicular Cancer pN2 TNM Finding v8","C140223","Testicular cancer with metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension; or more than five nodes positive, none larger than 5 cm; or evidence of extranodal extension of tumor. (from AJCC 8th Ed.)","Testicular Cancer pN2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538299","Testicular Cancer pN1 TNM Finding v8","C140222","Testicular cancer with metastasis with a lymph node mass 2 cm or smaller in greatest dimension and less than or equal to five nodes positive, none larger than 2 cm in greatest dimension. (from AJCC 8th Ed.)","Testicular Cancer pN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538300","Testicular Cancer pN0 TNM Finding v8","C140221","Testicular cancer with no regional lymph node metastasis. (from AJCC 8th Ed.)","Testicular Cancer pN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538301","Testicular Cancer pNX TNM Finding v8","C140220","Testicular cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Testicular Cancer pNX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538313","Testicular Cancer pM1b TNM Finding v8","C140208","Testicular cancer with non-pulmonary visceral metastases. (from AJCC 8th Ed.)","Testicular Cancer pM1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538314","Testicular Cancer pM1a TNM Finding v8","C140207","Testicular cancer with non-retroperitoneal nodal or pulmonary metastases. (from AJCC 8th Ed.)","Testicular Cancer pM1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538296","Testicular Cancer by AJCC v8 Stage","C140225","A term that refers to the staging of testicular cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to postpubertal germ cell tumors of the testis and malignant sex cord-stromal tumors of the testis. It does not apply to spermatocytic tumors (no AJCC staging system), nonmalignant sex cord-/gonadal -stromal tumors (no AJCC staging system), prepubertal germ cell tumors (no AJCC staging system), hematolymphoid tumors (hematologic malignancies staging system), and paratesticular neoplasms (no AJCC staging system).  (from AJCC 8th Ed.)","Testicular Cancer by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538306","Stage II Testicular Cancer AJCC v8","C140233","Stage II includes: Any pT/TX, N1-3, M0, SX. TX: Testicular cancer in which the primary tumor cannot be assessed. N1: Testicular cancer with metastasis with a lymph node mass 2 cm or smaller in greatest dimension and less than or equal to five nodes positive, none larger than 2 cm in greatest dimension. N2: Testicular cancer with metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension; or more than five nodes positive, none larger than 5 cm; or evidence of extranodal extension of tumor. N3: Testicular cancer with metastasis with a lymph node mass larger than 5 cm in greatest dimension. M0: Testicular cancer without evidence of distant metastasis. SX: Marker studies not available or not performed. (AJCC 8th ed.)","Stage II Testicular Cancer AJCC v8 | Stage II Testicular Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538307","Stage IS Testicular Cancer AJCC v8","C140232","Stage IS includes: Any pT/TX, N0, M0, S1-3. TX: Testicular cancer in which the primary tumor cannot be assessed. N0: Testicular cancer with no regional lymph node metastasis. M0: Testicular cancer without evidence of distant metastasis. S1: LDH less than 1.5 x N and hCG (mlU/mL) less than 5,000 and AFP (ng/mL) less than 1,000. S2: LDH 1.5-10 x N or hCG (mlU/mL) 5,000-50,000 or AFP (ng/mL) 1,000-10,000. S3: LDH more than 10 x N or hCG (mlU/mL) more than 50,000 or AFP (ng/mL) more than 10,000. N indicates the upper limit of normal for the LDH assay. (AJCC 8th ed.)","Stage IS Testicular Cancer AJCC v8 | Stage IS Testicular Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538404","Stage IIIC Testicular Cancer AJCC v8","C140240","Stage IIIC includes: (Any pT/TX, N1-3, M0, S3); (Any pT/TX, Any N, M1a, S3); (Any pT/TX, Any N, M1b, Any S). TX: Testicular cancer in which the primary tumor cannot be assessed. N1: Testicular cancer with metastasis with a lymph node mass 2 cm or smaller in greatest dimension and less than or equal to five nodes positive, none larger than 2 cm in greatest dimension. N2: Testicular cancer with metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension; or more than five nodes positive, none larger than 5 cm; or evidence of extranodal extension of tumor. N3: Testicular cancer with metastasis with a lymph node mass larger than 5 cm in greatest dimension. M0: Testicular cancer without evidence of distant metastasis. M1a: Testicular cancer with non-retroperitoneal nodal or pulmonary metastases. M1b: Testicular cancer with non-pulmonary visceral metastases. S3: LDH more than 10 x N or hCG (mlU/mL) more than 50,000 or AFP (ng/mL) more than 10,000. N indicates the upper limit of normal for the LDH assay. (AJCC 8th ed.)","Stage IIIC Testicular Cancer AJCC v8 | Stage IIIC Testicular Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538408","Stage IIC Testicular Cancer AJCC v8","C140236","Stage IIC includes: (Any pT/TX, N3, M0, S0); (Any pT/TX, N3, M0, S1). TX: Testicular cancer in which the primary tumor cannot be assessed. N3: Testicular cancer with metastasis with a lymph node mass larger than 5 cm in greatest dimension. M0: Testicular cancer without evidence of distant metastasis. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N and hCG (mlU/mL) less than 5,000 and AFP (ng/mL) less than 1,000. N indicates the upper limit of normal for the LDH assay. (AJCC 8th ed.)","Stage IIC Testicular Cancer AJCC v8 | Stage IIC Testicular Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538407","Stage III Testicular Cancer AJCC v8","C140237","Stage III includes: Any pT/TX, Any N, M1, SX. TX: Testicular cancer in which the primary tumor cannot be assessed. M1: Testicular cancer with distant metastasis. SX: Marker studies not available or not performed. (AJCC 8th ed.)","Stage III Testicular Cancer AJCC v8 | Stage III Testicular Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538405","Stage IIIB Testicular Cancer AJCC v8","C140239","Stage IIIB includes: (Any pT/TX, N1-3, M0, S2); (Any pT/TX, Any N, M1a, S2). TX: Testicular cancer in which the primary tumor cannot be assessed. N1: Testicular cancer with metastasis with a lymph node mass 2 cm or smaller in greatest dimension and less than or equal to five nodes positive, none larger than 2 cm in greatest dimension. N2: Testicular cancer with metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension; or more than five nodes positive, none larger than 5 cm; or evidence of extranodal extension of tumor. N3: Testicular cancer with metastasis with a lymph node mass larger than 5 cm in greatest dimension. M0: Testicular cancer without evidence of distant metastasis. M1a: Testicular cancer with non-retroperitoneal nodal or pulmonary metastases. S2: LDH 1.5-10 x N or hCG (mlU/mL) 5,000-50,000 or AFP (ng/mL) 1,000-10,000. N indicates the upper limit of normal for the LDH assay. (AJCC 8th ed.)","Stage IIIB Testicular Cancer AJCC v8 | Stage IIIB Testicular Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538304","Stage IIB Testicular Cancer AJCC v8","C140235","Stage IIB includes: (Any pT/TX, N2, M0, S0); (Any pT/TX, N2, M0, S1). TX: Testicular cancer in which the primary tumor cannot be assessed. N2: Testicular cancer with metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension; or more than five nodes positive, none larger than 5 cm; or evidence of extranodal extension of tumor. M0: Testicular cancer without evidence of distant metastasis. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N and hCG (mlU/mL) less than 5,000 and AFP (ng/mL) less than 1,000. N indicates the upper limit of normal for the LDH assay. (AJCC 8th ed.)","Stage IIB Testicular Cancer AJCC v8 | Stage IIB Testicular Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538308","Stage IB Testicular Cancer AJCC v8","C140229","Stage IB includes: (pT2, N0, M0, S0); (pT3, N0, M0, S0); (pT4, N0, M0, S0). pT2: Testicular cancer which is limited to testis (including rete testis invasion) with lymphovascular invasion or invades hilar soft tissue or epididymis or penetrates visceral mesothelial layer covering the external surface of tunica albuginea with or without lymphovascular invasion. pT3: Testicular cancer in which the tumor invades spermatic cord with or without lymphovascular invasion. pT4: Testicular cancer in which the tumor invades scrotum with or without lymphovascular invasion. N0: Testicular cancer with no regional lymph node metastasis. M0: Testicular cancer without evidence of distant metastasis. S0: Marker study levels within normal limits. (AJCC 8th ed.)","Stage IB Testicular Cancer AJCC v8 | Stage IB Testicular Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538406","Stage IIIA Testicular Cancer AJCC v8","C140238","Stage IIIA includes: (Any pT/TX, Any N, M1a, S0); (Any pT/TX, Any N, M1a, S1). TX: Testicular cancer in which the primary tumor cannot be assessed. M1a: Testicular cancer with non-retroperitoneal nodal or pulmonary metastases. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N and hCG (mlU/mL) less than 5,000 and AFP (ng/mL) less than 1,000. N indicates the upper limit of normal for the LDH assay. (AJCC 8th ed.)","Stage IIIA Testicular Cancer AJCC v8 | Stage IIIA Testicular Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538305","Stage IIA Testicular Cancer AJCC v8","C140234","Stage IIA includes: (Any pT/TX, N1, M0, S0); (Any pT/TX, N1, M0, S1). TX: Testicular cancer in which the primary tumor cannot be assessed. N1: Testicular cancer with metastasis with a lymph node mass 2 cm or smaller in greatest dimension and less than or equal to five nodes positive, none larger than 2 cm in greatest dimension. M0: Testicular cancer without evidence of distant metastasis. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N and hCG (mlU/mL) less than 5,000 and AFP (ng/mL) less than 1,000. N indicates the upper limit of normal for the LDH assay. (AJCC 8th ed.)","Stage IIA Testicular Cancer AJCC v8 | Stage IIA Testicular Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538309","Stage IA Testicular Cancer AJCC v8","C140228","Stage IA includes: pT1, N0, M0, S0. pT1: Testicular cancer which is limited to testis (including rete testis invasion) without lymphovascular invasion. N0: Testicular cancer with no regional lymph node metastasis. M0: Testicular cancer without evidence of distant metastasis. S0: Marker study levels within normal limits. (AJCC 8th ed.)","Stage IA Testicular Cancer AJCC v8 | Stage IA Testicular Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538310","Stage I Testicular Cancer AJCC v8","C140227","Stage I includes: pT1-T4, N0, M0, SX. pT1: Testicular cancer which is limited to testis (including rete testis invasion) without lymphovascular invasion. pT2: Testicular cancer which is limited to testis (including rete testis invasion) with lymphovascular invasion or invades hilar soft tissue or epididymis or penetrates visceral mesothelial layer covering the external surface of tunica albuginea with or without lymphovascular invasion. pT3: Testicular cancer in which the tumor invades spermatic cord with or without lymphovascular invasion. pT4: Testicular cancer in which the tumor invades scrotum with or without lymphovascular invasion. N0: Testicular cancer with no regional lymph node metastasis. M0: Testicular cancer without evidence of distant metastasis. SX: Marker studies not available or not performed. (AJCC 8th ed.)","Stage I Testicular Cancer AJCC v8 | Stage I Testicular Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512948","CDISC SDTM Urinary System Test Name Terminology","C129941","Terminology associated with the urinary system test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Urinary System Test Name Terminology | SDTM-URNSTS | URNSTS | Urinary System Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513970","Number of Renal Veins","C130196","The determination of the total number of renal veins.","Number of Renal Veins | RNLVNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513969","Number of Renal Arteries","C130195","The determination of the total number of renal arteries.","Number of Renal Arteries | RNLANUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522884","Graft Status","C135522","The condition of the donated organ or tissue.","Graft Status | GRFTSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512947","CDISC SDTM Urinary System Test Code Terminology","C129942","Terminology associated with the urinary system test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Urinary System Test Code Terminology | SDTM-URNSTSCD | URNSTSCD | Urinary System Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1698057","CDISC SDTM Respiratory Test Name Terminology","C111107","Terminology associated with the respiratory test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Respiratory Test Name Terminology | RETEST | Respiratory Test Name | SDTM-RETEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054935","Forced Expiratory Volume in 1 Second to Forced Vital Capacity in 6 Seconds","C123565","A calculated ratio of the forced expiratory volume in one second to the largest observed expired volume during the first six seconds of a forced vital capacity (FVC) maneuver.","Forced Expiratory Volume in 1 Second to Forced Vital Capacity in 6 Seconds | FEV1/FVC6 | FEV1FVC6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830088","Forced Expiratory Volume in 1 Second Reversibility","C112285","The change in FEV1 following administration of a bronchodilator relative to the pre-treatment FEV1 value. (CDISC)","Forced Expiratory Volume in 1 Second Reversibility | FEV1 Reversibility | FEV1REV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526648","Forced Expiratory Volume at Peak Expiratory Flow","C139249","The volume of gas that is forcibly exhaled at the peak of expiratory flow.","Forced Expiratory Volume at Peak Expiratory Flow | FEV at PEF | FEV_PEF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0429711","Expiratory Vital Capacity","C147484","The maximum volume of air an individual can exhale from the point of maximal inhalation.","Expiratory Vital Capacity | EVC",,,,,,,,,,,,,,,"4090664","Expiratory vital capacity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL522859","Elastance","C135493","A measure of the resistance of a system to expand, i.e. the pressure change that is required to elicit a unit volume change in the lungs; elastance is the reciprocal of compliance.","Elastance | ELSTNCE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055140","Diffusion Capacity of the Lung for Carbon Monoxide/Alveolar Volume Ratio","C120830","The calculated ratio of the lung's alveolar volume with respect to its diffusion capacity for carbon monoxide.","Diffusion Capacity of the Lung for Carbon Monoxide/Alveolar Volume Ratio | DLCO/VA | DLCOVA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936090","Alveolar Volume","C156584","The quantity of fresh gas that enters the alveoli during inspiration.","Alveolar Volume | ALVVOL | VA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001884","Airway Resistance Test","C120927","An assessment of the opposition to airflow through the respiratory tract on inspiration and/or expiration.","Airway Resistance | AIRRES | RAW | Raw",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503130","Airway Conductance","C124422","The instantaneous rate of gas flow in the airway, expressed as the pressure difference between any given part of the airway and the alveoli; it is the reciprocal of airway resistance (Raw).","Airway Conductance | GAW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520386","Forced Expiratory Volume in 3 Seconds","C132453","The volume exhaled during the first three seconds of a forced expiratory maneuver that is started from the level of total lung capacity.","Forced Expiratory Volume in 3 Seconds | FEV3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526741","Forced Expiratory Volume in 0.5 Second","C139262","The volume of air that can be forcibly exhaled during the first half second following maximal inhalation.","Forced Expiratory Volume in 0.5 Second | FEV 0.5s | FEV_5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526649","Forced Expiratory Volume in 0.2 Second","C139248","The volume of air that can be forcibly exhaled during the first 0.2 second following maximal inhalation.","Forced Expiratory Volume in 0.2 Second | FEV 0.2s | FEV_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526644","Forced Expiratory Volume in 0.2 Second to FVC Ratio Measurement","C139245","The ratio of the volume of gas that is forcibly exhaled during the first 0.2 seconds following maximal inhalation to that of the forced vital capacity.","Forced Expiratory Volume in 0.2 Second to FVC Ratio Measurement | EV_2FVC | Forced Expiratory Volume in 0.2 S/FVC | Forced Expiratory Volume in 0.2 Seconds over FVC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526642","Forced Expiratory Volume in 0.1 Second","C139247","The volume of air that can be forcibly exhaled during the first 0.1 second following maximal inhalation.","Forced Expiratory Volume in 0.1 Second | FEV 0.1s | FEV_1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526645","Forced Expiratory Volume in 0.1 Second to FVC Ratio Measurement","C139244","The ratio of the volume of gas that is forcibly exhaled during the first 0.1 seconds following maximal inhalation to that of the forced vital capacity.","Forced Expiratory Volume in 0.1 Second to FVC Ratio Measurement | EV_1FVC | Forced Expiratory Volume in 0.1 S/FVC | Forced Expiratory Volume in 0.1 Seconds over FVC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526643","Forced Expiratory Volume in 0.05 Second","C139246","The volume of air that can be forcibly exhaled during the first 0.05 second following maximal inhalation.","Forced Expiratory Volume in 0.05 Second | FEV 0.05s | FEV_05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526638","Forced Expiratory Volume in 0.05 Second to FVC Ratio Measurement","C139243","The ratio of the volume of gas that is forcibly exhaled during the first 0.05 seconds following maximal inhalation to that of the forced vital capacity.","Forced Expiratory Volume in 0.05 Second to FVC Ratio Measurement | EV_05FVC | Forced Expiratory Volume in 0.05 S/FVC | Forced Expiratory Volume in 0.05 Seconds over FVC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526653","Forced Expiratory Flow in 0.2 Second","C139252","The forced expiratory flow rate during the first 0.2 seconds of a forced exhalation.","Forced Expiratory Flow in 0.2 Second | FEF 0.2s | FEF_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526646","Forced Expiratory Flow in 0.1 Second","C139251","The forced expiratory flow rate during the first 0.1 seconds of a forced exhalation.","Forced Expiratory Flow in 0.1 Second | FEF 0.1s | FEF_1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526647","Forced Expiratory Flow in 0.05 Second","C139250","The forced expiratory flow rate during the first 0.05 seconds of a forced exhalation.","Forced Expiratory Flow in 0.05 Second | FEF 0.05s | FEF_05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526652","Forced Expiratory Flow at 50 Percent Forced Vital Capacity","C139253","The mean forced expiratory flow rate at 50% of the forced vital capacity.","Forced Expiratory Flow at 50 Percent Forced Vital Capacity | FEF50 | Forced Expiratory Flow 50%",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054206","Percent Predicted Hemoglobin Corrected Diffusion Capacity of the Lung for Carbon Monoxide/Alveolar Volume Ratio","C120828","The diffusion capacity of the lungs for carbon monoxide adjusted for the ratio of hemoglobin concentration to alveolar volume, and expressed as a proportion of the predicted normal value.","Percent Predicted Hemoglobin Corrected Diffusion Capacity of the Lung for Carbon Monoxide/Alveolar Volume Ratio | DLCOHVAP | Percent Predicted HGB Corrected DLCO/VA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054205","Percent Predicted Hemoglobin Corrected Diffusion Capacity of the Lung for Carbon Monoxide","C120826","The diffusion capacity of the lungs for carbon monoxide adjusted for hemoglobin concentration, expressed as a proportion of the predicted normal value.","Percent Predicted Hemoglobin Corrected Diffusion Capacity of the Lung for Carbon Monoxide | DLCOHCPP | Percent Predicted HGB Corrected DLCO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504651","Percent Predicted Functional Residual Capacity","C126052","The volume of air remaining in the lungs after a normal exhalation as a proportion of the predicted normal value. (CDISC)","Percent Predicted Functional Residual Capacity | FRCPP | Percent Predicted FRC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828596","Percent Predicted Forced Vital Capacity","C112381","Forced vital capacity as a proportion of the predicted normal value. (CDISC)","Percent Predicted Forced Vital Capacity | FVCPP | Percent Predicted FVC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828597","Percent Predicted Forced Inspiratory Volume in 1 Second","C112380","The volume of air that a subject can breathe in during the first second of inhalation after maximum exhalation as a proportion of the predicted normal value. (CDISC)","Percent Predicted Forced Inspiratory Volume in 1 Second | FIV1PP | Percent Predicted FIV1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828598","Percent Predicted Forced Inspiratory Flow Maximum","C112379","Forced inspiratory flow for a portion of the FVC curve at the point where the maximum portion of FVC is already inhaled as a proportion of the predicted normal value. (CDISC)","Percent Predicted Forced Inspiratory Flow Maximum | FIFMAXPP | Percent Predicted FIFmax",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828599","Percent Predicted Forced Expiratory Volume in 6 Seconds","C112378","Forced expiratory volume in six seconds as a proportion of the predicted normal value. (CDISC)","Percent Predicted Forced Expiratory Volume in 6 Seconds | FEV6PP | Percent Predicted FEV6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828600","Percent Predicted Forced Expiratory Volume in 1 Second Divided by Forced Vital Capacity","C112377","The proportion of total forced vital capacity that is expelled during the first second of a forced exhalation as a proportion of the predicted normal value. (CDISC)","Percent Predicted Forced Expiratory Volume in 1 Second Divided by Forced Vital Capacity | FEV1FVCP | Percent Predicted FEV1/FVC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0730561","Percent Predicted Forced Expiratory Volume in 1 Second","C112376","Forced expiratory volume in one second as a proportion of the predicted normal value. (CDISC)","Percent Predicted Forced Expiratory Volume in 1 Second | FEV1PP | Percent Predicted FEV1",,,,,,,,,,,,,,,"4208972","Percent predicted FEV1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897111","Percent Predicted Forced Expiratory Flow at 25-75 Percent","C119546","The mean forced expiratory flow rate at 25-75% of the forced vital capacity as a proportion of the predicted normal value.","Percent Predicted Forced Expiratory Flow at 25-75 Percent | FEF at 25-75% | FEF2575P | Percent Predicted FEF25-75",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828601","Percent Predicted Expiratory Reserve Volume","C112375","The maximum volume of air a subject can exhale from the lungs after a tidal exhalation as a proportion of the predicted normal value. (CDISC)","Percent Predicted Expiratory Reserve Volume | ERVPP | Percent Predicted ERV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054208","Percent Predicted Diffusion Capacity of the Lung for Carbon Monoxide/Alveolar Volume Ratio","C120831","The calculated ratio of the lung's alveolar volume with respect to its diffusion capacity for carbon monoxide, expressed as a proportion of the predicted normal value.","Percent Predicted Diffusion Capacity of the Lung for Carbon Monoxide/Alveolar Volume Ratio | DLCOVAPP | Percent Predicted DLCO/VA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054207","Percent Predicted Diffusion Capacity of the Lung for Carbon Monoxide","C120829","The degree to which inhaled carbon monoxide diffuses from the alveoli into the blood, expressed as a proportion of the predicted normal value.","Percent Predicted Diffusion Capacity of the Lung for Carbon Monoxide | DLCOPP | Percent Predicted DLCO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828624","Peak Expiratory Flow Reversibility","C112368","The change in PEF following administration of a bronchodilator relative to the pre-treatment PEF value. (CDISC)","Peak Expiratory Flow Reversibility | PEF Reversibility | PEFREV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0429205","Peak Nasal Inspiratory Flow","C119547","The maximal flow achieved during the maximally forced inspiration through the nose initiated at maximum exhalation.","Peak Nasal Inspiratory Flow | PNIF",,,,,,,,,,,,,,,"4089619","Nasal peak inspiratory flow",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL494646","Peak Inspiratory Flow Rate Test","C120939","The fastest flow rate of gas noted during the inspiratory cycle.","Peak Inspiratory Flow Rate | PIF | PKINSFL | Peak Inspiratory Flow",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526736","Peak Expiratory Flow Time","C139259","The time from the start of the test until the subject reaches his maximum expiratory gas flow rate.","Peak Expiratory Flow Time | PEF Time | PEFTIME",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518922","Peak Expiratory Flow","C41372","The maximum rate of gas flow, beginning at the point of peak inspiratory capacity, that can be sustained during forced exhalation for a defined period of time. This test is most often used in combination with other studies of lung function to diagnose and monitor obstructive and restrictive lung disease(s).","Peak Expiratory Flow | PEF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522862","Peak Cough Flow","C135498","The maximum rate of air flow expelled through the mouth, endotracheal, or tracheostomy tube during a cough.","Peak Cough Flow | CPF | Cough Peak Flow | PCF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054283","Oxygen Pulse","C123566","The volume of oxygen consumed by the body per heartbeat while at rest.","Oxygen Pulse | OXYPULSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1305742","Oxygen Consumption","C123570","The rate at which oxygen is absorbed and utilized by any given tissue in the body.","Oxygen Consumption | VO2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054566","Mean Carbon Monoxide Diffusing Capability Test","C123564","The mean volume of the carbon monoxide that is transferred from inspired gas into the pulmonary capillary blood.","Mean Carbon Monoxide Diffusing Capability Test | DLCOM | Mean Diffusion Capacity of Lung for CO | Mean TLCO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829169","Maximum Forced Inspiratory Flow","C112333","Forced inspiratory flow for a portion of the FVC curve at the point where the maximum portion of FVC is already inhaled. (CDISC)","Maximum Forced Inspiratory Flow | FIFMAX | FIFmax",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4083126","Maximal Inspiratory Pressure Test","C135496","The greatest amount of pressure that can be generated during inhalation against a fully occluded airway, which is used to measure the strength of respiratory muscles.","Maximal Inspiratory Pressure | MIP | NIF | Negative Inspiratory Force",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4082175","Maximal Expiratory Pressure Test","C135494","The greatest amount of pressure that can be generated by exhaling against a mouthpiece, which is a measure of the strength of respiratory muscles.","Maximal Expiratory Pressure | MEP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0231990","Lung Clearance Index","C124425","A representative measurement of the number of times the volume of gas in the lung at the start of the washout (the Functional Residual Capacity) must be recycled to eliminate the tracer to the pre-defined endpoint. Practically, this is the point where the end tidal concentration of inert gas is less than 1/40th of the opening concentration.","Lung Clearance Index | LCI",,,,,,,,,,,,,,,"4147697","Lung clearance index",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0429710","Inspiratory Vital Capacity","C124423","The maximum volume of gas an individual can inhale from the point of maximal exhalation.","Inspiratory Vital Capacity | IVC",,,,,,,,,,,,,,,"4092629","Inspiratory vital capacity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021613","Inspiratory Reserve Volume","C111237","The maximum volume of air a subject can inhale into the lungs after a tidal inhalation.","Inspiratory Reserve Volume | IRV",,,,,,,,,,,,,,,"4206339","Inspiratory reserve volume",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526651","Pulmonary Inertance","C139254","The measure of the force of the column of air in the conducting airways.","Pulmonary Inertance | INERTANC | Inertance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827361","Inspiratory Capacity Reversibility","C112321","The change in IC following administration of a bronchodilator relative to the pre-treatment IC value. (CDISC)","Inspiratory Capacity Reversibility | IC Reversibility | ICREV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054791","Hemoglobin Corrected Diffusion Capacity of the Lung for Carbon Monoxide/Alveolar Volume Ratio","C120827","The diffusion capacity of the lungs for carbon monoxide adjusted for the ratio of hemoglobin concentration to alveolar volume.","Hemoglobin Corrected Diffusion Capacity of the Lung for Carbon Monoxide/Alveolar Volume Ratio | DLCOHCVA | HGB Corrected DLCO/VA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016815","Functional Residual Capacity","C89800","The volume of air remaining in the lungs after a normal exhalation.","Functional Residual Capacity | FRC",,,,,,,,,,,,,,,"4279908","Functional residual capacity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086322","Forced Vital Capacity in 6 Seconds","C124421","The volume of gas a subject can forcefully exhale during the first six seconds following maximum inhalation.","Forced Vital Capacity in 6 Seconds | FVC6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827005","Forced Inspiratory Volume in 1 Second","C111360","The volume of air that a subject can breathe in during the first second of inhalation after maximum exhalation.","Forced Inspiratory Volume in 1 Second | FIV1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526740","Forced Inspiratory Vital Capacity","C139263","The difference in lung volume between maximal expiration to residual volume followed immediately by full inspiration to total lung capacity during forceful inhalation.","Forced Inspiratory Vital Capacity | FIVC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086321","Forced Inspiratory Flow at 75%","C124420","The forced inspiratory flow rate at the point on the inspiratory flow-volume curve where 75 percent of the total volume of gas has been inhaled.","Forced Inspiratory Flow at 75% | FIF75",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086320","Forced Inspiratory Flow at 50%","C124419","The forced inspiratory flow rate at the point on the inspiratory flow-volume curve where 50 percent of the total volume of gas has been inhaled.","Forced Inspiratory Flow at 50% | FIF50",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086319","Forced Inspiratory Flow at 25%","C124418","The forced inspiratory flow rate at the point on the inspiratory flow-volume curve where 25 percent of the total volume of gas has been inhaled.","Forced Inspiratory Flow at 25% | FIF25",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049798","Total Respiratory System Resistance","C122185","A calculated value based on all factors that influence the flow of gas from the airway opening to the alveoli, including airway resistance, and tissue resistance of the lung and chest wall.","Total Respiratory System Resistance | RRS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526742","Tissue Hysteresivity Measurement","C139261","The energy dissipated relative to the elastic energy stored in the tissue in a P-V cycle. Fredberg, J.J., Stamenovic, D. (1 December 1989). On the Imperfect Elasticity of Lung Tissue. Journal of Applied Physiology, Vol. 67. Retrieved from https://owl.english.purdue.edu/owl/resource/560/10/","Tissue Hysteresivity Measurement | TSUHYS | Tissue Hysteresivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526743","Tissue Elastance","C139260","A reflection of energy conservation within a given tissue.","Tissue Elastance | TSUELAS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040210","Tidal Volume","C111324","The volume of air moved into and out of the lungs during breathing at rest.","Tidal Volume | TIDALVOL | TV",,,,,,,,,,,,,,,"4029625","Tidal volume",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054003","Specific Airway Resistance","C123569","A measurement used to describe airway behavior irrespective of lung volume; it is calculated as airway resistance (Raw) multiplied by functional residual capacity (FRC).","Specific Airway Resistance | SRAW | sRAW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL480939","Specific Airway Conductance Measurement","C122186","A measurement of the airway conductance relative to lung volume.","Specific Airway Conductance | SGAW | sGaw",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526737","Salazar-Knowles Equation, K Parameter","C139258","The reflection of the curvature of the upper portion of the deflationary limb of the pressure-volume curve.","Salazar-Knowles Equation, K Parameter | SALKK | Salazar-Knowles Equation, K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526738","Salazar-Knowles Equation Parameter B","C139257","The difference between the volume at total lung capacity and the hypothesized volume at a transpulmonary pressure of zero.","Salazar-Knowles Equation Parameter B | SALKB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526739","Salazar-Knowles Equation Parameter A","C139256","A representation of the exponential function described by the Salazar-Knowles equation, and an estimation of a subject's inspiratory capacity.","Salazar-Knowles Equation Parameter A | SALKA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526650","Quasi-Static Compliance","C139255","The static elastic recoil pressure of the lungs at a given lung volume.","Quasi-Static Compliance | QUASCOMP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054142","Pulmonary Reactance","C123567","The measurement of the ability of the lung to store energy, which is required for passive expiration. Reactance consists of two components: the negative component reflects capacitive behavior (C) and corresponds to both the thoraco-pulmonary elasticity and to changes in the available lung volumes in the distal compartments of the lung; the positive component of reactance has inertial characteristics (I) describing the moving air column in the bronchial tree.","Pulmonary Reactance | PLMXRS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522863","Pulmonary Blood Flow Assessment","C135499","An evaluation of the perfusion of a specific lung segment.","Pulmonary Blood Flow Assessment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828589","Percent Predicted Total Lung Capacity","C112388","The total volume of air in the lungs after maximum inhalation as a proportion of the predicted normal value. (CDISC)","Percent Predicted Total Lung Capacity | TLCPP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828590","Percent Predicted Tidal Volume","C112387","The volume of air moved into and out of the lungs during breathing at rest as a proportion of the predicted normal value. (CDISC)","Percent Predicted Tidal Volume | TVPP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828591","Percent Predicted Slow Vital Capacity","C112386","The maximum volume of air that can be exhaled after slow maximum inhalation as a proportion of the predicted normal value. (CDISC)","Percent Predicted Slow Vital Capacity | Percent Predicted SVC | SVCPP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828592","Percent Predicted Residual Volume","C112385","The volume of air remaining in the lungs after maximum exhalation as a proportion of the predicted normal value. (CDISC)","Percent Predicted Residual Volume | RVPP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828593","Percent Predicted Peak Expiratory Flow","C112384","The maximal flow achieved during the maximally forced expiration initiated at maximum inhalation as a proportion of the predicted normal value. (CDISC)","Percent Predicted Peak Expiratory Flow | PEFPP | Percent Predicted PEF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522861","Percent Predicted Maximal Inspiratory Pressure","C135497","The greatest amount of pressure that can be generated during inhalation against a fully occluded airway, which is used to measure the strength of respiratory muscles expressed as a proportion of the predicted normal value.","Percent Predicted Maximal Inspiratory Pressure | MIPPP | Percent Predicted MIP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522860","Percent Predicted Maximal Expiratory Pressure","C135495","The greatest amount of pressure that can be generated by exhaling against a mouthpiece, which is a measure of the strength of respiratory muscles expressed as a proportion of the predicted normal value.","Percent Predicted Maximal Expiratory Pressure | MEPPP | Percent Predicted MEP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086739","Percent Predicted Inspiratory Vital Capacity","C124424","The maximum volume of gas an individual can inhale from the point of maximal exhalation expressed as a percentage of the expected result value for healthy individuals of similar age, sex, height, and race.","Percent Predicted Inspiratory Vital Capacity | IVCPP | Percent Predicted IVC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828594","Percent Predicted Inspiratory Reserve Volume","C112383","The maximum volume of air a subject can inhale into the lungs after a tidal inhalation as a proportion of the predicted normal value. (CDISC)","Percent Predicted Inspiratory Reserve Volume | IRVPP | Percent Predicted IRV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828595","Percent Predicted Inspiratory Capacity","C112382","The maximum volume of air a subject can inhale into the lungs after a tidal exhalation (IRV plus TV) as a proportion of the predicted normal value. (CDISC)","Percent Predicted Inspiratory Capacity | ICPP | Percent Predicted IC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826878","CDISC SDTM Respiratory Test Code Terminology","C111106","Terminology associated with the respiratory test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Respiratory Test Code Terminology | RETESTCD | Respiratory Test Code | SDTM-RETESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938087","Physician's Global Assessment Scale of Epidermal Chronic Graft versus Host Disease","C158590","A clinical outcome instrument to measure the severity of epidermal chronic graft versus host disease. Extent of cutaneous involvement is scored using a 5 point scale.","Physician's Global Assessment Scale of Epidermal Chronic Graft versus Host Disease | PGA-cGVHD | Physician Global Assessment of Epidermal Chronic Graft versus Host Disease | Physician's Global Assessment Scale of Cutaneous Epidermal Chronic Graft versus Host Disease | Physician's Global Assessment Scale of Epidermal Cutaneous Chronic Graft versus Host Disease | Physician's Global Assessment of Epidermal cGVHD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938104","Epidermal cGVHD Score 0","C158591","A score of 0 describing clear skin where residual hyperpigmentation may be present.","Epidermal cGVHD Score 0 | Clear | Score 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938109","Epidermal cGVHD Score 1","C158592","A score of 1 describing almost clear skin with light erythema, papules and/or scale involving 0-20% of the target area.","Epidermal cGVHD Score 1 | Almost Clear | Score 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938138","Epidermal cGVHD Score 2","C158593","A score of 2 describing mild disease with erythema, fine scale and/or papules involving >20% of the target area.","Epidermal cGVHD Score 2 | Mild | Score 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938139","Epidermal cGVHD Score 3","C158594","A score of 3 describing moderate disease with confluent erythema and scale and/or papules covering >50% of target area.","Epidermal cGVHD Score 3 | Moderate | Score 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938084","Epidermal cGVHD Score 4","C158595","A score of 4 describing severe disease with confluent erythema and scale and/or papules covering >80% of target area.","Epidermal cGVHD Score 4 | Score 4 | Severe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881241","Intraductal Lesion","C62214","A morphologic finding indicating the presence of a benign, atypical, or malignant cellular proliferation within the ducts in a tissue sample.","Intraductal Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520583","Autologous Blood Product Donation","C133268","Blood or blood product donations intended for transfusion at a later time to the donor.","Autologous Blood Product Donation | Autologous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896658","CDISC Functional Test Category Terminology","C115304","Terminology associated with the functional test domain categories of the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Functional Test Category Terminology | Category of Functional Test | FT-FTCAT | FTCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539753","Four Stair Ascend Test Functional Test","C141689","A timed function test, one of a series of exercise testing modalities that were initially introduced in the 1960s, that measures functional mobility by assessing the time taken and techniques used to climb four standard-size stairs.","Four Stair Ascend Test Functional Test | 4 Stair Ascend | 4-STAIR ASCEND | A4STR1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539756","10 Meter Walk/Run","C141686","A timed function test, one of a series of exercise testing modalities that were initially introduced in the 1960s, that assesses functional mobility by measuring walking or running speed in meters per second over ten meters.","10-Meter Walk/Run Test Functional Test | 10 Meter Walk/Run | 10-METER WALK/RUN | TENMW1 | Ten Meter Walk/Run | Ten Meter Walk/Run Test Functional Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897356","Timed 25-Foot Walk Functional Test","C115794","A standardized rating scale developed to measure walking ability through gait speed. This functional test is a quantitative mobility and leg function performance test where a study subject is asked to walk 25 feet from a marked starting point. The time is calculated from the initiation to the end of walking when the patient has reached the 25-foot mark. Scoring of this test is based on the average of two completed trials.","Timed 25-Foot Walk Functional Test | T25FW | T25FW1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891405","Symbol Digit Modalities Functional Test","C115793","A standardized rating scale developed by Aaron Smith in 1982, which is used to identify individuals with neurological impairment, as well as to assess divided attention, visual scanning and motor speed. This functional test measures the time to pair abstract symbols with specific numbers with a 90 second time limit. Scoring of this test is based on the total number of correctly coded items from 0-110 in 90 seconds.","Symbol Digit Modalities Functional Test | SDMT | SDMT01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539755","Rising From Floor Test Functional Test","C141687","A timed function test created by Araujo et al. (2012) that measures the time taken and techniques utilized to sit and rise from the floor with the minimum amount of support as a predictor of overall health and life expectancy.","Rising From Floor Test Functional Test | RISEF1; Stand From Supine | RISING FROM FLOOR | Rising From Floor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525827","Performance of the Upper Limb Module for DMD 2.0 Functional Test","C138335","A revised version of the Performance of the Upper Limb Module for DMD 1.2 Functional Test, which was developed by an international clinical outcomes group in 2011 to measure motor performance of the upper limb in patients with Duchenne muscular dystrophy (DMD). Functional tasks are subdivided into three dimensions that reflect disease progression from proximal to distal weakness, and from ambulatory to non-ambulatory.","Performance of the Upper Limb Module for DMD 2.0 Functional Test | PUL 2.0 | PUL V2.0 | PUL02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525828","Performance of the Upper Limb Module for DMD 1.2 Functional Test","C138334","A 22-item assessment scale developed by an international clinical outcomes group in 2011 to measure motor performance of the upper limb in patients with Duchenne muscular dystrophy (DMD). Functional tasks are subdivided into three dimensions that reflect disease progression from proximal to distal weakness, and from ambulatory to non-ambulatory.","Performance of the Upper Limb Module for DMD 1.2 Functional Test | PUL 1.2 | PUL V1.2 | PUL01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898036","Paced Auditory Serial Addition Functional Test","C115792","A standardized rating scale developed by DMA Gronwall et al in 1977 to assess auditory information processing speed and flexibility, as well as calculation ability. It is also used as a cognitive function test to evaluate sustained and divided attention. The test involves the presentation of single digits every 3 seconds and a study subject must add each new digit to the one immediately prior to it. Scoring of this test is based on the total number correct out of 60 possible answers.","Paced Auditory Serial Addition Functional Test | PASAT | PASAT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552757","Paced Tapping Test Functional Test","C150911","A cognitive test that is used to assess sensorimotor synchronization and timing of movement, where a subject produces a series of finger taps, at first in time with an external pacing stimulus and then continuing after the stimulus has ended.","Paced Tapping Test Functional Test | PACED TAPPING | PTAP1 | Paced Tapping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891812","Nine-Hole Peg Functional Test","C115791","A standardized rating scale developed by Mathiowetz et al in 1985 to measure unilateral finger dexterity to determine the extent of fine motor impairment in people experiencing difficulties with functional performance. This functional test requires the use of both dominant and non-dominant hands, and assesses fine motor and hand/eye coordination, as well as ability to follow simple directions. Scoring of this test is based on the average of 4 trials.","Nine-Hole Peg Functional Test | NHPT | NHPT01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3496286","Montreal Cognitive Assessment Functional Test","C123667","A standardized rating scale developed by Ziad Nasreddine in 1996 to screen for mild cognitive dysfunction and impairment. This instrument assesses the following cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation.","Montreal Cognitive Assessment Functional Test | MOCA | MOCA01 | Montreal Cognitive Assessment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552756","Mini-Mental State Examination 2 Standard Version Functional Test","C150910","An updated version of the Mini-Mental State Examination, a brief, quantitative measure of cognitive status in adults, that was originally developed by Marshal Folstein, Susan Folstein and Paul McHugh (Journal of Psychiatric Research, 1975), where the overall difficulty and raw score range remain the same despite modifications to some tasks and replacement of some items.","Mini-Mental State Examination 2 Standard Version Functional Test | MMS2 | MMSE-2 STANDARD VERSION | MMSE-2 Standard Version",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890899","Hauser Ambulation Index Functional Test","C115790","A standardized rating scale developed by Hauser et al in 1983 to assess mobility by evaluating the time and degree of assistance required to walk 25 feet. This functional test is scored from 0 (asymptomatic; fully active) to 9 (restricted to wheelchair; unable to transfer self independently).","Hauser Ambulation Index Functional Test | HAI | HAI01 | HAUSER AMBULATION INDEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552755","Emotion Recognition Test Functional Test","C150909","A standardized method for measuring visibly different facial movements that was developed by Ekman et al in 1976.","Emotion Recognition Test Functional Test | EMO1 | EMOTION RECOGNITION | ERT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055347","Brief Assessment of Cognition in Schizophrenia Functional Test","C121004","A standardized rating scale developed by Keefe et al in 2004 to assess cognitive function and impairment in patients with schizophrenia. This instrument consists 6 tests in the following areas: verbal memory, working memory, motor speed, verbal fluency, attention, and executive function.","Brief Assessment of Cognition in Schizophrenia Functional Test | BACS | BACS1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054062","Rey Auditory Verbal Learning Functional Test","C123668","A standardized rating scale modified from A. Rey in 1964 and Ceffen et al in 1994, which is used to evaluate verbal learning and memory abilities in both children and adults. The questionnaire contains 36 items and assesses overall memory performance, immediate span of memory for words, acquisition rate, interference effects, and recognition.","Rey Auditory Verbal Learning Functional Test | AVL02 | AVLT-REY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640516","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Functional Test","C102112","The Alzheimer's Disease Neuroimaging Initiative's (ADNI) version of the Auditory Verbal Learning Test (AVLT Version A). This version is modified from A. Rey in 1964 and is used to evaluate verbal learning and memory abilities in both children and adults. The test format consists of a list of 15 words that the patient recalls during 5 separate trials. A second list with 15 new words is read and the patient must recall the words in one trial. Immediately following this task, the patient must recall the words from the first list; then recall them again 30 minutes later. The total number of words and intrusions is tallied for each trial.","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Functional Test | ADNI-AVLT | AVL01 | AVLT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539754","Four Stair Descend Test Functional Test","C141688","A timed function test, one of a series of exercise testing modalities that were initially introduced in the 1960s, that measures functional mobility by assessing the time taken and techniques used to descend four standard-size stairs.","Four Stair Descend Test Functional Test | 4 Stair Descend | 4-STAIR DESCEND | D4STR1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1827465","Infusion route","C149577","The technique of administration of a pharmaceutical product, usually slowly and in larger volumes than for an injection, by introducing it into the body, usually after puncturing the skin; it is usually administered intravenously, but occasionally by other routes, e.g. subcutaneously.","Infusion Method of Administration | Infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950776","Anti-CD34 Monoclonal Antibody","C158686","Any monoclonal antibody that recognizes hematopoietic progenitor cell antigen CD34.","Anti-CD34 Monoclonal Antibody | CD34 Monoclonal Antibody | HPCA1 Monoclonal Antibody | Monoclonal Anti CD34 | Monoclonal Anti-Hematopoietic Progenitor Cell Antigen CD34 Antibody | gp105-120 Monoclonal Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950777","Anti-CD45RA Monoclonal Antibody","C158687","Any monoclonal antibody that recognizes receptor-type tyrosine-protein phosphatase C isoform CD45RA.","Anti-CD45RA Monoclonal Antibody | CD45RA Monoclonal Antibody | Monoclonal Anti CD45RA | Monoclonal Anti-Receptor-Type Tyrosine-Protein Phosphatase C Isoform CD45RA Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950782","Subject Reference Start Time","C158692","The time a subject reference began.","Subject Reference Start Time | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950781","Subject Reference End Time","C158691","The time a subject reference period has concluded.","Subject Reference End Time | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950779","Subject Reference Start Date","C158689","The date a subject reference began.","Subject Reference Start Date | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950780","Subject Reference End Date","C158690","The date a subject reference period has concluded.","Subject Reference End Date | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950631","STX11 Gene Mutation","C158651","A change in the nucleotide sequence of the STX11 gene.","STX11 Gene Mutation | FHL4 Gene Mutation | HLH4 Gene Mutation | HPLH4 Gene Mutation | Syntaxin 11 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950633","ITGB2 Gene Mutation","C158653","A change in the nucleotide sequence of the ITGB2 gene.","ITGB2 Gene Mutation | CD18 Gene Mutation | Integrin Subunit Beta 2 Gene Mutation | LAD Gene Mutation | LCAMB Gene Mutation | LFA-1 Gene Mutation | MAC-1 Gene Mutation | MF17 Gene Mutation | MFI7 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950634","PRF1 Gene Mutation","C158654","A change in the nucleotide sequence of the PRF1 gene.","PRF1 Gene Mutation | HPLH2 Gene Mutation | P1 Gene Mutation | PFP Gene Mutation | Perforin 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950635","LYST Gene Mutation","C158655","A change in the nucleotide sequence of the LYST gene.","LYST Gene Mutation | CHS Gene Mutation | CHS1 Gene Mutation | Chediak-Higashi Syndrome 1 Gene Mutation | Lysosomal Trafficking Regulator Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950638","XIAP Gene Mutation","C158658","A change in the nucleotide sequence of the XIAP gene.","XIAP Gene Mutation | API3 Gene Mutation | BIRC4 Gene Mutation | Baculoviral IAP Repeat-Containing 4 Gene Mutation | IAP-3 Gene Mutation | ILP1 Gene Mutation | MIHA Gene Mutation | X-Linked Inhibitor of Apoptosis Gene Mutation | XLP2 Gene Mutation | hIAP-3 Gene Mutation | hIAP3 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950639","UNC13D Gene Mutation","C158659","A change in the nucleotide sequence of the UNC13D gene.","UNC13D Gene Mutation | FHL3 Gene Mutation | HLH3 Gene Mutation | HPLH3 Gene Mutation | Munc13-4 Gene Mutation | Unc-13 Homolog D Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950640","STXBP2 Gene Mutation","C158660","A change in the nucleotide sequence of the STXBP2 gene.","STXBP2 Gene Mutation | FHL5 Gene Mutation | MUNC18-2 Gene Mutation | Syntaxin Binding Protein 2 Gene Mutation | UNC18-2 Gene Mutation | UNC18B Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950755","Elevated EBV DNA","C158663","A finding indicating elevated concentrations of Epstein-Barr virus DNA in a sample.","Elevated EBV DNA | EBV DNA Elevated | Elevated Epstein-Barr Virus DNA | Elevated HHV-4 DNA | Elevated HHV4 DNA | Elevated Human Herpesvirus 4 DNA | Elevated Human Herpesvirus-4 DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950758","RAB27A Gene Mutation","C158666","A change in the nucleotide sequence of the RAB27A gene.","RAB27A Gene Mutation | GS2 Gene Mutation | RAB27 Gene Mutation | RAB27A, Member RAS Oncogene Family Gene Mutation | RAM Gene Mutation | RAS-Related Gene From Megakaryocyte Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950759","SIX1 Gene Mutation","C158667","A change in the nucleotide sequence of the SIX1 gene.","SIX1 Gene Mutation | BOS3 Gene Mutation | DFNA23 Gene Mutation | SIX Homeobox 1 Gene Mutation | Sine Oculis Homeobox Homolog 1 Gene Mutation | TIP39 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950760","SIX2 Gene Mutation","C158668","A change in the nucleotide sequence of the SIX2 gene.","SIX2 Gene Mutation | SIX Homeobox 2 Gene Mutation | Sine Oculis Homeobox Homolog 2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950761","DROSHA Gene Mutation","C158669","A change in the nucleotide sequence of the DROSHA gene.","DROSHA Gene Mutation | Drosha Ribonuclease III Gene Mutation | ETOHI2 Gene Mutation | RANSE3L Gene Mutation | RN3 Gene Mutation | RNASE3L Gene Mutation | RNASEN Gene Mutation | RNase III Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950762","DGCR8 Gene Mutation","C158670","A change in the nucleotide sequence of the DGCR8 gene.","DGCR8 Gene Mutation | C22orf12 Gene Mutation | DGCR8 Microprocessor Complex Subunit Gene Mutation | DGCRK6 Gene Mutation | DiGeorge Syndrome Critical Region Gene 8 Gene Mutation | Gy1 Gene Mutation | Pasha Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950763","MLLT1 Gene Mutation","C158671","A change in the nucleotide sequence of the MLLT1 gene.","MLLT1 Gene Mutation | ENL Gene Mutation | LTG19 Gene Mutation | MLLT1, Super Elongation Complex Subunit Gene Mutation | Mixed Lineage Leukemia, Translocated To, 1 Eleven-Nineteen Leukemia Gene Mutation | Myeloid/Lymphoid Or Mixed-Lineage Leukemia; Translocated To, 1 Gene Mutation | YEATS1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413927","DCLK1 Gene","C158672","This gene is involved in microtubule polymerization, retrograde transport and neuronal development and migration.","DCLK1 Gene | DCLK1 | Doublecortin Like Kinase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950766","High Level of Hyaluronic Acid","C158675","A finding indicating high concentrations of hyaluronic acid in a sample.","High Level of Hyaluronic Acid | HA High | HA-High | High Hyaluronan | High Hyaluronic Acid | Hyaluronan High | Hyaluronan-High | Hyaluronic Acid High | Hyaluronic Acid-High",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950767","CDK12 Loss of Function Mutation","C158676","A change in the nucleotide sequence of the CDK12 gene that either inhibits expression or results in the translation of an inactive cyclin-dependent kinase 12 protein.","CDK12 Loss of Function Mutation | CDC2 Related Protein Kinase 7 Gene Loss of Function Mutation | CDK12 Inactivating Gene Mutation | CDK12 Inactivating Mutation | CDK12 Loss of Function Gene Mutation | CRK7 Loss of Function Mutation | CRKR Loss of Function Mutation | CRKRS Loss of Function Mutation | Cdc2-Related Kinase, Arginine/Serine-Rich Gene Loss of Function Mutation | Cyclin Dependent Kinase 12 Gene Loss of Function Mutation | Cyclin-Dependent Kinase 12 Gene Loss of Function Mutation | Inactivating CDK12 Gene Mutation | Inactivating CDK12 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950768","JAK2 Exon 12 Mutation","C158677","A molecular genetic abnormality indicating the presence of a mutation in exon 12 of the JAK2 gene.","JAK2 Exon 12 Mutation | JAK-2 Exon 12 Mutation | JAK2 Exon 12 Gene Mutation | JTK10 Exon 12 Mutation | Janus Kinase 2 Exon 12 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950769","Non-synonymous FBXW7 Gene Mutation","C158678","A point mutation in the FBXW7 gene that encodes an amino acid substitution in the F-box/WD repeat-containing protein 7 protein.","Non-synonymous FBXW7 Gene Mutation | FBXW7 Missense Gene Mutation | FBXW7 Missense Mutation | Non-synonymous AGO Gene Mutation | Non-synonymous Archipelago Homolog Gene Mutation | Non-synonymous Archipelago Homolog, Drosophila Gene Mutation | Non-synonymous CDC4 Gene Mutation | Non-synonymous F-Box and WD Repeat Domain Containing 7 Gene Mutation | Non-synonymous F-box and WD-40 Domain Protein 7 (Archipelago Homolog, Drosophila) Gene Mutation | Non-synonymous FBW6 Gene Mutation | Non-synonymous FBW7 Gene Mutation | Non-synonymous FBX30 Gene Mutation | Non-synonymous FBXW6 Gene Mutation | Non-synonymous SEL-10 Gene Mutation | Non-synonymous SEL10 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938067","BCL2 Gene Mutation","C158490","A change in the nucleotide sequence of the BCL2 gene.","BCL2 Gene Mutation | B-Cell CLL-Lymphoma 2 Gene Mutation | B-Cell CLL/Lymphoma 2 Gene Mutation | BCL2, Apoptosis Regulator Gene Mutation | Bcl-2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950643","KMT2A Fusion Positive","C158609","Indicates that the expression of a KMT2A fusion has been detected in a sample.","KMT2A Fusion Positive | ALL-1 Fusion Positive | ALL1 Fusion Positive | CXXC7 Fusion Positive | HRX Fusion Positive | HTRX Fusion Positive | Histone-Lysine N-Methyltransferase 2A Fusion Positive | Histone-Lysine N-Methyltransferase MLL Fusion Positive | KMT2A Fusion | Lysine (K)-Specific Methyltransferase 2A Fusion Positive | MLL Fusion | MLL Fusion Positive | Myeloid/Lymphoid or Mixed-Lineage Leukemia Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938027","Anti-MUC1* Antibody MNC2 Reactivity Present","C158467","An indication that the cells in sample have cell surface expression of antibody-detectable amounts of a specific membrane-bound fragment of the mucin-1 protein (MUC1), which results from extramembrane cleavage, has growth factor receptor-like activity and is comprised of the cytoplasmic tail, the transmembrane domain and at least forty-five amino acids of the extracellular domain.","MUC1*-Positive Cells Present | Anti-MUC1* Antibody MNC2 Reactivity Present | Anti-MUC1* Antibody Positive | Anti-MUC1* Antibody Positive Cells Present | Anti-MUC1* Antibody-Positive | Anti-MUC1* Positive | Anti-MUC1* Positive Cells Present | Antibody MNC2 Reactivity Present | MUC1* Positive | MUC1* Positive Cells Present | MUC1* Positive Cells Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950775","11q23 Abnormality","C158685","Any cytogenetic abnormality involving chromosome band 11q23.","11q23 Abnormality | 11q23 Aberration | 11q23 Alteration | 11q23 Anomaly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950783","Blasts 10-20 Percent of Bone Marrow Nucleated Cells","C158693","A semi-quantitative microscopic finding indicating that between 10 and 20 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 10-20 Percent of Bone Marrow Nucleated Cells | Blasts Between 10 and 20 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524547","Soft Tissue Sarcoma of the Trunk and Extremities TNM Finding v8","C136674","A finding about one or more characteristics of soft tissue sarcoma of the trunk and extremities, following the rules of the TNM AJCC v8 classification system. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Trunk and Extremities TNM Finding v8 | Soft Tissue Sarcoma Trunk and Extremities TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524557","Soft Tissue Sarcoma of the Trunk and Extremities pT4 TNM Finding v8","C136688","Soft tissue sarcoma of the trunk and extremities with tumor measuring more than 15 cm in greatest dimension. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Trunk and Extremities pT4 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524556","Soft Tissue Sarcoma of the Trunk and Extremities pT3 TNM Finding v8","C136687","Soft tissue sarcoma of the trunk and extremities with tumor measuring more than 10 cm and less than or equal to 15 cm in greatest dimension. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Trunk and Extremities pT3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524559","Soft Tissue Sarcoma of the Trunk and Extremities pT2 TNM Finding v8","C136686","Soft tissue sarcoma of the trunk and extremities with tumor measuring more than 5 cm and less than or equal to 10 cm in greatest dimension. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Trunk and Extremities pT2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524558","Soft Tissue Sarcoma of the Trunk and Extremities pT1 TNM Finding v8","C136685","Soft tissue sarcoma of the trunk and extremities with tumor measuring 5 cm or less in greatest dimension. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Trunk and Extremities pT1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524553","Soft Tissue Sarcoma of the Trunk and Extremities pT0 TNM Finding v8","C136684","Soft tissue sarcoma of the trunk and extremities with no evidence of primary tumor. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Trunk and Extremities pT0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524552","Soft Tissue Sarcoma of the Trunk and Extremities pTX TNM Finding v8","C136683","Soft tissue sarcoma of the trunk and extremities in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Trunk and Extremities pTX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524528","Soft Tissue Sarcoma of the Trunk and Extremities pN1 TNM Finding v8","C136691","Soft tissue sarcoma of the trunk and extremities with regional lymph node metastasis. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Trunk and Extremities pN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524531","Soft Tissue Sarcoma of the Trunk and Extremities pN0 TNM Finding v8","C136690","Soft tissue sarcoma of the trunk and extremities without regional lymph node metastasis or unknown lymph node status. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Trunk and Extremities pN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524554","Soft Tissue Sarcoma of the Trunk and Extremities pM1 TNM Finding v8","C136681","Soft tissue sarcoma of the trunk and extremities with distant metastasis. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Trunk and Extremities pM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524551","Soft Tissue Sarcoma of the Trunk and Extremities cM1 TNM Finding v8","C136678","Soft tissue sarcoma of the trunk and extremities with distant metastasis. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Trunk and Extremities cM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524550","Soft Tissue Sarcoma of the Trunk and Extremities cM0 TNM Finding v8","C136677","Soft tissue sarcoma of the trunk and extremities without distant metastasis. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Trunk and Extremities cM0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524534","Soft Tissue Sarcoma of the Trunk and Extremities by AJCC v8 Stage","C136694","A term that refers to the staging of soft tissue sarcoma of the trunk and extremities, following the rules of the TNM AJCC v8 classification system.","Soft Tissue Sarcoma of the Trunk and Extremities by AJCC v8 Stage | Soft Tissue Sarcoma Trunk and Extremities by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524540","Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8","C136706","Stage IV includes: (Any T, N1, M0, Any G); (Any T, Any N, M1, Any G). N1: Regional lymph node metastasis. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IV Soft Tissue Sarcoma of the Trunk and Extremities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524543","Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8","C136705","Stage IIIB includes: T3, T4, N0, M0, G2, G3. T3: Tumor measuring more than 10 cm and less than or equal to 15 cm in greatest dimension. T4: Tumor measuring more than 15 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. G2: Total differentiation, mitotic count and necrosis score of 4 or 5. G3: Total differentiation, mitotic count and necrosis score of 6, 7, or 8. (AJCC 8th ed.)","Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524542","Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8","C136703","Stage IIIA includes: T2, N0, M0, G2, G3. T2: Tumor measuring more than 5 cm and less than or equal to 10 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. G2: Total differentiation, mitotic count and necrosis score of 4 or 5. G3: Total differentiation, mitotic count and necrosis score of 6, 7, or 8. (AJCC 8th ed.)","Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524537","Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8","C136702","Stage III includes: IIIA: (T2, N0, M0, G2, G3); IIIB: (T3, T4, N0, M0, G2, G3). T2: Tumor measuring more than 5 cm and less than or equal to 10 cm in greatest dimension. T3: Tumor measuring more than 10 cm and less than or equal to 15 cm in greatest dimension. T4: Tumor measuring more than 15 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. G2: Total differentiation, mitotic count and necrosis score of 4 or 5. G3: Total differentiation, mitotic count and necrosis score of 6, 7, or 8. (AJCC 8th ed.)","Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage III Soft Tissue Sarcoma of the Trunk and Extremities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524536","Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8","C136701","Stage II includes: T1, N0, M0, G2, G3. T1: Tumor measuring 5 cm or less in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. G2: Total differentiation, mitotic count and necrosis score of 4 or 5. G3: Total differentiation, mitotic count and necrosis score of 6, 7, or 8. (AJCC 8th ed.)","Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage II Soft Tissue Sarcoma of the Trunk and Extremities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524539","Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8","C136700","Stage IB includes: T2, T3, T4, N0, M0, G1, GX. T2: Tumor measuring more than 5 cm and less than or equal to 10 cm in greatest dimension. T3: Tumor measuring more than 10 cm and less than or equal to 15 cm in greatest dimension. T4: Tumor measuring more than 15 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. GX: Grade cannot be assessed. G1: Total differentiation, mitotic count and necrosis score of 2 or 3. (AJCC 8th ed.)","Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IB Soft Tissue Sarcoma of the Trunk and Extremities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524538","Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8","C136698","Stage IA includes: T1, N0, M0, G1, GX. T1: Tumor measuring 5 cm or less in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. GX: Grade cannot be assessed. G1: Total differentiation, mitotic count and necrosis score of 2 or 3. (AJCC 8th ed.)","Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IA Soft Tissue Sarcoma of the Trunk and Extremities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524532","Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8","C136696","Stage I includes: IA: (T1, N0, M0, G1, GX); IB: (T2, T3, T4, N0, M0, G1, GX). T1: Tumor measuring 5 cm or less in greatest dimension. T2: Tumor measuring more than 5 cm and less than or equal to 10 cm in greatest dimension. T3: Tumor measuring more than 10 cm and less than or equal to 15 cm in greatest dimension. T4: Tumor measuring more than 15 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. GX: Grade cannot be assessed. G1: Total differentiation, mitotic count and necrosis score of 2 or 3. (AJCC 8th ed.)","Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage I Soft Tissue Sarcoma of the Trunk and Extremities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552046","Local Consolidation Therapy","C150254","Any of various localized therapies designed to kill cancer cells left after initial treatment.","Local Consolidation Therapy | LCT | Local Consolidative Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986924","Lenvatinib","C95124","A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. Lenvatinib blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis.","Lenvatinib | 6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]- 7-methoxy- | E 7080 | E-7080 | E7080 | ER-203492-00 | LENVATINIB | Multi-Kinase Inhibitor E7080",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555269","Everolimus/Lenvatinib","C154270","A regimen consisting of lenvatinib and everolimus that can be used for the treatment of kidney cancer.","Everolimus/Lenvatinib Regimen | Everolimus and Lenvatinib | Everolimus/Lenvatinib | Lenvatinib + Everolimus | Lenvatinib Plus Everolimus | Lenvatinib-Everolimus | Lenvatinib-Everolimus Regimen | Lenvatinib/Everolimus | Lenvatinib/Everolimus Regimen | Lenvatinib/Everolimus Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983670","Study End Date","C90462","The date on which the study concludes.","Clinical Study End Date | SENDTC | Study End Date | Study End Date",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563223","International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Criteria - Intermediate-Risk Group","C155845","A patient with 1-2 IMDC risk factors.","International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Criteria - Intermediate-Risk Group | IMDC Intermediate | IMDC Intermediate Risk | IMDC Intermediate Risk Group | Intermediate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563212","International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Criteria - Poor-Risk Group","C155846","A patient with 3-6 IMDC risk factors.","International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Criteria - Poor-Risk Group | IMDC Poor | IMDC Poor Risk | IMDC Poor Risk Group | Poor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562668","International Metastatic Renal Cell Carcinoma Database Consortium Criteria","C155843","A validated risk prediction tool for patients with metastatic renal cell carcinoma (mRCC) receiving first-line targeted therapy. The model considers: Karnofsky performance status less than 80%, time from diagnosis to first-line targeted therapy less than 1 year, hemoglobin concentration less than lower limit of normal, neutrophil count greater than upper limit of normal, platelet count greater than upper limit of normal, and serum calcium concentration greater than upper limit of normal.","International Metastatic Renal Cell Carcinoma Database Consortium Criteria | Heng Criteria | IMDC | IMDC Criteria | IMDC Risk | International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Criteria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278512","Metastatic Osteosarcoma","C7781","An osteosarcoma which has spread to another anatomical site.","Metastatic Osteosarcoma | Metastatic Osteogenic Sarcoma | Osteosarcoma, Metastatic",,,,,,,,,,,,,,,"45771486","Metastatic osteosarcoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL524463","Soft Tissue Sarcoma of the Head and Neck TNM Finding v8","C136655","A finding about one or more characteristics of soft tissue sarcoma of the head and neck, following the rules of the TNM AJCC v8 classification system. This classification system applies to soft tissue sarcomas of the head and neck except angiosarcoma, rhabdomyosarcoma of the embryonal and alveolar subtype, Kaposi sarcoma, and dermatofibrosarcoma protuberans, which do not share the same behavior and natural history. This is a new classification system that needs data collection before defining a stage grouping for head and neck sarcomas. Sarcomas of the orbit are staged according to the orbital sarcoma classification system. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Head and Neck TNM Finding v8 | Soft Tissue Sarcoma Head and Neck TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524450","Soft Tissue Sarcoma of the Head and Neck pT4b TNM Finding v8","C136670","Soft tissue sarcoma of the head and neck with tumor invading the brain parenchyma, prevertebral muscle, central nervous system via perineural spread, or carotid artery encasement. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Head and Neck pT4b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524449","Soft Tissue Sarcoma of the Head and Neck pT4a TNM Finding v8","C136669","Soft tissue sarcoma of the head and neck with tumor invading the orbit, skull base/dura, central compartment viscera, facial skeleton, or pterygoid muscles. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Head and Neck pT4a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524444","Soft Tissue Sarcoma of the Head and Neck pT4 TNM Finding v8","C136668","Soft tissue sarcoma of the head and neck with tumor invading adjoining structures. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Head and Neck pT4 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524443","Soft Tissue Sarcoma of the Head and Neck pT3 TNM Finding v8","C136667","Soft tissue sarcoma of the head and neck with tumor measuring more than 4 cm in greatest dimension. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Head and Neck pT3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524446","Soft Tissue Sarcoma of the Head and Neck pT2 TNM Finding v8","C136666","Soft tissue sarcoma of the head and neck with tumor measuring more than 2 cm but 4 cm or less in greatest dimension. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Head and Neck pT2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524445","Soft Tissue Sarcoma of the Head and Neck pT1 TNM Finding v8","C136665","Soft tissue sarcoma of the head and neck with tumor measuring 2 cm or less in greatest dimension. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Head and Neck pT1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524440","Soft Tissue Sarcoma of the Head and Neck pTX TNM Finding v8","C136664","Soft tissue sarcoma of the head and neck in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Head and Neck pTX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524546","Soft Tissue Sarcoma of the Head and Neck pN1 TNM Finding v8","C136673","Soft tissue sarcoma of the head and neck with regional lymph node metastasis. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Head and Neck pN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524448","Soft Tissue Sarcoma of the Head and Neck pN0 TNM Finding v8","C136672","Soft tissue sarcoma of the head and neck without regional lymph node metastases or unknown lymph node status. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Head and Neck pN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524442","Soft Tissue Sarcoma of the Head and Neck pM1 TNM Finding v8","C136662","Soft tissue sarcoma of the head and neck with distant metastasis. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Head and Neck pM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524435","Soft Tissue Sarcoma of the Head and Neck cM1 TNM Finding v8","C136659","Soft tissue sarcoma of the head and neck with distant metastasis. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Head and Neck cM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524438","Soft Tissue Sarcoma of the Head and Neck cM0 TNM Finding v8","C136658","Soft tissue sarcoma of the head and neck without distant metastasis. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Head and Neck cM0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524564","Soft Tissue Sarcoma of the Retroperitoneum TNM Finding v8","C136792","A finding about one or more characteristics of soft tissue sarcoma of the retroperitoneum, following the rules of the TNM AJCC v8 classification system. This classification system applies to common sarcomas in the retroperitoneum. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Retroperitoneum TNM Finding v8 | Retroperitoneal Soft Tissue Sarcoma TNM Finding v8 | Soft Tissue Sarcoma Retroperitoneum TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524665","Soft Tissue Sarcoma of the Retroperitoneum pT4 TNM Finding v8","C136806","Soft tissue sarcoma of the retroperitoneum measuring more than 15 cm in greatest dimension. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Retroperitoneum pT4 TNM Finding v8 | Retroperitoneal Soft Tissue Sarcoma pT4 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524667","Soft Tissue Sarcoma of the Retroperitoneum pT3 TNM Finding v8","C136805","Soft tissue sarcoma of the retroperitoneum measuring more than 10 cm and less than or equal to 15 cm in greatest dimension. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Retroperitoneum pT3 TNM Finding v8 | Retroperitoneal Soft Tissue Sarcoma pT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524666","Soft Tissue Sarcoma of the Retroperitoneum pT2 TNM Finding v8","C136804","Soft tissue sarcoma of the retroperitoneum measuring more than 5 cm and less than or equal to 10 cm in greatest dimension. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Retroperitoneum pT2 TNM Finding v8 | Retroperitoneal Soft Tissue Sarcoma pT2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524571","Soft Tissue Sarcoma of the Retroperitoneum pT1 TNM Finding v8","C136803","Soft tissue sarcoma of the retroperitoneum measuring 5 cm or less in greatest dimension. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Retroperitoneum pT1 TNM Finding v8 | Retroperitoneal Soft Tissue Sarcoma pT1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524570","Soft Tissue Sarcoma of the Retroperitoneum pT0 TNM Finding v8","C136802","Soft tissue sarcoma of the retroperitoneum with no evidence of primary tumor. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Retroperitoneum pT0 TNM Finding v8 | Retroperitoneal Soft Tissue Sarcoma pT0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524573","Soft Tissue Sarcoma of the Retroperitoneum pTX TNM Finding v8","C136801","Soft tissue sarcoma of the retroperitoneum in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Retroperitoneum pTX TNM Finding v8 | Retroperitoneal Soft Tissue Sarcoma pTX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524668","Soft Tissue Sarcoma of the Retroperitoneum pN1 TNM Finding v8","C136810","Soft tissue sarcoma of the retroperitoneum with regional lymph node metastasis. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Retroperitoneum pN1 TNM Finding v8 | Retroperitoneal Soft Tissue Sarcoma pN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524671","Soft Tissue Sarcoma of the Retroperitoneum pN0 TNM Finding v8","C136809","Soft tissue sarcoma of the retroperitoneum without regional lymph node metastasis or unknown lymph node status. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Retroperitoneum pN0 TNM Finding v8 | Retroperitoneal Soft Tissue Sarcoma pN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524567","Soft Tissue Sarcoma of the Retroperitoneum pM1 TNM Finding v8","C136799","Soft tissue sarcoma of the retroperitoneum with distant metastasis. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Retroperitoneum pM1 TNM Finding v8 | Retroperitoneal Soft Tissue Sarcoma pM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524568","Soft Tissue Sarcoma of the Retroperitoneum cM1 TNM Finding v8","C136796","Soft tissue sarcoma of the retroperitoneum with distant metastasis. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Retroperitoneum cM1 TNM Finding v8 | Retroperitoneal Soft Tissue Sarcoma cM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524563","Soft Tissue Sarcoma of the Retroperitoneum cM0 TNM Finding v8","C136795","Soft tissue sarcoma of the retroperitoneum without distant metastasis. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Retroperitoneum cM0 TNM Finding v8 | Retroperitoneal Soft Tissue Sarcoma cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524669","Retroperitoneal Sarcoma by AJCC v8 Stage","C136811","A term that refers to the staging of retroperitoneal soft tissue sarcoma, following the rules of the TNM AJCC v8 classification system. This staging system applies to common sarcomas in the retroperitoneum. (from AJCC 8th Ed.)","Retroperitoneal Sarcoma by AJCC v8 Stage | Soft Tissue Sarcoma Retroperitoneum by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524677","Stage IV Retroperitoneal Sarcoma AJCC v8","C136819","Stage IV includes: Any T, Any N, M1, Any G. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Retroperitoneal Sarcoma AJCC v8 | Stage IV Retroperitoneal Sarcoma | Stage IV Soft Tissue Retroperitoneal Sarcoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524676","Stage IIIB Retroperitoneal Sarcoma AJCC v8","C136818","Stage IIIB includes: (T3, T4, N0, M0, G2, G3); (Any T, N1, M0, Any G). T3: Tumor measuring more than 10 cm and less than or equal to 15 cm in greatest dimension. T4: Tumor measuring more than 15 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. N1: Regional lymph node metastasis. M0: No distant metastasis. G2: Total differentiation, mitotic count and necrosis score of 4 or 5. G3: Total differentiation, mitotic count and necrosis score of 6, 7, or 8. (AJCC 8th ed.)","Stage IIIB Retroperitoneal Sarcoma AJCC v8 | Stage IIIB Retroperitoneal Sarcoma | Stage IIIB Soft Tissue Retroperitoneal Sarcoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524679","Stage IIIA Retroperitoneal Sarcoma AJCC v8","C136817","Stage IIIA includes: T2, N0, M0, G2, G3. T2: Tumor measuring more than 5 cm and less than or equal to 10 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. G2: Total differentiation, mitotic count and necrosis score of 4 or 5. G3: Total differentiation, mitotic count and necrosis score of 6, 7, or 8. (AJCC 8th ed.)","Stage IIIA Retroperitoneal Sarcoma AJCC v8 | Stage IIIA Retroperitoneal Sarcoma | Stage IIIA Soft Tissue Retroperitoneal Sarcoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524673","Stage II Retroperitoneal Sarcoma AJCC v8","C136815","Stage II includes: T1, N0, M0, G2, G3. T1: Tumor measuring 5 cm or less in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. G2: Total differentiation, mitotic count and necrosis score of 4 or 5. G3: Total differentiation, mitotic count and necrosis score of 6, 7, or 8. (AJCC 8th ed.)","Stage II Retroperitoneal Sarcoma AJCC v8 | Stage II Retroperitoneal Sarcoma | Stage II Soft Tissue Retroperitoneal Sarcoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524672","Stage IB Retroperitoneal Sarcoma AJCC v8","C136814","Stage IB includes: T2, T3, T4, N0, M0, G1, GX. T2: Tumor measuring more than 5 cm and less than or equal to 10 cm in greatest dimension. T3: Tumor measuring more than 10 cm and less than or equal to 15 cm in greatest dimension. T4: Tumor measuring more than 15 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. GX: Grade cannot be assessed. G1: Total differentiation, mitotic count and necrosis score of 2 or 3. (AJCC 8th ed.)","Stage IB Retroperitoneal Sarcoma AJCC v8 | Stage IB Retroperitoneal Sarcoma | Stage IB Soft Tissue Retroperitoneal Sarcoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524675","Stage IA Retroperitoneal Sarcoma AJCC v8","C136813","Stage IA includes: T1, N0, M0, G1, GX. T1: Tumor measuring 5 cm or less in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. GX: Grade cannot be assessed. G1: Total differentiation, mitotic count and necrosis score of 2 or 3. (AJCC 8th ed.)","Stage IA Retroperitoneal Sarcoma AJCC v8 | Stage IA Retroperitoneal Sarcoma | Stage IA Soft Tissue Retroperitoneal Sarcoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524500","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs TNM Finding v8","C136724","A finding about one or more characteristics of soft tissue sarcoma of the abdomen and thoracic visceral organs, following the rules of the TNM AJCC v8 classification system. This classification system does not apply to desmoplastic small round cell tumor, epithelioid hemangioendothelioma, inflammatory myofibroblastic tumor, perivascular epithelioid cell tumor (PEComa), solitary fibrous tumor, gastrointestinal stromal tumor (GIST), uterine leiomyosarcoma, and retroperitoneal leiomyosarcoma.  This is a new classification system and there is no recommended prognostic stage grouping at this time. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs TNM Finding v8 | Soft Tissue Sarcoma Abdomen And Thoracic Visceral Organs TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524606","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pT4c TNM Finding v8","C136742","Soft tissue sarcoma of the abdomen and thoracic visceral organs with multifocal involvement (more than five sites). (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pT4c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524609","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pT4b TNM Finding v8","C136741","Soft tissue sarcoma of the abdomen and thoracic visceral organs with multifocal involvement (three to five sites). (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pT4b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524608","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pT4a TNM Finding v8","C136740","Soft tissue sarcoma of the abdomen and thoracic visceral organs with multifocal involvement (two sites). (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pT4a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524511","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pT4 TNM Finding v8","C136739","Soft tissue sarcoma of the abdomen and thoracic visceral organs with multifocal involvement. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pT4 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524510","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pT3 TNM Finding v8","C136738","Soft tissue sarcoma of the abdomen and thoracic visceral organs with tumor invading another organ. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pT3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524513","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pT2b TNM Finding v8","C136737","Soft tissue sarcoma of the abdomen and thoracic visceral organs with tumor extending beyond serosa (mesentery). (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pT2b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524512","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pT2a TNM Finding v8","C136736","Soft tissue sarcoma of the abdomen and thoracic visceral organs with tumor invading serosa or visceral peritoneum. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pT2a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524507","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pT2 TNM Finding v8","C136735","Soft tissue sarcoma of the abdomen and thoracic visceral organs with tumor extending into tissue beyond organ. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pT2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524506","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pT1 TNM Finding v8","C136734","Soft tissue sarcoma of the abdomen and thoracic visceral organs, organ confined. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pT1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524509","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pTX TNM Finding v8","C136733","Soft tissue sarcoma of the abdomen and thoracic visceral organs in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pTX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524612","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pN1 TNM Finding v8","C136745","Soft tissue sarcoma of the abdomen and thoracic visceral organs with lymph node involvement. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524611","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pN0 TNM Finding v8","C136744","Soft tissue sarcoma of the abdomen and thoracic visceral organs without lymph node involvement or unknown lymph node status. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524503","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pM1 TNM Finding v8","C136731","Soft tissue sarcoma of the abdomen and thoracic visceral organs with distant metastases. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524504","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs cM1 TNM Finding v8","C136728","Soft tissue sarcoma of the abdomen and thoracic visceral organs with distant metastases. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs cM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524499","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs cM0 TNM Finding v8","C136727","Soft tissue sarcoma of the abdomen and thoracic visceral organs without distant metastases. (from AJCC 8th Ed.)","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs cM0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0419179","Nothing by Mouth","C28250","A Latin abbreviation for 'nothing by mouth'.","Nothing by Mouth | NPO | nil peros",,,,,,,,,,,,,,,"4081119","Nil by mouth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0077408","Trospium Chloride","C61995","The chloride salt form of trospium, a quaternary ammonium compound and antimuscarinic agent, with antispasmodic activity. Upon administration of trospium chloride, trospium targets and competitively binds to and blocks the muscarinic receptor on smooth muscle. This relaxes and prevents spasms of the smooth muscles, including the bladder.","Trospium Chloride | Sanctura | TROSPIUM CHLORIDE | Trosec | spiro[8azoniabicyclo[3,2,1]octane-8,1'-pyrrolidinium]-3-[(hydroxydiphenyl-acetyl)-oxy]chloride(1alpha, 3beta, 5alpha)-(9Cl)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0058004","Difluprednate","C80259","A topical corticosteroid and prednisolone acetate derivative, with anti-inflammatory activity. Upon instillation into the eye, difluprednate binds to and activates the glucocorticoid receptor (GR). The receptor-ligand complex binds to promoter regions of certain genes and initiates RNA transcription. This results in an induction of synthesis of phospholipase A2 inhibitory proteins, thereby inhibiting the synthesis of arachidonic acid and preventing the synthesis of certain inflammatory mediators, such as prostaglandins and leukotrienes. This reduces ocular inflammation and pain.","Difluprednate | 21-(Acetyloxy)-6,9-difluoro-11-hydroxy-17-(1-oxobutoxy)pregna-1,4-diene-3,20-dione (6alpha,11beta)- | 6-alpha,9-alpha-Difluoroprednisolone 17-butyrate 21-acetate | CM 9155 | DFBA | DIFLUPREDNATE | Difluoroprednisolone Butyrate Acetate | Durezol | Pregna-1,4-diene-3,20-dione, 6-alpha,9-difluoro-11-beta,17,21-trihydroxy-, 21-acetate, 17-butyrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0244718","Perindopril Erbumine","C47666","The tert-butylamine salt of perindopril, the ethyl ester of a non-sulfhydryl angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Upon hydrolysis, perindopril erbumine is converted to its active form perindoprilat, inhibiting ACE and the conversion of angiotensin I to angiotensin II; consequently, angiotensin II-mediated vasoconstriction and angiotensin II-stimulated aldosterone secretion from the adrenal cortex are inhibited and diuresis and natriuresis ensue.","Perindopril Erbumine | 1H-Indole-2-carboxylic Acid, 1-(2-((1-(ethoxycarbonyl)butyl)amino)-1-oxopropyl)octahydro-,(2S-(1(R*(R*))2alpha,3abeta,7abeta))-, compound with 2-Methyl-2-propanamine(1:1) | Aceon | Coversyl | MCN-A-2833-109 | PERINDOPRIL ERBUMINE | Perindopril Tert-butylamine | S-9490-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332675","CCKBR Gene","C21596","This gene plays a role in the modulation of regulatory peptides in the brain and gastrointestinal tract.","CCKBR Gene | CCKBR | Cholecystokinin B Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950966","AH Amyloidosis","C158962","A rare type of amyloidosis characterized by the monoclonal deposition of immunoglobulin heavy chain fragments in organs and tissues. It is associated with plasma cell or B-cell lymphoproliferative disorders.","AH Amyloidosis | AH Amyloidosis ",,,,,,,,,,,,,,,"37164452","AH amyloidosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL950968","AHL Amyloidosis","C158964","An extremely rare type of amyloidosis characterized by the monoclonal deposition of immunoglobulin heavy chain and light chain fragments in organs and tissues.","AHL Amyloidosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950970","Light Chain Proximal Tubulopathy without Crystals","C158966","A morphologic variant of light chain proximal tubulopathy with no evidence of crystal formation. It is characterized by acute tubular injury with no evidence lysosomal immunoglobulin crystals.","Light Chain Proximal Tubulopathy without Crystals | Proximal Tubulopathy without Crystals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950971","Crystal-Storing Histiocytosis","C158967","A condition characterized by histiocytes containing intra-lysosomal accumulation of immunoglobulin light chains. Crystal-storing histiocytosis is often associated with plasma cell dyscrasias and lymphoproliferative disorders.","Crystal-Storing Histiocytosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268749","Fibrillary Glomerulonephritis","C96182","Glomerulonephritis characterized by the presence of Congo-red negative microfibrils in the mesangium and capillary walls of the glomeruli. It is associated with marked proteinuria and leads to progressive renal failure.","Fibrillary Glomerulonephritis | FGN | Non-Amyloid Fibrillary Glomerulonephritis",,,,,,,,,,,,,,,"4249737","Fibrillary glomerulonephritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL950972","Immunotactoid Glomerulopathy","C158968","Glomerulonephritis characterized by the presence of Congo-red negative microfibrils in the mesangium and capillary walls of the glomeruli. Morphologic findings include formation of microtubules, evident on electron microscopy, that are larger than those seen in fibrillary glomerulonephritis (30-50 versus 16-24 nm in diameter). There may be some overlap in the size of fibrils found in both conditions.","Immunotactoid Glomerulopathy | GOMMID | Glomerulonephritis with Organized Monoclonal Microtubular Immunoglobulin Deposits",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950973","Type I Cryoglobulinemic Glomerulonephritis","C158969","Glomerulonephritis caused by cryoglobulins which are composed of monoclonal immunoglobulins IgG, IgA, or IgM. It occurs in patients with lymphoproliferative disorders.","Type I Cryoglobulinemic Glomerulonephritis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950974","Proliferative Glomerulonephritis with Monoclonal IgG Deposits","C158970","A sub-type of monoclonal gammopathy of renal significance, characterized by restriction to a single immunoglobulin G heavy chain subclass and a single light chain isotype. Light microscopy often shows an endocapillary proliferative or membranoproliferative glomerulopathy. Electron microscopy reveals electron-dense subendothelial and mesangial deposits.","Proliferative Glomerulonephritis with Monoclonal IgG Deposits | PGNMID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950975","C3 Glomerulopathy with Monoclonal Gammopathy","C158971","A subset of C3 glomerulopathy in which there is an associated finding of monoclonal gammopathy.","C3 Glomerulopathy with Monoclonal Gammopathy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333947","Heavy Chain Deposition Disease","C7339","A subtype of monoclonal immunoglobulin deposition disease in which heavy chain deposition results in non-amyloid tissue deposits which may cause organ dysfunction.","Heavy Chain Deposition Disease | HCDD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950969","Light and Heavy Chain Deposition Disease","C158965","A subtype of monoclonal immunoglobulin deposition disease in which heavy and light chains deposition results in non-amyloid tissue deposits which may cause organ dysfunction.","Light and Heavy Chain Deposition Disease | LHCDD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL430558","survivin antigen vaccine DPX-Survivac","C97951","A lipid depot-based therapeutic cancer vaccine composed of survivin epitopes, a universal T Helper peptide and a polynucleotide adjuvant encapsulated in liposomes and then formulated in the hydrophobic carrier Montanide ISA51 VG, with potential immunopotentiating and antineoplastic activities. Upon injection of Maveropepimut-S, a depot is created at the injection site from which the antigens and adjuvant are released. This vaccine may elicit a long lasting cellular response against survivin-expressing cancers, resulting in a decrease in tumor cell proliferation and an induction of tumor cell death. Survivin, a member of the inhibitor of apoptosis (IAP) family expressed during embryonic development, is upregulated in a variety of human cancers while absent in most normal adult cells; its expression in tumors is associated with a more aggressive phenotype, decreased survival, and increased resistance to chemotherapy.","Maveropepimut-S | DPX-Survivac | MVP-S | Survivin Antigen Vaccine DPX-Survivac",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049114","Ipafricept","C102565","A proprietary fusion protein comprised of the cysteine-rich domain of frizzled family receptor 8 (Fzd8) fused to the human immunoglobulin Fc domain with potential antineoplastic activity. Upon intravenous administration, ipafricept competes with the membrane-bound Fzd8 receptor for its ligand, Wnt proteins, thereby antagonizing Wnt signaling. This may result in the inhibition of Wnt-driven tumor growth. Fzd8, a member of the Frizzled family of G protein-coupled receptors, is one of the components in the Wnt/beta-catenin signaling pathway that plays key roles in embryogenesis and cancer growth.","Ipafricept | Fusion Protein For Immune Applications (fpia) Comprising Homo Sapiens FZD8 (Frizzled Family Receptor 8, Frizzled-8) Extracellular Domain, Fused With Homo Sapiens Immunoglobulin G1 Fc Fragment | Fzd8-Fc | IPAFRICEPT | OMP 54F28 | OMP-54F28",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053601","Cemiplimab","C121540","A human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1) protein, with potential immune checkpoint inhibitory and antineoplastic activity. Upon administration, cemiplimab binds to PD-1, inhibits its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-cells. PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.","Cemiplimab | CEMIPLIMAB | Cemiplimab RWLC | Cemiplimab-rwlc | Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal REGN2810 Heavy Chain), Disulfide with Human Monoclonal REGN2810 kappa-chain, Dimer | Libtayo | REGN 2810 | REGN-2810 | REGN2810",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555275","Colorectal Cancer Peptide Vaccine PolyPEPI1018","C154278","A peptide cancer vaccine consisting of a combination of six synthetic polypeptides directed against cancer testis antigens (CTAs) frequently expressed in colorectal cancers, with potential antineoplastic and immunostimulatory activities. Colorectal cancer peptide vaccine PolyPEPI1018 potentially elicits a cytotoxic T-lymphocyte response against colorectal tumors expressing the CTAs associated with the vaccine, which may result in a reduction in tumor cell proliferation.","Colorectal Cancer Peptide Vaccine PolyPEPI1018 | PolyPEPI 1018 | PolyPEPI-1018 | PolyPEPI1018 | PolyPEPI1018 CRC Peptide Vaccine | PolyPEPI1018 CRC Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085229","Unclassified Abnormality","C124595","A non-specified abnormality; an abnormality that is not included in a specified grouping of abnormalities.","Unclassified Abnormality | UNCLASSIFIED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879915","CAPOX Regimen","C63596","A regimen consisting of capecitabine and oxaliplatin that can be used for the treatment of ampullary, appendiceal, pancreatic and small bowel adenocarcinomas, colorectal, gastric, esophageal and esophagogastric junction cancers, certain neuroendocrine tumors, occult primary tumors and mucinous carcinoma of the ovary. Low-dose CapeOX may be used for the treatment of gastric, esophageal and esophagogastric junction cancers.","CAPOX Regimen | CAPEOX Regimen | CAPOX | CapeOx | CapeOx Regimen | Capecitabine-Oxaliplatin | Capecitabine-Oxaliplatin Regimen | Capecitabine/Oxaliplatin | Capecitabine/Oxaliplatin Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053733","Chimeric Humanized Anti-CD47 Antibody","C122397","A humanized, high-chimeric antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, chimeric humanized anti-CD47 antibody selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","Chimeric Humanized Anti-CD47 Antibody | Humanized High-chimeric Antibody CD47",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562712","SRF 231","C155976","A human monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, urabrelimab selectively binds to CD47 on tumor cells and blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages. This prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","Urabrelimab | Anti-CD47 Monoclonal Antibody SRF231 | Anti-CD47 Monoclonal Antibody SRF231 | SRF 231 | SRF-231 | SRF231 | URABRELIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936985","IBI 188","C157385","A human immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47 with potential immunostimulating and antineoplastic activities. Upon intravenous administration, letaplimab selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","Letaplimab | Anti-CD47 Monoclonal Antibody IBI188 | Anti-CD47 Monoclonal Antibody IBI188 | IBI 188 | IBI-188 | IBI188 | LETAPLIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053657","Anti-CD47 Monoclonal Antibody CC-90002","C121211","A monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody CC-90002 selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","Anti-CD47 Monoclonal Antibody CC-90002 | Anti-CD47 Mab CC-90002 | CC 90002 | CC-90002",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474125","anti-CD47 monoclonal antibody Hu5F9-G4","C117730","A humanized monoclonal antibody targeting the human cell surface antigen CD47, with potential immunostimulating and antineoplastic activities. Upon administration, magrolimab selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with its ligand signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling, allows the activation of macrophages, through the induction of pro-phagocytic signaling mediated by calreticulin, which is specifically expressed on the surface of tumor cells, and results in specific tumor cell phagocytosis. In addition, blocking CD47 signaling activates an anti-tumor T-lymphocyte immune response and T-mediated cell killing. CD47, a tumor associated antigen expressed on normal, healthy hematopoietic stem cells (HSC), is overexpressed on the surface of a variety of cancer cells. Expression of CD47, and interaction with SIRP-alpha, leads to inhibition of macrophages and protects cancer cells from phagocytosis thereby allowing cancer cells to proliferate.","Magrolimab | Anti-CD47 Monoclonal Antibody Hu5F9-G4 | Hu5F9-G4 | MAGROLIMAB | ONO 7913 | ONO-7913 | ONO7913",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1966375","Nilotinib Hydrochloride Monohydrate","C95229","The monohydrate monohydrochloride form of nilotinib, an orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance resulting from Bcr-Abl kinase mutations, upon administration, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl portion of the Bcr-Abl fusion protein, resulting in the inhibition of the constitutive kinase activity of Bcr-Abl protein. This inhibits the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. Nilotinib also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R; PDGFR), mast/stem cell growth factor receptor Kit (c-Kit), and, to a lesser extent, colony-stimulating factor 1 receptor (CSF-1R; CSF1R), and discoidin domain-containing receptor 1 (DDR1).","Nilotinib Hydrochloride Monohydrate | 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide, Monohydrochloride | AMN 107 | AMN-107 | AMN107 | NILOTINIB HYDROCHLORIDE MONOHYDRATE | Nilotinib Monohydrochloride Monohydrate | Tasigna",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503123","Fragmented","C124536","A physical quality in which the entity or structure is broken into pieces.","Fragmented | FRAGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227877","Ovarian Capsule","C49265","A thick connective tissue, called the tunica albuginea, which encapsulates each ovary.","Ovarian Capsule | ",,,,,,,,,,,,,,,"4248883","Structure of capsule of ovary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1333992","Hereditary Ovarian Carcinoma","C36102","Ovarian carcinoma that has developed in relatives of patients that have a history of ovarian carcinoma.","Hereditary Ovarian Carcinoma | Familial Ovarian Carcinoma | Hereditary Ovarian Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0346153","Hereditary Breast Carcinoma","C4503","Breast carcinoma that has developed in relatives of patients with history of breast carcinoma.","Hereditary Breast Carcinoma | Familial Breast Carcinoma | Familial Cancer of Breast | Familial Cancer of the Breast | Hereditary Breast Cancer",,,,,,,,,,,,,,,"4110861","Familial cancer of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2370811","Bronchial Brush Biopsy","C93016","The use of a brush to obtain tissue samples from one or more bronchi.","Bronchial Brush Biopsy | bronchial brush biopsy | bronchial brushing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950981","Did Caregiving Responsibilities Make it Difficult to Work the Required Number of Job Hours","C158978","A question about if an individual's caregiving responsibilities made it difficult to work the required number of hours at their job.","Did Caregiving Responsibilities Make it Difficult to Work the Required Number of Job Hours | How much of the time did your caregiving responsibilities make it difficult for you to work the required number of hours at your job",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950982","Did Caregiving Responsibilities Make it Difficult to Get Going Easily at Beginning of Workday","C158979","A question about if an individual's caregiving responsibilities made it difficult to get going easily at the beginning the workday","Did Caregiving Responsibilities Make it Difficult to Get Going Easily at Beginning of Workday | How much of the time did your caregiving responsibilities make it difficult for you to get going easily at the beginning of your workday",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950983","Did Caregiving Responsibilities Make it Difficult to Start Job on Arrival at Work","C158980","A question about if an individual's caregiving responsibilities made it difficult to start on job as soon as arrival at work.","Did Caregiving Responsibilities Make it Difficult to Start Job on Arrival at Work | How much of the time did your caregiving responsibilities make it difficult for you to start on your job as soon as you arrived at work",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950984","Did Caregiving Responsibilities Make it Difficult to do Work Without Stopping For Breaks or Rests","C158981","A question about if an individual's caregiving responsibilities made it difficult to do work without stopping to take breaks for rests.","Did Caregiving Responsibilities Make it Difficult to do Work Without Stopping For Breaks or Rests | How much of the time did your caregiving responsibilities make it difficult for you to do your work without stopping to take breaks or rests",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950985","Did Caregiving Responsibilities Make it Difficult to Stick to Job Routine or Schedule","C158982","A question about if an individual's caregiving responsibilities made it difficult to stick to a routine or schedule in their job.","Did Caregiving Responsibilities Make it Difficult to Stick to Job Routine or Schedule | How much of the time did your caregiving responsibilities make it difficult for you to stick to a routine or schedule in your job",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951077","Have Difficulty with Sitting, Standing, or Staying in One Position Longer than 15 Minutes While Working Due to Caregiving Responsibilities","C159141","A question about if an individual was able to sit, stand, or stay in one position for longer than 15 minutes while working, without difficulty caused by caregiving responsibilities.","Have Difficulty with Sitting, Standing, or Staying in One Position Longer than 15 Minutes While Working Due to Caregiving Responsibilities Question | Did Caregiving Responsibilities Make it Difficult to Sit, Stand or Stay in One Position Longer than 15 Minutes While Working | Have Difficulty with Sitting, Standing, or Staying in One Position Longer than 15 Minutes While Working Due to Caregiving Responsibilities | Have Difficulty with Sitting, Standing, or Staying in One Position Longer than 15 Minutes While Working Due to Caregiving Responsibilities | How much of the time were you able to sit, stand, or stay in one position for longer than 15 minutes while working, without difficulty caused by your caregiving responsibilities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951078","Have Difficulty Repeating Same Motions Repeatedly While Working Due to Caregiving Responsibilities","C159142","A question about if an individual was able to repeat the same motions over and over again while working, without difficulty caused by caregiving responsibilities.","Have Difficulty Repeating Same Motions Repeatedly While Working Due to Caregiving Responsibilities Question | Did Caregiving Responsibilities Make it Difficult to Repeat Same Motions Repeatedly While Working | Have Difficulty Repeating Same Motions Repeatedly While Working Due to Caregiving Responsibilities | Have Difficulty Repeating Same Motions Repeatedly While Working Due to Caregiving Responsibilities | How much of the time were you able to repeat the same motions over and over again while working, without difficulty caused by your caregiving responsibilities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951079","Did Caregiving Responsibilities Make it Difficult to Keep Mind on Work","C159143","A question about if an individual's caregiving responsibilities made it difficult to keep their mind on work.","Did Caregiving Responsibilities Make it Difficult to Keep Mind on Work | How much of the time did your caregiving responsibilities make it difficult for you to keep your mind on your work",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951081","Did Caregiving Responsibilities Make it Difficult to Think Clearly When Working","C159145","A question about if an individual's caregiving responsibilities made it difficult to think clearly when working.","Did Caregiving Responsibilities Make it Difficult to Think Clearly When Working | How much of the time did your caregiving responsibilities make it difficult for you to think clearly when working",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951080","Did Caregiving Responsibilities Make it Difficult to Do Work Carefully","C159144","A question about if an individual's caregiving responsibilities made it difficult to work carefully.","Did Caregiving Responsibilities Make it Difficult to Do Work Carefully | How much of the time did your caregiving responsibilities make it difficult for you to do your work carefully",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951082","Did Caregiving Responsibilities Make it Difficult to Concentrate on Work","C159146","A question about if an individual's caregiving responsibilities made it difficult to concentrate on work.","Did Caregiving Responsibilities Make it Difficult to Concentrate on Work | How much of the time did your caregiving responsibilities make it difficult for you to concentrate on your work",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951083","Did Caregiving Responsibilities Make it Difficult to Work Without Losing Train of Thought","C159147","A question about if an individual's caregiving responsibilities made it difficult to work without losing train of thought.","Did Caregiving Responsibilities Make it Difficult to Work Without Losing Train of Thought | How much of the time did your caregiving responsibilities make it difficult for you to work without losing your train of thought",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951084","Did Caregiving Responsibilities Make it Difficult to Easily Read or Use Eyes When Working","C159148","A question about if an individual's caregiving responsibilities made it difficult to easily read or use their eyes when working.","Did Caregiving Responsibilities Make it Difficult to Easily Read or Use Eyes When Working | How much of the time did your caregiving responsibilities make it difficult for you to easily read or use your eyes when working",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951085","Did Caregiving Responsibilities Make it Difficult to Speak With People In-Person, in Meetings, or Phone When Working","C159149","A question about if an individual's caregiving responsibilities made it difficult to speak with people in-person, in meetings or on the phone when working.","Did Caregiving Responsibilities Make it Difficult to Speak With People In-Person, in Meetings, or Phone When Working | How much of the time did your caregiving responsibilities make it difficult for you to speak with people in-person, in meetings or on the phone when working",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951086","Did Caregiving Responsibilities Make it Difficult to Control Temper Around People When Working","C159150","A question about if an individual's caregiving responsibilities made it difficult to control their temper around people when working.","Did Caregiving Responsibilities Make it Difficult to Control Temper Around People When Working | How much of the time did your caregiving responsibilities make it difficult for you to control your temper around people when working",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951024","Did Caregiving Responsibilities Make it Difficult to Help Other People to Get Work Done","C159151","A question about if an individual's caregiving responsibilities made it difficult to help other people to get work done.","Did Caregiving Responsibilities Make it Difficult to Help Other People to Get Work Done | How much of the time did your caregiving responsibilities make it difficult for you to help other people to get work done",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951033","Did Caregiving Responsibilities Make it Difficult to Control Feelings of Sadness or Grief When Working","C159161","A question about if an individual's caregiving responsibilities made it difficult to control feelings of sadness or grief when working.","Did Caregiving Responsibilities Make it Difficult to Control Feelings of Sadness or Grief When Working | How much of the time did your caregiving responsibilities make it difficult for you to control feelings of sadness or grief when working",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951032","Did Caregiving Responsibilities Make it Difficult to Listen Well to New Information Given at Work","C159160","A question about if an individual's caregiving responsibilities made it difficult to listen well to new information given at work.","Did Caregiving Responsibilities Make it Difficult to Listen Well to New Information Given at Work | How much of the time did your caregiving responsibilities make it difficult for you to listen well to new information given to you at work",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951034","Did Caregiving Responsibilities Make it Difficult to Handle Workload","C159162","A question about if an individual's caregiving responsibilities made it difficult for them to handle the workload.","Did Caregiving Responsibilities Make it Difficult to Handle Workload | How much of the time did your caregiving responsibilities make it difficult for you to handle the workload",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951035","Did Caregiving Responsibilities Make it Difficult to Work Fast Enough","C159163","A question about if an individual's caregiving responsibilities made it difficult for them to work fast enough.","Did Caregiving Responsibilities Make it Difficult to Work Fast Enough | How much of the time did your caregiving responsibilities make it difficult for you to work fast enough",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951036","Did Caregiving Responsibilities Make it Difficult to Finish Work on Time","C159164","A question about if an individual's caregiving responsibilities made it difficult for them to finish work on time.","Did Caregiving Responsibilities Make it Difficult to Finish Work on Time | How much of the time did your caregiving responsibilities make it difficult for you to finish work on time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951037","Did Caregiving Responsibilities Make it Difficult to Do Work Without Making Mistakes","C159165","A question about if an individual's caregiving responsibilities made it difficult for them to do work without making mistake.","Did Caregiving Responsibilities Make it Difficult to Do Work Without Making Mistakes | How much of the time did your caregiving responsibilities make it difficult for you to do your work without making mistake",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951038","Did Caregiving Responsibilities Make it Difficult to Feel You've Done What You're Capable of Doing","C159166","A question about if an individual's caregiving responsibilities made it difficult for them to feel they have done what they are capable of doing.","Did Caregiving Responsibilities Make it Difficult to Feel You've Done What You're Capable of Doing | How much of the time did your caregiving responsibilities make it difficult for you to feel you've done what you are capable of doing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951039","Have Difficulty Doing Usual Household Chore or Activity Because of Caregiving Responsibilities","C159167","A question about if an individual had difficulty doing usual household chores or activities because of their caregiving responsibilities.","Have Difficulty Doing Usual Household Chore or Activity Because of Caregiving Responsibilities Question | Have Difficulty Doing Usual Household Chore or Activity Because of Caregiving Responsibilities | Have Difficulty Doing Usual Household Chore or Activity Because of Caregiving Responsibilities | How much of the time did you have difficulty doing your usual household chores or activities because of your caregiving responsibilities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951041","Someone There for Suggestions About How to Deal with Personal Problem","C159169","A question about if there is someone to turn to for suggestions about how to deal with a personal problem.","Someone There for Suggestions About How to Deal with Personal Problem | How often is there someone to turn to for suggestions about how to deal with a personal problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951042","Someone There to Love and Make You Feel Wanted","C159170","A question about if there is someone for an individual to love and make them feel wanted.","Someone There to Love and Make You Feel Wanted | How often is there someone to love and make you feel wanted | to love and make you feel wanted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951044","Someone There to Get Together for Relaxation","C159172","A question about if there is someone for an individual to get together with for relaxation.","Someone There to Get Together for Relaxation | How often is there someone to get together with for relaxation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951045","Someone There to Help With Daily Chores if Sick","C159173","A question about if there is someone for an individual to help with daily chores if they were sick.","Someone There to Help With Daily Chores if Sick | How often is there someone to help with daily chores if you were sick",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951046","How often is there someone to perform your caregiving responsibilities when you can't","C159174","A question about if there is someone for an individual to perform their caregiving responsibilities when they cannot.","Someone There to Perform Caregiving Responsibilities When You Cannot | How often is there someone to perform your caregiving responsibilities when you can't | There to Perform Caregiving Responsibilities When You Cannot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951047","Someone There for Questions or Concerns About Caregiving","C159175","A question about if there is someone for an individual to go to when they have questions or concerns about caregiving.","Someone There for Questions or Concerns About Caregiving | How often is there someone you can go to when you have questions or concerns about caregiving | Someone There for Questions or Concerns About Caregiving ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951048","Being Able to Provide Assistance as Caregiver is Emotionally Rewarding for Me","C159176","A question about whether an individual being able to provide assistance as a caregiver is emotionally rewarding.","Being Able to Provide Assistance as Caregiver is Emotionally Rewarding for Me | Being able to provide assistance as a caregiver is emotionally rewarding for me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951049","Being Able to Provide Assistance as Caregiver is Spiritually Rewarding for Me","C159177","A question about whether an individual being able to provide assistance as a caregiver is spiritually rewarding.","Being Able to Provide Assistance as Caregiver is Spiritually Rewarding for Me | Being able to provide assistance as a caregiver is spiritually rewarding for me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951050","Being Able to Provide Assistance as Caregiver Helps Me Feel in Control of Situation","C159178","A question about whether an individual being able to provide assistance as a caregiver helps them feel in control of the situation.","Being Able to Provide Assistance as Caregiver Helps Me Feel in Control of Situation | Being able to provide assistance as a caregiver helps me feel in control of the situation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951051","Being Able to Provide Assistance as Caregiver is Important to Me","C159179","A question about whether an individual being able to provide assistance as a caregiver is important to them.","Being Able to Provide Assistance as Caregiver is Important to Me | Being able to provide assistance as a caregiver is important to me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951052","Being Able to Provide Assistance as Caregiver is My Duty as Responsible Adult","C159180","A question about whether an individual being able to provide assistance as a caregiver is their duty as a responsible adult.","Being Able to Provide Assistance as Caregiver is My Duty as Responsible Adult | Being able to provide assistance as a caregiver is my duty as a responsible adult",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951053","Currently Paying Someone to Assist with Caregiving","C159181","A question about whether an individual is currently paying someone to assist them with caregiving.","Currently Paying Someone to Assist with Caregiving | Are you currently paying someone to assist you with caregiving",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951054","Plan to Take Leave of Absence From Work Over Next Year Because of Caregiving","C159182","A question about whether an individual plans to take a leave of absence from work over the next year because of their caregiving.","Plan to Take Leave of Absence From Work Over Next Year Because of Caregiving | Do you plan to take a leave of absence from work over the next year because of your caregiving",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951236","Difficult All of the Time","C159183","A response indicating that something is or was difficult all of the time.","Difficult All of the Time | Difficult all of the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951237","Difficult Most of the Time","C159184","A response indicating that something is or was difficult most of the time.","Difficult Most of the Time | Difficult most of the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951238","Difficult Some of the Time","C159185","A response indicating that something is or was difficult some of the time.","Difficult Some of the Time | Difficult some of the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951239","Difficult a Slight Bit of the Time","C159186","A response indicating that something is or was difficult a slight bit of the time.","Difficult a Slight Bit of the Time | Difficult a slight bit of the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951241","Difficult None of the Time","C159188","A response indicating that something is or was difficult none of the time.","Difficult None of the Time | Difficult none of the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951240","Does Not Apply to My Job","C159187","A response indicating that something does not apply to an individual's job.","Does Not Apply to My Job | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951242","Able All of the Time","C159189","A response indicating that an individual is or was able all of the time.","Able All of the Time | Able all of the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951243","Able Most of the Time","C159190","A response indicating that an individual is or was able most of the time.","Able Most of the Time | Able most of the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951244","Able Some of the Time","C159191","A response indicating that an individual is or was able some of the time.","Able Some of the Time | Able some of the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951245","Able a Slight bit of the Time","C159192","A response indicating that an individual is or was able a slight bit of the time.","Able a Slight bit of the Time | Able a slight bit of time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951246","Able None of the Time","C159193","A response indicating that an individual is or was able none of the time.","Able None of the Time | Able none of the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951247","Pay For Full-time Help","C159194","A response indicating that an individual pays someone for full-time help.","Pay For Full-time Help | Yes, I pay someone for full time help",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951248","Pay For Part-time Help","C159195","A response indicating that an individual pays someone for part-time help.","Pay For Part-time Help | Yes, I pay someone for part time help",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951249","Don't Want help","C159196","A response indicating that an individual does not want help.","Don't Want help | No, I don't want help",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951250","Can't Get Help","C159197","A response indicating that an individual wants help but can't get it.","Can't Get Help | No, I want the help but can't get it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347741","Quotient","C71610","A quantity obtained by division.","Quotient | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524517","Mucinous Bronchioloalveolar Carcinoma","C136709","An invasive adenocarcinoma that arises from the lung. It is characterized by the presence of tall columnar cells and mucin production. This category refers to cases formerly classified as mucinous bronchioloalveolar carcinoma, excluding cases that meet the criteria for adenocarcinoma in situ or mucinous minimally invasive adenocarcinoma.","Invasive Lung Mucinous Adenocarcinoma | Invasive mucinous adenocarcinoma | Mucinous Bronchioloalveolar Carcinoma | Mucinous Invasive Lung Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540691","Subject Risk","C142718","In clinical trials, the probability of harm or discomfort for subjects. NOTE: Acceptable risk differs depending on the condition for which a product is being tested. A product for sore throat, for example, will be expected to have a low incidence of troubling side effects. However, the possibility of unpleasant side effects may be an acceptable risk when testing a promising treatment for a life-threatening illness.","Subject Risk | risk | risks of a research study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517486","Gene Expression Process","C21049","Any subcellular or molecular event or process specifically, primarily, and directly designed for and involved in the production of mature functional biomolecular products encoded by a gene.","Gene Expression Process | Gene expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426926","KRT20 Gene","C96457","This gene plays a role in the formation of intestinal epithelia.","KRT20 Gene | KRT20 | Keratin 20 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013649","Special Education","C159269","The practice of educating students with identified disabilities through specialized instruction that addresses their individual differences and needs.","Special Education | Special Ed | Special-needs Education",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0870287","classroom","C159271","A room or space, especially in a school, where classes are held.","Classroom | Schoolroom",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037831","Speech Language Therapy","C159273","The treatment of communication disorders (speech disorders and language disorders), cognitive-communication disorders, voice disorders, and swallowing disorders.","Speech Language Therapy | ",,,,,,,,,,,,,,,"4201412","Speech therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL951201","Currently Receiving","C159274","An indication that an individual is receiving something at the present time.","Currently Receiving | Person Currently Receiving",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951202","Raw Score","C159275","A single score that is derived from a test or an observation and that has not been transformed or altered.","Raw Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL481405","Refractory Malignant Neoplasm","C120186","A malignant neoplasm that does not respond to treatment.","Refractory Malignant Neoplasm | Refractory Cancer | clinical resistance | refractory cancer | resistant cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0444439","Segmental Bronchus","C33526","One of the divisions of the lobar bronchus that supplies a bronchopulmonary segment.","Segmental Bronchus | Tertiary Bronchus",,,,,,,,,,,,,,,"4027879","Segmental bronchus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002690","Stump","C96294","The part of a limb or an internal organ (e.g., ureter) that remains after amputation or resection.","Stump | ",,,,,,,,,,,,,,,"4243623","Amputation stump",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL763667","None Identified","C157432","Nothing was identified.","None Identified | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504982","Serous Tubal Intraepithelial Carcinoma","C126449","A non-invasive serous carcinoma arising from the fallopian tube.","Serous Tubal Intraepithelial Carcinoma | STIC | Serous tubal intraepithelial carcinoma | Serous tubal intraepithelial carcinoma (STIC)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0269106","Peritoneal Endosalpingiosis","C40121","A benign pathologic process characterized by the transformation of the mesothelium into fallopian tube epithelium.  It occurs in the peritoneum and may affect the serosa surface of the uterus and the adnexa.  It may be asymptomatic or present as pelvic pain.","Peritoneal Endosalpingiosis | Endosalpingiosis",,,,,,,,,,,,,,,"4184134","Endosalpingiosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL357425","Monoclonal Immunoglobulin Deposition Disease","C7151","A mature B-cell neoplasm characterized by the deposition of immunoglobulin in tissues, resulting in impaired organ function. It includes the following entities: primary amyloidosis, heavy chain deposition disease, and light chain deposition disease.","Monoclonal Immunoglobulin Deposition Disease | Immunoglobulin Deposition Disease | Immunoglobulin deposition disease","9769/1","Immunoglobulin deposition disease",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C1708766","Lung Neuroendocrine Tumor G2","C45551","A neuroendocrine tumor of the lung characterized by the presence of 2-10 mitoses per 2 mm2 and/or necrosis (usually punctate).","Lung Neuroendocrine Tumor G2 | Lung Atypical Carcinoid Tumor | Lung Atypical Carcinoid Tumor | Lung NET G2 | Lung NET Grade 2 | Lung NET, Grade 2 | Lung Neuroendocrine Tumor G2 | Lung Neuroendocrine Tumor Grade 2 | Lung Neuroendocrine Tumor, Grade 2 | Malignant carcinoid tumor of the bronchus and lung",,,,,,,,,,,,,,,"765056","Malignant carcinoid tumor of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540737","Thoracic NUT Carcinoma","C142781","A highly aggressive, poorly differentiated carcinoma that arises from the thoracic structures. It is characterized by mutations and rearrangement of the NUT gene. It usually presents at an advanced stage with pleuritic chest pain and pleural effusion, non-productive cough, shortness of breath, and weigh loss.","Thoracic NUT Carcinoma | Thoracic NMC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708792","Lung Lymphoepithelial Carcinoma","C45519","A rare and distinctive type of lung carcinoma characterized by the presence of a syncytial growth pattern, large vesicular nuclei with eosinophilic nucleoli, and dense lymphoplasmacytic infiltration.","Lung Lymphoepithelial Carcinoma | Lung Lymphoepithelioma-Like Carcinoma | Lung Lymphoepithelioma-Like Carcinoma | Lymphoepithelioma-Like Lung Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523789","Lung Adenocarcinoma In Situ","C136486","A localized non-invasive adenocarcinoma of the lung measuring 3 cm or less. It is characterized by a pure lepidic growth pattern and the lack of stromal, vascular, or pleural invasion.","Lung Adenocarcinoma In Situ | Bronchioloalveolar Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554696","Lung Squamous Cell Carcinoma In Situ","C136719","A preinvasive bronchial neoplastic lesion affecting the squamous epithelium. It is characterized by the absence of progression of maturation from base to luminal surface, basilar zone expansion with cellular crowding throughout the epithelium, absence of the intermediate zone, and surface flattening confined to the most superficial cells. The nuclear-to-cytoplasmic ratio is often high and variable, the chromatin is coarse and uneven, and mitotic figures are present through full thickness. The cell size may be markedly increased. Anisocytosis and pleomorphism may be present. (Adapted from WHO, 2015)","Lung Squamous Cell Carcinoma In Situ | LUSC-CIS | Squamous Cell Lung Carcinoma In Situ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950757","CD40LG Gene Mutation","C158665","A change in the nucleotide sequence of the CD40LG gene.","CD40LG Gene Mutation | CD154 Gene Mutation | CD40 Ligand Gene Mutation | CD40L Gene Mutation | HIGM1 Gene Mutation | IGM Gene Mutation | IMD3 Gene Mutation | T-BAM Gene Mutation | TNFSF5 Gene Mutation | TRAP Gene Mutation | gp39 Gene Mutation | hCD40L Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951374","How Much Time Did it Take","C159341","A question about how much time it took to do something.","How Much Time Did it Take | How much time did it take",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951375","How Much Effort Did it Take","C159343","A question about how difficult it was to do something.","How Much Effort Did it Take | How Difficult was it | How much effort/difficulty did it take",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951325","Prepare and Give Medicines, Fluids, Nutrition Intravenously","C159345","A question about preparing and giving medicines, fluids, or nutrition intravenously.","Prepare and Give Medicines, Fluids, Nutrition Intravenously | Preparing and giving medicines, fluids and tpn (nutrition) intravenously (iv) (preparation includes: tubing, pumps, drawing up medications)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951326","Prepare and Give Medicine as Shot in Muscle or Under Skin","C159346","A question about preparing and giving medicine as a shot in the muscle or under the skin.","Prepare and Give Medicine as Shot in Muscle or Under Skin | Preparing and giving medicine as a shot in the muscle (im) or under the skin (sq) (this includes: drawing up medications, applying emla cream)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951327","Prepare and Give Medications by Mouth","C159347","A question about preparing and giving medications by mouth.","Prepare and Give Medications by Mouth | Preparing and giving medications by mouth (examples include: breaking up pills, disguising taste, etc.)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951329","Prepare and Give Catheter Flushes","C159349","A question about preparing and giving catheter flushes.","Prepare and Give Catheter Flushes | Preparing and giving catheter flushes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951331","Change Dressing on Your Child's Catheter and Change Catheter Cap","C159351","A question about an individual changing their child's catheter dressing and catheter cap.","Change Dressing on Your Child's Catheter and Change Catheter Cap | Changing the dressing on your child's catheter (i.e., broviac, hickman, port, etc.) and changing catheter cap(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951332","Manage Child's Side Effects of Cancer or its Treatment","C159352","A question about an individual managing side effects of cancer or its treatment for their child with cancer.","Manage Child's Side Effects of Cancer or its Treatment | Managing side effects of cancer or its treatment (examples include: vomiting, mouth sores, diarrhea, frequent voiding/diaper changing)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951333","Keep Your Child Comfortable and Without Pain","C159353","A question about an individual keeping their child comfortable and without pain.","Keep Your Child Comfortable and Without Pain | Keeping your child comfortable and without pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951334","Manage Other Childhood Illnesses for Your Child with Cancer","C159354","A question about an individual managing other childhood illnesses for their child with cancer.","Manage Other Childhood Illnesses for Your Child with Cancer | Managing other childhood illnesses for your child with cancer (examples include: cold, flu, ear infections, other)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951345","Manage Unexpected Events Related to Your Child's Illness","C159374","A question about an individual managing unexpected events related to their child's illness.","Manage Unexpected Events Related to Your Child's Illness | Managing unexpected events related to your child's illness (examples include: admission for fever, unscheduled appointment for blood transfusion, changes in treatment schedule because of low blood counts)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951346","Additional Household Tasks Related to Your Child's Illness","C159375","A question about an individual's additional household tasks related to their child's illness.","Additional Household Tasks Related to Your Child's Illness | Additional household tasks related to your child's illness (examples include: cleaning and maintenance of equipment, etc.)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951297","Travel to and From Hospital for Medical Care","C159377","A question about travel to and from the hospital for medical care.","Travel to and From Hospital for Medical Care | Travel to and from the hospital for medical care",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951298","How Much Time Spent at Hospital for Appointments","C159378","A question about how much time was spent at the hospital for appointments.","How Much Time Spent at Hospital for Appointments | How much time was spent at the hospital for appointments (examples include: oncology, neurology, radiation oncology, surgery clinic, scans, and other tests)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951299","How Much Effort or Difficulty for Time Spent at Hospital for Appointments","C159379","A question about how much effort or difficulty for time spent at the hospital for appointments.","How Much Effort or Difficulty for Time Spent at Hospital for Appointments | How much effort/difficulty did it take for time spent at the hospital for appointments (examples include: oncology, neurology, radiation oncology, surgery clinic, scans, and other tests)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951300","Provide Emotional Support for Your Child with Cancer","C159380","A question about an individual providing emotional support for their child with cancer.","Provide Emotional Support for Your Child with Cancer | Providing emotional support for your child with cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951301","Provide Emotional Support for Other Children in the Family","C159381","A question about an individual providing emotional support for the extended family.","Provide Emotional Support for Other Children in the Family | Providing emotional support for other children in the family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951302","Provide Emotional Support for Extended Family","C159382","A question about an individual providing emotional support for other children in the family.","Provide Emotional Support for Extended Family | Providing emotional support for the extended family (examples include: grandparents, aunts, uncles, friends, etc.)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951303","Provide Support for Spouse or Partner","C159383","A question about an individual providing emotional support for their spouse or partner.","Provide Support for Spouse or Partner | Providing emotional support for your spouse/partner",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951304","Meet Your Own Emotional Support Needs","C159384","A question about an individual meeting their own emotional support needs.","Meet Your Own Emotional Support Needs | Meeting your own emotional support needs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951305","Comfort Your Child Through Pain of Cancer and its Treatment","C159385","A question about an individual comforting their child through the pain of the cancer and its treatment.","Comfort Your Child Through Pain of Cancer and its Treatment | Comforting your child through the pain of the cancer and its treatment (examples include: procedures, mouth sores, bone pain, etc.)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951306","Take Care of Discipline and/or Behavior Problems of Child with Cancer","C159386","A question about taking care of discipline and/or behavior problems of the child with cancer.","Take Care of Discipline and/or Behavior Problems of Child with Cancer | Taking care of discipline and/or behavior problems of the child with cancer (crying, irritability, moodiness)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951307","Take Care of Finances, Bills, and Forms Related to Child's Illness","C159387","A question about an individual taking care of finances, bills, and forms related to their child's illness.","Take Care of Finances, Bills, and Forms Related to Child's Illness | Taking care of finances, bills, and forms related to the child's illness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951308","Plan Activities for Your Child with Cancer Around Treatment and Illness","C159388","A question about an individual planning activities for their child with cancer around the treatment and illness.","Plan Activities for Your Child with Cancer Around Treatment and Illness | Planning activities for your child with cancer around the treatment and illness (examples include: school, playtime, rest, things for the child to do, other)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951309","Plan Activities for Your Family Around Treatment and Illness","C159389","A question about an individual planning activities for their family around the treatment and illness of their child with cancer.","Plan Activities for Your Family Around Treatment and Illness | Plan Activities for Your Family Around Treatment and Illness  | Planning activities for your family around the treatment and illness (examples include: recreation, vacation, school functions, other)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951310","Get Child Care or Babysitting Help for Your Ill Child","C159390","A question about an individual getting child care or babysitting help for their ill child.","Get Child Care or Babysitting Help for Your Ill Child | Getting child care/babysitting help for your ill child",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951311","Get Child Care or Babysitting for Siblings of Ill Child","C159391","A question about an individual getting child care or babysitting for brothers and sisters of the ill child.","Get Child Care or Babysitting for Siblings of Ill Child | Obtaining child care/babysitting for brothers and sisters of the ill child",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951312","Communicate Information About Cancer to Schools, Day Care, Babysitters, Extended Family, and Friends","C159392","A question about an individual communicating information about cancer to schools, day care, babysitters, extended family, and friends.","Communicate Information About Cancer to Schools, Day Care, Babysitters, Extended Family, and Friends | Communicating information about cancer to schools, day care, babysitters, extended family and friends",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951313","Watch for and Report Your Child's Physical Symptoms and Medical Condition to Medical Team","C159393","A question about an individual watching for and reporting their child's physical symptoms and medical condition to the medical team.","Watch for and Report Your Child's Physical Symptoms and Medical Condition to Medical Team | Watching for and reporting your child's physical symptoms and medical condition to the medical team",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951314","Get Information on Your Child's Illness and Treatment","C159394","A question about an individual getting information on their child's illness and treatment.","Get Information on Your Child's Illness and Treatment | Getting information on your child's illness and the treatment (examples include: library, medical team, community agencies)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951315","Anything Else You Wish to Tell About Taking Care of Your Child with Cancer","C159395","A question asking an individual to tell about anything else not asked about taking care of their child with cancer.","Anything Else You Wish to Tell About Taking Care of Your Child with Cancer | Is there anything else that you wish to tell us about taking care of your child with cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951316","A Great Deal of Effort","C159396","A response indicating that something took a great deal of effort.","A Great Deal of Effort | A great deal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951317","Quite a lot of Effort","C159397","A response indicating that something took quite a lot of effort.","Quite a lot of Effort | Quite a lot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951318","A Moderate Amount of Effort","C159398","A response indicating that something took a moderate amount of effort.","A Moderate Amount of Effort | Moderate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951319","A Small Amount of Effort","C159399","A response indicating that something took only a small amount of effort.","A Small Amount of Effort | A small amount",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938256","No Effort","C159400","A response indicating that something took no effort.","No Effort | None",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0277589","Death by Undetermined Cause","C82466","Death resulting from an unknown cause.","Death by Undetermined Cause | DIED - UNDETERMINED | Death Due to Indeterminate Cause | Unknown Cause of Death",,,,,,,,,,,,,,,"4276823|441413","Undetermined manner of death|Death of unknown cause",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL951347","Borderline Ovarian Mucinous Tumor/Atypical Proliferative Ovarian Mucinous Tumor with Intraepithelial Carcinoma","C159312","A low grade ovarian epithelial neoplasm characterized by the presence of neoplastic mucinous epithelial cells, atypia, and the presence of intraepithelial carcinoma.","Borderline Ovarian Mucinous Tumor/Atypical Proliferative Ovarian Mucinous Tumor with Intraepithelial Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951180","Borderline Ovarian Mucinous Tumor/Atypical Proliferative Ovarian Mucinous Tumor with Microinvasion","C159311","A low grade ovarian epithelial neoplasm characterized by the presence of neoplastic mucinous epithelial cells, atypia, and microinvasion of the ovarian stroma.","Borderline Ovarian Mucinous Tumor/Atypical Proliferative Ovarian Mucinous Tumor with Microinvasion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951348","Borderline Ovarian Seromucinous Tumor/Atypical Proliferative Ovarian Seromucinous Tumor with Microinvasion","C159313","A low grade ovarian epithelial neoplasm characterized by the presence of atypical neoplastic serous and mucinous cells. Microinvasion of the ovarian stroma is present.","Borderline Ovarian Seromucinous Tumor/Atypical Proliferative Ovarian Seromucinous Tumor with Microinvasion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951330","Right Tubo-Ovarian","C159350","A term that implies the right fallopian tube and right ovary.","Right Tubo-Ovarian | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951328","Left Tubo-Ovarian","C159348","A term that implies the left fallopian tube and left ovary.","Left Tubo-Ovarian | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0405789","Ascites Drainage","C159342","The systematic withdrawal of ascitic fluid  from the abdominal cavity.","Ascites Drainage | ",,,,,,,,,,,,,,,"4121002","Drainage of ascites",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0817432","Abdominal Peritoneum","C159355","A membranous lining of the abdominal cavity and abdominal organs.","Abdominal Peritoneum | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031148","Peritoneal Lavage","C159340","A minimally invasive procedure that permits sampling of peritoneal fluid for cytopathologic analysis.","Peritoneal Lavage | Peritoneal Washing",,,,,,,,,,,,,,,"4306203","Peritoneal lavage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL951699","Chemotherapy Response Score","C159367","A three-tier chemotherapy response score (CRS) system used to assess the histopathologic response and prognosis of patients with tubo-ovarian high-grade serous carcinoma (HGSC) receiving neoadjuvant chemotherapy.","Chemotherapy Response Score | CRS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951342","Chemotherapy Response Score 1","C159368","No or minimal tumor response.","Chemotherapy Response Score 1 | CRS1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951735","Chemotherapy Response Score 2","C159369","Appreciable tumor response amid viable tumor that is readily identifiable.","Chemotherapy Response Score 2 | CRS2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3715051","CRANIOSYNOSTOSIS 3","C159370","Complete or near complete response with no residual tumor OR minimal irregularly scatter tumor foci seen as individual cells, cell groups, or nodules up to 2 mm maximum size.","Chemotherapy Response Score 3 | CRS3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053516","Borderline Ovarian Mucinous Tumor/Atypical Proliferative Ovarian Mucinous Tumor","C122586","A non-invasive neoplasm that arises from the ovary and is composed of gastrointestinal-type, mucin-containing epithelial cells.  It shows greater cellular proliferation and cytologic atypia as compared to benign ovarian mucinous tumors.","Borderline Ovarian Mucinous Tumor/Atypical Proliferative Ovarian Mucinous Tumor | MBT/APMT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053505","Borderline Ovarian Serous Tumor/Atypical Proliferative Ovarian Serous Tumor","C122584","A non-invasive serous neoplasm that arises from the ovary and shows greater cellular proliferation and cytologic atypia as compared to benign ovarian serous tumors, but less as compared to low-grade ovarian serous carcinoma.","Borderline Ovarian Serous Tumor/Atypical Proliferative Ovarian Serous Tumor | SBT/APST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951477","Light Chain Fanconi Syndrome","C159456","Fanconi syndrome that is caused by light chain deposition resulting in a proximal tubulopathy.","Light Chain Fanconi Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0502381","Subsegmental Bronchus","C41266","A part the bronchial tree, an air passage arising from the segmental bronchus and passing to the naturally delimited part of lung segment (subsegment), where it further subdivides into smaller passages.","Subsegmental Bronchus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951484","Partly Agree","C159463","A response indicating that an individual is in partial agreement with something.","Partly Agree | Partially Agree",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951485","Partly Disagree","C159464","A response indicating that an individual is in partial disagreement with something.","Partly Disagree | Partially Disagree",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0857285","Bone Marrow Aspirate","C133261","Aspirate from bone marrow.","Bone Marrow Aspirate | BONE MARROW, LIQUID | Human Bone Marrow Aspirate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280135","Ovarian Mixed Germ Cell Tumor","C8114","An ovarian malignant germ cell tumor characterized by the presence of at least two different germ cell tumor components. The most common combination of germ cell tumors is dysgerminoma and yolk sac tumor.","Ovarian Mixed Germ Cell Tumor | Mixed Germ Cell Neoplasm of Ovary | Mixed Germ Cell Neoplasm of the Ovary | Mixed Germ Cell Tumor of Ovary | Mixed Germ Cell Tumor of the Ovary | Ovarian Mixed Germ Cell Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518705","Ovarian Dermoid Cyst with Secondary Carcinoma","C39997","A secondary carcinoma that has developed in an ovarian dermoid cyst.  In the majority of cases, the secondary carcinoma is a squamous cell carcinoma.","Ovarian Dermoid Cyst with Secondary Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0346188","Ovarian Yolk Sac Tumor","C8107","A usually rapidly growing malignant germ cell tumor arising from the ovary.  It usually occurs in children and adolescents.  Signs and symptoms include abdominal pain and a large abdominal or pelvic mass.  The serum alpha-fetoprotein is almost always elevated preoperatively.  Morphologically, there is marked heterogeneity due to numerous patterns of differentiation coexisting in the same tumor.  The most common pattern is reticular.","Ovarian Yolk Sac Tumor | Endodermal Sinus Neoplasm of Ovary | Endodermal Sinus Neoplasm of the Ovary | Endodermal Sinus Tumor of Ovary | Endodermal Sinus Tumor of the Ovary | Germ Cell Endodermal Sinus Neoplasm of Ovary | Germ Cell Endodermal Sinus Neoplasm of the Ovary | Germ Cell Endodermal Sinus Tumor of Ovary | Germ Cell Endodermal Sinus Tumor of the Ovary | Ovarian Endodermal Sinus Neoplasm | Ovarian Endodermal Sinus Tumor | Ovarian Germ Cell Endodermal Sinus Neoplasm | Ovarian Germ Cell Endodermal Sinus Tumor | Ovarian Yolk Sac Neoplasm | Yolk Sac Neoplasm of Ovary | Yolk Sac Neoplasm of the Ovary | Yolk Sac Tumor of Ovary | Yolk Sac Tumor of the Ovary",,,,,,,,,,,,,,,"4110870","Endodermal sinus tumor of ovary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334304","Juvenile Ovarian Granulosa Cell Tumor","C7289","An ovarian granulosa cell tumor that affects females in the first three decades of life. It presents unilaterally as stage I disease in the vast majority of cases. The prognosis is usually good.","Juvenile Ovarian Granulosa Cell Tumor | Juvenile Type Ovarian Granulosa Cell Tumor | Juvenile Type Ovarian Granulosa Cell Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332218","Ovarian Granulosa Cell Tumor","C7288","A low-grade malignant sex cord-stromal tumor that occurs in the ovary and affects middle aged to post-menopausal women. It is composed of granulosa cells in an often fibrothecomatous stroma. The neoplastic cells may form various patterns including the microfollicular, which is characterized by the presence of Call-Exner bodies, macrofollicular, insular, trabecular, and diffuse pattern. Signs and symptoms include abdominal mass, hemoperitoneum, and ascites. Estrogenic and rarely androgenic manifestations may be present. The vast majority of cases present as stage I tumors; however, all tumors have a potential for aggressive clinical course.","Adult Ovarian Granulosa Cell Tumor | Adult Type Ovarian Granulosa Cell Tumor | Adult Type Ovarian Granulosa Cell Tumor | Ovarian Granulosa Cell Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518736","Ovarian Small Cell Carcinoma, Hypercalcemic Type","C40439","An undifferentiated small cell carcinoma that arises from the ovary and is associated with hypercalcemia.  Electron microscopic studies show neurosecretory granules are either absent or, when present, are in small numbers.","Ovarian Small Cell Carcinoma, Hypercalcemic Type | SCCOHT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504878","Borderline Ovarian Clear Cell Tumor/Atypical Proliferative Ovarian Clear Cell Tumor","C126308","A non-invasive clear cell adenofibromatous neoplasm that arises from the ovary. It is characterized by the presence of atypia in the glandular epithelium.","Borderline Ovarian Clear Cell Tumor/Atypical Proliferative Ovarian Clear Cell Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227902","Left Fallopian Tube","C32959","The fallopian tube that extends from the uterus to the ovary in the left side of the pelvic cavity.","Left Fallopian Tube | Fallopian Tube, Left",,,,,,,,,,,,,,,"4034043","Structure of left fallopian tube",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0404193","Left Salpingectomy","C51607","Surgery to remove part or all of the left fallopian tube.","Left Salpingectomy | ",,,,,,,,,,,,,,,"4074877","Left salpingectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0404194","Right Salpingectomy","C51606","Surgery to remove part or all of the right fallopian tube.","Right Salpingectomy | ",,,,,,,,,,,,,,,"4074424","Right salpingectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0195509","Bilateral Salpingectomy","C51667","Surgery to remove part or all of both fallopian tubes.","Bilateral Salpingectomy | ",,,,,,,,,,,,,,,"4093429","Total excision of bilateral fallopian tubes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL951487","Occasional Urinary Incontinence","C159466","A response indicating that an individual has an occasional accident related to urinary incontinence.","Occasional Urinary Incontinence | Occasional Urinary Accident | occasional accident",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951488","Occasional Fecal Incontinence","C159467","A response indicating that an individual has an occasional accident related to fecal incontinence.","Occasional Fecal Incontinence | Occasional Fecal Accident | occasional accident",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951489","Immobile or Less Than 50 Yards","C159468","A response indicating that an individual is immobile or can move less than 50 yards.","Immobile or Less Than 50 Yards | immobile or less than 50 yards",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951491","Walks with Help of One Person, Greater Than 50 Yards","C159470","A response indicating that an individual can walk with verbal or physical help of one person and can move more than 50 yards.","Walks with Help of One Person, Greater Than 50 Yards | walks with help of one person (verbal or physical) greater than 50 yards",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951492","Mobility Independent But May Use Any Aid, Greater Than 50 Yards","C159471","A response indicating that an individual is independently mobile but may use any aid and can move more than 50 yards.","Mobility Independent But May Use Any Aid, Greater Than 50 Yards | independent (but may use any aid; for example, stick) greater than 50 yards",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950649","Borderline Ovarian Mixed Epithelial Tumor/Atypical Proliferative Ovarian Mixed Epithelial Tumor","C158616","A low grade, non-invasive mixed epithelial proliferative neoplasm that arises from the ovary. In most cases is composed of serous and endocervical-type mucinous cells.","Borderline Ovarian Mixed Epithelial Tumor/Atypical Proliferative Ovarian Mixed Epithelial Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951445","Borderline Ovarian Endometrioid Tumor/Atypical Proliferative Ovarian Endometrioid Tumor with Microinvasion","C159486","A low grade ovarian epithelial neoplasm characterized by the presence of glandular or cystic spaces which contain atypical glandular epithelial cells resembling endometrial cells. Microinvasion of the ovarian stroma is present.","Borderline Ovarian Endometrioid Tumor/Atypical Proliferative Ovarian Endometrioid Tumor with Microinvasion | 'Borderline Ovarian Endometrioid Tumor/Atypical Proliferative Ovarian Endometrioid Tumor with Microinvasion | Borderline Ovarian Endometrioid Tumor/Atypical Proliferative Ovarian Endometrioid Tumor with Microinvasion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951447","Bone Marrow Core Biopsy Sample","C159488","A specimen of bone marrow tissue obtained by using a relatively large diameter needle designed to acquire a core specimen.","Bone Marrow Core Biopsy Sample | BONE MARROW, CORE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951449","Negativity Scale","C159490","Uses the 'N' items that received a score of 3. It indicates the degree to which the respondent answers selected questions in an unusually negative manner.","Negativity Scale | Negativity Scale Score | Negativity Scale Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951450","Inconsistency Scale","C159491","Uses the 10 item pairs. For each pair the absolute value of the difference for the items is summed to get the Inconsistency Scale score.","Inconsistency Scale | Inconsistency Scale Score | Inconsistency Scale Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951451","Infrequency Scale","C159492","Measures the extent to which the respondent endorsed items in an atypical fashion. This consists of three items where marking Sometimes or Often to any of the items is highly unusual, even for adolescents with severe cognitive impairment.","Infrequency Scale | Infrequency Scale Score | Infrequency Scale Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951452","Highly Elevated","C159493","An indication that something is highly raised or increased above normal levels or limits.","Highly Elevated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0442809","Inconsistent","C159494","Not in agreement.","Inconsistent | ",,,,,,,,,,,,,,,"4127662","Inconsistent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1511883","Diagnostic Sensitivity","C41394","The probability that a test will produce a true postive result when used on effected subjects as compared to a reference or 'gold standard'. The sensitivity of a test can be determined by calculating: number of true positive results divided by the sum of true positive results plus number of false negative results.","Diagnostic Sensitivity | Sensitivity | Sensitivity of Diagnostic Test | sensitivity | sensitivity (medical test)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951702","Normal Immune Presence","C159472","Less than 10 percent of the tissue surface area is occupied by immune cell infiltration.","Normal Immune Presence | Normal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951432","Mild Immune Presence","C159473","Approximately 10-20 percent of the tissue surface area is occupied by immune cell infiltration.","Mild Immune Presence | Mild immune presence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951433","Moderate Immune Presence","C159474","Greater than 20-50 percent of the tissue surface area is occupied by immune cell infiltration.","Moderate Immune Presence | Moderate immune presence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951434","Severe Immune Presence","C159475","Greater than 50 percent of the tissue surface area is occupied by immune cell infiltration.","Severe Immune Presence | Severe immune presence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007578","Cell Adhesion Molecules","C16393","A diverse family of cell surface and extracellular glycoproteins involved in cell-cell adhesion, cell-extracellular matrix adhesion, recognition, and activation. There are four main classes of cell adhesion molecules: integrins, selectins, cadherins, and immunoglobulin-like adhesion molecules.","Cell Adhesion Molecule | Adhesion Molecule | CAM | CAMs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513400","Molecular Profiling","C19771","Analysis of the RNA expression pattern in a tissue sample using molecular techniques.","Molecular Profiling | Expression Profiling | Expression Signature | Molecular Fingerprinting | Molecular Signature | Pathology Molecular Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985397","Molecular Risk Assessment","C93018","A procedure in which biomarkers (for example, biological molecules or changes in tumor cell DNA) are used to estimate a person's risk for developing cancer. Specific biomarkers may be linked to particular types of cancer.","Molecular Risk Assessment | molecular risk assessment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951734","Traditional Education","C159512","Education that takes place in a public school, divided into grades, and governed by a school district.","Traditional Education | Conventional Education | Conventional Schooling | Traditional | Traditional Classroom | Traditional Schooling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951414","homeschooling","C159513","Education that takes place outside of a traditional school, in a home or other facility, with the teaching being conducted by a parent, tutor, or online instructor.","Home School | Home Education | Home Schooled | Home Schooling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525395","Homebound Instruction","C159514","Instruction to children unable to attend school because of physical disabilities, special health problems, or temporary injuries or illness. This instruction is usually provided by the local school district, usually with a teacher visiting the child in their home, but would include alternative methods, such as online teaching.","Homebound Instruction | Homebound | Homebound Education",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951419","Dual-probe in Situ Hybridization","C159521","An in situ hybridization assay for HER2/Neu that uses probes for both HER2 and chromosome 17.","Dual-probe in Situ Hybridization | DISH | Dual in Situ Hybridization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539371","Mycosis Fungoides and Sezary Syndrome Primary Tumor TNM Finding v8","C141330","A finding about one or more characteristics of mycosis fungoides and Sezary syndrome, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor (skin).","Mycosis Fungoides and Sezary Syndrome Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539466","Mycosis Fungoides and Sezary Syndrome T4 TNM Finding v8","C141338","Confluence of erythema covering 80% or more of body surface area. (from AJCC 8th Ed.)","Mycosis Fungoides and Sezary Syndrome T4 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539467","Mycosis Fungoides and Sezary Syndrome T3 TNM Finding v8","C141337","One or more tumors (equal or greater than 1 cm in diameter). Note: for skin, tumor indicates at least 1 cm diameter solid or nodular lesion with evidence of depth and/or vertical growth. Note the total number of lesions, total volume of lesions, largest size lesion, and region of body involved. Also note whether there is histologic evidence of large-cell transformation. Phenotyping for CD30 is encouraged. (from AJCC 8th Ed.)","Mycosis Fungoides and Sezary Syndrome T3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539468","Mycosis Fungoides and Sezary Syndrome T2b TNM Finding v8","C141336","T2b (plaque +/- patch). (from AJCC 8th Ed.)","Mycosis Fungoides and Sezary Syndrome T2b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539469","Mycosis Fungoides and Sezary Syndrome T2a TNM Finding v8","C141335","T2a (patch only). (from AJCC 8th Ed.)","Mycosis Fungoides and Sezary Syndrome T2a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539367","Mycosis Fungoides and Sezary Syndrome T2 TNM Finding v8","C141334","Patches, papules, or plaques covering 10% or more of the skin surface.  (from AJCC 8th Ed.)","Mycosis Fungoides and Sezary Syndrome T2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539368","Mycosis Fungoides and Sezary Syndrome T1b TNM Finding v8","C141333","T1b (plaque +/- patch). (from AJCC 8th Ed.)","Mycosis Fungoides and Sezary Syndrome T1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539369","Mycosis Fungoides and Sezary Syndrome T1a TNM Finding v8","C141332","T1a (patch only). (from AJCC 8th Ed.)","Mycosis Fungoides and Sezary Syndrome T1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539370","Mycosis Fungoides and Sezary Syndrome T1 TNM Finding v8","C141331","Limited patches, papules, and/or plaques covering less than 10% of the skin surface. Note: for skin, patch indicates any size skin lesion without significant elevation or induration. Presence/absence of hypo- or hyperpigmentation, scale, crusting, and/or poikiloderma should be noted. Plaque indicates any size skin lesion that is elevated or indurated. Presence or absence of scale, crusting, and/or poikiloderma should be noted. Histologic features such as folliculotropism, large-cell transformation (more than 25% large cells), and CD30 positivity or negativity, as well as clinical features such as ulceration are important to document. (from AJCC 8th Ed.)","Mycosis Fungoides and Sezary Syndrome T1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539376","Mycosis Fungoides and Sezary Syndrome Lymph Nodes TNM Finding v8","C141309","A finding about one or more characteristics of mycosis fungoides and Sezary syndrome, following the rules of the TNM AJCC v8 classification system as they pertain to staging of peripheral lymph nodes.","Mycosis Fungoides and Sezary Syndrome Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539375","Mycosis Fungoides and Sezary Syndrome NX TNM Finding v8","C141310","Clinically abnormal peripheral lymph nodes; no histologic confirmation. (from AJCC 8th Ed.)","Mycosis Fungoides and Sezary Syndrome NX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508156","EGFR Exon 19 Deletion Mutation","C126892","In-frame deletions occurring within the exon 19-encoded part of the epidermal growth factor receptor (EGFR) kinase domain. These mutations are commonly seen in non-small cell lung cancer and are associated with increased sensitivity to EGFR tyrosine kinase inhibitors.","EGFR Exon 19 Deletion Mutation | EGFR DEL19 | EGFR DEL19 Mutation | EGFR Ex19Del | EGFR Exon 19 Gene Deletion Mutation | EGFR del19 | ERBB Exon 19 Deletion Mutation | ERBB1 Exon 19 Deletion Mutation | Epidermal Growth Factor Receptor Gene Exon 19 Deletion Mutation | Ex19Del | Exon 19 Deletion | HER1 Exon 19 Deletion Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281163","Educational Intervention","C17874","An educational activity that is intended to prevent disease or alter the course of a disease in a patient or population.","Educational Intervention | Education for Intervention | Intervention by Education | Intervention through Education | Intervention, Educational",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539365","Mycosis Fungoides and Sezary Syndrome N3 TNM Finding v8","C141320","Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3-4 or NCI LN4; clone positive or negative. Note: EORTC N3 classification includes: Dutch grade 3: partial effacement of lymph node architecture; many atypical cerebriform mononuclear cells. Dutch grade 4: complete effacement of lymph node. NCI LN4: partial/complete effacement of nodal architecture by atypical lymphocytes or frankly neoplastic cells. (from AJCC 8th Ed.)","Mycosis Fungoides and Sezary Syndrome N3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539366","Mycosis Fungoides and Sezary Syndrome N2b TNM Finding v8","C141319","Clone positive. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene. (from AJCC 8th Ed.)","Mycosis Fungoides and Sezary Syndrome N2b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539383","Mycosis Fungoides and Sezary Syndrome N2a TNM Finding v8","C141318","Clone negative. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene.  (from AJCC 8th Ed.)","Mycosis Fungoides and Sezary Syndrome N2a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539385","Mycosis Fungoides and Sezary Syndrome N2 TNM Finding v8","C141316","Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. Note: EORTC N2 classification includes Dutch grade 2: dermatopathic lymphadenopathy; early involvement by mycosis fungoides (presence of cerebriform nuclei less than 7.5 micrometers). NCI LN3: aggregates of atypical lymphocytes; nodal architecture preserved. (from AJCC 8th Ed.)","Mycosis Fungoides and Sezary Syndrome N2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539386","Mycosis Fungoides and Sezary Syndrome N1b TNM Finding v8","C141315","Clone positive. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene. (from AJCC 8th Ed.)","Mycosis Fungoides and Sezary Syndrome N1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539387","Mycosis Fungoides and Sezary Syndrome N1a TNM Finding v8","C141314","Clone negative. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene. (from AJCC 8th Ed.)","Mycosis Fungoides and Sezary Syndrome N1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539388","Mycosis Fungoides and Sezary Syndrome N1 TNM Finding v8","C141312","Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. Note: EORTC N1 classification includes: Dutch grade 1: dermatopathic lymphadenopathy. NCI LN0: no atypical lymphocytes. NCI LN1: occasional and isolated atypical lymphocytes (not arranged in clusters). NCI LN2: many atypical lymphocytes or lymphocytes in 3-6 cell clusters. (from AJCC 8th Ed.)","Mycosis Fungoides and Sezary Syndrome N1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539389","Mycosis Fungoides and Sezary Syndrome N0 TNM Finding v8","C141311","No clinically abnormal peripheral lymph nodes; biopsy not required. Note: for node, abnormal peripheral lymph node(s) indicates any palpable peripheral node that on physical examination is firm, irregular, clustered, fixed or 1.5 cm or larger in diameter. Node groups examined on physical examination include cervical, supraclavicular, epitrochlear, axillary, and inguinal. Central nodes, which generally are not amenable to pathological assessment, currently are not considered in the nodal classification unless used to establish N3 histopathologically. (from AJCC 8th Ed.)","Mycosis Fungoides and Sezary Syndrome N0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539379","Mycosis Fungoides and Sezary Syndrome Distant Metastasis TNM Finding v8","C141306","A finding about one or more characteristics of mycosis fungoides and Sezary syndrome, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases (visceral). (from AJCC 8th Ed.)","Mycosis Fungoides and Sezary Syndrome Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539377","Mycosis Fungoides and Sezary Syndrome M1 TNM Finding v8","C141308","Visceral involvement (must have pathology confirmation and organ involved should be specified). Note: for viscera, spleen and liver may be diagnosed by imaging criteria. (from AJCC 8th Ed.)","Mycosis Fungoides and Sezary Syndrome M1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539378","Mycosis Fungoides and Sezary Syndrome M0 TNM Finding v8","C141307","No visceral organ involvement. (from AJCC 8th Ed.)","Mycosis Fungoides and Sezary Syndrome M0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539363","Mycosis Fungoides and Sezary Syndrome Peripheral Blood Involvement TNM Finding v8","C141322","A finding about one or more characteristics of mycosis fungoides and Sezary syndrome, following the rules of the TNM AJCC v8 classification system as they pertain to peripheral blood involvement.","Mycosis Fungoides and Sezary Syndrome Peripheral Blood Involvement TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539372","Mycosis Fungoides and Sezary Syndrome B2 TNM Finding v8","C141329","High blood tumor burden: 1,000 per microliter or more Sezary cells with positive clone. Note 1: for blood, Sezary cells are defined as lymphocytes with hyperconvoluted cerebriform nuclei. If Sezary cells cannot be used to determine tumor burden for B2, then one of the following modified ISCL criteria along with a positive clonal rearrangement of the TCR may be used instead: (1) expanded CD4+ or CD3+ cells with CD4/CD8 ratio of 10 or more, (2) expanded CD4+ cells with abnormal immunophenotype including loss of CD7 or CD26. Note 2: A T-cell clone is defined by PCR or Southern blot analysis of the T-cell receptor gene. (from AJCC 8th Ed.)","Mycosis Fungoides and Sezary Syndrome B2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539373","Mycosis Fungoides and Sezary Syndrome B1b TNM Finding v8","C141328","Clone positive. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene. (from AJCC 8th Ed.)","Mycosis Fungoides and Sezary Syndrome B1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539374","Mycosis Fungoides and Sezary Syndrome B1a TNM Finding v8","C141327","Clone negative. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene. (from AJCC 8th Ed.)","Mycosis Fungoides and Sezary Syndrome B1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539359","Mycosis Fungoides and Sezary Syndrome B1 TNM Finding v8","C141326","Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary) cells but does not meet the criteria of B2. (from AJCC 7th Ed.)","Mycosis Fungoides and Sezary Syndrome B1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539360","Mycosis Fungoides and Sezary Syndrome B0b TNM Finding v8","C141325","Clone positive. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene. (from AJCC 8th Ed.)","Mycosis Fungoides and Sezary Syndrome B0b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539361","Mycosis Fungoides and Sezary Syndrome B0a TNM Finding v8","C141324","Clone negative. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene. (from AJCC 8th Ed.)","Mycosis Fungoides and Sezary Syndrome B0a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539362","Mycosis Fungoides and Sezary Syndrome B0 TNM Finding v8","C141323","Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). Note: for blood, Sezary cells are defined as lymphocytes with hyperconvoluted cerebriform nuclei. If Sezary cells cannot be used to determine tumor burden for B2, then one of the following modified ISCL criteria along with a positive clonal rearrangement of the TCR may be used instead: (1) expanded CD4+ or CD3+ cells with CD4/CD8 ratio of 10 or more, (2) expanded CD4+ cells with abnormal immunophenotype including loss of CD7 or CD26. (from AJCC 8th Ed.)","Mycosis Fungoides and Sezary Syndrome B0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336663","TPMT Gene","C21595","This gene plays a role in the metabolism of thiopurine drugs.","TPMT Gene | TPMT | Thiopurine S-Methyltransferase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539416","RISS Stage","C141392","A plasma cell myeloma stage defined according to the Revised International Staging System (RISS) criteria.","RISS Stage | Revised International Staging System Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539427","Revised International Staging System Stage IIII Plasma Cell Myeloma","C141396","Serum beta-2-microglobulin 5.5 mg/L or more and high-risk cytogenetics and/or high LDH. High risk cytogenetics consist of one or more of the following: del17p, t(4;14), or t(14;16). (from AJCC 8th Ed.)","RISS Stage III Multiple Myeloma | RISS Stage III Plasma Cell Myeloma | RISS Stage III Plasma Cell Myeloma | Revised International Staging System Stage IIII Plasma Cell Myeloma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539428","Revised International Staging System Stage II Plasma Cell Myeloma","C141395","Not stage I or III. (from AJCC 8th Ed.)","RISS Stage II Multiple Myeloma | RISS Stage II Plasma Cell Myeloma | RISS Stage II Plasma Cell Myeloma | Revised International Staging System Stage II Plasma Cell Myeloma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539429","Revised International Staging System Stage I Plasma Cell Myeloma","C141394","Serum beta-2-microglobulin less than 3.5 mg/L and serum albumin 3.5 g/dL or more and no high-risk cytogenetics and normal LDH. High risk cytogenetics consist of one or more of the following: del17p, t(4;14), or t(14;16). (from AJCC 8th Ed.)","RISS Stage I Multiple Myeloma | RISS Stage I Plasma Cell Myeloma | RISS Stage I Plasma Cell Myeloma | Revised International Staging System Stage I Plasma Cell Myeloma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242687","Early Intervention","C159524","A range of targeted services and supports that are available to babies and young children with developmental delays or specific health conditions.","Early Intervention | Early Intervention Services",,,,,,,,,,,,,,,"4313758","Provision of early intervention service for child",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL951422","Tissue Donor Eligibility","C159526","Determination that potential adult or cord blood donor does or does not possess risk factors for relevant communicable diseases (as defined by the FDA) and identified through screening, testing, physical evidence, and review of readily available relevant medical records.","Tissue Donor Eligibility | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951423","Tissue Donor Suitability","C159527","Determination that a potential donor is healthy and medically fit to proceed with the donation process.","Tissue Donor Suitability | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951424","Hematopoietic Cell Donor Eligibility","C159528","Determination that potential hematopoietic cell donor does or does not possess risk factors for relevant communicable diseases (as defined by the FDA) and identified through screening, testing, physical evidence, and review of readily available relevant medical records.","Hematopoietic Cell Donor Eligibility | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951425","Hematopoietic Cell Donor Suitability","C159529","Determination that a potential hematopoietic cell donor is healthy and medically fit to proceed with the donation process.","Hematopoietic Cell Donor Suitability | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951381","Bethesda Assay","C159543","An assay designed to standardize measurement of serum inhibitors of blood clotting in a factor VIII neutralization assay.","Bethesda Assay | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951382","Nijmegen-Bethesda Assay","C159544","A modification of the Bethesda Assay where the pH and the protein concentration of the test mixture is further standardized, such that the factor VIII coagulant activity (FVIII:C) in the test mixture is less prone to artifactual deterioration and the test has improved specificity.","Nijmegen-Bethesda Assay | Bethesda Assay with Nijmegen Modification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951388","One-Stage Clotting Factor Assay","C159550","A clotting factor assay where FVIII-deficient plasma is added to test plasma and the APTT reagent, mixed and incubated for 3-5 min. The mixture is then recalcified, and the coagulation time is recorded and compared to a standard curve.","One-Stage Clotting Factor Assay | One-Stage Clotting Assay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0373773","Chromogenic Substrate Clotting Factor Assay","C159552","A reagent containing purified coagulation factors (FIXa, FX and thrombin) in optimal concentrations is added to test plasma in the first stage, which does not rely on the extrinsic or intrinsic initiation pathways as the thrombin activates FVIII. The amount of FXa generated in the first stage is measured by its action on a specific chromogenic substrate, which releases a chromophore upon cleavage. The color intensity produced is directly proportional to the amount of FXa, which in turn is directly proportional to the FVIII activity in the sample.","Chromogenic Substrate Clotting Factor Assay | Chromogenic Substrate Assay",,,,,,,,,,,,,,,"4014031","Chromogenic substrate assay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL951390","Hemophilia Joint Health Score","C159553","A physiotherapist-administered assessment that measures the impact of recurrent bleeding on the elbows, knees, and ankles across 11 symptoms: swelling, duration of swelling, muscle atrophy, axial alignment, crepitus on motion, flexion loss, instability, joint pain, strength, and gait. Each of the 11 symptoms is rated on a Likert-style scale ranging from 1 to 4, with higher numbers indicating greater severity of symptoms. Scores from the individual items are added together to give a joint score, gait score, and a total score, with higher scores indicating greater joint damage.","Hemophilia Joint Health Score | HJHS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951391","Validated Hemophilia Regimen Treatment Adherence Scale - On-Demand","C159554","A standardized tool for evaluating adherence to episodic hemophilia treatment regimens. The tool consists of 24 questions presented as a 5-point Likert scale ranging from Always to Never. Total scores can range from 24 (most adherent) to 120 (least adherent), with subscores ranging from 1-4 in six categories: treat, time, dose, plan, remember, and communicate.","Validated Hemophilia Regimen Treatment Adherence Scale - On-Demand | VERITAS-PRN | Validated Hemophilia Regimen Treatment Adherence Scale - On-Demand (VERITAS-PRN)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951392","Validated Hemophilia Regimen Treatment Adherence Scale - Prophylaxis","C159555","A standardized tool for evaluating adherence to hemophilia prophylaxis, consisting of 24 questions utilizing 5-point Likert scales, with total scores ranging from 24 (most adherent) to 120 (least adherent). In addition to producing a total adherence score, questions are divided into six subscales (time, dose, plan, remember, skip, and communicate) to delineate the areas of nonadherence.","Validated Hemophilia Regimen Treatment Adherence Scale - Prophylaxis | VERITAS-Pro | Validated Hemophilia Regimen Treatment Adherence Scale - Prophylaxis (VERITAS-Pro)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951398","HAL","C159561","A disease-specific, self- or proxy-administered questionnaire that includes 53 multiple-choice items across seven domains: sitting/kneeling/standing, functions of the legs, functions of the arms, use of transportation, self-care, household tasks, and leisure activities and sports. Each item is rated on a 6-point Likert scale that ranges from 1 (impossible) to 6 (never), describing difficulty due to hemophilia in the past month. Scores from individual items can be summed to give a total score or component scores for upper extremity, basic lower extremity, and complex lower extremity activities. Higher scores indicate greater functional status.","Hemophilia Activities List | HAL | Haemophilia Activities List | Haemophilia Activities List | Haemophilia Activities List (HAL)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951577","Paediatric Haemophilia Activities List","C159574","An adapted version of the Haemophilia Activities List designed to assess the impact of hemophilia on a child's activities of daily living. The questionnaire consists of  53 multiple-choice items across seven domains: sitting/kneeling/standing, functions of the legs, functions of the arms, use of transportation, self-care, household tasks, and leisure activities and sports. A parent/proxy is designed for children ages 4-8) and a self-administered version for children ages 8-18.","Paediatric Haemophilia Activities List | Paediatric Haemophilia Activities List (PedHAL) | PedHAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4278463","Emicizumab","C159541","A humanized, immunoglobulin G4 (IgG4), bispecific monoclonal antibody against both the activated coagulation factor IX (FIXa) and factor X (FX) that can be used for the treatment of hemophilia A (HA). Upon administration, emicizumab targets and binds to both the FIXa and to FX, thereby bridging FIXa and FX, activating FX, and allowing for the activation and continuation of the coagulation cascade. FX is normally activated by coagulation factor VIII (FVIII); FVIII is missing in HA patients.","Emicizumab | ACE 910 | ACE-910 | ACE910 | EMICIZUMAB | Emicizumab-kxwh | Hemlibra | Immunoglobulin G4-kappa, Bispecific, Anti-(Homo sapiens F9a (Activated Coagulation Factor F9, Activated Coagulation Factor IX) and Anti-(Homo sapiens F10 (Coagulation Factor 10, Coagulation Factor X)), Humanized Monoclonal Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935963","With Tumor","C156849","There is evidence of a tumor in an individual.","With Tumor | WT-With Tumor | With tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935966","Tumor Free","C156848","There is no evidence of a tumor in the individual.","Tumor Free | TF-Tumor Free | Tumor free",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951562","Response Evaluation Criteria In Lymphoma 2017","C159617","The 2017 update to an international-consensus set of response criteria for lymphoma first established in 1999. These guidelines were refined in 2007 to incorporate assessment of tumor metabolism by [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) and further refined in 2017 to incorporate a scoring system to enhance the reproducibility of the interpretation and reporting of FDG-PET results, and to update the recommended procedures for staging evaluation.","Response Evaluation Criteria In Lymphoma 2017 | RECIL | RECIL 2017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951563","RECIL CR","C159618","Complete disappearance of all target lesions and all nodes with long axis less than10mm; greater than or equal to 30 percent decrease in the sum of longest diameters of target lesions (partial response) with normalization of FDG-PE.","RECIL CR | CR | Complete Response | RECIL Complete Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951710","RECIL PR","C159619","Greater than or equal to 30 percent decrease in the sum of longest diameters of target lesions but not a complete response.","RECIL PR | PR | Partial Response | RECIL Partial Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951706","RECIL MR","C159620","Greater than or equal to 10 percent decrease in the sum of longest diameters of target lesions but not a partial response.","RECIL MR | MR | Minor Response | RECIL Minor Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951709","RECIL SD","C159621","Less Than 10 percent decrease or less than or equal to 20 percent increase in the sum of longest diameters of target lesions.","RECIL SD | RECIL Stable Disease | SD | Stable Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951717","RECIL PD","C159622","Greater than 20 percent increase in the sum of longest diameters of target lesions; For small lymph nodes measuring less than15 mm post therapy, a minimum absolute increase of 5 mm and the long diameter should exceed 15 mm; Appearance of a new lesion.","RECIL PD | PD | Progressive Disease | RECIL Progressive Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015674","Chronic Fatigue Syndrome","C3037","A syndrome of unknown etiology. Chronic fatigue syndrome (CFS) is a clinical diagnosis characterized by an unexplained persistent or relapsing chronic fatigue that is of at least six months' duration, is not the result of ongoing exertion, is not substantially alleviated by rest, and results in substantial reduction of previous levels of occupational, educational, social, or personal activities. Common concurrent symptoms of at least six months duration include impairment of memory or concentration, diffuse pain, sore throat, tender lymph nodes, headaches of a new type, pattern, or severity, and nonrestorative sleep. The etiology of CFS may be viral or immunologic. Neurasthenia and fibromyalgia may represent related disorders. Also known as myalgic encephalomyelitis.","Chronic Fatigue Syndrome | Myalgic Encephalomyelitis | Myalgic encephalomyelitis/chronic fatigue syndrome | chronic fatigue syndrome",,,,,,,,,,,,,,,"432738","Chronic fatigue syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1429678","Nucleolysin TIA-1 Isoform p40, Human","C127899","Nucleolysin TIA-1 isoform p40 (386 aa, ~43 kDa) is encoded by the human TIA1 gene. This protein is involved in RNA binding, alternative splicing, translational regulation and nucleolysis.","Nucleolysin TIA-1 Isoform p40 | P40-TIA-1 | RNA-Binding Protein TIA-1 | T-Cell-Restricted Intracellular Antigen-1 | TIA-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0087050","T-Cell Receptors delta-Chain","C26429","One component of the gamma-delta T-cell receptor. Encoded by a locus on chromosome 14. Somatic recombination results in formation of the active gene.","T-Cell Receptor Delta Chain | T-Cell Receptor Delta | TCRD | TRD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0913648","T-box 21 protein, human","C104250","T-box transcription factor TBX21 (535 aa, ~58 kDa) is encoded by the human TBX21 gene. This protein is involved in the regulation of interferon-gamma gene expression.","T-Box Transcription Factor TBX21 | T-Box Expressed In T Cells | T-Box Protein 21 | T-Cell-Specific T-Box Transcription Factor T-Bet | TBX21 | Transcription Factor TBLYM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0135710","PDCD1 protein, human","C94697","Programmed cell death protein 1 (288 aa, ~32 kDa) is encoded by the human PDCD1 gene. This protein is involved in the regulation of apoptosis.","Programmed Cell Death Protein 1 | Antigen CD279 | CD279 | CD279 Antigen | PD1 | PDCD1 | Protein PD-1 | hPD-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1570399","Inducible T-Cell Costimulator, Human","C94803","Inducible T-cell costimulator (199 aa, ~23 kDa) is encoded by the human ICOS gene. This protein is involved in the regulation of T-cell antigen-mediated responses.","Inducible T-Cell Costimulator | Activation-Inducible Lymphocyte Immunomediatory Molecule | Antigen CD278 | CD278 | CD278 Antigen | ICOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0061878","Granzyme B","C104268","Granzyme B (247 aa, ~28 kDa) is encoded by the human GZMB gene. This protein plays a role in the mediation of cell-dependent cytotoxicity.","Granzyme B | C11 | CTLA-1 | CTSGL1 | Cathepsin G-Like 1 | Cytotoxic Serine Protease B | Cytotoxic T-Lymphocyte Proteinase 2 | Cytotoxic T-Lymphocyte-Associated Serine Esterase 1 | EC 3.4.21.79 | Fragmentin | Fragmentin-2 | GZMB | Granzyme 2 | Granzyme-2 | HLP | Human Lymphocyte Protein | Lymphocyte Protease | SECT | T-Cell Serine Protease 1-3E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1307598","Trans-Acting T-Cell-Specific Transcription Factor GATA-3, Human","C75494","Trans-acting T-cell-specific transcription factor GATA-3 (443 aa, ~48 kDa) is encoded by the human GATA3 gene. This protein plays a role in transcription.","Trans-Acting T-Cell-Specific Transcription Factor GATA-3 | Enhancer-Binding Protein GATA3 | GATA Binding Factor 3 | GATA-3 | GATA-Binding Factor 3 | GATA-Binding Protein 3 | GATA3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1504708","60S Ribosomal Protein L22, Human","C97763","60S ribosomal protein L22 (128 aa, ~15 kDa) is encoded by the human RPL22 gene. This protein is involved in the mediation of translation.","60S Ribosomal Protein L22 | EAP | EBER-Associated Protein | Epstein-Barr Virus Small RNA-Associated Protein | Heparin-Binding Protein HBp15 | RPL22",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0056184","Complement Receptor Type 2","C104979","Complement receptor type 2 (1033 aa, ~113 kDa) is encoded by the human CR2 gene. This protein plays a role in the activation of complement-mediated immunity.","Complement Receptor Type 2 | CD21 | CD21 Antigen | CR2 | Complement C3d Receptor | Cr2 | EBV Receptor | Epstein-Barr Virus Receptor",,,,,,,,,,,,,,,"4051918","Lymphocyte antigen CD21",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1438056","C-C Chemokine Receptor Type 4, Human","C129067","C-C chemokine receptor type 4 (360 aa, ~41 kDa) is encoded by the human CCR4 gene. This protein is involved in leukocyte chemotaxis.","C-C Chemokine Receptor Type 4 | C-C CKR-4 | CC Chemokine Receptor 4 | CC-CKR-4 | CCR-4 | CCR4 | CD194 Antigen | K5-5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517677","Bone Marrow Involvement","C8288","Infiltration of the bone marrow by a malignant neoplasm.","Bone Marrow Involvement | Marrow Involvement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511242","Bone Marrow Flow Cytometry","C38063","Flow cytometry using cells derived from a bone marrow sample.","Bone Marrow Flow Cytometry | Bone Marrow Cytometry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511221","Blood Flow Cytometry","C38062","Flow cytometry used to examine and quantitate the constituents of the blood.","Blood Flow Cytometry | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562975","HD Methotrexate-Leucovorin","C156264","A regimen consisting of high-dose methotrexate and leucovorin that can potentially be used for the treatment of various central nervous system (CNS) cancers and various types of lymphoma.","Leucovorin/High-dose Methotrexate Regimen | HD Methotrexate-Leucovorin | HD Methotrexate/Leucovorin | HD-MTX-LCV | High-Dose Methotrexate/Leucovorin | High-dose Methotrexate/Leucovorin Regimen | High-dose Methotrexate/Leucovorin Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951510","Modified Severity Weighted Assessment Tool","C159687","A clinical measurement tool for measuring skin tumor burden in mycosis fungoides (MF) and Sezary syndrome (SS). It involves determining the percentage of body surface area (BSA) covered by patch, plaque, or tumor of MF/SS, then multiplying each lesion BSA by a factor that gives gradations of weight to patch versus plaque versus tumor and summing these scores. The change in mSWAT from the beginning of treatment can be used to assess overall response.","Modified Severity Weighted Assessment Tool | Modified Severity Weighted Assessment Tool - mSWAT | mSWAT",,,,,,,,,,,,,,,"3655524","modified Severity Weighted Assessment Tool",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL951394","DHAX Regimen","C159557","A regimen consisting of dexamethasone, cytarabine and oxaliplatin that can be used to treat relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) and T-cell lymphoma and mycosis fungoides/Sezary syndrome.","DHAX Regimen | DHA-Ox | DHA-Oxaliplatin | DHA-Oxaliplatin Regimen | DHAX | Dexamethasone/Cytarabine/Oxaliplatin | Dexamethasone/Cytarabine/Oxaliplatin Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951395","CHP-Brentuximab Vedotin Regimen","C159558","A regimen consisting of brentuximab vedotin, cyclophosphamide, doxorubicin and prednisone that can be used to treat T-cell lymphomas, primary cutaneous CD30+ T-cell lymphoproliferative disorders and post-transplant lymphoproliferative disorders.","CHP-Brentuximab Vedotin Regimen | BV-CHP | BV-CHP Regimen | Brentuximab Vedotin with CHP | Brentuximab Vedotin with CHP Regimen | Brentuximab Vedotin/Cyclophosphamide/Doxorubicin/Prednisone | Brentuximab Vedotin/Cyclophosphamide/Doxorubicin/Prednisone Regimen | CHP-BV | CHP-Brentuximab Vedotin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951397","GELOX Regimen","C159560","A regimen consisting of gemcitabine, oxaliplatin and asparaginase that can be used to treat extranodal natural killer (NK)/T-cell lymphoma.","GELOX Regimen | GELOX | Gemcitabine/Asparaginase/Oxaliplatin | Gemcitabine/Asparaginase/Oxaliplatin Regimen | Gemcitabine/L-asparaginase/Oxaliplatin | Gemcitabine/L-asparaginase/Oxaliplatin Regimen | Gemcitabine/Oxaliplatin/Asparaginase | Gemcitabine/Oxaliplatin/Asparaginase Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2363744","EBV-Related Lymphoproliferative Disorder","C159717","A lymphoproliferative disorder associated with Epstein-Barr virus. This category includes, but is not limited to, Burkitt lymphoma, classic Hodgkin lymphoma, and lymphomas arising in immunocompromised individuals.","EBV-Related Lymphoproliferative Disorder | EBV Lymphoproliferation | Epstein-Barr Virus-Associated Lymphoproliferative Disorder | Epstein-Barr Virus-Related Lymphoproliferative Disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL421192","Modulation","C90063","To adjust, or change.","Modulation | Modulated | Modulating | modulate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951693","How Many Places Lived with Child","C159725","A question about the number of places an individual has lived with their child.","How Many Places Lived with Child | How many places have you and your child lived in the past year",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987057","Defined Medical Condition Result","C95332","A medical condition that has a concise explanation of the meaning of term.","Defined Medical Condition Result | DefinedMedicalConditionResult",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555448","Reporting Source Type Code","C154672","A coded value specifying the kind of medical record that provided the best information when abstracting the relevant healthcare data.","Reporting Source Type Code | reportingSourceTypeCode",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503796","Behavior Assessment System for Children, Third Edition","C126685","A comprehensive set of rating scales designed to facilitate the differential diagnosis and classification of a variety of emotional and behavioral disorders of children, aid in the design of treatment plans, and provide insight into an individual's thoughts and feelings. Version three incorporates additional questionnaires, scales and forms.","Behavior Assessment System for Children, Third Edition | BASC-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951697","Utility Company Threatened to Shut Off Services for not Paying Bills","C159729","A question about whether an individual has utility companies threatening to cut off service due to not paying bills.","Utility Company Threatened to Shut Off Services for not Paying Bills | Has the gas/electric/oil company sent you a letter threatening to shut off or not deliver the gas/electricity/oil to the house for not paying bills",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951698","Utility Company Shut Off Services for not Paying Bills","C159730","A question about whether an individual had utility companies cut off service due to not paying bills.","Utility Company Shut Off Services for not Paying Bills | Has  the gas/electric/oil company shut off electricity/gas or refused to deliver oil for not paying bills | Has the gas/electric/oil company shut off electricity/gas or refused to deliver oil for not paying bills",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951643","Days Home Not Heated or Cooled Because Bills Not Paid","C159731","A question about whether an individual did not heat or cool their home because they did not pay the bills.","Days Home Not Heated or Cooled Because Bills Not Paid | Were there any days that your home was not heated/cooled because you couldn't pay the bills",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951644","Used Cooking Stove to Heat Home Because Bills Not Paid","C159732","A question about whether an individual used a cooking stove to heat their home because they did not pay the bills.","Used Cooking Stove to Heat Home Because Bills Not Paid | Have you had to use a cooking stove to heat your home because you couldn't pay the bills",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951645","Telephone Service Disconnected Due to Bill Not Paid","C159733","A question about whether an individual's phone service was cut off due to not paying bills.","Telephone Service Disconnected Due to Bill Not Paid | Did you have service disconnected on your telephone (including cell phones) because you couldn't pay the bill",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951647","Food Bought Didn't Last and Didn't Have Money to Get More","C159735","A question about whether an individual's food didn't last and didn't have money to get more.","Food Bought Didn't Last and Didn't Have Money to Get More | The food that we bought just didn't last, and we didn't have money to get more",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951648","If Lose Current Income Sources and Live Off Savings, How Long Could Continue to Live at Current Address and Standard of Living","C159736","A question about how long an individual could live at their current address and standard of living if they lost their income source and lived off of savings.","If Lose Current Income Sources and Live Off Savings, How Long Could Continue to Live at Current Address and Standard of Living | If you lost all of your current sources of income and had to live off of your savings, how long could you continue to live at your current address and standard of living",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951649","Family Received Food from Food Pantry or Soup Kitchen","C159737","A question about whether a family received food from a food pantry or soup kitchen.","Family Received Food from Food Pantry or Soup Kitchen | Did your family receive food from a food pantry (sometimes called a food bank or soup kitchen)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951650","Family Received Energy Assistance","C159738","A question about whether a family received any energy assistance or discounts.","Family Received Energy Assistance | Did your family receive any energy assistance (discounted gas/electric bills such as LIHEAP or utility discounts)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951651","Family Received Disability Benefits","C159739","A question about whether a family received disability benefits.","Family Received Disability Benefits | Did your family receive Disability benefits (i.e. SSI, Supplemental Security Income)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951652","Family Received Low-Income or Subsidized Housing","C159740","A question about whether a family received low-income housing or subsidized housing.","Family Received Low-Income or Subsidized Housing | Did your family receive any low-income or subsidized housing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951653","Family Received Free or Subsidized School Lunch","C159741","A question about whether a family received free or subsidized school lunches.","Family Received Free or Subsidized School Lunch | Did your family receive free/subsidized school lunch",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951654","Family Received Income Support","C159742","A question about whether a family received income support, such as welfare or social assistance.","Family Received Income Support | Did your family receive income support (e.g. welfare or social assistance)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951655","Family Received Employment Insurance","C159743","A question about whether a family received employment insurance.","Family Received Employment Insurance | Did your family receive employment insurance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951656","Family Received Canada Child Benefit","C159744","A question about whether a family received Canada child benefit (CCB).","Family Received Canada Child Benefit | Did your family receive Canada Child Tax Credit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951657","Family Received Disability Tax Credit","C159745","A question about whether a family received disability tax credits.","Family Received Disability Tax Credit | Did your family receive Disability Tax Credit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0682187","college completed","C159746","Indicates that a person has attended college and receive a degree.","College Completion | College | College Degree | College Graduate | College graduate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0442516","Mobile Home","C159747","A dwelling on a trailer that that can be parked in one place, connected to utilities, and used as permanent housing.","Mobile Home | Mobile home",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951658","Rented Room","C159748","A room within a larger dwelling used as an individual living space in exchange for money.","Rented Room | Rented room",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951659","Shelter or Transitional Living Situation","C159749","Indicates that a person lives or lived in an emergency shelter or in transitional housing.","Shelter or Transitional Living Situation | Shelter or transitional living situation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951660","No Steady Place to Sleep at Night","C159750","Indicates that a person did not have a single fixed location to sleep each night.","No Steady Place to Sleep at Night | No steady place to sleep at night",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951661","Own Car","C159751","Transportation using a vehicle that is owned by the individual.","Own Car | Own car",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951662","Rides from Others","C159752","Getting rides from other people for transportation.","Rides from Others | Rides from others (friends or family)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951663","Volunteer Driving Program","C159753","A transportation service where volunteers provide rides.","Volunteer Driving Program | Volunteer driving program",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951664","Handicap Transportation Service","C159754","A transportation service directed to, or reserved for, handicapped individuals.","Handicap Transportation Service | Handibus (or other ride system)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951665","Can Do Very Well","C159755","An indication that someone can do something quite well.","Can Do Very Well | Very Well | Very Well",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3842451","Not True at All","C159756","A subjective response indicating that something is not at all true.","Not True at All | Not at All True | Not at all true | Not true at all",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951666","Rarely True","C159757","A subjective response indicating that something is rarely true.","Rarely True | Rarely true",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4036310","Sometimes True","C159758","A subjective response indicating that something is sometime true.","Sometimes True | Sometimes true",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL783663","Often True","C159759","A subjective response indicating that something is often true.","Often True | Often true",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951667","True Nearly All of the Time","C159760","A subjective response indicating that something is true nearly all of the time.","True Nearly All of the Time | True nearly all the time | Very true",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3845714","Several Days","C159761","A subjective response indicating that something is true or present several days.","Several Days | Several days",,,,,,,,,,,,,,,"763663","Several days",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL951622","True or Present More than Half the Days","C159763","A subjective response indicating that something is true or present more than half of the days.","True or Present More than Half the Days | More than Half of the Days | More than half the days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951668","True or Present Nearly Every Day","C159762","A subjective response indicating that something is true or present nearly every day.","True or Present Nearly Every Day | Nearly Every Day | Nearly everyday",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951694","Struggle with Rent or Mortgage Due to Financial Difficulties","C159726","A question about whether an individual struggled with rent or mortgage due to financial difficulties.","Struggle with Rent or Mortgage Due to Financial Difficulties Question | In the 6 months before your child's diagnosis, was there a time when you were not able to pay the rent or mortgage on time because of financial difficulties | Struggle with Rent or Mortgage Due to Financial Difficulties",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951695","Live with Others Due to Financial Difficulties","C159727","A question about whether an individual lived with others due to financial difficulties.","Live with Others Due to Financial Difficulties | In the 6 months before your child's diagnosis, did you and your child had to temporarily live with other people because of financial difficulties",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951696","Lack of Reliable Transportation Keeps from Appointments, Meetings, Work, or Daily Living","C159728","A question about whether an individual was unable to get to medical appointments, meetings, work, or getting things needed for daily living due to lack of reliable transportation.","Lack of Reliable Transportation Keeps from Appointments, Meetings, Work, or Daily Living Question | In the 6 months before your child's diagnosis, did lack of reliable transportation keep you or anyone in your family from medical appointments, meetings, work or getting things needed for daily living | Lack of Reliable Transportation Keeps from Appointments, Meetings, Work, or Daily Living | Lack of Reliable Transportation Keeps from Appointments, Meetings, Work, or Daily Living",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951604","International Myeloma Working Group Minimal Residual Disease Criteria","C159799","Uniform consensus criteria created by the International Myeloma Working Group to describe response to treatment for minimal residual disease.","International Myeloma Working Group Minimal Residual Disease Criteria | IMWG Minimal Residual Disease Criteria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951605","IMWG Sustained MRD-negative","C159800","Minimal residual disease negativity in the marrow, by next-generation flow cytometry or next-generation sequencing, or both, and by imaging, confirmed a minimum of 1 year apart.","IMWG Sustained MRD-negative | Sustained MRD-negative | Sustained Minimal Residual Disease Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951606","IMWG Flow MRD-negative","C159801","Absence of phenotypically aberrant clonal plasma cells by next-generation flow cytometry on bone marrow aspirates using the EuroFlow standard operation procedure for minimal residual disease detection in multiple myeloma (or validated equivalent method) with a minimum sensitivity of 1 in 10^5 nucleated cells or higher.","IMWG Flow MRD-negative | Flow MRD-negative | Flow Minimal Residual Disease-negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951607","IMWG Sequencing MRD-negative","C159802","Absence of clonal plasma cells by next-generation sequencing on bone marrow aspirate in which presence of a clone is defined as less than two identical sequencing reads obtained after DNA sequencing of bone marrow aspirates using the LymphoSIGHT platform (or validated equivalent method) with a minimum sensitivity of 1 in 10^5 nucleated cells or higher.","IMWG Sequencing MRD-negative | Sequencing MRD-negative | Sequencing Minimal Residual Disease-negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951608","IMWG Imaging plus MRD-negative","C159803","Minimal residual disease negativity as defined by next-generation flow cytometry or next-generation sequencing plus disappearance of every area of increased tracer uptake found at baseline or a preceding PET/CT or decrease to less mediastinal blood pool standard uptake value or decrease to less than that of surrounding normal tissue.","IMWG Imaging plus MRD-negative | Imaging plus MRD-negative | Imaging plus Minimal Residual Disease-negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951609","International Myeloma Working Group Standard Response Criteria","C159804","Uniform consensus criteria created by the International Myeloma Working Group to describe response to treatment.","International Myeloma Working Group Standard Response Criteria | IMWG Standard Response Criteria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951610","IMWG Stringent Complete Response","C159805","Complete response, plus normal free light chain ratio and absence of clonal cells in bone marrow biopsy by immune-histochemistry (kappa/lambda ratio less than or equal to 4:1 or greater than or equal to 1:2 for kappa and lambda patients, respectively, after counting at least 100 plasma cells).","IMWG Stringent Complete Response | Stringent Complete Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951611","IMWG Complete Response","C159806","Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and less than 5 percent plasma cells in bone marrow aspirates.","IMWG Complete Response | Complete Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951612","IMWG Very Good Partial Response","C159807","Serum and urine M-protein detectable by immunofixation but not on electrophoresis or at least 90 percent reduction in serum M-protein plus urine M-protein level less than 100 mg per 24 hours.","IMWG Very Good Partial Response | Very Good Partial Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951613","IMWG Partial Response","C159808","At least 50 percent reduction of serum M-protein plus reduction in 24 hour urinary M-protein by at least 90 percent or to less than 200 mg per 24 hour. If the serum and urine M-protein are unmeasurable, at least a 50 percent decrease in the difference between involved and uninvolved free light chain levels is required in place of the M-protein criteria. If serum and urine M-protein are unmeasurable, and serum-free light assay is also unmeasurable, at least a 50 percent reduction in plasma cells is required in place of M-protein, provided baseline bone marrow plasma-cell percentage was at least 30 percent. In addition to these criteria, if present at baseline, at least 50 percent reduction in the size (sum of products of diameters) of soft tissue plasmacytomas is also required.","IMWG Partial Response | Partial Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951614","IMWG Minimal Response","C159809","At least 25 percent but less than 50 percent reduction of serum M-protein and reduction in 24-hour urine M-protein by 50-89 percent. In addition to the above listed criteria, if present at baseline, at least a 50 percent reduction in the size (sum of products of diameters) of soft tissue plasmacytomas is also required.","IMWG Minimal Response | Minimal Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951615","IMWG Stable Disease","C159810","Not recommended for use as an indicator of response. Stability of disease is best described by providing the time-to-progression estimates. Not meeting criteria for complete response, very good partial response, partial response, minimal response, or progressive disease.","IMWG Stable Disease | Stable Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951616","IMWG Progressive Disease","C159811","Any one or more of the following criteria: increase of 25 percent from lowest confirmed response value in one or more of the following criteria: serum M-protein (absolute increase must be at least 0.5 g/dL); serum M-protein increase at least 1 g/dL, if the lowest M component was at least 5 g/dL; urine M-protein (absolute increase must be at least 200 mg/24 h); in patients without measurable serum and urine M-protein levels, the difference between involved and uninvolved free light chain levels (absolute increase must be greater than 10 mg/dL); in patients without measurable serum and urine M-protein levels and without measurable involved free light chain levels, bone marrow plasma-cell percentage irrespective of baseline status (absolute increase must be at least 10 percent); appearance of a new lesion(s), at least 50 percent increase from nadir in sum of products of diameters of greater than 1 lesion, or at least 50 percent increase in the longest diameter of a previous lesion greater than 1 cm in short axis; at least 50 percent increase in circulating plasma cells (minimum of 200 cells per uL) if this is the only measure of disease.","IMWG Progressive Disease | Progressive Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708397","Hydroa Vacciniforme Lymphoproliferative Disorder","C45327","A rare, EBV-positive cutaneous T-cell lymphoproliferative disorder, composed of CD8 positive cytotoxic T-lymphocytes.  It affects children, almost exclusively in Latin America and Asia. Patients present with papulovesicular skin lesions, clinically resembling hydroa vacciniforme, in areas of sun-exposed skin.","Hydroa Vacciniforme Lymphoproliferative Disorder | HV LPD | HV-LPD | HV-Like LPD | HV-Like Lymphoma | Hydroa Vacciniforme-Like Cutaneous T-Cell Lymphoma | Hydroa Vacciniforme-Like Lymphoma | Hydroa Vacciniforme-Like Lymphoproliferative Disorder | Hydroa Vacciniforme-Like Lymphoproliferative Disorder | Hydroa vacciniforme-like lymphoma",,,,,,,,,,,,,,,"35622312|37311489|42872912|607419","Hydroa vacciniforme-like lymphoma|Hydroa vacciniforme-like lymphoproliferative disorder|Hydroa vacciniforme-like lymphoma|Hydroa vacciniforme-like cutaneous T-cell lymphoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--|--"
"C1334841","Myeloblasts 20 Percent or More of Bone Marrow Nucleated Cells","C36231","A semi-quantitative microscopic finding indicating that at least 20 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells of myeloid origin.","Myeloblasts 20 Percent or More of Bone Marrow Nucleated Cells | Myeloblasts 20% or More of Bone Marrow Nucleated Cells | Myeloblasts Greater than or Equal to 20 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334842","Myeloblasts 20 Percent or More of Peripheral Blood White Cells","C36232","A semi-quantitative microscopic finding indicating that at least 20 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells of myeloid origin.","Myeloblasts 20 Percent or More of Peripheral Blood White Cells | Myeloblasts 20% or More of Peripheral Blood White Cells | Myeloblasts Greater than or Equal to 20 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951627","Testosterone Greater than or Equal to 150 ng/dL","C159774","A semiquantitative finding indicating that the concentration of testosterone in a sample is greater than or equal to 150 ng/dL.","Testosterone Greater than or Equal to 150 ng/dL | Testosterone Greater than or Equal to 150 Nanograms per Deciliter | Testosterone Greater than or Equal to 150 Nanograms/Deciliter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951629","PSA Level Twenty to One Hundred Fifty","C159777","A blood concentration of prostate specific antigen between 20 ng/mL and 150 ng/mL.","PSA Level Twenty to One Hundred Fifty | PSA Level 20 to 150 | PSA Level Between 20 and 150 | PSA Level Between Twenty and One Hundred Fifty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413770","CST1 Gene","C159784","This gene plays a role in cysteine proteinase inhibition in saliva and other tissues.","CST1 Gene | CST1 | Cystatin SN Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413771","CST2 Gene","C159788","This gene plays a role in cysteine proteinase inhibition in submandibular and sublingual saliva.","CST2 Gene | CST2 | Cystatin SA Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413773","CST4 Gene","C159791","This gene plays a role in the inhibition of cysteine proteinases in the saliva, tears, urine and seminal fluid.","CST4 Gene | CST4 | Cystatin S Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413774","CST5 Gene","C159794","This gene is involved in the inhibition of cathepsins in the oral cavity.","CST5 Gene | CST5 | Cystatin D Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951630","Fanconi Anemia Complementation Group Gene Mutation Negative","C159778","A genetic finding indicating that Fanconi anemia complementation group gene mutations have not been detected in a sample.","Fanconi Anemia Complementation Group Gene Mutation Negative | FA Complementation Group Gene Mutation Negative | FA Complementation Group Gene Wild-Type | FA/BRCA Pathway Gene Wild-Type | FANC Family Gene Mutation Negative | FANC Gene Mutation Negative | FANC Wild-Type | FANC Wildtype | FANC wt | Fanconi Anemia Complementation Family Gene Mutation Negative | Fanconi Anemia Complementation Group Wild-Type | Fanconi Anemia Group Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951621","Healthcare Device Direct Feed Reporting","C159821","An indication that vital sign data came directly from a device in a healthcare facility.","Healthcare Device Direct Feed Reporting | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951631","PALB2 Gene Mutation Negative","C159779","A genetic finding indicating that PALB2 gene mutations have not been detected in a sample.","PALB2 Gene Mutation Negative | FANCN Gene Mutation Negative | Fanconi Anemia, Complementation Group N Gene Mutation Negative | PALB2 Gene Wild-Type | PALB2 Wild-Type | PALB2 Wildtype | PALB2 wt | PNCA3 Gene Mutation Negative | Partner and Localizer of BRCA2 Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951632","BRIP1 Gene Mutation Negative","C159780","A genetic finding indicating that BRIP1 gene mutations have not been detected in a sample.","BRIP1 Gene Mutation Negative | BACH1 Gene Mutation Negative | BRCA1 Interacting Protein C-Terminal Helicase 1 Gene Mutation Negative | BRIP1 Gene Wild-Type | BRIP1 Wild-Type | BRIP1 Wildtype | BRIP1 wt | FANCJ Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951633","FANCL Gene Mutation Negative","C159781","A genetic finding indicating that FANCL gene mutations have not been detected in a sample.","FANCL Gene Mutation Negative | FAAP43 Gene Mutation Negative | FACL Gene Mutation Negative | FANCL Gene Wild-Type | FANCL Wild-Type | FANCL Wildtype | FANCL wt | Fanconi Anemia Complementation Group L Gene Mutation Negative | Fanconi Anemia, Complementation Group L Gene Mutation Negative | PHD Finger Protein 9 Gene Mutation Negative | PHF9 Gene Mutation Negative | POG Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951634","RAD51 Gene Mutation Negative","C159782","A genetic finding indicating that RAD51 gene mutations have not been detected in a sample.","RAD51 Gene Mutation Negative | BRCC5 Gene Mutation Negative | FANCR Gene Mutation Negative | HRAD51 Gene Mutation Negative | HsRad51 Gene Mutation Negative | RAD51 Gene Wild-Type | RAD51 Homolog (S. cerevisiae) Gene Mutation Negative | RAD51 Recombinase Gene Mutation Negative | RAD51 Wild-Type | RAD51 Wildtype | RAD51 wt | RAD51, S. cerevisiae, Homolog of A Gene Mutation Negative | RAD51A Gene Mutation Negative | RECA Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951635","ATM Gene Mutation Negative","C159783","A genetic finding indicating that ATM gene mutations have not been detected in a sample.","ATM Gene Mutation Negative | A-T Mutated Gene Mutation Negative | AT Mutated Gene Mutation Negative | ATM Gene Wild-Type | ATM Serine/Threonine Kinase Gene Mutation Negative | ATM Wild-Type | ATM Wildtype | ATM wt | Ataxia Telangiectasia Mutated Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950963","Testosterone Greater than 200 ng/dL","C158959","A semiquantitative finding indicating that the concentration of testosterone in a sample is greater than 200 ng/dL.","Testosterone Greater than 200 ng/dL | Testosterone Greater than 200 Nanograms per Deciliter | Testosterone Greater than 200 Nanograms/Deciliter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950714","SOX11 Positive","C158748","An indication that SOX11 expression has been detected in a sample.","SOX11 Positive | SOX-11 Positive | SRY Box 11 Positive | SRY-Box 11 Positive | SRY-Related HMG-Box 11 Positive | Sex-Determining Region Y-Box 11 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950698","GRPR Overexpression Positive","C158729","An indication that overexpression of GRPR has been detected in a sample.","GRPR Overexpression Positive | BB2 Overexpression Positive | BB2R Overexpression Positive | Bombesin Receptor 2 Overexpression Positive | GRPR Overexpression | Gastrin Releasing Peptide Receptor Overexpression Positive | Gastrin-Releasing Peptide Receptor Overexpression Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1504344","Hepatitis B Antigen Positive","C158737","An indication that hepatitis B antigens have been detected in a sample.","Hepatitis B Antigen Positive | HBV Antigen Positive | Hepatitis B Viral Antigen Positive | Hepatitis B Virus Antigen Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950998","PSA Level Greater than One Hundred Fifty","C158931","A blood concentration of prostate specific antigen greater than 150 ng/mL.","PSA Level Greater than One Hundred Fifty | PSA Level Greater than 150 | PSA Level Greater than One Hundred and Fifty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951031","ESR2 Positive","C159159","An indication that expression of ESR2 has been detected in a sample.","ESR2 Positive | ER Beta Positive | ER-Beta Positive | ERB Positive | ESR-Beta Positive | ESRB Positive | ESTRB Positive | Estrogen Receptor 2 Positive | Estrogen Receptor Beta Positive | NR3A2 Positive | Nuclear Receptor Subfamily 3 Group A Member 2 Positive | Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951219","Homologous Recombination Repair Proficient","C159228","A finding indicating that a sample exhibits normal or near normal levels of homologous recombination DNA repair activity.","Homologous Recombination Repair Proficient | HR Proficient | HR-Deficiency Negative | HR-Proficient | HRD Negative | HRD-Proficient | HRR Proficient | Homologous Recombination Repair Deficiency Negative | Homologous Recombination Repair Proficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951415","SLAMF7 Positive","C159517","An indication that SLAMF7 expression has been detected in a sample.","SLAMF7 Positive | 19A Positive | CD319 Positive | CRACC Positive | CS1 Positive | SLAM Family Member 7 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951280","EGFR NP_005219.2:p.R108K","C159422","A change in the amino acid residue at position 108 in the epidermal growth factor receptor protein where arginine has been replaced by lysine.","EGFR NP_005219.2:p.R108K | Activating R108K Mutation | EGFR Arg108Lys | EGFR NP_005219.2:p.Arg108Lys | EGFR R108K | EGFR R108K Mutation | EGFR p.Arg108Lys | EGFR p.R108K | Epidermal Growth Factor Receptor Arg108Lys | Epidermal Growth Factor Receptor R108K | NP_005219.2:p.Arg108Lys | NP_005219.2:p.R108K | Proto-Oncogene c-ErbB-1 Arg108Lys | Proto-Oncogene c-ErbB-1 R108K | Receptor Tyrosine-Protein Kinase erbB-1 Arg108Lys | Receptor Tyrosine-Protein Kinase erbB-1 R108K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951282","EGFR NP_005219.2:p.T263P","C159424","A change in the amino acid residue at position 263 in the epidermal growth factor receptor protein where threonine has been replaced by proline.","EGFR NP_005219.2:p.T263P | EGFR NP_005219.2:p.Thr263Pro | EGFR T263P | EGFR T263P Mutation | EGFR Thr263Pro | EGFR p.T263P | EGFR p.Thr263Pro | Epidermal Growth Factor Receptor T263P | Epidermal Growth Factor Receptor Thr263Pro | NP_005219.2:p.T263P | NP_005219.2:p.Thr263Pro | Proto-Oncogene c-ErbB-1 T263P | Proto-Oncogene c-ErbB-1 Thr263Pro | Receptor Tyrosine-Protein Kinase erbB-1 T263P | Receptor Tyrosine-Protein Kinase erbB-1 Thr263Pro",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951284","EGFR NP_005219.2:p.A289V","C159427","A change in the amino acid residue at position 289 in the epidermal growth factor receptor protein where alanine has been replaced by valine.","EGFR NP_005219.2:p.A289V | Activating A289V Mutation | EGFR A289V | EGFR A289V Mutation | EGFR Ala289Val | EGFR NP_005219.2:p.Ala289Val | EGFR p.A289V | EGFR p.Ala289Val | Epidermal Growth Factor Receptor A289V | Epidermal Growth Factor Receptor Ala289Val | NP_005219.2:p.A289V | NP_005219.2:p.Ala289Val | Proto-Oncogene c-ErbB-1 A289V | Proto-Oncogene c-ErbB-1 Ala289Val | Receptor Tyrosine-Protein Kinase erbB-1 A289V | Receptor Tyrosine-Protein Kinase erbB-1 Ala289Val",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951286","EGFR NP_005219.2:p.A289D","C159429","A change in the amino acid residue at position 289 in the epidermal growth factor receptor protein where alanine has been replaced by aspartic acid.","EGFR NP_005219.2:p.A289D | EGFR A289D | EGFR A289D Mutation | EGFR Ala289Asp | EGFR NP_005219.2:p.Ala289Asp | EGFR p.A289D | EGFR p.Ala289Asp | Epidermal Growth Factor Receptor A289D | Epidermal Growth Factor Receptor Ala289Asp | NP_005219.2:p.A289D | NP_005219.2:p.Ala289Asp | Proto-Oncogene c-ErbB-1 A289D | Proto-Oncogene c-ErbB-1 Ala289Asp | Receptor Tyrosine-Protein Kinase erbB-1 A289D | Receptor Tyrosine-Protein Kinase erbB-1 Ala289Asp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951288","EGFR NP_005219.2:p.A289T","C159431","A change in the amino acid residue at position 289 in the epidermal growth factor receptor protein where alanine has been replaced by threonine.","EGFR NP_005219.2:p.A289T | Activating A289T Mutation | EGFR A289T | EGFR A289T Mutation | EGFR Ala289Thr | EGFR NP_005219.2:p.Ala289Thr | EGFR p.A289T | EGFR p.Ala289Thr | Epidermal Growth Factor Receptor A289T | Epidermal Growth Factor Receptor Ala289Thr | NP_005219.2:p.A289T | NP_005219.2:p.Ala289Thr | Proto-Oncogene c-ErbB-1 A289T | Proto-Oncogene c-ErbB-1 Ala289Thr | Receptor Tyrosine-Protein Kinase erbB-1 A289T | Receptor Tyrosine-Protein Kinase erbB-1 Ala289Thr",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951290","EGFR NP_005219.2:p.G598V","C159433","A change in the amino acid residue at position 598 in the epidermal growth factor receptor protein where glycine has been replaced by valine.","EGFR NP_005219.2:p.G598V | Activating G598V Mutation | EGFR G598V | EGFR G598V Mutation | EGFR Gly598Val | EGFR NP_005219.2:p.Gly598Val | EGFR p.G598V | EGFR p.Gly598Val | Epidermal Growth Factor Receptor G598V | Epidermal Growth Factor Receptor Gly598Val | NP_005219.2:p.G598V | NP_005219.2:p.Gly598Val | Proto-Oncogene c-ErbB-1 G598V | Proto-Oncogene c-ErbB-1 Gly598Val | Receptor Tyrosine-Protein Kinase erbB-1 G598V | Receptor Tyrosine-Protein Kinase erbB-1 Gly598Val",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951291","EGFR Exon 20 Deletion Mutation","C159434","A molecular genetic abnormality indicating the presence of an in-frame deletion mutation occurring within exon 20 of the EGFR gene.","EGFR Exon 20 Deletion Mutation | EGFR Exon 20 Gene Deletion Mutation | ERBB Exon 20 Deletion Mutation | ERBB1 Exon 20 Deletion Mutation | Epidermal Growth Factor Receptor Gene Exon 20 Deletion Mutation | HER1 Exon 20 Deletion Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950979","High Neoplasm Polygenic Risk Score","C158976","A polygenic risk score value that indicates that an individual patient is likely to develop a specified neoplastic disease in their lifetime.","High Neoplasm Polygenic Risk Score | High PRS | High Polygenic Risk Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950980","Low Neoplasm Polygenic Risk Score","C158977","A polygenic risk score value that indicates that an individual patient is unlikely to develop a specified neoplastic disease in their lifetime.","Low Neoplasm Polygenic Risk Score | Low PRS | Low Polygenic Risk Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951541","PSCA Positive","C159656","An indication that PSCA expression has been detected in a sample.","PSCA Positive | PRO232 Positive | Prostate Stem Cell Antigen Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968993","Aberrant Clonal Plasma Cell Population","C159854","A population of plasma cells which display atypical morphological features, an abnormal immunophenotypic profile, and molecular genetic characteristics of clonality (monoclonality).","Aberrant Clonal Plasma Cell Population | Aberrant Clonal Plasma Cells | Abnormal Clonal Plasma Cell Population",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968973","Usually Stay on Top of Things","C159827","A question about whether an individual and their family is able to stay on top of things.","Usually Stay on Top of Things Question | Usually Stay on Top of Things | Usually Stay on Top of Things | We are usually able to stay on top of things",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968972","Home is a Zoo","C159828","A question about whether an individual's home is or was like a zoo.","Home is a Zoo | It's a real zoo in our home",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968971","Can't Hear Yourself Think at Home","C159829","A question about whether you can hear yourself think in an individual's home.","Can't Hear Yourself Think at Home | You can't hear yourself think in our home",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968970","Usually a Television is On","C159830","A question about whether there is usually a television turned on in an individual's home.","Usually a Television is On | There is usually a television turned on somewhere in our home",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968969","Home Atmosphere is Calm","C159831","A question about whether an individual's home atmosphere is calm.","Home Atmosphere is Calm | The atmosphere in our home is calm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968968","Have a Regular Morning Routine in Our Home","C159832","A question about whether an individual and their family has a regular morning routine at home.","Have a Regular Morning Routine in Our Home | We have a regular morning routine in our home",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968967","Able to Adapt When Changes Occur","C159833","A question about whether an individual is able to adapt when changes occur.","Able to Adapt When Changes Occur Question | Able to Adapt When Changes Occur | Able to Adapt When Changes Occur | I am able to adapt when changes occur",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968966","Can Deal with Whatever Comes my Way","C159834","A question about whether an individual is able to deal with whatever comes their way.","Can Deal with Whatever Comes my Way | I can deal with whatever comes my way",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968981","Try to See Humorous Side of Things When Faced with Problems","C159835","A question about whether an individual tries to see the humorous side of things when faced with problems.","Try to See Humorous Side of Things When Faced with Problems | I try to see the humorous side of things when I am faced with problems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968980","Having to Cope with Stress can Make me Stronger","C159836","A question about whether an individual feels that coping with stress can make them stronger.","Having to Cope with Stress can Make me Stronger | Having to cope with stress can make me stronger",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968979","Tend to Bounce Back After Illness, Injury, or Other Hardships","C159837","A question about whether an individual tends to bounce back after illness, injury, or other hardships.","Tend to Bounce Back After Illness, Injury, or Other Hardships | I tend to bounce back after illness, injury, or other hardships",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968978","Can Achieve my Goals, Even if There are Obstacles","C159838","A question about whether an individual believes they can achieve their goals, even if there are obstacles.","Can Achieve my Goals, Even if There are Obstacles | I believe I can achieve my goals, even if there are obstacles",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968977","Stay Focused and Think Clearly Under Pressure","C159839","A question about whether an individual is able to stay focused and think clearly under pressure.","Stay Focused and Think Clearly Under Pressure | Under pressure, I stay focused and think clearly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968976","Not Easily Discouraged by Failure","C159840","A question about whether an individual is not easily discouraged by failure.","Not Easily Discouraged by Failure | I am not easily discouraged by failure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968975","Think of Myself as a Strong Person When Dealing with Life's Challenges and Difficulties","C159841","A question about whether an individual thinks of themselves as a strong person when dealing with life's challenges and difficulties.","Think of Myself as a Strong Person When Dealing with Life's Challenges and Difficulties | I think of myself as a strong person when dealing with life's challenges and difficulties",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968974","Able to Handle Unpleasant or Painful Feelings","C159842","A question about whether an individual is able to handle unpleasant or painful feelings, like sadness, fear, and anger.","Able to Handle Unpleasant or Painful Feelings Question | Able to Handle Unpleasant or Painful Feelings | Able to Handle Unpleasant or Painful Feelings | I am able to handle unpleasant or painful feelings like sadness, fear, and anger",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968989","Treated with Less Courtesy or Respect than Other People","C159843","A question about whether an individual feels or felt that they are treated with less courtesy and respect than other people.","Treated with Less Courtesy or Respect than Other People | You are treated with less courtesy or respect than other people",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968988","Receive Poorer Service Than Other People at Restaurant or Stores","C159844","A question about whether an individual feels or felt that they receive poorer service than other people at restaurants or stores.","Receive Poorer Service Than Other People at Restaurant or Stores | You receive poorer service than other people at restaurants or stores",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968987","People Act as if They Think You are Not Smart","C159845","A question about whether an individual feels or felt that people act as if they think the individual is not smart.","People Act as if They Think You are Not Smart | People act as if they think you are not smart",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968986","People Act as if They are Afraid of You","C159846","A question about whether an individual feels or felt that people act as if they are afraid of the individual.","People Act as if They are Afraid of You | People act as if they are afraid of you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968985","Threatened or Harassed","C159847","A question about whether an individual feels or felt that they have been threatened or harassed.","Threatened or Harassed | You are threatened or harassed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968983","If Answered","C159849","A directive to do something if a question was answered in a particular way.","If Answered | If you answered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968984","Reason for the Experience","C159848","A question about what an individual feels is the reason for their experiences.","Reason for the Experience | what do you think is the main reason for these experiences",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968982","Less Than Once a Year","C159850","Happening less than one time during a year.","Less Than Once a Year | Less than once a year",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968996","A Few Times a Year","C159851","Happening a few times during a year.","A Few Times a Year | A few times a year",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968995","A Few Times a Month","C159852","Happening a few times during a month.","A Few Times a Month | A few times a month",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968994","At Least Once a Week","C159853","Happening at least once during a week.","At Least Once a Week | At least once a week",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968992","Other Aspect of Physical Appearance","C159855","A response about some other aspect of an individual's physical appearance.","Other Aspect of Physical Appearance | Some other aspect of your physical appearance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971209","Aboriginal North American","C159826","Denotes any of the indigenous people who lived in North America at the time Europeans reached the continent, including Native American, First Nations, Inuit, and Metis people.","Aboriginal North American | Aboriginal | Indigenous North America | Indigenous People of North America",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968991","Very Well","C159856","A subjective response of strong agreement or ability.","Very Well | Very well",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545166","Exploratory Research","C147146","Any action or process to perform research on a hypothetical or theoretical idea in order to determine whether the phenomena is new (which may lead to additional studies) or can be explained by an existing and well-substantiated theory.","Exploratory Research | exploratory research",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951646","Worried Food Would Run Out Before Get Money to Buy More","C159734","A question about whether an individual is or was worried their food would run out before getting money to buy more.","Worried Food Would Run Out Before Get Money to Buy More | We worried whether our food would run out before we got money to buy more",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983146","Postgraduate","C89835","Of, relating to, happening, or engaged in studies beyond a bachelor's degree.","Postgraduate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971186","Family Received Food Stamps","C159898","A question about whether a family received assistance to buy food, such as from the Supplemental Nutrition Assistance Program (SNAP).","Family Received Food Stamps | Family received food stamps | Food Stamps | SNAP | Supplemental Nutrition Assistance Program",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983616","Housing Type","C90397","The classification of a residential structure.","Housing Type | HOUSETYP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0237154","Homeless","C85868","Without a stable or permanent residence.","Homeless | ",,,,,,,,,,,,,,,"4139934","Homeless",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL968946","BASC-3 F Index","C159860","A classically derived infrequency scale, designed to assess the possibility that a rater has depicted a child's behavior in an inordinately negative fashion.","BASC-3 F Index | F Index | F-Index",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968945","BASC-3 Response Pattern Index","C159861","Detects two types of repeat patterns: repeated and cylindrical response patterning.","BASC-3 Response Pattern Index | Response Pattern Index",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968944","BASC-3 Consistency Index","C159862","Flags cases in which child has given different responses to items that usually are answered similarly; a measure of random responding.","BASC-3 Consistency Index | Consistency Index",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969106","Coaxial Biopsy","C159942","A biopsy system that uses a special needle to permit obtaining multiple samples through a single puncture.","Coaxial Biopsy | Coaxial Biopsy System | Coaxial System | Coaxial Technique",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969104","Global Response Score","C159944","A scoring system for assessing overall response to treatment in skin, lymph nodes, blood, and viscera.","Global Response Score | GR Score | GRS | Global Response Score in Mycosis Fungoides and Sezary Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969103","Global Response","C159945","An indication of response to disease treatment that takes into account multiple body systems.","Global Response | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969102","Global Complete Response","C159946","Complete disappearance of all clinical evidence of disease with skin, nodes, blood and viscera categories having complete response or noninvolvement.","Global Complete Response | Complete Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971156","Global Partial Response","C159947","Regression of measurable disease with complete response in skin and nodes, blood and viscera categories not having complete response or noninvolvement and where no category has progressive disease. Partial response is also assigned when there is partial response in skin and no nodes, blood and viscera category has a progressive disease and if any category involved at baseline at least one has a complete or partial response.","Global Partial Response | PR | Partial Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971146","Global Stable Disease","C159948","Failure to attain complete response, partial response, or progressive disease representative of all disease.  Partial response in skin and no nodes, blood and viscera category has a progressive disease and if any category involved at baseline, no complete or partial response in any.","Global Stable Disease | SD | Stable Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971138","Global Progressive Disease","C159949","Progressive disease in any skin, nodes, blood, or viscera category.","Global Progressive Disease | PD | Progressive Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035020","Global Relapse","C159950","Recurrence of disease in prior complete response or relapse in any skin, nodes, blood, or viscera category.","Global Relapse | Relapse",,,,,,,,,,,,,,,"4136153","Relapse phase",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1286259","Global Response in Skin","C159951","Criteria for the response to treatment in skin lesions, as a component of global response.","Global Response in Skin | Global Skin Response | Response in Skin | Skin Response",,,,,,,,,,,,,,,"4264817","Skin response",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL971149","Global Complete Response in Skin","C159952","100 percent clearance of skin lesions.","Global Complete Response in Skin | CR | Complete Response | Complete Response in Skin | Skin Complete Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971154","Global Partial Response in Skin","C159953","50-99 percent clearance of skin disease from baseline without new tumors (T3) in patients with T1, T2, or T4 only skin disease.","Global Partial Response in Skin | PR | Partial Response | Partial Response in Skin | Skin Partial Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971144","Global Stable Disease in Skin","C159954","Less than 25 percent increase to less than 50 percent clearance in skin disease from baseline without new tumors (T3) in patients with T1, T2, or T4, only skin disease.","Global Stable Disease in Skin | SD | Skin Stable Disease | Stable Disease | Stable Disease in Skin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971142","Global Progressive Disease in Skin","C159955","25 percent or greater increase in skin disease from baseline; or new tumors (T3) in patients with T1, T2, or T4 only skin disease; or loss of response: in those with complete or partial response, increase of skin score of greater than the sum of nadir plus 50 percent baseline score.","Global Progressive Disease in Skin | PD | Progressive Disease | Progressive Disease in Skin | Skin Progressive Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969068","Global Relapse in Skin","C159956","Any disease recurrence in those with complete response.","Global Relapse in Skin | Relapse | Relapse in Skin | Skin Relapse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969067","Global Response in Lymph Nodes","C159957","Criteria for the response to treatment in lymph nodes, as a component of global response.","Global Response in Lymph Nodes | Global Lymph Node Response | Lymph Node Response | Response in Lymph Nodes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971153","Global Partial Response in Lymph Nodes","C159959","Cumulative reduction of 50 percent or more of the sum of products of diameter of each abnormal lymph node at baseline and no new lymph node greater than 1.5 cm in the diameter of the long axis or greater than 1.0 cm in the diameter of the short axis if the long axis is 1-1.5 cm diameter.","Global Partial Response in Lymph Nodes | Lymph Node Partial Response | PR | Partial Response | Partial Response in Lymph Nodes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971148","Global Stable Disease in Lymph Nodes","C159960","Fails to attain the criteria for complete response, partial response, or progressive disease.","Global Stable Disease in Lymph Nodes | Lymph Node Stable Disease | SD | Stable Disease | Stable Disease in Lymph Nodes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971143","Global Progressive Disease in Lymph Nodes","C159961","50 percent or greater increase in the sum of products of diameter from baseline of lymph nodes; or any new node greater than 1.5 cm in the long axis or greater than 1cm in the short axis if 1-1.5 cm in the long axis that is proven to be N3 histologically; or loss of response with greater than 50 percent increase from nadir in sum of products of diameter of lymph nodes in those with partial response (whichever occurs first).","Global Progressive Disease in Lymph Nodes | Lymph Node Progressive Disease | PD | Progressive Disease | Progressive Disease in Lymph Nodes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969065","Global Relapse in Lymph Nodes","C159962","Any new lymph node greater than 1.5 cm in the long axis in those with complete response proven to be N3 histologically.","Global Relapse in Lymph Nodes | Lymph Node Relapse | Relapse | Relapse in Lymph Nodes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969064","Global Response in Viscera","C159963","Criteria for the response to treatment in viscera, as a component of global response.","Global Response in Viscera | Global Viscera Response | Response in Viscera | Viscera Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969074","Global Complete Response in Viscera","C159964","Liver or spleen or any organ considered involved at baseline should not be enlarged on physical exam and should be considered normal by imaging; no nodules should be present on imaging of liver or spleen; any post treatment mass must be determined by biopsy to be negative for lymphoma.","Global Complete Response in Viscera | CR | Complete Response | Complete Response in Viscera | Viscera Complete Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969073","Global Partial Response in Viscera","C159965","50 percent or greater regression in any splenic or liver nodules, or in measurable disease (sum of products of diameter) in any organs abnormal at baseline; no increase in size of liver or spleen and no new sites of involvement.","Global Partial Response in Viscera | PR | Partial Response | Partial Response in Viscera | Viscera Partial Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971145","Global Stable Disease in Viscera","C159966","Fails to attain the criteria for complete response, partial response, or progressive disease.","Global Stable Disease in Viscera | SD | Stable Disease | Stable Disease in Viscera | Viscera Stable Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971140","Global Progressive Disease in Viscera","C159967","Greater than 50 percent increase in size by sum of products of diameter (SPD) of any organs involved at baseline; or new organ involvement or loss of response: greater than 50 percent increase from nadir in the size (SPD) of any previous organ involvement in those with partial response (whichever occurs first).","Global Progressive Disease in Viscera | PD | Progressive Disease | Progressive Disease in Viscera | Viscera Progressive Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969072","Global Relapse in Viscera","C159968","New organ involvement in those with complete response.","Global Relapse in Viscera | Relapse | Relapse in Viscera | Viscera Relapse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969071","Global Response in Blood","C159969","Criteria for the response to treatment in blood, as a component of global response.","Global Response in Blood | Blood Response | Global Blood Response | Response in Blood",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969070","Global Complete Response in Blood","C159970","A score of B0 by repeat bone marrow biopsy with no residual disease.","Global Complete Response in Blood | Blood Complete Response | CR | Complete Response | Complete Response in Blood",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969069","Global Partial Response in Blood","C159971","Greater than 50 percent decrease in quantitative measurements of blood tumor burden in baseline from those with high tumor burden at baseline (B2).","Global Partial Response in Blood | Blood Partial Response | PR | Partial Response | Partial Response in Blood",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969080","Global Stable Disease in Blood","C159974","Fails to attain the criteria for complete response, partial response, or progressive disease.","Global Stable Disease in Blood | Blood Stable Disease | SD | Stable Disease | Stable Disease in Blood",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971141","Global Progressive Disease in Blood","C159975","A change from B0 to B2; or greater than 50 percent increase from baseline and at least 5,000 neoplastic cells per microliter; or loss of response: in those with partial response who were originally B2 at baseline, greater than 50 percent increase from nadir and at least 5,000 neoplastic cells per microliter.","Global Progressive Disease in Blood | Blood Progressive Disease | PD | Progressive Disease | Progressive Disease in Blood",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969079","Global Relapse in Blood","C159976","Increase of neoplastic blood lymphocytes to B1 or greater in those with complete response.","Global Relapse in Blood | Blood Relapse | Relapse | Relapse in Blood",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642255","Low-Grade Ovarian Serous Adenocarcinoma","C105556","A slow-growing serous adenocarcinoma that arises from the ovary.  It usually originates from borderline neoplastic processes or adenofibromas.  It is characterized by the presence of low grade cytologic features and infrequent mitotic figures.","Ovarian Low Grade Serous Adenocarcinoma | Invasive Ovarian Micropapillary Serous Carcinoma | Low Grade Ovarian Serous Adenocarcinoma | Low Grade Ovarian Serous Adenocarcinoma | Low-Grade Ovarian Serous Adenocarcinoma | Ovarian Low-Grade Serous Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518737","Ovarian Small Cell NEC","C40440","An aggressive small cell neuroendocrine carcinoma that arises from the ovary.  Morphologically, it resembles the small cell carcinoma that arises from the lung.","Ovarian Small Cell Carcinoma, Pulmonary-Type | Ovarian Small Cell Carcinoma, Pulmonary Type | Ovarian Small Cell NEC | Ovarian Small Cell Neuroendocrine Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518355","Non-Gestational Ovarian Choriocarcinoma","C39991","A malignant germ cell tumor that arises from the ovary and is composed of cytotrophoblasts, syncytiotrophoblasts, and extravillous trophoblasts.  The prognosis is less favorable than gestational choriocarcinoma.","Non-Gestational Ovarian Choriocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706277","None","C50083","An indication that there is no device or component that matches the criteria.","None Device | None",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0338240","Intraoperative Radiation Therapy","C15623","The use of any form of radiation therapy during a surgical procedure.","Intraoperative Radiation Therapy | IORT | Intraoperative Radiotherapy | Radiotherapy - intraoperative control (procedure) | intraoperative radiation therapy | radiotherapy, intraoperative",,,,,,,,,,,,,,,"4059385","Radiotherapy - intraoperative control",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL969160","Brass Mesh Bolus","C160148","A brass mesh material used to increase the radiation dose at or near the skin surface. This material is used in place of tissue-equivalent bolus material to achieve improved conformity to the chest wall.","Brass Mesh Bolus | BMB | Brass mesh",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937506","MammoSite Brachytherapy","C157915","A method for brachytherapy that uses an implanted catheter to deliver a radioactive seed into the breast site. During a lumpectomy procedure a catheter with a balloon tip is temporarily implanted into the site where the tumor was removed. After surgery a radioactive seed is fed through the catheter to the tumor site.","MammoSite Brachytherapy | Balloon Brachytherapy | Breast Balloon Brachytherapy | Breast Brachytherapy | MammoSite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242358","Tight Junction","C13333","Found near the apical surface of cells in simple epithelia. Forms a sealing 'gasket' around the cell by the fusion of adjacent cell membranes which encircle the apical cell surface like a belt or fence. Prevents fluid moving through the intercellular gap and the lateral diffusion of intrinsic membrane proteins between apical and basolateral domains of the plasma membrane as well as occludes the movement of solute molecules between cells. Various proteins components of this junction have been identified, but how they are linked to form the ultrastructure of the junction is not known.","Tight Junction | Occluding Junction | Zonula Occludens",,,,,,,,,,,,,,,"4084002","Tight junction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1927728","Hardness Measurement","C134264","The determination of the breaking point and structural integrity of a material.","Hardness Measurement | Hardness | Hardness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968931","Lymphedema Symptom Intensity and Distress Survey - Arm","C159908","A self-report tool designed to evaluate arm lymphedema and associated symptoms in breast cancer survivors.","Lymphedema Symptom Intensity and Distress Survey - Arm | LSIDS-A | Lymphedema Symptom Intensity and Distress Survey-Arm | Lymphedema Symptom Intensity and Distress Survey-Arm (LSIDS-A)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968928","Have Heaviness in Your Arm","C159911","A question about whether an individual experiences or experienced heaviness in their arm.","Have Heaviness in Your Arm | Heaviness in your arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968927","Have Tightness in Your Arm","C159912","A question about whether an individual experiences or experienced tightness in their arm.","Have Tightness in Your Arm | Tightness in your arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968926","Have Pain in Your Arm","C159913","A question about whether an individual experiences or experienced pain in their arm.","Have Pain in Your Arm | Pain in your arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968925","Have Stabbing Pain in Your Arm","C159914","A question about whether an individual experiences or experienced stabbing pain in their arm.","Have Stabbing Pain in Your Arm | Stabbing pain in your arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968940","Have Cramping Pain in Your Arm","C159915","A question about whether an individual experiences or experienced cramping pain in their arm.","Have Cramping Pain in Your Arm | Cramping pain in your arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968939","Have Numbness in Your Arm","C159916","A question about whether an individual experiences or experienced numbness in their arm.","Have Numbness in Your Arm | Numbness in your arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968938","Have Achiness in Your Arm","C159917","A question about whether an individual experiences or experienced achiness in their arm.","Have Achiness in Your Arm | Achiness in your arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968937","Have Swelling in Your Arm","C159918","A question about whether an individual experiences or experienced swelling in their arm.","Have Swelling in Your Arm | Swelling in your arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968936","Have Hardness in Your Arm","C159919","A question about whether an individual experiences or experienced hardness in their arm.","Have Hardness in Your Arm | Hardness in your arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968935","Have Tingling in Your Arm","C159920","A question about whether an individual experiences or experienced tingling in their arm.","Have Tingling in Your Arm | Tingling in your arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968934","Have Pins and Needles in Your Arm","C159921","A question about whether an individual experiences or experienced pins and needles in their arm.","Have Pins and Needles in Your Arm | Pins and needles in your arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968933","Have Difficulty Moving Arm Side to Side","C159922","A question about whether an individual experiences or experienced difficulty moving their arm from side to side.","Have Difficulty Moving Arm Side to Side | Difficulty moving arm side to side",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969097","Have Difficulty Raising Arm Above Head","C159923","A question about whether an individual experiences or experienced difficulty raising their arm above their head.","Have Difficulty Raising Arm Above Head | Difficulty in raising arm above head",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969096","Have Lack of Confidence in Self","C159924","A question about whether an individual experiences or experienced a lack of confidence in their self.","Have Lack of Confidence in Self | Lack of confidence in self",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969095","Have Lack of Confidence in Insurance Provider","C159925","A question about whether an individual experiences or experienced a lack of confidence in their insurance provider.","Have Lack of Confidence in Insurance Provider | Lack of confidence in your insurance provider",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969094","Have Concerns About How You Look","C159926","A question about whether an individual experiences or experienced concerns about how they look.","Have Concerns About How You Look | Concerns about how you look",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969093","Feel Misunderstood by Spouse or Significant Other","C159927","A question about whether an individual feels or felt misunderstood by their spouse or significant other.","Feel Misunderstood by Spouse or Significant Other | Feeling misunderstood by spouse/significant other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969092","Feel Frustration with Insurance Company","C159928","A question about whether an individual feels or felt frustration with their insurance company.","Feel Frustration with Insurance Company | Frustration with your insurance company",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969091","Have Loss of Confidence in Body","C159929","A question about whether an individual feels or felt a loss of confidence in their body.","Have Loss of Confidence in Body | Loss of confidence in your body",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969090","Partner Has Lack of Interest in Sex","C159930","A question about whether an individual's partner has or had a lack of interest in sex.","Partner Has Lack of Interest in Sex | Partner having lack of interest in sex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969101","Have Inability to Complete Hobbies or Leisure Activities","C159931","A question about whether an individual has or had an inability to complete hobbies or leisure activities they used to do.","Have Inability to Complete Hobbies or Leisure Activities | Inability to complete hobbies or leisure activities you used to do",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969100","Consistently Decreased Social Activities","C159932","A question about whether an individual experiences or experienced consistently decreased interest or participation in social activities.","Consistently Decreased Social Activities | Consistently decreased social activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969099","Have Decrease in Sexual Activity","C159933","A question about whether an individual has or had a decrease in sexual activity.","Have Decrease in Sexual Activity | Decrease in sexual activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969098","Symptoms Intensity and Distress Likert Scale","C159934","A scale for the subjective scoring of a symptom's intensity and distress that ranges from 1: Slight to 5: Severe.","Symptoms Intensity and Distress Likert Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971158","Intensity and Distress 1","C159935","A subjective score of 1 on a symptom's intensity and distress scale that ranges from 1: Slight to 5: Severe.","Intensity and Distress 1 | 1 | 1 - Slight | 1 Slight | Slight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971147","Intensity and Distress 2","C159936","A subjective score of 2 on a symptom's intensity and distress scale that ranges from 1: Slight to 5: Severe.","Intensity and Distress 2 | 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971194","Intensity and Distress 3","C159937","A subjective score of 3 on a symptom's intensity and distress scale that ranges from 1: Slight to 5: Severe.","Intensity and Distress 3 | 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971178","Intensity and Distress 4","C159938","A subjective score of 4 on a symptom's intensity and distress scale that ranges from 1: Slight to 5: Severe.","Intensity and Distress 4 | 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971162","Intensity and Distress 5","C159939","A subjective score of 5 on a symptom's intensity and distress scale that ranges from 1: Slight to 5: Severe.","Intensity and Distress 5 | 5 | 5 Severe | 5-Severe | Severe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3645570","US English","C160183","A form of the English language spoken in the United States.","US English | English, US | United States English",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969334","US Spanish","C160189","A form of the Spanish language spoken in the United States.","US Spanish | Spanish, US | United States Spanish",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969325","Canadian English","C160184","A form of the English language spoken in Canada.","Canadian English | English, Canada",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969321","Canadian French","C160188","A form of the French language spoken in Canada.","Canadian French | French, Canada",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551009","MVA-BN-Brachyury-TRICOM Vaccine","C148400","A cancer priming vaccine consisting of a proprietary version of the recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN), encoding the human transcription factor and tumor-associated antigen (TAA) brachyury, and a triad of T-cell co-stimulatory molecules (TRICOM), which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration of MVA-BN-brachyury vaccine, the vector expresses the brachyury protein. The expressed brachyury protein may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing brachyury. The MVA-BN-brachyury vaccine, which is a priming vaccine, is followed by multiple boosting doses of the fowlpox virus (FPV)-brachyury vaccine. The expression of brachyury, a member of the T-box family of transcription factors that is overexpressed in numerous cancer cell types, is correlated with increased epithelial-mesenchymal transition (EMT), cancer resistance, cancer progression and metastasis. TRICOM enhances antigen-specific T-cell activation.","MVA-BN-Brachyury-TRICOM Vaccine | MVA-BN-BRACHYURY-TRICOM VACCINE | MVA-BN-Brachyury | MVA-BN-Brachyury Prime Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551011","FPV-Brachyury-TRICOM Vaccine","C148402","A cancer vaccine consisting of a recombinant fowlpox viral (FPV) vector encoding the human transcription factor and tumor-associated antigen (TAA) brachyury, and a triad of T-cell co-stimulatory molecules (TRICOM), which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration occurring after the administration of a proprietary modified vaccinia Ankara developed by Bavarian Nordic-based prime vaccine (MVA-BN-brachyury), the booster vaccine FPV-brachyury vaccine potentiates a cytotoxic T-lymphocyte (CTL) response against brachyury-expressing tumor cells. The expression of brachyury, a member of the T-box family of transcription factors that is overexpressed in numerous cancer cell types, is correlated with increased epithelial-mesenchymal transition (EMT), cancer resistance, cancer progression and metastasis. TRICOM enhances antigen-specific T-cell activation.","FPV-Brachyury-TRICOM Vaccine | FPV-Brachyury | FPV-Brachyury Boost Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986994","Guadecitabine","C95209","A dinucleotide antimetabolite composed of a decitabine linked via phosphodiester bond to a deoxyguanosine, with potential antineoplastic activity. Following metabolic activation via cleavage of the phosphodiester bond and incorporation of the decitabine moiety into DNA, guadecitabine inhibits DNA methyltransferase, thereby causing non-specific, genome-wide hypomethylation, and induction of cell cycle arrest at S-phase. This agent is resistant to cytidine deaminase, which may result in gradual release of decitabine both extra- and intra-cellularly, leading to prolonged exposure to decitabine.","Guadecitabine | DNMT inhibitor SGI-110 | GUADECITABINE | S110 | SGI 110 | SGI-110 | SGI110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985807","Not Applicable Indicator","C93604","Specifies whether something is not relevant in the current context.","Not Applicable Indicator | notApplicableIndicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0391853","Decreased Physical Activity","C122444","A reduction in the normal physical activity for an individual.","Decreased Physical Activity | ",,,,,,,,,,,,,,,"4195475","Behavior showing reduced motor activity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL969293","Needed Medical Care or Prescription Medicine but Unable to Afford it","C160219","A question about whether a household member was unable to get  needed medical care or a prescription medicine because the family couldn't afford it.","Needed Medical Care or Prescription Medicine but Unable to Afford it Question | Needed Medical Care or Prescription Medicine but Unable to Afford it | Needed Medical Care or Prescription Medicine but Unable to Afford it | Was there a time when you or another household member needed medical care or a prescription medicine but were unable to get it because your family could not afford it.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969292","Who Needed Medical Care but Family Unable to Afford it","C160220","A question about which household member was unable to get needed medical care because the family couldn't afford it.","Who Needed Medical Care but Family Unable to Afford it Question | Who Needed Medical Care but Family Unable to Afford it | Who Needed Medical Care but Family Unable to Afford it | Who needed medical care but were unable to get it because your family could not afford it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969306","Who Needed Prescription Medicine but Family Unable to Afford it","C160221","A question about which household member was unable to get needed prescription medicine because the family couldn't afford it.","Who Needed Prescription Medicine but Family Unable to Afford it Question | Who Needed Prescription Medicine but Family Unable to Afford it | Who Needed Prescription Medicine but Family Unable to Afford it | Who needed a prescription medicine but were unable to get it because your family could not afford it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0496675","Medical Care","C160222","Services obtained from a medical professional for the maintenance of health, prevention of illness, and treatment of illness or injury.","Medical Care | ",,,,,,,,,,,,,,,"36674533","Medical care",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL969305","More Than Enough Money Left Over","C160223","A response indicating that there was more than enough money left over.","More Than Enough Money Left Over | More than enough money left over",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969304","Some Money Left Over","C160224","A response indicating that there was some money left over.","Some Money Left Over | Some money left over",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969303","Just Enough to Make Ends Meet","C160225","A response indicating that there was just enough money left over to make ends meet.","Just Enough to Make Ends Meet | Just enough to make ends meet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969302","Almost Enough to Make Ends Meet","C160226","A response indicating that there was almost enough money left over to make ends meet.","Almost Enough to Make Ends Meet | Almost enough to make ends meet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969301","Not Enough to Make Ends Meet","C160227","A response indicating that there was not enough money left over to make ends meet.","Not Enough to Make Ends Meet | Not enough to make ends meet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897550","Special Event of Interest Document","C115558","Documentation describing an event of special interest experienced by the subject in the clinical trial, which is defined by the clinical study protocol.","Clinical Trial Special Events of Interest Documentation | Medical Events of Interest | SEI | Special Event of Interest Document | Special Events of Interest",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274604","EWSR1/FLI1 Fusion Gene Type 1","C99203","A fusion gene (~4.1 kb) that results from a chromosomal translocation t(11;22)(q24;q12) which fuses the first seven exons of the EWSR1 gene with exon 6 of the FLI1 gene. This rearrangement is associated with Ewing tumor/peripheral primitive neuroectodermal tumor.","EWSR1/FLI1 Fusion Gene Type 1 | EWS-FLI1 Fusion Gene Type 1 | EWS/FLI1 Fusion Gene Type 1 | EWSR1-FLI1 Fusion Gene Type 1 | EWSR1::FLI1 Fusion Gene Type 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025115","Medication Error","C156627","An error associated with the prescribing, dispensing, or giving/taking a medication by a healthcare professional, patient, or consumer that causes or leads to inappropriate medication use or patient harm.","Medication Error | medication error",,,,,,,,,,,,,,,"4162376","Medication error",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526847","Sabotage or Intentional Misuse","C139482","Problems occurred because of willful damage or reckless misuse. This term indicates that there was an apparent intent to cause damage or injury.","Sabotage or Intentional Misuse | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333869","Pancreatic Intraepithelial Neoplasia-1","C6820","A pancreatic intraepithelial neoplasia characterized by the presence of tall columnar cells that form flat or papillary, micropapillary, and basally pseudostratified architectural patterns.  Mild cytological atypia is present.","Pancreatic Intraepithelial Neoplasia-1 | Grade 1 Pancreatic Intraepithelial Neoplasia | Grade I Pancreatic Intraepithelial Neoplasia | PanIN-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987143","Pancreatic Intraepithelial Neoplasia-1B","C95430","A pancreatic intraepithelial neoplasia characterized by the presence of tall columnar cells that form papillary, micropapillary, or basally pseudostratified architectural patterns.  Mild cytological atypia is present.","Pancreatic Intraepithelial Neoplasia-1B | PanIN-1B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0191918","Mastopexy","C96204","A surgical procedure to lift the female breast or to change the shape of it for cosmetic reasons.","Mastopexy | Breast Lift",,,,,,,,,,,,,,,"4179928","Fixation of pendulous breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4270763","Prophylactic Surgery","C94458","Any surgical procedure undertaken prior to the occurrence of a disease/disorder, the goal of which is to prevent the disease/disorder from developing.","Prophylactic Surgery | prophylactic surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883301","Therapeutic Surgical Procedure","C64982","A therapeutic procedure performed by manual and/or instrumental means, generally involving an incision and the removal or replacement of a diseased organ or tissue.","Therapeutic Surgical Procedure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1504478","24 Hour Urine for Total Protein","C135567","The measurement of the total protein present in a urine sample that was collected over a period of 24 hours.","24 Hour Urine for Total Protein | 24 Hour Urine Protein | 24 Hour Urine Protein Test | 24 h Urine for Total Protein | 24-Hour Urine Protein | 24-Hour Urine Protein Test | 24h PTU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969687","Adjacent Tissue Transfer or Rearrangement","C160576","A reconstructive procedure that relocates a flap of healthy skin from a donor site to an adjacent laceration, scar, or other discontinuity. A portion of the flap is left intact to supply blood to the grafted area. Adjacent tissue transfer/rearrangement (ATT/R) may be for repair of traumatic skin wounds, lesion excision, or rearrangement/reconstruction of tissues.","Adjacent Tissue Transfer or Rearrangement | ATT/R | Adjacent Tissue Rearrangement | Adjacent Tissue Transfer | Adjacent Tissue Transfer/Rearrangement | Local Tissue Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504855","Autologous Fat Graft","C126279","The transfer of an individual's own body fat from one location to another.","Autologous Fat Graft | Autologous Fat Cell Transplantation | Autologous Fat Injection | Autologous Fat Transfer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969672","TRAM Flap Procedure","C160624","A grafting procedure where a piece of tissue, including skin, fat, and all or part of the underlying transverse rectus abdominis muscle are used for breast reconstruction.","TRAM Flap Procedure | TRAM Flap | Transverse Rectus Abdominis Myocutaneous Flap",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971210","Latissimus Dorsi Flap Reconstruction","C160625","A grafting procedure where an oval flap of skin, fat, muscle, and blood vessels from your upper back (latissimus dorsi muscle) is used for breast reconstruction.","Latissimus Dorsi Flap Reconstruction | Latissimus Dorsi Flap",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969684","Tissue Expander-Implant Breast Reconstruction","C160627","A method of breast reconstruction. During the mastectomy procedure a tissue expander is implanted beneath the chest wall muscle. Over a period or weeks or months the volume of the implant is increased, causing the overlying muscle and skin to stretch. Later, the expander is removed and replaced by a permanent breast implant.","Tissue Expander-Implant Breast Reconstruction | Implant Surgery after Expanders | Tissue Expander Followed by Implant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205355","Permanent","C160628","Continuing or enduring over time, without fundamental or marked change.","Permanent | Permanence",,,,,,,,,,,,,,,"4238885","Permanent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL388374","Accelerated Partial Breast Irradiation","C116436","Radiation therapy following lumpectomy, that uses highly effective doses of radiation over a reduced treatment time. Radiation may be administered by brachytherapy, or through external radiation beam techniques.","Accelerated Partial Breast Irradiation | APBI | Accelerated Partial Breast Radiation Therapy",,,,,,,,,,,,,,,"42535382","Accelerated partial breast irradiation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL388375","3-Dimensional Conformal Accelerated Partial Breast Irradiation","C116435","Accelerated partial breast radiation therapy that uses 3-dimensional conformal radiation techniques.","3-Dimensional Conformal Accelerated Partial Breast Irradiation | 3D Conformal Accelerated Partial Breast Irradiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969646","Archival Tissue","C160656","Tissue stored in a biospecimen repository for future study use.","Archival Tissue | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524883","Breast Pleomorphic Lobular Carcinoma In Situ","C137839","Breast lobular carcinoma in situ characterized by the presence of neoplastic large cells with marked nuclear pleomorphism.","Breast Pleomorphic Lobular Carcinoma In Situ | Non-Invasive Pleomorphic Lobular Carcinoma of the Breast | PLCIS | Pleomorphic Lobular Breast Carcinoma In Situ | Pleomorphic Lobular Breast Carcinoma In Situ | Pleomorphic Lobular Carcinoma in Situ of the Breast | pLCIS","8519/2","Lobular carcinoma in situ, pleomorphic",,,,,,,,,,,,,"42539348","Pleomorphic lobular carcinoma in situ of breast",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1641588","Urologic Oncology","C19102","The branch of oncology concerned with the study, diagnosis, and treatment of cancer of the genitourinary tract.","Urologic Oncology | ",,,,,,,,,,,,,,,"4303533","Urological oncology",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518931","Pediatric Oncology","C17852","The medical specialty that focuses on tumors in children.","Pediatric Oncology | Oncology, Pediatric",,,,,,,,,,,,,,,"4166881","Pediatric oncology",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021423","Information Sciences","C16733","The sciences concerned with gathering and manipulating and storing and retrieving and classifying recorded information.","Information Sciences | Information Technology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0403172","Supervisor","C134832","An individual who is responsible for managing or operating a business, organization, team or department.","Supervisor | Administrator | Administrator/Supervisor",,,,,,,,,,,,,,,"4341530","Supervisor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL449148","Receptor Status","C94299","Refers to the presence or absence of specific receptor molecules on the surface of a cells in a specimen.","Receptor Status | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4015571","75 (qualifier value)","C160687","A natural number greater than seventy-four and less than seventy-six and the quantity that it denotes.","Seventy Five | 75 | Seventy-Five",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518345","Nodular Lesion","C41425","A lesion characterized by the presence of one or more nodules.","Nodular Lesion | Nodular lesion | Nodular lesion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554462","Metastatic Breast Cancer in the Lymph Nodes","C153227","A carcinoma that arises from the breast and has spread to the lymph nodes.","Metastatic Breast Carcinoma in the Lymph Nodes | Breast Carcinoma Metastatic in Lymph Node | Breast Carcinoma Metastatic in Lymph Node | Breast Carcinoma Metastatic in the Lymph Nodes | Breast Carcinoma Metastatic in the Lymph Nodes | Metastatic Breast Cancer in the Lymph Nodes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969819","Residual Cancer Burden","C160722","An indication of the amount of invasive cancer in breast or lymph node tissue after completion of neoadjuvant chemotherapy.","Residual Cancer Burden | RCB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2919369","Residual Cancer Burden Index","C160723","A score estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. Variables used in the calculation include: primary tumor bed area, overall cancer cellularity, percentage of cancer that is in situ disease, number of positive lymph nodes, and diameter of largest metastasis. These scores are divided into 4 classes that stratify patients based on their chance of disease recurrence.","Residual Cancer Burden Index | RCB Index",,,,,,,,,,,,,,,"40482010","Residual cancer burden index",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL971246","Residual Cancer Burden Class","C160724","Residual cancer burden classes that use pre-defined cut-points representing progressively greater extents of residual cancer and indicating a greater risk of recurrence.","Residual Cancer Burden Class | RCB Class",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971157","Residual Cancer Burden Class 0","C160725","No traces of residual disease; lowest chance of disease recurrence.","Residual Cancer Burden Class 0 | RCB-0 | pCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969831","Residual Cancer Burden Class 1","C160726","Minimal residual disease; low chance of disease recurrence.","Residual Cancer Burden Class 1 | RCB-I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969830","Residual Cancer Burden Class 2","C160727","Moderate residual disease; moderate chance of disease recurrence.","Residual Cancer Burden Class 2 | RCB-II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969829","Residual Cancer Burden Class 3","C160728","Extensive residual disease; highest chance of disease recurrence.","Residual Cancer Burden Class 3 | RCB-III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540672","Trial Termination","C142739","The discontinuation of a clinical trial prior to the planned end date.","Trial Termination | Trial Terminated | termination (of a clinical trial)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937518","Driving Simulation Training","C157831","Learning how to drive with a machine that simulates the motor vehicle of choice.","Driving Simulation Training | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969757","Discrete Set Data Type IV","C160774","A collection of identifiers from an external system that contains distinct and discrete values in no particular order.","Discrete Set Data Type IV | DSET<IV>",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969756","Discrete Set Telecommunication URL Data Type","C160775","A collection of locatable resources that are identified by a URI, such as a web page, a telephone number (voice, fax or some other resource mediated by telecommunication equipment), an e-mail address, or any other locatable resource that can be specified by a URL that returns binary content.","Discrete Set Telecommunication URL Data Type | DSET<TEL_URL>",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545809","Low Density Array","C148032","A card containing 384 wells that can be loaded with cDNA probe sets and cDNA reverse transcribed from samples of interest. The card is designed to be placed into a thermocycler to perform quantitative reverse transcriptase-based PCR (QRT-PCR) analysis.","Low Density Array | LDA | Low-Density Array",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826025","Mixed Phenotype Acute Leukemia","C82179","An acute leukemia of ambiguous lineage.  It is characterized by the presence of either separate populations of blasts of more than one lineage, or one population of blasts co-expressing markers of more than one lineage.","Mixed Phenotype Acute Leukemia | MPAL | Mixed phenotype (biphenotypic) acute leukemia",,,,,,,,,,,,,,,"37162251|42872918","Mixed phenotype acute leukemia|Mixed phenotype acute leukemia",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL971219","Clinical Laboratory Evaluation Program","C160785","A program of the New York State Department of Health that administers the activities of the Clinical Laboratory Reference System and provides the oversight of over 1,000 clinical laboratories and blood banks, including out-of-state facilities that accept clinical specimens collected in New York State. CLEP seeks to ensure the accuracy and reliability of results of laboratory tests on specimens obtained within the state through on-site inspections, review of proficiency testing performance, and evaluation of the qualifications of personnel of state permit-holding clinical laboratories and blood banks.","Clinical Laboratory Evaluation Program | CLEP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969735","Anchor Date","C160815","The base date from which all other dates within a cohort or data set are derived.","Anchor Date | Anchor date | Base date",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935850","New Primary Tumor","C156806","A finding indicating the development of a tumor in a patient with a history of a previously diagnosed tumor with a different histopathologic profile in another anatomic site as compared to the most recent one.","New Primary Tumor | New Primary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553208","Blasts Expressing B-Lymphoid, T-Lymphoid, and Myeloid Markers Present","C151986","A finding indicating the presence of blasts with evidence of trilineage (B-cell, T-cell, and myeloid lineage) assignment.","Blasts Expressing B-Lymphoid, T-Lymphoid, and Myeloid Markers Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0965498","Rimiducid","C82412","A lipid-permeable tacrolimus analogue with homodimerizing activity. Dimerizer drug AP1903 homodimerizes an analogue of human protein FKBP12 (Fv) which contains a single acid substitution (Phe36Val) so that AP1903 binds to wild-type FKBP12 with 1000-fold lower affinity. This agent is used to homodimerize the Fv-containing drug-binding domains of genetically engineered receptors such as the iCD40 receptor of the autologous dendritic cell vaccine BP-GMAX-CD1, resulting in receptor activation.","Rimiducid | 2-Piperidinecarboxylic acid, 1-(1-Oxo-2-(3,4,5-trimethoxyphenyl)butyl)-, 1,2-Ethanediylbis(imino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylene(3-(3,4-dimethoxyphenyl)propylidene)) Ester, (2S-(1(R*),2R*(S*(S*(1(R*),2R*)))))- | AP-1903 | AP1903 | RIMIDUCID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518069","Lymphoepithelial Lesion","C38730","No Value Exists","Lymphoepithelial Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016709","Fresh Frozen Plasma","C89783","The plasma that is separated from the whole blood and frozen quickly after a blood donation in order to be used for blood transfusions.","Fresh Frozen Plasma | FFP",,,,,,,,,,,,,,,"4223728","Fresh frozen plasma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2986662","Multifocal Breast Carcinoma","C94770","A breast carcinoma characterized by the presence of multiple cancerous tumors that originate from the same clone and are usually located in the same quadrant of the breast.","Multifocal Breast Carcinoma | Multifocal Breast Cancer | multifocal breast cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL427831","Predominantly Fatty Breast","C160849","The breasts are almost entirely fatty, as defined by the visually estimated content of fibroglandular-density tissue within the breast, based on updated editions of the American College of Radiology's Breast Imaging Reporting and Data System (BI-RADS).","Predominantly Fatty Breast | Predominantly fatty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1268645","Breast Scattered Fibroglandular Densities","C160850","There are scattered areas of fibroglandular density, as defined by the visually estimated content of fibroglandular-density tissue within the breast, based on updated editions of the American College of Radiology's Breast Imaging Reporting and Data System (BI-RADS).","Breast Scattered Fibroglandular Densities | Scattered Fibroglandular Densities in Breast | Scattered Fibroglandular Densities of Breast | Scattered fibroglandular densities",,,,,,,,,,,,,,,"4031228","Scattered fibroglandular densities",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517508","Genetic Information Processing Pathway","C39736","A sequence of biological or biochemical events that are involved in the conversion of genetic information into physiologically active molecules, such as functional RNA and proteins.","Genetic Information Processing Pathway | Genetic Information Processing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473334","5' Nucleotidase Family","C19637","A class of enzymes present in various organs and in many cells that catalyze the hydrolysis of a 5'-ribonucleotide to a ribonucleoside and orthophosphate in the presence of water. Serum 5'-N'Tase is measured as an indicator of liver damage resulting primarily from interference with the secretion of bile. Serum 5'-N'Tase is not as sensitive as some other enzymes (for example, ALP, AST, and ALT) to liver damage, but it is a more liver-specific enzyme. The level of this enzyme parallels alkaline phosphatase (ALP). It is used mostly to differentiate elevations in the above enzymes due to liver damage from damage to skeletal muscle.","5' Nucleotidase Family | 5' Nucleotidase | 5'-N'Tase | 5'-NT | 5'-NTase | 5-Nucleotidase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551862","TNIP1 Gene","C150067","This gene is involved in the positive regulation of tumor necrosis factor alpha-induced protein 3 (TNFAIP3)-mediated deubiquitination activity.","TNIP1 Gene | TNFAIP3 Interacting Protein 1 Gene | TNIP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336605","TERF2 Gene","C20562","This gene is involved in the negative regulation of telomerase activity.","TERF2 Gene | TERF2 | Telomeric Repeat Binding Factor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826789","RCSD1 Gene","C119661","This gene is involved in binding to F-actin.","RCSD1 Gene | RCSD Domain Containing 1 Gene | RCSD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538565","PAG1 Gene","C24654","This gene is involved in signal transduction and plays a role in the immune response.","PAG1 Gene | PAG1 | Phosphoprotein Membrane Anchor with Glycosphingolipid-Enriched Microdomains 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426677","ATF7IP Gene","C119670","This gene is involved in the regulation of both histone methylation and transcription.","ATF7IP Gene | ATF7IP | Activating Transcription Factor 7 Interacting Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL427833","Extremely Dense Breast","C132104","A mammographic finding of extremely dense breast composition, as defined by the visually estimated content of fibroglandular-density tissue within the breast, based on updated editions of the American College of Radiology's Breast Imaging Reporting and Data System (BI-RADS).","Extremely Dense Breast | Extremely dense | Mammographically Extremely Dense Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL427832","Heterogeneously Dense Breast","C132103","A mammographic finding of heterogeneously dense breast composition, as defined by the visually estimated content of fibroglandular-density tissue within the breast, based on updated editions of the American College of Radiology's Breast Imaging Reporting and Data System (BI-RADS).","Heterogeneously Dense Breast | Heterogeneously dense | Mammographically Heterogeneously Dense Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935839","CPTAC Case Identifier","C156807","The identifier assigned to a case within the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC).","CPTAC Case Identifier | CPTAC Case ID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475445","Site of Tumor","C157120","The anatomic site of the tumor.","Site of Tumor | TUMOR_SITE | Tumor Site | Tumor site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971206","Gender Identity Measure","C160854","A multi-tiered question asking participants to describe their gender identity. Multiple response options are provided along with open-ended self-defined options.","Gender Identity Measure | Gender Identity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL515877","Clinical Evaluation of Language Fundamentals, Fifth Edition","C160855","An interviewer-administered test designed to assess a student's language and communication skills in a variety of contexts, determine the presence of a language disorder, describe the nature of the language disorder and plan for intervention or treatment. It asks a student to imitate sentences presented by the examiner. As the test progresses, the sentences become longer and more complex. Respondents are scored for the number of errors made in each sentence.","Clinical Evaluation of Language Fundamentals, Fifth Edition | CELF-5 | Clinical Evaluation of Language Fundamentals-Fifth Edition (CELF-5)",,,,,,,,,,,,,,,"36714012","CELF-5 - Clinical Evaluation of Language Fundamentals Fifth Edition",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL969935","Rice Grammaticality Judgment Task","C160856","An examiner-administered, 20-item grammar judgment task. The respondent listens to a series of prerecorded sentences (items) and indicates whether the sentence is grammatically correct.","Rice Grammaticality Judgment Task | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969934","Aging Voice Index","C160857","A questionnaire specifically designed for aging adults with voice disorders. It consists of a 23-item, self-administered questionnaire that asks individuals about the effects of their voice on their lives.","Aging Voice Index | AVI | Aging Voice Index (AVI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969933","Test of Word Reading Efficiency, Second Edition","C160858","A measure designed to provide professionals in schools and clinics with a reliable and valid measure of fluency and accuracy of print-based word-reading skills. It is a nationally normed measure of word reading accuracy and speed, comprised of two subtests: the Sight Word Efficiency (SWE) subtest, a measure of an individual's ability to pronounce printed words, and the Phonemic Decoding Efficiency (PDE) subtest, a measure of an individual's ability to pronounce phonemically regular nonwords.","Test of Word Reading Efficiency, Second Edition | TOWRE-2 | Test of Word Reading Efficiency-Second Edition (TOWRE-2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969932","Oral Mechanism/Cranial Nerve Examination for Young Children","C160859","A clinical protocol developed for the purpose of assessing the oral and speech motor abilities of children. The protocol can be administered in 7-10 minutes, and a child's performance can be compared to developmental norms.","Oral Mechanism/Cranial Nerve Examination for Young Children | Cranial Nerve/Oral Mech Exam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4274490","Consensus Auditory-Perceptual Evaluation of Voice","C160860","A tool for clinical auditory-perceptual assessment of voice. Its primary purpose is to describe the severity of auditory-perceptual attributes of a voice problem, in a way that can be communicated among clinicians. Its secondary purpose is to contribute to hypotheses regarding the anatomic and physiological bases of voice problems and to evaluate the need for additional testing.","Consensus Auditory-Perceptual Evaluation of Voice | CAPE-V | Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V)",,,,,,,,,,,,,,,"37397444","Consensus Auditory-Perceptual Evaluation of Voice",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL969931","hearScreen USA","C160861","A clinically validated, US national hearing screening application (app) designed for accurate detection of hearing impairment. The screening analyzes the person's ability to perceive speech-in-noise. Based on the person's response, the app automatically generates a hearing score that indicates whether there may be a possible hearing loss.","hearScreen USA | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969892","Phonological Awareness Test","C160862","A test to assess the ability of the respondent to repeat multi-syllable nonsense words. It is is used to assess an individual's ability to code and temporarily store information phonologically. This ability is related to verbal memory and language acquisition.","Phonological Awareness Test | Phonological Awareness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971215","Syllable Repetition Task","C160863","An 18-item imitation task that assesses a speaker's ability to repeat nonwords. This nonword repetition task was designed specifically for speakers whose incomplete inventories invalidate use of conventional nonword repetition tasks and/or who have speech production patterns that are difficult to transcribe and score.","Syllable Repetition Task | SRT | Syllable Repetition Task (SRT)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969891","Tinnitus Screener","C160864","An interviewer-administered questionnaire that assesses, during the past year, whether tinnitus is present at all, and, if so, whether it is acute or chronic, constant or temporary, intermittent or occasional.","Tinnitus Screener | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474109","chimeric fibril-reactive monoclonal antibody 111F4","C117241","A chimeric monoclonal antibody specifically targeting human immunoglobulin light chain (LC)-related fibrils, which may potentially be used in the treatment of light chain-associated (AL) amyloidosis. Upon administration, anselamimab targets and binds to the amyloid-related, conformational epitope on LC-related fibrils. This inhibits fibrillogenesis, induces an Fc-mediated cellular inflammatory response, increases degradation and elimination of AL amyloidomas, and prevents systemic LC-associated amyloid deposits. In AL amyloidosis the amyloid fibrils are composed of immunoglobulin light chain fragments.","Anselamimab | 11-1F4 | 111F4 | ANSELAMIMAB | CAEL 101 | CAEL-101 | CAEL101 | Chimeric Amyloid-reactive Monoclonal Antibody CAEL-101 | Chimeric Fibril-reactive Monoclonal Antibody 111F4 | Chimeric Fibril-reactive Monoclonal Antibody CAEL-101 | Chimeric Fibril-reactive Monoclonal Antibody CAEL-101 | c11-1F4 mAb | mAb-11-1F4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986682","Locally Recurrent Malignant Neoplasm","C94796","The reemergence of a malignant neoplasm after a period of remission at the site of the original tumor or adjacent to it.","Locally Recurrent Malignant Neoplasm | Locally Recurrent Cancer | Loco-Regional | Locoregional Recurrence | locally recurrent cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1302401","Colorectal Adenoma","C5673","An adenoma that arises from the colon or rectum.  The group of colorectal adenomas includes tubular, villous, and tubulovillous adenomas, traditional serrated adenomas, sessile serrated adenomas/polyps, and familial adenomatous polyposis.","Colorectal Adenoma | Adenoma of Large Bowel | Adenoma of Large Intestine | Adenoma of the Large Bowel | Adenoma of the Large Intestine | Large Bowel Adenoma | Large Intestine Adenoma",,,,,,,,,,,,,,,"4161540","Adenoma of large intestine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL969887","Biopsy Clip","C160869","A surgically placed marker that is used to identify the site of a biopsy.","Biopsy Clip | Biopsy Marker",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0883092","Biopsy Guidance","C160875","Any of various methods to assist in directing a biopsy needle into the area of interest.","Biopsy Guidance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526418","Double-Expressor Lymphoma","C138899","A diffuse large B-cell lymphoma characterized by double expression of MYC and BCL2 proteins without MYC and BCL2 gene aberrations. These lymphomas may have a worse prognosis than other diffuse large B-cell lymphomas, not otherwise specified, but they are not as aggressive as the high-grade B-cell lymphomas, with rearrangements of MYC and BCL2 and/or BCL6 genes.","Double-Expressor Lymphoma | DEL | Double Expressor Lymphoma | Double-Expressing Lymphoma | double expressor lymphoma | double_expressor_lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504553","High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements","C125904","High-grade B-cell lymphoma characterized by the abnormal rearrangement of two genes, MYC gene and either BCL2 or BCL6 genes. Patients with this type of lymphoma usually respond poorly to standard treatments and have a poor prognosis.","High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements | DH Lymphoma | DHL | Double Hit Lymphoma | Double-Hit Lymphoma | HGBCL-DH | High-Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements | double hit lymphoma | double_hit_lymphoma",,,,,,,,,,,,,,,"37206742","High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042939","Voice","C92692","Sound produced by vibration of the vocal cords during an expiration of air.","Voice | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL427859","Non-mass-like Enhancement","C160918","An area of enhancement on MRI that does not belong to a 3D mass or have distinct features of a mass. These lesions are characterized by their distribution, internal enhancement pattern, and symmetry (or lack thereof). (BI-RADS)","Non-mass-like Enhancement | Magnetic Resonance Imaging Non-mass Like Enhancement | NMLE | Non-mass Enhancement | Non-masslike Enhancement | Nonmass Enhancement | Nonmass-like Enhancement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017249","Gender Identity","C158277","A person's internally held sense of their gender, which may or may not correspond to the individual's genotypic or phenotypic sex.","Gender Identity | GENIDENT",,,,,,,,,,,,,,,"37171290","Gender identity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3845569","Specify Other","C157106","A directive to indicate a response not listed.","Specify Other | Other, Specify | Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024770","Maori","C158274","The native people of New Zealand.","Maori | MAORI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937649","Zhuang Chinese","C158159","A Chinese person from the Zhuang ethnic group.","Zhuang Chinese | ZH | ZHUANG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937678","Zang Chinese","C158166","A Chinese person from the Zang (including Amdowa, Khampa and some Pumi speakers) ethnic group.","Zang Chinese | ZA | ZANG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937806","Yugur Chinese","C158205","A Chinese person from the Yugur ethnic group.","Yugur Chinese | YG | YUGUR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937679","Yi Chinese","C158164","A Chinese person from the Yi ethnic group.","Yi Chinese | YI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938097","Yao Chinese","C158170","A Chinese person from the Yao ethnic group.","Yao Chinese | YA | YAO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937675","Xibe Chinese","C158188","A Chinese person from the Xibe ethnic group.","Xibe Chinese | XB | XIBE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938159","Va Chinese","C158182","A Chinese person from the Va ethnic group.","Va Chinese | VA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937805","Uzbek Chinese","C158206","A Chinese person from the Uzbek ethnic group.","Uzbek Chinese | UZ | UZBEK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937646","Uygur Chinese","C158162","A Chinese person from the Uygur ethnic group.","Uygur Chinese | UG | UYGUR | Uighur Chinese",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937680","Tujia Chinese","C158165","A Chinese person from the Tujia ethnic group.","Tujia Chinese | TJ | TUJIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938098","Tu Chinese","C158186","A Chinese person from the Tu ethnic group.","Tu Chinese | TU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337909","Tatar Chinese","C158213","A Chinese person from the Tatar ethnic group.","Tatar Chinese | TATAR | TT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937672","Tajik Chinese","C158195","A Chinese person from the Tajik ethnic group.","Tajik Chinese | TA | TAJIK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938093","Sui Chinese","C158183","A Chinese person from the Sui ethnic group.","Sui Chinese | SU | SUI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938137","She Chinese","C158177","A Chinese person from the She ethnic group.","She Chinese | SH | SHE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937673","Salar Chinese","C158192","A Chinese person from the Salar ethnic group.","Salar Chinese | SALAR | SL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938135","Russ Chinese","C158204","A Chinese person from the Russ ethnic group.","Russ Chinese | RS | RUSS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938106","Qiang Chinese","C158185","A Chinese person from the Qiang ethnic group.","Qiang Chinese | QI | QIANG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1379039","Pumi Chinese","C158196","A Chinese person from the Pumi ethnic group.","Pumi Chinese | PM | PUMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938125","Oroqen Chinese","C158208","A Chinese person from the Oroqen ethnic group.","Oroqen Chinese | OR | OROQEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938095","Nu Chinese","C158198","A Chinese person from the Nu ethnic group.","Nu Chinese | NU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938151","Naxi Chinese","C158184","A Chinese person from the Naxi (including Mosuo) ethnic group.","Naxi Chinese | NAXI | NX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938133","Mulao Chinese","C158187","A Chinese person from the Mulao (including the Qago) ethnic group.","Mulao Chinese | ML | MULAO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337892","Mongol Chinese","C158167","A Chinese person from the Mongol ethnic group.","Mongol Chinese | MG | MONGOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938121","Monba Chinese","C158207","A Chinese person from the Monba ethnic group.","Monba Chinese | MB | MONBA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937647","Miao Chinese","C158163","A Chinese person from the Miao (Including Hmong) ethnic group.","Miao Chinese | MH | MIAO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938116","Maonan Chinese","C158194","A Chinese person from the Maonan (including the Then) ethnic group.","Maonan Chinese | MAONAN | MN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938140","Man Chinese","C158161","A Chinese person from the Man ethnic group.","Man Chinese | MA | MAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938113","Lisu Chinese","C158178","A Chinese person from the Lisu ethnic group.","Lisu Chinese | LISU | LS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938126","Li Chinese","C158174","A Chinese person from the Li ethnic group.","Li Chinese | LI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937803","Lhoba Chinese","C158212","A Chinese person from the Lhoba ethnic group.","Lhoba Chinese | LB | LHOBA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938129","Lahu Chinese","C158181","A Chinese person from the Lahu ethnic group.","Lahu Chinese | LAHU | LH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337902","Kirgiz Chinese","C158189","A Chinese person from the Kirgiz ethnic group.","Kirgiz Chinese | KG | KIRGIZ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937677","Kazak Chinese","C158175","A Chinese person from the Kazak ethnic group.","Kazak Chinese | KAZAK | KZ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937807","Jino Chinese","C158201","A Chinese person from the Jino ethnic group.","Jino Chinese | JINO | JN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938122","Jingpo Chinese","C158190","A Chinese person from the Jingpo ethnic group.","Jingpo Chinese | JINGPO | JP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937648","Hui Chinese","C158160","A Chinese person from the Hui (including Utsuls of Hainan, descended from Cham refugees) ethnic group.","Hui Chinese | HU | HUI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937804","Hezhen Chinese","C158210","A Chinese person from the Hezhen ethnic group.","Hezhen Chinese | HEZHEN | HZ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938100","Hani Chinese","C158173","A Chinese person from the Hani (including Sangkong) ethnic group.","Hani Chinese | HANI | HN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0814942","Han Chinese","C158158","A Chinese person from the Han ethnic group (including Chuanqing).","Han Chinese | HA | HAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938124","Gin Chinese","C158200","A Chinese person from the Gin ethnic group.","Gin Chinese | GI | GIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937676","Gelao Chinese","C158180","A Chinese person from the Gelao ethnic group.","Gelao Chinese | GELAO | GL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938120","Gaoshan Chinese","C158211","A Chinese person from the Gaoshan ethnic group.","Gaoshan Chinese | GAOSHAN | GS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937808","Ewenki Chinese","C158199","A Chinese person from the Ewenki ethnic group.","Ewenki Chinese | EW | EWENKI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938131","Dongxiang Chinese","C158179","A Chinese person from the Dongxiang ethnic group.","Dongxiang Chinese | DONGXIANG | DX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938117","Dong Chinese","C158168","A Chinese person from the Dong ethnic group.","Dong Chinese | DO | DONG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938123","Derung Chinese","C158209","A Chinese person from the Derung ethnic group.","Derung Chinese | DERUNG | DR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938119","Deang Chinese","C158202","A Chinese person from the Deang ethnic group.","Deang Chinese | DE | DEANG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937674","Daur Chinese","C158191","A Chinese person from the Daur ethnic group.","Daur Chinese | DAUR | DU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938134","Dai Chinese","C158176","A Chinese person from the Dai (including several different Tai-speaking groups historically referred to as Bai-yi) ethnic group.","Dai Chinese | DA | DAI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938127","Chosen Chinese","C158172","A Chinese person from the Chosen ethnic group.","Chosen Chinese | CHOSEN | CS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938158","Buyei Chinese","C158169","A Chinese person from the Buyei ethnic group.","Buyei Chinese | BUYEI | BY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938094","Bonan Chinese","C158203","A Chinese person from the Bonan ethnic group.","Bonan Chinese | BN | BONAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938132","Blang Chinese","C158193","A Chinese person from the Blang ethnic group.","Blang Chinese | BL | BLANG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938128","Bai Chinese","C158171","A Chinese person from the Bai ethnic group.","Bai Chinese | BA | BAI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938111","Achang Chinese","C158197","A Chinese person from the Achang ethnic group.","Achang Chinese | AC | ACHANG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937651","7 Lead Placement Standard for Non-Human Subjects","C158157","An electrocardiogram lead placement for non-human species using a five-electrode lead set to monitor and/or record 7 ECG leads, analogous to the standard and augmented human limb leads and one chest lead. (CDISC)","7 Lead Placement Standard for Non-Human Subjects | 7 LEAD STANDARD, NON-HUMAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937802","Extended Release Capsule, Softgel Dosage Form","C158215","A capsule, covered with a soft gelatin shell and containing a liquid, suspension, or semisolid, that is designed to release active and/or inert ingredient(s) at a controlled, prolonged rate to reduce dosing frequency.","Extended Release Capsule, Softgel Dosage Form | CAPSULE, SOFTGEL, EXTENDED RELEASE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937801","Extended Release Capsule, Hard Dosage Form","C158214","A capsule, covered with a rigid outer shell, that is designed to release active and/or inert ingredient(s) at a controlled, prolonged rate to reduce dosing frequency.","Extended Release Capsule, Hard Dosage Form | CAPSULE, HARD, EXTENDED RELEASE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937799","HIV-2 Seroreactivity Measurement","C158216","The determination of the HIV-2 seroreactivity present in a sample.","HIV-2 Seroreactivity Measurement | HIV-2 Seroreactivity | HIV2SR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937800","HIV-1 Seroreactivity Measurement","C158217","The determination of the HIV-1 seroreactivity present in a sample.","HIV-1 Seroreactivity Measurement | HIV-1 Seroreactivity | HIV1SR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937827","Pyridoxal Phosphate Measurement","C158237","The determination of the amount of pyridoxal phosphate present in a sample.","Pyridoxal Phosphate Measurement | Active Vitamin B6 | PLP | Pyridoxal Phosphate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938101","Large Lymphocyte Count","C158236","The determination of the number of large lymphocytes present in a sample.","Large Lymphocyte Count | LYMLG | Large Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937829","Complement C5b-9 Measurement","C158235","The determination of the amount of complement C5b-9 present in a sample.","Complement C5b-9 Measurement | C5B9 | Complement C5b-9 | MAC Measurement | Membrane Attack Complex Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938107","Hemoglobin H Inclusion Bodies Measurement","C158234","The determination of the amount of hemoglobin H inclusion bodies present in a sample.","Hemoglobin H Inclusion Bodies Measurement | HBH Inclusion Bodies | HBHIB | HGH Inclusion Bodies | Hemoglobin H Inclusion Bodies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3495706","Asymmetric Dimethylarginine Measurement","C158233","The determination of the amount of asymmetric dimethylarginine present in a sample.","Asymmetric Dimethylarginine Measurement | ADMA | Asymmetric Dimethylarginine | N,N-dimethylarginine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937831","Symmetric Dimethylarginine Measurement","C158232","The determination of the amount of symmetric dimethylarginine present in a sample.","Symmetric Dimethylarginine Measurement | N,N'-dimethylarginine | SDMA | Symmetric Dimethylarginine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937830","Sezary Cells to Leukocytes Ratio Measurement","C158231","The determination of the ratio of Sezary cells compared to total leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Sezary Cells to Leukocytes Ratio Measurement | SEZCELE | Sezary Cells/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937832","Plasmacytoid Lymphocytes to Leukocytes Ratio Measurement","C158229","The determination of the ratio of plasmacytoid lymphocytes compared to total leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Plasmacytoid Lymphocytes to Leukocytes Ratio Measurement | LYMPLLE | Plasmacytoid Lymphocytes/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937792","Glycated Albumin to Albumin Ratio Measurement","C158228","The determination of the ratio of glycated albumin compared to total albumin present in a sample. The measurement may be expressed as a ratio or percentage.","Glycated Albumin to Albumin Ratio Measurement | ALBGALB | Glycated Albumin/Albumin | Glycosylated Albumin to Albumin Ratio Measurement | Glycosylated Albumin/Albumin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937791","Direct Bilirubin to Bilirubin Ratio Measurement","C158226","The determination of the ratio of direct bilirubin compared to total bilirubin present in a sample. The measurement may be expressed as a ratio or percentage.","Direct Bilirubin to Bilirubin Ratio Measurement | BILDIRBI | Direct Bilirubin/Bilirubin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937794","Aspartate Aminotransferase to Creatine Kinase Ratio Measurement","C158225","The determination of the ratio of aspartate aminotransferase compared to creatine kinase present in a sample. The measurement may be expressed as a ratio or percentage.","Aspartate Aminotransferase to Creatine Kinase Ratio Measurement | AST to CK Ratio Measurement | AST/Creatine Kinase | ASTCK | Aspartate Aminotransferase/CPK | Aspartate Aminotransferase/Creatine Kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937793","Threonine to Creatinine Ratio Measurement","C158224","The determination of the ratio of threonine compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Threonine to Creatinine Ratio Measurement | THRCREAT | Threonine/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937795","Taurine to Creatinine Ratio Measurement","C158223","The determination of the ratio of taurine compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Taurine to Creatinine Ratio Measurement | TAURCRT | Taurine/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2711587","Apolipoprotein A to Apolipoprotein B Ratio Measurement","C158222","The determination of the ratio of apolipoprotein A compared to apolipoprotein B present in a sample. The measurement may be expressed as a ratio or percentage.","Apolipoprotein A to Apolipoprotein B Ratio Measurement | ALAALB | Apolipoprotein A/Apolipoprotein B",,,,,,,,,,,,,,,"40480045","Measurement of ratio of apolipoprotein A to apolipoprotein B",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937797","Glycine to Creatinine Ratio Measurement","C158221","The determination of the ratio of glycine compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Glycine to Creatinine Ratio Measurement | GLYCREAT | Glycine/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937796","Soluble Interleukin 2 Receptor Measurement","C158220","The determination of the amount of soluble interleukin 2 receptor present in a sample.","Soluble Interleukin 2 Receptor Measurement | IL2SR | Soluble CD25 | Soluble IL-2Ra | Soluble IL2R Measurement | Soluble Interleukin 2 Receptor | Soluble Interleukin 2 Receptor Subunit Alpha | sCD25 | sIL2R Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202385","Fluoxetine Measurement","C158219","The determination of the amount of fluoxetine present in a sample.","Fluoxetine Measurement | FLUOXTN | Fluoxetine",,,,,,,,,,,,,,,"4139670","Fluoxetine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937798","Monoclonal Protein Spike Region Identification","C158218","The determination of a monoclonal protein spike region present in a sample.","Monoclonal Protein Spike Region Identification | MPROTR | MSPIKER | Monoclonal Protein Band Region | Monoclonal Protein Region | Monoclonal Protein Spike Region",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937658","Interleukin 2 Receptor Measurement","C158147","The determination of the amount of interleukin 2 receptor present in a sample.","Interleukin 2 Receptor Measurement | IL2R | IL2R Measurement | Interleukin 2 Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523595","Carboplatin/Pemetrexed Regimen","C136284","A regimen consisting of carboplatin and pemetrexed that is used for the treatment of non-small cell lung cancer (NSCLC), and malignant peritoneal and pleural mesothelioma.","Carboplatin/Pemetrexed Regimen | Carboplatin and Pemetrexed | Carboplatin-Alimta Regimen | Carboplatin-Pemetrexed | Carboplatin-Pemetrexed Regimen | Carboplatin/Pemetrexed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229881","Tonsillar Fossa","C12235","A triangular shaped space that lies on each side of the oropharynx and houses the palatine tonsils.","Tonsillar Fossa | Tonsillar fossa",,,,,,,,,,,,,,,"4138234","Tonsillar fossa structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL969893","Activating ERK Family Gene Mutation","C160877","A mutation in a ERK family gene that encodes a constitutively active MAP family serine/threonine-protein kinase and results in aberrant activation of its downstream pathways.","Activating ERK Family Gene Mutation | Activating ERK Mutation | Activating Extracellular Signal-Regulated Kinase Family Gene Mutation | Activating MAPK Family Gene Mutation | Activating MAPK Mutation | Activating Mitogen-Activated Protein Kinase Family Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969376","Activating Non-V600 BRAF Mutation","C160435","A change in the nucleotide sequence of the BRAF gene that occurs outside of codon 600 and results in activation of both serine/threonine-protein kinase B-raf and its downstream signaling pathways.","Activating Non-V600 BRAF Mutation | Activating Non-Codon 600 BRAF Gene Mutation | Activating Non-Codon 600 BRAF Mutation | BRAF Class II Alteration | BRAF Class II Mutation | Class 2 BRAF Mutation | Class II BRAF Alteration | Class II BRAF Mutation | Non-Codon 600 Activating BRAF Gene Mutation | Non-Codon 600 Activating BRAF Mutation | Non-Codon 600 Activating BRAF1 Mutation | Non-Codon 600 B-RAF Activating Mutation | Non-Codon 600 B-RAF1 Activating Mutation | Non-Codon 600 BRAF Activating Mutation | Non-V600 Activating BRAF Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969315","Adenovirus Reactivation","C160242","The switching of latent adenovirus to a lytic infection.","Adenovirus Reactivation | AdV Reactivation | Adenoviral Reactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968918","CEACAM6 Positive","C159905","An indication that CEACAM6 expression has been detected in a sample.","CEACAM6 Positive | CD66c Antigen Positive | CD66c Positive | CEAL Positive | Carcinoembryonic Antigen Related Cell Adhesion Molecule 6 Positive | Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6 Positive | NCA Positive | Non-Specific Cross Reacting Antigen Positive | Non-Specific Crossreacting Antigen Positive | Nonspecific Crossreacting Antigen Positive | Normal Cross-Reacting Antigen Positive | Normal Crossreacting Antigen Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969904","Deleterious CYSLTR2 Gene Mutation","C160878","A change in the nucleotide sequence of the CYSLTR2 gene that is associated with increased risk of disease.","Deleterious CYSLTR2 Gene Mutation | CYSLTR2 Driver Mutation | Deleterious CYSLT2 Gene Mutation | Deleterious CYSLT2R Gene Mutation | Deleterious Cysteinyl Leukotriene Receptor 2 Gene Mutation | Deleterious GPCR21 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969927","Elevated Type I Collagen Cross-Linked N-Telopeptide","C160851","A laboratory test result indicating the presence of an increased level of the bone resorption marker type I collagen cross-linked N-telopeptide (NTx or NTxI) in a biological sample.","Elevated Type I Collagen Cross-Linked N-Telopeptide | Elevated Collagen Cross-Linked N-Telopeptide | Elevated Cross-Linked Type I Collagen N-Telopeptide | Elevated N-Telopeptide | Elevated N-Telopeptide of Type I Collagen | Elevated N-Terminal Telopeptide | Elevated N-Terminal Type I Collagen Cross-Linked | Elevated NTx | Elevated NTxI | Elevated Type I Collagen N-Telopeptide | Elevated Type I Collagen X-Linked N-Telopeptides",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968951","FGFR2B Overexpression","C159871","An indication that overexpression of FGFR2B has been detected in a sample.","FGFR2B Overexpression | FGFR-2 IIIb Overexpression | FGFR2 IIIb Overexpression | FGFR2(IIIb) Overexpression | FGFR2-IIIb Overexpression | FGFR2IIIb Overexpression | Fibroblast Growth Factor Receptor 2 Isoform IIIb Overexpression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969903","Deleterious GNAQ Gene Mutation","C160879","A change in the nucleotide sequence of the GNAQ gene that is associated with increased risk of disease.","Deleterious GNAQ Gene Mutation | Deleterious CMC1 Gene Mutation | Deleterious G Protein Subunit Alpha q Gene Mutation | Deleterious G-ALPHA-q Gene Mutation | Deleterious GAQ Gene Mutation | Deleterious Guanine Nucleotide Binding Protein (G Protein), Q Polypeptide Gene Mutation | GNAQ Driver Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919711","Hepatitis B Virus Surface Antigen Negative","C160371","An indication that the hepatitis B virus surface protein antigen has not been detected in a sample.","Hepatitis B Virus Surface Antigen Negative | HBs Antigen Negative | HBs Negative | HBsAg Negative | Hepatitis B Surface Antigen Negative | Hepatitis B Surface Protein Antigen Negative | Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0948251","Hepatitis B Virus Core Antibody Negative","C160370","An indication that antibodies that recognize a hepatitis B virus core protein have not been detected in a sample.","Hepatitis B Virus Core Antibody Negative | Anti-HBc Antibody Negative | Anti-HBc Negative | Anti-HBcAb Negative | Anti-Hepatitis B Core Antibody Negative | Anti-Hepatitis B Virus Core Antibody Negative | HBcAb Negative | Hepatitis B Core Antibody Negative | Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969353","Hepatitis B Virus Negative","C160410","An indication that hepatitis virus B has not been detected in a sample.","Hepatitis B Virus Negative | HBV Negative | Hep B Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281863","Hepatitis C Virus Antibody Positive","C160411","An indication that antibodies that recognize the hepatitis C virus have been detected in a sample.","Hepatitis C Virus Antibody Positive | Anti-HCV Antibody Positive | Anti-Hepatitis C Antibody Positive | Anti-Hepatitis C Virus Antibody Positive | HCV Antibody Positive | Hepatitis C Antibody Positive | Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968911","ERBB2 Gene Amplification Negative","C159897","An indication that amplification of the ERBB2 gene was not detected in a sample.","ERBB2 Gene Amplification Negative | ERBB2 Non-Amplified | Erb-B2 Receptor Tyrosine Kinase 2 Gene Amplification Negative | Erb-B2 Receptor Tyrosine Kinase Gene Amplification Negative | HER-2 Gene Amplification Negative | HER2 Gene Amplification Negative | HER2 Non-Amplified | HER2/neu Gene Amplification Negative | NEU Gene Amplification Negative | Negative | v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 Gene Amplification Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969636","IDH1 NP_005887.2:p.R132V","C160650","A change in the amino acid residue at position 132 in the isocitrate dehydrogenase [NADP] cytoplasmic protein where arginine has been replaced by valine.","IDH1 NP_005887.2:p.R132V | Cytosolic NADP-Isocitrate Dehydrogenase Protein Arg132Val | Cytosolic NADP-Isocitrate Dehydrogenase Protein R132V | IDH1 Arg132Val | IDH1 NP_005887.2:p.Arg132Val | IDH1 R132V | IDH1 R132V Mutation | IDH1 p.Arg132Val | IDH1 p.R132V | Isocitrate Dehydrogenase [NADP] Cytoplasmic Arg132Val | Isocitrate Dehydrogenase [NADP] Cytoplasmic R132V | NP_005887.2:p.Arg132Val | NP_005887.2:p.R132V",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969647","IDH2 NP_002159.2:p.R140L","C160655","A change in the amino acid residue at position 140 in the isocitrate dehydrogenase [NADP], mitochondrial protein where arginine has been replaced by leucine.","IDH2 NP_002159.2:p.R140L | IDH2 Arg140Leu | IDH2 NP_002159.2:p.Arg140Leu | IDH2 R140L | IDH2 R140L Mutation | IDH2 p.Arg140Leu | IDH2 p.R140L | Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial Arg140Leu | Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial R140L | Isocitrate Dehydrogenase [NADP], Mitochondrial Arg140Leu | Isocitrate Dehydrogenase [NADP], Mitochondrial R140L | NP_002159.2:p.Arg140Leu | NP_002159.2:p.R140L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969657","IDH2 NP_002159.2:p.R140Q","C160661","A change in the amino acid residue at position 140 in the isocitrate dehydrogenase [NADP], mitochondrial protein where arginine has been replaced by glutamine.","IDH2 NP_002159.2:p.R140Q | IDH2 Arg140Gln | IDH2 NP_002159.2:p.Arg140Gln | IDH2 R140Q | IDH2 R140Q Mutation | IDH2 p.Arg140Gln | IDH2 p.R140Q | Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial Arg140Gln | Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial R140Q | Isocitrate Dehydrogenase [NADP], Mitochondrial Arg140Gln | Isocitrate Dehydrogenase [NADP], Mitochondrial R140Q | NP_002159.2:p.Arg140Gln | NP_002159.2:p.R140Q",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969650","IDH2 NP_002159.2:p.R140W","C160652","A change in the amino acid residue at position 140 in the isocitrate dehydrogenase [NADP], mitochondrial protein where arginine has been replaced by tryptophan.","IDH2 NP_002159.2:p.R140W | IDH2 Arg140Trp | IDH2 NP_002159.2:p.Arg140Trp | IDH2 R140W | IDH2 R140W Mutation | IDH2 p.Arg140Trp | IDH2 p.R140W | Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial Arg140Trp | Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial R140W | Isocitrate Dehydrogenase [NADP], Mitochondrial Arg140Trp | Isocitrate Dehydrogenase [NADP], Mitochondrial R140W | NP_002159.2:p.Arg140Trp | NP_002159.2:p.R140W",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969902","NRAS Gene Amplification","C160880","A molecular genetic abnormality indicating the presence of multiple copies of the NRAS gene.","NRAS Gene Amplification | N-RAS Gene Amplification | NRAS Amplification | NRAS Proto-Oncogene, GTPase Gene Amplification | NRAS1 Gene Amplification | Neuroblastoma RAS Viral Oncogene Homolog Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969888","PSA Level Greater than 0.5","C160868","A blood concentration of prostate specific antigen greater than 0.5 ng/mL.","PSA Level Greater than 0.5 | PSA Level Greater than 0.5 ng/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969901","PSA Level Greater than or Equal to Fifty","C160881","A blood concentration of prostate specific antigen greater than or equal to 50 ng/mL.","PSA Level Greater than or Equal to Fifty | PSA Level 50 or Greater | PSA Level Fifty or Greater | PSA Level Greater than or Equal to 50",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969543","PTEN Gene Mutation Negative","C160488","A genetic finding indicating that PTEN gene mutations have not been detected in a sample.","PTEN Gene Mutation Negative | MMAC1 Gene Mutation Negative | Mutated in Multiple Advanced Cancers 1 Gene Mutation Negative | No | No mutation detected | PTEN Mutation Negative | PTEN Wild-Type | PTEN Wildtype | PTEN wt | Phosphatase and Tensin Homolog Gene Mutation Negative | TEP1 Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969900","VTCN1 Positive","C160882","An indication that VTCN1 expression has been detected in a sample.","VTCN1 Positive | B7 Homolog 4 Positive | B7-H4 Positive | B7H4 Positive | B7S1 Positive | B7X Positive | B7h.5 Positive | V-Set Domain Containing T Cell Activation Inhibitor 1 Positive | V-Set Domain-Containing T-Cell Activation Inhibitor 1 Positive | VCTN1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969912","PLCB4 Gene Mutation","C160887","A change in the nucleotide sequence of the PLCB4 gene.","PLCB4 Gene Mutation | ARCND2 Gene Mutation | PI-PLC Gene Mutation | Phospholipase C Beta 4 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969911","Deleterious PLCB4 Gene Mutation","C160888","A change in the nucleotide sequence of the PLCB4 gene that is associated with increased risk of disease.","Deleterious PLCB4 Gene Mutation | Deleterious ARCND2 Gene Mutation | Deleterious PI-PLC Gene Mutation | Deleterious Phospholipase C Beta 4 Gene Mutation | PLCB4 Driver Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4760910","Spindle cell squamous carcinoma of skin (disorder)","C4666","A squamous cell carcinoma of the skin with a prominent spindle cell component.","Skin Spindle Cell Squamous Cell Carcinoma | Skin Pseudosarcomatous Squamous Cell Carcinoma | Skin Spindle Cell (Sarcomatoid) Squamous Cell Carcinoma | Skin Spindle Cell Squamous Carcinoma | Skin Spindle Cell Squamous Carcinoma | Skin Spindle Cell Squamous Cell Carcinoma | Skin Spindle Cell Squamous Cell Carcinoma | Spindle Cell (Sarcomatoid) Squamous Cell Skin Carcinoma | Spindle Cell (Sarcomatoid) Squamous Cell Skin Carcinoma | Spindle Cell Squamous Carcinoma of Skin | Spindle Cell Squamous Carcinoma of the Skin | Spindle cell squamous cell carcinoma",,,,,,,,,,,,,,,"4111922","Spindle cell squamous carcinoma of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332428","Ann Arbor Stage III Lymphoma","C8320","Ann Arbor Classification: Stage III: Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S).","Ann Arbor Stage III Lymphoma | Lymphoma Stage III | Stage III Lymphoma",,,,,,,,,,,,,,,"4210767","Lymphoma stage III",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332434","Ann Arbor Stage IV Lymphoma","C8321","Ann Arbor Classification: Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s); or any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid.","Ann Arbor Stage IV Lymphoma | Lymphoma Stage IV | Stage IV Lymphoma",,,,,,,,,,,,,,,"4283505","Lymphoma stage IV",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332424","Ann Arbor Stage I Lymphoma","C8318","Ann Arbor Classification: Stage I: Involvement of a single lymph node region (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE) (rare in Hodgkin lymphoma).","Ann Arbor Stage I Lymphoma | Lymphoma Stage I | Stage I Lymphoma",,,,,,,,,,,,,,,"4147822","Lymphoma stage I",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0332426","Ann Arbor Stage II Lymphoma","C8319","Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE).","Ann Arbor Stage II Lymphoma | Lymphoma Stage II | Stage II Lymphoma",,,,,,,,,,,,,,,"4297142","Lymphoma stage II",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0226805","Median Basilic Vein","C33070","A vein between the biceps and pronator radii teres muscles that unites with the common ulnar vein to form the basilic vein within the forearm.","Median Basilic Vein | MEDIAN BASILIC VEIN | Median Cubital Vein",,,,,,,,,,,,,,,"4104547","Structure of median basilic vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003153","Anterior Eye Segment","C12668","The part of the eye anterior to the lens, including but not limited to the anterior chamber, cornea and related structures.","Anterior Eye Segment | EYE, ANTERIOR SEGMENT",,,,,,,,,,,,,,,"4138680","Anterior eyeball segment structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937828","HIV-1 RNA Measurement","C158238","The determination of the amount of HIV-1 RNA present in a sample.","HIV-1 RNA Measurement | HIV-1 RNA | HIV1RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937815","Targeted Genome Sequencing","C158253","A DNA sequencing technique in which selected regions of an individual's genome are sequenced.","Targeted Genome Sequencing | TARGETED GENOME SEQUENCING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937818","Targeted Transcriptome Sequencing","C158252","A type of whole transcriptome shotgun sequencing technique in which select portions of the transcriptome are selected for sequencing.","Targeted Transcriptome Sequencing | TARGETED TRANSCRIPTOME SEQUENCING | Targeted RNA-Seq",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937817","In vitro Gene Expression Assay","C158251","A method that detects gene transcription associated with an in vitro cellular stimulus, through detection of the resulting transcribed mRNA or translated protein.","In vitro Gene Expression Assay | IN VITRO GENE EXPRESSION ASSAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937820","Multiplex Real-time Polymerase Chain Reaction Assay","C158250","An assay technique that utilizes the polymerase chain reaction (PCR) method to amplify multiple DNA sequences in a single cycle, with the accumulation of amplification product being measured as the reaction progresses.","Multiplex Real-time Polymerase Chain Reaction Assay | MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY | Multiplex Real-Time PCR | Real-Time Multiplex PCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937819","Immune Repertoire Deep Sequencing","C158249","DNA sequencing of the full complement of genes associated with T and B cell antigen-specific receptors in an individual, performed with a high number of replications.","Immune Repertoire Deep Sequencing | IMMUNE REPERTOIRE DEEP SEQUENCING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937822","Cell-of-Origin Assay","C158248","An assay that utilizes gene expression profiling of RNA extracted from formalin-fixed, paraffin-embedded tissue biopsies, in order to determine the cell of origin of the tumor.","Cell-of-Origin Assay | CELL OF ORIGIN ASSAY | COO Assay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937821","Fluorescent Antibody Virus Neutralization Assay","C158247","An immunofluorescence assay method that measures the level of virus-specific neutralizing antibodies in a serum or a plasma sample by the detection of fluorescence in susceptible cells incubated with serial dilutions of the serum/plasma and fluorophore-conjugated virus.","Fluorescent Antibody Virus Neutralization Assay | FAVN | FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937823","Sloan Letter Eye Chart 100 Percent","C158246","A diagrammatic method of vision testing that utilizes black letters on a white background to assess high contrast visual acuity that uses the Sloan optotypes and a 100% contrast level.","Sloan Letter Eye Chart 100 Percent | SLOAN LETTER EYE CHART 100%",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1294077","Myeloperoxidase Stain","C158245","Immunohistochemical or enzyme cytochemical staining method to detect myeloperoxidase, a lysosomal protein that has peroxidase enzyme activity and is present in granulocytic and monocytic cells, but absent in lymphocytes.","Myeloperoxidase Stain | MPO Stain | MYELOPEROXIDASE STAIN",,,,,,,,,,,,,,,"4035390","Myeloperoxidase stain method",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937825","Thermal Ionization Mass Spectrometry","C158244","A mass spectrometry method in which chemically-purified samples are heated to create positively ionized atoms that are then accelerated by an electric field and mass separated by an electromagnet.","Thermal Ionization Mass Spectrometry | THERMAL IONIZATION MASS SPECTROMETRY | TIMS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937824","Slit Lamp Photography","C158243","A method of capturing images of the structures of the eye using a horizontally mounted microscope with an attached slit lamp.","Slit Lamp Photography | SLIT LAMP PHOTOGRAPHY | Slit Lamp Biomicrography",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1318787","Fluorescein Stain","C158242","A vital staining method that utilizes an orange phthalic indicator dye, which emits green fluorescence in the presence of alkaline solutions.","Fluorescein Stain | FLUORESCEIN STAIN",,,,,,,,,,,,,,,"4229244","Fluorescein stain method",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937826","Lissamine Green Stain","C158241","A vital staining method that utilizes a green, synthetically-produced phenyl methane dye that preferentially stains degenerate and dead epithelial cells and stroma.","Lissamine Green Stain | LISSAMINE GREEN STAIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1318844","Romanowsky Stain","C158240","A microscopy staining method that utilizes both cationic and anionic dyes (typically methylene blue and eosin Y, respectively) for the morphological assessment of cells in a biological specimen.","Romanowsky Stain | ROMANOWSKY STAIN",,,,,,,,,,,,,,,"4238093","Romanowsky stain method",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017231","Immunodiffusion","C158239","A quantitative technique used to detect and estimate the concentration of an antigen by measuring the precipitation which is formed as a result of the interaction of the antigen and an antibody at optimal concentration.","Immunodiffusion | IMMUNODIFFUSION",,,,,,,,,,,,,,,"4138558|45769415","Immunodiffusion measurement|Immunodiffusion",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL937816","Chalkley Score","C158254","A microscopic measurement of the volumetric or area ratios of components of tissues or organs. (Chalkley HW. Method for the quantitative morphological analysis of tissues. J Natl Cancer Inst; 4: 47-52)","Chalkley Score | CHALKLEY SCORE | Chalkley Count",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937813","Flagged Mutations Present Indicator","C158255","An indication as to whether the pre-specified mutations of interest are present in the subject.","Flagged Mutations Present Indicator | FLMUTIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937811","Lean Mass","C158257","The weight of a body part or whole body, minus the weight of the fat associated with that body part or whole body.","Lean Mass | LEANMASS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937814","Fat Mass","C158256","The weight of the body fat associated with either a particular body part or the whole body.","Fat Mass | FATMASS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937761","Glycerophosphorylcholine and Phosphorylcholine Measurement","C158261","The determination of the amount of glycerophosphorylcholine and phosphorylcholine present in a sample.","Glycerophosphorylcholine and Phosphorylcholine Measurement | GPC+PCh | GPCPC | Glycerophosphorylcholine + Phosphorylcholine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937810","Creatine and Phosphocreatine Measurement","C158260","The determination of the amount of creatine and phosphocreatine present in a sample.","Creatine and Phosphocreatine Measurement | CTNPCTN | Creatine+Phosphocreatine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937809","Free Choline and Glycerophosphorylcholine and Phosphorylcholine Measurement","C158259","The determination of the amount of free choline, glycerophosphorylcholine, and phosphorylcholine present in a sample.","Free Choline and Glycerophosphorylcholine and Phosphorylcholine Measurement | Choline, Free + Glycerophosphorylcholine + Phosphorylcholine | Choline, Free+GPC+PCh | FCGPCPC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937812","N-acetylaspartate and N-acetyl-aspartylglutamate Measurement","C158258","The determination of the amount of N-acetylaspartate and N-acetyl-aspartylglutamate present in a sample.","N-acetylaspartate and N-acetyl-aspartylglutamate Measurement | N-acetylaspartate + N-acetyl-aspartylglutamate | NAA + NAAG Measurement | NAA+NAAG | NAANAAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937756","Volume of Distribution of Fraction Dose Predicted Corrected for Unbound Drug","C158267","The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using the predicted value at the time of the last non-zero concentration and corrected for unbound drug.","Volume of Distribution of Fraction Dose Predicted Corrected for Unbound Drug | VZFPUB | Vz Pred by F for UB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937759","Volume of Distribution Predicted for Unbound Drug","C158266","The volume of distribution associated with the terminal slope following administration, calculated using the predicted value at the time of the last non-zero concentration and corrected for unbound drug.","Volume of Distribution Predicted for Unbound Drug | VZPUB | Vz Pred for UB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937758","Volume of Distribution Observed for Unbound Drug","C158265","The volume of distribution associated with the terminal slope following administration, calculated using the observed value of the last non-zero concentration and corrected for unbound drug.","Volume of Distribution Observed for Unbound Drug | VZOUB | Vz Obs for UB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937750","Estimated Next Menstrual Period Start Date","C158276","The approximate date of the first day of the next menstrual cycle.","Estimated Next Menstrual Period Start Date | ENMPSDTC | Est Next Menstrual Period Start Date",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3172256","Number of Births","C158275","A measurement of the total number of birth events experienced by a female.","Number of Births | BRTHN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086894","Tanner Scale-Girl - Pubic Hair Stages","C124719","Tanner Scale Girl Version (Tanner Scale-Girl) Pubic hair stages.","Tanner Scale-Girl - Pubic Hair Stages | TANN01-Pubic Hair Stages | TANN0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086893","Tanner Scale-Girl - Breast Stages","C124718","Tanner Scale Girl Version (Tanner Scale-Girl) Breast stages.","Tanner Scale-Girl - Breast Stages | TANN01-Breast Stages | TANN0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086891","Tanner Scale-Boy - Pubic Hair Stages","C124717","Tanner Scale Boy Version (Tanner Scale-Boy) Pubic hair stages.","Tanner Scale-Boy - Pubic Hair Stages | TANN02-Pubic Hair Stages | TANN0202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086890","Tanner Scale-Boy - Genitalia Stages","C124716","Tanner Scale Boy Version (Tanner Scale-Boy) Genitalia stages.","Tanner Scale-Boy - Genitalia Stages | TANN02-Genitalia Stages | TANN0201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1261248","Urine Sediment","C158282","Material that has settled out of solution in urine.","Urine Sediment | URINE SEDIMENT",,,,,,,,,,,,,,,"4297102","Urine sediment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0440739","Mixed Venous Blood","C158281","The de-oxygenated blood flowing into the right side of the heart, composed of a mixture of venous blood from the entirety of the systemic circulation.","Mixed Venous Blood | MIXED VENOUS BLOOD",,,,,,,,,,,,,,,"4023419","Mixed venous blood",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0556638","Gray per Minute","C158296","A unit of absorbed radiation dose rate defined as the number of Grays per minute.","Gray per Minute | Gray/Minute | Gy/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0556637","Gray per Hour","C158295","A unit of absorbed radiation dose rate defined as the number of Grays per hour.","Gray per Hour | Gray/Hour | Gy/h",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937790","Ten Million Colony Forming Units","C158294","A unit of measurement of viable bacterial numbers equal to 10 to the seventh power colony forming units.","Ten Million Colony Forming Units | 10*7.[CFU] | 10^7 CFU | 10^7.[CFU] | Ten Million CFU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937789","Ten Thousand Colony Forming Units","C158293","A unit of measurement of viable bacterial numbers equal to 10 to the fourth power colony forming units.","Ten Thousand Colony Forming Units | 10*4.[CFU] | 10^4 CFU | 10^4.[CFU] | Ten Thousand CFU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3697705","Microgram per Liter Fibrinogen Equivalent Units","C158292","A unit of equivalent concentration equal to the number of micrograms of fibrinogen per unit volume equal to one liter.","Microgram per Liter Fibrinogen Equivalent Units | FEU ug/L | ng/mL FEU | ug FEU/L | ug-L-FEU | ug/L FEU | ug/L[FEU]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3697540","Milligram per Liter Fibrinogen Equivalent Units","C158291","A unit of equivalent concentration equal to the number of milligrams of fibrinogen per unit volume equal to one liter.","Milligram per Liter Fibrinogen Equivalent Units | FEU mg/L | mg FEU/L | mg-L-FEU | mg/L FEU | mg/L[FEU] | ug/mL FEU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937787","Fetal Head Circumference","C158297","A circumferential measurement of the fetal head at the widest point.","Fetal Head Circumference | FTHDCIRC",,,,,,,,,,,,,,,"37167982","Head circumference of fetus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1707291","NUT Carcinoma","C45716","A rare, highly aggressive and lethal carcinoma that affects children and young adults.  It arises from midline epithelial structures, most commonly the head, neck, and mediastinum.  It is a poorly differentiated carcinoma and is characterized by mutations and rearrangement of the NUT gene.  A balanced translocation t(15;19) is present that results in the creation of a fusion gene involving the NUT gene, most commonly BRD4-NUT fusion gene.","NUT Carcinoma | Carcinoma with t(15;19)(q13;p13.1) Translocation | Midline Carcinoma of Children and Young Adults with NUT Rearrangement | Midline carcinoma of children and young adults with NUT rearrangement | NMC | NUT Midline Carcinoma | NUT carcinoma | NUT midline carcinoma | Nuclear Protein in Testis (NUT) Midline Carcinoma | Nuclear Protein in Testis Midline Carcinoma",,,,,,,,,,,,,,,"37162409","NUT (nuclear protein in testis) carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334771","Minor Salivary Gland Carcinoma","C5957","A carcinoma that arises from the minor salivary glands.  Representative examples include adenoid cystic carcinoma, acinic cell carcinoma, polymorphous low grade adenocarcinoma, and mucinous adenocarcinoma.","Minor Salivary Gland Carcinoma | Carcinoma of Minor Salivary Gland | Carcinoma of the Minor Salivary Gland | Minor Salivary Gland Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711278","Nasopharyngeal Papillary Adenocarcinoma","C54400","A low-grade exophytic adenocarcinoma with papillary growth that arises from the epithelium of the nasopharynx. If it is completely removed, the prognosis is excellent.","Nasopharyngeal Low Grade Papillary Adenocarcinoma | Low Grade Nasopharyngeal Papillary Adenocarcinoma | Low-Grade Nasopharyngeal Papillary Adenocarcinoma | Nasopharyngeal Low-Grade Papillary Adenocarcinoma | Nasopharyngeal Papillary Adenocarcinoma | Nasopharyngeal Papillary Adenocarcinoma | Nasopharyngeal Throat Papillary Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280321","Hypopharyngeal Squamous Cell Carcinoma","C4043","A squamous cell carcinoma arising from the hypopharynx.  Signs and symptoms include dysphagia, hemoptysis, and the presence of a neck mass.","Hypopharyngeal Squamous Cell Carcinoma | Epidermoid Carcinoma of Hypopharynx | Epidermoid Carcinoma of the Hypopharynx | Hypopharyngeal Conventional Squamous Cell Carcinoma | Hypopharyngeal Epidermoid Carcinoma | Hypopharyngeal Throat Squamous Cell Cancer | Squamous Cell Carcinoma of Hypopharynx | Squamous Cell Carcinoma of the Hypopharynx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152335","Anterior Commissure","C32086","A rounded band or bundle of nerve fibers that connects the two hemispheres of the brain.","Anterior Commissure | ",,,,,,,,,,,,,,,"4271198","Structure of anterior commissure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227121","Upper Gingiva","C54205","The gingiva covering the maxillary alveolar bone.","Upper Gingiva | Upper Gum | Upper Gums | Upper gum | gingiva of upper jaw",,,,,,,,,,,,,,,"4047029","Structure of gum of maxilla",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152327","Posterior Commissure","C33356","A small fasciculus that decussates in the inferior pineal lamina in the midbrain, and is the junctional landmark between the diencephalon and the mesencephalon.","Posterior Commissure | ",,,,,,,,,,,,,,,"4091098","Posterior cerebral commissure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227150","Posterior Wall of the Pharynx","C54222","The dorsal portion of the fibromuscular tube that extends from the skull base to the lower border of the cricoid cartilage, and acts as a conduit for both the digestive and respiratory systems.","Posterior Wall of the Pharynx | Posterior Pharyngeal Wall",,,,,,,,,,,,,,,"4141892","Dorsal pharyngeal wall structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227151","Lateral Wall of the Pharynx","C129817","The walls on either side of the swallowing passage.","Lateral Wall of the Pharynx | Lateral Pharyngeal Wall",,,,,,,,,,,,,,,"4101998","Structure of lateral pharyngeal wall",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3272625","Parotid Gland Deep Lobe","C96176","The portion of the parotid gland parenchyma lying deep to the facial nerve.","Parotid Gland Deep Lobe | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714591","Floor","C66795","The lower inner surface of an open space or hollow organ.","Floor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226933","Mucosa of the Upper Lip","C12224","The lining of the superior fleshy fold bordering the mouth. It is comprised of the epithelium, basement membrane, lamina propria mucosae, and lamina muscularis mucosae.","Mucosa of the Upper Lip | Mucosa of Upper Lip | Mucosa of upper lip",,,,,,,,,,,,,,,"4086480","Structure of mucous membrane of upper lip",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0226939","Mucosa of the Lower Lip","C12225","The lining of the inferior fleshy fold bordering the mouth. It is comprised of the epithelium, basement membrane, lamina propria mucosae, and lamina muscularis mucosae.","Mucosa of the Lower Lip | Mucosa of Lower Lip | Mucosa of lower lip",,,,,,,,,,,,,,,"4187931","Structure of mucous membrane of lower lip",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227123","Lower Gingiva","C54204","The gingiva covering the mandibular alveolar bone.","Lower Gingiva | Lower Gums | Lower gum | gingiva of lower jaw",,,,,,,,,,,,,,,"4210919","Structure of gum of mandible",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1773636","Laryngeal Ventricle","C32935","A fusiform fossa on the lateral sides of the larynx between the inferior and superior vocal cords.","Laryngeal Ventricle | ",,,,,,,,,,,,,,,"4030723","Structure of ventricle of larynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0226924","Commissure of the Lip","C12227","The junction of the upper and lower lips at the corner of the mouth.","Commissure of the Lip | Commissure of Lip | Commissure of lip | LABIAL JUNCTION | Labial Commissure (Mouth) | Labial Junction",,,,,,,,,,,,,,,"4307358","Commissure of lips",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL950724","Resection","C158758","The surgical removal of an organ or a part of an organ.","Resection | SURGICAL RESECTION | Surgical Resection | resection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0193317","Parotidectomy","C51490","Surgery involving complete or partial excision of the parotid gland.","Parotidectomy | Parotidectomy, NOS | parotidectomy",,,,,,,,,,,,,,,"4219222","Parotidectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0554011","Superficial Parotidectomy","C51910","Surgery involving excision of the superficial portion of the parotid gland.","Superficial Parotidectomy | ",,,,,,,,,,,,,,,"4172218","Superficial parotidectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0407589","Partial Maxillectomy","C51657","Surgery to remove part of the maxilla.","Partial Maxillectomy | ",,,,,,,,,,,,,,,"4075890","Partial maxillectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0189234","Partial Laryngectomy","C94240","An operation to remove part of the larynx (voice box).","Partial Laryngectomy | partial laryngectomy",,,,,,,,,,,,,,,"4214730","Partial laryngectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0189242","Laryngopharyngectomy","C150660","Surgery involving the complete or partial excision of the larynx and pharynx.","Laryngopharyngectomy | ",,,,,,,,,,,,,,,"4243808","Laryngopharyngectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0185566","Mandibulectomy","C51664","Surgery to remove part or all of the mandible.","Mandibulectomy | Excision of Mandible",,,,,,,,,,,,,,,"4273761","Excision of mandible",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1831716","carboplatin/cetuximab/fluorouracil","C150686","A regimen consisting of carboplatin, fluorouracil (5-FU) and cetuximab that can be used for the treatment of head and neck cancer.","Carboplatin/Cetuximab/Fluorouracil Regimen | Carboplatin, Fluorouracil, Cetuximab | Carboplatin-Fluorouracil-Cetuximab | Carboplatin-Fluorouracil-Cetuximab Regimen | Carboplatin/5-FU/Cetuximab | Carboplatin/5-FU/Cetuximab Regimen | Carboplatin/5-Fluorouracil/Cetuximab | Carboplatin/Fluorouracil Plus Cetuximab | Carboplatin/Fluorouracil/Cetuximab | Carboplatin/Fluorouracil/Cetuximab Regimen | Carboplatin/Fluorouracil/Cetuximab Regimen | Cetuximab-Carboplatin-5-Fluorouracil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032461","Polycythemia","C26863","Abnormally high mass or concentration of red blood cells in the blood, either due to an increase in erythropoiesis or a decrease in plasma volume.","Polycythemia | ",,,,,,,,,,,,,,,"4130681","Erythrocytosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3807509","Polyneuropathy","C26951","A disease or disorder affecting more than one nerve.","Polyneuropathy | ",,,,,,,,,,,,,,,"4174262","Polyneuropathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL494699","Pulmonary Artery Systolic Pressure","C120943","The blood pressure in the pulmonary artery during the contraction of the left ventricle of the heart.","Pulmonary Artery Systolic Pressure | PA systolic pressure | PULSYSBP | Pulmonary Systolic Pressure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1378340","Squamous Papillomatosis","C9009","A benign squamous neoplasm characterized by a papillary growth pattern, diffusely involving a specific anatomic site.","Squamous Papillomatosis | Squamous papillomatosis","8060/0","Squamous papillomatosis",,,,,,,,,,,,,"4218400","Squamous papillomatosis",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C2826606","Fungal Colonization","C82980","Collection of fungal organisms in an anatomic site or medical device.","Fungal Colonization | Colonization, Fungal | Colonization; fungal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509047","Colonization","C128361","The presence of microorganisms (not contamination) on a body surface, including the skin and mucosal surfaces (e.g., respiratory, gastrointestinal, and urogenital tracts). Colonization implies the lack of signs or symptoms of infection but often precedes infection.","Colonization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970125","Extravascular Volume Overload","C161588","Fluid volume expansion that occurs outside of the vascular system, which may be characterized by peripheral edema, pleural effusion, ascites, and pericardial effusion.","Extravascular Volume Overload | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0240274","LYMPH NODE, FIXED","C161610","A lymph node that has reduced mobility or is attached to adjacent structures.","Fixed Lymph Node | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969344","Thyroid, NOS","C160209","An area of the thyroid gland not otherwise specified.","Thyroid, NOS | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970342","International Prognostic Index Score","C161645","The score in a prognostic index based on: age (> 60 years); increased serum LDH; ECOG Performance status > 1; clinical stage III or IV.","International Prognostic Index Score | IPI Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970341","IPI Score 0-1","C161646","A score of 0 or 1 on the International Prognostic Index indicating that an individual has a low risk of progression of non-Hodgkin lymphoma and a 5 year survival of 73%.","IPI Score 0-1 | IPI 0-1 | Score 0-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971136","IPI Score 2","C161647","A score of 2 on the International Prognostic Index indicating that an individual has a low-intermediate risk of progression of non-Hodgkin lymphoma and a 5 year survival of 69%.","IPI Score 2 | IPI 2 | Score 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971139","IPI Score 3","C161648","A score of 3 on the International Prognostic Index indicating that an individual has a high-intermediate risk of progression of non-Hodgkin lymphoma and a 5 year survival of 46%.","IPI Score 3 | IPI 3 | Score 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970291","IPI Score 4-5","C161650","A score of 4 or 5 on the International Prognostic Index indicating that an individual has a high risk of progression of non-Hodgkin lymphoma and a 5 year survival of 32%.","IPI Score 4-5 | IPI 4-5 | Score 4-5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970006","Mandibular Alveolar Process","C160975","The portion of the mandible that contains the sockets of the teeth.","Mandibular Alveolar Process | Alveolar process, mandibular",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970008","Maxillary Alveolar Process","C160973","The portion of the maxilla that contains the sockets of the teeth.","Maxillary Alveolar Process | Alveolar process, maxillary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970002","Laryngeal Surface of the Epiglottis","C160979","The surface of the epiglottis that is oriented toward the larynx.","Laryngeal Surface of the Epiglottis | Epiglottis, laryngeal aspect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969977","Glottic Laryngeal Tumor with Subglottic Extension","C161004","A finding of glottic involvement from a laryngeal tumor with extension of the tumor into the subglottis.","Glottic Laryngeal Tumor with Subglottic Extension | Glottic Laryngeal Tumor with Subgolttic Extension | Glottis, with subglottic extension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519756","Cord Blood Bank","C133263","A facility whose primary operation is cord blood recovery, processing, and storage for future autologous use or use of the stem cells to treat other people.","Cord Blood Bank | Cord blood bank",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970013","Lateral Surface of the Tongue","C160983","The side of the tongue.","Lateral Surface of the Tongue | Lateral border of tongue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456482","Lateral Wall of the Nose","C160988","The outside wall of the nasal passages.","Lateral Wall of the Nose | Nasal lateral wall",,,,,,,,,,,,,,,"4082010","Structure of lateral nasal wall",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0225427","Nasal Vestibule","C160989","The most anterior part of the nasal cavity, lined by squamous epithelium.","Nasal Vestibule | Nasal vestibule",,,,,,,,,,,,,,,"4167678","Structure of nasal vestibule",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL970020","Parotid Gland Superficial Lobe","C160992","The portion of the parotid gland that is superficial to the facial vein and facial nerve.","Parotid Gland Superficial Lobe | Parotid gland, superficial lobe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970019","Mandibular Vestibule of the Mouth","C160993","The area of the mouth between the cheeks and the teeth of the mandible.","Mandibular Vestibule of the Mouth | Vestibule of mouth, mandibular",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970018","Maxillary Vestibule of the Mouth","C160994","The area of the mouth between the cheeks and the teeth of the maxilla.","Maxillary Vestibule of the Mouth | Vestibule of mouth, maxillary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970016","Transglottic Extension of Laryngeal Tumor","C160996","Extension of a laryngeal tumor beyond the glottic opening into the ventricles and vocal cords.","Transglottic Extension of Laryngeal Tumor | Transglottic Extension | transglottic extension | transglottic_extension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1737220","Palatectomy","C160997","Surgical removal of part or all of the palate.","Palatectomy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969981","Endolaryngeal Excision","C160999","Surgical excision performed through the mouth and glottic opening.","Endolaryngeal Excision | Endolaryngeal excision",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969979","Deep Parotidectomy","C161002","Surgical removal of part or all of the deep lobe of the parotid gland.","Deep Parotidectomy | Parotidectomy, deep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970007","Cribriform Adenocarcinoma of Minor Salivary Gland","C160974","A minor salivary gland adenocarcinoma characterized by a cribriform pattern. It often metastasizes to the neck lymph nodes.","Cribriform Adenocarcinoma of Minor Salivary Gland | CAMSG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970012","Sinonasal Adenocarcinoma, Intestinal-Type with Papillary Pattern","C160984","An intestinal-type adenocarcinoma that arises from the sinonasal tract. It is characterized by the presence of a papillary growth pattern.","Sinonasal Adenocarcinoma, Intestinal-Type with Papillary Pattern | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970010","Sinonasal Adenocarcinoma, Intestinal-Type with Colonic Pattern","C160986","An intestinal-type adenocarcinoma that arises from the sinonasal tract. It is characterized by the presence of a tubuloglandular growth pattern.","Sinonasal Adenocarcinoma, Intestinal-Type with Colonic Pattern | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970009","Sinonasal Adenocarcinoma, Intestinal-Type with Solid Pattern","C160987","An intestinal-type adenocarcinoma that arises from the sinonasal tract. It is characterized by the presence of a solid growth pattern.","Sinonasal Adenocarcinoma, Intestinal-Type with Solid Pattern | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970017","Sinonasal Adenocarcinoma, Intestinal-Type with Mucinous Pattern","C160995","An intestinal-type adenocarcinoma that arises from the sinonasal tract. It is characterized by the presence of malignant glandular cells with intracytoplasmic mucin.","Sinonasal Adenocarcinoma, Intestinal-Type with Mucinous Pattern | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969980","Sinonasal Adenocarcinoma, Intestinal-Type with Mixed Pattern","C161000","An intestinal-type adenocarcinoma that arises from the sinonasal tract. It is characterized by the presence of a mixture of growth patterns.","Sinonasal Adenocarcinoma, Intestinal-Type with Mixed Pattern | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970004","Sinonasal Adenocarcinoma, Non-Intestinal-Type","C160977","An adenocarcinoma that arises from the sinonasal tract. It is characterized by the absence of features that resemble intestinal adenocarcinoma.","Sinonasal Adenocarcinoma, Non-Intestinal-Type  | Nasal Cavity and Paranasal Sinus Adenocarcinoma, Non-Intestinal-Type | Sinonasal Adenocarcinoma, Non-Intestinal-Type | Sinonasal Adenocarcinoma, Non-Intestinal-Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970015","Head and Neck Small Cell Carcinoma","C160981","A neuroendocrine carcinoma that arises from the head and neck and is composed of malignant small cells. The mitotic count is more than 10 per 2 mm2 and/or the Ki-67 index is more than 20% (often more than 70%).","Head and Neck Small Cell Neuroendocrine Carcinoma | Head and Neck Small Cell Carcinoma | Head and Neck Small Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970014","Head and Neck Large Cell Neuroendocrine Carcinoma","C160982","A neuroendocrine carcinoma that arises from the head and neck and is composed of malignant large cells. The mitotic count is more than 10 per 2 mm2 and/or the Ki-67 index is more than 20% (often more than 55%).","Head and Neck Large Cell Neuroendocrine Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970003","Head and Neck Sebaceous Carcinoma","C160978","A sebaceous carcinoma that arises from the head and neck region.","Head and Neck Sebaceous Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969991","Keratinizing Dysplasia","C161017","Epithelial dysplasia in which the dysplastic changes, although limited to the lower basal zone, are so severe, that there is a high probability of progression to invasive carcinoma.","Keratinizing Dysplasia | Keratinizing | Keratinizing dysplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969992","Non-Keratinizing Dysplasia","C161016","Intraepithelial proliferation of dysplastic epithelial cells not associated with keratin formation.","Non-Keratinizing Dysplasia | Nonkeratinizing | Nonkeratinizing Dysplasia | Nonkeratinizing dysplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969990","High Grade Transformation","C161018","Dedifferentiation of a malignant neoplasm.","High Grade Transformation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969481","TCF Regimen","C160553","A regimen consisting of carboplatin, docetaxel and 5-fluorouracil that can be used in the treatment of gastric, cervical, head and neck, and esophageal and esophagogastric junction cancers.","TCF Regimen | Carboplatin-Docetaxel-Fluorouracil | Carboplatin/Docetaxel/Fluorouracil | Carboplatin/Docetaxel/Fluorouracil Regimen | Docetaxel/Carboplatin/Fluorouracil | TCF | Taxotere/Carboplatin/Fluorouracil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969851","Carboplatin/Fluorouracil/Pembrolizumab Regimen","C160959","A regimen consisting of carboplatin, fluorouracil (5-FU) and pembrolizumab that may be used in the treatment of head and neck cancers.","Carboplatin/Fluorouracil/Pembrolizumab Regimen | Carboplatin, Fluorouracil, Pembrolizumab | Carboplatin-Fluorouracil-Pembrolizumab | Carboplatin-Fluorouracil-Pembrolizumab Regimen | Carboplatin/5-FU/Pembrolizumab | Carboplatin/Fluorouracil/Keytruda | Carboplatin/Fluorouracil/Pembrolizumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562746","M1 Macrophage","C156004","A macrophage that expresses CD80 and CD86 on the cell surface, produces high levels of interleukin (IL)-8 and IL-12 and converts arginine to nitric oxide. These cells promote inflammation.","M1 Macrophage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970426","International Prognostic Index Risk Group","C161805","A risk group based on: age (> 60 years); increased serum LDH; ECOG Performance status > 1; clinical stage III or IV.","International Prognostic Index Risk Group | IPI Risk Group",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970425","International Prognostic Index Low Risk Group","C161806","A risk group associated with a total score of 0 or 1 on the International Prognostic Index indicating that an individual has a 5 year survival prognosis of 73%.","International Prognostic Index Low Risk Group | IPI Low Risk | IPI Low Risk Group | Low Risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970424","International Prognostic Index Low-Intermediate Risk Group","C161807","A risk group associated with a total score of 2 on the International Prognostic Index indicating that an individual has a 5 year survival prognosis of 69%.","International Prognostic Index Low-Intermediate Risk Group | IPI Low-Intermediate Risk | IPI Low-Intermediate Risk Group | Low-Intermediate Risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970423","International Prognostic Index High-Intermediate Risk Group","C161808","A risk group associated with a total score of 3 on the International Prognostic Index indicating that an individual has a 5 year survival prognosis of 46%.","International Prognostic Index High-Intermediate Risk Group | High-Intermediate Risk | IPI High-Intermediate Risk | IPI High-Intermediate Risk Group",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970375","International Prognostic Index High Risk Group","C161809","A risk group associated with a total score of 4 or 5 on the International Prognostic Index indicating that an individual has a 5 year survival prognosis of 32%.","International Prognostic Index High Risk Group | High Risk | IPI High Risk | IPI Low High Group",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970410","Peripheral T-cell Lymphoma Prognostic Index Score","C161790","A list of four factors to assess how an individual with peripheral T-cell lymphoma might respond to treatment and predict the risk of disease recurrence. The factors are: patient's age, LDH levels: serum levels often correlate with the amount of tumor in the body, performance status, and bone marrow involvement.","Peripheral T-cell Lymphoma Prognostic Index Score | PIT Score | Prognostic Index Score for Peripheral T-cell Lymphoma | Prognostic Index for Peripheral T-cell Lymphoma (PIT) Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970409","Peripheral T-cell Lymphoma Prognostic Index Score 0","C161791","A risk group associated with a total score of 0 on the Prognostic Index for Peripheral T-cell Lymphoma indicating that an individual has a low risk.","Peripheral T-cell Lymphoma Prognostic Index Score 0 | PIT Score 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970408","Peripheral T-cell Lymphoma Prognostic Index Score 1","C161792","A risk group associated with a total score of 1 on the Prognostic Index for Peripheral T-cell Lymphoma indicating that an individual has a low-intermediate risk.","Peripheral T-cell Lymphoma Prognostic Index Score 1 | PIT Score 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970421","Peripheral T-cell Lymphoma Prognostic Index Score 2","C161794","A risk group associated with a total score of 2 on the Prognostic Index for Peripheral T-cell Lymphoma indicating that an individual has a intermediate-high risk.","Peripheral T-cell Lymphoma Prognostic Index Score 2 | PIT Score 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970420","Peripheral T-cell Lymphoma Prognostic Index Score 3-4","C161795","A risk group associated with a total score of 3 or 4 on the Prognostic Index for Peripheral T-cell Lymphoma indicating that an individual has a high risk.","Peripheral T-cell Lymphoma Prognostic Index Score 3-4 | PIT Score 3-4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937601","CPTAC Medical Conditions Codelist","C158035","Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on medical conditions.","CPTAC Medical Conditions Codelist | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970380","Non-VEGFR Tyrosine Kinase Inhibitor","C161820","Any tyrosine kinase inhibitor that does not target and inhibit vascular endothelial growth factor receptor (VEGFR).","Non-VEGFR Tyrosine Kinase Inhibitor | Non-VEGFR TK Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970395","Biochemical Diagnosis","C161837","An indication that a patient had cancer diagnosed using biochemical markers specific to the disease.","Biochemical Diagnosis | Biochemical | Biochemical Markers Diagnosis | Biochemical Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970393","Ki-67 Positive Cells Less than 10 Percent","C161839","A semi-quantitative microscopic finding indicating that less than 10 percent of the cells in a sample are detected following staining using an anti-Ki-67 antibody.","Ki-67 Positive Cells Less than 10 Percent | Antigen Ki-67 Positive Cells Less than 10 Percent | KI67 Positive Cells Less than 10 Percent | Ki-67 Antigen Positive Cells Less than 10 Percent | Ki-67 Less than 10 percent positive | Less than 10 percent positive | MKI67 Positive Cells Less than 10 Percent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970392","Ki-67 Positive Cells 10-20 Percent","C161840","A semi-quantitative microscopic finding indicating that between 10 and 20 percent of the cells in a sample are detected following staining using an anti-Ki-67 antibody.","Ki-67 Positive Cells 10-20 Percent | 10-20 percent positive | Antigen Ki-67 Positive Cells 10-20 Percent | KI67 Positive Cells 10-20 Percent | Ki-67 10-20 percent positive | Ki-67 Antigen Positive Cells 10-20 Percent | MKI67 Positive Cells 10-20 Percent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970350","Ki-67 Positive Cells Greater than 20 Percent","C161841","A semi-quantitative microscopic finding indicating that more than 20 percent of the cells in a sample are detected following staining using an anti-Ki-67 antibody.","Ki-67 Positive Cells Greater than 20 Percent | Antigen Ki-67 Positive Cells Greater than 20 Percent | Greater than 20 percent positive | KI67 Positive Cells Greater than 20 Percent | Ki-67 Antigen Positive Cells Greater than 20 Percent | Ki-67 Greater than 20 percent positive | MKI67 Positive Cells Greater than 20 Percent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969654","IDH2 NP_002159.2:p.R172S","C160665","A change in the amino acid residue at position 172 in the isocitrate dehydrogenase [NADP], mitochondrial protein where arginine has been replaced by serine.","IDH2 NP_002159.2:p.R172S | IDH2 Arg172Ser | IDH2 NP_002159.2:p.Arg172Ser | IDH2 R172S | IDH2 R172S Mutation | IDH2 p.Arg172Ser | IDH2 p.R172S | Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial Arg172Ser | Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial R172S | Isocitrate Dehydrogenase [NADP], Mitochondrial Arg172Ser | Isocitrate Dehydrogenase [NADP], Mitochondrial R172S | NP_002159.2:p.Arg172Ser | NP_002159.2:p.R172S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969546","Percentage of Ki-67 Positive Nuclei","C160485","A quantitative measurement of the percent of nuclei that are positive for expression of antigen Ki-67 compared to the total number of nuclei in a sample.","Percentage of Ki-67 Positive Nuclei | MIB-1 (%) | Percent of Ki-67 Positive Nuclei | Percentage of positive nuclei",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1304235","AL Amyloidosis","C158963","The most common type of amyloidosis. It is characterized by the monoclonal deposition of immunoglobulin light chain fragments in organs and tissues. It is associated with plasma cell or B-cell lymphoproliferative disorders.","AL Amyloidosis | Ig Light Chain Amyloidosis | Immunoglobulin-Related Amyloidosis",,,,,,,,,,,,,,,"4047607","AL amyloidosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL523575","Carfilzomib-Lenalidomide-Dexamethasone Regimen","C136264","A regimen consisting of carfilzomib, lenalidomide and dexamethasone that is used for the treatment of plasma cell (multiple) myeloma.","KRd Regimen | CRd | Carfilzomib-Lenalidomide-Dexamethasone | Carfilzomib-Lenalidomide-Dexamethasone Regimen | Carfilzomib//Dexamethasone /Lenalidomide | Carfilzomib/Lenalidomide/Dexamethasone | Carfilzomib/Lenalidomide/Dexamethasone Regimen | Carfilzomib/Lenalidomide/Dexamethasone Regimen | KRd | Kyprolis/Revlimid/Dexamethasone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523578","Daratumumab-Bortezomib-Dexamethasone Regimen","C136267","A regimen consisting of daratumumab, bortezomib and dexamethasone that is used for the treatment of plasma cell myeloma.","Dara-Vd Regimen | DVD | Dara-Vd | Daratumumab-Bortezomib-Dexamethasone | Daratumumab-Bortezomib-Dexamethasone Regimen | Daratumumab/Bortezomib/Dexamethasone | Daratumumab/Bortezomib/Dexamethasone Regimen | Daratumumab/Bortezomib/Dexamethasone Regimen | Darzalex/Velcade/Dexamethasone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274945","Year of Onset","C99800","The year in which an event began.","Year of Onset | Year of Onset (YYYY)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538987","Cardiovascular System Findings Domain","C102605","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to cardiovascular system findings.","Cardiovascular System Findings Domain | CV | Cardiovascular System Findings",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086129","Cardiovascular System Findings Group Identifier","C123970","A character or string that represents a cardiovascular system findings group.","Cardiovascular System Findings Group Identifier | CVGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986904","Respiratory Domain","C95098","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to the respiratory system.","Respiratory Domain | RE | Respiratory System Findings",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086811","Respiratory System Findings Group Identifier","C123972","A character or string that represents a respiratory system findings group.","Respiratory System Findings Group Identifier | REGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938086","Height at Time of Procedure","C158589","The height of an individual at the time of a procedure.","Height at Time of Procedure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937975","Weight at Time of Procedure","C158523","The weight of an individual at the time of a procedure.","Weight at Time of Procedure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935843","History of Treatment","C156811","A question about whether there is a known history of treatments.","Is there a History of Treatment | History of Treatment | History of Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935844","Medical History Source","C156812","The source providing the medical history.","Medical History Source | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937126","Month/Year of Diagnosis","C157434","The month and the year of the diagnosis.","Month/Year of Diagnosis | Month / Year of Diagnosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935842","Date of Last Therapy","C156814","The date of the last radiation treatment, chemotherapy, molecular targeted therapy, or immunotherapy treatment.","Date of Last Therapy | Date of Last Radiation Therapy, Chemotherapy, Molecular Targeted Therapy, Immunotherapy Treatment | date of last dose any therapy | date_of_last_dose_any_therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935831","Medical Record Documentation about this History of Cancer Treatment","C156817","The documentation in the medical record regarding previous treatment for cancer.","Medical Record Documentation about this History of Cancer Treatment | Is there Medical Record Documentation of this History of Cancer and Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0746467","Current Medication","C156818","The current medications an individual is taking.","Current Medication | Current Medications",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935835","Date of Last Administration","C156819","The date of the last administration of the substance of interest.","Date of Last Administration | date last medication administration | date_last_medication_administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935826","Number of years Participant has consumed more than 2 drinks per day for men and more than 1 drink per day for women","C156824","The number of years an individual has consumed more than 2 drinks per day for men and more than 1 drink per day for women.","Number of Years When Consumed More than 2 Drinks per Day for Men and More than 1 Drink per Day for Women | Number of years Participant has consumed more than 2 drinks per day for men and more than 1 drink per day for women",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935979","Age Which Participant Stopped Smoking","C156832","The chronological age at which an individual stopped smoking.","Age Which Participant Stopped Smoking | The age at which the participant stopped smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935976","When Participant Smoked, How many Cigarettes Smoked","C156833","How many cigarettes did an individual smoke when they smoked.","When Participant Smoked, How many Cigarettes Smoked | On the days that the Participant smoked, how many cigarettes did s/he usually smoke?",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951579","Was the Individual Exposed to Second-Hand Smoke","C159576","A question about whether an individual has been exposed to secondhand tobacco smoke.","Was the Individual Exposed to Second-Hand Smoke | Secondhand Smoke Exposure | Was the Participant exposed to secondhand smoke",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086142","Cardiovascular System Findings Sponsor Defined Identifier","C124003","One or more sponsor defined characters used to identify, name, or characterize the cardiovascular system findings.","Cardiovascular System Findings Sponsor Defined Identifier | CVSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086133","Cardiovascular System Findings Original Result","C123983","The outcome of the cardiovascular system assessment as originally received or collected.","Cardiovascular System Findings Original Result | CVORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086139","Cardiovascular System Findings Reason Not Done","C123992","The explanation given as to why cardiovascular system test was not performed.","Cardiovascular System Findings Reason Not Done | CVREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086126","Cardiovascular System Findings Elapsed Time","C123953","The interval between two cardiovascular system measurement reference time points.","Cardiovascular System Findings Elapsed Time | CVELTM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087004","Cardiovascular System Findings Time Point Reference","C124033","The point in time that acts as a fixed reference point to a cardiovascular system findings assessment.","Cardiovascular System Findings Time Point Reference | CVTPTREF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897544","Sponsor Device Identifier","C117060","A sponsor-defined sequence of characters used to identify, name, or characterize the device.","Sponsor Device Identifier | SPDEVID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334270","Sinonasal Non-Keratinizing Squamous Cell Carcinoma","C54287","A squamous cell carcinoma of the sinonasal tract characterized by a plexiform or ribbon-like growth pattern, cytological atypia, and lack of histological evidence of keratinization.","Sinonasal Non-Keratinizing Squamous Cell Carcinoma | Non-Keratinizing Sinonasal Squamous Cell Carcinoma | Non-Keratinizing Sinonasal Squamous Cell Carcinoma | Ringertz Carcinoma | Schneiderian Carcinoma | Schneiderian carcinoma | Sinonasal Cylindrical Cell Carcinoma | Sinonasal Schneiderian Carcinoma | Sinonasal Transitional Cell Carcinoma","8121/3","Schneiderian carcinoma",,,,,,,,,,,,,"4206785","Schneiderian carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"CL545695","Oropharyngeal Squamous Cell Carcinoma, p16INK4a Negative","C147906","An oropharyngeal squamous cell carcinoma which is negative for p16INK4a by immunohistochemistry. This negative immunohistochemistry result does not exclude human papillomavirus infection.","Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma | Oropharyngeal Squamous Cell Carcinoma, p16INK4a Negative | p16INK4a Negative Oropharyngeal Squamous Cell Cancer | p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma | p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828150","Oropharyngeal Human Papillomavirus-Related Squamous Cell Carcinoma","C87055","A squamous cell carcinoma that arises from the oropharynx and is associated with human papillomavirus type 16 infection.","Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma | HPV-Associated Oropharyngeal Squamous Cell Carcinoma | HPV-Positive Oropharyngeal Squamous Cell Carcinoma | HPV-Related Oropharyngeal Squamous Cell Carcinoma | Human Papilloma Virus Associated Oropharyngeal Squamous Cell Carcinoma | Human Papilloma Virus Positive Oropharyngeal Squamous Cell Carcinoma | Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma | Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma | Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma | Oropharyngeal HPV-Associated Squamous Cell Carcinoma | Oropharyngeal HPV-Positive Squamous Cell Carcinoma | Oropharyngeal HPV-Related Squamous Cell Carcinoma | Oropharyngeal Human Papillomavirus Positive Squamous Cell Carcinoma | Oropharyngeal Human Papillomavirus-Associated Squamous Cell Carcinoma | Oropharyngeal Human Papillomavirus-Positive Squamous Cell Carcinoma | Oropharyngeal Human Papillomavirus-Positive Squamous Cell Carcinoma | Oropharyngeal Human Papillomavirus-Related Squamous Cell Carcinoma | Oropharyngeal Human Papillomavirus-Related Squamous Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882972","Low Grade Salivary Duct Carcinoma","C62192","A rare, low-grade adenocarcinoma that arises from the salivary glands.  It is characterized by the presence of cystic structures lined by ductal cells which are arranged in cribriform patterns.  Adjacent ducts show intraductal proliferation.","Salivary Gland Intraductal Carcinoma | Intraductal Carcinoma of the Minor Salivary Gland | Low Grade Salivary Duct Carcinoma | Salivary Gland Low Grade Cribriform Cystadenocarcinoma | Salivary Gland Low Grade Cribriform Cystadenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512709","Salivary Gland MASC","C123384","A rare, low-grade carcinoma of the salivary gland with favorable clinical outcome.  It usually arises from the parotid gland and less often from the minor salivary glands.  It shares the same histopathologic features and molecular characteristics (ETV6 gene rearrangement) with secretory breast carcinoma.","Salivary Gland Secretory Carcinoma | Mammary Analog Secretory Carcinoma of Salivary Gland | Mammary Analog Secretory Carcinoma of Salivary Gland | Mammary Analogue Secretory Carcinoma of Salivary Gland | Salivary Gland MASC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280306","Oral Cavity Verrucous Carcinoma","C8174","A well differentiated squamous cell carcinoma arising from the oral cavity.  It is an exophytic, warty, slow growing tumor, usually affecting older males.  Chronic use of smokeless tobacco is associated with the development of verrucous carcinoma in the oral cavity.  Five year disease-free survival rates between 80% and 90% have been reported in patients who underwent extensive surgical removal of the tumor.","Oral Cavity Verrucous Carcinoma | Ackerman Tumor | Mouth Verrucous Carcinoma | Oral Cavity Verrucous Cancer | Verrucous Carcinoma of Mouth | Verrucous Carcinoma of Oral Cavity | Verrucous Carcinoma of the Mouth | Verrucous Carcinoma of the Oral Cavity",,,,,,,,,,,,,,,"4300554","Verrucous carcinoma of oral cavity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334254","Nasopharyngeal-Type Undifferentiated Carcinoma","C4107","A nonkeratinizing carcinoma which occurs predominantly in the nasopharynx but also in the tonsils and rarely in other anatomic sites.  It is characterized by the presence of large malignant cells with vesicular nuclei, prominent nucleoli, syncytial growth pattern, and a lymphoplasmacytic infiltrate.","Nasopharyngeal-Type Undifferentiated Carcinoma | Lymphoepithelial Carcinoma | Lymphoepithelial carcinoma | Lymphoepithelioma | Lymphoepithelioma-Like Carcinoma | Lymphoepithelioma-like carcinoma | Nasopharyngeal Type Undifferentiated Carcinoma | Nasopharyngeal Type Undifferentiated Carcinoma | Schmincke Tumor | lymphoepithelioma","8082/3","Lymphoepithelial carcinoma",,,,,,,,,,,,,"35622758|4247661","Lymphoepithelial carcinoma|Lymphoepithelial carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0225560","Aryepiglottic Fold","C32147","A membranous fold extending between the arytenoid cartilage and the epiglottis.","Aryepiglottic Fold | Aryepiglottic Folds | Aryteno-Epiglottic Fold",,,,,,,,,,,,,,,"4185090","Aryepiglottic fold structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0796302","Gemcitabine/Paclitaxel","C11430","No Value Exists","Gemcitabine/Paclitaxel | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552495","Cisplatin/Paclitaxel/Cetuximab Regimen","C150693","A regimen consisting of cisplatin, paclitaxel and cetuximab that can be used for the treatment of head and neck cancer.","Cisplatin/Paclitaxel/Cetuximab Regimen | Cisplatin-Paclitaxel-Cetuximab | Cisplatin-Paclitaxel-Cetuximab Regimen | Cisplatin/Paclitaxel/Cetuximab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1328046","carboplatin/cetuximab/paclitaxel","C37597","A regimen consisting of paclitaxel, carboplatin, and cetuximab that can be used for the treatment of squamous cell carcinoma of the head and neck (SCCHN).","PCC Regimen | Carboplatin and Paclitaxel (CP) and Cetuximab | Carboplatin-Cetuximab-Paclitaxel | Carboplatin-Cetuximab-Paclitaxel Regimen | Carboplatin/Cetuximab/Paclitaxel | Carboplatin/Cetuximab/Paclitaxel Regimen | PCC | Paclitaxel-Carboplatin-Cetuximab | Paclitaxel/Carboplatin/Cetuximab | Paclitaxel/Carboplatin/Cetuximab Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937130","Self-Reported and Medical Record","C157430","Information that was obtained from the individual and the medical record.","Self-Reported and Medical Record | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937462","CPTAC Neoplasms Codelist","C156966","Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on neoplasms.","CPTAC Neoplasms Codelist | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935825","Alcohol Use History Not Available","C156823","An indication that the alcohol use history of an individual is unavailable.","Alcohol Use History Not Available | Alcohol consumption history not available",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935834","Consumed alcohol in the past, but currently a non-drinker","C156822","An indication that an individual has consumed alcohol in the past, but is currently a non-drinker.","Current non-drinker with Past Alcohol Consumption | Consumed alcohol in the past, but currently a non-drinker",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935833","Alcohol consumption more than 2 drinks per day for men and more than 1 drink per day for women","C156821","Alcohol consumption more than two drinks per day for men and more than one drink per day for women.","Alcohol Consumption More than 2 Drinks per Day for Men and More than 1 Drink per Day for Women | Alcohol consumption more than 2 drinks per day for men and more than 1 drink per day for women",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935836","Alcohol consumption equal to or less than 2 drinks per day for men and 1 drink or less per day for women","C156820","Alcohol consumption equal to or less than two drinks per day for men and one drink or less per day for women.","Alcohol Consumption Equal to or Less than 2 Drinks per Day for Men and 1 Drink or Less per Day for Women | Alcohol consumption equal to or less than 2 drinks per day for men and 1 drink or less per day for women",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935978","Smoking History Not Available","C156831","An indication that the smoking history of an individual is unavailable.","Smoking History Not Available | Smoking history not available",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935828","Current Reformed Smoker, Years Unknown","C156830","An individual who stopped smoking an unknown number of years prior.","Current Reformed Smoker, Years Unknown | 5 | Current Reformed Smoker, Duration Not Specified | Current reformed smoker, years unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935827","Current Reformed Smoker Within Past 15 Years","C156829","An individual who stopped smoking within the past 15 years.","Current Reformed Smoker Within Past 15 Years | 4 | Current Reformed Smoker for < or = 15 yrs | Current reformed smoker within past 15 years",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935830","Current Reformed Smoker, More than 15 Years","C156828","An individual who stopped smoking more than 15 years prior.","Current Reformed Smoker, More than 15 Years | 3 | Current Reformed Smoker for > 15 yrs | Current reformed smoker, more than 15 years",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935824","Lifelong non-smoker Less than 100 cigarettes smoked in lifetime","C156826","An individual who has smoked less than 100 cigarettes in their lifetime.","Lifelong non-smoker Less than 100 cigarettes smoked in lifetime | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970376","Factor X Antigen Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970377","Amyloid Fibril-Directed Therapy","C161823","Any therapeutic modality that directly blocks the formation of amyloid fibril formation or, especially, those that directly target the accumulated proteins for clearance.","Amyloid Fibril-Directed Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970378","Next Generation Flow","C161822","A highly-sensitive variant of flow cytometry used to monitor minimal residual disease (MRD). It makes use of an optimized combination of fluorochromes and antibody reagents for increased specificity at very low MRD levels.","Next Generation Flow | NGF | NGF-MRD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970379","Negative Exponent","C161821","How many times to divide by a number.","Negative Exponent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2987394","Poorly Cohesive Malignant Cellular Infiltrate","C95744","A morphologic finding indicating the presence of a malignant cellular infiltrate characterized by the presence of individual cells and/or tiny cellular aggregates.","Poorly Cohesive Malignant Cellular Infiltrate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274991","BRD4/C15orf55 Fusion Gene","C99831","A fusion gene (~6 kb) that results from a chromosomal translocation t(15;19)(q14;p13) which fuses the first 10 exons of the BRD4 gene with exon 2 of the NUTM1 gene. This rearrangement is associated with a rare, aggressive, and lethal carcinoma arising in midline organs of young people.","BRD4/NUTM1 Fusion Gene | BRD4-C15orf55 Fusion Gene | BRD4-NUT Fusion Gene | BRD4-NUTM1 Fusion Gene | BRD4/C15orf55 Fusion Gene | BRD4/NUT Fusion Gene | BRD4::NUTM1 Fusion Gene | NUT/BRD4 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424142","MAML3 Gene","C117094","This gene plays a role in both transcriptional activation and signaling.","MAML3 Gene | MAML3 | Mastermind Like Transcriptional Coactivator 3 Gene | Mastermind-Like 3 (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1533585","Fusion Gene","C28510","A hybrid gene created by joining portions of two different genes (to produce a new protein) or by joining a gene to a different promoter (to alter or regulate gene transcription). These can be created by chromosomal aberration or by laboratory methods.","Fusion Gene | fusion gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3275265","ETV6/NTRK3 Fusion Gene","C99413","A fusion gene that results from a chromosomal translocation t(12;15)(p13;q25) which fuses the 5' half of the ETV6 gene to the 3' half of the NTRK3 gene. This fusion is associated with congenital fibrosarcoma, congenital mesoblastic nephroma (cellular and mixed variants), and secretory ductal carcinoma of breast.","ETV6/NTRK3 Fusion Gene | ETV6-NTRK3 | ETV6-NTRK3 Fusion Gene | ETV6::NTRK3 Fusion Gene | NTRK3/ETV6 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890579","Functional Tests Domain","C117756","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to a functional test.","Functional Tests Domain | FT | Functional Tests",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1843759","CRTC1/MAML2 Fusion Gene","C99741","A fusion gene (~3.8 kb) that results from a chromosomal translocation t(11;19)(q14-q21;p13-p12) which fuses exon 1 of the CRTC1 gene to exons 2-5 of the MAML2 gene. This rearrangement is associated with mucoepidermoid carcinoma, Warthin's tumor and clear cell hidradenoma.","CRTC1/MAML2 Fusion Gene | CRTC1-MAML2 Fusion Gene | CRTC1::MAML2 Fusion Gene | MAML2/MECT1 Fusion Gene | MECT1-MAML2 Fusion Gene | MECT1/MAML2 Fusion Gene | WAMTP1-MAML2 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0795620","Green Tea","C67048","Tea derived from the dried leaves of the plant Camellia sinensis with potential antioxidant, chemopreventive, and lipid-lowering activities. Green tea contains polyphenols that are believed to be responsible for its chemopreventive effect. The polyphenol fraction contains mainly Epigallocatechin-3-gallate (EGCG) and other catechins, such as epicatechin (EC), gallocatechin gallate (GCG), epigallocatechin (EGC), and epicatechin gallate (ECG). Green tea polyphenols act as antioxidants and free radical scavengers and may affect enzymes involved in cellular replication and tumor angiogenesis by modulating angiogenic factors, such as vascular endothelial growth factor (VEGF).","Green Tea | GREEN TEA LEAF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935972","Secondhand Smoke Exposure History Not Available","C156839","The history of secondhand smoke exposure is not available.","Secondhand Smoke Exposure History Not Available | Exposure to secondhand smoke history not available",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935981","Secondhand Smoke Exposure in Current Household","C156838","Secondhand smoke exposure is present in the current household.","Secondhand Smoke Exposure in Current Household | Exposure to secondhand smoke in Participant's current household",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935980","Secondhand Smoke Exposure in Household during Childhood","C156837","Secondhand smoke exposure was present in the household during childhood.","Secondhand Smoke Exposure in Household during Childhood | Exposure to secondhand smoke in household during Participant's childhood",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935982","Participant Exposed to Secondhand Smoke","C156835","The individual was exposed to secondhand smoke.","Participant Exposed to Secondhand Smoke | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935983","No/Minimal Secondhand Smoke Exposure","C156836","There has been no or minimal exposure to second hand smoke.","No/Minimal Secondhand Smoke Exposure | No or minimal exposure to secondhand smoke",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0429928","Test Time","C82577","The point in time when an assessment was performed.","Test Time | TIM",,,,,,,,,,,,,,,"4090056","Test time",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL951200","Description of Epochs of O2 Desaturation Less than 92% Greater than 5 Minutes Prior to Organ Excision","C159272","A textual representation of the information regarding an O2 desaturation epoch of less than 92 percent, lasting greater than 5 minutes, prior to organ excision.","Description of Epochs of O2 Desaturation Less than 92% Greater than 5 Minutes Prior to Organ Excision | Describe Epochs of Oxygen (O2) desaturation of <92% for >5 minutes prior to organ excision | Description Of Epochs O2 Desaturation Prior To Organ Excision",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970638","CellSave Blood Collection Tube","C162038","A proprietary blood collection tube designed for venous blood collection, containing EDTA anticoagulant and a cell preservative. The EDTA absorbs calcium ions, which prevents the blood from clotting. The preservative preserves the morphology and cell surface antigen expression of the epithelial cells and leukocytes. This blood collection tube has been used for the preservation of circulating tumor cells and lymphocyte subsets.","CellSave Blood Collection Tube | CellSave BCT | CellSave Preservative Tube | CellSave Tube",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970665","Functional Tests Group Identifier","C162007","A character or string that represents a functional test group.","Functional Tests Group Identifier | FTGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970664","Meal Data Group Identifier","C162008","A character or string that represents a meal data group.","Meal Data Group Identifier | MLGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970663","Musculoskeletal Findings, Connective and Soft Tissue Findings Group Identifier","C162009","A character or string that represents a musculoskeletal system findings group.","Musculoskeletal Findings, Connective and Soft Tissue Findings Group Identifier | MKGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970677","Nervous System Findings Group Identifier","C162011","A character or string that represents a nervous system findings group.","Nervous System Findings Group Identifier | NVGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970676","Ophthalmic Examinations Group Identifier","C162012","A character or string that represents an ophthalmic examinations group.","Ophthalmic Examinations Group Identifier | OEGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970675","Procedure Agents Group Identifier","C162013","A character or string that represents a procedure agents group.","Procedure Agents Group Identifier | AGGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970674","Urinary System Findings Group Identifier","C162014","A character or string that represents a urinary system findings group.","Urinary System Findings Group Identifier | URGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970671","Cardiovascular System Findings Link Identifier","C162017","A sequence of characters used as a linkage between related cardiovascular system findings identifier records.","Cardiovascular System Findings Link Identifier | CVLNKID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970670","Microbiology Specimen Link Identifier","C162018","A sequence of characters used as a linkage between related microbiology specimen identifier records.","Microbiology Specimen Link Identifier | MBLNKID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970685","Microbiology Susceptibility Link Identifier","C162019","A sequence of characters used as a linkage between related microbiology susceptibility test identifier records.","Microbiology Susceptibility Link Identifier | MSLNKID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970684","Musculoskeletal Findings, Connective and Soft Tissue Findings Link Identifier","C162020","A sequence of characters used as a linkage between related musculoskeletal system findings identifier records.","Musculoskeletal Findings, Connective and Soft Tissue Findings Link Identifier | MKLNKID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970683","Nervous System Findings Link Identifier","C162021","A sequence of characters used as a linkage between related nervous system identifier records.","Nervous System Findings Link Identifier | NVLNKID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970682","Ophthalmic Examinations Link Identifier","C162022","A sequence of characters used as a linkage between related ophthalmic examinations identifier records.","Ophthalmic Examinations Link Identifier | OELNKID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970681","Procedure Agents Link Identifier","C162023","A sequence of characters used as a linkage between related procedure agents identifier records.","Procedure Agents Link Identifier | AGLNKID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970680","Reproductive System Findings Link Identifier","C162024","A sequence of characters used as a linkage between related reproductive system findings identifier records.","Reproductive System Findings Link Identifier | RPLNKID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970679","Respiratory System Link Identifier","C162025","A sequence of characters used as a linkage between related respiratory system findings identifier records.","Respiratory System Link Identifier | RELNKID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970678","Urinary System Findings Link Identifier","C162026","A sequence of characters used as a linkage between related urinary system findings identifier records.","Urinary System Findings Link Identifier | URLNKID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970692","Microbiology Specimen Link Group Identifier","C162028","A sequence of characters used to link multiple microbiology specimen records to a single finding.","Microbiology Specimen Link Group Identifier | MBLNKGRP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970691","Musculoskeletal Findings, Connective and Soft Tissue Findings Link Group Identifier","C162029","A sequence of characters used to link multiple musculoskeletal system findings records to a single finding.","Musculoskeletal Findings, Connective and Soft Tissue Findings Link Group Identifier | MKLNKGRP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970690","Procedure Agents Link Group Identifier","C162030","A sequence of characters used to link multiple procedure agents records to a single finding.","Procedure Agents Link Group Identifier | AGLNKGRP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970689","Reproductive System Findings Link Group Identifier","C162031","A sequence of characters used to link multiple reproductive system findings records to a single finding.","Reproductive System Findings Link Group Identifier | RPLNKGRP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970688","Tumor Identification Link Group Identifier","C162032","A sequence of characters used to link multiple tumor identification records to a single finding.","Tumor Identification Link Group Identifier | TULNKGRP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970687","Urinary System Findings Link Group Identifier","C162033","A sequence of characters used to link multiple urinary system findings records to a single finding.","Urinary System Findings Link Group Identifier | URLNKGRP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970686","Cardiovascular System Findings Link Group","C162034","A sequence of characters used to link multiple cardiovascular system findings to a single finding.","Cardiovascular System Findings Link Group | CVLNKGRP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970641","Nervous System Findings Link Group","C162035","A sequence of characters used to link multiple nervous system findings to a single finding.","Nervous System Findings Link Group | NVLNKGRP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970640","Ophthalmic Examinations Link Group","C162036","A sequence of characters used to link multiple ophthalmic examinations to a single finding.","Ophthalmic Examinations Link Group | OELNKGRP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970639","Respiratory System Link Group","C162037","A sequence of characters used to link multiple respiratory system findings to a single finding.","Respiratory System Link Group | RELNKGRP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899258","Evaluation Interval Text","C117044","A textual description of the evaluation interval.","Evaluation Interval Text | EVINTX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826266","Normal Range Indicator","C82532","A indication that a result lies within normal parameters.","Normal Range Indicator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826316","Lower Limit of Quantitation","C82589","The lowest threshold for reliably quantifying the amount of substance measured by a specific test.","Lower Limit of Quantitation | LLOQ | Lower Limit Value",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827740","Upper Limit of Quantitation","C85533","The highest value in a standard range of values.","Upper Limit of Quantitation | ULOQ | Upper Limit Value",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563184","Succinate Dehydrogenase-Deficient Renal Cell Carcinoma","C156464","A very rare renal cell carcinoma that usually affects young adults. It is characterized by mutations in one of the four subunits of the SDH complex (SDHA, SDHB, SDHC, or SDHD gene). Most frequently, the mutations occur in the SDHB subunit. It has a relatively good prognosis.","Succinate Dehydrogenase-Deficient Renal Cell Carcinoma | SDH Deficient Renal Cell Carcinoma | SDH-Deficient Renal Cell Carcinoma | SDH-RCC | Succinate Dehydrogenase Renal Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708350","Hereditary Leiomyomatosis and Renal Cell Carcinoma","C51302","An autosomal dominant inherited syndrome caused by germline mutations in the FH gene. It is characterized by predisposition to renal cell carcinoma, leiomyomas of the skin and uterus, and leiomyosarcoma of the uterus.","Hereditary Leiomyomatosis and Renal Cell Carcinoma | FH Deficiency | HLRCC | Hereditary Leiomyomatosis and Renal Cell Cancer | Hereditary Leiomyomatosis and Renal Cell Cancer | Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome | Hereditary leiomyomatosis & RCC-associated renal cell carcinoma | hereditary leiomyomatosis and renal cell cancer syndrome",,,,,,,,,,,,,,,"37160584","Hereditary leiomyomatosis and renal cell carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054076","Clear Cell Papillary Renal Tumor","C121955","An encapsulated epithelial neoplasm that arises from the kidney. It is composed of cytologically bland epithelial cells with clear cytoplasm forming tubular and papillary patterns. The nuclei are arranged linearly away from the basement membrane. Tumor necrosis, perirenal invasion, and vascular invasion are not present. The clinical course is indolent.","Clear Cell Papillary Renal Tumor | CCPRCT | Clear Cell Papillary Renal Cell Carcinoma | Clear Cell Papillary Renal Neoplasm | Clear Cell Papillary Renal Neoplasm | Clear Cell Papillary Renal Tumor | Clear Cell Tubulopapillary Renal Cell Carcinoma | Renal Angiomyoadenomatous Tumor",,,,,,,,,,,,,,,"37116953|37116954","Clear cell papillary renal cell carcinoma|Clear cell papillary renal cell carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL558162","Acquired Cystic Disease-Associated Renal Cell Carcinoma","C157718","The most common renal cell carcinoma that develops in patients with end-stage renal disease and acquired cystic disease.","Acquired Cystic Disease-Associated Renal Cell Carcinoma | ACD-RCC | Acquired cystic disease-associated renal cell carcinoma (RCC) | Cyst-associated renal cell carcinoma","8316/3","Cyst-associated renal cell carcinoma",,,,,,,,,,,,,"35622697|4029511","Acquired cystic disease associated renal cell carcinoma|Cyst-associated renal cell carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1335746","TFEB-Rearranged Renal Cell Carcinoma","C37210","A rare renal cell carcinoma affecting young patients. It is characterized by the presence of the chromosomal translocation t(6;11) which fuses the TFEB transcription factor gene, located on chromosome 6, with the MALAT1 gene, located on chromosome 11.","TFEB-Rearranged Renal Cell Carcinoma | Renal Cell Carcinoma with t(6;11);(p21;q12); MALAT1-TFEB | Renal Cell Carcinoma with t(6;11);(p21;q12); MALAT1-TFEB | Renal Cell Carcinoma with t(6;11);(p21;q12); MALAT1::TFEB | TFEB-Altered Renal Cell Carcinoma | t(6;11) Renal Cell Carcinoma | t(6;11);(p21;q12) Renal Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL557969","Renal Cell Carcinoma with MiT Translocations","C154494","A renal cell carcinoma usually seen in children or young adults. It is characterized by papillary, alveolar and nested growth patterns with clear and eosinophilic cells. The carcinomas range from microscopic lesions to clinically symptomatic tumors. It is associated with translocations/gene fusions involving members of the MiT family of transcription factors. There are two subtypes: TFE3-rearranged renal cell carcinoma [Xp11 translocation renal cell carcinoma] and TFEB-rearranged renal cell carcinoma [t(6;11) renal cell carcinoma].","Renal Cell Carcinoma with MiT Translocations | MiT Family Translocation-Associated Renal Cell Carcinoma | MiT Family Translocation-Associated Renal Cell Carcinoma | MiT family translocation renal cell carcinoma",,,,,,,,,,,,,,,"35622644|37116862","MiT family translocation renal cell carcinoma|MiT family translocation renal cell carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0176996","Total Nephrectomy","C51632","No Value Exists","Total Nephrectomy | ",,,,,,,,,,,,,,,"4021108","Total nephrectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086120","Cardiovascular System Findings Body Position","C123987","The physical bearing of the body during a cardiovascular system assessment.","Cardiovascular System Findings Body Position | CVPOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086132","Cardiovascular System Findings Original Result Unit","C123985","The unit of measure for the result of the cardiovascular system assessment as originally received or collected.","Cardiovascular System Findings Original Result Unit | CVORRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970599","Gerota Fascia","C162125","A fibrous connective tissue covering the kidney and adrenal gland, which separates the perinephric fat from paranephric fat.","Gerota Fascia | Anterior Perirenal Fascia | Gerota's Fascia | Gerota's fascia | Renal Fascia | renal fascia",,,,,,,,,,,,,,,"4035623","Structure of perirenal fascia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086122","Cardiovascular System Findings Completion Status","C124006","A term used to describe the state or condition of the completeness of the cardiovascular system findings data.","Cardiovascular System Findings Completion Status | CVSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086130","Cardiovascular System Findings Method","C123979","The technique used to administer the cardiovascular system assessment.","Cardiovascular System Findings Method | CVMETHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539059","Musculoskeletal Findings, Connective and Soft Tissue Findings Domain","C102674","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to musculoskeletal findings, connective and soft tissue findings.","Musculoskeletal Findings, Connective and Soft Tissue Findings Domain | MK | Musculoskeletal System Findings",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898070","Original Result or Finding","C117221","The outcome of the test or finding as originally received or collected.","Original Result or Finding | ORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540591","Nervous System Findings Domain","C102677","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to nervous system findings.","Nervous System Findings Domain | NV | Nervous System Findings",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085649","Respiratory System Findings Test","C124025","A character or string that represents the long name of the respiratory system findings assessment.","Respiratory System Findings Test | RETEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086814","Respiratory System Findings Original Result Unit","C123986","The unit of measure for the result of the respiratory system assessment as originally received or collected.","Respiratory System Findings Original Result Unit | REORRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827015","Substance Use Route of Administration","C83426","The method a substance was introduced to a subject.","Substance Use Route of Administration | SUROUTE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550645","Ophthalmic Examinations Domain","C147180","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to ophthalmic examinations.","Ophthalmic Examinations Domain | OE | Ophthalmic Examinations",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879606","Hereditary Kidney Oncocytoma","C8960","An inherited condition characterized by the development of kidney oncocytomas which are often bilateral and multifocal.  This condition may be connected to Birt-Hogg-Dube syndrome.","Hereditary Kidney Oncocytoma | Familial Renal Oncocytoma | Hereditary Renal Oncocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412456","Hereditary Renal Cell Carcinoma","C39789","Renal cell carcinoma that has developed in relatives of patients with history of renal cell carcinoma.","Hereditary Renal Cell Carcinoma | Familial Renal Cancer | Hereditary Renal Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0346010","Birt-Hogg-Dube Syndrome","C28244","A rare genetic syndrome with an autosomal dominant pattern of inheritance. It is caused by a mutation in the FLCN gene which encodes the protein folliculin. Clinical signs include multiple benign growths of the skin and lungs that begin to manifest in the second or third decade of life. The clinical course is characterized by the progressive growth of new and existing neoplasms. In those with mutations in both copies of FLCN, the kidneys may also be affected by the growth of benign or malignant neoplasms.","Birt-Hogg-Dube Syndrome | Birt-Hogg-Dube syndrome",,,,,,,,,,,,,,,"37166981","Birt Hogg Dubé syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3554237","Kidney Cyst","C3970","Abnormal fluid filled sac within the kidney, either acquired or congenital.","Kidney Cyst | Cyst of Kidney | Cyst of the Kidney | Renal Cyst",,,,,,,,,,,,,,,"36716270","Cyst of kidney",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL951707","Middle","C159238","A tumor located in the middle section of the kidney.","Kidney Tumor, Middle Section | Middle | Middle Section of Kidney Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518352","Non-Contiguous Disease","C39768","A term that usually refers to the clinical course of lymphomas and indicates that the cancerous lymph nodes are not next to each other, but are on the same side of the diaphragm.","Non-Contiguous Disease | noncontiguous lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553240","Beyond","C151408","Past a place or outside an area.","Beyond | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041349","Tubulointerstitial Disease","C123036","Disease affecting the renal tubules and interstitium of the kidney.","Tubulointerstitial Disease | Tubulointerstitial disease",,,,,,,,,,,,,,,"4177206","Tubulointerstitial nephritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0852683","Glomerular Vascular Disorder","C35605","A disorder that is caused by pathologic changes in the glomerular vasculature.","Glomerular Vascular Disorder | Glomerular Disease | Glomerular disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969046","Bevacizumab Regimen","C159998","A regimen consisting of bevacizumab that may be used in the treatment of soft tissue sarcoma, including angiosarcoma, and AIDS-related Kaposi sarcomas; anaplastic gliomas and glioblastomas; adult intracranial and spinal ependymomas (excluding subependymomas and myxopapillary ependymomas); and otherr central nervous system (CNS) cancers, kidney, cervical, endometrial, ovarian/fallopian tube/primary peritoneal and non-small cell lung cancers (NSCLCs), and malignant sex cord-stromal tumors.","Bevacizumab Regimen | Avastin Regimen | Bevacizumab monotherapy | Bevacizumab-tnjn monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969182","Pembrolizumab Regimen","C160108","A regimen consisting of pembrolizumab that may be used in the treatment of anal, anaplastic, Merkel cell, and thymic carcinomas; ampullary, appendiceal, pancreatic, and small bowel adenocarcinomas; alveolar soft part sarcoma; soft tissue sarcoma, uterine sarcoma, and Kaposi sarcoma; bladder, breast, esophageal and esophagogastric junction, kidney, occult primary, gastric, bone, colorectal, cervical, non-small cell lung, small cell lung, penile, testicular, prostate, hepatobiliary, endometrial, vaginal, vulvar, ovarian, fallopian tube and primary peritoneal cancers; head and neck cancer including cancer of the nasopharynx; gestational trophoblastic neoplasia; chronic lymphocytic leukemia (CLL); small lymphocytic lymphoma (SLL); diffuse large B-cell lymphoma (DLBCL); Hodgkin lymphoma; T-cell lymphomas; mycosis fungoides/Sezary syndrome; follicular, medullary, papillary and Hurthle cell thyroid carcinomas; malignant germ cell tumors; adrenal gland and neuroendocrine tumors (NETs); extrapulmonary poorly differentiated neuroendocrine carcinoma, large or small cell carcinoma, and mixed neuroendocrine-non-neuroendocrine neoplasm; squamous cell skin cancer; and cutaneous and uveal melanoma.","Pembrolizumab Regimen | Keytruda Regimen | Pembrolizumab monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970590","Procedure Agent Sponsor Identifier","C162118","One or more sponsor defined characters used to identify, name, or characterize the procedure agents.","Procedure Agent Sponsor Identifier | AGSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970589","Procedure Agent Reported Name","C162119","The name of a medical product, practice, or application reported in a clinical trial.","Procedure Agent Reported Name | AGTRT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970588","Procedure Agent Modified Reported Name","C162120","An indication or description of a change in a procedure agent name.","Procedure Agent Modified Reported Name | AGMODIFY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970587","Procedure Agent Class","C162121","The variable assigned to a procedure agent class.","Procedure Agent Class | AGCLAS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970586","Procedure Agent Class Code","C162122","A character or string that represents a procedure agent class.","Procedure Agent Class Code | AGCLASCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970601","Procedure Agent Dose per Administration","C162123","The dose of study procedure agent taken per administration.","Procedure Agent Dose per Administration | AGDOSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970600","Procedure Agent Dose Description","C162124","A textual description of the procedure agent dose level(s) or range(s) per subject, according to the study protocol.","Procedure Agent Dose Description | AGDOSTXT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970598","Cardiovascular System Findings Reference Identifier","C162127","A character or string used to name, or characterize a cardiovascular system findings reference.","Cardiovascular System Findings Reference Identifier | CVREFID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970597","Description of Unplanned Actual Arm","C162128","Description of the unplanned actual arm (of the clinical trial) in which the subject participated during the trial.","Description of Unplanned Actual Arm | ACTARMUD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970596","Disease Response Elapsed Time","C162129","The interval between two disease response reference time points.","Disease Response Elapsed Time | RSELTM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970595","Disease Response Time Point Reference","C162130","The point in time that acts as a fixed reference point to a disease response assessment.","Disease Response Time Point Reference | RSTPTREF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970594","Functional Tests Reference Identifier","C162131","A character or string that represents a functional test assessment event reference.","Functional Tests Reference Identifier | FTREFID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970792","Functional Tests Sponsor-Defined Identifier","C162132","One or more sponsor-defined characters used to identify, name, or characterize the functional tests.","Functional Tests Sponsor-Defined Identifier | FTSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970791","FTORRES","C162133","The outcome of the functional test assessment as originally received or collected.","Functional Test Result or Finding in Original Units | FTORRES | Functional Tests Result or Finding in Original Units",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970790","Functional Tests External File Path","C162134","The literal identifier of a functional test external file name.","Functional Tests External File Path | FTXFN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970789","Functional Tests Vendor Name","C162135","The literal identifier of the vendor or laboratory that performs a functional test assessment.","Functional Tests Vendor Name | FTNAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981587","Substance Usage Pre-specified","C88004","An indication or description that substance usage was previously determined, characterized, or detailed.","Substance Usage Pre-specified | SUPRESP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970788","Functional Tests Elapsed Time","C162136","The interval between two functional test reference time points.","Functional Tests Elapsed Time | FTELTM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970787","Functional Tests Time Point Reference","C162137","The point in time that acts as a fixed reference point to a functional test assessment.","Functional Tests Time Point Reference | FTTPTREF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970786","Meal Data Sponsor-Defined Identifier","C162138","One or more sponsor defined characters used to identify, name, or characterize the meal data.","Meal Data Sponsor-Defined Identifier | MLSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970799","Meal Data Name","C162140","Verbatim food product name that is either pre-printed or collected on a CRF.","Meal Data Name | MLTRT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970797","Microbiology Specimen Focus of Study-Specific Interest","C162143","Identification of a focus of study-specific interest on or within a microbiology specimen as called out in the protocol for which a measurement, test, or examination was performed.","Microbiology Specimen Focus of Study-Specific Interest | MBFOCID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827002","Substance Use Class","C83413","The variable assigned to a substance usage class.","Substance Use Class | SUCLAS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970796","Microbiology Specimen Measurement, Test or Examination Detail","C162144","Further description of a microbiology test or microbiology test code.","Microbiology Specimen Measurement, Test or Examination Detail | MBTSTDTL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970795","Microbiology Susceptibility Non-host Organism Identifier","C162145","Sponsor-defined identifier for a non-host organism.","Microbiology Susceptibility Non-host Organism Identifier | NHOID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970794","Microbiology Susceptibility Measurement, Test or Examination Detail","C162146","Further description of a microbiology susceptibility test or microbiology susceptibility test code.","Microbiology Susceptibility Measurement, Test or Examination Detail | MSTSTDTL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970793","Microbiology Susceptibility Agent Name","C162147","The name of the agent for which resistance is tested. The agent specified may be based on genetic markers or direct phenotypic drug sensitivity testing.","Microbiology Susceptibility Agent Name | MSAGENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827005","Substance Use Dose","C83416","The amount of substance that a subject has used.","Substance Use Dose | SUDOSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970807","Microbiology Susceptibility Modified Reported Name","C162148","An indication or description of a change in a microbiology susceptibility agent.","Microbiology Susceptibility Modified Reported Name | MSMODIFY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827006","Substance Use Dose Form","C83417","The dosage form of a substance in use.","Substance Use Dose Form | SUDOSFRM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970806","Microbiology Susceptibility External File Path","C162149","The literal identifier of a microbiology susceptibility external file name.","Microbiology Susceptibility External File Path | MSXFN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827007","Substance Use Daily Dose","C83418","The total amount of substance the subject uses on a daily basis.","Substance Use Daily Dose | SUDOSTOT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970805","Microbiology Susceptibility Analysis Method","C162150","Analysis method applied to obtain a summarized microbiology susceptibility result.","Microbiology Susceptibility Analysis Method | MSANMETH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970804","Microbiology Susceptibility Collected Duration","C162151","Collected duration of a microbiology susceptibility event or finding.","Microbiology Susceptibility Collected Duration | MSCDUR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827013","Substance Use Occurrence","C83424","An indication or description regarding an episode of substance usage.","Substance Use Occurrence | SUOCCUR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086803","Respiratory System Findings Completion Status","C124008","A term used to describe the state or condition of the completeness of the respiratory system findings data.","Respiratory System Findings Completion Status | RESTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541338","Urinary System Findings Domain","C102726","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to urinary system findings.","Urinary System Findings Domain | UR | Urinary System Findings",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0877858","Aleukemic Leukemia","C4982","A leukemia characterized by the absence of leukemic cells in the peripheral blood.","Aleukemic Leukemia | Aleukemic leukemia, NOS",,,,,,,,,,,,,,,"4121332","Aleukemic leukemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332226","Alcohol-Related Carcinoma","C27927","A carcinoma that is caused by alcohol abuse.","Alcohol-Related Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0236022","Aggravated Malignant Neoplasm","C3851","A malignant neoplasm that shows clinical and/or pathologic progression.","Aggravated Malignant Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554307","Advanced Lymphoma","C153172","Lymphoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332206","Adult Lymphoma","C7587","A lymphoma that occurs in adults.","Adult Lymphoma | Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334298","Appendix Neuroendocrine Tumor G1","C4138","A well-differentiated, low-grade neuroendocrine neoplasm that arises from the appendix. The mitotic count is less than 2 per 2 mm2 and the Ki-67 index is less than 3%.","Appendix Neuroendocrine Tumor G1 | Appendiceal Carcinoid Tumor | Appendix Carcinoid Tumor | Appendix NET G1 | Appendix NET G1 (Carcinoid) | Appendix Neuroendocrine Tumor G1 (Carcinoid) | Carcinoid Tumor of Appendix | Carcinoid Tumor of the Appendix | Malignant carcinoid tumor of the appendix",,,,,,,,,,,,,,,"4329832|437238|761916","Carcinoid tumor of uncertain malignant potential|Carcinoid tumor of appendix|Malignant carcinoid tumor of appendix",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C1332287","Anaplastic Malignant Neoplasm","C36025","A malignant neoplasm characterized by the presence of poorly differentiated, often large neoplastic cells with bizarre morphologic characteristics, associated with high mitotic activity and necrotic changes.","Anaplastic Malignant Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970760","First Study Treatment Date","C162165","The date of the subject's first study treatment.","First Study Treatment Date | Date of First Study Treatment | Demographics Date of First Study Treatment | RFXSTDAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970756","First Study Treatment Time","C162169","The time of the subject's first study treatment.","First Study Treatment Time | Demographics Time of First Study Treatment | RFXSTTIM | Time of First Study Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970758","Last Study Treatment Date","C162167","The date of the subject's final study treatment.","Last Study Treatment Date | Date of Last Study Treatment | Demographics Date of Last Study Treatment | RFXENDAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970755","Last Study Treatment Time","C162170","The time of the subject's final study treatment.","Last Study Treatment Time | Demographics Time of Last Study Treatment | RFXENTIM | Time of Last Study Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985782","Informed Consent Date","C93579","The date (and time) the patient gives consent to a surgical or medical procedure or participation in a clinical study after achieving an understanding of the relevant medical facts and the risks involved.","Informed Consent Date | Date of Informed Consent | Demographics Date of Informed Consent | RFICDAT | date of informed consent | date_of_informed_consent | informedConsentDate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970769","Participation End Date","C162172","The date of the end of a subject's participation in the study.","Participation End Date | Date of End of Participation | Demographics Date of End of Participation | RFPENDAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970768","Participation End Time","C162173","The time of the end of a subject's participation in the study.","Participation End Time | Demographics Time of End of Participation | RFPENTIM | Time of End of Participation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970767","Disease Response Assessment Date","C162174","The date on which a disease response assessment is completed.","Disease Response Assessment Date | Disease Response Date of Assessment | RSDAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970766","Disease Response Assessment Time","C162175","The time at which a disease response assessment is completed.","Disease Response Assessment Time | Disease Response Time of Assessment | RSTIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970765","Study Subject Assessment Date","C162176","The date of the subject status assessment.","Study Subject Assessment Date | SSDAT | Study Subject Date of Assessment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970764","Study Subject Assessment Time","C162177","The time of the subject status assessment.","Study Subject Assessment Time | SSTIM | Study Subject Time of Assessment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970763","Tumor Identification Date","C162178","The date of tumor identification data collection.","Tumor Identification Date | Date of Tumor Identification | TUDAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970762","Tumor Identification Time","C162179","The time of tumor identification data collection.","Tumor Identification Time | TUTIM | Time of Tumor Identification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970777","Tumor Results Measurement Date","C162180","The date of the tumor scan, image, or physical exam.","Tumor Results Measurement Date | Date of Tumor/Lesion Measurement | TRDAT | Tumor Results Date of Measurement | Tumor/Lesion Measurement Date",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970776","Tumor Results Measurement Time","C162181","The time of the tumor scan, image, or physical exam.","Tumor Results Measurement Time | TRTIM | Time of Tumor/Lesion Measurement | Tumor Results Time of Measurement | Tumor/Lesion Measurement Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0243071","Analog","C1513","A synthetic chemical which structurally or functionally resembles a naturally occurring compound.","Analog | Analogue | analog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970780","Focus of Study-Specific Interest","C162195","Identification of a focus of study-specific interest on or within a subject or specimen as called out in the protocol for which a measurement, test, or examination was performed.","Focus of Study-Specific Interest | FOCID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970778","Musculoskeletal Findings, Connective and Soft Tissue Findings Sponsor-Defined Identifier","C162198","One or more sponsor defined characters used to identify, name, or characterize the musculoskeletal finding.","Musculoskeletal Findings, Connective and Soft Tissue Findings Sponsor-Defined Identifier | MKSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970730","Musculoskeletal Findings, Connective and Soft Tissue Findings Elapsed Time","C162201","The interval between two musculoskeletal findings reference time points.","Musculoskeletal Findings, Connective and Soft Tissue Findings Elapsed Time | MKELTM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970725","Musculoskeletal Findings, Connective and Soft Tissue Findings Reference Identifier","C162206","A character or string that represents a musculoskeletal finding event reference.","Musculoskeletal Findings, Connective and Soft Tissue Findings Reference Identifier | MKREFID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970737","Musculoskeletal Findings, Connective and Soft Tissue Findings Time Point Reference","C162210","The point in time that acts as a fixed reference point to a musculoskeletal finding.","Musculoskeletal Findings, Connective and Soft Tissue Findings Time Point Reference | MKTPTREF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970740","Nervous System Reference Identifier","C162207","A character or string that represents a nervous system assessment event reference.","Nervous System Reference Identifier | NVREFID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970732","Nervous System Sponsor-Defined Identifier","C162199","One or more sponsor defined characters used to identify, name, or characterize the nervous system finding.","Nervous System Sponsor-Defined Identifier | NVSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970729","Nervous System Elapsed Time","C162202","The interval between two nervous system findings reference time points.","Nervous System Elapsed Time | NVELTM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970736","Nervous System Time Point Reference","C162211","The point in time that acts as a fixed reference point to a nervous system finding.","Nervous System Time Point Reference | NVTPTREF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970728","Ophthalmic Examinations Elapsed Time","C162203","The interval between two ophthalmic examination reference time points.","Ophthalmic Examinations Elapsed Time | OEELTM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970735","Ophthalmic Examinations Time Point Reference","C162212","The point in time that acts as a fixed reference point to an ophthalmic examination.","Ophthalmic Examinations Time Point Reference | OETPTREF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970727","Reproductive System Findings Elapsed Time","C162204","The interval between two reproductive system findings reference time points.","Reproductive System Findings Elapsed Time | RPELTM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970734","Reproductive System Findings Time Point Reference","C162213","The point in time that acts as a fixed reference point to a reproductive system finding.","Reproductive System Findings Time Point Reference | RPTPTREF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970739","Respiratory System Findings Reference Identifier","C162208","A character or string that represents a respiratory system findings procedure event reference.","Respiratory System Findings Reference Identifier | REREFID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970733","Respiratory System Findings Reference Result in Original Units","C162214","The reference result for continuous respiratory measurements in original units.","Respiratory System Findings Reference Result in Original Units | REORREF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970738","Urinary System Findings Reference Identifier","C162209","A character or string that represents a urinary system findings event reference.","Urinary System Findings Reference Identifier | URREFID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970731","Urinary System Findings Sponsor-Defined Identifier","C162200","One or more sponsor defined characters used to identify, name, or characterize the urinary system finding.","Urinary System Findings Sponsor-Defined Identifier | URSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970726","Urinary System Findings Elapsed Time","C162205","The interval between two urinary system findings reference time points.","Urinary System Findings Elapsed Time | URELTM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935840","Tissue Source Site Identifier","C156808","An identifier assigned to a tissue source site.","Tissue Source Site Identifier | TSS ID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936812","Date of Initial Cancer Diagnosis","C157121","The date of the initial cancer diagnosis.","Initial Cancer Diagnosis Date | Date of Initial Cancer Diagnosis | Date of Initial Pathologic Diagnosis | Initial Cancer Diagnosis | Initial Pathologic Diagnosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936905","Chemical/Occupational Exposure History","C157151","A record of the individual's history of exposure to chemicals and/or occupational hazard.","Chemical/Occupational Exposure History | Chemical or Occupational Exposure History | History of Chemical/Occupational Exposures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936770","If yes, please select exposure types (select all that apply)","C157103","A directive to select all the relevant exposure types.","Select Exposure Types | If yes, please select exposure types (select all that apply) | exposure type | exposure_type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510972","Autoimmune Lymphoproliferative Syndrome-Associated Lymphoma","C39578","A lymphoma that arises in the context of autoimmune lymphoproliferative syndrome.","Autoimmune Lymphoproliferative Syndrome-Related Lymphoma | ALPS-Related Lymphoma | Autoimmune Lymphoproliferative Syndrome-Associated Lymphoma | Autoimmune Lymphoproliferative Syndrome-Associated Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0346156","Benign Breast Neoplasm","C4505","A neoplasm that arises from the breast and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Breast Neoplasm | Benign Breast Tumor | Benign Neoplasm of Breast | Benign Neoplasm of the Breast | Benign Tumor of Breast | Benign Tumor of the Breast",,,,,,,,,,,,,,,"72576","Benign tumor of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153959","Benign Bone Neoplasm","C4880","A mesenchymal neoplasm that arises from bone or articular cartilage and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Bone Neoplasm | Benign Bone Tumor | Benign Neoplasm of Bone | Benign Neoplasm of the Bone | Benign Osseous Neoplasm | Benign Osseous Tumor | Benign Tumor of Bone | Benign Tumor of the Bone",,,,,,,,,,,,,,,"74606","Benign neoplasm of bone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0154017","Benign Bladder Neoplasm","C3618","A neoplasm that arises from the bladder and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Bladder Neoplasm | Benign Bladder Tumor | Benign Neoplasm of Bladder | Benign Neoplasm of Urinary Bladder | Benign Neoplasm of the Bladder | Benign Neoplasm of the Urinary Bladder | Benign Tumor of Bladder | Benign Tumor of Urinary Bladder | Benign Tumor of the Bladder | Benign Tumor of the Urinary Bladder | Benign Urinary Bladder Neoplasm | Benign Urinary Bladder Tumor",,,,,,,,,,,,,,,"201824","Benign neoplasm of bladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0154040","Benign Adrenal Gland Neoplasm","C3629","A neoplasm that arises from the adrenal gland and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Adrenal Gland Neoplasm | Benign Adrenal Gland Tumor | Benign Adrenal Neoplasm | Benign Adrenal Tumor | Benign Neoplasm of Adrenal Gland | Benign Neoplasm of the Adrenal Gland | Benign Tumor of Adrenal Gland | Benign Tumor of the Adrenal Gland",,,,,,,,,,,,,,,"192273","Benign neoplasm of adrenal gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937980","CPTAC Codelists Terminology","C158520","Terminology used to support the various lists of data useful for tracking trends by CPTAC.","CPTAC Codelists Terminology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0347481","Benign Connective and Soft Tissue Neoplasm","C53684","A neoplasm that arises from connective and soft tissue and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential. Representative examples include lipoma, leiomyoma, fibroma, and osteoma.","Benign Connective and Soft Tissue Neoplasm | Benign Connective and Soft Tissue Tumor | Benign Mesenchymal Cell Neoplasm | Benign Neoplasm of the Soft Tissue and Bone | Benign Tumor of the Soft Tissue and Bone | CONNECTIVE AND SOFT TISSUE NEOPLASM, BENIGN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004991","Benign Colon Neoplasm","C2894","A neoplasm that arises from the colon and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Colon Neoplasm | Benign Colon Tumor | Benign Colonic Neoplasm | Benign Colonic Tumor | Benign Neoplasm of Colon | Benign Neoplasm of the Colon | Benign Tumor of Colon | Benign Tumor of the Colon",,,,,,,,,,,,,,,"77234","Benign neoplasm of colon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0947770","Benign Female Reproductive System Neoplasm","C4934","A neoplasm that arises from the female reproductive system and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Female Reproductive System Neoplasm | Benign Female Reproductive System Tumor | Benign Gynecologic Neoplasm | Benign Gynecologic Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0339107","Benign Eyelid Neoplasm","C4354","A neoplasm that arises from the upper or lower eyelid and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Eyelid Neoplasm | Benign Eyelid Tumor | Benign Neoplasm of Eyelid | Benign Neoplasm of the Eyelid | Benign Tumor of Eyelid | Benign Tumor of the Eyelid",,,,,,,,,,,,,,,"4242957|4333986","Benign neoplasm of skin of eyelid|Benign tumor of eyelid",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0347285","Benign Exocrine Pancreas Neoplasm","C4613","A neoplasm that arises from the exocrine pancreas and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Exocrine Pancreas Neoplasm | Benign Exocrine Pancreas Tumor | Benign Exocrine Pancreatic Neoplasm | Benign Neoplasm of Exocrine Pancreas | Benign Neoplasm of the Exocrine Pancreas | Benign Tumor of Exocrine Pancreas | Benign Tumor of the Exocrine Pancreas",,,,,,,,,,,,,,,"4156048","Benign tumor of exocrine pancreas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0497538","Benign Digestive System Neoplasm","C4787","A neoplasm that arises from the digestive system and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Digestive System Neoplasm | Benign Digestive System Tumor | Benign GI Neoplasm | Benign GI System Neoplasm | Benign GI System Tumor | Benign GI Tumor | Benign Gastrointestinal Neoplasm | Benign Gastrointestinal System Tumor | Benign Gastrointestinal Tumor | Benign Neoplasm of Digestive System | Benign Neoplasm of Gastrointestinal System | Benign Neoplasm of the Digestive System | Benign Tumor of Digestive System | Benign Tumor of GI System | Benign Tumor of Gastrointestinal System | Benign Tumor of the Digestive System | Benign Tumor of the GI System | Benign Tumor of the Gastrointestinal System",,,,,,,,,,,,,,,"4243411","Benign neoplasm of gastrointestinal tract",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1511205","Bladder Urachal Cancer","C39842","A rare variant of carcinoma of the urachal remnant of bladder.","Urachal Carcinoma | Bladder Urachal Cancer | Bladder Urachal Carcinoma | Bladder Urachal Carcinoma | Urachal carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0153933","Benign Tongue Neoplasm","C3592","A neoplasm that arises from the tongue and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Tongue Neoplasm | Benign Neoplasm of Tongue | Benign Neoplasm of the Tongue | Benign Tongue Tumor | Benign Tumor of Tongue | Benign Tumor of the Tongue | Tongue Neoplasm, Benign",,,,,,,,,,,,,,,"440668","Benign neoplasm of tongue",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0154038","Benign Thyroid Gland Neoplasm","C3628","A neoplasm that arises from the thyroid gland and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Thyroid Gland Neoplasm | Benign Neoplasm of Thyroid | Benign Neoplasm of Thyroid Gland | Benign Neoplasm of Thyroid Glands | Benign Neoplasm of the Thyroid | Benign Neoplasm of the Thyroid Gland | Benign Thyroid Gland Tumor | Benign Thyroid Neoplasm | Benign Thyroid Neoplasm NOS | Benign Thyroid Tumor | Benign Tumor of Thyroid | Benign Tumor of Thyroid Gland | Benign Tumor of the Thyroid | Benign Tumor of the Thyroid Gland | Thyroid Neoplasm, Benign",,,,,,,,,,,,,,,"141249","Benign neoplasm of thyroid gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0345975","Benign Thymus Neoplasm","C4458","A non-metastasizing neoplasm that arises from the thymus.","Benign Thymus Neoplasm | Benign Neoplasm of Thymus | Benign Neoplasm of the Thymus | Benign Thymic Neoplasm | Benign Thymic Tumor | Benign Thymus Tumor | Benign Tumor of Thymus | Benign Tumor of the Thymus",,,,,,,,,,,,,,,"438107","Benign neoplasm of thymus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0751588","Benign Supratentorial Neoplasm","C4963","A neoplasm that arises from above the cerebellar tentorium and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Supratentorial Neoplasm | Benign Supratentorial Neoplasms | Benign Supratentorial Tumor | Benign Supratentorial Tumors | Benign neoplasm of brain, supratentorial | Supratentorial Neoplasms, Benign",,,,,,,,,,,,,,,"4093950","Benign neoplasm of brain, supratentorial",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153944","Benign Small Intestinal Neoplasm","C3600","A neoplasm that arises from the small intestine and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Small Intestinal Neoplasm | Benign Neoplasm of Small Intestine | Benign Neoplasm of the Small Intestine | Benign Small Intestinal Neoplasm NOS | Benign Small Intestinal Tumor | Benign Small Intestine Neoplasm | Benign Small Intestine Tumor | Benign Tumor of Small Intestine | Benign Tumor of the Small Intestine",,,,,,,,,,,,,,,"4242962","Benign neoplasm of small intestine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004998","Benign Skin Neoplasm","C2896","A neoplasm that arises from the skin and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Skin Neoplasm | Benign Cutaneous Neoplasm | Benign Cutaneous Tumor | Benign Neoplasm of Skin | Benign Neoplasm of the Skin | Benign Skin Tumor | Benign Tumor of Skin | Benign Tumor of the Skin | Skin Neoplasms, Benign",,,,,,,,,,,,,,,"138102","Benign neoplasm of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0496873","Benign Retroperitoneal Neoplasm","C4447","A neoplasm that arises from the retroperitoneum and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Retroperitoneal Neoplasm | ",,,,,,,,,,,,,,,"4242974","Benign neoplasm of retroperitoneum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0588348","Benign Respiratory System Neoplasm","C8531","A neoplasm that arises from the respiratory system and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Respiratory System Neoplasm | Benign Respiratory Tract Neoplasm | Benign Respiratory Tract Neoplasm",,,,,,,,,,,,,,,"4240153","Benign neoplasm of respiratory tract",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0496901","Benign Pituitary Gland Neoplasm","C4782","A neoplasm that arises from the anterior or posterior lobe of pituitary gland and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Pituitary Gland Neoplasm | Benign Neoplasm of Pituitary | Benign Neoplasm of Pituitary Gland | Benign Neoplasm of the Pituitary | Benign Neoplasm of the Pituitary Gland | Benign Pituitary Gland Tumor | Benign Pituitary Neoplasm | Benign Pituitary Tumor | Benign Tumor of Pituitary | Benign Tumor of Pituitary Gland | Benign Tumor of the Pituitary | Benign Tumor of the Pituitary Gland | Benign neoplasm of pituitary gland | Pituitary Neoplasms, Benign | Pituitary Tumor, Benign",,,,,,,,,,,,,,,"4242816","Benign neoplasm of pituitary gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153940","Benign Pharyngeal Neoplasm","C3597","A neoplasm that arises from the pharynx and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Pharyngeal Neoplasm | Benign Neoplasm of Pharynx | Benign Neoplasm of the Pharynx | Benign Pharyngeal Tumor | Benign Pharynx Neoplasm | Benign Pharynx Tumor | Benign Tumor of Pharynx | Benign Tumor of the Pharynx | Pharyngeal Neoplasm Benign",,,,,,,,,,,,,,,"30356","Benign neoplasm of pharynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004997","Benign Ovarian Neoplasm","C2895","A neoplasm that arises from the ovary and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential. Representative examples include serous cystadenoma, mucinous cystadenoma, clear cell adenofibroma, benign Brenner tumor, thecoma, and fibroma.","Benign Ovarian Neoplasm | Benign Neoplasm of Ovary | Benign Neoplasm of the Ovary | Benign Ovarian Tumor | Benign Tumor of Ovary | Benign Tumor of the Ovary",,,,,,,,,,,,,,,"199764","Benign neoplasm of ovary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0154023","Benign Orbit Neoplasm","C3620","A neoplasm that arises from the orbit and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Orbital Neoplasm | Benign Neoplasm of Orbit | Benign Neoplasm of the Orbit | Benign Orbit Neoplasm | Benign Orbit Neoplasm | Benign Orbit Tumor | Benign Orbital Neoplasm | Benign Orbital Tumor | Benign Tumor of Orbit | Benign Tumor of the Orbit",,,,,,,,,,,,,,,"433987","Benign neoplasm of orbit",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0348426","Benign Neoplasm of the Meninges","C4957","A neoplasm that arises from the meninges and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Neoplasm of the Meninges | Benign Meningeal Neoplasm | Benign Meningeal Neoplasms | Benign Meningeal Tumor | Benign Meningeal Tumors | Benign Meninges Neoplasm | Benign Meninges Tumor | Benign Neoplasm of Meninges | Benign Neoplasms of Meninges | Benign Neoplasms of the Meninges | Benign Tumor of Meninges | Benign Tumor of the Meninges | Benign neoplasm of meninges | Benign neoplasm of meninges, unspecified | Meningeal Tumors, Benign",,,,,,,,,,,,,,,"4003171|4260192","Benign neoplasm of meninges|Benign meningeal neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0004994","Benign Neoplasm of Mandible","C34417","A non-metastasizing neoplasm that arises from the mandible.","Benign Neoplasm of Mandible | Benign Neoplasm of Lower Jaw Bone | Benign Neoplasm of Lower Jaw Bone",,,,,,,,,,,,,,,"373166","Benign neoplasm of mandible",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3273007","Benign Liver and Intrahepatic Bile Duct Epithelial Neoplasm","C96756","A neoplasm that arises from the hepatocytes or intrahepatic bile duct epithelial cells and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential. Representative examples include hepatocellular adenoma and bile duct adenoma.","Benign Liver Epithelial Neoplasm | Benign Liver and Intrahepatic Bile Duct Epithelial Neoplasm | Benign Liver and Intrahepatic Bile Duct Epithelial Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0346118","Benign Lipomatous Neoplasm","C4502","A mesenchymal neoplasm composed of adipose (fatty) tissue. There is no evidence of atypical or malignant cytological and architectural features, invasive features, or metastases.","Benign Lipomatous Neoplasm | Benign Adipose Tissue Neoplasm | Benign Adipose Tissue Tumor | Benign Lipomatous Tumor | Benign Neoplasm of Adipose Tissue | Benign Neoplasm of the Adipose Tissue | Benign Tumor of Adipose Tissue | Benign Tumor of the Adipose Tissue",,,,,,,,,,,,,,,"4112852","Benign lipomatous tumor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153952","Benign Laryngeal Neoplasm","C3601","A neoplasm that arises from the larynx and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Laryngeal Neoplasm | Benign Laryngeal Tumor | Benign Larynx Neoplasm | Benign Larynx Tumor | Benign Neoplasm of Larynx | Benign Neoplasm of the Larynx | Benign Tumor of Larynx | Benign Tumor of the Larynx | Laryngeal Neoplasm, Benign",,,,,,,,,,,,,,,"23731","Benign neoplasm of larynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0496892","Benign Kidney Neoplasm","C4778","A neoplasm that arises from the kidney and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Kidney Neoplasm | Benign Kidney Tumor | Benign Neoplasm of Kidney | Benign Neoplasm of the Kidney | Benign Renal Neoplasm | Benign Renal Tumor | Benign Tumor of Kidney | Benign Tumor of the Kidney | Renal Neoplasm, Benign | Renal Tumor, Benign",,,,,,,,,,,,,,,"195498","Benign neoplasm of kidney",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512683","Central Nervous System Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor","C129537","A rare Ewing sarcoma/peripheral primitive neuroectodermal tumor that affects the central nervous system either as a primary dural neoplasm or by direct extension from adjacent soft tissues or bone.","Central Nervous System Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698997","Carcinoma Arising from Craniopharyngioma","C79949","A rare condition characterized by the development of a carcinoma in a pre-existing craniopharyngioma.","Carcinoma Arising from Craniopharyngioma | CRANIOPHARYNGIOMA, MALIGNANT | Carcinoma Arising From Craniopharyngioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0346787","Breast Melanoma","C8410","A melanoma that arises usually from the breast skin and less often from the breast glandular tissue.  Primary breast melanomas are rare.","Breast Melanoma | Malignant Breast Melanoma | Malignant Melanoma of Breast | Malignant Melanoma of the Breast",,,,,,,,,,,,,,,"4089865","Malignant melanoma of breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514273","Childhood Melanoma","C131506","A melanoma that occurs during childhood.","Childhood Melanoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332979","Childhood Lymphoma","C5165","A Hodgkin or non-Hodgkin lymphoma that occurs during childhood.","Childhood Lymphoma | Lymphoma | Pediatric Lymphoma",,,,,,,,,,,,,,,"37156205","Malignant lymphoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332977","Childhood Leukemia","C4989","An acute or chronic leukemia that occurs during childhood.","Childhood Leukemia | Leukemia",,,,,,,,,,,,,,,"37156146","Leukemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL562681","Chest Wall Sarcoma","C155873","A sarcoma that arises from the anatomic structures that surround the lungs and the pleura.","Chest Wall Sarcoma | Primary Thoracic Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519811","Cutaneous Squamous Cell Carcinoma of the Head and Neck","C133252","A squamous cell carcinoma that arises from the skin of the head and neck.","Cutaneous Squamous Cell Carcinoma of the Head and Neck | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010267","Cranial Nerve Neoplasm","C2963","Abnormal growth of the cells that comprise the cranial nerves.","Cranial Nerve Neoplasm | Cranial Nerve Neoplasms | Cranial Nerve Tumor | Neoplasm of Cranial Nerve | Neoplasm of the Cranial Nerve | Neoplasm of uncertain behavior of cranial nerves | Tumor of Cranial Nerve | Tumor of the Cranial Nerve",,,,,,,,,,,,,,,"4131106","Neoplasm of cranial nerve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0346367","Corneal Melanoma","C4553","A melanoma that arises from the cornea.","Corneal Melanoma | Cornea Melanoma | Malignant Cornea Melanoma | Malignant Corneal Melanoma | Malignant Melanoma of Cornea | Malignant Melanoma of the Cornea | Melanoma of Cornea | Melanoma of the Cornea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0346360","Conjunctival Melanoma","C4550","A melanoma that arises from the conjunctiva.","Conjunctival Melanoma | Conjunctiva Melanoma | Malignant Conjunctiva Melanoma | Malignant Conjunctival Melanoma | Malignant Melanoma of Conjunctiva | Malignant Melanoma of the Conjunctiva | Melanoma of Conjunctiva | Melanoma of the Conjunctiva",,,,,,,,,,,,,,,"4112982","Malignant melanoma of conjunctiva",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0346935","Conjunctival Kaposi Sarcoma","C4578","A Kaposi sarcoma arising from the conjunctiva.","Conjunctival Kaposi Sarcoma | Conjunctival Kaposi's Sarcoma | Kaposi's Sarcoma of Conjunctiva | Kaposi's Sarcoma of the Conjunctiva",,,,,,,,,,,,,,,"4114340","Kaposi's sarcoma of conjunctiva",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1279296","Chronic Leukemia","C3483","A slowly progressing leukemia characterized by a clonal (malignant) proliferation of maturing and mature myeloid cells or mature lymphocytes.  When the clonal cellular population is composed of myeloid cells, the process is called chronic myelogenous leukemia.  When the clonal cellular population is composed of lymphocytes, it is classified as chronic lymphocytic leukemia, hairy cell leukemia, or T-cell large granular lymphocyte leukemia.","Chronic Leukemia | Chronic leukemia, NOS | chronic leukemia",,,,,,,,,,,,,,,"140057|40459049","Chronic leukemia|Chronic leukemia",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL970716","Thousand Cells per Kilogram","C162249","A derived unit expressed as a number of cells in thousands per unit of mass equal to one kilogram.","Thousand Cells per Kilogram | 1000 cells per kilogram | 10E3 Cells/kg | 10^3 Cells/Kilogram | 10^3 Cells/kg | 10^3{Cells}/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970714","Semantic Clustering","C162251","The tendency to group items according to their semantic category.","Semantic Clustering | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970713","Learning Slope","C162252","A measure of an individual's learning rate.","Learning Slope | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970712","Recognition Hits","C162253","Correctly recognized items.","Recognition Hits | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1377617","Carcinoma in a Polyp","C7682","Carcinoma arising in a polyp.","Carcinoma in a Polyp | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0346903","Malignant Cerebral Neoplasm","C4577","A malignant neoplasm involving the cerebrum.","Malignant Cerebral Neoplasm | Cerebral Cancer | Malignant Cerebral Hemispheric Neoplasm | Malignant Cerebral Hemispheric Tumor | Malignant Cerebral Tumor | Malignant Neoplasm of Cerebral Hemispheres | Malignant Neoplasm of Cerebrum | Malignant Neoplasm of the Cerebral Hemispheres | Malignant Neoplasm of the Cerebrum | Malignant Tumor of Cerebral Hemispheres | Malignant Tumor of Cerebrum | Malignant Tumor of the Cerebral Hemispheres | Malignant Tumor of the Cerebrum",,,,,,,,,,,,,,,"443561","Malignant neoplasm of cerebrum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334593","Malignant Intracranial Neoplasm","C5114","A malignant neoplasm involving the intracranial space.","Malignant Intracranial Neoplasm | Intracranial Cancer | Intracranial Neoplasms, Malignant | Intracranial Tumors, Malignant | Malignant Intracranial Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL497348","Malignant Neoplasm of Multiple Primary Sites","C35427","A malignant neoplasm arising in multiple primary sites.","Malignant Neoplasm of Multiple Primary Sites | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334691","Melanomatosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334791","Moderately Differentiated Malignant Neoplasm","C36049","A neoplasm whose histologic characteristics are intermediate between poorly differentiated and well differentiated.","Moderately Differentiated Malignant Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278869","Ocular Melanoma with Extraocular Extension","C7913","A melanoma arising from and extending beyond the structures of the eye.","Ocular Melanoma with Extraocular Extension | Extraocular Extension Melanoma | Extraocular Extension of Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335444","Poorly Differentiated Malignant Neoplasm","C36050","A neoplasm whose histologic characteristics have regressed and are more similar to stem cells.","Poorly Differentiated Malignant Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278884","Recurrent Melanoma","C7087","The reemergence of a melanoma after a period of remission.","Recurrent Melanoma | Recurrent Malignant Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336860","Undifferentiated Malignant Neoplasm","C36051","A neoplasm that has minimal to no differentiating features.","Undifferentiated Malignant Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336967","Virus-Related Carcinoma","C27698","Carcinoma that develops in the context of an individual infected with a virus.","Virus-Related Carcinoma | Virus Related Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1337019","Well Differentiated Malignant Neoplasm","C36052","A malignant neoplasm with morphological features reminiscent of the tissue from which it arose.","Well Differentiated Malignant Neoplasm | Well-Differentiated Malignant Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970718","Meal Data Elapsed Time","C162263","The interval between two meal data reference time points.","Meal Data Elapsed Time | MLELTM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970900","Meal Data Time Point Reference","C162264","The point in time that acts as a fixed reference point to meal data.","Meal Data Time Point Reference | MLTPTREF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970899","Disease Milestone Instance Name","C162265","The name of a specific event or activity that can be anticipated in the course of a disease, but whose timing is not controlled by the study schedule.","Disease Milestone Instance Name | MIDS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970898","Temporal Relation to Milestone Instance","C162266","A textual description of the temporal relationship between the observation and the disease milestone.","Temporal Relation to Milestone Instance | RELMIDS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970897","Disease Milestone Instance Date","C162267","The date of a specific disease milestone.","Disease Milestone Instance Date | MIDSDAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970896","Disease Milestone Instance Time","C162268","The time of a specific disease milestone.","Disease Milestone Instance Time | MIDSTTIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1717821","Extraprostatic Extension","C162259","A finding indicating the presence of a prostatic carcinoma that has invaded the prostatic capsule and has spread to nearby tissues or distant anatomic sites.","Extraprostatic Extension | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969986","Prostate Intraductal Carcinoma","C161022","An intra-acinar and/or intraductal neoplastic epithelial proliferation in the prostate gland that has some features of high-grade prostatic intraepithelial neoplasia but exhibits much greater architectural and/or cytological atypia, typically associated with high-grade, high-stage prostate carcinoma. (WHO 2016)","Prostate Intraductal Carcinoma | IDC-P | Intraductal Carcinoma of the Prostate | Intraductal Prostate Adenocarcinoma | Intraductal Prostate Carcinoma | Intraductal Prostate Carcinoma | Intraductal Prostate Carcinoma

 | Prostate Intraductal Carcinoma | Prostate Intraductal carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334407","Localized Carcinoma","C7625","A carcinoma that is confined to a specific site without evidence of spread to other anatomic sites.","Localized Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021864","Intracavitary Radiation Therapy","C28049","Radiotherapy in which the radiation source is placed directly within the body cavity being treated.","Intracavitary Radiation Therapy | BRACHYTHERAPY, INTRACAVITARY | CAV | Intracavitary Radiation | Intracavitary brachytherapy (procedure) | intracavitary radiation therapy",,,,,,,,,,,,,,,"4293738","Intracavitary brachytherapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545989","Subject Disease Milestones Domain","C147184","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to subject disease milestones.","Subject Disease Milestones Domain | SM | Subject Disease Milestones",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970903","MET NP_000236.2:p.M1250T","C162277","A change in the amino acid residue at position 1250 in the hepatocyte growth factor receptor protein where methionine has been replaced by threonine.","MET NP_000236.2:p.M1250T | C-MET M1250T | C-MET Met1250Thr | HGF Receptor M1250T | HGF Receptor Met1250Thr | HGFR M1250T | HGFR Met1250Thr | Hepatocyte Growth Factor Receptor M1250T | Hepatocyte Growth Factor Receptor Met1250Thr | MET M1250T | MET Met1250Thr | MET NP_000236.2:p.Met1250Thr | MET p.M1250T | MET p.Met1250Thr | NP_000236.2:p.M1250T | NP_000236.2:p.Met1250Thr | NP_001120972.1:p.M1268T | NP_001120972.1:p.Met1268Thr | Proto-Oncogene c-Met M1250T | Proto-Oncogene c-Met Met1250Thr | Scatter Factor Receptor M1250T | Scatter Factor Receptor Met1250Thr | Tyrosine-Protein Kinase Met M1250T | Tyrosine-Protein Kinase Met Met1250Thr",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970902","MET NP_000236.2:p.S1236R","C162278","A change in the amino acid residue at position 1236 in the hepatocyte growth factor receptor protein where serine has been replaced by arginine.","MET NP_000236.2:p.S1236R | C-MET S1236R | C-MET Ser1236Arg | HGF Receptor S1236R | HGF Receptor Ser1236Arg | HGFR S1236R | HGFR Ser1236Arg | Hepatocyte Growth Factor Receptor S1236R | Hepatocyte Growth Factor Receptor Ser1236Arg | MET NP_000236.2:p.Ser1236Arg | MET S1236R | MET Ser1236Arg | MET p.S1236R | MET p.Ser1236Arg | NP_000236.2:p.S1236R | NP_000236.2:p.Ser1236Arg | NP_001120972.1:p.S1254R | NP_001120972.1:p.Ser1254Arg | Proto-Oncogene c-Met S1236R | Proto-Oncogene c-Met Ser1236Arg | Scatter Factor Receptor S1236R | Scatter Factor Receptor Ser1236Arg | Tyrosine-Protein Kinase Met S1236R | Tyrosine-Protein Kinase Met Ser1236Arg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970916","MET NP_000236.2:p.Y1230H","C162280","A change in the amino acid residue at position 1230 in the hepatocyte growth factor receptor protein where tyrosine has been replaced by histdine.","MET NP_000236.2:p.Y1230H | C-MET Tyr1230His | C-MET Y1230H | HGF Receptor Tyr1230His | HGF Receptor Y1230H | HGFR Tyr1230His | HGFR Y1230H | Hepatocyte Growth Factor Receptor Tyr1230His | Hepatocyte Growth Factor Receptor Y1230H | MET NP_000236.2:p.Tyr1230His | MET Tyr1230His | MET Y1230H | MET p.Tyr1230His | MET p.Y1230H | NP_000236.2:p.Tyr1230His | NP_000236.2:p.Y1230H | NP_001120972.1:p.Tyr1248His | NP_001120972.1:p.Y1248H | Proto-Oncogene c-Met Tyr1230His | Proto-Oncogene c-Met Y1230H | Scatter Factor Receptor Tyr1230His | Scatter Factor Receptor Y1230H | Tyrosine-Protein Kinase Met Tyr1230His | Tyrosine-Protein Kinase Met Y1230H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970914","MET NP_000236.2:p.Y1230C","C162282","A change in the amino acid residue at position 1230 in the hepatocyte growth factor receptor protein where tyrosine has been replaced by cysteine.","MET NP_000236.2:p.Y1230C | C-MET Tyr1230Cys | C-MET Y1230C | HGF Receptor Tyr1230Cys | HGF Receptor Y1230C | HGFR Tyr1230Cys | HGFR Y1230C | Hepatocyte Growth Factor Receptor Tyr1230Cys | Hepatocyte Growth Factor Receptor Y1230C | MET NP_000236.2:p.Tyr1230Cys | MET Tyr1230Cys | MET Y1230C | MET p.Tyr1230Cys | MET p.Y1230C | NP_000236.2:p.Tyr1230Cys | NP_000236.2:p.Y1230C | NP_001120972.1:p.Tyr1248Cys | NP_001120972.1:p.Y1248C | Proto-Oncogene c-Met Tyr1230Cys | Proto-Oncogene c-Met Y1230C | Scatter Factor Receptor Tyr1230Cys | Scatter Factor Receptor Y1230C | Tyrosine-Protein Kinase Met Tyr1230Cys | Tyrosine-Protein Kinase Met Y1230C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970912","MET NP_000236.2:p.D1228N","C162284","A change in the amino acid residue at position 1228 in the hepatocyte growth factor receptor protein where aspartic acid has been replaced by asparagine.","MET NP_000236.2:p.D1228N | C-MET Asp1228Asn | C-MET D1228N | HGF Receptor Asp1228Asn | HGF Receptor D1228N | HGFR Asp1228Asn | HGFR D1228N | Hepatocyte Growth Factor Receptor Asp1228Asn | Hepatocyte Growth Factor Receptor D1228N | MET Asp1228Asn | MET D1228N | MET NP_000236.2:p.Asp1228Asn | MET p.Asp1228Asn | MET p.D1228N | NP_000236.2:p.Asp1228Asn | NP_000236.2:p.D1228N | NP_001120972.1:p.Asp1246Asn | NP_001120972.1:p.D1246N | Proto-Oncogene c-Met Asp1228Asn | Proto-Oncogene c-Met D1228N | Scatter Factor Receptor Asp1228Asn | Scatter Factor Receptor D1228N | Tyrosine-Protein Kinase Met Asp1228Asn | Tyrosine-Protein Kinase Met D1228N",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970910","MET NP_000236.2:p.L1205V","C162286","A change in the amino acid residue at position 1205 in the hepatocyte growth factor receptor protein where leucine has been replaced by valine.","MET NP_000236.2:p.L1205V | C-MET L1205V | C-MET Leu1205Val | HGF Receptor L1205V | HGF Receptor Leu1205Val | HGFR L1205V | HGFR Leu1205Val | Hepatocyte Growth Factor Receptor L1205V | Hepatocyte Growth Factor Receptor Leu1205Val | MET L1205V | MET Leu1205Val | MET NP_000236.2:p.Leu1205Val | MET p.L1205V | MET p.Leu1205Val | NP_000236.2:p.L1205V | NP_000236.2:p.Leu1205Val | NP_001120972.1:p.L1223V | NP_001120972.1:p.Leu1223Val | Proto-Oncogene c-Met L1205V | Proto-Oncogene c-Met Leu1205Val | Scatter Factor Receptor L1205V | Scatter Factor Receptor Leu1205Val | Tyrosine-Protein Kinase Met L1205V | Tyrosine-Protein Kinase Met Leu1205Val",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970924","MET NP_000236.2:p.F1200I","C162288","A change in the amino acid residue at position 1200 in the hepatocyte growth factor receptor protein where phenylalanine has been replaced by isoleucine.","MET NP_000236.2:p.F1200I | C-MET F1200I | C-MET Phe1200Ile | HGF Receptor F1200I | HGF Receptor Phe1200Ile | HGFR F1200I | HGFR Phe1200Ile | Hepatocyte Growth Factor Receptor F1200I | Hepatocyte Growth Factor Receptor Phe1200Ile | MET F1200I | MET NP_000236.2:p.Phe1200Ile | MET Phe1200Ile | MET p.F1200I | MET p.Phe1200Ile | NP_000236.2:p.F1200I | NP_000236.2:p.Phe1200Ile | NP_001120972.1:p.F1218I | NP_001120972.1:p.Phe1218Ile | Proto-Oncogene c-Met F1200I | Proto-Oncogene c-Met Phe1200Ile | Scatter Factor Receptor F1200I | Scatter Factor Receptor Phe1200Ile | Tyrosine-Protein Kinase Met F1200I | Tyrosine-Protein Kinase Met Phe1200Ile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970922","MET NP_000236.2:p.H1094Y","C162290","A change in the amino acid residue at position 1094 in the hepatocyte growth factor receptor protein where histidine has been replaced by tyrosine.","MET NP_000236.2:p.H1094Y | C-MET H1094Y | C-MET His1094Tyr | HGF Receptor H1094Y | HGF Receptor His1094Tyr | HGFR H1094Y | HGFR His1094Tyr | Hepatocyte Growth Factor Receptor H1094Y | Hepatocyte Growth Factor Receptor His1094Tyr | MET H1094Y | MET His1094Tyr | MET NP_000236.2:p.His1094Tyr | MET p.H1094Y | MET p.His1094Tyr | NP_000236.2:p.H1094Y | NP_000236.2:p.His1094Tyr | NP_001120972.1:p.H1112Y | NP_001120972.1:p.His1112Tyr | Proto-Oncogene c-Met H1094Y | Proto-Oncogene c-Met His1094Tyr | Scatter Factor Receptor H1094Y | Scatter Factor Receptor His1094Tyr | Tyrosine-Protein Kinase Met H1094Y | Tyrosine-Protein Kinase Met His1094Tyr",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970920","MET NP_000236.2:p.V1092I","C162292","A change in the amino acid residue at position 1092 in the hepatocyte growth factor receptor protein where valine has been replaced by isoleucine.","MET NP_000236.2:p.V1092I | C-MET V1092I | C-MET Val1092Ile | HGF Receptor V1092I | HGF Receptor Val1092Ile | HGFR V1092I | HGFR Val1092Ile | Hepatocyte Growth Factor Receptor V1092I | Hepatocyte Growth Factor Receptor Val1092Ile | MET NP_000236.2:p.Val1092Ile | MET V1092I | MET Val1092Ile | MET p.V1092I | MET p.Val1092Ile | NP_000236.2:p.V1092I | NP_000236.2:p.Val1092Ile | NP_001120972.1:p.V1110I | NP_001120972.1:p.Val1110Ile | Proto-Oncogene c-Met V1092I | Proto-Oncogene c-Met Val1092Ile | Scatter Factor Receptor V1092I | Scatter Factor Receptor Val1092Ile | Tyrosine-Protein Kinase Met V1092I | Tyrosine-Protein Kinase Met Val1092Ile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970918","MET NP_000236.2:p.V1070M","C162294","A change in the amino acid residue at position 1070 in the hepatocyte growth factor receptor protein where valine has been replaced by methionine.","MET NP_000236.2:p.V1070M | C-MET V1070M | C-MET Val1070Met | HGF Receptor V1070M | HGF Receptor Val1070Met | HGFR V1070M | HGFR Val1070Met | Hepatocyte Growth Factor Receptor V1070M | Hepatocyte Growth Factor Receptor Val1070Met | MET NP_000236.2:p.Val1070Met | MET V1070M | MET Val1070Met | MET p.V1070M | MET p.Val1070Met | NP_000236.2:p.V1070M | NP_000236.2:p.Val1070Met | NP_001120972.1:p.V1088M | NP_001120972.1:p.Val1088Met | Proto-Oncogene c-Met V1070M | Proto-Oncogene c-Met Val1070Met | Scatter Factor Receptor V1070M | Scatter Factor Receptor Val1070Met | Tyrosine-Protein Kinase Met V1070M | Tyrosine-Protein Kinase Met Val1070Met",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970868","MET NP_000236.2:p.V1070G","C162297","A change in the amino acid residue at position 1070 in the hepatocyte growth factor receptor protein where valine has been replaced by glycine.","MET NP_000236.2:p.V1070G | C-MET V1070G | C-MET Val1070Gly | HGF Receptor V1070G | HGF Receptor Val1070Gly | HGFR V1070G | HGFR Val1070Gly | Hepatocyte Growth Factor Receptor V1070G | Hepatocyte Growth Factor Receptor Val1070Gly | MET NP_000236.2:p.Val1070Gly | MET V1070G | MET Val1070Gly | MET p.V1070G | MET p.Val1070Gly | NP_000236.2:p.V1070G | NP_000236.2:p.Val1070Gly | NP_001120972.1:p.V1088G | NP_001120972.1:p.Val1088Gly | Proto-Oncogene c-Met V1070G | Proto-Oncogene c-Met Val1070Gly | Scatter Factor Receptor V1070G | Scatter Factor Receptor Val1070Gly | Tyrosine-Protein Kinase Met V1070G | Tyrosine-Protein Kinase Met Val1070Gly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970866","MET NP_000236.2:p.V1070E","C162299","A change in the amino acid residue at position 1070 in the hepatocyte growth factor receptor protein where valine has been replaced by glutamic acid.","MET NP_000236.2:p.V1070E | C-MET V1070E | C-MET Val1070Glu | HGF Receptor V1070E | HGF Receptor Val1070Glu | HGFR V1070E | HGFR Val1070Glu | Hepatocyte Growth Factor Receptor V1070E | Hepatocyte Growth Factor Receptor Val1070Glu | MET NP_000236.2:p.Val1070Glu | MET V1070E | MET Val1070Glu | MET p.V1070E | MET p.Val1070Glu | NP_000236.2:p.V1070E | NP_000236.2:p.Val1070Glu | NP_001120972.1:p.V1088E | NP_001120972.1:p.Val1088Glu | Proto-Oncogene c-Met V1070E | Proto-Oncogene c-Met Val1070Glu | Scatter Factor Receptor V1070E | Scatter Factor Receptor Val1070Glu | Tyrosine-Protein Kinase Met V1070E | Tyrosine-Protein Kinase Met Val1070Glu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970864","MET NP_000236.2:p.V504L","C162301","A change in the amino acid residue at position 504 in the hepatocyte growth factor receptor protein where valine has been replaced by leucine.","MET NP_000236.2:p.V504L | C-MET V504L | C-MET Val504Leu | HGF Receptor V504L | HGF Receptor Val504Leu | HGFR V504L | HGFR Val504Leu | Hepatocyte Growth Factor Receptor V504L | Hepatocyte Growth Factor Receptor Val504Leu | MET NP_000236.2:p.Val504Leu | MET V504L | MET Val504Leu | MET p.V504L | MET p.Val504Leu | NP_000236.2:p.V504L | NP_000236.2:p.Val504Leu | NP_001120972.1:p.V504L | NP_001120972.1:p.Val504Leu | Proto-Oncogene c-Met V504L | Proto-Oncogene c-Met Val504Leu | Scatter Factor Receptor V504L | Scatter Factor Receptor Val504Leu | Tyrosine-Protein Kinase Met V504L | Tyrosine-Protein Kinase Met Val504Leu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970862","MET NP_000236.2:p.I639L","C162303","A change in the amino acid residue at position 639 in the hepatocyte growth factor receptor protein where isoleucine has been replaced by leucine.","MET NP_000236.2:p.I639L | C-MET I639L | C-MET Ile639Leu | HGF Receptor I639L | HGF Receptor Ile639Leu | HGFR I639L | HGFR Ile639Leu | Hepatocyte Growth Factor Receptor I639L | Hepatocyte Growth Factor Receptor Ile639Leu | MET I639L | MET Ile639Leu | MET NP_000236.2:p.Ile639Leu | MET p.I639L | MET p.Ile639Leu | NP_000236.2:p.I639L | NP_000236.2:p.Ile639Leu | NP_001120972.1:p.I639L | NP_001120972.1:p.Ile639Leu | Proto-Oncogene c-Met I639L | Proto-Oncogene c-Met Ile639Leu | Scatter Factor Receptor I639L | Scatter Factor Receptor Ile639Leu | Tyrosine-Protein Kinase Met I639L | Tyrosine-Protein Kinase Met Ile639Leu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970752","Cervical Cancer by FIGO Stage 2018","C162225","A term that refers to the staging of cervical cancer according to the International Federation of Gynecology and Obstetrics (FIGO) staging, 2018.","Cervical Cancer by FIGO Stage 2018 | Cervical Carcinoma by FIGO Stage 2018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970751","Stage I Cervical Cancer FIGO 2018","C162226","The carcinoma is strictly confined to the cervix (extension to the uterine corpus should be disregarded). (FIGO 2018)","Stage I Cervical Cancer FIGO 2018 | Stage I Cervical Carcinoma FIGO 2018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970750","Stage IA Cervical Cancer FIGO 2018","C162227","Invasive cervical carcinoma that can be diagnosed only by microscopy, with maximum depth of invasion less than 5 mm. (FIGO 2018)","Stage IA Cervical Cancer FIGO 2018 | Stage IA Cervical Carcinoma FIGO 2018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970749","Stage IA1 Cervical Cancer FIGO 2018","C162228","Cervical carcinoma with measured stromal invasion less than 3 mm in depth. (FIGO 2018)","Stage IA1 Cervical Cancer FIGO 2018 | Stage IA1 Cervical Carcinoma FIGO 2018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970748","Stage IA2 Cervical Cancer FIGO 2018","C162229","Cervical carcinoma with measured stromal invasion equal or more than 3 mm and less than 5 mm in depth. (FIGO 2018)","Stage IA2 Cervical Cancer FIGO 2018 | Stage IA2 Cervical Carcinoma FIGO 2018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970747","Stage IB Cervical Cancer FIGO 2018","C162230","Invasive cervical carcinoma with measured deepest invasion equal or more than 5 mm (greater than Stage IA), lesion limited to the cervix uteri. (FIGO 2018)","Stage IB Cervical Cancer FIGO 2018 | Stage IB Cervical Carcinoma FIGO 2018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970746","Stage IB1 Cervical Cancer FIGO 2018","C162231","Invasive cervical carcinoma with equal or more than 5 mm depth of stromal invasion, and less than 2 cm in greatest dimension. (FIGO 2018)","Stage IB1 Cervical Cancer FIGO 2018 | Stage IB1 Cervical Carcinoma FIGO 2018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970701","Stage IB2 Cervical Cancer FIGO 2018","C162232","Invasive cervical carcinoma equal or more than 2 cm and less than 4 cm in greatest dimension. (FIGO 2018)","Stage IB2 Cervical Cancer FIGO 2018 | Stage IB2 Cervical Carcinoma FIGO 2018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970700","Stage IB3 Cervical Cancer FIGO 2018","C162233","Invasive cervical carcinoma equal or more than 4 cm in greatest dimension. (FIGO 2018)","Stage IB3 Cervical Cancer FIGO 2018 | Stage IB3 Cervical Carcinoma FIGO 2018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970699","Stage II Cervical Cancer FIGO 2018","C162234","The cervical carcinoma invades beyond the uterus, but has not extended onto the lower third of the vagina or to the pelvic wall. (FIGO 2018)","Stage II Cervical Cancer FIGO 2018 | Stage II Cervical Carcinoma FIGO 2018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970698","Stage IIA Cervical Cancer FIGO 2018","C162235","Cervical carcinoma limited to the upper two-thirds of the vagina without parametrial involvement. (FIGO 2018)","Stage IIA Cervical Cancer FIGO 2018 | Stage IIA Cervical Carcinoma FIGO 2018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970697","Stage IIA1 Cervical Cancer FIGO 2018","C162236","Cervical carcinoma limited to the upper two-thirds of the vagina without parametrial involvement, less than 4 cm in greatest dimension. (FIGO 2018)","Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Carcinoma FIGO 2018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970696","Stage IIA2 Cervical Cancer FIGO 2018","C162237","Cervical carcinoma limited to the upper two-thirds of the vagina without parametrial involvement, equal or more than 4 cm in greatest dimension. (FIGO 2018)","Stage IIA2 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical Carcinoma FIGO 2018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970695","Stage IIB Cervical Cancer FIGO 2018","C162238","Cervical carcinoma with parametrial involvement but not up to the pelvic wall. (FIGO 2018)","Stage IIB Cervical Cancer FIGO 2018 | Stage IIB Cervical Carcinoma FIGO 2018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970694","Stage III Cervical Cancer FIGO 2018","C162239","Cervical carcinoma that involves the lower third of the vagina and/or extends to the pelvic wall and/or causes hydronephrosis or nonfunctioning kidney and/or involves pelvic and/or para-aortic lymph nodes. (FIGO 2018)","Stage III Cervical Cancer FIGO 2018 | Stage III Cervical Carcinoma FIGO 2018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970709","Stage IIIA Cervical Cancer FIGO 2018","C162240","Cervical carcinoma that involves the lower third of the vagina, with no extension to the pelvic wall. (FIGO 2018)","Stage IIIA Cervical Cancer FIGO 2018 | Stage IIIA Cervical Carcinoma FIGO 2018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970708","Stage IIIB Cervical Cancer FIGO 2018","C162241","Cervical carcinoma with extension to the pelvic wall and/or hydronephrosis or nonfunctioning kidney (unless known to be due to another cause). (FIGO 2018)","Stage IIIB Cervical Cancer FIGO 2018 | Stage IIIB Cervical Carcinoma FIGO 2018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970707","Stage IIIC Cervical Cancer FIGO 2018","C162242","Cervical carcinoma with involvement of pelvic and/or para-aortic lymph nodes, irrespective of tumor size and extent (with r and p notations). (FIGO 2018)","Stage IIIC Cervical Cancer FIGO 2018 | Stage IIIC Cervical Carcinoma FIGO 2018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970706","Stage IIIC1 Cervical Cancer FIGO 2018","C162243","Cervical carcinoma with pelvic lymph node metastasis only. (FIGO 2018)","Stage IIIC1 Cervical Cancer FIGO 2018 | Stage IIIC1 Cervical Carcinoma FIGO 2018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970705","Stage IIIC2 Cervical Cancer FIGO 2018","C162244","Cervical carcinoma with para-aortic lymph node metastasis. (FIGO 2018)","Stage IIIC2 Cervical Cancer FIGO 2018 | Stage IIIC2 Cervical Carcinoma FIGO 2018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970704","Stage IV Cervical Cancer FIGO 2018","C162245","The cervical carcinoma has extended beyond the true pelvis or has involved (biopsy proven) the mucosa of the bladder or rectum. (A bullous edema, as such, does not permit a case to be allotted to Stage IV). (FIGO 2018)","Stage IV Cervical Cancer FIGO 2018 | Stage IV Cervical Carcinoma FIGO 2018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970703","Stage IVA Cervical Cancer FIGO 2018","C162246","The cervical carcinoma has spread to adjacent pelvic organs. (FIGO 2018)","Stage IVA Cervical Cancer FIGO 2018 | Stage IVA Cervical Cancer FIGO 2018
 | Stage IVA Cervical Carcinoma FIGO 2018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970702","Stage IVB Cervical Cancer FIGO 2018","C162247","The cervical carcinoma has spread to distant organs. (FIGO 2018)","Stage IVB Cervical Cancer FIGO 2018 | Stage IVB Cervical Carcinoma FIGO 2018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970742","FIGO Stage IB3","C162222","A FIGO stage term that applies to gynecologic cancers. For cervical cancer, it refers to invasive cancer measuring 4 cm or more in greatest dimension.","FIGO Stage IB3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970741","FIGO Stage IIA1","C162223","A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer limited to the upper two-thirds of the vagina without parametrial involvement, less than 4 cm in greatest dimension.","FIGO Stage IIA1 | Stage IIA1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970753","FIGO Stage IIA2","C162224","A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer limited to the upper two-thirds of the vagina without parametrial involvement, equal or more than 4 cm in greatest dimension.","FIGO Stage IIA2 | Stage IIA2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970744","Axitinib/Pembrolizumab Regimen","C162220","A regimen consisting of axitinib and pembrolizumab that can be used for the treatment of renal cell carcinoma (RCC) and alveolar soft part sarcoma (ASPS).","Axitinib/Pembrolizumab Regimen | Axitinib and Pembrolizumab | Axitinib-Pembrolizumab | Axitinib/Pembrolizumab | Inlyta/Keytruda | Keytruda/Inlyta | Pembrolizumab-Axitinib | Pembrolizumab/Axitinib | Pembrolizumab/Axitinib Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1134504","bevacizumab/interferon alfa","C12075","A regimen consisting of bevacizumab and interferon-alfa that can be used for the treatment of advanced renal cell carcinoma (RCC).","Bevacizumab/Interferon Alfa Regimen | Avastin/Interferon Alfa | Bevacizumab-Interferon Alfa | Bevacizumab-Interferon Alfa Regimen | Bevacizumab/Interferon Alfa | Interferon Alfa-Bevacizumab | Interferon Alfa/Avastin | Interferon Alfa/Bevacizumab | Interferon Alfa/Bevacizumab Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970745","Renal Calyx and Pelvis","C162216","The portion of the kidney comprising the renal calices and pelvis.","Renal Calyx and Pelvis | Pelvicalyceal System | Pyelocalyceal | Pyelocalyceal Region",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227628","Renal Parenchyma","C162217","The functional part of the kidney, comprising the renal cortex and medulla.","Renal Parenchyma | Renal Cortex and Medulla",,,,,,,,,,,,,,,"4106394","Structure of parenchyma of kidney",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227617","Perinephric Fat","C162218","A layer of fatty tissue surrounding the kidney, bounded by the renal capsule and the renal fascia.","Perinephric Fat | ",,,,,,,,,,,,,,,"4137444","Structure of fatty capsule of kidney",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227672","Renal Sinus","C162219","A cavity in the kidney containing the pelvicalyceal system, blood vessels, nerves and fat. It communicates with the perinephric space.","Renal Sinus | ",,,,,,,,,,,,,,,"4280239","Renal sinus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL970743","Metastatic Diagnosis","C162221","Any diagnosis indicating the presence of metastatic disease.","Metastatic Diagnosis | Diagnosis of Metastasis | Metastasis Diagnosis | metastasis at diagnosis | metastasis_at_diagnosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970879","Ophthalmic Examinations External File Path","C162317","The literal identifier of an ophthalmic examination external file name.","Ophthalmic Examinations External File Path | OEXFN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970878","Urinary System Findings Time Point Reference","C162318","The point in time that acts as a fixed reference point to a urinary system finding.","Urinary System Findings Time Point Reference | URTPTREF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970877","Adverse Event Previous Occurrence","C162319","An indication or description that a particular adverse event happened in the past.","Adverse Event Previous Occurrence | AEPRIOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970892","Clinical Event Previous Occurrence","C162320","An indication or description that a particular disease response or clinical classification happened in the past.","Clinical Event Previous Occurrence | CEPRIOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970891","Disease Response or Clinical Classification Previous Occurrence","C162321","An indication or description that a particular disease response or clinical classification was obtained in the past.","Disease Response or Clinical Classification Previous Occurrence | RSPRIOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970890","Functional Tests Previous Occurrence","C162322","An indication or description that a particular functional test happened in the past.","Functional Tests Previous Occurrence | FTPRIOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970889","Healthcare Encounter Previous Occurrence","C162323","An indication or description that a particular healthcare encounter event happened in the past.","Healthcare Encounter Previous Occurrence | HOPRIOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970888","Microbiology Susceptibility Previous Occurrence","C162324","An indication or description that a particular microbiology susceptibility event happened in the past.","Microbiology Susceptibility Previous Occurrence | MSPRIOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970887","Agent Previous Occurrence","C162325","An indication or description that a particular agent administration event happened in the past.","Agent Previous Occurrence | AGPRIOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970886","Substance Use Previous Occurrence","C162326","An indication or description that a particular substance use event happened in the past.","Substance Use Previous Occurrence | SUPRIOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970885","Disease Response or Clinical Classification Ongoing","C162327","An indication or description that assessment of disease response or clinical classification of the disease is continuing.","Disease Response or Clinical Classification Ongoing | RSONGO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970839","Ongoing Microbiology Susceptibility","C162328","An indication or description that a microbiology susceptibility assessment is continuing.","Ongoing Microbiology Susceptibility | MSONGO | Microbiology Susceptibility Ongoing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970838","Ongoing Procedure Agents","C162329","An indication or description that a procedure agent administration is continuing.","Ongoing Procedure Agents | AGONGO | Procedure Agents Ongoing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970837","Ongoing Substance Use","C162330","An indication or description that substance usage is continuing.","Ongoing Substance Use | SUONGO | Substance Use Ongoing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970836","Functional Tests Completion Status","C162331","A term used to describe the state or condition of the completeness of the functional test data.","Functional Tests Completion Status | FTSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970835","Meal Data Completion Status","C162332","A term used to describe the state or condition of the completeness of the meal data.","Meal Data Completion Status | MLSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970834","Musculoskeletal Findings, Connective and Soft Tissue Findings Completion Status","C162333","A term used to describe the state or condition of the completeness of the musculoskeletal system findings data.","Musculoskeletal Findings, Connective and Soft Tissue Findings Completion Status | MKSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970833","Nervous System Findings Completion Status","C162334","A term used to describe the state or condition of the completeness of the nervous system findings data.","Nervous System Findings Completion Status | NVSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970832","Ophthalmic Examinations Completion Status","C162335","A term used to describe the state or condition of the completeness of the ophthalmic examination data.","Ophthalmic Examinations Completion Status | OESTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970847","Procedure Agents Completion Status","C162336","A term used to describe the state or condition of the completeness of the procedure agent administration data.","Procedure Agents Completion Status | AGSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970846","Substance Use Completion Status","C162337","A term used to describe the state or condition of the completeness of the substance use data.","Substance Use Completion Status | SUSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970845","Urinary System Findings Completion Status","C162338","A term used to describe the state or condition of the completeness of the urinary system findings data.","Urinary System Findings Completion Status | URSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970850","Ophthalmic Examinations Normal or Reference Range Indicator","C162349","A indication that ophthalmic examination data is outside the normal or reference range.","Ophthalmic Examinations Normal or Reference Range Indicator | OENRIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970849","Microbiology Susceptibility Normal or Reference Range Indicator","C162350","A indication that microbiology susceptibility data is outside the normal or reference range.","Microbiology Susceptibility Normal or Reference Range Indicator | MSNRIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970848","Microbiology Susceptibility Specimen Type","C162351","The type of material sample used for microbiology susceptibility testing.","Microbiology Susceptibility Specimen Type | MSSPEC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970861","Urinary System Findings Specimen Type","C162352","The type of material sample used for urinary system testing.","Urinary System Findings Specimen Type | URSPEC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970860","Procedure Agent Yes No Indicator","C162353","An indication of whether procedure agent usage has occurred.","Procedure Agent Yes No Indicator | AGYN | Procedure Agent Yes No Indicator ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970859","Microbiology Susceptibility Agent Concentration Unit","C162354","The unit of measure related to the microbiology susceptibility agent concentration.","Microbiology Susceptibility Agent Concentration Unit | MSCONCU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970823","Fagotti Score","C162368","A laparoscopy-based score to predict the chances of optimal cytoreductive surgery in advanced ovarian cancer patients. It consists of seven criteria (omental cake, peritoneal carcinosis, diaphragmatic carcinosis, mesenteric retraction, bowel infiltration, stomach infiltration, and liver metastases), each assigned a predictive index value of 0-2. The total Fagotti score ranges from 0-14.","Fagotti Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970051","Effusion Volume Measurement","C161424","The amount of three dimensional space occupied by the effusion fluid.","Effusion Volume Measurement | EFFVOL | Effusion Volume",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970095","Malignant Disease Indicator","C161423","An indication as to whether a malignancy is present.","Malignant Disease Indicator | MALIND | Malignancy Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970096","Effusion Indicator","C161422","An indication as to whether effusion is present.","Effusion Indicator | EFFIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969969","Evidence of Malignant Disease Description","C161312","A description of the basis for the determination that a malignancy is present.","Evidence of Malignant Disease Description | MALEVDES | Malignancy Evidence Description",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950802","Prostate Neuroendocrine Carcinoma","C158912","An aggressive high-grade carcinoma with neuroendocrine differentiation that arises from the prostate gland. It is classified as either small or large cell neuroendocrine carcinoma based on the size of the malignant cells, the prominence of the nucleoli, and the amount of cytoplasm.","Prostate Neuroendocrine Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969722","Cabazitaxel Regimen","C160797","A regimen consisting of cabizitaxel that may be used in the treatment of metastatic, castration-resistant prostate cancer (mCRPC).","Cabazitaxel Regimen | Jevtana Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0285171","Cisplatin Vindesine Protocol","C63382","A regimen consisting of etoposide and cisplatin that can be used in the treatment of non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), testicular cancer, gestational trophoblastic neoplasia, malignant sex cord-stromal tumors, malignant germ cell tumors, and thymomas and thymic carcinomas.","EP Regimen | Cisplatin and Etoposide (EP) | Cisplatin/Etoposide | Cisplatin/Etoposide Regimen | EP | Etoposide-Cisplatin | Etoposide-Cisplatin Regimen | Etoposide-Platinol Regimen | Etoposide/Cisplatin | PE | PE Regimen | VPP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551993","Prolaris Prostate Cancer Testing","C150175","A proprietary prognostic test which directly measures tumor cell growth characteristics for stratifying the risk of disease progression in prostate cancer patients. It provides a measure of the aggressiveness of an individual's prostate cancer and predicts disease-specific mortality.","Prolaris Prostate Cancer Testing | Prolaris | Prolaris Testing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221204","Lytic Bone Lesion","C41040","Destruction of an area of bone due to a disease process, such as cancer.","Lytic Bone Lesion | lytic lesion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969034","Axitinib Regimen","C159994","A regimen consisting of axitinib that may be used in the treatment of follicular, papillary and Hurthle cell thyroid carcinomas, and kidney cancer.","Axitinib Regimen | Axitinib monotherapy | Inlyta Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969040","Cabozantinib Regimen","C160004","A regimen consisting of cabozantinib that may be used in the treatment of follicular, medullary, papillary and Hurthle cell thyroid carcinomas; bone, hepatobiliary, endometrial and kidney cancers, gastrointestinal stromal tumors (GIST), and non-small cell lung cancer (NSCLC).","Cabozantinib Regimen | Cabometyx Regimen | Cabozantinib S-malate Regimen | Cabozantinib monotherapy | Cometriq Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969185","Pazopanib Regimen","C160105","A regimen consisting of pazopanib that may be used in the treatment of alveolar soft part sarcoma, bone cancer, desmoid tumors, ovarian, fallopian tube and primary peritoneal cancers, solitary fibrous tumor, soft tissue and uterine sarcomas, Merkel cell, follicular, medullary, papillary and Hurthle cell thyroid carcinomas, gastrointestinal stromal tumors (GISTs), kidney cancer.","Pazopanib Regimen | Pazopanib HCl Regimen | Pazopanib Hydrochloride Regimen | Pazopanib monotherapy | Votrient Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969141","Sunitinib Regimen","C160119","A regimen consisting of sunitinib that may be used in the treatment of soft tissue sarcomas (including alveolar soft part sarcomas and angiosarcoma); follicular, medullary, papillary, Hurthle cell thyroid carcinomas; thymic carcinomas and thymomas; gastrointestinal stromal tumors (GISTs); kidney and bone cancers; solitary fibrous tumor/hemangiopericytoma; and pancreatic neuroendocrine tumors (NETs), pheochromocytoma/paraganglioma, myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions, and meningioma.","Sunitinib Regimen | Sunitinib Malate Regimen | Sunitinib monotherapy | Sutent Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969356","Peritoneal Surface","C160423","The outer layer of the serous membrane that lines the abdominal cavity.","Peritoneal Surface | Peritoneal Surfaces",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970954","Spectral Domain-Optical Coherence Tomography","C162464","A modification of optical coherence tomography with an increased ability to provide depth-resolved tissue structure information. It is used to perform high-resolution cross-sectional imaging and analysis of structural changes in the eye during disease progression.","Spectral Domain-Optical Coherence Tomography | SD-OCT | Spectral Domain Optical Coherence Tomography | Spectral Domain Optical Coherence Tomography",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378583","Fundus Autofluorescence Imaging","C162465","A retinal imaging test that maps the presence of lipofuscin in the retina pigment epithelium.","Fundus Autofluorescence Imaging | FAF | Fundus Autofluorescence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086808","Respiratory System Findings Elapsed Time","C123954","The interval between two respiratory system measurement reference time points.","Respiratory System Findings Elapsed Time | REELTM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086825","Respiratory System Findings Time Point Reference","C124030","The point in time that acts as a fixed reference point to a respiratory system findings assessment.","Respiratory System Findings Time Point Reference | RETPTREF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826314","Original Result Unit","C82586","The unit of measure for the result of the test or finding as originally received or collected.","Original Result Unit | ORRESU | Result in Original Units",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348328","Dosage Form Unit","C73558","The unit of measure for the dosage form.","Dosage Form Unit | DF | DOSU | Dosage Form | Dose Units | TRTDOSU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831349","Biospecimen Usability","C105758","A qualitative or quantitative measure that describes a biospecimen's suitability for testing purposes.","Biospecimen Usability | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897030","Accepted Record Flag","C117038","An indication that a record that is considered to be the accepted and final evaluation.","Accepted Record Flag | ACPTFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830331","Eighty Nine","C105789","A natural number greater than eighty-eight and less than ninety and the quantity that it denotes.","Eighty Nine | 89 | Eighty-Nine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556231","Modified FOLFOX6 Regimen","C155746","A regimen consisting of leucovorin, infusional fluorouracil and oxaliplatin used for the treatment of anal carcinoma, esophageal and esophagogastric junction, gastric, occut primary, colorectal cancers, and appendiceal, small bowel, non-urothelial and urothelial bladder cancer, well-differentiated grade 3 neuroendocrine tumors (NETs), NETs of the pancreas, and extrapulmonary poorly differentiated neuroendocrine carcinoma/large or small cell carcinoma/mixed neuroendocrine-non-neuroendocrine neoplasm. This modified version differs from the FOLFOX6 regimen in that the dose of oxaliplatin is lower.","Modified FOLFOX6 Regimen | Modified FOLFOX-6 | Modified FOLFOX6 | Modified Folinic Acid-Fluorouracil-Oxaliplatin-6 Regimen | mFOLFOX-6 | mFOLFOX-6 Regimen | mFOLFOX6 | mFOLFOX6 (L-Leucovorin)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970944","MYCN Negative","C162510","An indication that MYCN expression has not been detected in a sample.","MYCN Negative | N-Myc Negative | N-Myc Proto-Oncogene Negative | NMYC Negative | Neuroblastoma MYC Negative | v-myc Avian Myelocytomatosis Viral Oncogene Neuroblastoma Derived Homolog Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970943","MYC Negative","C162511","An indication that MYC expression has not been detected in a sample.","MYC Negative | Myc Proto-Oncogene Negative | Proto-Oncogene c-Myc Negative | c-MYC Negative | v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970942","Blasts 1 Percent or More of Bone Marrow Nucleated Cells","C162512","A semi-quantitative microscopic finding indicating that at least 1 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 1 Percent or More of Bone Marrow Nucleated Cells | Blasts Greater than or Equal to 1 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970941","MLL Gene Mutation","C162513","A change in the nucleotide sequence of the MLL (KMT2A) gene.","MLL Gene Mutation | KMT2A Gene Mutation | KMT2A Gene Mutation | KMT2A Mutation | Lysine (K)-Specific Methyltransferase 2A Gene Mutation | Lysine Methyltransferase 2A Gene Mutation | MLL Mutation | Mixed Lineage Leukemia Gene Mutation | Myeloid/Lymphoid Leukemia Gene Mutation | Myeloid/Lymphoid or Mixed Lineage Leukemia Gene Mutation | Myeloid/Lymphoid or Mixed-Lineage Leukemia (Trithorax Homolog, Drosophila) Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970940","Deleterious GNA11 Gene Mutation","C162514","A change in the nucleotide sequence of the GNA11 gene that is associated with increased risk of disease.","Deleterious GNA11 Gene Mutation | Deleterious G Protein Subunit Alpha 11 Gene Mutation | Deleterious GA11 Gene Mutation | Deleterious GNA-11 Gene Mutation | Deleterious Guanine Nucleotide Binding Protein (G Protein), Alpha 11 Gene Mutation | Deleterious Guanine Nucleotide-Binding Protein, Alpha-11 Gene Mutation | GNA11 Deleterious Gene Mutation | GNA11 Deleterious Mutation | GNA11 Driver Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970953","Loss of MSH2 Expression","C162515","A molecular abnormality indicating the absence of MSH2 protein.","Loss of MSH2 Expression | Loss of DNA Mismatch Repair Protein Msh2 Expression | Loss of MSH2 Protein Expression | Loss of MutS Homolog 2 Expression | Loss of MutS Protein Homolog 2 Expression | MSH2 Loss of Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970952","Somatic Hypermutation","C162516","The presence of a hypermutation phenotype in non-germline cells.","Somatic Hypermutation | Somatic Hypermutation Phenotype | Somatic Hypermutator Phenotype",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970951","Alpha-Fetoprotein Positive","C162517","An indication that alpha-fetoprotein has been detected in a sample.","Alpha-Fetoprotein Positive | AFP Positive | Alpha Fetoprotein Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970950","Nicotine Metabolite Ratio Measurement","C162518","A measurement of the ratio of the nicotine metabolites 3-hydroxycotinine (3HC) to cotinine in a sample.","Nicotine Metabolite Ratio Measurement | 3-Hydroxycotinine to Cotinine Ratio Measurement | NMR | Nicotine Metabolite Ratio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418652","PLOD2 Gene","C162519","This gene is involved in the synthesis of hydroxylysine, which promotes collagen glycosylation and increases the stability of cross-linked collagen fibrils.","PLOD2 Gene | PLOD2 | Procollagen-Lysine,2-Oxoglutarate 5-Dioxygenase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971109","COL7A1 Exon 73 Mutation","C162523","A molecular genetic abnormality indicating the presence of a mutation in exon 73 of the COL7A1 gene.","COL7A1 Exon 73 Mutation | COL7A1 Exon 73 Gene Mutation | Collagen Type VII Alpha 1 Chain Exon 73 Mutation | Collagen, Type VII, Alpha 1 Exon 73 Mutation | EBD1 Exon 73 Mutation | EBDCT Exon 73 Mutation | EBR1 Exon 73 Mutation | NDNC8 Exon 73 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970798","HLA-C*08 Positive Cells Present","C162142","An indication that cells expressing HLA-C*08 have been detected in a sample.","HLA-C*08 Positive Cells Present | HLA-C*08 | HLA-C*08 Positive | HLA-C08 | HLA-C08 Positive | HLA-C08 Positive Cells Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970970","EMSY Gene Mutation","C162478","A change in the nucleotide sequence of the EMSY gene.","EMSY Gene Mutation | C11orf30 Gene Mutation | EMSY Transcriptional Repressor, BRCA2 Interacting Gene Mutation | EMSY, BRCA2 Interacting Transcriptional Repressor Gene Mutation | EMSY, BRCA2-Interacting Transcriptional Repressor Gene Mutation | GL002 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970991","COL7A1 Gene Mutation","C162448","A change in the nucleotide sequence of the COL7A1 gene.","COL7A1 Gene Mutation | Collagen Type VII Alpha 1 Chain Gene Mutation | Collagen, Type VII, Alpha 1 Gene Mutation | EBD1 Gene Mutation | EBDCT Gene Mutation | EBR1 Gene Mutation | NDNC8 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970870","Inosinic Acid","C162311","A purine ribonucleotide with hypoxanthine as the base and one phosphate group attached to the sugar moiety. Inosinic acid and its salt forms are used as flavor enhancers in industrial food production. In vivo, inosinic acid is involved in purine metabolism and acts as an intermediate in the synthesis of adenine and guanine, which are precursors for the second messenger signaling molecules adenosine monophosphate (AMP) and guanosine monophosphate (GMP), respectively.","Inosinic Acid | 2'-Inosine-5'-Monophosphate | 5'-IMP | 5'-Inosinate | 5'-Inosine Monophosphate | 5'-Inosinic Acid | Hypoxanthosine 5'-Monophosphate | IMP | Inosine 5'-Monophosphate | Inosine 5'-Phosphate | Inosine Monophosphate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970874","MLH1 Negative","C162307","An indication that expression of MLH1 has not been detected in a sample.","MLH1 Negative | COCA2 Negative | DNA Mismatch Repair Protein Mlh1 Negative | HNPCC2 Negative | MutL Homolog 1 Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970873","MSH2 Negative","C162308","An indication that expression of MSH2 has not been detected in a sample.","MSH2 Negative | COCA1 Negative | DNA Mismatch Repair Protein Msh2 Negative | HNPCC1 Negative | MutS Homolog 2 Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970872","MSH6 Negative","C162309","An indication that expression of MSH6 has not been detected in a sample.","MSH6 Negative | DNA Mismatch Repair Protein Msh6 Negative | G/T Mismatch-Binding Protein Negative | GTBP Negative | GTMBP Negative | HNPCC5 Negative | MutS Homolog 6 Negative | Sperm-Associated Protein Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970871","PMS2 Negative","C162310","An indication that expression of PMS2 has not been detected in a sample.","PMS2 Negative | Mismatch Repair Endonuclease PMS2 Negative | PMS1 Homolog 2 Negative | PMS1 Homolog 2, Mismatch Repair System Component Negative | PMS2CL Negative | PMSL2 Negative | Postmeiotic Segregation Increased 2 Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970773","Somatic BRCA1 Gene Mutation","C162184","A change in the nucleotide sequence of the BRCA1 gene that originates in non-germline cells.","Somatic BRCA1 Gene Mutation | Somatic BRCA1 Mutation | Somatic BROVCA1 Gene Mutation | Somatic Breast Cancer Type 1 Susceptibility Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970774","Somatic BRCA2 Gene Mutation","C162183","A change in the nucleotide sequence of the BRCA2 gene that originates in non-germline cells.","Somatic BRCA2 Gene Mutation | Somatic BRCA2 Mutation | Somatic BROVCA2 Gene Mutation | Somatic Breast Cancer Type 2 Susceptibility Gene Mutation | Somatic FANCD1 Gene Mutation | Somatic XRCC11 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4076788","(68)Ga-labeled Glu-urea-Lys(Ahx)-HBED-CC","C118961","A radioconjugate composed of a human prostate specific membrane antigen (PSMA)-targeting ligand, Glu-urea-Lys(Ahx) (Glu-NH-CO-NH-Lys(Ahx)), conjugated, via the acyclic radiometal chelator N,N'-bis [2-hydroxy-5-(carboxyethyl)benzyl] ethylenediamine-N,N'-diacetic acid (HBED-CC), to the radioisotope gallium Ga 68, with potential use as a tracer for PSMA-expressing tumors during positron emission tomography (PET). Upon intravenous administration of the gallium Ga 68 gozetotide, the Glu-urea-Lys(Ahx) moiety targets and binds to PSMA-expressing tumor cells. Upon internalization, PSMA-expressing tumor cells can be detected during PET imaging. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.","Gallium Ga 68 Gozetotide | (68)Ga labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC | (68)Ga-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC | (68)Ga-labeled Glu-urea-Lys(Ahx)-HBED-CC | (68)Gallium-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC | (68Ga)Glu-urea-Lys(Ahx)-HBED-CC | 68Ga-DKFZ-PSMA-11 | 68Ga-HBED-CC-PSMA | 68Ga-PSMA | 68Ga-PSMA-11 | 68Ga-PSMA-HBED-CC | 68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC | AAA 517 | AAA-517 | AAA517 | GA-68 PSMA-11 | GALLIUM GA-68 GOZETOTIDE | Ga PSMA | Ga-68 labeled DKFZ-PSMA-11 | Ga-68 labeled PSMA-11 | GaPSMA | Gallium Ga 68 PSMA-11 | Gallium Ga 68-labeled PSMA-11 | Gallium Ga 68-labeled PSMA-11 | Gallium-68 PSMA | Gallium-68 PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC | PSMA-HBED-CC GA-68 | [68Ga] Prostate-specific Membrane Antigen 11 | [68Ga]GaPSMA-11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1098488","Carbon-11 Acetate","C38712","The acetate salt of the radioisotope carbon-11. Although the mechanism is unclear, carbon-11 acetate preferentially accumulates in tumor tissue, serving as a tracer for imaging tumors with positron emission tomography (PET). (NCI04)","Carbon-11 Acetate | 11C-Acetate | ACETIC ACID C-11 | C-11 Acetate | C11 Acetate | [11C] Acetate | carbon-11 acetate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698585","Carbon C 11 Choline","C78485","A radiotracer consisting of choline labeled with the positron-emitting isotope carbon C 11 with potential imaging use. Upon administration, C-11 choline incorporates into tumor cells through an active, carrier-mediated transport mechanism for choline and then is phosphorylated intracellularly by choline kinase, an enzyme frequently upregulated in human tumors, yielding phosphoryl C-11 choline. In turn, phosphoryl C-11 choline is integrated into phospholipids in the cell membrane as part of phosphatidylcholine. As the proliferation of cancer cells is much higher than normal cells, tumor cells exhibit an increased rate of C-11 choline uptake and incorporation, allowing tumor imaging with positron emission tomography (PET).","Carbon C 11 Choline | C-11 Choline | C11 Choline | CHOLINE C-11 | Ethanaminium, 2-hydroxy-N,N-dimethyl-N-(methyl-11C)-",,,,,,,,,,,,,,,"37110965","Carbon (11-C) choline",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3502775","Akt inhibitor AZD5363","C102564","A novel pyrrolopyrimidine derivative, and an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. Capivasertib binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism. A wide range of solid and hematological malignancies show dysregulated PI3K/AKT/mTOR signaling due to mutations in multiple signaling components. By targeting AKT, the key node in the PIK3/AKT signaling network, this agent may be used as monotherapy or combination therapy for a variety of human cancers.","Capivasertib | AZD 5363 | AZD-5363 | AZD5363 | CAPIVASERTIB | Truqap",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971093","99mTc Bone Scintography","C162575","An imaging modality that reflects alterations in the metabolic activity of bone through the use of radiopharmaceutical agents, commonly technetium-99m-labeled methylene diphosphonate (MDP).","99mTc Bone Scintography | 99mTc Bone Scintigraphy | 99mTc Bone Scintiscan | 99mTc Bone Scintiscanning | 99mTc Bone Scintography ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971092","ProMark Proteomic Prognostic Test","C162576","A proprietary tissue-based test that uses multiplex immunofluorescent staining with monoclonal antibodies to provide a personalized prediction for prostate cancer aggressiveness. It detects an 8-protein signature (DERL1, CUL2, SMAD4, PDSS2, HSPA9, FUS, pS6 (phosphorylated S6), YBOX1).","ProMark Proteomic Prognostic Test | ProMark | ProMark Proteomic Prognostic Test for Prostate Cancer | Promark",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038527","Subarachnoid Space","C156507","The space between the arachnoid membrane and the pia mater; it contains connective tissue, cerebrospinal fluid, and large blood vessels that supply the brain and spinal cord.","Subarachnoid Space | SUBARACHNOID SPACE | Subarachnoid | Subarachnoid Area",,,,,,,,,,,,,,,"4261532","Subarachnoid space structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545131","Adverse Events Supplemental Qualifiers Dataset","C147185","A dataset containing supplemental information, specifically non-standard variables, to parent records in the adverse events domain.","Adverse Events Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936099","Consolidation Clinical Trial Setting","C156599","A clinical trial or treatment setting in which the therapy of interest is considered consolidation therapy.","Consolidation Clinical Trial Setting | CONSOLIDATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2982514","Dose Frequency","C89081","The number of times a substance is administered within a specific time period.","Dose Frequency | DOSFRQ | Dosing Frequency | treatment frequency | treatment_frequency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971065","QC Slide Review","C162621","Tissue Source Sites (TSS) will perform a QC review of tumor biospecimens by review of slides from corresponding FFPE QC blocks. For each tumor segment, an H&E-stained slide is to be prepared and reviewed by the TSS pathologist to confirm accuracy of tissue diagnosis and tumor composition.","QC Slide Review | Quality Control Slide Review | Slide Review | Slide Review, Quality Control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971064","Tumor Segment","C162622","Sufficient total material from each patient, divided to yield a minimum of one aliquot, preferably divided into three to five aliquots, of specified cancer tissue suitable for processing for proteomic and genomic analysis.","Tumor Segment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971063","Normal Tissue Segment","C162623","Tissue sample with cellular composition and architectural patterns expected for the particular anatomic site in which it belongs. There is no evidence of abnormal cellular infiltrates or tumor mass formation.","Normal Tissue Sample | Normal Tissue | Normal Tissue Segment | Normal Tissue Segment | Uninvolved Tissue, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL564709","Diaries","C159580","A written record of an inividual's experiences and observations.","Diary | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525039","Chimeric Antigen Receptor T-cells","C137999","Autologous or allogeneic T-lymphocytes that are engineered to contain a chimeric antigen receptor (CAR) that specifically targets a particular antigen.","Chimeric Antigen Receptor T-cells | CAR T Cell | CAR T Cell Preparation | CAR T Cells | CAR T Cells Preparation | CAR T-cells | CAR-T Cell | CAR-T Cells | CAR-modified T-cells | Chimeric Antigen Receptor T-Cell Therapy | Chimeric-antigen Receptor T-lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562669","International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Criteria - Favorable-Risk Group","C155844","A patient with 0 IMDC risk factors.","International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Criteria - Favorable-Risk Group | Favorable | IMDC Favorable | IMDC Favorable Risk | IMDC Favorable Risk Group",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550759","Nodal Peripheral T-Cell Lymphoma of TFH Cell Origin","C139005","A group of node-based peripheral T-cell lymphomas with phenotypic features of T follicular helper (TFH) cells. This category includes the following: follicular helper T-cell lymphoma, angioimmunoblastic-type; follicular helper T-cell lymphoma, follicular-type; and follicular helper T-cell lymphoma, not otherwise specified.","Follicular Helper T-Cell Lymphoma | Nodal Follicular Helper T-Cell Lymphoma | Nodal Peripheral T-Cell Lymphoma of T Follicular Helper Cell Origin | Nodal Peripheral T-Cell Lymphoma of T Follicular Helper Cell Origin | Nodal Peripheral T-Cell Lymphoma of TFH Cell Origin | TFH Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970636","Inactivating ATM Gene Mutation","C162040","A change in the nucleotide sequence of the ATM gene that either inhibits expression of the serine-protein kinase ATM protein or results in the translation of an inactive serine-protein kinase ATM protein.","Inactivating ATM Gene Mutation | ATM Gene Inactivation | ATM Loss of Function Gene Mutation | ATM Loss of Function Mutation | Inactivating A-T Mutated Gene Mutation | Inactivating AT Mutated Gene Mutation | Inactivating ATM Serine/Threonine Kinase Gene Mutation | Inactivating Ataxia Telangiectasia Mutated Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970635","Deleterious FBXW7 Gene Mutation","C162041","A change in the nucleotide sequence of the FBXW7 gene that is associated with increased risk of disease.","Deleterious FBXW7 Gene Mutation | Deleterious AGO Gene Mutation | Deleterious Archipelago Homolog Gene Mutation | Deleterious Archipelago Homolog, Drosophila Gene Mutation | Deleterious CDC4 Gene Mutation | Deleterious F-Box and WD Repeat Domain Containing 7 Gene Mutation | Deleterious F-box and WD-40 Domain Protein 7 (Archipelago Homolog, Drosophila) Gene Mutation | Deleterious FBW6 Gene Mutation | Deleterious FBW7 Gene Mutation | Deleterious FBX30 Gene Mutation | Deleterious FBXW6 Gene Mutation | Deleterious FBXW7 Mutation | Deleterious SEL-10 Gene Mutation | Deleterious SEL10 Gene Mutation | FBXW7 Deleterious Gene Mutation | FBXW7 Deleterious Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970000","Blasts 15 Percent or Less of Bone Marrow Nucleated Cells","C160963","A semi-quantitative microscopic finding indicating that at most 15 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 15 Percent or Less of Bone Marrow Nucleated Cells | Blasts Less than or Equal to 15 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898089","Orbital Melanoma","C118828","A melanoma that arises from the structures of the orbit.","Orbital Melanoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0558356","Ocular Melanoma","C8562","A melanoma that arises from the structures of the eye or ocular adnexa.","Ocular Melanoma | Eye Melanoma | Melanoma of Eye | Melanoma of the Eye | ocular melanoma",,,,,,,,,,,,,,,"4170619","Malignant melanoma of eye",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0854899","Non-Cutaneous Melanoma","C8711","A melanoma that arises from a site other than skin.","Non-Cutaneous Melanoma | Extracutaneous Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1377610","Peritoneal Mesothelioma","C7633","A mesothelial neoplasm that arises from the peritoneum. It includes adenomatoid tumor, well differentiated papillary mesothelial tumor, multicystic mesothelioma, and malignant mesothelioma.","Peritoneal Mesothelial Neoplasm | Mesothelial Neoplasm of Peritoneum | Mesothelial Neoplasm of the Peritoneum | Mesothelial Tumor of Peritoneum | Mesothelial Tumor of the Peritoneum | Mesothelioma of Peritoneum | Mesothelioma of peritoneum | Mesothelioma of the Peritoneum | Peritoneal Mesothelial Tumor | Peritoneal Mesothelioma | Peritoneal Mesothelioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335346","Parasite-Related Carcinoma","C27767","A term that refers to a group of carcinomas that are caused by parasites.","Parasite-Related Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0153562","Palate Kaposi Sarcoma","C6749","Kaposi sarcoma arising from the palate.","Palate Kaposi Sarcoma | Kaposi's Sarcoma of Palate | Kaposi's Sarcoma of the Palate | Kaposi's sarcoma of palate | Palate Kaposi's Sarcoma",,,,,,,,,,,,,,,"140958","Kaposi's sarcoma of palate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0747548","Pharyngeal Carcinoma","C9466","Carcinoma, predominantly squamous cell, arising from the epithelial cells of the pharynx.","Pharyngeal Carcinoma | Cancer of Pharynx | Cancer of the Pharynx | Carcinoma of Pharynx | Carcinoma of the Pharynx | Pharyngeal Cancer | Pharyngeal Throat Cancer | Pharynx Cancer | Pharynx Carcinoma | pharyngeal cancer",,,,,,,,,,,,,,,"40486208","Carcinoma of pharynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1335469","Precursor Lymphoid Neoplasm","C7055","A neoplasm of immature malignant lymphocytes (lymphoblasts) committed to the B-cell or T-cell lineage.  Neoplasms involving the bone marrow and the peripheral blood are called precursor lymphoblastic leukemias or acute lymphoblastic leukemias.  Neoplasms involving primarily lymph nodes or extranodal sites are called lymphoblastic lymphomas.","Precursor Lymphoid Neoplasm | Precursor Lymphoblastic Leukemia/Lymphoma | Precursor Lymphoblastic Lymphoma/Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032229","Pleural Neoplasm","C3332","A benign or malignant neoplasm that involves the serous membrane that lines the lungs and thoracic cavity. Most pleural neoplasms are metastatic. Diffuse malignant mesothelioma is the most common primary malignant neoplasm of the pleura.","Pleural Neoplasm | Neoplasm of Pleura | Neoplasm of the Pleura | Pleural Tumor | Tumor of Pleura | Tumor of the Pleura",,,,,,,,,,,,,,,"4129382","Neoplasm of pleura",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1377913","Pleural Mesothelial Neoplasm","C9351","A mesothelial neoplasm that arises from the pleura. It includes adenomatoid tumor, well differentiated papillary mesothelial tumor, and malignant mesothelioma.","Pleural Mesothelial Neoplasm | Mesothelial Neoplasm of Pleura | Mesothelial Neoplasm of the Pleura | Mesothelial Tumor of Pleura | Mesothelial Tumor of the Pleura | Mesothelioma of Pleura | Mesothelioma of pleura | Mesothelioma of the Pleura | Pleural Mesothelial Tumor | Pleural Mesothelioma | Pleural Mesothelioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023488","Radiation-Related Leukemia","C26814","Leukemia that is caused by radiation.","Radiation-Related Leukemia | Radiation-Induced Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027654","Embryonal Neoplasm","C3264","A usually malignant neoplasm composed of primitive (immature) tissues that resemble fetal tissues.  Medulloblastoma, ependymoblastoma, pineoblastoma, and Wilms tumor are representative embryonal neoplasms.","Embryonal Neoplasm | embryonal tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919607","Duodenal Neuroendocrine Tumor G1","C6425","A well-differentiated, low-grade neuroendocrine neoplasm that arises from the duodenum. The mitotic count is less than 2 per 2 mm2 and the Ki-67 index is less than 3%.","Duodenal Neuroendocrine Tumor G1 | Carcinoid Tumor of Duodenum | Carcinoid Tumor of the Duodenum | Duodenal Carcinoid Tumor | Duodenal NET G1 | Malignant carcinoid tumor of the duodenum",,,,,,,,,,,,,,,"760961","Malignant carcinoid tumor of duodenum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0154057","Digestive System Carcinoma In Situ","C35180","An intraepithelial carcinoma arising from any part of the digestive system without evidence of invasion.","Digestive System Carcinoma In Situ | Carcinoma in situ of digestive organ, unspecified | Gastrointestinal System Carcinoma In Situ",,,,,,,,,,,,,,,"196064","Carcinoma in situ of digestive organ",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0151544","Digestive System Carcinoma","C96963","A malignant neoplasm that arises from the epithelium of any part of the digestive system.  Representative examples include colorectal carcinoma, esophageal carcinoma, and pancreatic carcinoma.","Digestive System Carcinoma | Carcinoma of the Gastrointestinal System | Gastrointestinal System Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333279","Descending Colon Neuroendocrine Tumor G1","C6428","A well-differentiated, low-grade neuroendocrine neoplasm that arises from the descending colon. The mitotic count is less than 2 per 2 mm2 and the Ki-67 index is less than 3%.","Descending Colon Neuroendocrine Tumor G1 | Carcinoid Tumor of Descending Colon | Carcinoid Tumor of the Descending Colon | Descending Colon Carcinoid Tumor | Descending Colon NET G1 | Malignant carcinoid tumor of the descending colon",,,,,,,,,,,,,,,"760957","Malignant carcinoid tumor of descending colon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0346957","Disseminated Malignant Neoplasm","C27470","Cancer that is spread throughout the body, a metastatic phenomenon.","Disseminated Malignant Neoplasm | Disseminated malignant neoplasm, unspecified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085668","Secondary Carcinoma","C36310","A carcinoma that arises from a pre-existing lower grade epithelial lesion, or as a result of a primary carcinoma that has spread to secondary sites, or due to a complication of a cancer treatment.","Secondary Carcinoma | Secondary carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335929","Schwannomatosis","C6557","Rare genetic disorder caused by mutations in the SMARCB1 and LZTR1 genes. It is characterized by the presence of multiple Schwannomas.","Schwannomatosis | Neurilemmomatosis | Neurinomatosis",,,,,,,,,,,,,,,"36683644","Schwannomatosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556149","Sarcoma of the Extremity","C155647","A sarcoma that arises from the soft tissues or bones of the upper or lower extremity.","Sarcoma of the Extremity | Extremity Sarcoma | Primary Extremity Sarcoma | Primary Sarcoma of the Extremity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0948749","Retroperitoneal Carcinoma","C7352","A rare carcinoma that arises from the retroperitoneal space.","Retroperitoneal Carcinoma | Carcinoma of Retroperitoneum | Carcinoma of the Retroperitoneum | Retroperitoneal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0853394","Retinal Melanoma","C8601","A melanoma affecting the retinal portion of the eye.","Retinal Melanoma | Malignant Melanoma of Retina | Malignant Melanoma of the Retina | Malignant Retinal Melanoma | Melanoma of Retina | Melanoma of the Retina",,,,,,,,,,,,,,,"4313766","Malignant melanoma of retina",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035244","Respiratory System Neoplasm","C3355","A benign or malignant, primary or metastatic neoplasm involving the respiratory system.","Respiratory System Neoplasm | Respiratory Tract Neoplasm | Respiratory Tract Neoplasm",,,,,,,,,,,,,,,"252280|40491439","Neoplasm of respiratory tract|Tumor of respiratory system",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL552323","Resectable Malignant Neoplasm","C150602","A malignant neoplasm that is amenable to surgical resection.","Resectable Malignant Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552319","Resectable Carcinoma","C150604","A carcinoma that is amenable to surgical resection.","Resectable Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3163938","Renal Pelvis Carcinoma","C6142","A carcinoma arising in the renal pelvis.  The majority of renal pelvis carcinomas are transitional cell and less frequently squamous cell carcinomas.","Renal Pelvis Carcinoma | Carcinoma of Kidney Pelvis | Carcinoma of Renal Pelvis | Carcinoma of the Kidney Pelvis | Carcinoma of the Renal Pelvis | Kidney Pelvis Carcinoma | Renal Pelvis Cancer",,,,,,,,,,,,,,,"40488899","Carcinoma of renal pelvis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334427","Regressing Melanoma","C4228","A skin lesion characterized by the disappearance of the melanoma cells from the primary melanoma site. The disappearance of the malignant cells is associated with fibroplasia of the papillary dermis. According to some authors, complete regression of the primary melanoma may occur in 4-8% of patients.","Regressing Melanoma | Malignant melanoma, regressing | Regressing Malignant Melanoma","8723/3","Malignant melanoma, regressing",,,,,,,,,,,,,"4220803","Malignant melanoma, regressing",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"CL550890","Refractory Sarcoma","C148301","A sarcoma that does not respond to treatment.","Refractory Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545854","Refractory Melanoma","C147983","Melanoma that does not respond to treatment.","Refractory Melanoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555017","Refractory Malignant Central Nervous System Neoplasm","C153842","A primary malignant central nervous system neoplasm that is resistant to treatment.","Refractory Primary Malignant Central Nervous System Neoplasm | Refractory Malignant Central Nervous System Neoplasm | Refractory Malignant Central Nervous System Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521933","Refractory Lymphoma","C134154","A lymphoma that does not respond to treatment.","Refractory Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550989","Refractory Leukemia","C148426","Leukemia that is resistant to treatment.","Refractory Leukemia | Advanced Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550893","Recurrent Sarcoma","C148302","The reemergence of sarcoma after a period of remission.","Recurrent Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555012","Recurrent Malignant Central Nervous System Neoplasm","C153823","The reemergence of a primary malignant central nervous system neoplasm after a period of remission.","Recurrent Primary Malignant Central Nervous System Neoplasm | Recurrent Malignant Central Nervous System Neoplasm | Recurrent Malignant Central Nervous System Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521935","Recurrent Lymphoma","C134157","The reemergence of a lymphoma after a period of remission.","Recurrent Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0920028","Recurrent Leukemia","C148425","The reemergence of leukemia after a period of remission.","Recurrent Leukemia | Leukemia, unspecified, in relapse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278787","Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive","C9070","The reemergence of chronic myeloid leukemia, BCR-ABL1 positive after a period of remission.","Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive | Chronic myeloid leukemia, BCR/ABL-positive, in relapse | Recurrent Chronic Myelogenous Leukemia | Recurrent Chronic Myelogenous Leukemia (CML) | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Chronic Myelogenous Leukemia, BCR::ABL1 Positive | Recurrent Chronic Myeloid Leukemia | Recurrent Chronic Myeloid Leukemia, BCR::ABL1 Positive | Relapsed CGL | Relapsed CML | Relapsed Chronic Myelogenous Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0854802","Recurrent Chronic Lymphocytic Leukemia","C8645","The reemergence of chronic lymphocytic leukemia after a period of remission.","Recurrent Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia Recurrent | Chronic lymphocytic leukemia of B-cell type in relapse | Recurrent B-Cell Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia (CLL) | Recurrent Chronic Lymphoid Leukemia | Relapsed Chronic Lymphocytic Leukemia | Relapsed Chronic Lymphoid Leukemia",,,,,,,,,,,,,,,"760935","Chronic lymphoid leukemia in relapse",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2861599","Recurrent Acute Myelomonocytic Leukemia","C156717","The reemergence of acute myelomonocytic leukemia after a period of remission.","Recurrent Acute Myelomonocytic Leukemia | Acute myelomonocytic leukemia, in relapse | Relapsed Acute Myelomonocytic Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935859","Recurrent Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A","C156719","The reemergence of acute myeloid leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A after a period of remission.","Recurrent Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A | Recurrent Acute Myeloid Leukemia with t (9;11) (p21.3; q23.3); MLLT3 (AF9)-KMT2A | Recurrent Acute Myeloid Leukemia with t (9;11) (p21.3; q23.3); MLLT3-KMT2A | Recurrent Acute Myeloid Leukemia with t (9;11) (p21.3; q23.3); MLLT3-KMT2A | Recurrent Acute Myeloid Leukemia with t (9;11) (p21.3; q23.3); MLLT3-MLL | Recurrent Acute Myeloid Leukemia with t (9;11) (p22.3; q23.3); MLLT3-KMT2A | Recurrent Acute Myeloid Leukemia with t (9;11)(p22.3; q23.3); MLLT3::KMT2A | Recurrent Acute Myeloid Leukemia with t(9;11)(p21.3; q23.3); MLLT3 (AF9)-KMT2A | Recurrent Acute Myeloid Leukemia with t(9;11)(p21.3; q23.3); MLLT3-MLL | Recurrent Acute Myeloid Leukemia with t(9;11)(p21.3; q23.3); MLLT3::MLL | Recurrent Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A Fusion | Recurrent Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3::KMT2A | Recurrent Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3::KMT2A Fusion | Relapsed Acute Myeloid Leukemia with t (9;11) (p21.3; q23.3); MLLT3-KMT2A | Relapsed Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2861610","Recurrent Acute Myeloid Leukemia with Multilineage Dysplasia","C156720","The reemergence of acute myeloid leukemia with multilineage dysplasia after a period of remission.","Recurrent Acute Myeloid Leukemia with Multilineage Dysplasia | Acute myeloid leukemia with multilineage dysplasia, in relapse | Recurrent Acute Myeloid Leukemia (AML) with Multilineage Dysplasia | Relapsed Acute Myeloid Leukemia with Multilineage Dysplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1142169","Recurrent Acute Myeloid Leukemia","C148427","The reemergence of acute myeloid leukemia after a period of remission.","Recurrent Acute Myeloid Leukemia | Acute myeloblastic leukemia, in relapse | Recurrent Acute Myeloid Leukemia (AML)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2861618","Recurrent Acute Monoblastic and Monocytic Leukemia","C156722","The reemergence of acute monoblastic and monocytic leukemia after a period of remission.","Recurrent Acute Monoblastic and Monocytic Leukemia | Acute monoblastic/monocytic leukemia, in relapse | Relapsed Acute Monoblastic and Monocytic Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2367455","Recurrent Acute Megakaryoblastic Leukemia","C156731","The reemergence of acute megakaryoblastic leukemia after a period of remission.","Recurrent Acute Megakaryoblastic Leukemia | Acute megakaryoblastic leukemia, in relapse | Relapsed Acute Megakaryoblastic Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1504525","Recurrent Acute Lymphoblastic Leukemia","C142810","The reemergence of acute lymphoblastic leukemia after a period of remission.","Recurrent Acute Lymphoblastic Leukemia | Acute lymphoblastic leukemia, in relapse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550990","Recurrent Acute Leukemia","C148429","The reemergence of acute leukemia after a period of remission.","Recurrent Acute Leukemia | Acute leukemia of unspecified cell type, in relapse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2861632","Recurrent Acute Erythroid Leukemia","C156723","The reemergence of acute erythroid leukemia after a period of remission.","Recurrent Acute Erythroid Leukemia | Acute erythroid leukemia, in relapse | Relapsed Acute Erythroid Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335678","Rectal Neuroendocrine Tumor G1","C5547","A well-differentiated, low-grade neuroendocrine neoplasm that arises from the rectum. The mitotic count is less than 2 per 2 mm2 and the Ki-67 index is less than 3%.","Rectal Neuroendocrine Tumor G1 | Carcinoid Tumor of Rectum | Carcinoid Tumor of the Rectum | Carcinoid of Rectum | Carcinoid of the Rectum | Malignant carcinoid tumor of the rectum | Rectal Carcinoid | Rectal Carcinoid Tumor | Rectal NET G1",,,,,,,,,,,,,,,"37017100|37018934","Carcinoid tumor of rectum|Malignant carcinoid tumor of rectum",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0349529","Gastric Neuroendocrine Tumor G1","C4635","A well-differentiated, low-grade neuroendocrine neoplasm that arises from the stomach. Most cases arise from the corpus-fundus region. The mitotic count is less than 2 per 2 mm2 and the Ki-67 index is less than 3%. It may be associated with autoimmune chronic atrophic gastritis, multiple endocrine neoplasia type 1, or it may be sporadic.","Gastric Neuroendocrine Tumor G1 | Gastric Carcinoid Tumor | Gastric ECL Cell NET | Gastric ECL Cell NET G1 | Gastric ECL Cell, Histamine-Producing NET | Gastric ECL-Cell Carcinoid Tumor | Gastric Enterochromaffin-Like Cell Carcinoid Tumor | Gastric Enterochromaffin-Like Cell Neuroendocrine Tumor | Gastric NET G1 | Malignant carcinoid tumor of the stomach",,,,,,,,,,,,,,,"194306","Carcinoid tumor of stomach",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825739","Fibroblastic Reticular Cell Sarcoma","C81758","A very rare dendritic cell sarcoma affecting the lymph nodes, spleen, and soft tissues. Morphologically it is similar to the interdigitating dendritic cell sarcoma or follicular dendritic cell sarcoma. The tumor cells are positive for cytokeratin and CD68.","Fibroblastic Reticular Cell Sarcoma | Fibroblastic Dendritic Cell Tumor | Fibroblastic Reticular Cell Tumor | Fibroblastic Reticular Cell Tumor | Fibroblastic reticular cell tumor","9759/3","Fibroblastic reticular cell tumor",,,,,,,,,,,,,"36715592|42872917","Fibroblastic reticular cell neoplasm|Fibroblastic reticular cell tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0339116","Eyelid Melanoma","C4358","A melanoma that arises from the upper or lower eyelid.","Eyelid Melanoma | Malignant Eyelid Melanoma | Malignant Melanoma of Eyelid | Malignant Melanoma of the Eyelid | Melanoma of Eyelid | Melanoma of the Eyelid",,,,,,,,,,,,,,,"4338760","Malignant melanoma of eyelid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0848866","Eye Carcinoma","C6079","A carcinoma that arises from any of the structures of the eye.","Eye Carcinoma | Carcinoma of Eye | Carcinoma of the Eye | Ocular Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333494","External Ear Squamous Cell Carcinoma","C6083","A squamous cell carcinoma that arises from the external ear.","External Ear Squamous Cell Carcinoma | Epidermoid Carcinoma of External Ear | Epidermoid Carcinoma of the External Ear | External Ear Epidermoid Carcinoma | Squamous Cell Carcinoma of External Ear | Squamous Cell Carcinoma of the External Ear",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333491","External Ear Basal Cell Carcinoma","C6082","A basal cell carcinoma that arises from the skin of the external ear.","External Ear Basal Cell Carcinoma | Basal Cell Carcinoma of External Ear | Basal Cell Carcinoma of the External Ear",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333600","Hereditary Malignant Neoplasm","C9479","Malignant neoplasms occurring in families at a rate greater than that expected by chance and caused by germline mutations in a specific gene.","Hereditary Malignant Neoplasm | Familial Cancer | Familial Malignant Neoplasm | Hereditary Cancer | familial cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333950","Helicobacter Pylori-Related Carcinoma","C27764","A carcinoma that is caused by Helicobacter pylori.","Helicobacter Pylori-Related Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268205","Hand-Schuller-Christian Disease","C6920","A multifocal, unisystem form of Langerhans-cell histiocytosis. There is involvement of multiple sites in one organ system, most frequently the bone. Patients are usually young children presenting with multiple destructive bone lesions.","Hand-Schuller-Christian Disease | Classic Multifocal Langerhans Cell Histiocytosis | Hand-Schuller-Christian disease | Hand-Schüller-Christian Disease | Multifocal Unisystem Langerhans Cell Histiocytosis | Multifocal and unisystemic Langerhans-cell histiocytosis",,,,,,,,,,,,,,,"4217892","Hand-Schüller-Christian disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0154088","Grade III Prostatic Intraepithelial Neoplasia","C3642","High grade prostatic intraepithelial neoplasia characterized by the presence of severe architectural and cytologic abnormalities.","Grade III Prostatic Intraepithelial Neoplasia | Adenocarcinoma in situ of Prostate | Adenocarcinoma in situ of the Prostate | Carcinoma in situ of prostate | Grade 3 PIN | Grade 3 Prostatic Intraepithelial Neoplasia | Grade III PIN | PIN III | Prostate Adenocarcinoma in situ | Prostatic intraepithelial neoplasia, grade III",,,,,,,,,,,,,,,"200970","Carcinoma in situ of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL411899","Grade 3 Meningioma","C38938","A malignant meningioma with aggressive clinical course.  It recurs in approximately 50-78% of the cases.  This category includes the anaplastic (malignant) meningioma, papillary meningioma, and rhabdoid meningioma.","Grade 3 Meningioma | Grade III Meningioma | Grade III Meningioma | MENINGIOMA, MALIGNANT | WHO Grade 3 Meningioma | WHO Grade III Meningioma | Who Grade III Meningioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334319","Glycogen-Rich Carcinoma","C4153","A carcinoma characterized by the presence of malignant epithelial cells with abundant clear cytoplasm which contains glycogen. A representative example is the glycogen-rich, clear cell breast carcinoma.","Glycogen-Rich Carcinoma | Glycogen-rich carcinoma","8315/3","Glycogen-rich carcinoma",,,,,,,,,,,,,"4253228","Glycogen-rich carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1336065","Splenic Manifestation of Leukemia","C7296","Infiltration and expansion of the white and/or red pulp and sinusoids of the spleen by leukemic cells.","Splenic Manifestation of Leukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0349536","Small Intestinal Neuroendocrine Tumor G1","C4638","A well-differentiated, low-grade neuroendocrine neoplasm that arises from the small intestine. The mitotic count is less than 2 per 2 mm2 and the Ki-67 index is less than 3%.","Small Intestinal Neuroendocrine Tumor G1 | Carcinoid Tumor of Small Bowel | Carcinoid Tumor of Small Intestine | Carcinoid Tumor of the Small Bowel | Carcinoid Tumor of the Small Intestine | Small Bowel Carcinoid Tumor | Small Intestinal Carcinoid Tumor | Small Intestinal NET G1 | Small Intestine Carcinoid Tumor",,,,,,,,,,,,,,,"198100","Carcinoid tumor of small intestine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206652","Small Cell Sarcoma","C3746","A sarcoma characterized by the presence of small round or elongated malignant cells with a small amount of cytoplasm.","Small Cell Sarcoma | Small Cell Sarcomas | Small cell sarcoma","8803/3","Small cell sarcoma",,,,,,,,,,,,,"4249150","Small cell sarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0153560","Skin Kaposi Sarcoma","C3550","A Kaposi sarcoma arising from the skin.  It presents with patches, plaques, or nodules.","Skin Kaposi Sarcoma | Cutaneous (Skin) Kaposi Sarcoma | Cutaneous Kaposi Sarcoma | Cutaneous Kaposi's Sarcoma | Kaposi's Sarcoma of Skin | Kaposi's Sarcoma of the Skin | Kaposi's sarcoma of skin | Skin Kaposi's Sarcoma",,,,,,,,,,,,,,,"258981","Kaposi's sarcoma of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0347073","Stage 0 Oral Cavity Cancer AJCC v6 and v7","C4587","Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage 0 Oral Cavity Cancer AJCC v6 and v7 | Carcinoma in situ of Mouth | Carcinoma in situ of Oral Cavity | Carcinoma in situ of oral cavity, unspecified site | Carcinoma in situ of the Mouth | Carcinoma in situ of the Oral Cavity | Mouth Carcinoma in situ | Oral Cavity Carcinoma in situ | Stage 0 Carcinoma of Mouth | Stage 0 Carcinoma of Oral Cavity | Stage 0 Carcinoma of the Mouth | Stage 0 Carcinoma of the Oral Cavity | Stage 0 Mouth Carcinoma | Stage 0 Oral Cavity Cancer | Stage 0 Oral Cavity Cancer AJCC v6 | Stage 0 Oral Cavity Cancer AJCC v7 | Stage 0 Oral Cavity Carcinoma",,,,,,,,,,,,,,,"37206188|4243266","Carcinoma in situ of oral cavity|Carcinoma in situ of mouth",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0854756","Stage 0 Lip and Oral Cavity Cancer AJCC v6 and v7","C7939","Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage 0 Lip and Oral Cavity Cancer AJCC v6 and v7 | Lip and Oral Cavity Cancer Stage 0 | Lip and Oral Cavity Carcinoma Stage 0 | Stage 0 Lip and Oral Cavity Cancer | Stage 0 Lip and Oral Cavity Cancer AJCC v6 | Stage 0 Lip and Oral Cavity Cancer AJCC v7 | Stage 0 Lip and Oral Cavity Carcinoma | stage 0 lip and oral cavity carcinoma in situ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0154061","Stage 0 Colon Cancer AJCC v6 and v7","C3638","Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ: intraepithelial or invasion of lamina propria.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage 0 Colon Cancer AJCC v6 and v7 | Carcinoma in situ of Colon | Carcinoma in situ of colon | Carcinoma in situ of the Colon | Colon Cancer Stage 0 | Colon Carcinoma in situ | Colonic Carcinoma in situ | Stage 0 Carcinoma of Colon | Stage 0 Carcinoma of the Colon | Stage 0 Colon Cancer | Stage 0 Colon Cancer AJCC v6 | Stage 0 Colon Cancer AJCC v7 | Stage 0 Colon Carcinoma | Stage 0 Colonic Carcinoma",,,,,,,,,,,,,,,"75512","Carcinoma in situ of colon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334160","Immunodeficiency-Related Malignant Neoplasm","C27770","Malignant neoplasm occurring in immunodeficient patients.","Immunodeficiency-Related Malignant Neoplasm | Immunosuppression-Related Cancer | Immunosuppression-Related Malignancy | Immunosuppression-Related Malignant Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0745216","Ileal Neuroendocrine Tumor G1","C4935","A well-differentiated, low-grade neuroendocrine neoplasm that arises from the ileum. The mitotic count is less than 2 per 2 mm2 and the Ki-67 index is less than 3%.","Ileal Neuroendocrine Tumor G1 | Carcinoid Tumor of Ileum | Carcinoid Tumor of the Ileum | Ileal Carcinoid Tumor | Ileal NET G1 | Malignant carcinoid tumor of the ileum",,,,,,,,,,,,,,,"432271|761917","Carcinoid tumor of ileum|Malignant carcinoid tumor of ileum",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0153398","Hypopharyngeal Carcinoma","C9465","Carcinoma, predominantly squamous cell, arising from the epithelial cells of the hypopharynx.","Hypopharyngeal Carcinoma | Cancer of Hypopharynx | Cancer of the Hypopharynx | Carcinoma of Hypopharynx | Carcinoma of the Hypopharynx | Hypopharyngeal Cancer | Hypopharyngeal Throat Cancer | hypopharyngeal cancer",,,,,,,,,,,,,,,"40490990","Malignant epithelial neoplasm of hypopharynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0686584","Leukemia in Remission","C4896","A finding of leukemia that is not growing and responds to treatment.","Leukemia in Remission | Leukemia (in Remission) | Leukemia, unspecified, in remission",,,,,,,,,,,,,,,"135766","Leukemia in remission",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0220641","Lip and Oral Cavity Carcinoma","C9315","A carcinoma arising in the lip or oral cavity.  Most oral cavity carcinomas are squamous cell carcinomas of the tongue, buccal mucosa, or gums.  Less frequent morphologic variants include mucoepidermoid carcinoma and adenocarcinoma.  Lip carcinomas are usually basal cell or squamous cell carcinomas.","Lip and Oral Cavity Carcinoma | Lip and Oral Cavity Cancer | Oral Cancer | Oral Carcinoma | oral cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279739","Lip Basal Cell Carcinoma","C8014","A basal cell carcinoma arising from the lip.","Lip Basal Cell Carcinoma | Basal Cell Carcinoma of Lip | Basal Cell Carcinoma of the Lip | Lip Basal Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0149637","Lip Carcinoma","C3490","A malignant epithelial neoplasm arising from the lips.","Lip Carcinoma | Carcinoma of Lip | Carcinoma of the Lip | Lip Cancer",,,,,,,,,,,,,,,"4153887","Carcinoma of lip",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0280302","Lip Squamous Cell Carcinoma","C4042","A squamous cell carcinoma that arises from the lip.  It affects males more often than females and it usually involves the lower lip.  Risk factors include UV exposure, alcohol consumption, smoking, and immunosuppression.","Lip Squamous Cell Carcinoma | Lip SCC | SCC of Lip | SCC of the Lip | Squamous Cell Carcinoma of Lip | Squamous Cell Carcinoma of the Lip",,,,,,,,,,,,,,,"4113108","Squamous cell carcinoma of lip",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0345907","Liver Angiosarcoma","C4438","A malignant vascular neoplasm arising from the liver.","Liver Angiosarcoma | Angiosarcoma of Liver | Angiosarcoma of liver | Angiosarcoma of the Liver | Hemangiosarcoma of Liver | Hemangiosarcoma of the Liver | Hepatic Angiosarcoma | Hepatic Hemangiosarcoma | Kupffer cell sarcoma | Liver Hemangiosarcoma | Primary Angiosarcoma of Liver | Primary Angiosarcoma of the Liver","9124/3","Kupffer cell sarcoma",,,,,,,,,,,,,"4003021|4239698","Angiosarcoma of liver|Kupffer cell sarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C1333963","Liver Neuroendocrine Tumor","C5783","An extremely rare, well-differentiated neuroendocrine neoplasm arising from the liver. The neoplastic cells express immunohistochemical evidence of neuroendocrine differentiation.","Liver Neuroendocrine Tumor | Carcinoid Tumor of Liver | Carcinoid Tumor of the Liver | HNET | Hepatic Carcinoid Tumor | Hepatic Neuroendocrine Tumor | Liver Carcinoid Tumor | Liver Well Differentiated Neuroendocrine Neoplasm | Liver Well-Differentiated Neuroendocrine Neoplasm | Primary Hepatic Neuroendocrine Tumor | Primary Liver Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039981","Thoracic Neoplasm","C3406","A benign or malignant, primary or metastatic neoplasm involving the tissues of the thorax.","Thoracic Neoplasm | Neoplasm of Thorax | Neoplasm of the Thorax | Thoracic Tumor | Tumor of Thorax | Tumor of the Thorax",,,,,,,,,,,,,,,"4111018","Neoplasm of thorax",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825306","Therapy-Related Leukemia","C80683","A leukemia arising as a result of the mutagenic effect of chemotherapy agents that are used for the treatment of a malignant tumor or exposure to ionizing radiation.","Therapy-Related Leukemia | Therapy Related Leukemia | Treatment Induced Leukemia | Treatment Related Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0154073","Stage 0 Skin Cancer","C3640","Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No clinical or radiographic evidence of distant metastasis.  (AJCC 6th and 7th eds.)","Stage 0 Skin Cancer | Carcinoma in situ of Skin | Carcinoma in situ of skin, unspecified | Carcinoma in situ of the Skin | Carcinoma of Skin Stage 0 | Carcinoma of the Skin Stage 0 | Cutaneous Carcinoma in situ | Skin Cancer Stage 0 | Skin Carcinoma Stage 0 | Skin Carcinoma in situ | Stage 0 Skin Cancer AJCC v6 | Stage 0 Skin Cancer AJCC v7 | Stage 0 Skin Carcinoma | nonmelanoma carcinoma in situ | stage 0 nonmelanoma skin carcinoma in situ",,,,,,,,,,,,,,,"138996","Carcinoma in situ of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0154062","Stage 0 Rectal Cancer AJCC v6 and v7","C4853","Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ: intraepithelial or invasion of the lamina propria.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)","Stage 0 Rectal Cancer AJCC v6 and v7 | Carcinoma in situ of Rectum | Carcinoma in situ of rectum | Carcinoma in situ of the Rectum | Marked Dysplasia of Rectum | Marked Dysplasia of the Rectum | Marked Rectal Dysplasia | Rectal Carcinoma in situ | Severe Dysplasia of Rectum | Severe Dysplasia of the Rectum | Severe Rectal Dysplasia | Stage 0 Carcinoma of Rectum | Stage 0 Carcinoma of the Rectum | Stage 0 Rectal Cancer | Stage 0 Rectal Cancer AJCC v6 | Stage 0 Rectal Cancer AJCC v7 | Stage 0 Rectal Carcinoma",,,,,,,,,,,,,,,"4204032|75210","Severe dysplasia of rectum|Carcinoma in situ of rectum",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0347098","Stage 0 Pharyngeal Cancer","C4942","Stage 0 carcinoma of the pharynx according to the American Joint Committee on Cancer, 6th, 7th, and 8th editions.","Stage 0 Pharyngeal Cancer | Carcinoma in situ of Pharynx | Carcinoma in situ of pharynx | Carcinoma in situ of the Pharynx | Pharyngeal Cancer Stage 0 | Pharyngeal Carcinoma in situ | Pharynx Carcinoma in situ | Stage 0 Carcinoma of Pharynx | Stage 0 Carcinoma of the Pharynx | Stage 0 Pharyngeal Carcinoma | Stage 0 Pharyngeal Throat Cancer | Stage 0 Pharynx Carcinoma",,,,,,,,,,,,,,,"4244639","Carcinoma in situ of pharynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0600079","Ureter Carcinoma","C8993","A carcinoma of the ureter.  The majority of ureter carcinomas are transitional cell and less frequently squamous cell carcinomas or adenocarcinomas.","Ureter Carcinoma | Carcinoma of Ureter | Carcinoma of the Ureter | Ureter Cancer | Ureteral Carcinoma",,,,,,,,,,,,,,,"40492017","Carcinoma of ureter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL550967","Unresectable Sarcoma","C148331","A sarcoma which is not amenable to surgical resection.","Unresectable Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551147","Unresectable Melanoma","C148517","Melanoma which is not amenable to surgical resection.","Unresectable Melanoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336869","Unresectable Malignant Neoplasm","C27359","A malignant neoplasm which is not amenable to surgical resection.","Unresectable Malignant Neoplasm | Unresectable Malignant Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550822","Unresectable Carcinoma","C148124","Carcinoma that is not amenable to surgical resection.","Unresectable Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336808","Transplant-Related Carcinoma","C27633","A carcinoma that arises in a patient with a history of organ transplantation.","Transplant-Related Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0154070","Tracheal Carcinoma In Situ","C3639","A carcinoma that arises from the tracheal mucosa and is confined to the epithelial layer without evidence of further tissue invasion.","Tracheal Carcinoma In Situ | Carcinoma in situ of Trachea | Carcinoma in situ of the Trachea | Carcinoma in situ of trachea | Severe Epithelial Dysplasia of Trachea | Trachea Carcinoma in situ",,,,,,,,,,,,,,,"439772","Carcinoma in situ of trachea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040136","Thyroid Gland Neoplasm","C3414","A benign or malignant neoplasm affecting the thyroid gland.","Thyroid Gland Neoplasm | Neoplasm of Thyroid | Neoplasm of Thyroid Gland | Neoplasm of the Thyroid | Neoplasm of the Thyroid Gland | Thyroid Gland Tumor | Thyroid Neoplasm | Thyroid Neoplasms | Thyroid Tumor | Tumor of Thyroid | Tumor of Thyroid Gland | Tumor of the Thyroid | Tumor of the Thyroid Gland",,,,,,,,,,,,,,,"4131909","Neoplasm of thyroid gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1336968","Virus-Related Lymphoma","C27699","Lymphoma that is caused by a virus infection.","Virus-Related Lymphoma | Virus Related Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700101","Urethral Carcinoma","C9106","A carcinoma that arises from the urethra. Morphologically, the tumors are similar to those described in the bladder.","Urethral Carcinoma | Carcinoma of Urethra | Carcinoma of the Urethra | Urethra Carcinoma | Urethral Cancer | urethral cancer",,,,,,,,,,,,,,,"40492509","Carcinoma of urethra",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0746343","Localized Lymphoma","C4938","A lymphoma that is confined to a specific site without evidence of spread to other anatomic sites.","Localized Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280089","Lung Neuroendocrine Tumor","C4038","A well-differentiated neuroendocrine neoplasm that arises from the lung. It is characterized by the presence of uniform polygonal cells with small or moderate amount of cytoplasm and inconspicuous nucleoli. The cells are usually arranged in organoid and trabecular patterns. It is classified as grade 1 (G1-typical carcinoid tumor) or grade 2 (G2-atypical carcinoid tumor) based on the number of mitotic figures and the absence or presence of necrosis. Grade 2 neuroendocrine tumors have a worse prognosis.","Lung Neuroendocrine Tumor | Carcinoid Tumor of Lung | Carcinoid Tumor of the Lung | Lung Carcinoid Tumor | Lung Carcinoid Tumor | Lung NET | Lung Neuroendocrine Tumor | Pulmonary Carcinoid Tumor",,,,,,,,,,,,,,,"257513","Carcinoid tumor of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334457","Lymphadenopathic Kaposi Sarcoma","C27500","A Kaposi sarcoma affecting the lymph nodes.","Lymphadenopathic Kaposi Sarcoma | Kaposi's sarcoma of lymph nodes | Lymphadenopathic Kaposi's Sarcoma",,,,,,,,,,,,,,,"312846","Kaposi's sarcoma of lymph nodes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL935867","Malignant Abdominal Neoplasm","C156714","A primary or metastatic malignant neoplasm that affects the organs and structures of the abdomen.","Malignant Abdominal Neoplasm | Malignant neoplasm of abdomen",,,,,,,,,,,,,,,"197506","Malignant neoplasm of abdomen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0344456","Malignant Adrenal Medulla Neoplasm","C4396","A primary or metastatic malignant neoplasm affecting the adrenal medulla.","Malignant Adrenal Medulla Neoplasm | Malignant Adrenal Medulla Tumor | Malignant Neoplasm of Adrenal Medulla | Malignant Neoplasm of the Adrenal Medulla | Malignant Tumor of Adrenal Medulla | Malignant Tumor of the Adrenal Medulla | Malignant neoplasm of medulla of unspecified adrenal gland",,,,,,,,,,,,,,,"4155167","Malignant neoplasm of adrenal medulla",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153454","Malignant Ampulla of Vater Neoplasm","C3536","A primary or metastatic malignant neoplasm involving the ampulla of Vater.","Malignant Ampulla of Vater Neoplasm | Malignant Ampulla of Vater Tumor | Malignant Neoplasm of Ampulla of Vater | Malignant Neoplasm of the Ampulla of Vater | Malignant Tumor of Ampulla of Vater | Malignant Tumor of the Ampulla of Vater | Malignant neoplasm of ampulla of Vater",,,,,,,,,,,,,,,"4178966","Malignant tumor of ampulla of Vater",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334559","Malignant Anterior Tongue Neoplasm","C6061","A primary or metastatic malignant neoplasm that affects the anterior portion of the tongue.","Malignant Anterior Tongue Neoplasm | Malignant Anterior Tongue Tumor | Malignant Neoplasm of Anterior Tongue | Malignant Neoplasm of the Anterior Tongue | Malignant Tumor of Anterior Tongue | Malignant Tumor of the Anterior Tongue | Malignant neoplasm of anterior two-thirds of tongue, part unspecified",,,,,,,,,,,,,,,"4177098","Malignant tumor of anterior two-thirds of tongue",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0496779","Malignant Appendix Neoplasm","C9333","A primary or metastatic malignant neoplasm that affects the appendix.  Representative examples include carcinoma and lymphoma.","Malignant Appendix Neoplasm | Malignant Appendix Tumor | Malignant Neoplasm of Appendix | Malignant Neoplasm of Appendix Vermiformis | Malignant Neoplasm of the Appendix | Malignant Tumor of Appendix | Malignant Tumor of the Appendix | Malignant neoplasm of appendix",,,,,,,,,,,,,,,"443383","Malignant neoplasm of appendix",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2703042","Malignant Bone Marrow Neoplasm","C35501","Malignant neoplasms that either originate from the bone marrow (e.g. myeloid leukemias) or involve the bone marrow as secondary-metastatic tumors (e.g. metastatic carcinomas to the bone marrow).","Malignant Bone Marrow Neoplasm | Malignant Bone Marrow Tumor | bone marrow cancer",,,,,,,,,,,,,,,"4247726","Primary malignant neoplasm of bone marrow",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153641","Malignant Brain Stem Neoplasm","C3570","A primary or metastatic malignant neoplasm that affects the brain stem.","Malignant Brain Stem Neoplasm | Malignant Brain Stem Tumor | Malignant Brainstem Neoplasm | Malignant Brainstem Tumor | Malignant Neoplasm of Brain Stem | Malignant Neoplasm of Brainstem | Malignant Neoplasm of the Brain Stem | Malignant Neoplasm of the Brainstem | Malignant Tumor of Brain Stem | Malignant Tumor of Brainstem | Malignant Tumor of the Brain Stem | Malignant Tumor of the Brainstem | Malignant neoplasm of brain stem",,,,,,,,,,,,,,,"4180908","Malignant neoplasm of brainstem",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153373","Malignant Buccal Mucosa Neoplasm","C9320","A primary or metastatic malignant neoplasm involving the buccal mucosa.","Malignant Buccal Mucosa Neoplasm | Malignant Buccal Mucosa Tumor | Malignant Neoplasm of Buccal Mucosa | Malignant Neoplasm of the Buccal Mucosa | Malignant Tumor of Buccal Mucosa | Malignant Tumor of the Buccal Mucosa | Malignant neoplasm of cheek mucosa",,,,,,,,,,,,,,,"4180786","Malignant tumor of buccal mucosa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153500","Malignant Cardiac Neoplasm","C3548","A primary or metastatic malignant neoplasm involving the heart.","Malignant Cardiac Neoplasm | Cardiac Neoplasm, Malignant | Heart Cancer | Malignant Cardiac Tumor | Malignant Heart Neoplasm | Malignant Heart Tumor | Malignant Neoplasm of Heart | Malignant Neoplasm of the Heart | Malignant Tumor of Heart | Malignant Tumor of the Heart | Malignant neoplasm of heart | heart cancer",,,,,,,,,,,,,,,"4180796","Malignant tumor of heart",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL416228","Malignant Cardiovascular Neoplasm","C114940","A primary or metastatic malignant neoplasm involving the cardiovascular system.","Malignant Cardiovascular Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0153437","Malignant Cecum Neoplasm","C9329","A primary or metastatic malignant neoplasm that affects the cecum.  Representative examples include carcinoma, lymphoma, and sarcoma.","Malignant Cecum Neoplasm | Malignant Cecal Neoplasm | Malignant Cecum Tumor | Malignant Neoplasm of Cecum | Malignant Neoplasm of the Cecum | Malignant Tumor of Cecum | Malignant Tumor of the Cecum | Malignant neoplasm of cecum",,,,,,,,,,,,,,,"443391","Malignant tumor of cecum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708864","Malignant Central Nervous System Germ Cell Tumor","C54099","A germ cell tumor that affects the central nervous system, characterized by the presence of malignant morphologic characteristics.  Representative examples include choriocarcinoma, embryonal carcinoma, and germinoma.","Malignant Central Nervous System Germ Cell Tumor | Malignant Central Nervous System Germ Cell Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334571","Malignant Central Nervous System Mesenchymal, Non-Meningothelial Neoplasm","C6758","A metastasizing mesenchymal, non-meningothelial neoplasm that arises from the central nervous system.","Malignant Central Nervous System Mesenchymal, Non-Meningothelial Neoplasm | Malignant CNS Soft Tissue Neoplasm | Malignant CNS Soft Tissue Tumor | Malignant Central Nervous System Mesenchymal, Non-Meningothelial Tumor | Malignant Central Nervous System Soft Tissue Neoplasm | Malignant Central Nervous System Soft Tissue Tumor | Malignant Soft Tissue Neoplasm of CNS | Malignant Soft Tissue Neoplasm of Central Nervous System | Malignant Soft Tissue Neoplasm of the CNS | Malignant Soft Tissue Neoplasm of the Central Nervous System | Malignant Soft Tissue Tumor of CNS | Malignant Soft Tissue Tumor of Central Nervous System | Malignant Soft Tissue Tumor of the CNS | Malignant Soft Tissue Tumor of the Central Nervous System | Soft Tissue Cancer of Central Nervous System | Soft Tissue Cancer of the Central Nervous System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0153640","Malignant Cerebellar Neoplasm","C3569","Primary and secondary (metastatic) malignant tumors that occur in the cerebellum.  Histologic types include medulloblastomas, high grade (WHO Stage III or IV) cerebellar astrocytomas, lymphomas, gangliogliomas, gliosarcomas, and several other subtypes.  The most frequent malignant cerebellar neoplasm of childhood is medulloblastoma. In adults, metastases from other sites are relatively common. Clinical features include ataxia, headache, nausea, dizziness, nystagmus, diplopia, papilledema, etc.","Malignant Cerebellar Neoplasm | Cancer of Cerebellum | Cancer of the Cerebellum | Cerebellar Cancer | Cerebellar Neoplasm, Malignant | Cerebellar Tumor, Malignant | Malignant Cerebellar Neoplasms | Malignant Cerebellar Tumor | Malignant Neoplasm of Cerebellum | Malignant Neoplasm of the Cerebellum | Malignant Tumor of Cerebellum | Malignant Tumor of the Cerebellum | Malignant neoplasm of cerebellum",,,,,,,,,,,,,,,"40487143","Malignant neoplasm of cerebellum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153630","Malignant Choroid Neoplasm","C3566","A primary or metastatic malignant neoplasm that affects the choroid.","Malignant Choroid Neoplasm | Malignant Choroid Tumor | Malignant Neoplasm of Choroid | Malignant Neoplasm of the Choroid | Malignant Tumor of Choroid | Malignant Tumor of the Choroid | Malignant neoplasm of unspecified choroid",,,,,,,,,,,,,,,"4181479","Malignant tumor of choroid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153589","Malignant Clitoral Neoplasm","C3557","A malignant neoplasm that affects the clitoris.","Malignant Clitoral Neoplasm | Malignant Clitoral Tumor | Malignant Clitoris Neoplasm | Malignant Clitoris Tumor | Malignant Neoplasm of Clitoris | Malignant Neoplasm of the Clitoris | Malignant Tumor of Clitoris | Malignant Tumor of the Clitoris | Malignant neoplasm of clitoris",,,,,,,,,,,,,,,"4155168","Malignant neoplasm of clitoris",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0346629","Malignant Colorectal Neoplasm","C4978","A primary or metastatic malignant neoplasm that affects the colon or rectum.  Representative examples include carcinoma, lymphoma, and sarcoma.","Malignant Colorectal Neoplasm | Malignant Colorectal Tumor | Malignant Large Bowel Neoplasm | Malignant Large Bowel Tumor | Malignant Large Intestine Neoplasm | Malignant Large Intestine Tumor | Malignant Neoplasm of Large Bowel | Malignant Neoplasm of Large Intestine | Malignant Neoplasm of the Large Bowel | Malignant Neoplasm of the Large Intestine | Malignant Tumor of Large Bowel | Malignant Tumor of Large Intestine | Malignant Tumor of the Large Bowel | Malignant Tumor of the Large Intestine",,,,,,,,,,,,,,,"443396","Malignant tumor of large intestine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153629","Malignant Corneal Neoplasm","C3565","A primary or metastatic malignant neoplasm that affects the cornea.","Malignant Corneal Neoplasm | Malignant Cornea Neoplasm | Malignant Cornea Tumor | Malignant Corneal Tumor | Malignant Neoplasm of Cornea | Malignant Neoplasm of the Cornea | Malignant Tumor of Cornea | Malignant Tumor of the Cornea | Malignant neoplasm of unspecified cornea",,,,,,,,,,,,,,,"4181478","Malignant tumor of cornea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153644","Malignant Cranial Nerve Neoplasm","C3571","A primary or metastatic malignant neoplasm that affects a cranial nerve.","Malignant Cranial Nerve Neoplasm | Cranial Nerve Neoplasm, Malignant | Malignant Cranial Nerve Tumor | Malignant Neoplasm of Cranial Nerve | Malignant Neoplasm of the Cranial Nerve | Malignant Tumor of Cranial Nerve | Malignant Tumor of the Cranial Nerve | Malignant neoplasm of unspecified cranial nerve",,,,,,,,,,,,,,,"4095302","Malignant tumor of cranial nerve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153426","Malignant Duodenal Neoplasm","C9328","A primary or metastatic malignant neoplasm that affects the duodenum.  Representative examples include carcinoma, lymphoma, and sarcoma.","Malignant Duodenal Neoplasm | Malignant Duodenal Tumor | Malignant Neoplasm of Duodenum | Malignant Neoplasm of the Duodenum | Malignant Tumor of Duodenum | Malignant Tumor of the Duodenum | Malignant neoplasm of duodenum",,,,,,,,,,,,,,,"443386","Malignant tumor of duodenum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153569","Malignant Endocervical Neoplasm","C3553","A malignant neoplasm that affects the endocervix.","Malignant Endocervical Neoplasm | Malignant Endocervical Tumor | Malignant Endocervix Neoplasm | Malignant Endocervix Tumor | Malignant Neoplasm of Endocervix | Malignant Neoplasm of Uterine Endocervix | Malignant Neoplasm of the Endocervix | Malignant Neoplasm of the Uterine Endocervix | Malignant Tumor of Endocervix | Malignant Tumor of Uterine Endocervix | Malignant Tumor of the Endocervix | Malignant Tumor of the Uterine Endocervix | Malignant Uterine Endocervix Neoplasm | Malignant Uterine Endocervix Tumor | Malignant neoplasm of endocervix",,,,,,,,,,,,,,,"4095156|4157449","Malignant neoplasm of endocervical canal|Malignant neoplasm of endocervix",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0585946","Malignant Epiglottis Neoplasm","C4836","A malignant neoplasm that affects the epiglottis.  The vast majority of cases are squamous cell carcinomas.","Malignant Epiglottis Neoplasm | Malignant Epiglottic Neoplasm | Malignant Epiglottic Tumor | Malignant Epiglottis Tumor | Malignant Neoplasm of Epiglottis | Malignant Neoplasm of the Epiglottis | Malignant Tumor of Epiglottis | Malignant Tumor of the Epiglottis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0349576","Malignant External Ear Neoplasm","C4653","A malignant neoplasm that affects the external ear.  Representative examples include squamous cell carcinoma, basal cell carcinoma, and ceruminous adenocarcinoma.","Malignant External Ear Neoplasm | Malignant External Auditory Canal Neoplasm | Malignant External Ear Tumor | Malignant Neoplasm of External Ear | Malignant Neoplasm of the External Ear | Malignant Tumor of External Ear | Malignant Tumor of the External Ear",,,,,,,,,,,,,,,"4082011","Malignant tumor of external ear",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153453","Malignant Extrahepatic Bile Duct Neoplasm","C7483","A primary or metastatic malignant neoplasm that affects the extrahepatic bile ducts.  Representative examples include carcinoma and sarcoma.","Malignant Extrahepatic Bile Duct Neoplasm | Malignant Extrahepatic Bile Duct Tumor | Malignant Neoplasm of Extrahepatic Bile Duct | Malignant Neoplasm of the Extrahepatic Bile Duct | Malignant Tumor of Extrahepatic Bile Duct | Malignant Tumor of the Extrahepatic Bile Duct | Malignant neoplasm of extrahepatic bile duct",,,,,,,,,,,,,,,"4177105","Malignant tumor of extrahepatic bile duct",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448349","Malignant Eyelid Neoplasm","C6786","A primary or metastatic malignant neoplasm that affects the eyelid.","Malignant Eyelid Neoplasm | Malignant Eyelid Tumor | Malignant Neoplasm of Eyelid | Malignant Neoplasm of the Eyelid | Malignant Tumor of Eyelid | Malignant Tumor of the Eyelid",,,,,,,,,,,,,,,"4338758","Malignant tumor of eyelid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054579","Malignant Fibrohistiocytic Neoplasm","C121500","A fibrohistiocytic neoplasm that metastasizes to other anatomic sites.","Malignant Fibrohistiocytic Neoplasm | ",,,,,,,,,,,,,,,"37152447","Malignant fibrohistiocytic neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153368","Malignant Floor of the Mouth Neoplasm","C9318","A primary or metastatic malignant neoplasm that affects the floor of the mouth.  The majority of cases are carcinomas.","Malignant Floor of the Mouth Neoplasm | Malignant Floor of Mouth Neoplasm | Malignant Floor of Mouth Tumor | Malignant Floor of the Mouth Tumor | Malignant Neoplasm of Floor of Mouth | Malignant Neoplasm of the Floor of the Mouth | Malignant Tumor of Floor of Mouth | Malignant Tumor of the Floor of the Mouth | Malignant neoplasm of floor of mouth, unspecified",,,,,,,,,,,,,,,"4177101","Malignant tumor of floor of mouth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0751569","Malignant Genitourinary System Neoplasm","C156484","A primary or metastatic malignant neoplasm that affects the genitourinary system.","Malignant Genitourinary System Neoplasm | Genitourinary Cancer | Genitourinary System Cancer | Malignant Genitourinary Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334229","Malignant Giant Cell Neoplasm","C4090","A malignant neoplasm characterized by then presence of atypical giant cells.","Malignant Giant Cell Neoplasm | GIANT CELL TUMOR, MALIGNANT | Malignant Giant Cell Tumor | Malignant tumor, giant cell type","8003/3","Malignant tumor, giant cell type",,,,,,,,,,,,,"4223100","Malignant tumor, giant cell type",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0153364","Malignant Gingival Neoplasm","C9317","A primary or metastatic malignant neoplasm that affects the gums.","Malignant Gingival Neoplasm | Malignant Gingival Tumor | Malignant Gum Neoplasm | Malignant Gum Tumor | Malignant Neoplasm of Gingiva | Malignant Neoplasm of Gum | Malignant Neoplasm of the Gingiva | Malignant Neoplasm of the Gum | Malignant Tumor of Gingiva | Malignant Tumor of Gum | Malignant Tumor of the Gingiva | Malignant Tumor of the Gum | Malignant neoplasm of gum, unspecified",,,,,,,,,,,,,,,"4178963","Malignant tumor of gum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153483","Malignant Glottis Neoplasm","C3544","A malignant neoplasm that affects the glottic area of the larynx.  The vast majority of cases represent squamous cell carcinomas.","Malignant Glottis Neoplasm | Malignant Glottis Tumor | Malignant Neoplasm of Glottis | Malignant Neoplasm of the Glottis | Malignant Tumor of Glottis | Malignant Tumor of the Glottis | Malignant neoplasm of glottis",,,,,,,,,,,,,,,"4092211","Malignant tumor of glottis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153375","Malignant Hard Palate Neoplasm","C3528","A primary or metastatic malignant neoplasm that affects the hard palate.","Malignant Hard Palate Neoplasm | Malignant Hard Palate Tumor | Malignant Neoplasm of Hard Palate | Malignant Neoplasm of the Hard Palate | Malignant Tumor of Hard Palate | Malignant Tumor of the Hard Palate | Malignant neoplasm of hard palate",,,,,,,,,,,,,,,"4180787","Malignant tumor of hard palate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0854176","Malignant Hepatobiliary Neoplasm","C8609","A malignant neoplasm that affects the liver parenchyma, bile ducts, and gallbladder.  Representative examples include hepatocellular carcinoma, intrahepatic and extrahepatic cholangiocarcinoma, and gallbladder carcinoma.","Malignant Hepatobiliary Neoplasm | Malignant Hepato-Biliary Neoplasm | Malignant Liver and Biliary Neoplasm | Malignant Liver and Biliary System Neoplasm | Malignant neoplasm of biliary tract, unspecified",,,,,,,,,,,,,,,"4181345","Malignant tumor of biliary tract",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL371823","Malignant Hypopharyngeal Neoplasm","C7190","A primary or metastatic malignant neoplasm that affects the hypopharynx.","Malignant Hypopharyngeal Neoplasm | Malignant Hypopharyngeal Tumor | Malignant Neoplasm of Hypopharynx | Malignant Neoplasm of the Hypopharynx | Malignant Tumor of Hypopharynx | Malignant Tumor of the Hypopharynx | Malignant neoplasm of hypopharynx, unspecified",,,,,,,,,,,,,,,"4181342","Malignant tumor of hypopharynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0346627","Malignant Intestinal Neoplasm","C4572","A primary or metastatic malignant neoplasm involving the small intestine, large intestine, or both.  Representative examples are carcinomas, lymphomas, and sarcomas.","Malignant Intestinal Neoplasm | Bowel Cancer | Cancer of Intestine | Cancer of the Intestine | Intestinal Cancer | Intestinal Neoplasms, Malignant | Intestinal Tumors, Malignant | Malignant Intestinal Neoplasms | Malignant Intestinal Tumor | Malignant Intestinal Tumors | Malignant Intestine Neoplasm | Malignant Intestine Tumor | Malignant Neoplasm of Intestine | Malignant Neoplasm of the Intestine | Malignant Tumor of Intestine | Malignant Tumor of the Intestine | Malignant neoplasm of intestinal tract, part unspecified",,,,,,,,,,,,,,,"443398","Malignant tumor of intestine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0496814","Malignant Labia Majora Neoplasm","C7638","A malignant neoplasm that affects the labia majora.","Malignant Labia Majora Neoplasm | Malignant Labia Majora Tumor | Malignant Neoplasm of Labia Majora | Malignant Neoplasm of the Labia Majora | Malignant Tumor of Labia Majora | Malignant Tumor of the Labia Majora | Malignant neoplasm of labium majus",,,,,,,,,,,,,,,"4178970","Malignant neoplasm of labia majora",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007107","Malignant Laryngeal Neoplasm","C7484","A primary or metastatic malignant neoplasm involving the larynx.  The majority are carcinomas.","Malignant Laryngeal Neoplasm | Malignant Laryngeal Tumor | Malignant Larynx Neoplasm | Malignant Larynx Tumor | Malignant Neoplasm of Larynx | Malignant Neoplasm of the Larynx | Malignant Tumor of Larynx | Malignant Tumor of the Larynx | Malignant neoplasm of larynx, unspecified",,,,,,,,,,,,,,,"4178968","Malignant tumor of larynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153340","Malignant Lip Neoplasm","C7485","A primary or metastatic malignant neoplasm involving the lip.","Malignant Lip Neoplasm | Malignant Lip Tumor | Malignant Neoplasm of Lip | Malignant Neoplasm of the Lip | Malignant Tumor of Lip | Malignant Tumor of the Lip | Malignant neoplasm of lip, unspecified",,,,,,,,,,,,,,,"4180779","Malignant tumor of lip",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0496763","Malignant Major Salivary Gland Neoplasm","C4762","A primary or metastatic malignant neoplasm affecting the major salivary glands.  Representative examples include carcinoma, lymphoma, and sarcoma.","Malignant Major Salivary Gland Neoplasm | Malignant Major Salivary Gland Tumor | Malignant Neoplasm of Major Salivary Gland | Malignant Neoplasm of the Major Salivary Gland | Malignant Tumor of Major Salivary Gland | Malignant Tumor of the Major Salivary Gland | Malignant neoplasm of major salivary gland, unspecified",,,,,,,,,,,,,,,"4181333","Malignant tumor of major salivary gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1541840","Malignant Mastocytosis","C8991","A group of malignant mast cell disorders including aggressive systemic mastocytosis, mast cell leukemia, mast cell sarcoma, and systemic mastocytosis with an associated myeloid neoplasm. Individuals with advanced systemic mastocytosis have a reduced life expectancy, with median survival measured in months to years.","Malignant Mastocytosis | MAST CELL TUMOR, MALIGNANT | Malignant mast cell neoplasm, unspecified | Malignant mast cell tumor | Malignant mastocytosis","9741/3","Malignant mastocytosis",,,,,,,,,,,,,"40515091","Malignant mastocytosis",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0153476","Malignant Maxillary Sinus Neoplasm","C3540","A primary or metastatic malignant neoplasm involving the maxillary sinus.","Malignant Maxillary Sinus Neoplasm | Malignant Maxillary Sinus Tumor | Malignant Neoplasm of Maxillary Sinus | Malignant Neoplasm of the Maxillary Sinus | Malignant Tumor of Maxillary Sinus | Malignant Tumor of the Maxillary Sinus | Malignant neoplasm of maxillary sinus",,,,,,,,,,,,,,,"4181347","Malignant tumor of maxillary sinus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0496788","Malignant Middle Ear Neoplasm","C4765","A malignant neoplasm that affects the middle ear.  Representative examples include adenocarcinoma and squamous cell carcinoma.","Malignant Middle Ear Neoplasm | Malignant Middle Ear Tumor | Malignant Neoplasm of Middle Ear | Malignant Neoplasm of the Middle Ear | Malignant Tumor of Middle Ear | Malignant Tumor of the Middle Ear | Malignant neoplasm of middle ear",,,,,,,,,,,,,,,"4178957","Malignant tumor of middle ear",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0684743","Malignant Muscle Neoplasm","C4883","A malignant neoplasm affecting the skeletal or smooth muscles.  Malignant neoplasms arising from the skeletal muscles are called rhabdomyosarcomas.  Malignant neoplasms arising from the smooth muscles are called leiomyosarcomas.","Malignant Muscle Neoplasm | Malignant Muscle Tumor | Malignant Neoplasm of Muscle | Malignant Neoplasm of the Muscle | Malignant Tumor of Muscle | Malignant Tumor of the Muscle | Myosarcoma","8895/3","Myosarcoma",,,,,,,,,,,,,"4177239","Malignant tumor of muscle",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0728864","Malignant Nasal Cavity Neoplasm","C4918","A malignant neoplasm affecting the nasal cavity.  Representative examples include carcinoma and lymphoma.","Malignant Nasal Cavity Neoplasm | Malignant Nasal Cavity Tumor | Malignant Neoplasm of Nasal Cavity | Malignant Neoplasm of the Nasal Cavity | Malignant Tumor of Nasal Cavity | Malignant Tumor of the Nasal Cavity | Malignant neoplasm of nasal cavity",,,,,,,,,,,,,,,"4177107","Malignant tumor of nasal cavity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153392","Malignant Nasopharyngeal Neoplasm","C9321","A primary or metastatic malignant neoplasm involving the nasopharynx.","Malignant Nasopharyngeal Neoplasm | Malignant Nasopharyngeal Tumor | Malignant Neoplasm of Nasopharynx | Malignant Neoplasm of the Nasopharynx | Malignant Tumor of Nasopharynx | Malignant Tumor of the Nasopharynx | Malignant neoplasm of nasopharynx, unspecified",,,,,,,,,,,,,,,"4095312","Malignant tumor of nasopharynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153511","Malignant Neoplasm of Mandible","C35178","A primary or metastatic malignant neoplasm that affects the mandible.","Malignant Neoplasm of Mandible | Malignant Neoplasm of Lower Jaw Bone | Malignant Neoplasm of Lower Jaw Bone | Malignant neoplasm of mandible",,,,,,,,,,,,,,,"40490993","Malignant neoplasm of mandible",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0496775","Malignant Neoplasm of the Abdominal Esophagus","C4764","A primary or metastatic malignant neoplasm involving the abdominal region of the esophagus.","Malignant Neoplasm of the Abdominal Esophagus | Malignant Neoplasm of Abdominal Esophagus | Malignant Tumor of Abdominal Esophagus | Malignant Tumor of the Abdominal Esophagus",,,,,,,,,,,,,,,"4095316","Malignant tumor of abdominal part of esophagus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0496773","Malignant Neoplasm of the Cervical Esophagus","C4763","A primary or metastatic malignant neoplasm involving the cervical region of the esophagus.","Malignant Neoplasm of the Cervical Esophagus | Malignant Neoplasm of Cervical Esophagus",,,,,,,,,,,,,,,"4094854","Malignant tumor of cervical part of esophagus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153415","Malignant Neoplasm of the Lower Third of the Esophagus","C3535","A primary or metastatic malignant neoplasm involving the lower third segment of the esophagus.","Malignant Neoplasm of the Lower Third of the Esophagus | Malignant Lower Third of Esophagus Neoplasm | Malignant Lower Third of Esophagus Tumor | Malignant Lower Third of the Esophagus Neoplasm | Malignant Lower Third of the Esophagus Tumor | Malignant Neoplasm of Distal Third of Esophagus | Malignant Neoplasm of Lower Third of Esophagus | Malignant Neoplasm of the Distal Third of the Esophagus | Malignant Tumor of Distal Third of Esophagus | Malignant Tumor of Lower Third of Esophagus | Malignant Tumor of the Distal Third of the Esophagus | Malignant Tumor of the Lower Third of the Esophagus | Malignant neoplasm of lower third of esophagus",,,,,,,,,,,,,,,"4089656","Malignant tumor of lower third of esophagus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0348375","Malignant Meningeal Neoplasm","C4628","A primary or metastatic malignant tumor occurring in the meninges, which surround the brain and spinal cord.  The most common are meningiomas.","Malignant Meningeal Neoplasm | Cancer of Meninges | Cancer of the Meninges | Malignant Meningeal Tumor | Malignant Meninges Neoplasm | Malignant Meninges Tumor | Malignant Neoplasm of Meninges | Malignant Neoplasm of the Meninges | Malignant Neoplasm of the Meninges | Malignant Neoplasms of Meninges | Malignant Tumor of Meninges | Malignant Tumor of the Meninges | Malignant neoplasm of meninges, unspecified | Meningeal Cancer | Meningeal Tumors, Malignant",,,,,,,,,,,,,,,"4189335","Malignant meningeal neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153414","Malignant Neoplasm of the Middle Third of the Esophagus","C3534","A primary or metastatic malignant neoplasm involving the middle third segment of the esophagus.","Malignant Neoplasm of the Middle Third of the Esophagus | Malignant Middle Third of Esophagus Neoplasm | Malignant Middle Third of Esophagus Tumor | Malignant Middle Third of the Esophagus Neoplasm | Malignant Middle Third of the Esophagus Tumor | Malignant Neoplasm of Middle Third of Esophagus | Malignant Tumor of Middle Third of Esophagus | Malignant Tumor of the Middle Third of the Esophagus | Malignant neoplasm of middle third of esophagus",,,,,,,,,,,,,,,"4092060","Malignant tumor of middle third of esophagus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153411","Malignant Neoplasm of the Thoracic Esophagus","C3532","A primary or metastatic malignant neoplasm involving the thoracic region of the esophagus.","Malignant Neoplasm of the Thoracic Esophagus | Malignant Neoplasm of Thoracic Esophagus",,,,,,,,,,,,,,,"4092059","Malignant tumor of thoracic part of esophagus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153413","Malignant Neoplasm of the Upper Third of the Esophagus","C3533","A primary or metastatic malignant neoplasm involving the upper third segment of the esophagus.","Malignant Neoplasm of the Upper Third of the Esophagus | Malignant Neoplasm of Proximal Third of Esophagus | Malignant Neoplasm of Upper Third of Esophagus | Malignant Neoplasm of the Proximal Third of the Esophagus | Malignant Tumor of Proximal Third of Esophagus | Malignant Tumor of Upper Third of Esophagus | Malignant Tumor of the Proximal Third of the Esophagus | Malignant Tumor of the Upper Third of the Esophagus | Malignant neoplasm of upper third of esophagus",,,,,,,,,,,,,,,"4094855","Malignant tumor of upper third of esophagus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334224","Malignant Neoplasm, Uncertain Whether Primary or Metastatic","C65153","A malignant neoplasm in which the examined tissue can not be determined with certainty if it represents the primary site of tumor growth or tumor spread from another anatomic site.","Malignant Neoplasm, Uncertain Whether Primary or Metastatic | Neoplasm, malignant, uncertain whether primary or metastatic","8000/9","Neoplasm, malignant, uncertain whether primary or metastatic",,,,,,,,,,,,,"4268747","Neoplasm, malignant, uncertain whether primary or metastatic",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0497549","Malignant Nervous System Neoplasm","C4788","A primary or metastatic malignant neoplasm involving the nervous system.","Malignant Nervous System Neoplasm | Malignant Neoplasm of Nervous System | Malignant Neoplasm of the Nervous System | Malignant Nervous System Tumor | Malignant Tumor of Nervous System | Malignant Tumor of the Nervous System | Nervous System Neoplasms, Malignant",,,,,,,,,,,,,,,"4157331","Malignant neoplasm of nervous system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0859086","Malignant Nipple Neoplasm","C5213","A malignant neoplasm that affects the area of the nipple.","Malignant Nipple Neoplasm | Malignant Neoplasm of Nipple | Malignant Neoplasm of the Nipple | Malignant Nipple Tumor | Malignant Tumor of Nipple | Malignant Tumor of the Nipple",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448458","Malignant Oral Neoplasm","C9316","A primary or metastatic malignant neoplasm that affects the lip and/or oral cavity.  The majority of cases are carcinomas.","Malignant Oral Neoplasm | Malignant Lip and Oral Cavity Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0153626","Malignant Orbit Neoplasm","C3562","A primary or metastatic malignant neoplasm involving the orbit.","Malignant Orbital Neoplasm | Malignant Neoplasm of Orbit | Malignant Neoplasm of the Orbit | Malignant Orbit Neoplasm | Malignant Orbit Neoplasm | Malignant Orbit Tumor | Malignant Orbital Neoplasm | Malignant Orbital Tumor | Malignant Tumor of Orbit | Malignant Tumor of the Orbit | Malignant neoplasm of unspecified orbit",,,,,,,,,,,,,,,"4180906","Malignant tumor of orbit",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153382","Malignant Oropharyngeal Neoplasm","C7398","A primary or metastatic malignant neoplasm that affects the oropharynx.","Malignant Oropharyngeal Neoplasm | Malignant Neoplasm of Oropharynx | Malignant Neoplasm of the Oropharynx | Malignant Oropharyngeal Tumor | Malignant Tumor of Oropharynx | Malignant Tumor of the Oropharynx | Malignant neoplasm of oropharynx, unspecified",,,,,,,,,,,,,,,"4181338","Malignant tumor of oropharynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153378","Malignant Palate Neoplasm","C3530","A primary or metastatic malignant neoplasm that affects the hard palate, soft palate, or uvula.","Malignant Palate Neoplasm | Cancer of Palate | Cancer of the Palate | Malignant Neoplasm of Palate | Malignant Neoplasm of the Palate | Malignant Palate Tumor | Malignant Tumor of Palate | Malignant Tumor of the Palate | Malignant neoplasm of palate, unspecified | Palate Cancer",,,,,,,,,,,,,,,"4178964","Malignant tumor of palate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1533592","Metastatic Paraganglioma","C8559","A paraganglioma that metastasizes to regional or distant anatomic sites.  Extraadrenal paragangliomas have a higher tendency to metastasize, as compared to pheochromocytomas.  Common sites of metastasis include the lymph nodes, lungs, bones, and liver.","Metastatic Paraganglioma | Malignant Neoplasm of Paraganglion | Malignant Neoplasm of the Paraganglion | Malignant Paraganglioma | Malignant Paraganglioma | Malignant Paraganglion Neoplasm | Malignant Paraganglion Tumor | Malignant Paraganglionic Neoplasm | Malignant Paraganglionic Tumor | Malignant Tumor of Paraganglion | Malignant Tumor of the Paraganglion | PARAGANGLIOMA, MALIGNANT | Paraganglioma, malignant | Paraganglion Neoplasm, Malignant",,,,,,,,,,,,,,,"4321605","Paraganglioma, malignant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153474","Malignant Paranasal Sinus Neoplasm","C7487","A primary or metastatic malignant neoplasm involving the paranasal sinuses.","Malignant Paranasal Sinus Neoplasm | Malignant Accessory Sinus Neoplasm | Malignant Accessory Sinus Tumor | Malignant Neoplasm of Accessory Sinus | Malignant Neoplasm of Paranasal Sinus | Malignant Neoplasm of the Accessory Sinus | Malignant Neoplasm of the Paranasal Sinus | Malignant Paranasal Sinus Tumor | Malignant Tumor of Accessory Sinus | Malignant Tumor of Paranasal Sinus | Malignant Tumor of the Accessory Sinus | Malignant Tumor of the Paranasal Sinus | Malignant neoplasm of accessory sinus, unspecified",,,,,,,,,,,,,,,"4181486","Malignant tumor of nasal sinuses",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0747273","Malignant Parotid Gland Neoplasm","C3525","A primary or metastatic malignant neoplasm involving the parotid gland.  Representative examples include carcinoma, malignant mixed tumor, and non-Hodgkin lymphoma.","Malignant Parotid Gland Neoplasm | Cancer of Parotid | Cancer of Parotid Gland | Cancer of the Parotid | Cancer of the Parotid Gland | Malignant Neoplasm of Parotid | Malignant Neoplasm of Parotid Gland | Malignant Neoplasm of the Parotid | Malignant Neoplasm of the Parotid Gland | Malignant Parotid Gland Tumor | Malignant Parotid Neoplasm | Malignant Parotid Tumor | Malignant Tumor of Parotid | Malignant Tumor of Parotid Gland | Malignant Tumor of the Parotid | Malignant Tumor of the Parotid Gland | Malignant neoplasm of parotid gland | Parotid Gland Cancer | parotid gland cancer",,,,,,,,,,,,,,,"4180784","Malignant tumor of parotid gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0751416","Malignant Pelvic Neoplasm","C156715","A primary or metastatic malignant neoplasm that affects the organs and structures of the pelvis.","Malignant Pelvic Neoplasm | Malignant neoplasm pelvis | Pelvis Cancer",,,,,,,,,,,,,,,"4177236","Malignant tumor of pelvis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153601","Malignant Penile Neoplasm","C7547","A primary or metastatic malignant neoplasm that affects the penis.  Representative examples include penile carcinoma and penile sarcoma.","Malignant Penile Neoplasm | Malignant Neoplasm of Penis | Malignant Neoplasm of the Penis | Malignant Penile Tumor | Malignant Tumor of Penis | Malignant Tumor of the Penis | Malignant neoplasm of penis, unspecified",,,,,,,,,,,,,,,"4181488","Malignant tumor of penis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL935862","Malignant Peritoneal and Retroperitoneal Neoplasm","C156711","A primary or metastatic malignant neoplasm that affects the peritoneum and/or retroperitoneum.","Malignant Peritoneal and Retroperitoneal Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0153405","Malignant Pharyngeal Neoplasm","C7545","A primary or metastatic malignant neoplasm that affects the pharynx.","Malignant Pharyngeal Neoplasm | Malignant Pharyngeal Tumor | Malignant Pharynx Neoplasm | Malignant Pharynx Tumor | Malignant Tumor of Pharynx | Malignant Tumor of the Pharynx | Malignant neoplasm of pharynx, unspecified",,,,,,,,,,,,,,,"4177243","Malignant tumor of pharynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0496842","Malignant Pituitary Gland Neoplasm","C4769","A primary or metastatic malignant neoplasm affecting the pituitary gland.","Malignant Pituitary Gland Neoplasm | Malignant Neoplasm of Pituitary | Malignant Neoplasm of Pituitary Gland | Malignant Neoplasm of the Pituitary | Malignant Neoplasm of the Pituitary Gland | Malignant Pituitary Gland Tumor | Malignant Pituitary Neoplasm | Malignant Pituitary Tumor | Malignant Tumor of Pituitary | Malignant Tumor of Pituitary Gland | Malignant Tumor of the Pituitary | Malignant Tumor of the Pituitary Gland | Malignant neoplasm of pituitary gland | Pituitary Neoplasms, Malignant | Pituitary Tumor, Malignant",,,,,,,,,,,,,,,"4177235","Malignant tumor of pituitary gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153572","Malignant Placental Neoplasm","C3555","A primary or metastatic neoplasm that affects the placenta.","Malignant Placental Neoplasm | DECIDUOMA, MALIGNANT | Malignant Neoplasm of Placenta | Malignant Neoplasm of the Placenta | Malignant Placenta Neoplasm | Malignant Placenta Tumor | Malignant Placental Tumor | Malignant Tumor of Placenta | Malignant Tumor of the Placenta | Malignant neoplasm of placenta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971042","Localized Metastasis","C162650","The focal spread of a malignant tumor in a single anatomic site.","Localized Metastasis | Focal Metastasis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971041","Widespread Metastasis","C162651","The spread of a malignant tumor in multiple distant anatomic sites.","Widespread Metastasis | Extensive Metastasis | Non-Focal Metastasis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512837","Perinatal Depression","C116313","A condition characterized by cardiorespiratory and neurological depression following birth.","Perinatal Depression | Birth Asphyxia | Birth Depression | Fetal Asphyxia | Intrapartum Asphyxia | Perinatal Asphyxia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030528","Paratyphoid Fever","C34897","A condition resembling typhoid fever that is caused by infection by Salmonella enterica serovar Parathyphi.","Paratyphoid Fever | ",,,,,,,,,,,,,,,"195177","Paratyphoid fever",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030446","Paralytic Ileus","C93045","An ileus caused by abdominal or pelvic surgery, infections, disorders that affect the muscles and nerves, and medications.  Signs and symptoms include those of intestinal obstruction.","Paralytic Ileus | paralytic ileus",,,,,,,,,,,,,,,"192357","Paralytic ileus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937623","Non-infective Inflammatory Bowel Disease","C157936","A disease of the intestines that is inflammatory but not infectious.","Non-infective Inflammatory Bowel Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971039","ISUP Grade Pattern 1","C162654","Circumscribed nodule of closely packed but separate, uniform, rounded to oval, medium-sized acini (larger glands than pattern 3).","ISUP Grade Pattern 1 | Grade Group 1 | Pattern 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971038","ISUP Grade Pattern 2","C162655","Like pattern 1, fairly circumscribed, yet at the edge of the tumor nodule there may be minimal infiltration; Glands are more loosely arranged and not quite as uniform as Gleason pattern 1.","ISUP Grade Pattern 2 | Grade Group 2 | Pattern 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971037","ISUP Grade Pattern 3","C162656","Discrete glandular units; typically smaller glands than seen in Gleason pattern 1 or 2; infiltrates in and amongst nonneoplastic prostate acini; marked variation in size and shape; smoothly circumscribed small cribriform nodules of tumor.","ISUP Grade Pattern 3 | Grade Group 3 | Pattern 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971134","ISUP Grade Pattern 4","C162657","Fused microacinar glands; ill-defined glands with poorly formed glandular lumina; large cribriform glands; cribriform glands with an irregular border; hypernephromatoid.","ISUP Grade Pattern 4 | Grade Group 4 | Pattern 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971133","ISUP Grade Pattern 5","C162658","Essentially no glandular differentiation, composed of solid sheets, cords, or single cells; comedocarcinoma with central necrosis surrounded by papillary, cribriform, or solid masses.","ISUP Grade Pattern 5 | Grade Group 5 | Pattern 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033677","Protein Energy Malnutrition","C34952","A nutritional deficit that is caused by inadequate protein or calorie intake.","Protein Energy Malnutrition | Unspecified protein-calorie malnutrition",,,,,,,,,,,,,,,"4079894|4156515|4157389|433163","Dystrophy due to malnutrition|Malnutrition (calorie)|Protein deficiency disease|Deficiency of macronutrients",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--|--"
"CL388421","Tandem Hematopoietic Stem Cell Transplantation","C116469","A type of autologous stem cell transplant, during which the patient receives two sequential courses of high-dose chemotherapy with stem cell transplant.","Tandem Hematopoietic Stem Cell Transplantation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4017769","Self-Injury","C118206","Self-inflicted harm without the intent to die.","Self-Injury | Self-Harm | Self-harm",,,,,,,,,,,,,,,"4092411","Self-injurious behavior",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1744708","Tracheal Carcinoma","C9347","Malignant epithelial neoplasm arising from the tracheal mucosa.","Tracheal Carcinoma | Cancer of Trachea | Cancer of the Trachea | Carcinoma of Trachea | Carcinoma of the Trachea | Trachea Cancer | Trachea Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540677","Treatment-Emergent Adverse Event","C142733","A situation that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state. (ICH)","Treatment-Emergent Adverse Event | Adverse Effects of Medical Treatment | treatment-emergent adverse event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041466","Typhoid Fever","C35089","A bacterial infectious disorder contracted by consumption of food or drink contaminated with Salmonella typhi. This disorder is common in developing countries and can be treated with antibiotics.","Typhoid Fever | ",,,,,,,,,,,,,,,"192819","Typhoid fever",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1336827","Tropical Disease","C28356","Infectious and parasitic diseases endemic in tropical and subtropical zones, including Chagas' disease, leishmaniasis, leprosy, malaria, onchocerciasis, schistosomiasis, sleeping sickness, yellow fever, and others; often water- or insect-borne.","Tropical Disease | Tropical Diseases",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3553271","Urolithiasis","C114688","Stone(s) within the urinary tract.","Urolithiasis | Urinary Stones",,,,,,,,,,,,,,,"4319447","Urolithiasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0080276","Genitourinary System Disorder","C156660","A non-neoplastic or neoplastic disorder that affects the genitourinary system.","Genitourinary System Disorder | Genitourinary Disorder | Urogenital Disease",,,,,,,,,,,,,,,"4171379","Disorder of the genitourinary system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042140","Uterine Prolapse","C35108","The sliding of the uterus into the vaginal canal. It results from the weakening of the pelvic floor muscles and ligaments and is usually seen in postmenopausal women with several vaginal deliveries. Clinical manifestations include sensation of heaviness in the pelvis, urinary difficulties, and tissue protrusion from the vagina.","Uterine Prolapse | Genital Prolapse",,,,,,,,,,,,,,,"4092565","Uterine prolapse",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL951383","Bladder, NOS","C159545","An unspecified area of the bladder.","Bladder, NOS | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0496769","Malignant Postcricoid Neoplasm","C9323","A primary or metastatic malignant neoplasm that affects the postcricoid region.","Malignant Postcricoid Neoplasm | Malignant Neoplasm of Postcricoid Area | Malignant Neoplasm of the Postcricoid Area | Malignant Postcricoid Tumor | Malignant Tumor of Postcricoid Area | Malignant Tumor of the Postcricoid Area",,,,,,,,,,,,,,,"4177104","Malignant tumor of postcricoid region",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153350","Malignant Posterior Tongue Neoplasm","C3524","A primary or metastatic malignant neoplasm that affects the base of the tongue.","Malignant Posterior Tongue Neoplasm | Malignant Base of Tongue Neoplasm | Malignant Base of Tongue Tumor | Malignant Base of the Tongue Neoplasm | Malignant Base of the Tongue Tumor | Malignant Neoplasm of Base of Tongue | Malignant Neoplasm of Posterior Tongue | Malignant Neoplasm of the Base of the Tongue | Malignant Neoplasm of the Posterior Tongue | Malignant Posterior Tongue Tumor | Malignant Tumor of Base of Tongue | Malignant Tumor of Posterior Tongue | Malignant Tumor of the Base of the Tongue | Malignant Tumor of the Posterior Tongue | Malignant neoplasm of base of tongue",,,,,,,,,,,,,,,"4181332","Malignant tumor of base of tongue",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153400","Malignant Pyriform Fossa Neoplasm","C3531","A primary or metastatic malignant neoplasm that affects the pyriform sinus.","Malignant Pyriform Fossa Neoplasm | Malignant Neoplasm of Pyriform Fossa | Malignant Neoplasm of Pyriform Sinus | Malignant Neoplasm of the Pyriform Fossa | Malignant Neoplasm of the Pyriform Sinus | Malignant Pyriform Fossa Tumor | Malignant Pyriform Sinus Neoplasm | Malignant Pyriform Sinus Tumor | Malignant Tumor of Pyriform Fossa | Malignant Tumor of Pyriform Sinus | Malignant Tumor of the Pyriform Fossa | Malignant Tumor of the Pyriform Sinus | Malignant neoplasm of pyriform sinus",,,,,,,,,,,,,,,"4180789","Malignant tumor of pyriform fossa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153443","Malignant Rectosigmoid Neoplasm","C7420","A primary or metastatic malignant neoplasm that affects the rectosigmoid area.  Representative examples include carcinoma, lymphoma, and sarcoma.","Malignant Rectosigmoid Neoplasm | Malignant Neoplasm of Rectosigmoid Junction | Malignant Neoplasm of the Rectosigmoid Junction | Malignant Rectosigmoid Tumor | Malignant Tumor of Rectosigmoid Junction | Malignant Tumor of the Rectosigmoid Junction | Malignant neoplasm of rectosigmoid junction",,,,,,,,,,,,,,,"4180792","Malignant tumor of rectosigmoid junction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153618","Malignant Renal Pelvis Neoplasm","C7525","A primary or metastatic malignant neoplasm that affects the renal pelvis.","Malignant Renal Pelvis Neoplasm | Malignant Neoplasm of Renal Pelvis | Malignant Neoplasm of the Renal Pelvis | Malignant Renal Pelvis Tumor | Malignant Tumor of Renal Pelvis | Malignant Tumor of the Renal Pelvis | Malignant neoplasm of unspecified renal pelvis",,,,,,,,,,,,,,,"4181357","Malignant tumor of renal pelvis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0346616","Malignant Respiratory System Neoplasm","C4571","A primary or metastatic malignant neoplasm that affects the lung parenchyma, bronchial tree, or trachea.  Representative examples include lung carcinoma, carcinoid tumor, lung lymphoma, lung sarcoma, and tracheal carcinoma.","Malignant Respiratory System Neoplasm | Malignant Respiratory Tract Neoplasm | Malignant Respiratory Tract Neoplasm | Malignant neoplasm of unspecified part of unspecified bronchus or lung",,,,,,,,,,,,,,,"40493428","Malignant neoplasm of respiratory system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024622","Malignant Retinal Neoplasm","C3216","A primary or metastatic malignant neoplasm that affects the retina.","Malignant Retinal Neoplasm | Malignant Neoplasm of Retina | Malignant Neoplasm of the Retina | Malignant Retina Neoplasm | Malignant Retina Tumor | Malignant Retinal Tumor | Malignant Tumor of Retina | Malignant Tumor of the Retina | Malignant neoplasm of unspecified retina",,,,,,,,,,,,,,,"4178973","Malignant tumor of retina",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153465","Malignant Retroperitoneal Neoplasm","C3537","A primary or metastatic malignant neoplasm involving the retroperitoneum.  The vast majority of cases are carcinomas, lymphomas, or sarcomas.","Malignant Retroperitoneal Neoplasm | Malignant neoplasm of retroperitoneum",,,,,,,,,,,,,,,"4180794","Malignant retroperitoneal tumor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153604","Malignant Scrotal Neoplasm","C3560","A primary or metastatic malignant neoplasm affecting the scrotum.","Malignant Scrotal Neoplasm | Malignant Neoplasm of Scrotum | Malignant Neoplasm of the Scrotum | Malignant Scrotal Tumor | Malignant Tumor of Scrotum | Malignant Tumor of the Scrotum | Malignant neoplasm of scrotum",,,,,,,,,,,,,,,"4178971","Malignant tumor of scrotum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153425","Malignant Small Intestinal Neoplasm","C7523","A primary or metastatic malignant neoplasm involving the small intestine.","Malignant Small Intestinal Neoplasm | Malignant Neoplasm of Small Bowel | Malignant Neoplasm of Small Intestine | Malignant Neoplasm of the Small Bowel | Malignant Neoplasm of the Small Intestine | Malignant Small Bowel Neoplasm | Malignant Small Bowel Tumor | Malignant Small Intestine Neoplasm | Malignant Small Intestine Tumor | Malignant Tumor of Small Bowel | Malignant Tumor of Small Intestine | Malignant Tumor of the Small Bowel | Malignant Tumor of the Small Intestine | Malignant neoplasm of small intestine, unspecified",,,,,,,,,,,,,,,"443397","Malignant tumor of small intestine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153376","Malignant Soft Palate Neoplasm","C3529","A primary or metastatic malignant neoplasm that affects the soft palate.","Malignant Soft Palate Neoplasm | Malignant Neoplasm of Soft Palate | Malignant Neoplasm of the Soft Palate | Malignant Soft Palate Tumor | Malignant Tumor of Soft Palate | Malignant Tumor of the Soft Palate | Malignant neoplasm of soft palate",,,,,,,,,,,,,,,"4181336","Malignant tumor of soft palate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1698088","Malignant Solid Neoplasm","C132146","A malignant neoplasm arising from tissues that do not include fluid areas. Representative examples include carcinomas and sarcomas. Hematopoietic and lymphoid tissue malignancies are not considered solid neoplasms.","Malignant Solid Neoplasm | Malignant Solid Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0153603","Malignant Spermatic Cord Neoplasm","C3559","A primary or metastatic malignant neoplasm that affects the spermatic cord.","Malignant Spermatic Cord Neoplasm | Malignant Neoplasm of Spermatic Cord | Malignant Neoplasm of the Spermatic Cord | Malignant Spermatic Cord Tumor | Malignant Tumor of Spermatic Cord | Malignant Tumor of the Spermatic Cord | Malignant neoplasm of unspecified spermatic cord",,,,,,,,,,,,,,,"4181356","Malignant tumor of spermatic cord",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153479","Malignant Sphenoid Sinus Neoplasm","C3543","A primary or metastatic malignant neoplasm involving the sphenoid sinus.","Malignant Sphenoid Sinus Neoplasm | Malignant Neoplasm of Sphenoid Sinus | Malignant Neoplasm of Sphenoidal Sinus | Malignant Neoplasm of the Sphenoid Sinus | Malignant Neoplasm of the Sphenoidal Sinus | Malignant Sphenoid Sinus Tumor | Malignant Sphenoidal Sinus Neoplasm | Malignant Sphenoidal Sinus Tumor | Malignant Tumor of Sphenoid Sinus | Malignant Tumor of Sphenoidal Sinus | Malignant Tumor of the Sphenoid Sinus | Malignant Tumor of the Sphenoidal Sinus | Malignant neoplasm of sphenoid sinus",,,,,,,,,,,,,,,"4177110","Malignant tumor of sphenoid sinus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153646","Malignant Spinal Cord Neoplasm","C3572","A primary or metastatic malignant neoplasm affecting the spinal cord.  Representative examples include lymphoma, melanoma, and sarcoma.","Malignant Spinal Cord Neoplasm | Malignant Neoplasm of Spinal Cord | Malignant Neoplasm of the Spinal Cord | Malignant Spinal Cord Tumor | Malignant Tumor of Spinal Cord | Malignant Tumor of the Spinal Cord | Malignant neoplasm of spinal cord | spine cancer",,,,,,,,,,,,,,,"4177234","Malignant tumor of spinal cord",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153485","Malignant Subglottis Neoplasm","C3546","A malignant neoplasm that affects the subglottic area of the larynx.  The vast majority of cases are squamous cell carcinomas.","Malignant Subglottis Neoplasm | Malignant Neoplasm of Subglottis | Malignant Neoplasm of the Subglottis | Malignant Subglottic Neoplasm | Malignant Subglottic Tumor | Malignant Subglottis Tumor | Malignant Tumor of Subglottis | Malignant Tumor of the Subglottis | Malignant neoplasm of subglottis",,,,,,,,,,,,,,,"4177111","Malignant tumor of subglottis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153361","Malignant Sublingual Gland Neoplasm","C3527","A rare malignant neoplasm that arises from the sublingual gland.  The majority are carcinomas.","Malignant Sublingual Gland Neoplasm | Malignant Neoplasm of Sublingual Gland | Malignant Neoplasm of the Sublingual Gland | Malignant Sublingual Gland Tumor | Malignant Tumor of Sublingual Gland | Malignant Tumor of the Sublingual Gland | Malignant neoplasm of sublingual gland",,,,,,,,,,,,,,,"4180785","Malignant tumor of sublingual gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153360","Malignant Submandibular Gland Neoplasm","C3526","A malignant neoplasm that arises from the submandibular gland.  The majority are carcinomas.","Malignant Submandibular Gland Neoplasm | Malignant Neoplasm of Submandibular Gland | Malignant Neoplasm of the Submandibular Gland | Malignant Submandibular Gland Tumor | Malignant Tumor of Submandibular Gland | Malignant Tumor of the Submandibular Gland | Malignant neoplasm of submandibular gland",,,,,,,,,,,,,,,"22557","Malignant tumor of submandibular gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153484","Malignant Supraglottis Neoplasm","C3545","A malignant neoplasm that affects the supraglottic area of the larynx.  The vast majority of cases are squamous cell carcinomas.","Malignant Supraglottis Neoplasm | Malignant Neoplasm of Supraglottis | Malignant Neoplasm of the Supraglottis | Malignant Supraglottic Neoplasm | Malignant Supraglottic Tumor | Malignant Supraglottis Tumor | Malignant Tumor of Supraglottis | Malignant Tumor of the Supraglottis | Malignant neoplasm of supraglottis",,,,,,,,,,,,,,,"4092212","Malignant tumor of supraglottis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0751552","Malignant Thymus Neoplasm","C4962","A primary or metastatic malignant neoplasm involving the thymus. This category includes malignant thymomas, thymic lymphomas, primary thymic carcinomas, and metastatic carcinomas from other anatomic sites.","Malignant Thymus Neoplasm | Cancer of Thymus | Cancer of the Thymus | Malignant Neoplasm of Thymus | Malignant Neoplasm of the Thymus | Malignant Thymic Neoplasm | Malignant Thymus Tumor | Malignant Tumor of Thymus | Malignant Tumor of the Thymus | Malignant neoplasm of thymus | Thymus Cancer",,,,,,,,,,,,,,,"443380","Malignant tumor of thymus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007115","Malignant Thyroid Gland Neoplasm","C7510","A primary or metastatic malignant neoplasm affecting the thyroid gland.","Malignant Thyroid Gland Neoplasm | Malignant Neoplasm of Thyroid | Malignant Neoplasm of Thyroid Gland | Malignant Neoplasm of the Thyroid | Malignant Neoplasm of the Thyroid Gland | Malignant Thyroid Gland Tumor | Malignant Thyroid Neoplasm | Malignant Thyroid Tumor | Malignant Tumor of Thyroid | Malignant Tumor of Thyroid Gland | Malignant Tumor of the Thyroid | Malignant Tumor of the Thyroid Gland | Malignant neoplasm of thyroid gland",,,,,,,,,,,,,,,"4178976","Malignant tumor of thyroid gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153349","Malignant Tongue Neoplasm","C9345","A malignant neoplasm affecting the tongue.  The vast majority of cases are carcinomas.","Malignant Tongue Neoplasm | Malignant Neoplasm of Tongue | Malignant Neoplasm of the Tongue | Malignant Tongue Tumor | Malignant Tumor of Tongue | Malignant Tumor of the Tongue | Malignant neoplasm of tongue, unspecified | Tongue Neoplasm Malignant Stage Unspecified | Tongue Neoplasm, Malignant",,,,,,,,,,,,,,,"4178962","Malignant tumor of tongue",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0751560","Malignant Tonsillar Neoplasm","C7404","A primary or metastatic malignant neoplasm that affects the tonsil.","Malignant Tonsillar Neoplasm | Malignant Neoplasm of Tonsil | Malignant Neoplasm of the Tonsil | Malignant Tonsil Neoplasm | Malignant Tonsil Tumor | Malignant Tonsillar Tumor | Malignant Tumor of Tonsil | Malignant Tumor of the Tonsil | Malignant neoplasm of tonsil, unspecified",,,,,,,,,,,,,,,"4181339","Malignant tumor of tonsil",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153489","Malignant Tracheal Neoplasm","C9346","A primary or metastatic malignant neoplasm involving the trachea.","Malignant Tracheal Neoplasm | Malignant Neoplasm of Trachea | Malignant Neoplasm of the Trachea | Malignant Trachea Neoplasm | Malignant Trachea Tumor | Malignant Tracheal Tumor | Malignant Tumor of Trachea | Malignant Tumor of the Trachea | Malignant neoplasm of trachea",,,,,,,,,,,,,,,"4177112","Malignant tumor of trachea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153619","Malignant Ureter Neoplasm","C7543","A primary or metastatic malignant tumor involving the ureter.  The majority are carcinomas.","Malignant Ureter Neoplasm | Malignant Neoplasm of Ureter | Malignant Neoplasm of the Ureter | Malignant Tumor of Ureter | Malignant Tumor of the Ureter | Malignant Ureter Tumor | Malignant Ureteral Neoplasm | Malignant Ureteral Tumor | Malignant neoplasm of unspecified ureter",,,,,,,,,,,,,,,"4178972","Malignant tumor of ureter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153620","Malignant Urethral Neoplasm","C7507","A primary or metastatic malignant neoplasm involving the urethra.","Malignant Urethral Neoplasm | Malignant Neoplasm of Urethra | Malignant Neoplasm of the Urethra | Malignant Tumor of Urethra | Malignant Tumor of the Urethra | Malignant Urethra Neoplasm | Malignant Urethra Tumor | Malignant Urethral Tumor | Malignant neoplasm of urethra",,,,,,,,,,,,,,,"4177230","Malignant tumor of urethra",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153574","Malignant Uterine Corpus Neoplasm","C3556","A malignant neoplasm that affects the uterine corpus. Representative examples include endometrial carcinoma, carcinosarcoma, leiomyosarcoma, and adenosarcoma.","Malignant Uterine Corpus Neoplasm | Malignant Corpus Uteri Neoplasm | Malignant Corpus Uteri Tumor | Malignant Neoplasm of Uterine Body | Malignant Neoplasm of the Uterine Body | Malignant Tumor of Uterine Body | Malignant Tumor of the Uterine Body | Malignant Uterine Body Neoplasm | Malignant Uterine Body Tumor | Malignant Uterine Corpus Tumor | Malignant neoplasm of corpus uteri, unspecified",,,,,,,,,,,,,,,"4156113","Malignant neoplasm of body of uterus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0864950","Malignant Uterine Ligament Neoplasm","C126498","A primary or metastatic malignant neoplasm that affects the broad or other uterine ligaments.","Malignant Uterine Ligament Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0153377","Malignant Uvula Neoplasm","C35177","A primary or metastatic malignant neoplasm that affects the uvula.","Malignant Uvula Neoplasm | Malignant Uvula Tumor | Malignant Uvula Tumour | Malignant Uvular Neoplasm | Malignant Uvular Tumor | Malignant Uvular Tumour | Malignant neoplasm of uvula",,,,,,,,,,,,,,,"4181337","Malignant tumor of uvula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0375071","Malignant Vulvar Neoplasm","C7502","A primary or metastatic malignant neoplasm involving the vulva.","Malignant Vulvar Neoplasm | Malignant Neoplasm of Vulva | Malignant Neoplasm of the Vulva | Malignant Tumor of Vulva | Malignant Tumor of the Vulva | Malignant Vulva Neoplasm | Malignant Vulva Tumor | Malignant Vulvar Tumor | Malignant neoplasm of vulva, unspecified",,,,,,,,,,,,,,,"4178959","Malignant tumor of vulva",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937132","Extrahepatic/Distal Bile Duct","C157419","Located or occurring outside the liver, including the distal portion of bile duct.","Extrahepatic/Distal Bile Duct | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937139","Proximal Bile Duct","C157418","These include the bile ducts which are located at the hilum of the liver as well as the segment where the left and right hepatic ducts join just outside the liver to form the common bile duct.","Proximal Bile Duct | Hilar/Perihilar | Hilar/Perihilar Bile Duct",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951565","Endocervix Tumor","C159624","An indication that the tumor is in the endocervix.","Endocervix Tumor | Endocervix",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951564","Exocervix Tumor","C159623","An indication that the tumor is in the exocervix.","Exocervix Tumor | Exocervix",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335939","Secondary Cardiac Lymphoma","C5369","A lymphoma that has spread to the heart from another primary anatomic site.","Secondary Heart Lymphoma | Metastatic Lymphoma in the Heart | Secondary Cardiac Lymphoma | Secondary Lymphoma in the Heart",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0854198","Metastatic Malignant Neoplasm in the Abdominal Cavity","C8615","The spread of a malignant neoplasm from a primary site to an unspecified organ in the abdominal cavity.","Metastatic Malignant Neoplasm in the Abdominal Cavity | Metastases to the Abdominal Cavity | Metastasis to the Abdominal Cavity | Metastatic Malignant Neoplasm to the Abdominal Cavity | Metastatic Neoplasm to the Abdominal Cavity | Metastatic Tumor to the Abdominal Cavity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0153691","Metastatic Malignant Neoplasm in the Adrenal Gland","C8610","A malignant tumor that has spread to the adrenal gland from an adjacent or distant anatomic site.  The majority of cases are metastatic carcinomas, and less frequently lymphomas.","Metastatic Malignant Neoplasm in the Adrenal Gland | Metastases to Adrenals | Metastasis to Adrenals | Metastatic Malignant Neoplasm to the Adrenal Gland | Metastatic Neoplasm to the Adrenal Gland | Metastatic Neoplasm to the Adrenals | Metastatic Tumor to the Adrenal Gland | Metastatic Tumor to the Adrenals | Secondary malignant neoplasm of adrenal gland | Secondary malignant neoplasm of unspecified adrenal gland",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0347011","Metastatic Malignant Neoplasm in the Bladder","C7650","The spread of a malignant neoplasm to the urinary bladder wall from an adjacent or distant anatomic site.","Metastatic Malignant Neoplasm in the Bladder | Metastases to Bladder | Metastasis to Bladder | Metastatic Malignant Neoplasm to the Bladder | Metastatic Neoplasm to the Bladder | Metastatic Neoplasm to the Urinary Bladder | Metastatic Tumor to the Bladder | Metastatic Tumor to the Urinary Bladder | Secondary malignant neoplasm of bladder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0686377","Metastatic Malignant Neoplasm in the Central Nervous System","C4015","A malignant neoplasm that has spread to the central nervous system from another anatomic site or system. The majority are carcinomas (usually lung or breast carcinomas).","Metastatic Malignant Neoplasm in the Central Nervous System | CNS Metastases | CNS Metastasis | CNS metastasis | Central Nervous System Metastases | Central Nervous System Metastasis | Metastatic Malignant Neoplasm to the Central Nervous System | Metastatic Neoplasm to the CNS | Metastatic Neoplasm to the Central Nervous System | Metastatic Tumor to the CNS | Metastatic Tumor to the Central Nervous System | central nervous system metastasis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0346973","Metastatic Malignant Neoplasm in the Large Intestine","C4581","The spread of a malignant neoplasm to the large intestine.  This may be from a primary large intestine malignant neoplasm, or from a malignant neoplasm at a distant site.","Metastatic Malignant Neoplasm in the Large Intestine | Metastases to Large Intestine | Metastasis to Large Bowel | Metastasis to the Large Bowel | Metastasis to the Large Intestine | Metastatic Malignant Neoplasm to the Large Intestine | Metastatic Neoplasm to the Large Intestine | Metastatic Tumor to the Large Intestine | Secondary malignant neoplasm of large intestine and rectum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0153677","Metastatic Malignant Neoplasm in the Mediastinum","C3578","The spread of a malignant neoplasm to the mediastinum from an adjacent or distant anatomic site.","Metastatic Malignant Neoplasm in the Mediastinum | Metastases to Mediastinum | Metastases to the Mediastinum | Metastasis to the Mediastinum | Metastatic Malignant Neoplasm to the Mediastinum | Metastatic Neoplasm to the Mediastinum | Metastatic Tumor to the Mediastinum | Secondary malignant neoplasm of mediastinum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0347014","Metastatic Malignant Neoplasm in the Nervous System","C8547","The spread of a malignant neoplasm to the nervous system.  This may be from a primary nervous system malignant neoplasm, or from a malignant neoplasm at a distant site.","Metastatic Malignant Neoplasm in the Nervous System | Metastases to Nervous System | Metastasis to the Nervous System | Metastatic Malignant Neoplasm to the Nervous System | Metastatic Neoplasm to the Nervous System | Metastatic Tumor to the Nervous System | Secondary Malignant Neoplasm to the Nervous System | Secondary Malignant Tumor to the Nervous System | Secondary malignant neoplasm of unspecified part of nervous system",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3647143","Metastatic Malignant Neoplasm in the Ovary","C7456","The spread of a malignant neoplasm to the ovary.  This may be from a primary ovarian malignant neoplasm involving the opposite ovary, or from a malignant neoplasm at a distant site.","Metastatic Malignant Neoplasm in the Ovary | Metastases to Ovary | Metastasis to Ovary | Metastatic Malignant Neoplasm to the Ovary | Metastatic Malignant Tumor to the Ovary | Ovarian Metastasis | Secondary malignant neoplasm of ovary | Secondary malignant neoplasm of unspecified ovary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0748505","Metastatic Sarcoma","C152076","A sarcoma that has spread from its original site of growth to another anatomic site.","Metastatic Sarcoma | ",,,,,,,,,,,,,,,"40480137","Metastatic sarcoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545000","Metastatic Neuroendocrine Tumor","C147065","A neuroendocrine tumor that has spread from its original site of growth to another anatomic site.","Metastatic Neuroendocrine Tumor | Metastatic Carcinoid Tumor | Metastatic Well Differentiated Neuroendocrine Neoplasm | Metastatic Well Differentiated Neuroendocrine Neoplasm | Secondary carcinoid tumors | Secondary carcinoid tumors, unspecified site | Secondary neuroendocrine tumors",,,,,,,,,,,,,,,"37158761|45767695","Metastatic carcinoid tumor|Metastatic carcinoid tumor",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL552569","Methotrexate-Associated Lymphoma","C150678","A non-Hodgkin or Hodgkin lymphoma that develops in patients who are immunosuppressed with methotrexate.","Methotrexate-Associated Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334442","Mixed Epithelioid and Spindle Cell Melanoma","C66756","A melanoma characterized by the presence of malignant large epithelioid melanocytes and malignant spindle-shaped melanocytes.","Mixed Epithelioid and Spindle Cell Melanoma | Mixed epithelioid and spindle cell melanoma",,,,,,,,,,,,,,,"4179920","Mixed epithelioid and spindle cell melanoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL054990","Mucin-Producing Carcinoma","C27825","A carcinoma that produces mucin.","Mucin-Producing Carcinoma | Mucin-producing carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882062","Neoplastic Syndrome","C54705","A broad classification for disorders in which the development of neoplasms typically occur in association with a characteristic set of signs or symptoms. These disorders may be inherited or acquired.","Neoplastic Syndrome | Cancer-Related Syndrome | Tumor Syndrome",,,,,,,,,,,,,,,"438112","Neoplastic disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027766","Nervous System Neoplasm","C3268","A benign or malignant, primary or metastatic neoplasm involving the central or peripheral nervous system.","Nervous System Neoplasm | Neoplasm of Nervous System | Neoplasm of the Nervous System | Nervous System Neoplasms | Nervous System Tumor | Nervous System Tumour | Tumor of Nervous System | Tumor of the Nervous System",,,,,,,,,,,,,,,"444200","Neoplasm of nervous system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0079613","Adoptive Immunotherapy","C15351","A technique for enhancing cell-mediated immunity by: 1) artificially increasing the number of specific immunocompetent cells through inoculation of either ex-vivo expanded primarily activated cytotoxic lymphocytes or genetically engineered lymphocytes with enhanced cytotoxic ability or 2) by altering tumor cells to make them more immunogenic.","Adoptive Immunotherapy | ACT | ACT Therapy | Adoptive Cell Immunotherapy | Adoptive Cell Transfer | Adoptive Cell Transfer Immunotherapy | Adoptive Cell Transfer Therapy | adoptive cellular immunotherapy | adoptive cellular therapy | cellular adoptive immunotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032615","Polyunsaturated Fatty Acid","C67038","A fatty acid containing more than one double bond (C=C). The essential fatty acids omega-3 and omega-6 are polyunsaturated fatty acids (PUFAs) that contain 2 or more cis double bonds. Dietary intake of some PUFAs may have beneficial effects on blood pressure, serum lipds, and inflammation. Some PUFAs, such as omega-3 PUFAs, may have antineoplastic or chemopreventive activities.","Polyunsaturated Fatty Acid | Fatty Acid, Total Polyunsaturated | PUFA | Polyunsaturated Fatty Acids",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274009","KRAS Protein Variant","C98362","A variation in the amino acid sequence for the GTPase KRas protein.","KRAS Protein Variant | GTPase KRas Protein Variant | K-Ras 2 Protein Variant | Ki-Ras Protein Variant | c-K-ras Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0346402","Malignant Adrenal Cortical Neoplasm","C9327","A primary or metastatic malignant neoplasm affecting the adrenal cortex.","Malignant Adrenal Cortical Neoplasm | Adrenal cortical tumor, malignant | Malignant Adrenal Cortex Neoplasm | Malignant Adrenal Cortex Neoplasm | Malignant Adrenal Cortex Tumor | Malignant Adrenocortical Neoplasm | Malignant Adrenocortical Tumor | Malignant Neoplasm of Adrenal Cortex | Malignant Neoplasm of the Adrenal Cortex | Malignant Tumor of Adrenal Cortex | Malignant Tumor of the Adrenal Cortex | Malignant neoplasm of cortex of unspecified adrenal gland",,,,,,,,,,,,,,,"4162116","Malignant neoplasm of adrenal cortex",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153477","Malignant Ethmoid Sinus Neoplasm","C3541","A primary or metastatic malignant neoplasm involving the ethmoid sinus.","Malignant Ethmoid Sinus Neoplasm | Malignant Ethmoid Sinus Tumor | Malignant Ethmoidal Sinus Neoplasm | Malignant Ethmoidal Sinus Tumor | Malignant Neoplasm of Ethmoid Sinus | Malignant Neoplasm of Ethmoidal Sinus | Malignant Neoplasm of the Ethmoid Sinus | Malignant Neoplasm of the Ethmoidal Sinus | Malignant Tumor of Ethmoid Sinus | Malignant Tumor of Ethmoidal Sinus | Malignant Tumor of the Ethmoid Sinus | Malignant Tumor of the Ethmoidal Sinus | Malignant neoplasm of ethmoidal sinus",,,,,,,,,,,,,,,"4177109","Malignant tumor of ethmoid sinus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153570","Malignant Exocervical Neoplasm","C3554","A malignant neoplasm that affects the exocervix.","Malignant Exocervical Neoplasm | Malignant Exocervical Tumor | Malignant Exocervix Neoplasm | Malignant Exocervix Tumor | Malignant Neoplasm of Exocervix | Malignant Neoplasm of Uterine Exocervix | Malignant Neoplasm of the Exocervix | Malignant Neoplasm of the Uterine Exocervix | Malignant Tumor of Exocervix | Malignant Tumor of Uterine Exocervix | Malignant Tumor of the Exocervix | Malignant Tumor of the Uterine Exocervix | Malignant Uterine Exocervix Neoplasm | Malignant Uterine Exocervix Tumor | Malignant neoplasm of exocervix",,,,,,,,,,,,,,,"4162876","Malignant neoplasm of exocervix",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031436","Phenothiazine","C740","A class of agents exhibiting antiemetic, antipsychotic, antihistaminic, and anticholinergic activities.  Phenothiazines antagonize the dopamine D2-receptor in the chemoreceptor trigger zone (CTZ) of the brain, potentially preventing chemotherapy-induced emesis.  In addition, these agents have peripherally or centrally antagonistic activity against alpha adrenergic, serotonergic, histaminic, and muscarinic receptors. (NCI)","Phenothiazine | PHENOTHIAZINE | phenothiazine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415663","HOXB1 Gene","C162630","This gene is involved in the development of anterior embryonic structures and facial nerves.","HOXB1 Gene | HOXB1 | Homeobox B1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0156221","Acute Glomerulonephritis","C35213","An acute inflammation of the glomeruli, generally secondary to infection or injury.","Acute Glomerulonephritis | ",,,,,,,,,,,,,,,"435308","Acute glomerulonephritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0276609","Acute Hepatitis B Infection","C157781","A new infection by the hepatitis B virus, which can be transmitted by direct contact of infected blood with mucous membranes or open areas of the skin. Signs and symptoms may include loss of appetite, joint and muscle pain, low-grade fever and stomach pain. Two to six percent of adults progress to a chronic infection, while 90% of infants become chronically ill. A vaccine is available for those at risk.","Acute Hepatitis B Infection | Acute Hepatitis B",,,,,,,,,,,,,,,"197795","Acute type B viral hepatitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0400914","Acute Hepatitis C Infection","C157782","A new infection by the hepatitis C virus, which can be detected in blood. Signs and symptoms may include right upper quadrant abdominal pain, jaundice, dark urine, white stools and nausea. Approximately 15%-25% individuals clear the virus from their bodies without treatment. 75%-85% individuals develop chronic hepatitis C. There are possible treatments depending on individual characteristics.","Acute Hepatitis C Infection | Acute Hepatitis C",,,,,,,,,,,,,,,"192242","Acute hepatitis C",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937420","Acute Hepatitis E Infection","C157783","A new infection by the hepatitis E virus, which is usually spread by the fecal-oral route. Signs and symptoms may include fever, fatigue, loss of appetite, nausea, vomiting, abdominal pain, jaundice, dark urine, clay-colored stools and joint pain. There is no specific anti-viral treatment, the infection resolves on its own.","Acute Hepatitis E Infection | Acute Hepatitis E",,,,,,,,,,,,,,,"197490","Acute hepatitis E",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1332228","Alcohol-Related Hepatocellular Carcinoma","C27924","A hepatocellular carcinoma that develops following alcohol-induced injury of the liver parenchyma.","Alcohol-Related Hepatocellular Carcinoma | Alcohol-Related Hepatocellular Cancer | Liver Cancer Secondary to Alcohol Use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937419","Amoebiasis","C157785","A parasitic infection of the colon by Entamoeba histolytica. Signs and symptoms include cramping, diarrhea, bloody stools and fever. It can be treated with antibiotics.","Amoebiasis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937417","Amphetamine Use Disorder","C157786","The use of amphetamines that results in the development of a dependency that adversely affects an individual's life.","Amphetamine Use Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003950","Ascariasis","C128392","An infection that is caused by the roundworm Ascaris lumbricoides, many cases of which remain asymptomatic. During the transient larval migratory phase, shortness of breath, fever, and eosinophilia can occur. Depending on the intestinal worm burden, a spectrum of gastrointestinal tract symptoms can occur.","Ascariasis | ",,,,,,,,,,,,,,,"192259","Ascariasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004063","Assault","C157707","A physical attack.","Assault | ",,,,,,,,,,,,,,,"439237","Assault",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0418370","Assault By Firearm","C157790","A physical attack with a gun.","Assault By Firearm | ",,,,,,,,,,,,,,,"435166","Assault by firearms",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0480664","Assault By Sharp Object","C157791","A physical attack with a pointed object.","Assault By Sharp Object | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937414","Bacterial Skin Disorder","C157794","A cutaneous disorder attributed to a bacterial infection.","Bacterial Skin Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937407","Campylobacter Enteritis","C157804","A gastrointestinal infection attributed to the bacteria campylobacter. It is usually contracted by consuming raw or undercooked poultry or consuming a food that has been in contact with raw poultry. It is characterized by abdominal pain, fever, and  diarrhea and usually resolves in two to five days.","Campylobacter Enteritis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008049","Chicken Pox","C97132","A contagious childhood disorder caused by the varicella zoster virus. It is transmitted via respiratory secretions and contact with chickenpox blister contents. It presents with a vesicular skin rash, usually associated with fever, headache, and myalgias. The pruritic fluid-filled vesicles occur 10-21 days after exposure and last for 3-4 days. An additional 3-4 days of malaise follows before the affected individual feels better. An individual is contagious 1-2 days prior to the appearance of the blisters until all blisters are crusted over. Generally, healthy individuals recover without complications.","Chicken Pox | Chicken Pox Infection | Chickenpox | Varicella",,,,,,,,,,,,,,,"434272","Varicella",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008354","Cholera","C157812","An acute diarrheal illness caused by consuming water or food contaminated by the bacterium Vibrio cholerae. Adequate rehydration is key to surviving this illness.","Cholera | ",,,,,,,,,,,,,,,"198677","Cholera",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937530","Chronic Kidney Disease due to Diabetes Mellitus","C157813","Longstanding kidney disease as a complication of diabetes.","Chronic Kidney Disease due to Diabetes Mellitus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0264220","Non-Neoplastic Chronic Respiratory System Disorder","C157816","A non-neoplastic longstanding disorder of the respiratory system.","Non-Neoplastic Chronic Respiratory System Disorder | Chronic Respiratory Disease | Chronic Respiratory Disease",,,,,,,,,,,,,,,"4063381","Chronic disease of respiratory system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937528","Cirrhosis of the Liver Secondary to Hepatitis B","C157817","Cirrhosis of the liver that develops as a sequelae of a hepatitis b infection.","Cirrhosis of the Liver Secondary to Hepatitis B | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937526","Cirrhosis of the Liver Secondary to Hepatitis C","C157818","Cirrhosis of the liver that develops as a sequelae of a hepatitis c infection.","Cirrhosis of the Liver Secondary to Hepatitis C | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937527","Cocaine Use Disorder","C157819","The use of cocaine that results in the development of a dependency that adversely affects an individual's life.","Cocaine Use Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937523","Communicable Disorder","C157825","A disease that can be transmitted from one individual to another.","Communicable Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010418","Cryptosporidiosis","C128408","An infection that is caused by Cryptosporidium parvum or hominis, which is acquired by inhalation or ingestion of infectious spores, and which typically manifests as acute enteritis.","Cryptosporidiosis | Cryptosporidium Infection",,,,,,,,,,,,,,,"194265","Cryptosporidiosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL973113","Revised International Prognostic Scoring System","C162677","A revision of the International Prognostic Scoring System for Myelodysplastic Syndromes. It covers the same disease factors as the IPSS, but the factors are identified in a more detailed way. The revised version includes: blasts in the bone marrow, cytogenetic abnormalities, hemoglobin level, absolute neutrophil count, and platelet count.","Revised International Prognostic Scoring System | IPSS-R | Revised International Prognostic Scoring System (IPSS-R) | Revised International Prognostic Scoring System for Myelodysplastic Syndromes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973117","IPSS-R Risk Category","C162679","The risk category for myelodysplastic syndrome progression that is derived from IPSS-R risk score.","IPSS-R Risk Category | Revised International Prognostic Scoring System for Myelodysplastic Syndrome Risk Category",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973412","IPSS-R Risk Category Very Low","C162680","A total IPSS-R score of 1.5 or lower, indicating very low risk.","IPSS-R Risk Category Very Low | IPSS-R Very Low Risk | Revised International Prognostic Scoring System for Myelodysplastic Syndrome Very Low Risk Category | Very Low | Very Low Risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973409","IPSS-R Risk Category Low","C162681","A total IPSS-R score of more than 1.5 to 3, indicating low risk.","IPSS-R Risk Category Low | IPSS-R Low Risk | Low | Low Risk | Revised International Prognostic Scoring System for Myelodysplastic Syndrome Low Risk Category",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973408","IPSS-R Risk Category Intermediate","C162682","A total IPSS-R score of 3.5 to 4.5, indicating intermediate risk.","IPSS-R Risk Category Intermediate | IPSS-R Intermediate Risk | Intermediate | Intermediate Risk | Revised International Prognostic Scoring System for Myelodysplastic Syndrome Intermediate Risk Category",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973410","IPSS-R Risk Category High","C162683","A total IPSS-R score of 5 to 6, indicating high risk.","IPSS-R Risk Category High | High | High Risk | IPSS-R High Risk | Revised International Prognostic Scoring System for Myelodysplastic Syndrome High Risk Category",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973415","IPSS-R Risk Category Very High","C162684","A total IPSS-R score of 6.5 or higher, indicating very high risk.","IPSS-R Risk Category Very High | IPSS-R Very High Risk | Revised International Prognostic Scoring System for Myelodysplastic Syndrome Very High Risk Category | Very High | Very High Risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013298","Duodenitis","C94409","Acute or chronic inflammation of the duodenum. Causes include bacterial and viral infections and gastroesophageal reflux disease. Symptoms include vomiting and abdominal pain.","Duodenitis | duodenitis",,,,,,,,,,,,,,,"433516","Duodenitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019288","Femoral Hernia","C34689","The protrusion of contents of the abdominal cavity, into the weak area at the posterior wall of the femoral canal, just inferior to the inguinal ligament.","Femoral Hernia | ",,,,,,,,,,,,,,,"4178874","Femoral hernia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL505177","Gonococcal Infection","C35730","An infection that is caused by Gonococcus.","Gonococcal Infection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333977","Hepatitis B Virus-Related Hepatocellular Carcinoma","C27687","A hepatocellular carcinoma that develops following hepatitis B virus exposure and injury of the liver parenchyma.","Hepatitis B Virus-Related Hepatocellular Carcinoma | Hepatitis B Virus Related Hepatocellular Carcinoma | Liver Cancer Secondary to Hepatitis B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333978","Hepatitis C Virus-Related Hepatocellular Carcinoma","C27688","A hepatocellular carcinoma that develops following hepatitis C virus exposure and injury of the liver parenchyma.","Hepatitis C Virus-Related Hepatocellular Carcinoma | Hepatitis C Virus Related Hepatocellular Carcinoma | Liver Cancer Secondary to Hepatitis C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0852260","Hypertension-Associated Pregnancy Disorder","C9243","A hypertensive disorder that develops during pregnancy.","Hypertension-Associated Pregnancy Disorder | Hypertension Associated Disorders of Pregnancy | Hypertensive Disorders of Pregnancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3277616","Inguinal Hernia","C34690","The protrusion of a sac-like structure containing fibroadipose tissue through an abnormal opening in the inguinal region.","Inguinal Hernia | ",,,,,,,,,,,,,,,"4288544","Inguinal hernia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0149725","Lower Respiratory Tract Infection","C35158","An acute or chronic, viral or bacterial infectious process that affects the lower respiratory tract.","Lower Respiratory Tract Infection | Lower Respiratory Infection",,,,,,,,,,,,,,,"4175297","Lower respiratory tract infection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025007","Measles","C96406","A highly contagious viral infection caused by the measles virus. Symptoms appear 8-12 days after exposure and include a rash, cough, fever and muscle pains that can last 4-7 days. Measles vaccines are available to provide prophylaxis, usually combined with mumps and rubella vaccines (MMR).","Measles | Rubeola | Rubeola Infection",,,,,,,,,,,,,,,"4030555","Measles",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021290","Neonatal Disorder","C98996","A non-neoplastic or neoplastic disorder which occurs during the neonatal period.","Neonatal Disorder | ",,,,,,,,,,,,,,,"4042220","Neonatal disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0235820","Neonatal Encephalopathy","C119758","Abnormal functioning of the central nervous system in the newborn period that may be due to a variety of etiologies including hypoxia/ischemia, metabolic disturbance, or infection.","Neonatal Encephalopathy | ",,,,,,,,,,,,,,,"4318859","Neonatal encephalopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1263836","Neonatal Infectious Disorder","C99231","An infectious disorder that occurs during the neonatal period. Representative examples include streptococcal infection, E.coli infection, and bacterial meningitis.","Neonatal Infectious Disorder | ",,,,,,,,,,,,,,,"4134142","Neonatal infectious disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005604","Neonatal Injury Related to Birth","C101035","An injury sustained to a neonate during the birthing process.","Neonatal Injury Related to Birth | Birth Injury | Birth Trauma | Neonatal Birth Injury",,,,,,,,,,,,,,,"435641","Birth trauma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0456103","Neonatal Sepsis","C116802","An infectious disorder of newborn infants that is characterized by a systemic inflammatory response most commonly caused by bacteria.","Neonatal Sepsis | ",,,,,,,,,,,,,,,"4071063","Sepsis of the newborn",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL973085","Slide ID Examined by Pathologist","C162690","The identifier for an slide that has been examined by a pathologist.","Slide ID Examined by Pathologist | hpe slide id | hpe_slide_id",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973086","Image ID Examined by Pathologist","C162691","The identifier for an image that has been examined by a pathologist.","Image ID Examined by Pathologist | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973083","Aperio Format","C162692","A data storage format consisting of a single-file pyramidal tiled TIFF, with non-standard metadata and compression format.","Aperio Format | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2718747","Ferumoxytol","C87701","A superparamagnetic iron oxide nanoparticle coated with a low molecular weight semi-synthetic carbohydrate, polyglucose sorbitol carboxymethyl ether, with potential anti-anemic and imaging properties. After intravenous administration, ferumoxytol replaces iron stores with fewer side effects compared to the use of oral iron.  In addition, this agent generates T1 relaxation, producing a magnetic field and enhancing T2 relaxation, thereby darkening contrast media-containing structures in magnetic resonance imaging (MRI). Due to small particle size, ferumoxytol remains in the intravasculature for a prolonged period and so may be used as a blood pool agent.","Ferumoxytol | FERUMOXYTOL NON-STOICHIOMETRIC MAGNETITE | Feraheme | Ferumoxytol Non-Stoichiometric Magnetite | ferumoxytol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950753","Specify Site if cM1b","C158726","A directive to indicate the anatomic sites if metastasis is categorized as cM1b.","Specify Site if cM1b | If cM1b, specify site(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936773","If cM1, specify site(s)","C157098","A directive to indicate the anatomic sites if metastasis is categorized as cM1.","If cM1, specify site(s) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936774","If distant metastasis documented, specify site(s), if known","C157099","A directive to specify the anatomic location of any documented distant metastasis.","Specify Site if Documented Distant Metastasis | If distant metastasis documented, specify site | If distant metastasis documented, specify site(s), if known",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936899","Indeterminate or Unknown","C157157","An indication that something is indeterminate or unknown.","Indeterminate or Unknown | Indeterminate or Unknown: Could not be determined or unsure. | Unknown: Could not be determined or unsure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0578022","Body Mass Index Finding","C138901","The result of a body mass index measurement.","Body Mass Index Finding | BMI | Body Mass Index",,,,,,,,,,,,,,,"4103471","Finding of body mass index",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL969974","Treatment Group","C161322","A study population that receives an intervention(s) within a trial. This could include the investigational product(s) or a comparator (e.g., placebo or an approved intervention).","Treatment Group | Clinical trial arm",,,,,,,,,,,,,,,"618771","Clinical trial arm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014859","Esophageal Neoplasm","C3028","A benign or malignant neoplasm involving the esophagus.","Esophageal Neoplasm | Esophageal Neoplasms, Benign and Malignant | Esophageal Tumor | Esophageal Tumors | Esophagus Neoplasm | Esophagus Tumor | Neoplasm of Esophagus | Neoplasm of the Esophagus | Tumor of Esophagus | Tumor of the Esophagus",,,,,,,,,,,,,,,"4130990","Neoplasm of esophagus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0458698","Central Zone of Prostate","C128572","This region of the prostate gland that is located between the peripheral and transition zones, surrounding the ejaculatory ducts. It gives rise to a very small percentage of prostate cancers, though these cancers are frequently more aggressive, often resulting in invasion of the seminal vesicles.","Central Zone of Prostate | Central Zone | Central zone",,,,,,,,,,,,,,,"4089569","Central zone of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0458696","Peripheral Zone of Prostate","C128570","The region of the prostate that is located most superficial and posterior as compared to the other prostate zones. It is located closest to the rectum, and is easily palpated on digital rectal exam. This zone of the prostate surrounds the distal urethra, and is the zone of origin for the vast majority of prostatic cancers.","Peripheral Zone of Prostate | Peripheral Zone | Peripheral zone",,,,,,,,,,,,,,,"4088951","Peripheral zone of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937104","Overlapping/Multiple Zones of Prostate","C157522","A term that indicates involvement of multiple zones of prostate.","Overlapping/Multiple Zones of Prostate | Overlapping/Multiple Zones | Overlapping/multiple zones",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042162","Uveal Neoplasm","C3436","A neoplasm that affects the uvea.  Uveal melanoma is a representative example.","Uveal Neoplasm | Neoplasm of Uvea | Neoplasm of the Uvea | Tumor of Uvea | Tumor of the Uvea | Uvea Neoplasm | Uvea Tumor | Uveal Tract Neoplasm | Uveal Tumor",,,,,,,,,,,,,,,"4130668","Neoplasm of uveal tract",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL973102","Anti-CD70 CAR-expressing T Lymphocytes","C162699","A preparation of human T-lymphocytes transduced with a recombinant viral vector encoding a chimeric T-cell receptor (chimeric antigen receptor or CAR) consisting of one or more binding domains that target the tumor-associated antigen (TAA) CD70 (CD27 ligand; tumor necrosis factor superfamily member 7; TNFSF7) fused to one or more co-stimulatory TCR-signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD70 CAR-expressing T-lymphocytes, express anti-CD70-CAR on their cell surfaces and bind to the CD70 antigen on tumor cell surfaces thereby neutralizing the activity of CD70. This may induce antibody-dependent cellular cytotoxicity (ADCC) against CD70-expressing tumor cells. CD70, a cytokine belonging to the tumor necrosis superfamily (TNFSF) and the ligand for the costimulatory receptor CD27, is expressed on the surfaces of various types of cancer cells; its overexpression may play an important role in the evasion of immune surveillance.","Anti-CD70 CAR-expressing T Lymphocytes | Anti-CD70 CAR-expressing T-cells | CD70 CAR T-cells | CD70 CAR T-lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969998","Sensitizing EGFR Mutation Negative","C160967","A finding indicating that mutations in the EGFR gene that impart increased sensitivity to EGFR inhibitory agents were not detected in a sample.","Sensitizing EGFR Mutation Negative | EGFR Sensitizing Gene Mutation Negative | EGFR Sensitizing Mutation Negative | Sensitizing EGFR Gene Mutation Negative | Sensitizing ERBB1 Mutation Negative | Sensitizing Epidermal Growth Factor Receptor Mutation Negative | Sensitizing HER1 Mutation Negative | Sensitizing c-erbB1 Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970396","Testosterone Less than or Equal to 50 ng/dL","C161836","A semiquantitative finding indicating that the concentration of testosterone in a sample is less than or equal to 50 ng/dL.","Testosterone Less than or Equal to 50 ng/dL | Testosterone Less than or Equal to 50 Nanograms per Deciliter | Testosterone Less than or Equal to 50 Nanograms/Deciliter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970521","Non-BRCA Gene Mutation","C161911","A genetic finding indicating the presence of gene mutations in a sample that may be associated with cancer predisposition and are in located in genes other than BRCA1 and BRCA2.","Non-BRCA Gene Mutation | Non-BRCA Gene Mutation Positive | Non-BRCA Gene Mutation Present | Non-BRCA Gene Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL383459","Aglatimagene Besadenovec","C73996","An adenoviral vector engineered to express the herpes simplex virus thymidine kinase (HSV-tk) gene, which, when administered in conjunction with a synthetic acyclic guanosine analogue, possesses potential antineoplastic activity. Aglatimagene besadenovec is transduced into tumor cells, sensitizing tumor cells that overexpress HSV-tk to synthetic acyclic guanosine analogues. Subsequently, a low dose of a synthetic acyclic guanosine analogue such as valacyclovir (VCV) or ganciclovir (GCV) is given, which may preferentially kill tumor cells containing the adenoviral vector and overexpressing HSV-tk. Release of tumor-associated antigens (TAAs) by dying tumor cells may then stimulate an antitumor cytotoxic T lymphocyte (CTL) response.","Aglatimagene Besadenovec | ADV-tk | AGLATIMAGENE BESADENOVEC | CAN 2409 | CAN-2409 | CAN2409 | GliAtak | ProstAtak | Virafir",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973094","Montreal Cognitive Assessment Visuospatial/Executive Test","C162709","These two abilities are assessed through the Trails B Test, which requires an individual to draw a line to correctly sequence alternating digits and numbers (1-A, 2-B, etc.) and through a task which requires them to draw a copy of a cube shape.","Montreal Cognitive Assessment Visuospatial/Executive Test | Visuospatial/Executive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973411","Montreal Cognitive Assessment Naming Test","C162710","In this test three pictures of animals are shown and the individual is asked to name each one.","Montreal Cognitive Assessment Naming Test | Naming",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973098","Montreal Cognitive Assessment Attention - Digits Test","C162711","This test involves repeating digits forward and backward.","Montreal Cognitive Assessment Attention - Digits Test | Attention - Digits",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973096","Montreal Cognitive Assessment Attention - Letters Test","C162712","This test involves acknowledging spoken letters.","Montreal Cognitive Assessment Attention - Letters Test | Attention - Letters",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973097","Montreal Cognitive Assessment Attention - Subtraction Test","C162713","This test requires an individual to count backward from 100 by sevens.","Montreal Cognitive Assessment Attention - Subtraction Test | Attention - Subtraction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973225","Montreal Cognitive Assessment Language - Repeat Test","C162714","This task consists of repeating two sentences correctly.","Montreal Cognitive Assessment Language - Repeat Test | Language - Repeat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973416","Montreal Cognitive Assessment Language - Fluency Test","C162715","This task requires an individual to list all of the words from two sentences they can be recalled that begin with the letter 'F'.","Montreal Cognitive Assessment Language - Fluency Test | Language - Fluency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973417","Montreal Cognitive Assessment Abstraction Test","C162716","This task requires an individual to explain how two items are alike, such as a train and a bicycle.","Montreal Cognitive Assessment Abstraction Test | Abstraction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973224","Montreal Cognitive Assessment Delayed Recall Test","C162717","Five words are read, the test-taker is asked to repeat them, they are read again and asked to repeat again. After completing other tasks, the person is asked to repeat each of the five words again and given a cue of the category that the word belongs to if they are not able to recall them without the cue.","Montreal Cognitive Assessment Delayed Recall Test | Delayed Recall",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973227","Montreal Cognitive Assessment Orientation Test","C162718","The individual is asked to state the date, month, year, day, place, and city.","Montreal Cognitive Assessment Orientation Test | Orientation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973414","Montreal Cognitive Assessment Total Score","C162720","The total score received in a Motreal Congitive Assessment test.","Montreal Cognitive Assessment Total Score | Total Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1828121","Injection Method of Administration","C149592","The technique of administration of a pharmaceutical product by introducing it into the body, usually after puncturing the skin; one or more of a variety of routes may be specified, the most common being intravenous, intramuscular and subcutaneous.","Injection Method of Administration | Injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951176","Pre-operative IV Sedation administered","C159307","A question about whether preoperative intravenous sedation was administered.","Was Preoperative IV Sedation Administered | Pre-operative IV Sedation administered | Preoperative IV Sedation Administered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936826","Select All That Apply","C157108","A directive to choose all that apply to the situation.","Select All That Apply | Or, Select all that apply",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951175","Other IV Sedation (specify)","C159306","A directive to specify any intravenous sedation administered that is not on the form.","Specify Other Preoperative IV Sedation Administered | Other IV Sedation (specify) | Specify Other IV Sedation Administered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951174","Pre-operative IV Opiates Administered","C159305","A question about whether preoperative intravenous opiates were administered.","Were Preoperative IV Opiates Administered | Pre-operative IV Opiates Administered | Preoperative IV Opiates Administered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951173","Pre-operative IV Antiemetics administered","C159304","A question about whether preoperative intravenous antiemetics were administered.","Were Preoperative IV Antiemetics Administered | Pre-operative IV Antiemetics administered | Preoperative IV Antiemetics Administered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951172","Pre-operative IV Anti-acids administered","C159303","A question about whether preoperative intravenous antacids were administered.","Were Preoperative IV Antacids Administered | Pre-operative IV Anti-acids administered | Preoperative IV Antacids Administered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951171","Other Pre-operative IV Medications administered","C159302","A question about whether other preoperative intravenous medications were administered.","Were Other Preoperative IV Medications Administered | Other Pre-operative IV Medications administered | Other Preoperative IV Medications Administered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950883","Local Anesthesia agents administered","C158808","A question about whether local anesthesia agents were administered.","Were Local Anesthesia Agents Administered | Local Anesthesia Agents Administered | Local Anesthesia agents administered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951170","Regional (Spinal/Epidural) Anesthesia agents administered","C159301","A question about whether regional anesthesia was administered.","Was Regional Anesthesia Administered | Regional (Spinal/Epidural) Anesthesia agents administered | Regional Anesthesia Administered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951169","Was IV Anesthesia Administered","C159299","A question about whether intravenous anesthesia was administered.","Was IV Anesthesia Administered | IV Anesthesia Administered | IV Anesthesia Agents Administered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951421","IV Narcotic/Opiate agents administered","C159523","A question about whether intravenous narcotics or opiates were administered.","Were IV Narcotic/Opiate Agents Administered | IV Narcotic or Opiate Agents Administered | IV Narcotic/Opiate Agents Administered | IV Narcotic/Opiate agents administered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951167","IV Muscle Relaxants Administered","C159297","A question about whether intravenous muscle relaxants were administered.","Were IV Muscle Relaxants Administered | IV Muscle Relaxants Administered | IV Muscle Relaxants Administered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951165","Was Inhalation Anesthesia Administered","C159295","A question about whether inhalation anesthesia was administered.","Was Inhalation Anesthesia Administered | Inhalation Anesthesia Administered | Inhalation Anesthesia agents administered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951417","Additional Anesthesia Agents Used","C159519","A question about whether additional anesthesia was administered.","Additional Anesthesia Agents Used | Additional Anesthesia agents used | Were Additional Anesthesia Agents Used",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951161","Was Insulin administered during surgery","C159291","A question about whether insulin was administered during surgery.","Was Insulin Administered During Surgery | Insulin Administered During Surgery | Was Insulin administered during surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951160","Were Steroids administered during surgery","C159290","A question about whether steroids were administered during surgery.","Were Steroids Administered During Surgery | Steroids Administered During Surgery | Were Steroids administered during surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951159","Antibiotics Administered During Surgery","C159289","A question about whether antibiotics were administered during surgery.","Antibiotics Administered During Surgery | Were Antibiotics Administered During Surgery | Were Antibiotics administered during surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951158","Were other medications administered during surgery","C159288","A question about whether other medications were administered during surgery.","Were Other Medications Administered During Surgery | Other Medications Administered During Surgery | Were other medications administered during surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504006","Lisocabtagene Maraleucel","C125192","A preparation of a defined ratio of CD4+ and CD8+ autologous T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-CD19 single chain variable fragment (scFv) fused to the signaling domain of 4-1BB (CD137), the zeta chain of the TCR/CD3 complex (CD3-zeta), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, lisocabtagene maraleucel is directed to and induces selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a cetuximab-induced antibody dependent cellular cytotoxicity (ADCC) response. The 4-1BB costimulatory signaling domain enhances both proliferation of T-cells and antitumor activity.","Lisocabtagene Maraleucel | Anti-CD19-CAR Genetically Engineered Autologous T Lymphocytes JCAR017 | Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes JCAR017 | Autologous Anti-CD19-EGFRt-4-1BB-zeta-modified CAR CD8+ and CD4+ T-lymphocytes JCAR017 | Breyanzi | JCAR 017 | JCAR-017 | JCAR017 | LISOCABTAGENE MARALEUCEL | Liso-cel | Lisocabtagene maraleucel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333078","Collagen Fibrosis of the Bone Marrow","C35821","No Value Exists","Collagen Fibrosis of the Bone Marrow | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950860","3q Abnormality","C158849","An irregularity in the structure of the long arm of chromosome 3.","3q Abnormality | 3q | 3q Aberration | Chromosome 3q Abnormality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517974","Loss of Chromosome 20q","C36403","A cytogenetic abnormality that refers to loss of all or part of the long arm of chromosome 20 (20q).","Loss of Chromosome 20q | del (20q) | del(20q)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517989","Loss of Chromosome 7","C36524","A cytogenetic abnormality that refers to loss of all or part of chromosome 7.","Loss of Chromosome 7 | -7 | -7 or del(7q) | del(7)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517985","Loss of Chromosome 5","C36526","A cytogenetic abnormality that refers to loss of all or part of chromosome 5.","Loss of Chromosome 5 | -5 | -5 or del(5q) | del(5)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969839","Gender Fluid","C160940","An individual who describes their gender identity as fluctuating between male, female, and/or other.","Gender Fluid Identity | Gender Fluid | Gender Fluid | Genderfluid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969838","Gender Variant","C160941","Having a gender that is neither male nor female.","Non-Binary Gender | Enby | Gender Variant | Gender Variant | NB | Non-Binary Gender | Non-binary | Non-binary Gender | Nonbinary | Nonbinary Gender",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2830069","Sonidegib","C82385","An orally bioavailable small-molecule smoothened (Smo) antagonist with potential antineoplastic activity. Sonidegib selectively binds to the hedgehog (Hh)-ligand cell surface receptor Smo, which may result in the suppression of the Hh signaling pathway and, so, the inhibition of tumor cells in which this pathway is abnormally activated. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair. Inappropriate activation of Hh pathway signaling and uncontrolled cellular proliferation, as is observed in a variety of cancers, may be associated with mutations in the Hh-ligand cell surface receptor Smo.","Sonidegib | (1,1'-Biphenyl)-3-carboxamide, N-(6-((2R,6S)-2,6-dimethyl-4-morpholinyl)-3-pyridinyl)-2- methyl-4'-(trifluoromethoxy)-, rel- | Erismodegib | LDE 225 | LDE-225 | LDE225 | Odomzo | SONIDEGIB | Smoothened Antagonist LDE225",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951199","Other Notable Events During Surgery","C159270","A question about other notable events that happened during surgery.","Other Notable Events During Surgery | Other notable events during surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474124","Idecabtagene Vicleucel","C117729","A preparation of autologous peripheral blood T-lymphocytes (PBTLs) that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the B-cell maturation antigen (BCMA), with potential immunostimulating and antineoplastic activities. Upon administration, idecabtagene vicleucel specifically recognizes and kills BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.","Idecabtagene Vicleucel | Abecma | Anti-BCMA CAR T Cells BB2121 | Anti-BCMA-CAR-transduced T Cells BB2121 | BB2121 | BCMA-specific CAR-expressing T Lymphocytes BB2121 | BCMA-specific CAR-expressing T Lymphocytes BB2121 | IDECABTAGENE VICLEUCEL | Ide-cel | Idecabtagene Vicleucel | Idecabtagene vicleucel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880665","FU-LV-Bevacizumab Regimen","C63610","A regimen consisting of fluorouracil, leucovorin, and bevacizumab used for the treatment of advanced-stage colorectal cancer.","FU-LV-Bevacizumab Regimen | 5FU/LV-Bevacizumab Regimen | FU-LV-Avastin Regimen | FULV and Bevacizumab | FULV and Bevacizumab-adcd | FULV and Bevacizumab-awwb | FULV and Bevacizumab-aybi | FULV and Bevacizumab-bvzr | FULV and Bevacizumab-equi | FULV and Bevacizumab-maly | FULV and Bevacizumab-onbe | FULV and Bevacizumab-tnjn | FULV and Bevacizumab-tnjn (L-Leucovorin)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523569","Irinotecan-Bevacizumab Regimen","C136258","A regimen consisting of irinotecan and bevacizumab that can be used for the treatment of colorectal cancer and appendiceal adenocarcinoma.","Bevacizumab/Irinotecan Regimen | Irinotecan and Bevacizumab | Irinotecan and Bevacizumab-adcd | Irinotecan and Bevacizumab-awwb | Irinotecan and Bevacizumab-aybi | Irinotecan and Bevacizumab-bvzr | Irinotecan and Bevacizumab-equi | Irinotecan and Bevacizumab-maly | Irinotecan and Bevacizumab-onbe | Irinotecan and Bevacizumab-tnjn | Irinotecan-Avastin Regimen | Irinotecan-Bevacizumab | Irinotecan-Bevacizumab Regimen | Irinotecan/Avastin Regimen | Irinotecan/Bevacizumab | Irinotecan/Bevacizumab Regimen | Irinotecan/Bevacizumab Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881267","Cetuximab-Irinotecan Regimen","C63606","A regimen consisting of irinotecan and cetuximab that can be used for the treatment of colorectal cancer.","Cetuximab/Irinotecan Regimen | Cetuximab-Irinotecan | Cetuximab-Irinotecan Regimen | Cetuximab/Irinotecan | Irinotecan and Cetuximab | Irinotecan-Cetuximab Regimen | Irinotecan-Cetuximab Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554976","Irinotecan/Panitumumab Regimen","C153481","A regimen consisting of irinotecan and panitumumab that can be used for the treatment of colorectal cancer.","Irinotecan/Panitumumab Regimen | Irinotecan + Panitumumab Regimen | Irinotecan-Panitumumab | Irinotecan-Panitumumab Regimen | Irinotecan/Panitumumab | Panitumumab/Irinotecan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969156","Lonsurf Regimen","C160136","A regimen consisting of tipiracil and trifluridine that may be used in the treatment of appendiceal adenocarcinoma, esophageal and esophagogastric junction and gastric cancers, and metastatic colorectal cancers.","Tipiracil/Trifluridine Regimen | Lonsurf Regimen | Trifluridine and Tipiracil Regimen | Trifluridine and Tipiracil Regimen | Trifluridine and tipiracil monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951164","Specify Additional Anesthesia","C159294","A directive to specify additional anesthesia agents administered.","Specify Additional Anesthesia | Specify additional anesthesia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0051510","Aluminum Acetate","C47387","A topical astringent that is used as an antiseptic agent. Aluminum acetate is used to treat inflammation, itching, and stinging of the infected skin and promotes healing.","Aluminum Acetate | ALUMINUM ACETATE | Hydroxyaluminium Di(acetate) | Hydroxyaluminum Di(acetate)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0991555","Topical Solution Dosage Form","C64905","A solution intended for administration to a body surface.","Topical Solution Dosage Form | Cutaneous solution | Top Sol | Topical Solution | Topical Solution Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006863","Cannabidiol","C118452","A phytocannabinoid derived from Cannabis species, which is devoid of psychoactive activity, with analgesic, anti-inflammatory, antineoplastic and chemopreventive activities. Upon administration, cannabidiol (CBD) exerts its anti-proliferative, anti-angiogenic and pro-apoptotic activity through various mechanisms, which likely do not involve signaling by cannabinoid receptor 1 (CB1), CB2, or vanilloid receptor 1. CBD stimulates endoplasmic reticulum (ER) stress and inhibits AKT/mTOR signaling, thereby activating autophagy and promoting apoptosis. In addition, CBD enhances the generation of reactive oxygen species (ROS), which further enhances apoptosis. This agent also upregulates the expression of intercellular adhesion molecule 1 (ICAM-1) and tissue inhibitor of matrix metalloproteinases-1 (TIMP1) and decreases the expression of inhibitor of DNA binding 1 (ID-1). This inhibits cancer cell invasiveness and metastasis. CBD may also activate the transient receptor potential vanilloid type 2 (TRPV2), which may increase the uptake of various cytotoxic agents in cancer cells. The analgesic effect of CBD is mediated through the binding of this agent to and activation of CB1.","Cannabidiol | 1,3-Benzenediol, 2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-, (1R-trans)- | CANNABIDIOL | CBD | CBD Oil | Epidiolex | GWP42003-P",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1565750","Sitagliptin","C73838","An orally available, competitive, beta-amino acid-derived inhibitor of dipeptidyl peptidase 4 (DDP-4) with hypoglycemic activity. Sitagliptin may cause an increased risk in the development of pancreatitis.","Sitagliptin | SITAGLIPTIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0063491","Indole-3-Carbinol","C1135","A naturally occurring, orally available cleavage product of the glucosinolate glucobrassicanin, a natural compound present in a wide variety of plant food substances including members of the family Cruciferae with antioxidant and potential chemopreventive properties. Indole-3-carbinol scavenges free radicals and induces various hepatic cytochrome P450 monooxygenases. Specifically, this agent induces the hepatic monooxygenase cytochrome P4501A1 (CYP1A1), resulting in increased 2-hydroxylation of estrogens and increased production of the chemoprotective estrogen 2-hydroxyestrone.","Indole-3-Carbinol | 1H-indole-3-methanol | 3-Hydroxymethylindole | I3C | INDOLE-3-CARBINOL | Indole-3-carbinol | Indole-3-methanol | indole-3-carbinol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL432946","Varlilumab","C99127","A human agonistic monoclonal antibody (MoAb) specific for CD27, with potential immunostimulating and antineoplastic activity. Upon administration of varlilumab, this MoAb binds to CD27 and may potentiate the immune response by increasing the cytotoxic T-lymphocyte (CTL) response against CD27-expressing tumor cells. This may lead to growth inhibition of CD27-expressing tumor cells. In addition, this agent may increase the proliferation and activation of antigen-specific T lymphocytes upon co-administration of TAA-containing vaccines, such as dendritic cell vaccines. CD27, a co-stimulatory molecule and member of the tumor necrosis factor family overexpressed in certain tumor cell types, is constitutively expressed on mature T-lymphocytes, memory B cells and natural killer cells and plays an important role in NK cell mediated cytolytic activity and T and B lymphocyte proliferation and activation.","Varlilumab | CDX 1127 | CDX-1127 | CDX1127 | Immunoglobulin G1, Anti-(Human CD Antigen CD27) (Human Monoclonal CDX-1127 Clone 1f5 Heavy Chain), Disulfide with Human Monoclonal CDX-1127 Clone 1f5 Kappa-chain, Dimer | VARLILUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896776","anti-CEA/CD3 bispecific antibody RO6958688","C120097","An anti-carcinoembryonic antigen (CEA)/anti-CD3 bispecific monoclonal antibody with potential antineoplastic activity. Cibisatamab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CEA, a tumor-associated antigen that is specifically expressed on certain tumor cells. Upon intravenous administration, cibisatamab binds to both T-cells and CEA-expressing tumor cells, which cross-links the T-cells with the tumor cells. This may result in a potent cytotoxic T-lymphocyte (CTL) response against CEA-expressing tumor cells. CEA is overexpressed in many cancer cell types.","Cibisatamab | CIBISATAMAB | RG-7802 | RG7802 | RO6958688 | WHO 10636",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545011","Apremilast","C147044","An orally bioavailable, small molecule inhibitor of phosphodiesterase 4 (PDE4), with potential anti-inflammatory activity. Upon oral administration, apremilast targets, binds to and inhibits the activity of PDE4, thereby blocking cyclic adenosine monophosphate (cAMP) degradation and increasing intracellular cAMP levels. This may decrease the production of the proinflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha). PDE4 is an enzyme that plays an important role in the degradation of cAMP and in cytokine production in inflammatory cells.","Apremilast | (+)-N-(2-((1S)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxo- 2,3-dihydro-1H-isoindol-4-yl)acetamide | APREMILAST | CC 10004 | CC-10004 | CC10004 | Otezla",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523557","Leucovorin/Fluorouracil/Oxaliplatin/Cetuximab","C136246","A regimen consisting of leucovorin, fluorouracil and oxaliplatin (FOLFOX), plus cetuximab that is used for the treatment of colon cancer.","FOLFOX-Cetuximab Regimen | FOLFOX Plus Cetuximab | FOLFOX Plus Erbitux | FOLFOX-Cetuximab | FOLFOX/Cetuximab | FOLFOX/Cetuximab Regimen | FOLFOX/Cetuximab Regimen | FOLFOX/Erbitux Regimen | Folinic Acid/Fluorouracil/Oxaliplatin/Cetuximab Regimen | Leucovorin/Fluorouracil/Oxaliplatin/Cetuximab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523558","FOLFOX Plus Panitumumab","C136247","A regimen consisting of leucovorin, fluorouracil and oxaliplatin (FOLFOX), plus panitumumab that is used for the treatment of colon cancer.","FOLFOX-Panitumumab Regimen | FOLFOX Plus Panitumumab | FOLFOX Plus Vectibix | FOLFOX-Panitumumab | FOLFOX/Panitumumab | FOLFOX/Panitumumab Regimen | FOLFOX/Panitumumab Regimen | FOLFOX/Vectibix | FOLFOX/Vectibix Regimen | Folinic Acid/Fluorouracil/Oxaliplatin/Panitumumab Regimen | Leucovorin/Fluorouracil/Oxaliplatin/Panitumumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL439099","FOLFIRI-Cetuximab Regimen","C104152","A regimen consisting of leucovorin (folinic acid), 5-fluorouracil, and irinotecan plus cetuximab that can be used for the treatment of colorectal cancer.","FOLFIRI-Cetuximab Regimen | FOLFIRI and Cetuximab | FOLFIRI and Cetuximab (L-Leucovorin) | FOLFIRI-Erbitux Regimen | FOLFIRI/Cetuximab Regimen | Leucovorin-Fluorouracil-Irinotecan-Cetuximab Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523560","FOLFIRI Plus Vectibix","C136249","A regimen consisting of leucovorin, fluorouracil and irinotecan (FOLFIRI), plus panitumumab that is used for the treatment of colorectal cancer.","FOLFIRI-Panitumumab Regimen | FOLFIRI Plus Panitumumab | FOLFIRI Plus Vectibix | FOLFIRI and Panitumumab | FOLFIRI-Vectibix Regimen | FOLFIRI/Panitumumab Regimen | FOLFIRI/Panitumumab Regimen | FOLFIRI/Vectibix Regimen | Folinic Acid/Fluorouracil/Irinotecan/Panitumumab Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880657","FOLFIRI-Bevacizumab Regimen","C63608","A regimen consisting of bevacizumab, fluorouracil, irinotecan and leucovorin that may be used in the treatment of ampullary and appendiceal adenocarcinoma, colorectal cancer, and small bowel adenocarcinoma.","FOLFIRI-Bevacizumab Regimen | Bevacizumab + IFL | FOLFIRI and Bevacizumab | FOLFIRI and Bevacizumab (L-Leucovorin) | FOLFIRI and Bevacizumab-adcd | FOLFIRI and Bevacizumab-adcd (L-Leucovorin) | FOLFIRI and Bevacizumab-awwb | FOLFIRI and Bevacizumab-awwb (L-Leucovorin) | FOLFIRI and Bevacizumab-aybi | FOLFIRI and Bevacizumab-aybi (L-Leucovorin) | FOLFIRI and Bevacizumab-bvzr | FOLFIRI and Bevacizumab-bvzr (L-Leucovorin) | FOLFIRI and Bevacizumab-equi | FOLFIRI and Bevacizumab-equi (L-Leucovorin) | FOLFIRI and Bevacizumab-maly | FOLFIRI and Bevacizumab-maly (L-Leucovorin) | FOLFIRI and Bevacizumab-onbe | FOLFIRI and Bevacizumab-onbe (L-Leucovorin) | FOLFIRI and Bevacizumab-tnjn | FOLFIRI and Bevacizumab-tnjn (L-Leucovorin) | FOLFIRI-Avastin Regimen | FOLFIRI-Avastin regimen | FOLFIRI-bevacizumab regimen | FOLFIRI/Bevacizumab Regimen | Folinic Acid-Fluorouracil-Irinotecan-Bevacizumab Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879914","CAPOX-Bevacizumab Regimen","C63609","A regimen consisting of bevacizumab, capecitabine and oxaliplatin that may be used in the treatment of colorectal cancer, small bowel, appendiceal, and ampullary adenocarcinoma and mucinous carcinoma of the ovary.","CAPOX-Bevacizumab Regimen | B-CAPOX | CAPOX Plus Bevacizumab | CAPOX-Avastin Regimen | CAPOX-B | CapeOx and Bevacizumab | CapeOx and Bevacizumab-adcd | CapeOx and Bevacizumab-awwb | CapeOx and Bevacizumab-aybi | CapeOx and Bevacizumab-bvzr | CapeOx and Bevacizumab-equi | CapeOx and Bevacizumab-maly | CapeOx and Bevacizumab-onbe | CapeOx and Bevacizumab-tnjn | CapeOx/Bevacizumab | Capecitabine-Oxaliplatin-Bevacizumab Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969051","Cetuximab Regimen","C160009","A regimen consisting of cetuximab that may be used in the treatment of colorectal, penile, and head and neck cancers.","Cetuximab Regimen | Cetuximab monotherapy | Erbitux Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969186","Panitumumab Regimen","C160104","A regimen consisting of panitumumab that may be used in the treatment of wild-type RAS metastatic colorectal cancer.","Panitumumab Regimen | Panitumumab monotherapy | Vectibix Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969866","ICD-O-3 Behavior Code","C160910","The code for the behavior of the tumor being reported using ICD-O-3.","ICD-O-3 Behavior Code | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0771315","Omeprazole Sodium","C74598","The sodium salt form of a benzimidazole with selective and irreversible proton pump inhibitor activity. In the acidic compartment of parietal cells, omeprazole is protonated and converted into the active achiral sulfenamide; the active sulfenamide forms one or more covalent disulfide bonds with the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase), thereby inhibiting its activity and the parietal cell secretion of H+ ions into the gastric lumen, the final step in gastric acid production. H+/K+ ATPase is an integral membrane protein of the gastric parietal cell.","Omeprazole Sodium | OMEPRAZOLE SODIUM | Omeprazole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0132182","Chloroprocaine Hydrochloride","C47444","A synthetic, aminoester, local, anesthetic agent. At the injection site, chloroprocaine hydrochloride acts by inhibiting sodium influx through binding to specific membrane sodium ion channels in the neuronal cell membranes, restricting sodium permeability, and blocking nerve impulse conduction. This leads to a loss of sensation. Chloroprocaine hydrochloride is short-acting due to rapid hydrolysis by pseudocholinesterase into para-aminobenzoic acid in plasma.","Chloroprocaine Hydrochloride | 2-Diethylaminoethyl 4-amino-2-chlorobenzoate Hydrochloride | Benzoic Acid, 4-amino-2-chloro-, 2-(diethylamino)ethyl Ester, Hydrochloride | CHLOROPROCAINE HYDROCHLORIDE | Chloroprocaine | Nesacaine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0546864","Fentanyl Citrate","C47994","The citrate salt of fentanyl, a synthetic opioid related to the phenylpiperidines with analgesic and anesthetic properties. Fentanyl exerts its analgesic effect by selectively binding to the mu-opioid receptor in the central nervous system (CNS), thereby mimicking the effects of endogenous opiates. Additional pharmacological effects of fentanyl include anxiolysis, euphoria, feelings of relaxation, respiratory depression, constipation, miosis, and cough suppression.","Fentanyl Citrate | Actiq | FENTANYL CITRATE | Fentanyl | Fentyl | Oralet | Sublimaze | fentanyl citrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0304448","Methohexital Sodium","C66117","The sodium salt of methohexital, a rapid, short-acting barbituric acid derivative, with anesthetic activity. Methohexital binds to the chloride ionophore site of the gamma-aminobutyric acid (GABA)-A/chloride ionophore receptor complex, thereby enhancing the inhibitory actions of GABA-A in the brain. This leads to synaptic inhibition, decreased neuronal excitability and induction of anesthesia. In addition, this agent decreases glutamate (Glu) responses.","Methohexital Sodium | Brevital | METHOHEXITAL SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042435","Vecuronium Bromide","C47782","The bromide salt form of vecuronium, a synthetic steroid derivative of the naturally occurring alkaloids of curare with a muscle relaxant property. Vecuronium bromide competes with acetylcholine for the nicotinic receptors at the neuromuscular junction of skeletal muscles, thereby inhibiting the action of acetylcholine and blocking the neural transmission without depolarizing the postsynaptic membrane. This leads to skeletal muscle relaxation and paralysis.","Vecuronium Bromide | NC-45 | Norcuron | Piperidinium, 1-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)-2-(1-piperidinyl)androstan-16-yl)-1-methyl-, Bromide | VECURONIUM BROMIDE | Vercuronium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030311","Pancuronium Bromide","C47651","The bromide salt form of pancuronium, a synthetic, long-acting ammonio steroid muscle relaxant with curarimimetic, some antimuscarinic and sympathomimetic effects. Pancuronium bromide competitively binds to the nicotinic receptor at the neuromuscular junction, thereby preventing acetylcholine binding and resulting in skeletal muscle relaxation and paralysis.","Pancuronium Bromide | 2beta,16beta-Dipiperidino-5alpha-androstane-3alpha,17beta-diol Diacetate Dimethobromide | PANCURONIUM BROMIDE | Pancuronium | Pavulon | Piperidinium, 1,1'-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1-methyl)-, Dibromide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973186","Beclomethasone Dipropionate/Formoterol Fumarate Inhalation Solution","C162757","An inhalation solution composed of a fixed combination of the dipropionate salt form of the synthetic glucocorticoid beclomethasone and the fumarate salt form of the long-acting and selective sympathomimetic beta-receptor agonist formoterol, with anti-inflammatory and bronchial smooth muscle-relaxing activities. Upon pressurized inhalation of the beclomethasone/formoterol solution, beclomethasone binds to intracellular glucocorticoid receptors (GRs), exhibiting inhibitory activities against multiple cell types and mediators associated with allergic inflammation. Formoterol selectively binds to beta-2 adrenergic receptors in bronchial smooth muscle, activating intracellular adenylyl cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3', 5'-adenosine monophosphate (cAMP). Increased intracellular cAMP results in the relaxation of bronchial smooth muscle and inhibition of the cellular release of mediators of immediate hypersensitivity, especially from mast cells. This may improve lung function.","Beclomethasone Dipropionate/Formoterol Fumarate Inhalation Solution | Beclomethasone/Formoterol Inhalation Solution | Fostair Inhalation Solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951151","Time of First Temperature","C159280","A question about the time that the first body temperature was recorded.","Time of First Temperature | Time of first temperature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951152","Time of Second Temperature","C159281","A question about the time that the second body temperature was recorded.","Time of Second Temperature | Time of second temperature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449961","Number of Units","C158697","The number of units.","Number of Units | #units",,,,,,,,,,,,,,,"4129634","Number of units",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL951254","CO2 Level at Organ Excision Time","C159202","A question about the CO2 level that was recorded at the time closest to organ excision.","CO2 Level at Organ Excision Time | Carbon Dioxide level (CO2) recorded at time closest to organ excision",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951156","Time Specimen Left OR","C159285","A question about the time that a specimen left the operating room.","Time Specimen Left OR | Time Specimen left OR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897311","Tumor Findings Laterality","C119931","A qualifier for the side of the body the tumor findings assessment is performed.","Tumor Findings Laterality | TFLAT | TUMOR_LATERALITY | Tumor Laterality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL557059","Mantle Cell Lymphoma International Prognostic Index","C162781","A prognostic index for mantle cell lymphoma based on: age, performance status, lactate dehydrogenase (LDH), and leukocyte count. It differentiates patients into low-, intermediate-, and high-risk groups.","Mantle Cell Lymphoma International Prognostic Index | MCL International Prognostic Index | MIPI",,,,,,,,,,,,,,,"35621945","MIPI - Mantle Cell Lymphoma International Prognostic Index",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2698302","BRAF V600E Mutation Present","C80275","A molecular finding indicating the presence of a BRAF V600E mutation in a tissue sample.","BRAF V600E Mutation Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1261214","Transition Zone of Prostate","C128571","The region of the prostate gland that is located deep to both the central and peripheral zones; it surrounds the proximal urethra, and is the zone of the prostate gland that grows throughout life, most often causing a condition called benign prostatic hypertrophy.","Transition Zone of Prostate | Transition zone",,,,,,,,,,,,,,,"4160601","Transition zone of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL935974","Follow-Up Information","C156846","Information regarding the follow-up period.","Follow-Up Information | Follow Up | Follow-Up | Follow-Up Data | follow up data | follow_up_data",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935971","Follow-Up Period","C156841","The period of time determined to be follow-up.","Follow-Up Period | follow-up (clinical study)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968998","Is Individual Lost to Follow-Up","C159824","A question about whether the individual was lost to follow-up.","Is Individual Lost to Follow-Up | Is this Patient Lost to Follow-Up | Patient Lost to Follow-Up | lost to followup | lost_to_followup",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936104","Date of Last Contact","C156916","The date of the last contact.","Date of Last Contact | Date of Last Contact (if living) | Last Contact Date | date of last contact | date_of_last_contact",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935917","Number of Days from Date of Initial Cancer Diagnosis to Date of Last Contact","C156918","The number of days from the date of initial cancer diagnosis to the date of last contact.","Number of Days from Date of Initial Cancer Diagnosis to Date of Last Contact | Number of Days from Date of Initial Pathologic Diagnosis to Date of Last Contact",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969611","Number of Days from Date of Collection to Date of Last Contact","C160677","The number of days from the date of collection of the specimen to the date of last contact.","Number of Days from Date of Collection to Date of Last Contact | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935913","Number of Days from Date of Initial Cancer Diagnosis to Date of Death","C156915","The number of days from the date of initial cancer diagnosis to the date of death.","Number of Days from Date of Initial Cancer Diagnosis to Date of Death | Number of Days from Date of Initial Pathologic Diagnosis to Date of Death",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935915","Post-operative Therapy","C156914","Treatments after surgery with the intention of achieving the best possible surgical outcome.","Post-operative Therapy | Post-Operative Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936779","Specify Therapeutic Agent","C157096","A directive to record the therapeutic agent or agents.","Specify Therapeutic Agent | Therapeutic Agent | Therapeutic Agent(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935965","Outcome after Follow-Up Form Completion","C156847","The individual's outcome after the follow-up.","Outcome after Follow-Up Form Completion | Outcome at completion of this Follow-up Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935922","Tumor Status at Date of Last Contact or Death","C156912","The tumor status at date of last contact or death.","Tumor Status at Date of Last Contact or Death | Tumor Status (at date of last contact or death)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935914","Date of Performance Status Assessment","C156913","The date of the Performance Status Assessment.","Date of Performance Status Assessment | Performance Status Assessment Date",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935838","New Tumor Event Information","C156810","Data pertinent to a newly discovered tumor.","New Tumor Event Information | New Tumor Event | YYYY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968924","Was a New Tumor Event Present After Initial Treatment","C159899","A question about whether a new tumor was present after the initial treatment.","Was a New Tumor Event Present After Initial Treatment | Event After Initial Treatment | New Tumor Event After Initial Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935970","Type of New Tumor Event (Check all that apply)","C156852","The kind of new tumor activity.","Type of New Tumor Event (Check all that apply) | New Tumor Event Type | Type of New Tumor Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935967","Site of New Tumor Event","C156853","A question about the anatomic site of the new tumor activity.","What is the Site of the New Tumor Event | New Tumor Event Site | Site | Site of New Tumor Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951576","Specify Site of Other New Tumor Event","C159573","A directive to specify the site of the other new tumor event.","Specify Site of Other New Tumor Event | Other New Tumor Event Site | Other Site | Specify other Site of New Tumor Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935957","Date of New Tumor Event","C156855","The date of the new tumor event.","Date of New Tumor Event | Event Date | New Tumor Event Date",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935958","Number of Days from Date of Initial Cancer Diagnosis to Date of New Tumor Event after Initial Treatment","C156856","The number of days from the date of the initial cancer diagnosis to the date of the new tumor event after initial treatment.","Number of Days from Date of Initial Cancer Diagnosis to Date of New Tumor Event after Initial Treatment | Number of Days from Date of Initial Pathologic Diagnosis to Date of New Tumor Event after Initial Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935956","Additional Surgery for New Tumor Event","C156858","A question about any additional surgery performed for the new tumor.","Was Additional Surgery for New Tumor Event Performed | Additional Surgery for New Tumor Event | New Tumor Additional Surgery Performed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935961","Date of Additional Surgery for New Tumor Event","C156859","The date of additional surgery for the new tumor event.","Date of Additional Surgery for New Tumor Event | Additional Surgery Date | New Tumor Additional Surgery Date",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935955","Number of Days from Date of Initial Pathologic Diagnosis to Date of Additional Surgery for New Tumor Event","C156857","The number of days from the date of the initial pathologic diagnosis to the date of additional surgery for new tumor event.","Number of Days from Date of Initial Pathologic Diagnosis to Date of Additional Surgery for New Tumor Event | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935973","48 Months","C156845","A period of time of forty-eight months.","48 Months | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973167","Left Ventricular Hypertrophy with Strain","C162788","A finding of left ventricular hypertrophy based on the analysis of diagnostic metrics that may indicate a higher risk for cardiovascular events.","Left Ventricular Hypertrophy with Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969345","Bilateral Thyroid Glands","C160208","Both the left and the right thyroid glands.","Bilateral Thyroid Glands | Bilateral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951405","Stomach, NOS","C159568","An area of the stomach, not otherwise specified.","Stomach, NOS | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950697","Is there a Cancer History","C158728","A question about whether a history of cancer exists.","Is there a Cancer History | Cancer History | History of Cancer | History of prior cancer diagnosis | Is there a history of cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028798","Occupational Exposure","C16929","The exposure to potentially harmful agents that occurs as a result of one's occupation.","Occupational Exposure | OCCUPATIONAL EXPOSURE | Occupational | Work-related Exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936775","If other type of exposure, please specify","C157100","A directive to specify the type of exposure when the listed responses are not sufficient.","Specify Other Type of Exposure | If other type of exposure, please specify | Other,specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936798","CPTAC Environmental/Occupational Exposure Codelist","C157075","Terminology used to support the collection of patient environmental and occupational hazardous exposure data by CPTAC.","CPTAC Environmental/Occupational Exposure Codelist | CPTAC Chemical or Occupational Exposure Codelist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0815184","treatment setting","C124444","The surroundings or environment within which the subject receives therapeutic treatment.","Treatment Environmental Setting | Encounter Environment | TRTSETT | Treatment Setting | Treatment Setting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951574","History of any Treatments","C159571","The history of known treatments for an individual.","History of any Treatments | Is there a History of any Treatments",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950740","Unknown Tumor Status","C158709","The tumor status is unknown.","Unknown Tumor Status | Unknown tumor status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973327","Immune Effector Cell Associated Neurotoxicity Syndrome","C162909","Neurotoxicity associated with immune effector cell therapy. It may be characterized by aphasia, altered level of consciousness, motor weakness, seizures, and cerebral edema.","Immune Effector Cell Associated Neurotoxicity Syndrome | ICANS | IEC-associated Neurotoxicity Syndrome | Immune Effector Cell Encephalopathy",,,,,,,,,,,,,,,"37151422","Immune effector cell-associated neurotoxicity syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL973291","Immune Effector Encephalopathy - ICE Assessment","C162916","A grading system for Immune Effector Cell Associated Neurotoxicity Syndrome that includes: orientation to year, month, city, hospital; ability to name objects; ability to follow simple commands; ability to write a standard sentence; and ability to count backwards from 100 by 10. Grading ranges from 10: no impairment to 0: patient unarousable and unable to perform ICE assessment.","Immune Effector Encephalopathy - ICE Assessment | ICE Assessment | ICE Tool | Immune Effector Encephalopathy Assessment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519185","Camphor/Menthol-based Formulation","C29445","A combination preparation containing camphor and menthol with anti-pruritic activity. Camphor, a terpenoid extracted from camphor laurel (Cinnamonum camphora) tree, can be absorbed readily through the skin and produces a cooling feeling similar to that of menthol. This formulation is used to relieve itching and cools irritated skin due to sunburn, dry and itchy skin, poison ivy, poison oak, insect bites, minor cuts, burns and abrasions.","Camphor/Menthol-based Formulation | Sarna",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541478","Adenoviral Brachyury Vaccine ETBX-051","C143034","A therapeutic cancer vaccine composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human transcription factor brachyury encoded, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the adenoviral brachyury vaccine ETBX-051 expresses the brachyury protein. The expressed brachyury may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing brachyury, thereby resulting in both immune-mediated inhibition of tumor cell proliferation and tumor cell death. Deletion of the E1, E2b and E3 genes from Ad5 prevents anti-adenovirus immune responses. Brachyury, a tumor-associated antigen (TAA) and member of the T-box family of transcription factors, is overexpressed in a variety of tumor types. It plays an important role in cancer progression and metastasis.","Adenoviral Brachyury Vaccine ETBX-051 | Ad5-brachyury vaccine | ETBX 051 | ETBX-051",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541479","Adenoviral MUC1 Vaccine ETBX-061","C143035","A therapeutic cancer vaccine composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human glycoprotein mucin 1 (MUC1) encoded, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the adenoviral MUC1 vaccine ETBX-061 expresses the MUC1 protein. The expressed MUC1 may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing MUC1, thereby resulting in both immune-mediated inhibition of tumor cell proliferation and tumor cell death. Deletion of the E1, E2b and E3 genes from Ad5 prevents anti-adenovirus immune responses. MUC1, a tumor-associated antigen (TAA) and type I transmembrane protein, is overexpressed in a variety of tumor types. It plays an important role in cancer progression and metastasis.","Adenoviral MUC1 Vaccine ETBX-061 | Ad5-MUC1 vaccine | ETBX 061 | ETBX-061",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970098","East Asian","C161419","A person having origins in any of the original peoples of East Asian, including China, Japan, Korea, or Mongolia.","East Asian | EAST ASIAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969936","Every Six Days","C161335","Planned or occurring every six days.","Every Six Days | Q6D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969945","Every Sixteen Weeks","C161336","Planned or occurring every sixteen weeks.","Every Sixteen Weeks | EVERY 16 WEEKS | Q16S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0585344","Every Five Years","C161334","Planned or occurring every five years.","Every Five Years | EVERY 5 YEARS",,,,,,,,,,,,,,,"4144051","Every five years",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0585343","Every Three Years","C161333","Planned or occurring every three years.","Every Three Years | EVERY 3 YEARS",,,,,,,,,,,,,,,"4146469","Every three years",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL969937","Every Twelve Weeks","C161332","Planned or occurring every twelve weeks.","Every Twelve Weeks | EVERY 12 WEEKS | Q12S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970583","Solid Dispersion Immediate Release Tablet Dosage Form","C162112","A solid dosage form containing one or more active pharmaceutical ingredient which can be dispersed in a carrier at solid state, and immediately released upon administration.","Solid Dispersion Immediate Release Tablet Dosage Form | TABLET, IMMEDIATE RELEASE, SOLID DISPERSION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969944","T-Lymphocyte Proliferation Index","C161337","A relative measurement (ratio or percentage) of T-lymphocyte proliferation due to stimulation by an antigen of interest to a non-stimulated T-lymphocyte proliferation control.","T-Lymphocyte Proliferation Index | TLYMPIDX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3533225","Unspecified Cells to Leukocytes Ratio Measurement","C161364","The determination of the ratio of unspecified cells compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Unspecified Cells to Leukocytes Ratio Measurement | UNSPCELE | Unspecified Cells/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971245","Thyroid Stimulating Immunoglobulin Actual to Control Ratio Measurement","C161368","The determination of the ratio of the thyroid stimulating immunoglobulin in a subject's specimen compared to a control sample. The measurement may be expressed as a ratio or percentage.","Thyroid Stimulating Immunoglobulin Actual to Control Ratio Measurement | TSI Actual/Control | TSIAC | Thyroid Stimulating Immunoglobulin Actual/Control | Thyroid Stimulating Immunoglobulin Actual/Normal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266765","Tramadol Measurement","C161376","The determination of the amount of tramadol present in a sample.","Tramadol Measurement | TRAMADOL | Tramadol",,,,,,,,,,,,,,,"4006686","Tramadol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL970111","Thrombin Time Actual to Control Ratio Measurement","C161370","The determination of the ratio of the thrombin time in a subject's specimen compared to a control sample. The measurement may be expressed as a ratio or percentage.","Thrombin Time Actual to Control Ratio Measurement | TTAC | Thrombin Time Actual/Control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971240","Thrombin Antithrombin Complex Measurement","C161371","The determination of the amount of thrombin antithrombin complex present in a sample.","Thrombin Antithrombin Complex Measurement | TAT | TATC | Thrombin Antithrombin Complex | Thrombin Antithrombin Complex Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970103","Progressive Spermatozoa to Total Spermatozoa Ratio Measurement","C161365","The determination of the ratio of progressive spermatozoa compared to total spermatozoa present in a sample. The measurement may be expressed as a ratio or percentage.","Progressive Spermatozoa to Total Spermatozoa Ratio Measurement | SPMPSPM | Spermatozoa, Progressive/Spermatozoa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971242","Progressive Spermatozoa Measurement","C161366","The determination of the amount of progressive spermatozoa present in a sample.","Progressive Spermatozoa Measurement | SPERMP | Spermatozoa, Progressive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969954","Pus Measurement","C161359","The determination of the amount of pus present in a sample.","Pus Measurement | PUS | Pus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970102","pH Adjusted for Body Temperature Measurement","C161367","The determination of the pH, adjusted for body temperature, present in a sample.","pH Adjusted for Body Temperature Measurement | PHADJT | pH Adjusted for Body Temp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266653","Nitrate Measurement","C161352","The determination of the amount of nitrate present in a sample.","Nitrate Measurement | NITRATE | Nitrate | Nitric Acid | Nitric Acid Measurement",,,,,,,,,,,,,,,"4005839","Nitrate measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2363831","Large Platelets to Total Platelets Ratio Measurement","C161353","The determination of the ratio of large platelets compared to total platelets present in a sample. The measurement may be expressed as a ratio or percentage.","Large Platelets to Total Platelets Ratio Measurement | Large Platelets/Total Platelets | PLCR | PLTLPLT | Platelet Large Cell Ratio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969946","Kappa Light Chain to Lambda Light Chain Ratio Measurement","C161351","The determination of the ratio of kappa light chain compared to lambda light chain present in a sample. The measurement may be expressed as a ratio or percentage.","Kappa Light Chain to Lambda Light Chain Ratio Measurement | KLCLLC | Kappa Lambda Ratio | Kappa Light Chain/Lambda Light Chain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971236","Inorganic Pyrophosphate Measurement","C161358","The determination of the amount of inorganic pyrophosphate present in a sample.","Inorganic Pyrophosphate Measurement | Inorganic Pyrophosphate | PPI | PPi Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970104","Hemoglobin Fraction Pattern","C161363","A description of the hemoglobin fraction pattern in a biological specimen.","Hemoglobin Fraction Pattern | HGBFPATN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969947","Fructosamine Corrected for Total Protein Measurement","C161350","The determination of the amount of fructosamine, corrected for total protein, present in a sample.","Fructosamine Corrected for Total Protein Measurement | FRUMCRTP | Fructosamine Corrected for Total Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969948","Fractional Iron Absorption","C161349","A relative measurement (ratio or percentage) of the iron absorbed into tissue or cells to the total available iron.","Fractional Iron Absorption | FRFEABS | IAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971238","Erythrocyte Inclusion Bodies Measurement","C161375","The determination of the amount of erythrocyte inclusion bodies present in a sample.","Erythrocyte Inclusion Bodies Measurement | Erythrocyte Inclusion Bodies | INCLBRBC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970109","dRVVT Screen to Confirm Percent Difference","C161373","A measurement to confirm the presence of Lupus anticoagulants, calculated as [(Screen dRVVT - Confirm dRVVT)/Screen dRVVT]x100.","dRVVT Screen to Confirm Percent Difference | DRVTSCPD | dRVVT Screen to Confirm Pct Difference",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969956","Cytochrome P450 2C9 Activity Measurement","C161356","The determination of the amount of the biological activity of cytochrome P450 2C9 in a sample.","Cytochrome P450 2C9 Activity Measurement | CYP2C9 Activity Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969957","Cytochrome P450 2C9 Measurement","C161355","The determination of the amount of cytochrome P450 2C9 present in a sample.","Cytochrome P450 2C9 Measurement | CYP2C9 | CYP2C9 Measurement | Cytochrome P450 2C9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969955","Free Complement C5 Measurement","C161357","The determination of the amount of free complement C5 present in a sample.","Free Complement C5 Measurement | C5FR | Complement C5, Free | Free C5 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971220","Complement C5 Measurement","C160935","The determination of the amount of complement C5 present in a sample.","Complement C5 Measurement | C5 | C5 Measurement | Complement C5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970108","Choriogonadotropin Adjusted for Maternal Weight Measurement","C161374","The determination of the amount of choriogonadotropin, adjusted for maternal weight, present in a sample.","Choriogonadotropin Adjusted for Maternal Weight Measurement | CGADJMW | Choriogonadotropin Adj for Maternal Wt | Choriogonadotropin Adjusted for Maternal Weight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970107","Chemokine (C-X-C Motif) Ligand 11 Measurement","C161360","The determination of the amount of chemokine (C-X-C Motif) ligand 11 present in a sample.","Chemokine (C-X-C Motif) Ligand 11 Measurement | CXCL11 | CXCL11 Measurement | Chemokine (C-X-C Motif) Ligand 11 | I-TAC | IFN-inducible T Cell Alpha Chemoattractant | ITAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970106","Chemokine (C-X3-C Motif) Ligand 1 Measurement","C161361","The determination of the amount of chemokine (C-X3-C Motif) ligand 1 present in a sample.","Chemokine (C-X3-C Motif) Ligand 1 Measurement | CX3CL1 | CX3CL1 Measurement | Chemokine (C-X3-C Motif) Ligand 1 | Chemokine (C-X3-C motif) Ligand 1 | Fractalkine | Fractalkine Measurement | Neurotactin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970105","Chemokine (C-C Motif) Ligand 20 Measurement","C161362","The determination of the amount of chemokine (C-C Motif) ligand 20 present in a sample.","Chemokine (C-C Motif) Ligand 20 Measurement | CCL20 | CCL20 Measurement | Chemokine (C-C Motif) Ligand 20 | LARC | Liver Activation Regulated Chemokine | MIP3A | Macrophage Inflammatory Protein-3 Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970110","APTT-LA Screen to Confirm Percent Difference","C161372","A measurement to confirm the presence of Lupus anticoagulants, calculated as [(Screen aPTT - Confirm aPTT)/Screen aPTT]x100.","APTT-LA Screen to Confirm Percent Difference | APLASCPD | APTT-LA Screen to Confirm Pct Difference | PTT-LA Screen to Confirm Pct Difference",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970112","APTT-LA Actual to Control Ratio Measurement","C161369","The determination of the ratio of the Lupus anticoagulant sensitive APTT in a subject's specimen compared to a control sample. The measurement may be expressed as a ratio or percentage.","APTT-LA Actual to Control Ratio Measurement | APTT-LA Actual/Control | APTTLAAC | Lupus Anticoagulant Sensitive APTT Actual/Control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971241","Anisochromia Measurement","C161354","A measurement of the color variation of erythrocytes in a biological specimen.","Anisochromia Measurement | ANISOCHR | Anisochromia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970719","HLA-B*07 Positive Cells Present","C162262","An indication that cells expressing HLA-B*07 have been detected in a sample.","HLA-B*07 Positive Cells Present | HLA-B*07 Positive | HLA-B07 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540831","B-Cell Aplasia","C162941","A condition characterized by extremely low B-cell counts. It occurs when anti-CD19 CAR T-cells attack and kill CD19-expressing B-lymphocytes.","B-Cell Aplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0222173","Skin of the Inguinal Region","C161380","The integument that covers the inguinal region.","Skin of the Inguinal Region | SKIN OF THE INGUINAL REGION",,,,,,,,,,,,,,,"4215281","Skin structure of inguinal region",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0222149","Skin of the Chest","C161379","The integument that covers the chest.","Skin of the Chest | SKIN OF THE CHEST",,,,,,,,,,,,,,,"4252576","Skin structure of chest",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0222215","Skin of the Forearm","C161378","The integument that covers the forearm.","Skin of the Forearm | SKIN OF THE FOREARM",,,,,,,,,,,,,,,"4238998","Skin structure of forearm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0447612","Vaginal Wall","C161377","The tissue layers that enclose the vaginal canal.","Vaginal Wall | VAGINAL WALL | Vaginal wall (body structure)",,,,,,,,,,,,,,,"4136870","Vaginal wall",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0222275","Knee Skin","C64859","The skin of the hinge joint that is located between the thigh and lower leg.","Knee Skin | SKIN OF THE KNEE",,,,,,,,,,,,,,,"4272029","Skin structure of knee",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0222213","Elbow Skin","C52755","The skin of the hinge joint that is located between the forearm and upper arm.","Elbow Skin | SKIN OF THE ELBOW",,,,,,,,,,,,,,,"4254263","Skin structure of elbow",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0222289","Foot Skin","C52750","The skin covering the foot.","Foot Skin | SKIN OF THE FOOT",,,,,,,,,,,,,,,"4263673","Skin structure of foot",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL522927","Serum Quantitative Immunoglobulins","C135570","The determination of the total amount of IgG, IgM, and IgA present in a serum sample.","Serum Quantitative Immunoglobulins | Serum Total Immunoglobulins",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970115","Skin of the Infrascapular Region","C161391","The integument that covers the region of the back, lateral to the vertebral region and below the scapula.","Skin of the Infrascapular Region | SKIN OF THE INFRASCAPULAR REGION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970116","Ankle Joint Anterior Extensor Tendons","C161390","The tendons in the anterior compartment of the leg that cross the tibiotalar joint anteriorly and connect muscles that originate on the surfaces of the tibia and fibula to bones in the toes and enable dorsiflexion of the foot at the ankle and extension of the toes.","Ankle Joint Anterior Extensor Tendons | ANKLE JOINT ANTERIOR EXTENSOR TENDONS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970117","Ankle Joint Anterior Flexor Tendons","C161389","The tendons in the anterior compartment of the leg that connect muscles that originate on the surfaces of the femur, tibia, and fibula to bones in the toes and enable plantar flexion of the foot at the ankle.","Ankle Joint Anterior Flexor Tendons | ANKLE JOINT ANTERIOR FLEXOR TENDONS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970118","Knee Joint Tendons","C161388","The tendons that connect the quadriceps muscles to the kneecap, the hamstring muscles to the shin bone and fibula, and the patella to the top part of the fibula, enabling flexion, extension, and slight rotation of the knee.","Knee Joint Tendons | KNEE JOINT TENDONS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970119","Shoulder Joint Tendons","C161387","The tendons that connect the muscles and bones that comprise the glenohumeral and acromioclavicular joints and enable abduction of the arm and stabilization of the shoulder.","Shoulder Joint Tendons | SHOULDER JOINT TENDONS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970120","Wrist Joint Extensor Tendons","C161386","The tendons located along the back part of the forearm that cross to the thumb side of the wrist and connect muscles of the forearm to the base of hand bones, enabling bending of the wrist back and towards the thumb.","Wrist Joint Extensor Tendons | WRIST JOINT EXTENSOR TENDONS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970121","Wrist Joint Flexor Tendons","C161385","The tendons located along the inside of the forearm that cross at the wrist and connect muscles of the forearm to wrist and hand bones, enabling bending of the wrist towards the palm.","Wrist Joint Flexor Tendons | WRIST JOINT FLEXOR TENDONS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224927","Finger Extensor Tendons","C161384","The tendons located on the dorsal side of the fingers that connect muscles of the forearm and hand to bones in the fingers, enabling straightening of the fingers.","Finger Extensor Tendons | FINGER EXTENSOR TENDONS",,,,,,,,,,,,,,,"4275025","Structure of extensor tendon within finger",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224909","Finger Flexor Tendons","C161383","The tendons located on the palm side of the fingers that connect the flexor muscles of the forearm and hand to bones in the fingers, enabling flexion towards the palm.","Finger Flexor Tendons | FINGER FLEXOR TENDONS",,,,,,,,,,,,,,,"4283440","Structure of flexor tendon within finger",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL970113","Heel of the Hand","C161382","The raised part of the palm of the hand that is adjacent to the wrist.","Heel of the Hand | HEEL OF THE HAND | Heel of the Palm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970114","Heel of the Foot","C161381","The rounded back part of the foot below the ankle and behind the arch.","Heel of the Foot | HEEL OF THE FOOT | Heel (calcaneus)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970082","Candida albicans Measurement","C161404","The determination of the amount of Candida albicans present in a sample.","Candida albicans Measurement | CAL | Candida albicans | Candida stellatoidea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970083","Trichomonas vaginalis Measurement","C161403","The determination of the amount of Trichomonas vaginalis present in a sample.","Trichomonas vaginalis Measurement | TVA | Trichomonas vaginalis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970084","Gardnerella vaginalis Measurement","C161402","The determination of the amount of Gardnerella vaginalis present in a sample.","Gardnerella vaginalis Measurement | Corynebacterium vaginalis | GVA | Gardnerella vaginalis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970085","Gram Negative Cocci Measurement","C161401","The determination of the amount of gram negative cocci present in a sample.","Gram Negative Cocci Measurement | GMNCOC | Gram Negative Cocci",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970086","Bacterial Beta-lactamase Measurement","C161400","The determination of the amount of bacterial Beta-lactamase present in a sample.","Bacterial Beta-lactamase Measurement | BACBLACT | Bacterial Beta-lactamase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970073","Neisseria gonorrhoeae, Beta-lactamase Negative Measurement","C161399","The determination of the amount of beta-lactamase negative Neisseria gonorrhoeae present in a sample.","Neisseria gonorrhoeae, Beta-lactamase Negative Measurement | N. gonorrhoeae, Beta-lactamase Negative | NGOBLN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970074","Neisseria gonorrhoeae, Beta-lactamase Positive Measurement","C161398","The determination of the amount of beta-lactamase positive Neisseria gonorrhoeae present in a sample.","Neisseria gonorrhoeae, Beta-lactamase Positive Measurement | N. gonorrhoeae, Beta-lactamase Positive | NGOBLP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970076","Enterococcus faecalis Measurement","C161396","The determination of the amount of Enterococcus faecalis present in a sample.","Enterococcus faecalis Measurement | EFA | Enterococcus faecalis | Streptococcus faecalis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971167","Human Immunodeficiency Virus Measurement","C161395","The determination of the amount of Human Immunodeficiency Virus present in a sample.","Human Immunodeficiency Virus Measurement | HIV | HIV Measurement | Human Immunodeficiency Virus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970077","Cytomegalovirus DNA Measurement","C161394","The determination of the amount of Cytomegalovirus DNA present in a sample.","Cytomegalovirus DNA Measurement | CMVDNA | Cytomegalovirus DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970078","HIV-1/2 RNA Measurement","C161393","The determination of the amount of HIV-1/2 RNA present in a sample.","HIV-1/2 RNA Measurement | HIV-1/2 RNA | HIV12RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970079","Chlamydia trachomatis DNA Measurement","C161392","The determination of the amount of Chlamydia trachomatis DNA present in a sample.","Chlamydia trachomatis DNA Measurement | CTRDNA | Chlamydia trachomatis DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969842","Beta-lactamase Negative Bacteria Measurement","C160937","A measurement of the beta-lactamase negative bacteria in a biological specimen.","Beta-lactamase Negative Bacteria Measurement | BLNBAC | Beta-lactamase Negative Bacteria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969843","Beta-lactamase Positive Bacteria Measurement","C160936","A measurement of the beta-lactamase positive bacteria in a biological specimen.","Beta-lactamase Positive Bacteria Measurement | BLPBAC | Beta-lactamase Positive Bacteria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970093","Kleihauer-Betke Staining Procedure","C161409","A biospecimen collection and staining procedure in which maternal blood smear is prepared and stained using Shepard's staining method, followed by microscopic examination to identify fetal-maternal hemorrhage (fetal hemoglobin transference to the mother's bloodstream).","Kleihauer-Betke Staining Procedure | KLEIHAUER-BETKE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970094","Multiple Inert Gas Elimination Technique","C161408","A technique that measures the pulmonary exchange of a set of six different inert gases dissolved together in saline (or dextrose) and infused intravenously. The measurements are then used to compute the distribution of ventilation/perfusion ratios that best describes the exchange of the six gases simultaneously. (Wagner PD. The multiple inert gas elimination technique (MIGET). Intensive Care Med. 2008 Jun;34(6):994-1001.)","Multiple Inert Gas Elimination Technique | MIGET",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970080","Dynamometry","C161407","A technique that measures the torque, or force, of muscle action.","Dynamometry | DYNAMOMETRY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970081","Single-Molecule Array","C161406","A type of enzyme-linked immunoassay in which single molecules can be detected through the use of femtomolar-sized reaction chambers and an excess of fluorescently labeled antibody-bound beads.","Single-Molecule Array | SINGLE-MOLECULE ARRAY | SiMoA | Single Molecule Array Immunoassay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0412669","Quantitative Computed Tomography","C161405","A type of computed tomography in which a calibration standard correlates radiodensity values to quantitative tissue density values.","Quantitative Computed Tomography | QCT | QUANTITATIVE COMPUTED TOMOGRAPHY",,,,,,,,,,,,,,,"4318967","CT bone density",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448910","Surface Plasmon Resonance","C18117","A quantum optical-electrical phenomena consisting of an alteration in light reflectance as a result of binding of molecules to a surface from which total internal reflection is occurring. Used to detect macromolecular interactions, SPR can be used as the basis for a sensor which is capable of sensitive and quantitative measurement of a broad spectrum of chemical and biological entities.","Surface Plasmon Resonance | SURFACE PLASMON RESONANCE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970091","Non-Compliance With Study Schedule","C161411","An indication that a study subject has not followed the schedule of activities.","Non-Compliance With Study Schedule | NON-COMPLIANCE WITH STUDY SCHEDULE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970092","Subject Removed at Sponsor Request","C161410","An indication that the study subject was removed from the study at the sponsor's request.","Subject Removed at Sponsor Request | SPONSOR REQUEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973241","Grade I Breast Capsule Contracture","C162738","Breast is soft and appears natural in size and shape.","Grade I Breast Capsule Contracture | Capsular Contracture Grade I | Grade I Capsular Contracture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973231","Grade II Breast Capsule Contracture","C162739","Minimal contracture; there is some firmness, but the breast appears natural.","Grade II Breast Capsule Contracture | Capsular Contracture Grade II | Grade II Capsular Contracture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973232","Grade III Breast Capsule Contracture","C162740","Moderate contracture; the breast is firm and appears abnormal.","Grade III Breast Capsule Contracture | Capsular Contracture Grade III | Grade III Capsular Contracture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973229","Grade IV Breast Capsule Contracture","C162741","Severe contracture; the breast is hard, painful to touch, and appears abnormal.","Grade IV Breast Capsule Contracture | Capsular Contracture Grade IV | Grade IV Capsular Contracture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970090","No Steroid Use Beyond Physiologic Replacement Dose","C161412","An indication that the subject's steroid dose is the same as their physiologic replacement dose.","No Steroid Use Beyond Physiologic Replacement Dose | NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970101","PK Swing","C161416","The difference between Cmax and Cmin standardized to Cmin within a dosing interval.","PK Swing | SWING | Swing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970087","Natural Log Transformed Cmax","C161415","The natural log transformed maximum concentration occurring at Tmax.","Natural Log Transformed Cmax | CMAXLN | Max Conc LN Transformed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970088","Natural Log Transformed Area Under the Curve From Dosing to Last Concentration","C161414","The natural log transformed area under the curve (AUC) from the time of dosing to the last measurable concentration.","Natural Log Transformed Area Under the Curve From Dosing to Last Concentration | AUC to Last Nonzero Conc LN Transformed | AUCLSTLN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970089","Natural Log Transformed Observed Area Under the Curve Infinity","C161413","The natural log transformed area under the curve (AUC) extrapolated to infinity, calculated using the observed value of the last non-zero concentration.","Natural Log Transformed Observed Area Under the Curve Infinity | AUC Infinity Obs LN Transformed | AUCIFOLN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973388","Classical Leptomeningeal Disease Finding","C162991","A finding of diffuse spread of neoplastic cells to the leptomeninges that may be characterized by thin, linear leptomeningeal enhancement in the central nervous system on MRI.","Classical Leptomeningeal Disease Finding | Classical Leptomeningeal Disease | cLMD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973389","Nodular Leptomeningeal Disease Finding","C162992","A finding of diffuse spread of neoplastic cells to the leptomeninges that may be characterized by focal nodular enhancement on the dural, pial, or meningeal surface on MRI.","Nodular Leptomeningeal Disease Finding | Nodular Leptomeningeal Disease | nLMD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970286","Diabetes Distress Scale for Adults with Type 1 Diabetes Questionnaire","C161655","A standardized 28-item self-report questionnaire first published by Fisher et al. in 2015 that utilizes a six-point response scale to assess seven major sources of diabetes distress for adults with Type 1 Diabetes: powerlessness, management distress, hypoglycemia distress, negative social perceptions, eating distress, physician distress, and friends/family distress.","Diabetes Distress Scale for Adults with Type 1 Diabetes Questionnaire | DDS01 | T1-DDS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970287","EOR01","C161654","A standardized 30-item self-administered quality of life questionnaire, developed by the European Organization for the Research and Treatment of Cancer Quality of Life Group in 1995 as an update to the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 36 (EORTC QLQ-C36), which was originally developed in 1987 and then modified to become EORTC QLQ-C30 in 1993. EORTC QLQ-C30 V3.0 utilizes a four-point response scale to assess functional, symptom, and global health status/quality of life scales, as well as five additional single symptoms and perceived financial impact, and a seven-point response scale to assess overall health and quality of life.","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 | EOR01 | EORTC QLQ-C30 V3.0 | EORTC QLQ-C30 Version 3 | European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970288","EOR02","C161653","A standardized 15-item questionnaire, developed in 2006 by the European Organization for Research and Treatment of Cancer as an abbreviated version of the cancer-specific quality of life questionnaire European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30), that utilizes a four-point response scale to assess the symptoms and problems for which patients are frequently treated in palliative care, and a seven-point response scale to assess overall quality of life.","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Paliative Care Version 1.0 | EOR02 | EORTC QLQ-C15-PAL V1.0 | EORTC QLQ-C15-PAL Version 1 | European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire - Paliative Care Version 1.0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969032","BCG Regimen","C159996","A regimen consisting of Bacillus Calmette-Guerin (BCG) that may be used in the treatment of bladder cancer.","BCG Regimen | Bacillus Calmette-Guerin (BCG) monotherapy | Bacillus Calmette-Guerin Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970049","Anatomical Location of Interest","C161481","The identification of an anatomical location that may contain a tumor, lesion or site of disease, and is part of the assessment of the response to the therapeutic intervention.","Anatomical Location of Interest | Anatomic LOI | LOCATION OF INTEREST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970045","Cardiovascular Lesion Indicator","C161485","An indication as to whether a cardiovascular lesion is present.","Cardiovascular Lesion Indicator | CVLIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970046","Fibrotic Lesion Indicator","C161484","An indication as to whether a fibrotic lesion is present.","Fibrotic Lesion Indicator | FIBLIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970047","Non-Target Indicator","C161483","An indication as to whether a non-target tumor, lesion, or site of disease is present.","Non-Target Indicator | NTIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970048","Measurable Tumor Indicator","C161482","An indication as to whether a measurable tumor is present.","Measurable Tumor Indicator | MEASIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0857127","Induction Therapy","C158876","The first choice of treatment for a particular type of cancer.","Induction Therapy | Induction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970204","Phosphatidylserine IgA Antibody Unit","C161498","A unit for semiquantitative measurement of IgA autoantibodies to proteins associated with phosphatidylserine evaluated against an established reference standard.","Phosphatidylserine IgA Antibody Unit | APS U | IgA Antiphosphatidylserine Unit | Immunoglobin A Phosphatidylserine Units | {APS U} | {APS'U}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970205","Phosphatidylserine IgG Antibody Unit","C161497","A unit for semiquantitative measurement of IgG autoantibodies to proteins associated with phosphatidylserine evaluated against an established reference standard.","Phosphatidylserine IgG Antibody Unit | GPS U | Immunoglobin G Phosphatidylserine Units | {GPS U}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970206","Phosphatidylserine IgM Antibody Unit","C161496","A unit for semiquantitative measurement of IgM autoantibodies to proteins associated with phosphatidylserine evaluated against an established reference standard.","Phosphatidylserine IgM Antibody Unit | Immunoglobin M Phosphatidylserine Units | MPS U | {MPS U}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970195","Micrograms DDU Per Liter","C161495","A unit of equivalent concentration equal to the number of micrograms of D-dimer per unit volume equal to one liter.","Micrograms DDU Per Liter | ug DDU/L | ug.{DDU}/L | ug.{DDU}/l | ug/L DDU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL529450","D-Dimer Unit","C161494","A unit of measure for the concentration of fibrin degradation products in a sample, calculated based upon the mass of D-dimers contained within that sample.","D-Dimer Unit | DDU | {DDU}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017399","Genomic Equivalents","C161493","A unit defined as the number of whole organism genomes in a sample.","Genomic Equivalents | GE | genEq | {genEq}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970196","Genomic Equivalents per Milliliter","C161492","A unit of concentration defined as the number of genomic equivalents per milliliter.","Genomic Equivalents per Milliliter | GE/mL | genEq/mL | {genEq}/mL | {genEq}/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970197","Electrochemiluminescence Unit","C161491","A unit for measuring concentration or/and reactivity of a test substance as defined in the literature reference standard for the particular quantitative electrochemiluminescent method.","Electrochemiluminescence Unit | ECL unit | {ECL unit}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971165","Per Millisecond","C161490","A unit of time, which is equal to the reciprocal of one thousandth of a second.","Per Millisecond | /ms | 1/ms | Reciprocal of Millisecond | ms^-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971232","Square Millisecond","C161489","A unit of time which is equal to one thousandth of a second squared.","Square Millisecond | ms2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970198","Degree Per Millimeter","C161488","A unit of rotation expressed as the number of degrees per unit of length equal to one millimeter.","Degree Per Millimeter | deg/mm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971182","Drink Dosing Unit","C161487","A dosing measurement based on the drink unit.","Drink Dosing Unit | DRINK | {DRINK}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970044","Milligram Per Kilogram Per Week","C161486","A dose calculation unit expressed in milligram(s) per kilogram per period of time equal to seven days.","Milligram Per Kilogram Per Week | Milligram per Kilogram per Week | mg/kg/week | mg/kg/wk | ng/ukg/week | ug/g/week",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826223","Dip Dosing Unit","C82483","A dosing measurement based on the dip unit.","Dip Dosing Unit | DIP | Dip | Snuff Dosing Unit | {DIP}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1552993","United States Pharmacopeia Unit","C48469","An arbitrary unit for the measurement of the biologic activity of antibiotics, endocrine preparations, sera, toxins, vaccines, and related products established by the United States Pharmacopeia (USP), the official public standards-setting authority for all prescription and over-the-counter medicines, dietary supplements, and other healthcare products manufactured and sold in the US. For each substance to which this unit applies, USP determines a Reference Standard and a specified assay. If the standard is the same as the WHO-approved International Biological Reference Preparation, and the same assay procedure was used for the biological effect evaluation, the USP unit is considered equal to International Unit.","United States Pharmacopeia Unit | UNITED STATES PHARMACOPEIA UNIT | USP U | USP unit | USP'U | United States Pharmacopeia unit | United States pharmacopoeia unit | [USP'U]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL375797","Fluorine F 18 Fluoroethylcholine","C70594","Ethylcholine labeled with fluorine F 18, a positron-emitting isotope. Fluorine F 18 fluoroethylcholine incorporates into tumor cells through an active, carrier-mediated transport mechanism for choline and then is phosphorylated intracellularly by choline kinase, yielding a phosphoryl derivative, and finally is integrated into cellular phospholipids, probably primarily into a phosphatidyl derivative; concentration of this agent in tumor cells as various fluorine F 18 fluoroethylcholine derivatives enables tumor imaging using positron emission tomography (PET). Choline kinase, the enzyme responsible for the phosphorylation of choline, is frequently up-regulated in human tumor cell lines.","Fluorine F 18 Fluoroethylcholine | 18F-Fluoroethylcholine | FLUOROETHYLCHOLINE ION F-18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049507","Recurrent Urothelial Carcinoma","C157631","The reemergence of urothelial carcinoma after a period of remission.","Recurrent Urothelial Carcinoma | Recurrent Urothelial Cancer | Relapsed Urothelial Cancer | Relapsed Urothelial Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504702","Metastatic Urothelial Carcinoma","C126109","A carcinoma that arises from the urothelium and has spread from its original site of growth to another anatomic site.","Metastatic Urothelial Carcinoma | Metastatic Transitional Cell Carcinoma of the Urinary Tract | Metastatic Urothelial Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971036","Paraneoplastic Antibody","C162640","Any autoantibody produced by an individual organism in response to antigens expressed by a neoplasm present in that individual. These antibodies can cause harmful autoimmune responses in tissues or organs that are distant from the site of the neoplasm.","Paraneoplastic Antibody | Anti-Paraneoplastic Antigen Antibody | Paraneoplastic Antigen Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971023","Paraneoplastic Antibody Positive","C162639","An indication that autoantibodies that recognize paraneoplastic antigens have been detected in a sample.","Paraneoplastic Antibody Positive | Anti-Paraneoplastic Antigen Antibody Positive | Paraneoplastic Antigen Antibody Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973087","EPCAM Loss of Nuclear Expression","C162697","An indication that expression of EPCAM was not detected in the nuclei of cells in a sample.","EPCAM Loss of Nuclear Expression | CD326 Antigen Loss of Nuclear Expression | CD326 Loss of Nuclear Expression | Ep-CAM Loss of Nuclear Expression | Epithelial Cell Adhesion Molecule Loss of Nuclear Expression | GA733-2 Loss of Nuclear Expression | Gastrointestinal Tumor-Associated Antigen 2 Loss of Nuclear Expression | KSA Glycoprotein Loss of Nuclear Expression | Loss of Nuclear EPCAM | TACSTD1 Loss of Nuclear Expression | Tumor-Associated Calcium Signal Transducer 1 Loss of Nuclear Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973101","MSH3 Loss of Nuclear Expression","C162698","An indication that expression of MSH3 was not detected in the nuclei of cells in a sample.","MSH3 Loss of Nuclear Expression | DNA Mismatch Repair Protein Msh3 Loss of Nuclear Expression | DUP Loss of Nuclear Expression | Divergent Upstream Protein Loss of Nuclear Expression | Loss of Nuclear MSH3 | MRP1 Loss of Nuclear Expression | Mismatch Repair Protein 1 Loss of Nuclear Expression | hMSH3 Loss of Nuclear Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973235","Deleterious STK11 Gene Mutation","C162744","A change in the nucleotide sequence of the STK11 gene that is associated with increased risk of disease.","Deleterious STK11 Gene Mutation | Deleterious LKB1 Gene Mutation | Deleterious Liver Kinase B1 Gene Mutation | Deleterious STK11 Mutation | Deleterious Serine/Threonine Kinase 11 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973233","Deleterious DICER1 Gene Mutation","C162745","A change in the nucleotide sequence of the DICER1 gene that is associated with increased risk of disease.","Deleterious DICER1 Gene Mutation | DCR1 Gene Mutation | Deleterious DCR-1 Gene Mutation | Deleterious DCR1 Gene Mutation | Deleterious DICER Gene Mutation | Deleterious Dicer 1, Double-Stranded RNA-Specific Endoribonuclease Gene Mutation | Deleterious Dicer 1, Ribonuclease III Gene Mutation | Deleterious Dicer 1, Ribonuclease Type III Gene Mutation | Deleterious HERNA Gene Mutation | Deleterious MNG1 Gene Mutation | Deleterious RMSE2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973234","Deleterious SMARCA4 Gene Mutation","C162746","A change in the nucleotide sequence of the SMARCA4 gene that is associated with increased risk of disease.","Deleterious SMARCA4 Gene Mutation | Deleterious BAF190 Gene Mutation | Deleterious BAF190A Gene Mutation | Deleterious BRG-1 Gene Mutation | Deleterious BRG1 Gene Mutation | Deleterious BRM/SWI2-Related Gene 1 Mutation | Deleterious SNF2 Gene Mutation | Deleterious SNF2-Beta Gene Mutation | Deleterious SNF2L4 Gene Mutation | Deleterious SNF2LB Gene Mutation | Deleterious SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily A, Member 4 Gene Mutation | Deleterious SWI1 Gene Mutation | Deleterious SWI2 Gene Mutation | Deleterious hSNF2b Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973196","Deleterious CDH1 Gene Mutation","C162747","A change in the nucleotide sequence of the CDH1 gene that is associated with increased risk of disease.","Deleterious CDH1 Gene Mutation | Deleterious Arc-1 Gene Mutation | Deleterious CD324 Gene Mutation | Deleterious CDHE Gene Mutation | Deleterious Cadherin 1 Gene Mutation | Deleterious Cadherin 1, Type 1, E-Cadherin (Epithelial) Gene Mutation | Deleterious Cadherin, Epithelial Gene Mutation | Deleterious Calcium-Dependent Adhesion Protein, Epithelial Gene Mutation | Deleterious E-Cadherin Gene Mutation | Deleterious ECAD Gene Mutation | Deleterious LCAM Gene Mutation | Deleterious UVO Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973213","ASPH-Positive Neoplastic Cells Present","C162769","An immunophenotypic finding indicating the expression of ASPH gene in the neoplastic cells of a tumor sample.","ASPH-Positive Neoplastic Cells Present | ASP Beta-Hydroxylase-Positive Neoplastic Cells Present | Aspartate Beta-Hydroxylase-Positive Neoplastic Cells Present | Aspartyl/Asparaginyl-Beta-Hydroxylase-Positive Neoplastic Cells Present | HAAH-Positive Neoplastic Cells Present | Peptide-Aspartate Beta-Dioxygenase-Positive Neoplastic Cells Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1142096","Human Immunodeficiency Virus Antibody Negative","C162779","An indication that antibodies that recognize the human immunodeficiency virus have not been detected in a sample.","Human Immunodeficiency Virus Antibody Negative | Anti-HIV Antibody Negative | Anti-Human Immunodeficiency Virus Antibody Negative | HIV Antibody Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973159","Testosterone Greater than 50 ng/dL","C162795","A semiquantitative finding indicating that the concentration of testosterone in a sample is greater than 50 ng/dL.","Testosterone Greater than 50 ng/dL | Testosterone Greater than 50 | Testosterone Greater than 50 Nanograms per Deciliter | Testosterone Greater than 50 Nanograms/Deciliter | Testosterone Level Greater than 50",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973403","ASPH Positive","C163005","An indication that ASPH expression has been detected in a sample.","ASPH Positive | ASP Beta-Hydroxylase Positive | Aspartate Beta-Hydroxylase Positive | Aspartyl/Asparaginyl-Beta-Hydroxylase Positive | HAAH Positive | Peptide-Aspartate Beta-Dioxygenase Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973401","Blasts 60 Percent or More of Peripheral Blood White Cells","C163007","A semi-quantitative microscopic finding indicating that 60 percent or more of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.","Blasts 60 Percent or More of Peripheral Blood White Cells | Blasts Greater than or Equal to 60 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973402","Blasts 60 Percent or More of Bone Marrow Nucleated Cells","C163008","A semi-quantitative microscopic finding indicating that at least 60 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 60 Percent or More of Bone Marrow Nucleated Cells | Blasts Greater than or Equal to 60 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973378","ATM Proficient Tumor","C163009","A finding indicating that the expression and activity of ATM in a tumor sample is detected at or near normal levels.","ATM Proficient Tumor | A-T Mutated Proficient Tumor | AT Mutated Proficient Tumor | ATM Serine/Threonine Kinase Proficient Tumor | Ataxia Telangiectasia Mutated Proficient Tumor | Serine-Protein Kinase ATM Proficient Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973379","CKB Positive","C163010","An indication that CKB expression has been detected in a sample.","CKB Positive | B-CK Positive | Brain Creatine Kinase Positive | CK-BB Positive | CKBB Positive | Creatine Kinase B-Type Positive | Creatine Kinase-B Chain Positive | Creatine Kinase-B Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973376","HLA-C*0802 Positive Cells Present","C163011","An indication that cells expressing HLA-C*0802 have been detected in a sample.","HLA-C*0802 Positive Cells Present | HLA-C*0802 Positive | HLA-C*08:02 Positive | HLA-C*08:02 Positive Cells Present | HLA-C0802 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973377","Loss of PMS2 Expression","C163012","A molecular abnormality indicating the absence of PMS2 protein.","Loss of PMS2 Expression | Loss of DNA Mismatch Repair Protein PMS2 Expression | Loss of Mismatch Repair Endonuclease PMS2 Expression | Loss of PMS1 Protein Homolog 2 Expression | Loss of PMS2 Protein Expression | PMS2 Loss of Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973382","Loss of MSH3 Expression","C163013","A molecular abnormality indicating the absence of MSH3 protein.","Loss of MSH3 Expression | Loss of DNA Mismatch Repair Protein Msh3 Expression | Loss of DUP Expression | Loss of Divergent Upstream Protein Expression | Loss of MRP1 Expression | Loss of MSH3 Protein Expression | Loss of Mismatch Repair Protein 1 Expression | Loss of hMSH3 Expression | MSH3 Loss of Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973383","Loss of EPCAM Expression","C163014","A molecular abnormality indicating the absence of EPCAM protein.","Loss of EPCAM Expression | EPCAM Loss of Expression | Loss of CD326 Antigen Expression | Loss of CD326 Expression | Loss of EPCAM Protein Expression | Loss of Ep-CAM Expression | Loss of Epithelial Cell Adhesion Molecule Expression | Loss of GA733-2 Expression | Loss of Gastrointestinal Tumor-Associated Antigen 2 Expression | Loss of KSA Glycoprotein Expression | Loss of TACSTD1 Expression | Loss of Tumor-Associated Calcium Signal Transducer 1 Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973380","Loss of MSH6 Expression","C163015","A molecular abnormality indicating the absence of MSH6 protein.","Loss of MSH6 Expression | Loss of DNA Mismatch Repair Protein Msh6 Expression | Loss of G/T Mismatch Binding Protein Expression | Loss of G/T Mismatch-Binding Protein Expression | Loss of GTBP Expression | Loss of GTMBP Expression | Loss of MSH6 Protein Expression | Loss of MutS Homolog 6 Expression | Loss of MutS-Alpha 160 kDa Subunit Expression | Loss of Sperm-Associated Protein Expression | MSH6 Loss of Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973381","Loss of MLH1 Expression","C163016","A molecular abnormality indicating the absence of MLH1 protein.","Loss of MLH1 Expression | Loss of COCA2 Expression | Loss of DNA Mismatch Repair Protein Mlh1 Expression | Loss of FCC2 Expression | Loss of HNPCC Expression | Loss of HNPCC2 Expression | Loss of MLH1 Protein Expression | Loss of Mismatch DNA Repair Protein MLH1 Expression | Loss of Mismatch Repair Protein MLH1 Expression | Loss of MutL Protein Homolog 1 Expression | MLH1 Loss of Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973371","25-Hydroxyvitamin D Less than 32 ng/ml","C163017","A semiquantitative finding indicating that the concentration of 25-hydroxyvitamin D2 plus 25-hydroxyvitamin D3 is less than 32 ng/mL.","25-Hydroxyvitamin D Less than 32 ng/ml | 25(OH)D Less than 32 Nanograms per Milliliter | 25(OH)D Less than 32 Nanograms/Milliliter | 25(OH)D Less than 32 ng/mL | 25-Hydroxyvitamin D Less than 32 Nanograms per Milliliter | 25-Hydroxyvitamin D Less than 32 Nanograms/Milliliter | 25-OH-VitD Less than 32 Nanograms per Milliliter | 25-OH-VitD Less than 32 Nanograms/Milliliter | 25-OH-VitD Less than 32 ng/mL | 25-OH-Vitamin D Less than 32 Nanograms per Milliliter | 25-OH-Vitamin D Less than 32 Nanograms/Milliliter | 25-OH-Vitamin D Less than 32 ng/mL | Calcidiol Less than 32 Nanograms per Milliliter | Calcidiol Less than 32 Nanograms/Milliliter | Calcidiol Less than 32 ng/mL | Calcifediol Less than 32 Nanograms per Milliliter | Calcifediol Less than 32 Nanograms/Milliliter | Calcifediol Less than 32 ng/mL | Vitamin D Less than 32 ng/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973369","t(4;22)","C163019","A chromosomal translocation that involves the chromosomes 4 and 22.","t(4;22) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521916","Colorectal Cancer TNM Finding v8","C134133","A finding about one or more characteristics of colorectal cancer, following the rules of the TNM AJCC v8 classification system. Adenocarcinomas, high-grade neuroendocrine carcinomas, and squamous cell carcinomas of the colon and rectum are covered by this staging system. Appendiceal carcinomas, anal carcinomas, and well-differentiated neuroendocrine tumors (carcinoids) are not covered by this staging system. (from AJCC 8th Ed.)","Colorectal Cancer TNM Finding v8 | Colorectal Carcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521943","Colorectal Cancer pT4b TNM Finding v8","C134165","Colorectal cancer with tumor directly invading or adhering to adjacent organs or structures. (from AJCC 8th Ed.)","Colorectal Cancer pT4b TNM Finding v8 | Colorectal Carcinoma pT4b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521942","Colorectal Cancer pT4a TNM Finding v8","C134164","Colorectal cancer with tumor invading through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). (from AJCC 8th Ed.)","Colorectal Cancer pT4a TNM Finding v8 | Colorectal Carcinoma pT4a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521941","Colorectal Cancer pT4 TNM Finding v8","C134163","Colorectal cancer with tumor invading the visceral peritoneum or invading or adhering to adjacent organ or structure. (from AJCC 8th Ed.)","Colorectal Cancer pT4 TNM Finding v8 | Colorectal Carcinoma pT4 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521940","Colorectal Cancer pT3 TNM Finding v8","C134162","Colorectal cancer with tumor invading through the muscularis propria into pericolorectal tissues. (from AJCC 8th Ed.)","Colorectal Cancer pT3 TNM Finding v8 | Colorectal Carcinoma pT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521939","Colorectal Cancer pT2 TNM Finding v8","C134161","Colorectal cancer with tumor invading the muscularis propria. (from AJCC 8th Ed.)","Colorectal Cancer pT2 TNM Finding v8 | Colorectal Carcinoma pT2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521938","Colorectal Cancer pT1 TNM Finding v8","C134160","Colorectal cancer with tumor invading the submucosa (through the muscularis mucosa but not into the muscularis propria). (from AJCC 8th Ed.)","Colorectal Cancer pT1 TNM Finding v8 | Colorectal Carcinoma pT1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521937","Colorectal Cancer pTis TNM Finding v8","C134159","Colorectal cancer with a finding of carcinoma in situ, intramucosal carcinoma (involvement of lamina propria with no extension through muscularis mucosae). (from AJCC 8th Ed.)","Colorectal Cancer pTis TNM Finding v8 | Colorectal Carcinoma pTis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521936","Colorectal Cancer pT0 TNM Finding v8","C134158","Colorectal cancer with no evidence of primary tumor. (from AJCC 8th Ed.)","Colorectal Cancer pT0 TNM Finding v8 | Colorectal Carcinoma pT0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521934","Colorectal Cancer pTX TNM Finding v8","C134156","Colorectal cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Colorectal Cancer pTX TNM Finding v8 | Colorectal Carcinoma pTX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521957","Colorectal Cancer pN2b TNM Finding v8","C134179","Colorectal cancer in which seven or more regional lymph nodes are positive. (from AJCC 8th Ed.)","Colorectal Cancer pN2b TNM Finding v8 | Colorectal Carcinoma pN2b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521956","Colorectal Cancer pN2a TNM Finding v8","C134178","Colorectal cancer in which four to six regional lymph nodes are positive. (from AJCC 8th Ed.)","Colorectal Cancer pN2a TNM Finding v8 | Colorectal Carcinoma pN2a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521952","Colorectal Cancer pN1c TNM Finding v8","C134174","Colorectal cancer in which no regional lymph nodes are positive, but there are tumor deposits in the subserosa, mesentery, or nonperitonealized pericolic, or perirectal/mesorectal tissues. (from AJCC 8th Ed.)","Colorectal Cancer pN1c TNM Finding v8 | Colorectal Carcinoma pN1c TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521951","Colorectal Cancer pN1b TNM Finding v8","C134173","Colorectal cancer in which two or three regional lymph nodes are positive. (from AJCC 8th Ed.)","Colorectal Cancer pN1b TNM Finding v8 | Colorectal Carcinoma pN1b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521949","Colorectal Cancer pN1a TNM Finding v8","C134171","Colorectal cancer in which one regional lymph node is positive. (from AJCC 8th Ed.)","Colorectal Cancer pN1a TNM Finding v8 | Colorectal Carcinoma pN1a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521948","Colorectal Cancer pN1 TNM Finding v8","C134170","Colorectal cancer in which one to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. (from AJCC 8th Ed.)","Colorectal Cancer pN1 TNM Finding v8 | Colorectal Carcinoma pN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521947","Colorectal Cancer pN0 TNM Finding v8","C134169","Colorectal cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","Colorectal Cancer pN0 TNM Finding v8 | Colorectal Carcinoma pN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521945","Colorectal Cancer pNX TNM Finding v8","C134167","Colorectal cancer in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)","Colorectal Cancer pNX TNM Finding v8 | Colorectal Carcinoma pNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521926","Colorectal Cancer Pathologic Distant Metastasis TNM Finding v8","C134147","A pathologic finding about one or more characteristics of colorectal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Colorectal Cancer Pathologic Distant Metastasis TNM Finding v8 | Colorectal Carcinoma Pathologic Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521930","Colorectal Cancer pM1c TNM Finding v8","C134151","Colorectal cancer with metastasis to the peritoneal surface alone or with other site or organ metastases. (from AJCC 8th Ed.)","Colorectal Cancer pM1c TNM Finding v8 | Colorectal Carcinoma pM1c TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521929","Colorectal Cancer pM1b TNM Finding v8","C134150","Colorectal cancer with metastasis to two or more sites or organs without peritoneal metastasis. (from AJCC 8th Ed.)","Colorectal Cancer pM1b TNM Finding v8 | Colorectal Carcinoma pM1b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521928","Colorectal Cancer pM1a TNM Finding v8","C134149","Colorectal cancer with metastasis to one site or organ without peritoneal metastasis. (from AJCC 8th Ed.)","Colorectal Cancer pM1a TNM Finding v8 | Colorectal Carcinoma pM1a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521927","Colorectal Cancer pM1 TNM Finding v8","C134148","Colorectal cancer with metastasis to one or more distant sites or organs or peritoneal metastasis is identified. (from AJCC 8th Ed.)","Colorectal Cancer pM1 TNM Finding v8 | Colorectal Carcinoma pM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521920","Colorectal Cancer cM1 TNM Finding v8","C134137","Colorectal cancer with metastasis to one or more distant sites or organs or peritoneal metastasis is identified. (from AJCC 8th Ed.)","Colorectal Cancer cM1 TNM Finding v8 | Colorectal Carcinoma cM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521919","Colorectal Cancer cM0 TNM Finding v8","C134136","Colorectal cancer without evidence of distant metastasis by imaging, etc.; no evidence of tumor in distant sites or organs. This category is not assigned by pathologists. (from AJCC 8th Ed.)","Colorectal Cancer cM0 TNM Finding v8 | Colorectal Carcinoma cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521918","Colorectal Cancer Clinical Distant Metastasis TNM Finding v8","C134135","A clinical finding about one or more characteristics of colorectal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Colorectal Cancer Clinical Distant Metastasis TNM Finding v8 | Colorectal Carcinoma Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521924","Colorectal Cancer cM1c TNM Finding v8","C134143","Colorectal cancer with metastasis to the peritoneal surface alone or with other site or organ metastases. (from AJCC 8th Ed.)","Colorectal Cancer cM1c TNM Finding v8 | Colorectal Carcinoma cM1c TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521923","Colorectal Cancer cM1b TNM Finding v8","C134142","Colorectal cancer with metastasis to two or more sites or organs without peritoneal metastasis. (from AJCC 8th Ed.)","Colorectal Cancer cM1b TNM Finding v8 | Colorectal Carcinoma cM1b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521922","Colorectal Cancer cM1a TNM Finding v8","C134141","Colorectal cancer with metastasis to one site or organ without peritoneal metastasis. (from AJCC 8th Ed.)","Colorectal Cancer cM1a TNM Finding v8 | Colorectal Carcinoma cM1a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521959","Stage 0 Colorectal Cancer AJCC v8","C134182","Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ, intramucosal carcinoma (involvement of lamina propria with no extension through muscularis mucosae). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0 Colorectal Cancer AJCC v8 | Stage 0 Colorectal (Colon or Rectal) Cancer | Stage 0 Colorectal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521974","Stage IVC Colorectal Cancer AJCC v8","C134198","Stage IVC includes: Any T, Any N, M1c. M1c: Metastasis to the peritoneal surface alone or with other site or organ metastases. (AJCC 8th ed.)","Stage IVC Colorectal Cancer AJCC v8 | Stage IVC Colorectal (Colon or Rectal) Cancer | Stage IVC Colorectal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521973","Stage IVB Colorectal Cancer AJCC v8","C134197","Stage IVB includes: Any T, Any N, M1b. M1b: Metastasis to two or more sites or organs without peritoneal metastasis.  (AJCC 8th ed.)","Stage IVB Colorectal Cancer AJCC v8 | Stage IVB Colorectal (Colon or Rectal) Cancer | Stage IVB Colorectal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521972","Stage IVA Colorectal Cancer AJCC v8","C134196","Stage IVA includes: Any T, Any N, M1a. M1a: Metastasis to one site or organ without peritoneal metastasis. (AJCC 8th ed.)","Stage IVA Colorectal Cancer AJCC v8 | Stage IVA Colorectal (Colon or Rectal) Cancer | Stage IVA Colorectal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521970","Stage IIIC Colorectal Cancer AJCC v8","C134194","Stage IIIC includes: (T4a, N2a, M0); (T3-T4a, N2b, M0); (T4b, N1-N2, M0). T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). T4b: Tumor directly invades or adheres to adjacent organs or structures. N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N2: Four or more regional lymph nodes are positive. N2a: Four to six regional lymph nodes are positive. N2b: Seven or more regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIC Colorectal Cancer AJCC v8 | Stage IIIC Colorectal (Colon or Rectal) Cancer | Stage IIIC Colorectal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521969","Stage IIIB Colorectal Cancer AJCC v8","C134193","Stage IIIB includes: (T3-T4a, N1/N1c, M0); (T2-T3, N2a, M0); (T1-T2, N2b, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N1c: No regional lymph nodes are positive, but there are tumor deposits in the subserosa, mesentery, or nonperitonealized pericolic, or perirectal/mesorectal tissues. N2a: Four to six regional lymph nodes are positive. N2b: Seven or more regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIB Colorectal (Colon or Rectal) Cancer | Stage IIIB Colorectal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521968","Stage IIIA Colorectal Cancer AJCC v8","C134192","Stage IIIA includes: (T1-T2, N1/N1c, M0); (T1, N2a, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N1c: No regional lymph nodes are positive, but there are tumor deposits in the subserosa, mesentery, or nonperitonealized pericolic, or perirectal/mesorectal tissues. N2a: Four to six regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIA Colorectal (Colon or Rectal) Cancer | Stage IIIA Colorectal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521966","Stage IIC Colorectal Cancer AJCC v8","C134190","Stage IIC includes: T4b, N0, M0. T4b: Tumor directly invades or adheres to adjacent organs or structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIC Colorectal Cancer AJCC v8 | Stage IIC Colorectal (Colon or Rectal) Cancer | Stage IIC Colorectal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521964","Stage IIB Colorectal Cancer AJCC v8","C134188","Stage IIB includes: T4a, N0, M0. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIB Colorectal Cancer AJCC v8 | Stage IIB Colorectal (Colon or Rectal) Cancer | Stage IIB Colorectal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521963","Stage IIA Colorectal Cancer AJCC v8","C134187","Stage IIA includes: T3, N0, M0. T3: Tumor invades through the muscularis propria into pericolorectal tissues. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIA Colorectal Cancer AJCC v8 | Stage IIA Colorectal (Colon or Rectal) Cancer | Stage IIA Colorectal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522744","Colorectal Neuroendocrine Tumor TNM Finding v8","C135161","A finding about one or more characteristics of a colorectal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system. This classification system applies to colorectal 'carcinoid' tumors (neuroendocrine tumor G1 and G2, and rare-well differentiated G3). It does not apply to high-grade neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas of the colon and rectum. (from AJCC 8th Ed.)","Colorectal Neuroendocrine Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522763","Colorectal Neuroendocrine Tumor pTX TNM Finding v8","C135184","Colorectal neuroendocrine tumor in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Colorectal Neuroendocrine Tumor pTX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522770","Colorectal Neuroendocrine Tumor pT4 TNM Finding v8","C135192","Colorectal neuroendocrine tumor invading the visceral peritoneum (serosa) or other organs or adjacent structures. (from AJCC 8th Ed.)","Colorectal Neuroendocrine Tumor pT4 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522769","Colorectal Neuroendocrine Tumor pT3 TNM Finding v8","C135191","Colorectal neuroendocrine tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. (from AJCC 8th Ed.)","Colorectal Neuroendocrine Tumor pT3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522768","Colorectal Neuroendocrine Tumor pT2 TNM Finding v8","C135190","Colorectal neuroendocrine tumor invading the muscularis propria or measuring more than 2 cm with invasion of the lamina propria or submucosa.  (from AJCC 8th Ed.)","Colorectal Neuroendocrine Tumor pT2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522767","Colorectal Neuroendocrine Tumor pT1b TNM Finding v8","C135188","Colorectal neuroendocrine tumor measuring 1-2 cm in greatest dimension. (from AJCC 8th Ed.)","Colorectal Neuroendocrine Tumor pT1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522766","Colorectal Neuroendocrine Tumor pT1a TNM Finding v8","C135187","Colorectal neuroendocrine tumor measuring less than 1 cm in greatest dimension. (from AJCC 8th Ed.)","Colorectal Neuroendocrine Tumor pT1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522765","Colorectal Neuroendocrine Tumor pT1 TNM Finding v8","C135186","Colorectal neuroendocrine tumor invading the lamina propria or submucosa and measuring 2 cm or less. (from AJCC 8th Ed.)","Colorectal Neuroendocrine Tumor pT1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522764","Colorectal Neuroendocrine Tumor pT0 TNM Finding v8","C135185","Colorectal neuroendocrine tumor with no evidence of primary tumor. (from AJCC 8th Ed.)","Colorectal Neuroendocrine Tumor pT0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522759","Colorectal Neuroendocrine Tumor pNX TNM Finding v8","C135179","Colorectal neuroendocrine tumor in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)","Colorectal Neuroendocrine Tumor pNX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522761","Colorectal Neuroendocrine Tumor pN1 TNM Finding v8","C135182","Colorectal neuroendocrine tumor with regional lymph node metastasis. (from AJCC 8th Ed.)","Colorectal Neuroendocrine Tumor pN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522760","Colorectal Neuroendocrine Tumor pN0 TNM Finding v8","C135181","Colorectal neuroendocrine tumor without regional lymph node metastasis. (from AJCC 8th Ed.)","Colorectal Neuroendocrine Tumor pN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522746","Colorectal Neuroendocrine Tumor Clinical Distant Metastasis TNM Finding v8","C135163","A clinical finding about one or more characteristics of a colorectal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Colorectal Neuroendocrine Tumor Clinical Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522754","Colorectal Neuroendocrine Tumor pM1 TNM Finding v8","C135171","Colorectal neuroendocrine tumor with distant metastasis. (from AJCC 8th Ed.)","Colorectal Neuroendocrine Tumor pM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522751","Colorectal Neuroendocrine Tumor cM1c TNM Finding v8","C135168","Colorectal neuroendocrine tumor with both hepatic and extrahepatic metastases. (from AJCC 8th Ed.)","Colorectal Neuroendocrine Tumor cM1c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522750","Colorectal Neuroendocrine Tumor cM1b TNM Finding v8","C135167","Colorectal neuroendocrine tumor with metastasis in at least one extrahepatic site (e.g., lung, ovary, nonregional lymph node, peritoneum, bone). (from AJCC 8th Ed.)","Colorectal Neuroendocrine Tumor cM1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522749","Colorectal Neuroendocrine Tumor cM1a TNM Finding v8","C135166","Colorectal neuroendocrine tumor with metastasis confined to liver. (from AJCC 8th Ed.)","Colorectal Neuroendocrine Tumor cM1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522748","Colorectal Neuroendocrine Tumor cM1 TNM Finding v8","C135165","Colorectal neuroendocrine tumor with distant metastasis. (from AJCC 8th Ed.)","Colorectal Neuroendocrine Tumor cM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522747","Colorectal Neuroendocrine Tumor cM0 TNM Finding v8","C135164","Colorectal neuroendocrine tumor without evidence of distant metastasis. (from AJCC 8th Ed.)","Colorectal Neuroendocrine Tumor cM0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522753","Colorectal Neuroendocrine Tumor Pathologic Distant Metastasis TNM Finding v8","C135170","A pathologic finding about one or more characteristics of a colorectal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Colorectal Neuroendocrine Tumor Pathologic Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522757","Colorectal Neuroendocrine Tumor pM1c TNM Finding v8","C135175","Colorectal neuroendocrine tumor with both hepatic and extrahepatic metastases. (from AJCC 8th Ed.)","Colorectal Neuroendocrine Tumor pM1c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522756","Colorectal Neuroendocrine Tumor pM1b TNM Finding v8","C135174","Colorectal neuroendocrine tumor with metastasis in at least one extrahepatic site (e.g., lung, ovary, nonregional lymph node, peritoneum, bone). (from AJCC 8th Ed.)","Colorectal Neuroendocrine Tumor pM1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522755","Colorectal Neuroendocrine Tumor pM1a TNM Finding v8","C135173","Colorectal neuroendocrine tumor with metastasis confined to liver. (from AJCC 8th Ed.)","Colorectal Neuroendocrine Tumor pM1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522535","Colorectal Neuroendocrine Tumor by AJCC v8 Stage","C135205","A term that refers to the staging of a colorectal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system. This staging system applies to colorectal 'carcinoid' tumors (neuroendocrine tumor G1 and G2, and rare-well differentiated G3). High-grade neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas of the colon and rectum are not staged using this staging system. (from AJCC 8th Ed.)","Colorectal Neuroendocrine Tumor by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522788","Stage IV Colorectal Neuroendocrine Tumor AJCC v8","C135211","Stage IV includes: (T1, Any N, M1); (T2, Any N, M1); (T3, Any N, M1); (T4, Any N, M1). T1: Tumor invading the lamina propria or submucosa and measuring 2 cm or less. T2: Tumor invading the muscularis propria or measuring more than 2 cm with invasion of the lamina propria or submucosa. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. T4: Tumor invading the visceral peritoneum (serosa) or other organs or adjacent structures. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Colorectal Neuroendocrine Tumor AJCC v8 | Stage IV Colorectal Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522787","Stage IIIB Colorectal Neuroendocrine Tumor AJCC v8","C135210","Stage IIIB includes: (T1, N1, M0); (T2, N1, M0); (T3, N1, M0); (T4, N1, M0). T1: Tumor invading the lamina propria or submucosa and measuring 2 cm or less. T2: Tumor invading the muscularis propria or measuring more than 2 cm with invasion of the lamina propria or submucosa. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. T4: Tumor invading the visceral peritoneum (serosa) or other organs or adjacent structures. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIB Colorectal Neuroendocrine Tumor AJCC v8 | Stage IIIB Colorectal Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522786","Stage IIIA Colorectal Neuroendocrine Tumor AJCC v8","C135209","Stage IIIA includes: T4, N0, M0. T4: Tumor invading the visceral peritoneum (serosa) or other organs or adjacent structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIA Colorectal Neuroendocrine Tumor AJCC v8 | Stage IIIA Colorectal Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522785","Stage IIB Colorectal Neuroendocrine Tumor AJCC v8","C135208","Stage IIB includes: T3, N0, M0. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIB Colorectal Neuroendocrine Tumor AJCC v8 | Stage IIB Colorectal Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522784","Stage IIA Colorectal Neuroendocrine Tumor AJCC v8","C135207","Stage IIA includes: T2, N0, M0. T2: Tumor invading the muscularis propria or measuring more than 2 cm with invasion of the lamina propria or submucosa. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIA Colorectal Neuroendocrine Tumor AJCC v8 | Stage IIA Colorectal Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522783","Stage I Colorectal Neuroendocrine Tumor AJCC v8","C135206","Stage I includes: T1, N0, M0. T1: Tumor invading the lamina propria or submucosa and measuring 2 cm or less. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Colorectal Neuroendocrine Tumor AJCC v8 | Stage I Colorectal Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272610","Colorectal Neuroendocrine Tumor","C96159","A well-differentiated, low-, intermediate-, or high-grade neoplasm with neuroendocrine differentiation that arises from the colon or rectum.","Colorectal Neuroendocrine Tumor | Colorectal NET | Colorectal Well Differentiated Endocrine Tumor | Colorectal Well Differentiated Endocrine Tumor/Carcinoma | Colorectal Well Differentiated Neuroendocrine Neoplasm | Colorectal Well-Differentiated Neuroendocrine Neoplasm | Large Intestinal Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951153","First OR Temperature","C159282","The first body temperature recorded in the operating room for the participant.","First OR Temperature | First Operating Room Temperature | First Participant temperature recorded in OR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951154","Second OR Temperature","C159283","The second body temperature recorded in the operating room for the participant.","Second OR Temperature | Second Operating Room Temperature | Second Participant temperature recorded in OR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976999","Feasibility","C163761","The state or degree of being easily or conveniently done, used, made, or dealt with.","Feasibility | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509618","HPV-16 E7 TCR Expressing T-cells","C128485","A preparation of allogeneic, genetically engineered T-lymphocytes transduced with a retroviral vector MSGV1 that encodes a T-cell receptor (TCR) targeting a specific epitope of the human papillomavirus (HPV) type 16 oncoprotein E7 (HPV-16 E7 TCR), with potential antineoplastic activity. The TCR especially recognizes and binds with high affinity to the HPV 16 E7 11-19 epitope. Upon administration, HPV-16 E7 expressing T-cells target and bind to tumor cells expressing the HPV-16 E7 antigen leading to selective cytotoxicity in HLA-A2-positive, HPV-16 E7-expressing tumor cells. HPV16 E7, a tumor-associated antigen (TAA), overexpressed in a variety of tumor cell types while not expressed in normal, healthy cells, plays a key role in tumor cell proliferation. E7 11-19 is a naturally processed epitope of HPV-16 E7 that binds specifically to human leukocyte antigen (HLA)-A*02:01 and that has been isolated from the surface of HPV-16 positive, HLA-A*02:01-positive tumor cells.","HPV-16 E7 TCR Expressing T-cells | HPV-16 E7 TCR Expressing T-lymphocytes | HPV-16 E7 TCR-expressing T Lymphocytes | Human Papillomavirus Type 16 E7 TCR Expressing T-cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539024","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma TNM Finding v8","C140897","A finding about one or more characteristics of papillary, follicular, Hurthle cell, poorly differentiated, and anaplastic (undifferentiated) thyroid carcinoma, following the rules of the TNM AJCC v8 classification system. Medullary thyroid cancers are staged according to the classification for thyroid-medullary. Thyroid lymphomas are staged according to the classification for Hodgkin and non-Hodgkin lymphoma. There are no AJCC staging systems for thyroid cancer arising from thyroglossal duct cyst and thyroid cancer in malignant struma ovarii. (from AJCC 8th Ed.)","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539023","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma Clinical TNM Finding v8","C140898","A clinical finding about one or more characteristics of papillary, follicular, Hurthle cell, poorly differentiated, and anaplastic thyroid carcinoma, following the rules of the TNM AJCC v8 classification system.","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma Clinical TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539028","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma Pathologic TNM Finding v8","C140909","A pathologic finding about one or more characteristics of papillary, follicular, Hurthle cell, poorly differentiated, and anaplastic thyroid carcinoma, following the rules of the TNM AJCC v8 classification system.","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma Pathologic TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976995","Illness Intrusiveness Ratings Scale","C163766","A questionnaire and scale designed to assess the extent that a person's illness, and/or its treatment, interferes with aspects of their life. Responses range from 1: Not Very Much to 7: Very Much.","Illness Intrusiveness Ratings Scale | IIRS | Illness Intrusiveness Ratings Scale (IIRS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978371","Illness Intrusiveness Rating 1","C163767","A response of 1 on an illness intrusiveness scale that ranges from 1: Not Very Much to 7: Very Much.","Illness Intrusiveness Rating 1 | 1 | Not Very Much",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978377","Illness Intrusiveness Rating 2","C163768","A response of 2 on an illness intrusiveness scale that ranges from 1: Not Very Much to 7: Very Much.","Illness Intrusiveness Rating 2 | 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978367","Illness Intrusiveness Rating 3","C163769","A response of 3 on an illness intrusiveness scale that ranges from 1: Not Very Much to 7: Very Much.","Illness Intrusiveness Rating 3 | 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978372","Illness Intrusiveness Rating 4","C163770","A response of 4 on an illness intrusiveness scale that ranges from 1: Not Very Much to 7: Very Much.","Illness Intrusiveness Rating 4 | 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978374","Illness Intrusiveness Rating 5","C163771","A response of 5 on an illness intrusiveness scale that ranges from 1: Not Very Much to 7: Very Much.","Illness Intrusiveness Rating 5 | 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978366","Illness Intrusiveness Rating 6","C163772","A response of 6 on an illness intrusiveness scale that ranges from 1: Not Very Much to 7: Very Much.","Illness Intrusiveness Rating 6 | 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978365","Illness Intrusiveness Rating 7","C163773","A response of 7 on an illness intrusiveness scale that ranges from 1: Not Very Much to 7: Very Much.","Illness Intrusiveness Rating 7 | 7 | Very Much",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976993","How Much Does Illness and/or Treatment Interfere with Health","C163775","A question about how much an individual's illness and/or treatment interferes with their health.","How Much Does Illness and/or Treatment Interfere with Health | How much does your illness and/or its treatment interfere with your HEALTH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976968","How Much Does Illness and/or Treatment Interfere with Diet","C163776","A question about how much an individual's illness and/or treatment interferes with their diet.","How Much Does Illness and/or Treatment Interfere with Diet | How much does your illness and/or its treatment interfere with your DIET",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976967","How Much Does Illness and/or Treatment Interfere with Work","C163777","A question about how much an individual's illness and/or treatment interferes with their work.","How Much Does Illness and/or Treatment Interfere with Work | How much does your illness and/or its treatment interfere with your WORK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976966","How Much Does Illness and/or Treatment Interfere with Active Recreation","C163778","A question about how much an individual's illness and/or treatment interferes with their active recreation.","How Much Does Illness and/or Treatment Interfere with Active Recreation | How much does your illness and/or its treatment interfere with your ACTIVE RECREATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976965","How Much Does Illness and/or Treatment Interfere with Passive Recreation","C163779","A question about how much an individual's illness and/or treatment interferes with their passive recreation.","How Much Does Illness and/or Treatment Interfere with Passive Recreation | How much does your illness and/or its treatment interfere with your PASSIVE RECREATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976963","How Much Does Illness and/or Treatment Interfere with Relationship with Spouse","C163781","A question about how much an individual's illness and/or treatment interferes with their relationship with their spouse.","How Much Does Illness and/or Treatment Interfere with Relationship with Spouse | How much does your illness and/or its treatment interfere with your RELATIONSHIP WITH YOUR SPOUSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976962","How Much Does Illness and/or Treatment Interfere with Sex Life","C163782","A question about how much an individual's illness and/or treatment interferes with their sex life.","How Much Does Illness and/or Treatment Interfere with Sex Life | How much does your illness and/or its treatment interfere with your SEX LIFE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976961","How Much Does Illness and/or Treatment Interfere with Family Relations","C163783","A question about how much an individual's illness and/or treatment interferes with their family relations.","How Much Does Illness and/or Treatment Interfere with Family Relations | How much does your illness and/or its treatment interfere with your FAMILY RELATIONS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976960","How Much Does Illness and/or Treatment Interfere with Other Social Relations","C163784","A question about how much an individual's illness and/or treatment interferes with their social relations.","How Much Does Illness and/or Treatment Interfere with Other Social Relations | How much does your illness and/or its treatment interfere with your OTHER SOCIAL RELATIONS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976959","How Much Does Illness and/or Treatment Interfere with Self-Expression or Self-Improvement","C163785","A question about how much an individual's illness and/or treatment interferes with their self-expression or self-improvement.","How Much Does Illness and/or Treatment Interfere with Self-Expression or Self-Improvement | How much does your illness and/or its treatment interfere with your SELF-EXPRESSION/SELF-IMPROVEMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976958","How Much Does Illness and/or Treatment Interfere with Religious Expression","C163786","A question about how much an individual's illness and/or treatment interferes with their religious expression.","How Much Does Illness and/or Treatment Interfere with Religious Expression | How much does your illness and/or its treatment interfere with your RELIGIOUS EXPRESSION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976957","How Much Does Illness and/or Treatment Interfere with Community and Civic Involvement","C163787","A question about how much an individual's illness and/or treatment interferes with their community and civic involvement.","How Much Does Illness and/or Treatment Interfere with Community and Civic Involvement | How much does your illness and/or its treatment interfere with your COMMUNITY AND CIVIC INVOLVEMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976953","Reproductive Concerns After Cancer","C163791","A scale that measures concerns related to fertility and parenthood for young adult female cancer survivors, including concerns about fertility potential, partner disclosure, child's health, personal health, acceptance, and becoming pregnant.","Reproductive Concerns After Cancer | RCAC | Reproductive Concerns After Cancer (RCAC)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976984","Afraid Won't be Able to Have (More) Children","C163792","A question about whether an individual is afraid they won't be able to have any, or more, children.","Afraid Won't be Able to Have (More) Children Question | Afraid Won't be Able to Have (More) Children | Afraid Won't be Able to Have (More) Children | I am afraid I won't be able to have any (more) children.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976983","Worried About Passing on Genetic Risk for Cancer to Children","C163793","A question about whether an individual is worried about passing on a genetic risk for cancer to their children.","Worried About Passing on Genetic Risk for Cancer to Children | I am worried about passing on a genetic risk for cancer to my children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976982","Worry About Telling Spouse or Partner May be Unable to Have Children","C163794","A question about whether an individual is worried about telling their current or potential spouse or partner that they may be unable to have children.","Worry About Telling Spouse or Partner May be Unable to Have Children Question | I worry about telling my (potential) spouse/partner that I may be unable to have children | Worry About Telling Spouse or Partner May be Unable to Have Children | Worry About Telling Spouse or Partner May be Unable to Have Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976981","Scared of Not Being Around to Take Care of Children Someday","C163795","A question about whether an individual is scared of not being around to take care of their children someday.","Scared of Not Being Around to Take Care of Children Someday | I am scared of not being around to take care of my children someday",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976980","Can Accept if I am Unable to Have (More) Children","C163796","A question about whether an individual can accept if they are unable to have any, or more, children.","Can Accept if I am Unable to Have (More) Children Question | Can Accept if I am Unable to Have (More) Children | Can Accept if I am Unable to Have (More) Children | I can accept it if I'm unable to have (more) children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976979","Overwhelmed by Thought of Trying to get Pregnant","C163797","A question about whether an individual is overwhelmed by the thought of trying to get pregnant.","Overwhelmed by Thought of Trying to get Pregnant | I am overwhelmed by the thought of trying to get pregnant (again)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976978","Concerned that Spouse or Partner Will be Disappointed if Can't Get Pregnant","C163798","A question about whether an individual is concerned that their current or potential spouse or partner will be disappointed if they can't get pregnant.","Concerned that Spouse or Partner Will be Disappointed if Can't Get Pregnant | I am concerned that my (potential) spouse/partner will be disappointed if I can't get pregnant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976977","Worried About Ability to Get Pregnant","C163799","A question about whether an individual is worried about their ability to get pregnant.","Worried About Ability to Get Pregnant | I am worried about my ability to get pregnant (again)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976976","Worried About How Family History Might Affect Children's Health","C163800","A question about whether an individual is worried about how their family history might affect their children's health.","Worried About How Family History Might Affect Children's Health | I am worried about how my family history might affect my children's health",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976975","Will Be Happy with Life Whether or Not I Have (More) Children Someday","C163801","A question about whether an individual will be happy with life whether or not they have any, or more, children someday.","Will Be Happy with Life Whether or Not I Have (More) Children Someday | I will be happy with life whether or not I have (more) children someday",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976974","Having (More) Children Will Make me More Nervous About Getting Cancer Again","C163802","A question about whether an having any, or more, children will make an individual nervous about getting cancer again.","Having (More) Children Will Make me More Nervous About Getting Cancer Again | Having (more) children will make me more nervous about getting cancer again",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976973","Worry that Getting Pregnant Would Take Too Much Time and Effort","C163803","A question about whether an individual worries that getting pregnant (again) would take too much time and effort.","Worry that Getting Pregnant Would Take Too Much Time and Effort | I worry that getting pregnant (again) would take too much time and effort",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976972","Am Cautious About Having (More) Children Because Might Not be Around to Raise Them","C163804","A question about whether an individual is cautious about having any, or more, children because they might not be around to raise them.","Am Cautious About Having (More) Children Because Might Not be Around to Raise Them | I am cautious about having (more) children because I might not be around to raise them",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976971","Stressful to Think About Trying to Get Pregnant","C163805","A question about whether it is stressful for an individual to think about trying to get pregnant.","Stressful to Think About Trying to Get Pregnant | It is stressful to think about trying to get pregnant (again)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976970","Will Feel Content if do Not Have (More) Children","C163806","A question about whether an individual will feel content if they do not have any, or more, children.","Will Feel Content if do Not Have (More) Children | I will feel content if I do not have (more) children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977168","Thought of Telling Spouse or Partner that I May be Unable to Have Children Makes me Uncomfortable","C163808","A question about whether the thought of telling their current or potential spouse or partner that they may be unable to have children makes an individual uncomfortable.","Thought of Telling Spouse or Partner that I May be Unable to Have Children Makes me Uncomfortable Question | The thought of telling my (potential) spouse/partner that I may be unable to have children makes me uncomfortable | Thought of Telling Spouse or Partner that I May be Unable to Have Children Makes me Uncomfortable | Thought of Telling Spouse or Partner that I May be Unable to Have Children Makes me Uncomfortable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977167","Concerned May Not be Able to Have (More) Children","C163809","A question about whether an individual is concerned that they may not be able to have any, or more, children.","Concerned May Not be Able to Have (More) Children Question | Concerned May Not be Able to Have (More) Children | Concerned May Not be Able to Have (More) Children | I am concerned that I may not be able to have (more) children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977166","Afraid Children Would Have High Chance of Getting Cancer","C163810","A question about whether an individual is afraid that their children would have a high chance of getting cancer.","Afraid Children Would Have High Chance of Getting Cancer Question | Afraid Children Would Have High Chance of Getting Cancer | Afraid Children Would Have High Chance of Getting Cancer | I am afraid my children would have a high chance of getting cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517950","Loss of Chromosome 11","C36549","A cytogenetic abnormality that refers to loss of all or part of chromosome 11.","Loss of Chromosome 11 | -11 | del(11)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970623","DNTT Positive","C162085","An indication that DNTT expression has been detected in a sample.","DNTT Positive | Deoxynucleotidyl Terminal Transferase Positive | TDT Positive | Terminal Transferase Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951256","Fanconi Anemia Complementation Group Gene Mutation","C159204","A change in the nucleotide sequence for a gene that is a member of the Fanconi anemia complementation group.","Fanconi Anemia Complementation Group Gene Mutation | BRCA2 and FANC gene mutations | FA Complementation Group Gene Mutation | FANC Family Gene Mutation | FANC Gene Mutation | Fanconi Anemia Complementation Family Gene Mutation | Fanconi Anemia Group Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282523","CpG Island","C54668","Short region of DNA in which the frequency of the CG sequence is higher than in other regions.","CpG Island | CG Island | CGI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950645","Donor Information","C158611","Information about the donor.","Donor Information | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977246","Mismatched Related Donor","C163979","A donor who is related to the recipient but is mismatched at at least 1 HLA locus.","Mismatched Related Donor | PMRD | Partially Mismatched Related Donor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977243","Montreal Cognitive Assessment, Version 8.1","C163982","The version of the Montreal Cognitive Assessment that added the Memory Index Score to the MoCA test. It contains additional scoring precisions and replaced version 7.1.","Montreal Cognitive Assessment, Version 8.1 | MOCA v8.1 | Montreal Cognitive Assessment (MoCA) version 8.1 | Montreal Cognitive Assessment, v8.1",,,,,,,,,,,,,,,"606671","Montreal Cognitive Assessment version 8.1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL977242","Montreal Cognitive Assessment, Version 8.2","C163983","An alternate version of MOCA v8 that can be administered to decrease any potential test re-test interactions.","Montreal Cognitive Assessment, Version 8.2 | MOCA v8.2 | Montreal Cognitive Assessment (MoCA) version 8.2 | Montreal Cognitive Assessment, v8.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977269","Montreal Cognitive Assessment, Version 8.3","C163984","An alternate version of MOCA v8 that can be administered to decrease any potential test re-test interactions.","Montreal Cognitive Assessment, Version 8.3 | MOCA v8.3 | Montreal Cognitive Assessment (MoCA) version 8.3 | Montreal Cognitive Assessment, v8.3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538758","Stage IIIC Choroidal and Ciliary Body Melanoma AJCC v8","C140667","Stage IIIC includes: T4d-e, N0, M0. T4d: Tumor size category 4 with ciliary body involvement and extraocular extension less than or equal to 5 mm in largest diameter. T4e: Any tumor size category with extraocular extension more than 5 mm in largest diameter. N0: No regional lymph node metastasis. M0: No distant metastasis.  (AJCC 8th ed.)","Stage IIIC Choroidal and Ciliary Body Melanoma AJCC v8 | Stage IIIC Choroidal and Ciliary Body Melanoma | Stage IIIC Posterior Uveal Melanoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699512","Squamous Metaplasia of Bronchial Mucosa","C80354","Replacement of the bronchial glandular epithelial cells by squamous cells.","Squamous Metaplasia of Bronchial Mucosa | LUSC - Metaplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882974","Salivary Gland Oncocytic Carcinoma","C62194","A high grade adenocarcinoma that arises from the salivary glands. The vast majority of cases have been described in the parotid gland.  It is characterized by the presence of malignant oncocytes.  It recurs and metastasizes to regional or distant anatomic sites.","Salivary Gland Oncocytic Adenocarcinoma | Salivary Gland Oncocytic Carcinoma | Salivary Gland Oncocytic Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0728774","Petrolatum","C29538","A thick, greasy, substance with no odor or taste made from petroleum (mixture of oily liquids found in the earth). Petrolatum is used on the skin to prevent drying and to help heal scrapes and burns. It is also used as a base for some ointments.","Petrolatum | PETROLATUM | Petrolatum, White | Petroleum Jelly | Vaseline | petrolatum | petroleum jelly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0718405","Aloe vera","C28815","A succulent, fibrous plant, of the family Liliaceae, with basal leaves, having toothed or fibrous margins. Native to southern Africa, it is a popular ornamental, and its juice is used alone or in preparations to soothe minor burns and skin irritations. (BioTech Life Sciences Dictionary)","Aloe vera | ALOE VERA WHOLE | Aloe barbadensis P. Mill. | Aloe vulgaris Lam. | Barbados Aloe",,,,,,,,,,,,,,,"37151216","Aloe vera",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL977208","Vinegar Soaks","C164055","A topical treatment consisting of white vinegar diluted in water. The vinegar solution may be applied to the skin using an applicator material, or a body part may be immersed in it.","Vinegar Soaks | Vinegar Soak | Vinegar Water Soaks",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986725","Blank Radiographic Scan","C94865","Scan without any subject or attenuating material, but with a source, present.","Blank Radiographic Scan | Blank Scan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977361","Sexual Adjustment and Body Image Scale for Gynecologic Cancer","C164108","A 9-item self-report measure developed to assess disturbances in body image and sexual adjustment after gynecologic cancer.","Sexual Adjustment and Body Image Scale for Gynecologic Cancer | SABIS-G | Sexual Adjustment and Body Image Scale for Gynecologic Cancer (SABIS-G)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977360","How Satisfied with Physical Attractiveness After Gynecologic Cancer","C164109","A question about how satisfied an individual is with their physical attractiveness after having gynecologic cancer.","How Satisfied with Physical Attractiveness After Gynecologic Cancer | After having gynecologic cancer, how satisfied are you with your physical attractiveness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977359","How Comfortable with Showing Your Body After Gynecologic Cancer","C164110","A question about how comfortable an individual is with showing their body to others after having gynecologic cancer.","How Comfortable with Showing Your Body After Gynecologic Cancer | After having gynecologic cancer, how comfortable are you with showing your body to others",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977358","How Comfortable with Changes in Your Body After Gynecologic Cancer","C164111","A question about how comfortable an individual is with the changes in their body after having gynecologic cancer.","How Comfortable with Changes in Your Body After Gynecologic Cancer | How comfortable are you with the changes in your body after having gynecologic cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977357","How has Gynecologic Cancer Affected Your Desire for Sexual Contact","C164112","A question about how having gynecologic cancer has affected an individual's desire for sexual contact.","How has Gynecologic Cancer Affected Your Desire for Sexual Contact | How has having gynecologic cancer affected your desire for sexual contact",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977356","How has Gynecologic Cancer Affected Your Sexual Relationships","C164113","A question about how having gynecologic cancer has affected an individual's sexual relationship(s).","How has Gynecologic Cancer Affected Your Sexual Relationships | How has having gynecologic cancer affected your sexual relationship(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977386","How has Gynecologic Cancer Affected How Often You Initiate Sexual Contact","C164114","A question about how having gynecologic cancer has affected how often an individual initiates sexual contact.","How has Gynecologic Cancer Affected How Often You Initiate Sexual Contact | How has having gynecologic cancer affected how often you initiate sexual contact",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977383","How has Gynecologic Cancer Affected Your Sexual Satisfaction when You have Sex","C164117","A question about how having gynecologic cancer has affected an individual's satisfaction when they have sex.","How has Gynecologic Cancer Affected Your Sexual Satisfaction when You have Sex | How has having gynecologic cancer affected your sexual satisfaction when you have sex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978357","Not At All Satisfied","C164122","A subjective response indicating that an individual is not at all satisfied.","Not At All Satisfied | not at all satisfied",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977378","Not At All Comfortable","C164123","A subjective response indicating that an individual is not at all comfortable.","Not At All Comfortable | not at all comfortable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977374","Somewhat Comfortable","C164128","A subjective response indicating that an individual is or was somewhat comfortable.","Somewhat Comfortable | somewhat comfortable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977373","Moderately Comfortable","C164129","A subjective response indicating that an individual is or was moderately comfortable.","Moderately Comfortable | moderately comfortable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977372","Very Comfortable","C164130","A subjective response indicating that an individual is or was very comfortable.","Very Comfortable | very comfortable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977342","Extremely Comfortable","C164131","A subjective response indicating that an individual is or was extremely comfortable.","Extremely Comfortable | extremely comfortable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977341","Substantially Decreased","C164133","A subjective response indicating that something is or was substantially decreased.","Substantially Decreased | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978348","Decreased","C164132","A subjective response indicating that something is or has decreased.","Decreased | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978353","No Effect","C164134","A subjective response indicating that something has or had no effect.","No Effect | No effect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0442808","Increased","C164135","A subjective response indicating that something is or was increased.","Increased | ",,,,,,,,,,,,,,,"4124456","Increasing",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL977340","Substantially Increased","C164136","A subjective response indicating that something is or was substantially increased.","Substantially Increased | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977337","Very Much Improved","C164139","A subjective response indicating that something is or was very much improved.","Very Much Improved | Very much Improved",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977351","Miltenyi Biotec","C164151","A global provider of products and services associated with advance biomedical research and cellular therapy that support scientists, clinical researchers, and physicians across basic research, translational research, and clinical applications.","Miltenyi Biotec | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977313","Microwave Tissue Processing","C164168","A tissue processing technique that uses a microwave oven to uniformly warm the tissue blocks from within the tissue, allowing faster penetration of tissue processing chemicals and resulting in more a rapid process for making paraffin blocks.","Microwave Tissue Processing | Microwave Processing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540414","Analysis Dataset","C142389","An organized collection of data or information to be used for the analysis of results for a clinical study.","Analysis Dataset | analysis dataset",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977323","Prescreen","C164190","To screen in advance of a time or event, often before a more detailed selection process.","Prescreen | Prescreened | Prescreening",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516208","Cancer Institute of New Jersey","C39344","The Cancer Institute of New Jersey is dedicated to improving the prevention, detection, treatment, and care of patients with cancer, through the translation of laboratory discoveries into clinical practice. Research at the Center is integrated with the Robert Wood Johnson University Hospital, School of Public Health, and several schools and departments of Rutgers, The State University of New Jersey, and Princeton University. It became an NCI-designated cancer center in 1997 and achieved comprehensive status in 2003.","Cancer Institute of New Jersey | CINJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517306","Fox Chase Cancer Center","C39407","The mission of the Fox Chase Cancer Center is to prevail over cancer by marshalling hearts and minds in bold scientific discovery, pioneering prevention, and compassionate care. Clinical, basic, and population research conducted by experts across disciplines enables FCCC to translate new research findings into medical applications that may become models for improved cancer care. It became an NCI-designated comprehensive cancer center in 1974, and joined Temple Health in 2012.","Fox Chase Cancer Center | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976964","How Much Does Illness and/or Treatment Interfere with Financial Situation","C163780","A question about how much an individual's illness and/or treatment interferes with their financial situation.","How Much Does Illness and/or Treatment Interfere with Financial Situation | How much does your illness and/or its treatment interfere with your FINANCIAL SITUATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0058733","Doxylamine Succinate","C47501","A pyridine derivate histamine H1 antagonist with pronounced sedative properties. Doxylamine succinate competitively blocks the histamine H1 receptor and limits the typical allergic and anaphylactic responses, including bronchoconstriction, vasodilation, increased capillary permeability, and spasmodic contraction of gastrointestinal smooth muscle, caused by actions of histamine on bronchial and gastrointestinal smooth muscles, and on capillaries. This drug also prevents histamine-induced pain and itching of the skin and mucous membranes.","Doxylamine Succinate | Butanedioic Acid, compound with N,N-dimethyl-2-[1-phenyl-1-(2-pyridinyl)ethoxy]ethanamine(1:1) | DOXYLAMINE SUCCINATE | Decapryn | Dimethylaminoethoxy-methyl-benzyl-pyridine Succinate | Mereprine | N,N-dimethyl-2-[1-phenyl-1-(2-pyridinyl)ethoxy] ethanamine, butanedioate(1:1) | Sedaplus | Unisom",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977322","Janssen Pharmaceuticals","C164191","A pharmaceutical company providing medicines for an array of health concerns in several therapeutic areas. The company conducts research and development into oncology, mental illness, neurological disorders, gastrointestinal disorders, fungal infection, and allergies.","Janssen Pharmaceuticals | JRD | Janssen | Janssen Pharmaceutica | Janssen Research and Development | Johnson & Johnson",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2033037","Pancreatic Vipoma","C95599","A usually malignant pancreatic neuroendocrine tumor producing vasoactive intestinal peptide (VIP).  It is associated with watery diarrhea, hypokalemia, and hypochlorhydria or achlorhydria.  One third of cases are metastatic at the time of diagnosis.","Pancreatic Vipoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0345933","Pancreatic Serotonin-Producing Neuroendocrine Tumor","C4446","A pancreatic neuroendocrine tumor that secretes serotonin. When it metastasizes to the liver or retroperitoneum, it produces the carcinoid syndrome. Most cases are graded G1 or G2.","Pancreatic Serotonin-Producing Neuroendocrine Tumor | Carcinoid Neoplasm of Pancreas | Carcinoid Neoplasm of the Pancreas | Carcinoid Tumor of Pancreas | Carcinoid Tumor of the Pancreas | EC Cell, Serotonin Producing Pancreatic NET | EC Cell, Serotonin Producing Pancreatic Neuroendocrine Tumor | Enterochromaffin Cell Serotonin-Producing Pancreatic Neuroendocrine Tumor | Pancreatic Carcinoid Tumor | Pancreatic Serotonin Producing Neoplasm | Pancreatic Serotonin Producing Tumor | Serotonin-Producing Pancreatic Neuroendocrine Tumor | Serotonin-Producing Pancreatic Neuroendocrine Tumor | Serotonin-Producing Tumor of Pancreas | Serotonin-Producing Tumor of the Pancreas",,,,,,,,,,,,,,,"4115274","Carcinoid tumor of pancreas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL977334","Mepitel Film","C164142","A proprietary transparent film dressing designed to protect fragile and sensitive skin and minimize risk of skin breakdown. It provides a flexible transparent covering to protect a wound from microbial contamination, fluid strikethrough, or other external contamination.","Mepitel Film | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977505","Biphenotypic Sinonasal Sarcoma","C164205","A rare, slow-growing, low-grade soft tissue sarcoma arising from the sinonasal tract. It presents with non-specific obstructive nasal symptoms. Morphologically, it is an infiltrative, cellular spindle cell neoplasm. It is associated with rearrangement of the PAX3 gene.","Biphenotypic Sinonasal Sarcoma | BSNS | Biphenotypic sinonasal sarcoma | Low Grade Sinonasal Sarcoma with Neural and Myogenic Differentiation | Low-Grade Sinonasal Sarcoma with Neural and Myogenic Differentiation | Sinonasal Biphenotypic Sarcoma",,,,,,,,,,,,,,,"37311513","Biphenotypic sinonasal sarcoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL977321","Testosterone Greater than or Equal to 125 ng/dL","C164192","A semiquantitative finding indicating that the concentration of testosterone in a sample is greater than or equal to 125 ng/dL.","Testosterone Greater than or Equal to 125 ng/dL | Testosterone Greater than or Equal to 125 Nanograms per Deciliter | Testosterone Greater than or Equal to 125 Nanograms/Deciliter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977320","NRG1 Gene Fusion Positive","C164193","An indication that the expression of a fusion containing sequences derived from the NRG1 gene has been detected in a sample.","NRG1 Gene Fusion Positive | ARIA Gene Fusion Positive | GGF2 Gene Fusion Positive | HGL Gene Fusion Positive | HRG Gene Fusion Positive | HRG1 Gene Fusion Positive | HRGA Gene Fusion Positive | Heregulin Gene Fusion Positive | Heregulin, Alpha Gene Fusion Positive | NDF Gene Fusion Positive | NEU Differentiation Factor Gene Fusion Positive | NRG1 Fusion | NRG1 Fusion Mutation | NRG1 Gene Fusion | Neuregulin 1 Gene Fusion Positive | SMDF Gene Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977319","Loss of SDH Expression","C164194","A molecular abnormality indicating the absence of the SDH protein complex.","Loss of SDH Expression | Loss of Mitochondrial Complex II Expression | Loss of Mitochondrial Respiratory Chain Complex II Expression | Loss of Respiratory Complex II Expression | Loss of SDH Complex Expression | Loss of SDH Protein Complex Expression | Loss of SQR Expression | Loss of Succinate Dehydrogenase Expression | Loss of Succinate-Coenzyme Q Reductase Expression | Loss of Succinic Dehydrogenase Expression | SDH Expression Loss",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977318","Loss of FH Expression","C164195","A molecular abnormality indicating the absence of FH protein.","Loss of FH Expression | FH Expression Loss | FH Loss of Expression | Loss of FH Protein Expression | Loss of Fumarase Expression | Loss of Fumarate Hydratase Expression | Loss of Fumarate Hydratase, Mitochondrial Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977513","Activating FGFR2 Gene Mutation","C164196","A change in the nucleotide sequence of the FGFR2 gene that that results in constitutive activation of fibroblast growth factor 2 and its downstream signaling pathways.","Activating FGFR2 Gene Mutation | Activating BEK Gene Mutation | Activating CD332 Gene Mutation | Activating ECT1 Gene Mutation | Activating FGFR-2 Gene Mutation | Activating FGFR2 Mutation | Activating Fibroblast Growth Factor Receptor 2 Gene Mutation | Activating K-SAM Gene Mutation | Activating KGFR Gene Mutation | FGFR2 Activating Mutation | FGFR2 Gain of Function Gene Mutation | FGFR2 Gain of Function Mutation | Gain of Function FGFR2 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977512","Activating FGFR1 Gene Mutation","C164197","A change in the nucleotide sequence of the FGFR1 gene that that results in constitutive activation of fibroblast growth factor 1 and its downstream signaling pathways.","Activating FGFR1 Gene Mutation | Activating BFGFR Gene Mutation | Activating CD331 Gene Mutation | Activating CEK Gene Mutation | Activating FGFBR Gene Mutation | Activating FGFR-1 Gene Mutation | Activating FGFR1 Mutation | Activating FLG Gene Mutation | Activating FLT-2 Gene Mutation | Activating FLT2 Gene Mutation | Activating FMS-Like Tyrosine Kinase 2 Gene Mutation | Activating Fibroblast Growth Factor Receptor 1 Gene Mutation | Activating KAL2 Gene Mutation | Activating N-SAM Gene Mutation | Activating OGD Gene Mutation | FGFR1 Activating Mutation | FGFR1 Gain of Function Gene Mutation | FGFR1 Gain of Function Mutation | Gain of Function FGFR1 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977511","Folate Receptor Family Negative","C164199","An indication that expression of a member of the folate receptor family has not been detected in a sample.","Folate Receptor Family Negative | Folate Binding Protein Negative | Folate Receptor Negative | Folate-Binding Protein Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977510","CYP3A5 Polymorphism Positive","C164200","An indication that polymorphism of the CYP3A5 gene has been detected in a sample.","CYP3A5 Polymorphism Positive | CP35 Polymorphism Positive | CYP3A5 Gene Polymorphism Positive | CYPIIIA5 Polymorphism Positive | Cytochrome P450 Family 3 Subfamily A Member 5 Polymorphism Positive | P450PCN3 Polymorphism Positive | PCN3 Polymorphism Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977509","CYP3A4 Polymorphism Positive","C164201","An indication that polymorphism of the CYP3A4 gene has been detected in a sample.","CYP3A4 Polymorphism Positive | CP33 Polymorphism Positive | CP34 Polymorphism Positive | CYP3A3 Polymorphism Positive | CYP3A4 Gene Polymorphism Positive | CYPIIIA3 Polymorphism Positive | CYPIIIA4 Polymorphism Positive | Cytochrome P450 Family 3 Subfamily A Member 4 Polymorphism Positive | HLP Polymorphism Positive | NF-25 Polymorphism Positive | P450C3 Polymorphism Positive | P450PCN1 Polymorphism Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977507","Percent Free Prostate-Specific Antigen Less than 25","C164203","An indication that less than 25 percent of the prostate-specific antigen in the blood is not bound to other proteins.","Percent Free Prostate-Specific Antigen Less than 25 | Free PSA Less than 25 Percent | Percent Free PSA Less than 25 | Percent Free PSA Less than 25 Percent | Percent Free Prostate-Specific Antigen Less than 25 Percent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977506","Elevated LIF","C164204","A finding indicating elevated concentrations of LIF in a sample.","Elevated LIF | Elevated D Factor | Elevated Differentiation-Stimulating Factor | Elevated Leukemia Inhibitory Factor | Elevated Leukemia-Inhibitory Factor | Elevated MLPLI | Elevated Melanoma-Derived LPL Inhibitor | LIF High | LIF-High | Leukemia Inhibitory Factor High | Leukemia Inhibitory Factor-High",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977504","BRD4 Gene Translocation","C164206","A cytogenetic abnormality that refers to a translocation involving the BRD4 gene.","BRD4 Gene Translocation | BRD4 Translocation | Bromodomain Containing 4 Gene Translocation | Bromodomain-Containing 4 Gene Translocation | CAP Gene Translocation | Chromosome-Associated Protein Gene Translocation | HUNK1 Gene Translocation | HUNKI Gene Translocation | MCAP Gene Translocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977502","BRD3 Gene Translocation","C164208","A cytogenetic abnormality that refers to a translocation involving the BRD3 gene.","BRD3 Gene Translocation | BRD3 Translocation | Bromodomain Containing 3 Gene Translocation | Bromodomain-Containing 3 Gene Translocation | ORFX Gene Translocation | RING3-Like Gene Translocation | RING3L Gene Translocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977501","MYCN Gene Translocation","C164209","A cytogenetic abnormality that refers to a translocation involving the MYCN gene.","MYCN Gene Translocation | MYCN Proto-Oncogene, bHLH Transcription Factor Gene Translocation | MYCN Translocation | N-myc Gene Translocation | NMYC Gene Translocation | Neuroblastoma-Derived V-Myc Avian Myelocytomatosis Viral Related Oncogene Translocation | V-Myc Avian Myelocytomatosis Viral Oncogene Neuroblastoma Derived Homolog Gene Translocation | bHLHe37 Gene Translocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977500","PTGS2 c.-765G/C Polymorphism Profile","C164210","The determination of the whether the nucleotide at position -765 upstream of the start site of the PTGS2 gene is a guanine or cytosine. The presence of cytosine at this site may indicate a decreased risk for coronary artery disease and an increased risk for gastric cancer in certain populations.","PTGS2 c.-765G/C Polymorphism Profile | COX-2 -765G/C Polymorphism Profile | COX2 -765G/C Polymorphism Profile | PTGS2 -765G/C Polymorphism Profile | PTGS2 -765G/C SNP Polymorphism Profile | PTGS2 -765G/C SNP Profile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976996","Lymphoblasts Less than 5 Percent of Bone Marrow Nucleated Cells","C163765","A semi-quantitative microscopic finding indicating that less than 5 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells of lymphoid origin.","Lymphoblasts Less than 5 Percent of Bone Marrow Nucleated Cells | Lymphoblasts Under 5 Percent of Bone Marrow Nucleated Cells | Lymphoblasts Under 5% of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976988","EGFR NP_005219.2:p.V769L","C163752","A change in the amino acid residue at position 769 in the epidermal growth factor receptor protein where valine has been replaced by leucine.","EGFR NP_005219.2:p.V769L | EGFR NP_005219.2:p.Val769Leu | EGFR V769L | EGFR V769L Mutation | EGFR Val769Leu | EGFR p.V769L | EGFR p.Val769Leu | Epidermal Growth Factor Receptor V769L | Epidermal Growth Factor Receptor Val769Leu | NP_005219.2:p.V769L | NP_005219.2:p.Val769Leu | Proto-Oncogene c-ErbB-1 V769L | Proto-Oncogene c-ErbB-1 Val769Leu | Receptor Tyrosine-Protein Kinase erbB-1 V769L | Receptor Tyrosine-Protein Kinase erbB-1 Val769Leu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976991","EGFR NP_005219.2:p.L833F","C163746","A change in the amino acid residue at position 833 in the epidermal growth factor receptor protein where leucine has been replaced by phenylalanine.","EGFR NP_005219.2:p.L833F | EGFR L833F | EGFR L833F Mutation | EGFR Leu833Phe | EGFR NP_005219.2:p.Leu833Phe | EGFR p.L833F | EGFR p.Leu833Phe | Epidermal Growth Factor Receptor L833F | Epidermal Growth Factor Receptor Leu833Phe | NP_005219.2:p.L833F | NP_005219.2:p.Leu833Phe | Proto-Oncogene c-ErbB-1 L833F | Proto-Oncogene c-ErbB-1 Leu833Phe | Receptor Tyrosine-Protein Kinase erbB-1 L833F | Receptor Tyrosine-Protein Kinase erbB-1 Leu833Phe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977350","PSA Level Greater than or Equal to 0.7","C164152","A blood concentration of prostate specific antigen greater than or equal to 0.7 ng/mL.","PSA Level Greater than or Equal to 0.7 | PSA Level 0.7 or Greater",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969049","Cisplatin Regimen","C160011","A regimen consisting of cisplatin that may be used in the treatment of head and neck, including cancer of the nasopharynx, bladder, endometrial, vulvar, ovarian, fallopian tube, primary peritoneal, breast, cervical, and certain central nervous system (CNS) cancers. High-dose cisplatin regimen may be used for the treatment of head and neck cancers.","Cisplatin Regimen | Cisplatin monotherapy | Platinol Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412939","TPX2 Gene","C116082","This gene plays a role in the assembly of the mitotic spindle.","TPX2 Gene | TPX2 | TPX2 Microtubule Nucleation Factor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0442696","Awaken","C164189","To wake up or become awake.","Awaken | Awake | Wake | Wake Up",,,,,,,,,,,,,,,"4113288","Waking",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0231474","Decerebrate Posture","C164187","A posture characterized body rigidity and by extension of the neck, arms, and legs. It may indicate brain stem damage and may suggest herniation of the brain.","Decerebrate Posture | Decerebrate Posturing",,,,,,,,,,,,,,,"4048788","Decerebrate posture",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0231475","Decorticate Posture","C164188","A posture characterized by body rigidity, flexion of the arms over the chest, clenched fists,  and extension of the legs. It may indicate cerebral damage.","Decorticate Posture | Decorticate Posturing",,,,,,,,,,,,,,,"4310245","Decorticate posture",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL977518","Cushing Triad","C164221","A group of signs that often occurs in response to increased intracranial pressure: hypertension, bradycardia, and irregular breathing.","Cushing Triad | Cushing's Triad",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978369","Identified By","C164229","Indicates the person or authoritative body who made an identification.","Identified By | Identifier | Identifying Person",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441722","Force","C48161","The influence that produces a change in a physical quantity; physical energy or intensity.","Force | Forced",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540683","Study Participant","C142710","Any individiual that has a role in a study, including study personnel and study subjects.","Study Participant | study participant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521181","Eligibility Criteria Met By Subject","C132447","An indication that the subject has fulfilled the criteria needed to continue to the next study period.","Eligibility Criteria Met By Subject | ELIGIBILITY CRITERIA MET",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540551","Legally Acceptable Representative","C142600","An individual or juridical or other body authorized under applicable law to consent, on behalf of a prospective subject, to the subject's participation in the clinical trial. (ICH)","Legally Acceptable Representative | LAR | LEGALLY AUTHORIZED REPRESENTATIVE | legally acceptable representative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978351","Clinical Trial Auditor","C164285","A person who audits and monitors a clinical trial. Duties include reviews of protocols and amendments, verification of proper reporting, auditing and monitoring study data, including the consent process, eligibility criteria, and case report forms, generation of audit reports.","Clinical Trial Auditor | Auditor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977465","Clinical Trial Executive Officer","C164286","A top-level manager who is responsible for the running of a clinical trial, usually overseeing the day-to-day activities.","Clinical Trial Executive Officer | Executive Officer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0871893","Script","C96999","A program or a sequence of instructions that are interpreted or carried out by another program or by a person.","Script | script",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518533","Occupation or Discipline","C19160","A grouping of occupations and fields of study.","Occupation or Discipline | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978368","U.S. Postal Service","C164293","An independent agency of the executive branch of the United States federal government responsible for providing postal service in the United States.","U.S. Postal Service | Postal Service | The Post Office | U.S. Mail | US Mail | US Post Office | US Postal Service | USPS | United States Post Office | United States Postal Service",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027988","Newsletter","C115434","A regularly issued printed or electronic report describing a main topic of interest to its subscribers.","Newsletter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3178910","Text Message","C157352","A short electronic communication, usually sent and received by a mobile phone.","Text Message | SMS Text | SMS Text Message | TEXT MESSAGE | Text",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977425","Wheelchair Bed Transfer","C164299","A question about an individual's ability to move from wheelchair to bed and back.","Wheelchair Bed Transfer | Move from Wheelchair to Bed and Return | Moving from wheelchair to bed and return",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977424","Walk on Level Surface","C164300","A question about an individual's ability to walk on a level surface.","Walk on Level Surface Question | Walk on Level Surface | Walk on Level Surface | Walking on level surface",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977423","Propel Wheelchair","C164301","A question about an individual's ability to propel a wheelchair.","Propel Wheelchair Question | Propel Wheelchair | Propel Wheelchair | Propel wheelchair",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0150446","Advocacy","C17551","The process of defending or pleading the cause of another individual or group (from PSY94)","Advocacy | ",,,,,,,,,,,,,,,"4155279","Advocacy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL978358","Independent for Feeding","C164302","A response indicating that an individual can feed themselves independent of help from others.","Independent for Feeding | Feeding Independent | Feeding independent | Feeds Self without Help",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977422","Needs Help with Transfer","C164303","A response indicating that an individual needs help with moving from wheelchair to bed and return.","Needs Help with Transfer | Moving from wheelchair to bed and return with help | Needs Help Moving Between Wheelchair and Bed | Needs Help with Wheelchair Transfer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977421","Needs Help for Toilet Use","C164304","A response indicating that an individual is able to use the toilet with help.","Needs Help for Toilet Use | Getting on and off toilet (handling clothes, wipe, flush) with help | Uses Toilet with Help",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977420","Needs Help to Walk on Level Surface","C164305","A response indicating that an individual is able to walk on a level surface with help.","Needs Help to Walk on Level Surface | Walking on level surface with help | Walks on Level Surface with Help",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977419","Independent Walking on Level Surface","C164306","A response indicating that an individual is able to walk on a level surface independent of help from others.","Independent Walking on Level Surface | Walking on level surface independent | Walks on Level Surface without Help",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977418","Needs Help to Propel Wheelchair","C164307","A response indicating that an individual is able propel their wheelchair with help.","Needs Help to Propel Wheelchair | Propel wheelchair with help | Propels Wheelchair with Help",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977417","Independent to Propel Wheelchair","C164308","A response indicating that an individual is able to propel their wheelchair independent of help from others.","Independent to Propel Wheelchair | Independent  to Propel Wheelchair | Propel wheelchair independent | Propels Wheelchair without Help",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977416","Needs Help Controlling Bowels","C164309","A response indicating that an individual is able to control their bowels with help.","Needs Help Controlling Bowels | Controlling bowels with help | Controls Bowels with Help",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977443","Needs Help Controlling Bladder","C164310","A response indicating that an individual is able to control their bladder with help.","Needs Help Controlling Bladder | Controlling bladder with help | Controls Bladder with Help",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977442","Independent for Controlling Bladder","C164311","A response indicating that an individual is able to control their bladder independent of help from others.","Independent for Controlling Bladder | Controlling bladder independent | Controls Bladder without Help",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0199974","Cytokine Therapy","C15411","The use of cytokines in the treatment of any disease or disorder.","Cytokine Therapy | ",,,,,,,,,,,,,,,"4224323","Cytokine therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4229623","Interstitial Lung Disease","C164315","A category of lung diseases characterized by varying degrees of inflammation and fibrosis of the interstitial lung tissue. Causes include occupational lung exposures and drugs. In a minority of cases there is no clear cause and such cases are termed idiopathic interstitial pneumonia.","Interstitial Lung Disease | ",,,,,,,,,,,,,,,"4119786","Interstitial lung disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3815179","Pharmacogenomics Findings Domain","C111289","A findings domain for gene expression and genetic variation assessments.","Pharmacogenomics Findings Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826265","Reference ID","C82531","A sequence of characters that represents a reference identification.","Reference ID | REFID | Reference Identifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983577","Alternate Identifier","C90353","A backup sequence of characters used to identify an entity.","Alternate Identifier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826268","External Filename","C82536","The literal identifier of a file that is not located within a specific record.","External Filename | XFN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698109","Analytical Methods and Validation Reports","C79368","An indication or description of the process by which the truth of something is tested or found.","Analytical Methods and Validation Reports | ANALYTICAL METHODS AND VALIDATION REPORTS | Analytical Methods And Validation Reports | FDA RPS Analytical Methods And Validation Reports",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977643","Did Not Meet Eligibility Criteria","C164344","An indication that the subject has not fulfilled the criteria needed to continue to the next study period.","Did Not Meet Eligibility Criteria | Did not meet eligibility criteria | ELIGIBILITY CRITERIA NOT MET | Eligibility Criteria Not Met By Subject | Subject Did Not Meet Eligibility Criteria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977642","Informed Consent Process Deviation","C164345","An indication that the informed consent processes or procedures defined the study protocol were not followed.","Informed Consent Process Deviation | Informed Consent (IC) process deviation | Informed consent (IC) process",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977641","Failure to Follow Trial Randomization","C164346","An indication that the trial randomization processes or procedures defined in the study protocol were not followed.","Failure to Follow Trial Randomization | Failure to follow trial randomization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977640","Failure to Discontinue Treatment","C164347","An indication that a subject's treatment was not discontinued as per the protocol.","Failure to Discontinue Treatment | Failure to discontinue treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977639","Study Procedure Deviation","C164348","An indication that a protocol deviation involved the trial processes or procedures defined in the study protocol.","Study Procedure Deviation | Study procedures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977638","Study Agent Deviation","C164349","An indication that a protocol deviation involved a study agent.","Study Agent Deviation | Study agent/medication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977637","Concomitant Medication Used was not Permitted per Protocol","C164350","An indication that a concomitant agent was administered but this agent was not permitted by the protocol.","Concomitant Medication Used was not Permitted per Protocol | Con med used was not permitted per protocol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977636","Lab, Imaging, or Other Investigation Deviation","C164351","An indication that a protocol deviation involved a lab test or procedure, an imaging event, or some other investigation.","Lab, Imaging, or Other Investigation Deviation | Lab/Imaging/Other Investigation Deviation | Lab/Imaging/Other investigation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977635","Failure to Report Serious Adverse Event within Defined Timeframe","C164352","An indication that a protocol deviation was due to a failure to report a serious adverse event within the timeframe established in the study protocol.","Failure to Report Serious Adverse Event within Defined Timeframe | Failure to report SAE within defined timeframe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977634","Patient Did Not Have a Safety Follow Up as Required","C164353","An indication that a subject's safely follow up did not occur as required by the study protocol.","Patient Did Not Have a Safety Follow Up as Required | Patient does not have a safety follow up as required",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977633","Baseline Assessments Are Out of Window","C164354","An indication that a subject's baseline assessments did not occur within the time window required by the study protocol.","Baseline Assessments Are Out of Window | Baseline assessments are out of window",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977632","Disease Outcome or Response","C164355","An indication that a subject's disease outcome or response is not covered by the study protocol.","Disease Outcome or Response  Not Covered | Disease Outcome or Response | Disease Outcome or Response | Disease Outcome/Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977631","Study Device Deviation","C164356","An indication that a protocol deviation involved a study device.","Study Device Deviation | Study device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524916","Endorectal Magnetic Resonance Imaging","C137917","Magnetic resonance imaging done from inside the rectum that usually utilizes a surface coil within a latex balloon to generate the magnetic field.","Endorectal Magnetic Resonance Imaging | Endorectal MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162566","Porphyria Cutanea Tarda","C27725","A cutaneous form of the genetic photosensitive disease, porphyria, that is characterized by onset in adult life and the presence of scarring bullae, hyperpigmentation, facial hypertrichosis, and sometimes sclerodermatous thickenings and alopecia.  Uroporphyrins are found in the urine due to a deficiency of uroporphyrinogen decarboxylase, an enzyme required for the synthesis of heme.","Porphyria Cutanea Tarda | ",,,,,,,,,,,,,,,"4264925","Porphyria cutanea tarda",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545121","Protocol Deviations Supplemental Qualifiers Dataset","C147206","A dataset containing supplemental information, specifically non-standard variables, to parent records in the protocol deviations domain.","Protocol Deviations Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540431","Direct Data Entry","C142512","Recording of data by human or automated action where an electronic record is the original means of capturing the data into an electronic records system without a paper source document. Examples are an individual keying original observations into a system or the automatic recording into the system of the output from measuring devices such as a balance that measures subject's body weight or an ECG machine. Compare to data entry, data acquisition.","Direct Data Entry | direct entry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540331","Data Entry","C142379","The process by which original, source data is inputed by a human into a digital, structured format for later use and analysis.","Data Entry | data entry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977681","Genetic Region of Interest","C164530","The region or sub-location of the genetic or genomic sequence that is described by the test.","Genetic Region of Interest | geneticRegionOfInterest",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977825","Pharmacogenomics Read Depth","C164669","The number of times that a pharmacogenomics region of interest was fully sequenced.","Pharmacogenomics Read Depth | Pharmacogenomics Coverage | Pharmacogenomics Sequence Coverage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977824","Pharmacogenomics Alternative Sequence Read Depth","C164670","The number of times that a variant sequence was found in a read of a pharmacogenomics region of interest.","Pharmacogenomics Alternative Sequence Read Depth | Pharmacogenomics Alternative Coverage | Pharmacogenomics Alternative Sequence Coverage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977823","Pharmacogenomics Reference Sequence Read Depth","C164671","The number of times that a known reference sequence was found in a read of a pharmacogenomics region of interest.","Pharmacogenomics Reference Sequence Read Depth | Pharmacogenomics Reference Coverage | Pharmacogenomics Reference Sequence Coverage | Pharmacogenomics Reference Sequence Read Depth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977822","Pharmacogenomics Read Count","C164672","The number of sequencing reaction results that were pooled to obtain the pharmacogenomics coverage.","Pharmacogenomics Read Count | Pharmacogenomics Read Counts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977821","Pharmacogenomics Copy Number","C164673","The number of times that a pharmacogenomics region of interest is present in the genome.","Pharmacogenomics Copy Number | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977820","Single Nucleotide Variant","C164674","A variation of a single nucleotide at a specific location of the genome due to base substitution, which is found at any frequency in the population.","Single Nucleotide Variant | SNV | SNV, NOS | Single Nucleotide Variants | Single-Nucleotide Variant | snv variant | snv_variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1956002","Indel Mutation","C99752","A mutation class that includes insertion mutations, deletion mutations and mutation events where both an insertion and a deletion has occurred.","Indel Mutation | INDEL | Indel | Insertion-Deletion | indel variant | indel_variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896593","CDISC SDTM Pharmacogenomics Findings Test Code Terminology","C116106","Terminology associated with the pharmacogenomics findings test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Pharmacogenomics Findings Test Code Terminology | SDTM-PFTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522851","Gene Expression Level Analysis","C135484","The determination of the level of gene transcription in a biological specimen. (CDISC)","Gene Expression Level Analysis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1947946","Aim (idea)","C60761","The goal intended to be attained (and which is believed to be attainable).","Aim | Aims",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520346","Amplicon Size","C132434","The number of base pairs present in an RNA or DNA sequence, which is the product of an amplification process.","Amplicon Size | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520343","Allelic Family","C132433","A subgroup of alleles of a polymorphic gene that may form clusters (e.g., phylogenetic) based on high sequence similarity, which may include either a shared single nucleotide polymorphism or a shared set of polymorphic sites.","Allelic Family | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515118","System for Public Use","C19659","A computer system designed for direct use by the public.","System for Public Use | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526735","Percent of Nucleotide Markers Exhibiting Instability","C139284","The relative measurement (percentage) of nucleotide repeat markers exhibiting instability to all nucleotide repeat markers tested in a biological specimen.","Percent of Nucleotide Markers Exhibiting Instability | msi score | msi_score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526728","Number of Nucleotide Markers Exhibiting Instability","C139283","The total number of nucleotide repeat markers tested that exhibit instability in a biological specimen.","Number of Nucleotide Markers Exhibiting Instability | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526734","Microsatellite Instability Overall Status","C139285","The state or condition of a subject's microsatellite sequences with respect to the inability of their mismatch repair (MMR) proteins to fix a DNA replication error.","Microsatellite Instability Overall Status | MICROSATELLITE INSTABILITY OVERALL STATUS | MSI Overall Status | MSIOSTAT | Microsatellite Instability Overall Stat | Microsatellite Instability Status | msi status | msi_status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018555","Chinese Hamster","C77091","Originating in the deserts of northern China and Mongolia and kept in captivity since 1919, these hamsters exhibit a whitish/grey/brown coat color with a black stripe down the spine, and have a life span of two to three years. The Chinese hamster has a relatively long thin body and tail in comparison to other hamster breeds and is crepuscular year round in captivity. Of note, Chinese hamster ovary cell lines are highly transfectable and are used in a variety of pre-clinical research applications.","Chinese Hamster | CHINESE | CRICETULUS GRISEUS | Chinese | Cricetulus barabensis griseus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162610","Caenorhabditis elegans","C14303","A roundworm of the phylum Nematoda often utilized as a biological model system for research.","Caenorhabditis elegans | C. elegans",,,,,,,,,,,,,,,"4268021","Caenorhabditis elegans",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025914","Mus musculus","C45247","The common mouse species, Mus musculus.","Mus musculus | House Mouse | MUS MUSCULUS",,,,,,,,,,,,,,,"40493369","House mouse",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1880002","Carboplatin-Taxol Regimen","C63402","A regimen consisting of carboplatin and paclitaxel that may be used for the treatment of breast, kidney, cervical, vulvar, endometrial, ovarian, fallopian tube, primary peritoneal, head and neck, including cancer of the nasopharynx, esophageal and esophagogastric junction, and gastric cancers; non-small cell lung cancer (NSCLC); anaplastic carcinoma; anal, and non-urothelial and urothelial bladder cancer; salivary gland, malignant germ cell and malignant sex cord-stromal tumors; cutaneous and uveal melanoma; squamous cell skin cancer; thymomas and thymic carcinoma; small bowel adenocarcinoma, occult primary adenocarcinoma or squamous cell carcinoma. Paclitaxel/carboplatin every 21 days regimen may be used for the treatment of esophageal and esophagogastric junction, and gastric cancers.","Carboplatin/Paclitaxel Regimen | CaT Regimen | CaT regimen | Carbo-Tax Regimen | Carbo-Tax regimen | Carboplatin and Paclitaxel (CP) | Carboplatin-Paclitaxel | Carboplatin-Paclitaxel Regimen | Carboplatin-Paclitaxel Regimen | Carboplatin-Taxol | Carboplatin-Taxol Regimen | Carboplatin/Paclitaxel | PC Regimen | PC regimen | Paclitaxel-Carboplatin | Paclitaxel-Carboplatin Regimen | Paclitaxel/Carboplatin | Paclitaxel/Carboplatin Regimen | TC Regimen | carboplatin-Taxol regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0458074","HIV Status","C157155","The result of testing to determine if an individual is infected with the human immunodeficiency virus.","HIV Status | ",,,,,,,,,,,,,,,"4149958","HIV status",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0806692","Lymph Node Involvement","C35529","A finding indicating the spread of cancer to regional or distant lymph node(s).","Lymph Node Involvement | NODAL_INVOLVEMENT | lymph node involvement | lymph_node_involvement",,,,,,,,,,,,,,,"4119350","Lymphomatous nodal involvement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1513363","Mixed Cellular Population","C41610","A morphologic finding indicating the presence of a cellular infiltrate with a mixed population of cells in a tissue sample.","Mixed Cellular Population | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552347","Muscle Invasion","C150571","A morphologic finding indicating the presence of a malignant cellular infiltrate invading muscle in a tissue sample.","Muscle Invasion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879532","Absence of Muscle Invasion","C61108","No Value Exists","Absence of Muscle Invasion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986412","Objective Improvement","C94227","An improvement that can be measured by the health care provider (for example, when a tumor shrinks or there are fewer cancer cells in the blood).","Objective Improvement | objective improvement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971160","Tumor Laterality Left","C160200","A finding indicating the tumor location is on the left side of the specimen.","Tumor Laterality Left | Left",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938201","Tumor Laterality Right","C160199","A finding indicating the tumor location is on the right side of the specimen.","Tumor Laterality Right | Right",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969338","Tumor Laterality Bilateral","C160201","A finding indicating the tumor location is on the both sides of the specimen.","Tumor Laterality Bilateral | Bilateral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978399","Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Center Group","C165217","A multidisciplinary, membership-based scientific organization that designs and conducts biomarker-driven cancer research involving adults who have or are at risk of developing cancer. The Group's stated purpose is to achieve research advances in all aspects of cancer care and thereby reduce the burden of cancer and improve the quality of life and survival in patients with cancer.","Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Center Group | ECOG-ACRIN | ECOG-ACRIN Cancer Research Group",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978386","Conductive Chemohyperthermia System","C165234","A treatment system that combines hyperthermia with intravesical chemotherapy. A chemotherapy solution is heated externally and then instilled into and circulated through the bladder in a closed system.","Conductive Chemohyperthermia System | Conductive CHT | Conductive Hyperthermia System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978419","Hyperprogression","C165207","Paradoxical acceleration of tumor progression following the initiation of therapy.","Hyperprogression | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349419","Treatment Assignment Code","C165236","An identification code assigned to each unique treatment regimen to uniformly group patients for separate analysis of adverse events and response data.","Treatment Assignment Code | TAC | Treatment Identification Code | ctep treatment assignment code | ctep_treatment_assignment_code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978709","Treatment Assignment Description","C165237","A complete description of each unique treatment regimen to uniformly group patients for separate analysis of adverse events and response data.","Treatment Assignment Description | TAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900047","Analysis Method","C117039","A means, manner of procedure, or systematic course of actions that are performed in order to examine and interpret an event or entity.","Analysis Method | ANMETH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827032","Trial Inclusion Exclusion Criteria Version","C83444","A specific variant of the original trial inclusion exclusion criterion.","Trial Inclusion Exclusion Criteria Version | TIVERS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969884","CDISC SDTM Laboratory Analytical Method Calculation Formula Terminology","C160922","Terminology associated with the laboratory analytical method calculation formula codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Laboratory Analytical Method Calculation Formula Terminology | LBANMET | Laboratory Analytical Method Calculation Formula | SDTM-LBANMET",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969949","Schwartz Method For Children Formula","C161348","A formula to estimate glomerular filtration rate in children that takes into account age, height, and serum creatinine. eGFR (mL/min/1.73 m2) = k x Height (cm)/Serum creatinine (mg/dL) where k=0.33 for pre-term babies, 0.45 for full-term babies and 0.55 for girls ages 1-13 or 0.70 for boys ages 1-13. (Schwartz GJ, Gauthier B. A simple estimate of glomerular filtration rate in adolescent boys. J Pediatr. 1985 Mar;106(3):522-6.)","Schwartz Method For Children Formula | SCHWARTZ METHOD FOR CHILDREN FORMULA | Schwartz Method for Children 1985 Formula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969950","MDRD Enzymatic Japanese Formula","C161347","A formula to estimate glomerular filtration rate in Japanese subjects that takes into account age, sex, and serum creatinine. eGFR (ml/min/1.73m2) = 194 x PD93 power^-1.094 x Age power^- 0.287 x Sex; where PD93 = Serum Cr (mg/dL), Sex = 1.00 for male and 0.739 for female. (Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S. Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan. Am J Kidney Dis. 2007 Dec;50(6):927-37.)","MDRD Enzymatic Japanese Formula | MDRD ENZYMATIC JAPANESE FORMULA | MDRD Enzymatic Japanese 2007 Formula | MDRD Enzymatic Japanese Imai 2007 Formula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969951","MDRD Enzymatic Formula","C161346","A formula to estimate glomerular filtration rate that takes into account age, sex, race, and serum creatinine. eGFR (mL/min/1.73 m2)=175 x (serum Cr [conv mg/dL])^-1.154 x (Age)^ -0.203 x (0.742 if female) x (1.212 if black), for conventional units. eGFR=175 x (serum Cr [SI UMOL/L]/88.4)^-1.154 x (Age)^ -0.203 x (0.742 if female) x (1.212 if black), for SI units. (Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-12.)","MDRD Enzymatic Formula | IDMS MDRD | MDRD ENZYMATIC FORMULA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969952","MDRD 6 Variable Formula","C161345","A formula to estimate glomerular filtration rate that takes into account age, sex, race, serum creatinine, serum urea nitrogen, and albumin. eGFR (mL/min/1.73 m2) = 170 x (SCr/88.4)^-0.999 x age^-0.176 x (SU x 2.78)^-0.170 x albumin^0.318 x (0.762, if female) x (1.18, if African American). (Levey AS, Greene T, Kusek JW, Beck GJ, MDRD study group. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000; 11: A0828.)","MDRD 6 Variable Formula | MDRD 6 VARIABLE FORMULA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969953","MDRD 5 Variable Formula","C161344","A formula to estimate glomerular filtration rate that takes into account age, sex, race, serum creatinine and serum urea nitrogen. eGFR (mL/min/1.73 m = 270 x creatinine (mg/dl)^-1.007 x age^-0.180 x 1.178 (if black) x 0.762 (if female) x serum urea nitrogen^-0.169. (Levey AS, Greene T, Kusek JW, Beck GJ, MDRD study group. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000; 11: A0828.)","MDRD 5 Variable Formula | MDRD 5 VARIABLE FORMULA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969939","MDRD 4 Variable Formula","C161343","A formula to estimate glomerular filtration rate that takes into account age, sex, race, and serum creatinine (Scr). eGFR (mL/min/1.73 m2) = 186 x (Scr)^-1.154 x (Age)^-0.203 x (0.742 if female) x (1.210 if African American). (Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-70.)","MDRD 4 Variable Formula | MDRD 4 VARIABLE FORMULA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2924627","Cockcroft-Gault Formula","C161342","A formula to estimate creatinine clearance that takes into account sex, age, weight, and serum creatinine (SCr). CCr=(140 - Age) x Wgt (Kg) / 72xCrt (mg/dL) x 1 (if M) or 0.85 (if F), for conventional units. CCr=(140 - Age) x Wgt (Kg) / 72xCrt (MCMOL/L) x 88.4 x 1 (if M) or 0.85 (if F) [If Wgt is in lbs; Wgt (Kg) = Wgt (lbs) x 0.45], for SI units. (Cockcroft, D.W. and M.H. Gault. Prediction of creatinine clearance from serum creatinine. Nephron. 1976. 16(1):31-41.)","Cockcroft-Gault Formula | COCKCROFT-GAULT FORMULA",,,,,,,,,,,,,,,"45766326","Cockcroft-Gault formula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL969940","CKD-EPI Formula","C161341","An unspecified formula to estimate glomerular filtration rate that takes into account factors such as sex, age, race, and biomarker measurements.","CKD-EPI Formula | CKD-EPI FORMULA | CKD-EPI GFR Formula | CKD-EPI GFR Formula Unspecified | Chronic Kidney Disease Epidemiology Collaboration Formula | Chronic Kidney Disease Epidemiology Collaboration Formula Unspecified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969942","CKD-EPI Cystatin C Formula","C161339","A formula to estimate glomerular filtration rate that takes into account sex, age, race, and serum cystatin C (Scys). eGFR(mL/min/1.73 m2)=133 x min(Scys/0.8, 1)^-0.499 x max (Scys/0.8, 1)^-1.328 x 0.996^Age x 0.932 [if female]. (Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20-29.)","CKD-EPI Cystatin C Formula | CKD-EPI CYSTATIN C FORMULA | CKD-EPI Cystatin C 2012 Formula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969943","CKD-EPI Creatinine Formula","C161338","A formula to estimate glomerular filtration rate that takes into account sex, age, race, and serum creatinine (SCr). eGFR(mL/min/1.73 m2)=141 x min(SCr/k, 1)^a x max(SCr/k, 1)^-1.209 x 0.993^Age x 1.018 [if female] x 1.159 [if black] where: SCr is in mg/dL; k=0.7 for Female and 0.9 for Male; a=-0.329 for female and -0.411 for male. (Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.)","CKD-EPI Creatinine Formula | CKD-EPI CREATININE FORMULA | CKD-EPI Creatinine 2009 Formula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969941","CKD-EPI Creatinine-Cystatin C Formula","C161340","A formula to estimate glomerular filtration rate that takes into account sex, age, race, serum creatinine (SCr) and serum cystatin C (Scys). eGFR(mL/min/1.73 m2)=135 x min(SCr/k, 1)a x max(SCr/k, 1)-0.601 x min(Scys/0.8, 1)-0.375 x max(Scys/0.8, 1)-0.711 x 0.995^Age x 0.969 [if female] x 1.08 [if black]. (Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20-29.)","CKD-EPI Creatinine-Cystatin C Formula | CKD-EPI CREATININE-CYSTATIN C FORMULA | CKD-EPI Creatinine-Cystatin C 2012 Formula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978552","Decipher Bladder Cancer Assay","C165251","A genomic subtyping tool designed to identify muscle invasive bladder cancer patients who may benefit from neoadjuvant chemotherapy prior to surgery.","Decipher Bladder Cancer Assay | Decipher Bladder | Decipher Bladder Assay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031041","Pericardial Window Procedure","C51618","A procedure in which an opening is made in the pericardium.","Pericardial Window Procedure | PERICARDIAL WINDOW | Pericardial Window | Pericardiostomy",,,,,,,,,,,,,,,"4238653","Pericardiostomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2986808","Radioactive Tracers","C94962","A substance containing a radioisotope that has an affinity for and binds to a chosen biologic substance of interest to enable quantification of biologic processes.","Radioactive Label | Radioactive Tag | Radioactive Tracer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037661","Somatostatin-Producing Neuroendocrine Tumor","C3379","A rare, usually malignant neuroendocrine tumor arizing from delta cells.  This neoplasm produces large amounts of somatostatin, which may result in a syndrome characterized by diarrhea, steatorrhea, weight loss, and gastric hyposecretion. Sixty percent are found in the pancreas and 40% in the duodenum or jejunum. The peak incidence occurs between 40 and 60 years of age; women are affected more than men by 2:1.","Somatostatin-Producing Neuroendocrine Tumor | Delta Cell Tumor | Somatostatin Cell Tumor | Somatostatin Producing Tumor | Somatostatin cell tumor, NOS | Somatostatin-Producing NET | Somatostatin-Producing Tumor | Somatostatinoma | Somatostatinoma, NOS | Tumor of Delta Cells | Tumor of the Delta Cells",,,,,,,,,,,,,,,"4029978|4098952","Somatostatinoma|Somatostatinoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL978542","Lymphodepletion Therapy","C165275","The destruction of lymphocytes prior to immunotherapy.","Lymphodepletion Therapy | Lymphodepleting Therapy | Lymphodepletion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978389","PSA Level Greater than Zero","C165239","A blood concentration of prostate specific antigen greater than 0 ng/mL.","PSA Level Greater than Zero | PSA Level Greater than 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978392","BRD4/NUTM1 Fusion Negative","C165242","An indication that expression of a BRD4/NUTM1 fusion has not been detected in a sample.","BRD4/NUTM1 Fusion Negative | BRD4-C15orf55 Fusion Negative | BRD4-NUT Fusion Negative | BRD4-NUT Rearrangement Negative | BRD4-NUTM1 Fusion Negative | BRD4-NUTM1 Rearrangement Negative | BRD4/C15orf55 Fusion Negative | BRD4/NUT Fusion Negative | BRD4/NUT Rearrangement Negative | BRD4/NUTM1 Rearrangement Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978544","Strata Immune Signature Positive","C165243","An indication that a tumor sample subjected to the proprietary StrataNGS (next-generation sequencing) protocol has a molecular profile that may respond to treatment with an immunotherapeutic agent.","Strata Immune Signature Positive | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978545","NUTM1 Gene Translocation","C165244","A cytogenetic abnormality that refers to any translocation involving the NUTM1 gene.","NUTM1 Gene Translocation | C15orf55 Gene Translocation | FAM22H Gene Translocation | NUT Gene Translocation | NUT Midline Carcinoma, Family Member 1 Gene Translocation | NUT Translocation | NUTM1 Translocation | Nuclear Protein in Testis Gene Translocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978547","Reduced WAS Protein Expression","C165246","An indication that reduced expression of Wiskott-Aldrich Syndrome protein (WASP; WASp) has been detected in a sample.","Reduced WAS Protein Expression | Reduced WASP Expression | Reduced WASp Expression | Reduced Wiskott-Aldrich Syndrome Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978549","t(17;19)","C165248","A cytogenetic abnormality that involves a translocation between chromosomes 17 and 19.","t(17;19) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978550","Testosterone Less than 100 ng/dL","C165249","A semiquantitative finding indicating that the concentration of testosterone in a sample is less than 100 ng/dL.","Testosterone Less than 100 ng/dL | Testosterone Less than 100 Nanograms per Deciliter | Testosterone Less than 100 Nanograms/Deciliter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978551","PCA3 Score Greater than 35","C165250","An indication that the ratio of prostate cancer antigen 3 (PCA3) RNA to prostate specific antigen (PSA) mRNA multiplied by 1000 is greater than 35.","PCA3 Score Greater than 35 | PCA3 Level Greater than 35 | Prostate Cancer Antigen 3 Score Greater than 35 | Prostate Cancer Associated 3 Score Greater than 35",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978546","NUTM1 Positive","C165245","An indication that NUTM1 expression has been detected in a sample.","NUTM1 Positive | NUT Family Member 1 Positive | NUT Midline Carcinoma Family Member 1 Positive | NUT Positive | Nuclear Protein in Testis Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978514","Glucagon-Producing","C165279","Describes cells or tissues that produce glucagon.","Glucagon-Producing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978513","Insulin-Producing","C165278","Describes cells or tissues that produce insulin.","Insulin-Producing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985948","Biologic Specimen Accession Number","C93748","An alphanumeric identifier (not necessarily unique to the specimen) assigned by a receiving lab to specimens that are received together as a set.","Biologic Specimen Accession Number | BiologicSpecimen.accessionNumberText",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030234","Palmitic Acid","C61873","A saturated long-chain fatty acid with a 16-carbon backbone. Palmitic acid is found naturally in palm oil and palm kernel oil, as well as in butter, cheese, milk and meat.","Palmitic Acid | Fatty Acid 16:0 | Hexadecanoic Acid | PALMITIC ACID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831717","cetuximab/cisplatin/fluorouracil","C150691","A regimen consisting of cisplatin, fluorouracil (5-FU) and cetuximab used for the treatment of various types of head and neck cancer.","Cetuximab/Cisplatin/Fluorouracil Regimen | Cisplatin and Fluorouracil (CF) and Cetuximab | Cisplatin-Fluorouracil-Cetuximab | Cisplatin-Fluorouracil-Cetuximab Regimen | Cisplatin/5-FU/Cetuximab | Cisplatin/5-FU/Cetuximab Regimen | Cisplatin/5-Fluorouracil/Cetuximab | Cisplatin/Fluorouracil Plus Cetuximab | Cisplatin/Fluorouracil/Cetuximab | Cisplatin/Fluorouracil/Cetuximab Regimen | Cisplatin/Fluorouracil/Cetuximab Regimen | PFE | Platinol/Fluorouracil/Erbitux",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978500","Computed Tomography Dose Index","C165294","A metric that quantifies the radiation dose delivered by a computed tomography examination by estimating the average dose absorbed at several locations in an imaged volume.","Computed Tomography Dose Index | CTDI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517002","Expected Adverse Event","C41333","Any adverse event associated with a medical product or procedure, whose nature and severity have been previously observed, identified in nature, severity, or frequency, and documented in the investigator brochure, investigational plan, protocol, current consent form, scientific publication, or in other relevant and reliable document. The old term Side Effect is retired and should not be used.","Expected Adverse Event | Anticipated Adverse Event | EAE | Expected | anticipated adverse event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978635","Modified Radiation-induced Skin Reaction Assessment Scale","C165421","An eight-item assessment tool that is used to evaluate the extent of radiation-induced skin reactions. It consists of a researcher component that utilizes a five-point scale to rate the visible extent of the skin reactions, and a patient component that utilizes a four-point scale to rate the level of pain, itchiness, burning, and effect on day-to-day life.","Modified Radiation-induced Skin Reaction Assessment Scale | mRISRAS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978608","Have Tenderness, Discomfort, or Pain of Skin in Treatment Area","C165423","A question about whether an individual has or had any tenderness, discomfort, or pain of the skin in the treatment area.","Have Tenderness, Discomfort, or Pain of Skin in Treatment Area | Do you have any tenderness, discomfort or pain of your skin in the treatment area | Tenderness, Discomfort, or Pain of Skin in Treatment Area",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978609","Does Skin in Treatment Area Itch","C165424","A question about whether an individual's skin in the treatment area itches.","Does Skin in Treatment Area Itch | Does your skin in the treatment area itch | Skin in Treatment Area Itch",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978610","Have Burning Sensation of Skin in Treatment Area","C165425","A question about whether an individual has or had a burning sensation of the skin in the treatment area.","Have Burning Sensation of Skin in Treatment Area | Do you have a burning sensation of your skin in the treatment area",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978611","Extent to Which Skin Reaction and Symptoms Affect Day to Day Activities","C165426","A question about whether an individual has or had a burning sensation of the skin in the treatment area.","Extent to Which Skin Reaction and Symptoms Affect Day to Day Activities | Extent that Skin Reaction and Symptoms Affect Day to Day Activities | To what extent has your skin reaction and your symptoms affected your day to day activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978612","Dry Desquamation","C165427","A skin reaction characterized by scaling and pruritus.","Dry Desquamation | Dry desquamation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978613","Moist Desquamation","C165428","A skin reaction characterized by sloughing of the epidermis and serous exudate.","Moist Desquamation | Moist desquamation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0151799","Skin Necrosis","C112114","Death of one or more layers of skin.","Skin Necrosis | Necrosis",,,,,,,,,,,,,,,"4317266","Skin necrosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL978614","Less than Twenty Five Percent","C165429","A response that indicates less then twenty-five percent.","Less than Twenty Five Percent | Less than 25%",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978615","Between Twenty Five and Fifty Percent","C165430","A response that indicates between twenty-five and fifty percent.","Between Twenty Five and Fifty Percent | 25-50%",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978616","Between Fifty and Seventy Five Percent","C165431","A response that indicates between fifty and seventy-five percent.","Between Fifty and Seventy Five Percent | 50-75%",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978617","Greater than Seventy Five Percent","C165432","A response that indicates greater than seventy-five percent.","Greater than Seventy Five Percent | Greater than 75%",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897549","Specimen Label","C115528","Documentation detailing the identification and collection of a specimen for the clinical trial.","Clinical Trial Specimen Label Documentation | Sample Label | Specimen Label | Specimen Label | Specm Labl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811654","Biospecimen Events Domain","C111138","An events domain that documents biospecimen collection and storage information.","Biospecimen Events Domain | BE | Biospecimen Events",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890718","Accountable Party","C117052","The person or organization responsible for an entity or event.","Accountable Party | PARTY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519565","Toxicology, Antidotes/Treatment","C19071","The treatment or medication that can be administered to a person who has been exposed to a toxic substance","Toxicology, Antidotes/Treatment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978623","Specimen Toothpick","C165438","A fine, hard object that may be tapered on one or both ends and is used to scrape off a specimen from a histological section of tissue.","Specimen Toothpick | Toothpick",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978592","Tissue on Cap","C165439","The deposition of a tissue sample onto a plastic surface as a result of a tissue dissection procedure.","Tissue on Cap | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978593","Tissue in Tube","C165440","The deposition of a tissue sample into a micro-tube or the well of a micro-well plate as a result of a tissue dissection procedure.","Tissue in Tube | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978594","RNA in Tube","C165441","The deposition of an RNA sample into a collection tube as a result of an RNA extraction procedure.","RNA in Tube | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978595","Indexed Sequencing","C165442","A sequencing method that involves the addition of a unique identifier called an index sequence to samples during library preparation. This allows multiple libraries to be pooled and processed together.","Indexed Sequencing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978596","Index Sequence","C165443","A unique nucleotide sequence that is added to a sample during library preparation to serve as a unique identifier for the sample.","Index Sequence | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978597","Single-indexed Sequencing","C165444","An indexed sequencing method that includes one index read.","Single-indexed Sequencing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978598","Dual-indexed Sequencing","C165445","An indexed sequencing method that includes two index reads.","Dual-indexed Sequencing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879952","CDISC SDTM Trial Summary Parameter Terminology by Code","C66738","Terminology codelist used with Trial Summary Parameter within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.","CDISC SDTM Trial Summary Parameter Short Name Terminology | SDTM-TSPARMCD | TSPARMCD | Trial Summary Parameter Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274372","Actual Subject Number","C98703","The actual number of subjects entered into a clinical trial.","Actual Subject Number | ACTSUB | Actual Number of Subjects",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504656","Biospecimen Retained and/or Contains DNA Indicator","C126058","An indication as to whether biospecimens have been retained and/or whether those retained biospecimens contain DNA.","Biospecimen Retained and/or Contains DNA Indicator | BIOSPRET | Biospecimen Retention Contains DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544938","Adaptive Study Design Indicator","C146995","An indication as to whether a study's design includes a prospectively planned opportunity for modification of one or more specified aspects of the study design and/or hypotheses based on analysis of data, usually interim data.","Adaptive Study Design Indicator | ADAPT | Adaptive Design | adaptiveDesignIndicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509434","Data Monitoring Committee Indicator","C127790","An indication as to whether a clinical trial has an appointed data monitoring committee.","Data Monitoring Committee Indicator | DMCIND | dataMonitoringCommitteeIndicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522876","Delayed Graft Function Diagnostic Criteria Name","C135514","The name of a standard criterion from which a judgment concerning an occurrence of a delayed graft function (DGF) can be established.","Delayed Graft Function Diagnostic Criteria Name | DGFCRIT | Delayed Graft Function Diagnostic Criteria | Delayed Graft Function Dx Criteria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274384","Data Cutoff Date","C98717","The date on which subsequently collected data will not be considered as part of the analysis.","Data Cutoff Date | DCUTDTC | dataCutoffDate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274385","Data Cutoff Date Description","C98718","A textual description of the data cutoff date.","Data Cutoff Date Description | DCUTDESC | Data Cutoff Description",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935794","CDISC Therapeutic Area User Guide Name and Version","C156602","The name and version of the CDISC therapeutic area user guide that is being used in the study submission.","CDISC Therapeutic Area User Guide Name and Version | CDISC Therapeutic Area User Guide | CTAUG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526722","Clinical Study Report Archive Date","C139273","The date when the clinical study report was archived.","Clinical Study Report Archive Date | CSRARDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274382","Confirmed Response Minimum Duration","C98715","The minimum amount of time required to meet the criteria for a confirmed response to treatment.","Confirmed Response Minimum Duration | CRMDUR | confirmedResponseMinimumDuration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347178","Active Comparator Drug","C68612","A therapeutically active agent that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","Active Comparator Drug | COMPTRT | Comparative Treatment Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508974","Sponsor Commercial Status","C127789","The state or condition of the sponsor as it pertains to whether the sponsor is considered a commercial entity.","Sponsor Commercial Status | CMSPSTAT | Commercial Sponsor Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509042","Clinical Study Citation","C127788","A bibliographical reference to a particular study.","Clinical Study Citation | CITNSTDY | Citation Used in Study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526723","Blinded Status at SDTM Dataset Generation","C139272","The blinding status of the trial at the point in time when the SDTM datasets are generated.","Blinded Status at SDTM Dataset Generation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976928","Trial Exploratory Objective","C163559","The exploratory purpose of the trial.","Trial Exploratory Objective | Exploratory Objective | OBJEXP | Study Exploratory Objective | exploratory objective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509288","Number of Trial Sites within European Union State","C127795","The number of trial sites within a European Union state.","Number of Trial Sites within European Union State | NUMSEUST | Number of Trial Sites EU State",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504661","Number of Groups or Cohorts","C126063","The number of groups or cohorts that are part of the study.","Number of Groups or Cohorts | NCOHORT | Number of Groups/Cohorts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274432","Planned Number of Arms","C98771","The planned number of intervention groups.","Planned Number of Arms | NARMS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509481","Multiple Site European Union State Trial Indicator","C127794","An indication as to whether the clinical study is being conducted at multiple sites within the European Union member state concerned by the application.","Multiple Site European Union State Trial Indicator | MSEUTIND | Multiple Site EU State Trial Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086226","Country of Manufacture","C124455","The name of the country within which the product under study is made.","Country of Manufacture | MNFCNTRY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274412","Intervention Type","C98747","The kind of product or procedure studied in a trial.","Intervention Type | INTTYPE | Study Intervention Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274411","Intervention Model","C98746","The trial design developed to compare treatment groups.","Intervention Model | INTMODEL | Intervention Model Type | Interventional Study Design",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL455310","Trial Indication","C112038","The disease under study which serves as the basis for initiation of a study treatment in a clinical trial.","Trial Indication | Disease/Condition Indication Description | INDC | INDIC | Indication for Use | Trial Disease/Condition Indication | Trial Disease/Condition Indication Description",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274404","Healthy Subject Indicator","C98737","Specifies whether an individual who is or becomes a participant in a research study and has no significant health-related issues including those related to the condition being tested.","Healthy Subject Indicator | HLTSUBJI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935791","FDA Technical Specification Name and Version","C156603","The name and version of the FDA technical specification that is being used in the study submission.","FDA Technical Specification Name and Version | FDA Technical Specification | FDATCHSP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055026","FDA-Regulated Device Study Indicator","C123629","An indication as to whether the study involves an FDA-regulated device.","FDA-Regulated Device Study Indicator | FDADEIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274431","Planned Country of Investigational Site","C98770","The planned country within which the investigation, trial or study is taking place.","Planned Country of Investigational Site | FCNTRY | Planned Country of Investigational Sites",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526721","Extension Trial Indicator","C139274","An indication as to whether the clinical trial is an extension trial.","Extension Trial Indicator | EXTTIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509060","Trial Expanded Access Status","C127793","The state or condition of an experimental drug or device as it pertains to its availability for use in expanded access studies.","Trial Expanded Access Status | EXPASTAT | Expanded Access Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509059","Clinicaltrials.gov NCT Number for the Expanded Access Record","C127792","The unique alphanumeric identifier for a study with associated expanded access record, as assigned by the clinicaltrials.gov PRS system.","Clinicaltrials.gov NCT Number for the Expanded Access Record | EXPARECN | Expanded Access Record NCT Number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504687","EudraVigilance Sender Organization","C126090","The name of the group or institution that is transmitting an adverse drug reaction report to the EudraVigilance system.","EudraVigilance Sender Organization | EVSNDORG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504659","EudraVigilance Sender Identifier","C126061","A unique identifier assigned to the organization that is transmitting an adverse drug reaction report to the EudraVigilance system.","EudraVigilance Sender Identifier | EVSNDID | EudraVigilance Sender ID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504658","EudraCT Resubmission Indicator","C126060","An indication as to whether the trial being submitted to the EudraCT is a trial that has been previously submitted to the EudraCT system and withdrawn.","EudraCT Resubmission Indicator | EURSBIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504657","EMA Decision Number for Pediatric Investigation Plan","C126059","An alphnumeric code assigned by the European Medicines Agency (EMA) to an EMA regulatory decision.","EMA Decision Number for Pediatric Investigation Plan | EMA Decision Number for PIP | EMPIPDCN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509052","E-mail Address for XML File Feedback","C127791","The E-mail address to which copies of the XML format of the CT application should be sent.","E-mail Address for XML File Feedback | EMAILXML | Email Address for XML File",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899324","ECG T Wave Algorithm","C119582","The defined procedure used to identify the end of the T wave.","ECG T Wave Algorithm | ECG Twave Algorithm | EGTWVALG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899326","ECG Replicates On-Treatment Indicator","C119566","An indication as to whether replicate ECGs for time points during the on-treatment portion of the study were included.","ECG Replicates On-Treatment Indicator | ECG Replicates On-Treatment | EGREPLTR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899325","ECG Replicates at Baseline Indicator","C119565","An indication as to whether replicate ECGs for time points during the baseline portion of the study were included.","ECG Replicates at Baseline Indicator | ECG Replicates at Baseline | EGREPLBL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899328","ECG Read Method Degree of Automation","C119564","The degree of automation of the method by which the ECG output is read by the evaluator.","ECG Read Method Degree of Automation | ECG Read Method | EGRDMETH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899319","ECG Used Same Lead Indicator","C119563","An indication as to whether ECG interval measurements were based on the same lead.","ECG Used Same Lead Indicator | ECG Used Same Lead | EGLEADSM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899329","ECG Planned Primary Lead for Study","C119562","A description of the ECG lead that is planned to be used as the planned, primary lead for the study.","ECG Planned Primary Lead for Study | ECG Planned Primary Lead | EGLEADPR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899331","ECG Continuous Monitoring Indicator","C119561","An indication as to whether the 10-second ECGs for this study were extracted from a continuous recording.","ECG Continuous Monitoring Indicator | ECG Continuous Monitoring | EGCTMON",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899330","ECG Evaluator Blinding Parameters","C119560","A description of the parameters to which the ECG assessors were blinded to within the study.","ECG Evaluator Blinding Parameters | ECG Reading Blinded | EGBLIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504669","Resubmission Letter","C126071","An alphabetic character that describes the incremental order of trial submissions or resubmissions.","Resubmission Letter | RESUBLTR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274381","Clinical Trial Registry Identifier","C98714","A sequence of letters, numbers, or other characters that uniquely identifies a clinical trial within a clinical trial registry.","Clinical Trial Registry Identifier | REGID | Registry Identifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504668","Rare Disease Indicator","C126070","An indication as to whether the condition under study is considered a rare or orphan disease.","Rare Disease Indicator | RDIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274436","Randomization Quotient","C98775","The number of planned subjects to be exposed to investigational therapy, independent of dose or other factors, divided by the total number of planned subjects.","Randomization Quotient | RANDQT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509298","PUBMEDID","C127797","A globally unique identifier for a biomedical article, as assigned by PubMed.","PubMed Unique Identifier | PMID_REF | PUBMEDID | PubMed ID | PubMed ID for Citation Used in Study | PubMed Identifier | PubMed Identifier for Citation Used in Study | PubMed Indexing Number | PubMed Unique Identifier | pubmed id | pubmed_id",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526727","Planned Treatment Duration","C139276","The period of time during which the treatment is intended to be given.","Planned Treatment Duration | PTRTDUR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526726","Protocol Risk Assessment","C139277","The potential future harm that may arise from some protocol-related activity.","Protocol Risk Assessment | PROTRSK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509648","Planned Trial Duration","C127796","The approximate period of time over which a clinical trial is planned to occur.","Planned Trial Duration | PLNTRDUR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504667","Pediatric Investigation Plan Indicator","C126069","An indication as to whether the trial is part of the pediatric investigation plan.","Pediatric Investigation Plan Indicator | PIPIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054218","Pediatric Study Indicator","C123632","An indication as to whether the study is a pediatric study.","Pediatric Study Indicator | PDSTIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054220","Pediatric Postmarket Study Indicator","C123631","An indication as to whether the study is a pediatric postmarket study.","Pediatric Postmarket Study Indicator | PDPSTIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274429","Pharmacological Class of Investigational Therapy","C98768","The drug class of the therapy being investigated in the study or trial.","Pharmacological Class of Investigational Therapy | PCLAS | PCLASS | Pharmacologic Class | Study Product Pharmacologic Class",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526720","Post Authorization Safety Study Indicator","C139275","An indication as to whether the clinical study is a post authorization safety study.","Post Authorization Safety Study Indicator | PASSIND | Post Authorization Safety Study Ind",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274440","Secondary Outcome Measure","C98781","Other key measures that will be used to evaluate the intervention(s) or, for observational studies, that are a focus of the study. These are the outcome measures used to assess the secondary objective(s).","Secondary Outcome Measure | OUTMSSEC | SECONDARY OUTCOME MEASURE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274433","Primary Outcome Measure","C98772","The primary measurement(s) or observation(s) used to measure the effect of experimental variables in a study, or for observational studies, to describe patterns of diseases or traits or associations with exposures, risk factors or treatment. These are the outcome measures used to assess the primary objective(s).","Primary Outcome Measure | OUTMSPRI | PRIMARY OUTCOME MEASURE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274391","Exploratory Outcome Measure","C98724","Exploratory measures that are used to evaluate and/or form hypotheses about the intervention outcome(s).","Exploratory Outcome Measure | EXPLORATORY OUTCOME MEASURE | OUTMSEXP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935793","Additional Outcome Measure","C156601","Additional key measures that will be used to evaluate the intervention(s) or, for observational studies, that are a focus of the study, but which are not considered primary or secondary outcome measures.","Additional Outcome Measure | OUTMSADD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504666","Observational Study Sampling Method Description","C126068","A textual description of the sampling method used to assign study participants into groups or cohorts within an observational study.","Observational Study Sampling Method Description | OBSTSMMD | Obs Study Sampling Method Description",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504665","Observational Study Sampling Method","C126067","The process by which subjects are selected to participate in observational studies.","Observational Study Sampling Method | OBSTSMM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504664","Observational Study Population Description","C126066","A textual description of the population group from which the group or cohort will be selected for observational studies.","Observational Study Population Description | OBSTPOPD | Obs Study Population Description",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504663","Observational Time Perspective of Study","C126065","The temporal relationship between the observation period and time of subject enrollment. (ClinicalTrials.gov)","Observational Time Perspective of Study | OBSTIMP | Observational Time Perspective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504662","Observational Model","C126064","The trial design developed to compare biomedical and/or health outcomes in pre-defined and non-assigned groups of individuals.","Observational Model | OBSMODEL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827977","Trial Secondary Objective","C85827","The auxiliary purpose of the trial.","Trial Secondary Objective | OBJSEC | Study Secondary Objective | secondary objective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827976","Trial Primary Objective","C85826","The principal purpose of the trial.","Trial Primary Objective | OBJPRIM | Study Primary Objective | primary objective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508982","Study Protocol Uniform Resource Locator Description","C127802","A textual description for the uniform resource locator of a clinical study protocol.","Study Protocol Uniform Resource Locator Description | URL Related to Study Description | URLSTDYD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508983","Study Protocol Uniform Resource Locator","C127801","The uniform resource locator for a clinical study protocol.","Study Protocol Uniform Resource Locator | URL Related to Study | URLSTDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504675","Planned Follow-Up Duration","C126077","The anticipated time period over which each study participant is to be followed. (clinicaltrials.gov)","Planned Follow-Up Duration | TRGFUDUR | Target Follow-Up Duration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540168","Study Type","C142175","The nature of the investigation or the investigational use for which the study is being done.","Study Type | STUDY_TYPE | STYPE | Study Type Classification | clinical study type | clinical_study_type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504674","Substudy Planned Indicator","C126076","An indication as to whether a study performed on a subgroup of subjects included in the original trial is planned to be included as part of the current study.","Substudy Planned Indicator | SSTDYIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504673","Substudy Details","C126075","A textual description of the substudy.","Substudy Details | SSTDYDTL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509558","Single Site European Union State Trial Indicator","C127800","An indication as to whether the clinical study is being conducted at only one site within the European Union member state concerned by the application.","Single Site European Union State Trial Indicator | SSEUTIND | Single Site EU State Trial Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504672","SUSAR Reporting to National Competent Authority Indicator","C126074","An indication as to whether suspected unexpected serious adverse reactions will be reported to national competent authorities.","SUSAR Reporting to National Competent Authority Indicator | SRNCAIND | SUSAR Reporting to NCA Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504671","SUSAR Reporting to EudraVigiliance Clinical Trial Module Indicator","C126073","An indication as to whether suspected unexpected serious adverse reactions will be reported to a EudraVigiliance clinical trial module.","SUSAR Reporting to EudraVigiliance Clinical Trial Module Indicator | SREVIND | SUSAR Reporting to EVCTM Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509347","Requires Secure Email Delivery of XML Indicator","C127799","An indication as to whether the XML copy of the CT application requires secure E-mail delivery.","Requires Secure Email Delivery of XML Indicator | SDXMLIND | Secure Delivery XML Required Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935785","Study Data Tabulation Model Version","C156605","The version of the CDISC Study Data Tabulation Model that is being used in the study submission.","Study Data Tabulation Model Version | SDTM Version | SDTMVER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935792","Study Data Tabulation Model Implementation Guide Version","C156604","The version of the CDISC Study Data Tabulation Model implementation guide that is being used in the study submission.","Study Data Tabulation Model Implementation Guide Version | SDTIGVER | SDTM IG Version | SDTM Implementation Guide Version | SDTMIG Version",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274442","Stable Disease Minimum Duration","C98783","The minimum amount of time required to meet the definition of stable disease.","Stable Disease Minimum Duration | SDMDUR | stableDiseaseMinimumDuration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508984","Study Saved as XML Indicator","C127798","An indication as to whether the data submitted to EudraCT should be saved to EudraCT as an XML file.","Study Saved as XML Indicator | RXMLCIND | Request for XML Copy of Study Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504670","Retained Biospecimen Description","C126072","A textual description of the specimen types, which are collected during the course of the study.","Retained Biospecimen Description | RTSPCDES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978583","Checkbox","C165459","A space on a paper form or an on-screen graphical display that can be filled or selected to choose an option.","Checkbox | Check Box | Tick Box | Tickbox",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978584","Courier","C165460","A person or group that facilitates the exchange of items or information.","Courier | COURIER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978585","Dusky Pink Erythema","C165461","A response that indicates that the degree of erythematous color change is dusky pink.","Dusky Pink Erythema | Dusky Pink",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978586","Dull Red Erythema","C165462","A response that indicates that the degree of erythematous color change is dull red.","Dull Red Erythema | Dull Red",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978587","Brilliant Red Erythema","C165463","A response that indicates that the degree of erythematous color change is brilliant red.","Brilliant Red Erythema | Brilliant Red",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978588","Deep Red-purple Erythema","C165464","A response that indicates that the degree of erythematous color change is deep red-purple.","Deep Red-purple Erythema | Deep Red-purple | Red-purple Erythema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978578","Looking for Work","C165487","An indication that an individual is seeking work.","Looking for Work | Looking for work | Seeking Employment | Seeking a Job",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978559","Raising Children Full-time or Keeping House","C165488","An indication that an individual is employed in their home, either raising children full-time or keeping house.","Raising Children Full-time or Keeping House | Raising children full-time or keeping house",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0683798","laid off","C165486","An indication that an individual is not working due to being laid off.","Laid Off | Laid off",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826773","Drug Accountability Treatment Dispensation Date","C83166","The drug accountability information that indicates the date that the study treatment was dispensed.","Drug Accountability Treatment Dispensation Date | DADDAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826774","Drug Accountability Treatment Return Date","C83167","The The drug accountability information that indicates the date that the study treatment was returned.","Drug Accountability Treatment Return Date | DARDAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642254","High-Grade Ovarian Serous Adenocarcinoma","C105555","A rapidly growing serous adenocarcinoma that arises from the ovary. It is characterized by the presence of high grade cytologic features and frequent mitotic figures.","Ovarian High Grade Serous Adenocarcinoma | High Grade Ovarian Serous Adenocarcinoma | High Grade Ovarian Serous Adenocarcinoma | High-Grade Ovarian Serous Adenocarcinoma | Ovarian High-Grade Serous Adenocarcinoma","8461/3","High grade serous carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C1335954","Sex Cord-Like Pattern","C35932","No Value Exists","Sex Cord-Like Pattern | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1135918","Smooth Muscle Cell","C13001","An elongated spindle-shaped contractile cell, peculiar to an involuntary muscle, containing a single nucleus and longitudinally arranged myofibrils.","Smooth Muscle Cell | Leiomyocyte | Smooth Muscle Tissue Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205816","Myxoid Leiomyosarcoma","C3701","A morphologic variant of leiomyosarcoma characterized by the presence of cellular pleomorphism, malignant cells with large nuclei, and a myxoid stroma.","Myxoid Leiomyosarcoma | Myxoid leiomyosarcoma","8896/3","Myxoid leiomyosarcoma",,,,,,,,,,,,,"4059632","Myxoid leiomyosarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"CL950683","Dedifferentiated Lesion","C158781","A lesion composed of cells that have undergone transformation to less mature forms.","Dedifferentiated Lesion | De-Differentiated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516857","Serous Endometrial Intraepithelial Carcinoma","C40152","A precursor of endometrial serous adenocarcinoma characterized by the replacement of the normal endometrial cells by malignant glandular cells that resemble the malignant cells of invasive serous adenocarcinoma. The endometrial neoplastic process is non-invasive. It may coexist with invasive endometrial adenocarcinoma or can be associated with metastases outside the uterus, in the absence of invasive endometrial carcinoma.","Serous Endometrial Intraepithelial Carcinoma | Carcinoma in situ of endometrium | EIC | Endometrial Intraepithelial Carcinoma | Endometrial Serous Carcinoma in Situ | Endometrial Serous Intraepithelial Carcinoma | Endometrial Surface Serous Carcinoma | SEIC | Serous endometrial intraepithelial carcinoma","8441/2","Serous intraepithelial carcinoma",,,,,,,,,,,,,"4241777","Carcinoma in situ of endometrium",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1266057","Endometrial Endometrioid Adenocarcinoma, Secretory Variant","C27839","An endometrioid adenocarcinoma arising from the endometrium. Morphologically it is characterized by the presence of malignant glandular cells containing glycogen vacuoles which are usually subnuclear and reminiscent of early secretory endometrium.","Endometrial Endometrioid Adenocarcinoma, Secretory Variant | Endometrioid adenocarcinoma, secretory variant | Secretory Uterine Corpus Endometrioid Adenocarcinoma","8382/3","Endometrioid adenocarcinoma, secretory variant",,,,,,,,,,,,,"4029993","Endometrioid adenocarcinoma, secretory variant",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1336962","Villoglandular Endometrial Endometrioid Adenocarcinoma","C27846","A primary endometrioid adenocarcinoma of the endometrium characterized by the presence of numerous finger-like villi lined by neoplastic columnar cells.","Villoglandular Endometrial Endometrioid Adenocarcinoma | Endometrioid adenocarcinoma, villoglandular",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0854925","Endometrial Squamous Cell Carcinoma","C8719","A primary carcinoma of the endometrium characterized by the presence of malignant squamous cells.","Endometrial Squamous Cell Carcinoma | Squamous Cell Carcinoma of Endometrium | Squamous Cell Carcinoma of the Endometrium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704617","Perivascular Epithelioid Cell","C45634","A perivascular cell with abundant clear or eosinophilic cytoplasm that contains glycogen. -- 2005","Perivascular Epithelioid Cell | PEC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709351","Osseous Differentiation","C53444","No Value Exists","Osseous Differentiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707309","Cartilaginous Differentiation","C53445","No Value Exists","Cartilaginous Differentiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335781","Rhabdomyosarcomatous Differentiation","C35937","No Value Exists","Rhabdomyosarcomatous Differentiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL033042","Uterine Corpus Undifferentiated Sarcoma","C8972","A rare, high grade sarcoma that arises from the endometrial stroma or myometrium without a specific type of differentiation. It was previously also known as high grade endometrial stromal sarcoma. In 2014, high grade endometrial stromal sarcoma was reclassified and is currently considered a distinct and rare neoplasm. Undifferentiated uterine sarcoma has a worse prognosis.","Uterine Corpus Undifferentiated Sarcoma | Undifferentiated Uterine Sarcoma | Undifferentiated uterine sarcoma | Uterine Corpus Undifferentiated Endometrial Sarcoma",,,,,,,,,,,,,,,"37152181|4290926|44783287","Endometrial stromal sarcoma|Endometrial stromal sarcoma, high grade|High grade endometrial stromal sarcoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C0563529","Left Oophorectomy","C51601","Surgery to remove the left ovary.","Left Oophorectomy | ",,,,,,,,,,,,,,,"4114635","Left oophorectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0563528","Right Oophorectomy","C51602","Surgery to remove the right ovary.","Right Oophorectomy | ",,,,,,,,,,,,,,,"4120985","Right oophorectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL969975","Condition or Disease under Study","C161319","Primary disease(s) or condition(s) being studied in the trial, or the focus of the study. (clinicaltrials.gov)","Condition or Disease under Study | diagnosis is primary disease | diagnosis_is_primary_disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985700","Study Protocol Version","C93490","A plan at a particular point in time for a formal investigation to assess the utility, impact, pharmacological, physiological, and/or psychological effects of a particular treatment, procedure, drug, device, biologic, food product, cosmetic, care plan, or subject characteristic.","Study Protocol Version | StudyProtocolVersion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513393","Molecular Fingerprinting of Tumor","C19967","The determination of the active and inactive genes present in a tumor sample.","Molecular Fingerprinting of Tumor | Tumor Profiling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507996","Endometrial Dedifferentiated Carcinoma","C126769","A carcinoma that arises from the endometrium and is characterized by the presence of an undifferentiated carcinomatous component and a second component of either FIGO grade 1 or 2 endometrioid carcinoma.","Endometrial Dedifferentiated Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556361","Endometrial Mixed Cell Adenocarcinoma","C40153","An adenocarcinoma that arises from the endometrium and is characterized by the presence of both type I and type II endometrial adenocarcinoma components.  The minor component constitutes at least 5% of the entire tumor.","Endometrial Mixed Cell Adenocarcinoma | Endometrial Mixed Carcinoma | Mixed cell adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976985","Targeted Therapy Agent","C163758","Any agent that specifically targets or interferes with the synthesis or function of a molecule that is expressed specifically in or on cells of the tumor and/or the tumor microenvironment (TME), such as immune cells or surrounding blood vessels. The targeted molecule is usually overexpressed or mutated in tumors but minimally or not expressed by normal, healthy tissues; additionally, expression is typically associated with tumor cell proliferation, progression and/or survival. By blocking the function or expression of the tumor-associated target, the targeted therapy agent may exert potential antineoplastic and/or immunomodulatory activities.","Targeted Therapy Agent | Anti-tumor Targeted Therapy Agent | Molecularly Targeted Therapy Agent | Targeted Agent | Targeted Therapeutic Agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951229","Myometrial Invasion","C159241","A finding indicating that there is invasion of the myometrium by cancer.","Myometrial Invasion | Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274130","PIK3CA NP_006209.2:p.H1047Q","C98482","A change in the amino acid residue at position 1047 in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform protein where histidine has been replaced by glutamine.","PIK3CA NP_006209.2:p.H1047Q | NP_006209.2:p.His1047Gln | PI3Kalpha H1047Q | PIK3CA H1047Q | PIK3CA His1047Gln | PIK3CA NP_006209.2:p.His1047Gln | PIK3CA p.H1047Q | PIK3CA p.His1047Gln | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 110 kDa Catalytic Subunit Alpha H1047Q | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Isoform H1047Q | Phosphoinositide-3-Kinase Catalytic Alpha Polypeptide H1047Q | p110alpha H1047Q",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274135","PIK3CA NP_006209.2:p.H1047Y","C98487","A change in the amino acid residue at position 1047 in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform protein where histidine has been replaced by tyrosine.","PIK3CA NP_006209.2:p.H1047Y | NP_006209.2:p.His1047Tyr | PI3Kalpha H1047Y | PIK3CA H1047Y | PIK3CA His1047Tyr | PIK3CA NP_006209.2:p.His1047Tyr | PIK3CA p.H1047Y | PIK3CA p.His1047Tyr | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 110 kDa Catalytic Subunit Alpha H1047Y | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Isoform H1047Y | Phosphoinositide-3-Kinase Catalytic Alpha Polypeptide H1047Y | p110alpha H1047Y",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274128","PIK3CA NP_006209.2:p.H1047L","C98480","A change in the amino acid residue at position 1047 in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform protein where histidine has been replaced by leucine.","PIK3CA NP_006209.2:p.H1047L | NP_006209.2:p.His1047Leu | PI3Kalpha H1047L | PIK3CA H1047L | PIK3CA His1047Leu | PIK3CA NP_006209.2:p.His1047Leu | PIK3CA p.H1047L | PIK3CA p.His1047Leu | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 110 kDa Catalytic Subunit Alpha H1047L | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Isoform H1047L | Phosphoinositide-3-Kinase Catalytic Alpha Polypeptide H1047L | p110alpha H1047L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274118","PIK3CA NP_006209.2:p.E545Q","C98470","A change in the amino acid residue at position 545 in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform protein where glutamic acid has been replaced by glutamine.","PIK3CA NP_006209.2:p.E545Q | NP_006209.2:p.Glu545Gln | PI3Kalpha E545Q | PIK3CA E545Q | PIK3CA Glu545Gln | PIK3CA NP_006209.2:p.Glu545Gln | PIK3CA p.E545Q | PIK3CA p.Glu545Gln | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 110 kDa Catalytic Subunit Alpha E545Q | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Isoform E545Q | Phosphoinositide-3-Kinase Catalytic Alpha Polypeptide E545Q | p110alpha E545Q",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274114","PIK3CA NP_006209.2:p.E545G","C98466","A change in the amino acid residue at position 545 in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform protein where glutamic acid has been replaced by glycine.","PIK3CA NP_006209.2:p.E545G | NP_006209.2:p.Glu545Gly | PI3Kalpha E545G | PIK3CA E545G | PIK3CA Glu545Gly | PIK3CA NP_006209.2:p.Glu545Gly | PIK3CA p.E545G | PIK3CA p.Glu545Gly | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 110 kDa Catalytic Subunit Alpha E545G | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Isoform E545G | Phosphoinositide-3-Kinase Catalytic Alpha Polypeptide E545G | p110alpha E545G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274109","PIK3CA NP_006209.2:p.E545A","C98461","A change in the amino acid residue at position 545 in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform protein where glutamic acid has been replaced by alanine.","PIK3CA NP_006209.2:p.E545A | NP_006209.2:p.Glu545Ala | PI3Kalpha E545A | PIK3CA E545A | PIK3CA Glu545Ala | PIK3CA NP_006209.2:p.Glu545Ala | PIK3CA p.E545A | PIK3CA p.Glu545Ala | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 110 kDa Catalytic Subunit Alpha E545A | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Isoform E545A | Phosphoinositide-3-Kinase Catalytic Alpha Polypeptide E545A | p110alpha E545A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274111","PIK3CA NP_006209.2:p.E545D","C98463","A change in the amino acid residue at position 545 in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform protein where glutamic acid has been replaced by aspartic acid.","PIK3CA NP_006209.2:p.E545D | NP_006209.2:p.Glu545Asp | PI3Kalpha E545D | PIK3CA E545D | PIK3CA Glu545Asp | PIK3CA NP_006209.2:p.Glu545Asp | PIK3CA p.E545D | PIK3CA p.Glu545Asp | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 110 kDa Catalytic Subunit Alpha E545D | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Isoform E545D | Phosphoinositide-3-Kinase Catalytic Alpha Polypeptide E545D | p110alpha E545D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274126","PIK3CA NP_006209.2:p.E542V","C98478","A change in the amino acid residue at position 542 in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform protein where glutamic acid has been replaced by valine.","PIK3CA NP_006209.2:p.E542V | NP_006209.2:p.Glu542Val | PI3Kalpha E542V | PIK3CA E542V | PIK3CA Glu542Val | PIK3CA NP_006209.2:p.Glu542Val | PIK3CA p.E542V | PIK3CA p.Glu542Val | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 110 kDa Catalytic Subunit Alpha E542V | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Isoform E542V | Phosphoinositide-3-Kinase Catalytic Alpha Polypeptide E542V | p110alpha E542V",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274124","PIK3CA NP_006209.2:p.E542Q","C98476","A change in the amino acid residue at position 542 in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform protein where glutamic acid has been replaced by glutamine.","PIK3CA NP_006209.2:p.E542Q | NP_006209.2:p.Glu542Gln | PI3Kalpha E542Q | PIK3CA E542Q | PIK3CA Glu542Gln | PIK3CA NP_006209.2:p.Glu542Gln | PIK3CA p.E542Q | PIK3CA p.Glu542Gln | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 110 kDa Catalytic Subunit Alpha E542Q | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Isoform E542Q | Phosphoinositide-3-Kinase Catalytic Alpha Polypeptide E542Q | p110alpha E542Q",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950826","Primary Site of Disease","C158874","The anatomic location where a disease of interest originated.","Primary Site of Disease | primary disease site | primary site | primary_disease_site | primary_site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448366","Progestogen","C2296","Substances that produce effects similar to those of progesterone, the only natural progestogen. All other progestogens are synthetic and are often referred to as progestins. All progestogens have antiestrogenic and antigonadotropic properties.","Progestogen | Gestagens | Progestagen | Progestational Hormones | Progestogens",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021900","Intrauterine Device","C42771","A device usually made of plastic or metal, inserted into the uterus to prevent conception. IUCD can be a coil, loop, triangle, or T in shape; its material can be impregnated with a pharmaceutical agent. The primary action of all IUCDs is the induction of a foreign-body reaction within the endometrium. This sterile inflammatory process is toxic to gametes, primarily spermatozoa, and effectively prevents viable sperm from passing into the fallopian tubes. The copper-bearing device has an independent toxic effect on spermatozoa. The progestin-releasing devices produce changes in endometrial architecture and function that reduce the potential for implantation of a fertilized egg. The progestin effect on the cervical mucus also reduces the penetrability of sperm.","Intrauterine Device | IUCD | IUD | Intrauterine Contraceptive Device | intrauterine device",,,,,,,,,,,,,,,"40355609","Intrauterine contraceptive device",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519691","Histologic Subtype","C19790","The classification of tumors based on their histology.","Histologic Subtype | Histology | Subtype, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079220","Destination","C165585","A place to which one is traveling or to which something is sent.","Destination | Destination Site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0220654","Meningeal Carcinomatosis","C27383","Diffuse spread of cancer to the meninges.","Meningeal Carcinomatosis | Carcinomatosis of the Meninges | meningeal carcinomatosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978820","Extra-Abdominal Lymph Node","C165584","A lymph node outside the abdominal cavity.","Extra-Abdominal Lymph Node | EXTRAABDOMINAL LYMPH NODE | Extraadominal Lymph Node",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978833","PTEN NP_000305.3:p.R130G","C165571","A change in the amino acid residue at position 130 in the phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN protein where arginine has been replaced by glycine.","PTEN NP_000305.3:p.R130G | Mutated in Multiple Advanced Cancers 1 Arg130Gly | Mutated in Multiple Advanced Cancers 1 R130G | NP_000305.3:p.Arg130Gly | NP_000305.3:p.R130G | PTEN Arg130Gly | PTEN NP_000305.3:p.Arg130Gly | PTEN R130G | PTEN Tyrosine Phosphatase Arg130Gly | PTEN Tyrosine Phosphatase R130G | PTEN p.Arg130Gly | PTEN p.R130G | Phosphatase and Tensin Homolog Arg130Gly | Phosphatase and Tensin Homolog R130G | Phosphatase and Tensin-Like Protein Arg130Gly | Phosphatase and Tensin-Like Protein R130G | Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN Arg130Gly | Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN R130G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978838","PTEN NP_000305.3:p.R130Q","C165577","A change in the amino acid residue at position 130 in the phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN protein where arginine has been replaced by glutamine.","PTEN NP_000305.3:p.R130Q | Mutated in Multiple Advanced Cancers 1 Arg130Gln | Mutated in Multiple Advanced Cancers 1 R130Q | NP_000305.3:p.Arg130Gln | NP_000305.3:p.R130Q | PTEN Arg130Gln | PTEN NP_000305.3:p.Arg130Gln | PTEN R130Q | PTEN Tyrosine Phosphatase Arg130Gln | PTEN Tyrosine Phosphatase R130Q | PTEN p.Arg130Gln | PTEN p.R130Q | Phosphatase and Tensin Homolog Arg130Gln | Phosphatase and Tensin Homolog R130Q | Phosphatase and Tensin-Like Protein Arg130Gln | Phosphatase and Tensin-Like Protein R130Q | Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN Arg130Gln | Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN R130Q",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978842","PTEN NP_000305.3:p.R130L","C165573","A change in the amino acid residue at position 130 in the phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN protein where arginine has been replaced by leucine.","PTEN NP_000305.3:p.R130L | Mutated in Multiple Advanced Cancers 1 Arg130Leu | Mutated in Multiple Advanced Cancers 1 R130L | NP_000305.3:p.Arg130Leu | NP_000305.3:p.R130L | PTEN Arg130Leu | PTEN NP_000305.3:p.Arg130Leu | PTEN R130L | PTEN Tyrosine Phosphatase Arg130Leu | PTEN Tyrosine Phosphatase R130L | PTEN p.Arg130Leu | PTEN p.R130L | Phosphatase and Tensin Homolog Arg130Leu | Phosphatase and Tensin Homolog R130L | Phosphatase and Tensin-Like Protein Arg130Leu | Phosphatase and Tensin-Like Protein R130L | Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN Arg130Leu | Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN R130L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978844","PTEN NP_000305.3:p.R130P","C165575","A change in the amino acid residue at position 130 in the phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN protein where arginine has been replaced by proline.","PTEN NP_000305.3:p.R130P | Mutated in Multiple Advanced Cancers 1 Arg130Pro | Mutated in Multiple Advanced Cancers 1 R130P | NP_000305.3:p.Arg130Pro | NP_000305.3:p.R130P | PTEN Arg130Pro | PTEN NP_000305.3:p.Arg130Pro | PTEN R130P | PTEN Tyrosine Phosphatase Arg130Pro | PTEN Tyrosine Phosphatase R130P | PTEN p.Arg130Pro | PTEN p.R130P | Phosphatase and Tensin Homolog Arg130Pro | Phosphatase and Tensin Homolog R130P | Phosphatase and Tensin-Like Protein Arg130Pro | Phosphatase and Tensin-Like Protein R130P | Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN Arg130Pro | Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN R130P",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978822","TP53 NP_000537.3:p.R273S","C165581","A change in the amino acid residue at position 273 in the cellular tumor antigen p53 protein where arginine has been replaced by serine.","TP53 NP_000537.3:p.R273S | Antigen NY-CO-13 Arg273Ser | Antigen NY-CO-13 R273S | Cellular Tumor Antigen p53 Arg273Ser | Cellular Tumor Antigen p53 R273S | NP_000537.3:p.Arg273Ser | NP_000537.3:p.R273S | TP53 Arg273Ser | TP53 NP_000537.3:p.Arg273Ser | TP53 R273S | TP53 p.Arg273Ser | TP53 p.R273S | Transformation-Related Protein 53 Arg273Ser | Transformation-Related Protein 53 R273S | Tumor Protein p53 Arg273Ser | Tumor Protein p53 R273S | Tumor Suppressor p53 Arg273Ser | Tumor Suppressor p53 R273S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978840","TP53 NP_000537.3:p.R175C","C165579","A change in the amino acid residue at position 175 in the cellular tumor antigen p53 protein where arginine has been replaced by cysteine.","TP53 NP_000537.3:p.R175C | Antigen NY-CO-13 Arg175Cys | Antigen NY-CO-13 R175C | Cellular Tumor Antigen p53 Arg175Cys | Cellular Tumor Antigen p53 R175C | NP_000537.3:p.Arg175Cys | NP_000537.3:p.R175C | TP53 Arg175Cys | TP53 NP_000537.3:p.Arg175Cys | TP53 R175C | TP53 p.Arg175Cys | TP53 p.R175C | Transformation-Related Protein 53 Arg175Cys | Transformation-Related Protein 53 R175C | Tumor Protein p53 Arg175Cys | Tumor Protein p53 R175C | Tumor Suppressor p53 Arg175Cys | Tumor Suppressor p53 R175C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4042900","Morcellation","C165586","The process of cutting tissue into smaller pieces.","Morcellation | Morcellated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227691","Bladder Mucosa","C32205","The mucous membrane that is the inner lining of the urinary bladder.","Bladder Mucosa | Urinary Bladder Mucosa | mucosa of urinary bladder",,,,,,,,,,,,,,,"4097677","Structure of mucous membrane of urinary bladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517309","Fred Hutchinson/University of Washington Cancer Consortium","C39408","The Fred Hutchinson/University of Washington Cancer Consortium is a research collaboration comprising the Fred Hutchinson Cancer Research Center, the University of Washington, Seattle Children's Hospital, and the Seattle Cancer Care Alliance. The consortium's mission is the elimination of cancer and related diseases as causes of human suffering and death. The Center became designated as an NCI comprehensive center in 1976, which was expanded to include the entire Consortium in 2003.","Fred Hutchinson/University of Washington Cancer Consortium | Fred Hutchinson Cancer Research Center",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508216","Uterine Corpus Rhabdomyosarcoma","C127058","A rare malignant heterologous neoplasm with skeletal muscle differentiation arising from the uterine corpus. It usually manifests with vaginal bleeding. The prognosis is poor.","Uterine Corpus Rhabdomyosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951715","Other Edition","C159627","An indication that the edition is other than those listed.","Other Edition | Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978798","Main Daily Activities or Responsibilities","C165613","A question that requests a description of an individual's main daily activities or responsibilities.","Main Daily Activities or Responsibilities | Main Daily Activities or Responsibilities Description",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978799","Percent Tumor Cell Nuclei","C165615","A quantitative measurement of the percent of tumor cell nuclei in a sample compared to the total number of nuclei in the sample.","Percent Tumor Cell Nuclei | Percent tumor nuclei | percent tumor nuclei | percent_tumor_nuclei",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978793","Percent Immune Cell Nuclei","C165616","A quantitative measurement of the percent of immune cell nuclei in a sample compared to the total number of nuclei in the sample.","Percent Immune Cell Nuclei | Percent immune cell nuclei",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978794","Percent Stromal Cell Nuclei","C165617","A quantitative measurement of the percent of stromal cell nuclei in a sample compared to the total number of nuclei in the sample.","Percent Stromal Cell Nuclei | Percent stromal cell nuclei",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978795","Percent Necrotic Surface Area","C165618","A quantitative measurement of the area of tissue surface undergoing necrosis compared to the total tissue area present the sample.","Percent Necrotic Surface Area | Percent of the surface area of the tissue section that is necrotic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1299478","Nuclear Pleomorphism Score","C138978","A score assigned to a biopsy sample based on the appearance of nuclei in a tumor.","Nuclear Pleomorphism Score | ",,,,,,,,,,,,,,,"4161170","Nuclear pleomorphism score",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526440","Mitotic Rate Score","C138982","A score assigned to a biopsy sample to indicate the number of mitotic cells present in a tumor.","Mitotic Rate Score | MITOSCR | Mitotic Count Score | Mitotic Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950730","/10 HPF, or for GISTs","C158699","A unit of measurement of the number of entities per unit of area equal to ten high powered fields.","Per 10 High Powered Fields | /10 HPF, or for GISTs | /10 HPFs | /10.[HPF] | Per 10HPF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086369","Gross Pathology Result","C125008","The outcome of a gross, or macroscopic, pathologic examination.","Gross Pathology Result | Gross Pathologic Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640189","LONGEST_DIAM_DIM2","C101702","The second longest possible length of a straight line passing through the center of a nearly circular or spheroid object that connects two points on the circumference.","Second Longest Diameter | LONGEST_DIAM_DIM2 | Second Greatest Diameter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640196","LONGEST_DIAM_DIM3","C101709","The third longest possible length of a straight line passing through the center of a nearly circular or spheroid object that connects two points on the circumference.","Third Longest Diameter | LONGEST_DIAM_DIM3 | Third Greatest Diameter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936777","CDR Entry Completed by (signature)","C157094","A directive to add the signature of the individual completing the Comprehensive Data Resource (CDR).","CDR Entry Completed by (signature) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814390","Biospecimen Domain","C111137","A findings domain that documents biospecimen handling information.","Biospecimen Domain | BS | Biospecimen Findings",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2924091","Vendor Name","C117200","The literal identifier of the vendor that performs an assessment or examination.","Vendor Name | NAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937504","Maternal Hemorrhage","C157916","Uncontrolled bleeding from a pregnant or a woman who has recently given birth.","Maternal Hemorrhage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025295","Pneumococcal Meningitis","C157958","Meningitis that is attributed to the bacteria Streptococcus pneumonia.","Pneumococcal Meningitis | ",,,,,,,,,,,,,,,"432879","Pneumococcal meningitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0343363","Rotaviral Enteritis","C157973","Enteritis attributed to the rotavirus.","Rotaviral Enteritis | ",,,,,,,,,,,,,,,"4188688","Viral gastroenteritis due to Rotavirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937548","Enterotoxigenic E coli Infection","C157842","A pathotype of Escherichia coli, which is a gram-negative bacteria that is transmitted through the fecal-oral route. It has an incubation period of 10-72 hours and a duration of 1-5 days. Symptoms may include acute, occasionally severe diarrhea without fever.","Enterotoxigenic E coli Infection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937550","Enteropathogenic E coli Infection","C157841","A pathotype of Escherichia coli, which is a gram-negative bacteria that is transmitted through the fecal-oral route. It has an incubation period of 9-12 hours and a duration of 12 days. Symptoms may include persistent severe acute diarrhea.","Enteropathogenic E coli Infection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3695318","Chronic Kidney Disease due to Hypertension","C157814","Longstanding kidney disease as a complication of hypertension.","Chronic Kidney Disease due to Hypertension | ",,,,,,,,,,,,,,,"44782429","Chronic kidney disease due to hypertension",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL772769","Noncommunicable Diseases","C157935","A disorder that is not transmissible from one person to another.","Non-Communicable Disorder | Non-communicable Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL932432","Maternal Sepsis","C157917","A pathologic response to infection in a mother or pregnant woman.","Maternal Sepsis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342199","Iodine Deficiency","C157895","A deficiency of iodine in the diet.","Iodine Deficiency | ",,,,,,,,,,,,,,,"4031955","Iodine deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0276919","Intestinal Nematode Infection","C157886","An infection in the gastrointestinal tract by a nematode.","Intestinal Nematode Infection | ",,,,,,,,,,,,,,,"4212089","Intestinal nematode infection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937486","Hypertensive Heart Disease","C157879","Heart conditions that are caused by high blood pressure, including coronary artery disease and heart failure.","Hypertensive Heart Disease | Hypertensive Heart Diseaase",,,,,,,,,,,,,,,"442604","Hypertensive heart disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937535","H influenze type B Pneumonia","C157868","Pneumonia that is attributed to the bacteria H influenze type B.","H influenze type B Pneumonia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937536","H influenze type B Meningitis","C157867","Meningitis that is attributed to the bacteria H influenze type B.","H influenze type B Meningitis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937551","Venomous Animal Contact","C158031","Contact with a venomous animal.","Venomous Animal Contact | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937555","Transport Injury","C158022","An injury to an individual during transport between or to/from departments or facilities.","Transport Injury | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0549584","Subcutaneous Disorders","C157995","A disorder of the subcutaneous tissue.","Subcutaneous Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013371","Shigellosis","C157978","An intestinal disease cause by Shigella bacteria.","Shigellosis | ",,,,,,,,,,,,,,,"201780","Shigellosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937641","Sexually Transmitted Chlamydial Disease","C157977","A chlamydial infection that was sexually transmitted.","Sexually Transmitted Chlamydial Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036114","Salmonellosis","C157974","An intestinal bacterial disease caused by Salmonella bacteria.","Salmonellosis | ",,,,,,,,,,,,,,,"196328|4117914|4288241","Salmonella gastroenteritis|Salmonella food poisoning|Salmonella enterica subspecies arizonae infection",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"CL937643","Road Injury","C157972","An injury that occurs on a road or motor way.","Road Injury | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152413","Respiratory Syncytial Virus Pneumonia","C157971","Pneumonia that is attributed to the respiratory syncytial virus.","Respiratory Syncytial Virus Pneumonia | ",,,,,,,,,,,,,,,"436145","Pneumonia due to respiratory syncytial virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937608","Preterm Birth Complication","C157961","A complication related to a premature birth that occurs to a baby born prior to 37 weeks gestation.","Preterm Birth Complication | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0155862","Pneumococcal Pneumonia","C157959","Pneumonia that is attributed to the bacteria Streptococcus pneumonia.","Pneumococcal Pneumonia | ",,,,,,,,,,,,,,,"258785","Pneumococcal pneumonia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937614","Pedestrian Injury By Road Vehicle","C157949","An injury to a pedestrian sustained by a vehicle that travels on the road.","Pedestrian Injury By Road Vehicle | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937619","Opioid Use Disorder","C157942","The use of opioids that results in the development of a dependency that adversely affects an individual's life.","Opioid Use Disorder | Opiod Use Disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152156","Obstructed Labor","C157939","A physical barrier to the natural delivery of a baby.","Obstructed Labor | ",,,,,,,,,,,,,,,"193827","Obstructed labor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162429","Nutritional Deficiency","C157938","A deficiency of a necessary nutrient.","Nutritional Deficiency | ",,,,,,,,,,,,,,,"4165539","Nutritional deficiency state",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937624","Non-ischemic Stroke","C157937","Any stroke that is not related to an obstructed blood vessel.","Non-ischemic Stroke | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010454","Growth Medium","C85504","A liquid or gel containing nutrients, salts, and other factors formulated to support the growth of microorganisms, cells, or plants.","Growth Medium | Culture Medium | Media | Medium",,,,,,,,,,,,,,,"4227064","Culture medium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0400883","Intestinal Vascular Disorder","C157888","A non-neoplastic or neoplastic vascular disorder that affects the intestines.","Intestinal Vascular Disorder | Vascular Disorders of Intestine | Vascular disorder of intestine, unspecified",,,,,,,,,,,,,,,"4134603","Vascular disorder of intestine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL978942","Charged Slide","C165677","A microscope slide that has a positive surface charge to electrostatically attract and bind tissue sections to the slide.","Charged Slide | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978943","Uncharged Slide","C165678","A microscope slide that lacks a positive surface charge.","Uncharged Slide | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978921","Multi-Spin Echo","C165679","Stimulation of a magnetic resonance signal with additional 180 degree-pulse(s) to generate additional echo(es).","Multi-Spin Echo | Multi-echo Spin Echo | Multiple Spin Echo | Multiple Spin Echo Magnetic Resonance Imaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978922","Orientation","C165680","The position or alignment of something relative to points of the compass, other specific directions, or some other indexing system.","Orientation | Generic Orientation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978923","Selected Suppression","C165681","Any technique designed to reduce a specific response, effect, or phenomenon.","Selected Suppression | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978924","Integrated","C165682","Combining things, people, or ideas of different types in one effective unit, group, or system.","Integrated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978917","Defined","C165683","Clearly characterized or delimited.","Defined | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969871","ICD-O Tumor Topography Code","C160903","A code for the primary site of a tumor being reported using either ICD-O-2 or ICD-O-3.","ICD-O Tumor Topography Code | ICD-O Topography Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936872","Serum CA 19-9 Measurement","C157253","The determination of the amount of cancer antigen 19-9 present in a serum sample.","Serum CA 19-9 Measurement | Serum CA 19-9 | Serum CA 19-9 Assay | Serum CA-19-9 Measurement | Serum CA19-9 Measurement | Serum Cancer Antigen 19-9 | Serum Carbohydrate Antigen 19-9 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971196","Serum CA 19-9 Low","C162049","The amount of cancer antigen 19-9 present in a serum sample is low.","Serum CA 19-9 Low | Low",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971170","Serum CA 19-9 Normal","C162048","The amount of cancer antigen 19-9 present in a serum sample is normal.","Serum CA 19-9 Normal | Normal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970643","Serum CA 19-9 Elevated","C162047","The amount of cancer antigen 19-9 present in a serum sample is elevated.","Serum CA 19-9 Elevated | Elevated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936879","Serum CEA Measurement","C157252","The determination of the amount of carcinoembryonic antigen present in a serum sample.","Serum CEA Measurement | Serum CEA | Serum Carcinoembryonic Antigen | Serum Carcinoembryonic Antigen Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970644","Serum CEA Level Elevated","C162044","The amount of carcinoembryonic antigen present in a serum sample is elevated.","Serum CEA Level Elevated | Elevated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971199","Serum CEA Level Low","C162046","The amount of carcinoembryonic antigen present in a serum sample is low.","Serum CEA Level Low | Low",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971171","Serum CEA Level Normal","C162045","The amount of carcinoembryonic antigen present in a serum sample is normal.","Serum CEA Level Normal | Normal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936936","CDH1 Mutation Analysis","C157176","A procedure used to detect and identify mutations in the CDH1 gene.","CDH1 Mutation Analysis | CD324 Mutation Analysis | CDH1 Mutation Status | CDHE Mutation Analysis | Cadherin 1 Mutation Analysis | E-Cadherin Mutation Analysis | ECAD Mutation Analysis | LCAM Mutation Analysis | UVO Mutation Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937168","Epstein-Barr Viral Status","C157444","A viral load assay of the Epstein-Barr virus which may be an indicator of disease status.","Epstein-Barr Viral Status | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936878","MET Amplification Status","C157251","A procedure used to detect amplifications involving all or part of the MET gene.","MET Amplification Status | HGFR Amplification Analysis | Hepatocyte Growth Factor Receptor Amplification Analysis | MET Amplification Analysis | MET Proto-Oncogene, Receptor Tyrosine Kinase Amplification Analysis | c-Met Amplification Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937122","Helicobacter pylori Status","C157436","The finding of whether an individual is infected with the H.pylori bacteria.","Helicobacter pylori Status | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938056","Androgen Receptor Status","C158502","Refers to the presence or absence of androgen receptor molecules on the surface of the cells in a specimen.","Androgen Receptor Status | AR Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936926","ERG Rearrangement Analysis","C157189","A procedure used to detect and identify rearrangements involving the ERG gene.","ERG Rearrangement Analysis | ERG Rearrangement Status | ETS Transcription Factor ERG Rearrangement Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054738","Immunohistochemical Status of PD-L1","C122807","An immunohistochemical test result that refers to the overexpression or lack of expression of PD-L1 in a tissue sample of a primary or metastatic malignant neoplasm.","Immunohistochemical Status of PD-L1 | CD274 Immunohistochemistry | CD274 Status by Immunohistochemistry | Immunohistochemical Status of CD274 | PD-L1 IHC Status | PD-L1 Immunohistochemistry | PD-L1 Immunohistochemistry Status | PD-L1 Status by Immunohistochemistry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936927","ETV Rearrangement Analysis","C157190","A procedure used to detect and identify rearrangements involving ETV family genes.","ETV Rearrangement Analysis | ETV Family Rearrangement Analysis | ETV Rearrangement Status | Ets Variant Family Rearrangement Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773668","Clinical Data Interchange Standards Consortium","C65168","An open, non-profit standards developing organization that develops and supports global data standards to improve the quality and interoperability of medical research and healthcare. CDISC partners with the National Cancer Institute's Enterprise Vocabulary Services to develop and support controlled terminology as foundational standards.","Clinical Data Interchange Standards Consortium | CDISC | CDISC Organization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551471","Intrauterine Delivery System Dosage Form","C149614","Solid single-dose delivery system intended for intrauterine use that releases its contents of active substance(s) over an extended period of time.","Intrauterine Delivery System Dosage Form | INTRAUTERINE SYSTEM | Intrauterine delivery system",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706912","Barrier","C49838","A structure or object that impedes free movement.","Barrier Device | Barrier | barrier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936802","Greatest Dimension Tumor","C157135","A measurement of the widest portion of a tumor.","Greatest Dimension Tumor | Greatest Measured Dimension | Tumor Size - greatest dimension | Tumor Size - greatest dimension (largest tumor if multiple) | greatest tumor dimension | greatest_tumor_dimension | tumor largest dimension diameter | tumor_largest_dimension_diameter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1300586","Tumor Focality","C157425","The characterization of the location of the tumor.","Tumor Focality | tumor focality | tumor_focality",,,,,,,,,,,,,,,"4244984","Tumor focality",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508204","SDHA Gene Mutation","C126829","A change in the nucleotide sequence of the SDHA gene.","SDHA Gene Mutation | Succinate Dehydrogenase Complex Flavoprotein Subunit A Gene Mutation | Succinate Dehydrogenase Complex, Subunit A, Flavoprotein (Fp) Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937161","SDHAF2 Gene Mutation","C157451","A change in the nucleotide sequence of the SDHAF2 gene.","SDHAF2 Gene Mutation | C11orf79 Gene Mutation | PGL2 Gene Mutation | Paraganglioma or Familial Glomus Tumors 2 Gene Mutation | SDH5 Gene Mutation | Succinate Dehydrogenase Complex Assembly Factor 2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951686","Undetermined Histologic Type","C159718","Unable to determine the histologic type.","Undetermined Histologic Type | Indeterminate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978915","Revised Olweus Bully/Victim Questionnaire","C165705","A questionnaire consisting of 40 questions for the measurement of aspects of bully/victim problems: physical, verbal, indirect, racial, sexual forms of bullying harassment; initiation of various forms of bullying other students; where the bullying occurs; pro-bullying and pro-victim attitudes; and the extent to which teachers, peers, and parents are informed about and react to the bullying.","Revised Olweus Bully/Victim Questionnaire | Bully/Victim Questionnaire-Revised | OBVQ-R | Olweus Bully-Victim Questionnaire-Revised (OBVQ-R) | Olweus Bully/Victim Questionnaire, Revised",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978916","Diagnostic Infant and Preschool Assessment","C165706","A diagnostic instrument for assessing DSM-IV syndromes in children aged 6 years or younger, administered as an interview for their caregivers.","Diagnostic Infant and Preschool Assessment | DIPA | Diagnostic Infant Preschool Assessment | Diagnostic Infant Preschool Assessment (DIPA)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978910","Finnegan Neonatal Abstinence Score Tool","C165707","A standardized scoring tool designed to assess opioid withdrawal in a newborn. It is used by well-trained healthcare professionals and enables the practitioner to make an assessment, identify the withdrawal symptoms, document the infant's withdrawal, and initiate the appropriate treatment regimen, when needed.","Finnegan Neonatal Abstinence Score Tool | FNAST | Finnegan Neonatal Abstinence Score Tool (FNAST) | Finnegan's Neonatal Abstinence Scoring Tool",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978911","Alabama Parenting Questionnaire","C165708","A 42-item questionnaire that measures five dimensions of parenting: 1) positive involvement with children, 2) supervision and monitoring, 3) use of positive discipline techniques, 4) consistency in the use of such discipline, and 5) use of corporal punishment.","Alabama Parenting Questionnaire | APQ | Alabama Parenting Questionnaire (APQ)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978912","PROMIS Peer Relationships","C165709","Questionnaires designed to assess self-reported quality of relationships with friends and other acquaintances. The peer relationships short forms   are universal rather than disease-specific and are available for pediatric self-report (ages 8-17) and for parents serving as proxy reporters for their child (youth ages 5-17).","PROMIS Peer Relationships | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978913","Child and Youth Resilience Measure","C165710","A questionnaire designed as a screening tool to explore the resources (individual, relational, communal, and cultural) available to individuals, that may bolster their resilience. Versions are available as Child, designed for ages five through nine years old and Youth, designed for ages ten through 23 years old.","Child and Youth Resilience Measure | CYRM | Child and Youth Resilience Measure (CYRM)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978895","Child Behavior Checklist for Ages 6-18","C165711","A standardized measure designed to detect behavioral and emotional problems in children and adolescents. It is completed by the parent/caretaker who spends the most time with the child and provides ratings for 20 competence and 120 problem items.","Child Behavior Checklist for Ages 6-18 | CBCL/6-18 | Child Behavior Checklist for Ages 6-18 (CBCL/6-18)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978896","Child Behavior Checklist for Ages 1.5-5","C165712","A standardized measure designed to detect behavioral and emotional problems in children 1.5-5 years old. The forms obtain parents', daycare providers', and teachers' ratings of 99 problem items plus descriptions of problems, disabilities, what concerns respondents most about the child, and the best things about the child.","Child Behavior Checklist for Ages 1.5-5 | CBCL/1.5-5 | Child Behavior Checklist for Ages 1.5-5 (CBCL/1.5-5)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978897","Achenbach System of Empirically Based Assessment-Adult Self-Report and Adult Behavior Checklist","C165713","Assessment tools that span the ages 18-59, the Adult Self-Report (ASR) and the Adult Behavior Checklist (ABCL) obtain information from the adult client and from others who know the adult well. Both forms are valuable for assessing adults in a variety of settings, such as mental health, forensic, counseling, medical, and substance abuse. Profiles display scale scores in relation to norms for each gender at ages 18-35 years and 36-59 years. Includes a Critical Items scale, and both forms have parallel scales for Substance Use, Critical Items, Internalizing, Externalizing, and Total Problems.","Achenbach System of Empirically Based Assessment-Adult Self-Report and Adult Behavior Checklist | Achenbach System of Empirically Based Assessment (ASEBA)-Adult Self-Report (ASR) and Adult Behavior Checklist (ABCL)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978894","Conners Kiddie Continuous Performance Test, 2nd Edition","C165718","A 7.5-minute-long computer-based assessment of attention deficits in children aged 4 through 7 years old. It utilizes images of objects that are familiar to young children requiring a response from the child as they appear on the screen.","Conners Kiddie Continuous Performance Test, 2nd Edition | Conners K-CPT 2 | Conners Kiddie Continuous Performance Test 2nd Edition (Conners K-CPT 2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978901","Home Observation for Measurement of the Environment, Revised Edition","C165719","A 38-item questionnaire that evaluates the quality of a child's home environment filled out by the child's primary caregiver. The questions vary based on the age of the child.","Home Observation for Measurement of the Environment, Revised Edition | Home Observation for Measurement of the Environment (HOME), Revised Edition- National Longitudinal Study of Youth Children and Young Adults | Home Observation for Measurement of the Environment (HOME)-Revised Edition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951443","Percent of Tumor Cells","C159484","A quantitative measurement of the percent of tumor cells compared to the number of total cells present in a sample.","Percent of Tumor Cells | Percent Tumor Cells | percent tumor cells | percent_tumor_cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950786","Indeterminate Microsatellite Instability","C158894","An indication that microsatellite instability was not assessed or that it is not known if it was assessed.","Indeterminate Microsatellite Instability | Indeterminate | MSI Indeterminate | MSI-I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978893","PSA Level 0.5 to Ten","C165717","A blood concentration of prostate specific antigen between 0.5 and 10 ng/mL.","PSA Level 0.5 to Ten | PSA Level 0.5 to 10 | PSA Level Between 0.5 and 10 | PSA Level Between 0.5 and Ten",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978902","BCL6 Gene Mutation","C165720","A change in the nucleotide sequence of the BCL6 gene.","BCL6 Gene Mutation | B-Cell CLL/Lymphoma 6 Gene Mutation | BCL5 Gene Mutation | Bcl-6 Gene Mutation | LAZ3 Gene Mutation | ZBTB27 Gene Mutation | ZNF51 Gene Mutation | Zinc Finger Protein 51 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978900","LY75 Positive","C165727","An indication that expression of LY75 has been detected in a sample.","LY75 Positive | C-Type Lectin Domain Family 13 Member B Positive | CD205 Antigen Positive | CD205 Positive | DEC-205 Positive | DEC205 Positive | Ly-75 Positive | Lymphocyte Antigen 75 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978879","Myeloblasts 10 Percent or More of Peripheral Blood White Cells","C165728","A semi-quantitative microscopic finding indicating that at least 10 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells of myeloid origin.","Myeloblasts 10 Percent or More of Peripheral Blood White Cells | Myeloblasts Greater than or Equal to 10 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978880","del(17p13.1)","C165729","A deletion of chromosomal material at 17p13.1. This chromosomal aberration includes deletion of the TP53 gene and is associated with chronic lymphocytic leukemia.","del(17p13.1) | -17p13.1 | 17p13.1 Deletion | del(17)(p13.1)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978881","ZRSR2 Gene Nonsense Mutation","C165730","A change in the sequence of the ZRSR2 gene that encodes a premature stop codon.","ZRSR2 Gene Nonsense Mutation | U2AF1-RS2 Nonsense Mutation | U2AF1L2 Nonsense Mutation | U2AF1RS2 Nonsense Mutation | URP Nonsense Mutation | ZC3H22 Nonsense Mutation | ZRSR2 Nonsense Mutation | Zinc Finger CCCH-type, RNA Binding Motif and Serine/Arginine Rich 2 Gene Nonsense Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978875","ZRSR2 Gene Frameshift Mutation","C165733","A deletion or insertion mutation in the ZRSR2 gene that shifts the reading frame for the transcript.","ZRSR2 Gene Frameshift Mutation | U2AF1-RS2 Frameshift Mutation | U2AF1L2 Frameshift Mutation | U2AF1RS2 Frameshift Mutation | URP Frameshift Mutation | ZC3H22 Frameshift Mutation | ZRSR2 Frame Shift Mutation | ZRSR2 Frameshift Mutation | ZRSR2 Gene Frame Shift Mutation | Zinc Finger CCCH-type, RNA Binding Motif and Serine/Arginine Rich 2 Gene Frameshift Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978876","PSA Level Less than or Equal to One Hundred","C165734","A blood concentration of prostate specific antigen less than or equal to 100 ng/mL.","PSA Level Less than or Equal to One Hundred | PSA Level 100 or Less | PSA Level Less Than or Equal to 100 ng/mL | PSA Level Less than or Equal to 100 | PSA Level One Hundred or Less",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978825","MUC17 Positive","C165592","An indication that MUC17 expression has been detected in a sample.","MUC17 Positive | MUC-17 Positive | MUC-3 Positive | MUC3 Positive | Mucin 17 Positive | Mucin-17 Positive | Small Intestinal Mucin-3 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978700","PSA Level 0.2 or Less","C165510","A blood concentration of prostate specific antigen less than or equal to 0.2 ng/mL.","PSA Level Less than or Equal to 0.2 | PSA Less Than or Equal to 0.2 | PSA Less than or Equal to 0.2 | PSA Level 0.2 or Less | PSA Level Less Than or Equal to 0.2 | PSA Level Less than or Equal to 0.2 ng/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978800","PSA Level Greater than or Equal to 0.5","C165625","A blood concentration of prostate specific antigen greater than or equal to 0.5 ng/mL.","PSA Level Greater than or Equal to 0.5 | PSA Level 0.5 or Greater | PSA Level Equal to or Greater than 0.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978699","PSA Decline Greater than or Equal to 50 Percent","C165509","A finding indicating that the blood concentration of prostate specific antigen in a subject's sample has decreased by at least 50 percent from the concentration recorded for a previous sample from that subject.","PSA Decline Greater than or Equal to 50 Percent | Greater than or Equal to 50 Percent Reduction in Baseline PSA | Greater than or Equal to 50% Reduction in Baseline PSA | PSA Decline 50 Percent or Greater | PSA Decline 50 Percent or More | PSA Decline Fifty Percent or Greater | PSA Decline Fifty Percent or More | PSA Decline Greater than or Equal to Fifty Percent | PSA Decreased Greater than or Equal to 50 Percent | PSA Decreased Greater than or Equal to Fifty Percent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978701","PSA Decline Greater than or Equal to 25 Percent","C165511","A finding indicating that the blood concentration of prostate specific antigen in a subject's sample has decreased by at least 25 percent from the concentration recorded for a previous sample from that subject.","PSA Decline Greater than or Equal to 25 Percent | PSA Decline 25 Percent or Greater | PSA Decline 25 Percent or More | PSA Decline Greater than or Equal to Twenty Five Percent | PSA Decline Greater than or Equal to Twenty-Five Percent | PSA Decline Twenty Five Percent or Greater | PSA Decline Twenty Five Percent or More | PSA Decline Twenty-Five Percent or Greater | PSA Decline Twenty-Five Percent or More | PSA Decreased Greater than or Equal to 25 Percent | PSA Decreased Greater than or Equal to Twenty Five Percent | PSA Decreased Greater than or Equal to Twenty-Five Percent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978807","Tumor Panel Sequencing","C165600","An application of next-generation targeted sequencing where tumor-specific genes are selected for sequencing. Using next-generation techniques, chosen sequences can be sequenced to high depths that facilitate the identification of variants that are present at low allele frequencies.","Tumor Panel Sequencing | Tumor Gene Panel Sequencing | Tumor-Targeted Gene Sequencing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978561","FLT3 NP_004110.2:p.I836X","C165490","A change in the amino acid residue at position 836 in the receptor-type tyrosine-protein kinase FLT3 protein where isoleucine has been replaced by another amino acid.","FLT3 NP_004110.2:p.I836X | CD135 Antigen I836X | CD135 Antigen Ile836Xxx | FLT3 I836 Mutation | FLT3 NP_004110.2:p.Ile836Xxx | FLT3 p.I836X | FLT3 p.Ile836Xxx | FLT3-TKD/I836 Mutation | Fetal Liver Kinase-2 I836X | Fetal Liver Kinase-2 Ile836Xxx | Flt-3 Receptor I836X | Flt-3 Receptor Ile836Xxx | Fms-Related Tyrosine Kinase 3 I836X | Fms-Related Tyrosine Kinase 3 Ile836Xxx | I836 | I836X | NP_004110.2:p.I836X | NP_004110.2:p.Ile836Xxx | Receptor-Type Tyrosine-Protein Kinase FLT3 I836X | Receptor-Type Tyrosine-Protein Kinase FLT3 Ile836Xxx | Stem Cell Tyrosine Kinase 1 I836X | Stem Cell Tyrosine Kinase 1 Ile836Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978636","MUC1 with Truncated O-Glycans Positive Neoplastic Cells Present","C165422","An indication that a the surfaces of cells in sample have detectable amounts of a glycosylated mucin-1 protein (MUC1) that includes a cancer-specific truncated O-glycan modification.","MUC1 with Truncated O-Glycans-Positive Neoplastic Cells Present | MUC1 with Truncated O-Glycans Positive Neoplastic Cells Present | MUC1 with Truncated O-Glycans Positive Neoplastic Cells Present | STnMUC1 Positive Neoplastic Cells Present | Tn-MUC1 Positive | Tn-MUC1 Positive Neoplastic Cells Present | TnMUC1 Positive | TnMUC1 Positive Neoplastic Cells Present | Truncated O-Glycan MUC1 Positive Neoplastic Cells Present | Tumor Antigen TnMUC1 Positive Neoplastic Cells Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524921","Ultrasound of the Neck","C137925","An ultrasound of the neck.","Ultrasound of the Neck | Neck Ultrasound",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936906","Number of Lymph Nodes Positive for Tumor by IHC Staining Only","C157145","The quantity of lymph nodes that were positive for a neoplastic lesion with immunohistochemical (IHC) staining procedures.","Number of Lymph Nodes Positive for Tumor by IHC Staining Only | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936903","IHC Staining not Done","C157156","An indication that immunohistochemical staining was not performed.","IHC Staining not Done | IHC staining not done",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936907","Number of Lymph Nodes Positive for Tumor by H&E","C157146","The quantity of lymph nodes that were positive for a neoplastic lesion with hematoxylin and eosin (H&E) procedures.","Number of Lymph Nodes Positive for Tumor by H&E | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936769","If pM1, specify site(s)","C157102","A directive to indicate the anatomic sites if metastasis is categorized as pM1.","Specify Site if pM1 | If pM1, specify site(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950754","Specify Site if pM1b","C158727","A directive to indicate the anatomic sites if metastasis is categorized as pM1b.","Specify Site if pM1b | If pM1b, specify site(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025741","Methyldopa","C47616","A phenylalanine derivative and an aromatic amino acid decarboxylase inhibitor with antihypertensive activity. Methyldopa is a prodrug and is metabolized in the central nervous system. The antihypertensive action of methyldopa seems to be attributable to its conversion into alpha-methylnorepinephrine, which is a potent alpha-2 adrenergic agonist that binds to and stimulates potent central inhibitory alpha-2 adrenergic receptors. This results in a decrease in sympathetic outflow and decreased blood pressure.","Methyldopa | 3-Hydroxy-alpha-methyl-L-tyrosine | Aldomet | Amodopa | Dopamet | L-2-Amino-2-methyl-3-(3,4-dihydroxyphenyl)propionic Acid | Levo-3-(3,4-Dihydroxyphenyl)-2-methylalanine | METHYLDOPA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0966225","Omalizumab","C29299","A humanized monoclonal antibody directed against the C-epsilon 3 domain of immunoglobulin E.  Olizumab binds to this IgE domain, thereby preventing IgE from binding to its high-affinity mast-cell receptor. (NCI04)","Omalizumab | Anti-IgE Monoclonal Antibody E25 | IGE 025 | OMALIZUMAB | Olizumab | Xolair | rhuMAb-E25",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029083","Ophthalmic Solution","C29302","A sterile solution containing a substance or multiple substances administered to the external eye, usually in the form of droplets. An ophthalmic solution may contain different drugs with different mechanisms of actions, to target symptoms and their underlying cause. Classes of pharmacological agents used may include antibiotics, beta-adrenergic agents, antihistamines, corticosteroids and prostanoids. The ophthalmic solution may be used to treat increased intraocular pressure, symptoms of allergic conjunctivitis, and ocular bacterial infections, among others.","Ophthalmic Solution | Eye Drop",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0724655","Opium Tincture","C29300","Also known as Laudanum and formulated for oral administration, Opium tincture is made of air-dried poppy (Papaver somniferum) latex and contains alkaloids such as morphine and codeine. As an antidiarrheal agent, it slows transit of intestinal contents by increasing intestinal smooth muscle tone and inhibiting motility; water is absorbed from fecal contents, decreasing diarrhea. (NCI04)","Opium Tincture | Laudanum | OPIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0771892","Olopatadine Hydrochloride","C61867","The hydrochloride salt form of olopatadine, a dual action selective histamine H1 receptor antagonist and mast cell stabilizer with anti-allergic activity. Olopatadine stabilizes mast cells and prevents histamine release from mast cells. In addition, this agent also blocks histamine H1 receptors, thereby preventing histamine from binding to these receptors. Both actions prevent the effects of histamine on capillaries, bronchial smooth muscle, and gastrointestinal (GI) smooth muscle, including histamine-induced vasodilation, increased capillary permeability, bronchoconstriction, and spasmodic contraction of GI smooth muscle. This drug also prevents histamine-induced pain and itching of mucous membranes.","Olopatadine Hydrochloride | ALO-4943A | Dibenz[B,E]Oxepin-2-Acetic Acid, 11-[3-(Dimethylamino)Propylidene]-6,11-Dihydro-, Hydrochloride, (Z)- | KW-4679 | OLOPATADINE HYDROCHLORIDE | Pataday | Patanase | Patanol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031441","Phenoxybenzamine","C62065","A synthetic, dibenzamine alpha adrenergic antagonist with antihypertensive and vasodilatory properties. Phenoxybenzamine non-selectively and irreversibly blocks the postsynaptic alpha-adrenergic receptor in smooth muscle, thereby preventing vasoconstriction, relieving vasospasms, and decreasing peripheral resistance. Reflex tachycardia may occur and may be enhanced by blockade of alpha-2 receptors which enhances norepinephrine release. Phenoxybenzamine is reasonably anticipated to be a human carcinogen.","Phenoxybenzamine | N-(2-chloroethyl)-N-(1-methyl-2-phenoxyethyl)-benzenemethanamine | PHENOXYBENZAMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0076107","Terazosin","C61964","A drug used to treat urinary problems caused by an enlarged prostate. It is also used to treat high blood pressure and is being studied in the treatment of other conditions. Terazosin relaxes muscle tissue in blood vessels and in the prostate. It is a type of alpha blocker.","Terazosin | TERAZOSIN | terazosin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032912","Prazosin","C767","A synthetic piperazine derivative and an alpha-1 adrenergic receptor inhibitor used primarily as an anti-hypertensive. Prazosin's effects are most pronounced in the large resistance vessels (i.e. arterioles) and result in a decrease in total systemic vascular resistance (SVR) without a rebound or reflex tachycardia. To a lesser extent, this agent also decreases the tone of the bladder sphincter, thereby allowing the opening of the bladder into the urethra and thus relieving the urinary conditions associated with benign prostatic hypertrophy.","Prazosin | 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine | 2-[4-(2-furoyl)piperazin-1-yl]-4-amino-6,7-dimethoxyquinazoline | Furazosin | PRAZOSIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025859","Metoprolol","C61845","A cardioselective competitive beta-1 adrenergic receptor antagonist with antihypertensive properties and devoid of intrinsic sympathomimetic activity. Metoprolol antagonizes beta 1-adrenergic receptors in the myocardium, thereby reducing the rate and force of myocardial contraction leading to a reduction in cardiac output. This agent may also reduce the secretion of renin with subsequent reduction in levels of angiotensin II thereby preventing vasoconstriction and aldosterone secretion.","Metoprolol | METOPROLOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033497","Propranolol","C62073","A synthetic, nonselective beta-adrenergic receptor blocker with antianginal, antiarrhythmic, antihypertensive properties. Propranolol competitively antagonizes beta-adrenergic receptors, thereby causing negative chronotropic and inotropic effects leading to a reduction in cardiac output.","Propranolol | 1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol | 1-[(1-Methylethyl)amino]-3-(1-naphthalenyloxy)-2-propanol | PROPRANOLOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421876","AICDA Gene","C101413","This gene plays a role in both class-switch recombination in B-lymphocytes and cytidine deamination.","AICDA Gene | AICDA | Activation Induced Cytidine Deaminase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0357797","Oxymetazoline Hydrochloride","C29313","The hydrochloride salt form of oxymetazoline, an imidazole derivative with a direct acting sympathomimetic property. Oxymetazoline binds to and activates alpha-2 adrenergic receptors. Upon nasal or ocular administration, oxymetazoline constricts the arterioles in the nose and eye, resulting in decreased nasal and conjunctival congestion, respectively.","Oxymetazoline Hydrochloride | Afrin | OXYMETAZOLINE HYDROCHLORIDE | Ocuclear | Visine L.R.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0722364","Oxycodone Hydrochloride","C48010","The hydrochloride salt of oxycodone, a methylether of oxymorphone and semisynthetic opioid agonist with analgesic and antitussive properties. Oxycodone binds to mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opiates. In addition to analgesia and a depressive effect on the cough center in the medulla, this agent may cause euphoria, anxiolysis, miosis, sedation, physical dependence, constipation, and respiratory depression, depending on dosage and variations in individual metabolism.","Oxycodone Hydrochloride | 4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one Hydrochloride | OXYCODONE HYDROCHLORIDE | Oxecta | OxyContin | Roxicodone | oxycodone hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0134394","Oxybutynin Chloride","C73597","The chloride salt form of oxybutynin, a tertiary amine and anticholinergic agent with antispasmodic activity. Oxybutynin chloride exerts its antimuscarinic effect on bladder smooth muscle by blocking muscarinic receptors in smooth muscle, thereby inhibiting acetylcholine binding. This results in a relaxation of bladder smooth muscle, a reduction of involuntary muscle contractions and delays the initial desire to void.","Oxybutynin Chloride | 4-(diethylamino)-2-butynyl ()-,alpha-phenylcyclohexaneglycolate Hydrochloride | Ditropan | Gelnique | MJ-4309-1 | OXYBUTYNIN CHLORIDE | Oxybutynin Hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029997","Oxazepam","C47642","A synthetic benzodiazepine derivative with anxiolytic and sedative hypnotic properties. Although the mechanism of action has not been fully elucidated, oxazepam appears to enhance gamma-aminobutyric acid (GABA) receptor affinity for GABA, thereby prolonging synaptic actions of GABA.","Oxazepam | 2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-3-hydroxy-5-phenyl- | OXAZEPAM | Ro 5-6789 | Serax | Seresta | WY-3498 | Zaxopam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0069739","Oxaprozin","C29307","A nonsteroidal anti-inflammatory drug (NSAID) derivative of oxazole-propionic acid with analgesic and antipyretic properties.  As a first generation NSAID inhibitor, oxaprozin binds to and inactivates both isoforms of cyclooxygenase (COX-1 and-2), thereby blocking the conversion of arachidonic acid to pro-inflammatory prostaglandins.  When inhibiting COX-2, this agent may be effective in relieving pain and inflammation; when inhibiting COX-1, it may produce unacceptable gastrointestinal side effects. (NCI04)","Oxaprozin | 4,5-Diphenyl-2-oxazolepropionic Acid | Daypro | OXAPROZIN | Wy 21743",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0717762","Ethinyl Estradiol/Norgestimate","C29304","An oral preparation combination containing the semisynthetic estrogen ethinyl estradiol and the synthetic progestagen norgestimate with contraceptive activity. Ethinyl estradiol and norgestimate act by negative feed back mechanism at pituitary gland suppressing the release of gonadotropin hormones follicle stimulating hormone (FSH) and luteinizing hormone (LH). This combination inhibits ovulation and promotes the thickening of the cervical mucus and the endometrium. The combination of ethinyl estradiol and norgestimate may also be used in the treatment of acne.","Ethinyl Estradiol/Norgestimate | Oral Contraceptive, Combination | Ortho Cyclen | Orthotricyclen | Previfem | Sprintec",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0076275","Orlistat","C29303","A reversible active-site inhibitor of gastrointestinal lipases.  Orlistat forms a covalent bond with the active serine site in gastric and pancreatic lipases, thereby inhibiting their activity and preventing dietary fat from being hydrolyzed and absorbed. (NCI04)","Orlistat | Alli | ORLISTAT | Xenical",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030864","Pentamidine Isethionate","C29349","A synthetic amidine derivative, Pentamidine Isethionate is an antiprotozoal and antifungal agent that appears to interact with the minor groove of AT-rich DNA regions of the pathogen genome, interfering with DNA replication and function. It is effective in the treatment of trypanosomiasis, leishmaniasis, some fungal infections, and Pneumocystis carinii pneumonia in HIV-infected patients. (NCI04)","Pentamidine Isethionate | PENTAMIDINE ISETHIONATE | Pentacarinat | Pentam | pentamidine isethionate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031469","Phenylephrine","C62067","A direct-acting sympathomimetic amine chemically related to adrenaline and ephedrine with potent vasoconstrictor property. Phenylephrine is a post-synaptic alpha-adrenergic receptor agonist that causes vasoconstriction, increases systolic/diastolic pressures, reflex bradycardia, and stroke output.","Phenylephrine | PHENYLEPHRINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1445789","Phenylephrine/Phenylpropanolamine/Guaifenesin","C29362","A combination preparation containing phenylephrine, phenylpropanolamine and guaifenesin with decongestant and expectorant activities. Phenylephrine and phenylpropanolamine, direct-acting sympathicomimetic amines, activate alpha-adrenergic receptors in the nasal mucosa thereby causing vasoconstriction, reduces swelling of nasal mucous membranes and decreasing nasal and sinus congestion. Phenylpropanolamine also releases norepinephrine from its storage sites resulting in the effects already described. Guaifenesin increases respiratory tract mucus secretions and reduces the viscosity of mucus secretion by reducing adhesiveness and surface tension as well as increasing hydration of mucus, thereby increasing the efficiency of removing accumulated secretions from the upper and lower airways and making cough more productive.","Phenylephrine/Phenylpropanolamine/Guaifenesin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282304","Phentermine Hydrochloride","C29361","The hydrochloride salt form of phentermine, a sympathomimetic amine with central nervous system (CNS) stimulant and appetite depressant properties. Phentermine hydrochloride stimulates the release of norepinephrine and dopamine from nerve endings and blocks the reuptake of these monoamines at the neuronal junctions, resulting in CNS stimulation and metabolic effects, including appetite-suppression, decreased gastric acid secretion and increased blood pressure.","Phentermine Hydrochloride | PHENTERMINE HYDROCHLORIDE | Phentermine HCl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0701367","Phenoxybenzamine Hydrochloride","C44435","The hydrochloride salt form of phenoxybenzamine, a synthetic, dibenzamine alpha-adrenergic antagonist with antihypertensive and vasodilatory properties. Phenoxybenzamine non-selectively and irreversibly blocks the postsynaptic alpha-adrenergic receptor in smooth muscle, thereby preventing vasoconstriction, relieving vasospasms, and decreasing peripheral resistance. Reflex tachycardia may occur and may be enhanced by blockade of alpha-2 receptors which enhances norepinephrine release. Phenoxybenzamine is reasonably anticipated to be a human carcinogen.","Phenoxybenzamine Hydrochloride | Dibenzyline | N-(2-chloroethyl)-N-(1-methyl-2-phenoxyethyl)-benzenemethanamine Hydrochloride | PHENOXYBENZAMINE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600489","Phenolphthalein","C29359","An organic compound used as a laboratory reagent and pH indicator. Phenolphthalein exerts laxative effects by stimulating the intestinal mucosa and constricting smooth muscles. However, phenolphthalein is no longer used as a laxative due to the suspected carcinogenicity of this compound.","Phenolphthalein | 3,3-Bis(4-hydroxyphenyl)-1(3H)-isobenzofuranone | 3,3-Bis(p-hydroxyphenyl)phthalide | PHENOLPHTHALEIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031379","Phenazopyridine","C29357","A synthetic pyridine derivative anesthetic, Phenazopyridine is used as a local anesthetic in urinary tract disorders to relieve pain of lower urinary-tract irritation, as in cystitis, urethritis or prostatitis. Compatible with relief of pain and discomfort in antibacterial therapy, its use is limited however due to toxicity (primarily blood disorders) and potential carcinogenicity. (NCI04)","Phenazopyridine | PHENAZOPYRIDINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031184","Perphenazine","C29355","A phenothiazine derivative and a dopamine antagonist with antiemetic and antipsychotic properties. Perphenazine blocks postsynaptic dopamine 2(D2) receptors in the mesolimbic and medullary chemoreceptor trigger zone (CTZ), thereby preventing the excess of dopamine in the brain. This leads to reduction in psychotic symptoms, such as hallucinations and delusions. Perphenazine appears to exert its antiemetic activity by blocking the dopamine and histamine-1 receptor in the CTZ thereby relieving nausea and vomiting in the brain. In addition, perphenazine binds to alpha-adrenergic receptors.","Perphenazine | 4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazineethanol | PERPHENAZINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0771019","Paroxetine Hydrochloride","C1837","The hydrochloride salt form of paroxetine, a phenylpiperidine derivative and a selective serotonin reuptake inhibitor (SSRI) with antidepressant and anxiolytic properties. Paroxetine binds to the pre-synaptic serotonin transporter complex resulting in negative allosteric modulation of the complex thereby blocking reuptake of serotonin by the pre-synaptic transporter. Inhibition of serotonin recycling enhances serotonergic function through serotonin accumulation in the synaptic cleft, resulting in long-term desensitization and downregulation of 5HT1 (serotonin) receptors and leading to symptomatic relief of depressive illness.","Paroxetine Hydrochloride | (-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine Hydrochloride | PAROXETINE HYDROCHLORIDE ANHYDROUS | Paxil | Paxil CR | paroxetine hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0081876","Pantoprazole","C29346","A substituted benzimidazole and proton pump inhibitor with antacid activity. Pantoprazole is a lipophilic weak base that crosses the parietal cell membrane and enters the acidic parietal cell canaliculus where it becomes protonated, producing the active metabolite sulphenamide, which forms an irreversible covalent bond with two sites of the H+/K+-ATPase enzyme located on the gastric parietal cell, thereby inhibiting both basal and stimulated gastric acid production.","Pantoprazole | PANTOPRAZOLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0770343","Pancrelipase","C29345","A standardized enzyme concentrate containing the pancreatic enzymes, lipase, protease and amylase used in enzyme substitution therapy. Lipase, protease and amylase break down fat, protein, and starches, respectively in the small intestine, thereby promoting digestion. Pancrelipase is used to reduce malabsorption when the pancreas is unable to secrete sufficient amounts of these enzymes.","Pancrelipase | Creon | PANCRELIPASE | Pancrease | Ultresa | Viokace | Zenpep | Zymase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1310734","Palonosetron Hydrochloride","C47650","The hydrochloride salt of palonosetron, a carbazole derivative and a selective serotonin receptor antagonist with antiemetic activity. Palonosetron competitively blocks the action of serotonin at 5-hydroxytryptamine type 3 (5-HT3) receptors located on vagal afferents in the chemoreceptor trigger zone (CTZ), resulting in suppression of chemotherapy-induced nausea and vomiting. The CTZ is located in the area postrema on the dorsal surface of the medulla oblongata at the caudal end of the fourth ventricle and outside the blood-brain barrier (BBB).","Palonosetron Hydrochloride | 1H-Benz(de)isoquinolin-1-one, 2-(3S)-1-azabicyclo(2.2.2)oct-3-yl-2,3,3a,4,5,6-hexahydro-, Monohydrochloride,(3aS)- | Aloxi | PALONOSETRON HYDROCHLORIDE | RS 25259-197 | palonosetron HCl | palonosetron hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031862","Phytonadione","C29365","An analogue of the naphthoquinone vitamin K found in plants.  The vitamins K are essential for blood coagulation as it is necessary for the hepatic synthesis of the coagulation factors II, VII, IX, and X; deficiency results in a bleeding diathesis. These vitamins are lipo-soluble; absorption via intestinal lymphatics requires the presence of bile salts. (NCI04)","Phytonadione | AquaMephyton | Konakion | PHYTONADIONE | Phylloquinone | Vitamin K | Vitamin K1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031495","Phenylpropanolamine","C29364","An alpha- and beta-adrenergic receptor agonist with sympathomimetic activity. Phenylpropanolamine (PPA) binds to and activates alpha- and beta-adrenergic receptors in the mucosa of the respiratory tract resulting in vasoconstriction and reduction in swelling of nasal mucous membranes and reduction in tissue hyperemia, edema, and nasal congestion. This agent also stimulates the release of norepinephrine from its storage sites resulting in the effects already described. Finally, PPA indirectly stimulates beta-receptors producing tachycardia and a positive inotropic effect.","Phenylpropanolamine | PHENYLPROPANOLAMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031923","Pilocarpine","C62068","A natural alkaloid extracted from plants of the genus Pilocarpus with cholinergic agonist activity. As a cholinergic parasympathomimetic agent, pilocarpine predominantly binds to muscarinic receptors, thereby inducing exocrine gland secretion and stimulating smooth muscle in the bronchi, urinary tract, biliary tract, and intestinal tract. When applied topically to eyes, this agent stimulates the sphincter pupillae to contract, resulting in miosis; stimulates the ciliary muscle to contract, resulting in spasm of accommodation; and may cause a transitory rise in intraocular pressure followed by a more persistent fall due to opening of the trabecular meshwork and an increase in the outflow of aqueous humor.","Pilocarpine | Ocusert Pilo | PILOCARPINE | pilocarpine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031955","Piperacillin","C62069","A broad-spectrum semisynthetic, ampicillin-derived ureidopenicillin antibiotic. Piperacillin binds to penicillin binding proteins (PBP), the enzymes that catalyze the synthesis of peptidoglycan, a critical component of the bacterial cell wall. This blockade leads to the interruption of cell wall synthesis, consequently, leading to bacterial cell growth inhibition and cell lysis.","Piperacillin | (2S,5R,6R)-6-((R)-2-(4-Ethyl-2,3-dioxo-1-piperazinecarboxamido)-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid Monohydrate | PIPERACILLIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032623","Polyvinyl Alcohol","C29370","A water-soluble synthetic polymer that is used for a wide variety of applications.","Polyvinyl Alcohol | POLYVINYL ALCOHOL, UNSPECIFIED | PVA | Polydesis | Polyviol | Poval 420 | Vinarol DT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0722698","Citrate-containing Alkalinizing Agent","C29369","A combination of sodium citrate and potassium citrate with alkalizing and antiurolithic effects. Polycitra is metabolized to bicarbonates, thereby increasing urinary pH by increasing the excretion of free bicarbonate ions. A rise in urinary pH increases the solubility of cystine in the urine and the ionization of uric acid to more soluble urate ion. In addition, increased urinary citrate and pH decreases calcium ion activity by increasing calcium complexation to dissociated anions and thus decreasing the saturation of calcium oxalate. By increasing the level of plasma bicarbonate this agent also buffers excess hydrogen ion concentration and raises blood pH, thereby reversing the clinical manifestations of acidosis.","Citrate-containing Alkalinizing Agent | Cytra-3 | Polycitra",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032334","Podofilox","C29368","A pure, stabilized form of podophyllin, in which only the biologically active portion of the compound is present.  Podophyllotoxin is a toxic, polycyclic antimitotic agent isolated primarily from the rhizome of the plant Podophyllum peltatum. This agent is formulated for topical applications. (NCI04)","Podofilox | PODOFILOX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031937","Pindolol","C47673","An aryloxypropanolamine derivative with antihypertensive property. Pindolol competitively binds to beta-adrenergic receptors, resulting in a decrease in beta-adrenergic activities, i.e., vasodilation, and negative chronotropic and inotropic effects. In addition, this agent blocks serotonin (5-HT) 1A receptors, thereby increasing the available serotonin in the brain. Increased serotonin levels augment the antidepressant action of selective serotonin reuptake inhibitors and monoamine oxidase inhibitors.","Pindolol | 1-(1H-Indol-4-yloxy)-3-((1-methylethyl)amino)-2-propanol | Carvisken | PINDOLOL | Visken",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0301527","Potassium Gluconate","C81070","No Value Exists","Potassium Gluconate | POTASSIUM GLUCONATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0137996","Potassium Citrate","C29372","The potassium salt form of citrate, with alkalinizing activity and that can be used for potassium supplementation. Upon oral administration, potassium citrate provides potassium. Potassium maintains normal fluid and electrolyte balance, regulates the proper functioning of heart and muscle contractions, supports healthy bone density and blood pressure. It also plays an important role in the transmission of nerve impulses and energy production. Amino acid chelated minerals are highly bioavailable and better absorbed than non-amino acid-chelated minerals. Potassium citrate also causes increased plasma bicarbonate concentration, thereby raising blood and urinary pH. A simultaneous decrease in calcium ion activity occurs as a result of increasing calcium complex formation with dissociated anions. Levels of urinary citrate are increased due to modification of the renal handling of citrate. By promoting excretion of free bicarbonate ion and by increasing urinary pH in addition to an increased ionization of uric acid to more soluble urate ions, this agent exerts alkalizing and anti-urolithic effect.","Potassium Citrate | 2-Hydroxy-1,2,3-propanetricarboxylic Acid, Potassium Salt | POTASSIUM CITRATE | Potassium Citrate Monohydrate | Potassium Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033126","Primaquine","C62071","A synthetic, 8-aminoquinoline derivative with antimalarial properties.  Although its mechanism of action is unclear, primaquine bind to and alter the properties of protozoal DNA.  This agent eliminates tissue (exo-erythrocytic) malarial infection, preventing the development of the erythrocytic forms of the parasite which are responsible for relapses in Plasmodium vivax and ovale malaria.  Primaquine is active against late hepatic stages (hypnozoites, schizonts). (NCI04)","Primaquine | PRIMAQUINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0071888","Preparation H","C29378","A brand of combination medications, by Wyeth Pharmaceuticals, used in the treatment of hemorrhoids. Preparation H is used to relieve pain, swelling and pruritis, as well as, to soothe and protect the hemorrhoidal tissue. Preparation H products are formulated as a cream, ointment, cooling gel, suppositories and witch hazel wipes.","Anti-hemorrhoidal Formulation | Preparation H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0722753","Conjugated Estrogen/Medroxyprogesterone-containing Formulation","C29377","A combination preparation of conjugated estrogens, including sodium estrone sulfate, sodium equilin sulfate, and the progestin medroxyprogesterone acetate. The conjugated estrogens increase the diminishing levels of estrogen in menopausal and postmenopausal women. Maintaining adequate estrogen levels decreases symptoms such as hot flashes, night sweats, irregular menstruation, fat redistribution, mood swings, sleep disorders, vaginal dryness and osteoporosis. Medroxyprogesterone acetate is added to prevent endometrial proliferation and a subsequent elevated risk of estrogen-induced endometrial cancer.","Conjugated Estrogen/Medroxyprogesterone-containing Formulation | Prempro",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0772054","Pramipexole Dihydrochloride","C29374","The hydrochloride salt of pramipexole, a benzothiazole derivative. As a nonergot dopamine agonist, pramipexole binds to D2 and D3 dopamine receptors in the striatum and substantia nigra of the brain. Compared to other dopamine agonists, the use of this agent may be associated with fewer dyskinetic side effects in treated subjects. (NCI04)","Pramipexole Dihydrochloride | Mirapex | PRAMIPEXOLE DIHYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0245561","Duloxetine","C65495","A drug used to treat depression and peripheral neuropathy (pain, numbness, tingling, burning, or weakness in the hands or feet) that can occur with diabetes. It is also being studied in the treatment of peripheral neuropathy caused by certain anticancer drugs. Cymbalta increases the amount of certain chemicals in the brain that help relieve depression and pain. It is a type of serotonin and norepinephrine reuptake inhibitor.","Duloxetine | DULOXETINE | duloxetine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937409","Brain Tumor Radiation","C157800","The use of radiation, either via external beams or small radioactive pellets, to treat a tumor in the brain.","Brain Tumor Radiation | Brain Tumor Irradiation | Brain Tumor Radiation Therapy | Brain Tumor Radiotherapy | Radiation for Brain Tumors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475287","Stage RX","C139581","Presence of residual tumor after treatment cannot be assessed.","RX | RX | RX: Presence of residual tumor cannot be assessed | RX: The presence of residual tumor or margin status cannot be assessed. | Residual Tumor Cannot Be Assessed | Residual Tumor Stage RX | Residual Tumor Stage Unknown | Residual Tumor Stage X | Residual Tumor Unknown | Stage RX",,,,,,,,,,,,,,,"37163891","RX",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0475826","Stage R2","C139580","Presence of macroscopic residual tumor after treatment.","R2 | Gross Residual Tumor | Macroscopic Residual Tumor | R2 | R2 - Gross Residual Disease | R2: Macroscopic residual tumor | R2: Macroscopic residual tumor. Grossly visible residual disease. | Residual Tumor Stage 2 | Residual Tumor Stage R2 | Stage R2",,,,,,,,,,,,,,,"37163890","R2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526878","Stage R1","C139579","Presence of microscopic residual tumor after treatment.","R1 | Microscopic Residual Tumor | R1 | R1 - Complete Resection, Positive Margins | R1 - Complete Resection, Positive Margins - Microscopically Positive | R1: Microscopic residual tumor | R1: Microscopic residual tumor. No gross residual disease but positive microscopic margins. | Residual Tumor Stage 1 | Residual Tumor Stage R1 | Stage R1",,,,,,,,,,,,,,,"37163889","R1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0475288","Stage R0","C139578","No detectable presence of residual tumor after treatment","R0 | No Residual Tumor | R0 | R0 - Complete Resection, Negative Margins | R0: No residual tumor | R0: No residual tumor and negative microscopic margins in resected specimen. | Residual Tumor Stage 0 | Residual Tumor Stage R0 | Stage R0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
,,"C15438","Use of techniques, biologically active substances, and procedures to enhance or restore the ability of the host immune system to fight cancer. Also used to lessen adverse effects that may be caused by some cancer treatments.","Cancer Immunotherapy | Immuno-Chemotherapy | Immunotherapy, Cancer, General | immunotherapy for cancer",,,,,,,,,,,,,,,"4274159","Immunotherapy for cancer",,,,,,,,,,,,,,,,,,,,,,"--"
"CL937704","Any Metastatic Diagnosis","C158075","A question about whether a diagnosis of metastatic disease has or has not been made.","Is Any Metastatic Diagnosis Present | Any Metastatic Diagnosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0559116","Family History of Stomach Cancer","C157441","A question about a family history of stomach cancer.","Family History of Stomach Cancer | ",,,,,,,,,,,,,,,"4169010","FH: Stomach cancer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL936911","Other testing performed","C157144","A question asking if any additional tests were performed during the study.","Was Additional Testing Performed | Other testing performed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827912","Stranded Seed Implant","C105731","An implant consisting of multiple radioactive pellets linked together.","Stranded Seed Implant | Stranded Seed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0474700","Tumor Marker Level","C157523","The amount of a tumor marker in a given sample.","Tumor Marker Level | Tumor Level",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0718203","Propoxyphene Napsylate/Acetaminophen","C29387","A combination preparation of propoxyphene napsylate and acetaminophen, with analgesic and antipyretic activities. Propoxyphene napsylate is a mild narcotic analgesic that binds to mu-opioid receptors in the central nervous system (CNS), thereby mimicking the effect of endogenous opioids. Acetaminophen possesses analgesic and antipyretic effects by interfering with prostaglandin synthesis.","Propoxyphene Napsylate/Acetaminophen | Darvocet | Propacet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033495","Propoxyphene Napsylate","C29386","A synthetic diphenyl propionate derivative structurally related to methadone, Propoxyphene Napsylate acts as a central narcotic and analgesic agent by interaction with mu opioid receptors, but with less selectivity then morphine. The dextro-isomer has analgesic effect, while the levo-isomer exerts an antitussive effect. The napsylate salt allows better dosage formulation than the hydrochloride salt. (NCI04)","Propoxyphene Napsylate | Darvon-N | PROPOXYPHENE NAPSYLATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449034","Propoxyphene Hydrochloride","C29385","The hydrochloride salt form of the d-isomer of synthetic diphenyl propionate derivative propoxyphene, with narcotic analgesic effect. This agent mimics the effects of the endogenous opiate dextropropoxyphene, by binding to mu receptors located throughout the central nervous system. The binding results in GTP to GDP exchanges on the mu-G-protein complex, by which effector adenylate cyclase is inactivated thereby decreasing intracellular cAMP. This, in turn, inhibits the release of various nociceptive neurotransmitters, such as substance P, gamma-aminobutyric acid (GABA), dopamine, acetylcholine, noradrenaline, vasopressin, and somatostatin. In addition, dextropropoxyphene closes N-type voltage-gated calcium channels and opens calcium-dependent inwardly rectifying potassium channels. This results in hyperpolarization, thereby reducing neuronal excitability, which further decreases the perception of pain.","Propoxyphene Hydrochloride | Dextropropoxyphene Hydrochloride | Dolene | Dolotard | Doloxene | Doraphen | PROPOXYPHENE HYDROCHLORIDE | SK 65 | Zideron | alpha-d-Propoxyphene Hydrochloride | d-4-Dimethylamino-3-methyl-1,2-diphenyl-2-butanol Propionate Hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033448","Propantheline Bromide","C29383","The bromide salt form of propantheline, a quaternary ammonium compound structurally related to belladonna alkaloids. Propantheline bromide competitively antagonizes acetylcholine activity mediated by muscarinic receptors at neuroeffector sites on smooth muscle and exocrine gland cells. An aspartic acid residue present in the N-terminal portion of the third trans-membrane helix of the muscarinic receptor is believed to form an ionic bond with the tertiary or quaternary nitrogen of the antagonist. Antagonism leads to a reduction of exocrine glands secretions and to relax bronchial muscle and reduce tone and motility of intestinal smooth muscle.","Propantheline Bromide | PROPANTHELINE BROMIDE | Pro-banthine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0546876","Promethazine Hydrochloride","C45907","The hydrochloride salt form of promethazine, a phenothiazine derivative with antihistaminic, sedative and antiemetic properties. Promethazine hydrochloride selectively blocks peripheral H1 receptors thereby diminishing the effects of histamine on effector cells. Promethazine hydrochloride also blocks the central histaminergic receptors, thereby depressing the reticular system causing sedative and hypnotic effects. In addition, promethazine hydrochloride also has centrally acting anticholinergic properties and probably mediates nausea and vomiting by acting on the medullary chemoreceptive trigger zone.","Promethazine Hydrochloride | Anergan | N-(2-Dimethylaminopropyl-1)phenothiazine Hydrochloride | PROMETHAZINE HYDROCHLORIDE | Phencen | Phenergan | Prometh | Promethazine HCl | Prorex | Provigan | Remsed | V-Gan | Zipan-50",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0722820","Hydrocortisone/Pramoxine-containing Preparation","C29380","A combination preparation containing the glucocorticoid hydrocortisone acetate and the local anesthetic pramoxine hydrochloride, in aerosol foam form. Hydrocortisone has topical anti-inflammatory, vasoconstrictive and anti-pruritic activities and is used to relieve anorectal inflammation, pain, swelling, and pruritus caused by hemorrhoids.","Hydrocortisone/Pramoxine-containing Preparation | Proctofoam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0717652","Probenecid/Colchicine","C29379","A combination of probenecid and colchicine with antihyperuricemic activity. Probenecid, a benzoic acid derivative, competitively inhibits the reabsorption of urate at the proximal tubule in the kidney, thereby increasing urinary excretion of uric acid and lowering serum urate concentrations. This prevents urate deposition and promotes resolution of existing urate deposits. Colchicine is a natural alkaloid with anti-gout and anti-inflammatory properties. Colchicine binds to tubulin, thereby interfering with the polymerization of tubulin, interrupting microtubule dynamics, and disrupting mitosis leading to an inhibition of leukocyte migration and reduction of the inflammatory response to deposited urate crystals. This agent also interrupts monosodium urate crystal deposition in joint tissues, thereby preventing the resultant inflammatory response.","Probenecid/Colchicine | Col-Probenecid | Colbenemid | Proben-C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033209","Probenecid","C772","A benzoic acid derivative with antihyperuricemic property. Probenecid competitively inhibits the active reabsorption of urate at the proximal tubule in the kidney thereby increasing urinary excretion of uric acid and lowering serum urate concentrations. This prevents urate deposition and promotes resolution of existing urate deposits. In addition, probenecid modulates the transport of organic acids and acidic drugs at the proximal and distal renal tubule, thereby increasing the drug serum concentration.","Probenecid | Benemid | PROB | PROBENECID | SK-Probenecid | probenecid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0378482","Rabeprazole","C29410","An alpha-pyridylmethylsulfinyl benzimidazole and a selective and irreversible proton pump inhibitor with antisecretory property. Rabeprazole enters the parietal cell and accumulates in the acidic secretory canaliculi where the agent is activated by a proton-catalyzed process that results in the formation of a thiophilic sulfonamide or sulfenic acid. The activated rabeprazole forms covalent bonds with the sulfhydryl amino acids cysteine on the extracellular domain of the proton pump (H+/K+ ATPase) at the secretory surface, thereby inhibiting the transport of hydrogen ions, via exchange with potassium ions, into the gastric lumen. Binding to cysteine 813, in particular, is essential for inhibition of gastric acid production.","Rabeprazole | 2-(((4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole | LY307640 | RABEPRAZOLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034422","Quinine Sulfate","C29399","The sulfate salt form of the quinidine alkaloid isolate quinine. Quinine has many mechanisms of action, including reduction of oxygen intake and carbohydrate metabolism; disruption of DNA replication and transcription via DNA intercalation; and reduction of the excitability of muscle fibers via alteration of calcium distribution.  This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04)","Quinine Sulfate | Chininum Sulphuricum | Cinchonan-9-ol, 6'-methoxy-, (8 alpha,9R)-, Sulfate, Hydrate (2:1:2) | QUININE SULFATE | Qualaquin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0072857","Quinapril","C62074","A prodrug and non-sulfhydryl angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Quinapril is hydrolized into its active form quinaprilat, which binds to and inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This abolishes the potent vasoconstrictive actions of angiotensin II and leads to vasodilatation. Quinapril also causes a decrease in angiotensin II-induced aldosterone secretion by the adrenal cortex, thereby promoting diuresis and natriuresis, and increases bradykinin levels.","Quinapril | QUINAPRIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0724680","Quetiapine Fumarate","C47700","The fumarate salt form of quetiapine, a dibenzothiazepine derivative with antipsychotic property. Quetiapine fumarate antagonizes serotonin activity mediated by 5-HT 1A and 5-HT2 receptors. With a lower affinity, this agent also reversibly binds to dopamine D1 and D2 receptors in the mesolimbic and mesocortical areas of the brain leading to decreased psychotic effects, such as hallucinations and delusions. In addition, quetiapine fumarate also binds to other alpha-1, alpha-2 adrenergic and histamine H1 receptors.","Quetiapine Fumarate | Ethanol, 2-(2-(4-dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)-,(E)-2-butenedioate(2:1)(salt) | QUETIAPINE FUMARATE | Seroquel XR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034272","Pyridoxine","C62619","A nutrient in the vitamin B complex that the body needs in small amounts to function and stay healthy. Pyridoxine helps keep nerves and skin healthy, fight infections, keep blood sugar levels normal, produce red blood cells, and some enzymes work properly. Pyridoxine is a group of related compounds (pyridoxine, pyridoxal, and pyridoxamine) found in cereals, beans, peas, nuts, meat, poultry, fish, eggs, and bananas. It is water-soluble (can dissolve in water). Not enough pyridoxine can cause mouth and tongue sores and nervous disorders. Pyridoxine is being studied in the prevention of hand-foot syndrome (a disorder caused by certain anticancer drugs and marked by pain, swelling, numbness, tingling, or redness of the hands or feet).","Pyridoxine | PYRIDOXINE | pyridoxine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034262","Pyridostigmine Bromide","C47697","The bromide salt form of pyridostigmine, a quaternary ammonium carbamate derivative and a acetylcholinesterase inhibitor. Pyridostigmine bromide binds reversibly to acetylcholinesterase active sites in the peripheral nervous system, thereby preventing the breakdown of acetylcholine. This leads to an accumulation of acetylcholine at cholinergic synapses and facilitates transmission of impulses across the neuromuscular junction. Mediated through muscarinic receptors, this agent increases contraction of bronchial and intestinal smooth muscle and the exocrine glands secretions, while it causes paralysis of the skeletal muscles mediated through nicotinic receptors. In addition, pyridostigmine is used as a reversible blocking agent to prevent organophosphates from binding to the acetylcholinesterase receptors and thereby protect the nervous system from the effects of nerve agents such as Soman.","Pyridostigmine Bromide | 3-(((Dimethylamino)carbonyl)oxy)-1-methylpyridinium Bromide | 3-Hydroxy-1-methylpyridinium Bromide Dimethylcarbamate | Carbamic Acid,Dimethyl-, Ester with 3-Hydroxy-1-methylpyridinium Bromide | Kalimin | Mestinon Bromide | PYRIDOSTIGMINE BROMIDE | Regonal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0304431","Pseudoephedrine Sulfate","C47696","The sulfate salt form of pseudoephedrine, a phenethylamine and a diastereomer of ephedrine with sympathomimetic property. Pseudoephedrine sulfate displaces norepinephrine from storage vesicles in presynaptic neurones, thereby releasing norepinephrine into the neuronal synapses where it stimulates primarily alpha-adrenergic receptors. It also has weak direct agonist activity at alpha- and beta- adrenergic receptors. Receptor stimulation results in vasoconstriction and decreases nasal and sinus congestion.","Pseudoephedrine Sulfate | Afrin | Afrinol | Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alphaS)-,Sulfate (2:1) (salt) | D-Isoephedrine Sulfate | PSEUDOEPHEDRINE SULFATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0304430","Pseudoephedrine Hydrochloride","C29390","The hydrochloride salt form of pseudoephedrine, a phenethylamine and an diastereomer of ephedrine with sympathomimetic property. Pseudoephedrine hydrochloride displaces norepinephrine from storage vesicles in presynaptic neurones, thereby releasing norepinephrine into the neuronal synapses where it stimulates primarily alpha-adrenergic receptors. It also has weak direct agonist activity at alpha- and beta- adrenergic receptors. Receptor stimulation results in vasoconstriction and decreases nasal and sinus congestion.","Pseudoephedrine Hydrochloride | PSEUDOEPHEDRINE HYDROCHLORIDE | Pseudoephedrine.HCl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282321","Propranolol Hydrochloride","C29382","The hydrochloride form of propranolol, a synthetic beta-adrenergic receptor blocker with antianginal, antiarrhythmic, and antihypertensive properties. Propranolol competitively antagonizes beta-adrenergic receptors, thereby inhibiting beta-adrenergic reactions, such as vasodilation, and negative chronotropic and inotropic effects.","Propranolol Hydrochloride | 2-Propanol-1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy) Hydrochloride | Inderal | Innopran XL | PROPRANOLOL HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977618","Surgical Finding","C164341","A finding or observation that is made during surgery.","Surgical Finding | surgical finding | surgical_finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332850","Surgical Site","C164323","The anatomical site on which surgery was performed.","Surgical Site | PROCEDURE_SITE | anatomical site of surgery | anatomical_site_of_surgery",,,,,,,,,,,,,,,"4184327","Operative site",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0965129","Rosuvastatin","C66523","A statin with antilipidemic and potential antineoplastic activities. Rosuvastatin selectively and competitively binds to and inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a precursor of cholesterol. This leads to a decrease in hepatic cholesterol levels and increase in uptake of LDL cholesterol. In addition, rosuvastatin, like other statins, exhibits pro-apoptotic, growth inhibitory, and pro-differentiation activities in a variety of tumor cell types; these antineoplastic activities may be due, in part, to inhibition of the isoprenylation of Ras and Rho GTPases and related signaling cascades.","Rosuvastatin | ROSUVASTATIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035891","Roxithromycin","C818","A semi-synthetic derivative of the macrolide antibiotic erythromycin that includes an N-oxime side chain on the lactone ring, with antibacterial and anti-malarial activities. Roxithromycin binds to the subunit 50S of the bacterial ribosome, which inhibits bacterial protein synthesis and leads to inhibition of bacterial cell growth and replication.","Roxithromycin | (3R,4S,5S,6R,7R,9R,11S,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-d-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-10-(2-methoxyethoxymethoxyimino)-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecan-2-one | (9E)-Erythromycin, 9-[O-[(2-methoxyethoxy)methyl]oxime] | 9-(2',5'-Dioxahexyloxyimino)erythromycin | ROXITHROMYCIN | RU 28965 | RU 965 | Roxitromycine | Rulide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0289313","Rosiglitazone","C62076","An agent belonging to the glitazone class of antidiabetic agents with antihyperglycemic and anti-inflammatory activities. In addition to its selective affinity for peroxisome proliferator-activated receptor (PPAR) gamma and its ability to lower blood glucose levels, rosiglitazone also exerts anti-inflammatory activity through its ability to inhibit nuclear factor-kappaB (NF-KB) activity and increase I-kappaB levels. In addition, rosiglitazone may cause fluid retention and may worsen congestive heart failure. This agent is also associated with an increased risk of heart attacks.","Rosiglitazone | ROSIGLITAZONE | rosiglitazone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0304114","Rosemary Oil","C107360","The essential oil of Rosmarinus officinalis. Rosemary oil is used primarily for its aromatic properties.","Rosemary Oil | ROSEMARY OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0771826","Ropivacaine Hydrochloride","C52198","The hydrochloride salt of ropivacaine, a local anesthetic of the amide type with analgesic activity. Ropivacaine binds to voltage-gated sodium ion channels in the neuronal membrane, thereby preventing the permeability of sodium ions and resulting in a stabilization of the neuronal membrane and inhibition of depolarization; nerve impulse generation and propagation are blocked, resulting in a reversible loss of sensation.","Ropivacaine Hydrochloride | (S)-(-)-1-Propylpiperidine-2-carboxylic acid (2,6-dimethylphenyl)amide Hydrochloride Monohydrate | Naropin | ROPIVACAINE HYDROCHLORIDE | Ropivacaine Hydrochloride Monohydrate | S-(-)-1-propyl-2,6-pipecoloxylidide Hydrochloride Monohydrate | ropivacaine hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0771840","Ropinirole Hydrochloride","C47710","The hydrochloride salt form of ropinirole, a non-ergot dopamine agonist with antiparkinsonian property. Acting as a substitute for dopamine, ropinirole hydrochloride binds to and activates dopamine D2 and D3 receptors within the caudate putamen in the brain, thereby improving motor function.","Ropinirole Hydrochloride | 2(H)-Indol-2-one, 4-(2-(dipropylamino)ethyl)-1,3-dihydro-, Monohydrochloride | 4-(2-(Dipropylamino)ethyl)-2-indolinone Monohydrochloride | ROPINIROLE HYDROCHLORIDE | Requip | SK&F 101468-A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0762662","Rofecoxib","C1832","A synthetic, nonsteroidal derivative of phenyl-furanone with antiinflammatory, antipyretic and analgesic properties and potential antineoplastic properties.  Rofecoxib binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in an inhibition of the conversion of arachidonic acid to prostaglandins.  COX-related metabolic pathways may represent key regulators of cell proliferation and neo-angiogenesis. Some epithelial tumor cell types overexpress pro-angiogenic COX-2. (NCI04)","Rofecoxib | 4-[4'-(Methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone | MK 966 | ROFECOXIB | Vioxx | rofecoxib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0772420","Rizatriptan Benzoate","C47708","The benzoate salt form of rizatriptan, a member of the triptan class agents with anti-migraine property. Rizatriptan benzoate selectively binds to and activates serotonin (5-HT) 1B receptors expressed in intracranial arteries, and to 5-HT 1D receptors located on peripheral trigeminal sensory nerve terminals in the meninges and central terminals in brain stem sensory nuclei. Receptor binding results in constriction of cranial vessels and inhibition of nociceptive transmission, thereby providing relief of migraine headaches. Rizatriptan benzoate may also relief migraine headaches by inhibition of pro-inflammatory neuropeptide release.","Rizatriptan Benzoate | 1H-Indole-3-ethanamine, N,N-dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-, Monobenzoate | L 705,126 | Maxalt | RIZATRIPTAN BENZOATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0073393","Risperidone","C29416","A benzisoxazole derivative with antipsychotic property. Risperidone selectively antagonizes serotonin (5-HT) effects via cortical 5-HT2 receptor, and, to a lesser extent, competes with dopamine at the limbic dopamine D2 receptor. The antagonism leads to decreased psychotic effects, such as hallucinations and delusions. In addition, risperidone has low to moderate affinity for histamine H1, 5-HT1A, 5-HT1C, and 5-HT1D receptors, while it has weak affinity for dopamine D1 and haloperidol-sensitive sigma site receptors.","Risperidone | RISPERIDONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0073374","Rifaximin","C61926","An orally administered, semi-synthetic, nonsystemic antibiotic derived from rifamycin SV with antibacterial activity. Rifaximin binds to the beta-subunit of bacterial DNA-dependent RNA polymerase, inhibiting bacterial RNA synthesis and bacterial cell growth. As rifaximin is not well absorbed, its antibacterial activity is largely localized to the gastrointestinal tract.","Rifaximin | RIFAXIMIN | Xifaxan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4082558","Human Rho(D) Immune Globulin","C80832","A preparation of immunoglobulin G (IgG) antibodies against Rho(D) antigen (anti-RhD; anti-Rho(D); anti-Rhesus factor; anti-Rh; anti-D), manufactured from pools of human donor plasma containing anti-D, that can be used in the prevention of an immune response and suppression of Rhesus (Rh) immunization to Rho(D)-positive blood in people with an Rho(D)-negative blood type during pregnancy or transfusion with Rho(D)-positive red blood cells (RBCs). Upon intravenous or intramuscular administration, human Rho(D) immune globulin provides Rho(D) antibodies against Rho(D) antigens which suppresses Rh isoimmunization. By providing sufficient anti-Rho(D) antibodies, human anti-Rho(D) immune globulin accelerates the phagocytosis of Rho(D)-positive RBCs, which clears these RBCs from the circulation. This prevents the recognition of Rho(D)-positive RBCs by the immune system and the subsequent formation of anti-Rho(D) antibodies in individuals with Rh-negative blood after exposure to Rh-positive RBCs. This prevents the production of alloantibodies to paternally inherited RhD antigen expressed on fetal erythrocytes in Rho-negative mothers and prevents hemolytic diseases in newborns. Rho(D) immune globulin increases platelet counts and reduces bleeding in Rho-positive patients with immune thrombocytopenic purpura (ITP) by inhibiting autoantibody-mediated platelet clearance. A Rh-negative person can be exposed to Rh-positive blood through a mismatched blood transfusion or during pregnancy when the baby has the opposite blood type.","Human Rho(D) Immune Globulin | Anti-D Immunoglobulin  (Human) | Anti-Rh Immunoglobulins | HUMAN RHO(D) IMMUNE GLOBULIN | IgG Anti-D Antibodies | MICRhoGAM | Rh Immune Globulin | RhIG | Rho(D) Immune Globulin | Rho(D) immune globulin | RhoD Immune Globulin Human | RhoGAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0251132","Polycarbophil/Carbomer/Glycerin/Palm Oil Glyceride/Mineral Oil-containing Vaginal Moisturizer","C29414","A commercial combination preparation that contains an adhesive polycarbophil polymer, which is used for vaginal lubrication. Polycarbophil is an insoluble compound that absorbs water and, after topical administration, adheres to vaginal epithelial cells. As a result, it helps both moisturize vaginal tissue and relieve the discomfort that is associated with vaginal dryness.","Polycarbophil/Carbomer/Glycerin/Palm Oil Glyceride/Mineral Oil-containing Vaginal Moisturizer | Replens",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0246689","Repaglinide","C47703","A nonsulfonylurea insulin secretagogue belonging to the melgitinide class with hypoglycemic activity. Repaglinide is rapidly absorbed and has a rapid onset and short duration of action. This agent is metabolized in the liver by CYP2C8 and CYP3A4 and its metabolites are excreted in the bile. Repaglinide has a half-life of one hour.","Repaglinide | (+)-2-Ethoxy-alpha-(((S)-alpha-isobutyl-o-piperidinobenzyl)carbamoyl)-p-toluic Acid | AG-EE 623 ZW | Benzoic Acid, 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-,(S)- | Prandin | REPAGLINIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0771827","Remifentanil Hydrochloride","C47702","The hydrochloride salt form of remifentanil, a synthetic anilidopiperidine derivative and short-acting opiate agonist with analgesic and anesthetic properties. Remifentanil selectively binds to and activates the mu-opioid receptor, thereby producing analgesia, respiratory depression, miosis, reduced gastrointestinal motility, and euphoria.","Remifentanil Hydrochloride | 1-Piperidinepropanoic Acid, 4-(methoxycarbonyl)-4-((1-oxopropyl)phenylamino)-, Methyl Ester, Monohydrochloride | REMIFENTANIL HYDROCHLORIDE | Ultiva",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0723002","Mineral Oil/Petrolatum-containing Eye Ointment","C29413","A preparation of ophthalmic ointment containing mineral oil and white petrolatum that may be used to moisturize and relieve discomfort due to ocular dryness and irritation.","Mineral Oil/Petrolatum-containing Eye Ointment | Refresh Lacri-Lube | Refresh Lacri-Lube Eye Ointment | Refresh PM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1565316","Ramelteon","C66504","A synthetic melatonin analogue with hypnotic and circadian rhythm-modulating activities. Ramelteon binds to and activates melatonin receptors 1 and 2 in the suprachiasmatic nucleus (SCN) of the brain, thereby promoting the onset of sleep. Unlike the nonbenzodiazepine sedative hypnotics zolpidem and zaleplon, this agent does not activate GABA receptors and, so, produces no GABA receptor-mediated anxiolytic, myorelaxant, and amnesic effects.","Ramelteon | RAMELTEON | Rozerem | TAK-375",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936902","Therapeutic Ionizing Radiation to Head History","C157154","A record of an individual's history of exposure to ionizing radiation to the head.","Therapeutic Ionizing Radiation to Head History | History of Therapeutic Ionizing Radiation to Head",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449276","Extent of Resection","C157443","The degree to which the lesion has been cut out, or resected.","Extent of Resection | EXTRSCT | PROCEDURE_EXTENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639400","KPS Scale - Karnofsky Performance Status","C100417","Karnofsky Performance Status Scale (KPS Scale) Karnofsky Performance Status.","KPS Scale - Karnofsky Performance Status | KPSS01-Karnofsky Performance Status | KPSS0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525916","LPSS - Lansky Play-Performance Status","C138364","The Lansky Play-Performance Status Scale (LPSS) Lansky play-performance status.","LPSS - Lansky Play-Performance Status | LPPSS1-Lansky Play-Performance Status | LPPSS101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0886414","Body Temperature Measurement","C164325","The result of the measurement of the body temperature.","Body Temperature Measurement | Vital Signs – Body Temperature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979182","Complete Disagreement","C166157","A subjective answer of complete disagreement.","Complete Disagreement | Completely Disagree | Disagree Completely | Full Disagreement | Fully Disagree",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979191","Acute Oxaliplatin-Induced Peripheral Neuropathy Measure","C166144","A questionnaire for measuring the severity of neuropathy symptoms that a patient is experiencing following chemotherapy with oxaliplatin.","Acute Oxaliplatin-Induced Peripheral Neuropathy Measure | Acute OIPN Measure | OIPN | OIPN Measure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979192","Sensitivity to Touching Cold Items","C166145","A question about whether an individual experienced sensitivity to touching cold items.","Sensitivity to Touching Cold Items | Did you experience sensitivity to touching cold items within the last 24 hours | Experience Sensitivity to Touching Cold Items",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979193","Discomfort Swallowing Cold Liquids","C166146","A question about whether an individual experienced discomfort swallowing cold liquids.","Discomfort Swallowing Cold Liquids | Did you experience discomfort swallowing cold liquids within the last 24 hours | Experience Discomfort Swallowing Cold Liquids",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979194","Have Throat Discomfort","C166147","A question about whether an individual noticed any throat discomfort.","Have Throat Discomfort | Did you notice any throat discomfort within the last 24 hours | Notice Throat Discomfort;Throat Discomfort",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979200","Have Muscle Cramps","C166148","A question about whether an individual suffered from muscle cramps.","Have Muscle Cramps | Did you suffer from muscle cramps within the last 24 hours | Suffer Muscle Cramps",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979201","Difficulty Buttoning Shirt or Tying Shoelaces","C166149","A question about whether an individual had difficulties buttoning their shirt or tying their shoelaces.","Difficulty Buttoning Shirt or Tying Shoelaces | Did you have any difficulties buttoning your shirt or tying shoelaces within the last 24 hours",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979202","Experience Other Side Effects From Chemotherapy Treatment","C166150","A question about whether an individual experienced other side effects from chemotherapy treatment that was not mentioned.","Experience Other Side Effects From Chemotherapy Treatment | Did you experience any other side effects from the chemotherapy treatment that we did not mention | Experience Other Side Effects From Chemotherapy Treatment Not Mentioned",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936876","ERBB2 Amplification Status","C157249","A procedure used to detect amplifications involving all or part of the ERBB2 gene.","ERBB2 Amplification Status | ERBB2 / HER2 Amplification Status | ERBB2 Amplification Analysis | ERBB2/HER2 Amplification Status | Erb-B2 Receptor Tyrosine Kinase 2 Amplification Analysis | Erb-B2 Receptor Tyrosine Kinase Amplification Analysis | HER2 Amplification Analysis | HER2/neu Amplification Analysis | NEU Amplification Analysis | v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 Amplification Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978920","Shared Decision Making Questionnaire","C165686","A 9-item questionnaire that measures the extent to which patients are involved in the process of decision-making.","Shared Decision Making Questionnaire | SDM-Q-9 | Shared Decision Making Questionnaire (SDM-Q-9)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978929","Doctor Made Clear that a Decision Needs to be Made","C165687","A question about whether an individual's doctor made it clear that a decision needs to be made.","Doctor Made Clear that a Decision Needs to be Made | My doctor made clear that a decision needs to be made",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978930","Doctor Wanted to Know Exactly How I Want to be Involved in Making Decision","C165688","A question about whether an individual's doctor wanted to know exactly how they wanted to be involved in making the decision.","Doctor Wanted to Know Exactly How I Want to be Involved in Making Decision | My doctor wanted to know exactly how I want to be involved in making the decision",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978931","Doctor Told me That There are Different Options for Treating Medical Condition","C165689","A question about whether an individual's doctor told them that there are different options for treating their medical condition.","Doctor Told me That There are Different Options for Treating Medical Condition | My doctor told me that there are different options for treating my medical condition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978932","Doctor Precisely Explained Advantages and Disadvantages of Treatment Options","C165690","A question about whether an individual's doctor explained the advantages and disadvantages of the treatment options.","Doctor Precisely Explained Advantages and Disadvantages of Treatment Options | My doctor precisely explained the advantages and disadvantages of the treatment options",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978925","Doctor Helped Me Understand All Information","C165691","A question about whether an individual's doctor helped them understand all the information.","Doctor Helped Me Understand All Information | My doctor helped me understand all the information",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978926","Doctor Asked Which Treatment Option I Prefer","C165692","A question about whether an individual's doctor asked them which treatment option they prefer.","Doctor Asked Which Treatment Option I Prefer | My doctor asked me which treatment option I prefer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978927","Doctor and I Thoroughly Weighed Different Treatment Options","C165693","A question about whether an individual and their doctor thoroughly weighed the different treatment options.","Doctor and I Thoroughly Weighed Different Treatment Options | My doctor and I thoroughly weighed the different treatment options",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978928","Doctor and I Selected Treatment Option Together","C165694","A question about whether an individual and their doctor selected a treatment option together.","Doctor and I Selected Treatment Option Together | My doctor and I selected a treatment option together",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978907","Doctor and I Reached Agreement on how to Proceed","C165695","A question about whether an individual and their doctor reached agreement on how to proceed.","Doctor and I Reached Agreement on how to Proceed | My doctor and I reached an agreement on how to proceed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985881","Study Registration Date","C93681","The date (and time) the subject has been registered to the study.","Study Registration Date | date of registration | date_of_registration | registrationDate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541881","Device Identifiers Domain","C102618","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to device identifiers.","Device Identifiers Domain | DI | Device Identifiers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829140","Medical Device Model Family","C101686","A grouping of medical devices based upon model name or number.","Medical Device Model Family | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541240","Device Events Domain","C102616","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to device events.","Device Events Domain | DE | Device Events",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828075","Suboptimal Image Reason","C86975","An image of inferior quality, may still be adequate to make a diagnosis.","Suboptimal Image Reason | Suboptimal Image",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971438","Neurotoxic Chemotherapy","C166178","Chemotherapy that causes damage to the nervous system.","Neurotoxic Chemotherapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971472","Do Not Own Smartphone or Tablet","C166211","A response indicating that an individual does not own a smartphone or tablet.","Do Not Own Smartphone or Tablet | I do not own a smartphone/tablet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971471","Have Concerns About Data Privacy or Security with the App","C166212","A response indicating that an individual has concerns about data privacy or security with the app.","Have Concerns About Data Privacy or Security with the App | I have concerns about data privacy/security with the app",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971474","Do Not Want to Download Apps to Personal Smartphone or Tablet for the Trial","C166213","A response indicating that an individual does not want to download apps to their personal smartphone or tablet for the trial.","Do Not Want to Download Apps to Personal Smartphone or Tablet for the Trial | I do not want to download apps to my personal smartphone/tablet for the trial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971473","Do Not Have Wi-Fi and/or Have Concerns with Having Reliable Internet Connection","C166214","A response indicating that an individual does not have a Wi-Fi connection and/or has concerns with using a reliable internet connection.","Do Not Have Wi-Fi and/or Have Concerns with Having Reliable Internet Connection | I do not have a Wi-Fi connection and/or have concerns with using reliable internet connection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971264","Have Concerns About Data Usage and/or no Data Plan","C166215","A response indicating that an individual has concerns about data usage and/or no data plan.","Have Concerns About Data Usage and/or no Data Plan | I have concerns about data usage and/or no data plan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971263","Uncomfortable and/or Unfamiliar with Technology","C166216","A response indicating that an individual is uncomfortable and/or unfamiliar with technology.","Uncomfortable and/or Unfamiliar with Technology | I am uncomfortable and/or unfamiliar with technology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971266","Have Difficulties Using Smartphones or Tablets","C166217","A response indicating that an individual has difficulties using smartphones or tablets.","Have Difficulties Using Smartphones or Tablets | I have difficulties using smartphones/tablets (seeing information on the screen, using a touch screen, etc.)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332755","CHGB Gene","C21201","Encodes Chromogranin B, a tyrosine-sulfated secretory protein found in a wide variety of peptidergic endocrine cells.  Chromogranin functions as a neuroendocrine secretory granule protein which may be the precursor for other biologically active peptides. (LocusLink)","CHGB Gene | CHGB | Chromogranin B (Secretogranin 1) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4013456","Angle Closure Glaucoma","C34639","The sudden increase of intraocular pressure, resulting in pain and an abrupt decrease in visual acuity.","Angle Closure Glaucoma | Closed Angle Glaucoma | Narrow Angle Glaucoma | Primary Angle Closure Glaucoma",,,,,,,,,,,,,,,"4191001","Angle-closure glaucoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL973018","Offer","C166358","To provide or supply something, such as a product or service.","Offer | Offered | Offering",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971620","Jelliffe Equation for Creatinine Clearance","C166364","A formula for evaluating renal function for adults with normal muscle mass and Scr less than 5 mg/dL. For males: 98 - 0.8 (A - 20) / Scr; for females: 88 - 0.7 (A - 20) / Scr; where A = age in yrs; CLcr = creatinine clearance in mL/min/1.73 m^2","Jelliffe Equation for Creatinine Clearance | Jelliffe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971619","Sanaka Equation for Creatinine Clearance","C166367","A formula to predict creatinine clearance (CCr, ml/min) in the elderly with chronic muscle atrophy using serum albumin (Alb, g/dl). For males: ABW (19 Alb +32) / 100 Scr; for females: ABW (13 Alb +29) / 100 Scr; where: Alb = plasma albumin level (g/dL); Scr = serum creatinine (mg/dL); ABW = actual body weight in Kg","Sanaka Equation for Creatinine Clearance | Sanaka",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971622","Cockcroft-Gault Formula Utilizing Adjusted Body Weight","C166368","A variation of the Cockcroft-Gault formula to predict creatinine clearance that uses an adjusted body weight.","Cockcroft-Gault Formula Utilizing Adjusted Body Weight | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971621","Cockcroft-Gault Formula Utilizing Ideal Body Weight","C166369","A variation of the Cockcroft-Gault formula to predict creatinine clearance that uses an idealized body weight. For males, ideal body weight=50 kg + 2.3 kg for each inch over 5 feet; for females, 45.5 kg + 2.3 kg for each inch over 5 feet.","Cockcroft-Gault Formula Utilizing Ideal Body Weight | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971624","Cockcroft-Gault Formula Utilizing Total Body Weight","C166370","A variation of the Cockcroft-Gault formula to predict creatinine clearance that uses total body weight.","Cockcroft-Gault Formula Utilizing Total Body Weight | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971614","Lapatinib/Temozolomide Regimen","C166359","A regimen consisting of lapatinib and temozolomide that can be used for the treatment of recurrent ependymoma.","Lapatinib/Temozolomide Regimen | Lapatinib-Temozolomide | Lapatinib-Temozolomide Regimen | Lapatinib/Temozolomide | Temozolomide-Lapatinib | Temozolomide/Lapatinib | Temozolomide/Lapatinib Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969522","Bevacizumab/Carboplatin Regimen","C160527","A regimen consisting of bevacizumab and carboplatin that can be used for the treatment of recurrent malignant glioma.","Bevacizumab/Carboplatin Regimen | Bevacizumab-Carboplatin | Bevacizumab-Carboplatin Regimen | Bevacizumab/Carboplatin | Carboplatin and Bevacizumab | Carboplatin and Bevacizumab-adcd | Carboplatin and Bevacizumab-awwb | Carboplatin and Bevacizumab-aybi | Carboplatin and Bevacizumab-bvzr | Carboplatin and Bevacizumab-equi | Carboplatin and Bevacizumab-maly | Carboplatin and Bevacizumab-onbe | Carboplatin and Bevacizumab-tnjn | Carboplatin-Bevacizumab | Carboplatin/Bevacizumab | Carboplatin/Bevacizumab Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969523","Bevacizumab/Lomustine Regimen","C160526","A regimen consisting of bevacizumab and lomustine that can be used for the treatment of certain central nervous system (CNS) cancers including oligodendroglioma, astrocytoma, glioblastoma (GBM) and gliosarcoma.","Bevacizumab/Lomustine Regimen | Bevacizumab-Lomustine | Bevacizumab/Lomustine | Lomustine and Bevacizumab | Lomustine and Bevacizumab-adcd | Lomustine and Bevacizumab-awwb | Lomustine and Bevacizumab-aybi | Lomustine and Bevacizumab-bvzr | Lomustine and Bevacizumab-equi | Lomustine and Bevacizumab-maly | Lomustine and Bevacizumab-onbe | Lomustine and Bevacizumab-tnjn | Lomustine-Bevacizumab | Lomustine/Bevacizumab | Lomustine/Bevacizumab Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280558","cisplatin/cyclophosphamide/etoposide/vincristine protocol","C9714","A regimen consisting of cyclophosphamide, vincristine, cisplatin, and etoposide that may be used in the treatment of small cell lung cancer (SCLC).","COPE Regimen | CDDP/CTX/VCR/VP-16 | COPE | Cisplatin/Cyclophosphamide/Etoposide/Vincristine | Cyclophosphamide-Vincristine-Cisplatin-Etoposide | Cyclophosphamide/Oncovin/Platinol/Etoposide | Cyclophosphamide/Vincristine/Cisplatin/Etoposide | Cyclophosphamide/Vincristine/Cisplatin/Etoposide Regimen | EPOC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502607","anti-IL-8 monoclonal antibody HuMax-IL8","C124227","A human monoclonal antibody against the pro-inflammatory mediator interleukin-8 (IL-8; CXCL8), with potential antineoplastic activities. Upon administration, adakitug directly binds to IL-8, thereby inhibiting the binding of IL-8 to its receptors CXCR1 and CXCR2. This inhibits activation of IL-8-mediated signaling transduction pathways, which decreases proliferation of susceptible tumor cells. Also, BMS-986253 effectively blocks binding of IL-8 to neutrophils and inhibits neutrophil activation and recruitment towards sites of inflammation, which reduces inflammation. IL-8, a member of the CXC chemokine family, is upregulated in a variety of cancer cell types and inflammatory diseases; it plays a key role in tumor cell proliferation, endothelial cell proliferation, and cancer stem cell (CSC) renewal.","Adakitug | ADAKITUG | Anti-IL-8 Monoclonal Antibody BMS-986253 | Anti-IL-8 Monoclonal Antibody BMS-986253 | Anti-IL-8 Monoclonal Antibody HuMax-IL8 | BMS 986253 | BMS-986253 | BMS986253 | HUMAX-IL8 | HuMax-IL-8 | HuMax-IL8 | MDX 018 | MDX-018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473930","Brachyury-expressing Modified Vaccinia Ankara-TRICOM Vaccine","C116777","A cancer vaccine composed of a replication-deficient, attenuated derivative of the vaccinia virus strain Ankara expressing both a CD8+ T-cell epitope from the brachyury protein and a triad of T-cell co-stimulatory molecules (MVA Brachyury-TRICOM), with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration of the brachyury-expressing modified vaccinia Ankara (MVA)-TRICOM vaccine, the expressed brachyury protein induces specific CD8+ and CD4+ T-cell responses against brachyury-expressing tumor cells. This causes both tumor cell lysis and a decrease in the growth of brachyury-expressing tumor cells. Brachyury, a member of the T-box family of transcription factors that is overexpressed in numerous cancer cell types, is correlated with increased epithelial-mesenchymal transition (EMT), cancer resistance and cancer progression. TRICOM, a triad of three human T-cell co-stimulatory molecules, B7.1, ICAM-1 and LFA-3, enhances antigen-specific T-cell activation.","Brachyury-expressing Modified Vaccinia Ankara-TRICOM Vaccine | MVA Brachyury-TRICOM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514261","BXQ-350 Nanovesicle Formulation","C131491","A stable, nanovesicle formulation composed of a synthetic form of the human glycoprotein saposin C (SapC) linked to the phospholipid dioleoylphosphatidylserine (DOPS), with potential antineoplastic activity. Upon intravenous administration, the BXQ-350 nanovesicle formulation selectively targets and preferentially accumulates in tumor vessels and cells, due to the leaky nature of tumor vasculature and the presence of phosphatidylserine (PS) lipids in tumor cell membranes. Upon binding to the phospholipids in the tumor cell membrane, SapC fuses with the membrane and is internalized leading to its accumulation within the internal membrane. SapC becomes active in the acidic tumor microenvironment and as a lysosomal sphingolipid activator protein, activates lysosomal enzymes, such as beta-glucosidase, acid sphingomyelinase, and beta-galactosylceramidase. This leads to the degradation of glucosylceramide and sphingomyelin, and the conversion of galactosylceramide to ceramide, respectively. This elevates intracellular ceramide levels, activates caspases and induces ceramide-mediated apoptosis, which together lead to an inhibition of tumor cell growth. SapC plays key roles in lipid transport and organization of biological membranes and has strong lipid membrane binding activity.","BXQ-350 Nanovesicle Formulation | BXQ-350 | SAPOSIN C (NON-GLYCOSYLATED) | SapC-DOPS Nanovesicles | Saposin C-Dioleoylphosphatidylserine Complexes | Saposin C-Dioleoylphosphatidylserine Nanovesicles",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540681","Device-In-Use Domain","C102622","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to device-in-use.","Device-In-Use Domain | DU | Device In-Use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986845","Scanner Patient Bed","C95011","A scanner's narrow horizontal platform on which the subject lies to be moved axially within the gantry in order to position appropriate subject sections within the scanner's field of view.","Scanner Patient Bed | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704435","Test Dosing Unit","C48545","A dosing unit equal to the amount of active ingredient(s) needed to assess or examine the (potency of the) substance being used.","Test Dosing Unit | TEST | Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272486","p16-Positive Neoplastic Cells Present","C95990","An immunohistochemical test result indicating that there are neoplastic cells stained positive with the p16 INK4a monoclonal antibody.","p16-Positive Neoplastic Cells Present | p16 INK4a-Positive Neoplastic Cells Present | p16 Positive Neoplastic Cells Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971648","Sub-Specimen Identifier","C166394","A unique alphanumeric identifier assigned to a discrete part of a specimen, such as an individual tube from a multi-tube blood draw.","Sub-Specimen Identifier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972940","Inclusive","C166400","Including the stated limits.","Inclusive | Including",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937183","Chromosome Arm 1p Loss of Heterozygosity","C157626","A molecular abnormality that results in monoallelic loss of function mutations located within the short arm of chromosome 1 (1p).","Chromosome Arm 1p Loss of Heterozygosity | 1p LOH | 1p Loss of Heterozygosity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971658","Chromosome Arm 19q Loss of Heterozygosity","C166408","A molecular abnormality that results in monoallelic loss of function mutations located within the long arm of chromosome 19 (19q).","Chromosome Arm 19q Loss of Heterozygosity | 19q LOH | 19q Loss of Heterozygosity | Chromosome 19q Loss of Heterozygosity | Chromosome Arm 9q Loss of Heterozygosity ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971659","Cyclin Gene Mutation","C166407","A change in the nucleotide sequence in a cyclin family gene.","Cyclin Gene Mutation | CCNx Gene Mutation | Cyclin Gene Family Mutation | Cyclin Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971056","Additional Surgery for New Tumor Event Not Evaluated","C162603","The need for additional surgery for a new tumor event was not evaluated.","Additional Surgery for New Tumor Event Not Evaluated | Not-Evaluated: Not provided or available",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968913","Unknown Outcome","C159895","The outcome is unknown.","Unknown Outcome | Unknown: Could not be determined or unsure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968912","Not Applicable Outcome","C159896","The outcome is not applicable.","Not Applicable Outcome | Not Applicable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951575","Other Site of New Tumor Event","C159572","The site of the new tumor event was identified in the study but is not present in the form.","Other Site of New Tumor Event | Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969108","Unknown Site of New Tumor Event","C160156","The site of the new tumor event is unknown.","Unknown Site of New Tumor Event | Unknown | Unknown: Could not be determined or unsure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968948","Treatment Regimen #1","C159874","The first treatment regimen.","Treatment Regimen #1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968959","Treatment Regimen #2","C159875","The second treatment regimen.","Treatment Regimen #2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968958","Treatment Regimen #3","C159876","The third treatment regimen.","Treatment Regimen #3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968957","Treatment Regimen #4","C159877","The fourth treatment regimen.","Treatment Regimen #4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968956","Treatment Regimen #5","C159878","The fifth treatment regimen.","Treatment Regimen #5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0746919","No Therapy","C157513","An indication that no therapy was done or administered.","No Therapy | No Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951685","RECIST Progressive Disease","C159716","At lease a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.","RECIST Progressive Disease | Progressive Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951684","RECIST Complete Response","C159715","Disappearance of all target lesions.","RECIST Complete Response | Complete Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951385","RECIST Partial Response","C159547","At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter.","RECIST Partial Response | Partial Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951384","RECIST Stable Disease","C159546","Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter since start of treatment.","RECIST Stable Disease | Stable Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972043","Disease Risk Index for Allogeneic Stem Cell Transplantation","C167051","A tool designed to assign allogeneic hematopoietic cell transplantation patients into one of four overall survival (OS) risk groups based on disease type and disease status at the time of transplantation. This index applies regardless of age, conditioning regimen, donor type, and graft source.","Disease Risk Index for Allogeneic Stem Cell Transplantation | DRI | Disease Risk Index | Disease Risk Index (DRI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973043","Disease Risk Index Low Risk","C167052","A Disease Risk Index category corresponding to low disease risk and low stage risk.","Disease Risk Index Low Risk | DRI Low Risk | Low Risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972045","Disease Risk Index Intermediate Risk","C167053","A Disease Risk Index category corresponding to low disease risk and high stage risk.","Disease Risk Index Intermediate Risk | DRI Intermediate Risk | Intermediate Risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972046","Disease Risk Index High Risk","C167054","A Disease Risk Index category corresponding to intermediate disease risk and high stage risk.","Disease Risk Index High Risk | DRI High Risk | High Risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL962354","Disease Risk Index Very High Risk","C167055","A Disease Risk Index category corresponding to high disease risk and high stage risk.","Disease Risk Index Very High Risk | DRI Very High Risk | Very High Risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517478","Gene Abnormality","C36327","A variation in or modification of the nucleic acid sequence of a gene that can alter its expression and may result in either a congenital disorder or the clinical presentation of a disease.","Gene Abnormality | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335962","Signaling Protein","C18515","Proteins or peptides that participate in signal transduction processes in the cell.","Signaling Protein | Signaling Pathway Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826886","CDISC SDTM Device Identifier Parameter Short Name Terminology","C106481","Terminology associated with the device identifier short name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Device Identifier Parameter Short Name Terminology | DIPARMCD | Device Identifier Short Name | SDTM-DIPARMCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827938","Stereotactic Surgery Frame Type","C106570","The type or classification of the cage structure used to immobilize the head or other body part in preparation for stereotactic surgery.","Stereotactic Surgery Frame Type | SFMTYP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830329","Electrical Lead Locking Type","C111191","The type of locking device used to securely fasten the electrical leads to the device.","Electrical Lead Locking Type | SECURLD | Secure Lead Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0073385","Lactated Ringer's Solution","C65149","No Value Exists","Lactated Ringer Solution | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0530105","Cisatracurium Besylate","C47451","The besylate salt form of cisatracurium, a non-depolarizing skeletal muscle relaxant of the benzylisoquinolinium class, with skeletal muscle relaxing activity. Cisatracurium besylate acts as a competitive acetylcholine antagonist that binds to nicotinic receptors at the neuromuscular junction. This blocks neuromuscular transmission and causes neuromuscular relaxation.","Cisatracurium Besylate | (1R,2R)-2-(2-Carboxyethyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-veratrylisoquinolinium Benzenesulfonate, Pentamethylene Ester | 51W89 | Atracurium besylate 1R-cis,1R'-cis form | CISATRACURIUM BESYLATE | Nimbex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0245109","Anakinra","C38717","A recombinant human nonglycosylated interleukin-1 (IL-1) receptor antagonist with potential antineoplastic activity. Anakinra binds to the IL-1 receptor, thereby blocking the binding of the IL-1 to and activation of its receptor. Blockade of IL-1 activity may inhibit the cascade of downstream pro-angiogenic factors such as vascular endothelial cell growth factor, tumor necrosis factor-alpha, and IL-6, resulting in inhibition of tumor angiogenesis. (NCI04)","Anakinra | ANAKINRA | Kinaret | Kineret | anakinra | rIL-1ra | rIL1RN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972399","Vacutainer with K2EDTA","C167172","An evacuated blood collection tube containing K2-EDTA, designed to work as an anti-coagulant.","Vacutainer with K2EDTA | Blood Collection Tube with K2EDTA | K2-EDTA Tube",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280138","cytarabine/hydrocortisone/methotrexate protocol","C10201","A regimen consisting of cytarabine, hydrocortisone, and methotrexate that may be used in the treatment and prevention of central nervous system (CNS) involvement in leukemias and lymphomas, including acute promyelocytic leukemia (APL), diffuse large B-cell lymphoma (DLBCL), and acute lymphoblastic leukemia (ALL).","Cytarabine/Hydrocortisone/Methotrexate Regimen | ARA-C/HC/MTX | Cytarabine-Hydrocortisone-Methotrexate | Cytarabine/Hydrocortisone/Methotrexate | MHA | TIT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4068538","Dose Administered","C167190","A quantity of an agent given to an individual at one time.","Dose Administered | Agent Administration Dose | Dosage | Dose Delivered | Medication Dosage | medication actual dose | medication_actual_dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972388","FLT3 NP_004110.2:p.A690V","C167159","A change in the amino acid residue at position 680 in the receptor-type tyrosine-protein kinase FLT3 protein where alanine has been replaced by valine.","FLT3 NP_004110.2:p.A690V | A690V | CD135 Antigen A690V | CD135 Antigen Ala690Val | FLT3 A690V | FLT3 Ala690Val | FLT3 NP_004110.2:p.Ala690Val | FLT3 p.A690V | FLT3 p.Ala690Val | Fetal Liver Kinase-2 A690V | Fetal Liver Kinase-2 Ala690Val | Flt-3 Receptor A690V | Flt-3 Receptor Ala690Val | Fms-Related Tyrosine Kinase 3 A690V | Fms-Related Tyrosine Kinase 3 Ala690Val | NP_004110.2:p.A690V | NP_004110.2:p.Ala690Val | Receptor-Type Tyrosine-Protein Kinase FLT3 A690V | Receptor-Type Tyrosine-Protein Kinase FLT3 Ala690Val | Stem Cell Tyrosine Kinase 1 A690V | Stem Cell Tyrosine Kinase 1 Ala690Val",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972390","FLT3 NP_004110.2:p.D839E","C167161","A change in the amino acid residue at position 839 in the receptor-type tyrosine-protein kinase FLT3 protein where aspartic acid has been replaced by glutamic acid.","FLT3 NP_004110.2:p.D839E | CD135 Antigen Asp839Glu | CD135 Antigen D839E | D839E | FLT3 Asp839Glu | FLT3 D839E | FLT3 NP_004110.2:p.Asp839Glu | FLT3 p.Asp839Glu | FLT3 p.D839E | Fetal Liver Kinase-2 Asp839Glu | Fetal Liver Kinase-2 D839E | Flt-3 Receptor Asp839Glu | Flt-3 Receptor D839E | Fms-Related Tyrosine Kinase 3 Asp839Glu | Fms-Related Tyrosine Kinase 3 D839E | NP_004110.2:p.Asp839Glu | NP_004110.2:p.D839E | Receptor-Type Tyrosine-Protein Kinase FLT3 Asp839Glu | Receptor-Type Tyrosine-Protein Kinase FLT3 D839E | Stem Cell Tyrosine Kinase 1 Asp839Glu | Stem Cell Tyrosine Kinase 1 D839E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972392","FLT3 NP_004110.2:p.D839G","C167163","A change in the amino acid residue at position 839 in the receptor-type tyrosine-protein kinase FLT3 protein where aspartic acid has been replaced by glycine.","FLT3 NP_004110.2:p.D839G | CD135 Antigen Asp839Gly | CD135 Antigen D839G | D839G | FLT3 Asp839Gly | FLT3 D839G | FLT3 NP_004110.2:p.Asp839Gly | FLT3 p.Asp839Gly | FLT3 p.D839G | Fetal Liver Kinase-2 Asp839Gly | Fetal Liver Kinase-2 D839G | Flt-3 Receptor Asp839Gly | Flt-3 Receptor D839G | Fms-Related Tyrosine Kinase 3 Asp839Gly | Fms-Related Tyrosine Kinase 3 D839G | NP_004110.2:p.Asp839Gly | NP_004110.2:p.D839G | Receptor-Type Tyrosine-Protein Kinase FLT3 Asp839Gly | Receptor-Type Tyrosine-Protein Kinase FLT3 D839G | Stem Cell Tyrosine Kinase 1 Asp839Gly | Stem Cell Tyrosine Kinase 1 D839G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972391","FLT3 NP_004110.2:p.F594Y","C167164","A change in the amino acid residue at position 594 in the receptor-type tyrosine-protein kinase FLT3 protein where phenylalanine has been replaced by tyrosine.","FLT3 NP_004110.2:p.F594Y | CD135 Antigen F594Y | CD135 Antigen Phe594Tyr | F594Y | FLT3 F594Y | FLT3 NP_004110.2:p.Phe594Tyr | FLT3 Phe594Tyr | FLT3 p.F594Y | FLT3 p.Phe594Tyr | Fetal Liver Kinase-2 F594Y | Fetal Liver Kinase-2 Phe594Tyr | Flt-3 Receptor F594Y | Flt-3 Receptor Phe594Tyr | Fms-Related Tyrosine Kinase 3 F594Y | Fms-Related Tyrosine Kinase 3 Phe594Tyr | NP_004110.2:p.F594Y | NP_004110.2:p.Phe594Tyr | Receptor-Type Tyrosine-Protein Kinase FLT3 F594Y | Receptor-Type Tyrosine-Protein Kinase FLT3 Phe594Tyr | Stem Cell Tyrosine Kinase 1 F594Y | Stem Cell Tyrosine Kinase 1 Phe594Tyr",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972394","FLT3 NP_004110.2:p.F594C","C167165","A change in the amino acid residue at position 594 in the receptor-type tyrosine-protein kinase FLT3 protein where phenylalanine has been replaced by cysteine.","FLT3 NP_004110.2:p.F594C | CD135 Antigen F594C | CD135 Antigen Phe594Cys | F594C | FLT3 F594C | FLT3 NP_004110.2:p.Phe594Cys | FLT3 Phe594Cys | FLT3 p.F594C | FLT3 p.Phe594Cys | Fetal Liver Kinase-2 F594C | Fetal Liver Kinase-2 Phe594Cys | Flt-3 Receptor F594C | Flt-3 Receptor Phe594Cys | Fms-Related Tyrosine Kinase 3 F594C | Fms-Related Tyrosine Kinase 3 Phe594Cys | NP_004110.2:p.F594C | NP_004110.2:p.Phe594Cys | Receptor-Type Tyrosine-Protein Kinase FLT3 F594C | Receptor-Type Tyrosine-Protein Kinase FLT3 Phe594Cys | Stem Cell Tyrosine Kinase 1 F594C | Stem Cell Tyrosine Kinase 1 Phe594Cys",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972396","FLT3 NP_004110.2:p.L576R","C167167","A change in the amino acid residue at position 576 in the receptor-type tyrosine-protein kinase FLT3 protein where leucine has been replaced by arginine.","FLT3 NP_004110.2:p.L576R | CD135 Antigen L576R | CD135 Antigen Leu576Arg | FLT3 L576R | FLT3 Leu576Arg | FLT3 NP_004110.2:p.Leu576Arg | FLT3 p.L576R | FLT3 p.Leu576Arg | Fetal Liver Kinase-2 L576R | Fetal Liver Kinase-2 Leu576Arg | Flt-3 Receptor L576R | Flt-3 Receptor Leu576Arg | Fms-Related Tyrosine Kinase 3 L576R | Fms-Related Tyrosine Kinase 3 Leu576Arg | L576R | NP_004110.2:p.L576R | NP_004110.2:p.Leu576Arg | Receptor-Type Tyrosine-Protein Kinase FLT3 L576R | Receptor-Type Tyrosine-Protein Kinase FLT3 Leu576Arg | Stem Cell Tyrosine Kinase 1 L576R | Stem Cell Tyrosine Kinase 1 Leu576Arg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972403","FLT3 NP_004110.2:p.N676K","C167176","A change in the amino acid residue at position 676 in the receptor-type tyrosine-protein kinase FLT3 protein where asparagine has been replaced by lysine.","FLT3 NP_004110.2:p.N676K | CD135 Antigen Asn676Lys | CD135 Antigen N676K | FLT3 Asn676Lys | FLT3 N676K | FLT3 NP_004110.2:p.Asn676Lys | FLT3 p.Asn676Lys | FLT3 p.N676K | Fetal Liver Kinase-2 Asn676Lys | Fetal Liver Kinase-2 N676K | Flt-3 Receptor Asn676Lys | Flt-3 Receptor N676K | Fms-Related Tyrosine Kinase 3 Asn676Lys | Fms-Related Tyrosine Kinase 3 N676K | N676K | NP_004110.2:p.Asn676Lys | NP_004110.2:p.N676K | Receptor-Type Tyrosine-Protein Kinase FLT3 Asn676Lys | Receptor-Type Tyrosine-Protein Kinase FLT3 N676K | Stem Cell Tyrosine Kinase 1 Asn676Lys | Stem Cell Tyrosine Kinase 1 N676K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972405","FLT3 NP_004110.2:p.N676S","C167178","A change in the amino acid residue at position 676 in the receptor-type tyrosine-protein kinase FLT3 protein where asparagine has been replaced by serine.","FLT3 NP_004110.2:p.N676S | CD135 Antigen Asn676Ser | CD135 Antigen N676S | FLT3 Asn676Ser | FLT3 N676S | FLT3 NP_004110.2:p.Asn676Ser | FLT3 p.Asn676Ser | FLT3 p.N676S | Fetal Liver Kinase-2 Asn676Ser | Fetal Liver Kinase-2 N676S | Flt-3 Receptor Asn676Ser | Flt-3 Receptor N676S | Fms-Related Tyrosine Kinase 3 Asn676Ser | Fms-Related Tyrosine Kinase 3 N676S | N676S | NP_004110.2:p.Asn676Ser | NP_004110.2:p.N676S | Receptor-Type Tyrosine-Protein Kinase FLT3 Asn676Ser | Receptor-Type Tyrosine-Protein Kinase FLT3 N676S | Stem Cell Tyrosine Kinase 1 Asn676Ser | Stem Cell Tyrosine Kinase 1 N676S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972407","FLT3 NP_004110.2:p.N841X","C167180","A change in the amino acid residue at position 841 in the receptor-type tyrosine-protein kinase FLT3 protein where asparagine has been replaced by another amino acid.","FLT3 NP_004110.2:p.N841X | CD135 Antigen Asn841Xxx | CD135 Antigen N841X | FLT3 Asn841Xxx | FLT3 N841 Mutation | FLT3 N841X | FLT3 NP_004110.2:p.Asn841Xxx | FLT3 p.Asn841Xxx | FLT3 p.N841X | Fetal Liver Kinase-2 Asn841Xxx | Fetal Liver Kinase-2 N841X | Flt-3 Receptor Asn841Xxx | Flt-3 Receptor N841X | Fms-Related Tyrosine Kinase 3 Asn841Xxx | Fms-Related Tyrosine Kinase 3 N841X | N841 | N841X | NP_004110.2:p.Asn841Xxx | NP_004110.2:p.N841X | Receptor-Type Tyrosine-Protein Kinase FLT3 Asn841Xxx | Receptor-Type Tyrosine-Protein Kinase FLT3 N841X | Stem Cell Tyrosine Kinase 1 Asn841Xxx | Stem Cell Tyrosine Kinase 1 N841X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972409","FLT3 NP_004110.2:p.V592A","C167182","A change in the amino acid residue at position 592 in the receptor-type tyrosine-protein kinase FLT3 protein where valine has been replaced by alanine.","FLT3 NP_004110.2:p.V592A | CD135 Antigen V592A | CD135 Antigen Val592Ala | FLT3 NP_004110.2:p.Val592Ala | FLT3 V592A | FLT3 Val592Ala | FLT3 p.V592A | FLT3 p.Val592Ala | Fetal Liver Kinase-2 V592A | Fetal Liver Kinase-2 Val592Ala | Flt-3 Receptor V592A | Flt-3 Receptor Val592Ala | Fms-Related Tyrosine Kinase 3 V592A | Fms-Related Tyrosine Kinase 3 Val592Ala | NP_004110.2:p.V592A | NP_004110.2:p.Val592Ala | Receptor-Type Tyrosine-Protein Kinase FLT3 V592A | Receptor-Type Tyrosine-Protein Kinase FLT3 Val592Ala | Stem Cell Tyrosine Kinase 1 V592A | Stem Cell Tyrosine Kinase 1 Val592Ala | V592A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972411","FLT3 NP_004110.2:p.V592G","C167184","A change in the amino acid residue at position 592 in the receptor-type tyrosine-protein kinase FLT3 protein where valine has been replaced by glycine.","FLT3 NP_004110.2:p.V592G | CD135 Antigen V592G | CD135 Antigen Val592Gly | FLT3 NP_004110.2:p.Val592Gly | FLT3 V592G | FLT3 Val592Gly | FLT3 p.V592G | FLT3 p.Val592Gly | Fetal Liver Kinase-2 V592G | Fetal Liver Kinase-2 Val592Gly | Flt-3 Receptor V592G | Flt-3 Receptor Val592Gly | Fms-Related Tyrosine Kinase 3 V592G | Fms-Related Tyrosine Kinase 3 Val592Gly | NP_004110.2:p.V592G | NP_004110.2:p.Val592Gly | Receptor-Type Tyrosine-Protein Kinase FLT3 V592G | Receptor-Type Tyrosine-Protein Kinase FLT3 Val592Gly | Stem Cell Tyrosine Kinase 1 V592G | Stem Cell Tyrosine Kinase 1 Val592Gly | V592A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972413","FLT3 NP_004110.2:p.Y599C","C167186","A change in the amino acid residue at position 599 in the receptor-type tyrosine-protein kinase FLT3 protein where tyrosine has been replaced by cysteine.","FLT3 NP_004110.2:p.Y599C | CD135 Antigen Tyr599Cys | CD135 Antigen Y599C | FLT3 NP_004110.2:p.Tyr599Cys | FLT3 Tyr599Cys | FLT3 Y599C | FLT3 p.Tyr599Cys | FLT3 p.Y599C | Fetal Liver Kinase-2 Tyr599Cys | Fetal Liver Kinase-2 Y599C | Flt-3 Receptor Tyr599Cys | Flt-3 Receptor Y599C | Fms-Related Tyrosine Kinase 3 Tyr599Cys | Fms-Related Tyrosine Kinase 3 Y599C | NP_004110.2:p.Tyr599Cys | NP_004110.2:p.Y599C | Receptor-Type Tyrosine-Protein Kinase FLT3 Tyr599Cys | Receptor-Type Tyrosine-Protein Kinase FLT3 Y599C | Stem Cell Tyrosine Kinase 1 Tyr599Cys | Stem Cell Tyrosine Kinase 1 Y599C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972416","FLT3 NP_004110.2:p.Y842X","C167187","A change in the amino acid residue at position 842 in the receptor-type tyrosine-protein kinase FLT3 protein where tyrosine has been replaced by another amino acid.","FLT3 NP_004110.2:p.Y842X | CD135 Antigen Tyr842Xxx | CD135 Antigen Y842X | FLT3 NP_004110.2:p.Tyr842Xxx | FLT3 Tyr842Xxx | FLT3 Y842 Mutation | FLT3 Y842X | FLT3 p.Tyr842Xxx | FLT3 p.Y842X | Fetal Liver Kinase-2 Tyr842Xxx | Fetal Liver Kinase-2 Y842X | Flt-3 Receptor Tyr842Xxx | Flt-3 Receptor Y842X | Fms-Related Tyrosine Kinase 3 Tyr842Xxx | Fms-Related Tyrosine Kinase 3 Y842X | NP_004110.2:p.Tyr842Xxx | NP_004110.2:p.Y842X | Receptor-Type Tyrosine-Protein Kinase FLT3 Tyr842Xxx | Receptor-Type Tyrosine-Protein Kinase FLT3 Y842X | Stem Cell Tyrosine Kinase 1 Tyr842Xxx | Stem Cell Tyrosine Kinase 1 Y842X | Y842 | Y842X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972926","Absolute Phagocyte Count","C167191","The number of phagocytes (neutrophils and monocytes-macrophages) in a cubic millimeter of blood. The APC is the sum of the neutrophils (segs and bands), monocytes, and macrophages times one hundredth (1/100) of the white blood cell count.","Absolute Phagocyte Count | APC | Absolute phagocyte count (APC)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972080","Acute Myeloid Leukemia with RAM Immunophenotype","C167089","A high risk pediatric acute myeloid leukemia with an extremely poor prognosis. The blasts show bright CD56 expression, dim-to-negative expression of CD45 and CD38, and lack of HLA-DR expression. This immunophenotype was named after one of the pediatric patient's initials (RAM), from Children's Oncology Group (COG) clinical trial AAML0531.","Acute Myeloid Leukemia with RAM Immunophenotype | AML with RAM Immunophenotype",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972425","Felt I Had Nothing to Look Forward To","C167200","A question about whether an individual feels or felt they had nothing to look forward to.","Felt I Had Nothing to Look Forward To | I felt that I had nothing to look forward to",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972428","Felt That Nothing Could Cheer Me Up","C167201","A question about whether an individual feels or felt that nothing could cheer them up.","Felt That Nothing Could Cheer Me Up | I felt that nothing could cheer me up",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972419","t(8;16)(p11.2;p13.3)","C167194","A cytogenetic abnormality that refers to the translocation of the short arm (p11.2) of chromosome 8 and the short arm (p13.3) of chromosome 16. It is associated with KAT6A/CREBBP fusions and acute myeloid leukemia.","t(8;16)(p11.2;p13.3) | t(8;16)(p11;p13)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972422","inv(16)(p13.3;q24.3)","C167195","A pericentric chromosomal inversion that involves chromosome 16. It is associated with CBFA2T3/GLIS2 fusions and pediatric acute megakaryoblastic leukemia.","inv(16)(p13.3;q24.3) | inv(16)(p13.3q24.3) | inv(16)(p13;q24) | inv(16)(p13q24)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972421","t(10;11)(p12.3;q23.3)","C167196","A cytogenetic abnormality that refers to the translocation of the short arm (p12.3) of chromosome 10 and the long arm (q23.3) of chromosome 11. It is associated with KMT2A (MLL) fusions and acute myeloid leukemia.","t(10;11)(p12.3;q23.3) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972424","t(10;11)(p12.1;q23.3)","C167197","A cytogenetic abnormality that refers to the translocation of the short arm (p12.1) of chromosome 10 and the long arm (q23.3) of chromosome 11. It is associated with KMT2A (MLL) fusions.","t(10;11)(p12.1;q23.3) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972423","Rearrangement of 10p12.3","C167198","A cytogenetic abnormality indicating the presence of rearrangement involving the short arm segment p12.3 of chromosome 10.","Rearrangement of 10p12.3 | 10p12.3 Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972426","CEBPA bZIP Domain Mutation","C167199","A change in the nucleotide sequence of the CEBPA gene that alters the amino acid sequence of the DNA-binding basic leucine zipper domain of CCAAT/enhancer binding protein alpha.","CEBPA bZIP Domain Mutation | C/EBP-Alpha bZIP Domain Mutation | C/EBPalpha bZIP Domain Mutation | CCAAT Enhancer Binding Protein Alpha bZIP Domain Mutation | CCAAT/Enhancer Binding Protein, Alpha bZIP Domain Mutation | CEBP bZIP Domain Mutation | CEBPA bZIP Domain Gene Mutation | CEBPA bZIP Mutation | CEBPalpha bZIP Domain Mutation | CEBPalpha bZIP Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0694649","Left Deltoid","C105634","The muscle that creates the rounded contour of the shoulder which originates from the lateral third of the clavicle, the superior surface of the acromion process, and the posterior border of the spine of the scapula and inserts on the lateral side of the shaft of the humerus. The deltoid muscle is innervated by the brachial plexus arising from the fifth and sixth cervical nerves and controls abduction, extension, flexion, and rotation of the arm. This is the deltoid on the left side of the body.","Left Deltoid | LD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2744850","Tedizolid","C84222","An antibacterial agent of the oxazolidinone class, that is used for the treatment of acute bacterial skin and skin structure infections caused by certain Gram-positive microorganisms. Upon intravenous administration, tedizolid targets and binds to the 50S subunit of the bacterial ribosome. This inhibits bacterial protein synthesis.","Tedizolid | (5R)-3-(3-Fluoro-4-(6-(2-Methyl-2H-Tetrazol-5-yl)Pyridin-3-yl)Phenyl)-5-(Hydroxymethyl)Oxazolidin-2-One | 2-Oxazolidinone, 3-(3-Fluoro-4-(6-(2-Methyl-2H-Tetrazol-5-yl)-3-Pyridinyl)Phenyl)-5-(Hydroxymethyl)-, (5R)- | TEDIZOLID | TR-700 | Torezolid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554424","Equine Thymocyte Immune Globulin","C80824","A purified, concentrated and sterile solution of horse-derived gamma globulin obtained by the immunization of horses with human T-lymphocytes, with T-cell depleting and immunosuppressive activities. Upon administration, horse anti-thymocyte globulin (hATG) specifically recognizes, modulates and destroys T-lymphocytes. Although the exact mechanism of action by which hATG causes immunosuppression is not completely understood, it is likely caused by a combination of T-lymphocyte depletion, reduction in T-cell activation and modulation of their cytotoxic activities. Administering of hATG prior to transplantation may reduce the risk of graft-versus-host disease (GvHD).","Equine Thymocyte Immune Globulin | Antithymocyte Globulin Equine | Antithymocyte Globulin Horse | Atgam | EQUINE THYMOCYTE IMMUNE GLOBULIN | Equine ATG | Equine Anti-human Thymocyte Immunoglobulin | Horse ATG | Horse Anti-thymocyte Globulin | Lymphocyte Immune Globulin, Anti-Thymocyte Globulin | eATG | hATG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986807","Radioactive Activity","C94961","Parameter used to quantify radioactivity and represents radioactive source transformations, i.e. disintegrations or emissions, per unit time.","Radioactive Activity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521824","Pyrogenicity/Endotoxin Assessment","C133983","Tests to measure the ability of a substance to produce an endotoxin or febrile and/or inflammatory reaction in response to administration of a substance.","Pyrogenicity/Endotoxin Assessment | Pyrogenicity/Endotoxin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972074","Homovanillic Acid","C167083","A monocarboxylic acid that is a catecholamine metabolite.  Homovanillic acid may be used a marker for metabolic stress, tobacco usage or the presence of a catecholamine secreting tumor, such as neuroblastoma or pheochromocytoma.","Homovanillic Acid | (4-Hydroxy-3-methoxyphenyl)acetic Acid | 3-Methoxy-4-hydroxyphenylacetic Acid | 4-Hydroxy-3-methoxybenzeneacetic Acid | 4-Hydroxy-3-methoxyphenylacetic Acid | Acetic Acid, (4-Hydroxy-3-methoxyphenyl)- (8CI) | Benzeneacetic Acid, 4-Hydroxy-3-methoxy- | HMPA | HVA | Vanillacetic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972073","3-methoxy-4-hydroxymandelic acid","C167084","An aromatic ether that is a product of catecholamine metabolism. Vanillylmandelic acid may be a used as marker for tumors that secrete catecholamines, such as neuroblastoma or pheochromocytoma.","Vanillylmandelic Acid | 2-Hydroxy-2-(4-hydroxy-3-methoxyphenyl)acetic Acid | 3-Methoxy-4-hydroxymandelic Acid | 4-Hydroxy-3-methoxymandelic Acid | Benzeneacetic Acid, 4-Hydroxy-3-methoxy- | VMA | Vanillyl Mandelic Acid | Vanilmandelic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972079","Inactivating BRCA Gene Mutation","C167090","A change in the nucleotide sequence of a gene in the BRCA family that either inhibits expression or results in the translation of an inactive BRCA family protein.","Inactivating BRCA Gene Mutation | BRCA Family Gene Inactivation | BRCA Gene Inactivation | BRCA Loss of Function Gene Mutation | BRCA Loss of Function Mutation | Inactivating BRCA Family Mutation | Inactivating BRCA Gene Family Mutation | Inactivating BRCA Mutation | Non-Functional BRCA Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972082","BRCA Variant of Unknown Significance","C167091","A change in the nucleotide sequence of a gene in the BRCA family whose association with disease risk is unknown or uncertain.","BRCA Variant of Unknown Significance | BRCA Family Gene VUS | BRCA Family VUS | BRCA Gene Family VUS | BRCA Gene VUS | BRCA Gene Variant of Unknown Significance | BRCA VUS | VUS BRCA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972084","Inactivating DAXX Gene Mutation","C167093","A change in the nucleotide sequence of the DAXX gene that either inhibits expression or results in the translation of an inactive death domain-associated protein 6 protein.","Inactivating DAXX Gene Mutation | DAXX Gene Inactivation | DAXX Loss of Function Gene Mutation | DAXX Loss of Function Mutation | Inactivating BING2 Gene Mutation | Inactivating DAP6 Gene Mutation | Inactivating DAXX Mutation | Inactivating Death-Associated Protein 6 Gene Mutation | Inactivating Death-Domain Associated Protein Gene Mutation | Inactivating EAP1 Gene Mutation | Loss of Function DAXX Gene Mutation | Loss of Function DAXX Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972083","Inactivating ATRX Gene Mutation","C167094","A change in the nucleotide sequence of the ATRX gene that either inhibits expression or results in the translation of an inactive transcriptional regulator ATRX protein.","Inactivating ATRX Gene Mutation | ATRX Gene Inactivation | ATRX Loss of Function Gene Mutation | ATRX Loss of Function Mutation | Inactivating ATRX Mutation | Inactivating ATRX, Chromatin Remodeler Gene Mutation | Inactivating Alpha Thalassemia/Mental Retardation Syndrome X-Linked Gene Mutation | Inactivating RAD54 Gene Mutation | Inactivating RAD54 Homolog Gene Mutation | Inactivating RAD54L Gene Mutation | Inactivating XH2 Gene Mutation | Inactivating XNP Gene Mutation | Inactivating ZNF-HX Gene Mutation | Loss of Function ATRX Gene Mutation | Loss of Function ATRX Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972086","Inactivating ARID1A Gene Mutation","C167095","A change in the nucleotide sequence of the ARID1A gene that either inhibits expression or results in the translation of an inactive AT-rich interactive domain-containing protein 1A protein.","Inactivating ARID1A Gene Mutation | ARID1A Gene Inactivation | ARID1A Loss of Function Gene Mutation | ARID1A Loss of Function Mutation | Inactivating ARID1A Mutation | Inactivating AT Rich Interactive Domain 1A Gene Mutation | Inactivating B120 Gene Mutation | Inactivating BAF250 Gene Mutation | Inactivating BAF250a Gene Mutation | Inactivating BRG1-Associated Factor 250a Gene Mutation | Inactivating ZNF-HX Gene Mutation | Loss of Function ARID1A Gene Mutation | Loss of Function ARID1A Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972085","SMC3 Gene Mutation","C167096","A change in the nucleotide sequence of the SMC3 gene.","SMC3 Gene Mutation | BAM Gene Mutation | BMH Gene Mutation | Bamacan Gene Mutation | CSPG6 Gene Mutation | Chondroitin Sulfate Proteoglycan 6 Gene Mutation | HCAP Gene Mutation | SMC3L1 Gene Mutation | Structural Maintenance of Chromosomes 3 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972088","PDS5B Gene Mutation","C167097","A change in the nucleotide sequence of the PDS5B gene.","PDS5B Gene Mutation | APRIN Gene Mutation | AS3 Gene Mutation | Androgen-Induced Proliferation Inhibitor Gene Mutation | PDS5 Cohesin Associated Factor B Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972087","RAD21 Gene Mutation","C167098","A change in the nucleotide sequence of the RAD21 gene.","RAD21 Gene Mutation | HR21 Gene Mutation | HRAD21 Gene Mutation | MCD1 Gene Mutation | NXP1 Gene Mutation | RAD21 Cohesin Complex Component Gene Mutation | RAD21 Homolog Gene Mutation | SCC1 Gene Mutation | hHR21 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972090","Clonal Plasma Cells in Bone Marrow","C167099","A finding indicating that clonal plasma cells have been detected in a bone marrow sample.","Clonal Plasma Cells in Bone Marrow | Clonal Plasma Cells Detected in Bone Marrow | Clonal Plasma Cells Present in Bone Marrow | Detectable Clonal Bone Marrow Plasma Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972089","MET Exon 14 Skipping Mutation Negative","C167100","A genetic finding indicating that activating MET exon 14 skipping mutations have not been detected in a sample.","MET Exon 14 Skipping Mutation Negative | Deletion of MET Exon 14 Negative | Deletion of c-MET Exon 14 Negative | HGFR Exon 14 Skipping Alteration Negative | HGFR Exon 14 Skipping Mutation Negative | HGFR Exon 14 Splice Mutation Negative | Loss of MET Exon 14 Negative | Loss of c-MET Exon 14 Negative | MET Exon 14 Deletion Mutation Negative | MET Exon 14 Skipping Alteration Negative | MET Exon 14 Splice Mutation Negative | c-MET Exon 14 Deletion Mutation Negative | c-MET Exon 14 Splice Mutation Negative | c-Met Exon 14 Skipping Alteration Negative | c-Met Exon 14 Skipping Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972092","Activating KRAS Gene Mutation Negative","C167101","A genetic finding indicating that mutations in the KRAS gene which encode constitutively active forms of the GTPase KRas protein are not present in a sample.","Activating KRAS Gene Mutation Negative | Activating KRAS Mutation Negative | KRAS Activating Mutation Negative | KRAS Proto-Oncogene, GTPase Activating Mutation Negative | KRAS-2 Activating Mutation Negative | KRAS2 Activating Mutation Negative | c-K-ras Activating Mutation Negative | v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Activating Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972091","ROS1 Gene Fusion Negative","C167102","An indication that a ROS1 fusion gene has not been detected in a sample.","ROS1 Gene Fusion Negative | MCF3 Gene Fusion Negative | ROS Fusion Negative | ROS Gene Fusion Negative | ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Fusion Negative | ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene Fusion Negative | ROS1 Fusion Gene Negative | Receptor Tyrosine Kinase c-Ros Oncogene 1 Fusion Negative | Receptor Tyrosine Kinase c-Ros Oncogene 1 Gene Fusion Negative | c-ros-1 Gene Fusion Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972093","ALK Gene Fusion Negative","C167104","An indication that an ALK fusion gene has not been detected in a sample.","ALK Gene Fusion Negative | ALK Fusion Gene Negative | ALK Fusion Oncogene Negative | Anaplastic Lymphoma Kinase Fusion Gene Negative | Anaplastic Lymphoma Kinase Fusion Oncogene Negative | Anaplastic Lymphoma Receptor Tyrosine Kinase Fusion Gene Negative | CD246 Fusion Gene Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972096","NTRK3 Gene Amplification","C167105","A molecular genetic abnormality indicating the presence of multiple copies of the NTRK3 gene.","NTRK3 Gene Amplification | NTRK3 Amplification | Neurotrophic Receptor Tyrosine Kinase 3 Gene Amplification | Neurotrophic Tyrosine Kinase Receptor 3 Gene Amplification | Neurotrophic Tyrosine Kinase Receptor Type 3 Gene Amplification | Neurotrophic Tyrosine Kinase, Receptor, Type 3 Gene Amplification | TRKC Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972095","NTRK2 Gene Amplification","C167106","A molecular genetic abnormality indicating the presence of multiple copies of the NTRK2 gene.","NTRK2 Gene Amplification | NTRK2 Amplification | Neurotrophic Receptor Tyrosine Kinase 2 Gene Amplification | Neurotrophic Tyrosine Kinase Receptor 2 Gene Amplification | Neurotrophic Tyrosine Kinase Receptor Type 2 Gene Amplification | TRKB Tyrosine Kinase Gene Amplification | Tropomyosin-Related Kinase B Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972098","Inactivating CDKN2C Gene Mutation","C167107","A change in the nucleotide sequence of the CDKN2C gene that either inhibits expression or results in the translation of an inactive cyclin-dependent kinase 4 inhibitor C protein.","Inactivating CDKN2C Gene Mutation | CDKN2C Gene Inactivation | CDKN2C Loss of Function Gene Mutation | CDKN2C Loss of Function Mutation | Inactivating CDKN2C Mutation | Inactivating CDKN6 Gene Mutation | Inactivating Cyclin Dependent Kinase Inhibitor 2C Gene Mutation | Inactivating Cyclin-Dependent Kinase Inhibitor 2C Gene Mutation | Inactivating INK4C Gene Mutation | Inactivating p18 Gene Mutation | Inactivating p18(INK4C) Gene Mutation | Inactivating p18-INK4C Gene Mutation | Inactivating p18-INK6 Gene Mutation | Loss of Function CDKN2C Gene Mutation | Loss of Function CDKN2C Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972100","Inactivating CDKN2B Gene Mutation","C167109","A change in the nucleotide sequence of the CDKN2B gene that either inhibits expression or results in the translation of an inactive cyclin-dependent kinase 4 inhibitor B protein.","Inactivating CDKN2B Gene Mutation | CDKN2B Gene Inactivation | CDKN2B Loss of Function Gene Mutation | CDKN2B Loss of Function Mutation | Inactivating CDK4I Gene Mutation | Inactivating CDKN2B Mutation | Inactivating Cyclin Dependent Kinase Inhibitor 2B Gene Mutation | Inactivating Cyclin-Dependent Kinase Inhibitor 2B Gene Mutation | Inactivating INK4B Gene Mutation | Inactivating INK4C Gene Mutation | Inactivating MTS2 Gene Mutation | Inactivating P15 Gene Mutation | Inactivating TP15 Gene Mutation | Inactivating p15INK4b Gene Mutation | Loss of Function CDKN2B Gene Mutation | Loss of Function CDKN2B Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972099","STAT5 Protein Family","C167110","Two highly conserved members of the signal transducer and activator of transcription (STAT) protein family, STAT5A and STAT5B. Constitutive phosphorylation of STAT5 proteins, which leads to constitutive activation and aberrant expression of STAT5-dependent genes, has been observed in various neoplastic diseases.","STAT5 Protein Family | STAT5 | STAT5 Protein | Signal Transducer and Activator of Transcription 5 | Signal Transducer and Activator of Transcription 5 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972102","AXIN2 Gene Mutation","C167111","A change in the nucleotide sequence of the AXIN2 gene.","AXIN2 Gene Mutation | AXIL Gene Mutation | AXIS Inhibitor 2 Gene Mutation | Axin 2 Gene Mutation | Conductin, Mouse, Homolog of Gene Mutation | ODCRCS Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972101","AXIN1 Gene Mutation","C167112","A change in the nucleotide sequence of the AXIN1 gene.","AXIN1 Gene Mutation | AXIN Gene Mutation | AXIS Inhibitor 1 Gene Mutation | Axin 1 Gene Mutation | Fused, Mouse, Homolog of Gene Mutation | PPP1R49 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972104","RSPO3 Gene Mutation","C167113","A change in the nucleotide sequence of the RSPO3 gene.","RSPO3 Gene Mutation | CRISTIN1 Gene Mutation | PWTSR Gene Mutation | R-Spondin 3 Gene Mutation | THSD2 Gene Mutation | Thrombospondin, Type I, Domain Containing 2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972103","RSPO2 Gene Mutation","C167114","A change in the nucleotide sequence of the RSPO2 gene.","RSPO2 Gene Mutation | CRISTIN2 Gene Mutation | HHRRD Gene Mutation | R-Spondin 2 Gene Mutation | TETAMS2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972106","ZNRF3 Gene Mutation","C167115","A change in the nucleotide sequence of the ZNRF3 gene.","ZNRF3 Gene Mutation | RNF203 Gene Mutation | Zinc and Ring Finger 3 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL930823","Influenza B Virus Positive","C167117","An indication that influenza B virus has been detected in a sample.","Influenza B Virus Positive | Influenza Type B Virus Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL580267","Influenza A Virus Positive","C167118","An indication that influenza A virus has been detected in a sample.","Influenza A Virus Positive | Influenza Type A Virus Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972350","SBDS Gene Mutation","C167119","A change in the nucleotide sequence of the SBDS gene.","SBDS Gene Mutation | CGI-97 Gene Mutation | SBDS Ribosome Maturation Factor Gene Mutation | SDS Gene Mutation | SWDS Gene Mutation | Shwachman-Bodian-Diamond Syndrome Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972351","SRSF2 NP_003007.2:p.P95 Deletion","C167122","Any deletion in the amino acid sequence for the serine/arginine-rich splicing factor 2 protein that includes the proline at position 95.","SRSF2 NP_003007.2:p.P95 Deletion | NP_003007.2:p.P95 Deletion | NP_003007.2:p.Pro95 Deletion | Protein PR264 P95 Deletion | Protein PR264 Pro95 Deletion | SC-35 P95 Deletion | SC-35 Pro95 Deletion | SR Splicing Factor 2 P95 Deletion | SR Splicing Factor 2 Pro95 Deletion | SRSF2 NP_003007.2:p.Pro95 Deletion | SRSF2 P95 Deletion | SRSF2 Pro95 Deletion | SRSF2 p.P95 Deletion | SRSF2 p.Pro95 Deletion | Serine/Arginine-Rich Splicing Factor 2 P95 Deletion | Serine/Arginine-Rich Splicing Factor 2 Pro95 Deletion | Splicing Component, 35 kDa P95 Deletion | Splicing Component, 35 kDa Pro95 Deletion | Splicing Factor SC35 P95 Deletion | Splicing Factor SC35 Pro95 Deletion | Splicing Factor, Arginine/Serine-Rich 2 P95 Deletion | Splicing Factor, Arginine/Serine-Rich 2 Pro95 Deletion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972356","U2AF1 NP_006749.1:p.Q157X","C167125","A change in the amino acid residue at position 157 in the splicing factor U2AF 35 kDa subunit protein where glutamine has been replaced by another amino acid.","U2AF1 NP_006749.1:p.Q157X | NP_006749.1:p.Gln157Xxx | NP_006749.1:p.Q157X | Splicing Factor U2AF 35 kDa Subunit Gln157Xxx | Splicing Factor U2AF 35 kDa Subunit Q157X | U2 Auxiliary Factor 35 kDa Subunit Gln157Xxx | U2 Auxiliary Factor 35 kDa Subunit Q157X | U2 snRNP Auxiliary Factor Small Subunit Gln157Xxx | U2 snRNP Auxiliary Factor Small Subunit Q157X | U2(RNU2) Small Nuclear RNA Auxiliary Factor Binding Protein Gln157Xxx | U2(RNU2) Small Nuclear RNA Auxiliary Factor Binding Protein Q157X | U2AF1 Gln157Xxx | U2AF1 NP_006749.1:p.Gln157Xxx | U2AF1 Q157 Mutation | U2AF1 Q157X | U2AF1 p.Gln157Xxx | U2AF1 p.Q157X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972355","U2AF1 NP_006749.1:p.R156X","C167126","A change in the amino acid residue at position 156 in the splicing factor U2AF 35 kDa subunit protein where arginine has been replaced by another amino acid.","U2AF1 NP_006749.1:p.R156X | NP_006749.1:p.Arg156Xxx | NP_006749.1:p.R156X | Splicing Factor U2AF 35 kDa Subunit Arg156Xxx | Splicing Factor U2AF 35 kDa Subunit R156X | U2 Auxiliary Factor 35 kDa Subunit Arg156Xxx | U2 Auxiliary Factor 35 kDa Subunit R156X | U2 snRNP Auxiliary Factor Small Subunit Arg156Xxx | U2 snRNP Auxiliary Factor Small Subunit R156X | U2(RNU2) Small Nuclear RNA Auxiliary Factor Binding Protein Arg156Xxx | U2(RNU2) Small Nuclear RNA Auxiliary Factor Binding Protein R156X | U2AF1 Arg156Xxx | U2AF1 NP_006749.1:p.Arg156Xxx | U2AF1 R156 Mutation | U2AF1 R156X | U2AF1 p.Arg156Xxx | U2AF1 p.R156X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972358","U2AF1 NP_006749.1:p.S34X","C167127","A change in the amino acid residue at position 34 in the splicing factor U2AF 35 kDa subunit protein where serine has been replaced by another amino acid.","U2AF1 NP_006749.1:p.S34X | NP_006749.1:p.S34X | NP_006749.1:p.Ser34Xxx | Splicing Factor U2AF 35 kDa Subunit S34X | Splicing Factor U2AF 35 kDa Subunit Ser34Xxx | U2 Auxiliary Factor 35 kDa Subunit S34X | U2 Auxiliary Factor 35 kDa Subunit Ser34Xxx | U2 snRNP Auxiliary Factor Small Subunit S34X | U2 snRNP Auxiliary Factor Small Subunit Ser34Xxx | U2(RNU2) Small Nuclear RNA Auxiliary Factor Binding Protein Protein Variant Ser34Xxx | U2(RNU2) Small Nuclear RNA Auxiliary Factor Binding Protein S34X | U2AF1 NP_006749.1:p.Ser34Xxx | U2AF1 S34 Mutation | U2AF1 S34X | U2AF1 Ser34Xxx | U2AF1 p.S34X | U2AF1 p.Ser34Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972360","SF3B1 NP_036565.2:p.D781X","C167129","A change in the amino acid residue at position 781 in the splicing factor 3B subunit 1 protein where aspartic acid has been replaced by another amino acid.","SF3B1 NP_036565.2:p.D781X | NP_036565.2:p.Asp781Xxx | NP_036565.2:p.D781X | Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Asp781Xxx | Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit D781X | SAP 155 Asp781Xxx | SAP 155 D781X | SF3B1 Asp781Xxx | SF3B1 D781 Mutation | SF3B1 D781X | SF3B1 NP_036565.2:p.Asp781Xxx | SF3B1 p.Asp781Xxx | SF3B1 p.D781X | SF3b155 Asp781Xxx | SF3b155 D781X | Spliceosome-Associated Protein 155 Asp781Xxx | Spliceosome-Associated Protein 155 D781X | Splicing Factor 3B Subunit 1 Asp781Xxx | Splicing Factor 3B Subunit 1 D781X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972359","SF3B1 NP_036565.2:p.A774X","C167130","A change in the amino acid residue at position 774 in the splicing factor 3B subunit 1 protein where alanine has been replaced by another amino acid.","SF3B1 NP_036565.2:p.A774X | NP_036565.2:p.A774X | NP_036565.2:p.Ala774Xxx | Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit A774X | Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Ala774Xxx | SAP 155 A774X | SAP 155 Ala774Xxx | SF3B1 A774 Mutation | SF3B1 A774X | SF3B1 Ala774Xxx | SF3B1 NP_036565.2:p.Ala774Xxx | SF3B1 p.A774X | SF3B1 p.Ala774Xxx | SF3b155 A774X | SF3b155 Ala774Xxx | Spliceosome-Associated Protein 155 A774X | Spliceosome-Associated Protein 155 Ala774Xxx | Splicing Factor 3B Subunit 1 A774X | Splicing Factor 3B Subunit 1 Ala774Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972362","SF3B1 NP_036565.2:p.G742X","C167131","A change in the amino acid residue at position 742 in the splicing factor 3B subunit 1 protein where glycine has been replaced by another amino acid.","SF3B1 NP_036565.2:p.G742X | NP_036565.2:p.G742X | NP_036565.2:p.Gly742Xxx | Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit G742X | Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Gly742Xxx | SAP 155 G742X | SAP 155 Gly742Xxx | SF3B1 G742 Mutation | SF3B1 G742X | SF3B1 Gly742Xxx | SF3B1 NP_036565.2:p.Gly742Xxx | SF3B1 p.G742X | SF3B1 p.Gly742Xxx | SF3b155 G742X | SF3b155 Gly742Xxx | Spliceosome-Associated Protein 155 G742X | Spliceosome-Associated Protein 155 Gly742Xxx | Splicing Factor 3B Subunit 1 G742X | Splicing Factor 3B Subunit 1 Gly742Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978948","Immuno-oncology Therapy","C165652","Immunotherapy that focuses on mobilizing the patient's own immune cells to recognize and eliminate cancer cells.","Immuno-oncology Therapy | IO Therapy | Immunooncology Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972361","SF3B1 NP_036565.2:p.K741X","C167132","A change in the amino acid residue at position 741 in the splicing factor 3B subunit 1 protein where lysine has been replaced by another amino acid.","SF3B1 NP_036565.2:p.K741X | NP_036565.2:p.K741X | NP_036565.2:p.Lys741Xxx | Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit K741X | Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Lys741Xxx | SAP 155 K741X | SAP 155 Lys741Xxx | SF3B1 K741 Mutation | SF3B1 K741X | SF3B1 Lys741Xxx | SF3B1 NP_036565.2:p.Lys741Xxx | SF3B1 p.K741X | SF3B1 p.Lys741Xxx | SF3b155 K741X | SF3b155 Lys741Xxx | Spliceosome-Associated Protein 155 K741X | Spliceosome-Associated Protein 155 Lys741Xxx | Splicing Factor 3B Subunit 1 K741X | Splicing Factor 3B Subunit 1 Lys741Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972364","SF3B1 NP_036565.2:p.G740X","C167133","A change in the amino acid residue at position 740 in the splicing factor 3B subunit 1 protein where glycine has been replaced by another amino acid.","SF3B1 NP_036565.2:p.G740X | NP_036565.2:p.G740X | NP_036565.2:p.Gly740Xxx | Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit G740X | Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Gly740Xxx | SAP 155 G740X | SAP 155 Gly740Xxx | SF3B1 G740 Mutation | SF3B1 G740X | SF3B1 Gly740Xxx | SF3B1 NP_036565.2:p.Gly740Xxx | SF3B1 p.G740X | SF3B1 p.Gly740Xxx | SF3b155 G740X | SF3b155 Gly740Xxx | Spliceosome-Associated Protein 155 G740X | Spliceosome-Associated Protein 155 Gly740Xxx | Splicing Factor 3B Subunit 1 G740X | Splicing Factor 3B Subunit 1 Gly740Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972363","SF3B1 NP_036565.2:p.I704X","C167134","A change in the amino acid residue at position 704 in the splicing factor 3B subunit 1 protein where isoleucine has been replaced by another amino acid.","SF3B1 NP_036565.2:p.I704X | NP_036565.2:p.I704X | NP_036565.2:p.Ile704Xxx | Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit I704X | Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Ile704Xxx | SAP 155 I704X | SAP 155 Ile704Xxx | SF3B1 I704 Mutation | SF3B1 I704X | SF3B1 Ile704Xxx | SF3B1 NP_036565.2:p.Ile704Xxx | SF3B1 p.I704X | SF3B1 p.Ile704Xxx | SF3b155 I704X | SF3b155 Ile704Xxx | Spliceosome-Associated Protein 155 I704X | Spliceosome-Associated Protein 155 Ile704Xxx | Splicing Factor 3B Subunit 1 I704X | Splicing Factor 3B Subunit 1 Ile704Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972366","SF3B1 NP_036565.2:p.V701X","C167135","A change in the amino acid residue at position 701 in the splicing factor 3B subunit 1 protein where valine has been replaced by another amino acid.","SF3B1 NP_036565.2:p.V701X | NP_036565.2:p.V701X | NP_036565.2:p.Val701Xxx | Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit V701X | Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Val701Xxx | SAP 155 V701X | SAP 155 Val701Xxx | SF3B1 NP_036565.2:p.Val701Xxx | SF3B1 V701 Mutation | SF3B1 V701X | SF3B1 Val701Xxx | SF3B1 p.V701X | SF3B1 p.Val701Xxx | SF3b155 V701X | SF3b155 Val701Xxx | Spliceosome-Associated Protein 155 V701X | Spliceosome-Associated Protein 155 Val701Xxx | Splicing Factor 3B Subunit 1 V701X | Splicing Factor 3B Subunit 1 Val701Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972365","SF3B1 NP_036565.2:p.K700X","C167136","A change in the amino acid residue at position 700 in the splicing factor 3B subunit 1 protein where lysine has been replaced by another amino acid.","SF3B1 NP_036565.2:p.K700X | NP_036565.2:p.K700X | NP_036565.2:p.Lys700Xxx | Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit K700X | Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Lys700Xxx | SAP 155 K700X | SAP 155 Lys700Xxx | SF3B1 K700 Mutation | SF3B1 K700X | SF3B1 Lys700Xxx | SF3B1 NP_036565.2:p.Lys700Xxx | SF3B1 p.K700X | SF3B1 p.Lys700Xxx | SF3b155 K700X | SF3b155 Lys700Xxx | Spliceosome-Associated Protein 155 K700X | Spliceosome-Associated Protein 155 Lys700Xxx | Splicing Factor 3B Subunit 1 K700X | Splicing Factor 3B Subunit 1 Lys700Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972368","SF3B1 NP_036565.2:p.K666X","C167137","A change in the amino acid residue at position 666 in the splicing factor 3B subunit 1 protein where lysine has been replaced by another amino acid.","SF3B1 NP_036565.2:p.K666X | NP_036565.2:p.K666X | NP_036565.2:p.Lys666Xxx | Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit K666X | Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Lys666Xxx | SAP 155 K666X | SAP 155 Lys666Xxx | SF3B1 K666 Mutation | SF3B1 K666X | SF3B1 Lys666Xxx | SF3B1 NP_036565.2:p.Lys666Xxx | SF3B1 p.K666X | SF3B1 p.Lys666Xxx | SF3b155 K666X | SF3b155 Lys666Xxx | Spliceosome-Associated Protein 155 K666X | Spliceosome-Associated Protein 155 Lys666Xxx | Splicing Factor 3B Subunit 1 K666X | Splicing Factor 3B Subunit 1 Lys666Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972370","SF3B1 NP_036565.2:p.H662X","C167139","A change in the amino acid residue at position 662 in the splicing factor 3B subunit 1 protein where histidine has been replaced by another amino acid.","SF3B1 NP_036565.2:p.H662X | NP_036565.2:p.H662X | NP_036565.2:p.His662Xxx | Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit H662X | Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit His662Xxx | SAP 155 H662X | SAP 155 His662Xxx | SF3B1 H662 Mutation | SF3B1 H662X | SF3B1 His662Xxx | SF3B1 NP_036565.2:p.His662Xxx | SF3B1 p.H662X | SF3B1 p.His662Xxx | SF3b155 H662X | SF3b155 His662Xxx | Spliceosome-Associated Protein 155 H662X | Spliceosome-Associated Protein 155 His662Xxx | Splicing Factor 3B Subunit 1 H662X | Splicing Factor 3B Subunit 1 His662Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972369","SF3B1 NP_036565.2:p.N626X","C167140","A change in the amino acid residue at position 626 in the splicing factor 3B subunit 1 protein where asparagine has been replaced by another amino acid.","SF3B1 NP_036565.2:p.N626X | NP_036565.2:p.Asn626Xxx | NP_036565.2:p.N626X | Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Asn626Xxx | Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit N626X | SAP 155 Asn626Xxx | SAP 155 N626X | SF3B1 Asn626Xxx | SF3B1 N626 Mutation | SF3B1 N626X | SF3B1 NP_036565.2:p.Asn626Xxx | SF3B1 p.Asn626Xxx | SF3B1 p.N626X | SF3b155 Asn626Xxx | SF3b155 N626X | Spliceosome-Associated Protein 155 Asn626Xxx | Spliceosome-Associated Protein 155 N626X | Splicing Factor 3B Subunit 1 Asn626Xxx | Splicing Factor 3B Subunit 1 N626X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972372","SF3B1 NP_036565.2:p.R625X","C167141","A change in the amino acid residue at position 625 in the splicing factor 3B subunit 1 protein where arginine has been replaced by another amino acid.","SF3B1 NP_036565.2:p.R625X | NP_036565.2:p.Arg625Xxx | NP_036565.2:p.R625X | Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Arg625Xxx | Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit R625X | SAP 155 Arg625Xxx | SAP 155 R625X | SF3B1 Arg625Xxx | SF3B1 NP_036565.2:p.Arg625Xxx | SF3B1 R625 Mutation | SF3B1 R625X | SF3B1 p.Arg625Xxx | SF3B1 p.R625X | SF3b155 Arg625Xxx | SF3b155 R625X | Spliceosome-Associated Protein 155 Arg625Xxx | Spliceosome-Associated Protein 155 R625X | Splicing Factor 3B Subunit 1 Arg625Xxx | Splicing Factor 3B Subunit 1 R625X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972371","SF3B1 NP_036565.2:p.Y623X","C167142","A change in the amino acid residue at position 623 in the splicing factor 3B subunit 1 protein where tyrosine has been replaced by another amino acid.","SF3B1 NP_036565.2:p.Y623X | NP_036565.2:p.Tyr623Xxx | NP_036565.2:p.Y623X | Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Tyr623Xxx | Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Y623X | SAP 155 Tyr623Xxx | SAP 155 Y623X | SF3B1 NP_036565.2:p.Tyr623Xxx | SF3B1 Tyr623Xxx | SF3B1 Y623 Mutation | SF3B1 Y623X | SF3B1 p.Tyr623Xxx | SF3B1 p.Y623X | SF3b155 Tyr623Xxx | SF3b155 Y623X | Spliceosome-Associated Protein 155 Tyr623Xxx | Spliceosome-Associated Protein 155 Y623X | Splicing Factor 3B Subunit 1 Tyr623Xxx | Splicing Factor 3B Subunit 1 Y623X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972374","SF3B1 NP_036565.2:p.E622X","C167143","A change in the amino acid residue at position 622 in the splicing factor 3B subunit 1 protein where glutamic acid has been replaced by another amino acid.","SF3B1 NP_036565.2:p.E622X | NP_036565.2:p.E622X | NP_036565.2:p.Glu622Xxx | Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit E622X | Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Glu622Xxx | SAP 155 E622X | SAP 155 Glu622Xxx | SF3B1 E622 Mutation | SF3B1 E622X | SF3B1 Glu622Xxx | SF3B1 NP_036565.2:p.Glu622Xxx | SF3B1 p.E622X | SF3B1 p.Glu622Xxx | SF3b155 E622X | SF3b155 Glu622Xxx | Spliceosome-Associated Protein 155 E622X | Spliceosome-Associated Protein 155 Glu622Xxx | Splicing Factor 3B Subunit 1 E622X | Splicing Factor 3B Subunit 1 Glu622Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972373","KMT2A Gene Translocation","C167144","A cytogenetic abnormality that refers to any translocation involving the MLL (KMT2A) gene.","KMT2A Gene Translocation | KMT2A Gene Translocation | KMT2A Gene Translocation | KMT2A Translocation | Lysine (K)-Specific Methyltransferase 2A Gene Translocation | Lysine Methyltransferase 2A Gene Translocation | MLL Gene Translocation | MLL Rearrangement (Translocation) | MLL Translocation | Mixed Lineage Leukemia Gene Translocation | Myeloid/Lymphoid Leukemia Gene Translocation | Myeloid/Lymphoid or Mixed Lineage Leukemia Gene Translocation | Myeloid/Lymphoid or Mixed-Lineage Leukemia (Trithorax Homolog, Drosophila) Gene Translocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972375","ERBB2 Gene Fusion Positive","C167146","An indication that an ERBB2 fusion gene has been detected in a sample.","ERBB2 Gene Fusion Positive | ERBB2 Fusion Gene Positive | Erb-B2 Receptor Tyrosine Kinase 2 Gene Fusion Positive | Erb-B2 Receptor Tyrosine Kinase Gene Fusion Positive | HER-2 Fusion Gene Positive | HER-2 Gene Fusion Positive | HER2 Fusion Gene Positive | HER2 Gene Fusion Positive | HER2/neu Gene Fusion Positive | NEU Gene Fusion Positive | v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 Gene Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972378","ERBB3 Gene Amplification","C167147","A molecular genetic abnormality indicating the presence of multiple copies of the ERBB3 gene.","ERBB3 Gene Amplification | ERBB3 Amplification | Erb-B2 Receptor Tyrosine Kinase 3 Gene Amplification | ErbB-3 Gene Amplification | HER-3 Gene Amplification | HER3 Gene Amplification | V-Erb-A Erythroblastic Leukemia Viral Oncogene Homolog 3 Gene Amplification | c-erbB-3 Gene Amplification | c-erbB3 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972380","ERBB3 Gene Fusion Positive","C167149","An indication that an ERBB3 fusion gene has been detected in a sample.","ERBB3 Gene Fusion Positive | ERBB3 Fusion Gene Positive | Erb-B2 Receptor Tyrosine Kinase 3 Gene Fusion Positive | ErbB-3 Gene Fusion Positive | HER-3 Fusion Gene Positive | HER-3 Gene Fusion Positive | HER3 Fusion Gene Positive | HER3 Gene Fusion Positive | V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 3 Gene Fusion Positive | c-erbB-3 Gene Fusion Positive | c-erbB3 Gene Fusion Positive | v-Erb-A Avian Erythroblastic Leukemia Viral Oncogene Homolog 3 Gene Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972379","FGFR4 Gene Amplification","C167150","A molecular genetic abnormality indicating the presence of multiple copies of the FGFR4 gene.","FGFR4 Gene Amplification | CD334 Gene Amplification | FGFR-4 Gene Amplification | FGFR4 Amplification | Fibroblast Growth Factor Receptor 4 Gene Amplification | JKT2 Gene Amplification | JTK2 Gene Amplification | TKF Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972381","Activating ERBB2 Point Mutation","C167151","A point mutation in the nucleotide sequence of the ERBB2 gene that that results in constitutive receptor tyrosine-protein kinase erbB-2-dependent signal transduction and activation of downstream signaling pathways.","Activating ERBB2 Point Mutation | Activating ERBB2 Gene Point Mutation | Activating HER2 Point Mutation | CD340 Activating Point Mutation | ERBB2 Activating Point Mutation | HER-2 Activating Point Mutation | HER2 Activating Point Mutation | HER2/Neu Activating Point Mutation | c-erbB2 Activating Point Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418226","PA2G4 Gene","C167152","This gene is involved in RNA processing, cell survival and cellular differentiation.","PA2G4 Gene | PA2G4 | Proliferation-Associated 2G4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972384","Blasts 2 Percent or More of Bone Marrow Nucleated Cells","C167155","A semi-quantitative microscopic finding indicating that at least 2 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 2 Percent or More of Bone Marrow Nucleated Cells | Blasts Greater than or Equal to 2 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972055","Blasts 6-24 Percent of Bone Marrow Nucleated Cells","C167065","A semi-quantitative microscopic finding indicating that between 6 and 24 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 6-24 Percent of Bone Marrow Nucleated Cells | Blasts 6-24% of Bone Marrow Nucleated Cells | Blasts Between 6 and 24 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935841","Initial Diagnosis","C156813","The first diagnosis of the individual's condition.","Initial Diagnosis | INITIAL DIAGNOSIS | INTIAL DIAGNOSIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972248","IDH2 NP_002159.2:p.R140G","C167258","A change in the amino acid residue at position 140 in the isocitrate dehydrogenase [NADP], mitochondrial protein where arginine has been replaced by glycine.","IDH2 NP_002159.2:p.R140G | IDH2 Arg140Gly | IDH2 NP_002159.2:p.Arg140Gly | IDH2 R140G | IDH2 R140G Mutation | IDH2 p.Arg140Gly | IDH2 p.R140G | Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial Arg140Gly | Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial R140G | Isocitrate Dehydrogenase [NADP], Mitochondrial Arg140Gly | Isocitrate Dehydrogenase [NADP], Mitochondrial R140G | NP_002159.2:p.Arg140Gly | NP_002159.2:p.R140G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226859","Superior Sagittal Sinus","C12515","An intracranial venous sinus that lies in a superior and midline location above the interhemispheric fissure along the superior border of the falx cerebri of the brain. The sinus receives blood from the cerebral veins and drains posteriorly into the lateral sinuses of the brain, which in turn drain into the internal jugular veins.","Superior Sagittal Sinus | Greater Sagittal Sinus | SUPERIOR SAGITTAL SINUS | Sagittal Sinus, Greater | Sagittal Sinus, Superior | Supratentorial Localization",,,,,,,,,,,,,,,"4085037","Superior sagittal sinus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937697","Deep Gray Matter","C158080","The gray matter that includes the basal ganglia and/or thalamus.","Deep Gray Matter | Deep Gray (e.g. Basal Ganglia, Thalamus) | Deep Gray (e.g. Basal ganglia or Thalamus)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936842","First Presenting Symptom Related to Disease","C157233","A question about the first symptom that is related to a disease of interest.","What is the First Presenting Symptom Related to Disease | First Presenting Symptom Related to Disease | first symptom prior to diagnosis | first_symptom_prior_to_diagnosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937125","Motor / Movement Change","C157433","An alteration in the motor/movement of an individual.","Motor / Movement Change | Motor or Movement Changes | Motor/Movement Changes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937129","Sensory Change","C157429","An alteration in the perceptual senses an individual.","Sensory Change | Sensory Changes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0750280","Visual changes","C157424","An alteration in the visual system of an individual.","Visual Change | Vision Changes | Visual Changes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937121","Mental Status Change","C157435","An alteration in the mental status of an individual.","Mental Status Change | Mental Status Changes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936877","Ki-67 Labeling Index","C157250","The percentage of cells in a sample that are dividing that is determined by immunohistochemical staining techniques using MIB-1 antibody (anti-Ki-67 protein antibody).","Ki-67 Labeling Index | Anti-KI67 Labeling Index | Anti-Ki-67 Labeling Index | Anti-MKI67 Labeling Index | Ki-67 MIB1 Labeling Index | MIB-1 Antibody Labeling Index | MIB-1 Labeling Index | MIB1 Antibody Labeling Index | MIB1 Labeling Index",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936901","1p/19q Codeletion Status","C157160","A procedure used to detect concurrent deletion of chromosome arms 1p and 19q.","1p/19q Codeletion Status | 1p/19q Co-deletion Status | 1p/19q Deletion | 1p/19q Status | del(1p/19q) Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936893","ATRX Mutation Status by Sequencing","C157166","An indication that the presence or absence of ATRX gene mutations was determined using sequencing techniques.","ATRX Mutation Status by Sequencing | ATRX Sequencing | Alpha Thalassemia/Mental Retardation Syndrome X-Linked Mutation Analysis by Sequencing | RAD54 Homolog Mutation Analysis by Sequencing | RAD54 Mutation Analysis by Sequencing | RAD54L Mutation Analysis by Sequencing | XH2 Mutation Analysis by Sequencing | XNP Mutation Analysis by Sequencing | ZNF-HX Mutation Analysis by Sequencing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936931","IDH1/2 Mutation Status by Sequencing","C157186","An indication that the presence or absence of IDH1/IDH2 gene mutations was determined using sequencing techniques.","IDH1/2 Mutation Status by Sequencing | IDH1 / IDH2 Mutation Status by Sequencing | IDH1/2 Mutation Analysis by Sequencing | IDH1/2 Sequencing | IDH1/IDH2 Sequencing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936891","TP53 Mutation Status by Sequencing","C157238","An indication that the presence or absence of TP53 gene mutations was determined using sequencing techniques.","TP53 Mutation Status by Sequencing | TP53 Sequencing | Tumor Protein p53 Mutation Analysis by Sequencing | p53 Mutation Analysis by Sequencing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937123","First Degree Family History of Cancer","C157438","A question about whether the parents, siblings or children of an individual have a history of cancer.","First Degree Family History of Cancer | Cancer in the immediate family | Family History of Cancer (First degree relatives parents, siblings, or children)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937172","Family History of Primary Brain Tumor (First degree relatives parents, siblings, or children)","C157440","A question about whether the parents, siblings or children of an individual have a history of a primary brain tumor.","Is there a First Degree Family History of Primary Brain Tumor | Family History of Primary Brain Tumor (First degree relatives parents, siblings, or children)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937114","Non-Neoplastic Finding","C157510","Clinical, laboratory or molecular evidence, or absence of evidence of a non-neoplastic disease.","Non-Neoplastic Finding | Non-Neoplastic Findings",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971163","Non-Neoplastic Finding Absent","C160178","There is no non-neoplastic finding.","Non-Neoplastic Finding Absent | None | None Identified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0455624","Risk Factor History","C157153","A record of an individual's attribute, characteristic or exposure that increases the likelihood of developing a disease or injury. (WHO)","Risk Factor History | History of Risk Factors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552484","Risk Factor History Negative","C159672","The determination that an individual's risk factor history is negative.","Risk Factor History Negative | None",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936896","Ishak Score 3-4","C157161","Fibrosis extends beyond the portal areas and bridging fibrosis is present.","Ishak Score 3-4 | 3,4 - Fibrous Septa | 3-4 (Fibrous Septa)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936900","Ishak Score 1-2","C157159","Portal fibrosis is present.","Ishak Score 1-2 | 1,2 - Portal Fibrosis | 1-2 (Portal Fibrosis)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936937","CTNNB1 Mutation Analysis","C157177","A procedure used to detect and identify mutations in the CTNNB1 gene.","CTNNB1 Mutation Analysis | Beta Catenin Mutation Analysis | Beta-Catenin Mutation Analysis | CTNNB Mutation Analysis | CTNNB1 Mutation Status | Catenin Beta 1 Mutation Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0718658","Thyroid Extract","C2565","An animal source of thyroid used in hormonal replacement therapy. Thyroid extract or desiccated thyroid contains both levothyroxine (thyroxine or T4) and liothyronine (triiodothyronine or T3). Levothyroxine is deiodinated in the peripheral tissues to produce increased levels of its active form, liothyronine (T3). Thyroid hormones play an important role in the regulation of cellular respiration, thermogenesis, cellular growth and differentiation as well as regulating the metabolism of proteins, carbohydrates, and lipids.","Thyroid Extract | Armour Thyroid | Levothyroxine/Liothyronine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3249825","Povidone-Iodine","C766","An iodophor solution containing a water-soluble complex of iodine and polyvinylpyrrolidone (PVP) with broad microbicidal activity. Free iodine, slowly liberated from the polyvinylpyrrolidone iodine (PVPI) complex in solution, kills eukaryotic or prokaryotic cells through iodination of lipids and oxidation of cytoplasmic and membrane compounds. This agent exhibits a broad range of microbicidal activity against bacteria, fungi, protozoa, and viruses. Slow release of iodine from the PVPI complex in solution minimizes iodine toxicity towards mammalian cells.","Povidone-Iodine | Betadine | E-Z Prep | E-Z Scrub | Iodine Povidone Topical | Iodopovidone | POVIDONE-IODINE | PVP iodine | PVP-I | PVP-Iodine | Povidone iodine | Povidone-Iodine Solution | Povidone-iodine | Traumasept | Ultradine | Videne",,,,,,,,,,,,,,,"4299861","Povidone iodine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014479","Ephedrine","C472","An alkaloid that is an hydroxylated form of phenethylamineand sympathomimetic amine, with potential bronchodilatory and anti-hypotensive activities. Following administration, ephedrine activates post-synaptic noradrenergic receptors. Activation of alpha-adrenergic receptors in the vasculature induces vasoconstriction, and activation of beta-adrenergic receptors in the lungs leads to bronchodilation.","Ephedrine | (-)-Ephedrine | EPHEDRINE | [R-(R*,S*)]-alpha-[1-(Methylamino)ethyl]benzenemethanol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0072510","Proparacaine","C61910","A benzoic acid derivative anesthetic agent, with local anesthetic activity. Upon administration, proparacaine stabilizes the neuronal membrane by binding to and inhibiting voltage-gated sodium channels. This inhibits the sodium ion influx required for the initiation and conduction of impulses within the neuronal cell, increases the threshold for electrical stimulation and results in a loss of sensation.","Proparacaine | 2-(Diethylamino)ethyl 3-amino-4-propoxybenzoate | 3-Amino-4-propoxybenzoic acid 2-(diethylamino)ethyl Ester | PROPARACAINE | Proxymetacaine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053877","Ventriculostomy Drain","C122610","A hollow tube that is surgically placed a cerebral ventricle to drain excess cerebrospinal fluid.","Ventriculostomy Drain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005575","Biotin","C309","Hexahydro-2-oxo-1H-thieno(3,4-d)imidazole-4-pentanoic acid. Growth factor present in minute amounts in every living cell. It occurs mainly bound to proteins or polypeptides and is abundant in liver, kidney, pancreas, yeast, and milk. The biotin content of cancerous tissue is higher than that of normal tissue.","Biotin | (+)-Biotin | -(+)-Biotin | 5-(3-oxo-7-thia-2,4-diazabicyclo[3.3.0]oct-8-yl)pentanoic acid | BIOTIN | Vitamin B-7 | Vitamin H | biotin | vitamin H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0854467","Myelosuppression","C9230","A laboratory test result indicating low production of erythrocytes, leukocytes and/or thrombocytes from the bone marrow.","Myelosuppression | myelosuppression",,,,,,,,,,,,,,,"4156433","Myelosuppression",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937118","HCV Genotype Finding","C157506","The determination of the genotype of hepatitis c virus in a blood sample.","HCV Genotype Finding | HCV Genotype",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936890","TERT Promoter Mutation Analysis","C157237","A procedure used to detect and identify mutations in the promoter sequences for the TERT gene.","TERT Promoter Mutation Analysis | TERT Promoter Mutation Status | TRT Promoter Mutation Analysis | Telomerase Reverse Transcriptase Promoter Mutation Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937134","International Normalized Ratio of Prothrombin Time Level Finding","C157421","A finding that indicates the international normalized ratio of prothrombin time level in a sample.","International Normalized Ratio of Prothrombin Time Level Finding | Prothrombin Time INR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936930","IDH1/IDH2 Mutation Analysis","C157185","A procedure used to detect and identify mutations in the IDH1 and IDH2 genes.","IDH1/IDH2 Mutation Analysis | IDH1 / IDH2 Mutation Status | IDH1/2 Mutation Analysis | IDH1/2 Mutation Status | IDH1/IDH2 Mutation Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951440","Percent of Necrosis","C159481","A quantitative measurement of the percent of cells undergoing necrosis compared to the number of total cells present in a sample.","Percent of Necrosis | % Necrosis | NECROSIS | NECROSIS_PCT | Percent Necrosis | necrosis percent | necrosis_percent | percent necrosis | percent_necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978404","Tissue Slide","C165223","A slide on which a tissue section has been mounted.","Tissue Slide | Slides",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972262","ZNF532/NUTM1 Fusion Gene","C167275","A fusion gene that results from a chromosomal translocation t(15;18)(q14;q21.32) which fuses either the first 4 exons or the first 10 exons of the ZNF532 gene with either intron 1 or exon 2 of the NUTM1 gene, respectively. This rare rearrangement is associated with NUT carcinoma.","ZNF532/NUTM1 Fusion Gene | ZNF532-NUT Fusion Gene | ZNF532-NUT Translocation | ZNF532-NUTM1 Fusion Gene | ZNF532/NUT Fusion Gene | ZNF532/NUT Translocation | ZNF532::NUTM1 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969411","MET Gene Amplification Negative","C160400","An indication that amplification of the MET gene was not detected in a sample.","MET Gene Amplification Negative | HGFR Gene Amplification Negative | Hepatocyte Growth Factor Receptor Gene Amplification Negative | MET Amplification Negative | MET Proto-Oncogene, Receptor Tyrosine Kinase Gene Amplification Negative | Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Gene Amplification Negative | Negative | c-MET Gene Amplification Negative | c-Met Amplification Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972983","QuickDASH Outcome Measure","C167293","An 11-item questionnaire designed to measure physical function and symptoms in people with any or multiple musculoskeletal disorders of the upper limb.","QuickDASH Outcome Measure | Q-DASH | QuickDASH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972278","Ability to Open Tight or New Jar","C167294","A question about an individual's ability to open a tight or new jar.","Ability to Open Tight or New Jar Question | Ability to Open Tight or New Jar | Ability to Open Tight or New Jar | Open a tight or new jar",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972279","Ability to Wash Your Back","C167297","A question about an individual's ability to wash their back.","Ability to Wash Your Back Question | Ability to Wash Your Back | Ability to Wash Your Back | Wash your back",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972282","Ability to Use Knife to Cut Food","C167298","A question about an individual's ability to use a knife to cut food.","Ability to Use Knife to Cut Food Question | Ability to Use Knife to Cut Food | Ability to Use Knife to Cut Food | Use a knife to cut food",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972281","Ability to do Recreational Activities which Require Force or Impact Through Arm, Shoulder, or Hand","C167299","A question about an individual's ability to do recreational activities which require force or impact through their arm, shoulder, or hand.","Ability to do Recreational Activities which Require Force or Impact Through Arm, Shoulder, or Hand Question | Ability to do Recreational Activities Which Takes Some Force or Impact Through Arm, Shoulder or Hand | Ability to do Recreational Activities which Require Force or Impact Through Arm, Shoulder, or Hand | Ability to do Recreational Activities which Require Force or Impact Through Arm, Shoulder, or Hand | Recreational activities in which you take some force or impact through your arm, shoulder or hand (e.g., golf, hammering, tennis, etc.)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972284","Extent that Arm, Shoulder, or Hand Problem Interfered with Normal Social Activities","C167300","A question about the extent that an individual's arm, shoulder, or hand problems interfered with their normal social activities.","Extent that Arm, Shoulder, or Hand Problem Interfered with Normal Social Activities | To what extent has your arm, shoulder or hand problem interfered with your normal social activities with family, friends, neighbors or groups",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972283","Extent that Arm, Shoulder, or Hand Problem Limited Work or Other Regular Activities","C167301","A question about the extent that an individual's arm, shoulder, or hand problems limited their work or other regular, daily activities.","Extent that Arm, Shoulder, or Hand Problem Limited Work or Other Regular Activities | Limited in Work or Other Regular Daily Activities as Result of Arm, Shoulder or Hand Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972286","Severity of Arm, Shoulder, or Hand Pain","C167302","A question about the severity of pain in an individual's arm, shoulder, or hand.","Severity of Arm, Shoulder, or Hand Pain | Arm, Shoulder or Hand Pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972285","Severity of Tingling in Arm, Shoulder, or Hand","C167303","A question about the severity of tingling in an individual's arm, shoulder, or hand.","Severity of Tingling in Arm, Shoulder, or Hand | Tingling (pins and needles) in your arm, shoulder or hand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972288","Severity of Sleep Difficulty Because of Pain in Arm, Shoulder, or Hand","C167304","A question about the difficulty an individual had in sleeping because of the pain in their arm, shoulder, or hand.","Severity of Sleep Difficulty Because of Pain in Arm, Shoulder, or Hand | How much difficulty have you had sleeping because of the pain in your arm, shoulder or hand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972287","Impact of Arm, Shoulder, or Hand Problem on Ability to Use Usual Technique for Work","C167305","A question about the impact of an individual's arm, shoulder, or hand problem in using their usual technique for their work.","Impact of Arm, Shoulder, or Hand Problem on Ability to Use Usual Technique for Work | Using your usual technique for your work",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972290","Impact of Arm, Shoulder, or Hand Problem on Ability to Do Usual Work","C167306","A question about the impact of an individual's arm, shoulder, or hand problem in doing their usual work.","Impact of Arm, Shoulder, or Hand Problem on Ability to Do Usual Work | Doing your usual work because of arm, shoulder or hand pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972289","Impact of Arm, Shoulder, or Hand Problem on Ability to Do Work as Well as Would Like","C167307","A question about the impact of an individual's arm, shoulder, or hand problem in working as well as they would like.","Impact of Arm, Shoulder, or Hand Problem on Ability to Do Work as Well as Would Like | Doing your work as well as you would like",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972292","Impact of Arm, Shoulder, or Hand Problem on Ability to Spend Usual Amount of Time Doing Work","C167308","A question about the impact of an individual's arm, shoulder, or hand problem in spending the usual amount of time doing their work.","Impact of Arm, Shoulder, or Hand Problem on Ability to Spend Usual Amount of Time Doing Work | Spending your usual amount of time doing your work",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972291","Impact of Arm, Shoulder, or Hand Problem on Ability to Use Usual Technique for Playing Instrument or Sport","C167309","A question about the impact of an individual's arm, shoulder, or hand problem in using their usual technique for playing their instrument or sport.","Impact of Arm, Shoulder, or Hand Problem on Ability to Use Usual Technique for Playing Instrument or Sport Question | Impact of Arm, Shoulder, or Hand Problem on Ability to Use Usual Technique for Playing Instrument or Sport | Impact of Arm, Shoulder, or Hand Problem on Ability to Use Usual Technique for Playing Instrument or Sport | Using your usual technique for playing your instrument or sport",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972294","Impact of Arm, Shoulder, or Hand Problem on Ability to Play Instrument or Sport","C167310","A question about the impact of an individual's arm, shoulder, or hand problem for playing their instrument or sport.","Impact of Arm, Shoulder, or Hand Problem on Ability to Play Instrument or Sport Question | Impact of Arm, Shoulder, or Hand Problem on Ability to Play Instrument or Sport | Impact of Arm, Shoulder, or Hand Problem on Ability to Play Instrument or Sport | Playing your musical instrument or sport because of arm, shoulder or hand pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972293","Impact of Arm, Shoulder, or Hand Problem on Ability to Play Instrument or Sport as Well as Would Like","C167311","A question about the impact of an individual's arm, shoulder, or hand problem for playing their instrument or sport as well as they would like.","Impact of Arm, Shoulder, or Hand Problem on Ability to Play Instrument or Sport as Well as Would Like Question | Impact of Arm, Shoulder, or Hand Problem on Ability to Play Instrument or Sport as Well as Would Like | Impact of Arm, Shoulder, or Hand Problem on Ability to Play Instrument or Sport as Well as Would Like | Playing your musical instrument or sport as well as you would like",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972296","Impact of Arm, Shoulder, or Hand Problem on Ability to Spend Usual Amount of Time Playing Instrument or Sport","C167312","A question about the impact of an individual's arm, shoulder, or hand problem in spending the usual amount of time playing their instrument or sport.","Impact of Arm, Shoulder, or Hand Problem on Ability to Spend Usual Amount of Time Playing Instrument or Sport Question | Impact of Arm, Shoulder, or Hand Problem on Ability to Spend Usual Amount of Time Playing Instrument or Sport | Impact of Arm, Shoulder, or Hand Problem on Ability to Spend Usual Amount of Time Playing Instrument or Sport | Spending your usual amount of time practising or playing your instrument or sport",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972295","No Difficulty","C167313","A response indicating that an individual has or had no difficulty doing something.","No Difficulty | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972297","Mild Difficulty","C167314","A response indicating that an individual has or had mild difficulty doing something.","Mild Difficulty | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3843247","Moderate Difficulty","C167315","A response indicating that an individual has or had moderate difficulty doing something.","Moderate Difficulty | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972298","Severe Difficulty","C167316","A response indicating that an individual has or had sevete difficulty doing something.","Severe Difficulty | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL973033","Does Not Interfere","C167317","A response indicating that something does not interfere at all.","Does Not Interfere | Does Not Interfere at All | Interferes Not at All | Not at All",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972988","Interferes Slightly","C167318","A response indicating that something interferes slightly.","Interferes Slightly | Slightly | Slightly Interfering",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972299","Interferes Moderately","C167319","A response indicating that something interferes moderately.","Interferes Moderately | Moderately | Moderately Interfering",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972301","Interferes Quite a Bit","C167320","A response indicating that something interferes quite a bit.","Interferes Quite a Bit | Quite a Bit | Quite a Bit Interfering",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972300","Extremely Interfering","C167321","A response indicating that something is extremely interfering.","Extremely Interfering | Extremely",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3845318","Moderately Limited","C167322","A response indicating that an individual is or feels moderately limited.","Moderately Limited | Moderately limited",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972302","So Much Difficulty Can't Sleep","C167323","A response indicating that an individual had so much pain in their arm, shoulder, or hand that they could not sleep.","So Much Difficulty Can't Sleep | So much difficulty that I can't sleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520162","Nasopharyngeal Cancer TNM Finding v8","C132792","A finding about one or more characteristics of nasopharyngeal cancer, following the rules of the TNM AJCC v8 classification system. Epithelial tumors of the nasopharynx are staged using this staging system. Mucosal melanoma, lymphoma, and sarcoma of soft tissue, bone, and cartilage are not included in this classification. (from AJCC 8th Ed.)","Nasopharyngeal Cancer TNM Finding v8 | Nasopharyngeal Carcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520176","Nasopharyngeal Cancer pTX TNM Finding v8","C132796","Nasopharyngeal cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Nasopharyngeal Cancer pTX TNM Finding v8 | Nasopharyngeal Carcinoma pTX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520175","Nasopharyngeal Cancer pT4 TNM Finding v8","C132801","Nasopharyngeal cancer with intracranial extension, involvement of cranial nerves, hypopharynx, orbit, parotid gland, and/or extensive soft tissue infiltration beyond the lateral surface of the lateral pterygoid muscle. (from AJCC 8th Ed.)","Nasopharyngeal Cancer pT4 TNM Finding v8 | Nasopharyngeal Carcinoma pT4 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520174","Nasopharyngeal Cancer pT3 TNM Finding v8","C132800","Nasopharyngeal cancer with tumor infiltrating bony structures at skull base, cervical vertebrae, pterygoid structures, and/or paranasal sinuses. (from AJCC 8th Ed.)","Nasopharyngeal Cancer pT3 TNM Finding v8 | Nasopharyngeal Carcinoma pT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520173","Nasopharyngeal Cancer pT2 TNM Finding v8","C132799","Nasopharyngeal cancer with extension to parapharyngeal space, and/or adjacent soft tissue involvement (medial pterygoid, lateral pterygoid, prevertebral muscles). (from AJCC 8th Ed.)","Nasopharyngeal Cancer pT2 TNM Finding v8 | Nasopharyngeal Carcinoma pT2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520172","Nasopharyngeal Cancer pT1 TNM Finding v8","C132798","Nasopharyngeal cancer with tumor confined to the nasopharynx, or tumor extending to oropharynx and/or nasal cavity without parapharyngeal involvement. (from AJCC 8th Ed.)","Nasopharyngeal Cancer pT1 TNM Finding v8 | Nasopharyngeal Carcinoma pT1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520177","Nasopharyngeal Cancer pTis TNM Finding v8","C132802","Nasopharyngeal cancer with a finding of carcinoma in situ. (from AJCC 8th Ed.)","Nasopharyngeal Cancer pTis TNM Finding v8 | Nasopharyngeal Carcinoma pTis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520171","Nasopharyngeal Cancer pT0 TNM Finding v8","C132797","No tumor identified, but EBV-positive cervical node(s) involvement is present. (from AJCC 8th Ed.)","Nasopharyngeal Cancer pT0 TNM Finding v8 | Nasopharyngeal Carcinoma pT0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520169","Nasopharyngeal Cancer pN3 TNM Finding v8","C132808","Nasopharyngeal cancer with unilateral or bilateral metastasis in cervical lymph node(s), larger than 6 cm in greatest dimension, and/or extension below the caudal border of cricoid cartilage. (from AJCC 8th Ed.)","Nasopharyngeal Cancer pN3 TNM Finding v8 | Nasopharyngeal Carcinoma pN3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520168","Nasopharyngeal Cancer pN2 TNM Finding v8","C132807","Nasopharyngeal cancer with bilateral metastasis in cervical lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage. (from AJCC 8th Ed.)","Nasopharyngeal Cancer pN2 TNM Finding v8 | Nasopharyngeal Carcinoma pN2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520167","Nasopharyngeal Cancer pN1 TNM Finding v8","C132806","Nasopharyngeal cancer with unilateral metastasis in cervical lymph node(s), and/or unilateral or bilateral metastasis in retropharyngeal lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage. (from AJCC 8th Ed.)","Nasopharyngeal Cancer pN1 TNM Finding v8 | Nasopharyngeal Carcinoma pN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520166","Nasopharyngeal Cancer pN0 TNM Finding v8","C132805","Nasopharyngeal cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","Nasopharyngeal Cancer pN0 TNM Finding v8 | Nasopharyngeal Carcinoma pN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520170","Nasopharyngeal Cancer pNX TNM Finding v8","C132804","Nasopharyngeal cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Nasopharyngeal Cancer pNX TNM Finding v8 | Nasopharyngeal Carcinoma pNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972367","SF3B1 NP_036565.2:p.T663X","C167138","A change in the amino acid residue at position 663 in the splicing factor 3B subunit 1 protein where threonine has been replaced by another amino acid.","SF3B1 NP_036565.2:p.T663X | NP_036565.2:p.T663X | NP_036565.2:p.Thr663Xxx | Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit T663X | Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Thr663Xxx | SAP 155 T663X | SAP 155 Thr663Xxx | SF3B1 NP_036565.2:p.Thr663Xxx | SF3B1 T663 Mutation | SF3B1 T663X | SF3B1 Thr663Xxx | SF3B1 p.T663X | SF3B1 p.Thr663Xxx | SF3b155 T663X | SF3b155 Thr663Xxx | Spliceosome-Associated Protein 155 T663X | Spliceosome-Associated Protein 155 Thr663Xxx | Splicing Factor 3B Subunit 1 T663X | Splicing Factor 3B Subunit 1 Thr663Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520165","Nasopharyngeal Cancer pM1 TNM Finding v8","C132810","Nasopharyngeal cancer with distant metastasis. (from AJCC 8th Ed.)","Nasopharyngeal Cancer pM1 TNM Finding v8 | Nasopharyngeal Carcinoma pM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520164","Nasopharyngeal Cancer cM1 TNM Finding v8","C132813","Nasopharyngeal cancer with distant metastasis. (from AJCC 8th Ed.)","Nasopharyngeal Cancer cM1 TNM Finding v8 | Nasopharyngeal Carcinoma cM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520163","Nasopharyngeal Cancer cM0 TNM Finding v8","C132812","Nasopharyngeal cancer without evidence of distant metastasis. (from AJCC 8th Ed.)","Nasopharyngeal Cancer cM0 TNM Finding v8 | Nasopharyngeal Carcinoma cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520178","Nasopharyngeal Carcinoma by AJCC v8 Stage","C132816","A term that refers to the staging of nasopharyngeal carcinoma according to the American Joint Committee on Cancer, 8th edition.","Nasopharyngeal Carcinoma by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520970","Stage IVB Nasopharyngeal Carcinoma AJCC v8","C132822","Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","Stage IVB Nasopharyngeal Carcinoma AJCC v8 | Stage IVB Nasopharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520966","Stage IVA Nasopharyngeal Carcinoma AJCC v8","C132821","Stage IVA includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0); (Any T, N3, M0); T4: Tumor with intracranial extension, involvement of cranial nerves, hypopharynx, orbit, parotid gland, and/or extensive soft tissue infiltration beyond the lateral surface of the lateral pterygoid muscle.  N0: No regional lymph node metastasis. N1: Tumor with unilateral metastasis in cervical lymph node(s), and/or unilateral or bilateral metastasis in retropharyngeal lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage. N2: Tumor with bilateral metastasis in cervical lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage. N3: Tumor with unilateral or bilateral metastasis in cervical lymph node(s), larger than 6 cm in greatest dimension, and/or extension below the caudal border of cricoid cartilage. M0: No distant metastasis. (AJCC 8th ed.)","Stage IVA Nasopharyngeal Carcinoma AJCC v8 | Stage IVA Nasopharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520958","Stage III Nasopharyngeal Carcinoma AJCC v8","C132819","Stage III includes: (T1, N2, M0); (T0, N2, M0); (T2, N2, M0); (T3, N0, M0); (T3, N1, M0); (T3, N2, M0). T1: Tumor confined to the nasopharynx, or tumor extending to oropharynx and/or nasal cavity without parapharyngeal involvement. T0: No tumor identified, but EBV-positive cervical node(s) involvement is present. T2: Tumor with extension to parapharyngeal space, and/or adjacent soft tissue involvement (medial pterygoid, lateral pterygoid, prevertebral muscles). T3: Tumor infiltrating bony structures at skull base, cervical vertebrae, pterygoid structures, and/or paranasal sinuses. N0: No regional lymph node metastasis. N1: Tumor with unilateral metastasis in cervical lymph node(s), and/or unilateral or bilateral metastasis in retropharyngeal lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage. N2: Tumor with bilateral metastasis in cervical lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Nasopharyngeal Carcinoma AJCC v8 | Stage III Nasopharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521282","Stage II Nasopharyngeal Carcinoma AJCC v8","C132818","Stage II includes: (T1, N1, M0); (T0, N1, M0); (T2, N0, M0); (T2, N1, M0). T1: Tumor confined to the nasopharynx, or tumor extending to oropharynx and/or nasal cavity without parapharyngeal involvement. T0: No tumor identified, but EBV-positive cervical node(s) involvement is present. T2: Tumor with extension to parapharyngeal space, and/or adjacent soft tissue involvement (medial pterygoid, lateral pterygoid, prevertebral muscles). N0: No regional lymph node metastasis. N1: Tumor with unilateral metastasis in cervical lymph node(s), and/or unilateral or bilateral metastasis in retropharyngeal lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Nasopharyngeal Carcinoma AJCC v8 | Stage II Nasopharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521278","Stage I Nasopharyngeal Carcinoma AJCC v8","C132817","Stage I includes: T1, N0, M0. T1: Tumor confined to the nasopharynx, or tumor extending to oropharynx and/or nasal cavity without parapharyngeal involvement. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Nasopharyngeal Carcinoma AJCC v8 | Stage I Nasopharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435381","Methemoglobin Reductase Deficiency","C101043","Less than the necessary amount of the enzyme that converts methemoglobin into hemoglobin.","Methemoglobin Reductase Deficiency | Cytochrome B5 Reductase Deficiency | NADH-CYB5R Deficiency | NADH-Cytochrome B5 Reductase Deficiency | NADH-Dependent Methemoglobin Reductase Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545924","Patient-Reported Survey Instrument","C142631","A document or collection or documents that contain a patient-reported survey (e.g., questionnaire) in addition to the information and instructions that document how to use the survey.","Patient-Reported Survey Instrument | instrument",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704763","B Vitamin Family","C45812","A class of nutrients that are in the water-soluble B-vitamin family.  B vitamins include thiamine, riboflavin, niacin (nicotinic acid), niacinamide (nicotinamide), the vitamin B6 group (including pyridoxine, pyridoxal, pyridoxamine), biotin, pantothenic acid, folic acid, and possibly para-aminobenzoic.","B Vitamin | B Vitamin Family | B Vitamins | Vitamin B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0723276","SENOKOT-S","C29450","A combination preparation composed of a standardized senna concentrate and the sodium salt form of the emollient laxative docusate, with laxative and stool softening activity. Senna concentrate consists of the anthraquinone glycosides sennosides extracted from senna leaves. Sennosides act on and irritate the lining of the intestine wall, thereby causing increased intestinal muscle contractions leading to vigorous bowel movement and relief of constipation. Docusate, an anionic surfactant, decreases surface tension and emulsification of fecal matter and allows water to penetrate and mix with stool. This softens the stool for smoother and easier evacuation.","Docusate Sodium-Senna | Docusate Sodium/Senna Glycoside | Docusate Sodium/Sennosides | Senokot-S | Senokot-S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1569608","Varenicline","C73609","A partial agonist of the nicotinic acetylcholine receptor (nAChR) subtype alpha4beta2. Nicotine stimulation of central alpha4beta2 nAChRs located at presynaptic terminals in the nucleus accumbens causes the release of the neurotransmitter dopamine, which may be associated with the experience of pleasure; nicotine addiction constitutes a physiologic dependence related to this dopaminergic reward system. As an AChR partial agonist, varenicline attenuates the craving and withdrawal symptoms that occur with abstinence from nicotine but is not habit-forming itself.","Varenicline | 7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino(2,3-h)(3)benzazepine (2R,3R)-2,3-dihydroxybutqanedioate | CP-526555 | Champix | Chantix | VARENICLINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972324","Musical Instrument","C167351","A device used to make musical tones or sounds.","Musical Instrument | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518423","Not Defined","C19377","No definition provided; unspecified.","Not Defined | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2353170","Fedratinib","C88293","An orally bioavailable, small-molecule, ATP-competitive inhibitor of Janus-associated kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration, fedratinib competes with wild-type JAK2 as well as mutated forms for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, inhibition of tumor cell proliferation and induction of tumor cell apoptosis. JAK2 is the most commonly mutated gene in bcr-abl-negative myeloproliferative disorders (MPDs). In addition, fedratinib targets, binds to and inhibits the activity of FLT3. This inhibits uncontrolled FLT3 signaling and results in the inhibition of proliferation in tumor cells overexpressing FLT3. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias and plays a key role in tumor cell proliferation.","Fedratinib | Benzenesulfonamide, N-(1,1-dimethylethyl)-3-((5-methyl-2-((4-(2-(1-pyrrolidinyl)ethoxy)phenyl)amino)-4-pyrimidinyl)amino)- | FEDRATINIB | SAR 302503 | SAR-302503 | SAR302503 | TG 101348 | TG-101348 | TG101348",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515666","inv(3)(q21.3;q26.2)","C36407","A cytogenetic abnormality that refers to a paracentric inversion involving breakpoints on the long (q23.1 and q26.2) of chromosome 3. It is associated with acute myeloid leukemia.","inv(3)(q21.3;q26.2) | inv(3)(q21.3q26.2) | inv(3)(q21;q26.2) | inv(3)(q21q26.2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515763","t(3;21)(q26;q22)","C36606","A cytogenetic abnormality that refers to the translocation of the long arm (q26) of chromosome 3 and the long arm (q22) of chromosome 21. It is associated with RUNX1/MECOM fusions, chronic myelogenous leukemia in blast crisis (BC-CML), myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).","t(3;21)(q26;q22) | t(3;21)(q26.2;q22)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515781","t(6;9)(p23;q34)","C36532","A cytogenetic abnormality that refers to the translocation of the short arm (p22.3) of chromosome 6 and the long arm (q34.1) of chromosome 9. It is associated with DEK/NUP214 fusions, acute myeloid leukemia and myelodysplastic syndromes.","t(6;9)(p22.3;q34.1) | t(6;9)(p22.3;q34.1) | t(6;9)(p22;q34) | t(6;9)(p23;q34) | t(6;9)(p23;q34.1) | t(6;9)(p23;q34.1)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515727","t(16;21)(p11;q22)","C36616","A chromosomal translocation involving the FUS gene on chromosome 16p11 and the ERG gene on chromosome 21q22.","t(16;21)(p11;q22) | t(16;21)(p11.2;q22.2) | t(16;21)(p11;q22) (Ewing sarcoma) | t(16;21)(p11;q22)FUS/ERG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515711","t(11;19)(q23.3;p13.3)","C36372","A cytogenetic abnormality that refers to the translocation of the long arm (q23.3) of chromosome 11 and the short arm (p13.3) of chromosome 19. It is associated with KMT2A (MLL)/MLLT1 (ENL) fusions and acute myeloid leukemia.","t(11;19)(q23.3;p13.3) | t(11;19)(q23;p13.3)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951015","Rearrangement Detected","C158948","An indication that a cytogenetic rearrangement was detected in a sample.","Rearrangement Detected | Chromosomal Rearrangement Detected | Chromosome Rearrangement Detected | Cytogenetic Rearrangement Detected | Cytogenetic Rearrangement Positive | Cytogenetic Rearrangement Present | Rearrangement Positive | Rearrangement Present | Rearrangement identified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520479","12p13.2","C14116","A chromosome band present on 12p","12p13.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972344","Data Refresh","C167375","A process where all the data in a database environment is updated.","Data Refresh | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972568","PD-L1 IHC 22C3 PharmDx","C167384","A proprietary assay for PD-L1 (Programmed Cell Death 1 Ligand 1). It uses antibody 22C3 to specifically bind PD-L1 on the cell membrane of immune cells and normal and tumor cells of epithelial origin in formalin-fixed, paraffin-embedded (FFPE) specimens.","PD-L1 IHC 22C3 PharmDx | 22C3 PharmDx | Dako 22C3 | PD-L1 IHC 22C3 pharmDx | PD-L1 by clone 22C3 [Presence] in Tissue by Immune stain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972571","PD-L1 IHC 28-8 PharmDx","C167385","A proprietary assay for PD-L1 (Programmed Cell Death 1 Ligand 1). It uses antibody 28-8 to specifically bind PD-L1 on the cell membrane of immune cells and normal and tumor cells of epithelial origin in formalin-fixed, paraffin-embedded (FFPE) specimens.","PD-L1 IHC 28-8 PharmDx | 28-8 PharmDx | Dako 28-8 | PD-L1 IHC 28-8 pharmDx | PD-L1 by clone 28-8 [Presence] in Tissue by Immune stain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979257","Screening Not Completed","C166074","An indication that recruitment was closed before the subject could be randomized.","Screening Not Completed | SCREENING NOT COMPLETED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972581","Ventana PD-L1 SP263","C167398","A proprietary assay for PD-L1 (Programmed Cell Death 1 Ligand 1). It uses antibody SP263 to specifically bind PD-L1 on the cell membrane of immune cells and normal and tumor cells of epithelial origin in formalin-fixed, paraffin-embedded (FFPE) specimens.","Ventana PD-L1 SP263 | SP263 | Ventana PD-L1 (SP263) Assay | Ventana SP263",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042211","Vaccines, Attenuated","C97116","Any vaccine created by reducing the virulence of the infectious agent but still keeping the agent viable (live). In the production of an attenuated vaccine, the infectious agent is altered so that it becomes harmless or less virulent. This is in contrast to those vaccines produced by killing the pathogen (inactivated vaccine).","Attenuated Live Vaccine | LAV | Live Attenuated Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280962","Bone Marrow Suppression","C74440","A condition in which the production of red blood cells, white blood cells, and/or platelets by bone marrow stem cells is inhibited, usually as a side effect of treatment with various anti-cancer agents, radiation, or tumor development within the bone marrow.","Bone Marrow Suppression | Bone Marrow Depression | Myelosuppression",,,,,,,,,,,,,,,"4145241|4215820","Bone marrow depression|Hypocellular bone marrow",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1883251","Survey Administration","C64252","The act of presenting a survey, questionnaire, or similar item to a person to obtain their responses.","Survey Administration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541270","Data Mapping","C142485","The process of connecting an item or symbol to a code or concept.","Data Mapping | mapping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972883","EORTC Quality of Life Questionnaire - Lung Cancer Module","C168555","A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials.","EORTC Quality of Life Questionnaire - Lung Cancer Module | EOR18 | EORTC QLQ Lung Cancer Module | EORTC QLQ-LC13 | EORTC Study Group on Quality of Life 13-item Lung Cancer-Specific Questionnaire | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer Module",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972882","How Much Did You Cough","C168556","A question about how much an individual coughed.","How Much Did You Cough | How much did you cough",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972885","Did You Cough Up Blood","C168557","A question about whether an individual coughed up blood.","Did You Cough Up Blood | Did you cough up blood",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972884","Short of Breath When You Rested","C168558","A question about whether an individual is or was short of breath when they rested.","Short of Breath When You Rested | Were you short of breath when you rested",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972887","Short of Breath When You Walked","C168559","A question about whether an individual is or was short of breath when they walked.","Short of Breath When You Walked Question | Short of Breath When You Walked | Short of Breath When You Walked | Were you short of breath when you walked",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972886","Short of Breath When You Climbed Stairs","C168560","A question about whether an individual is or was short of breath when they climbed stairs.","Short of Breath When You Climbed Stairs | Were you short of breath when you climbed stairs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972889","Had Sore Mouth or Tongue","C168561","A question about whether an individual has or had a sore mouth or tongue.","Had Sore Mouth or Tongue | Have you had a sore mouth or tongue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972890","Tingling Hands or Feet","C168563","A question about whether an individual has or had tingling in hands or feet.","Tingling Hands or Feet | Had Tingling Hands or Feet | Have you had tingling hands or feet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972891","Had Pain in Other Parts of Body","C168566","A question about whether an individual has or had pain in other parts of their body.","Had Pain in Other Parts of Body | Have you had pain in other parts of your body",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972894","Take Medicine for Pain","C168567","A question about whether an individual took or is taking any medicine for their pain.","Take Medicine for Pain | Did you take any medicine for pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972898","IDH Inhibitor Associated Differentiation Syndrome","C168571","A constellation of signs and symptoms occurring in the context of administration of isocitrate dehydrogenase (IDH) inhibitors in hematologic malignancies. It is characterized by dyspnea, unexplained fever, pulmonary infiltrates, hypoxia, pleural effusion, acute kidney injury, pericardial effusion, arthralgia, lymphadenopathy, edema and weight gain.","IDH Inhibitor Associated Differentiation Syndrome | IDH-DS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972902","European Consensus on Grading of Bone Marrow Fibrosis","C168575","A grading scheme that includes both a qualitative (reticulin or collagen) and quantitative evaluation of bone marrow fibrosis comprising four increasing categories.","European Consensus on Grading of Bone Marrow Fibrosis | Grading for Marrow Fibrosis | Marrow Fibrosis Grading System | Updated WHO Fibrosis Classification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972901","Marrow Fibrosis Grade 0","C168576","Scattered linear reticulin with no intersections (crossovers) corresponding to normal bone marrow.","Marrow Fibrosis Grade 0 | MF-0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972904","Marrow Fibrosis Grade 1","C168577","Loose network of reticulin with many intersections, especially in perivascular areas.","Marrow Fibrosis Grade 1 | MF-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972903","Marrow Fibrosis Grade 2","C168578","Diffuse and dense increase in reticulin with extensive intersections, occasionally with focal bundles of thick fibers mostly consistent with collagen and/or focal osteosclerosis.","Marrow Fibrosis Grade 2 | MF-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972906","Marrow Fibrosis Grade 3","C168579","Diffuse and dense increase in reticulin with extensive intersections and coarse bundles of thick fibers mostly consistent with collagen, usually associated with osteosclerosis.","Marrow Fibrosis Grade 3 | MF-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539670","SH2B3 wt Allele","C102803","Human SH2B3 wild-type allele is located in the vicinity of 12q24 and is approximately 46 kb in length. This allele, which encodes SH2B adapter protein 3, is involved in signal transduction. Mutation of the gene is associated with susceptibility to both celiac disease type 13 and insulin-dependent diabetes mellitus.","SH2B3 wt Allele | IDDM20 | LNK | SH2B Adaptor Protein 3 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972913","Low Transfusion Burden","C168594","Generally defined as 3-7 RBC units in 16 weeks in at least 2 transfusion episodes, maximum 3 in 8 weeks.","Low Transfusion Burden | LTB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972912","High Transfusion Burden","C168595","Generally defined as greater than or equal to 8 RBC units in 16 weeks, greater than or equal to 4 transfusion episodes in 8 weeks.","High Transfusion Burden | HTB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514168","Myelodysplastic Syndrome with Ring Sideroblasts and Single Lineage Dysplasia","C130037","A myelodysplastic syndrome with ring sideroblasts and dysplastic changes involving only one myeloid cell lineage in the bone marrow.","Myelodysplastic Syndrome with Ring Sideroblasts and Single Lineage Dysplasia | MDS-RS-SLD",,,,,,,,,,,,,,,"37166856","Myelodysplastic neoplasm with low blasts and SF3B1 mutation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2826323","Refractory Cytopenia of Childhood","C82596","A myeloid disorder that occurs in childhood and is characterized by persistent cytopenia, dysplastic changes in at least two hematopoietic lineages or in 10% or more of cells in one hematopoietic lineage, less than 5% blasts in bone marrow, and less than 2% blasts in peripheral blood, absence of bone marrow fibrosis, and absence of history of prior cytotoxic chemotherapy or radiation therapy. In a subset of cases, somatic mutations or cytogenetic abnormalities can be identified. Other cases are the result of pre-existing disorders with germline mutations, including Fanconi anemia, Shwachman-Diamond syndrome, and dyskeratosis congenita.","Refractory Cytopenia of Childhood | RCC | Refractory cytopenia of childhood",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438394","Luspatercept","C104012","A soluble, recombinant fusion protein composed of a modified form of the extracellular domain of human activin receptor type IIb (ActRIIb) and linked to the human IgG1 Fc domain, with red blood cell stimulating activity. Upon subcutaneous administration, luspatercept inhibits several ligands in the transforming growth factor (TGF)-beta superfamily. This prevents activation of a variety of TGF-beta superfamily members involved in late stage erythropoiesis and results in an increased differentiation and proliferation of erythroid progenitors. luspatercept acts at a different, later stage than erythropoietin. This agent ultimately enhances red blood cell production and prevents anemia.","Luspatercept | (79-L-aspartic Acid(L>D))Human Activin Receptor Type-2B (ACTR-IIB, EC=2.7.11.30) Precursor-(25-131)-peptide (Extracellular Domain Fragment) Fusion Protein with Triglycyl-human Immunoglobulin Heavy Constant Gamma 1 Fc Fragment-(8-232)-peptide Dimer (114-114':117-117')-bisdisulfide | ACE 536 | ACE-536 | ACE536 | LUSPATERCEPT | Luspatercept-aamt | Reblozyl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388369","Smoldering Systemic Mastocytosis","C115460","Slowly progressive systemic mastocytosis with uncertain prognosis. It is characterized by organomegaly and absence of aggressive disease.","Smoldering Systemic Mastocytosis | ",,,,,,,,,,,,,,,"37157722|37164748","Smoldering systemic mastocytosis|Smoldering systemic mastocytosis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0392939","recombinant human thrombopoietin","C878","A recombinantly produced form of human thrombopoietin (rHuTPO). rHuTPO stimulates platelet formation and has potential use as a therapeutic agent to prevent thrombocytopenia in patients receiving chemotherapy.","Recombinant Human Thrombopoietin | Megakaryocyte Growth and Development Factor | RECOMBINANT HUMAN THROMBOPOIETIN | Recombinant Human TPO | rHuTPO | rhTPO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976683","Acid Labile Subunit Measurement","C163419","The determination of the amount of acid labile subunit present in a sample.","Acid Labile Subunit Measurement | ALS | Acid Labile Subunit | IGFALS | IGFALS Measurement | Insulin Like Growth Factor Binding Protein Acid Labile Subunit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976810","Alpha-Smooth Muscle Actin Measurement","C163422","The determination of the amount of alpha-smooth muscle actin present in a sample.","Alpha-Smooth Muscle Actin Measurement | A-SMA Measurement | ASMA Measurement | ASMACT | Alpha-Actin 2 | Alpha-SMA | Alpha-SMA Measurement | Alpha-Smooth Muscle Actin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976681","Angiopoietin 2 Measurement","C163421","The determination of the amount of angiopoietin 2 present in a sample.","Angiopoietin 2 Measurement | ANG2 | ANGPT2 | ANGPT2 Measurement | Ang-2 Measurement | Ang2 Measurement | Angiopoietin 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976682","Anti-Neutrophil Cytoplasmic IgG Antibody Measurement","C163420","The determination of the amount of anti-neutrophil cytoplasmic IgG antibody present in a sample.","Anti-Neutrophil Cytoplasmic IgG Antibody Measurement | ANCA IgG Measurement | ANCIGAB | Anti-Neutrophil Cytoplasmic IgG Antibody | Antineutrophil Cytoplasmic IgG Antibody Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1295141","Estrone Sulfate Measurement","C163431","The determination of the amount of estrone sulfate present in a sample.","Estrone Sulfate Measurement | E1S | Estrone 3-Sulfate | Estrone Sulfate",,,,,,,,,,,,,,,"4007657","Estrone sulfate measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL978350","Dilute Russell's Viper Venom Time to Confirm Ratio Measurement","C163430","The determination of the dilute Russell's viper venom time (dRVVT) without the presence of excess phospholipid to the dRVVT in the presence of excess phospholipid in a biological sample. The measurement may be expressed as either a ratio or a percentage.","Dilute Russell's Viper Venom Time to Confirm Ratio Measurement | DRVVT Screen to Confirm Ratio | DRVVTSCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976804","Dopamine Excretion Rate","C163429","The determination of the amount of dopamine being excreted in a biological specimen over a defined period of time.","Dopamine Excretion Rate | DOPAMEXR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976805","DEAD Box Protein 58 Measurement","C163428","The determination of the amount of DEAD box protein 58 present in a sample.","DEAD Box Protein 58 Measurement | Antiviral Innate Immune Response Receptor RIG-I Measurement | DDX58 | DDX58 Measurement | DEAD Box Protein 58 | DExD/H-Box Helicase 58 | Probable ATP-Dependent RNA Helicase DDX58 | RIGI Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976806","Free Cortisol Excretion Rate","C163427","The determination of the amount of free cortisol being excreted in a biological specimen over a defined period of time.","Free Cortisol Excretion Rate | CRTFREXR | Cortisol, Free Excretion Rate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976807","Cytidine-Uridine Monophosphate Kinase 2 Measurement","C163426","The determination of the amount of cytidine-uridine monophosphate kinase 2 present in a sample.","Cytidine-Uridine Monophosphate Kinase 2 Measurement | CMPK2 | CMPK2 Measurement | Cytidine-Uridine Monophosphate Kinase 2 | Cytidine/Uridine Monophosphate Kinase 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976808","Citrate Excretion Rate","C163425","The determination of the amount of citrate being excreted in a biological specimen over a defined period of time.","Citrate Excretion Rate | CITRTEXR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976809","Carnitine Excretion Rate","C163424","The determination of the amount of carnitine being excreted in a biological specimen over a defined period of time.","Carnitine Excretion Rate | CARNTEXR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978354","Complement C3a DesArg Measurement","C163423","The determination of the amount of complement C3a DesArg present in a sample.","Complement C3a DesArg Measurement | ASP | Acylation-Stimulating Protein | C3ADARG | C3a DesArg Measurement | Complement C3a DesArg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976826","Factor XII Activity Measurement","C163438","The determination of the amount of factor XII activity present in a sample.","Factor XII Activity Measurement | F12a Measurement | FACTXIIA | FXIIa Measurement | Factor XII Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976799","Factor XII Measurement","C163437","The determination of the amount of factor XII present in a sample.","Factor XII Measurement | F12 Measurement | FACTXII | FXII Measurement | Factor XII",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976800","Factor XI Activity Measurement","C163436","The determination of the amount of factor XI activity present in a sample.","Factor XI Activity Measurement | F11a Measurement | FACTXIA | FXIa Measurement | Factor XI Activity | Factor XIa Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976801","Factor XI Measurement","C163435","The determination of the amount of factor XI present in a sample.","Factor XI Measurement | F11 Measurement | FACTXI | FXI Measurement | Factor XI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976802","Epithelial Stromal Interaction 1 Measurement","C163434","The determination of the amount of epithelial stromal interaction 1 protein present in a sample.","Epithelial Stromal Interaction 1 Measurement | BRESI1 | EPSTI1 | EPSTI1 Measurement | Epithelial Stromal Interaction Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976803","Epinephrine Excretion Rate","C163433","The determination of the amount of epinephrine being excreted in a biological specimen over a defined period of time.","Epinephrine Excretion Rate | Adrenaline Excretion Rate | EPINEXR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0729723","Endomysial Antibody Measurement","C163432","The determination of the amount of endomysial antibody present in a sample.","Endomysial Antibody Measurement | EDMAB | Endomysial Antibody | Endomysium Antibody",,,,,,,,,,,,,,,"4078687","Endomysial antibody measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL972851","KRAS Gene Rearrangement","C168523","A molecular abnormality indicating rearrangement of the KRAS gene.","KRAS Gene Rearrangement | KRAS Rearrangement | KRAS-2 Gene Rearrangement | KRAS2 Gene Rearrangement | c-K-ras Gene Rearrangement | v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972854","ERBB Family Gene Fusion Positive","C168524","An indication that a fusion containing ERBB family gene sequences have been detected in a sample.","ERBB Family Gene Fusion Positive | EGF Receptor Family Gene Fusion Positive | ERBB Family Gene Fusion | ERBB Receptor-Tyrosine Kinase Family Gene Fusion Positive | Epidermal Growth Factor Receptor Family Gene Fusion Positive | ErbB Receptor Family Gene Fusion Positive | ErbB Receptor Tyrosine Kinase Family Gene Fusion Positive | HER Family Gene Fusion Positive | HER Family Receptor Gene Fusion Positive | Human Epidermal Growth Factor Receptor Family Gene Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972853","FH Alteration Positive","C168525","An indication that mislocalization, loss or gain of activity, underexpression, overexpression, mutation, fusion or rearrangement involving FH has been detected in a sample.","FH Alteration Positive | FH Alteration | FMRD Alteration Positive | Fumarase Alteration Positive | Fumarate Hydratase Alteration Positive | HsFH Alteration Positive | MCL Alteration Positive | MCUL1 Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972856","SDH Complex Alteration Positive","C168526","An indication that mislocalization, loss or gain of activity, underexpression, overexpression, mutation, fusion or rearrangement involving a either a member of or the entire SDH complex has been detected in a sample.","SDH Complex Alteration Positive | Mitochondrial Complex II Alteration Positive | Mitochondrial Respiratory Chain Complex II Alteration Positive | SDH Alteration | SDH Alteration Positive | SDH Family Alteration Positive | Succinate Dehydrogenase Alteration Positive | Succinate-CoQ Reductase Alteration Positive | Succinate-Coenzyme Q Reductase Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972858","VHL Alteration Positive","C168528","An indication that mislocalization, loss or gain of activity, underexpression, overexpression, mutation, fusion or rearrangement involving VHL has been detected in a sample.","VHL Alteration Positive | VHL Alteration | VHL1 Alteration Positive | Von Hippel-Lindau Disease Tumor Suppressor Alteration Positive | von Hippel Lindau Tumor Suppressor Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972857","Elevated MET Protein Expression","C168529","An indication that elevated concentrations of MET protein were found in a sample.","Elevated MET Protein Expression | Elevated HGF Receptor Protein Expression | Elevated HGFR Protein Expression | Elevated Hepatocyte Growth Factor Receptor Protein Expression | Elevated Proto-Oncogene c-Met Protein Expression | Elevated Scatter Factor Receptor Protein Expression | Elevated Tyrosine-Protein Kinase Met Protein Expression | Elevated c-Met Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972860","FUS Gene Translocation","C168530","A cytogenetic abnormality that refers to any translocation involving the FUS gene.","FUS Gene Translocation | FUS RNA Binding Protein Gene Translocation | FUS Translocation | FUS Translocation Present | FUS1 Gene Translocation | Fused In Sarcoma Gene Translocation | Fusion Gene In Myxoid Liposarcoma Gene Translocation | TLS Gene Translocation | Translocated In Liposarcoma Gene Translocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972862","EGF Antibody","C168532","Any immunoglobulin that recognizes epidermal growth factor protein.","EGF Antibody | Anti-EGF | Anti-EGF Antibody | Anti-Epidermal Growth Factor | Anti-Epidermal Growth Factor Antibody | Anti-Urogastrone Antibody | Epidermal Growth Factor Antibody | Urogastrone Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972861","Circulating EGF Measurement","C168533","A measurement of the unbound epidermal growth factor in a peripheral blood-derived specimen.","Circulating EGF Measurement | Circulating Epidermal Growth Factor Measurement | Free EGF Measurement | Free Epidermal Growth Factor Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4277548","Cancer-Associated Fibroblasts","C168534","A fibroblast found proximal to or within cancerous tissue.","Cancer-Associated Fibroblast | CAF | CAFs | Cancer Associated Fibroblast | TAF | Tumor Associated Fibroblast | Tumor-Associated Fibroblast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972863","Circulating Cancer-Associated Fibroblast","C168535","A fibroblast found in the peripheral blood that is associated with a neoplastic disease and may colocalize with circulating tumor cells.","Circulating Cancer-Associated Fibroblast | Circulating Cancer Associated Fibroblast | cCAF | cCAFs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976818","Plasma Equivalent Glucose Measurement","C163446","The determination of the amount of plasma equivalent glucose present in a sample.","Plasma Equivalent Glucose Measurement | GLUCPE | Plasma Equivalent Glucose | Plasma-Equivalent Glucose Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976819","Alpha Globulin Measurement","C163445","The determination of the amount of alpha globulin present in a sample.","Alpha Globulin Measurement | Alpha Globulin | GLOBA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976820","Growth Hormone Binding Protein Measurement","C163444","The determination of the amount of growth hormone binding protein present in a sample.","Growth Hormone Binding Protein Measurement | GH Binding Protein | GHBP | GHBP Measurement | GHR Measurement | Growth Hormone Binding Protein | Somatotropin Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972865","Kappa Light Chain-Restriction","C168536","An increase in the ratio of cells expressing the immunoglobulin light chain (Ig LC) kappa versus those expressing Ig LC lambda in a sample.","Kappa Light Chain-Restriction | IGK Restriction | Kappa Light Chain Restriction | Kappa Restriction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976821","Glomerular Filtration Rate from Creatinine, Urea Nitrogen, and Albumin Adjusted for Body Surface Area Measurement","C163443","The determination of the glomerular filtration rate by measurement of creatinine, urea nitrogen, and albumin clearance and whose result is adjusted for body surface area.","Glomerular Filtration Rate from Creatinine, Urea Nitrogen, and Albumin Adjusted for Body Surface Area Measurement | GFR from Creat,UreaN,Alb Adj BSA | GFR from Creatinine, Urea Nitrogen and Albumin Adjusted for BSA | GFRBSCUA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976822","Glomerular Filtration Rate from Creatinine and Urea Nitrogen Adjusted for Body Surface Area Measurement","C163442","The determination of the glomerular filtration rate by measurement of creatinine and urea nitrogen clearance and whose result is adjusted for body surface area.","Glomerular Filtration Rate from Creatinine and Urea Nitrogen Adjusted for Body Surface Area Measurement | GFR from Creat and UreaN Adj BSA | GFR from Creatinine and Urea Nitrogen Adjusted for BSA | GFRBSCU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976823","Guanylate Binding Protein 2 Measurement","C163441","The determination of the amount of guanylate binding protein 2 present in a sample.","Guanylate Binding Protein 2 Measurement | GBP2 | GBP2 Measurement | Guanylate Binding Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976824","Guanylate Binding Protein 1 Measurement","C163440","The determination of the amount of guanylate binding protein 1 present in a sample.","Guanylate Binding Protein 1 Measurement | GBP1 | GBP1 Measurement | Guanylate Binding Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976825","Galactose Mutarotase Measurement","C163439","The determination of the amount of galactose mutarotase present in a sample.","Galactose Mutarotase Measurement | GALM | GALM Measurement | Galactose Mutarotase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972864","KEAP1 Alteration Positive","C168537","An indication that mislocalization, loss or gain of activity, underexpression, overexpression, mutation, fusion or rearrangement involving KEAP1 has been detected in a sample.","KEAP1 Alteration Positive | KLHL19 Alteration Positive | Kelch-Like ECH-Associated Protein 1 Alteration Positive | Kelch-Like Family Member 19 Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972867","KEAP1 Gene Alteration Positive","C168538","An indication that underexpression, overexpression, mutation, amplification, fusion or rearrangement involving the KEAP1 gene has been detected in a sample.","KEAP1 Gene Alteration Positive | INRF2 Gene Alteration Positive | KLHL19 Gene Alteration Positive | Kelch-Like ECH-Associated Protein 1 Gene Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1429015","ZNF532 Gene","C167272","This gene may be involved in DNA binding and transcriptional regulation.","ZNF532 Gene | ZNF532 | Zinc Finger Protein 532 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976815","Glutathione S-Transferase Y1 Subunit Measurement","C163449","The determination of the amount of glutathione S-transferase Y1 subunit present in a sample.","Glutathione S-Transferase Y1 Subunit Measurement | GSTY1 | Glutathione S-Transferase, Y1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976817","Plasma Equivalent Glucose Distribution Measurement","C163447","The determination of the amount of plasma equivalent glucose distribution present in a sample.","Plasma Equivalent Glucose Distribution Measurement | GLUCPED | Plasma Equivalent Glucose Distribution | Plasma-Equivalent Glucose Distribution Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976771","Metanephrine Excretion Rate","C163468","The determination of the amount of metanephrine being excreted in a biological specimen over a defined period of time.","Metanephrine Excretion Rate | METANEXR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976772","M Protein Excretion Rate","C163467","The determination of the amount of monoclonal protein spike being excreted in a biological specimen over a defined period of time.","Monoclonal Protein Excretion Rate | M Protein Excretion Rate | M-Spike Protein Excretion Rate | MPROTEXR | MSPIKEXR | Monoclonal Protein Spike Excretion Rate | Monoclonal Protein Spike Excretion Rate | Myeloma Protein Excretion Rate | Paraprotein Excretion Rate | Spike Protein Excretion Rate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976773","Macrophage Migration Inhibitory Factor Measurement","C163466","The determination of the amount of macrophage migration inhibitory factor present in a sample.","Macrophage Migration Inhibitory Factor Measurement | MIF | MIF Measurement | MMIF | MMIF Measurement | Macrophage Migration Inhibitory Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976774","Mitochondrial M2 IgG Antibody Measurement","C163465","The determination of the amount of mitochondrial M2 IgG antibody present in a sample.","Mitochondrial M2 IgG Antibody Measurement | AMA-M2 IgG Measurement | Anti-Mitochondrial M2 IgG Antibody Measurement | MM2IGAB | Mitochondrial M2 IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976775","Macrophage Inflammatory Protein 1 Measurement","C163464","The determination of the amount of macrophage inflammatory protein 1 present in a sample.","Macrophage Inflammatory Protein 1 Measurement | MIP1 | Macrophage Inflammatory Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976776","Lymphocyte Antigen 6E Measurement","C163463","The determination of the amount of lymphocyte antigen 6E present in a sample.","Lymphocyte Antigen 6E Measurement | LY6E | LY6E Measurement | Lymphocyte Antigen 6 Family Member E | Lymphocyte Antigen 6E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976777","Kidney Injury Molecule-1 Excretion Rate","C163462","The determination of the amount of kidney injury molecule-1 being excreted in a biological specimen over a defined period of time.","Kidney Injury Molecule-1 Excretion Rate | HAVCR1 Excretion Rate | Hepatitis A Virus Cellular Receptor 1 Excretion Rate | KIM1EXR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976778","Ubiquitin-Like Protein ISG15 Measurement","C163461","The determination of the amount of ubiquitin-like protein ISG15 present in a sample.","Ubiquitin-Like Protein ISG15 Measurement | ISG15 | ISG15 Measurement | ISG15 Ubiquitin-Like Modifier | Ubiquitin-Like Protein ISG15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976779","Interferon-Induced 60 kDa Protein Measurement","C163460","The determination of the amount of interferon-induced 60 kDa protein present in a sample.","Interferon-Induced 60 kDa Protein Measurement | IFIT3 | IFIT3 Measurement | Interferon-Induced 60 kDa Protein | Interferon-Induced Protein With Tetratricopeptide Repeats 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976780","Interferon-Induced 56 kDa Protein Measurement","C163459","The determination of the amount of interferon-induced 56 kDa protein present in a sample.","Interferon-Induced 56 kDa Protein Measurement | IFIT1 | IFIT1 Measurement | Interferon-Induced 56 kDa Protein | Interferon-Induced Protein With Tetratricopeptide Repeats 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976781","Interferon Alpha-Inducible Protein 6 Measurement","C163458","The determination of the amount of interferon alpha-inducible protein 6 present in a sample.","Interferon Alpha-Inducible Protein 6 Measurement | IFI6 | IFI6 Measurement | Interferon Alpha-Inducible Protein 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976782","Interferon-Induced Protein 44-Like Measurement","C163457","The determination of the amount of interferon-induced protein 44-Like present in a sample.","Interferon-Induced Protein 44-Like Measurement | IFI44L | IFI44L Measurement | Interferon-Induced Protein 44-Like",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976783","Interferon-Induced Protein 44 Measurement","C163456","The determination of the amount of interferon-induced protein 44 present in a sample.","Interferon-Induced Protein 44 Measurement | IFI44 | IFI44 Measurement | Interferon-Induced Protein 44",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976784","Interferon Alpha-Inducible Protein 27 Measurement","C163455","The determination of the amount of interferon alpha-inducible protein 27 present in a sample.","Interferon Alpha-Inducible Protein 27 Measurement | IFI27 | IFI27 Measurement | Interferon Alpha-Induced Protein 27 | Interferon Alpha-Inducible Protein 27",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976785","5-Hydroxyindoleacetic Acid Excretion Rate","C163454","The determination of the amount of 5-hydroxyindoleacetic acid being excreted in a biological specimen over a defined period of time.","5-Hydroxyindoleacetic Acid Excretion Rate | 5-HIAA Excretion Rate | 5-HydroxyindoleaceticAcid Excretion Rate | IA5OHEXR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976811","Hect Domain and RLD 5 Measurement","C163453","The determination of the amount of Hect domain and RLD 5 protein present in a sample.","Hect Domain and RLD 5 Measurement | E3 ISG15--Protein Ligase HERC5 | HECT and RLD Domain Containing E3 Ubiquitin Protein Ligase 5 | HERC5 | HERC5 Measurement | Hect Domain and RLD 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976812","Human Epididymis Protein 4 Measurement","C163452","The determination of the amount of human epididymis protein 4 present in a sample.","Human Epididymis Protein 4 Measurement | HE4 | Human Epididymis Protein 4 | WAP Four-Disulfide Core Domain Protein 2 Measurement | WFDC2 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976813","Hemoglobin A1B Measurement","C163451","The determination of the amount of hemoglobin A1B present in a sample.","Hemoglobin A1B Measurement | Glycated Hemoglobin 1B | Glycosylated Hemoglobin 1B | HBA1B | Hb A1b Measurement | Hemoglobin A1B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976814","Hemoglobin A1A Measurement","C163450","The determination of the amount of hemoglobin A1A present in a sample.","Hemoglobin A1A Measurement | Glycated Hemoglobin 1A | Glycosylated Hemoglobin 1A | HBA1A | Hb A1a Measurement | Hemoglobin A1A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976789","Oxalate Excretion Rate","C163480","The determination of the amount of oxalate being excreted in a biological specimen over a defined period of time.","Oxalate Excretion Rate | OXAEXR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976790","O-Demethylase Measurement","C163479","The determination of the amount of O-demethylase present in a sample.","O-Demethylase Measurement | O-Demethylase | ODMTASE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976791","2-5-Oligoadenylate Synthase 3 Measurement","C163478","The determination of the amount of 2-5-oligoadenylate synthase 3 present in a sample.","2-5-Oligoadenylate Synthase 3 Measurement | 2-5-Oligoadenylate Synthase 3 | OAS3 | OAS3 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976792","2-5-Oligoadenylate Synthase 2 Measurement","C163477","The determination of the amount of 2-5-oligoadenylate synthase 2 present in a sample.","2-5-Oligoadenylate Synthase 2 Measurement | 2-5-Oligoadenylate Synthase 2 | OAS2 | OAS2 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976793","2-5-Oligoadenylate Synthase 1 Measurement","C163476","The determination of the amount of 2-5-oligoadenylate synthase 1 present in a sample.","2-5-Oligoadenylate Synthase 1 Measurement | 2-5-Oligoadenylate Synthase 1 | OAS1 | OAS1 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523790","Neurotensin Measurement","C163475","The determination of the amount of neurotensin present in a sample.","Neurotensin Measurement | NT Measurement | NTENS | NTS | Neurotensin",,,,,,,,,,,,,,,"4020546","Neurotensin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL976794","Normetanephrine Excretion Rate","C163474","The determination of the amount of normetanephrine being excreted in a biological specimen over a defined period of time.","Normetanephrine Excretion Rate | NORMEEXR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976795","Neurokinin A Measurement","C163473","The determination of the amount of neurokinin A present in a sample.","Neurokinin A Measurement | NKA | NKA Measurement | NKINA | Neurokinin A | Substance K | Substance K Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976796","Norepinephrine Excretion Rate","C163472","The determination of the amount of norepinephrine being excreted in a biological specimen over a defined period of time.","Norepinephrine Excretion Rate | NOREPEXR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976797","N-Demethylase Measurement","C163471","The determination of the amount of N-demethylase present in a sample.","N-Demethylase Measurement | N-Demethylase | NDMTASE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976798","N-acetyl-Beta-D-glucosaminidase to Creatinine Ratio Measurement","C163470","The determination of the N-acetyl-B-D-glucosaminidase to creatinine in a biological sample. The measurement may be expressed as either a ratio or a percentage.","N-acetyl-Beta-D-glucosaminidase to Creatinine Ratio Measurement | N-acetyl-B-D-glucosaminidase/Creatinine | NAGASECR | OGA to Creatinine Ratio Measurement | Protein O-GlcNAcase to Creatinine Ratio Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976770","Interferon-Induced Protein p78 Measurement","C163469","The determination of the amount of interferon-induced protein p78 present in a sample.","Interferon-Induced Protein p78 Measurement | Interferon-Induced GTP-Binding Protein Mx1 | Interferon-Induced Protein p78 | MX1 | MX1 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976764","Peptide Transporter TAP1 Measurement","C163486","The determination of the amount of peptide transporter TAP1 present in a sample.","Peptide Transporter TAP1 Measurement | ABCB2 Measurement | Antigen Peptide Transporter 1 | Peptide Transporter TAP1 | TAP1 | TAP1 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978349","Steroid Sulfatase Activity Measurement","C163485","The determination of the amount of steroid sulfatase activity present in a sample.","Steroid Sulfatase Activity Measurement | STS Activity Measurement | Steryl-Sulfatase Activity Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976786","Cytomegalovirus-Induced Gene 5 Protein Measurement","C163484","The determination of the amount of cytomegalovirus-induced gene 5 protein present in a sample.","Cytomegalovirus-Induced Gene 5 Protein Measurement | Cytomegalovirus-Induced Gene 5 Protein | RSAD2 | RSAD2 Measurement | Radical S-adenosyl Methionine Domain-Containing Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976787","Phospholipid Scramblase 1 Measurement","C163483","The determination of the amount of phospholipid scramblase 1 present in a sample.","Phospholipid Scramblase 1 Measurement | PLSCR1 | PLSCR1 Measurement | Phospholipid Scramblase 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978360","Placental Growth Factor Measurement","C163482","The determination of the amount of placental growth factor present in a sample.","Placental Growth Factor Measurement | PGF | PGF Measurement | PIGF | PLCGF | PLGF | PLGF Measurement | Placental Growth Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976788","Platelet Derived Growth Factor Isoform AA Measurement","C163481","The determination of the amount of platelet derived growth factor isoform AA present in a sample.","Platelet Derived Growth Factor Isoform AA Measurement | PDGF Isoform AA | PDGFA Homodimer Measurement | PDGFAA | Platelet Derived Growth Factor IsoformAA | Platelet Derived Growth Factor-AA Isoform",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976769","Vanillyl Mandelic Acid Excretion Rate","C163503","The determination of the amount of vanillyl mandelic acid being excreted in a biological specimen over a defined period of time.","Vanillyl Mandelic Acid Excretion Rate | VMA Excretion Rate | VMAEXR | Vanillylmandelic Acid Excretion Rate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202248","Vasoactive Intestinal Polypeptide Measurement","C163502","The determination of the amount of vasoactive intestinal polypeptide present in a sample.","Vasoactive Intestinal Polypeptide Measurement | VIP | VIP Measurement | Vasoactive Intestinal Polypeptide",,,,,,,,,,,,,,,"4245134","Vasoactive intestinal polypeptide measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL976751","Vascular Endothelial Growth Factor C Measurement","C163501","The determination of the amount of vascular endothelial growth factor C present in a sample.","Vascular Endothelial Growth Factor C Measurement | FLT4 Ligand Measurement | VEGF-C Measurement | VEGFC | VRP Measurement | Vascular Endothelial Growth Factor C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976752","Urothelial Cell Count","C163500","The determination of the amount of urothelial cells present in a sample.","Urothelial Cell Count | UROTHCE | Urothelial Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976753","Urea Nitrogen Excretion Rate","C163499","The determination of the amount of urea nitrogen being excreted in a biological specimen over a defined period of time.","Urea Nitrogen Excretion Rate | UREANEXR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976754","Urate Excretion Rate","C163498","The determination of the amount of urate being excreted in a biological specimen over a defined period of time.","Urate Excretion Rate | URATEEXR | Uric Acid Excretion Rate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976755","11-Dehydro-Thromboxane B2 Excretion Rate","C163497","The determination of the amount of 11-dehydro-thromboxane B2 being excreted in a biological specimen over a defined period of time.","11-Dehydro-Thromboxane B2 Excretion Rate | 11-Dehydrothromboxane B2 Excretion Rate | TXB2D11R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976756","Tissue Transglutaminase IgG Antibody Measurement","C163496","The determination of the amount of tissue transglutaminase IgG antibody present in a sample.","Tissue Transglutaminase IgG Antibody Measurement | TG2 IgG Measurement | TGC IgG Measurement | TGM2 IgG Measurement | TTGIGGAB | Tissue Transglutaminase IgG Antibody | tTG IgG Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976757","Thrombospondin 1 Measurement","C163495","The determination of the amount of thrombospondin 1 present in a sample.","Thrombospondin 1 Measurement | THBS1 | THBS1 Measurement | TSP-1 Measurement | TSP1 | Thrombospondin 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0391949","Trypsin Measurement","C163494","The determination of the amount of trypsin present in a sample.","Trypsin Measurement | TRYPSIN | Trypsin",,,,,,,,,,,,,,,"4021292","Trypsin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL976758","Tryptophan to Creatinine Ratio Measurement","C163493","The determination of the tryptophan to creatinine in a biological sample. The measurement may be expressed as either a ratio or a percentage.","Tryptophan to Creatinine Ratio Measurement | TRPCRT | Tryptophan/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976759","Tripartite Motif Containing Protein 38 Measurement","C163492","The determination of the amount of tripartite motif containing protein 38 present in a sample.","Tripartite Motif Containing Protein 38 Measurement | RNF15 Measurement | TRIM38 | TRIM38 Measurement | Tripartite Motif Containing Protein 38",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976760","Tripartite Motif Containing Protein 21 Measurement","C163491","The determination of the amount of tripartite motif containing protein 21 present in a sample.","Tripartite Motif Containing Protein 21 Measurement | E3 Ubiquitin-Protein Ligase TRIM21 | Ro(SS-A) | Sjogren Syndrome Type A Antigen | TRIM21 | TRIM21 Measurement | Tripartite Motif Containing Protein 21",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976761","TPR-Ankyrin Repeat-containing Protein 1 Measurement","C163490","The determination of the amount of TPR-ankyrin repeat-containing protein 1 present in a sample.","TPR-Ankyrin Repeat-containing Protein 1 Measurement | TPR and Ankyrin Repeat-Containing Protein 1 | TPR-Ankyrin Repeat-Containing Protein 1 | TRANK1 | TRANK1 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976762","Free Tau Protein Measurement","C163489","The determination of the amount of free tau protein present in a sample.","Free Tau Protein Measurement | TPROTFR | Tau Protein, Free",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1167688","Tissue Polypeptide Antigen Measurement","C163488","The determination of the amount of tissue polypeptide antigen present in a sample.","Tissue Polypeptide Antigen Measurement | TPA | TPAG | Tissue Polypeptide Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976763","Translocase Inner Mitochondrial Membrane 10 Measurement","C163487","The determination of the amount of translocase inner mitochondrial membrane 10 present in a sample.","Translocase Inner Mitochondrial Membrane 10 Measurement | TIMM10 | TIMM10 Measurement | Translocase Inner Mitochondrial Membr 10 | Translocase of Inner Mitochondrial Membrane 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4227537","Pancytopenia","C34889","A finding of low numbers of red and white blood cells and platelets in the peripheral blood.","Pancytopenia | ",,,,,,,,,,,,,,,"432881","Pancytopenia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL978996","Orchard Grass Pollen IgE Antibody RAST Score Measurement","C165883","A classification of the amount of Dactylis glomerata pollen antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Orchard Grass Pollen IgE Antibody RAST Score Measurement | C165883 | Dactylis glomerata Pollen IgE Antibody RAST Score Measurement | Orchard Grass Pollen IgE AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979015","White Elm Pollen IgE Antibody RAST Score Measurement","C165882","A classification of the amount of Ulmus americana pollen antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","White Elm Pollen IgE Antibody RAST Score Measurement | C165882 | Ulmus americana Pollen IgE Antibody RAST Score Measurement | White Elm Pollen IgE AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979014","White Elm Pollen IgE Antibody Measurement","C165881","The determination of the amount of Ulmus americana pollen antigen IgE antibody present in a sample.","White Elm Pollen IgE Antibody Measurement | C165881 | Ulmus americana Pollen IgE Antibody Measurement | White Elm Pollen IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979013","Dermatophagoides pteronyssinus IgE Antibody RAST Score Measurement","C165880","A classification of the amount of Dermatophagoides pteronyssinus antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Dermatophagoides pteronyssinus IgE Antibody RAST Score Measurement | C165880 | D. pteronyssinus IgE AB RAST Score | Dermatophagoides pteronyssinus IgE Antibody RAST Score | European House Dust Mite IgE Antibody RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979012","Dermatophagoides farinae IgE Antibody RAST Score Measurement","C165879","A classification of the amount of Dermatophagoides farinae IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Dermatophagoides farinae IgE Antibody RAST Score Measurement | American House Dust Mite IgE Antibody RAST Score | C165879 | D. farinae IgE AB RAST Score | Dermatophagoides farinae IgE Antibody RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979019","German Cockroach IgE Antibody RAST Score Measurement","C165878","A classification of the amount of Blattella germanica antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","German Cockroach IgE Antibody RAST Score Measurement | Blattella germanica IgE Antibody RAST Score Measurement | C165878 | German Cockroach IgE AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979018","Cat Dander IgE Antibody RAST Score Measurement","C165877","A classification of the amount of Felis catus dander antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Cat Dander IgE Antibody RAST Score Measurement | C165877 | Cat Dander IgE AB RAST Score | Felis cattus Dander IgE Antibody RAST Score Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979017","Birch Pollen IgE Antibody RAST Score Measurement","C165876","A classification of the amount of Betula pollen antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Birch Pollen IgE Antibody RAST Score Measurement | Betula Pollen IgE Antibody RAST Score Measurement | Birch Pollen IgE AB RAST Score | C165876",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979016","Bermuda Grass Pollen IgE Antibody RAST Score Measurement","C165875","A classification of the amount of Cynodon dactylon pollen antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Bermuda Grass Pollen IgE Antibody RAST Score Measurement | Bermuda Grass Pollen IgE AB RAST Score | C165875 | Cynodon dactylon Pollen IgE Antibody RAST Score Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978858","Bruton's Tyrosine Kinase Measurement","C165772","The determination of the amount of Bruton's tyrosine kinase present in a sample.","Bruton's Tyrosine Kinase Measurement | ATK | Agammaglobulinemia Tyrosine Kinase | B-cell Progenitor Kinase | BTK | BTK Measurement | Bruton Agammaglobulinemia Tyrosine Kinase Measurement | Bruton Tyrosine Kinase | Bruton Tyrosine Kinase Measurement | Bruton's Tyrosine Kinase | Tyrosine-protein kinase BTK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978992","English Plantain Pollen IgE Antibody RAST Score Measurement","C165887","A classification of the amount of Plantagio lanceolata pollen antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","English Plantain Pollen IgE Antibody RAST Score Measurement | C165887 | English Plantain Pollen IgE AB RAST Score | EnglishPlantain Pollen IgE AB RAST Score | Plantagio lanceolata Pollen IgE Antibody RAST Score Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978999","White Oak Pollen IgE Antibody RAST Score Measurement","C165886","A classification of the amount of Quercus alba pollen antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","White Oak Pollen IgE Antibody RAST Score Measurement | C165886 | Quercus alba Pollen IgE Antibody RAST Score Measurement | White Oak Pollen IgE AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978998","Olive Tree Pollen IgE Antibody RAST Score Measurement","C165885","A classification of the amount of Olea europaea pollen antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Olive Tree Pollen IgE Antibody RAST Score Measurement | C165885 | Olea europaea Pollen IgE Antibody RAST Score Measurement | Olive Tree Pollen IgE AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978997","Olive Tree Pollen IgE Antibody Measurement","C165884","The determination of the amount of Olea europaea pollen antigen IgE antibody present in a sample.","Olive Tree Pollen IgE Antibody Measurement | C165884 | Olea europaea Pollen IgE Antibody Measurement | Olive Tree Pollen IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL372099","liposomal cytarabine-daunorubicin CPX-351","C67504","A liposomal formulation containing a fixed combination of the antineoplastic agents cytarabine and daunorubicin in a 5:1 molar ratio. Liposome-encapsulated daunorubicin-cytarabine has been designed to provide optimal delivery of a specific ratio of cytarabine to daunorubicin, one that has been shown to be synergistic in vitro. The antimetabolite cytarabine competes with cytidine for incorporation into DNA, inhibiting DNA synthesis. This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Daunorubicin, an intercalator and a topoisomerase II inhibitor, prevents DNA replication and inhibits protein synthesis. This agent also generates oxygen free radicals, resulting in the cytotoxic lipid peroxidation of cell membrane lipids.","Liposome-encapsulated Daunorubicin-Cytarabine | CPX 351 | CPX-351 | CPX351 | Cytarabine and Daunorubicin Liposomal | Cytarabine and daunorubicin liposomal | Cytarabine-Daunorubicin Liposome for Injection | Daunorubicin and Cytarabine (Liposomal) | Liposomal AraC-Daunorubicin CPX-351 | Liposomal Cytarabine-Daunorubicin | Liposome-encapsulated Combination of Daunorubicin and Cytarabine | Vyxeos",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2242628","Fecal Microbiota Transplantation","C118643","The transplantation of fecal bacteria, via enema, colonoscopy, or other method, from a healthy individual to a recipient.","Fecal Microbiota Transplantation | FMT | Fecal Material Transplantation | Fecal Transplantation | Poo Transplant | Poop Transplant | Stool Transplant",,,,,,,,,,,,,,,"36715384","Fecal microbiota transplantation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3529795","Utomilumab","C116619","A human, agonistic immunoglobulin (Ig) G2 monoclonal antibody (mAb) targeting 4-1BB (CD137, TNFRSF9), with potential immunostimulating activity. Upon administration, utomilumab binds to and activates 4-1BB expressed on various immune cells, such as CD8-positive and CD4-positive T cells and natural killer (NK) cells. This enhances 4-1BB-mediated signaling, induces cytokine production and promotes anti-tumor immune responses. 4-1BB, a member of the tumor necrosis factor (TNF)/nerve growth factor (NGF) family of receptors, plays an important role in the regulation of immune responses.","Utomilumab | PF 05082566 | PF 5082566 | PF-05082566 | PF-2566 | UTOMILUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978960","German Cockroach IgG Antibody RAST Score Measurement","C165919","A classification of the amount of Blattella germanica antigen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","German Cockroach IgG Antibody RAST Score Measurement | Blattella germanica IgG Antibody RAST Score Measurement | C165919 | German Cockroach IgG AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978967","American Cockroach IgG Antibody RAST Score Measurement","C165918","A classification of the amount of Periplaneta americana antigen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","American Cockroach IgG Antibody RAST Score Measurement | American Cockroach IgG AB RAST Score | C165918 | Periplaneta americana IgG Antibody RAST Score Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978966","Dermatophagoides pteronyssinus IgG Antibody RAST Score Measurement","C165917","A classification of the amount of Dermatophagoides pteronyssinus antigen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Dermatophagoides pteronyssinus IgG Antibody RAST Score Measurement | C165917 | D. pteronyssinus Antigen IgG AB RAST Score | D. pteronyssinus IgG AB RAST Score | Dermatophagoides pteronyssinus IgG Antibody | European House Dust Mite IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978965","Dermatophagoides farinae IgG Antibody RAST Score Measurement","C165916","A classification of the amount of Dermatophagoides farinae antigen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Dermatophagoides farinae IgG Antibody RAST Score Measurement | American House Dust Mite IgG Antibody RAST Score | C165916 | D. farinae IgG AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978964","Dog Dander IgG Antibody RAST Score Measurement","C165915","A classification of the amount of Canis lupus IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Dog Dander IgG Antibody RAST Score Measurement | C165915 | Canus lupus Dander IgG Antibody RAST Score Measurement | Dog Dander IgG AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978986","Nut Mix IgG Antibody RAST Score Measurement","C165913","A classification of the amount of nut mix IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Nut Mix IgG Antibody RAST Score Measurement | C165913 | Nut Mix IgG AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978985","Shellfish Mix IgG Antibody RAST Score Measurement","C165912","A classification of the amount of shellfish mix IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Shellfish Mix IgG Antibody RAST Score Measurement | C165912 | Shellfish Mix IgG AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978984","Dairy Mix IgG Antibody RAST Score Measurement","C165911","A classification of the amount of dairy mix IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Dairy Mix IgG Antibody RAST Score Measurement | C165911 | Dairy Mix IgG AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978991","Bee Mix IgG Antibody RAST Score Measurement","C165910","A classification of the amount of bee mix IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Bee Mix IgG Antibody RAST Score Measurement | Bee Mix IgG AB RAST Score | C165910",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978990","Industrial Mix IgG Antibody RAST Score Measurement","C165909","A classification of the amount of industrial mix IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Industrial Mix IgG Antibody RAST Score Measurement | C165909 | Industrial Mix IgG AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978989","Animal Mix IgG Antibody RAST Score Measurement","C165908","A classification of the amount of animal mix IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Animal Mix IgG Antibody RAST Score Measurement | Animal Mix IgG AB RAST Score | C165908",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978988","Mold Mix IgG Antibody RAST Score Measurement","C165907","A classification of the amount of mold mix IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Mold Mix IgG Antibody RAST Score Measurement | C165907 | Mold Mix IgG AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978979","Weed Mix Pollen IgG Antibody RAST Score Measurement","C165906","A classification of the amount of weed mix pollen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Weed Mix Pollen IgG Antibody RAST Score Measurement | C165906 | Weed Mix Pollen IgG AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978978","Grass Mix Pollen IgG Antibody RAST Score Measurement","C165905","A classification of the amount of tree grass pollen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Grass Mix Pollen IgG Antibody RAST Score Measurement | C165905 | Grass Mix Pollen IgG AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978977","Tree Mix Pollen IgG Antibody RAST Score Measurement","C165904","A classification of the amount of tree mix pollen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Tree Mix Pollen IgG Antibody RAST Score Measurement | C165904 | Tree Mix Pollen IgG AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978976","Western Ragweed Pollen IgG Antibody RAST Score Measurement","C165903","A classification of the amount of Ambrosia psilostachya pollen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Western Ragweed Pollen IgG Antibody RAST Score Measurement | Ambrosia psilostachya Pollen IgG Antibody RAST Score Measurement | C165903 | Western Ragweed Pollen IgG AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978983","Timothy Grass Pollen IgG Antibody RAST Score Measurement","C165902","A classification of the amount of Phleum pratense pollen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Timothy Grass Pollen IgG Antibody RAST Score Measurement | C165902 | Phleum pratense Pollen IgG Antibody RAST Score Measurement | Timothy Grass Pollen IgG AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978982","English Plantain Pollen IgG Antibody RAST Score Measurement","C165901","A classification of the amount of Plantagio lanceolata pollen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","English Plantain Pollen IgG Antibody RAST Score Measurement | C165901 | English Plantain Pollen IgG AB RAST Score | EnglishPlantain Pollen IgG AB RAST Score | Plantagio lanceolata Pollen IgG Antibody RAST Score Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978981","Orchard Grass Pollen IgG Antibody RAST Score Measurement","C165900","A classification of the amount of Dactylis glomerata pollen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Orchard Grass Pollen IgG Antibody RAST Score Measurement | C165900 | Cocksfoot Grass Pollen IgG RAST Score | Dactylis glomerata Pollen IgG Antibody RAST Score Measurement | Orchard Grass Pollen IgG AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978980","Silver Birch Pollen IgG Antibody RAST Score Measurement","C165899","A classification of the amount of Betula verrucosa pollen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Silver Birch Pollen IgG Antibody RAST Score Measurement | Betula verricosa Pollen IgG Antibody RAST Score Measurement | C165899 | Silver Birch Pollen IgG AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979003","Birch Pollen IgG Antibody RAST Score Measurement","C165898","A classification of the amount of Betula pollen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Birch Pollen IgG Antibody RAST Score Measurement | Betula Pollen IgG Antibody RAST Score Measurement | Birch Pollen IgG AB RAST Score | C165898",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979002","Bermuda Grass Pollen IgG Antibody RAST Score Measurement","C165897","A classification of the amount of Cynodon dactylon pollen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Bermuda Grass Pollen IgG Antibody RAST Score Measurement | Bermuda Grass Pollen IgG AB RAST Score | C165897 | Cynodon dactylon Pollen IgG Antibody RAST Score Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979001","Dermatophagoides pteronyssinus Antigen IgG4 Antibody Measurement","C165896","The determination of the amount of Dermatophagoides pteronyssinus antigen IgG4 antibody present in a sample.","Dermatophagoides pteronyssinus Antigen IgG4 Antibody Measurement | C165896 | D. pteronyssinus Antigen IgG4 Antibody | Dermatophagoides pteronyssinus IgG4 Antibody | European House Dust Mite IgG4 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979000","Johnson Grass Pollen IgG4 Antibody Measurement","C165895","The determination of the amount of Sorghum halepense pollen IgG4 antibody present in a sample.","Johnson Grass Pollen IgG4 Antibody Measurement | C165895 | Johnson Grass Pollen IgG4 Antibody | Sorghum halepense Pollen IgG4 Antibody Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979007","Dermatophagoides farinae Antigen IgG4 Antibody Measurement","C165894","The determination of the amount of Dermatophagoides farinae antigen IgG4 antibody present in a sample.","Dermatophagoides farinae Antigen IgG4 Antibody Measurement | American House Dust Mite IgG4 Antibody | C165894 | D. farinae Antigen IgG4 Antibody | Dermatophagoides farinae IgG4 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979006","Wild Rye Pollen IgE Antibody RAST Score Measurement","C165893","A classification of the amount of Elymus tricoides pollen antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Wild Rye Pollen IgE Antibody RAST Score Measurement | C165893 | Elymus tricoides Pollen IgE Antibody RAST Score Measurement | Wild Rye Pollen IgE AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979005","Wild Rye Pollen IgE Antibody Measurement","C165892","The determination of the amount of Elymus tricoides pollen antigen IgE antibody present in a sample.","Wild Rye Pollen IgE Antibody Measurement | C165892 | Elymus tricoides Pollen IgE Antibody Measurement | Wild Rye Pollen IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979004","Western Ragweed Pollen IgE Antibody RAST Score Measurement","C165891","A classification of the amount of Ambrosia psilostachya pollen antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Western Ragweed Pollen IgE Antibody RAST Score Measurement | Ambrosia psilostachya Pollen IgE Antibody RAST Score Measurement | C165891 | Western Ragweed Pollen IgE AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978995","Timothy Grass Pollen IgE Antibody RAST Score Measurement","C165890","A classification of the amount of Phleum pratense pollen antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Timothy Grass Pollen IgE Antibody RAST Score Measurement | C165890 | Phleum pratense Pollen IgE Antibody RAST Score Measurement | Timothy Grass Pollen IgE AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978994","Russian Thistle Pollen IgE Antibody RAST Score Measurement","C165889","A classification of the amount of Salsola tragus pollen antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Russian Thistle Pollen IgE Antibody RAST Score Measurement | C165889 | Russian Thistle Pollen IgE AB RAST Score | Salsola tragus Pollen IgE Antibody RAST Score Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978993","Russian Thistle Pollen IgE Antibody Measurement","C165888","The determination of the amount of Salsola tragus pollen antigen IgE antibody present in a sample.","Russian Thistle Pollen IgE Antibody Measurement | C165888 | Russian Thistle Pollen IgE Antibody | Salsola tragus Pollen IgE Antibody Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979138","Granulin Measurement","C165963","The determination of the amount of granulin present in a sample.","Granulin Measurement | GRANULIN | GRN Measurement | Granulin | Granulins Measurement | PEPI Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979158","Gamma Glutamyl Transferase Excretion Rate","C165962","The determination of the amount of gamma glutamyl transferase being excreted in a biological specimen over a defined amount of time (e.g. one hour).","Gamma Glutamyl Transferase Excretion Rate | GGT Excretion Rate | GGTEXR | GammaGlutamyl Transferase Excretion Rate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979157","Galactose-Deficient IgA1 Measurement","C165961","The determination of the amount of galactose-deficient IgA1 present in a sample.","Galactose-Deficient IgA1 Measurement | GDIGA1 | Galactose-Deficient IgA1 | Gd-IgA1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979265","Fas Cell Surface Death Receptor Measurement","C165960","The determination of the amount of Fas cell surface death receptor present in a sample.","Fas Cell Surface Death Receptor Measurement | ALPS1A | APT1 | CD95 | CD95 Measurement | FAS | FAS Measurement | FAS1 | FASTM | Fas Cell Surface Death Receptor | Soluble CD95 | TNF Receptor Superfamily Member 6 | TNFRSF6 | TNFRSF6 Measurement | Tumor Necrosis Factor Receptor Superfamily Member 6 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979156","Pseudo-Eosinophils to Leukocyte Ratio Measurement","C165959","A relative measurement (ratio or percentage) of the pseudo-eosinophils to the leukocytes in a biological sample. The measurement may be expressed as either a ratio or a percentage.","Pseudo-Eosinophils to Leukocyte Ratio Measurement | EOSPSDLE | Pseudo-Eosinophils/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979161","Pseudo-Eosinophil Count","C165958","The determination of the amount of pseudo-eosinophils present in a sample.","Pseudo-Eosinophil Count | EOSPSD | Pseudo-Eosinophils",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979278","Dickkopf WNT Signaling Path Inhibitor 1 Measurement","C165957","The determination of the amount of dickkopf WNT signaling pathway inhibitor 1 present in a sample.","Dickkopf WNT Signaling Path Inhibitor 1 Measurement | DKK-1 | DKK1 | DKK1 Measurement | Dickkopf WNT Signaling Path Inhibitor 1 | Dickkopf WNT Signaling Pathway Inhibitor 1 | Dickkopf-Related Protein 1 Measurement | SK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979160","Chemokine (C-X-C Motif) Ligand 9 Measurement","C165956","The determination of the amount of CXCL9, chemokine (C-X-C motif) ligand 9, present in a sample.","Chemokine (C-X-C Motif) Ligand 9 Measurement | C-X-C Motif Chemokine 9 Measurement | CMK | CXCL9 | CXCL9 Measurement | Chemokine (C-X-C Motif) Ligand 9 | Humig | MIG | Monokine Induced by Gamma Interferon | SCYB9 | crg-10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979159","Chemokine (C-X-C Motif) Ligand 7 Measurement","C165955","The determination of the amount of pro-platelet basic protein present in a sample.","Chemokine (C-X-C Motif) Ligand 7 Measurement | B-TG1 | Beta-TG | C-X-C Motif Chemokine 7 Measurement | CTAP-III | CTAP3 | CTAPIII | CXCL7 | CXCL7 Measurement | Chemokine (C-X-C Motif) Ligand 7 | LA-PF4 | LDGF | MDGF | NAP-2 | NAP-2 Measurement | NAP2 Measurement | Neutrophil-Activating Peptide 2 | PBP | PBP Measurement | PPBP | PPBP Measurement | Platelet Basic Protein Measurement | Pro-Platelet Basic Protein | Pro-Platelet Basic Protein Measurement | SCYB7 | TC1 | TC2 | TGB | TGB1 | THBGB | THBGB1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979151","Chemokine (C-X-C Motif) Ligand 12 Measurement","C165954","The determination of the amount of CXCL12, chemokine (C-X-C motif) ligand 12, present in a sample.","Chemokine (C-X-C Motif) Ligand 12 Measurement | C-X-C Motif Chemokine 12 Measurement | CXCL12 | CXCL12 Measurement | Chemokine (C-X-C Motif) Ligand 12 | IRH | PBSF | SCYB12 | SDF1 | SDF1 Measurement | SDF1A | SDF1B | Stromal Cell-Derived Factor 1 Measurement | Stromal Cell-Derived Factor-1 Alpha | Stromal Cell-Derived Factor-1 Beta | TLSF | TPAR1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979267","Carboxypeptidase B2 Measurement","C165953","The determination of the amount of carboxypeptidase B2 present in a sample.","Carboxypeptidase B2 Measurement | CPB2 | CPB2 Measurement | CPU | CPU Measurement | Carboxypeptidase B2 | PCPB | TAFI | TAFI Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979150","CD27 Expressing Cell Count","C165952","A count of the CD27 expressing cells per unit present in a sample.","CD27 Expressing Cell Count | TNFRSF7 Expressing Cell Count | TNFRSF7 Expressing Cell Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979149","Chemokine (C-C Motif) Ligand 8 Measurement","C165951","The determination of the amount of CCL8, chemokine (C-C motif) ligand 8, present in a sample.","Chemokine (C-C Motif) Ligand 8 Measurement | C-C Motif Chemokine 8 Measurement | CCL8 | CCL8 Measurement | Chemokine (C-C Motif) Ligand 8 | HC14 | MCP-2 Measurement | MCP2 | Monocyte Chemoattractant Protein 2 Measurement | SCYA10 | SCYA8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979155","Chemokine (C-C Motif) Ligand 25 Measurement","C165950","The determination of the amount of CCL25, chemokine (C-C motif) ligand 25, present in a sample.","Chemokine (C-C Motif) Ligand 25 Measurement | C-C Motif Chemokine 25 Measurement | CCL25 | CCL25 Measurement | Chemokine (C-C Motif) Ligand 25 | Ckb15 | SCYA25 | TECK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979154","Chemokine (C-C Motif) Ligand 23 Measurement","C165949","The determination of the amount of CCL23, chemokine (C-C motif) ligand 23, present in a sample.","Chemokine (C-C Motif) Ligand 23 Measurement | C-C Motif Chemokine 23 Measurement | CCL23 | CCL23 Measurement | CK-BETA-8 | CKb8 | Chemokine (C-C Motif) Ligand 23 | Ckb-8-1 | Hmrp-2a | MIP-3 Measurement | MIP3 | MPIF-1 | MPIF-1 Measurement | Macrophage Inflammatory Protein 3 Measurement | Myeloid Progenitor Inhibitory Factor 1 Measurement | SCYA23",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979153","Chemokine (C-C Motif) Ligand 16 Measurement","C165948","The determination of the amount of CCL16, chemokine (C-C motif) ligand 16, present in a sample.","Chemokine (C-C Motif) Ligand 16 Measurement | C-C Motif Chemokine 16 Measurement | CCL16 | CCL16 Measurement | CKb12 | Chemokine (C-C Motif) Ligand 16 | Chemokine CC-4 | HCC-4 | ILINCK | LCC-1 | LEC | LMC | Mtn-1 | NCC4 | SCYA16 | SCYL4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979152","Chemokine (C-C Motif) Ligand 13 Measurement","C165947","The determination of the amount of CCL13, chemokine (C-C motif) ligand 13, present in a sample.","Chemokine (C-C Motif) Ligand 13 Measurement | C-C Motif Chemokine 13 Measurement | C-C Motif Chemokine Ligand 13 | CCL13 | CCL13 Measurement | CKb10 | Chemokine (C-C Motif) Ligand 13 | MCP-4 | MCP-4 Measurement | Monocyte Chemoattractant Protein 4 Measurement | NCC1 | SCYA13 | SCYL1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979172","Cannabinoid Metabolite Measurement","C165946","A measurement of any cannabinoid drug class metabolite(s) present in a sample.","Cannabinoid Metabolite Measurement | CANNABM | Cannabinoid Metabolites | Cannabis Metabolites | Marijuana Metabolites",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979171","Collagen III Neo-Peptide C3M Measurement","C165945","The determination of the amount of collagen III neo-peptide C3M present in a sample.","Collagen III Neo-Peptide C3M Measurement | C3M | C3M Measurement | Collagen III Neo-Peptide C3M | Collagen III Neoantigen Peptide C3M Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979170","Free Bruton's Tyrosine Kinase Measurement","C165944","The determination of the amount of free Bruton's tyrosine kinase present in a sample.","Free Bruton's Tyrosine Kinase Measurement | BTKFR | Bruton's Tyrosine Kinase, Free | Free BTK Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979272","AXL Receptor Tyrosine Kinase Measurement","C165943","The determination of the amount of AXL receptor tyrosine kinase present in a sample.","AXL Receptor Tyrosine Kinase Measurement | ARK | AXL | AXL Measurement | AXL Receptor Tyrosine Kinase | JTK11 | Tyro7 | UFO | UFO Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979176","Alkaline Phosphatase Excretion Rate","C165942","The determination of the amount of alkaline phosphatase being excreted in a biological specimen over a defined amount of time (e.g. one hour).","Alkaline Phosphatase Excretion Rate | ALPEXR | AlkPhos Excretion Rate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979175","Common Ragweed Pollen IgE Antibody RAST Score Measurement","C165941","A classification of the amount of Ambrosia artemisiifolia pollen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Common Ragweed Pollen IgE Antibody RAST Score Measurement | Ambrosia artemisiifolia Pollen IgE Antibody Measurement | C165941 | Common Ragweed Pollen IgE AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979174","Boxelder Pollen IgE Antibody RAST Score Measurement","C165940","A classification of the amount of Acer negundo pollen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Boxelder Pollen IgE Antibody RAST Score Measurement | Acer negundo Pollen IgE Antibody Measurement | Boxelder Pollen IgE AB RAST Score | C165940",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979173","Egg White IgE Antibody RAST Score Measurement","C165939","A classification of the amount of egg white antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Egg White IgE Antibody RAST Score Measurement | C165939 | Egg White IgE AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979165","Cow Milk Protein IgE Antibody RAST Score Measurement","C165938","A classification of the amount of cow milk protein IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Cow Milk Protein IgE Antibody RAST Score Measurement | C165938 | Cow Milk Protein IgE AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979164","Zea mays IgE Antibody RAST Score Measurement","C165937","A classification of the amount of Zea mays IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Zea mays IgE Antibody RAST Score Measurement | C165937 | Zea mays IgE AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979163","Glycine max IgE Antibody RAST Score Measurement","C165936","A classification of the amount of Glycine max antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Glycine max IgE Antibody RAST Score Measurement | C165936 | Glycine max IgE AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979162","Triticum aestivum IgE Antibody RAST Score Measurement","C165935","A classification of the amount of Triticum aestivum antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Triticum aestivum IgE Antibody RAST Score Measurement | C165935 | Triticum aestivum IgE AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979169","Arachis hypogaea IgE Antibody RAST Score Measurement","C165934","A classification of the amount of Arachis hypogaea antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Arachis hypogaea IgE Antibody RAST Score Measurement | Arachis hypogaea IgE AB RAST Score | C165934",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979168","American Cockroach IgE Antibody RAST Score Measurement","C165933","A classification of the amount of Periplaneta americana antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","American Cockroach IgE Antibody RAST Score Measurement | American Cockroach IgE AB RAST Score | C165933 | Periplaneta americana IgE Antibody RAST Score Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979167","Dog Dander IgE Antibody RAST Score Measurement","C165932","A classification of the amount of canis lupus dander IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Dog Dander IgE Antibody RAST Score Measurement | C165932 | Canus lupus Dander IgE Antibody RAST Score Measurement | Dog Dander IgE AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979166","Nut Mix IgE Antibody RAST Score Measurement","C165931","A classification of the amount of nut mix pollen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Nut Mix IgE Antibody RAST Score Measurement | C165931 | Nut Mix IgE AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978971","Shellfish Mix IgE Antibody RAST Score Measurement","C165930","A classification of the amount of shellfish mix pollen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Shellfish Mix IgE Antibody RAST Score Measurement | C165930 | Shellfish Mix IgE AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978970","Bee Mix IgE Antibody RAST Score Measurement","C165929","A classification of the amount of bee mix pollen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Bee Mix IgE Antibody RAST Score Measurement | Bee Mix IgE AB RAST Score | C165929",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978969","Industrial Mix IgE Antibody RAST Score Measurement","C165928","A classification of the amount of industrial mix pollen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Industrial Mix IgE Antibody RAST Score Measurement | C165928 | Industrial Mix IgE AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978968","Animal Mix IgE Antibody RAST Score Measurement","C165927","A classification of the amount of animal mix pollen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Animal Mix IgE Antibody RAST Score Measurement | Animal Mix IgE AB RAST Score | C165927",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978975","Mold Mix IgE Antibody RAST Score Measurement","C165926","A classification of the amount of mold mix pollen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Mold Mix IgE Antibody RAST Score Measurement | C165926 | Mold Mix IgE AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978974","Weed Mix Pollen IgE Antibody RAST Score Measurement","C165925","A classification of the amount of weed mix pollen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Weed Mix Pollen IgE Antibody RAST Score Measurement | C165925 | Weed Mix Pollen IgE AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978973","Grass Mix Pollen IgE Antibody RAST Score Measurement","C165924","A classification of the amount of grass mix pollen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Grass Mix Pollen IgE Antibody RAST Score Measurement | C165924 | Grass Mix Pollen IgE AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978972","Tree Mix Pollen IgE Antibody RAST Score Measurement","C165923","A classification of the amount of tree mix pollen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Tree Mix Pollen IgE Antibody RAST Score Measurement | C165923 | Tree Mix Pollen IgE AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978963","Mixed Antigen IgE Antibody RAST Score Measurement","C165922","A classification of the amount of mixed antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Mixed Antigen IgE Antibody RAST Score Measurement | C165922 | Mixed Antigen IgE AB RAST Score | Mixed Antigen IgE Antibody RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978962","Silver Birch Pollen IgE Antibody RAST Score Measurement","C165921","A classification of the amount of Betula pollen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Silver Birch Pollen IgE Antibody RAST Score Measurement | Betula verricosa Pollen IgE Antibody RAST Score Measurement | C165921 | Silver Birch Pollen IgE AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978961","White Elm Pollen IgG Antibody RAST Score Measurement","C165920","A classification of the amount of Ulmus americana pollen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","White Elm Pollen IgG Antibody RAST Score Measurement | C165920 | Ulmus americana Pollen IgG Antibody RAST Score Measurement | White Elm Pollen IgG AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979135","Heparin Measurement","C165967","The determination of the amount of heparin present in a sample.","Heparin Measurement | HEPARIN | Heparin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979141","Helicase MOV-10 Protein Measurement","C165966","A measurement of helicase MOV-10 protein present in a sample.","Helicase MOV-10 Protein Measurement | HELMOV10 | Helicase MOV-10 Protein | MOV10 Measurement | Moloney Leukemia Virus 10 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979140","Human Anti-Human Antibody Measurement","C165965","The determination of the amount of total human anti-human antibody present in a sample.","Human Anti-Human Antibody Measurement | HAHA | HAHA Measurement | Human Anti-Human Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518830","PTEN Gene Inactivation","C36692","A molecular genetic abnormality indicating the presence of an inactivating mutation in the PTEN gene on chromosome 10q23.","PTEN Gene Inactivation | Inactivating MMAC1 Gene Mutation | Inactivating Mutated in Multiple Advanced Cancers 1 Gene Mutation | Inactivating PTEN Gene Mutation | Inactivating PTEN Mutation | Inactivating PTEN1 Gene Mutation | Inactivating Phosphatase and Tensin Homolog Gene Mutation | Inactivating TEP1 Gene Mutation | Loss of Function PTEN Gene Mutation | Loss of Function PTEN Mutation | PTEN Loss of Function Gene Mutation | PTEN Loss of Function Mutation | PTEN Tumor-Suppressor Gene Inactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018283","Epiphyseal Plate","C168638","A layer of cartilage located in the metaphysis of long bones in children and adolescents that is the site of longitudinal bone growth until skeletal maturity.","Epiphyseal Plate | Growth Plate | Physis | Structure of epiphyseal plate (body structure)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970578","IGK Positive","C162101","An indication that IGK expression has been detected in a sample.","IGK Positive | Ig Kappa Chain Positive | Ig Light Chain Kappa Positive | Immunoglobulin Kappa Chain Positive | Immunoglobulin Kappa Light Chain Positive | Immunoglobulin Kappa Light-Chain Positive | Immunoglobulin Kappa Positive | Kappa Light Chain Positive | Kappa Positive | kappa Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979142","N-acetyl-beta-D-glucosaminidase Excretion Rate","C165975","The determination of the amount of N-acetyl-beta-D-glucosaminidase being excreted in a biological specimen over a defined amount of time (e.g. one hour).","N-acetyl-beta-D-glucosaminidase Excretion Rate | N-Acetyl Beta-D-Glucosaminidase Measurement | NAGASE Excretion Rate | NAGASEXR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979148","Metarubricyte to Leukocyte Ratio Measurement","C165974","A relative measurement (ratio or percentage) of the metarubricytes to leukocytes in a biological sample. The measurement may be expressed as either a ratio or a percentage.","Metarubricyte to Leukocyte Ratio Measurement | METARBLE | Metarubricytes/Leukocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979147","Leucine Rich Alpha-2-Glycoprotein 1 Measurement","C165973","The determination of the amount of leucine rich alpha-2-glycoprotein 1 present in a sample.","Leucine Rich Alpha-2-Glycoprotein 1 Measurement | HMFT1766 | LRG Measurement | LRG1 | LRG1 Measurement | Leucine Rich Alpha-2-Glycoprotein 1 | Leucine-Rich Alpha-2-Glycoprotein Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979146","Lactate Dehydrogenase Excretion Rate","C165972","The determination of the amount of lactate dehydrogenase being excreted in a biological specimen over a defined amount of time (e.g. one hour).","Lactate Dehydrogenase Excretion Rate | LDH Excretion Rate | LDHEXR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979145","Soluble Kidney Injury Molecule-1 Measurement","C165971","The determination of the amount of soluble kidney injury molecule-1 present in a sample.","Soluble Kidney Injury Molecule-1 Measurement | KIM1S | Soluble Hepatitis A Virus Cellular Receptor 1 | Soluble Hepatitis A Virus Cellular Receptor 1 Measurement | Soluble KIM-1 | Soluble Kidney Injury Molecule-1 | sHAVCR1 Measurment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979137","Interleukin 1 Receptor Type 2 Measurement","C165970","The determination of the amount of interleukin 1 receptor type 2 present in a sample.","Interleukin 1 Receptor Type 2 Measurement | CD121b | CD121b Measurement | CDw121b | IL-1R-2 | IL-1RT2 | IL1R2 | IL1R2 Measurement | IL1R2c | IL1RB | Interleukin 1 Receptor Type 2 | Interleukin-1 Receptor Type 2 Measurement | Soluble CD121b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979274","Insulin-Like Growth Factor Binding Protein 7 Measurement","C165969","The determination of the amount of insulin-like growth factor binding protein 7 present in a sample.","Insulin-Like Growth Factor Binding Protein 7 Measurement | AGM | Angiomodulin Measurement | FSTL2 | IBP-7 | IGFBP-7 | IGFBP-7 Measurement | IGFBP-7v | IGFBP7 | IGFBP7 Measurement | IGFBPRP1 | Insulin-Like Growth Factor Binding Prot7 | Insulin-like Growth Factor Binding Protein 7 | MAC25 | PSF | RAMSVPS | TAF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979136","Intercellular Adhesion Molecule 3 Measurement","C165968","The determination of the amount of intercellular adhesion molecule 3 present in a sample.","Intercellular Adhesion Molecule 3 Measurement | CD50 Measurement | ICAM3 | ICAM3 Measurement | Intercellular Adhesion Molecule 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378762","Myelodysplastic Syndrome, Unclassifiable, Based on Defining Cytogenetic Abnormality","C168678","Myelodysplastic syndrome, unclassifiable characterized by persistent cytopenia (s) with 1 percent or fewer blasts in the blood and fewer than 5% in the bone marrow, unequivocal dysplasia in less than 10 percent of the cells in one or more myeloid lineages, and cytogenetic abnormalities considered as presumptive evidence of myelodysplastic syndrome.","Myelodysplastic Syndrome, Unclassifiable, with Defining Cytogenetic Abnormality | Myelodysplastic Syndrome, Unclassifiable, Based on Defining Cytogenetic Abnormality | Myelodysplastic Syndrome, Unclassifiable, Based on Defining Cytogenetic Abnormality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378763","Myelodysplastic Syndrome, Unclassifiable, with 1 Percent Blasts","C168677","Myelodysplastic syndrome, unclassifiable characterized by refractory cytopenia with unilineage dysplasia or refractory cytopenia with multilineage dysplasia but with 1 percent blasts in the peripheral blood.","Myelodysplastic Syndrome, Unclassifiable, with 1 Percent Blasts | Myelodysplastic Syndrome, Unclassifiable, With 1 Percent Blasts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378620","Myelodysplastic Syndrome, Unclassifiable, with Single Lineage Dysplasia","C168681","Myelodysplastic syndrome, unclassifiable characterized by unilineage dysplasia and associated pancytopenia.","Myelodysplastic Syndrome, Unclassifiable, with Single Lineage Dysplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378724","IWG-MRT Criteria for Treatment Response in Myelofibrosis","C168633","Criteria in inducing remission or improvement in myelofibrosis according to the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT).","IWG-MRT Criteria for Treatment Response in Myelofibrosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378727","IWG-MRT Myelofibrosis Complete Remission","C168634","Bone marrow: Age-adjusted normocellularity; less than 5 percent blasts; less than or equal to grade 1 myelofibrosis and Peripheral blood: Hemoglobin greater than or equal to 100 g/L and less than upper normal limit; neutrophil count greater than or equal 1x10^9/L and less than upper normal limit; Platelet count greater or equal to 100x10^9/L and less than upper normal limit; less than 2 percent immature myeloid cells and Clinical: Resolution of disease symptoms; spleen and liver not palpable; no evidence of extramedullary hematopoiesis (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)","IWG-MRT Myelofibrosis Complete Remission | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378726","IWG-MRT Myelofibrosis Partial Remission","C168635","Peripheral blood: Hemoglobin greater than or equal to 100 g/L and less than upper normal limit; neutrophil count greater than or equal to 1x10^9/L and less than upper normal limit; platelet count greater than or equal to 100x10^9/L and less than upper normal limit; less than 2 percent immature myeloid cells and Clinical: Resolution of disease symptoms; spleen and liver not palpable; no evidence of extramedullary hematopoiesis or Bone marrow: Age-adjusted normocellularity; less than 5 percent blasts; less than grade 1 myelofibrosis and peripheral blood: Hemoglobin greater than or equal to 85 but less than 100 g/L and less than upper normal limit; neutrophil count greater than 1x10^9/L and less than upper normal limit; platelet count greater than or equal to 50 but less than 100x10^9/L and less than upper normal limit; less than 2 percent immature myeloid cells and Clinical: Resolution of disease symptoms; spleen and liver not palpable; no evidence of extramedullary hematopoiesis(adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)","IWG-MRT Myelofibrosis Partial Remission | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378735","IWG-MRT Myelofibrosis Cytogenetic/Molecular Relapse","C168636","Re-emergence of a pre-existing cytogenetic or molecular abnormality that is confirmed by repeat testing (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)","IWG-MRT Myelofibrosis Cytogenetic/Molecular Relapse | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378736","IWG-MRT Myelofibrosis Clinical Improvement","C168641","The achievement of anemia spleen or symptoms response without progressive disease or increase in severity of anemia thrombocytopenia or neutropenia (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)","IWG-MRT Myelofibrosis Clinical Improvement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378732","IWG-MRT Myelofibrosis Relapse","C168642","No longer meeting criteria for at least clinical improvement after achieving complete response partial response or clinical improvement or loss of anemia response persisting for at least 1 month or loss of spleen response persisting for at least 1 month (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)","IWG-MRT Myelofibrosis Relapse | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378731","IWG-MRT Myelofibrosis Symptom Response","C168643","A greater than or equal to 50 percent reduction in the myeloproliferative neoplasm symptom assessment form total symptom score (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)","IWG-MRT Myelofibrosis Symptom Response | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378734","IWG-MRT Myelofibrosis Stable Disease","C168644","Belonging to none of the above listed response categories (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)","IWG-MRT Myelofibrosis Stable Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378733","IWG-MRT Myelofibrosis Progressive Disease","C168645","Appearance of a new splenomegaly that is palpable at least 5 cm below the left costal margin or A greater than or equal to 100 percent increase in palpable distance, below left costal margin, for baseline splenomegaly of 5 to 10 cm or A 50 percent increase in palpable distance, below left costal margin, for baseline splenomegaly of greater than 10 cm or Leukemic transformation confirmed by a bone marrow blast count of greater than or equal to 20 percent or A peripheral blood blast content of greater than or equal to 20 percent associated with an absolute blast count of greater than or equal to 1x10^9/L that lasts for at least 2 weeks (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD, 22 AUGUST 2013 x VOLUME 122, NUMBER 8)","IWG-MRT Myelofibrosis Progressive Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378743","IWG-MRT Myelofibrosis Anemia Response","C168646","Transfusion-independent patients: a greater than or equal to 20 g/L increase in hemoglobin level or for transfusion-dependent patients: becoming transfusion-independent (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)","IWG-MRT Myelofibrosis Anemia Response | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378742","IWG-MRT Myelofibrosis Cytogenetic Remission","C168650","At least 10 metaphases must be analyzed for cytogenetic response evaluation and requires confirmation by repeat testing within 6 months window. Complete response: eradication of a preexisting abnormality. Partial response: greater than or equal to 50 percent reduction in abnormal metaphases. (partial response applies only to patients with at least ten abnormal metaphases at baseline) (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)","IWG-MRT Myelofibrosis Cytogenetic Remission | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378744","IWG-MRT Myelofibrosis Spleen Response","C168652","A baseline splenomegaly that is palpable at 5-10 cm below the left costal margin becomes not palpable or A baseline splenomegaly that is palpable at greater than 10 cm below the left costal margin decreases by greater than or equal to 50 percent. A baseline splenomegaly that is palpable at less than 5 cm below the left costal margin is not eligible for spleen response. A spleen response requires confirmation by MRI or computed tomography showing greater than or equal to 35 percent spleen volume reduction. (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)","IWG-MRT Myelofibrosis Spleen Response | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378739","IWG-MRT Myelofibrosis Molecular Remission","C168653","Molecular response evaluation must be analyzed in peripheral blood granulocytes and requires confirmation by repeat testing within 6 months window. Complete response: Eradication of a pre-existing abnormality. Partial response: greater than or equal to 50 percent decrease in allele burden (partial response applies only to patients with at least 20 percent mutant allele burden at baseline.) (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)","IWG-MRT Myelofibrosis Molecular Remission | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523980","Vitronectin Measurement","C165995","The determination of the amount of vitronectin present in a sample.","Vitronectin Measurement | V75 | VN | VNT | VTN | VTN Measurement | VTRNCTN | Vitronectin",,,,,,,,,,,,,,,"4020711","Vitronectin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL979133","Soluble Vascular Endothelial Growth Factor Receptor Type 3 Measurement","C165994","The determination of the amount of soluble vascular endothelial growth factor receptor 3 present in a sample.","Soluble Vascular Endothelial Growth Factor Receptor Type 3 Measurement | Soluble FLT4 Measurement | Soluble VEGFR-3 Measurement | Soluble VEGFR3 Measurement | Soluble Vasc Endoth Growth Factor Rec3 | Soluble Vascular Endothelial Growth Factor Receptor 3 | VEGFR3S | sFLT4 Measurement | sVEGFR-3 Measurement | sVEGFR3 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979132","Soluble Vascular Endothelial Growth Factor Receptor Type 2 Measurement","C165993","The determination of the amount of soluble vascular endothelial growth factor receptor 2 present in a sample.","Soluble Vascular Endothelial Growth Factor Receptor Type 2 Measurement | Soluble FLK-1 Measurement | Soluble FLK1 Measurement | Soluble KDR Measurement | Soluble VEGFR-2 Measurement | Soluble VEGFR2 Measurement | Soluble Vasc Endoth Growth Factor Rec2 | Soluble Vascular Endothelial Growth Factor Receptor 2 | VEGFR2S | sFLK-1 Measurement | sFLK1 Measurement | sKDR Measurement | sVEGFR-2 Measurement | sVEGFR2 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979131","Soluble Vascular Endothelial Growth Factor Receptor Type 1 Measurement","C165992","The determination of the amount of soluble vascular endothelial growth factor receptor 1 present in a sample.","Soluble Vascular Endothelial Growth Factor Receptor Type 1 Measurement | Soluble FLT1 Measurement | Soluble VEGFR-1 Measurement | Soluble VEGFR1 Measurement | Soluble Vasc Endoth Growth Factor Rec1 | Soluble Vascular Endothelial Growth Factor Receptor 1 | VEGFR1S | sFLT1 Measurement | sVEGFR-1 Measurement | sVEGFR1 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979130","TNF Receptor 1B Measurement","C165991","The determination of the amount of tumor necrosis factor receptor superfamily member 1B present in a sample.","TNF Receptor 1B Measurement | CD120b | CD120b Measurement | Soluble CD120b | TBPII | TNF Receptor 1B | TNF-R-II | TNF-R-II Measurement | TNF-R75 | TNFBR | TNFBR Measurement | TNFR1B | TNFR2 | TNFR2 Measurement | TNFR80 | Tumor Necrosis Factor Receptor 2 | Tumor Necrosis Factor Receptor Superfamily Member 1B Measurement | p75 | p75TNFR | p75TNFR Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979275","TNF Superfamily Member 12 Measurement","C165990","The determination of the amount of total tumor necrosis factor superfamily member 12 present in a sample.","TNF Superfamily Member 12 Measurement | APO3 Ligand Measurement | APO3L | APO3L Measurement | DR3LG | TNF Superfamily Member 12 | TNF-Related Weak Inducer of Apoptosis Measurement | TNF12 | TNFSF12 Measurement | TNLG4A | TWEAK | TWEAK Measurement | Tumor Necrosis Factor Ligand Superfamily Member 12 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979134","TNF Superfamily Member 10 Measurement","C165989","The determination of the amount of total tumor necrosis factor superfamily member 10 present in a sample.","TNF Superfamily Member 10 Measurement | APO2 Ligand Measurement | APO2L | APO2L Measurement | CD253 | Soluble CD253 | TL2 | TNF Superfamily Member 10 | TNF-Related Apoptosis Inducing Ligand Measurement | TNF-Related Apoptosis-Inducing Ligand | TNF10 | TNFSF10 | TNFSF10 Measurement | TNLG6A | TRAIL | TRAIL Measurement | Tumor Necrosis Factor Ligand Superfamily Member 10 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979281","Tissue Inhibitor of Metalloproteinase 3 Measurement","C165988","The determination of the amount of tissue inhibitor of metalloproteinase 3 present in a sample.","Tissue Inhibitor of Metalloproteinase 3 Measurement | HSMRK222 | K222 | K222TA2 | MIG-5 Measurement | Metalloproteinase Inhibitor 3 | Metalloproteinase Inhibitor 3 Measurement | Protein MIG-5 | SFD | TIMP-3 Measurement | TIMP3 | TIMP3 Measurement | Tissue Inhibitor of Metalloproteinase 3 | Tissue Inhibitor of Metalloproteinase-3 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979264","Transforming Growth Factor Beta 3 Measurement","C165987","The determination of the amount of transforming growth factor beta 3 present in a sample.","Transforming Growth Factor Beta 3 Measurement | ARVD | ARVD1 | LAP Measurement | LDS5 | Latency-Associated Peptide Measurement | RNHF | TGF Beta 3 Measurement | TGF-Beta-3 Measurement | TGF-beta3 | TGFB3 | TGFB3 Measurement | TGFbeta3 Measurement | Transforming Growth Factor Beta 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979277","Transforming Growth Factor Beta 2 Measurement","C165986","The determination of the amount of transforming growth factor beta 2 present in a sample.","Transforming Growth Factor Beta 2 Measurement | G-TSF | LDS4 | TGF Beta 2 Measurement | TGF-Beta-2 Measurement | TGF-beta2 | TGFB2 | TGFbeta2 Measurement | Transforming Growth Factor Beta 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979288","Transforming Growth Factor Alpha Measurement","C165985","The determination of the amount of transforming growth factor alpha present in a sample.","Transforming Growth Factor Alpha Measurement | TGF Alpha Measurement | TGF-Alpha Measurement | TGFA | TGFA Measurement | TGFalpha Measurement | Transforming Growth Factor Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979126","Somatostatin Receptor Type 2 Measurement","C165984","The determination of the amount of somatostatin receptor type 2 present in a sample.","Somatostatin Receptor Type 2 Measurement | SRIF-1 | SSTR2 | SSTR2 Measurement | Somatostatin Receptor Type 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979125","SH2 Domain Containing 1A Protein Measurement","C165983","The determination of the amount of SH2 domain containing 1A protein present in a sample.","SH2 Domain Containing 1A Protein Measurement | DSHP | Duncan Disease SH2-Protein | EBVS | IMD5 | LYP | MTCP1 | SAP | SAP Measurement | SAP/SH2D1A | SH2 Domain Containing 1A Protein | SH2D1A | SH2D1A Measurement | SLAM-Associated Protein Measurement | XLP | XLPD | XLPD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979129","Serum Amyloid A1 Measurement","C165982","The determination of the amount of serum amyloid A1 present in a sample.","Serum Amyloid A1 Measurement | PIG4 | SAA Measurement | SAA1 | SAA1 Measurement | Serum Amyloid A-1 Protein | Serum Amyloid A1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979128","Phosphorylated 40S Ribosomal Protein S6 Measurement","C165981","The determination of the amount of phosphorylated S6 protein of the 40S ribosomal subunit present in a sample.","Phosphorylated 40S Ribosomal Protein S6 Measurement | Phos-S6 Ribosomal Protein | Phospho-40S Ribosomal Protein S6 Measurement | Phospho-RPS6 Measurement | Phosphorylated S6 protein of the 40S ribosomal subunit | S6PHS | pRPS6 Measurement | pS6RP Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972952","Receptor Advanced Glycation Endproducts Measurement","C165980","The determination of the amount of receptor advanced glycation endproducts present in a sample.","Receptor Advanced Glycation Endproducts Measurement | AGER | AGER Measurement | Advanced Glycosylation End Product-Specific Receptor Measurement | Advanced Glycosylation End-Product Specific Receptor | RAGE | RAGE Measurement | Receptor Advanced Glycation Endproducts | Receptor for Advanced Glycosylation End Products Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979127","Pro-C6 Measurement","C165979","The determination of the amount of pro-C6 present in a sample.","Pro-C6 Measurement | C-Terminal Propeptide of Collagen Alpha-3(IV) Measurement | C-Terminal Propeptide of Type 6a3 Collagen | C-Terminal Propeptide of Type VIa3 Collagen | C-terminal Pro-Peptide of the Alpha 3 Type VI Collagen Chain | Endotrophin | Endotrophin Measurement | PROC6 | Pro-C6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979144","Platelet-Granulocyte Aggregate Measurement","C165978","The determination of the amount of aggregates composed of platelets and granulocytes present in a sample.","Platelet-Granulocyte Aggregate Measurement | PGAG | Platelet-Granulocyte Agg | Platelet-Granulocyte Aggregates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979285","Neuropilin-1 Measurement","C165977","The determination of the amount of neuropilin-1 present in a sample.","Neuropilin-1 Measurement | BDCA4 | CD304 | NP1 | NRP | NRP Measurement | NRP1 | NRP1 Measurement | Neuropilin-1 | Soluble CD304 | VEGF165R | VEGF165R Measurement | Vascular Endothelial Cell Growth Factor 165 Receptor Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378633","Bothered by Genital Itching and/or Irritation","C168700","A question about the extent to which an individual is bothered by genital itching and/or irritation.","Bothered by Genital Itching and/or Irritation | Extent Bothered by Genital Itching and/or Irritation | Genital itching/irritation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1379134","Bothered by Decreased Appetite","C168702","A question about the extent to which an individual is bothered by decreased appetite","Bothered by Decreased Appetite | Decreased appetite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378630","Bothered by Upset Stomach and/or Indigestion","C168703","A question about the extent to which an individual is bothered by upset stomach and/or indigestion.","Bothered by Upset Stomach and/or Indigestion | Bothered by Stomach Upset and/or Indigestion | Extent Bothered by Upset Stomach and/or Indigestion | Upset stomach, indigestion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1379137","Bothered by Sinus Problems","C168704","A question about the extent to which an individual is bothered by sinus problems.","Bothered by Sinus Problems | Extent Bothered by Sinus Problems | Sinus problems",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378636","Bothered by Coughing","C168705","A question about the extent to which an individual is bothered by coughing.","Bothered by Coughing | Coughing | Extent Bothered by Coughing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378635","Bothered by Swelling of Hands or Feet","C168706","A question about the extent to which an individual is bothered by swelling of hands or feet.","Bothered by Swelling of Hands or Feet | Extent Bothered by Swelling of Hands or Feet | Swelling of hands or feet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1379133","Bothered by Early Awakening","C168707","A question about the extent to which an individual is bothered by early awakening.","Bothered by Early Awakening | Early awakening | Extent Bothered by Early Awakening",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378637","Extent of Symptoms Likert Scale","C168708","A scale for the subject scoring of symptoms extent that ranges from 0: Not at All to 4: Very Bothered.","Extent of Symptoms Likert Scale | Extent of Symptoms | Extent of Symptoms Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1379038","Symptoms Extent Score 0","C168709","A subject score of 0 on a symptoms extent scale that ranges from 0: Not at All to 4: Very Bothered.","Symptoms Extent Score 0 | 0 | Not at All Bothered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407111","Symptoms Extent Score 1","C168710","A subject score of 1 on a symptoms extent scale that ranges from 0: Not at All to 4: Very Bothered.","Symptoms Extent Score 1 | 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1379031","Symptoms Extent Score 2","C168711","A subject score of 2 on a symptoms extent scale that ranges from 0: Not at All to 4: Very Bothered.","Symptoms Extent Score 2 | 2 | Somewhat Bothered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1379035","Symptoms Extent Score 4","C168713","A subject score of 4 on a symptoms extent scale that ranges from 0: Not at All to 4: Very Bothered.","Symptoms Extent Score 4 | 4 | Very Bothered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL941813","IDH1 inhibitor","C168618","Any agent that inhibits isocitrate dehydrogenase (IDH) type 1 (IDH1, IDH1 [NADP+] soluble) found in the cytoplasm.","IDH1 inhibitor | Cytosolic Isocitrate Dehydrogenase (NADP(+)) 1 Inhibitor | Isocitrate Dehydrogenase Type 1 Inhibitor",,,,,,,,,,,,,,,"36676368","Isocitrate dehydrogenase-1 inhibitor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL550698","Isocitrate Dehydrogenase 2 Inhibitors [MoA]","C168619","Any agent that inhibits isocitrate dehydrogenase (IDH) type 2 (IDH2, isocitrate dehydrogenase [NADP+], mitochondrial) found in the mitochondria.","IDH2 inhibitor | Isocitrate Dehydrogenase Type 2 Inhibitor | Mitochondrial Isocitrate Dehydrogenase (NADP (+)) 2 Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826970","SAMD9L Gene","C168734","This gene may be involved in endocytosis and the attenuation of receptor signaling.","SAMD9L Gene | SAMD9L | Sterile Alpha Motif Domain Containing 9 Like Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378658","SAMD9- Associated Familial MDS","C168746","A familial myelodysplastic syndrome caused by inherited mutations in the SAMD9 gene.","SAMD9-Associated Hereditary Myelodysplastic Syndrome | SAMD9- Associated Familial MDS | SAMD9-Associated Familial Myelodysplastic Syndrome | SAMD9-Associated Familial Myelodysplastic Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378657","SAMD9L-Associated Familial MDS","C168747","A familial myelodysplastic syndrome caused by inherited mutations in the SAMD9L gene.","SAMD9L-Associated Hereditary Myelodysplastic Syndrome | SAMD9L-Associated Familial MDS | SAMD9L-Associated Familial Myelodysplastic Syndrome | SAMD9L-Associated Familial Myelodysplastic Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553398","Telomere Syndrome","C152065","A group of disorders caused by mutation(s) that disrupt the maintenance of telomeres, resulting in the short telomere defect.","Telomere Syndrome | Telomere Biology Disorders | Telomere Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1832388","Familial Platelet Disorder with Associated Myeloid Malignancy","C162696","An autosomal dominant condition caused by mutation(s) in the RUNX1 gene, encoding runt-related transcription factor 1. It is characterized by thrombocytopenia, abnormal platelet function, and a propensity to develop acute myeloid leukemia.","Familial Platelet Disorder with Associated Myeloid Malignancy | FPD/AML | FPDMM | Familial Platelet Disorder and AML Syndrome",,,,,,,,,,,,,,,"37110713","Familial platelet syndrome with predisposition to acute myelogenous leukemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL553244","Hematologic Neoplasm with Germline DDX41 Mutation","C151901","An autosomal dominant familial myelodysplastic syndrome/acute myeloid leukemia syndrome characterized by inherited mutations in the gene on chromosome 5 encoding the DEAD box RNA helicase DDX41. Patients usually present with leukopenia, hypocellular bone marrow with prominent erythroid dysplasia and a normal karyotype, often leading to erythroleukemia. The prognosis is generally poor. (WHO 2017)","Hematologic Neoplasm with Germline DDX41 Mutation | Myeloid Neoplasms with Germline DDX41 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023218","Leg Cramp","C34762","An involuntary contraction of a muscle supporting the femur.","Leg Cramp | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039142","Syringe","C43202","A device for the administration of drug products that consists of a rigid barrel fitted with septum with a plunger at one end and a seal or needle at the other end. The needle assembly may be part of the device or separate.","Syringe | Injection syringe | SYRINGE | syringe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224460","Medial Head of Gastrocnemius Muscle","C163520","One of two heads of the gastrocnemius muscle, originating on the medial femoral condyle.","Medial Head of Gastrocnemius Muscle | GASTROCNEMIUS MUSCLE, MEDIAL HEAD",,,,,,,,,,,,,,,"4018338","Structure of medial head of gastrocnemius muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224459","Lateral Head of Gastrocnemius Muscle","C163519","One of two heads of the gastrocnemius muscle, originating on the lateral femoral condyle.","Lateral Head of Gastrocnemius Muscle | GASTROCNEMIUS MUSCLE, LATERAL HEAD",,,,,,,,,,,,,,,"4012628","Structure of lateral head of gastrocnemius muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL976735","Flexor Digitorum Brevis Muscle","C163518","A muscle in the foot that allows flexion of the four lateral toes and supports the medial and lateral longitudinal arches. It originates on the medial process of the posterior calcaneal tuberosity and inserts as tendons into the borders of the middle phalanx of the four lateral toes. It is innervated by the medial plantar nerve and supplied by the medial and lateral plantar arteries.","Flexor Digitorum Brevis Muscle | FLEXOR DIGITORUM BREVIS MUSCLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976765","Finger Flexors","C163517","A group of muscles that originate on the bones on the palmar side of the arm and forearm and insert into the bones of the phalanges of the hand through long tendons; the finger flexors, including the flexor digitorum superficialis, flexor digitorum profundus, and flexor pollicis longus muscles, allow for bending of the fingers.","Finger Flexors | FINGER FLEXOR MUSCLES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976766","Finger Extensors","C163516","A group of muscles that originate on the bones on the posterior side of the forearm and insert into the bones of the phalanges through long tendons. The finger extensors, including the abductor pollicis longus, extensor pollicis brevis, extensor pollicis longus, extensor indicis, extensor digitorum, and extensor digiti minimi muscles, allow for straightening of the fingers to open the hand.","Finger Extensors | FINGER EXTENSOR MUSCLES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224467","Extensor Hallucis Brevis Muscle","C163515","A muscle on the dorsal side of the foot that helps to extend the big toe. It originates on the superior surface of the anterior calcaneus and inserts into the dorsal surface of the base of the proximal phalanx of the big toe. It is innervated by the deep fibular nerve and supplied by the dorsalis pedis artery.","Extensor Hallucis Brevis Muscle | EXTENSOR HALLUCIS BREVIS MUSCLE",,,,,,,,,,,,,,,"4305250","Structure of extensor hallucis brevis muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224465","Extensor Digitorum Brevis Muscle","C163514","A muscle on the dorsal side of the foot that helps to extend the second, third and fourth toes. It originates on the superolateral surface of the anterior calcaneus and inserts into the lateral sides of the tendons of extensor digitorum longus on the second, third and fourth toes. It is innervated by the deep peroneal nerve and supplied by the dorsalis pedis artery.","Extensor Digitorum Brevis Muscle | EXTENSOR DIGITORUM BREVIS MUSCLE",,,,,,,,,,,,,,,"4227741","Structure of extensor digitorum brevis muscle of foot",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL976767","Elbow Flexors","C163513","A group of three muscles located in the upper extremity, the brachialis, biceps brachii, and the brachioradialis, that allow for bending of the arm at the elbow joint.","Elbow Flexors | ELBOW FLEXOR MUSCLES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976768","Elbow Extensors","C163512","Two muscles located in the upper extremity, the triceps brachii and anconeus, that allow for straightening of the arm at the elbow joint.","Elbow Extensors | ELBOW EXTENSOR MUSCLES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224127","Corrugator Supercilii Muscle","C163511","One of two small facial muscles that are located behind the occipitofrontalis and orbicularis oculis muscles, with which they blend, and allow movement of the eyebrows. They originate in the medial superciliary arch and insert into the skin above the middle of the supraorbital margins. They are innervated by the temporal branch of the facial nerve and supplied by branches from the superficial temporal and ophthalmic arteries.","Corrugator Supercilii Muscle | CORRUGATOR SUPERCILII MUSCLE",,,,,,,,,,,,,,,"4337130","Structure of corrugator supercilii muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224438","Adductor Magnus Muscle","C163510","A muscle located in the medial compartment of the thigh that adducts, flexes, extends, and medially rotates the thigh at the hip joint. It originates on the ischiopubic ramus and ischial tuberosity, and inserts into the gluteal tuberosity of the femur, medial lip of the linea aspera, medial supracondylar ridge, and adductor tubercle. It is innervated by the obturator and tibial nerves and supplied by branches of the deep femoral and popliteal arteries, and the inferior gluteal and obturator arteries.","Adductor Magnus Muscle | ADDUCTOR MAGNUS MUSCLE",,,,,,,,,,,,,,,"4048936","Structure of adductor magnus muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0584891","Adductor Longus Muscle","C163509","A muscle located in the medial compartment of the thigh that adducts and medially rotates the thigh. It originates on the external surface of the pubis body and inserts into the middle third of the linea aspera. It is innervated by the obturator nerve and branches of the sciatica nerve and supplied by the obturator and medial circumflex femoral arteries.","Adductor Longus Muscle | ADDUCTOR LONGUS MUSCLE",,,,,,,,,,,,,,,"4311696","Adductor longus muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224486","Transverse Head of Adductor Hallucis Muscle","C163508","The smaller of two heads of the adductor hallucis muscle. It originates from the deep transverse metatarsal ligament and the plantar surface of the metatarsophalangeal joints of the lateral three toes.","Transverse Head of Adductor Hallucis Muscle | ADDUCTOR HALLUCIS MUSCLE, TRANSVERSE HEAD",,,,,,,,,,,,,,,"4228826","Structure of transverse head of adductor hallucis muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224485","Oblique Head of Adductor Hallucis Muscle","C163507","The larger of two heads of the adductor hallucis muscle. It originates from the sheath of the peroneus longus tendon and the plantar surface of the bases of the second to fourth metatarsal bones in the foot.","Oblique Head of Adductor Hallucis Muscle | ADDUCTOR HALLUCIS MUSCLE, OBLIQUE HEAD",,,,,,,,,,,,,,,"4219252","Structure of oblique head of adductor hallucis muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224436","Adductor Brevis Muscle","C163506","A muscle in the lower extremity that adducts, flexes, and helps to rotate the thigh. It originates on the external surface of body of pubis and the anterior surface of the inferior pubic ramus and inserts in the pectineal line and the medial lip of the linea aspera. It is innervated by the anterior or posterior division of the obturator nerve and is supplied by the obturator and medial circumflex femoral arteries.","Adductor Brevis Muscle | ADDUCTOR BREVIS MUSCLE",,,,,,,,,,,,,,,"4323834","Structure of adductor brevis muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224490","Abductor Hallucis Muscle","C163505","A muscle in the foot that abducts and flexes the great toe at metatarsophalangeal joint. It originates in the medial process of the posterior calcaneal tuberosity and the flexor retinaculum and inserts into the medial side of the base of the proximal phalanx of the great toe. It is innervated by the medial plantar nerve and is supplied by the medial plantar artery.","Abductor Hallucis Muscle | ABDUCTOR HALLUCIS MUSCLE",,,,,,,,,,,,,,,"4180858","Structure of abductor hallucis muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL379295","Abductor Digiti Minimi Muscle","C163504","A muscle in the foot that flexes and abducts the fifth toe at the metatarsophalangeal joint and supports the lateral arch. It originates in the medial and lateral processes of the posterior calcaneal tuberosity and inserts into the lateral side of the base of the proximal phalanx of the fifth toe and the fifth metatarsal. It is innervated by the lateral planter nerve and is supplied by the lateral planter artery.","Abductor Digiti Minimi Muscle | ABDUCTOR DIGITI QUINTI MUSCLE | Abductor Digiti Minimi | Abductor Minimi Digiti",,,,,,,,,,,,,,,"4009865","Structure of abductor digiti minimi muscle of foot",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL979121","Wrist Joint Flexor Muscles","C166004","A group of muscles located in the anterior compartment of the forearm that allow plantar flexion of the wrist, as well as other movements of the wrist and fingers. The wrist flexors, including the flexor carpi radialis, palmaris longus, flexor carpi ulnaris, flexor digitorum superficialis, flexor digitorum profundus, and flexor pollicis longus muscles, originate on the medial distal humerus or anterior ulna and radius, and insert into the anterior surfaces of the carpals, metacarpals and phalanges.","Wrist Joint Flexor Muscles | WRIST JOINT FLEXOR MUSCLES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979116","Wrist Joint Extensor Muscles","C166003","A group of muscles located in the posterior compartment of the forearm that allow dorsiflexion of the wrist, as well as other movements of the wrist and fingers. The wrist extensors, including the extensor carpi radialis longus, extensor carpi radialis brevis, extensor digitorum, extensor digiti minimi, extensor carpi ulnaris, extensor indicis, extensor pollicis longus, extensor pollicis brevis, and abductor pollicis longus muscles, originate on the posterior ulna and radius, and the distal humerus, and insert into the backs of the carpals, metacarpals and phalanges.","Wrist Joint Extensor Muscles | WRIST JOINT EXTENSOR MUSCLES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224220","Procerus Muscle","C166001","A pyramid-shaped muscle in the face that allows movement of the skin between the eyebrows. It originates on the lower part of the nasal bone and inserts into the frontalis muscle in the forehead. It is innervated by branches of the facial nerve and supplied by the facial artery.","Procerus Muscle | PROCERUS MUSCLE",,,,,,,,,,,,,,,"4328483","Structure of procerus muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL979115","Paraspinal Region","C166000","The area of the body near the spinal column.","Paraspinal Region | PARASPINAL REGION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979114","Hymenal Ring","C165999","The outer edge of the hymen or hymenal remnants.","Hymenal Ring | HYMENAL RING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224483","Flexor Hallucis Brevis Muscle","C165998","A muscle in the foot that is involved in the flexion of the first toe and the support of the medial longitudinal arch. It originates on the plantar surface of the cuboid bone and inserts into the medial and lateral sesamoid bones at the base of the proximal phalanx of the first toe. It is innervated by the medial plantar nerve and supplied by the medial plantar artery.","Flexor Hallucis Brevis Muscle | FLEXOR HALLUCIS BREVIS MUSCLE",,,,,,,,,,,,,,,"4119096","Structure of flexor hallucis brevis muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224279","Abductor Pollicis Brevis Muscle","C165997","A muscle of the hand, in general extending from the flexor retinaculum and the tubercles of the scaphoid and trapezium bones to the outer side of the base of the proximal phalanx of the thumb. Primary function is abduction of the thumb away from the palm.","Abductor Pollicis Brevis Muscle | ABDUCTOR POLLICIS BREVIS MUSCLE",,,,,,,,,,,,,,,"4138832","Structure of abductor pollicis brevis muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1267094","Abductor Digiti Minimi Muscle of the Hand","C165996","A muscle of the hand, in general extending from the pisiform bone, the pisohamate ligament, and the flexor retinaculum to the ulnopalmar margin of the proximal phalanx. Primary function is abduction of the little finger and flexion of the phalanx nearest the hand.","Abductor Digiti Minimi Muscle of the Hand | ABDUCTOR DIGITI MINIMI MUSCLE OF THE HAND",,,,,,,,,,,,,,,"4021995","Structure of abductor digiti minimi muscle of hand",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224463","Posterior Tibialis Muscle","C140526","A muscle of the lower leg that is located in the deep posterior compartment, originating on the inner posterior borders of the tibia and fibula, with further attachments to the interosseous membrane; the tendon of the posterior tibialis muscle, the posterior tibial tendon, terminates by dividing into plantar, main and recurring components, all of which have terminal insertions: plantar portion inserts into the bases of the second, third and fourth metatarsals; the intermediate and lateral cuneiforms, and the cuboid; the main portion inserts into the tuberosity of the navicular and the plantar surface of the medial cuneiform; the recurrent portion inserts into the sustentaculum tali of he calcaneus. The muscle functions to stabilize the ankle, as well as invert and plantar flex the foot at the ankle.","Posterior Tibialis Muscle | TIBIALIS POSTERIOR MUSCLE",,,,,,,,,,,,,,,"4253349","Tibialis posterior muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0457053","Urethral Sphincter","C128573","One or both of the muscles that surround the urethra and contract to control the flow of urine, either involuntarily (the internal sphincter) or voluntarily (the external sphincter).","Urethral Sphincter | URETHRAL SPHINCTER",,,,,,,,,,,,,,,"4082670","Urethral sphincter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0687025","Gluteal Muscle","C78205","Any of the skeletal muscles that form the buttocks. These muscles are responsible for hip abduction and extension as well as movement of the thigh.","Gluteal Muscle | GLUTEAL MUSCLE | MUSCLE, GLUTEUS",,,,,,,,,,,,,,,"4008011","Muscle of buttock",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0699800","Adductor Group of the Leg","C53039","A group of muscles causing movement of the leg towards the midline of the body.","Adductor Group of the Leg | HIP ADDUCTORS | MUSCLE, ADDUCTOR",,,,,,,,,,,,,,,"4195328","Structure of adductor muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224473","Flexor Hallucis Longus","C52925","A muscle in the lower leg and foot beginning at the fibula and ending with a tendon attaching to the distal surface of the great toe phalanx in order to flex the toe.","Flexor Hallucis Longus | FLEXOR HALLUCIS LONGUS MUSCLE",,,,,,,,,,,,,,,"4264059","Flexor hallucis longus muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1261048","Flexor Digitorum Longus","C52921","A muscle in the lower leg and foot beginning at the tibia and ending with four tendons proceeding to the second, third, fourth, and fifth toes acting to curl the toes into the foot.","Flexor Digitorum Longus | FLEXOR DIGITORUM LONGUS MUSCLE | MUSCLE, FLEXOR DIGITORUM LONGUS",,,,,,,,,,,,,,,"4076859","Flexor digitorum longus muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025058","Median Nerve","C52815","A branch of the brachial plexus that extends along the anterior aspect of the forearm and the hand.","Median Nerve | MEDIAN NERVE | NERVE, MEDIAN",,,,,,,,,,,,,,,"4242696","Structure of median nerve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034518","Radial Nerve","C52812","A large nerve that arises from the brachial plexus and enervates the extensor muscles and skin of the entire upper limb's posterior aspect.","Radial Nerve | NERVE, RADIAL | RADIAL NERVE",,,,,,,,,,,,,,,"4214863","Structure of radial nerve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041602","Ulnar Nerve","C52807","A major peripheral nerve of the upper limb; it originates as the medial cord of the brachial plexus, and contains fibers from the C8-T1 nerve roots. It functions to supply both sensory and motor innervation to parts of the forearm and hand.","Ulnar Nerve | NERVE, ULNAR | ULNAR NERVE",,,,,,,,,,,,,,,"4243188","Structure of ulnar nerve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0584884","Subscapularis Muscle","C33651","One of four rotator cuff muscles that form a musculotendinous cuff around the glenohumeral joint, which provides muscular support to the shoulder. It originates on the subscapular fossa with insertion onto the lesser tubercle of the humerus, and functions to medially rotate the humerus.","Subscapularis Muscle | SUBSCAPULARIS MUSCLE",,,,,,,,,,,,,,,"4235135","Subscapularis muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224434","Sartorius Muscle","C33515","A long, thin striated muscle of the anterior compartment of the thigh, which takes its origin from the anterior superior iliac spine of the pelvic bone, and inserts on the anteromedial surface of the upper tibia in the pes anserinus; it functions to flex, abduct, and laterally rotate the thigh at the hip joint, and to flex the leg at the knee joint.","Sartorius Muscle | SARTORIUS MUSCLE | Sartorius | Tailor's Muscle",,,,,,,,,,,,,,,"4128899","Structure of sartorius muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224347","Pectoralis Minor","C33285","Either of two small, triangular, bilateral muscles located inferior the pectoralis major muscle, which originate from the third to fifth ribs near their costal cartilages and inserting on the medial border and superior surface of the coracoid process of the scapula, and which function to stabilize the scapula against the thoracic wall.","Pectoralis Minor | Musculus Pectoralis Minor | PECTORALIS MINOR MUSCLE",,,,,,,,,,,,,,,"4093310","Pectoralis minor muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0229315","Lobule of the Auricle","C32999","The soft fleshy portion of the lower external ear composed of areolar and adipose connective tissues.","Lobule of the Auricle | EARLOBE | Earlobe",,,,,,,,,,,,,,,"4169078","Ear lobule structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0226865","Sinus Sigmoideus","C166111","Either of the two dural venous sinuses that receive blood from the transverse sinus and empty into the internal jugular vein.","Sinus Sigmoideus | Pars Sigmoid | Pars Signmoid | SIGMOID SINUS | Sigmoid Sinus",,,,,,,,,,,,,,,"4207378","Structure of sigmoid sinus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1136169","Pathogenicity","C168796","The likelihood of an entity to produce pathologic changes or disease.","Pathogenicity | pathogenicity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378695","Germline Pathogenicity","C168797","The likelihood that germline variant is causally related to a heritable disease.","Germline Pathogenicity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378703","ACMG Classification of Genomic Variant Pathogenicity","C168798","A five-tiered classification from the American College of Medical Genetics designed to describe the likelihood that a genomic sequence variant is causative of an inherited disease.","ACMG Classification of Genomic Variant Pathogenicity | American College of Medical Genetics Classification of Genomic Variant Pathogenicity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1379138","Pathogenic Variant","C168799","A genetic variant that is known to directly contribute to the development of disease.","Pathogenic Variant | Pathogenic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1379135","Likely Pathogenic Variant","C168800","A genetic variant that is known to have a high likelihood (greater than 90% certainty) to contribute to the development of a disease.","Likely Pathogenic Variant | Likely Pathogenic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1379136","Variant Likely Benign","C168801","A genetic variant that is not expected to contribute to the development of a disease, but the scientific evidence may be insufficient to prove this conclusively.","Variant Likely Benign | Likely Benign | Likely Benign Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378700","Variant Benign","C168802","A genetic variant that is known to not contribute to the development of a disease.","Variant Benign | Benign | Benign Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378699","Variant Pathogenic/Likely Pathogenic","C168803","An ad hoc category that describes genetic variants with 90% or greater certainty of contributing to the development of a disease.","Variant Pathogenic/Likely Pathogenic | Pathogenic/Likely Pathogenic | Pathogenic/Likely Pathogenic Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378693","Operation of Heavy Machinery","C168795","The use of heavy-duty vehicles or equipment for personal or professional work.","Operation of Heavy Machinery | Operate Heavy Machinery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378709","NUTM1 Gene Fusion Positive","C168806","An indication that a NUTM1 fusion gene has been detected in a sample.","NUTM1 Gene Fusion Positive | C15orf55 Fusion Gene Positive | FAM22H Fusion Gene Positive | NUT Fusion Gene | NUT Fusion Gene Positive | NUT Gene Fusion Positive | NUT Midline Carcinoma, Family Member 1 Fusion Gene Positive | NUTM1 Fusion Gene | NUTM1 Gene Fusion | Nuclear Protein in Testis Fusion Gene Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979266","Granzyme B Measurement","C166073","The determination of the amount of granzyme B present in a sample.","Granzyme B Measurement | C11 | CCPI | CGL1 | CSPB | CTLA1 | CTSGL1 | GZMB | GZMB Measurement | Granzyme B | HLP | SECT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979256","Forkhead Box Protein P3 Measurement","C166072","The determination of the amount of forkhead box protein 3 present in a sample.","Forkhead Box Protein P3 Measurement | AIID | DIETER | FOXP3 | FOXP3 Measurement | Forkhead Box P3 | Forkhead Box Protein 3 | IPEX | JM2 | PIDX | SCURFIN | XPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272300","Pre-Procedure","C100058","The time period prior to a diagnostic or therapeutic procedure.","Pre-Procedure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378787","FDG-Avid Tumor","C168968","A radiologic finding indicating high uptake of FDG by a solid tumor during positron emission tomography (PET).","FDG-Avid Tumor | FDG Avid | FDG-AVID | FDG-PET Avid | Fluorine 18 Fluorodeoxyglucose-Avid Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539061","Device Properties Domain","C102619","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to device properties.","Device Properties Domain | DO | Device Properties",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826260","Test Occurrence","C82525","An indication or description that a test has occurred.","Test Occurrence | PERF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525680","Subsolid Pulmonary Nodule","C138144","A term that refers to a pure ground-glass pulmonary nodule or a part-solid pulmonary nodule on CT scan examination.","Subsolid Pulmonary Nodule | SSN | Sub-Solid Lesion | Sub-Solid Pulmonary Nodule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520469","12p11.2","C24926","A chromosome band present on 12p","12p11.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521305","3q21","C13764","A chromosome band present on 3q","3q21 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508713","EPIC-CP - Hot Flashes or Breast Tenderness","C127412","Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) How big a problem, if any, has each of the following been for you? Hot flashes or breast tenderness/enlargement.","EPIC-CP - Hot Flashes or Breast Tenderness | EPIC2-Problem Hot Flash/Breast Tender | EPIC210A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508717","EPIC-CP - Overall Problem Urinary Function","C127399","Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) Overall, how much of a problem has your urinary function been for you?","EPIC-CP - Overall Problem Urinary Function | EPIC2-Overall Problem Urinary Function | EPIC201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508710","EPIC-CP - Best Describes Urinary Control","C127400","Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) Which of the following best describes your urinary control?","EPIC-CP - Best Describes Urinary Control | EPIC2-Best Describes Urinary Control | EPIC202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508709","EPIC-CP - Adult Diapers Used per Day","C127401","Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) How many pads or adult diapers per day have you been using for urinary leakage?","EPIC-CP - Adult Diapers Used per Day | EPIC2-Pads or Adult Diapers per Day | EPIC203",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508725","EPIC-CP - Rectal Pain or Urgency of Bowel Movements","C127406","Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) How big a problem, if any, has each of the following been for you? Rectal pain or urgency of bowel movements.","EPIC-CP - Rectal Pain or Urgency of Bowel Movements | EPIC2-Problem Rectal Pain/Urgent Bowel | EPIC206A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508724","EPIC-CP - Rate Ability to Reach Orgasm","C127409","Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) How would you rate your ability to reach orgasm (climax)?","EPIC-CP - Rate Ability to Reach Orgasm | EPIC2-Rate Ability to Reach Orgasm | EPIC207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508723","EPIC-CP - Quality of Erections","C127410","Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) How would you describe the usual quality of your erections?","EPIC-CP - Quality of Erections | EPIC2-Quality of Your Erections | EPIC208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1318869","Trypan Blue Staining Method","C163743","A microscopy staining method that utilizes trypan blue, an acid azo dye that can traverse the cell membrane of dead cells and is used to differentiate between living and dead cells.","Trypan Blue Staining Method | TRYPAN BLUE STAIN",,,,,,,,,,,,,,,"4238097","Trypan blue stain method",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL976737","Orchidometry","C163548","A method used to measure testicular volume by comparing the size of one's testicles to the beads in a orchidometer, which consists of a string of 12 numbered beads of increasing sizes of 1 to 6, 8, 10, 12, 15, 20, and 25mL.","Orchidometry | ORCHIDOMETERY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976738","Immuno-Positron Emission Tomography Scan","C163547","A type of positron emission tomography in which labeled monoclonal antibodies are tracked and quantitated after administration to the subject.","Immuno-Positron Emission Tomography Scan | IMMUNO-PET SCAN | Immuno-PET Scan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978370","Double Immunodiffusion","C163546","A qualitative technique used to identify specific antibodies bound to an antigen by the appearance of a precipitation band (precipitin band) formed between wells in an agar gel plate as a result of the interaction of the antigen and antibodies at optimal concentration.","Double Immunodiffusion | DID | DOUBLE IMMUNODIFFUSION | Ouchterlony Double Immunodiffusion | Passive Double Immunodiffusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976739","BrdU Cellular Proliferation Assay","C163545","A type of cellular proliferation assay in which bromodeoxyuridine (BrdU) is used as a substitute for thymidine in the DNA of replicating cells.","BrdU Cellular Proliferation Assay | BRDU CELLULAR PROLIFERATION ASSAY | BrdU Assay | Bromodeoxyuridine Cellular Proliferation Assay | Broxuridine Cellular Proliferation Assay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL421570","Cell Proliferation Assay","C116553","Any method to measure the number of dividing cells in a culture, or to measure the change in the proportion of cells that are dividing.","Cell Proliferation Assay | CELLULAR PROLIFERATION ASSAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508721","EPIC-CP - Problem Lack of Sexual Function","C127411","Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) Overall, how much of a problem has your sexual function or lack of sexual function been for you?","EPIC-CP - Problem Lack of Sexual Function | EPIC2-Overall Problem Sexual Function | EPIC209",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508727","EPIC-CP - Urinary Incontinence Symptom Score","C127415","Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) Urinary incontinence symptom score.","EPIC-CP - Urinary Incontinence Symptom Score | EPIC2-Urinary Incontinence Symptom Score | EPIC211",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508728","EPIC-CP - Urinary Irritation/Obstruction Symptom Score","C127416","Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) Urinary irritation/obstruction symptom score.","EPIC-CP - Urinary Irritation/Obstruction Symptom Score | EPIC2-Urinary Irrit/Obstr Symptom Score | EPIC212",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508711","EPIC-CP - Bowel Symptom Score","C127417","Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) Bowel symptom score.","EPIC-CP - Bowel Symptom Score | EPIC2-Bowel Symptom Score | EPIC213",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508729","EPIC-CP - Vitality/Hormonal Symptom Score","C127419","Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) Vitality/hormonal symptom score.","EPIC-CP - Vitality/Hormonal Symptom Score | EPIC2-Vitality/Hormonal Symptom Score | EPIC215",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508719","EPIC-CP - Overall Score","C127420","Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) Overall prostate cancer QOL score.","EPIC-CP - Overall Score | EPIC2-Overall Prostate Cancer QOL Score | EPIC216",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979260","Sickle Cell Solubility Test","C166070","A method of screening for sickle cell disease or trait in which sodium dithionite or a similar chemical is used to lyse red blood cells in a blood sample. This allows any hemoglobin S, which does not dissolve easily in plasma, to form crystals that visibly cloud the plasma.","Sickle Cell Solubility Test | SICKLE CELL SOLUBILITY TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0597266","polygraphy","C166069","A method of simultaneously recording variations in multiple physiological pulsations.","Polygraphy | POLYGRAPHY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979259","Non-Invasive Dielectric Sensing","C166068","A method in which the dielectric tissue properties are measured based on the emission and reflection of low-power electromagnetic signals in between two sensors attached to the body.","Non-Invasive Dielectric Sensing | NON-INVASIVE DIELECTRIC SENSING | Noninvasive Remote Dielectric Sensing | ReDS (BR) | Remote Dielectric Sensing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979252","Multiplexed Digital Gene Expression Analysis","C166067","A type of digital gene expression analysis to detect or quantify targeted RNA transcripts using bar code indexing.","Multiplexed Digital Gene Expression Analysis | MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979284","Electrical Impedance Myography","C166065","A method of applying and measuring high-frequency, low-intensity electrical currents at the surface of localized areas of muscle to assess neuromuscular disorders.","Electrical Impedance Myography | EIM | ELECTRICAL IMPEDANCE MYOGRAPHY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979250","Droplet Digital PCR","C166064","A type of digital polymerase chain reaction technique in which the sample is fractionated into thousands of tiny droplets using a water-oil emulsion droplet technology, within which individual PCR reactions occur in each droplet.","Droplet Digital PCR | DROPLET DIGITAL PCR | ddPCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979255","Digital Polymerase Chain Reaction","C166063","A type of polymerase chain reaction technique in which the sample is fractionated, within which individual PCR reactions occur in each fraction.","Digital Polymerase Chain Reaction | DIGITAL PCR | dPCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0200000","Cystometry","C166062","A method of bladder function testing in which pressure and volume measurements are taken during the filling and voiding phases of micturition.","Cystometry | CYSTOMETRY",,,,,,,,,,,,,,,"4188081","Cystometrogram",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL979254","Chromogenic Assay","C166061","An assay in which the reaction product produces a visible color change.","Chromogenic Assay | CHROMOGENIC ASSAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979253","Automated Capillary Electrophoresis Western Blot","C166060","An automated Western Blot system that uses capillary electrophoresis to characterize and separate proteins of interest by size or charge.","Automated Capillary Electrophoresis Western Blot | AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT | Simple Western Assay | Simple Western Size-based Assay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972436","Measurable Lesion","C167209","A finding indicating that a localized pathological lesion can be measured in at least one dimension.","Measurable Lesion | measurable lesion | measurable_lesion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524894","FDG-Positron Emission Tomography and Computed Tomography Scan","C137817","An imaging procedure that combines FDG PET with a CT scan to overlay activity data onto detailed anatomic images.","FDG-Positron Emission Tomography and Computed Tomography Scan | FDG PET/CT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0232804","Renal Function","C164220","Pertaining to the physiologic processes of the kidneys.","Renal Function | Kindey Function",,,,,,,,,,,,,,,"40282772","Renal function",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0232973","Not Pregnant","C82475","Observed to be negative for a pregnancy test or not pregnant.","Not Pregnant | NOT PREGNANT",,,,,,,,,,,,,,,"4243056","Not pregnant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554471","Metastatic Breast Carcinoma","C153238","A carcinoma that arises from the breast and has metastasized to another anatomic site.","Metastatic Breast Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937171","First Degree Family History of Esophageal or Gastric Esophageal Cancer","C157439","Parents, siblings or children of an individual have a history of esophageal or gastric esophageal cancer.","First Degree Family History of Esophageal or Gastric Esophageal Cancer | Family History of Esophageal or Gastric Esophageal Cancer in First Degree Relative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936895","Barrett Esophagus With Metaplastic Goblet Cell Columnar Epithelium","C157170","A finding in an esophageal biopsy specimen indicating the diagnosis of Barrett esophagus associated with the presence of metaplastic columnar epithelium containing goblet cells.","Barrett Esophagus With Metaplastic Goblet Cell Columnar Epithelium | Barrett's Esophagus With Goblet Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936939","Barrett Esophagus With Metaplastic Non-Goblet Cell Columnar Epithelium","C157171","A finding in an esophageal biopsy specimen indicating the diagnosis of Barrett esophagus associated with the presence of metaplastic non-goblet cell columnar epithelium.","Barrett Esophagus With Metaplastic Non-Goblet Cell Columnar Epithelium | Barrett's Esophagus Without Goblet Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937165","Clinical Diagnosis of Reflux Disease","C157447","An indication that an individual has been clinically diagnosed with gastric reflux disease.","Clinical Diagnosis of Reflux Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512907","Antineoplastic Enzyme Inhibitor","C129825","Any agent that specifically inhibits a particular enzyme that is overexpressed and/or mutated in cancer cell pathways. Antineoplastic enzyme inhibitors specifically target tumor cells by targeting enzymes that are not normally expressed or are minimally expressed in normal, healthy tissues.","Antineoplastic Enzyme Inhibitor | Anti-cancer Enzyme Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382257","AIDS-Related Kaposi Sarcoma T0 (Good Risk): Skin and/or Lymph Nodes","C169109","AIDS-related Kaposi sarcoma localized in the skin and/or the lymph nodes. This stage is associated with good risk of recovery.","AIDS-Related Kaposi Sarcoma T0 (Good Risk): Skin and/or Lymph Nodes | AIDS-Related Kaposi Sarcoma T0: Skin and/or Lymph Nodes | Stage 0 - Skin and/or Lymph Nodes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382254","AIDS-Related Kaposi Sarcoma T0 (Good Risk): Minimal Oral Disease","C169110","AIDS-related Kaposi sarcoma localized on the palate. The lesions are small and flat rather than raised. This stage is associated with good risk of recovery.","AIDS-Related Kaposi Sarcoma T0 (Good Risk): Minimal Oral Disease | AIDS-Related Kaposi Sarcoma T0: Minimal Oral Disease | Stage 0 - Minimal Oral Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936940","BRAF Mutation Analysis","C157172","A procedure used to detect and identify mutations in the BRAF gene.","BRAF Mutation Analysis | B-RAF Mutation Analysis | B-RAF1 Mutation Analysis | BRAF Mutation Status | BRAF1 Mutation Analysis | v-raf Murine Sarcoma Viral OncoHomolog B1 Mutation Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936925","BRAF Rearrangement Analysis","C157188","A procedure used to detect and identify rearrangements involving the BRAF gene.","BRAF Rearrangement Analysis | B-RAF Gene Rearrangement Analysis | B-RAF1 Gene Rearrangement Analysis | BRAF Rearrangement | BRAF Rearrangement Status | BRAF1 Gene Rearrangement Analysis | v-raf Murine Sarcoma Viral Oncogene Homolog B1 Gene Rearrangement Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936929","HRAS Mutation Analysis","C157184","A procedure used to detect and identify mutations in the HRAS gene.","HRAS Mutation Analysis | C-H-RAS Mutation Analysis | C-HA-RAS1 Mutation Analysis | H-ras Mutation Analysis | HRAS Mutation Status | HRAS1 Mutation Analysis | Ha-ras Mutation Analysis | Harvey Rat Sarcoma Viral Oncogene Homolog Mutation Analysis | RASH1 Mutation Analysis | v-Ha-ras Harvey Rat Sarcoma Viral Oncogene Homolog Mutation Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936924","NRAS Mutation Analysis","C157187","A procedure used to detect and identify mutations in the NRAS gene.","NRAS Mutation Analysis | N-RAS Mutation Analysis | NRAS Mutation | NRAS Mutation Status | Neuroblastoma RAS Viral Oncogene Homolog Mutation Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936923","PAX8 Rearrangement Analysis","C157194","A procedure used to detect and identify rearrangements involving the PAX8 gene.","PAX8 Rearrangement Analysis | PAX8 Rearrangement Status | Paired Box 8 Rearrangement Analysis | Paired Box Gene 8 Rearrangement Analysis | Paired Domain Gene 8 Rearrangement Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936917","RET Rearrangement Analysis","C157195","A procedure used to detect and identify rearrangements involving the RET gene.","RET Rearrangement Analysis | RET Rearrangement | RET Rearrangement Status | RET/PTC Rearrangement Analysis | Ret Proto-Oncogene Rearrangement Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936894","BAP1 Mutation Analysis","C157167","A procedure used to detect and identify mutations in the BAP1 gene.","BAP1 Mutation Analysis | BAP1 Mutation Status | BRCA1 Associated Protein 1 Mutation Analysis | BRCA1-Associated Protein 1 Mutation Analysis | UCHL2 Mutation Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936935","GNA11 Mutation Analysis","C157182","A procedure used to detect and identify mutations in the GNA11 gene.","GNA11 Mutation Analysis | G Protein Subunit Alpha 11 Mutation Analysis | GA11 Mutation Analysis | GNA-11 Mutation Analysis | GNA11 Mutation Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936928","GNAQ Mutation Analysis","C157183","A procedure used to detect and identify mutations in the GNAQ gene.","GNAQ Mutation Analysis | CMC1 Mutation Analysis | G Protein Subunit Alpha q Mutation Analysis | G-ALPHA-q Mutation Analysis | GAQ Mutation Analysis | GNAQ Mutation Status | SWS Mutation Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382631","Formal Search","C170397","A detailed search of a donor registry designed to find an unrelated donor match. Potential donor samples are tested to verify the original typing and are then tested at a higher level of resolution and at all HLA loci required by the transplant center's protocol.","Formal Search | Formal Donor Registry Search | Formal Donor Search | Formal Unrelated Donor Search",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936897","Adjuvant I-131 Therapy","C157162","A question whether radioiodine therapy was administered with the intent of suppressing secondary tumor formation.","Was Adjuvant I-131 Therapy Administered | Adjuvant I-131 Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937173","Family History of Thyroid Cancer (for First Degree Relatives Only)","C157442","A question whether parents, siblings or children of an individual have a history of thyroid cancer.","Is there a First Degree Family History of Thyroid Cancer | Family History of Thyroid Cancer (for First Degree Relatives Only)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0455620","History of Radiation Exposure","C157152","A question about an individual's history of exposure to radiation.","Was there a History of Radiation Exposure | History of Radiation Exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015396","Eye Color","C157437","The color of the iris of the eye.","Eye Color | eye color | eye_color",,,,,,,,,,,,,,,"4081639","Iris pigmentation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937124","Red and Violet","C157431","The combination of red and violet colors.","Red and Violet | Red & Violet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971179","Are Tumor Infiltrating Lymphocytes Present","C160832","A question whether tumor infiltrating lymphocytes are present.","Are Tumor Infiltrating Lymphocytes Present | Tumor Infiltrating Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971226","Many Tumor Infiltrating Lymphocytes","C160235","A finding of many tumor infiltrating lymphocytes in a biospecimen.","Many Tumor Infiltrating Lymphocytes | Many",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969307","Moderate Tumor Infiltrating Lymphocytes","C160236","A finding of a moderate number of tumor infiltrating lymphocytes in a biospecimen.","Moderate Tumor Infiltrating Lymphocytes | Moderate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969308","Few Tumor Infiltrating Lymphocytes","C160234","A finding of few tumor infiltrating lymphocytes in a biospecimen.","Few Tumor Infiltrating Lymphocytes | Few",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382906","Downstaging","C170463","A term that refers to the decrease in the cancer size and extend of metastases, and/or lymph node involvement by cancer, to a lower (less extensive) stage.","Downstaging | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539879","Tumor Response Domain","C102722","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to tumor response.","Tumor Response Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382962","IWG-MRT Myelodysplastic Syndrome Major Hematologic Improvement-Erythroid Response in High Transfusion Burden","C170520","Major hematologic improvement-erythroid response in high transfusion burden patients corresponds to transfusion independence, defined by the absence of any transfusions over a period of a minimum of 8 weeks within an observation period of 16 to 24 weeks with the same transfusion policy (defined in '1.2.4. Transfusion policy') compared with 16 weeks prior to treatment. Only a response duration of at least 16 weeks, however, is considered clinically meaningful. (Adapted from Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials; Blood 2019 133: 1020-1030)","IWG-MRT Myelodysplastic Syndrome Major Hematologic Improvement-Erythroid Response in High Transfusion Burden | HI-E Major Response | IWG-MRT Major HI-E Response in HTB | IWG-MRT Myelodysplastic Syndrome Major Hematologic Improvement-Erythroid Response in High Transfusion Burden ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382963","IWG-MRT Myelodysplastic Syndrome Minor Hematologic Improvement-Erythroid Response in High Transfusion Burden","C170521","Minor hematologic improvement-erythroid response in high transfusion burden patients is defined as a reduction by at least 50% of RBCs over a minimum of 8 weeks with the same transfusion policy (defined in '1.2.4. Transfusion policy') compared with 16 weeks prior to treatment. Only a response duration of at least 16 weeks, however, is considered clinically meaningful. (Adapted from Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials; Blood 2019 133: 1020-1030)","IWG-MRT Myelodysplastic Syndrome Minor Hematologic Improvement-Erythroid Response in High Transfusion Burden | HI-E Minor Response | IWG-MRT Myelodysplastic Syndrome Minor Hematologic Improvement-Erythroid Response in High Transfusion Burden 

 | SYN: IWG-MRT Minor HI-E Response in HTB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508633","MLH3 Gene Mutation","C170405","A change in the nucleotide sequence of the MLH3 gene.","MLH3 Gene Mutation | HNPCC7 Gene Mutation | MLH3 Mutation | MutL (E. coli) Homolog 3 Gene Mutation | MutL Homolog 3 (E. coli) Gene Mutation | MutL Homolog 3 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382873","PIK3R2 Gene Mutation","C170406","A change in the nucleotide sequence of the PIK3R2 gene.","PIK3R2 Gene Mutation | P85B Gene Mutation | Phosphoinositide-3-Kinase Regulatory Subunit 2 Gene Mutation | p85-BETA Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382622","Blasts 6 Percent or More of Bone Marrow Nucleated Cells","C170399","A semi-quantitative microscopic finding indicating that at least 6 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts 6 Percent or More of Bone Marrow Nucleated Cells | Blasts Greater than or Equal to 6 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382874","Deleterious MUTYH Gene Mutation","C170407","A change in the nucleotide sequence of the MUTYH gene that is associated with increased risk of disease.","Deleterious MUTYH Gene Mutation | Deleterious MUTYH Mutation | Deleterious MYH Gene Mutation | Deleterious MutY (E. Coli) Homolog Gene Mutation | Deleterious MutY DNA Glycosylase Gene Mutation | Deleterious MutY Homolog (E. coli) Gene Mutation | Deleterious MutY Homolog Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382871","LIG3 Gene Mutation","C170408","A change in the nucleotide sequence of the LIG3 gene.","LIG3 Gene Mutation | DNA Ligase 3 Gene Mutation | DNA Ligase III Gene Mutation | LIG2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382872","LIG4 Gene Mutation","C170409","A change in the nucleotide sequence of the LIG4 gene.","LIG4 Gene Mutation | DNA Ligase 4 Gene Mutation | DNA Ligase IV Gene Mutation | LIG4S Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382876","Deleterious POLE Gene Mutation","C170410","A change in the nucleotide sequence of the POLE gene that is associated with increased risk of disease.","Deleterious POLE Gene Mutation | Deleterious DNA Polymerase Epsilon Catalytic Subunit A Gene Mutation | Deleterious DNA Polymerase Epsilon, Catalytic Subunit Gene Mutation | Deleterious POLE Mutation | Deleterious POLE1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382866","INPP4A Gene Mutation","C170417","A change in the nucleotide sequence of the INPP4A gene.","INPP4A Gene Mutation | INPP4 Gene Mutation | Inositol Polyphosphate-4-Phosphatase Type I A Gene Mutation | Inositol Polyphosphate-4-Phosphatase, Type I, 107kDa Gene Mutation | TVAS1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382870","INPPL1 Gene Mutation","C170418","A change in the nucleotide sequence of the INPPL1 gene.","INPPL1 Gene Mutation | Inositol Polyphosphate Phosphatase Like 1 Gene Mutation | Inositol Polyphosphate Phosphatase-Like 1 Gene Mutation | OPSMD Gene Mutation | SHIP2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407110","PIK3CD Gene Mutation","C170419","A change in the nucleotide sequence of the PIK3CD gene.","PIK3CD Gene Mutation | APDS Gene Mutation | IMD14 Gene Mutation | P110DELTA Gene Mutation | PI3K-Delta Gene Mutation | PIK3CD Mutation | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta Gene Mutation | p110D Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382868","PIK3C2G Gene Mutation","C170420","A change in the nucleotide sequence of the PIK3C2G gene.","PIK3C2G Gene Mutation | PI3K-C2-Gamma Gene Mutation | PI3K-C2GAMMA Gene Mutation | Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Gamma Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382869","XRCC6 Gene Mutation","C170421","A change in the nucleotide sequence of the XRCC6 gene.","XRCC6 Gene Mutation | CTC75 Gene Mutation | CTCBF Gene Mutation | G22P1 Gene Mutation | Ku70 Gene Mutation | ML8 Gene Mutation | TLAA Gene Mutation | X-Ray Repair Complementing Defective Repair In Chinese Hamster Cells 6 Gene Mutation | X-Ray Repair Cross Complementing 6 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382884","MDC1 Gene Mutation","C170422","A change in the nucleotide sequence of the MDC1 gene.","MDC1 Gene Mutation | Mediator of DNA Damage Checkpoint 1 Gene Mutation | NFBD1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382624","Ki-67 Positive Cells 20 Percent or Less","C170402","A semi-quantitative microscopic finding indicating that 20 percent or less of the cells in a sample are detected following staining using an anti-Ki-67 antibody.","Ki-67 Positive Cells 20 Percent or Less | Antigen Ki-67 Positive Cells 20 Percent or Less | KI67 Positive Cells 20 Percent or Less | Ki-67 Antigen Positive Cells 20 Percent or Less | Ki-67 Positive Cells Less than or Equal to 20 Percent | MKI67 Positive Cells 20 Percent or Less",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382885","PIK3R3 Gene Mutation","C170423","A change in the nucleotide sequence of the PIK3R3 gene.","PIK3R3 Gene Mutation | Phosphoinositide-3-Kinase Regulatory Subunit 3 Gene Mutation | p55 Gene Mutation | p55-GAMMA Gene Mutation | p55PIK Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382882","PIK3C3 Gene Mutation","C170424","A change in the nucleotide sequence of the PIK3C3 gene.","PIK3C3 Gene Mutation | Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3 Gene Mutation | VPS34 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382883","Deleterious CDKN2A Gene Mutation","C170425","A change in the nucleotide sequence of the CDKN2A gene that is associated with increased risk of disease.","Deleterious CDKN2A Gene Mutation | CDKN2A Deleterious Mutation | Deleterious CDK4I Gene Mutation | Deleterious Cyclin-Dependent Kinase Inhibitor 2A Gene Mutation | Deleterious p14ARF Gene Mutation | Deleterious p16 Gene Mutation | Deleterious p16-INK4A Gene Mutation | Deleterious p16INK4 Gene Mutation | Deleterious p16INK4a Gene Mutation | Deleterious p19ARF Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382888","Deleterious POLD1 Gene Mutation","C170426","A change in the nucleotide sequence of the POLD1 gene that is associated with increased risk of disease.","Deleterious POLD1 Gene Mutation | Deleterious CDC2 Gene Mutation | Deleterious CRCS10 Gene Mutation | Deleterious DNA Polymerase Delta 1, Catalytic Subunit Gene Mutation | Deleterious MDPL Gene Mutation | Deleterious POLD Gene Mutation | POLD1 Deleterious Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382889","INPP4B Gene Mutation","C170427","A change in the nucleotide sequence of the INPP4B gene.","INPP4B Gene Mutation | Inositol Polyphosphate-4-Phosphatase Type II B Gene Mutation | Inositol Polyphosphate-4-Phosphatase, Type II, 105kDa Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382887","SEM1 Gene Mutation","C170429","A change in the nucleotide sequence of the SEM1 gene.","SEM1 Gene Mutation | C7orf76 Gene Mutation | DSS1 Gene Mutation | Deleted In Split-Hand/Split-Foot 1 Gene Mutation | ECD Gene Mutation | SEM1 26S Proteasome Complex Subunit Gene Mutation | SHFD1 Gene Mutation | SHFM1 Gene Mutation | SHSF1 Gene Mutation | Shfdg1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382879","Deleterious GREM1 Gene Mutation","C170431","A change in the nucleotide sequence of the GREM1 gene that is associated with increased risk of disease.","Deleterious GREM1 Gene Mutation | Deleterious CKTSF1B1 Gene Mutation | Deleterious CRAC1 Gene Mutation | Deleterious CRCS4 Gene Mutation | Deleterious DAND2 Gene Mutation | Deleterious DRM Gene Mutation | Deleterious GREMLIN Gene Mutation | Deleterious GREMLIN1 Gene Mutation | Deleterious Gremlin 1, DAN Family BMP Antagonist Gene Mutation | Deleterious IHG-2 Gene Mutation | Deleterious PIG2 Gene Mutation | GREM1 Deleterious Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382619","Myeloblasts 5 Percent or More of Peripheral Blood White Cells","C170400","A semi-quantitative microscopic finding indicating that at least 5 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells of myeloid origin.","Myeloblasts 5 Percent or More of Peripheral Blood White Cells | Myeloblasts Greater than or Equal to 5 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382877","RET Gene Alteration Positive","C170432","A finding indicating that mutation, overexpression or rearrangement of the RET gene has been detected in a sample.","RET Gene Alteration Positive | RET Gene Alteration | RET/PTC Gene Alteration Positive | Ret Proto-Oncogene Alteration Positive | Ret Proto-Oncogene Gene Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382886","INPP5D Gene Mutation","C170428","A change in the nucleotide sequence of the INPP5D gene.","INPP5D Gene Mutation | Inositol Polyphosphate-5-Phosphatase D Gene Mutation | Inositol Polyphosphate-5-Phosphatase, 145kDa Gene Mutation | SHIP Gene Mutation | SHIP-1 Gene Mutation | SHIP1 Gene Mutation | SIP-145 Gene Mutation | hp51CN Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969856","Multi-agent Therapeutic Regimens","C160952","A course of drugs that contain multiple substances.","Multi-agent Therapeutic Regimens | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383138","Target Area Under Curve","C170737","The desired area under the concentration times time curve.","Target Area Under Curve | Target AUC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1379073","Symptomatic Therapy","C170740","Therapy that treats adverse events without addressing the basic cause of those adverse events.","Symptomatic Therapy | Symptomatic | Symptomatic Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383141","Vigorous Supportive Therapy","C170741","Invasive treatment, such as surgery, CPR, or ventilator support, given to a patient to treat adverse events.","Vigorous Supportive Therapy | Vigorous Supportive | Vigorous Supportive Care | Vigorous Supportive Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383205","Precontrast, 3-dimensional, Isotropic, IR-prepped T1-weighted Gradient Echo MRI","C170793","3-dimensional, T1-weighted magnetic resonance imaging that uses gradient-echo acquisition with inversion recovery, in the absence of a contrast agent.","Precontrast, 3-dimensional, Isotropic, IR-prepped T1-weighted Gradient Echo MRI | 3D Pre-Contrast T1-Weighted IR-GRE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383206","2-dimensional Fluid-attenuated Inversion Recovery MRI","C170794","2-dimensional magnetic resonance imaging that uses an inversion recovery set to null fluids.","2-dimensional Fluid-attenuated Inversion Recovery MRI | 2D FLAIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383203","2-dimensional, Diffusion-weighted Imaging/ Diffusion Tensor Imaging","C170795","2-dimension, T2-weighted magnetic resonance imaging that uses the diffusion of water molecules to generate contrast in MR images. Diffusion tensor imaging (DTI), a specific type of DWI, can be used to map white matter tractography in the brain.","2-dimensional, Diffusion-weighted Imaging/ Diffusion Tensor Imaging | 2D T2-Weighted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383204","2-dimensional T2-weighted MRI","C170796","2-dimensional magnetic resonance imaging that highlights differences in the T2 relaxation time of tissues.","2-dimensional T2-weighted MRI | 2D T2-Weighted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383210","2-dimensional Proton Density, T2-weighted MRI","C170798","2-dimensional magnetic resonance imaging that uses proton density weighting and T2 weighting to suppress the signal from fatty tissues.","2-dimensional Proton Density, T2-weighted MRI | 2D PD/T2-Weighted MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383207","Postcontrast, 3-dimensional, Isotropic, IR-prepped T1-weighted Gradient Echo MRI","C170799","3-dimensional, T1-weighted magnetic resonance imaging that uses gradient-echo acquisition with inversion recovery, done after injection of a contrast agent.","Postcontrast, 3-dimensional, Isotropic, IR-prepped T1-weighted Gradient Echo MRI | 3D Post-Contrast T1-Weighted IR-GRE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508691","EPIC-26 - Dripping or Leaking Urine","C127376","The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How big a problem, if any, has each of the following been for you during the last 4 weeks? Dripping or leaking urine.","EPIC-26 - Dripping or Leaking Urine | EPIC1-Problem Dripping or Leaking Urine | EPIC104A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508695","EPIC-26 - How Often Have You Leaked Urine","C127373","The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) Over the past 4 weeks, how often have you leaked urine?","EPIC-26 - How Often Have You Leaked Urine | EPIC1-How Often Have You Leaked Urine | EPIC101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508686","EPIC-26 - Best Describes Urinary Control","C127374","The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) Which of the following best describes your urinary control during the last 4 weeks?","EPIC-26 - Best Describes Urinary Control | EPIC1-Best Describes Urinary Control | EPIC102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508702","EPIC-26 - Pads or Adult Diapers per Day","C127375","The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How many pads or adult diapers per day did you usually use to control leakage during the last 4 weeks?","EPIC-26 - Pads or Adult Diapers per Day | EPIC1-Pads or Adult Diapers per Day | EPIC103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508703","EPIC-26 - Pain or Burning on Urination","C127377","The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How big a problem, if any, has each of the following been for you during the last 4 weeks? Pain or burning on urination.","EPIC-26 - Pain or Burning on Urination | EPIC1-Problem Pain/Burning on Urination | EPIC104B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508687","EPIC-26 - Bleeding With Urination","C127378","The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How big a problem, if any, has each of the following been for you during the last 4 weeks? Bleeding with urination.","EPIC-26 - Bleeding With Urination | EPIC1-Problem Bleeding With Urination | EPIC104C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508707","EPIC-26 - Weak Urine Stream or Incomplete Emptying","C127379","The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How big a problem, if any, has each of the following been for you during the last 4 weeks? Weak urine stream or incomplete emptying.","EPIC-26 - Weak Urine Stream or Incomplete Emptying | EPIC1-Problem Weak Urine Stream/Emptying | EPIC104D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508706","EPIC-26 - Urinate Frequently During the Day","C127380","The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How big a problem, if any, has each of the following been for you during the last 4 weeks? Need to urinate frequently during the day.","EPIC-26 - Urinate Frequently During the Day | EPIC1-Problem Need to Urinate Frequently | EPIC104E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508701","EPIC-26 - Overall Problem Urinary Function","C127381","The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) Overall, how big a problem has your urinary function been for you during the last 4 weeks?","EPIC-26 - Overall Problem Urinary Function | EPIC1-Overall Problem Urinary Function | EPIC105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508683","EPIC-26 - Ability to Function Sexually","C127392","The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) Overall, how would you rate your ability to function sexually during the last 4 weeks?","EPIC-26 - Ability to Function Sexually | EPIC1-Rate Ability to Function Sexually | EPIC111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508700","EPIC-26 - Overall Problem Sexual Function","C127393","The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) Overall, how big a problem has your sexual function or lack of sexual function been for you during the last 4 weeks?","EPIC-26 - Overall Problem Sexual Function | EPIC1-Overall Problem Sexual Function | EPIC112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508694","EPIC-26 - Hot Flashes","C127394","The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How big a problem during the last 4 weeks, if any, has each of the following been for you? Hot flashes.","EPIC-26 - Hot Flashes | EPIC1-Problem Hot Flashes | EPIC113A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508689","EPIC-26 - Breast Tender or Enlargement","C127395","The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How big a problem during the last 4 weeks, if any, has each of the following been for you? Breast tenderness/enlargement.","EPIC-26 - Breast Tender or Enlargement | EPIC1-Problem Breast Tender/Enlargement | EPIC113B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508692","EPIC-26 - Feeling Depressed","C127396","The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How big a problem during the last 4 weeks, if any, has each of the following been for you? Feeling depressed.","EPIC-26 - Feeling Depressed | EPIC1-Problem Feeling Depressed | EPIC113C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508697","EPIC-26 - Lack of Energy","C127397","The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How big a problem during the last 4 weeks, if any, has each of the following been for you? Lack of energy.","EPIC-26 - Lack of Energy | EPIC1-Problem Lack of Energy | EPIC113D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508690","EPIC-26 - Change in Body Weight","C127398","The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How big a problem during the last 4 weeks, if any, has each of the following been for you? Change in body weight.","EPIC-26 - Change in Body Weight | EPIC1-Problem Change in Body Weight | EPIC113E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508705","EPIC-26 - Urgency to Have a Bowel Movement","C127382","The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How big a problem, if any, has each of the following been for you? Urgency to have a bowel movement.","EPIC-26 - Urgency to Have a Bowel Movement | EPIC1-Problem Urgency of Bowel Movement | EPIC106A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508696","EPIC-26 - Increased Frequency of Bowel Movements","C127383","The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How big a problem, if any, has each of the following been for you? Increased frequency of bowel movements.","EPIC-26 - Increased Frequency of Bowel Movements | EPIC1-Problem Increased Freq Bowel Move | EPIC106B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508698","EPIC-26 - Losing Control of Stools","C127384","The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How big a problem, if any, has each of the following been for you? Losing control of your stools.","EPIC-26 - Losing Control of Stools | EPIC1-Problem Losing Control of Stools | EPIC106C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508688","EPIC-26 - Bloody Stools","C127385","The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How big a problem, if any, has each of the following been for you? Bloody stools.","EPIC-26 - Bloody Stools | EPIC1-Problem Bloody Stools | EPIC106D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508682","EPIC-26 - Abdominal or Pelvic or Rectal Pain","C127386","The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How big a problem, if any, has each of the following been for you? Abdominal/pelvic/rectal pain.","EPIC-26 - Abdominal or Pelvic or Rectal Pain | EPIC1-Problem Abdom/Pelvic/Rectal Pain | EPIC106E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508699","EPIC-26 - Overall Problem Bowel Habits","C127387","The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) Overall, how big a problem have your bowel habits been for you during the last 4 weeks?","EPIC-26 - Overall Problem Bowel Habits | EPIC1-Overall Problem Bowel Habits | EPIC107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508684","EPIC-26 - Ability to Have an Erection","C127388","The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How would you rate each of the following during the last 4 weeks? Your ability to have an erection?","EPIC-26 - Ability to Have an Erection | EPIC1-Rate Ability to Have an Erection | EPIC108A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508685","EPIC-26 - Ability to Reach Orgasm","C127389","The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How would you rate each of the following during the last 4 weeks? Your ability to reach orgasm (climax)?","EPIC-26 - Ability to Reach Orgasm | EPIC1-Rate Ability to Reach Orgasm | EPIC108B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508704","EPIC-26 - Quality of Erections","C127390","The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How would you describe the usual quality of your erections during the last 4 weeks?","EPIC-26 - Quality of Erections | EPIC1-Quality of Your Erections | EPIC109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508693","EPIC-26 - Frequency of Erections","C127391","The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How would you describe the frequency of your erections during the last 4 weeks?","EPIC-26 - Frequency of Erections | EPIC1-Frequency of Your Erections | EPIC110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332559","Flat Intraepithelial Lesion of the Bladder","C37266","A flat urothelial lesion of variable thickness in the bladder, devoid of papillary structures containing cytologically malignant cells. (WHO 2016)","Bladder Urothelial Carcinoma In Situ | Bladder Flat Intraepithelial Lesion | Flat Intraepithelial Lesion of the Bladder | Flat Intraepithelial Lesion of the Urinary Bladder | Urinary Bladder Flat Intraepithelial Lesion | Urothelial Carcinoma In Situ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0935598","Sagittal Plane","C94973","Pertaining to a plane containing a line parallel to the long axis of the subject's body, and additionally giving a left or right view. This plane is perpendicular to both the transaxial and coronal planes.","Sagittal Plane | Sagittal",,,,,,,,,,,,,,,"4150919","Median plane",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897461","Study Subject Magnetic Resonance Imaging","C115539","Magnetic resonance imaging of a study participant as part of a clinical trial.","Study Subject Magnetic Resonance Imaging | Study Subj MRI | Study Subject MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383012","FACT-ICM Toxicity Questionnaire","C170845","A health related quality of life questionnaire designed to record patient reported outcomes in patients receiving immune checkpoint modulator (ICM) therapy.","FACT-ICM Toxicity Questionnaire | FACT-ICM Toxicity | FACT-ICM Toxicity Subscale | FACT-ICM Toxicity Subscale Questionnaire | Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383013","Fatigue Prevents Me from Doing Things I Want to Do","C170846","A question about whether fatigue prevents or prevented an individual from doing things they want to do.","Fatigue Prevents Me from Doing Things I Want to Do | My fatigue keeps me from doing the things I want to do",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383018","Bothered by Skin Rash","C170847","A question about whether an individual is or was bothered by skin rash.","Bothered by Skin Rash | I am bothered by a skin rash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383019","Bothered by Itching","C170848","A question about whether an individual is or was bothered by itching.","Bothered by Itching | I am bothered by itching",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383016","Bothered by White Patches on Skin","C170849","A question about whether an individual is or was bothered by white patches appearing on their skin.","Bothered by White Patches on Skin | I am bothered by white patches appearing on my skin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383017","Feel Pain, Soreness, or Aches in Some Areas of Body","C170850","A question about whether an individual feels or felt pain, soreness, or aches in some areas of their body.","Feel Pain, Soreness, or Aches in Some Areas of Body | I feel pain, soreness or aches in some areas of my body",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383009","Have Trouble Sleeping at Night","C170851","A question about whether an individual has or had trouble sleeping at night.","Have Trouble Sleeping at Night | I have trouble sleeping at night",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383010","Bothered by Short-term Treatment Reactions Experienced Immediately After or Within 24 Hours of an Infusion","C170852","A question about whether an individual is or was bothered by short-term treatment reactions that they experienced immediately after, or within 24 hours of, an infusion.","Bothered by Short-term Treatment Reactions Experienced Immediately After or Within 24 Hours of an Infusion | I am bothered by short-term treatment reactions that I experience immediately after, or within 24 hours of, an infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383007","Troubled by Not Knowing Side Effects Timing, Length, or Severity","C170853","A question about whether an individual is or was troubled by not knowing when exactly their effects will happen, how long they will last, or how bad they will be.","Troubled by Not Knowing Side Effects Timing, Length, or Severity | I am troubled by not knowing when exactly my side effects will happen, how long they will last and how bad they will be",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383008","Worry About Negative Impacts of Treatment On Long Term Health","C170854","A question about whether an individual is or was worried about negative impacts that their treatment may have upon their long term health.","Worry About Negative Impacts of Treatment On Long Term Health | I worry about negative impacts that my treatment may have upon my long term health",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3472482","Impact of Events Scale-Revised","C170860","A 22-item self-report measure that assesses subjective distress caused by traumatic events. It contains seven additional items related to the hyperarousal symptoms of PTSD, which were not included in the original IES.","Impact of Events Scale-Revised | IES-R | Impact of Events Scale-Revised (IES-R)",,,,,,,,,,,,,,,"42872734","Impact of event scale revised",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1383028","Reminder Brought Back Feelings of Event","C170862","A question about whether any reminder brought back feelings about the event for an individual.","Reminder Brought Back Feelings of Event | Any reminder brought back feelings about it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383032","Have Trouble Staying Asleep","C170863","A question about whether an individual has or had trouble staying asleep.","Have Trouble Staying Asleep | I had trouble staying asleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383033","Other Things Made Me Think About Event","C170864","A question about whether other things made or make an individual think about the event.","Other Things Made Me Think About Event | Other things kept making me think about it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383030","Feel Irritable and Angry","C170865","A question about whether an individual feels or felt irritable and angry.","Feel Irritable and Angry | I felt irritable and angry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383031","Avoid Getting Upset When Thought or Reminded of Event","C170866","A question about whether an individual avoided getting upset then they thought about the event or was reminded of it.","Avoid Getting Upset When Thought or Reminded of Event | I avoided letting myself get upset when I thought about it or was reminded of it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383022","Thought of Event When Didn't Mean To","C170867","A question about whether an individual thought about the event when they didn't mean to.","Thought of Event When Didn't Mean To | I thought about it when I didn't mean to",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383023","Felt as if Event Didn't Happen or Wasn't Real","C170868","A question about whether an individual feels or felt like the event hadn't happened or wasn't real.","Felt as if Event Didn't Happen or Wasn't Real | I felt as if it hadn't happened or wasn't real",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383020","Stay Away from Reminders of Event","C170869","A question about whether an individual stays away from reminders of the event.","Stay Away from Reminders of Event | I stayed away from reminders about it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383021","Pictures of Event Pop into Mind","C170870","A question about whether pictures of the event pop into an individual's mind.","Pictures of Event Pop into Mind | Pictures about it popped into my mind",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383026","Jumpy and Easily Startled","C170871","A question about whether an individual is or was jumpy and easily startled.","Jumpy and Easily Startled | I was jumpy and easily startled",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383027","Try Not to Think About Event","C170872","A question about whether an individual tries or tried not to think about the event.","Try Not to Think About Event | I tried not to think about it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383024","Aware of Feeling about Event but Didn't Deal with Them","C170873","A question about whether an individual is or was aware that they still had lots of feelings about the event, but didn't deal with them.","Aware of Feeling about Event but Didn't Deal with Them | I was aware that I still had a lot of feelings about it, but I didn't deal with them",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383025","Feeling Numb About Event","C170874","A question about whether an individual's feelings about the event are or were kind of numb.","Feeling Numb About Event | My feelings about it were kind of numb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383041","Acting or Feeling Like at Time of Event","C170875","A question about whether an individual found themselves acting or feeling like they were back at the time of the event.","Acting or Feeling Like at Time of Event | I found myself acting or feeling like I was back at that time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383042","Have Waves of Strong Feelings about Event","C170876","A question about whether an individual has or had waves of strong feelings about the event.","Have Waves of Strong Feelings about Event | I had waves of strong feelings about it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383039","Tried to Remove Event from Memory","C170877","A question about whether an individual tried to remove the event from their memory.","Tried to Remove Event from Memory | I tried to remove it from my memory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383040","Reminders of the Event Cause Physical Reactions","C170878","A question about whether reminders of the event caused an individual to have physical reactions, such as sweating, trouble breathing, nausea, or a pounding heart.","Reminders of the Event Cause Physical Reactions | Reminders of it caused me to have physical reactions, such as sweating, trouble breathing, nausea, or a pounding heart",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383044","Dream about Event","C170879","A question about whether an individual has or had dreams about the event.","Dream about Event | I had dreams about it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383045","Feel Watchful and on Guard","C170880","A question about whether an individual feels or felt watchful and on guard.","Feel Watchful and on Guard | I felt watchful and on guard",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383043","Tried Not Talking about Event","C170881","A question about whether an individual tries or tried not to talk about the event.","Tried Not Talking about Event | I tried not to talk about it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378879","SARS Coronavirus 2","C169076","A positive-sense single-stranded RNA virus in the genus Betacoronavirus. It is the causative agent of the 2019-2020 severe acute respiratory syndrome outbreak.","SARS Coronavirus 2 | 2019 Novel Coronavirus | 2019-nCoV | COVID-19 Virus | HCoV-19 | Human Coronavirus 2019 | Novel Coronavirus | SARS-2 | SARS-CoV-2 | SARS2 | SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 | Severe Acute Respiratory Syndrome Coronavirus 2 | nCoV",,,,,,,,,,,,,,,"37311065","SARS-CoV-2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937110","Single Agent Therapy","C157514","Pharmacotherapy consisting of a single agent.","Single Agent Therapy | Monotherapy | Single Agent Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383221","Patient-Derived Models Repository","C170946","A national repository comprised of patient-derived xenografts (PDX), in vitro patient-derived tumor cell cultures (PDC) and cancer associated fibroblasts (CAF) as well as patient-derived organoids (PDOrg). These models will serve as a resource for public-private partnerships and for academic drug discovery efforts. These materials will be clinically annotated with molecular information available in an easily accessible database and will be available to the extramural community.","Patient-Derived Models Repository | PDMR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879749","Assent","C62281","Agreement with a statement or proposal to do something.","Assent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937748","Thawed Specimen","C158280","A specimen that has changed from a frozen to a liquid or semi-liquid state.","Thawed Specimen | THAWED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898438","Broken Component","C118638","A part of a device has been fractured or damaged.","Broken Component | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830528","Destroyed Medical Device","C112270","A finding referring to a medical device that has been demolished.","Destroyed Medical Device | DESTROYED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226897","Vestibule of Mouth","C165195","The area inside the mouth between the cheek or lips, and the teeth.","Vestibule of Mouth | Vestibule of mouth",,,,,,,,,,,,,,,"4144069","Structure of vestibule of mouth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043085","Weather","C170964","The state of the atmosphere at a given time and place, with respect to variables such as temperature, moisture, wind velocity, and barometric pressure.","Weather | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346665","Leaking Specimen","C70716","A specimen that has escaped its enclosure, in part or in total.","Leaking Specimen | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011303","Demyelinating Disorder","C34527","A broad group of disorders that affect the myelin sheaths that cover the neurons. Myelin sheathes cover neuronal axons in the central and peripheral nervous system and function to increase travelling impulse speeds. Disruption of this sheath impairs neuronal transmission and can result in disorders such as multiple sclerosis and Guillain-Barre syndrome, among others.","Demyelinating Disorder | Demyelinating Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971223","Facial","C161327","Of, or related to, or in the direction of the face.","Facial | FACIAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0815275","Subcortical","C165870","Denoting the area below a cortex.","Subcortical | SUBCORTICAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL381317","Periventricular","C165869","Of, or pertaining to, the area surrounding the ventricles of the brain.","Periventricular | PERIVENTRICULAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979011","Anterotemporal","C165868","Denoting the area of the body in front and toward the cranium, brain, and eye.","Anterotemporal | ANTEROTEMPORAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979269","Observation Study Epoch","C165873","A period in a clinical study during which subjects are observed, without planned interventions.","Observation Study Epoch | OBSERVATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971322","Rockport One Mile Walk Test Version 1.0 Functional Test","C166279","A submaximal fitness test, developed by Kline et al. in 1987, that utilizes the fastest time taken to walk one mile (T1), heart rate measured at the fourth quarter of the mile (HR1-4), sex (SEX; male = 1, female = 0), age in years (AGE), and body weight in pounds (WT) to estimate maximal oxygen consumption (VO2max) using the equation: VO2max = 6.9652 + (0.0091*WT) - (0.0257*AGE) + (0.5955*SEX) - (0.2240*T1) - (0.0115*HR1-4).","Rockport One Mile Walk Test Version 1.0 Functional Test | RFWT Version 1 | ROCK01 | ROCKPORT ONE MILE WALK TEST V1.0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971323","Huntington's Disease Cognitive Assessment Battery Functional Test","C166278","A set of six tests that were combined by Stout et al. in 2014 as an assessment tool for the effects of Huntington's disease treatment on cognition. The battery of tests, which include the Symbol Digit Modalities Test (SDMT), Emotion Recognition, Trail Making Test, Hopkins Verbal Learning Test (HVLT), Paced Tapping, and One Touch Stockings of Cambridge (OTS), cover a range of cognitive abilities known to decline in Huntington's disease, including attention, processing speed, visuospatial processing, timing, emotion processing, memory, and executive function.","Huntington's Disease Cognitive Assessment Battery Functional Test | HD-CAB | HDCAB1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976948","Weight-for-Height Percentile","C163570","A measurement of an individual's weight in relationship to height, in comparison to a reference percentile curve.","Weight-for-Height Percentile | WTHTPCTL",,,,,,,,,,,,,,,"603037","Weight for height percentile",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL976949","Weight-for-Age Percentile","C163569","A measurement of an individual's weight in relationship to age, in comparison to a reference percentile curve.","Weight-for-Age Percentile | WTAPCTL",,,,,,,,,,,,,,,"607552","Weight for age percentile",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL976950","Height-for-Age Percentile","C163568","A measurement of an individual's height in relationship to age, in comparison to a reference percentile curve.","Height-for-Age Percentile | HTAPCTL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976951","BMI-for-Age Percentile","C163567","A measurement of an individual's body mass index in relationship to age, in comparison to a reference percentile curve.","BMI-for-Age Percentile | BMIAPCTL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541379","Anti-K-RAS G12V mTCR-transduced Autologous Peripheral Blood Lymphocytes","C142888","Autologous peripheral blood lymphocytes (PBLs) transduced with an HLA class I histocompatibility antigen A*11:01 (HLA-A1101)-restricted murine T-cell receptor (mTCR) that recognizes the glycine to valine point mutation at position 12 (G12V) variant of K-RAS, with potential antineoplastic activity. HLA-A1101 positive PBLs are harvested from a K-RAS G12V-expressing cancer patient and transfected with a retroviral vector that encodes anti-K-RAS G12V mTCR. The transduced PBLs are then expanded in culture. When reintroduced to the patient, these anti-K-RAS G12V mTCR-expressing PBLs target and bind to K-RAS G12V-overexpressing tumor cells, which results in both cytokine secretion and tumor cell lysis. K-RAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutation of K-RAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.","Anti-K-RAS G12V mTCR-transduced Autologous Peripheral Blood Lymphocytes | Anti-K-RAS G12V mTCR-transduced Autologous PBLs | Anti-KRAS G12V mTCR-transduced Autologous Peripheral Blood Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935986","Anti-K-RAS G12D mTCR-transduced Autologous Peripheral Blood Lymphocytes","C156889","Autologous peripheral blood lymphocytes (PBLs) transduced with a retroviral vector encoding for an HLA class I histocompatibility antigen A*11:01 (HLA-A1101)-restricted murine T-cell receptor (mTCR) that recognizes the glycine (Gly, G) to aspartic acid (Asp, D) point mutation at position 12 (G12D) variant of K-RAS (KRAS), with potential immunomodulating and antineoplastic activities. HLA-A1101-positive PBLs are harvested from a K-RAS G12D-expressing cancer patient and transfected with a retroviral vector that encodes anti-K-RAS G12D mTCR. The transduced PBLs are then expanded in culture. When reintroduced to the patient, these anti-K-RAS G12D mTCR-expressing PBLs target and bind to K-RAS G12D-overexpressing tumor cells, which results in both cytokine secretion, including interferon-gamma (IFN-g), and tumor cell lysis. K-RAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutation of K-RAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.","Anti-K-RAS G12D mTCR-transduced Autologous Peripheral Blood Lymphocytes | Anti-K-RAS G12D mTCR-transduced Autologous PBLs | Anti-KRAS G12D mTCR-transduced Autologous Peripheral Blood Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937747","Non-Hemolyzed Specimen","C158279","A specimen that has not undergone the destruction of red blood cells followed by the release of the hemoglobin.","Non-Hemolyzed Specimen | NON-HEMOLYZED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937749","Lactescent Specimen","C158278","A specimen that has become or appears milky.","Lactescent Specimen | LACTESCENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979224","Agglutinated Specimen","C166094","A specimen that has undergone agglutination, a process by which particles collect to form a cohesive mass or cluster.","Agglutinated Specimen | AGGLUTINATED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979232","Microvolts Squared","C166102","A unit of electromotive force equal to a microvolt squared.","Microvolts Squared | uV2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979231","Steps Per Minute","C166101","The number of steps occurring within a minute unit of time.","Steps Per Minute | steps/min | {steps}/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979230","Milliliter Per Second Per Square Meter","C166100","A metric unit of volumetric flow rate defined as the rate at which one milliliter of matter travels during the period of time equal to one second per meter squared.","Milliliter Per Second Per Square Meter | Milliliter Per Second Per Meter Squared | mL/s/m2 | mL/sec/m2 | ml/s/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979221","Gram Per Unit","C166099","A unit of concentration or mass density equal to one gram of substance per unit(s) of substance.","Gram Per Unit | g/U | g/{U}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979220","Degrees Squared","C166098","A non-SI unit of solid angle equal to approximately 3.0462x10^-4 steradians.","Degrees Squared | deg2 | sq. deg.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979219","Degrees Per Second","C166097","A unit of angular velocity defined as the number of degrees per unit of time equal to one second.","Degrees Per Second | deg/s",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979218","Ten Million Colony Forming Units Per Liter","C166096","A unit of measurement of viable bacterial organisms in a unit volume of substance of interest defined as the number of 10 to the seventh power colony forming units in one liter of substance.","Ten Million Colony Forming Units Per Liter | 10*7.[CFU]/mL | 10*7.[CFU]/ml | 10^7 CFU/mL | 10^7.[CFU]/mL | 10^7.[CFU]/ml | Ten Million CFU/mL | Ten Million Colony Forming Units per Milliliter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979225","Ten Thousand Colony Forming Units Per Liter","C166095","A unit of measurement of viable bacterial organisms in a unit volume of substance of interest defined as the number of 10 to the fourth power colony forming units in one liter of substance.","Ten Thousand Colony Forming Units Per Liter | 10*4.[CFU]/mL | 10*4.[CFU]/ml | 10^4 CFU/mL | 10^4.[CFU]/mL | 10^4.[CFU]/ml | Ten Thousand CFU/mL | Ten Thousand Colony Forming Units per Milliliter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL941627","Non-Alcoholic Fatty Liver Disease Fibrosis Score","C171090","A non-invasive scoring system that helps to estimate the amount of scarring in the liver and identify patients whose NAFLD has advanced to liver fibrosis. The scoring uses selected laboratory values (serum glucose, platelet count, albumin, AST/ALT ratio) and readily available patient characteristics (age, BMI, and diabetes status).","Non-Alcoholic Fatty Liver Disease Fibrosis Score | NAFLD Fibrosis Score",,,,,,,,,,,,,,,"36676223","NAFLD (Non-Alcoholic Fatty Liver Disease) fibrosis score",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1405422","NTRK Gene Rearrangement","C171043","A molecular abnormality indicating cytogenetic rearrangement involving an NTRK family gene.","NTRK Gene Rearrangement | NTRK Family Gene Rearrangement | NTRK Family Rearrangement | NTRK Rearranged | TRK Family Gene Rearrangement | TRK Receptor Family Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405421","Neoplastic Plasma Cells Under 5 Percent of Peripheral Blood White Cells","C171044","A semi-quantitative microscopic finding indicating that less than 5 percent of the nucleated cells in a peripheral leukocyte sample are neoplastic plasma cells.","Neoplastic Plasma Cells Under 5 Percent of Peripheral Blood White Cells | Neoplastic Plasma Cells Less than 5 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405441","KIR3DL2 Positive","C171048","An indication that expression of KIR3DL2 has been detected in a sample.","KIR3DL2 Positive | CD158K Positive | CL-5 Positive | Killer Cell Immunoglobulin Like Receptor, Three Ig Domains and Long Cytoplasmic Tail 2 Positive | Killer Cell Immunoglobulin-Like Receptor 3DL2 Positive | NKAT-4 Positive | NKAT4 Positive | Natural Killer-Associated Transcript 4 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405439","APC NP_000029.2:p.I1307K","C171050","A change in the amino acid residue at position 1307 in the adenomatosis polyposis coli protein where isoleucine has been replaced by lysine.","APC NP_000029.2:p.I1307K | APC I1307K | APC I1307K Mutation | APC Ile1307Lys | APC NP_000029.2:p.Ile1307Lys | APC Protein I1307K | APC Protein Ile1307Lys | APC p.I1307K | APC p.Ile1307Lys | APCI1307K Mutation | Adenomatosis Polyposis Coli Tumor Suppressor I1307K | Adenomatosis Polyposis Coli Tumor Suppressor Ile1307Lys | Adenomatous Polyposis Coli Protein I1307K | Adenomatous Polyposis Coli Protein Ile1307Lys | Deleted In Polyposis 2.5 I1307K | Deleted In Polyposis 2.5 Ile1307Lys | NP_000029.2:p.I1307K | NP_000029.2:p.Ile1307Lys | Protein APC I1307K | Protein APC Ile1307Lys",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405438","FGF23 Overexpression Positive","C171051","An indication that overexpression of FGF23 has been detected in a sample.","FGF23 Overexpression Positive | Elevated FGF23 Expression | Excessive FGF23 | FGF-23 Overexpression | FGF-23 Overexpression Positive | FGF23 Overexpression | Fibroblast Growth Factor 23 Overexpression Positive | High FGF23 Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405437","Ki-67 Positive Cells Greater than or Equal to 15 Percent","C171052","A semi-quantitative microscopic finding indicating that at least 15 percent of the cells in a sample are detected following staining using an anti-Ki-67 antibody.","Ki-67 Positive Cells Greater than or Equal to 15 Percent | Antigen Ki-67 Positive Cells Greater than or Equal to 15 Percent | KI67 Positive Cells Greater than or Equal to 15 Percent | Ki-67 Antigen Positive Cells Greater than or Equal to 15 Percent | MKI67 Positive Cells Greater than or Equal to 15 Percent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405436","Chromosome 17p Abnormality","C171053","An irregularity in the structure of the short arm of chromosome 17.","Chromosome 17p Abnormality | 17p Aberration | 17p Abnormality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405435","Chromosome 12 Abnormality","C171054","An irregularity in the structure of chromosome 12.","Chromosome 12 Abnormality | Chromosome 12 Aberration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405434","Chromosome 13q Abnormality","C171055","An irregularity in the structure of the long arm of chromosome 13.","Chromosome 13q Abnormality | 13q Aberration | 13q Abnormality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405432","Innate Lymphoid Cell","C171057","Innate immune cells in the lymphoid lineage that do not express recombination-activating genes (RAGs), T-cell or B-cell receptors, or any myeloid or dendritic cell markers. There are several subtypes of innate lymphoid cells (ILC): group 1 ILC express TBX21 and Th1 cytokines, group 2 ILC produce type 2 cytokines, group 3 ILC produce interleukin-17A (IL-17A) and/or IL-22 and lymphoid tissue inducer cells (LTi cells) do not express CD3 but do express IL-7, CD45, CD4 and a large number of additional markers.","Innate Lymphoid Cell | ILC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405431","Innate Lymphoid Cell Count","C171058","The determination of the amount of innate lymphoid cells present in a sample.","Innate Lymphoid Cell Count | ILC | ILC Count | Innate LC | Innate Lymphoid Cell Counts | Innate Lymphoid Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405429","Low ADAMTS13 Activity","C171060","A finding indicating that a significantly lower than expected activity for the proteinase a disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13) is detected in a sample. This finding is associated with thrombotic thrombocytopenic purpura.","Low ADAMTS13 Activity | ADAMTS 13 Deficiency | ADAMTS-13 Deficiency | ADAMTS13 Deficiency | Low A Disintegrin and Metalloproteinase With Thrombospondin Motifs 13 Activity | Low vWF-CP Activity | Low vWF-Cleaving Protease Activity | vWF-CP Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405428","Triggering Receptors Expressed on Myeloid Cells Family Protein","C171061","A protein family containing receptors expressing a single variable-type immunoglobulin domain that stimulate cell activation and promote immune responses by myeloid lineage cells.","Triggering Receptors Expressed on Myeloid Cells Family Protein | TREM | TREM Family | TREM Family Protein | Triggering Receptors Expressed on Myeloid Cells Family | Triggering Receptors Expressed on Myeloid Cells Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405458","CD33 Expression 20 Percent or More of Neoplastic Cells","C171062","A semi-quantitative immunochemistry finding indicating that expression of CD33 was detected in at least 20 percent of the cells in a tumor sample.","CD33 Expression 20 Percent or More of Neoplastic Cells | CD33 Antigen Expression 20 Percent or More of Neoplastic Cells | CD33 Expression 20 Percent or More | CD33 Molecule Expression 20 Percent or More of Neoplastic Cells | Myeloid Cell Surface Antigen CD33 Expression 20 Percent or More of Neoplastic Cells | SIGLEC-3 Expression 20 Percent or More of Neoplastic Cells | SIGLEC3 Expression 20 Percent or More of Neoplastic Cells | gp67 Expression 20 Percent or More of Neoplastic Cells | p67 Expression 20 Percent or More of Neoplastic Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405457","Bone Marrow Blasts Percentage Decreased by 5 to 25 Percent","C171063","A semiquantitative finding indicating that the amount of immature mononuclear cells in a subject's sample of nucleated cells from bone marrow has decreased by between 5 and 25 percent from a previous percentage recorded for a sample from that subject.","Bone Marrow Blasts Percentage Decreased by 5 to 25 Percent | Bone Marrow Blasts Percentage Decreased between 5 and 25 Percent | Decrease of Bone Marrow Blast Percentage by 5 to 25 Percent | Decrease of Bone Marrow Blast Percentage to 5 Percent to 25 Percent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405452","HTLV Positive","C171068","An indication that HTLV was detected in a sample.","HTLV Positive | Human T Cell Lymphotropic Virus Positive | Human T-Cell Lymphotropic Virus Positive | Human T-Lymphotropic Virus Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405451","PTK7 Positive","C171069","An indication that PTK7 expression has been detected in a sample.","PTK7 Positive | CCK-4 Positive | CCK4 Positive | Colon Carcinoma Kinase 4 Positive | Colon Carcinoma Kinase-4 Positive | Inactive Tyrosine-Protein Kinase 7 Positive | Protein-Tyrosine Kinase PTK7 Positive | Pseudo Tyrosine Kinase Receptor 7 Positive | Tyrosine-Protein Kinase-Like 7 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405449","Deleterious BAP1 Gene Mutation","C171071","A change in the nucleotide sequence of the BAP1 gene that is associated with increased risk of disease.","Deleterious BAP1 Gene Mutation | Deleterious BAP1 Mutation | Deleterious BRCA1 Associated Protein 1 Gene Mutation | Deleterious BRCA1-Associated Protein 1 Gene Mutation | Deleterious UCHL2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405447","Deleterious ATRX Gene Mutation","C171073","A change in the nucleotide sequence of the ATRX gene that is associated with increased risk of disease.","Deleterious ATRX Gene Mutation | Deleterious ATRX Mutation | Deleterious ATRX, Chromatin Remodeler Gene Mutation | Deleterious Alpha Thalassemia/Mental Retardation Syndrome X-Linked Gene Mutation | Deleterious RAD54 Gene Mutation | Deleterious RAD54 Homolog Gene Mutation | Deleterious RAD54L Gene Mutation | Deleterious XH2 Gene Mutation | Deleterious XNP Gene Mutation | Deleterious ZNF-HX Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405446","Deleterious BLM Gene Mutation","C171074","A change in the nucleotide sequence of the BLM gene that is associated with increased risk of disease.","Deleterious BLM Gene Mutation | Deleterious BLM Mutation | Deleterious BS Gene Mutation | Deleterious Bloom Syndrome Gene Mutation | Deleterious RECQ2 Gene Mutation | Deleterious RECQL2 Gene Mutation | Deleterious RECQL3 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405445","Deleterious ARID1A Gene Mutation","C171075","A change in the nucleotide sequence of the ARID1A gene that is associated with increased risk of disease.","Deleterious ARID1A Gene Mutation | Deleterious ARID1A Mutation | Deleterious AT Rich Interactive Domain 1A Gene Mutation | Deleterious B120 Gene Mutation | Deleterious BAF250 Gene Mutation | Deleterious BAF250a Gene Mutation | Deleterious BRG1-Associated Factor 250a Gene Mutation | Deleterious SMARCF1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405444","PSA Density Less than 0.15","C171076","A finding indicating that the ratio of serum prostate specific antigen to prostate volume is less than 0.15 ng/ml/g.","PSA Density Less than 0.15 | PSA Density Less than 0.15 ng/mL/g | PSAD Less than 0.15 | PSAD Less than 0.15 ng/mL/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405443","CDKN2B Negative","C171077","An indication that expression of CDKN2B has not been detected in a sample.","CDKN2B Negative | CDK4I Negative | Cyclin Dependent Kinase Inhibitor 2B Negative | Cyclin-Dependent Kinase Inhibitor 2B Negative | INK4B Negative | MTS-2 Negative | MTS2 Negative | Multiple Tumor Suppressor 2 Negative | P14-INK4B Negative | P15-INK4B Negative | TP15 Negative | p15INK4b Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405334","Sensitizing BRAF Gene Mutation","C171078","A change in the sequence of the BRAF gene that results in increased sensitivity to BRAF targeting agents.","Sensitizing BRAF Gene Mutation | Sensitizing B-RAF Gene Mutation | Sensitizing B-RAF1 Gene Mutation | Sensitizing BRAF Mutation | Sensitizing BRAF1 Gene Mutation | Sensitizing v-raf Murine Sarcoma Viral Oncogene Homolog B1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405333","Sensitizing ROS1 Gene Mutation","C171079","A change in the sequence of the ROS1 gene that results in increased sensitivity to ROS1 targeting agents.","Sensitizing ROS1 Gene Mutation | Sensitizing MCF3 Gene Mutation | Sensitizing ROS Gene Mutation | Sensitizing ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene Mutation | Sensitizing ROS1 Mutation | Sensitizing c-ros-1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976929","Products of Conception Examined Indicator","C163557","An indication as to whether the products of conception have been examined.","Products of Conception Examined Indicator | PRDCEIND | Products of Conception Examined Ind",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978356","Pregnancy End Date","C163558","The date on which the pregnancy ended.","Pregnancy End Date | Date Pregnancy Ended | PRGENDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0259863","Endocrinologist","C17817","A doctor who specializes in diagnosing and treating conditions affecting the endocrine system.","Endocrinologist | ENDOCRINOLOGIST | endocrinologist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1378566","Solid Dosage Form","C45235","A substance having definite shape and volume manufactured for the administration of active and/or inert ingredient(s). Solids include tablets, capsules, powders, granules and certain suppositories.","Solid Dosage Form | SOLID | Solid | Solid Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979258","Percent Recovered To Last Nonzero Concentration","C166075","The percentage of the administered dose that is recovered from the specimen type, from the time of dosing to the last non-zero concentration.","Percent Recovered To Last Nonzero Concentration | Pct Rec to Last Nonzero Conc | RCPCLST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707410","Clear Cell Variant Thyroid Gland Papillary Carcinoma","C46094","A morphologic variant of papillary carcinoma of the thyroid gland characterized by the predominance of malignant follicular clear cells.  These cells have the nuclear features that characterize the papillary carcinomas of the thyroid gland.","Clear Cell Variant Thyroid Gland Papillary Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0346398","Follicular Variant Thyroid Gland Papillary Carcinoma","C126594","An encapsulated or nonencapsulated variant of papillary carcinoma of the thyroid gland characterized by the predominance of follicular structures. The malignant follicular cells display the nuclear features that characterize the papillary adenocarcinomas of the thyroid gland.","Follicular Variant Thyroid Gland Papillary Carcinoma | FVPTC | Papillary Thyroid Carcinoma, Follicular Variant | Papillary carcinoma, follicular variant","8340/3","Papillary carcinoma, follicular variant",,,,,,,,,,,,,"4072320|4116229","Papillary carcinoma, follicular variant|Mixed follicular and papillary thyroid carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"CL1405367","Bothered by Dry Skin","C171134","A question about whether an individual is or was bothered by dry skin.","Bothered by Dry Skin | Drying skin | I am bothered by dry skin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439841","Ambulatory","C171135","Able to walk.","Ambulatory | ",,,,,,,,,,,,,,,"4114508","Ambulatory",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1382811","Most Recent Flare","C170607","The most recent occurrence of a disease flare.","Most Recent Flare | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382759","Prepared Amount","C170562","The quantity of a product that has been made ready for use.","Prepared Amount | PREPAMT | amount",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382760","Remaining Amount","C170563","The quantity of a product that remains after dosing, consumption, or use.","Remaining Amount | REMAMT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382765","Parieto-Occipital","C170564","Of, or related to, the area of the body where the parietal and occipital lobes of the brain meet.","Parieto-Occipital | PARIETO-OCCIPITAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950827","Reinduction Therapy","C158877","Treatment administered after a relapse of cancer.","Reinduction Therapy | Re-Induction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382780","Death Witnessed Indicator","C170571","An indication as to whether the death event was witnessed by another individual.","Death Witnessed Indicator | DTHWIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382783","Short Modified Release Tablet Dosage Form","C170574","A tablet exhibiting an altered inherent rate of release of active and/or inert ingredient(s) that is classified as short.","Short Modified Release Tablet Dosage Form | TABLET, MODIFIED RELEASE, SHORT DURATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382786","Long Modified Release Tablet Dosage Form","C170573","A tablet exhibiting an altered inherent rate of release of active and/or inert ingredient(s) that is classified as long.","Long Modified Release Tablet Dosage Form | TABLET, MODIFIED RELEASE, LONG DURATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382893","Modified Release Tablet Dosage Form","C170453","A tablet exhibiting an altered inherent rate of release of active and/or inert ingredient(s).","Modified Release Tablet Dosage Form | TABLET, MODIFIED RELEASE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024219","Lymphangiography","C38069","The examination of the lymph nodes and lymphatic vessels following the injection of a radiopaque substance.","Lymphangiography | LYMPHANGIOGRAPHY | Lymphography | lymphangiography | lymphography",,,,,,,,,,,,,,,"4177386","Lymphangiogram",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1382830","EOR06","C170644","An updated modular supplement to the European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) that was developed in 2007 and is used to assess quality of life in patients with colorectal cancer. The patient-report questionnaire utilizes a four point rating scale to assess symptoms or problems experienced over the last week.","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Colorectal Cancer Module Version 2.1 | EOR06 | EORTC QLQ-CR29 V2.1 | EORTC QLQ-CR29 Version 2.1 | European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire - Colorectal Cancer Module Version 2.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382825","FAS-NACC UDS V3.0","C170643","A standardized ten-item clinician-report questionnaire, originally developed by Pfeffer et al. 1982, that utilizes a five-point rating scale to assess a patient's instrumental activities of daily living (IADLs) in the past four weeks. Version 3 of the questionnaire was implemented in 2015 as part of the National Alzheimer's Coordinating Center Uniform Data Set initial visit packet.","Functional Assessment Scale-NACC UDS Version 3.0 Clinical Classification | FAS-NACC UDS V3.0 | FAS-NACC UDS Version 3.0 | FASNA1 | Functional Assessment Scale-NACC UDS Version 3.0 Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977160","Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes Questionnaire","C163817","A 21-item self-administered questionnaire, published by Hessler et al. in 2016, that utilizes a five-point rating scale to assess diabetes distress in partners of adults with type 1 diabetes; the instrument includes four subscales that address key dimensions of partner-related distress, including 'my partner's diabetes management', 'how best to help', 'diabetes and me', and hypoglycemia.","Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes Questionnaire | DDS03 | PARTNER-DDS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977161","Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes Questionnaire","C163816","A 20-item self-administered questionnaire, published by Hessler et al. in 2016, that utilizes a five-point rating scale to assess diabetes distress in parents of teens with type 1 diabetes; the instrument includes four subscales that address key dimensions of parent-related distress, including personal distress, teen management distress, parent/teen relationship distress and healthcare team distress.","Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes Questionnaire | DDS02 | PARENT-DDS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978361","Hypoglycemic Confidence Scale Questionnaire","C163815","A nine-item self-administered questionnaire, published by Polonsky et al. in 2017, that utilizes a four-point rating scale to assess the degree to which patients with diabetes feel secure regarding their ability to stay safe from hypoglycemia-related problems.","Hypoglycemic Confidence Scale Questionnaire | HCS | HCS01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977162","The Glucose Monitoring Satisfaction Survey Version: Type 1 Diabetes Questionnaire","C163814","A 15-item self-administered questionnaire, published by Polonsky et al. in 2015, that utilizes a five-point rating scale to assess patient treatment satisfaction with glucose monitoring devices for type 1 diabetes; the instrument includes four subscales that address openness, emotional burden, behavioral burden, and trust.","The Glucose Monitoring Satisfaction Survey Version: Type 1 Diabetes Questionnaire | GMSS VERSION TYPE 1 DIABETES | GMSS Version Type 1 Diabetes | GMSS01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977163","Generalized Anxiety Disorder - 7 Version 2 Questionnaire","C163813","A revised version of the Generalized Anxiety Disorder - 7 Questionnaire, which is a seven-item, self-administered assessment tool published by Spitzer et al. in 2006 that utilizes a four-point rating scale to screen for and measure the severity of generalized anxiety disorder. The revised questionnaire has alternative wording in two of the rating scale options, and does not include the supplementary question at the end of the questionnaire.","Generalized Anxiety Disorder - 7 Version 2 Questionnaire | GAD-7 V2 | GAD-7 Version 2 | GAD02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977164","Asthma Nighttime Symptom Diary V1.0 Questionnaire","C163812","A six-item self-administered questionnaire, developed by Gater et al. in 2016, that utilizes a ten-point rating scale to assess a patient's experience with core asthma symptoms during the preceding night, including difficulty breathing, wheezing, shortness of breath, chest tightness, chest pain, and cough.","Asthma Nighttime Symptom Diary V1.0 Questionnaire | ANSD V1.0 | ANSD Version 1.0 | ANSD01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977165","Asthma Daytime Symptom Diary V1.0 Questionnaire","C163811","A six-item self-administered questionnaire, developed by Gater et al. in 2016, that utilizes a ten-point rating scale to assess a patient's experience with core asthma symptoms during the preceding day, including difficulty breathing, wheezing, shortness of breath, chest tightness, chest pain, and cough.","Asthma Daytime Symptom Diary V1.0 Questionnaire | ADSD V1.0 | ADSD Version 1.0 | ADSD01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382817","Serum or Plasma or Blood","C170628","A specimen type containing serum, plasma or blood.","Serum or Plasma or Blood | SERUM OR PLASMA OR BLOOD | Ser/Plas/Bld",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0455807","Crown to Heel Length","C170639","A measurement of the length of the body from the crown of the head to the bottom of the heel.","Crown to Heel Length | CRWNHEEL | Crown-to-Heel Length",,,,,,,,,,,,,,,"600652","Recumbent body height",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL972314","Glioblastoma, IDH-mutant","C167335","IDH-mutant astrocytoma characterized by the presence of necrosis and/or microvascular proliferation or homozygous deletion of CDKN2A and/or CDKN2B genes. The term glioblastoma no longer applies to central nervous system WHO grade 4 IDH-mutant astrocytomas. (WHO 2021)","Astrocytoma, IDH-Mutant, Grade 4 | Astrocytoma, IDH-Mutant, Grade IV | Glioblastoma, IDH-Mutant | Glioblastoma, IDH-Mutant | Glioblastoma, IDH-mutant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346701","Log10 Plaque Forming Unit","C73568","A logarithmic-scale (base 10) potency unit for measuring the quantity of individual infectious particles (usually viral particles) based on the number of plaques formed in a cell culture infected with the virus.","Log10 Plaque Forming Unit | log10 PFU | log10 plaque forming unit(s) | {log10}.{PFU}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383298","Lens Dosing Unit","C170638","A dosing measurement based on the lens unit.","Lens Dosing Unit | LENS | {LENS}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383308","Mask Dosing Unit","C170637","A dosing measurement based on the mask unit.","Mask Dosing Unit | MASK | {MASK}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382833","Per 50,000 White Blood Cells","C170636","Natural number unit of measurement for a portion of a particular type of cell (excluding white blood cell subtypes) per 50,000 white blood cells.","Per 50,000 White Blood Cells | /50000{WBC} | /5x10^4 WBC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0556976","Hours Per Week","C170635","A unit of measurement equal to the number of hours within a period of time equal to one week.","Hours Per Week | h/wk | hours/week | hr/wk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0556971","Days Per Month","C170634","A unit of measurement equal to the number of days within a period of time equal to one month.","Days Per Month | d/mo | days/month",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677547","Days Per Week","C170633","A unit of measurement equal to the number of days within a period of time equal to one week.","Days Per Week | d/wk | days/week | days/wk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382832","DNA Copies Per Microgram","C170632","A unit of measurement equal to the number of deoxyribonucleic acid (DNA) copies per unit of mass equal to one microgram.","DNA Copies Per Microgram | DNA copies/ug | {DNA Copies}/ug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382816","log10 Plaque Forming Units Per Milliliter","C170631","A logarithmic-scale (base 10) unit for measuring plaque forming units per unit of volume equal to one milliliter.","log10 Plaque Forming Units Per Milliliter | log10 PFU/mL | {log10}.{PFU}/mL | {log10}.{PFU}/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0556639","Kilovolt","C170630","A unit of electric potential and electromotive force, equal to one thousand volts.","Kilovolt | kV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552472","Plug Dosing Unit","C149763","A unit of presentation used to represent the quantity of product that is found in a single discrete entity where the pharmaceutical dose form is a type of plug.","Plug Dosing Unit | PLUG | Plug | {PLUG}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976952","Vector Genomes per Kilogram","C163566","A unit for the vector amount expressed as the number of vector genomes per kilogram of body weight.","Vector Genomes per Kilogram | VGC/kg | Vector Genomic Copies/kg | vg/kg | {vg}/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976923","Millisecond per Millimeter Mercury","C163565","A unit of measure equal to one millisecond per one millimeter of mercury (mmHg).","Millisecond per Millimeter Mercury | ms/mmHg | ms/mm[Hg] | msec/mmHg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976712","Mean Fluorescence Intensity Unit","C163046","A unit of measure for the mean fluorescence intensity.","Mean Fluorescence Intensity Unit | MFI | Mean Fluorescence Intensity | MnFI | {MnFI}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976924","Milliliter per Cubic Centimeter per Minute","C163564","A unit of flow rate equal to one milliliter per cm3 per unit of time equal to one minute.","Milliliter per Cubic Centimeter per Minute | mL/cm3/min | mL/mL/min | ml/cm3/min",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976925","Geometric Mean Fluorescence Intensity Unit","C163563","A unit of measure for the geometric mean fluorescence intensity.","Geometric Mean Fluorescence Intensity Unit | gMFI | {gMFI}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976713","Fluorescence Intensity Unit","C163045","A unit of measure for the fluorescence intensity when the mathematic calculation is unspecified or unknown.","Fluorescence Intensity Unit | FIU | Fluorescence Intensity | MFI | {MFI}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700201","Focus Forming Unit","C75303","A quantitative unit of measure of cell clusters of a specific interest.","Focus Forming Unit | FFU | FOCUS-FORMING UNITS | Focus-forming Units | [FFU]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976926","Arithmetic Mean Fluorescence Intensity Unit","C163562","A unit of measure for the arithmetic mean fluorescence intensity.","Arithmetic Mean Fluorescence Intensity Unit | aMFI | {aMFI}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976927","Billion per Dose","C163561","A dose calculation unit equal to 10 to the ninth power of the number of entities per single dose.","Billion per Dose | 10*9/{dose} | 10^9/dose | 10^9/{dose}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978375","Percent per Second","C163560","A unit of frequency expressed as the percentage of entities or events per second.","Percent per Second | %/s | %/sec",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0222110","Ear Skin","C49481","The skin of the organ responsible for detecting sound and establishing balance.","Ear Skin | SKIN OF THE EAR",,,,,,,,,,,,,,,"4078238","Skin structure of ear",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1382810","Skin of the Sole","C170606","The integument that covers the underside of the foot.","Skin of the Sole | SKIN OF THE SOLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221997","Nail Bed","C170605","The integument under the nail plate.","Nail Bed | NAIL BED",,,,,,,,,,,,,,,"4209864","Nail bed structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1382807","Skin of the Bending Joint","C170603","The integument that covers the bending joints.","Skin of the Bending Joint | SKIN OF THE BENDING JOINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL952057","skin fold (abnormality)","C170602","Integument that folds in upon itself.","Skinfold | SKIN FOLD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382809","Perifacial Lymph Node","C170601","A lymph node that is located above the mandibular margin of the submandibular triangle and is associated with the anterior facial vein and facial artery.","Perifacial Lymph Node | PERIFACIAL LYMPH NODE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382808","Skin Around the Mouth","C170600","The skin surrounding the mouth, including the skin of the lip.","Skin Around the Mouth | SKIN AROUND THE MOUTH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382789","Skin Around the Eye","C170599","The skin surrounding the eye, including the skin of the eyelid.","Skin Around the Eye | SKIN AROUND THE EYE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0222226","Skin of the Palm","C170604","The integument that covers the palms.","Skin of the Palm | SKIN OF THE PALM",,,,,,,,,,,,,,,"4321993","Skin structure of palmar area of hand",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3482113","Immature Platelets to Total Platelets Ratio Measurement","C170580","The determination of the ratio of immature platelets compared to total platelets present in a sample. The measurement may be expressed as a ratio or percentage.","Immature Platelets to Total Platelets Ratio Measurement | IPF | Immature Platelet Fraction | Immature Platelets/Total Platelets | PLTIMPLT | Reticulated Platelets/Total Platelets",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383301","Soluble Complement C5b-9 Measurement","C170579","The determination of the amount of soluble complement C5b-9 present in a sample.","Soluble Complement C5b-9 Measurement | C5B9S | Smac | Soluble Complement C5b-9 | Soluble MAC | Soluble Membrane Attack Complex | Soluble Membrane Attack Complex Measurement | TCC | Terminal Complement Complex | sC5b-9 | sC5b-9 Measurement | sMAC Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1446045","5-Hydroxyindoleacetic Acid to Creatinine Ratio Measurement","C170578","The determination of the ratio of 5-hydroxyindoleacetic acid compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","5-Hydroxyindoleacetic Acid to Creatinine Ratio Measurement | 5-Hydroxyindoleacetic Acid/Creatinine | IAA5OHCR",,,,,,,,,,,,,,,"4135537","5-Hydroxyindoleacetic acid/creatinine ratio measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1382776","Soluble B Cell Maturation Antigen Measurement","C170577","The determination of the amount of soluble B cell maturation antigen present in a sample.","Soluble B Cell Maturation Antigen Measurement | BCMAS | Soluble B Cell Maturation Antigen | Soluble BCM | Soluble BCMA | Soluble BCMA Measurement | Soluble CD269 | Soluble CD269 Measurement | Soluble TNF Receptor Superfamily Member 17 | Soluble TNFRSF13A | Soluble TNFRSF17 Measurement | Soluble Tumor Necrosis Factor Receptor Superfamily Member 17 Measurement | sBCMA Measurement | sCD269 Measurement | sTNFRSF13 Measurement | sTNFRSF17 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0189386","Tracheoscopy","C171172","Examination of the interior of the trachea using an endoscope.","Tracheoscopy | ",,,,,,,,,,,,,,,"4080522","Endoscopy of trachea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0279694","Monoclonal Antibody Therapy","C15490","The use of monoclonal antibodies in the treatment of any disease or disorder.","Monoclonal Antibody Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555454","Normalized Fluorescence Intensity Unit","C154680","A relative fluorescence intensity unit that is adjusted to a reference standard.","Normalized Fluorescence Intensity Unit | NFIU | NIU | Normalized Intensity Unit | {NIU}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405417","Diamandopoulos' A. formula","C171195","A formula for estimating creatinine clearance, defined as Ccr=80/Scr (70 for females).","Diamandopoulos' A. formula | DAF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0189896","Right Heart Catheterization","C80411","A diagnostic procedure in which a catheter is guided into the right heart, where pressures may be measured and radiocontrast material may be injected to visualize blood flow in and around the right heart.","Right Heart Catheterization | Pulmonary Artery Catheterization | Swan-Ganz Catheterization",,,,,,,,,,,,,,,"4223626","Catheterization of right heart",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1405564","Leidos Biomedical Research","C171251","A wholly-owned subsidiary of Leidos, Inc that develops and applies advanced technologies to help translate research discoveries into treatments for cancer and AIDS.","Leidos Biomedical Research | LBR | Leidos Biomedical Research, Inc",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521158","11q Aberration","C131912","A cytogenetic abnormality characterized by deregulation of genes in 11q.","11q Aberration | 11q Abnormality | Aberration of 11q | Chromosome 11q Abnormality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473407","Contractual Agreement","C115464","A legally binding accord between two or more people that details any and all arrangements regarding a specific situation(s).","Contractual Agreement | Authorization to Proceed | Change Order | Contract | Contractl Agrmnt | Contractual | Financial Agreement | Letter of Agreement | Project Work Order | Scope of Work | Service Agreement | contract",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405574","Alloantibody","C171260","An antibody that is produced following exposure to non-self antigens from other members of the same species.","Alloantibody | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0454512","Incentive Spirometry","C171271","Use of an incentive spirometer to take slow, deep breaths, and maximize lung capacity. Visual feedback from the spirometer is designed to help the user execute sustained maximal inhalations.","Incentive Spirometry | ",,,,,,,,,,,,,,,"4046481","Incentive spirometry",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL541610","Prostate Specific Antigen Density","C143161","The ratio of serum prostate specific antigen to prostate volume.","Prostate Specific Antigen Density | PSA Density | PSAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541614","PSA Doubling Time","C143149","The number of months observed or calculated for PSA to increase two-fold.","PSA Doubling Time | PSA-DT | PSADT | Prostate Specific Antigen Doubling Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382828","Short Physical Performance Battery Version 1.2 Functional Test","C170646","A standardized five-item 10-minute assessment tool, developed by Guralnik et al. 1994, that is used for the evaluation of lower extremity physical function and consists of three subtests, including standing balance, walking, and rising from a chair.","Short Physical Performance Battery Version 1.2 Functional Test | SPPB V1.2 | SPPB Version 1.2 | SPPB1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950612","Initial Pathologic Diagnosis Method","C158632","A question about the method to obtain the initial pathologic diagnosis.","Initial Pathologic Diagnosis Method | Method of Initial Pathologic Diagnosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001621","Adrenal Gland Disorder","C26690","Any disease affecting the adrenal gland.","Adrenal Gland Disorder | Adrenal Gland Disease | Adrenal Gland Diseases | Adrenal Gland Disorders",,,,,,,,,,,,,,,"193165","Disorder of adrenal gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1382804","Metabolite Ratio AUC From T1 to T2","C170615","The ratio of AUC from T1 to T2 for the metabolite to the AUC from T1 to T2 for the parent analyte or other metabolite.","Metabolite Ratio AUC From T1 to T2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382803","Accumulation Ratio AUC Infinity Predicted Normalized by Dose","C170614","The area under the curve (AUC) extrapolated to infinity, calculated using the predicted value of the last non-zero concentration divided by the area under the curve (AUC) extrapolated to infinity, calculated using the predicted value of the last non-zero concentration during the initial dosing interval, each divided by the associated dose.","Accumulation Ratio AUC Infinity Predicted Normalized by Dose | ARAUCIPD | Accum Ratio AUCIFP Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382806","Accumulation Ratio AUC Infinity Observed Normalized by Dose","C170613","The area under the curve (AUC) extrapolated to infinity, calculated using the observed value of the last non-zero concentration divided by the area under the curve (AUC) extrapolated to infinity, calculated using the observed value of the last non-zero concentration during the initial dosing interval, each divided by the associated dose.","Accumulation Ratio AUC Infinity Observed Normalized by Dose | ARAUCIOD | Accum Ratio AUCIFO Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382805","Accumulation Ratio AUC Infinity Predicted","C170612","The area under the curve (AUC) extrapolated to infinity, calculated using the predicted value of the last non-zero concentration divided by the area under the curve (AUC) extrapolated to infinity, calculated using the predicted value of the last non-zero concentration during the initial dosing interval.","Accumulation Ratio AUC Infinity Predicted | ARAUCIFP | Accum Ratio AUC Infinity Pred",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382800","Accumulation Ratio AUC Infinity Observed","C170611","The area under the curve (AUC) extrapolated to infinity, calculated using the observed value of the last non-zero concentration divided by the area under the curve (AUC) extrapolated to infinity, calculated using the observed value of the last non-zero concentration during the initial dosing interval.","Accumulation Ratio AUC Infinity Observed | ARAUCIFO | Accum Ratio AUC Infinity Obs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332547","Bi-Cytopenia","C36227","A deficiency of two of the three blood cell lineages; erythrocytes, leukocytes and platelets.","Bi-Cytopenia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382686","Netarsudil","C170213","An amino-isoquinoline amide and inhibitor of Rho kinase (ROCK) and norepinephrine transporter (NET), with potential intraocular pressure (IOP)-lowering activity. Upon ocular administration, netarsudil inhibits ROCK and the Rho pathway, increases aqueous humor (AH) outflow via the trabecular pathway, and lowers IOP. In addition, netarsudil may lower IOP by decreasing episcleral venous pressure and decreasing the production of aqueous humor through inhibition of NET. ","Netarsudil | NETARSUDIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2001271","Tapentadol","C72139","An orally available, synthetic benzenoid that acts as an agonist for the mu-opioid receptor (MOR) and inhibits the reuptake of noradrenaline, with potential anti-nociceptive activity. Upon oral administration, tapentadol binds to the MOR which enhances MOR-mediated signaling, interferes with the sensation of pain and results in an analgesic effect. Tapentadol also inhibits the reuptake of noradrenaline, which increases the levels of noradrenaline (NA), activates the inhibitory alpha-2 receptors and results in an analgesic effect.","Tapentadol | TAPENTADOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475440","Tumor Size","C120284","The size of a tumor in its greatest dimension.","Tumor Size | ",,,,,,,,,,,,,,,"4139794","Length dimension of neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0449453","Lesion Size","C171342","The size of a lesion in its greatest dimension.","Lesion Size | ",,,,,,,,,,,,,,,"4084390","Lesion size",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1405460","Clinical Status Ordinal Scale","C171345","A scale designed to assess a patient's clinical status at enrollment, prior to any on-study therapy.","Clinical Status Ordinal Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406301","Clinical Status Ordinal Scale Outcome 1","C171346","A status indicating that an individual was discharged at enrollment.","Clinical Status Ordinal Scale Outcome 1 | 1 | Discharge | Discharged at Enrollment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406300","Clinical Status Ordinal Scale Outcome 2","C171347","A status indicating that an individual was admitted to a non-ICU hospital ward at enrollment, but did not require oxygen.","Clinical Status Ordinal Scale Outcome 2 | 2 | Non-ICU, Hospital Ward, No O2 | Non-ICU, hospital ward, NO O2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406298","Clinical Status Ordinal Scale Outcome 3","C171349","A status indicating that an individual was admitted to a non-ICU hospital ward at enrollment, but required oxygen.","Clinical Status Ordinal Scale Outcome 3 | 3 | Non-ICU, Hospital Ward, On O2 | Non-ICU, hospital ward, on O2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406305","Clinical Status Ordinal Scale Outcome 4","C171350","A status indicating that an individual was admitted to either an ICU or non-ICU at enrollment, but required non-invasive ventilatory support or high flow O2.","Clinical Status Ordinal Scale Outcome 4 | 4 | ICU or Non-ICU, Requires Non-Invasive Ventilatory Support or High Flow O2 | ICU or non-ICU, requires non-invasive ventilatory support or high flow O2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205451","5","C171351","A status indicating that an individual was admitted to the ICU at enrollment and required mechanical or imminent ventilation or intubation.","Clinical Status Ordinal Scale Outcome 5 | 5 | ICU Requires Mechanical or Imminent Ventilation or Intubation | ICU requires mechanical or imminent ventilation/intubation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406304","Clinical Status Ordinal Scale Outcome 6","C171352","A status indicating that an individual was admitted to the ICU at enrollment and required ECMO and additional 02 support and organ support.","Clinical Status Ordinal Scale Outcome 6 | 6 | ICU Requires ECMO and Additional O2 Support and Organ Support | ICU requires ECMO and additional O2 support and organ support, e.g. vasopressors, renal replacement therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406308","Clinical Status Ordinal Scale Outcome 7","C171353","A status indicating that an individual was dead at enrollment.","Clinical Status Ordinal Scale Outcome 7 | 7 | Dead at Enrollment | Death",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1381981","COVID-19 Infection","C171133","An acute infection of the respiratory tract that is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Based on currently available information, SARS-CoV-2 is thought to mainly spread from person to person through respiratory droplets. Typically, there is a two- to 14-day incubation period and infected persons can present with no symptoms or mild to severe fever, dry cough, fatigue, and difficulty breathing. Dysgeusia, anosmia, and gastrointestinal and flu-like symptoms have also been reported. Older adults and persons of any age who have serious underlying medical conditions may be of higher risk for severe illness, including secondary infections, respiratory failure, and multi-organ dysfunction.","COVID-19 Infection | 2019-nCoV Infection | Acute COVID-19 | Acute COVID-19 case | COVID-19 | COVID-19 Virus Infection | HCoV-19 Infection | Human Coronavirus 2019 Infection | SARS Coronavirus 2 Infection | SARS Coronavirus 2 Infection | SARS-2 Infection | SARS-CoV-2 Disease | SARS-CoV-2 Infection | SARS-CoV2 Disease | SARS-CoV2 Infection | SARS2 Infection | Severe Acute Respiratory Syndrome Coronavirus 2 Infection",,,,,,,,,,,,,,,"605554","Acute COVID-19",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1405527","Have Trouble Falling Asleep or Staying Asleep","C171421","A question about whether an individual had or has trouble falling asleep or staying asleep because of pictures or thoughts about the event that came to their mind.","Have Trouble Falling Asleep or Staying Asleep | Have Trouble Falling Asleep or Staying Asleep Because of Pictures or Thoughts | I had trouble falling asleep or staying asleep because of pictures or thoughts about it that came to my mind",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383309","Ethyl Sulfate Measurement","C170585","The determination of the amount of ethyl sulfate present in a sample.","Ethyl Sulfate Measurement | ETS | Ethyl Sulfate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382778","Ethyl Glucuronide And Ethyl Sulfate Measurement","C170583","The determination of the amount of ethyl glucuronide and/or ethyl sulfate present in a sample.","Ethyl Glucuronide And Ethyl Sulfate Measurement | ETGETS | Ethyl Glucuronide Ethyl Sulfate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382794","Ethyl Glucuronide Measurement","C170584","The determination of the amount of ethyl glucuronide present in a sample.","Ethyl Glucuronide Measurement | ETG | Ethyl Glucuronide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383303","Antithrombin Actual to Control Ratio Measurement","C170592","The determination of the ratio of the antithrombin in a subject's specimen compared to a control sample. The measurement may be expressed as a ratio or percentage.","Antithrombin Actual to Control Ratio Measurement | ATHMBAC | Antithrombin Actual/Control | Antithrombin Actual/Normal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0428221","Amphetamine Measurement","C75347","The determination of the amount of amphetamine present in a sample.","Amphetamine Measurement | AMPEA | Alpha-Methylphenethylamine | Alpha-Methylphenethylamine Measurement | Amphetamine",,,,,,,,,,,,,,,"4273557","Amphetamine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1382788","Protein S Actual to Control Ratio Measurement","C170593","The determination of the ratio of the protein S in a subject's specimen compared to a control sample. The measurement may be expressed as a ratio or percentage.","Protein S Actual to Control Ratio Measurement | PTSAC | Protein S Actual/Control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382791","von Willebrand Factor Actual to Control Ratio Measurement","C170597","The determination of the ratio of the von Willebrand factor in a subject's specimen compared to a control sample. The measurement may be expressed as a ratio or percentage.","von Willebrand Factor Actual to Control Ratio Measurement | VWFAC | vWF Actual to Control Ratio Measurement | von Will Factor Actual/Control | von Willebrand Factor Actual/Control | von Willebrand Factor Actual/Normal | von Willebrand Factor Actual/von Willebrand Factor Control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202024","Free Thyroxine Index","C170598","A measurement of the thyroid status (function, disease diagnosis, or therapy effectiveness) in a biological specimen. This is calculated by a mathematical formula that takes into account the total thyroxine and unbound thyroxine binding globulins.","Free Thyroxine Index | T4FRIDX | Thyroxine, Free Index",,,,,,,,,,,,,,,"4219024","Free thyroxine index",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1382777","Ritalinic Acid Measurement","C170582","The determination of the amount of ritalinic acid present in a sample.","Ritalinic Acid Measurement | RITALAC | Ritalinic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383304","Renal Epithelial Cells Measurement","C170595","The determination of the amount of renal epithelial cells present in a sample.","Renal Epithelial Cells Measurement | EPIRCE | Renal Epithelial Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382796","Prothrombin Time Actual to Control Ratio Measurement","C170591","The determination of the ratio of the prothrombin time in a subject's specimen compared to a control sample. The measurement may be expressed as a ratio or percentage.","Prothrombin Time Actual to Control Ratio Measurement | PTAC | Prothrombin Time Actual/Control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382790","Free Protein S Actual to Control Ratio Measurement","C170596","The determination of the ratio of the free protein S in a subject's specimen compared to a control sample. The measurement may be expressed as a ratio or percentage.","Free Protein S Actual to Control Ratio Measurement | PTSFAC | Protein S, Free Actual/Control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524188","Methylphenidate Measurement","C170581","The determination of the amount of methylphenidate present in a sample.","Methylphenidate Measurement | METHPHEN | Methylphenidate",,,,,,,,,,,,,,,"4022374","Methylphenidate measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1382787","Factor XIV Actual to Control Ratio Measurement","C170594","The determination of the ratio of the factor XIV in a subject's specimen compared to a control sample. The measurement may be expressed as a ratio or percentage.","Factor XIV Actual to Control Ratio Measurement | FXIVAC | Factor XIV Actual/Control | Protein C Actual/Control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382795","Factor X Actual to Control Ratio Measurement","C170590","The determination of the ratio of the factor X in a subject's specimen compared to a control sample. The measurement may be expressed as a ratio or percentage.","Factor X Actual to Control Ratio Measurement | FXAC | Factor X Actual/Control | Factor X Actual/Normal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382792","Factor X Activity Actual/Control Ratio Measurement","C170586","The determination of the ratio of the biological activity of factor X dependent coagulation in a subject's specimen when compared to the same activity in a control specimen. The measurement may be expressed as a ratio or percentage.","Factor X Activity Actual/Control Ratio Measurement | FXAAC | Factor X Activity Actual/Control | Factor X Activity Actual/Factor X Activity Control | Factor X Activity Actual/Normal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382798","Factor VII Activity Actual to Control Ratio Measurement","C170589","The determination of the ratio of the biological activity of factor VII dependent coagulation in a subject's specimen when compared to the same activity in a control specimen. The measurement may be expressed as a ratio or percentage.","Factor VII Activity Actual to Control Ratio Measurement | FVIIAAC | Factor VII Activity Actual/Control | Factor VII Activity Actual/Factor VII Activity Control | Factor VII Activity Actual/Normal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382793","Factor V Activity Actual to Control Ratio Measurement","C170587","The determination of the ratio of the biological activity of factor V dependent coagulation in a subject's specimen when compared to the same activity in a control specimen. The measurement may be expressed as a ratio or percentage.","Factor V Activity Actual to Control Ratio Measurement | FVAAC | Factor V Activity Actual/Control | Factor V Activity Actual/Factor V Activity Control | Factor V Activity Actual/Normal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382797","Factor IX Activity Actual to Control Ratio Measurement","C170588","The determination of the ratio of the biological activity of factor IX dependent coagulation in a subject's specimen when compared to the same activity in a control specimen. The measurement may be expressed as a ratio or percentage.","Factor IX Activity Actual to Control Ratio Measurement | FIXAAC | Factor IX Activity Actual/Control | Factor IX Activity Actual/Factor IX Activity Control | Factor IX Activity Actual/Normal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405522","How Frequently True","C171427","A question asking an individual how frequently something was true for them.","How Frequently True | How frequently these comments were true",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976725","Adenovirus IgM Antibody Measurement","C163530","The determination of the amount of Adenovirus IgM antibody present in a sample.","Adenovirus IgM Antibody Measurement | ADVIGMAB | Adenovirus IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976726","Adenovirus IgG Antibody Measurement","C163529","The determination of the amount of Adenovirus IgG antibody present in a sample.","Adenovirus IgG Antibody Measurement | ADVIGGAB | Adenovirus IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979101","Aspergillus fumigatus IgG Antibody RAST Score Measurement","C166019","A classification of the amount of Aspergillus fumigatus antigen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Aspergillus fumigatus IgG Antibody RAST Score Measurement | A. fumigatus IgG AB RAST Score | C166019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979113","Aspergillus fumigatus IgE Antibody RAST Score Measurement","C166023","A classification of the amount of Aspergillus fumigatus antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Aspergillus fumigatus IgE Antibody RAST Score Measurement | A. fumigatus IgE AB RAST Score | C166023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979111","Alternaria alternata IgG Antibody RAST Score Measurement","C166021","A classification of the amount of Alternaria alternata antigen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Alternaria alternata IgG Antibody RAST Score Measurement | A. alternata IgG AB RAST Score | A. tenuis alternata IgG AB RAST Score | C166021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979107","Alternaria alternata IgE Antibody RAST Score Measurement","C166025","A classification of the amount of Alternaria alternata antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Alternaria alternata IgE Antibody RAST Score Measurement | A. alternata IgE AB RAST Score | A. tenuis alternata IgE AB RAST Score | C166025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979087","Aspergillus Antibody Measurement","C166028","The determination of the amount of antibody to any member of the genus Aspergillus present in a sample.","Aspergillus Antibody Measurement | ASPAB | Aspergillus Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976748","Chlamydia pneumoniae IgG Antibody Measurement","C163536","The determination of the amount of Chlamydia pneumoniae IgG antibody present in a sample.","Chlamydia pneumoniae IgG Antibody Measurement | CPNIGGAB | Chlamydia pneumoniae IgG Antibody | Chlamydophila pneumoniae IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979105","Campylobacter coli, Campylobacter jejuni and/or Campylobacter upsaliensis DNA Measurement","C166015","The determination of the amount of Campylobacter coli, Campylobacter jejuni and/or Campylobacter upsaliensis DNA present in a sample.","Campylobacter coli, Campylobacter jejuni and/or Campylobacter upsaliensis DNA Measurement | C. coli/jejuni/upsaliensis DNA | C166015 | Campylobacter coli/jejuni/upsaliensis DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976750","Bordetella pertussis Toxin Antibody Measurement","C163534","The determination of the amount of Bordetella pertussis toxin antibody present in a sample.","Bordetella pertussis Toxin Antibody Measurement | BPETXNAB | Bordetella pertussis Toxin Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976724","Bordetella pertussis Serotype Fimbrae 2/3 Antibody Measurement","C163531","The determination of the amount of Bordetella pertussis serotype Fimbrae 2/3 antibody present in a sample.","Bordetella pertussis Serotype Fimbrae 2/3 Antibody Measurement | BPEF23AB | Bordetella pertussis Serotype Fim 2/3 AB | Bordetella pertussis Serotype Fimbriae 2/3 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976722","Bordetella pertussis Pertactin Antibody Measurement","C163533","The determination of the amount of Bordetella pertussis pertactin antibody present in a sample.","Bordetella pertussis Pertactin Antibody Measurement | BPEPRNAB | Bordetella pertussis PRN Antibody | Bordetella pertussis Pertactin Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382802","Human rhinovirus/enterovirus RNA","C170609","The determination of the amount of human rhinovirus/enterovirus RNA present in a sample.","Human rhinovirus and/or enterovirus RNA Measurement | Human rhinovirus/enterovirus RNA | Human rhinovirus/enterovirus RNA Measurement | RVENTRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979081","Rotavirus A RNA Measurement","C166054","The determination of the amount of Rotavirus A RNA present in a sample.","Rotavirus A RNA Measurement | RROARNA | Rotavirus A RNA | Rotavirus Group A RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976723","Bordetella pertussis Filament Haemagglutinin Antibody Measurement","C163532","The determination of the amount of Bordetella pertussis filament haemagglutinin antibody present in a sample.","Bordetella pertussis Filament Haemagglutinin Antibody Measurement | B. pertussis Filament Haemagglutinin AB | BPEFHAAB | Bordetella pertussis FHA Antibody | Bordetella pertussis Filamentous Haemagglutinin Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979088","Cyclospora cayetanensis DNA Measurement","C166029","The determination of the amount of Cyclospora cayetanensis DNA present in a sample.","Cyclospora cayetanensis DNA Measurement | CCADNA | Cyclospora cayetanensis DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979108","Cladosporium herbarum IgE Antibody RAST Score Measurement","C166026","A classification of the amount of Cladosporium herbarum IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Cladosporium herbarum IgE Antibody RAST Score Measurement | C166026 | Cladosporium herbarum IgE AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639341","BPI Short Form - Areas of Pain","C100357","Brief Pain Inventory Short Form (BPI Short Form) On the diagram, shade in the areas where you feel pain.","BPI Short Form - Areas of Pain | BPI2-Areas of Pain | BPI202A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639342","BPI Short Form - Area that Hurts Most","C100358","Brief Pain Inventory Short Form (BPI Short Form) On the diagram, put an X on the area that hurts the most.","BPI Short Form - Area that Hurts Most | BPI2-Area Hurts Most | BPI202B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1275856","Clinical Distant Metastasis TNM Finding","C162610","A clinical finding about one or more characteristics of a specific cancer, following the rules of the TNM classification system as they pertain to evaluating distant metastases.","Clinical Distant Metastasis TNM Finding | Clinical M Category",,,,,,,,,,,,,,,"4164182","cM category",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL278860","Pathologic Distant Metastasis TNM Finding","C48886","A pathologic finding about one or more characteristics of a specific cancer, following the rules of the TNM classification system as they pertain to evaluating distant metastases.","Pathologic Distant Metastasis TNM Finding | Pathologic M Category",,,,,,,,,,,,,,,"4154262","pM category",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL951029","WHO AML Classification of Tumors","C159157","A classification of acute myeloid leukemia tumors by the World Health Organization (WHO).","WHO AML Classification of Tumors | AML World Health Organization (WHO) Classification | WHO_AML",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3494174","Food Insecurity","C171542","An individual's concern about consistent access to sufficient quantities of affordable, nutritious food for an active, healthy life.","Food Insecurity | ",,,,,,,,,,,,,,,"37116643","Food insecurity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL523596","Ramucirumab-Docetaxel Regimen","C136285","A regimen consisting of ramucirumab and docetaxel that is used for the treatment of non-small cell lung cancer (NSCLC).","Docetaxel/Ramucirumab Regimen | Cyramza/Docetaxel Regimen | Docetaxel and Ramucirumab | Ramucirumab-Docetaxel | Ramucirumab-Docetaxel Regimen | Ramucirumab/Docetaxel | Ramucirumab/Docetaxel Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405789","Employment Insecurities","C171544","An individual's concern about the continued existence of their job in the future.","Job Insecurity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563823","Occupational Prestige","C171545","The differential social worth which is ascribed to jobs or occupations.","Occupational Prestige | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279765","Endometrial Clear Cell Adenocarcinoma","C8028","A high-grade endometrial adenocarcinoma characterized by the presence of large neoplastic cells that display at least focal cytoplasmic clearing.  The neoplastic cells form papillary, glandular, or sheet-like structures.","Endometrial Clear Cell Adenocarcinoma | Clear Cell Carcinoma of Endometrium | Clear Cell Carcinoma of the Endometrium | Clear cell carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405818","Household Wealth","C171578","A demographic parameter indicating a family's accumulated financial assets (monetary value of all possessions, minus debt).","Household Wealth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405812","Since Starting Treatment","C171584","Any time after the start of treatment.","Since Starting Treatment | Starting Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979102","Enterotoxigenic Escherichia coli LtA, ST1a, and/or ST1b DNA Measurement","C166012","The determination of the amount of enterotoxigenic Escherichia coli LtA, ST1a and/or ST1b DNA present in a sample.","Enterotoxigenic Escherichia coli LtA, ST1a, and/or ST1b DNA Measurement | C166012 | ETEC LtA/ST1a/ST1b DNA | ETEC LtA/ST1a/ST1b DNA Measurement | Enterotoxigenic Escherichia coli LtA/ST1a/ST1b DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979095","Escherichia coli O157 DNA Measurement","C166037","The determination of the amount of Escherichia coli O157 DNA present in a sample.","Escherichia coli O157 DNA Measurement | EO157DNA | Escherichia coli O157 DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979086","Epstein-Barr DNA Measurement","C166035","The determination of the amount of Epstein-Barr virus DNA present in a sample.","Epstein-Barr DNA Measurement | EBDNA | EBV DNA | Epstein-Barr DNA | Human Herpesvirus 4 DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979103","Enteropathogenic Escherichia coli eae DNA Measurement","C166013","The determination of the amount of enteropathogenic Escherichia coli eae DNA present in a sample.","Enteropathogenic Escherichia coli eae DNA Measurement | C166013 | EPEC eae DNA | EPEC eae DNA Measurement | Enteropathogenic Escherichia coli eae DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979094","Entamoeba histolytica DNA Measurement","C166036","The determination of the amount of Entamoeba histolytica DNA present in a sample.","Entamoeba histolytica DNA Measurement | EHIDNA | Entamoeba histolytica DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979104","Enteroaggregative Escherichia coli pAA Plasmid aggR and/or aatA DNA Measurement","C166014","The determination of the amount of enteroaggregative Escherichia coli pAA plasmid aggR and/or aatA DNA present in a sample.","Enteroaggregative Escherichia coli pAA Plasmid aggR and/or aatA DNA Measurement | C166014 | EAEC pAA Plasmid aggR/aatA DNA | EAEC pAA Plasmid aggR/aatA DNA Measurement | Enteroaggregative Escherichia coli pAA Plasmid aggR/aatA DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382801","Cytomegalovirus pp65 Antigen Measurement","C170608","The determination of the amount of cytomegalovirus pp65 antigen present in a sample.","Cytomegalovirus pp65 Antigen Measurement | CMVP65AG | Cytomegalovirus Phosphoprotein 65 Antigen | Cytomegalovirus pp65 Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979084","Cryptosporidium DNA Measurement","C166033","The determination of the amount of DNA from any member of the genus Cryptosporidium present in a sample.","Cryptosporidium DNA Measurement | CRYPTDNA | Cryptosporidium DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979085","Cryptosporidium Antigen Measurement","C166034","The determination of the amount of antigen from any member of the genus Cryptosporidium present in a sample.","Cryptosporidium Antigen Measurement | CSPORAG | Cryptosporidium Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976749","Corynebacterium diphtheriae Toxoid Antibody Measurement","C163535","The determination of the amount of Corynebacterium diphtheriae toxoid antibody present in a sample.","Corynebacterium diphtheriae Toxoid Antibody Measurement | CDITDAB | Corynebacterium diphtheriae Toxoid Ab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1294596","Coccidioides immitis Antibody Measurement","C166030","The determination of the amount of Coccidioides immitis antibody present in a sample.","Coccidioides immitis Antibody Measurement | CIMAB | Coccidioides immitis Antibody",,,,,,,,,,,,,,,"4007828","Measurement of Coccidioides immitis antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL979083","Coccidioides IgM Antibody Measurement","C166032","The determination of the amount of IgM antibody from any member of the genus Coccidioides present in a sample.","Coccidioides IgM Antibody Measurement | COCCIGM | Coccidioides IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979089","Coccidioides IgG Antibody Measurement","C166031","The determination of the amount of IgG antibody from any member of the genus Coccidioides present in a sample.","Coccidioides IgG Antibody Measurement | COCCIGG | Coccidioides IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976747","Clostridium tetani Toxin Antibody Measurement","C163537","The determination of the amount of Clostridium tetani toxin antibody present in a sample.","Clostridium tetani Toxin Antibody Measurement | CTETXNAB | Clostridium tetani TeNT Antibody | Clostridium tetani Toxin Antibody | Tetanospasmin Antibody | Tetanus Neurotoxin Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979090","Hepatitis B Virus Nucleic Acid Measurement","C166040","The determination of the amount of hepatitis B virus nucleic acid present in a sample.","Hepatitis B Virus Nucleic Acid Measurement | HBNUAC | HBV Nucleic Acid Measurement | Hepatitis B Virus Nucleic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979097","Hepatitis B Virus Core Antigen Measurement","C166039","The determination of the amount of Hepatitis B virus core antigen present in a sample.","Hepatitis B Virus Core Antigen Measurement | HBCAG | Hepatitis B Virus Core Antigen",,,,,,,,,,,,,,,"4234718","Hepatitis B core antigen measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL976746","Hepatitis A Virus IgG Antibody Measurement","C163538","The determination of the amount of Hepatitis A virus IgG antibody present in a sample.","Hepatitis A Virus IgG Antibody Measurement | HAIGGAB | Hepatitis A Virus IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979096","Giardia lamblia DNA Measurement","C166038","The determination of the amount of Giardia lamblia DNA present in a sample.","Giardia lamblia DNA Measurement | GLADNA | Giardia duodenalis DNA | Giardia intestinalis DNA | Giardia lamblia DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979091","Hepatitis C Virus Nucleic Acid Measurement","C166041","The determination of the amount of hepatitis C virus nucleic acid present in a sample.","Hepatitis C Virus Nucleic Acid Measurement | HCNUAC | HCV Nucleic Acid Measurement | Hepatitis C Virus Nucleic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976729","HIV-1 gp41 Antibody Measurement","C163526","The determination of the amount of HIV-1 gp41 antibody present in a sample.","HIV-1 gp41 Antibody Measurement | C163526 | HIV-1 Glycoprotein 41 Antibody | HIV-1 gp41 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976731","HIV-1 gp160 Antibody Measurement","C163524","The determination of the amount of HIV-1 gp160 antibody present in a sample.","HIV-1 gp160 Antibody Measurement | C163524 | HIV-1 Glycoprotein 160 Antibody | HIV-1 gp160 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979093","HIV-1 Antibody and HIV-1 p24 Antigen Measurement","C166043","The determination of the amount of antibody reaction to the HIV-1 virus and the measurement of HIV-1 p24 antigen present in a sample.","HIV-1 Antibody and HIV-1 p24 Antigen Measurement | HIV-1 Antibody + HIV-1 p24 Antigen | HIV1AB24",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979092","Hepatitis E Virus Antigen Measurement","C166042","The determination of the amount of Hepatitis E virus antigen present in a sample.","Hepatitis E Virus Antigen Measurement | HEAG | Hepatitis E Virus Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976745","HIV-1/2 Antigen/Antibody Measurement","C163539","The determination of the amount of HIV-1/HIV-2 antigens and/or HIV-1/HIV-2 antibodies present in a sample.","HIV-1/2 Antigen/Antibody Measurement | HIV-1/2 Antigen/Antibody | HIV12AGB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976732","HIV-1 p31 Antibody Measurement","C163523","The determination of the amount of HIV-1 p31 antibody present in a sample.","HIV-1 p31 Antibody Measurement | C163523 | HIV-1 Protein 31 Antibody | HIV-1 p31 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976730","HIV-1 p24 Antibody Measurement","C163525","The determination of the amount of HIV-1 p24 antibody present in a sample.","HIV-1 p24 Antibody Measurement | C163525 | HIV-1 Protein 24 Antibody | HIV-1 p24 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979099","Human adenovirus 40 and/or Human adenovirus 41 DNA Measurement","C166017","The determination of the amount of Human adenovirus type 40 and/or Human adenovirus type 41 DNA present in a sample.","Human adenovirus 40 and/or Human adenovirus 41 DNA Measurement | C166017 | Human adenovirus 40/41 DNA | Human adenovirus F40/F41 DNA | Mastadenovirus 40/41 DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976734","HIV-2 gp36 Antibody Measurement","C163521","The determination of the amount of HIV-2 gp36 antibody present in a sample.","HIV-2 gp36 Antibody Measurement | C163521 | HIV-2 Glycoprotein 36 Antibody | HIV-2 gp36 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976733","HIV-2 gp140 Antibody Measurement","C163522","The determination of the amount of HIV-2 gp140 antibody present in a sample.","HIV-2 gp140 Antibody Measurement | C163522 | HIV-2 Glycoprotein140 Antibody | HIV-2 gp140 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979073","HIV-2 Antibody And HIV-1 p24 Antigen Measurement","C166044","The determination of the amount of antibody reaction to the HIV-2 virus and the measurement of HIV-1 p24 antigen present in a sample.","HIV-2 Antibody And HIV-1 p24 Antigen Measurement | HIV-2 Antibody + HIV-1 p24 Antigen | HIV2AB24",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979075","Lactobacillus crispatus DNA Measurement","C166046","The determination of the amount of Lactobacillus crispatus DNA present in a sample.","Lactobacillus crispatus DNA Measurement | LCRDNA | Lactobacillus crispatus DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976744","JC Virus DNA Measurement","C163540","The determination of the amount of JC virus DNA present in a sample.","JC Virus DNA Measurement | JC Polyomavirus DNA | JC Virus DNA | JCV DNA | JCVDNA | John Cunningham Virus DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979098","Human astrovirus 1, 2, 3, 4, 5, 6, 7, and/or 8 RNA Measurement","C166016","The determination of the amount of Human astrovirus 1, 2, 3, 4, 5, 6, 7 and/or 8 RNA present in a sample.","Human astrovirus 1, 2, 3, 4, 5, 6, 7, and/or 8 RNA Measurement | C166016 | Human astrovirus 1/2/3/4/5/6/7/8 RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976727","Malassezia Species IgE Antibody Measurement","C163528","The determination of the amount of Malassezia species IgE antibody present in a sample.","Malassezia Species IgE Antibody Measurement | C163528 | Malassezia IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979109","Penicillium chrysogenum IgE Antibody RAST Score Measurement","C166027","A classification of the amount of Penicillium chrysogenum IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Penicillium chrysogenum IgE Antibody RAST Score Measurement | C166027 | Penicillium chrysogenum IgE AB RAST Score | Penicilliumchrysogenum IgE AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979110","Penicillium notatum IgG Antibody RAST Score Measurement","C166020","A classification of the amount of Penicillium notatum antigen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Penicillium notatum IgG Antibody RAST Score Measurement | C166020 | P. notatum IgG AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979106","Penicillium notatum IgE Antibody RAST Score Measurement","C166024","A classification of the amount of Penicillium notatum antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Penicillium notatum IgE Antibody RAST Score Measurement | C166024 | P. notatum IgE AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979071","Norwalk virus RNA Measurement","C166050","The determination of the amount of Norwalk virus RNA present in a sample.","Norwalk virus RNA Measurement | NOVRNA | Norwalk calicivirus RNA | Norwalk virus RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979124","Norovirus Genogroup II.4 IgM Antibody Measurement","C166007","A measurement of Norovirus genogroup II.4 IgM antibody present in a sample.","Norovirus Genogroup II.4 IgM Antibody Measurement | C166007 | Norovirus GII.4 IgM antibody | Norovirus Genogroup GII.4 IgM antibody | Norovirus Genogroup II.4 IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979122","Norovirus Genogroup II.4 IgG Antibody Measurement","C166005","A measurement of Norovirus genogroup II.4 IgG antibody present in a sample.","Norovirus Genogroup II.4 IgG Antibody Measurement | C166005 | Norovirus GII.4 IgG antibody | Norovirus Genogroup GII.4 IgG antibody | Norovirus Genogroup II.4 IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979123","Norovirus Genogroup II.4 IgA Antibody Measurement","C166006","A measurement of Norovirus genogroup II.4 IgA antibody present in a sample.","Norovirus Genogroup II.4 IgA Antibody Measurement | C166006 | Norovirus GII.4 IgA antibody | Norovirus Genogroup GII.4 IgA antibody | Norovirus Genogroup II.4 IgA Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979072","Norovirus Genogroup II RNA Measurement","C166051","A measurement of Norovirus genogroup II RNA present in a sample.","Norovirus Genogroup II RNA Measurement | Human Calicivirus Genogroup 2 RNA | NVGIIRNA | Norovirus GII RNA | Norovirus Genogroup II RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979120","Norovirus Genogroup I and/or II RNA Measurement","C166011","A measurement of Norovirus genogroup I and/or II RNA present in a sample.","Norovirus Genogroup I and/or II RNA Measurement | C166011 | Norovirus GI/GII RNA | Norovirus Genogroup I/II RNA | Norovirus genogroup I and/or genogroup II RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979079","Norovirus Genogroup I RNA Measurement","C166052","A measurement of Norovirus genogroup I RNA present in a sample.","Norovirus Genogroup I RNA Measurement | Human Calicivirus Genogroup 1 RNA | NVGIRNA | Norovirus GI RNA | Norovirus Genogroup 1 RNA | Norovirus Genogroup I RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979070","Mycoplasma pneumophila IgM Antibody Measurement","C166049","The determination of the amount of Mycoplasma pneumophila IgM antibody present in a sample.","Mycoplasma pneumophila IgM Antibody Measurement | MPPIGMAB | Mycoplasma pneumophila IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979069","Mycoplasma pneumophila IgG Antibody Measurement","C166048","The determination of the amount of Mycoplasma pneumophila IgG antibody present in a sample.","Mycoplasma pneumophila IgG Antibody Measurement | MPPIGGAB | Mycoplasma pneumophila IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976741","Mycoplasma pneumoniae IgM Antibody Measurement","C163543","The determination of the amount of Mycoplasma pneumoniae IgM antibody present in a sample.","Mycoplasma pneumoniae IgM Antibody Measurement | MPNIGMAB | Mycoplasma pneumoniae IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976742","Mycoplasma pneumoniae IgA Antibody Measurement","C163542","The determination of the amount of Mycoplasma pneumoniae IgA antibody present in a sample.","Mycoplasma pneumoniae IgA Antibody Measurement | MPNIGAAB | Mycoplasma pneumoniae IgA Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979282","Mycoplasma genitalium Measurement","C166047","The determination of the amount of Mycoplasma genitalium present in a sample.","Mycoplasma genitalium Measurement | MGE | Mycoplasma genitalium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976743","Mumps Virus IgM Antibody Measurement","C163541","The determination of the amount of Mumps virus IgM antibody present in a sample.","Mumps Virus IgM Antibody Measurement | MMPIGMAB | Mumps Rubulavirus IgM Antibody | Mumps Virus IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979100","Mucor racemosus IgG Antibody RAST Score Measurement","C166018","A classification of the amount of Mucor racemosus IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Mucor racemosus IgG Antibody RAST Score Measurement | C166018 | Mucor racemosus IgG AB RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979112","Mucor racemosus IgE Antibody RAST Score Measurement","C166022","A classification of the amount of Mucor racemosus antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.","Mucor racemosus IgE Antibody RAST Score Measurement | C166022 | Mucor racemosus IgE AB RAST Score | Mucor racemosus IgE RAST Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976740","Rubella IgM Antibody Measurement","C163544","The determination of the amount of Rubella IgM antibody present in a sample.","Rubella IgM Antibody Measurement | RUBIGMAB | Rubella IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979080","Plesiomonas shigelloides DNA Measurement","C166053","The determination of the amount of Plesiomonas shigelloides DNA present in a sample.","Plesiomonas shigelloides DNA Measurement | PSHDNA | Plesiomonas shigelloides DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979078","Yersinia enterocolitica DNA Measurement","C166059","The determination of the amount of Yersinia enterocolitica DNA present in a sample.","Yersinia enterocolitica DNA Measurement | YENDNA | Yersinia enterocolitica DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979077","Vibrio cholerae DNA Measurement","C166058","The determination of the amount of Vibrio cholerae DNA present in a sample.","Vibrio cholerae DNA Measurement | VCHDNA | Vibrio cholerae DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979117","Vibrio cholerae, Vibrio parahaemolyticus, and/or Vibrio vulnificus DNA Measurement","C166008","The determination of the amount of Vibrio cholerae, Vibrio parahaemolyticus, and/or Vibrio vulnificus DNA present in a sample.","Vibrio cholerae, Vibrio parahaemolyticus, and/or Vibrio vulnificus DNA Measurement | C166008 | V. chol/parahaemolyticus/vulnificus DNA | Vibrio cholerae/parahaemolyticus/vulnificus DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979076","Toxoplasma gondii IgG and/or IgM Antibody Measurement","C166057","The determination of the amount of Toxoplasma gondii IgG and/or IgM antibody present in a sample.","Toxoplasma gondii IgG and/or IgM Antibody Measurement | TGOGMAB | Toxoplasma gondii IgG/IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979118","Shigella and/or Enteroinvasive Escherichia coli ipaH DNA Measurement","C166009","The determination of the amount of invasion plasmid antigen H DNA from any members of the genus Shigella and/or enteroinvasive Escherichia coli present in a sample.","Shigella and/or Enteroinvasive Escherichia coli ipaH DNA Measurement | C166009 | Invasion Plasmid Antigen H Gene | Shigella species and/or Enteroinvasive Escherichia coli Invasion Plasmid Antigen H DNA | Shigella/EIEC ipaH DNA | ipaH gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1294634","Schistosoma mansoni Antibody Measurement","C166056","The determination of the amount of Schistosoma mansoni antibody present in a sample.","Schistosoma mansoni Antibody Measurement | SMAAB | Schistosoma mansoni Antibody",,,,,,,,,,,,,,,"4047033","Measurement of Schistosoma mansoni antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL979119","Sapovirus Genogroups I, II, IV, and/or V RNA Measurement","C166010","The determination of the amount of Sapovirus genogroups I, II, IV and/or V RNA present in a sample.","Sapovirus Genogroups I, II, IV, and/or V RNA Measurement | C166010 | Sapovirus Genogroups I/II/IV/V RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979082","Salmonella enterica and/or Salmonella bongori DNA Measurement","C166055","The determination of the amount of Salmonella enterica and/or Salmonella bongori DNA present in a sample.","Salmonella enterica and/or Salmonella bongori DNA Measurement | SENBODNA | Salmonella enterica/bongori DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382819","Specific Airway Volume","C170618","A parameter used in functional respiratory imaging, derived by dividing the airway volume of a specified intrapulmonary region by the total volume of the same specified intrapulmonary region.","Specific Airway Volume | SAWVOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976930","Relative Size Change","C163556","An assessment of the size difference in comparison to a baseline or previous value.","Relative Size Change | RELSZCHG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382821","Percent Predicted Specific Airway Volume","C170622","A parameter used in functional respiratory imaging, derived by dividing the airway volume of a specified intrapulmonary region by the total volume of the same specified intrapulmonary region, expressed as a proportion of the predicted normal value.","Percent Predicted Specific Airway Volume | SAWVOLPP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382814","Percent Predicted Specific Airway Resistance","C170624","A measurement used to describe airway behavior irrespective of lung volume; it is calculated as airway resistance (Raw) multiplied by functional residual capacity (FRC), as a proportion of the predicted normal value.","Percent Predicted Specific Airway Resistance | Percent Predicted Sp Airway Resistance | SRAWPP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382813","Percent Predicted Forced Expiratory Volume in 3 Seconds","C170627","Forced expiratory volume in three seconds as a proportion of the predicted normal value.","Percent Predicted Forced Expiratory Volume in 3 Seconds | FEV3PP | Percent Predicted FEV3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382824","Percent Predicted Airway Volume","C170621","The total volume of gas in a specified airway or set of airways at a specified point in time in the respiratory cycle, expressed as a proportion of the predicted normal value.","Percent Predicted Airway Volume | AWVOLPP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382822","Percent Predicted Airway Resistance","C170623","A measurement of respiratory tract resistance to airflow during inspiration and expiration, as a proportion of the predicted normal value.","Percent Predicted Airway Resistance | RAWPP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382815","Forced Expiratory Volume in 3 Seconds to Forced Vital Capacity Ratio Measurement","C170625","A relative measurement (ratio or percentage) of the forced expiratory volume during the first three seconds of exhalation to the largest observed expired volume during a forced vital capacity maneuver.","Forced Expiratory Volume in 3 Seconds to Forced Vital Capacity Ratio Measurement | FEV3/FVC | FEV3FVC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382812","Forced Expiratory Volume in 1 Second to Slow Vital Capacity Ratio Measurement","C170626","A relative measurement (ratio or percentage) of the forced expiratory volume during the first second of exhalation to the largest observed expired volume during a slow vital capacity maneuver.","Forced Expiratory Volume in 1 Second to Slow Vital Capacity Ratio Measurement | FEV1/SVC | FEV1SVC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053803","Expiration Relaxation Time","C120931","The amount of time required to reach a specific tidal volume as measured from the start of exhalation.","Expiration Relaxation Time | EXPRELTM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382820","Airway Wall Volume","C170619","The volume of the entirety of the airway tissue in a specified intrapulmonary region.","Airway Wall Volume | AWWVOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382823","Air Trapping Measurement","C170620","A measurement of the gas retention in a specified intrapulmonary space at the end of exhalation.","Air Trapping Measurement | AIRTRAP | Air Trapping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405810","EPA Air Quality Index","C171587","A nationally uniform color-coded index developed by EPA for reporting and forecasting daily air quality. The AQI reports the most common ambient air pollutants that are regulated under the Clean Air Act, including ozone and particle pollution. The AQI informs the public about air quality in the area, tells who may be affected, and provides steps to take to reduce exposure when pollution levels are unhealthy.","EPA Air Quality Index | AQI | Air Quality Index | Environmental Protection Agency (EPA) Air Quality Index",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405809","Concentrated Poverty Index","C171588","Describes geospatial areas such as neighborhoods or census tracts where high poverty households are prevalent and community resources are likely to be limited. It is defined by the US census as areas where 40 percent or more of the tract population is living below the federal poverty threshold.","Concentrated Poverty Index | Concentrated Poverty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406312","California Health Interview Survey","C171589","A California state-wide survey designed to yield comprehensive data on the health of Californians. It gathers data on a wide range of health topics, including asthma, diabetes, obesity, immigrant health, and health insurance coverage.","California Health Interview Survey | CHIS | Disparate Health Care Quality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406322","Community Educational Attainment","C171590","A measure of the percentage of people with a college degree living in a census unit, based on data from the U.S. Census Bureau.","Community Educational Attainment | Educational Attainment | Educational Attainment - Community",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405808","English Proficiency Test","C171591","An individual-level measurement of spoken English language proficiency.","English Proficiency Test | English Proficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405807","Environmental Justice Screening and Mapping Tool","C171592","A tool that allows users to access environmental and demographic information for locations in the United States at the census block level.","Environmental Justice Screening and Mapping Tool | EJSCREEN | EPA Environmental Justice Screening and Mapping Tool | Environmental Justice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405806","USDA Six-Item Standard Measure","C171593","A six-item standard measure from the U.S. Department of Agriculture Economic Research Service designed to measure an individual's or family's availability, accessibility, and affordability of nutritionally adequate food.","USDA Six-Item Standard Measure | Food Insecurity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405829","Traditional Retail Food Environment Index","C171594","An index derived from the Food Environment Atlas that calculates for a county the number of fast food restaurants and convenience stores divided by the number of grocery stores and supermarkets.","Traditional Retail Food Environment Index | Food Swamp | RFEI | Retail Food Environment Index",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406321","Health Literacy","C171595","A questionnaire that is used to assess an adult's health literacy level, the degree to which individuals have the capacity to obtain, process, and understand basic health information and services needed to make appropriate health decisions.","Short Assessment of Health Literacy-English | Health Literacy | SAHL-E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405828","Numeracy Understanding in Medicine Instrument","C171596","A tool designed to assess the degree to which an individual has the capacity to understand and apply health information conveyed with numbers, tables, graphs, probabilities, and statistics.","Numeracy Understanding in Medicine Instrument | Health Numeracy | NUMi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406311","General Social Survey","C171597","A survey designed to assess an individual's perception of how likely it is that they will lose their job in the next 12 months and their ability to find another job.","General Social Survey | GSS | Job Insecurity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405827","Current Population Survey, Labor Force Items","C171598","Selected items from the U.S. Census Bureau Current Population Survey used to determine the percentage of wage and salary workers who are members of unions or are covered by union agreements in the private and public sectors of the non-agricultural labor force, aggregated by state and metropolitan area.","Current Population Survey, Labor Force Items | Percent Unionized for Non-Agricultural Labor Force",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407061","American Community Survey","C171599","Data extracted from the U.S. Census to determine the degree of race/ethnic residential segregation, the degree to which various groups reside in different neighborhoods.","American Community Survey | ACS | Race/Ethnic Residential Segregation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405826","Social Vulnerability Index","C171600","An index that evaluates census tracts on 15 social factors, including unemployment, minority status, and disability, and groups them into four related themes: socioeconomic, household composition and disability, minority status and language, and housing and transportation.","Social Vulnerability Index | SVI | Social Vulnerability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405825","Panel Study of Income Dynamics, Wealth Supplement","C171601","A tool designed to a family's accumulated financial assets (monetary value of all possessions, minus debt).","Panel Study of Income Dynamics, Wealth Supplement | Household Wealth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3658315","Social Determinants of Health","C171586","The conditions in which people are born, grow, live, work and age. They include socioeconomic status, education, neighborhood and physical environment, employment, and social support networks, as well as access to health care.","Social Determinants of Health | SDoH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205157","Remote","C171936","Far away in distance or space; happening at a distance.","Remote | Remotely",,,,,,,,,,,,,,,"4209878","Remote",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1382912","Airway Volume","C170457","The total volume of gas in a specified airway or set of airways at a specified point in time in the respiratory cycle.","Airway Volume | AWVOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405837","HRAS Positive","C171617","An indication that HRAS expression has been detected in a sample.","HRAS Positive | C-HA-RAS1 Positive | GTPase HRas Positive | H-Ras Positive | HRAS1 Positive | Ha-Ras Positive | Ha-Ras-1 Positive | Ha-Ras1 Positive | Harvey Rat Sarcoma Viral Oncogene Homolog Positive | RASH1 Positive | c-H-Ras Positive | p21 H-Ras Positive | v-Ha-Ras Harvey Rat Sarcoma Viral Oncogene Homolog Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405836","NRAS Positive","C171618","An indication that NRAS expression has been detected in a sample.","NRAS Positive | GTPase NRas Positive | N-Ras Positive | Neuroblastoma RAS Viral Oncogene Homolog Positive | p21 N-Ras Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405835","MDM2 Gene Amplification Negative","C171619","An indication that amplification of the MDM2 gene was not detected in a sample.","MDM2 Gene Amplification Negative | ACTFS Gene Amplification Negative | Double Minute 2 Homolog Gene Amplification Negative | HDMX Gene Amplification Negative | MDM2 Amplification Negative | MDM2 Proto-Oncogene Gene Amplification Negative | MDM2 Proto-Oncogene, E3 Ubiquitin Protein Ligase Gene Amplification Negative | Mouse Double Minute 2 Homolog Gene Amplification Negative | hdm2 Gene Amplification Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405834","Monoallelic MUTYH Gene Mutation","C171620","The presence of mutations in only one allele of the MUTYH gene.","Monoallelic MUTYH Gene Mutation | Monoallelic MUTYH Mutation | Monoallelic MYH Gene Mutation | Monoallelic MutY (E. Coli) Homolog Gene Mutation | Monoallelic MutY DNA Glycosylase Gene Mutation | Monoallelic MutY Homolog (E. coli) Gene Mutation | Monoallelic MutY Homolog Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405833","iFGF23 Level Greater Than or Equal to 100 pg/mL","C171622","A finding indicating that the amount of the intact fibroblast growth factor 23 in a sample is greater than or equal to 100 pg/mL.","iFGF23 Level Greater Than or Equal to 100 pg/mL | Intact FGF23 Level Greater Than or Equal to 100 pg/mL | Intact Fibroblast Growth Factor 23 Level Greater than or Equal to 100 pg/mL | iFGF23 Level Greater Than or Equal to 100",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405832","del(5q31)","C171623","A cytogenetic abnormality that refers to any loss of genetic material from the long arm of chromosome 5 that includes the band at 5q31.","del(5q31) | 5q Deletion Including 5q31 Deletion | 5q31 Deletion | Chromosome 5q31 Deletion | Loss of 5q31 | Loss of Chromosome 5q Including 5q31",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405831","del(12p13.2)","C171624","A cytogenetic abnormality that refers to any loss of genetic material from the short arm of chromosome 12 that includes the band at 12p13.2.","del(12p13.2) | 12p Deletion Including 12p13.2 Deletion | 12p13.2 Deletion | Chromosome 12p13.2 Deletion | Loss of 12p13.2 | Loss of Chromosome 12p Including 12p13.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405830","Rearrangement of 11p15","C171625","A cytogenetic abnormality indicating the presence of rearrangement involving the short arm segment p15 of chromosome 11.","Rearrangement of 11p15 | 11p15 Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405859","Rearrangement of 12p13.2","C171626","A cytogenetic abnormality indicating the presence of rearrangement involving the short arm segment p12.3 of chromosome 12.","Rearrangement of 12p13.2 | 12p13.2 Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405856","DNA Topoisomerase 1 Cleavable Complex","C171629","A complex between the enzyme DNA topoisomerase 1 (TOP1) and its DNA substrate. Under normal conditions these complexes are transient and found at low levels. In the presence of therapeutic TOP1 inhibitors these complexes are stabilized, which prevents DNA religation and induces lethal DNA strand breaks.","DNA Topoisomerase 1 Cleavable Complex | DNA Topoisomerase I Cleavable Complex | TOP1-DNA Intermediate | TOPI Cleavable Complex | Top1 Cleavable Complex | Topo I Cleavable Complex | Topoisomerase 1 Cleavable Complex | Topoisomerase I Cleavable Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405855","HLA Class I Histocompatibility Antigen, B-5501 Alpha Chain","C171630","HLA class I histocompatibility antigen, B-5501 alpha chain (362 aa, ~40 kDa) is encoded by the human HLA-B gene. This protein is involved in the presentation of foreign antigens to the immune system.","HLA Class I Histocompatibility Antigen, B-5501 Alpha Chain | HLA-B*5501 | HLA-B*55:01 | Human Leukocyte Antigen B-5501 | MHC Class I Antigen B*5501",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405853","HLA Class I Histocompatibility Antigen, B-3508 Alpha Chain","C171632","HLA class I histocompatibility antigen, B-3508 alpha chain (362 aa, ~40 kDa) is encoded by the human HLA-B gene. This protein plays a role in antigen presentation and viral immunity.","HLA Class I Histocompatibility Antigen, B-3508 Alpha Chain | HLA-B*3508 | HLA-B*35:08 | Human Leukocyte Antigen B-3508 | MHC Class I Antigen B*3508",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405849","HLA Class II Histocompatibility Antigen, DR Beta 3-0202 Chain","C171636","HLA class II histocompatibility antigen, DR beta 3-0202 chain (266 aa, ~30 kDa) is encoded by the human HLA-DRB3 gene. This protein is involved in antigen presentation. Expression of this serotype is associated with type 1 diabetes mellitus, Graves disease, acute necrotizing encephalopathy and sarcoidosis.","HLA Class II Histocompatibility Antigen, DR Beta 3-0202 Chain | DR52b | HLA Class II Histocompatibility Antigen, DRB3-0202 Beta Chain | HLA-DRB3*0202 | HLA-DRB3*02:02 | MHC Class II Antigen DRB3*0202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405851","HLA Class I Histocompatibility Antigen, C-0401 Alpha Chain","C171634","HLA class I histocompatibility antigen, C-0401 alpha chain (366 aa, ~41 kDa) is encoded by the human HLA-C gene. This protein plays a role in the presentation of viral epitopes to the immune system.","HLA Class I Histocompatibility Antigen, C-0401 Alpha Chain | HLA Class I Histocompatibility Antigen, C-0401 Alpha Chain Protein | HLA-C*0401 | HLA-C*04:01 | Human Leukocyte Antigen C-0401 | MHC Class I Antigen C*0401",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405848","HLA Class II Histocompatibility Antigen, DR Beta 3-0101 Chain","C171637","HLA class II histocompatibility antigen, DR beta 3-0101 chain (266 aa, ~30 kDa) is encoded by the human HLA-DRB3 gene. This protein plays a role in antigen presentation. Expression of this serotype is associated with type 1 diabetes mellitus, sarcoidosis, Lofgren syndrome and Graves disease.","HLA Class II Histocompatibility Antigen, DR Beta 3-0101 Chain | DR52a | HLA Class II Histocompatibility Antigen, DRB3-0101 Beta Chain | HLA class II Histocompatibility Antigen, DR Beta 3 Chain | HLA-DRB3*0101 | HLA-DRB3*01:01 | MHC Class II Antigen DRB3 | MHC Class II Antigen DRB3*0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405850","HLA Class I Histocompatibility Antigen, C-0102 Alpha Chain","C171635","HLA class I histocompatibility antigen, C-0102 alpha chain (366 aa, ~41 kDa) is encoded by the human HLA-C gene. This protein is involved in the inhibition of immunosuppression and the promotion of lysis of infected cells.","HLA Class I Histocompatibility Antigen, C-0102 Alpha Chain | HLA Class I Histocompatibility Antigen, C-0102 Alpha Chain Protein | HLA-C*0102 | HLA-C*01:02 | Human Leukocyte Antigen C-0102 | MHC Class I Antigen C*0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405847","CA125 to CEA Ratio Greater than or Equal to 25","C171638","An indication that the ratio of CA125 antigen to carcinoembryonic antigen (CEA) found in a sample is greater than or equal to 25.","CA125 to CEA Ratio Greater than or Equal to 25 | CA-125 to CEA Ratio Greater than or Equal to 25 | CA-125/CEA Ratio Greater than or Equal to 25 | CA125/CEA Ratio Greater than or Equal to 25 | CA125:CEA Greater than or Equal to 25 | Cancer Antigen 125 to Carcinoembryonic Antigen Ratio Greater than or Equal to 25 | Cancer Antigen 125/Carcinoembryonic Antigen Ratio Greater than or Equal to 25 | Cancer Antigen 125:Carcinoembryonic Antigen Ratio Greater than or Equal to 25",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405846","CD37 Positive","C171639","An indication that CD37 expression has been detected in a sample.","CD37 Positive | CD37 Antigen Positive | CD37 Molecule Positive | Cell Differentiation Antigen 37 Positive | GP52-40 Positive | Leukocyte Antigen CD37 Positive | Leukocyte Surface Antigen CD37 Positive | TSPAN26 Positive | Tetraspanin-26 Positive | Tspan-26 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405845","SLFN11 Positive","C171640","An indication that SLFN11 expression has been detected in a sample.","SLFN11 Positive | SLFN8/9 Positive | Schlafen Family Member 11 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405844","UGT1A1*6 Allele","C171641","Human UGT1A1*6 allele is located in the vicinity of 2q37 and is approximately 13 kb in length. This allele, which encodes UDP-glucuronosyltransferase 1-1*6 protein, plays a role in the transformation of small lipophilic molecules into water-soluble metabolites. Homozygous expression of the UGT1A1*6 allele is associated with decreased enzymatic activity and Gilbert syndrome, neonatal hyperbilirubinemia and intermittent unconjugated hyperbilirubinemia.","UGT1A1*6 Allele | NM_000463.3:c.211G>A | UDP Glucuronosyltransferase Family 1 Member A1 c.211G>A | UDP Glucuronosyltransferase Family 1 Member A1*6 Allele | UDP Glycosyltransferase 1 Family, Polypeptide A1 c.211G>A | UDP Glycosyltransferase 1 Family, Polypeptide A1*6 Allele | UGT1A1 NM_000463.3:c.211G>A | UGT1A1 c.211G>A | UGT1A1*6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405637","UGT1A1*60 Allele","C171642","Human UGT1A1*60 allele is located in the vicinity of 2q37 and is approximately 13 kb in length. This allele, which encodes UDP-glucuronosyltransferase 1-1 protein, plays a role in the catabolism of small lipophilic molecules. Homozygous expression of the UGT1A1*60 allele is associated with Crigler-Najjar syndrome type II and heterozygous expression is associated with Gilbert syndrome.","UGT1A1*60 Allele | UDP Glucuronosyltransferase Family 1 Member A1 c.-3279T>G | UDP Glucuronosyltransferase Family 1 Member A1*60 Allele | UDP Glycosyltransferase 1 Family, Polypeptide A1 c.-3279T>G | UDP Glycosyltransferase 1 Family, Polypeptide A1*60 Allele | UGT1A1 c.-3279T>G | UGT1A1*60",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405634","ERBB2 NP_004439.2:p.C805S","C171645","A change in the amino acid residue at position 805 in the receptor tyrosine-protein kinase erbB-2 protein where cysteine has been replaced by serine.","ERBB2 NP_004439.2:p.C805S | ERBB2 C805S | ERBB2 Cys805Ser | ERBB2 NP_004439.2:p.Cys805Ser | ERBB2 p.C805S | ERBB2 p.Cys805Ser | HER2 C805S | HER2 C805S Mutation | HER2 Cys805Ser | NP_004439.2:p.C805S | NP_004439.2:p.Cys805Ser | Proto-Oncogene Neu C805S | Proto-Oncogene Neu Cys805Ser | Receptor Tyrosine-Protein Kinase erbB-2 C805S | Receptor Tyrosine-Protein Kinase erbB-2 Cys805Ser | Tyrosine Kinase-Type Cell Surface Receptor HER2 C805S | Tyrosine Kinase-Type Cell Surface Receptor HER2 Cys805Ser",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405633","Lymphoblasts 5 Percent or Less of Bone Marrow Nucleated Cells","C171646","A semi-quantitative microscopic finding indicating that 5 percent or less of the nucleated cells in a bone marrow sample are immature mononuclear cells of lymphoid origin.","Lymphoblasts 5 Percent or Less of Bone Marrow Nucleated Cells | Lymphoblasts Less than or Equal to 5 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405631","SARS Coronavirus 2 IgM Antibody Positive","C171648","An indication that antibodies of the IgM class that recognize SARS coronavirus 2 have been detected in a sample.","SARS Coronavirus 2 IgM Antibody Positive | 2019 Novel Coronavirus IgM Antibody Positive | 2019 Novel Coronavirus IgM Positive | 2019-nCoV IgM Antibody Positive | 2019-nCoV IgM Positive | Anti-2019 Novel Coronavirus IgM Antibody Positive | Anti-2019-nCoV IgM Antibody Positive | Anti-SARS Coronavirus 2 IgM Antibody Positive | Anti-SARS-2 IgM Antibody Positive | Anti-SARS-CoV-2 IgM Antibody Positive | Anti-SARS2 IgM Antibody Positive | Anti-Severe Acute Respiratory Syndrome Coronavirus 2 IgM Antibody Positive | Anti-nCoV IgM Antibody Positive | SARS Coronavirus 2 IgM Positive | SARS-2 IgM Antibody Positive | SARS-2 IgM Positive | SARS-CoV-2 IgM Antibody Positive | SARS-CoV-2 IgM Positive | SARS2 IgM Antibody Positive | SARS2 IgM Positive | Severe Acute Respiratory Syndrome Coronavirus 2 IgM Antibody Positive | Severe Acute Respiratory Syndrome Coronavirus 2 IgM Positive | nCoV IgM Antibody Positive | nCoV IgM Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405632","SARS Coronavirus 2 Positive","C171647","An indication that SARS coronavirus 2 has been detected in a sample.","SARS Coronavirus 2 Positive | 2019 Novel Coronavirus Positive | 2019-nCoV Positive | COVID-19 Virus Positive | SARS-2 Positive | SARS-CoV-2 Positive | SARS2 Positive | Severe Acute Respiratory Syndrome Coronavirus 2 Positive | nCoV Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698313","B Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities","C80328","B lymphoblastic leukemias/lymphomas characterized by the presence of recurring cytogenetic and/or molecular abnormalities.","B Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities | B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0451226","Impact of Events Scale","C171621","A set of 15 questions designed to measure the amount of distress a person associates with a specific event by assessing the frequency with which they experience intrusive thoughts and avoidant behaviors.","Impact of Events Scale | IES",,,,,,,,,,,,,,,"4164980","Impact of event scale",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4228215","Liver Fibrosis","C168581","A condition in which the liver parenchyma is replaced by fibrous tissue. It may progress to cirrhosis of the liver.","Liver Fibrosis | Hepatic fibrosis | Hepatic fibrosis, unspecified",,,,,,,,,,,,,,,"4267417","Hepatic fibrosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517911","Liver Acinus Zone 1","C32993","An area of hepatocytes that are closest to an arteriole. Because of their close proximity to oxygenated blood, the cells in this zone carry out oxidative processes such as beta-oxidation, cholesterol synthesis and gluconeogenesis.","Liver Acinus Zone 1 | Periportal Zone | Zone 1 | Zone 1 of Liver Acinus | Zone 1 of Lliver Acinus | Zone 1 of the Liver Acinus | Zone 1 of the Lliver Acinus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406231","Cytoplasmic Immunoglobulin","C172121","Immunoglobulins found within intact cells. The proportion of cells expressing cytoplasmic immunoglobulin can be a diagnostic criterion in B-cell lymphoproliferative disorders.","Cytoplasmic Immunoglobulin | CyIg | Cytoplasmic Ig | Immunoglobulin, Cytoplasmic | cIg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406230","Splenic Function","C172122","The way the spleen is working with regard to immune surveillance and phagocytosis of circulating blood elements. Patients with diminished splenic function are at risk for immune dysfunction and increased risk of infection.","Splenic Function | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406229","WHO Quality of Life Measure - Spirituality, Religion and Personal Beliefs","C172123","A questionnaire consisting of 32 questions, covering 8 quality of life aspects, that ask about an individual's spiritual, religious, or personal beliefs and how these beliefs affect their quality of life, including positive feelings, social support, self-esteem, pain, energy, work capacity, health and social care, and leisure activities.","WHO Quality of Life Measure - Spirituality, Religion and Personal Beliefs | Spirituality, Religiousness and Personal Beliefs (SRPB) | WHOQOL Spirituality, Religiousness and Personal Beliefs (SRPB) Field-Test Instrument | WHOQOL-SRPB | WHOQOL-SRPB Field Test Instrument | World Health Organization Quality of Life Measure, Spirituality, Religion and Personal Beliefs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086638","Number of Episodes","C124281","A measurement of the total number of events that have occurred.","Number of Episodes | EPSDNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405545","Endotracheal Fluid","C171504","The fluid collected from the lumen of the trachea.","Endotracheal Fluid | ENDOTRACHEAL FLUID | ETA Fluid | Endotracheal Aspirate Fluid | Tracheal Aspirate | Tracheal Aspirate Fluid",,,,,,,,,,,,,,,"40483760","Specimen from trachea obtained by aspiration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1405543","Estimated Fluid Output","C171508","A measurement of the total volume of fluid discharged over a set period of time.","Estimated Fluid Output | FLUDOUTE | Fluid Output, Estimated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406325","Fluid Output","C171455","A measurement of the total volume of fluid discharged over a set period of time.","Fluid Output | FLUIDOUT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937754","Visual Analog Scale (50 mm)","C158269","A type of visual analog scale composed of a 50mm vertical or horizontal line.","Visual Analog Scale (50 mm) | 50mm VAS | 50mm Visual Analog Scale | VAS (50 mm) | VISUAL ANALOG SCALE (50 MM)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937757","Visual Analog Scale (100 mm)","C158268","A type of visual analog scale composed of a 100mm vertical or horizontal line.","Visual Analog Scale (100 mm) | 100mm VAS | 100mm Visual Analog Scale | VAS (100 mm) | VISUAL ANALOG SCALE (100 MM)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405770","Severe Acute Respiratory Syndrome Coronavirus 2 Measurement","C171532","The determination of the amount of severe acute respiratory syndrome coronavirus 2 in a sample.","Severe Acute Respiratory Syndrome Coronavirus 2 Measurement | SARS-CoV-2 | SARS-CoV-2 Measurement | SARSCOV2 | Severe Acute Resp Syndrome Coronavirus 2 | Severe Acute Respiratory Syndrome Coronavirus 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405771","SARS-CoV-2 RNA Measurement","C171531","The determination of the amount of SARS-CoV-2 RNA in a sample.","SARS-CoV-2 RNA Measurement | SAR2RNA | SARS-CoV-2 RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405772","SARS-CoV-2 IgM Antibody Measurement","C171530","The determination of the amount of SARS-CoV-2 IgM antibody in a sample.","SARS-CoV-2 IgM Antibody Measurement | SAR2IGM | SARS-CoV-2 IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405773","SARS-CoV-2 IgG and/or IgM Antibody Measurement","C171529","The determination of the amount of SARS-CoV-2 IgG and/or IgM antibodies in a sample.","SARS-CoV-2 IgG and/or IgM Antibody Measurement | SAR2IGGM | SARS-CoV-2 IgG/IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405774","SARS-CoV-2 IgG Antibody Measurement","C171528","The determination of the amount of SARS-CoV-2 IgG antibody in a sample.","SARS-CoV-2 IgG Antibody Measurement | SAR2IGG | SARS-CoV-2 IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405749","SARS-CoV-2 IgA Antibody Measurement","C171527","The determination of the amount of SARS-CoV-2 IgA antibody in a sample.","SARS-CoV-2 IgA Antibody Measurement | SAR2IGA | SARS-CoV-2 IgA Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406330","Respiratory Syncytial Virus Measurement","C171526","The determination of the amount of respiratory syncytial virus in a sample.","Respiratory Syncytial Virus Measurement | RSV | Respiratory Syncytial Virus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405758","MERS-CoV RNA Measurement","C171515","The determination of the amount of MERS-CoV RNA in a sample.","MERS-CoV RNA Measurement | MERS-CoV RNA | MERSRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405550","Adenoviridae Measurement","C171498","The determination of the amount of adenoviridae in a sample.","Adenoviridae Measurement | ADENOVIR | Adenoviridae | Adenovirus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405551","Coronaviridae Measurement","C171456","The determination of the amount of coronaviridae in a sample.","Coronaviridae Measurement | CRONAVIR | Coronaviridae | Coronavirus | Coronavirus Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938247","Elevated LDH","C161592","An indication that the concentration of lactate dehydrogenase found in a sample is higher than previous noted or above the normal range.","Elevated LDH | Elevated | Elevated Lactate Dehydrogenase | LDH Elevated | LDH Increased | Lactate Dehydrogenase Elevated | Lactate Dehydrogenase Increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538763","Choroidal and Ciliary Body Melanoma pT3d TNM Finding v8","C140645","Choroidal and ciliary body melanoma, tumor size category 3 with ciliary body involvement and extraocular extension 5 mm or less in largest diameter. (from AJCC 8th Ed.)","Choroidal and Ciliary Body Melanoma pT3d TNM Finding v8 | pT3d",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514958","State or Local Health Department","C19043","A part of the public health system that includes administrative and service units concerned with the health of persons in specific jurisdictions, i.e., county or state.","State or Local Health Department | Health Department",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406264","Household Contact with SARS-CoV-2 Positive Individual","C172148","Exposure to an individual that lives in the same residence and that has tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).","Household Contact with SARS-CoV-2 Positive Individual | Household Contact with COVID-19 Positive Individual",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406263","Non-Household Contact with SARS-CoV-2 Positive Individual","C172149","Exposure to an individual that does not live in the same residence but has tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).","Non-Household Contact with SARS-CoV-2 Positive Individual | Non-Household Contact with COVID-19 Positive Individual",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406262","Community Exposure to SARS-CoV-2","C172150","Exposure in a local area, outside of a hospital setting, where individuals with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) have been reported.","Community Exposure to SARS-CoV-2 | Community Exposure | Community Exposure to COVID-19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515764","t(3;3)(q21.3;q26.2)","C36406","A cytogenetic abnormality that refers to the translocation where both breakpoints are on the long arm (q23.1 and q26.2) of chromosome 3. It is associated with acute myeloid leukemia.","t(3;3)(q21.3;q26.2) | t(3;3)(q21.3q26.2) | t(3;3)(q21;q26.2) | t(3;3)(q26;q21)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406260","Drug Accumulation Index","C172152","An index reflecting the extent of drug accumulation in the body. It is usually expressed as the ratio of the area under a plasma concentration-time curve (AUC) during a dosage interval at steady state compared to the AUC of a dosage interval after the first dose. It is affected by rate of dose administration, bioavailability, and clearance.","Drug Accumulation Index | RAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406333","Drug Accumulation Less than 1.2","C172153","A drug accumulation of less than 1.2. It is associated with no risk of toxic drug accumulation.","Drug Accumulation Less than 1.2 | Less than 1.2 | No Risk of Toxic Accumulation | None",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405759","Infant Less Than One Year Indicator","C171513","An indication as to whether the subject is less than one year of age.","Infant Less Than One Year Indicator | INL1YIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405549","Appropriate Developmental Age Indicator","C171499","An indication as to whether the subject's chronological age matches their physical, emotional, social, and cognitive functioning.","Appropriate Developmental Age Indicator | ADEVAIND | Appropriate Development For Age Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406259","Drug Accumulation 1.2 to 1.99","C172154","A drug accumulation of 1.2 to 1.99. It is associated with weak risk of toxic drug accumulation.","Drug Accumulation 1.2 to 1.99 | 1.2 to 1.99 | Weak Risk of Toxic Accumulation | Weak risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406310","Drug Accumulation 2.0 to 4.99","C172155","A drug accumulation of 2 to 4.99. It is associated with moderate risk of toxic drug accumulation.","Drug Accumulation 2.0 to 4.99 | 2.0 to 4.99 | Moderate Risk of Toxic Accumulation | Moderate risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406258","Drug Accumulation Greater than 5","C172156","A drug accumulation greater than 5. It is associated with high risk of toxic drug accumulation.","Drug Accumulation Greater than 5 | Greater than 5.0 | High Risk of Toxic Accumulation | High risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405754","Pneumonia Indicator","C171521","An indication as to whether pneumonia has occurred.","Pneumonia Indicator | PNEUMIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405760","Infiltrates Indicator","C171512","An indication as to whether infiltrates have occurred.","Infiltrates Indicator | INFLTIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279692","Uveal Epithelioid Cell Melanoma","C35780","A uveal melanoma characterized by the presence of malignant large epithelioid melanocytes.","Uveal Epithelioid Cell Melanoma | Epithelioid Cell Uveal Melanoma | Epithelioid Cell Uveal Melanoma | Uveal Epithelioid Cell Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279687","Uveal Spindle Cell Melanoma","C7986","A melanoma arising from the choroid, ciliary body, or the iris.  It is characterized by the presence of spindle-shaped melanocytes.","Uveal Spindle Cell Melanoma | Spindle Cell Intraocular Melanoma | Spindle Cell Melanoma of Uvea | Spindle Cell Melanoma of the Uvea | Spindle Cell Uveal Melanoma | Spindle Cell Uveal Melanoma | Uveal Spindle Cell Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406257","Ventana PD-L1 SP142","C172157","A proprietary assay for PD-L1 (Programmed Cell Death 1 Ligand 1). It uses rabbit monoclonal antibody SP142 to specifically bind PD-L1 on the cell membrane of immune cells and normal and tumor cells of epithelial origin in formalin-fixed, paraffin-embedded (FFPE) specimens.","Ventana PD-L1 SP142 | PD-L1 by clone SP142 [Presence] in Tissue by Immune stain | SP142 | Ventana PD L1 SP142 | Ventana PD-L1 (SP142) Assay | Ventana SP142",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422064","ACE2 Gene","C102527","This gene plays a role in both proteolysis and vasodilation.","ACE2 Gene | ACE2 | Angiotensin I Converting Enzyme 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969438","Helicobacter pylori Positive","C160369","An indication that Helicobacter pylori has been detected in a sample.","Helicobacter pylori Positive | H. pylori Positive | Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1873118","Ceftaroline Fosamil","C81034","An N-phosphono prodrug of the fifth-generation cephalosporin derivative ceftaroline with antibacterial activity. Ceftaroline fosamil is hydrolyzed to the active form ceftaroline in vivo. Ceftaroline binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.","Ceftaroline Fosamil | (6R,7R)-7-(((2Z)-(Ethoxyimino)(5-(phosphonoamino)-1,2,4-thiadiazol-3-yl)acetyl)amino)-3-((4-(1-methylpyridinium-4-yl)thiazol-2-yl)sulfanyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carboxylate Monoacetate Monohydrate | CEFTAROLINE FOSAMIL | PPI-0903 | TAK-599 | Teflaro",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552009","PGAP3 wt Allele","C150292","Human PGAP3 wild-type allele is located in the vicinity of 17q21.2 and is approximately 26 kb in length. This allele, which encodes post-GPI attachment to proteins factor 3 protein, plays a role in posttranslational protein modifications. Mutations in this gene are associated with autosomal recessive neurologic hyperphosphatasia with cognitive disability type 4 (HPMRS4).","PGAP3 wt Allele | AGLA546 | CAB2 | Gene Coamplified wth ERBB2 | MGC9753 | PERLD1 | PP1498 | Post-GPI Attachment to Proteins 3 wt Allele | UNQ546/PRO1100 | hCOS16",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705412","GTF3C1 wt Allele","C52627","Human GTF3C1 wild-type allele is located in the vicinity of 16p12 and is approximately 89 kb in length. This allele, which encodes general transcription factor 3C polypeptide 1 protein, is involved in the regulation of the transcription of a number of small cytoplasmic and nuclear RNA species.","GTF3C1 wt Allele | DKFZp686A111 | General Transcription Factor IIIC, Polypeptide 1, Alpha 220kDa wt Allele | TFIIIC | TFIIIC220 | TFIIICalpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705608","GTF3C5 wt Allele","C52632","Human GTF3C5 wild-type allele is located in the vicinity of 9q34 and is approximately 28 kb in length. This allele, which encodes general transcription factor 3C polypeptide 5 protein, is involved in the regulation of the synthesis of transfer RNA, 5S ribosomal RNA and other small RNA types.","GTF3C5 wt Allele | FLJ20857 | General Transcription Factor IIIC, Polypeptide 5, 63kDa wt Allele | TFIIIC63 | TFIIICepsilon | TFiiiC2-63",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3178988","First Responder","C172263","A person with specialized training who is among those responsible for going immediately to the scene of an accident or emergency to provide assistance.","First Responder | Emergency Response Worker",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010963","Dancing","C172269","A physical activity that consists of moving your feet and body rhythmically, usually in response to music.","Dancing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0336949","Bowling","C172270","A physical activity during which balls are rolled at an object or group of objects with the aim of knocking them over.","Bowling | ",,,,,,,,,,,,,,,"4226529","Bowling",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2985664","Study Registry","C93453","An organization (typically a government agency) that administers the registration of studies.","Study Registry | Clinical Study Registry | StudyRegistry | registry | registry (study)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977215","Solid Tissue Specimen","C164014","A biological sample containing components collected from non-liquid tissue of an experimental subject.","Solid Tissue Specimen | Solid Tissue | Solid Tissue Sample",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814410","TXNRD1 protein, human","C107618","Thioredoxin reductase 1, cytoplasmic (649 aa, ~71 kDa) is encoded by the human TXNRD1 gene. This protein plays a role in cellular redox reactions.","Thioredoxin Reductase 1, Cytoplasmic | EC 1.8.1.9 | GRIM-12 | Gene Associated With Retinoic And IFN-Induced Mortality 12 Protein | Gene Associated With Retinoic And Interferon-Induced Mortality 12 Protein | KM-102-Derived Reductase-Like Factor | TR | TXNRD1 | Thioredoxin Reductase GRIM-12 | Thioredoxin Reductase TR1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406275","NCCN ALL Response Criteria for Blood and Bone Marrow Complete Remission","C172169","No circulating lymphoblasts or extramedullary disease, trilineage hematopoiesis (TLH) and less than 5 percent blasts, ANC greater than 1,000 per microL, platelets greater than 100,000 per microL, no recurrence for 4 weeks. (Adapted from NCCN Guidelines, Version 1.2020, February 20,2020)","NCCN ALL Response Criteria for Blood and Bone Marrow Complete Remission | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406274","NCCN ALL Response Criteria for Blood and Bone Marrow Complete Remission with Incomplete Blood Count Recovery","C172170","Meets all criteria for NCCN ALL complete response except platelet count or ANC. (Adapted from NCCN Guidelines, Version 1.2020, February 20,2020)","NCCN ALL Response Criteria for Blood and Bone Marrow Complete Remission with Incomplete Blood Count Recovery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406282","National Comprehensive Cancer Network Risk Stratification and Response Criteria for Acute Lymphoblastic Leukemia","C172162","Risk stratification and response criteria terminology used by the National Comprehensive Cancer Network (NCCN) in accordance with NCCN clinical practice guidelines for acute lymphoblastic leukemia. (NCCN Guidelines, Version 1.2020, February 20,2020)","National Comprehensive Cancer Network Risk Stratification and Response Criteria for Acute Lymphoblastic Leukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406273","NCCN ALL Response Criteria for Blood and Bone Marrow Progressive Disease","C172171","Increase of at least 25 percent in the absolute number of circulating or bone marrow blasts or development of extramedullary disease. (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","NCCN ALL Response Criteria for Blood and Bone Marrow Progressive Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406272","NCCN ALL Response Criteria for Blood and Bone Marrow Refractory Disease","C172172","Failure to achieve complete remission at the end of induction. (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","NCCN ALL Response Criteria for Blood and Bone Marrow Refractory Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406271","NCCN ALL Response Criteria for Blood and Bone Marrow Relapsed Disease","C172173","Reappearance of blasts in the blood or bone marrow ( greater than 5 percent) or in any extramedullary site after complete remission. (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","NCCN ALL Response Criteria for Blood and Bone Marrow Relapsed Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406269","NCCN ALL Response Criteria for CNS Disease CNS Relapse","C172175","New development of CNS-3 status or clinical signs of CNS leukemia such as facial nerve palsy, brain/eye involvement, or hypothalamic syndrome without another explanation. (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","NCCN ALL Response Criteria for CNS Disease CNS Relapse | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406270","NCCN ALL Response Criteria for CNS Disease CNS Remission","C172174","Achievement of CNS-1 status in a patient with CNS-2 or CNS-3 status at study entry. (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","NCCN ALL Response Criteria for CNS Disease CNS Remission | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406268","NCCN ALL Response Criteria for Lymphomatous Extramedullary Disease Complete Remission","C172176","Complete resolution of lymphomatous enlargement by CT. For patients with a previous positive PET scan, a post-treatment residual mass of any size is considered a CR as long as it is PET negative. (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","NCCN ALL Response Criteria for Lymphomatous Extramedullary Disease Complete Remission | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406296","NCCN ALL Response Criteria for Lymphomatous Extramedullary Disease No Response","C172179","Failure to qualify for partial response or progressive disease. (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","NCCN ALL Response Criteria for Lymphomatous Extramedullary Disease No Response | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406267","NCCN ALL Response Criteria for Lymphomatous Extramedullary Disease Partial Remission","C172177","Greater than 50 percent disease in the sum of product of greatest perpendicular diameters (SPD) of the mediastinal enlargement for patients with a previous positive PET scan, post-treatment PET must be positive in at least one previously involved site. (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","NCCN ALL Response Criteria for Lymphomatous Extramedullary Disease Partial Remission | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406297","NCCN ALL Response Criteria for Lymphomatous Extramedullary Disease Progressive Disease","C172178","Greater than 25 percent increase in the SPD of patients with mediastinal enlargement. For patients with previous positive PET scan, post-treatment PET must be positive in at least one previously involved site. (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","NCCN ALL Response Criteria for Lymphomatous Extramedullary Disease Progressive Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406295","NCCN ALL Response Criteria for Lymphomatous Extramedullary Disease Relapse","C172180","Recurrence of mediastinal enlargement after achieving CR. For patients with a previous positive PET scan, post-treatment PET must be positive in at least one previously involved site. (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","NCCN ALL Response Criteria for Lymphomatous Extramedullary Disease Relapse | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406278","NCCN Cytogenetic Risk Group for ALL","C172166","A classification strategy for Acute Lymphoblastic Leukemia (ALL) developed by NCCN that stratifies risk groups based on the cytogenetic and molecular features of ALL. (NCCN Guidelines, Version 1.2020, February 20, 2020)","NCCN Cytogenetic Risk Group for ALL | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406277","NCCN Cytogenetic Risk Group for ALL, Good Risk","C172167","ALL characterized by hyperploidy (51-65 chromosomes or t(122;21)(p13;q22): ETV6-RUNX1. (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","NCCN Cytogenetic Risk Group for ALL, Good Risk | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406276","NCCN Cytogenetic Risk Group for ALL, Poor Risk","C172168","ALL characterized by hypoploidy (less than 44 chromosomes, KMT2A rearranged (t[4;11] or others), t(v;14q32)IgH, t(9;22)(q34;11.2): BCR-ABL1 (defined as high risk in the pre-TKI era), complex karyotype (5 or more chromosomal abnormalities), Ph-like ALL; intrachromosomal amplification of chromosome 21 (iAMP21). (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","NCCN Cytogenetic Risk Group for ALL, Poor Risk | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406279","NCCN Philadelphia Chromosome Negative ALL Adult Risk Group","C172165","A subgroup of patients, aged 40 or more years, diagnosed with Philadelphia Chromosome negative ALL. (NCCN Guidelines, Version 1.2020, February 20, 2020)","NCCN Philadelphia Chromosome Negative ALL Adult Risk Group | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406294","NCCN Philadelphia Chromosome Positive ALL Adolescent and Young Adult Risk Group","C172181","A subgroup of patients, aged 15 to 39 years, diagnosed with Philadelphia chromosome positive ALL. (NCCN Guidelines, Version 1.2020, February 20, 2020)","NCCN Philadelphia Chromosome Positive ALL Adolescent and Young Adult Risk Group | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406281","NCCN Philadelphia Chromosome Positive ALL Adult Risk Group","C172163","A subgroup of patients, aged 40 or more years, diagnosed with Philadelphia Chromosome positive ALL. (NCCN Guidelines, Version 1.2020, February 20, 2020)","NCCN Philadelphia Chromosome Positive ALL Adult Risk Group | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406280","NCCN Philadelphia Chromosome Negative ALL Adolescent and Young Adult Risk Group","C172164","A subgroup of patients, aged 15 to 39 years, diagnosed with Philadelphia Chromosome negative ALL. (NCCN Guidelines, Version 1.2020, February 20, 2020)","NCCN Philadelphia Chromosome Negative ALL Adolescent and Young Adult Risk Group | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406162","Medication Understanding and Use Self-Efficacy Scale","C172283","A tool designed to measure an individual's belief in their ability to understand instructions, use prescription medications, and adhere to medication regimens.","Medication Understanding and Use Self-Efficacy Scale | MUSE | Medication Understanding and Use Self-Efficacy Scale (MUSE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406161","Taking Medicine on Time was Easy","C172284","A response indicating that an individual feels or felt that taking their medicine on time was easy.","Taking Medicine on Time was Easy | It is easy for me to take my medicine on time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406160","Asking Pharmacist Questions About the Medicine was Easy","C172285","A response indicating that an individual feels or felt that asking the pharmacist questions about their medicine was easy.","Asking Pharmacist Questions About the Medicine was Easy | It is easy for me to ask my pharmacist questions about my medicine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406159","Understanding Pharmacist's Instructions for the Medicine was Easy","C172286","A response indicating that an individual feels or felt that understanding the pharmacist's instructions about their medicine was easy.","Understanding Pharmacist's Instructions for the Medicine was Easy | It is easy for me to understand my pharmacist's instructions for my medicine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406158","Understanding Instructions on the Medicine Bottle was Easy","C172287","A response indicating that an individual feels or felt that understanding the instructions on their medicine bottles was easy.","Understanding Instructions on the Medicine Bottle was Easy | It is easy for me to understand instructions on medicine bottles",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406157","Getting All Information Needed About the Medicine was Easy","C172288","A response indicating that an individual feels or felt that getting all of the information they needed about their medicine was easy.","Getting All Information Needed About the Medicine was Easy | It is easy for me to get all the information I need about my medicine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406155","Remembering to Take All Medicine was Easy","C172290","A response indicating that an individual feels or felt that remembering to take all their medicines was easy.","Remembering to Take All Medicine was Easy | It is easy to remember to take all my medicines",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514460","Prior Hormone Therapy","C16175","An indication that an individual has been previously treated with hormonal therapy.","Prior Hormone Therapy | prior hormonal therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406154","Setting a Schedule to Take Medicine Each Day was Easy","C172291","A response indicating that an individual feels or felt that setting a schedule to take their medicine each day was easy.","Setting a Schedule to Take Medicine Each Day was Easy | It is easy for me to set a schedule to take my medicines each day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406153","Taking Medicine Every Day was Easy","C172292","A response indicating that an individual feels or felt that taking their medicine every day was easy.","Taking Medicine Every Day was Easy | It is easy for me to take my medicines every day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830485","Digital Data Repository","C114457","A storage location for digital data.","Digital Data Repository | Repository",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520576","14q11","C13747","A chromosome band present on 14q","14q11 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022354","Obstructive Jaundice","C34742","A finding indicating increased bilirubin levels in the blood and urine, due to intrahepatic or extrahepatic obstruction of the biliary system.","Obstructive Jaundice | Cholestatic Jaundice",,,,,,,,,,,,,,,"4242900","Obstructive hyperbilirubinemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1406149","Global Longitudinal Strain","C172266","A parameter that is used to assess global left ventricular systolic function by quantifying the percent change in myocardial length from a relaxed to a contractile state using tissue tracking imaging techniques.","Global Longitudinal Strain | GLS | Left Ventricular Global Longitudinal Strain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1275743","Comorbid Condition","C161320","Medical or health condition that is concomitant or concurrent with the primary condition or disease under study.","Comorbid Condition | concurrent disease | concurrent_disease | synchronous malignancy | synchronous_malignancy",,,,,,,,,,,,,,,"4160039","Co-morbid conditions",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4014084","Rhabdomyolysis","C118318","A clinical syndrome resulting from direct or indirect muscle injury and subsequent release of myoglobin into the plasma.","Rhabdomyolysis | ",,,,,,,,,,,,,,,"4230337|4345578","Rhabdomyolysis|Rhabdomyolysis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0425078","Live in Own Home","C113780","An indication that an individual is living in their home.","Live in Own Home | Live in own home | Living in Own Home",,,,,,,,,,,,,,,"4059643","Lives in own home",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1960973","Home Oxygen Therapy","C99516","Treatment in which a oxygen is administered to an individual at their residence.","Home Oxygen Therapy | ",,,,,,,,,,,,,,,"4140455","Home oxygen therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3873567","Chemotherapy-Induced Peripheral Neuropathy","C156348","Any disorder affecting the peripheral nerves resulting from exposure to chemotherapeutic agents.","Chemotherapy-Induced Peripheral Neuropathy | CIPN | Chemotherapeutic Drug - Induced Peripheral Neuropathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936006","Smartphone Application","C156877","An application designed specifically for use on a smartphone.","Smartphone Application | App | Smartphone App",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040654","Transcutaneous Electrical Nerve Stimulation","C21032","A non-invasive form of nerve stimulation that typically uses conductive gel pads to transmit electrical energy from an external stimulator to peripheral nerves. While it is usually used for treating peripheral neuropathic pain it has other applications.","Transcutaneous Electrical Nerve Stimulation | TENS | transcutaneous electric nerve stimulation",,,,,,,,,,,,,,,"4042698","Transcutaneous electrical nerve stimulation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL978418","Responsive Disease","C165206","An indication that a patient's disease is responding to treatment.","Responsive Disease | RD-Responsive Disease | RP-Response | Response observed | response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407084","Reschedule","C172422","To move an event to a different time or date.","Reschedule | Rescheduled",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513833","NF1 Gene Inactivation","C36685","A mutation in the NF1 gene that either inhibits expression or results in the translation of an inactive NF1 protein.","NF1 Gene Inactivation | Inactivating NF1 Gene Mutation | Inactivating NFNS Gene Mutation | Inactivating Neurofibromin 1 Gene Mutation | NF-1 Tumor-Suppressor Gene Inactivation | NF1 Inactivating Mutation | NF1 Tumor-Suppressor Gene Inactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513834","NF2 Gene Inactivation","C36686","A mutation in the NF2 gene that either inhibits expression or results in the translation of an inactive NF2 protein.","NF2 Gene Inactivation | Inactivating ACN Gene Mutation | Inactivating BANF Gene Mutation | Inactivating Merlin Gene Mutation | Inactivating NF2 Gene Mutation | Inactivating Neurofibromin 2 Gene Mutation | Inactivating SCH Gene Mutation | NF-2 Tumor-Suppressor Gene Inactivation | NF2 Inactivating Mutation | NF2 Tumor-Suppressor Gene Inactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711435","WRN Gene Mutation","C43292","A change in the nucleotide sequence of the WRN gene.","WRN Gene Mutation | RECQ3 Gene Mutation | RECQL2 Gene Mutation | RECQL3 Gene Mutation | WRN Mutation | Werner Syndrome Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406476","Deleterious IDH1 Gene Mutation","C172343","A mutation in the IDH1 gene that is associated with an increased risk of disease.","Deleterious IDH1 Gene Mutation | Deleterious IDH Mutation | Deleterious IDH1 Mutation | Deleterious Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic Gene Mutation | Deleterious Isocitrate Dehydrogenase 1 (NADP+), Soluble Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406475","Deleterious IDH2 Gene Mutation","C172344","A mutation in the IDH2 gene that is associated with an increased risk of disease.","Deleterious IDH2 Gene Mutation | Deleterious IDH Mutation | Deleterious IDH2 Mutation | Deleterious Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial Gene Mutation | Deleterious Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406478","Deleterious RPA1 Gene Mutation","C172345","A mutation in the RPA1 gene that is associated with an increased risk of disease.","Deleterious RPA1 Gene Mutation | Deleterious RF-A Gene Mutation | Deleterious RP-A Gene Mutation | Deleterious RPA1 Mutation | Deleterious RPA70 Gene Mutation | Deleterious Replication Protein A1 Gene Mutation | Deleterious Replication Protein A1, 70kDa Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406477","Deleterious SEM1 Gene Mutation","C172346","A mutation in the SEM1 gene that is associated with an increased risk of disease.","Deleterious SEM1 Gene Mutation | Deleterious C7orf76 Gene Mutation | Deleterious DSS1 Gene Mutation | Deleterious Deleted In Split-Hand/Split-Foot 1 Gene Mutation | Deleterious ECD Gene Mutation | Deleterious SEM1 26S Proteasome Complex Subunit Gene Mutation | Deleterious SEM1 Mutation | Deleterious SHFD1 Gene Mutation | Deleterious SHFM1 Gene Mutation | Deleterious SHFM1 Mutation | Deleterious SHSF1 Gene Mutation | Deleterious Shfdg1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406480","Deleterious WRN Gene Mutation","C172347","A mutation in the WRN gene that is associated with an increased risk of disease.","Deleterious WRN Gene Mutation | Deleterious RECQ3 Gene Mutation | Deleterious RECQL2 Gene Mutation | Deleterious RECQL3 Gene Mutation | Deleterious WRN Mutation | Deleterious Werner Syndrome Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406479","Deleterious XRCC2 Gene Mutation","C172348","A mutation in the XRCC2 gene that is associated with an increased risk of disease.","Deleterious XRCC2 Gene Mutation | Deleterious DNA Repair Protein XRCC2 Gene Mutation | Deleterious FANCU Gene Mutation | Deleterious X-Ray Repair Complementing Defective Repair in Chinese Hamster Cells 2 Gene Mutation | Deleterious X-Ray Repair Cross Complementing 2 Gene Mutation | Deleterious XRCC2 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406482","Deleterious Biallelic MUTYH Gene Mutation","C172349","The presence of nucleotide sequence changes in both alleles of the MUTYH gene that are associated with increased risk of disease.","Deleterious Biallelic MUTYH Gene Mutation | Biallelic Deleterious MUTYH Gene Mutation | Deleterious Biallelic MUTYH Mutation | Deleterious Biallelic MYH Gene Mutation | Deleterious Biallelic MutY (E. Coli) Homolog Gene Mutation | Deleterious Biallelic MutY DNA Glycosylase Gene Mutation | Deleterious Biallelic MutY Homolog (E. coli) Gene Mutation | Deleterious Biallelic MutY Homolog Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406481","Mismatch Repair Gene Promoter Methylation","C172350","A genetic finding indicating that DNA methylation in the promoter region of a gene involved in DNA mismatch repair has been detected in a sample.","Mismatch Repair Gene Promoter Methylation | DNA Mismatch Repair Gene Promoter Methylation | MMR Gene Promoter Methylation | MMR Promoter Methylation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406484","FLT3 Non-Internal Tandem Duplication Activating Mutation Positive","C172351","A genetic finding indicating that activating mutations in the FLT3 gene are detected in a sample but these are not internal tandem duplication mutations.","FLT3 Non-Internal Tandem Duplication Activating Mutation Positive | FLT3 Non-ITD Activating Mutation | FLT3 Non-ITD Activating Mutation Positive | FLT3 Non-ITD Activating Mutation Present | FLT3 Non-Internal Tandem Duplication Activating Mutation | FLT3 Non-Internal Tandem Duplication Activating Mutation Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406483","PSA Doubling Time Less than or Equal to 12 Months","C172352","An indication that the number of months that a subject's blood concentration of prostate specific antigen took to double was twelve months or less.","PSA Doubling Time Less than or Equal to 12 Months | PSA Doubling Time Less than or Equal to Twelve Months | PSA-DT Less than or Equal to 12 Months | PSADT Less than or Equal to 12 Months",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406486","Deleterious NF1 Gene Mutation","C172353","A mutation in the NF1 gene that is associated with an increased risk of disease.","Deleterious NF1 Gene Mutation | Deleterious NF1 Mutation | Deleterious NFNS Gene Mutation | Deleterious Neurofibromin 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406485","Deleterious NF2 Gene Mutation","C172354","A mutation in the NF2 gene that is associated with an increased risk of disease.","Deleterious NF2 Gene Mutation | Deleterious ACN Gene Mutation | Deleterious BANF Gene Mutation | Deleterious Merlin Gene Mutation | Deleterious NF2 Mutation | Deleterious Neurofibromin 2 Gene Mutation | Deleterious SCH Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406488","Deleterious PIK3R1 Gene Mutation","C172355","A mutation in the PIK3R1 gene that is associated with an increased risk of disease.","Deleterious PIK3R1 Gene Mutation | Deleterious GRB1 Gene Mutation | Deleterious PIK3R1 Mutation | Deleterious Phosphoinositide-3-Kinase Regulatory Subunit 1 Gene Mutation | Deleterious p85-ALPHA Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406487","Deleterious TSC1 Gene Mutation","C172356","A mutation in the TSC1 gene that is associated with an increased risk of disease.","Deleterious TSC1 Gene Mutation | Deleterious Hamartin Gene Mutation | Deleterious TSC Gene Mutation | Deleterious TSC1 Mutation | Deleterious Tuberous Sclerosis 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406490","Deleterious TSC2 Gene Mutation","C172357","A mutation in the TSC2 gene that is associated with an increased risk of disease.","Deleterious TSC2 Gene Mutation | Deleterious TSC2 Mutation | Deleterious Tuberin Gene Mutation | Deleterious Tuberous Sclerosis 2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406523","APC Promoter 1B","C172363","A distal promoter element in the 5' regulatory region of the APC gene on chromosome 5.","APC Promoter 1B | APC Gene Promoter 1B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406525","Germline APC Promoter 1B Variant","C172365","A mutation or chromosomal abnormality occurring in the gametes that involves the distal promoter element in the 5' regulatory region of the APC gene.","Germline APC Promoter 1B Variant | APC Promoter 1B Germline Variant | Germline APC Gene Promoter 1B Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406528","DDR2 NP_001014796.1:p.I638F","C172370","A change in the amino acid residue at position 638 in the discoidin domain-containing receptor 2 protein where isoleucine has been replaced by phenylalanine.","DDR2 NP_001014796.1:p.I638F | CD167 Antigen-Like Family Member B I638F | CD167 Antigen-Like Family Member B Ile638Phe | CD167b Antigen I638F | CD167b Antigen Ile638Phe | CD167b I638F | CD167b Ile638Phe | DDR2 I638F | DDR2 I638F Mutation | DDR2 Ile638Phe | DDR2 NP_001014796.1:p.Ile638Phe | DDR2 p.I638F | DDR2 p.Ile638Phe | Discoidin Domain Receptor 2 I638F | Discoidin Domain Receptor 2 Ile638Phe | Discoidin Domain-Containing Receptor 2 I638F | Discoidin Domain-Containing Receptor 2 Ile638Phe | Discoidin Domain-Containing Receptor Tyrosine Kinase 2 I638F | Discoidin Domain-Containing Receptor Tyrosine Kinase 2 Ile638Phe | NP_001014796.1:p.I638F | NP_001014796.1:p.Ile638Phe | NTRKR3 I638F | NTRKR3 Ile638Phe | Neurotrophic Tyrosine Kinase, Receptor-Related 3 I638F | Neurotrophic Tyrosine Kinase, Receptor-Related 3 Ile638Phe | Receptor Protein-Tyrosine Kinase TKT I638F | Receptor Protein-Tyrosine Kinase TKT Ile638Phe | Tyrosine-Protein Kinase TYRO10 I638F | Tyrosine-Protein Kinase TYRO10 Ile638Phe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406530","DDR2 NP_001014796.1:p.L239R","C172372","A change in the amino acid residue at position 239 in the discoidin domain-containing receptor 2 protein where leucine has been replaced by arginine.","DDR2 NP_001014796.1:p.L239R | CD167 Antigen-Like Family Member B L239R | CD167 Antigen-Like Family Member B Leu239Arg | CD167b Antigen L239R | CD167b Antigen Leu239Arg | CD167b L239R | CD167b Leu239Arg | DDR2 L238R Mutation | DDR2 L239R | DDR2 Leu239Arg | DDR2 NP_001014796.1:p.Leu239Arg | DDR2 p.L239R | DDR2 p.Leu239Arg | Discoidin Domain Receptor 2 L239R | Discoidin Domain Receptor 2 Leu239Arg | Discoidin Domain-Containing Receptor 2 L239R | Discoidin Domain-Containing Receptor 2 Leu239Arg | Discoidin Domain-Containing Receptor Tyrosine Kinase 2 L239R | Discoidin Domain-Containing Receptor Tyrosine Kinase 2 Leu239Arg | NP_001014796.1:p.L239R | NP_001014796.1:p.Leu239Arg | NTRKR3 L239R | NTRKR3 Leu239Arg | Neurotrophic Tyrosine Kinase, Receptor-Related 3 L239R | Neurotrophic Tyrosine Kinase, Receptor-Related 3 Leu239Arg | Receptor Protein-Tyrosine Kinase TKT L239R | Receptor Protein-Tyrosine Kinase TKT Leu239Arg | Tyrosine-Protein Kinase TYRO10 L239R | Tyrosine-Protein Kinase TYRO10 Leu239Arg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406532","DDR2 NP_001014796.1:p.S768R","C172374","A change in the amino acid residue at position 768 in the discoidin domain-containing receptor 2 protein where serine has been replaced by arginine.","DDR2 NP_001014796.1:p.S768R | CD167 Antigen-Like Family Member B S768R | CD167 Antigen-Like Family Member B Ser768Arg | CD167b Antigen S768R | CD167b Antigen Ser768Arg | CD167b S768R | CD167b Ser768Arg | DDR2 NP_001014796.1:p.Ser768Arg | DDR2 S768R | DDR2 S768R Mutation | DDR2 Ser768Arg | DDR2 p.S768R | DDR2 p.Ser768Arg | Discoidin Domain Receptor 2 S768R | Discoidin Domain Receptor 2 Ser768Arg | Discoidin Domain-Containing Receptor 2 S768R | Discoidin Domain-Containing Receptor 2 Ser768Arg | Discoidin Domain-Containing Receptor Tyrosine Kinase 2 S768R | Discoidin Domain-Containing Receptor Tyrosine Kinase 2 Ser768Arg | NP_001014796.1:p.S768R | NP_001014796.1:p.Ser768Arg | NTRKR3 S768R | NTRKR3 Ser768Arg | Neurotrophic Tyrosine Kinase, Receptor-Related 3 S768R | Neurotrophic Tyrosine Kinase, Receptor-Related 3 Ser768Arg | Receptor Protein-Tyrosine Kinase TKT S768R | Receptor Protein-Tyrosine Kinase TKT Ser768Arg | Tyrosine-Protein Kinase TYRO10 S768R | Tyrosine-Protein Kinase TYRO10 Ser768Arg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406504","Deleterious Inactivating NF1 Gene Mutation","C172375","A mutation in the NF1 gene that is associated with an increased risk of disease and either inhibits expression or results in the translation of an inactive NF1 protein.","Deleterious Inactivating NF1 Gene Mutation | Deleterious Inactivating NF1 Mutation | Deleterious Inactivating NFNS Gene Mutation | Deleterious Inactivating Neurofibromin 1 Gene Mutation | Deleterious NF1 Gene Inactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406503","Activating GNA11 Gene Mutation","C172376","A change in the nucleotide sequence of the GNA11 gene that that results in constitutive activation of both guanine nucleotide-binding protein subunit alpha-11 and its downstream signaling pathways.","Activating GNA11 Gene Mutation | Activating G Protein Subunit Alpha 11 Gene Mutation | Activating GA11 Gene Mutation | Activating GNA-11 Gene Mutation | Activating GNA11 Mutation | Activating Guanine Nucleotide Binding Protein (G Protein), Alpha 11 Gene Mutation | Activating Guanine Nucleotide-Binding Protein, Alpha-11 Gene Mutation | GNA11 Activating Gene Mutation | GNA11 Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406506","Activating GNAQ Gene Mutation","C172377","A change in the nucleotide sequence of the GNAQ gene that that results in constitutive activation of both guanine nucleotide-binding protein G(q) subunit alpha and its downstream signaling pathways.","Activating GNAQ Gene Mutation | Activating CMC1 Gene Mutation | Activating G Protein Subunit Alpha q Gene Mutation | Activating G-ALPHA-q Gene Mutation | Activating GAQ Gene Mutation | Activating GNAQ Mutation | Activating Guanine Nucleotide Binding Protein (G Protein), Q Polypeptide Gene Mutation | Activating SWS Gene Mutation | GNAQ Activating Gene Mutation | GNAQ Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406502","Interleukin-6 Greater than or Equal to 80 pg/ml","C172341","A finding indicating that the concentration of the interleukin-6 in a sample is greater than or equal to 80 pg/mL.","Interleukin-6 Greater than or Equal to 80 pg/ml | IL-6 80 pg/ml or Greater | IL-6 Greater than or Equal to 80 pg/ml | IL-6 Level 80 pcg/ml or Greater | Interleukin-6 80 pg/ml or Greater",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406501","Rabies-Specific IgG Antibody","C172339","An immunoglobulin of the IgG isotype that recognizes rabies virus.","Rabies-Specific IgG Antibody | Anti-Rabies IgG | Anti-Rabies IgG Antibody | Rabies-Specific IgG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406500","Rabies-Specific IgM Antibody","C172340","An immunoglobulin of the IgM isotype that recognizes rabies virus.","Rabies-Specific IgM Antibody | Anti-Rabies IgM | Anti-Rabies IgM Antibody | Rabies-Specific IgM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970990","Peptide Receptor Radionuclide Therapy","C162449","Treatment with a radioactive substance that is linked to a peptide receptor so that it will attach to a specific cell type when injected into the body. It is currently being used to treat neuroendocrine tumors, using octreotide as the targeting peptide.","Peptide Receptor Radionuclide Therapy | PRRT | Peptide Receptor Radionuclide Therapy (PRRT) | Peptide Receptor Radiotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406371","Disruption to Therapy Because Patient Too Ill Due to COVID-19","C172424","A response indicating that there was a disruption in a patient's therapy because they were too ill due to COVID-19.","Disruption to Therapy Because Patient Too Ill Due to COVID-19 | Patient was too ill due to COVID-19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406370","Disruption to Therapy Because of Risk of COVID-19 Exposure to Health Care Staff","C172425","A response indicating that there was a disruption in a patient's therapy due to the risk of COVID-19 exposure to the health care staff.","Disruption to Therapy Because of Risk of COVID-19 Exposure to Health Care Staff | Risk of COVID-19 exposure to health care staff",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406373","Disruption to Therapy Because Patient's Travel Restricted Due to COVID-19","C172426","A response indicating that there was a disruption in a patient's therapy because their travel was restricted due to COVID-19.","Disruption to Therapy Because Patient's Travel Restricted Due to COVID-19 | Patient's travel restricted due to COVID-19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406372","Disruption to Therapy Because of Patient Decision to Change Care Plan Due to COVID-19","C172427","A response indicating that there was a disruption in a patient's therapy because they decided to change their care plan due to COVID-19.","Disruption to Therapy Because of Patient Decision to Change Care Plan Due to COVID-19 | Patient decision to change care plan due to COVID-19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406375","Disruption to Therapy Because of Physician Decision to Change Care Plan Due to COVID-19","C172428","A response indicating that there was a disruption in a patient's therapy because their physician decided to change the patient's care plan due to COVID-19.","Disruption to Therapy Because of Physician Decision to Change Care Plan Due to COVID-19 | Physician decision to change care plan due to COVID-19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406374","Disruption to Therapy Because of Institutional Restrictions on Care Due to COVID-19","C172429","A response indicating that there was a disruption in a patient's therapy because of institutional restrictions on care due to COVID-19.","Disruption to Therapy Because of Institutional Restrictions on Care Due to COVID-19 | Institutional restrictions on care due to COVID-19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406377","Disruption to Therapy Because of Lack of Institutional Resources Due to COVID-19","C172430","A response indicating that there was a disruption in a patient's therapy because of a lack of institutional resources due to COVID-19.","Disruption to Therapy Because of Lack of Institutional Resources Due to COVID-19 | Lack of institutional resources due to COVID-19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406376","Disruption to Therapy Because of Non-COVID-19-Related Comorbidity","C172431","A response indicating that there was a disruption in a patient's therapy because of non-COVID-19-related comorbidity.","Disruption to Therapy Because of Non-COVID-19-Related Comorbidity | Non-COVID-19 related co-morbidity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406379","Unknown Status Due to Lack of Assessment Due to COVID-19 Diagnosis","C172432","A response indicating that a patient's disease status is unknown due to a lack of follow-up assessment due to a COVID-19 diagnosis.","Unknown Status Due to Lack of Assessment Due to COVID-19 Diagnosis | Unknown due to lack of disease/tumor assessment due to COVID-19 diagnosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406378","Unknown Status Due to COVID-19-Related Travel Restrictions","C172433","A response indicating that a patient's disease status is unknown due to COVID-19-related travel restrictions.","Unknown Status Due to COVID-19-Related Travel Restrictions | Unknown due to general COVID-19 related travel restrictions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005911","Weight Change","C9232","An increase or decrease in the weight of an individual.","Weight Change | ",,,,,,,,,,,,,,,"4086522","Weight change",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2985799","Missed Indicator","C93596","Specifies whether a planned or preestablished event or activity did not occur.","Missed Indicator | missedIndicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1446397","Full-time Student","C172448","A person who is enrolled in a college, university, or other higher educational institution and is taking a full course load, generally considered 12 or more hours per week or credits per term.","Full-time Student | Full-time",,,,,,,,,,,,,,,"4137058","Student in full time education",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1546913","Part-time Student","C172449","A person who is enrolled in a college, university, or other higher educational institution and is taking less than a full course load, generally less than 12 hours per week or credits per term.","Part-time Student | Part-time",,,,,,,,,,,,,,,"764654","Student in part-time education",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0086593","Maternity leave","C172445","The time that a woman takes off from work following the birth or adoption of a child.","Maternity Leave | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406364","Medical Leave","C172446","The time that a person takes off from work to care for their serious medical condition, or that of an eligible family member.","Medical Leave | Sick Leave",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1367867","Intensive Care Unit Stay","C171454","The subject or patient has been admitted as an inpatient to a intensive care unit.","Intensive Care Unit Stay | ICU Stay | INTENSIVE CARE UNIT STAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1718255","Reason for Assessment","C171003","The explanation for why a test, measurement, or assessment is executed.","Reason for Assessment | ",,,,,,,,,,,,,,,"762604","Reason for assessment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL519759","Cryoprecipitated Antihemophilic Factor","C133260","A preparation containing antihemophilic factor obtained from a single unit of plasma.","Cryoprecipitated Antihemophilic Factor | Cryoprecipitated AHF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706091","Cannula Device","C50343","A small flexible tube inserted into a body cavity for draining off fluid or introducing medication.","Cannula Device | Cannula",,,,,,,,,,,,,,,"4006507","Cannula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014009","Empyema","C34572","An accumulation of pus in the pleural space.","Empyema | Pleural Empyema",,,,,,,,,,,,,,,"4209859|4280377","Empyema|Empyema",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0226513","Superficial Vein","C33666","Any of the veins carrying deoxygenated blood from the subcutaneous tissue layers.","Superficial Vein | ",,,,,,,,,,,,,,,"4206481","Structure of superficial vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004626","Bacterial Pneumonia","C26704","Acute infection of the lung parenchyma caused by bacteria (e.g., Streptococcus pneumoniae, Haemophilus influenzae, Chlamydia pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila).  Signs and symptoms include productive cough, fever, chills, shortness of breath, and chest pain.","Bacterial Pneumonia | ",,,,,,,,,,,,,,,"257315","Bacterial pneumonia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1406550","Pitted Erythrocyte Count","C172658","The number of pitted erythrocytes in a blood sample, expressed as a percentage. It is used as an indicator of splenic function.","Pitted Erythrocyte Count | PitE Count | Pitted Erythrocyte Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936771","Specify if Yes","C157104","A directive to provide a more specific response if the answer to the question is yes.","Specify if Yes | If yes, please specify | If yes, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1960093","Non-Rebreather Mask","C172681","A facemask with a reservoir bag designed to deliver oxygen at a higher concentration than a low-flow nasal cannula or standard mask. It has a one-way valve between the mask and the reservoir so that oxygen flows only from the reservoir bag to the mask. A second one-way valve lets exhaled air flow out to the atmosphere while preventing atmospheric air entering back in.","Non-Rebreather Mask | NRB | Non-Rebreather | Non-Rebreather Facemask",,,,,,,,,,,,,,,"4145528","Nonrebreather oxygen mask",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1406534","Overt Stroke","C172674","A cerebral infarction that is evident by new neurological symptoms lasting greater than 24 hours or having an area of diffusion restriction or a T2 or fluid-attenuated inversion recovery (FLAIR) hyperintensity on an MRI of the brain that was consistent with the neurological findings.","Overt Stroke | OCI | Overt Cerebral Infarction | Overt Stroke ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406537","Silent Stroke","C172675","An asymptomatic cerebral infarction that was incidentally noted by T2 or fluid-attenuated inversion recovery (FLAIR) hyperintensities on an MRI of the brain.","Silent Stroke | SCI | Silent Cerebral Infarction | Silent Stroke ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0151945","Cerebral Vein Thrombosis","C132727","The formation of a blood clot in a cerebral vein.","Cerebral Vein Thrombosis | Cerebral Venous Thrombosis | Cerebral venous thrombosis",,,,,,,,,,,,,,,"4319329","Thrombosis of cerebral veins",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540541","Natural Language","C142612","Spoken or written language as used in ordinary communications between individuals and groups.","Natural Language | natural language",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0855970","Splenic Scan","C172726","A radionuclide imaging technique that is used to evaluate the size and shape of the spleen, and to detect and evaluate lesions, rupture, and hematomas.","Splenic Scan | Spleen Scan | Spleen Scintigraphy | Splenic Scintigraphy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406612","Someone to Have a Good Time With","C172729","A question about whether an individual has someone to love and make them feel wanted.","Someone to Have a Good Time With | To have a good time with",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406619","Average Amount","C172739","The usual amount of something.","Average Amount | On Average",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406621","Have Felt Unusual Weakness","C172740","A question about whether an individual feels or felt unusual weakness.","Have Felt Unusual Weakness | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348970","High-Intensity Focused Ultrasound Ablation","C68681","A non-invasive treatment which uses an high-energy ultrasound transducer to generate sound waves to destroy diseased tissue.","High-Intensity Focused Ultrasound Ablation | Echopulse | Echotherapy | HIFU | High Intensity Focused Ultrasound | High Intensity Focused Ultrasound Therapy | High-intensity Focused Ultrasound | High-intensity Focused Ultrasound Therapy | high-intensity focused ultrasound therapy",,,,,,,,,,,,,,,"36676810","High intensity focused ultrasound ablation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0771210","Asparaginase Erwinia chrysanthemi","C64260","A recombinant form of asparaginase derived from the bacterium Erwinia chrysanthemi, genetically engineered to be produced in Pseudomonas fluorescens, with potential antineoplastic activity. Upon administration, asparaginase Erwinia chrysanthemi hydrolyzes L-asparagine to L-aspartic acid and ammonia. This depletes cancer cells of asparagine, which blocks protein synthesis and tumor cell proliferation. Asparagine is critical to protein synthesis in cancer cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Asparaginase Erwinia chrysanthemi can be used as an alternative in patients who are hypersensitive to Escherichia (E.) coli-derived asparaginase products.","Asparaginase Erwinia chrysanthemi | ASPARAGINASE ERWINIA CHRYSANTHEMI | Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn | Asparaginase Erwinia chrysanthemi (Recombinant)-rywn | Asparaginase Erwinia chrysanthemi, Recombinant-rywn | Asparaginase Erwinia chrysanthemi-rywn | Asparaginase erwinia chrysanthemi-rywn | Crisantaspase | Crisantaspase Biobetter JZP-458 | Crisantaspasum | Enrylaze | Erwinase | Erwinaze | JZP 458 | JZP-458 | JZP458 | L-asparginase (Erwinia ) | PF743 | RC-P JZP-458 | Recombinant Asparaginase erwinia chrysanthemi JZP-458 | Recombinant Crisantaspase JZP-458 | Recombinant Erwinia asparaginase JZP-458 | Rylaze",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540702","Autologous CD19/CD22 CAR T Cells","C142834","A preparation of autologous human T-lymphocytes engineered to express a chimeric T-cell receptor (chimeric antigen receptor or CAR) consisting of one or more binding domains targeting the tumor-associated antigens (TAAs) CD19 and CD22 and fused to one or more co-stimulatory TCR-signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous CD19/CD22 CAR T-cells CT120 bind to CD19 and CD22 on the surface of, and induce selective toxicity against, tumor cells expressing CD19 and CD22. CD19 and CD22, both transmembrane phosphoglycoproteins expressed on the surface of cells in the B lineage, are overexpressed on malignant B-cells.","Autologous CD19/CD22 Chimeric Antigen Receptor T-cells CT120 | Autologous Anti-CD19/CD22 CAR-T Cells | Autologous CD19/CD22 CAR T Cells | Autologous CD19/CD22 CAR T-cells | Autologous CD19/CD22 Chimeric Antigen Receptor T Cells | Autologous CD19/CD22 Chimeric Antigen Receptor T-cells | CD19/CD22 Bispecific CAR-T | CD19/CD22 CAR-T | CT 120 | CT-120 | CT120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554393","Lapine T-Lymphocyte Immune Globulin","C80833","A preparation of purified, pasteurized, gamma globulin obtained by the immunization of rabbits with human thymocytes, with T-cell depleting and immunosuppressive activities. Upon administration, rabbit anti-thymocyte globulin (rATG) specifically recognizes, modulates and destroys T-lymphocytes. Although the exact mechanism of action by which rATG causes immunosuppression is not completely understood, it is likely caused by a combination of T-lymphocyte depletion and reduction in T-cell activation and their cytotoxic activities. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host disease (GvHD).","Lapine T-Lymphocyte Immune Globulin | Anti-Thymocyte Globulin Rabbit | Anti-thymocyte Globulin Rabbit | Antithymocyte Globulin Rabbit | Antithymocyte globulin rabbit ATG | Grafalon | Imtix | LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN | Rabbit ATG | Rabbit Anti-Human Thymocyte Globulin (RATG) | Rabbit Anti-Thymocyte Globulin | Rabbit Antithymocyte Globulin | Thymoglobulin | rATG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0935690","Vincristine Sulfate Liposome","C2702","A sphingomyelin/cholesterol liposomal formulation of vincristine sulfate with potential antineoplastic activity. Vincristine, a vinca alkaloid isolated from the plant Vinca rosea, irreversibly binds to and stabilizes tubulin, thereby interrupting microtubule assembly/disassembly dynamics, thereby preventing the formation of the mitotic spindle and leading to cell cycle arrest in metaphase. Liposomal encapsulation prolongs bioavailability of vincristine, increases its delivery to tumor tissues and reduces its toxicity profile. Compared to standard liposomal delivery, sphingosomal drug delivery further increases circulation time of serum drug and enhances drug accumulation at tumor sites, thereby leading to a further increase in efficacy.","Vincristine Sulfate Liposome | Marqibo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406603","Skindex-29 Questionnaire","C172756","A disease-specific questionnaire that assesses the effects of skin diseases on a patient's quality of life. It is designed to discriminate between patients with different effects, as well as to detect changes in a patient over time.","Skindex-29 Questionnaire | Skindex-29",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406606","Skin Hurts","C172757","A response indicating that an individual's skin hurts.","Skin Hurts | My skin hurts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406605","Skin Condition Affect Sleep Quality","C172758","A response indicating that an individual's skin condition affects how well they sleep.","Skin Condition Affect Sleep Quality | My skin condition affects how well I sleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406608","Worry that Skin Condition May Be Serious","C172759","A response indicating that an individual worries that their skin condition may be serious.","Worry that Skin Condition May Be Serious | I worry that my skin condition may be serious",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406607","Skin Condition Makes it Hard to Work or Do Hobbies","C172760","A response indicating an individual's skin condition makes it hard to work or do hobbies.","Skin Condition Makes it Hard to Work or Do Hobbies | My skin condition makes it hard to work or do hobbies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406636","Skin Condition Affects Social Life","C172761","A response indicating an individual's skin condition affects their social life.","Skin Condition Affects Social Life | My skin condition affects my social life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406635","Skin Condition Causes Feelings of Depression","C172762","A response indicating that an individual's skin condition makes them feel depressed.","Skin Condition Causes Feelings of Depression | My skin condition makes me feel depressed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406638","Skin Condition Burns or Stings","C172763","A response indicating that an individual's skin condition burns or stings.","Skin Condition Burns or Stings | My skin condition burns or stings",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406637","Tend to Stay at Home Because of Skin Condition","C172764","A response indicating that an individual tends to stay at home because of their skin condition.","Tend to Stay at Home Because of Skin Condition | I tend to stay at home because of my skin condition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406640","Worry About Getting Scars from Skin Condition","C172765","A response indicating that an individual worries about getting scars from their skin condition.","Worry About Getting Scars from Skin Condition | I worry about getting scars from my skin condition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406639","Skin Itches","C172766","A response indicating that an individual's skin itches.","Skin Itches | My skin itches",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406642","Skin Condition Affects Closeness with Loved Ones","C172767","A response indicating that an individual's skin condition affects how close they can be with loved ones.","Skin Condition Affects Closeness with Loved Ones | My skin condition affects how close I can be with those I love",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406641","Ashamed of Skin Condition","C172768","A response indicating that an individual feels ashamed of their skin condition.","Ashamed of Skin Condition | I am ashamed of my skin condition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406644","Worry that Skin Condition May Get Worse","C172769","A response indicating that an individual worries that their skin condition may get worse.","Worry that Skin Condition May Get Worse | I worry that my skin condition may get worse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406643","Tend to Do Things Alone Because of Skin Condition","C172770","A response indicating that an individual tends to do things alone because of their skin condition.","Tend to Do Things Alone Because of Skin Condition | I tend to do things by myself because of my skin condition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406646","Angry About Skin Condition","C172771","A response indicating that an individual is angry about their skin condition.","Angry About Skin Condition | I am angry about my skin condition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406645","Water Bothers Skin Condition","C172772","A response indicating that water bothers an individual's skin condition.","Water Bothers Skin Condition | Water bothers my skin condition (bathing, washing hands)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406647","Worry About Side-Effects from Skin Medications and Treatments","C172774","A response indicating that an individual worries about the side-effects from skin medications and treatments.","Worry About Side-Effects from Skin Medications and Treatments | I worry about side-effects from skin medications / treatments",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406650","Skin is Irritated","C172775","A response indicating that an individual's skin is irritated.","Skin is Irritated | My skin is irritated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406649","Skin Condition Affects Interactions with Others","C172776","A response indicating that an individual's skin condition affects their interactions with others.","Skin Condition Affects Interactions with Others | My skin condition affects my interactions with others",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406623","Embarrassed by Skin Condition","C172777","A response indicating that an individual is embarrassed by their skin condition.","Embarrassed by Skin Condition | I am embarrassed by my skin condition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406622","Skin Condition is a Problem for Loved Ones","C172778","A response indicating that an individual's skin condition is a problem for their loved ones.","Skin Condition is a Problem for Loved Ones | My skin condition is a problem for the people I love",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406625","Frustrated By Skin Condition","C172779","A response indicating that an individual is frustrated by their skin condition.","Frustrated By Skin Condition | I am frustrated by my skin condition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406624","Skin is Sensitive","C172780","A response indicating that an individual's skin is sensitive.","Skin is Sensitive | My skin is sensitive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406627","Skin Condition Affects Desire to Be with People","C172781","A response indicating that an individual's skin condition affects their desire to be with people.","Skin Condition Affects Desire to Be with People | My skin condition affects my desire to be with people",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406626","Humiliated by Skin Condition","C172782","A response indicating that an individual is humiliated by their skin condition.","Humiliated by Skin Condition | I am humiliated by my skin condition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406629","Skin Condition Bleeds","C172783","A response indicating that an individual's skin condition bleeds.","Skin Condition Bleeds | My skin condition bleeds",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406628","Annoyed By Skin Condition","C172784","A response indicating that an individual is annoyed by their skin condition.","Annoyed By Skin Condition | I am annoyed by my skin condition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406631","Skin Condition Interferes with Sex Life","C172785","A response indicating that an individual's skin condition interferes with their sex life.","Skin Condition Interferes with Sex Life | My skin condition interferes with my sex life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406630","Skin Condition Causes Tiredness","C172786","A response indicating that an  individual's skin condition makes them tired.","Skin Condition Causes Tiredness | My skin condition makes me tired",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553297","Voxelotor","C152089","An orally bioavailable modulator and stabilizer of sickle cell hemoglobin (HbS), with potential use in the treatment of sickle cell disease (SCD).  Upon administration, voxelotor targets and covalently binds to the N-terminal valine of the alpha chain of HbS. This stabilizes HbS, thereby improving oxygen binding affinity. The binding of voxelotor to HbS prevents HbS polymerization, reduces sickling, decreases red blood cell (RBC) damage and increases the half-life of RBCs. This improves blood flow and decreases hemolytic anemia.","Voxelotor | Benzaldehyde, 2-Hydroxy-6-((2-(1-(1-methylethyl)-1H-pyrazol-5-yl)-3-pyridinyl)methoxy)- | GBT 440 | GBT-440 | GBT440 | GTX 011 | GTX-011 | GTX011 | Oxbryta | VOXELOTOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519758","Crizanlizumab","C133543","A humanized monoclonal immunoglobulin G1 anti-P-selectin antibody with vaso-protective and anti-vaso-occlusive properties. Upon administration, crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand-1 (PSGL-1; SELPLG) on neutrophils and monocytes. P-selectin, a glycoprotein that functions as a cell adhesion molecule (CAM), translocates to the surface of activated endothelial cells and platelets, upon stimulation, where it binds to its ligand and mediates the rolling of platelets and neutrophils on activated endothelial cells. Therefore, blockade of p-selectin may inhibit platelet aggregation, maintain blood flow and minimize sickle cell-related pain crises (SCPC).","Crizanlizumab | Adakveo | CRIZANLIZUMAB | Crizanlizumab-tmca | SEG 101 | SEG-101 | SEG101 | SelG1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951713","Other Histologic Type","C159613","A selected option that indicated an other histologic type.","Other Histologic Type | Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0272084","Sickle Cell-Hemoglobin D Disease","C155310","A variant of sickle cell disease due to heterozygosity for hemoglobin S and hemoglobin D mutations. Patients present with the symptoms of sickle cell disease but the symptoms are less frequent and severe compared to patients with hemoglobin SS disease.","Sickle Cell-Hemoglobin D Disease | Hemoglobin SD Disease",,,,,,,,,,,,,,,"4103763","Sickle cell-hemoglobin D disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0271985","Delta-Beta Thalassemia","C172823","A form of beta thalassemia characterized by decreased or absent synthesis of both the delta- and beta-globin chains, which leads to a compensatory increase in fetal gamma-chain synthesis. This disorder results in a microcytic anemia that is clinically mild.","Delta-Beta Thalassemia | Delta Beta 0 Thalassemia | Hb delta beta0 Thalassemia",,,,,,,,,,,,,,,"4038772","Delta beta thalassemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1849766","Periportal Fibrosis","C172824","Fibrosis surrounding a portal tract that may extend to the adjacent liver parenchyma. It may be associated with periportal inflammation, hepatocyte necrosis, chronic active hepatitis and chronic cholestasis.","Periportal Fibrosis | PPF | Peri-Portal Fibrosis",,,,,,,,,,,,,,,"3655942","Periportal fibrosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1406886","5-D Itch Scale","C172827","A questionnaire consisting of 5 items used to measure the course of itch by asking for the degree, duration, disability, and distribution of the pruritus within the last 2 weeks.","5-D Itch Scale | 5-D | 5D-Itch",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406888","Pruritus Duration Per Day","C172829","A question about the daily duration of pruritus experienced by an individual.","Pruritus Duration Per Day | Duration: During the last 2 weeks, how many hours a day have you been itching",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406887","Pruritus Degree","C172830","A question about the intensity of pruritus experienced by an individual.","Pruritus Degree | Degree: Please rate the intensity of your itching over the past 2 weeks",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406890","Pruritus Direction","C172831","A question about whether an individual's pruritus improved or worsened compared to the previous month.","Pruritus Direction | Direction: Over the past 2 weeks, has your itching gotten better or worse compared to the previous month | Pruritus Improvement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406889","Pruritus Disability","C172832","A question about the impact of pruritus on an individual's activities.","Pruritus Disability | Disability: Rate the impact of your itching on the following activities over the last 2 weeks",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406892","Pruritus Sleep Disability","C172833","A question about the impact of pruritus on an individual's sleep.","Pruritus Sleep Disability | Sleep Disability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406891","Pruritus Leisure or Social Disability","C172834","A question about the impact of pruritus on an individual's leisure or social activities.","Pruritus Leisure or Social Disability | Leisure/Social",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406894","Pruritus Housework or Errands Disability","C172835","A question about the impact of pruritus on an individual's housework or errand activities.","Pruritus Housework or Errands Disability | Housework/Errands",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406893","Pruritus Work or School Disability","C172836","A question about the impact of pruritus on an individual's work or school activities.","Pruritus Work or School Disability | Work/School",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406896","Unbearable","C172837","A subjective response indicating that something is unbearable.","Unbearable | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406895","Completely Resolved","C172838","A subjective response indicating that something has completely resolved.","Completely Resolved | Completely resolved | Resolved Completely",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406898","Much Better, Still Present","C172839","A subjective response indicating that something is much better, but still present.","Much Better, Still Present | Much better, but still present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406897","Little Better, Still Present","C172840","A subjective response indicating that something is a little bit better, but still present.","Little Better, Still Present | Little bit better, but still present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714497","Reactive Airway Disease","C113673","Coughing, wheezing, or shortness of breath that is triggered by allergens, infection, or other irritants.","Reactive Airway Disease | Hyperactive Airway Disease | Reactive Airway Disease (AQ)",,,,,,,,,,,,,,,"42873168","Reactive airway disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0346202","Cervical Adenosquamous Carcinoma","C4519","An uncommon carcinoma arising from the cervix.  It is composed of malignant glandular epithelial cells and malignant squamous epithelial cells.","Cervical Adenosquamous Carcinoma | Adenosquamous Carcinoma | Adenosquamous Cell Carcinoma of Cervix | Adenosquamous Cell Carcinoma of Cervix Uteri | Adenosquamous Cell Carcinoma of Uterine Cervix | Adenosquamous Cell Carcinoma of the Cervix | Adenosquamous Cell Carcinoma of the Cervix Uteri | Adenosquamous Cell Carcinoma of the Uterine Cervix | Cervical Adenosquamous Cancer | Cervical Adenosquamous Cell Carcinoma | Cervix Adenosquamous Cell Carcinoma | Cervix Uteri Adenosquamous Cell Carcinoma | Uterine Cervix Adenosquamous Cell Carcinoma",,,,,,,,,,,,,,,"4116081","Adenosquamous carcinoma of cervix",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518366","Cervical Non-Keratinizing Squamous Cell Carcinoma","C40188","A variant of cervical squamous cell carcinoma characterized by the presence of polygonal squamous cells. Intercellular bridges and cytoplasmic keratinization may be present, but keratin pearls are absent.","Cervical Non-Keratinizing Squamous Cell Carcinoma | Cervical Nonkeratinizing Squamous Cell Carcinoma | Squamous Cell Carcinoma, Non-Keratinizing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517658","Cervical Keratinizing Squamous Cell Carcinoma","C40187","A variant of cervical squamous cell carcinoma characterized by the presence of keratin pearls. Intercellular bridges and cytoplasmic keratinization are usually present.","Cervical Keratinizing Squamous Cell Carcinoma | Squamous Cell Carcinoma, Keratinizing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951626","Menopause Status not Evaluated","C159772","The menopause status has not been evaluated.","Menopause Status not Evaluated | Not Evaluated: Not provided or available",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951569","Indeterminate or Unknown Menopause Status","C159630","The menopause status is unknown.","Indeterminate or Unknown Menopause Status | Indeterminate or Unknown: Could not be determined or unsure.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937145","Use of Hormonal Contraceptives","C157410","The current status of an individual with regards to contraceptive use.","What is the Hormonal Contraceptive Use Status | Use of Hormonal Contraceptives | hormonal contraceptive use | hormonal_contraceptive_use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969600","Never Used Hormonal Contraceptives","C160673","The individual has never used of hormonal contraceptives.","Never Used Hormonal Contraceptives | Never Used",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969601","Former Hormonal Contraceptive User","C160672","The individual is a former user of hormonal contraceptives.","Former Hormonal Contraceptive User | Former User",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969602","Current Hormonal Contraceptive User","C160671","The individual is a current user of hormonal contraceptives.","Current Hormonal Contraceptive User | Current User",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951712","HPV-Other Type","C159818","An indication that the strain of human papillomavirus (HPV) was identified in the study but is not present in the form.","HPV-Other Type | Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936873","HPV-Low Risk","C157254","Any of a number of strains of human papillomavirus (HPV) that cause genital warts in humans and are rarely associated with carcinogenesis.","HPV-Low Risk | Low Risk HPV | Low Risk Human Papilloma Virus | Low Risk Human Papillomavirus | Low-Risk HPV | Low-Risk HPV Strain | Low-Risk HPV Subtype | Low-Risk Human Papilloma Virus | Low-Risk Human Papillomavirus | Low-Risk Subtype (6, 11, etc.)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936874","HPV Typing Method","C157255","The method used to perform human papillomavirus (HPV) genotyping.","HPV Typing Method | Human Papilloma Virus Typing Method | Human Papillomavirus Typing Method | Method of HPV Typing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951714","Other HPV Typing Method","C159820","An indication that the method used to perform human papillomavirus (HPV) genotyping was identified in the study but is not present in the form.","Other HPV Typing Method | Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937141","Roche HPV Lab Test","C157414","A human papilloma virus test developed by Roche laboratories.","Roche HPV Lab Test | Roche",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937136","Qiagen HPV Lab Test","C157415","A human papilloma virus test developed by Qiagen laboratories.","Qiagen HPV Lab Test | Qiagen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936821","Specify HPV Genotype","C157110","A directive to specify the genotype determined by HPV Genotyping.","Specify HPV Genotype | HPV Genotype | hpv positive type | hpv strain | hpv_positive_type | hpv_strain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545859","ROS1 Gene Inversion","C148100","A genetic rearrangement that refers to any inversion involving the ROS1 gene.","ROS1 Gene Inversion | MCF3 Gene Inversion | ROS Gene Inversion | ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene Inversion | ROS1 Inversion | ROS1 Inversion Mutation | c-ros-1 Gene Inversion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406929","FoundationOne Genomic Profiling","C172873","A set of proprietary genomic profiling techniques that utilize next generation sequencing. FoundationOne CDX is optimized for PPFE samples from solid tumors; FoundationOne Liquid is optimized for peripheral whole blood, targeting solid tumors; FoundationOne Heme is optimized for leukemias, lymphomas, sarcomas, and solid tumors using RNA sequencing on samples obtained from FFPE, peripheral whole blood, or bone marrow aspirate.","FoundationOne Genomic Profiling | FoundationOne",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406928","Guardant360 Genomic Profiling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406931","Extrapelvic","C172875","Situated outside of the pelvis.","Extrapelvic | Extra-pelvic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015357","Extracorporeal Membrane Oxygenation","C171507","A technique that utilizes a device to pump a patient's blood outside of the body, oxygenate it, and return it to the body.","Extracorporeal Membrane Oxygenation | ECMO | EXTRACORPOREAL MEMBRANE OXYGENATION",,,,,,,,,,,,,,,"4052536","Extracorporeal membrane oxygenation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2986496","Noninvasive","C94381","In medicine, it describes a procedure that does not require inserting an instrument through the skin or into a body opening. In cancer, it describes disease that has not spread outside the tissue in which it began.","Noninvasive | noninvasive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4048192","Intrapelvic","C94249","Within the pelvis, the lower part of the abdomen between the hip bones.","Intrapelvic | intrapelvic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502477","Distribution","C123937","The placement, arrangement of instance of entities within a space.","Distribution | DISTR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406760","Micromole Iron per Gram Liver (Dry Weight)","C172930","A measurement of iron in the liver expressed as a ratio of micromoles of iron to grams of dry weight of the liver sample.","Micromole Iron per Gram Liver (Dry Weight) | umol Fe/g liver dry weight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3846005","Room Air","C172931","Unmodified air as existing in the immediate surroundings.","Room Air | Ambient Air",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406764","Never Affects Sleep","C172933","A response indicating that something never affects an individual's sleep.","Never Affects Sleep | 1 - Never affects sleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406763","Occasionally Delays Falling Asleep","C172934","A response indicating that something occasionally delays an individual's falling sleep.","Occasionally Delays Falling Asleep | 2 - Occasionally delays falling asleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406766","Frequently Delays Falling Asleep","C172935","A response indicating that something frequently delays an individual's falling sleep.","Frequently Delays Falling Asleep | 3 - Frequently delays falling asleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406765","Delays Falling Asleep and Occasionally Wakes Me Up at Night","C172936","A response indicating that something delays an individual's falling sleep and occasionally wakes them up at night.","Delays Falling Asleep and Occasionally Wakes Me Up at Night | 4 - Delays falling asleep and occasionally wakes me up at night",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406768","Delays Falling Asleep and Frequently Wakes Me Up at Night","C172937","A response indicating that something delays an individual's falling sleep and frequently wakes them up at night.","Delays Falling Asleep and Frequently Wakes Me Up at Night | 5 - Delays falling asleep and frequently wakes me up at night",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406761","Gram Iron per kilogram liver (Dry Weight)","C172929","A measurement of iron in the liver expressed as a ratio of grams of iron to kilograms of dry weight of the liver sample.","Gram Iron per kilogram liver (Dry Weight) | g Fe/kg liver dry weight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1300813","Abdominal Circumference","C172954","The measurement of the distance around the abdomen, usually at the level of the umbilicus.","Abdominal Circumference | Abdominal Girth",,,,,,,,,,,,,,,"4245376","Abdominal circumference",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1406751","Hemoglobin A1","C172943","A tetrameric complex of 2 molecules of hemoglobin subunit alpha (encoded by either the HBA1 or HBA2 gene) and 2 molecules of hemoglobin subunit beta (encoded by the HBB gene).","Hemoglobin A1 | Adult Hemoglobin | Hb A | Hb A1 | Hb a2b2 | Hemoglobin A | Hemoglobin Alpha2Beta2 | Hgb A1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407066","Hemoglobin A2","C172944","A tetrameric complex of 2 molecules of hemoglobin subunit alpha (encoded by either the HBA1 or HBA2 gene) and 2 molecules of hemoglobin subunit delta (encoded by the HBD gene).","Hemoglobin A2 | Hb A2 | Hb a2d2 | Hemoglobin Alpha2Delta2 | Hgb A2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407060","Hemoglobin C","C172947","A tetrameric complex of 2 molecules of hemoglobin subunit alpha (encoded by either the HBA1 or HBA2 gene) and 2 molecules of a hemoglobin subunit beta variant where the glutamic acid residue at position 7 has been replaced by lysine.","Hemoglobin C | Hb C | Hgb C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015936","Hemoglobin F","C172948","A tetrameric complex of 2 molecules of hemoglobin subunit alpha (encoded by either the HBA1 or HBA2 gene) and 2 molecules of hemoglobin subunit gamma (encoded by either the HBG1 or HBG2 gene).","Hemoglobin F | Fetal Hemoglobin | Hb F | Hb a2g2 | Hemoglobin Alpha2Gamma2 | Hgb F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3888302","HEMOGLOBIN S PHENOTYPE","C172950","A tetrameric complex of 2 molecules of hemoglobin subunit alpha (encoded by either the HBA1 or HBA2 gene) and 2 molecules of a hemoglobin subunit beta variant where the glutamic acid residue at position 7 has been replaced by valine.","Hemoglobin S | Hb S | Hgb S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407088","Concerns About Recurrence Scale","C172882","A scale designed to systematically assess the extent and nature of a woman's fears about the possibility of breast cancer recurrence.","Concerns About Recurrence Scale | CARS | Concerns About Recurrence Scale (CARS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406906","How Much Time Spent Thinking About Possibility of Breast Cancer Recurrence","C172884","A question about how much time an individual spends thinking about the possibility that their breast cancer could recur.","How Much Time Spent Thinking About Possibility of Breast Cancer Recurrence | How much time do you spend thinking about the possibility that your breast cancer could recur",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406909","How Upset About Possibility of Breast Cancer Recurrence","C172885","A question about how much the possibility that their breast cancer could recur upsets an individual.","How Upset About Possibility of Breast Cancer Recurrence | How much does the possibility that your breast cancer could recur upset you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406908","How Often Worry About Possibility of Breast Cancer Recurrence","C172886","A question about how often an individual worries about the possibility that their breast cancer could recur.","How Often Worry About Possibility of Breast Cancer Recurrence | How often do you worry about the possibility that your breast cancer could recur",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406911","How Afraid That Breast Cancer May Recur","C172887","A question about how afraid an individual is that their breast cancer may recur.","How Afraid That Breast Cancer May Recur | How afraid are you that your breast cancer may recur",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406910","Worry That Breast Cancer Recurrence Would Cause Emotional Upset","C172888","A question about whether an individual worries that recurrence of their breast cancer would upset them emotionally.","Worry That Breast Cancer Recurrence Would Cause Emotional Upset | Upset me emotionally",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406913","Worry that Breast Cancer Recurrence Would Keep Me From Doing Planned Things","C172889","A question about whether an individual worries that recurrence of their breast cancer would keep them from doing things they had planned to do.","Worry that Breast Cancer Recurrence Would Keep Me From Doing Planned Things | Keep me from doing the things I had planned to do",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406912","Worry that Breast Cancer Recurrence Would Threaten Physical Health","C172890","A question about whether an individual worries that recurrence of their breast cancer would threaten their physical health.","Worry that Breast Cancer Recurrence Would Threaten Physical Health | Threaten my physical health",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406915","Worry that Breast Cancer Recurrence Would Make Me Feel Less of a Woman","C172891","A question about whether an individual worries that recurrence of their breast cancer would make them feel less of a woman.","Worry that Breast Cancer Recurrence Would Make Me Feel Less of a Woman | Make me feel I am less of a woman",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406914","Worry that Breast Cancer Recurrence Would Require Chemotherapy","C172892","A question about whether an individual worries that recurrence of their breast cancer would require chemotherapy.","Worry that Breast Cancer Recurrence Would Require Chemotherapy | Require chemotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406949","Worry that Breast Cancer Recurrence Would Hurt Relationships with Friends and Family","C172893","A question about whether an individual worries that recurrence of their breast cancer would hurt relationships with friends and family.","Worry that Breast Cancer Recurrence Would Hurt Relationships with Friends and Family | Hurt my relationships with friends and family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406948","Worry that Breast Cancer Recurrence Would Make Me Feel I Don't Have Control Over my Life","C172894","A question about whether an individual worries that recurrence of their breast cancer would make them feel they don't have control over their life.","Worry that Breast Cancer Recurrence Would Make Me Feel I Don't Have Control Over my Life | Make me feel that I don't have control over my life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406951","Worry that Breast Cancer Recurrence Would Threaten My Identity","C172895","A question about whether an individual worries that recurrence of their breast cancer would threaten their identity.","Worry that Breast Cancer Recurrence Would Threaten My Identity | Threaten my identity (how I see myself)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406950","Worry that Breast Cancer Recurrence Would Interfere with Physical Ability to Carry Out Daily Activities","C172896","A question about whether an individual worries that recurrence of their breast cancer would interfere with their physical ability to carry out daily activities.","Worry that Breast Cancer Recurrence Would Interfere with Physical Ability to Carry Out Daily Activities | Interfere with my physical ability to carry out daily activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406953","Worry that Breast Cancer Recurrence Would Threaten my Life","C172897","A question about whether an individual worries that recurrence of their breast cancer would threaten their life.","Worry that Breast Cancer Recurrence Would Threaten my Life | Threaten my life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406952","Worry that Breast Cancer Recurrence Would Harm Self-Confidence","C172898","A question about whether an individual worries that recurrence of their breast cancer would harm their self-confidence.","Worry that Breast Cancer Recurrence Would Harm Self-Confidence | Harm my self-confidence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406955","Worry that Breast Cancer Recurrence Would be More Serious than First Diagnosis","C172899","A question about whether an individual worries that recurrence of their breast cancer would be more serious than the first diagnosis.","Worry that Breast Cancer Recurrence Would be More Serious than First Diagnosis | Be more serious than the first diagnosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406954","Worry that Breast Cancer Recurrence Would Cause Financial Problems","C172900","A question about whether an individual worries that recurrence of their breast cancer would cause them financial problems.","Worry that Breast Cancer Recurrence Would Cause Financial Problems | Cause financial problems for me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406957","Worry that Breast Cancer Recurrence Would Interfere with Sense of Sexuality","C172901","A question about whether an individual worries that recurrence of their breast cancer would interfere with their sense of sexuality.","Worry that Breast Cancer Recurrence Would Interfere with Sense of Sexuality | Interfere with my sense of sexuality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406956","Worry that Breast Cancer Recurrence Would Require Radiation Treatment","C172902","A question about whether an individual worries that recurrence of their breast cancer would require radiation treatment.","Worry that Breast Cancer Recurrence Would Require Radiation Treatment | Require radiation treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406959","Worry that Breast Cancer Recurrence Would Cause Pain and Suffering","C172903","A question about whether an individual worries that recurrence of their breast cancer would cause them pain and suffering.","Worry that Breast Cancer Recurrence Would Cause Pain and Suffering | Cause me pain and suffering",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406958","Worry that Breast Cancer Recurrence Would Mean Losing my Breast(s)","C172904","A question about whether an individual worries that recurrence of their breast cancer would mean losing their breast(s).","Worry that Breast Cancer Recurrence Would Mean Losing my Breast(s) | Mean losing my breasts(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406961","Worry that Breast Cancer Recurrence Would Interfere with Ability to Plan for Future","C172905","A question about whether an individual worries that recurrence of their breast cancer would interfere with their ability to plan for the future.","Worry that Breast Cancer Recurrence Would Interfere with Ability to Plan for Future | Interfere with my ability to plan for the future",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406960","Worry that Breast Cancer Recurrence Would Threaten My Spirituality or Faith","C172906","A question about whether an individual worries that recurrence of their breast cancer would threaten their spirituality or faith.","Worry that Breast Cancer Recurrence Would Threaten My Spirituality or Faith | Threaten my spirituality or faith",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406963","Worry that Breast Cancer Recurrence Would Lead Me to Feel Less Feminine","C172907","A question about whether an individual worries that recurrence of their breast cancer would lead them to feel less feminine.","Worry that Breast Cancer Recurrence Would Lead Me to Feel Less Feminine | Lead me to feel less feminine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406933","Worry that Breast Cancer Recurrence Would Require Further Surgery","C172909","A question about whether an individual worries that recurrence of their breast cancer would require further surgery.","Worry that Breast Cancer Recurrence Would Require Further Surgery | Require further surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406932","Worry that Breast Cancer Recurrence Would Cause Me to Die","C172910","A question about whether an individual worries that recurrence of their breast cancer would cause them to die.","Worry that Breast Cancer Recurrence Would Cause Me to Die | Cause me to die",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406935","Worry that Breast Cancer Recurrence Would Damage my Romantic Relationship(s)","C172911","A question about whether an individual worries that recurrence of their breast cancer would damage their romantic relationship(s).","Worry that Breast Cancer Recurrence Would Damage my Romantic Relationship(s) | Damage my romantic relationship(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406934","Worry that Breast Cancer Recurrence Would Keep me From Fulfilling Responsibilities","C172912","A question about whether an individual worries that recurrence of their breast cancer would keep them from their fulfilling responsibilities.","Worry that Breast Cancer Recurrence Would Keep me From Fulfilling Responsibilities | Keep me from fulfilling my responsibilities (in my job or at home)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406937","Worry that Breast Cancer Recurrence Would Make Me Feel Badly about how My Body Looks or Feels","C172913","A question about whether an individual worries that recurrence of their breast cancer would make them feel badly about how their body looks or feels.","Worry that Breast Cancer Recurrence Would Make Me Feel Badly about how My Body Looks or Feels | Make me feel badly about how my body looks or feels",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406942","Thought Likert Scale","C172920","A scale for the subjective scoring of thought that ranges from 1: I don't think about it at all to 6: I think about it all the time.","Thought Likert Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541318","Thought Score 1","C172956","A response of 1 on a scale for the subjective scoring of thought that ranges from 1: I don't think about it at all to 6: I think about it all the time.","Thought Score 1 | 1 | 1: I Don't think about it at all",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407100","Thought Score 2","C172957","A response of 2 on a scale for the subjective scoring of thought that ranges from 1: I don't think about it at all to 6: I think about it all the time.","Thought Score 2 | 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407096","Thought Score 3","C172958","A response of 3 on a scale for the subjective scoring of thought that ranges from 1: I don't think about it at all to 6: I think about it all the time.","Thought Score 3 | 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407097","Thought Score 4","C172959","A response of 4 on a scale for the subjective scoring of thought that ranges from 1: I don't think about it at all to 6: I think about it all the time.","Thought Score 4 | 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407092","Thought Score 5","C172960","A response of 5 on a scale for the subjective scoring of thought that ranges from 1: I don't think about it at all to 6: I think about it all the time.","Thought Score 5 | 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407073","Thought Score 6","C172961","A response of 6 on a scale for the subjective scoring of thought that ranges from 1: I don't think about it at all to 6: I think about it all the time.","Thought Score 6 | 6 | 6: I think about it all the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406945","Upset Likert Scale","C172921","A scale for the subjective scoring of upset that ranges from 1: It does not upset me at all to 6: It makes me extremely upset.","Upset Likert Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407094","Upset Score 1","C172962","A response of 1 on a scale for the subject scoring of upset that ranges from 1: It does not upset me at all to 6: It makes me extremely upset.","Upset Score 1 | 1 | 1: It does not upset me at all",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407098","Upset Score 2","C172963","A response of 2 on a scale for the subject scoring of upset that ranges from 1: It does not upset me at all to 6: It makes me extremely upset.","Upset Score 2 | 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407108","Upset Score 3","C172964","A response of 3 on a scale for the subject scoring of upset that ranges from 1: It does not upset me at all to 6: It makes me extremely upset.","Upset Score 3 | 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407107","Upset Score 4","C172965","A response of 4 on a scale for the subject scoring of upset that ranges from 1: It does not upset me at all to 6: It makes me extremely upset.","Upset Score 4 | 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978373","Upset Score 5","C172966","A response of 5 on a scale for the subject scoring of upset that ranges from 1: It does not upset me at all to 6: It makes me extremely upset.","Upset Score 5 | 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406782","Upset Score 6","C172967","A response of 6 on a scale for the subject scoring of upset that ranges from 1: It does not upset me at all to 6: It makes me extremely upset.","Upset Score 6 | 6: It makes me extremely upset",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406944","Worry Likert Scale","C172922","A scale for the subjective scoring of worry that ranges from 1: I never worry about it to 6: I worry about it all the time.","Worry Likert Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407104","Worry Score 1","C172968","A response of 1 on a scale for the subjective scoring of worry that ranges from 1: I never worry about it to 6: I worry about it all the time.","Worry Score 1 | 1 | 1: I never worry about it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407101","Worry Score 2","C172969","A response of 2 on a scale for the subjective scoring of worry that ranges from 1: I never worry about it to 6: I worry about it all the time.","Worry Score 2 | 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407102","Worry Score 3","C172970","A response of 3 on a scale for the subjective scoring of worry that ranges from 1: I never worry about it to 6: I worry about it all the time.","Worry Score 3 | 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407105","Worry Score 4","C172971","A response of 4 on a scale for the subjective scoring of worry that ranges from 1: I never worry about it to 6: I worry about it all the time.","Worry Score 4 | 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439084","Worry Score 5","C172972","A response of 5 on a scale for the subjective scoring of worry that ranges from 1: I never worry about it to 6: I worry about it all the time.","Worry Score 5 | 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407072","Worry Score 6","C172973","A response of 6 on a scale for the subjective scoring of worry that ranges from 1: I never worry about it to 6: I worry about it all the time.","Worry Score 6 | 6 | 6: I worry about it all the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406947","Fear Likert Scale","C172923","A scale for the subjective scoring of fear that ranges from 1: Not at all afraid to 6: Very afraid.","Fear Likert Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407093","Fear Score 1","C172974","A response of 1 on a scale for the subjective scoring of fear that ranges from 1: Not at all afraid to 6: I Very afraid.","Fear Score 1 | 1 | 1: Not at all afraid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1314971","Fear Score 2","C172975","A response of 2 on a scale for the subjective scoring of fear that ranges from 1: Not at all afraid to 6: Very afraid.","Fear Score 2 | 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407099","Fear Score 3","C172976","A response of 3 on a scale for the subjective scoring of fear that ranges from 1: Not at all afraid to 6: Very afraid.","Fear Score 3 | 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407106","4+ Answer to question","C172977","A response of 4 on a scale for the subjective scoring of fear that ranges from 1: Not at all afraid to 6: Very afraid.","Fear Score 4 | 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407091","Fear Score 5","C172978","A response of 5 on a scale for the subjective scoring of fear that ranges from 1: Not at all afraid to 6: Very afraid.","Fear Score 5 | 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406772","Fear Score 6","C172979","A response of 6 on a scale for the subjective scoring of fear that ranges from 1: Not at all afraid to 6: Very afraid.","Fear Score 6 | 6 | 6: Very afraid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406776","Bothered by Vaginal Discharge","C172983","A question about whether an individual is or was bothered by vaginal discharge.","Bothered by Vaginal Discharge | Vaginal discharge",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406775","Bothered by Vaginal Bleeding or Spotting","C172984","A question about whether an individual is or was bothered by vaginal bleeding or spotting.","Bothered by Vaginal Bleeding or Spotting | Vaginal bleeding or spotting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406778","Bothered by Lack of Interest in Sex","C172985","A question about whether an individual is or was bothered by lack of interest in sex.","Bothered by Lack of Interest in Sex | Lack of interest in sex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406777","Bothered by Low Sexual Enjoyment","C172986","A question about whether an individual is or was bothered by low sexual enjoyment.","Bothered by Low Sexual Enjoyment | Low sexual enjoyment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406811","PROMIS Short Form-Social Isolation-4a","C173003","A patient reported outcomes measure that assesses perceptions of being avoided, excluded, detached, disconnected from, or unknown by, others.","PROMIS Short Form-Social Isolation-4a | PROMIS Item Bank v2.0 - Social Isolation - Short Form 4a | PROMIS Short Form - Social Isolation - 4a | PROMIS Short Form v2.0 - Social Isolation 4a | PROMIS-SI-4a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4034876","Feel People Barely Know Me","C173007","A question about whether an individual feels that people barely know them.","Feel People Barely Know Me | I feel that people barely know me | People Barely Know Me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4034874","Feel People Are Around Me but Not with Me","C173010","A question about whether an individual feels that people are around them but not with them.","Feel People Are Around Me but Not with Me | I feel that people are around me but not with me | People Are Around Me but Not with Me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407068","Very Low Density Lipoprotein","C173032","The lipoprotein fraction in plasma that primarily transports triglycerides synthesized in the liver to peripheral tissues where they may be utilized to generate energy in muscle or stored as reserves in adipose. As the triglycerides are hydrolyzed from their very low density lipoprotein (VLDL) carriers, the VLDL remnants (intermediate density lipoproteins, IDLs) may be further metabolized into low density lipoproteins (LDLs) which may ultimately promote atherogenesis. Alternatively, VLDL remnants may accept cholesterol esters transferred from high density lipoproteins (HDLs) and then be recycled to the liver.","Very Low Density Lipoprotein | VLDL",,,,,,,,,,,,,,,"4017203","pre-beta-Lipoprotein measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1406797","Mean Fluorescence Intensity of Donor-Specific Antibodies","C173024","A measurement of antibodies in an individual that are directed against HLAs in a donor tissue and can cause antibody-mediated transplant rejection. The mean fluorescence intensity (MFI) is a measure of the degree of saturation of total antigens present on the beads by antibodies in an ELISA assay and is used as a surrogate marker for the level of antibody titers.","Mean Fluorescence Intensity of Donor-Specific Antibodies | MFI of DSA | MFI of Donor-Specific Antibodies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406988","Symptoms Consistent with COVID-19","C173069","An indication that an individual's symptoms are consistent with a diagnosis of COVID-19.","Symptoms Consistent with COVID-19 | Symptoms consistent with COVID-19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406989","Routine COVID-19 Test Prior to Anti-cancer Treatment","C173068","Testing for Sars-CoV-2 virus or antibodies against the virus in an asymptomatic individual, prior to them receiving anti-cancer treatment.","Routine COVID-19 Test Prior to Anti-cancer Treatment | Routine test prior to anti-cancer treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1096489","Vitamin K Antagonist","C173064","Any agent that inhibits the function of vitamin K, with anticoagulant activity.","Vitamin K Antagonist | VKA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407074","Direct Thrombin Inhibitor","C173066","Any agent that directly binds to and inactivates thrombin (factor IIa), with anticoagulant activity.","Direct Thrombin Inhibitor | DTI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406987","Direct Factor Xa Inhibitor","C173067","Any agent that binds to and inactivates factor Xa, with anticoagulant activity.","Direct Factor Xa Inhibitor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405796","Exposed to COVID-19","C171571","A finding indicating that an individual has been exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).","Exposed to COVID-19 | Exposed to COVID-19 patient | Exposed to SARS-CoV-2 | Exposure to infectious COVID-19 case",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555442","US Dollar","C173109","The unit of currency used in the United States and its territories. It is also used as the official currency of some foreign countries.","US Dollar | American Dollar | Dollar | Dollars | U.S. Dollar | USD | United States Dollar",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407010","MVI Regimen","C173100","A regimen that is similar to regimen M, consisting of vincristine, dactinomycin and doxorubicin plus cyclophosphamide and etoposide, but in which some of the high-dose cyclophosphamide and etoposide cycles are replaced by vincristine and irinotecan to minimize toxicity and that may be used in the treatment of Wilms tumor.","MVI Regimen | MVI | Regimen MVI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407009","VIVA Regimen","C173101","A regimen consisting of dactinomycin, irinotecan and vincristine that may be used in the treatment of Wilms tumor.","VIVA Regimen | Dactinomycin/Irinotecan/Vincristine | Regimen VIVA | VIVA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3806041","Anisopoikilocytosis","C96206","A test result indicating the presence of red cells of various sizes and shapes in the peripheral blood.","Anisopoikilocytosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407087","Processing Speed Scaled Score","C173116","The sum of the scaled scores for processing speed from subtests within selected scales for intelligence.","Processing Speed Scaled Score | Processing Speed | Processing Speed Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280551","cyclophosphamide/etoposide protocol","C9713","A regimen consisting of high-dose cyclophosphamide and etoposide that may be used in the treatment of refractory acute myeloid leukemia (AML) and central nervous system (CNS) cancers.","Cyclophosphamide/Etoposide Regimen | CTX/VP-16 | CV | Cyclophosphamide and Etoposide | Cyclophosphamide-Etoposide | Cyclophosphamide/Etoposide | Etoposide-Cyclophosphamide | Etoposide/Cyclophosphamide | High-dose Cyclophosphamide/Etoposide Regimen | VP-16/Cyclophosphamide | VP-CY | VP/CY | VP/CY Regimen | VPCy | VePesid/Cyclophosphamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2605784","Vincristine-Dactinomycin-Doxorubicin Wilm's Tumor Regimen","C67303","A regimen consisting of vincristine, dactinomycin and doxorubicin, administered on a pulse-intensive dosing schedule, given in combination with radiation therapy following nephrectomy and used as a treatment for clear cell sarcoma of the kidney (CCSK) as well as advanced-stage Wilm's tumor with a favorable histology, including focal anaplastic disease.","DD-4A Regimen | DD4A | NWTS DD-4A Regimen | NWTS-DD4A | Regimen DD4A | Vincristine-Dactinomycin-Doxorubicin Wilm's Tumor Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880436","Vincristine-Dactinomycin Wilm's Tumor Regimen","C67293","A regimen consisting of vincristine and dactinomycin, administered after nephrectomy and used for the treatment of limited-stage Wilm's tumor with a favorable histology, including focal anaplastic disease.","EE-4A Regimen | EE-4A | EE4A | NWTS EE-4A Regimen | NWTS-EE4A | Vincristine-Dactinomycin Wilm's Tumor Regimen | Vincristine-Pulse Intense Dactinomycin Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951413","Education Type","C159511","An indication of the type of schooling an individual receives or received.","Education Type | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407023","Disease Free","C173158","An indication that an individual shows no signs of having or carrying a disease.","Disease Free | Disease-free",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407024","Environmental and Social Factors Domain","C173157","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to environmental and social factors that might influence a subject's disease or medical condition.","Environmental and Social Factors Domain | ER | Environmental and Social Factors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407272","NCI Drug Resistance and Sensitivity Network","C173181","An NCI program developed to conduct preclinical research focused on innovative strategies to understand and combat mechanisms of tumor resistance (intrinsic or acquired) and/or to exploit tumor sensitivity to anti-cancer therapies. It is a critical preclinical component to NCI's overall clinical drug development program. The DRSN is a part of the Cancer Moonshot initiative.","NCI Drug Resistance and Sensitivity Network | DRSN | Drug Resistance and Sensitivity Network",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407609","Cold Knife Cone Biopsy","C173180","Conization using a scalpel or laser scalpel.","Cold Knife Cone Biopsy | CKC | Cold Knife | Cold Knife Cone | Cold Knife Conization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407044","Peritoneal Implant","C173164","Deposits of borderline, malignant, and rarely benign tumors, usually from the ovary, on the peritoneal surface.","Peritoneal Implant | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972933","Medication Taken","C168327","An indication that the patient has taken medication.","Medication Taken | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405322","Autologous Bispecific CD19/CD22-targeted CAR-T Cells GC022","C171093","A preparation of autologous human T-lymphocytes engineered to express chimeric T-cell receptors (chimeric antigen receptors or CARs) targeting the tumor-associated antigens (TAAs) CD19 and CD22 and fused to as of yet not fully elucidated co-stimulatory domains, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous bispecific CD19/CD22-targeted CAR-T cells GC022 bind to CD19 and CD22 on the surface of, and induce selective toxicity against, tumor cells expressing CD19 and CD22. CD19 and CD22, both transmembrane phosphoglycoproteins expressed on the surface of cells in the B lineage, are overexpressed on malignant B-cells.","Autologous Bispecific CD19/CD22-targeted CAR-T Cells GC022 | Bispecific CAR T Cells GC022 | Dual CAR-T Cells GC022 | GC 022 | GC-022 | GC022 | GC022F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880104","Clinical Data Interchange Standards Consortium Terminology Subset","C61410","The terminology that includes terms relevant to the Clinical Data Interchange Standards Consortium.","Clinical Data Interchange Standards Consortium Terminology | CDISC | CDISC Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407245","Cerebral Blood Flow Velocity","C173396","The rate of blood flow through the cerebral arteries.","Cerebral Blood Flow Velocity | CBF Velocity | CBFV | Transcranial Doppler Velocity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206063","Radiation-Induced Pneumonitis","C27932","Pneumonitis that is associated with irradiation.","Radiation-Induced Pneumonitis | ",,,,,,,,,,,,,,,"4221865","Radiation pneumonitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL369942","metastatic_site","C172233","The anatomical location where metastasis was detected.","Site of Metastasis | Anatomic Site of Metastasis | EXTENSION_SITE | Metastatic Site | metastatic site | metastatic_site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272561","Proprietary Method","C96103","An analysis that contains protected intellectual property preventing full disclosure of information about the method and/or restricting or limiting the use or distribution of the method or materials for its performance without express permission or licensing.","Proprietary Method | Proprietary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1675748","PD0325901","C52195","An orally bioavailable, synthetic organic molecule targeting mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity. Upon administration, mirdametinib selectively binds to and inhibits MEK, which may result in the inhibition of the phosphorylation and activation of MAPK/ERK and the inhibition of tumor cell proliferation. The dual specific threonine/tyrosine kinase MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors.","Mirdametinib | MEK Inhibitor PD0325901 | MEK Inhibitor PD0325901 | MIRDAMETINIB | PD 901 | PD-0325901",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443120","Plasma Product","C133266","The fluid (noncellular) portion of the circulating blood, as distinguished from the serum that is the fluid portion of the blood.","Plasma Product | Plasma",,,,,,,,,,,,,,,"4103791","Plasma product",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1407484","Mild Acute Respiratory Distress Syndrome","C173483","A form of acute respiratory distress syndrome (ARDS) that is marked by mild hypoxemia. Based on the Berlin criteria, onset must occur within one week of a clinical insult or there must be evidence of new or worsening respiratory symptoms. Chest imaging reveals bilateral opacities consistent with pulmonary edema that are not fully explained by effusions, lobar/lung collapse, or nodules. Respiratory failure is not fully explained by heart failure or fluid overload and objective assessment, e.g. echocardiography, is required to exclude hydrostatic edema if no risk factor is present. Additionally, oxygenation as measured by a partial pressure of arterial oxygen (PaO2) to the fraction of inspired oxygen (FIO2) is equivalent to between 200 and 300 mm Hg with positive end-expiratory pressure (PEEP) or continuous positive airway pressure (CPAP) of at least 5 cm of water (Ranieri VM et al., JAMA. 2012;307(23):2526-2533).","Mild Acute Respiratory Distress Syndrome | Mild ARDS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407485","Moderate Acute Respiratory Distress Syndrome","C173484","A form of acute respiratory distress syndrome (ARDS) that is marked by moderate hypoxemia. Based on the Berlin criteria, onset must occur within one week of a clinical insult or there must be evidence of new or worsening respiratory symptoms. Chest imaging reveals bilateral opacities consistent with pulmonary edema that are not fully explained by effusions, lobar/lung collapse, or nodules. Respiratory failure is not fully explained by heart failure or fluid overload and objective assessment, e.g. echocardiography, is required to exclude hydrostatic edema if no risk factor is present. Additionally, oxygenation as measured by a partial pressure of arterial oxygen (PaO2) to the fraction of inspired oxygen (FIO2) is equivalent to between 100 and 200 mm Hg with positive end-expiratory pressure (PEEP) of at least 5 cm of water (Ranieri VM et al., JAMA. 2012;307(23):2526-2533).","Moderate Acute Respiratory Distress Syndrome | Moderate ARDS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406505","Severe Acute Respiratory Distress Syndrome","C172378","A form of acute respiratory distress syndrome (ARDS) that is marked by severe hypoxemia. Based on the Berlin criteria, onset must occur within one week of a clinical insult or there must be evidence of new or worsening respiratory symptoms. Chest imaging reveals bilateral opacities consistent with pulmonary edema that are not fully explained by effusions, lobar/lung collapse, or nodules. Respiratory failure is not fully explained by heart failure or fluid overload and objective assessment, e.g. echocardiography, is required to exclude hydrostatic edema if no risk factor is present. Additionally, oxygenation as measured by a partial pressure of arterial oxygen (PaO2) to the fraction of inspired oxygen (FIO2) is equivalent to 100 mm Hg or less with positive end-expiratory pressure (PEEP) of at least 5 cm of water (Ranieri VM et al., JAMA. 2012;307(23):2526-2533). Severe ARDS may be associated with cytokine release syndrome.","Severe Acute Respiratory Distress Syndrome | Severe ARDS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828536","Plasma Protein Cryoprecipitation","C112940","A process to isolate plasma proteins by cooling the plasma to form a precipitate.","Plasma Protein Cryoprecipitation | Production, Blood Products Cyroprecipitate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407472","Berlin Criteria for Acute Respiratory Distress Syndrome","C173500","A consensus definition for acute respiratory distress syndrome that establishes three mutually exclusive categories of ARDS based on degree of hypoxemia, radiographic severity, respiratory system compliance, positive end-expiratory pressure, and corrected expired volume per minute.","Berlin Criteria for Acute Respiratory Distress Syndrome | Berlin Criteria | Berlin Criteria for ARDS | Berlin Definition | Berlin Definition of ARDS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040383","Toluene","C77930","An aromatic hydrocarbon composed of a benzene ring linked to one methyl group. Toluene is used a solvent or as a chemical intermediate in various industrial applications. Rapid inhalation of high concentrations of toluene can cause severe neurological complications.","Toluene | Benzene, Methyl- | Methane, Phenyl- | Methylbenzene | Phenylmethane | TOLUENE | Toluol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407433","2-Methylhippuric Acid","C173416","An isoform of methylhippuric acid where the methyl and glycine groups are bound to carbon-1 and carbon-2 on the benzene ring, respectively. Since 2-methylhippuric acid (2-MHA) is a metabolite of o-xylene, the measurement of 2-MHA in urine may be correlated to a subject's level of xylene exposure.","2-Methylhippuric Acid | 2-METHYLHIPPURIC ACID | 2-MHA | Glycine, N-(2-Methylbenzoyl)- (9CI) | N-(2-Methylbenzoyl)Glycine | N-(o-Toluoyl)Glycine | o-Methylhippuric Acid | o-Toluric Acid | ortho-Methylhippuric Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407434","4-methylhippuric acid","C173417","An isoform of methylhippuric acid where the methyl and glycine groups are bound to carbon-1 and carbon-4 on the benzene ring, respectively. Since 4-methylhippuric acid (4-MHA) is a metabolite of p-xylene, the measurement of 4-MHA in urine may be correlated to a subject's level of xylene exposure.","4-Methylhippuric Acid | 4-METHYLHIPPURIC ACID | 4-MHA | Glycine, N-(4-Methylbenzoyl)- (9CI) | Hippuric Acid, p-Methyl- (8CI) | N-(4-Methylbenzoyl)Glycine | N-(p-Toluoyl)Glycine | p-Methylhippuric Acid | p-Toluric Acid | para-Methylhippuric Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407428","muconic acid","C173419","An all trans dicarboxylic acid that is a metabolite of benzene and is used as a marker for occupational or environmental exposure to benzene.","t,t-Muconic Acid | (2E,4E)-2,4-Hexadienedioic Acid | (2E,4E)-Hexa-2,4-Dienedioic Acid | (E,E)-2,4-Hexadienedioic Acid | (E,E)-Muconic Acid | 2,4-Hexadienedioic Acid, (E,E)- | MUCONIC ACID | Muconic Acid | t,t-MA | trans, trans-Muconic Acid | trans,trans-2,4-Hexadienedioic Acid | trans,trans-Buta-1,3-Diene-1,4-Dicarboxylic Acid | trans,trans-Muconic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407439","3-Methylhippuric Acid","C173423","An isoform of methylhippuric acid where the methyl and glycine groups are bound to carbon-1 and carbon-3 on the benzene ring, respectively. Since 3-methylhippuric acid (3-MHA) is a metabolite of m-xylene, the measurement of 3-MHA in urine may be correlated to a subject's level of xylene exposure.","3-Methylhippuric Acid | 3-METHYLHIPPURIC ACID | 3-MHA | Glycine, N-(3-Methylbenzoyl)- (9CI) | N-(3-Methylbenzoyl)Glycine | N-(m-Toluoyl)Glycine | m-Methylhippuric Acid | m-Toluric Acid | meta-Methylhippuric Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407440","phenylglyoxylic acid","C173424","An aromatic hydrocarbon comprised of glyoxylic acid where the aldehyde hydrogen is substituted by a phenyl group. Since phenylglyoxylic acid (PGA) is a metabolite of styrenes, the measurement of PGA in urine may be correlated to a subject's level of styrene exposure.","Phenylglyoxylic Acid | 2-Oxo-2-Phenylacetic Acid | 2-Phenylethanoic Acid | Benzeneacetic Acid, Alpha-Oxo- (9CI) | Benzeneglyoxylic Acid | Benzoylformic Acid | Formic Acid, Benzoyl- | Glyoxylic Acid, Phenyl- | Glyoxylic Acid, Phenyl- (8CI) | Oxophenylacetic Acid | PGA | PHENYLGLYOXYLIC ACID | Phenylgloxylic Acid | Phenylglyoxalate | Phenyloxoacetic Acid | alpha-Ketophenylacetic Acid | alpha-Oxobenzeneacetic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889043","Hepatitis C Virus Genotype 4 Positive","C173431","An indication that hepatitis C virus genotype 4 has been detected in a sample.","Hepatitis C Virus Genotype 4 Positive | GT4 Positive | HCV GT4 Positive | Hep C GT4 Positive | Hepatitis C Genotype 4 Positive | Hepatitis C Virus 4 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407415","Loss of Serine-Protein Kinase ATM Expression","C173432","A molecular abnormality indicating the absence of serine-protein kinase ATM expression.","Loss of Serine-Protein Kinase ATM Expression | ATM Expression Loss | ATM Loss of Expression | Loss of A-T Mutated Protein Expression | Loss of ATM Expression | Loss of ATM Protein Expression | Loss of ATM Serine/Threonine Protein Kinase Expression | Loss of Ataxia Telangiectasia Mutated Protein Expression | Loss of Ataxia Telangiectasia Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407416","Deleterious GATA2 Gene Mutation","C173433","A change in the nucleotide sequence of the GATA2 gene that is associated with increased risk of disease.","Deleterious GATA2 Gene Mutation | Deleterious GATA Binding Protein 2 Gene Mutation | Deleterious GATA2 Mutation | Deleterious NFE1B Gene Mutation | GATA2 Deleterious Gene Mutation | GATA2 Deleterious Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407423","ARID2 Gene Mutation","C173440","A change in the nucleotide sequence of the ARID2 gene.","ARID2 Gene Mutation | AT-Rich Interactive Domain 2 Gene Mutation | BAF200 Gene Mutation | p200 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407419","ARID1B Gene Mutation","C173444","A change in the nucleotide sequence of the ARID1B gene.","ARID1B Gene Mutation | AT-Rich Interactive Domain 1B Gene Mutation | BAF250B Gene Mutation | BRIGHT Gene Mutation | DAN15 Gene Mutation | OSA2 Gene Mutation | P250R Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407420","Activating KRAS Exon 4 Mutation","C173445","A change in the nucleotide sequence of exon 4 of the KRAS gene that results in constitutive activation of both GTPase KRas protein and its downstream signaling pathways.","Activating KRAS Exon 4 Mutation | Activating KRAS Exon 4 Gene Mutation | Activating KRAS-2 Exon 4 Mutation | Activating KRAS2 Exon 4 Mutation | Activating c-K-ras Exon 4 Mutation | Activating v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Exon 4 Mutation | KRAS Exon 4 Activating Gene Mutation | KRAS Exon 4 Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407422","Activating KRAS Exon 3 Mutation","C173447","A change in the nucleotide sequence of exon 3 of the KRAS gene that results in constitutive activation of both GTPase KRas protein and its downstream signaling pathways.","Activating KRAS Exon 3 Mutation | Activating KRAS Exon 3 Gene Mutation | Activating KRAS-2 Exon 3 Mutation | Activating KRAS2 Exon 3 Mutation | Activating c-K-ras Exon 3 Mutation | Activating v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Exon 3 Mutation | KRAS Exon 3 Activating Gene Mutation | KRAS Exon 3 Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407458","Activating KRAS Exon 2 Mutation","C173448","A change in the nucleotide sequence of exon 2 of the KRAS gene that results in constitutive activation of both GTPase KRas protein and its downstream signaling pathways.","Activating KRAS Exon 2 Mutation | Activating KRAS Exon 2 Gene Mutation | Activating KRAS-2 Exon 2 Mutation | Activating KRAS2 Exon 2 Mutation | Activating c-K-ras Exon 2 Mutation | Activating v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Exon 2 Mutation | KRAS Exon 2 Activating Gene Mutation | KRAS Exon 2 Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407459","Non-V600 BRAF Gene Mutation","C173449","A change in the nucleotide sequence of the BRAF gene that occurs outside of codon 600.","Non-V600 BRAF Gene Mutation | Non-Codon 600 B-RAF Mutation | Non-Codon 600 B-RAF1 Mutation | Non-Codon 600 BRAF Gene Mutation | Non-Codon 600 BRAF Mutation | Non-Codon 600 BRAF1 Mutation | Non-V600 BRAF Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407454","CHEK2 NP_009125.1:p.I157T","C173452","A change in the amino acid residue at position 157 in the serine/threonine-protein kinase Chk2 protein where isoleucine has been replaced by threonine.","CHEK2 NP_009125.1:p.I157T | CHEK2 I157T | CHEK2 I157T Mutation | CHEK2 Ile157Thr | CHEK2 NP_009125.1:p.Ile157Thr | CHEK2 p.I157T | CHEK2 p.Ile157Thr | Cds1 Homolog I157T | Cds1 Homolog Ile157Thr | Checkpoint Kinase 2 I157T | Checkpoint Kinase 2 Ile157Thr | Checkpoint-Like Protein CHK2 I157T | Checkpoint-Like Protein CHK2 Ile157Thr | NP_009125.1:p.I157T | NP_009125.1:p.Ile157Thr | Serine/Threonine-Protein Kinase Chk2 I157T | Serine/Threonine-Protein Kinase Chk2 Ile157Thr",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407457","CHEK2 NP_009125.1:p.S428F","C173455","A change in the amino acid residue at position 428 in the serine/threonine-protein kinase Chk2 protein where serine has been replaced by phenylalanine.","CHEK2 NP_009125.1:p.S428F | CHEK2 NP_009125.1:p.Ser428Phe | CHEK2 S428F | CHEK2 S428F Mutation | CHEK2 Ser428Phe | CHEK2 p.S428F | CHEK2 p.Ser428Phe | Cds1 Homolog S428F | Cds1 Homolog Ser428Phe | Checkpoint Kinase 2 S428F | Checkpoint Kinase 2 Ser428Phe | Checkpoint-Like Protein CHK2 S428F | Checkpoint-Like Protein CHK2 Ser428Phe | NP_009125.1:p.S428F | NP_009125.1:p.Ser428Phe | Serine/Threonine-Protein Kinase Chk2 S428F | Serine/Threonine-Protein Kinase Chk2 Ser428Phe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407465","HTLV-2 Positive","C173456","An indication that HTLV-2 was detected in a sample.","HTLV-2 Positive | HTLV-II Positive | Human T Cell Lymphotropic Virus 2 Positive | Human T-Cell Lymphotropic Virus 2 Positive | Human T-Lymphotropic Virus 2 Positive | Human T-Lymphotropic Virus Type 2 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515642","hMLH1 Mismatch Repair Gene Inactivation","C36698","A change in the nucleotide sequence of the MLH1 gene that either inhibits expression or results in the translation of an inactive DNA mismatch repair protein Mlh1 protein.","Inactivating MLH1 Gene Mutation | Inactivating MLH1 Mutation | Loss of Function COCA2 Gene Mutation | Loss of Function HNPCC2 Gene Mutation | Loss of Function MLH1 Gene Mutation | Loss of Function MLH1 Mutation | Loss of Function MutL Homolog 1 Gene Mutation | Loss of Function MutL, E. coli, Homolog of, 1 Gene Mutation | MLH1 Gene Inactivation | MLH1 Loss of Function Gene Mutation | MLH1 Loss of Function Mutation | hMLH1 Mismatch Repair Gene Inactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515644","hMSH6 Mismatch Repair Gene Inactivation","C36701","A change in the nucleotide sequence of the MSH6 gene that either inhibits expression or results in the translation of an inactive DNA mismatch repair protein Msh6 protein.","Inactivating MSH6 Gene Mutation | Inactivating MSH6 Mutation | Loss of Function HNPCC5 Gene Mutation | Loss of Function MSH6 Gene Mutation | Loss of Function MSH6 Mutation | Loss of Function MutS Homolog 6 Gene Mutation | Loss of Function MutS, E. coli, Homolog of, 6 Gene Mutation | MSH6 Gene Inactivation | MSH6 Loss of Function Gene Mutation | MSH6 Loss of Function Mutation | hMSH6 Mismatch Repair Gene Inactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518800","PMS2 Mismatch Repair Gene Inactivation","C36703","A change in the nucleotide sequence of the PMS2 gene that either inhibits expression or results in the translation of an inactive mismatch repair endonuclease PMS2 protein.","Inactivating PMS2 Gene Mutation | Loss of Function HNPCC4 Gene Mutation | Loss of Function MLH4 Gene Mutation | Loss of Function PMS1 Homolog 2, Mismatch Repair System Component Gene Mutation | Loss of Function PMS2 Gene Mutation | Loss of Function PMS2 Mutation | Loss of Function PMS2CL Gene Mutation | Loss of Function PMSL2 Gene Mutation | Loss of Function Postmeiotic Segregation Increased 2 Gene Mutation | PMS2 Gene Inactivation | PMS2 Loss of Function Gene Mutation | PMS2 Loss of Function Mutation | PMS2 Mismatch Repair Gene Inactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515643","hMSH2 Mismatch Repair Gene Inactivation","C36697","A change in the nucleotide sequence of the MSH2 gene that either inhibits expression or results in the translation of an inactive DNA mismatch repair protein Msh2 protein.","Inactivating MSH2 Gene Mutation | Inactivating MSH2 Mutation | Loss of Function COCA1 Gene Mutation | Loss of Function HNPCC Gene Mutation | Loss of Function HNPCC1 Gene Mutation | Loss of Function MSH2 Mutation | Loss of Function MutS Homolog 2 Gene Mutation | Loss of Function MutS, E. coli, Homolog of, 2 Gene Mutation | MSH2 Gene Inactivation | MSH2 Loss of Function Gene Mutation | MSH2 Loss of Function Mutation | hMSH2 Mismatch Repair Gene Inactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407464","Biallelic ADA2 Gene Mutation","C173463","The presence of mutations in both alleles of the ADA2 gene.","Biallelic ADA2 Gene Mutation | ADA2 Biallelic Gene Mutation | ADA2 Biallelic Mutation | Biallelic ADA2 Mutation | Biallelic ADGF Gene Mutation | Biallelic Adenosine Deaminase 2 Gene Mutation | Biallelic CECR1 Gene Mutation | Biallelic PAN Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407443","SARS Coronavirus 2 Antibody","C173464","Any antibody that recognizes the severe acute respiratory syndrome 2 virus.","SARS Coronavirus 2 Antibody | 2019 Novel Coronavirus Antibody | 2019-nCoV Antibody | Anti-2019 Novel Coronavirus Antibody | Anti-2019-nCoV Antibody | Anti-COVID-19 Virus Antibody | Anti-SARS Coronavirus 2 Antibody | Anti-SARS-2 Antibody | Anti-SARS-CoV-2 Antibody | Anti-SARS2 Antibody | Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Antibody | Anti-nCoV Antibody | COVID-19 Virus Antibody | SARS-2 Antibody | SARS-CoV-2 Antibody | SARS2 Antibody | Severe Acute Respiratory Syndrome Coronavirus 2 Antibody | Total | nCoV Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407444","Procalcitonin","C173465","Procalcitonin (116 aa, ~13 kDa) is encoded by the human CALCA gene. This protein plays a role in sepsis.","Procalcitonin | Pro-CALCA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1627345","High-Dependency Unit","C173510","A ward for patients who need more intensive observation, treatment, and nursing care than is possible in a general ward but less than that given in intensive care.","High-Dependency Unit | HDU | Intermediate Care Unit | Progressive Care Unit | Step-Down Unit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0275524","Co-infection","C173511","The simultaneous infection of a host by multiple pathogen species.","Co-infection | Coinfection",,,,,,,,,,,,,,,"4163969","Mixed infectious disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018150","Gram Negative Bacteria","C173514","Any bacteria with a thin peptidoglycan layer and an outer lipid membrane that stains pink with the Gram staining technique.","Gram Negative Bacteria | Gram Negative Bacterium | Gram negative bacteria | Gram-Negative Bacteria | Gram-Negative Bacterium",,,,,,,,,,,,,,,"4217941","Gram-negative bacterium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018154","Gram Positive Bacteria","C173515","Any bacteria with a thick peptidoglycan layer and no outer lipid membrane that stains dark purple with the Gram staining technique.","Gram Positive Bacteria | Gram Positive Bacterium | Gram positive bacteria | Gram-Positive Bacteria | Gram-Positive Bacterium",,,,,,,,,,,,,,,"4337977","Gram-positive bacteria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0238408","Rectus Sheath Hematoma","C173513","A collection of blood in the rectus sheath due to disruption of the superior or inferior epigastric arteries, which may present following direct trauma to the rectus abdominis muscle or anticoagulation therapy.","Rectus Sheath Hematoma | ",,,,,,,,,,,,,,,"4147276","Hematoma of rectus sheath",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512741","Invasive Bladder Nested Urothelial Carcinoma","C39819","Invasive bladder urothelial carcinoma characterized by a nested growth pattern.","Invasive Bladder Nested Urothelial Carcinoma | Bladder Nested Urothelial Carcinoma | Infiltrating Bladder Urothelial Carcinoma, Nested Variant | Infiltrating Bladder Urothelial Carcinoma, Nested Variant | Invasive Bladder Urothelial Carcinoma, Nested Variant | Nested urothelial carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517579","Invasive Bladder Micropapillary Urothelial Carcinoma","C27202","An invasive bladder urothelial carcinoma exhibiting micropapillary growth pattern.","Invasive Bladder Micropapillary Urothelial Carcinoma | Bladder Micropapillary Urothelial Carcinoma | Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant | Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant | Invasive Bladder Urothelial Carcinoma, Micropapillary Variant | Micropapillary Urothelial Carcinoma",,,,,,,,,,,,,,,"37163178","Micropapillary urothelial carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL970634","Hepatitis C Virus RNA Positive","C162042","An indication that hepatitis C RNA has been detected in a sample.","Hepatitis C Virus RNA Positive | HCV RNA Positive | Hep C RNA Positive | Hepatitis C RNA Positive | Hepatitis C Viral RNA Positive | Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382878","GREM1 Gene Mutation","C170430","A change in the nucleotide sequence of the GREM1 gene.","GREM1 Gene Mutation | CKTSF1B1 Gene Mutation | CRAC1 Gene Mutation | CRCS4 Gene Mutation | DAND2 Gene Mutation | DRM Gene Mutation | GREMLIN Gene Mutation | GREMLIN1 Gene Mutation | Gremlin 1, DAN Family BMP Antagonist Gene Mutation | IHG-2 Gene Mutation | PIG2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417668","NEFL Gene","C88041","This gene is involved in the structure of neuronal processes.","NEFL Gene | NEFL | Neurofilament Light Chain Gene | Neurofilament Light Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526634","Decreased Cellularity Present","C139138","A decrease in the number of cells as compared to a standard or norm.","Decreased Cellularity Present | CELLULARITY, DECREASED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540435","Demographic Data","C142508","Aspects of individuals or groups of individuals in a study, including basic descriptive information like age and sex.","Demographic Data | demographic | demographic data",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541315","Clinical Outcome Assessment","C142378","A measure of a patient's symptoms, overall mental state, or the effects of a disease or condition on how the patient functions as reported by the patient, a clinician, or an observer.","Clinical Outcome Assessment | COA | clinical outcome assessment (COA)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972979","Illicit Drug Use History","C168265","A description of an individual's current and past use of illicit drugs.","Illicit Drug Use History | Illicit Drug Use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0412038","Diaphragm Fluoroscopy","C159678","A fluoroscopic medical test done to evaluate the function of the diaphragm. The subject is asked to sniff quickly and the movement of the diaphragm is monitored with a fluoroscope. It is a quick and easy real-time assessment of diaphragmatic motor function.","Diaphragm Fluoroscopy | Sniff Test",,,,,,,,,,,,,,,"4058173","Fluoroscopy of diaphragm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540380","discontinuation","C142444","The act of concluding participation by an enrolled subject prior to completion of all protocol-required elements in a trial. NOTE: Four categories of discontinuation are distinguished: a) dropout: Active discontinuation by a subject (also a noun referring to such a discontinued subject); b) investigator initiated discontinuation (e.g., for cause); c) loss to follow-up: cessation of participation without notice or action by the subject; d) sponsor initiated discontinuation. Note that subject discontinuation does not necessarily imply exclusion of subject data from analysis. 'Termination of subject' has a history of synonymous use, but is now considered nonstandard. [After ICH E3, section 10.1 and FDA Guidance for Industry: Submission of Abbreviated Reports & Synopses in Support of Marketing Applications, IV A]","Study Subject Discontinuation | Clinical Trial Discontinuation | Clinical Trial Participant Discontinuation | Study Discontinuation | discontinuation | discontinue (participant)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405777","COVID-19-Associated Anosmia","C171558","Anosmia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).","COVID-19-Associated Anosmia | Loss of smell (anosmia) | SARS-CoV-2-Associated Anosmia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640860","Homeless During Past Year","C102645","An individual without a stable or permanent residence within the last 365 days.","Homeless During Past Year | HOMELESS DURING PAST YEAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407511","Indwelling Central Venous Catheter","C173528","An indwelling catheter designed for central venous access.","Indwelling Central Venous Catheter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0336535","Environmental Agent","C173527","Chemicals or factors in the environment to which humans are exposed that may cause adverse health effects.","Environmental Agent | ",,,,,,,,,,,,,,,"4242705","Environmental agent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1406666","Burkholderia multivorans Measurement","C172530","The determination of the amount of Burkholderia multivorans in a sample.","Burkholderia multivorans Measurement | BMU | Burkholderia multivorans",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406663","Achromobacter xylosoxidans Measurement","C172529","The determination of the amount of Achromobacter xylosoxidans in a sample.","Achromobacter xylosoxidans Measurement | AXY | Achromobacter xylosoxidans",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406664","Aspergillus Measurement","C172528","The determination of the amount of Aspergillus in a sample.","Aspergillus Measurement | ASPERGIL | Aspergillus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407063","Chlamydia Measurement","C172527","The determination of the amount of Chlamydia in a sample.","Chlamydia Measurement | CHLAMYD | Chlamydia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406511","Pseudomonas Measurement","C172384","The determination of the amount of Pseudomonas in a sample.","Pseudomonas Measurement | PSEUDOMO | Pseudomonas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2928676","Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate","C157403","A fixed combination of efavirenz, a non-nucleoside reverse transcriptase (RT) inhibitor (NNRTI); emtricitabine, a nucleoside RT inhibitor (NRTI) analog of cytidine; and tenofovir disoproxil fumarate, an NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, efavirenz, emtricitabine, and tenofovir disoproxil fumarate inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate | Atripla | EFV/FTC/TDF | Efavirenz/Emtricitabine/Tenofovir",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406670","Burkholderia pyrrocinia Measurement","C172537","The determination of the amount of Burkholderia pyrrocinia in a sample.","Burkholderia pyrrocinia Measurement | BPY | Burkholderia pyrrocinia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407057","Burkholderia anthina Measurement","C172536","The determination of the amount of Burkholderia anthina in a sample.","Burkholderia anthina Measurement | BAN | Burkholderia anthina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407056","Burkholderia ambifaria Measurement","C172535","The determination of the amount of Burkholderia ambifaria in a sample.","Burkholderia ambifaria Measurement | BAM | Burkholderia ambifaria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406669","Burkholderia dolosa Measurement","C172534","The determination of the amount of Burkholderia dolosa in a sample.","Burkholderia dolosa Measurement | BDO | Burkholderia dolosa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406667","Burkholderia vietnamiensis Measurement","C172533","The determination of the amount of Burkholderia vietnamiensis in a sample.","Burkholderia vietnamiensis Measurement | BVI | Burkholderia vietnamiensis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406668","Burkholderia stabilis Measurement","C172532","The determination of the amount of Burkholderia stabilis in a sample.","Burkholderia stabilis Measurement | BST | Burkholderia stabilis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406665","Burkholderia cenocepacia Measurement","C172531","The determination of the amount of Burkholderia cenocepacia in a sample.","Burkholderia cenocepacia Measurement | BCE | Burkholderia cenocepacia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3244537","Emtricitabine/Rilpivirine Hydrochloride/Tenofovir Disoproxil Fumarate","C157408","A fixed combination of emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine; rilpivirine, a non-nucleoside RT inhibitor (NNRTI); and tenofovir disoproxil fumarate, an NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, rilpivirine binds to HIV RT, thereby blocking RNA and DNA-dependent DNA polymerase activities including viral replication. Emtricitabine and tenofovir disoproxil fumarate inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","Emtricitabine/Rilpivirine Hydrochloride/Tenofovir Disoproxil Fumarate | Complera | Emtricitabine/Rilpivirine/Tenofovir | Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate | Eviplera | Eviplera; Eviplera | FTC/RPV/TDF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406654","Rotavirus Measurement","C172549","The determination of the amount of Rotavirus in a sample.","Rotavirus Measurement | ROTAVIRU | Rotavirus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407076","Enterovirus Measurement","C172548","The determination of the amount of Enterovirus in a sample.","Enterovirus Measurement | ENTEROVI | Enterovirus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406653","Pseudomonas aeruginosa Measurement","C172546","The determination of the amount of Pseudomonas aeruginosa in a sample.","Pseudomonas aeruginosa Measurement | PAE | Pseudomonas aeruginosa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407069","Mycobacterium fortuitum Measurement","C172545","The determination of the amount of Mycobacterium fortuitum in a sample.","Mycobacterium fortuitum Measurement | MFO | Mycobacterium fortuitum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407071","Mycobacterium chelonae Measurement","C172544","The determination of the amount of Mycobacterium chelonae in a sample.","Mycobacterium chelonae Measurement | MCH | Mycobacterium chelonae",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407067","Mycobacterium abscessus Measurement","C172543","The determination of the amount of Mycobacterium abscessus in a sample.","Mycobacterium abscessus Measurement | MAB | Mycobacterium abscessus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406652","Mycobacterium simiae Measurement","C172542","The determination of the amount of Mycobacterium simiae in a sample.","Mycobacterium simiae Measurement | MSI | Mycobacterium simiae",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0275706","Mycobacterium kansasii Measurement","C172541","The determination of the amount of Mycobacterium kansasii in a sample.","Mycobacterium kansasii Measurement | MKA | Mycobacterium kansasii",,,,,,,,,,,,,,,"4071178","Infection due to Mycobacterium kansasii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1406651","Mycobacterium avium Complex Measurement","C172540","The determination of the amount of Mycobacterium avium Complex in a sample.","Mycobacterium avium Complex Measurement | MAVCM | Mycobacterium avium Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407058","Klebsiella Measurement","C172539","The determination of the amount of Klebsiella in a sample.","Klebsiella Measurement | KLEBSIEL | Klebsiella",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407059","Escherichia coli Measurement","C172538","The determination of the amount of Escherichia coli in a sample.","Escherichia coli Measurement | ECO | Escherichia coli",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3837723","Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination","C157404","A fixed combination of elvitegravir, a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI); cobicistat, a cytochrome P450 3A (CYP3A) inhibitor; emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine; and tenofovir disoproxil fumarate, an NRTI analog of adenosine monophosphate, that is used to treat HIV infection. Upon oral administration, elvitegravir inhibits the activity of integrase, an HIV-1 coded enzyme that is necessary for viral replication. Inhibition of integrase prevents the integration of HIV-1 DNA into host genomic DNA. Cobicistat inhibits CYP3A, thereby limiting the oxidative metabolism of elvitegravir and increases its systemic exposure. Emtricitabine and tenofovir disoproxil fumarate inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate | EVG/COBI/FTC/TDF | Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir | Stribild",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936918","ESR1 Status by Immunohistochemistry","C157196","An indication that expression or absence of ESR1 in a sample was determined using immunohistochemical staining techniques.","ESR1 Status by Immunohistochemistry | ER Status by IHC | ER Status by Immunohistochemistry | ER alpha (ESR1) Status by Immunohistochemistry | ER alpha Status by Immunohistochemistry | ERA Status by Immunohistochemistry | ESR Status by Immunohistochemistry | ESRA Status by Immunohistochemistry | Estrogen Receptor 1 Status by Immunohistochemistry | Estrogen Receptor Status by Immunohistochemistry | NR3A1 Status by Immunohistochemistry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1373111","Nucleoside Reverse Transcriptase Inhibitor","C97452","A substance with a structure similar to a nucleoside molecule that is capable of occupying the active catalytic site of a reverse transcriptase resulting in inhibition of enzyme function, chain termination, and inhibition of viral replication. These compounds are converted to their active phosphorylated forms by cellular kinases.","Nucleoside Reverse Transcriptase Inhibitor | NRTI | Nucleoside Analog Reverse Transcriptase Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1613391","Abacavir Sulfate/Lamivudine","C157405","A fixed combination of abacavir sulfate, a nucleoside reverse transcriptase inhibitor (NRTI) analog of guanosine and lamivudine, an NRTI analog of cytidine, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, abacavir and lamivudine are phosphorylated into active metabolites that compete for incorporation into viral DNA. These metabolites inhibit the HIV reverse transcriptase (RT) enzyme competitively and act as a chain terminator of DNA synthesis. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","Abacavir Sulfate/Lamivudine | ABC/3TC | Abacavir/Lamivudine | Epzicom | Kivexa | Kivexa; Kivexa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406673","Tear Secretion Rate","C172575","A measurement of the amount of tears being secreted over a defined amount of time (e.g. 5 minutes).","Tear Secretion Rate | TEARSCRR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407089","Tear Secretion Amount","C172574","A measurement of the amount of tears produced by the subject.","Tear Secretion Amount | TEARSCR | Tear Secretion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936919","ESR2 Status by Immunohistochemistry","C157197","An indication that expression or absence of ESR2 in a sample was determined using immunohistochemical staining techniques.","ESR2 Status by Immunohistochemistry | ER beta (ESR2) Status by Immunohistochemistry | ER-Beta Status by Immunohistochemistry | ESR-BETA Status by Immunohistochemistry | ESR2 Status by IHC | ESRB Status by Immunohistochemistry | ESTRB Status by Immunohistochemistry | Estrogen Receptor 2 Status by Immunohistochemistry | Estrogen Receptor Beta Status by Immunohistochemistry | NR3A2 Status by Immunohistochemistry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406677","MRD Indicator","C172578","An indication as to whether the subject has minimal residual disease.","Measurable Residual Disease Indicator | MRD Indicator | MRDIND | Minimal Residual Disease Indicator | Minimal Residual Disease Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406674","Minor Pathological Response Indicator","C172577","An indication as to whether minor pathological response occurred.","Minor Pathological Response Indicator | MNPTHIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406675","Major Pathological Response Indicator","C172576","An indication as to whether major pathological response occurred.","Major Pathological Response Indicator | MJPTHIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936892","AR Status by Immunohistochemistry","C157165","An indication that expression or absence of AR in a sample was determined using immunohistochemical staining techniques.","Androgen Receptor Status by Immunochemistry | AR Status by IHC | AR Status by Immunochemistry | AR Status by Immunochemistry | AR Status by Immunohistochemistry | Androgen Receptor Status by Immunochemistry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406683","K Slope of Distribution","C172584","The distribution rate constant.","K Slope of Distribution | KDIST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406680","Half-Life Distribution","C172583","Half-life calculated from the distributional phase.","Half-Life Distribution | DISTHL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936938","ERBB2 Mutation Analysis","C157178","A procedure used to detect and identify mutations in the ERBB2 gene.","ERBB2 Mutation Analysis | ERBB2 / HER2 Mutation Status | ERBB2 Mutation | ERBB2/HER2 Mutation Status | Erb-B2 Receptor Tyrosine Kinase 2 Mutation Analysis | Erb-B2 Receptor Tyrosine Kinase Mutation Analysis | HER2 Mutation Analysis | HER2/neu Mutation Analysis | NEU Mutation Analysis | v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 Mutation Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406682","Hours Times DNA Copies Per Microgram","C172585","Hours times DNA copies per microgram (area under the curve).","Hours Times DNA Copies Per Microgram | h*DNA copies/ug | h.{DNA copies}/ug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936932","FGFR1 Mutation Analysis","C157179","A procedure used to detect and identify mutations in the FGFR1 gene.","FGFR1 Mutation Analysis | BFGFR Mutation Analysis | CD331 Mutation Analysis | CEK Mutation Analysis | FGFBR Mutation Analysis | FGFR-1 Mutation Analysis | FGFR1 Mutation Status | FLG Mutation Analysis | FLT-2 Mutation Analysis | FLT2 Mutation Analysis | FMS-Like Tyrosine Kinase 2 Mutation Analysis | Fibroblast Growth Factor Receptor 1 Mutation Analysis | KAL2 Mutation Analysis | N-SAM Mutation Analysis | OGD Mutation Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936933","FGFR2 Mutation Analysis","C157180","A procedure used to detect and identify mutations in the FGFR2 gene.","FGFR2 Mutation Analysis | BEK Mutation Analysis | CD332 Mutation Analysis | ECT1 Mutation Analysis | FGFR-2 Mutation Analysis | FGFR2 Mutation Status | Fibroblast Growth Factor Receptor 2 Mutation Analysis | K-SAM Mutation Analysis | KGFR Mutation Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936934","FGFR3 Mutation Analysis","C157181","A procedure used to detect and identify mutations in the FGFR3 gene.","FGFR3 Mutation Analysis | CD333 Mutation Analysis | FGFR-3 Mutation Analysis | FGFR3 Mutation Status | Fibroblast Growth Factor Receptor 3 Mutation Analysis | JKT4 Mutation Analysis | JTK4 Mutation Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406708","Hours Times Nanogram Per Milliliter Per Milligram Per Square Centimeter","C172589","Hour times nanograms per milliliter (area under the curve), divided by milligrams per centimeter squared (body mass index).","Hours Times Nanogram Per Milliliter Per Milligram Per Square Centimeter | h*ng/mL/(mg/cm2) | h.ng/mL/(mg/cm2) | h.ng/ml/(mg/cm2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406709","Nanogram Per Milliliter Per Milligram Per Square Centimeter","C172588","Nanograms per milliliter (concentration), divided by milligrams per centimeter squared (body mass index).","Nanogram Per Milliliter Per Milligram Per Square Centimeter | ng/mL/(mg/cm2) | ng/ml/(mg/cm2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1641242","Microgram Equivalents Per Milliliter","C172587","A concentration unit measured as a number of microgram equivalent of solute per milliliter of solution.","Microgram Equivalents Per Milliliter | mg.Eq/L | mg.Eq/l | mgEq/L | ng.Eq/uL | ng.Eq/ul | ngEq/uL | ug.Eq/mL | ug.Eq/ml | ugEq/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406684","Hours Squared Time DNA Copies Per Microgram","C172586","Hours squared times DNA copies per microgram (area under the moment curve).","Hours Squared Time DNA Copies Per Microgram | h*h*DNA copies/ug | h2*DNA copies/ug | h2.{DNA copies}/ug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936920","FGFR1 Rearrangement Analysis","C157191","A procedure used to detect and identify rearrangements involving the FGFR1 gene.","FGFR1 Rearrangement Analysis | BFGFR Rearrangement Analysis | CD331 Rearrangement Analysis | CEK Rearrangement Analysis | FGFBR Rearrangement Analysis | FGFR-1 Rearrangement Analysis | FGFR1 Rearrangement Status | FLG Rearrangement Analysis | FLT-2 Rearrangement Analysis | FLT2 Rearrangement Analysis | FMS-Like Tyrosine Kinase 2 Rearrangement Analysis | Fibroblast Growth Factor Receptor 1 Rearrangement Analysis | KAL2 Rearrangement Analysis | N-SAM Rearrangement Analysis | OGD Rearrangement Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936921","FGFR2 Rearrangement Analysis","C157192","A procedure used to detect and identify rearrangements involving the FGFR2 gene.","FGFR2 Rearrangement Analysis | BEK Rearrangement Analysis | CD332 Rearrangement Analysis | ECT1 Rearrangement Analysis | FGFR-2 Rearrangement Analysis | FGFR2 Rearrangement Status | Fibroblast Growth Factor Receptor 2 Rearrangement Analysis | K-SAM Rearrangement Analysis | KGFR Rearrangement Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936922","FGFR3 Rearrangement Analysis","C157193","A procedure used to detect and identify rearrangements involving the FGFR3 gene.","FGFR3 Rearrangement Analysis | CD333 Rearrangement Analysis | FGFR-3 Rearrangement Analysis | FGFR3 Rearrangement Status | Fibroblast Growth Factor Receptor 3 Rearrangement Analysis | JKT4 Rearrangement Analysis | JTK4 Rearrangement Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406357","Barratt Impulsiveness Scale 1995 Version Questionnaire","C172402","A standardized 30-item questionnaire developed by Patton et al. 1995 that utilizes a four-point rating scale to assess impulsiveness. The items describe common impulsive and non-impulsive behaviors and preferences.","Barratt Impulsiveness Scale 1995 Version Questionnaire | BIS-11 | BIS01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406718","Pharyngeal Route of Administration","C172600","Administration directly upon the pharynx.","Pharyngeal Route of Administration | PHARYNGEAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406717","Physical Activity Level","C172601","An assessment of the level or degree in which an individual moves or exercises.","Physical Activity Level | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986691","Inherited Bone Marrow Failure Syndrome","C94810","A group of inherited genetic hematopoietic stem cell disorders characterized by bone marrow failure that involves one or more cell lines. Representative examples include Fanconi anemia, Diamond-Blackfan anemia, and Shwachman-Diamond syndrome.","Inherited Bone Marrow Failure Syndrome | IBMFS | inherited bone marrow failure syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0939216","Abacavir Sulfate/Lamivudine/Zidovudine","C157473","A fixed combination of abacavir sulfate, a nucleoside reverse transcriptase inhibitor (NRTI) analog of guanosine; lamivudine, an NRTI analog of cytidine; and zidovudine, an NRTI analog of thymidine, that may be used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, abacavir, lamivudine, and zidovudine are phosphorylated into active metabolites that inhibit the HIV reverse transcriptase (RT) enzyme competitively and act as a chain terminator of DNA synthesis. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","Abacavir Sulfate/Lamivudine/Zidovudine | ABC/3TC/ZDV | Abacavir/Lamivudine/Zidovudine | Trizivir",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL939667","Severe Congenital Neutropenia Type 3, Autosomal Recessive","C166153","Severe congenital neutropenia inherited in an autosomal recessive pattern and caused by HCLS1-associated protein X-1 (HAX1) mutations.","Severe Congenital Neutropenia Type 3, Autosomal Recessive | Autosomal Recessive SCN, Type 3 | Autosomal Recessive Severe Congenital Neutropenia | Kostmann Syndrome | Kostmann disease | Kostmann neutropenia | Kostmann syndrome | Neutropenia, Severe Congenital, 3, Autosomal Recessive",,,,,,,,,,,,,,,"36674945","Kostmann syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937093","Emtricitabine/Tenofovir Disoproxil Fumarate","C157535","A fixed combination of emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine, and tenofovir disoproxil fumarate, an NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, emtricitabine and tenofovir inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","Emtricitabine/Tenofovir Disoproxil Fumarate | FTC/TDF | Truvada",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406720","Primary Tumor Site Indicator","C172602","An indication as to whether an anatomical location is the primary tumor site of disease.","Primary Tumor Site Indicator | PTSIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406699","Diastolic Blood Pressure-for-Age Percentile","C172610","A measurement of an individual's diastolic blood pressure in relationship to age, in comparison to a reference percentile curve.","Diastolic Blood Pressure-for-Age Percentile | DBPAPCTL | Diastolic BP-for-Age Percentile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406696","Diastolic Blood Pressure-for-Height Percentile","C172609","A measurement of an individual's diastolic blood pressure in relationship to height, in comparison to a reference percentile curve.","Diastolic Blood Pressure-for-Height Percentile | DBPHPCTL | Diastolic BP-for-Height Percentile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406697","Systolic Blood Pressure-for-Age Percentile","C172608","A measurement of an individual's systolic blood pressure in relationship to age, in comparison to a reference percentile curve.","Systolic Blood Pressure-for-Age Percentile | SBPAPCTL | Systolic BP-for-Age Percentile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406694","Systolic Blood Pressure-for-Height Percentile","C172607","A measurement of an individual's systolic blood pressure in relationship to height, in comparison to a reference percentile curve.","Systolic Blood Pressure-for-Height Percentile | SBPHPCTL | Systolic BP-for-Height Percentile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972514","Capillary Refill Test","C168125","An assessment performed to estimate peripheral perfusion and hydration status. The test is most often conducted by applying constant manual pressure for a set time on a patient's nail bed and then releasing while observing the length of time it takes for color to return to the tissue. A prolonged return to baseline coloring may indicate compromise of peripheral blood flow.","Capillary Refill Test | CPLRFLT | Capillary Refill Time | Examination of the Extremities – Capillary Refill Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0584869","Supraspinatus Muscle","C33709","One of four rotator cuff muscles that form a musculotendinous cuff around the glenohumeral joint, which provides muscular support to the shoulder. It arises from the supraspinous fossa of the scapula, inserts into the greater tubercle of the humerus, and assists to abduct the arm.","Supraspinatus Muscle | SUPRASPINATUS MUSCLE",,,,,,,,,,,,,,,"4272489","Supraspinatus muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0149573","Posterior Inferior Cerebellar Artery","C33362","An artery arising from the vertebral artery that supplies the cerebellum, choroid plexus and the lateral medulla.","Posterior Inferior Cerebellar Artery | PICA | POSTERIOR INFERIOR CEREBELLAR ARTERY",,,,,,,,,,,,,,,"4163683","Structure of posterior inferior cerebellar artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0226245","Anterior Inferior Cerebellar Artery","C32091","A basilar artery branch that supplies the anterior portion of the inferior surface of the cerebellum.","Anterior Inferior Cerebellar Artery | AICA | ANTERIOR INFERIOR CEREBELLAR ARTERY",,,,,,,,,,,,,,,"4177347","Structure of anterior inferior cerebellar artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1406671","Approved Drug Available For Indication","C172573","An indication that an approved drug is available for use for the disease indication.","Approved Drug Available For Indication | APPROVED DRUG AVAILABLE FOR INDICATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406672","Never Dosed","C172572","An indication that a subject has not ever been dosed with the study treatment or investigational product.","Never Dosed | NEVER DOSED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522517","Sponsor Study Reference Identifier","C135009","The reference identifier that is assigned by the sponsor and by which the study is known to the sponsor.","Sponsor Study Reference Identifier | SPREFID | Sponsor's Study Reference ID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406695","Juvenile Diabetes Foundation Unit","C172606","A unit of measure, defined by the Juvenile Diabetes Foundation, used to express the amount of islet cell antibodies in a biological sample; it is calculated by multiplying the titer by five.","Juvenile Diabetes Foundation Unit | JDF U | JDF Unit | {JDF Unit}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406692","Ounce Equivalent","C172605","A unit of relative amount of a substance equal to one ounce.","Ounce Equivalent | oz eq | oz-eq | {oz eq}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406693","Cup Equivalent","C172604","A unit of relative amount of a substance equal to one cup.","Cup Equivalent | cup eq | cup-eq | {cup eq}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406719","Teaspoon Equivalent","C172603","A unit of relative amount of a substance equal to one teaspoon.","Teaspoon Equivalent | tsp eq | tsp-eq | {tsp eq}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406394","Fibrometer Formula","C172489","A formula that estimates liver pathology through the assessment of a six-parameter blood test, taking into account subject age. Fibrometer regression function = -0.007 platelets (Giga/L) - 0.049 prothrombin index (%) + 0.012 aspartate aminotransferase (UI/L) + 0.005 alpha2-macroglobulin (mg/dL) + 0.021 hyaluronate (g/L) - 0.270 urea (mmol/L) + 0.027 age (years) + 3.718. (Cales P, Oberti F, Michalak S et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology. 2005 Dec;42(6):1373-81.)","Fibrometer Formula | FIBROMETER FORMULA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406395","Hepascore Formula","C172488","A formula that estimates liver pathology through the assessment of a four-parameter blood test, taking into account subject age and sex. Hepascore = y/(1 + y) with y = exp (-4.185818 - (0.0249 x age) + (0.7464 x 1 if male, 0 if female gender) + (1.0039 x a2 macroglobulin) + (0.0302 x hyaluronate) + (0.0691 x bilirubin) - (0.0012 x gamma-glutamyl transferase)). (Adams LA, Bulsara M, Rossi E et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem. 2005 Oct;51(10):1867-73.)","Hepascore Formula | HEPASCORE FORMULA | Hepatoscore Formula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406392","NASH Fibrosure Formula","C172487","A proprietary algorithm derived from the FibroTest liver fibrosis algorithm that is used to measure liver fibrosis, hepatic steatosis, and non-alcoholic steatohepatitis. It includes ten serum markers: alpha-2-macroglobulin, apolipoprotein A1, total bilirubin, gamma-glutamyltransferase, haptoglobin, alanine aminotransferase, aspartate aminotransferase, glucose, total cholesterol, and triglycerides, and adjusts for age, gender, height, and weight.","NASH Fibrosure Formula | NASH FIBROSURE FORMULA | NASH FibroSURE Formula | NASH Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406393","ASH Fibrosure Formula","C172486","A proprietary algorithm derived from the FibroTest liver fibrosis algorithm that is used to measure liver fibrosis, hepatic steatosis, and alcoholic steatohepatitis. It includes ten serum markers: alpha-2-macroglobulin, apolipoprotein A1, total bilirubin, gamma-glutamyltransferase, haptoglobin, alanine aminotransferase, aspartate aminotransferase, glucose, total cholesterol, and triglycerides, and adjusts for age, gender, height, and weight.","ASH Fibrosure Formula | ASH FIBROSURE FORMULA | ASH FibroSURE Formula | ASH Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406390","Fibrotest Formula","C172485","A formula that estimates liver pathology through the assessment of a six-parameter blood test, taking into account subject age and sex. z = 4.467 x log10[Alpha2-Macroglobulin(g/L)] - 1.357 x log10[Haptoglobulin(g/L) + 1.017 x log10[Gamma Glutamyl Transferase (IU/L)] +0.0281 x [Age] + 1.737 x log10[Bilirubin umol/L] - 1.184 x [Apolipoprotein A1(g/L)] + 0.301 x [Sex (female=0, Male=1) - 5.54. (US Patent 6631330)","Fibrotest Formula | FIBROTEST FORMULA | FibroSURE Formula | FibroTest Formula | FibroTest-HCV Formula | FibroTest/FibroSURE Formula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1277077","Blood Irradiation","C133275","Irradiation of blood products before transfusion.","Blood Irradiation | Irradiated | Irradiated Blood Product | Irradiated Blood Product",,,,,,,,,,,,,,,"4054725","Irradiated blood product",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042829","Visual Pathways","C41445","A set of neural connections within the central nervous system, beginning with the retina and terminating in the occipital cortex, that provides the ability to process visual images.","Visual Pathway | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1880492","Eltrombopag Olamine","C62501","The orally active ethanolamine salt of eltrombopag, a small-molecule, nonpeptide thrombopoietin receptor agonist with megakaryopoiesis-stimulating activity. Eltrombopag binds to and stimulates the transmembrane domain of the platelet thrombopoietin receptor (TPO-R or CD110), a member of the hematopoietin receptor superfamily. Activation of TPO-R leads to the proliferation and differentiation of cells in the megakaryocytic lineage and an increase in platelet production.","Eltrombopag Olamine | ELTROMBOPAG OLAMINE | Promacta | SB 497115 GR | SB-497115-GR | SB497115GR | eltrombopag olamine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406657","Computerized Corneal Topography","C172554","A non-invasive, computer-assisted method of measuring the shape of the cornea of the eye.","Computerized Corneal Topography | COMPUTERIZED CORNEAL TOPOGRAPHY | Computer-Assisted Corneal Topography",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406655","Charcoal Enhanced Flocculation","C172553","A flocculation process in which microscopic charcoal particles are used to enhance the visibility of aggregated masses in suspension.","Charcoal Enhanced Flocculation | FLOCCULATION, CHARCOAL ENHANCED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406656","Pseudovirion-Based Neutralization Assay","C172552","An immunoassay that is used to determine whether antibodies that can block pseudovirus replication are present in a biological specimen.","Pseudovirion-Based Neutralization Assay | PBNA | PSEUDOVIRION-BASED NEUTRALIZATION ASSAY | Pseudotyped Virus Neutralization Assay | Pseudovirus Neutralization Assay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2940788","Farr Assay","C172551","A type of radioimmunoprecipitation assay that uses ammonium sulfate to precipitate immune complexes formed with radiolabeled antigen. This is most commonly used to detect levels of DNA antibody complexes.","Farr Assay | FARR ASSAY",,,,,,,,,,,,,,,"4197917","Quantitative anti-DNA antibody measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034584","Radioimmunoprecipitation Assay","C172383","An immunoassay method that involves the binding of antibodies to radiolabeled antigen, precipitation of the antibody/antigen complex using a special reagent, and analysis of the precipitate, usually by gel electrophoresis.","Radioimmunoprecipitation Assay | RADIOIMMUNOPRECIPITATION ASSAY | RIPA",,,,,,,,,,,,,,,"4069567","Radioimmunoprecipitation assay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1406689","Contrast Enhanced Spiral CT Scan","C172560","A type of spiral CT scan in which images are enhanced by the addition of contrast agents into the body.","Contrast Enhanced Spiral CT Scan | CONTRAST ENHANCED SPIRAL CT SCAN | Spiral CT Scan With Contrast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406686","Cell Cytotoxicity Neutralization Assay","C172559","An assay that is used to detect the presence of a toxin in a biological sample by inoculating two sets of tissue cell cultures, one prepared with anti-toxin and one prepared without anti-toxin, with filtrates of the sample and assessing for a cytopathic effect after an incubation period.","Cell Cytotoxicity Neutralization Assay | CCNA | CELL CYTOTOXICITY NEUTRALIZATION ASSAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406687","Agar Proportion","C172558","A method that is used to determine microbial susceptibility to antibiotics by evaluating the extent of growth of several dilutions of a standardized inoculum of microorganism in drug-free and drug-containing agar mediums. The number of colony-forming units grown are compared and expressed as a percentage.","Agar Proportion | AGAR PROPORTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406685","Chemiluminescent Microparticle Immunoassay","C172557","A type of chemiluminescent immunoassay that uses paramagnetic microparticles bound to antigen or primary antibodies as a substrate for analyte binding prior to labeling with a luminescent compound.","Chemiluminescent Microparticle Immunoassay | CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY | CMIA | Chemiluminescent Magnetic Microparticle Immunoassay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388496","Bioimpedance Spectroscopy","C172556","A technique of measuring resistance to electrical current to assess tissue composition and fluid levels.","Bioimpedance Spectroscopy | BIOIMPEDANCE SPECTROSCOPY",,,,,,,,,,,,,,,"604452","Bioelectrical impedance spectroscopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL519559","Plaque Reduction Neutralization Assay","C172555","A serological test that measures the ability of antibodies in specific concentrations of serum to prevent the formation of plaques in a cell monolayer when combined with a viral suspension.","Plaque Reduction Neutralization Assay | PLAQUE REDUCTION NEUTRALIZATION ASSAY | PRNT | Plaque Reduction Neutralization Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3805144","Ergospirometry","C172564","An exercise testing method that continuously measures respiratory volume and frequency, oxygen intake, carbon-dioxide output, and heart rate during ergometer exercise to assess integrative cardiopulmonary, musculoskeletal, and metabolic response to physical stress.","Ergospirometry | ERGOSPIROMETRY | Spiroergometry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406690","Ultrasonographic Elastography","C172563","A noninvasive technique that is used to measure organ or tissue stiffness. An ultrasound wave is passed into the organ or tissue from a small transducer on the end of an ultrasound probe which measures the velocity of the shear wave (in meters per second) as this wave passes through the organ or tissue. The shear wave velocity can then be converted into organ or tissue stiffness. This technique may be used as an alternative to organ or tissue biopsy.","Ultrasonographic Elastography | ULTRASONOGRAPHIC ELASTOGRAPHY | Ultrasound Elastography",,,,,,,,,,,,,,,"40491501","Ultrasound elastography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1406691","Contrast Enhanced PET Scan","C172562","A type of positron emission tomography scan in which the images are not enhanced by the addition of contrast agents into the body.","Contrast Enhanced PET Scan | CONTRAST ENHANCED PET SCAN | PET Scan With Contrast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406688","Spiral CT Scan Without Contrast","C172561","A type of spiral CT scan in which the images are not enhanced by the addition of contrast agents into the body.","Spiral CT Scan Without Contrast | SPIRAL CT SCAN WITHOUT CONTRAST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2981478","Laboratory Test Date Time of Reference Timepoint","C87894","The date and time of a laboratory test reference point.","Laboratory Test Date Time of Reference Timepoint | LBRFTDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406422","Galectin-3 Measurement","C172493","The determination of the amount of galectin-3 in a sample.","Galectin-3 Measurement | GALIG | GALIG Measurement | GLCTN3 | Galactose-Specific Lectin 3 | Galactose-Specific Lectin 3 Measurement | Galectin-3 | LGALS3 Measurement | MAC-2 | MAC-2 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406423","8-Hydroxydeoxyguanosine Measurement","C172492","The determination of the amount of 8-hydroxydeoxyguanosine in a sample.","8-Hydroxydeoxyguanosine Measurement | 8-Hydroxydeoxyguanosine | 8-OHdG | 8-OHdG Measurement | OHDG8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406421","Cocaine Metabolites Measurement","C172491","The determination of the amount of cocaine metabolites in a sample.","Cocaine Metabolites Measurement | COCAM | Cocaine Metabolites",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL564704","Cocaine And/Or Metabolites Measurement","C172490","A measurement of the cocaine and/or its metabolite(s) present in a biological specimen, for an assay that can measure both cocaine and its metabolites but may not distinguish either in the result.","Cocaine And/Or Metabolites Measurement | COCAAOM | Cocaine and/or Metabolites",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406427","Chenodeoxycholate Measurement","C172498","The determination of the amount of chenodeoxycholate in a sample.","Chenodeoxycholate Measurement | CDCA | Chenic Acid | Chenic Acid Measurement | Chenocholic Acid | Chenocholic Acid Measurement | Chenodeoxycholate | Chenodeoxycholic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266275","Beta and Gamma Tocopherol Measurement","C172497","The determination of the amount of beta and gamma tocopherol in a sample.","Beta and Gamma Tocopherol Measurement | BGTCPHRL | Beta and Gamma Tocopherol | Beta+Gamma Tocopherol",,,,,,,,,,,,,,,"4005372","beta-gamma-Tocopherol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1406426","Vascular Endothelial Growth Factor D Measurement","C172496","The determination of the amount of vascular endothelial growth factor D in a sample.","Vascular Endothelial Growth Factor D Measurement | FIGF | FIGF Measurement | VEGF D Measurement | VEGFD | VEGFD Measurement | Vascular Endothelial Growth Factor D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406424","Soluble L-Selectin Measurement","C172495","The determination of the amount of soluble L-selectin in a sample.","Soluble L-Selectin Measurement | LSELS | Soluble CD62L | Soluble CD62L Measurement | Soluble L-Selectin | Soluble SELL Measurement | sL-Selectin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406425","Neoplastic Plasma Cell Count","C172494","The determination of the amount of neoplastic plasma cells in a sample.","Neoplastic Plasma Cell Count | Clonal Plasma Cell Count | Clonal Plasma Cells | Monoclonal Plasma Cell Count | Monoclonal Plasma Cells | Monotypic Plasma Cell Count | Monotypic Plasma Cells | Neoplastic Plasma Cells | PLSNCE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406429","Soluble Programmed Death Ligand 1 Measurement","C172503","The determination of the amount of soluble programmed death ligand 1 in a sample.","Soluble Programmed Death Ligand 1 Measurement | PDL1S | Soluble CD274 | Soluble CD274 Measurement | Soluble PD-L1 | Soluble PD-L1 Measurement | Soluble PDL1 | Soluble PDL1 Measurement | Soluble Programmed Death Ligand 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407070","MHC Class I Chain Related Protein A Measurement","C172502","The determination of the amount of MHC class I chain related protein A in a sample.","MHC Class I Chain Related Protein A Measurement | MHC Class I Chain Related Protein A | MIC-A Measurement | MICA | MICA Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406428","Phosphorylated Neurofilament Heavy Chain Measurement","C172501","The determination of the amount of phosphorylated neurofilament heavy chain in a sample.","Phosphorylated Neurofilament Heavy Chain Measurement | NFHP | Phosphorylated NEFH Measurement | Phosphorylated Neurofilament Heavy Chain | Phosphorylated Neurofilament-H Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523597","Deoxycholate Measurement","C172500","The determination of the amount of deoxycholate in a sample.","Deoxycholate Measurement | DCA | Deoxycholate | Deoxycholic Acid | Deoxycholic Acid Measurement",,,,,,,,,,,,,,,"4017062","Deoxycholate measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523562","Cholate Measurement","C172499","The determination of the amount of cholate in a sample.","Cholate Measurement | CHOLATE | Cholate | Cholic Acid | Cholic Acid Measurement",,,,,,,,,,,,,,,"4018187","Cholic acid measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1406410","Cellular Fibronectin Measurement","C172507","The determination of the amount of cellular fibronectin in a sample.","Cellular Fibronectin Measurement | Cellular FN Measurement | Cellular FN1 Measurement | FBNCTCE | Fibronectin, Cellular | Insoluble Fibronectin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407082","Vitamin D Binding Protein Measurement","C172506","The determination of the amount of vitamin D binding protein in a sample.","Vitamin D Binding Protein Measurement | DBP | GC Vitamin D Binding Protein | GC Vitamin D Binding Protein Measurement | VDBP | VDBP Measurement | VITDBP | Vitamin D Binding Protein | Vitamin D-Binding Protein Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406430","Soluble Programmed Death-1 Measurement","C172505","The determination of the amount of soluble programmed death-1 in a sample.","Soluble Programmed Death-1 Measurement | PD1 Measurement | PD1S | Soluble CD279 | Soluble CD279 Measurement | Soluble PD-1 | Soluble PD-1 Measurement | Soluble PD1 | Soluble PDCD1 Measurement | Soluble Programmed Cell Death Protein 1 | Soluble Programmed Death-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406431","Soluble Lymphocyte Activation Gene-3 Measurement","C172504","The determination of the amount of soluble lymphocyte activation gene-3 in a sample.","Soluble Lymphocyte Activation Gene-3 Measurement | LAG3S | Soluble CD223 Antigen | Soluble CD223 Antigen Measurement | Soluble LAG-3 | Soluble LAG-3 Measurement | Soluble LAG3 Measurement | Soluble Lymphocyte Activation Gene 3 Protein | Soluble Lymphocyte Activation Gene-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001857","Absolute Reticulocyte Count","C173537","The number of reticulocytes present in a cubic millimeter of blood, expressed as the product of the reticulocyte percentage and the red blood cell count.","Absolute Reticulocyte Count | ARC | Absolute Retic Count",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407497","Extended Phenotype Matching","C173546","A process in which blood or tissue samples are analyzed for antigens beyond the standard panel. Extended typing may include typing for K, E, C, Fya, Fyb, Jka , Jkb, S, M, Lea, or e antigens.","Extended Phenotype Matching | Extended Phenotype Match",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406418","Betaines Measurement","C172517","The determination of the amount of betaines in a sample.","Betaines Measurement | BETAINES | Betaines",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406419","S-Adenosylhomocysteine Measurement","C172516","The determination of the amount of S-adenosylhomocysteine in a sample.","S-Adenosylhomocysteine Measurement | S-Adenosylhomocysteine | S-adenosyl-L-homocysteine | SAH | SAHOMC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407090","S-Adenosylmethionine Measurement","C172515","The determination of the amount of S-adenosylmethionine in a sample.","S-Adenosylmethionine Measurement | S-Adenosylmethionine | S-adenosyl-L-methionine | SAM-e | SAMETH | SAMMY | SAMe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406417","Hepatocyte Growth Factor Receptor Measurement","C172514","The determination of the amount of hepatocyte growth factor receptor in a sample.","Hepatocyte Growth Factor Receptor Measurement | HGFR | HGFR Protein Measurement | Hepatocyte Growth Factor Receptor | MET Measurement | MET Proto-Oncogene, Receptor Tyrosine Kinase | Tyrosine-Protein Kinase Met | c-Met",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406415","Interleukin 18 Binding Protein Measurement","C172513","The determination of the amount of interleukin 18 binding protein in a sample.","Interleukin 18 Binding Protein Measurement | IL18 Binding Protein Measurement | IL18BP | IL18BP Measurement | Interleukin 18 Binding Protein | Interleukin-18-Binding Protein Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406416","Decorin Measurement","C172512","The determination of the amount of decorin in a sample.","Decorin Measurement | DCN | DCN Measurement | DECORIN | Decorin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406413","CEA Cell Adhesion Molecule 1 Measurement","C172511","The determination of the amount of CEA cell adhesion molecule 1 in a sample.","CEA Cell Adhesion Molecule 1 Measurement | BGP | Biliary Glycoprotein | Biliary Glycoprotein Measurement | CD66a | CD66a Measurement | CEA Cell Adhesion Molecule 1 | CEA Related Cell Adhesion Molecule 1 | CEACAM1 | CEACAM1 Measurement | Carcinoembryonic Antigen Cell Adhesion Molecule 1 | Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Measurement | Soluble CD66a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406414","Carbonic Anhydrase 9 Measurement","C172510","The determination of the amount of carbonic anhydrase 9 in a sample.","Carbonic Anhydrase 9 Measurement | CA9 | CA9 Measurement | CAIX | CAIX Measurement | CBANH9 | Carbonic Anhydrase 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406411","Endostatin Measurement","C172509","The determination of the amount of endostatin in a sample.","Endostatin Measurement | Collagen Type XVIII Alpha 1 Chain | Collagen Type XVIII Alpha 1 Chain Measurement | ENDOSTN | Endostatin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406412","Plasma Fibronectin Measurement","C172508","The determination of the amount of plasma fibronectin in a sample.","Plasma Fibronectin Measurement | FBNCTPL | Fibronectin, Plasma | Plasma FN Measurement | Plasma FN1 Measurement | Soluble Fibronectin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1373120","Non-nucleoside Reverse Transcriptase Inhibitor","C97453","A substance structurally unlike a nucleoside molecule that is capable of inhibiting the function of a reverse transcriptase. These compounds do not bind to the active site of the polymerase but in a less conserved pocket near the active site, causing a distortion in the shape of the active site and resulting in inhibition of enzymatic function, chain termination, and inhibition of viral replication.","Non-nucleoside Reverse Transcriptase Inhibitor | NNRTI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1566826","Rilpivirine","C76929","A second-generation non-nucleoside reverse transcriptase inhibitor. Rilpivirine is a diarylpyrimidine.","Rilpivirine | 4-((4-((4-((1E)-2-Cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile | Edurant | R 278474 | R278474 | RILPIVIRINE | TMC278",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202344","Butabarbital Measurement","C75364","The determination of the amount of butabarbital present in a sample.","Butabarbital Measurement | BTLBARTL | Butabarbital",,,,,,,,,,,,,,,"4210758","Butabarbital measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2700236","Gamma-Hydroxybutyrate Measurement","C75357","The determination of the amount of gamma-hydroxybutyrate (GHB) present in a sample.","Gamma-Hydroxybutyrate Measurement | 4-Hydroxybutanoic Acid | GHB | GHB Measurement | Gamma-Hydroxybutyrate | Gamma-Hydroxybutyric Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406660","Acetaminophen-Cysteine Adduct Measurement","C172525","The determination of the amount of acetaminophen-cysteine adduct in a sample.","Acetaminophen-Cysteine Adduct Measurement | APAP-CYS | APAP-CYS Measurement | APAP-Protein | APAPCYS | Acetaminophen Protein Adduct | Acetaminophen-Cysteine Adduct",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406661","7-alpha-Hydroxy-4-cholesten-3-one Measurement","C172524","The determination of the amount of 7-alpha-hydroxy-4-cholesten-3-one in a sample.","7-alpha-Hydroxy-4-cholesten-3-one Measurement | 7 alpha-Hydroxy-4-cholesten-3-one Measurement | 7 alpha-Hydroxycholest-4-en-3-one Measurement | 7-Alpha hydroxy-4-cholesten-3-one | 7-alpha-Hydroxy-4-cholesten-3-one | 7-alpha-Hydroxycholest-4-en-3-one Measurement | 7AC4 Measurement | 7alpha-Hydroxy-4-cholesten-3-one Measurement | 7alpha-Hydroxycholest-4-en-3-one Measurement | 7alphaC4 Measurement | A73OXC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406658","Mid-Regional Pro-Atrial Natriuretic Peptide Measurement","C172523","The determination of the amount of mid-Regional pro-atrial natriuretic peptide in a sample.","Mid-Regional Pro-Atrial Natriuretic Peptide Measurement | ANPPROMR | MR-proANP | MRproANP | Mid-Reg Pro-Atrial Natriuretic Peptide | Mid-Regional Pro-Atrial Natriuretic Peptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406659","Ferritin Light Chain Measurement","C172522","The determination of the amount of ferritin light chain in a sample.","Ferritin Light Chain Measurement | FRTNLC | FTL | Ferritin Light Chain | L Apoferritin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407079","Ferritin Heavy Chain Measurement","C172521","The determination of the amount of ferritin heavy chain in a sample.","Ferritin Heavy Chain Measurement | Apoferritin | FRTNHC | FTH | FTH1 | Ferritin Heavy Chain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407083","Cystathionine Beta-Synthase Measurement","C172520","The determination of the amount of cystathionine beta-synthase in a sample.","Cystathionine Beta-Synthase Measurement | CBS | CBS Measurement | Cystathionine Beta-Synthase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406420","Dimethylglycine Measurement","C172519","The determination of the amount of dimethylglycine in a sample.","Dimethylglycine Measurement | DMG | Dimethylglycine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1295123","Cysteine Measurement","C172518","The determination of the amount of cysteine in a sample.","Cysteine Measurement | CYSTEINE | Cysteine",,,,,,,,,,,,,,,"4008121","Cysteine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1327915","Congenital Amegakaryocytic Thrombocytopenia","C115207","A rare, autosomal recessive inherited disorder caused by mutation in the c-Mpl gene.  It is characterized by thrombocytopenia and absence of megakaryocytes.  It presents with bleeding in the first month of life.","Congenital Amegakaryocytic Thrombocytopenia | ",,,,,,,,,,,,,,,"37396502","Congenital amegakaryocytic thrombocytopenia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4045491","Doravirine","C171848","A pyridinone non-nucleoside reverse transcriptase inhibitor (NNRTI) of human immunodeficiency virus type 1 (HIV-1), that is used to treat HIV infection. Upon oral administration, doravirine non-competitively inhibits HIV-1 reverse transcriptase (RT), thereby inhibiting HIV-1 viral replication.","Doravirine | DORAVIRINE | Pifeltro",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512434","Bladder Non-Invasive Papillary Urothelial Carcinoma, High Grade","C27876","Bladder non-invasive papillary urothelial carcinoma characterized by marked architectural and cytologic abnormalities and frequent mitotic figures (at all levels of the urothelium).","Bladder Non-Invasive Papillary Urothelial Carcinoma, High Grade | High-Grade Papillary Urothelial Carcinoma | Non-Invasive Bladder Papillary Urothelial Carcinoma, High Grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518006","Bladder Non-Invasive Papillary Urothelial Carcinoma, Low Grade","C27875","Bladder non-invasive papillary urothelial carcinoma characterized by minimal cytologic atypia and infrequent mitotic figures (usually limited to the lower half of the tumor). This type of carcinoma recurs frequently, may invade the bladder wall, and has a low risk of progression.","Bladder Non-Invasive Papillary Urothelial Carcinoma, Low Grade | Low-Grade Papillary Urothelial Carcinoma | Non-Invasive Bladder Papillary Urothelial Carcinoma, Low Grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1612190","Tipranavir Disodium","C66604","A disodium salt form of tipranavir, a non-peptidomimetic agent that inhibits both wild type and drug resistant forms of human immunodeficiency virus (HIV) protease.","Tipranavir Disodium | Aptivus | TIPRANAVIR DISODIUM | tipranavir sodium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521119","Leukocytes Reduced","C133276","Processing of blood products before issue to remove leukocytes.","Leukodepletion | Leukocytes Reduced | Leukocytes Reduced Blood Product | Leukocytes Reduced Blood Product | Leukodepleted | Leukoreduction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0286737","Saquinavir Mesylate","C1602","The mesylate salt form of saquinavir, a peptidomimetic inhibitor of human immunodeficiency virus (HIV) protease.","Saquinavir Mesylate | Invirase | SAQUINAVIR MESYLATE | saquinavir mesylate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0553741","Fluid Management","C173582","The promotion of optimal fluid balance, especially in the inpatient setting, through ongoing clinical assessment and monitoring of intravascular volume, and accurate replacement of fluid losses.","Fluid Management | ",,,,,,,,,,,,,,,"4175359","Fluid balance regulation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1725651","Darunavir Ethanolate","C77389","The ethanolate form of darunavir, a human immunodeficiency virus type 1 (HIV-1) protease nonpeptidic inhibitor, with activity against HIV. Upon oral administration, darunavir selectively targets and binds to the active site of HIV-1 protease, and inhibits the dimerization and catalytic activity of HIV-1 protease. This inhibits the proteolytic cleavage of viral Gag and Gag-Pol polyproteins in HIV-infected cells. This inhibition leads to the production of immature, non-infectious viral proteins that are unable to form mature virions, and prevents HIV replication.","Darunavir Ethanolate | DARUNAVIR ETHANOLATE | Prezista | TMC114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0886530","Nelfinavir Mesylate","C1624","The mesylate salt form of nelfinavir, a synthetic antiviral agent that selectively binds to and inhibits human immunodeficiency virus (HIV) protease. Nelfinavir has activity against HIV 1 and 2.","Nelfinavir Mesylate | AG1343 | NELFINAVIR MESYLATE | Viracept | nelfinavir mesylate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1449715","HIV Entry Inhibitor","C157400","An agent that prevents the human immunodeficiency virus (HIV) from entering a cell.","HIV Entry Inhibitor | Cell Entry Inhibitor | Entry Inhibitor | Virus Entry Inhibitor",,,,,,,,,,,,,,,"36675072","Human immunodeficiency virus entry inhibitor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1407349","Macrometastasis Greater than 2.0 mm","C173590","A finding of a macrometastasis measuring more than 2 mm along the greatest dimension.","Macrometastasis Greater than 2.0 mm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407348","Micrometastasis 0.2 mm to 2.0 mm","C173589","A finding of a micrometastasis measuring from 0. 2mm to 2 mm along the greatest dimension.","Micrometastasis 0.2 mm to 2.0 mm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407358","Isolated Tumor Cells Less than 0.2 mm","C173591","A cluster of metastatic malignant cells measuring less than 0.2 mm along the greatest dimension.","Isolated Tumor Cells Less than 0.2 mm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937378","HIV Integrase Inhibitor","C157401","An agent that blocks the activity of the human immunodeficiency virus (HIV) integrase enzyme.","HIV Integrase Inhibitor | INI | Integrase Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1966407","Raltegravir Potassium","C73823","The orally bioavailable potassium salt of a human immunodeficiency virus (HIV) integrase strand transfer inhibitor (HIV-1 INSTI) with HIV-1 antiviral activity. Raltegravir binds to and inhibits integrase, an HIV enzyme that inserts viral genetic material into the genetic material of the infected human cell. Inhibition of integrase prevents insertion of HIV DNA into the human DNA genome, thus blocking HIV replication.","Raltegravir Potassium | Isentress | N-[(4-Fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[ (5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino]ethyl]-6-oxo-4-pyrimidinecarboxamide Monopotassium Salt | RALTEGRAVIR POTASSIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008269","Chloroquine","C61671","A 4-aminoquinoline with antimalarial, anti-inflammatory, and potential chemosensitization and radiosensitization activities. Although the mechanism is not well understood, chloroquine is shown to inhibit the parasitic enzyme heme polymerase that converts the toxic heme into non-toxic hemazoin, thereby resulting in the accumulation of toxic heme within the parasite. This agent may also interfere with the biosynthesis of nucleic acids. Chloroquine's potential chemosensitizing and radiosensitizing activities in cancer may be related to its inhibition of autophagy, a cellular mechanism involving lysosomal degradation that minimizes the production of reactive oxygen species (ROS) related to tumor reoxygenation and tumor exposure to chemotherapeutic agents and radiation.","Chloroquine | CHLOROQUINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0872278","Stem Cell Therapy","C165194","A treatment modality that leverages stem cells to prevent or treat disease.","Stem Cell Therapy | Stem Cell Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826210","Complete Recovery","C82467","An indication that a patient is free of symptoms, with no lasting health problems.","Complete Recovery | Fully recovered | Recovered / Normal | Symptoms_Resolved",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405688","Bictegravir","C171719","A human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), that is used to treat HIV infection. Upon oral administration, bictegravir inhibits the strand transfer activity of HIV-1 integrase, an HIV-1 coded enzyme that is necessary for viral replication. Inhibition of integrase prevents the integration of linear HIV-1 DNA into host genomic DNA.","Bictegravir | BICTEGRAVIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550911","Tenofovir Alafenamide","C148276","A lipophilic phosphonamidate prodrug of tenofovir, a synthetic antiviral acyclic nucleotide analog of adenosine 5-monophosphate and a nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity against hepatitis B virus (HBV) and potentially against human immunodeficiency virus (HIV). Upon oral administration, tenofovir alafenamide is taken up by hepatocytes through passive diffusion and through the hepatic uptake transporters organic anion transporting polypeptides 1B1 (OATP1B1) and 1B3 (OATP1B3). Inside the hepatocytes, tenofovir alafenamide is hydrolyzed and converted to tenofovir by carboxylesterase 1 (CES1). Intracellular tenofovir is phosphorylated by cellular kinases to its pharmacologically active form, tenofovir diphosphate. Tenofovir diphosphate is incorporated into viral DNA instead of the natural substrate deoxyadenosine 5-triphosphate, and inhibits HBV reverse transcriptase, resulting in DNA chain-termination and inhibition of HBV replication. In addition, tenofovir diphosphate is incorporated into HIV DNA instead of the natural substrate deoxyadenosine 5-triphosphate, thereby inhibiting HIV-1 reverse transcriptase (RT) and resulting in DNA chain termination and impairment of HIV replication.","Tenofovir Alafenamide | GS 7340 | GS-7340 | L-Alanine, N-((S)-(((1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)phenoxyphosphinyl)-, 1-Methylethyl Ester | TENOFOVIR ALAFENAMIDE | TFV Alafenamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937256","Emtricitabine/Tenofovir Alafenamide Fumarate","C157538","A fixed combination of emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine and tenofovir alafenamide fumarate, the fumarate salt form of the lipophilic phosphonamidate prodrug of tenofovir, a NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, emtricitabine and tenofovir inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","Emtricitabine/Tenofovir Alafenamide Fumarate | Descovy | Emtricitabine/Tenofovir Alafenamide | FTC/TAF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3883388","Atazanavir/Cobicistat","C157541","A fixed combination of atazanavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, and cobicistat, a cytochrome P450 3A (CYP3A) inhibitor that may be used to treat HIV-1 infection. Upon oral administration, atazanavir selectively binds to the active site of HIV-1 protease and inhibits the proteolytic cleavage of viral Gag and Gag-Pol polyproteins in HIV-infected cells. This inhibition leads to the production of immature, non-infectious viral proteins that are unable to form mature virions. Cobicistat inhibits CYP3A, thereby limiting the metabolism of atazanavir and increasing its systemic exposure.","Atazanavir/Cobicistat | ATV/COBI | Evotaz",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4058850","Genvoya","C157537","A fixed combination of elvitegravir, a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI); cobicistat, a cytochrome P450 3A (CYP3A) inhibitor; emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine; and tenofovir alafenamide fumarate, the fumarate salt form of the lipophilic phosphonamidate prodrug of tenofovir, a NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, elvitegravir inhibits the activity of integrase, an HIV-1 coded enzyme that is necessary for viral replication. Inhibition of integrase prevents the integration of HIV-1 DNA into host genomic DNA. Cobicistat inhibits CYP3A, thereby limiting the oxidative metabolism of elvitegravir and increases its systemic exposure. Emtricitabine and tenofovir inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate | EVG/COBI/FTC/TAF | Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide | Genvoya",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937257","Emtricitabine/Rilpivirine/Tenofovir Alafenamide Fumarate","C157539","A fixed combination of emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine; rilpivirine, a diarylpyrimidine derivative and non-nucleoside RT inhibitor (NNRTI); and tenofovir alafenamide fumarate, the fumarate salt form of the lipophilic phosphonamidate prodrug of tenofovir, a NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, emtricitabine and tenofovir inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions. Rilpivirine, a non-competitive NNRTI binds to RT and inhibits RNA and DNA-dependent polymerase activities, including viral replication.","Emtricitabine/Rilpivirine/Tenofovir Alafenamide Fumarate | Emtricitabine/Rilpivirine/Tenofovir Alafenamide | FTC/RPV/TAF | Odefsey",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3871454","Darunavir/Cobicistat","C157536","A fixed combination of darunavir, an inhibitor of the human immunodeficiency virus (HIV) protease; and cobicistat, a cytochrome P450 3A (CYP3A) inhibitor that may be used to treat HIV infection. Upon oral administration, darunavir binds to and inhibits the dimerization and catalytic activity of the HIV aspartyl protease. This inhibits the cleavage of HIV-encoded Gag and Gag-Pol polyproteins in virus-infected cells, which prevents the formation of mature infectious virions. Cobicistat inhibits CYP3A, thereby limiting the metabolism of darunavir and increases its systemic exposure.","Darunavir/Cobicistat | DRV/COBI | Prezcobix | Rezolsta | Rezolsta; Rezolsta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3854896","Abacavir/Dolutegravir/Lamivudine","C157543","A fixed combination of abacavir sulfate, a nucleoside reverse transcriptase inhibitor (NRTI) analog of guanosine; dolutegravir, an integrase strand-transfer inhibitor (INSTI); and lamivudine, an NRTI analog of cytidine, that may be used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, abacavir and lamivudine are phosphorylated into active metabolites that inhibit the HIV reverse transcriptase (RT) enzyme competitively and act as a chain terminator of DNA synthesis. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions. Dolutegravir binds to the active site of integrase, an HIV enzyme that catalyzes the transfer of viral genetic material into human chromosomes. This prevents integrase from binding to retroviral deoxyribonucleic acid (DNA), and blocks the strand transfer step, which is essential for the HIV replication cycle. This further prevents HIV-1 replication.","Abacavir/Dolutegravir/Lamivudine | ABC/DTG/3TC | Triumeq",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1701505","Elvitegravir","C76493","A modified quinolone antibiotic with activity against human immunodeficiency virus 1. Elvitegravir is an inhibitor of viral integrase and retains activity against integrase mutants that are resistant to Raltegravir.","Elvitegravir | 6-(3-Chloro-2-fluorobenzyl)-1-((2S)-1-hydroxy-3-methylbutan-2-yl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid | ELVITEGRAVIR | GS 9137 | GS-9137 | JTK 303 | JTK-303",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1434792","Ibalizumab","C88612","A humanized monoclonal antibody against CD4, with anti-human immunodeficiency virus (HIV) activity. Ibalizumab binds to CD4, the primary receptor for HIV, thereby inhibiting HIV entry into CD4-positive T-cells. This leads to a reduction in viral load.","Ibalizumab | IBALIZUMAB | Ibalizumab-uiyk | Ibalizumab-uiyk; Trogarzo; Ibalizumab-uiyk | Immunoglobulin G4, Anti-(Human CD4 (Antigen)) (Human-Mouse Monoclonal 5A8 Gamma-4-Chain), Disulfide with Human-Mouse Monoclonal 5A8 Kappa-Chain, Dimer | TNX-355 | Trogarzo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3864947","Recombinant Human Papillomavirus Nonavalent Vaccine","C119664","A non-infectious, recombinant, nonavalent vaccine prepared from highly purified virus-like particles (VLPs) comprised of the major capsid (L1) proteins from human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, and 58, with active immunizing activity. Upon administration, the recombinant HPV nonavalent vaccine activates the immune system to produce antibodies against the 9 HPV types. This protects against HPV infection and HPV-related cancers. Altogether, HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 account for the majority of the HPV types that cause cervical, vulvar, vaginal and anal cancers.","Recombinant Human Papillomavirus Nonavalent Vaccine | Gardasil 9 | Nonavalent HPV VLP Vaccine | Recombinant HPV Nonavalent Vaccine | Recombinant Human Papillomavirus 9-valent Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2741594","Meningococcal Conjugate Vaccine MCV4","C96391","A conjugate vaccine of meningococcal polysaccharide used for active immunization against invasive meningococcal disease caused by Neisseria meningiditis serogroups A, C, Y, and W-135.","Meningococcal Conjugate Vaccine MCV4 | MCV4 | Menactra | Meningococcal Conjugate Vaccine MCV-4 | Meningococcal Polysaccharide (Serogroups A, C, Y and W-135) Diphtheria Toxoid Conjugated Vaccine | Menveo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0078048","Varicella-Zoster Virus Strain Oka/Merck Live Antigen","C77799","A sterile, lyophilized preparation of the Oka/Merck strain of the live, attenuated varicella-zoster virus (VZV), that can be used to prevent varicella, commonly known as chickenpox, or herpes zoster (HZ), commonly known as shingles. Upon reconstitution and subcutaneous vaccination with the VZV strain Oka/Merck live antigen, this vaccine induces antigen-specific T-cell and B-cell immune responses against the VZV, thereby protecting against VZV infection.","Varicella-Zoster Virus Strain Oka/Merck Live Antigen | Chickenpox Vaccine | Human Herpesvirus 3 Live (Attenuated) Antigen | Shingles Vaccine | VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN | Varicella Vaccine | Varicella Virus Vaccine Live | Varivax | Zostavax | Zoster Vaccine Live",,,,,,,,,,,,,,,"37310934","Live attenuated Human alphaherpesvirus 3 Oka-Merck strain antigen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0718003","Poliovirus Vaccine, Inactivated","C91715","A vaccine consisting of inactivated poliovirus (IPV) types 1,2 and 3, with active immunizing activity against poliomyelitis. Upon intramuscular vaccination, inactivated poliovirus vaccine (IPV) activates the immune system to develop antibodies against polioviruses.","Inactivated Poliovirus Vaccine | IPOL | IPV | Poliorix | Poliovirus Vaccine Inactivated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4083280","Vaping","C173621","Inhaling the vapor produced by an electronic cigarette or similar device.","Vaping | Vape",,,,,,,,,,,,,,,"37311286","Vaping",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1412910","Travel History","C173619","A record of the places that a person has been.","Travel History | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162468","Social Impacts","C173620","The effect on people and communities that happens as a result of an action, event, activity, project, program, or policy.","Social Impact | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407302","PIGA Deficiency","C173571","An X-linked recessive inherited disorder caused by loss of function mutations in the PIGA gene. It is characterized by deficient GPI-anchor synthesis. Patients may develop somatic paroxysmal nocturnal hemoglobinuria (PNH) or multiple congenital anomalies-hypotonia-seizures syndrome 2 (MCAHS2; early infantile epileptic encephalopathy 20; EIEE20).","PIGA Deficiency | PIGA GPI Anchor Protein Defect | PIGA GPI Anchor Protein Deficiency | Phosphatidylinositol N-Acetylglucosaminyltransferase Subunit A Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407303","Response Assessment in Neuro-Oncology Brain Metastases","C173572","A working group that is leading an international, multidisciplinary effort to develop standard response and progression criteria for use in clinical trials of treatment for brain metastases.","Response Assessment in Neuro-Oncology Brain Metastases | RANO-BM | Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407310","RPL5 Gene Mutation","C173581","A change in the nucleotide sequence of the RPL5 gene.","RPL5 Gene Mutation | L5 Gene Mutation | PPP1R135 Gene Mutation | Ribosomal Protein L5 Gene Mutation | uL18 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407350","ELANE Gene Mutation","C173583","A change in the nucleotide sequence of the ELANE gene.","ELANE Gene Mutation | ELA2 Gene Mutation | ELANE Gene Mutation  | Elastase 2, Neutrophil Gene Mutation | Elastase, Neutrophil Expressed Gene Mutation | GE Gene Mutation | HLE Gene Mutation | HNE Gene Mutation | NE Gene Mutation | PMN-E Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407334","Disease Panel Gene Sequencing","C173599","An application of next-generation targeted sequencing where a disease-specific group of genes or loci are assayed for sequence alterations as a screening procedure for the disease.","Disease Panel Gene Sequencing | Gene Mutation Panel | Genetic Mutation Panel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407378","Meningococcal Group B Vaccine","C173628","A vaccine containing recombinant bacterial proteins derived from the bacterium Neisseria meningitidis serogroup B, that is used to provide active immunization against and to prevent invasive disease caused by Neisseria meningitidis serogroup B. Upon intramuscular vaccination with meningococcal group B vaccine, the recombinant proteins activate the immune system to produce antibodies directed against the recombinant proteins. This provides active immunization and protection against invasive meningococcal disease by complement-mediated antibody-dependent killing of N. meningitidis.","Meningococcal Group B Vaccine | Bexsero | MenB Vaccine | Meningococcal B Vaccine | Serogroup B Meningococcal Vaccine | Trumenba",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407379","COVID-19-Associated Ageusia","C173629","Ageusia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).","COVID-19-Associated Ageusia | COVID-19 Associated Loss of Taste | COVID-19-Associated Loss of Taste | Loss of taste (ageusia)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0850149","Non-Productive Cough","C173623","A cough that is not accompanied by expectorated secretions.","Non-Productive Cough | Dry Cough",,,,,,,,,,,,,,,"4038519","Dry cough",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0239161","Dactylitis","C173627","Inflammation of the fingers or toes. This may be accompanied by pain and discoloration.","Dactylitis | Painful swelling or discoloration of fingers/toes",,,,,,,,,,,,,,,"4131942","Dactylitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2364111","Ageusia","C116374","Inability to taste.","Ageusia | Loss of taste",,,,,,,,,,,,,,,"4289517","Loss of taste",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003126","Anosmia","C116369","Inability to smell.","Anosmia | Loss of smell",,,,,,,,,,,,,,,"4185711","Loss of sense of smell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0079161","Contact Tracing","C173558","The process of identifying and tracking individuals who may have been exposed to a person with an infectious disease in order to monitor and disrupt disease spread.","Contact Tracing | ",,,,,,,,,,,,,,,"4021317","Contact tracing",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007585","Cell Culture Techniques","C116004","Any laboratory procedure for growing cells or tissues in vitro.","Cell Culture Procedure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0425229","Household Crowding","C173632","A condition where the number of occupants exceeds the capacity of a living space, resulting in adverse physical and/or mental health outcomes. Overcrowding is often measured by persons-per-room in a dwelling unit, but it can also be measure by total number of persons in a unit, regardless of unit size; the ratio of persons to floor space in square feet; and the person-to-size ratio adjusted for household composition, structure type, location, or lot size.","Household Crowding | Crowding | Overcrowding | Overcrowding in Housing",,,,,,,,,,,,,,,"4022083","Overcrowded in house",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1407366","Shared Living Space","C173634","A living arrangement where groups of people share private and common space.","Shared Living Space | Co-Living Space | Cohousing | Common Housing | Congregate Housing | Congregate Living | Shared Housing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0203860","Neuroimaging","C173635","The use of various techniques to directly or indirectly image the anatomy and function of the central nervous system.","Neuroimaging | Brain Imaging",,,,,,,,,,,,,,,"40481383","Imaging of brain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1407612","Social Distancing","C173636","The practice of keeping a safe space between yourself and other people.","Social Distancing | Physical Distancing | Social Distancing or Physical Distancing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0444215","Rectal Swab Specimen","C173641","A biospecimen collected from the rectum by swabbing.","Rectal Swab Specimen | Rectal Swab",,,,,,,,,,,,,,,"4124280","Rectal swab",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1407368","Symtuza","C173644","A four-drug fixed combination of the ethanolate salt form of darunavir, a human immunodeficiency virus type 1 (HIV-1) protease nonpeptidic inhibitor; cobicistat, a cytochrome P450 3A (CYP3A) inhibitor; emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine; and tenofovir alafenamide fumarate, the fumarate salt form of the lipophilic phosphonamidate prodrug of tenofovir, a NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration of darunavir ethanolate/cobicistat/emtricitabine/tenofovir alafenamide fumarate, darunavir selectively targets and binds to the active site of HIV-1 protease and inhibits the dimerization and catalytic activity of HIV-1 protease. This inhibits the proteolytic cleavage of viral Gag and Gag-Pol polyproteins in HIV-infected cells. This inhibition leads to the production of immature, non-infectious viral proteins that are unable to form mature virions, and prevents HIV replication. Cobicistat inhibits CYP3A, thereby limiting the oxidative metabolism of darunavir and increases its systemic exposure. Emtricitabine and tenofovir alafenamide, after being converted in vivo to tenofovir, inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain and resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","Darunavir Ethanolate/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate | Symtuza",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936578","Transfusion Dependent Thalassemia","C173642","Thalassemia that results in severe anemia and requires regular blood transfusions for patient survival.","Transfusion Dependent Thalassemia | Transfusion-dependent Thalassemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407367","Transfusion Dependent Beta Thalassemia","C173643","Beta thalassemia that results in severe anemia and requires regular blood transfusions for patient survival.","Transfusion Dependent Beta Thalassemia | Transfusion-dependent Beta Thalassemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985345","Early Post-Partum Recovery","C92924","The early stages in the recuperation process of a mother after her pregnancy and delivery.","Early Post-Partum Recovery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0746102","Chronic Lung Disorder","C98541","A persistent non-neoplastic disorder of the lungs. Representative examples include: chronic obstructive pulmonary disease, chronic bronchitis, emphysema, pulmonary fibrosis, pneumoconiosis, asbestosis, atelectasis, radiation induced pneumonitis, and radiation fibrosis.","Chronic Lung Disorder | Chronic Lung Disease | Chronic_Lung_Disease",,,,,,,,,,,,,,,"4186898","Chronic lung disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509779","Total Number","C127787","The determination of the amount of total number of entities.","Total Number | TOTNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349740","Non-Invasive Mechanical Ventilation","C171457","A type of mechanical ventilation procedure that uses a non-invasive means, such as a face mask or nasal mask, to deliver oxygenated air into the lungs.","Non-Invasive Mechanical Ventilation | NIV | NON-INVASIVE MECHANICAL VENTILATION | Non-Invasive Ventilation | Noninvasive mechanical ventilatory support",,,,,,,,,,,,,,,"4177224","Non-invasive ventilation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1407396","Repatriation","C173652","The act or process of  returning someone or something to their country of origin.","Repatriation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407398","Infection Control Practice","C173654","A set of precautions used to prevent transmission of diseases that can be acquired by person to person or person to environment contact with blood, body fluids, non-intact skin (including rashes), and mucous membranes. These include standard precautions used for all patient care, consisting of risk assessment, common sense practices, and the use of personal protective equipment, as well as transmission-based precautions used with patients who may be infected or colonized with certain infectious agents for which additional precautions are needed to prevent infection transmission.","Infection Control Practice | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407407","National Notifiable Diseases Surveillance System","C173655","A multifaceted public health disease surveillance system established in 1961 that provides the underlying data that public health officials at the Centers for Disease Control and Prevention (CDC) use to monitor disease trends, study risk factors, evaluate prevention and control efforts, and target public health resources.","National Notifiable Diseases Surveillance System | NNDSS | National Notifiable Diseases Surveillance System (NNDSS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407408","Patient Under Investigation","C173656","A person who has been in close contact with a individual with a confirmed infection, or who may have been to a location of a disease outbreak and is exhibiting symptoms of the infection.","Patient Under Investigation | PUI | Patient under investigation (PUI) | Person Under Investigation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407409","Epidemic Information Exchange","C173657","A secure, Centers for Disease Control and Prevention (CDC)-controlled web network that connects public health professionals involved in identifying, investigating, and responding to public health threats. It provides rapid reporting, immediate notification, editorial support, and coordination between public health professionals during public health investigations.","Epidemic Information Exchange | Epi-X | Epidemic Information Exchange (Epi-X)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407410","Point of Entry","C173658","A port where customs officials are stationed to oversee the entry and exit of people and merchandise.","Point of Entry | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407535","Autologous Hematologic Recovery","C173679","The return of host hematopoiesis following graft failure.","Autologous Hematologic Recovery | Autologous Recovery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407573","Division of Global Migration and Quarantine","C173721","A division of the National Center for Preparedness, Detection, and Control of Infectious Diseases (NCPDCID), Centers for Disease Control and Prevention (CDC). Its mission is to reduce morbidity and mortality among immigrants, refugees, travelers, expatriates, and other globally mobile populations, and to prevent the introduction, transmission, and spread of communicable diseases through regulation, science, research, preparedness, and response.","Division of Global Migration and Quarantine | DGMQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038913","Urologic Surgical Procedure","C15334","Any surgery performed on any part of the urinary tract or on any part of the male genitalia.","Urologic Surgical Procedure | Urinary Tract Surgery | Urologic Surgery | Urological Surgical Procedure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951471","Partial Penectomy","C159450","Surgical removal of part of the penis.","Partial Penectomy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0194708","Penectomy","C51621","Surgical removal of part or all of the penis.","Penectomy | Amputation of Penis | penectomy",,,,,,,,,,,,,,,"4216997","Amputation of penis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897811","Public Health Department Facility","C114860","A healthcare facility that is operated or managed by a local, state or national public health department or program.","Public Health Department Facility | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407736","Very Severe Aplastic Anemia","C173788","Aplastic anemia that is characterized by bone marrow (BM) cellularity less than 25% (or less than 50% if BM is comprised of less than 30% hematopoietic cells), and two or more of the following: absolute neutrophil count of less than 200 per microliter; platelet count of less than 20,000 per microliter; or an absolute reticulocyte count of less than 20,000 per microliter.","Very Severe Aplastic Anemia | VSAA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407733","Non-Severe Aplastic Anemia","C173789","Aplastic anemia that is characterized by bone marrow cellularity less than 30% and does not meet criteria for severe aplastic anemia.","Non-Severe Aplastic Anemia | Moderate Aplastic Anemia | NSAA | Non Severe Aplastic Anemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405383","Transfusion Recipient","C171149","A person who receives a direct injection of whole blood or blood products derived from a blood donor.","Transfusion Recipient | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0436503","Abnormal Chest Radiograph","C168098","A history of having had an abnormal chest radiograph.","Abnormal Chest Radiograph | Abnormal Chest X-Ray | Chest x-ray | Patient_had_abnormal_chest_X-ray",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1535926","Neurodevelopmental Disorder","C89338","A childhood disorder that has a neurological basis and manifests as a developmental disability.","Neurodevelopmental Disorder | ",,,,,,,,,,,,,,,"45771096","Neurodevelopmental disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008679","Chronic Disease","C165593","A disease condition that persists over a significant span of time.","Chronic Disease | ",,,,,,,,,,,,,,,"443783","Chronic disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705913","Rapid Antigen Test","C53465","An immunoassay that can quickly detect the presence of specific antigens in a sample and return results during a patient visit.","Rapid Antigen Test | Lateral Flow Assay | RAPID ANTIGEN TEST | RAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407630","Wuhan","C173821","The capital of Hubei province in east central China and a major commercial and industrial city. It is located at the junction of the Han and Yangtze Rivers, and comprises the former cities of Hankou, Hanyang, and Wuchang.","Wuhan | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL441498","Hubei","C173822","A province in east central China that forms a part of the middle basin of the Yangtze River. Its capital, Wuhan, is a major commercial and industrial city.","Hubei | Hupeh",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407632","Mainland China","C173823","The People's Republic of China, other than Hong Kong Special Administrative Region, Macau Special Administrative Region, and Taiwan.","Mainland China | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407631","Visitor","C173824","A person who spends time in a place, or with someone, temporarily.","Visitor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407628","Subjective Fever","C173825","A symptom report of fever without an objective temperature measurement.","Subjective Fever | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407627","Healthcare Worker","C173826","A person, including a healthcare professional or aide, technician, or other skilled or unskilled worker, who delivers health-related care or services.","Healthcare Worker | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014279","Engineering","C16548","The discipline concerned with the application of scientific knowledge to solve practical issues in commerce or industry.","Engineering | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540376","Clinical Laboratory","C142432","A laboratory that analyzes patient or subject samples collected as part of healthcare treatment or clinical research.","Clinical Laboratory | laboratory (clinical)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0241148","Skin Plaque","C39624","A large (greater than 5-10 mm) raised skin lesion with a wide, flat surface.","Skin Plaque | Plaque | Plaque Lesion",,,,,,,,,,,,,,,"4077979","Skin plaque",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0263978","Soft Tissue Disorder","C27042","A non-neoplastic or neoplastic disorder that affects the soft tissue.","Soft Tissue Disorder | Soft Tissue Disease | Soft Tissue Diseases | Soft Tissue Disorders",,,,,,,,,,,,,,,"376208","Disorder of soft tissue",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640839","Casual Contact","C102606","A way of contracting a disease through everyday interactions (nonsexual) with an infected person.","Casual Contact | CASUAL CONTACT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407672","Multidimensional Fatigue Symptom Inventory-Short Form","C173905","A 30-item short form of the Multidimensional Fatigue Symptom Inventory that yields scores only for the empirically derived subscales.","Multidimensional Fatigue Symptom Inventory-Short Form | MFSI-SF | Multidimensional Fatigue Symptom Inventory - Short Form (MFSI-SF)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1408433","Muscles Ache","C173906","A question about whether an individual's muscles ache.","Muscles Ache | My muscles ache",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407674","Feel Upset","C173907","A question about whether an individual feels upset.","Feel Upset | I feel upset",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407669","Head Feels Heavy","C173908","A question about whether an individual's head feels heavy.","Head Feels Heavy | My head feels heavy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407668","Feel Lively","C173909","A question about whether an individual feels lively.","Feel Lively | I feel lively",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407671","Feel Relaxed","C173910","A question about whether an individual feels relaxed.","Feel Relaxed | I feel relaxed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407670","Feel Pooped","C173911","A question about whether an individual feels pooped.","Feel Pooped | I feel pooped",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407710","Am Confused","C173912","A question about whether an individual feels confused.","Am Confused | Feel Confused | I am confused",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407709","Arms Feel Weak","C173913","A question about whether an individual's arms feel weak.","Arms Feel Weak | My arms feel weak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407712","Feel Run Down","C173914","A question about whether an individual feels run down.","Feel Run Down | I feel run down",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407711","Ache All Over","C173915","A question about whether an individual aches all over.","Ache All Over | I ache all over",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407708","Feel Refreshed","C173918","A question about whether an individual feels refreshed.","Feel Refreshed | I feel refreshed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407707","Feel Energetic","C173919","A question about whether an individual feels energetic.","Feel Energetic | I feel energetic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407716","Make More Mistakes than Usual","C173920","A question about whether an individual makes more mistakes than usual.","Make More Mistakes than Usual | I make more mistakes than usual",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407715","Body Feels Heavy All Over","C173921","A question about whether an individual's body feels heavy all over.","Body Feels Heavy All Over | My body feels heavy all over",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407718","Am Forgetful","C173922","A question about whether an individual is forgetful.","Am Forgetful | Feel Forgetful | I am forgetful",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407717","Am Distressed","C173923","A question about whether an individual feels distressed.","Am Distressed | Feel Distressed | I am distressed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407654","Respiratory Syncytial Virus Positive","C173858","An indication that respiratory syncytial virus has been detected in a sample.","Respiratory Syncytial Virus Positive | RSV Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407653","KEAP1 Gene Mutation Negative","C173859","A genetic finding indicating that KEAP1 gene mutations have not been detected in a sample.","KEAP1 Gene Mutation Negative | INRF2 Gene Mutation Negative | KEAP1 Mutation Negative | KEAP1 Wildtype | KEAP1 wt | KLHL19 Gene Mutation Negative | Kelch-Like ECH-Associated Protein 1 Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407656","NFE2L2 Gene Mutation Negative","C173860","A genetic finding indicating that NFE2L2 gene mutations have not been detected in a sample.","NFE2L2 Gene Mutation Negative | NFE2L2 Mutation Negative | NFE2L2 Wildtype | NFE2L2 wt | NRF2 Gene Mutation Negative | Nuclear Factor, Erythroid 2 Like 2 Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407655","ROS1 Gene Mutation Negative","C173861","A genetic finding indicating that ROS1 gene mutations have not been detected in a sample.","ROS1 Gene Mutation Negative | MCF3 Gene Mutation Negative | ROS Gene Mutation Negative | ROS Mutation Negative | ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene Mutation Negative | ROS Wildtype | ROS wt | ROS1 Mutation Negative | ROS1 Wildtype | ROS1 wt | c-ros-1 Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407636","NTRK Family Gene Mutation Negative","C173862","A genetic finding indicating that NTRK family gene mutations have not been detected in a sample.","NTRK Family Gene Mutation Negative | NTRK Family Mutation Negative | NTRK Family Wildtype | NTRK Family wt | NTRK Gene Mutation Negative | NTRK Mutation Negative | NTRK Wildtype | NTRK wt | TRK Family Gene Mutation Negative | TRK Gene Mutation Negative | TRK Receptor Family Gene Mutation Negative | TRK Receptor Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407635","CDKN2A Gene Amplification","C173863","A molecular genetic abnormality indicating the presence of multiple copies of the CDKN2A gene.","CDKN2A Gene Amplification | CDK4I Gene Amplification | CDKN2A Amplification | CDKN2A Copy Number Gain | CDKN2A-p16 Gene Amplification | Cyclin-Dependent Kinase Inhibitor 2A Gene Amplification | p14ARF Gene Amplification | p16 Gene Amplification | p16-INK4A Gene Amplification | p16INK4a Gene Amplification | p19ARF Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407638","CCND2 3' Untranslated Region Deletion Mutation","C173864","The loss of one or more nucleotides encoding the 3' untranslated region of the CCND2 gene.","CCND2 3' Untranslated Region Deletion Mutation | CCND2 3' UTR Deletion | CCND2 3' UTR Deletion Mutation | CCND2 3'-UTR Deletion Mutation | CCND2 3'UTR Loss | Cyclin D2 3' Untranslated Region Deletion Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407637","CCND3 3' Untranslated Region Deletion Mutation","C173865","The loss of one or more nucleotides encoding the 3' untranslated region of the CCND3 gene.","CCND3 3' Untranslated Region Deletion Mutation | CCND3 3' UTR Deletion | CCND3 3' UTR Deletion Mutation | CCND3 3'-UTR Deletion Mutation | CCND3 3'UTR Loss | Cyclin D3 3' Untranslated Region Deletion Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407634","CCNK Gene Deletion","C173870","A molecular abnormality referring to the loss of at least one copy of the CCNK gene.","CCNK Gene Deletion | CPR4 Gene Deletion | CYCK Gene Deletion | Cyclin K Gene Deletion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407643","CCNE1 Gene Amplification Negative","C173871","An indication that amplification of the CCNE1 gene was not detected in a sample.","CCNE1 Gene Amplification Negative | CCNE Amplification Negative | CCNE1 Amplification Negative | Cyclin E1 Gene Amplification Negative | Lack of CCNE Amplification | Lack of CCNE Gene Amplification | Lack of CCNE1 Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407642","CCND1 3' Untranslated Region Deletion Mutation","C173872","The loss of one or more nucleotides encoding the 3' untranslated region of the CCND1 gene.","CCND1 3' Untranslated Region Deletion Mutation | BCL-1 3' Untranslated Region Deletion Mutation | BCL1 3' Untranslated Region Deletion Mutation | CCND1 3' UTR Deletion | CCND1 3' UTR Deletion Mutation | CCND1 3'-UTR Deletion Mutation | CCND1 3'UTR Loss | Cyclin D1 3' Untranslated Region Deletion Mutation | PRAD1 3' Untranslated Region Deletion Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407639","FBXO3 Gene Deletion","C173876","A molecular abnormality referring to the loss of at least one copy of the FBXO3 gene.","FBXO3 Gene Deletion | F-Box Protein 3 Gene Deletion | FBA Gene Deletion | FBX03 Loss | FBX3 Gene Deletion | FBXO3 Copy Number Loss | FBXO3 Loss",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407640","FBXO31 Gene Deletion","C173878","A molecular abnormality referring to the loss of at least one copy of the FBXO31 gene.","FBXO31 Gene Deletion | F-Box Protein 31 Gene Deletion | FBX14 Gene Deletion | FBXO14 Gene Deletion | FBXO31 Copy Number Loss | FBXO31 Loss | Fbx31 Gene Deletion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407679","CCND1 Gene Translocation","C173880","A cytogenetic abnormality that refers to a translocation involving the CCND1 gene.","CCND1 Gene Translocation | BCL-1 Gene Translocation | BCL1 Gene Translocation | CCND1 Translocation | Cyclin D1 Gene Translocation | PRAD1 Gene Translocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407681","NF2 Gene Deletion","C173882","A molecular abnormality referring to the loss of at least one copy of the NF2 gene.","NF2 Gene Deletion | ACN Gene Deletion | BANF Gene Deletion | Merlin Gene Deletion | NF-2 Gene Deletion | NF2 Deletion | Neurofibromin 2 Gene Deletion | SCH Gene Deletion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407676","PSA Doubling Time Greater than 6 Months","C173883","An indication that it took more than six months for a subject's blood concentration of prostate specific antigen to double.","PSA Doubling Time Greater than 6 Months | PSA Doubling Time Greater than Six Months | PSA-DT Greater than 6 Months | PSADT Greater than 6 Months",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407675","Activating CBL Gene Mutation","C173884","A change in the nucleotide sequence of the CBL gene that that results in constitutive activation of both E3 ubiquitin-protein ligase CBL and its downstream signaling pathways.","Activating CBL Gene Mutation | Activating CBL Mutation | Activating Cas-Br-M Murine Ecotropic Retroviral Transforming Sequence Gene Mutation | Activating Casitas B-Lineage Lymphoma Proto-Oncogene Mutation | Activating Cbl Proto-Oncogene Gene Mutation | Activating RNF55 Gene Mutation | Activating c-CBL Gene Mutation | CBL Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407688","Activating KIT Gene Mutation","C173887","A change in the nucleotide sequence of the KIT gene that that results in constitutive activation of both mast/stem cell growth factor receptor Kit and its downstream signaling pathways.","Activating KIT Gene Mutation | Activating C-KIT Mutation | Activating CD117 Gene Mutation | Activating KIT Mutation | Activating KIT Proto-Oncogene Tyrosine Protein Kinase Gene Mutation | Activating c-KIT Gene Mutation | Activating v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Gene Mutation | KIT Activating Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1550390","disposition of patient discharged to","C101863","Terminology associated with the discharge disposition codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Discharge Disposition Terminology | DISCHDX | Discharge Disposition | SDTM-DISCHDX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407864","Paid Hours","C173947","Work undertaken for which wages are due.","Paid Hours | Paid | Paid Hours Worked",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407859","Unpaid Hours","C173948","Work, or a period of leave, for which no wages are due.","Unpaid Hours | Unpaid | Unpaid Hours Taken",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011066","Death Certificate","C163970","A certified document issued by either a medical practitioner or a governmental agency that details the date, location and cause of a death of an individual.","Death Certificate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038916","Surgical Clamp","C173957","A surgical device used for compressing or holding an anatomic structure or other object.","Surgical Clamp | Surgical Forceps",,,,,,,,,,,,,,,"45767996","Surgical clamp",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1407871","Employer-sponsored Disability Insurance","C173956","Insurance that is available through an employer that provides income in the event that an employee is unable to perform their work due to a disability.","Employer-sponsored Disability Insurance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545135","Biospecimen Findings Supplemental Qualifiers Dataset","C147189","A dataset containing supplemental information, specifically non-standard variables, to parent records in the biospecimen findings domain.","Biospecimen Findings Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545842","GUSB Gene","C148004","This gene is involved in the degradation of glycosaminoglycans.","GUSB Gene | GUSB | Glucuronidase Beta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1299238","Exocervical Carcinoma","C7453","A carcinoma that arises from the squamous epithelium of the exocervix.","Exocervical Carcinoma | Carcinoma of Exocervix | Carcinoma of the Exocervix | Exocervical Cancer | Exocervix Carcinoma",,,,,,,,,,,,,,,"4157450","Carcinoma of exocervix",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017973","Glycosaminoglycan","C28153","Linear polysaccharides composed of disaccharide repeating units of glycosamine-glycans, two monosaccharide units (hexosamine and the repeating disaccharide of either hexuronate or galactose) located on the surface of cells or in the extracellular matrix contributing to adhesion, elasticity, and viscosity of extracellular substances.","Glycosaminoglycan | GAG | Mucopolysaccharide | glycosaminoglycan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1442485","IDUA Gene","C115252","This gene plays a role in glycosaminoglycan metabolism.","IDUA Gene | Alpha-L-Iduronidase Gene | IDUA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407901","Missed Medicine Dose Question","C173985","A question about an individual missing a dose of medicine.","Missed Medicine Dose Question | Domains of Subjective Extent of Nonadherence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407903","Missed Taking Medicine","C173987","A question about whether an individual missed taking their medicine.","Missed Taking Medicine | I missed my medicine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407902","Skipped Dose of Medicine","C173988","A question about whether an individual skipped a dose of their medicine.","Skipped Dose of Medicine | I skipped a dose of my medicine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407898","Did Not Take Dose of Medicine","C173989","A question about whether an individual did not take a dose of their medicine.","Did Not Take Dose of Medicine | I did not take a dose of my medicine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407897","Missed Medicine Dose Because Out of Routine","C173990","A question about whether an individual missed their dose of medicine because they were out of their routine.","Missed Medicine Dose Because Out of Routine | I missed my dose because I was out of my routine | Out of Routine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1408432","Missed Medicine Dose Because Forgot","C173991","A question about whether an individual missed their dose of medicine because they forgot.","Missed Medicine Dose Because Forgot | Forgot | I missed my dose because I forgot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407899","Missed Medicine Dose Because Medication Caused Side Effects","C173992","A question about whether an individual missed their dose of medicine because the medication caused side effects.","Missed Medicine Dose Because Medication Caused Side Effects | I missed my dose because the medication caused side effects | Medication Caused Side Effects",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407878","Missed Medicine Dose Because Food Requirements Could Not be Met","C173993","A question about whether an individual missed their dose of medicine because they could not meet the food requirements.","Missed Medicine Dose Because Food Requirements Could Not be Met | Food Requirements Could Not be Met | I missed my dose because I could not meet the food requirements",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407877","Missed Medicine Dose Because Did Not Have Medicines with Me","C173994","A question about whether an individual missed their dose of medicine because they did not have their medicines with them.","Missed Medicine Dose Because Did Not Have Medicines with Me | Did Not Have Medicines with Me | I missed my dose because I did not have my medicines with me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407879","Missed Medicine Dose Because Could Not Afford Medication","C173996","A question about whether an individual missed their dose of medicine because they could not afford the medication.","Missed Medicine Dose Because Could Not Afford Medication | Could Not Afford Medication | I missed my dose because I could not afford the medication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407874","Missed Medicine Dose Because Medication Not Working","C173997","A question about whether an individual missed their dose of medicine because the medication was not working.","Missed Medicine Dose Because Medication Not Working | I missed my dose because the medication was not working | Medication Not Working",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407873","Missed Medicine Dose Because Did Not Want Others to see Medications","C173998","A question about whether an individual missed their dose of medicine because they did not want others to see their medications.","Missed Medicine Dose Because Did Not Want Others to see Medications | Did Not Want Others to see Medications | I missed my dose because I did not want others to see my medications",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407875","Missed Medicine Dose Because Medication Affected Sex Life","C174000","A question about whether an individual missed their dose of medicine because the medication affected their sex life.","Missed Medicine Dose Because Medication Affected Sex Life | I missed my dose because the medication affected my sex life | Medication Affected Sex Life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407886","Missed Medicine Dose Because Too Late with Dose","C174001","A question about whether an individual missed their dose of medicine because they were too late with their dose.","Missed Medicine Dose Because Too Late with Dose | I missed my dose because I was too late with my dose | Too Late with Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407885","Missed Medicine Dose Because Was Asleep","C174002","A question about whether an individual missed their dose of medicine because they were asleep.","Missed Medicine Dose Because Was Asleep | I missed my dose because I was asleep | Was Asleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407888","Missed Medicine Dose Because No One to Help","C174003","A question about whether an individual missed their dose of medicine because there was no one to help them.","Missed Medicine Dose Because No One to Help | I missed my dose because there was no one to help me | No One to Help",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407887","Missed Medicine Dose Because Treatment was Hard on Family","C174004","A question about whether an individual missed their dose of medicine because treatment was hard on their family.","Missed Medicine Dose Because Treatment was Hard on Family | I missed my dose because treatment was hard on my family | Treatment was Hard on Family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407882","Missed Medicine Dose Because Had Other Medications to Take","C174005","A question about whether an individual missed their dose of medicine because they had other medications to take.","Missed Medicine Dose Because Had Other Medications to Take | Had Other Medications to Take | I missed my dose because I had other medications to take",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407881","Missed Medicine Dose Because Medication Ran Out","C174006","A question about whether an individual missed their dose of medicine because they ran out of medication.","Missed Medicine Dose Because Medication Ran Out | I missed my dose because I ran out of medication | Medication Ran Out",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407884","Missed Medicine Dose Because Afraid Medication Would Interact with Other Medications","C174007","A question about whether an individual missed their dose of medicine because they were afraid the mediation would interact with other medications they take.","Missed Medicine Dose Because Afraid Medication Would Interact with Other Medications | Afraid Medication Would Interact with Other Medications | I missed my dose because I was afraid the medication would interact with other medication I take",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407883","Missed Medicine Dose Because Feeling Too Sick","C174008","A question about whether an individual missed their dose of medicine because they were feeling too sick to take it.","Missed Medicine Dose Because Feeling Too Sick | Feeling Too Sick | I missed my dose because I was feeling too sick to take it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407924","Missed Medicine Dose Because Could Not Get Answers to Questions about Medication","C174009","A question about whether an individual missed their dose of medicine because they could not get answers to their questions about the medication.","Missed Medicine Dose Because Could Not Get Answers to Questions about Medication | Could Not Get Answers to Questions about Medication | I missed my dose because I could not get answers to my questions about the medication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407920","Ischemia Time","C174013","The time interval from blood supply separation or reduction to further processing, preservation, or blood supply reconnection for a tissue, organ, or body part.","Ischemia Time | Ischemic Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985793","Mandatory Indicator","C93590","Specifies whether something is required or obligatory.","Mandatory Indicator | mandatoryIndicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971470","Cohort Description","C166209","The description of the characteristics that define a cohort.","Cohort Description | cohort description | cohort_description",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2347451","Participation Status","C71470","The status of a person in relationship to his participation in a given activity.","Participation Status | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639117","CDISC SDTM Relationship to Subject Terminology","C100130","Terminology associated with the relationship to subject codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Relationship to Subject Terminology | RELSUB | Relationship to Subject | SDTM-RELSUB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513767","Accidental Association","C130052","A person whose association to an individual is unintentional.","Accidental Association | ACCIDENTAL ASSOCIATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520995","Suspected Source Case","C132452","An individual who is believed to have likely transmitted a disease to another individual.","Suspected Source Case | SUSPECTED SOURCE CASE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337564","Biological Son","C150888","A male progeny with genetic makeup inherited from the parent.","Biological Son | Natural Son | SON, BIOLOGICAL | Son",,,,,,,,,,,,,,,"4014096","Natural son",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3827310","Full Sister","C111202","A female who shares with her sibling the genetic makeup inherited from both of the biological parents.","Full Sister | SISTER, FULL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272937","Half-sister with Father as Common Parent","C96657","A female sibling who shares the genetic makeup inherited from only the biological father.","Half-sister with Father as Common Parent | Paternal Half Sister | SISTER, BIOLOGICAL PATERNAL HALF",,,,,,,,,,,,,,,"36717756","Paternal half sister",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3272938","Half-sister with Mother as Common Parent","C96658","A female sibling who shares the genetic makeup inherited from only the biological mother.","Half-sister with Mother as Common Parent | Maternal Half Sister | SISTER, BIOLOGICAL MATERNAL HALF",,,,,,,,,,,,,,,"36714503","Maternal half sister",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0337515","Biological Sister","C96586","A female who shares with her sibling the genetic makeup inherited from one or both of their shared biological parents.","Biological Sister | Natural Sister | SISTER, BIOLOGICAL | Sister",,,,,,,,,,,,,,,"4251326","Natural sister",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509328","Schoolmate","C127784","Any individual with whom the subject attends or attended the same school.","Schoolmate | SCHOOLMATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639750","Third Degree Relative","C100808","Any individual related biologically or legally to another individual and considered two degrees removed from the immediate family as in the case of cousins.","Third Degree Relative | RELATIVE, THIRD DEGREE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509517","Non-household Relative","C127783","Any individual who is related biologically or legally to another individual, but who does not reside in the same residence.","Non-household Relative | RELATIVE, NON-HOUSEHOLD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509453","Household Relative","C127782","Any individual who is related biologically or legally to another individual, and who resides in the same residence.","Household Relative | RELATIVE, HOUSEHOLD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970097","Second Degree Biological Relative","C161421","Any individual related biologically to another individual and considered one degree removed from the immediate family as in the case of grandparents, aunts and uncles.","Second Degree Biological Relative | RELATIVE, BIOLOGICAL, SECOND DEGREE",,,,,,,,,,,,,,,"44783070","Second degree blood relative",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266851","First Degree Biological Relative","C161420","Any individual related biologically to another individual and considered immediate family as in the case of a parent, sibling or child.","First Degree Biological Relative | RELATIVE, BIOLOGICAL, FIRST DEGREE",,,,,,,,,,,,,,,"4053607","First degree blood relative",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL519686","Biological Relative, Paternal","C132451","Any individual related biologically to an individual's father.","Biological Relative, Paternal | RELATIVE, BIOLOGICAL PATERNAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919624","Pregnancy Partner","C100811","An individual who provides support to a pregnant individual.","Pregnancy Partner | PREGNANCY PARTNER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337488","Stepmother","C132450","A female who is married to a spouse with children whom are not biologically related to her.","Stepmother | MOTHER, STEP | Step Mother",,,,,,,,,,,,,,,"4276365","Stepmother",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL979223","Biological Mother of Subject's Child","C166093","The biological mother of the offspring of the male subject.","Biological Mother of Subject's Child | MOTHER, BIOLOGICAL OF SUBJECT'S CHILD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828639","Paternal Biological Grandparent","C111286","A relative who is the biological parent of the biological father.","Paternal Biological Grandparent | GRANDPARENT, BIOLOGICAL PATERNAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829175","Maternal Biological Grandparent","C111248","A relative who is the biological parent of the biological mother.","Maternal Biological Grandparent | GRANDPARENT, BIOLOGICAL MATERNAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337472","Biological Grandparent","C100806","A biological parent of the biological father or biological mother.","Biological Grandparent | GRANDPARENT, BIOLOGICAL | Natural Grandparent",,,,,,,,,,,,,,,"4301632","Natural grandparent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3272880","Biological Paternal Grandmother","C96584","A female relative who is the biological mother of the biological father.","Biological Paternal Grandmother | GRANDMOTHER, BIOLOGICAL PATERNAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272875","Biological Maternal Grandmother","C96578","A female relative who is the biological mother of the biological mother.","Biological Maternal Grandmother | GRANDMOTHER, BIOLOGICAL MATERNAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337476","Biological Grandmother","C96574","A female relative who is the biological mother of either the biological mother or the biological father.","Biological Grandmother | GRANDMOTHER, BIOLOGICAL | Natural Grandmother",,,,,,,,,,,,,,,"4077002","Natural grandmother",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3272879","Biological Paternal Grandfather","C96583","A male relative who is the biological father of the biological father.","Biological Paternal Grandfather | GRANDFATHER, BIOLOGICAL PATERNAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272874","Biological Maternal Grandfather","C96577","A male relative who is the biological father of the biological mother.","Biological Maternal Grandfather | GRANDFATHER, BIOLOGICAL MATERNAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337477","Biological Grandfather","C96573","A male relative who is the biological father of either the biological mother or the biological father.","Biological Grandfather | GRANDFATHER, BIOLOGICAL | Natural Grandfather",,,,,,,,,,,,,,,"4265919","Natural grandfather",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3639748","Biological Grandchild","C100805","A biological child of an individual's biological child.","Biological Grandchild | GRANDCHILD, BIOLOGICAL | Natural Grandchild",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337496","Step Father","C154851","A male that is related to a child or children through marriage to their biological parent.","Step Father | FATHER, STEP | Stepfather",,,,,,,,,,,,,,,"4147842","Stepfather",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL979222","Biological Father of Subject's Child","C166092","The biological father of the offspring of the female subject.","Biological Father of Subject's Child | FATHER, BIOLOGICAL OF SUBJECT'S CHILD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0260788","Kidney Donor","C130054","Someone from whom one or more kidneys are removed for transplantation or other purpose.","Kidney Donor | DONOR, KIDNEY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005795","Blood Donor","C132448","Someone from whom blood is removed for transplantation or other purpose.","Blood Donor | DONOR, BLOOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011011","Biological Daughter","C150887","A female progeny with genetic makeup inherited from the parent.","Biological Daughter | DAUGHTER, BIOLOGICAL | Daughter",,,,,,,,,,,,,,,"4278823","Daughter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3830065","Full Brother","C111201","A male who shares with his sibling the genetic makeup inherited from both of the biological parents.","Full Brother | BROTHER, FULL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272935","Half-brother with Father as Common Parent","C96655","A male sibling who shares the genetic makeup inherited from only the biological father.","Half-brother with Father as Common Parent | BROTHER, BIOLOGICAL PATERNAL HALF | Paternal Half Brother",,,,,,,,,,,,,,,"36714501","Paternal half brother",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3272936","Half-brother with Mother as Common Parent","C96656","A male sibling who shares the genetic makeup inherited from only the biological mother.","Half-brother with Mother as Common Parent | BROTHER, BIOLOGICAL MATERNAL HALF | Maternal Half Brother",,,,,,,,,,,,,,,"36714504","Maternal half brother",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0337528","Biological Brother","C96570","A male who shares with his sibling the genetic makeup inherited from one or both of their shared biological parents.","Biological Brother | BROTHER, BIOLOGICAL | Brother | Natural Brother",,,,,,,,,,,,,,,"4263682","Natural brother",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513393","Biologically Unrelated","C130053","A person who is biologically unrelated to another individual.","Biologically Unrelated | BIOLOGICALLY UNRELATED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545130","Related Subjects Dataset","C147183","A dataset used to represent relationships between study subjects. (CDISC)","Related Subjects Dataset | RELSUB | Related Subjects",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897429","Subject, Device, or Study Relationship","C117709","A qualifier to describe the relationships of the associated person(s) to the related subject or pool of subjects, to the related device, or to the study.","Subject, Device, or Study Relationship | SREL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978423","Hand Assisted Laparoscopic Radical Nephrectomy","C165179","A radical nephrectomy procedure performed using hand assisted laparoscopy.","Hand Assisted Laparoscopic Radical Nephrectomy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978442","Endorectal Tumor Resection","C165178","The use of an endoscope to guide the surgical removal of tumor and any surrounding tissue located inside the rectum.","Endorectal Tumor Resection | Endo Rectal Tumor Resection | Endorectal Endoscopic Tumor Resection | Endorectal Surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406180","Buccal Mucosal Resection","C172322","Surgical removal of the mucosal lining of the inside of the cheek through the mouth.","Buccal Mucosal Resection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523042","Liquid Biopsy","C135727","Sampling and analysis of non-solid biological material (primarily blood), usually to determine if cancer cells or circulating-free cancer DNA is present.","Liquid Biopsy | Plasma Biopsy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978425","Laparoscopic Radical Prostatectomy","C165184","A radical prostatectomy procedure performed with the aid of a laparoscope.","Laparoscopic Radical Prostatectomy | Laparoscopic Radical Prostatectomy without Robotics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978424","Laparoscopic Radical Prostatectomy with Robotics","C165183","A radical prostatectomy procedure performed with the aid of a robotic laparoscope.","Laparoscopic Radical Prostatectomy with Robotics | RARP | Robot-assisted Radical Prostatectomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2584683","Laparoscopic Radical Nephrectomy","C165182","A radical nephrectomy procedure performed with the aid of a laparoscope.","Laparoscopic Radical Nephrectomy | ",,,,,,,,,,,,,,,"4258410","Laparoscopic radical nephrectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1144661","Laparoscopic Partial Nephrectomy","C165181","A partial nephrectomy procedure performed with the aid of a laparoscope.","Laparoscopic Partial Nephrectomy | ",,,,,,,,,,,,,,,"4206400","Laparoscopic partial nephrectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0198536","Laparoscopic Biopsy","C165180","A biospy procedure performed with the aid of a laparoscope.","Laparoscopic Biopsy | ",,,,,,,,,,,,,,,"4269232","Laparoscopy with biopsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0407611","Total Maxillectomy","C172324","Surgical removal of the entire maxilla, hard palate and orbital floor on one side of the face.","Total Maxillectomy | Radical Maxillectomy",,,,,,,,,,,,,,,"4072543","Total maxillectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL978429","Open Radical Prostatectomy","C165188","A radical prostatectomy procedure performed using a long incision for visualization and the insertion of instruments.","Open Radical Prostatectomy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978428","Open Radical Nephrectomy","C165187","A radical nephrectomy procedure performed using a long incision for visualization and the insertion of instruments.","Open Radical Nephrectomy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978427","Open Partial Nephrectomy","C165186","A partial nephrectomy procedure performed using a long incision for visualization and the insertion of instruments.","Open Partial Nephrectomy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0198373","Thoracoscopic Biopsy","C163997","The use of a thoracoscope to obtain a biopsy from the pleural cavity and/or thoracic cavity.","Thoracoscopic Biopsy | ",,,,,,,,,,,,,,,"4094651","Thoracoscopy with biopsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0194809","Subtotal Prostatectomy","C172325","Surgical removal of part of the prostate.","Subtotal Prostatectomy | Simple Prostatectomy",,,,,,,,,,,,,,,"4147673","Subtotal prostatectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL936686","Tumor Resection","C164212","A surgical procedure in which cancerous tissue is surgically removed.","Tumor Resection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407960","Unobtainable","C174058","Not able to be acquired.","Unobtainable | ",,,,,,,,,,,,,,,"618772","Unobtainable",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL502609","MSB0011359C","C124229","A bifunctional fusion protein composed of an anti-programmed death ligand 1 (PD-L1) human monoclonal antibody, bound to the soluble extracellular domain of human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), with potential antineoplastic and immune checkpoint modulating activities. Upon administration, bintrafusp alfa binds to and neutralizes activated TGFbeta and binds to PD-L1. This prevents TGFbeta- and PD-L1-mediated signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This inhibits tumor cell proliferation in susceptible tumor cells. TGFbeta and PD-L1 are both upregulated in certain types of cancers; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.","Bintrafusp Alfa | Anti-PD-L1/TGFbetaRII Fusion Protein M7824 | Anti-PDL1/TGFb Trap MSB0011359C | BINTRAFUSP ALFA | M7824 | MSB0011359C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513447","CEA-MUC-1-TRICOM Vaccine CV301","C131129","A cancer prime/boost vaccine-based immunotherapeutic consisting of a prime, which is comprised of a proprietary version of the recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN) and a recombinant fowlpox viral vector, used for the boosts, encoding both the two tumor-associated antigens (TAA), carcinoembryonic antigen (CEA) and mucin-1 (MUC-1), and TRICOM, which is comprised of three immune-enhancing co-stimulatory molecules, B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. The administration of the vaccinia priming dose is followed by multiple boosting doses of the fowlpox vector. CEA-MUC-1-TRICOM Vaccine CV301 may enhance presentation of CEA and MUC-1 to antigen-presenting cells (APCs) and may activate a cytotoxic T-lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells. In addition, CV301 upregulates the expression of PD-L1 due to CTL-mediated tumor attack; additionally, when combined with a PD-1 immune checkpoint inhibitor, the antitumor effect may be increased. CEA and MUC-1 are overexpressed in certain cancers.","CEA-MUC-1-TRICOM Vaccine CV301 | CV-301 | CV301 | CV301-V/F | CVAC-301 | MVA-BN/Fowlpox-CEA-MUC-1-TRICOM Vaccine CV301 | PANVAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520248","Rilimogene Galvacirepvec/Rilimogene Glafolivec","C132990","A vaccine formulation consisting of rilimogene galvacirepvec (V-PSA-TRICOM; PROSTVAC-V), a recombinant vaccinia virus, and rilimogene glafolivec (F-PSA-TRICOM; PROSTVAC-F), a recombinant fowlpox virus, with potential immunostimulating and antineoplastic activities. Both viruses encode modified forms of human prostate specific antigen (PSA) and the three co-stimulatory molecule transgenes (TRIad of COstimulatory Molecules; TRICOM), B7.1 (CD80), intercellular adhesion molecule-1 (ICAM-1), and lymphocyte function-associated antigen-3 (LFA-3). Using a prime-boost vaccine regimen, with a primary vaccination of rilimogene galvacirepvec followed by multiple booster vaccinations of rilimogene glafolivec, the PSA-TRICOM vaccines infect antigen-presenting cells (APCs), such as dendritic cells (DCs). Upon processing and expression of the PSA and TRICOM proteins on their surfaces, the DCs are able to initiate cytotoxic T-lymphocyte (CTL) responses against PSA-expressing cancer cells. The combination of PSA and TRICOM greatly enhances T-cell activation and T-cell-mediated tumor cell killing.","Rilimogene Galvacirepvec/Rilimogene Glafolivec | PROSTVAC | PROSTVAC-V-PROSTVAC-F | PROSTVAC-V/F | PROSTVAC-VF-TRICOM | PROSTVAC-VF/TRICOM | Recombinant Vaccinia-B7.1 | Recombinant Vaccinia-B7.1 Vaccine | Recombinant Vaccinia-Fowlpox-Prostate-specific Antigen-TRICOM Vaccine | Rilimogene Galvacirepvec-Rilimogene Glafolivec",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711350","Interquartile Range","C53245","The difference between the 3d and 1st quartiles is called the interquartile range and it is used as a measure of variability (dispersion).","Interquartile Range | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412909","Controlled Attenuation Parameter","C174123","A physical parameter applied to vibration-controlled transient elastography to measure attenuation of shear wave velocity as a means for evaluating liver fibrosis or liver steatosis.","Controlled Attenuation Parameter | CAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407772","Genomic Medicine","C174131","A medical discipline that uses genomic information about an individual as part of their clinical care (e.g. for diagnostic or therapeutic decision-making) and for the health outcomes and policy implications of that clinical use. (NIH/NHGRI)","Genomic Medicine | Genomics-Informed Personalized Medicine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407775","Advantage","C174132","A state or circumstance that is favorable to success or a desired outcome.","Advantage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407774","Feelings about Genomic Testing Results","C174133","An instrument designed to measure the psychosocial impact of returning genomic findings to patients in research and clinical practice.","Feelings about Genomic Testing Results | FACToR | Feelings About genomiC Testing Results (FACToR)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1408430","Genetic Counseling Satisfaction Scale","C174134","A 6-item, 5-point Likert scale used to assess patient satisfaction with genetic counseling.","Genetic Counseling Satisfaction Scale | GCSS | Genetic Counseling Satisfaction Scale (GCSS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407965","Genomics Outcome Scale","C174135","A 6-item patient-reported outcome used to evaluate patient empowerment after they have received genetic counseling and testing services.","Genomics Outcome Scale | GOS | Genomics Outcome Scale (GOS) | Patient Empowerment After Genetic Services and Counseling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407771","KnowGene Scale","C174136","A 16-item scale administered to patients after genetic testing and/or genetic counseling to measure their understanding of the health implications of their genetic testing results.","KnowGene Scale | KnowGene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407770","Organizational Readiness for Implementing Change","C174137","A 12-item instrument designed to assess an organization's readiness to implement a change to their current processes.","Organizational Readiness for Implementing Change | ORIC | Organizational Readiness for Implementing Change (ORIC)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407780","University of North Carolina Genomic Knowledge Scale","C174138","A survey that healthcare providers can use to assess the relative advantage of a genomic intervention over their current practice.","University of North Carolina Genomic Knowledge Scale | Genomic Knowledge Scale | UNC Genomic Knowledge Scale | UNC-GKS | University of North Carolina Genomic Knowledge Scale (UNC-GKS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407812","Godin Leisure-Time Exercise Questionnaire","C174146","A short self-report questionnaire used to identify the leisure-time physical activities of adults.","Godin Leisure-Time Exercise Questionnaire | GSLTPAQ | Godin-Shephard Leisure-Time Physical Activity Questionnaire | Godin-Shephard Leisure-Time Physical Activity Questionnaire (GSLTPAQ) | Leisure-Time Exercise Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407811","Leisure Time Activity to Produce Sweat","C174147","A question about how often, in their leisure time, an individual engages in regular activity long enough to produce sweat.","Leisure Time Activity to Produce Sweat Question | In your leisure time, how often do you engage in any regular activity long enough to work up a sweat | Leisure Time Activity to Produce Sweat | Leisure Time Activity to Produce Sweat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407777","Strenuous","C174145","Requiring high effort, energy, or strength.","Strenuous | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407814","Liquid Nitrogen Vapor","C174159","The gaseous state of liquid nitrogen with a temperature of -167 degrees Celsius.","Liquid Nitrogen Vapor | LN2 Vapor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407799","Perceived Compatibility with Current Clinical Practice","C174164","A survey for healthcare providers to assess the compatibility and value of a genomic intervention at their clinical practice.","Perceived Compatibility with Current Clinical Practice | Perceived Compatibility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334391","Complex Epithelial Neoplasm","C4198","No Value Exists","Complex Epithelial Neoplasm | ",,,,,,,,,,,,,,,"4019909","Complex epithelial neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0229664","Peripheral Blood","C173496","Blood drawn from a limb.","Peripheral Blood | Peripheral Blood Specimen | Peripheral blood",,,,,,,,,,,,,,,"4001219","Peripheral blood",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1407781","CD274 Gene Amplification","C174141","A molecular genetic abnormality indicating the presence of multiple copies of the CD274 gene.","CD274 Gene Amplification | B7-H Gene Amplification | B7H1 Gene Amplification | CD274 Amplification | CD274 Antigen Gene Amplification | CD274 Copy Number Gain | CD274 Molecule Gene Amplification | PD-L1 Copy Number Gain | PD-L1 Gene Amplification | PDCD1L1 Gene Amplification | PDCD1LG1 Gene Amplification | PDL1 Copy Number Gain | PDL1 Gene Amplification | Programmed Cell Death 1 Ligand 1 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407776","t(9;22) Negative","C174142","A cytogenetic finding indicating that the translocation t(9;22) has not been detected in a sample.","t(9;22) Negative | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407813","Lymphoblasts 1 Percent or More of Bone Marrow Nucleated Cells","C174149","A semi-quantitative microscopic finding indicating that 1 percent or more of the nucleated cells in a bone marrow sample are immature mononuclear cells of lymphoid origin.","Lymphoblasts 1 Percent or More of Bone Marrow Nucleated Cells | Lymphoblasts Greater than or Equal to 1 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508630","MSH3 Gene Mutation","C174150","A change in the nucleotide sequence of the MSH3 gene.","MSH3 Gene Mutation | DUC1 Gene Mutation | DUG Gene Mutation | DUP Gene Mutation | MRP1 Gene Mutation | MSH3 Mutation | MutS Homolog 3 Gene Mutation | MutS, E. coli, Homolog of, 3 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407810","TP53 NP_000537.3:p.S127Y","C174152","A change in the amino acid residue at position 127 in the cellular tumor antigen p53 protein where serine has been replaced by tyrosine.","TP53 NP_000537.3:p.S127Y | Antigen NY-CO-13 S127Y | Antigen NY-CO-13 Ser127Tyr | Cellular Tumor Antigen p53 S127Y | Cellular Tumor Antigen p53 Ser127Tyr | NP_000537.3:p.S127Y | NP_000537.3:p.Ser127Tyr | TP53 NP_000537.3:p.Ser127Tyr | TP53 S127Y | TP53 S127Y Mutation | TP53 Ser127Tyr | TP53 p.S127Y | TP53 p.Ser127Tyr | Transformation-Related Protein 53 S127Y | Transformation-Related Protein 53 Ser127Tyr | Tumor Protein p53 S127Y | Tumor Protein p53 Ser127Tyr | Tumor Suppressor p53 S127Y | Tumor Suppressor p53 Ser127Tyr",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407819","CTNNB1 NP_001895.1:p.S45P","C174154","A change in the amino acid residue at position 45 in the catenin beta-1 protein where serine has been replaced by proline.","CTNNB1 NP_001895.1:p.S45P | Beta Catenin S45P | Beta Catenin Ser45Pro | Beta-Catenin S45P | Beta-Catenin Ser45Pro | CTNNB S45P | CTNNB Ser45Pro | CTNNB1 NP_001895.1:p.Ser45Pro | CTNNB1 S45P | CTNNB1 S45P Mutation | CTNNB1 Ser45Pro | CTNNB1 p.S45P | CTNNB1 p.Ser45Pro | Cadherin-Associated Protein, Beta S45P | Cadherin-Associated Protein, Beta Ser45Pro | Catenin Beta-1 S45P | Catenin Beta-1 Ser45Pro | Catenin, Beta-1 S45P | Catenin, Beta-1 Ser45Pro | NP_001895.1:p.S45P | NP_001895.1:p.Ser45Pro",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407821","TP53 NP_000537.3:p.R249M","C174156","A change in the amino acid residue at position 249 in the cellular tumor antigen p53 protein where arginine has been replaced by methionine.","TP53 NP_000537.3:p.R249M | Antigen NY-CO-13 Arg249Met | Antigen NY-CO-13 R249M | Cellular Tumor Antigen p53 Arg249Met | Cellular Tumor Antigen p53 R249M | NP_000537.3:p.Arg249Met | NP_000537.3:p.R249M | TP53 Arg249Met | TP53 NP_000537.3:p.Arg249Met | TP53 R249M | TP53 R249M Mutation | TP53 p.Arg249Met | TP53 p.R249M | Transformation-Related Protein 53 Arg249Met | Transformation-Related Protein 53 R249M | Tumor Protein p53 Arg249Met | Tumor Protein p53 R249M | Tumor Suppressor p53 Arg249Met | Tumor Suppressor p53 R249M",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407820","TP53 NP_000537.3:p.K132E","C174157","A change in the amino acid residue at position 132 in the cellular tumor antigen p53 protein where lysine has been replaced by glutamic acid.","TP53 NP_000537.3:p.K132E | Antigen NY-CO-13 K132E | Antigen NY-CO-13 Lys132Glu | Cellular Tumor Antigen p53 K132E | Cellular Tumor Antigen p53 Lys132Glu | NP_000537.3:p.K132E | NP_000537.3:p.Lys132Glu | TP53 K132E | TP53 K132E Mutation | TP53 Lys132Glu | TP53 NP_000537.3:p.Lys132Glu | TP53 p.K132E | TP53 p.Lys132Glu | Transformation-Related Protein 53 K132E | Transformation-Related Protein 53 Lys132Glu | Tumor Protein p53 K132E | Tumor Protein p53 Lys132Glu | Tumor Suppressor p53 K132E | Tumor Suppressor p53 Lys132Glu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407816","CTNNB1 NP_001895.1:p.S45F","C174161","A change in the amino acid residue at position 45 in the catenin beta-1 protein where serine has been replaced by phenylalanine.","CTNNB1 NP_001895.1:p.S45F | Beta Catenin S45F | Beta Catenin Ser45Phe | Beta-Catenin S45F | Beta-Catenin Ser45Phe | CTNNB S45F | CTNNB Ser45Phe | CTNNB1 NP_001895.1:p.Ser45Phe | CTNNB1 S45F | CTNNB1 S45F Mutation | CTNNB1 Ser45Phe | CTNNB1 p.S45F | CTNNB1 p.Ser45Phe | Cadherin-Associated Protein, Beta S45F | Cadherin-Associated Protein, Beta Ser45Phe | Catenin Beta-1 S45F | Catenin Beta-1 Ser45Phe | Catenin, Beta-1 S45F | Catenin, Beta-1 Ser45Phe | NP_001895.1:p.S45F | NP_001895.1:p.Ser45Phe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407796","CTNNB1 NP_001895.1:p.S37F","C174163","A change in the amino acid residue at position 37 in the catenin beta-1 protein where serine has been replaced by phenylalanine.","CTNNB1 NP_001895.1:p.S37F | Beta Catenin S37F | Beta Catenin Ser37Phe | Beta-Catenin S37F | Beta-Catenin Ser37Phe | CTNNB S37F | CTNNB Ser37Phe | CTNNB1 NP_001895.1:p.Ser37Phe | CTNNB1 S37F | CTNNB1 S37F Mutation | CTNNB1 Ser37Phe | CTNNB1 p.S37F | CTNNB1 p.Ser37Phe | Cadherin-Associated Protein, Beta S37F | Cadherin-Associated Protein, Beta Ser37Phe | Catenin Beta-1 S37F | Catenin Beta-1 Ser37Phe | Catenin, Beta-1 S37F | Catenin, Beta-1 Ser37Phe | NP_001895.1:p.S37F | NP_001895.1:p.Ser37Phe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407798","Biallelic MUTYH Gene Mutation","C174165","The presence of nucleotide sequence changes in both alleles of the MUTYH gene.","Biallelic MUTYH Gene Mutation | Biallelic MUTYH Mutation | Biallelic MYH Gene Mutation | Biallelic MutY (E. Coli) Homolog Gene Mutation | Biallelic MutY DNA Glycosylase Gene Mutation | Biallelic MutY Homolog (E. coli) Gene Mutation | Biallelic MutY Homolog Gene Mutation | MUTYH Biallelic Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407792","ERCC Family Gene Mutation","C174168","A change in the nucleotide sequence in a ERCC family gene.","ERCC Family Gene Mutation | ERCC Family Mutation | ERCC Gene Family Mutation | ERCC Gene Mutation | ERCC Mutation | Excision Repair Cross Complementing-Group Gene Mutation | Excision Repair Cross-Complementing Family Gene Mutation | Excision Repair Cross-Complementing Family Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407794","FEN1 Gene Mutation","C174170","A change in the nucleotide sequence in the FEN1 gene.","FEN1 Gene Mutation | DNase IV Gene Mutation | FEN-1 Gene Mutation | FEN1 Mutation | Flap Structure-Specific Endonuclease 1 Gene Mutation | MF1 Gene Mutation | Maturation Factor-1 Gene Mutation | RAD2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407804","CDK2 Gene Mutation","C174172","A change in the nucleotide sequence in the CDK2 gene.","CDK2 Gene Mutation | CDK2 Mutation | Cdc2-Related Protein Kinase Gene Mutation | Cell Division Protein Kinase 2 Gene Mutation | Cyclin Dependent Kinase 2 Gene Mutation | P33(CDK2) Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407807","SLX4 Gene Mutation","C174173","A change in the nucleotide sequence of the SLX4 gene.","SLX4 Gene Mutation | BTB (POZ) Domain Containing 12 Gene Mutation | BTBD12 Gene Mutation | FANCP Gene Mutation | Fanconi Anemia Complementation Group P Gene Mutation | Fanconi Anemia, Complementation Group P Gene Mutation | MUS312 Gene Mutation | SLX4 Mutation | SLX4 Structure-Specific Endonuclease Subunit Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407806","RAD52 Gene Mutation","C174174","A change in the nucleotide sequence of the RAD52 gene.","RAD52 Gene Mutation | RAD52 Homolog, DNA Repair Protein Gene Mutation | RAD52 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407801","XRCC Family Gene Mutation","C174175","A change in the nucleotide sequence in a XRCC family gene.","XRCC Family Gene Mutation | X-Ray Cross Complementing Family Gene Mutation | X-Ray Cross Complementing Gene Family Mutation | X-Ray Cross Complementing Group Gene Mutation | XRCC Family Mutation | XRCC Gene Family Mutation | XRCC Gene Mutation | XRCC Group Gene Mutation | XRCC Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407800","Inactivating MSH3 Gene Mutation","C174176","A change in the nucleotide sequence of the MSH3 gene that either inhibits expression or results in the translation of an inactive DNA mismatch repair protein Msh3 protein.","Inactivating MSH3 Gene Mutation | Inactivating DUC1 Gene Mutation | Inactivating DUG Gene Mutation | Inactivating DUP Gene Mutation | Inactivating MRP1 Gene Mutation | Inactivating MSH3 Mutation | Loss of Function MSH3 Gene Mutation | Loss of Function MSH3 Mutation | Loss of Function MutS Homolog 3 Gene Mutation | Loss of Function MutS, E. coli, Homolog of, 3 Gene Mutation | MSH3 Gene Inactivation | MSH3 Loss of Function Gene Mutation | MSH3 Loss of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407803","Inactivating EPCAM Gene Mutation","C174177","A change in the nucleotide sequence of the EPCAM gene that either inhibits expression or results in the translation of an inactive epithelial cell adhesion molecule protein.","Inactivating EPCAM Gene Mutation | EPCAM Inactivating Gene Mutation | EPCAM Inactivating Mutation | EPCAM Loss of Function Gene Mutation | EPCAM Loss of Function Mutation | Inactivating EPCAM Mutation | Inactivating Ep-CAM Gene Mutation | Inactivating Epithelial Cell Adhesion Molecule Gene Mutation | Inactivating HNPCC8 Gene Mutation | Inactivating TACSTD1 Gene Mutation | Inactivating Tumor-Associated Calcium Signal Transducer 1 Gene Mutation | Loss of Function EPCAM Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407802","JAK2 Exon 14 Mutation","C174178","A molecular genetic abnormality indicating the presence of a mutation in exon 14 of the JAK2 gene.","JAK2 Exon 14 Mutation | JAK-2 Exon 14 Mutation | JAK2 Exon 14 Gene Mutation | JTK10 Exon 14 Mutation | Janus Kinase 2 Exon 14 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407834","JAK2 Exon 16 Mutation","C174179","A molecular genetic abnormality indicating the presence of a mutation in exon 16 of the JAK2 gene.","JAK2 Exon 16 Mutation | JAK-2 Exon 16 Mutation | JAK2 Exon 16 Gene Mutation | JTK10 Exon 16 Mutation | Janus Kinase 2 Exon 16 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407833","Human Papillomavirus-11 Positive","C174180","An indication that human papillomavirus-11 has been detected in a sample.","Human Papillomavirus-11 Positive | HPV-11 Positive | HPV11 Positive | Human Papilloma Virus 11 Positive | Human Papilloma Virus-11 Positive | Human Papillomavirus 11 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407836","LAG3 Positive","C174181","An indication that LAG3 expression has been detected in a sample.","LAG3 Positive | CD223 Antigen Positive | CD223 Positive | FDC Positive | LAG-3 Positive | Lymphocyte Activating 3 Positive | Lymphocyte Activation Gene 3 Protein Positive | Lymphocyte-Activation Gene 3 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407835","BTK C481 Resistance Mutation","C174182","A change in the cysteine at position 481 of the tyrosine-protein kinase BTK protein to another amino acid that confers resistance to pharmacological inhibitors targeting BTK activity, such as ibrutinib.","BTK C481 Resistance Mutation | BTK C481X Resistance Mutation | BTK Cys481 Resistance Mutation | BTK Cys481Xxx Resistance Mutation | BTK NP_000052.1:p.C481X Resistance Mutation | BTK NP_000052.1:p.Cys481Xxx Resistance Mutation | BTK p.C481X Resistance Mutation | BTK p.Cys481Xxx Resistance Mutation | Bruton Tyrosine Kinase C481 Resistance Mutation | Bruton Tyrosine Kinase Cys481 Resistance Mutation | Cys481 Resistant Mutation | Cysteine-481 BTK Mutation | Cysteine-481 BTK Resistance Mutation | Tyrosine-Protein Kinase BTK C481 Resistance Mutation | Tyrosine-Protein Kinase BTK Cys481 Resistance Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407831","PSA Density Less than 0.3","C174183","A finding indicating that the ratio of serum prostate specific antigen to prostate volume is less than 0.3 ng/ml/g.","PSA Density Less than 0.3 | PSA Density Less than 0.3 ng/mL/g | PSAD Less than 0.3 | PSAD Less than 0.3 ng/mL/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407832","Testosterone Less than 200 Nanograms per Deciliter","C174185","A semiquantitative finding indicating that the concentration of testosterone in a sample is less than 200 ng/dL.","Testosterone Less than 200 ng/dL | Testosterone Less Than 200 ng/dL | Testosterone Less than 200 Nanograms per Deciliter | Testosterone Less than 200 Nanograms/Deciliter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407839","Flow Cytometry Panel for CD55/CD16/CD59","C174194","A flow cytometry screening panel for paroxysmal nocturnal hemoglobinuria consisting of reagents that identify the cell-surface proteins CD55, CD16, and CD59.","Flow Cytometry Panel for CD55/CD16/CD59 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407827","Complete Response in Aplastic Anemia","C174195","A hematologic response to treatment for aplastic anemia that meets the criteria of normal hemoglobin level for age, absolute neutrophil count, and platelet count.","Complete Response in Aplastic Anemia | Complete Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407826","Partial Response in Aplastic Anemia","C174196","A hematologic response to treatment for aplastic anemia that does not meet the criteria for a complete response, but meets the criteria for less severe disease and allows the patient to become or remain transfusion-independent.","Partial Response in Aplastic Anemia | Partial Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407829","No Response in Aplastic Anemia","C174197","Worsening of, or no apparent change in, the severity of aplastic anemia in response to treatment, including recurrence of transfusion dependency.","No Response in Aplastic Anemia | None/Recurrence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0232602","Retching","C94475","Involuntary spasms of the stomach and esophagus resulting in vomiting or dry heaving.","Retching | Retch | retch",,,,,,,,,,,,,,,"4309379","Retching",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1411780","Ulcerative Colitis Disease Activity Index","C174204","A four-item instrument that utilizes a four-point rating scale to assess the severity of ulcerative colitis based on stool frequency, rectal bleeding, mucosal appearance at endoscopy, and physician rating of disease activity.","Ulcerative Colitis Disease Activity Index | Mayo Clinical Index for Ulcerative Colitis | Mayo Score for Ulcerative Colitis | UCDAI | Ulcerative Colitis Disease Activity Index (UCDAI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411777","Agreement Likert Scale","C174207","A 5-point Likert scale for agreement that goes from 1: Not at All to 5: Very Much.","Agreement Likert Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412623","Agreement Score 1","C174209","A subjective score of 1 on an agreement scale that goes from 1: Not at All to 5: Very Much.","Agreement Score 1 | 1 | Not at All",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411779","Agreement Score 2","C174210","A subjective score of 2 on an agreement scale that goes from 1: Not at All to 5: Very Much.","Agreement Score 2 | 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412612","Agreement Score 3","C174211","A subjective score of 3 on an agreement scale that goes from 1: Not at All to 5: Very Much.","Agreement Score 3 | 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412914","Agreement Score 4","C174212","A subjective score of 4 on an agreement scale that goes from 1: Not at All to 5: Very Much.","Agreement Score 4 | 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411778","Agreement Score 5","C174213","A subjective score of 5 on an agreement scale that goes from 1: Not at All to 5: Very Much.","Agreement Score 5 | 5 | Very Much",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412622","Every Time","C174214","A response indicating something happens or happened at each occurrence or occasion without exception.","Every Time | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1379017","TP53 NP_000537.3:p.K132N","C169079","A change in the amino acid residue at position 132 in the cellular tumor antigen p53 protein where lysine has been replaced by asparagine.","TP53 NP_000537.3:p.K132N | Antigen NY-CO-13 K132N | Antigen NY-CO-13 Lys132Asn | Cellular Tumor Antigen p53 K132N | Cellular Tumor Antigen p53 Lys132Asn | NP_000537.3:p.K132N | NP_000537.3:p.Lys132Asn | TP53 K132N | TP53 K132N Mutation | TP53 Lys132Asn | TP53 NP_000537.3:p.Lys132Asn | TP53 p.K132N | TP53 p.Lys132Asn | Transformation-Related Protein 53 K132N | Transformation-Related Protein 53 Lys132Asn | Tumor Protein p53 K132N | Tumor Protein p53 Lys132Asn | Tumor Suppressor p53 K132N | Tumor Suppressor p53 Lys132Asn",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274077","KRAS NP_004976.2:p.Q61K","C98429","A change in the amino acid residue at position 61 in the GTPase KRas protein where glutamine has been replaced by lysine.","KRAS NP_004976.2:p.Q61K | GTPase KRas Gln61Lys | GTPase KRas Q61K | K-Ras 2 Q61K | KRAS Gln61Lys | KRAS NP_004976.2:p.Gln61Lys | KRAS Q61K | KRAS p.Gln61Lys | KRAS p.Q61K | Ki-Ras Q61K | NP_004976.2:p.Gln61Lys | NP_004976.2:p.Q61K | c-K-ras Q61K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274006","ERBB2 A775_G776insYVMA","C98359","A tandem duplication of four amino acids, tyrosine-valine-methionine-alanine, between the alanine at position 775 and the glycine at position 776 of the receptor tyrosine-protein kinase erbB-2 protein.","ERBB2 NP_004439.2:p.Y772_A775dup | A771_Y772insYVMA | ERBB2 771_772insYVMA insertion mutation | ERBB2 774_775insAYVM insertion mutation | ERBB2 A771_Y772insYVMA | ERBB2 A775_G776insYVMA | ERBB2 NP_004439.2:p.A771_Y772insYVMA | ERBB2 NP_004439.2:p.A775_G776insYVMA | ERBB2 NP_004439.2:p.A775_G776insYVMA | ERBB2 NP_004439.2:p.Ala775_Gly776insTyrValMetAla | ERBB2 NP_004439.2:p.Tyr772_Ala775dup | ERBB2 NP_004439.2:p.Y772_A775dup | ERBB2 Tyr772_Ala775dup | ERBB2 Y772 A775dup | ERBB2 Y772_A775dup | ERBB2 p.A775_G776insYVMA | ERBB2 p.E770delinsEAYVM | ERBB2 p.M774insAYVM | ERBB2 p.Tyr772_Ala775dup | ERBB2 p.Y772_A775dup | NP_004439.2:p.A771_Y772insYVMA | NP_004439.2:p.Ala775_Gly776insTyrValMetAla | NP_004439.2:p.E770delinsEAYVM | NP_004439.2:p.M774insAYVM | Proto-Oncogene Neu A775_G776insYVMA | Receptor Tyrosine-Protein Kinase erbB-2 A775_G776insYVMA | Tyrosine Kinase-Type Cell Surface Receptor HER2 A775_G776insYVMA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273962","BRAF NP_004324.2:p.G466V","C98314","A change in the amino acid residue at position 466 in the serine/threonine protein kinase B-raf protein where glycine has been replaced by valine.","BRAF NP_004324.2:p.G466V | BRAF G466V | BRAF Gly466Val | BRAF NP_004324.2:p.Gly466Val | BRAF p.G466V | BRAF p.Gly466Val | NP_004324.2:p.Gly466Val | Serine/Threonine-Protein Kinase B-raf G466V | Serine/Threonine-Protein Kinase B-raf Gly466Val",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977468","CTNNB1 NP_001091679.1:p.T41A","C164281","A change in the amino acid residue at position 41 in the catenin beta-1 protein where threonine has been replaced by alanine.","CTNNB1 NP_001091679.1:p.T41A | Beta Catenin T41A | Beta Catenin Thr41Ala | Beta-Catenin T41A | Beta-Catenin Thr41Ala | CTNNB T41A | CTNNB Thr41Ala | CTNNB1 NP_001091679.1:p.Thr41Ala | CTNNB1 T41A | CTNNB1 T41A Mutation | CTNNB1 Thr41Ala | CTNNB1 p.T41A | CTNNB1 p.Thr41Ala | Cadherin-Associated Protein, Beta T41A | Cadherin-Associated Protein, Beta Thr41Ala | Catenin Beta-1 T41A | Catenin Beta-1 Thr41Ala | Catenin, Beta-1 T41A | Catenin, Beta-1 Thr41Ala | NP_001091679.1:p.T41A | NP_001091679.1:p.Thr41Ala",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0745442","Venous Catheter","C122590","A hollow tube that is inserted into a vein.","Venous Catheter | Venous Line",,,,,,,,,,,,,,,"4124377","Venous catheter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1515729","t(17;19)(q22;p13)","C36361","No Value Exists","t(17;19)(q22;p13) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1792978","Anti-Androgen","C242","Substances that inhibit or antagonize the biosynthesis or biologic effects of androgens by either antagonizing the responsiveness of androgen sensitive tissues or competing with their binding sites.","Anti-Androgen | Androgen Antagonists | Anti-Androgen Agents | Antiandrogen Agents | Antiandrogen Therapy | Antiandrogens | antiandrogen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512498","Hormone Responsive","C28024","In oncology, describes cancer that responds to hormone treatment.","Hormone Responsive | Hormone-sensitive | hormone responsive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562687","Well Differentiated Neuroendocrine Lesion","C155861","A neoplastic lesion with neuroendocrine differentiation and well differentiated histological features.","Well Differentiated Neuroendocrine Lesion | Neuroendocrine tumor, well differentiated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411973","Tempus Blood RNA Tube","C174427","A proprietary blood collection tube for stabilization and isolation of total RNA from whole blood for gene expression analysis. When blood is drawn into the tube and mixed with the proprietary stabilizing reagent, lysis occurs almost immediately. The stabilizing reagent inactivates cellular RNases and selectively precipitates RNA, with genomic DNA and proteins remaining in solution.","Tempus Blood RNA Tube | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411970","BD Vacutainer ACD Solution B Tube","C174428","A blood collection tube designed for the collection of whole blood or plasma. ACD Solution B contains trisodium citrate (13.2g/L), citric acid (4.8g/L) and dextrose (14.7g/L) and is identified by a yellow closure.","BD Vacutainer ACD Solution B Tube | ACD-B BCT | BD Vacutainer Glass ACD Solution B Tube",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411971","Sodium Heparin Green-Top Tube","C174429","A blood collection tube that contains sodium heparin as an anticoagulant. This tube is used for preparing heparinized plasma, whole blood, and bone marrow specimens. It is identified by a green closure.","Sodium Heparin Green-Top Tube | Green-Top Sodium Heparin Tube | Green-Top Tube | Green-Top Tube (sodium heparin) | Sodium heparin tube",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411976","Smart Tube","C174430","A proprietary blood collection tube used in the proprietary Smart Tube blood collection system. that is designed to stabilize whole blood samples for single-cell proteomics. Smart Tube is optimized to work with 1 milliliter of whole blood, proprietary Proteomic Stabilizer and reagents, and a base station that automates the temperature-controlled incubation and stabilization of samples for downstream single-cell analysis.","Smart Tube | Smart Tube System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411977","Lee Chronic Graft-versus-Host Disease Symptom Scale","C174431","A self-report questionnaire containing 30 items in 7 subscales (skin, eye, mouth, lung, nutrition, energy, and psychological), developed to measure symptoms of chronic graft-versus-host disease. Patients report their level of symptom bother on a 5-point Likert scale.","Lee Chronic Graft-versus-Host Disease Symptom Scale | Lee cGVHD Symptom Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887950","Associated Persons Domain","C117304","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to associated persons.","Associated Persons Domain | AP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698908","Protocol Event","C74589","Other important events that occur during a trial but are not driven by protocol requirements.","Protocol Event | event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1096691","BK Virus Infection","C123276","An infection caused by the BK virus. It usually causes an asymptomatic infection, except in immunocompromised individuals where it may cause nephropathy or hemorrhagic cystitis.","BK Virus Infection | BK Viral Infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3278161","Gross Hematuria","C114702","The visible presence of blood in the urine.","Gross Hematuria | Visible Hematuria",,,,,,,,,,,,,,,"75004","Frank hematuria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0194423","Bladder Irrigation","C15397","Instillation of a solution into the bladder to provide cleansing or medication.","Bladder Irrigation | irrigation of urinary bladder | simple bladder irrigation",,,,,,,,,,,,,,,"4302745","Irrigation of urinary bladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937976","Skin Lesion","C158524","A localized pathological or traumatic structural change, damage, deformity, or discontinuity of skin.","Skin Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0870935","Napping","C113417","A short sleep, usually during normal waking hours.","Nap | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086899","Red Cell Mass result","C174451","The portion of total blood volume occupied by red blood cells.","Red Cell Mass | RCM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521673","Yttrium-90 Microsphere Radioembolization","C133735","Antineoplastic treatment consisting of catheter injection of yttrium Y 90 microspheres. When injected into the tumor vascular bed, yttrium Y 90 microspheres occlude tumor blood vessels and deliver a cytotoxic dose of beta radiation to the tumor site, which may result in tumor cell death and tumor regression.","Yttrium-90 Microsphere Radioembolization | Yttrium Y 90 Microsphere Therapy | Yttrium-90 Radioembolization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475704","Skin Color","C174437","The hue or shade of an individual's skin resulting from pigmentation, sun exposure, inflammation, or disease processes","Skin Color | ",,,,,,,,,,,,,,,"4077969","Finding of color of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540522","Electronic Case Report Form","C142523","An auditable electronic record of information that is reported to the sponsor (or sponsor's agent such as an EDC provider) on each trial subject to enable data pertaining to a clinical investigation protocol to be systematically captured, reviewed, managed, stored, analyzed, and reported. The eCRF is a CRF in which related data items and their associated comments, notes, and signatures are linked programmatically. See also case report form, CRF, eSRF.[CSUICI; Revised from FDA Final Guidance on eSource]","Electronic Case Report Form | eCRF | eCRF (electronic case report form)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0240069","Israeli","C43875","Denotes the inhabitants of Israel, a person from there, or their descendants elsewhere.","Israeli | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411818","Photon Counting Computed Tomography","C174537","A computed tomography technique that uses energy-resolving x-ray detectors to count the number of incoming photons and measure photon energy. This results in higher contrast-to-noise ratio, improved spatial resolution, and optimized spectral imaging. It can reduce radiation exposure, reconstruct images at a higher resolution, and optimize the use of contrast agents.","Photon Counting Computed Tomography | PCCT | PCD-CT | Photon-Counting CT | Photon-Counting Computed Tomography | Photon-counting Detector CT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796373","Videothoracoscopy","C18306","Endoscopic examination of the thoracic cavity, with a camera or similar device attached to an endoscope for viewing or recording the images generated during the procedure.","Videothoracoscopy | VATS | Video-Assisted Thoracoscopy",,,,,,,,,,,,,,,"40486150","Video assisted thoracoscopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1411837","Computed Tomography Imaging Mesothelioma Probability Score","C174525","A prospective scoring system related to suspicion of malignancy, including mesothelioma, as measured by all modalities of computed tomographic imaging.","Computed Tomography Imaging Mesothelioma Probability Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411838","CT Score 0","C174526","A score of 0 that indicates no abnormalities detected as measured by all modalities of computed tomographic imaging.","CT Score 0 | Computed Tomography Imaging Mesothelioma Probability Score 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411827","CT Score 1","C174527","A score of 1 that indicates abnormalities unrelated to malignancy as measured by all modalities of computed tomographic imaging.","CT Score 1 | Computed Tomography Imaging Mesothelioma Probability Score 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411828","CT Score 2A","C174528","A score of 2A that indicates abnormalities with a low suspicion for malignancy-mesothelioma as measured by all modalities of computed tomographic imaging.","CT Score 2A | Computed Tomography Imaging Mesothelioma Probability Score 2A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411825","CT Score 2B","C174529","A score of 2B that indicates abnormalities with a low suspicion for malignancy-other neoplasm (specify) as measured by all modalities of computed tomographic imaging.","CT Score 2B | Computed Tomography Imaging Mesothelioma Probability Score 2B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411826","VATS and Laparoscopy Surveillance Result Score","C174530","A prospective scoring system related to suspicion of malignancy, including mesothelioma, as measured by video-assisted thoracoscopy and laparoscopy.","VATS and Laparoscopy Surveillance Result Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411831","VATS and Laparoscopy Score 0","C174531","A score of 0 that indicates no abnormalities detected as seen using video-assisted thoracoscop and laparoscopy.","VATS and Laparoscopy Score 0 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411832","VATS and Laparoscopy Score 1A","C174532","A score of 1A that indicates abnormality with malignancy not identified-atypical mesothelial proliferation as seen using video-assisted thoracoscopy and laparoscopy.","VATS and Laparoscopy Score 1A | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411829","VATS and Laparoscopy Score 1B","C174533","A score of 1B that indicates abnormality with malignancy not identified-other: (pleural plaque, etc.) as seen using video-assisted thoracoscopy and laparoscopy.","VATS and Laparoscopy Score 1B | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411830","VATS and Laparoscopy Score 2A.1","C174534","A score of 2A.1 that indicates abnormality with low suspicion for malignancy-mesothelioma, localized, as seen using video-assisted thoracoscopy and laparoscopy.","VATS and Laparoscopy Score 2A.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411820","VATS and Laparoscopy Score 2A.2","C174535","A score of 2A.2 that indicates abnormality with low suspicion for malignancy-mesothelioma, diffuse, as seen using video-assisted thoracoscopy and laparoscopy.","VATS and Laparoscopy Score 2A.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411821","VATS and Laparoscopy Score 2B","C174536","A score of 2B that indicates abnormality with low suspicion for malignancy-other neoplasm (specify) as seen using video-assisted thoracoscopy and laparoscopy.","VATS and Laparoscopy Score 2B | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411865","Transplant-Associated Thrombotic Microangiopathy","C174553","Thrombotic microangiopathy that presents in some patients undergoing hematopoietic stem cell transplantation (HSCT). Though similar in presentation to thrombotic thrombocytopenic purpura (TTP) and atypical hemolytic uremic syndrome (aHUS), transplant-associated thrombotic microangiopathy (TA-TMA) is a distinct disorder. Several risk factors may be associated with TA-TMA, including high-dose chemotherapy, radiation therapy, HLA mismatch, use of calcineurin inhibitors, acute graft-versus-host disease (GVHD), and infections.","Transplant-Associated Thrombotic Microangiopathy | TA-TMA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411866","Bridge Therapy","C174554","Therapy intended to transition a patient from one therapy or medication to another or maintain their health or status until they are a candidate for a therapy or have decided on a therapy.","Bridge Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383431","Other Chemotherapy","C174557","A chemotherapy other than the one specified.","Other Chemotherapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411869","Anti-GD2 Therapy","C174558","Any therapy that specifically targets the tumor-associated antigen (TAA) disialoganglioside GD2.","Anti-GD2 Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411859","Dinutuximab/Irinotecan/Temozolomide Regimen","C174559","A regimen consisting of dinutuximab, irinotecan and temozolomide that can potentially be used for the treatment of neuroblastoma.","Dinutuximab/Irinotecan/Temozolomide Regimen | Dinutuximab + Irinotecan and Temozolomide | Dinutuximab-Irinotecan-Temozolomide | Dinutuximab/Irinotecan/Temozolomide | Irinotecan, Temozolomide, Dinutuximab | Irinotecan-Temozolomide-Dinutuximab | Irinotecan/Temozolomide/Dinutuximab | Temozolomide-Irinotecan-Dinutuximab | Temozolomide/Irinotecan/Dinutuximab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640251","CDISC SDTM Normal Abnormal Response Terminology","C101834","Terminology associated with the normal abnormal response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Normal Abnormal Response Terminology | NORMABNM | Normal Abnormal Response | SDTM-NORMABNM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882372","Physiological Support","C66895","Therapeutic care designed to maintain the natural processes of the body and return to a more normal state of health.","Physiological Support | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411864","Curie Relative Bone Score","C174564","The ratio of the Curie score without the soft-tissue component at the time of response assessment and at diagnosis.","Curie Relative Bone Score | Curie Scale Relative Bone Score | Curie Scale Relative Score | Relative Score by Curie Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4227896","Severe Congenital Neutropenia","C166152","A congenital disorder characterized by chronic neutropenia with absolute neutrophil count less than 500/uL and arrest of neutrophil maturation at the promyelocyte/myelocyte level. It is inherited in autosomal recessive or autosomal dominant patterns. Sporadic cases have also been reported. It is usually diagnosed in the first year of life. Patients present with frequent and life-threatening infections.","Severe Congenital Neutropenia | SCN",,,,,,,,,,,,,,,"434895","Congenital neutropenia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0237314","Irregular Heart Beat","C168284","A clinical finding in which the rhythm of the heart is noted to be abnormal. (ACC/AHA)","Irregular Heart Beat | Dysrhythmia | Irregular heart beat",,,,,,,,,,,,,,,"4263255","Irregular heart beat",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3554752","Easy Bruising","C119027","Appearance of skin bruises following perceived minimal contact or injury.","Easy Bruising | ",,,,,,,,,,,,,,,"4314452","Easy bruising",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526540","Multiple Myeloma by ISS Stage","C139009","A header term that refers to the staging of multiple myeloma according to the International Staging System.","Multiple Myeloma by ISS Stage | Plasma Cell Myeloma by ISS Stage | Plasma Cell Myeloma by ISS Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539430","Plasma Cell Myeloma by Revised International Staging System Stage","C141393","A staging system for multiple myeloma based on the Revised International Staging System (RISS) criteria. This staging system does not apply to smoldering multiple myeloma (no AJCC staging system), monoclonal gammopathy of undetermined significance (no AJCC staging system), and Waldenstrom macroglobulinemia (no AJCC staging system). (from AJCC 8th Ed.)","Multiple Myeloma by RISS Stage | Plasma Cell Myeloma by RISS Stage | Plasma Cell Myeloma by RISS Stage | Plasma Cell Myeloma by Revised International Staging System Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502530","antibody-drug conjugate ABBV-085","C124134","An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against leucine-rich repeat containing 15 (LRRC15) linked, via the protease-cleavable valine-citrulline linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of samrotamab vedotin, the samrotamab moiety targets and binds to LRRC15 expressed on cancer-associated fibroblasts (CAFs) and tumor cells. Upon binding and internalization, MMAE is released after proteolytic cleavage. MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in LRRC15-expressing CAFs and tumor cells. LRRC15, a type I membrane protein and a member of the LRR superfamily, is highly expressed on CAFs in the tumor microenvironment (TME) within some tumor stroma and on tumor cells in certain tumors.","Samrotamab Vedotin | ABBV-085 | ADC ABBV-085 | PR-1498487 PAB-MMAE | SAMROTAMAB VEDOTIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879547","irinotecan/temozolomide","C11820","A regimen consisting of irinotecan and temozolomide that can be used for the treatment of Ewing sarcoma or mesenchymal chondrosarcoma.","Irinotecan/Temozolomide Regimen | Irinotecan and Temozolomide | Irinotecan-Temozolomide | Irinotecan/Temozolomide | Irinotecan/Temozolomide | Irinotecan/Temozolomide Regimen | Temozolomide-Irinotecan | Temozolomide/Irinotecan | Temozolomide/Irinotecan Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826250","Collection Date Time","C82515","The date or date and time of the specimen or data collection.","Collection Date Time | DTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412587","Incidental Gallbladder Carcinoma","C175214","Gallbladder carcinoma that is discovered incidental to gallbladder surgery for another indication.","Incidental Gallbladder Carcinoma | IGBC | Incidental Gallbladder Cancer | Occult Gallbladder Cancer | Occult Gallbladder Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831327","Blood Product Storage","C113072","Keeping a stock of blood products under conditions that ensure those products are suitable for future use.","Blood Product Storage | Storage, Blood Products",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522349","Non-Healthcare Professional","C134833","An individual qualified in a profession outside the healthcare field.","Non-Healthcare Professional | NON-HEALTH CARE PROFESSIONAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407933","Quality of Life in Inflammatory Bowel Disease Questionnaire","C174070","A standardized 32-item self-report or clinician-administered questionnaire, developed by Irvine et al. 1989, that utilizes a seven-point Likert scale and a two week recall of bowel, systemic, emotional, and social functioning to assess quality of life in patients with inflammatory bowel diseases.","Quality of Life in Inflammatory Bowel Disease Questionnaire | IBDQ | IBDQ01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407934","Short Form 12 Health Survey Acute, US Version 2.0 Questionnaire","C174069","A standardized 12-item self-report questionnaire, originally adapted from the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) in 1996 and revised in 2002, that utilizes a one week recall of eight domains of physical and psychosocial functioning to assess the impact of health on an individual's everyday life.","Short Form 12 Health Survey Acute, US Version 2.0 Questionnaire | SF12 V2.0 ACUTE | SF12 v2.0 Acute | SF124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407939","Short Form 12 Health Survey Standard, US Version 2.0 Questionnaire","C174068","A standardized 12-item self-report questionnaire, originally adapted from the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) in 1996 and revised in 2002, that utilizes a four week recall of eight domains of physical and psychosocial functioning to assess the impact of health on an individual's everyday life.","Short Form 12 Health Survey Standard, US Version 2.0 Questionnaire | SF12 V2.0 STANDARD | SF12 v2.0 Standard | SF123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407940","Short Form 12 Health Survey Acute, US Version 1.0 Questionnaire","C174067","A standardized 12-item self-report questionnaire, adapted from the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) in 1996, that utilizes a one week recall of eight domains of physical and psychosocial functioning to assess the impact of health on an individual's everyday life.","Short Form 12 Health Survey Acute, US Version 1.0 Questionnaire | SF12 V1.0 ACUTE | SF12 v1.0 Acute | SF122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407937","Short Form 12 Health Survey Standard, US Version 1.0 Questionnaire","C174066","A standardized 12-item self-report questionnaire, adapted from the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) in 1996, that utilizes a four week recall of eight domains of physical and psychosocial functioning to assess the impact of health on an individual's everyday life.","Short Form 12 Health Survey Standard, US Version 1.0 Questionnaire | SF12 V1.0 STANDARD | SF12 v1.0 Standard | SF121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407938","Short Form 10 Health Survey for Children Acute, US Version 1.0 Questionnaire","C174065","A standardized 10-item parent-report survey, adapted from the Child Health Questionnaire in 2003, that utilizes a one week recall of eight domains of physical and psychosocial functioning to assess health-related quality of life in the pediatric population.","Short Form 10 Health Survey for Children Acute, US Version 1.0 Questionnaire | SF10 V1.0 CHILDREN ACUTE | SF10 v1.0 Children Acute | SF102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407958","Short Form 10 Health Survey for Children Standard, US Version 1.0 Questionnaire","C174064","A standardized 10-item parent-report survey, adapted from the Child Health Questionnaire in 2003, that utilizes a four week recall of eight domains of physical and psychosocial functioning to assess health-related quality of life in the pediatric population.","Short Form 10 Health Survey for Children Standard, US Version 1.0 Questionnaire | SF10 V1.0 CHILDREN STANDARD | SF10 v1.0 Children Standard | SF101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407959","Short Form 8 Health Survey Acute, US Version 1.0 Questionnaire","C174063","A standardized eight-item short version of the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) that utilizes a five-point rating scale and a one week recall to assess health-related quality of life. The measured dimensions include general health, physical functioning, role-physical, bodily pain, vitality, social functioning, mental health, and role-emotional.","Short Form 8 Health Survey Acute, US Version 1.0 Questionnaire | SF8 V1.0 ACUTE | SF8 v1.0 Acute | SF82",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407957","Short Form 8 Health Survey Standard, US Version 1.0 Questionnaire","C174062","A standardized eight-item short version of the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) that utilizes a five-point rating scale and a four week recall to assess health-related quality of life. The measured dimensions include general health, physical functioning, role-physical, bodily pain, vitality, social functioning, mental health, and role-emotional.","Short Form 8 Health Survey Standard, US Version 1.0 Questionnaire | SF8 V1.0 STANDARD | SF8 v1.0 Standard | SF81",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522182","Gallbladder Cancer TNM Finding v8","C134635","A finding about one or more characteristics of gallbladder cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to gallbladder carcinomas. Well-differentiated neuroendocrine tumors and sarcomas are not staged using this staging system. (from AJCC 8th Ed.)","Gallbladder Cancer TNM Finding v8 | Gallbladder Carcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522201","Gallbladder Cancer pT4 TNM Finding v8","C134654","Gallbladder cancer with tumor invading the main portal vein or hepatic artery or invading two or more extrahepatic organs or structures. (from AJCC 8th Ed.)","Gallbladder Cancer pT4 TNM Finding v8 | Gallbladder Carcinoma pT4 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522200","Gallbladder Cancer pT3 TNM Finding v8","C134653","Gallbladder cancer with tumor perforating the serosa (visceral peritoneum) and/or directly invading the liver and/or one other adjacent organ or structure, such as the stomach, duodenum, colon, pancreas, omentum, or extrahepatic bile ducts. (from AJCC 8th Ed.)","Gallbladder Cancer pT3 TNM Finding v8 | Gallbladder Carcinoma pT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522199","Gallbladder Cancer pT2b TNM Finding v8","C134652","Gallbladder cancer with tumor invading the perimuscular connective tissue on the hepatic side, with no extension into the liver. (from AJCC 8th Ed.)","Gallbladder Cancer pT2b TNM Finding v8 | Gallbladder Carcinoma pT2b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522198","Gallbladder Cancer pT2a TNM Finding v8","C134651","Gallbladder cancer with tumor invading the perimuscular connective tissue on the peritoneal side, without involvement of the serosa (visceral peritoneum). (from AJCC 8th Ed.)","Gallbladder Cancer pT2a TNM Finding v8 | Gallbladder Carcinoma pT2a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522197","Gallbladder Cancer pT2 TNM Finding v8","C134650","Gallbladder cancer with tumor invading the perimuscular connective tissue on the peritoneal side, without involvement of the serosa (visceral peritoneum); or tumor invading the perimuscular connective tissue on the hepatic side, with no extension into the liver. (from AJCC 8th Ed.)","Gallbladder Cancer pT2 TNM Finding v8 | Gallbladder Carcinoma pT2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522196","Gallbladder Cancer pT1b TNM Finding v8","C134649","Gallbladder cancer with tumor invading the muscular layer. (from AJCC 8th Ed.)","Gallbladder Cancer pT1b TNM Finding v8 | Gallbladder Carcinoma pT1b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522195","Gallbladder Cancer pT1a TNM Finding v8","C134648","Gallbladder cancer with tumor invading the lamina propria. (from AJCC 8th Ed.)","Gallbladder Cancer pT1a TNM Finding v8 | Gallbladder Carcinoma pT1a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522194","Gallbladder Cancer pT1 TNM Finding v8","C134647","Gallbladder cancer with tumor invading the lamina propria or muscular layer. (from AJCC 8th Ed.)","Gallbladder Cancer pT1 TNM Finding v8 | Gallbladder Carcinoma pT1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522193","Gallbladder Cancer pTis TNM Finding v8","C134646","Gallbladder cancer with a finding of carcinoma in situ. (from AJCC 8th Ed.)","Gallbladder Cancer pTis TNM Finding v8 | Gallbladder Carcinoma pTis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522192","Gallbladder Cancer pT0 TNM Finding v8","C134645","Gallbladder cancer with no evidence of primary tumor. (from AJCC 8th Ed.)","Gallbladder Cancer pT0 TNM Finding v8 | Gallbladder Carcinoma pT0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522191","Gallbladder Cancer pTX TNM Finding v8","C134644","Gallbladder cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Gallbladder Cancer pTX TNM Finding v8 | Gallbladder Carcinoma pTX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013273","Ductus Arteriosus","C52854","An embryonic blood vessel that allows blood to bypass the lungs by connecting the pulmonary artery and the proximal descending aorta. In the vast majority of neonates it atrophies at birth, becoming the ligamentum arteriosum.","Ductus Arteriosus | DUCTUS ARTERIOSUS",,,,,,,,,,,,,,,"4195786","Structure of ductus arteriosus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162858","Ulnar Artery","C12839","A terminal branch of the brachial artery arising just below the elbow that runs along the ulna into the wrist with numerous branches supplying the forearm, wrist and hand.","Ulnar Artery | ULNAR ARTERY | Ulnar",,,,,,,,,,,,,,,"4261482","Structure of ulnar artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL522206","Gallbladder Cancer pN2 TNM Finding v8","C134659","Gallbladder cancer with metastases to four or more regional lymph nodes. (from AJCC 8th Ed.)","Gallbladder Cancer pN2 TNM Finding v8 | Gallbladder Carcinoma pN2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522205","Gallbladder Cancer pN1 TNM Finding v8","C134658","Gallbladder cancer with metastases to one to three regional lymph nodes. (from AJCC 8th Ed.)","Gallbladder Cancer pN1 TNM Finding v8 | Gallbladder Carcinoma pN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522204","Gallbladder Cancer pN0 TNM Finding v8","C134657","Gallbladder cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","Gallbladder Cancer pN0 TNM Finding v8 | Gallbladder Carcinoma pN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522203","Gallbladder Cancer pNX TNM Finding v8","C134656","Gallbladder cancer in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)","Gallbladder Cancer pNX TNM Finding v8 | Gallbladder Carcinoma pNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522189","Gallbladder Cancer pM1 TNM Finding v8","C134642","Gallbladder cancer with distant metastasis. (from AJCC 8th Ed.)","Gallbladder Cancer pM1 TNM Finding v8 | Gallbladder Carcinoma pM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522186","Gallbladder Cancer cM1 TNM Finding v8","C134639","Gallbladder cancer with distant metastasis. (from AJCC 8th Ed.)","Gallbladder Cancer cM1 TNM Finding v8 | Gallbladder Carcinoma cM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522185","Gallbladder Cancer cM0 TNM Finding v8","C134638","Gallbladder cancer without evidence of distant metastasis. (from AJCC 8th Ed.)","Gallbladder Cancer cM0 TNM Finding v8 | Gallbladder Carcinoma cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522207","Gallbladder Cancer by AJCC v8 Stage","C134660","A term that refers to the staging of gallbladder cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to gallbladder carcinomas. Well-differentiated neuroendocrine tumors and sarcomas are not staged using this staging system. (from AJCC 8th Ed.)","Gallbladder Cancer by AJCC v8 Stage | Gallbladder Carcinoma by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522220","Stage IVB Gallbladder Cancer AJCC v8","C134678","Stage IVB includes: (Any T, N2, M0); (Any T, Any N, M1). N2: Metastases to four or more regional lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)","Stage IVB Gallbladder Cancer AJCC v8 | Stage IVB Gallbladder Cancer | Stage IVB Gallbladder Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522219","Stage IVA Gallbladder Cancer AJCC v8","C134676","Stage IVA includes: T4, N0-1, M0. T4: Tumor invading the main portal vein or hepatic artery or invading two or more extrahepatic organs or structures. N0: No regional lymph node metastasis. N1: Metastases to one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage IVA Gallbladder Cancer AJCC v8 | Stage IVA Gallbladder Cancer | Stage IVA Gallbladder Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522218","Stage IV Gallbladder Cancer AJCC v8","C134675","Stage IV includes: IVA: T4, N0-1, M0; IVB: (Any T, N2, M0); (Any T, Any N, M1). T4: Tumor invading the main portal vein or hepatic artery or invading two or more extrahepatic organs or structures. N0: No regional lymph node metastasis. N1: Metastases to one to three regional lymph nodes. N2: Metastases to four or more regional lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Gallbladder Cancer AJCC v8 | Stage IV Gallbladder Cancer | Stage IV Gallbladder Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522217","Stage IIIB Gallbladder Cancer AJCC v8","C134674","Stage IIIB includes: T1-3, N1, M0. T1: Tumor invading the lamina propria or muscular layer. T2: Tumor invading the perimuscular connective tissue on the peritoneal side, without involvement of the serosa (visceral peritoneum); or tumor invading the perimuscular connective tissue on the hepatic side, with no extension into the liver. T3: Tumor perforating the serosa (visceral peritoneum) and/or directly invading the liver and/or one other adjacent organ or structure, such as the stomach, duodenum, colon, pancreas, omentum, or extrahepatic bile ducts. N1: Metastases to one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIB Gallbladder Cancer AJCC v8 | Stage IIIB Gallbladder Cancer | Stage IIIB Gallbladder Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522215","Stage III Gallbladder Cancer AJCC v8","C134672","Stage III includes: IIIA: (T3, N0, M0); IIIB: (T1-3, N1, M0). T1: Tumor invading the lamina propria or muscular layer. T2: Tumor invading the perimuscular connective tissue on the peritoneal side, without involvement of the serosa (visceral peritoneum); or tumor invading the perimuscular connective tissue on the hepatic side, with no extension into the liver. T3: Tumor perforating the serosa (visceral peritoneum) and/or directly invading the liver and/or one other adjacent organ or structure, such as the stomach, duodenum, colon, pancreas, omentum, or extrahepatic bile ducts. N0: No regional lymph node metastasis. N1: Metastases to one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Gallbladder Cancer AJCC v8 | Stage III Gallbladder Cancer | Stage III Gallbladder Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522214","Stage IIB Gallbladder Cancer AJCC v8","C134671","Stage IIB includes: T2b, N0, M0. T2b: Tumor invading the perimuscular connective tissue on the hepatic side, with no extension into the liver. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIB Gallbladder Cancer AJCC v8 | Stage IIB Gallbladder Cancer | Stage IIB Gallbladder Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522213","Stage IIA Gallbladder Cancer AJCC v8","C134670","Stage IIA includes: T2a, N0, M0. T2a: Tumor invading the perimuscular connective tissue on the peritoneal side, without involvement of the serosa (visceral peritoneum). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIA Gallbladder Cancer AJCC v8 | Stage IIA Gallbladder Cancer | Stage IIA Gallbladder Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522211","Stage II Gallbladder Cancer AJCC v8","C134667","Stage II includes: IIA: T2a, N0, M0; IIB: T2b, N0, M0. T2a: Tumor invading the perimuscular connective tissue on the peritoneal side, without involvement of the serosa (visceral peritoneum). T2b: Tumor invading the perimuscular connective tissue on the hepatic side, with no extension into the liver. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Gallbladder Cancer AJCC v8 | Stage II Gallbladder Cancer | Stage II Gallbladder Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522210","Stage I Gallbladder Cancer AJCC v8","C134665","Stage I includes: T1, N0, M0. T1: Tumor invading the lamina propria or muscular layer. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Gallbladder Cancer AJCC v8 | Stage I Gallbladder Cancer | Stage I Gallbladder Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522209","Stage 0 Gallbladder Cancer AJCC v8","C134663","Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0 Gallbladder Cancer AJCC v8 | Stage 0 Gallbladder Cancer | Stage 0 Gallbladder Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407964","Rett Syndrome Severity Scale Clinical Classification","C174061","A seven-item ratings scale developed by Hoffbuhr et al. 2001 that utilizes a four-point Likert scale to assess the severity of Rett Syndrome clinical presentation. The measured parameters include frequency and manageability of seizures, respiratory irregularities, scoliosis, ability to walk, hand use, speech, and sleep problems.","Rett Syndrome Severity Scale Clinical Classification | RETT1 | RSSS | RSSS01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407152","Disease Involvement Site","C173263","The anatomic site of the disease.","Disease Involvement Site | DISEASE SITE | DISEASE_SITE | Site of Disease | sites of involvement | sites_of_involvement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018811","Fetal Heart Rate","C92716","The number of fetal cardiac beats per minute.","Fetal Heart Rate | FTHR | Fetal HR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554128","Umeclidinium","C152796","No Value Exists","Umeclidinium | UMECLIDINIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0542331","Shunt Device","C50174","An implantable device designed to drain fluid from a body cavity.","Shunt Device | Shunt | shunt",,,,,,,,,,,,,,,"4106154","Shunt",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028420","Nortriptyline","C62060","A tricyclic antidepressant agent used for short-term treatment of various forms of depression. Nortriptyline blocks the norepinephrine presynaptic receptors, thereby blocking the reuptake of this neurotransmitter and raising the concentration in the synaptic cleft in the CNS. Nortriptyline also binds to alpha-adrenergic, histaminergic and cholinergic receptors. Long-term treatment with nortriptyline produces a downregulation of adrenergic receptors due to the increased stimulation of these receptors.","Nortriptyline | NORTRIPTYLINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1099456","Escitalopram","C61754","The active S-stereoisomer of the selective serotonin reuptake inhibitor (SSRI) citalopram with antidepressant, anti-obsessive-compulsive and antibulimic properties. Escitalopram inhibits the reuptake of the neurotransmitter serotonin (5-HT) at the serotonin reuptake pump of the neuronal membrane of the presynaptic cell, thereby increasing levels of 5-HT within the synaptic cleft and enhancing the actions of serotonin on 5HT1A autoreceptors. Unlike other SSRIs, escitalopram appears to not only bind to a primary high-affinity site on the serotonin transporter protein but also to a secondary lower-affinity allosteric site that is considered to stabilize and prolong drug binding.","Escitalopram | (S)-Citalopram | ESCITALOPRAM | S(+)-Citalopram | Seroplex | escitalopram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0076829","Topiramate","C47764","A sulfamate-substituted monosaccharide with anticonvulsant property. Although the mechanism of action has not been fully elucidated, topiramate antagonizes kainate/AMPA subtype of the glutamate receptors, which are ligand-activated cation channels that mediate the fast component of excitatory postsynaptic currents in neurons of the central nervous system. This antagonistic action results in stabilizing hyper-excited neural membranes, inhibiting repetitive neuronal firing, and decreasing propagation of synaptic impulses, thereby impedes seizure occurrences. In addition, this agent augments gamma-aminobenzoic acid (GABA) activity and thereby attenuating GABAnergic inhibitory transmission.","Topiramate | TOPIRAMATE | Topamax | beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, Sulfamate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033405","Promethazine","C779","A phenothiazine derivative with antiemetic and antihistaminic properties. Promethazine antagonizes the central and peripheral effects of histamine mediated by histamine H1 receptors. The effects include bronchoconstriction, vasodilation and spasmodic contractions of gastrointestinal smooth muscle. In addition, this agent binds to muscarinic receptors, resulting in anticholinergic and antiemetic activities.","Promethazine | PROMETHAZINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011816","Dextromethorphan","C62022","A synthetic, methylated dextrorotary analogue of levorphanol, a substance related to codeine and a non-opioid derivate of morphine. Dextromethorphan exhibits antitussive activity and is devoid of analgesic or addictive property. This agent crosses the blood-brain-barrier and activates sigma opioid receptors on the cough center in the central nervous system, thereby suppressing the cough reflex.","Dextromethorphan | DEXTROMETHORPHAN | DXM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034414","Quinidine","C793","An alkaloid extracted from the bark of the Cinchona tree with class 1A antiarrhythmic and antimalarial effects. Quinidine stabilizes the neuronal membrane by binding to and inhibiting voltage-gated sodium channels, thereby inhibiting the sodium influx required for the initiation and conduction of impulses resulting in an increase of the threshold for excitation and decreased depolarization during phase 0 of the action potential. In addition, the effective refractory period (ERP), action potential duration (APD), and ERP/APD ratios are increased, resulting in decreased conduction velocity of nerve impulses. Quinidine exerts its antimalarial activity by acting primarily as an intra-erythrocytic schizonticide through association with the heme polymer (hemazoin) in the acidic food vacuole of the parasite thereby preventing further polymerization by heme polymerase enzyme. This results in accumulation of toxic heme and death of the parasite.","Quinidine | QUINIDINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038689","Sulfamethoxazole","C47737","A sulfonamide bacteriostatic antibiotic that is most commonly used in combination with trimethoprim as the drug Bactrim. Sulfamethoxazole competitively inhibits dihydropteroate synthase preventing the formation of dihydropteroic acid, a precursor of folic acid which is required for bacterial growth.","Sulfamethoxazole | Benzenesulfonamide, 4-amino-N-(5-methyl-3-isoxazolyl)- | Gamazole | Metoxal | Radonil | SULFAMETHOXAZOLE | Sulfanilamide, N'-(5-methyl-3-isoxazolyl)- | Sulfisomezole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025631","Methazolamide","C61318","A sulfonamide derivate and carbonic anhydrase inhibitor with potential antineoplastic activity. Methazolamide inhibits tumor-associated carbonic anhydrase IX (CAIX), which may result in increased cell death in hypoxic tumors. As a hypoxia-inducible transmembrane glycoprotein, CAIX catalyzes the rapid interconversion of carbon dioxide and water into carbonic acid, protons, and bicarbonate ions, helping to maintain acidification of the tumor microenvironment and enhance resistance to cytotoxic therapy in some hypoxic tumors.","Methazolamide | Glauctabs | METHAZOLAMIDE | MZM | N-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]-acetamide | Neptazane",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012086","Dichlorphenamide","C65376","No Value Exists","Dichlorphenamide | DICHLORPHENAMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206558","Simplex Virus","C112419","A genus of enveloped, spherical or pleomorphic viruses with a capsid with T=16 icosahedral symmetry and surrounded by amorphous tegument, in the family Herpesviridae. The genome is composed of monopartite, linear double-stranded DNA. Simplexviruses are found in humans and mammals, may remain latent in neurons and cause skin blisters and mucosal ulcers in humans.","Simplex Virus | HHV | HSV | Herpes Simplex Virus | Herpes Simplex Virus | Human Herpes Simplex Virus | SIMPLEXVIRUS | Simplexvirus | herpes simplex virus | human herpesvirus",,,,,,,,,,,,,,,"4064704|4152720","Human herpes simplex virus|Simplexvirus",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL1412774","7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid","C175292","A polyunsaturated dihydroxydocosahexaenoic acid that is a metabolite of docosahexaenoic acid (DHA), with potential analgesic, anti-inflammatory, and protective activities.","Maresin 1 | (4Z,7R,8E,10E,12Z,14S,16Z,19Z)-7,14-Dihydroxydocosa-4,8,10,12,16,19-Hexaenoic Acid | (4Z,7R,8E,10E,12Z,14S,16Z,19Z)-7,14-Dihydroxydocosahexaenoic Acid | (7R,14S)-Dihydroxy-(4Z,8E,10E,12Z,16Z,19Z)-Docosahexaenoic Acid | MaR1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412773","Resolvin D2","C175293","A polyunsaturated fatty acid in the resolvin family that is a poly-hydroxyl metabolite of docosahexaenoic acid (DHA), with potential anti-inflammatory, analgesic and protective activities.","Resolvin D2 | (4Z,7R,8E,10Z,12E,14E,16R,17S,19Z)-7,16,17-Trihydroxydocosa-4,8,10,12,14,19-Hexaenoic Acid | 7S,16R,17S-Trihydroxy-4Z,8E,10Z,12E,14E,19Z-Docosahexaenoic Acid | 7S,16R,17S-Trihydroxy-DHA | RvD2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412768","Resolvin E1","C175294","A polyunsaturated fatty acid in the resolvin family that is a poly-hydroxyl metabolite of docosahexaenoic acid (DHA), with potential analgesic and anti-inflammatory activities.","Resolvin E1 | (5S,12R,18R)-Trihydroxy-(6Z,8E,10E,14Z,16E)-Eicosapentaenoic Acid | (5S,12R,18R)-Trihydroxy-(6Z,8E,10E,14Z,16E)-Icosapentaenoic Acid | (5S,6Z,8E,10E,12R,14Z,16E,18R)-5,12,18-Trihydroxyicosa-6,8,10,14,16-Pentaenoic Acid | (6Z,8E,10E,14Z,16E)-5,12,18-Trihydroxyicosa-6,8,10,14,16-Pentaenoic Acid | 5S,12R,18R-Trihydroxy-6Z,8E,10E,14Z,16E-EPA | 5S,12R,18R-Trihydroxy-6Z,8E,10E,14Z,16E-Eicosapentaenoic Acid | 5S,12R,18R-Trihydroxy-EPA | RvE1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412767","resolvin D1","C175295","A polyunsaturated fatty acid in the resolvin family that is a poly-hydroxyl metabolite of docosahexaenoic acid (DHA), with potential anti-inflammatory and analgesic activities.","Resolvin D1 | (4Z,7S,8R,9E,11E,13Z,15E,17S,19Z)-7,8,17-Trihydroxydocosa-4,9,11,13,15,19-Hexaenoic Acid | 7S,8,17S-Trihydroxy-Docosa-4Z,9E,11E,13Z,15E,19Z-Hexaenoic Acid | 7S,8R,17S-Trihydroxy-DHA | RvD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412770","Lipoxin A4","C175296","A hydroxy polyunsaturated fatty acid that is a metabolite of arachidonic acid, with potential anti-inflammatory, antifibrinolytic and analgesic activities.","Lipoxin A4 | (5S,6R,15S)-Trihydroxy-7,9,13-trans-11-cis-Eicosatetraenoic Acid | (5S,6R,7E,9E,11Z,13E,15S)-5,6,15-Trihydroxy-7,9,11,13-Eicosatetraenoic Acid | (5S,6R,7E,9E,11Z,13E,15S)-5,6,15-Trihydroxyeicosa-7,9,11,13-Tetraenoic Acid | (5S,6R,7E,9E,11Z,13E,15S)-5,6,15-Trihydroxyicosa-7,9,11,13-Tetraenoic Acid | (7E,9E,11Z,13E)-(5S,6R,15S)-5,6,15-Trihydroxyicosa-7,9,11,13-Tetraenoic Acid | 5(S),6(R),15(S)-Trihydroxyeicosa-7E,9E,11Z,13E-Tetraenoic Acid | 5S,6R,15S-Trihydroxy-7,9,13-trans-11-cis-Eicosatetraenoic Acid | 5S,6R,15S-Trihydroxy-7E,9E,11Z,13E-Eicosatetraenoic Acid | 5S,6R-LipoxinA4 | 6R-LXA4 | LXA4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412769","t(4;14) Negative","C175297","A cytogenetic finding indicating that the translocation t(4;14) has not been detected in a sample.","t(4;14) Negative | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412651","t(4;14) Positive","C175298","A cytogenetic finding indicating that the translocation t(4;14) has been detected in a sample.","t(4;14) Positive | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412626","Inactivating KDM6A Gene Mutation","C175326","A change in the nucleotide sequence of the KDM6A gene that inhibits expression or results in the translation of either low-activity or inactive forms of the lysine-specific demethylase 6A protein.","Inactivating KDM6A Gene Mutation | Inactivating KABUK2 Gene Mutation | Inactivating KDM6A Mutation | Inactivating Lysine (K)-Specific Demethylase 6A Gene Mutation | Inactivating Lysine Demethylase 6A Gene Mutation | Inactivating UTX Gene Mutation | KDM6A Gene Inactivation | KDM6A Inactivating Gene Mutation | KDM6A Inactivating Mutation | KDM6A Inactivation | KDM6A Loss of Function Gene Mutation | KDM6A Loss of Function Mutation | Loss of Function KDM6A Gene Mutation | Loss of Function KDM6A Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412627","Inactivating KMT2C Gene Mutation","C175328","A change in the nucleotide sequence of the KMT2C gene that inhibits expression or results in the translation of either low-activity or inactive forms of the histone-lysine N- methyltransferase 2C protein.","Inactivating KMT2C Gene Mutation | Inactivating HALR Gene Mutation | Inactivating KMT2C Mutation | Inactivating Lysine (K)-Specific Methyltransferase 2C Gene Mutation | Inactivating Lysine Methyltransferase 2C Gene Mutation | Inactivating MLL3 Gene Mutation | Inactivating Myeloid/Lymphoid or Mixed-Lineage Leukemia 3 Gene Mutation | KMT2C Gene Inactivation | KMT2C Inactivating Gene Mutation | KMT2C Inactivating Mutation | KMT2C Inactivation | KMT2C Loss of Function Gene Mutation | KMT2C Loss of Function Mutation | Loss of Function KMT2C Gene Mutation | Loss of Function KMT2C Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412682","Inactivating KMT2D Gene Mutation","C175331","A change in the nucleotide sequence of the KMT2D gene that inhibits expression or results in the translation of either low-activity or inactive forms of the histone-lysine N- methyltransferase 2D protein.","Inactivating KMT2D Gene Mutation | Inactivating ALR Gene Mutation | Inactivating CAGL114 Gene Mutation | Inactivating KABUK1 Gene Mutation | Inactivating KMS Gene Mutation | Inactivating KMT2D Mutation | Inactivating Lysine (K)-Specific Methyltransferase 2D Gene Mutation | Inactivating Lysine Methyltransferase 2D Gene Mutation | Inactivating MLL2 Gene Mutation | Inactivating MLL4 Gene Mutation | Inactivating Myeloid/Lymphoid or Mixed-Lineage Leukemia 2 Gene Mutation | Inactivating TNRC21 Gene Mutation | KMT2D Gene Inactivation | KMT2D Inactivating Gene Mutation | KMT2D Inactivating Mutation | KMT2D Inactivation | KMT2D Loss of Function Gene Mutation | KMT2D Loss of Function Mutation | Loss of Function KMT2D Gene Mutation | Loss of Function KMT2D Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412663","SMARCA2 Gene Inactivation","C175350","A change in the nucleotide sequence of the SMARCA2 gene that inhibits expression or results in the translation of either low-activity or inactive forms of the probable global transcription activator SNF2L2 protein.","SMARCA2 Gene Inactivation | Inactivating BAF190B Gene Mutation | Inactivating BRM Gene Mutation | Inactivating SMARCA2 Gene Mutation | Inactivating SMARCA2 Mutation | Inactivating SNF2-Like 2 Gene Mutation | Inactivating SNF2A Gene Mutation | Inactivating SNF2L2 Gene Mutation | Inactivating SNF2LA Gene Mutation | Inactivating SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily A, Member 2 Gene Mutation | Loss of Function SMARCA2 Mutation | SMARCA2 Inactivating Gene Mutation | SMARCA2 Inactivating Mutation | SMARCA2 Inactivation | SMARCA2 Loss of Function Gene Mutation | SMARCA2 Loss of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412664","EGFR NP_005219.2:p.L833V","C175353","A change in the amino acid residue at position 833 in the epidermal growth factor receptor protein where leucine has been replaced by valine.","EGFR NP_005219.2:p.L833V | EGFR L833V | EGFR L833V Mutation | EGFR Leu833Val | EGFR NP_005219.2:p.Leu833Val | EGFR p.L833V | EGFR p.Leu833Val | Epidermal Growth Factor Receptor L833V | Epidermal Growth Factor Receptor Leu833Val | NP_005219.2:p.L833V | NP_005219.2:p.Leu833Val | Proto-Oncogene c-ErbB-1 L833V | Proto-Oncogene c-ErbB-1 Leu833Val | Receptor Tyrosine-Protein Kinase erbB-1 L833V | Receptor Tyrosine-Protein Kinase erbB-1 Leu833Val",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412661","EGFR NP_005219.2:p.V834L","C175356","A change in the amino acid residue at position 834 in the epidermal growth factor receptor protein where valine has been replaced by leucine.","EGFR NP_005219.2:p.V834L | EGFR NP_005219.2:p.Val834Leu | EGFR V834L | EGFR V834L Mutation | EGFR Val834Leu | EGFR p.V834L | EGFR p.Val834Leu | Epidermal Growth Factor Receptor V834L | Epidermal Growth Factor Receptor Val834Leu | NP_005219.2:p.V834L | NP_005219.2:p.Val834Leu | Proto-Oncogene c-ErbB-1 V834L | Proto-Oncogene c-ErbB-1 Val834Leu | Receptor Tyrosine-Protein Kinase erbB-1 V834L | Receptor Tyrosine-Protein Kinase erbB-1 Val834Leu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412660","EGFR NP_005219.2:p.A871E","C175357","A change in the amino acid residue at position 871 in the epidermal growth factor receptor protein where alanine has been replaced by glutamic acid.","EGFR NP_005219.2:p.A871E | EGFR A871E | EGFR A871E Mutation | EGFR Ala871Glu | EGFR NP_005219.2:p.Ala871Glu | EGFR p.A871E | EGFR p.Ala871Glu | Epidermal Growth Factor Receptor A871E | Epidermal Growth Factor Receptor Ala871Glu | NP_005219.2:p.A871E | NP_005219.2:p.Ala871Glu | Proto-Oncogene c-ErbB-1 A871E | Proto-Oncogene c-ErbB-1 Ala871Glu | Receptor Tyrosine-Protein Kinase erbB-1 A871E | Receptor Tyrosine-Protein Kinase erbB-1 Ala871Glu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412655","EGFR NP_005219.2:p.K860I","C175358","A change in the amino acid residue at position 860 in the epidermal growth factor receptor protein where lysine has been replaced by isoleucine.","EGFR NP_005219.2:p.K860I | EGFR K860I | EGFR K860I Mutation | EGFR Lys860Ile | EGFR NP_005219.2:p.Lys860Ile | EGFR p.K860I | EGFR p.Lys860Ile | Epidermal Growth Factor Receptor K860I | Epidermal Growth Factor Receptor Lys860Ile | NP_005219.2:p.K860I | NP_005219.2:p.Lys860Ile | Proto-Oncogene c-ErbB-1 K860I | Proto-Oncogene c-ErbB-1 Lys860Ile | Receptor Tyrosine-Protein Kinase erbB-1 K860I | Receptor Tyrosine-Protein Kinase erbB-1 Lys860Ile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412654","EGFR NP_005219.2:p.A859S","C175359","A change in the amino acid residue at position 859 in the epidermal growth factor receptor protein where alanine has been replaced by serine.","EGFR NP_005219.2:p.A859S | EGFR A859S | EGFR A859S Mutation | EGFR Ala859Ser | EGFR NP_005219.2:p.Ala859Ser | EGFR p.A859S | EGFR p.Ala859Ser | Epidermal Growth Factor Receptor A859S | Epidermal Growth Factor Receptor Ala859Ser | NP_005219.2:p.A859S | NP_005219.2:p.Ala859Ser | Proto-Oncogene c-ErbB-1 A859S | Proto-Oncogene c-ErbB-1 Ala859Ser | Receptor Tyrosine-Protein Kinase erbB-1 A859S | Receptor Tyrosine-Protein Kinase erbB-1 Ala859Ser",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412707","EGFR NP_005219.2:p.V843I","C175362","A change in the amino acid residue at position 843 in the epidermal growth factor receptor protein where valine has been replaced by isoleucine.","EGFR NP_005219.2:p.V843I | EGFR NP_005219.2:p.Val843Ile | EGFR V843I | EGFR V843I Mutation | EGFR Val843Ile | EGFR p.V843I | EGFR p.Val843Ile | Epidermal Growth Factor Receptor V843I | Epidermal Growth Factor Receptor Val843Ile | NP_005219.2:p.V843I | NP_005219.2:p.Val843Ile | Proto-Oncogene c-ErbB-1 V843I | Proto-Oncogene c-ErbB-1 Val843Ile | Receptor Tyrosine-Protein Kinase erbB-1 V843I | Receptor Tyrosine-Protein Kinase erbB-1 Val843Ile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412703","EGFR NP_005219.2:p.E709K","C175366","A change in the amino acid residue at position 709 in the epidermal growth factor receptor protein where glutamic acid has been replaced by lysine.","EGFR NP_005219.2:p.E709K | Activating E709K Mutation | EGFR E709K | EGFR E709K Mutation | EGFR Glu709Lys | EGFR NP_005219.2:p.Glu709Lys | EGFR p.E709K | EGFR p.Glu709Lys | Epidermal Growth Factor Receptor E709K | Epidermal Growth Factor Receptor Glu709Lys | NP_005219.2:p.E709K | NP_005219.2:p.Glu709Lys | Proto-Oncogene c-ErbB-1 E709K | Proto-Oncogene c-ErbB-1 Glu709Lys | Receptor Tyrosine-Protein Kinase erbB-1 E709K | Receptor Tyrosine-Protein Kinase erbB-1 Glu709Lys",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412702","EGFR NP_005219.2:p.H870R","C175367","A change in the amino acid residue at position 870 in the epidermal growth factor receptor protein where histidine has been replaced by arginine.","EGFR NP_005219.2:p.H870R | EGFR H870R | EGFR H870R Mutation | EGFR His870Arg | EGFR NP_005219.2:p.His870Arg | EGFR p.H870R | EGFR p.His870Arg | Epidermal Growth Factor Receptor H870R | Epidermal Growth Factor Receptor His870Arg | NP_005219.2:p.H870R | NP_005219.2:p.His870Arg | Proto-Oncogene c-ErbB-1 H870R | Proto-Oncogene c-ErbB-1 His870Arg | Receptor Tyrosine-Protein Kinase erbB-1 H870R | Receptor Tyrosine-Protein Kinase erbB-1 His870Arg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412704","EGFR NP_005219.2:p.H835L","C175369","A change in the amino acid residue at position 835 in the epidermal growth factor receptor protein where histidine has been replaced by leucine.","EGFR NP_005219.2:p.H835L | EGFR H835L | EGFR H835L Mutation | EGFR His835Leu | EGFR NP_005219.2:p.His835Leu | EGFR p.H835L | EGFR p.His835Leu | Epidermal Growth Factor Receptor H835L | Epidermal Growth Factor Receptor His835Leu | NP_005219.2:p.H835L | NP_005219.2:p.His835Leu | Proto-Oncogene c-ErbB-1 H835L | Proto-Oncogene c-ErbB-1 His835Leu | Receptor Tyrosine-Protein Kinase erbB-1 H835L | Receptor Tyrosine-Protein Kinase erbB-1 His835Leu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417913","OAS2 Gene","C175370","This gene plays a role in viral RNA degradation and the inhibition of viral replication.","OAS2 Gene | 2'-5'-Oligoadenylate Synthetase 2 Gene | OAS2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415898","IFITM3 Gene","C175373","This gene is involved in interferon-induced disruption of intracellular cholesterol homeostasis.","IFITM3 Gene | IFITM3 | Interferon Induced Transmembrane Protein 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415892","IFIT1 Gene","C175377","This gene plays a role in viral RNA binding.","IFIT1 Gene | IFIT1 | Interferon Induced Protein with Tetratricopeptide Repeats 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412697","Clostridium difficile Toxin A Positive","C175381","An indication that Clostridium difficile toxin A was detected in a sample.","Clostridium difficile Toxin A Positive | C. diff. Toxin A Positive | C. difficile Toxin A Positive | Clostridium difficile A Toxin Positive | TcdA Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412694","Clostridium difficile Toxin B Positive","C175382","An indication that Clostridium difficile toxin B was detected in a sample.","Clostridium difficile Toxin B Positive | C. diff. Toxin B Positive | C. difficile Toxin B Positive | Clostridium difficile B Toxin Positive | TcdB Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538595","PBK Gene","C175385","This gene plays a role in the phosphorylation of p38 MAP kinase.","PBK Gene | PBK | PDZ Binding Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412692","CD27 Positive","C175388","An indication that CD27 expression has been detected in a sample.","CD27 Positive | CD27 Antigen Positive | CD27 Molecule Positive | CD27L Receptor Positive | T-Cell Activation Antigen CD27 Positive | T-Cell Activation Antigen S152 Positive | TNFRSF7 Positive | Tumor Necrosis Factor Receptor Superfamily Member 7 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412686","Free Testosterone Less than 70 pg/mL","C175391","A semiquantitative finding indicating that the concentration of free testosterone in a sample is less than 70 pg/mL.","Free Testosterone Less than 70 pg/mL | Free Testosterone Less than 70 Picograms per Milliliter | Free Testosterone Less than 70 Picograms/Milliliter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412689","Testosterone Less than 348 ng/dL","C175392","A semiquantitative finding indicating that the concentration of testosterone in a sample is less than 348 ng/dL.","Testosterone Less than 348 ng/dL | Testosterone Less than 348 Nanograms per Deciliter | Testosterone Less than 348 Nanograms/Deciliter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412688","MAGEA1 Positive","C175393","An indication that expression of MAGEA1 has been detected in a sample.","MAGEA1 Positive | Antigen MZ2 E Positive | Antigen MZ2-E Positive | CT1.1 Positive | Cancer/Testis Antigen 1.1 Positive | MAGE-1 Antigen Positive | MAGE1 Positive | Melanoma-Associated Antigen 1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412735","NTHL1 Gene Mutation","C175394","A change in the nucleotide sequence of the NTHL1 gene.","NTHL1 Gene Mutation | NTH1 Gene Mutation | Nth Like DNA Glycosylase 1 Gene Mutation | OCTS3 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412734","SMAD4 Gene Mutation","C175395","A change in the nucleotide sequence of the SMAD4 gene.","SMAD4 Gene Mutation | DPC4 Gene Mutation | JIP Gene Mutation | MADH4 Gene Mutation | MYHRS Gene Mutation | Mothers Against Decapentaplegic Homolog 4 Gene Mutation | SMAD Family Member 4 Gene Mutation | SMAD4/DPC4 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412737","Inactivating BRIP1 Gene Mutation","C175396","A mutation in the BRIP1 gene that either inhibits the expression of or results in the translation of an inactive Fanconi anemia group J protein.","Inactivating BRIP1 Gene Mutation | BRIP1 Gene Inactivation | BRIP1 Inactivating Gene Mutation | BRIP1 Inactivating Mutation | BRIP1 Inactivation | BRIP1 Loss of Function Gene Mutation | BRIP1 Loss of Function Mutation | Inactivating BACH1 Gene Mutation | Inactivating BRCA1 Interacting Protein C-Terminal Helicase 1 Gene Mutation | Inactivating BRIP1 Mutation | Inactivating FANCJ Gene Mutation | Inactivating FANCJ Mutation | Loss of Function BRIP1 Gene Mutation | Loss of Function BRIP1 Mutation | Loss of Function FANCJ Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412736","Inactivating FANCG Gene Mutation","C175397","A mutation in the FANCG gene that either inhibits the expression of or results in the translation of an inactive Fanconi anemia group G protein.","Inactivating FANCG Gene Mutation | FANCG Gene Inactivation | FANCG Inactivating Gene Mutation | FANCG Inactivating Mutation | FANCG Inactivation | FANCG Loss of Function Gene Mutation | FANCG Loss of Function Mutation | Inactivating FA Complementation Group G Gene Mutation | Inactivating FACG Gene Mutation | Inactivating FAG Gene Mutation | Inactivating FANCG Mutation | Inactivating Fanconi Anemia Complementation Group G Gene Mutation | Inactivating Fanconi Anemia, Complementation Group G Gene Mutation | Inactivating X-Ray Repair Complementing Defective Repair In Chinese Hamster Cells 9 Gene Mutation | Inactivating XRCC9 Gene Mutation | Loss of Function FANCG Gene Mutation | Loss of Function FANCG Mutation | Loss of Function XRCC9 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412731","Inactivating PALB2 Gene Mutation","C175398","A mutation in the PALB2 gene that either inhibits the expression of or results in the translation of an inactive partner and localizer of BRCA2 protein.","Inactivating PALB2 Gene Mutation | Inactivating FANCN Gene Mutation | Inactivating FANCN Mutation | Inactivating Fanconi Anemia, Complementation Group N Gene Mutation | Inactivating PALB2 Mutation | Inactivating PNCA3 Gene Mutation | Inactivating Partner and Localizer of BRCA2 Gene Mutation | Loss of Function FANCN Gene Mutation | Loss of Function PALB2 Gene Mutation | Loss of Function PALB2 Mutation | PALB2 Gene Inactivation | PALB2 Inactivating Gene Mutation | PALB2 Inactivating Mutation | PALB2 Inactivation | PALB2 Loss of Function Gene Mutation | PALB2 Loss of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412730","Inactivating FANCL Gene Mutation","C175399","A mutation in the FANCL gene that either inhibits the expression of or results in the translation of an inactive Fanconi anemia group L protein.","Inactivating FANCL Gene Mutation | FANCL Gene Inactivation | FANCL Inactivating Gene Mutation | FANCL Inactivating Mutation | FANCL Inactivation | FANCL Loss of Function Gene Mutation | FANCL Loss of Function Mutation | Inactivating FAAP43 Gene Mutation | Inactivating FANCL Mutation | Inactivating Fanconi Anemia Complementation Group L Gene Mutation | Inactivating Fanconi Anemia, Complementation Group L Gene Mutation | Inactivating PHD Finger Protein 9 Gene Mutation | Inactivating PHF9 Gene Mutation | Inactivating POG Gene Mutation | Loss of Function FANCL Gene Mutation | Loss of Function FANCL Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412733","Inactivating FANCM Gene Mutation","C175400","A mutation in the FANCM gene that either inhibits the expression of or results in the translation of an inactive Fanconi anemia group M protein.","Inactivating FANCM Gene Mutation | FANCM Gene Inactivation | FANCM Inactivating Gene Mutation | FANCM Inactivating Mutation | FANCM Inactivation | FANCM Loss of Function Gene Mutation | FANCM Loss of Function Mutation | Inactivating FAAP250 Gene Mutation | Inactivating FANCM Mutation | Inactivating Fanconi Anemia Complementation Group M Gene Mutation | Inactivating Fanconi Anemia, Complementation Group M Gene Mutation | Loss of Function FANCM Gene Mutation | Loss of Function FANCM Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412732","Inactivating FANCE Gene Mutation","C175401","A mutation in the FANCE gene that either inhibits the expression of or results in the translation of an inactive Fanconi anemia group E protein.","Inactivating FANCE Gene Mutation | FANCE Gene Inactivation | FANCE Inactivating Gene Mutation | FANCE Inactivating Mutation | FANCE Inactivation | FANCE Loss of Function Gene Mutation | FANCE Loss of Function Mutation | Inactivating FACE Gene Mutation | Inactivating FAE Gene Mutation | Inactivating FANCE Mutation | Inactivating Fanconi Anemia Complementation Group E Gene Mutation | Inactivating Fanconi Anemia, Complementation Group E Gene Mutation | Loss of Function FANCE Gene Mutation | Loss of Function FANCE Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412727","Inactivating FANCD2 Gene Mutation","C175402","A mutation in the FANCD2 gene that either inhibits the expression of or results in the translation of an inactive Fanconi anemia group D2 protein.","Inactivating FANCD2 Gene Mutation | FANCD2 Gene Inactivation | FANCD2 Inactivating Gene Mutation | FANCD2 Inactivating Mutation | FANCD2 Inactivation | FANCD2 Loss of Function Gene Mutation | FANCD2 Loss of Function Mutation | Inactivating FA-D2 Gene Mutation | Inactivating FA4 Gene Mutation | Inactivating FACD Gene Mutation | Inactivating FAD Gene Mutation | Inactivating FAD2 Gene Mutation | Inactivating FANCD2 Mutation | Inactivating Fanconi Anemia Complementation Group D2 Gene Mutation | Inactivating Fanconi Anemia, Complementation Group D2 Gene Mutation | Loss of Function FANCD2 Gene Mutation | Loss of Function FANCD2 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412726","Inactivating FANCF Gene Mutation","C175403","A mutation in the FANCF gene that either inhibits the expression of or results in the translation of an inactive Fanconi anemia group F protein.","Inactivating FANCF Gene Mutation | FANCF Gene Inactivation | FANCF Inactivating Gene Mutation | FANCF Inactivating Mutation | FANCF Inactivation | FANCF Loss of Function Gene Mutation | FANCF Loss of Function Mutation | Inactivating FAF Gene Mutation | Inactivating FANCF Mutation | Inactivating Fanconi Anemia Complementation Group F Gene Mutation | Inactivating Fanconi Anemia, Complementation Group F Gene Mutation | Loss of Function FANCF Gene Mutation | Loss of Function FANCF Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412729","Inactivating FANCI Gene Mutation","C175404","A mutation in the FANCI gene that either inhibits the expression of or results in the translation of an inactive Fanconi anemia group I protein.","Inactivating FANCI Gene Mutation | FANCI Gene Inactivation | FANCI Inactivating Gene Mutation | FANCI Inactivating Mutation | FANCI Inactivation | FANCI Loss of Function Gene Mutation | FANCI Loss of Function Mutation | Inactivating FA Complementation Group I Gene | Inactivating FACI Gene Mutation | Inactivating FANCI Mutation | Inactivating Fanconi Anemia Complementation Group I Gene Mutation | Inactivating Fanconi Anemia, Complementation Group I Gene Mutation | Loss of Function FANCI Gene Mutation | Loss of Function FANCI Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412728","Inactivating FANCB Gene Mutation","C175405","A mutation in the FANCB gene that either inhibits the expression of or results in the translation of an inactive Fanconi anemia group B protein.","Inactivating FANCB Gene Mutation | FANCB Gene Inactivation | FANCB Inactivating Gene Mutation | FANCB Inactivating Mutation | FANCB Inactivation | FANCB Loss of Function Gene Mutation | FANCB Loss of Function Mutation | Inactivating FA Complementation Group B Gene Mutation | Inactivating FA2 Gene Mutation | Inactivating FAAP90 Gene Mutation | Inactivating FAAP95 Gene Mutation | Inactivating FAB Gene Mutation | Inactivating FACB Gene Mutation | Inactivating FANCB Mutation | Inactivating Fanconi Anemia Complementation Group B Gene Mutation | Inactivating Fanconi Anemia, Complementation Group B Gene Mutation | Loss of Function FANCB Gene Mutation | Loss of Function FANCB Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412723","Inactivating FANCC Gene Mutation","C175406","A mutation in the FANCC gene that either inhibits the expression of or results in the translation of an inactive Fanconi anemia group C protein.","Inactivating FANCC Gene Mutation | FANCC Gene Inactivation | FANCC Inactivating Gene Mutation | FANCC Inactivating Mutation | FANCC Inactivation | FANCC Loss of Function Gene Mutation | FANCC Loss of Function Mutation | Inactivating FA3 Gene Mutation | Inactivating FAC Gene Mutation | Inactivating FACC Gene Mutation | Inactivating FANCC Mutation | Inactivating Fanconi Anemia Complementation Group C Gene Mutation | Inactivating Fanconi Anemia, Complementation Group C Gene Mutation | Inactivating Fanconi Anemia, Type 3 Gene Mutation | Loss of Function FANCC Gene Mutation | Loss of Function FANCC Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412722","Inactivating FANCA Gene Mutation","C175407","A mutation in the FANCA gene that either inhibits the expression of or results in the translation of an inactive Fanconi anemia group A protein.","Inactivating FANCA Gene Mutation | FANCA Gene Inactivation | FANCA Inactivating Gene Mutation | FANCA Inactivating Mutation | FANCA Inactivation | FANCA Loss of Function Gene Mutation | FANCA Loss of Function Mutation | Inactivating FA Gene Mutation | Inactivating FA-H Gene Mutation | Inactivating FA1 Gene Mutation | Inactivating FAA Gene Mutation | Inactivating FACA Gene Mutation | Inactivating FAH Gene Mutation | Inactivating FANCA Mutation | Inactivating FANCH Gene Mutation | Inactivating Fanconi Anemia Complementation Group A Gene Mutation | Inactivating Fanconi Anemia, Complementation Group A Gene Mutation | Inactivating Fanconi Anemia, Complementation Group H Gene Mutation | Inactivating Fanconi Anemia, Type 1 Gene Mutation | Loss of Function FANCA Gene Mutation | Loss of Function FANCA Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412725","HLA-DRB1*04:01 Positive Cells Present","C175408","An indication that cells expressing HLA-DRB1*04:01 have been detected in a sample.","HLA-DRB1*04:01 Positive Cells Present | DRB1*0401 Positive | DRB1*0401 Positive Cells Present | HLA-DRB1*0401 Positive | HLA-DRB1*0401 Positive Cells Present | HLA-DRB1*04:01 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412724","HLA-DRB1*04:04 Positive Cells Present","C175409","An indication that cells expressing HLA-DRB1*04:04 have been detected in a sample.","HLA-DRB1*04:04 Positive Cells Present | DRB1*0404 Positive | DRB1*0404 Positive Cells Present | HLA-DRB1*0404 Positive | HLA-DRB1*0404 Positive Cells Present | HLA-DRB1*04:04 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412720","IA-2-autoantibody","C175410","An autoantibody that recognizes receptor-type tyrosine-protein phosphatase-like N protein.","PTPRN Autoantibody | Anti-IA-2 Autoantibody | Anti-IA2 Autoantibody | Anti-ICA 512 Autoantibody | Anti-Insulinoma-Associated Tyrosine-Phosphatase-Like Protein Autoantibody | Anti-Islet Antigen 2 Autoantibody | Anti-PTP IA-2 Autoantibody | Anti-PTPRN Autoantibody | Anti-R-PTP-N Autoantibody | Anti-Receptor-Type Tyrosine-Protein Phosphatase-Like N Autoantibody | IA-2 Autoantibody | IA-2A | IA2 Autoantibody | ICA 512 Autoantibody | Insulinoma-Associated Protein 2 Autoantibody | Insulinoma-Associated Tyrosine-Phosphatase-Like Protein Autoantibody | Islet Antigen 2 Autoantibody | Islet Cell Antigen 2 Autoantibody | Islet Cell Antigen 512 Autoantibody | Islet Cell Autoantigen 3 Autoantibody | Islet-Antigen 2 Specific Autoantibody | PTP IA-2 Autoantibody | Protein Tyrosine Phosphatase-Like N Autoantibody | R-PTP-N Autoantibody | Receptor Type Protein Tyrosine Phosphatase N Autoantibody | Receptor-Type Tyrosine-Protein Phosphatase-Like N Autoantibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412721","HLA-DRB1*15:01/HLA-DQA1*01:02/HLA-DQB1*06:02 Positive","C175412","A finding indicating that an individual has a human leukocyte antigen (HLA) genotype profile that includes expression of HLA-DRB1*15:01, HLA-DQA1*01:02 and HLA-DQB1*06:02.","HLA-DRB1*15:01/HLA-DQA1*01:02/HLA-DQB1*06:02 Positive | HLA-DRB1*1501-DQA1*0102-DQB1*0602 | HLA-DRB1*1501-DQA1*0102-DQB1*0602 Positive | HLA-DRB1*1501/HLA-DQA1*0102/HLA-DQB1*0602 | HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 | HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Positive | HLA-DRB1*15:01/HLA-DQA1*01:02/HLA-DQB1*06:02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412718","SLC30A8 Autoantibody","C175416","An autoantibody that recognizes zinc transporter 8 protein.","SLC30A8 Autoantibody | Anti-SLC30A8 Autoantibody | Anti-Solute Carrier Family 30 Member 8 Autoantibody | Anti-ZNT8 Autoantibody | Anti-Zinc Transporter 8 Autoantibody | Anti-ZnT-8 Autoantibody | Solute Carrier Family 30 Member 8 Autoantibody | ZNT8 Autoantibody | ZNT8A | Zinc Transporter 8 Autoantibody | ZnT-8 Autoantibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412717","MAP2K2 Fusion Positive","C175417","An indication that the expression of a MAP2K2 fusion has been detected in a sample.","MAP2K2 Fusion Positive | Dual Specificity Mitogen-Activated Protein Kinase Kinase 2 Fusion Positive | ERK Activator Kinase 2 Fusion Positive | MAP Kinase Kinase 2 Fusion Positive | MAPK/ERK Kinase 2 Fusion Positive | MAPKK 2 Fusion Positive | MAPKK2 Fusion Positive | MEK 2 Fusion Positive | MEK-2 Fusion Positive | MEK2 Fusion Positive | MKK 2 Fusion Positive | MKK2 Fusion Positive | Mitogen-Activated Protein Kinase Kinase 2 Fusion Positive | PRKMK2 Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412713","MAPK3 Gene Mutation","C175418","A change in the nucleotide sequence of the MAPK3 gene.","MAPK3 Gene Mutation | ERK-1 Gene Mutation | ERK1 Gene Mutation | ERT2 Gene Mutation | Mitogen-Activated Protein Kinase 3 Gene Mutation | P44ERK1 Gene Mutation | P44MAPK Gene Mutation | PRKM3 Gene Mutation | p44-ERK1 Gene Mutation | p44-MAPK Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412712","MAPK1 Fusion Positive","C175419","An indication that the expression of a MAPK1 fusion has been detected in a sample.","MAPK1 Fusion Positive | ERK-2 Fusion Positive | ERK2 Fusion Positive | Extracellular Signal-Regulated Kinase 2 Fusion Positive | MAPK 1 Fusion Positive | MAPK2 Fusion Positive | Mitogen-Activated Protein Kinase 1 Fusion Positive | P42MAPK Fusion Positive | PRKM1 Fusion Positive | PRKM2 Fusion Positive | p42-MAPK Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412715","MAP2K1 Fusion Positive","C175420","An indication that the expression of a MAP2K1 fusion has been detected in a sample.","MAP2K1 Fusion Positive | Dual Specificity Mitogen-Activated Protein Kinase Kinase 1 Fusion Positive | ERK Activator Kinase 1 Fusion Positive | MAP Kinase Kinase 1 Fusion Positive | MAPK/ERK Kinase 1 Fusion Positive | MAPKK 1 Fusion Positive | MAPKK1 Fusion Positive | MEK 1 Fusion Positive | MEK-1 Fusion Positive | MEK1 Fusion Positive | MKK 1 Fusion Positive | MKK1 Fusion Positive | Mitogen-Activated Protein Kinase Kinase 1 Fusion Positive | PRKMK1 Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412714","MAPK3 Fusion Positive","C175421","An indication that the expression of a MAPK3 fusion has been detected in a sample.","MAPK3 Fusion Positive | ERK-1 Fusion Positive | ERK1 Fusion Positive | ERT2 Fusion Positive | Extracellular Signal-Regulated Kinase 1 Fusion Positive | Insulin-Stimulated MAP2 Kinase Fusion Positive | MAPK 3 Fusion Positive | Microtubule-Associated Protein 2 Kinase Fusion Positive | Mitogen-Activated Protein Kinase 3 Fusion Positive | P44ERK1 Fusion Positive | P44MAPK Fusion Positive | PRKM3 Fusion Positive | p44-ERK1 Fusion Positive | p44-MAPK Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412711","NTSR1 Positive","C175425","An indication that NTSR1 expression has been detected in a sample.","NTSR1 Positive | NT-R-1 Positive | NTR Positive | NTR1 Positive | NTRH Positive | Neurotensin Receptor 1 Positive | Neurotensin Receptor Type 1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412827","Oxidized RyR1 Measurement","C175426","The determination of the amount of oxidized ryanodine receptor 1 in a sample.","Oxidized RyR1 Measurement | Oxidized Ryanodine Receptor 1 Measurement | RyR1 Oxidation Measurement | Ryanodine Receptor 1 Oxidation Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1168499","Thyroglobulin Antibody Positive","C175427","An indication that antibodies that recognize thyroglobulin have been detected in a sample.","Thyroglobulin Antibody Positive | Anti-TG Antibody Positive | Anti-Thyroglobulin Antibody Positive | TG Antibody Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977857","subjectHeight","C164634","The vertical measurement or distance from the base to the top of a subject or participant.","Body Height | Height | height | subjectHeight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1275564","Every Seventy Two Hours","C174288","Planned or occurring every seventy-two hours.","Every Seventy Two Hours | Every 72 hours | Q72H",,,,,,,,,,,,,,,"4262460","Every seventy two hours",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1411674","Sudden Death Indicator","C174284","An indication as to whether death was unexpected or occurred without warning.","Sudden Death Indicator | SDTHIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411678","QTc Correction Method Unspecified, Aggregate","C174285","A QT aggregate interval that is corrected for heart rate by unspecified correction method, or by non-standard correction methods.","QTc Correction Method Unspecified, Aggregate | QTCUNSAG | QTc Corr Method Unspecified, Aggregate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411722","Glucose Management Indicator Mmol/mol Formula","C174290","A formula to calculate the glucose management indicator (GMI) in mmol/mol. GMI = 12.71 + 4.70587 x [mean glucose in mmol/L]. (Richard M. Bergenstal, Roy W. Beck, Kelly L. Close, et al. Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring. Diabetes Care 2018 Nov; 41(11): 2275-2280.)","Glucose Management Indicator Mmol/mol Formula | GMI MMOL/MOL FORMULA | Glucose Management Indicator mmol/mol Formula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411721","Glucose Management Indicator Percentage Formula","C174289","A formula to calculate the glucose management indicator (GMI) as a percentage. GMI = 3.31 + 0.02392 x [mean glucose in mg/dL]. (Richard M. Bergenstal, Roy W. Beck, Kelly L. Close, et al. Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring. Diabetes Care 2018 Nov; 41(11): 2275-2280.)","Glucose Management Indicator Percentage Formula | GMI % FORMULA | Glucose Management Indicator % Formula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411959","Hepcidin Measurement","C174387","A measurement of the hepcidin in a sample.","Hepcidin Measurement | HAMP Measurement | HEPCIDIN | Hepcidin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411704","B-Lymphocyte to Total Cells Ratio Measurement","C174317","A measurement of the B-lymphocyte to total cells ratio in a sample.","B-Lymphocyte to Total Cells Ratio Measurement | B-Lymphocytes to Total Cells Ratio Measurement | B-Lymphocytes/Total Cells | BLYCECE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411703","B-Lymphocyte to Leukocyte Ratio Measurement","C174316","The determination of the ratio of B-lymphocytes to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","B-Lymphocyte to Leukocyte Ratio Measurement | B Cells/Leukocytes | B-Lymphocytes to Leukocytes Ratio Measurement | B-Lymphocytes/Leukocytes | BLYCELE | BLym/Leuk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411705","B-Lymphocyte to Lymphocyte Ratio Measurement","C174315","A measurement of the B-lymphocyte to lymphocyte ratio in a sample.","B-Lymphocyte to Lymphocyte Ratio Measurement | B-Lymphocytes/Lymphocytes | BLYCELY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1167996","B-Lymphocyte Count","C174314","A measurement of the B-lymphocyte count in a sample.","B-Lymphocyte Count | B-Cell Count | B-Cell Lymphocytes | B-Cells | B-Lymphocytes | BLYCE",,,,,,,,,,,,,,,"4041971","B lymphocyte count",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0427597","Factor XIII Activity Measurement","C174313","A measurement of the factor XIII activity in a sample.","Factor XIII Activity Measurement | FCTXIIIA | Factor XIII Activity",,,,,,,,,,,,,,,"4194632","Clotting factor XIII assay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1411712","Soluble TNF Receptor Superfamily Member 5 Measurement","C174312","A measurement of the soluble TNF receptor superfamily member 5 in a sample.","Soluble TNF Receptor Superfamily Member 5 Measurement | Soluble B-cell Surface Antigen CD40 | Soluble Bp50 | Soluble CD40 | Soluble CD40 Measurement | Soluble CDW40 | Soluble TNF Receptor Superfamily Mem 5 | Soluble TNF Receptor Superfamily Member 5 | Soluble TNFRSF5 | Soluble TNFRSF5 Measurement | Soluble Tumor Necrosis Factor Receptor Superfamily, Member 5 | Soluble p50 | TNFR5S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411714","Oxygen Saturation/Fraction Inspired O2","C174311","A relative measurement (ratio or percentage) of the oxygen-hemoglobin saturation of a volume of blood to the volumetric fraction of oxygen in the inhaled gas.","Oxygen Saturation/Fraction Inspired O2 | SAO2FIO2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411713","Glucose Management Indicator","C174310","An approximate measure (expressed as a % or mmol/mol) of an individual's expected hemoglobin A1c/hemoglobin level, based on the mean glucose measured over a period of at least 10 days by continuous glucose monitoring.","Glucose Management Indicator | GMI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411709","8-Hydroxy-2'-Deoxyguanosine Measurement","C174309","A measurement of the 8-hydroxy-2'-deoxyguanosine in a sample.","8-Hydroxy-2'-Deoxyguanosine Measurement | 8-Hydroxy-2'-Deoxyguanosine | 8-OHdG Measurement | 8-Oxo-dG Measurement | 8-oxo-dG | OH8DXG2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411708","Soluble TNF Superfamily Member 5 Measurement","C174308","A measurement of the soluble TNF superfamily member 5 in a sample.","Soluble TNF Superfamily Member 5 Measurement | Soluble CD154 | Soluble CD154 Measurement | Soluble CD40 Ligand | Soluble CD40 Ligand Measurement | Soluble CD40L | Soluble CD40LG | Soluble CD40LG Measurement | Soluble T-BAM | Soluble TNF Superfamily Member 5 | Soluble TNFSF5 | Soluble TNFSF5 Measurement | Soluble TRAP | Soluble gp39 | TNF5S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411711","FMS-like Receptor Tyrosine Kinase 3 Measurement","C174307","A measurement of the FMS-like receptor tyrosine kinase 3 in a sample.","FMS-like Receptor Tyrosine Kinase 3 Measurement | CD135 | FLT3 | FMS-like Receptor Tyrosine Kinase 3 | Soluble CD135",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411710","FMS-like Tyrosine Kinase 3 Ligand Measurement","C174306","A measurement of the FMS-like tyrosine kinase 3 ligand in a sample.","FMS-like Tyrosine Kinase 3 Ligand Measurement | FLT3L | FLT3L Measurement | FLT3LG Measurement | FMS-like Tyrosine Kinase 3 Ligand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411717","Hyalogranular Casts","C174305","A measurement of the hyalogranular casts in a sample.","Hyalogranular Casts | CSHYGR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412615","Phosphate Crystals Measurement","C174304","A measurement of the phosphate crystals in a sample.","Phosphate Crystals Measurement | CYPHOS | Phosphate Crystals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411719","VLDL Triglyceride Measurement","C174303","A measurement of the VLDL triglyceride in a sample.","VLDL Triglyceride Measurement | VLDL Triglyceride | VLDLT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411715","VLDL Triglyceride and Chylomicron Triglyceride Measurement","C174301","A measurement of the VLDL triglyceride and chylomicron triglyceride in a sample.","VLDL Triglyceride and Chylomicron Triglyceride Measurement | VLDL Trig + Chylomicron Trig | VLDL Triglyceride + Chylomicron Triglyceride | VLDLTCT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524240","Phentermine Measurement","C174299","A measurement of the phentermine in a sample.","Phentermine Measurement | PHTRMN | Phentermine | Phenyl-tertiary-butylamine",,,,,,,,,,,,,,,"4022503","Phentermine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1411716","D-Norpseudoephedrine Measurement","C174298","A measurement of the D-norpseudoephedrine in a sample.","D-Norpseudoephedrine Measurement | (+)-Norpseudoephedrine | Cathine | D-Norpseudoephedrine | DNPSEPHD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202453","Phenylpropanolamine Measurement","C174297","A measurement of the phenylpropanolamine in a sample.","Phenylpropanolamine Measurement | Beta-Hydroxyamphetamine | Norephedrine | PPA | Phenylpropanolamine",,,,,,,,,,,,,,,"4056292","Phenylpropanolamine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524117","Ephedrine Measurement","C174296","A measurement of the ephedrine in a sample.","Ephedrine Measurement | EPHD | Ephedrine",,,,,,,,,,,,,,,"4019671","Ephedrine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1412618","3,4-methylenedioxy-N-ethylamphetamine Measurement","C174295","A measurement of the 3,4-methylenedioxy-n-ethylamphetamine in a sample.","3,4-methylenedioxy-N-ethylamphetamine Measurement | 3,4-methylenedioxy-N-ethylamphetamine | Eve | MDE | MDEA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411723","3,4-methylenedioxyamphetamine Measurement","C174294","A measurement of the 3,4-methylenedioxyamphetamine in a sample.","3,4-methylenedioxyamphetamine Measurement | 3,4-methylenedioxyamphetamine | MDA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412621","Leptocyte Measurement","C174293","A measurement of the leptocytes in a sample.","Leptocyte Measurement | LEPTO | Leptocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411720","Renal Tubular Epithelial Casts Measurement","C174292","A measurement of the renal tubular epithelial casts in a sample.","Renal Tubular Epithelial Casts Measurement | CSEPIRT | Renal Tubular Epithelial Casts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523751","Lipoprotein Lipase Measurement","C174291","The determination of the amount of lipoprotein lipase in a sample.","Lipoprotein Lipase Measurement | LPL | LPL Measurement | Lipoprotein Lipase",,,,,,,,,,,,,,,"4020423","Lipoprotein lipase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1411809","Renal Epithelial Casts Measurement","C174229","A measurement of the renal epithelial cell casts in a biological specimen.","Renal Epithelial Casts Measurement | CSEPIR | Renal Epithelial Casts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229244","Palpebral Fissure","C174322","The elliptical shaped curve of the bottom border of the upper eyelid, extending from the medial canthus to the lateral canthus.","Palpebral Fissure | PALPEBRAL FISSURE",,,,,,,,,,,,,,,"4241972","Structure of palpebral fissure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011325","Dental Arch","C174321","The curved or bowlike structure formed by the arrangement of teeth within the jaw.","Dental Arch | DENTAL ARCH",,,,,,,,,,,,,,,"4195929","Dental arch structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1411706","Distal Extrahepatic Bile Duct Region","C174320","The area of the body that extends from where the cystic duct meets the common bile duct to the common bile duct's insertion into the small intestine.","Distal Extrahepatic Bile Duct Region | DISTAL EXTRAHEPATIC BILE DUCT REGION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411707","Extrahepatic Perihilar Bile Duct Region","C174319","The area of the body where the right and left hepatic ducts exit the liver and join to form the common hepatic duct that is proximal to the origin of the cystic duct. (PDQ)","Extrahepatic Perihilar Bile Duct Region | EXTRAHEPATIC PERIHILAR BILE DUCT REGION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL380904","Ostiomeatal Complex","C174318","A narrow channel that connects the frontal sinus, anterior ethmoid air cells, and maxillary sinus to the middle meatus, allowing drainage and ventilation. It includes the maxillary ostium, infundibulum, ethmoid bulla, uncinate process, and hiatus semilunaris.","Ostiomeatal Complex | OMU | OSTIOMEATAL COMPLEX | Osteomeatal Complex | Ostiomeatal Unit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411744","SARS-CoV-2 Neutralizing Antibody Measurement","C174329","The determination of the amount of SARS-CoV-2 neutralizing antibody in a biological sample.","SARS-CoV-2 Neutralizing Antibody Measurement | SAR2NAB | SARS-CoV-2 Neutralizing Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411743","Severe Acute Respiratory Syndrome-related Coronavirus Measurement","C174328","The determination of the amount of Severe Acute Respiratory Syndrome-related coronavirus in a biological sample.","Severe Acute Respiratory Syndrome-related Coronavirus Measurement | SARS-CoV | SARS-CoV-1 | SARSCOV1 | Severe Acute Resp Syndro-Rel Coronavirus | Severe Acute Respiratory Syndrome-Related Coronavirus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411746","SARS-CoV-1/SARS-CoV-2 Antigen Measurement","C174327","The determination of the amount of SARS-CoV-1 and/or SARS-CoV-2 Antigen in a biological sample.","SARS-CoV-1/SARS-CoV-2 Antigen Measurement | SAR12AG | SARS-CoV-1/SARS-CoV-2 Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411745","SARS-CoV-2 IgA/IgM Antibody Measurement","C174326","The determination of the amount of SARS-CoV-2 IgA and/or IgM Antibody in a biological sample.","SARS-CoV-2 IgA/IgM Antibody Measurement | SAR2IGAM | SARS-CoV-2 IgA/IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411741","SARS-CoV-2 IgM/IgA/IgG Antibody Measurement","C174325","The determination of the amount of SARS-CoV-2 IgM, IgA, and/or IgG Antibody in a biological sample.","SARS-CoV-2 IgM/IgA/IgG Antibody Measurement | SAR2IMAG | SARS-CoV-2 IgM/IgA/IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411740","SARS-related Coronavirus RNA/MERS RNA Measurement","C174324","The determination of the amount of SARS-related and/or MERS Coronavirus RNA which includes but not limited to SARS-CoV, SARS-CoV-2, other SARS-like Coronavirus, and/or MERS-CoV in a biological sample.","SARS-related Coronavirus RNA/MERS RNA Measurement | SARRMRNA | SARS-related Coronavirus RNA/MERS RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411742","SARS-related Coronavirus RNA Measurement","C174323","The determination of the amount of SARS-related coronavirus RNA (including but not limited to SARS-CoV, SARS-CoV-2, and/or other SARS-like Coronavirus) in a biological sample.","SARS-related Coronavirus RNA Measurement | SARS-related Coronavirus RNA | SARSRRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411733","METMAB Score","C174344","The histopathological evaluation of MET staining in tissue based on the METMAB scoring system. (Spigel DR, Ervin TJ, Ramlau RA, et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2013;31:4105–14.)","METMAB Score | METMAB SCORE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411737","Virus Plaque Assay","C174336","An assay that is used to determine viral quantity by infecting monolayers of host cells with serially diluted virus, covering the monolayers with an immobilizing overlay after a period of incubation to restrict the spread of the virus to neighboring cells, and counting the resulting visible plaques of infected cells.","Virus Plaque Assay | VIRUS PLAQUE ASSAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411739","Coulometric Titration","C174335","A titration method in which the titrating agent is generated electrochemically in solution, and the amount of electricity used is measured.","Coulometric Titration | COULOMETRIC TITRATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411738","Static Perimetry","C174334","An eye examination technique that utilizes test objects with gradually increasing luminance that are positioned at fixed locations across the visual field to determine the threshold of visibility.","Static Perimetry | OPV | Ophthalmic Visual Field | STATIC PERIMETRY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411766","Minimum Concentration Normalized by Weight-Adjusted Dose","C174354","The minimum concentration between dose time and dose time plus Tau (at Tmin) divided by the body weight-adjusted dose.","Minimum Concentration Normalized by Weight-Adjusted Dose | CMINDW | Min Conc Norm by Dose/WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411729","Maximum Concentration Normalized by Weight-Adjusted Dose","C174353","The maximum concentration occurring at Tmax divided by the body weight-adjusted dose.","Maximum Concentration Normalized by Weight-Adjusted Dose | CMAXDW | Max Conc Norm by Dose/WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411728","Average Concentration from T1 to T2 Normalized by Weight-Adjusted Dose","C174352","The area under the curve over the interval from T1 to T2 (AUCINT) divided by the length of the interval divided by the body weight-adjusted dose.","Average Concentration from T1 to T2 Normalized by Weight-Adjusted Dose | Average Conc from T1 to T2 Norm by Dose per Body Weight | CAVGINT Norm by Dose/WT | CAVINTDW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411731","Average Concentration Normalized by Weight-Adjusted Dose","C174351","AUCTAU divided by TAU divided by the body weight-adjusted dose.","Average Concentration Normalized by Weight-Adjusted Dose | Average Concentration Norm by Dose/WT | CAVGDW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411730","AUC Over Dosing Interval Normalized by Weight-Adjusted Dose","C174350","The area under the curve (AUC) for the defined interval between doses (TAU) divided by the body weight-adjusted dose.","AUC Over Dosing Interval Normalized by Weight-Adjusted Dose | AUC Over Dosing Interval Norm by Dose per Body Weight | AUCTAU Norm by Dose/WT | AUCTAUDW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411725","AUC Infinity Predicted Normalized by Weight-Adjusted Dose","C174349","The area under the curve (AUC) extrapolated to infinity, calculated using the predicted value of the last non-zero concentration divided by the body weight-adjusted dose.","AUC Infinity Predicted Normalized by Weight-Adjusted Dose | AUC Infinity Pred Norm by Dose per Body Weight | AUCIFPDW | AUCIFPDW Norm by Dose/WT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411724","AUC from T1 to T2 Normalized by Weight-Adjusted Dose","C174348","The area under the curve (AUC) over the interval from T1 to T2 divided by the body weight-adjusted dose.","AUC from T1 to T2 Normalized by Weight-Adjusted Dose | AUC from T1 to T2 Norm by Dose per Body Weight | AUCINT Norm by Dose/WT | AUCINT Norm by Dose/kg WT | AUCINTDW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411727","AUC Dosing From Dosing to Last Concentration Normalized by Weight-Adjusted Dose","C174347","The area under the curve (AUC) from the time of dosing to the last measurable concentration divided by the body weight-adjusted dose.","AUC Dosing From Dosing to Last Concentration Normalized by Weight-Adjusted Dose | AUC to Last Nonzero Conc Norm by Dose per Body Weight | AUCLST Norm by Dose/WT | AUCLSTDW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411726","Amount Recovered to Last Nonzero Concentration","C174346","The cumulative amount recovered from the specimen type specified in PPSPEC, from the time of dosing to the last non-zero concentration.","Amount Recovered to Last Nonzero Concentration | Amt Rec to Last Nonzero Conc | RCAMLST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411734","AUC Infinity Observed Normalized by Weight-Adjusted Dose","C174345","The area under the curve (AUC) extrapolated to infinity, calculated using the observed value of the last non-zero concentration divided by the body weight-adjusted dose.","AUC Infinity Observed Normalized by Weight-Adjusted Dose | AUC Infinity Obs Norm by Dose/WT | AUCIFODW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411810","Concentration Normalized by Weight-Adjusted Dose","C174230","The quantity of a specified substance in a unit volume or weight of another substance divided by the body weight-adjusted dose.","Concentration Normalized by Weight-Adjusted Dose | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411765","Standing, Bent Forward","C174357","A body position wherein the individual is standing and bent forward at the waist.","Standing, Bent Forward | STANDING, BENT FORWARD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411764","Hour Times Nanogram Per Milliliter Per Milligram Per Centimeter Squared Per Day","C174356","Hours times nanograms per milliliter (area under the curve), divided by milligrams per centimeter squared per day (daily dose normalized by surface area).","Hour Times Nanogram Per Milliliter Per Milligram Per Centimeter Squared Per Day | h*ng/mL/(mg/cm2/day) | h.ng/mL/(mg/cm2/day) | h.ng/ml/(mg/cm2/day)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411767","Hour Times Picomole Per Liter Per Milligram Per Kilogram","C174355","Hours times picomoles per liter (area under the curve), divided by milligrams per kilogram (dose normalized by body weight).","Hour Times Picomole Per Liter Per Milligram Per Kilogram | h*pmol/L/(mg/kg) | h.pmol/L/(mg/kg) | h.pmol/l/(mg/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411759","Maximal Oxygen Consumption, Estimated","C174363","The predicted maximum rate of oxygen uptake that is derived from physiological responses to submaximal exercise performance and is used as a measure of cardiorespiratory fitness.","Maximal Oxygen Consumption, Estimated | Estimated Maximal Aerobic Capacity | VO2MAXE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411758","Forced Expiratory Volume in 0.75 Second","C174362","The volume of air that can be forcibly exhaled during the first 3/4 second following maximal inhalation.","Forced Expiratory Volume in 0.75 Second | FEV 0.75s | FEV_75",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411769","Percent Predicted Lobar Volume","C174361","The total volume of gas in a lobe of the lung at a specified point in time during the respiratory cycle, as a proportion of the predicted normal value.","Percent Predicted Lobar Volume | LOBVOLPP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411800","Lobar Volume","C174232","The total volume of gas in a lobe of the lung at a specified point in time during the respiratory cycle.","Lobar Volume | LOBVOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411757","GPS Coordinates of Potential Disease Exposure","C174365","The global position system (GPS) coordinates for the location at which the an individual was potentially exposed to a disease.","GPS Coordinates of Potential Disease Exposure | GPS Coord of Potential Disease Exposure | GPSDEXP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411756","District of Potential Disease Exposure","C174364","The district in which the an individual was potentially exposed to a disease.","District of Potential Disease Exposure | DISTDEXP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411761","Severity of Elevated Lesion","C174369","An indication of the severity of a lesion that is raised.","Severity of Elevated Lesion | LESELESV | Lesion Elevation Severity/Intensity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411760","Severity of Scaling Lesion","C174368","An indication of the severity of a lesion that has flaking dead skin and an increase of keratin in the stratum corneum.","Severity of Scaling Lesion | LESSCLSV | Lesion Scaling Severity/Intensity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411763","Severity of Erythematous Lesion","C174367","An indication of the severity of a lesion that has red discoloration.","Severity of Erythematous Lesion | LESERYSV | Lesion Erythema Severity/Intensity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005903","Body Temperature","C174446","A measurement of the temperature of the body.","Body Temperature | TEMP | Temperature | Temperature in Celsius or Fahrenheit | body temperature | body_temperature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411752","Ulnar Length","C174376","A measurement of the length of the ulna.","Ulnar Length | ULNARL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411755","Fetal Mandibular Length","C174375","A measurement of the length of the fetal mandible.","Fetal Mandibular Length | FTMANDL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411754","Fetal Weight-for-Gestational Age Percentile","C174374","An assessed relationship of the fetus' weight and gestational age to that of a reference population, expressed as a percentile.","Fetal Weight-for-Gestational Age Percentile | FTWTGAPL | Fetal Weight-for-Gest Age Percentile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411751","Fetal Sagittal Abdominal Diameter","C174373","A measurement of the sagittal abdominal diameter of the fetus.","Fetal Sagittal Abdominal Diameter | FTSAD | Fetal SAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411750","Fetal Estimated Weight","C174372","An approximate determination of the weight of the fetus.","Fetal Estimated Weight | FTEWT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456241","Peripheral Body Temperature","C174371","A measurement of the temperature on the surfaces of the outer areas or boundaries of the body.","Peripheral Body Temperature | TEMPPB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456240","Core Body Temperature","C174370","A measurement of the temperature within the deep tissues of the body.","Core Body Temperature | TEMPCB",,,,,,,,,,,,,,,"4174894","Core body temperature",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1411797","Mandibular Length","C174233","A measurement of the length of the mandible.","Mandibular Length | MANDL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225340","Transitional Cell","C12866","Cells that vary in shape depending on whether the tissue is being stretched.  The cells may be stretched without breaking apart.  They line hollow organs such as the bladder.","Transitional Cell | Transitional Cells | transitional cell",,,,,,,,,,,,,,,"4146756","Transitional epithelial cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3274621","Duvelisib","C99225","An orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. Upon administration, duvelisib prevents the activation of the PI3K delta/gamma-mediated signaling pathways which may lead to a reduction in cellular proliferation in PI3K delta/gamma-expressing tumor cells. Unlike other isoforms of PI3K, the delta and gamma isoforms are overexpressed primarily in hematologic malignancies and inflammatory and autoimmune diseases. By selectively targeting these PI3K isoforms, PI3K signaling in normal, non-neoplastic cells is minimally or not affected which would result in a more favorable side effect profile.","Duvelisib | 1(2H)-Isoquinolinone, 8-Chloro-2-phenyl-3-((1S)-1-(9H-purin-6-ylamino)ethyl)- | 8-Chloro-2-phenyl-3-((1S)-1-(7H-purin-6-ylamino)ethyl)isoquinolin-1(2H)-one | Copiktra | DUVELISIB | INK-1197 | IPI 145 | IPI-145 | IPI145",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826271","Planned Time Point Name","C82539","The literal identifier of a planned point in time.","Planned Time Point Name | TPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1827129","Wasp Venom Allergy","C172321","An allergic reaction triggered by being exposed to wasp venom following a wasp sting.","Wasp Venom Allergy | Allergy, Wasp | Wasp Sting Allergy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0577625","Shellfish Allergy","C172320","An allergic reaction triggered by exposure to allergens found in foods containing molluscs, crustaceans or echinoderms.","Shellfish Allergy | Allergy, Seafood",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406170","Mold or Dust Allergy","C172306","An allergic reaction triggered by exposure to airborne allergens expressed by dust mites or molds.","Mold or Dust Allergy | Allergy, Mold or Dust",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0859949","Meat Allergy","C172317","An allergic reaction triggered by exposure to foodborne allergens found in meat.","Meat Allergy | Allergy, Meat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0685901","Fruit Allergy","C172316","An allergic reaction triggered by exposure to foodborne allergens found in fruit.","Fruit Allergy | Allergy, Fruit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3280920","Food Allergy","C172304","An allergic reaction triggered by exposure to allergens found in food; exposure can occur through the skin, respiratory tract or digestive tract.","Food Allergy | Allergy, Food, NOS | Foodborne Allergy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0559469","Egg Allergy","C172313","An allergic reaction triggered by exposure to foodborne allergens found in eggs.","Egg Allergy | Allergy, Egg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0740913","Dog Allergy","C172311","An allergic reaction triggered by exposure to allergens expressed by dogs, includes allergenic factors found in canine saliva and dander.","Dog Allergy | Allergy, Dog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0339805","Cat Allergy","C172310","An allergic reaction triggered by exposure to allergens expressed by cats, includes allergenic factors found in feline saliva and dander.","Cat Allergy | Allergy, Cat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1828283","Bee Venom Allergy","C172308","An allergic reaction triggered by being exposed to bee venom following a bee sting.","Bee Venom Allergy | Allergy, Bee | Bee Sting Allergy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406169","Venomous Ant Bite Allergy","C172307","An allergic reaction triggered by exposure to ant venom, usually as a result of being bitten by a fire ant (Solenopsis spp.).","Venomous Ant Bite Allergy | Allergy, Ant | Ant Bite Allergy | Ant Sting Allergy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700360","Animal Allergy","C172303","An allergic reaction triggered by exposure to animal-associated allergens, includes allergenic factors in venom, saliva and dander.","Animal Allergy | Allergy, Animal, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407748","Chronic Systemic Steroid Use","C174112","An indication that the subject has been using a systemic steroid at the prescribed dose for a long period of time.","Chronic Systemic Steroid Use | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406124","Family History of BRCA Mutation","C172230","An indication that a variant in a BRCA family gene has been identified in a family member of a subject.","Family History of BRCA Mutation | BRCA Family History",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL558268","BAP1 Tumor Predisposition Syndrome","C172639","A syndrome caused by germline mutations in the BAP1 gene. It is inherited in an autosomal dominant pattern. Individuals carrying heterozygous BAP1 mutations have an increased risk of developing various tumor types, most commonly BAP1-inactivated nevi/melanocytomas of the skin, uveal and cutaneous melanomas, peritoneal and pleural mesotheliomas, clear cell renal cell carcinoma, and basal cell carcinoma. (WHO 2018)","BAP1 Tumor Predisposition Syndrome | BAP1-TPDS",,,,,,,,,,,,,,,"35622838","BAP1 tumor predisposition syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1412861","Dairy or Lactose Intolerance Allergy","C175520","An allergic reaction triggered by exposure to allergens found in foods containing lactose or other dairy components.","Dairy or Lactose Intolerance Allergy | Allergy, Dairy or Lactose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0577620","Nut Allergy","C175521","An allergic reaction triggered by exposure to allergens found in nuts.","Nut Allergy | Allergy, Nuts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412863","Processed Food Allergy","C175522","An allergic reaction triggered by exposure to allergens found in processed foods.","Processed Food Allergy | Allergy, Processed Foods",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085436","Cryptococcal Meningitis","C174113","A blood borne fungal infection of the membranes surrounding the brain and spinal column (meninges) caused by Cryptococcus, usually C. neoformans or C. gattii. It usually occurs in immunocompromised patients including persons with AIDS, transplant recipients, patients receiving cytotoxic chemotherapy, and patients with hematologic malignancies.","Cryptococcal Meningitis | ",,,,,,,,,,,,,,,"432310","Cryptococcal meningitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2747813","Bacterial Colonization","C171138","The detection of bacteria in or on an anatomic site, medical device or biospecimen.","Bacterial Colonization | Colonization, Bacterial | Colonization; bacterial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024266","Lymphocytic Meningitis","C174114","Meningitis in which lymphocytes predominate in the cerebrospinal fluid.","Lymphocytic Meningitis | ",,,,,,,,,,,,,,,"4175368","Lymphocytic meningitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019151","Hepatic Encephalopathy","C79596","A constellation of signs and symptoms characterized by changes in personality, consciousness, and reflexes, resulting from neuropsychiatric abnormalities secondary to liver failure without evidence of other brain disease.","Hepatic Encephalopathy | ",,,,,,,,,,,,,,,"4029488","Hepatic encephalopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2931456","Hereditary Prostate Carcinoma","C103817","Prostate carcinoma that has developed in relatives of patients with a history of prostate carcinoma.","Hereditary Prostate Carcinoma | Hereditary Prostate Cancer",,,,,,,,,,,,,,,"37395835","Familial prostate cancer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0269439","Elective Abortion Finding","C175527","An abortion performed due to individual choice, in the absence of a harmful medical condition caused by pregnancy.","Elective Abortion Finding | Elective Abortion",,,,,,,,,,,,,,,"4081422","Elective termination of pregnancy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1405562","Fusion Gene Downstream Gene Symbol","C171253","The gene symbol that represents the gene that comprises the 3' portion of the coding sequence for a fusion gene.","Fusion Gene Downstream Gene Symbol | GENE2 | Second Gene Symbol | gene2 | second gene symbol | second_gene_symbol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514382","DKFZp459F1927","C131615","Human GOLM2 wild-type allele is located in the vicinity of 15q15.3 and is approximately 127 kb in length. This allele, which encodes protein GOLM2, may be involved in tumor progression and Golgi activity. Aberrant expression of the gene is seen in tumors that overexpress the ERBB2 gene.","GOLM2 wt Allele | CASC4 | CASC4 wt Allele | Cancer Susceptibility 4 Gene | Cancer Susceptibility Candidate 4 Gene | Cancer Susceptibility Candidate Gene 4 | DKFZp459F1927 | GOLM2 | Gene Associated With HER-2/Neu Overexpression | Golgi Membrane Protein 2 wt Allele | H63 | UNQ2573/PRO6308",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550949","KDM4C wt Allele","C148357","Human KDM4C wild-type allele is located in the vicinity of 9p24.1 and is approximately 455 kb in length. This allele, which encodes lysine-specific demethylase 4C protein, plays a role in the demethylation of histone H3. Chromosomal aberrations involving the gene and aberrant expression of this gene may be associated with esophageal squamous cell carcinoma and other neoplastic diseases.","KDM4C wt Allele | GASC1 | Gene Amplified in Squamous Cell Carcinoma 1 | JHDM3C | JMJD2C | Jumonji Domain Containing 2C Gene | KIAA0780 | Lysine (K)-Specific Demethylase 4C Gene | Lysine Demethylase 4C wt Allele | TDRD14C | Tudor Domain Containing 14C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001758","Follow-Up Care","C116570","Any clinical attention received following a diagnosis or treatment, with the specific purpose of monitoring that specific diagnosis or treatment.","Follow-Up Care | ",,,,,,,,,,,,,,,"4186037","Aftercare",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1134632","Breast Imaging Study","C62683","Procedures for obtaining internal images of the breast.","Breast Imaging Study | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412896","Parent Biospecimen","C175532","The source specimen from which a subsequent specimen was derived or a specimen that becomes a component of a pooled specimen.","Parent Biospecimen | Parent Specimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334139","IRF3 Gene","C26306","This gene plays a role in the transcriptional activation of target genes.","IRF3 Gene | IRF3 | Interferon Regulatory Factor 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545333","Autologous Anti-BCMA CAR-T Cells JCARH 125","C147523","A preparation of autologous CD4- and CD8-positive T-lymphocytes that have been ex vivo transduced with a genetically-engineered lentiviral vector (LV) expressing a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) fused to the co-stimulatory domain of 4-1BB (CD137) and the CD3-zeta (CD3z) T-cell signaling domain, with potential immunostimulating and antineoplastic activities. Upon administration, orvacabtagene autoleucel specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.","Orvacabtagene Autoleucel | Autologous Anti-BCMA CAR-T Cells JCARH 125 | Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing CD4+/CD8+ T-lymphocytes JCARH125 | Autologous BCMA 41BBz CAR-T Cell JCARH-125 | Autologous BCMA-specific CAR-T Cells JCARH125 | Autologous BCMA-specific CAR4-1BB-CD3zeta-expressing CD4+/CD8+ T Lymphocytes JCARH 125 | JCARH 125 | JCARH-125 | JCARH125 | ORVACABTAGENE AUTOLEUCEL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551044","Ciltacabtagene Autoleucel","C148498","A preparation of autologous T-lymphocytes that are transduced, ex vivo, with LCAR-B38M, a lentiviral vector expressing a chimeric antigen receptor (CAR) containing two bispecific anti-B-cell maturation antigen (BCMA) variable fragments of llama heavy-chain murine antibodies fused to the signaling domain of 4-1BB (CD137), with potential immunostimulating and antineoplastic activities. The antigen-binding region of the CAR is a non-scFv structure targeting two distinct regions of BCMA. Upon intravenous administration back into the patient, ciltacabtagene autoleucel are directed to cells expressing BCMA, bind to two different epitopes on BCMA and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-associated antigen (TAA) and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is overexpressed on malignant plasma cells.","Ciltacabtagene Autoleucel | Autologous Anti-BCMA CAR-T Cells JNJ-68284528 | Autologous Bi-epitope BCMA-targeted CAR T-cells JNJ-68284528 | Autologous Bi-epitope CAR T-cells JNJ-68284528 | CARVYKTI | CILTACABTAGENE AUTOLEUCEL | Cilta-cel | Ciltacabtagene autoleucel | JNJ 68284528 | JNJ-68284528 | JNJ68284528 | LCAR B38M | LCAR-B38M | LCAR-B38M-transduced CAR-T Cells JNJ-68284528 | LCAR-B38M-transduced Car-T Cells JNJ-68284528 | LCARB38M",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382898","Brexucabtagene Autoleucel","C170439","A preparation of autologous peripheral blood T-lymphocytes (PBTL) that have been transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv) coupled to the costimulatory signaling domain CD28 and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3 zeta), with potential immunostimulating and antineoplastic activities. Upon intravenous infusion and re-introduction of abrexucabtagene autoleucel into the patient, these cells bind to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen that is expressed in all B-cell lineage malignancies. CD3 zeta is one of several membrane-bound polypeptides found in the TCR/CD3 complex; it regulates both the assembly and cell surface expression of TCR complexes. CD28 is essential for CD4+ T-cell proliferation, interleukin-2 production, and T-helper type-2 (Th2) development. KTE-X19 has the same construct as axicabtagene ciloleucel, but differs in the manufacturing process in that KTE-X19 includes specific T-cell selection and lymphocyte enrichment necessary for activity against certain B-cell malignancies.","Brexucabtagene Autoleucel | Anti-CD19 Autologous CAR-CD28 T-cells KTE-X19 | BREXUCABTAGENE AUTOLEUCEL | Brexu-cel | Brexucabtagene autoleucel | KTE X19 | KTE-X19 | KTEX19 | Tecartus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539805","DDX58 wt Allele","C101420","Human RIGI wild-type allele is located in the vicinity of 9p21.1 and is approximately 71 kb in length. This allele, which encodes antiviral innate immune response receptor RIG-I protein, is involved in the recognition of viral RNA and the activation of antiviral signaling pathways. Mutations in the gene are associated with Singleton-Merten syndrome 2.","RIGI wt Allele | DDX58 | DDX58 wt Allele | DDX58 wt Allele | DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 58 Gene | DEAD-Box Polypeptide 58 Gene | DEAD/H (Asp-Glu-Ala-Asp/His) Box Polypeptide 58 Gene | DEAD/H-Box 58 Gene | DExD/H-Box Helicase 58 Gene | DExD/H-Box Helicase 58 wt Allele | DKFZp434J1111 | FLJ13599 | RIG-I | RIG1 | RIGI | RLR-1 | RNA Helicase RIG-I Gene | RNA Sensor RIG-I wt Allele | Retinoic Acid Inducible Gene I | Retinoic Acid-Inducible Gene I | SGMRT2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412895","TruSight Oncology 500 Assay","C175538","A next-generation sequencing (NGS) assay that enables comprehensive genomic profiling of tumor samples. It targets 523 genes for assessment of all DNA and RNA variant types, in addition to microsatellite instability (MSI) and tumor mutational burden (TMB).","TruSight Oncology 500 Assay | TSO 500 | TSO 500 Assay | TSO 500 Gene Panel | TSO 500 Panel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412890","Daiichi Sankyo","C175540","A global pharmaceutical company committed to the development of innovative new and generic medicines, and new methods of drug discovery and delivery.","Daiichi Sankyo | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030392","Human Parainfluenza Virus 3","C112317","The serotype labeled 3 of the viral species Human parainfluenza virus, which is a single-stranded, negative-sense RNA virus of the Paramyxoviridae family and Respirovirus genus, and causes croup and respiratory infections in humans.","Human Parainfluenza Virus 3 | HPIV-3 | HUMAN PARAINFLUENZA VIRUS 3 | Human Parainfluenza Virus Type 3 | Human Respirovirus 3",,,,,,,,,,,,,,,"4231389","Human parainfluenza virus 3",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3272843","BMPR1A Gene Mutation","C96522","A molecular genetic abnormality that refers to the mutation of the BMPR1A (bone morphogenetic protein receptor, type 1A) gene on chromosome 10q22.3.","BMPR1A Gene Mutation | ACVRLK3 Gene Mutation | ALK3 Gene Mutation | Bone Morphogenetic Protein Receptor Type 1A Gene Mutation | SKR5 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0752304","Hypoxic Ischemic Encephalopathy","C35549","Ischemic brain damage in which the entire brain is deprived of oxygen. It may be fatal or lead to long term disabilities including developmental delays, intellectual disability, and seizures.","Hypoxic Ischemic Encephalopathy | Anoxic encephalopathy | HIE | Hypoxic ischemic encephalopathy | Hypoxic ischemic encephalopathy [HIE], unspecified",,,,,,,,,,,,,,,"45766189","Hypoxic ischemic encephalopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006287","Bronchopulmonary Dysplasia","C90599","Chronic lung disease requiring treatment with oxygen for at least 28 days and with a spectrum of severity from mild to severe, that predominantly affects premature infants. While the radiologic pattern is typical in the closer to term patient, the pattern in the small preterm infant is very non-discrete and variable.","Bronchopulmonary Dysplasia | BPD",,,,,,,,,,,,,,,"4283942","Bronchopulmonary dysplasia of newborn",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL970574","Iodoacetamide","C161898","A sulfhydryl alkylating reagent that forms covalent bonds with the thiol group of cysteines so the protein or peptide no longer forms disulfide bonds.","Iodoacetamide | 2-Iodoacetamide | Acetamide, 2-iodo- | IAA | Monoiodoacetamide | N-(3-Methoxy-4-butoxybenzyl)thiobarbituric acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055426","Autologous T-Cells Expressing Enhanced TCRs Specific for NY-ESO-1/LAGE-1a GSK3377794","C121379","Human autologous T-lymphocytes transduced with a lentiviral vector encoding a T-cell receptor (TCR) specific for the cancer-testis antigens (CTAs) NY-ESO-1 and L antigen family member 1 (LAGE-1; Cancer/Testis Antigen 2; CTAG2; CT2), with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and reintroduction into the patient, letetresgene autoleucel specifically target and bind to NY-ESO-1/LAGE-1-overexpressing tumor cells. This may result in a cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1/LAGE-1-positive cancer cells. NY-ESO-1 and LAGE-1, members of the cancer-testis antigen (CTA) family, are overexpressed on the surface of various tumor cell types.","Letetresgene Autoleucel | Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced c259 T Lymphocytes GSK3377794 | Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced c259 T Lymphocytes GSK3377794 | Autologous T-Cells Expressing Enhanced TCRs Specific for NY-ESO-1/LAGE-1a GSK3377794 | Genetically Engineered NY-ESO-1 Specific [c259] T Cells GSK3377794 | Genetically Engineered NY-ESO-1/LAGE-1 Specific (c259) T Cells GSK3377794 | LETETRESGENE AUTOLEUCEL | NY-ESO-1c259 T Cells GSK3377794",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383266","Planned Elapsed Time from Time Point Reference","C170994","The time interval between a planned time point and a reference time point.","Planned Elapsed Time from Time Point Reference | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412998","CIBMTR Center Support","C175544","A customer service model enabling the Center for International Blood and Marrow Transplant Research (CIBMTR) Data Operations to deliver a transparent, flexible, and service-oriented experience for participating transplant centers by unifying multiple processes and tools into a consistent and integrated system.","CIBMTR Center Support | CIBMTR Center Support Model | Center Support",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412999","Ticket Assignment","C175545","A process used by a customer support center to prioritize customer requests and reported issues and assign them to a team member for resolution.","Ticket Assignment | Ticket",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412996","Out of Specification","C175546","Test results for a product or drug that do not meet the predetermined specification criteria set by the manufacturer.","Out of Specification | OOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413027","Australia New Zealand Clinical Trial Registry","C175548","An online register of clinical trials being undertaken in Australia, New Zealand, and elsewhere. It includes trials for pharmaceuticals, surgical procedures, preventive measures, lifestyle, devices, treatment and rehabilitation strategies, and complementary therapies.","Australia New Zealand Clinical Trial Registry | ANZCTR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412889","Iovance Biotherapeutics","C175541","A biopharmaceutical company working to develop tumor-infiltrating lymphocyte therapies against cancer.","Iovance Biotherapeutics | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414618","FKBP1A Gene","C102483","This gene is involved in both signaling and protein folding.","FKBP1A Gene | FKBP Prolyl Isomerase 1A Gene | FKBP1A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003779","Argipressin","C926","A synthetic peptide identical to the endogenous nonapeptide hormone with antidiuretic property. Synthesized in the hypothalamus and stored/released from the posterior lobe of the pituitary, argipressin's primary function is regulating extracellular fluid volume. This agent can also act as a vasoconstrictor, increasing blood pressure and systemic vascular resistance.","Argipressin | Arginine Vasopressin | Recombinant Antidiuretic Hormone | Recombinant Vasopressin | Therapeutic ADH | VASOPRESSIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013030","Dopamine","C62025","A monoamine compound with positive inotropic activity. Dopamine is a naturally occurring catecholamine formed by decarboxylation of dehydroxyphenylalanine and a precursor of norepinephrine and epinephrine. Dopamine binds to alpha-1 and beta-1 adrenergic receptors. Mediated through myocardial beta-1 adrenergic receptors, dopamine increase heart rate and force, thereby increasing cardiac output. Alpha-1 adrenergic receptor stimulation on vascular smooth muscle, leads to vasoconstriction and results in an increase in systemic vascular resistance. Stimulation of dopaminergic receptors in renal vasculature, leads to renal blood vessel dilation, and an increase in glomerular filtration rate, renal blood flow, sodium excretion, and urine output.","Dopamine | DOPAMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1096155","Macrophage Activation Syndrome","C114471","A complication of rheumatic disease that is caused by excessive activation and uncontrolled proliferation of T lymphocytes and well-differentiated macrophages. It is characterized by fever, pancytopenia, liver insufficiency, coagulopathy and neurologic symptoms.","Macrophage Activation Syndrome | MAS | Reactive Hemophagocytic Lymphohistiocytosis",,,,,,,,,,,,,,,"4325546","Macrophage activation syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1443871","Personal Protective Equipment","C173748","Masks, shields, gloves, gowns, boots, or other equipment used to provide coverage against infectious agents or environmental hazards.","Personal Protective Equipment | PPE",,,,,,,,,,,,,,,"4248093","Personal protective equipment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL553263","ANKRD26 Gene","C151924","This gene plays a role in platelet functions, adipogenesis and appetite.","ANKRD26 Gene | ANKRD26 | Ankyrin Repeat Domain 26 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412357","ALOX12B Gene","C96337","This gene is involved in fatty acid oxidation.","ALOX12B Gene | ALOX12B | Arachidonate 12-Lipoxygenase, 12R Type Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332011","ACVR1B Gene","C21268","This gene plays a role in the transforming growth factor-beta signal transduction pathway. The gene also plays a role in the regulation of cellular growth, differentiation and signal transduction.","ACVR1B Gene | ACVR1B | Activin A Receptor, Type IB Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0051482","Alfaxalone","C72161","A synthetic neuroactive steroid, with anesthetic activity. Upon administration, alfaxalone binds to the gamma-aminobutyric acid (GABA)-A cell surface receptor, thereby enhancing the inhibitory actions of GABA-A in the brain. This leads to modulation of neuronal cell membrane chloride ion transport and induction and maintenance of anesthesia.","Alfaxalone | ALFAXALONE | Alfaxan | Alphaxalone | Alphaxolone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413019","Praziquantel/Pyrantel Pamoate","C175560","A fixed combination of praziquantel and pyrantel pamoate, with anthelminthic activity. Upon administration, praziquantel increases the permeability of the tegument of susceptible worms, resulting in an influx and increase in intra-tegumental calcium leading to rapid contractions and paralysis of the worm's musculature. In addition, vacuolization of the tegumental syncytium and blebbing results in tegument disintegration, leads to antigen exposure and elicit host defense responses to the worm. This results in granulomas formation and phagocytosis. Pyrantel pamoate acts as a depolarizing neuromuscular blocking agent resulting in spastic paralysis of the helminths. The parasites are then eliminated through intestinal tract peristalsis of the host.","Praziquantel/Pyrantel Pamoate | Drontal | Pyrantel Pamoate/Praziquantel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413018","Polysulfated Glycosaminoglycan","C175559","A semi-synthetic glycosaminoglycan (GAG) prepared by extracting GAGs from bovine tracheal cartilage and consisting of mostly chondroitin sulfate, with anti-arthritic activities in animals including dogs. Upon administration, polysulfated GAG (PSGAG), a proteolytic enzyme inhibitor, may inhibit various processes that lead to the loss of cartilaginous mucopolysaccharides. This may include the inhibition of interleukin-1 (IL-1)-mediated inflammation and degradation of cartilage proteoglycans and collagen. PSGAG may also stimulate the synthesis of protein, collagen, proteoglycans, and hyaluronic acid, which may improve joint function.","Polysulfated Glycosaminoglycan | Adequan Canine | POLYSULFATED GLYCOSAMINOGLYCAN | PSGAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413021","Gentamicin Sulfate/Betamethasone Valerate/Clotrimazole Otic Ointment","C175558","An otic ointment formulation of the broad-spectrum aminoglycoside antibiotic gentamicin sulfate, the synthetic adrenocorticoid betamethasone valerate and the broad-spectrum antifungal agent clotrimazole, with antibacterial, anti-inflammatory, and antifungal activities. Upon otic administration, gentamicin sulfate/betamethasone valerate/clotrimazole otic ointment inhibits bacterial protein synthesis and replication, inhibits fungal sterols biosynthesis which leads to fungal cell leakage and fungal cell lysis, and inhibits the inflammatory response by preventing phospholipid release, inhibiting eosinophil activity, and decreasing pro-inflammatory cytokine production.","Gentamicin Sulfate/Betamethasone Valerate/Clotrimazole Otic Ointment | Gentamicin Sulfate/Betamethasone Valerate/Clotrimazole Otic Ointment  | Gentamicin/Betamethasone/Clotrimazole Otic Ointment | Otomax",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332795","CSNK1A1 Gene","C24314","This gene plays a role in signal transduction and intercellular communication.","CSNK1A1 Gene | CSNK1A1 | Casein Kinase 1, Alpha 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554175","CENPA Gene","C152972","This gene plays a role in kinetochore assembly and cell cycle progression.","CENPA Gene | CENPA | Centromere Protein A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540653","Vulnerable Populations","C142747","Volunteers for clinical studies who may be unreasonably persuaded to participate by perceived benefits, or fear of punishment by superiors.","Vulnerable Subjects | Vulnerable Population | vulnerable subjects",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413016","Inducible Caspase 9","C175561","A dimerizable suicide gene system composed of the pro-apoptotic caspase-9 in which the caspase recruitment domain (CARD) is replaced with a mutated (F36V) dimerizer drug-binding domain from the human FK506-binding protein (FKBP12), that can be incorporated in therapeutic cells to avoid cell-related toxicities. When toxicity of the administered cells occur in which inducible caspase 9 (iCasp9) is incorporated, the expressed iCasp9, which is inactive, can become activated after administration of a specific chemical inducer of dimerization (CID), such as rimiducid (AP1903) or temsirolimus. The binding of the CID to the CID binding domain of iCasp9 cross-links and dimerizes iCasp9, which causes its activation. This results in the induction of caspase-mediated apoptosis of the transduced cells and allows for the removal of inappropriately activated cells, thereby preventing toxicity of the administered cells.","Inducible Caspase 9 | CaspaCIDe (R) | IC9 | Inducible Caspase-9 | iCasp9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333242","DNMT3B Gene","C24346","This gene plays a role in embryonic development, imprinting, and X-chromosome inactivation.","DNMT3B Gene | DNA (Cytosine-5-)-Methyltransferase 3 Beta Gene | DNMT3B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553256","DDX41 Gene","C151913","This gene may play a role in RNA splicing and tumor suppression.","DDX41 Gene | DDX41 | DEAD-Box Helicase 41 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333540","FGF9 Gene","C26578","This gene plays a role in the promotion of cellular growth/proliferation and negative regulation of apoptosis. It is also involved in glial cell development.","FGF9 Gene | FGF9 | Fibroblast Growth Factor 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919508","FGF5 Gene","C18571","This gene plays a role in the stimulation of cell proliferation.","FGF5 Gene | FGF5 | Fibroblast Growth Factor 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333536","FGF1 Gene","C24388","This gene plays a role in angiogenesis and organogenesis. It is also involved in the regulation of endothelial cell migration and proliferation.","FGF1 Gene | FGF1 | Fibroblast Growth Factor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515097","Survivin Antigen","C37449","A tumor-associated antigen. Vaccination with survivin antigen may result in a cytotoxic T-cell response against survivin antigen-expressing tumor cells, resulting in decreased tumor cell proliferation and tumor cell death. Overexpressed in many tumors, endogenous survivin inhibits tumor cell apoptosis.","Survivin Antigen | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413509","Coronavirus Racial Bias Scale","C175567","A self-report questionnaire that assesses an individual's beliefs about how the Coronavirus has negatively affected people of their race/ethnicity.","Coronavirus Racial Bias Scale | CRBS | Coronavirus Racial Bias Scale (CRBS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413507","Coronavirus Anxiety Scale","C175568","A self-report mental health screening tool for dysfunctional anxiety associated with the coronavirus crisis.","Coronavirus Anxiety Scale | CAS | Coronavirus Anxiety Scale (CAS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413010","Vulnerability to COVID-19","C175569","The quality or state of the possibility of being infected by the Sars-CoV-2 virus and developing Covid-19.","Vulnerability to COVID-19 | Vulnerability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413009","Cytoplasmic Fraction","C175572","The liquid produced by breaking cells apart and spinning out the insoluble components. It consists largely of dissolved macromolecules.","Cytoplasmic Fraction | Cyto | Cytosolic Fraction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413006","Mitochondrial and Nuclear Fraction","C175573","A cell lysate fraction that contains nuclear and mitochondrial components.","Mitochondrial and Nuclear Fraction | Mito/Nuc",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413007","In Person","C175574","Involving or requiring an individual's personal presence.","In Person | IN PERSON | In-Person",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413004","Not in Person","C175575","Not involving or requiring an individual's personal presence.","Not in Person | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413012","CD11 Protein Family","C175565","A family comprised of four integrin alpha subunits that are expressed on the surface of leukocytes and usually form a complex with integrin beta-2 (ITGB2/CD18). CD11/CD18 integrins play a role in leukocyte-endothelial cell adhesion through binding to intercellular adhesive molecule-1 (ICAM-1; CD54) or ICAM-2 (CD102), which are expressed on the surface of endothelial cells.","CD11 Protein Family | CD11 | CD11 Antigen | CD11 Family | CD11 Family Protein | CD11 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413013","synovial sarcoma X breakpoint proteins","C175566","A family of cancer/testis antigen proteins encoded by genes located on the short arm of the X chromosome within Xp11.22-Xp11.23. The initial members of this family were identified as fusion partners with either SS18 protein or SS18L protein in synovial sarcoma. SSX proteins play a role in the modulation of gene transcription and contain an N-terminal Krueppel-associated box (KRAB) domain and a C-terminal SSX repression domain (SSXRD).","SSX Protein Family | SSX | SSX Antigen | SSX Family | SSX Family Protein | Synovial Sarcoma X Breakpoint Protein | Synovial Sarcoma X Chromosome Breakpoint Protein | Synovial Sarcoma, X Breakpoint Family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545755","GABRA6 Gene","C147969","This gene is involved in neurotransmitter-dependent chloride transport.","GABRA6 Gene | GABRA6 | Gamma-Aminobutyric Acid Type A Receptor Alpha6 Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555449","H3-4 Gene","C154669","This gene is involved in the packaging of DNA into nucleosomes.","H3-4 Gene | H3-4 | H3.4 Histone Gene | HIST3H3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555427","H3C14 Gene","C154645","This gene plays a role in the incorporation of DNA into nucleosomes.","H3C14 Gene | H3 Clustered Histone 14 Gene | H3C14 | HIST2H3C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555421","H3C15 Gene","C154643","This gene is involved in the formation of complex DNA-containing structures.","H3C15 Gene | H3 Clustered Histone 15 Gene | H3C15 | HIST2H3A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555347","H3C12 Gene","C154546","This gene plays a role in chromatin structure.","H3C12 Gene | H3 Clustered Histone 12 Gene | H3C12 | HIST1H3J | HIST1H3J Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555340","H3C11 Gene","C154543","This gene is involved in the structure of nucleosomes.","H3C11 Gene | H3 Clustered Histone 11 Gene | H3C11 | HIST1H3I | HIST1H3I Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555337","H3C10 Gene","C154540","This gene plays a role in nucleosome formation.","H3C10 Gene | H3 Clustered Histone 10 Gene | H3C10 | HIST1H3H | HIST1H3H Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555339","H3C8 Gene","C154538","This gene is involved in the formation of higher order nucleosome structures.","H3C8 Gene | H3 Clustered Histone 8 Gene | H3C8 | HIST1H3G | HIST1H3G Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555334","H3C7 Gene","C154536","This gene plays a role in the formation of higher order chromosome structures.","H3C7 Gene | H3 Clustered Histone 7 Gene | H3C7 | HIST1H3F | HIST1H3F Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555315","H3C6 Gene","C154512","This gene is involved in the modulation of DNA compartmentalization.","H3C6 Gene | H3 Clustered Histone 6 Gene | H3C6 | HIST1H3E | HIST1H3E Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555412","H3C4 Gene","C154500","This gene plays a role in chromosome dynamics.","H3C4 Gene | H3 Clustered Histone 4 Gene | H3C4 | HIST1H3D | HIST1H3D Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555406","H3C3 Gene","C154489","This gene is involved in the regulation of chromosome dynamics.","H3C3 Gene | H3 Clustered Histone 3 Gene | H3C3 | HIST1H3C | HIST1H3C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555401","H3C1 Gene","C154487","This gene plays a role in DNA compartmentalization.","H3C1 Gene | H3 Clustered Histone 1 Gene | H3C1 | HIST1H3A | HIST1H3A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415386","H1-2 Gene","C162853","This gene plays a role in linker histone-dependent nucleosome spacing.","H1-2 Gene | H1-2 | H1.2 Linker Histone, Cluster Member Gene | HIST1H1C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555446","H3-5 Gene","C154666","This gene is involved in the regulation of DNA accessibility.","H3-5 Gene | H3-5 | H3.5 Histone Gene | H3F3C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539614","GREM1 Gene","C151999","This gene is involved in the downregulation of bone morphogenetic protein signaling.","GREM1 Gene | GREM1 | Gremlin 1, DAN Family BMP Antagonist Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413005","Simplified Chinese","C175576","A modified written form of the traditional Chinese language that is used officially in mainland China and Singapore, and is often used by the Chinese community in Malaysia. The standardized, simplified characters have fewer strokes, which is designed to make them easier to read and write.","Simplified Chinese | Simplified Chinese Language",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413002","Traditional Chinese","C175577","The conventional written form of the Chinese language that is used officially in Taiwan, Hong Kong, and Macau. Traditional characters retain the complex forms that have been used for thousands of years throughout Chinese history.","Traditional Chinese | Traditional Chinese Language",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825938","MAGI2 Gene","C95812","This gene plays a role in protein localization.","MAGI2 Gene | MAGI2 | Membrane Associated Guanylate Kinase, WW and PDZ Domain Containing 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334331","LATS2 Gene","C24542","This gene plays a role in the maintenance of genomic stability.","LATS2 Gene | LATS, Large Tumor Suppressor, Homolog 2 (Drosophila) Gene | LATS2 | Large Tumor Suppressor Kinase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1367460","LATS1 Gene","C24541","This gene is involved in the maintenance of genomic stability.","LATS1 Gene | LATS, Large Tumor Suppressor, Homolog 1 (Drosophila) Gene | LATS1 | Large Tumor Suppressor Kinase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1847413","KMT2B Gene","C115962","This gene is involved in both histone methylation and transcriptional regulation.","KMT2B Gene | KMT2B | Lysine (K)-Specific Methyltransferase 2B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022546","KEL Gene","C147984","This gene is involved in endothelin-converting enzyme activity.","KEL Gene | KEL | Kell Blood Group, Metallo-Endopeptidase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334138","IRF2 Gene","C24521","This gene is involved in the repression of IRF1-activated transcription. It also plays a role in the transcriptional activation of target genes.","IRF2 Gene | IRF2 | Interferon Regulatory Factor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334133","INSR Gene","C24516","This gene is involved in glucose uptake regulation.","INSR Gene | INSR | Insulin Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416442","INPP4A Gene","C170411","This gene is involved in the dephosphorylation of phosphoinositides.","INPP4A Gene | INPP4A | Inositol Polyphosphate-4-Phosphatase Type I A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334130","INHA Gene","C24512","This gene plays a role in negatively regulating stromal cell proliferation in the gonads. It is also involved in cell growth and differentiation.","INHA Gene | INHA | Inhibin, Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334083","IFNGR1 Gene","C37280","This gene is involved in receptor-mediated signal transduction in the interferon gamma signaling pathway.","IFNGR1 Gene | IFNGR1 | Interferon Gamma Receptor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417377","MST1 Gene","C131151","This gene plays a role in both macrophage activation and ciliary motility.","MST1 Gene | MST1 | Macrophage Stimulating 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422345","MGA Gene","C115316","This gene plays a role in the modulation of the expression of MYC and MAX target genes.","MGA Gene | MAX Dimerization Protein MGA Gene | MGA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545771","MAP3K4 Gene","C147955","This gene plays a role in environmental stress-activated signaling pathways.","MAP3K4 Gene | MAP3K4 | Mitogen-Activated Protein Kinase Kinase Kinase 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970618","CD14 Positive","C162090","An indication that CD14 expression has been detected in a sample.","CD14 Positive | CD14 Antigen Positive | CD14 Molecule Positive | Lipopolysaccharide Receptor Positive | Monocyte Differentiation Antigen CD14 Positive | Myeloid Cell-Specific Leucine-Rich Glycoprotein Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419124","PTPRS Gene","C124923","This gene is involved in protein dephosphorylation.","PTPRS Gene | PTPRS | Protein Tyrosine Phosphatase, Receptor Type, S Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418974","PRSS8 Gene","C26588","This gene is involved in proteolysis in seminal fluid.","PRSS8 Gene | PRSS8 | Protease, Serine, 8 (Prostasin) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418838","PPP2R2A Gene","C134506","This gene is involved in the regulation of protein phosphatase 2 activity.","PPP2R2A Gene | PPP2R2A | Protein Phosphatase 2 Regulatory Subunit Balpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424869","PNRC1 Gene","C96354","This gene plays a role in transcriptional regulation.","PNRC1 Gene | PNRC1 | Proline-Rich Nuclear Receptor Coactivator 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426344","PLK2 Gene","C24818","This gene is involved in normal cell division.","PLK2 Gene | PLK2 | Polo-Like Kinase 2 (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335215","PIK3R3 Gene","C24674","This gene plays a role in cell cycle regulation and hormonal signaling.","PIK3R3 Gene | PIK3R3 | Phosphoinositide-3-Kinase Regulatory Subunit 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418573","PIK3C2G Gene","C102945","This gene is involved in the phosphorylation of phosphoinositol.","PIK3C2G Gene | PIK3C2G | Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Gamma Gene | Phosphatidylinositol-4-Phosphate 3-Kinase, Catalytic Subunit Type 2 Gamma Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335204","PDPK1 Gene","C24669","This gene plays a role in cellular signaling and development.","PDPK1 Gene | 3-Phosphoinositide Dependent Protein Kinase-1 Gene | PDPK1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418270","PRKN Gene","C90311","This gene may play a role in the mediation of proteasomal targeting.","PRKN Gene | PARK2 | PRKN | Parkin RBR E3 Ubiquitin Protein Ligase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538830","COP1 Gene","C119604","This gene is involved in the ubiquitination of target proteins.","COP1 Gene | COP1 | COP1, E3 Ubiquitin Ligase Gene | RFWD2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419277","RASA1 Gene","C91775","This gene is involved in the modulation of GTPase activity.","RASA1 Gene | RAS p21 Protein Activator 1 Gene | RASA1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419748","RPS6KB1 Gene","C84314","This gene is involved in protein phosphorylation.","RPS6KB1 Gene | RPS6KB1 | Ribosomal Protein S6 Kinase, 70kDa, Polypeptide 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335645","RPS6KB2 Gene","C24754","This gene is involved in the regulation of cell growth and proliferation.","RPS6KB2 Gene | RPS6KB2 | Ribosomal Protein S6 Kinase, 70kDa, Polypeptide 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538143","ZBTB7A Gene","C43388","This gene is involved in regulation of transcription and plays a role in cell organization/biogenesis.","ZBTB7A Gene | ZBTB7A | Zinc Finger and BTB Domain Containing 7A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336657","TOP2A Gene","C26592","This gene plays a role in DNA replication, chromosome recombination and the regulation of DNA topology during transcription.","TOP2A Gene | DNA Topoisomerase II Alpha Gene | TOP2A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420627","ELOC Gene","C115421","This gene plays a role in transcriptional elongation.","ELOC Gene | ELOC | Elongin C Gene | TCEB1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420331","SOX9 Gene","C75516","This gene plays roles in transcription, osteogenesis, chondrogenesis and testis development.","SOX9 Gene | SOX9 | SRY-Box 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412943","Tandem Chimeric Antigen Receptor","C175586","A chimeric antigen receptor engineered to with two antigen domains linked consecutively, designed to target two distinct tumor antigens.","Tandem Chimeric Antigen Receptor | Bispecific CAR | Bispecific Chimeric Antigen Receptor | Dual-Targeted CAR | Dual-Targeted Chimeric Antigen Receptor | Tandem | Tandem CAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412941","Bicistronic Chimeric Antigen Receptor Vector","C175587","A genetic vector (plasmid, viral vector or artificial chromosome) that is engineered to express two distinct chimeric antigen receptor proteins.","Bicistronic Chimeric Antigen Receptor Vector | Bicistronic | Bicistronic CAR Construct | Bicistronic CAR Vector | Bicistronic Chimeric Antigen Receptor Construct",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0450357","Arabic numeral 32","C175622","The natural number greater than thirty-one and less than thirty-three and the quantity that it denotes.","Thirty Two | 32 | Thirty-Two",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0450358","Thirty Three","C175623","The natural number greater than thirty-two and less than thirty-four and the quantity that it denotes.","Thirty Three | 33 | Thirty-Three",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413512","Thirty Four","C175624","The natural number greater than thirty-three and less than thirty-five and the quantity that it denotes.","Thirty Four | 34 | Thirty-Four",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL535275","35 (qualifier value)","C175625","The natural number greater than thirty-four and less than thirty-six and the quantity that it denotes.","Thirty Five | 35 | Thirty-Five",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL535316","36 (qualifier value)","C175626","The natural number greater than thirty-five and less than thirty-seven and the quantity that it denotes.","Thirty Six | 36 | Thirty-Six",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL535320","37 (qualifier value)","C175627","The natural number greater than thirty-six and less than thirty-eight and the quantity that it denotes.","Thirty Seven | 37 | Thirty-Seven",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0450361","Arabic numeral 38","C175628","The natural number greater than thirty-seven and less than thirty-nine and the quantity that it denotes.","Thirty Eight | 38 | Thirty-Eight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427487","ANKRD11 Gene","C175612","This gene is involved in the modulation of chromatin remodeling.","ANKRD11 Gene | ANKRD11 | Ankyrin Repeat Domain 11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824894","DCUN1D1 Gene","C175615","This gene plays a role in the positive regulation of neddylation of cullin proteins.","DCUN1D1 Gene | DCUN1D1 | Defective in Cullin Neddylation 1 Domain Containing 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413955","DHX15 Gene","C175618","This gene is involved in spliceosome disassembly.","DHX15 Gene | DEAH-Box Helicase 15 Gene | DHX15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427021","EGFL7 Gene","C175629","This gene plays a role in vasculogenesis.","EGFL7 Gene | EGF Like Domain Multiple 7 Gene | EGFL7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424887","NEGR1 Gene","C175632","This gene may be involved in cell adhesion and axon sprouting.","NEGR1 Gene | NEGR1 | Neuronal Growth Regulator 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423829","PAK5 Gene","C175635","This gene plays a role in cytoskeletal modeling in brain cells.","PAK5 Gene | PAK5 | PAK7 | p21 (RAC1) Activated Kinase 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419203","RAB35 Gene","C175638","This gene is involved in cytokinesis and intracellular trafficking of membrane proteins.","RAB35 Gene | RAB35 | RAB35, Member RAS Oncogene Family Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419390","RIT1 Gene","C175641","This gene plays a role in the positive regulation of ephrin, mitogen-activated protein kinase and nerve growth factor signaling pathways.","RIT1 Gene | RIT1 | Ras Like Without CAAX 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419745","RPS6KA4 Gene","C175644","This gene is involved in the regulation of mitogen- and stress-dependent protein phosphorylation.","RPS6KA4 Gene | RPS6KA4 | Ribosomal Protein S6 Kinase A4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539769","SHQ1 Gene","C175647","This gene plays a role in both telomerase stabilization and H/ACA ribonucleoprotein complex assembly.","SHQ1 Gene | SHQ1 | SHQ1, H/ACA Ribonucleoprotein Assembly Factor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420385","SPTA1 Gene","C175650","This gene is involved in erythrocyte cytoskeleton assembly.","SPTA1 Gene | SPTA1 | Spectrin Alpha, Erythrocytic 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823134","STK40 Gene","C175653","This gene plays a role in the inhibition of p53-mediated transcription and TNF-dependent activation of NF-kappa-B.","STK40 Gene | STK40 | Serine/Threonine Kinase 40 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427175","ZBTB2 Gene","C175656","This gene may be involved in epigenetic repression of gene transcription.","ZBTB2 Gene | ZBTB2 | Zinc Finger and BTB Domain Containing 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412968","Clinician Dashboard","C175660","A web platform designed for clinicians that populates with patient information derived from the patient's interactions in an online treatment decision support tool. The CBD provides clinicians with a summary of their patient's level of knowledge, treatment concerns, and emotional state.","Clinician Dashboard | CDB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0581712","Devascularization","C175666","A procedure that interrupts blood supply to an organ or tissue.","Devascularization | Devascularization Procedure",,,,,,,,,,,,,,,"4185004","Devascularization - action",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1304687","Red Blood Cells Product","C133280","Red blood cells remaining after separating plasma from human blood, or collected by apheresis.","Red Blood Cells Product | RBC | Red Blood Cells",,,,,,,,,,,,,,,"4054726|4129597","Red blood cells, blood product|Human red blood cells, blood product",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1419776","RYBP Gene","C175671","This gene is involved in histone ubiquitination and transcriptional repression.","RYBP Gene | RING1 and YY1 Binding Protein Gene | RYBP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL535339","42 (qualifier value)","C175676","The natural number greater than forrty-one and less than forty-three and the quantity that it denotes.","Forty Two | 42 | Forty-Two",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL535332","45 (qualifier value)","C175677","The natural number greater than forty-four and less than forty-six and the quantity that it denotes.","Forty Five | 45 | Forty-Five",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL535364","48 (qualifier value)","C175678","The natural number greater than forty-seven and less than forty-nine and the quantity that it denotes.","Forty Eight | 48 | Forty-Eight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412995","Fifty One","C175679","The natural number greater than fifty and less than fifty-two and the quantity that it denotes.","Fifty One | 51 | Fifty-One",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL535348","54 (qualifier value)","C175680","The natural number greater than fifty-three and less than fifty-five and the quantity that it denotes.","Fifty Four | 54 | Fifty-Four",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL535390","57 (qualifier value)","C175681","The natural number greater than fifty-six and less than fifty-eight and the quantity that it denotes.","Fifty Seven | 57 | Fifty-Seven",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705336","FOLH1 wt Allele","C49386","Human FOLH1 wild-type allele is located in the vicinity of 11p11.2 and is approximately 62 kb in length. This allele, which encodes glutamate carboxypeptidase 2 protein, plays a role in both the uptake of folate in the intestine and the hydrolysis of N-aceylaspartylglutamate, the major neurotransmitter in the brain. This gene is overexpressed in human prostate cancer and may inhibit metastasis of this disease.","FOLH1 wt Allele | FGCP | FOLH | Folate Hydrolase (Prostate-Specific Membrane Antigen) 1 Gene | Folate Hydrolase 1 wt Allele | GCP2 | GCPII | GIG27 | NAALAD1 | NAALAdase | PSM | PSMA | mGCP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413513","ENABLE","C175704","A telehealth approach for palliative care targeted to rural patients with advanced cancer or other serious illnesses and their family caregivers.","ENABLE | Educate, Nurture, Advise Before Life Ends | Project ENABLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413179","Nurse Coach","C175713","A registered nurse with specialized training in peer and/or health and wellness coaching that provides guidance and resources to patients, colleagues, or institutions towards making positive changes and achieving goals.","Nurse Coach | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036800","Serum Globulins","C17125","A family of globular proteins found in blood that does not include albumin. These proteins are insoluble in water but solubility is increased in dilute salt solutions. Globulins are grouped into four categories (alpha 1, alpha 2, beta and gamma) based on differences in electrophoretic mobility.","Serum Globulin | Globulin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412993","PSA Level 0.05 to 0.7","C175682","A blood concentration of prostate specific antigen between 0.05 and 0.7 ng/mL.","PSA Level 0.05 to 0.7 | PSA Level Between 0.05 and 0.7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412994","CHIC2 Gene Deletion","C175683","A molecular abnormality referring to the loss of at least one copy of the CHIC2 gene.","CHIC2 Gene Deletion | BTL Gene Deletion | BrX-Like Gene Translocated in Leukemia Gene Deletion | CHIC2 Deletion | Cysteine Rich Hydrophobic Domain 2 Gene Deletion | Cysteine-Rich Hydrophobic Domain 2 Gene Deletion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412991","Globo H Positive","C175684","An indication that the hexasaccharide glycosphingolipid and human cancer antigen globohexaosylceramide (Globo H) has been detected in a sample.","Globo H Positive | Globo-H Positive | Globohexaosylceramide Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412992","MAP2K1 Gene Mutation Negative","C175685","A genetic finding indicating that MAP2K1 gene mutations have not been detected in a sample.","MAP2K1 Gene Mutation Negative | MAP2K1 Mutation Negative | MAP2K1 Wild Type | MAP2K1 Wildtype | MAP2K1 wt | MAPKK1 Gene Mutation Negative | MEK1 Gene Mutation Negative | MKK1 Gene Mutation Negative | Mitogen-Activated Protein Kinase Kinase 1 Gene Mutation Negative | PRKMK1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412989","Ki-67 Positive Cells Greater than or Equal to 20 Percent","C175686","A semi-quantitative microscopic finding indicating that at least 20 percent of the cells in a sample are detected following staining using an anti-Ki-67 antibody.","Ki-67 Positive Cells Greater than or Equal to 20 Percent | Antigen Ki-67 Positive Cells Greater than or Equal to 20 Percent | KI67 Positive Cells Greater than or Equal to 20 Percent | Ki-67 Antigen Positive Cells Greater than or Equal to 20 Percent | Ki-67 Positive Cells 20 Percent or Greater | Ki-67 Positive Cells 20 Percent or More | MKI67 Positive Cells Greater than or Equal to 20 Percent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412990","ARID1A Gene Mutation Negative","C175687","A genetic finding indicating that ARID1A gene mutations have not been detected in a sample.","ARID1A Gene Mutation Negative | ARID1A Mutation Negative | ARID1A Wild Type | ARID1A Wildtype | ARID1A wt | AT Rich Interactive Domain 1A Gene Mutation Negative | B120 Gene Mutation Negative | BAF250 Gene Mutation Negative | BAF250a Gene Mutation Negative | BRG1-Associated Factor 250a Gene Mutation Negative | SMARCF1 Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412987","TP53 Gene Nonsense Mutation","C175688","A change in the sequence of the TP53 gene that encodes a premature stop codon.","TP53 Gene Nonsense Mutation | LFS1 Gene Nonsense Mutation | Li-Fraumeni Syndrome Gene Nonsense Mutation | P53 Gene Nonsense Mutation | TP53 Nonsense Mutation | TRP53 Gene Nonsense Mutation | Tumor Protein p53 Gene Nonsense Mutation | p53 Nonsense Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412988","Non-Synonymous TP53 Gene Mutation","C175689","A change in the nucleotide sequence in the TP53 gene that encodes an amino acid substitution in the cellular tumor antigen p53 protein.","Non-Synonymous TP53 Gene Mutation | Non-Synonymous LFS1 Gene Mutation | Non-Synonymous Li-Fraumeni Syndrome Gene Mutation | Non-Synonymous P53 Gene Mutation | Non-Synonymous TP53 Mutation | Non-Synonymous TRP53 Gene Mutation | Non-Synonymous Tumor Protein p53 Gene Mutation | Non-Synonymous p53 Mutation | Non-synonymous TP53 Gene Mutation | TP53 Gene Missense Mutation | TP53 Missense Mutation | p53 Missense Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412985","RB1 Gene Nonsense Mutation","C175690","A change in the sequence of the RB1 gene that encodes a premature stop codon.","RB1 Gene Nonsense Mutation | RB Gene Nonsense Mutation | RB Nonsense Mutation | RB1 Nonsense Mutation | Retinoblastoma 1 Gene Nonsense Mutation | Retinoblastoma Gene Nonsense Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412986","RB1 Gene Frameshift Mutation","C175691","A deletion or insertion mutation in the RB1 gene that shifts the reading frame for the transcript.","RB1 Gene Frameshift Mutation | RB Frameshift Mutation | RB Gene Frameshift Mutation | RB1 Frameshift Mutation | Retinoblastoma 1 Gene Frameshift Mutation | Retinoblastoma Gene Frameshift Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412983","PTEN Gene Frameshift Mutation","C175692","A deletion or insertion mutation in the PTEN gene that shifts the reading frame for the transcript.","PTEN Gene Frameshift Mutation | MMAC1 Gene Frameshift Mutation | Mutated in Multiple Advanced Cancers 1 Gene Frameshift Mutation | PTEN Frameshift Mutation | PTEN1 Gene Frameshift Mutation | Phosphatase and Tensin Homolog Gene Frameshift Mutation | TEP1 Gene Frameshift Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412981","Non-Synonymous RB1 Gene Mutation","C175694","A change in the nucleotide sequence in the RB1 gene that encodes an amino acid substitution in the retinoblastoma-associated protein.","Non-Synonymous RB1 Gene Mutation | Non-Synonymous RB Gene Mutation | Non-Synonymous RB Mutation | Non-Synonymous RB1 Mutation | Non-Synonymous Retinoblastoma 1 Gene Mutation | Non-Synonymous Retinoblastoma Gene Mutation | Non-synonymous RB1 Gene Mutation | RB Missense Mutation | RB1 Gene Missense Mutation | RB1 Missense Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412984","TP53 Gene Frameshift Mutation","C175693","A deletion or insertion mutation in the TP53 gene that shifts the reading frame for the transcript.","TP53 Gene Frameshift Mutation | LFS1 Gene Frameshift Mutation | Li-Fraumeni Syndrome Gene Frameshift Mutation | P53 Gene Frameshift Mutation | TP53 Frameshift Mutation | TRP53 Gene Frameshift Mutation | Tumor Protein p53 Gene Frameshift Mutation | p53 Frameshift Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412982","Non-Synonymous PTEN Gene Mutation","C175695","A change in the nucleotide sequence in the PTEN gene that encodes an amino acid substitution in the phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN protein.","Non-Synonymous PTEN Gene Mutation | Non-Synonymous MMAC1 Gene Mutation | Non-Synonymous Mutated in Multiple Advanced Cancers 1 Gene Mutation | Non-Synonymous PTEN Mutation | Non-Synonymous PTEN1 Gene Mutation | Non-Synonymous Phosphatase and Tensin Homolog Gene Mutation | Non-Synonymous TEP1 Gene Mutation | Non-synonymous PTEN Gene Mutation | PTEN Gene Missense Mutation | PTEN Missense Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412979","PTEN Gene Nonsense Mutation","C175696","A change in the sequence of the PTEN gene that encodes a premature stop codon.","PTEN Gene Nonsense Mutation | MMAC1 Gene Nonsense Mutation | Mutated in Multiple Advanced Cancers 1 Gene Nonsense Mutation | PTEN Nonsense Mutation | PTEN1 Gene Nonsense Mutation | Phosphatase and Tensin Homolog Gene Nonsense Mutation | TEP1 Gene Nonsense Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412980","FGFR4 Gene Fusion Positive","C175697","An indication that a FGFR4 fusion gene has been detected in a sample.","FGFR4 Gene Fusion Positive | CD334 Gene Fusion Positive | FGFR-4 Gene Fusion Positive | FGFR4 Fusion | Fibroblast Growth Factor Receptor 4 Gene Fusion Positive | JKT2 Gene Mutation Fusion Positive | JTK2 Gene Mutation Fusion Positive | TKF Gene Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412977","Circulating Tumor-Derived RNA","C175698","Cell-free, neoplasm-derived RNA found in a blood, serum or plasma sample.","Circulating Tumor-Derived RNA | Circulating Tumor RNA | ctRNA | ctdRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412978","PSA Level Greater than Fifteen","C175699","A blood concentration of prostate specific antigen greater than 15 ng/mL.","PSA Level Greater than Fifteen | PSA Level Greater than 15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412976","NLRC4 Gene Mutation","C175709","A change in the nucleotide sequence of the NLRC4 gene.","NLRC4 Gene Mutation | CARD12 Gene Mutation | CLAN Gene Mutation | CLAN1 Gene Mutation | IPAF Gene Mutation | NLR Family CARD Domain Containing 4 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513753","Multipotent Bone Marrow Stem Cell","C41058","A bone marrow myeloid stem cell that can differentiate into all the blood lineages.","Multipotent Bone Marrow Stem Cell | Bone Marrow Stem Cell with Variable Lineage Potential | MPP | Multipotent Progenitor | Multipotent Progenitor Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596993","Myeloid Progenitor Cells","C12552","A hematopoietic stem cell found in the bone marrow that is committed to form erythrocytes, megakaryocytes, and all leukocytes except lymphocytes.","Bone Marrow Myeloid Stem Cell | CFU-GEMM | CFU-M | CMP | Common Myeloid Progenitor | Common Myeloid Progenitor Cell | Multipotent Bone Marrow Stem Cell with Wide Myeloid Potential | Myeloid Colony Forming Unit | Myeloid Progenitor Cell | Myeloid Progenitor Cells | Myeloid Stem Cell | Myeloid Stem Cells | Primitive Bone Marrow Myeloid Stem Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706982","Granulocyte-Monocyte Progenitor Cell","C42766","A primitive, undifferentiated blood cell which can undergo division and give rise to white blood cells in the neutrophil, eosinophil, basophil or monocyte lines.","Granulocyte-Monocyte Progenitor Cell | Bone Marrow Stem Cell with Potential to Differentiate to Granulocytic and Monocytic Lineages | Bone Marrow Stem Cell with Potential to Differentiate to Granulocytic and Monocytic Lineages | GM-CFC | GMP | Granulocyte-Monocyte Progenitor | Granulocyte-Monocyte Progenitor Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413120","Impact of Weight on Quality of Life-Lite","C175905","A 31-item, self-report questionnaire that utilizes a five-point rating scale to measure obesity-specific quality of life in adults. The assessment consists of a total score, as well as individual scores for each of five specific domains, including physical function, self-esteem, sexual life, public distress, and work.","Impact of Weight on Quality of Life-Lite | IWQOL-Lite | Impact of Weight on Quality of Life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413117","Because of My Weight","C175906","A question about the effects of an individual's weight.","Because of My Weight | Because of my weight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413118","Have Trouble Picking up Objects","C175907","A question about whether an individual has or had trouble picking up objects.","Have Trouble Picking up Objects | I have trouble picking up objects",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413115","HaveTrouble Tying Shoelaces","C175908","A question about whether an individual has or had trouble typing shoelaces.","Have Trouble Tying Shoelaces Question | Have Trouble Tying Shoelaces | Have Trouble Tying Shoelaces | HaveTrouble Tying Shoelaces | I have trouble tying my shoelaces",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413116","Have Difficulty Getting up From Chairs","C175909","A question about whether an individual has or had difficulty getting up from chairs.","Have Difficulty Getting up From Chairs Question | Have Difficulty Getting up From Chairs | Have Difficulty Getting up From Chairs | I have difficulty getting up from chairs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413113","Have Trouble Using Stairs","C175910","A question about whether an individual has or had trouble using stairs.","Have Trouble Using Stairs Question | Have Trouble Using Stairs | Have Trouble Using Stairs | I have trouble using stairs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413114","Have Difficulty Putting on or Taking Off Clothes","C175911","A question about whether an individual has or had difficulty putting on or taking off clothes.","Have Difficulty Putting on or Taking Off Clothes | I have difficulty putting on or taking off my clothes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413111","Have Trouble with Mobility","C175912","A question about whether an individual has or had trouble with mobility.","Have Trouble with Mobility | I have trouble with mobility (getting around)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413112","Have Trouble Crossing Legs","C175913","A question about whether an individual has or had trouble crossing legs.","Have Trouble Crossing Legs | I have trouble crossing my legs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413110","Feel Short of Breath with Only Mild Exertions","C175915","A question about whether an individual feels or felt short of breath with only mild exertions.","Feel Short of Breath with Only Mild Exertions | I feel short of breath with only mild exertions (e.g., climbing a single flight of stairs)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413107","Troubled by Painful or Stiff Joints","C175916","A question about whether an individual has or had trouble by painful or stiff joints.","Troubled by Painful or Stiff Joints | I am troubled by painful or stiff joints",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413108","Ankles and Lower Legs Swollen at End of the Day","C175917","A question about whether an individual has or had ankles and lower legs swollen at the end of the day.","Ankles and Lower Legs Swollen at End of the Day | My ankles and lower legs are swollen at the end of the day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413105","Am Self-Conscious","C175918","A question about whether an individual is or has been self-conscious.","Am Self-Conscious | I am self-conscious",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413106","Self-Esteem Not What it Could be","C175919","A question about whether an individual's self-esteem is or was not what it could be.","Self-Esteem Not What it Could be | My self-esteem is not what it could be",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413103","Feel Unsure of Myself","C175920","A question about whether an individual feels or felt unsure of themselves.","Feel Unsure of Myself | I feel unsure of myself",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413104","Afraid of Being Rejected","C175921","A question about whether an individual is or was afraid of being rejected.","Afraid of Being Rejected Question | Afraid of Being Rejected | Afraid of Being Rejected | I am afraid of being rejected",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413101","Embarrassed to be Seen in Public","C175922","A question about whether an individual is or was embarrassed to be seen in public places.","Embarrassed to be Seen in Public | I am embarrassed to be seen in public places",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413102","Avoid Looking in Mirrors","C175923","A question about whether an individual avoids or avoided looking in mirrors.","Avoid Looking in Mirrors | I avoid looking in mirrors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413099","Does Not Enjoy Sexual Activity","C175924","A question about whether an individual does or did not enjoy sexual activity.","Does Not Enjoy Sexual Activity | Do Not Enjoy Sexual Activity | I do not enjoy sexual activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413100","Have Little or no Sexual Desire","C175925","A question about whether an individual has or had little or no sexual desire.","Have Little or no Sexual Desire | I have little or no sexual desire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413097","Have Difficulty with Sexual Performance","C175926","A question about whether an individual has or had difficulty with sexual performance.","Have Difficulty with Sexual Performance | I have difficulty with sexual performance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413098","Avoid Sexual Encounters Whenever Possible","C175927","A question about whether an individual avoids or avoided sexual encounters whenever possible.","Avoid Sexual Encounters Whenever Possible | I avoid sexual encounters whenever possible",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413095","Experience Ridicule, Teasing or Unwanted Attention","C175928","A question about whether an individual has or had experienced ridicule, teasing or unwanted attention.","Experience Ridicule, Teasing or Unwanted Attention | I experience ridicule, teasing or unwanted attention",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413096","Worry About Fitting Into Seats in Public Places","C175929","A question about whether an individual worries or worried about fitting into seats in public places.","Worry About Fitting Into Seats in Public Places | I worry about fitting into seats in public places",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413093","Worry About Fitting Through Aisles or Turnstiles","C175930","A question about whether an individual worries or worried about fitting through aisles or turnstiles.","Worry About Fitting Through Aisles or Turnstiles | I worry about fitting through aisles or turnstiles",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413094","Worry About Finding Chairs That are Strong Enough to Hold Weight","C175931","A question about whether an individual worries or worried about finding chairs that are strong enough to hold their weight.","Worry About Finding Chairs That are Strong Enough to Hold Weight | I worry about finding chairs that are strong enough to hold my weight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413091","Experience Discrimination by Others","C175932","A question about whether an individual experiences or experienced discrimination by others.","Experience Discrimination by Others | I experience discrimination by others",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509685","Anti-PD1 Monoclonal Antibody","C128037","A monoclonal antibody directed against programmed cell death protein 1 (PD-1; PD1; CD279).","Anti-PD1 Monoclonal Antibody | Anti-PD-1 Monoclonal Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509684","Anti-PD-L1 Monoclonal Antibody","C128057","A monoclonal antibody directed against programmed death-ligand 1 (PD-L1; CD274).","Anti-PD-L1 Monoclonal Antibody | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0860978","Ionized Magnesium Measurement","C175951","A measurement of the ionized magnesium in a biological specimen.","Ionized Magnesium Measurement | MGION | Magnesium, Ionized",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413126","Have Trouble Getting Things Done or Carrying Out my Responsibilities","C175963","A question about whether an individual has or had trouble getting things done or carrying out their responsibilities.","Have Trouble Getting Things Done or Carrying Out my Responsibilities | I have trouble getting things done or carrying out my responsibilities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413123","Less Productive Than Could Be","C175964","A question about whether an individual is or was less productive than they could be.","Less Productive Than Could Be | I am less productive than I could be",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413124","Do Not Receive Appropriate Pay Increases, Promotions, or Recognition at Work","C175965","A question about whether an individual does or did not receive appropriate pay increases, promotions, or recognition at work.","Do Not Receive Appropriate Pay Increases, Promotions, or Recognition at Work | I don't receive appropriate pay increases, promotions or recognition at work",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413121","Afraid of Job Interviews","C175966","A question about whether an individual is or was afraid of job interviews.","Afraid of Job Interviews | I am afraid to go for job interviews",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551156","Exon Mutation","C148639","A change in the nucleotide sequence of an exon in a gene.","Exon Mutation | Coding Region Mutation | Coding Sequence Variant | Exon Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0599220","Protein Subunits","C118424","A polypeptide chain that associates with itself or at least one other chain to form a functional protein or protein complex.","Protein Subunit | PROTEIN SUBUNIT | Subunit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413327","ADA2 Gene","C173459","This gene plays a role in hydrolysis of adenosine.","ADA2 Gene | ADA2 | Adenosine Deaminase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412179","ADA Gene","C30156","This gene is involved in nucleotide metabolism and cellular immunity.","ADA Gene | ADA | Adenosine Deaminase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413223","CD3G Gene","C38900","This gene is involved in development and immunity/defense.","CD3G Gene | CD3G | CD3G Antigen, Gamma Polypeptide (TiT3 Complex) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332711","CD3E Gene","C24277","This gene plays a role in immunity/defense and the positive regulation of cell proliferation.","CD3E Gene | CD3E | CD3E Antigen, Epsilon Polypeptide (TiT3 Complex) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413222","CD3D Gene","C38898","This gene is involved in immunity/defense via the activation of T cells.","CD3D Gene | CD3D | CD3D Antigen, Delta Polypeptide (TiT3 Complex) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412546","ARPC1B Gene","C91769","This gene is involved in actin polymerization.","ARPC1B Gene | ARPC1B | Actin Related Protein 2/3 Complex, Subunit 1B, 41kDa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412186","ADAM17 Gene","C48217","This gene plays a role in the cleavage of membrane proteins, resulting in the release of their extracellular domains from cells.","ADAM17 Gene | ADAM Metallopeptidase Domain 17 Gene | ADAM17",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1333352","ERBIN Gene","C24374","This gene is involved in signal transduction and protein localization and function.","ERBIN Gene | ERBB2 Interacting Protein Gene | ERBB2IP | ERBIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427726","IRF2BP2 Gene","C107664","This gene plays a role in transcriptional repression.","IRF2BP2 Gene | IRF2BP2 | Interferon Regulatory Factor 2 Binding Protein 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334137","IRAK4 Gene","C26302","This gene plays a role in signal transduction and the immune response.","IRAK4 Gene | IRAK4 | Interleukin 1 Receptor Associated Kinase 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334116","IL2RG Gene","C24500","This gene plays a role in immune function and mediates T-cell responses.","IL2RG Gene | IL2RG | Interleukin 2 Receptor Subunit Gamma Gene | Interleukin 2 Receptor, Gamma Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334114","IL2RA Gene","C21563","This gene plays a role in clathrin-independent endocytosis and immune functions.","IL2RA Gene | IL2RA | Interleukin 2 Receptor Subunit Alpha Gene | Interleukin 2 Receptor, Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334097","IL10RB Gene","C24492","This gene plays a role in cytokine regulation and signal transduction.","IL10RB Gene | IL10RB | Interleukin 10 Receptor, Beta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416380","IKBKG Gene","C75607","This gene plays a role in the regulation of signal transduction.","IKBKG Gene | IKBKG | Inhibitor of Kappa Light Polypeptide Gene Enhancer in B-Cells, Kinase Gamma Gene | NEMO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0126732","NF-kappaB inhibitor alpha","C17678","NF-kappa-B inhibitor alpha (317 aa, ~36 kDa) is encoded by the human NFKBIA gene. This protein is involved in the cytoplasmic localization of the nuclear factor kappa B (NFkB) complex, which inhibits NFkB-mediated gene expression.","NF-Kappa-B Inhibitor Alpha | I Kappa B A | I Kappa B Alpha | I Kappa B-Alpha Protein | I-Kappa-B-Alpha | IKB-Alpha | IKBA | IKappaB-Alpha | IKappaB/MAD-3 | IkappaBalpha | Inhibitor of Kappa Light Chain Gene Enhancer in B Cells, Alpha | MAD-3 | MAD3 | Major Histocompatibility Complex Enhancer-Binding Protein MAD3 | NF-Kappa B Inhibitor Alpha | NFKBIA | Nuclear Factor Kappa-B Inhibitor Alpha | Nuclear Factor of Kappa Light Chain Gene Enhancer in B Cells Inhibitor, Alpha | Nuclear Factor of Kappa Light Polypeptide Gene Enhancer in B-Cells Inhibitor Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413406","Breast Cancer Self Efficacy Scale","C175992","A questionnaire designed to measure an individual's perceived ability to manage symptoms and quality-of-life problems resulting from the diagnosis and treatment of breast cancer.","Breast Cancer Self Efficacy Scale | BCSES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413407","Confident Am Able to Ask for Help for Problems Related to Breast Cancer","C175993","A question about whether an individual is confident that they can ask for help when they have problems related to their breast cancer.","Confident Am Able to Ask for Help for Problems Related to Breast Cancer | I am able to ask for help when I have problems related to my breast cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413404","Confident Am Able to Deal with Having Breast Cancer","C175994","A question about whether an individual is confident that they can deal with the fact that they have or had breast cancer.","Confident Am Able to Deal with Having Breast Cancer | I am able to deal with the fact that I had breast cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413405","Confident Am Able to Deal with Physical Symptoms of Breast Cancer","C175995","A question about whether an individual feels confident that they can deal with physical symptoms from breast cancer.","Confident Am Able to Deal with Physical Symptoms of Breast Cancer | I am able to deal with physical symptoms from having breast cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413402","Confident Am Able to Ask for Help for Breast Cancer Problems without Feeling Guilty","C175996","A question about whether an individual feels confident that they can ask for help for problems related to breast cancer without feeling guilty.","Confident Am Able to Ask for Help for Breast Cancer Problems without Feeling Guilty | I am able to ask for help for problems related to breast cancer without feeling guilty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413403","Confident Am Able to Handle Fears About Breast Cancer Returning","C175997","A question about whether an individual feels confident that they can handle their fears about breast cancer returning.","Confident Am Able to Handle Fears About Breast Cancer Returning | I am able to handle any fears I have about breast cancer returning",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413400","Confident Am Able to Successfully Handle Life Situations Since Having Breast Cancer","C175998","A question about whether an individual feels confident that they can successfully handle life situations since having breast cancer.","Confident Am Able to Successfully Handle Life Situations Since Having Breast Cancer | I am able to successfully handle life situations since I had breast cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413401","Confident Am Able to Have a Productive Work Life Even Though Had Breast Cancer","C175999","A question about whether an individual feels confident that they can have a productive work life even though they had breast cancer.","Confident Am Able to Have a Productive Work Life Even Though Had Breast Cancer | I am able to have a productive work life even though I had breast cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413446","Confident Am Able to Successfully Work Toward Personal Goals Since Having Breast Cancer","C176000","A question about whether an individual feels confident that they can successfully work toward their personal goals since they had breast cancer.","Confident Am Able to Successfully Work Toward Personal Goals Since Having Breast Cancer | I am able to successfully work toward my personal goals since I had breast cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413447","Confident Am Able to Successfully Deal with Emotions Since Having Breast Cancer","C176001","A question about whether an individual feels confident that they can successfully deal with their emotions since they had breast cancer.","Confident Am Able to Successfully Deal with Emotions Since Having Breast Cancer | I am able to successfully deal with my emotions since I had breast cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413444","Confident Am Able to Identify Body Changes Related to Return of Breast Cancer","C176002","A question about whether an individual feels confident that they can identify changes in their body that may be related to a return of their breast cancer.","Confident Am Able to Identify Body Changes Related to Return of Breast Cancer | I am able to identify changes in my body that may be related to a return of my breast cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413445","Comfortable Calling Healthcare Provider About Symptom that May be Related to Return of Breast Cancer","C176003","A question about whether an individual feels comfortable calling their healthcare provider if they notice a symptom that may be related to a return of their breast cancer.","Comfortable Calling Healthcare Provider About Symptom that May be Related to Return of Breast Cancer | I am comfortable calling my healthcare provider if I notice a symptom that may be related to a return of my breast cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413440","Aspiculate","C176006","Without, or lacking, spicules.","Aspiculate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413442","Defective T-Cell Receptor Signaling","C176004","An indication that T-cell receptor (TCR)-dependent signaling pathways in a immunologic sample are compromised. TCR signaling defects lead to impaired development of T-lymphocytes and are usually caused by deletion or loss of function mutations affecting one or more proteins involved in TCR-dependent signaling pathways, including the subunits of the TCR complex.","Defective T-Cell Receptor Signaling | Defective TCR Signaling | T Cell Receptor Signaling Defect | T-Cell Receptor Signaling Defect | TCR Signaling Defect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937232","MAGT1 Gene","C157561","This gene is involved in protein glycosylation and magnesium ion transport.","MAGT1 Gene | MAGT1 | Magnesium Transporter 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537630","LYST Gene","C24298","This gene plays a role in lysosomal protein trafficking and mutations in the gene cause Chediak-Higashi syndrome.","LYST Gene | LYST | Lysosomal Trafficking Regulator Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551932","PRKCD Gene","C150118","This gene plays a role in the regulation of both cell death and cell survival.","PRKCD Gene | PRKCD | Protein Kinase C Delta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417772","PNP Gene","C43239","This gene is involved in purine catabolism.","PNP Gene | PNP | Purine Nucleoside Phosphorylase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538486","NRK Gene","C88934","This gene is involved in intracellular signaling.","NRK Gene | NRK | Nik Related Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417693","NFAT5 Gene","C93131","This gene is involved in gene transcription and cellular stress responses.","NFAT5 Gene | NFAT5 | Nuclear Factor of Activated T-Cells 5, Tonicity-Responsive Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420507","STXBP2 Gene","C114622","This gene is involved in intracellular vesicle trafficking.","STXBP2 Gene | STXBP2 | Syntaxin Binding Protein 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420494","STX11 Gene","C114618","This gene plays a role in the targeting and fusion of intracellular transport vesicles.","STX11 Gene | STX11 | Syntaxin 11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420481","STK4 Gene","C99480","This gene is involved in both protein phosphorylation and the hippo signaling pathway.","STK4 Gene | STK4 | Serine/Threonine Kinase 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419248","RAG2 Gene","C80069","This gene plays a role in immunoglobulin diversity.","RAG2 Gene | RAG2 | Recombination Activating 2 Gene | Recombination Activating Gene 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085218","RAG1 Gene","C80068","This gene is involved in immunoglobulin diversity.","RAG1 Gene | RAG1 | Recombination Activating 1 Gene | Recombination Activating Gene 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419195","RAB27A Gene","C119634","This gene plays a role in the formation and release of lymphocytic granules.","RAB27A Gene | RAB27A | RAB27A, Member RAS Oncogene Family Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1865371","Severe Combined Immunodeficiency, Athabascan Type","C162694","An autosomal recessive condition caused by mutation(s) in the DCLRE1C gene, encoding protein artemis. It is characterized by severe combined immunodeficiency that is T-cell negative, B-cell negative, NK-cell positive. Sensitivity to ionizing radiation and a high incidence of occurrence amongst the Athabascan Indians are also characteristic of this disease.","Severe Combined Immunodeficiency, Athabascan Type | ART-SCID | Artemis-Deficient SCID | Artemis-Deficient Severe Combined Immunodeficiency | RS-SCID | Severe Combined Immunodeficiency, Athabaskan Type",,,,,,,,,,,,,,,"37396241","Severe combined immunodeficiency due to DCLRE1C deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1847827","LIG4 Syndrome","C122657","A very rare genetic disorder caused by mutation in the LIG4 gene.  It is characterized by unusual facial features, microcephaly, growth and developmental delay, severe immunodeficiency, and skin abnormalities.","LIG4 Syndrome | ",,,,,,,,,,,,,,,"37110102","LIG4 syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221026","X-Linked Agammaglobulinemia","C3822","An X-linked recessive inherited immunodeficiency disorder caused by mutation of the BTK gene, which is located on the X chromosome. It almost always affects males. Individuals with this disorder have low numbers of B-cells and extremely low levels of all types of immunoglobulins. This results in susceptibility to recurrent infections, leading to organ damage.","X-Linked Agammaglobulinemia | Bruton's Sex-Linked Agammaglobulinemia | Bruton's X-Linked Agammaglobulinemia | XLA",,,,,,,,,,,,,,,"4279923","X-linked agammaglobulinemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL495086","Autosomal Dominant Severe Congenital Neutropenia","C166155","Severe congenital neutropenia inherited in an autosomal dominant pattern. Mutations in the ELANE gene have been reported in approximately half of the cases.","Autosomal Dominant Severe Congenital Neutropenia | Autosomal Dominant SCN",,,,,,,,,,,,,,,"36674950","Autosomal dominant severe congenital neutropenia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0342288","Immune Dysregulation, Polyendocrinopathy, and Enteropathy X-Linked Syndrome","C131009","An X-linked recessive autoimmune condition caused by mutation(s) in the FOXP3 gene, encoding the forkhead box P3 transcription factor. The condition is characterized by infantile onset of severe diarrhea due to enteropathy, type 1 diabetes mellitus, and dermatitis. Associated features may include hypothyroidism, autoimmune hemolytic anemia, thrombocytopenia, lymphadenopathy, hepatitis, and nephritis. The condition is usually fatal before age 2 years if not treated with bone marrow transplantation.","Immune Dysregulation, Polyendocrinopathy, and Enteropathy X-Linked Syndrome | IPEX | Immune Dysfunction and Diarrhea Syndrome | Immune Dysregulation, Polyendocrinopathy, and Enteropathy X-linked Syndrome | X linked Polyendocrinopathy | XLAAD | XPID",,,,,,,,,,,,,,,"36716320|37110165","Autoimmune enteropathy and endocrinopathy with susceptibility to chronic infection syndrome|X-linked immune dysregulation, polyendocrinopathy, enteropathy syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C4035149","Always True","C176030","A subjective response indicating that something is always true.","Always True | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4036309","Usually True","C176031","A subjective response indicating that something is usually true.","Usually True | Quite true",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL783662","Never True","C176032","A subjective response indicating that something is never true.","Never True | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1143018","Obeticholic Acid","C80837","An orally bioavailable semi-synthetic bile acid derivative and an agonist of the nuclear bile acid receptor farnesoid X receptor (FXR) that may be used to lower hepatic exposure to bile acids. Upon oral administration, obeticholic acid targets and binds to FXR expressed in the liver and intestine, activating FXR-mediated bile acid, inflammatory, fibrotic, and metabolic pathways. This suppresses the production of bile acid in the hepatocytes and increases bile acid transport out of the hepatocytes, thereby reducing hepatic exposure to bile acids. FXR plays an important role in bile acid homeostasis and is involved in hepatic and intestinal inflammation and liver fibrosis.","Obeticholic Acid | INT-747 | OBETICHOLIC ACID | Ocaliva",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008532","Christianity","C176033","A religion based on the teachings of Jesus Christ, as embodied in the New Testament of the Bible, emphasizing the role of Jesus as savior.","Christianity | Christian",,,,,,,,,,,,,,,"4175383","Christian religion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006343","Buddhism","C176034","A non-theistic religion that originated in India in the late sixth century and is based the teachings of Siddhartha Gautama, who taught that enlightenment is a state of inner peace and wisdom and that the end of suffering can be achieved by eliminating the desire for material comforts.","Buddhism | Buddhist",,,,,,,,,,,,,,,"4143324","Buddhism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019550","Hinduism","C176035","A religion that is native to India and is characterized by a belief in reincarnation and a supreme being of many forms and natures, the view that opposing theories are aspects of one eternal truth, and a desire for liberation from earthly evils.","Hinduism | Hindu",,,,,,,,,,,,,,,"4266084","Hinduism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0337696","Sikhism","C176036","A religion founded in northern India in the 16th century by Guru Nanak that combines elements of Hinduism and Islam.","Sikhism | Sikh",,,,,,,,,,,,,,,"4194769","Sikhism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0337687","Atheism","C176037","The belief or theory that there is no God.","Atheism | Atheist",,,,,,,,,,,,,,,"4171749","Atheist movement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026394","Molluscum Contagiosum Virus","C112357","A species of enveloped and brick-shaped viruses in the Poxviridae family and Molluscipoxvirus genus. The genome is composed of non-segmented, linear double-stranded DNA. Molluscum contagiosum viruses are found in humans and can cause the disease Molluscum contagiosum. Molluscum contagiosum viruses are transmitted via direct person-to-person contact and contact with infected fomites.","Molluscum Contagiosum Virus | MCV | MOCV | MOLLUSCUM CONTAGIOSUM VIRUS",,,,,,,,,,,,,,,"4286189","Molluscum contagiosum virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0398686","Primary Immune Deficiency Disorder","C152105","A group of immunodeficiencies caused by damaging germline mutations in single genes. Patients are at an increased risk to develop infections, autoimmunity, bone marrow failure, and malignancies, usually lymphomas.","Inborn Error of Immunity | IEI | PID | Primary Immune Deficiency Disorder | Primary Immunodeficiency | Primary Immunodeficiency Disorder | Primary Immunodeficiency Syndrome | Primary Immunodeficiency Syndrome",,,,,,,,,,,,,,,"4239314","Primary immune deficiency disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0045183","2'-deoxyadenosine","C1503","A purine nucleoside component of DNA comprised of adenosine linked by its N9 nitrogen to the C1 carbon of deoxyribose.","2'-deoxyadenosine | 2'-DEOXYADENOSINE | 9-(2-Deoxy-Beta-D-Erythro-Pentofuranosyl)Adenine | Deoxyadenosine | Desoxyadenosine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007613","Cell physiology","C20480","Any process that takes place on the cellular level, though not necessarily restricted to a single cell.","Cellular Process | Cell Function | Cell Process | Cellular Function",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035552","Ribosomal Proteins","C21210","Proteins present within the ribosomal subunits. In eukaryotes there are 50 proteins in the large subunit and 33 in the small subunit.","Ribosomal Protein | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1565156","Wiskott-Aldrich Syndrome Protein, Human","C43238","Actin nucleation-promoting factor WAS (502 aa, ~53 kDa) is encoded by the human WAS gene. This protein is involved in the regulation of GTPase activity.","Actin Nucleation-Promoting Factor WAS | IMD2 | WAS | WASP | WASP Actin Nucleation Promoting Factor | WASp | Wiskott-Aldrich Syndrome Protein | Wiskott-Aldrich Syndrome Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0272236","Hyperimmunoglobulin M Syndrome","C3990","An immunodeficiency state characterized by very low serum IgG and IgA but either a normal or, more frequently, a markedly elevated concentration of polyclonal IgM.","Hyperimmunoglobulin M Syndrome | Hyper IgM | Hyper IgM Syndrome",,,,,,,,,,,,,,,"432287","Hyperimmunoglobulin M syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2936739","Hyperimmunoglobulin E Syndrome","C3144","A condition that is characterized by elevated serum IgE, dermatitis, and respiratory infections.","Hyperimmunoglobulin E Syndrome | Hyper IgE",,,,,,,,,,,,,,,"4177007","Hyperimmunoglobulin E syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0427544","Monocytopenia","C113714","Abnormally low level of monocytes in the blood.","Monocytopenia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642539","Charlson Comorbidity Index","C176422","A method of predicting mortality risk or disease burden for patients with specific comorbid conditions. The conditions are assigned a weight from 1 to 6, based on ICD diagnosis codes, and these weights are summed to produce a single comorbidity score.","Charlson Comorbidity Index | CCI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642535","Single Item Literacy Screener","C176425","A single-question instrument designed to identify individuals with limited reading ability in order to identify those who need help with written or printed health material.","Single Item Literacy Screener | SILS | Single Item Literacy Screener (SILS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1389691","How Often Need Help Reading Instructions, Pamphlets, or other Written Material from Doctor or Pharmacy","C176428","A question about how often an individual needs or needed help to read instructions, pamphlets, or other written material from their doctor or pharmacy.","How Often Need Help Reading Instructions, Pamphlets, or other Written Material from Doctor or Pharmacy | How often do you need to have someone help you when you read instructions, pamphlets, or other written material from your doctor or pharmacy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830315","End Organ Damage from Diabetes","C113717","Irreparable damage to multiple organs/systems which is the result of chronic complications of diabetes.  The affected organs/systems include the cardiovascular system, kidneys, eyes, nervous system, joints and feet.","End Organ Damage from Diabetes | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280856","Vulvar Squamous Cell Carcinoma","C4052","A squamous cell carcinoma that arises from the vulva. It is classified as human papillomavirus-related or human papillomavirus-independent. When p16 immunohistochemistry or HPV testing is not available, the morphological diagnosis of squamous cell carcinoma, not otherwise specified is acceptable.","Vulvar Squamous Cell Carcinoma | Epidermoid Carcinoma of Vulva | Epidermoid Carcinoma of the Vulva | Epidermoid Cell Carcinoma of Vulva | Epidermoid Cell Carcinoma of the Vulva | Squamous Cell Carcinoma of Vulva | Squamous Cell Carcinoma of the Vulva | Vulva Epidermoid Carcinoma | Vulva Epidermoid Cell Carcinoma | Vulva Squamous Cell Carcinoma | Vulvar Epidermoid Carcinoma | Vulvar Epidermoid Cell Carcinoma | Vulvar Squamous Cell Cancer",,,,,,,,,,,,,,,"4116084","Squamous cell carcinoma of vulva",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL935697","Biosimilars","C156644","A biological product that is highly similar in structure and function to, and has no clinically meaningful differences from, an FDA-approved reference product.","Biosimilar | biosimilar",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642396","Approach","C176499","The act of making contact in order to propose, request, or suggest something.","Approach | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642390","Modified Health Care Climate Questionnaire for Breast Cancer Treatment","C176487","A shortened version of the Health Care Climate Questionnaire (HCCQ) adapted for breast cancer patients. It uses 6 questions and a 7-point Likert scale to measure the patient's perception of their physician's support for patient autonomy.","Modified Health Care Climate Questionnaire for Breast Cancer Treatment | Modified Health Care Climate Questionnaire | Modified Health Care Climate Questionnaire (mHCCQ) for Breast Cancer Treatment | mHCCQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642391","Feel that Physician Provided Choices and Options for Breast Cancer Treatment","C176488","A question about whether an individual feels or felt that their physician provided choices and options for their breast cancer treatment.","Feel that Physician Provided Choices and Options for Breast Cancer Treatment | I feel that my physician provided me with choices and options for my breast cancer treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642388","Feel that Physician Understood How I Saw Things with Respect to Breast Cancer","C176489","A question about whether an individual feels or felt that their physician understood how they saw things with respect to their breast cancer.","Feel that Physician Understood How I Saw Things with Respect to Breast Cancer | I feel that my physician understood how I saw things with respect to my breast cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642389","Feel that Physician Expressed Confidence in my Ability to Make Decisions","C176490","A question about whether an individual feels or felt that their physician expressed confidence in their ability to make decisions.","Feel that Physician Expressed Confidence in my Ability to Make Decisions | I feel that my physician expressed confidence in my ability to make decisions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642399","Feel that Physician Listened to how I would Like to Handle Breast Cancer Treatment","C176491","A question about whether an individual feels or felt that their physician listened to how they would like to handle their breast cancer treatment.","Feel that Physician Listened to how I would Like to Handle Breast Cancer Treatment | I feel that my physician listened to how I would like to handle my breast cancer treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642400","Feel that Physician Encouraged Me to Ask Questions","C176492","A question about whether an individual feels or felt that their physician encouraged them to ask questions.","Feel that Physician Encouraged Me to Ask Questions | I feel that my physician encouraged me to ask questions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642398","Feel that Physician Tried to Understand How I Saw Things Before Offering Opinion","C176493","I feel that my physician tried to understand how I saw things before offering an opinion","Feel that Physician Tried to Understand How I Saw Things Before Offering Opinion | I feel that my physician tried to understand how I saw things before offering an opinion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642738","Patient Assessment of Cancer Communication Experiences","C176528","A survey tool designed to assess a patient's perspective on the communication they had over the course of their cancer care, with a focus on the patient's perception of whether specific communication goals had been achieved.","Patient Assessment of Cancer Communication Experiences | PACE | Patient Assessment of cancer Communication Experiences (PACE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642373","Was Treated with Sensitivity and Respect","C176530","A question about whether an individual is or was treated with sensitivity and respect.","Was Treated with Sensitivity and Respect | I was treated with sensitivity and respect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642374","Felt Known as a Person","C176531","A question about whether an individual feels or felt that they were known as a person.","Felt Known as a Person | I felt known as a person",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642426","Felt Listened to","C176532","A question about whether an individual feels or felt that they were listened to.","Felt Listened to | I felt listened to",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642427","Felt Comfortable Asking Questions and Voicing Concerns","C176533","A question about whether an individual feels or felt comfortable asking questions and voicing their concerns.","Felt Comfortable Asking Questions and Voicing Concerns | I felt comfortable asking questions and voicing my concerns",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642425","Felt Everyone Worked Together as a Team Taking Care of Me","C176534","A question about whether an individual feels or felt that everyone worked together as a team in taking care of them.","Felt Everyone Worked Together as a Team Taking Care of Me | I felt that everyone worked together as a team in taking care of me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642423","Wishes Were Respected","C176536","A question about whether an individual feels or felt that their wishes were respected.","Wishes Were Respected | My wishes were respected",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642421","Got Information Needed When Needed","C176538","A question about whether an individual is getting or has gotten the information they needed, when they needed it.","Got Information Needed When Needed | I got the information I needed, when I needed it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642422","Got Clear, Understandable Information","C176539","A question about whether an individual is getting or has gotten clear, understandable information.","Got Clear, Understandable Information | I got clear, understandable information",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642434","Knew Who to Contact with a Question or Concern","C176541","A question about whether an individual knows or knew who to contact if they had a question or concern.","Knew Who to Contact with a Question or Concern | I knew who to contact if I had a question or concern",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642432","Felt Comfortable Bringing up Anything on Mind","C176543","A question about whether an individual feels or felt comfortable bringing up anything that was on their mind.","Felt Comfortable Bringing up Anything on Mind | I felt comfortable bringing up anything that was on my mind",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642433","Got Consistent Information from Doctors and Nurses","C176540","A question about whether an individual is getting or has gotten consistent information from all their doctors and nurses, and everyone is or was on the same page.","Got Consistent Information from Doctors and Nurses | I got consistent information from all my doctors and nurses; everyone was on the same page",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642429","Cancer Care Team Helped Coping with Uncertainty or Unknowns","C176547","A question about whether an individual's cancer care team helps or has helped them cope with any uncertainties or unknowns.","Cancer Care Team Helped Coping with Uncertainty or Unknowns | My cancer care team helped me cope with any uncertainty or unknowns",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642439","Cancer Care Team Helped with Difficult Feelings","C176548","A question about whether an individual's cancer care team helps or has helped them cope with difficult feelings, like fear, anxiety, and feeling down.","Cancer Care Team Helped with Difficult Feelings | My cancer care team helped me cope with difficult feelings, like fear, anxiety, and feeling down",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642430","Felt Optimism and Hope from Doctors and Nurses","C176544","A question about whether an individual feels or felt optimism and hope from their doctors and nurses.","Felt Optimism and Hope from Doctors and Nurses | I felt optimism and hope from my doctors and nurses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642436","Was Involved in Making Decisions as Much as Wanted","C176552","A question about whether an individual is or was as involved in making decisions as much as they wanted.","Was Involved in Making Decisions as Much as Wanted | I was involved in making decisions as much as I wanted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642440","Knew Who in Healthcare System to Reach Out to if Worried that Something had Gone Wrong with Care","C176549","A question about whether an individual knows or knew who in their healthcare system they could reach out to if they were worried that something had gone wrong with their care.","Knew Who in Healthcare System to Reach Out to if Worried that Something had Gone Wrong with Care | I knew who in the healthcare system I could reach out to if I was worried that something had gone wrong with my care",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642437","Rate Overall Experience with Communication Related to Cancer Care","C176553","A question about how an individual would rate their experiences with communication related to their cancer care overall, from the time there was a suspicion that they might have cancer, through the present.","Rate Overall Experience with Communication Related to Cancer Care | Overall, how would you rate your experiences with communication related to your cancer care, from the time there was a suspicion that you might have cancer, through the present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642736","CPS","C176582","A measurement of PD-L1 expression in a tumor sample, calculated as the number of PD-L1 staining cells (tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100.","PD-L1 Combined Positive Score | CD274 CPS | CPS | Cells.programmed cell death ligand 1/100 viable tumor cells in Tissue by Immune stain | Combined Positive Score | Combined Positive Score | PD-L1 CPS | PDL1 CPS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642501","Cancer Worry Scale","C176441","An 8-item questionnaire that utilizes a 4-point Likert scale to assess concerns about developing cancer or cancer recurrence, and the impact of these concerns on daily functioning, among individuals at risk for hereditary cancer.","Cancer Worry Scale | CWS | Cancer Worry Scale (CWS) | Cancer Worry Scale in Breast Cancer Survivors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642502","How Often Thought about Chances of Cancer Recurrence","C176442","A question about how often an individual thought about their chances of cancer recurrence.","How Often Thought about Chances of Cancer Recurrence | How often have you thought about your chances of getting cancer (again)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642512","Have Thoughts of Chances of Cancer Recurrence Affected Mood","C176444","A question about whether an individual's thoughts about their chances of cancer recurrence affect or have affected their mood.","Have Thoughts of Chances of Cancer Recurrence Affected Mood | Have these thoughts affected your mood",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642509","Have Thoughts about Chances of Cancer Recurrence Interfered with Ability to Carry out Daily Activities","C176445","A question about whether an individual's thoughts about their chances of cancer recurrence interfere or have interfered with their ability to carry out their daily activities.","Have Thoughts about Chances of Cancer Recurrence Interfered with Ability to Carry out Daily Activities | Have these thoughts interfered with your ability to carry out your daily activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642510","How Concerned about Possibility of Cancer Recurrence","C176446","A question about how concerned an individual is or was about the possibility of cancer recurrence.","How Concerned about Possibility of Cancer Recurrence | How concerned are you about the possibility of one day getting cancer (again)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642507","How Often Worry about Developing Cancer","C176447","A question about how often an individual worries or has worried about developing cancer.","How Often Worry about Developing Cancer | How Often Worry about Cancer Developing Cancer | How often do you worry about developing cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642508","How Much Problem is Worry About Developing Cancer","C176448","A question about how much of a problem an individual has or had because of their worry about cancer recurrence.","How Much Problem is Worry About Developing Cancer | How much of a problem is this worry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642505","How Often Worry about Chance of Family Members Developing Cancer","C176449","A question about how often an individual worries or has worried about the chance of family members developing cancer.","How Often Worry about Chance of Family Members Developing Cancer | How often do you worry about the chance of family members developing cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642506","How Concerned About Possibility of Needing Surgery Again","C176450","A question about how concerned an individual is or was about the possibility of needing surgery again.","How Concerned About Possibility of Needing Surgery Again | How concerned are you about the possibility that you will ever need surgery (again)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890737","Autoinflammatory Syndrome","C119050","A group of disorders of the innate immune system characterized by attacks of seemingly unprovoked inflammation without significant levels of either autoantibodies or autoreactive T cells more characteristic of autoimmune disease.","Autoinflammatory Syndrome | ",,,,,,,,,,,,,,,"37171756","Autoinflammatory disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3278795","Autoimmune Enteropathy","C94694","A rare autoimmune disorder that usually affects children. It is associated with the presence of circulating autoantibodies that act against the gut epithelial cells. It is characterized by diarrhea and weight loss due to malabsorption.","Autoimmune Enteropathy | autoimmune enteropathy",,,,,,,,,,,,,,,"4341626","Autoimmune enteropathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL977254","Tissue Transglutaminase Antibody Measurement","C163969","No Value Exists","Tissue Transglutaminase Antibody Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406091","GBM Antigens and Alloantigens Immunotherapeutic Vaccine","C172199","An orally bioavailable, immunotherapeutic vaccine composed of hydrolyzed and formulated glioblastoma multiforme (GBM) antigens and alloantigens derived from a pool of patients' cancer cells in the blood and samples of tumor tissues, with potential immunomodulating and antineoplastic activities. Upon oral administration of the GBM antigens and alloantigens immunotherapeutic vaccine, the GBM antigens and alloantigens may stimulate the host immune system via antigen-presenting cells (APCs) lining the gut to mount an immune response against tumor cells expressing these antigens. This may lead to tumor cell death.","GBM Antigens and Alloantigens Immunotherapeutic Vaccine | V-Boost | V-Boost Immunitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4227882","Polyarticular Arthritis","C26996","An arthritis affecting five or more separate joints.","Polyarticular Arthritis | Polyarthritis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420588","TARDBP Gene","C80020","This gene is involved in transcription and mRNA splicing.","TARDBP Gene | TAR DNA Binding Protein Gene | TARDBP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642658","Primary Immune Regulatory Disorder","C176600","A group of immune diseases characterized predominantly by immune dysregulation leading to organ-specific autoimmunity, excessive inflammation, and non-malignant lymphoproliferation. Unlike classical primary immunodeficiencies, susceptibility to infections is typically less prominent in these disorders.","Primary Immune Regulatory Disorder | PIRD | Primary Immune Dysregulation Disorder | Primary Immune Dysregulation Disorder | Primary Immune Regulatory Disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642419","Congenital Defects of Phagocyte Number, Function, or Both","C176593","A group of diseases or disorders caused by genetic defects within the immune system and comprising: Congenital neutropenia; Defects of motility; Defects of respiratory burst; and other nonlymphoid defects.","Congenital Defects of Phagocyte Number, Function, or Both | Congenital Defect of Phagocyte | Congenital Defects of Phagocytes | Congenital Phagocytic Defect | Congenital Phagocytic Disease | Congenital Phagocytic Disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642417","Defects in Intrinsic and Innate Immunity","C176594","A group of diseases or disorders caused by genetic defects within the immune system, comprised by: Mendelian susceptibility to mycobacterial disease (MSMD); Epidermodysplasia verruciformis (HPV); Predisposition to severe viral infection; Herpes simplex encephalitis (HSE); Predisposition to invasive fungal diseases; Predisposition to mucocutaneous candidiasis; TLR signaling pathway deficiencies with bacterial susceptibility; and other inborn errors of immunity related to nonhematopoietic tissues.","Defects in Intrinsic and Innate Immunity | Defects of Intrinsic and Innate Immunity | Defects of Intrinsic and Innate Immunity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642726","MRD Less than 0.1 Percent","C176684","An indication that a biomarker for a neoplastic disease is present in less than 0.1 percent of a sample.","Measurable Residual Disease Less than 0.1 Percent | MRD Less than 0.1 Percent | Minimal Residual Disease Less Than 0.1 Percent | Minimal Residual Disease Less than 0.1 Percent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642727","Neoplastic Plasma Cells 5 Percent or More of Peripheral Blood White Cells","C176685","A semi-quantitative microscopic finding indicating that at least 5 percent of the leukocytes in a peripheral blood sample are neoplastic plasma cells.","Neoplastic Plasma Cells 5 Percent or More of Peripheral Blood White Cells | Circulating Plasma Cells 5 Percent or More of Peripheral Blood White Cells | Circulating Plasma Cells Greater than or Equal to 5 Percent of Peripheral Blood White Cells | Neoplastic Plasma Cells Greater than or Equal to 5 of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642724","Crosslinked Multimeric Type III Procollagen Propeptide","C176686","Crosslinked complexes comprised of multiple copies of the N-terminal propeptide derived from type III procollagen. Quantitation of the level of these peptides in blood samples may serve as a marker for liver fibrosis or steatosis.","Crosslinked Multimeric Type III Procollagen Propeptide | Cross-Linked Multimeric PRO-C3 | Cross-Linked Multimeric Type III Procollagen Propeptide | Crosslinked Multimeric Type III Procollagen N-Terminal Peptide | Crosslinked Type III Procollagen N-Terminal Peptide Multimers | Crosslinked Type III Procollagen Propeptide Multimers | XM-PRO-C3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642725","Ki-67 Positive Cells Greater than or Equal to 5 Percent","C176687","A semi-quantitative microscopic finding indicating that at least 5 percent of the cells in a sample are detected following staining using an anti-Ki-67 antibody.","Ki-67 Positive Cells Greater than or Equal to 5 Percent | Antigen Ki-67 Positive Cells Greater than or Equal to 5 Percent | KI67 Positive Cells Greater than or Equal to 5 Percent | Ki-67 Antigen Positive Cells Greater than or Equal to 5 Percent | MKI67 Positive Cells Greater than or Equal to 5 Percent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642722","SARS Coronavirus 2 Negative","C176688","An indication that SARS coronavirus 2 has not been detected in a sample.","SARS Coronavirus 2 Negative | 2019 Novel Coronavirus Negative | 2019-nCoV Negative | COVID-19 Virus Negative | SARS-2 Negative | SARS-CoV-2 Negative | SARS2 Negative | Severe Acute Respiratory Syndrome Coronavirus 2 Negative | nCoV Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642723","Activating NTRK Family Gene Mutation","C176689","A mutation in an NTRK family gene that results in constitutive activation of the encoded NTRK family receptor protein and downstream pathways.","Activating NTRK Family Gene Mutation | Activating NTRK Family Mutation | Activating NTRK Gene Mutation | Activating NTRK Mutation | Activating TRK Family Gene Mutation | Activating TRK Gene Mutation | Activating TRK Receptor Family Gene Mutation | Activating TRK Receptor Gene Mutation | Gain of Function NTKR Family Gene Mutation | Gain of Function NTKR Family Mutation | Gain of Function NTKR Gene Mutation | Gain of Function NTKR Mutation | NTRK Gain of Function Gene Mutation | NTRK Gain of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642721","Activating MET Exon 14 Skipping Mutation","C176691","A change in the nucleotide sequence of the MET gene that that results in loss of transcription of MET exon 14 and constitutive activation of hepatocyte growth factor receptor and its downstream signaling pathways.","Activating MET Exon 14 Skipping Mutation | Activating HGFR Exon 14 Skipping Mutation | Activating HGFR Exon 14 Splice Mutation | Activating Hepatocyte Growth Factor Receptor Exon 14 Skipping Mutation | Activating MET Exon 14 Deletion Mutation | Activating MET Exon 14 Splice Mutation | Activating MET Proto-Oncogene, Receptor Tyrosine Kinase Exon 14 Skipping Mutation | Activating c-MET Exon 14 Deletion Mutation | Activating c-MET Exon 14 Splice Mutation | Activating c-Met Exon 14 Skipping Alteration | Activating c-Met Exon 14 Skipping Mutation | MET Exon 14 Skipping Gain of Function Gene Mutation | MET Exon 14 Skipping Gain of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4013411","Autosomal Dominant Inheritance","C94245","Autosomal dominant inheritance refers to genetic conditions that occur when a mutation is present in one copy of a given gene (i.e., the person is heterozygous).","Autosomal Dominant Inheritance | autosomal dominant",,,,,,,,,,,,,,,"4135502","Autosomal dominant inheritance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4013412","Autosomal Recessive Inheritance","C94246","Autosomal recessive inheritance refers to genetic conditions that occur only when mutations are present in both copies of a given gene (i.e., the person is homozygous for a mutation, or carries two different mutations of the same gene, a state referred to as compound heterozygosity).","Autosomal Recessive Inheritance | autosomal recessive",,,,,,,,,,,,,,,"4121053","Autosomal recessive inheritance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2699709","Calaspargase Pegol","C78198","An intravenous formulation containing E.coli-derived L-asparaginase II conjugated with succinimidyl carbonate monomethoxypolyethylene glycol (SC-PEG), with potential antineoplastic activity. Upon administration of calaspargase pegol, L-asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting cells of asparagine; asparagine depletion blocks protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle and ultimately induces tumor cell death. Asparagine is critical to protein synthesis in acute lymphoblastic leukemia (ALL) cells which, unlike normal cells, cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Pegylation decreases enzyme antigenicity and increases its half life. SC is used as a PEG linker to facilitate attachment to asparaginase and enhances the stability of the formulation.","Calaspargase Pegol | Asparaginase (Escherichia coli Isoenzyme II), Conjugate with alpha-(((2,5-Dioxo-1-pyrrolidinyl)oxy)carbonyl)-omega-methoxypoly(oxy-1,2-ethanediyl) | Asparlas | CALASPARGASE PEGOL | Calaspargase Pegol | Calaspargase Pegol-mknl | Calaspargase Pegol-mknl | EZN-2285 | SC-PEG E. Coli L-Asparaginase | SC-PEG E. coli L-asparaginase | Succinimidyl Carbonate Monomethoxypolyethylene Glycol E. coli L-Asparaginase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0237070","Discipline","C17716","Activities designed to promote appropriate behavior, conduct, or action including time out, limits, and controls.","Discipline | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642543","Ancestry","C176763","A person's descent or lineage, from a person or from a population.","Ancestry | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642737","Birthplace","C176764","The location where someone was born, usually referring to a town, city, or country.","Birthplace | Place of Birth",,,,,,,,,,,,,,,"4014292","Place of birth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1513838","NFKB Signaling Pathway","C39163","Nuclear factor kB (NF-kB) is a nuclear transcription factor that regulates expression of a large number of genes that are critical for the regulation of apoptosis, viral replication, tumorigenesis, inflammation, and various autoimmune diseases. ","NFKB Signaling Pathway | NF-kB Signaling Pathway | NFKB Signaling Pathway ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642715","HLA-A*03:01 Positive Cells Present","C176683","A laboratory test result indicating the presence of HLA-A*03:01 positive cells in a tissue sample.","HLA-A*03:01 Positive Cells Present | HLA-A*0301 Positive | HLA-A*0301 Positive Cells Present | HLA-A*03:01 Positive | HLA-A0301 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642590","Medical Expenditure Panel Survey","C176828","A survey about the lasting effects of cancer and cancer treatments on the lives of those who have been diagnosed with cancer. It asks about the effects of cancer, its treatment, or the lasting effects of that treatment on employment, finances, health insurance coverage, and life in general.","Medical Expenditure Panel Survey | MEPS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642741","Self-Administered Comorbidity Questionnaire","C176829","A self-report that assesses the presence of medical problems and allows the subject to note the severity of each comorbid condition and their perception of its impact on their function.","Self-Administered Comorbidity Questionnaire | SCQ | Self-Administered Comorbidity Questionnaire (SCQ)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642599","Fear of Cancer Recurrence Questionnaire","C176830","A 7-item self-report measure of a patient's fear of cancer recurrence. It enables a cancer survivor to assess the emotional distress caused by concern that their cancer will return or progress after anti-cancer treatment.","Fear of Cancer Recurrence Questionnaire | FCR7 | Fear of Cancer Recurrence | Fear of Cancer Recurrence (FCR7)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1638092","Financial Hardship","C176832","Difficulty in paying debts and/or loan installments when they are due.","Financial Hardship | Financial Problem | Financial problem (finding)",,,,,,,,,,,,,,,"4052625","Financial problem",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1642596","Patient-Centered Communication in Cancer Care-Long Form","C176833","A self-report questionnaire for cancer patients that assesses how well health care professionals are communicating with their patients. It consists of 36 items in six domains, each scored using a five point Likert scale.","Patient-Centered Communication in Cancer Care-Long Form | PCC-Ca | PCC-Ca-36 | Patient-Centered Communication in Cancer Care (PCC-Ca) | Patient-Centered Communication in Cancer Care - Long Form | Patient-Centered Communication in Cancer Care 36-Item Instrument",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642594","CAHPS Cancer Care Survey","C176835","A standardized instrument designed to assess the experiences of adult patients with cancer treatment provided in outpatient and inpatient settings. The survey consists of three parallel instruments specific for either radiation therapy, chemotherapy, or cancer surgery.","CAHPS Cancer Care Survey | CAHPS | Consumer Assessment of Healthcare Providers and Systems Cancer Care Survey",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642595","EORTC Quality of Life Questionnaire-Core 30","C176836","An integrated system for assessing the quality of life of cancer patients participating in clinical trials and other types of research. It incorporates five functional scales: Physical, Role, Cognitive, Emotional, and Social Functioning; three symptom scales: Fatigue, Pain, and Nausea/Vomiting; a Global Health Status/QoL scale; and six single item scales: Dyspnea, Insomnia, Appetite Loss, Constipation, Diarrhea, and Financial Difficulties.","EORTC Quality of Life Questionnaire-Core 30 | EORTC-QLQ-C30 | European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 | QLQ-C30 | Quality of Life Questionnaire-Core 30",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642606","Quality of Life Patient/Cancer Survivor Version","C176838","A 41-item self-report questionnaire designed to assess physical well-being, psychological well-being, social well-being, and spiritual well-being in cancer survivors.","Quality of Life Patient/Cancer Survivor Version | QOL-CSV | Quality of Life Patient/Cancer Survivor Version (QOL-CSV)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642605","Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being 12 Item Scale","C176837","A 12-item questionnaire that uses a 5-point Likert scale to measure spiritual well-being in people with cancer or other chronic illnesses.","Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being 12 Item Scale | FACIT-Sp-12 | FACIT-Spiritual Well-Being, 12 Item Scale | Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being (FACIT-Sp-12) | Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being (FACIT-Sp-12)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642603","Supportive Care Needs Survey-Short Form 34","C176839","A 34 item questionnaire that measures a cancer patient's need and level of need for supportive care across five domains: physical and daily living; psychological; sexuality; patient care and support; and health system and information needs.","Supportive Care Needs Survey-Short Form 34 | SCNS-SF34 | Supportive Care Needs Survey-Short Form 34 (SCNS-SF34)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642604","Survivor Unmet Needs Survey","C176840","A questionnaire that assesses a cancer survivor's unmet needs across four domains relevant to cancer care: information needs; work and financial needs; access and continuity of care needs; and coping, sharing, and emotional needs.","Survivor Unmet Needs Survey | SF-SUNS | Survivor Unmet Needs Survey (SF-SUNS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544752","ABI SOLiD Sequencing","C146811","A proprietary next-generation DNA sequencing system from Applied Biosystems that utilizes DNA ligase. DNA fragments attached to beads are clonally amplified and ligated to fluorescently labeled 'interrogation probes'. Ligation frees the fluor, which is detected and identifies the specific probe. The marker of the attached probe is then removed and a 5'-phosphate group is regenerated. Multiple cycles of ligation, detection, and cleavage are performed.","ABI SOLiD Sequencing | ABI SOLiD | SOLiD | SOLiD Sequencing Technology | Sequencing of Oligonucleotides by Ligation/Detection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977262","miRNA Size Fractionated Genomic Library","C163991","A RNA library that has been fractionated by size exclusion methods to enrich for microRNAs.","miRNA Size Fractionated Genomic Library | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977263","rRNA Depleted Genomic Library","C163990","A genomic library where the sample has been subjected to a ribosomal RNA depletion step before it is amplified.","rRNA Depleted Genomic Library | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977265","Poly-T Enriched Genomic Library","C163988","A genomic library where the sample has been subjected to enrichment via binding to immobilized poly-T oligonucleotides, which will preferentially isolate polyadenylated (poly-A) RNAs.","Poly-A Enriched Genomic Library | Poly(A) Enriched Genomic Library | Poly(A) Selected Genomic Library | Poly-A Enriched Genomic Library | Poly-A Selected Genomic Library | Poly-T Enriched Genomic Library | Poly-T Enriched Genomic Library | Poly-T Enrichment | PolyA Selected Genomic Library",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0949934","Human Parainfluenza Virus 4","C112318","The serotype labeled 4 of the viral species Human parainfluenza virus, which is a single-stranded, negative-sense RNA virus of the Paramyxoviridae family and Rubulavirus genus, and causes bronchiolitis and pneumonia in humans.","Human Parainfluenza Virus 4 | HPIV Type 4 | HPIV-4 | HUMAN PARAINFLUENZA VIRUS 4 | Human Parainfluenza Virus Type 4 | Human Rubulavirus 4 | Human orthorubulavirus 4",,,,,,,,,,,,,,,"4228363","Human parainfluenza virus 4",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030391","Human Parainfluenza Virus 2","C112316","The serotype labeled 2 of the viral species Human parainfluenza virus, which is a single-stranded, negative-sense RNA virus of the Paramyxoviridae family and Rubulavirus genus, and causes croup and respiratory infections in humans.","Human Parainfluenza Virus 2 | HPIV-2 | HUMAN PARAINFLUENZA VIRUS 2 | Human Parainfluenza Virus Type 2 | Human Rubulavirus 2 | Human orthorubulavirus 2",,,,,,,,,,,,,,,"4253152","Human parainfluenza virus 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030390","Human Parainfluenza Virus 1","C14254","A single-stranded, negative-sense RNA virus of the paramyxovirus group that causes croup in children.","Human Parainfluenza Virus 1 | HA2 | HPIV-1 | HUMAN PARAINFLUENZA VIRUS 1 | Hemadsorption Type 2 Virus | Human Parainfluenza Virus Type 1 | Human Respirovirus 1",,,,,,,,,,,,,,,"4253151","Human parainfluenza virus 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1642609","Healthcare Utilization","C176849","The use of healthcare services by an individual for preventing or curing health problems, promoting maintenance of health and well-being, or obtaining information about one's health status and prognosis.","Healthcare Utilization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012764","District of Columbia","C108007","The area in the United States comprised of a 68 square mile area northeast of the Potomac River donated by the state of Maryland.  The District of Columbia, also known as D.C., is not a state, nor is it part of any state.  It is a 'federal district' established by the US Constitution as the seat of government. The district is occupied entirely by the city of Washington.","District of Columbia | D.C. | DC | DC001 | District of Columbia, DC | US: District of Columbia | Washington, DC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642878","Grade 3 Seizure, ASTCT ICANS","C176860","Any clinical seizure focal or generalized that resolves rapidly or nonconvulsive seizures on EEG that resolve with intervention, as defined by the American Society for Transplantation and Cellular Therapy (ASTCT) and the Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) Consensus Grading for Adults.","Grade 3 Seizure, ASTCT ICANS | Grade 3 Seizure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642879","Grade 4 Seizure, ASTCT ICANS","C176861","Life-threatening prolonged seizure (>5 min); or repetitive clinical or electrical seizures without return to baseline in between seizures, as defined by the American Society for Transplantation and Cellular Therapy (ASTCT) and the Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) Consensus Grading for Adults.","Grade 4 Seizure, ASTCT ICANS | Grade 4 Seizure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969660","Surgical Procedure was Curative Therapy","C160609","A response that a surgical procedure was the curative therapy.","Surgical Procedure was Curative Therapy | Surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3696939","Smoking Device","C171257","An object or device designed for the intake of smoke or vapor from tobacco or another such substance.","Smoking Device | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826263","Group ID","C82529","A sequence of characters that represents a particular group.","Group ID | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1411679","QTc Correction Method Unspecified, Single Beat","C174286","A QT interval that is corrected for heart rate by unspecified correction method, or by non-standard correction methods, based on a QT interval measured on a single beat utilizing one or more ECG leads.","QTc Correction Method Unspecified, Single Beat | QTCUNSSB | QTc Corr Method Unspecified, Single Beat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697561","Hallucinogen Measurement","C75343","The determination of the amount of any hallucinogen present in a sample.","Hallucinogen Measurement | HALLUC | Hallucinogen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205032","Skin of the Upper Extremity","C164048","The integumentary covering of the upper extremities.","Skin of the Upper Extremity | SKIN OF THE UPPER LIMB | Skin of the Upper Limb | Skin, upper extremity, local | Upper Extremity Skin | forelimb skin",,,,,,,,,,,,,,,"4159864","Skin structure of upper limb",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266887","Skin of the Lower Extremity","C164047","The integumentary covering of the lower extremities.","Skin of the Lower Extremity | Lower Extremity Skin | SKIN OF THE LOWER LIMB | Skin of the Lower Limb | Skin, lower extremity, local | hindlimb skin",,,,,,,,,,,,,,,"4159862","Skin structure of lower limb",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641002","Great Blood Vessel","C102955","Any of the major arteries or veins attached to the cardiac atria or ventricles. This includes the aorta, superior and inferior vena cava and the pulmonary arteries and veins.","Great Blood Vessel | GREAT VESSELS | Structure of great blood vessel (organ) (body structure)",,,,,,,,,,,,,,,"4290464","Structure of great blood vessel (organ)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1511987","Disease Stage Qualifier","C28108","An adjectival term that can specify or describe a disease stage.","Disease Stage Qualifier | stage of disease | stage_of_disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0687080","Paw","C77660","The foot of a quadruped animal, including canines, felines, mice, rats, and bears. The paw contains claws or nails and pads composed of a thick keratinized dermis covering collagenous adipose tissue.","Paw | PAW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522391","Hindlimb","C77625","The posterior limb of an animal.","Hind Limb | HINDLIMB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004526","Azygos Vein","C53029","A blood vessel which returns blood to the heart from the posterior walls of the thorax and abdomen.","Azygos Vein | AZYGOS VEIN | Structure of azygous vein (body structure)",,,,,,,,,,,,,,,"4218136","Structure of azygous vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL414773","Vertebral Bone","C33868","Any of the small bones that comprise the vertebral column. Their inner part consists of cancellous bone covered by cortical bone in the surface.","Vertebral Bone | BONE, VERTEBRA | VERTEBRA | Vertebra | vertebra | vertebra bone | vertebrae",,,,,,,,,,,,,"UBERON:0002412","vertebra",,,,,,,,,,,,,,,"--"
"CL1405537","Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Measurement","C171439","The determination of the amount of severe acute respiratory syndrome coronavirus 2 antibody in a sample.","Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Measurement | SAR2AB | SARS-CoV-2 Antibody | SARS-CoV-2 Antibody Measurement",,,,,,,,,,,,,,,"37310258","Measurement of SARS-CoV-2 antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009244","Cognitive Behavior Therapy","C64345","A type of psychotherapy utilized to treat different forms of mental disorders.The treatment involves the identification of unhelpful or destructive patterns of thinking and behaviors and the subsequent replacement with behaviors that are beneficial and constructive.","Cognitive Behavior Therapy | CBT | CT | cognitive behavior therapy | cognitive therapy",,,,,,,,,,,,,,,"4036569|4043071|4079938","Cognitive therapy|Cognitive and behavioral therapy|Psychotherapy - cognitive",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C3538916","CDISC SDTM Subject Characteristic Test Code Terminology","C74559","Terminology codelist used for Subject Characteristic Codes within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.","CDISC SDTM Subject Characteristic Test Code Terminology | SCTESTCD | SDTM-SCTESTCD | Subject Characteristic Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537342","Insomnia Severity Index","C176880","A seven-item questionnaire that uses a 5-point Likert scale to detect and assess the nature, severity, and impact of insomnia, and to monitor treatment response in adults. The evaluated dimensions include perceived severity of difficulties initiating sleep, staying asleep, and early morning awakenings, satisfaction with current sleep pattern, interference with daily functioning, noticeability of impairment attributed to the sleep problem, and degree of distress or concern caused by the sleep problem.","Insomnia Severity Index | ISI",,,,,,,,,,,,,,,"764401","Insomnia severity index",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1642936","Nucleated Cell Separation Tube","C176884","A specimen processing tube that is used to separate nucleated cells from the plasma and red blood cell fractions in a whole blood sample based on density.","Nucleated Cell Separation Tube | AccuCyte Separation Tube",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642713","Immunodeficiency due to Functional Defects","C176669","An indication that an immunodeficiency disorder is caused by the presence of immune cells that are dysfunctional.","Immunodeficiency due to Functional Defects | Functional defects",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382880","X-linked Lymphoproliferative Syndrome 1","C170434","An X-linked recessive condition caused by mutation(s) in the SH2D1A gene, encoding SH2 domain-containing protein 1A. It is characterized by a susceptibility to severe EBV infection, acquired hypogammaglobulinemia, hemophagocytic lymphohistiocytosis, and/or lymphoma.","X-linked Lymphoproliferative Syndrome 1 | IMD5 | Immunodeficiency 5 | SH2D1A deficiency/XLP1 | X-linked lymphoproliferative disease 1 | XLP1 | XLP1/SAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642748","Interleukin 10 Receptor","C176754","A heterotetrameric complex comprised of two molecules of interleukin-10 receptor subunit alpha and two molecules interleukin-10 receptor subunit beta. This receptor complex has high affinity for interleukin-10 and modulates interleukin signaling.","Interleukin 10 Receptor | IL-10 Receptor | IL-10R | IL10 Receptor | IL10R | Interleukin-10 Receptor | Interleukin-10 receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1638002","T Follicular Helper Cells","C176755","A subtype of antigen-experienced CD4+ T cells that are primarily found within B cell follicles near the periphery of secondary lymphoid organs and are involved in the formation and maintenance of germinal centers. These cells express CXCR5 and CD40L and secrete IL-21 and IL-4.","Follicular Helper T Cell | CD4+ CD45RA- CXCR5+ Tfh Cells | Follicular B Helper T Cell | T Follicular Helper Cell | Tfh",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642585","Tumor-Infiltrating Follicular Helper T Cell","C176756","A follicular helper T cell that has migrated into a tumor.","Tumor-Infiltrating Follicular Helper T Cell | CD4+ CD45RA- CXCR5+ tumor-infiltrating T follicular helper cells | Tumor-Infiltrating T Follicular Helper Cell | Tumor-Infiltrating Tfh | Tumor-Infiltrating Tfh Cell | tumor-infiltrating T follicular helper cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642546","Tumor-Infiltrating T Helper 17 Cell","C176757","A T helper 17 cell that has migrated into a tumor.","Tumor-Infiltrating T Helper 17 Cell | Tumor-Infiltrating Th17 | Tumor-Infiltrating Th17 Cell | Tumor-infiltrating Th17 cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3149380","Autoimmune Neutropenia","C176730","A condition characterized by the autoantibody-induced destruction of neutrophils.","Autoimmune Neutropenia | AIN",,,,,,,,,,,,,,,"4125635","Autoimmune neutropenia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL517887","Type 1 Autoimmune Hepatitis","C176731","The most common subtype of autoimmune hepatitis (AIH). It is characterized by the presence of antinuclear antibody (ANA) and anti-smooth-muscle antibody (ASMA), a prevalence of female patients, and is highly corticosteroid-responsive. It may be associated with other concomitant autoimmune disorders including autoimmune thyroiditis, Graves disease, and ulcerative colitis.","Type 1 Autoimmune Hepatitis | Autoimmune Hepatitis, Type 1 | Type 1 AIH",,,,,,,,,,,,,,,"36715923","Autoimmune hepatitis type 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL517888","Type 2 Autoimmune Hepatitis","C176732","A subtype of autoimmune hepatitis (AIH). In contrast to type 1 AIH, patients tend to be younger, have more severe disease, a poorer response to corticosteroid therapy, and more frequent relapses. It is characterized by the presence of anti-liver kidney microsomal antibody type 1 (anti-LKM1) and/or anti-liver cytosol type 1 (anti-LC1) autoantibodies. It may be associated with other concomitant autoimmune disorders including diabetes mellitus type 1, vitiligo, and autoimmune thyroiditis.","Type 2 Autoimmune Hepatitis | Autoimmune Hepatitis, Type 2 | Type 2 AIH",,,,,,,,,,,,,,,"36717496","Autoimmune hepatitis type 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1642578","Variant Autoimmune Hepatitis","C176733","A form of autoimmune hepatitis (AIH) that has features of overlapping cholestatic autoimmune liver diseases including primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), or autoimmune cholangitis (AIC).","Variant Autoimmune Hepatitis | Autoimmune Hepatitis, Variant | Variant AIH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642547","SP100 Antibody Measurement","C176758","A measurement of SP100-specific antibodies in a biological specimen.","SP100 Antibody Measurement | Anti SP100 Antibody Measurement | Anti nuclear dot (sp100) | Anti-SP100 Antibody Measurement | Anti-Sp-100 Antibody Measurement | Sp-100 Antibody Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642545","Nuclear Pore gp120 Antibody Measurement","C176759","A measurement of the nuclear pore glycoprotein 120-specific antibodies in a biological specimen.","Nuclear Pore gp120 Antibody Measurement | Anti Nuclear Pore gp120 Antibody Measurement | Anti nuclear pore (gp120) | Anti-Nuclear Pore gp120 Antibody Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2739807","Platelet Antibody Measurement","C176760","A measurement of the total amount of anti-platelet antibody in a biological specimen.","Platelet Antibody Measurement | APA | APA Measurement | Anti platelet | Anti-Platelet Antibody Measurement | Antiplatelet Antibody Measurement",,,,,,,,,,,,,,,"4206459","Measurement of platelet antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1295002","Granulocyte Antibody Measurement","C176762","A measurement of the total amount of anti-granulocyte antibody in a biological specimen.","Granulocyte Antibody Measurement | Anti Granulocyte Antibody Measurement | Anti-Granulocyte Antibody Measurement | Anti-granulocyte, (Neutrophil Antibody, Anti Leukocyte Antibody, Granulocyte Ab)",,,,,,,,,,,,,,,"4045650","Measurement of granulocyte antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1142272","Neutrophilic Dermatosis","C176734","A type of dermatosis characterized by dense infiltration of neutrophils in the skin without evidence of infection or vasculitis. It may be secondary to an underlying systemic illness.","Neutrophilic Dermatosis | ",,,,,,,,,,,,,,,"37110555","Neutrophilic dermatosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0239573","FEVER, HIGH GRADE","C176698","Body temperature of 104 degrees Fahrenheit (40 degrees Celsius) or higher.","High Grade Fever | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642418","Immune Dysregulation Disorder","C176595","A group of autoimmune disorders characterized by defects in self-tolerance (central or peripheral) resulting in autoimmune disease with or without recurrent infections, comprised by: Familial hemophagocytic lymphohistiocytosis (FHL) syndromes; FHL syndromes with hypopigmentation; Regulatory T cell (Treg) defects (eg, IPEX); Autoimmunity with or without lymphoproliferation (eg, autoimmune polyendocrinopathy with candidiasis and ectodermal dystrophy [APECED]); Autoimmune lymphoproliferative syndrome (ALPS); Immune dysregulation with colitis; and Susceptibility to Epstein-Barr virus (EBV) and lymphoproliferative conditions.","Immune Dysregulation Disorder | Diseases of Immune Dysregulation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512496","Hormone Receptor Test","C18313","A hormone receptor test measures the amount of certain hormone receptors proteins in cancer tissue. Hormones (such as estrogen and progesterone that naturally occur in the body) can attach to these proteins. If the test is positive, it indicates that the hormone is probably helping the cancer cells grow.","Hormone Receptor Test | hormone receptor test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406234","Oncotype DX Breast Recurrence Score","C172116","A number between 0-100, based on the results of Oncotype DX breast cancer assay, that assesses the 9-year risk of distant recurrence in node-negative patients, 5-year distant recurrence or mortality in node-positive patients, and the likelihood that chemotherapy will benefit the patient.","Oncotype DX Breast Recurrence Score | Oncotype DX Recurrence Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550874","Arm and Breast Questionnaire","C148197","A questionnaire developed by the Canadian Cancer Trials Group, Queens University, using questions from other validated questionnaires, for use in-house.","Arm and Breast Questionnaire | Arm and Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412306","AK2 Gene","C176468","This gene is involved in adenine nucleotide metabolism and cellular energy homeostasis.","AK2 Gene | AK2 | Adenylate Kinase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412448","AP3D1 Gene","C176496","This gene plays a role in budding of vesicles from the Golgi membrane, T- and NK-cell degranulation and intracellular trafficking.","AP3D1 Gene | AP3D1 | Adaptor Related Protein Complex 3 Subunit Delta 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413622","CORO1A Gene","C176417","This gene is involved in membrane dynamics in motile cells.","CORO1A Gene | CORO1A | Coronin 1A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414128","DOCK2 Gene","C176500","This gene is involved in guanine nucleotide exchange for RAC1 and RAC2.","DOCK2 Gene | DOCK2 | Dedicator of Cytokinesis 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428419","G6PC3 Gene","C176506","This gene plays a role in glucose metabolism.","G6PC3 Gene | G6PC3 | Glucose-6-Phosphatase Catalytic Subunit 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415044","GFI1 Gene","C176510","This gene is involved in transcriptional repression and hematopoiesis.","GFI1 Gene | GFI-1 Gene | GFI1 | Growth Factor Independent 1 Transcriptional Repressor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825449","HAX1 Gene","C176518","This gene plays a role in reorganization of the cytoskeleton, cytokine signaling and clathrin-mediated endocytosis.","HAX1 Gene | HAX-1 Gene | HAX1 | HCLS1 Associated Protein X-1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1845100","HNRNPH2 Gene","C176521","This gene is involved in pre-mRNA metabolism.","HNRNPH2 Gene | HNRNPH2 | Heterogeneous Nuclear Ribonucleoprotein H2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826773","RBCK1 Gene","C176427","This gene is involved in the polyubiquitination of protein substrates.","RBCK1 Gene | HOIL1 | HOIL1 Gene | RANBP2-Type And C3HC4-Type Zinc Finger Containing 1 Gene | RBCK1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423923","RNF31 Gene","C176431","This gene plays a role in polyubiquitination and inflammation.","RNF31 Gene | HOIP | HOIP Gene | RNF31 | Ring Finger Protein 31 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415993","IGHM Gene","C176524","This gene plays a role in immunoglobulin heavy chain structure.","IGHM Gene | IGHM | Immunoglobulin Heavy Constant Mu Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422257","ITCH Gene","C176435","This gene is involved in protein ubiquitination that promotes protein degradation and regulates inflammatory signaling pathways.","ITCH Gene | ITCH | Itchy E3 Ubiquitin Protein Ligase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537430","JAGN1 Gene","C176527","This gene is involved in neutrophil function and vesicle-mediated transport.","JAGN1 Gene | JAGN1 | Jagunal Homolog 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425844","LAT Gene","C176438","This gene plays a role in immune responsive and inflammatory signaling pathways.","LAT Gene | LAT | Linker for Activation of T Cells Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413266","LRBA Gene","C176542","This gene plays a role in the localization of immune effector molecules.","LRBA Gene | LPS Responsive Beige-Like Anchor Protein Gene | LRBA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825876","LRRC8A Gene","C176554","This gene is involved in osmotic homeostasis.","LRRC8A Gene | LRRC8A | Leucine Rich Repeat Containing 8 VRAC Subunit A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418518","PGM3 Gene","C176559","This gene plays a role in the interconversion of glucose-1-phosphate and glucose-6-phosphate.","PGM3 Gene | PGM3 | Phosphoglucomutase 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419051","PSTPIP1 Gene","C176458","This gene is involved in cytoskeletal modeling and immunoregulation.","PSTPIP1 Gene | PSTPIP1 | Proline-Serine-Threonine Phosphatase Interacting Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419363","RFX5 Gene","C176566","This gene is involved in transcriptional activation of major histocompatibility class II genes.","RFX5 Gene | RFX5 | Regulatory Factor X5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419364","RFXANK Gene","C176571","This gene plays a role in the promotion of class II major histocompatibility gene transcription.","RFXANK Gene | RFXANK | Regulatory Factor X Associated Ankyrin Containing Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419365","RFXAP Gene","C176575","This gene is involved in the regulation of major histocompatibility class II gene expression.","RFXAP Gene | RFXAP | Regulatory Factor Associated Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642415","RMRP Gene","C176583","This gene plays a role in the replication of mitochondrial DNA and processing of mitochondrial RNA.","RMRP Gene | RMRP | RNA Component of Mitochondrial RNA Processing Endoribonuclease Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1540111","TTC7A Gene","C176589","This gene is involved in the regulation of phosphatidylinositol 4-kinase localization.","TTC7A Gene | TTC7A | Tetratricopeptide Repeat Domain 7A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823643","VPS45 Gene","C176603","This gene plays a role in trafficking of inflammatory mediators.","VPS45 Gene | VPS45 | Vacuolar Protein Sorting 45 Homolog Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823857","WIPF1 Gene","C176613","This gene is involved in actin binding and stabilization of Wiskott-Aldrich syndrome protein.","WIPF1 Gene | WAS/WASL Interacting Protein Family Member 1 Gene | WIP Gene | WIPF1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423893","ZNF341 Gene","C176618","This gene plays a role in transcriptional regulation and immune homeostasis.","ZNF341 Gene | ZNF 341 Gene | ZNF341 | Zinc Finger Protein 341 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642516","T-Cells Absent and Normal Natural Killer Cells and B-Cells","C176465","A hematology test result indicating that a subject has a normal amount of B-cells and natural killer cells but T-cells are either absent or found at abnormally low amounts.","T-Cells Absent and Normal Natural Killer Cells and B-Cells | B-Lymphocytes and Natural Killer Cells Normal, T-Lymphocytes Absent | T-B+NK+",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642517","T-Cells and B-Cells Absent and Natural Killer Cells Normal","C176466","A hematology test result indicating that a subject has a normal amount of natural killer cells but B-cells and T-cells are either absent or found at abnormally low amounts.","T-Cells and B-Cells Absent and Natural Killer Cells Normal | T-B-NK+ | T-Lymphocytes and B-Lymphocytes Absent and Normal Natural Killer Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1305211","Bone Marrow Donation","C64258","Traditionally, minor surgery to draw marrow from the hipbones followed by collection of the stems cells from the donated marrow. Today the most common way of collecting the stem cells is by filtering them directly from the blood. Although this procedure is technically called peripheral blood stem cell donation, it is still commonly referred to as bone marrow donation.","Bone Marrow Donation | ",,,,,,,,,,,,,,,"4108842","Donation of bone marrow",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021072","Immunoprotein","C16725","A protein whose activities affect or play a role in immune system functions.","Immunoprotein | Immune Regulatory Proteins",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0687694","Case Management Nurse","C20853","Case management includes nursing activities of coordination, advocacy, and referral. These activities involve facilitating service delivery on behalf of the client, communicating with health and human service providers, promoting assertive client communication, and guiding the client toward use of appropriate community resources.","Case Management Nurse | Care Manager | Case Manager",,,,,,,,,,,,,,,"4086457","Care manager",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1551285","Urgent Care Center","C53528","A healthcare facility that provides immediate and semi-urgent healthcare and treatment for the sick or the injured who do not have a life-threatening condition.","Urgent Care Center | URGENT CARE CENTER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513052","Medical-Surgical Nurse Specialist","C20840","Graduate-prepared clinical specialists in Medical-Surgical Nursing provide care for individuals who have a known or predicted physiological alteration. Clinical specialists demonstrate an in-depth understanding of complex medical-surgical problems, as well as interventions to manage and improve patient care. Guided by theory and research, their practice considers all influences on health status and the related social and behavioral problems arising because of the patient's physiological condition. Clinical specialists are engaged in education, case management, expert clinical practice, consultation, research, and administration. Clinical specialists practice in settings where primary, acute, or long-term nursing care is delivered. (ANCC)","Medical-Surgical Nurse Specialist | Clinical Specialist in Medical-Surgical Nursing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335206","PF4 Gene","C26600","This gene plays a role in platelet aggregation and promotes blood coagulation.","PF4 Gene | CXCL4 Gene | PF4 | Platelet Factor 4 (Chemokine (C-X-C Motif) Ligand 4) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221023","Cyclic Neutropenia","C3820","A hematologic disorder caused by a mutation in the ELANE (ELA2) gene; clinical manifestations include recurrent neutropenia with resultant susceptibility to infection leading to fever.","Cyclic Neutropenia | CH | CN | Cyclic Agranulocytosis | Cyclic Hematopoiesis | Dysplasia, Myelocytic Periodic | Periodic Neutropenia | cyclic neutropenia | periodic neutropenia",,,,,,,,,,,,,,,"432297","Cyclical neutropenia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1334085","IFNG Gene","C28603","This gene plays a role in signal transduction and immunoregulation. It is also involved in cell communication, migration, growth and proliferation.","IFNG Gene | IFNG | Interferon, Gamma Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334084","IFNGR2 Gene","C37287","This gene is involved in receptor-mediated signal transduction in the interferon gamma signaling pathway and mediates innate immune responses.","IFNGR2 Gene | IFNGR2 | Interferon Gamma Receptor 2 (Interferon Gamma Transducer 1) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427947","UNC13D Gene","C114613","This gene is involved in vesicle maturation and secretion.","UNC13D Gene | UNC13D | Unc-13 Homolog D (C. elegans) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642339","Three Times Per Cycle","C176289","Three times per cycle.","Three Times Per Cycle | 3 TIMES PER CYCLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642338","Two Times Per Cycle","C176288","Two times per cycle.","Two Times Per Cycle | 2 TIMES PER CYCLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642475","Lymphocyte Function-Associated Antigen 1 Measurement","C176341","The determination of the amount of lymphocyte function-associated antigen 1 in a sample.","Lymphocyte Function-Associated Antigen 1 Measurement | Integrin AlphaL/Beta2 Measurement | LFA1 | LFA1 Measurement | Lymphocyte Function-Associated Antigen 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642478","Number of Abnormal Tissue Samples","C176340","The total number of tissue samples in which a pathological abnormality has been observed.","Number of Abnormal Tissue Samples | TISABNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642477","Paneth Cell Metaplasia Assessment","C176339","An evaluation of the presence or degree of paneth cell metaplasia in a sample.","Paneth Cell Metaplasia Assessment | PNTHCEMP | Paneth Cell Metaplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642327","Epithelial Integrity Assessment","C176338","An evaluation of the presence or degree of epithelial integrity in a sample.","Epithelial Integrity Assessment | EPITHINT | Epithelial Integrity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642326","Crypt Architectural Damage Assessment","C176337","An evaluation of the presence or degree of crypt architectural damage in a sample.","Crypt Architectural Damage Assessment | CRYPARCD | Crypt Architectural Damage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642328","Crypt Abscess Assessment","C176336","An evaluation of the presence or degree of crypt abscess in a sample.","Crypt Abscess Assessment | CRYPABSC | Crypt Abscess",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642749","Cryptitis Assessment","C176335","An evaluation of the presence or degree of cryptitis in a sample.","Cryptitis Assessment | CRYPTTS | Cryptitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642329","Granuloma Assessment","C176334","An evaluation of the presence or degree of granuloma in a sample.","Granuloma Assessment | GRNLMA | Granuloma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642756","Ulceration Assessment","C176333","An evaluation of the presence or degree of ulceration in a sample.","Ulceration Assessment | ULCER | Ulceration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1533164","Megabase Pair","C176388","A number representing one million paired nucleotides in a DNA or RNA sequence.","Megabase Pair | MBP | Mb | Mbp | {Mbp} | {Mb}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642463","/MBP","C176387","A unit equal to one million base pairs used as a denominator to build a derived unit expressed as a ratio.","Per Megabase Pair | /10^6 BP | /MBP | /Mb | /Mbp | /{Mbp} | /{Mb}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642452","Microgram per Mole","C176385","A unit of mass commonly used to express the molar mass of a substance in microgram(s) per mole.","Microgram per Mole | ng/mmol | pg/umol | ug/mol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642455","European Pharmacopoeia Unit","C176384","An arbitrary unit of measurement established by the European Pharmacopoeia that corresponds to 1800 Kallidinogenase Inactivator units.","European Pharmacopoeia Unit | EP U | {EP U}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642454","Nanokatal per Gram Hemoglobin","C176383","A unit of catalytic activity concentration defined as the catalytic activity equal to one billionth of katal (10E-9 katal) per gram hemoglobin.","Nanokatal per Gram Hemoglobin | Nanokatals per Gram Hemoglobin | nkat/g Hb | nkat/g{HGB}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642456","Breaths per Thirty Seconds","C176382","The number of breaths (inhalation and exhalation) taken within a period of time equal to thirty seconds.","Breaths per Thirty Seconds | Breaths per 30 Seconds | breaths/30 s | breaths/30s | {breaths}/30.s",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0556973","Minute per Day","C176381","A unit of measurement equal to the number of minutes within a period of time equal to one day.","Minute per Day | Minutes per Day | min/d | min/day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0556974","Hour per Day","C176380","A unit of measurement equal to the number of hours within a period of time equal to one day.","Hour per Day | Hours per Day | h/d | hr/day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642457","Nanomole per Kilogram per Day","C176379","A dose calculation unit expressed in nanomoles per kilogram per day.","Nanomole per Kilogram per Day | fmol/mg/d | nmol/kg/d | nmol/kg/day | pmol/g/d | pmol/g/day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642446","Gram per Liter per Day","C176378","A dose calculation unit expressed in milligrams per milliliter per day.","Gram per Liter per Day | g/L/24 Hours | g/L/d | g/L/day | g/l/d | mg/mL/24 Hours | mg/mL/d | mg/mL/day | mg/ml/d | ng/nL/d | ng/nl/d | ug/uL/d | ug/ul/d",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439338","Picogram Per Cell","C176377","A unit of mass concentration for the number of picograms of substance per cell.","Picogram Per Cell | pg/cell | pg/{cell}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642473","Logistical Problem With Clinical Study","C176343","A problem with some logistical aspect of a clinical study, either on the part of the participant or the site.","Logistical Problem With Clinical Study | LOGISTICAL PROBLEM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642476","Study Consent Withdrawn","C176342","An indication that the consent to participate in the study or one or more segments of the study has been revoked.","Study Consent Withdrawn | Informed Consent Withdrawn | Subject Withdrawal of Consent | WITHDRAWAL OF CONSENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642450","Endometrial Tissue","C176371","The mucous membrane comprising the inner layer of the uterine wall; it consists of a simple columnar epithelium and a lamina propria that contains simple tubular uterine glands. The structure, thickness, and state of the endometrium undergo marked change with the menstrual cycle.","Endometrial Tissue | ENDOMETRIAL TISSUE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642495","Plasma Ultrafiltrate","C176370","The fluid that is produced from the movement of whole blood across a semipermeable membrane in response to a pressure gradient, removing blood cells and large proteins.","Plasma Ultrafiltrate | PLASMA ULTRAFILTRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642494","Arterialized Capillary Blood","C176369","Capillary blood collected from a puncture site that has been warmed or treated with creams containing a hyperemic or vasodilatory agent to increase arterial blood flow.","Arterialized Capillary Blood | ARTERIALIZED CAPILLARY BLOOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642496","Emotional Tear","C176368","A type of tear produced in response to negative and positive emotions; contains higher amounts of proteins and stress-related hormones in comparison to other tear types.","Emotional Tear | EMOTIONAL TEAR | Psychic Tear",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL931320","Reflex Tear","C176367","A type of tear produced in response to irritation from foreign particles, vapors, bright lights, or peppery substances; contains higher amounts of antibodies in comparison to other tear types.","Reflex Tear | REFLEX TEAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642498","Basal Tear","C176366","A type of tear that is spread across the surface of the eye at regular intervals with blinking, coating the eyes to keep them moist.","Basal Tear | BASAL TEAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413455","Simple Endoscopic Score for Crohn's Disease Version 1 Clinical Classification","C176060","A standardized endoscopic scoring system that was developed as a simplified alternative to the Crohn's Disease Endoscopic Index of Severity (CDEIS) by Daperno et al. 2004. The presence and size of ulcerations and the extent of the inflammatory area and stenosis are assessed in each of the five ileocolonic segments (rectum, sigmoid and left colon, transverse colon, right colon, and ileum) and given a severity score ranging from zero to three, and the cumulative score is determined, with higher scores indicating severe disease.","Simple Endoscopic Score for Crohn's Disease Version 1 Clinical Classification | SES-CD V1 | SES-CD Version 1 | SES01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413454","Crohn's Disease Activity Index Version 1 Clinical Classification","C176059","A standardized index that was developed by Best et al 1976 as part of the National Cooperative Crohn's Disease Study to assess the severity of Crohn's Disease. A multiple regression computer program was utilized to derive an equation for the prediction of disease activity from eight variables assessed over the past seven days, including number of stools, abdominal pain, general well-being, extraintestinal complications, antidiarrheal agents used, abdominal mass felt on palpation, hematocrit, and body weight. Scores range from 0 to 600, with a score of less than 150 corresponding to remission, 150 to 219 corresponding to mildly active disease, 220 to 450 corresponding to moderately active disease, and greater than 450 corresponding to severe disease.","Crohn's Disease Activity Index Version 1 Questionnaire | CDAI V1 | CDAI Version 1 | CDAI01 | Crohn's Disease Activity Index Version 1 Clinical Classification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1413457","Apgar Score Version 1 Clinical Classification","C176057","A scoring system, developed by Dr. Virginia Apgar in 1952, that is used to evaluate the clinical status of the newborn infant by assigning individual scores ranging from zero to two in the assessment of respiratory effort, reflex irritability, muscle tone, heart rate, and color. The cumulative score is reported at one minute after birth, and at five minute intervals up to 20 minutes after birth for infants with a one minute cumulative score of less than seven.","Apgar Score Version 1 Clinical Classification | APGAR SCORE V1 | APGAR Score Version 1 | APGR01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642340","Information Source for Cause of Death","C176287","The authoritative source that provided the cause of death information.","Information Source for Cause of Death | INFOSCOD | cause of death source | cause_of_death_source",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642746","SARS-CoV-2 Antigen Measurement","C176327","The determination of the amount of SARS-CoV-2 antigen in a biological sample.","SARS-CoV-2 Antigen Measurement | SAR2AG | SARS-CoV-2 Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642750","Dosing Interval","C176355","The duration of time between two doses.","Dosing Interval | TAU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642480","Ratio Amount Recovered Infinity Observed","C176354","The ratio of two amount recovered infinity observed values.","Ratio Amount Recovered Infinity Observed | RARECIFO | Ratio Amt Rec Infinity Obs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642479","Ratio Concentration Trough","C176353","The ratio of two concentration trough values.","Ratio Concentration Trough | CTROUGH Ratio | RACTRGH | Ratio Conc Trough",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642482","Ratio Maximum Concentration Normalized by Dose","C176352","The ratio of two maximum concentration normalized by dose values.","Ratio Maximum Concentration Normalized by Dose | RACMAXD | Ratio Max Conc Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642481","Ratio AUC Over Dosing Interval","C176351","The ratio of two area under the curve values each measured over the interval between two doses.","Ratio AUC Over Dosing Interval | AUCTAU Ratio | RAAUCTAU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642484","Ratio AUC to Last Nonzero Concentration Normalized by Dose","C176350","The ratio of two AUC to last nonzero concentration normalized by dose values.","Ratio AUC to Last Nonzero Concentration Normalized by Dose | RAAUCLSD | Ratio AUC to Last Nonzero Conc Norm by Dose | RatioAUC to Last Nonzero Conc NormByDose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642483","Ratio AUC from T1 to T2 Normalized by Dose","C176349","The ratio of two AUC from T1 to T2 normalized by dose values.","Ratio AUC from T1 to T2 Normalized by Dose | RAAUCIND | Ratio AUC from T1 to T2 Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642486","Ratio AUC Infinity Observed Normalized by Dose","C176348","The ratio of two AUC infinity observed normalized by dose values.","Ratio AUC Infinity Observed Normalized by Dose | AUC Infinity Observed Normalized by Dose Ratio | RAAUCIOD | Ratio AUC Infinity Obs Norm by Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642485","Ratio Amount Recovered from T1 to T2","C176347","The ratio of two amount recovered from T1 to T2 values.","Ratio Amount Recovered from T1 to T2 | RARECINT | Ratio Amt Rec from T1 to T2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642472","Minimum Concentration Ratio","C176346","The ratio of two minimum concentration values.","Minimum Concentration Ratio | RACMIN | Ratio Min Conc | Ratio Minimum Concentration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642471","Average Concentration Ratio","C176345","The ratio of two average concentration values.","Average Concentration Ratio | RACAVG | Ratio Average Concentration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642474","AUC All Ratio","C176344","The ratio of two AUC All values.","AUC All Ratio | RAAUCALL | Ratio AUC All",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642310","Ratio AUC to Last Nonzero Concentration","C176237","The ratio of two AUC to last nonzero concentration values.","Ratio AUC to Last Nonzero Concentration | RAAUCLST | Ratio AUC to Last Nonzero Conc",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642309","Ratio AUC From T1 to T2","C176236","The ratio of two AUC from T1 to T2 values.","Ratio AUC From T1 to T2 | AUC Ratio from T1 to T2 | RAAUCINT | Ratio AUC from T1 to T2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642312","Concentration Ratio","C176235","The ratio of two concentration values.","Concentration Ratio | RACONC | Ratio Concentration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL463830","Waiting Room","C176974","A room or enclosed area that is designated for people who are waiting for a service.","Waiting Room | Waiting Area",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642792","KLB Positive","C176958","An indication that KLB expression has been detected in a sample.","KLB Positive | BKL Positive | Beta-Klotho Positive | BetaKlotho Positive | Klotho Beta Like Positive | Klotho Beta-Like Positive | b-Klotho Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642765","PAX/FOXO1 Fusion Gene","C176966","A fusion gene resulting from a chromosomal translocation that fuses a PAX family gene (usually PAX3 or PAX7, on chromosome 2 or 1, respectively) with the FOXO1 gene on chromosome 13. These rearrangements result in expression of fusion proteins consisting of the intact PAX family N-terminal DNA binding domain fused in-framed to the intact FOXO1 C-terminal transcriptional activation domain and are associated with alveolar rhabdomyosarcoma.","PAX/FOXO1 Fusion Gene | PAX Family/FOXO1 Fusion Gene | PAX Family/Forkhead Box O1 Gene Fusion | PAX-FOXO1 Fusion Gene | PAX/FKHR Fusion Gene | PAX/Forkhead Box O1 Gene Fusion | PAX::FOXO1 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642487","Term Pregnancy Category","C176361","A classification of the gestation duration of the pregnancy at the time of infant birth.","Term Pregnancy Category | TRMPGCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642490","Hospitalized Due to Pregnancy Complication Indicator","C176360","An indication as to whether the individual was hospitalized due to a pregnancy complication.","Hospitalized Due to Pregnancy Complication Indicator | HSPGCIND | Hosp Due to Pregnancy Complication Ind",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642489","Vaginal Bleeding and/or Spotting Frequency Description","C176359","A description of the frequency at which vaginal bleeding and/or spotting has occurred.","Vaginal Bleeding and/or Spotting Frequency Description | VBSFRQD | Vaginal Bleeding/Spotting Freq Desc | Vaginal Bleeding/Spotting Frequency Description",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642766","FGFR4 Gene Rearrangement","C176967","A molecular abnormality indicating rearrangement of the FGFR4 gene.","FGFR4 Gene Rearrangement | CD334 Gene Rearrangement | FGFR-4 Gene Rearrangement | FGFR4 Rearrangement | Fibroblast Growth Factor Receptor 4 Gene Rearrangement | JKT2 Gene Rearrangement | JTK2 Gene Rearrangement | TKF Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642769","EZH2 Gene Copy Number Alteration Positive","C176970","A genetic finding indicating that the number of copies of the EZH2 gene in a samples is either increased (amplified) or decreased (deleted) from the normal copy number (2).","EZH2 Gene Copy Number Alteration Positive | ENX-1 Gene Copy Number Alteration Positive | ENX1 Gene Copy Number Alteration Positive | EZH2 Copy Number Alteration | EZH2 Copy Number Alteration Positive | EZH2 Gene Copy Number Alteration | EZH2b Gene Copy Number Alteration Positive | Enhancer of Zeste 2 Gene Copy Number Alteration Positive | Enhancer of Zeste 2 Polycomb Repressive Complex 2 Subunit Gene Copy Number Alteration Positive | KMT6 Gene Copy Number Alteration Positive | KMT6A Gene Copy Number Alteration Positive | KTM6A Gene Copy Number Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642770","POLE Gene Mutation Negative","C176971","A genetic finding indicating that POLE gene mutations have not been detected in a sample.","POLE Gene Mutation Negative | DNA Polymerase Epsilon Catalytic Subunit A Exonuclease Gene Mutation Negative | DNA Polymerase Epsilon, Catalytic Subunit Exonuclease Gene Mutation Negative | POLE Mutation Negative | POLE Wild-Type | POLE Wildtype | POLE wt | POLE1 Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642771","Testosterone Greater than or Equal to 50 ng/dL","C176972","A semiquantitative finding indicating that the concentration of testosterone in a sample is greater than or equal to 50 ng/dL.","Testosterone Greater than or Equal to 50 ng/dL | Testosterone Greater than or Equal to 50 Nanograms per Deciliter | Testosterone Greater than or Equal to 50 Nanograms/Deciliter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642759","FGFR4 Positive","C176973","An indication that FGFR4 expression has been detected in a sample.","FGFR4 Positive | CD334 Antigen Positive | CD334 Positive | FGFR-4 Positive | Fibroblast Growth Factor Receptor 4 Positive | JKT2 Positive | JTK2 Positive | TKF Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642497","Country of Permanent Address","C176365","The country in which an individual permanently resides.","Country of Permanent Address | CTRYPAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642500","Village of Permanent Address","C176364","The village in which an individual permanently resides.","Village of Permanent Address | VILLPAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642499","District of Permanent Address","C176363","The district in which an individual permanently resides.","District of Permanent Address | DISTPAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642488","County of Permanent Address","C176362","The county in which an individual permanently resides.","County of Permanent Address | CNTYPAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642794","Cytokine Receptor Common Subunit Gamma Measurement","C176960","The determination of the amount of cytokine receptor common subunit gamma present in a sample.","Cytokine Receptor Common Subunit Gamma Measurement | CD132 Measurement | Common Gamma Chain Measurement | Gamma c expression | GammaC Measurement | IL-2 Receptor Subunit Gamma Measurement | IL-2R Subunit Gamma Measurement | IL-2RG Measurement | IL2RG Measurement | Interleukin 2 Receptor Gamma Measurement | Interleukin-2 Receptor Subunit Gamma Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642795","CD4, CD25, FOXP3 Expressing Regulatory T-Lymphocyte Count","C176961","The determination of the number of regulatory T-lymphocytes expressing CD4, CD25 and FOXP3 present in a sample.","CD4, CD25, FOXP3 Expressing Regulatory T-Lymphocyte Count | CD4+ CD25+ FOXP3+ Treg Cell Count | CD4+ CD25+ FOXP3+ Treg cell count | CD4+CD25+ Foxp3+ Regulatory T Cell Count | CD4+CD25+Foxp3+ Regulatory T Cell | CD4+CD25+Foxp3+ T Regulatory Cell Count | CD4+CD25+Foxp3+T regulatory cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0450279","Epitrochlear Region","C165193","The inner surface of the upper arm adjacent to the elbow.","Epitrochlear Region | Epitrochlear",,,,,,,,,,,,,,,"4130891","Epitrochlear",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1184145","Occipital","C161326","Of, or related to, or in the direction of the occiput, or back of the head.","Occipital | OCCIPITAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642448","Study Contact Postal Address","C176376","A physical location used by a study contact for the purpose of receiving postal mail deliveries.","Study Contact Postal Address | CONMAIL | Contact Mailing Address | Study Contact Mailing Address",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642447","Study Contact E-mail Address","C176375","A text string identifier for a location to which e-mail for the study contact can be delivered.","Study Contact E-mail Address | CONEMAIL | Contact E-Mail Address",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642747","Study Contact Telephone Number","C176374","A sequence of decimal digits (0-9) that is used for identifying a destination telephone line or other device in a telephone network that is used by the study contact.","Study Contact Telephone Number | CONPHONE | Contact Phone Number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642449","Study Contact Name","C176373","A non-unique textual identifier for the study contact.","Study Contact Name | CONNAME | Contact Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642451","Study Contact Role","C176372","A title that describes the function of a study contact within their organization.","Study Contact Role | CONROLE | Contact Role",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642761","Brachial Region","C176976","The area of the body that includes the upper arm, from the shoulder to the elbow.","Brachial Region | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230417","Femoral Region","C176978","The area of the body that includes the thigh, from the hip to the knee.","Femoral Region | ",,,,,,,,,,,,,,,"4307815","Femoral region structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0816951","Inguinal part of abdomen","C176977","An area of the lower abdomen to the left or right of the hypogastric (suprapubic) region, overlying an iliac crest.","Iliac Region | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642661","Combined Immunodeficiencies Associated with Syndromic Features","C176596","A group of genetic immunodeficiency syndromes with unique clinical features and well-characterized underlying immune defects, comprised of: CID with congenital thrombocytopenia; CID due to DNA repair defects other than forms of SCID in category I; CID due to thymic defects with additional congenital anomalies; CID with immunoosseous dysplasias; Hyper-IgE syndromes (HIES); CID due to defects of vitamin B12 and folate metabolism; Anhidrotic ectodermal dysplasia with immunodeficiency; CID due to calcium channel defects; and various other CID with unique clinical phenotypes.","Combined Immunodeficiencies Associated with Syndromic Features | Combined Cellular and Humoral Immunodeficiencies Associated with Syndromic Features | Immunodeficiencies Affecting Cellular and Humoral Immunity Associated with Syndromic Features",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642662","Immunodeficiencies Affecting Cellular and Humoral Immunity - Combined Immune Deficiency","C176597","A group of immunodeficiency disorders that include combined immunodeficiencies (CIDs) generally less profound than SCID.","Immunodeficiencies Affecting Cellular and Humoral Immunity - Combined Immune Deficiency | Immunodeficiencies Affecting Cellular and Humoral Immunity/ Combined Immune Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642659","Immunodeficiencies Affecting Cellular and Humoral Immunity - Severe Combined Immune Deficiency","C176598","A group of immunodeficiency disorders that include T cell-negative, B cell-positive severe combined immunodeficiencies; and T cell-negative, B cell-negative severe combined immunodeficiencies.","Immunodeficiencies Affecting Cellular and Humoral Immunity - Severe Combined Immune Deficiency | Immunodeficiencies Affecting Cellular and Humoral Immunity/ Severe Combined Immune Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642660","Predominantly Antibody Deficiencies","C176599","A group of primary immunodeficiency diseases caused predominantly by antibody deficiencies, comprised of: Agammaglobulinemia with absent B cells; Severe reduction in at least two serum immunoglobulins, common variable immunodeficiency (CVID) phenotype; Severe reduction in serum IgG and IgA with normal or elevated IgM, hyper-IgM; and Isotype, light chain, or functional deficiencies with generally normal numbers of B cells.","Predominantly Antibody Deficiencies | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642518","T-Cells, B-Cells and Natural Killer Cells Absent","C176463","A hematology test result indicating that a subject's T-cells, B-cells and natural killer cells are either absent or found at abnormally low amounts.","T-Cells, B-Cells and Natural Killer Cells Absent | T-B-NK- | T-Lymphocytes, B-Lymphocytes and Natural Killer Cells Absent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642520","T-Cells and Natural Killer Cells Absent B-Cells Normal","C176461","A hematology test result indicating that a subject has a normal amount of B-cells but both T-cells and natural killer cells are either absent or found at abnormally low amounts.","T-Cells and Natural Killer Cells Absent B-Cells Normal | T-B+NK- | T-Lymphocytes and Natural Killer Cells Absent B-Lymphocytes Normal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642521","T-Cells Absent, T-Cell Receptor Signaling Defective and Natural Killer Cells and B-Cells Normal","C176462","A hematology test result indicating that a subject has a normal amount of B-cells and natural killer cells but T-cells are absent or found at abnormally low amounts and a defect in T-cell receptor signaling pathways has been observed.","T-Cells Absent, T-Cell Receptor Signaling Defective and Natural Killer Cells and B-Cells Normal | T-B+NK+ Defective TCR Signaling | T-B+NK+ with Defective TCR Signaling | T-Lymphocytes Absent, T-Cell Receptor Signaling Defective and Normal Natural Killer Cells and B-Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642679","EBV Susceptibility","C176692","An immune system finding indicating that an individual has a likelihood for developing Epstein Barr virus infections.","EBV Susceptibility | Epstein Barr Virus Susceptibility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2984327","Jak-STAT Signaling Pathway","C91519","The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is one of a handful of pleiotropic cascades used to transduce a multitude of signals for development and homeostasis in animals, from humans to flies.  In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors. Following the binding of cytokines to their cognate receptor, STATs are activated by members of the JAK family of tyrosine kinases. Once activated, they dimerize and translocate to the nucleus and modulate the expression of target genes. In addition to the activation of STATs, JAKs mediate the recruitment of other molecules such as the MAP kinases, PI3 kinase etc. These molecules process downstream signals via the Ras-Raf-MAP kinase and PI3 kinase pathways which results in the activation of additional transcription factors.","Jak-STAT Signaling Pathway | JAK/STAT | Jak-STAT signaling pathway | Janus Kinase/Signal Transducer and Activator of Transcription",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1336788","Transcription Regulatory Protein","C26199","A protein that is involved in the regulation of transcription.","Transcription Regulatory Protein | Transcription Regulation Protein | Transcriptional Regulators | Transcriptional Regulatory Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642710","Immunodeficiency due to Quantitative Defects","C176670","An indication that an immunodeficiency disorder is caused by a partial or complete loss of one or more of the hematopoietic cell lineages that are involved in host defense.","Immunodeficiency due to Quantitative Defects | Quantitative defects",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3266863","Mendelian Susceptibility to Mycobacterial Diseases","C176601","A rare inherited disorder typically presenting in childhood characterized by a susceptibly to infection (local and disseminated), particularly from mycobacteria. This disorder has been associated with mutations in several genes including: IFNGR1, IFNGR2, STAT1, IL12B, IL12RB1, IRF8,  ISG15, IKBKG, CYBB.","Mendelian Susceptibility to Mycobacterial Diseases | MSMD",,,,,,,,,,,,,,,"37161024","Mendelian susceptibility to mycobacterial disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1642680","Predisposition to Bacterial Infections","C176693","An immune system finding indicating that an individual has a higher than normal tendency to develop bacterial infections.","Predisposition to Bacterial Infections | Predisposition to bacterial infections",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642677","Predisposition to Fungal Infections","C176694","An immune system finding indicating that an individual has a higher than normal tendency to develop fungal infections.","Predisposition to Fungal Infections | Predisposition to fungal infections",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642678","Predisposition to Viral Infections","C176695","An immune system finding indicating that an individual has a higher than normal tendency to develop viral infections.","Predisposition to Viral Infections | Predominant predisposition to viral infections",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642675","Repeat Expansion Disease","C176696","A class of genetic diseases that occur when microsatellite repeats expand beyond a threshold length.","Repeat Expansion Disease | Expansion Repeat Disease | Expansion Repeat Disorder | Repeat Expansion Disorder | Repeat expansion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1832241","Agammaglobulinemia, non-Bruton type","C176822","A genetically heterogenous group of primary immunodeficiencies characterized by low or absent circulating antibodies/or and low or absent B-cells.","Autosomal Recessive Agammaglobulinemia | Autosomal Recessive Agammaglobulinemia (AR Agammaglobulinemia)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2677481","Ectodermal Dysplasia, Anhidrotic, With T-Cell Immunodeficiency, Autosomal Dominant","C176826","A rare disorder caused by mutations in the NFKBIA gene resulting in an autosomal dominant inheritance pattern. It is characterized by abnormal development of ectodermal tissues including the skin, hair, teeth, and sweat glands and immune system deficiency. It results in dry and wrinkled skin, sparse scalp and body hair, missing teeth, and reduced ability to sweat. Patients have abnormally low levels of antibodies causing inability to fight infections.","Ectodermal Dysplasia and Immunodeficiency 2 | Autosomal Dominant Anhidrotic Ectodermal Dysplasia | EDAID2 | Ectodermal Dysplasia, Anhidrotic, with Immunodeficiency 2 | Ectodermal Dysplasia, Anhidrotic, with T-Cell Immunodeficiency, Autosomal Dominant | Ectodermal Dysplasia, Hypohidrotic, with Immunodeficiency 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL965939","PROTEASOME-ASSOCIATED AUTOINFLAMMATORY SYNDROME 1","C176619","An autosomal recessive condition caused by mutation(s) in the PSMB8 gene, encoding proteasome subunit beta type-8. It is characterized by early onset annular erythematous plaques, partial lipodystrophy, and recurrent fever.","Proteasome-Associated Autoinflammatory Syndrome 1 | CANDLE | Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature (CANDLE) Syndrome | Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature Syndrome | PRAAS1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1847973","B-Cell Expansion with NFKB and T-Cell Anergy","C176791","An autosomal dominant condition caused by heterozygous germline gain-of-function mutation(s) in the CARD11 gene, encoding caspase recruitment domain-containing protein 11. It is characterized by splenomegaly and lymphocytosis resulting from polyclonal expansion of B-cells.","B-Cell Expansion with NFKB and T-Cell Anergy | BENTA | CARD 11/BENTA",,,,,,,,,,,,,,,"35622391","Persistent polyclonal B-cell lymphocytosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL786201","IMMUNODEFICIENCY 11B WITH ATOPIC DERMATITIS","C176630","An autosomal dominant condition caused by mutation(s) in the CARD11 gene, encoding caspase recruitment domain-containing protein 11. It is characterized by the onset of moderate to severe atopic dermatitis in early childhood, defects in T-cell activation, increased IgE, and eosinophilia.","Immunodeficiency 11B with Atopic Dermatitis | Atopic Dermatitis, Elevated IgE, and Eosinophilia | CARD11/CID | IMD11B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1720957","HIGM3 Syndromes","C176416","An autosomal recessive subtype of immunodeficiency with hyper-IgM caused by mutation(s) in the CD40 gene, encoding tumor necrosis factor receptor superfamily member 5.","Immunodeficiency with Hyper-IgM, Type 3 | CD40 Deficiency | CD40 deficiency | HIGM3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4225328","DOCK2-Associated Immunodeficiency","C176799","An autosomal recessive combined immunodeficiency caused by mutation(s) in the DOCK2 gene, encoding dedicator of cytokinesis protein 2. It is characterized by combined immunodeficiency, primarily affecting T-cells, with more variable defects in B-cell and NK-cell function, resulting in viral and bacterial infections that may lead to death in severe cases.","DOCK2-Associated Immunodeficiency | DOCK2 Deficiency | IMD40 | Immunodeficiency 40",,,,,,,,,,,,,,,"37162779","DOCK2 deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4013949","IL12RB1 deficiency","C176800","An autosomal recessive condition caused by mutation(s) in the IL12RB1 gene, encoding interleukin-12 receptor subunit beta-1. It is characterized by a susceptibility to mycobacterial disease. IL12RB1 associated with IL12RB2 results in a high affinity receptor for IL12. IL12RB1 combined with IL23R forms the interleukin-23 receptor.","IL12RB1-Associated Immunodeficiency | IL-12 Receptor B Deficiency | IL12RB1 Deficiency | IMD30 | Immunodeficiency 30",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4016927","IMMUNODEFICIENCY, COMMON VARIABLE, 11","C176801","An autosomal recessive subtype of common variable immunodeficiency caused by mutation(s) in the IL21 gene, encoding interleukin-21.","Immunodeficiency, Common Variable, 11 | CVID11 | IL21 Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1837028","Severe Combined Immunodeficiency, Autosomal Recessive, T Cell Negative, B Cell Positive, NK Cell Positive","C176804","An autosomal recessive severe combined immunodeficiency, the phenotype of which is caused by mutation(s) in the IL7R or PTPRC genes, encoding interleukin-7 receptor subunit alpha and receptor-type tyrosine-protein phosphatase C (CD45) respectively.","Severe Combined Immunodeficiency, Autosomal Recessive, T-Cell Negative, B Cell-Positive, NK Cell-Positive | IL7R Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2930924","Immunodeficiency 27A","C176806","A genetic condition caused by mutation(s) in the IFNGR1 gene, encoding interferon gamma receptor 1, resulting in impairment of interferon-gamma mediated immunity. Clinically, it is characterized by predisposition to illness caused by moderately virulent mycobacterial species.","Immunodeficiency 27A | Autosomal Recessive IFNGR1 Deficiency | Autosomal Recessive Interferon Gamma Receptor 1 Deficiency | IFNGR 1 Deficiency | IFNGR1 Deficiency | IMD27A | Interferon Gamma Receptor 1 Deficiency | Interferon Gamma Receptor 1 Deficiency | MSMD due to Complete IFNGR1 Deficiency | MSMD due to Complete IFNgammaR1 Deficiency | Mendelian Susceptibility to Mycobacterial Diseases due to Complete IFNgammaR1 Deficiency",,,,,,,,,,,,,,,"37397560","Mendelian susceptibility to mycobacterial disease due to complete interferon gamma receptor 1 deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4013947","IMMUNODEFICIENCY 28","C176805","A genetic condition caused by mutation(s) in the IFNGR2 gene, encoding interferon gamma receptor 2, resulting in impairment of interferon-gamma mediated immunity. Clinically, it is characterized by predisposition to illness caused by moderately virulent mycobacterial species.","Interferon Gamma Receptor 2 Deficiency | IFNGR 2 Deficiency | IFNGR2 Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524166","Pharmacogenomic Test","C68762","An assay intended to study interindividual variations in whole genome or candidate gene maps, biomarkers, and alterations in gene expression or inactivation that may be correlated with pharmacological function and therapeutic response. Compare to pharmacogenetic test.","Pharmacogenomic Test | pharmacogenomic test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642591","Interferon Regulatory Factor 8 Deficiency","C176825","A genetic condition caused by mutation(s) in the IRF8 gene encoding interferon regulatory factor 8. Autosomal dominant (Immunodeficiency 32A) and autosomal recessive (Immunodeficiency 32B) genetic alterations result in different phenotypes, both of which have impairment of function in dendritic cells.","Interferon Regulatory Factor 8 Deficiency | IRF8 Deficiency | IRF8, Dendritic cell immunodeficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642711","Activating JAK1 Gene Mutation","C176671","A change in the nucleotide sequence of the JAK1 gene that that results in constitutive activation of both tyrosine-protein kinase JAK1 and its downstream signaling pathways. These mutations are involved in autoinflammation, immune dysregulation, and eosinophilia (AIIDE).","Activating JAK1 Gene Mutation | Activating JAK1 Mutation | Activating JTK3 Gene Mutation | Activating Janus Kinase 1 Gene Mutation | Gain of Function JAK1 Gene Mutation | Gain of Function JAK1 Mutation | JAK1 Activating Gene Mutation | JAK1 Activating Mutation | JAK1 GOF | JAK1 Gain of Function Gene Mutation | JAK1 Gain of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642745","Severe Combined Immunodeficiency, Autosomal Recessive, T-Cell Negative, B-Cell Positive, NK-Cell Negative","C176807","An autosomal recessive severe combined immunodeficiency caused by mutation(s) in the JAK3 gene, encoding tyrosine-protein kinase JAK3. It is characterized by decreased concentrations of T-cells and NK-cells and normal concentrations of B-cells.","JAK3-deficient Severe Combined Immunodeficiency | Autosomal Recessive T cell-negative, B cell-positive, NK cell-negative Severe Combined Immunodeficiency | Autosomal Recessive T-B+NK- SCID | Autosomal recessive T cell-negative, B cell-positive, NK cell-negative severe combined immunodeficiency | Autosomal recessive T-B+NK- SCID | JAK3 Deficiency | JAK3 SCID | JAK3 deficiency | JAK3-deficient Severe Combined Immunodeficiency | SCID, T- B+ NK-, JAK3 mutation | Severe Combined Immunodeficiency, Autosomal Recessive, T-Cell Negative, B-Cell Positive, NK-Cell Negative | Severe Combined Immunodeficiency, Autosomal Recessive, T-Cell Negative, B-Cell Positive, NK-Cell Negative | T cell-negative, B cell-positive, NK cell-negative SCID | T- B+ NK-, JAK3 mutation | T-B+ Severe Combined Immunodeficiency due to JAK3 deficiency | T-B+ severe combined immunodeficiency due to JAK3 deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642511","LAT Gene Mutation","C176443","A change in the nucleotide sequence of the LAT gene.","LAT Gene Mutation | LAT mutations | LAT1 Gene Mutation | Linker for Activation of T Cells Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4016253","IMMUNODEFICIENCY 22","C176808","An extremely rare autosomal recessive condition caused by mutation(s) in the LCK gene, encoding tyrosine-protein kinase Lck. It is characterized by T-cell dysfunction.","LCK-Associated Immunodeficiency | IMD22 | Immunodeficiency 22 | LCK Deficiency | LCK Deficiency (T Lymphocyte-specific protein TK)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3553512","IMMUNODEFICIENCY, COMMON VARIABLE, 8, WITH AUTOIMMUNITY","C176809","An autosomal recessive common variable immunodeficiency caused by mutation(s) in the LRBA gene, encoding lipopolysaccharide-responsive and beige-like anchor protein. It is characterized by recurrent infections and the development of autoimmune disorders.","Immunodeficiency, Common Variable, 8, with Autoimmunity | CVID8 | LRBA Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642592","MHC Class II Deficiency","C176823","A genetic disorder caused by molecular defects in the genes encoding for four regulatory factors controlling transcription of MHC class II genes. The phenotype is similar to SCID, and susceptibility to infection by viral, bacterial, fungal and protozoal agents is characteristic of the disease.","MHC Class II Deficiency | MHC class II deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825233","OTULIN Gene","C176454","This gene plays a role in the removal of linear polyubiquitin chains from protein substrates.","OTULIN Gene | OTU Deubiquitinase With Linear Linkage Specificity Gene | OTULIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642634","PIK3R1 Deficiency","C176631","A deficiency caused by mutation(s) in the PIK3R1 gene, encoding phosphatidylinositol 3-kinase regulatory subunit alpha. It is associated with autosomal recessive agammaglobulinemia 7, immunodeficiency 36 and SHORT (short stature, hyperextensibility of joints or hernia, ocular depression, Rieger anomaly, teething delay) syndrome.","PIK3R1 Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545820","Activating PIK3CD Gene Mutation","C148028","A mutation in PIK3CD, the gene encoding the p110delta catalytic subunit of PI3K, that results in induction of PI3K signaling. Mutations of this type are associated with immunodeficiency 14 (PASLI: activated PI3k-delta syndrome, p110-delta-activating mutation causing senescent T-cells, lymphadenopathy, and immunodeficiency).","Activating PIK3CD Gene Mutation | Activating APDS Gene Mutation | Activating IMD14 Gene Mutation | Activating P110DELTA Gene Mutation | Activating PI3K mutation/PASLI | Activating PI3K-Delta Gene Mutation | Activating PIK3CD Mutation | Activating Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta Gene Mutation | Activating p110D Gene Mutation | PIK3CD (GOF) | PIK3CD Gain of Function | PIK3CD Gain of Function Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642625","Purine Nucleoside Phosphorylase Deficiency","C176817","A rare autosomal recessive immunodeficiency caused by mutation(s) in the PNP gene, encoding purine nucleoside phosphorylase. It is characterized by recurrent infections resulting from severe T-cell dysfunction.","Purine Nucleoside Phosphorylase Deficiency | PNP Deficiency | PNPD | Purine-Nucleoside Phosphorylase Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642666","Severe Combined Immunodeficiency due to CD45 Deficiency","C176605","An autosomal recessive condition caused by mutation(s) in the PTPRC (CD45) gene, encoding receptor-type tyrosine-protein phosphatase C. It is characterized by severe combined immunodeficiency that is T-cell negative, B-cell positive, and NK cell positive.","Severe Combined Immunodeficiency due to CD45 Deficiency | CD45 Deficiency | SCID-PTPRC | Severe Combined Immunodeficiency, T cell-Negative, B-cell/Natural Killer Cell Positive, PTPRC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642663","Severe Combined Immunodeficiency due to RAG1 Deficiency","C176606","An inherited condition caused by mutation(s) in the RAG1 gene, encoding V(D)J recombination-activating protein 1. It is characterized by severe combined immunodeficiency that is both T-cell and B-cell negative.","Severe Combined Immunodeficiency due to RAG1 Deficiency | RAG1 Deficiency | SCID-RAG1 | Severe Combined Immunodeficiency, T cell-Negative, B cell-Negative, RAG1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968145","EPIDERMODYSPLASIA VERRUCIFORMIS, SUSCEPTIBILITY TO, 4","C176608","An autosomal recessive condition caused by mutation(s) in the RHOH gene, encoding Rho-related GTP-binding protein RhoH. It presents in childhood and is characterized by defects in T-cell development and signaling leading to increased susceptibility to certain human papilloma viruses (HPV) that cause warty skin lesions that are unresponsive to treatment.","Epidermodysplasia Verruciformis, Susceptibility to, 4 | EV4 | RhoH Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2751288","Neutropenia, Severe Congenital, Autosomal Dominant 2","C176610","Severe congenital neutropenia inherited in an autosomal dominant pattern and caused by mutation(s) in the GFI1 gene, encoding zinc finger protein Gfi-1.","Severe Congenital Neutropenia Type 2, Autosomal Dominant | Neutropenia, Severe Congenital, 2, Autosomal Dominant | SCN 2-Autosomal Dominant | SCN2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2675526","Neutropenia, Severe Congenital, Autosomal Recessive 4","C176611","Severe congenital neutropenia inherited in an autosomal recessive pattern and caused by mutation(s) in the G6PC3 gene, encoding glucose-6-phosphatase 3. It is characterized by cardiac abnormalities, hepatosplenomegaly, intermittent thrombocytopenia and a prominent superficial venous pattern.","Severe Congenital Neutropenia Type 4, Autosomal Recessive | Dursun Syndrome | Neutropenia, Severe Congenital, 4, Autosomal Recessive | SCN 4-Autosomal Recessive | SCN4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3809031","NEUTROPENIA, SEVERE CONGENITAL, 5, AUTOSOMAL RECESSIVE","C176612","Severe congenital neutropenia inherited in an autosomal recessive pattern and caused by mutation(s) in the VPS45 gene, encoding vacuolar protein sorting-associated protein 45. It is characterized by neutrophil dysfunction, a lack of response to G-CSF, life-threatening infections, bone marrow fibrosis, and renal extramedullary hematopoiesis.","Severe Congenital Neutropenia Type 5, Autosomal Recessive | Neutropenia, Severe Congenital, 5, Autosomal Recessive | SCN 5-Autosomal Recessive | SCN5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4014954","NEUTROPENIA, SEVERE CONGENITAL, 6, AUTOSOMAL RECESSIVE","C176602","Severe congenital neutropenia inherited in an autosomal recessive pattern and caused by mutation(s) in the JAGN1 gene, encoding protein jagunal homolog 1.","Severe Congenital Neutropenia Type 6, Autosomal Recessive | Neutropenia, Severe Congenital, 6, Autosomal Recessive | SCN 6-Autosomal Recessive | SCN6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL602273","NEUTROPENIA, SEVERE CONGENITAL, 7, AUTOSOMAL RECESSIVE","C176614","Severe congenital neutropenia inherited in an autosomal recessive pattern and caused by mutation(s) in the CSF3R gene, encoding granulocyte colony-stimulating factor receptor. It is characterized by the onset of recurrent infections in infancy or early childhood and peripheral neutropenia, despite normal granulocyte maturation, that is unresponsive to treatment with G-CSF.","Severe Congenital Neutropenia Type 7, Autosomal Recessive | Neutropenia, Severe Congenital, 7, Autosomal Recessive | SCN 7-Autosomal Recessive | SCN7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1859966","Neutropenia, Severe Congenital, Autosomal Dominant 1","C176827","Severe congenital neutropenia inherited in an autosomal dominant pattern and caused by mutation(s) in the ELANE gene, encoding neutrophil elastase","Severe Congenital Neutropenia Type 1, Autosomal Dominant | Neutropenia, Severe Congenital, 1, Autosomal Dominant | SCN1 | Severe Congenital neutropenia (SCN) 1 -  Includes cyclic neutropenia | Severe Congenital neutropenia (SCN) 1 - Includes cyclic neutropenia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1845987","Neutropenia, Severe Congenital, X-Linked","C176818","An X-linked recessive condition caused by mutation(s) in the WAS gene, encoding Wiskott-Aldrich syndrome protein. It is characterized by severe neutropenia and early onset severe bacterial infections.","Neutropenia, Severe Congenital, X-Linked | SCNX | Severe neutropenia - congenital X-Linked",,,,,,,,,,,,,,,"36713881","X-linked severe congenital neutropenia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1642709","Inactivating STAT1 Gene Mutation","C176673","A change in the nucleotide sequence of the STAT1 gene that either inhibits expression or results in the translation of an inactive signal transducer and activator of transcription 1-alpha/beta protein.","Inactivating STAT1 Gene Mutation | Inactivating CANDF7 Gene Mutation | Inactivating ISGF-3 Gene Mutation | Inactivating STAT1 Mutation | Inactivating STAT91 Gene Mutation | Inactivating Signal Transducer and Activator of Transcription 1 Gene Mutation | STAT1 LOF | STAT1 Loss of Function | STAT1 Loss of Function Gene Mutation | STAT1 Loss of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642706","Inactivating STAT5B Gene Mutation","C176674","A change in the nucleotide sequence of the STAT5B gene  that either inhibits expression or results in the translation of an inactive signal transducer and activator of transcription 5B protein.","Inactivating STAT5B Gene Mutation | Inactivating STAT5B Mutation | Inactivating Signal Transducer and Activator of Transcription 5B Gene Mutation | STAT5B Loss of Function | STAT5B Loss of Function Gene Mutation | STAT5B Loss of Function Mutation | STAT5B-LOF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0472817","Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome","C176819","An autosomal dominant immunodeficiency syndrome caused by mutation(s) in the CXCR4 gene, encoding C-X-C chemokine receptor type 4. It is characterized by neutropenia, hypogammaglobulinemia, extensive human papillomavirus (HPV) infection, and myelokathexis.","Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome | WHIM | WHIM Syndrome | WHIMS",,,,,,,,,,,,,,,"4123092","Warts, hypogammaglobulinemia, infections, and myelokathexis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4016786","WISKOTT-ALDRICH SYNDROME 2","C176820","An autosomal recessive condition caused by mutation(s) in the WIPF1 gene, encoding WAS/WASL-interacting protein family member 1. It is characterized by recurrent infections, eczema, thrombocytopenia, and T-cell and NK-cell dysfunction.","Wiskott-Aldrich Syndrome 2 | WAS2 | WIP Deficiency | Wiskott-Aldrich Syndrome Interacting Protein Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1839163","Thrombocytopenia 1","C176617","An X-linked recessive bleeding disorder caused by mutation(s) in the WAS gene, encoding Wiskott-Aldrich syndrome protein, resulting in thrombocytopenia.","Thrombocytopenia 1 | THC1 | X-Linked Thrombocytopenia | XL-Thrombocytopenia | XLT",,,,,,,,,,,,,,,"608088","X-linked thrombocytopenia with normal platelets",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2931299","Immunodeficiency 48","C176821","An autosomal recessive immunodeficiency caused by mutation(s) in the ZAP70 gene, encoding tyrosine-protein kinase ZAP-70. It is characterized by absent CD8+ cells.","Immunodeficiency 48 | Immunodeficiency 48; Selective T-Cell Defect; STCD | STCD | Selective T-Cell Defect | ZAP 70 deficiency",,,,,,,,,,,,,,,"37399014","Deficiency of Zeta-chain associated protein kinase 70",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL973088","Severe Combined Immunodeficiency due to NHEJ1 Deficiency","C162695","An autosomal recessive condition caused by mutation(s) in the NHEJ1 gene, encoding non-homologous end-joining factor 1. It is characterized by severe combined immunodeficiency that is T-cell negative, B-cell negative, NK-cell positive. Microcephaly, growth retardation, and sensitivity to ionizing radiation are also characteristic of this disease.","Severe Combined Immunodeficiency due to NHEJ1 Deficiency | Cernunnos / XLF deficiency | NHEJ1-SCID",,,,,,,,,,,,,,,"36717427","Severe combined immunodeficiency, microcephaly, growth retardation, sensitivity to ionizing radiation syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1642615","Gastrointestinal Defects and Immunodeficiency Syndrome","C176792","An autosomal recessive condition caused by mutation(s) in the TTC7A gene encoding tetratricopeptide repeat protein 7A. It is characterized by multiple intestinal atresia, multi-organ impairment and associated with T- and B-cell dysfunction.","Gastrointestinal Defects and Immunodeficiency Syndrome | CID with multiple intestinal atresia | CID-MIA | GIDID | Multiple Intestinal Atresia With Combined Immune Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4014833","IMMUNODEFICIENCY 26 WITH OR WITHOUT NEUROLOGIC ABNORMALITIES","C176795","An autosomal recessive severe combined immunodeficiency caused by mutation(s) in the PRKDC gene, encoding DNA-dependent protein kinase catalytic subunit.","Immunodeficiency 26 with or without Neurologic Abnormalities | DNA PKcs deficiency | DNA-PKcs Deficiency | IMD26",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421504","FOXN1 Gene","C176420","This gene plays a role in development of the thymic epithelium, differentiation of T lineage progenitors and keratinization of the skin.","FOXN1 Gene | FOXN1 | Forkhead Box N1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417508","MVK Gene","C176451","This gene is involved in isoprenoid and sterol synthesis.","MVK Gene | MVK | Mevalonate Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935875","PPM1D Gene Mutation","C156760","A change in the nucleotide sequence of the PPM1D gene.","PPM1D Gene Mutation | IDDGIP Gene Mutation | PP2C-DELTA Gene Mutation | PPMID | Protein Phosphatase 1D Gene Mutation | Protein Phosphatase 1D Magnesium-Dependent, Delta Isoform Gene Mutation | Protein Phosphatase 2C, Delta Isoform Gene Mutation | Protein Phosphatase, Mg2+/Mn2+ Dependent 1D Gene Mutation | WIP1 Gene Mutation | Wild-Type p53-Induced Phosphatase 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824677","CD247 Gene","C38902","This gene plays a role in immunity/defense.","CD247 Gene | CD247 | CD247 Molecule Gene | CD3Z Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516667","Monoclonal Cellular Population Present","C41179","A finding indicating that a monoclonal population of cells were detected in a sample.","Monoclonal Cellular Population Present | Clonal | Clonal Cellular Population Present | Monotypic | Monotypic Cell Population Present | Monotypic Cells Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0502419","Sternebra","C176320","Any of the segments of the body of the sternum.","Sternebra | STERNEBRA | Sternebrae",,,,,,,,,,,,,,,"4282535","Structure of sternebra",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1642319","Caudal Vertebra","C176319","Any of the vertebrae below or posterior to the sacral vertebrae and that form the tail.","Caudal Vertebra | CAUDAL VERTEBRA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642321","Ileum Lymph Node","C176318","Any lymph node within the ileum.","Ileum Lymph Node | ILEUM LYMPH NODE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642320","Colon Lymph Node","C176317","Any lymph node within the colon.","Colon Lymph Node | COLON LYMPH NODE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0734003","Ileum Wall","C176316","The portion of the gastrointestinal tract wall that surrounds the cavity of the ileum and contains collections of lymphatic tissue called Peyer patches, as well as receptors for bile salts and vitamin B12.","Ileum Wall | ILEUM WALL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0734007","Colon Wall","C176315","The portion of the gastrointestinal tract wall that surrounds the cavity of the colon and contains teniae coli, haustra, and epiploic appendages.","Colon Wall | COLON WALL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2339732","Upper Gastrointestinal Tract Wall","C176314","The portion of the gastrointestinal tract wall that surrounds the cavities of the esophagus and stomach. The proximal duodenum is also sometimes considered part of the upper gastrointestinal tract.","Upper Gastrointestinal Tract Wall | GASTROINTESTINAL TRACT, UPPER, WALL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2331886","Lower Gastrointestinal Tract Wall","C176241","The portion of the gastrointestinal tract wall that surrounds the cavities of the duodenum, jejunum, ileum, colon, rectum, and anus.","Lower Gastrointestinal Tract Wall | GASTROINTESTINAL TRACT, LOWER, WALL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642311","Lower Gastrointestinal Tract Lymph Node","C176234","Any lymph node within the lower gastrointestinal tract.","Lower Gastrointestinal Tract Lymph Node | LOWER GASTROINTESTINAL TRACT LYMPH NODE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2332919","Gastrointestinal Tract Wall","C176233","The multiple layers of specialized tissue that surround the cavity of the gastrointestinal tract, including the mucosa, submucosa, muscular layers, and serosa.","Gastrointestinal Tract Wall | GASTROINTESTINAL TRACT, WALL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0154270","Fat Pad","C176326","Encapsulated adipose tissue within the body.","Fat Pad | FAT PAD",,,,,,,,,,,,,,,"438731","Localized adiposity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1642325","Eye Bulge","C176325","The protuberance of the eye seen when the eyelid is closed.","Eye Bulge | EYE BULGE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0231058","Genital Tubercle","C176324","A body of tissue that forms in the ventral, caudal region during embryonic development.","Genital Tubercle | GENITAL TUBERCLE",,,,,,,,,,,,,,,"4321567","Structure of genital tubercle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008919","Claw","C176323","The curved, pointed appendage on the distal end of a digit, composed of keratin.","Claw | CLAW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225924","Atrioventricular Valve","C176322","One of two valves in the heart situated between the atria and ventricles, including the mitral valve and the tricuspid valve.","Atrioventricular Valve | ATRIOVENTRICULAR VALVE",,,,,,,,,,,,,,,"4009505","Atrioventricular valve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016555","Forelimb","C176321","The anterior, front or upper limb of an animal.","Fore Limb | FORELIMB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642313","Anti-Neutrophil Antibody Measurement","C176313","The determination of the total anti-neutrophil antibody present in a sample.","Anti-Neutrophil Antibody Measurement | ANA Measurement | ANAB | Anti-Neutrophil Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642315","Phosphorylated Tau Protein to Amyloid Beta1-42 Ratio Measurement","C176312","The determination of the ratio of phosphorylated Tau protein compared to amyloid beta 1-42 present in a sample. The measurement may be expressed as a ratio or percentage.","Phosphorylated Tau Protein to Amyloid Beta1-42 Ratio Measurement | PTAUAB42 | Phosphorylated Tau Prot/Amyloid Beta1-42 | Phosphorylated Tau Protein/Amyloid Beta 1-42",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642314","Coefficient of Fat Absorption Measurement","C176311","A measurement of the coefficient of fat absorption in a biological specimen.","Coefficient of Fat Absorption Measurement | CFA | CFA Measurement | Coefficient of Fat Absorption",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642734","Coefficient of Nitrogen Absorption Measurement","C176310","A measurement of the coefficient of nitrogen absorption in a biological specimen.","Coefficient of Nitrogen Absorption Measurement | CAN | CNA Measurement | Coefficient of Nitrogen Absorption",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642316","Taurolithocholate Measurement","C176309","The determination of the amount of taurolithocholate in a sample.","Taurolithocholate Measurement | TLCHT | Taurolithocholate | Taurolithocholic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642318","Glycolithocholate Measurement","C176308","The determination of the amount of glycolithocholate in a sample.","Glycolithocholate Measurement | GLCHT | Glycolithocholate | Glycolithocholic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642317","Lithocholate Measurement","C176307","The determination of the amount of lithocholate in a sample.","Lithocholate Measurement | LCHT | Lithocholate | Lithocholic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642353","Taurochenodeoxycholate Measurement","C176306","The determination of the amount of taurochenodeoxycholate in a sample.","Taurochenodeoxycholate Measurement | TCDCA | Taurochenodeoxycholate | Taurochenodeoxycholic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642352","Glycochenodeoxycholate Measurement","C176305","The determination of the amount of glycochenodeoxycholate in a sample.","Glycochenodeoxycholate Measurement | GCDCA | Glycochenodeoxycholate | Glycochenodeoxycholic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642355","Epimerized Ursodeoxycholate Measurement","C176304","The determination of the amount of epimerized ursodeoxycholate in a sample.","Epimerized Ursodeoxycholate Measurement | EUDCA | Epimerized Ursodeoxycholate | Epimerized Ursodeoxycholic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642354","Tauroursodeoxycholate Measurement","C176303","The determination of the amount of tauroursodeoxycholate in a sample.","Tauroursodeoxycholate Measurement | TUDCA | Tauroursodeoxycholate | Tauroursodeoxycholic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642357","Glycoursodeoxycholate Measurement","C176302","The determination of the amount of glycoursodeoxycholate in a sample.","Glycoursodeoxycholate Measurement | GUDCA | Glycoursodeoxycholate | Glycoursodeoxycholic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642356","Taurocholate Measurement","C176301","The determination of the amount of taurocholate in a sample.","Taurocholate Measurement | TCHT | Taurocholate | Taurocholic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642359","Hyocholate Measurement","C176300","The determination of the amount of hyocholate in a sample.","Hyocholate Measurement | HCHT | Hyocholate | Hyocholic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642358","Glycocholate Measurement","C176299","The determination of the amount of glycocholate in a sample.","Glycocholate Measurement | Cholylglycine | GCHT | Glycocholate | Glycocholic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642346","Ursodeoxycholate Measurement","C176298","The determination of the amount of ursodeoxycholate in a sample.","Ursodeoxycholate Measurement | UDCA | Ursodeoxycholate | Ursodeoxycholic Acid | Ursodiol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642345","Aspartate Aminotransferase to Alanine Aminotransferase Ratio Measurement","C176297","The determination of the ratio of aspartate aminotransferase (AST) compared to alanine aminotransferase (ALT) present in a sample. The measurement may be expressed as a ratio or percentage.","Aspartate Aminotransferase to Alanine Aminotransferase Ratio Measurement | AST/ALT | ASTALT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642347","Whole Blood Equivalent Glucose Measurement","C176296","The determination of the amount of whole blood equivalent glucose in a sample.","Whole Blood Equivalent Glucose Measurement | GLUCWBE | Whole Blood Equivalent Glucose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642306","Lithocholate Compounds Measurement","C176240","The determination of the amount of lithocholic acid, glycolithocholic acid, and taurolithocholic acid in a sample.","Lithocholate Compounds Measurement | LCHLCM | Lithocholate Compounds | Lithocholic Acid Compounds",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642308","Chenodeoxycholate Compounds Measurement","C176239","The determination of the amount of chenodeoxycholic acid, glycochenodeoxycholic acid, and taurochenodeoxycholic acid in a sample.","Chenodeoxycholate Compounds Measurement | CDCACM | Chenodeoxycholate Compounds | Chenodeoxycholic Acid Compounds",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642307","Ursodeoxycholate Compounds Measurement","C176238","The determination of the amount of ursodeoxycholic acid, glycoursodeoxycholic acid, tauroursodeoxycholic acid, and epimerized ursodeoxycholic acid in a sample.","Ursodeoxycholate Compounds Measurement | UDCACM | Ursodeoxycholate Compounds | Ursodeoxycholic Acid Compounds",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642300","Cholate Compounds Measurement","C176232","The determination of the amount of cholic acid, glycocholic acid, hyocholic acid, and taurocholic acid in a sample.","Cholate Compounds Measurement | CHOLCM | Cholate Compounds | Cholic Acid Compounds",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978410","Complete Response Unconfirmed","C165198","An indication that a finding of complete response to treatment has not been confirmed.","Complete Response Unconfirmed | CRU-Complete Response Unconfirmed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333865","Cytologic Atypia","C8326","The presence of irregularly shaped or sized cells as compared to the cells that are normally present.","Cytologic Atypia | Atypical | Atypical Cell Present",,,,,,,,,,,,,,,"4174659","Cytologic atypia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1642378","pH Meter Measurement Method","C176471","A measurement methodology in which a pH meter device is used for measuring the alkalinity or acidity of a liquid or semi-solid substance.","pH Meter Measurement Method | PH METER MEASUREMENT METHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642381","Vernier Caliper Measurement Method","C176470","A measurement methodology in which a caliper device is used for measuring the length of dimension, consisting of two hinged legs (that may be inturned or outturned) usually, but not always, attached to a ruled scale, dial, or digital display.","Vernier Caliper Measurement Method | CALIPER MEASUREMENT METHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642380","Ruler Measurement Method","C176469","A measurement methodology in which a ruler device is used for measuring distance, consisting of an elongated piece of material marked with units of length.","Ruler Measurement Method | RULER MEASUREMENT METHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282646","Indirect Immunofluorescence","C176332","A fluorescent antibody technique in which a secondary fluorophore-conjugated antibody is used to detect a primary, unconjugated antibody directed against a target antigen.","Indirect Immunofluorescence | INDIRECT IMMUNOFLUORESCENCE | Secondary Immunofluorescence",,,,,,,,,,,,,,,"4132408","Indirect tissue immunofluorescence procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4274338","Magnetic Resonance Enterography","C176331","A magnetic resonance imaging technique that allows for the visualization of the entire small bowel by imaging the abdomen and pelvis during the enteric phase of digestion following oral administration of large volumes of enteric contrast material for bowel distention and intravenous contrast administration.","Magnetic Resonance Enterography | MAGNETIC RESONANCE ENTEROGRAPHY | MRE",,,,,,,,,,,,,,,"4330516","MRI of small intestine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1642323","Autorefraction","C176330","An eye examination method in which a computer-controlled electronic optometer is used to automatically measure refractive error.","Autorefraction | AR | AUTOREFRACTION | Auto-refraction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642322","Sodium Lauryl Sulphate Method","C176329","A hemoglobin estimation technique that utilizes sodium lauryl sulphate, a surfactant that lyses erythrocytes, converts the released hemoglobin into methemoglobin, and forms a sodium lauryl sulphate-methemoglobin complex with a characteristic light absorbance spectrum.","Sodium Lauryl Sulphate Method | Cyanide-Free SLS Method | Cyanide-free SLS | Cyanide-free Sodium Lauryl Sulphate Method | SLS Hemoglobin Detection Method | SLS-Hb | SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642324","Sheath Flow Direct Current Detection","C176328","A cytometry technique that utilizes hydrodynamic focusing to create a sheath flow and that measures direct current impedance signals.","Sheath Flow Direct Current Detection | DC SHEATH FLOW | Sheath Flow DC Detection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1718423","Tumor Regression","C160836","A decrease in the size of a tumor or in the extent of cancer in the body.","Tumor Regression | Decreasing | Present | Tumor Decreasing | regression",,,,,,,,,,,,,,,"4263380","Tumor regression finding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL524929","FDG-Positron Emission Tomography/Computed Tomography of the Whole Body","C137907","Positron emission tomography combined with computed tomography of the whole body, with the use of the contrast agent fludeoxyglucose F 18 (18F-FDG) to enhance the image.","FDG-Positron Emission Tomography/Computed Tomography of the Whole Body | EXPLORER Scanner | PET/CT, Whole Body, FDG | Positron Emission Tomography/Computed Tomography, Whole Body, FDG | Total-Body Positron Emission Tomography/Computed Tomography | WB PET/CT Scan with FDG | Whole Body FDG-PET/CT | Whole Body FDG-Positron Emission Tomography/Computed Tomography | Whole Body [18]F- Fludeoxyglucose Positron Emission Tomography/Computed Tomography | Whole-body 18F FDG PET/CT | Whole-body FDG-PET/CT | [18]F-FDG PET/CT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642943","None of These Describe Me","C177109","A response indicating that an individual feels that no option listed is a good description for them.","None of These Describe Me | None of These Describe Me

 | None of these describe me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1451672","MAL protein, human","C177105","Myelin and lymphocyte protein (153 aa, ~17 kDa) is encoded by the human MAL gene. This protein plays a role in glycosphingolipid binding in myelin and plasma membrane lipid rafts.","Myelin and Lymphocyte Protein | MAL | T-Cell Differentiation Protein | T-Lymphocyte Maturation-Associated Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643090","More than 1 Mitosis per 50 HPF and Less than 3 Mitoses per 10 HPF","C177113","A microscopic finding indicating the presence of more than one mitotic figure per fifty high power fields and less than three mitotic figures per ten high power fields in a sample.","More than 1 Mitosis per 50 HPF and Less than 3 Mitoses per 10 HPF | Greater than 1 Mitosis per 50 HPF and Less than 3 Mitoses per 10 HPF | Mitotic Index >1/50 HPF and <3/10 HPF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643089","Between 3 and 9 Mitoses per 10 HPF","C177114","A microscopic finding indicating the presence of at least three and at most nine mitotic figures per ten high power fields in a sample.","Between 3 and 9 Mitoses per 10 HPF | Mitotic Index 3-9/10 HPF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643119","Greater than or Equal to 10 Mitoses per 10 HPF","C177115","A microscopic finding indicating the presence of at least ten mitotic figures per ten high power fields in a sample.","Greater than or Equal to 10 Mitoses per 10 HPF | 10 or More Mitoses per 10 HPF | Mitotic Index > or = 10/10 HPF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643118","Hypercellularity","C177116","An increase in the number of cells in an organ or tissue.","Hypercellularity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643120","Neurofibroma Architecture","C177117","The characteristic shape or pattern of neoplastic cells seen in a neurofibroma.","Neurofibroma Architecture | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1635954","COVID-19 Vaccine","C173023","Any vaccine that may prevent coronavirus disease-2019 (COVID-19) that is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).","COVID-19 Vaccine | SARS-CoV-2 Vaccine | SARS-CoV-2 vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524654","JNJ 64007957","C136823","A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, with potential antineoplastic activity. Upon administration, teclistamab binds to both CD3 on T-cells and BCMA expressed on malignant plasma cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against BCMA-expressing plasma cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.","Teclistamab | JNJ 64007957 | JNJ-64007957 | JNJ64007957 | TECLISTAMAB | Teclistamab-cqyv | Tecvayli",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545429","Talquetamab","C171840","A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, talquetamab binds to both CD3 on T-cells and GPRC5D expressed on certain tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against GPRC5D-expressing tumor cells. GPRC5D is overexpressed on certain tumors, such as multiple myeloma, while minimally expressed on normal, healthy cells, and plays a key role in tumor cell proliferation.","Talquetamab | Anti-CD3/Anti-GPRC5D Bispecific Monoclonal Antibody JNJ-64407564 | GPRC5D x CD3 Bispecific Antibody JNJ-64407564 | GPRC5D x CD3 DuoBody Antibody JNJ-64407564 | GPRC5D/CD3 DuoBody Antibody JNJ-64407564 | Humanized GPRC5D x CD3 DuoBody Antibody JNJ-64407564 | JNJ 64407564 | JNJ-64407564 | JNJ64407564 | TALQUETAMAB | Talquetamab-tgvs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512126","(S)-3-(4-((4-(Morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione","C129048","A modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with immunomodulating and pro-apoptotic activities. Upon administration, iberdomide specifically binds to the cereblon (CRBN) part of the ligase complex, thereby affecting the ubiquitin E3 ligase activity, and targeting certain substrate proteins for ubiquitination. This induces the proteasome-mediated degradation of certain transcription factors, including Ikaros (IKZF1) and Aiolos (IKZF3) which are transcriptional repressors in T-cells. This leads to a reduction of their protein levels, and the modulation of the immune system, including activation of T-lymphocytes. In addition, this leads to a downregulation of other proteins, including interferon regulatory factor 4 (IRF4), which plays a key role in the proliferation of certain cancer cell types. CRBN, the substrate recognition component of the E3 ubiquitin ligase complex, plays a key role in the ubiquitination of certain proteins.","Iberdomide | (S)-3-(4-((4-(Morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione | CC 220 | CC-220 | IBERDOMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471808","Belantamab Mafodotin","C114299","An antibody-drug conjugate (ADC) consisting of belantamab, an afucosylated, humanized monoclonal antibody, directed against the B-cell maturation antigen (BCMA), conjugated to mafodotin, an auristatin analogue and microtubule inhibitor monomethyl auristatin phenylalanine (MMAF), with potential antineoplastic activity. Upon administration of belantamab mafodotin, the anti-BCMA antibody moiety selectively binds to BCMA on tumor cell surfaces. Upon internalization, the MMAF moiety binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces tumor cell apoptosis. In addition, belantamab mafodotin induces antibody-dependent cellular cytotoxicity (ADCC). Altogether, this results in the inhibition of cellular proliferation in tumor cells that overexpress BCMA. BCMA, a receptor for a proliferation-inducing ligand and B-cell activating factor, is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in plasma cell survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells. Afucosylation of the antibody moiety increases ADCC.","Belantamab Mafodotin | BELANTAMAB MAFODOTIN | Belantamab Mafodotin-blmf | Belantamab mafodotin | Blenrep | GSK 2857916 | GSK-2857916 | GSK2857916 | J6M0-mcMMAF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643122","Pfizer","C177123","An American multinational pharmaceutical corporation headquartered in New York, NY. The company develops and produces medicines and vaccines for a wide range of medical disciplines.","Pfizer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643115","Moderna","C177124","An American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. The company focuses on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA.","Moderna | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643114","AstraZeneca","C177125","A global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company focuses on the discovery, development and commercialization of prescription medicines.","AstraZeneca | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936768","If Other, Specify","C157101","A directive to specify when the listed responses are not sufficient.","If Other, Specify | If other, please comment | If other, please indicate | If other, please specify | If other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018576","Disabled Persons","C16661","Groups with similar restrictions or lack or ability to perform physical or mental activities in a manner or within the range considered normal for a human being.","Disabled Population | Disabled",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504913","Primary Peritoneal High Grade Serous Adenocarcinoma","C126353","A serous adenocarcinoma that arises from the lining of the peritoneum. It is characterized by high grade histopathologic features.","Primary Peritoneal High Grade Serous Adenocarcinoma | Primary Peritoneal High-Grade Serous Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643495","Forceps Biopsy","C177206","The removal of a tissue sample using a specially-designed endoscope consisting of a slender flexible forceps with movable cup-shaped jaws. The jaws are closed around the tissue to be collected and while closed the forceps are withdrawn to capture the biopsy tissue.","Forceps Biopsy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643028","Believe","C177209","To accept (something) as true; feel sure of the truth of.","Believe | Belief | Beliefs | Believes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643030","A Goal of Palliative Care is to Address Psychological Issues due to Serious Illness","C177211","A question about whether an individual believes that the goal of palliative health care is to address psychological issues due to serious illnesses.","A Goal of Palliative Care is to Address Psychological Issues due to Serious Illness | A goal of palliative care is to address any psychological issues brought up by serious illness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642998","Stress from Serious Illness Can Be Addressed by Palliative Care","C177212","A question about whether an individual believes that stress from a serious illness being addressed through palliative care.","Stress from Serious Illness Can Be Addressed by Palliative Care | Stress from serious illness can be addressed by palliative care",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642997","Palliative Care Can Help People Manage Side Effects of Their Medical Treatments","C177213","A question about whether an individual believes that palliative care can help an individual manage the side effects of their medical treatment.","Palliative Care Can Help People Manage Side Effects of Their Medical Treatments | Palliative care can help people manage the side effects of their medical treatments",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643000","When People Receive Palliative Care, They Must Give Up Their Other Doctors","C177214","A question about whether an individual believes that when people receive palliative care they must give up their other doctors.","When People Receive Palliative Care, They Must Give Up Their Other Doctors | When people receive palliative care, they must give up their other doctors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642999","Palliative Care is Exclusively for People Who Are in the Last Six Months of Life","C177215","A question about whether an individual believes that palliative care is exclusively for people who are in the last six months of life.","Palliative Care is Exclusively for People Who Are in the Last Six Months of Life | Palliative care is exclusively for people who are in the last 6 months of life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643002","Palliative Care is Specifically for People with Cancer","C177216","A question about whether an individual believes that palliative care is specifically for people with cancer.","Palliative Care is Specifically for People with Cancer | Palliative care is specifically for people with cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643001","People Must Be in the Hospital to Receive Palliative Care","C177217","A question about whether an individual believes that people must be in the hospital in order to receive palliative care.","People Must Be in the Hospital to Receive Palliative Care | People must be in the hospital to receive palliative care",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643004","Palliative Care is Designed Specifically for Older Adults","C177218","A question about whether an individual believes that palliative care is specifically designed for older adults.","Palliative Care is Designed Specifically for Older Adults | Palliative care is designed specifically for older adults",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643003","Palliative Care is a Team-Based Approach to Care","C177219","A question about whether an individual believes that palliative care is a team-based approach to care.","Palliative Care is a Team-Based Approach to Care | Palliative care is a team-based approach to care",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642993","A Goal of Palliative Care is to Help People Better Understand Their Treatment Options","C177220","A question about whether an individual believes that palliative care is to help people better understand their treatment options.","A Goal of Palliative Care is to Help People Better Understand Their Treatment Options | A goal of palliative care is to help people better understand their treatment options",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642992","Palliative Care Encourages People to Stop Treatment Aimed at Curing Their Illness","C177221","A question about whether an individual believes that palliative care encourages people to stop treatment aimed at curing their illness.","Palliative Care Encourages People to Stop Treatment Aimed at Curing Their Illness | Palliative care encourages people to stop treatments aimed at curing their illness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642995","A Goal of Palliative Care is to Improve a Person's Ability to Participate in Daily Activities","C177222","A question about whether an individual believes that a goal of palliative care is to improve an person's ability to participate in daily activities.","A Goal of Palliative Care is to Improve a Person's Ability to Participate in Daily Activities | A goal of palliative care is to improve a person's ability to participate in daily activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642994","Palliative Care Helps the Whole Family Cope with a Serious Illness","C177223","A question about whether an individual believes that palliative care helps the whole family cope with a serious illness.","Palliative Care Helps the Whole Family Cope with a Serious Illness | Palliative care helps the whole family cope with a serious illness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830467","Disseminated Bacillus Calmette-Guerin Infection","C113669","A rare systemic and life-threatening infection associated with vaccination with the live attenuated strain of Mycobacterium bovis, bacillus Calmette-Guerin.","Disseminated Bacillus Calmette-Guerin Infection | BCGosis | Disseminated BCG Infection | Disseminated BCGitis | Disseminated Bacillus Calmette-Guérin Infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643016","What I Feel When I Hear Palliative Care","C177230","A question about how strongly an individual agrees that they would feel a specified emotion when they hear the term 'palliative care'.","What I Feel When I Hear Palliative Care | When I hear the term palliative care, I feel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643015","What I Would Feel if Referred for Palliative Care","C177231","A question about how strongly an individual agrees that they would have certain specified thoughts or feelings if a palliative care referral was suggested for them today.","What I Would Feel if Referred for Palliative Care | If a palliative care referral was suggested for me today, I would",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643017","The More Support I Get the Better I Would Feel","C177233","A question about how strongly an individual agrees that they would think that the more support they get the better they will feel.","The More Support I Get the Better I Would Feel | Think the more support I get, the better I will feel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643018","My Doctor Really Cares about what is Happening to Me","C177232","A question about how strongly an individual agrees that they would think that their doctor really cares about them.","My Doctor Really Cares about what is Happening to Me | Think my doctor really cares about what is happening to me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643020","Nothing More Can be Done for My Disease","C177234","A question about how strongly an individual agrees that they would think that nothing more can be done for their disease.","Nothing More Can be Done for My Disease | Think nothing more can be done for my disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643019","My Doctor has Given Up on Me","C177235","A question about how strongly an individual agrees that they would think that their doctor has given up on them.","My Doctor has Given Up on Me | Think my doctor has given up on me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643006","Am at the End of the Road","C177236","A question about how strongly an individual agrees that they would think that they are at the end of the road.","Am at the End of the Road | Think I am at the end of the road",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643005","My Disease is Out of Control","C177237","A question about how strongly an individual agrees that they would think that their disease is out of control.","My Disease is Out of Control | Think my disease is out of control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643008","Will Lose Contact with Current Doctors and Nurses","C177238","A question about how strongly an individual agrees that they would think that they would lose contact with their current doctors and nurses.","Will Lose Contact with Current Doctors and Nurses | Think I will lose contact with my current doctors and nurses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643007","Think about the Future More Positively","C177239","A question about how strongly an individual agrees that they would think about the future more positively.","Think about the Future More Positively | Think about the future more positively",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643010","Feel More in Control of Situation","C177240","A question about how strongly an individual agrees that they would feel more in control of their situation.","Feel More in Control of Situation | Feel more in control of my situation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643009","Worry that Palliative Care Would Disrupt My Daily Routine","C177241","A question about how strongly an individual agrees that they would be worried that palliative care would disrupt their daily routine.","Worry that Palliative Care Would Disrupt My Daily Routine | Be worried that palliative care would disrupt my daily routine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643012","Worry that Palliative Care Would Talk to Me about Dying","C177242","A question about how strongly an individual agrees that they would worry that palliative care would talk to them about dying.","Worry that Palliative Care Would Talk to Me about Dying | Worry that palliative care would talk to me about dying",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643084","Family or Friends Need Help with My Physical Care","C177262","A question about how strongly an individual agrees that their family or friends need help with the individual's care.","Family or Friends Need Help with My Physical Care | My family or friends need help with my physical care",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643083","Need Help to Manage Physical Symptoms","C177263","A question about how strongly an individual agrees that they need help to manage their physical symptoms.","Need Help to Manage Physical Symptoms | I need help to manage physical symptoms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643086","Need Emotional Support","C177264","A question about how strongly an individual agrees that they need emotional support.","Need Emotional Support | I need emotional support",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643085","Need Help to Manage Medication","C177265","A question about how strongly an individual agrees that they need help to manage their medication.","Need Help to Manage Medication | I need help to manage my medication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643088","Need Spiritual Support","C177266","A question about how strongly an individual agrees that they need spiritual support.","Need Spiritual Support | I need spiritual support",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643087","Want Someone to Talk to My Family or Friends about My Illness","C177267","A question about how strongly an individual agrees that they want someone to talk to their family or friends about their illness.","Want Someone to Talk to My Family or Friends about My Illness | I want someone to talk to my family or friends about my illness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643074","Want Help to Find Meaning of Transplant Experience","C177268","A question about how strongly an individual agrees that they want help to find meaning of their transplant experience.","Want Help to Find Meaning of Transplant Experience | I want help to find meaning of my transplant experience",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643073","Want to Prepare Now for What Might Happen in the Future","C177269","A question about how strongly an individual agrees that they want to prepare now for what might happen in the future.","Want to Prepare Now for What Might Happen in the Future | I want to prepare now for what might happen in the future",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643076","Need Help with Daily Activities","C177270","A question about how strongly an individual agrees that they need help with daily activities such as showering.","Need Help with Daily Activities | I need help with my daily activities such as showering",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643075","Want to Talk to Someone Who Understands What I'm Going Through","C177271","A question about how strongly an individual agrees that they want to talk to someone who understands what they are going through.","Want to Talk to Someone Who Understands What I'm Going Through | I want to talk to someone who understands what I am going through",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643078","Want to Talk to Someone about Dying","C177272","A question about how strongly an individual agrees that they want to talk to someone about dying.","Want to Talk to Someone about Dying | I want to talk to someone about dying",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643077","Family or Friends Need Emotional Support","C177273","A question about how strongly an individual agrees that their family or friends need emotional support.","Family or Friends Need Emotional Support | My family or friends need emotional support",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643080","When I Think About My Current Health Situation","C177274","A question about how strongly an individual agrees with having certain thoughts or worries when they think about their current health situation.","When I Think About My Current Health Situation | When I think about my current health situation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643079","Worry am Burden to Others","C177275","A question about how strongly an individual agrees that they worry that they are a burden to others.","Worry am Burden to Others | I worry I am a burden to others",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643044","Feel too Dependent on Others to Do Things for Me","C177276","A question about how strongly an individual agrees that they feel too dependent on others to do things for them.","Feel too Dependent on Others to Do Things for Me | I feel I depend too much on others to do things for me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643043","Worry that Family or Friends Don't have Enough Times for Themselves Because of What They Do for Me","C177277","A question about how strongly an individual agrees that they worry that family or friends don't have enough time for themselves because of what they do for the individual.","Worry that Family or Friends Don't have Enough Times for Themselves Because of What They Do for Me | I worry that my family and friends don't have enough time for themselves because of what they do for me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642783","Physician Orders for Life Sustaining Treatment","C176984","A medical order form, signed by a medical professional, that outlines a plan for end of life care that reflects both a patient's preferences concerning care at life's end and a physician's judgment based on a medical evaluation.","Physician Orders for Life Sustaining Treatment | Medical order for life-sustaining treatment | POLST | Physician Orders for Life Sustaining Treatment (POLST)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643097","Unanticipated Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985725","Birth Country Code","C93516","A coded value specifying the name of the country in which the biologic entity is born.","Birth Country Code | BRCTRYCD | Country of Birth Code | birthCountryCode",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643262","CRS/HIPEC Completeness of Cytoreduction Score","C177317","An assessment of residual disease after a maximal surgical effort and heated intraperitoneal chemotherapy. It serves as a prognostic indicator for survival after cytoreductive treatment is completed.","CRS/HIPEC Completeness of Cytoreduction Score | Completeness of Cytoreduction Score | Completeness of Cytoreduction Score for Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643265","CRS/HIPEC Completeness of Cytoreduction Score CC-0","C177318","Absence of macroscopic residual disease; no peritoneal seeding visualized within the operative field.","CRS/HIPEC Completeness of Cytoreduction Score CC-0 | CC-0 | Completeness of Cytoreduction Score CC-0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643264","CRS/HIPEC Completeness of Cytoreduction Score CC-1","C177319","The presence of residual tumor nodules with a diameter less than 0.25 cm within the operative field.","CRS/HIPEC Completeness of Cytoreduction Score CC-1 | CC-1 | Completeness of Cytoreduction Score CC-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643267","CRS/HIPEC Completeness of Cytoreduction Score CC-2","C177320","The presence of residual tumor nodules measuring from 0.25 to 2.5 cm within the operative field.","CRS/HIPEC Completeness of Cytoreduction Score CC-2 | CC-2 | Completeness of Cytoreduction Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643266","CRS/HIPEC Completeness of Cytoreduction Score CC-3","C177321","The presence of residual nodules greater than 2.5 cm within the operative field.","CRS/HIPEC Completeness of Cytoreduction Score CC-3 | CC-3 | Completeness of Cytoreduction Score CC-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643309","Novavax","C177432","An American biotechnology company headquartered in Gaithersburg, MD that was founded in 1987 and focuses on the discovery, development, and commercialization of vaccines.","Novavax | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0331843","Johnson and Johnson","C177434","An American multinational company headquartered in New Brunswick, NJ that was founded in 1886 and operates through consumer, pharmaceutical, and medical device segments to engage in research and development, manufacture, and sale of products in the health care field.","Johnson and Johnson | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038826","Superinfection","C177386","A secondary infection that occurs during an existing infection, or immediately following a previous infection, especially when caused by microorganisms that are resistant or have become resistant to the antibiotics used earlier.","Superinfection | ",,,,,,,,,,,,,,,"4105019","Superimposed infection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1413530","Reinfection","C177387","A second infection by the same pathogen that follows a period of recovery.","Reinfection | ",,,,,,,,,,,,,,,"4116365","Reinfection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3241958","Myocardial Disorder","C35544","A disorder that affects the muscle tissue of the heart. Representative examples include myocardial infarction, myocarditis, and cardiomyopathy.","Myocardial Disorder | ",,,,,,,,,,,,,,,"4239975","Myocardial disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1291764","Immune System Finding","C39723","Symptoms, physical examination results, and/or laboratory test results related to the immune system.","Immune System Finding | IMMUNE SYSTEM",,,,,,,,,,,,,,,"4024018","Immune system finding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1406747","Cellular Granularity Present","C172636","A morphologic finding indicating the presence of prominent cellular granularity in a tissue sample.","Cellular Granularity Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643170","Blasts 20,000 or Less of Peripheral Blood White Cells","C177441","A quantitative microscopic finding indicating that 20,000 or fewer nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.","Blasts 20,000 or Less of Peripheral Blood White Cells | Absolute Blasts 20,000 or Less of Peripheral Blood White Cells | Absolute Blasts 20000 or Less of Peripheral Blood White Cells | Absolute Blasts in Peripheral Blood Less Than or Equal to 20,000 | Absolute Blasts in Peripheral Blood Less Than or Equal to 20000 | Blasts 20000 or Less of Peripheral Blood White Cells | Blasts Less than or Equal to 20,000 in Peripheral Blood White Cells | Blasts Less than or Equal to 20000 in Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643173","Blasts Less Than 50 Percent of Bone Marrow Nucleated Cells","C177442","A semi-quantitative microscopic finding indicating that less than 50 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts Less Than 50 Percent of Bone Marrow Nucleated Cells | Blasts Under 50 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643172","BRAF NP_004324.2:p.G469X","C177443","A change in the amino acid residue at position 469 in the serine/threonine-protein kinase B-raf protein where glycine has been replaced by another amino acid.","BRAF NP_004324.2:p.G469X | BRAF Codon 469 Mutation | BRAF G469 Mutation | BRAF G469X | BRAF Gly469Xxx | BRAF NP_004324.2:p.Gly469Xxx | BRAF p.G469X | BRAF p.Gly469Xxx | NP_004324.2:p.G469X | NP_004324.2:p.Gly469Xxx | Serine/Threonine-Protein Kinase B-raf G469X | Serine/Threonine-Protein Kinase B-raf Gly469Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643175","BRAF NP_004324.2:p.L485X","C177447","A change in the amino acid residue at position 485 in the serine/threonine-protein kinase B-raf protein where leucine has been replaced by another amino acid.","BRAF NP_004324.2:p.L485X | BRAF Codon 485 Mutation | BRAF L485 Mutation | BRAF L485X | BRAF Leu485Xxx | BRAF NP_004324.2:p.Leu485Xxx | BRAF p.L485X | BRAF p.Leu485Xxx | NP_004324.2:p.L485X | NP_004324.2:p.Leu485Xxx | Serine/Threonine-Protein Kinase B-raf L485X | Serine/Threonine-Protein Kinase B-raf Leu485Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643174","BRAF NP_004324.2:p.L597X","C177448","A change in the amino acid residue at position 597 in the serine/threonine-protein kinase B-raf protein where leucine has been replaced by another amino acid.","BRAF NP_004324.2:p.L597X | BRAF Codon 597 Mutation | BRAF L597 Mutation | BRAF L597X | BRAF Leu597Xxx | BRAF NP_004324.2:p.Leu597Xxx | BRAF p.L597X | BRAF p.Leu597Xxx | NP_004324.2:p.L597X | NP_004324.2:p.Leu597Xxx | Serine/Threonine-Protein Kinase B-raf L597X | Serine/Threonine-Protein Kinase B-raf Leu597Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643164","THBD Positive","C177449","An indication that THBD expression has been detected in a sample.","THBD Positive | BDCA3 Positive | CD141 Antigen Positive | CD141 Positive | THPH12 Positive | THRM Positive | TM Positive | Thrombomodulin Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643163","CD16 Negative","C177450","An indication that CD16 expression has not been detected in a sample.","CD16 Negative | CD16 Antigen Negative | CD16 Protein Negative | FCG3 Negative | FCGR3 Negative | Fc Gamma Receptor III Negative | Fc-Gamma RIII Negative | Fc-Gamma Receptor III Negative | FcRIII Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643166","Elevated ALCAM","C177454","A finding indicating elevated concentrations of ALCAM in a sample.","Elevated ALCAM | Elevated Activated Leukocyte Cell Adhesion Molecule | Elevated CD166 | Elevated CD166 Antigen | Elevated CD6 Ligand | Elevated CD6L | High ALCAM Expression | High CD166 Expression | High CD6L Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643169","CD1C Positive","C177455","An indication that CD1C expression has been detected in a sample.","CD1C Positive | CD1c Antigen Positive | CD1c Molecule Positive | CD1c Positive | Cortical Thymocyte Antigen CD1C Positive | T-Cell Surface Glycoprotein CD1c Positive | Thymocyte Antigen CD1C Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643185","EGFR NP_005219.2:p.A864V","C177457","A change in the amino acid residue at position 864 in the epidermal growth factor receptor protein where alanine has been replaced by valine.","EGFR NP_005219.2:p.A864V | Activating A864V Mutation | EGFR A864V | EGFR A864V Mutation | EGFR Ala864Val | EGFR NP_005219.2:p.Ala864Val | EGFR p.A864V | EGFR p.Ala864Val | Epidermal Growth Factor Receptor A864V | Epidermal Growth Factor Receptor Ala864Val | NP_005219.2:p.A864V | NP_005219.2:p.Ala864Val | Proto-Oncogene c-ErbB-1 A864V | Proto-Oncogene c-ErbB-1 Ala864Val | Receptor Tyrosine-Protein Kinase erbB-1 A864V | Receptor Tyrosine-Protein Kinase erbB-1 Ala864Val",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643186","EGFR NP_005219.2:p.P596L","C177460","A change in the amino acid residue at position 596 in the epidermal growth factor receptor protein where proline has been replaced by leucine.","EGFR NP_005219.2:p.P596L | Activating P596L Mutation | EGFR NP_005219.2:p.Pro596Leu | EGFR P596L | EGFR P596L Mutation | EGFR Pro596Leu | EGFR p.P596L | EGFR p.Pro596Leu | Epidermal Growth Factor Receptor P596L | Epidermal Growth Factor Receptor Pro596Leu | NP_005219.2:p.P596L | NP_005219.2:p.Pro596Leu | Proto-Oncogene c-ErbB-1 P596L | Proto-Oncogene c-ErbB-1 Pro596Leu | Receptor Tyrosine-Protein Kinase erbB-1 P596L | Receptor Tyrosine-Protein Kinase erbB-1 Pro596Leu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643188","EGFR NP_005219.2:p.R222C","C177462","A change in the amino acid residue at position 222 in the epidermal growth factor receptor protein where arginine has been replaced by cysteine.","EGFR NP_005219.2:p.R222C | Activating R222C Mutation | EGFR Arg222Cys | EGFR NP_005219.2:p.Arg222Cys | EGFR R222C | EGFR R222C Mutation | EGFR p.Arg222Cys | EGFR p.R222C | Epidermal Growth Factor Receptor Arg222Cys | Epidermal Growth Factor Receptor R222C | NP_005219.2:p.Arg222Cys | NP_005219.2:p.R222C | Proto-Oncogene c-ErbB-1 Arg222Cys | Proto-Oncogene c-ErbB-1 R222C | Receptor Tyrosine-Protein Kinase erbB-1 Arg222Cys | Receptor Tyrosine-Protein Kinase erbB-1 R222C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643190","EGFR NP_005219.2:p.R831C","C177464","A change in the amino acid residue at position 831 in the epidermal growth factor receptor protein where arginine has been replaced by cysteine.","EGFR NP_005219.2:p.R831C | Activating R831C Mutation | EGFR Arg831Cys | EGFR NP_005219.2:p.Arg831Cys | EGFR R831C | EGFR R831C Mutation | EGFR p.Arg831Cys | EGFR p.R831C | Epidermal Growth Factor Receptor Arg831Cys | Epidermal Growth Factor Receptor R831C | NP_005219.2:p.Arg831Cys | NP_005219.2:p.R831C | Proto-Oncogene c-ErbB-1 Arg831Cys | Proto-Oncogene c-ErbB-1 R831C | Receptor Tyrosine-Protein Kinase erbB-1 Arg831Cys | Receptor Tyrosine-Protein Kinase erbB-1 R831C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643176","EGFR NP_005219.2:p.R831H","C177466","A change in the amino acid residue at position 831 in the epidermal growth factor receptor protein where arginine has been replaced by histidine.","EGFR NP_005219.2:p.R831H | Activating R831H Mutation | EGFR Arg831His | EGFR NP_005219.2:p.Arg831His | EGFR R831H | EGFR R831H Mutation | EGFR p.Arg831His | EGFR p.R831H | Epidermal Growth Factor Receptor Arg831His | Epidermal Growth Factor Receptor R831H | NP_005219.2:p.Arg831His | NP_005219.2:p.R831H | Proto-Oncogene c-ErbB-1 Arg831His | Proto-Oncogene c-ErbB-1 R831H | Receptor Tyrosine-Protein Kinase erbB-1 Arg831His | Receptor Tyrosine-Protein Kinase erbB-1 R831H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643181","EGFR NP_005219.2:p.V742I","C177469","A change in the amino acid residue at position 742 in the epidermal growth factor receptor protein where valine has been replaced by isoleucine.","EGFR NP_005219.2:p.V742I | Activating V742I Mutation | EGFR NP_005219.2:p.Val742Ile | EGFR V742I | EGFR V742I Mutation | EGFR Val742Ile | EGFR p.V742I | EGFR p.Val742Ile | Epidermal Growth Factor Receptor V742I | Epidermal Growth Factor Receptor Val742Ile | NP_005219.2:p.V742I | NP_005219.2:p.Val742Ile | Proto-Oncogene c-ErbB-1 V742I | Proto-Oncogene c-ErbB-1 Val742Ile | Receptor Tyrosine-Protein Kinase erbB-1 V742I | Receptor Tyrosine-Protein Kinase erbB-1 Val742Ile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643183","EGFR NP_005219.2:p.V769M","C177471","A change in the amino acid residue at position 769 in the epidermal growth factor receptor protein where valine has been replaced by methionine.","EGFR NP_005219.2:p.V769M | Activating V769M Mutation | EGFR NP_005219.2:p.Val769Met | EGFR V769M | EGFR V769M Mutation | EGFR Val769Met | EGFR p.V769M | EGFR p.Val769Met | Epidermal Growth Factor Receptor V769M | Epidermal Growth Factor Receptor Val769Met | NP_005219.2:p.V769M | NP_005219.2:p.Val769Met | Proto-Oncogene c-ErbB-1 V769M | Proto-Oncogene c-ErbB-1 Val769Met | Receptor Tyrosine-Protein Kinase erbB-1 V769M | Receptor Tyrosine-Protein Kinase erbB-1 Val769Met",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643140","EGFR NP_005219.2:p.V774M","C177473","A change in the amino acid residue at position 774 in the epidermal growth factor receptor protein where valine has been replaced by methionine.","EGFR NP_005219.2:p.V774M | Activating V774M Mutation | EGFR NP_005219.2:p.Val774Met | EGFR V774M | EGFR V774M Mutation | EGFR Val774Met | EGFR p.V774M | EGFR p.Val774Met | Epidermal Growth Factor Receptor V774M | Epidermal Growth Factor Receptor Val774Met | NP_005219.2:p.V774M | NP_005219.2:p.Val774Met | Proto-Oncogene c-ErbB-1 V774M | Proto-Oncogene c-ErbB-1 Val774Met | Receptor Tyrosine-Protein Kinase erbB-1 V774M | Receptor Tyrosine-Protein Kinase erbB-1 Val774Met",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643144","ERBB2 NP_004439.2:p.D769N","C177477","A change in the amino acid residue at position 769 in the receptor tyrosine-protein kinase erbB-2 protein where aspartic acid has been replaced by asparagine.","ERBB2 NP_004439.2:p.D769N | Activating D769N Mutation | ERBB2 Asp769Asn | ERBB2 D769N | ERBB2 NP_004439.2:p.Asp769Asn | ERBB2 p.Asp769Asn | ERBB2 p.D769N | HER2 Asp769Asn | HER2 D769N | HER2 D769N Mutation | NP_004439.2:p.Asp769Asn | NP_004439.2:p.D769N | Proto-Oncogene Neu Asp769Asn | Proto-Oncogene Neu D769N | Receptor Tyrosine-Protein Kinase erbB-2 Asp769Asn | Receptor Tyrosine-Protein Kinase erbB-2 D769N | Tyrosine Kinase-Type Cell Surface Receptor HER2 Asp769Asn | Tyrosine Kinase-Type Cell Surface Receptor HER2 D769N",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643146","ERBB2 NP_004439.2:p.I655V","C177479","A change in the amino acid residue at position 655 in the receptor tyrosine-protein kinase erbB-2 protein where isoleucine has been replaced by valine.","ERBB2 NP_004439.2:p.I655V | Activating I655V Mutation | ERBB2 I655V | ERBB2 Ile655Val | ERBB2 NP_004439.2:p.Ile655Val | ERBB2 p.I655V | ERBB2 p.Ile655Val | HER2 I655V | HER2 I655V Mutation | HER2 Ile655Val | NP_004439.2:p.I655V | NP_004439.2:p.Ile655Val | Proto-Oncogene Neu I655V | Proto-Oncogene Neu Ile655Val | Receptor Tyrosine-Protein Kinase erbB-2 I655V | Receptor Tyrosine-Protein Kinase erbB-2 Ile655Val | Tyrosine Kinase-Type Cell Surface Receptor HER2 I655V | Tyrosine Kinase-Type Cell Surface Receptor HER2 Ile655Val",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643132","ERBB2 NP_004439.2:p.I767M","C177481","A change in the amino acid residue at position 767 in the receptor tyrosine-protein kinase erbB-2 protein where isoleucine has been replaced by methionine.","ERBB2 NP_004439.2:p.I767M | Activating I767M Mutation | ERBB2 I767M | ERBB2 Ile767Met | ERBB2 NP_004439.2:p.Ile767Met | ERBB2 p.I767M | ERBB2 p.Ile767Met | HER2 I767M | HER2 I767M Mutation | HER2 Ile767Met | NP_004439.2:p.I767M | NP_004439.2:p.Ile767Met | Proto-Oncogene Neu I767M | Proto-Oncogene Neu Ile767Met | Receptor Tyrosine-Protein Kinase erbB-2 I767M | Receptor Tyrosine-Protein Kinase erbB-2 Ile767Met | Tyrosine Kinase-Type Cell Surface Receptor HER2 I767M | Tyrosine Kinase-Type Cell Surface Receptor HER2 Ile767Met",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643131","ERBB2 NP_004439.2:p.L755X","C177482","A change in the amino acid residue at position 755 in the receptor tyrosine-protein kinase erbB-2 protein where leucine has been replaced by another amino acid.","ERBB2 NP_004439.2:p.L755X | Activating L755X Mutation | ERBB2 L755X | ERBB2 Leu755Xxx | ERBB2 NP_004439.2:p.Leu755Xxx | ERBB2 p.L755X | ERBB2 p.Leu755Xxx | HER2 L755X | HER2 L755X Mutation | HER2 Leu755Xxx | NP_004439.2:p.L755X | NP_004439.2:p.Leu755Xxx | Proto-Oncogene Neu L755X | Proto-Oncogene Neu Leu755Xxx | Receptor Tyrosine-Protein Kinase erbB-2 L755X | Receptor Tyrosine-Protein Kinase erbB-2 Leu755Xxx | Tyrosine Kinase-Type Cell Surface Receptor HER2 L755X | Tyrosine Kinase-Type Cell Surface Receptor HER2 Leu755Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643133","ERBB2 NP_004439.2:p.L786V","C177484","A change in the amino acid residue at position 786 in the receptor tyrosine-protein kinase erbB-2 protein where leucine has been replaced by valine.","ERBB2 NP_004439.2:p.L786V | Activating L786V Mutation | ERBB2 L786V | ERBB2 Leu786Val | ERBB2 NP_004439.2:p.Leu786Val | ERBB2 p.L786V | ERBB2 p.Leu786Val | HER2 L786V | HER2 L786V Mutation | HER2 Leu786Val | NP_004439.2:p.L786V | NP_004439.2:p.Leu786Val | Proto-Oncogene Neu L786V | Proto-Oncogene Neu Leu786Val | Receptor Tyrosine-Protein Kinase erbB-2 L786V | Receptor Tyrosine-Protein Kinase erbB-2 Leu786Val | Tyrosine Kinase-Type Cell Surface Receptor HER2 L786V | Tyrosine Kinase-Type Cell Surface Receptor HER2 Leu786Val",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643138","ERBB2 NP_004439.2:p.L869R","C177487","A change in the amino acid residue at position 869 in the receptor tyrosine-protein kinase erbB-2 protein where leucine has been replaced by arginine.","ERBB2 NP_004439.2:p.L869R | Activating L869R Mutation | ERBB2 L869R | ERBB2 Leu869Arg | ERBB2 NP_004439.2:p.Leu869Arg | ERBB2 p.L869R | ERBB2 p.Leu869Arg | HER2 L869R | HER2 L869R Mutation | HER2 Leu869Arg | NP_004439.2:p.L869R | NP_004439.2:p.Leu869Arg | Proto-Oncogene Neu L869R | Proto-Oncogene Neu Leu869Arg | Receptor Tyrosine-Protein Kinase erbB-2 L869R | Receptor Tyrosine-Protein Kinase erbB-2 Leu869Arg | Tyrosine Kinase-Type Cell Surface Receptor HER2 L869R | Tyrosine Kinase-Type Cell Surface Receptor HER2 Leu869Arg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643156","ERBB2 NP_004439.2:p.R678Q","C177489","A change in the amino acid residue at position 678 in the receptor tyrosine-protein kinase erbB-2 protein where arginine has been replaced by glutamine.","ERBB2 NP_004439.2:p.R678Q | Activating R678Q Mutation | ERBB2 Arg678Gln | ERBB2 NP_004439.2:p.Arg678Gln | ERBB2 R678Q | ERBB2 p.Arg678Gln | ERBB2 p.R678Q | HER2 Arg678Gln | HER2 R678Q | HER2 R678Q Mutation | NP_004439.2:p.Arg678Gln | NP_004439.2:p.R678Q | Proto-Oncogene Neu Arg678Gln | Proto-Oncogene Neu R678Q | Receptor Tyrosine-Protein Kinase erbB-2 Arg678Gln | Receptor Tyrosine-Protein Kinase erbB-2 R678Q | Tyrosine Kinase-Type Cell Surface Receptor HER2 Arg678Gln | Tyrosine Kinase-Type Cell Surface Receptor HER2 R678Q",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643158","ERBB2 NP_004439.2:p.S310F","C177491","A change in the amino acid residue at position 310 in the receptor tyrosine-protein kinase erbB-2 protein where serine has been replaced by phenylalanine.","ERBB2 NP_004439.2:p.S310F | Activating S310F Mutation | ERBB2 NP_004439.2:p.Ser310Phe | ERBB2 S310F | ERBB2 Ser310Phe | ERBB2 p.S310F | ERBB2 p.Ser310Phe | HER2 S310F | HER2 S310F Mutation | HER2 Ser310Phe | NP_004439.2:p.S310F | NP_004439.2:p.Ser310Phe | Proto-Oncogene Neu S310F | Proto-Oncogene Neu Ser310Phe | Receptor Tyrosine-Protein Kinase erbB-2 S310F | Receptor Tyrosine-Protein Kinase erbB-2 Ser310Phe | Tyrosine Kinase-Type Cell Surface Receptor HER2 S310F | Tyrosine Kinase-Type Cell Surface Receptor HER2 Ser310Phe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643160","ERBB2 NP_004439.2:p.S310Y","C177493","A change in the amino acid residue at position 310 in the receptor tyrosine-protein kinase erbB-2 protein where serine has been replaced by tyrosine.","ERBB2 NP_004439.2:p.S310Y | Activating S310Y Mutation | ERBB2 NP_004439.2:p.Ser310Tyr | ERBB2 S310Y | ERBB2 Ser310Tyr | ERBB2 p.S310Y | ERBB2 p.Ser310Tyr | HER2 S310Y | HER2 S310Y Mutation | HER2 Ser310Tyr | NP_004439.2:p.S310Y | NP_004439.2:p.Ser310Tyr | Proto-Oncogene Neu S310Y | Proto-Oncogene Neu Ser310Tyr | Receptor Tyrosine-Protein Kinase erbB-2 S310Y | Receptor Tyrosine-Protein Kinase erbB-2 Ser310Tyr | Tyrosine Kinase-Type Cell Surface Receptor HER2 S310Y | Tyrosine Kinase-Type Cell Surface Receptor HER2 Ser310Tyr",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643162","ERBB2 NP_004439.2:p.T733I","C177495","A change in the amino acid residue at position 733 in the receptor tyrosine-protein kinase erbB-2 protein where threonine has been replaced by isoleucine.","ERBB2 NP_004439.2:p.T733I | Activating T733I Mutation | ERBB2 NP_004439.2:p.Thr733Ile | ERBB2 T733I | ERBB2 Thr733Ile | ERBB2 p.T733I | ERBB2 p.Thr733Ile | HER2 T733I | HER2 T733I Mutation | HER2 Thr733Ile | NP_004439.2:p.T733I | NP_004439.2:p.Thr733Ile | Proto-Oncogene Neu T733I | Proto-Oncogene Neu Thr733Ile | Receptor Tyrosine-Protein Kinase erbB-2 T733I | Receptor Tyrosine-Protein Kinase erbB-2 Thr733Ile | Tyrosine Kinase-Type Cell Surface Receptor HER2 T733I | Tyrosine Kinase-Type Cell Surface Receptor HER2 Thr733Ile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643161","ERBB2 NP_004439.2:p.T862I","C177496","A change in the amino acid residue at position 862 in the receptor tyrosine-protein kinase erbB-2 protein where threonine has been replaced by isoleucine.","ERBB2 NP_004439.2:p.T862I | Activating T862I Mutation | ERBB2 NP_004439.2:p.Thr862Ile | ERBB2 T862I | ERBB2 Thr862Ile | ERBB2 p.T862I | ERBB2 p.Thr862Ile | HER2 T862I | HER2 T862I Mutation | HER2 Thr862Ile | NP_004439.2:p.T862I | NP_004439.2:p.Thr862Ile | Proto-Oncogene Neu T862I | Proto-Oncogene Neu Thr862Ile | Receptor Tyrosine-Protein Kinase erbB-2 T862I | Receptor Tyrosine-Protein Kinase erbB-2 Thr862Ile | Tyrosine Kinase-Type Cell Surface Receptor HER2 T862I | Tyrosine Kinase-Type Cell Surface Receptor HER2 Thr862Ile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643147","ERBB2 NP_004439.2:p.V659E","C177498","A change in the amino acid residue at position 659 in the receptor tyrosine-protein kinase erbB-2 protein where valine has been replaced by glutamic acid.","ERBB2 NP_004439.2:p.V659E | Activating V659E Mutation | ERBB2 NP_004439.2:p.Val659Glu | ERBB2 V659E | ERBB2 Val659Glu | ERBB2 p.V659E | ERBB2 p.Val659Glu | HER2 V659E | HER2 V659E Mutation | HER2 Val659Glu | NP_004439.2:p.V659E | NP_004439.2:p.Val659Glu | Proto-Oncogene Neu V659E | Proto-Oncogene Neu Val659Glu | Receptor Tyrosine-Protein Kinase erbB-2 V659E | Receptor Tyrosine-Protein Kinase erbB-2 Val659Glu | Tyrosine Kinase-Type Cell Surface Receptor HER2 V659E | Tyrosine Kinase-Type Cell Surface Receptor HER2 Val659Glu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643154","ERBB2 NP_004439.2:p.V773M","C177503","A change in the amino acid residue at position 773 in the receptor tyrosine-protein kinase erbB-2 protein where valine has been replaced by methionine.","ERBB2 NP_004439.2:p.V773M | Activating V773M Mutation | ERBB2 NP_004439.2:p.Val773Met | ERBB2 V773M | ERBB2 Val773Met | ERBB2 p.V773M | ERBB2 p.Val773Met | HER2 V773M | HER2 V773M Mutation | HER2 Val773Met | NP_004439.2:p.V773M | NP_004439.2:p.Val773Met | Proto-Oncogene Neu V773M | Proto-Oncogene Neu Val773Met | Receptor Tyrosine-Protein Kinase erbB-2 V773M | Receptor Tyrosine-Protein Kinase erbB-2 Val773Met | Tyrosine Kinase-Type Cell Surface Receptor HER2 V773M | Tyrosine Kinase-Type Cell Surface Receptor HER2 Val773Met",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643221","ERBB2 NP_004439.2:p.V777L","C177506","A change in the amino acid residue at position 777 in the receptor tyrosine-protein kinase erbB-2 protein where valine has been replaced by leucine.","ERBB2 NP_004439.2:p.V777L | Activating V777L Mutation | ERBB2 NP_004439.2:p.Val777Leu | ERBB2 V777L | ERBB2 Val777Leu | ERBB2 p.V777L | ERBB2 p.Val777Leu | HER2 V777L | HER2 V777L Mutation | HER2 Val777Leu | NP_004439.2:p.V777L | NP_004439.2:p.Val777Leu | Proto-Oncogene Neu V777L | Proto-Oncogene Neu Val777Leu | Receptor Tyrosine-Protein Kinase erbB-2 V777L | Receptor Tyrosine-Protein Kinase erbB-2 Val777Leu | Tyrosine Kinase-Type Cell Surface Receptor HER2 V777L | Tyrosine Kinase-Type Cell Surface Receptor HER2 Val777Leu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643223","ERBB2 NP_004439.2:p.V777M","C177508","A change in the amino acid residue at position 777 in the receptor tyrosine-protein kinase erbB-2 protein where valine has been replaced by methionine.","ERBB2 NP_004439.2:p.V777M | Activating V777M Mutation | ERBB2 NP_004439.2:p.Val777Met | ERBB2 V777M | ERBB2 Val777Met | ERBB2 p.V777M | ERBB2 p.Val777Met | HER2 V777M | HER2 V777M Mutation | HER2 Val777Met | NP_004439.2:p.V777M | NP_004439.2:p.Val777Met | Proto-Oncogene Neu V777M | Proto-Oncogene Neu Val777Met | Receptor Tyrosine-Protein Kinase erbB-2 V777M | Receptor Tyrosine-Protein Kinase erbB-2 Val777Met | Tyrosine Kinase-Type Cell Surface Receptor HER2 V777M | Tyrosine Kinase-Type Cell Surface Receptor HER2 Val777Met",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643226","EDNRB Positive","C177509","An indication that EDNRB expression has been detected in a sample.","EDNRB Positive | ET-B Positive | ET-BR Positive | ETB Positive | ETB1 Positive | ETBR Positive | ETRB Positive | Endothelin B Receptor Positive | Endothelin Receptor Non-Selective Type Positive | Endothelin Receptor Type B Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643225","FBXW7 Gene Mutation Negative","C177510","A genetic finding indicating that FBXW7 gene mutations have not been detected in a sample.","FBXW7 Gene Mutation Negative | AGO Gene Mutation Negative | Archipelago Homolog Gene Mutation Negative | CDC4 Gene Mutation Negative | F-Box and WD Repeat Domain Containing 7 Gene Mutation Negative | FBW6 Gene Mutation Negative | FBW7 Gene Mutation Negative | FBX30 Gene Mutation Negative | FBXW6 Gene Mutation Negative | FBXW7 Mutation Negative | FBXW7 Wild-Type | FBXW7 Wildtype | FBXW7 wt | SEL-10 Gene Mutation Negative | SEL10 Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643228","JAK2 Gene Mutation Negative","C177511","A genetic finding indicating that JAK2 gene mutations have not been detected in a sample.","JAK2 Gene Mutation Negative | JAK-2 Gene Mutation Negative | JAK2 Mutation Negative | JAK2 Wild-Type | JAK2 Wildtype | JAK2 wt | JTK10 Gene Mutation Negative | Janus Kinase 2 (A Protein Tyrosine Kinase) Gene Mutation Negative | Janus Kinase 2 Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643227","Elevated MHC Class II","C177512","A finding indicating elevated concentrations of MHC class II in a sample.","Elevated MHC Class II | Elevated Class II MHC | Elevated Major Histocompatibility Complex Class II | MHC Class II High",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643215","NOTCH1 Gene Mutation Negative","C177513","A genetic finding indicating that NOTCH1 gene mutations have not been detected in a sample.","NOTCH1 Gene Mutation Negative | NOTCH1 Mutation Negative | NOTCH1 Wild-Type | NOTCH1 Wildtype | NOTCH1 wt | Notch 1 Gene Mutation Negative | Notch Homolog 1 Gene Mutation Negative | TAN1 Gene Mutation Negative | hN1 Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643214","PSA Level Greater than One Hundred","C177514","A blood concentration of prostate specific antigen greater than 100 ng/mL.","PSA Level Greater than One Hundred | PSA Level Greater than 100",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643217","NECTIN2 Positive","C177515","An indication that NECTIN2 expression has been detected in a sample.","NECTIN2 Positive | CD112 Antigen Positive | CD112 Positive | HVEB Positive | Herpes Virus Entry Mediator B Positive | Herpesvirus Entry Mediator B Positive | Herpesvirus Entry Protein B Positive | Nectin 2 Positive | Nectin Cell Adhesion Molecule 2 Positive | Nectin-2 Positive | PRR2 Positive | PVRL2 Positive | PVRR2 Positive | Poliovirus Receptor-Like 2 Positive | Poliovirus Receptor-Related 2 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643179","TREM2 Positive","C177467","An indication that TREM2 expression has been detected in a sample.","TREM2 Positive | TREM-2 Positive | Triggering Receptor Expressed On Monocytes 2 Positive | Triggering Receptor Expressed On Myeloid Cells 2 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643142","ERBB2 NP_004439.2:p.V842I","C177475","A change in the amino acid residue at position 842 in the receptor tyrosine-protein kinase erbB-2 protein where valine has been replaced by isoleucine.","ERBB2 NP_004439.2:p.V842I | Activating V842I Mutation | ERBB2 NP_004439.2:p.Val842Ile | ERBB2 V842I | ERBB2 Val842Ile | ERBB2 p.V842I | ERBB2 p.Val842Ile | HER2 V842I | HER2 V842I Mutation | HER2 Val842Ile | NP_004439.2:p.V842I | NP_004439.2:p.Val842Ile | Proto-Oncogene Neu V842I | Proto-Oncogene Neu Val842Ile | Receptor Tyrosine-Protein Kinase erbB-2 V842I | Receptor Tyrosine-Protein Kinase erbB-2 Val842Ile | Tyrosine Kinase-Type Cell Surface Receptor HER2 V842I | Tyrosine Kinase-Type Cell Surface Receptor HER2 Val842Ile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643491","Heaviness of Smoking Index","C177520","A two-question self-report measure designed to determine an individual's dependence or addiction to nicotine. The measure includes time to first cigarette (TTFC) and cigarettes per day (CPD).","Heaviness of Smoking Index | HIS | Heaviness of Smoking Index (HIS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643234","Nicotine Metabolite Ratio","C177522","A biomarker of nicotine clearance that uses the ratio of two nicotine metabolites derived from smoking (3'-hydroxycotinine [3HC]/cotinine). This ratio reflects the activity CYP2A6 enzyme in the liver, and captures environmental influences on nicotine clearance as well.","Nicotine Metabolite Ratio | NMR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1639121","Point Prevalence","C177523","The proportion of persons with a particular disease or attribute at a particular point in time.","Point Prevalence | Point prevalence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643235","Partner Interaction Questionnaire","C177521","A 20-item questionnaire to assess social support provided by a spouse or partner for adults wanting to stop smoking. It includes two subscales for assessing positive and negative behaviors of the partner.","Partner Interaction Questionnaire | PIQ-20 | Partner Interaction Questionnaire (PIQ-20)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555931","ERBB2 NP_004439.2:p.D769Y","C155300","A change in the amino acid residue at position 769 in the receptor tyrosine-protein kinase erbB-2 protein where aspartic acid has been replaced by tyrosine.","ERBB2 NP_004439.2:p.D769Y | Activating D769Y Mutation | ERBB2 Asp769Tyr | ERBB2 D769Y | ERBB2 NP_004439.2:p.Asp769Tyr | ERBB2 p.Asp769Tyr | ERBB2 p.D769Y | HER2 Asp769Tyr | HER2 D769Y | HER2 D769Y Mutation | NP_004439.2:p.Asp769Tyr | NP_004439.2:p.D769Y | Proto-Oncogene Neu Asp769Tyr | Proto-Oncogene Neu D769Y | Receptor Tyrosine-Protein Kinase erbB-2 Asp769Tyr | Receptor Tyrosine-Protein Kinase erbB-2 D769Y | Tyrosine Kinase-Type Cell Surface Receptor HER2 Asp769Tyr | Tyrosine Kinase-Type Cell Surface Receptor HER2 D769Y",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555937","ERBB2 NP_004439.2:p.D769H","C155302","A change in the amino acid residue at position 769 in the receptor tyrosine-protein kinase erbB-2 protein where aspartic acid has been replaced by histidine.","ERBB2 NP_004439.2:p.D769H | Activating D769H Mutation | ERBB2 Asp769His | ERBB2 D769H | ERBB2 NP_004439.2:p.Asp769His | ERBB2 p.Asp769His | ERBB2 p.D769H | HER2 Asp769His | HER2 D769H | HER2 D769H Mutation | NP_004439.2:p.Asp769His | NP_004439.2:p.D769H | Proto-Oncogene Neu Asp769His | Proto-Oncogene Neu D769H | Receptor Tyrosine-Protein Kinase erbB-2 Asp769His | Receptor Tyrosine-Protein Kinase erbB-2 D769H | Tyrosine Kinase-Type Cell Surface Receptor HER2 Asp769His | Tyrosine Kinase-Type Cell Surface Receptor HER2 D769H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513785","Myeloblasts Under 10 Percent of Peripheral Blood White Cells","C41402","A semi-quantitative microscopic finding indicating that less than 10 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells of myeloid origin.","Myeloblasts Under 10 Percent of Peripheral Blood White Cells | Myeloblasts Less than 10 Percent of Peripheral Blood White Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334846","Myeloblasts Under 10 Percent of Bone Marrow Nucleated Cells","C36219","A semi-quantitative microscopic finding indicating less than 10 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells of myeloid origin.","Myeloblasts Under 10 Percent of Bone Marrow Nucleated Cells | Myeloblasts Less Than 10 Percent of Bone Marrow Nucleated Cells | Myeloblasts Under 10% of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643497","Bioptic","C177644","A qualifier referring to a tissue sample obtained by a guided biopsy procedure.","Bioptic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643231","Bladder Flat Urothelial Carcinoma","C177531","An in situ or invasive urothelial carcinoma that arises from the bladder wall and does not grow toward the hollow part of the bladder.","Bladder Flat Urothelial Carcinoma | Bladder Sessile Urothelial Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643467","Gross Appearance","C177646","A description of a tumor based on the predominant macroscopic features by pathologic gross examination.","Gross Appearance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643447","Population Assessment of Tobacco and Health (PATH) Study","C177677","A national longitudinal study of tobacco use and how it affects the health of people in the United States. It is designed to learn how and why people start using tobacco products, quit using them, and start using them again after they've quit, as well as how different tobacco products affect health outcomes over time.","Population Assessment of Tobacco and Health (PATH) Study | PATH Study | Population Assessment of Tobacco and Health | Population Assessment of Tobacco and Health Study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643446","Harmfulness Category","C177678","A set of descriptors to assess the relative perceived harmfulness of something.","Harmfulness Category | Harm Category | Harmful Category",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0338034","Walk-in Clinic","C177655","A healthcare facility where an individual can visit a medical professional without needing an appointment.","Walk-in Clinic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643483","Temporary Leave","C177653","An indication that an individual is not working due to being laid off, but that it is only temporary.","Temporary Leave | Temporarily Laid Off",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475309","Health Center","C177654","A healthcare facility that provides comprehensive, high-quality primary health care services. Health centers often integrate access to pharmacy, mental health, substance use disorder, and oral health services.","Health Center | Healthcare Center",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643484","Retail Clinic","C177656","A healthcare facility located inside of a retail store.","Retail Clinic | Walk-in Retail Health Clinic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643478","Veterans Administration Medical Center","C177657","A comprehensive healthcare facility that  provides health care services to veterans.","Veterans Administration Medical Center | VA Medical Center | Veterans Administration Hospital",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643480","Veterans Affairs Community-Based Outpatient Clinic","C177659","A healthcare facility run by the Veterans Health Administration that is geographically distinct or separate from its parent VA medical facility designed to facilitate access to primary care closer to where veterans reside.","Veterans Affairs Community-Based Outpatient Clinic | CBOC | VA Community-Based Outpatient Clinics | VA Outpatient Clinic | Veterans Administration Outpatient Clinic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647571","Organic Product","C177734","A product manufactured with materials that meet specific guidelines that limit or prohibit the use of synthetic chemicals, radiation, pesticides, additives, or genetically engineered technologies in their cultivation.","Organic Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378708","Protocol Treatment Course","C168807","The type of protocol treatment course administered.","Protocol Treatment Course | COURSE | Treatment Course",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL383597","Topical Steroid Therapy","C116545","The application of steroid medications to the skin for the treatment of various conditions.","Topical Steroid Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1705193","Sensor","C50166","A device designed to respond to a stimulus by generating a signal that can be measured or interpreted.","Sensor Device | Device Sensor | Sensor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552428","Application","C113519","Putting something to a special use or purpose.","Apply | Application | Applied",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647592","Technology Attitude Scale","C177742","A 15-item questionnaire that utilizes a six-point rating scale to assess an individual's attitude toward the use of technology, including their confidence in using technology, the value of using technology, and their perceptions of technology and its usefulness in specific settings.","Technology Attitude Scale | TAS | Technology Attitude Scale (TAS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647590","Knowing How to Use Technology is Necessary Skill","C177744","A question about how strongly an individual agrees that knowing how to use technology is a necessary skill for them.","Knowing How to Use Technology is Necessary Skill | Knowing how to use technology is a necessary skill for me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647588","Like Using Technology","C177746","A question about how strongly an individual agrees that they like using technology.","Like Using Technology | I like using technology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647585","Feel Confident with Ability to Learn about Technology","C177747","A question about how strongly an individual agrees that they feel confident with their ability to learn about technology.","Feel Confident with Ability to Learn about Technology | I feel confident with my ability to learn about technology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647586","Learning about Technology is Worthwhile","C177748","A question about how strongly an individual agrees that learning about technology is worthwhile.","Learning about Technology is Worthwhile | Learning about technology is worthwhile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647583","Working with Technology Makes Me Feel Nervous","C177749","A question about how strongly an individual agrees that working with technology makes them feel nervous.","Working with Technology Makes Me Feel Nervous | Working with technology makes me feel nervous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647584","Technology Makes Me Feel Stupid","C177750","A question about how strongly an individual agrees that technology makes them feel stupid.","Technology Makes Me Feel Stupid | Technology makes me feel stupid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647581","Important to Know about Technology in Future Career","C177751","A question about how strongly an individual agrees that it is important to know about technology.","Important to Know about Technology in Future Career | Important to Know about Technology | Important to Know about Technology in my future career",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647582","Not the Type to do Well with Technology","C177752","A question about how strongly an individual agrees that they are not the type of person that does well with technology.","Not the Type to do Well with Technology | I'm not the type to do well with technology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647579","Using Technology Will Facilitate Learning","C177753","A question about how strongly an individual agrees that using technology will facilitate their learning.","Using Technology Will Facilitate Learning | Using technology will facilitate my learning",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647580","Know That Will do Better if Work Hard to Learn About Technology","C177754","A question about how strongly an individual agrees that if they work hard to learn about technology they will do better.","Know That Will do Better if Work Hard to Learn About Technology | I know if I work hard to learn about technology, I will do better",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647577","Think Using Technology Will be Difficult for Me","C177755","A question about how strongly an individual agrees that they think using technology will be difficult for them.","Think Using Technology Will be Difficult for Me | I think using technology will be difficult for me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647578","Feel Uncomfortable Using Most Technology","C177756","A question about how strongly an individual agrees that they feel uncomfortable using most technology.","Feel Uncomfortable Using Most Technology | I feel uncomfortable using most technology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647551","Technology Will Not Help Me to Learn Better","C177757","A question about how strongly an individual agrees that technology won't help them to learn any better.","Technology Will Not Help Me to Learn Better | Technology really won't help me to learn any better",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647552","Completely Confident Can Use Any Smartphone Application","C177758","A question about how strongly an individual agrees that they are completely confident that they can use any smartphone app.","Completely Confident Can Use Any Smartphone Application | I am completely confident that I can use any smartphone app",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647549","Like Answering Survey Questions Using Smartphone Application","C177759","A question about how strongly an individual agrees that they like answering survey questions using a smartphone app.","Like Answering Survey Questions Using Smartphone Application | I like answering survey questions using a smartphone app",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348898","Green Vegetable","C71977","A vegetable whose foliage, or foliage-bearing stalks, are the chief edible part.","Green Vegetable | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032846","Potato","C72045","The edible tuber of Solanum tuberosum.","Potato | POTATO",,,,,,,,,,,,,,,"42536307","Potato",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025017","Meat","C126482","The flesh of animals used as food.","Meat | ",,,,,,,,,,,,,,,"4102784","Meat",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016163","Fish","C14207","A grouping of jawed and jawless vertebrate animals usually having fins and a covering of scales or plates, breathing by means of gills, and living almost entirely in the water.","Fish | FISH | Fish (NOS)",,,,,,,,,,,,,,,"4235765","Fish",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0271635","Uncomplicated Diabetes Mellitus","C177763","Diabetes mellitus that does not show any evidence of tissue or organ damage.","Uncomplicated Diabetes Mellitus | Diabetes Mellitus without Complications | Diabetes without Complications | Uncomplicated Diabetes",,,,,,,,,,,,,,,"4008576","Diabetes mellitus without complication",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL969375","Was Additional Surgery for New Loco-Regional Tumor Event Performed","C160436","A question about any additional surgery performed for the new loco-regional tumor.","Was Additional Surgery for New Loco-Regional Tumor Event Performed | Additional Surgery for New Tumor Event: Loco-regional",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969373","Was Additional Surgery for New Metastatic Tumor Event Performed","C160438","A question about any additional surgery performed for the new metastatic tumor.","Was Additional Surgery for New Metastatic Tumor Event Performed | Additional Surgery for New Tumor Event: Metastasis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647993","Cytogenetic Analysis of Hematologic Neoplasm","C177773","A cytogenetic test to define and interpret chromosomal aberrations that occur in neoplastic cells associated with hematologic malignancies.","Cytogenetic Analysis of Hematologic Neoplasm | Chromosome Analysis Hematologic Neoplasm | Chromosome Analysis of Hematologic Neoplasm | Chromosome Analysis, Hematologic Malignancy | Chromosomes, Hematologic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647545","Cell Culture without Plant Mitogens","C177772","A method of growing cells in culture that does not involve the use of mitogenic plant lectins.","Cell Culture without Plant Mitogens | Cell Culture without Mitogens",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969372","Date of Additional Surgery for New Tumor Event: Loco-Regional","C160439","Date of additional surgery for the new loco-regional tumor event.","Date of Additional Surgery for New Tumor Event: Loco-Regional | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950614","Number of Days from Date of Initial Pathologic Diagnosis to Date of Additional Surgery for New Tumor Event Loco-Regional","C158634","The number of days from the date of the initial pathologic diagnosis to the date of additional surgery for new loco-regional tumor event.","Number of Days from Date of Initial Pathologic Diagnosis to Date of Additional Surgery for New Tumor Event Loco-Regional | Number of Days from Date of Initial Cancer Diagnosis to Date of Additional Surgery for Loco-Regional Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950726","Residual Tumor After Surgery for New Tumor Event","C158760","A question about the residual tumor status after surgery.","What is the Status of the Residual Tumor After Surgery for New Tumor Event | Residual Tumor After Surgery for New Tumor Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950615","Number of Days from Date of Initial Pathologic Diagnosis to Date of Additional Surgery for New Tumor Event Metastasis","C158635","The number of days from the date of the initial pathologic diagnosis to the date of additional surgery for new metastatic tumor event.","Number of Days from Date of Initial Pathologic Diagnosis to Date of Additional Surgery for New Tumor Event Metastasis | Number of Days from Date of Initial Cancer Diagnosis to Date of Additional Surgery for Metastatic Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969572","Date of Additional Surgery for New Tumor Event: Metastatic","C160441","Date of additional surgery for the new metastatic tumor event.","Date of Additional Surgery for New Tumor Event: Metastatic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831321","Bone Marrow Collection","C112933","Any process that harvests bone marrow for clinical or manufacturing purposes.","Bone Marrow Collection | Collection, Bone Marrow",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647499","Brain Metastasis Velocity","C177914","Describes the recurrence rate of new brain metastases after initial treatment with radiosurgery. Brain metastasis velocity is calculated by dividing the cumulative number of new brain metastases after initial radiosurgery by the time in years since first radiosurgery. It is being employed as a tool to differentiate patients requiring salvage whole brain radiation from those where stereotactic radiosurgery is appropriate.","Brain Metastasis Velocity | BMV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643171","Activating MET Exon 14 Gene Mutation","C177440","A change in the nucleotide sequence of exon 14 the MET gene that results constitutive activation of hepatocyte growth factor receptor and its downstream signaling pathways.","Activating MET Exon 14 Gene Mutation | Activating HGFR Exon 14 Mutation | Activating Hepatocyte Growth Factor Receptor Exon 14 Mutation | Activating MET Exon 14 Mutation | Activating MET Proto-Oncogene, Receptor Tyrosine Kinase Exon 14 Gene Mutation | Activating METex14 mutation | Activating Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Exon 14 Mutation | Activating c-Met Exon 14 Mutation | MET Exon 14 Activating Mutation | MET Exon 14 Gain of Function Gene Mutation | MET Exon 14 Gain of Function Mutation | c-MET Exon 14 Gain of Function Gene Mutation | c-MET Exon 14 Gain of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647561","MET Gene Alteration Positive","C177780","An indication that mutation, overexpression, fusion or rearrangement involving the MET gene has been detected in a sample.","MET Gene Alteration Positive | Genetic Defect in MET | HGFR Gene Alteration Positive | Hepatocyte Growth Factor Receptor Gene Alteration Positive | MET Gene Defect | MET Gene Defect Detected | MET Gene Defect Positive | MET Proto-Oncogene, Receptor Tyrosine Kinase Gene Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647559","del(17p) Negative","C177781","An indication that cytogenetic loss of all or part of the short arm of chromosome 17 (17p) was not detected in a sample.","del(17p) Negative | 17p Deletion Negative | Chromosome 17p Deletion Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647560","MTAP Gene Deletion","C177782","A molecular abnormality referring to the loss of at least one copy of the MTAP gene.","MTAP Gene Deletion | MSAP Gene Deletion | MTAP Deletion | Methylthioadenosine Phosphorylase Gene Deletion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647557","PSA Doubling Time Greater than or Equal to 10 Months","C177783","An indication that the number of months that a subject's blood concentration of prostate specific antigen took at least 10 months to double.","PSA Doubling Time Greater than or Equal to 10 Months | PSA Doubling Time Greater than or Equal to Ten Months | PSA-DT Greater than or Equal to 10 Months | PSADT Greater than or Equal to 10 Months",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647555","Activating RAS Q61X","C177785","A change in the amino acid residue at position 61 of a RAS family (HRAS, KRAS or NRAS) protein where the glutamine is replaced by another amino acid and the encoded GTPase is resistant to GTP hydrolysis, which results in constitutive activation of its activity and downstream pathways.","Activating RAS Q61X | Activating RAS Family Codon 61 Mutation | Activating RAS Family Gln61 Mutation | Activating RAS Family Q61 Mutation | Activating RAS Gln61 Mutation | Activating RAS Gln61Xxx | Activating RAS Q61 Mutation | Activating RASQ61 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647556","Activating BRAF NP_004324.2:p.V600X","C177786","A change in the valine at position 600 of the serine/threonine-protein kinase B-raf protein to another amino acid that results in constitutive activation of both serine/threonine-protein kinase B-raf and its downstream signaling pathways.","Activating BRAF NP_004324.2:p.V600X | Activating BRAF Codon 600 Mutation | Activating BRAF NP_004324.2:p.Val600 Mutation | Activating BRAF NP_004324.2:p.Val600Xxx | Activating BRAF V600 Mutation | Activating BRAF V600 Protein Variation | Activating BRAF V600X | Activating BRAF V600X Mutation | Activating BRAF p.V600 Mutation | Activating BRAF p.V600X | Activating BRAF p.Val600 Mutation | Activating BRAF p.Val600Xxx | Activating Serine/Threonine-Protein Kinase B-raf Protein V600 Mutation | Activating Serine/Threonine-Protein Kinase B-raf Protein V600 Protein Variation | Activating Serine/Threonine-Protein Kinase B-raf Protein V600X | Activating Serine/Threonine-Protein Kinase B-raf Protein Val600 Mutation | Activating Serine/Threonine-Protein Kinase B-raf Protein Val600Xxx | BRAF Class I Alteration | BRAF Class I Mutation | Class I BRAF Alteration | Class I BRAF Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647553","PSA Nadir Greater than or Equal to 0.5 ng/mL","C177787","A finding indicating that the lowest blood concentration of prostate specific antigen for a subject was greater than or equal to 0.5 ng/mL.","PSA Nadir Greater than or Equal to 0.5 ng/mL | PSA Nadir Greater than or Equal to 0.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647554","PSA Nadir Less than 0.5 ng/mL","C177788","A finding indicating that the lowest blood concentration of prostate specific antigen for a subject was less than 0.5 ng/mL.","PSA Nadir Less than 0.5 ng/mL | PSA Nadir Less than 0.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647462","Activating RET Fusion Gene Mutation Positive","C177789","An indication that a fusion involving the RET gene that results in constitutive proto-oncogene tyrosine-protein kinase receptor Ret-dependent signal transduction and activation of downstream signaling pathways has been detected in a sample.","Activating RET Fusion Gene Mutation Positive | Activating RET Fusion Gene Positive | Activating RET Fusion Mutation | Activating RET Fusion Mutation Positive | Activating RET Fusion Positive | Activating Ret Proto-Oncogene Fusion Mutation Positive | RET Activating Fusion Mutation Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647463","WNT Pathway Activation Negative","C177790","A finding indicating that the activation of the WNT signaling pathway was not detected in a sample.","WNT Pathway Activation Negative | Non-WNT | Non-WNT Pathway Activation | WNT Signaling Pathway Activation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647460","MYC Gene Amplification Negative","C177791","An indication that amplification of the MYC gene was not detected in a sample.","MYC Gene Amplification Negative | MRTL Gene Amplification Negative | MYC Amplification Negative | MYCC Gene Amplification Negative | Non-MYC Gene Amplification | bHLHe39 Gene Amplification Negative | c-myc Gene Amplification Negative | v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog Gene Amplification Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647461","SHH Pathway Activation Negative","C177792","A finding indicating that the activation of the hedgehog/patch signaling pathway was not detected in a sample.","SHH Pathway Activation Negative | Non-SHH | Non-SHH Pathway Activation | SHH Signaling Pathway Activation Negative | SHH/PTCH Pathway Activation Negative | Sonic Hedgehog/Patch Pathway Activation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0396583","Extrapleural Pneumonectomy","C94446","The surgical removal of all or part of a lung and some surrounding tissue, including a portion of the pericardium, a portion of the diaphragm, and a portion of the parietal pleura.","Extrapleural Pneumonectomy | extrapleural pneumonectomy",,,,,,,,,,,,,,,"4339613","Extrapleural pneumonectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL969247","Additional Surgery for New Tumor Event Absent","C160300","Additional surgery for the new tumor event was not performed.","Additional Surgery for New Tumor Event Absent | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969260","Additional Surgery for New Tumor Event Unknown","C160302","Additional surgery for the new tumor event is unknown.","Additional Surgery for New Tumor Event Unknown | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969248","Additional Surgery for New Tumor Event Present","C160299","Additional surgery for the new tumor event was performed.","Additional Surgery for New Tumor Event Present | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647659","Structural Neuroimaging","C178133","An imaging modality used to characterize the anatomic features of the central nervous system.","Structural Neuroimaging | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3178877","Functional Neuroimaging","C178134","An imaging modality used to characterize the physiologic, cellular or molecular processes of the central nervous system, particularly in the assessment of neuronal activity.","Functional Neuroimaging | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0069805","Oxybutynin","C47647","A tertiary amine possessing antimuscarinic and antispasmodic properties. Oxybutynin blocks muscarinic receptors in smooth muscle, hence inhibiting acetylcholine binding and subsequent reduction of involuntary muscle contractions. Oxybutynin is used to reduce bladder contractions by relaxing bladder smooth muscle.","Oxybutynin | 4-Diethylamino-2-butynyl alpha-phenylcyclohexaneglycolate | Anturol | Benzeneacetic Acid, alpha-cyclohexyl-alpha-hydroxy-, 4-(diethylamino)-2-butynyl Ester | OXYBUTYNIN | Oxytrol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523828","Analytical Procedure Range","C134240","The interval between the upper and lower concentration (amounts) of analyte in the sample (including these concentrations) for which it has been demonstrated that the analytical procedure has a suitable level of precision, accuracy and linearity.","Analytical Procedure Range | Range",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0872319","Underserved Population","C18476","Populations that do not have adequate access to medical care. This includes rural, elderly, low-literacy, blue collar, and poor populations. Minorities per se are not included but often belong to one or more or the included categories.","Underserved Population | Medically Underserved Population | Underserved Populations",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL370089","Population Density","C53338","The number of individuals per unit geographic area.","Population Density | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035962","Rural Population","C17110","Populations living away from the congestion of city or suburb.","Rural Population | Rural Populations",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041935","Urban Population","C17240","The inhabitants of a city or town, including metropolitan areas and suburban areas.","Urban Population | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708485","Incidence Rate","C53348","The frequency of new occurrences of an event during a specified time period.","Incidence Rate | incidence rate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647981","Milk Beverage","C178180","Any milk product used for human consumption, inclusive of both dairy milk and non-dairy milk.","Milk Beverage | Milk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0452714","Reduced-fat Milk","C178185","Dairy milk where milk fat is 2 percent of the total weight of the milk.","Reduced-fat Milk | 2 Percent Milk | 2 percent | 2% fat or reduced-fat milk | Reduced-fat",,,,,,,,,,,,,,,"4024038","Semi-skimmed milk",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1647990","Low-fat Milk","C178186","Dairy milk where milk fat is 1 percent of the total weight of the milk.","Low-fat Milk | 1 Percent | 1 Percent Milk | Low-fat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647906","Fat-free Milk","C178187","Dairy milk with less than 0.5% milk fat.","Fat-free Milk | Fat-free | Non-fat Milk | Nonfat Milk | Nonfat milk | Skim Milk | Skim milk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647907","Soy Milk","C178188","A plant-based drink produced by soaking and grinding soybeans, boiling the mixture, and filtering out the particulates. It is a stable emulsion of oil, water, and protein.","Soy Milk | Soy milk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647905","Lactose-Free Milk","C178189","Dairy milk that has been processed to eliminate lactose.","Lactose-Free Milk | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647996","Coffee","C178190","A drink made by passing water over roasted and ground coffee beans.","Coffee | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647903","Tea","C178191","A drink made by pouring hot water onto the dried leaves, fruit, or flowers of plants, especially the leaves of Camellia sinensis.","Tea | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647904","Vegetable","C178192","Any of various herbaceous plants or their parts cultivated for food.","Vegetable | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647921","Frying","C178199","Cooking in fat or oil.","Frying | Fried | Fry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647902","Dried Bean","C178196","Any type of bean that has been preserved by dehydration.","Dried Bean | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647899","Whole Grains","C178197","A grain of any cereal and pseudocereal that contains the endosperm, germ, and bran.","Whole Grain | Whole-Grain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647900","White Rice","C178198","The seed of the grass species Oryza sativa from which the hull and bran have been removed by milling.","White Rice | WHITE RICE | White rice",,,,,,,,,,,,,,,"4025777","White rice",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1647920","Pasta","C178202","A dough made from flour and water and sometimes egg that is made in different shapes and typically cooked in boiling water. It can be dried or used fresh.","Pasta | ",,,,,,,,,,,,,,,"4024033","Pasta",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1647918","Whole Grain Bread","C178204","A bread made from whole-grain flour.","Whole Grain Bread | Whole grain bread",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647915","White Bread","C178205","A bread made from flour that has had the bran and germ removed.","White Bread | ",,,,,,,,,,,,,,,"4028437","White bread",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1647916","Pizza","C178206","An open pie typically made of thin bread dough spread with tomato sauce and cheese. Additional topping ingredients may be used and some versions omit the tomato sauce.","Pizza | ",,,,,,,,,,,,,,,"4036898","Pizza",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1647913","Cheese","C178207","A solid food prepared from the pressed curd of milk.","Cheese | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647919","Baking","C178201","Cooking by dry heat in an oven.","Baking | Bake | Baked",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647914","Dessert","C178208","A dish served as the last course of a meal, usually a fruit or sweet dish.","Dessert | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647877","Bulk Cell Specimen","C178223","A biospecimen consisting of multiple cells intended to be analyzed as a pool.","Bulk Cell Specimen | Bulk Cell | Bulk cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647878","Bulk Nucleus Specimen","C178224","A biospecimen consisting of multiple nuclei intended to be analyzed as a pool.","Bulk Nucleus Specimen | Bulk Nucleus | Bulk nuclei",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647875","Bulk Tissue Specimen","C178225","A biospecimen either derived from a whole tissue specimen or tissue section, which may consist of heterogeneous cells or tissues.","Bulk Tissue Specimen | Bulk Tissue | Bulk tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647876","Single Cell Specimen","C178226","A biospecimen that contains the contents of a single cell.","Single Cell Specimen | Single Cell | Single Cell Sample | Single-cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647873","Single Nucleus Specimen","C178227","A biospecimen that contains the contents of a single nucleus.","Single Nucleus Specimen | Single Nucleus | Single-nuclei",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647874","NCI COVID-19 in Cancer Patients Study","C178228","A natural history study of children and adults who are receiving treatment for cancer and have tested positive for SARS Coronavirus 2. The study is designed to determine how COVID-19 affects the outcomes of patients undergoing cancer treatment and how cancer affects the severity of COVID-19.","NCI COVID-19 in Cancer Patients Study | NCCAPS | NCCAPS: NCI COVID-19 in Cancer Patients Study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647871","COVNET: Large-scale Genome-wide Association Study and Whole Genome Sequencing of COVID-19 Severity","C178229","A large genome-wide association study (GWAS) designed to identify common and rare germline genetic variants associated with susceptibility to severe or fatal COVID-19 disease.","COVNET: Large-scale Genome-wide Association Study and Whole Genome Sequencing of COVID-19 Severity | COVNET | COVNET GWAS | COVNET Large Genome-wide Association Study | COVNET Large Genome-wide Association Study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054544","calretinin","C123858","Calretinin (271 aa, ~32 kDa) is encoded by the human CALB2 gene. This protein is involved in calcium homeostasis.","Calretinin | 29 kDa Calbindin | CR | Calbindin D29k | Calbindin-D29k",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704265","Epithelial Cell Adhesion Molecule","C2461","Ep-CAM (epithelial cell adhesion molecule) is a tumor-associated antigen, 40-kDa transmembrane glycoprotein, overexpressed in many solid tumors, including carcinomas of the lung, breast, ovary, colorectum, and squamous cell carcinoma of the head and neck. The role of Ep-CAM in carcinogenesis and malignant progression is unclear, but there is increasing evidence that it modulates cell-cell interactions and that its expression correlates with the rate of cell proliferation; a promoting role of Ep-CAM in tissue invasion and metastasis has been suggested. The limited expression of Ep-CAM in normal epithelial tissues and immunogenic MHC class I and II restricted epitopes identified on Ep-CAM, provide opportunities for developing effective multiepitope cancer vaccines targeting Ep-CAM. NR-LU-10 is an IgG2b murine monoclonal antibody against Ep-CAM.","Ep-CAM | 17-1A | EGP-2 | Epithelial Cell Adhesion Molecule | GA733-2 | NR-LU-10 Antigen | NR-LU-10 antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0077505","tumor-associated antigen 72","C1269","Tumor-associated oncofetal glycoprotein 72 (TAG-72) is a high molecular weight (220-400 kD) complex expressed by a wide variety of human adenocarcinomas. This antigen is expressed by a majority of invasive ductal breast carcinomas, and most colon, pancreatic, gastric, esophageal, lung (non-small cell), ovarian and endometrial adenocarcinomas, and on normal secretory endometrium, but not on other normal tissues. It is not expressed by leukemias, lymphomas, sarcomas, mesotheliomas, melanomas or benign tumors. The monoclonal antibodies against TAG-72 have been widely employed for the immunohistochemical analysis of adenocarcinomas as well as for radioimmunoscintigraphy and radioimmunoguided surgery.","TAG-72 Antigen | Antitumor-Associated Glycoprotein 72 | CA 72-4 | CA-72-4 | CA72-4 | Cancer Antigen 72-4 | TAG-72 | TAG-72 antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647872","Homovanillic Acid to Creatinine Ratio Measurement","C178230","The determination of the ratio of homovanillic acid compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Homovanillic Acid to Creatinine Ratio Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647897","Vanillylmandelic Acid to Creatinine Ratio Measurement","C178231","The determination of the ratio of vanillylmandelic acid compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Vanillylmandelic Acid to Creatinine Ratio Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL374275","Adenovirus Encoding Human Aquaporin-1","C68932","A replication-deficient, recombinant adenovirus encoding human aquaporin-1 with potential membrane water channel activity. Upon transfection of salivary glands, adenovirus encoding human aquaporin-1 (AdhAQP1) directs human aquaporin-1 (hAQP1) expression in the apical and basolateral plasma membranes of salivary secretory cells, which may result in increased saliva production. hAQP1, a water channel protein, is one of several highly conserved water channel proteins that mediate water permeability in cells of water-transporting tissues.","Adenovirus Encoding Human Aquaporin-1 | AAV2 hAQP1 | AAV2-hAQP1 | AAV2hAQP1 | AdhAQP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039267","Talc","C854","Finely-powdered native hydrous magnesium silicate.  When administered into the pleural space, talc initiates an inflammatory reaction, resulting in adhesion of the visceral pleura to the parietal pleura and fibrosis, thereby effectively closing the pleural space and preventing further accumulation of fluid. This agent exhibits no intrinsic antineoplastic activity. (NCI04)","Talc | Sclerosol Intrapleural Aerosol | Sterile Talc Powder | Steritalc | TALC | sterile talc powder | talc",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647889","BerEp4 IHC Staining Method","C178239","An immunohistochemical technique utilizing the mouse monoclonal IgG1 antibody BerEp4, which is directed against epithelial cell adhesion molecule (EPCAM). BerEp4 specifically binds to EPCAM, a protein that is selectively expressed in most normal epithelium but not expressed in squamous epithelium and mesothelium. This staining method is used to identify certain cancers and may be used to distinguish neoplasms derived from squamous epithelium and mesothelium from other epithelial-derived neoplasms.","BerEp4 IHC Staining Method | Anti-EPCAM BerEp4 Staining Method | Anti-Epithelial Cell Adhesion Molecule BerEp4 Staining Method | Antibody BerEp4 Staining Method | Ber-EP4 Staining Method | BerEp4 | BerEp4 Antibody Staining Method | BerEp4 Histology Staining Method | BerEp4 Stain | BerEp4 Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647890","BG8 IHC Staining Method","C178240","An immunohistochemical technique utilizing the mouse monoclonal antibody BG8, which is directed against the type 2 fucosylated antigen Lewis Y (LeY). BG8 specifically binds to LeY, a blood group Lewis carbohydrate determinant expressed on certain glycolipids and glycoproteins. In healthy subjects, LeY is expressed in low levels by a few types of epithelial cells; however, it is aberrantly expressed in high levels in many carcinomas. This method is use in the detection of certain tumors, such as carcinomas of the breast, lung, and colon. Additionally, it may distinguish neoplasms derived from mesothelium from other epithelial-derived neoplasms.","BG8 IHC Staining Method | Anti-Anti-Lewis Y BG8 Staining Method | Anti-Anti-Lewis-Y BG8 Staining Method | Anti-LeY BG8 Staining Method | Antibody BG8 Staining Method | BG-8 Staining Method | BG8 | BG8 Antibody Staining Method | BG8 Staining Method | Lewis Y Antigen Blood Group 8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647892","D2-40 IHC Staining Method","C178238","An immunohistochemical technique utilizing the mouse monoclonal IgG1 antibody D2-40, which is directed against the human O-linked sialoglycoprotein podoplanin (PDPN). D2-40 specifically binds to PDPN, a protein that is selectively expressed in normal lymphatic endothelium as well as in vascular lesions of lymphatic origin. This staining method can detect aberrant expression of lymphatic epithelium, which is associated with lymphangioma, Kaposi sarcoma, epithelioid mesothelioma and seminoma.","D2-40 IHC Staining Method | Anti-PDPN D2-40 Staining Method | Anti-Podoplanin D2-40 Staining Method | Antibody D2-40 Staining Method | D2-40 | D2-40 Antibody Staining Method | D2-40 Monoclonal Antibody | D2-40 Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647988","Circulating Endothelial Cell","C178241","An endothelial cell found in the peripheral blood.","Circulating Endothelial Cell | CEC | Circulating Endothelial Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539106","CLEC12A Gene","C162376","This gene is involved in carbohydrate binding, signal transduction and the negative regulation of macrophage/granulocyte functions.","CLEC12A Gene | C-Type Lectin Domain Family 12 Member A Gene | CLEC12A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333598","Asbestos Body","C36015","No Value Exists","Asbestos Body | Asbestos bodies",,,,,,,,,,,,,,,"4236013","Deposition of asbestos fibers",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0903677","TACSTD1 protein, human","C20209","Epithelial cell adhesion molecule (314 aa, ~35 kDa) is encoded by the human EPCAM gene. This protein is involved in both cell adhesion and cellular proliferation.","Epithelial Cell Adhesion Molecule | Adenocarcinoma-Associated Antigen | Antigen CD326 | CD326 | CD326 Antigen | Cell Surface Glycoprotein Trop-1 | EGP | EGP314 | EGP40 | EPCAM | Ep-CAM | Epithelial Cell Surface Antigen | Epithelial Cellular Adhesive Molecule | Epithelial Glycoprotein | Epithelial Glycoprotein 314 | Epithelial Glycoprotein 40 | GA733-2 Antigen | Gastrointestinal Tumor-Associated Antigen 2 | KS 1/4 Antigen | KSA | KSA Glycoprotein | M4S1 Protein | MOC31 | Major Gastrointestinal Tumor-Associated Protein GA733-2 | Membrane Component, Chromosome 4, Surface Marker 1 | TACSTD1 | TROP-1 | Tumor-Associated Calcium Signal Transducer 1 | hEGP314",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334990","Non-Metastatic Mass","C36111","A benign or malignant solid pathologic process that has not spread from its site of origin to another anatomic site.","Non-Metastatic Mass | Non-Metastatic Solid Tumor | Nonmetastatic Mass",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647952","PLCOm2012 Score","C178263","The percentage probability of 6-year lung cancer risk predicated by the PLCOm2012 lung cancer model.","PLCOm2012 Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647970","Forty One","C178273","A natural number greater than forty and less than forty two and the quantity that it denotes.","Forty One | 41 | Forty-one",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL535330","44 (qualifier value)","C178274","A natural number greater than forty three and less than forty five and the quantity that it denotes.","Forty Four | 44 | Forty-four",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647968","Forty Six","C178275","A natural number greater than forty five and less than forty seven and the quantity that it denotes.","Forty Six | 46 | Forty-six",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647967","Forty Seven","C178277","A natural number greater than forty six and less than forty eight and the quantity that it denotes.","Forty Seven | 47 | Forty-seven",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086533","KSHV Inflammatory Cytokine Syndrome","C125711","A syndrome caused by Kaposi sarcoma-associated herpesvirus (KSHV) infection. It manifests with fever, weight loss, and fluid retention in the legs or abdomen. Patients are at risk of developing KSHV-related cancers including Kaposi sarcoma and lymphoma.","KSHV Inflammatory Cytokine Syndrome | KICS | Kaposi-sarcoma Associated Herpesvirus (KSHV) Inflammatory Cytokine Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1881352","Laboratory Biomarker Analysis","C64263","An assay designed to identify biomarkers useful for laboratory testing.","Laboratory Biomarker Analysis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554441","Castration-Sensitive Prostate Carcinoma","C153336","A prostate carcinoma that is sensitive to castration therapy.","Castration-Sensitive Prostate Carcinoma | CSPC | Hormone-Sensitive Prostate Carcinoma | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | mHSPC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456853","Computed Tomography Assisted Biopsy","C137909","Biopsy of tissue using computed tomography as an aid in directing a biopsy needle into the area of interest.","Computed Tomography Assisted Biopsy | CT Assisted Biopsy | CT Guided Biopsy | Computed Tomography Biopsy | Computed Tomography-Guided Needle Biopsy",,,,,,,,,,,,,,,"4082482","CT guided biopsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2825225","Cytokeratin 5/6 Immunohistochemical Expression","C80497","An immunohistochemical diagnostic test utilizing an antibody to detect both cytokeratin 5 and 6 in tissues.","Cytokeratin 5/6 Immunohistochemical Expression | CK 5/6 Expression | CK 5/6 Immunohistochemical Expression | CK5/6 | Cytokeratin 5/6 Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509002","Belumosudil","C128786","An orally bioavailable inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2; ROCK-II), with potential immunomodulating activity. Upon oral administration, belumosudil binds to and inhibits the serine/threonine kinase activity of ROCK2. This inhibits ROCK2-mediated signal transduction pathways and modulates various pro- and anti-inflammatory immune cell responses through the regulation of signal transducer and activator of transcription 3 and 5 (STAT3/STAT5) phosphorylation. This downregulates pro-inflammatory Th17 cells and increases regulatory T (Treg) cells. Belumosudil also inhibits ROCK2-mediated fibrotic processes, including stress fiber formation, myofibroblast activation and pro-fibrotic gene transcription. ROCK2 is upregulated in various diseases, including various fibrotic, neurodegenerative and autoimmune diseases.","Belumosudil | 2-[3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy]-N-(1-methylethyl)-acetamide | BELUMOSUDIL | KD 025 | KD-025 | KD025 | ROCK-II Inhibitor KD025 | ROCK2 Inhibitor KD025 | Rho-associated Coiled-coil Kinase 2 Inhibitor KD025 | SLx 2119 | SLx-2119 | SLx2119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407861","Study Eligiblity Criterion Type Indicator","C173950","An indication as to whether the criteria applied to a subject or case established that the subject should be included in or excluded from a study, trial or arm.","Study Eligiblity Criterion Type Indicator | Eligiblity Criterion Type Indicator | criterion type | criterion_type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3661604","Calcium Supplement","C137864","A dietary supplement containing the mineral calcium.","Calcium Supplement | Dietary Calcium Supplement",,,,,,,,,,,,,,,"763324","Calcium supplement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521016","Therapeutic Exchange Plasma","C133348","Plasma obtained from a patient who undergoes plasma exchange (also called therapeutic plasmapheresis).","Therapeutic Exchange Plasma | TEP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648151","Urbanized Area","C178428","A delineated geographic area encompassing residential, commercial, and other non-residential urban land uses with a residential population of 50,000 or more people and a density of 1,000 people or more per square mile.","Urbanized Area | UA | Urban",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648152","Urban Cluster","C178429","A delineated geographic area encompassing residential, commercial, and other non-residential urban land uses with a residential population of at least 2,500 but fewer than 50,000 people.","Urban Cluster | UC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0178837","rural area","C178430","A non-urbanized geographic area. 'Rural' encompasses densely settled small towns with a residential population of less than 2,500 people, more sparsely populated areas, and remote areas.","Rural Area | RA | Rural",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648585","Influenza Vaccine","C178427","A vaccine intended to prevent infections caused by influenza viruses.","Influenza Vaccine | Flu Vaccine | Flu shot | Flu vaccination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977343","Therapeutic Growth Hormone","C164163","Any agent that is chemically identical to, similar to or can be used as a replacement for endogenous human growth hormone (GH).","Therapeutic Growth Hormone | Therapeutic GH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648029","Case Classification","C178496","The designation of the type of case based on the presence of clinical criteria, epidemiologic evidence, laboratory test results, or vital records criteria.","Case Classification | Case Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648589","Probable Case","C178497","A designation of a case that indicates that an individual's medical condition is likely a case of a disease or other problem, but that it has not been fully confirmed.","Probable Case | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648030","Probable Case Based on Clinical and Epidemiologic Evidence","C178498","The designation of a case as probable based on clinical criteria and epidemiologic evidence, without confirmatory laboratory results.","Probable Case Based on Clinical and Epidemiologic Evidence | Probable Case, Clinical and Epidemiologic Evidence, No Lab Testing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648031","Probable Case Based on Laboratory Results and Clinical or Epidemiologic Evidence","C178499","The designation of a case as probable based on presumptive laboratory evidence and either clinical criteria or epidemiologic evidence.","Probable Case Based on Laboratory Results and Clinical or Epidemiologic Evidence | Probable Case, Lab Evidence and Clinical Criteria or Epidemiologic Evidence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648032","Probable Case Based on Vital Records","C178500","The designation of a case as probable based on vital records criteria, without confirmatory laboratory results.","Probable Case Based on Vital Records | Probable Case, Vital Records Criteria, No Lab Testing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950738","Post-Adjuvant Therapy","C158707","Therapy administered after to the initial therapy.","Post-Adjuvant Therapy | Post Adjuvant | Post Adjuvant Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563175","Post Neoadjuvant Therapy Sample","C156444","A biospecimen derived from a subject after treatment with a neoadjuvant therapeutic.","Post Neoadjuvant Therapy Sample | Post Neo-adjuvant Therapy Sample | Post neo-adjuvant therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0871396","Spatial Frequency","C75389","The number of occurrences of something within a given spatial interval.","Spatial Frequency | Frequency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1646825","Multisystem Inflammatory Syndrome in Adults","C178502","A rare syndrome found in adults with positive test results for SARS-CoV-2 by polymerase chain reaction or antibody assays indicating recent infection that is marked by cardiovascular, gastrointestinal, dermatologic, and neurologic symptoms without severe respiratory illness. The most common signs and symptoms that have been reported to date include fever, low blood pressure, abdominal pain, vomiting, diarrhea, neck pain, rash, chest pain, and tiredness not attributable to other infections.","Multisystem Inflammatory Syndrome in Adults | MIS-A | Multisystem Inflammatory Syndrome (MIS) | Multisystem inflammatory syndrome in adults (MIS-A)",,,,,,,,,,,,,,,"605555","Multisystem inflammatory syndrome in adults",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1648034","Time from COVID-19 Symptom Onset to Hospitalization","C178503","The amount of time that elapsed between the onset of an individual's COVID-19 symptoms and their hospital admission.","Time from COVID-19 Symptom Onset to Hospitalization | COVID-19 Symptom Onset to Hospital Admission Time | Time from COVID-19 Symptom Onset to Hospital Admission",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648035","Time from COVID-19 Diagnosis to Hospitalization","C178504","The amount of time that elapsed between an individual's COVID-19 diagnosis and their hospital admission.","Time from COVID-19 Diagnosis to Hospitalization | COVID-19 Diagnosis to Hospital Admission Time | Time from COVID-19 Diagnosis to Hospital Admission",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648036","60 Months","C178505","A period of time of sixty months.","60 Months | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648010","Biological Cryopreservation Medium","C178539","A serum- and protein-free cryopreservation medium for biological specimens that minimizes cellular damage following freezing and thawing.","Biological Cryopreservation Medium | CryoStor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648005","Carnoy's Solution","C178534","A denaturing fixative consisting of ethanol, chloroform and glacial acetic acid in a 6:3:1 ratio. It is particularly effective for the preservation of nuclei and in retaining glycogen.","Carnoy's Solution | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648007","Poloxamer","C178536","A non-ionic triblock copolymer comprised of a hydrophobic core of polyoxypropylene flanked by two hydrophilic side chains of polyoxyethylene, that may be used as a fixative and as solubilizer, emulsifier and stabilizer in drug delivery systems.","Poloxamer | Pluronic | Polyethylene-propylene Glycol Copolymer | Supronic | Tetronic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648093","Geboes Grading System","C178552","A grading scale for histological assessment of inflammation in ulcerative colitis. The score is determined by the level of abnormality in six categories: structural change, chronic inflammation, lamina propria neutrophils, neutrophils in epithelium, crypt destruction, and erosions or ulcers.","Geboes Grading System | GGS | Geboes Scale | Geboes Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648092","Mutation Load","C178551","The reduction in the average fitness of an individual or a population resulting from accumulated deleterious mutations.","Mutation Load | Mutation Burden",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648047","Promonocyte to Leukocyte Ratio Measurement","C178485","The determination of the ratio of promonocytes compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Promonocyte to Leukocyte Ratio Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039409","Tear","C33739","A fluid containing oils, mucin, and proteins, which is secreted by the lacrimal gland and cleans and lubricates the eye.","Tear | TEAR",,,,,,,,,,,,,,,"4223345","Tears",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1648039","SRSF2 Gene Mutation Negative","C178508","A genetic finding indicating that SRSF2 gene mutations have not been detected in a sample.","SRSF2 Gene Mutation Negative | SC35 Gene Mutation Negative | SFRS2 Gene Mutation Negative | SRSF2 Mutation Negative | SRSF2 Wild Type | SRSF2 Wild-Type | SRSF2 Wildtype | SRSF2 wt | Serine and Arginine Rich Splicing Factor 2 Gene Mutation Negative | Serine/Arginine-Rich Splicing Factor 2 Gene Mutation Negative | Splicing Factor, Arginine/Serine-Rich 2 Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648040","U2AF1 Gene Mutation Negative","C178509","A genetic finding indicating that U2AF1 gene mutations have not been detected in a sample.","U2AF1 Gene Mutation Negative | FP793 Gene Mutation Negative | RN Gene Mutation Negative | RNU2AF1 Gene Mutation Negative | U2 Small Nuclear RNA Auxiliary Factor 1 Gene Mutation Negative | U2AF1 Mutation Negative | U2AF1 Wild Type | U2AF1 Wild-Type | U2AF1 Wildtype | U2AF1 wt | U2AF35 Gene Mutation Negative | U2AFBP Gene Mutation | U2AFBP Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648041","ZRSR2 Gene Mutation Negative","C178510","A genetic finding indicating that ZRSR2 gene mutations have not been detected in a sample.","ZRSR2 Gene Mutation Negative | U2AF1-RS2 Gene Mutation Negative | U2AF1L2 Gene Mutation Negative | U2AF1RS2 Gene Mutation Negative | URP Gene Mutation Negative | ZC3H22 Gene Mutation Negative | ZRSR2 Mutation Negative | ZRSR2 Wild Type | ZRSR2 Wild-Type | ZRSR2 Wildtype | ZRSR2 wt | Zinc Finger CCCH-type, RNA Binding Motif and Serine/Arginine Rich 2 Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648015","SRSF2 NP_003007.2:p.P95X","C178513","A change in the amino acid residue at position 95 in the serine/arginine-rich splicing factor 2 protein where proline has been replaced by another amino acid.","SRSF2 NP_003007.2:p.P95X | NP_003007.2:p.P95X | NP_003007.2:p.Pro95Xxx | Protein PR264 P95X | Protein PR264 Pro95Xxx | SC-35 P95X | SC-35 Pro95Xxx | SR Splicing Factor 2 P95X | SR Splicing Factor 2 Pro95Xxx | SRSF2 NP_003007.2:p.Pro95Xxx | SRSF2 P95 Mutation | SRSF2 P95X | SRSF2 Pro95Xxx | SRSF2 p.P95X | SRSF2 p.Pro95Xxx | Serine/Arginine-Rich Splicing Factor 2 P95X | Serine/Arginine-Rich Splicing Factor 2 Pro95Xxx | Splicing Component, 35 kDa P95X | Splicing Component, 35 kDa Pro95Xxx | Splicing Factor SC35 P95X | Splicing Factor SC35 Pro95Xxx | Splicing Factor, Arginine/Serine-Rich 2 P95X | Splicing Factor, Arginine/Serine-Rich 2 Pro95Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648042","SF3B1 Gene Mutation Negative","C178511","A genetic finding indicating that SF3B1 gene mutations have not been detected in a sample.","SF3B1 Gene Mutation Negative | Hsh155 Gene Mutation Negative | MDS Gene Mutation Negative | PRP10 Gene Mutation | PRP10 Gene Mutation Negative | PRPF10 Gene Mutation Negative | Pre-mRNA Processing 10 Gene Mutation Negative | SAP155 Gene Mutation Negative | SF3B1 Mutation Negative | SF3B1 Wild Type | SF3B1 Wild-Type | SF3B1 Wildtype | SF3B1 wt | SF3b155 Gene Mutation Negative | Splicing Factor 3b Subunit 1 Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648017","ALCAM Positive","C178515","An indication that expression of ALCAM has been detected in a sample.","ALCAM Positive | Activated Leukocyte Cell Adhesion Molecule Positive | CD166 Antigen Positive | CD166 Positive | CD6 Ligand Positive | CD6L Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648018","EGFRvIII Negative","C178516","An indication that expression of EGFRvIII has not been detected in a sample.","EGFRvIII Negative | EGFR Variant III Negative | Epidermal Growth Factor Receptor Class III Variant Negative | Epidermal Growth Factor Receptor Variant III Negative | Epidermal Growth Factor Receptor vIII Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648021","TYRP1 Positive","C178520","An indication that expression of TYRP1 has been detected in a sample.","TYRP1 Positive | 5,6-Dihydroxyindole-2-Carboxylic Acid Oxidase Positive | CATB Positive | Catalase B Positive | GP75 Positive | Melanoma Antigen gp75 Positive | OCA3 Positive | TRP Positive | TRP-1 Positive | TRP1 Positive | TYRP Positive | Tyrosinase-Related Protein 1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648000","PMS2 Protein Variant","C178529","A variation in the amino acid sequence for mismatch repair endonuclease PMS2.","PMS2 Protein Variant | DNA Mismatch Repair Protein PMS2 Protein Variant | Mismatch Repair Endonuclease PMS2 Protein Variant | PMS1 Protein Homolog 2 Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648001","MLH1 Protein Variant","C178530","A variation in the amino acid sequence for DNA mismatch repair protein Mlh1.","MLH1 Protein Variant | COCA2 Protein Variant | DNA Mismatch Repair Protein Mlh1 Protein Variant | FCC2 Protein Variant | HNPCC2 Protein Variant | Mismatch DNA Repair Protein MLH1 Protein Variant | Mismatch Repair Protein MLH1 Protein Variant | MutL Protein Homolog 1 Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648002","MSH6 Protein Variant","C178531","A variation in the amino acid sequence for DNA mismatch repair protein Msh6.","MSH6 Protein Variant | DNA Mismatch Repair Protein Msh6 Protein Variant | G/T Mismatch Binding Protein Variant | G/T Mismatch-Binding Protein Variant | GTBP Protein Variant | GTMBP Protein Variant | MutS Homolog 6 Protein Variant | MutS-Alpha 160 kDa Subunit Protein Variant | Sperm-Associated Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648003","ATM Protein Variant","C178532","A variation in the amino acid sequence for serine-protein kinase ATM.","ATM Protein Variant | A-T Mutated Protein Variant | ATM Serine/Threonine Protein Kinase Protein Variant | Ataxia Telangiectasia Mutated Protein Variant | Ataxia Telangiectasia Protein Variant | Serine-Protein Kinase ATM Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648004","STK11 Protein Variant","C178533","A variation in the amino acid sequence for serine/threonine-protein kinase STK11.","STK11 Protein Variant | LKB1 Protein Variant | Liver Kinase B1 Protein Variant | Polarization-Related Protein LKB1 Protein Variant | Renal Carcinoma Antigen NY-REN-19 Protein Variant | Serine/Threonine Protein Kinase 11 Protein Variant | Serine/Threonine-Protein Kinase LKB1 Protein Variant | Serine/Threonine-Protein Kinase STK11 Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648006","PRSS1 Protein Variant","C178535","A variation in the amino acid sequence for trypsin-1.","PRSS1 Protein Variant | Beta-trypsin Protein Variant | Cationic Trypsinogen Protein Variant | Serine Protease 1 Protein Variant | Trypsin 1 Protein Variant | Trypsin I Protein Variant | Trypsin-1 Protein Variant | Trypsinogen 1 Protein Variant | Trypsinogen A Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648008","EPCAM Protein Variant","C178537","A variation in the amino acid sequence for epithelial cell adhesion molecule protein.","EPCAM Protein Variant | CD326 Antigen Protein Variant | CD326 Protein Variant | Ep-CAM Protein Variant | Epithelial Cell Adhesion Molecule Protein Variant | GA733-2 Protein Variant | Gastrointestinal Tumor-Associated Antigen 2 Protein Variant | KSA Glycoprotein Protein Variant | TACSTD1 Protein Variant | Tumor-Associated Calcium Signal Transducer 1 Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648009","PALB2 Protein Variant","C178538","A variation in the amino acid sequence for partner and localizer of BRCA2 protein.","PALB2 Protein Variant | FANCN Protein Variant | Partner and Localizer of BRCA2 Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648025","MCPyV Positive","C178524","An indication that Merkel cell polyomavirus has been detected in a sample.","MCPyV Positive | MCV Positive | Merkel Cell Polyomavirus Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648011","FAN1 Gene Mutation","C178540","A change in the nucleotide sequence of the FAN1 gene.","FAN1 Gene Mutation | FAN1 Mutation | FANCD2/FANCI-Associated Nuclease 1 Gene Mutation | KMIN Gene Mutation | MTMR15 Gene Mutation | Myotubularin Related Protein 15 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648087","FAAP20 Gene Mutation","C178545","A change in the nucleotide sequence of the FAAP20 gene.","FAAP20 Gene Mutation | FA Core Complex Associated Protein 20 Gene Mutation | Fanconi Anemia Core Complex Associated Protein 20 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648026","SARS Coronavirus 2 RNA Positive","C178525","An indication that SARS coronavirus 2 RNA has been detected in a sample.","SARS Coronavirus 2 RNA Positive | 2019 Novel Coronavirus RNA Positive | 2019-nCoV RNA Positive | SARS-2 RNA Positive | SARS-CoV-2 RNA Positive | SARS2 RNA Positive | Severe Acute Respiratory Syndrome Coronavirus 2 RNA Positive | nCoV RNA Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648027","Elevated HMGA2","C178526","A finding indicating elevated concentrations of HMGA2 in a sample.","Elevated HMGA2 | Elevated Activated Leukocyte Cell Adhesion Molecule | Elevated HMGA2 Expression | Elevated HMGI-C | Elevated HMGIC | Elevated High Mobility Group AT-Hook 2 | Elevated High-Mobility Group Protein HMGI-C | HMGA2 Elevated | HMGA2 Expression High | HMGA2 High Expression | High HMGA2 Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648028","TNFRSF8 Negative","C178527","An indication that expression of TNFRSF8 has not been detected in a sample.","TNFRSF8 Negative | CD30 Antigen Negative | CD30 Negative | Ki-1 Antigen Negative | Ki-1 Negative | Tumor Necrosis Factor Receptor Superfamily Member 8 Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648089","SSEA-4 Antigen","C178548","A ganglioside comprised of a glycosphingolipid (GSL) containing a terminal sialic acid residue (N-acetylneuraminic acid) that is synthesized by the enzyme ST3 beta-galactoside alpha-2,3-sialyltransferase 2 (ST3GAL2). This epitope is expressed on the surface of human embryonic stem cells and human embryonic germ cells. Its expression is turned off once these cells differentiate during development. Reactivation of expression is found on the surface of embryonal carcinoma cells.","SSEA-4 Antigen | SSEA-4 | SSEA4 | Stage Specific Embryonic Antigen 4 | Stage-Specific Embryonic Antigen 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648090","TRA-1-81 Antigen","C178549","A neuraminidase-resistant carbohydrate epitope on the keratan sulfated glycoprotein podocalyxin. This epitope is expressed on the surface of human embryonic stem cells and its expression is turned off once these cells differentiate during development. Reactivation of expression is found on the surface of embryonal carcinoma cells.","TRA-1-81 Antigen | TRA-1-81 | TRA181 | tra1-81",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648091","TRA-1-60 Antigen","C178550","A carbohydrate epitope on the keratan sulfated glycoprotein podocalyxin. This epitope is expressed on the surface of human embryonic stem cells and its expression is turned off once these cells differentiate during development. Reactivation of expression is found on the surface of embryonal carcinoma cells.","TRA-1-60 Antigen | TRA-1-60 | TRA160 | tra1-60",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648014","RET Gene Mutation Negative","C178512","A genetic finding indicating that RET gene mutations have not been detected in a sample.","RET Gene Mutation Negative | RET Mutation Negative | RET Wild Type | RET Wild-Type | RET Wildtype | RET wt | Ret Proto-Oncogene Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647631","Polysaccharides and Mucosubstances Measurement","C178047","The determination of the amount of polysaccharides and mucosubstances in a sample.","Polysaccharides and Mucosubstances Measurement | PYSACMSB | Polysaccharides and Mucosubstances",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647739","Tumor Regression Assessment","C178046","An evaluation of the presence or degree of tumor regression present in a sample.","Tumor Regression Assessment | TUMRGR | Tumor Regression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647738","Erosion and/or Ulceration Assessment","C178045","An evaluation of the presence or degree of erosion and/or ulceration present in a sample.","Erosion and/or Ulceration Assessment | EROULC | Erosion and/or Ulceration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647741","Neutrophils in Epithelium Assessment","C178044","An evaluation of the presence or degree of neutrophils in the epithelium present in a sample.","Neutrophils in Epithelium Assessment | NEUTEPI | Neutrophils in Epithelium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647740","Neutrophils in Lamina Propria Assessment","C178043","An evaluation of the presence or degree of neutrophils in the lamina propria present in a sample.","Neutrophils in Lamina Propria Assessment | Lamina Propria Neutrophils | NEUTLP | Neutrophils in Lamina Propria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647743","Chronic Inflammatory Infiltrate Assessment","C178042","An evaluation of the presence or degree of chronic inflammatory infiltrate present in a sample.","Chronic Inflammatory Infiltrate Assessment | CHINFINL | Chronic Inflammatory Infiltrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647742","Number of Biopsy Specimens Affected","C178041","The total number of biopsy specimens in which a finding has been observed.","Number of Biopsy Specimens Affected | BIAFFNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647745","Polymorphonuclear Cells in Epithelium Assessment","C178040","An evaluation of the presence or degree of polymorphonuclear cells in the epithelium present in a sample.","Polymorphonuclear Cells in Epithelium Assessment | PMNEPI | Polymorphonuclear Cells in Epithelium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647744","Infiltration of Polymorphonuclear Cells in Lamina Propria Assessment","C178039","An evaluation of the presence or degree of infiltration of polymorphonuclear cells into the lamina propria present in a sample.","Infiltration of Polymorphonuclear Cells in Lamina Propria Assessment | Infilt of PMN Cells in Lamina Propria | Infiltration of Polymorphonuclear Cells in Lamina Propria | PMNINLLP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647747","Infiltration of Mononuclear Cells in Lamina Propria Assessment","C178038","An evaluation of the presence or degree of infiltration of mononuclear cells into the lamina propria present in a sample.","Infiltration of Mononuclear Cells in Lamina Propria Assessment | Infilt of Mono Cells in Lamina Propria | Infiltration of Mononuclear Cells in Lamina Propria | MNCINLLP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647746","Architectural Changes Assessment","C178037","An evaluation of the presence or degree of tissue architectural changes present in a sample.","Architectural Changes Assessment | ARCHCHG | Architectural Changes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647749","Epithelial Damage Assessment","C178036","An evaluation of the presence or degree of epithelial damage present in a sample.","Epithelial Damage Assessment | EPIDMG | Epithelial Damage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647748","Intraepithelial Lymphocytes to Enterocytes Ratio Measurement","C178035","A relative measurement (ratio or percentage) of the lymphocytes to enterocytes within the epithelium of a biological specimen.","Intraepithelial Lymphocytes to Enterocytes Ratio Measurement | Epithelial Lymphocytes/Enterocytes | Intraepithelial Lymphocytes/Enterocytes | LYEPIENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648083","Buffer TCL","C178572","A proprietary buffer containing RNase inhibitors designed for cell lysis and the extraction and collection of mRNA from cell samples.","Buffer TCL | TCL Lysis Buffer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648084","NP40 Lysis Buffer","C178573","A detergent-based cell lysis buffer suitable for total protein extraction. The formulation helps retain the protein structure and function for enzyme assays or immunoassays.","NP40 Lysis Buffer | NP-40 Lysis Buffer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3204335","Smartphone","C175504","A mobile cellular telephone that has an integrated computer with an operating system capable of web browsing and running downloaded applications.  Smartphones typically have touchscreen interfaces, video calling capabilities, and other advanced built-in features and applications.","Smartphone | ",,,,,,,,,,,,,,,"37162239","Smartphone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0929369","Terminal Ductal Lobular Unit","C12480","The epithelial structures within the breast that produce milk during lactation.","Terminal Ductal Lobular Unit | TDLU | Terminal Ductal Lobular Units",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648303","NCI Cancer Atlas","C178610","An interactive digital atlas that enables users to generate geographic maps of cancer rates, risk factors for cancer, screening statistics, and other geographical data related to cancer. The NCI Cancer Atlas provides access to the Surveillance, Epidemiology, and End Results (SEER) Program  cancer incidence rates for 2013 to 2017, US mortality rates for 2014 to 2018, five or ten year historical mortality rates from 1970 to 2014, demographics from the American Community Survey for 2014 to 2018, screening and risk factors from the Behavioral Risk Factor Surveillance System, ultraviolet exposure by county, and cancer prevalence projected counts for 2017.","NCI Cancer Atlas | National Cancer Institute Cancer Atlas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648297","Covering Cough or Sneeze","C178632","The use of a sleeve, elbow, hand, tissue, or other body part or object to shield the nose and mouth during a cough or sneeze.","Covering Cough or Sneeze | Covering Cough/Sneeze",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648294","Limit or Avoid Gatherings Greater than 10 People","C178629","Refraining from assembling in groups that include more than 10 people.","Limit or Avoid Gatherings Greater than 10 People | Limit or avoidance of gatherings greater than 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648295","Limit or Avoid Public Places","C178630","The act of keeping away from publicly accessible gathering spaces.","Limit or Avoid Public Places | Limit or avoidance of public places (shopping, restaurants, travel)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648296","Limit Gatherings to Cohabitants","C178631","The act of limit gatherings to those people living together in the same dwelling.","Limit Gatherings to Cohabitants | Limit gatherings to those living in your house",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648309","Worried that it will Affect Health","C178620","A response indicating that an individual is worried that something will affect their health.","Worried that it will Affect Health | Worried that it will affect their health",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648310","Worried about Working at Home or Taking or Being Asked to Take Sick Leave","C178621","A response indicating that an individual is worried about working at home, taking sick leave, or being asked to take sick leave.","Worried about Working at Home or Taking or Being Asked to Take Sick Leave | Worried about working at home, taking sick leave, or being asked to take sick leave because of it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648311","Worried about Being Unable to Pay Bills","C178622","A response indicating that an individual is worried that something will make them unable to pay their bills.","Worried about Being Unable to Pay Bills | Worried that it will make them unable to pay their bills",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648291","Staying Home More than Usual","C178625","A response indicating that an individual is staying home more than they used to.","Staying Home More than Usual | Staying at home more than they are used to",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648312","Worried about Not Getting Good Medical Care if Sick","C178623","A response indicating that an individual is worried that they will not be able to get good medical care if they get sick.","Worried about Not Getting Good Medical Care if Sick | Worried that if they get sick they will not be able to get good medical care",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648293","Comfortable with Local Government Preparation","C178627","A response indicating that an individual is comfortable with the amount of preparation by the local government for their community or neighborhood.","Comfortable with Local Government Preparation | Comfortable with the amount of preparation for it in their community or neighborhood by the local government",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648313","Feeling of Being Treated Differently","C178624","A response indicating that an individual feels that they have been treated differently.","Feeling of Being Treated Differently | Feeling that they have been treated differently because of it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950611","What is the First Course Treatment Completion Measure of Success of Outcome","C158631","A question regarding the success outcome after initial first course treatment.","What is the First Course Treatment Completion Measure of Success of Outcome | Measure of success of outcome at the completion of initial first course treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0795657","Therapeutic Human Alpha-1-Proteinase Inhibitor","C82258","Human serum-derived alpha-1 proteinase inhibitor (alpha-1-antitrypsin or AAT) with immunomodulating and anti-inflammatory activity. Upon administration, AAT reduces the production of proinflammatory cytokines, such as tumor necrosis factor-alpha, interleukin (IL)-1 beta, IL-32, IL-6, and proteinase 3, and induces the production of anti-inflammatory cytokines, such as IL-10 and the IL-1 receptor antagonist IL-1RN. This agent also downregulates heparan sulfate and reduces the expansion of cytotoxic effector T cells, interferes with the maturation of dendritic cells and increases T regulatory cells. Altogether, AAT may attenuate acute graft-versus-host disease (GvHD) and may facilitate graft acceptance and survival. In addition, AAT enhances levels of cAMP and activation of cAMP-dependent protein kinase A. AAT, a 52kD protein and serine protease inhibitor, belongs to the serpin superfamily.","Alpha-1-Proteinase Inhibitor Human | .ALPHA.1-PROTEINASE INHIBITOR HUMAN | A1AT | A1PI | AAT | Alpha 1 Antitrypsin | Alpha-1 Antitrypsin | Alpha-1-Antiproteinase | Aralast | Glassia | Prolastin-C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704776","Bag","C49834","A flexible container, often with a single opening.","Bag Device | Bag",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648320","Fecal Incontinence Quality of Life Scale","C178808","A 29-question quality of life scale developed to address issues related specifically to fecal incontinence.","Fecal Incontinence Quality of Life Scale | FIQOL | Fecal Incontinence Quality of Life Scale (FIQOL)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648322","Due to Accidental Bowel Leakage","C178810","A question about how often or how strongly an individual agrees that they had certain feelings, thoughts, or experiences due to an accidental bowel leakage.","Due to Accidental Bowel Leakage | Due to accidental bowel leakage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648323","Afraid to Go Out","C178811","A question about how often an individual is afraid to go out.","Afraid to Go Out | I am afraid to go out",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648324","Avoid Visiting Friends","C178812","A question about how often an individual avoids visiting friends.","Avoid Visiting Friends | I avoid visiting friends",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648325","Avoid Staying Overnight Away from Home","C178813","A question about how often an individual avoids staying overnight away from home.","Avoid Staying Overnight Away from Home | I avoid staying overnight away from home",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648329","Difficult to Get Out and Do Things","C178817","A question about how often an individual has difficulty getting out and doing things.","Difficult to Get Out and Do Things | It is difficult for me to get out and do things like going to a movie or to church",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648198","Cut Down on How Much Eaten Before Going Out","C178819","A question about how often an individual cuts down on how much they eat before they go out.","Cut Down on How Much Eaten Before Going Out | I cut down on how much I eat before I go out",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648199","Stay Near Restroom as Much as Possible When Away from Home","C178820","A question about how often an individual, whenever away from home, tries to stay near a restroom as much as possible.","Stay Near Restroom as Much as Possible When Away from Home | Whenever I am away from home, I try to stay near a restroom as much as possible",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648202","Important to Plan Daily Activity Schedule around Bowel Pattern","C178823","A question about how often it is important for an individual to plan their daily activity schedule around their bowel pattern.","Important to Plan Daily Activity Schedule around Bowel Pattern | It is important to plan my schedule (daily activities) around my bowel pattern",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648326","Avoid Traveling","C178814","A question about how often an individual avoids traveling.","Avoid Traveling | I avoid traveling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648203","Worry about Being Unable to Reach Toilet in Time","C178824","A question about how often an individual worries about being unable to reach a toilet in time.","Worry about Being Unable to Reach Toilet in Time | I worry about not being able to get to the toilet in time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648204","Feel I Have No Control Over My Bowels","C178825","A question about how often an individual feels they have no control over their bowels.","Feel I Have No Control Over My Bowels | I feel I have no control over my bowels",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648205","Cannot Hold Bowel Movement Long Enough to Reach Bathroom","C178828","A question about how often an individual cannot hold their bowel movement long enough to reach the bathroom.","Cannot Hold Bowel Movement Long Enough to Reach Bathroom | can't hold my bowel movement long enough to get to the bathroom",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648206","Leak Stool Without Knowing It","C178829","A question about how often an individual leaks stool without knowing it.","Leak Stool Without Knowing It | I leak stool without even knowing it",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648200","Try to Prevent Bowel Accidents by Staying Very Near Bathroom","C178821","A question about how often an individual tries to prevent bowel accidents by staying very near a bathroom.","Try to Prevent Bowel Accidents by Staying Very Near Bathroom | I try to prevent bowel accidents by staying very near a bathroom",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648592","Feeling ashamed","C178830","A question about how strongly an individual agrees that they feel ashamed.","Feel Ashamed | I feel ashamed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648182","Cannot Do Many Things I Want to Do","C178834","A question about how strongly an individual agrees that they cannot do many things that they want to do.","Cannot Do Many Things I Want to Do Question | Cannot Do Many Things I Want to Do | Cannot Do Many Things I Want to Do | I cannot do many of the things I want to do",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648183","Worry about Bowel Accidents","C178835","A question about how strongly an individual agrees that they worry about bowel accidents.","Worry about Bowel Accidents | I worry about bowel accidents",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648184","Worry about Others Smelling Stool on Me","C178836","A question about how strongly an individual agrees that they worry about others smelling stool on them.","Worry about Others Smelling Stool on Me | I worry about others smelling stool on me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648207","Feel I am Not a Healthy Person","C178831","A question about how strongly an individual agrees that they feel like they are not a healthy person.","Feel I am Not a Healthy Person | I feel like I am not a healthy person",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648185","Enjoy Life Less","C178837","A question about how strongly an individual agrees that they enjoy life less.","Enjoy Life Less | I enjoy life less",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648186","Have Sex Less Often than Would Like To","C178838","A question about how strongly an individual agrees that they have sex less often than they would like to.","Have Sex Less Often than Would Like To | I have sex less often than I would like to",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648208","Feel Different from Other People","C178832","A question about how strongly an individual agrees that they feel different from other people.","Feel Different from Other People | I feel different from other people",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648187","Possibility of Bowel Accidents is Always On My Mind","C178839","A question about how strongly an individual agrees that the possibility of bowel accidents is always on their mind.","Possibility of Bowel Accidents is Always On My Mind | The possibility of bowel accidents is always on my mind",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648327","Avoid Traveling by Plane or Train","C178815","A question about how strongly an individual agrees that they avoid traveling by plane or train.","Avoid Traveling by Plane or Train | I avoid traveling by plane or train",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648328","Avoid Going Out to Eat","C178816","A question about how strongly an individual agrees that they avoid going out to eat.","Avoid Going Out to Eat | I avoid going out to eat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648201","Specifically Locate Bathrooms When Going Someplace New","C178822","A question about how strongly an individual agrees that they specifically locates where bathrooms are when going someplace new.","Specifically Locate Bathrooms When Going Someplace New | When I go someplace new, I specifically locate where the bathrooms are",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648188","Have Felt So Sad, Discouraged, Hopeless, or Had So Many Problems Wondered if Anything was Worthwhile","C178840","A question about whether an individual felt so sad, discouraged, hopeless or had so many problems that they wondered if anything was worthwhile.","Have Felt So Sad, Discouraged, Hopeless, or Had So Many Problems Wondered if Anything was Worthwhile | During the past month, have you felt so sad, discouraged, hopeless, or had so many problems that you wondered if anything was worthwhile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648591","ANCHOR Health-Related Symptom Index","C179028","A 25-item self-report questionnaire that utilizes a five-point rating scale to assess the physical and psychological symptoms and physical impact of anal cancer experienced in the past seven days.","ANCHOR Health-Related Symptom Index | ANCHOR | ANCHOR Health-Related Symptom Index (a-HRSI) | a-HRSI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648558","Have Anal Pain","C179029","A question about whether an individual has or had anal pain.","Have Anal Pain | I have anal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648559","Have Pain Other than Anal Pain","C179030","A question about whether an individual has or had pain other than anal pain.","Have Pain Other than Anal Pain | I have pain other than anal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648560","Have Pain During Bowel Movements","C179031","A question about whether an individual has or had pain during bowel movements.","Have Pain During Bowel Movements | I have pain during bowel movements",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648562","Have Bleeding from Anus","C179033","A question about whether an individual has or had bleeding from the anus.","Have Bleeding from Anus | I have bleeding from the anus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648563","Have Itching in or Around Anus","C179035","A question about whether an individual has or had itching in or around anus.","Have Itching in or Around Anus | Have Perianal Itching | I have itching in or around the anus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648564","Have Discharge or Wetness in Anal Area","C179036","A question about whether an individual has or had discharge or wetness in their anal area.","Have Discharge or Wetness in Anal Area | Have Perianal Discharge or Wetness | I have discharge (wetness in my anal area)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648565","Have Burning Sensations in Anal Area","C179037","A question about whether an individual has or had burning sensations in the anal area.","Have Burning Sensations in Anal Area | Have Perianal Burning | I have burning sensations in the anal area",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648566","Have Urgency for Bowel Movements","C179038","A question about whether an individual has or had urgency for bowel movements.","Have Urgency for Bowel Movements | Have Defecation Urgency | Have Fecal Urgency | I have urgency for bowel movements",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648567","Have Problems with Physical Ability to Move Around","C179039","A question about whether an individual has or had problems with their physical ability to move around.","Have Problems with Physical Ability to Move Around | I have problems with my physical ability to move around",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648568","Have Problems with Sitting","C179040","A question about whether an individual has or had problems with sitting.","Have Problems with Sitting | I have problems with my sitting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648569","Have Problems Completing Daily Household Chores","C179041","A question about whether an individual has or had problems completing daily household chores.","Have Problems Completing Daily Household Chores | I have problems completing daily household chores (e.g., cleaning, cooking, laundry, house maintenance)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648570","Have Problems Taking Care of Myself","C179042","A question about whether an individual has or had problems taking care of themselves.","Have Problems Taking Care of Myself | I have problems taking care of myself (e.g., bathing, dressing, shaving)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648542","Have Problems Participating in Leisure Activities","C179043","A question about whether an individual has or had problems participating in leisure activities.","Have Problems Participating in Leisure Activities Question | Have Problems Participating in Leisure Activities | Have Problems Participating in Leisure Activities | I have problems participating in leisure activities (e.g., watching television, relaxing)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648543","Have Problems Participating in Social Activities","C179044","A question about whether an individual has or had problems participating in social activities.","Have Problems Participating in Social Activities Question | Have Problems Participating in Social Activities | Have Problems Participating in Social Activities | I have problems participating in social activities (e.g., going out to eat, visiting friends)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648544","Have Problems with Work Productivity","C179045","A question about whether an individual has or had problems with work productivity.","Have Problems with Work Productivity | I have problems with work productivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648545","Have Decreased Enjoyment of Anal Sexual Activity","C179046","A question about whether an individual has or had decreased enjoyment of anal sexual activity.","Have Decreased Enjoyment of Anal Sexual Activity | I have a decreased enjoyment of anal sexual activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648546","Have Decreased Enjoyment of Sexual Activity Other than Anal Activity","C179047","A question about whether an individual has or had decreased enjoyment of forms of sexual activity other than anal activity.","Have Decreased Enjoyment of Sexual Activity Other than Anal Activity | I have a decreased enjoyment of forms of sexual activity other than anal sexual activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648547","Have Decreased Desire for Anal Sexual Activity","C179048","A question about whether an individual has or had decreased desire for anal sexual activity.","Have Decreased Desire for Anal Sexual Activity | I have a decreased desire for anal sexual activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648548","Have Decreased Desire for Sexual Activity Other than Anal Sexual Activity","C179049","A question about whether an individual has or had decreased desire for forms of sexual activity other than anal sexual activity.","Have Decreased Desire for Sexual Activity Other than Anal Sexual Activity | I have a decreased desire for forms of sexual activity other than anal sexual activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648549","Worry about My Condition Worsening","C179050","A question about whether an individual worries or worried about their condition worsening.","Worry about My Condition Worsening | I am worried about my condition getting worse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648550","Have Problems with Intimate Relationships","C179051","A question about whether an individual has or had problems with their intimate relationships.","Have Problems with Intimate Relationships | I have problems with my intimate relationships",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647626","Lipase Unit","C178059","A dosing unit based on lipase activity.","Lipase Unit | Lipase Units | {Lipase Units}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647625","Lipase Units per Kilogram","C178058","A dosing unit based on lipase activity per kilogram of body mass.","Lipase Units per Kilogram | Lipase Units/kg | {Lipase Units}/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226446","Common Palmar Digital Artery","C52744","Three arteries arising from the superficial palmar arch which run distally on the second, third and fourth lumbricals muscles to the interdigital clefts where each artery then separates into two proper palmar digital arteries.","Common Palmar Digital Artery | COMMON PALMAR DIGITAL ARTERY",,,,,,,,,,,,,,,"4279710","Structure of common palmar digital artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1647774","Perivesical Region","C178003","The region of the body surrounding the urinary bladder.","Perivesical Region | PERIVESICAL REGION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647776","Cervicovaginal Region","C178002","The region of the body that comprises the uterine cervix and vagina.","Cervicovaginal Region | CERVICOVAGINAL REGION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475433","Ileocecal Junction","C178001","The segment of the gastrointestinal tract where the terminal ileum transitions to the cecum, and where the ileocecal sphincter regulates the movement of chyme from the small intestine into the large intestine.","Ileocecal Junction | ILEOCECAL JUNCTION | Ileocecal Region",,,,,,,,,,,,,,,"4136268","Ileocecal junction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1647778","Hand Digit 1 Artery","C178000","An artery that supplies blood to the thumb; either the ulnopalmar, radiopalmar, ulnodorsal, or radiodorsal digital artery to the thumb, or the princeps pollicis artery.","Hand Digit 1 Artery | HAND DIGIT 1 ARTERY | Thumb Artery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647777","Hand Digit 4 Artery","C177999","An artery that supplies blood to the ring finger, either the ulnar or radial proper digital artery.","Hand Digit 4 Artery | HAND DIGIT 4 ARTERY | Ring Finger Artery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647754","Hand Digit 3 Artery","C177998","An artery that supplies blood to the middle finger, either the ulnar or radial proper digital artery.","Hand Digit 3 Artery | HAND DIGIT 3 ARTERY | Middle Finger Artery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647753","Hand Digit 5 Artery","C177997","An artery that supplies blood to the little finger, either the ulnar or radial proper digital artery.","Hand Digit 5 Artery | HAND DIGIT 5 ARTERY | Little Finger Artery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647755","Hand Digit 2 Artery","C177996","An artery that supplies blood to the index finger, either the radial artery of the index finger or the ulnar proper digital artery.","Hand Digit 2 Artery | HAND DIGIT 2 ARTERY | Index Finger Artery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0559907","Penile Artery","C177995","Any of the arteries that supply blood to the penis, including the common penile artery, and the bulbourethral, dorsal, and cavernosal branches of the common penile artery.","Penile Artery | PENILE ARTERY",,,,,,,,,,,,,,,"4106213","Structure of penile artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1647756","Palmar Digital Artery","C177994","A type of artery that supplies blood to the fingers and includes the common palmar digital arteries, the dorsal digital arteries of the hand, and the proper palmar digital arteries.","Palmar Digital Artery | PALMAR DIGITAL ARTERY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226435","Digital Artery","C177918","A type of artery that supplies blood to the fingers and toes. In the hand, the digital arteries include the common palmar digital arteries that arise from the superficial palmar arch, the proper palmar digital arteries that are branches of the common palmar digital arteries and occasionally have dorsal branches distal to the proximal interphalangeal joints, and the dorsal digital arteries that are branches of the dorsal metacarpal arteries. In the foot, the digital arteries include the plantar digital arteries that arise from the plantar arch and the dorsal digital arteries that are branches of the dorsal metatarsal arteries.","Digital Artery | DIGITAL ARTERY",,,,,,,,,,,,,,,"4185449","Digital artery structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1647685","Walnut Antigen IgE Antibody Measurement","C177961","The determination of the amount of walnut antigen IgE antibody in a sample.","Walnut Antigen IgE Antibody Measurement | C177961 | Juglans Species Nut Antigen IgE Antibody | Walnut Antigen IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647684","Hazelnut Antigen IgE Antibody Measurement","C177960","The determination of the amount of hazelnut antigen IgE antibody in a sample.","Hazelnut Antigen IgE Antibody Measurement | C177960 | Corylus Species Nut Antigen IgE Antibody | Hazelnut Antigen IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647687","Triticum Species Antigen IgE Antibody Measurement","C177959","The determination of the amount of triticum species antigen IgE antibody in a sample.","Triticum Species Antigen IgE Antibody Measurement | C177959 | Triticum Species Antigen IgE Antibody | Wheat Antigen IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647686","Cashew Antigen IgE Antibody Measurement","C177958","The determination of the amount of cashew antigen IgE antibody in a sample.","Cashew Antigen IgE Antibody Measurement | Anacardium occidentale Nut Antigen IgE Antibody | C177958 | Cashew Antigen IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266330","2-Methylcitrate Measurement","C177957","The determination of the amount of 2-methylcitrate in a sample.","2-Methylcitrate Measurement | 2-Methylcitrate | 2-Methylcitric Acid | MCA | MCA2 | Methylcitrate | Methylcitric Acid",,,,,,,,,,,,,,,"4008270","2-Methylcitrate measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1647688","Kidney Injury Molecule-1/Creatinine Ratio Measurement","C177955","The determination of the ratio of kidney injury molecule-1 compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Kidney Injury Molecule-1/Creatinine Ratio Measurement | KIM1CRT | Kidney Injury Molecule-1/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266394","Alpha-Hydroxyalprazolam Measurement","C177954","The determination of the amount of alpha-hydroxyalprazolam in a sample.","Alpha-Hydroxyalprazolam Measurement | Alpha-Hydroxyalprazolam | HALPRZLA",,,,,,,,,,,,,,,"4006867","alpha-Hydroxyalprazolam measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1647689","Noroxycodone Measurement","C177953","The determination of the amount of noroxycodone in a sample.","Noroxycodone Measurement | NOXYCDN | Noroxycodone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647691","Norhydrocodone Measurement","C177952","The determination of the amount of norhydrocodone in a sample.","Norhydrocodone Measurement | NHYDCDN | Norhydrocodone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647690","Maternal and Fetal Fibronectin Measurement","C177951","The determination of the amount of maternal and fetal fibronectin in a sample.","Maternal and Fetal Fibronectin Measurement | FBNCTMFT | Fibronectin, Maternal + Fetal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647695","Brexpiprazole Measurement","C177973","The determination of the amount of brexpiprazole in a sample.","Brexpiprazole Measurement | BRXPIPZL | Brexpiprazole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647697","Risperidone and 9-Hydroxyrisperidone Measurement","C177971","The determination of the amount of risperidone and 9-hydroxyrisperidone in a sample.","Risperidone and 9-Hydroxyrisperidone Measurement | RSOH9RS | Risperidone+9-Hydroxyrisperidone | Risperidone+Paliperidone | Risperidone+Paliperidone Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266392","9-Hydroxyrisperidone Measurement","C177970","The determination of the amount of 9-hydroxyrisperidone in a sample.","9-Hydroxyrisperidone Measurement | 9-Hydroxyrisperidone | OH9RS | Paliperidone | Paliperidone Measurement",,,,,,,,,,,,,,,"4006866","9-Hydroxyrisperidone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266731","Risperidone Measurement","C177969","The determination of the amount of risperidone in a sample.","Risperidone Measurement | RSPDN | Risperidone",,,,,,,,,,,,,,,"4007981","Risperidone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202359","Chlorpromazine Measurement","C177968","The determination of the amount of chlorpromazine in a sample.","Chlorpromazine Measurement | CHLRPMZN | Chlorpromazine",,,,,,,,,,,,,,,"4184043","Chlorpromazine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1647698","N-Desmethylolanzapine Measurement","C177967","The determination of the amount of N-desmethylolanzapine in a sample.","N-Desmethylolanzapine Measurement | DMO | Desmethylolanzapine | N-Desmethylolanzapine | NDMOLZPN | Norolanzapine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266674","Olanzapine Measurement","C177966","The determination of the amount of olanzapine in a sample.","Olanzapine Measurement | OLANZAPN | Olanzapine",,,,,,,,,,,,,,,"4007018","Olanzapine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1997945","Quetiapine Measurement","C177965","The determination of the amount of quetiapine in a sample.","Quetiapine Measurement | QUETIAPN | Quetiapine",,,,,,,,,,,,,,,"4327879","Measurement of quetiapine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0919241","Haloperidol Measurement","C177964","The determination of the amount of haloperidol in a sample.","Haloperidol Measurement | HALOPRDL | Haloperidol",,,,,,,,,,,,,,,"4096080","Haloperidol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1647683","Lurasidone Measurement","C177963","The determination of the amount of lurasidone in a sample.","Lurasidone Measurement | LURASIDN | Lurasidone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647682","Osteopontin to Creatinine Ratio Measurement","C177962","The determination of the ratio of osteopontin compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Osteopontin to Creatinine Ratio Measurement | OPNCRT | Osteopontin/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202486","Thioridazine Measurement","C177978","The determination of the amount of thioridazine in a sample.","Thioridazine Measurement | THIORDZN | Thioridazine",,,,,,,,,,,,,,,"4272969","Thioridazine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524172","Loxapine Measurement","C177977","The determination of the amount of loxapine in a sample.","Loxapine Measurement | LOXAPN | Loxapine",,,,,,,,,,,,,,,"4020385","Loxapine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524281","Thiothixene Measurement","C177976","The determination of the amount of thiothixene in a sample.","Thiothixene Measurement | THIOTHXN | Thiothixene",,,,,,,,,,,,,,,"4022513","Thiothixene measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1647694","Cariprazine Measurement","C177975","The determination of the amount of cariprazine in a sample.","Cariprazine Measurement | CARIPRZN | Cariprazine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647696","Aripiprazole Measurement","C177974","The determination of the amount of aripiprazole in a sample.","Aripiprazole Measurement | ARPIPZL | Aripiprazole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202493","Trifluoperazine Measurement","C177982","The determination of the amount of trifluoperazine in a sample.","Trifluoperazine Measurement | TRIFLPZN | Trifluoperazine",,,,,,,,,,,,,,,"4119113","Trifluoperazine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266630","Molindone Measurement","C177981","The determination of the amount of molindone in a sample.","Molindone Measurement | MOLINDN | Molindone",,,,,,,,,,,,,,,"4006353","Molindone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202387","Fluphenazine Measurement","C177980","The determination of the amount of fluphenazine in a sample.","Fluphenazine Measurement | FLUPHZN | Fluphenazine",,,,,,,,,,,,,,,"4137786","Fluphenazine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524177","Mesoridazine Measurement","C177979","The determination of the amount of mesoridazine in a sample.","Mesoridazine Measurement | MESORDZN | Mesoridazine",,,,,,,,,,,,,,,"4019681","Mesoridazine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1648530","Multiphasic Contrast-enhanced MRI","C179062","Multiphasic magnetic resonance imaging performed prior to and after contrast administration.","Multiphasic Contrast-enhanced MRI | MCE-MRI | Multiphase Contrast-enhanced MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648531","Multiphasic Unenhanced MRI","C179063","Multiphasic magnetic resonance imaging performed without contrast administration.","Multiphasic Unenhanced MRI | Multiphase Unenhanced MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648532","Delayed-phase Contrast Enhancement Magnetic Resonance Imaging","C179064","A magnetic resonance (MR) imaging technique used to enhance the capability of detecting anomalies by administering intravenous contrast then allowing for a delay of several minutes before imaging in order to maximize the contrast difference between normal and affected tissue. Imaging too early after contrast administration may lead to overestimation of affected tissue due to insufficient washout of contrast whereas imaging too late may lead to excessive washout and poor signal-to-noise ratio.","Delayed-phase Contrast Enhancement Magnetic Resonance Imaging | Delayed Phase Contrast Enhancement Magnetic Resonance Imaging | Late Phase Contrast Injection | Late Phase Contrast Injection Magnetic Resonance Imaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647763","Iloperidone Measurement","C177984","The determination of the amount of iloperidone in a sample.","Iloperidone Measurement | ILOPRDN | Iloperidone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4076660","Prochlorperazine Measurement","C177983","The determination of the amount of prochlorperazine in a sample.","Prochlorperazine Measurement | PCHLRPZN | Prochlorperazine",,,,,,,,,,,,,,,"37016752","Prochlorperazine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1647983","Steroid Sulfatase Measurement","C177993","The determination of the amount of steroid sulfatase in a sample.","Steroid Sulfatase Measurement | STS | Steroid Sulfatase | Steryl-sulfatase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647758","Dipeptidyl Peptidase-4 Measurement","C177992","The determination of the amount of dipeptidyl peptidase-4 in a sample.","Dipeptidyl Peptidase-4 Measurement | DPP4 Measurement | DPPIV | Dipeptidyl Peptidase-4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647757","Metanephrine and Normetanephrine Excretion Rate","C177991","The determination of the amount of metanephrine and normetanephrine being excreted in a biological specimen over a defined period of time.","Metanephrine and Normetanephrine Excretion Rate | MTNMTEXR | Metanephrine+Normetanephrine Excr Rate | Metanephrine+Normetanephrine Excretion Rate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647760","Metanephrine and Normetanephrine Measurement","C177990","The determination of the amount of metanephrine and normetanephrine   in a sample.","Metanephrine and Normetanephrine Measurement | MTNNMTN | Metanephrine+Normetanephrine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647759","Sonic Hedgehog Measurement","C177989","The determination of the amount of sonic hedgehog in a sample.","Sonic Hedgehog Measurement | SHH | Sonic Hedgehog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524232","Perphenazine Measurement","C177988","The determination of the amount of perphenazine in a sample.","Perphenazine Measurement | PERPHNZN | Perphenazine",,,,,,,,,,,,,,,"4022500","Perphenazine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266704","Pimozide Measurement","C177987","The determination of the amount of pimozide in a sample.","Pimozide Measurement | PIMOZIDE | Pimozide",,,,,,,,,,,,,,,"4006670","Pimozide measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1647762","Ziprasidone Measurement","C177986","The determination of the amount of ziprasidone in a sample.","Ziprasidone Measurement | ZIPRASDN | Ziprasidone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647761","Asenapine Measurement","C177985","The determination of the amount of asenapine in a sample.","Asenapine Measurement | ASENAPN | Asenapine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647675","Dipstick Measurement Method","C178142","A measurement methodology in which a dipstick device is used to detect the presence of an analyte in a liquid by producing a color change.","Dipstick Measurement Method | DIPSTICK MEASUREMENT METHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647752","International Reading Speed Text Test","C178032","A standardized set of ten equivalent paragraphs of text, based on everyday life reading demands with equivalent levels of difficulty, that is used to provide repeat assessments of reading performance for a wide range of subjects. It is available in multiple languages.","International Reading Speed Text Test | INTERNATIONAL READING SPEED TEXT TEST | IReST Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3872568","Rapid Immunoassay","C178031","An immunoassay where results can be generated immediately or within minutes from antibody/antigen interactions with an analyte of interest in a biological specimen with little or no sample processing.","Rapid Immunoassay | RAPID IMMUNOASSAY",,,,,,,,,,,,,,,"45769446","Rapid immunoassay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1647728","Ligand Binding Assay","C178030","An immunoassay that utilizes the interactions between two molecules, or the binding of molecules to antibodies, to detect and quantify analytes of interest.","Ligand Binding Assay | LIGAND BINDING ASSAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647989","Self Assessment","C178029","The evaluation of oneself or one's actions or performance without external input.","Self Assessment | SELF ASSESSMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647730","Competitive Enzyme-linked Immunosorbent Assay","C178028","A type of ELISA assay that uses a reference antigen to competitively bind labeled antibody against an antigen of interest. The strength of the signal interference caused by antibody bound to the reference antigen is used to determine the concentration of the antigen of interest.","Competitive Enzyme-linked Immunosorbent Assay | COMPETITIVE ELISA | Competitive ELISA | Competitive Immunoassay | Inhibition ELISA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647729","Indirect Binding Electrochemiluminescence Immunoassay","C178027","A type of electrochemiluminescence assay that utilizes primary and secondary antibodies in a two-step binding process.","Indirect Binding Electrochemiluminescence Immunoassay | INDIRECT BINDING ELECTROCHEMILUMINESCENCE IMMUNOASSAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647977","Intracellular Cytokine Stain Flow Cytometric Assay","C178026","A technique that is used with flow cytometry to measure cytokine production in isolated cells. Cells are stimulated with an antigen or mitogen, and cytokine secretion is blocked using protein transport inhibitors. The cells are then stained with fluorochrome labeled monoclonal antibodies that target surface markers, fixed and permeabilized, and stained with fluorochrome labeled anti-cytokine monoclonal antibodies prior to analysis by flow cytometry.","Intracellular Cytokine Stain Flow Cytometric Assay | ICS | INTRACELLULAR CYTOKINE STAIN FLOW CYTOMETRIC ASSAY | Intracellular Cytokine Staining",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647731","Van de Kamer Titration Method","C178025","A chemical titration method described by van de Kamer, et al. in 1949 in which fecal fat is quantitatively measured by conversion of fecal lipids into fatty acids through saponification with ethanolic potassium hydroxide, release of the free fatty acids by the addition of hydrochloric acid and extraction into ether, and titration of the fatty acids against sodium hydroxide.","Van de Kamer Titration Method | VAN DE KAMER TITRATION METHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647733","Resting Functional Magnetic Resonance Imaging","C178024","A type of functional magnetic resonance imaging that is performed on an organ or brain tissue in the absence of a stimulus or task.","Resting Functional Magnetic Resonance Imaging | RESTING FUNCTIONAL MRI | Resting Functional MRI | Resting State Functional MRI | Resting fMRI | rs-fMRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647732","Task Functional Magnetic Resonance Imaging","C178023","A type of functional MRI that images dynamic changes in brain tissue while the subject performs a task or experiences a sensory stimulus designed to target specific cognitive processes.","Task Functional Magnetic Resonance Imaging | TASK FUNCTIONAL MRI | Task Functional MRI | Task fMRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471828","Computed Tomography Perfusion Imaging","C116442","An application of CT imaging used to assess the quality of blood flow to an organ or tissue.","Computed Tomography Perfusion Imaging | COMPUTED TOMOGRAPHY PERFUSION | CT Perfusion | CTP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647677","Partial Thromboplastin Time","C178140","A measurement of the length of time that it takes for clotting to occur when no activating reagents are added to a biological specimen. The test is partial due to the absence of tissue factor (Factor III) from the reaction mixture.","Partial Thromboplastin Time | PTT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648459","Multiphasic Magnetic Resonance Imaging","C179164","Magnetic resonance imaging that captures lesion enhancement data during combinations of non-contrast or pre-contrast, arterial, venous, and delayed imaging sequential time ranges.","Multiphasic Magnetic Resonance Imaging | Multiphase MRI | Multiphase Magnetic Resonance Imaging | Multiphasic MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL382208","Arterial-phase Contrast Enhancement Magnetic Resonance Imaging","C179165","MR imaging post-injection of a contrast agent when full enhancement of hepatic arteries is present, but antegrade enhancement of hepatic veins is absent.","Arterial-phase Contrast Enhancement Magnetic Resonance Imaging | Arterial Phase | Arterial Phase Contrast Enhancement Magnetic Resonance Imaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648587","Venous-phase Contrast Enhancement Magnetic Resonance Imaging","C179166","MR imaging post-injection of a contrast agent when antegrade enhancement of hepatic veins is present.","Venous-phase Contrast Enhancement Magnetic Resonance Imaging | Venous Phase | Venous Phase Contrast Enhancement Magnetic Resonance Imaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514310","MSH2 Protein Variant","C131462","A variation in the amino acid sequence for DNA mismatch repair protein Msh2.","MSH2 Protein Variant | DNA Mismatch Repair Protein Msh2 Protein Variant | MutS Homolog 2 Protein Variant | MutS Protein Homolog 2 Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648462","International Pediatric Non-Hodgkin Lymphoma Response Criteria","C179170","A consensus response criteria for pediatric non-Hodgkin lymphoma, based on the change in the sum of the products of the largest diameter and the perpendicular diameter (SPD) for each tumor mass, up to 6; and [18F] fluorodeoxyglucose (FDG) uptake for metabolic response assessment.","International Pediatric Non-Hodgkin Lymphoma Response Criteria | International Pediatric NHL Response Criteria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969410","MET Gene Mutation Negative","C160401","A genetic finding indicating that MET gene mutations have not been detected in a sample.","MET Gene Mutation Negative | HGFR Gene Mutation Negative | Hepatocyte Growth Factor Receptor Gene Mutation Negative | MET Mutation Negative | MET Proto-Oncogene, Receptor Tyrosine Kinase Gene Mutation Negative | MET Wild-Type | MET Wildtype | MET wt | Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Gene Mutation Negative | No mutation detected | c-MET Gene Mutation Negative | c-Met Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1851465","EWSR1/ERG Fusion Gene","C99211","A fusion gene that results from a chromosomal translocation t(21;22)(q21;q12) which fuses the EWSR1 gene with the ERG gene. This rearrangement is associated with both Ewing tumor/peripheral primitive neuroectodermal tumor and desmoplastic small round cell sarcoma.","EWSR1/ERG Fusion Gene | ERG-EWSR1 Fusion Gene | ERG/EWS Fusion Gene | EWS RNA-Binding Protein 1-ETS Transcription Factor ERG Fusion Gene | EWS RNA-Binding Protein 1/ETS Transcription Factor ERG Fusion Gene | EWS-ERG Fusion Gene | EWS/ERG Fusion Gene | EWSR1-ERG | EWSR1-ERG Fusion Gene | EWSR1::ERG Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648442","Solicit","C179173","To request something.","Solicit | Solicited | Soliciting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648444","Solicited Adverse Event","C179175","An adverse event that is reported by a healthcare professional, consumer, or patient through an organized data collection system.","Solicited Adverse Event | Solicited | Solicited AE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648445","Unsolicited Adverse Event","C179176","An adverse event that is voluntarily reported by a healthcare professional, consumer, or patient outside of an organized data collection system.","Unsolicited Adverse Event | Unsolicited | Unsolicited AE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647629","Target Indicator","C178053","An indication as to whether a target tumor, lesion, or site of disease is present.","Target Indicator | TIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647987","Percent Change Nadir in Sum of Volume","C178054","The current sum of volumes minus the lowest sum of volumes previously recorded divided by the lowest sum of volumes previously recorded, multiplied by 100.","Percent Change Nadir in Sum of Volume | PCNSV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647623","Calf Circumference","C178060","A circumferential measurement of the lower leg in the region of the calf at the widest point.","Calf Circumference | CALFCIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647737","Chlamydia Pneumoniae Measurement","C178016","The determination of the amount of Chlamydia pneumoniae in a sample.","Chlamydia Pneumoniae Measurement | CPN | Chlamydia pneumoniae",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647736","Bordetella Parapertussis Measurement","C178015","The determination of the amount of Bordetella parapertussis in a sample.","Bordetella Parapertussis Measurement | BPA | Bordetella parapertussis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647765","Human Parainfluenza Virus 4 Measurement","C178014","The determination of the amount of Human Parainfluenza Virus 4 in a sample.","Human Parainfluenza Virus 4 Measurement | HPIV-4 Measurement | HPIV4 | Human Parainfluenza Virus 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647764","Human Parainfluenza Virus 3 Measurement","C178013","The determination of the amount of Human Parainfluenza Virus 3 in a sample.","Human Parainfluenza Virus 3 Measurement | HPIV-3 Measurement | HPIV3 | Human Parainfluenza Virus 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647767","Human Parainfluenza Virus 2 Measurement","C178012","The determination of the amount of Human Parainfluenza Virus 2 in a sample.","Human Parainfluenza Virus 2 Measurement | HPIV-2 Measurement | HPIV2 | Human Parainfluenza Virus 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647766","Human Metapneumovirus Measurement","C178011","The determination of the amount of Human Metapneumovirus in a sample.","Human Metapneumovirus Measurement | HMPV | Human Metapneumovirus | hMPV Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647769","Human Coronavirus OC43 Measurement","C178010","The determination of the amount of Human Coronavirus OC43 in a sample.","Human Coronavirus OC43 Measurement | HCOVOC43 | Human Coronavirus OC43",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647768","Human Coronavirus NL63 Measurement","C178009","The determination of the amount of Human Coronavirus NL63 in a sample.","Human Coronavirus NL63 Measurement | HCOVNL63 | Human Coronavirus NL63",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647771","Human Coronavirus HKU1 Measurement","C178008","The determination of the amount of Human Coronavirus HKU1 in a sample.","Human Coronavirus HKU1 Measurement | HCOVHKU1 | Human Coronavirus HKU1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647770","Human Coronavirus 229E Measurement","C178007","The determination of the amount of Human Coronavirus 229E in a sample.","Human Coronavirus 229E Measurement | HCOV229E | Human Coronavirus 229E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647773","SARS-CoV-2 Spike Protein Antibody Measurement","C178006","The determination of the amount of SARS-CoV-2 spike protein antibody in a sample.","SARS-CoV-2 Spike Protein Antibody Measurement | Anti-SARS-CoV-2 S Protein Antibody Measurement | Anti-SARS-CoV-2 Spike Protein Antibody Measurement | Anti-Spike Protein SARS-CoV-2 Antibody Measurement | SAR2SPAB | SARS-CoV-2 S Protein Antibody | SARS-CoV-2 S Protein Antibody Measurement | SARS-CoV-2 Spike Protein Antibody | Spike Protein SARS-CoV-2 Antibody Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647772","SARS-CoV-2 Nucleocapsid Protein Antibody Measurement","C178005","The determination of the amount of SARS-CoV-2 nucleocapsid protein antibody in a sample.","SARS-CoV-2 Nucleocapsid Protein Antibody Measurement | SAR2NPAB | SARS-CoV-2 N Protein Antibody | SARS-CoV-2 Nucleocapsid Protein Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647775","Pathological Diagnosis","C178004","Diagnosis based on a pathological assessment.","Pathological Diagnosis | PATHOLOGICAL DIAGNOSIS | Pathologic diagnosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647751","Robarts Histopathology Index Score","C178034","A score developed by Mosli et al. (2017) and assigned based on the histologic evaluation of disease activity in ulcerative colitis. (Mahmoud H Mosli, Brian G Feagan, Guangyong Zou, et al. Development and validation of a histological index for UC. Gut. 2017 Jan;66(1):50-58.)","Robarts Histopathology Index Score | RHI SCORE | RHI Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647750","Global Histologic Disease Activity Score","C178033","A score originally developed by D'Haens et al. (1998) and assigned based on the histologic evaluation of acute and chronic inflammatory changes, epithelial damage, and the extent of inflammation in Crohn's disease mucosal biopsy specimens, according to the Global Histologic Disease Activity Score. (G R D'Haens, K Geboes, M Peeters, F Baert, F Penninckx, P Rutgeerts. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998 Feb;114(2):262-7).","Global Histologic Disease Activity Score | GHAS SCORE | GHAS Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647735","Appendicular Skeletal Muscle Mass","C178018","A measurement of the mass of the muscles of the arms and legs.","Appendicular Skeletal Muscle Mass | ASMM | ASMMASS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647734","Skeletal Muscle Mass","C178017","A measurement of the mass of all skeletal muscle in the body.","Skeletal Muscle Mass | SMMASS | Skeletal Muscle Mass Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647994","Edema Evaluation","C178049","An evaluation of edema in a biological specimen or location.","Edema Evaluation | EDEMA | Edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647632","Hyperemia Evaluation","C178048","An evaluation of hyperemia in a biological specimen or location.","Hyperemia Evaluation | HYPERMIA | Hyperemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647627","Dimopoulos Waldenstroms Macroglobulinemia 2018 Oncology Response Criteria","C178056","Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia. (Dimopoulos MA, Tedeschi A, Trotman J, Garcia Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia for the iNNOVATE Study Group and the European Consortium for Waldenstrom's Macroglobulinemia. N Engl J Med 2018;378:2399-410.)","Dimopoulos Waldenstroms Macroglobulinemia 2018 Oncology Response Criteria | DIMOPOULOS WALDENSTROMS MACROGLOBULINEMIA 2018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647628","IWC Hallek CLL 2018 Oncology Response Criteria","C178055","Guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the 2008 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) published consensus guidelines for the design and conduct of clinical trials for patients with CLL. (Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ. Blood. 2018 Jun 21;131(25):2745-60.)","IWC Hallek CLL 2018 Oncology Response Criteria | IWC HALLEK CLL 2018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707533","Cubic Meter per Kilogram","C42577","A SI derived unit of specific volume, a property of materials defined as the number of cubic meters occupied by one kilogram of a particular substance. Specific volume is inversely proportional to density.","Cubic Meter per Kilogram | Cubic Meter/Kilogram | L/g | Liter per Gram | fL/fg | l/g | m3/kg | mL/mg | ml/mg | nL/ng | pL/pg | uL/ug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519970","Hour Times Micromole per Liter per Milligram per Kilogram","C132446","Hours times micromoles per liter, divided by milligrams per kilograms.","Hour Times Micromole per Liter per Milligram per Kilogram | h*umol/L/(mg/kg) | h.umol/L/(mg/kg) | h.umol/l/(mg/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519971","Hour Times Nanomole per Liter per Milligram per Kilogram","C132445","Hours times nanomoles per liter, divided by milligrams per kilograms.","Hour Times Nanomole per Liter per Milligram per Kilogram | h*nmol/L/(mg/kg) | h.nmol/L/(mg/kg) | h.nmol/l/(mg/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519817","Day Times Microgram per Milliliter Times Kilogram per Milligram","C132444","Days times microgram per milliliter, divided by milligrams times kilograms.","Day Times Microgram per Milliliter Times Kilogram per Milligram | d.ug/mL/(mg/kg) | d.ug/ml/(mg/kg) | day*ug/mL/(mg/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825079","Dairy Milk","C178184","Milk for human consumption that is derived from cows milk.","Dairy Milk | Milk",,,,,,,,,,,,,,,"4323432","Milk",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0452453","Fruit Juice","C71952","The liquid produced by squeezing or crushing fruit.","Fruit Juice | ",,,,,,,,,,,,,,,"4032218","Fruit juice",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0235222","Diastolic Hypertension","C3838","Hypertension characterized diastolic blood pressure greater than 90 mmHg on two occasions.","Diastolic Hypertension | ",,,,,,,,,,,,,,,"4167358","Diastolic hypertension",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221155","Systolic Hypertension","C3823","Abnormally high systolic blood pressure.","Systolic Hypertension | ",,,,,,,,,,,,,,,"4209293","Systolic hypertension",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1648434","Reactogenicity","C179193","An expected set of reactions that may occur soon after injection of a vaccine. These expected adverse reactions are a physical manifestation of the inflammatory response to the vaccine.","Reactogenicity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0277885","Systolic Hypotension","C179189","Systolic blood pressure that is abnormally low.","Systolic Hypotension | Low Systolic Blood Pressure",,,,,,,,,,,,,,,"4217168","Decreased systolic arterial pressure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0277890","Diastolic Hypotension","C179190","Diastolic blood pressure that is abnormally low.","Diastolic Hypotension | Low Diastolic Blood Pressure",,,,,,,,,,,,,,,"4175340","Decreased diastolic arterial pressure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1648432","Hypotensive Shock","C179191","Shock resulting from abnormally low blood pressure.","Hypotensive Shock | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648433","Injectable Product-Related Reaction","C179192","A reaction to the injection of a pharmacological or biological substance.","Injectable Product-Related Reaction | Reaction to Injectable Product",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647903","Tea","C178191","A drink made by pouring hot water onto the dried leaves, fruit, or flowers of plants, especially the leaves of Camellia sinensis.","Tea | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1509510","Fruit Flavor","C73389","A characteristic of a medicinal product, specifying that its most predominant agreeable savor detected by the unified sensation of taste and olfactory receptors resembles fruit.","Fruit Flavor | FRUIT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004896","Bean","C71990","The pod-enclosed seed of various leguminous herbs as well as other vegetable seeds or fruits that resemble true beans.","Bean | BEAN",,,,,,,,,,,,,,,"4103602","Bean",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013710","egg food product","C72064","The egg of a fowl, typically a chicken, consumed as a food.","Egg, Poultry | EGG | Egg (Poultry)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951187","Palms of Hands and Soles of Feet","C159254","The palmar aspect of the hands and the bottom of the feet.","Palms of Hands and Soles of Feet | Palms and soles",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332907","Agenesis","C120864","A congenital abnormality resulting in the absence of an anatomical structure.","Agenesis | APLASIA",,,,,,,,,,,,,,,"36684087","Agenesis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL563162","Non-Cancer Related Death","C156428","A death attributed to any cause other than the progression of a cancer-related pathologic condition.","Non-Cancer Related Death | Non-Cancer Death | Non-Cancer Related | Not Cancer Related",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950691","Related to Another Cancer","C158790","A response that relates an event to another cancer.","Related to Another Cancer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950690","Related to Head and Neck Cancer","C158789","A response that there is a relationship to head and neck cancer.","Related to Head and Neck Cancer | Related to Head & Neck Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950752","Performance Status Scale: Timing","C158725","A question about the performance status scale.","Performance Status Scale: Timing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951267","Margin Uninvolved by Invasive Melanoma","C159409","A result that the margin is uninvolved by invasive melanoma.","Margin Uninvolved by Invasive Melanoma | Margins uninvolved by invasive melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969805","Margin Status Cannot be Assessed","C160705","A result that the margin status cannot be assessed.","Margin Status Cannot be Assessed | Cannot be assessed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950731","Mitotic Rate Greater than or Equal to One per Square Millimeter","C158700","A result of a mitotic rate equal to or greater than one per square millimeter.","Mitotic Rate Greater than or Equal to One per Square Millimeter | >=1/mm2 | Mitoses Greater than or Equal to One per Square Millimeter | ≥1/mm2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951521","Was BRAF Mutation Analysis Performed","C159635","A question asking if BRAF mutations were analyzed during the study.","Was BRAF Mutation Analysis Performed | BRAF Mutational Analysis Performed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1718038","Margin Involved by Invasive Melanoma","C159232","A result that the margin is involved by invasive melanoma.","Margin Involved by Invasive Melanoma | Margin(s) involved by invasive melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950999","Is Another BRAF Mutation Present","C158932","A question to determine if a BRAF mutation that is not listed on the form was found in the study.","Is Another BRAF Mutation Present | Other BRAF mutation | Other BRAF mutation present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273992","BRAF NM_004333.4:c.1799T>A","C98344","A nucleotide substitution at position 1799 of the coding sequence of the BRAF gene where thymine has been mutated to adenine.","BRAF NM_004333.4:c.1799T>A | B-RAF1 c.1799T>A | BRAF V600E (c.1799T>A) mutation | BRAF c.1799T>A | NM_004333.4:c.1799T>A | v-raf Murine Sarcoma Viral Oncogene Homolog B1 c.1799T>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950694","Specify Cause of Death","C158794","A directive to specify the cause of death.","Specify Cause of Death | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950867","BRAF Mutation Analysis Testing Method","C158856","A request to enter the specific molecular analysis method used to detect and identify mutations in the BRAF gene.","BRAF Mutation Analysis Testing Method | BRAF Mutational Analysis Testing Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951533","Was NRAS Mutation Analysis Performed","C159647","A question asking if NRAS mutations were analyzed during the study.","Was NRAS Mutation Analysis Performed | NRAS Mutational Analysis Performed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950732","Adjuvant Post-Operative Radiation Therapy","C158701","A question whether adjuvant post-operative radiation therapy was administered.","Was Adjuvant Post-operative Radiation Therapy Administered | Adjuvant Post-Operative Radiation Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951009","Is Another NRAS Mutation Present","C158942","A question to determine if a NRAS mutation that is not listed on the form was found in the study.","Is Another NRAS Mutation Present | Other NRAS mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950994","NRAS NM_002524.4:c.37G>A","C158926","A nucleotide substitution at position 37 of the coding sequence of the NRAS gene where guanine has been mutated to adenine.","NRAS NM_002524.4:c.37G>A | N-ras c.37G>A | NM_002524.4:c.37G>A | NRAS G13S (c.37G>A) mutation | NRAS c.37G>A | NRAS1 c.37G>A | Neuroblastoma RAS Viral (v-ras) Oncogene Homolog c.37G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556284","NRAS NM_002524.4:c.37G>C","C155674","A nucleotide substitution at position 37 of the coding sequence of the NRAS gene where guanine has been mutated to cytosine.","NRAS NM_002524.4:c.37G>C | N-ras c.37G>C | NM_002524.4:c.37G>C | NRAS G13R (c.37G>C) mutation | NRAS c.37G>C | NRAS1 c.37G>C | Neuroblastoma RAS Viral (v-ras) Oncogene Homolog c.37G>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538412","NRAS NM_002524.4:c.35G>T","C140248","A nucleotide substitution at position 35 of the coding sequence of the NRAS gene where guanine has been mutated to thymine.","NRAS NM_002524.4:c.35G>T | N-ras c.35G>T | NM_002524.4:c.35G>T | NRAS G12V (c.35G>T) mutation | NRAS c.35G>T | NRAS1 c.35G>T | Neuroblastoma RAS Viral (v-ras) Oncogene Homolog c.35G>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556280","NRAS NM_002524.4:c.35G>A","C155670","A nucleotide substitution at position 35 of the coding sequence of the NRAS gene where guanine has been mutated to adenine.","NRAS NM_002524.4:c.35G>A | N-ras c.35G>A | NM_002524.4:c.35G>A | NRAS G12D (c.35G>A) mutation | NRAS c.35G>A | NRAS1 c.35G>A | Neuroblastoma RAS Viral (v-ras) Oncogene Homolog c.35G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556278","NRAS NM_002524.4:c.34G>A","C155672","A nucleotide substitution at position 34 of the coding sequence of the NRAS gene where guanine has been mutated to adenine.","NRAS NM_002524.4:c.34G>A | N-ras c.34G>A | NM_002524.4:c.34G>A | NRAS G12S (c.34G>A) mutation | NRAS c.34G>A | NRAS1 c.34G>A | Neuroblastoma RAS Viral (v-ras) Oncogene Homolog c.34G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950814","NRAS NM_002524.4:c.34G>C","C158925","A nucleotide substitution at position 34 of the coding sequence of the NRAS gene where guanine has been mutated to cytosine.","NRAS NM_002524.4:c.34G>C | N-ras c.34G>C | NM_002524.4:c.34G>C | NRAS G12R (c.34G>C) mutation | NRAS c.34G>C | NRAS1 c.34G>C | Neuroblastoma RAS Viral (v-ras) Oncogene Homolog c.34G>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274092","NRAS NM_002524.4:c.183A>T","C98444","A nucleotide substitution at position 183 of the coding sequence of the NRAS gene where adenine has been mutated to thymine.","NRAS NM_002524.4:c.183A>T | N-ras c.183A>T | NM_002524.4:c.183A>T | NRAS Q61H (c.183A>T) mutation | NRAS c.183A>T | NRAS1 c.183A>T | Neuroblastoma RAS Viral (v-ras) Oncogene Homolog c.183A>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274098","NRAS NM_002524.4:c.182A>T","C98450","A nucleotide substitution at position 182 of the coding sequence of the NRAS gene where adenine has been mutated to thymine.","NRAS NM_002524.4:c.182A>T | N-ras c.182A>T | NM_002524.4:c.182A>T | NRAS Q61L (c.182A>T) mutation | NRAS c.182A>T | NRAS1 c.182A>T | Neuroblastoma RAS Viral (v-ras) Oncogene Homolog c.182A>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274094","NRAS NM_002524.4:c.181C>A","C98446","A nucleotide substitution at position 181 of the coding sequence of the NRAS gene where cytosine has been mutated to adenine.","NRAS NM_002524.4:c.181C>A | N-ras c.181C>A | NM_002524.4:c.181C>A | NRAS Q61K (c.181C>A) mutation | NRAS c.181C>A | NRAS1 c.181C>A | Neuroblastoma RAS Viral (v-ras) Oncogene Homolog c.181C>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274105","NRAS NM_002524.4:c.182A>G","C98457","A nucleotide substitution at position 182 of the coding sequence of the NRAS gene where adenine has been mutated to guanine.","NRAS NM_002524.4:c.182A>G | N-ras c.182A>G | NM_002524.4:c.182A>G | NRAS Q61R (c.182A>G) mutation | NRAS c.182A>G | NRAS1 c.182A>G | Neuroblastoma RAS Viral (v-ras) Oncogene Homolog c.182A>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950813","NRAS Mutation Analysis Testing Method","C158924","A request to enter the specific molecular analysis method used to detect and identify mutations in the NRAS gene.","NRAS Mutation Analysis Testing Method | NRAS Mutational Analysis Testing Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950733","Adjuvant Post-Operative Chemotherapy","C158702","A question whether adjuvant post-operative chemotherapy was administered.","Was Adjuvant Post-Operative Chemotherapy Administered | Adjuvant Post-Operative Chemotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950735","Adjuvant Post-Operative Immunological Therapy","C158704","A question whether adjuvant post-operative immunological therapy was administered.","Was Adjuvant Post-Operative Immunological Therapy Administered | Adjuvant Post-Operative Immunological Therapy | Adjuvant Post-Operative Immunotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662075","Mitotic Rate Less than One per Square Millimeter","C179202","A finding of a mitotic rate less than one per square millimeter.","Mitotic Rate Less than One per Square Millimeter | <1/mm2 | Less than 1/mm^2 | Mitoses Less than One per Square Millimeter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951527","Was KIT Mutation Analysis Performed","C159641","A question asking if KIT mutations were analyzed during the study.","Was KIT Mutation Analysis Performed | KIT Mutational Analysis Performed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950737","Adjuvant Post-Operative Target Molecular Therapy","C158706","A question whether adjuvant post-operative targeted molecular therapy was administered.","Was Adjuvant Post-Operative Targeted Molecular Therapy Administered | Adjuvant Post-Operative Target Molecular Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951004","Is Another KIT Mutation Present","C158937","A question to determine if a KIT mutation that is not listed on the form was found in the study.","Is Another KIT Mutation Present | Other KIT mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950789","KIT NM_000222.2:c.1669T>A","C158897","A nucleotide substitution at position 1669 of the coding sequence of the KIT gene where thymine has been mutated to adenine.","KIT NM_000222.2:c.1669T>A | CD117 c.1669T>A | KIT Proto-Oncogene Tyrosine Protein Kinase c.1669T>A | KIT W557R (c.1669T>A) mutation | KIT c.1669T>A | NM_000222.2:c.1669T>A | c-KIT c.1669T>A | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.1669T>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950788","KIT NM_000222.2:c.1676T>C","C158896","A nucleotide substitution at position 1676 of the coding sequence of the KIT gene where thymine has been mutated to cytosine.","KIT NM_000222.2:c.1676T>C | CD117 c.1676T>C | KIT Proto-Oncogene Tyrosine Protein Kinase c.1676T>C | KIT V559A (c.1676T>C) mutation | KIT c.1676T>C | NM_000222.2:c.1676T>C | c-KIT c.1676T>C | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.1676T>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556286","KIT NM_000222.2:c.1924A>G","C155680","A nucleotide substitution at position 1924 of the coding sequence of the KIT gene where adenine has been mutated to guanine.","KIT NM_000222.2:c.1924A>G | CD117 c.1924A>G | KIT K642E (c.1942A>G) mutation | KIT Proto-Oncogene Tyrosine Protein Kinase c.1924A>G | KIT c.1924A>G | NM_000222.2:c.1924A>G | c-KIT c.1924A>G | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.1924A>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950787","KIT NM_000222.2:c.1727T>C","C158895","A nucleotide substitution at position 1727 of the coding sequence of the KIT gene where thymine has been mutated to cytosine.","KIT NM_000222.2:c.1727T>C | CD117 c.1727T>C | KIT L576P (c.1727T>C) mutation | KIT Proto-Oncogene Tyrosine Protein Kinase c.1727T>C | KIT c.1727T>C | NM_000222.2:c.1727T>C | c-KIT c.1727T>C | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.1727T>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950795","KIT Mutation Analysis Testing Method","C158903","A request to enter the specific molecular analysis method used to detect and identify mutations in the KIT gene.","KIT Mutation Analysis Testing Method | KIT Mutational Analysis Testing Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951524","Was Immunohistochemical Testing Performed","C159638","A question asking if any immunohistochemical tests were performed during the study.","Was Immunohistochemical Testing Performed | Immunohistochemistry performed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951573","Specify New Primary Tumor","C159570","A directive to specify the new primary tumor.","Specify New Primary Tumor | New Primary Tumor, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951205","Microsatellitosis","C159278","One or more discontinuous nests of melanoma cells measuring at least 0.3 mm in diameter and separated from the primary lesion by more than 0.05 mm of normal tissue.","Microsatellitosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412753","Image File","C175246","An electronic file containing imaging data.","Image File | Imaging File",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647951","PLCOm2012 Lung Cancer Model","C178262","A logical regression lung cancer risk model, based on data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO), that incorporates 11 predictors, including age, smoking status, smoking intensity, duration of smoking, and duration of quitting, to estimate the six-year lung cancer risk in individuals who have greater than or equal to 30 pack-years of smoking and less than 15 years since quitting.","PLCOm2012 Lung Cancer Model | PLCOm2012",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950681","Diagnostic Evidence of Recurrence/Relapse","C158779","Evidence from testing or observation that there has been a recurrence or relapse.","Diagnostic Evidence of Recurrence/Relapse | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551925","Biomarker Positive Malignant Neoplasm","C150123","A finding indicating the presence of a biomarker in a tumor sample from a patient with a malignant neoplasm.","Biomarker Positive Malignant Neoplasm | Biomarker Positive Cancer | Positive Biomarker in Cancer | Positive Biomarker in Malignant Neoplasm | Positive Biomarker(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950684","Convincing Image Source","C158782","Radiologic evidence that supports a diagnosis.","Convincing Image Source | Convincing Image (i.e. CT/PET/MRI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950682","Biopsy with Histologic Confirmation","C158780","A biopsy with microscopic confirmation.","Biopsy with Histologic Confirmation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969683","Was Radiation Administered as an Additional Treatment for a New Tumor Event","C160629","A question whether radiation was administered as an additional treatment for a new tumor event.","Was Radiation Administered as an Additional Treatment for a New Tumor Event | Additional Treatment for New Tumor Event Radiation Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969682","Was Chemotherapy Administered as an Additional Treatment for a New Tumor Event","C160630","A question whether chemotherapy was administered as an additional treatment for a new tumor event.","Was Chemotherapy Administered as an Additional Treatment for a New Tumor Event | Additional Treatment for New Tumor Event Chemotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969681","Was Immunotherapy Administered as an Additional Treatment for a New Tumor Event","C160631","A question whether immunotherapy was administered as an additional treatment for a new tumor event.","Was Immunotherapy Administered as an Additional Treatment for a New Tumor Event | Additional Treatment for New Tumor Event Immunotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969679","Was Targeted Molecular Therapy Administered as an Additional Treatment for a New Tumor Event","C160633","A question whether targeted molecular therapy was administered as an additional treatment for a new tumor event.","Was Targeted Molecular Therapy Administered as an Additional Treatment for a New Tumor Event | Additional Treatment for New Tumor Event Targeted Molecular Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517223","Fluorescence Bronchoscopy","C20035","Fluorescence bronchoscopy is based on the fact that normal tissue fluoresces differently than abnormal tissue when exposed to an appropriate wavelength of light and that this difference can be detected.","Fluorescence Bronchoscopy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3494253","Narrow Band Imaging","C116496","A high-resolution endoscopic technique that uses two specific wavelengths of blue and green light, chosen for their differing ability to peneatrate tissue. These wavelengths are strongly absorbed by hemoglobin and separately visualize both superficial and deeper vasculature.","Narrow Band Imaging | NBI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951253","Biospecimen Submitted to BCR","C159201","A section header about biospecimens submitted to BCR.","Biospecimen Submitted to BCR | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951189","Specimen Source Site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951206","Melanoma Involvement of Regional Cutaneous or Subcutaneous Tissue","C159279","A finding indicating the spread of cutaneous melanoma to regional cutaneous or subcutaneous tissue, including satellite and in-transit metastasis.","Melanoma Involvement of Regional Cutaneous or Subcutaneous Tissue | Regional cutaneous or subcutaneous tissue (includes satellite & in-transit metastasis)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL763697","Growth Phase","C159261","The morphologic architectural pattern in which the tumor cells spread.","Growth Phase | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951194","Indeterminate Growth Phase","C159263","A response that the growth phase is undetermined.","Indeterminate Growth Phase | Indeterminate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951689","Specify Site If Distant Metastasis Submitted","C159721","A request to specify the site if distant metastasis was submitted.","Specify Site If Distant Metastasis Submitted | If distant metastasis submitted, specify site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951190","Prior to the resection of the specimen submitted, did the donor receive interferon gamma treatment","C159257","A question about whether interferon gamma treatment was administered prior to the specimen resection.","Was Interferon Gamma Treatment Administered Prior to Specimen Resection | Prior to the resection of the specimen submitted, did the donor receive interferon gamma treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951191","If administered, was interferon gamma treatment administered at least 90 days prior to the resection of the study specimen","C159258","A question about whether interferon gamma treatment was administered 90 days prior to the specimen resection.","Was Interferon Gamma Treatment Administered 90 Days Prior to Specimen Resection | If administered, was interferon gamma treatment administered at least 90 days prior to the resection of the study specimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978381","Test Value Reported Indicator","C165229","An indication as to whether a test value has been reported or recorded.","Test Value Reported Indicator | Test Value Reported",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978385","Expression Negative","C165233","An indication that expression of a gene, RNA species or protein is not detected in a sample.","Expression Negative | Absent | LOST | Loss of Expression | Negative | Not Expressed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969739","Is Macroscopic Satellite Nodule Present","C160827","A question about whether the macroscopic satellite nodule is present.","Is Macroscopic Satellite Nodule Present | Macroscopic Satellite Nodule(s) | satellite nodule present | satellite_nodule_present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206646","Abdominal (Mesenteric) Fibromatosis","C3741","An insidious poorly circumscribed neoplasm arising from the deep soft tissues of the abdomen. It is characterized by the presence of elongated spindle-shaped fibroblasts, collagenous stroma formation, and an infiltrative growth pattern.","Abdominal (Mesenteric) Fibromatosis | Abdominal Desmoid | Abdominal Desmoid Tumor | Abdominal Fibromatosis | Abdominal desmoid | Abdominal fibromatosis | Intraabdominal Desmoid | Intraabdominal Desmoid Tumor | Intraabdominal Fibromatosis | Mesenteric Desmoid | Mesenteric Desmoid Tumor | Mesenteric Fibromatosis | Mesenteric fibromatosis | Peritoneal Desmoid Fibromatosis","8822/1","Abdominal fibromatosis",,,,,,,,,,,,,"4266333","Abdominal fibromatosis",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C2737003","Margin Involved by Invasive Carcinoma","C159230","A result that the margin is involved by invasive carcinoma.","Margin Involved by Invasive Carcinoma | Margin(s) involved by invasive carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951223","Margin Uninvolved by Invasive Carcinoma","C159234","A result that the margin is not uninvolved by invasive carcinoma.","Margin Uninvolved by Invasive Carcinoma | Margins uninvolved by invasive carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879503","Adriamycin-Cytoxan Regimen","C63415","A regimen consisting of cyclophosphamide and doxorubicin that can be used in the treatment for breast cancer. Cyclophosphamide/doxorubicin every 21 days regimen may be used for the treatment of breast cancer.","AC Regimen | A-C | AC | AC regimen | Adriamycin-Cytoxan Regimen | CA Regimen | Cyclophosphamide and Doxorubicin (AC) | Doxorubicin/Cyclophosphamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525061","FAC Regimen","C138099","A regimen consisting of fluorouracil, doxorubicin and intravenous cyclophosphamide, used as a treatment for recurrent and metastatic breast cancer.","FAC Regimen | 5-Fluorouracil/Adriamycin/IV Cyclophosphamide | Cyclophosphamide/Doxorubicin/Fluorouracil | FAC | Fluorouracil-Doxorubicin-IV Cyclophosphamide | Fluorouracil/Doxorubicin/IV Cyclophosphamide | Fluorouracil/Doxorubicin/Intravenous Cyclophosphamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640943","Sacituzumab Govitecan","C102783","An antibody drug conjugate containing the humanized monoclonal antibody, hRS7, against tumor-associated calcium signal transducer 2 (TACSTD2 or TROP2) and linked to the active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), with potential antineoplastic activity. The antibody moiety of sacituzumab govitecan selectively binds to TROP2. After internalization and proteolytic cleavage, SN-38 selectively stabilizes topoisomerase I-DNA covalent complexes, resulting in DNA breaks that inhibit DNA replication and trigger apoptosis. TROP2, also known as epithelial glycoprotein-1 (EGP-1), is a transmembrane calcium signal transducer that is overexpressed by a variety of human epithelial carcinomas; this antigen is involved in the regulation of cell-cell adhesion and its expression is associated with increased cancer growth, aggressiveness and metastasis.","Sacituzumab Govitecan | IMMU 132 | IMMU-132 | IMMU132 | RS7 SN38 | RS7-SN38 | RS7SN38 | SACITUZUMAB GOVITECAN | Sacituzumab Govitecan-hziy | Sacituzumab govitecan | Trodelvy | hRS7-SN38 Antibody Drug Conjugate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1883257","TAC Regimen","C63435","A regimen consisting of docetaxel, doxorubicin and cyclophosphamide that can be used in the treatment of breast cancer.","TAC Regimen | Cyclophosphamide/Docetaxel/Doxorubicin | Docetaxel/Doxorubicin/Cyclophosphamide | Docetaxel/Doxorubicin/Cyclophosphamide Regimen | TAC | TAC (Docetaxel) | TAC regimen | Taxotere-Adriamycin-Cytoxan Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334432","Nonpigmented Nevus","C27095","A benign nevus characterized by the absence of melanin pigment in the melanocytes.","Nonpigmented Nevus | Nonpigmented nevus","8730/0","Nonpigmented nevus",,,,,,,,,,,,,"4010102","Nonpigmented nevus",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334389","Acinar Cell Adenoma","C4196","A benign glandular epithelial neoplasm consisting of secretory cells forming acinar patterns.","Acinar Cell Adenoma | ADENOMA, ACINAR CELL, BENIGN | Acinar Adenoma | Acinar adenoma | Acinar cell adenoma | Acinic Cell Adenoma | Acinic cell adenoma","8550/0","Acinar cell adenoma",,,,,,,,,,,,,"4194522","Acinar cell adenoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334311","Pituitary Gland Acidophil Carcinoma","C4147","A malignant epithelial neoplasm of the anterior pituitary gland in which the neoplastic cells stain positive with acidic dyes.","Pituitary Gland Acidophil Carcinoma | ","8280/3","Acidophil carcinoma",,,,,,,,,,,,,"4196825","Acidophil carcinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0001433","Pituitary Gland Acidophil Adenoma","C6780","An epithelial neoplasm of the anterior pituitary gland in which the neoplastic cells stain positive with acidic dyes.","Pituitary Gland Acidophil Adenoma | ","8280/0","Acidophil adenoma",,,,,,,,,,,,,"4050832","Acidophil adenoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C3898779","Immunotoxin D2C7-(scdsFv)-PE38KDEL","C119739","A recombinant immunotoxin fusion protein consisting of single-chain variable-region antibody fragments (scFvs), which contain disulfide stabilized heavy- (Vh) and light- (Vl) chain variable regions of the monoclonal antibody D2C7 (D2C7-scdsFv), targeting both the wild-type form (EGFRwt) and the in-frame deletion mutant form (EGFRvIII) of epidermal growth factor receptor (EGFR), and fused, via a 15-amino acid peptide linker to domains II and III of the Pseudomonas exotoxin A (PE38KDEL) (D2C7-(scdsFv)-PE38KDEL), with potential antineoplastic activity. Upon intratumoral administration by convection-enhanced delivery, the scFv moiety of immunotoxin anti-EGFR scFv monoclonal antibody fragment immunotoxin D2C7-(scdsFv)-PE38KDEL targets and binds to a specific amino acid epitope present in the extracellular domain of both the EGFRwt and EGFRvIII proteins. This binding facilitates the internalization of the immunotoxin by tumor cells. Inside the cells, the exotoxin portion of the fusion protein binds to translation elongation factor 2 (EF-2), and deactivates EF-2 through ADP ribosylation. This results in the inhibition of protein synthesis, the induction of apoptosis and a reduction in cell proliferation of EGFRwt/EGFRvIII-expressing tumor cells. Compared to intact IgG antibodies and single-chain antibodies, scFvs are smaller with increased tumor-penetrating capacity which may enhance therapeutic efficacy. The EGFR gene, a transmembrane receptor tyrosine kinase, and its mutant form, EGFRvIII, which contains a deletion of exons 2-7 of the EGFR gene, are frequently amplified and overexpressed in a variety of cancers. KDEL increases the toxin's intracellular retention, thereby enhancing its cytotoxicity.","Immunotoxin D2C7-(scdsFv)-PE38KDEL | D2C7-(scdsFv)-PE38KDEL | D2C7-(scdsFv)-PE38KDEL Immunotoxin | D2C7-IT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0346073","Tufted Hemangioma","C4487","A rare cutaneous hemangioma characterized by the presence of multiple scattered and tightly packed lobules of capillaries in the dermis and rarely the subcutaneous tissue. It usually affects infants and children and manifests with macules, papules, nodules, or plaques.","Tufted Hemangioma | Acquired tufted hemangioma | Angioblastoma of Nakagawa | TA | Tufted Angioma | Tufted Angioma | Tufted Angioma of Skin | Tufted Angioma of the Skin | Tufted Hemangioma | Tufted Hemangioma of Skin | Tufted Hemangioma of the Skin | Tufted Skin Angioma","9161/0","Acquired tufted hemangioma",,,,,,,,,,,,,"45767677","Tufted angioma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"CL1661876","Arterial-phase Magnetic Resonance Imaging","C179303","MR imaging done at the time that a contrast agent would enhance hepatic arteries, but antegrade enhancement of hepatic veins would be absent.","Arterial-phase Magnetic Resonance Imaging | Arterial Phase | Arterial Phase MRI | Arterial Phase Magnetic Resonance Imaging | Arterial-phase MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663171","Venous-phase Magnetic Resonance Imaging","C179304","MR imaging done at a time that a contrast agent would provide antegrade enhancement of hepatic veins.","Venous-phase Magnetic Resonance Imaging | Venous Phase | Venous Phase MRI | Venous Phase Magnetic Resonance Imaging | Venous-phase MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663170","Delayed-phase Magnetic Resonance Imaging","C179306","MR imaging done several minutes after the time that a contrast agent would normally be administered.","Delayed-phase Magnetic Resonance Imaging | Delayed-phase MRI | Late Phase MRI | Late Phase Magnetic Resonance Imaging | Late-phase | Late-phase MRI | Late-phase Magnetic Resonance Imaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661883","D2C7 1+ Staining","C179310","A finding of 1+ staining with D2C7 monoclonal antibody in a sample.","D2C7 1+ Staining | D2C7 1+ Staining Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661882","D2C7 2+ Staining","C179311","A finding of 2+ staining with D2C7 monoclonal antibody in a sample.","D2C7 2+ Staining | D2C7 2+ Staining Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661981","D2C7 3+ Staining","C179313","A finding of 3+ staining with D2C7 monoclonal antibody in a sample.","D2C7 3+ Staining | D2C7 3+ Staining Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662044","NUP214/ABL1 Fusion Gene","C179232","A fusion gene that results from a chromosomal rearrangement of 9q34 which fuses almost all or the 5' half of the NUP214 gene with intron 1 of the ABL1 gene. This fusion is associated with T-cell acute lymphoblastic leukemia.","NUP214/ABL1 Fusion Gene | ABL1/NUP214 Fusion Gene | CAN-ABL Fusion Gene | CAN/ABL Fusion Gene | NUP-ABL1 (T cell) | NUP214-ABL1 Fusion Gene | NUP214::ABL1 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969226","Liposomal Doxorubicin Regimen","C160080","A regimen consisting of liposomal doxorubicin that may be used in the treatment of desmoid tumors (aggressive fibromatoses); soft tissue, uterine, and Kaposi sarcomas; mycosis fungoides and Sezary syndrome; Castleman disease; and ovarian, fallopian tube, primary peritoneal, breast, and endometrial cancers.","Liposomal Doxorubicin Regimen | Doxil Regimen | Doxorubicin Hydrochloride Liposomal Regimen | Liposomal Doxorubicin HCl Regimen | Liposomal Doxorubicin Hydrochloride Regimen | Pegylated liposomal doxorubicin monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540402","Baseline Characteristics","C142401","Subject data gathered prior to an event or intervention, which may include medical history, demographic, and clinical data.","Baseline Characteristics | baseline characteristics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969821","Is Lymphatic Invasion Present","C160720","A question about whether lymphatic invasion is present.","Is Lymphatic Invasion Present | Lymph-vascular Invasion | lymphatic invasion present | lymphatic_invasion_present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519775","Cutaneous Squamous Cell Carcinoma of the Head and Neck Pathologic Primary Tumor TNM Finding v8","C133203","A pathologic finding about one or more characteristics of cutaneous squamous cell carcinoma of the head and neck, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Cutaneous Squamous Cell Carcinoma of the Head and Neck Pathologic Primary Tumor TNM Finding v8 | Pathologic Staging: Primary Tumor (pT)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519808","Cutaneous Squamous Cell Carcinoma of the Head and Neck pT4b TNM Finding v8","C133211","Cutaneous squamous cell carcinoma of the head and neck with skull base invasion and/or skull base foramen involvement.  (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck pT4b TNM Finding v8 | pT4b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519807","Cutaneous Squamous Cell Carcinoma of the Head and Neck pT4a TNM Finding v8","C133210","Cutaneous squamous cell carcinoma of the head and neck with gross cortical bone/marrow invasion.  (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck pT4a TNM Finding v8 | pT4a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519806","Cutaneous Squamous Cell Carcinoma of the Head and Neck pT4 TNM Finding v8","C133209","Cutaneous squamous cell carcinoma of the head and neck with gross cortical bone/marrow, skull base invasion and/or skull base foramen invasion.  (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck pT4 TNM Finding v8 | pT4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519805","Cutaneous Squamous Cell Carcinoma of the Head and Neck pT3 TNM Finding v8","C133208","Cutaneous squamous cell carcinoma of the head and neck with tumor 4 cm or larger in greatest dimension or minor bone erosion or perineural invasion or deep invasion. Deep invasion is defined as invasion beyond the subcutaneous fat or larger than 6 mm; perineural invasion for T3 classification is defined as tumor cells within the nerve sheath of a nerve lying deeper than the dermis or measuring 0.1 mm or larger in caliber, or presenting with clinical or radiographic involvement of named nerves without skull base invasion or transgression.  (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck pT3 TNM Finding v8 | pT3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519804","Cutaneous Squamous Cell Carcinoma of the Head and Neck pT2 TNM Finding v8","C133207","Cutaneous squamous cell carcinoma of the head and neck with tumor 2 cm or larger, but smaller than 4 cm in greatest dimension. (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck pT2 TNM Finding v8 | pT2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519803","Cutaneous Squamous Cell Carcinoma of the Head and Neck pT1 TNM Finding v8","C133206","Cutaneous squamous cell carcinoma of the head and neck with tumor smaller than 2 cm in greatest dimension. (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck pT1 TNM Finding v8 | pT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519810","Cutaneous Squamous Cell Carcinoma of the Head and Neck pTis TNM Finding v8","C133205","Cutaneous squamous cell carcinoma of the head and neck with a finding of carcinoma in situ. (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck pTis TNM Finding v8 | pTis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519809","Cutaneous Squamous Cell Carcinoma of the Head and Neck pTX TNM Finding v8","C133204","Cutaneous squamous cell carcinoma of the head and neck in which the primary tumor cannot be identified. (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck pTX TNM Finding v8 | pTX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1337012","Well Differentiated Papillary Mesothelial Tumor","C7635","A localized or multifocal mesothelial neoplasm arising from the peritoneum and less often the pleura and paratesticular region. Cases arising from the peritoneum predominantly occur in women. It is characterized by the formation of papillae, covered by a single layer of blunt mesothelial cells. Mitotic figures are not present. There is no evidence of severe cytologic atypia. It has a relatively favorable clinical outcome, compared to malignant mesothelioma.","Well Differentiated Papillary Mesothelial Tumor | Benign/Intermediate Mesothelioma | WDPM | WDPMT | Well Differentiated Papillary Mesothelioma | Well Differentiated Papillary Mesothelioma | Well-Differentiated Mesothelial Papillary Neoplasm | Well-Differentiated Mesothelial Papillary Tumor | Well-Differentiated Papillary Mesothelial Tumor | Well-Differentiated Papillary Neoplasm of Mesothelium | Well-Differentiated Papillary Neoplasm of the Mesothelium | Well-Differentiated Papillary Tumor of Mesothelium | Well-Differentiated Papillary Tumor of the Mesothelium",,,,,,,,,,,,,,,"37117010","Well-differentiated papillary mesothelioma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206680","Multicystic Mesothelioma","C3765","A mesothelial neoplasm that arises from the peritoneum and rarely the pleura. It is characterized by the presence of multiple cysts lined by flattened or cuboidal mesothelial cells. There is no evidence of significant cytologic atypia or increased mitotic activity. It may reoccur. Rare cases of transformation to malignant mesothelioma have been reported.","Multicystic Mesothelioma | Cystic Mesothelioma | Intermediate Mesothelioma | Multicystic mesothelioma, benign",,,,,,,,,,,,,,,"4029195|4314781","Multicystic mesothelioma, benign|Cystic mesothelioma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL1661941","Rescreening","C179373","The process of performing a systematic examination or assessment an additional time.","Rescreening | Re-screening | Rescreen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519934","Head and Neck Cancer Clinical Regional Lymph Nodes TNM Finding v8","C132634","A clinical finding about one or more characteristics of head and neck cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Head and Neck Cancer Clinical Regional Lymph Nodes TNM Finding v8 | Pathologic Staging: Regional Lymph Nodes (pN)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519954","Head and Neck Cancer pN3b TNM Finding v8","C132653","Head and neck cancer with metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes, any with ENE(+). (from AJCC 8th Ed.)","Head and Neck Cancer pN3b TNM Finding v8 | pN3b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519953","Head and Neck Cancer pN3a TNM Finding v8","C132652","Head and neck cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Head and Neck Cancer pN3a TNM Finding v8 | pN3a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519951","Head and Neck Cancer pN2c TNM Finding v8","C132650","Head and neck cancer with metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Head and Neck Cancer pN2c TNM Finding v8 | pN2c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519950","Head and Neck Cancer pN2b TNM Finding v8","C132649","Head and neck cancer with metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); (from AJCC 8th Ed.)","Head and Neck Cancer pN2b TNM Finding v8 | pN2b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519949","Head and Neck Cancer pN2a TNM Finding v8","C132648","Head and neck cancer with metastasis in a single ipsilateral lymph node 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Head and Neck Cancer pN2a TNM Finding v8 | pN2a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519948","Head and Neck Cancer pN2 TNM Finding v8","C132647","Head and neck cancer with metastasis in a single ipsilateral lymph node 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, ENE(-). (from AJCC 8th Ed.)","Head and Neck Cancer pN2 TNM Finding v8 | pN2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519947","Head and Neck Cancer pN1 TNM Finding v8","C132646","Head and neck cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (extranodal extension)(-). (from AJCC 8th Ed.)","Head and Neck Cancer pN1 TNM Finding v8 | pN1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519946","Head and Neck Cancer pN0 TNM Finding v8","C132645","Head and neck cancer in which no regional lymph node metastases are detected. (from AJCC 8th Ed.)","Head and Neck Cancer pN0 TNM Finding v8 | pN0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519955","Head and Neck Cancer pNX TNM Finding v8","C132644","Head and neck cancer in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)","Head and Neck Cancer pNX TNM Finding v8 | pNX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951529","Was Lymph Node Dissection Performed","C159643","A question asking if lymph node dissection was performed during the study.","Was Lymph Node Dissection Performed | Lymph Node Neck Dissection performed | lymph nodes removed | lymph_nodes_removed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951358","Not done, Left","C159324","A response that the left lymph node dissection was not done.","Left Lymph Node Dissection not Done | Not done, Left",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951359","Not done, Right","C159325","A response that the left lymph node dissection was not done.","Right Lymph Node Dissection not Done | Not done, Right",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519779","Cutaneous Squamous Cell Carcinoma of the Head and Neck by AJCC v8 Stage","C133253","A term that refers to the staging of cutaneous squamous cell carcinoma of the head and neck according to the American Joint Committee on Cancer, 8th edition.","Cutaneous Squamous Cell Carcinoma of the Head and Neck by AJCC v8 Stage | Tumor Stage (Pathological)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520961","Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8","C133259","Stage IV includes: (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (Any T, N3, M0); (T4, Any N, M0); (Any T, Any N, M1). T1: Tumor smaller than 2 cm in greatest dimension. T2: Tumor 2 cm or larger, but smaller than 4 cm in greatest dimension. T3: Tumor 4 cm or larger in greatest dimension or minor bone erosion or perineural invasion or deep invasion. Deep invasion is defined as invasion beyond the subcutaneous fat or larger than 6 mm; perineural invasion for T3 classification is defined as tumor cells within the nerve sheath of a nerve lying deeper than the dermis or measuring 0.1 mm or larger in caliber, or presenting with clinical or radiographic involvement of named nerves without skull base invasion or transgression. T4: Tumor with gross cortical bone/marrow, skull base invasion and/or skull base foramen invasion. N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-).  N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes, any with ENE(+). M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Stage IV | Stage IV Head and Neck Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520956","Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8","C133258","Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T3: Tumor 4 cm or larger in greatest dimension or minor bone erosion or perineural invasion or deep invasion. Deep invasion is defined as invasion beyond the subcutaneous fat or larger than 6 mm; perineural invasion for T3 classification is defined as tumor cells within the nerve sheath of a nerve lying deeper than the dermis or measuring 0.1 mm or larger in caliber, or presenting with clinical or radiographic involvement of named nerves without skull base invasion or transgression. T1: Tumor smaller than 2 cm in greatest dimension.  T2: Tumor 2 cm or larger, but smaller than 4 cm in greatest dimension. N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-). M0: No distant metastasis. (AJCC 8th ed.)","Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Stage III | Stage III Head and Neck Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521280","Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8","C133257","Stage II includes: T2, N0, M0. T2: Tumor 2 cm or larger, but smaller than 4 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Stage II | Stage II Head and Neck Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951023","TP53 Mutation Analysis","C158957","A procedure used to detect and identify mutations in the TP53 gene.","TP53 Mutation Analysis | P53 Mutation Analysis | TP53 Gene Mutation Analysis | TP53 Mutation Status | Tumor Protein p53 Mutation Analysis | p53 Gene Analysis | p53 Mutation Analysis | p53 Mutation Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950823","EGFR Amplification Status","C158871","A procedure used to detect and identify amplification of the EGFR gene.","EGFR Amplification Status | EGFR Amplification Analysis | EGFR Gene Amplification Analysis | EGFR amplification status | Epidermal Growth Factor Receptor Amplification Analysis | HER1 Amplification Analysis | c-erbB1 Amplification Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951360","HPV Status by PCR","C159326","A procedure to determine the HPV status by PCR.","HPV Status by PCR | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951361","HPV Status by ISH","C159327","A procedure to determine HPV status by in situ hybridization.","HPV Status by ISH | HPV Status by ISH Testing | HPV Status by in situ Hybridization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332155","Acute Myeloid Leukemia with t(16;16)(p13.1;q22); CBFB-MYH11","C9019","Acute myeloid leukemia characterized by the presence of abnormal bone marrow eosinophils and the characteristic cytogenetic abnormality t(16;16)(p13.1;q22) which results in the expression of the fusion protein CBFB-MYH11.","Acute Myeloid Leukemia with t(16;16)(p13.1;q22); CBFB-MYH11 | Acute Myeloid Leukemia with t(16;16)(p13.1;q22); CBFB-MYH11 Fusion | Acute Myeloid Leukemia with t(16;16)(p13.1;q22); CBFB::MYH11 | Acute Myeloid Leukemia with t(16;16)(p13.1;q22); CBFB::MYH11 Fusion | Acute Myeloid Leukemia with t(16;16)(p13;q22) | Acute Myeloid Leukemia, t(16;16)(p13;q22) | Acute myeloid leukemia, t(16;16)(p 13;q 11)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407773","Acute Myeloid Leukemia with KMT2A Rearrangement","C174129","An acute myeloid leukemia characterized by rearrangement of the KMT2A gene. It affects infants, children and adults. It is usually associated with poor prognosis.","Acute Myeloid Leukemia with KMT2A Rearrangement | Acute Myeloid Leukemia with 11q23 Abnormalities | Acute Myeloid Leukemia with KMT2A/MLL Rearrangement | Acute Myeloid Leukemia with MLL Rearrangement | Acute Myeloid Leukemia with MLL Rearrangement | Acute Myeloid Leukemia with MLLr | Acute Myeloid Leukemia, MLL | Acute myeloid leukemia, 11q23 abnormalities | Acute myeloid leukemia, MLL","9897/3","Acute myeloid leukemia, 11q23 abnormalities",,,,,,,,,,,,,"608277","Acute myeloid leukemia with 11q23 abnormality",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1377630","Adenocarcinoma In Situ in a Polyp",,,,,,,,,,,,,,,,,,"4094124","Adenocarcinoma in situ in a polyp",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334295","Adenocarcinoma in Multiple Adenomatous Polyps","C4136","Adenocarcinomas that develop in gastrointestinal tract adenomas in patients with multiple adenomatous polyps.","Adenocarcinoma in Multiple Adenomatous Polyps | Adenocarcinoma in Multiple Gastrointestinal Adenomatous Polyps | Adenocarcinoma in multiple adenomatous polyps","8221/3","Adenocarcinoma in multiple adenomatous polyps",,,,,,,,,,,,,"4187508","Adenocarcinoma in multiple adenomatous polyps",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334293","Adenocarcinoma in Adenomatous Polyposis Coli","C4134","Adenocarcinomas that develop in colorectal adenomas in patients with a history of adenomatous polyposis coli. The mean age of development of adenocarcinoma is about 40 years.","Adenocarcinoma in Adenomatous Polyposis Coli | Adenocarcinoma in adenomatous polyposis coli","8220/3","Adenocarcinoma in adenomatous polyposis coli",,,,,,,,,,,,,"4212084","Adenocarcinoma in adenomatous polyposis coli",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"CL509697","Cervical Adenocarcinoma Admixed with Neuroendocrine Carcinoma","C127915","A carcinoma that arises from the cervix and is characterized by the presence of a cervical adenocarcinoma variant and a neuroendocrine carcinoma component.","Cervical Adenocarcinoma Admixed with Neuroendocrine Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334565","Adenomatoid Odontogenic Tumor","C4310","A benign, slow growing neoplasm arising from tooth-forming tissues. The vast majority of cases are intraosseous and most often grow in the maxilla. It is characterized by the presence of odontogenic epithelium which is embedded in a connective tissue stroma. Local excision is curative and recurrences are very rare.","Adenomatoid Odontogenic Tumor | AOT | Adenomatoid Odontogenic Neoplasm | Adenomatoid odontogenic tumor","9300/0","Adenomatoid odontogenic tumor",,,,,,,,,,,,,"4244885","Adenomatoid odontogenic tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1377621","Adenocarcinoma in Tubular Adenoma","C7677","An adenocarcinoma that arises from a tubular adenoma.","Adenocarcinoma in Tubular Adenoma | Adenocarcinoma in tubular adenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334309","Adenocarcinoma in Tubulovillous Adenoma","C4145","An adenocarcinoma that arises from a tubulovillous adenoma.","Adenocarcinoma in Tubulovillous Adenoma | Adenocarcinoma in tubolovillous adenoma | Adenocarcinoma in tubulovillous adenoma","8263/3","Adenocarcinoma in tubulovillous adenoma",,,,,,,,,,,,,"4209587","Adenocarcinoma in tubulovillous adenoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334304","Adenocarcinoma In Situ in Villous Adenoma","C8376","An intramucosal adenocarcinoma that arises from a villous adenoma.","Adenocarcinoma In Situ in Villous Adenoma | Adenocarcinoma in situ in villous adenoma","8261/2","Adenocarcinoma in situ in villous adenoma",,,,,,,,,,,,,"37018669|4171344","Adenocarcinoma in situ in villous adenoma|Adenocarcinoma in situ in villous adenoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C0334308","Adenocarcinoma In Situ in Tubulovillous Adenoma","C4144","An intramucosal adenocarcinoma that arises from a tubulovillous adenoma.","Adenocarcinoma In Situ in Tubulovillous Adenoma | Adenocarcinoma in situ in tubulovillous adenoma","8263/2","Adenocarcinoma in situ in tubulovillous adenoma",,,,,,,,,,,,,"4201431","Adenocarcinoma in situ in tubulovillous adenoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1377632","Adenocarcinoma In Situ in Tubular Adenoma","C7679","An intramucosal adenocarcinoma that arises from a tubular adenoma.","Adenocarcinoma In Situ in Tubular Adenoma | Adenocarcinoma in situ in tubular adenoma",,,,,,,,,,,,,,,"4244728","Adenocarcinoma in situ in adenomatous polyp",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334290","Adenocarcinoma In Situ in Adenomatous Polyp","C7678","An intramucosal adenocarcinoma that arises from an adenomatous polyp.","Adenocarcinoma In Situ in Adenomatous Polyp | Adenocarcinoma In Situ in Gastrointestinal Adenomatous Polyp | Adenocarcinoma in situ in adenomatous polyp","8210/2","Adenocarcinoma in situ in adenomatous polyp",,,,,,,,,,,,,"4244728","Adenocarcinoma in situ in adenomatous polyp",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C3811240","Subject Biomarker Domain","C106571","A special purpose domain that associates the subject with the medical conclusions contained in the PB domain based on the observations reported in PF.","Subject Biomarker Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3819255","Pharmacogenomics Biomarker Domain","C106552","A special purpose domain and reference dataset that associates observed genetic mutations with medical conclusions (e.g. disease diagnosis, drug resistance).","Pharmacogenomics Biomarker Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1377647","Adenocarcinoma with Cartilaginous Metaplasia","C7685","An adenocarcinoma characterized by the presence of cartilaginous metaplasia.","Adenocarcinoma with Cartilaginous Metaplasia | Adenocarcinoma with cartilaginous metaplasia",,,,,,,,,,,,,,,"4209562","Adenocarcinoma with cartilaginous and osseous metaplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334396","Adenocarcinoma with Apocrine Metaplasia","C4202","An invasive adenocarcinoma characterized by focal or extensive transformation of the malignant glandular cells to cells with abundant, usually granular eosinophilic cytoplasm.","Adenocarcinoma with Apocrine Metaplasia | Adenocarcinoma with apocrine metaplasia | Carcinoma with apocrine metaplasia","8573/3","Adenocarcinoma with apocrine metaplasia",,,,,,,,,,,,,"4332050","Adenocarcinoma with apocrine metaplasia",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C3840223","Rete Ovarii Adenocarcinoma","C40017","An exceptionally rare adenocarcinoma that arises from the rete ovarii.","Rete Ovarii Adenocarcinoma | Adenocarcinoma of rete ovarii",,,,,,,,,,,,,,,"45766489","Adenocarcinoma of rete ovarii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266027","Anal Glands Adenocarcinoma","C5609","An anal adenocarcinoma arising from the epithelium of the anal glands.  The overlying anal mucosa does not show evidence of neoplastic changes.","Anal Glands Adenocarcinoma | Adenocarcinoma of Anal Gland | Adenocarcinoma of Anal Glands | Adenocarcinoma of anal glands | Adenocarcinoma of the Anal Gland","8215/3","Adenocarcinoma of anal glands",,,,,,,,,,,,,"4029508","Adenocarcinoma of anal glands",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334305","Adenocarcinoma in Villous Adenoma","C4141","An adenocarcinoma that arises from a villous adenoma.","Adenocarcinoma in Villous Adenoma | Adenocarcinoma in villous adenoma","8261/3","Adenocarcinoma in villous adenoma",,,,,,,,,,,,,"4262979|765158","Adenocarcinoma in villous adenoma|Adenocarcinoma in villous adenoma",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"CL950632","Organ Based","C158652","A header indicating the choices are organ based.","Organ Based | Organ based",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951406","Pelvic, Specify","C159569","A request to specify the area of the pelvis.","Pelvic, Specify | Pelvic, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951224","Margin Uninvolved by Sarcoma","C159235","The margin of the sample has no sarcoma.","Margin Uninvolved by Sarcoma | Margins uninvolved by sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951222","Margin Involved by Sarcoma","C159233","The margin of the sample has sarcoma.","Margin Involved by Sarcoma | Margin(s) involved by sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1377648","Adenocarcinoma with Osseous Metaplasia","C7684","An adenocarcinoma characterized by the presence of osseous metaplasia.","Adenocarcinoma with Osseous Metaplasia | Adenocarcinoma with osseous metaplasia",,,,,,,,,,,,,,,"4209562","Adenocarcinoma with cartilaginous and osseous metaplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266088","Adenocarcinoma with Neuroendocrine Differentiation","C66745","An invasive adenocarcinoma characterized by the presence of focal or extensive neuroendocrine differentiation.","Adenocarcinoma with Neuroendocrine Differentiation | Adenocarcinoma with neuroendocrine differentiation","8574/3","Adenocarcinoma with neuroendocrine differentiation",,,,,,,,,,,,,"4029015","Adenocarcinoma with neuroendocrine differentiation",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1515857","APC Tumor-Suppressor Gene Inactivation","C36683","A change in the nucleotide sequence of the APC gene that either inhibits expression or results in the translation of an inactive adenomatosis polyposis coli protein.","Inactivating APC Gene Mutation | APC Gene Inactivation | APC Gene Inactivation | APC Inactivating Gene Mutation | APC Inactivating Mutation | APC Loss of Function Gene Mutation | APC Loss of Function Mutation | APC Tumor-Suppressor Gene Inactivation | Inactivating APC Gene Mutation | Inactivating APC Mutation | Inactivating APC, WNT Signaling Pathway Regulator Gene Mutation | Inactivating Adenomatosis Polyposis Gene Mutation | Inactivating BTPS2 Gene Mutation | Inactivating FAP Gene Mutation | Inactivating FPC Gene Mutation | Inactivating PPP1R46 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661884","Inactivating AXIN2 Gene Mutation","C179305","A change in the nucleotide sequence of the AXIN2 gene that either inhibits expression or results in the translation of an inactive axin-2 protein.","Inactivating AXIN2 Gene Mutation | AXIN2 Gene Inactivation | AXIN2 Inactivating Gene Mutation | AXIN2 Inactivating Mutation | AXIN2 Loss of Function Gene Mutation | AXIN2 Loss of Function Mutation | Inactivating AXIL Gene Mutation | Inactivating AXIN2 Mutation | Inactivating Axin 2 Gene Mutation | Inactivating Conductin, Mouse, Homolog of Gene Mutation | Inactivating ODCRCS Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661885","Inactivating FBXW7 Gene Mutation","C179307","A change in the nucleotide sequence of the FBXW7 gene that either inhibits expression or results in the translation of an inactive F-box/WD repeat-containing protein 7.","Inactivating FBXW7 Gene Mutation | FBXW7 Gene Inactivation | FBXW7 Inactivating Gene Mutation | FBXW7 Inactivating Mutation | FBXW7 Loss of Function Gene Mutation | FBXW7 Loss of Function Mutation | Inactivating AGO Gene Mutation | Inactivating Archipelago Homolog Gene Mutation | Inactivating CDC4 Gene Mutation | Inactivating F-Box and WD Repeat Domain Containing 7 Gene Mutation | Inactivating FBW6 Gene Mutation | Inactivating FBW7 Gene Mutation | Inactivating FBX30 Gene Mutation | Inactivating FBXW6 Gene Mutation | Inactivating FBXW7 Mutation | Inactivating SEL-10 Gene Mutation | Inactivating SEL10 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661881","BAP1 Negative","C179308","An indication that expression of BAP1 has not been detected in a sample.","BAP1 Negative | BAP1 Loss of Expression | BRCA1 Associated Protein 1 Negative | BRCA1 Associated Protein-1 Negative | BRCA1-Associated Protein 1 Negative | Cerebral Protein 6 Negative | Cerebral Protein-13 Negative | Cerebral Protein-6 Negative | UCHL2 Negative | Ubiquitin Carboxyl-Terminal Hydrolase BAP1 Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970621","MME Positive","C162087","An indication that MME expression has been detected in a sample.","MME Positive | CALLA Positive | CD10 Positive | Common ALL Antigen Positive | Common Acute Lymphoblastic Leukemia Antigen Positive | Membrane Metalloendopeptidase Positive | NEP Positive | Neprilysin Positive | SFE Positive | Skin Fibroblast Elastase Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661982","Circulating Blasts 4-9 Percent","C179312","A laboratory test result indicating that 4-9 percent of the cells in a peripheral blood sample are immature mononuclear cells.","Circulating Blasts 4-9 Percent | Circulating Blasts Between 4 and 9 Percent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661983","CXCL13 Positive","C179315","An indication that expression of CXCL13 has been detected in a sample.","CXCL13 Positive | B-Cell Chemoattractant Positive | B-Cell-Attracting Chemokine 1 Positive | B-Cell-Homing Chemokine Positive | B-Lymphocyte Chemoattractant Positive | BCA-1 Positive | BCA1 Positive | BLC Positive | BLR1L Positive | Burkitt's Lymphoma Receptor-1 Ligand Positive | C-X-C Motif Chemokine 13 Positive | CXC Chemokine BLC Positive | Chemokine (C-X-C Motif) Ligand 13 Positive | SCYB13 Positive | Small-Inducible Cytokine B13 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661984","(R)-2-Hydroxyglutarate","C179314","The R-enantiomer of alpha-hydroxyglutarate (2-HG) where the hydroxy group is attached to the right side of the asymmetric carbon furthest from the carbonyl. This isoform is the predominant form found in gliomas associated with the expression of isocitrate dehydrogenase (IDH) mutants. Therefore, measurement of the expression of the R-form may be correlated more closely with those diseases than measurement of total 2-HG.","(R)-2-Hydroxyglutarate | (2R)-2-Hydroxypentanedioic Acid | (R)-2-Hydroxyglutaric Acid | (R)-2HG | (R)-Hydroxyglutarate | D-2-HG | D-2-Hydroxyglutarate | D-2HG | D2HG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661979","CYBB Gene Mutation","C179316","A change in the nucleotide sequence of the CYBB gene.","CYBB Gene Mutation | CGDX Gene Mutation | CYBB Mutation | Cytochrome B-245 Beta Chain Gene Mutation | GP91-1 Gene Mutation | GP91-PHOX Gene Mutation | NOX2 Gene Mutation | gp91 phox Gene Mutation | gp91phox Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661978","Decreased CYBB Expression","C179317","An indication that the expression of CYBB is lower than the normal range of values.","Decreased CYBB Expression | CYBB Reduced Expression | Decreased CGDX Expression | Decreased Cytochrome B(558) Subunit Beta Expression | Decreased Cytochrome B-245 Beta Chain Expression | Decreased Cytochrome B-245 Heavy Chain Expression | Decreased Cytochrome B558 Subunit Beta Expression | Decreased GP91-1 Expression | Decreased GP91-PHOX Expression | Decreased NADPH Oxidase 2 Expression | Decreased NOX2 Expression | Decreased Superoxide-Generating NADPH Oxidase Heavy Chain Subunit Expression | Decreased gp91 phox Expression | Decreased gp91phox Expression | gp91 phox Reduced Expression | gp91-phox Reduced Expression | gp91phox Reduced Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1856605","Glutathione deficiency","C179318","An indication that a lower than average level of glutathione was detected in a sample.","Low Glutathione Level | GSH Deficiency | GSH Deficient | Glutathione Deficiency | Glutathione Deficient | Low GSH | Low Glutathione",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661985","Activating GSK3B Gene Mutation","C179325","A change in the nucleotide sequence of the GSK3B gene that that results in constitutive activation of both glycogen synthase kinase-3 beta and its downstream signaling pathways.","Activating GSK3B Gene Mutation | Activating GSK3B Mutation | Activating Glycogen Synthase Kinase 3 Beta Gene Mutation | GSK3B Activating Gene Mutation | GSK3B Activating Mutation | GSK3B Gain of Function Gene Mutation | GSK3B Gain of Function Mutation | Gain of Function GSK3B Gene Mutation | Gain of Function GSK3B Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415616","HMGCS1 Gene","C179335","This gene plays a role in hydroxymethylglutaryl Coenzyme A (HMG-CoA) synthesis.","HMGCS1 Gene | 3-Hydroxy-3-Methylglutaryl-CoA Synthase 1 Gene | HMGCS1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661977","ICOS Positive","C179338","An indication that expression of ICOS has been detected in a sample.","ICOS Positive | AILIM Positive | Activation-Inducible Lymphocyte Immunomediatory Molecule Positive | Antigen CD278 Positive | CD278 Positive | Inducible T-Cell Co-Stimulator Positive | Inducible T-Cell Costimulator Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661972","Inactivating BARD1 Gene Mutation","C179340","A change in the nucleotide sequence of the BARD1 gene that either inhibits expression or results in the translation of an inactive BRCA1-associated RING domain protein 1.","Inactivating BARD1 Gene Mutation | BARD1 Gene Inactivation | BARD1 Inactivating Gene Mutation | BARD1 Inactivating Mutation | BARD1 Loss of Function Gene Mutation | BARD1 Loss of Function Mutation | Inactivating BARD-1 Gene Mutation | Inactivating BARD1 Mutation | Inactivating BRCA1 Associated RING Domain 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661971","Inactivating BLM Gene Mutation","C179341","A change in the nucleotide sequence of the BLM gene that either inhibits expression or results in the translation of an inactive Bloom syndrome protein.","Inactivating BLM Gene Mutation | BLM Gene Inactivation | BLM Inactivating Gene Mutation | BLM Inactivating Mutation | BLM Loss of Function Gene Mutation | BLM Loss of Function Mutation | Inactivating BLM Mutation | Inactivating BS Gene Mutation | Inactivating Bloom Syndrome Gene Mutation | Inactivating RECQ2 Gene Mutation | Inactivating RECQL2 Gene Mutation | Inactivating RECQL3 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661973","Inactivating CHEK1 Gene Mutation","C179343","A change in the nucleotide sequence of the CHEK1 gene that either inhibits expression or results in the translation of an inactive serine/threonine-protein kinase Chk1 protein.","Inactivating CHEK1 Gene Mutation | CHEK1 Gene Inactivation | CHEK1 Inactivating Gene Mutation | CHEK1 Inactivating Mutation | CHEK1 Loss of Function Gene Mutation | CHEK1 Loss of Function Mutation | Inactivating CHEK1 Mutation | Inactivating CHK1 Gene Mutation | Inactivating Checkpoint Kinase 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661953","Inactivating CHEK2 Gene Mutation","C179344","A change in the nucleotide sequence of the CHEK2 gene that either inhibits expression or results in the translation of an inactive serine/threonine-protein kinase Chk2 protein.","Inactivating CHEK2 Gene Mutation | CHEK2 Gene Inactivation | CHEK2 Inactivating Gene Mutation | CHEK2 Inactivating Mutation | CHEK2 Loss of Function Gene Mutation | CHEK2 Loss of Function Mutation | Inactivating CDS1 Gene Mutation | Inactivating CHEK2 Mutation | Inactivating CHK2 Gene Mutation | Inactivating Checkpoint Kinase 2 Gene Mutation | Inactivating LFS2 Gene Mutation | Inactivating RAD53 Gene Mutation | Inactivating hCds1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661955","Inactivating ERCC1 Gene Mutation","C179346","A change in the nucleotide sequence of the ERCC1 gene that either inhibits expression or results in the translation of an inactive DNA excision repair protein ERCC-1.","Inactivating ERCC1 Gene Mutation | ERCC1 Gene Inactivation | ERCC1 Inactivating Gene Mutation | ERCC1 Inactivating Mutation | ERCC1 Loss of Function Gene Mutation | ERCC1 Loss of Function Mutation | Inactivating COFS4 Gene Mutation | Inactivating ERCC Excision Repair 1, Endonuclease Non-Catalytic Subunit Gene Mutation | Inactivating ERCC1 Mutation | Inactivating Excision Repair Cross-Complementation Group 1 Gene Mutation | Inactivating Excision-Repair, Complementing Defective, In Chinese Hamster, 1 Gene Mutation | Inactivating RAD10 Gene Mutation | Inactivating UV20 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661954","Inactivating ERCC2 Gene Mutation","C179347","A change in the nucleotide sequence of the ERCC2 gene that either inhibits expression or results in the translation of an inactive general transcription and DNA repair factor IIH helicase subunit XPD protein.","Inactivating ERCC2 Gene Mutation | ERCC2 Gene Inactivation | ERCC2 Inactivating Gene Mutation | ERCC2 Inactivating Mutation | ERCC2 Loss of Function Gene Mutation | ERCC2 Loss of Function Mutation | Inactivating CXPD Gene Mutation | Inactivating EM9 Gene Mutation | Inactivating ERCC Excision Repair 2, TFIIH Core Complex Helicase Subunit Gene Mutation | Inactivating ERCC2 Mutation | Inactivating Excision Repair Cross-Complementing Rodent Repair Deficiency, Complementation Group 2 Gene Mutation | Inactivating Excision-Repair, Complementing Defective, In Chinese Hamster, 2 Gene Mutation | Inactivating MAG Gene Mutation | Inactivating TTD Gene Mutation | Inactivating TTD1 Gene Mutation | Inactivating XP4 Gene Mutation | Inactivating XPD Gene Mutation | Inactivating XPDC Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661949","Inactivating ERCC3 Gene Mutation","C179348","A change in the nucleotide sequence of the ERCC3 gene that either inhibits expression or results in the translation of an inactive TFIIH basal transcription factor complex helicase XPB subunit protein.","Inactivating ERCC3 Gene Mutation | ERCC3 Gene Inactivation | ERCC3 Inactivating Gene Mutation | ERCC3 Inactivating Mutation | ERCC3 Loss of Function Gene Mutation | ERCC3 Loss of Function Mutation | Inactivating BTF2 Gene Mutation | Inactivating ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit Gene Mutation | Inactivating ERCC3 Mutation | Inactivating Excision Repair Cross-Complementation Group 3 Gene Mutation | Inactivating Excision Repair Cross-Complementing Rodent Repair Deficiency, Complementation Group 3 Gene Mutation | Inactivating Excision-Repair, Complementing Defective, in Chinese Hamster, 3 Gene Mutation | Inactivating GTF2H Gene Mutation | Inactivating RAD25 Gene Mutation | Inactivating TTD2 Gene Mutation | Inactivating XPB Gene Mutation | Inactivating Xeroderma Pigmentosum Group B Complementing Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661951","Inactivating ERCC4 Gene Mutation","C179350","A change in the nucleotide sequence of the ERCC4 gene that either inhibits expression or results in the translation of an inactive DNA repair endonuclease XPF protein.","Inactivating ERCC4 Gene Mutation | ERCC4 Gene Inactivation | ERCC4 Inactivating Gene Mutation | ERCC4 Inactivating Mutation | ERCC4 Loss of Function Gene Mutation | ERCC4 Loss of Function Mutation | Inactivating ERCC Excision Repair 4, Endonuclease Catalytic Subunit Gene Mutation | Inactivating ERCC11 Gene Mutation | Inactivating ERCC4 Mutation | Inactivating Excision Repair Cross-Complementing Rodent Repair Deficiency, Complementation Group 4 Gene Mutation | Inactivating Excision-Repair, Complementing Defective, In Chinese Hamster, 4 Gene Mutation | Inactivating FANCQ Gene Mutation | Inactivating RAD1 Gene Mutation | Inactivating XPF Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661961","Inactivating ERCC5 Gene Mutation","C179352","A change in the nucleotide sequence of the ERCC5 gene that either inhibits expression or results in the translation of an inactive DNA repair protein complementing XP-G cells protein.","Inactivating ERCC5 Gene Mutation | ERCC5 Gene Inactivation | ERCC5 Inactivating Gene Mutation | ERCC5 Inactivating Mutation | ERCC5 Loss of Function Gene Mutation | ERCC5 Loss of Function Mutation | Inactivating COFS3 Gene Mutation | Inactivating ERCC Excision Repair 5, Endonuclease Gene Mutation | Inactivating ERCC5 Mutation | Inactivating ERCM2 Gene Mutation | Inactivating Excision Repair Cross-Complementing Rodent Repair Deficiency, Complementation Group 5 Gene Mutation | Inactivating Excision-Repair, Complementing Defective, In Chinese Hamster, 5 Gene Mutation | Inactivating UVDR Gene Mutation | Inactivating XPG Gene Mutation | Inactivating XPGC Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661960","Inactivating MRE11 Gene Mutation","C179353","A change in the nucleotide sequence of the MRE11 gene that either inhibits expression or results in the translation of an inactive double-strand break repair protein MRE11.","Inactivating MRE11 Gene Mutation | Inactivating ATLD Gene Mutation | Inactivating HNGS1 Gene Mutation | Inactivating MRE11 Homolog A, Double Strand Break Repair Nuclease Gene Mutation | Inactivating MRE11 Homolog, Double Strand Break Repair Nuclease Gene Mutation | Inactivating MRE11 Mutation | Inactivating MRE11A Gene Mutation | Inactivating MRE11B Gene Mutation | MRE11 Gene Inactivation | MRE11 Inactivating Gene Mutation | MRE11 Inactivating Mutation | MRE11 Loss of Function Gene Mutation | MRE11 Loss of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661963","Inactivating NBN Gene Mutation","C179354","A change in the nucleotide sequence of the NBN gene that either inhibits expression or results in the translation of an inactive nibrin protein.","Inactivating NBN Gene Mutation | Inactivating AT-V1 Gene Mutation | Inactivating AT-V2 Gene Mutation | Inactivating ATV Gene Mutation | Inactivating NBN Mutation | Inactivating NBS Gene Mutation | Inactivating NBS1 Gene Mutation | Inactivating Nibrin Gene Mutation | Inactivating Nijmegen Breakage Syndrome 1 Gene Mutation | Inactivating P95 Gene Mutation | NBN Gene Inactivation | NBN Inactivating Gene Mutation | NBN Inactivating Mutation | NBN Loss of Function Gene Mutation | NBN Loss of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661962","Inactivating PRKDC Gene Mutation","C179355","A change in the nucleotide sequence of the PRKDC gene that either inhibits expression or results in the translation of an inactive DNA-dependent protein kinase catalytic subunit protein.","Inactivating PRKDC Gene Mutation | Inactivating DNA-PKcs Gene Mutation | Inactivating DNAPK Gene Mutation | Inactivating DNPK1 Gene Mutation | Inactivating HYRC Gene Mutation | Inactivating HYRC1 Gene Mutation | Inactivating Hyper-Radiosensitivity of Murine SCID Mutation, Complementing 1 Gene Mutation | Inactivating PRKDC Mutation | Inactivating Protein Kinase, DNA-Activated, Catalytic Polypeptide Gene Mutation | Inactivating XRCC7 Gene Mutation | Inactivating p350 Gene Mutation | PRKDC Gene Inactivation | PRKDC Inactivating Gene Mutation | PRKDC Inactivating Mutation | PRKDC Loss of Function Gene Mutation | PRKDC Loss of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661957","Inactivating RAD50 Gene Mutation","C179356","A change in the nucleotide sequence of the RAD50 gene that either inhibits expression or results in the translation of an inactive DNA repair protein RAD50.","Inactivating RAD50 Gene Mutation | Inactivating NBSLD Gene Mutation | Inactivating RAD50 Double Strand Break Repair Protein Gene Mutation | Inactivating RAD50 Homolog (S. cerevisiae) Gene Mutation | Inactivating RAD50 Homolog, Double Strand Break Repair Protein Gene Mutation | Inactivating RAD50 Mutation | Inactivating RAD50-2 Gene Mutation | Inactivating RAD502 Gene Mutation | Inactivating hRad50 Gene Mutation | RAD50 Gene Inactivation | RAD50 Inactivating Gene Mutation | RAD50 Inactivating Mutation | RAD50 Loss of Function Gene Mutation | RAD50 Loss of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661956","Inactivating RAD51 Gene Mutation","C179357","A change in the nucleotide sequence of the RAD51 gene that either inhibits expression or results in the translation of an inactive DNA repair protein RAD51 homolog 1.","Inactivating RAD51 Gene Mutation | Inactivating BRCC5 Gene Mutation | Inactivating FANCR Gene Mutation | Inactivating HRAD51 Gene Mutation | Inactivating HsRad51 Gene Mutation | Inactivating RAD51 Mutation | Inactivating RAD51 Recombinase Gene Mutation | Inactivating RAD51A Gene Mutation | Inactivating RECA Gene Mutation | RAD51 Gene Inactivation | RAD51 Inactivating Gene Mutation | RAD51 Inactivating Mutation | RAD51 Loss of Function Gene Mutation | RAD51 Loss of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661959","Inactivating RAD51C Gene Mutation","C179358","A change in the nucleotide sequence of the RAD51C gene that either inhibits expression or results in the translation of an inactive DNA repair protein RAD51 homolog 3.","Inactivating RAD51C Gene Mutation | Inactivating BROVCA3 Gene Mutation | Inactivating FANCO Gene Mutation | Inactivating RAD51 Homolog C Gene Mutation | Inactivating RAD51 Paralog C Gene Mutation | Inactivating RAD51C Mutation | Inactivating RAD51L2 Gene Mutation | RAD51C Gene Inactivation | RAD51C Inactivating Gene Mutation | RAD51C Inactivating Mutation | RAD51C Loss of Function Gene Mutation | RAD51C Loss of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661937","Inactivating RAD51D Gene Mutation","C179361","A change in the nucleotide sequence of the RAD51D gene that either inhibits expression or results in the translation of an inactive DNA repair protein RAD51 homolog 4.","Inactivating RAD51D Gene Mutation | Inactivating BROVCA4 Gene Mutation | Inactivating R51H3 Gene Mutation | Inactivating RAD51 Homolog D Gene Mutation | Inactivating RAD51 Paralog D Gene Mutation | Inactivating RAD51-Like 3 Gene Mutation | Inactivating RAD51L3 Gene Mutation | Inactivating TRAD Gene Mutation | RAD51D Gene Inactivation | RAD51D Inactivating Gene Mutation | RAD51D Inactivating Mutation | RAD51D Loss of Function Gene Mutation | RAD51D Loss of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661939","Inactivating WRN Gene Mutation","C179363","A change in the nucleotide sequence of the WRN gene that either inhibits expression or results in the translation of an inactive Werner syndrome ATP-dependent helicase protein.","Inactivating WRN Gene Mutation | Inactivating RECQ3 Gene Mutation | Inactivating RECQL2 Gene Mutation | Inactivating RECQL3 Gene Mutation | Inactivating WRN Mutation | Inactivating Werner Syndrome Gene Mutation | WRN Gene Inactivation | WRN Inactivating Gene Mutation | WRN Inactivating Mutation | WRN Loss of Function Gene Mutation | WRN Loss of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520115","WT-1 Tumor-Suppressor Gene Inactivation","C36684","A change in the nucleotide sequence of the WT1 gene that either inhibits expression or results in the translation of an inactive Wilms tumor protein.","Inactivating WT1 Gene Mutation | Inactivating GUD Gene Mutation | Inactivating WAGR Gene Mutation | Inactivating WIT-2 Gene Mutation | Inactivating WT1 Gene Mutation | Inactivating WT1 Mutation | Inactivating WT33 Gene Mutation | Inactivating Wilms Tumor 1 Gene Mutation | WT-1 Tumor-Suppressor Gene Inactivation | WT1 Gene Inactivation | WT1 Gene Inactivation | WT1 Inactivating Gene Mutation | WT1 Inactivating Mutation | WT1 Loss of Function Gene Mutation | WT1 Loss of Function Mutation | WT1 Tumor-Suppressor Gene Inactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661934","Inactivating XRCC2 Gene Mutation","C179364","A change in the nucleotide sequence of the XRCC2 gene that either inhibits expression or results in the translation of an inactive DNA repair protein XRCC2.","Inactivating XRCC2 Gene Mutation | Inactivating DNA Repair Protein XRCC2 Gene Mutation | Inactivating X-Ray Repair Complementing Defective Repair in Chinese Hamster Cells 2 Gene Mutation | Inactivating X-Ray Repair Cross Complementing 2 Gene Mutation | Inactivating XRCC2 Mutation | XRCC2 Gene Inactivation | XRCC2 Inactivating Gene Mutation | XRCC2 Inactivating Mutation | XRCC2 Loss of Function Gene Mutation | XRCC2 Loss of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661936","Inactivating XRCC3 Gene Mutation","C179366","A change in the nucleotide sequence of the XRCC3 gene that either inhibits expression or results in the translation of an inactive DNA repair protein XRCC3.","Inactivating XRCC3 Gene Mutation | Inactivating DNA Repair Protein XRCC3 Gene Mutation | Inactivating X-Ray Repair Complementing Defective Repair in Chinese Hamster Cells 3 Gene Mutation | Inactivating X-Ray Repair Cross Complementing 3 Gene Mutation | Inactivating X-Ray Repair Cross-Complementing Protein 3 Gene Mutation | Inactivating XRCC3 Mutation | XRCC3 Gene Inactivation | XRCC3 Inactivating Gene Mutation | XRCC3 Inactivating Mutation | XRCC3 Loss of Function Gene Mutation | XRCC3 Loss of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661945","Activating LGR5 Gene Mutation","C179368","A change in the nucleotide sequence of the LGR5 gene that that results in constitutive activation of both leucine-rich repeat-containing G-protein coupled receptor 5 and its downstream signaling pathways.","Activating LGR5 Gene Mutation | Activating FEX Gene Mutation | Activating GPR49 Gene Mutation | Activating GPR67 Gene Mutation | Activating GRP49 Gene Mutation | Activating HG38 Gene Mutation | Activating LGR5 Mutation | Activating Leucine-Rich Repeat Containing G Protein-Coupled Receptor 5 Gene Mutation | Gain of Function LGR5 Gene Mutation | Gain of Function LGR5 Mutation | LGR5 Activating Gene Mutation | LGR5 Activating Mutation | LGR5 Gain of Function Gene Mutation | LGR5 Gain of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1661947","Activating LRP6 Gene Mutation","C179370","A change in the nucleotide sequence of the LRP6 gene that that results in constitutive activation of both low-density lipoprotein receptor-related protein 6 and its downstream signaling pathways.","Activating LRP6 Gene Mutation | Activating ADCAD2 Gene Mutation | Activating LDL Receptor Related Protein 6 Gene Mutation | Activating LRP-6 Gene Mutation | Activating LRP6 Mutation | Activating Low Density Lipoprotein Receptor-Related Protein 6 Gene Mutation | Gain of Function LRP6 Gene Mutation | Gain of Function LRP6 Mutation | LRP6 Activating Gene Mutation | LRP6 Activating Mutation | LRP6 Gain of Function Gene Mutation | LRP6 Gain of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663137","Inactivating MPO Gene Mutation","C179372","A change in the nucleotide sequence of the MPO gene that either inhibits expression or results in the translation of an inactive myeloperoxidase protein.","Inactivating MPO Gene Mutation | Inactivating MPO Mutation | Inactivating Myeloperoxidase Gene Mutation | MPO Deficiency | MPO Deficient | MPO Gene Inactivation | MPO Inactivating Gene Mutation | MPO Inactivating Mutation | MPO Loss of Function | MPO Loss of Function Gene Mutation | MPO Loss of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662242","CYBA Gene Mutation","C179379","A change in the nucleotide sequence of the CYBA gene.","CYBA Gene Mutation | CYBA Mutation | Cytochrome B Light Chain Gene Mutation | Cytochrome B(558), Alpha Subunit Gene Mutation | Cytochrome B, Alpha Polypeptide Gene Mutation | Cytochrome B-245 Alpha Chain Gene Mutation | p22 phox Gene Mutation | p22-PHOX Gene Mutation | p22phox Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662239","Decreased CYBA Expression","C179380","An indication that the expression of CYBA is lower than the normal range of values.","Decreased CYBA Expression | CYBA Reduced Expression | Decreased Cytochrome B-245 Alpha Chain Expression | Decreased Cytochrome B-245 Light Chain Expression | Decreased Cytochrome B558 Subunit Alpha Expression | Decreased Superoxide-Generating NADPH Oxidase Heavy Chain Subunit Expression | Decreased Superoxide-Generating NADPH Oxidase Light Chain Subunit Expression | Decreased p22 phox Expression | Decreased p22-PHOX Expression | Decreased p22phox Expression | p22 phox Reduced Expression | p22-phox Reduced Expression | p22phox Reduced Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662247","NCF4 Gene Mutation","C179384","A change in the nucleotide sequence of the NCF4 gene.","NCF4 Gene Mutation | NCF Gene Mutation | NCF4 Mutation | Neutrophil Cytosolic Factor 4 Gene Mutation | P40PHOX Gene Mutation | SH3PXD4 Gene Mutation | p40 phox Gene Mutation | p40-phox Gene Mutation | p40phox Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662246","Decreased NCF4 Expression","C179385","An indication that the expression of NCF4 is lower than the normal range of values.","Decreased NCF4 Expression | Decreased Neutrophil Cytosol Factor 4 Expression | Decreased Neutrophil Cytosolic Factor 4 Expression | Decreased SH3 and PX Domain-Containing Protein 4 Expression | Decreased p40 phox Expression | Decreased p40-phox Expression | Decreased p40phox Expression | NCF4 Reduced Expression | p40 phox Reduced Expression | p40-phox Reduced Expression | p40phox Reduced Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662243","NCF1 Gene Mutation","C179389","A change in the nucleotide sequence of the NCF1 gene.","NCF1 Gene Mutation | NCF1 Mutation | NCF1A Gene Mutation | NOXO2 Gene Mutation | Neutrophil Cytosolic Factor 1 Gene Mutation | SH3PXD1A Gene Mutation | p47 phox Gene Mutation | p47-phox Gene Mutation | p47phox Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662245","Decreased NCF1 Expression","C179390","An indication that the expression of NCF1 is lower than the normal range of values.","Decreased NCF1 Expression | Decreased NCF-1 Expression | Decreased NCF-2 Expression | Decreased NOXO2 Expression | Decreased Neutrophil Cytosol Factor 1 Expression | Decreased Neutrophil Cytosolic Factor 1 Expression | Decreased Nox Organizer 2 Expression | Decreased SH3 and PX Domain-Containing Protein 1A Expression | Decreased p47 phox Expression | Decreased p47-phox Expression | Decreased p47phox Expression | NCF1 Reduced Expression | p47 phox Reduced Expression | p47-phox Reduced Expression | p47phox Reduced Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662244","NCF2 Gene Mutation","C179391","A change in the nucleotide sequence of the NCF2 gene.","NCF2 Gene Mutation | NCF2 Mutation | NOXA2 Gene Mutation | Neutrophil Cytosolic Factor 2 Gene Mutation | P67-PHOX Gene Mutation | P67PHOX Gene Mutation | SH3PXD1A Gene Mutation | p67 phox Gene Mutation | p67phox Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662229","Decreased NCF2 Expression","C179392","An indication that the expression of NCF2 is lower than the normal range of values.","Decreased NCF2 Expression | Decreased NCF-2 Expression | Decreased Neutrophil Cytosol Factor 2 Expression | Decreased Neutrophil Cytosolic Factor 2 Expression | Decreased p67 phox Expression | Decreased p67-phox Expression | Decreased p67phox Expression | NCF2 Reduced Expression | p67 phox Reduced Expression | p67-phox Reduced Expression | p67phox Reduced Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662228","PDCD1 Positive","C179393","An indication that expression of PDCD1 has been detected in a sample.","PDCD1 Positive | Antigen CD279 Positive | CD279 Antigen Positive | CD279 Positive | PD-1 Positive | PD1 Positive | Programmed Cell Death Protein 1 Positive | hPD-1 Positive | hPD-l Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662231","Plasma Tumor DNA","C179394","Neoplasm-derived DNA that is found in blood plasma and is not associated with cells in the circulation.","Plasma Tumor DNA | Plasma Tumor-Derived DNA | ptDNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419185","QSOX1 Gene","C179396","This gene plays a role in extracellular protein disulfide bond formation and fibroblast quiescence.","QSOX1 Gene | QSOX1 | Quiescin Sulfhydryl Oxidase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662237","Inactivating RAC2 Gene Mutation","C179403","A change in the nucleotide sequence of the RAC2 gene that either inhibits expression or results in the translation of an inactive Ras-related C3 botulinum toxin substrate 2 protein.","Inactivating RAC2 Gene Mutation | Inactivating EN-7 Gene Mutation | Inactivating Gx Gene Mutation | Inactivating RAC2 Mutation | Inactivating Rac Family Small GTPase 2 Gene Mutation | Inactivating Ras-Related C3 Botulinum Toxin Substrate 2 Gene Mutation | Inactivating p21-Rac2 Gene Mutation | RAC2 Deficiency | RAC2 Deficient | RAC2 Gene Inactivation | RAC2 Inactivating Gene Mutation | RAC2 Inactivating Mutation | RAC2 Loss of Function | RAC2 Loss of Function Gene Mutation | RAC2 Loss of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662230","Inactivating RNF43 Gene Mutation","C179395","A change in the nucleotide sequence of the RNF43 gene that either inhibits expression or results in the translation of an inactive E3 ubiquitin-protein ligase RNF43 protein.","Inactivating RNF43 Gene Mutation | Inactivating RNF124 Gene Mutation | Inactivating RNF43 Mutation | Inactivating Ring Finger Protein 43 Gene Mutation | Inactivating URCC Gene Mutation | RNF43 Gene Inactivation | RNF43 Inactivating Gene Mutation | RNF43 Inactivating Mutation | RNF43 Loss of Function Gene Mutation | RNF43 Loss of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662232","Inactivating TCF7L2 Gene Mutation","C179405","A change in the nucleotide sequence of the TCF7L2 gene that either inhibits expression or results in the translation of an inactive transcription factor 7-like 2 protein.","Inactivating TCF7L2 Gene Mutation | Inactivating TCF-4 Gene Mutation | Inactivating TCF4 Gene Mutation | Inactivating TCF7L2 Mutation | Inactivating Transcription Factor 7 Like 2 Gene Mutation | TCF7L2 Gene Inactivation | TCF7L2 Inactivating Gene Mutation | TCF7L2 Inactivating Mutation | TCF7L2 Loss of Function | TCF7L2 Loss of Function Gene Mutation | TCF7L2 Loss of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523903","Diffuse Type Adenocarcinoma","C4127","An adenocarcinoma characterized by the presence of a diffuse cellular infiltrate which is composed of poorly cohesive cells with minimal or no glandular formations. Representative example is the gastric diffuse adenocarcinoma.","Diffuse Type Adenocarcinoma | Adenocarcinoma, Diffuse Type | Adenocarcinoma, diffuse type | Carcinoma, diffuse type | Diffuse Type Carcinoma","8145/3","Carcinoma, diffuse type",,,,,,,,,,,,,"4074210","Carcinoma, diffuse type",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1335913","FNCLCC Sarcoma Grade 1","C9024","A sarcoma with a total score of 2 or 3 according to the FNCLCC guidelines.","Sarcoma G1 | AJCC G1 Sarcoma | AJCC Grade 1 Sarcoma | AJCC Grade I Sarcoma | FNCLCC Sarcoma Grade 1 | FNCLCC Sarcoma Grade 1 | G1 Grade 1 | Sarcoma Differentiation Score 1 | Sarcoma FNCLCC Grade 1 | Sarcoma Grade 1 | Well Differentiated Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969827","FNCLCC Sarcoma Grade GX Grade cannot be assessed","C160730","A sarcoma with a GX  grade that cannot be assessed.","FNCLCC Sarcoma Grade GX Grade cannot be assessed | GX Grade cannot be assessed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969826","GIST Histologic Grade","C160731","An assessment of the GIST histologic grade.","GIST Histologic Grade | Histologic Grade (GISTs)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969780","GIST Grade 2","C160733","A grade that may refer to GISTs with malignant histologic characteristics.","GIST Grade 2 | G2 High grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969781","GIST Grade 1","C160732","A grade that may refer to GISTs with benign histologic characteristics.","GIST Grade 1 | G1 Low grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1711149","t(2;2)(q35;p23)","C45449","A pericentric translocation involving q35 and p23 on chromosome 2.","t(2;2)(q35;p23) | t(2 ;2)(q35 ;p23) (Rhabdomyosarcoma)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053816","t(1;13)(p36;q14)","C36376","A chromosomal translocation involving the PAX7 gene on chromosome 1p36 and the FOXO1 gene on chromosome 13q14.","t(1;13)(p36;q14) | t(1;13)(p36;q14) (Rhabdomyosarcoma)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515752","t(2;13)(q35;q14)","C36389","A chromosomal translocation involving the PAX3 gene on chromosome 2q35 and the FOXO1 gene on chromosome 13q14.","t(2;13)(q35;q14) | t(2;13)(q35;q14) (Rhabdomyosarcoma)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0795843","Ring Chromosome 12","C158951","An aberration of chromosome 12 where the arms have fused to form a ring.","Ring Chromosome 12 | Ring form of chromosome 12 (Liposarcoma) | r12",,,,,,,,,,,,,,,"36674763","Ring chromosome 12 syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1515664","inv(22q12)","C38635","A cytogenetic abnormality that involves an inversion at 22q12.","inv(22q12) | inv(22)(q12q12) | inv(22)(q12q12) (Ewing sarcoma)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515787","t(7;22)(p22;q12)","C36368","A cytogenetic abnormality that refers to the translocation of the short arm (p22) of chromosome 7 and the long arm (q12) of chromosome 22.","t(7;22)(p22;q12) | t(7;22)(p22;q12) (Ewing sarcoma)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515755","t(2;22)(q33;q12)","C37249","A chromosomal translocation involving the CREB1 gene on chromosome 2q33 and the EWSR1 gene on chromosome 22q12.","t(2;22)(q33;q12) | t(2;22)(q33;q12) (Ewing sarcoma) | t(2;22)(q33;q12) (Ewing sarcoma, Clear cell sarcoma)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515713","t(11;22)(q24;q12)","C27214","A chromosomal translocation involving the FLI1 gene on chromosome 11q24 and the EWSR1 gene on chromosome 22q12.","t(11;22)(q24;q12) | t(11;22) (q24;q12) | t(11;22) EWS-FLI1 | t(11;22)(q24;q12) (Ewing sarcoma) | t(11;22)(q24;q12)(EWS/FLI-1)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL358505","t(X;17)(p11.2;q25)","C36392","A chromosomal translocation involving the TFE3 gene on chromosome Xp11.2 and the ASPSCR1 gene on chromosome 17q25.","t(X;17)(p11.2;q25) | t(X;17)(p11;q25) | t(X;17)(p11;q25) (Alveolar soft part sarcoma)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969813","GIST Grade Cannot be Assessed","C160713","A GIST grade that cannot be assessed.","GIST Grade Cannot be Assessed | GX Grade cannot be assessed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662217","Essential Worker","C179411","A worker employed in operations and services that are essential to ensure the continuity of critical infrastructure operations.","Essential Worker | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662212","Frontline Worker","C179412","A worker who cannot feasibly work from home.","Frontline Worker | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507906","1341200-45-0","C127116","An orally available and selective inhibitor of the receptor tyrosine kinase AXL (UFO), with potential antineoplastic activity. Upon administration, dubermatinib targets and binds to AXL and prevents its activity. This blocks AXL-mediated signal transduction pathways and inhibits the epithelial-mesenchymal transition (EMT), which, in turn, inhibits tumor cell proliferation and migration. In addition, TP-0903 enhances chemo-sensitivity to certain other chemotherapeutic agents. AXL, a member of the Tyro3, AXL and Mer (TAM) family of receptor tyrosine kinases and overexpressed by many tumor cell types, plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance and poor prognosis.","Dubermatinib | 2-((5-Chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide | DUBERMATINIB | TP 0903 | TP-0903 | TP0903",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555284","Sotorasib","C154287","An orally available inhibitor of the specific KRAS mutation, p.G12C, with potential antineoplastic activity. Upon oral administration, sotorasib selectively targets, binds to and inhibits the activity of the KRAS p.G12C mutant. This may inhibit growth in KRAS p.G12C-expressing tumor cells. The KRAS p.G12C mutation is seen in some tumor cell types and plays a key role in tumor cell proliferation.","Sotorasib | AMG 510 | AMG-510 | AMG510 | Lumakras | Lumykras | SOTORASIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662214","ABL Class Rearrangement Positive Ph-Like B Acute Lymphoblastic Leukemia","C179414","A finding indicating that activating rearrangements of an ABL class tyrosine kinase gene (which includes ABL1, ABL2, PDGFRB, and CSF1R) have been detected in a patient with Ph-like B acute lymphoblastic leukemia. This finding is associated with a higher relapse risk and may be amenable to treatment that utilizes tyrosine kinase inhibitors.","ABL Class Rearrangement Positive Ph-Like B Acute Lymphoblastic Leukemia | ABL Class Fusion Positive ALL | ABL Class Ph-Like B-ALL | ABL Class Rearrangement Positive Ph-Like B-ALL | ABL-Class Fusion Positive | ABL-Class Fusion Positive ALL | ABL-Class Ph-Like B-ALL | Ph-like ABL Class Fusion Positive | Ph-like ABL class | Ph-like ABL-Class Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662224","Activating JAK-STAT Pathway Positive Ph-Like B Acute Lymphoblastic Leukemia","C179416","A finding indicating that JAK-STAT pathway activating mutations or rearrangements have been detected in a patient with Ph-like B acute lymphoblastic leukemia. This finding is associated with a higher relapse risk and may amenable to treatment that utilizes JAK-STAT pathway inhibitors.","Activating JAK-STAT Pathway Positive Ph-Like B Acute Lymphoblastic Leukemia | Activating JAK-STAT Pathway Positive Ph-Like B-ALL | Gain of Function JAK-STAT Pathway Positive Ph-Like B Acute Lymphoblastic Leukemia | Gain of Function JAK-STAT Pathway Positive Ph-Like B-ALL | JAK-STAT Class Positive Ph-Like B Acute Lymphoblastic Leukemia | JAK-STAT Class Positive Ph-Like B-ALL | Ph-like JAK STAT class",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382408","Dulaglutide","C169923","A glucagon-like peptide-1 (GLP-1) receptor agonist that is 90% homologous to native human GLP-1 (7-37) and is composed of a dipeptidyl peptidase-IV-protected GLP-1 analog covalently linked to a human immunoglobulin G4 (IgG4)-Fc heavy chain, with antihyperglycemic activity. Upon administration, dulaglutide binds to and activates GLP-1 receptors, thereby increasing intracellular cyclic AMP (cAMP) in pancreatic beta cells. This increases glucose-dependent insulin release. Dulaglutide also reduces the elevated glucagon secretion by inhibiting alpha cells of the pancreas and slows gastric emptying. Altogether this lowers the postprandial glucose level. GLP-1 is normally secreted by L cells of the gastrointestinal (GI) mucosa in response to a meal to normalize blood glucose levels.","Dulaglutide | DULAGLUTIDE | LY2189265 | Trulicity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971169","Radiation Therapy was Curative Therapy","C160612","A response that radiation therapy was the curative therapy.","Radiation Therapy was Curative Therapy | Definitive | Radiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969670","Concurrent Chemotherapy was Curative Therapy","C160611","A response that concurrent chemotherapy was the curative therapy.","Concurrent Chemotherapy was Curative Therapy | Concurrent Chemotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969659","Non-Concurrent Chemotherapy was Curative Therapy","C160610","A response that non-concurrent chemotherapy was the curative therapy.","Non-Concurrent Chemotherapy was Curative Therapy | Chemotherapy (not given concurrently)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977770","Completion Date","C164472","The date on which the activity or entity is finished.","Completion Date | completionDate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950876","Method of Definitive (Curative) Therapy","C158801","A question about what is the definitive therapy method.","What is the Definitive Therapy Method | Definitive Therapy Method | Method of Definitive (Curative) Therapy | Method of Definitive Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950879","After the completion of definitive (curative) therapy, was there evidence of disease","C158804","A question about whether evidence of disease was present after the completion of therapy.","Was Evidence of Disease Present after Completion of Therapy | After the completion of definitive (curative) therapy, was there evidence of disease | Evidence of Disease Present after Completion of Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662295","Consolidation Therapy with High-Dose Chemotherapy and Stem Cell Rescue","C179468","Treatment of cancer with high dose chemotherapy and autologous stem cell rescue after initial induction therapy.","Consolidation Therapy with High-Dose Chemotherapy and Stem Cell Rescue | Consolidation Therapy with HDC-SCR | Consolidation Therapy with HDC/SCR | Consolidation Therapy with HDCSCR | Consolidation Therapy with High-Dose Chemotherapy and Tandem Autologous Stem Cell Rescue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662296","Whole Ventricular and Spinal Canal Irradiation","C179467","Delivery of radiation therapy to the whole ventricular system and spinal canal.","Whole Ventricular and Spinal Canal Irradiation | WVSCI | Whole Ventricular Spinal Canal Irradiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985698","Safety Report","C93488","A report that provides notification of an adverse event, product problem, and/or information that is relevant to either. A report typically includes causal association, management strategies, authorship, sender/receiver organizations, subject of adverse event, or name of product.","Safety Report | Safety Reports | SafetyReportVersion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950857","Specify Mutation Analysis Method","C158846","A request to enter the specific molecular analysis method used to detect and identify mutations in that section of the form.","Specify Mutation Analysis Method | Mutational Analysis Testing Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086785","Reduced Number","C124577","A decrease in the quantity of an entity.","Reduced Number | Fewer | Fewer Than Expected | REDUCED NUMBER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662105","Genome Variation","C179559","All of the differences in the complete genomic sequence of an organism when compared to a reference sequence.","Genome Variation | Genome Variant | Genomic Variant | Genomic Variation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662090","SARS Coronavirus 2 B.1.1.7","C179573","A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: deletions of the amino acids at positions 69, 70 and 144 and amino acid substitutions N501Y, A570D, D614G, P681H, T716I, S982A and D1118H. The substitutions E484K, S494P and K1191N have also been detected in some but not all sequences for this lineage.","SARS Coronavirus 2 B.1.1.7 | Alpha | Alpha (B.1.1.7 and Q lineages) | B.1.1.7 | B.1.1.7 UK | SARS Coronavirus 2 Variant Lineage B.1.1.7 | SARS-CoV-2 B.1.1.7 | SARS2 B.1.1.7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663129","SARS Coronavirus 2 B.1.351","C179575","A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: deletions of the amino acids at positions 241-242 and amino acid substitutions D80A, D215G, K417N, E484K, N501Y, D614G and A701V.","SARS Coronavirus 2 B.1.351 | B.1.351 | B.1.351 South Africa | Beta | Beta (B.1.351 and descendant lineages) | SARS Coronavirus 2 Variant Lineage B.1.351 | SARS-CoV-2 B.1.351 | SARS2 B.1.351",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663110","SARS Coronavirus 2 B.1.427","C179576","A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: amino acid substitutions L452R and D614G.","SARS Coronavirus 2 B.1.427 | B.1.427 | B.1.427 US California | Epsilon | Epsilon (B.1.427 and B.1.429) | SARS Coronavirus 2 Variant Lineage B.1.427 | SARS-CoV-2 B.1.427 | SARS2 B.1.427",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662190","SARS Coronavirus 2 B.1.429","C179577","A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: amino acid substitutions S13I, W152C, L452R and D614G.","SARS Coronavirus 2 B.1.429 | B.1.429 | B.1.429 US California | Epsilon | Epsilon (B.1.429) | SARS Coronavirus 2 Variant Lineage B.1.429 | SARS-CoV-2 B.1.429 | SARS2 B.1.429",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663123","SARS Coronavirus 2 B.1.525","C179579","A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: deletions of the amino acids at positions 69, 70 and 144 and amino acid substitutions A67V, E484K, D614G, Q677H and F888L.","SARS Coronavirus 2 B.1.525 | B.1.525 | B.1.525 UK/Nigeria December 2020 | Eta | Eta (B.1.525) | SARS Coronavirus 2 Variant Lineage B.1.525 | SARS-CoV-2 B.1.525 | SARS2 B.1.525",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663128","SARS Coronavirus 2 B.1.526","C179580","A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: amino acid substitutions T95I, D253G and D614G. The substitutions L5F, S477N, E484K and A701V have also been detected in some but not all sequences for this lineage.","SARS Coronavirus 2 B.1.526 | B.1.526 | B.1.526 US New York November 2020 | Iota | Iota (B.1.526) | SARS Coronavirus 2 Variant Lineage B.1.526 | SARS-CoV-2 B.1.526 | SARS2 B.1.526",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662185","SARS Coronavirus 2 B.1.526.1","C179582","A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: deletion of the amino acids at position 144 and amino acid substitutions D80G, F157S, L452R, D614G and D950H. The substitutions T791I and T859N have also been detected in some but not all sequences for this lineage.","SARS Coronavirus 2 B.1.526.1 | B.1.526.1 | B.1.526.1 US New York October 2020 | SARS Coronavirus 2 Variant Lineage B.1.526.1 | SARS-CoV-2 B.1.526.1 | SARS2 B.1.526.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662188","SARS Coronavirus 2 B.1.617","C179583","A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: amino acid substitutions L452R, E484Q and D614G.","SARS Coronavirus 2 B.1.617 | B.1.617 | B.1.617 India February 2021 | SARS Coronavirus 2 Variant Lineage B.1.617 | SARS-CoV-2 B.1.617 | SARS2 B.1.617",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663122","SARS Coronavirus 2 B.1.617.1","C179585","A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: amino acid substitutions G142D, E154K, L452R, E484Q, D614G, P681R and Q1071H. The substitution T95I has also been detected in some but not all sequences for this lineage.","SARS Coronavirus 2 B.1.617.1 | B.1.617.1 | B.1.617.1 India December 2020 | Kappa | Kappa (B.1.617.1) | SARS Coronavirus 2 Variant Lineage B.1.617.1 | SARS-CoV-2 B.1.617.1 | SARS2 B.1.617.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663109","SARS Coronavirus 2 B.1.617.2","C179586","A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: deletions of the amino acids at positions 156 and 157 and amino acid substitutions T19R, R158G, L452R, T478K, D614G, P681R and D950N. The substitution G142D has also been detected in some but not all sequences for this lineage.","SARS Coronavirus 2 B.1.617.2 | B.1.617.2 | B.1.617.2 India December 2020 | Delta | Delta (B.1.617.2 and AY lineages) | SARS Coronavirus 2 Variant Lineage B.1.617.2 | SARS-CoV-2 B.1.617.2 | SARS2 B.1.617.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662175","SARS Coronavirus 2 B.1.617.3","C179596","A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: amino acid substitutions T19R, G142D, L452R, E484Q, D614G, P681R, D950N.","SARS Coronavirus 2 B.1.617.3 | B.1.617.3 | B.1.617.3 India October 2020 | SARS Coronavirus 2 Variant Lineage B.1.617.3 | SARS-CoV-2 B.1.617.3 | SARS2 B.1.617.3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663113","SARS-CoV-2 P.2 variant","C179598","A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: amino acid substitutions E484K, D614G and V1176F. The substitution F565L has also been detected in some but not all sequences for this lineage.","SARS Coronavirus 2 P.2 | B.1.1.28.2 | B.1.128.2 | P.2 | P.2 Brazil April 2020 | SARS Coronavirus 2 Variant Lineage P.2 | SARS-CoV-2 B.1.128.2 | SARS-CoV-2 P.2 | SARS2 P.2 | Zeta | Zeta (P.2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663130","SARS Coronavirus 2 P.1","C179599","A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: amino acid substitutions L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I and V1176F.","SARS Coronavirus 2 P.1 | B.1.1.28.1 | B.1.128.1 | Gamma | Gamma (P.1 and descendant lineages) | P.1 | P.1 Japan/Brazil | SARS Coronavirus 2 Variant Lineage P.1 | SARS-CoV-2 B.1.128.1 | SARS-CoV-2 P.1 | SARS2 P.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662173","SARS Coronavirus 2 B.1.128","C179600","A variant lineage of SARS coronavirus 2 that is the ancestor for the P.1 and P.2 lineages.","SARS Coronavirus 2 B.1.128 | B.1.1.28 | B.1.128 | B.1.128 Brazil | SARS Coronavirus 2 Variant Lineage B.1.128 | SARS-CoV-2 B.1.128 | SARS2 B.1.128",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662177","SARS Coronavirus 2 Spike Glycoprotein D614G Substitution Positive","C179606","An indication that expression of SARS coronavirus 2 spike glycoprotein where the aspartic acid at amino acid position 614 has been substituted with glycine has been detected in a sample.","SARS Coronavirus 2 Spike Glycoprotein D614G Substitution Positive | D614G | SARS Coronavirus 2 S Protein D614G Substitution Positive | SARS Coronavirus 2 Spike Glycoprotein Asp614Gly Substitution Detected | SARS Coronavirus 2 Spike Glycoprotein Asp614Gly Substitution Positive | SARS Coronavirus 2 Spike Glycoprotein Asp614Gly Substitution Present | SARS Coronavirus 2 Spike Glycoprotein D614G Positive | SARS Coronavirus 2 Spike Glycoprotein D614G Substitution Detected | SARS Coronavirus 2 Spike Glycoprotein D614G Substitution Present | SARS2 Spike Glycoprotein D614G Substitution Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662179","SARS Coronavirus 2 Spike Glycoprotein N501Y Substitution Positive","C179608","An indication that expression of SARS coronavirus 2 spike glycoprotein where the asparagine at amino acid position 501 has been substituted with tyrosine has been detected in a sample.","SARS Coronavirus 2 Spike Glycoprotein N501Y Substitution Positive | N501Y | SARS Coronavirus 2 S Protein N501Y Substitution Positive | SARS Coronavirus 2 Spike Glycoprotein Asn501Tyr Substitution Detected | SARS Coronavirus 2 Spike Glycoprotein Asn501Tyr Substitution Positive | SARS Coronavirus 2 Spike Glycoprotein Asn501Tyr Substitution Present | SARS Coronavirus 2 Spike Glycoprotein N501Y Substitution Detected | SARS Coronavirus 2 Spike Glycoprotein N501Y Substitution Present | SARS2 Spike Glycoprotein N501Y Substitution Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662162","SARS Coronavirus 2 Spike Glycoprotein K417N/T Substitution Positive","C179609","An indication that expression of SARS coronavirus 2 spike glycoprotein where the lysine at amino acid position 417 has been substituted with either asparagine or threonine has been detected in a sample.","SARS Coronavirus 2 Spike Glycoprotein K417N/T Substitution Positive | K417N/T | SARS Coronavirus 2 S Protein K417N/T Substitution Positive | SARS Coronavirus 2 Spike Glycoprotein K417N or K417T Substitution Positive | SARS Coronavirus 2 Spike Glycoprotein K417N/T Substitution Detected | SARS Coronavirus 2 Spike Glycoprotein K417N/T Substitution Present | SARS Coronavirus 2 Spike Glycoprotein Lys417Asn or Lys417Thr Substitution Positive | SARS Coronavirus 2 Spike Glycoprotein Lys417Asn/Thr Substitution Detected | SARS Coronavirus 2 Spike Glycoprotein Lys417Asn/Thr Substitution Positive | SARS Coronavirus 2 Spike Glycoprotein Lys417Asn/Thr Substitution Present | SARS2 Spike Glycoprotein K417N/T Substitution Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662161","SARS Coronavirus 2 Spike Glycoprotein E484K Substitution Positive","C179610","An indication that expression of SARS coronavirus 2 spike glycoprotein where the glutamic acid at amino acid position 484 has been substituted with lysine has been detected in a sample.","SARS Coronavirus 2 Spike Glycoprotein E484K Substitution Positive | E484K | SARS Coronavirus 2 S Protein E484K Substitution Positive | SARS Coronavirus 2 Spike Glycoprotein E484K Substitution Detected | SARS Coronavirus 2 Spike Glycoprotein E484K Substitution Present | SARS Coronavirus 2 Spike Glycoprotein Glu484Lys Substitution Detected | SARS Coronavirus 2 Spike Glycoprotein Glu484Lys Substitution Positive | SARS Coronavirus 2 Spike Glycoprotein Glu484Lys Substitution Present | SARS2 Spike Glycoprotein E484K Substitution Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662164","SARS Coronavirus 2 Spike Glycoprotein P681H Substitution Positive","C179611","An indication that expression of SARS coronavirus 2 spike glycoprotein where the proline at amino acid position 681 has been substituted with histidine has been detected in a sample.","SARS Coronavirus 2 Spike Glycoprotein P681H Substitution Positive | P681H | SARS Coronavirus 2 S Protein P681H Substitution Positive | SARS Coronavirus 2 Spike Glycoprotein P681H Substitution Detected | SARS Coronavirus 2 Spike Glycoprotein P681H Substitution Present | SARS Coronavirus 2 Spike Glycoprotein Pro681His Substitution Detected | SARS Coronavirus 2 Spike Glycoprotein Pro681His Substitution Positive | SARS Coronavirus 2 Spike Glycoprotein Pro681His Substitution Present | SARS2 Spike Glycoprotein P681H Substitution Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662158","SARS Coronavirus 2 Spike Glycoprotein 69/70 Deletion Positive","C179614","An indication that expression of SARS coronavirus 2 spike glycoprotein where the amino acids at positions 69 and 70 have been deleted has been detected in a sample.","SARS Coronavirus 2 Spike Glycoprotein 69/70 Deletion Positive | 69/70 Deletion | SARS Coronavirus 2 S Protein 69/70 Deletion Positive | SARS Coronavirus 2 Spike Glycoprotein 69/70 Deletion Detected | SARS Coronavirus 2 Spike Glycoprotein 69/70 Deletion Present | SARS2 Spike Glycoprotein 69/70 Deletion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226926","External Lip","C12223","One of two visible fleshy folds that surround the orifice of the mouth.","External Lip | External lip, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273989","v-raf Murine Sarcoma Viral Oncogene Homolog B1 c.1799_1800TG>AT","C98341","A complex substitution where the nucleotide sequence at positions 1799 and 1780 of the coding sequence of the BRAF gene has changed from thymine-guanine to adenine-thymine.","BRAF NM_004333.4:c.1799_1800delinsAT | B-RAF1 c.1799_1800TG>AT | BRAF NM_004333.4:c.1799_1800delTGinsAT | BRAF NM_004333.4:c.1799_1800delTGinsAT | BRAF V600D (c.1799_1800TG>AT) mutation | BRAF c.1799_1800TG>AT | BRAF c.1799_1800delTGinsAT | NM_004333.4:c.1799_1800TG>AT | NM_004333.4:c.1799_1800delTGinsAT | NM_004333.4:c.1799_1800delinsAT | NM_004333.6:c.1799_1800delinsAT | v-raf Murine Sarcoma Viral Oncogene Homolog B1 c.1799_1800TG>AT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3274002","v-raf Murine Sarcoma Viral Oncogene Homolog B1 c.1798_1799GT>AG","C98354","A complex substitution where the nucleotide sequence at positions 1798 and 1799 of the coding sequence of the BRAF gene has changed from guanine-thymine to adenine-guanine.","BRAF NM_004333.4:c.1798_1799delinsAG | B-RAF1 c.1798_1799GT>AG | BRAF NM_004333.4:c.1798_1799delGTinsAG | BRAF NM_004333.4:c.1798_1799delGTinsAG | BRAF V600R (c.1798_1799GT>AG) mutation | BRAF c.1798_1799GT>AG | BRAF c.1798_1799delGTinsAG | NM_004333.4:c.1798_1799GT>AG | NM_004333.4:c.1798_1799delGTinsAG | NM_004333.4:c.1798_1799delinsAG | NM_004333.6:c.1798_1799delinsAG | v-raf Murine Sarcoma Viral Oncogene Homolog B1 c.1798_1799GT>AG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL025607","Other and Ill-Defined Sites within Respiratory System and Intrathoracic Organs ICD-O-3","C148338","Anatomic sites within the respiratory system and intrathoracic organs that are referenced in topographic category C39 of ICD-O-3.","Other and Ill-Defined Sites within Respiratory System and Intrathoracic Organs ICD-O-3 | Ill-defined sites within respiratory system | Other and Ill-Defined Sites within Respiratory System and Intrathoracic Organs | Other and ill-defined sites within respiratory system and intrathoracic organs",,,,,,,,,,,,,,,"4156081","Respiratory tract structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518054","Lymph Node of Inguinal Region or Leg","C12362","Any lymph node that is located in the inguinal region or in either leg.","Lymph Node of Inguinal Region or Leg | Lymph Nodes of Inguinal Region or Leg | Lymph nodes of inguinal region or leg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518669","Other Specified Parts of Pancreas","C12273","Any component associated with the pancreas that is different from the one(s) previously specified or mentioned.","Other Specified Parts of Pancreas | Other specified parts of pancreas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL365219","Other and Unspecified Male Genital Organs ICD-O-3","C148341","Male genital organs that are referenced in topographic category C63 of ICD-O-3.","Other and Unspecified Male Genital Organs ICD-O-3 | Other and Unspecified Male Genital Organs | Other and unspecified male genital organs | Other specified parts of male genital organs","C63.7","Other specified parts of male genital organs",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"CL025605","Other and Unspecified Female Genital Organs ICD-O-3","C148339","Female genital organs that are referenced in topographic category C57 of ICD-O-3.","Other and Unspecified Female Genital Organs ICD-O-3 | Other and Unspecified Female Genital Organs | Other and unspecified female genital organs | Other specified parts of female genital organs","C57.7","Other specified parts of female genital organs",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"CL1662467","Cannot Be Determined","C179711","An indication that a reason or result cannot be established.","Cannot Be Determined | Could Not Be Determined | Unable to Determine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643458","Gene Amplification Negative","C177681","An indication that amplification of one or more genes of interest was not detected in a sample.","Gene Amplification Negative | Amplification Negative | Amplification Not Detected | Not Amplified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662463","Overlapping Lesion","C179724","A lesion that extends over the margins of a contiguous lesion.","Overlapping Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969696","Specify KIT Exons Assessed","C160583","A request to enter the KIT exons assessed for mutations in this section of the form.","Specify KIT Exons Assessed | Exons assessed | KIT Exons Assessed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1260195","Anoctamin-1, Human","C115175","Anoctamin-1 (986 aa, ~114 kDa) is encoded by the human ANO1 gene. This protein plays a role in calcium-dependent transport of chloride.","Anoctamin-1 | ANO1 | Anoctamin 1 | DOG1 | DOG1 (ANO1) | Discovered on Gastrointestinal Stromal Tumors Protein 1 | Oral Cancer Overexpressed Protein 2 | Transmembrane Protein 16A | Tumor-Amplified and Overexpressed Sequence 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1308226","Succinate Dehydrogenase [Ubiquinone] Iron-Sulfur Subunit, Mitochondrial, Human","C97775","Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial (280 aa, ~32 kDa) is encoded by the human SDHB gene. This protein plays a role in the mediation of redox reactions in the mitochondrial electron transport chain.","Succinate Dehydrogenase [Ubiquinone] Iron-Sulfur Subunit, Mitochondrial | EC 1.3.5.1 | Ip | Iron-Sulfur Subunit Of Complex II | SDHB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662380","FET Family Gene Translocation","C179848","A cytogenetic abnormality that refers to the translocation of involving a member of the FET (FUS, EWSR1 or TAF15) gene family.","FET Family Gene Translocation | FET Family Translocation | FET Translocation | FET-Family Translocation | FUS-EWSR1-TAF15 Family Gene Translocation | FUS-EWSR1-TAF15 Gene Translocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662382","IRF4 Positive","C179849","An indication that expression of IRF4 has been detected in a sample.","IRF4 Positive | IRF-4 Positive | Interferon Regulatory Factor 4 Positive | LSIRF Positive | Lymphocyte-Specific IRF Positive | Lymphocyte-Specific Interferon Regulatory Factor Positive | MUM1 Positive | Multiple Myeloma Oncogene 1 Positive | NF-EM5 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662381","Oncotype DX Breast Cancer Recurrence Score Less than or Equal to Eighteen","C179850","A genetic finding indicating that the Oncotype DX breast cancer recurrence score for a sample was less than or equal to 18.","Oncotype DX Breast Cancer Recurrence Score Less than or Equal to Eighteen | Oncotype DX Breast Cancer Recurrence Score 18 or Less | Oncotype DX Breast Cancer Recurrence Score Eighteen or Less | Oncotype DX Breast Cancer Recurrence Score Less than or Equal to 18 | Oncotype DX Recurrence Score 18 or Less | Oncotype DX Recurrence Score Eighteen or Less | Oncotype DX Recurrence Score Less than or Equal to 18 | Oncotype Recurrence Score Less Than or Equal to 18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662372","PSA Level Less than Forty","C179851","A blood concentration of prostate specific antigen less than 40 ng/mL.","PSA Level Less than Forty | PSA Level Less than 40",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662371","PSA Level Greater than or Equal to Forty","C179852","A blood concentration of prostate specific antigen greater than or equal to 40 ng/mL.","PSA Level Greater than or Equal to Forty | PSA Level 40 or Greater | PSA Level Forty or Greater | PSA Level Greater than or Equal to 40",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662374","HLA-B*44:03 Positive Cells Present","C179853","An indication that cells expressing HLA-B*44:03 have been detected in a sample.","HLA-B*44:03 Positive Cells Present | HLA-B*4403 Positive | HLA-B*4403 Positive Cells Present | HLA-B*44:03 Positive | HLA-B4403 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662373","HLA-B*44:02 Positive Cells Present","C179854","An indication that cells expressing HLA-B*44:02 have been detected in a sample.","HLA-B*44:02 Positive Cells Present | HLA-B*4402 Positive | HLA-B*4402 Positive Cells Present | HLA-B*44:02 Positive | HLA-B4402 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662368","PRC2 Loss of Function Gene Mutation","C179855","A change in the nucleotide sequence of a gene encoding a protein that is a component of polycomb repressive complex 2 (PRC2) and results in a decrease or loss of PRC2 histone methyltransferase activity.","PRC2 Loss of Function Gene Mutation | Inactivating PRC2 Gene Mutation | Inactivating PRC2 Mutation | Inactivating UCHL2 Gene Mutation | PRC2 Inactivating Gene Mutation | PRC2 Inactivating Mutation | PRC2 Loss | PRC2 Loss of Function Mutation | Polycomb Repressive Complex 2 Loss of Function Gene Mutation | Polycomb Repressive Complex 2 Loss of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662367","CCR5 Positive","C179856","An indication that CCR5 expression has been detected in a sample.","CCR5 Positive | C-C Chemokine Receptor Type 5 Positive | C-C Motif Chemokine Receptor 5 Positive | CC Chemokine Receptor 5 Positive | CC-CKR-5 Positive | CCCKR5 Positive | CCR-5 Positive | CD195 Antigen Positive | CD195 Positive | CKR-5 Positive | CKR5 Positive | CMKBR5 Positive | Chemokine Receptor CCR5 Positive | HIV-1 Fusion Co-Receptor Positive | HIV-1 Fusion Coreceptor Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662369","G6PC3 Loss of Function Gene Mutation","C179858","A change in the nucleotide sequence of the G6PC3 gene that either inhibits expression or results in the translation of an inactive glucose-6-phosphatase 3 protein.","G6PC3 Loss of Function Gene Mutation | G6PC3 Deficiency | G6PC3 Deficient | G6PC3 Inactivating Gene Mutation | G6PC3 Inactivating Mutation | G6PC3 Loss of Function Mutation | Glucose-6-Phosphatase 3 Loss of Function Gene Mutation | Glucose-6-Phosphatase Catalytic Subunit 3 Loss of Function Gene Mutation | Inactivating G6PC3 Gene Mutation | Inactivating G6PC3 Mutation | SCN4 Loss of Function Gene Mutation | UGRP Loss of Function Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414895","SLC37A4 Gene","C179859","This gene is involved in the transport of inorganic phosphate and glucose-6-phosphate across the endoplasmic reticulum membrane.","SLC37A4 Gene | SLC37A4 | Solute Carrier Family 37 Member 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662376","SLC37A4 Loss of Function Gene Mutation","C179865","A change in the nucleotide sequence of the SLC37A4 gene that either inhibits expression or results in the translation of an inactive glucose-6-phosphate exchanger SLC37A4 protein.","SLC37A4 Loss of Function Gene Mutation | G6PT Loss of Function Gene Mutation | Inactivating SLC37A4 Gene Mutation | Inactivating SLC37A4 Mutation | SLC37A4 Inactivating Gene Mutation | SLC37A4 Inactivating Mutation | SLC37A4 Loss of Function Mutation | Solute Carrier Family 37 Member 4 Loss of Function Gene Mutation | TRG-19 Loss of Function Gene Mutation | TRG19 Loss of Function Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662355","Wisconsin Predicting Patients' Relapse","C179896","A brief, seven-item questionnaire that considers physical dependence, environmental factors, and individual difference characteristics in predicting a patient's relapse from smoking cessation.","Wisconsin Predicting Patients' Relapse | WI PREPARE | Wisconsin Predicting Patient Relapse Measure | Wisconsin Predicting Patient Relapse Survey | Wisconsin Predicting Patients' Relapse Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662651","Have to Leave in Order to Smoke","C179899","A question about whether an individual needs to leave the house to be able to smoke.","Have to Leave in Order to Smoke | If someone in your household wants to smoke, does he/she have to leave in order to smoke",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662357","Place of Work's Smoking Policy for Work Areas","C179897","A question about the smoking policy in work areas at an individual's place of work.","Place of Work's Smoking Policy for Work Areas | Which of these statements best describes your place of work's smoking policy for work areas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662650","Around Smokers Much of the Time","C179900","A question about whether an individual is around smokers much of the time.","Around Smokers Much of the Time | I'm around smokers much of the time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1367849","Craving Gets Intolerable When Unable to Smoke for a few Hours","C179902","A question about whether an individual's cravings get intolerable if they have not been able to smoke for a few hours.","Craving Gets Intolerable When Unable to Smoke for a few Hours | When I haven't been able to smoke for a few hours, the craving gets intolerable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662647","Smoking Not Allowed in Any Work Areas","C179903","A response indicating that smoking is not allowed in any work areas.","Smoking Not Allowed in Any Work Areas | Smoking is not allowed in any work areas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662646","Smoking Not Allowed in Some Work Areas","C179904","A response indicating that smoking is not allowed in some work areas.","Smoking Not Allowed in Some Work Areas | Smoking is allowed in some work areas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662649","Smoking Allowed in All Work Areas","C179905","A response indicating that smoking is allowed in all work areas.","Smoking Allowed in All Work Areas | Smoking is allowed in all work areas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662648","True Likert Scale","C179906","A scale for the subjective scoring of truth that ranges from 1: Not true at all to 7: Extremely true of me.","True Likert Scale | How true for me",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662656","Technical School Attendance","C179907","Indicates that a person has attended technical school.","Technical School Attendance | Technical School",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642360","G6PC3 wt Allele","C176507","Human G6PC3 wild-type allele is located in the vicinity of 17q21.31 and is approximately 6 kb in length. This allele, which encodes glucose-6-phosphatase 3 protein, is involved in gluconeogenesis. Mutation of the gene is associated with autosomal dominant severe congenital neutropenia 4 (SCN4).","G6PC3 wt Allele | Glucose 6 Phosphatase, Catalytic, 3 Gene | Glucose-6-Phosphatase Catalytic Subunit 3 wt Allele | Glucose-6-Phosphatase, Beta Gene | Glucose-6-Phosphatase, Catalytic, 3 Gene | SCN4 | UGRP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006050","Botulinum Toxin Type A","C82623","An injectable formulation of a neurotoxin derived through the fermentation of the Hall strain of Clostridium botulinum type A with neuromuscular transmission inhibitory and analgesic activities. Upon injection into the affected muscle, the heavy chain portion of botulinum toxin type A (BTX-A) binds to the cell membrane of the motor nerve and is internalized via endocytosis. Upon entry, the light chain portion of the toxin is activated and cleaves the protein SNAP-25, thereby preventing the fusion of acetylcholine (ACh)-containing synaptic vesicles with the cell membrane and, so, the release of ACh into the neuromuscular junction; subsequent binding of ACH to motor end-plate nicotinic acid receptors and ACh-mediated muscle contraction are thus blocked. In addition to ACh, BTX-A may inhibit the release of neuropeptides, such as substance P and glutamate, which may contribute to its analgesic activity.","Botulinum Toxin Type A | AbobotulinumtoxinA | BOTULINUM TOXIN TYPE A | BTX-A | Botox | Botox Cosmetic | Botulinum A Toxin | Botulinum Neurotoxin Type A | Botulinum Toxin A | DaxibotulinumtoxinA | Dysport | EvabotulinumtoxinA | IncobotulinumtoxinA | OnabotulinumtoxinA | Onaclostox | Prabotulinumtoxin A | Xeomin | botulinum toxin A | onabotulinumtoxinA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273754","Efinaconazole","C97998","A triazole compound, with antifungal activity. Upon administration, efinaconazole targets, binds to and inhibits 14-alpha-demethylase, a cytochrome P450-dependent enzyme. Inhibition of 14-alpha-demethylase prevents the conversion of lanosterol to ergosterol, an important component of the fungal cell wall. Inhibition of ergosterol synthesis changes the fungal cell membrane composition and integrity, alters membrane permeability and eventually leads to fungal cell lysis.","Efinaconazole | (2R,3R)-2-(2,4-difluorofenil)-3-(4-metilenopiperidin-1-il)-1-(1h-1,2,4-triazin-1-il)butan-2-ol | 1-Piperidineethanol, alpha-(2,4-Difluorophenyl)-beta-methyl-4-methylene-alpha-(1H-1,2,4-triazol-1- ylmethyl)-, (alphaR,betaR)- | Clenafin | EFINACONAZOLE | Jublia | KP 103 | KP-103 | KP103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL387581","Sodium Ferric Gluconate Complex in Sucrose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017440","Gentian Violet","C61776","A blue, aniline-derived dye with antifungal and antimitotic properties. Gentian violet (GV) dissociates into positive (GV+) and negative ions (Cl-) that penetrate both gram-positive and gram-negative bacterial cells. The GV+ ions interact with negatively charged components of the bacterial cell wall including lipopolysaccharide, peptidoglycan and DNA. This agent is also a mutagen and mitotic poison. GV elicits a photodynamic action mediated by a free-radical mechanism. Furthermore, this agent dissipates the action potential on prokaryotic or eukaryotic membranes by inducing permeability, thereby leading to respiratory inhibition and subsequent cell death.","Gentian Violet | Basic Violet 3 | CI 42555 | Crystal Violet | GENTIAN VIOLET | Genapax | Hexamethyl-P-Rosaniline Chloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005301","Betahistine","C83554","A histamine analog with weak histamine H1 agonistic and more potent histamine H3 antagonistic properties. Upon intranasal administration, betahistine binds to histamine H1 and H3 receptors and exerts its agonistic and antagonistic actions locally and centrally. This promotes cochlear, vestibular and cerebral blood flow, decreases neuronal firing in the vestibular nuclei and increases histamine synthesis and release in the brain which facilitates vestibular compensation. Increased blood flow around the inner ear reduces the amount of fluid in the inner ear and may alleviate vertigo, tinnitus, and hearing loss.","Betahistine | BETAHISTINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016875","Fusidic Acid","C65793","A bacteriostatic antibiotic derived from the fungus Fusidium coccineum and used as a topical medication to treat skin infections. Fusidic acid acts as a bacterial protein synthesis inhibitor by preventing the turnover of elongation factor G (EF-G) from the ribosome. Fusidic acid is effective primarily on gram-positive bacteria.","Fusidic Acid | FUSIDIC ACID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412819","Celiac Plexus Neurolysis","C116513","A treatment that involves injection of local anesthetic and alcohol to the celiac plexus, causing temporary degeneration of the nerve fibers. The procedure is performed in an effort to alleviate intractable pain, generally caused by cancer or chronic pancreatitis.","Celiac Plexus Neurolysis | Celiac Nerve Block",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662745","Pansexuality","C180327","Sexual, romantic, or emotional attraction towards people regardless of their sex or gender identity, including agender, non-binary, and gender fluid.","Pansexuality | PANSEXUAL | Pan | Pansexual",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662720","Clostridial Collagenase Ointment","C179971","A topical ointment formulation containing the enzyme collagenase derived from the fermentation by Clostridium histolyticum in a white petrolatum base, with enzymatic debriding activity. Upon topical application of clostridial collagenase ointment, the collagenase digests collagen in necrotic tissue resulting in enzymatic debridement which may promote wound healing.","Clostridial Collagenase Ointment | Collagenase | Collagenase Ointment | Collagenase Topical Ointment | Santyl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662753","Xylitol-containing Oral Adhering Discs","C180311","A formulation containing orally adhering discs containing the natural sweetener xylitol, with protective, saliva producing and moisturizing activities. Upon administration of the xylitol-containing oral adhering disc, the disc, that sticks to the teeth, slowly releases xylitol. Xylitol produces saliva and may protect against cavities. This relieves persistent dry mouth and hydrates the mouth.","Xylitol-containing Oral Adhering Discs | Saliva Substitute | XyliMelts | Xylimelts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4079208","Encorafenib","C98283","An orally available Raf kinase inhibitor with potential antineoplastic activity. Encorafenib specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells. The Raf mutation BRAF V600E is frequently upregulated in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival.","Encorafenib | Braftovi | ENCORAFENIB | LGX 818 | LGX-818 | LGX818",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027617","Newborn Screening","C81178","A specific type of newborn examination performed to allow for early detection of disease(s) and/or disorder(s).","Newborn Screening | Newborn Assessment",,,,,,,,,,,,,,,"4246502","Neonatal screening",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1662733","Candy","C180340","A sweet confection usually made with sugar or other sweeteners.","Candy | ",,,,,,,,,,,,,,,"4039077","Candy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526621","Growth Plate Closed","C139148","A finding indicating that the epiphyseal plate is fully calcified.","Growth Plate Closed | GROWTH PLATE CLOSED | Physis Closed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555699","Growth Plate Open","C154893","An indication that the epiphyseal plate is made of hyaline cartilage and is not yet fused by bone.","Growth Plate Open | GROWTH PLATE OPEN | Physis Open",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008299","Chocolate","C68655","A food or ingredient made from ground and roasted beans of the cacao.","Chocolate | ",,,,,,,,,,,,,,,"4008007","Chocolate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1663111","Zaidi Recurrence Risk Score","C180414","A prognostic risk score that stratifies recurrence-free survival for patients with resected pancreatic neuroendocrine tumors. A recurrence risk score is calculated based on presence of symptomatic tumors (0 or 1), tumor size greater than 2 cm (0 or 2), Ki-67 index (0, 1, or 6), and lymph node positivity (0 or 1).","Zaidi Recurrence Risk Score | RRS | Recurrence Risk Score | Zaidi Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663035","Zaidi Recurrence Risk Score Less than 6","C180415","A score of less than 6 using the Zaidi criteria for recurrence risk for resected pancreatic neuroendocrine tumors. This score correlates with low to intermediate risk of recurrence.","Zaidi Recurrence Risk Score Less than 6 | Recurrence Risk Score Less than 6 | Score Less than 6 | Zaidi Score Less than 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663031","Zaidi Recurrence Risk Score Greater than or Equal to 6","C180416","A score of greater than or equal to 6 using the Zaidi criteria for recurrence risk for resected pancreatic neuroendocrine tumors. This score correlates with high risk of recurrence.","Zaidi Recurrence Risk Score Greater than or Equal to 6 | Recurrence Risk Score Greater than or Equal to 6 | Score Greater than or Equal to 6 | Zaidi Score Greater than or Equal to 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1334991","Localized Neoplasm","C36037","A neoplasm that is confined to a specific site without evidence of spread to other anatomic sites.","Localized Neoplasm | Non-Metastatic Neoplasm | Non-metastatic Disease | tumor confined to organ of origin | tumor_confined_to_organ_of_origin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3711381","Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia","C153289","A rapidly progressive neurodegenerative disorder, caused by mutations in the colony-stimulating factor 1 receptor (CSF1R) gene, that presents in adulthood with a variety of neuropsychiatric and motor disturbances. Hallmark features include diffuse myelin loss and axonal destruction, neuroaxonal spheroids, and pigmented macrophages and other glia.","Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia | ALSP | HDLS | Hereditary Diffuse Leukoencephalopathy with Spheroids | POLD | Pigmentary Orthochromatic Leukodystrophy",,,,,,,,,,,,,,,"4043401|45765478","Neuroaxonal leukodystrophy|Hereditary diffuse leukoencephalopathy with spheroids",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2830066","Lurbinectedin","C82382","A synthetic tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-one alkaloid analogue with potential antineoplastic activity. Lurbinectedin covalently binds to residues lying in the minor groove of DNA, which may result in delayed progression through S phase, cell cycle arrest in the G2/M phase and cell death.","Lurbinectedin | LURBINECTEDIN | PM 01183 | PM-01183 | PM01183 | Zepzelca",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498221","Avapritinib","C123827","An orally bioavailable inhibitor of specific mutated forms of platelet-derived growth factor receptor alpha (PDGFR alpha; PDGFRa) and mast/stem cell factor receptor c-Kit (SCFR), with potential antineoplastic activity. Upon oral administration, avapritinib specifically binds to and inhibits specific mutant forms of PDGFRa and c-Kit, including the PDGFRa D842V mutant and various KIT exon 17 mutants. This results in the inhibition of PDGFRa- and c-Kit-mediated signal transduction pathways and the inhibition of proliferation in tumor cells that express these PDGFRa and c-Kit mutants. PDGFRa and c-Kit, protein tyrosine kinases and tumor-associated antigens (TAAs), are mutated in various tumor cell types; they play key roles in the regulation of cellular proliferation.","Avapritinib | (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1Hpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-yl)pyrimidin-5-yl)ethan-1-amine | AVAPRITINIB | AYVAKIT | Ayvakyt | BLU 285 | BLU-285 | BLU285 | CS3007 | PDGFR alpha/KIT Mutant-specific Inhibitor BLU-285",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502501","Ripretinib","C124067","An orally bioavailable switch pocket control inhibitor of wild-type and mutated forms of the tumor-associated antigens (TAA) mast/stem cell factor receptor (SCFR) KIT and platelet-derived growth factor receptor alpha (PDGFR-alpha; PDGFRa), with potential antineoplastic activity. Upon oral administration, ripretinib targets and binds to both wild-type and mutant forms of KIT and PDGFRa specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. This abrogates KIT/PDGFRa-mediated tumor cell signaling and prevents proliferation in KIT/PDGFRa-driven cancers. DCC-2618 also inhibits several other kinases, including vascular endothelial growth factor receptor type 2 (VEGFR2; KDR), angiopoietin-1 receptor (TIE2; TEK), PDGFR-beta and macrophage colony-stimulating factor 1 receptor (FMS; CSF1R), thereby further inhibiting tumor cell growth. KIT and PDGFRa are tyrosine kinase receptors that are upregulated or mutated in a variety of cancer cell types; mutated forms play a key role in the regulation of tumor cell proliferation and resistance to chemotherapy.","Ripretinib | 1-N'-[2,5-difluoro-4-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxyphenyl]-1-N'-phenylcyclopropane-1,1-dicarboxamide | DCC 2618 | DCC-2618 | DCC2618 | KIT/PDGFR Inhibitor DCC-2618 | Qinlock | RIPRETINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663053","Empagliflozin/Linagliptin","C180533","A fixed dose combination of empagliflozin, an inhibitor of sodium-glucose co-transporter 2 (SGLT2; SLC5A2), and linagliptin, a dihydropurinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with antihyperglycemic activity. Upon oral administration of empagliflozin/linagliptin, empagliflozin selectively and potently inhibits SGLT2 in the kidneys, thereby suppressing the reabsorption of glucose in the proximal tubule. Inhibition of SGLT2 increases urinary glucose excretion by the kidneys, resulting in a reduction of plasma glucose levels in an insulin-independent manner. Linagliptin binds to and inhibits DPP-4, thereby inhibiting the breakdown of the incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This prolongs the activity of these incretin hormones, increases postprandial insulin secretion from pancreatic beta cells, decreases glucagon secretion and lowers blood glucose levels. SGLT2, a transport protein exclusively expressed in the proximal renal tubules, mediates approximately 90% of renal glucose reabsorption from tubular fluid. DPP-4 is a serine protease that degrades the incretin hormones GLP-1 and GIP, which play important roles in the regulation of glucose homeostasis.","Empagliflozin/Linagliptin | Empagliflozin and Linagliptin | Empagliflozin-Linagliptin | Empagliflozin/Linagliptin Combination Agent | Glyxambi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0996244","Chondrus crispus","C180534","An edible red seaweed, with potential antioxidant, anti-inflammatory and anti-microbial activities. Chondrus crispus contains a variety of bioactive compounds, such as caroteinoids, including beta-carotene, zeaxanthin and lutein, polyphenols, including flavonoids and tannins, and sulfated polysaccharides, including carrageenans. Upon administration, the active compounds in Chondrus crispus scavenge reactive oxygen species (ROS) and may protect cells from the damage of oxidative stress, and may prevent inflammation and microbial infections.","Chondrus crispus | CHONDRUS CRISPUS | Irish Moss | Sea Moss",,,,,,,,,,,,,,,"4005150","Chondrus crispus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1999375","Ticagrelor","C76404","An orally bioavailable cyclopentyltriazolopyrimidine, with antiplatelet activity. Upon oral administration, ticagrelor and its major metabolite targets and reversibly binds to the platelet adenosine diphosphate (ADP) P2Y12 receptor (P2Y12R) at a site distinct from that of the endogenous agonist ADP. This blocks the platelet signaling pathway, thereby inhibiting the activation of the glycoprotein complex GPIIb/IIIa, fibrinogen binding to platelets and platelet adhesion and aggregation.","Ticagrelor | (1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol | AR-C126532XX | AZD6140 | Brilinta | Brilique | TICAGRELOR | Thioxlant-6C | Ticalog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971499","Patiromer","C166500","No Value Exists","Patiromer | PATIROMER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519771","Cutaneous Squamous Cell Carcinoma of the Head and Neck Clinical Distant Metastasis TNM Finding v8","C133198","A clinical finding about one or more characteristics of cutaneous squamous cell carcinoma of the head and neck, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Cutaneous Squamous Cell Carcinoma of the Head and Neck Clinical Distant Metastasis TNM Finding v8 | Clinical Staging: Distant Metastasis (cM)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662970","Thrombotic Disorder","C180553","A disorder in which there is pathological development of blood clots within the cardiovascular system.","Thrombotic Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639888","CGI - Global Improvement","C100956","Clinical Global Impression (CGI) Rate total improvement whether or not, in your judgment, it is due entirely to drug treatment. Compared to his condition at admission to the project, how much has he changed?","CGI - Global Improvement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0582791","Bone of the Extremity","C32223","A bone within a limb of the body.","Bone of the Extremity | Bone of Extremity | Bone of limb, NOS",,,,,,,,,,,,,,,"4174982","Bone structure of extremity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227174","Posterior Wall of the Hypopharynx","C12249","The region of the hypopharynx demarcated by a plane drawn at the level of the tip of the epiglottis to a plane at the inferior border of the cricoid.","Posterior Wall of the Hypopharynx | Posterior Wall of Hypopharynx | Posterior wall of hypopharynx",,,,,,,,,,,,,,,"4102600","Structure of posterior wall of hypopharynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227155","Posterior Wall of the Oropharynx","C12240","The dorsal portion of the oropharyngeal cavity that is formed by the muscular pharyngeal wall comprising the superior and middle pharyngeal constrictor muscles.","Posterior Wall of the Oropharynx | Posterior Wall of Oropharynx | Posterior wall of oropharynx | posterior wall of oropharynx",,,,,,,,,,,,,,,"4045435","Structure of posterior wall of oropharynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0225484","Posterior Wall of the Nasopharynx","C12243","The dorsal portion of the nasopharyngeal cavity that contains the pharyngeal tonsil.","Posterior Wall of the Nasopharynx | Posterior Wall of Nasopharynx | Posterior wall of nasopharynx",,,,,,,,,,,,,,,"4146741","Structure of posterior wall of nasopharynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0222212","Skin of the Upper Limb and Shoulder","C12296","The integumentary covering of the upper limb and shoulder region.","Skin of the Upper Limb and Shoulder | Skin of Upper Limb and Shoulder | Skin of upper limb and shoulder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522650","Skin of the Scalp and Neck","C12294","The integumentary covering of the scalp and neck.","Skin of the Scalp and Neck | Skin of Scalp and Neck | Skin of scalp and neck",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0222268","Skin of the Lower Limb and Hip","C12297","The integumentary covering of the lower limb and hip region.","Skin of the Lower Limb and Hip | Skin of Lower Limb and Hip | Skin of lower limb and hip",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037938","Spinal Meninges","C12350","Connective tissue membranes that surround and support the spinal cord and cauda equina. They are continuous with cerebral meninges, which surround and support the brain.","Spinal Meninges | Spinal Meninx | Spinal meninges | meninx of spinal cord",,,,,,,,,,,,,,,"4294663","Spinal cord meninges structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL025608","Other and Ill-Defined Sites in Lip, Oral Cavity and Pharynx ICD-O-3","C148337","Anatomic sites in the lip, oral cavity and pharynx that are referenced in topographic category C14 of ICD-O-3.","Other and Ill-Defined Sites in Lip, Oral Cavity and Pharynx ICD-O-3 | Other and Ill-Defined Sites in Lip, Oral Cavity and Pharynx | Other and ill-defined sites in lip, oral cavity and pharynx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL025599","Other Endocrine Glands and Related Structures ICD-O-3","C148346","Endocrine glands and related structures that are referenced in topographic category C75 of ICD-O-3.","Other Endocrine Glands and Related Structures ICD-O-3 | Other Endocrine Glands and Related Structures | Other endocrine glands and related structures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550961","Other and Unspecified Urinary Organs ICD-O-3","C148345","Urinary organs that are referenced in topographic category C68 of ICD-O-3.","Other and Unspecified Urinary Organs ICD-O-3 | Other and Unspecified Urinary Organs | Other and unspecified urinary organs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL018479","Peritoneum and Retroperitoneum","C156712","A term that refers to the peritoneum and the space behind it (retroperitoneum).","Peritoneum and Retroperitoneum | Retroperitoneum and peritoneum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL025603","Other and Unspecified Parts of Mouth ICD-O-3","C148343","Components of the mouth that are referenced in topographic category C06 of ICD-O-3.","Other and Unspecified Parts of Mouth ICD-O-3 | Other and Unspecified Parts of Mouth | Other and unspecified parts of mouth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0222648","Short Bone","C33545","A bone that consists mainly of spongy bone, and which is generally equidimensional, allowing it to provide support and stability with minimal movement.","Short Bone | ",,,,,,,,,,,,,,,"4063551","Structure of short bone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1099354","Small Interfering RNA","C2191","A 20 to 25-nucleotide double-stranded RNA which is involved in a sequence-specific messenger RNA degradation process known as RNA interference.","Small Interfering RNA | SMALL INTERFERING RNA | siRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827561","HBB wt Allele","C84952","Human HBB wt allele is located in the vicinity of 11p15.5 and is approximately 4 kb in length. This allele, which encodes hemoglobin subunit beta protein, plays a role in the transport of oxygen to tissues of the body. Mutations in this gene are associated with beta-thalassemia.","HBB wt Allele | B-Globin Gene | Beta-Globin Gene | CD113t-C | ECYT6 | Hemoglobin Beta wt Allele | Hemoglobin, Beta Gene | Hemoglobin--Beta Locus | Hemoglobin-Beta Locus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242613","Gene Targeting","C17742","A technique that involves integration of an exogenous DNA sequence encoding a specific gene into the genome of an organism by homologous recombination.","Gene Targeting | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519774","Cutaneous Squamous Cell Carcinoma of the Head and Neck Pathologic Distant Metastasis TNM Finding v8","C133201","A pathologic finding about one or more characteristics of cutaneous squamous cell carcinoma of the head and neck, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Cutaneous Squamous Cell Carcinoma of the Head and Neck Pathologic Distant Metastasis TNM Finding v8 | Pathologic Staging: Distant Metastasis (pM)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950896","No Pathologic Evidence of Distant Metastasis","C158827","A result that there is no pathologic evidence of distant metastasis.","No Pathologic Evidence of Distant Metastasis | No pathologic evidence of distant metastasis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951692","Incomplete Staging (pM)","C159724","A lack of clinical and/or pathology information to assign a pM stage conclusively.","Incomplete Staging (pM) | Incomplete Staging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519792","Cutaneous Squamous Cell Carcinoma of the Head and Neck pM1 TNM Finding v8","C133202","Cutaneous squamous cell carcinoma of the head and neck with distant metastasis. (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck pM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519778","Cutaneous Squamous Cell Carcinoma of the Head and Neck TNM Finding v8","C133194","A finding about one or more characteristics of cutaneous squamous cell carcinoma of the head and neck, following the rules of the TNM AJCC v8 classification system. It applies to cutaneous squamous cell carcinoma of the head and neck and all other nonmelanoma skin carcinomas of the head and neck (except Merkel cell carcinoma). It also applies to the adenocarcinomas that develop from eccrine or sebaceous glands and to the spindle cell variant of cutaneous squamous cell carcinoma. (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck TNM Finding v8 | Head and Neck Cutaneous Squamous Cell Carcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519781","Cutaneous Squamous Cell Carcinoma of the Head and Neck cM1 TNM Finding v8","C133200","Cutaneous squamous cell carcinoma of the head and neck with distant metastasis. (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck cM1 TNM Finding v8 | cM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519780","Cutaneous Squamous Cell Carcinoma of the Head and Neck cM0 TNM Finding v8","C133199","Cutaneous squamous cell carcinoma of the head and neck without evidence of distant metastasis. (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck cM0 TNM Finding v8 | cM0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519791","Cutaneous Squamous Cell Carcinoma of the Head and Neck cNX TNM Finding v8","C133213","Cutaneous squamous cell carcinoma of the head and neck in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck cNX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519773","Cutaneous Squamous Cell Carcinoma of the Head and Neck Clinical TNM Finding v8","C133195","A clinical finding about one or more characteristics of cutaneous squamous cell carcinoma of the head and neck, following the rules of the TNM AJCC v8 classification system.","Cutaneous Squamous Cell Carcinoma of the Head and Neck Clinical TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519777","Cutaneous Squamous Cell Carcinoma of the Head and Neck Pathologic TNM Finding v8","C133196","A pathologic finding about one or more characteristics of cutaneous squamous cell carcinoma of the head and neck, following the rules of the TNM AJCC v8 classification system.","Cutaneous Squamous Cell Carcinoma of the Head and Neck Pathologic TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519802","Cutaneous Squamous Cell Carcinoma of the Head and Neck pNX TNM Finding v8","C133223","Cutaneous squamous cell carcinoma of the head and neck in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck pNX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519776","Cutaneous Squamous Cell Carcinoma of the Head and Neck Pathologic Regional Lymph Nodes TNM Finding v8","C133222","A pathologic finding about one or more characteristics of cutaneous squamous cell carcinoma of the head and neck, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Cutaneous Squamous Cell Carcinoma of the Head and Neck Pathologic Regional Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519790","Cutaneous Squamous Cell Carcinoma of the Head and Neck cN3b TNM Finding v8","C133236","Cutaneous squamous cell carcinoma of the head and neck with metastasis in any lymph node(s) and ENE(+). (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck cN3b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519789","Cutaneous Squamous Cell Carcinoma of the Head and Neck cN3a TNM Finding v8","C133221","Cutaneous squamous cell carcinoma of the head and neck with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck cN3a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519787","Cutaneous Squamous Cell Carcinoma of the Head and Neck cN2c TNM Finding v8","C133219","Cutaneous squamous cell carcinoma of the head and neck with metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-).  (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck cN2c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519786","Cutaneous Squamous Cell Carcinoma of the Head and Neck cN2b TNM Finding v8","C133218","Cutaneous squamous cell carcinoma of the head and neck with metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-).  (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck cN2b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519785","Cutaneous Squamous Cell Carcinoma of the Head and Neck cN2a TNM Finding v8","C133217","Cutaneous squamous cell carcinoma of the head and neck with metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck cN2a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519784","Cutaneous Squamous Cell Carcinoma of the Head and Neck cN2 TNM Finding v8","C133216","Cutaneous squamous cell carcinoma of the head and neck with metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-).  (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck cN2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519783","Cutaneous Squamous Cell Carcinoma of the Head and Neck cN1 TNM Finding v8","C133215","Cutaneous squamous cell carcinoma of the head and neck with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-).  (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck cN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519782","Cutaneous Squamous Cell Carcinoma of the Head and Neck cN0 TNM Finding v8","C133214","Cutaneous squamous cell carcinoma of the head and neck without metastasis in the regional lymph nodes.  (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck cN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519801","Cutaneous Squamous Cell Carcinoma of the Head and Neck pN3b TNM Finding v8","C133235","Cutaneous squamous cell carcinoma of the head and neck with metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes, any with ENE(+). (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck pN3b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519800","Cutaneous Squamous Cell Carcinoma of the Head and Neck pN3a TNM Finding v8","C133234","Cutaneous squamous cell carcinoma of the head and neck with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck pN3a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519799","Cutaneous Squamous Cell Carcinoma of the Head and Neck pN3 TNM Finding v8","C133233","Cutaneous squamous cell carcinoma of the head and neck with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes, any with ENE(+). (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck pN3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519798","Cutaneous Squamous Cell Carcinoma of the Head and Neck pN2c TNM Finding v8","C133232","Cutaneous squamous cell carcinoma of the head and neck with metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-).  (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck pN2c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519797","Cutaneous Squamous Cell Carcinoma of the Head and Neck pN2b TNM Finding v8","C133231","Cutaneous squamous cell carcinoma of the head and neck with metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-).  (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck pN2b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519796","Cutaneous Squamous Cell Carcinoma of the Head and Neck pN2a TNM Finding v8","C133229","Cutaneous squamous cell carcinoma of the head and neck with metastasis in a single ipsilateral or contralateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck pN2a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519795","Cutaneous Squamous Cell Carcinoma of the Head and Neck pN2 TNM Finding v8","C133228","Cutaneous squamous cell carcinoma of the head and neck with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-).  (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck pN2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519794","Cutaneous Squamous Cell Carcinoma of the Head and Neck pN1 TNM Finding v8","C133226","Cutaneous squamous cell carcinoma of the head and neck with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-).  (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck pN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519793","Cutaneous Squamous Cell Carcinoma of the Head and Neck pN0 TNM Finding v8","C133225","Cutaneous squamous cell carcinoma of the head and neck without metastasis in the regional lymph nodes.  (from AJCC 8th Ed.)","Cutaneous Squamous Cell Carcinoma of the Head and Neck pN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415485","HBG1 Gene","C84955","This gene plays a role in the transport of oxygen to tissues of the body in the fetus and neonate.","HBG1 Gene | HBG1 | Hemoglobin Gamma A Gene | Hemoglobin Subunit Gamma 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415486","HBG2 Gene","C84958","This gene plays a role in the transport of oxygen to tissues of the body in the fetus and the neonate.","HBG2 Gene | HBG2 | Hemoglobin Gamma G Gene | Hemoglobin Subunit Gamma 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663136","Raymond Neurologic Function Scale","C180564","A 25-point scale used to evaluate the severity of gross neurologic dysfunction by scoring 15 disabilities across multiple domains.","Raymond Neurologic Function Scale | NFS | Neurologic Function Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662961","Raymond Neurologic Function Scale Domain","C180565","A specific area of neurological interest within the Raymond neurologic function scale, subdivided into 3 or 4 levels of function with scores based on discrete quantifiable measures.","Raymond Neurologic Function Scale Domain | NFS Domain | Neurologic Function Scale Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043143","Wheelchair","C180566","A chair fitted with wheels for use as a means of transport by a person who is unable to walk as a result of illness, injury, or disability. The chair may be propelled by the occupant, pushed by another person, or electrically propelled.","Wheelchair | ",,,,,,,,,,,,,,,"4240470","Wheelchair",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0243102","Enzyme Activity","C180567","The rate of reaction catalyzed by an enzyme, usually expressed as micromoles of product formed or substrate transformed per minute.","Enzyme Activity | Enzymatic Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1160185","DNA Transduction","C180568","The introduction of DNA into a cell by a virus or viral vector.","DNA Transduction | Gene Transduction | Transduction | Transduction Gene Transfer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550718","Adeno-Associated Virus Vector","C180569","A recombinant adeno-associated virus genome that has been engineered to carry a sequence of interest between viral inverted terminal repeats for packaging into a virus capsid and transduction into a mammalian cell.","Adeno-Associated Virus Vector | AAV Vector | Recombinant AAV | rAAV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662971","Non-Febrile Seizure","C180556","A seizure that is not associated with fever.","Non-Febrile Seizure | Nonfebrile Seizure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4012122","Apraxia","C180557","A neurological disorder characterized by the inability to execute skilled movements, despite having the willingness, physical ability and understanding of how to perform them.","Apraxia | ",,,,,,,,,,,,,,,"132342","Apraxia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4228636","Spastic Gait","C180558","A pattern of walking found in individuals with chronically-contracted leg muscles in which the affected leg or legs drag in a stiff, semicircular motion during ambulation. This may be seen in patients with cerebral palsy or multiple sclerosis.","Spastic Gait | ",,,,,,,,,,,,,,,"4248196","Spastic gait",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1662958","Opening Pressure at Lumbar Puncture","C180559","The initial pressure of cerebrospinal fluid when sampled via lumbar puncture. It is a surrogate measurement of intracranial pressure.","Opening Pressure at Lumbar Puncture | Opening Pressure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662957","Gadolinium Enhancement","C180560","An imaging technique that utilizes a gadolinium-based contrast agent to improve the characterization of tissue in the area of interest.","Gadolinium Enhancement | Gadolinium Contrast Enhancement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662939","Base Editing","C180577","A technique for the direct conversion of a specific DNA base into another at a targeted genomic locus. This technique uses a Cas nickase, or Cas fused to a deaminase, that makes the edit and a guide RNA that targets Cas to a specific locus. Cytosine base editors mediate a C to T change and adenine base editors mediate an A to G change.","Base Editing | Base Editor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662938","CRISPR-Associated Protein 9","C180578","CRISPR (clustered regularly interspaced short palindromic repeat)-associated protein 9 (160 kDa) is encoded by the Streptococcus pyogenes CAS9 gene. This protein is involved in the adaptive immune system of Streptococcus pyogenes. It has been adapted for use in targeted base editing.","Cas9 Protein | CRISPR Associated Protein 9 | CRISPR-Associated Endonuclease Cas9 | CRISPR-Associated Endonuclease Cas9/Csn1 | Cas5 | Csn1 | Csx12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662941","Transcription Activator-like Effector Nuclease","C180579","A class of custom, sequence-specific DNA endonucleases created by fusing an engineered transcription activator-like effector protein to the catalytic cleavage domain of the FokI restriction enzyme.","Transcription Activator-like Effector Nuclease | TAL Nuclease | TALE Nuclease | TALEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662940","Zinc Finger Nucleases","C180580","A class of artificial DNA endonucleases that consists of an engineered zinc finger protein fused to the catalytic cleavage domain of the FokI restriction enzyme.","Zinc Finger Nuclease | ZFN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662950","Discretion","C180582","The freedom or authority to act according to one's own judgment.","Discretion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521276","Stage I Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8","C133256","Stage I includes: T1, N0, M0. T1: Tumor smaller than 2 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Stage I | Stage I Head and Neck Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521274","Stage 0 Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8","C133255","Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0 Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Stage 0 Head and Neck Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662937","Vector Copy Number","C180599","The number of vector molecules present in a cell or sub-cellular location, sometimes stated as copies per diploid genome.","Vector Copy Number | VCN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3552938","Hyperreflexia","C43248","Autonomic nervous system overreaction to stimuli, most commonly after spinal cord injury at a T-5 level and above.","Hyperreflexia | Corticospinal tract signs: hyperreflexia",,,,,,,,,,,,,,,"4313132","Hyperreflexia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4014034","Cortical Blindness","C118707","Visual impairment due to visual cortex dysfunction.","Cortical Blindness | ",,,,,,,,,,,,,,,"253482","Cortical blindness",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018979","Hemianopsia","C118731","Lack of sight in half of the normal field of vision.","Hemianopsia | ",,,,,,,,,,,,,,,"4300870","Hemianopia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1662979","History of Pediatric Multisystem Inflammatory Syndrome","C180611","An indication that an individual had pediatric multisystem inflammatory syndrome.","History of Pediatric Multisystem Inflammatory Syndrome | History of MIS-C | History of Multisystem Inflammatory Syndrome in Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036064","Wages","C180612","Money or other benefits received in exchange for work.","Pay | Compensation | Wage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951691","Incomplete Staging (cM)","C159723","A lack of clinical and/or pathology information to assign a cM stage conclusively.","Incomplete Staging (cM) | Staging Incomplete",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662986","Externalizing Disorder Symptoms","C180615","Impulsive, disruptive, or aggressive behaviors that typically emerge in childhood or early adolescence and are associated with significant functional impairment. Child and adolescent externalizing disorders include conduct disorder, oppositional defiant disorder, and attention-deficit/hyperactivity disorder.","Externalizing Disorder Symptoms | Externalizing Behaviors | Externalizing Disorder Behaviors | Externalizing Symptoms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663441","Closing Pressure at Lumbar Puncture","C180618","The measured pressure in the spinal canal after cerebrospinal fluid collection during lumbar puncture.","Closing Pressure at Lumbar Puncture | Closing Pressure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663440","Unilateral Numbness","C180617","A loss of the sensation of feeling on one side of the body.","Unilateral Numbness | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334277","Metastatic Adenocarcinoma","C4124","An adenocarcinoma that has spread from its original site of growth to another anatomic site.","Metastatic Adenocarcinoma | Adenocarcinoma, metastatic, NOS","8140/6","Adenocarcinoma, metastatic, NOS",,,,,,,,,,,,,"4263459","Adenocarcinoma, metastatic",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1266007","Skin Adenoid Basal Cell Carcinoma","C27535","A variant of basal cell carcinoma morphologically characterized by the presence of thin strands of basaloid cells forming a reticulate pattern.","Skin Adenoid Basal Cell Carcinoma | Adenoid Basal Cell Carcinoma","8098/3","Adenoid basal carcinoma",,,,,,,,,,,,,"4028534|4299419","Adenoid basal carcinoma|Basal cell carcinoma - adenoid",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"CL1663435","Direct Oral Anticoagulant","C180619","An agent taken orally to prevent blood clot formation by directly inhibiting certain coagulation factors including thrombin (factor IIa) or factor Xa.","Direct Oral Anticoagulant | DOAC | DOACs | Direct Oral Anticoagulants | NOAC | Novel Oral Anticoagulant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1547668","Level of Care","C180620","A health care facility designation that is based on the skills and specialties of the providers and the medical complexity of the cases being treated.","Level of Care | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0743838","Exertional fatigue","C180621","Prolonged, extreme exhaustion after physical or mental effort or stress.","Exertional Fatigue | Post Exertional Fatigue | Post-exertional Fatigue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1440776","Teleworking","C180631","An employment arrangement that allows employees to perform the duties and responsibilities of their position from alternative worksites.","Telework | Remote Work | Telecommuting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663505","Arizona Tobacco Survey","C180623","A random, computerized, telephone survey of Arizona residents over 18 years old, conducted in 1996 and 1999, designed to track changes in tobacco use, the knowledge and opinions of Arizona residents about tobacco use, and the proportion of smokers advised to quit smoking by healthcare providers.","Arizona Tobacco Survey | ATS | Arizona Adult Tobacco Survey",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663437","Usually Inhale Tobacco Smoke Only to Mouth","C180624","A question about whether an individual usually inhales or inhaled tobacco smoke to their mouth only.","Usually Inhale Tobacco Smoke Only to Mouth | Do you usually inhale tobacco smoke to your mouth only",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663438","Usually Inhale Tobacco Smoke to Chest","C180625","A question about whether an individual usually inhales or inhaled tobacco smoke to their chest.","Usually Inhale Tobacco Smoke to Chest | Do you usually inhale tobacco smoke to your chest",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663439","Amount of Cigarette Smoked","C180626","A question about the amount of a cigarette that an individual smokes or smoked.","Amount of Cigarette Smoked | How much of the cigarette do you smoke | Portion of Cigarette Smoked",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663429","Prior to Age Twenty","C180627","Occurring in the period of time before an individual's twentieth year.","Prior to Age Twenty | Before age 20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663430","Smoked Pipe or Cigar at Least Twenty Times in Lifetime","C180628","A question about whether an individual has or had smoked a pipe or cigar at least twenty times in their lifetime.","Smoked Pipe or Cigar at Least Twenty Times in Lifetime | Have you smoked a pipe or cigar at least 20 times in your life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663431","Times Smoked Pipe or Cigar per Week","C180629","A question about how many times per week an individual smokes or smoked a pipe and/or cigar.","Times Smoked Pipe or Cigar per Week | How many times a week do you smoke a pipe and/or cigar",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663432","Mother Smoked Cigarettes While Pregnant with You","C180630","A question about whether an individual's mother smoked cigarettes when she was pregnant with the individual.","Mother Smoked Cigarettes While Pregnant with You | Did your mother smoke cigarettes when she was pregnant with you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL372060","Digital Image Analysis","C67525","A method in which an image or other type of data is changed into a series of dots or numbers so that it can be viewed and studied on a computer. In medicine, this type of image analysis is being used to study organs or tissues, and in the diagnosis and treatment of disease.","Digital Image Analysis | digital image analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950817","Chromosome Deletion Detected","C158863","An indication that a chromosomal deletion was detected in a sample.","Chromosome Deletion Detected | Chromosomal Deletion Detected | Cytogenetic Deletion Detected | Deletion Identified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1882252","Procarbazine-CCNU-Vincristine Regimen","C63491","A regimen consisting of procarbazine, lomustine and vincristine that may be used for the treatment of certain central nervous system (CNS) cancers including glioma, oligodendroglioma and astrocytoma.","PCV Regimen | Matulane-CCNU-Oncovin Regimen | PCV | POC | Procarbazine-Lomustine-Vincristine Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663391","Enzyme Substrate","C180669","Any chemical that can be modified or consumed by an enzyme during a chemical reaction or biological process.","Enzyme Substrate | Enzymatic Substrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086635","NovoTTF-100A Device","C125103","A portable, battery-operated device that is used to apply low intensity, alternating electric fields, also called tumor treatment fields (TTFs; TTFields), that can potentially be used to kill cancer cells. Upon placement of the insulated electrodes of the NovoTTF-100A device on the skin's surface encircling the tumor area, electrical charges are delivered, and the resulting electrical fields interfere with cell division. This induces cell death in and inhibits proliferation of tumor cells.","NovoTTF-100A Device | NovoTTF-100A | NovoTTF-100A System | NovoTTF-100A system (Optune) | NovoTTFields | NovoTumor Treatment Fields | Optune | Optune Device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663333","Erythema of the Oropharyngeal Mucosa","C180690","Erythema of the mucus membranes lining the part of the pharynx located between the soft palate and the upper portion of the epiglottis.","Erythema of the Oropharyngeal Mucosa | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556218","FGFR Inhibitor","C155727","Any agent that inhibits the fibroblast growth factor receptor (FGFR).","FGFR Inhibitor | Fibroblast Growth Factor Receptor Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969415","Radiation Therapy Status Unknown","C160347","No Value Exists","Radiation Therapy Status Unknown | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969416","Radiation Therapy Not Received","C160346","No Value Exists","Radiation Therapy Not Received | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978430","Conventional Radiotherapy","C165189","A course of radiotherapy where minimal imaging support (i.e. X-rays films) is used to determine the positioning of radiotherapy.","Conventional Radiotherapy | 2-Dimensional Conventional Radiation Therapy | 2D Conventional Radiotherapy | 2D Radiotherapy | 2D-RT | Radiation, 2D Conventional",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829113","Bisulfite Sequencing","C106054","A DNA sequencing technique that can differentiate cytosine from 5-methylcytosine in a DNA sample. First, a denatured DNA sample is treated with bisulfite which converts non-methylated cytosine to uracil. Next, the sample is amplified using a PCR method that does not discriminate between non-methylated and methylated sequences. The amplified DNA is subjected to nucleotide sequencing. The resulting sequence is compared to an identical control sample of DNA that was not treated with bisulfite. Unmethylated cytosines will be displayed as cytosines in the control sample and as thymines in the bisulfite-treated sample.","Bisulfite Sequencing | BS-Seq | Bisulfite-Seq | Bisulfite-Seq (sequencing following treatment of DNA with bisulfite to convert cytosine residues to uracil) | Bisulphite Conversion Followed by Sequencing | DNA Methylation Sequencing | Methyl-C-Seq | MethylC-Seq | Methylation Sequencing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334342","Skin Appendage Adenoma","C7580","A benign epithelial neoplasm arising from the sebaceous or sweat glands. Representative examples include sebaceous adenoma, tubular apocrine adenoma, and hidradenoma.","Skin Appendage Adenoma | ADENOMA, ADNEXAL, BENIGN | Adenoma of Adnexa | Adenoma of Skin Appendage | Adnexal Adenoma | Skin appendage adenoma","8390/0","Skin appendage adenoma",,,,,,,,,,,,,"4208106","Skin appendage adenoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1368669","Benign Adrenal Cortical Neoplasm","C9004","A neoplasm that arises from the adrenal cortex and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Adrenal Cortical Neoplasm | Adrenal cortical tumor, benign | Benign Adrenal Cortex Neoplasm | Benign Adrenal Cortex Neoplasm | Benign Adrenal Cortex Tumor",,,,,,,,,,,,,,,"4240656|603136","Benign neoplasm of adrenal cortex|Benign adrenal cortical adenoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0334333","Pigmented Adrenal Cortical Adenoma","C4164","A usually functioning adenoma of the adrenal cortex. Grossly, it has a dark brown appearance and is characterized by the presence of neoplastic cells containing abundant intracytoplasmic lipofuscin. It may be associated with Cushing syndrome.","Pigmented Adrenal Cortical Adenoma | Adrenal cortical adenoma, pigmented | Black Adenoma | Black adenoma | Heavily Pigmented Adrenal Cortex Adenoma | Heavily Pigmented Adrenal Cortical Adenoma | Heavily Pigmented Adrenocortical Adenoma | Pigmented Adrenal Cortex Adenoma | Pigmented Adrenal Cortex Adenoma | Pigmented Adrenal Gland Adenoma | Pigmented adenoma","8372/0","Adrenal cortical adenoma, pigmented",,,,,,,,,,,,,"4290634","Adrenal cortical adenoma, pigmented",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334336","Adrenal Cortical Mixed Cell Adenoma","C4167","An adenoma of the adrenal cortex composed of a mixed neoplastic cellular population, including varying numbers of neoplastic clear and compact cells.","Adrenal Cortical Mixed Cell Adenoma | Adrenal Cortex Mixed Cell Adenoma | Adrenal Cortex Mixed Cell Adenoma | Adrenal Gland Mixed Cell Adenoma | Adrenal cortical adenoma, mixed cell | Mixed Cell Adrenal Cortex Adenoma | Mixed Cell Adrenal Cortical Adenoma | Mixed Cell Adrenocortical Adenoma","8375/0","Adrenal cortical adenoma, mixed cell",,,,,,,,,,,,,"4219319","Adrenal cortical adenoma, mixed cell",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334335","Adrenal Cortical Glomerulosa Cell Adenoma","C4166","An adenoma of the adrenal cortex composed of neoplastic cells with cytologic features of glomerulosa cells.","Adrenal Cortical Glomerulosa Cell Adenoma | Adrenal Cortex Glomerulosa Cell Adenoma | Adrenal Cortex Glomerulosa Cell Adenoma | Adrenal Gland Glomerulosa Cell Adenoma | Adrenal cortical adenoma, glomerulosa cell | Glomerulosa Cell Adrenal Cortex Adenoma | Glomerulosa Cell Adrenal Cortical Adenoma | Glomerulosa Cell Adrenocortical Adenoma","8374/0","Adrenal cortical adenoma, glomerulosa cell",,,,,,,,,,,,,"4078714","Adrenal cortical adenoma, glomerulosa cell",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334332","Adrenal Cortical Compact Cell Adenoma","C4163","An adenoma of the adrenal cortex composed of neoplastic compact cells with eosinophilic cytoplasm.","Adrenal Cortical Compact Cell Adenoma | Adrenal Cortex Compact Cell Adenoma | Adrenal Cortex Compact Cell Adenoma | Adrenal Gland Compact Cell Adenoma | Adrenal cortical adenoma, compact cell | Compact Cell Adrenal Cortex Adenoma | Compact Cell Adrenal Cortical Adenoma | Compact Cell Adrenocortical Adenoma","8371/0","Adrenal cortical adenoma, compact cell",,,,,,,,,,,,,"4270185","Adrenal cortical adenoma, compact cell",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334334","Adrenal Cortical Clear Cell Adenoma","C4165","An adenoma of the adrenal cortex composed of neoplastic clear cells containing intracytoplasmic lipid droplets.","Adrenal Cortical Clear Cell Adenoma | Adrenal Cortex Clear Cell Adenoma | Adrenal Cortex Clear Cell Adenoma | Adrenal Gland Clear Cell Adenoma | Adrenal cortical adenoma, clear cell | Clear Cell Adrenal Cortex Adenoma | Clear Cell Adrenal Cortical Adenoma | Clear Cell Adrenocortical Adenoma","8373/0","Adrenal cortical adenoma, clear cell",,,,,,,,,,,,,"4077757","Adrenal cortical adenoma, clear cell",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"CL033098","Adult Cystic Teratoma","C9012","No Value Exists","Adult Cystic Teratoma | Adult cystic teratoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001630","Adrenal Rest Tumor","C2860","A benign, testicular or ovarian tumor, derived from adrenal embryonic rest cells. It is composed of hyperplastic adrenal cortical tissue, and it is associated with congenital adrenal hyperplasia.","Adrenal Rest Tumor | Adrenal Rest Neoplasm | Adrenal rest tumor","8671/0","Adrenal rest tumor",,,,,,,,,,,,,"4184292","Adrenal rest tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1708998","Metastatic Adrenal Gland Pheochromocytoma","C4220","A pheochromocytoma that metastasizes to other anatomic sites.  Common sites of metastasis include lymph nodes, bones, liver, and lung.  Morphologic features associated with malignant pheochromocytomas include: atypical mitotic figures, capsular and vascular invasion, tumor cell necrosis, and high mitotic activity.","Metastatic Adrenal Gland Pheochromocytoma | Adrenal medullary paraganglioma, malignant | Malignant Adrenal Gland Chromaffin Neoplasm | Malignant Adrenal Gland Chromaffin Paraganglioma | Malignant Adrenal Gland Chromaffin Tumor | Malignant Adrenal Gland Chromaffinoma | Malignant Adrenal Gland Paraganglioma | Malignant Adrenal Gland Pheochromocytoma | Malignant Adrenal Gland Pheochromocytoma | Malignant Adrenal Medullary Paraganglioma | Malignant Adrenal Medullary Pheochromocytoma | Malignant Adrenal Pheochromocytoma | Malignant Pheochromocytoma | Metastatic Pheochromocytoma | PHEOCHROMOCYTOMA, MALIGNANT | Pheochromoblastoma | Pheochromocytoma, malignant",,,,,,,,,,,,,,,"37016244|4104978","Malignant pheochromocytoma|Malignant pheochromocytoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL1406611","Smoked Cigarettes","C172730","A question about an individual's cigarette smoking.","Smoked Cigarettes | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025368","Menthol","C80301","An organic compound made synthetically or obtained from peppermint or mint oils with flavoring and local anesthetic properties. When added to pharmaceuticals and foods, menthol functions as a fortifier for peppermint flavors. It also has a counterirritant effect on skin and mucous membranes, thereby producing a local analgesic or anesthetic effect.","Menthol | MENTHOL, UNSPECIFIED FORM | menthol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600549","Tobacco Use Cessation","C96001","Discontinuation of the use of tobacco in any form.","Tobacco Product Use Cessation | CESSATION | Tobacco Use Cessation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448528","Cigarette Smoker","C17949","An individual who currently, or recently, smokes cigarettes regularly.","Cigarette Smoker | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977371","Cigarette Smoke Exposure","C164098","Environmental, occupational or consumer-based exposure to airborne gases and particulates produced by direct or nearby use of a cigarette.","Cigarette Smoke Exposure | Tobacco smoke, cigarette",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0312422","Blacking Out","C180702","A temporary loss of consciousness or a temporary state of altered consciousness that results in memory loss.","Blacking Out | Black Out | Blackout | Passing Out",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663294","T1-Weighted Magnetic Resonance Imaging","C180727","A method of magnetic resonance imaging (MRI) that creates contrast between tissues based on differences in the longitudinal relaxation of a tissue's net magnetization vector; it measures the time taken for spinning protons to realign with the external magnetic field. This MRI sequence is produced by using short  time to echo (TE) and repetition times (TR).","T1-Weighted Magnetic Resonance Imaging | Spin-lattice Relaxation MRI | T1-Weighted MRI | T1W MRI | T1WI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663295","T1-Weighted Magnetic Resonance Imaging with Contrast","C180728","T1 weighted magnetic resonance imaging done with the addition of a contrast agent to enhance tissues.","T1-Weighted Magnetic Resonance Imaging with Contrast | Spin-lattice Relaxation MRI with Contrast | T1-Weighted MRI with Contrast | T1W MRI with Contrast | T1WI with Contrast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663296","T2-Weighted Magnetic Resonance Imaging","C180729","A method of magnetic resonance imaging (MRI) that creates contrast between tissues based on differences in the transverse relaxation of a tissue's net magnetization vector; it measures the time taken for spinning protons to lose phase coherence among the nuclei spinning perpendicular to the main field. This MRI sequence is produced by using a longer time to echo (TE) and repetition time (TR) than a T1-weighted sequence.","T2-Weighted Magnetic Resonance Imaging | T2-Weighted MRI | T2W MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937283","Anal Intraepithelial Neoplasia 3","C157575","Anal canal or perianal skin intraepithelial neoplasia with severe dysplasia.","Anal Intraepithelial Neoplasia 3 | AIN III | AIN3 | Anal Squamous Intraepithelial Neoplasia 3 | Anal intraepithelial neoplasia, grade III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334547","Aggressive Osteoblastoma","C66796","An osteoblastoma characterized by the presence of prominent epithelioid osteoblasts and recurrences.","Aggressive Osteoblastoma | Aggressive osteoblastoma","9200/1","Aggressive osteoblastoma",,,,,,,,,,,,,"4322468","Aggressive osteoblastoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
,,,,,,,,,,,,,,,,,,,"37158799","Digital papillary adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,"--"
"C1368888","Adult Teratoma","C9013","No Value Exists","Adult Teratoma | Adult teratoma, NOS | Teratoma",,,,,,,,,,,,,,,"4175497","Teratoma, benign",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334667","Aleukemic Lymphoid Leukemia","C4343","No Value Exists","Aleukemic Lymphoid Leukemia | Aleukemic Lymphatic Leukemia | Aleukemic Lymphogenous Leukemia | Aleukemic lymphatic leukemia | Aleukemic lymphoid leukemia",,,,,,,,,,,,,,,"40284464|4094549","Aleukemic lymphoid leukemia|Aleukemic lymphoid leukemia",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3282876","Aleukemic Chronic Lymphocytic Leukemia","C7176","No Value Exists","Aleukemic Chronic Lymphocytic Leukemia | Aleukemic Lymphocytic Leukemia | Aleukemic lymphocytic leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4078806","Polatuzumab Vedotin","C104153","An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against B-cell antigen receptor complex-associated protein beta chain (CD79B) conjugated, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity.  Upon administration, the monoclonal antibody moiety of polatuzumab vedotin selectively binds to CD79B, a protein which is abundantly expressed on the surface of B-cells. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. CD79B, a component of the B-cell receptor (BCR), plays a key role in B-cell receptor signaling and is expressed on the surface of almost all types of malignant B-cells.","Polatuzumab Vedotin | ADC DCDS4501A | Antibody-Drug Conjugate DCDS4501A | DCDS4501A | FCU 2711 | FCU-2711 | FCU2711 | POLATUZUMAB VEDOTIN | Polatuzumab vedotin | Polivy | RG 7596 | RG-7596 | RG7596 | Ro 5541077-000 | polatuzumab vedotin-piiq",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552621","SIRPa-IgG4 Fc","C150756","A soluble recombinant antibody-like fusion protein composed of the N-terminal CD47 binding domain of human signal-regulatory protein alpha (SIRPa; CD172a) linked to an Fc domain derived from human immunoglobulin G subtype 4 (IgG4), with potential immune checkpoint inhibitory, phagocytosis-inducing and antineoplastic activities. Upon administration, maplirpacept selectively targets and binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with endogenous SIRPa, a cell surface protein expressed on macrophages. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation. This induces pro-phagocytic signaling resulting from the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1) expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects tumor cells from phagocytosis, thereby allowing these cells to proliferate and survive.","Maplirpacept | MAPLIRPACEPT | PF 07901801 | PF-07901801 | PF07901801 | SIRPa-IgG4 Fc | SIRPa-IgG4 Fc TTI-622 | SIRPa-IgG4-Fc Fusion Protein TTI-622 | SIRPa-IgG4-Fc Fusion Protein TTI-622 | TTI 622 | TTI-622 | TTI622",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663298","Dexamethasone/Liposomal Doxorubicin/Etoposide/Rituximab/Temozolomide Regimen","C180731","A regimen consisting of dexamethasone, pegylated liposomal doxorubicin, etoposide, rituximab and temozolomide that may be used in the treatment of central nervous system (CNS) lymphoma.","Dexamethasone/Liposomal Doxorubicin/Etoposide/Rituximab/Temozolomide Regimen | Dexamethasone/Liposomal Doxorubicin/Etoposide/Rituximab/Temozolomide | TEDD Plus Rituximab | TEDD-R | TEDD-R Regimen | Temozolomide/Etoposide/Doxil/Dexamethasone and Rituximab | Temozolomide/Etoposide/Doxil/Dexamethasone/Rituximab | Temozolomide/Etoposide/Doxil/Dexamethasone/Rituximab Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334282","Malignant Pancreatic Glucagonoma","C65187","A glucagon-producing neuroendocrine tumor arising from the alpha cells of the pancreas.  It may be associated with necrolytic erythema migrans, diarrhea, diabetes, glossitis, weight loss, malabsorption, and anemia.  It displays vascular invasion and metastasizes to other anatomic sites.","Malignant Pancreatic Glucagonoma | Alpha cell tumor, malignant | Glucagonoma, malignant | Malignant Glucagonoma | Pancreatic Alpha Cell Carcinoma",,,,,,,,,,,,,,,"4282771","Glucagonoma, malignant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1663284","Aruvant Sciences","C180733","A clinical-stage biopharmaceutical company that is developing and commercializing gene therapies for rare diseases.","Aruvant Sciences | Aruvant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663285","Avrobio","C180734","A clinical-stage biotechnology company that is developing lentivirus-based gene therapies designed to halt or reverse disease with a single dose, with a focus on lysosomal disorders.","Avrobio | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663286","Beam Therapeutics","C180735","A biotechnology company developing precision genetic therapies through base editing.","Beam Therapeutics | Beam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663287","CRISPR Therapeutics","C180736","A gene editing company focused on developing gene-based medicines and therapies using its proprietary CRISPR/Cas9 platform.","CRISPR Therapeutics | CRISPR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663288","Editas Medicine","C180737","A clinical-stage biotechnology company which is developing gene-edited therapies based on CRISPR/Cas9 technology, using both in vivo and ex vivo modalities.","Editas Medicine | Editas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663289","Graphite Bio","C180738","A clinical-stage gene-editing company using CRISPR technology and gene replacement to develop therapies to treat or cure human diseases.","Graphite Bio | Graphite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663290","Mustang Bio","C180739","A clinical-stage biopharmaceutical company focused on translating cell and gene therapies into potential cures for hematologic cancers, glioblastoma, and rare genetic diseases.","Mustang Bio | MustangBio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663385","Orchard Therapeutics","C180740","A biopharmaceutical company that uses ex vivo autologous gene therapy to develop cures for rare and often-fatal diseases.","Orchard Therapeutics | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663386","Rocket Pharmaceuticals","C180741","A clinical-stage biotechnology company focusing on developing curative gene therapy treatments using adeno-associated viral vector (AAV) and lentiviral vector (LVV) approaches.","Rocket Pharmaceuticals | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663506","Vertex Pharmaceuticals","C180742","A global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. They are developing small molecule medicines as well as genetic and cell therapies.","Vertex Pharmaceuticals | Vertex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663372","Dexamethasone/Liposomal Doxorubicin/Etoposide/Ibrutinib/Rituximab/Temozolomide Regimen","C180769","A regimen consisting of dexamethasone, pegylated liposomal doxorubicin, etoposide, ibrutinib, rituximab and temozolomide that may be used in the treatment of central nervous system (CNS) lymphoma.","Dexamethasone/Liposomal Doxorubicin/Etoposide/Ibrutinib/Rituximab/Temozolomide Regimen | Dexamethasone/Liposomal Doxorubicin/Etoposide/Ibrutinib/Rituximab/Temozolomide | TEDDI Plus Rituximab | TEDDI-R | TEDDI-R Regimen | Temozolomide/Etoposide/Doxil/Dexamethasone/Ibrutinib and Rituximab | Temozolomide/Etoposide/Doxil/Dexamethasone/Ibrutinib/Rituximab | Temozolomide/Etoposide/Doxil/Dexamethasone/Ibrutinib/Rituximab Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334573","Ameloblastic Fibrosarcoma","C4317","A locally aggressive malignant neoplasm arising from odontogenic tissue. It occurs in the mandible and less often in the maxilla.  It is characterized by the presence of a malignant connective tissue component and a benign epithelial component.  The frequency of distal metastases is low.","Ameloblastic Fibrosarcoma | AFS | Ameloblastic fibrosarcoma | Ameloblastic sarcoma","9330/3","Ameloblastic fibrosarcoma",,,,,,,,,,,,,"4098563","Ameloblastic fibrosarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"CL1407559","Ameloblastic Fibroodontosarcoma","C173740","An odontogenic sarcoma producing enamel/enameloid and dentin.","Ameloblastic Fibro-Odontosarcoma | Ameloblastic Fibroodontosarcoma | Ameloblastic Fibroodontosarcoma | Ameloblastic fibro-odontosarcoma | Ameloblastic odontosarcoma | Odontogenic fibrosarcoma","9290/3","Ameloblastic odontosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C0334572","Ameloblastic Fibroma","C4316","A rare neoplasm arising from tooth-forming tissues. It usually arises from the posterior mandible. It is characterized by the presence of an epithelial component and fibromyxoid stroma. It may recur and rarely shows malignant transformation to ameloblastic fibrosarcoma. It is treated with enucleation and curettage.","Ameloblastic Fibroma | Ameloblastic fibroma | Fibrodentinoma","9330/0","Ameloblastic fibroma",,,,,,,,,,,,,"4007615","Ameloblastic fibroma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334564","Ameloblastic Fibrodentinosarcoma","C173739","An odontogenic sarcoma producing dentin/dentinoid.","Ameloblastic Fibrodentinosarcoma | Ameloblastic fibrodentinosarcoma",,,,,,,,,,,,,,,"4069657","Ameloblastic odontosarcoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0457520","Ameloblastic Fibrodentinoma","C66800","A rare neoplasm arising from tooth-forming tissues. It usually arises from the posterior mandible. It is characterized by the presence of an epithelial component, fibromyxoid stroma, and dentin formation. It is treated with enucleation and curettage. Recurrences may occur.","Ameloblastic Fibrodentinoma | Ameloblastic fibrodentinoma","9271/0","Ameloblastic fibrodentinoma",,,,,,,,,,,,,"4275269","Ameloblastic fibrodentinoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0205865","Ameloblastic Fibro-Odontoma","C3710","A rare benign neoplasm arising from tooth-forming tissues. It is characterized by the presence of a fibromyxoid stroma, epithelial component, dentin, and enamel. Recurrences are rare.","Ameloblastic Fibro-Odontoma | Ameloblastic Fibroodontoma | Ameloblastic fibro-odontoma | Fibroameloblastic Odontoma | Fibroameloblastic odontoma | ODONTOMA, AMELOBLASTIC, BENIGN","9290/0","Ameloblastic fibro-odontoma",,,,,,,,,,,,,"4225759","Ameloblastic fibro-odontoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1314678","Ameloblastic Carcinoma","C7492","A rare, cytologically malignant ameloblastoma that may metastasize.","Ameloblastic Carcinoma | AC | Ameloblastic carcinoma | ODONTOMA, AMELOBLASTIC, MALIGNANT",,,,,,,,,,,,,,,"37153944","Ameloblastic carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032972","Pregnancy Outcome","C90491","Findings observed at the end of a pregnancy.","Pregnancy Outcome | PREGOUT | PRGOUT | pregnancy outcome | pregnancy_outcome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647630","Actual Date of Delivery","C178050","The date on which the delivery event occurred.","Actual Date of Delivery | ADLVRDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647674","Number of Live Births","C178141","A measurement of the total number of live-born offspring a female has delivered.","Number of Live Births | BRTHLVN | Live Birth Count",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662311","Surgical Damage Indicator","C179824","An indication as to whether damage occurred related to a surgical procedure.","Surgical Damage Indicator | SGDMGIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662312","Hematoma Indicator","C179823","An indication as to whether a hematoma is present.","Hematoma Indicator | HEMAIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662440","p16-INK4A Measurement","C179766","The determination of the amount of p16-INK4A present in a sample.","p16-INK4A Measurement | CDK4I | CDK4I Measurement | Cyclin Dependent Kinase Inhibitor 2A p16 | Cyclin Dependent Kinase Inhibitor 2A p16 Measurement | P16INK4A | p16 | p16 Inhibitors of CDK4 | p16 Inhibitors of CDK4 Measurement | p16 Measurement | p16-INK4 Measurement | p16-INK4A | p16-INK4a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152309","Superior Temporal Gyrus","C33698","A gyrus or ridge on the outer surface of the temporal lobe between the horizontal portion of the fissure of Sylvius and the superior temporal sulcus.","Superior Temporal Gyrus | SUPERIOR TEMPORAL GYRUS | Superior Temporal Convolution",,,,,,,,,,,,,,,"4147067","Structure of superior temporal gyrus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152310","Middle Temporal Gyrus","C33125","A gyrus or ridge on the outer surface of the temporal lobe between the superior and middle temporal sulci.","Middle Temporal Gyrus | MIDDLE TEMPORAL GYRUS | Middle Temporal Convolution",,,,,,,,,,,,,,,"4148206","Structure of middle temporal gyrus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152311","Inferior Temporal Gyrus","C32791","A gyrus or ridge on the outer surface of the temporal lobe below the middle sulcus.","Inferior Temporal Gyrus | INFERIOR TEMPORAL GYRUS | Inferior Temporal Convolution",,,,,,,,,,,,,,,"4250636","Structure of inferior temporal gyrus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1553342","Guamanian or Chamorro","C43837","A person having origins in any of the original peoples of Guam or the Mariana Islands.","Guamanian or Chamorro | GUAMANIAN OR CHAMORRO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662315","Reaction Grade","C179819","The position on a scale to assess the response to some kind of stimulus.","Reaction Grade | REACTGR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662719","PASI02","C179972","A standardized survey developed by Feldman and Krueger in 2005 to calculate the intensity and extent of psoriatic lesions before, during, and after treatment in chronic plaquetype psoriasis. The instrument utilizes a 5-point rating scale to measure intensity and assigns a numerical score for the percentage of anatomical involvement.","Psoriasis Area and Severity Index Feldman Version Clinical Classification | PASI FELDMAN | PASI Feldman Version | PASI V2 | PASI Version 2 | PASI02 | Psoriasis Area and Severity Index Version 2 Clinical Classification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662438","Staphylococcus saprophyticus Measurement","C179764","The determination of the amount of Staphylococcus saprophyticus present in a sample.","Staphylococcus saprophyticus Measurement | SSA | Staphylococcus saprophyticus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662439","Serratia Measurement","C179763","The determination of the amount of Serratia present in a sample.","Serratia Measurement | SERRATIA | Serratia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662432","Streptococcus agalactiae Measurement","C179762","The determination of the amount of Streptococcus agalactiae present in a sample.","Streptococcus agalactiae Measurement | SAG | Streptococcus agalactiae",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662433","Human Rhinovirus and/or Enterovirus Measurement","C179761","The determination of the amount of human rhinovirus/enterovirus present in a sample.","Human Rhinovirus and/or Enterovirus Measurement | Human rhinovirus/enterovirus | RVENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662431","Proteus mirabilis Measurement","C179760","The determination of the amount of Proteus mirabilis present in a sample.","Proteus mirabilis Measurement | PMI | Proteus mirabilis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663149","Morganella Measurement","C179759","The determination of the amount of Morganella present in a sample.","Morganella Measurement | MORGANEL | Morganella",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662435","Enterobacter Measurement","C179758","The determination of the amount of Enterobacter present in a sample.","Enterobacter Measurement | ENTEROBA | Enterobacter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663127","Candida Measurement","C179757","The determination of the amount of Candida present in a sample.","Candida Measurement | CANDIDA | Candida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663150","Bordetella pertussis Measurement","C179756","The determination of the amount of Bordetella pertussis present in a sample.","Bordetella pertussis Measurement | BPE | Bordetella pertussis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662434","Acinetobacter Measurement","C179755","The determination of the amount of Acinetobacter present in a sample.","Acinetobacter Measurement | ACINETOB | Acinetobacter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1321546","Anaplastic Lymphoma","C6916","A diffuse large B-cell lymphoma variant characterized by the presence of large round, oval, or polygonal cells with bizarre pleomorphic nuclei resembling Hodgkin or Reed-Sternberg cells. It is unrelated to anaplastic large cell lymphoma which is a T-cell non-Hodgkin lymphoma.","Anaplastic Lymphoma | Anaplastic Large B-Cell Lymphoma | Anaplastic large B-cell lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334567","Metastasizing Ameloblastoma","C54297","A rare, well differentiated, cytologically benign ameloblastoma which paradoxically metastasizes.","Metastasizing Ameloblastoma | AMELOBLASTOMA, MALIGNANT | Ameloblastoma, malignant | Malignant Ameloblastoma",,,,,,,,,,,,,,,"4339416","Ameloblastoma, malignant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1662341","SIOPEN Lewington Neuroblastoma 2017 Oncology Response Criteria","C179784","123I-MIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting, method by an international panel. (Lewington V., Lambert B., Poetschger U., Bar Sever Z., Giammarile F., McEwan A.J.B., Rita Castellani R., Lynch T., Shulkin B., Drobics M., Staudenherz A., Landenstein R. 123I-MIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting, method by an international panel. J Nucl Med Mol Imaging. 2017 Feb;44(2):234-241.)","SIOPEN Lewington Neuroblastoma 2017 Oncology Response Criteria | SIOPEN LEWINGTON NEUROBLASTOMA 2017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662342","Owen Waldenstroms Macroglobulinemia 2013 Oncology Response Criteria","C179783","Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop. (Roger G. Owen, Robert A. Kyle, Marvin J. Stone, Andy C. Rawstron, Veronique Leblond, et al. Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013 Jan;160(2):171-6.)","Owen Waldenstroms Macroglobulinemia 2013 Oncology Response Criteria | OWEN WALDESTROMS MACROGLOBULINEMIA 2013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662346","MRECIST Armato Mesothelioma 2018 Oncology Response Criteria","C179782","Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. (Armato SG 3rd, Nowak AK. Revised modified response evaluation criteria in solid tumors for assessment of response in malignant pleural mesothelioma (Version 1.1). J. Thorac. Oncol. 2018 Apr;13(7):1012-21.)","MRECIST Armato Mesothelioma 2018 Oncology Response Criteria | MRECIST ARMATO MESOTHELIOMA 2018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662347","itRECIST Goldmacher 2020 Oncology Response Criteria","C179781","Response criteria for intratumoral immunotherapy in solid tumors: itRECIST (Goldmacher GV, Khilnani AD, MD1, Andtbacka RHI, Luke JJ, Hodi FS, Marabelle A, Harrington K, Perrone A, Tse A, Madoff DC, Schwartz LH. Response criteria for intratumoral immunotherapy in solid tumors: itRECIST. J Clin Oncol. 2020 Aug 10;38(23):2667-2676.)","itRECIST Goldmacher 2020 Oncology Response Criteria | Intratumoral RECIST | itRECIST GOLDMACHER 2020",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662344","ITMIG MRECIST Benveniste Thymic Epithelial Tumors 2014 Oncology Response Criteria","C179780","A practical guide from the International Thymic Malignancy Interest Group (ITMIG) regarding radiographic assessment of treatment response of thymic epithelial tumors using modified RECIST criteria. (Marcelo F Benveniste, Robert J Korst, Arun Rajan, Frank C Detterbeck, Edith M Marom, International Thymic Malignancy Interest Group. A practical guide from the International Thymic Malignancy Interest Group (ITMIG) regarding the radiographic assessment of treatment response of thymic epithelial tumors using modified RECIST criteria. J Thorac Oncol. 2014 Sep;9(9 Suppl 2):S119-24.)","ITMIG MRECIST Benveniste Thymic Epithelial Tumors 2014 Oncology Response Criteria | ITMIG MRECIST BENVENISTE THYMIC EPITHELIAL TUMORS 2014 | ITMIG MRECIST Response Criteria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662345","ELN Dohner AML 2017 Oncology Response Criteria","C179779","Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. (Hartmut Dohner, Elihu Estey, David Grimwade, Sergio Amadori, Frederick R. Appelbaum, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood (2017) 129 (4): 424-447.)","ELN Dohner AML 2017 Oncology Response Criteria | ELN DOHNER AML 2017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662335","Ady Neuroblastoma 1995 Oncology Response Criteria","C179778","A new 123I-MIBG whole body scan scoring method--application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. (N Ady, J M Zucker, B Asselain, V Edeline, F Bonnin, J Michon, R Gongora, L Manil. A new 123I-MIBG whole body scan scoring method--application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer. 1995;31A(2):256-61.)","Ady Neuroblastoma 1995 Oncology Response Criteria | ADY NEUROBLASTOMA 1995",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334609","Hemangioblastic Meningioma","C66817","An obsolete term referring to hemangiopericytoma of the central nervous system.","Hemangioblastic Meningioma | ","9535/0","Hemangioblastic meningioma",,,,,,,,,,,,,"4261967","Hemangioblastic meningioma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334406","Malignant Sertoli Cell Tumor","C67006","A Sertoli cell tumor that arises from the testis or the ovary. It is characterized by nuclear pleomorphism, increased mitotic activity and necrotic changes. Metastases may be present at diagnosis.","Malignant Sertoli Cell Tumor | Malignant Androblastoma | SERTOLI CELL TUMOR, MALIGNANT | Sertoli cell carcinoma","8630/3|8640/3","Androblastoma, malignant|Sertoli cell carcinoma",,,,,,,,,,,,,"4047944|4196034","Androblastoma, malignant|Sertoli cell carcinoma",,,,,,,,,,,,,"--","--|--",,,,,,,,"--|--"
"C0334405","Benign Sertoli Cell Tumor","C67012","A Sertoli cell tumor of the testis or the ovary which remains localized and does not metastasize to another anatomic site.","Benign Sertoli Cell Tumor | Benign Androblastoma | SERTOLI CELL TUMOR, BENIGN","8630/0","Androblastoma, benign",,,,,,,,,,,,,"4221707","Androblastoma, benign",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1536561","Ancient Schwannoma","C6556","A schwannoma that is characterized by degenerative changes such as hyalinization, hemorrhage, calcification and cystic change.","Ancient Schwannoma | Ancient Neurilemmoma | Ancient schwannoma | Degenerated Neurilemmoma | Degenerated Schwannoma | Degenerated schwannoma",,,,,,,,,,,,,,,"4256243|4298151","Ancient schwannoma|Ancient schwannoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL1662716","PT01","C179975","The first version of a database containing 124 questions that represent 78 symptomatic adverse events taken from the Common Terminology Criteria for Adverse Events.","Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events Item Library Version 1.0 Questionnaire | PRO-CTCAE V1.0 | PRO-CTCAE V1.0 VERSION DATE 4/26/2020 | PRO-CTCAE V1.0 Version | PRO-CTCAE V1.0 Version Date 4/26/2020 | PT01 | Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events Item Library Version 1.0 Version Date 4/26/2020 Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662721","Functional Assessment of Cancer Therapy-Bone Pain Version 4 Questionnaire","C179974","The fourth version of a standardized 16-item questionnaire originally developed by Broom et al. in 2009 that utilizes a five point rating scale to assess the general functioning, physical, and pain aspects of quality of life in cancer patients with bone metastases; it supplements the core quality of life questionnaire, Functional Assessment of Cancer Therapy General Questionnaire (FACT-G).","Functional Assessment of Cancer Therapy-Bone Pain Version 4 Questionnaire | FAC074 | FACT-BP V4 | FACT-BP Version 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3533274","Functional Assessment of Anorexia/Cachexia Treatment Version 4 Questionnaire","C179973","The fourth version of a standardized 39-item quality of life questionnaire owned and copyrighted by David Cella et al. that combines the FACT-G general quality of life questionnaire and a subscale complement that specifically addresses anorexia/cachexia-related concerns in patients with cancer, AIDS, and some chronic diseases.","Functional Assessment of Anorexia/Cachexia Treatment Version 4 Questionnaire | FAACT V4 | FAACT Version 4 | FAC065",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
,,,,,,,,,,,,,,,,,,,"4097374","Angiokeratoma",,,,,,,,,,,,,,,,,,,,,,"--"
"CL331771","Angiocentric Immunoproliferative Lesion","C40970","A neoplastic lymphoproliferative process characterized by an angiocentric arrangement of tumor cells and associated angiodestruction. It includes lymphomatoid granulomatosis which is a lymphoproliferative lesion derived from mature B-lymphocytes and cases of extranodal NK/T-cell lymphomas of nasal type.","Angiocentric Immunoproliferative Lesion | AIL | Angiocentric immunoproliferative lesion","9766/1","Angiocentric immunoproliferative lesion",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C0877849","Askin Tumor","C7542","A primitive neuroectodermal tumor (small round blue cell tumor) of the thorax which can involve the periosteum, thoracic wall and/or pleura though it spares the lung parenchyma.","Askin Tumor | Askin tumor | Askin's Tumor | PNET of Thoracopulmonary Region | Peripheral Neuroectodermal Tumor of Thoracopulmonary Region | Small Cell Tumor of Thoracopulmonary Region","9365/3","Askin tumor",,,,,,,,,,,,,"4030141","Askin tumor",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1704335","Apocrine Hidrocystoma","C43342","A slow-growing, usually solitary, dome-shaped benign sweat gland adenoma, most frequently located on the eyelid.  It is characterized by a cystic proliferation of apocrine glands. Surgical excision is curative.","Apocrine Hidrocystoma | Apocrine Hydrocystoma",,,,,,,,,,,,,,,"4112757","Apocrine cystadenoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0334417","Aorticopulmonary Paraganglioma","C4218","An extra-adrenal parasympathetic paraganglioma that arises from paraganglia adjacent to the base of the heart and great vessels.","Aorticopulmonary Paraganglioma | Aortic Body Neoplasm | Aortic Body Paraganglioma | Aortic Body Tumor | Aortic body paraganglioma | Aortic body tumor | Aorticopulmonary paraganglioma | Neoplasm of Aortic Body | Neoplasm of the Aortic Body | Paraganglioma of Aortic Body | Paraganglioma of the Aortic Body | Tumor of Aortic Body | Tumor of the Aortic Body",,,,,,,,,,,,,,,"4205591","Aortic body tumor",,,,,,,,,,,,,"--",,,,,,,,,"--"
,,,,,,,,,,,,,,,,,,,"4239956|4301654","Angiomyxoma|Angiomyxoma",,,,,,,,,,,,,,,,,,,,,,"--|--"
"C0334479","Angiomyosarcoma","C66771","A malignant smooth muscle neoplasm characterized by the presence of atypical spindle cells and formation of vascular channels.","Angiomyosarcoma | ","8894/3","Angiomyosarcoma",,,,,,,,,,,,,"4103528","Angiomyosarcoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0334478","Bizarre Leiomyoma","C4257","A morphologic variant of leiomyoma characterized by the presence of pleomorphic muscle cells with bizarre hyperchromatic nuclei and eosinophilic cytoplasm.","Bizarre Leiomyoma | Atypical Leiomyoma | Atypical leiomyoma | Bizarre leiomyoma | Pleomorphic Leiomyoma | Pleomorphic leiomyoma","8893/0","Bizarre leiomyoma",,,,,,,,,,,,,"4169101","Bizarre leiomyoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1266046","Thyroid Gland Well-Differentiated Tumor of Uncertain Malignant Potential","C27729","An encapsulated or well-circumscribed thyroid gland tumor composed of well-differentiated follicular cells with well-developed or partially developed nuclear features of papillary thyroid carcinoma and with questionable capsular or vascular invasion. This is a tumor indeterminate between follicular adenoma and follicular carcinoma. Tumors in which vascular invasion has been excluded by all means are called non-invasive follicular thyroid neoplasms with papillary-like nuclear features. (WHO)","Thyroid Gland Well-Differentiated Tumor of Uncertain Malignant Potential | Atypical Follicular Adenoma | Atypical follicular adenoma | Thyroid Gland Atypical Follicular Adenoma | Thyroid Gland Well-Differentiated Neoplasm of Uncertain Malignant Potential | WDT-UMP","8330/1|8348/1","Atypical follicular adenoma|Well differentiated tumor of uncertain malignant potential",,,,,,,,,,,,,"4029682","Atypical follicular adenoma",,,,,,,,,,,,,"--","--|--",,,,,,,,"--"
"C1292772","Myeloid Leukemia, Philadelphia-Negative","C3176","Myeloid leukemia characterized by the absence of Philadelphia chromosome.","Myeloid Leukemia, Philadelphia-Negative | Myeloid Leukemia, Philadelphia- Negative | Philadelphia-Negative Myelogenous Leukemia | Philadelphia-Negative Myelogenous Leukemia | Philadelphia-Negative Myeloid Leukemia",,,,,,,,,,,,,,,"4030262","Myelodysplastic and myeloproliferative neoplasm with neutrophilia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1305409","Atypical Adenoma","C7559","An adenoma characterized by increased cellularity and nuclear atypia without evidence of vascular or capsular invasion. A representative example is thyroid gland atypical follicular adenoma.","Atypical Adenoma | Atypical adenoma","8140/1","Atypical adenoma",,,,,,,,,,,,,"4087702","Atypical adenoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"CL1647888","Maximal Oxygen Uptake","C178242","The point at which oxygen uptake no longer increases and beyond which no level of effort can raise it.","Maximal Oxygen Uptake | Maximal Oxygen Consumption | V'O2 Max | VO2 Max | VO2MAX | VO2max",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662327","Physical Activity Lifestyle","C179818","A description of the subject's lifestyle with respect to physical activity.","Physical Activity Lifestyle | PHYACLFS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662451","Vitamin D2 and Vitamin D3 Measurement","C179751","The determination of the amount of vitamin D2 and vitamin D3 present in a sample.","Vitamin D2 and Vitamin D3 Measurement | Calciferol + Cholecalciferol | VITD23 | Vitamin D2 + Vitamin D3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663118","Specimen Appearance Assessment","C179695","An evalation of the outward or visible aspect of a biospecimen.","Specimen Appearance Assessment | APPEAR | Specimen Appearance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663316","Leukotriene D4","C180700","A leukotriene synthesized from leukotriene C4 secreted by basophils via removal of a glutamic acid group by cell surface proteases. Leukotriene D4 (LTD4) induces the contraction of smooth muscle cells, which results in bronchoconstriction and vasoconstriction, and increases vascular permeability. LTD4  can be further cleaved by cell surface proteases that remove a glycine group to form leukotriene E4.","Leukotriene D4 | (5S,6R,7E,9E,11Z,14Z)-6-({(2R)-2-Amino-3-[(Carboxymethyl)Amino]-3-Oxopropyl}Sulfanyl)-5-Hydroxyicosa-7,9,11,14-Tetraenoic Acid | (R-(R*,S*-(E,E,Z,Z)))-N-(S-(1-(4-Carboxy-1-Hydroxybutyl)-2,4,6,9-Pentadecatetraenyl)-L-Cysteinyl)Glycine | 5S-Hydroxy-6R-(S-Cysteinylglycinyl)-7E,9E,11E,14Z-Eicosatetraenoic Acid | Glycine, N-(S-(1-(4-Carboxy-1-Hydroxybutyl)-2,4,6,9-Pentadecatetraenyl)-L-Cysteinyl)-, (R-(R*,S*-(E,E,Z,Z)))- | LEUKOTRIENE D4 | LTD4 | S-{(1R,2E,4E,6Z,9Z)-1-[(1S)-4-Carboxy-1-Hydroxybutyl]Pentadeca-2,4,6,9-Tetraen-1-Yl}-L-Cysteinylglycine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663387","UGT1A1 Gene Mutation Negative","C180743","A genetic finding indicating that UGT1A1 gene mutations have not been detected and biallelic expression of the wild-type allele (UGT1A1 1*) has been detected in a sample.","UGT1A1 Gene Mutation Negative | Biallelic Expression of UGT1A1*1 Allele | GNT1 Gene Mutation Negative | Homozygous UGT1A1*1 | Homozygous UGT1A1*1 Genotype Positive | Homozygous UGT1A1*1 Positive | UDP Glucuronosyltransferase Family 1 Member A1 Gene Mutation Negative | UDPGT 1-1 Gene Mutation Negative | UDPGT Gene Mutation Negative | UGT1 Gene Mutation Negative | UGT1A Gene Mutation Negative | UGT1A1 1*/1* | UGT1A1 Polymorphism Negative | UGT1A1 Wild Type | UGT1A1 Wild-Type | UGT1A1 Wildtype | UGT1A1 wt | UGT1A1*1/*1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3267002","UGT1A1 Gene Mutation","C180744","A change in the nucleotide sequence of the UGT1A1 gene.","UGT1A1 Gene Mutation | GNT1 Gene Mutation | UDP Glucuronosyltransferase Family 1 Member A1 Gene Mutation | UDPGT 1-1 Gene Mutation | UDPGT Gene Mutation | UGT1 Gene Mutation | UGT1A Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663388","GSTM1 Gene Mutation","C180745","A change in the nucleotide sequence of the GSTM1 gene.","GSTM1 Gene Mutation | GST1 Gene Mutation | GSTM1-1 Gene Mutation | GTH4 Gene Mutation | GTM1 Gene Mutation | Glutathione S-Transferase M1 Gene Mutation | Glutathione S-Transferase Mu 1 Gene Mutation | H-B Gene Mutation | MU Gene Mutation | MU-1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663389","GSTP1 Gene Mutation","C180746","A change in the nucleotide sequence of the GSTP1 gene.","GSTP1 Gene Mutation | FAEES3 Gene Mutation | GST3 Gene Mutation | GSTP Gene Mutation | Glutathione S-Transferase Pi 1 Gene Mutation | Glutathione S-Transferase Pi Gene Mutation | PI Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3805092","MTHFR Gene Mutation","C180747","A change in the nucleotide sequence of the MTHFR gene.","MTHFR Gene Mutation | Methylenetetrahydrofolate Reductase Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663379","RSPO3 Gene Fusion Positive","C180748","An indication that the expression of a fusion containing sequences from the RSPO3 gene has been detected in a sample.","RSPO3 Gene Fusion Positive | CRISTIN1 Gene Fusion Positive | PWTSR Gene Fusion Positive | R-Spondin 3 Gene Fusion Positive | RSPO3 Fusion Gene Positive | RSPO3 Gene Fusion | THSD2 Gene Fusion Positive | Thrombospondin, Type I, Domain Containing 2 Gene Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663380","RSPO2 Gene Fusion Positive","C180749","An indication that the expression of a fusion containing sequences from the RSPO2 gene has been detected in a sample.","RSPO2 Gene Fusion Positive | CRISTIN2 Gene Fusion Positive | HHRRD Gene Fusion Positive | R-Spondin 2 Gene Fusion Positive | RSPO2 Fusion Gene Positive | RSPO2 Gene Fusion | TETAMS2 Gene Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663381","AKT Family Gene Alteration Positive","C180750","An indication that mutation, overexpression or rearrangement of an AKT family member gene has been detected in a sample.","AKT Family Gene Alteration Positive | AKT Family Alteration Positive | AKT Gene Alteration | AKT Gene Alteration Positive | AKT Serine/Threonine Kinase Family Gene Alteration Positive | v-akt Murine Thymoma Viral Oncogene Homolog Gene Family Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663383","RFC5 Gene Mutation","C180754","A change in the nucleotide sequence of the RFC5 gene.","RFC5 Gene Mutation | RFC36 Gene Mutation | Replication Factor C Subunit 5 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663384","EXO1 Gene Mutation","C180755","A change in the nucleotide sequence of the EXO1 gene.","EXO1 Gene Mutation | EXOI Gene Mutation | Exonuclease 1 Gene Mutation | HEX1 Gene Mutation | hExoI Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663376","Inactivating SSBP1 Gene Mutation","C180760","A change in the nucleotide sequence of the SSBP1 gene that either inhibits expression or results in the translation of an inactive single-stranded DNA-binding protein, mitochondrial protein.","Inactivating SSBP1 Gene Mutation | Inactivating Mt-SSB Gene Mutation | Inactivating SOSS-B1 Gene Mutation | Inactivating SSBP Gene Mutation | Inactivating SSBP1 Mutation | Inactivating Single Stranded DNA Binding Protein 1 Gene Mutation | Inactivating mtSSB Gene Mutation | SSBP1 Gene Inactivation | SSBP1 Inactivating Gene Mutation | SSBP1 Inactivating Mutation | SSBP1 Loss of Function Gene Mutation | SSBP1 Loss of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663377","RFC4 Gene Mutation","C180761","A change in the nucleotide sequence of the RFC4 gene.","RFC4 Gene Mutation | RFC37 Gene Mutation | Replication Factor C Subunit 4 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663368","RFC3 Gene Mutation","C180765","A change in the nucleotide sequence of the RFC3 gene.","RFC3 Gene Mutation | RFC38 Gene Mutation | Replication Factor C Subunit 3 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663369","VHL Gene Amplification","C180766","A molecular genetic abnormality indicating the presence of multiple copies of the VHL gene.","VHL Gene Amplification | HRCA1 Gene Amplification | RCA1 Gene Amplification | VHL Amplification | VHL1 Gene Amplification | Von Hippel-Lindau Syndrome Gene Amplification | Von Hippel-Lindau Tumor Gene Amplification | Von Hippel-Lindau Tumor Suppressor Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663370","PCNA Gene Mutation","C180767","A change in the nucleotide sequence of the PCNA gene.","PCNA Gene Mutation | Proliferating Cell Nuclear Antigen Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663371","RPA3 Gene Mutation","C180768","A change in the nucleotide sequence of the RPA3 gene.","RPA3 Gene Mutation | REPA3 Gene Mutation | RP-A p14 Gene Mutation | RPA14 Gene Mutation | Replication Protein A3 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663364","RFC1 Gene Mutation","C180773","A change in the nucleotide sequence of the RFC1 gene.","RFC1 Gene Mutation | MHCBFB Gene Mutation | PO-GA Gene Mutation | RECC1 Gene Mutation | RFC Gene Mutation | RFC140 Gene Mutation | Replication Factor C Subunit 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663366","RFC2 Gene Mutation","C180777","A change in the nucleotide sequence of the RFC2 gene.","RFC2 Gene Mutation | RFC40 Gene Mutation | Replication Factor C Subunit 2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663367","CSF1R Gene Amplification","C180779","A molecular genetic abnormality indicating the presence of multiple copies of the CSF1R gene.","CSF1R Gene Amplification | C-FMS Gene Amplification | CD115 Gene Amplification | CSF-1R Gene Amplification | CSF1R Amplification | CSFR Gene Amplification | Colony Stimulating Factor 1 Receptor Gene Amplification | FMS Gene Amplification | M-CSF-R Gene Amplification | Macrophage Colony-Stimulating Factor 1 Receptor Gene Amplification | McDonough Feline Sarcoma Viral (V-Fms) Oncogene Homolog Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663357","Deleterious ALK Gene Mutation","C180781","A mutation in the ALK gene that is associated with an increased risk of disease.","Deleterious ALK Gene Mutation | ALK Driver Mutation | Deleterious ALK Mutation | Deleterious ALK Receptor Tyrosine Kinase Gene Mutation | Deleterious Anaplastic Lymphoma Kinase Receptor Gene Mutation | Deleterious Anaplastic Lymphoma Receptor Tyrosine Kinase Gene Mutation | Deleterious CD246 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663358","Ki-67 Positive Cells 15 Percent or Less","C180782","A semi-quantitative microscopic finding indicating that 15 percent or less of the cells in a sample are detected following staining using an anti-Ki-67 antibody.","Ki-67 Positive Cells 15 Percent or Less | Antigen Ki-67 Positive Cells 15 Percent or Less | KI67 Positive Cells 15 Percent or Less | Ki-67 Antigen Positive Cells 15 Percent or Less | Ki-67 Positive Cells Less than or Equal to 15 Percent | MKI67 Positive Cells 15 Percent or Less",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663359","ERBB2 Gene Alteration Positive","C180783","A finding indicating that mutation, overexpression or rearrangement of the ERBB2 gene has been detected in a sample.","ERBB2 Gene Alteration Positive | ERBB2 Alteration Positive | Erb-B2 Receptor Tyrosine Kinase 2 Gene Alteration Positive | Erb-B2 Receptor Tyrosine Kinase Gene Alteration Positive | HER-2 Gene Alteration Positive | HER2 Alteration Positive | HER2 Gene Alteration Positive | HER2/neu Gene Alteration Positive | NEU Gene Alteration Positive | v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 Gene Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663360","RRAS Gene Mutation","C180784","A change in the nucleotide sequence of the RRAS gene.","RRAS Gene Mutation | Oncogene RRAS Gene Mutation | R-Ras Gene Mutation | RAS Related Gene Mutation | Related RAS Viral Oncogene Homolog Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663361","MRAS Gene Mutation","C180785","A change in the nucleotide sequence of the MRAS gene.","MRAS Gene Mutation | M-RAS Gene Mutation | Muscle RAS Oncogene Homolog Gene Mutation | Muscle RAS Viral Oncogene Homolog Gene Mutation | R-RAS3 Gene Mutation | RRAS3 Gene Mutation | Related RAS Viral Oncogene Homolog 3 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663362","MAP3K8 Gene Mutation","C180786","A change in the nucleotide sequence of the MAP3K8 gene.","MAP3K8 Gene Mutation | COT Gene Mutation | Cancer Osaka Thyroid Gene Mutation | EST Gene Mutation | ESTF Gene Mutation | MEKK8 Gene Mutation | Mitogen-Activated Protein Kinase Kinase Kinase 8 Gene Mutation | TPL-2 Gene Mutation | TPL2 Gene Mutation | c-COT Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663363","PPP1CB Gene Mutation","C180787","A change in the nucleotide sequence of the PPP1CB gene.","PPP1CB Gene Mutation | MP Gene Mutation | PP-1B Gene Mutation | PP1B Gene Mutation | PP1beta Gene Mutation | PP1c Gene Mutation | PPP1CD Gene Mutation | PPP1beta Gene Mutation | Protein Phosphatase 1 Catalytic Subunit Beta Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663348","SOS1 Gene Mutation","C180788","A change in the nucleotide sequence of the SOS1 gene.","SOS1 Gene Mutation | SOS Ras/Rho Guanine Nucleotide Exchange Factor 1 Gene Mutation | SOS-1 Gene Mutation | SOS1 mutation | Son of Sevenless Homolog 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663349","RIT1 Gene Mutation","C180789","A change in the nucleotide sequence of the RIT1 gene.","RIT1 Gene Mutation | RIBB Gene Mutation | RIT Gene Mutation | ROC1 Gene Mutation | Ras Like Without CAAX 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663350","SPRED1 Gene Mutation","C180790","A change in the nucleotide sequence of the SPRED1 gene.","SPRED1 Gene Mutation | Spread-1 Gene Mutation | Sprouty Related EVH1 Domain Containing 1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663351","SHOC2 Gene Mutation","C180791","A change in the nucleotide sequence of the SHOC2 gene.","SHOC2 Gene Mutation | SHOC2 Leucine Rich Repeat Scaffold Protein Gene Mutation | SOC2 Gene Mutation | SUR8 Gene Mutation | Soc-2 Suppressor of Clear Homolog Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663352","RASA1 Gene Mutation","C180792","A change in the nucleotide sequence of the RASA1 gene.","RASA1 Gene Mutation | GAP Gene Mutation | RAS p21 Protein Activator 1 Gene Mutation | RASA Gene Mutation | RASGAP Gene Mutation | p120GAP Gene Mutation | p120RASGAP Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663353","RASA2 Gene Mutation","C180793","A change in the nucleotide sequence of the RASA2 gene.","RASA2 Gene Mutation | GAP1M Gene Mutation | RAS p21 Protein Activator 2 Gene Mutation | RASGAP Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663354","LZTR1 Gene Mutation","C180794","A change in the nucleotide sequence of the LZTR1 gene.","LZTR1 Gene Mutation | BTBD29 Gene Mutation | LZTR-1 Gene Mutation | Leucine Zipper Like Transcription Regulator 1 Gene Mutation | Leucine-Zipper-Like Transcription Regulator 1 Gene Mutation | TCFL2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663355","Activating AKT3 Gene Mutation","C180795","A change in the nucleotide sequence of the AKT3 gene that that results in constitutive activation of RAC-gamma serine/threonine-protein kinase and its downstream signaling pathways.","Activating AKT3 Gene Mutation | AKT3 Activating Mutation | AKT3 Gain of Function Gene Mutation | AKT3 Gain of Function Mutation | AKT3 Gene Activating Mutation | Activating AKT Serine/Threonine Kinase 3 Gene Mutation | Activating PKB-GAMMA Gene Mutation | Activating PKBG Gene Mutation | Activating PRKBG Gene Mutation | Activating RAC-Gamma Gene Mutation | Activating RAC-PK-Gamma Gene Mutation | Activating STK-2 Gene Mutation | Gain of Function AKT3 Gene Mutation | Gain of Function AKT3 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663342","Activating AKT2 Gene Mutation","C180796","A change in the nucleotide sequence of the AKT2 gene that that results in constitutive activation of RAC-beta serine/threonine-protein kinase and its downstream signaling pathways.","Activating AKT2 Gene Mutation | AKT2 Activating Mutation | AKT2 Gain of Function Gene Mutation | AKT2 Gain of Function Mutation | AKT2 Gene Activating Mutation | Activating AKT Serine/Threonine Kinase 2 Gene Mutation | Activating PKBB Gene Mutation | Activating PKBBETA Gene Mutation | Activating PRKBB Gene Mutation | Activating RAC-BETA Gene Mutation | Activating RAC-PK-Beta Gene Mutation | Activating v-akt Murine Thymoma Viral Oncogene Homolog 2 Gene Mutation | Gain of Function AKT2 Gene Mutation | Gain of Function AKT2 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663343","Deleterious RET Gene Mutation","C180797","A change in the nucleotide sequence of the RET gene that is associated with increased risk of disease.","Deleterious RET Gene Mutation | Deleterious RET Mutation | Deleterious RET/PTC Gene Mutation | Deleterious Ret Proto-Oncogene Gene Mutation | Deleterious Ret Proto-Oncogene Mutation | RET Driver Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663344","Deleterious ROS1 Gene Mutation","C180798","A change in the nucleotide sequence of the ROS1 gene that is associated with increased risk of disease.","Deleterious ROS1 Gene Mutation | Deleterious MCF3 Gene Mutation | Deleterious ROS Gene Mutation | Deleterious ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene Mutation | Deleterious ROS1 Mutation | Deleterious c-ros-1 Gene Mutation | ROS1 Driver Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663345","SLFN12 Positive","C180799","An indication that SLFN12 expression has been detected in a sample.","SLFN12 Positive | SLFN3 Positive | Schlafen Family Member 12 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663347","PDE3A Positive","C180803","An indication that PDE3A expression has been detected in a sample.","PDE3A Positive | CGI-PDE A Positive | CGI-PDE Positive | CGI-PDE-A Positive | Cyclic GMP-Inhibited Phosphodiesterase A Positive | Phosphodiesterase 3A Positive | cGMP-Inhibited 3',5'-Cyclic Phosphodiesterase A Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663479","FGFR3/TACC3v3 Fusion Gene","C180812","A fusion gene that results from a complex rearrangement involving deletion, duplication and insertion of sequences at 4p16 that fuses all of exon 17 of the FGFR3 gene with exon 10 of the TACC3 gene.","FGFR3/TACC3v3 Fusion Gene | FGFR3-TACC3v3 | FGFR3-TACC3v3 Fusion Gene | FGFR3::TACC3v3 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663480","FGFR3/TACC3v1 Fusion Gene","C180813","A fusion gene that results from a complex rearrangement involving deletion, duplication and insertion of sequences at 4p16 that fuses all of exon 17 of the FGFR3 gene with exon 11 of the TACC3 gene.","FGFR3/TACC3v1 Fusion Gene | FGFR3-TACC3v1 | FGFR3-TACC3v1 Fusion Gene | FGFR3::TACC3v1 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663481","FGFR3/BAIAP2L1 Fusion Gene","C180814","A fusion gene that results from a chromosomal translocation t(4;7)(p16;q22) that fuses exon 18 of the FGFR3 gene with exon 2 of the BAIAP2L1 gene. This translocation is associated with bladder cancer.","FGFR3/BAIAP2L1 Fusion Gene | FGFR3-BAIAP2L1 | FGFR3-BAIAP2L1 Fusion Gene | FGFR3::BAIAP2L1 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663482","FGFR2/BICC1 Fusion Gene","C180815","A fusion gene that results from a chromosomal translocation t(10;10)(q21;q26) that fuses exon 19 of the FGFR2 gene with exon 10 of the BICC1 gene. This translocation is associated with cholangiocarcinoma.","FGFR2/BICC1 Fusion Gene | FGFR2-BICC1 | FGFR2-BICC1 Fusion Gene | FGFR2::BICC1 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663483","FGFR2/CASP7 Fusion Gene","C180816","A fusion gene that results from a chromosomal translocation t(10;10)(q25;q26) that fuses most of the FGFR2 gene with most of the CASP7 gene. This translocation is associated with breast cancer.","FGFR2/CASP7 Fusion Gene | FGFR2-CASP7 | FGFR2-CASP7 Fusion Gene | FGFR2::CASP7 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662452","1,25-Dihydroxyvitamin D3 Measurement","C179754","The determination of the amount of 1,25-dihydroxyvitamin D3 present in a sample.","1,25-Dihydroxyvitamin D3 Measurement | 1,25-Dihydroxycholecalciferol | 1,25-Dihydroxyvitamin D | 1,25-Dihydroxyvitamin D3 | Calcitriol | VTD3125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662453","1,25-Dihydroxyvitamin D2 and 1,25-Dihydroxyvitamin D3 Measurement","C179753","The determination of the amount of 1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 present in a sample.","1,25-Dihydroxyvitamin D2 and 1,25-Dihydroxyvitamin D3 Measurement | 1,25-Di(OH)vitamin D2 + 1,25-Di(OH)vitamin D3 | 1,25-DihydroxyvitD2+1,25-DihydroxyvitD3 | 1,25-Dihydroxyvitamin D2 + 1,25-Dihydroxyvitamin D3 | VTD23125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662450","1,25-Dihydroxyvitamin D2 Measurement","C179752","The determination of the amount of 1,25-dihydroxyvitamin D2 present in a sample.","1,25-Dihydroxyvitamin D2 Measurement | 1,25-Dihydroxycalciferol | 1,25-Dihydroxyergocalciferol | 1,25-Dihydroxyvitamin D2 | Ercalcitriol | VTD2125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662441","Roth-28 Hue Test","C179765","A standardized method of color vision testing that is a shortened version of the Farnsworth-Munsell 100-Hue test (FM100), using every third of the FM100's 85 color caps that are arranged in rows of four color families. The subject must put the hues in order based on the anchor colors at the ends of each row.","Roth-28 Hue Test | ROTH 28 HUE TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085117","Pulsed-Field Gel Electrophoresis","C17426","Pulsed-field gel electrophoresis (PFGE) is a method used to separate proteins or high molecular weight linear DNA fragments that are greater than 50 kilobases (kb) in size. Fragments are separated by pulsing an electrical field across an agarose gel rather than applying the constant field used in conventional electrophoresis.","Pulsed-Field Gel Electrophoresis | Electrophoresis, Gel, Pulsed-Field | Fractionation, Pulse Field | PFGE | PULSED-FIELD GEL ELECTROPHORESIS",,,,,,,,,,,,,,,"4101781","Pulsed-field gel electrophoresis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1662456","Tape Adhesion Specimen Collection Method","C179750","A technique for specimen collection that utilizes an adhesive-based ribbon.","Tape Adhesion Specimen Collection Method | Adhesive Tape Method | TAPE ADHESION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600109","Receptivity","C180852","A willingness or readiness to consider or accept suggestions and ideas.","Receptivity | Receptive | Willing | Willingness",,,,,,,,,,,,,,,"4023035","Willing",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545227","Exposure as Collected Supplemental Qualifiers Dataset","C147208","A dataset containing supplemental information, specifically non-standard variables, to parent records in the exposure as collected domain.","Exposure as Collected Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663500","Cryoprecipitated Plasma","C180873","A frozen blood product prepared from frozen plasma that contains fibrinogen (factor I), antihemophilic factor (factor VIII), factor XIII, von Willebrand factor (vWF) and fibronectin.","Cryoprecipitated Plasma | CRYOPRECIPITATE | Cryo | Cryoprecipitate | Cryoprecipitated Plasma with Antihemophilic Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023546","Leukotriene B4","C609","A leukotriene synthesized from leukotriene A4 by leukotriene A-4 hydrolase in monocytes, lymphocytes, neutrophils, reticulocytes, platelets and fibroblasts. Leukotriene B4 modulates inflammation by promoting neutrophil activation and inducing adhesion, activation, and transendothelial migration of leukocytes.","Leukotriene B4 | 5S,12R-dihydroxy-6Z,8E,10E,14Z-eicosatetraenoic Acid | LEUKOTRIENE B4 | LTB4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007674","Central America","C90602","The isthmus joining North America and South America, extending from the southern border of Mexico to the northern border of Colombia.","Central America | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969443","Mutation Analysis Was Performed","C160315","An indication that mutation analysis was performed during the study.","Mutation Analysis Was Performed | Mutation Analysis Performed | Mutational Analysis Performed | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950663","Did the Individual have Multiple Known Primary Tumors at Initial Melanoma Diagnosis","C158630","A question about whether the individual has multiple known primary tumors at the initial melanoma diagnosis.","Did the Individual have Multiple Known Primary Tumors at Initial Melanoma Diagnosis | Did the patient have multiple known primaries at the time of initial melanoma diagnosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950620","Number of Known Primaries at the Time of Initial Melanoma Diagnosis","C158640","A request to indicate the number of known primaries at the time of the melanoma diagnosis.","Number of Known Primaries at the Time of Initial Melanoma Diagnosis | Number of known primaries at the time of initial melanoma diagnosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663718","Appointment","C180916","A meeting arranged with someone at a particular time and place.","Appointment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002422","Ambulance","C180918","A vehicle specially equipped for transporting the injured or sick.","Ambulance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950844","Did the patient have subsequent known primary melanoma(s) during the follow-up period","C158831","A question about whether subsequent known primary melanoma(s) were found during the follow-up period.","Were Subsequent Known Primary Melanoma(s) Found During the Follow-Up | Did the patient have subsequent known primary melanoma(s) during the follow-up period",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663548","Spiked-in Standard","C180957","A control sample that contains one or more materials with standardized molecular sizes or weights and/or known concentrations or reaction intensities and can be either added to or run at the same time as one or more experimental samples. The characteristics of the spiked-in standard can be measured and plotted on a graph. The observed characteristics for the experimental sample(s) can be quantified if they are within the boundaries of the curve generated for the standard.","Spiked-in Standard | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663541","Prenol Lipid","C180966","A group of lipids synthesized from five-carbon isoprene units in a wide variety of combinations and configurations. It includes fat-soluble vitamins such as vitamins E and K as well as the ubiquinones.","Prenol Lipid | Prenol Lipids",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663543","Polyketide","C180968","A structurally diverse group of compounds created by repeated condensations and modifications catalyzed by polyketide synthases (PKSs). Polyketides may be derived from malonyl- and methylmalonyl-coenzyme A (CoA) extender units and simple acyl-CoA starter units, such as acetyl-, propionyl-, and isobutyryl-CoA. It includes numerous antimicrobial, antiparasitic, and anticancer agents such as erythromycins, tetracylines, nystatins, avermectins and antitumor epothilones, as well as some potent toxins.","Polyketide | Polyketides",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663528","Fatty Acyl","C180969","A major lipid building block of complex lipids comprised of carbon atoms arranged in chains of various length, unsaturation, branching and other features. It includes the saturated fatty acids palmitic acid and stearic acid, the monounsaturated fatty acid oleic acid, the polyunsaturated fatty acids linoleic acid and arachidonic acid, the eicosanoids prostaglandins and leukotrienes, and other compounds such as fatty acyl-CoA's and fatty amides.","Fatty Acyl | Fatty Acyls",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663639","Homologous Recombination Repair Gene Alteration Positive","C180928","An indication that mutation, overexpression, or rearrangement of a gene involved in homologous recombination repair of DNA has been detected in a sample.","Homologous Recombination Repair Gene Alteration Positive | HHR Gene Alteration | HRR Gene Alteration Positive | Homologous Recombination Pathway Gene Alteration Positive | Recombination Repair Gene Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663626","KMT2A Gene Alteration Positive","C180929","An indication that mutation, overexpression, or rearrangement of the KMT2A gene has been detected in a sample.","KMT2A Gene Alteration Positive | KMT2A Gene Alteration | Lysine (K)-Specific Methyltransferase 2A Gene Alteration Positive | Lysine Methyltransferase 2A Gene Alteration Positive | MLL Gene Alteration | MLL Gene Alteration Positive | Mixed Lineage Leukemia Gene Alteration Positive | Myeloid/Lymphoid Leukemia Gene Alteration Positive | Myeloid/Lymphoid or Mixed Lineage Leukemia Gene Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663627","NPM1 Gene Alteration Positive","C180930","An indication that mutation (including nucleotide insertions or deletions), overexpression, or rearrangement of the NPM1 gene has been detected in a sample.","NPM1 Gene Alteration Positive | Nucleophosmin 1 Gene Alteration | Nucleophosmin 1 Gene Alteration Positive | Nucleophosmin Gene Alteration Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3850088","Neutrophil Extracellular Trap","C180931","A network of extracellular fibrillar structures containing granule proteins, chromatin fibers and DNA that are released by neutrophils as part of the host defense response. Extracellular release of antimicrobial proteins such as neutrophil elastase, cathepsin G and histones can bind, disarm, and kill microbes independent of phagocytosis and the fibrillar nature of these structures may target these effects locally by preventing diffusion of these proteins outside the target site.","Neutrophil Extracellular Trap | NET",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663629","H3 G35X Variant","C180933","A change in the amino acid residue at position 35 in histone H3 where glycine has been replaced by another amino acid.","H3 G35X Variant | H3 G34 Mutation | H3 G34X | H3 G34X Mutation | H3 G35X | H3 G35X Mutation | H3 Gly34Xxx | H3 Gly35Xxx | H3 p.G35X | H3 p.Gly35Xxx | H3G34-Mutant | H3G34X | Histone 3 G34X Mutation | Histone 3 G35X Mutation | Histone H3 G34 Mutation | Histone H3 G34X | Histone H3 G35 Mutation | Histone H3 G35X | Histone H3 Gly34Xxx | Histone H3 Gly35Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663631","MYB Gene Fusion Positive","C180935","An indication that a MYB fusion gene has been detected in a sample.","MYB Gene Fusion Positive | Avian Myeloblastosis Viral Oncogene Homolog Fusion Gene Positive | Cmyb Fusion Gene Positive | MYB Fusion Gene Positive | MYB Gene Fusion | MYB Proto-Oncogene, Transcription Factor Fusion Gene Positive | V-Myb Avian Myeloblastosis Viral Oncogene Homolog Fusion Gene Positive | c-MYB Fusion Gene Positive | efg Fusion Gene Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663632","MYBL1 Gene Fusion Positive","C180936","An indication that a MYBL1 fusion gene has been detected in a sample.","MYBL1 Gene Fusion Positive | A-MYB Fusion Gene Positive | AMYB Fusion Gene Positive | MYBL1 Fusion Gene Positive | MYBL1 Gene Fusion | V-Myb Avian Myeloblastosis Viral Oncogene Homolog-Like 1 Fusion Gene Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663618","MYB Gene Rearrangement","C180937","A molecular abnormality indicating rearrangement of the MYB gene.","MYB Gene Rearrangement | Avian Myeloblastosis Viral Oncogene Homolog Rearrangement | Cmyb Rearrangement | MYB Proto-Oncogene, Transcription Factor Rearrangement | MYB Rearrangement | V-Myb Avian Myeloblastosis Viral Oncogene Homolog Gene Rearrangement | c-MYB Rearrangement | efg Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663619","MYBL1 Gene Rearrangement","C180938","A molecular abnormality indicating rearrangement of the MYBL1 gene.","MYBL1 Gene Rearrangement | A-MYB Rearrangement | AMYB Rearrangement | MYB Proto-Oncogene Like 1 Rearrangement | MYBL1 Rearrangement | V-Myb Avian Myeloblastosis Viral Oncogene Homolog-Like 1 Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663620","Non-Synonymous KRAS Gene Mutation","C180939","A point mutation in the KRAS gene that encodes an amino acid substitution in the GTPase KRas protein.","Non-Synonymous KRAS Gene Mutation | KRAS Gene Missense Mutation | KRAS Missense Mutation | Non-Synonymous KRAS Mutation | Non-Synonymous KRAS-2 Gene Mutation | Non-Synonymous KRAS2 Gene Mutation | Non-Synonymous c-K-ras Gene Mutation | Non-Synonymous v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663621","Biallelic RB1 Gene Mutation","C180940","The presence of mutations in both alleles of the RB1 gene.","Biallelic RB1 Gene Mutation | Biallelic RB Gene Mutation | Biallelic RB1 Mutation | Biallelic Retinoblastoma 1 Gene Mutation | Biallelic Retinoblastoma Gene Mutation | RB Biallelic Mutation | RB1 Biallelic Gene Mutation | RB1 Biallelic Mutation | RB1 Gene Biallelic Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663622","Monoallelic RB1 Gene Mutation","C180941","The presence of mutations in only one allele of the RB1 gene.","Monoallelic RB1 Gene Mutation | Monoallelic RB Gene Mutation | Monoallelic RB1 Mutation | Monoallelic Retinoblastoma 1 Gene Mutation | Monoallelic Retinoblastoma Gene Mutation | RB Monoallelic Mutation | RB1 Gene Monoallelic Mutation | RB1 Monoallelic Gene Mutation | RB1 Monoallelic Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663623","Chromosome 9 Abnormality","C180942","A cytogenetic abnormality that refers to any structural irregularity in chromosome 9.","Chromosome 9 Abnormality | Aberrant Chromosome 9 | Chromosome 9 Aberration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663625","BRAF Gene Alteration Negative","C180944","An indication that mutation, overexpression, fusion or rearrangement involving the BRAF gene has not been detected in a sample.","BRAF Gene Alteration Negative | B-RAF Gene Alteration Negative | B-RAF1 Gene Alteration Negative | BRAF Alteration Negative | v-raf Murine Sarcoma Viral Oncogene Homolog B1 Gene Alteration Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663556","NTRK Family Gene Alteration Negative","C180949","An indication that mutation, overexpression, fusion or rearrangement of an NTRK family member gene has not been detected in a sample.","NTRK Family Gene Alteration Negative | NTRK Alteration Negative | NTRK Family Alteration Negative | NTRK Gene Alteration Negative | TRK Family Gene Alteration Negative | TRK Gene Alteration Negative | TRK Receptor Family Gene Alteration Negative | TRK Receptor Gene Alteration Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663557","ROS1 Gene Alteration Negative","C180950","An indication that mutation, overexpression, fusion or rearrangement involving the ROS1 gene has not been detected in a sample.","ROS1 Gene Alteration Negative | MCF3 Gene Alteration Negative | ROS Alteration Negative | ROS Gene Alteration Negative | ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene Alteration Negative | ROS1 Alteration Negative | c-ros-1 Gene Alteration Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663558","Activating EGFR Exon 18 Mutation","C180951","A molecular genetic abnormality indicating the presence of a mutation in exon 18 of the EGFR gene that results in constitutive epidermal growth factor receptor-dependent signal transduction and activation of downstream signaling pathways.","Activating EGFR Exon 18 Mutation | Activating EGFR Exon 18 Gene Mutation | Activating ERBB Exon 18 Mutation | Activating ERBB1 Exon 18 Mutation | Activating Epidermal Growth Factor Receptor Exon 18 Mutation | Activating HER1 Exon 18 Mutation | EGFR Exon 18 Activating Gene Mutation | EGFR Exon 18 Activating Mutation | EGFR Exon 18 Gain of Function Gene Mutation | EGFR Exon 18 Gain of Function Mutation | Gain of Function EGFR Exon 18 Gene Mutation | Gain of Function EGFR Exon 18 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663559","Activating EGFR Exon 19 Mutation","C180952","A molecular genetic abnormality indicating the presence of a mutation in exon 19 of the EGFR gene that results in constitutive epidermal growth factor receptor-dependent signal transduction and activation of downstream signaling pathways.","Activating EGFR Exon 19 Mutation | Activating EGFR Exon 19 Gene Mutation | Activating ERBB Exon 19 Mutation | Activating ERBB1 Exon 19 Mutation | Activating Epidermal Growth Factor Receptor Exon 19 Mutation | Activating HER1 Exon 19 Mutation | EGFR Exon 19 Activating Gene Mutation | EGFR Exon 19 Activating Mutation | EGFR Exon 19 Gain of Function Gene Mutation | EGFR Exon 19 Gain of Function Mutation | Gain of Function EGFR Exon 19 Gene Mutation | Gain of Function EGFR Exon 19 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663544","Activating EGFR Exon 20 Mutation","C180953","A molecular genetic abnormality indicating the presence of a mutation in exon 20 of the EGFR gene that results in constitutive epidermal growth factor receptor-dependent signal transduction and activation of downstream signaling pathways.","Activating EGFR Exon 20 Mutation | Activating EGFR Exon 20 Gene Mutation | Activating ERBB Exon 20 Mutation | Activating ERBB1 Exon 20 Mutation | Activating Epidermal Growth Factor Receptor Exon 20 Mutation | Activating HER1 Exon 20 Mutation | EGFR Exon 20 Activating Gene Mutation | EGFR Exon 20 Activating Mutation | EGFR Exon 20 Gain of Function Gene Mutation | EGFR Exon 20 Gain of Function Mutation | Gain of Function EGFR Exon 20 Gene Mutation | Gain of Function EGFR Exon 20 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663538","Activating EGFR Exon 21 Mutation","C180963","A molecular genetic abnormality indicating the presence of a mutation in exon 21 of the EGFR gene that results in constitutive epidermal growth factor receptor-dependent signal transduction and activation of downstream signaling pathways.","Activating EGFR Exon 21 Mutation | Activating EGFR Exon 21 Gene Mutation | Activating ERBB Exon 21 Mutation | Activating ERBB1 Exon 21 Mutation | Activating Epidermal Growth Factor Receptor Exon 21 Mutation | Activating HER1 Exon 21 Mutation | EGFR Exon 21 Activating Gene Mutation | EGFR Exon 21 Activating Mutation | EGFR Exon 21 Gain of Function Gene Mutation | EGFR Exon 21 Gain of Function Mutation | Gain of Function EGFR Exon 21 Gene Mutation | Gain of Function EGFR Exon 21 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663542","EGFR NP_005219.2:p.L861X","C180967","A change in the amino acid residue at position 861 in the epidermal growth factor receptor protein where leucine has been replaced by another amino acid.","EGFR NP_005219.2:p.L861X | EGFR L861X | EGFR L861X Mutation | EGFR Leu861Xxx | EGFR NP_005219.2:p.Leu861Xxx | EGFR p.L861X | EGFR p.Leu861Xxx | Epidermal Growth Factor Receptor L861X | Epidermal Growth Factor Receptor Leu861Xxx | NP_005219.2:p.L861X | NP_005219.2:p.Leu861Xxx | Proto-Oncogene c-ErbB-1 L861X | Proto-Oncogene c-ErbB-1 Leu861Xxx | Receptor Tyrosine-Protein Kinase erbB-1 L861X | Receptor Tyrosine-Protein Kinase erbB-1 Leu861Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663529","EGFR NP_005219.2:p.S768X","C180970","A change in the amino acid residue at position 768 in the epidermal growth factor receptor protein where serine has been replaced by another amino acid.","EGFR NP_005219.2:p.S768X | EGFR NP_005219.2:p.Ser768Xxx | EGFR S768X | EGFR S768X Mutation | EGFR Ser768Xxx | EGFR p.S768X | EGFR p.Ser768Xxx | Epidermal Growth Factor Receptor S768X | Epidermal Growth Factor Receptor Ser768Xxx | NP_005219.2:p.S768X | NP_005219.2:p.Ser768Xxx | Proto-Oncogene c-ErbB-1 S768X | Proto-Oncogene c-ErbB-1 Ser768Xxx | Receptor Tyrosine-Protein Kinase erbB-1 S768X | Receptor Tyrosine-Protein Kinase erbB-1 Ser768Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663533","Deleterious RECQL Gene Mutation","C180974","A change in the nucleotide sequence of the RECQL gene that is associated with increased risk of disease.","Deleterious RECQL Gene Mutation | Deleterious RECQL Mutation | Deleterious RECQL1 Gene Mutation | Deleterious RecQ Like Helicase Gene Mutation | Deleterious RecQ1 Gene Mutation | RECQL Driver Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663534","Tumor Mutation Burden Greater than or Equal to 10 Mutations per Megabase","C180975","A semiquantitative genetic finding indicating that the tumor mutation burden is greater than or equal to 10 mutations per megabase of sequenced DNA.","Tumor Mutation Burden Greater than or Equal to 10 Mutations per Megabase | TMB Greater than or Equal to 10 mut/Mb | Tumor Mutation Burden Greater than or Equal to 10 mut/Mb | Tumor Mutation Burden Greater than or Equal to Ten Mutations per Megabase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663535","EWSR1/WT1 Fusion Positive","C180976","An indication that expression of the EWSR1/WT1 fusion has been detected in a sample.","EWSR1/WT1 Fusion Positive | EWSR1-WT1 Fusion Positive | EWSR1-WT1 Positive | EWSR1/WT1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950617","Number of Days from Date of Initial Pathologic Diagnosis to Date of Tumor Progression after Initial Treatment","C158637","The number of days from date of the initial cancer diagnosis to the date of tumor progression after the initial treatment.","Number of Days from Date of Initial Pathologic Diagnosis to Date of Tumor Progression after Initial Treatment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950693","Type of New Melanoma Related Tumor Event","C158793","A directive to specify the type of new melanoma related tumor event.","Type of New Melanoma Related Tumor Event | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950850","Site of New Distant Metastasis Tumor Event","C158837","A directive to specify the site of the new distant metastatic tumor event.","Site of New Distant Metastasis Tumor Event | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950849","Site of New Primary Melanoma","C158836","A directive to specify the site of the new primary melanoma.","Site of New Primary Melanoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950728","Number of Primary Tumors in this Location","C158696","A directive to specify the number of primary tumors in the specified location.","Number of Primary Tumors in this Location | # of Primaries in this location",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951578","Other Site of New Primary Melanoma","C159575","A directive to specify the other site of the new primary melanoma.","Other Site of New Primary Melanoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950848","Histological Type of New Non-Melanoma Tumor Event","C158835","A directive to identify the histological type of new non-melanoma tumor event.","Histological Type of New Non-Melanoma Tumor Event | New Non-Melanoma Tumor Histological Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950847","Primary Site of New Non-Melanoma Tumor Event","C158834","A directive to identify the primary site to the new non-melanoma tumor event.","Primary Site of New Non-Melanoma Tumor Event | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224593","Sacrococcygeal Joint","C33506","The amphiarthrodial joint between the sacrum and coccyx.","Sacrococcygeal Joint | Sacrococcygeal",,,,,,,,,,,,,,,"4298803","Joint structure of sacrococcygeal junction of spine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1663517","Polysexuality","C180989","Sexual, romantic, or emotional attraction towards multiple genders.","Polysexuality | Poly | Polysexual",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663518","Omnisexuality","C180990","Sexual, romantic, or emotional attraction towards all genders.","Omnisexuality | Omni | Omnisexual | Omnisexuality

",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663519","Sapiosexuality","C180991","Sexual, romantic, or emotional attraction toward others based on intelligence.","Sapiosexuality | Sapiosexual",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663516","Two-spirit","C180988","A term used by some Indigenous people as a designation for a person who has the combined traits of both male and female.","Two-spirit | Two Spirit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950995","NRAS NP_002515.1:p.G12R","C158927","A change in the amino acid residue at position 12 in the GTPase NRas protein where glycine has been replaced by arginine.","NRAS NP_002515.1:p.G12R | GTPase NRas G12R | GTPase NRas Gly12Arg | NP_002515.1:p.G12R | NP_002515.1:p.Gly12Arg | NRAS G12R | NRAS G12R Mutation | NRAS Gly12Arg | NRAS NP_002515.1:p.Gly12Arg | NRAS p.G12R | NRAS p.Gly12Arg | Transforming Protein N-Ras G12R | Transforming Protein N-Ras Gly12Arg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1847320","TOX Gene","C147946","This gene plays a role in T-cell development.","TOX Gene | TOX | Thymocyte Selection Associated High Mobility Group Box Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2983686","Tumor Examination","C90479","An assessment or evaluation of a neoplastic mass.","Tumor Examination | TUMEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545118","Disposition Supplemental Qualifiers Dataset","C147203","A dataset containing supplemental information, specifically non-standard variables, to parent records in the disposition domain.","Disposition Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2826979","Qualifier Data Value","C83390","The value of the data modifier.","Qualifier Data Value | QVAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378694","Hematopoietic Cell Transplantation Conditioning Regimen","C168794","A regimen that can be used as a conditioning regimen for hematopoietic stem cell transplantation (HSCT).","Hematopoietic Cell Transplantation Conditioning Regimen | HCT Conditioning Regimen | HSCT Conditioning Regimen | Stem Cell Transplant Conditioning",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555011","FerriScan","C153820","A proprietary method to determine liver iron concentration through an MRI-based imaging technology that uses R2-MRI relaxometry.","FerriScan | FerriScan R2-MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663510","Sequential Mass Spectrometry","C181005","A mass spectrometry technique that uses an ion trap and Fourier-transform ion-cyclotron resonance (FT-ICR) type instrument to re-fragment the product ions from a mass spec pass. The process can be repeated n times where 'n' represents the number of times the isolation-fragmentation-measurement cycle has been carried out.","Sequential Mass Spectrometry | MSn | Multi Stage Mass Spectrometry | Multistage Mass Spectrometry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663511","Metabolite Identification Confidence Level","C181006","A set of terms used to communicate the confidence of annotation and identification results for known features in global, untargeted metabolomics studies.","Metabolite Identification Confidence Level | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663712","1 level (imaging property)","C181007","Identification is fully validated by confirming the structure and metabolite assignment using a reference standard.","Level 1 Metabolite Identification Confidence | Level 1 | Level 1 - validation identification | Metabolite Identification Confidence Level 1 | Validation Identification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663715","Level 2 Metabolite Identification Confidence","C181008","Putative identification reveals probable structure using fragmentation data from literature and/or libraries and databases.","Level 2 Metabolite Identification Confidence | Level 2 | Level 2 - putative identification | Metabolite Identification Confidence Level 2 | Putative Identification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663714","Level 3 Metabolite Identification Confidence","C181009","Tentative structural identification includes a unique match of the parent ion (via mass spectrometry) data searched through literature and/or libraries and databases.","Level 3 Metabolite Identification Confidence | Level 3 | Level 3 - tentative structure  identification | Level 3 - tentative structure identification | Metabolite Identification Confidence Level 3 | Tentative Structure Identification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663717","Level 4 Metabolite Identification Confidence","C181010","Molecular formula identification of features is completed via isotope abundance distribution, charge state and adduct ion determination.","Level 4 Metabolite Identification Confidence | Level 4 | Level 4 - molecular formula identification | Metabolite Identification Confidence Level 4 | Molecular Formula Identification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663713","Level 5 Metabolite Identification Confidence","C181011","Unique features are identified via exact mass measurement accuracy (unique mass-to-charge ratio and retention time).","Level 5 Metabolite Identification Confidence | Level 5 | Level 5 - unique feature identification | Metabolite Identification Confidence Level 5 | Unique Feature Identification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663509","MRI Quantification of Liver Iron Concentration","C181004","A magnetic resonance imaging method used to quantitate liver iron concentrations. Water ions moving near magnetic iron deposits destroy the homogeneity of the magnetic field causing the MRI image to darken at a rate proportional to the iron concentration.","MRI Quantification of Liver Iron Concentration | Liver Iron Concentration MRI | Liver Iron Concentration MRI R2 | Liver Iron Concentration MRI R2* | Liver Iron Concentration R2 MRI | Liver Iron Concentration R2* MRI | Liver Iron Concentration by MRI | MRI Quantification of Hepatic Iron Concentration | MRI R2 | MRI R2* | R2 MRI | R2* MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663613","Psychosocial Assessment of Candidates for Transplantation","C181012","A tool to address psychosocial risks in transplant recipients. It consists of an 8-item rating scale with four sections: social support, psychological health, lifestyle factors, and understanding of transplant and follow-up. The instrument can also capture the clinician's assessment of a patient's substance abuse, compliance, and coping strategies. The overall impression of the patient's suitability for transplantation is assigned a final PACT score.","Psychosocial Assessment of Candidates for Transplantation | PACT | Psychosocial Assessment of Candidates for Transplantation (PACT)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971211","Metastatic site, specify","C158875","A request to specify the site of the metastasis.","Specify Site of Metastasis | Metastatic site, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663609","Percent Tumor Surface Area","C181020","A quantitative measurement of the area of tissue surface in a sample that is tumorous tissue, expressed as a percentage.","Percent Tumor Surface Area | Percent of the surface area of the entire section that is tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378988","Study Subject Not Enrolled","C168929","The study subject is/was not enrolled.","Study Subject Not Enrolled | Not Enrolled | Subject Not Registered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472325","Enfortumab Vedotin","C114500","An antibody drug conjugate (ADC) containing a human monoclonal antibody AGS-22 targeting the cell adhesion molecule nectin-4 and conjugated to the cytotoxic agent monomethyl auristatin E (MMAE), via a proprietary enzyme-cleavable linker (AGS-22CE), with potential antineoplastic activity. The monoclonal antibody moiety of enfortumab vedotin selectively binds to nectin-4. After internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces apoptosis in nectin-4 overexpressing tumor cells. Nectin-4, a tumor associated antigen belonging to the nectin family, is overexpressed in a variety of cancers, including breast, bladder, lung and pancreatic cancer.","Enfortumab Vedotin | AGS 22ME | AGS-22M6E | ASG 22CE | ASG-22CE | ASG22CE | Anti-Nectin 4 ADC ASG-22CE | Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E | ENFORTUMAB VEDOTIN | Enfortumab Vedotin-ejfv | Enfortumab vedotin | Padcev",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641169","Erdafitinib","C103273","An orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity. Upon oral administration, erdafitinib binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways and thus the inhibition of tumor cell proliferation and tumor cell death in FGFR-overexpressing tumor cells. FGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival.","Erdafitinib | 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)- | Balversa | ERDAFITINIB | JNJ 42756493 | JNJ-42756493 | JNJ42756493",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969030","High-Dose Cytarabine Regimen","C160046","A regimen consisting of high-dose cytarabine that may be used in the treatment of acute myeloid leukemia (AML) and primary central nervous system (CNS) lymphoma.","High-Dose Cytarabine Regimen | Cytarabine High-dose Regimen | HiDAC | High-dose Ara-C Regimen | High-dose Cytarabine monotherapy (HiDAC)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664759","Open Microscopy Environment Tagged Image File Format","C181618","A tagged image file format (TIFF) image file format that contains an Open Microscopy Environment (OME) XML metadata block in the file header for storing microscopy information (pixels and metadata) using the OME Data Model.","Open Microscopy Environment Tagged Image File Format | OME-TIFF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334517","Testicular Spermatocytic Tumor","C39921","A testicular germ cell tumor derived from postpubertal-type germ cells. It is characterized by the presence of three cell types: round cells with eosinophilic cytoplasm, small cells with dark nucleus and a small amount of cytoplasm, and mono-or multinucleated giant cells. The neoplastic cells are not cohesive. There is an edematous stroma present; lymphocytic infiltrates are rarely seen. Most patients are older males.","Testicular Spermatocytic Tumor | Spermatocytic Seminoma | Spermatocytic Tumor | Spermatocytic seminoma | Testicular Spermatocytic Seminoma","9063/3","Spermatocytic seminoma",,,,,,,,,,,,,"4244815","Spermatocytic seminoma",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"CL1664793","Byte Order","C181701","The sequence or order of bytes (and bits) arranged to form larger values used to store and share files.","Byte Order | Byte Ordering | Endianness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664797","Big Endian Byte Order","C181703","A binary number consisting of multiple bytes in which the most significant bit is encoded first with the remaining bytes encoded in decreasing order of significance.","Big Endian Byte Order | Big Endian",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977620","Age of Enrollment","C164338","The age of a subject when entering a group, catalog, list, or study.","Age of Enrollment | patient age at enrollment | patient_age_at_enrollment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830549","Decimal Point","C113687","A dot placed between the integer part and fractional part of a number in the decimal system.","Decimal Point | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405400","Electronic File Name","C171191","The literal identifier for an electronic file.","Electronic File Name | File Name | file name | file_name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405563","Electronic File Format","C171252","The structure of the information in an electronic file.","Electronic File Format | File Format | Format | data format | data_format | file format | file_format",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520201","Protocol Identifier","C132299","A sequence of letters, numbers, or other characters that uniquely identifies a study protocol.","Protocol Identifier | Protocol Identifying Number | protocol identifier | protocol_identifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978393","Analysis Metadata","C165211","Supporting information that describes the processes used to analyze the experimental data in a study.","Analysis Metadata | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664688","Human Tumor Atlas Network","C181842","A collaborative network, funded by the National Cancer Institute's Cancer Moonshot initiative, that was established to develop a clinical, experimental, computational, and organizational framework for the construction of three-dimensional atlases of cancer transitions for a diverse set of human tumor types.","Human Tumor Atlas Network | HTAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664896","Johns Hopkins Frailty Assessment Calculator","C181867","A standardized assessment tool that assesses frailty by measuring five phenotypic criteria: unintentional weight loss, exhaustion, low energy expenditure, low grip strength, and/or slowed walking speed. A single score is automatically generated and interpreted as either frail (score 3-5), pre-frail (score 1 or 2), or non-frail or robust (score 0).","Johns Hopkins Frailty Assessment Calculator | Frailty Assessment Calculator | Johns Hopkins Frailty Assessment Instrument (Physical Frailty Phenotype)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664885","Have Felt Unusually Tired During the Day","C181868","A question about whether an individual has been feeling unusually tired during the day, on the average.","Have Felt Unusually Tired During the Day | Feeling Unusually Tired During The Day | In the past month, on the average, have you been feeling unusually tired during the day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664886","Have Felt Unusually Weak","C181869","A question about whether an individual has been feeling unusually weak, on the average.","Have Felt Unusually Weak | Feeling Unusually Weak | In the past month, on the average, have you felt unusually weak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664883","Usual Energy While Awake","C181870","A question about how an individual would rate their usual energy level while awake on a scale from 0 to 10, where 0 is no energy and 10 is the most energy that they have ever had.","Usual Energy While Awake | Using the scale below, would you please rate your usual energy level on a scale from 0 to 10 where 0 is no energy and 10 is the most energy that you have ever had. Please give me a number between 0 and 10 that describes your usual energy while awake in the last month | Usual Energy Level While Awake",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664889","Energy Level 0","C181872","A subjective score of 0 on a scale that rates energy level from 0 (no energy) to 10 (most energy).","Energy Level 0 | Usual Awake Energy Score 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664890","Energy Level 1","C181873","A subjective score of 1 on a scale that rates energy level from 0 (no energy) to 10 (most energy).","Energy Level 1 | Usual Awake Energy Score 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664887","Energy Level 2","C181874","A subjective score of 2 on a scale that rates energy level from 0 (no energy) to 10 (most energy).","Energy Level 2 | Usual Awake Energy Score 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664888","Energy Level 3","C181875","A subjective score of 3 on a scale that rates energy level from 0 (no energy) to 10 (most energy).","Energy Level 3 | Usual Awake Energy Score 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664877","Energy Level 4","C181876","A subjective score of 4 on a scale that rates energy level from 0 (no energy) to 10 (most energy).","Energy Level 4 | Usual Awake Energy Score 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664878","Energy Level 5","C181877","A subjective score of 5 on a scale that rates energy level from 0 (no energy) to 10 (most energy).","Energy Level 5 | Usual Awake Energy Score 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664875","Energy Level 6","C181878","A subjective score of 6 on a scale that rates energy level from 0 (no energy) to 10 (most energy).","Energy Level 6 | Usual Awake Energy Score 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664876","Energy Level 7","C181879","A subjective score of 7 on a scale that rates energy level from 0 (no energy) to 10 (most energy).","Energy Level 7 | Usual Awake Energy Score 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664881","Energy Level 8","C181880","A subjective score of 8 on a scale that rates energy level from 0 (no energy) to 10 (most energy).","Energy Level 8 | Usual Awake Energy Score 8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664882","Energy Level 9","C181881","A subjective score of 9 on a scale that rates energy level from 0 (no energy) to 10 (most energy).","Energy Level 9 | Usual Awake Energy Score 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664879","Energy Level 10","C181882","A subjective score of 10 on a scale that rates energy level from 0 (no energy) to 10 (most energy).","Energy Level 10 | Usual Awake Energy Score 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664880","Walked for Exercise","C181883","A question about whether an individual has walked for exercise.","Walked for Exercise | During the past two weeks have you walked for exercise",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664869","Have Done Moderately Strenuous Household Chores","C181884","A question about whether an individual has done moderately strenuous household chores like scrubbing and vacuuming.","Have Done Moderately Strenuous Household Chores Question | During the past two weeks have you done moderately strenuous household chores, like scrubbing and vacuuming | Have Done Moderately Strenuous Household Chores | Have Done Moderately Strenuous Household Chores | Have Done Moderately Strenuous Household Chores Like Scrubbing and Vacuuming",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664870","Have Done Moderately Strenuous Outdoor Chores","C181885","A question about whether an individual has done moderately strenuous outdoor chores like raking, mowing the lawn, shoveling snow, or working in the garden.","Have Done Moderately Strenuous Outdoor Chores Question | During the past two weeks have you done moderately strenuous outdoor chores, like raking or mowing the lawn, shoveling snow, or working in the garden | Have Done Moderately Strenuous Outdoor Chores | Have Done Moderately Strenuous Outdoor Chores | Have Done Moderately Strenuous Outdoor Chores Like Raking or Mowing the Lawn Shoveling Snow or Working in the Garden",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664867","Have Been Dancing","C181886","A question about whether an individual has been dancing.","Have Been Dancing Question | During the past two weeks have you been dancing | Have Been Dancing | Have Been Dancing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664868","Have Been Bowling","C181887","A question about whether an individual has been bowling.","Have Been Bowling Question | During the past two weeks have you been bowling | Have Been Bowling | Have Been Bowling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664873","Have Participated in Regular Exercise Program","C181888","A question about whether an individual has participated in a regular exercise program, such as stretching or strengthening exercises, swimming or any other regular exercise program.","Have Participated in Regular Exercise Program Question | During the past two weeks have you participated in any regular exercise program, such as stretching or strengthening exercises, swimming or any other regular exercise program | Have Participated in Regular Exercise Program | Have Participated in Regular Exercise Program | Have Participated in Regular Exercise Program Such as Stretching or Strengthening Exercises Swimming or Other Regular Exercise Program",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664874","Have Completed Walking Test","C181889","A question about whether an individual has completed a walking test.","Have Completed Walking Test | Walking Test Completed | Was the walking test completed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664871","First Usual Pace Walk Time","C181890","A question about an individual's time for their first usual pace walk.","First Usual Pace Walk Time | Time for first usual pace walk | Usual Pace Walk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664872","Delayed Recall With No Cue","C181891","A question about whether an individual was able to correctly recall specific words spontaneously as part of the Montreal Cognitive Assessment Delayed Recall Test.","Delayed Recall With No Cue | Montreal Cognitive Assessment Delayed Recall Test - With No Cue | With No Cue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664861","Delayed Recall With Category Cue","C181892","A question about whether an individual was able to correctly recall specific words with category cues as part of the Montreal Cognitive Assessment Delayed Recall Test.","Delayed Recall With Category Cue | Category cue | Montreal Cognitive Assessment Delayed Recall Test - Category Cue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664862","Delayed Recall With Multiple Choice Cue","C181893","A question about whether an individual was able to correctly recall specific words with multiple choice cues as part of the Montreal Cognitive Assessment Delayed Recall Test.","Delayed Recall With Multiple Choice Cue | Montreal Cognitive Assessment Delayed Recall Test - Multiple Choice Cue | Multiple choice cue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664860","Lawton-Brody Instrumental Activities of Daily Living Scale","C181894","A functional assessment instrument that was developed by Lawton and Brody in 1969 to assess an individual's ability to perform eight complex tasks of daily living that are necessary for living in a community.","Lawton-Brody Instrumental Activities of Daily Living Scale | Lawton IADL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664963","Does Laundry","C181895","A question about how much of their personal laundry an individual is able to do.","Do Laundry Question | Ability to Do Laundry | Do Laundry | Does Laundry | Does Laundry | Laundry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664865","Travel Mode Ability Level","C181896","A question about how independently an individual is able to travel.","Travel Mode Ability Level Question | Mode of Transportation | Travel Mode Ability Level | Travel Mode Ability Level",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664866","How Much Responsibility for Own Medications","C181897","A question about how much responsibility individual is able to handle for taking their medications at the correct dose and time.","How Much Responsibility for Own Medications Question | How Much Responsibility for Own Medications | How Much Responsibility for Own Medications | Responsibility for Own Medications",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664863","Ability to Handle Finances","C181898","A question about an individual's ability to handle their finances.","Ability to Handle Finances Question | Ability to Handle Finances | Ability to Handle Finances",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509722","Complete Patient Questionnaire","C128525","The patient must complete a questionnaire.","Complete Patient Questionnaire | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1451418","CLEC12A protein, human","C162378","C-type lectin domain family 12 member A (265 aa, ~31 kDa) is encoded by the human CLEC12A gene. This protein is involved in carbohydrate binding and signal transduction.","C-Type Lectin Domain Family 12 Member A | C-Type Lectin Protein CLL-1 | C-Type Lectin-Like Molecule 1 | C-Type Lectin-Like Molecule-1 | CD371 | CD371 Antigen | CLEC12A | CLL-1 | CLL1 | DCAL-2 | Dendritic Cell-Associated Lectin 2 | MICL | Myeloid Inhibitory C-Type Lectin-Like Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985419","CD276 wt Allele","C93064","The CD276 wild-type allele is located within 15q23-q24 and is approximately 30 kb in length. This allele, which encodes CD276 antigen protein, plays a role in regulation of both the immune response and T cell proliferation.","CD276 wt Allele | 4Ig-B7-H3 | B7-H3 | B7H3 | B7RP-2 | CD276 Antigen Gene | CD276 Molecule wt Allele | PSEC0249 | UNQ309/PRO352",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1384654","Tumor Necrosis Factor Receptor Superfamily Member 13C, Human","C111797","Tumor necrosis factor receptor superfamily member 13C (184 aa, ~19 kDa) is encoded by the human TNFRSF13C gene. This protein plays a role in regulating the survival of peripheral B-cells.","Tumor Necrosis Factor Receptor Superfamily Member 13C | B Cell-Activating Factor Receptor | B-Cell-Activating Factor Receptor | BAFF Receptor | BAFF-R | BLyS Receptor 3 | CD268 Antigen | Prolixin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664846","Second Usual Pace Walk Time","C181908","A question about an individual's time for their second usual pace walk.","Second Usual Pace Walk Time | Time for second usual pace walk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382981","Electronic Health Record Review","C170821","Checking and assessing the data present in an electronic health record.","Electronic Health Record Review | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520912","Planned End Date","C133397","The calendar date that an event or activity is intended to be completed.","Planned End Date | Proposed End Date",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664850","Did Not Attempt or Failed Side-by-Side-Stand","C181912","A question about whether an individual did not attempt or failed the Side-by-Side Stand test as part of the Short Physical Performance Battery.","Did Not Attempt or Failed Side-by-Side-Stand | Did Not Attempt or Failed Side-by-Side-Stand  | Did not attempt or failed side-by-side-stand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664851","Did Not Attempt or Failed Tandem Stand","C181913","A question about whether an individual did not attempt or failed the Tandem Stand as part of the Short Physical Performance Battery.","Did Not Attempt or Failed Tandem Stand | Did not attempt or failed Tandem Stand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664848","Did Not Attempt or Failed Semi-Tandem Stand","C181914","A question about whether an individual did not attempt or failed the Semi-Tandem Stand as part of the Short Physical Performance Battery.","Did Not Attempt or Failed Semi-Tandem Stand | Did not attempt or failed Semi-Tandem Stand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664849","Time Series","C181915","A series of data points indexed in time order, most commonly, at successive equally spaced points in time.","Time Series | T-Series",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383096","SPPB Version 1.2 - Side-by-Side Score","C170693","Short Physical Performance Battery Version 1.2 (SPPB Version 1.2) Side-By-Side Stand: Side-by-side score.","SPPB Version 1.2 - Side-by-Side Score | SPPB1-Side-by-Side Score | SPPB101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383093","SPPB Version 1.2 - Side-by-Side Seconds Held If <10","C170694","Short Physical Performance Battery Version 1.2 (SPPB Version 1.2) Side-By-Side Stand: Number of seconds held if less than 10 sec.","SPPB Version 1.2 - Side-by-Side Seconds Held If <10 | SPPB1-Side-by-Side Seconds Held If <10 | SPPB101A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383094","SPPB Version 1.2 - Semi-Tandem Stand Score","C170695","Short Physical Performance Battery Version 1.2 (SPPB Version 1.2) Semi-Tandem Stand: Semi-tandem stand score.","SPPB Version 1.2 - Semi-Tandem Stand Score | SPPB1-Semi-Tandem Stand Score | SPPB102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383115","SPPB Version 1.2 - Semi-Tandem Seconds Held If <10","C170696","Short Physical Performance Battery Version 1.2 (SPPB Version 1.2) Semi-Tandem Stand: Number of seconds held if less than 10 sec.","SPPB Version 1.2 - Semi-Tandem Seconds Held If <10 | SPPB1-Semi-Tandem Seconds Held If <10 | SPPB102A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383116","SPPB Version 1.2 - Tandem Stand Score","C170697","Short Physical Performance Battery Version 1.2 (SPPB Version 1.2) Tandem Stand: Tandem stand score.","SPPB Version 1.2 - Tandem Stand Score | SPPB1-Tandem Stand Score | SPPB103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383113","SPPB Version 1.2 - Tandem Seconds If <10","C170698","Short Physical Performance Battery Version 1.2 (SPPB Version 1.2) Tandem Stand: Number of seconds if less than 10 sec.","SPPB Version 1.2 - Tandem Seconds If <10 | SPPB1-Tandem Seconds If <10 | SPPB103A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383120","SPPB Version 1.2 - Total Balance Tests Score","C170701","Short Physical Performance Battery Version 1.2 (SPPB Version 1.2) Total balance tests score.","SPPB Version 1.2 - Total Balance Tests Score | SPPB1-Total Balance Tests Score | SPPB105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972335","Gait Assessment Test","C167363","Any method or test designed to identify structural, biomechanical, and functional limitations in walking, and to develop treatment plans and assess the effect of treatment.","Gait Assessment Test | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383118","SPPB Version 1.2 - Time for 3 or 4 Meters 1st Gait","C170703","Short Physical Performance Battery Version 1.2 (SPPB Version 1.2) Gait Speed Test - First Gait Speed Test: Time for 3 or 4 meters.","SPPB Version 1.2 - Time for 3 or 4 Meters 1st Gait | SPPB1-Time for 3 or 4 Meters 1st Gait | SPPB107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383107","SPPB Version 1.2 - Did Not Attempt 1st Gait","C170704","Short Physical Performance Battery Version 1.2 (SPPB Version 1.2) Gait Speed Test - First Gait Speed Test: If participant did not attempt test.","SPPB Version 1.2 - Did Not Attempt 1st Gait | SPPB1-Did Not Attempt 1st Gait | SPPB107A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383108","SPPB Version 1.2 - Did Not Attempt 1st Gait Specify","C170705","Short Physical Performance Battery Version 1.2 (SPPB Version 1.2) Gait Speed Test - First Gait Speed Test: If participant did not attempt test: Other (specify).","SPPB Version 1.2 - Did Not Attempt 1st Gait Specify | SPPB1-Did Not Attempt 1st Gait Specify | SPPB107B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642349","Emergency Room Visit","C176294","The subject or patient has been admitted as an outpatient to an emergency room.","Emergency Room Visit | EMERGENCY ROOM VISIT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383105","SPPB Version 1.2 - Aids Used 1st Gait","C170706","Short Physical Performance Battery Version 1.2 (SPPB Version 1.2) Gait Speed Test - First Gait Speed Test: Aids used for first walk.","SPPB Version 1.2 - Aids Used 1st Gait | SPPB1-Aids Used 1st Gait | SPPB107C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383111","SPPB Version 1.2 - Time for 3 or 4 Meters - 2nd Gait","C170708","Short Physical Performance Battery Version 1.2 (SPPB Version 1.2) Gait Speed Test - Second Gait Speed Test: Time for 3 or 4 meters.","SPPB Version 1.2 - Time for 3 or 4 Meters - 2nd Gait | SPPB1-Time for 3 or 4 Meters - 2nd Gait | SPPB108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383112","SPPB Version 1.2 - Did Not Attempt or Failed 2nd Gait","C170709","Short Physical Performance Battery Version 1.2 (SPPB Version 1.2) Gait Speed Test - Second Gait Speed Test: If participant did not attempt or failed.","SPPB Version 1.2 - Did Not Attempt or Failed 2nd Gait | SPPB1-Did Not Attempt or Failed 2nd Gait | SPPB108A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383109","SPPB Version 1.2 - Did Not Attempt 2nd Gait Specify","C170710","Short Physical Performance Battery Version 1.2 (SPPB Version 1.2) Gait Speed Test - Second Gait Speed Test: If participant did not attempt or failed: Other (specify).","SPPB Version 1.2 - Did Not Attempt 2nd Gait Specify | SPPB1-Did Not Attempt 2nd Gait Specify | SPPB108B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383110","SPPB Version 1.2 - Aids Used 2nd Gait","C170711","Short Physical Performance Battery Version 1.2 (SPPB Version 1.2) Gait Speed Test - Second Gait Speed Test: Aids used for second walk.","SPPB Version 1.2 - Aids Used 2nd Gait | SPPB1-Aids Used 2nd Gait | SPPB108C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383131","SPPB Version 1.2 - For 4-Meter Walk","C170713","Short Physical Performance Battery Version 1.2 (SPPB Version 1.2) Gait Speed Test: For 4-meter walk.","SPPB Version 1.2 - For 4-Meter Walk | SPPB1-For 4-Meter Walk | SPPB109A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664837","Objective Lens","C181919","The optical element nearest to the specimen being viewed that magnifies and projects the image of the specimen.","Objective Lens | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664842","Nominal Magnification","C181920","The product of the reference seeing distance and the equivalent power, expressed in diopters.","Nominal Magnification | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664843","Lens Numerical Aperture","C181921","A number that characterizes the range of angles over which the objective lens can accept or emit light.","Lens Numerical Aperture | LensNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664840","Working Distance","C181922","The distance between the front end of the objective lens and the specimen surface when the specimen is in focus.","Working Distance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383128","SPPB Version 1.2 - For 3-Meter Walk","C170714","Short Physical Performance Battery Version 1.2 (SPPB Version 1.2) Gait Speed Test: For 3-meter walk.","SPPB Version 1.2 - For 3-Meter Walk | SPPB1-For 3-Meter Walk | SPPB109B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383129","SPPB Version 1.2 - Safe to Stand Without Help","C170715","Short Physical Performance Battery Version 1.2 (SPPB Version 1.2) Chair Stand Test - Single Chair Stand Test: Safe to stand without help.","SPPB Version 1.2 - Safe to Stand Without Help | SPPB1-Safe to Stand Without Help | SPPB110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383134","SPPB Version 1.2 - Results Single Chair","C170716","Short Physical Performance Battery Version 1.2 (SPPB Version 1.2) Chair Stand Test - Single Chair Stand Test: Results.","SPPB Version 1.2 - Results Single Chair | SPPB1-Results Single Chair | SPPB111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383135","SPPB Version 1.2 - Did Not Attempt Single Chair","C170717","Short Physical Performance Battery Version 1.2 (SPPB Version 1.2) Chair Stand Test - Single Chair Stand Test: If participant did not attempt or failed.","SPPB Version 1.2 - Did Not Attempt Single Chair | SPPB1-Did Not Attempt Single Chair | SPPB111A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383132","SPPB Version 1.2 - Not Attempt Single Chair Specify","C170718","Short Physical Performance Battery Version 1.2 (SPPB Version 1.2) Chair Stand Test - Single Chair Stand Test: If participant did not attempt or failed: Other (specify).","SPPB Version 1.2 - Not Attempt Single Chair Specify | SPPB1-Not Attempt Single Chair Specify | SPPB111B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383133","SPPB Version 1.2 - Safe to Stand Five Times","C170719","Short Physical Performance Battery Version 1.2 (SPPB Version 1.2) Chair Stand Test - Repeated Chair Stand Test: Safe to stand five times.","SPPB Version 1.2 - Safe to Stand Five Times | SPPB1-Safe to Stand Five Times | SPPB112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383123","SPPB Version 1.2 - Time to Complete Five Stands","C170720","Short Physical Performance Battery Version 1.2 (SPPB Version 1.2) Chair Stand Test - Repeated Chair Stand Test: Time to complete five stands.","SPPB Version 1.2 - Time to Complete Five Stands | SPPB1-Time to Complete Five Stands | SPPB113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383124","SPPB Version 1.2 - Did Not Attempt Repeated Chair","C170721","Short Physical Performance Battery Version 1.2 (SPPB Version 1.2) Chair Stand Test - Repeated Chair Stand Test: If participant did not attempt test or failed.","SPPB Version 1.2 - Did Not Attempt Repeated Chair | SPPB1-Did Not Attempt Repeated Chair | SPPB113A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383121","SPPB Version 1.2 - Not Attempt Repeated Chair Specify","C170722","Short Physical Performance Battery Version 1.2 (SPPB Version 1.2) Chair Stand Test - Repeated Chair Stand Test: If participant did not attempt test or failed: Other (specify).","SPPB Version 1.2 - Not Attempt Repeated Chair Specify | SPPB1-Not Attempt Repeated Chair Specify | SPPB113B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383122","SPPB Version 1.2 - Chair Stand Score Repeated","C170723","Short Physical Performance Battery Version 1.2 (SPPB Version 1.2) Chair Stand Test - Repeated Chair Stand Test: Chair stand score.","SPPB Version 1.2 - Chair Stand Score Repeated | SPPB1-Chair Stand Score Repeated | SPPB113C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1383126","SPPB Version 1.2 - Total Score","C170724","Short Physical Performance Battery Version 1.2 (SPPB Version 1.2) Total score.","SPPB Version 1.2 - Total Score | SPPB1-Total Score | SPPB114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407186","Intensive Care Unit Admission Status","C173316","An indication of whether the subject was admitted to the intensive care unit.","Intensive Care Unit Admission Status | AE_ICU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700631","Cane - plant part","C79627","A long, hollow or pithy, jointed woody stem that usually lives only one or two years.","Cane | Caulis medullosus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664947","Tissue-Based Cyclic Immunofluorescence","C181929","A method for immunofluorescence imaging of formalin-fixed, paraffin-embedded (FFPE) specimens mounted on glass slides that generates images using an iterative, cycling process in which conventional fluorescence images capturing up to 60 targets are repeatedly collected from the same sample and then assembled into a high-dimensional representation of the spacial relationships between the multiplex targets.","Tissue-Based Cyclic Immunofluorescence | Tissue Cyclic Immunofluorescence | t-CyCIF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664942","Multiplexed Immunohistochemistry","C181927","A method that enables simultaneous detection of multiple biomarkers on a single tissue section using immunohistochemistry techniques.","Multiplexed Immunohistochemistry | MULTIPLEX IMMUNOHISTOCHEMISTRY | Multiplex IHC | Multiplex Immunoassay | Multiplex Immunohistochemistry | MxIHC | mIHC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664946","Multiplexed Immunofluorescence","C181928","A method that enables simultaneous detection of multiple biomarkers on a single tissue section using immunofluorescence techniques.","Multiplexed Immunofluorescence | MULTIPLEX IMMUNOFLUORESCENCE | Multiplex IF | Multiplex Immunofluorescence | MxIF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664945","CO-Detection by indEXing","C181931","A highly multiplexed cytometric imaging approach used to create multiplexed datasets for a single tissue staining reaction. CODEX iteratively visualizes antibody binding events using DNA barcodes, fluorescent dNTP analogs, and an in situ polymerization-based indexing procedure.","CO-Detection by indEXing | CODEX | CODEX Multiplexed Imaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664935","GeoMx Digital Spatial Profiler","C181933","A method to stain for RNA or protein from tissue sections that combines spatial and molecular profiling technologies by generating a whole tissue image at single cell resolution along with digital profiling data. A tissue section is reacted with up to 4 fluorescent morphology markers and tens to thousands of RNA or protein detection reagents barcoded with unique photocleavable oligonucleotides. The oligonucleotide markers are then imaged from regions of interest to be identified and quantitated.","GeoMx Digital Spatial Profiler | GeoMx-DSP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664944","Multiplexed Ion Beam Imaging","C181930","A method for multiplexed immunohistochemistry that uses secondary ion mass spectrometry to image antibodies tagged with isotopically pure elemental metal reporters. Multiplexed ion beam imaging (MIBI) is capable of analyzing up to 100 targets simultaneously over a five-log dynamic range. This technique enables comprehensive phenotypic profiling and spatial analysis of the tissue microenvironment.","Multiplexed Ion Beam Imaging | MIBI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346481","Inch British","C69446","A traditional unit of length equal to 2.539998 centimeters, used before 1959 when the unified international definitions for units of British Imperial system were established and inch was defined as 2.54 centimeters.","Inch British | Inch Imperial unit | [in_br] | inch",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349166","Yard British","C71244","An English unit of length that comprises 3 feet or 36 inches. Since 1959 it is by international agreement standardized as exactly 0.9144 meters.","Yard British | British Yard | Yard Imperial unit | [yd_br] | yard",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1552960","Line Unit of Length","C71221","A unit of length equal 1/12 inch, approximately 2.1167 millimeters.","Line Unit of Length | Line | Line Imperial unit | [lne] | l | lin | line",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1552926","mil unit of measure","C71223","A unit of length equal to one thousandth of an international inch or 25.4 microns; used predominantly to specify thickness.","Mil | International Mil | [mil_i] | mil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349168","Yoctometer","C71214","A metric unit of length equal to one septillionth of a meter (10E-24 meter).","Yoctometer | ym",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346517","Zeptometer","C71213","A metric unit of length equal to one sextillionth of a meter (10E-21 meter).","Zeptometer | zm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346872","Attometer","C71212","A metric unit of length equal to one quintillionth of a meter (10E-18 meter).","Attometer | am",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978376","Child Individual","C164216","An individual between the ages of 2-12. There can be some variation depending on the culture.","Child Individual | Child",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545231","Findings About Events or Interventions Supplemental Qualifiers Dataset","C147212","A dataset containing supplemental information, specifically non-standard variables, to parent records in the findings about events or interventions domain.","Findings About Events or Interventions Supplemental Qualifiers Dataset | SUPPFA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664910","Short Physical Performance Battery Gait Speed Test","C181968","A physical assessment designed to assess the ability of an individual to walk 3 or 4 meters.","Short Physical Performance Battery Gait Speed Test | SPPB-GST | Short Physical Performance Battery (SPPB) Gait Speed Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664915","Shorter of Two Times for Gait Speed Test","C181969","A request for the shorter time of the two gait speed tests completed by an individual.","Shorter of Two Times for Gait Speed Test | Record the shorter of the two times",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664916","Gait Speed Test Time if Only One Walk Completed","C181970","A request for the time of the one gait speed test that was completed by an individual.","Gait Speed Test Time if Only One Walk Completed | If only 1 walk done, record that time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664914","Unable to Complete Gait Speed Test","C181972","A question about whether an individual was unable to complete the Gait Speed Test.","Unable to Complete Gait Speed Test | If the participant was unable to do the walk | Participant Unable to Complete Gait Speed Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2985420","CD276 Antigen, Human","C93066","CD276 antigen (534 aa, ~57 kDa) is encoded by the human CD276 gene. This protein is involved in the mediation of T cell proliferation and activation.","CD276 Antigen | 4Ig-B7-H3 | Antigen CD276 | Antigen Identified by the Monoclonal Antibody 8H9 | B7 Homolog 3 | B7-H3 | CD Antigen CD276 | CD276 | Costimulatory Molecule | M8H9 Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663512","F-18 DCFPyL PSMA Positron Emission Tomography","C180993","A positron emission tomography imaging technique that uses F-18 labelled DCFPyL to bind to prostate-specific membrane antigen-expressing tumor cells to locate cancer lesions.","F-18 DCFPyL PSMA Positron Emission Tomography | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664818","Immersion Medium","C182013","A fluid used to fill the space between a microscope's objective lens and the coverslip. It is used to increase the effective numerical aperture of the lens.","Immersion Medium | Immersion Media",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664948","Pyramid Representation","C182015","An image processing method where an image is decomposed into multi-resolution representations allowing for analysis and manipulation of the image over a range of spatial scales.","Pyramid Representation | Image Pyramid | Pyramid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664812","Z-Stacking","C182016","A digital image processing method which combines multiple images taken at different focal distances to create a composite image with a greater depth of field than is possible for a single image.","Z-Stacking | Focal Plane Merging | Focus Stack | Focus Stacking | Z-Stack",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1770703","Sexual Activity","C182017","Any activity, solitary or between two or more individuals, that induces sexual arousal.","Sexual Activity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648181","Assay Technology Type","C178865","The type of a technology on which an assay is based.","Assay Technology Type | Technology_Type | Type of Assay Technology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937631","Stereotactic Ablative Radiotherapy","C157991","A highly focused radiation therapy which delivers an intense dose of radiation to a tumor.","Stereotactic Ablative Radiotherapy | SABER | SABR/SBRT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773283","Research Center","C182021","A facility established for research, often designed to promote interactions between faculty, scholars, students, and industry.","Research Center | Research Institute",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773290","Image File Directory","C182022","A section of a Tag Image File Format (TIFF) file where the first two bytes state the number of fields that the image file directory contains, followed by a sequence of 12-byte field entries, and then the final 4 bytes give the offset to the next image file directory (IFD) from the start of the header. There must be at least one IFD in a TIFF file and each IFD must have at least one entry.","Image File Directory | IFD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1770707","Pixel Array","C182023","A two-dimensional grid of data that defines the form and color of each pixel in a digital image.","Pixel Array | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335525","Cribriform Prostate Hyperplasia","C5594","A rare type of prostatic hyperplasia. It is characterized by hyperplastic glandular cells with clear cytoplasm.","Prostatic Clear Cell Cribriform Hyperplasia | CCCH | CCCH of the Prostate | Clear Cell Cribriform Hyperplasia of the Prostate | Cribriform Hyperplasia of Prostate | Cribriform Hyperplasia of the Prostate | Cribriform Prostate Hyperplasia | Prostatic CCCH | Prostatic Cribriform Hyperplasia | Prostatic Cribriform Hyperplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1335524","Prostatic Basal Cell Hyperplasia","C5593","A type of prostatic hyperplasia.  It is characterized by the presence of nodules of dark basal cells around residual prostatic secretory cells.","Prostatic Basal Cell Hyperplasia | Basal Cell Hyperplasia of Prostate | Basal Cell Hyperplasia of the Prostate | Basal Cell Prostate Hyperplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643293","Dana Farber Cancer Institute","C177330","An institute founded in 1947 in Boston, Massachusetts, committed to providing treatment for adults and children with cancer, and developing cures with cutting-edge research.","Dana Farber Cancer Institute | DFCI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553612","Sacituzumab","C152280","No Value Exists","Sacituzumab | Immunoglobulin G1, Anti-(Human Tumor-associated Calcium Signal Transducer 2) (Human-mus musculus Monoclonal HRS7 Heavy Chain), Disulfide with Human-mus musculus Monoclonal HRS7 kappa-chain, Dimer | RS7 | SACITUZUMAB | hRS7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1770607","Away from Home","C182114","Any location other than an individual's home.","Away from Home | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1770621","PSA Level Greater than 0 but Less than 0.2","C182129","A blood concentration of prostate specific antigen greater than 0 and less than 0.2 ng/mL.","PSA Level Greater than 0 but Less than 0.2 | PSA Level 0 to 0.2 | PSA Level Between 0 and 0.2 | PSA Level Between Zero and 0.2 | PSA Level Greater Than 0 but Less Than 0.2 | PSA Level Greater than 0 but Less than 0.2 ng/mL | PSA Level Greater than Zero but Less than 0.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664964","Feel Healthy","C182014","A response indicating that an individual feels or felt healthy.","Feel Healthy | Feel Good | Felt Good | Felt Healthy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773203","Well","C182125","A subjective response of good agreement or ability.","Well | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773340","Not Well","C182124","A subjective response of poor agreement or ability.","Not Well | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026609","Motor Neuron","C12644","An efferent neuron that sends impulses from the central nervous system to skeletal muscles.","Motor Neuron | Efferent Neuron | Motoneuron | Motor Neurons",,,,,,,,,,,,,,,"4135600","Motor neuron",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3550922","Psychomotor Retardation","C117194","Abnormally slow physical movement.","Psychomotor Retardation | ",,,,,,,,,,,,,,,"606336","Psychomotor retardation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1453161","LY9 protein, human","C182440","T-lymphocyte surface antigen Ly-9 (655 aa, ~72 kDa) is encoded by the human LY9 gene. This protein is involved in the positive regulation of helper T-cell Th17 differentiation.","T-Lymphocyte Surface Antigen Ly-9 | CD229 | CD229 Antigen | Cell Surface Molecule Ly-9 | LY9 | Lymphocyte Antigen 9 | SLAM Family Member 3 | SLAMF3 | Signaling Lymphocytic Activation Molecule 3 | T-lymphocyte surface antigen Ly-9 | cluster of differentiation 229",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2750808","Stereotypy","C116731","Persistent repetition of non-purposeful speech or movement.","Stereotypy | ",,,,,,,,,,,,,,,"4207660","Stereotypy habit disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3554322","Parkinsonism","C116922","One or more of the following symptoms including bradykinesia associated with rigidity, resting tremor, gait disturbance, which may be due to multiple etiologies.","Parkinsonism | Parkinsonian Symptoms",,,,,,,,,,,,,,,"4140090","Parkinsonism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL474527","Myoclonus","C116924","A rapid, involuntary jerk of a muscle or group of muscles.","Myoclonus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3554084","Bradykinesia","C116707","Slow movement.","Bradykinesia | ",,,,,,,,,,,,,,,"4161417","Bradykinesia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0233471","Flat Affect","C117196","The absence of emotional expressiveness.","Flat Affect | ",,,,,,,,,,,,,,,"4245464","Flat affect",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2985212","Cells per Millimeter Squared","C92614","A cell based measurement for cell count per square millimeter area.","Cells per Millimeter Squared | cells/m2 | cells/mm2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227961","Posterior Surface of the Prostate","C13095","The flattened aspect of the prostate with a slight furrow facing the rectum and anus.","Posterior Surface of the Prostate | ",,,,,,,,,,,,,,,"4174378","Structure of posterior surface of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1517752","Lateral Surface of the Prostate","C32949","The aspect of the prostate facing the anterior portions of the Levatores ani muscles.","Lateral Surface of the Prostate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227960","Anterior Surface of the Prostate","C13089","The aspect of the prostate facing the pubic symphysis.","Anterior Surface of the Prostate | ",,,,,,,,,,,,,,,"4290548","Structure of anterior surface of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1771126","Tumor Antigen Escape","C182446","A mechanism by which tumor cells evade the host immune system or targeted therapy through loss, downregulation, or modification of target antigens.","Tumor Antigen Escape | Tumor Antigenic Escape",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771127","Pulse Steroids","C182447","Intermittent therapeutic administration of high doses of steroids over short periods of time.","Pulse Steroids | Corticosteroids - Pulse dose | Pulse Steroid Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0666480","Tumor Necrosis Factor Receptor Superfamily Member 13B, Human","C127903","Tumor necrosis factor receptor superfamily member 13B (293 aa, ~32 kDa) is encoded by the human TNFRSF13B gene. This protein plays a role in cytokine binding and lymphocyte activation.","Tumor Necrosis Factor Receptor Superfamily Member 13B | CD267 Antigen | TACI | TNFRSF13B | Transmembrane Activator and CAML Interactor | Tumor Necrosis Factor Receptor 13B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538763","KLRK1 wt Allele","C101751","Human KLRK1 wild-type allele is located within 12p13.2-p12.3 and is approximately 19 kb in length. This allele, which encodes NKG2-D type II integral membrane protein, is involved in both ligand binding and lymphocyte activation.","KLRK1 wt Allele | CD314 | D12S2489E | DNA Segment on Chromosome 12 (Unique) 2489 Expressed Sequence Gene | FLJ17759 | FLJ75772 | KLR | Killer Cell Lectin-Like Receptor Subfamily K, Member 1 wt Allele | NKG2-D | NKG2D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545782","GPRC5D Gene","C147934","This gene plays a role in retinoid acid-independent G protein-coupled receptor signaling.","GPRC5D Gene | G Protein-Coupled Receptor Class C Group 5 Member D Gene | GPRC5D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0123745","ITGB7 protein, human","C104253","Integrin beta-7 (798 aa, ~87 kDa) is encoded by the human ITGB7 gene. This protein plays a role in both cell adhesion and the mediation of integrin signaling.","Integrin Beta-7 | Gut Homing Receptor Beta Subunit | ITGB7 | Integrin Beta 7 Subunit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664531","Cross-Reactive Binding Antidrug IgM Antibody Measurement","C181380","The determination of the cross-reactive antidrug binding IgM antibody in a biospecimen.","Cross-Reactive Binding Antidrug IgM Antibody Measurement | ADBXIGM | Cross-Reactive Binding Antidrug IgM AB | Cross-Reactive Binding Antidrug IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664530","Cross-Reactive Binding Antidrug IgE Antibody Measurement","C181379","The determination of the cross-reactive antidrug binding IgE antibody in a biospecimen.","Cross-Reactive Binding Antidrug IgE Antibody Measurement | ADBXIGE | Cross-Reactive Binding Antidrug IgE AB | Cross-Reactive Binding Antidrug IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664533","Cross-Reactive Binding Antidrug IgA Antibody Measurement","C181378","The determination of the cross-reactive antidrug binding IgA antibody in a biospecimen.","Cross-Reactive Binding Antidrug IgA Antibody Measurement | ADBXIGA | Cross-Reactive Binding Antidrug IgA AB | Cross-Reactive Binding Antidrug IgA Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664532","Neutralizing Binding Antidrug IgG4 Antibody Measurement","C181377","The determination of the neutralizing antidrug binding IgG4 antibody in a biospecimen.","Neutralizing Binding Antidrug IgG4 Antibody Measurement | ADNIGG4 | Neutralizing Binding Antidrug IgG4 AB | Neutralizing Binding Antidrug IgG4 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664528","Neutralizing Cross-Reactive Binding Antidrug Antibody IgG/IgM Measurement","C181389","The determination of the neutralizing cross-reactive antidrug binding IgG and/or IgM antibody in a biospecimen.","Neutralizing Cross-Reactive Binding Antidrug Antibody IgG/IgM Measurement | ADNXIGGM | Neut Cross-Reactive Binding ADA IgG/IgM | Neutralizing Cross-Reactive Binding Antidrug IgG/IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664523","Neutralizing Cross-Reactive Binding Antidrug Antibody IgM Measurement","C181388","The determination of the neutralizing cross-reactive antidrug binding IgM antibody in a biospecimen.","Neutralizing Cross-Reactive Binding Antidrug Antibody IgM Measurement | ADNXIGM | Neut Cross-Reactive Binding ADA IgM | Neutralizing Cross-Reactive Binding Antidrug IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664522","Neutralizing Cross-Reactive Binding Antidrug Antibody IgE Measurement","C181387","The determination of the neutralizing cross-reactive antidrug binding IgE antibody in a biospecimen.","Neutralizing Cross-Reactive Binding Antidrug Antibody IgE Measurement | ADNXIGE | Neut Cross-Reactive Binding ADA IgE | Neutralizing Cross-Reactive Binding Antidrug IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664525","Neutralizing Cross-Reactive Binding Antidrug Antibody IgA Measurement","C181386","The determination of the neutralizing cross-reactive antidrug binding IgA antibody in a biospecimen.","Neutralizing Cross-Reactive Binding Antidrug Antibody IgA Measurement | ADNXIGA | Neut Cross-Reactive Binding ADA IgA | Neutralizing Cross-Reactive Binding Antidrug IgA Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664524","Cross-Reactive Binding Antidrug IgG4 Antibody Measurement","C181385","The determination of the cross-reactive antidrug binding IgG4 antibody in a biospecimen.","Cross-Reactive Binding Antidrug IgG4 Antibody Measurement | ADBXIGG4 | Cross-Reactive Binding Antidrug IgG4 AB | Cross-Reactive Binding Antidrug IgG4 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664535","Cross-Reactive Binding Antidrug IgG3 Antibody Measurement","C181384","The determination of the cross-reactive antidrug binding IgG3 antibody in a biospecimen.","Cross-Reactive Binding Antidrug IgG3 Antibody Measurement | ADBXIGG3 | Cross-Reactive Binding Antidrug IgG3 AB | Cross-Reactive Binding Antidrug IgG3 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664534","Cross-Reactive Binding Antidrug IgG2 Antibody Measurement","C181383","The determination of the cross-reactive antidrug binding IgG2 antibody in a biospecimen.","Cross-Reactive Binding Antidrug IgG2 Antibody Measurement | ADBXIGG2 | Cross-Reactive Binding Antidrug IgG2 AB | Cross-Reactive Binding Antidrug IgG2 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664537","Cross-Reactive Binding Antidrug IgG1 Antibody Measurement","C181382","The determination of the cross-reactive antidrug binding IgG1 antibody in a biospecimen.","Cross-Reactive Binding Antidrug IgG1 Antibody Measurement | ADBXIGG1 | Cross-Reactive Binding Antidrug IgG1 AB | Cross-Reactive Binding Antidrug IgG1 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664536","Cross-Reactive Binding Antidrug Antibody IgG/IgM Measurement","C181381","The determination of the cross-reactive antidrug binding IgG and/or IgM antibody in a biospecimen.","Cross-Reactive Binding Antidrug Antibody IgG/IgM Measurement | ADBXIGGM | Cross-Reactive Binding ADA IgG/IgM | Cross-Reactive Binding Antidrug IgG/IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664520","Cytokine-secreting Cells Measurement","C181400","The determination of the cytokine-secreting cells in a biospecimen.","Cytokine-secreting Cells Measurement | CYKSCCL | Cytokine-secreting Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664958","Antibody-secreting Cells Measurement","C181399","The determination of the antibody-secreting cells in a biospecimen.","Antibody-secreting Cells Measurement | ABSCCL | Antibody-secreting Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664521","Allergen-induced IgE Antibody Measurement","C181398","The determination of the allergen-induced, binding IgE antibody in a biospecimen.","Allergen-induced IgE Antibody Measurement | ARIGEAB | Allergen-induced IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272321","Autoantibody Measurement","C181397","The determination of the binding autoantibody in a biospecimen.","Autoantibody Measurement | ATAB | Autoantibody",,,,,,,,,,,,,,,"4192936","Autoantibody measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1664517","Neutralizing Microbial-induced Antibody Measurement","C181396","The determination of the neutralizing binding of microbial-induced antibody in a biospecimen. A neutralizing microbial-induced antibody is a type of functional antibody that's defined as antibodies that bind to, block and prevent microbes from infecting cells. The production of this antibody may be triggered by naturally occurring infection and/or vaccination using a whole microbe or component(s) of a microbe.","Neutralizing Microbial-induced Antibody Measurement | MBNAB | Neutralizing Microbial-induced Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664516","Functional Microbial-induced Antibody Measurement","C181395","The determination of the functional binding of microbial-induced antibody in a biospecimen. A functional microbial-induced antibody is defined as antibodies that have agonist or antagonist effects on pathogens or their toxins in the presence of other effector molecules or cells. For example, the effects of functional antibodies can include neutralization, phagocytosis, antibody-dependent cellular cytotoxicity, and complement-mediated lysis. The production of this antibody may be triggered by naturally occurring infection and/or vaccination using a whole microbe or component(s) of a microbe.","Functional Microbial-induced Antibody Measurement | Functional Microbial-induced Antibody | MBFAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664519","Microbial-induced IgG Antibody Measurement","C181394","The determination of the microbial-induced, binding IgG antibody in a biological specimen; the production of this antibody may be triggered by naturally occurring infection and/or vaccination using a whole microbe or component(s) of a microbe.","Microbial-induced IgG Antibody Measurement | MBIGGAB | Microbial-induced IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664518","Neutralizing Cross-Reactive Binding Antidrug Antibody IgG4 Measurement","C181393","The determination of the neutralizing cross-reactive antidrug binding IgG4 antibody in a biospecimen.","Neutralizing Cross-Reactive Binding Antidrug Antibody IgG4 Measurement | ADNXIGG4 | Neut Cross-Reactive Binding ADA IgG4 | Neutralizing Cross-Reactive Binding Antidrug IgG4 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664527","Neutralizing Cross-Reactive Binding Antidrug Antibody IgG3 Measurement","C181392","The determination of the neutralizing cross-reactive antidrug binding IgG3 antibody in a biospecimen.","Neutralizing Cross-Reactive Binding Antidrug Antibody IgG3 Measurement | ADNXIGG3 | Neut Cross-Reactive Binding ADA IgG3 | Neutralizing Cross-Reactive Binding Antidrug IgG3 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664526","Neutralizing Cross-Reactive Binding Antidrug Antibody IgG2 Measurement","C181391","The determination of the neutralizing cross-reactive antidrug binding IgG2 antibody in a biospecimen.","Neutralizing Cross-Reactive Binding Antidrug Antibody IgG2 Measurement | ADNXIGG2 | Neut Cross-Reactive Binding ADA IgG2 | Neutralizing Cross-Reactive Binding Antidrug IgG2 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664529","Neutralizing Cross-Reactive Binding Antidrug Antibody IgG1 Measurement","C181390","The determination of the neutralizing cross-reactive antidrug binding IgG1 antibody in a biospecimen.","Neutralizing Cross-Reactive Binding Antidrug Antibody IgG1 Measurement | ADNXIGG1 | Neut Cross-Reactive Binding ADA IgG1 | Neutralizing Cross-Reactive Binding Antidrug IgG1 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664368","Cross-Reactive Binding Antidrug IgG Antibody Measurement","C181190","The determination of the amount of cross-reactive binding antidrug IgG antibody present in a sample.","Cross-Reactive Binding Antidrug IgG Antibody Measurement | ADBXIGG | Cross-Reactive Binding Antidrug IgG AB | Cross-Reactive Binding Antidrug IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664367","Neutralizing Binding Antidrug IgG Antibody Measurement","C181189","The determination of the amount of neutralizing binding antidrug IgG antibody present in a sample.","Neutralizing Binding Antidrug IgG Antibody Measurement | ADNIGG | Neutralizing Binding Antidrug IgG AB | Neutralizing Binding Antidrug IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664364","Binding Antidrug IgG Antibody Measurement","C181188","The determination of the amount of binding antidrug IgG antibody present in a sample.","Binding Antidrug IgG Antibody Measurement | ADBIGG | Binding Antidrug IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664540","Binding Antidrug IgG4 Antibody Measurement","C181369","The determination of the antidrug binding IgG4 antibody in a biospecimen.","Binding Antidrug IgG4 Antibody Measurement | ADBIGG4 | Binding Antidrug IgG4 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664551","Binding Antidrug IgG3 Antibody Measurement","C181368","The determination of the antidrug binding IgG3 antibody in a biospecimen.","Binding Antidrug IgG3 Antibody Measurement | ADBIGG3 | Binding Antidrug IgG3 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664550","Binding Antidrug IgG2 Antibody Measurement","C181367","The determination of the antidrug binding IgG2 antibody in a biospecimen.","Binding Antidrug IgG2 Antibody Measurement | ADBIGG2 | Binding Antidrug IgG2 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664553","Binding Antidrug IgG1 Antibody Measurement","C181366","The determination of the antidrug binding IgG1 antibody in a biospecimen.","Binding Antidrug IgG1 Antibody Measurement | ADBIGG1 | Binding Antidrug IgG1 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664552","Binding Antidrug IgG/IgM Antibody Measurement","C181365","The determination of the antidrug binding IgG and/or IgM antibody in a biospecimen.","Binding Antidrug IgG/IgM Antibody Measurement | ADBIGGM | Binding Antidrug IgG/IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664547","Binding Antidrug IgM Antibody Measurement","C181364","The determination of the antidrug binding IgM antibody in a biospecimen.","Binding Antidrug IgM Antibody Measurement | ADBIGM | Binding Antidrug IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664546","Binding Antidrug IgE Antibody Measurement","C181363","The determination of the antidrug binding IgE antibody in a biospecimen.","Binding Antidrug IgE Antibody Measurement | ADBIGE | Binding Antidrug IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664549","Binding Antidrug IgA Antibody Measurement","C181362","The determination of the antidrug binding IgA antibody in a biospecimen.","Binding Antidrug IgA Antibody Measurement | ADBIGA | Binding Antidrug IgA Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664365","Neutralizing Cross-Reactive Binding Antidrug Antibody IgG Measurement","C181191","The determination of the amount of neutralizing cross-reactive binding antidrug antibody IgG present in a sample.","Neutralizing Cross-Reactive Binding Antidrug Antibody IgG Measurement | ADNXIGG | Neut Cross-Reactive Binding ADA IgG | Neutralizing Cross-Reactive Binding Antidrug IgG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664539","Neutralizing Binding Antidrug IgM Antibody Measurement","C181372","The determination of the neutralizing antidrug binding IgM antibody in a biospecimen.","Neutralizing Binding Antidrug IgM Antibody Measurement | ADNIGM | Neutralizing Binding Antidrug IgM AB | Neutralizing Binding Antidrug IgM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664538","Neutralizing Binding Antidrug IgE Antibody Measurement","C181371","The determination of the neutralizing antidrug binding IgE antibody in a biospecimen.","Neutralizing Binding Antidrug IgE Antibody Measurement | ADNIGE | Neutralizing Binding Antidrug IgE AB | Neutralizing Binding Antidrug IgE Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664541","Neutralizing Binding Antidrug IgA Antibody Measurement","C181370","The determination of the neutralizing antidrug binding IgA antibody in a biospecimen.","Neutralizing Binding Antidrug IgA Antibody Measurement | ADNIGA | Neutralizing Binding Antidrug IgA AB | Neutralizing Binding Antidrug IgA Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664543","Neutralizing Binding Antidrug IgG3 Antibody Measurement","C181376","The determination of the neutralizing antidrug binding IgG3 antibody in a biospecimen.","Neutralizing Binding Antidrug IgG3 Antibody Measurement | ADNIGG3 | Neutralizing Binding Antidrug IgG3 AB | Neutralizing Binding Antidrug IgG3 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664542","Neutralizing Binding Antidrug IgG2 Antibody Measurement","C181375","The determination of the neutralizing antidrug binding IgG2 antibody in a biospecimen.","Neutralizing Binding Antidrug IgG2 Antibody Measurement | ADNIGG2 | Neutralizing Binding Antidrug IgG2 AB | Neutralizing Binding Antidrug IgG2 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664545","Neutralizing Binding Antidrug IgG1 Antibody Measurement","C181374","The determination of the neutralizing antidrug binding IgG1 antibody in a biospecimen.","Neutralizing Binding Antidrug IgG1 Antibody Measurement | ADNIGG1 | Neutralizing Binding Antidrug IgG1 AB | Neutralizing Binding Antidrug IgG1 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664544","Neutralizing Binding Antidrug IgG/IgM Antibody Measurement","C181373","The determination of the neutralizing antidrug binding IgG and/or IgM antibody in a biospecimen.","Neutralizing Binding Antidrug IgG/IgM Antibody Measurement | ADNIGGM | Neutralizing Binding Antidrug IgG/IgM AB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664973","Salmonella Measurement","C181460","The determination of the organisms that are assigned to the Salmonella genus level in a biospecimen.","Salmonella Measurement | SALMONEL | Salmonella",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664576","Shigella Measurement","C181459","The determination of the organisms that are assigned to the Shigella genus level in a biospecimen.","Shigella Measurement | SHIGELLA | Shigella",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664962","Vaccinia Virus Measurement","C181458","The determination of the Vaccinia virus in a biospecimen.","Vaccinia Virus Measurement | VACCINIA | Vaccinia Virus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664577","Human Poliovirus 3 Neutralizing Antibody Measurement","C181457","The determination of the Human poliovirus 3 neutralizing antibody in a biospecimen.","Human Poliovirus 3 Neutralizing Antibody Measurement | ENC3NAB | Human Poliovirus 3 Neutralizing Antibody | Type 3 Poliovirus Neutralizing Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664585","Human Poliovirus 1 Neutralizing Antibody Measurement","C181456","The determination of the Human poliovirus 1 neutralizing antibody in a biospecimen.","Human Poliovirus 1 Neutralizing Antibody Measurement | ENC1NAB | Human Poliovirus 1 Neutralizing Antibody | Type 1 Poliovirus Neutralizing Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664432","Greulich and Pyle Bone Age Estimation","C181502","An estimated assessment of an individual's skeletal maturity (bone age) based on comparison of standard radiographic images of the bones of the hand and wrist. (Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist. The American Journal of the Medical Sciences. 1959;238(3):393.)","Greulich and Pyle Bone Age Estimation | GPBAEST | Greulich and Pyle Skeletal Maturity Estimation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664431","Muscle Endurance Measurement","C181501","A measurement of a muscle's ability to perform repetitive contractions against a force.","Muscle Endurance Measurement | ENDURM | Muscle Endurance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664426","Isometric Muscle Strength, Adduction","C181500","An assessment of muscle strength that measures the force produced by static muscle contraction during the movement of a body part toward the midline of the body.","Isometric Muscle Strength, Adduction | ISOMSADD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664425","Isometric Muscle Strength, External Rotation","C181499","An assessment of muscle strength that measures the force produced by static muscle contraction during the rotational movement of a body part outward, away from the body.","Isometric Muscle Strength, External Rotation | ISOMSER | Isometric Muscle Strength, Extern Rotat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664428","Isometric Muscle Strength, Internal Rotation","C181498","An assessment of muscle strength that measures the force produced by static muscle contraction during the rotational movement of a body part inward, toward the body.","Isometric Muscle Strength, Internal Rotation | ISOMSIR | Isometric Muscle Strength, Intern Rotat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664427","Isometric Muscle Strength, Dorsiflexion","C181497","An assessment of muscle strength that measures the force produced by static muscle contraction during the movement of a body part bending upwards towards the dorsal surface of the body.","Isometric Muscle Strength, Dorsiflexion | ISOMSDOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664437","Isometric Muscle Strength, Abduction","C181496","An assessment of muscle strength that measures the force produced by static muscle contraction during the movement of a body part away from the midline of the body.","Isometric Muscle Strength, Abduction | ISOMSABD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664486","Auditory Brainstem Response Wave V, Presence","C181575","An assessment of the presence of the auditory brainstem response wave V of the auditory evoked potential waveform.","Auditory Brainstem Response Wave V, Presence | ABR Wave V, Presence | ABRVP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664489","Auditory Brainstem Response Wave V, Amplitude","C181574","A measurement of the magnitude, or height, of the auditory brainstem response wave V of the auditory evoked potential waveform.","Auditory Brainstem Response Wave V, Amplitude | ABR Wave V, Amplitude | ABRVA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664488","Auditory Brainstem Response Wave V, Absolute Latency","C181573","A measurement of the absolute latency of the auditory brainstem response wave V of the auditory evoked potential waveform.","Auditory Brainstem Response Wave V, Absolute Latency | ABR Wave V, Absolute Latency | ABRVAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664483","Auditory Brainstem Response Wave I, Absolute Latency","C181572","A measurement of the absolute latency of the auditory brainstem response wave I of the auditory evoked potential waveform.","Auditory Brainstem Response Wave I, Absolute Latency | ABR Wave I, Absolute Latency | ABRIAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664430","Corrective Lens Type for Distance","C181512","A description of the type of eye lens(es) worn by the subject to correct for distance.","Corrective Lens Type for Distance | CLDISTYP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664429","Corrective Lens for Distance Indicator","C181511","An indication as to whether an eye lens(es) is worn by the subject to correct for distance.","Corrective Lens for Distance Indicator | CLDISIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0554976","Bradyphrenia","C182449","Slowness of mental processing that is associated with cerebral dysfunction.","Bradyphrenia | ",,,,,,,,,,,,,,,"4111210","Bradyphrenia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0233643","Incoherent","C182450","Unintelligibility of verbal or written communication due to a lack of clarity or connectedness.","Incoherent | Incoherence | Incoherent  | Incoherent Expression",,,,,,,,,,,,,,,"4272627","Incoherent thinking",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3810448","Cogwheel Rigidity","C182451","Muscular rigidity that is characterized by jerky incremental movements of a limb when passively moved through the range of motion of a joint. Cogwheel rigidity is often an early sign of Parkinson's disease.","Cogwheel Rigidity | Cogwheeling",,,,,,,,,,,,,,,"4208094","Cogwheel muscle rigidity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0234144","Dysgraphia","C182452","A neurological disorder characterized by impairment of handwriting ability that may be associated with other learning disabilities in children or traumatic damage to the parietal lobe in adults.","Dysgraphia | ",,,,,,,,,,,,,,,"4339222","Dysgraphia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3278729","Essential Tremor","C182453","A movement disorder characterized by involuntary and rhythmic shaking of parts of the body, most often the hands or arms, that can be triggered or worsened by physical or environmental stressors. Essential tremor may be progressive and can be inherited in an autosomal dominant manner.","Essential Tremor | ",,,,,,,,,,,,,,,"43531003","Essential tremor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1664414","Hour Times Milli-international Unit per Milliliter","C181522","Hours times milli-international units per milliliter.","Hour Times Milli-international Unit per Milliliter | h*mIU/mL | h.mIU/mL | h.mIU/ml | mIU*h/mL | mIU.h/mL | mIU.h/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664413","Hour Times Micro-international Unit per Milliliter","C181521","Hours times microinternational units per milliliter.","Hour Times Micro-international Unit per Milliliter | h*uIU/mL | h.uIU/mL | h.uIU/ml | uIU*h/mL | uIU.h/mL | uIU.h/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664950","Percent Administered Dose Recovered Per Gram","C181520","Percentage of the administered dose recovered per gram of matrix or tissue, normalized by the sample weight.","Percent Administered Dose Recovered Per Gram | %/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4012958","Resting Tremor","C182454","A movement disorder characterized by involuntary and rhythmic shaking of a body part that is relaxed and not held against gravity, and where the tremor amplitude decreases with voluntary movements. Resting tremor is a common sign of Parkinson's disease.","Resting Tremor | Rest Tremor",,,,,,,,,,,,,,,"4096245","Resting tremor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508414","Hypomimia","C182455","Diminished facial expressiveness due to a loss of motor control of the muscles in the face. Hypomimia is a common sign of Parkinson's disease.","Hypomimia | Facial Masking | Reduced facial expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771138","Comma Separated Values Format","C182456","A text file format that separates data elements with commas.","Comma Separated Values Format | CSV | CSV Format | Comma-separated Values Format",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2986847","Standardized Uptake Value Peak","C95013","Standardized uptake value of the average for a limited number pixels (voxels) that includes the pixel (voxel) having SUVmax.","Standardized Uptake Value Peak | Peak Standardized Uptake Value | SUVPEAK | SUVpeak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664503","Peak Standardized Uptake Value Corrected for Lean Body Mass","C181547","The peak of standardized uptake value corrected for lean body mass distribution, generated by a histogram of all SUV values, across a defined area or volume of interest (VOI).","Peak Standardized Uptake Value Corrected for Lean Body Mass | SULPEAK | SUV Peak Corrected for Lean Body Mass | Standardized Uptake Value Peak Corrected for Lean Body Mass",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664505","Mean Standardized Uptake Value Corrected for Lean Body Mass","C181546","The arithmetic mean of a group of standardized uptake values corrected for lean body mass within a defined area or volume of interest (VOI).","Mean Standardized Uptake Value Corrected for Lean Body Mass | SULMEAN | SUV Mean Corrected for Lean Body Mass | Standardized Uptake Value Mean Corrected for Lean Body Mass",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664504","Maximum Standardized Uptake Value Corrected for Lean Body Mass","C181545","The standardized uptake value corrected for lean body mass of the pixel or voxel with the strongest signal, within a defined area or volume of interest (VOI).","Maximum Standardized Uptake Value Corrected for Lean Body Mass | SULMAX | SUV Maximum Corrected for Lean Body Mass | Standardized Uptake Value Maximum Corrected for Lean Body Mass",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272866","Standardized Uptake Value Mean","C181544","The arithmetic mean of a group of standardized (by total body weight) uptake values within a defined area or volume of interest (VOI).","Standardized Uptake Value Mean | Average Metabolic Standard Uptake Value | Mean Standardized Uptake Value | SUVMEAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664622","IDMS-MDRD Study Equation With JSN-CKDI Coefficient 0.741 Imai et al. 2007","C181401","A formula to estimate glomerular filtration rate in Japanese subjects that takes into account age, sex, and serum creatinine. eGFR (mL/min/1.73 m2) = 0.741 x SCr^-1.154 x 175 x Age^-0.203 x 0.742 (if female). (Enyu Imai, Masaru Horio, Kosaku Nitta, Kunihiro Yamagata, Kunitoshi Iseki, Yusuke Tsukamoto, Sadayoshi Ito, Hirofumi Makino, Akira Hishida, Seiichi Matsuo. Modification of the Modification of Diet in Renal Disease (MDRD) Study Equation for Japan. Am J Kidney Dis. 2007 Dec;50(6):927-37.)","IDMS-MDRD Study Equation With JSN-CKDI Coefficient 0.741 Imai et al. 2007 | IDMS-MDRD STUDY EQUATION WITH JSN-CKDI COEFFICIENT 0.741 IMAI 2007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664412","Subdural Route of Administration","C181523","Administration beneath the dura mater.","Subdural Route of Administration | SUBDURAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664578","Cold Precipitation","C181464","The process of precipitating proteins from solution by exposing the sample to cold temperatures.","Cold Precipitation | COLD PRECIPITATION | Cryoprecipitation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162621","Titrimetry","C181463","Adjust a condition by a dropwise addition of a solution.","Titrimetry | TITRIMETRY | Titration | Titration Method",,,,,,,,,,,,,,,"4024955","Titration method",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1664580","Secondary Electrospray Ionization High-resolution Mass Spectrometry","C181462","A type of mass spectrometry in which a nano-electrospray produces charging agents that collide with analyte molecules in gas-phase, creating an ionized vapor that is then analyzed via high resolution mass spectrometry.","Secondary Electrospray Ionization High-resolution Mass Spectrometry | SESI-HRMS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664579","Penicillin Zone Edge","C181461","A method that is used to detect beta-lactamase production by assessing the zone edge of penicillin-susceptible bacteria isolates after disk diffusion. A fuzzy zone edge indicates a beta-lactamase negative result and a sharp zone edge indicates a beta-lactamase positive result.","Penicillin Zone Edge | DISK DIFFUSION ZONE EDGE TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471823","Susceptibility Weighted Imaging","C121377","An imaging technique that uses phase differences between tissues due to differences in magnetic susceptibilities to produce an enhanced contrast magnitude image. These phase differences can provide excellent contrast between gray matter and white matter, iron-laden tissues, venous blood vessels, and other tissues with susceptibilities that are different from the background tissue. The technique is commonly used for imaging in cases of traumatic brain injuries and for high resolution brain venographies.","Susceptibility Weighted Imaging | BOLD Venographic Imaging | BOLD Venography | SUSCEPTIBILITY WEIGHTED MRI | SWI | SWI MRI | SWI-Phase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664446","H Score Staining Intensity 3+","C181476","A measurement of the amount or proportion of cells that have a staining intensity of 3+, based on the H Score scoring system, in a biological specimen. (McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716-721).","H Score Staining Intensity 3+ | H SCORE STAINING INTENSITY 3+",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664445","H Score Staining Intensity 2+","C181475","A measurement of the amount or proportion of cells that have a staining intensity of 2+, based on the H Score scoring system, in a biological specimen. (McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716-721).","H Score Staining Intensity 2+ | H SCORE STAINING INTENSITY 2+",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664448","H Score Staining Intensity 1+","C181474","A measurement of the amount or proportion of cells that have a staining intensity of 1+, based on the H Score scoring system, in a biological specimen. (McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716-721).","H Score Staining Intensity 1+ | H SCORE STAINING INTENSITY 1+",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664447","H Score Staining Intensity 0","C181473","A measurement of the amount or proportion of cells that have a staining intensity of 0, based on the H Score scoring system, in a biological specimen. (McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716-721).","H Score Staining Intensity 0 | H SCORE STAINING INTENSITY 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664456","Non-Alcoholic Fatty Liver Disease Activity Score","C181472","The histopathological evaluation of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) based on the NAFLD scoring system. (Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005 Jun;41(6):1313-21.)","Non-Alcoholic Fatty Liver Disease Activity Score | NAFLD ACTIVITY SCORE | NAFLD Activity Score | NAS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664455","iDworak et al Tumor Regression Grade (1997)","C181471","A grading system developed by Dworak et al (1997) to assess a decrease in tumor size or extent in the body. (Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. (1997) 12:19-23.)","iDworak et al Tumor Regression Grade (1997) | IDWORAK TUMOR REGRESSION GRADE 1997",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664458","Hartman et al Tumor Regression Grade (2012)","C181470","A grading system developed by Hartman et al (2012) to assess a decrease in tumor size or extent in the body (Hartman DJ, Krasinskas AM. Assessing treatment effect in pancreatic cancer. Arch Pathol Lab Med. (2012) 136:100-9.)","Hartman et al Tumor Regression Grade (2012) | HARTMAN TUMOR REGRESSION GRADE 2012",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664457","Evans et al Tumor Regression Grade (1992)","C181469","A grading system developed by Evans et al (1992) to assess a decrease in tumor size or extent in the body. (Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. (1992) 127:1335-9.)","Evans et al Tumor Regression Grade (1992) | EVANS TUMOR REGRESSION GRADE 1992",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664454","MD Anderson Tumor Regression Grade (2012)","C181468","A grading system developed by Chatterjee et al (2012) to assess a decrease in tumor size or extent in the body. (Chatterjee D, Katz MH, Rashid A, Wolff RA, Wang H, Lee JE, et al. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. Cancer. (2012) 118:3182-90.)","MD Anderson Tumor Regression Grade (2012) | MD ANDERSON TUMOR REGRESSION GRADE 2012",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664453","College of American Pathology Tumor Regression Grade","C181467","A grading system developed by the College of American Pathology to assess a decrease in tumor size or extent in the body (Shi C, Adsay V, Bergsland E, Berlin J, Branton P, Fitzgibbons P, et al. College of American pathologist, protocol for the examination of specimens from patients with carcinoma of the pancreas. Version: PancreasExocrine 4.0.0.1. (2017).)","College of American Pathology Tumor Regression Grade | CAP TUMOR REGRESSION GRADE | CAP Tumor Regression Grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664506","Hundred Thousand Colony Forming Units per Milliliter","C181551","A unit of measurement of colony forming cells or microorganisms in a unit volume of substance of interest defined as the number of 10 to the fifth power colony forming units in one milliliter of substance.","Hundred Thousand Colony Forming Units per Milliliter | 10*5.[CFU]/mL | 10*5.[CFU]/ml | 10^5 CFU/mL | 10^5.[CFU]/mL | 10^5.[CFU]/ml | Hundred Thousand CFU/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664422","Mean Residence Time Intravenous Continuous Infusion to Last Nonzero Concentration","C181519","Mean residence time (MRT) from the time of dosing to the time of the last measurable concentration, for a substance administered by constant rate of continuous intravascular infusion.","Mean Residence Time Intravenous Continuous Infusion to Last Nonzero Concentration | MRT IV Cont Inf to Last Nonzero Conc | MRTICLST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664424","Mean Residence Time Intravenous Continuous Infusion Infinity Predicted","C181518","The mean residence time (MRT) extrapolated to infinity for a substance administered by constant rate of continuous intravascular infusion, calculated using the predicted value of the last non-zero concentration.","Mean Residence Time Intravenous Continuous Infusion Infinity Predicted | MRT IV Cont Inf Infinity Pred | MRTICIFP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664423","Mean Residence Time Intravenous Continuous Infusion Infinity Observed","C181517","The mean residence time (MRT) extrapolated to infinity for a substance administered by constant rate of continuous intravascular infusion, calculated using the observed value of the last non-zero concentration.","Mean Residence Time Intravenous Continuous Infusion Infinity Observed | MRT IV Cont Inf Infinity Obs | MRTICIFO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664420","Average of Trough Concentration","C181516","The arithmetic average of two or more trough concentrations.","Average of Trough Concentration | Average of Conc Trough | CAVGTR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664419","Concentration at End Infusion","C181515","The observed concentration at the end of the infusion.","Concentration at End Infusion | CONCEINF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664421","Amount of Analyte at Time T","C181514","The amount of analyte in the body at any time t.","Amount of Analyte at Time T | AMTT | Amt of Analyte at Time T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663197","Amount of Analyte at Steady State","C181513","The amount of analyte in the body at steady state.","Amount of Analyte at Steady State | AMSS | Amt of Analyte at Steady State",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3489408","Hospital Stays","C171453","The subject or patient has been admitted as an inpatient to a hospital.","Hospital Stay | HOSPITAL STAY | Inpatient Hospital Stay | Inpatient Hospitalization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2699082","Right Anteroinferior Segment","C79736","Couinaud segment V, corresponding to the anterior segment of the right lobe of the liver, located inferiorly.","Right Anteroinferior Segment | Couinaud Segment V | LIVER, RIGHT LOBE ANTEROINFERIOR SEGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224452","Semimembranosus Muscle","C52987","One of the three muscles that compose the hamstring muscles (semitendinosus, semimembranosus, bicepsfemoris); it is located in the posterior compartment of the thigh, and originates from the ischial tuberosity, inserts on the medial tibial condyle, and functions, in conjunction with the other muscles of the hamstring group, to extend the leg at the hip and to flex the leg at the knee.","Semimembranosus Muscle | MUSCLE, SEMIMEMBRANOSUS | SEMIMEMBRANOSUS MUSCLE",,,,,,,,,,,,,,,"4223222","Semimembranosus muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0228214","Supramarginal Gyrus","C33706","A convolution located on the anterior part of the inferior parietal lobe of the brain. In the dominant hemisphere, it plays a role in the comprehension of written language.","Supramarginal Gyrus | SUPRAMARGINAL GYRUS",,,,,,,,,,,,,,,"4031684","Structure of supramarginal gyrus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152296","Superior Frontal Gyrus","C33674","A large region of the frontal lobe of the brain located above the superior frontal sulcus that participates with the primary motor cortex in the control and initiation of voluntary movements and possibly contributes to higher cognitive functions.","Superior Frontal Gyrus | SUPERIOR FRONTAL GYRUS | Superior Frontal Convolution",,,,,,,,,,,,,,,"4262861","Structure of superior frontal gyrus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152299","Precentral Gyrus","C33393","A convolution located on the convex side of both cerebral hemispheres, anterior to the post central gyrus and parallel to the central sulcus, which separates the pre and post central gyri; much of the primary motor cortex corresponds to this gyrus.","Precentral Gyrus | PRECENTRAL GYRUS",,,,,,,,,,,,,,,"4262691","Structure of ascending frontal gyrus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152302","Postcentral Gyrus","C33346","A large convolution located on the parietal lobe of the brain, located between the central and postcentral sulci, that corresponds to the primary somatic sensory cortex area.","Postcentral Gyrus | POSTCENTRAL GYRUS",,,,,,,,,,,,,,,"4237134","Structure of postcentral gyrus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152297","Middle Frontal Gyrus","C33118","A relatively large region on the lateral surface of the frontal lobe and part of the prefrontal cortex, which lies between the superior and the inferior frontal sulci and rostral to the precentral gyrus.","Middle Frontal Gyrus | MIDDLE FRONTAL GYRUS | Middle Frontal Convolution",,,,,,,,,,,,,,,"4252743","Structure of middle frontal gyrus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1664584","Tibial Growth Plate","C181455","A layer of cartilaginous tissue located in the tibia of children and adolescents that separates the epiphysis from the metaphysis and is the site of longitudinal bone growth until skeletal maturity.","Tibial Growth Plate | TIBIAL GROWTH PLATE | Tibial Epiphyseal Plate | Tibial Physis | Tibial Plateau Growth Plate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0926818","Oropharyngeal isthmus","C181454","The anatomical opening formed by the arch of the hard palate at the back of the mouth, where the oral cavity and pharynx meet.","Oropharyngeal Isthmus | FAUCES | Fauces | Isthmus of Fauces",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015460","Facial Muscle","C13073","A skeletal muscle located under the skin of the face that is supplied by the facial nerve and controls facial expression.","Facial Muscle | FACIAL MUSCLE | Facial Muscles | Mimetic Muscles",,,,,,,,,,,,,,,"44784133","Skeletal muscle structure of face",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039433","Tectum Mesencephali","C12460","The dorsal part or roof plate of the midbrain, which consists of the pretectal area and the paired superior and inferior colliculi.","Tectum Mesencephali | TECTUM MESENCEPHALI",,,,,,,,,,,,,,,"4056611","Tectum structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0734933","Ureterovesical Junction","C106202","The area where the ureter joins the urinary bladder.","Ureterovesical Junction | UVJ | VESICOURETERIC JUNCTION | VUJ",,,,,,,,,,,,,,,"4128125","Vesicoureteric junction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2734068","Arm Span","C181553","A measurement of the length from the tip of the middle finger on one hand to the tip of the middle finger on the other hand with the individual standing against the wall with both arms abducted to 90 degrees, the elbows and wrists extended, and the palms facing directly forward. (Philip H. Quanjer, Andre Capderou, Mumtaz M. Mazicioglu, Ashutosh N. Aggarwal, Sudip Datta Banik, Stevo Popovic, Francis A.K. Tayie, Mohammad Golshan, Mary S.M. Ip, Marc Zelter. European Respiratory Journal 2014 44: 905-912)","Arm Span | ARMSPAN | Armspan | Reach | Wingspan",,,,,,,,,,,,,,,"764566","Arm span",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1664507","Waist to Heel Length","C181552","A measurement from the top of the waist to the bottom of the heel.","Waist to Heel Length | WASTHEEL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664957","Ballooning degeneration","C181484","An evaluation of the presence or degree of hepatocellular ballooning in a sample.","Hepatocellular Ballooning Assessment | Ballooning Degeneration | HEPBLLN | Hepatocellular Ballooning",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664975","Portal Inflammation Assessment","C181483","An evaluation of the presence or degree of portal inflammation in a sample.","Portal Inflammation Assessment | PORTINF | Portal Inflammation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664441","Large Lipogranuloma Assessment","C181482","An evaluation of the presence or degree of large lipogranuloma in a sample.","Large Lipogranuloma Assessment | LPGNLMLG | Large Lipogranuloma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664440","Microgranuloma Assessment","C181481","An evaluation of the presence or degree of microgranuloma in a sample.","Microgranuloma Assessment | MCGNLM | Microgranuloma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664450","Lobular Inflammation Assessment","C181480","An evaluation of the presence or degree of lobular inflammation in a sample.","Lobular Inflammation Assessment | LOBLINF | Lobular Inflammation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664449","Microvesicular Steatosis Assessment","C181479","An evaluation of the presence or degree of crypt architectural damage in a sample.","Microvesicular Steatosis Assessment | MVSTS | Microvesicular Steatosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664452","Steatosis Location","C181478","An evaluation of the predominant distribution pattern of steatosis (fatty tissue) in a biological specimen.","Steatosis Location | STSLOC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664451","Steatosis Extent","C181477","An evaluation of the amount or degree of steatosis (fatty tissue) in a biological specimen.","Steatosis Extent | STSEXT | Steatosis Grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202148","Ecto-5'-Nucleotidase Measurement","C181656","The determination of the amount of ecto-5'-nucleotidase in a sample.","Ecto-5'-Nucleotidase Measurement | 5'-NT | 5'-NT Measurement | 5'-Nucleotidase | 5'-Nucleotidase Ecto | 5'-Nucleotidase Measurement | CD73 | E5NT | Ecto-5'-Nucleotidase | NT5E | NT5E Measurement",,,,,,,,,,,,,,,"4098639","5' Nucleotidase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1664436","Apoptotic Cell Count","C181495","The determination of the amount of apoptotic cells in a sample.","Apoptotic Cell Count | APOCE | Apoptotic Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664439","Apoptotic Cell to Total Cell Count","C181494","The determination of the ratio of apoptotic cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Apoptotic Cell to Total Cell Count | APOCECE | Apoptotic Cells/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664438","Lymph Node Involvement Indicator","C181493","An indication as to whether cancer is present in the lymph nodes.","Lymph Node Involvement Indicator | LNININD | Positive Lymph Node Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664434","Nuclear Pleomorphism Assessment","C181492","An evaluation of the presence or degree of nuclear pleomorphism in a sample.","Nuclear Pleomorphism Assessment | NCRPLEOM | Nuclear Pleomorphism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664433","Tubule Formation Assessment","C181491","An evaluation of the presence or degree of tubule formation in a sample.","Tubule Formation Assessment | TBLFRM | Tubule Formation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664435","Intraepithelial Neoplasia Assessment","C181490","An evaluation of the presence or degree of intraepithelial neoplasia in a sample.","Intraepithelial Neoplasia Assessment | Epithelial Neoplasia | IEPINEOA | Intraepithelial Neoplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664966","Glycogenated Nuclei Assessment","C181489","An evaluation of the presence or degree of glycogenated nuclei in a sample.","Glycogenated Nuclei Assessment | Glycogenated Nuclei | NUCLGLCG | Nuclei, Glycogenated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664959","Mallory Body Assessment","C181488","An evaluation of the presence or degree of mallory bodies in a sample.","Mallory Body Assessment | MALLBOD | Mallory Body | Mallory Hyaline | Mallory's Hyaline | Mallory-Denk Body",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664442","Megamitochondria Assessment","C181487","An evaluation of the presence or degree of megamitochondria in a sample.","Megamitochondria Assessment | Giant Mitochondria Assessment | MEGAMITC | Megamitochondria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664444","Pigmented Macrophage Assessment","C181486","An evaluation of the presence or degree of pigmented macrophages in a sample.","Pigmented Macrophage Assessment | MPHGPIG | Macrophage, Pigmented | Pigmented Macrophage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664443","Acidophil Body Assessment","C181485","An evaluation of the presence or degree of acidophil body in a sample.","Acidophil Body Assessment | ACDOBOD | Acidophil Bodies | Acidophil Body",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664416","Number of Continuous Days of Menstrual Bleeding and/or Spotting","C181528","The number of days one has experienced continuous menstrual bleeding and/or spotting.","Number of Continuous Days of Menstrual Bleeding and/or Spotting | BLDSPNUM | Number of Continuous Days of Bleed/Spot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664415","Condom Use Frequency","C181527","The reported frequency of condom use.","Condom Use Frequency | CNDUFRQD | Condom Use Frequency Desc | Condom Use Frequency Description",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664418","Condom Use for Most Recent Sexual Intercourse Indicator","C181526","An indication as to whether a condom was used during the most recent occurrence of sexual intercourse.","Condom Use for Most Recent Sexual Intercourse Indicator | CNDMIND | Condom Use Most Recent Sex Interc Ind",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664417","Total Number of Sexual Partners","C181525","The total count of all sexual partners.","Total Number of Sexual Partners | TSXPARTN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3165133","Date of Last Sexual Intercourse","C181524","The date on which the most recent sexual intercourse occurred.","Date of Last Sexual Intercourse | Date of Most Recent Sexual Intercourse | MRSXIDTC",,,,,,,,,,,,,,,"40486681","Date of last sexual intercourse",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1664614","HLA DR Beta 3 Histocompatibility Antigen Measurement","C181412","The determination of the amount of HLA DR Beta 3 antigen present in a sample.","HLA DR Beta 3 Histocompatibility Antigen Measurement | HLA DR Beta3 Antigen | HLA-DR Beta3 Antigen | HLA-DRB3 Antigen Measurement | HLADRB3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266561","Hydroxyethylflurazepam Measurement","C181419","The determination of the amount of hydroxyethylflurazepam present in a sample.","Hydroxyethylflurazepam Measurement | 2-Hydroxyethylflurazepam | H2FLRZPM | Hydroxyethylflurazepam",,,,,,,,,,,,,,,"4007187","Hydroxyethylflurazepam measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1664609","Alpha-Hydroxytriazolam Measurement","C181418","The determination of the amount of alpha-hydroxytriazolam present in a sample.","Alpha-Hydroxytriazolam Measurement | AHTRZLM | Alpha-Hydroxytriazolam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664608","HLA DP Alpha1 Histocompatibility Antigen Measurement","C181417","The determination of the amount of HLA DP Alpha 1 antigen present in a sample.","HLA DP Alpha1 Histocompatibility Antigen Measurement | HLA DP Alpha1 Antigen | HLA-DP Alpha1 Antigen | HLA-DPA1 Antigen Measurement | HLADPA1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664617","HLA DQ Alpha1 Histocompatibility Antigen Measurement","C181416","The determination of the amount of HLA DQ Alpha 1 antigen present in a sample.","HLA DQ Alpha1 Histocompatibility Antigen Measurement | HLA DQ Alpha1 Antigen | HLA-DQ Alpha1 Antigen | HLA-DQA1 Antigen Measurement | HLADQA1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664616","HLA DR Beta 2 Histocompatibility Antigen Measurement","C181415","The determination of the amount of HLA DR Beta 2 antigen present in a sample.","HLA DR Beta 2 Histocompatibility Antigen Measurement | HLA DR Beta2 Antigen | HLA-DR Beta2 Antigen | HLA-DRB2 Antigen Measurement | HLADRB2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664619","HLA DR Beta 5 Histocompatibility Antigen Measurement","C181414","The determination of the amount of HLA DR Beta 5 antigen present in a sample.","HLA DR Beta 5 Histocompatibility Antigen Measurement | HLA DR Beta5 Antigen | HLA-DR Beta5 Antigen | HLA-DRB5 Antigen Measurement | HLADRB5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664618","HLA DR Beta 4 Histocompatibility Antigen Measurement","C181413","The determination of the amount of HLA DR Beta 4 antigen present in a sample.","HLA DR Beta 4 Histocompatibility Antigen Measurement | HLA DR Beta4 Antigen | HLA-DR Beta4 Antigen | HLA-DRB4 Antigen Measurement | HLADRB4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664599","27-Hydroxycholesterol Measurement","C181427","The determination of the amount of 27-hydroxycholesterol present in a sample.","27-Hydroxycholesterol Measurement | 27-Hydroxycholesterol | CHOLH27",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664602","25-Hydroxycholesterol Measurement","C181426","The determination of the amount of 25-hydroxycholesterol present in a sample.","25-Hydroxycholesterol Measurement | 25-Hydroxycholesterol | CHOLH25",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664601","24(S)-Hydroxycholesterol Measurement","C181425","The determination of the amount of 24(S)-hydroxycholesterol present in a sample.","24(S)-Hydroxycholesterol Measurement | 24(S)-Hydroxycholesterol | CHOLH24S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664611","24(R)-Hydroxycholesterol Measurement","C181424","The determination of the amount of 24(R)-hydroxycholesterol present in a sample.","24(R)-Hydroxycholesterol Measurement | 24(R)-Hydroxycholesterol | CHOLH24R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664610","24(S),25-Epoxycholesterol Measurement","C181423","The determination of the amount of 24(S),25-epoxycholesterol present in a sample.","24(S),25-Epoxycholesterol Measurement | 24(S),25-Epoxycholesterol | CHE24S25",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664613","22(S)-Hydroxycholesterol Measurement","C181422","The determination of the amount of 22(S)-hydroxycholesterol present in a sample.","22(S)-Hydroxycholesterol Measurement | 22(S)-Hydroxycholesterol | CHOLH22S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664612","22(R)-Hydroxycholesterol Measurement","C181421","The determination of the amount of 22(R)-hydroxycholesterol present in a sample.","22(R)-Hydroxycholesterol Measurement | 22(R)-Hydroxycholesterol | CHOLH22R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664604","7alpha-Hydroxycholesterol Measurement","C181432","The determination of the amount of 7alpha-hydroxycholesterol present in a sample.","7alpha-Hydroxycholesterol Measurement | 7alpha-Hydroxycholesterol | CHOLH7A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664603","7alpha,27-Dihydroxycholesterol Measurement","C181431","The determination of the amount of 7alpha,27-dihydroxycholesterol present in a sample.","7alpha,27-Dihydroxycholesterol Measurement | 7alpha,27-Dihydroxycholesterol | CHDH7A27",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664606","7alpha,25-Dihydroxycholesterol Measurement","C181430","The determination of the amount of 7alpha,25-Dihydroxycholesterol present in a sample.","7alpha,25-Dihydroxycholesterol Measurement | 7alpha,25-Dihydroxycholesterol | CHDH7A25",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664605","4-Hydroxytestosterone Measurement","C181429","The determination of the amount of 4-hydroxytestosterone present in a sample.","4-Hydroxytestosterone Measurement | 4-Hydroxytestosterone | TST4OH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664600","3beta-Hydroxy-5-Cholestenoic Acid Measurement","C181428","The determination of the amount of 3beta-hydroxy-5-cholestenoic acid present in a sample.","3beta-Hydroxy-5-Cholestenoic Acid Measurement | 3-HCOA | 3-Hydroxy-5-cholestenoic acid | 3beta-Hydroxy-5-Cholestenoic Acid | HCOA3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664598","Clot Retraction Time Measurement","C181437","A measurement of the amount of time it takes for a clot to retract, or pull away from, the wall of a glass collection container.","Clot Retraction Time Measurement | CLOTRTCT | Clot Retraction Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1295111","Cholesterol Sulfate Measurement","C181436","The determination of the amount of cholesterol sulfate present in a sample.","Cholesterol Sulfate Measurement | CHOLSULF | Cholesterol Sulfate",,,,,,,,,,,,,,,"4005374","Cholesterol sulfate measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523567","Cholestanol Measurement","C181435","The determination of the amount of cholestanol present in a sample.","Cholestanol Measurement | 5alpha-Cholestanol | Beta-Cholestanol | CHOLSTNL | Cholestanol | Dehydrocholesterol | Zymostanol",,,,,,,,,,,,,,,"4019547","Cholestanol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1664595","7-Ketocholesterol Measurement","C181434","The determination of the amount of 7-ketocholesterol present in a sample.","7-Ketocholesterol Measurement | 7-Ketocholesterol | 7-Oxocholesterol | CHOLK7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664594","7beta-Hydroxycholesterol Measurement","C181433","The determination of the amount of 7beta-Hydroxycholesterol present in a sample.","7beta-Hydroxycholesterol Measurement | 7beta-Hydroxycholesterol | CHOLH7B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664586","Free Hepatocyte Growth Factor Receptor Measurement","C181453","The determination of the amount of free hepatocyte growth factor receptor present in a sample.","Free Hepatocyte Growth Factor Receptor Measurement | HGFRFR | Hepatocyte Growth Factor Receptor, Free",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664581","Free Epidermal Growth Factor Receptor Measurement","C181452","The determination of the amount of free epidermal growth factor receptor present in a sample.","Free Epidermal Growth Factor Receptor Measurement | EGFRFR | Epidermal Growth Factor Receptor, Free",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524289","Triazolam Measurement","C181451","The determination of the amount of triazolam present in a sample.","Triazolam Measurement | TRZLM | Triazolam",,,,,,,,,,,,,,,"4022516","Triazolam measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1664583","Neutrophilic Myelocytes to Lymphocytes Ratio Measurement","C181450","The determination of the ratio of neutrophilic myelocytes compared to lymphocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Neutrophilic Myelocytes to Lymphocytes Ratio Measurement | NEUMYLLY | Neutrophilic Myelocytes/Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664582","Eosinophilic Myelocytes to Lymphocytes Ratio Measurement","C181449","The determination of the ratio of eosinophilic myelocytes compared to lymphocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Eosinophilic Myelocytes to Lymphocytes Ratio Measurement | EOSMYLLY | Eosinophilic Myelocytes/Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664591","Basophilic Myelocytes to Lymphocytes Ratio Measurement","C181448","The determination of the ratio of basophilic myelocytes compared to lymphocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Basophilic Myelocytes to Lymphocytes Ratio Measurement | BASOMYLY | Basophilic Myelocytes/Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664956","Urokinase Plasminogen Activator Measurement","C181447","The determination of the amount of urokinase plasminogen activator present in a sample.","Urokinase Plasminogen Activator Measurement | UPA | Urokinase Measurement | Urokinase Plasminogen Activator | uPA | uPA Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664593","Thyrotropin to Free Thyroxine Ratio Measurement","C181446","The determination of the ratio of thyrotropin compared to free thyroxine present in a sample. The measurement may be expressed as a ratio or percentage.","Thyrotropin to Free Thyroxine Ratio Measurement | THS to Free T4 Ratio Measurement | TSHT4FR | Thyroid Stimulating Hormone/Free T4 | Thyrotropin/Thyroxine, Free",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664592","Free Iodine Measurement","C181445","The determination of the amount of free iodine present in a sample.","Free Iodine Measurement | IODINEFR | Iodine, Free",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664588","HLA DP Beta Histocompatibility Antigen Measurement","C181444","The determination of the amount of HLA DP beta antigen present in a sample.","HLA DP Beta Histocompatibility Antigen Measurement | HLA DP Beta Antigen | HLA-DP Beta Antigen | HLA-DPB Antigen Measurement | HLADPB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664587","HLA A3 Histocompatibility Antigen Measurement","C181443","The determination of the amount of HLA A3 antigen present in a sample.","HLA A3 Histocompatibility Antigen Measurement | HLA A3 Antigen | HLA-A*3 Measurement | HLA-A3 Antigen | HLA-A3 Measurement | HLAA3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664590","HLA A24 Histocompatibility Antigen Measurement","C181442","The determination of the amount of HLA A24 antigen present in a sample.","HLA A24 Histocompatibility Antigen Measurement | HLA A24 Antigen | HLA-A*24 Measurement | HLA-A24 Antigen | HLA-A24 Measurement | HLAA24",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664589","HLA A2 Histocompatibility Antigen Measurement","C181441","The determination of the amount of HLA A2 antigen present in a sample.","HLA A2 Histocompatibility Antigen Measurement | HLA A2 Antigen | HLA-A*2 Measurement | HLA-A2 Antigen | HLA-A2 Measurement | HLAA2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664597","HLA A03 Histocompatibility Antigen Measurement","C181440","The determination of the amount of HLA A03 antigen present in a sample.","HLA A03 Histocompatibility Antigen Measurement | HLA A03 Antigen | HLA-A*03 Measurement | HLA-A03 Antigen | HLA-A03 Measurement | HLAA03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664596","HLA Cw Histocompatibility Antigen Measurement","C181439","The determination of the amount of HLA Cw antigen present in a sample.","HLA Cw Histocompatibility Antigen Measurement | HLA Cw Antigen | HLA-C Antigen Measurement | HLA-C Measurement | HLA-Cw Antigen | HLA-Cw Antigen Measurement | HLA-Cw Measurement | HLACW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009069","Qualitative Clot Retraction Measurement","C181438","A qualitative assessment of clot retraction in a sample.","Qualitative Clot Retraction Measurement | CLOTRTC | Clot Retraction | Clot Retraction, Qualitative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663674","NTRK3 Fusion Negative","C181137","An indication that the expression of a NTRK3 fusion has not been detected in a sample.","NTRK3 Fusion Negative | NT-3 Growth Factor Receptor Fusion Negative | Neurotrophic Receptor Tyrosine Kinase 3 Fusion Negative | TRKC Tyrosine Kinase Fusion Negative | TrkC Fusion Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663673","NTRK2 Fusion Negative","C181136","An indication that the expression of a NTRK2 fusion has not been detected in a sample.","NTRK2 Fusion Negative | BDNF/NT-3 Growth Factors Receptor Fusion Negative | Neurotrophic Receptor Tyrosine Kinase 2 Fusion Negative | TRKB Tyrosine Kinase Fusion Negative | TrkB Fusion Negative | Tropomyosin-Related Kinase B Fusion Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663672","NTRK1 Fusion Negative","C181135","An indication that the expression of a NTRK1 fusion has not been detected in a sample.","NTRK1 Fusion Negative | High Affinity Nerve Growth Factor Receptor Fusion Negative | Neurotrophic Receptor Tyrosine Kinase 1 Fusion Negative | TRK1 Fusion Negative | TRKA Fusion Negative | Trk-A Fusion Negative | Tropomyosin-Related Kinase A Fusion Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663698","SS18/SSX Rearrangement Positive","C181087","An indication that rearrangement involving SS18 and one of three SSX family members (SSX1, SSX2 or SSX4) has been detected in a sample.","SS18/SSX Rearrangement Positive | SS18-SSX Family Rearrangement | SS18-SSX Family Rearrangement Positive | SS18-SSX Rearrangement Positive | SS18/SSX Family Rearrangement | SS18/SSX Family Rearrangement Positive | SS18/SSX Rearrangement | SSXT-SSX Rearrangement Positive | SYT-SSX Rearrangement Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0071189","IGFBP1 protein, human","C17505","Insulin-like growth factor-binding protein 1 (259 aa, ~28 kDa) is encoded by the human IGFBP1 gene. This protein is involved in cell migration and both insulin-like growth factor binding and signaling.","Insulin-Like Growth Factor-Binding Protein 1 | AFBP | Alpha-Pregnancy-Associated Endometrial Globulin | Amniotic Fluid Binding Protein | Binding Protein-25 | Binding Protein-26 | Binding Protein-28 | Growth Hormone Independent-Binding Protein | IBP-1 | IGF Binding Protein 1 | IGF-Binding Protein 1 | IGFBP-1 | IGFBP1 | Insulin-Like Growth Factor Binding Protein 1 | PP12 | Placental Protein 12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664623","Monomethylarginine Measurement","C181407","The determination of the amount of monomethylarginine present in a sample.","Monomethylarginine Measurement | MMARG | Monomethylarginine | Tilarginine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664626","Growth Differentiation Factor 15 Measurement","C181406","The determination of the amount of growth differentiation factor 15 present in a sample.","Growth Differentiation Factor 15 Measurement | GDF-15 | GDF15 | Growth Differentiation Factor 15 | MIC-1 | Macrophage Inhibitory Cytokine-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664625","Phospholipase A2 Measurement","C181405","The determination of the amount of phospholipase A2 present in a sample.","Phospholipase A2 Measurement | PLA2 | Phospholipase A2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664621","Functional Alpha-1 Antitrypsin Measurement","C181404","The determination of the amount of alpha-1 antitrypsin, Functional present in a sample.","Functional Alpha-1 Antitrypsin Measurement | A1ANTRPF | Alpha-1 Antitrypsin, Functional | Functional SERPIN1A Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664620","N-Desmethyltramadol Measurement","C181403","The determination of the amount of N-desmethyltramadol present in a sample.","N-Desmethyltramadol Measurement | N-DSMT | N-Desmethyltramadol | NDSMT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266671","O-Desmethyltramadol Measurement","C181402","The determination of the amount of O-desmethyltramadol present in a sample.","O-Desmethyltramadol Measurement | Desmetramadol | O-DSMT | O-Desmethyltramadol | ODSMT",,,,,,,,,,,,,,,"4040046","O-Desmethyltramadol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523726","Iodine Measurement","C181193","The determination of the amount of iodine present in a sample.","Iodine Measurement | IODINE | Iodine",,,,,,,,,,,,,,,"4017197","Iodine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1664366","HLA DR Beta Histocompatibility Antigen Measurement","C181192","The determination of the amount of HLA DR beta histocompatibility antigen present in a sample.","HLA DR Beta Histocompatibility Antigen Measurement | HLA DR Beta Antigen | HLA-DR Beta Antigen | HLA-DRB Measurement | HLADRB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642796","DR Measurement","C176962","The determination of the amount of HLA-DR protein present in a sample.","HLA DR Histocompatibility Antigen Measurement | DR Measurement | HLA Class II Histocompatibility Antigen DR Measurement | HLA Class II Histocompatibility Antigen, DR Measurement | HLA DR Antigen | HLA-DR Antigen | HLA-DR Antigen Measurement | HLADR | Human Leukocyte Antigen DR Measurement | Human Leukocyte Antigen-DR Isotype Measurement | MHC Class I Antigen DR Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664949","Valproate Measurement","C181410","The determination of the amount of valproate present in a sample.","Valproate Measurement | VALPRATE | Valproate | Valproic Acid | Valproic Acid Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664615","Hypochromic Erythrocytes to Erythrocytes Ratio Measurement","C181409","The determination of the ratio of hypochromic erythrocytes compared to total erythrocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Hypochromic Erythrocytes to Erythrocytes Ratio Measurement | HORBCRBC | Hypochromic Erythrocytes/Erythrocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1295154","Hexosaminidase A Measurement","C181411","The determination of the amount of hexosaminidase A present in a sample.","Hexosaminidase A Measurement | Beta-Hexosaminidase Subunit Alpha | Beta-N-Acetylhexosaminidase Subunit Alpha | HEXA | Hexosaminidase A | Hexosaminidase Subunit A | Hexosaminidase Subunit Alpha | N-Acetyl-Beta-Glucosaminidase Subunit Alpha",,,,,,,,,,,,,,,"4007660","Hexosaminidase A measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL979242","Microgram Equivalents Per Milliliter Per Milligram Equivalents","C166088","A concentration unit measured as a number of microgram equivalents of solute per milliliter of solution per milligram equivalents.","Microgram Equivalents Per Milliliter Per Milligram Equivalents | ug.eq/mL/mg.eq | ug.eq/ml/mg.eq | ugEq/mL/mgEq",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979249","Microgram Equivalents Per Gram","C166087","A concentration unit measured as a number of microgram equivalents per gram of substance.","Microgram Equivalents Per Gram | ngEq/mg | pgEq/ug | ug.eq/g | ugEq/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979248","Picogram Equivalents Per Milliliter Per Milligram Equivalents","C166086","A concentration unit measured as a number of picogram equivalents of solute per milliliter of solution per milligram equivalents.","Picogram Equivalents Per Milliliter Per Milligram Equivalents | pg.eq/mL/mg.eq | pg.eq/ml/mg.eq | pgEq/mL/mgEq",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979247","Picogram Equivalents Per Milliliter","C166085","A concentration unit measured as a number of picogram equivalents of solute per milliliter of solution.","Picogram Equivalents Per Milliliter | ngEq/L | pg.eq/mL | pg.eq/ml | pgEq/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979246","Picogram Equivalents Per Gram","C166084","A concentration unit measured as a number of picogram equivalents per gram of substance.","Picogram Equivalents Per Gram | pg.eq/g | pgEq/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979237","Nanogram Equivalents Per Milliliter Per Milligram Equivalents","C166083","A concentration unit measured as a number of nanogram equivalents of solute per milliliter of solution per milligram equivalents.","Nanogram Equivalents Per Milliliter Per Milligram Equivalents | ng.eq/mL/mg.eq | ng.eq/ml/mg.eq | ngEq/mL/mgEq",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979236","Nanogram Equivalents Per Gram","C166082","A concentration unit measured as a number of nanogram equivalents per gram of substance.","Nanogram Equivalents Per Gram | ng.Eq/g | ng.eq/g | ngEq/g | pgEq/mg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979235","Hour Times Microgram Equivalents Per Milliliter Per Milligram Equivalents","C166081","A unit of measure defined as hours times microgram equivalents per milliliter per milligram equivalents.","Hour Times Microgram Equivalents Per Milliliter Per Milligram Equivalents | h*ugEq/mL/mgEq | h.ug.eq/mL/mg.eq | h.ug.eq/ml/mg.eq",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979234","Hour Times Microgram Equivalents Per Milliliter","C166080","A unit of measure defined as hours times microgram equivalents per milliliter.","Hour Times Microgram Equivalents Per Milliliter | h*ugEq/mL | h.ug.eq/mL | h.ug.eq/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979241","Hour Times Picogram Equivalents Per Milliliter Per Milligram Equivalents","C166079","A unit of measure defined as hours times picogram equivalents per milliliter per milligram equivalents.","Hour Times Picogram Equivalents Per Milliliter Per Milligram Equivalents | h*pgEq/mL/mgEq | h.pg.eq/mL/mg.eq | h.pg.eq/ml/mg.eq",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979240","Hour Times Picogram Equivalents Per Milliliter","C166078","A unit of measure defined as hours times picogram equivalents per milliliter.","Hour Times Picogram Equivalents Per Milliliter | h*ngEq/L | h*pgEq/mL | h.pg.eq/mL | h.pg.eq/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979239","Hour Times Nanogram Equivalents Per Milliliter Per Milligram Equivalents","C166077","A unit of measure defined as hours times nanogram equivalents per milliliter per milligram equivalents.","Hour Times Nanogram Equivalents Per Milliliter Per Milligram Equivalents | h*ngEq/mL/mgEq | h.ng.eq/mL/mg.eq | h.ng.eq/ml/mg.eq",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL979238","Hour Times Nanogram Equivalents Per Milliliter","C166076","A unit of measure defined as hours times nanogram equivalents per milliliter.","Hour Times Nanogram Equivalents Per Milliliter | h*ngEq/mL | h.ng.eq/mL | h.ng.eq/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976931","Hour Times Becquerel per milliliter","C163555","A unit of specific radioactivity used to determine the area under the curve that is equal to hours times becquerel per milliliter.","Hour Times Becquerel per milliliter | h*Bq/mL | h.Bq/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976932","Hour Times Becquerel per Gram","C163554","A unit of specific radioactivity used to determine the area under the curve that is equal to hours times becquerel per gram.","Hour Times Becquerel per Gram | h*Bq/g | h.Bq/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2348854","Gigabecquerel per Microliter","C73562","A metric unit of volumetric radioactivity concentration defined as a concentration of a radionuclide with an activity equal to one billion becquerels per unit volume equal to one millionth of a liter.","Gigabecquerel per Microliter | GBq/uL | GBq/ul | Gigabecquerel/Microliter | gigabecquerel/microlitre",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976933","Gigabecquerel/nL","C163553","A metric unit of volumetric radioactivity concentration defined as a concentration of a radionuclide with an activity equal to one gigabecquerel per unit volume equal to one nanoliter.","Gigabecquerel/nL | GBq/nL | GBq/nl | MBq/pL | TBq/nL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976934","Hour Times Becquerel per Milliliter per Kilobecquerel per Kilogram","C163552","A unit of specific radioactivity that is equal to hours times becquerel per milliliter divided by dose in kilobecquerel per kilogram body weight.","Hour Times Becquerel per Milliliter per Kilobecquerel per Kilogram | (h*Bq/mL)/(Bq/g) | (h*Bq/mL)/(kBq/kg) | (h.Bq/mL)/(kBq/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976935","Hour Times Becquerel per Gram per Kilobecquerel per Kilogram","C163551","A unit of specific radioactivity that is equal to hours times becquerel per gram divided by dose in kilobecquerel per kilogram body weight.","Hour Times Becquerel per Gram per Kilobecquerel per Kilogram | (h*Bq/g)/(Bq/g) | (h*Bq/g)/(kBq/kg) | (h.Bq/g)/(kBq/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976936","Becquerel per Milliliter per Kilobecquerel per Kilogram","C163550","A unit of specific radioactivity that is equal to becquerel per milliliter divided by dose in kilobecquerel per kilogram body weight.","Becquerel per Milliliter per Kilobecquerel per Kilogram | (Bq/mL)/(Bq/g) | (Bq/mL)/(kBq/kg) | (Bq/ml)/(kBq/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL976736","Becquerel per Gram per Kilobecquerel per Kilogram","C163549","A unit of specific radioactivity that is equal to becquerel per gram divided by dose in kilobecquerel per kilogram body weight.","Becquerel per Gram per Kilobecquerel per Kilogram | (Bq/g)/(Bq/g) | (Bq/g)/(kBq/kg)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406329","Riker Sedation-Agitation Scale Clinical Classification","C171418","A standardized seven-point rating scale developed by Riker et al. 1999 to assess the level of alertness and agitation in critically ill patients. The assigned score ranges from 1 to 7, with three levels of sedation ranging from unarousable to sedated, one level indicating calm and cooperative, and three levels of agitation, ranging from agitated to dangerous agitation.","Riker Sedation-Agitation Scale Clinical Classification | SAS | SAS01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405507","Richmond Agitation-Sedation Scale Clinical Classification","C171417","A standardized 10-point rating scale, developed by Sessler et al. 2002, that is used to assess the level of alertness and agitation in critically ill patients. The assigned score ranges from +4 to -5, with four levels of anxiety or agitation, a score of zero denoting a calm and alert state, and five levels of sedation.","Richmond Agitation-Sedation Scale Clinical Classification | RASS | RASS01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405479","National Early Warning Score 2 Clinical Classification","C171357","A 2017 update to the Royal College of Physicians of London's 2012 National Early Warning Score (NEWS), which is a weighted scoring system for six routinely monitored vital sign parameters, including respiration rate, oxygen saturation, systolic blood pressure, pulse rate, level of consciousness, and temperature, to standardize the assessment and response to acute illness. NEWS2 includes several modifications to the vital sign weightings and a new SpO2 scoring scale for patients at risk of type II respiratory failure.","National Early Warning Score 2 Clinical Classification | NEWS1 | NEWS2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382831","Kidney Disease Improving Global Outcomes Staging For Acute Kidney Injury Clinical Classification","C170645","Standardized clinical practice guidelines for acute kidney injury staging that were developed by the Kidney Disease Improving Global Outcomes (KDIGO) in 2012. The three-stage classification, which builds off the 2004 Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease (RIFLE) and 2007 Acute Kidney Injury Network (AKIN) classifications, is based on changes in serum creatinine and urine output.","Kidney Disease Improving Global Outcomes Staging For Acute Kidney Injury Clinical Classification | KDIGO AKI | KDIGO-AKI | KDIGO1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970298","Emory Treatment Resistance Interview for PTSD Clinical Classification","C161658","A standardized clinician-administered semi-structured interview tool created by Dunlop et al. in 2014 that assesses the adequacy and benefit derived from a patient's past treatment for posttraumatic stress disorder (PTSD) in order to quantify the degree of treatment resistance PTSD.","Emory Treatment Resistance Interview for PTSD Clinical Classification | E-TRIP | ETRP01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970299","Brief Psychiatric Rating Scale 1988 Version Clinical Classification","C161657","A standardized 18-item clinician-rated instrument, initially published as a 16-item questionnaire in 1962 by Drs. John Overall and Donald Gorham and revised in 1974 and 1988, that utilizes a seven-point response scale to assess the symptoms of somatic concern, anxiety, emotional withdrawal, conceptual disorganization, guilt feelings, tension, mannerisms and posturing, grandiosity, depressive mood, hostility, suspiciousness, hallucinatory behavior, motor retardation, uncooperativeness, unusual thought content, blunted affect, excitement, and disorientation in individuals with psychotic disorders.","Brief Psychiatric Rating Scale 1988 Version Clinical Classification | BPRS 1988 VERSION | BPRS 1988 Version | BPRS01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970300","Alert Verbal Painful Unresponsive Scale Clinical Classification","C161656","A standardized assessment algorithm published by the American College of Surgeons Committee on Trauma in the Advanced Trauma Life Support protocol in 1989 that uses the criterion of 'alert', 'responsive to verbal stimulation', 'responsive to painful stimulation', or 'unresponsive' to determine a patient's level of consciousness.","Alert Verbal Painful Unresponsive Scale Clinical Classification | AVPU | AVPU01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1770952","Foamy Cell Proliferation","C182619","A morphologic finding indicating the presence of xanthomatous cells in a tissue sample.","Foamy Cell Proliferation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1770951","Non-Papillary Pattern","C182618","A morphologic finding indicating the presence of a cellular infiltrate without a papillary growth in a tissue sample.","Non-Papillary Pattern | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771359","Fully Vaccinated","C183123","A status indicating that an individual has received all the required vaccinations.","Fully Vaccinated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771360","Partially Vaccinated","C183124","A status indicating that an individual has received some of the required vaccinations.","Partially Vaccinated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771357","Not Vaccinated","C183125","A status indicating that an individual has not received any of the required vaccinations.","Not Vaccinated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL594659","Non-focal","C183150","Not limited to a specific area.","Non-focal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937489","Hearing Devices","C157872","Devices that are used to enhance hearing.","Hearing Devices | Hearing Device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009199","Cochlear Implants","C157820","A two part electronic device with one part that is implanted under the skin with wires that connect to the cochlea, and an external portion that receives the sound. It is for individuals with severe hearing impairment.","Cochlear Implants | Cochlear Implant",,,,,,,,,,,,,,,"4182413","Cochlear prosthesis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL951736","Additional Pathologic Findings","C158809","A section header that includes additional pathologic findings.","Additional Pathologic Findings | additional pathology findings | additional_pathology_findings",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4011504","Action Tremor","C183162","A tremor that occurs with the voluntary movement of a muscle. Subcategories include postural, kinetic, and isometric tremors.","Action Tremor | ",,,,,,,,,,,,,,,"4148954","Intention tremor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1773339","Uninvolved Anatomy","C183164","An indication that an anatomy site or entity does not show signs of a disease process.","Uninvolved Anatomy | Uninvolved",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977317","White Light Endoscopy","C164164","Endoscopic examination that uses full-spectrum visible light. An image is captured using a standard color camera, sensitive only to red, green and blue spectral components, replicating the vision of the human eye.","White Light Endoscopy | WLE | White Light Endoscopic Imaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771392","Distinguish","C183168","To recognize or detect the differences between things.","Distinguish | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771393","Intraprostatic Incision","C183165","Inadvertent transection of a prostatic tumor during prostatectomy, resulting in a positive surgical margin.","Intraprostatic Incision | Capsular Incision | IPI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771368","Circulating Tumor-Derived DNA Negative","C183129","An indication that circulating tumor-derived DNA has not been detected in a sample.","Circulating Tumor-Derived DNA Negative | Circulating Tumor DNA Negative | ctDNA Negative | ctDNA- | ctdDNA Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771369","Circulating Tumor-Derived DNA Positive","C183130","An indication that circulating tumor-derived DNA has been detected in a sample.","Circulating Tumor-Derived DNA Positive | Circulating Tumor DNA Positive | ctDNA Positive | ctDNA+ | ctdDNA Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771401","Hearing Environments and Reflection on Quality of Life","C183179","Questionnaires designed to assess how a child or adolescent is affected by their hearing loss, and to aid a clinician in determining where intervention is warranted to improve the patient's overall wellbeing.","Hearing Environments and Reflection on Quality of Life | HEAR-QL | Hearing Environments and Reflection on Quality of Life Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771402","Hearing Environments and Reflection on Quality of Life for Children","C183180","A questionnaire designed to assess how a child is affected by their hearing loss, and to aid a clinician in determining where intervention is warranted to improve the child's overall wellbeing.","Hearing Environments and Reflection on Quality of Life for Children | HEAR-QL-26",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771400","Hearing Environments and Reflection on Quality of Life for Adolescents","C183181","A questionnaire designed to determine how an adolescent is affected by their hearing loss, and aid a clinician in determining where intervention is warranted to improve theadolescent's overall wellbeing.","Hearing Environments and Reflection on Quality of Life for Adolescents | HEAR-QL-28",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018768","Hearing Aid","C183182","A battery-powered electronic device designed to improve hearing. Most are worn in or behind the ear.","Hearing Aid | ",,,,,,,,,,,,,,,"4246497","Hearing aid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL957154","FM System","C183183","A wireless electronic device designed to improve hearing, especially in noisy environments, by transmitting sound over a distance from a microphone to a receiver using radio waves.","FM Hearing Aid System | FM System | FM System | Frequency Modulation Hearing Aid System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771696","Have Trouble Hearing When Someone Whispers to Me","C183186","A question about whether an individual has or had trouble hearing when someone whispers to them.","Have Trouble Hearing When Someone Whispers to Me | Hard to Hear When Someone Whispers to Me | I have trouble hearing when someone whispers to me | Is it hard to hear when someone whispers to you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771693","Have Misunderstandings with Family Members Because of My Hearing","C183187","A question about whether an individual has or had misunderstandings with family members because of the individual's hearing.","Have Misunderstandings with Family Members Because of My Hearing | I have misunderstandings with family members because of my hearing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771694","Have Trouble Watching Movies and TV Because of Hearing","C183188","A question about whether an individual has or had trouble watching movies or TV because of their hearing.","Have Trouble Watching Movies and TV Because of Hearing | I have trouble watching movies or TV because of my hearing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771691","Have Problems at Restaurants Because of Hearing","C183189","A question about whether an individual has or had problems at restaurants because of their hearing.","Have Problems at Restaurants Because of Hearing | I have problems at restaurants because of my hearing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771692","Have Hard Time Hearing in Noisy Places","C183190","A question about whether an individual has or had a hard time hearing in noisy places.","Have Hard Time Hearing in Noisy Places | I have a hard time hearing in noisy places (restaurants, ball games, concerts, etc.)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771689","Have Hard Time Hearing in the Car","C183191","A question about whether an individual has or had a hard time hearing in the car.","Have Hard Time Hearing in the Car | I have a hard time hearing in the car",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771690","Interact with Friends Less than I Would Because of Hearing","C183192","A question about whether an individual interacts with friends less than they would because of the individual's hearing.","Interact with Friends Less than I Would Because of Hearing | I interact with friends less than I would because of my hearing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771703","Interact with Family Less than I Would Like Because of Hearing","C183193","A question about whether an individual interacts with family less than they would like to because of the individual's hearing.","Interact with Family Less than I Would Like Because of Hearing | I interact with family (parents, brothers, sisters) less than I would like because of my hearing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771704","Interact with Extended Family Less than I Would Like Because of Hearing","C183194","A question about whether an individual interacts with extended family less than they would like because of the individual's hearing.","Interact with Extended Family Less than I Would Like Because of Hearing | I interact with extended family (grandparents, aunts, uncles, cousins) less than I would like because of my hearing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771701","Does Not Interact Socially with Some People Outside of School Because of Hearing","C183195","A question about whether an individual interacts socially with some people outside of school because of the individual's hearing.","Does Not Interact Socially with Some People Outside of School Because of Hearing | I do not interact socially with some people outside of school because of my hearing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771702","Participate Less in Sports or Activities than I Would Like Because of Hearing","C183196","A question about whether an individual participates less in sports or activities than they would like because of their hearing.","Participate Less in Sports or Activities than I Would Like Because of Hearing | I participate less in sports or activities than I would like because of my hearing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771699","Go to Parties Less than I Would Like Because of Hearing","C183197","A question about whether an individual goes to parties less than they would like because of their hearing.","Go to Parties Less than I Would Like Because of Hearing | I go to parties less than I would like because of my hearing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771700","Go to Movies Less than I Would Like Because of Hearing","C183198","A question about whether an individual goes to movies less than they would like because of their hearing.","Go to Movies Less than I Would Like Because of Hearing | I go to movies less than I would like because of my hearing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771697","My Hearing Makes it Hard to Participate in School","C183199","A question about whether an individual's hearing makes it hard to participate in school.","My Hearing Makes it Hard to Participate in School | My hearing makes it hard to participate in school (ask or answer questions)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771698","Have Problems in Gym Class Because of Hearing","C183200","A question about whether an individual has or had problems in gym class because of their hearing.","Have Problems in Gym Class Because of Hearing | I have problems in gym class (Physical Education, PE) because of my hearing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771711","Have Problems Hearing Friends in the Cafeteria","C183201","A question about whether an individual has or had problems hearing their friends in the cafeteria.","Have Problems Hearing Friends in the Cafeteria | I have problems hearing friends in the cafeteria (lunch room)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771712","Have Hard Time Paying Attention in Class Because of Hearing","C183202","A question about whether an individual has or had a hard time paying attention in class because of their hearing.","Have Hard Time Paying Attention in Class Because of Hearing | I have a hard time paying attention in class because of my hearing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771710","Attend School Social Events Less Because of Hearing","C183204","A question about whether an individual attends school social events less because of their hearing.","Attend School Social Events Less Because of Hearing | I attend school social events less because of my hearing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771707","Would Do Better in School if Could Hear Better","C183205","A question about whether an individual feels that they would do better in school if they could hear better.","Would Do Better in School if Could Hear Better | I would do better in school if I could hear better",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771708","Feel Shy When Meeting New People Because of Hearing","C183206","A question about whether an individual feels shy when meeting new people because of their hearing.","Feel Shy When Meeting New People Because of Hearing | Do you feel shy when meeting new people because of your hearing | I feel shy when meeting new people because of my hearing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771705","Hearing Loss Makes Me Feel Different from Other Teens","C183207","A question about whether an individual's hearing loss makes them feel different from other teens.","Hearing Loss Makes Me Feel Different from Other Teens | My hearing loss makes me feel different from other teens",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771706","Hearing Loss Makes Me Nervous","C183208","A question about whether an individual's hearing loss makes them nervous.","Hearing Loss Makes Me Nervous | Does your hearing cause you to be nervous | My hearing loss makes me nervous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771718","Have Problems with Hearing Loss that Make Me Angry","C183209","A question about whether an individual has or had problems with their hearing that makes them angry.","Have Problems with Hearing Loss that Make Me Angry | I have problems with my hearing that make me angry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771719","Worry About Hearing Loss Getting Worse","C183210","A question about whether an individual worries about their hearing loss getting worse.","Worry About Hearing Loss Getting Worse | Do you worry about your hearing loss getting worse | I worry about my hearing loss getting worse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771716","Feel Left Out When I am with a Group of People Because of My Hearing","C183211","A question about whether an individual feels left out when they are with a group of people because of the individual's hearing.","Feel Left Out When I am with a Group of People Because of My Hearing | I feel left out when I am with a group of people because of my hearing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771717","Have Hard Time Asking Someone to Speak Louder or Repeat What They Said","C183212","A question about whether an individual has or had a hard time asking someone to speak louder or to repeat what they said.","Have Hard Time Asking Someone to Speak Louder or Repeat What They Said | If you can't hear someone, do you have a hard time asking them to speak louder or repeat what they said | When I can't hear people, I have a hard time asking them to speak louder or repeat what they said",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771714","Get Frustrated When I Respond Incorrectly to a Statement or Question Because I Don't Hear Correctly","C183213","A question about whether an individual gets frustrated when they respond incorrectly to a statement or question because they did not hear correctly.","Get Frustrated When I Respond Incorrectly to a Statement or Question Because I Don't Hear Correctly | I get frustrated when I respond incorrectly to a statement or question because I don't hear correctly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771713","Hard to Hear Friends When Playing","C183217","A question about whether an individual has or had a hard time hearing their friends when playing.","Hard to Hear Friends When Playing | Is it hard to hear you friends when you are playing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771726","Hard to Hear Friends at Recess","C183218","A question about whether an individual has or had a hard time hearing their friends at recess.","Hard to Hear Friends at Recess | Do you have a hard time hearing your friends at recess",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771727","Hard to Hear in Gym Class","C183219","A question about whether an individual has or had a hard time hearing in gym class.","Hard to Hear in Gym Class | Is it hard to hear in gym class (Physical Education, PE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771724","Harder Time Hearing in Noisy Places than Friends","C183220","A question about whether an individual thinks that they have or had a harder time hearing in noisy places than their friends.","Harder Time Hearing in Noisy Places than Friends | Do you think you have a harder time hearing than your friends in noisy places (restaurants, ball games, field trips, etc.)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771725","Harder to Hear at Parties than Friends","C183221","A question about whether an individual has or had a harder time hearing at parties than their friends.","Harder to Hear at Parties than Friends | Is it harder for you to hear at parties than it is for your friends",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771722","Hard to Hear at Restaurants","C183222","A question about whether an individual has or had a hard time hearing at restaurants.","Hard to Hear at Restaurants | Is it hard to hear at restaurants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771723","Hard to Hear in Classroom","C183223","A question about whether an individual has or had a hard time hearing in their classroom.","Hard to Hear in Classroom | Is it hard to hear in your classroom",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771720","Hard to Hear in the Cafeteria","C183224","A question about whether an individual has or had a hard time hearing in the cafeteria.","Hard to Hear in the Cafeteria | Is it hard to hear in the cafeteria (lunch room)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771721","Hard to Hear Friends When Playing Outside","C183225","A question about whether an individual has or had a hard time hearing their friends when playing outside.","Hard to Hear Friends When Playing Outside | Is it hard to hear your friends when playing outside",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771734","Hard to Hear My Family","C183226","A question about whether an individual has or had a hard time hearing their family.","Hard to Hear My Family | Is it hard to hear your family (mom, dad, brother, sister)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771735","Hard to Hear on the Phone","C183227","A question about whether an individual has or had a hard time hearing on the phone.","Hard to Hear on the Phone | Is it hard to hear on the phone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771732","Hard to Hear Movies or TV Because of Hearing","C183228","A question about whether an individual has or had a hard time hearing movies or TV because of their hearing.","Hard to Hear Movies or TV Because of Hearing | Is it hard to hear movies or TV because of your hearing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771733","Play with Fewer People Because of Hearing","C183229","A question about whether an individual plays with fewer people because of their hearing.","Play with Fewer People Because of Hearing | Do you play with fewer people because of your hearing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771730","Do Not Play with Certain People Outside of School Because of Hearing","C183230","A question about whether an individual does not play with certain people outside of school because of their hearing.","Do Not Play with Certain People Outside of School Because of Hearing | Do you not play with certain people outside of school because of your hearing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771731","Play with Friends or Relatives Less Often than Want Because of Hearing","C183231","A question about whether an individual plays with friends or relatives less often than they want to because of the individual's hearing.","Play with Friends or Relatives Less Often than Want Because of Hearing | Do you play with friends or relatives less often than you want to because of your hearing | Play with Friends or Relatives Less Often than Want Because of  Hearing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771728","Go to Parties Less Because of Hearing","C183232","A question about whether an individual goes to parties less because of their hearing.","Go to Parties Less Because of Hearing | Do you go to parties less because of your hearing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771729","Play Fewer Sports or Participate in Fewer Activities than Friends Because of Hearing","C183233","A question about whether an individual plays fewer sports or participates in fewer activities than their friends because of the individual's hearing.","Play Fewer Sports or Participate in Fewer Activities than Friends Because of Hearing | Do you play fewer sports or participate in fewer activities than your friends because of your hearing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771742","Parents Do Not Let Me Do Certain Things Because of Hearing","C183234","A question about whether an individual's parents do not let them do certain things because of the individual's hearing.","Parents Do Not Let Me Do Certain Things Because of Hearing | Do your parents not let you do certain things because of your hearing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771743","Hearing Loss Makes Me Feel Different from Everyone Else","C183235","A question about whether an individual's hearing loss makes them feel different from everyone else.","Hearing Loss Makes Me Feel Different from Everyone Else | Do you feel different from others because of your hearing | Does your hearing loss make you feel different from everyone else",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771740","Hearing Loss Makes Me Angry","C183236","A question about whether an individual's hearing loss makes them angry.","Hearing Loss Makes Me Angry | Does your hearing make you angry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771741","Bicinchoninic Acid Assay","C183237","A copper-based colorimetric assay for total protein quantification. This assay relies on the formation of a Cu2+-protein complex in a basic environment, followed by reduction of the Cu2+ to Cu+, causing a change of color from green to purple, with a strong absorbance at 562nm.","Bicinchoninic Acid Assay | BCA | Smith Assay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771751","Bioanalyzer","C183243","A chip-based capillary electrophoresis device for quality control of RNA, DNA, and protein samples. Digital data provides objective assessment of sizing, quantitation, integrity, and purity.","Bioanalyzer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771738","Quant-iT PicoGreen Assay","C183238","A method for quantitation of RNA, DNA, or protein. This assay uses fluorophores that become fluorescent upon binding and the fluorescence intensity directly correlates with the amount of the target molecule in the sample.","Quant-iT PicoGreen Assay | Quant-iT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771739","Qubit Assay","C183239","A quantitative assay that uses target-selective dyes that emit fluorescence when bound to DNA, RNA, or protein.","Qubit Assay | Qubit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771750","TapeStation","C183242","An automated electrophoresis method for quality control of DNA and RNA samples. The system analyzes size, quantity, and integrity of nucleotide samples through the integration of instrumentation, data processing software, reagents, and proprietary ScreenTape devices specific for DNA and RNA.","TapeStation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771736","DNA Integrity Number","C183240","An assessment of the amount of fragmentation in a genomic DNA sample. It is derived by an algorithm that assesses the distribution of signal across the size range and generates a calculated integrity number.","DNA Integrity Number | DIN | DNA DIN | DNA Integrity Number Assay | Integrity Number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771737","DV200 Assay","C183241","A method to determine the quality of RNA obtained from a sample. DV200 evaluates the percentage of fragments of greater than 200 nucleotides.","DV200 Assay | DV200 | DV200 Index",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972019","Plecanatide","C167027","An agonist of intestinal guanylate cyclase type C (GC-C) which is almost structurally identical to human uroguanylin, with laxative and anti-nociceptive activities.  Upon oral administration, plecanatide binds to and activates GC-C receptors located on endothelial cells on the luminal surface of the intestinal epithelium. This increases the concentration of intracellular cyclic guanosine monophosphate (cGMP). cGMP activates the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel and stimulates the secretion of chloride and bicarbonate into the intestinal lumen. This also promotes sodium excretion into the lumen and osmosis. The increased intestinal fluid secretion accelerates gastrointestinal transit of intestinal contents, improves bowel movement, softens stool, and relieves constipation. In addition, plecanatide exerts its anti-nociceptive effects by increasing the concentration of extracellular cGMP which inhibits the activity of pain-sensitive nerves, decreases muscle contractions and may relieve intestinal pain.","Plecanatide | PLECANATIDE | Trulance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1958126","Alogliptin","C76906","A selective, orally bioavailable, pyrimidinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. In addition to its effect on glucose levels, alogliptin may inhibit inflammatory responses by preventing the toll-like receptor 4 (TLR-4)-mediated formation of proinflammatory cytokines.","Alogliptin | ALOGLIPTIN | Benzonitrile, 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)- pyrimidinyl]methyl]-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771747","Lawton-Brody Instrumental Activities of Daily Living Total Score","C183247","The total score received in a Lawton-Brody Instrumental Activities of Daily Living test.","Lawton-Brody Instrumental Activities of Daily Living Total Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771744","Montreal Cognitive Assessment Functional Test Memory, 1st Trial Test","C183248","An individual's first attempt at completing the Montreal Cognitive Assessment functional memory test.","Montreal Cognitive Assessment Functional Test Memory, 1st Trial Test | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771745","Montreal Cognitive Assessment Functional Test Memory, 2nd Trial Test","C183249","An individual's second attempt at completing the Montreal Cognitive Assessment functional memory test.","Montreal Cognitive Assessment Functional Test Memory, 2nd Trial Test | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648173","Assay Name","C178857","The name of the assay.","Assay Name | Assay_Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771632","Hearing Environments and Reflection on Quality of Life Parent-proxy","C183256","A questionnaire designed to assess how a preschool child is affected by their hearing loss. Items are tailored to the experiences of preschool-aged children and administered as a parent-proxy (or caregiver) questionnaire.","Hearing Environments and Reflection on Quality of Life Parent-proxy | HEAR-QL-Preschool | Hearing Environments and Reflection on Quality of Life Parent-proxy Measure | Hearing Environments and Reflection on Quality of Life Parent-proxy Measure | Hearing Environments and Reflection on Quality of Life Parent-proxy Measure for Preschool-aged Children | Hearing Environments and Reflection on Quality of Life Parent-proxy Measure for Preschool-aged Children (2-6 years old) | Parent-Proxy Preschool HEAR-QL | Preschool HEAR-QL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771633","Child has Difficulty Following Directions","C183257","A question about whether a child has or had difficulty following directions.","Child has Difficulty Following Directions | My child has a hard time following directions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771645","Child Disobeys Rules or Gets in Trouble at Home","C183258","A question about whether a child disobeys rules or gets in trouble at home.","Child Disobeys Rules or Gets in Trouble at Home | My child disobeys rules or gets in trouble at home",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771646","Child Disobeys Rules or Gets in Trouble at School or Daycare","C183259","A question about whether a child disobeys rules at school or at daycare.","Child Disobeys Rules or Gets in Trouble at School or Daycare | My child disobeys rules or gets in trouble at school or daycare",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771643","Child Seeks Attention by Misbehaving","C183260","A question about whether a child seeks attention by misbehaving.","Child Seeks Attention by Misbehaving | My child seeks attention by misbehaving",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771644","Child Inattentive at School or Daycare","C183261","A question about whether a child was or is inattentive at school or daycare.","Child Inattentive at School or Daycare | My child does not pay attention in school or daycare",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771641","Child Inattentive at Home","C183262","A question about whether a child was or is inattentive at home.","Child Inattentive at Home | My child does not pay attention at home",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771642","Child Easily Distracted or Impulsive","C183263","A question about whether a child was or is easily distracted or impulsive.","Child Easily Distracted or Impulsive | My child is easily distracted or impulsive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771639","Child is Hyperactive","C183264","A question about whether a child was or is hyperactive.","Child is Hyperactive | My child is hyperactive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771640","Child Can be Rebellious","C183265","A question about whether a child is sometimes rebellious.","Child Can be Rebellious | My child can be rebellious",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771653","Child Has Difficulty Communicating or Expressing Themself","C183266","A question about whether a child had or has difficulty communicating or expressing themselves.","Child Has Difficulty Communicating or Expressing Themself | My child has a hard time communicating or expressing himself/herself",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771654","Others Have Difficulty Understanding Child","C183267","A question about whether other people had or have difficulty understanding the child.","Others Have Difficulty Understanding Child | Other people have difficulty understanding my child",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771651","Difficult for Child to Hear Movies or TV","C183268","A question about whether a child had or has difficulty hearing movies or TV.","Difficult for Child to Hear Movies or TV | It is hard for my child to hear movies or the TV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771652","Difficult for Child to Use Phone","C183269","A question about whether a child had or has difficulty using a telephone.","Difficult for Child to Use Phone | It is hard for my child to use the phone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771649","Difficult for Child to Hear in Restaurants","C183270","A question about whether a child had or has difficulty hearing in restaurants.","Difficult for Child to Hear in Restaurants | It is hard for my child to hear in restaurants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771650","Difficult for Child to Hear from Distance","C183271","A question about whether a child had or has difficulty hearing from a distance.","Difficult for Child to Hear from Distance | It is hard for my child to hear from a distance (e.g. at playgrounds, playing fields, etc.)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771647","Difficult for Child to Hear in Large Groups","C183272","A question about whether a child had or has difficulty hearing in large groups.","Difficult for Child to Hear in Large Groups | It is hard for my child to hear in large groups (e.g. birthday parties, family get-togethers, field trips, etc.)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771648","Difficult for Child to Interact in Dark Places","C183273","A question about whether a child had or has difficulty interacting in dark places.","Difficult for Child to Interact in Dark Places | It is hard for my child to interact in dark places (e.g. movie theaters, dark bedrooms, etc.)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771661","Child Dislikes New Situations","C183274","A question about whether a child had or has dislike for new situations.","Child Dislikes New Situations | My child does not like being in new situations",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771662","Child Anxious When Meeting New People","C183275","A question about whether a child was or is anxious when meeting new people.","Child Anxious When Meeting New People | My child becomes anxious when meeting new people",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771659","Child is Withdrawn or Shy","C183276","A question about whether a child was or is withdrawn or shy.","Child is Withdrawn or Shy | My child is withdrawn or shy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771657","Child Needs Help Playing with Other Children","C183278","A question about whether a child needed or needs help playing with other children.","Child Needs Help Playing with Other Children | My child needs help to play with other children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771658","Child has Difficulty Interacting with Peers","C183279","A question about whether a child had or  has difficulty interacting with similar-age peers.","Child has Difficulty Interacting with Peers | My child has difficulty interacting with his/her similar-age peers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771655","Child Excluded by Peers in Activities or Play","C183280","A question about whether a child was or is excluded by peers in activities or play.","Child Excluded by Peers in Activities or Play | My child's peers do not include my child in activities or play",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771656","PROMIS v2.0 Brief Profile Sexual Function and Satisfaction (Female)","C183281","A 14-item self-administered questionnaire for adult women focusing on satisfaction and physical functioning during sexual activity.","PROMIS v2.0 Brief Profile Sexual Function and Satisfaction (Female) | PROMIS SexFS Brief v2.0 | PROMIS SexFS v2.0 Brief Profile (Female) | SexFS Brief-Female | Sexual Function and Satisfaction v2.0 Brief Profile (Female)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771669","How Often Wanted Sexual Activity","C183282","A question about how often an individual has felt that they wanted to have sexual activity.","How Often Wanted Sexual Activity | How often have you felt like you wanted to have sexual activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771670","Have Any Type of Sexual Activity","C183283","A question about whether an individual had any type of sexual activity.","Have Any Type of Sexual Activity | Did you have any type of sexual activity (Examples of sexual activity are masturbation, oral sex, and sexual intercourse)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771667","No Sexual Activity Reason","C183284","A question about the reasons why an individual did not have any sexual activity.","No Sexual Activity Reason | What are the reasons why you did not have sexual activity in the past 30 days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771668","How Often Become Lubricated During Sexual Activity or Intercourse","C183285","A question about how difficult it was for an individual to maintain their lubrication until completion of sexual activity or intercourse.","How Often Become Lubricated During Sexual Activity or Intercourse | How often did you become lubricated ('wet') during sexual activity or intercourse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771665","How Difficult to Maintain Lubrication Until Completion of Sexual Activity or Intercourse","C183286","A question about how difficult it was for an individual to maintain their lubrication until completion of sexual activity or intercourse.","How Difficult to Maintain Lubrication Until Completion of Sexual Activity or Intercourse | How difficult was it to maintain your lubrication ('wetness') until completion of sexual activity or intercourse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771666","How Much Vaginal Discomfort During Sexual Activity","C183287","A question about how much vaginal discomfort an individual felt during sexual activity.","How Much Vaginal Discomfort During Sexual Activity | When you have had sexual activity, how much discomfort have you felt inside your vagina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771663","How Much Vaginal Pain During Sexual Activity","C183288","A question about how much vaginal pain an individual felt during sexual activity.","How Much Vaginal Pain During Sexual Activity | When you have had sexual activity, how much pain have you felt inside your vagina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771664","How Much Labia Pain During Sexual Activity","C183289","A question about how much labia pain an individual had during sexual activity.","How Much Labia Pain During Sexual Activity | How Much Labial Pain During Sexual Activity | When you have had sexual activity, how much discomfort have you had in your labia (lips around the opening of the vagina)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771677","How Much Clitoris Discomfort During Sexual Activity","C183290","A question about how much clitoral discomfort an individual had during sexual activity.","How Much Clitoris Discomfort During Sexual Activity | How Much Clitoral Discomfort During Sexual Activity | When you have had sexual activity, how much discomfort have you had in your clitoris (clit)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771678","How Often Have Orgasm or Climax When Wanted","C183291","A question about how often an individual orgasmed or climaxed when they wanted to.","How Often Have Orgasm or Climax When Wanted | How often have you been able to have an orgasm/climax when you wanted to",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771675","How Satisfying Are Orgasms or Climaxes","C183292","A question about how satisfying an individual's orgasms or climaxes have been.","How Satisfying Are Orgasms or Climaxes | How satisfying have your orgasms or climaxes been",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771676","How Much Pleasure from Sex Life","C183293","A question about how much pleasure an individual gets from their sex life.","How Much Pleasure from Sex Life | How much pleasure has your sex life given you",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771673","Not Interested in Sexual Activity","C183294","A response indicating that an individual is or was not interested in having sexual activity.","Not Interested in Sexual Activity | Was not interested in having sexual activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771674","Had Vaginal Dryness or Pain","C183295","A response indicating that an individual had dryness or pain in or around their vagina.","Had Vaginal Dryness or Pain | Dryness or pain in or around my vagina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771671","Had Difficulty with Orgasm or Climax","C183296","A response indicating that an individual had difficulties with orgasm or climax.","Had Difficulty with Orgasm or Climax | Difficulties with orgasm/climax",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771672","Do Not Enjoy Sexual Activity","C183297","A response indicating that an individual does not enjoy sexual activity.","Do Not Enjoy Sexual Activity | Don't enjoy sexual activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773268","Health Condition Prevented Sexual Activity","C183298","A response indicating that an individual's health condition prevented them from having sexual activity.","Health Condition Prevented Sexual Activity | Health condition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771685","Partner's Absence Prevented Sexual Activity","C183299","A response indicating that a partner's absence prevented an individual from having sexual activity.","Partner's Absence Prevented Sexual Activity | Partner was away",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771683","Partner's Lack of Interest Prevented Sexual Activity","C183300","A response indicating that a partner's lack of interest prevented an individual from having sexual activity.","Partner's Lack of Interest Prevented Sexual Activity | Partner was not interested in sexual activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771684","Partner's Health Condition Prevented Sexual Activity","C183301","A response indicating that a partner's health condition prevented an individual from having sexual activity.","Partner's Health Condition Prevented Sexual Activity | Partner's health condition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771681","Proximal Urethral Margin","C183302","The radical prostatectomy surgical margin that is located near the base of the prostate.","Proximal Urethral Margin | Bladder Neck Base Margin | PUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771682","Distal Urethral Margin","C183303","The radical prostatectomy surgical margin that is located near the apex of the prostate.","Distal Urethral Margin | Apex of Prostate Margin | Apical Margin | DUM | Prostatic Apex Margin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771455","Well-Defined Tumor Margin","C183110","Sharp tumor/normal parenchymal boundaries on all margins.","Well-Defined Tumor Margin | Well-defined",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771585","Uninterrupted Margin","C183317","An indication that a uniform margin was obtained around the entire excised lesion.","Uninterrupted Margin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771592","Oncogenic","C183322","Related to or causing tumor formation.","Oncogenic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773240","Vaginal Assessment Scale","C183347","A four-item clinician-administered measure that utilizes a four-point rating scale to assess a patient's perception of dryness, soreness, irritation, and pain for their vaginal area.","Vaginal Assessment Scale | VAS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773212","Have Vaginal Soreness","C183351","A question about whether an individual has or had vaginal soreness.","Have Vaginal Soreness | Soreness | Vaginal Soreness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773243","Have Vaginal Irritation","C183352","A question about whether an individual has or had vaginal irritation.","Have Vaginal Irritation | Irritation | Vaginal Irritation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773312","Have Dyspareunia","C183353","A question about whether an individual has or had painful intercourse.","Have Dyspareunia | Dyspareunia | Dyspareunia (Pain w/intercourse) | Have Painful Intercourse | Pain with Intercourse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773286","Have Vulvar Dryness","C183356","A question about whether an individual has or had vulvar dryness.","Have Vulvar Dryness | Dryness | Vulvar Dryness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771616","Have Vulvar Soreness","C183357","A question about whether an individual has or had vulvar soreness.","Have Vulvar Soreness | Soreness | Vulvar Soreness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771614","Have Vulvar Irritation","C183358","A question about whether an individual has or had vulvar irritation.","Have Vulvar Irritation | Irritation | Vulvar Irritation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771615","Have Vulvar Pain When Touched","C183359","A question about whether an individual has or had vulvar pain when touched.","Have Vulvar Pain When Touched | Painful to Touch",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771612","How often Use Vaginal Lubricant or Dilator with Sexual Activity","C183360","A question about how often an individual uses vaginal lubricant or a dilator as a vaginal health promotion strategy with sexual activity.","How often Use Vaginal Lubricant or Dilator with Sexual Activity | Vaginal Lubricant with Sexual Activity and/or Vaginal Health Promotion Strategy (dilator)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771613","Type of Vaginal Lubricant","C183361","A question about the type of vaginal lubricant an individual uses with sexual activity.","Type of Vaginal Lubricant | Type of Lubricant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771625","How Often Done Pelvic Floor Exercises","C183362","A question about how often an individual performs or has performed pelvic floor exercises.","How Often Done Pelvic Floor Exercises | Pelvic Floor Exercises",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771626","How Often Use Internal Vaginal Moisturizer","C183363","A question about how often an individual uses or used internal vaginal moisturizer with sexual activity.","How Often Use Internal Vaginal Moisturizer | Internal Vaginal Moisturizer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771623","Type of Internal Vaginal Moisturizer","C183364","A question about the type of internal vaginal moisturizer an individual uses.","Type of Internal Vaginal Moisturizer | Type (used internally)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771624","Use External Vaginal Moisturizer","C183365","A question about whether an individual uses an external vaginal moisturizer.","Use External Vaginal Moisturizer | External Moisturizer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771621","Type of External Vaginal Moisturizer","C183366","A question about the type of external vaginal moisturizer an individual uses.","Type of External Vaginal Moisturizer | Type (used externally)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771622","How Often Done Vaginal Dilation Therapy","C183367","A question about how often an individual did or does vaginal dilation therapy.","How Often Done Vaginal Dilation Therapy | Dilation Therapy | Dilator Therapy | Vaginal Dilator Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771619","Vaginal Dilator Size","C183368","A question about the size of vaginal dilator that an individual uses.","Vaginal Dilator Size | If using, size of dilator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771620","Have Pain with Dilator Use","C183369","A question about whether an individual experiences pain with the use of a vaginal dilator.","Have Pain with Dilator Use | If using, pain with dilator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771630","Have Pain with Gynecologic Examination","C183370","A question about whether an individual has or had pain with gynecologic examination.","Have Pain with Gynecologic Examination | Pain with Gynecologic Exam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771886","Lowest Grade","C183509","A morphologic grade that refers to the minimum grade that a malignant tumor can exhibit (usually grade I-well differentiated).","Lowest Grade | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443935","Anti-Ribonucleoprotein Antibody","C121325","An antinuclear antibody directed against U1 snRNP, that is strongly associated with mixed connective tissue disease and commonly detected in lupus.","Anti-Ribonucleoprotein Antibody | Anti-RNP | Anti-RNP Antibody | Anti-Ribonucleoprotein | RNP Antibody | Ribonucleoprotein Antibody",,,,,,,,,,,,,,,"4127326","Ribosomal ribonucleoprotein antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1771891","Anti-Histidine-tRNA Ligase, Cytoplasmic Autoantibody","C183519","An autoantibody that recognizes histidyl-tRNA synthetase, cytoplasmic protein.","Anti-Histidine-tRNA Ligase, Cytoplasmic Autoantibody | Anti-HARS1 | Anti-HARS1 Autoantibody | Anti-HisRS | Anti-HisRS Autoantibody | Anti-Histidine-tRNA Ligase, Cytoplasmic Antibody | Anti-Histidyl-tRNA Synthetase | Anti-Histidyl-tRNA Synthetase Autoantibody | Anti-Jo-1 | Anti-Jo-1 Antibody | Anti-Jo-1 Antigen | Anti-Jo-1 Antigen Antibody | HARS1 Autoantibody | HisRS Autoantibody | Histidyl-tRNA Synthetase Autoantibody | Jo-1 Antibody | Jo-1 Antigen Antibody",,,,,,,,,,,,,,,"4187656","Anti Jo-1 antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1771888","Anti-Major Centromere Autoantigen B Autoantibody","C183520","An autoantibody that recognizes major centromere autoantigen B protein.","Anti-Major Centromere Autoantigen B Autoantibody | Anti-CENP-B | Anti-CENP-B Autoantibody | Anti-CENPB | Anti-CENPB Autoantibody | Anti-Centromere B | Anti-Centromere B Autoantibody | Anti-Major Centromere Autoantigen B | Anti-Major Centromere Autoantigen B Antibody | CENP-B Autoantibody | CENPB Autoantibody | Centromere B Autoantibody | Major Centromere Autoantigen B Autoantibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771902","SIOP Grade","C183533","A grade ranging from 0 to 4 that indicates the range and decibel (dB) loss of hearing loss at specific frequency ranges resulting from ototoxicity in childhood cancer patients who have received platinum-based chemotherapy.","SIOP Grade | International Society of Pediatric Oncology Grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771903","Overall SIOP Grade","C183534","A grade that represents the overall hearing loss resulting from ototoxicity in childhood cancer patients who have received platinum-based chemotherapy.","Overall SIOP Grade | International Society of Pediatric Oncology Overall Grade | Overall International Society of Pediatric Oncology Grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772611","No Attempt to Orgasm or Climax","C184303","A response indicating that an individual has not tried to have an orgasm or climax.","No Attempt to Orgasm or Climax | Have not tried to have an orgasm/climax",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772612","No Orgasm or Climax","C184304","A response indicating that an individual has not had an orgasm or climax.","No Orgasm or Climax | Have not had an orgasm/climax",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772613","A Little Satisfied","C184301","A subjective response indicating that an individual is a little satisfied.","A Little Satisfied | A little bit satisfied",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772614","Quite Satisfied","C184302","A subjective response indicating that an individual is quite satisfied.","Quite Satisfied | Quite a bit satisfied",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772635","Evaluable","C184325","Able to be evaluated.","Evaluable | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3469597","Medication Administration","C128534","The administration of a drug to a patient.","Medication Administration | ",,,,,,,,,,,,,,,"4088217","Administration of medication",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704240","Magnitude","C49158","Greatness in size or extent; a number assigned to a quantity so that it may be compared with other quantities.  (Dictionary.com)","Magnitude | ",,,,,,,,,,,,,,,"4152518","Magnitudes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3273704","Gene Product Sequence Variation","C97928","A variation in the sequence of a specific gene product.","Gene Product Sequence Variation | AA_MUTATION | Gene Product Sequence Variant | amino acid change | amino_acid_change",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0301630","Reduction","C157203","A chemical reaction that results in a gain of electrons by one of the chemical species involved in the reaction.","Reduction | ",,,,,,,,,,,,,,,"4238513","Reduction (chemical)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0681848","Panel Study","C53311","A type of longitudinal study where the same participants are used through the study period, often over a long period of time.","Panel Study | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406225","Multisystem Inflammatory Syndrome in Children","C172127","A rare syndrome temporally associated with COVID-19 in children, marked by persistent fever, inflammation (neutrophilia, elevated C-reactive protein (CRP), and lymphopenia), poor function in one or more organs, and other specific clinical and laboratory features not attributable to other infections. The characteristics of this syndrome appear to be similar to toxic shock syndrome and Kawasaki disease. The following variable signs and symptoms have been most commonly reported to date: coagulopathy, cardiac dysfunction, diarrhea, abdominal distension, other GI symptoms (with some children having positive stool tests for SARS-CoV-2), and acute kidney injury. Respiratory symptoms are not always a prominent feature in these cases.","Multisystem Inflammatory Syndrome in Children | COVID-19-Related Pediatric Inflammatory Multisystem Syndrome | MIS-C | MISC | Multisystem Inflammatory Syndrome in Children (MIS-C) | Multisystem Inflammatory Syndrome in Children Associated with COVID-19 | Multisystem inflammatory syndrome in children (MIS-C) | PIMS | PMIS | Pediatric Inflammatory Multisystem Syndrome | Pediatric Multi-System Inflammatory Syndrome Potentially Associated with COVID-19 | Pediatric Multisystem Inflammatory Syndrome | Pediatric Multisystem Inflammatory Syndrome",,,,,,,,,,,,,,,"619428","Multisystem inflammatory syndrome in children",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL972795","Known History of Kawasaki Disease","C168302","An indication that the patient has a history of Kawasaki disease.","Known History of Kawasaki Disease | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514593","Bone Marrow Transplantation Recipient","C131759","An individual receiving a bone marrow transplant.","Bone Marrow Transplant Recipient | Bone Marrow Transplantation Recipient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562966","Feeding Tube Dependency","C156238","The inability of a patient to received their nutrition other than through a feeding tube.","Feeding Tube Dependency | Feeding Tube Dependence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023015","Language Disorder","C97155","A category of disorders characterized by an impairment in the development of an individual's language capabilities, which is in contrast to his/her non-verbal intellect.","Language Disorder | Language Deficits",,,,,,,,,,,,,,,"437896","Disorder of language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3276355","Intellectual Disability","C97250","A broad category of disorders characterized by an impairment to the intelligence an individual possesses. These impairments can result from trauma, birth, or disease and are not restricted to any particular age group.","Intellectual Disability | Intellectual Disabilities",,,,,,,,,,,,,,,"40277917","Intellectual disability",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3278623","Developmental Delay","C116942","Failure to meet, or late achievement of developmental milestones.","Developmental Delay | Delayed developmental milestones",,,,,,,,,,,,,,,"436077","Developmental delay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3809495","Autism","C97161","A disorder characterized by marked impairments in social interaction and communication accompanied by a pattern of repetitive, stereotyped behaviors and activities. Developmental delays in social interaction and language surface prior to age 3 years.","Autism | Autistic Disorder",,,,,,,,,,,,,,,"4254211|434902","Infantile autism|Autistic disorder of childhood onset",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3809115","Asperger Syndrome","C97159","A disorder most often diagnosed in the pediatric years in which the individual displays marked impairment in social interaction and a repetitive, stereotyped pattern of behavior. The individual, however, displays no delay in language or cognitive development, which differentiates Asperger Syndrome from autism.","Asperger Syndrome | ",,,,,,,,,,,,,,,"4053178","Asperger's disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524528","Pervasive Developmental Disorder","C97179","A category of developmental disorders characterized by impaired communication and socialization skills. The impairments are incongruent with the individual's developmental level or mental age. These disorders can be associated with general medical or genetic conditions.","Pervasive Developmental Disorder | ",,,,,,,,,,,,,,,"439776","Autism spectrum disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4229461","Tracheomalacia","C98634","A congenital or acquired abnormality of the wall of the trachea. In congenital cases, there is lack of rigidity in the cartilage of the tracheal wall. In acquired cases, the cartilage of the tracheal wall is degenerated, secondary to tracheostomy or prolonged presence of a breathing tube, or as a complication of a tracheoesophageal fistula surgical repair. Symptoms include stridor, noisy breathing, and upper respiratory infections.","Tracheomalacia | ",,,,,,,,,,,,,,,"4316221","Tracheomalacia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513997","Solid Organ Transplantation Recipient","C130200","An individual who is receiving a transplant of a solid organ.","Solid Organ Transplant Recipient | Solid Organ Transplantation Recipient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407576","Mitigation Strategy","C173767","A plan used to minimize the effects of a deleterious phenomenon.","Mitigation Strategy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412911","Face Mask","C173747","A barrier device that covers the nose and mouth, used in infection control.","Protective Face Mask | Face Mask | Mask",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334369","Breast Ductal Carcinoma In Situ, Comedo Type","C176005","Breast ductal carcinoma in situ characterized by the presence of sheets of tumor cells with evidence of central necrosis and associated karyorrhectic/nuclear debris.","Breast Ductal Carcinoma In Situ, Comedo Type | Breast Intraductal Comedo Adenocarcinoma | Comedocarcinoma, noninfiltrating | DCIS - Comedo | comedo carcinoma","8501/2","Comedocarcinoma, noninfiltrating",,,,,,,,,,,,,"4302294","Comedocarcinoma, noninfiltrating",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C1827547","Repetitive Behavior","C117193","Recurring actions that are often non-purposeful.","Repetitive Behavior | Repetitive Behaviors",,,,,,,,,,,,,,,"4312369","Repetitious behavior",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2983679","Test Site Location","C90471","The geographic location in which a test is managed.","Test Site Location | TSLOC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969242","Testing Was Performed","C160289","An indication that specific tests were performed during the study.","Testing Was Performed | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1261478","Specified Viral Load Test","C174331","A measurement of the total number of viral particles of a pre-specified virus in a specimen.","Specified Viral Load Test | VIRAL LOAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0566528","Expectorate","C85859","To clear material from the throat or lungs by coughing it up and spitting it out.","Expectorate | EXPECTORATION",,,,,,,,,,,,,,,"4122569|4125282","Does expectorate|Does spit",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3279469","Hyperpyrexia","C111817","Body temperature of 106 degrees Fahrenheit (41.1 degrees Celsius) or higher.","Hyperpyrexia | ",,,,,,,,,,,,,,,"4260205","Hyperpyrexia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1406253","COVID Toes","C172128","A self-limited dermatologic manifestation seen on the toes of some patients with COVID-19 that resembles chilblains (perniosis). The lesions may be pink, red, blue or purple and have a similar appearance to frostbite. It appears to resolve once the infection has been cleared.","COVID Toes | COVID-19 Toes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3280232","Impaired Balance","C122435","A deficit in equilibrium, which may manifest as unsteady ambulation or inability to maintain an upright position.","Impaired Balance | Balance Problems | Loss of Balance",,,,,,,,,,,,,,,"4087040","Difficulty balancing",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0458247","Allodynia","C180616","Pain caused by a stimulus that would not normally provoke pain.","Allodynia | ",,,,,,,,,,,,,,,"4083293","Allodynia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897410","Symptom Onset Date","C119242","The date and time on which the symptoms began or were first noted.","Symptom Onset Date | Date_of_Symptom_Onset | SYMSTDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0180446","Vaginal Dilator","C157720","A device designed to enlarge the vaginal canal in depth or diameter.","Vaginal Dilator | ",,,,,,,,,,,,,,,"4232674","Vaginal dilator",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0878787","Growth Failure","C113100","Less than normal linear growth in an infant or child.","Growth Failure | Linear Growth Failure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972757","History of Failure to Gain Weight","C168252","A history of less than normal weight gain.","History of Failure to Gain Weight | Failure to Gain Weight/Thrive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0344315","Depressed Mood","C117199","An emotional state characterized by feelings of sadness, emptiness, and/or tearfulness.","Depressed Mood | Decreased Mood | Depressed | Low Mood",,,,,,,,,,,,,,,"40546087","Depressed mood",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0241262","Strawberry Tongue","C168443","A pathological finding in which inflammation, hyperemia and enlarged papillae of the dorsum of the tongue resemble a strawberry. It may be seen in variety of bacterial and viral disorders, and in non-infectious disorders such as Kawasaki disease.","Strawberry Tongue | Strawberry tongue",,,,,,,,,,,,,,,"4175036","Strawberry tongue",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0235592","Cervical Lymphadenopathy","C40989","Enlargement of the cervical lymph nodes usually due to infections or involvement by malignant neoplasms.","Cervical Lymphadenopathy | ",,,,,,,,,,,,,,,"4133459","Cervical lymphadenopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0425470","Intercostal Retractions","C87087","The marked inward movement of the muscles between the ribs during inhalation, indicating that there is reduced pressure in the thoracic cavity, and which can be a sign of breathing difficulties.","Intercostal Retractions | Intercostal Recession | Retractions",,,,,,,,,,,,,,,"4272647","Intercostal recession",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034642","Rales","C119216","Abnormal breath sounds (crackles) heard on auscultation, indicating inflammation, fluid, or infection of the lung.","Rales | PULMONARY RALES/CRACKLES/CREPITATIONS | Pulmonary Rales",,,,,,,,,,,,,,,"4167669","Respiratory crackles",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1772901","Sexual Activity Not Attempted","C184938","A response indicating that an individual did not attempt any sexual activity.","Sexual Activity Not Attempted | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1138226","Favipiravir","C81605","A pyrazinecarboxamide derivative with activity against RNA viruses. Favipiravir is converted to the ribofuranosyltriphosphate derivative by host enzymes and selectively inhibits the influenza viral RNA-dependent RNA polymerase.","Favipiravir | 6-Fluoro-3-hydroxy-2-pyrazinecarboxamide | Avipiravir | FAVIPIRAVIR | T-705",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553517","Remdesivir","C152185","A prodrug of an adenosine triphosphate (ATP) analog, with potential antiviral activity against a variety of RNA viruses. Upon administration, remdesivir, being a prodrug, is metabolized into its active form GS-441524. As an ATP analog, GS-441524 competes with ATP for incorporation into RNA and inhibits the action of viral RNA-dependent RNA polymerase. This results in the termination of RNA transcription and decreases viral RNA production.","Remdesivir | 2-Ethylbutyl (2S)-2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate | GS-5734 | L-Alanine, N-((S)-hydroxyphenoxyphosphinyl)-, 2-Ethylbutyl Ester, 6-Ester with 2-C-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-2,5-anhydro-D-altrononitrile | RDV | REMDESIVIR | SARS-CoV-2 antiviral agents: remdesivir | Veklury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405852","COVID-19 Convalescent Plasma","C171633","Plasma that has been collected from patients who have recovered from the novel coronavirus disease, COVID-19. This plasma contains antibodies developed against the SARS-CoV-2 virus and is being investigated for the treatment of COVID-19.","COVID-19 Convalescent Plasma | COVID-19 Plasma | COVID-19 convalescent plasma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0126174","Losartan","C66869","A non-peptide angiotensin II antagonist with antihypertensive activity. Upon administration, losartan and its active metabolite selectively and competitively blocks the binding of angiotensin II to the angiotensin I (AT1) receptor. This blocks the vasoconstricting and aldosterone-secreting actions of angiotensin II, leading to a decrease in blood pressure. Angiotensin II, formed from angiotensin I by angiotensin-converting enzyme (ACE), stimulates the adrenal cortex to synthesize and secrete aldosterone, which decreases the excretion of sodium and increases the excretion of potassium. Angiotensin II also acts as a vasoconstrictor in vascular smooth muscle.","Losartan | 2-Butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol | LOSARTAN | losartan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0932441","Pelvic Floor Muscle","C33290","The muscles, composed of the levator ani and the coccygeus muscles, that create a division between the pelvic cavity and the perineal region.","Pelvic Floor Muscle | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772910","Vaginal Moisturizer","C184953","Any moisturizer that is used to treat vaginal dryness.","Vaginal Moisturizer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0430649","High Frequency Audiometry","C184945","Audiometric testing for hearing in the range of 8 to 20 kHz.","High Frequency Audiometry | HFA | High Frequency Audiometric Testing",,,,,,,,,,,,,,,"4093103","High frequency audiometry",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1773186","Brainstem Responses, Auditory","C184949","A neurologic test of auditory brainstem function in response to auditory stimuli, used to diagnose suspected neurologic abnormalities of the 8th cranial nerve as well as the associated auditory pathways. It is an objective measurement of auditory pathway function from the auditory nerve to the mesencephalon.","Auditory Brainstem Response | ABR | BAEP | BAER | Brainstem Auditory Evoked Potentials | Brainstem Auditory Evoked Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1769399","Auditory Steady-state Response","C184950","A neurologic test that measures the electrophysiologic response to rapid auditory stimuli. The test uses statistical measures to determine if and when a threshold is present. It is used to create an estimated audiogram for individuals unable or unwilling to participate in traditional behavioral tests.","Auditory Steady-state Response | ASSR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773341","Distortion Product Otoacoustic Emissions","C184951","A neurologic test that provides a preneural, noninvasive assessment of cochlear function. Distortion-product otoacoustic emissions are generated in the cochlea in response to two tones of a given frequency and sound pressure level presented in the ear canal and are an objective indicator of normally functioning cochlea outer hair cells.","Distortion Product Otoacoustic Emissions | DPOAE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3844828","Transient Evoked Otoacoustic Emissions","C184946","A non-invasive test of outer hair cell function up to 14.7 kHz. Otoacoustic emissions are measured by presenting a series of sounds to the ear through a probe that is inserted in the ear canal. The probe contains a loudspeaker that generates the sounds and a microphone that measures the resulting OAEs that are produced in the cochlea and are transmitted through the middle ear into the outer ear canal.","Transient Evoked Otoacoustic Emissions | TEOAE | TOAE | Transient Otoacoustic Emissions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772903","Headphones Audiometry Testing","C184947","An audiometry test where the subject wears headphones and hears a range of sounds directed to one ear at a time.","Headphones Audiometry Testing | Audiometry earphones | Headphones | Headphones Audiometric Testing | Headphones Audiometry | Headphones Audiometry Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772904","Soundfield Testing","C184948","A method for audiology testing that takes place in a sound-isolated room via speakers rather than the use of headphones or earphones.","Soundfield Testing | Sound Field | Sound Field Testing | Soundfield",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772902","Extremely High Frequency","C184952","The band of radio frequencies in the electromagnetic spectrum from 30 to 300 gigahertz.","Extremely High Frequency | EHF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950978","Neoplasm Polygenic Risk Score","C158975","A numeric value that estimates the risk of development of a specified neoplastic disease that is based on weighted regression analysis of disease-specific gene variants at multiple genetic loci.","Neoplasm Polygenic Risk Score | Neoplasm Genetic Risk Score | Neoplasm Polygenic Score | PRS | Polygenic Risk Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405801","COVID-19-Associated Acute Liver Injury","C171566","Acute liver injury caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).","COVID-19-Associated Acute Liver Injury | SARS-CoV-2-Associated Acute Liver Injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3178789","Pain Amplification Syndrome","C119048","A condition in which the nerves register normal stimuli (lack of tissue injury) as pain, resulting in feelings of intense pain with even minor sensory input.","Pain Amplification Syndrome | Amplified Musculoskeletal Pain Syndrome | Chronic Widespread Pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0181598","Left Ventricular Assist Device","C80473","A mechanical pump which also includes a control system and an energy supply. It receives blood from the left ventricle and delivers it to the aorta, thus helping the heart to pump sufficient blood to the body.","Left Ventricular Assist Device | LVAD",,,,,,,,,,,,,,,"4235161","Left ventricular assist device",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1980011","Vasoactive","C94301","Able to have an effect on blood vessels.","Vasoactive | vasoactive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406326","Mechanical Component","C172006","A device that is designed to be part of a machine.","Mechanical Component | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643946","Post-Acute Sequelae of COVID-19","C179263","A constellation of signs and symptoms that can persist for weeks or months after acute infection with SARS-CoV-2, or appear weeks after infection.  This condition may be characterized by fatigue, shortness of breath, difficulty focusing or concentrating ('brain fog'), sleep disorders, fevers, gastrointestinal symptoms, anxiety, and depression.","Post-Acute Sequelae of COVID-19 | Long COVID | Long COVID-19 Syndrome | PASC | Post-acute sequelae of COVID-19 (>= 4 weeks) | Postacute sequelae of SARS-CoV-2 infection (PASC)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1405785","COVID-19-Associated Pneumonia","C171550","Pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is characterized by the presence of ground glass opacities on CT scan images.","COVID-19-Associated Pneumonia | Pneumonia | SARS-CoV-2 -Associated Pneumonia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1709763","Psychiatric Facility","C53536","A place designed and staffed to house and treat individuals that need assistance with mental dysfunctions.","Psychiatric Facility | PSYCHIATRIC FACILITY | PSYCHIATRIC HOSPITAL OR A PSYCHIATRIC-DISTINCT PART UNIT OF A HOSPITAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773113","HPV Status Correlated to CDKN2A-p16 Expression Status","C185050","An indication of whether a neoplastic sample is positive or negative for expression of CDKN2A-p16. Positive expression of CDKN2A-p16 indicates that the tumor is related to a current or prior HPV infection, especially infections caused by high-risk HPV genotypes.","HPV Status Correlated to CDKN2A-p16 Expression Status | HPV Status by p16 | Human Papilloma Virus Status by p16 | Human Papillomavirus Status by p16",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977940","Gene Name","C164806","The English language identifier of a gene as defined by the specified source.  EXAMPLE(S):  Breast cancer type 1 susceptibility gene  OTHER NAME(S):  NOTE(S):","Gene Name | Gene.name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0200044","Gynecological Examination","C137854","Physical examination pertaining to the female reproductive system.","Gynecological Examination | Gynecological Exam",,,,,,,,,,,,,,,"4306780","Gynecologic examination",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4273905","Pain Catastrophizing Scale","C185080","A 13-item self-administered questionnaire that measures heightened negative cognitive and affective pain responses. Each item is rated on a 5-point Likert style scale from 0 (not at all) to 4 (all the time) with higher scores indicating more catastrophizing.","Pain Catastrophizing Scale | PCS-A | Pain Catastrophizing-Adult",,,,,,,,,,,,,,,"37397272","Pain Catastrophizing Scale",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1773125","Pain Catastrophizing Scale-Child Version","C185081","A 13-item version of the Pain Catastrophizing Scale designed for answering by a child. It measures heightened negative cognitive and affective pain responses, with each item rated on a 5-point Likert style scale.","Pain Catastrophizing Scale-Child Version | PCS-C | Pain Catastrophizing Scale-Child Version (PCS-C)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773135","Pain Catastrophizing Scale-Parent Proxy","C185083","A 13-item version of the Pain Catastrophizing Scale designed for a parent to answer about their child's pain. It measures heightened negative cognitive and affective pain responses when the respondent's child is in pain. Each item rated on a 5-point Likert style scale.","Pain Catastrophizing Scale-Parent Proxy | PCS-P | Pain Catastrophizing Scale-Parent Version (PCS-P)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773134","Pain Coping Strategies Questionnaire-Adult","C185085","A 14-item questionnaire designed to rapidly assess pain-related beliefs and coping strategies. All items in this self-report instrument are scored on a scale from 0 to 6, with 0 equivalent to 'Never Do That' and 6 representing 'Always Do That'.","Pain Coping Strategies Questionnaire-Adult | CSQ | Coping Strategies Questionnaire | Pain Coping Scale | Pain Coping-Adult",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773131","Pain Coping Strategies Questionnaire-Child","C185089","A self-administered 16-item questionnaire designed to assess pain coping strategies in children and adolescents, with each item rated on a 5-point Likert style scale.","Pain Coping Strategies Questionnaire-Child | Pain Coping-Child",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773132","Pain Intensity Scale-Adolescent and Adult","C185090","A single self-administered question assessing acute and chronic pain intensity for an adult or adolescent during the past 7 days. The item is measured on an 11-point scale.","Pain Intensity Scale-Adolescent and Adult | Pain Intensity-Adolescent and Adult | Pain Intensity-Adult",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773142","Pain Intensity Scale-Child","C185091","A single interviewer-administered question for children aged 4- to 12-years-old assessing acute pain intensity. The item is measured on an 11-point scale.","Pain Intensity Scale-Child | Pain Intensity-Child",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773143","Pain Interference-Adult","C185092","An 8-item self-report questionnaire for adults that assesses how pain impacted daily activities of living and the enjoyment of those activities, with each item rated on a 5-point Likert style scale.","Pain Interference-Adult | Pain Interference-Short Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773140","Pain Interference-Child","C185093","An 8-item self-report questionnaire for children that assesses how pain impacts a child's daily activities of living and the enjoyment of those activities, with each item rated on a 5-point Likert style scale.","Pain Interference-Child | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773141","Pain Interference-Parent Proxy","C185094","An 8-item self-report questionnaire answered by a parent for their child that assesses how pain impacts a child's daily activities of living and the enjoyment of those activities, with each item rated on a 5-point Likert style scale.","Pain Interference-Parent Proxy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773138","Sickle Cell Disease Pain Location Body Map-Adult","C185095","A single question designed to assess the number and location of sites on the body where pain symptoms are felt.","Sickle Cell Disease Pain Location Body Map-Adult | Pain Location-Adult | Sickle Cell Pain Diary Question 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773139","Pain Location Body Map-Child","C185096","A self-administered body map with 21 scored areas that can be marked to indicate where a child has experienced pain.","Pain Location Body Map-Child | CARRA Pain Chart | Pain Location-Child",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773136","Pain Quality Descriptors (Affective)-Children","C185097","A self-administered questionnaire for 8- to 17-year-olds that assesses 8 descriptors of affective pain quality.","Pain Quality Descriptors (Affective)-Children | Pain Quality Descriptors (Affective)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773137","Pain Quality Descriptors (Sensory)-Children","C185098","A self-administered pain quality survey for 8- to 17-year-olds that assesses 8 descriptors of sensory pain quality across 5 severity levels.","Pain Quality Descriptors (Sensory)-Children | Pain Quality Descriptors (Sensory)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773148","Patient Global Impression of Health Change","C185099","A single, self-administered question asking an individual to rate how their condition has changed since a certain point in time. The response is measured on a 7 point scale.","Patient Global Impression of Health Change | Patient Global Impression of Change | Patient Reported Impression of Change",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773149","Physical Mobility-Adult","C185100","A 44-item self-administered questionnaire that assesses how well an individual can perform a specified task that utilizes physical mobility. Each is rated on a 5-point Likert scale from 1: Unable to do, to 5: Without any difficulty.","Physical Mobility-Adult | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773147","Physical Mobility-Child","C185101","An 8-item self-administered questionnaire that assesses how well a child can perform a specified task that utilizes physical mobility. Each is rated on a 5-point Likert scale from 1: Not able to do, to 5: With no trouble.","Physical Mobility-Child | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773145","Physical Mobility-Hospitalized Individuals","C185103","A 12-item self-administered questionnaire that assesses how well a hospitalized individual can perform a specified task that utilizes physical mobility. Each is rated on a 5-point Likert scale from Not Difficult, to Extremely Difficult.","Physical Mobility-Hospitalized Individuals | Physical Mobility-Hospitalized",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773144","Oral Morphine Milligram Equivalents","C185105","A table containing conversion factors that allows different opioid medications to be converted to consistent units.","Oral Morphine Milligram Equivalents | MME | Opioid Oral Morphine Milligram Equivalents (MME) Conversion Factors | Opioid Oral Morphine Milligram Equivalents Conversion Factors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773150","PAXgene Tissue System","C185113","A proprietary system comprised of a formalin-free tissue fixative and stabilizing reagent designed to preserve tissue structures without damaging biomolecules. This allows both histologic examination and isolation of RNA, miRNA, DNA, and/or proteins from a single sample.","PAXgene Tissue System | PAXgene Tissue | PAXgene Tissue FIX | PAXgene Tissue STABILIZER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773153","95% Ethyl Alcohol","C185110","An aqueous dilution of ethanol containing 95% ethanol by volume, which may be used as a solvent, disinfectant or fixative.","95% Ethyl Alcohol | 95% Ethanol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773152","Diimidoester","C185112","A group of reagents that reacts with the epsilon-amino group of lysine and forms intermolecular cross-links within proteins. These agents may be used as tissue fixatives for electron microscopy and immunohistochemistry.","Diimidoester | Diimidoesters",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773151","Carbodiimide","C185111","A group of reagents that crosslinks amines and carboxylates, that may be used as a fixative and in peptide conjugation.","Carbodiimide | Carbodiimides",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540493","Feels","C142557","A patient's physical sensation (e.g., symptoms) or perceived mental state. A patient may feel pain, feel feverish, or perceive a severely low mood (as with depression). [FDA Clinical Outcome Assessment (COA) Glossary]","Feels | feels",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706451","Alarm Device","C49813","A device designed to signal the occurrence of a particular event.","Alarm Device | Alarm",,,,,,,,,,,,,,,"4220345","Alarm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706099","Amplifier","C49825","An electronic device designed to take an input signal and output an increased signal strength.","Amplifier Device | Amplifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643457","Gene Amplification Positive","C177682","An indication that amplification of one or more genes of interest was detected in a sample.","Gene Amplification Positive | Amplification Detected | Amplification Positive | Amplified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773457","DM Hearing Aid System","C185116","A wireless electronic device designed to improve hearing, especially in noisy environments, by transmitting sound over a distance from a microphone to a receiver using digital signals.","DM Hearing Aid System | DM System | Digital Modulation Hearing Aid System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3881509","Bone-anchored Hearing Aid","C185117","A hearing device that includes a sound processor and a small titanium fixture that is surgically-implanted behind the ear to transfer sound vibrations to a functioning cochlea through direct bone conduction, typically in individuals with outer or middle ear malformations or unilateral hearing loss.","Bone-anchored Hearing Aid | BAHA Device | Bone-anchored Auditory Implant",,,,,,,,,,,,,,,"45762009","Anchored bone-conduction hearing aid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1773459","Closed Captioning","C185118","A display of words and other descriptive text that is encoded within a video signal and provides an optional transcript of all audio information.","Closed Captioning | Closed Caption | Closed-Captioning",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512717","Medulloblastoma, SHH-Activated","C129441","A molecular subtype of medulloblastoma associated with activation of the sonic hedgehog (SHH) pathway. TP53 mutations may be present or absent. Patients in this group are young children and adults. Overall survival is variable and depends on the presence or absence of metastatic disease, histology, and the age at diagnosis.","Medulloblastoma, SHH-Activated | SHH-Activated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3276776","Conductive Hearing Loss","C27645","Hearing loss caused by impaired transmission of signals from the external auditory canal or middle ear to the cochlea.","Conductive Hearing Loss | Conductive Deafness",,,,,,,,,,,,,,,"377888","Conductive hearing loss",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3816747","Five Hundred","C133760","The natural number greater than 499 and less than 501 and the quantity that it denotes.","Five Hundred | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378621","High Risk Prostate Carcinoma","C168684","Prostate carcinoma with clinicopathologic, cytogenetic, and molecular findings that define a prostate carcinoma as high risk.","High Risk Prostate Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773488","California Verbal Learning Test - Third Edition","C185142","The third published version of the California Verbal Learning Test, a neuropsychological test developed to make a comprehensive and detailed assessment of verbal learning and memory in individuals ranging in age from 16 to 89 years. This edition includes a new index that is designed to provide a more refined assessment of yes/no recognition memory by minimizing potential influences of source and semantic interference.","California Verbal Learning Test - Third Edition | CVLT3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773491","Visual Working Memory Index (WMS-IV)","C185143","A subtest of the Wechsler Memory Scale, 4th Edition that assesses visual working and visual-spatial working memory using recognition memory and free recall formats.","Visual Working Memory Index (WMS-IV) | VWMI | Visual Working Memory Index",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3273703","Molecular Sequence Variation","C97926","A variation in or modification of the molecular sequence of a gene or gene product.","Molecular Sequence Variation | VARIANT_TYPE | molecular consequence | molecular_consequence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008034","Chest Tube","C122599","A hollow tube that is inserted into the pleural space through a surgical incision in the chest wall.","Chest Tube | ",,,,,,,,,,,,,,,"4121351","Chest drain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021234","Indocyanine Green","C65913","A nontoxic, fluorescent, tricarbocyanine dye with a peak spectral absorption at 790 nm, with application in determining cardiac output, hepatic function, liver blood flow, as well as ophthalmic angiography. Upon administration, indocyanine green (ICG) rapidly binds to its principle carrier, plasma protein, and is thereby confined to the vascular space. This agent, with a half-life of 150 to 180 seconds, is removed exclusively by the liver from circulation to bile juice. Furthermore, due to poor uptake, ICG is not suitable for angiography or functional output analysis of kidney, lung, cerebro-spinal, or peripheral tissues.","Indocyanine Green | ICG | INDOCYANINE GREEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2368278","Intraoperative Ultrasound","C93009","A procedure that uses ultrasound (high-energy sound waves that are bounced off internal tissues and organs) during surgery. Sonograms (pictures made by ultrasound) of the inside of the body are viewed on a computer to help a surgeon find tumors or other problems during the operation.","Intraoperative Ultrasound | IOUS | intraoperative ultrasound",,,,,,,,,,,,,,,"42537377","Intraoperative ultrasonography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1771611","Inactivating PARP1 Gene Mutation","C183349","A mutation in the PARP1 gene that either inhibits the expression or results in the translation of an inactive Poly [ADP-ribose] polymerase 1 protein.","Inactivating PARP1 Gene Mutation | Inactivating ADPRT 1 Gene Mutation | Inactivating ADPRT Gene Mutation | Inactivating ADPRT1 Gene Mutation | Inactivating ARTD1 Gene Mutation | Inactivating PARP Gene Mutation | Inactivating PARP-1 Gene Mutation | Inactivating PARP1 Mutation | Inactivating PPOL Gene Mutation | Inactivating Poly (ADP Ribose) Polymerase 1 Gene Mutation | Inactivating Poly (ADP-Ribose) Polymerase 1 Gene Mutation | Inactivating Poly (ADP-Ribose) Polymerase Gene Mutation | Inactivating Poly(ADP-Ribose) Polymerase 1 Gene Mutation | Inactivating Poly(ADP-Ribose) Polymerase Gene Mutation | Inactivating pADPRT-1 Gene Mutation | Loss of Function PARP1 Gene Mutation | Loss of Function PARP1 Mutation | PARP1 Inactivating Gene Mutation | PARP1 Inactivating Mutation | PARP1 Loss of Function Gene Mutation | PARP1 Loss of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771610","Inactivating POLD1 Gene Mutation","C183348","A mutation in the POLD1 gene that either inhibits the expression or results in the translation of an inactive DNA polymerase delta catalytic subunit protein.","Inactivating POLD1 Gene Mutation | Inactivating CDC2 Gene Mutation | Inactivating CRCS10 Gene Mutation | Inactivating DNA Polymerase Delta 1, Catalytic Subunit Gene Mutation | Inactivating MDPL Gene Mutation | Inactivating POLD Gene Mutation | Inactivating POLD1 Mutation | Loss of Function POLD1 Gene Mutation | Loss of Function POLD1 Mutation | POLD1 Inactivating Gene Mutation | POLD1 Inactivating Mutation | POLD1 Loss of Function Gene Mutation | POLD1 Loss of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771688","Meiotic Recombination Gene Mutation","C183307","A change in the nucleotide sequence of a gene involved in meiotic recombination.","Meiotic Recombination Gene Mutation | MRE Gene Mutation | MRE Mutation | Meiotic Recombination Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771687","Base Excision Repair Gene Mutation","C183306","A change in the nucleotide sequence of a gene involved in DNA base excision repair.","Base Excision Repair Gene Mutation | BER Gene Mutation | BER Mutation | Base Excision Repair Mutation | DNA Base Excision Repair Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773505","Long Delay Free Recall","C185158","A memory task where an individual is presented with material to remember and then asked to recall it later, without prompts. The individual is usually occupied with another task during the delay period.","Long Delay Free Recall | LDFR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520913","Planned Start Date","C133396","The calendar date that an event or activity is intended to begin.","Planned Start Date | Proposed Start Date",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772617","Monoallelic BRCA2 Gene Inactivation","C184313","Any gain, loss, or exchange of DNA that results in monoallelic loss of function mutations in the BRCA2 gene.","Monoallelic BRCA2 Gene Inactivation | BRCA2 Gene LOH | BRCA2 Homozygous Loss | BRCA2 LOH | BRCA2 Loss of Heterozygosity | LOH BRCA2 | Monoallelic BRCA2 Inactivating Gene Mutation | Monoallelic BRCA2 Inactivating Mutation | Monoallelic BRCA2 Loss of Function | Monoallelic BRCA2 Loss of Function Gene Mutation | Monoallelic BRCA2 Loss of Function Mutation | Monoallelic BRCC2 Gene Inactivation | Monoallelic BROVCA2 Gene Inactivation | Monoallelic Breast Cancer 2 Gene Inactivation | Monoallelic Breast Cancer 2, Early Onset Gene Inactivation | Monoallelic Breast Cancer Type 2 Susceptibility Gene Inactivation | Monoallelic FANCD1 Gene Inactivation | Monoallelic Inactivating BRCA2 Gene Mutation | Monoallelic Inactivating BRCA2 Mutation | Monoallelic XRCC11 Gene Inactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772620","Monoallelic BRCA1 Gene Inactivation","C184312","Any gain, loss, or exchange of DNA that results in monoallelic loss of function mutations in the BRCA1 gene.","Monoallelic BRCA1 Gene Inactivation | BRCA1 Gene LOH | BRCA1 Homozygous Loss | BRCA1 LOH | BRCA1 Loss of Heterozygosity | LOH BRCA1 | Monoallelic BRCA1 Inactivating Gene Mutation | Monoallelic BRCA1 Inactivating Mutation | Monoallelic BRCA1 Loss of Function | Monoallelic BRCA1 Loss of Function Gene Mutation | Monoallelic BRCA1 Loss of Function Mutation | Monoallelic BROVCA1 Gene Inactivation | Monoallelic Breast Cancer 1 Gene Inactivation | Monoallelic Breast Cancer 1, Early Onset Gene Inactivation | Monoallelic Breast Cancer Type 1 Susceptibility Gene Inactivation | Monoallelic Inactivating BRCA1 Gene Mutation | Monoallelic Inactivating BRCA1 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951476","Chromosome 7 Abnormality","C159455","A cytogenetic abnormality that refers to any structural irregularity in chromosome 7.","Chromosome 7 Abnormality | -7, del(7q) or t(7q) | Aberrant Chromosome 7 | Chromosome 7 Aberration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771629","CCND3 Gene Translocation","C183372","A cytogenetic abnormality that refers to a translocation involving the CCND3 gene.","CCND3 Gene Translocation | CCND3 Translocation | Cyclin D3 Gene Translocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771631","CCND2 Gene Translocation","C183371","A cytogenetic abnormality that refers to a translocation involving the CCND2 gene.","CCND2 Gene Translocation | CCND2 Translocation | Cyclin D2 Gene Translocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771617","EWSR1 Fusion Positive","C183354","An indication that a EWSR1 fusion has been detected in a sample.","EWSR1 Fusion Positive | EWS Fusion Positive | EWS RNA-Binding Protein 1 Fusion Positive | Ewing Sarcoma Breakpoint Region 1 Fusion Positive | RNA-Binding Protein EWS Fusion Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772603","HSD3B1 NM_000862.2:c.1100=","C184298","A nucleotide substitution at position 1100 of the coding sequence of the HSD3B1 gene where adenine has been mutated to cytosine.","HSD3B1 NM_000862.2:c.1100= | 3BETAHSD c.1100= | 3BETAHSD c.1100A>C | HSD3B c.1100= | HSD3B c.1100A>C | HSD3B1 (1245A>C) | HSD3B1 (1245C) | HSD3B1 (1245C) Mutation | HSD3B1 1245A>C | HSD3B1 1245C | HSD3B1 c.1100A>C | HSD3B1 c.1100C= | HSD3B1(1245C) | HSDB3 c.1100= | HSDB3 c.1100A>C | HSDB3A c.1100= | HSDB3A c.1100A>C | Hydroxy-Delta-5-Steroid Dehydrogenase, 3 Beta- and Steroid Delta-Isomerase 1 c.1100= | Hydroxy-Delta-5-Steroid Dehydrogenase, 3 Beta- and Steroid Delta-Isomerase 1 c.1100A>C | NM_000862.2:c.1100= | SDR11E1 c.1100= | SDR11E1 c.1100A>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771920","Human Papillomavirus-33 Positive","C183564","An indication that human papillomavirus-33 has been detected in a sample.","Human Papillomavirus-33 Positive | HPV-33 Positive | HPV33 Positive | Human Papilloma Virus 33 Positive | Human Papilloma Virus-33 Positive | Human Papillomavirus 33 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773208","Gene Signature Assessment","C181333","An assessment of the unique pattern of gene expression of one to many genes associated with a normal or abnormal biological process.","Gene Signature Assessment | GENESIG | Gene Expression Profile | Gene Expression Signature | Gene Signature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771928","Elevated Choriogonadotropin Subunit Beta","C183568","A finding indicating elevated concentrations of human chorionicgonadotropin subunit beta in a sample.","Elevated Choriogonadotropin Subunit Beta | Elevated Beta-hCG | Elevated CG-Beta | Elevated CGB3 | Elevated Choriogonadotropin Beta Chain | Elevated Choriogonadotropin Subunit Beta 3 | Elevated Chorionic Gonadotrophin Beta Subunit | Elevated Chorionic Gonadotropin Beta 3 Subunit | Elevated Chorionic Gonadotropin Beta Chain | Elevated Chorionic Gonadotropin Beta Polypeptide | Elevated Chorionic Gonadotropin Chain Beta | Elevated Chorionic Gonadotropin Subunit Beta | Elevated Human Chorionic Gonadotropin Beta Subunit | Elevated hCG-Beta | Elevated hCGBeta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772619","Monoallelic BARD1 Gene Inactivation","C184311","Any gain, loss, or exchange of DNA that results in monoallelic loss of function mutations in the BARD1 gene.","Monoallelic BARD1 Gene Inactivation | BARD1 Gene LOH | BARD1 Homozygous Loss | BARD1 Loss of Heterozygosity | Monoallelic BARD-1 Gene Inactivation | Monoallelic BARD1 Inactivating Gene Mutation | Monoallelic BARD1 Inactivating Mutation | Monoallelic BARD1 Inactivation | Monoallelic BARD1 Loss of Function | Monoallelic BARD1 Loss of Function Gene Mutation | Monoallelic BARD1 Loss of Function Mutation | Monoallelic BRCA1 Associated RING Domain 1 Gene Inactivation | Monoallelic Inactivating BARD1 Gene Mutation | Monoallelic Inactivating BARD1 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772627","Monoallelic RAD51D Gene Inactivation","C184320","Any gain, loss, or exchange of DNA that results in monoallelic loss of function mutations in the RAD51D gene.","Monoallelic RAD51D Gene Inactivation | Monoallelic BROVCA4 Gene Inactivation | Monoallelic Inactivating RAD51D Gene Mutation | Monoallelic Inactivating RAD51D Mutation | Monoallelic R51H3 Gene Inactivation | Monoallelic RAD51 Homolog D Gene Inactivation | Monoallelic RAD51 Paralog D Gene Inactivation | Monoallelic RAD51-Like 3 Gene Inactivation | Monoallelic RAD51D Inactivating Gene Mutation | Monoallelic RAD51D Inactivating Mutation | Monoallelic RAD51D Inactivation | Monoallelic RAD51D Loss of Function | Monoallelic RAD51D Loss of Function Gene Mutation | Monoallelic RAD51D Loss of Function Mutation | Monoallelic RAD51L3 Gene Inactivation | Monoallelic TRAD Gene Inactivation | RAD51D Gene LOH | RAD51D Homozygous Loss | RAD51D Loss of Heterozygosity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772629","Monoallelic RAD51C Gene Inactivation","C184318","Any gain, loss, or exchange of DNA that results in monoallelic loss of function mutations in the RAD51C gene.","Monoallelic RAD51C Gene Inactivation | Monoallelic BROVCA3 Gene Inactivation | Monoallelic FANCO Gene Inactivation | Monoallelic Inactivating RAD51C Gene Mutation | Monoallelic Inactivating RAD51C Mutation | Monoallelic RAD51 Homolog C Gene Inactivation | Monoallelic RAD51 Paralog C Gene Inactivation | Monoallelic RAD51C Inactivating Gene Mutation | Monoallelic RAD51C Inactivating Mutation | Monoallelic RAD51C Inactivation | Monoallelic RAD51C Loss of Function | Monoallelic RAD51C Loss of Function Gene Mutation | Monoallelic RAD51C Loss of Function Mutation | Monoallelic RAD51L2 Gene Inactivation | RAD51C Gene LOH | RAD51C Homozygous Loss | RAD51C Loss of Heterozygosity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772628","Monoallelic RAD51B Gene Inactivation","C184317","Any gain, loss, or exchange of DNA that results in monoallelic loss of function mutations in the RAD51B gene.","Monoallelic RAD51B Gene Inactivation | Monoallelic Inactivating RAD51B Gene Mutation | Monoallelic Inactivating RAD51B Mutation | Monoallelic R51H2 Gene Inactivation | Monoallelic RAD51 Paralog B Gene Inactivation | Monoallelic RAD51B Inactivating Gene Mutation | Monoallelic RAD51B Inactivating Mutation | Monoallelic RAD51B Inactivation | Monoallelic RAD51B Loss of Function | Monoallelic RAD51B Loss of Function Gene Mutation | Monoallelic RAD51B Loss of Function Mutation | Monoallelic RAD51L1 Gene Inactivation | Monoallelic REC2 Gene Inactivation | RAD51B Gene LOH | RAD51B Homozygous Loss | RAD51B Loss of Heterozygosity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772616","Monoallelic RAD51 Gene Inactivation","C184316","Any gain, loss, or exchange of DNA that results in monoallelic loss of function mutations in the RAD51 gene.","Monoallelic RAD51 Gene Inactivation | Monoallelic BRCC5 Gene Inactivation | Monoallelic FANCR Gene Inactivation | Monoallelic HRAD51 Gene Inactivation | Monoallelic HsRad51 Gene Inactivation | Monoallelic Inactivating RAD51 Gene Mutation | Monoallelic Inactivating RAD51 Mutation | Monoallelic RAD51 Inactivating Gene Mutation | Monoallelic RAD51 Inactivating Mutation | Monoallelic RAD51 Inactivation | Monoallelic RAD51 Loss of Function | Monoallelic RAD51 Loss of Function Gene Mutation | Monoallelic RAD51 Loss of Function Mutation | Monoallelic RAD51 Recombinase Gene Inactivation | Monoallelic RAD51A Gene Inactivation | Monoallelic RECA Gene Inactivation | RAD51 Gene LOH | RAD51 Homozygous Loss | RAD51 Loss of Heterozygosity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772615","Monoallelic PALB2 Gene Inactivation","C184315","Any gain, loss, or exchange of DNA that results in monoallelic loss of function mutations in the PALB2 gene.","Monoallelic PALB2 Gene Inactivation | Monoallelic FANCN Gene Inactivation | Monoallelic Fanconi Anemia, Complementation Group N Gene Inactivation | Monoallelic Inactivating PALB2 Gene Mutation | Monoallelic Inactivating PALB2 Mutation | Monoallelic PALB2 Inactivating Gene Mutation | Monoallelic PALB2 Inactivating Mutation | Monoallelic PALB2 Inactivation | Monoallelic PALB2 Loss of Function | Monoallelic PALB2 Loss of Function Gene Mutation | Monoallelic PALB2 Loss of Function Mutation | Monoallelic PNCA3 Gene Inactivation | Monoallelic Partner and Localizer of BRCA2 Gene Inactivation | PALB2 Gene LOH | PALB2 Homozygous Loss | PALB2 Loss of Heterozygosity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772618","Monoallelic BRIP1 Gene Inactivation","C184314","Any gain, loss, or exchange of DNA that results in monoallelic loss of function mutations in the BRIP1 gene.","Monoallelic BRIP1 Gene Inactivation | BRIP1 Gene LOH | BRIP1 Homozygous Loss | BRIP1 Loss of Heterozygosity | Monoallelic BACH1 Gene Inactivation | Monoallelic BRCA1 Interacting Protein C-Terminal Helicase 1 Gene Inactivation | Monoallelic BRIP1 Inactivating Gene Mutation | Monoallelic BRIP1 Inactivating Mutation | Monoallelic BRIP1 Loss of Function | Monoallelic BRIP1 Loss of Function Gene Mutation | Monoallelic BRIP1 Loss of Function Mutation | Monoallelic FANCJ Gene Inactivation | Monoallelic Inactivating BARD1 Gene Mutation | Monoallelic Inactivating BRIP1 Gene Mutation | Monoallelic Inactivating BRIP1 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511231","Blur","C37919","A dim, vague appearance.","Blurry | Blur | Blur",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771910","Interferon Type I","C183541","A family of cytokines that play roles in inflammation, immunoregulation, tumor cell recognition and T-cell responses. Interferon type I encompasses all interferons that bind to the interferon alpha receptor complex.","Interferon Type I | IFN-I | Type I IFN | Type I Interferon | Type-I IFN | Type-I IFN Family | Type-I Interferon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771896","FOXP3-Expressing Regulatory T-Lymphocyte Count Percent Change From Baseline","C183539","The percent change for the number of regulatory T-lymphocytes expressing FOXP3 present in the last sample from a subject versus the value for the initial sample from the same subject.","FOXP3-Expressing Regulatory T-Lymphocyte Count Percent Change From Baseline | FOXP3-Expressing Regulatory T-Lymphocyte Percent Change From Baseline | FoxP3+ T Regulatory Cell Percent Change From Baseline | FoxP3+ Treg Percent Change From Baseline | FoxP3+ Tregs Percent Change From Baseline | Foxp3+ Regulatory T Cell Percent Change From Baseline",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772610","Phytocannabinoid","C184306","A class of compounds produced by plants, especially cannabis and related plants, which is capable of activating cannabinoid receptors.","Phytocannabinoid | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772609","Endocannabinoid","C184305","A class of endogenously expressed compounds capable of activating cannabinoid receptors.","Endocannabinoid | Endogenous Cannabinoid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772601","hexabrominated diphenyl ether 153","C184300","A solid containing aromatic rings connected by an ether bond and containing six bromine atoms. It had been used in industrial applications as a flame retardant but has been phased out of industrial use because of environmental persistence and potential hormone-disrupting effects in humans.","Hexabrominated Diphenyl Ether 153 | 1,2,4-tribromo-5-(2,4,5-tribromophenoxy)benzene | 2,2',4,4',5,5'-HEXABROMODIPHENYL ETHER | 2,2',4,4',5,5'-Hexabromodiphenyl Ether | BDE 153 | BDE-153 | PBDE 153 | Polybrominated Diphenyl Ether-153",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771927","NTRK Gene Amplification","C183567","A molecular genetic abnormality indicating the presence of multiple copies of an NTRK family gene.","NTRK Gene Amplification | NTRK Amplification | NTRK Family Amplification | NTRK Family Gene Amplification | TRK Family Gene Amplification | TRK Receptor Family Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772606","HDAC2 mRNA Measurement","C184294","A determination of the amount of HDAC2 mRNA in a biological sample.","HDAC2 mRNA Measurement | HD2 mRNA Measurement | Histone Deacetylase 2 mRNA Measurement | RPD3 mRNA Measurement | YAF1 mRNA Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772605","DNMT3B mRNA Measurement","C184293","A determination of the amount of DNMT3B mRNA in a biological sample.","DNMT3B mRNA Measurement | DNA Methyltransferase 3 Beta mRNA Measurement | DNA Methyltransferase 3B mRNA Measurement | DNA Methyltransferase HsaIIIB mRNA Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772593","MBD2 mRNA Measurement","C184292","A determination of the amount of MBD2 mRNA in a biological sample.","MBD2 mRNA Measurement | DMTase mRNA Measurement | Methyl-CpG Binding Domain Protein 2 mRNA Measurement | NY-CO-41 mRNA Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771823","DNA Demethylation Pathway mRNA Measurement","C183574","A determination of the amount of DNA demethylation pathway-related mRNA in a biological sample.","DNA Demethylation Pathway mRNA Measurement | DNA Demethylase mRNA Measurement | DNA Demethylation-Related mRNA Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771926","G2 Arrest Time","C183570","A measurement of the average time that cells are arrested in the G2 phase of the cell cycle.","G2 Arrest Time | G2 Arrest Measurement | G2 Delay Measurement | G2 Delay Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771822","Circulating Human Papillomavirus DNA","C183573","Viral DNA that originates from a human papillomavirus that is found in the circulation.","Circulating Human Papillomavirus DNA | Circulating HPV DNA | Circulating Human Papilloma Virus DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771930","Human Papillomavirus-35 Positive","C183566","An indication that human papillomavirus-35 has been detected in a sample.","Human Papillomavirus-35 Positive | HPV-35 Positive | HPV35 Positive | Human Papilloma Virus 35 Positive | Human Papilloma Virus-35 Positive | Human Papillomavirus 35 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771929","Human Papillomavirus-31 Positive","C183565","An indication that human papillomavirus-31 has been detected in a sample.","Human Papillomavirus-31 Positive | HPV-31 Positive | HPV31 Positive | Human Papilloma Virus 31 Positive | Human Papilloma Virus-31 Positive | Human Papillomavirus 31 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511025","BRCA2 Tumor-Suppressor Gene Inactivation","C36689","A mutation in the BRCA2 gene that either leads to loss of expression or results in the translation of an inactive breast cancer type 2 susceptibility protein.","Inactivating BRCA2 Gene Mutation | BRCA2 Gene Inactivation | BRCA2 Inactivation | BRCA2 Loss of Function Gene Mutation | BRCA2 Loss of Function Mutation | BRCA2 Tumor-Suppressor Gene Inactivation | Inactivating BRCA2 Mutation | Inactivating BRCC2 Gene Mutation | Inactivating BROVCA2 Gene Mutation | Inactivating Breast Cancer 2 Gene Mutation | Inactivating Breast Cancer 2, Early Onset Gene Mutation | Inactivating Breast Cancer Type 2 Susceptibility Gene Mutation | Inactivating FANCD1 Gene Mutation | Inactivating XRCC11 Gene Mutation | Loss of Function BRCA2 Gene Mutation | Loss of Function BRCA2 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511023","BRCA1 Tumor-Suppressor Gene Inactivation","C36688","A mutation in the BRCA1 gene that either leads to loss of expression or results in the translation of an inactive breast cancer type 1 susceptibility protein.","Inactivating BRCA1 Gene Mutation | BRCA1 Gene Inactivation | BRCA1 Inactivation | BRCA1 Loss of Function Gene Mutation | BRCA1 Loss of Function Mutation | BRCA1 Tumor-Suppressor Gene Inactivation | Inactivating BRCA1 Mutation | Inactivating BROVCA1 Gene Mutation | Inactivating Breast Cancer 1 Gene Mutation | Inactivating Breast Cancer 1, Early Onset Gene Mutation | Inactivating Breast Cancer Type 1 Susceptibility Gene Mutation | Loss of Function BRCA1 Gene Mutation | Loss of Function BRCA1 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771925","Ki-67 Positive Cells 3-55 Percent","C183569","A semi-quantitative microscopic finding indicating that between 3 and 55 percent of the cells in a sample are detected following staining using an anti-Ki-67 antibody.","Ki-67 Positive Cells 3-55 Percent | Antigen Ki-67 Positive Cells 3-55 Percent | KI67 Positive Cells 3-55 Percent | Ki-67 Antigen Positive Cells 3-55 Percent | Ki-67 Positive Cells Between 3 and 55 Percent | Ki-67 Positive Cells Greater than or Equal to 3 Percent and Less than or Equal to 55 Percent | MKI67 Positive Cells 3-55 Percent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771898","Cancer Antigen 72-4 Positive","C183537","An indication that expression of cancer antigen 72-4 has been detected in a sample.","Cancer Antigen 72-4 Positive | Antitumor-Associated Glycoprotein 72 Positive | CA 72-4 Positive | CA-72-4 Positive | CA72-4 Positive | TAG-72 Antigen Positive | TAG-72 Positive | TAG72 Positive | Tumor-Associated Glycoprotein 72 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771899","Inactivating PIK3R1 Gene Mutation","C183538","A change in the nucleotide sequence of the PIK3R1 gene that either inhibits expression or results in the translation of an inactive phosphatidylinositol 3-kinase regulatory subunit alpha protein.","Inactivating PIK3R1 Gene Mutation | Inactivating GRB1 Gene Mutation | Inactivating PIK3R1 Mutation | Inactivating Phosphoinositide-3-Kinase Regulatory Subunit 1 Gene Mutation | Inactivating p85-ALPHA Gene Mutation | Loss of Function PIK3R1 Gene Mutation | Loss of Function PIK3R1 Mutation | PIK3R1 Loss of Function Gene Mutation | PIK3R1 Loss of Function Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771908","CGAS Positive","C183543","An indication that expression of CGAS has been detected in a sample.","CGAS Positive | 2'3'-cGAMP Synthase Positive | Cyclic GMP-AMP Synthase Positive | MB21D1 Positive | Mab21 Domain-Containing Protein 1 Positive | cGAMP Synthase Positive | cGAS Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823437","STING1 Gene","C101586","This gene plays a role in the immune response.","STING1 Gene | STING | STING1 | Stimulator of Interferon Response cGAMP Interactor 1 Gene | TMEM173",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771635","NTRK Fusion Gene Positive","C183255","An indication that a fusion containing NTRK family gene sequences has been detected in a sample.","NTRK Fusion Gene Positive | NTRK Family Fusion Gene Positive | NTRK Family Gene Fusion Positive | NTRK Fusion Gene | NTRK Gene Fusion Positive | TRK Family Fusion Gene Positive | TRK Fusion Gene | TRK Fusion Gene Positive | TRK Gene Fusion Positive | TRK Receptor Family Fusion Gene | TRK Receptor Family Fusion Gene Positive | TRK Receptor Fusion Gene | TRK Receptor Fusion Gene Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771634","ROS1 Fusion Gene Positive","C183254","An indication that a ROS1 fusion gene has been detected in a sample.","ROS1 Fusion Gene Positive | MCF3 Fusion Gene Positive | Proto-Oncogene c-Ros Fusion Gene Positive | ROS Fusion Gene Positive | ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Fusion Gene Positive | ROS1 Fusion Gene | ROS1 Gene Fusion | ROS1 Gene Fusion Positive | c-Ros-1 Fusion Gene Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1332065","AIM2 Gene","C21391","This gene plays a role in cellular proliferation and may be involved in tumor reversion.","AIM2 Gene | AIM2 | Absent In Melanoma 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1368803","PTPN12 Gene","C24706","This gene plays a role in the regulation of cell shape and mobility.","PTPN12 Gene | PTPN12 | Protein Tyrosine Phosphatase, Non-Receptor Type 12 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662235","BRCA Gene Mutation","C179406","A change in the nucleotide sequence of a gene in the BRCA family.","BRCA Gene Mutation | BRCA Family Gene Mutation | BRCA Family Mutation | BRCA Gene Family Mutation | BRCA Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040958","Triclosan","C61986","A polychloro phenoxy phenol with antibacterial and antifungal activity. Triclosan is added to toothpastes to prevent gingivitis and has been added to many household products for its topical antibiotic activity.","Triclosan | TRICLOSAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0057934","Diethyl Phthalate","C76749","A clear, colorless liquid used as a plasticizer for fabricating flexible materials for many household products. It is also used in cosmetics, insecticides and aspirin.","Diethyl Phthalate | 1,2-Benzenedicarboxylic Acid, 1,2-Diethyl Ester | 1,2-Benzenedicarboxylic Acid, Diethyl Ester | DEP | DIETHYL PHTHALATE | Di-n-Ethyl Phthalate | Diethyl 1,2-Benzenedicarboxylate | Diethyl o-Phenylenediacetate | Diethyl o-Phthalate | Phthalic Acid, Diethyl Ester | o-Benzenedicarboxylic Acid Diethyl Ester | o-Bis(ethoxycarbonyl)benzene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4243600","Wall of anterior cranial fossa","C180372","The portion of the skull that is formed laterally by the orbital plates of the frontal bone, medially by the cribriform palate and crista galli of the ethmoid bone, and posteriorly by the planum sphenoidale and lesser wings of the sphenoid bone.","Anterior Base of Skull | ASB | Anterior Skull Base",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0427245","Shoulder Girdle","C33547","The bony arch formed by the collarbones and shoulder blades.","Shoulder Girdle | Bone Shoulder Girdle",,,,,,,,,,,,,,,"4096787","Shoulder girdle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL610972","Paratestis","C162491","A small anatomical compartment that contains the testicular collecting system, and mesothelial and mesenchymal components that represent extensions of the abdominal cavity and retroperitoneum.","Paratesticular Region | Paratesticular | Testicular Adnexa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515068","Superior Maxillary Bone","C33682","The facial bone that forms the medial floor of the orbit.","Superior Maxillary Bone | Superior Maxilla",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1770781","Imaging Centrally Reviewed","C182308","A question whether the image was centrally reviewed.","Imaging Centrally Reviewed | Imaging centrally reviewed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773410","Hundred Million Infectious Units per Milliliter","C185174","Unit of measure of viral infectious potency expressed as one hundred million infectious units per one milliliter of solution.","Hundred Million Infectious Units per Milliliter | 10E8 IFU/mL | 10E8 infectious units per milliliter | 10E8 infectious units/mL | 10^8 IFU/mL | 10^8 infectious units per milliliter | 10^8 infectious units/mL | Hundred Million Infectious Units per Milliliter ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773409","Billion Infectious Units per Milliliter","C185175","Unit of measure of viral infectious potency expressed as one billion infectious units per one milliliter of solution.","Billion Infectious Units per Milliliter | 10E9 IFU/mL | 10E9 infectious units per milliliter | 10E9 infectious units/mL | 10^9 IFU/mL | 10^9 infectious units per milliliter | 10^9 infectious units/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772855","Death Expected Indicator","C184505","An indication as to whether the death was expected.","Death Expected Indicator | DTHEXIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772856","Capsule Softgel Pharmaceutical Dosage Form","C184506","A capsule, covered with a soft gelatin shell and containing a liquid, suspension, or semisolid, that is designed to release active and/or inert ingredient(s)","Capsule Softgel Pharmaceutical Dosage Form | CAPSULE, SOFTGEL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007793","Cerebral Peduncle","C32291","A region of the brain encompassing the crus cerebri and the midbrain tegmentum.","Cerebral Peduncle | CEREBRAL PEDUNCLE",,,,,,,,,,,,,,,"4263923","Cerebral peduncle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152305","Angular Gyrus","C32077","The portion of the brain located in the parietal lobe that plays a role in intersensory processing, language comprehension, and cognition.","Angular Gyrus | ANGULAR GYRUS",,,,,,,,,,,,,,,"4239790","Structure of angular gyrus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2985415","Neuroradiologist","C93058","A doctor trained in radiology who specializes in creating and interpreting pictures of the nervous system. The pictures are produced using forms of radiation, such as x-rays, sound waves, or other types of energy.","Neuroradiologist | NEURORADIOLOGIST | Radiology Neuroradiology | neuroradiologist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772728","Neuroradiologist 2","C184677","A neuroradiologist performing the assessment who is given the designation of two.","Neuroradiologist 2 | NEURORADIOLOGIST 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772717","Neuroradiologist 1","C184676","A neuroradiologist performing the assessment who is given the designation of one.","Neuroradiologist 1 | NEURORADIOLOGIST 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772723","Isothermal Amplification","C184684","Nucleic acid amplification at a constant temperature.","Isothermal Amplification | ISOTHERMAL AMPLIFICATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772722","Competitive DNA Hybridization","C184683","A hybridization method in which complementary single-stranded DNA from different sources compete to form complexes with target DNA sequences.","Competitive DNA Hybridization | COMPETITIVE DNA HYBRIDIZATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772725","Methylation-Sensitive Quantitative Locked Nucleic Acid Polymerase Chain Reaction","C184682","A modified polymerase chain reaction (PCR) technique in which bisulphite-converted methylated CpG target sequences are amplified in the presence of locked nucleic acid (LNA) modified primers.","Methylation-Sensitive Quantitative Locked Nucleic Acid Polymerase Chain Reaction | METHYLATION-SENSITIVE QUANTITATIVE LOCKED NUCLEIC ACID PCR | MS-qLNAPCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772724","Quantitative Methylation-Specific Polymerase Chain Reaction","C184681","A modified polymerase chain reaction (PCR) technique in which bisulphite-converted methylated DNA target sequences are amplified in the presence of an excess of unmethylated counterpart sequences.","Quantitative Methylation-Specific Polymerase Chain Reaction | QUANTITATIVE METHYLATION-SPECIFIC PCR | qMSP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772727","Pinhole Occlusion Method","C184680","A visual acuity method using a pinhole occluder device, an opaque disk-shaped eye shield with one or more holes, that is used to differentiate between reduced visual acuity caused by refractive error and ocular pathology.","Pinhole Occlusion Method | PINHOLE OCCLUSION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772726","Microflocculation Assay","C184679","A type of flocculation method in which particles in suspension aggregate in loosely clumped microscopic masses, which are then detected via microscope.","Microflocculation Assay | MICROFLOCCULATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772729","Macroflocculation Assay","C184678","A type of flocculation method in which particles in suspension aggregate in loosely clumped macroscopic masses, which are then detected with the naked eye.","Macroflocculation Assay | MACROFLOCCULATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772730","Most Recent Diagnosis","C184685","The latest diagnosis of the disease.","Most Recent Diagnosis | Current Diagnosis | MOST RECENT DIAGNOSIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772740","Androgen Receptor Variant 7 Measurement","C184703","The determination of the amount of androgen receptor variant 7 protein present in a sample.","Androgen Receptor Variant 7 Measurement | AR-V7 | AR-v7 Measurement | ARV7 | Androgen Receptor Variant 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772742","Lymph Node Extracapsular Spread Assessment","C184702","An evaluation of the presence or degree of lymph node extracapsular spread present in a sample.","Lymph Node Extracapsular Spread Assessment | LNEXCPSD | Lymph Node Extracapsular Spread",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772741","Premalignant Cell Morphology Assessment","C184701","An examination or assessment of the form and structure of premalignant cells.","Premalignant Cell Morphology Assessment | PMLIGCEM | Premalignant Cell Morphology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772732","Premalignant Cell Count","C184700","The determination of the amount of premalignant cells present in a sample.","Premalignant Cell Count | PMLIGCE | Precancerous Cells | Premalignant Cells | Premalignant Lesions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772731","Extramural Venous Invasion Assessment","C184699","An evaluation of the presence or degree of extramural venous invasion present in a sample.","Extramural Venous Invasion Assessment | EMVI | Extramural Venous Invasion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643420","Anatomic Site for Involved Surgical Margin","C177569","The anatomic site where there is one or more surgical margins where diseased tissue is present.","Anatomic Site for Involved Surgical Margin | SGMGIREG | Surgical Margin Involvement Region | margins involved site | margins_involved_site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1407180","Bone Marrow Response","C173307","The response of the bone marrow to the treatment.","Bone Marrow Response | BMRRESP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773206","Fraction of the Dose Metabolized","C184704","The fraction of the bioavailable dose which has been metabolized.","Fraction of the Dose Metabolized | FM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772738","Nanogram Equivalents","C184705","A unit of relative amount of substance equal to one billionth of a gram of an equivalent weight.","Nanogram Equivalents | Nanogram Equivalent | ng.Eq | ng.eq | ngEq",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771847","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Breast Reconstruction","C183598","A standardized 23-item questionnaire module developed in 2017 to supplement the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 core questionnaire in assessing the quality of life in patients after breast reconstruction.","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Breast Reconstruction | EOR32 | EORTC QLQ-BRECON23",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771846","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Breast Cancer Phase IV Module Version","C183597","A standardized 45-item questionnaire module developed in 2020 to supplement the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 core questionnaire as an update of the EORTC QLQ-BR23 in assessing the quality of life in patients with breast cancer.","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Breast Cancer Phase IV Module Version | EOR31 | EORTC QLQ-BR45 PHASE IV MODULE | EORTC QLQ-BR45 Phase IV Module Version",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771833","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Anal Cancer","C183596","A standardized 27-item questionnaire module developed in 2018 to supplement the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 core questionnaire in assessing the quality of life in patients with anal cancer. It consists of four health-related quality of life domains: pain, bowel, and sexual and stoma care problems, and five single items: frequent urination, keeping clean, proximity to toilet, lower limb oedema, and planning activities.","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Anal Cancer | EOR30 | EORTC QLQ-ANL27",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771832","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Chronic lymphocytic leukemia","C183595","A standardized 17-item questionnaire module developed by the European Organisation for Research and Treatment of Cancer (EORTC) in 2017 that is designed to supplement the EORTC QLQ-C30 core questionnaire in assessing the quality of life in patients with chronic lymphocytic leukemia.","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Chronic lymphocytic leukemia | EOR29 | EORTC QLQ-CLL17",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771835","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Non-Muscle-Invasive Bladder Cancer","C183594","A standardized 24-item questionnaire module developed by the European Organisation for Research and Treatment of Cancer (EORTC) in 2014 that is designed to supplement the EORTC QLQ-C30 core questionnaire in assessing the quality of life in patients with non-muscle-invasive bladder cancer (NMIBC).","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Non-Muscle-Invasive Bladder Cancer | EOR28 | EORTC QLQ-NMIBC24",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771834","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Pancreatic Cancer Phase III Module Version","C183593","A standardized 26-item questionnaire module developed by the European Organisation for Research and Treatment of Cancer (EORTC) in 1999 that is designed to supplement the EORTC QLQ-C30 core questionnaire in assessing the quality of life in patients with pancreatic cancer.","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Pancreatic Cancer Phase III Module Version | EOR26 | EORTC QLQ-PAN26 PHASE III MODULE | EORTC QLQ-PAN26 Phase III Module Version",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771837","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Cholangiocarcinoma and Gallbladder Cancer","C183592","A standardized 21-item questionnaire module developed by the European Organisation for Research and Treatment of Cancer (EORTC) in 2011 that is designed to supplement the EORTC QLQ-C30 core questionnaire in assessing the quality of life in patients with cholangiocarcinoma and cancer of the gallbladder.","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Cholangiocarcinoma and Gallbladder Cancer | EOR24 | EORTC QLQ-BIL21",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771836","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Prostate","C183591","A standardized 25-item questionnaire module developed by the European Organisation for Research and Treatment of Cancer (EORTC) in 2008 that is designed to supplement the EORTC QLQ-C30 core questionnaire in assessing the quality of life of prostate cancer patients.","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Prostate | EOR23 | EORTC QLQ-PR25",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771839","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Ovarian","C183590","A standardized 28-item questionnaire module developed by the European Organisation for Research and Treatment of Cancer (EORTC) in 2003 that is designed to supplement the EORTC QLQ-C30 core questionnaire in assessing the quality of life of women with ovarian cancer.","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Ovarian | EOR22 | EORTC QLQ-OV28",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771838","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Esophago-Gastric Phase IV Module Version","C183589","A standardized 25-item questionnaire module developed by the European Organisation for Research and Treatment of Cancer (EORTC) in 2007 that is designed to supplement the EORTC QLQ-C30 core questionnaire in assessing quality of life in patients with tumors of the esophagus, esophago-gastric junction, or stomach. This module is derived from the QLQ-OES18 (esophageal) and QLQ-STO22 (stomach) modules.","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Esophago-Gastric Phase IV Module Version | EOR21 | EORTC QLQ-OG25 PHASE IV MODULE | EORTC QLQ-OG25 Phase IV Module Version",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771825","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Esophageal","C183588","A standardized 18-item questionnaire module developed by the European Organisation for Research and Treatment of Cancer (EORTC) in 2003 that is designed to supplement the EORTC QLQ-C30 core questionnaire in assessing quality of life in patients with esophageal cancer. This module was updated from the EORTC QLQ-OE24 that was developed in 1996.","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Esophageal | EOR20 | EORTC QLQ-OES18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771824","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Information","C183587","A standardized 25-item questionnaire module developed by the European Organisation for Research and Treatment of Cancer (EORTC) in 2010 that is designed to supplement the EORTC QLQ-C30 core questionnaire in assessing the level of information received by cancer patients.","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Information | EOR17 | EORTC QLQ-INFO25",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771827","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Hepatocellular Carcinoma","C183586","A standardized 18-item questionnaire module developed by the European Organisation for Research and Treatment of Cancer (EORTC) in 2004 that is designed to supplement the EORTC QLQ-C30 core questionnaire in assessing quality of life in patients with hepatocellular carcinoma.","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Hepatocellular Carcinoma | EOR16 | EORTC QLQ-HCC18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771826","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Neuroendocrine Carcinoid, Date 20th February 2006 Version","C183585","The version of a standardized 21-item questionnaire module developed by the European Organisation for Research and Treatment of Cancer (EORTC) in 2006 that is designed to supplement the EORTC QLQ-C30 core questionnaire in assessing quality of life in the gut, pancreas, and liver neuroendocrine tumors, and is dated February 20, 2006.","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Neuroendocrine Carcinoid, Date 20th February 2006 Version | EOR15 | EORTC QLQ-GINET21 DATE 20TH FEBRUARY 2006 | EORTC QLQ-GINET21 Date 20th February 2006 Version",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771829","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Gastric","C183584","A standardized 22-item questionnaire module developed by the European Organisation for Research and Treatment of Cancer (EORTC) in 2001 that is designed to supplement the EORTC QLQ-C30 core questionnaire in assessing health-related quality of life in patients with gastric cancer.","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Gastric | EOR14 | EORTC QLQ-STO22",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771828","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Oral Health","C183583","A standardized 15-item questionnaire module developed by the European Organisation for Research and Treatment of Cancer (EORTC) in 2016 that is designed to supplement the EORTC QLQ-C30 core questionnaire in assessing oral health problems in cancer patients.","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Oral Health | EOR13 | EORTC QLQ-OH15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771831","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Colorectal Liver Metastases","C183582","A standardized 21-item questionnaire module developed by the European Organisation for Research and Treatment of Cancer (EORTC) in 2003 that is designed to supplement the EORTC QLQ-C30 core questionnaire in assessing quality of life in patients with liver metastases from colorectal cancer.","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Colorectal Liver Metastases | EOR12 | EORTC QLQ-LMC21",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771830","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Cancer Related Fatigue","C183581","A standardized 12-item questionnaire module developed by the European Organisation for Research and Treatment of Cancer (EORTC) in 2016 that is designed to supplement the EORTC QLQ-C30 core questionnaire in assessing cancer-related fatigue.","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Cancer Related Fatigue | EOR10 | EORTC QLQ-FA12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771817","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Endometrial","C183580","A standardized 24-item questionnaire module developed by the European Organisation for Research and Treatment of Cancer (EORTC) in 2010 that is designed to supplement the EORTC QLQ-C30 core questionnaire in assessing quality of life in patients with endometrial cancer.","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Endometrial | EOR09 | EORTC QLQ-EN24",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771816","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Elderly Cancer Patients","C183579","A standardized 14-item questionnaire module developed by the European Organisation for Research and Treatment of Cancer (EORTC) in 2013 that is designed to supplement the EORTC QLQ-C30 core questionnaire in assessing quality of life in cancer patients aged 70 and above with a strong focus on psychosocial issues. This questionnaire is revised from the QLQ-ELD15, which was developed by the EORTC in 2010.","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Elderly Cancer Patients | EOR08 | EORTC QLQ-ELD14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771819","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Cervical","C183578","A standardized 24-item questionnaire module developed by the European Organisation for Research and Treatment of Cancer (EORTC) in 2006 that is designed to supplement the EORTC QLQ-C30 core questionnaire in assessing quality of life in patients with cervical cancer.","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Cervical | EOR07 | EORTC QLQ-CX24",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771818","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Bone Metastases","C183577","A standardized 22-item questionnaire module developed by the European Organisation for Research and Treatment of Cancer (EORTC) in 2008 that is designed to supplement the EORTC QLQ-C30 core questionnaire in assessing quality of life in patients with bone metastases.","European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Bone Metastases | EOR03 | EORTC QLQ-BM22",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771821","Functional Assessment of Chronic Illness Therapy-Searchable Item Library Adult Version Questionnaire","C183576","A collection of over 700 items from over 100 Functional Assessment of Chronic Illness Therapy (FACIT) questionnaires that was compiled in 2018 and is used to create custom assessment tools that target a wide range of health-related quality of life issues.","Functional Assessment of Chronic Illness Therapy-Searchable Item Library Adult Version Questionnaire | FACIT-SEARCHABLE ITEM LIBRARY ADULT | FACIT-Searchable Item Library Adult Version | FSIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1771820","Diary for Irritable Bowel Syndrome Symptoms-Constipation Version 1.0 Questionnaire","C183575","The first version of a standardized questionnaire developed by Fehnel et al. 2017 that assesses severity of the core bowel movement and abdominal signs and symptoms associated with Irritable Bowel Syndrome-Constipation.","Diary for Irritable Bowel Syndrome Symptoms-Constipation Version 1.0 Questionnaire | DIBC01 | DIBSS-C V1.0 | DIBSS-C Version 1.0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772736","Intracochlear Route of Administration","C184707","Administration within the cochlea.","Intracochlear Route of Administration | INTRACOCHLEAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772737","Has Menstrual Periods Indicator","C184708","An indication as to whether the subject experiences menstrual cycles.","Has Menstrual Periods Indicator | HMPIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772748","Cauterized Specimen","C184709","A specimen that has been cauterized.","Cauterized Specimen | CAUTERIZED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772752","Milligram Per Breath","C184723","A unit of measure expressed in milligram(s) per inspiration or expiration of breath.","Milligram Per Breath | mg/breath | mg/{breath}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773249","Relative Luminescence Unit","C184722","An arbitrary unit used to measure the intensity of the emitted light from a sample; it is dependent on instrument and measurement parameters.","Relative Luminescence Unit | LU | Light Unit | Luminometer Unit | RLU | Relative Light Unit | {RLU}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772754","Tuberculin Unit per 100 Microliters","C184721","A unit of biologic activity of tuberculin expressed as a number of arbitrary units of tuberculin in one milliliter of preparation.","Tuberculin Unit per 100 Microliters | [tb'U]/(1/10).mL | [tb'U]/(1/10).ml | tuberculin unit/0.1mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773298","Serving Dosing Unit","C184720","A dosing measurement based on the serving unit.","Serving Dosing Unit | SERVING | {SERVING}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772755","Per Million","C184719","A unit equal to one million entities used as a denominator to build a derived unit expressed as a ratio.","Per Million | /10*6 | /10^6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772744","Ten Million Per Kilogram","C184717","A unit of measurement equal to 10 to the seventh power of the number of entities per unit of mass equal to one kilogram.","Ten Million Per Kilogram | 10*7/kg | 10/mg | 10^4/g | 10^7/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772743","Hundred Thousand Per Kilogram","C184715","A unit of measurement equal to 10 to the fifth power of the number of entities per unit of mass equal to one kilogram.","Hundred Thousand Per Kilogram | 10*5/kg | 10^2/g | 10^5/kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772745","Radians Per Second","C184714","An SI unit of angular velocity defined as the change in angular velocity equal to one radian per second.","Radians Per Second | rad/s | radian/s",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024814","Meters Times Percent","C184713","A unit of measure for the distance saturation product (DSP) defined as meters times percent.","Meters Times Percent | m% | m*% | m.%",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0058243","N,N-Dimethylacetamide","C29274","A dipolar aprotic solvent and reagent that may be used in the production of fibers and pharmaceuticals, and as a non-aldehyde fixative.","N,N-Dimethylacetamide | Acetic Acid, Dimethylamide | DMA | Dimethyl Acetamide | Dimethylacetamide | N,N-DIMETHYLACETAMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772716","Epstein-Barr Virus Measurement","C184675","The determination of the amount of Epstein-Barr virus in a biological sample.","Epstein-Barr Virus Measurement | EBV | EBV IgG | Epstein-Barr Virus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL564715","Influenza A/B Virus Measurement","C184674","The determination of the amount of influenza A and/or B virus in a biological sample.","Influenza A/B Virus Measurement | INFAB | Influenza A/B Virus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773333","Ebola Virus Measurement","C184673","The determination of the amount of Ebola virus in a biological sample.","Ebola Virus Measurement | EBOV | Ebola Virus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772719","Cytomegalovirus Measurement","C184672","The determination of the amount of Cytomegalovirus in a biological sample.","Cytomegalovirus Measurement | CMV | Cytomegalovirus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772718","Curved Bacillus Measurement","C184671","The determination of the amount of curved rod-shaped bacillus in a biological sample.","Curved Bacillus Measurement | CURVBAC | Curved Bacillus | Curved Rods",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772721","Shigella DNA Measurement","C184670","The determination of the amount of DNA from any member of the genus Shigella in a biological sample.","Shigella DNA Measurement | SHIGDNA | Shigella DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772720","Shiga Toxin Measurement","C184669","The determination of the amount of shiga toxin in a biological sample.","Shiga Toxin Measurement | SHIGATOX | Shiga Toxin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772710","Norovirus RNA Measurement","C184668","The determination of the amount of RNA from any member of the genus Norovirus in a biological sample.","Norovirus RNA Measurement | NVRNA | Norovirus RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772709","Bordetella pertussis DNA Measurement","C184667","The determination of the amount of Bordetella pertussis DNA in a biological sample.","Bordetella pertussis DNA Measurement | BPEDNA | Bordetella pertussis DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772711","Toxoplasma gondii DNA Measurement","C184665","The determination of the amount of Toxoplasma gondii DNA in a biological sample.","Toxoplasma gondii DNA Measurement | TGODNA | Toxoplasma gondii DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772714","Human Parainfluenza Virus 3 RNA Measurement","C184664","The determination of the amount of Human parainfluenza virus 3 RNA in a biological sample.","Human Parainfluenza Virus 3 RNA Measurement | HPIV3RNA | Human Parainfluenza Virus 3 RNA | Human Respirovirus 3 RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772713","Human Parainfluenza Virus 2 RNA Measurement","C184663","The determination of the amount of Human parainfluenza virus 2 RNA in a biological sample.","Human Parainfluenza Virus 2 RNA Measurement | HPIV2RNA | Human Orthorubulavirus 2 RNA | Human Parainfluenza Virus 2 RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772715","Human Parainfluenza Virus 1 RNA Measurement","C184662","The determination of the amount of Human parainfluenza virus 1 RNA in a biological sample.","Human Parainfluenza Virus 1 RNA Measurement | HPIV1RNA | Human Parainfluenza Virus 1 RNA | Human Respirovirus 1 RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL372468","Respiratory syncytial virus type B","C184661","The determination of the amount of respiratory syncytial virus type B in a biological sample.","Respiratory Syncytial Virus Type B Measurement | RSVB | Respiratory Syncytial Virus Type B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773185","Respiratory Syncytial Virus Type A Measurement","C184660","The determination of the amount of respiratory syncytial virus type A in a biological sample.","Respiratory Syncytial Virus Type A Measurement | RSVA | Respiratory Syncytial Virus Type A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772780","Chlamydia trachomatis Measurement","C184659","The determination of the amount of Chlamydia trachomatis in a biological sample.","Chlamydia trachomatis Measurement | CTR | Chlamydia trachomatis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772782","Mycoplasma pneumoniae DNA Measurement","C184658","The determination of the amount of Mycoplasma pneumoniae DNA in a biological sample.","Mycoplasma pneumoniae DNA Measurement | MPNDNA | Mycoplasma pneumoniae DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772781","Chlamydia pneumoniae DNA Measurement","C184657","The determination of the amount of Chlamydia pneumoniae DNA in a biological sample.","Chlamydia pneumoniae DNA Measurement | CPNDNA | Chlamydia pneumoniae DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772784","HBOVDNA","C184656","The determination of the amount of Human bocavirus DNA in a biological sample.","Human Bocavirus DNA Measurement | HBOVDNA | Human bocavirus DNA | Human bocavirus DNA Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772783","HCoV-HKU1 RNA Measurement","C184655","The determination of the amount of Human coronavirus HKU1 RNA in a biological sample.","HCoV-HKU1 RNA Measurement | HCoV-HKU1 RNA | HKU1RNA | Human Coronavirus HKU1 RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772786","HCoV-NL63 RNA Measurement","C184654","The determination of the amount of Human coronavirus NL63 RNA in a biological sample.","HCoV-NL63 RNA Measurement | HCoV-NL63 RNA | Human Coronavirus NL63 RNA | NL63RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772785","HCoV-OC43 RNA Measurement","C184653","The determination of the amount of Human coronavirus OC43 RNA in a biological sample.","HCoV-OC43 RNA Measurement | HCoV-OC43 RNA | Human Coronavirus OC43 RNA | OC43RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772774","HCoV-229E RNA Measurement","C184652","The determination of the amount of Human coronavirus 229E RNA in a biological sample.","HCoV-229E RNA Measurement | C229ERNA | HCoV-229E RNA | Human Coronavirus 229E RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772773","Human Parainfluenza Virus 4 RNA Measurement","C184651","The determination of the amount of Human parainfluenza virus 4 RNA in a biological sample.","Human Parainfluenza Virus 4 RNA Measurement | HPIV4RNA | Human Orthorubulavirus 4 RNA | Human Parainfluenza Virus 4 RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772776","Dengue Virus IgM Antibody Measurement","C184650","The determination of the amount of dengue virus IgM antibody in a biological sample.","Dengue Virus IgM Antibody Measurement | DNVIGMAB | Dengue Virus IGM Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772775","Dengue Virus IgG Antibody Measurement","C184649","The determination of the amount of dengue virus IgG antibody in a biological sample.","Dengue Virus IgG Antibody Measurement | DNVIGGAB | Dengue Virus IGG Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772777","Dengue Virus NS1 Antigen Measurement","C184648","The determination of the amount of dengue virus NS1 antigen in a biological sample.","Dengue Virus NS1 Antigen Measurement | DNVNS1AG | Dengue Virus NS1 Antigen | Dengue Virus Nonstructural Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773250","Treponema pallidum Measurement","C184647","The determination of the amount of Treponema pallidum in a biological sample.","Treponema pallidum Measurement | TPA | Treponema pallidum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664241","Natural Killer Cells to Lymphocytes Ratio Measurement","C181258","The determination of the ratio of the natural killer cells to lymphocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Natural Killer Cells to Lymphocytes Ratio Measurement | NK Cells/Lym | NKLY | Natural Killer Cells/Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1096793","p-Benzoquinone","C95317","No Value Exists","p-Benzoquinone | 1,4-Benzoquinone | 1,4-Cyclohexadiene Dioxide | Para-Benzoquinone | Para-quinone | Parabenzochinon | QUINONE | Quinone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773423","Not Recorded","C185193","The information was not captured or stored.","Not Recorded | Undocumented | Unrecorded",,,,,,,,,,,,,,,"37153555","Not recorded",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1773416","Trial 1 Correct","C185198","An indication of the number of correct answers in trial 1.","Trial 1 Correct | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773415","Trial 5 Correct","C185199","An indication of the number of correct answers in trial 5.","Trial 5 Correct | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773418","Trial B Correct","C185200","An indication of the number of correct answers in trial B.","Trial B Correct | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773417","Trials 1-5 Correct","C185201","An indication of the number of correct answers in trials 1-5.","Trials 1-5 Correct | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773433","Short Delay Free Recall Correct","C185202","An indication of the number of correct answers in the short delay free recall exercise.","Short Delay Free Recall Correct | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773432","Long Delay Free Recall Correct","C185203","An indication of the number of correct answers in the long delay free recall exercise.","Long Delay Free Recall Correct | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773435","Delayed Recall Correct Index Score","C185207","A score that reflects both short delayed recall performance and long delay recall performance.","Delayed Recall Correct Index Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773438","Total Recall Correct Index Score","C185208","A score that reflects total immediate recall, total delayed recall, and overall recall performance.","Total Recall Correct Index Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773426","Intrusion Errors Trials 1-5","C185210","An indication of the number of intrusion errors in trials 1-5.","Intrusion Errors Trials 1-5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773425","Intrusion Errors Free Recall","C185211","An indication of the number of intrusion errors during the free recall exercise.","Intrusion Errors Free Recall | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773427","Intrusion Errors Cued Recall","C185212","An indication of the number of intrusion errors during the cued recall exercise.","Intrusion Errors Cued Recall | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773613","Recognition Discriminability","C185213","The ability to distinguish target words from distractor words.","Recognition Discriminability | d'",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773437","Total Recall Responses Standard Score","C185209","The sum of raw scores from all recall exercises.","Total Recall Responses Standard Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773434","Index Score","C185205","A composite score calculated from individual raw scores.","Index Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773436","Standard Score","C185206","A score obtained by transformation of raw scores to a standard curve.","Standard Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879845","Biologic Sample Preservation Procedure","C64262","Procedures utilized to save organic substances from decay. Some preservation procedures are meant to maintain cells, tissues, or organisms in a viable state.","Biologic Sample Preservation Procedure | Tissue Archival | Tissue_Archival | sample preservation | sample_preservation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663563","Number of Days Between Index Date and Specimen Collection","C181071","The number of days between an index date and the date that a specimen collection procedure occurred.","Number of Days Between Index Date and Specimen Collection | Number of Days to Specimen Collection | days to collection | days to sample procurement | days_to_collection | days_to_sample_procurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647496","Cardiopulmonary Assessment","C177915","The evaluation of cardiopulmonary functioning, including the parameters of pulmonary gas exchange and tissue oxygen delivery and consumption.","Cardiopulmonary Assessment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648159","Biospecimen Identifier","C178872","A unique identifier assigned to a biological specimen.","Biospecimen Identifier | Biospecimen ID | Biospecimen_ID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1664272","Study Protocol Version Number","C181232","A string of numerals that uniquely identifies a specific version of a study protocol.","Study Protocol Version Number | Study Protocol Amendment Number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773445","Downstream Shipping","C185233","The process of shipping something from one facility to another, usually to a customer or end user, or to a more specialized facility.","Downstream Shipping | Downstream Shipment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772861","Immunoglobulin A to Complement C3 Measurement","C184515","A relative measurement (ratio) of the immunoglobulin A to complement C3 in a sample. The measurement may be expressed as a ratio or percentage.","Immunoglobulin A to Complement C3 Measurement | IGAC3 | IgA/C3 | IgA/C3 Ratio Measurement | IgA/Complement C3 | Immunoglobulin A/Complement C3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772864","IDL Apolipoprotein B Measurement","C184514","The determination of the amount of the apolipoprotein B in the intermediate density lipoprotein fraction of a biological specimen.","IDL Apolipoprotein B Measurement | IAPOB | IDL Apolipoprotein B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772863","Indocyanine Green Clearance Measurement","C184513","The determination of the amount of the volume of serum or plasma that would be cleared of indocyanine green by excretion for a specified unit of time (e.g. one minute).","Indocyanine Green Clearance Measurement | ICGCLR | Indocyanine Green Clearance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773259","Indocyanine Green Measurement","C184512","The determination of the amount of the indocyanine green in a sample.","Indocyanine Green Measurement | ICG | Indocyanine Green",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772865","Thymic Stromal Lymphopoietin Measurement","C184511","The determination of the amount of the thymic stromal lymphopoietin in a sample.","Thymic Stromal Lymphopoietin Measurement | TSLP | TSLP Measurement | Thymic Stromal Lymphopoietin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772866","Beta-Actin Measurement","C184510","The determination of the amount of the beta-actin in a sample.","Beta-Actin Measurement | ACTB | Actin Beta | Actin Beta Measurement | B-Actin | B-Actin Measurement | Beta-Actin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773260","Placental Specific Alkaline Phosphatase Measurement","C184509","The determination of the amount of the placental specific alkaline phosphatase isoform in a sample.","Placental Specific Alkaline Phosphatase Measurement | ALPPS | Placental Specific Alkaline Phosphatase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773334","Placental Alkaline Phosphatase to Total Alkaline Phosphatase Measurement","C184508","The determination of the ratio of placental specific alkaline phosphatase isoform compared to total alkaline phosphatase present in a sample. The measurement may be expressed as a ratio or percentage.","Placental Alkaline Phosphatase to Total Alkaline Phosphatase Measurement | ALPPALP | Alk Phos, Placental/Total Alk Phos | Alkaline Phosphatase, Placental/Total Alkaline Phosphatase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523340","Complement C3c Measurement","C184521","The determination of the amount of the complement C3c in a sample.","Complement C3c Measurement | C3C | Complement C3c",,,,,,,,,,,,,,,"4018035","Complement C3c measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1772869","Glucosylceramidase Beta Measurement","C184520","The determination of the amount of the glucosylceramidase beta in a sample.","Glucosylceramidase Beta Measurement | Beta-Glucocerebrosidase | Beta-Glucocerebrosidase Measurement | GBA | GBA Measurement | Glucocerebrosidase Beta | Glucocerebrosidase Beta Measurement | Glucosylceramidase | Glucosylceramidase Beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772868","Arachidonate 5-Lipoxygenase Measurement","C184519","The determination of the amount of the arachidonate 5-lipoxygenase in a sample.","Arachidonate 5-Lipoxygenase Measurement | 5-LO | 5-LO Measurement | 5-LOX | 5-LOX Measurement | 5-Lipoxygenase | 5-Lipoxygenase Measurement | ALOX5 | ALOX5 Measurement | Arachidonate 5-Lipoxygenase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772871","Amyloid Beta 1-41 Measurement","C184518","The determination of the amount of amyloid beta protein which is composed of peptides 1 to 41 in a sample.","Amyloid Beta 1-41 Measurement | AMYLB41 | Amyloid Beta 1-41 | Amyloid Beta 41 | Amyloid Beta 41 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772870","VLDL Apolipoprotein B Measurement","C184517","The determination of the amount of the apolipoprotein B in the very low density lipoprotein fraction of a biological specimen.","VLDL Apolipoprotein B Measurement | VAPOB | VLDL Apolipoprotein B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772862","Ganglioside GM3 Measurement","C184516","The determination of the amount of the ganglioside GM3 in a sample.","Ganglioside GM3 Measurement | GM3 | Ganglioside GM3 | Monosialodihexosylganglioside | Monosialodihexosylganglioside Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523673","Glyceraldehyde-3-Phosphate Dehydrogenase Measurement","C184524","The determination of the amount of the glyceraldehyde-3-phosphate dehydrogenase in a sample.","Glyceraldehyde-3-Phosphate Dehydrogenase Measurement | GAPDH | GAPDH Measurement | Glyceraldehyde 3 Phosphate Dehydrogenase | Glyceraldehyde-3-Phosphate Dehydrogenase",,,,,,,,,,,,,,,"4017761","Glyceraldehyde-3-phosphate dehydrogenase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1772867","Glucopsychosine Measurement","C184523","The determination of the amount of the glucopsychosine in a sample.","Glucopsychosine Measurement | Glucopsychosine | Glucosylsphingosine | Glucosylsphingosine Measurement | LYSOGL1 | Lyso-GL1 | Lyso-GL1 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2363956","Glucosylceramide Measurement","C184522","The determination of the amount of the glucosylceramide in a sample.","Glucosylceramide Measurement | GL1 | GL1 Measurement | Glucocerebroside | Glucocerebroside Measurement | Glucosylceramide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524111","Dipipanone Measurement","C184540","The determination of the amount of the dipipanone in a sample.","Dipipanone Measurement | DPIPANON | Dipipanone",,,,,,,,,,,,,,,"4020850","Dipipanone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1772787","AM-2201 Measurement","C184539","The determination of the amount of the AM-2201 in a sample.","AM-2201 Measurement | AM-2201 | AM2201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772789","AM694 N-5-hydroxypentyl Measurement","C184538","The determination of the amount of the synthetic cannabinoid metabolite AM694 N-5-hydroxypentyl in a sample.","AM694 N-5-hydroxypentyl Measurement | AM694 N-5-hydroxypentyl | AM694N5H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772788","Alpha-Methylfentanyl Measurement","C184537","The determination of the amount of the alpha-methylfentanyl in a sample.","Alpha-Methylfentanyl Measurement | Alpha-Methylfentanyl | FENAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772791","N,N-Dimethyltryptamine Measurement","C184536","The determination of the amount of the N,N-dimethyltryptamine in a sample.","N,N-Dimethyltryptamine Measurement | DMT | DMT Measurement | DMTNN | Dimethyltryptamine | N,N-Dimethyltryptamine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772790","Desomorphine Measurement","C184535","The determination of the amount of the desomorphine in a sample.","Desomorphine Measurement | Desomorphine | MORPHDS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772793","Cathinone Measurement","C184534","The determination of the amount of the cathinone in a sample.","Cathinone Measurement | CATHNON | Cathinone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772792","Butyrylfentanyl Measurement","C184533","The determination of the amount of the butyrylfentanyl in a sample.","Butyrylfentanyl Measurement | Butyrfentanyl | Butyrfentanyl Measurement | Butyryl Fentanyl | Butyryl Fentanyl Measurement | Butyrylfentanyl | FENBUT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772872","Butylone Measurement","C184532","The determination of the amount of the butylone in a sample.","Butylone Measurement | BUTYLN | Butylone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524037","Bufotenine Measurement","C184531","The determination of the amount of the bufotenine in a sample.","Bufotenine Measurement | BFTNN | Bufotenine",,,,,,,,,,,,,,,"4020831","Bufotenine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1772874","Beta-Hydroxythiofentanyl Measurement","C184530","The determination of the amount of the beta-hydroxythiofentanyl in a sample.","Beta-Hydroxythiofentanyl Measurement | Beta-Hydroxythiofentanyl | FENBOHT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772873","ADB-PINACA Measurement","C184529","The determination of the amount of the ADB-PINACA in a sample.","ADB-PINACA Measurement | ADB-PINACA | ADBPNCA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772876","Acetylfentanyl Measurement","C184528","The determination of the amount of the acetylfentanyl in a sample.","Acetylfentanyl Measurement | Acetyl Fentanyl | Acetylfentanyl | FENACE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772875","AB-PINACA Measurement","C184527","The determination of the amount of the synthetic cannabinoid AB-PINACA in a sample.","AB-PINACA Measurement | AB-PINACA | ABPNCA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772878","AB-FUBINACA Measurement","C184526","The determination of the amount of the synthetic cannabinoid AB-FUBINACA in a sample.","AB-FUBINACA Measurement | AB-FUBINACA | ABFBCA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772877","3-Methylfentanyl Measurement","C184525","The determination of the amount of the 3-methylfentanyl in a sample.","3-Methylfentanyl Measurement | 3-Methylfentanyl | FEN3M",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772795","JWH-398 Measurement","C184548","The determination of the amount of the JWH-398 in a sample.","JWH-398 Measurement | JWH-398 | JWH398",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772794","JWH-122 Measurement","C184547","The determination of the amount of the JWH-122 in a sample.","JWH-122 Measurement | JWH-122 | JWH122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772797","JWH-081 Measurement","C184546","The determination of the amount of the JWH-081 in a sample.","JWH-081 Measurement | JWH-081 | JWH081",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772796","JWH-250 Measurement","C184545","The determination of the amount of the JWH-250 in a sample.","JWH-250 Measurement | JWH-250 | JWH250",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772799","JWH-200 Measurement","C184544","The determination of the amount of the JWH-200 in a sample.","JWH-200 Measurement | JWH-200 | JWH200",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772798","JWH-073 Measurement","C184543","The determination of the amount of the JWH-073 in a sample.","JWH-073 Measurement | JWH-073 | JWH073",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772801","JWH-018 Measurement","C184542","The determination of the amount of the JWH-018 in a sample.","JWH-018 Measurement | JWH-018 | JWH018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772800","Furanylfentanyl Measurement","C184541","The determination of the amount of the furanylfentanyl in a sample.","Furanylfentanyl Measurement | FENFUR | Furanyl Fentanyl | Furanylfentanyl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772804","Mephedrone Measurement","C184551","The determination of the amount of the mephedrone in a sample.","Mephedrone Measurement | MPHDRN | Mephedrone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772806","MAB-CHMINACA Measurement","C184550","The determination of the amount of the MAB-CHMINACA in a sample.","MAB-CHMINACA Measurement | ADB-CHMINACA Measurement | MAB-CHMINACA | MABCHMCA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524164","Ketobemidone Measurement","C184549","The determination of the amount of the ketobemidone in a sample.","Ketobemidone Measurement | KBEMIDON | Ketobemidone",,,,,,,,,,,,,,,"4020278","Ketobemidone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1772812","Normorphine Measurement","C184557","The determination of the amount of the normorphine in a sample.","Normorphine Measurement | MORPHNR | Normorphine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524202","Nicomorphine Measurement","C184556","The determination of the amount of the nicomorphine in a sample.","Nicomorphine Measurement | MORPHNC | Nicomorphine",,,,,,,,,,,,,,,"4019684","Nicomorphine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266525","Ethylamphetamine Measurement","C184555","The determination of the amount of the ethylamphetamine in a sample.","Ethylamphetamine Measurement | EMA | Ethylamphetamine | Etilamfetamine | Etilamfetamine Measuremen | N-Ethylamphetamine",,,,,,,,,,,,,,,"4040052","Ethylamphetamine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1772803","Benzylpiperazine Measurement","C184554","The determination of the amount of the benzylpiperazine in a sample.","Benzylpiperazine Measurement | 1-benzylpiperazine | 1-benzylpiperazine Measurement | BZP | Benzylpiperazine | N-benzylpiperazine | N-benzylpiperazine Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772802","Naphyrone Measurement","C184553","The determination of the amount of the naphyrone in a sample.","Naphyrone Measurement | NAPHYRON | Naphyrone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772805","Methcathinone Measurement","C184552","The determination of the amount of the methcathinone in a sample.","Methcathinone Measurement | Ephedrone | Ephedrone Measurement | MCATHNON | Methcathinone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524018","Anileridine Measurement","C184568","The determination of the amount of the anileridine in a sample.","Anileridine Measurement | ANLRDN | Anileridine",,,,,,,,,,,,,,,"4020240","Anileridine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524001","Alphaprodine Measurement","C184567","The determination of the amount of the alphaprodine in a sample.","Alphaprodine Measurement | Alphaprodine | PRODINEA",,,,,,,,,,,,,,,"4021305","Alphaprodine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524000","Alfentanil Measurement","C184566","The determination of the amount of the alfentanil in a sample.","Alfentanil Measurement | ALFNTNL | Alfentanil",,,,,,,,,,,,,,,"4020819","Alfentanil measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1772814","UR-144 Measurement","C184565","The determination of the amount of the UR-144 in a sample.","UR-144 Measurement | UR-144 | UR144",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772807","U-47700 Measurement","C184564","The determination of the amount of the U-47700 in a sample.","U-47700 Measurement | Pink | Pinky | U-47700 | U4 | U4 Measurement | U47700",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524291","Trimeperidine Measurement","C184563","The determination of the amount of the trimeperidine in a sample.","Trimeperidine Measurement | TMEPRDN | Trimeperidine",,,,,,,,,,,,,,,"4019815","Trimeperidine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1772809","Pentylone Measurement","C184562","The determination of the amount of the pentylone in a sample.","Pentylone Measurement | PENTYLN | Pentylone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772808","Pentedrone Measurement","C184561","The determination of the amount of the pentedrone in a sample.","Pentedrone Measurement | PENDRN | Pentedrone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772811","5-fluoro PB-22 3-carboxyindole Measurement","C184560","The determination of the amount of the synthetic cannabinoid metabolite 5-fluoro PB-22 3-carboxyindole in a sample.","5-fluoro PB-22 3-carboxyindole Measurement | 5-fluoro PB-22 3-carboxyindole | PB225F3C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772810","PB-22 3-carboxyindole Measurement","C184559","The determination of the amount of the PB-22 3-carboxyindole in a sample.","PB-22 3-carboxyindole Measurement | PB-22 3-carboxyindole | PB223C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772813","Para-Fluorofentanyl Measurement","C184558","The determination of the amount of the para-fluorofentanyl in a sample.","Para-Fluorofentanyl Measurement | FENPF | Para-Fluorofentanyl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772758","Stenbolone Measurement","C184600","The determination of the amount of the stenbolone in a sample.","Stenbolone Measurement | Deacetylanatrofin | Deacetylanatrofin Measurement | STNBLN | Stenbolone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524270","Stanozolol Measurement","C184599","The determination of the amount of the stanozolol in a sample.","Stanozolol Measurement | STNZLL | Stanozolol",,,,,,,,,,,,,,,"4019706","Stanozolol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1772759","Prostanozol Measurement","C184598","The determination of the amount of the prostanozol in a sample.","Prostanozol Measurement | PRSTNZL | Prostanozol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524235","Phendimetrazine Measurement","C184597","The determination of the amount of the phendimetrazine in a sample.","Phendimetrazine Measurement | PHNDMTZN | Phendimetrazine",,,,,,,,,,,,,,,"4020405","Phendimetrazine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1772820","Perampanel Measurement","C184596","The determination of the amount of the perampanel in a sample.","Perampanel Measurement | PRMPNL | Perampanel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524223","Oxymesterone Measurement","C184595","The determination of the amount of the oxymesterone in a sample.","Oxymesterone Measurement | OXMSTRN | Oxymesterone",,,,,,,,,,,,,,,"4022994","Oxymesterone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524209","Norethandrolone Measurement","C184594","The determination of the amount of the norethandrolone in a sample.","Norethandrolone Measurement | NRENDRLN | Norethandrolone",,,,,,,,,,,,,,,"4022494","Norethandrolone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1772821","Norclostebol Measurement","C184593","The determination of the amount of the norclostebol in a sample.","Norclostebol Measurement | NCLOSTBL | Norclostebol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202429","Nalorphine Measurement","C184592","The determination of the amount of the nalorphine in a sample.","Nalorphine Measurement | Allorphine | Allorphine Measurement | Antorphine | Antorphine Measurement | N-allylnormorphine | N-allylnormorphine Measurement | NALORPHN | Nalorphine",,,,,,,,,,,,,,,"4294998","Nalorphine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202423","Methyprylon Measurement","C184591","The determination of the amount of the methyprylon in a sample.","Methyprylon Measurement | MPRYLON | Methyprylon",,,,,,,,,,,,,,,"4286019","Methyprylon measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523778","Methyltestosterone Measurement","C184590","The determination of the amount of the methyltestosterone in a sample.","Methyltestosterone Measurement | MTESTOS | Methyltestosterone",,,,,,,,,,,,,,,"4020541","Methyltestosterone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1772822","Methasterone Measurement","C184589","The determination of the amount of the methasterone in a sample.","Methasterone Measurement | MTHSTRN | Methasterone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524178","Mesterolone Measurement","C184588","The determination of the amount of the mesterolone in a sample.","Mesterolone Measurement | MSTRLN | Mesterelone | Mesterolone",,,,,,,,,,,,,,,"4022371","Mesterolone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524163","Ketamine Measurement","C184587","The determination of the amount of the ketamine in a sample.","Ketamine Measurement | KETAMINE | Ketamine",,,,,,,,,,,,,,,"4020277","Ketamine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1772816","Furazabol Measurement","C184586","The determination of the amount of the furazabol in a sample.","Furazabol Measurement | FURAZBL | Furazabol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524139","Fluoxymesterone Measurement","C184585","The determination of the amount of the fluoxymesterone in a sample.","Fluoxymesterone Measurement | FLXMSTRN | Fluoxymesterone",,,,,,,,,,,,,,,"4019676","Fluoxymesterone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1772818","Ethylestrenol Measurement","C184584","The determination of the amount of the ethylestrenol in a sample.","Ethylestrenol Measurement | ETHESTNL | Ethylestrenol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772817","Drostanolone Measurement","C184583","The determination of the amount of the drostanolone in a sample.","Drostanolone Measurement | DRSTNLN | Dromostanolone | Dromostanolone Measurement | Drostanolone | Medrosteron | Medrosteron Measurement | Medrotestron | Medrotestron Measurement | Metholone | Metholone Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772819","Desoxymethyltestosterone Measurement","C184582","The determination of the amount of the desoxymethyltestosterone in a sample.","Desoxymethyltestosterone Measurement | DOXMTST | Desoxymethyltestosterone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524085","Clostebol Measurement","C184581","The determination of the amount of the clostebol in a sample.","Clostebol Measurement | CLOSTBL | Clostebol",,,,,,,,,,,,,,,"4020840","Clostebol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524069","Chlorphentermine Measurement","C184580","The determination of the amount of the chlorphentermine in a sample.","Chlorphentermine Measurement | CLPHTRMN | Chlorphentermine",,,,,,,,,,,,,,,"4019664","Chlorphentermine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524032","Bolasterone Measurement","C184579","The determination of the amount of the bolasterone in a sample.","Bolasterone Measurement | BOLSTRN | Bolasterone",,,,,,,,,,,,,,,"4017477","Bolasterone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266382","Aprobarbital Measurement","C184578","The determination of the amount of the aprobarbital in a sample.","Aprobarbital Measurement | APRBRBTL | Aprobarbital",,,,,,,,,,,,,,,"4007024","Aprobarbital measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266753","Thebaine Measurement","C184577","The determination of the amount of the thebaine in a sample.","Thebaine Measurement | THEBAINE | Thebaine",,,,,,,,,,,,,,,"4006041","Thebaine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1772815","Tapentadol Measurement","C184576","The determination of the amount of the tapentadol in a sample.","Tapentadol Measurement | TPNTDL | Tapentadol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266736","Sufentanil Measurement","C184575","The determination of the amount of the sufentanil in a sample.","Sufentanil Measurement | SUFNTNL | Sufentanil",,,,,,,,,,,,,,,"4006036","Sufentanil measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524237","Phenmetrazine Measurement","C184574","The determination of the amount of the phenmetrazine in a sample.","Phenmetrazine Measurement | PHNMTZN | Phenmetrazine",,,,,,,,,,,,,,,"4023000","Phenmetrazine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524234","Phenazocine Measurement","C184573","The determination of the amount of the phenazocine in a sample.","Phenazocine Measurement | PHNZCN | Phenazocine",,,,,,,,,,,,,,,"4019696","Phenazocine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524169","Levorphanol Measurement","C184572","The determination of the amount of the levorphanol in a sample.","Levorphanol Measurement | LVRPHNL | Levorphanol",,,,,,,,,,,,,,,"4020384","Levorphanol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202393","Glutethimide Measurement","C184571","The determination of the amount of the glutethimide in a sample.","Glutethimide Measurement | GLTTHMD | Glutethimide",,,,,,,,,,,,,,,"4224616","Glutethimide measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524127","Ethylmorphine Measurement","C184570","The determination of the amount of the ethylmorphine in a sample.","Ethylmorphine Measurement | Ethylmorphine | MORPHET",,,,,,,,,,,,,,,"4022973","Ethylmorphine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266508","Diphenoxylate Measurement","C184569","The determination of the amount of the diphenoxylate in a sample.","Diphenoxylate Measurement | DPHNOXLT | Diphenoxylate",,,,,,,,,,,,,,,"4007177","Diphenoxylate measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1772760","Valerylfentanyl Measurement","C184607","The determination of the amount of the valerylfentanyl in a sample.","Valerylfentanyl Measurement | FENVAL | Valeryl Fentanyl | Valerylfentanyl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772761","Vinbarbital Measurement","C184606","The determination of the amount of the vinbarbital in a sample.","Vinbarbital Measurement | VINBRBTL | Vinbarbital",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266767","Trenbolone Measurement","C184605","The determination of the amount of the trenbolone in a sample.","Trenbolone Measurement | 17beta-Trenbolone | 17beta-Trenbolone Measurement | TRNBLN | Trenbolone | Trienbolone",,,,,,,,,,,,,,,"4006170","Trenbolone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524280","Thiopental Measurement","C184604","The determination of the amount of the thiopental in a sample.","Thiopental Measurement | THIOPNTL | Thiopental",,,,,,,,,,,,,,,"4020419","Thiopental measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266755","Thiamylal Measurement","C184603","The determination of the amount of the thiamylal in a sample.","Thiamylal Measurement | THMYLL | Thiamylal",,,,,,,,,,,,,,,"4005364","Thiamylal measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1772757","Tetrahydrogestrinone Measurement","C184602","The determination of the amount of the tetrahydrogestrinone in a sample.","Tetrahydrogestrinone Measurement | THGSTNON | Tetrahydrogestrinone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772756","Testolactone Measurement","C184601","The determination of the amount of the testolactone in a sample.","Testolactone Measurement | TSTLCTN | Testolactone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266423","Butorphanol Measurement","C184610","The determination of the amount of the butorphanol in a sample.","Butorphanol Measurement | BTRPHNL | Butorphanol",,,,,,,,,,,,,,,"4006499","Butorphanol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524034","Bromazepam Measurement","C184609","The determination of the amount of the bromazepam in a sample.","Bromazepam Measurement | BRMZPM | Bromazepam",,,,,,,,,,,,,,,"4019565","Bromazepam measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524025","Barbital Measurement","C184608","The determination of the amount of the barbital in a sample.","Barbital Measurement | BRBTL | Barbital",,,,,,,,,,,,,,,"4020242","Barbital measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524077","Clobazam Measurement","C184613","The determination of the amount of the clobazam in a sample.","Clobazam Measurement | CLOBAZAM | Clobazam | cloBAZam",,,,,,,,,,,,,,,"4021451","Clobazam measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202351","Chloral Hydrate Measurement","C184612","The determination of the amount of the chloral hydrate in a sample.","Chloral Hydrate Measurement | CHLRHDRT | Chloral Hydrate | Mickey Finn | Trichloroacetaldehyde Monohydrate | Trichloroacetaldehyde Monohydrate Measurement",,,,,,,,,,,,,,,"4298445","Chloral hydrate measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524046","Carisoprodol Measurement","C184611","The determination of the amount of the carisoprodol in a sample.","Carisoprodol Measurement | CRSPRDL | Carisoprodol",,,,,,,,,,,,,,,"4021444","Carisoprodol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1772769","Pregabalin Measurement","C184642","The determination of the amount of the pregabalin in a sample.","Pregabalin Measurement | PREGBLN | Pregabalin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772768","Lacosamide Measurement","C184641","The determination of the amount of the lacosamide in a sample.","Lacosamide Measurement | LACOSMD | Lacosamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772771","Ezogabine Measurement","C184640","The determination of the amount of the ezogabine in a sample.","Ezogabine Measurement | EZOGABIN | Ezogabine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772770","Brivaracetam Measurement","C184639","The determination of the amount of the brivaracetam in a sample.","Brivaracetam Measurement | BRVRCTM | Brivaracetam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772772","Zopiclone Measurement","C184638","The determination of the amount of the zopiclone in a sample.","Zopiclone Measurement | ZOPCLN | Zopiclone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524301","Zolpidem Measurement","C184637","The determination of the amount of the zolpidem in a sample.","Zolpidem Measurement | ZOLPIDEM | Zolpidem",,,,,,,,,,,,,,,"4023135","Zolpidem measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1772766","Zaleplon Measurement","C184636","The determination of the amount of the zaleplon in a sample.","Zaleplon Measurement | ZALEPLON | Zaleplon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772765","Sibutramine Measurement","C184635","The determination of the amount of the sibutramine in a sample.","Sibutramine Measurement | SBUTRMN | Sibutramine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266727","Quazepam Measurement","C184634","The determination of the amount of the quazepam in a sample.","Quazepam Measurement | QUZPM | Quazepam",,,,,,,,,,,,,,,"4007979","Quazepam measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524246","Pipradrol Measurement","C184633","The determination of the amount of the pipradrol in a sample.","Pipradrol Measurement | PIPRDROL | Pipradrol",,,,,,,,,,,,,,,"4020408","Pipradrol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202443","Pentazocine Measurement","C184632","The determination of the amount of the pentazocine in a sample.","Pentazocine Measurement | PNTZOCIN | Pentazocine",,,,,,,,,,,,,,,"4297985","Pentazocine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524229","Pemoline Measurement","C184631","The determination of the amount of the pemoline in a sample.","Pemoline Measurement | PEMOLINE | Pemoline",,,,,,,,,,,,,,,"4019694","Pemoline measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202440","Paraldehyde Measurement","C184630","The determination of the amount of the paraldehyde in a sample.","Paraldehyde Measurement | PARALD | Paraldehyde",,,,,,,,,,,,,,,"4048397","Paraldehyde measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524205","Nitrazepam Measurement","C184629","The determination of the amount of the nitrazepam in a sample.","Nitrazepam Measurement | NTRZPM | Nitrazepam",,,,,,,,,,,,,,,"4019685","Nitrazepam measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1772763","Modafinil Measurement","C184628","The determination of the amount of the modafinil in a sample.","Modafinil Measurement | MODAFNIL | Modafinil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266598","Methohexital Measurement","C184626","The determination of the amount of the methohexital in a sample.","Methohexital Measurement | MOHXITAL | Methohexital",,,,,,,,,,,,,,,"4006666","Methohexital measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202411","Meprobamate Measurement","C184625","The determination of the amount of the meprobamate in a sample.","Meprobamate Measurement | MPRBMATE | Meprobamate",,,,,,,,,,,,,,,"4264369","Meprobamate measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524175","Mefenorex Measurement","C184624","The determination of the amount of the mefenorex in a sample.","Mefenorex Measurement | MFENRX | Mefenorex",,,,,,,,,,,,,,,"4020387","Mefenorex measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266582","Mazindol Measurement","C184623","The determination of the amount of the mazindol in a sample.","Mazindol Measurement | MAZINDOL | Mazindol",,,,,,,,,,,,,,,"4005219","Mazindol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524171","Lormetazepam Measurement","C184622","The determination of the amount of the lormetazepam in a sample.","Lormetazepam Measurement | LRMZPM | Lormetazepam",,,,,,,,,,,,,,,"4022369","Lormetazepam measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1772764","Loprazolam Measurement","C184621","The determination of the amount of the loprazolam in a sample.","Loprazolam Measurement | LOPRAZLM | Loprazolam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524135","Fenproporex Measurement","C184620","The determination of the amount of the fenproporex in a sample.","Fenproporex Measurement | FENPRPRX | Fenproporex",,,,,,,,,,,,,,,"4022976","Fenproporex measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524133","Fenfluramine Measurement","C184619","The determination of the amount of the fenfluramine in a sample.","Fenfluramine Measurement | FENFLRMN | Fenfluramine",,,,,,,,,,,,,,,"4022974","Fenfluramine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524131","Fencamfamin Measurement","C184618","The determination of the amount of the fencamfamin in a sample.","Fencamfamin Measurement | FENCMFMN | Fencamfamin | Fencamfamine | Fencamfamine Measurement",,,,,,,,,,,,,,,"4020860","Fencamfamin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266521","Ethinamate Measurement","C184617","The determination of the amount of the ethinamate in a sample.","Ethinamate Measurement | ETHNMATE | Ethinamate",,,,,,,,,,,,,,,"4006011","Ethinamate measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202378","Ethchlorvynol Measurement","C184616","The determination of the amount of the ethchlorvynol in a sample.","Ethchlorvynol Measurement | ETHCHVNL | Ethchlorvynol",,,,,,,,,,,,,,,"4173879","Ethchlorvynol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524119","Estazolam Measurement","C184615","The determination of the amount of the estazolam in a sample.","Estazolam Measurement | ESTAZLM | Estazolam",,,,,,,,,,,,,,,"4019672","Estazolam measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524015","Diethylpropion Measurement","C184614","The determination of the amount of the diethylpropion in a sample.","Diethylpropion Measurement | DETHPRPN | Diethylpropion",,,,,,,,,,,,,,,"4017474","Amphepramone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524224","Oxymetholone Measurement","C75388","The determination of the amount of oxymetholone present in a sample.","Oxymetholone Measurement | OXMTHLN | Oxymethalone | Oxymethalone Measurement | Oxymethenolone | Oxymethenolone Measurement | Oxymetholone",,,,,,,,,,,,,,,"4019691","Oxymetholone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524219","Oxandrolone Measurement","C75381","The determination of the amount of oxandrolone present in a sample.","Oxandrolone Measurement | OXANDRLN | Ossandrolone | Ossandrolone Measurement | Oxandrolone",,,,,,,,,,,,,,,"4020403","Oxandrolone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524033","Boldenone Measurement","C75380","The determination of the amount of boldenone present in a sample.","Boldenone Measurement | BOLDNON | Boldenone",,,,,,,,,,,,,,,"4021440","Boldenone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524199","Nandrolone Measurement","C75377","The determination of the amount of nandrolone present in a sample.","Nandrolone Measurement | NANDRLN | Nandrolone | Norandrostenolone | Norandrostenolone Measurement | Nortestosterone | Nortestosterone Measurement",,,,,,,,,,,,,,,"4022993","Nandrolone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0524258","Psilocybine Measurement","C75356","The determination of the amount of psilocybine present in a sample.","Psilocybine Measurement | Magic Mushrooms | PSLCYBN | Psilocybin | Psilocybine",,,,,,,,,,,,,,,"4019702","Psilocybin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1266590","Mescaline Measurement","C75355","The determination of the amount of cocaine present in a sample.","Mescaline Measurement | 3,4,5-trimethoxyphenethylamine | 3,4,5-trimethoxyphenethylamine Measurement | MESCALIN | Mescaline",,,,,,,,,,,,,,,"4005222","Mescaline measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1772779","Interferon Alpha Type 2 Measurement","C184646","The determination of the amount of the interferon alpha type 2 in a sample.","Interferon Alpha Type 2 Measurement | IFNA2 | Interferon Alpha Type 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772778","Nephrin Measurement","C184645","The determination of the amount of the nephrin in a sample.","Nephrin Measurement | NEPHRIN | NPHS1 Adhesion Molecule, Nephrin | NPHS1 Measurement | Nephrin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1772767","Eosinophil-Derived Neurotoxin Measurement","C184644","The determination of the amount of the eosinophil-derived neurotoxin in a sample.","Eosinophil-Derived Neurotoxin Measurement | EDN | Eosinophil Protein-X | Eosinophil Protein-X Measurement | Eosinophil-Derived Neurotoxin | RAF3 | RAF3 Measurement | Ribonuclease A Family Member 2 | Ribonuclease A Family Member 2 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524260","Pyrovalerone Measurement","C184643","The determination of the amount of the pyrovalerone in a sample.","Pyrovalerone Measurement | PYROVLRN | Pyrovalerone",,,,,,,,,,,,,,,"4023006","Pyrovalerone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010799","Cytologic Test","C49132","A diagnostic test utilized to examine and define cellular anatomy or function. The test results are often used by a clinician to diagnose disease or disordered function.","Cytologic Test | ",,,,,,,,,,,,,,,"4023405","Cytologic test",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554306","Advanced Carcinoma","C153171","Carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1656919","Casirivimab/Imdevimab","C173743","A combination of two monoclonal antibodies, casirivimab and imdevimab, directed against the spike protein (SP) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19. Upon administration, casirivimab and imdevimab specifically target and bind to non-overlapping regions of the receptor-binding domain (RBD) of SP, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. Binding to two distinct regions of the RBD of SP may decrease the potential for virus escape mutants that occur upon treatment with a single SARS-CoV-2 antibody, and may provide enhanced protection against loss of efficacy.","Casirivimab/Imdevimab | Anti-COVID Cocktail REGN-COV2 | Anti-Spike SARS-CoV-2 Monoclonal Antibodies REGN-COV2 | Casirivimab Plus Imdevimab | Casirivimab and Imdevimab | Casirivimab+Imdevimab | Monoclonal antibodies against SARS-CoV-2: casirivimab/imdevimab | REGEN-COV | REGN COV2 | REGN-COV2 | REGN10933 Plus REGN10987 | REGN10933+REGN10987 | REGN10933/REGN10987 | REGNCOV2 | SARS-CoV-2-specific Antibodies REGN10933 and REGN10987",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2351042","Besifloxacin","C83553","A synthetic fourth-generation fluoroquinolone antibiotic, with broad spectrum antibacterial activity. Upon administration, besifloxacin targets, binds to and inhibits both bacterial DNA gyrase, an enzyme essential for DNA replication, transcription and repair of bacterial DNA, and bacterial topoisomerase IV, an enzyme required for partitioning of the chromosomal DNA during bacterial cell division. This inhibits DNA replication, transcription, and repair and cell division.","Besifloxacin | (+)-7-((3R)-3-Aminohexahydro-1H-Azepin-1-yl)-8-Chloro-1-Cyclopropyl-6-Fluoro-4-Oxo-1,4-Dihydroquinoline-3-Carboxylic Acid | 3-Quinolinecarboxylic Acid, 7-((3R)-3-Aminohexahydro-1H-Azepin-1-yl)-8-Chloro-1-Cyclopropyl-6-Fluoro-1,4-Dihydro-4-Oxo- | BESIFLOXACIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773562","FOLFOX-Nivolumab Regimen","C185309","A regimen consisting of leucovorin, fluorouracil and oxaliplatin (FOLFOX), plus nivolumab that can be used for the treatment of esophageal, esophagogastric junction and gastric cancers.","FOLFOX-Nivolumab Regimen | FOLFOX + Nivolumab | FOLFOX + Nivolumab Regimen | FOLFOX Plus Nivolumab Regimen | FOLFOX-Nivolumab | FOLFOX-Opdivo Regimen | FOLFOX/Nivolumab | FOLFOX/Nivolumab Regimen | FOLFOX/Opdivo Regimen | Folinic Acid/Fluorouracil/Oxaliplatin/Nivolumab | Folinic Acid/Fluorouracil/Oxaliplatin/Nivolumab Regimen | Leucovorin/Fluorouracil/Oxaliplatin/Nivolumab | Leucovorin/Fluorouracil/Oxaliplatin/Nivolumab Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773581","CAPOX-Nivolumab Regimen","C185315","A regimen consisting of capecitabine and oxaliplatin (CAPOX), plus nivolumab that can be used for the treatment of esophageal, esophagogastric junction and gastric cancers.","CAPOX-Nivolumab Regimen | CAPOX + Nivolumab | CAPOX + Nivolumab Regimen | CAPOX Plus Nivolumab Regimen | CAPOX-Nivolumab | CAPOX-Opdivo Regimen | CAPOX/Nivolumab | CAPOX/Nivolumab Regimen | CAPOX/Opdivo Regimen | CapeOx and Nivolumab | CapeOx-Nivolumab Regimen | Capecitabine/Oxaliplatin/Nivolumab | Capecitabine/Oxaliplatin/Nivolumab Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773605","4 Degrees Celsius","C185332","A temperature of 4 celsius.","4 Degrees Celsius | 4C | 4C Temperature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773597","25 Degrees Celsius","C185333","A temperature of 25 celsius.","25 Degrees Celsius | 25C | 25C Temperature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773596","Minus 20 Degrees Celsius","C185334","A temperature of minus 20 celsius.","Minus 20 Degrees Celsius | -20 Celsius | -20C | Minus 20 Celsius | Minus 20C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773599","Minus 70 Degrees Celsius","C185335","A temperature of minus 70 celsius.","Minus 70 Degrees Celsius | -70 Celsius | -70C | Minus 70 Celsius | Minus 70C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773598","Minus 80 Degrees Celsius","C185336","A temperature of minus 80 celsius.","Minus 80 Degrees Celsius | -80 Celsius | -80C | Minus 80 Celsius | Minus 80C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773601","Minus 150 Degrees Celsius","C185337","A temperature of minus 150 celsius.","Minus 150 Degrees Celsius | -150 Celsius | -150C | Minus 150 Celsius | Minus 150C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773600","Liquid Nitrogen Storage","C185338","An indication that a material has been stored in liquid nitrogen.","Liquid Nitrogen Storage | Frozen in liquid nitrogen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773588","Liquid Nitrogen Vapor Storage","C185339","An indication that a material has been stored in liquid nitrogen vapor.","Liquid Nitrogen Vapor Storage | Frozen in vapor phase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773587","Refrigerated Vacuum Chamber","C185340","A device designed to maintain a vacuum at a below-ambient temperature.","Refrigerated Vacuum Chamber | Refrigerated vacuum chamber",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773590","Material Storage Method","C185341","A specification of the way that a specimen is or was stored.","Material Storage Method | Storage Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2711227","Hepatic Steatosis","C150596","A morphologic finding indicating intracytoplasmic fat accumulation in the liver parenchyma.","Hepatic Steatosis | Fatty (change of) liver, not elsewhere classified | Fatty Liver Change | Liver Steatosis",,,,,,,,,,,,,,,"40482277|4059290","Steatohepatitis|Steatosis of liver",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL1773591","Storage at Room Temperature then Refrigerated","C185344","An indication that a specimen was maintained at room temperature before being refrigerated.","Storage at Room Temperature then Refrigerated | Room temperature then refrigerated | Stored at Room Temperature then Refrigerated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515688","recombinant fowlpox-PSA(L155)/TRICOM vaccine","C29560","A cancer vaccine consisting of a recombinant fowlpox virus encoding fragment of human prostate-specific antigen (PSA), PSA:154-163 (155L), and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM).  Administration of this agent may induce a cytotoxic T cell response against PSA-expressing tumor cells. Dendritic cells infected with TRICOM vectors greatly enhance naive T-cell activation and peptide-specific T-cell stimulation. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells.","Rilimogene Glafolivec | PROSTVAC-F | RILIMOGENE GLAFOLIVEC | Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine | rFowlpox-PSA(L155)/TRICOM Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0751608","cDNA Library","C15727","A collection of DNA molecules that have been cloned in vectors.  In the case of a cDNA library the DNA inserts are copies of RNAs that have been reverse-transcribed into DNA prior to cloning.","cDNA Library | Library",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545883","F-18 Sodium Fluoride Positron Emission Tomography and Magnetic Resonance Imaging","C148079","An imaging procedure that combines F-18 sodium fluoride PET with an MRI scan to overlay activity data onto detailed anatomic images.","F-18 Sodium Fluoride Positron Emission Tomography and Magnetic Resonance Imaging | F-18 Sodium Fluoride PET/MRI | F-18 Sodium Fluoride PET/MRI Scan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3711683","HAMP protein, human","C104274","Hepcidin (84 aa, ~9 kDa) is encoded by the human HAMP gene. This protein is involved in antimicrobial activity and iron absorption and storage.","Hepcidin | HAMP | LEAP-1 | Liver-Expressed Antimicrobial Peptide 1 | PLTR | Putative Liver Tumor Regressor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508067","Psychosocial Assessment","C126879","The act of determining, usually through interviews and observation, the state of an individual's psychological state and social environment.","Psychosocial Assessment | Psychosocial Studies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773961","Severity of Vaginal Agglutination","C185354","A question about the severity of an individual's vaginal agglutination.","Severity of Vaginal Agglutination | Labial Adhesion | Labial Agglutination | Vaginal Agglutination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773788","Severity of Vaginal Scarring or Adhesions","C185355","A question about the severity of an individual's vaginal scaring or adhesions.","Severity of Vaginal Scarring or Adhesions | Vaginal Scarring or Adhesions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773951","Vaginal pH","C185356","A question about an individual's vaginal pH.","Vaginal pH | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773787","Vaginal Moisture","C185357","A question about an individual's vaginal moisture.","Vaginal Moisture | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773791","Vaginal Rugosity","C185358","A question about an individual's vaginal rugosity.","Vaginal Rugosity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773792","Vaginal Elasticity","C185359","A question about an individual's vaginal elasticity.","Vaginal Elasticity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773789","Length of Vagina","C185360","A question about the length of an individual's vaginal.","Length of Vagina | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773790","Vaginal Thickness","C185361","A question about the thickness of an individual's vaginal walls.","Vaginal Thickness | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773782","Vaginal Epithelial Integrity","C185362","A question about the integrity of an individual's vaginal epithelium.","Vaginal Epithelial Integrity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773783","Appearance or Condition of Vaginal Vascularity","C185363","A question about the appearance or condition of an individual's vaginal vascularity.","Appearance or Condition of Vaginal Vascularity | Vaginal Vascularity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773780","Extent of Vulvar Atrophy","C185364","A question about the extent of an individual's vulvar atrophy.","Extent of Vulvar Atrophy | Vulvar Atrophy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773781","Presence of Vaginal Vestibular Irritation","C185365","A question about whether an individual has vaginal vestibular irritation.","Presence of Vaginal Vestibular Irritation | Vaginal Vestibular Irritation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773959","Presence of Vaginal Stenosis","C185366","A question about whether an individual has vaginal stenosis.","Presence of Vaginal Stenosis | Vaginal Stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773786","Incontinence Pad Use","C185367","A question about whether an individual uses incontinence pads.","Incontinence Pad Use | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773801","Myelodysplastic Syndrome-Specific Comorbidity Index","C185372","A disease-specific comorbidity index developed for predicting the effect of comorbidities on outcomes in myelodysplastic syndromes (MDS). It combines the effect of five comorbidity factors and identifies three groups of MDS patients with different probabilities of non-leukemic death and survival.","Myelodysplastic Syndrome-Specific Comorbidity Index | MDS-CI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773953","Clinical Frailty Scale","C185373","A judgement-based tool to screen for frailty and to broadly stratify degrees of fitness and frailty in elderly people.","Clinical Frailty Scale | CFS | Frailty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773806","Adherence to Refills and Medications Scale","C185374","A 12-item measure used to determine a respondent's adherence to taking a prescribed medication. It has two subscales: an 8-item subscale assessing a respondent's ability to correctly administer a prescribed medication regimen, and a 4-item subscale assessing a respondent's ability to refill prescriptions on schedule.","Adherence to Refills and Medications Scale | ARMS | Adherence to Refills and Medications Scale (ARMS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475447","Primary Tumor Site","C179451","The anatomic location of a primary tumor.","Primary Tumor Site | Anatomic Site of Primary Tumor Origin | PRYSTUOG | Primary Site of Tumor Origin | Primary tumor site",,,,,,,,,,,,,,,"4161164","Anatomic location of primary malignant neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL977348","Surgical Complication","C164157","A disease or disorder that occurs during, soon after or as a result of a surgical procedure.","Surgical Complication | Surgical Complications",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897460","Study Subject Medical Imaging Report","C115511","Records pertaining to the findings from a study subject's medical imaging results.","Study Subject Medical Imaging Report | Study Subj Med Img Rpt Unsp | Study Subject Medical Imaging Report Unspecified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773819","Neuropathic Pain Quality Scale","C185388","A five-item measure  to identify patients more likely to have neuropathic pain and to distinguish their levels of neuropathic pain.","Neuropathic Pain Quality Scale | Neuropathic Pain Quality | Neuropathic Pain Quality 5a | Neuropathic Pain Quality 5a Measure | PQ-Neuro | PROMIS Neuropathic Pain Quality 5a | PROMIS PQ-Neuro",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773799","Pain Felt Like Pins and Needles","C185383","A question about whether an individual's pain felt like pins and needles.","Pain Felt Like Pins and Needles | Did your pain feel like pins and needles",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773800","Pain Felt Tingly","C185384","A question about whether an individual's pain felt tingly.","Pain Felt Tingly | Did your pain feel tingly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773797","Pain Felt Stinging","C185385","A question about whether an individual's pain felt stinging.","Pain Felt Stinging | Did your pain feel stinging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773798","Pain Felt Electrical","C185386","A question about whether an individual's pain felt electrical.","Pain Felt Electrical | Did your pain feel electrical",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773818","Pain Felt Numb","C185387","A question about whether an individual's pain felt numb.","Pain Felt Numb | Did your pain feel numb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4014977","Hypersplenism","C34714","Overactive functioning of the spleen, resulting in excessive destruction of blood cells.","Hypersplenism | ",,,,,,,,,,,,,,,"192298","Hypersplenism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002453","Amenorrhea","C61443","The absence of menses in a woman who has achieved reproductive age.","Amenorrhea | ",,,,,,,,,,,,,,,"443800","Amenorrhea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1405393","Autologous Anti-CD123 CAR-T Cells","C171167","A preparation of autologous T-cells engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD123 (interleukin-3 receptor alpha chain or IL3RA), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-CD123 CAR-T cells target and bind to CD123 expressed on the surface of tumor cells. This induces selective toxicity in CD123-expressing tumor cells. CD123, the alpha subunit of the IL-3 receptor, regulates the proliferation, survival and differentiation of hematopoietic cells. It is overexpressed on a variety of cancers, including myeloid leukemia, and the increased expression of CD123 on leukemic stem cells (LSCs) is associated with poor prognosis.","Autologous Anti-CD123 CAR-T Cells | Autologous Anti-CD123 CAR T Cells | Autologous Anti-CD123 Chimeric Antigen Receptor T Cells | CD123 CAR-T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773813","Unbuffered Formalin Fixation","C185402","The use of unbuffered formalin for preservation of tissue samples.","Unbuffered Formalin Fixation | Formalin fixed - unbuffered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773831","Buffered Formalin Fixation","C185403","The use of buffered formalin for preservation of tissue samples.","Buffered Formalin Fixation | Formalin fixed - buffered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773832","Fresh Dissociated Tissue Preparation","C185404","A tissue preparation process that takes fresh tissue and dissociates it into single cell suspensions.","Fresh Dissociated Tissue Preparation | Fresh dissociated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773829","Fresh Dissociated Tissue Preparation, Single Cell Sorted","C185405","A tissue preparation process that separates fresh dissociated tissue cells into cell populations by single cell sorting.","Fresh Dissociated Tissue Preparation, Single Cell Sorted | Fresh dissociated and single cell sorted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773830","Fresh Dissociated Tissue Preparation, Single Cell Sorted into Plates","C185406","A tissue preparation process that takes dissociated, sorted cells and distributes them into cell propagation plates.","Fresh Dissociated Tissue Preparation, Single Cell Sorted into Plates | Fresh dissociated and single cell sorted into plates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773833","Dulbecco's Modified Eagle Medium","C185409","A serum-free medium for supporting the growth of adherent mammalian cells. It contains a combination of 6 salts, 13 essential amino acids, and 8 vitamins and is intended for use in a humidified incubator where the air contains 5% carbon dioxide.","Dulbecco's Modified Eagle Medium | DMEM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773958","Cell Culture Serum","C185408","The serum blood fraction obtained from an animal that can be used as a component of growth medium or as a negative control or blocking agent to reduce background in procedures that assay molecular interactions.","Cell Culture Serum | Serum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700320","Sectioning","C124327","To cut a an entity into slices.","Sectioning | SECTIONING | Section",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773962","Sexually Active","C185432","A response indicating that an individual is or was sexually active.","Sexually Active | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648250","Dulbecco's Phosphate-Buffered Saline","C178908","A buffered (pH range 7.2-7.6) saline solution used in cell culture applications.","Dulbecco's Phosphate-Buffered Saline | DPBS | PBS | Phosphate-Buffered Saline",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648508","Roswell Park Memorial Institute 1640 Medium","C178973","A sodium bicarbonate-buffered medium formulated for use in a 5-10% carbon dioxide atmosphere. It is used in the cell culture of human lymphoid cells.","Roswell Park Memorial Institute 1640 Medium | RPMI | RPMI Medium | RPMI-1640 | RPMI-1640, no L-Glutamine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230285","Rectovaginal Septum","C185451","The dense fibroconnective tissue layer separating the vagina and rectum. It contains the inferior hypogastric plexus and serves to stabilize the pelvic wall. The rectovesical septum (Denonvilliers fascia) is the male homolog.","Rectovaginal Septum | Fascia of Otto | RVS | Recto-vaginal Septum | Rectovaginal Fascia",,,,,,,,,,,,,,,"4284830","Structure of rectovaginal septum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0281857","Genital Tract Fistula","C185462","An abnormal communication between the genital tract and another organ or anatomic structure.","Genital Tract Fistula | Genital Fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773749","HBG2 NM_000184.2:c.-211C>T","C185439","A nucleotide substitution at position -211 in the upstream promoter region of the HBG2 gene where cytosine has been mutated to thymine.","HBG2 NM_000184.2:c.-211C>T | Ggamma -158C>T | HBG2 (XmnI) - rs7482144 C>T | HBG2 Promoter SNP (g. -158C>T) | HBG2 XmnI C>T Polymorphism | HBG2 c.-211C>T | HBG2, C-T, -158 | Hemoglobin Subunit Gamma 2 c.-211C>T | Hemoglobin, Gamma G c.-211C>T | NG_000007.3:g.42677C>T | NG_042299.1:g.1053G>A | NM_000184.2:c.-211C>T | Xmn1-HBG2 SNP C>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773747","BCL11A NC_000002.12:g.60490908=","C185441","A nucleotide substitution on chromosome 2 at genomic position 60490908 located within intron 2 of the BCL11A gene where thymine is present instead of guanine.","BCL11A NC_000002.12:g.60490908= | B Cell CLL/Lymphoma 11A c.386-22075= | BAF Chromatin Remodeling Complex Subunit BCL11A c.386-22075= | BCL11A - rs1427407 G>T | BCL11A NM_022893.4:c.386-22075= | BCL11A c.386-22075= | BCL11A c.386-22075G>T | CTIP1 c.386-22075= | EVI9 c.386-22075= | NG_011968.1:g.67591= | NM_022893.4:c.386-22075= | SMARCM1 c.386-22075= | ZNF856 c.386-22075=",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773748","BCL11A NC_000002.12:g.60486100A>G","C185442","A nucleotide substitution on chromosome 2 at genomic position 60486100 located within intron 2 of the BCL11A gene where adenine has been mutated to guanine.","BCL11A NC_000002.12:g.60486100A>G | B Cell CLL/Lymphoma 11A c.386-17267T>C | BAF Chromatin Remodeling Complex Subunit BCL11A c.386-17267T>C | BCL11A - rs10189857 A>G | BCL11A NM_022893.4:c.386-17267T>C | BCL11A c.386-22075G>T | CTIP1 c.386-17267T>C | EVI9 c.386-17267T>C | NC_000002.12:g.60486100A>G | NM_022893.4:c.386-17267T>C | SMARCM1 c.386-17267T>C | ZNF856 c.386-17267T>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773739","NC_000006.12:g.135097497_135097499del","C185446","An intergenic deletion of a three nucleotide sequence, cytosine-thymine-adenine, in the region between the HBS1L and MYB genes on chromosome 6 at genomic positions 135097497 through 135097499.","NC_000006.12:g.135097497_135097499del | HBS1L-MYB Intergenic Region NC_000006.12:g.135097497_135097499del | HMIP - rs66650371 wt>3bp deletion | HMIP NC_000006.12:g.135097497_135097499del | NC_000006.12:g.135097497_135097499delCTA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773759","KLF1 NM_006563.5:c.892G>C","C185455","A nucleotide substitution at position 892 of the coding sequence of the KLF1 gene where guanine has been mutated to cytosine.","KLF1 NM_006563.5:c.892G>C | EKLF c.892G>C | Erythroid Kruppel-Like Factor c.892G>C | KLF1 - c.892 G>C | KLF1 c.892G>C | Kruppel Like Factor 1 c.892G>C | NM_006563.5:c.892G>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773764","KLF1 NM_006563.5:c.115A>C","C185456","A nucleotide substitution at position 115 of the coding sequence of the KLF1 gene where adenine has been mutated to cytosine.","KLF1 NM_006563.5:c.115A>C | EKLF c.115A>C | Erythroid Kruppel-Like Factor c.115A>C | KLF1 - c.115 A>C | KLF1 c.115A>C | Kruppel Like Factor 1 c.115A>C | NM_006563.5:c.115A>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773752","Heterozygous HBA 3.7 kb Deletion","C185460","A cytogenetic abnormality where one copy of chromosome 16 has a 3.7 kb chromosomal deletion in the vicinity of 16p13.3, which is the region containing the 2 genes that encode hemoglobin subunit alpha (HBA; alpha-globin), HBA1 and HBA2. This chromosomal deletion either deletes one of these two genes (usually HBA1) or results in a single copy of a functional, in-frame fusion of the two HBA genes.","Heterozygous HBA 3.7 kb Deletion | -a3.7/aa | HBA1 - HBA deletion (- a3.7 / aa) | Heterozygous (-a3.7/aa) | Heterozygous Alpha Globin 3.7 kb Deletion | Heterozygous HBA 3.7 kb Rightward Deletion | Heterozygous Hemoglobin Subunit Alpha 3.7 kb Deletion | Monozygotic Alpha Globin Gene Deletion | Monozygotic HBA Gene Deletion | Monozygotic Hemoglobin Subunit Alpha Gene Deletion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773753","Heterozygous Anti-3.7 HBA Rearrangement","C185461","A complex cytogenetic abnormality where one copy of chromosome 16 has undergone chromosomal rearrangement in the vicinity of 16p13.3, which is the region containing the 2 genes that encode hemoglobin subunit alpha (HBA; alpha-globin), HBA1 and HBA2. This rearrangement results in amplification of a 3.7 kb fragment containing of one of the HBA genes (usually HBA2) and may lead to simultaneous deletion of the other HBA gene (usually HBA1).","Heterozygous Anti-3.7 HBA Rearrangement | Alpha Alpha Alpha Anti-3,7/Alpha Alpha | Alpha-Globin Gene Duplication | HBA Triplication | HBA1 - HBA triplication (aaaanti-3.7 / aa) | Heterozygous Alpha Alpha Alpha Anti-3,7 | Monozygotic Alpha Globin Gene Amplification | Monozygotic HBA Gene Amplification | Monozygotic Hemoglobin Subunit Alpha Gene Amplification | aaaanti-3.7 / aa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969863","Histology Type Code ICD-O-3","C160896","Codes for the histologic type of the tumor being reported using ICD-O-3.","Histology Type Code ICD-O-3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642784","Histology ICD-O Morphology Code","C176985","Codes for the histologic type of the tumor being reported using ICD-O.","Histology ICD-O Morphology Code | HIST_ICD_O_MORPH | Morphology | morphology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773698","Pediatric Quality of Life Stem Cell Transplant Module","C185505","A questionnaire designed to measure a pediatric stem cell transplant recipient's health-related quality of life.","Pediatric Quality of Life Stem Cell Transplant Module | PedsQL Stem Cell Transplant Module | PedsQL-SCT | PedsQL-Stem Cell Transplant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773695","How Much is Pain and Hurt a Problem","C185506","A question about how much of a problem an individual has or had with pain and hurt.","How Much is Pain and Hurt a Problem | Problems with Pain and Hurt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773696","How Much is Fatigue and Sleep a Problem","C185507","A question about how much of a problem an individual has or had with fatigue and sleep.","How Much is Fatigue and Sleep a Problem | Problems with Fatigue and Sleep",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773686","How Much is Nausea a Problem","C185508","A question about how much of a problem an individual has or had with nausea.","How Much is Nausea a Problem | Problems with Nausea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773687","How Much is Worry a Problem","C185509","A question about how much of a problem an individual has or had with worry.","How Much is Worry a Problem | Problems with Worry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773684","How Much is Nutrition a Problem","C185510","A question about how much of a problem an individual has or had with nutrition.","How Much is Nutrition a Problem | Problems with Nutrition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773685","How Much is Thinking a Problem","C185511","A question about how much of a problem an individual has or had with thinking.","How Much is Thinking a Problem | Problems with Thinking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773688","How Much is Communication a Problem","C185514","A question about how much of a problem an individual has or had with communication.","How Much is Communication a Problem | Problems with Communication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773689","How Much are Other Complaints a Problem","C185515","A question about how much of a problem an individual has or had with other complaints.","How Much are Other Complaints a Problem | Problem with Other Complaints",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773955","Hemoglobin E","C185498","A tetrameric complex of 2 molecules of hemoglobin subunit alpha (encoded by either the HBA1 or HBA2 gene) and 2 molecules of a hemoglobin subunit beta variant where the glutamic acid residue at position 27 has been replaced by lysine.","Hemoglobin E | Hb E | Hgb E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773691","Hemoglobin Alpha with Heterozygous Triplication","C185502","A genetic finding indicating that one copy of chromosome 16 has two functional copies of the hemoglobin alpha (HBA) genes and the other copy of chromosome 16 has three functional copies due to chromosomal rearrangement. This genotype is associated with the alpha thalassemia silent carrier trait.","Hemoglobin Alpha with Heterozygous Triplication | (aa/aaa) | HBA with Heterozygous Triplication Genotype | aa/aaa | alpha-globin genotype with triplication (aa / aaa)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773692","Hemoglobin Alpha Normal Genotype","C185503","A genetic finding indicating that both copies of chromosome 16 each has two functional copies of the hemoglobin alpha (HBA) genes, which includes 2 maternal alpha genes and 2 paternal alpha genes. This genotype is characterized by normal alpha globin production.","Hemoglobin Alpha Normal Genotype | (aa/aa) | HBA Normal Genotype | aa/aa | alpha-globin genotype ( aa / aa )",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773697","Hemoglobin Alpha One Copy Deleted Genotype","C185504","A genetic finding indicating that one copy of chromosome 16 has two functional copies of the hemoglobin alpha (HBA) genes and the other copy of has only one functional HBA gene. This genotype is associated with the alpha thalassemia silent trait.","Hemoglobin Alpha One Copy Deleted Genotype | (-a/aa) | (a-/aa) | (aa/-a) | (aa/a-) | -a/aa | HBA One Copy Deleted Genotype | a-/aa | aa/-a | aa/a- | alpha-globin genotype (aa / a -)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773954","Hemoglobin Alpha cis-Deletion Genotype","C185512","A genetic finding indicating that one copy of chromosome 16 has two functional copies of the hemoglobin alpha (HBA) genes and the other copy of has no functional HBA genes. This genotype is associated with the alpha thalassemia trait.","Hemoglobin Alpha cis-Deletion Genotype | (--/aa) | (aa/--) | --/aa | HBA cis-Deletion Genotype | aa/-- | alpha-globin genotype ( - - / aa)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773690","Hemoglobin Alpha trans-Deletion Genotype","C185513","A genetic finding indicating that both copies of chromosome 16 each have only one functional hemoglobin alpha (HBA) gene. This genotype is associated with the alpha thalassemia trait.","Hemoglobin Alpha trans-Deletion Genotype | (-a/-a) | (a-/a-) | -a/-a | HBA trans-Deletion Genotype | a-/a- | alpha-globin genotype ( a - / a - )",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1779354","Hemoglobin Alpha Three Copies Deleted Genotype","C185517","A genetic finding indicating that one copy of chromosome 16 has only one functional copy of a hemoglobin alpha (HBA) gene and the other copy of has no functional HBA genes. This genotype is associated with hemoglobin H disease.","Hemoglobin Alpha Three Copies Deleted Genotype | (--/-a) | (--/a-) | (-a;--) | (a-/--) | --/-a | --/a- | -a/-- | HBA Three Copies Deleted Genotype | a-/-- | alpha-globin genotype ( - - / a - )",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773711","Hemoglobin Alpha cis-Deletion with Constant Spring Genotype","C185520","A genetic finding indicating that one copy of chromosome 16 has one functional copy of a hemoglobin alpha (HBA) gene and one copy that encodes an HBA stop loss mutation called hemoglobin Constant Spring (CS), while the other copy of chromosome 16 has no functional HBA genes. This genotype is associated with a severe form of hemoglobin H disease.","Hemoglobin Alpha cis-Deletion with Constant Spring Genotype | (--/aCSa) | (aCSa/--) | --/aCSa | HBA cis-Deletion with CS Genotype | HBA cis-Deletion with Constant Spring Genotype | aCSa/-- | alpha-globin genotype ( - - / aCSa)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773956","Hemoglobin Alpha Homozygous Null Genotype","C185522","A genetic finding indicating that neither copy of chromosome 16 has any functional copies of the hemoglobin alpha (HBA) genes. This genotype is associated with hemoglobin Barts.","Hemoglobin Alpha Homozygous Null Genotype | (--/--) | --/-- | HBA Homozygous Null Genotype | HBA Null Genotype | Hemoglobin Alpha Null Genotype | alpha-globin genotype (- - / - - )",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773701","Hemoglobin Beta Normal Genotype","C185524","A genetic finding indicating that both copies of chromosome 16 each have one functional copy of the hemoglobin beta (HBB) gene. This genotype is characterized by normal beta globin production.","Hemoglobin Beta Normal Genotype | (B/B) | B/B | HBB Normal Genotype | beta-globin genotype (B/B)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773702","Hemoglobin Beta Homozygous Insufficient Genotype","C185525","A genetic finding indicating that both copies of chromosome 16 each have a copy of the hemoglobin beta gene (HBB) with mutations that lead to hemoglobin subunit beta insufficiency (B+). This genotype is associated with beta thalassemia intermedia.","Hemoglobin Beta Homozygous Insufficient Genotype | (B+/B+) | B+/B+ | HBB Homozygous Insufficient Genotype | HBB Insufficient Genotype | beta-globin genotype (B+/B+)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773706","Hemoglobin Beta Heterozygous Insufficiency Plus Null Genotype","C185529","A genetic finding indicating that one copy of chromosome 16 has a hemoglobin beta gene (HBB) with mutations that lead to hemoglobin subunit beta insufficiency (B+) and the other copy has HBB loss of function or gene deletion mutations (B0). This genotype is associated with beta thalassemia intermedia.","Hemoglobin Beta Heterozygous Insufficiency Plus Null Genotype | (B+/B0) | (B0/B+) | B+/B0 | B0/B+ | HBB Heterozygous Null with Insufficiency | beta-globin genotype (B+/B0)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773704","Hemoglobin Beta Heterozygous Hemoglobin E Plus Insufficiency Genotype","C185531","A genetic finding indicating that one copy of chromosome 16 has a hemoglobin beta gene (HBB) with mutations that lead to hemoglobin subunit beta insufficiency (B+) and the other copy has an HBB mutation that produces a hemoglobin subunit beta variant, the hemoglobin beta E variant, where the glutamic acid residue at position 27 has been replaced by lysine (BE). This genotype is associated with beta thalassemia intermedia.","Hemoglobin Beta Heterozygous Hemoglobin E Plus Insufficiency Genotype | (B+/BE) | (BE/B+) | B+/BE | BE/B+ | HBB Heterozygous Hb E with Insufficiency Genotype | HBB Heterozygous Hemoglobin E with Insufficiency Genotype | beta-globin genotype (BE/B+)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773719","Hemoglobin Beta Heterozygous Hemoglobin E Plus Null Genotype","C185532","A genetic finding indicating that one copy of chromosome 16 has a hemoglobin beta gene (HBB) with a mutation that produces a hemoglobin subunit beta variant, the hemoglobin beta E variant, where the glutamic acid residue at position 27 has been replaced by lysine (BE) and the other copy has HBB loss of function or gene deletion mutations (B0). This genotype is associated with beta thalassemia intermedia.","Hemoglobin Beta Heterozygous Hemoglobin E Plus Null Genotype | (B0/BE) | (BE/B0) | B0/BE | BE/B0 | HBB Heterozygous Hb E with Null Genotype | HBB Heterozygous Hemoglobin E with Null Genotype | beta-globin genotype (BE/B0)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773720","Hemoglobin Beta Homozygous Null Genotype","C185533","A genetic finding indicating that both copies of chromosome 16 each have a copy of the hemoglobin beta gene (HBB) with loss of function or gene deletion mutations (B0). This genotype is associated with beta thalassemia major.","Hemoglobin Beta Homozygous Null Genotype | (B0/B0) | B0/B0 | HBB Homozygous Null Genotype | HBB Null Genotype | beta-globin genotype (B0/B0)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773729","Thalassemic Osteopathy","C185434","Bone disorders that present in thalassemia patients.","Thalassemic Osteopathy | Thalassemia Bone Disease | Thalassemic Bone Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773934","Hemoglobin Beta Heterozygous Insufficiency Genotype","C185581","A genetic finding indicating that one copy of chromosome 16 has a functional copy (B) of the hemoglobin beta gene (HBB) and the other copy has HBB mutations that lead to hemoglobin subunit beta insufficiency (B+). This genotype is associated with beta thalassemia minor.","Hemoglobin Beta Heterozygous Insufficiency Genotype | (B+/B) | (B/B+) | B+/B | B/B+ | HBB Heterozygous Insufficiency Genotype | beta-globin genotype (B/B+)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773933","Hemoglobin Beta Heterozygous Null Genotype","C185582","A genetic finding indicating that one copy of chromosome 16 has a functional copy (B) of the hemoglobin beta gene (HBB) and the other copy has HBB loss of function or gene deletion mutations (B0). This genotype is associated with beta thalassemia minor.","Hemoglobin Beta Heterozygous Null Genotype | (B/B0) | (B0/B) | B/B0 | B0/B | HBB Heterozygous Null Genotype | beta-globin genotype (B/B0)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552163","CXCR1/2 Inhibitor SX-682","C150389","An orally bioavailable, selective and reversible antagonist of C-X-C motif chemokine receptors 1 (CXCR1) and 2 (CXCR2), with potential anti-inflammatory and antineoplastic activities. Upon administration CXCR1/2 inhibitor SX-682 selectively and allosterically binds to CXCR 1 and 2 and inhibits their activation by tumor-secreted chemokines. This inhibits CXCR1/2-mediated signaling, reduces both recruitment and migration of immunosuppressive myeloid-derived suppressor cells (MDSCs) and neutrophils in the tumor microenvironment (TME), inhibits inflammatory processes and abrogates the immunosuppressive-induced nature of the TME. This allows effector cells, such as natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs), to kill and eliminate cancer cells. This inhibits tumor cell migration, metastasis, angiogenesis and tumor cell proliferation. CXCR1 and 2, G protein-coupled receptor proteins located on myeloid cells and certain tumor cells, play key roles in the immunosuppressive nature of the TME, tumor metastasis, therapy-resistance and myeloid cell suppression. They play a key role in inflammation and their expression is elevated in several inflammatory-driven diseases.","CXCR1/2 Inhibitor SX-682 | (2-(((5-((4-Fluorophenyl)carbamoyl)pyrimidin-2-yl)thio)methyl)-4-(trifluoromethoxy)phenyl)boronic Acid | SX 682 | SX-682 | SX682",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773872","Curative Therapy","C185614","A therapy designed to cure a condition.","Curative Therapy | Curative | Curative Treatment",,,,,,,,,,,,,,,"4162591","Curative - procedure intent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL520659","Fourth-Line Therapy","C133522","Treatment that is given when the first three treatments don't work, or stop working.","Fourth-Line Therapy | Fourth Line Treatment | Fourth line of therapy | Fourth-Line Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773949","Straining","C185651","The act of making a very hard effort, possibly at one's limit.","Straining | Strain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520656","Fifth-Line Therapy","C133524","Treatment that is given when the first four treatments don't work, or stop working.","Fifth-Line Therapy | Fifth Line Treatment | Fifth line of therapy | Fifth-Line Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019164","Hepatitis B Virus Antibody","C62795","An antibody produced by B lymphocytes in response to hepatitis B hepadnaviral infection.","Hepatitis B Virus Antibody | ",,,,,,,,,,,,,,,"4046726","Antibody to hepatitis B virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL970781","Advanced Soft Tissue Sarcoma","C162194","A sarcoma of soft tissue that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Soft Tissue Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3257980","Other Symptom","C178962","A symptom that is not among those previously noted.","Other Symptom | Other_Symptom",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524938","Computed Tomography of the Pelvis with Contrast","C137894","Computed tomography of the pelvis with the use of a contrast agent to enhance the image.","Computed Tomography of the Pelvis with Contrast | CT Scan of the Pelvis with Contrast | Pelvic CT with Contrast | Pelvic Computed Tomography with Contrast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202840","Computed Tomography of the Abdomen with Contrast","C137878","Computed tomography of the abdomen with the use of a contrast agent to enhance the image.","Computed Tomography of the Abdomen with Contrast | Abdominal CT with Contrast | CT of the Abdomen with Contrast",,,,,,,,,,,,,,,"4139745","CT of abdomen with contrast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202824","Computed Tomography of the Chest with Contrast","C137883","Computed tomography of the chest with the use of a contrast agent to enhance the image.","Computed Tomography of the Chest with Contrast | Chest CT with Contrast",,,,,,,,,,,,,,,"4327032","CT of thorax with contrast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641908","Film Portal Imaging","C104993","The acquisition of images of an anatomic area that is being irradiated using radiotherapy beams and films as imaging media.","Film Portal Imaging | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011321","Optical Densitometry","C86063","Measuring the optical density of a substance by shining light on it and measuring its transmission.","Optical Densitometry | Densitometry | Densitometry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2316245","Computed Tomography of the Neck with Contrast","C137892","Computed tomography of the neck with the use of a contrast agent to enhance the image.","Computed Tomography of the Neck with Contrast | CT Scan of the Neck with Contrast | Neck CT with Contrast | Neck Computed Tomography with Contrast",,,,,,,,,,,,,,,"4196152","CT of neck with contrast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1406746","Molnupiravir","C172633","An orally bioavailable prodrug of EIDD-1931, the synthetic ribonucleoside derivative N4-hydroxycytidine and ribonucleoside analog, with potential antiviral activity against a variety of RNA viruses. Upon oral administration, molnupiravir, being a prodrug, is metabolized into its active form EIDD-1931 and converted into its triphosphate (TP) form. The TP form of EIDD-1931 is incorporated into RNA and inhibits the action of viral RNA-dependent RNA polymerase. This results in the termination of RNA transcription and decreases viral RNA production, and viral RNA replication.","Molnupiravir | EIDD 2801 | EIDD-2801 | EIDD2801 | Lagevrio | MK 4482 | MK-4482 | MK4482 | MOLNUPIRAVIR | N4-Hydroxycytidine, 5'-Isopropyl Ester | SARS-CoV-2 antiviral agents: molnupiravir | Uridine, 4-Oxime, 5'-(2-Methylpropanoate)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1406090","JAK Inhibitor","C172200","Any agent that targets, binds to and inhibits the activity of one or more of the Janus kinase family of enzymes.","JAK Inhibitor | JAK inhibitors | Janus Kinase Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0264490","Acute Respiratory Failure","C27043","Life-threatening respiratory failure that develops rapidly. Causes include injury, sepsis, drug overdose, and pancreatitis. It manifests with dyspnea and cyanosis and may lead to cardiovascular shock.","Acute Respiratory Failure | ",,,,,,,,,,,,,,,"319049","Acute respiratory failure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1779380","Norepinephrine Reuptake Inhibitor","C185721","Any agent that prevents the reuptake of (nor)epinephrine from the synapse into presynaptic neurons by the norepinephrine (NE) transporter (NET), thereby increasing the concentrations of (nor)epinephrine in the synaptic cleft and increasing adrenergic neurotransmission.","Norepinephrine Reuptake Inhibitor | ARI | Adrenergic Reuptake Inhibitor | NARI | NE Reuptake Inhibitor | NE Transporter Inhibitor | NERI | NET Inhibitor | NRI | Noradrenaline Reuptake Inhibitor | Norepinephrine Transporter Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517964","Loss of Chromosome 17","C36631","A cytogenetic abnormality that refers to loss of all or part of chromosome 17.","Loss of Chromosome 17 | del(17)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936945","Somatic Mutation Analysis","C157371","A procedure used to detect and identify mutations in the genome of a somatic cell sample.","Somatic Mutation Analysis | Somatic Mutation Testing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272878","Inhalation Vapor, Capsule Dosage Form","C149582","Solid preparation consisting of a capsule formulation intended for generation of vapor to be inhaled to obtain a local effect. The vapor is usually generated by adding the whole capsule or the capsule contents to hot water.","Inhalation Vapor, Capsule Dosage Form | Capsule for Inhalation | INHALATION VAPOR, CAPSULE | Inhalation vapour, capsule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1779368","ITMIG MRECIST Complete Response","C185854","Disappearance of all target lesions.","ITMIG MRECIST Complete Response | CR | Complete Response | International Thymic Malignancy Interest Group Modified Response Evaluation Criteria in Solid Tumors Complete Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1779365","ITMIG MRECIST Partial Response","C185855","Greater than or equal to 30% decrease in the sum of the diameters of up to five target lesions as compared to baseline sum of diameters.","ITMIG MRECIST Partial Response | International Thymic Malignancy Interest Group Modified Response Evaluation Criteria in Solid Tumors Partial Response | PR | Partial Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1779367","ITMIG MRECIST Progressive Disease","C185856","Greater than or equal to 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters in the study.","ITMIG MRECIST Progressive Disease | International Thymic Malignancy Interest Group Modified Response Evaluation Criteria in Solid Tumors Progressive Disease | PD | Progressive Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1779377","ITMIG MRECIST Stable Disease","C185857","Neither sufficient shrinkage to qualify for partial response nor sufficient growth to qualify for progressive disease.","ITMIG MRECIST Stable Disease | International Thymic Malignancy Interest Group Modified Response Evaluation Criteria in Solid Tumors Stable Disease | SD | Stable Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773002","CXCL8 Positive","C184813","An indication that expression of CXCL8 has been detected in a sample.","CXCL8 Positive | C-X-C Motif Chemokine 8 Positive | Chemokine (C-X-C Motif) Ligand 8 Positive | GCP-1 Positive | Granulocyte Chemotactic Protein 1 Positive | IL-8 Positive | IL8 Positive | Interleukin 8 Positive | Interleukin-8 Positive | MDNCF Positive | MONAP Positive | Monocyte-Derived Neutrophil Chemotactic Factor Positive | Monocyte-Derived Neutrophil-Activating Peptide Positive | NAP-1 Positive | Neutrophil-Activating Protein 1 Positive | SCYB8 Positive | T-Cell Chemotactic Factor Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333715","Robertsonian Translocation","C28447","A chromosomal translocation where the participating chromosomes each break at the centromere and the long arms fuse to form a single, large chromosome.","Robertsonian Translocation | Centric Fusion",,,,,,,,,,,,,,,"4216975","Robertsonian translocation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4082333","Proto-Oncogene c-Fos","C17438","Proto-oncogene c-Fos (380 aa, ~41 kDa) is encoded by the human FOS gene. This protein is involved in transcriptional regulation, DNA binding and signal transduction.","Proto-Oncogene c-Fos | Cellular Oncogene C-Fos | Cellular Oncogene Fos | FBJ Murine Osteosarcoma Viral Oncogene Homolog | FOS | FOS Protein | G0/G1 Switch Regulatory Protein 7 | c-fos Protein | p55",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001223","Acrylonitrile","C28130","A colorless, volatile liquid with a pungent, onion-like odor. Acrylonitrile is widely used in industry to produce rubber, resins, plastics, elastomers and synthetic fibers and to manufacture carbon fibers used in aircraft, defense and aerospace industries. Exposure to acrylonitrile irritates the mucous membranes and causes a headache, nausea, dizziness, impaired judgment, difficulty breathing, limb weakness, cyanosis, convulsions and collapse. Acrylonitrile is reasonably anticipated to be a human carcinogen and may be associated with an increased risk of developing lung and prostate cancer. (NCI05)","Acrylonitrile | 2-Propenenitrile | ACRYLONITRILE | Cyanoethylene | Vinyl Cyanide | Vinylcyanide | acrylonitrile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773384","BRCA Driver Mutation Negative","C185292","A genetic finding indicating that disease-causing (driver or deleterious) mutations in BRCA family genes were not detected in a sample.","BRCA Driver Mutation Negative | BRCA Driver Gene Mutation Negative | BRCA Family Driver Gene Mutation Negative | BRCA Family Driver Mutation Negative | BRCA Gene Driver Mutation Negative | BRCA Gene Family Driver Mutation Negative | Deleterious BRCA Family Gene Mutation Negative | Deleterious BRCA Gene Family Mutation Negative | Deleterious BRCA Gene Mutation Negative | Deleterious BRCA Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378915","European Society for Blood and Marrow Transplantation","C168842","A non-profit organization established in 1974 to allow scientists and physicians involved in clinical bone marrow transplantations to share experiences and develop co-operative studies.","European Society for Blood and Marrow Transplantation | European Society for Blood and Marrow Transplantation (EBMT)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555295","Other Action Taken","C82509","A description that an activity, other than one prespecified or previously characterized, has occurred.","Other Action Taken | ACNOTH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514676","Myeloablative Conditioning","C131679","A conditioning regimen with high doses of chemotherapy or radiation to eliminate host hematopoietic stem cells prior to restitution via transplantation.","Myeloablative Conditioning | Myeloablation | Myeloablative | Myeloablative Cytoreduction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1378707","Second Relapse","C168813","The reemergence of a disorder as diagnosed by clinical and/or laboratory evidence following two documented periods of remission.","Second Relapse | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0851887","Adenovirus Infection","C115149","An infectious process caused by adenovirus. The virus may cause respiratory illness, conjunctivitis, gastroenteritis, and cystitis.","Adenovirus Infection | AdV Infection | Adenoviral Infection",,,,,,,,,,,,,,,"433413","Disease due to Adenovirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1773756","BRD4 Gene Amplification","C185464","A molecular genetic abnormality indicating the presence of multiple copies of the BRD4 gene.","BRD4 Gene Amplification | BRD4 Amplification | BRD4 Copy Number Gain | Bromodomain Containing 4 Gene Amplification | Bromodomain-Containing 4 Gene Amplification | CAP Gene Amplification | Chromosome-Associated Protein Gene Amplification | HUNK1 Gene Amplification | HUNKI Gene Amplification | MCAP Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773740","TCIRG1 Gene Mutation","C185443","A change in the nucleotide sequence of the TCIRG1 gene.","TCIRG1 Gene Mutation | ATP6N1C Gene Mutation | ATP6V0A3 Gene Mutation | Atp6i Gene Mutation | OC116 Gene Mutation | OPTB1 Gene Mutation | T Cell Immune Regulator 1, ATPase H+ Transporting V0 Subunit A3 Gene Mutation | TIRC7 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773815","PSA Decline Greater than 90 Percent","C185400","A finding indicating that the blood concentration of prostate specific antigen in a subject's sample has decreased by more than 90 percent compared to the value recorded for a previous sample from that subject..","PSA Decline Greater than 90 Percent | PSA Decline Greater than Ninety Percent | PSA Decline More than 90 Percent | PSA Decline More than Ninety Percent | PSA Decreased Greater than 90 Percent | PSA Decreased Greater than Ninety Percent | PSA Decreased More than 90 Percent | PSA Decreased More than Ninety Percent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773794","PD-L1 Expression Less than 1 Percent","C185382","An immunohistochemical finding indicating that less than 1 percent of the cells in a sample are expressing PD-L1.","PD-L1 Expression Less than 1 Percent | B7 Homolog 1 Expression Less than 1 Percent | B7-H1 Expression Less than 1 Percent | B7H1 Expression Less than 1 Percent | CD274 Antigen Expression Less than 1 Percent | CD274 Expression Less than 1 Percent | CD274 Less than 1 Percent | CD274 Molecule Expression Less than 1 Percent | PCDC1 Ligand 1 Expression Less than 1 Percent | PD-L1 Less than 1 Percent | PDCD1 Ligand 1 Expression Less than 1 Percent | PDCD1L1 Expression Less than 1 Percent | PDCD1LG1 Expression Less than 1 Percent | PDL1 Expression Less than 1 Percent | Programmed Cell Death 1 Ligand 1 Expression Less than 1 Percent | Programmed Death Ligand 1 Expression Less than 1 Percent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773836","del(11q22.3)","C185349","A cytogenetic abnormality that refers to the deletion of the chromosomal band 11q22.3.","del(11q22.3) | 11q22.3 Deletion | del(11)(q22.3)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL359645","Myosin-Binding Protein C, Cardiac-Type","C138125","Myosin-binding protein C, cardiac-type (1274 aa, ~141 kDa) is encoded by the human MYBPC3 gene. This protein is involved in cardiac muscle cell contraction.","Myosin-Binding Protein C, Cardiac-Type | C-Protein, Cardiac Muscle Isoform | Cardiac MyBP-C | Cardiac Myosin-Binding Protein C | MYBPC3 | Myosin-Binding Protein C, Cardiac | cMyC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773941","Blasts Greater than or Equal to 5000 per mL","C185611","A semi-quantitative microscopic finding indicating that immature mononuclear cells are found at greater than or equal to 5000 per milliliter in a sample.","Blasts Greater than or Equal to 5000 per mL | Blasts Greater than or Equal to 5000 per Cubic Centimeter | Blasts Greater than or Equal to 5000 per Milliliter | Blasts Greater than or Equal to 5000 per cm3 | Blasts Greater than or Equal to 5000/Cubic Centimeter | Blasts Greater than or Equal to 5000/Milliliter | Blasts Greater than or Equal to 5000/cm3 | Blasts Greater than or Equal to 5000/mL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773672","Bacillus Calmette-Guerin Unresponsive Disease","C185492","An indication that a neoplastic disease, usually non-muscle invasive bladder cancer (NMIBC), is unresponsive to bacillus Calmette-Guerin (BCG) induction therapy and that additional BCG therapy is unlikely to benefit the subject. Unresponsive subjects include those with recurrent disease within 12 months of the completion of adequate BCG therapy, recurrent high-grade disease within 6 months of the completion of adequate BCG therapy or high-grade disease at the first evaluation after a BCG induction course.","Bacillus Calmette-Guerin Unresponsive Disease | BCG-Unresponsive | BCG-Unresponsive Disease | Bacillus Calmette-Guerin Unresponsive | Bacillus Calmette-Guérin Unresponsive | Bacillus Calmette-Guérin Unresponsive Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969266","Cytomegalovirus Virus Reactivation","C160246","The switching of latent cytomegalovirus to a lytic infection.","Cytomegalovirus Virus Reactivation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778643","Frederick National Laboratory for Cancer Research Molecular Characterization Laboratory","C186298","The Molecular Characterization Laboratory at the Frederick National Laboratory for Cancer Research (FNLCR) is a clinical and research laboratory that performs genomic sequencing in support of clinical and pre-clinical studies sponsored by the National Cancer Institute's Division of Cancer Treatment and Diagnosis (DCTD).","Frederick National Laboratory for Cancer Research Molecular Characterization Laboratory | FNLCR Molecular Characterization Laboratory | MoCha Lab | Molecular Characterization Laboratory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778601","Assay Failure","C186286","An indication that an assay did not return a valid result.","Assay Failure | Assay Failed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778602","Data Evaluable QC Metrics Good","C186287","An indication that the data can be evaluated and that the quality control metrics were good.","Data Evaluable QC Metrics Good | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778603","Data Evaluable Despite QC Metrics","C186288","An indication that the data can be evaluated even though the quality control metrics were not good.","Data Evaluable Despite QC Metrics | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778607","Data Not Evaluable","C186292","An indication that the existing data cannot be evaluated.","Data Not Evaluable | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778604","Insufficient DNA Yield","C186289","An indication that a DNA isolation procedure yielded an insufficient amount of DNA to proceed.","Insufficient DNA Yield | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778605","Insufficient RNA Yield","C186290","An indication that an RNA isolation procedure yielded an insufficient amount of RNA to proceed.","Insufficient RNA Yield | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778606","Insufficient Protein Yield","C186291","An indication that a protein isolation procedure yielded an insufficient amount of protein to proceed.","Insufficient Protein Yield | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778608","Request New Sample","C186293","A request for a new sample.","Request New Sample | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778609","Assay Needs to be Rerun","C186294","An indication that an assay should be repeated.","Assay Needs to be Rerun | Rerun",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778610","Return to Biobank","C186295","An indication that a sample should be returned to its biobank.","Return to Biobank | Return Sample to Biobank",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778611","NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank","C186296","A biorepository responsible for collecting, processing and storing a variety of human specimens from patients with cancer who are participating in NCI-funded Experimental Therapeutics Clinical Trials Network (ETCTN) and other NCI-supported early and experimental clinical trials.","NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank | EET Biobank | Early Phase and Experimental Clinical Trials Biospecimen Bank",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778612","Genomics Laboratory","C186297","A molecular biology laboratory that focuses on the development of genetics and genomics technologies, together with associated laboratory automation systems, data analysis, and information management tools.","Genomics Laboratory | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778648","National Clinical Laboratory Network","C186303","A laboratory network capable of providing centralized, well-characterized assays. It features a centralized specimen biorepository and the support of centralized data reporting and offers validated assays following harmonized standardized operating procedures (SOPs) while implementing uniform assay workflow, instrumentation, and data analysis across network labs.","National Clinical Laboratory Network | NCLN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778644","Molecular Pathology Laboratory Network","C186299","A contract diagnostic laboratory providing molecular diagnostics, specialty anatomic pathology, flow cytometry, fluorescence in situ hybridization, and cytogenetic testing.","Molecular Pathology Laboratory Network | MPLN | Molecular Pathology Laboratory Network, Inc. | Molecular Pathology Network | Molecular Pathology Laboratory Network",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778645","Pharmacodynamics Assay Laboratory","C186300","A laboratory that specializes in developing biomarkers and monitoring the biological effects of drugs during drug development.","Pharmacodynamics Assay Laboratory | PD Assay Lab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778646","Pharmacodynamics Assay Development Laboratory","C186301","A laboratory that specializes in developing biomarkers for use during drug development.","Pharmacodynamics Assay Development Laboratory | PADIS Lab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778647","MD Anderson Tissue Qualification Laboratory","C186302","A facility at the MD Anderson Cancer Center that stores clinical tissue specimens for archiving and retrieval.","MD Anderson Tissue Qualification Laboratory | MD Anderson Cancer Center Tissue Qualification Laboratory | MD Anderson TQL | MDACC Tissue Qualification Laboratory | MDACC Tissue Qualification Laboratory (TQL)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517310","Frederick Cancer Research and Development Center","C18801","A government-owned, contractor operated cancer research facility located in Frederick, MD.  Operated under the direction of the Division of Cancer Biology.","Frederick Cancer Research and Development Center | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825214","Hospitalization Event","C80481","The description of an event that occurred in an individual during the hospitalization period.","Hospitalization Event | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448751","Pancreaticoduodenectomy","C51933","Surgical excision of all or part of the pancreas and duodenum.","Pancreaticoduodenectomy | Pancreatoduodenectomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544350","Grade 5 Cystitis Noninfective, CTCAE","C146270","Death","Grade 5 Cystitis Noninfective, CTCAE | Grade 5 Cystitis noninfective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543883","Grade 4 Cystitis Noninfective, CTCAE","C145810","Life-threatening consequences; urgent invasive intervention indicated","Grade 4 Cystitis Noninfective, CTCAE | Grade 4 Cystitis noninfective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543411","Grade 3 Cystitis Noninfective, CTCAE","C145215","Gross hematuria; transfusion, IV medications, or hospitalization indicated; elective invasive intervention indicated","Grade 3 Cystitis Noninfective, CTCAE | Grade 3 Cystitis noninfective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542834","Grade 2 Cystitis Noninfective, CTCAE","C144597","Moderate hematuria; moderate increase in frequency, urgency, dysuria, nocturia or incontinence; urinary catheter placement or bladder irrigation indicated; limiting instrumental ADL","Grade 2 Cystitis Noninfective, CTCAE | Grade 2 Cystitis noninfective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542322","Grade 1 Cystitis Noninfective, CTCAE","C144045","Microscopic hematuria; minimal increase in frequency, urgency, dysuria, or nocturia; new onset of incontinence","Grade 1 Cystitis Noninfective, CTCAE | Grade 1 Cystitis noninfective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2742797","Vedolizumab","C95798","A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the human lymphocyte Peyer's patch adhesion molecule 1 (LPAM-1; alpha4beta7; a4b7), with immunomodulating, anti-inflammatory, and potential antineoplastic activities. Upon administration, vedolizumab selectively binds to integrin a4b7 and prevents the binding of a4b7, expressed on the surface of a subset of T-lymphocytes, to its natural ligand, mucosal addressin cell adhesion molecule-1 (MAdCAM-1), which is mainly expressed on the surface of gut endothelial cells. This prevents a4b7-mediated signaling, adhesion of lymphocytes to the endothelium and the migration of T-lymphocytes across the endothelium into inflamed gastrointestinal (GI) tissue. By preventing this infiltration to the affected area, inflammation is reduced. The human lymphocyte a4b7 integrin, plays a key role in gastrointestinal (GI) inflammation; it is overexpressed in certain types of cancer cells. The alpha4beta7/MAdCAM-1 signaling pathway plays a critical role in the homing of T-lymphocytes to intestinal tissue.","Vedolizumab | Entyvio | Immunoglobulin G1, Anti-(Human Integrin LPAM-1 (Lymphocyte Peyer's Patch Adhesion Molecule 1)) (Human-Mus musculus Heavy Chain), Disulfide with Human-Mus musculus kappa-chain, Dimer | Immunoglobulin G1, anti-(human integrin LPAM-1 (lymphocyte Peyer's patch adhesion molecule 1)) (human-Mus musculus heavy chain), disulfide with human-Mus musculus kappa-chain, dimer | LDP 02 | LDP-02 | LDP02 | MLN0002 | MLN02 | VEDOLIZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1172734","Natalizumab","C77862","A humanized recombinant IgG4 monoclonal antibody directed against the alpha4 subunit of the integrins alpha4beta1and alpha4beta7 with immunomodulating, anti-inflammatory, and potential antineoplastic activities.  Natalizumab binds to the alpha4-subunit of alpha4beta1 and alpha4beta7 integrins expressed on the surface of all leukocytes except neutrophils, inhibiting the alpha4-mediated adhesion of leukocytes to counter-receptor(s) such as vascular cell adhesion molecule-1 (VCAM-1); natalizumab-mediated disruption of VCAM-1 binding by these integrins may prevent the transmigration of leukocytes across the endothelium into inflamed parenchymal tissue.  Integrins are cellular adhesion molecules (CAMs) that are upregulated in various types of cancer and some autoimmune diseases; alpha4beta1 integrin (VLA4) has been implicated in the survival of myeloma cells, possibly by mediating their adhesion to stromal cells.","Natalizumab | AN100226 | Antegren | Anti-VLA4 | Anti-alph4 Integrin Monoclonal Antibody AN100226 | NATALIZUMAB | Tysabri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778867","UVA1 Phototherapy","C186479","Phototherapy that uses UV light in the 340-400nm range.","UVA1 Phototherapy | UVA1 | UVA1 Light Therapy | Ultraviolet A1 Phototherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526607","Date of First Enrollment into Study","C139171","The calendar date on which the first subject was enrolled into a study or trial.","Date of First Enrollment into Study | Date of First Enrollment | Enrollment Start Date | Study Enrollment | date of first enrollment | study initiation date (date of first enrollment)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896836","JAK1 inhibitor INCB039110","C116855","An orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1) with potential antineoplastic and immunomodulating activities. Upon oral administration, itacitinib selectively inhibits JAK-1, thereby inhibiting the phosphorylation of signal transducer and activator of transcription (STAT) proteins and the production of proinflammatory factors induced by other cytokines, including interleukin-23 (IL-23) and interleukin-6 (IL-6). The JAK-STAT pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","Itacitinib | 3-Azetidineacetonitrile, 1-(1-((3-Fluoro-2-(trifluoromethyl)-4-pyridinyl)carbonyl)-4-piperidinyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)- | INCB 039110 | INCB-039110 | INCB039110 | ITACITINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1779355","Bradford Assay","C186548","A colorimetric reaction used to calculate the concentration of total protein in a sample or solution. It uses quantitative binding of Coomassie Brilliant Blue G-250 dye to amino acids followed by measurement of spectroscopic absorbance at 595 nm and comparison to reference samples.","Bradford Assay | Bradford | Bradford Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1648155","Biospecimen Collection Date","C178868","The date that a biospecimen was collected.","Biospecimen Collection Date | Date of Biospecimen Collection | Date_of_Biospecimen_Collection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL773300","Risankizumab","C152227","A humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the p19 subunit of human interleukin 23 (IL-23) cytokine, with anti-inflammatory activity. Upon administration, risankizumab targets and binds to the p19 subunit of human IL-23, inhibiting the interaction of IL-23 with the IL-23 receptor complex. This inhibits IL-23/IL-23 receptor-mediated signaling and inhibits the release of pro-inflammatory cytokines and chemokines. IL-23 plays an important role in the development, maintenance and activation of Th17 cells, which produce pro-inflammatory cytokines including IL-17A, IL-17F, and IL-22. It is upregulated in various inflammatory and autoimmune diseases.","Risankizumab | ABBV-066 | BI-655066 | RISANKIZUMAB | Risankizumab-rzaa | Skyrizi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778848","Abnormal Phenotype","C186587","The expression of traits associated with a disease or abnormality, or the loss of expression of traits associated with a normal or healthy phenotype.","Abnormal Phenotype | Aberrant Phenotype",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778851","Lidocaine Hydrochloride/Epinephrine","C186590","A combination agent composed of the hydrochloride salt form of lidocaine, an aminoethylamide and a prototypical member of the amide class of anesthetics, and the synthetic form of the naturally occurring sympathomimetic amine epinephrine, with local vasoconstricting and anesthetic activities. Upon local administration of lidocaine hydrochloride/epinephrine by injection, epinephrine binds to and stimulates vascular alpha-adrenergic receptors, thereby causing vasoconstriction. Lidocaine interacts with voltage-gated sodium (Na+) channels in the nerve cell membranes and blocks the transient increase in permeability of excitable membranes to Na+. This prevents the generation and conduction of nerve impulses and produces a reversible loss of sensation. By administering epinephrine, lidocaine's potential to disperse into the surrounding tissue is reduced, thereby increasing its local efficacy, and enhancing and prolonging the anesthetic effect.","Lidocaine Hydrochloride/Epinephrine | Lidocaine HCI and Epinephrine | Lidocaine/Epinephrine | Xylocaine-Epinephrine | Xylocaine/Epinephrine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642840","Cilgavimab","C177058","A neutralizing human monoclonal antibody isolated from convalescent patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and directed against the spike (S) protein, that can potentially be used for passive immunization against Coronavirus disease 2019 (COVID-19). Upon administration, cilgavimab specifically targets and binds to the SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.","Cilgavimab | AZD 1061 | AZD-1061 | AZD1061 | CILGAVIMAB | COV2-2130",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1642820","Tixagevimab","C177082","A neutralizing human monoclonal antibody isolated from convalescent patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and directed against the spike (S) protein, that can potentially be used for passive immunization against Coronavirus disease 2019 (COVID-19). Upon administration, tixagevimab specifically targets and binds to the SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.","Tixagevimab | AZD 8895 | AZD-8895 | AZD8895 | COV2-2196 | TIXAGEVIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773406","Homozygous CDKN2A Gene Deletion","C185171","A molecular abnormality referring to the loss of both copies of the CDKN2A gene.","Homozygous CDKN2A Gene Deletion | Biallelic CDKN2A Deletion | Biallelic CDKN2A Gene Deletion | CDKN2A Gene Null | Homozygous CDK4I Gene Deletion | Homozygous CDKN2A Deletion | Homozygous CDKN2A-p16 Gene Deletion | Homozygous Loss of CDKN2A Gene | Homozygous Loss of Cyclin Dependent Kinase Inhibitor 2A Gene | Homozygous p14ARF Gene Deletion | Homozygous p16 Gene Deletion | Homozygous p16-INK4A Gene Deletion | Homozygous p16INK4a Gene Deletion | Homozygous p19ARF Gene Deletion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1779151","Air Conduction Assessment","C186675","An audiometric test of the transmission of sound through the air in the ear canal to the inner ear.","Air Conduction Assessment | Air Conduction Hearing Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937488","Hepatitis C Treatment","C157874","Treatment to cure a hepatitis C infection. Antiviral therapy is prescribed based on the hepatitis C genotype, co-existing medical conditions and prior treatments.","Hepatitis C Treatment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008149","Chlamydial Infection","C34463","An infection that is caused by Chlamydia trachomatis.","Chlamydial Infection | Chlamydia",,,,,,,,,,,,,,,"438066","Chlamydial infection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2718050","Detection Limit","C105701","The smallest concentration of an analyte that can be determined with a stated precision or confidence.","Detection Limit | LLOD | LOD | Limit of Detection | Lower Limit of Detection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562899","Human Papillomavirus-70","C156055","A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-70 may be associated with a high risk for cervical cancer.","Human Papillomavirus-70 | 70 | HPV 70 | HPV-70 | HPV70 | HUMAN PAPILLOMAVIRUS TYPE 70 | Human Papilloma Virus 70 | Human Papilloma Virus-70 | Human Papillomavirus 70",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1412498","Disease Relapse/Progression","C174991","Either the return of the disease or the progression of the disease.","Disease Relapse/Progression | Relapse/Progression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778255","PSAP Gene Mutation","C185874","A change in the nucleotide sequence of the PSAP gene.","PSAP Gene Mutation | GLBA Gene Mutation | PSAPD Gene Mutation | Prosaposin Gene Mutation | SAP1 Gene Mutation | SAP2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778254","ARSA Gene Mutation","C185873","A change in the nucleotide sequence of the ARSA gene.","ARSA Gene Mutation | ASA Gene Mutation | Arylsulfatase A Gene Mutation | MLD Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778473","NRAS Exon 2 Mutation Negative","C185895","A genetic finding indicating that NRAS exon 2 gene mutations have not been detected in a sample.","NRAS Exon 2 Mutation Negative | N-RAS Exon 2 Mutation Negative | NRAS Exon 2 Gene Mutation Negative | NRAS Proto-Oncogene, GTPase Exon 2 Mutation Negative | Neuroblastoma RAS Viral Oncogene Homolog Exon 2 Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778502","KRAS Exon 4 Mutation Negative","C185894","A genetic finding indicating that KRAS exon 4 gene mutations have not been detected in a sample.","KRAS Exon 4 Mutation Negative | KRAS Exon 4 Gene Mutation Negative | KRAS Proto-Oncogene, GTPase Exon 4 Mutation Negative | KRAS-2 Exon 4 Mutation Negative | KRAS2 Exon 4 Mutation Negative | c-K-ras Exon 4 Mutation Negative | v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Exon 4 Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778501","KRAS Exon 3 Mutation Negative","C185893","A genetic finding indicating that KRAS exon 3 gene mutations have not been detected in a sample.","KRAS Exon 3 Mutation Negative | KRAS Exon 3 Gene Mutation Negative | KRAS Proto-Oncogene, GTPase Exon 3 Mutation Negative | KRAS-2 Exon 3 Mutation Negative | KRAS2 Exon 3 Mutation Negative | c-K-ras Exon 3 Mutation Negative | v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Exon 3 Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778500","KRAS Exon 2 Mutation Negative","C185892","A genetic finding indicating that KRAS exon 2 gene mutations have not been detected in a sample.","KRAS Exon 2 Mutation Negative | KRAS Exon 2 Gene Mutation Negative | KRAS Proto-Oncogene, GTPase Exon 2 Mutation Negative | KRAS-2 Exon 2 Mutation Negative | KRAS2 Exon 2 Mutation Negative | c-K-ras Exon 2 Mutation Negative | v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Exon 2 Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778627","Biallelic SMARCB1 Gene Mutation","C186281","The presence of mutations in both alleles of the SMARCB1 gene.","Biallelic SMARCB1 Gene Mutation | Biallelic BAF47 Gene Mutation | Biallelic Ini1 Gene Mutation | Biallelic SMARCB1 Mutation | Biallelic SNF5 Gene Mutation | Biallelic SNF5L1 Gene Mutation | Biallelic SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily B, Member 1 Gene Mutation | Biallelic Snr1 Gene Mutation | Biallelic hSNFS Gene Mutation | SMARCB1 Biallelic Gene Mutation | SMARCB1 Biallelic Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778626","Biallelic SMARCA4 Gene Mutation","C186280","The presence of mutations in both alleles of the SMARCA4 gene.","Biallelic SMARCA4 Gene Mutation | Biallelic BAF190 Gene Mutation | Biallelic BAF190A Gene Mutation | Biallelic BRG-1 Gene Mutation | Biallelic BRG1 Gene Mutation | Biallelic BRM/SWI2-Related Gene 1 Mutation | Biallelic SMARCA4 Mutation | Biallelic SNF2 Gene Mutation | Biallelic SNF2-Beta Gene Mutation | Biallelic SNF2L4 Gene Mutation | Biallelic SNF2LB Gene Mutation | Biallelic SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily A, Member 4 Gene Mutation | Biallelic SWI1 Gene Mutation | Biallelic SWI2 Gene Mutation | Biallelic hSNF2b Gene Mutation | SMARCA4 Biallelic Gene Mutation | SMARCA4 Biallelic Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778475","NRAS Exon 4 Mutation Negative","C185897","A genetic finding indicating that NRAS exon 4 gene mutations have not been detected in a sample.","NRAS Exon 4 Mutation Negative | N-RAS Exon 4 Mutation Negative | NRAS Exon 4 Gene Mutation Negative | NRAS Proto-Oncogene, GTPase Exon 4 Mutation Negative | Neuroblastoma RAS Viral Oncogene Homolog Exon 4 Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778474","NRAS Exon 3 Mutation Negative","C185896","A genetic finding indicating that NRAS exon 3 gene mutations have not been detected in a sample.","NRAS Exon 3 Mutation Negative | N-RAS Exon 3 Mutation Negative | NRAS Exon 3 Gene Mutation Negative | NRAS Proto-Oncogene, GTPase Exon 3 Mutation Negative | Neuroblastoma RAS Viral Oncogene Homolog Exon 3 Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778973","Tetrahydrocannabinol Positive","C186436","An indication that tetrahydrocannabinols, metabolites of cannabis (marijuana) and hemp, have been detected in a sample.","Tetrahydrocannabinol Positive | Positive THC | THC Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778971","PSA Density Less than 0.2","C186434","A finding indicating that the ratio of serum prostate specific antigen to prostate volume is less than 0.2 ng/ml/g.","PSA Density Less than 0.2 | PSA Density Less than 0.2 ng/mL/g | PSAD Less than 0.2 | PSAD Less than 0.2 ng/mL/g",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778593","Blasts Less than 0.01 Percent of Bone Marrow Nucleated Cells","C186375","A semi-quantitative microscopic finding indicating that less than 0.01 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.","Blasts Less than 0.01 Percent of Bone Marrow Nucleated Cells | Blasts Under 0.01 Percent of Bone Marrow Nucleated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778548","ELOC Gene Mutation","C186361","A change in the nucleotide sequence of the ELOC gene.","ELOC Gene Mutation | Elongin C Gene Mutation | SIII Gene Mutation | TCEB1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778547","EPAS1 Gene Mutation","C186360","A change in the nucleotide sequence of the EPAS1 gene.","EPAS1 Gene Mutation | BHLHE73 Gene Mutation | Endothelial PAS Domain Protein 1 Gene Mutation | HIF2A Gene Mutation | HLF Gene Mutation | MOP2 Gene Mutation | PASD2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778541","HRAS Overexpression Positive","C186354","An indication that overexpression of HRAS has been detected in a sample.","HRAS Overexpression Positive | GTPase HRas Overexpression Positive | H-Ras Overexpression Positive | H-Ras-1 Overexpression Positive | HRAS1 Overexpression Positive | Ha-Ras Overexpression Positive | Ha-Ras1 Overexpression Positive | RASH1 Overexpression Positive | c-H-ras Overexpression Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1670974","CPT1A protein, human","C186489","Carnitine O-palmitoyltransferase 1, liver isoform (773 aa, ~88 kDa) is encoded by the human CPT1A gene. This protein is involved in both hepatic triglyceride metabolism and the transfer of the acyl group of long-chain fatty acid-CoA conjugates onto carnitine, which facilitates mitochondrial uptake.","Carnitine O-Palmitoyltransferase 1, Liver Isoform | CPT I | CPT IA | CPT1-Alpha | CPT1-L | CPT1A | CPTI-L | Carnitine O-Palmitoyltransferase I, Liver Isoform | Carnitine Palmitoyltransferase 1A | Carnitine Palmitoyltransferase IA | EC 2.3.1.21",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778965","Undetectable PSA","C186458","An indication that the PSA level in a blood sample was not detected or below the detection limit.","Undetectable PSA | PSA Negative | PSA Undetectable | Prostate-Specific Antigen Negative | Prostate-Specific Antigen Undetectable | Undetectable Prostate-Specific Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778912","Homozygous MTAP Gene Deletion","C186502","A molecular abnormality referring to the loss of both copies of the MTAP gene","Homozygous MTAP Gene Deletion | Biallelic MTAP Deletion | Biallelic MTAP Gene Deletion | Homozygous Loss of MTAP Gene | Homozygous Loss of Methylthioadenosine Phosphorylase Gene | Homozygous MSAP Gene Deletion | Homozygous Methylthioadenosine Phosphorylase Gene Deletion | MTAP Gene Null",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0442004","Septal","C186021","Of, or related to, or in the direction of, an anatomical septum.","Septal | SEPTAL",,,,,,,,,,,,,,,"4112429","Septal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521394","Craniocaudal Plane","C186020","Pertaining to an anatomical plane extending between the cranial (towards the head) and caudal (towards the tail) portions of a body.","Craniocaudal Plane | CRANIOCAUDAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778672","Staining Intensity 3+","C186202","A measurement of the amount or proportion of tissue or cells that have a staining intensity of 3+.","Staining Intensity 3+ | STAINING INTENSITY 3+",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778671","Staining Intensity 2+","C186201","A measurement of the amount or proportion of tissue or cells that have a staining intensity of 2+.","Staining Intensity 2+ | STAINING INTENSITY 2+",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778743","Staining Intensity 1+","C186200","A measurement of the amount or proportion of tissue or cells that have a staining intensity of 1+.","Staining Intensity 1+ | STAINING INTENSITY 1+",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778742","Staining Intensity 0","C186199","A measurement of the amount or proportion of tissue or cells that have a staining intensity of 0.","Staining Intensity 0 | STAINING INTENSITY 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778294","SF-6Dv2 Health Utility Survey Standard, English Version 2.0 Questionnaire","C185762","A standardized stand-alone six-item patient report questionnaire derived from the SF-6D that assesses a range of symptoms, experiences, and health outcomes in six health domains over the past four weeks in order to capture changes across physical and mental health conditions and produce a single health utility score.","SF-6Dv2 Health Utility Survey Standard, English Version 2.0 Questionnaire | SF6D V2.0 STANDARD | SF6D Version 2.0 Standard | SF6D1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778293","SF-6Dv2 Health Utility Survey Acute, English Version 2.0 Questionnaire","C185761","A standardized stand-alone six-item patient report questionnaire derived from the SF-6D that assesses a range of symptoms, experiences, and health outcomes in six health domains over the past week in order to capture changes across physical and mental health conditions and produce a single health utility score.","SF-6Dv2 Health Utility Survey Acute, English Version 2.0 Questionnaire | SF6D V2.0 ACUTE | SF6D Version 2.0 Acute | SF6D2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778682","Pregnancy Suspected Indicator","C186213","An indication that the subject is believed likely to be pregnant.","Pregnancy Suspected Indicator | PSUSPIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778683","Fertility Status","C186214","The status of an individual with respect to their ability to produce offspring.","Fertility Status | FRTLSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778684","Follow-Up Availability Status","C186215","An indication of the subject's availability to provide information about their health status after they are no longer receiving study treatment.","Follow-Up Availability Status | FUAVSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778685","Lesion Thickness","C186216","A measurement of the distance between two opposite surfaces of a lesion.","Lesion Thickness | LESTHICK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778658","Extramedullary Disease Indicator","C186218","An indication as to whether extramedullary disease is present.","Extramedullary Disease Indicator | TUEXMIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778686","Bone Tumors Indicator","C186217","An indication as to whether bone tumors are present.","Bone Tumors Indicator | TUBNIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778740","Wallace Rule of Nines","C186196","A method for estimating body surface area of second and third degree burns, based on assigned percentages for different regions of the body.","Wallace Rule of Nines | WALLACE RULE OF NINES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1508749","Tourniquet Test","C186195","A method of assessing capillary fragility that is used in the diagnosis of hemorrhagic fevers. After taking a blood pressure measurement, the cuff is inflated to a point midway between the assessed systolic and diastolic pressures and maintained for five minutes; the cuff is then released and, after two minutes, the number of petechiae below the antecubital fossa are counted.","Tourniquet Test | Hess | Hess Test | Rumpel-Leede | Rumpel-Leede Test | TOURNIQUET TEST",,,,,,,,,,,,,,,"4170254","Capillary fragility test",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1778739","Microfluidic Immunoassay","C186194","Any of a number of immunoassay-based techniques that use very small amounts (e.g., on a nanoliter scale) of biological fluids.","Microfluidic Immunoassay | MICROFLUIDIC IMMUNOASSAY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778738","Hand-held Dynamometry","C186193","A technique to assess isometric muscle strength using a hand-held dynamometer.","Hand-held Dynamometry | HAND-HELD DYNAMOMETRY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024489","Magnetoencephalography","C16811","The measurement of the magnetic fields produced by electrical activity in the brain, usually conducted externally, using extremely sensitive devices. The measurement of electric fields in the brain provides information about the localization of brain activity which is complementary to that provided by electroencephalography.","Magnetoencephalography | MAGNETOENCEPHALOGRAPHY | MEG | MEG Scan",,,,,,,,,,,,,,,"4098798","Magnetoencephalography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1778372","Ammonium to Creatinine Ratio Measurement","C186025","A relative measurement (ratio) of ammonium to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Ammonium to Creatinine Ratio Measurement | AMNMCRT | Ammonium/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778391","Ammonium Measurement","C186024","The determination of the amount of ammonium ion (NH4+) present in a sample.","Ammonium Measurement | AMNM | Ammonium | Ammonium Ion | NH4+",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202316","Amitriptyline Measurement","C186023","The determination of the amount of amitriptyline present in a sample.","Amitriptyline Measurement | AMITRPTL | Amitriptyline",,,,,,,,,,,,,,,"4288159","Amitriptyline measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1778390","Alpha-1 Microglobulin Excretion Rate Measurement","C186022","The determination of the amount of amount of alpha-1 microglobulin being excreted in a biological specimen over a defined amount of time (e.g. one hour).","Alpha-1 Microglobulin Excretion Rate Measurement | A1MCGEXR | Alpha-1 Microglobulin Excretion Rate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1779383","Beta-Hydroxybutyrate to Acetoacetate Ratio Measurement","C186028","The determination of the ratio of beta-hydroxybutyrate to acetoacetate present in a sample. The measurement may be expressed as a ratio or percentage.","Beta-Hydroxybutyrate to Acetoacetate Ratio Measurement | BHBACTAC | Beta-Hydroxybutyrate/Acetoacetate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523431","3-Alpha-Androstanediol Glucuronide Measurement","C186027","The determination of the amount of 3-alpha-androstanediol glucuronide present in a sample.","3-Alpha-Androstanediol Glucuronide Measurement | 3-Alpha-Androstanediol Glucuronide | ASTDLG3A",,,,,,,,,,,,,,,"4014778","3-alpha-androstanediol glucuronide measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002866","Androsterone Measurement","C186026","The determination of the amount of androsterone present in a sample.","Androsterone Measurement | ANDSTRN | Androsterone",,,,,,,,,,,,,,,"4019449","Androsterone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0546632","Catecholamine Measurement","C186037","The determination of the amount of total catecholamines present in a sample.","Catecholamine Measurement | CTCHLMN | Catecholamines",,,,,,,,,,,,,,,"4096235","Catecholamine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1778377","Apoptotic Circulating Tumor Cell Count","C186036","The determination of the amount of apoptotic circulating tumor cells present in a sample.","Apoptotic Circulating Tumor Cell Count | CTCAPOP | Circulating Tumor Cells, Apoptotic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1779351","Pathologic Cast Measurement","C186035","The determination of the amount of pathologic (non-hyaline) casts present in a sample.","Pathologic Cast Measurement | CSPATH | Non-Hyalin Casts | Non-Hyaline Casts | Pathologic Casts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0373568","Carotene Measurement","C186034","The determination of the amount of total carotenes present in a sample.","Carotene Measurement | CRTN | Carotene",,,,,,,,,,,,,,,"4103068","Carotene measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1778376","Alpha Cortolone Measurement","C186033","The determination of the amount of alpha cortolone present in a sample.","Alpha Cortolone Measurement | Alpha Cortolone | CORTOLNA | alpha-Cortolone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778375","Alpha Cortol Measurement","C186032","The determination of the amount of alpha cortol present in a sample.","Alpha Cortol Measurement | Alpha Cortol | CORTOLA | alpha-Cortol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778374","Clonazepam and/or Metabolites Measurement","C186031","The determination of the amount of clonazepam and/or its metabolite(s) present in a biological specimen, for an assay that can measure both clonazepam and its metabolites.","Clonazepam and/or Metabolites Measurement | CLZPMAOM | Clonazepam and/or Metabolites",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778373","Cyclic Adenosine 3,5 Monophosphate to Creatinine Ratio Measurement","C186030","The determination of the ratio of cyclic adenosine 3,5-monophosphate to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.","Cyclic Adenosine 3,5 Monophosphate to Creatinine Ratio Measurement | CAMPCRT | Cyclic Adenosine 3,5-Monophosphate/Creatinine | Cyclic Adenosine Monophosphate/Creat | Cyclic Adenosine Monophosphate/Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1779352","Complement C1q Measurement","C186029","The determination of the amount of complement C1q present in a sample.","Complement C1q Measurement | C1Q | Complement C1q",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778403","Erythroferrone Measurement","C186047","The determination of the amount of erythroferrone present in a sample.","Erythroferrone Measurement | ERFE | Erythroferrone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778402","21-Deoxycorticosterone Measurement","C186046","The determination of the amount of 21-deoxycorticosterone present in a sample.","21-Deoxycorticosterone Measurement | 21-Deoxycorticosterone | DXCSN21",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523579","11-Deoxycorticosterone Measurement","C186045","The determination of the amount of 11-deoxycorticosterone present in a sample.","11-Deoxycorticosterone Measurement | 11-Deoxycorticosterone | 21-Hydroxyprogesterone | Cortexone | DXCSN11 | Deoxycortone | Desoxycortone",,,,,,,,,,,,,,,"4017632","11-deoxycorticosterone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1778401","21-Deoxycortisol Measurement","C186044","The determination of the amount of 21-deoxycortisol present in a sample.","21-Deoxycortisol Measurement | 21-Deoxycortisol | DXCSL21",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0201970","11-Deoxycortisol Measurement","C186043","The determination of the amount of 11-deoxycortisol present in a sample.","11-Deoxycortisol Measurement | 11-Deoxycortisol | DXCSL11",,,,,,,,,,,,,,,"4252098","11-deoxycortisol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1778400","11-Deoxycorticosteroid Measurement","C186042","The determination of the amount of total 11-deoxycorticosteroids present in a sample.","11-Deoxycorticosteroid Measurement | 11-Deoxycorticoids | 11-Deoxycorticosteroid | 11-Deoxycorticosteroids | DXCSD11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778399","Doxepin And/Or Metabolites Measurement","C186041","The determination of the amount of doxepin and/or its metabolite(s) present in a biological specimen, for an assay that can measure both doxepin and its metabolites.","Doxepin And/Or Metabolites Measurement | DOXPNAOM | Doxepin and/or Metabolites",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202369","Desipramine Measurement","C186040","The determination of the amount of desipramine present in a sample.","Desipramine Measurement | DESIPRMN | Desipramine",,,,,,,,,,,,,,,"4012481","Desipramine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1778379","Chemokine (C-X-C Motif) Ligand 2 Measurement","C186039","The determination of the amount of CXCL2, chemokine (C-X-C motif) ligand 2, present in a sample.","Chemokine (C-X-C Motif) Ligand 2 Measurement | CXCL2 | Chemokine (C-X-C Motif) Ligand 2 | GRO Beta | GRO2 | MIP2-Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778378","Traditional Circulating Tumor Cell Count","C186038","The determination of the amount of traditional circulating tumor cells present in a sample.","Traditional Circulating Tumor Cell Count | CTCTRAD | Circulating Tumor Cells, Traditional",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1295171","18-Hydroxydeoxycorticosterone Measurement","C186068","The determination of the amount of 18-hydroxydeoxycorticosterone present in a sample.","18-Hydroxydeoxycorticosterone Measurement | 18-Hydroxydeoxycorticosterone | HXDX 18 | HXDX18",,,,,,,,,,,,,,,"4007006","18-Hydroxydeoxycorticosterone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523734","18-Hydroxycorticosterone Measurement","C186067","The determination of the amount of 18-hydroxycorticosterone present in a sample.","18-Hydroxycorticosterone Measurement | 18-Hydroxycorticosterone | HXCSN18",,,,,,,,,,,,,,,"4017200","18-Hydroxycorticosterone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1295170","18-Hydroxycortisol Measurement","C186066","The determination of the amount of 18-hydroxycortisol present in a sample.","18-Hydroxycortisol Measurement | 18-Hydroxycortisol | HXCSL18",,,,,,,,,,,,,,,"4005697","18-Hydroxycortisol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523706","17-Hydroxycorticosteroid Measurement","C186065","The determination of the amount of 17-hydroxycorticosteroids present in a sample.","17-Hydroxycorticosteroid Measurement | 17-Hydroxycorticoid | 17-Hydroxycorticosteroid | 17-Hydroxycorticosteroids | HXCSD17",,,,,,,,,,,,,,,"4017774","17-hydroxycorticosteroid measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523422","11-Hydroxyandrosterone Measurement","C186064","The determination of the amount of 11-hydroxyandrosterone present in a sample.","11-Hydroxyandrosterone Measurement | 11-Hydroxyandrosterone | HXANST11",,,,,,,,,,,,,,,"4017488","11-hydroxyandrosterone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523421","11-Hydroxyandrostenedione Measurement","C186063","The determination of the amount of 11-hydroxyandrostenedione present in a sample.","11-Hydroxyandrostenedione Measurement | 11-Hydroxyandrostenedione | HXANSD11",,,,,,,,,,,,,,,"4014775","11-hydroxyandrostenedione measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1778397","HLA DQ8 Antigen Measurement","C186062","The determination of the amount of HLA DQ8 antigen present in a sample.","HLA DQ8 Antigen Measurement | HLA DQ8 Antigen | HLA-DQ8 Antigen | HLADQ8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778396","HLA DQ2 Antigen Measurement","C186061","The determination of the amount of HLA DQ2 antigen present in a sample.","HLA DQ2 Antigen Measurement | HLA DQ2 Antigen | HLA-DQ2 Antigen | HLADQ2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778395","Hydrogen and Methane Measurement","C186060","The determination of the amount of hydrogen and methane present in a sample.","Hydrogen and Methane Measurement | H+CH4 | HCH4 | Hydrogen+Methane",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778394","6a OH-tetrahydro-11-Deoxycortisol Measurement","C186059","The determination of the amount of 6-alpha hydroxytetrahydro-11-deoxycortisol present in a sample.","6a OH-tetrahydro-11-Deoxycortisol Measurement | 6-Alpha Hydroxytetrahydro-11-Deoxycortisol | 6a OH-tetrahydro-11-Deoxycortisol | H411DS6A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778393","6a OH-tetrahydro-11-DeH-Corticosterone Measurement","C186058","The determination of the amount of 6-alpha hydroxytetrahydro-11-dehydrocorticosterone present in a sample.","6a OH-tetrahydro-11-DeH-Corticosterone Measurement | 6-Alpha Hydroxytetrahydro-11-Dehydrocorticosterone | 6a OH-tetrahydro-11-DeH-Corticosterone | H411DC6A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778392","Growth Regulated Oncogene Measurement","C186057","The determination of the amount of total growth regulated oncogene proteins present in a sample.","Growth Regulated Oncogene Measurement | GRO | Growth Regulated Oncogene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778411","Segmented Granulocyte Count","C186056","The determination of the amount of segmented granulocytes present in a sample.","Segmented Granulocyte Count | GRANSG | Granulocytes Segmented",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778410","Granulocytes Band Form Count","C186055","The determination of the amount of banded granulocytes present in a sample.","Granulocytes Band Form Count | Banded Granulocytes | GRANB | Granulocytes Band Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778409","Radiolabeled Glucose to Glucose Ratio Measurement","C186054","The determination of the ratio of radiolabeled glucose to total glucose present in a sample. The measurement may be expressed as a ratio or percentage.","Radiolabeled Glucose to Glucose Ratio Measurement | GLURLGLU | Glucose, Enriched/Glucose | Glucose, Radiolabeled/Glucose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778408","Galectin-3 Binding Protein Measurement","C186053","The determination of the amount of galectin-3 binding protein present in a sample.","Galectin-3 Binding Protein Measurement | GLCTN3BP | Galectin-3 Binding Protein | LGALS3BP | M2BP | Mac-2 Binding Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202027","Galactose-1-Phosphate Measurement","C186052","The determination of the amount of galactose-1-phosphate present in a sample.","Galactose-1-Phosphate Measurement | GAL1PHOS | Galactose-1-Phosphate",,,,,,,,,,,,,,,"4300762","Galactose-1-phosphate measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1778407","Flurazepam and/or Metabolites Measurement","C186051","The determination of the amount of flurazepam and/or its metabolite(s) present in a biological specimen, for an assay that can measure both flurazepam and its metabolites.","Flurazepam and/or Metabolites Measurement | FRZPMAOM | Flurazepam and/or Metabolites",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778406","Glycated Ferritin to Ferritin Ratio Measurement","C186050","The determination of the ratio of glycated ferritin to total ferritin present in a sample. The measurement may be expressed as a ratio or percentage.","Glycated Ferritin to Ferritin Ratio Measurement | FRNGFRN | Glycated Ferritin/Ferritin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778405","Glycated Ferritin Measurement","C186049","The determination of the amount of glycated ferritin present in a sample.","Glycated Ferritin Measurement | FRNG | Glycated Ferritin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778404","Flunitrazepam and/or Metabolites Measurement","C186048","The determination of the amount of flunitrazepam and/or its metabolite(s) present in a biological specimen, for an assay that can measure both flunitrazepam and its metabolites.","Flunitrazepam and/or Metabolites Measurement | FNZPMAOM | Flunitrazepam and/or Metabolites",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523822","Phenylalanine to Tyrosine Ratio Measurement","C81281","The determination of the ratio of phenylalanine compared to tyrosine present in a sample. The measurement may be expressed as a ratio or percentage.","Phenylalanine to Tyrosine Ratio Measurement | PHETYR | Phenylalanine/Tyrosine | Phenylalanine/Tyrosine Ratio Measurement",,,,,,,,,,,,,,,"4017224","Phenylalanine/tyrosine ratio measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202028","Galactose-1-Phosphate Uridyltransferase Measurement","C81251","The measurement of the galactose-1-phosphate uridyltransferase in a biologic specimen.","Galactose-1-Phosphate Uridyltransferase Measurement | G1PUT | GAL1PUT | GALT | GALT Measurement | Galactose 1 Phosphate Uridyl Transferase | Galactose-1-Phos Uridylyltransferase | Galactose-1-Phosphate Uridylyltransferase | Galactose-1-Phosphate Uridylyltransferase Measurement",,,,,,,,,,,,,,,"4247160","Galactose-1-phosphate uridyltransferase measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0391950","Xylose Measurement","C186099","The determination of the amount of xylose present in a sample.","Xylose Measurement | XYLOSE | Xylose",,,,,,,,,,,,,,,"4017367","Xylose measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1779376","Xylose to Xylose Dose Ratio Measurement","C186098","A relative measurement (percentage) of the xylose in a biological specimen to an administered dose of xylose.","Xylose to Xylose Dose Ratio Measurement | XLSXLSD | Xylose/Xylose Dose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266381","5-Alpha Tetrahydrocortisol Measurement","C186097","The determination of the amount of 5-alpha tetrahydrocortisol present in a sample.","5-Alpha Tetrahydrocortisol Measurement | 5-Alpha Tetrahydrocortisol | THDCSL5A",,,,,,,,,,,,,,,"4004870","5-alpha-Tetrahydrocortisol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1778350","Soluble Intercellular Adhesion Molecule 4 Measurement","C186096","The determination of the amount of soluble intercellular adhesion molecule 4 present in a sample.","Soluble Intercellular Adhesion Molecule 4 Measurement | SICAM4 | Soluble Intercell Adhesion Molecule 4 | Soluble Intercellular Adhesion Molecule 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523902","Succinylacetone Measurement","C186095","The determination of the amount of succinylacetone present in a sample.","Succinylacetone Measurement | SCNYLACT | Succinylacetone",,,,,,,,,,,,,,,"4017347","Succinylacetone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1778349","Schistocyte to Erythrocyte Ratio Measurement","C186094","The determination of the ratio of schistocytes to erythrocytes present in a sample. The measurement may be expressed as a ratio or percentage.","Schistocyte to Erythrocyte Ratio Measurement | SCHISRBC | Schistocytes/Erythrocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2711642","Serum-Ascites Albumin Gradient Measurement","C186093","The determination of the amount of serum-ascites albumin gradient, calculated by subtracting the amount of albumin in ascites fluid from the albumin in serum.","Serum-Ascites Albumin Gradient Measurement | SAAG | Serum-Ascites Albumin Gradient",,,,,,,,,,,,,,,"40481778","Serum ascites albumin gradient",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0337442","Pregnanediol Measurement","C186092","The determination of the amount of pregnanediol present in a sample.","Pregnanediol Measurement | PRGNNDL | Pregnanediol",,,,,,,,,,,,,,,"4231268","Pregnanediol measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1778348","Free Proprotein Convertase Subtilisin/Kexin Type 9 Measurement","C186091","The determination of the amount of free proprotein convertase subtilisin/kexin type 9 present in a sample.","Free Proprotein Convertase Subtilisin/Kexin Type 9 Measurement | PCSK9FR | Proprotein Convertase Subtilisin/Kexin Type 9 | Prprot Cnvrtase Subtilisin-Kexin 9, Free",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266681","Para-Aminobenzoate Measurement","C186090","The determination of the amount of para-aminobenzoate present in a sample.","Para-Aminobenzoate Measurement | PABA | Para-Aminobenzoate | Para-Aminobenzoic Acid",,,,,,,,,,,,,,,"4005050","Para-aminobenzoate measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1778347","Nitrazepam and/or Metabolites Measurement","C186089","The determination of the amount of nitrazepam and/or its metabolite(s) present in a biological specimen, for an assay that can measure both nitrazepam and its metabolites.","Nitrazepam and/or Metabolites Measurement | NTZPMAOM | Nitrazepam and/or Metabolites",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524214","Norpropoxyphene Measurement","C186088","The determination of the amount of norpropoxyphene present in a sample.","Norpropoxyphene Measurement | NRPROPOX | Norpropoxyphene",,,,,,,,,,,,,,,"4020400","Norpropoxyphene measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0202432","Nortriptyline Measurement","C186087","The determination of the amount of nortriptyline present in a sample.","Nortriptyline Measurement | NORTRPTL | Nortriptyline",,,,,,,,,,,,,,,"4150378","Nortryptyline measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1778358","Free Normetanephrine Measurement","C186086","The determination of the amount of free normetanephrine present in a sample.","Free Normetanephrine Measurement | NORMETFR | Normetanephrine, Free",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778357","Non-HDL Cholesterol to LDL Cholesterol Ratio Measurement","C186085","The determination of the ratio of non-HDL cholesterol to LDL cholesterol present in a sample. The measurement may be expressed as a ratio or percentage.","Non-HDL Cholesterol to LDL Cholesterol Ratio Measurement | NHDLLDL | Non-HDL Cholesterol/LDL Cholesterol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778356","Myeloid Progenitor Cell to Total Cell Ratio Measurement","C186084","The determination of the ratio of myeloid progenitor cells to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Myeloid Progenitor Cell to Total Cell Ratio Measurement | MYPCCE | Myeloid Progenitor Cells to Total Cells Ratio Measurement | Myeloid Progenitor Cells/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1779372","Free 3-Methoxytyramine Measurement","C186083","The determination of the amount of free 3-methoxytyramine present in a sample.","Free 3-Methoxytyramine Measurement | 3-Methoxytyramine, Free | MTHXT3FR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778355","Total 3-Methoxytyramine Measurement","C186082","The determination of the amount of total 3-methoxytyramine present in a sample.","Total 3-Methoxytyramine Measurement | 3-Methoxytyramine | MTHXT3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778354","Monoclonal Protein Immunoglobulin Isotype Determination","C186081","The identification of the monoclonal protein immunoglobulin isotype present in a sample.","Monoclonal Protein Immunoglobulin Isotype Determination | Immunoglobulin Immunofixation Interpretation | MPIGISO | Monoclonal Prot Immunoglobulin Isotype | Monoclonal Protein Immunoglobulin Class | Monoclonal Protein Immunoglobulin Isotype",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0523769","Methane Measurement","C186080","The determination of the amount of methane present in a sample.","Methane Measurement | CH4 | METHANE | Methane",,,,,,,,,,,,,,,"4017209","Methane measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1778353","Lymphocyte to Neutrophil Ratio Measurement","C186079","A relative measurement (ratio) of lymphocytes to neutrophils present in a sample. The measurement may be expressed as a ratio or percentage.","Lymphocyte to Neutrophil Ratio Measurement | LYMNE | Lymphocytes/Neutrophils",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778352","Lymphoma Cell to Total Cell Ratio Measurement","C186078","The determination of the ratio of lymphoma cells to total cells present in a sample. The measurement may be expressed as a ratio or percentage.","Lymphoma Cell to Total Cell Ratio Measurement | LYMMCECE | Lymphoma Cells to Total Cells Ratio Measurement | Lymphoma Cells/Total Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0429230","Lactose Measurement","C186077","The determination of the amount of lactose present in a sample.","Lactose Measurement | LACTOSE | Lactose",,,,,,,,,,,,,,,"4018446","Lactose measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0236402","17-Ketosteroid Measurement","C186076","The determination of the amount of total 17-ketosteroids present in a sample.","17-Ketosteroid Measurement | 17-Ketosteroids | KTSTR17",,,,,,,,,,,,,,,"4018340","17-Ketosteroids measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0702125","17-Ketogenic Steroid Measurement","C186075","The determination of the amount of total 17-ketogenic steroids present in a sample.","17-Ketogenic Steroid Measurement | 17-Ketogenic steroids | KTGSTR17",,,,,,,,,,,,,,,"4099168","17-Ketogenic steroids measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523425","11-Ketoetiocholanolone Measurement","C186074","The determination of the amount of 11-ketoetiocholanolone present in a sample.","11-Ketoetiocholanolone Measurement | 11-Ketoetiocholanolone | KTETCL11",,,,,,,,,,,,,,,"4018052","11-ketoetiocholanolone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0523424","11-Ketoandrosterone Measurement","C186073","The determination of the amount of 11-ketoandrosterone present in a sample.","11-Ketoandrosterone Measurement | 11-Ketoandrosterone | KTANST11",,,,,,,,,,,,,,,"4018051","11-ketoandrosterone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1779373","Intact Insulin Measurement","C186072","The determination of the amount of intact insulin present in a sample.","Intact Insulin Measurement | INSULINI | Insulin, Intact",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020935","Imipramine Measurement","C186071","The determination of the amount of imipramine present in a sample.","Imipramine Measurement | IMIPRMN | Imipramine",,,,,,,,,,,,,,,"4022365","Imipramine measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0045008","17-Hydroxypregnenolone Measurement","C186070","The determination of the amount of 17-hydroxypregnenolone present in a sample.","17-Hydroxypregnenolone Measurement | 17-Hydroxypregnenolone | HXPRGN17",,,,,,,,,,,,,,,"4014777","17-Hydroxypregnenolone measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1778398","11-Hydroxyetiocholanolone Measurement","C186069","The determination of the amount of 11-hydroxyetiocholanolone present in a sample.","11-Hydroxyetiocholanolone Measurement | 11-Hydroxyetiocholanolone | HXETCL11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778676","PMS1 Homolog 1 Measurement","C186206","The determination of the amount of PMS1 mismatch repair protein in a biological sample.","PMS1 Homolog 1 Measurement | PMS1 | PMS1 Homolog 1 | PMS1 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778675","Cellular Tumor Antigen p53 Measurement","C186205","The determination of the amount of tumor protein p53 in a biological sample.","Cellular Tumor Antigen p53 Measurement | P53 | TP53 Measurement | Tumor Protein p53 | p53 Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778674","MutS Homolog 3 Measurement","C186204","The determination of the amount of MSH3 mismatch repair protein in a biological sample.","MutS Homolog 3 Measurement | MSH3 | MSH3 Measurement | MutS Homolog 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778673","MutL Homolog 3 Measurement","C186203","The determination of the amount of MLH3 mismatch repair protein in a biological sample.","MutL Homolog 3 Measurement | MLH3 | MLH3 Measurement | MutL Homolog 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778508","Mismatch Repair Protein Measurement","C185932","An evaluation of the mismatch repair proteins in a biological sample.","Mismatch Repair Protein Measurement | MMR Proteins | MMRPROT | Mismatch Repair Proteins",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1634351","Human Papillomavirus-34","C186749","A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. It is uncertain whether infection with human papillomavirus-34 is associated a high or low risk of cervical intraepithelial neoplasia or with cervical cancer.","Human Papillomavirus-34 | 34 | HPV 34 | HPV-34 | HPV34 | HUMAN PAPILLOMAVIRUS TYPE 34 | Human Papillomavirus Type 34",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1779379","Human Papillomavirus-40","C186750","A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. It is uncertain whether infection with human papillomavirus-40 is associated a high or low risk of cervical intraepithelial neoplasia, but it is associated with a low risk of cervical cancer.","Human Papillomavirus-40 | 40 | HPV 40 | HPV-40 | HPV40 | HUMAN PAPILLOMAVIRUS TYPE 40 | Human Papillomavirus Type 40 | Human papillomavirus 40",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1779114","Human Papillomavirus-42","C186751","A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-42 is associated with a low risk of cervical intraepithelial neoplasia and with a low risk of cervical cancer.","Human Papillomavirus-42 | 42 | HPV 42 | HPV-42 | HPV42 | HUMAN PAPILLOMAVIRUS TYPE 42 | Human Papillomavirus Type 42 | Human papillomavirus 42",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1779115","Human Papillomavirus-43","C186752","A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-43 is associated with a low risk of cervical intraepithelial neoplasia and with a low risk of cervical cancer.","Human Papillomavirus-43 | 43 | HPV 43 | HPV-43 | HPV43 | HUMAN PAPILLOMAVIRUS TYPE 43 | Human Papillomavirus Type 43 | Human papillomavirus 43",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1779116","Human Papillomavirus-44","C186753","A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-44 is associated with a high risk of cervical intraepithelial neoplasia and with a low risk of cervical cancer.","Human Papillomavirus-44 | 44 | HPV 44 | HPV-44 | HPV44 | HUMAN PAPILLOMAVIRUS TYPE 44 | Human Papillomavirus Type 44 | Human papillomavirus 44",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1779139","Human Papillomavirus-54","C186754","A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-54 is associated with condyloma acuminata (genital warts) and with a low risk of cervical cancer.","Human Papillomavirus-54 | 54 | HPV 54 | HPV-54 | HPV54 | HUMAN PAPILLOMAVIRUS TYPE 54 | Human Papillomavirus Type 54 | Human papillomavirus 54",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1779381","Human Papillomavirus-69","C186755","A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. It is uncertain whether infection with human papillomavirus-69 is associated a high or low risk of cervical intraepithelial neoplasia or with cervical cancer.","Human Papillomavirus-69 | 69 | HPV 69 | HPV-69 | HPV69 | HUMAN PAPILLOMAVIRUS TYPE 69 | Human Papillomavirus Type 69 | Human papillomavirus 69",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778663","Therapeutic Cells per Square Meter","C186224","A dosing unit for the number of therapeutic cells given per meter squared of body surface area.","Therapeutic Cells per Square Meter | Therapeutic Cells/m2 | {Therapeutic Cells}/m2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778662","Phosphatidylserine IgM Antibody Unit per Milliliter","C186223","Unit of measure of potency of allergenic product expressed as a number of immunoglobin M phosphatidylserine units per one milliliter of formulation.","Phosphatidylserine IgM Antibody Unit per Milliliter | Immunoglobin M Phosphatidylserine Units/mL | MPS U/mL | Phosphatidylserine IgM Antibody Unit/mL | {MPS U}/mL | {MPS U}/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778661","Chewable Gel Dosing Unit","C186222","A dosing measurement based on the gummy unit.","Chewable Gel Dosing Unit | Chewable gel (Gummy) | GUMMY | Gummy | Gummy Dosing Unit | {GUMMY}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778660","Phosphatidylserine IgG Antibody Unit per Milliliter","C186221","Unit of measure of potency of allergenic product expressed as a number of immunoglobin G phosphatidylserine units per one milliliter of formulation.","Phosphatidylserine IgG Antibody Unit per Milliliter | GPS U/mL | Immunoglobin G Phosphatidylserine Units/mL | Phosphatidylserine IgG Antibody Unit/mL | {GPS U}/mL | {GPS U}/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1779361","Envelope Dosing Unit","C186220","A dosing measurement based on the envelope unit.","Envelope Dosing Unit | ENVELOPE | {ENVELOPE}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778659","Phosphatidylserine IgA Antibody Unit per Milliliter","C186219","Unit of measure of potency of allergenic product expressed as a number of immunoglobin A phosphatidylserine units per one milliliter of formulation.","Phosphatidylserine IgA Antibody Unit per Milliliter | APS U/mL | Immunoglobin A Phosphatidylserine Units/mL | Phosphatidylserine IgA Antibody Unit/mL | {APS U}/mL | {APS U}/ml",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1556080","Pump Dosing Unit","C111984","A dosing unit equal to the amount of active ingredient(s) contained in one actuation of a pumping device.","Pump Dosing Unit | PUMP | Pump | {PUMP}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1779374","Human Papillomavirus-74","C186780","A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-74 is associated with a low risk of cervical intraepithelial neoplasia. It is uncertain whether infection with human papillomavirus-74 is associated with cervical cancer.","Human Papillomavirus-74 | 74 | HPV 74 | HPV-74 | HPV74 | HUMAN PAPILLOMAVIRUS TYPE 74 | Human Papillomavirus Type 74 | Human papillomavirus 74",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225871","Atrioventricular Septum","C186104","The junction where the tissue of the atrial septum and the ventricular septum meet.","Atrioventricular Septum | ATRIOVENTRICULAR SEPTUM",,,,,,,,,,,,,,,"4032778","Structure of atrioventricular septum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0231077","Aorticopulmonary Septum","C186103","The wall that separates the aorta and pulmonary arteries during embryonic development.","Aorticopulmonary Septum | AORTICOPULMONARY SEPTUM",,,,,,,,,,,,,,,"4014689","Structure of aortopulmonary septum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1778351","Anorectum","C186102","The distal portion of the gastrointestinal tract that includes the anal canal and rectum.","Anorectum | ANORECTUM | anorectum","C21.8","Anorectum",,,,,,,,,,,"UBERON:8410050","anorectum",,,,,,,,,,,,,,,"--","--"
"C0224247","Anconeus Muscle","C186101","A small muscle in the posterior elbow that originates from the lateral epicondyle of the humerus and attaches to the lateral surface of the olecranon of the ulna; it functions to extend the forearm and stabilize the elbow joint.","Anconeus Muscle | ANCONEUS MUSCLE",,,,,,,,,,,,,,,"4182702","Structure of anconeus muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224288","Adductor Pollicis Muscle","C186100","A muscle of the hand that extends from the capitate and bases of the second and third metacarpals for the oblique head, and the anterior surface of body of the third metacarpal for the transverse head, to the base of proximal phalanx and extensor hood of the thumb; primary function is to draw the first metacarpal laterally to oppose the thumb toward the center of palm and rotate it medially.","Adductor Pollicis Muscle | ADDUCTOR POLLICIS MUSCLE",,,,,,,,,,,,,,,"4244566","Adductor pollicis muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002760","Anal Sphincter","C165177","The internal and external muscles surrounding the anus that maintain continence.","Anal Sphincter | ANAL SPHINCTER | Structure of sphincter ani muscle (body structure) | anal region sphincter | anal sphincter | sphincter analia",,,,,,,,,,,,,"UBERON:0004916","anal sphincter","4165580","Structure of sphincter ani muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL977221","Periorbital Soft Tissue","C164007","Any non-hardened or non-calcified tissue found in the periorbital area.","Periorbital Soft Tissue | PERI-ORBITAL SOFT TISSUE | Peri-orbital soft tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977222","Nasal Soft Tissue","C164006","Any non-hardened or non-calcified tissue found in the nose.","Nasal Soft Tissue | NASAL SOFT TISSUE | Nasal soft tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977224","Mediastinal Soft Tissue","C164004","Any non-hardened or non-calcified tissue found in the mediastinum.","Mediastinal Soft Tissue | MEDIASTINAL SOFT TISSUE | Mediastinal soft tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227349","Colonic Mucosa","C164003","The mucus membrane lining the inner surface of the colon.","Colonic Mucosa | COLONIC MUCOSA | colon mucosa | colon mucous membrane | colonic mucosa | colonic mucous membrane | large bowel mucosa | mucosa of colon | mucosa of large bowel",,,,,,,,,,,,,"UBERON:0000317","colonic mucosa","4285902","Colonic mucous membrane structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227814","Uterine Horn","C161570","The portion of the reproductive tract that connects the fallopian tubes to the uterus. The prominence of the uterine horns are variable across species and may be the location at which embryo implantation occurs in some species.","Uterine Horn | UTERINE HORN",,,,,,,,,,,,,,,"4075090","Cornu of fallopian tube",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0447620","Female Reproductive System Part","C13039","Any component of the female organs and tissues involved in the production and maturation of gametes and in their union and subsequent development as offspring.","Female Reproductive System Part | UTERINE WALL | Uterus Wall",,,,,,,,,,,,,,,"4075412","Structure of uterine wall",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224364","Rhomboid Minor Muscle","C186137","A muscle in the back that originates from the nuchal ligament and spinal processes of the seventh cervical and first thoracic vertebrae and attaches to the medial border of the scapula; along with the rhomboid major muscle, it functions to stabilize and retract the scapula.","Rhomboid Minor Muscle | RHOMBOID MINOR MUSCLE",,,,,,,,,,,,,,,"4276035","Structure of rhomboid minor muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224363","Rhomboid Major Muscle","C186136","A muscle in the back that originates from the spinous processes of the second to fifth thoracic vertebrae and attaches to the medial border of the scapula; along with the rhomboid minor muscle, it functions to stabilize and retract the scapula.","Rhomboid Major Muscle | RHOMBOID MAJOR MUSCLE",,,,,,,,,,,,,,,"4227573","Structure of rhomboid major muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4251783","Presphenoid Bone","C186135","One of the bones of the orbit, situated dorsally to the basisphenoid bone; it is present during fetal development and later fuses to form the anterior portion of the sphenoid bone.","Presphenoid Bone | PRESPHENOID BONE",,,,,,,,,,,,,,,"4010926","Structure of presphenoidal bone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1778365","Premaxilla Bone","C186134","Paired bones at the anterior tip of the upper jaw that are generally tooth bearing.","Premaxilla Bone | PREMAXILLA BONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778364","Plantar Flexor Muscles","C186133","A group of muscles that function to extend the ankle, flexing the foot downward toward the sole, and includes the gastrocnemius, soleus, plantaris, tibialis posterior, flexor hallucis longus, and flexor digitorum longus muscles.","Plantar Flexor Muscles | PLANTAR FLEXOR MUSCLES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224470","Peroneus Brevis Muscle","C186132","A short muscle in the lateral compartment of the lower leg that originates on the distal two-thirds of the lateral surface of the fibula and the anterior intermuscular septum, attaches to the tuberosity of the fifth metatarsal bone, and functions to plantar flex and evert the foot.","Peroneus Brevis Muscle | PERONEUS BREVIS MUSCLE",,,,,,,,,,,,,,,"4245632","Peroneus brevis muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1778363","Perimeningeal Space","C186131","The space surrounding the meninges.","Perimeningeal Space | PERIMENINGEAL SPACE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4248231","Upper Paratracheal Lymph Node","C186130","A lymph node located adjacent to the trachea within the mediastinum, above the inferior margin of the left brachiocephalic vein crossing the trachea on the left and the superior border of the aortic arch on the right.","Upper Paratracheal Lymph Node | PARATRACHEAL LYMPH NODE, UPPER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226908","Palatal Rugae","C186129","The creases or folds in the oral mucosa covering the roof of the oral cavity.","Palatal Rugae | PALATAL RUGAE | Palatine Rugae",,,,,,,,,,,,,,,"4238743","Structure of transverse folds of palate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224141","Mentalis Muscle","C186127","A paired facial muscle that originates from the incisive fossa of the mandible and extends upward to attach to the skin of the lower lip; it functions to elevate and protrude the lower lip and elevate and wrinkle the skin of the chin.","Mentalis Muscle | MENTALIS MUSCLE",,,,,,,,,,,,,,,"4278660","Structure of mentalis muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224482","Lumbrical Muscles of the Foot","C186126","A group muscles in the sole of the foot that originate from the tendons of the flexor digitorum longus muscle and attach to the medial bases of the proximal phalanges and the extensor expansion of the second through fifth digits; they function to flex and adduct the lateral four toes at the metatarsophalangeal joints and extend them at the interphalangeal joints.","Lumbrical Muscles of the Foot | LUMBRICAL MUSCLES OF THE FOOT",,,,,,,,,,,,,,,"4030391","Structure of lumbrical muscle of foot",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1778361","Knee Flexor Muscles","C186125","A group of muscles that function to flex the knee, including the sartorius, popliteus, gastrocnemius, gracilis, semi-tendinosis, semi-membranosis, and bicep femoris muscles.","Knee Flexor Muscles | KNEE FLEXOR MUSCLES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2326831","Kidney Interpolar Region","C186124","The portion of the kidney that is located between the upper and lower poles and contains the renal hilum.","Kidney Interpolar Region | KIDNEY INTERPOLAR REGION | Kidney, Middle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0687091","Interparietal Bone","C186123","A bone of the skull situated between the parietal and supraoccipital bones.","Interparietal Bone | INTERPARIETAL BONE",,,,,,,,,,,,,,,"4319175","Structure of interparietal bone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1778360","Hip Flexor Muscles","C186122","A group of muscles that function to move the leg or knee towards the torso and assist with bending at the waist, including the psoas major, iliacus, rectus femoris, pectineus, and sartorius.","Hip Flexor Muscles | HIP FLEXOR MUSCLES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778359","Hindpaw Phalanx","C186121","A bone of the hindpaw.","Hindpaw Phalanx | HINDPAW PHALANX | Hindpaw Phalange",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778371","Heart, Ventricular Chamber","C186120","The anatomical space of the cardiac ventricle.","Heart, Ventricular Chamber | HEART, VENTRICULAR CHAMBER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224110","Frontalis Muscle","C186119","A muscle in the forehead that originates from the galea aponeurotica at the top of the skull and attaches to the skin around the eyebrows and the top of the nose; it functions to raise the eyebrows and wrinkle the forehead.","Frontalis Muscle | FRONTALIS MUSCLE",,,,,,,,,,,,,,,"4148071","Structure of frontal belly of occipitofrontalis muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1778370","Forepaw Phalanx","C186118","A bone of the forepaw.","Forepaw Phalanx | FOREPAW PHALANX | Forepaw Phalange",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778369","Forearm Pronator Muscles","C186117","A group of muscles that function to rotate the forearm so that the palm faces downward when the arm is extended at a right angle to the body, including the brachioradialis, pronator teres, pronator quadratus, and flexor carpi radialis.","Forearm Pronator Muscles | FOREARM PRONATOR MUSCLES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224280","Flexor Pollicis Brevis Muscle","C186116","A muscle in the hand that has a superficial head that originates from the flexor retinaculum and tubercle of the trapezium bone and a deep head that originates from the trapezoid and capitate bones; it attaches to the lateral side of the base of the proximal phalanx of the thumb and functions to flex the thumb at the metacarpophalangeal joint.","Flexor Pollicis Brevis Muscle | FLEXOR POLLICIS BREVIS MUSCLE",,,,,,,,,,,,,,,"4047578","Flexor pollicis brevis muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224285","Extensor Pollicis Longus Muscle","C186115","A muscle in the posterior forearm that originates from the posterior surface of the middle third of the ulna and the adjacent interosseous membrane and attaches to the posterior surface of the base of distal phalanx of the thumb; it functions to extend the thumb at the metacarpophalangeal and interphalangeal joints and extend and abduct the wrist joint.","Extensor Pollicis Longus Muscle | EXTENSOR POLLICIS LONGUS MUSCLE",,,,,,,,,,,,,,,"4216193","Extensor pollicis longus muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224284","Extensor Pollicis Brevis Muscle","C186114","A muscle in the posterior forearm that originates from the posterior surface of distal third of radius and the adjacent interosseous membrane and attaches to the posterior surface of the base of the proximal phalanx of the thumb; it functions to extend the thumb at the carpometacarpal and metacarpophalangeal joints.","Extensor Pollicis Brevis Muscle | EXTENSOR POLLICIS BREVIS MUSCLE",,,,,,,,,,,,,,,"4243942","Structure of extensor pollicis brevis muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1778368","Extensor Indicis Proprius Muscle","C186113","A muscle in the posterior forearm that originates from the posterior surface of the ulna and attaches to the base of the second proximal phalanx and the tendon of the extensor digitorum muscle; it functions to extend the second digit at metacarpophalangeal and interphalangeal joints.","Extensor Indicis Proprius Muscle | EXTENSOR INDICIS PROPRIUS MUSCLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224466","Extensor Hallucis Longus Muscle","C186112","A muscle in the lower extremity that originates from the middle third of the medial surface of the fibula and the adjacent interosseous membrane and attaches to the base and dorsal center of the distal phalanx of the great toe; it functions to extend the big toe and dorsiflex the ankle.","Extensor Hallucis Longus Muscle | EXTENSOR HALLUCIS LONGUS MUSCLE",,,,,,,,,,,,,,,"4233365","Extensor hallucis longus muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224270","Extensor Digiti Minimi Muscle","C186111","A muscle in the posterior forearm that originates from the lateral epicondyle of the humerus and attaches to the extensor expansion of the fifth digit; it functions to extend the fifth digit at the metacarpophalangeal joint.","Extensor Digiti Minimi Muscle | EXTENSOR DIGITI MINIMI MUSCLE",,,,,,,,,,,,,,,"4313290","Extensor digiti minimi muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0222720","Exoccipital Bone","C186110","The lateral portions of the occipital bone lying on either side of the foramen magnum.","Exoccipital Bone | EXOCCIPITAL BONE",,,,,,,,,,,,,,,"4271856","Structure of lateral part of occipital bone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1778367","Dermal Papillae Of The Face","C186109","Dermal projection on the face, generally associated with whiskers. (Makris S, Solomon HM, Clark R, Shiota K, Barbellion S, Buschmann J, Ema M, Fujiwara M, Grote K, Hazelden KP, Hew KW, Horimoto M, Ooshima Y, Parkinson M, Wise LD. Terminology of developmental abnormalities in common laboratory mammals (Version 2). Part B. Birth Defects Res B Dev Reprod Toxicol. 2009 Aug;86(4):227-327.)","Dermal Papillae of the Face | DERMAL PAPILLAE OF THE FACE | Dermal Papillae Of The Face",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0458396","Cerebellar Lobe","C186108","Any one of the three lobes that make up the cerebellum of the brain.","Cerebellar Lobe | CEREBELLAR LOBE",,,,,,,,,,,,,,,"4078606","Cerebellar lobe structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1778366","Bronchial Stump","C186107","The part of a bronchus that remains after resection.","Bronchial Stump | BRONCHIAL STUMP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0687088","Basisphenoid Bone","C186106","One of the bones of the orbit, situated rostrally to the basilar part of the occipital bone; it is present during fetal development and later fuses to form the anterior portion of the sphenoid bone.","Basisphenoid Bone | BASISPHENOID BONE",,,,,,,,,,,,,,,"4009222","Structure of basisphenoid bone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004814","Basioccipital Bone","C186105","The basilar portion of the occipital bone.","Basioccipital Bone | BASIOCCIPITAL BONE",,,,,,,,,,,,,,,"4144954","Structure of basilar part of occipital bone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017136","Gastric Mucosa","C32656","The mucus membrane lining the inner surface of the stomach.","Gastric Mucosa | GASTRIC MUCOSA | Stomach Mucosa | gastric mucosa | gastric mucous membrane | mucosa of organ of stomach | mucosa of organ of ventriculus | mucosa of stomach | mucosa of ventriculus | mucous membrane of stomach | mucous membrane of ventriculus | organ mucosa of stomach | organ mucosa of ventriculus | stomach mucosa | stomach mucosa of organ | stomach mucous membrane | stomach organ mucosa | tunica mucosa (gaster) | tunica mucosa gastricae | ventriculus mucosa | ventriculus mucosa of organ | ventriculus mucous membrane | ventriculus organ mucosa",,,,,,,,,,,,,"UBERON:0001199","mucosa of stomach","4303072","Gastric mucous membrane structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224548","Fontanelle","C32621","The four gaps in the skull of a neonate or fetus where the sutures converge. The bulging or depression of the membranous soft spots can be indicative of intracranial fluid buildup or systemic dehydration.","Fontanelle | FONTANELLE | Fontanel | Soft Spot",,,,,,,,,,,,,,,"4194058","Structure of fontanel of skull",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011666","Descending Aorta","C32455","The portion of the aorta following the aortic arch passing into the chest and abdomen creating the thoracic and abdominal segments.","Descending Aorta | DESCENDING AORTA",,,,,,,,,,,,,,,"4093066","Descending aorta structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013450","Auditory Ossicle","C32164","The three small bones in the middle ear that transmit acoustic vibrations from the eardrum to the inner ear.","Auditory Ossicle | AUDITORY OSSICLE | BONE, AUDITORY OSSICLES | Bone of Tympanum | Bone of the Tympanum | Ossicles of the Ear",,,,,,,,,,,,,,,"4222565","Ear ossicle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042640","Vibrissae","C186144","Stiff sensory hair that projects outward from the body.","Whiskers | Vibrissa | Vibrissae | WHISKERS | Whisker",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0502420","Cranial Suture","C186143","Fibrous joints between the bones of the skull.","Cranial Suture | SUTURE",,,,,,,,,,,,,,,"4198072|4237248","Joint structure of suture of skull|Suture structure",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0687090","Supraoccipital Bone","C186142","The superior portion of the occipital bone on the dorsal side of the great foramen of the skull; it is present during fetal development and later fuses with the occipital bone.","Supraoccipital Bone | SUPRAOCCIPITAL BONE",,,,,,,,,,,,,,,"4009378","Structure of supraoccipital bone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224275","Supinator Muscle","C186141","A muscle in the posterior forearm that originates from the posterior proximal shaft of ulna and the lateral epicondyle of humerus and attaches to the proximal third of the radius on the anterolateral and posterior surface; it functions to supinate the forearm.","Supinator Muscle | SUPINATOR MUSCLE",,,,,,,,,,,,,,,"4237968","Structure of supinator muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227224","Stomach Wall","C186140","The tissue that forms the wall of the stomach. It consists of mucosa, submucosa, muscular coat, and serosal surface.","Stomach Wall | Gastric Wall | STOMACH WALL",,,,,,,,,,,,,,,"4192362","Stomach wall structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1778722","Spinal Cord Parenchyma","C186139","The parenchyma of the spinal cord, which consists of a canal surrounded by a neuron containing gray matter centrally and white matter containing myelinated nerve tracts peripherally.","Spinal Cord Parenchyma | SPINAL CORD PARENCHYMA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778721","Snout","C186138","The projection on the anterior part of the face that includes the nose or nose and mouth.","Snout | Muzzle | SNOUT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1779136","Parent Data File","C186781","A type of data file that can be subsetted into derived files for analysis and processing.","Parent Data File | Parent File",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224469","Peroneus Longus","C53171","The more superficial of the two muscles (peroneus longus and peroneus brevis) of the lateral compartment of the lower leg, which originates at the superior, lateral shaft of the fibula and inserts on the first metatarsal and the medial cuneiform, functioning to plantar flex and evert the foot, and which supports the lateral, longitudinal, and transverse arches.","Peroneus Longus | PERONEUS LONGUS MUSCLE",,,,,,,,,,,,,,,"4245875","Peroneus longus muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1384497","Tensor Fasciae Lata","C53072","A muscle of the gluteal region that arises from the iliac crest and inserts into the iliotibial tract of the fascia lata; it functions to stabilize the knee in extension and in hip flexion.","Tensor Fasciae Lata | TENSOR FASCIA LATA MUSCLE | TFL Muscle | Tensor Fasciae Latae Muscle",,,,,,,,,,,,,,,"4102152","Structure of tensor fasciae latae muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224425","Gluteus Medius","C52933","One of the three gluteal muscles on the lateral surface of the pelvic bone that abducts and rotates the thigh.","Gluteus Medius | GLUTEUS MEDIUS",,,,,,,,,,,,,,,"4302324","Structure of gluteus medius muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224194","Genioglossus","C52928","A fan shaped muscle running from the underside of the tongue to the mandible which depresses and protrudes the tongue.","Genioglossus | GENIOGLOSSUS MUSCLE",,,,,,,,,,,,,,,"4291480","Structure of genioglossus muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224464","Extensor Digitorum Longus","C52918","A muscle originating at the lateral condyle of the tibia and the upper portion of the anterior margin of the fibula and inserted at the dorsal surface of the proximal, middle and distal phalanges of the second, third, fourth, and fifth toes which controls their extension.","Extensor Digitorum Longus | EXTENSOR DIGITORUM LONGUS MUSCLE | Long Digital Extensor Muscle | MUSCLE, EXTENSOR DIGITORUM LONGUS",,,,,,,,,,,,,,,"4070942","Structure of extensor digitorum longus muscle of foot",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1707982","Extensor Digitorum Communis","C52916","A muscle originating at the lateral epicondyle of the humerus and inserted at the base of the proximal and middle phalanges as well as the base of the distal phalanges which controls the extension of the fingers.","Extensor Digitorum Communis | EXTENSOR DIGITORUM MUSCLE | Extensor Digitorum Muscle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224272","Extensor Carpi Ulnaris","C52914","A muscle originating at the humeral and ulnar heads and inserted at the base of the fifth metacarpal bone that controls the extension and abduction of the wrist toward the ulna.","Extensor Carpi Ulnaris | EXTENSOR CARPI ULNARIS MUSCLE",,,,,,,,,,,,,,,"4014112","Extensor carpi ulnaris muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1708548","Intestinal Wall Tissue","C49478","The tissue that forms the wall of the small and large intestine. It consists of mucosa, submucosa, muscular coat, and serosal surface.","Intestinal Wall Tissue | INTESTINAL WALL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016521","Foramen Ovale of the Fetal Heart","C34241","An opening between the right and left atria in the fetal heart that allows blood to bypass the lungs and flow directly into the systemic circulation.","Foramen Ovale of the Fetal Heart | HEART, FORAMEN OVALE",,,,,,,,,,,,,,,"4298328","Structure of foramen ovale of heart",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041637","Umbilical Vein","C33830","Either of two veins occurring during embryonic development including the right and left umbilical vein.","Umbilical Vein | UMBILICAL VEIN",,,,,,,,,,,,,,,"4279557","Structure of umbilical vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041632","Umbilical Artery","C33827","A pair of arteries occurring during embryonic development that are the continuation of the internal iliac artery which carry deoxygenated blood from the fetus through the umbilical cord to the placenta.","Umbilical Artery | UMBILICAL ARTERY",,,,,,,,,,,,,,,"4196669","Structure of umbilical artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227261","Small Intestinal Mucosa","C33568","Mucosa arranged into two fundamental structures - villi and crypts of Lieberkuhn. Villi are projections into the lumen of the small intestine, covered with simple columnar epithelium. Crypts of Lieberkuhn are moat-like invaginations of the epithelium around the villi that extend through the lamina propria down to the muscularis mucosae. Lymphocytes often invade the epithelium or form solitary lymphoid nodules in the lamina propria. Lymph nodules may form longitudinal aggregations of 30-50 nodules in the lamina propria of the ileum. These large aggregations are called Peyer's patches. The muscularis mucosae has two layers and extends into the intestinal villi, where the smooth muscle cells form a longitudinal bundle in the centre of the villi. The small intestinal mucosa secretes gastrin, somatostatin, cholecystokinin and secretin.","Small Intestinal Mucosa | SMALL INTESTINAL MUCOSA | Small Bowel Mucosa | mucosa of organ of small bowel | mucosa of organ of small intestine | mucosa of small bowel | mucosa of small intestine | mucous membrane of small bowel | mucous membrane of small intestine | organ mucosa of small bowel | organ mucosa of small intestine | small bowel mucosa | small bowel mucosa of organ | small bowel mucous membrane | small bowel organ mucosa | small intestinal mucosa | small intestine mucosa | small intestine mucosa of organ | small intestine mucous membrane | small intestine organ mucosa | tunica mucosa (intestinum tenue) | tunica mucosa intestini tenuis",,,,,,,,,,,,,"UBERON:0001204","mucosa of small intestine","4184481","Small intestine mucous membrane structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519264","Serratus Anterior Muscle","C33540","A large muscle of the axial skeleton, with origin from the first through the eighth or ninth rib, and insertion on the scapula, which is responsible for multiple arm movements, including anteversion of the arm, protraction of the scapula, and stabilization of the scapula against the thoracic wall.","Serratus Anterior Muscle | SERRATUS ANTERIOR MUSCLE | Serratus Magnus",,,,,,,,,,,,,,,"4079622","Structure of serratus anterior muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022666","Renal Papilla","C33460","The tip of a renal pyramid, which delivers urine into a minor calyx.","Renal Papilla | RENAL PAPILLA",,,,,,,,,,,,,,,"4136239","Renal papilla structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030352","Papillary Muscle","C33259","Any one of the group of small muscles located in the ventricles of the heart that insert onto the ventricular wall and are continuous at the opposite end with the chordae tendineae, which insert onto the free edge of the atrioventricular valves, functioning to keep the valves closed during ventricular systole.","Papillary Muscle | MUSCLE, PAPILLARY | PAPILLARY MUSCLE",,,,,,,,,,,,,,,"4147290","Structure of papillary muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0584882","Infraspinatus","C32797","One of the four muscles comprising the rotator cuff that is triangular in shape and extends from the infraspinatus fossa of the scapula to the greater tubercle of the humerus. The infraspinatus muscle extends and rotates the arm laterally.","Infraspinatus | INFRASPINATUS MUSCLE",,,,,,,,,,,,,,,"4219271","Infraspinatus muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1778719","Human rhinovirus A, B, and/or C Antigen Measurement","C186167","The determination of the amount of Human rhinovirus A, B and/or C antigen in a biological sample.","Human rhinovirus A, B, and/or C Antigen Measurement | HRV A/B/C Antigen | HRVABCAG | Human rhinovirus A/B/C Antigen | Human rhinovirus Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0318467","Human rhinovirus A, B, and/or C Measurement","C186166","The determination of the amount of Human rhinovirus A, B and/or C in a biological sample.","Human rhinovirus A, B, and/or C Measurement | HRV A/B/C | HRVABC | Human rhinovirus | Human rhinovirus A/B/C",,,,,,,,,,,,,,,"4085000","Human rhinovirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1778718","Human Papillomavirus E6/E7 mRNA Measurement","C186165","The determination of the amount of human papillomavirus E6 and/or E7 protein-making mRNA in a biological sample.","Human Papillomavirus E6/E7 mRNA Measurement | HPVE67MR | Human Papillomavirus E6/E7 Messenger RNA | Human Papillomavirus E6/E7 mRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778717","Human Parainfluenza Virus 3 Antigen Measurement","C186164","The determination of the amount of Human parainfluenza virus 3 antigen in a biological sample.","Human Parainfluenza Virus 3 Antigen Measurement | HPIV3AG | Human Parainfluenza Virus 3 Antigen | Human Respirovirus 3 Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778716","Human Parainfluenza Virus 2 Antigen Measurement","C186163","The determination of the amount of Human parainfluenza virus 2 antigen in a biological sample.","Human Parainfluenza Virus 2 Antigen Measurement | HPIV2AG | Human Orthorubulavirus 2 Antigen | Human Parainfluenza Virus 2 Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778715","Human Parainfluenza Virus 1 Measurement","C186162","The determination of the amount of Human parainfluenza virus 1 in a biological sample.","Human Parainfluenza Virus 1 Measurement | HPIV1 | Human Parainfluenza Virus 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778714","Human Parainfluenza Virus 1, 2, and/or 3 RNA Measurement","C186161","The determination of the amount of RNA from the Human Parainfluenza virus 1, 2, and/or 3 in a biological sample.","Human Parainfluenza Virus 1, 2, and/or 3 RNA Measurement | HP123RNA | Human Parainfluenza Virus 1/2/3 RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778713","Human Parainfluenza Virus 1, 2, and/or 3 Antigen Measurement","C186160","The determination of the amount of Human Parainfluenza virus 1, 2, and/or 3 antigen in a biological sample.","Human Parainfluenza Virus 1, 2, and/or 3 Antigen Measurement | HP123AG | Human Parainfluenza Virus 1/2/3 Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778712","Human Parainfluenza Virus 1, 2, 3, and/or 4 RNA Measurement","C186159","The determination of the amount of RNA from the Human Parainfluenza virus 1, 2, 3 and/or 4 in a biological sample.","Human Parainfluenza Virus 1, 2, 3, and/or 4 RNA Measurement | HP1234RN | Human Parainfluenza Virus 1/2/3/4 RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778711","Human Metapneumovirus Antigen Measurement","C186158","The determination of the amount of Human metapneumovirus antigen in a biological sample.","Human Metapneumovirus Antigen Measurement | HMPVAG | Human Metapneumovirus Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778710","Haemophilus influenzae DNA Measurement","C186157","The determination of the amount of Haemophilus influenza virus DNA in a biological sample.","Haemophilus influenzae DNA Measurement | HINDNA | Haemophilus influenzae DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778709","Hepatitis D Virus RNA Measurement","C186156","The determination of the amount of hepatitis D virus RNA in a biological sample.","Hepatitis D Virus RNA Measurement | HDVRNA | Hepatitis D Virus RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778708","Giardia DNA Measurement","C186155","The determination of the amount of DNA from any member of the genus Giardia in a biological sample.","Giardia DNA Measurement | GIARDDNA | Giardia DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778707","Enterovirus RNA Measurement","C186154","The determination of the amount of RNA from any member of the genus Enterovirus in a biological sample.","Enterovirus RNA Measurement | ENTRNA | Enterovirus RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778706","Escherichia coli K1 DNA Measurement","C186153","The determination of the amount of Escherichia coli K1 DNA in a biological sample.","Escherichia coli K1 DNA Measurement | ECOK1DNA | Escherichia coli K1 DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778730","Dientamoeba fragilis DNA Measurement","C186152","The determination of the amount of Dientamoeba fragilis DNA in a biological sample.","Dientamoeba fragilis DNA Measurement | DFRDNA | Dientamoeba fragilis DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778729","Chlamydia Trachomatis RNA Measurement","C186151","The determination of the amount of Chlamydia trachomatis RNA in a biological sample.","Chlamydia Trachomatis RNA Measurement | CTRRNA | Chlamydia trachomatis RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778728","Cryptococcus neoformans and/or gattii DNA Measurement","C186150","A measurement of Cryptococcus neoformans and/or Cryptococcus gattii DNA in a biological sample.","Cryptococcus neoformans and/or gattii DNA Measurement | CNEGADNA | Cryptococcus neoformans/gattii DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778727","Campylobacter jejuni Measurement","C186149","The determination of the amount of Campylobacter jejuni in a biological sample.","Campylobacter jejuni Measurement | CJE | Campylobacter jejuni",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778726","Campylobacter coli Measurement","C186148","The determination of the amount of Campylobacter coli in a biological sample.","Campylobacter coli Measurement | CCO | Campylobacter coli",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778725","Campylobacter DNA Measurement","C186147","The determination of the amount of DNA from any member of the genus Campylobacter in a biological sample.","Campylobacter DNA Measurement | CAMPYDNA | Campylobacter DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778724","Bordetella Parapertussis DNA Measurement","C186146","The determination of the amount of Bordetella parapertussis DNA in a biological sample.","Bordetella Parapertussis DNA Measurement | BPADNA | Bordetella parapertussis DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778723","Blastocystis hominis DNA Measurement","C186145","The determination of the amount of Blastocystis hominis DNA in a biological sample.","Blastocystis hominis DNA Measurement | BHODNA | Blastocystis hominis DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778737","Varicella Zoster Virus DNA Measurement","C186192","The determination of the amount of Varicella Zoster virus DNA in a biological sample.","Varicella Zoster Virus DNA Measurement | VZVDNA | Varicella Zoster Virus DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778736","Vancomycin-resistant Enterococcus Measurement","C186191","The determination of the amount of organisms that are vancomycin-resistant, and are not assigned to the species level but are assigned to the Enterococcus genus level in a biological sample.","Vancomycin-resistant Enterococcus Measurement | Enterococcus, Vancomycin-resistant | VRE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778735","Trichomonas vaginalis DNA Measurement","C186190","The determination of the amount of Trichomonas vaginalis DNA in a biological sample.","Trichomonas vaginalis DNA Measurement | TVADNA | Trichomonas vaginalis DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778733","SARS-CoV-2 RdRp RNA Measurement","C186188","The determination of the amount of SARS-CoV-2 RdRp RNA in a biological sample.","SARS-CoV-2 RdRp RNA Measurement | SARS-CoV-2 RNA-dependent RNA Polymerase RNA | SARS-CoV-2 RdRp Gene | SARS-CoV-2 RdRp RNA | SR2RDRPR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778732","Streptococcus pneumoniae DNA Measurement","C186187","A measurement of Streptococcus pneumoniae DNA in a biological sample.","Streptococcus pneumoniae DNA Measurement | SPNDNA | Streptococcus pneumoniae DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1779371","Shigella and/or Enteroinvasive Escherichia coli DNA Measurement","C186186","The determination of the amount of organisms that are not assigned to the species level but are assigned to the Shigella genus level and/or enteroinvasive Escherichia coli in a biological sample.","Shigella and/or Enteroinvasive Escherichia coli DNA Measurement | SHIGEIEC | Shigella/EIEC | Shigella/Enteroinvasive E. coli | Shigella/Enteroinvasive Escherichia coli",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778731","Staphylococcus haemolyticus Measurement","C186185","The determination of the amount of Staphylococcus haemolyticus in a biological sample.","Staphylococcus haemolyticus Measurement | SHA | Staphylococcus haemolyticus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778759","Staphylococcus aureus DNA Measurement","C186184","The determination of the amount of Staphylococcus aureus DNA in a biological sample.","Staphylococcus aureus DNA Measurement | SAUDNA | Staphylococcus aureus DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778758","Salmonella DNA Measurement","C186183","The determination of the amount of DNA from any member of the genus Salmonella in a biological sample.","Salmonella DNA Measurement | SALMODNA | Salmonella DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778757","Streptococcus agalactiae DNA Measurement","C186182","The determination of the amount of Streptococcus agalactiae DNA in a biological sample.","Streptococcus agalactiae DNA Measurement | SAGDNA | Streptococcus agalactiae DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778756","Respiratory Syncytial Virus RNA Measurement","C186181","The determination of the amount of respiratory syncytial virus RNA in a biological sample.","Respiratory Syncytial Virus RNA Measurement | RSVRNA | Respiratory Syncytial Virus RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778755","Rotavirus RNA Measurement","C186180","The determination of the amount of RNA from any member of the genus Rotavirus in a biological sample.","Rotavirus RNA Measurement | ROTRNA | Rotavirus RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778754","Pneumocystis jiroveci Antigen Measurement","C186179","The determination of the amount of Pneumocystis jiroveci antigen in a biological sample.","Pneumocystis jiroveci Antigen Measurement | PJIAG | Pneumocystis jiroveci Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778753","Parechovirus RNA Measurement","C186178","The determination of the amount of RNA from any member of the genus Parechovirus in a biological sample.","Parechovirus RNA Measurement | PARECRNA | Parechovirus RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778752","Neisseria meningitidis DNA Measurement","C186177","A measurement of Neisseria meningitidis DNA in a biological sample.","Neisseria meningitidis DNA Measurement | NMEDNA | Neisseria meningitidis DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778751","Neisseria gonorrhoeae RNA Measurement","C186176","The determination of the amount of Neisseria gonorrhoeae RNA in a biological sample.","Neisseria gonorrhoeae RNA Measurement | NGORNA | Neisseria gonorrhoeae RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778750","Neisseria gonorrhoeae DNA Measurement","C186175","The determination of the amount of Neisseria gonorrhoeae DNA in a biological sample.","Neisseria gonorrhoeae DNA Measurement | NGODNA | Neisseria gonorrhoeae DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778749","Mycobacterium Measurement","C186174","The determination of the amount of organisms that are not assigned to the species level but are assigned to the Mycobacterium genus level in a biological sample.","Mycobacterium Measurement | MYCOBACT | Mycobacterium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778748","Listeria monocytogenes DNA Measurement","C186173","The determination of the amount of Listeria monocytogenes DNA in a biological sample.","Listeria monocytogenes DNA Measurement | LSMDNA | Listeria monocytogenes DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778747","Legionella pneumophila DNA Measurement","C186172","The determination of the amount of Legionella pneumophila DNA in a biological sample.","Legionella pneumophila DNA Measurement | LPNDNA | Legionella pneumophila DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778746","Legionella pneumophila Measurement","C186171","The determination of the amount of Legionella pneumophila in a biological sample.","Legionella pneumophila Measurement | LPN | Legionella pneumophila",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778745","Herpes Simplex Virus 2 DNA Measurement","C186170","The determination of the amount of Herpes simplex virus 2 DNA in a biological sample.","Herpes Simplex Virus 2 DNA Measurement | HS2DNA | Herpes Simplex Virus 2 DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778744","Herpes Simplex Virus 1 DNA Measurement","C186169","The determination of the amount of herpes simplex virus 1 DNA in a biological sample.","Herpes Simplex Virus 1 DNA Measurement | HS1DNA | Herpes Simplex Virus 1 DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1778720","Herpes Simplex Virus 1 and/or 2 Antigen Measurement","C186168","The determination of the amount of herpes simplex virus 1 and/or 2 antigen in a biological sample.","Herpes Simplex Virus 1 and/or 2 Antigen Measurement | HS12AG | HSV 1/2 Antigen | Herpes Simplex Virus 1/2 Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1615608","Pandemics","C171519","An epidemic occurring worldwide, or over a very wide area, crossing international boundaries, and usually affecting a large number of people. (A dictionary of epidemiology, edited for the International Epidemiological Association by John M. Last, Oxford University Press 2001)","Pandemic Disorder | Pandemic | Pandemic Disease | pandemic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889831","eTMF Content Model Code","C115478","A designation for use within the eTMF content model.","eTMF Content Model Code | Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3842434","Tagalog Language","C154164","An Austronesian language spoken as a first language by a quarter of the population of the Philippines and as a second language by the majority.","Tagalog Language | TGL | Tagalog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1773575","Central","C185326","Conducts reviews on behalf of all study sites that agree to participate in the centralized review process with imaging experts.","Central Imaging Review | Central | Central Review",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1792047","Childhood Acute Leukemia","C187056","An acute leukemia that occurs during childhood.","Childhood Acute Leukemia | Pediatric Acute Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1662455","Biospecimen Shipping","C179747","The act or process of the logistical considerations for transporting a biological sample from the sender to the receiver.","Biospecimen Shipping | Biological Sample Shipment | Biological Sample Shipping | Biological Sample Transport | Specimen Ship",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449705","Specimen Anatomic Site","C171435","The anatomic site from which a biospecimen was obtained.","Specimen Anatomic Site | Biospecimen Anatomic Location | Biospecimen Anatomic Site | Sample Anatomic Location | Sample Anatomic Site | Sample Anatomic Site | Sample Source | Source of Submitted Specimen | Specimen Anatomic Location | Specimen Anatomic Site | Specimen Source | Specimen Source Site | biospecimen anatomic site | biospecimen_anatomic_site | sample site | sample_site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1792939","Manifest","C187058","A list of passengers, cargo, or goods.","Manifest | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1792038","Ready to Ship","C187059","A status indicating that something is ready to be transported.","Ready to Ship | Ready to ship",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1792039","Leukapharesis Specimen","C187060","A biospecimen that has been obtained by leukapharesis.","Leukapharesis Specimen | Leukapharesis Sample",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1792037","Lung Fluid Specimen","C187061","A biospecimen consisting of fluid obtained from within the lungs.","Lung Fluid Specimen | Lung Fluid | Lung Fluid Sample",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0438732","Pericardial Fluid Specimen","C187062","A biospecimen consisting of fluid obtained from within the pericardial sac.","Pericardial Fluid Specimen | Pericardial Fluid Sample | Pericardial fluid",,,,,,,,,,,,,,,"4048848","Pericardial fluid specimen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1792035","Buccal Swab Collection Tube","C187063","A collection tube used for storage, transport, and subsequent sample preparation of buccal swabs. They usually contain a solution designed to stabilize the sample.","Buccal Swab Collection Tube | Buccal swab collection tube",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1792036","Block Cassette","C187064","A device used to hold tissue block specimens during embedding, processing, and storage.","Block Cassette | Block cassette | Tissue Block Cassette",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1792046","Slide Cassette","C187065","A device used to hold slide specimens during staining, processing, and storage.","Slide Cassette | Slide cassette",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1792943","United Parcel Service","C187066","An American shipping, receiving, and supply chain management company.","United Parcel Service | UPS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1792044","Federal Express","C187067","An American shipping and receiving company originally known for their overnight air delivery service.","Federal Express | FedEx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1792045","DHL","C187068","A German logistics company providing courier, package delivery, and express mail services.","DHL | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1792042","Frozen on Dry Ice","C187069","A sample that is shipped in a frozen state maintained with dry ice.","Frozen on Dry Ice | Frozen dry ice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1792043","Frozen Shipper","C187070","An insulated shipping container designed to maintain frozen temperature ranges during transit.","Frozen Shipper | Frozen shipper",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1792040","Pre-enrollment","C187071","The period prior to enrollment.","Pre-enrollment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL365909","Buccal Cells","C172264","A sample comprised of cells collected from the inside of a subject's cheek.","Buccal Cell Sample | Buccal Cell | Buccal Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416647","KIR2DS1 Gene","C106092","This gene plays a role in the regulation of immune responses.","KIR2DS1 Gene | KIR2DS1 | Killer Cell Immunoglobulin-Like Receptor, Two Domains, Short Cytoplasmic Tail, 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1579319","Pneumococcal Conjugate Vaccine","C97123","An active immunizing vaccine used to prevent infection by the bacterium Streptococcus pneumoniae. It consists of a solution of saccharides of the capsular antigens of Streptococcus serotypes individually conjugated to proteins.","Pneumococcal Conjugate Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951718","Obese","C159658","Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.","Obese | Obesity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024225","Lymphangitis","C34790","Inflammation of the lymphatic vessels.","Lymphangitis | ",,,,,,,,,,,,,,,"439840","Lymphangitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1792002","Endobronchial Nodule","C187081","A nodule entirely contained within a bronchus; it may obstruct the airway, but does not breach the bronchial wall.","Endobronchial Nodule | Purely Endobronchial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1792958","Subpleural Nodule","C187082","A nodule that is directly underlying a pleural surface though there may be separation between the nodule margin and pleura.","Subpleural Nodule | Subpleural",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1442458","Half Hour","C69108","A unit of time is equal to 0.5 hour or 30 minutes.","Half Hour | 1/2 hr | 30 min | 30 minutes",,,,,,,,,,,,,,,"759870","Thirty minutes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3272303","Paced Ventricular Rhythm without Intrinsic Ventricular Complexes","C100061","An electrocardiographic finding that the cardiac rhythm is initiated by a cardiac pacemaker generated electrical impulse in the ventricle. Intrinsic ventricular complexes are absent.","Paced Ventricular Rhythm without Intrinsic Ventricular Complexes | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1955779","Chronic Total Coronary Artery Occlusion","C100062","Prolonged complete obstruction of the coronary artery. (ACC)","Chronic Total Coronary Artery Occlusion | ",,,,,,,,,,,,,,,"36712779","Chronic total occlusion of coronary artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0440761","Coronary Artery Graft","C100064","A vessel segment attached to a coronary artery to facilitate myocardial perfusion. (ACC)","Coronary Artery Graft | ",,,,,,,,,,,,,,,"4136419","Coronary artery graft",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3272306","Coronary Lesion Complexity","C100066","Characteristics of coronary lesions that contribute to procedural risk during coronary intervention.","Coronary Lesion Complexity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162563","Cardiac Ablation","C100068","A procedure intended to eliminate or modify a focus or re-entry circuit that causes an arrhythmia in the heart. (ACC)","Cardiac Ablation | ABLATION, CARDIAC | Catheter ablation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272308","Cardiac Valve Injury","C100069","An event causes abnormal valve function; this is usually a tear in leaflet or chordae tendinae and manifests as a new regurgitant. (ACC)","Cardiac Valve Injury | ",,,,,,,,,,,,,,,"42538803","Injury of cardiac valve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3272309","Coronary Venous Dissection","C100070","A tear within the wall of a coronary vein. (ACC)","Coronary Venous Dissection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1536105","Cardiac Computerized Tomographic Angiography","C100071","An imaging technique of the heart and neighboring structures involving helical computed tomography and computer software to generate high-resolution 2-dimensional and 3-dimensional images. (ACC)","Cardiac Computerized Tomographic Angiography | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1384495","Cardiac Stress Test","C100073","The use of physical activity to elicit signs and symptoms of myocardial ischemia. (ACC)","Cardiac Stress Test | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272312","Cardiac Ischemic Risk Score","C100074","The relative risk of developing ischemia determined by a cardiac stress test. (ACC)","Cardiac Ischemic Risk Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272313","Non-Invasive Cardiac Stress Test","C100075","Procedures intended to evaluate cardiac function without insertion of intravascular equipment into the central circulation. (ACC)","Non-Invasive Cardiac Stress Test | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272314","Luminal Carotid Thrombus","C100077","A blood clot (thrombus) in the lumen of the carotid artery. (ACC)","Luminal Carotid Thrombus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0302836","Smoking tobacco","C100079","Tobacco that is inhaled or puffed from a lit cigar, cigarette or pipe. (ACC)","Smoking Tobacco | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272316","Cardiac Stent Placement","C100080","A procedure performed during a percutaneous coronary intervention in which a device is deployed into the lumen of a coronary artery to expand and support the vessel wall such that the vessel remains patent and blood flow is uninhibited.","Cardiac Stent Placement | CARDIAC STENT PLACEMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272260","Staged Percutaneous Coronary Intervention","C100015","A subsequent Percutaneous Coronary Intervention in a planned series of procedures, where the first PCI could have been during a prior admission, or during this admission. (ACC)","Staged Percutaneous Coronary Intervention | STAGED PERCUTANEOUS CORONARY INTERVENTION (PCI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272261","Subject Delay in Providing Consent","C100016","The subject has not provided consent in a timely manner for the procedure to take place. (ACC)","Subject Delay in Providing Consent | Patient Delay in Providing Consent | SUBJECT DELAY IN PROVIDING CONSENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272262","Surgical Maze Procedure","C100017","A cardiac procedure intended to inhibit atrial fibrillation, in which a series of incisions are made in the atria to block abnormal electrical circuits that contribute to atrial fibrillation. (ACC)","Surgical Maze Procedure | Cox Maze | SURGICAL MAZE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272263","Syncope with High Risk Cardiac Characteristics","C100018","A sudden loss of consciousness with loss of postural tone not related to anesthesia with high risk characteristics. High risk characteristics include non-ischemic dilated cardiomyopathy, or ischemic heart disease with significant ventricular dysfunction, hypertrophic cardiomyopathy, Brugada Syndrome, or Long QT Syndrome. (ACC)","Syncope with High Risk Cardiac Characteristics | SYNCOPE WITH HIGH RISK CHARACTERISTICS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272264","Syncope with Inducible Ventricular Tachycardia by ECG Finding","C100019","An electrocardiographic finding of ventricular tachycardia accompanied by syncope in the individual.","Syncope with Inducible Ventricular Tachycardia by ECG Finding | SYNCOPE WITH INDUCIBLE VENTRICULAR TACHYCARDIA | Syncope with Inducible Ventricular Tachycardia | Syncope with Inducible Ventricular Tachycardia by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279326","cyclophosphamide/doxorubicin/melphalan/vincristine","C10001","A regimen consisting of cyclophosphamide, vincristine, melphalan, and doxorubicin for the treatment of osteosarcoma.","CONPADRI-I Regimen | CONPADRI-I | COPADRI-I | CTX/DOX/L-PAM/VCR | Cyclophosphamide-Vincristine-Melphalan-Doxorubicin | Cyclophosphamide/Doxorubicin/Melphalan/Vincristine | Cyclophosphamide/Oncovin/Phenylalanine Nitrogen Mustard/Adriamycin | Cyclophosphamide/Vincristine/Melphalan/Doxorubicin | Cyclophosphamide/Vincristine/Melphalan/Doxorubicin Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272265","Three Vessel Coronary Disease","C100020","There was greater than or equal to 50% stenosis (reduction in cross-sectional area) in three coronary arteries (or greater than or equal to 50% stenosis in the left main coronary artery and greater than or equal to 50% stenosis in the right coronary artery). (ACC)","Three Vessel Coronary Disease | THREE VESSEL DISEASE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272266","Thrombolysis in Myocardial Infarction Flow","C100021","A grading system for coronary blood flow based on the classification developed by the Thrombolysis in Myocardial Infarction Group. It classifies coronary blood flow into four classes based upon the angiographic appearance of the blood vessels. (ACC)","Thrombolysis in Myocardial Infarction Flow | TIMI Flow | TIMIFLOW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3509486","Transcatheter Aortic Valve Implantation","C100022","Use of a thin tube to deliver an artificial valve apparatus between the left ventricle of the heart and the aorta. (ACC)","Transcatheter Aortic Valve Implantation | TRANSCATHETER AORTIC VALVE IMPLANT",,,,,,,,,,,,,,,"36676805","Transcatheter aortic valve implantation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0581375","Two Vessel Coronary Disease","C100023","There was greater than or equal to 50% stenosis (reduction in cross-sectional area) in two coronary arteries (or greater than or equal to 50% stenosis in the left main coronary artery). (ACC)","Two Vessel Coronary Disease | TWO VESSEL DISEASE",,,,,,,,,,,,,,,"4108673","Double coronary vessel disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3272269","Unable to Obtain Acceptable Pacing Thresholds","C100025","The coronary sinus / left ventricular lead was not implanted because the operator was unable to obtain acceptable pacing thresholds. (ACC)","Unable to Obtain Acceptable Pacing Thresholds | COULD NOT OBTAIN ACCEPTABLE PACING THRESHOLDS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272270","Unable to Obtain Satisfactory Coronary Sinus Access","C100026","The coronary sinus / left ventricular lead was not implanted because the operator was unable to obtain satisfactory coronary sinus access. (ACC)","Unable to Obtain Satisfactory Coronary Sinus Access | UNABLE TO OBTAIN SATISFACTORY CORONARY SINUS ACCESS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272271","Unable to Obtain Satisfactory Vascular Access","C100027","The coronary sinus / left ventricular lead was not implanted because the operator was unable to obtain satisfactory vascular access. (ACC)","Unable to Obtain Satisfactory Vascular Access | UNABLE TO OBTAIN SATISFACTORY VASCULAR ACCESS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272272","Unable to Position Lead Due to Coronary Sinus Dissection","C100028","The coronary sinus / left ventricular lead was not implanted because the coronary sinus was dissected. (ACC)","Unable to Position Lead Due to Coronary Sinus Dissection | UNABLE TO POSITION LEAD DUE TO CORONARY SINUS DISSECTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272273","Unable to Position Lead In tributary Vein of Coronary Sinus","C100029","The coronary sinus / left ventricular lead was not implanted because the operator was unable to position the lead in the tributary vein of the coronary sinus. (ACC)","Unable to Position Lead In tributary Vein of Coronary Sinus | UNABLE TO POSITION LEAD IN TRIBUTARY VEIN OF CORONARY SINUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272274","Upgrade to Cardiac Device with Additional Pacing Capabilities","C100030","A device with additional pacing capabilities is replacing the current device. (ACC)","Upgrade to Cardiac Device with Additional Pacing Capabilities | UPGRADE TO A DEVICE WITH ADDITIONAL PACING CAPABILITIES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272276","American College of Cardiology/American Heart Association Lesion Complexity Class","C100032","A classification system for coronary stenosis based upon characteristics that influence the difficulty of percutaneous coronary revascularization. (ACC)","American College of Cardiology/American Heart Association Lesion Complexity Class | ACC/AHA Lesion Complexity Class | LSNCPCLS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272277","Cardiac Arrest/Arrhythmia Etiology Unknown","C100033","An episode of cardiac arrest or arrhythmia where the etiology was unknown. (ACC)","Cardiac Arrest/Arrhythmia Etiology Unknown | CARDIAC ARREST/ARRHYTHMIA ETIOLOGY UNKNOWN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272278","Cardiac Lead Dislodgement Requiring Reposition/Reoperation","C100034","The movement (macroscopic or microscopic) of an existing lead within the heart or vascular tree away from the original implantation site. (ACC)","Cardiac Lead Dislodgement Requiring Reposition/Reoperation | LEAD DISLODGEMENT REQUIRING REPOSITION/REOPERATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272279","Faulty Device Connector/Header","C100035","There is a faulty connector/header in the device. (ACC)","Faulty Device Connector/Header | FAULTY CONNECTOR/HEADER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272280","Idiopathic Primary Ventricular Tachycardia/Ventricular Flutter by ECG Finding","C100036","An electrocardiographic finding of ventricular tachycardia or ventricular fibrillation of unknown cause. (ACC)","Idiopathic Primary Ventricular Tachycardia/Ventricular Flutter by ECG Finding | IDIOPATHIC PRIMARY VENTRICULAR TACHYCARDIA/VENTRICULAR FLUTTER | Idiopathic Primary Ventricular Tachycardia/Ventricular Flutter | Idiopathic Primary Ventricular Tachycardia/Ventricular Flutter by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272281","American College of Cardiology/American Heart Association Lesion Complexity Score A","C100037","Discrete (less than 10 mm length) and concentric and readily accessible and non-angulated segment less than 45 degrees and smooth contour and little or no calcification and less than totally occlusive and not ostial in location and no major branch involvement and absence of thrombus. (ACC)","American College of Cardiology/American Heart Association Lesion Complexity Score A | ACC/AHA LESION COMPLEXITY SCORE A | ACC/AHA Lesion Complexity Score A | Low Risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272282","American College of Cardiology/American Heart Association Lesion Complexity Score B","C100038","Tubular (10-20 mm length) or eccentric or moderate tortuosity of proximal segment or moderately angulated segment, 45-90 degrees or irregular contour or moderate to heavy calcification or ostial in location or bifurcation lesions requiring double guidewires or some thrombus present or total occlusion less than 3 months old. (ACC)","American College of Cardiology/American Heart Association Lesion Complexity Score B | ACC/AHA LESION COMPLEXITY SCORE B | ACC/AHA Lesion Complexity Score B | Medium Risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272283","American College of Cardiology/American Heart Association Lesion Complexity Score C","C100039","Diffuse (length greater than 2cm) or excessive tortuosity of proximal segment or extremely angulated segments greater than 90 degrees or total occlusions greater than 3 months old and/or bridging collaterals or inability to protect major side branches or degenerated vein grafts with friable lesions. (ACC)","American College of Cardiology/American Heart Association Lesion Complexity Score C | ACC/AHA LESION COMPLEXITY SCORE C | ACC/AHA Lesion Complexity Score C | High Risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272284","Thrombolysis in Myocardial Infarction Flow-0","C100040","No perfusion: No antegrade flow beyond the point of occlusion. (www.TIMI.org accessed 21SEP2011) (ACC)","Thrombolysis in Myocardial Infarction Flow-0 | TIMI 0 | TIMI Flow-0 | TIMI GRADE 0 | Thrombolysis in Myocardial Infarction Flow - 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272285","Thrombolysis in Myocardial Infarction Flow-1","C100041","Penetration without perfusion: The contrast material passes beyond the area of obstruction, but fails to opacify the entire coronary bed distal to the obstruction for the duration of the cine run.  (www.TIMI.org accessed 21SEP2011) (ACC)","Thrombolysis in Myocardial Infarction Flow-1 | TIMI 1 | TIMI Flow-1 | TIMI GRADE 1 | Thrombolysis in Myocardial Infarction Flow - 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272287","Thrombolysis in Myocardial Infarction Flow-3","C100043","Complete perfusion: Antegrade flow into the bed distal to the obstruction occurs as promptly as into the bed proximal to the obstruction and clearance of contrast material from the involved bed is as rapid as from an uninvolved bed in the same vessel or the opposite artery. (www.TIMI.org accessed 21SEP2011) (ACC)","Thrombolysis in Myocardial Infarction Flow-3 | TIMI 3 | TIMI Flow-3 | TIMI GRADE 3 | Thrombolysis in Myocardial Infarction Flow - 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272288","Pulmonic Valvuloplasty","C100044","Dilation of the valve between the right ventricle and the pulmonary artery of the heart by inflating a balloon. (ACC)","Pulmonic Valvuloplasty | PULMONIC VALVULOPLASTY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272289","Manufacturer Recall","C100045","An imperative issued by the manufacturer of a device that the device needs to be returned to a designated source for repair or replacement. (ACC)","Manufacturer Recall | MANUFACTURER RECALL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433438","Evaux Spring Water-based Topical Spray","C100046","A skin spray composed of Evaux thermal spring water, the emulsifier polysorbate 20, the preservatives phenoxyethanol and chlorphenesin, zinc gluconate, and the moisturizer caprylyl glycol with prophylactic and calming activity. Evaux thermal spring water is rich in mineral elements particularly of lithium, strontium and manganese.  When sprayed directly onto the skin or scalp, this topical spray may have a calming, moisturizing, healing and nurturing effect. This agent may prevent or decrease skin rashes associated with the administration of EGFR inhibitors or with radiochemotherapy-induced skin reactions.","Evaux Spring Water-based Topical Spray | Evozac | Spring Water/Polysorbate 20/Phenoxyethanol/Zinc Gluconate/Caprylyl Glycol/Chlorphenesin Topical Spray",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272294","Needle Free Injection","C100050","A drug delivery system that permits injection of a liquid medication subcutaneously without the use of a needle.","Needle Free Injection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272296","Needle Free Injection Dosing Unit","C100052","A dosing unit equal to the amount of active ingredient(s) contained in a single needle free injection unit.","Needle Free Injection Dosing Unit | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272297","Sinus Node Functional Assessment","C100053","Description of electrical activity and conduction involving the sinoatrial node. (ACC)","Sinus Node Functional Assessment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272317","In Stent Restenosis","C100081","Fifty percent or greater stenosis within an existing stent. (ACC)","In Stent Restenosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272246","Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction-Stable After Successful Full-Dose Thrombolytic Therapy","C100001","A percutaneous coronary intervention is necessary for a myocardial infarction that presents with ST segment elevation and the subject does not have recurrent or persistent symptoms, symptoms of heart failure or ventricular arrhythmia after a successful dose of thrombolytic therapy. (ACC)","Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction-Stable After Successful Full-Dose Thrombolytic Therapy | PERCUTANEOUS CORONARY INTERVENTION (PCI) FOR ST ELEVATION MYOCARDIAL INFARCTION (STEMI) (STABLE AFTER SUCCESSFUL FULL-DOSE THROMBOLYTICS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272247","Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction-Unstable-Over 12 Hours From Symptom Onset","C100002","A percutaneous coronary intervention is necessary for a myocardial infarction that presents with ST segment elevation and the subject has recurrent or persistent symptoms, symptoms of heart failure or ventricular arrhythmia. The presentation is past twelve hours since onset of symptoms. (ACC)","Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction-Unstable-Over 12 Hours From Symptom Onset | PERCUTANEOUS CORONARY INTERVENTION (PCI) FOR ST ELEVATION MYOCARDIAL INFARCTION (STEMI) (UNSTABLE, >12 HRS FROM SYMPTOM ONSET)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272248","Percutaneous Mitral Valve Repair","C100003","Invasive procedure through a puncture in the skin, performed for the purpose of reducing regurgitation of the mitral valve. (ACC)","Percutaneous Mitral Valve Repair | PERCUTANEOUS MITRAL REPAIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272249","Pericardial Stripping","C100004","Removal or resection of the pericardium. (ACC)","Pericardial Stripping | PERICARDIAL STRIPPING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272250","Post-Cardiac Transplant Evaluation","C100005","A procedure to evaluate the health of the an individual after receiving a heart transplant. (ACC)","Post-Cardiac Transplant Evaluation | POST-CARDIAC TRANSPLANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272251","Pre-Operative Evaluation for Non-Cardiovascular Surgery","C100006","A procedure to evaluate the health of the cardiac system to determine feasibility of a non-cardiac related surgical procedure. (ACC)","Pre-Operative Evaluation for Non-Cardiovascular Surgery | PRE-OPERATIVE EVALUATION FOR NON-CARDIOVASCULAR SURGERY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272252","Previously Implanted Cardiac Lead","C100007","The coronary sinus / left ventricular lead was not implanted because a lead had been previously implanted. (ACC)","Previously Implanted Cardiac Lead | PREVIOUSLY IMPLANTED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272254","Reused Cardiac Lead","C100009","The cardiac lead has been left in situ and reused. (ACC)","Reused Cardiac Lead | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272255","Right Cardiac Ventricle Assist Device Procedure","C100010","A procedure involving a mechanical pump which receives blood from the right ventricle and delivers it to the pulmonary artery. (ACC)","Right Cardiac Ventricle Assist Device Procedure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272256","Right Cardiac Ventricle Pacing Malfunction","C100011","The cardiac rhythm device malfunction affected the right ventricular (RV) pacing. (ACC)","Right Cardiac Ventricle Pacing Malfunction | RIGHT VENTRICULAR PACING MALFUNCTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272257","Severe Cardiac Valve Regurgitation","C100012","Evidence of severe retrograde blood flow through the valve(s) of the heart. (ACC)","Severe Cardiac Valve Regurgitation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272258","Severe Cardiac Valve Stenosis","C100013","The cardiac valve orifice is abnormally narrow, to a severe degree. (ACC)","Severe Cardiac Valve Stenosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272259","Spontaneous Sustained Ventricular Tachycardia by ECG Finding","C100014","An electrocardiographic finding of ventricular tachycardia that occurs without provocation and does not resolve without intervention.","Spontaneous Sustained Ventricular Tachycardia by ECG Finding | SPONTANEOUS SUSTAINED VENTRICULAR TACHYCARDIA | Spontaneous Sustained Ventricular Tachycardia | Spontaneous Sustained Ventricular Tachycardia by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639130","CDISC Questionnaire NPI Test Name Terminology","C100143","Test names of questionnaire questions associated with the neuropsychiatric inventory (NPI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire NPI Test Name Terminology | NPI1TN | Neuropsychiatric Inventory Questionnaire Test Name | QS-NPI TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639131","CDISC Questionnaire NPI Test Code Terminology","C100144","Test codes of questionnaire questions associated with the neuropsychiatric inventory (NPI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire NPI Test Code Terminology | NPI1TC | Neuropsychiatric Inventory Questionnaire Test Code | QS-NPI TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639132","CDISC Questionnaire PDQUALIF Test Name Terminology","C100145","Test names of questionnaire questions associated with the Parkinson's disease quality of life scale (PDQUALIF) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire PDQUALIF Test Name Terminology | QS-PDQUALIF TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639133","CDISC Questionnaire PDQUALIF Test Code Terminology","C100146","Test codes of questionnaire questions associated with the Parkinson's disease quality of life scale (PDQUALIF) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire PDQUALIF Test Code Terminology | QS-PDQUALIF TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639134","QS-UPDRS TEST","C100147","Test names of clinical classification questions associated with the unified parkinson's disease rating scale (UPDRS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification UPDRS Test Name Terminology | QS-UPDRS TEST | UPD1TN | Unified Parkinson's Disease Rating Scale Clinical Classification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639135","QS-UPDRS TESTCD","C100148","Test codes of clinical classification questions associated with the unified parkinson's disease rating scale (UPDRS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification UPDRS Test Code Terminology | QS-UPDRS TESTCD | UPD1TC | Unified Parkinson's Disease Rating Scale Clinical Classification Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639136","CDISC Questionnaire CGI Test Name Terminology","C100149","Test names of questionnaire questions associated with the clinical global impression (CGI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire CGI Test Name Terminology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639138","CDISC Questionnaire MNSI Test Name Terminology","C100151","Test names of questionnaire questions associated with the Michigan neuropathy screening instrument (MNSI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire MNSI Test Name Terminology | MNSI1TN | Michigan Neuropathy Screening Instrument Questionnaire Test Name | QS-MNSI TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639139","CDISC Questionnaire MNSI Test Code Terminology","C100152","Test codes of questionnaire questions associated with the Michigan neuropathy screening instrument (MNSI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire MNSI Test Code Terminology | MNSI1TC | Michigan Neuropathy Screening Instrument Questionnaire Test Code | QS-MNSI TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639140","CDISC Questionnaire FPSR Test Name Terminology","C100153","Test names of questionnaire questions associated with the revised faces pain scale (FPSR) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire FPSR Test Name Terminology | FPSR1TN | Faces Pain Scale - Revised Questionnaire Test Name | QS-FPSR TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639141","CDISC Questionnaire FPSR Test Code Terminology","C100154","Test codes of questionnaire questions associated with the revised faces pain scale (FPSR) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire FPSR Test Code Terminology | FPSR1TC | Faces Pain Scale - Revised Questionnaire Test Code | QS-FPSR TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639142","CDISC Questionnaire Short-Form MPQ-2 Test Name Terminology","C100155","Test names of questionnaire questions associated with the short-form McGill pain questionnaire-2 for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire Short-Form MPQ-2 Test Name Terminology | QS-Short-Form MPQ-2 TEST | SFMP2TN | Short-Form McGill Pain Questionnaire-2 Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639143","CDISC Questionnaire Short-Form MPQ-2 Test Code Terminology","C100156","Test codes of questionnaire questions associated with the short-form McGill pain questionnaire-2 for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire Short-Form MPQ-2 Test Code Terminology | QS-Short-Form MPQ-2 TESTCD | SFMP2TC | Short-Form McGill Pain Questionnaire-2 Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639144","CDISC Questionnaire COMM Test Name Terminology","C100157","Test names of questionnaire questions associated with the current opioid misuse measure (COMM) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire COMM Test Name Terminology | COMM1TN | Current Opioid Misuse Measure Questionnaire Test Name | QS-COMM TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639145","CDISC Questionnaire COMM Test Code Terminology","C100158","Test codes of questionnaire questions associated with the current opioid misuse measure (COMM) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire COMM Test Code Terminology | COMM1TC | Current Opioid Misuse Measure Questionnaire Test Code | QS-COMM TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639147","CDISC Questionnaire SOAPP-R Test Code Terminology","C100160","Test codes of questionnaire questions associated with the revised screener and opiod assessment for patients with pain for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire SOAPP-R Test Code Terminology | QS-SOAPP-R TESTCD | SOAPR1TC | Screener and Opioid Assessment for Patients with Pain - Revised Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639148","CDISC Questionnaire BPI Test Name Terminology","C100161","Test names of questionnaire questions associated with the brief pain inventory (BPI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire BPI Test Name Terminology | BPI1TN | Brief Pain Inventory Questionnaire Test Name | QS-BPI TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639149","CDISC Questionnaire BPI Test Code Terminology","C100162","Test codes of questionnaire questions associated with the brief pain inventory (BPI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire BPI Test Code Terminology | BPI1TC | Brief Pain Inventory Questionnaire Test Code | QS-BPI TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639151","CDISC Questionnaire BPI Short Form Test Code Terminology","C100164","Test codes of questionnaire questions associated with the short-form brief pain inventory for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire BPI Short Form Test Code Terminology | BPI2TC | Brief Pain Inventory Short Form Questionnaire Test Code | QS-BPI Short Form TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639152","CDISC Questionnaire RDQ Test Name Terminology","C100165","Test names of questionnaire questions associated with the Roland Morris disability questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire RDQ Test Name Terminology | QS-RDQ TEST | RDQ01TN | Roland Morris Disability Questionnaire Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639153","CDISC Questionnaire RDQ Test Code Terminology","C100166","Test codes of questionnaire questions associated with the Roland Morris disability questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire RDQ Test Code Terminology | QS-RDQ TESTCD | RDQ01TC | Roland Morris Disability Questionnaire Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639154","CDISC Questionnaire C-SSRS Baseline Test Name Terminology","C100167","Test names of questionnaire questions associated with the Columbia-Suicide severity rating scale baseline questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire C-SSRS Baseline Test Name Terminology | CSS01TN | Columbia-Suicide Severity Rating Scale Baseline Questionnaire Test Name | QS-C-SSRS Baseline TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639155","CDISC Questionnaire C-SSRS Baseline Test Code Terminology","C100168","Test codes of questionnaire questions associated with the Columbia-Suicide severity rating scale baseline questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire C-SSRS Baseline Test Code Terminology | CSS01TC | Columbia-Suicide Severity Rating Scale Baseline Questionnaire Test Code | QS-C-SSRS Baseline TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639156","QS-KPS Scale TEST","C100169","Test names of clinical classification questions associated with the Karnofsky performance status scale questionnaire (KPS Scale) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification KPS Scale Test Name Terminology | KPSS01TN | Karnofsky Performance Status Scale Clinical Classification Test Name | QS-KPS Scale TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639157","QS-KPS Scale TESTCD","C100170","Test codes of clinical classification questions associated with the Karnofsky performance status scale questionnaire (KPS Scale) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification KPS Scale Test Code Terminology | KPSS01TC | Karnofsky Performance Status Scale Clinical Classification Test Code | QS-KPS Scale TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639158","SF36 v1.0 Standard Questionnaire Question","C100171","A question associated with the SF36 v1.0 questionnaire.","SF36 v1.0 Standard Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639159","WPAI:SHP v2.0 Questionnaire Question","C100172","A question associated with version 2.0 of the WPAI:SHP questionnaire.","WPAI:SHP v2.0 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639160","CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology","C100173","Test names of questionnaire questions associated with the Short Form 36 Health Survey Standard, US Version 1.0 (QS-SF36 v1.0 Standard) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology | QS-SF36 v1.0 Standard TEST | SF361TN | The Short Form 36 Health Survey Standard, US Version 1.0 Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639162","CDISC Questionnaire WPAI:SHP v2.0 Test Name Terminology","C100175","Test names of questionnaire questions associated with the the version 2.0 of the work productivity and activity impairment specific health problem questionnaire (WPAI:SHP) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire WPAI:SHP v2.0 Test Name Terminology | QS-WPAI-SHP TEST | WPAI01TN | Work Productivity and Activity Impairment Questionnaire - Specific Health Problem V2.0 Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639163","CDISC Questionnaire WPAI:SHP v2.0 Test Code Terminology","C100176","Test codes of questionnaire questions associated with the the version 2.0 of the work productivity and activity impairment specific health problem questionnaire (WPAI:SHP) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire WPAI:SHP v2.0 Test Code Terminology | QS-WPAI-SHP TESTCD | WPAI01TC | Work Productivity and Activity Impairment Questionnaire - Specific Health Problem V2.0 Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639164","CDISC ADAS-Cog - Word Recall Average Score","C100177","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recall task word average score of trials 1, 2, 3.","CDISC ADAS-Cog - Word Recall Average Score | ADCRL | Word Recall",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639165","CDISC ADAS-Cog - Word Recall Trial 1 Subscore","C100178","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Sub-score for word recall task trial 1.","CDISC ADAS-Cog - Word Recall Trial 1 Subscore | ADCRLT01 | Word Recall Trial 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639166","CDISC ADAS-Cog - Word Recall Trial 2 Subscore","C100179","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Sub-score for word recall task trial 2.","CDISC ADAS-Cog - Word Recall Trial 2 Subscore | ADCRLT02 | Word Recall Trial 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1868740","Conjunctival Melanocytic Intraepithelial Lesion","C100054","A spectrum of neoplastic changes that occur in the conjunctiva and range from melanocytic hyperplasia through degrees of atypia to melanoma in situ. The lesions are generally unilateral but often multifocal and appear as flat, irregular brown discolorations of the conjunctiva. They usually affect middle-aged and elderly Caucasians. (WHO 2018)","Conjunctival Melanocytic Intraepithelial Lesion | C-MIL | C-MIN | Conjunctival Melanocytic Intraepithelial Neoplasia | Conjunctival Melanocytic Intraepithelial Neoplasia | Conjunctival Melanocytic Intraepithelial Neoplasia (C-MIN Score of 2-4) | Conjunctival Melanoma In Situ | Conjunctival Precancerous Melanosis | Conjunctival Premalignant Melanosis | Conjunctival Primary Acquired Melanosis | Conjunctival Primary Acquired Melanosis with Atypia | Conjunctival Primary Acquired Melanosis with Atypia/Melanoma In Situ | PAM | PAM with Atypia | Primary Acquired Melanosis with Atypia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282163","Immigrant","C100055","An individual who changes his place of residency from one country to another.","Immigrant | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272298","Arterial Access Site","C100056","Anatomical location where an artery was accessed for a diagnostic or therapeutic procedure.","Arterial Access Site | Percutaneous arterial access",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0580203","Post-Procedure","C100059","The time period after a diagnostic or therapeutic procedure.","Post-Procedure | ",,,,,,,,,,,,,,,"4123428","Postprocedural period",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3272302","Intrinsic QRS Duration","C100060","The duration of the QRS complex that is generated by the subject's own heart. (ACC)","Intrinsic QRS Duration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL434402","Synthetic Breast Cancer Peptides-Tetanus Toxoid-Poly ICLC Vaccine","C100099","A cancer vaccine comprised of nine class I major histocompatibility complex (MHC)-restricted breast cancer associated peptides, the tetanus toxoid helper peptide and the Toll-like receptor 3 (TLR3) agonist poly ICLC, with potential immunostimulatory and antineoplastic activities. The nine peptides derived from six cancer associated proteins are epidermal growth factor receptor 2 (HER2/neu), carcinoembryonic antigen (CEA) and four cancer/testis antigens (CTAs: MAGE-A1, -A3, -A10, and NY-ESO-1). Vaccination with this vaccine may elicit a specific cytotoxic T-lymphocyte (CTL) response against cells overexpressing these tumor associated antigens (TAAs). As a nonspecific T-helper epitope, tetanus toxoid helper peptide binds to class II MHC and results in long-term immunopotentiation by increasing the helper T-cell response. Poly ICLC, the double-stranded RNA molecules of polyinosinic-polycytidylic acid stabilized with poly L-lysine in carboxymethylcellulose, binds to TLR3 and induces the release of cytokines which may help boost the immune response against the TAAs.","Synthetic Breast Cancer Peptides-Tetanus Toxoid-Poly ICLC Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514768","Recombinant Amphiregulin","C1000","A recombinant form of amphiregulin, a member of the heparin-binding epidermal growth factor (EGF) family. Endogenous amphiregulin is an autocrine growth factor, and binds to the EGF receptor. Overexpressed in several cancer cell types, endogenous amphiregulin may contribute to tumor cell proliferation and metastasis. (NCI04)","Recombinant Amphiregulin | AMPHIREGULIN | AR | CRDGF | KAF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433976","HPV E1/E2 Interaction Inhibitor Gel AP611074","C100100","A topical gel composed of a human papillomavirus (HPV) E1/E2 protein:protein interaction (PPI) inhibitor with potential antiviral activity. Upon topical application of AP611074, this agent prevents binding of the HPV viral proteins E1 to E2, thereby preventing viral DNA replication and growth of HPV. This inhibits viral proliferation and may prevent the formation of anogenital warts caused by HPV. The HPV proteins E1 and E2 are essential for HPV viral replication.","HPV E1/E2 Interaction Inhibitor Gel AP611074 | AP611074 | PPI inhibitor AP611074 | Protein/Protein Interaction Inhibitor AP611074",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639093","anti-CD37 antibody-drug conjugate IMGN529","C100101","An immunoconjugate that consists of a humanized IgG1 antibody K7153A against the cell-surface antigen CD37 and covalently linked via the uncleavable, maleimide-derived thioether-based linker SMCC to the maytansinoid DM1, with potential pro-apoptotic and cytotoxic activities. Upon administration of naratuximab emtansine, the antibody moiety of IMGN529 binds to CD37 on tumor B-cells and induces an antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), thereby showing pro-apoptotic activity. In addition, after the internalization of this agent and lysosomal degradation, the DM1 moiety binds to tubulin and inhibits tubulin polymerization and microtubule assembly, resulting in a disruption of microtubule activity and cell division, and eventually causing cell death in CD37-positive B-cells. CD37, a transmembrane glycoprotein, is overexpressed in B-cell malignancies. Compared to reducible, cleavable linkers, the non-reducible SMCC linker shows increased stability in plasma.","Naratuximab Emtansine | IMGN529 | MP 529 | MP-529 | MP529 | NARATUXIMAB EMTANSINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433980","Adenovirus/Cytomegalovirus/Epstein-Barr Virus-specific Allogeneic Cytotoxic T Lymphocytes","C100102","Allogeneic tri-viral specific, adenovirus, cytomegalovirus and Epstein-Barr virus (Adv, CMV and EBV or ACE), cytotoxic T-lymphocytes (CTLs) with potential antiviral activity. Donor-derived T-cells were exposed to dendritic cells nucelofected with DNA plasmids encoding Hexon and Penton (Adv), pp65 and IE1 (CMV), and LMP2, EBNA1 and BZLF1 (EBV), all are critical proteins for the proliferation of these viruses, and subsequently maintained in the presence of interleukins 4 and 7 with a novel culture device to expand and sustain the repertoire of CTLs. After an allogeneic hematopoietic stem cell transplant (HSCT), infusion of these CTLs primed towards Adv, CMV and EBV may prevent viral infection by these pathogens.","Adenovirus/Cytomegalovirus/Epstein-Barr Virus-specific Allogeneic Cytotoxic T Lymphocytes | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639095","Cellular Sheet Dosage Form","C100103","A skin graft sheet composed of viable cells layered on a supporting substrate.","Cellular Sheet Dosage Form | CELLULAR SHEET",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639096","ADAS-Cog CDISC Version Questionnaire Question","C100106","A question associated with the ADAS-Cog CDISC version functional test.","ADAS-Cog CDISC Version Functional Test Question | ADAS-Cog CDISC Version Questionnaire Question",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639097","BPI Questionnaire Question","C100107","A question associated with the BPI questionnaire.","BPI Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639098","BPI Short Form Questionnaire Question","C100108","A question associated with the BPI Short Form questionnaire.","BPI Short Form Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639099","BPRS-Anchored Clinical Classification Question","C100109","A question associated with the BPRS-Anchored clinical classification.","BPRS-Anchored Clinical Classification Question | BPRS-A Clinical Classification Question",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639174","CDISC ADAS-Cog - Word Recall: Word 7","C100187","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recall task word 7 for trial 1, 2, 3.","CDISC ADAS-Cog - Word Recall: Word 7 | ADCRLW07 | Word Recall: Word [7]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639175","CDISC ADAS-Cog - Word Recall: Word 8","C100188","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recall task word 8 for trial 1, 2, 3.","CDISC ADAS-Cog - Word Recall: Word 8 | ADCRLW08 | Word Recall: Word [8]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639176","CDISC ADAS-Cog - Word Recall: Word 9","C100189","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recall task word 9 for trial 1, 2, 3.","CDISC ADAS-Cog - Word Recall: Word 9 | ADCRLW09 | Word Recall: Word [9]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639177","CDISC ADAS-Cog - Word Recall: Word 10","C100190","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recall task word 10 for trial 1, 2, 3.","CDISC ADAS-Cog - Word Recall: Word 10 | ADCRLW10 | Word Recall: Word [10]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639178","CDISC ADAS-Cog - Naming Objects and Fingers Summary Score","C100191","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task summary score for object and fingers.","CDISC ADAS-Cog - Naming Objects and Fingers Summary Score | ADCOF | Naming Objects and Fingers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639179","CDISC ADAS-Cog - Naming Objects and Fingers: 1","C100192","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for object 1.","CDISC ADAS-Cog - Naming Objects and Fingers: 1 | ADCOFO01 | Naming Objects and Fingers: 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639180","CDISC ADAS-Cog - Naming Objects and Fingers: 2","C100193","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for object 2.","CDISC ADAS-Cog - Naming Objects and Fingers: 2 | ADCOFO02 | Naming Objects and Fingers: 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639181","CDISC ADAS-Cog - Naming Objects and Fingers: 3","C100194","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for object 3.","CDISC ADAS-Cog - Naming Objects and Fingers: 3 | ADCOFO03 | Naming Objects and Fingers: 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639182","CDISC ADAS-Cog - Naming Objects and Fingers: 4","C100195","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for object 4.","CDISC ADAS-Cog - Naming Objects and Fingers: 4 | ADCOFO04 | Naming Objects and Fingers: 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639183","CDISC ADAS-Cog - Naming Objects and Fingers: 5","C100196","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for object 5.","CDISC ADAS-Cog - Naming Objects and Fingers: 5 | ADCOFO05 | Naming Objects and Fingers: 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639184","CDISC ADAS-Cog - Naming Objects and Fingers: 6","C100197","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for object 6.","CDISC ADAS-Cog - Naming Objects and Fingers: 6 | ADCOFO06 | Naming Objects and Fingers: 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639186","CDISC ADAS-Cog - Naming Objects and Fingers: 8","C100199","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for object 8.","CDISC ADAS-Cog - Naming Objects and Fingers: 8 | ADCOFO08 | Naming Objects and Fingers: 8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279355","azacitidine/cytarabine/daunorubicin/prednisone/vincristine","C10019","A regimen consisting of daunorubicin, azacitidine, cytarabine, prednisone and vincristine that may be used in the treatment of childhood acute myeloid leukemia (AML).","DZAPO Regimen | ARA-C/AZA/DNR/PRED/VCR | Azacitidine/Cytarabine/Daunorubicin/Prednisone/Vincristine | Azacytidine/Cytarabine/Daunorubicin/Prednisone/Vincristine | DZAPO | Daunorubicin-Azacitidine-Cytarabine-Prednisone-Vincristine | Daunorubicin/Azacitidine/Ara-C/Prednisone/Oncovin | Daunorubicin/Azacitidine/Cytarabine/Prednisone/Vincristine | Daunorubicin/Azacitidine/Cytarabine/Prednisone/Vincristine Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1434913","Rintatolimod","C1001","A synthetic derivative of inosinic acid with antiretroviral and immunomodulatory properties. Atvogen acts through a number of pathways to stimulate intracellular antiviral activity of the immune system: it stimulates interferon production; activates the oligoadenylate synthase-RNase L pathway; stimulates natural killer cell activity; and acts as a non-mitogenic stimulator of the immune system. This agent also inhibits replication of human immunodeficiency virus (HIV) in vitro. (NCI04)","Rintatolimod | Ampligen | Atvogen | Poly(I).Poly(c12,U) | Poly(Inosinic Acid) Poly(Cytidylic(12), Uridylic)Acid | RINTATOLIMOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639100","CDISC Questionnaire Terminology","C100110","The terminology subset that includes terms pertaining to the CDISC questionnaire terminology.","CDISC Questionnaire Terminology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639101","CGI Questionnaire Question","C100111","A question associated with the CGI questionnaire.","CGI Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639102","COMM Questionnaire Question","C100112","A question associated with the COMM questionnaire.","COMM Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639104","EQ-5D-3L Questionnaire Question","C100114","A question associated with the EQ-5D-3L questionnaire.","EQ-5D-3L Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639105","FPSR Questionnaire Question","C100115","A question associated with the FPSR questionnaire.","FPSR Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639106","KPS Scale Questionnaire Question","C100116","A question associated with the KPS Scale questionnaire.","KPS Scale Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639107","MDS-UPDRS Questionnaire Question","C100117","A question associated with the MDS-UPDRS questionnaire.","MDS-UPDRS Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639108","MMSE Functional Test Question","C100118","A question associated with the MMSE functional test.","MMSE Functional Test Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639109","MNSI Questionnaire Question","C100119","A question associated with the MNSI questionnaire.","MNSI Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639110","NPI Questionnaire Question","C100120","A question associated with the NPI questionnaire.","NPI Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639112","RDQ Questionnaire Question","C100123","A question associated with the RDQ questionnaire.","RDQ Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639113","Short-Form MPQ-2 Questionnaire Question","C100124","A question associated with the Short-Form MPQ-2 questionnaire.","Short-Form MPQ-2 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639114","SOAPP-R Questionnaire Question","C100125","A question associated with the SOAPP-R questionnaire.","SOAPP-R Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639115","UPDRS Clinical Classification Question","C100126","A question associated with the UPDRS clinical classification.","UPDRS Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639116","HAMD-17 Questionnaire Question","C100127","A question associated with the HAMD-17 questionnaire.","HAMD-17 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639118","CDISC Questionnaire ADAS-Cog CDISC Version Test Name Terminology","C100131","Test names of functional test questions associated with the CDISC version of the alzheimer's disease assessment scale-cognitive (ADAS-Cog) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology | ADCTN | Alzheimer's Disease Assessment Scale - Cognitive CDISC Version Functional Test Test Name | Alzheimer's Disease Assessment Scale - Cognitive CDISC Version Questionnaire Test Name | CDISC Questionnaire ADAS-Cog CDISC Version Test Name Terminology | QS-ADAS-Cog CDISC Version TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639119","CDISC Questionnaire ADAS-Cog CDISC Version Test Code Terminology","C100132","Test codes of functional test questions associated with the CDISC version of the alzheimer's disease assessment scale-cognitive (ADAS-Cog) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology | ADCTC | Alzheimer's Disease Assessment Scale - Cognitive CDISC Version Functional Test Test Code | Alzheimer's Disease Assessment Scale - Cognitive CDISC Version Questionnaire Test Code | CDISC Questionnaire ADAS-Cog CDISC Version Test Code Terminology | QS-ADAS-Cog CDISC Version TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639120","QS-BPRS-A TEST","C100133","Test names of clinical classification questions associated with the Brief Psychiatric Rating Scale-Anchored (BPRS-A) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification BPRS-Anchored Test Name Terminology | BPRSA1TN | Brief Psychiatric Rating Scale-A Clinical Classification Test Name | Brief Psychiatric Rating Scale-Anchored Clinical Classification Test Name | CDISC Clinical Classification BPRS-A Test Name Terminology | QS-BPRS-A TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639121","QS-BPRS-A TESTCD","C100134","Test codes of clinical classification questions associated with the Brief Psychiatric Rating Scale-Anchored (BPRS-A) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification BPRS-Anchored Test Code Terminology | BPRSA1TC | Brief Psychiatric Rating Scale-A Clinical Classification Test Code | Brief Psychiatric Rating Scale-Anchored Clinical Classification Test Code | CDISC Clinical Classification BPRS-A Test Code Terminology | QS-BPRS-A TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639122","CDISC Questionnaire EQ-5D-3L Test Name Terminology","C100135","Test names of questionnaire questions associated with the EuroQOL (European Quality of Life) Five Dimension three level scale (EQ-5D-3L) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire EQ-5D-3L Test Name Terminology | EQ5D01TN | European Quality of Life Five Dimension Three Level Scale Questionnaire Test Name | QS-EQ-5D-3L TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639123","CDISC Questionnaire EQ-5D-3L Test Code Terminology","C100136","Test codes of questionnaire questions associated with the EuroQOL (European Quality of Life) Five Dimension three level scale (EQ-5D-3L) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire EQ-5D-3L Test Code Terminology | EQ5D01TC | European Quality of Life Five Dimension Three Level Scale Questionnaire Test Code | QS-EQ-5D-3L TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639124","CDISC Clinical Classification HAMD 17 Test Name Terminology","C100137","Test names of clinical classification questions associated with the 17 item Hamilton depression rating scale (HAMD-17) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification HAMD 17 Test Name Terminology | HAMD1TN | Hamilton Depression Rating Scale - 17 Item Clinical Classification Test Name | QS-HAMD 17 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639125","CDISC Clinical Classification HAMD 17 Test Code Terminology","C100138","Test codes of clinical classification questions associated with the 17 item Hamilton depression rating scale (HAMD-17) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification HAMD 17 Test Code Terminology | HAMD1TC | Hamilton Depression Rating Scale - 17 Item Clinical Classification Test Code | QS-HAMD 17 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639126","CDISC Questionnaire MDS-UPDRS Test Name Terminology","C100139","Test names of questionnaire questions associated with the the movement disorder society version of the unified parkinson's disease rating scale (MDS-UPDRS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire MDS-UPDRS Test Name Terminology | Movement Disorder Society Unified Parkinson's Disease Rating Scale Questionnaire Test Name | QS-MDS-UPDRS TEST | UPD2TN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639127","CDISC Questionnaire MDS-UPDRS Test Code Terminology","C100140","Test codes of questionnaire questions associated with the the movement disorder society version of the unified parkinson's disease rating scale (MDS-UPDRS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire MDS-UPDRS Test Code Terminology | Movement Disorder Society Unified Parkinson's Disease Rating Scale Questionnaire Test Code | QS-MDS-UPDRS TESTCD | UPD2TC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639128","QS-MMSE TEST","C100141","Test names of functional test questions associated with the mini-mental state examination (MMSE) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Functional Test MMSE Test Name Terminology | MMS1TN | Mini-Mental State Examination Functional Test Test Name | QS-MMSE TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639129","QS-MMSE TESTCD","C100142","Test codes of functional test questions associated with the mini-mental state examination (MMSE) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Functional Test MMSE Test Code Terminology | MMS1TC | Mini-Mental State Examination Functional Test Test Code | QS-MMSE TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639290","BPI - Pain Right Now","C100306","Brief Pain Inventory (BPI) Please rate your pain by circling the one number that tells how much pain you have right now.","BPI - Pain Right Now | BPI1-Pain Right Now | BPI115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639291","BPI - Things that Make Pain Feel Better","C100307","Brief Pain Inventory (BPI) What kinds of things make your pain feel better?","BPI - Things that Make Pain Feel Better | BPI1-Things that Make Pain Feel Better | BPI116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639292","BPI - Things that Make your Pain Worse","C100308","Brief Pain Inventory (BPI) What kinds of things make your pain feel worse?","BPI - Things that Make your Pain Worse | BPI1-Things that Make your Pain Worse | BPI117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639293","BPI - Treatments Receiving for Pain","C100309","Brief Pain Inventory (BPI) What treatments or medications are you receiving for your pain?","BPI - Treatments Receiving for Pain | BPI1-Treatments Receiving for Pain | BPI118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279380","DOX/MeCCNU","C10030","A regimen consisting of doxorubicin and semustine (methyl CCNU) that may be used in the treatment of metastatic sarcomas.","Doxorubicin/Semustine Regimen | DOX/MeCCNU | Doxorubicin-Semustine | Doxorubicin/Semustine | MAD | MeCCNU/Adriamycin | MeCCNU/Doxorubicin | Semustine-Doxorubicin | Semustine/Doxorubicin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639294","BPI - Relief Pain Treatments Provided","C100310","Brief Pain Inventory (BPI) In the last week, how much relief have pain treatments or medications provided? Please circle the one percentage that most shows how much relief you have received.","BPI - Relief Pain Treatments Provided | BPI1-Relief Pain Treatments Provided | BPI119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639295","BPI - Hours before Pain Returns","C100311","Brief Pain Inventory (BPI) If you take pain medication, how many hours does it take before the pain returns?","BPI - Hours before Pain Returns | BPI1-Hours before Pain Returns | BPI120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639296","BPI - Pain Due to Effects of Treatment","C100312","Brief Pain Inventory (BPI) I believe my pain is due to the effects of treatment.","BPI - Pain Due to Effects of Treatment | BPI1-Pain Due to Effects of Treatment | BPI1211",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639297","BPI - Pain Due to Primary Disease","C100313","Brief Pain Inventory (BPI) I believe my pain is due to my primary disease.","BPI - Pain Due to Primary Disease | BPI1-Pain Due to Primary Disease | BPI1212",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639298","BPI - Pain Due to Unrelated Medical Condition","C100314","Brief Pain Inventory (BPI) I believe my pain is due to a medical condition unrelated to my primary disease.","BPI - Pain Due to Unrelated Medical Condition | BPI1-Pain Due to Unrelated Med Condition | BPI1213",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639187","CDISC ADAS-Cog - Naming Objects and Fingers: 9","C100200","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for object 9.","CDISC ADAS-Cog - Naming Objects and Fingers: 9 | ADCOFO09 | Naming Objects and Fingers: 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639189","CDISC ADAS-Cog - Naming Objects and Fingers: 11","C100202","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for object 11.","CDISC ADAS-Cog - Naming Objects and Fingers: 11 | ADCOFO11 | Naming Objects and Fingers: 11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639190","CDISC ADAS-Cog - Naming Objects and Fingers: 12","C100203","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for object 12.","CDISC ADAS-Cog - Naming Objects and Fingers: 12 | ADCOFO12 | Naming Objects and Fingers: 12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639191","CDISC ADAS-Cog - Naming Objects and Fingers: Thumb","C100204","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for fingers of the dominant hand, thumb.","CDISC ADAS-Cog - Naming Objects and Fingers: Thumb | ADCOFF01 | Naming Objects and Fingers: Thumb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639207","CDISC ADAS-Cog - Delayed Word Recall: Word 5","C100220","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Delayed word recall task for word 5.","CDISC ADAS-Cog - Delayed Word Recall: Word 5 | ADCDRL05 | Delayed Word Recall: Word [5]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639208","CDISC ADAS-Cog - Delayed Word Recall: Word 6","C100221","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Delayed word recall task for word 6.","CDISC ADAS-Cog - Delayed Word Recall: Word 6 | ADCDRL06 | Delayed Word Recall: Word [6]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639209","CDISC ADAS-Cog - Delayed Word Recall: Word 7","C100222","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Delayed word recall task for word 7.","CDISC ADAS-Cog - Delayed Word Recall: Word 7 | ADCDRL07 | Delayed Word Recall: Word [7]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639211","CDISC ADAS-Cog - Delayed Word Recall: Word 9","C100224","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Delayed word recall task for word 9.","CDISC ADAS-Cog - Delayed Word Recall: Word 9 | ADCDRL09 | Delayed Word Recall: Word [9]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639212","CDISC ADAS-Cog - Delayed Word Recall: Word 10","C100225","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Delayed word recall task for word 10.","CDISC ADAS-Cog - Delayed Word Recall: Word 10 | ADCDRL10 | Delayed Word Recall: Word [10]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639213","CDISC ADAS-Cog - Constructional Praxis Summary Score","C100226","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Summary score for constructional praxis.","CDISC ADAS-Cog - Constructional Praxis Summary Score | ADCCP | Constructional Praxis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639214","CDISC ADAS-Cog - Constructional Praxis: Circle","C100227","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Constructional praxis task for copying a circle.","CDISC ADAS-Cog - Constructional Praxis: Circle | ADCCP01 | Constructional Praxis: Circle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639215","CDISC ADAS-Cog - Constructional Praxis: 2 Rectangles","C100228","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Constructional praxis task for copying two overlapping rectangles.","CDISC ADAS-Cog - Constructional Praxis: 2 Rectangles | ADCCP02 | Constructional Praxis: 2 Rectangles",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639216","CDISC ADAS-Cog - Constructional Praxis: Diamond","C100229","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Constructional praxis task for copying a diamond.","CDISC ADAS-Cog - Constructional Praxis: Diamond | ADCCP03 | Constructional Praxis: Diamond",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639217","CDISC ADAS-Cog - Constructional Praxis: Cube","C100230","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Constructional praxis task for copying a cube.","CDISC ADAS-Cog - Constructional Praxis: Cube | ADCCP04 | Constructional Praxis: Cube",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639218","CDISC ADAS-Cog - Attempt to Draw","C100231","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Constructional praxis attempted to draw, but drew no forms correctly.","CDISC ADAS-Cog - Attempt to Draw | ADCCPS | Attempt to Draw",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639219","CDISC ADAS-Cog - Ideational Praxis Summary Score","C100232","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Summary score for ideational praxis.","CDISC ADAS-Cog - Ideational Praxis Summary Score | ADCIP | Ideational Praxis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639220","CDISC ADAS-Cog - Ideational Praxis: Fold","C100233","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Ideational praxis task for folding the paper.","CDISC ADAS-Cog - Ideational Praxis: Fold | ADCIP01 | Ideational Praxis: Fold",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639222","CDISC ADAS-Cog - Ideational Praxis: Seal","C100235","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Ideational praxis task for seal the envelop.","CDISC ADAS-Cog - Ideational Praxis: Seal | ADCIP03 | Ideational Praxis: Seal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639224","CDISC ADAS-Cog - Ideational Praxis: Stamp","C100237","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Ideational praxis task for showing where the stamp goes.","CDISC ADAS-Cog - Ideational Praxis: Stamp | ADCIP05 | Ideational Praxis: Stamp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539923","CDISC ADAS-Cog - Orientation Summary Score","C100238","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Summary score for orientation.","CDISC ADAS-Cog - Orientation Summary Score | ADCOR | Orientation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639225","CDISC ADAS-Cog - Orientation: Full Name","C100239","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Orientation task for knowing one's own full name.","CDISC ADAS-Cog - Orientation: Full Name | ADCOR01 | Orientation: Full Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279365","doxorubicin/mitomycin/tegafur","C10023","A regimen consisting of doxorubicin, mitomycin, and tegafur that may be used in the treatment of non-small cell lung cancers (NSCLC).","Doxorubicin/Mitomycin/Tegafur Regimen | DOX/FT/MITO | Doxorubicin/Mitomycin/Tegafur | FURAM | FURAM Regimen | Ftorafur/Adriamycin/Mitomycin | Tegafur-Doxorubicin-Mitomycin | Tegafur/Doxorubicin/Mitomycin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639226","CDISC ADAS-Cog - Orientation: Month","C100240","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Orientation task for knowing the current month.","CDISC ADAS-Cog - Orientation: Month | ADCOR02 | Orientation: Month",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639227","CDISC ADAS-Cog - Orientation: Date","C100241","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Orientation task for knowing the current day.","CDISC ADAS-Cog - Orientation: Date | ADCOR03 | Orientation: Date",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639228","CDISC ADAS-Cog - Orientation: Year","C100242","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Orientation task for knowing the current year.","CDISC ADAS-Cog - Orientation: Year | ADCOR04 | Orientation: Year",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639229","CDISC ADAS-Cog - Orientation: Day of Week","C100243","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Orientation task for knowing the current day of the week.","CDISC ADAS-Cog - Orientation: Day of Week | ADCOR05 | Orientation: Day of Week",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639230","CDISC ADAS-Cog - Orientation: Season","C100244","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Orientation task for knowing the current season.","CDISC ADAS-Cog - Orientation: Season | ADCOR06 | Orientation: Season",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639232","CDISC ADAS-Cog - Orientation: Time","C100246","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Orientation task for knowing the approximate current clock time.","CDISC ADAS-Cog - Orientation: Time | ADCOR08 | Orientation: Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538907","CDISC ADAS-Cog - Word Recognition Summary Score","C100247","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Summary score for word recognition across trials 1-3.","CDISC ADAS-Cog - Word Recognition Summary Score | ADCRG | Word Recognition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639233","CDISC ADAS-Cog - Word Recognition Trial 1 Summary Score","C100248","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Sub-score for word recognition trial 1.","CDISC ADAS-Cog - Word Recognition Trial 1 Summary Score | ADCRGT01 | Word Recognition Trial 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639234","CDISC ADAS-Cog - Word Recognition Trial 2 Summary Score","C100249","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Sub-score for word recognition trial 2.","CDISC ADAS-Cog - Word Recognition Trial 2 Summary Score | ADCRGT02 | Word Recognition Trial 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279369","asparaginase/methotrexate","C10024","A regimen consisting of asparaginase and methotrexate that may be used in the treatment of pediatric acute myeloid leukemia (AML).","Asparaginase/Methotrexate Regimen | ASP/MTX | Asparaginase-Methotrexate | Asparaginase/Methotrexate | LAM | Methotrexate-Asparaginase | Methotrexate/Asparaginase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639235","CDISC ADAS-Cog - Word Recognition Trial 3 Summary Score","C100250","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Sub-score for word recognition trial 3.","CDISC ADAS-Cog - Word Recognition Trial 3 Summary Score | ADCRGT03 | Word Recognition Trial 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639236","CDISC ADAS-Cog - Word Recognition: Word 1","C100251","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 1 Trials 1, 2, 3.","CDISC ADAS-Cog - Word Recognition: Word 1 | ADCRGW01 | Word Recognition: Word [1]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639237","CDISC ADAS-Cog - Word Recognition: Word 2","C100252","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 2 Trials 1, 2, 3.","CDISC ADAS-Cog - Word Recognition: Word 2 | ADCRGW02 | Word Recognition: Word [2]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639238","CDISC ADAS-Cog - Word Recognition: Word 3","C100253","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 3 Trials 1, 2, 3.","CDISC ADAS-Cog - Word Recognition: Word 3 | ADCRGW03 | Word Recognition: Word [3]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639239","CDISC ADAS-Cog - Word Recognition: Word 4","C100254","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 4 Trials 1, 2, 3.","CDISC ADAS-Cog - Word Recognition: Word 4 | ADCRGW04 | Word Recognition: Word [4]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639240","CDISC ADAS-Cog - Word Recognition: Word 5","C100255","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 5 Trials 1, 2, 3.","CDISC ADAS-Cog - Word Recognition: Word 5 | ADCRGW05 | Word Recognition: Word [5]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639241","CDISC ADAS-Cog - Word Recognition: Word 6","C100256","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 6 Trials 1, 2, 3.","CDISC ADAS-Cog - Word Recognition: Word 6 | ADCRGW06 | Word Recognition: Word [6]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639242","CDISC ADAS-Cog - Word Recognition: Word 7","C100257","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 7 Trials 1, 2, 3.","CDISC ADAS-Cog - Word Recognition: Word 7 | ADCRGW07 | Word Recognition: Word [7]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639243","CDISC ADAS-Cog - Word Recognition: Word 8","C100258","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 8 Trials 1, 2, 3.","CDISC ADAS-Cog - Word Recognition: Word 8 | ADCRGW08 | Word Recognition: Word [8]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639244","CDISC ADAS-Cog - Word Recognition: Word 9","C100259","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 9 Trials 1, 2, 3.","CDISC ADAS-Cog - Word Recognition: Word 9 | ADCRGW09 | Word Recognition: Word [9]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639246","CDISC ADAS-Cog - Word Recognition: Word 11","C100261","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 11 Trials 1, 2, 3.","CDISC ADAS-Cog - Word Recognition: Word 11 | ADCRGW11 | Word Recognition: Word [11]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639192","CDISC ADAS-Cog - Naming Objects and Fingers: Pointer","C100205","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for fingers of the dominant hand, index, or pointer finger.","CDISC ADAS-Cog - Naming Objects and Fingers: Pointer | ADCOFF02 | Naming Objects and Fingers: Pointer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639193","CDISC ADAS-Cog - Naming Objects and Fingers: Middle","C100206","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for fingers of the dominant hand, middle finger.","CDISC ADAS-Cog - Naming Objects and Fingers: Middle | ADCOFF03 | Naming Objects and Fingers: Middle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639194","CDISC ADAS-Cog - Naming Objects and Fingers: Ring","C100207","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for fingers of the dominant hand, ring finger.","CDISC ADAS-Cog - Naming Objects and Fingers: Ring | ADCOFF04 | Naming Objects and Fingers: Ring",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639195","CDISC ADAS-Cog - Naming Objects and Fingers: Pinky","C100208","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for fingers of the dominant hand, little finger or pinky.","CDISC ADAS-Cog - Naming Objects and Fingers: Pinky | ADCOFF05 | Naming Objects and Fingers: Pinky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639196","CDISC ADAS-Cog - Commands Summary Score","C100209","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Summary score for commands.","CDISC ADAS-Cog - Commands Summary Score | ADCCMD | Commands",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639197","CDISC ADAS-Cog - Commands: Fist","C100210","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Commands task for making a fist.","CDISC ADAS-Cog - Commands: Fist | ADCCMD01 | Commands: Fist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639198","CDISC ADAS-Cog - Commands: Ceiling","C100211","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Commands task for pointing to the ceiling then to the floor.","CDISC ADAS-Cog - Commands: Ceiling | ADCCMD02 | Commands: Ceiling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639199","CDISC ADAS-Cog - Commands: Pencil","C100212","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Commands task for put the pencil on top of the card and then put it back.","CDISC ADAS-Cog - Commands: Pencil | ADCCMD03 | Commands: Pencil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639201","CDISC ADAS-Cog - Commands: Shoulder","C100214","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Commands task for tap each shoulder twice with two fingers keeping your eyes shut.","CDISC ADAS-Cog - Commands: Shoulder | ADCCMD05 | Commands: Shoulder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639202","CDISC ADAS-Cog - Delayed Word Recall Summary Score","C100215","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Summary score for delayed word recall.","CDISC ADAS-Cog - Delayed Word Recall Summary Score | ADCDRL | Delayed Word Recall",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639203","CDISC ADAS-Cog - Delayed Word Recall: Word 1","C100216","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Delayed word recall task for word 1.","CDISC ADAS-Cog - Delayed Word Recall: Word 1 | ADCDRL01 | Delayed Word Recall: Word [1]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639204","CDISC ADAS-Cog - Delayed Word Recall: Word 2","C100217","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Delayed word recall task for word 2.","CDISC ADAS-Cog - Delayed Word Recall: Word 2 | ADCDRL02 | Delayed Word Recall: Word [2]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639205","CDISC ADAS-Cog - Delayed Word Recall: Word 3","C100218","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Delayed word recall task for word 3.","CDISC ADAS-Cog - Delayed Word Recall: Word 3 | ADCDRL03 | Delayed Word Recall: Word [3]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639206","CDISC ADAS-Cog - Delayed Word Recall: Word 4","C100219","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Delayed word recall task for word 4.","CDISC ADAS-Cog - Delayed Word Recall: Word 4 | ADCDRL04 | Delayed Word Recall: Word [4]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639167","CDISC ADAS-Cog - Word Recall Trial 3 Subscore","C100180","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Sub-score for word recall task trial 3.","CDISC ADAS-Cog - Word Recall Trial 3 Subscore | ADCRLT03 | Word Recall Trial 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639168","CDISC ADAS-Cog - Word Recall: Word 1","C100181","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recall task word 1 for trial 1, 2, 3.","CDISC ADAS-Cog - Word Recall: Word 1 | ADCRLW01 | Word Recall: Word [1]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639169","CDISC ADAS-Cog - Word Recall: Word 2","C100182","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recall task word 2 for trial 1, 2, 3.","CDISC ADAS-Cog - Word Recall: Word 2 | ADCRLW02 | Word Recall: Word [2]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639170","CDISC ADAS-Cog - Word Recall: Word 3","C100183","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recall task word 3 for trial 1, 2, 3.","CDISC ADAS-Cog - Word Recall: Word 3 | ADCRLW03 | Word Recall: Word [3]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639171","CDISC ADAS-Cog - Word Recall: Word 4","C100184","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recall task word 4 for trial 1, 2, 3.","CDISC ADAS-Cog - Word Recall: Word 4 | ADCRLW04 | Word Recall: Word [4]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639172","CDISC ADAS-Cog - Word Recall: Word 5","C100185","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recall task word 5 for trial 1, 2, 3.","CDISC ADAS-Cog - Word Recall: Word 5 | ADCRLW05 | Word Recall: Word [5]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639173","CDISC ADAS-Cog - Word Recall: Word 6","C100186","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recall task word 6 for trial 1, 2, 3.","CDISC ADAS-Cog - Word Recall: Word 6 | ADCRLW06 | Word Recall: Word [6]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3272318","Guidewire Across Lesion","C100082","A measure of procedural success during a percutaneous coronary intervention when a guidewire can be deployed across a coronary artery lesion. (ACC)","Guidewire Across Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0340664","Coronary Artery Perforation","C100083","A dissection that extends through the full thickness of the coronary arterial wall. (ACC)","Coronary Artery Perforation | ",,,,,,,,,,,,,,,"4124846","Coronary artery perforation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3272319","Cardiac Diagnostic Procedure","C100084","Procedure to evaluate the structure and/or function of the heart. (ACC)","Cardiac Diagnostic Procedure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0702122","Intra-Aortic Balloon Pump","C100087","A medical device that increases myocardial oxygen perfusion while at the same time increasing cardiac output. (ACC)","Intra-Aortic Balloon Pump | IABP",,,,,,,,,,,,,,,"4044874","Intra-aortic balloon pump",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3500339","Interferon Gamma-1a","C100088","A recombinant form of the endogenous cytokine human interferon (IFN) gamma-1a, with immunomodulating activity. Upon administration, IFN gamma-1a targets, binds to, and activates the cell-surface IFN-gamma receptor, thereby stimulating innate and adaptive immune responses.","Interferon Gamma-1a | INTERFERON GAMMA-1A | Imunomax | Imunomax-gamma | Interferon gamma-1a | Recombinant interferon gamma-1a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1579322","Interferon Gamma-1b","C100089","A recombinant form of the endogenous cytokine human interferon (IFN) gamma-1b, with immunomodulating activity. Upon administration, IFN gamma-1b targets, binds to, and activates the cell-surface IFN-gamma receptor, stimulating antibody dependent cellular cytotoxicity (ADCC), activating natural killer (NK) cells, and enhancing the oxidative metabolism of macrophages. IFN-gamma plays important roles in the innate and adaptive immune responses.","Interferon Gamma-1b | Actimmune | IFN-g-1b | IFN-gamma 1b | IFNg-1b | INTERFERON GAMMA-1B | Interferon gamma-1b | Interferon gamma-1b, Recombinant | N(Sup 2)-L-Methionyl-1-139-Interferon G | N(sup 2)-L-Methionyl-1-139-interferon gamma (Human Lymphocyte Protein Moiety Reduced) | Recombinant Interferon Gamma-1b | gamma Interferon 1B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0055271","Eosinophil Lysophospholipase, Human","C100091","Eosinophil lysophospholipase (142 aa, ~16 kDa) is encoded by the human CLC gene. This protein is involved in phospholipid metabolism.","Eosinophil Lysophospholipase | CLC | Charcot-Leyden Crystal Protein | EC 3.1.1.5 | Gal-10 | Galectin-10 | Lysolecithin Acylhydrolase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0202613","Fistulagram","C100092","A diagnostic X-ray procedure on an arteriovenous (AV) fistula following the infusion of a radiopaque contrast material.","Fistulagram | AV Fistulagram | AV Fistulogram | Fistulogram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639089","HGNC_ID","C100094","Indicates that a concept in the 'Gene' branch of the NCI thesaurus maps to a HUGO Gene Nomenclature Committee certified gene.","HGNC_ID | HUGO_ID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1572169","ginger flavor","C100097","A characteristic of a medicinal product, specifying that its most predominant agreeable savor detected by the unified sensation of taste and olfactory receptors resembles ginger, the rhizome of the perennial plant Zingiber officinale.","Ginger Flavor | GINGER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL434401","Ademetionine","C100098","No value exists.","Ademetionine | (+-)-5'-((R*)-((R*)-3-Amino-3-carboxypropyl)methylsulfonio)-5'-deoxyadenosine Hydroxide, Inner Salt | ADEMETIONINE | Methionine, S-adenosyl-, DL- | S-Adenosyl-DL-methionine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639283","BPI - Pain Medications in the Last 7 Days","C100299","Brief Pain Inventory (BPI) Did you take pain medications in the last 7 days?","BPI - Pain Medications in the Last 7 Days | BPI1-Pain Medications in the Last 7 Days | BPI110A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514769","Recombinant Angiogenin","C1002","A 14kD non-glycosylated human derived angiogenesis factor, which has the ability to induce neovascularisation with a unique ribonucleolytic activity. (NCI)","Recombinant Angiogenin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639284","BPI - Pain Requires Medication Daily","C100300","Brief Pain Inventory (BPI) I feel I have some form of pain that requires medication each and every day.","BPI - Pain Requires Medication Daily | BPI1-Pain Requires Medication Daily | BPI110B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639285","BPI - Areas of Pain","C100301","Brief Pain Inventory (BPI) On the diagram, shade in the areas where you feel pain.","BPI - Areas of Pain | BPI1-Areas of Pain | BPI111A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639286","BPI - Area Hurts Most","C100302","Brief Pain Inventory (BPI) On the diagram, put an X on the area that hurts the most.","BPI - Area Hurts Most | BPI1-Area Hurts Most | BPI111B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639287","BPI - Pain at its Worst in Last Week","C100303","Brief Pain Inventory (BPI) Please rate your pain by circling the one number that best describes your pain at its worst in the last week.","BPI - Pain at its Worst in Last Week | BPI1-Pain at its Worst in Last Week | BPI112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639289","BPI - Pain on the Average","C100305","Brief Pain Inventory (BPI) Please rate your pain by circling the one number that best describes your pain on the average.","BPI - Pain on the Average | BPI1-Pain on the Average | BPI114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639343","BPI Short Form - Pain at its Worst in Last 24 Hours","C100359","Brief Pain Inventory Short Form (BPI Short Form) Please rate your pain by circling the one number that best describes your pain at its worst in the last 24 hours.","BPI Short Form - Pain at its Worst in Last 24 Hours | BPI2-Pain at its Worst in Last 24 Hours | BPI203",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639344","BPI Short Form - Pain at its Least in Last 24 Hours","C100360","Brief Pain Inventory Short Form (BPI Short Form) Please rate your pain by circling the one number that best describes your pain at its least in the last 24 hours.","BPI Short Form - Pain at its Least in Last 24 Hours | BPI2-Pain at its Least in Last 24 Hours | BPI204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639345","BPI Short Form - Pain on the Average","C100361","Brief Pain Inventory Short Form (BPI Short Form) Please rate your pain by circling the one number that best describes your pain on the average.","BPI Short Form - Pain on the Average | BPI2-Pain on the Average | BPI205",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639347","BPI Short Form - Treatments or Medications Receiving for Pain","C100363","Brief Pain Inventory Short Form (BPI Short Form) What treatments or medications are you receiving for your pain?","BPI Short Form - Treatments or Medications Receiving for Pain | BPI2-Treatments Receiving for Pain | BPI207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639348","BPI Short Form - Relief from Pain Treatments Provided","C100364","Brief Pain Inventory Short Form (BPI Short Form) In the last 24 hours, how much relief have pain treatments or medications provided? Please circle the one percentage that most shows how much relief you have received.","BPI Short Form - Relief from Pain Treatments Provided | BPI2-Relief Pain Treatments Provided | BPI208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639349","BPI Short Form - Pain Interfered with General Activity","C100365","Brief Pain Inventory Short Form (BPI Short Form) Circle the one number that describes how, during the past 24 hours, pain has interfered with your general activity.","BPI Short Form - Pain Interfered with General Activity | BPI2-Pain Interfered General Activity | BPI209A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639350","BPI Short Form - Pain Interfered with Mood","C100366","Brief Pain Inventory Short Form (BPI Short Form) Circle the one number that describes how, during the past 24 hours, pain has interfered with your mood.","BPI Short Form - Pain Interfered with Mood | BPI2-Pain Interfered with Mood | BPI209B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639351","BPI Short Form - Pain Interfered with Walking Ability","C100367","Brief Pain Inventory Short Form (BPI Short Form) Circle the one number that describes how, during the past 24 hours, pain has interfered with your walking ability.","BPI Short Form - Pain Interfered with Walking Ability | BPI2-Pain Interfered Walking Ability | BPI209C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639352","BPI Short Form - Pain Interfered with Normal Work","C100368","Brief Pain Inventory Short Form (BPI Short Form) Circle the one number that describes how, during the past 24 hours, pain has interfered with your normal work.","BPI Short Form - Pain Interfered with Normal Work | BPI2-Pain Interfered with Normal Work | BPI209D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639353","BPI Short Form - Pain Interfered with Relations","C100369","Brief Pain Inventory Short Form (BPI Short Form) Circle the one number that describes how, during the past 24 hours, pain has interfered with your relations with other people.","BPI Short Form - Pain Interfered with Relations | BPI2-Pain Interfered with Relations | BPI209E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279394","cytarabine/prednisone/vincristine/zorubicin","C10036","A regimen consisting of zorubicin, vincristine, cytarabine, and prednisone, that may be used in the treatment of acute myeloid leukemia (AML).","ROAP Regimen | ARA-C/PRED/VCR/RBZ | Cytarabine/Prednisone/Rubidazone/Vincristine | ROAP | Rubidazone-Vincristine-Cytarabine-Prednisone | Rubidazone/Oncovin/Ara-C/Prednisone | Rubidazone/Vincristine/Cytarabine/Prednisone | Rubidazone/Vincristine/Cytarabine/Prednisone Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639354","BPI Short Form - Pain Interfered with Sleep","C100370","Brief Pain Inventory Short Form (BPI Short Form) Circle the one number that describes how, during the past 24 hours, pain has interfered with your sleep.","BPI Short Form - Pain Interfered with Sleep | BPI2-Pain Interfered with Sleep | BPI209F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639355","BPI Short Form - Pain Interfered with Enjoyment of Life","C100371","Brief Pain Inventory Short Form (BPI Short Form) Circle the one number that describes how, during the past 24 hours, pain has interfered with your enjoyment of life.","BPI Short Form - Pain Interfered with Enjoyment of Life | BPI2-Pain Interfered Enjoyment of Life | BPI209G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639356","BPRSA1-Somatic Concern","C100372","Brief Psychiatric Rating Scale-Anchored (BPRS-A) Somatic concern.","BPRS-Anchored - Somatic Concern | BPRS-A - Somatic Concern | BPRSA1-Somatic Concern | BPRSA101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639357","BPRSA1-Anxiety","C100373","Brief Psychiatric Rating Scale-Anchored (BPRS-A) Anxiety.","BPRS-Anchored - Anxiety | BPRS-A - Anxiety | BPRSA1-Anxiety | BPRSA102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639358","BPRSA1-Emotional Withdrawal","C100374","Brief Psychiatric Rating Scale-Anchored (BPRS-A) Emotional withdrawal.","BPRS-Anchored - Emotional Withdrawal | BPRS-A - Emotional Withdrawal | BPRSA1-Emotional Withdrawal | BPRSA103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639359","BPRSA1-Conceptual Disorganization","C100375","Brief Psychiatric Rating Scale-Anchored (BPRS-A) Conceptual disorganization.","BPRS-Anchored - Conceptual Disorganization | BPRS-A - Conceptual Disorganization | BPRSA1-Conceptual Disorganization | BPRSA104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639360","BPRSA1-Guilt Feelings","C100376","Brief Psychiatric Rating Scale-Anchored (BPRS-A) Guilt feelings.","BPRS-Anchored - Guilt Feelings | BPRS-A - Guilt Feelings | BPRSA1-Guilt Feelings | BPRSA105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639361","BPRSA1-Tension","C100377","Brief Psychiatric Rating Scale-Anchored (BPRS-A) Tension.","BPRS-Anchored - Tension | BPRS-A - Tension | BPRSA1-Tension | BPRSA106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639363","BPRSA1-Grandiosity","C100379","Brief Psychiatric Rating Scale-Anchored (BPRS-A) Grandiosity.","BPRS-Anchored - Grandiosity | BPRS-A - Grandiosity | BPRSA1-Grandiosity | BPRSA108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639364","BPRSA1-Depressive Mood","C100380","Brief Psychiatric Rating Scale-Anchored (BPRS-A) Depressive mood.","BPRS-Anchored - Depressive Mood | BPRS-A - Depressive Mood | BPRSA1-Depressive Mood | BPRSA109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639365","BPRSA1-Hostility","C100381","Brief Psychiatric Rating Scale-Anchored (BPRS-A) Hostility.","BPRS-Anchored - Hostility | BPRS-A - Hostility | BPRSA1-Hostility | BPRSA110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639366","BPRSA1-Suspiciousness","C100382","Brief Psychiatric Rating Scale-Anchored (BPRS-A) Suspiciousness.","BPRS-Anchored - Suspiciousness | BPRS-A - Suspiciousness | BPRSA1-Suspiciousness | BPRSA111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639367","BPRSA1-Hallucinatory Behavior","C100383","Brief Psychiatric Rating Scale-Anchored (BPRS-A) Hallucinatory behavior.","BPRS-Anchored - Hallucinatory Behavior | BPRS-A - Hallucinatory Behavior | BPRSA1-Hallucinatory Behavior | BPRSA112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639368","BPRSA1-Motor Retardation","C100384","Brief Psychiatric Rating Scale-Anchored (BPRS-A) Motor retardation.","BPRS-Anchored - Motor Retardation | BPRS-A - Motor Retardation | BPRSA1-Motor Retardation | BPRSA113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639369","BPRSA1-Uncooperativeness","C100385","Brief Psychiatric Rating Scale-Anchored (BPRS-A) Uncooperativeness.","BPRS-Anchored - Uncooperativeness | BPRS-A - Uncooperativeness | BPRSA1-Uncooperativeness | BPRSA114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639370","BPRSA1-Unusual Thought Content","C100386","Brief Psychiatric Rating Scale-Anchored (BPRS-A) Unusual thought content.","BPRS-Anchored - Unusual Thought Content | BPRS-A - Unusual Thought Content | BPRSA1-Unusual Thought Content | BPRSA115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639371","BPRSA1-Blunted Affect","C100387","Brief Psychiatric Rating Scale-Anchored (BPRS-A) Blunted affect.","BPRS-Anchored - Blunted Affect | BPRS-A - Blunted Affect | BPRSA1-Blunted Affect | BPRSA116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639372","BPRSA1-Excitement","C100388","Brief Psychiatric Rating Scale-Anchored (BPRS-A) Excitement.","BPRS-Anchored - Excitement | BPRS-A - Excitement | BPRSA1-Excitement | BPRSA117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639373","BPRSA1-Disorientation","C100389","Brief Psychiatric Rating Scale-Anchored (BPRS-A) Disorientation.","BPRS-Anchored - Disorientation | BPRS-A - Disorientation | BPRSA1-Disorientation | BPRSA118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639374","Mean QRS Duration Ventricular Paced","C100390","The average (mean) duration (time) of the QRS interval, obtained from a set of measurements of the QRS interval while the ventricle rhythm is controlled by an electrical impulse from a mechanical cardiac pacemaker. The QRS interval is defined as the time from the beginning of the QRS complex to the end of the QRS complex, representing the time it takes for the ventricles to depolarize.","Mean QRS Duration Ventricular Paced | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639375","EQ-5D-3L - Mobility","C100392","The EuroQol (European Quality of Life) Five Dimension Three Level Scale (EQ-5D-3L) Indicate which statements best describe your own health state today: Mobility.","EQ-5D-3L - Mobility | EQ5D01-Mobility | EQ5D0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639377","EQ-5D-3L - Usual Activities","C100394","The EuroQol (European Quality of Life) Five Dimension Three Level Scale (EQ-5D-3L) Indicate which statements best describe your own health state today: Usual activities.","EQ-5D-3L - Usual Activities | EQ5D01-Usual Activities | EQ5D0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639378","EQ-5D-3L - Pain or Discomfort","C100395","The EuroQol (European Quality of Life) Five Dimension Three Level Scale (EQ-5D-3L) Indicate which statements best describe your own health state today: Pain or discomfort.","EQ-5D-3L - Pain or Discomfort | EQ5D01-Pain/Discomfort | EQ5D0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639379","EQ-5D-3L - Anxiety or Depression","C100396","The EuroQol (European Quality of Life) Five Dimension Three Level Scale (EQ-5D-3L) Indicate which statements best describe your own health state today: Anxiety or depression.","EQ-5D-3L - Anxiety or Depression | EQ5D01-Anxiety/Depression | EQ5D0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639381","HAMD-17 - Depressed Mood","C100398","Hamilton Depression Rating Scale 17 Item (HAMD-17) Depressed mood: sadness, hopeless, helpless, worthless.","HAMD-17 - Depressed Mood | HAMD1-Depressed Mood | HAMD101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639382","HAMD-17 - Feelings of Guilt","C100399","Hamilton Depression Rating Scale 17 Item (HAMD-17) Feelings of guilt.","HAMD-17 - Feelings of Guilt | HAMD1-Feelings of Guilt | HAMD102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0051936","Ansamycins","C1003","An antineoplastic antibiotic of macrocyclic benzoquinone isolated from the bacterial genus Streptomyces. Ansamycin antibiotics bind to and inhibit the cytosolic chaperone functions of heat shock protein 90 (HSP90). HSP90 maintains the stability and functional shape of many oncogenic signaling proteins and the inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins that may be over-expressed or overactive in tumor cells.","Ansamycin Antineoplastic Antibiotic | Ansamycin Antibiotics | Ansamycins | ansamycin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639383","HAMD-17 - Suicide","C100400","Hamilton Depression Rating Scale 17 Item (HAMD-17) Suicide.","HAMD-17 - Suicide | HAMD1-Suicide | HAMD103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639247","CDISC ADAS-Cog - Word Recognition: Word 12","C100262","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 12 Trials 1, 2, 3.","CDISC ADAS-Cog - Word Recognition: Word 12 | ADCRGW12 | Word Recognition: Word [12]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639248","CDISC ADAS-Cog - Word Recognition: Word 13","C100263","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 13 Trials 1, 2, 3.","CDISC ADAS-Cog - Word Recognition: Word 13 | ADCRGW13 | Word Recognition: Word [13]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639249","CDISC ADAS-Cog - Word Recognition: Word 14","C100264","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 14 Trials 1, 2, 3.","CDISC ADAS-Cog - Word Recognition: Word 14 | ADCRGW14 | Word Recognition: Word [14]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639250","CDISC ADAS-Cog - Word Recognition: Word 15","C100265","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 15 Trials 1, 2, 3.","CDISC ADAS-Cog - Word Recognition: Word 15 | ADCRGW15 | Word Recognition: Word [15]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639251","CDISC ADAS-Cog - Word Recognition: Word 16","C100266","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 16 Trials 1, 2, 3.","CDISC ADAS-Cog - Word Recognition: Word 16 | ADCRGW16 | Word Recognition: Word [16]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639252","CDISC ADAS-Cog - Word Recognition: Word 17","C100267","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 17 Trials 1, 2, 3.","CDISC ADAS-Cog - Word Recognition: Word 17 | ADCRGW17 | Word Recognition: Word [17]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639253","CDISC ADAS-Cog - Word Recognition: Word 18","C100268","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 18 Trials 1, 2, 3.","CDISC ADAS-Cog - Word Recognition: Word 18 | ADCRGW18 | Word Recognition: Word [18]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639254","CDISC ADAS-Cog - Word Recognition: Word 19","C100269","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 19 Trials 1, 2, 3.","CDISC ADAS-Cog - Word Recognition: Word 19 | ADCRGW19 | Word Recognition: Word [19]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639255","CDISC ADAS-Cog - Word Recognition: Word 20","C100270","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 20 Trials 1, 2, 3.","CDISC ADAS-Cog - Word Recognition: Word 20 | ADCRGW20 | Word Recognition: Word [20]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639256","CDISC ADAS-Cog - Word Recognition: Word 21","C100271","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 21 Trials 1, 2, 3.","CDISC ADAS-Cog - Word Recognition: Word 21 | ADCRGW21 | Word Recognition: Word [21]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639258","CDISC ADAS-Cog - Word Recognition: Word 23","C100273","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 23 Trials 1, 2, 3.","CDISC ADAS-Cog - Word Recognition: Word 23 | ADCRGW23 | Word Recognition: Word [23]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639259","CDISC ADAS-Cog - Word Recognition: Word 24","C100274","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 24 Trials 1, 2, 3.","CDISC ADAS-Cog - Word Recognition: Word 24 | ADCRGW24 | Word Recognition: Word [24]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639260","CDISC ADAS-Cog - Remembering Test Instructions","C100275","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Remembering test instructions.","CDISC ADAS-Cog - Remembering Test Instructions | ADCRI | Remembering Test Instructions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639261","CDISC ADAS-Cog - Spoken Language Ability","C100276","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Global rating of the quality of speech, or difficulty in making oneself understood.","CDISC ADAS-Cog - Spoken Language Ability | ADCSL | Spoken Language Ability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639262","CDISC ADAS-Cog - Word Difficulty in Spontaneous Speech","C100277","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Difficulty finding the desired word in spontaneous speech.","CDISC ADAS-Cog - Word Difficulty in Spontaneous Speech | ADCDIF | Word Finding Difficulty in Spont Speech",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542413","CDISC ADAS-Cog - Comprehension","C100278","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Ability to comprehend speech.","CDISC ADAS-Cog - Comprehension | ADCCMP | Comprehension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639263","CDISC ADAS-Cog - Concentration/Distractibility","C100279","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Ability to concentrate or easily be distracted.","CDISC ADAS-Cog - Concentration/Distractibility | ADCCON | Concentration/Distractibility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639264","CDISC ADAS-Cog - Number Cancellation Summary Score","C100280","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Summary score for the number cancellation tasks.","CDISC ADAS-Cog - Number Cancellation Summary Score | ADCNC | Number Cancellation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639265","CDISC ADAS-Cog - Number Cancellation: Correct","C100281","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Number of targets hit during the number cancellation task.","CDISC ADAS-Cog - Number Cancellation: Correct | ADCNC01 | Number Cancellation: Correct",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639266","CDISC ADAS-Cog - Number Cancellation: Errors","C100282","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Number of errors during the number cancellation task.","CDISC ADAS-Cog - Number Cancellation: Errors | ADCNC02 | Number Cancellation: Errors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639267","CDISC ADAS-Cog - Number Cancellation: Remind","C100283","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Number of times reminded for the number cancellation task.","CDISC ADAS-Cog - Number Cancellation: Remind | ADCNC03 | Number Cancellation: Remind",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639268","CDISC ADAS-Cog - Executive Function Maze Summary Score","C100284","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Summary score for the executive function maze tasks.","CDISC ADAS-Cog - Executive Function Maze Summary Score | ADCMZ | Executive Function Maze",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639269","CDISC ADAS-Cog - Executive Function Maze: Errors","C100285","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Number of errors during the executive function maze task.","CDISC ADAS-Cog - Executive Function Maze: Errors | ADCMZ01 | Executive Function Maze: Errors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639270","CDISC ADAS-Cog - Executive Function Maze: Time","C100286","Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) The time taken to complete the executive function maze task.","CDISC ADAS-Cog - Executive Function Maze: Time | ADCMZ02 | Executive Function Maze: Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639271","BPI - Marital Status","C100287","Brief Pain Inventory (BPI) Marital status.","BPI - Marital Status | BPI1-Marital Status | BPI101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639272","BPI - Education","C100288","Brief Pain Inventory (BPI) Education.","BPI - Education | BPI1-Education | BPI102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279375","carmustine/cyclophosphamide/melphalan/prednisone","C10028","A regimen consisting of melphalan, cyclophosphamide, carmustine, and prednisone that may be used in the treatment of plasma cell myeloma.","MCBP Regimen | BCNU/CTX/L-PAM/PRED | Carmustine/Cyclophosphamide/Melphalan/Prednisone | MCBP | Melphalan-Cyclophosphamide-Carmustine-Prednisone | Melphalan/Cyclophosphamide/BCNU/Prednisone | Melphalan/Cyclophosphamide/Carmustine/Prednisone | Melphalan/Cyclophosphamide/Carmustine/Prednisone Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639274","BPI - Current Occupation","C100290","Brief Pain Inventory (BPI) Current occupation.","BPI - Current Occupation | BPI1-Current Occupation | BPI103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639275","BPI - Spouse's Occupation","C100291","Brief Pain Inventory (BPI) Spouse's occupation.","BPI - Spouse's Occupation | BPI1-Spouse's Occupation | BPI104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639276","BPI - Current Job Status","C100292","Brief Pain Inventory (BPI) Which of the following best describes your current job status?","BPI - Current Job Status | BPI1-Current Job Status | BPI105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639277","BPI - How Long Since Diagnosis","C100293","Brief Pain Inventory (BPI) How long has it been since you first learned your diagnosis?","BPI - How Long Since Diagnosis | BPI1-How Long Since Diagnosis | BPI106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639278","BPI - Pain Due to Present Disease","C100294","Brief Pain Inventory (BPI) Have you ever had pain due to your present disease?","BPI - Pain Due to Present Disease | BPI1-Pain Due to Present Disease | BPI107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639279","BPI - Pain as a Symptom","C100295","Brief Pain Inventory (BPI) When you first received your diagnosis, was pain one of your symptoms?","BPI - Pain as a Symptom | BPI1-Pain One of Your Symptoms | BPI108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639280","BPI - Surgery in Past Month","C100296","Brief Pain Inventory (BPI) Have you had surgery in the past month?","BPI - Surgery in Past Month | BPI1-Surgery in Past Month | BPI109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639282","BPI - Pain Other than Everyday Kinds","C100298","Brief Pain Inventory (BPI) Have you had pain other than these everyday kinds of pain during the last week?","BPI - Pain Other than Everyday Kinds | BPI1-Pain Other than Everyday Kinds | BPI110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639318","BPI - Pain Interfered with Normal Work","C100334","Brief Pain Inventory (BPI) Circle the one number that describes how, during the past week, pain has interfered with your normal work.","BPI - Pain Interfered with Normal Work | BPI1-Pain Interfered with Normal Work | BPI123D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639319","BPI - Pain Interfered with Relations","C100335","Brief Pain Inventory (BPI) Circle the one number that describes how, during the past week, pain has interfered with your relations with other people.","BPI - Pain Interfered with Relations | BPI1-Pain Interfered with Relations | BPI123E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639320","BPI - Pain Interfered with Sleep","C100336","Brief Pain Inventory (BPI) Circle the one number that describes how, during the past week, pain has interfered with your sleep.","BPI - Pain Interfered with Sleep | BPI1-Pain Interfered with Sleep | BPI123F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639321","BPI - Pain Interfered with Enjoyment of Life","C100337","Brief Pain Inventory (BPI) Circle the one number that describes how, during the past week, pain has interfered with your enjoyment of life.","BPI - Pain Interfered with Enjoyment of Life | BPI1-Pain Interfered Enjoyment of Life | BPI123G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639323","BPI - Take my Pain Medicine","C100339","Brief Pain Inventory (BPI) I take my pain medicine (in a 24 hour period).","BPI - Take my Pain Medicine | BPI1-Take my Pain Medicine | BPI125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639324","BPI - Need Stronger Type of Pain Medication","C100340","Brief Pain Inventory (BPI) Do you feel you need a stronger type of pain medication?","BPI - Need Stronger Type of Pain Medication | BPI1-Need Stronger Type of Pain Med | BPI126",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639325","BPI - Need more Pain Medication than Prescribed","C100341","Brief Pain Inventory (BPI) Do you feel you need to take more of the pain medication than your doctor has prescribed?","BPI - Need more Pain Medication than Prescribed | BPI1-Need more Pain Med than Prescribed | BPI127",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639326","BPI - Concerned with Too Much Pain Medication Use","C100342","Brief Pain Inventory (BPI) Are you concerned that you use too much pain medication?","BPI - Concerned with Too Much Pain Medication Use | BPI1-Concerned Use Too Much Pain Med | BPI128",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639327","BPI - Why Concerned with Too Much Pain Medication Use","C100343","Brief Pain Inventory (BPI) Are you concerned that you use too much pain medication? If Yes, why?","BPI - Why Concerned with Too Much Pain Medication Use | BPI1-Why Concerned Use Too Much Pain Med | BPI128A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639328","BPI - Problems with Side Effects Pain Medication","C100344","Brief Pain Inventory (BPI) Are you having problems with side effects from your pain medication?","BPI - Problems with Side Effects Pain Medication | BPI1-Problems with Side Effects Pain Med | BPI129",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639329","BPI - What Side Effects from Pain Medication","C100345","Brief Pain Inventory (BPI) Are you having problems with side effects from your pain medication? Which side effects?","BPI - What Side Effects from Pain Medication | BPI1-Which Side Effects from Pain Med | BPI129A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639330","BPI - Need Further Information about Pain Medication","C100346","Brief Pain Inventory (BPI) Do you feel you need to receive further information about your pain medication?","BPI - Need Further Information about Pain Medication | BPI1-Need Further Info about Pain Med | BPI130",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639338","BPI - Specified Other Method to Relieve Pain","C100354","Brief Pain Inventory (BPI) Other methods I use to relieve pain include; other. Please specify.","BPI - Specified Other Method to Relieve Pain | BPI1-Other specify to Relieve Pain | BPI131H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639340","BPI Short Form - Pain Other Than Everyday Kinds","C100356","Brief Pain Inventory Short Form (BPI Short Form) Have you had pain other than these everyday kinds of pain today?","BPI Short Form - Pain Other Than Everyday Kinds | BPI2-Pain Other Than Everyday Kinds | BPI201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639299","BPI - Describe Unrelated Medical Condition","C100315","Brief Pain Inventory (BPI) I believe my pain is due to a medical condition unrelated to my primary disease. Please describe condition.","BPI - Describe Unrelated Medical Condition | BPI1-Describe Unrelated Med Condition | BPI1213A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639300","BPI - Aching","C100316","Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; aching.","BPI - Aching | BPI1-Aching | BPI122A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639302","BPI - Shooting","C100318","Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; shooting.","BPI - Shooting | BPI1-Shooting | BPI122C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639303","BPI - Stabbing","C100319","Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; stabbing.","BPI - Stabbing | BPI1-Stabbing | BPI122D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279383","dactinomycin/doxorubicin/methotrexate/vincristine","C10031","A regimen consisting of dactinomycin, doxorubicin, methotrexate and vincristine that can be used for the treatment of advanced soft tissue sarcoma.","Dactinomycin/Doxorubicin/Methotrexate/Vincristine Regimen | DACT/DOX/MTX/VCR | Dactinomycin-Doxorubicin-Methotrexate-Vincristine | Dactinomycin/Doxorubicin/Methotrexate/Vincristine | OMAD | VMAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639304","BPI - Gnawing","C100320","Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; gnawing.","BPI - Gnawing | BPI1-Gnawing | BPI122E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639305","BPI - Sharp","C100321","Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; sharp.","BPI - Sharp | BPI1-Sharp | BPI122F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639306","BPI - Tender","C100322","Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; tender.","BPI - Tender | BPI1-Tender | BPI122G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639307","BPI - Burning","C100323","Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; burning.","BPI - Burning | BPI1-Burning | BPI122H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639309","BPI - Tiring","C100325","Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; tiring.","BPI - Tiring | BPI1-Tiring | BPI122J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639311","BPI - Nagging","C100327","Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; nagging.","BPI - Nagging | BPI1-Nagging | BPI122L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522603","MMSE - Spell Backward Letter 5","C100569","Mini-Mental State Examination (MMSE) Spell backward, letter 5.","MMSE - Spell Backward Letter 5 | MMS1-Spell Backward Letter 5 | MMS104BE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522604","MMSE - Attention and Calculation Subtotal","C100570","Mini-Mental State Examination (MMSE) Attention and calculation subtotal.","MMSE - Attention and Calculation Subtotal | MMS1-Attention and Calculation Subtotal | MMS104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522605","MMSE - Recall Word 1","C100572","Mini-Mental State Examination (MMSE) What were those three words I asked you to remember: Word 1?","MMSE - Recall Word 1 | MMS1-Recall Word 1 | MMS105A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639521","MMSE - Recall Word 2","C100573","Mini-Mental State Examination (MMSE) What were those three words I asked you to remember: Word 2?","MMSE - Recall Word 2 | MMS1-Recall Word 2 | MMS105B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522606","MMSE - Recall Word 3","C100574","Mini-Mental State Examination (MMSE) What were those three words I asked you to remember: Word 3?","MMSE - Recall Word 3 | MMS1-Recall Word 3 | MMS105C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639523","MMSE - Question 6","C100575","The Mini-Mental State Examination (MMSE) Question 6.","MMSE - Question 6 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522607","MMSE - Naming Object 1","C100576","Mini-Mental State Examination (MMSE) What is this: Object 1?","MMSE - Naming Object 1 | MMS1-Naming Object 1 | MMS106A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522608","MMSE - Naming Object 2","C100577","Mini-Mental State Examination (MMSE) What is this: Object 2?","MMSE - Naming Object 2 | MMS1-Naming Object 2 | MMS106B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639421","MDS-UPDRS - Cognitive Impairment","C100473","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week have you had problems remembering things, following conversations, paying attention, thinking clearly, or finding your way around the house or in town?","MDS-UPDRS - Cognitive Impairment | UPD2-Cognitive Impairment | UPD2101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639422","MDS-UPDRS - Hallucinations and Psychosis","C100474","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week have you seen, heard, smelled or felt things that were not really there?","MDS-UPDRS - Hallucinations and Psychosis | UPD2-Hallucinations and Psychosis | UPD2102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639424","MDS-UPDRS - Anxious Mood","C100476","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week have you felt nervous, worried or tense? If yes, was this feeling for longer than one day at a time? Did it make it difficult for you to follow your usual activities or to be with other people?","MDS-UPDRS - Anxious Mood | UPD2-Anxious Mood | UPD2104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639425","MDS-UPDRS - Apathy","C100477","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you felt indifferent to doing activities or being with people?","MDS-UPDRS - Apathy | UPD2-Apathy | UPD2105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639426","MDS-UPDRS - Features of Dopamine Dysregulation Syndrome","C100478","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you had unusually strong urges that are hard to control? Do you feel driven to do or think about something and find it hard to stop?","MDS-UPDRS - Features of Dopamine Dysregulation Syndrome | UPD2-Ftrs Dopa Dysregulation Synd | UPD2106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639427","MDS-UPDRS - Sleep Problems","C100479","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you had trouble going to sleep at night or staying asleep through the night?","MDS-UPDRS - Sleep Problems | UPD2-Sleep Problems | UPD2107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639428","MDS-UPDRS - Daytime Sleepiness","C100480","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you had trouble staying awake during the daytime?","MDS-UPDRS - Daytime Sleepiness | UPD2-Daytime Sleepiness | UPD2108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639429","MDS-UPDRS - Pain and Other Sensations","C100481","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you had uncomfortable feelings in your body like pain, aches tingling or cramps?","MDS-UPDRS - Pain and Other Sensations | UPD2-Pain and other Sensations | UPD2109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639430","MDS-UPDRS - Urinary Problems","C100482","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you had trouble with urine control?","MDS-UPDRS - Urinary Problems | UPD2-Urinary Problems | UPD2110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639431","MDS-UPDRS - Constipation Problems","C100483","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week have you had constipation troubles that cause you difficulty moving your bowels?","MDS-UPDRS - Constipation Problems | UPD2-Constipation Problems | UPD2111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639432","MDS-UPDRS - Lightheadedness on Standing","C100484","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you felt faint, dizzy or foggy when you stand up after sitting or lying down?","MDS-UPDRS - Lightheadedness on Standing | UPD2-Lightheadedness on Standing | UPD2112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639433","MDS-UPDRS - Fatigue","C100485","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you usually felt fatigued?","MDS-UPDRS - Fatigue | UPD2-Fatigue | UPD2113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639434","MDS-UPDRS - Speech","C100486","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you had problems with your speech?","MDS-UPDRS - Speech | UPD2-Speech | UPD2201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639436","MDS-UPDRS - Chewing and Swallowing","C100488","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you usually had problems swallowing pills or eating meals?","MDS-UPDRS - Chewing and Swallowing | UPD2-Chewing and Swallowing | UPD2203",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639437","MDS-UPDRS - Eating Tasks","C100489","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you usually had troubles handling your food and using eating utensils?","MDS-UPDRS - Eating Tasks | UPD2-Eating Tasks | UPD2204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639438","MDS-UPDRS - Dressing","C100490","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you usually had problems dressing?","MDS-UPDRS - Dressing | UPD2-Dressing | UPD2205",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639439","MDS-UPDRS - Hygiene","C100491","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you usually been slow or do you need help with washing, bathing, shaving, brushing teeth, combing your hair or with other personal hygiene?","MDS-UPDRS - Hygiene | UPD2-Hygiene | UPD2206",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639440","MDS-UPDRS - Handwriting","C100492","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have people usually had trouble reading your handwriting?","MDS-UPDRS - Handwriting | UPD2-Handwriting | UPD2207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639441","MDS-UPDRS - Doing Hobbies and Other Activities","C100493","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you usually had trouble doing your hobbies or other things that you like to do?","MDS-UPDRS - Doing Hobbies and Other Activities | UPD2-Doing Hobbies/Other Activities | UPD2208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639442","MDS-UPDRS - Turning in Bed","C100494","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, do you usually have trouble turning over in bed?","MDS-UPDRS - Turning in Bed | UPD2-Turning in Bed | UPD2209",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639443","MDS-UPDRS - Tremor","C100495","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you usually had shaking or tremor?","MDS-UPDRS - Tremor | UPD2-Tremor | UPD2210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639444","MDS-UPDRS - Walking and Balance","C100496","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you usually had problems with balance and walking?","MDS-UPDRS - Walking and Balance | UPD2-Walking and Balance | UPD2212",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639313","BPI - Miserable","C100329","Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; miserable.","BPI - Miserable | BPI1-Miserable | BPI122N",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639314","BPI - Unbearable","C100330","Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; unbearable.","BPI - Unbearable | BPI1-Unbearable | BPI122O",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639315","BPI - Pain Interfered with General Activity","C100331","Brief Pain Inventory (BPI) Circle the one number that describes how, during the past week, pain has interfered with your general activity.","BPI - Pain Interfered with General Activity | BPI1-Pain Interfered General Activity | BPI123A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639316","BPI - Pain Interfered with Mood","C100332","Brief Pain Inventory (BPI) Circle the one number that describes how, during the past week, pain has interfered with your mood.","BPI - Pain Interfered with Mood | BPI1-Pain Interfered with Mood | BPI123B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639317","BPI - Pain Interfered with Walking Ability","C100333","Brief Pain Inventory (BPI) Circle the one number that describes how, during the past week, pain has interfered with your walking ability.","BPI - Pain Interfered with Walking Ability | BPI1-Pain Interfered Walking Ability | BPI123C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639507","MMSE - What is 100 Take Away 7","C100559","Mini-Mental State Examination (MMSE) What is 100 take away 7 [93]?","MMSE - What is 100 Take Away 7 | MMS1-What is 100 Take Away 7 | MMS104AA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522597","MMSE - Keep Subtracting 7 Step 2","C100560","Mini-Mental State Examination (MMSE) Keep going [86].","MMSE - Keep Subtracting 7 Step 2 | MMS1-Keep Subtracting 7 Step 2 | MMS104AB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522598","MMSE - Keep Subtracting 7 Step 3","C100561","Mini-Mental State Examination (MMSE) Keep going [79].","MMSE - Keep Subtracting 7 Step 3 | MMS1-Keep Subtracting 7 Step 3 | MMS104AC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522599","MMSE - Keep Subtracting 7 Step 4","C100562","Mini-Mental State Examination (MMSE) Keep going [72].","MMSE - Keep Subtracting 7 Step 4 | MMS1-Keep Subtracting 7 Step 4 | MMS104AD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639511","MMSE - Keep Subtracting 7 Step 5","C100563","Mini-Mental State Examination (MMSE) Keep going [65].","MMSE - Keep Subtracting 7 Step 5 | MMS1-Keep Subtracting 7 Step 5 | MMS104AE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639513","MMSE - Spell Backward Letter 1","C100565","Mini-Mental State Examination (MMSE) Spell backward, letter 1.","MMSE - Spell Backward Letter 1 | MMS1-Spell Backward Letter 1 | MMS104BA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522600","MMSE - Spell Backward Letter 2","C100566","Mini-Mental State Examination (MMSE) Spell backward, letter 2.","MMSE - Spell Backward Letter 2 | MMS1-Spell Backward Letter 2 | MMS104BB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522601","MMSE - Spell Backward Letter 3","C100567","Mini-Mental State Examination (MMSE) Spell backward, letter 3.","MMSE - Spell Backward Letter 3 | MMS1-Spell Backward Letter 3 | MMS104BC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522602","MMSE - Spell Backward Letter 4","C100568","Mini-Mental State Examination (MMSE) Spell backward, letter 4.","MMSE - Spell Backward Letter 4 | MMS1-Spell Backward Letter 4 | MMS104BD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639384","HAMD-17 - Insomnia - Early Night","C100401","Hamilton Depression Rating Scale 17 Item (HAMD-17) Insomnia; early in the night.","HAMD-17 - Insomnia - Early Night | HAMD1-Insomnia Early - Early Night | HAMD104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639385","HAMD-17 - Insomnia - Middle Night","C100402","Hamilton Depression Rating Scale 17 Item (HAMD-17) Insomnia; middle of the night.","HAMD-17 - Insomnia - Middle Night | HAMD1-Insomnia Middle - Middle Night | HAMD105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639386","HAMD-17 - Insomnia - Early Morning","C100403","Hamilton Depression Rating Scale 17 Item (HAMD-17) Insomnia; early hours of the morning.","HAMD-17 - Insomnia - Early Morning | HAMD1-Insomnia Early Hours - Morning | HAMD106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639387","HAMD-17 - Work and Activities","C100404","Hamilton Depression Rating Scale 17 Item (HAMD-17) Work and activities.","HAMD-17 - Work and Activities | HAMD1-Work and Activities | HAMD107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639388","HAMD-17 - Retardation","C100405","Hamilton Depression Rating Scale 17 Item (HAMD-17) Retardation.","HAMD-17 - Retardation | HAMD1-Retardation | HAMD108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639390","HAMD-17 - Psychic Anxiety","C100407","Hamilton Depression Rating Scale 17 Item (HAMD-17) Anxiety psychic.","HAMD-17 - Psychic Anxiety | HAMD1-Anxiety Psychic | HAMD110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639391","HAMD-17 - Somatic Anxiety","C100408","Hamilton Depression Rating Scale 17 Item (HAMD-17) Anxiety somatic: physiological concomitants of anxiety such as gastro-intestinal (dry mouth, wind, indigestion, diarrhea, cramps, belching), cardiovascular (palpitations, headaches), respiratory (hyperventilation, sighing), urinary frequency, sweating.","HAMD-17 - Somatic Anxiety | HAMD1-Anxiety Somatic | HAMD111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639392","HAMD112","C100409","Hamilton Depression Rating Scale 17 Item (HAMD-17) Somatic symptoms gastro-intestinal.","HAMD-17 - Somatic Symptoms Gastrointestinal | HAMD1-Somatic Symptoms Gastrointestinal | HAMD112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639393","HAMD-17 - General Somatic Symptoms","C100410","Hamilton Depression Rating Scale 17 Item (HAMD-17) General somatic symptoms.","HAMD-17 - General Somatic Symptoms | HAMD1-General Somatic Symptoms | HAMD113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639394","HAMD-17 - Genital Symptoms","C100411","Hamilton Depression Rating Scale 17 Item (HAMD-17) Genital symptoms: symptoms such as loss of libido, menstrual disturbances.","HAMD-17 - Genital Symptoms | HAMD1-Genital Symptoms | HAMD114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639395","HAMD-17 - Hypochondriasis","C100412","Hamilton Depression Rating Scale 17 Item (HAMD-17) Hypochondriasis.","HAMD-17 - Hypochondriasis | HAMD1-Hypochondriasis | HAMD115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639396","HAMD-17 - Loss of Weight According to Patient","C100413","Hamilton Depression Rating Scale 17 Item (HAMD-17) Loss of weight according to the patient.","HAMD-17 - Loss of Weight According to Patient | HAMD1-Loss of WT According to Patient | HAMD116A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639398","HAMD-17 - Insight","C100415","Hamilton Depression Rating Scale 17 Item (HAMD-17) Insight.","HAMD-17 - Insight | HAMD1-Insight | HAMD117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639399","HAMD-17 - Total Score","C100416","Hamilton Depression Rating Scale 17 Item (HAMD-17) Total Score.","HAMD-17 - Total Score | HAMD1-Total Score | HAMD118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639556","MNSI - Left Foot Appears Normal","C100608","Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; appearance of left foot - normal.","MNSI - Left Foot Appears Normal | MNSI1-Left Foot Appears Normal | MNSI123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639557","MNSI - Left Foot Deformities","C100609","Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; appearance of left foot - deformities.","MNSI - Left Foot Deformities | MNSI1-Left Foot Deformities | MNSI124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639559","MNSI - Left Foot Fissure","C100611","Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; appearance of left foot - fissure.","MNSI - Left Foot Fissure | MNSI1-Left Foot Fissure | MNSI127",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639560","MNSI - Left Foot Other Abnormal Specify","C100612","Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; appearance of left foot - other, specify.","MNSI - Left Foot Other Abnormal Specify | MNSI1-Left Foot Other Abnormal Specify | MNSI128",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639641","NPI - Rapidly Change Moods From One to Another","C100693","Neuropsychiatric Inventory (NPI) Does the patient rapidly change moods from one to another, being fine one minute and angry the next?","NPI - Rapidly Change Moods From One to Another | NPI1-Rapidly Change Moods | NPI1I02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639642","NPI - Sudden Flares of Anger","C100694","Neuropsychiatric Inventory (NPI) Does the patient have sudden flashes of anger?","NPI - Sudden Flares of Anger | NPI1-Sudden Anger | NPI1I03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639643","NPI - Impatient, Having Trouble Coping with Delays","C100695","Neuropsychiatric Inventory (NPI) Is the patient impatient, having trouble coping with delays or waiting for planned activities?","NPI - Impatient, Having Trouble Coping with Delays | NPI1-Impatient | NPI1I04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639644","NPI - Cranky and Irritable","C100696","Neuropsychiatric Inventory (NPI) Is the patient cranky and irritable?","NPI - Cranky and Irritable | NPI1-Cranky and Irritable | NPI1I05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639645","NPI - Argumentative and Difficult to Get Along With","C100697","Neuropsychiatric Inventory (NPI) Is the patient argumentative and difficult to get along with?","NPI - Argumentative and Difficult to Get Along With | NPI1-Argumentative | NPI1I06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639646","NPI - Show Any Other Signs of Irritability","C100698","Neuropsychiatric Inventory (NPI) Does the patient show any other signs of irritability?","NPI - Show Any Other Signs of Irritability | NPI1-Other Signs of Irritability | NPI1I07",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639647","NPI - Pace, Do Things Over and Over, Repeatedly Pick at Things","C100699","Neuropsychiatric Inventory (NPI) Does the patient pace, do things over and over such as opening closets or drawers, or repeatedly pick at things or wind string or threads?","NPI - Pace, Do Things Over and Over, Repeatedly Pick at Things | NPI1-Do Things Repeatedly | NPI1J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706673","Ammonium Trichlorotellurate","C1006","A synthetic non-toxic tellurium derivative, structurally similar to cisplatin, with immunostimulatory and anti-hair loss properties. Ammonium trichlorotellurate induces production of colony stimulating factor (CSF), interleukin-2 (IL-2), and IL-2 receptors by increasing the calcium ion influx through the cell membrane and subsequently exerts its immunostimulatory effects through the CSF-mediated increase in macrophage/granulocytes. This agent is also a potent inducer of interferon and a spectrum of cytokines such as IL-1, IL-6, and tumor necrosis factor (TNF). In animal studies, ammonium trichlorotellurate exerts its anti-hair loss effect by inducing anagen and obstructing spontaneous catagen via promoting follicular keratinocyte proliferation and interfering with terminal differentiation, respectively.","Ammonium Trichlorotellurate | AMMONIUM TRICHLOROTELLURATE | AS-101 | IVX-Q-101 | Ossirene | Tellurate(1-), trichloro[1,2-ethanediolato(2-)-kappa-O,kappa-O']-,ammonium, (SP-5-22)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639648","NPI - Pace Around the House Without Apparent Purpose","C100700","Neuropsychiatric Inventory (NPI) Does the patient pace around the house without apparent purpose?","NPI - Pace Around the House Without Apparent Purpose | NPI1-Pace | NPI1J01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639649","NPI - Rummage Around Opening and Unpacking Drawers or Closets","C100701","Neuropsychiatric Inventory (NPI) Does the patient rummage around opening and unpacking drawers or closets?","NPI - Rummage Around Opening and Unpacking Drawers or Closets | NPI1-Rummage Around and Unpack | NPI1J02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639650","NPI - Repeatedly Put On and Take Off Clothing","C100702","Neuropsychiatric Inventory (NPI) Does the patient repeatedly put on and take off clothing?","NPI - Repeatedly Put On and Take Off Clothing | NPI1-Repeatedly Change Clothing | NPI1J03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639651","NPI - Repetitive Activities or 'Habits'","C100703","Neuropsychiatric Inventory (NPI) Does the patient have repetitive activities or 'habits' that he/she performs over and over?","NPI - Repetitive Activities or 'Habits' | NPI1-Repetitive Activities or Habits | NPI1J04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639652","NPI - Engage in Repetitive Activities","C100704","Neuropsychiatric Inventory (NPI) Does the patient engage in repetitive activities such as handling buttons, picking, wrapping string, etc.?","NPI - Engage in Repetitive Activities | NPI1-Repetitive Activities | NPI1J05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639654","NPI - Do Any Other Activities Over and Over","C100706","Neuropsychiatric Inventory (NPI) Does the patient do any other activities over and over?","NPI - Do Any Other Activities Over and Over | NPI1-Other Repetitive Activities | NPI1J07",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639561","MNSI - Right Foot Ulceration","C100613","Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; right foot - ulceration.","MNSI - Right Foot Ulceration | MNSI1-Right Foot Ulceration | MNSI129",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639562","MNSI - Left Foot Ulceration","C100614","Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; left foot - ulceration.","MNSI - Left Foot Ulceration | MNSI1-Left Foot Ulceration | MNSI130",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639563","MNSI - Right Ankle Reflexes","C100615","Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; right ankle reflexes.","MNSI - Right Ankle Reflexes | MNSI1-Right Ankle Reflexes | MNSI131",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639564","MNSI - Left Ankle Reflexes","C100616","Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; left ankle reflexes.","MNSI - Left Ankle Reflexes | MNSI1-Left Ankle Reflexes | MNSI132",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639565","MNSI - Right Foot Vibration Great Toe","C100617","Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; right foot - vibration perception at great toe.","MNSI - Right Foot Vibration Great Toe | MNSI1-Right Foot Vibration Great Toe | MNSI133",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639566","MNSI - Left Foot Vibration Great Toe","C100618","Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; left foot - vibration perception at great toe.","MNSI - Left Foot Vibration Great Toe | MNSI1-Left Foot Vibration Great Toe | MNSI134",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639568","MNSI - Left Foot Monofilament","C100620","Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; left foot - monofilament.","MNSI - Left Foot Monofilament | MNSI1-Left Foot Monofilament | MNSI136",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639569","MNSI - Physical Assessment Total Score","C100621","Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; total score.","MNSI - Physical Assessment Total Score | MNSI1-Total Score | MNSI137",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639570","NPI - Have Beliefs That You Know are Not True","C100622","Neuropsychiatric Inventory (NPI) Does the patient have beliefs that you know are not true? (for example, insisting that people are trying to harm him/her or steal from him/her)? Has he/she said that family members are not who they say they are or that the house is not their home? I'm not asking about mere suspiciousness; I am interested if the patient is convinced that these things are happening to him/her.","NPI - Have Beliefs That You Know are Not True | NPI1-Beliefs Untrue | NPI1A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639571","NPI - He/She is in Danger","C100623","Neuropsychiatric Inventory (NPI) Does the patient believe that he/she is in danger (NPI) that others are planning to hurt him/her?","NPI - He/She is in Danger | NPI1-In Danger | NPI1A01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639572","NPI - Others are Stealing From Him/Her","C100624","Neuropsychiatric Inventory (NPI) Does the patient believe that others are stealing from him/her?","NPI - Others are Stealing From Him/Her | NPI1-Others Are Stealing | NPI1A02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639573","NPI - His/Her Spouse is Having an Affair","C100625","Neuropsychiatric Inventory (NPI) Does the patient believe that his/her spouse is having an affair?","NPI - His/Her Spouse is Having an Affair | NPI1-Spouse Having Affair | NPI1A03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639574","NPI - Unwelcome Guests are Living in His/Her House","C100626","Neuropsychiatric Inventory (NPI) Does the patient believe that unwelcome guests are living in his/her house?","NPI - Unwelcome Guests are Living in His/Her House | NPI1-Unwelcome Guests in House | NPI1A04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639575","NPI - His/Her Spouse or Others Are Not Who They Claim To Be","C100627","Neuropsychiatric Inventory (NPI) Does the patient believe that his/her spouse or others are not who they claim to be?","NPI - His/Her Spouse or Others Are Not Who They Claim To Be | NPI1-People Not Who They Claim | NPI1A05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639576","NPI - His/Her House Is Not His/Her Home","C100628","Neuropsychiatric Inventory (NPI) Does the patient believe that his/her house is not his/her home?","NPI - His/Her House Is Not His/Her Home | NPI1-House Not Their Home | NPI1A06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639578","NPI - Television or Magazine Figures Are Actually Present In the Home","C100630","Neuropsychiatric Inventory (NPI) Does the patient believe that television or magazine figures are actually present in the home? (Does he/she try to talk or interact with them?)","NPI - Television or Magazine Figures Are Actually Present In the Home | NPI1-TV/Magazine Figures Present | NPI1A08",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639579","NPI - Any Other Unusual Things That I Haven't Asked About","C100631","Neuropsychiatric Inventory (NPI) Does the patient believe any other unusual things that I haven't asked about?","NPI - Any Other Unusual Things That I Haven't Asked About | NPI1-Other Unusual Beliefs | NPI1A09",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639580","NPI - Hallucinations Such as Seeing False Visions or Hearing False Voices","C100632","Neuropsychiatric Inventory (NPI) Does the patient have hallucinations such as seeing false visions or hearing false voices? Does he/she seem to see, hear or experience things that are not present? By this question we do not mean just mistaken beliefs such as stating that someone who has died is still alive; rather we are asking if the patient actually has abnormal experiences of sounds or visions.","NPI - Hallucinations Such as Seeing False Visions or Hearing False Voices | NPI1-False Visions or Voices | NPI1B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639581","NPI - Describe Hearing Voices or Act as if He/She Hears Voices","C100633","Neuropsychiatric Inventory (NPI) Does the patient describe hearing voices or act as if he/she hears voices?","NPI - Describe Hearing Voices or Act as if He/She Hears Voices | NPI1-Hearing Voices | NPI1B01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639582","NPI - Talk to People Who Are Not There","C100634","Neuropsychiatric Inventory (NPI) Does the patient talk to people who are not there?","NPI - Talk to People Who Are Not There | NPI1-Talk to People Not There | NPI1B02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639584","NPI - Report Smelling Odors Not Smelled by Others","C100636","Neuropsychiatric Inventory (NPI) Does the patient report smelling odors not smelled by others?","NPI - Report Smelling Odors Not Smelled by Others | NPI1-Smell Odors Others Do Not Smell | NPI1B04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639445","MDS-UPDRS - Freezing","C100497","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, on your usual day when walking, do you suddenly stop or freeze as if your feet are stuck to the floor?","MDS-UPDRS - Freezing | UPD2-Freezing | UPD2213",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639446","MDS-UPDRS - Medication for Parkinson's Disease","C100498","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Is the patient on medication for treating the symptoms of Parkinson's Disease?","MDS-UPDRS - Medication for Parkinson's Disease | UPD2-Medication for PD | UPD23A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639447","MDS-UPDRS - Clinical State on Medication","C100499","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) If the patient is receiving medication for treating the symptoms of Parkinson's Disease, mark the patient's clinical state.","MDS-UPDRS - Clinical State on Medication | UPD2-Clinical State on Meds | UPD23B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0052080","antineoplaston A10","C1004","A piperidinedione antineoplaston with potential antineoplastic activity.  Antineoplaston A10 was originally isolated from human urine but is now synthetically derived.  This agent intercalates into DNA, resulting in cell cycle arrest in G1 phase, reduction of mitosis, and decreased protein synthesis.  Antineoplaston A10 may also inhibit ras-oncogene expression and activate tumor suppressor gene p53, leading to cell differentiation and apoptosis. (NCI04)","Antineoplaston A10 | 3-Phenylacetylamino-2, 6-piperidinedione | 3-Phenylacetylamino-2,6-piperidinedione | A10 | ANTINEOPLASTON A10 | Atengenal | Benzeneacetamide, N-(2,6-dioxo-3-piperidinyl)-, (S)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639448","MDS-UPDRS - Taking Levodopa","C100500","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Is the patient on Levodopa?","MDS-UPDRS - Taking Levodopa | UPD2-Taking Levodopa | UPD23C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639449","MDS-UPDRS - Minutes Since Levodopa Dose","C100501","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Minutes since last Levodopa dose.","MDS-UPDRS - Minutes Since Levodopa Dose | UPD2-Minutes Since Levodopa Dose | UPD23C1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639450","MDS-UPDRS - Speech Problems","C100502","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Speech problems.","MDS-UPDRS - Speech Problems | UPD2-Speech Problems | UPD2301",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639451","MDS-UPDRS - Facial Expression","C100503","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Facial expression.","MDS-UPDRS - Facial Expression | UPD2-Facial Expression | UPD2302",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639452","MDS-UPDRS - Rigidity Neck","C100504","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Rigidity neck.","MDS-UPDRS - Rigidity Neck | UPD2-Rigidity Neck | UPD2303A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639453","MDS-UPDRS - Rigidity Right Upper Extremity","C100505","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Rigidity right upper extremity.","MDS-UPDRS - Rigidity Right Upper Extremity | UPD2-Rigidity RT Upper Extremity | UPD2303B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639454","MDS-UPDRS - Rigidity Left Upper Extremity","C100506","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Rigidity left upper extremity.","MDS-UPDRS - Rigidity Left Upper Extremity | UPD2-Rigidity Left Upper Extremity | UPD2303C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639455","MDS-UPDRS - Rigidity Right Lower Extremity","C100507","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Rigidity right lower extremity.","MDS-UPDRS - Rigidity Right Lower Extremity | UPD2-Rigidity RT Lower Extremity | UPD2303D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639456","MDS-UPDRS - Rigidity Left Lower Extremity","C100508","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Rigidity left lower extremity.","MDS-UPDRS - Rigidity Left Lower Extremity | UPD2-Rigidity Left Lower Extremity | UPD2303E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639457","MDS-UPDRS - Right Finger Tapping","C100509","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Right finger tapping.","MDS-UPDRS - Right Finger Tapping | UPD2-Right Finger Tapping | UPD2304A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639458","MDS-UPDRS - Left Finger Tapping","C100510","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Left finger tapping.","MDS-UPDRS - Left Finger Tapping | UPD2-Left Finger Tapping | UPD2304B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639459","MDS-UPDRS - Right Hand Movements","C100511","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Right hand movements.","MDS-UPDRS - Right Hand Movements | UPD2-Right Hand Movements | UPD2305A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639460","MDS-UPDRS - Left Hand Movements","C100512","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Left hand movements.","MDS-UPDRS - Left Hand Movements | UPD2-Left Hand Movements | UPD2305B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639461","MDS-UPDRS - Pronanation-Supination Movement of Right Hand","C100513","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Pronation-supination movements of right hand.","MDS-UPDRS - Pronanation-Supination Movement of Right Hand | UPD2-Pron/Sup Movement of RT Hand | UPD2306A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639462","MDS-UPDRS - Pronanation-Supination Movement of Left Hand","C100514","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Pronation-supination movements of left hand.","MDS-UPDRS - Pronanation-Supination Movement of Left Hand | UPD2-Pron/Sup Movement of Left Hand | UPD2306B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639464","MDS-UPDRS - Left Toe Tapping","C100516","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Left toe tapping.","MDS-UPDRS - Left Toe Tapping | UPD2-Left Toe Tapping | UPD2307B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639465","MDS-UPDRS - Right Leg Agility","C100517","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Right leg agility.","MDS-UPDRS - Right Leg Agility | UPD2-Right Leg Agility | UPD2308A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639466","MDS-UPDRS - Left Leg Agility","C100518","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Left leg agility.","MDS-UPDRS - Left Leg Agility | UPD2-Left Leg Agility | UPD2308B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639467","MDS-UPDRS - Arising from Chair","C100519","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Arising from chair.","MDS-UPDRS - Arising from Chair | UPD2-Arising from Chair | UPD2309",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639468","MDS-UPDRS - Gait","C100520","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Gait.","MDS-UPDRS - Gait | UPD2-Gait | UPD2310",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639469","MDS-UPDRS - Freezing of Gait","C100521","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Freezing of gait.","MDS-UPDRS - Freezing of Gait | UPD2-Freezing of Gait | UPD2311",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639470","MDS-UPDRS - Postural Stability","C100522","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Postural stability.","MDS-UPDRS - Postural Stability | UPD2-Postural Stability | UPD2312",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639471","MDS-UPDRS - Posture","C100523","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Posture.","MDS-UPDRS - Posture | UPD2-Posture | UPD2313",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639472","MDS-UPDRS - Body Bradykinesia","C100524","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Global spontaneity of movement (body bradykinesia).","MDS-UPDRS - Body Bradykinesia | UPD2-Body Bradykinesia | UPD2314",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639473","MDS-UPDRS - Postural Tremor of Right Hand","C100525","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Postural tremor of the right hand.","MDS-UPDRS - Postural Tremor of Right Hand | UPD2-Postural Tremor of Right Hand | UPD2315A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639474","MDS-UPDRS - Kinetic Tremor of Left Hand","C100526","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Kinetic tremor of the left hand.","MDS-UPDRS - Kinetic Tremor of Left Hand | UPD2-Kinetic Tremor of Left Hand | UPD2316B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639475","MDS-UPDRS - Rest Tremor Amplitude Right Upper Extremity","C100527","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Rest tremor amplitude right upper extremity.","MDS-UPDRS - Rest Tremor Amplitude Right Upper Extremity | UPD2-Rest Tremor Amplitude RUE | UPD2317A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639476","MDS-UPDRS - Rest Tremor Amplitude Left Upper Extremity","C100528","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Rest tremor amplitude left upper extremity.","MDS-UPDRS - Rest Tremor Amplitude Left Upper Extremity | UPD2-Rest Tremor Amplitude LUE | UPD2317B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639477","MDS-UPDRS - Rest Tremor Amplitude Right Lower Extremity","C100529","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Rest tremor amplitude right lower extremity.","MDS-UPDRS - Rest Tremor Amplitude Right Lower Extremity | UPD2-Rest Tremor Amplitude RLE | UPD2317C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639478","MDS-UPDRS - Rest Tremor Amplitude Left Lower Extremity","C100530","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Rest tremor amplitude left lower extremity.","MDS-UPDRS - Rest Tremor Amplitude Left Lower Extremity | UPD2-Rest Tremor Amplitude LLE | UPD2317D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639479","MDS-UPDRS - Rest Tremor Amplitude Lip or Jaw","C100531","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Rest tremor amplitude lip/jaw.","MDS-UPDRS - Rest Tremor Amplitude Lip or Jaw | UPD2-Rest Tremor Amplitude Lip/Jaw | UPD2317E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639480","MDS-UPDRS - Consistency of Rest Tremor","C100532","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Consistency of rest tremor.","MDS-UPDRS - Consistency of Rest Tremor | UPD2-Consistency of Rest Tremor | UPD2318",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639481","MDS-UPDRS - Dyskinesias During Exam","C100533","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Were dyskinesias (chorea or dystonia) present during examination?","MDS-UPDRS - Dyskinesias During Exam | UPD2-Dyskinesias During Exam | UPD2DA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639484","MDS-UPDRS - Time Spent with Dyskinesias","C100536","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Time spent with dyskinesias.","MDS-UPDRS - Time Spent with Dyskinesias | UPD2-Time Spent with Dyskinesias | UPD2401",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639485","MDS-UPDRS - Functional Impact of Dyskinesias","C100537","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Functional impact of dyskinesias.","MDS-UPDRS - Functional Impact of Dyskinesias | UPD2-Functional Impact Dyskinesias | UPD2402",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639486","MDS-UPDRS - Time Spent in the Off State","C100538","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Time spent in the off state.","MDS-UPDRS - Time Spent in the Off State | UPD2-Time Spent in the Off State | UPD2403",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639487","MDS-UPDRS - Functional Impact of Fluctuations","C100539","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Functional impact of fluctuations.","MDS-UPDRS - Functional Impact of Fluctuations | UPD2-Functional Impact Fluctuations | UPD2404",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279419","cyclophosphamide/doxorubicin/fluorouracil/prednisone","C10053","A regimen consisting of cyclophosphamide, doxorubicin, fluorouracil, and prednisone for the treatment of breast cancer.","CAFP Regimen | CAFP | CTX/DOX/5-FU/PRED | Cyclophosphamide-Doxorubicin-Fluorouracil-Prednisone | Cyclophosphamide/Adriamycin/Fluorouracil/Prednisone | Cyclophosphamide/Doxorubicin/Fluorouracil/Prednisone | Cyclophosphamide/Doxorubicin/Fluorouracil/Prednisone Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639488","MDS-UPDRS - Complexity of Motor Fluctuations","C100540","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Complexity of motor fluctuations.","MDS-UPDRS - Complexity of Motor Fluctuations | UPD2-Complexity Motor Fluctuations | UPD2405",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639489","MDS-UPDRS - Painful Off-state Dystonia","C100541","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Painful off-state dystonia.","MDS-UPDRS - Painful Off-state Dystonia | UPD2-Painful Off-state Dystonia | UPD2406",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639490","MMSE - Question 1","C100542","The Mini-Mental State Examination (MMSE) Question 1.","MMSE - Question 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522592","MMSE - What Is the Year","C100543","Mini-Mental State Examination (MMSE) What is the year?","MMSE - What Is the Year | MMS1-What Is the Year | MMS101A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639492","MMSE - What Is the Season","C100544","Mini-Mental State Examination (MMSE) What is the season?","MMSE - What Is the Season | MMS1-What Is the Season | MMS101B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522593","MMSE - What Is the Date","C100545","Mini-Mental State Examination (MMSE) What is the date?","MMSE - What Is the Date | MMS1-What Is the Date | MMS101E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639494","MMSE - What Is the Day of Week","C100546","Mini-Mental State Examination (MMSE) What is the day of the week?","MMSE - What Is the Day of Week | MMS1-What Is the Day of Week | MMS101D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639495","MMSE - What Is the Month of Year","C100547","Mini-Mental State Examination (MMSE) What is the month of the year?","MMSE - What Is the Month of Year | MMS1-What Is the Month of Year | MMS101C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639496","MMSE - Question 2","C100548","The Mini-Mental State Examination (MMSE) Question 2.","MMSE - Question 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522594","MMSE - What Is the County","C100550","Mini-Mental State Examination (MMSE) Where are we now? What is the county (or city/town)?","MMSE - What Is the County | MMS1-What Is the County | MMS102B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639499","MMSE - What Is the City or Town","C100551","Mini-Mental State Examination (MMSE) Where are we now? What is the city/town (or part of city/neighborhood)?","MMSE - What Is the City or Town | MMS1-What Is the City/Town | MMS102C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522595","MMSE - What Is the Building","C100552","Mini-Mental State Examination (MMSE) Where are we now? What is the building (name or type)?","MMSE - What Is the Building | MMS1-What Is the Building | MMS102D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522596","MMSE - What Is the Floor","C100553","Mini-Mental State Examination (MMSE) Where are we now? What is the floor of the building (room number or address)?","MMSE - What Is the Floor | MMS1-What Is the Floor | MMS102E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639502","MMSE - Question 3","C100554","The Mini-Mental State Examination (MMSE) Question 3.","MMSE - Question 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639503","MMSE - Repeat Word 1","C100555","Mini-Mental State Examination (MMSE) Now repeat those words back to me: Word 1.","MMSE - Repeat Word 1 | MMS1-Repeat Word 1 | MMS103A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639504","MMSE - Repeat Word 2","C100556","Mini-Mental State Examination (MMSE) Now repeat those words back to me: Word 2.","MMSE - Repeat Word 2 | MMS1-Repeat Word 2 | MMS103B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639505","MMSE - Repeat Word 3","C100557","Mini-Mental State Examination (MMSE) Now repeat those words back to me: Word 3.","MMSE - Repeat Word 3 | MMS1-Repeat Word 3 | MMS103C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639545","MNSI - Symptoms Worse at Night","C100597","Michigan Neuropathy Screening Instrument (MNSI) History; are your symptoms worse at night?","MNSI - Symptoms Worse at Night | MNSI1-Symptoms Worse at Night | MNSI111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639546","MNSI - Legs Hurt When Walking","C100598","Michigan Neuropathy Screening Instrument (MNSI) History; do your legs hurt when you walk?","MNSI - Legs Hurt When Walking | MNSI1-Legs Hurt When Walking | MNSI112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639547","MNSI - Able to Sense Feet When Walking","C100599","Michigan Neuropathy Screening Instrument (MNSI) History; are you able to sense your feet when you walk?","MNSI - Able to Sense Feet When Walking | MNSI1-Able to Sense Feet When Walking | MNSI113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639548","MNSI - Skin So Dry That Feet Crack Open","C100600","Michigan Neuropathy Screening Instrument (MNSI) History; is the skin on your feet so dry that it cracks open?","MNSI - Skin So Dry That Feet Crack Open | MNSI1-Skin So Dry That Feet Crack Open | MNSI114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639549","MNSI - Ever Had Amputation","C100601","Michigan Neuropathy Screening Instrument (MNSI) History; have you ever had an amputation?","MNSI - Ever Had Amputation | MNSI1-Ever Had Amputation | MNSI115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639551","MNSI - Right Foot Appears Normal","C100603","Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; appearance of right foot - normal.","MNSI - Right Foot Appears Normal | MNSI1-Right Foot Appears Normal | MNSI117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639552","MNSI - Right Foot Deformities","C100604","Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; appearance of right foot - deformities.","MNSI - Right Foot Deformities | MNSI1-Right Foot Deformities | MNSI118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639553","MNSI - Right Foot Infection","C100605","Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; appearance of right foot - infection.","MNSI - Right Foot Infection | MNSI1-Right Foot Infection | MNSI120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639554","MNSI - Right Foot Fissure","C100606","Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; appearance of right foot - fissure.","MNSI - Right Foot Fissure | MNSI1-Right Foot Fissure | MNSI121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639555","MNSI - Right Foot Other Abnormal Specify","C100607","Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; appearance of right foot - other, specify.","MNSI - Right Foot Other Abnormal Specify | MNSI1-Right Foot Other Abnormal Specify | MNSI122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639613","NPI - Show Any Other Signs of Anxiety","C100665","Neuropsychiatric Inventory (NPI) Does the patient show any other signs of anxiety?","NPI - Show Any Other Signs of Anxiety | NPI1-Other Signs of Anxiety | NPI1E07",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639614","NPI - Seem Too Cheerful or Too Happy for No Reason","C100666","Neuropsychiatric Inventory (NPI) Does the patient seem too cheerful or too happy for no reason? I don't mean the normal happiness that comes from seeing friends, receiving presents, or spending time with family members. I am asking if the patient has a persistent and abnormally good mood or finds humor where others do not.","NPI - Seem Too Cheerful or Too Happy for No Reason | NPI1-Too Cheerful or Happy | NPI1F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639615","NPI - Appear to Feel Good or to Be Too Happy","C100667","Neuropsychiatric Inventory (NPI) Does the patient appear to feel good or to be too happy, different from his/her usual self?","NPI - Appear to Feel Good or to Be Too Happy | NPI1-Feel Good or Too Happy | NPI1F01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639617","NPI - Seem to Have a Childish Sense of Humor","C100669","Neuropsychiatric Inventory (NPI) Does the patient seem to have a childish sense of humor with a tendency to giggle or laugh inappropriately (such as when something unfortunate happens to others)?","NPI - Seem to Have a Childish Sense of Humor | NPI1-Childish Sense of Humor | NPI1F03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639618","NPI - Tell Jokes or Make Remarks That are Not Funny to Others","C100670","Neuropsychiatric Inventory (NPI) Does the patient tell jokes or make remarks that are not funny to others but seem funny to him/her?","NPI - Tell Jokes or Make Remarks That are Not Funny to Others | NPI1-Jokes Others Do Not Find Funny | NPI1F04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639619","NPI - Play Childish Pranks","C100671","Neuropsychiatric Inventory (NPI) Does he/she play childish pranks such as pinching or playing 'keep away' for the fun of it?","NPI - Play Childish Pranks | NPI1-Childish Pranks | NPI1F05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639620","NPI - Talk Big or Claim to Have More Abilities or Wealth Than is True","C100672","Neuropsychiatric Inventory (NPI) Does the patient 'talk big' or claim to have more abilities or wealth than is true?","NPI - Talk Big or Claim to Have More Abilities or Wealth Than is True | NPI1-Talk Big | NPI1F06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639621","NPI - Show Any Other Signs of Feeling Too Good or Being Too Happy","C100673","Neuropsychiatric Inventory (NPI) Does the patient show any other signs of feeling too good or being too happy?","NPI - Show Any Other Signs of Feeling Too Good or Being Too Happy | NPI1-Other Signs of Feeling Too Happy | NPI1F07",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639622","NPI - Lost Interest in the World Around Him/Her","C100674","Neuropsychiatric Inventory (NPI) Has the patient lost interest in the world around him/her? Has he/she lost interest in doing things or does he/she lack motivation for starting new activities? Is he/she more difficult to engage in conversation or in doing chores? Is the patient apathetic or indifferent?","NPI - Lost Interest in the World Around Him/Her | NPI1-Lost Interest in World | NPI1G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639623","NPI - Seem Less Spontaneous and Less Active Than Usual","C100675","Neuropsychiatric Inventory (NPI) Does the patient seem less spontaneous and less active than usual?","NPI - Seem Less Spontaneous and Less Active Than Usual | NPI1-Less Spontaneous or Active | NPI1G01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639624","NPI - Less Likely Initiate to Initiate a Conversation","C100676","Neuropsychiatric Inventory (NPI) Is the patient less likely to initiate a conversation?","NPI - Less Likely Initiate to Initiate a Conversation | NPI1-Less Likely Initiate Conversation | NPI1G02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639625","NPI - Less Affectionate or Lacking in Emotions","C100677","Neuropsychiatric Inventory (NPI) Is the patient less affectionate or lacking in emotions when compared to his/her usual self?","NPI - Less Affectionate or Lacking in Emotions | NPI1-Less Affectionate | NPI1G03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639626","NPI - Contribute Less to Household Chores","C100678","Neuropsychiatric Inventory (NPI) Does the patient contribute less to household chores?","NPI - Contribute Less to Household Chores | NPI1-Contribute Less to Chores | NPI1G04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522609","MMSE - Take in Right Hand","C100580","Mini-Mental State Examination (MMSE) Listen carefully because I am going to ask you to do something. Take this paper in your right hand.","MMSE - Take in Right Hand | MMS1-Take in Right Hand | MMS108A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522610","MMSE - Fold in Half","C100581","Mini-Mental State Examination (MMSE) Fold it in half.","MMSE - Fold in Half | MMS1-Fold in Half | MMS108B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639530","MMSE - Put on Floor or Table","C100582","Mini-Mental State Examination (MMSE) And put it on the floor (or table).","MMSE - Put on Floor or Table | MMS1-Put on Floor (or Table) | MMS108C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639531","MMSE - Read This and Do What It Says","C100583","Mini-Mental State Examination (MMSE) Please read this and do what it says.","MMSE - Read This and Do What It Says | MMS1-Read This and Do What It Says | MMS109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522611","MMSE - Write a Sentence","C100584","Mini-Mental State Examination (MMSE) Please write a sentence.","MMSE - Write a Sentence | MMS1-Write a Sentence | MMS110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639534","MMSE - Total Score","C100586","Mini-Mental State Examination (MMSE) Total score.","MMSE - Total Score | MMS1-Total Score | MMS112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639535","MNSI - Legs and/or Feet Numb","C100587","Michigan Neuropathy Screening Instrument (MNSI) History; are your legs and/or feet numb?","MNSI - Legs and/or Feet Numb | MNSI1-Are Your Legs and/or Feet Numb | MNSI101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639536","MNSI - Burning Pain Legs/Feet","C100588","Michigan Neuropathy Screening Instrument (MNSI) History; do you ever have any burning pain in your legs and/or feet?","MNSI - Burning Pain Legs/Feet | MNSI1-Ever Have Burning Pain Legs/Feet | MNSI102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639537","MNSI - Feet Too Sensitive to Touch","C100589","Michigan Neuropathy Screening Instrument (MNSI) History; are your feet too sensitive to touch?","MNSI - Feet Too Sensitive to Touch | MNSI1-Are Feet Too Sensitive to Touch | MNSI103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279427","altretamine/cisplatin/cyclophosphamide/fluorouracil","C10058","A regimen consisting of altretamine, cisplatin, cyclophosphamide and fluorouracil that can be used for the treatment of ovarian cancer.","Altretamine/Cisplatin/Cyclophosphamide/Fluorouracil Regimen | Altretamine-Cisplatin-Cyclophosphamide-Fluorouracil | Altretamine/Cisplatin/Cyclophosphamide/Fluorouracil | CDDP/CTX/5-FU/HMM | CHEX-UP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639538","MNSI - Muscle Cramps Legs/Feet","C100590","Michigan Neuropathy Screening Instrument (MNSI) History; do you get muscle cramps in your legs and/or feet?","MNSI - Muscle Cramps Legs/Feet | MNSI1-Get Muscle Cramps Legs/Feet | MNSI104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639539","MNSI - Prickling Feelings Legs/Feet","C100591","Michigan Neuropathy Screening Instrument (MNSI) History; do you ever have any prickling feelings in your legs or feet?","MNSI - Prickling Feelings Legs/Feet | MNSI1-Ever Prickling Feelings Legs/Feet | MNSI105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639540","MNSI - Hurt When Bed Covers Touch Skin","C100592","Michigan Neuropathy Screening Instrument (MNSI) History; does it hurt when the bed covers touch your skin?","MNSI - Hurt When Bed Covers Touch Skin | MNSI1-Hurt When Bed Covers Touch Skin | MNSI106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639542","MNSI - Open Sore on Foot","C100594","Michigan Neuropathy Screening Instrument (MNSI) History; have you ever had an open sore on your foot?","MNSI - Open Sore on Foot | MNSI1-Ever Had Open Sore on Foot | MNSI108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639543","MNSI - Doctor Says Diabetic Neuropathy","C100595","Michigan Neuropathy Screening Instrument (MNSI) History; has your doctor ever told you that you have diabetic neuropathy?","MNSI - Doctor Says Diabetic Neuropathy | MNSI1-Doctor Says Diabetic Neuropathy | MNSI109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639544","MNSI - Feel Weak All Over Most Times","C100596","Michigan Neuropathy Screening Instrument (MNSI) History; do you feel weak all over most of the time?","MNSI - Feel Weak All Over Most Times | MNSI1-Feel Weak All Over Most Times | MNSI110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639735","RDQ - Painful Almost All the Time","C100792","Roland Morris Disability Questionnaire (RDQ) My back is painful almost all the time.","RDQ - Painful Almost All the Time | RDQ01-Painful Almost All the Time | RDQ0113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639736","RDQ - Difficult to Turn Over in Bed","C100793","Roland Morris Disability Questionnaire (RDQ) I find it difficult to turn over in bed because of my back.","RDQ - Difficult to Turn Over in Bed | RDQ01-Difficult to Turn Over in Bed | RDQ0114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639737","RDQ - Appetite is Not Very Good","C100794","Roland Morris Disability Questionnaire (RDQ) My appetite is not very good because of my back pain.","RDQ - Appetite is Not Very Good | RDQ01-Appetite is Not Very Good | RDQ0115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639738","RDQ - Trouble Putting on Socks or Stockings","C100795","Roland Morris Disability Questionnaire (RDQ) I have trouble putting on my socks (or stockings) because of the pain in my back.","RDQ - Trouble Putting on Socks or Stockings | RDQ01-Trouble Putting on Socks/Stockings | RDQ0116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639739","RDQ - Only Walk Short Distances","C100796","Roland Morris Disability Questionnaire (RDQ) I only walk short distances because of my back.","RDQ - Only Walk Short Distances | RDQ01-Only Walk Short Distances | RDQ0117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639740","RDQ - Sleep Less Well","C100797","Roland Morris Disability Questionnaire (RDQ) I sleep less well because of my back.","RDQ - Sleep Less Well | RDQ01-Sleep Less Well | RDQ0118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639741","RDQ - Get Dressed With Help","C100798","Roland Morris Disability Questionnaire (RDQ) Because of my back pain, I get dressed with help from someone else.","RDQ - Get Dressed With Help | RDQ01-Get Dressed With Help | RDQ0119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639742","RDQ - Sit Down Most of the Day","C100799","Roland Morris Disability Questionnaire (RDQ) I sit down for most of the day because of my back.","RDQ - Sit Down Most of the Day | RDQ01-Sit Down Most of the Day | RDQ0120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639743","RDQ - Avoid Heavy Jobs","C100800","Roland Morris Disability Questionnaire (RDQ) I avoid heavy jobs around the house because of my back.","RDQ - Avoid Heavy Jobs | RDQ01-Avoid Heavy Jobs | RDQ0121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639744","RDQ - More Irritable With People","C100801","Roland Morris Disability Questionnaire (RDQ) Because of my back pain, I am more irritable and bad tempered with people than usual.","RDQ - More Irritable With People | RDQ01-More Irritable With People | RDQ0122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639745","RDQ - Go Upstairs More Slowly","C100802","Roland Morris Disability Questionnaire (RDQ) Because of my back, I go upstairs more slowly than usual.","RDQ - Go Upstairs More Slowly | RDQ01-Go Upstairs More Slowly | RDQ0123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639746","RDQ - Stay in Bed","C100803","Roland Morris Disability Questionnaire (RDQ) I stay in bed most of the time because of my back.","RDQ - Stay in Bed | RDQ01-Stay in Bed | RDQ0124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639747","RDQ - Total Derived Score","C100804","Roland Morris Disability Questionnaire (RDQ) RDQ total derived score.","RDQ - Total Derived Score | RDQ01-RDQ Total Score | RDQ0125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639655","NPI - Difficulty Sleeping","C100707","Neuropsychiatric Inventory (NPI) Does the patient have difficulty sleeping (do not count as present if the patient simply gets up once or twice per night to go the bathroom and falls back asleep immediately)? Is he/she up at night? Does he/she wander at night, get dressed, or disturb your sleep?","NPI - Difficulty Sleeping | NPI1-Difficulty Sleeping | NPI1K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639656","NPI - Difficulty Falling Asleep","C100708","Neuropsychiatric Inventory (NPI) Does the patient have difficulty falling asleep?","NPI - Difficulty Falling Asleep | NPI1-Difficulty Falling Asleep | NPI1K01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639657","NPI - Get Up During the Night","C100709","Neuropsychiatric Inventory (NPI) Does the patient get up during the night (do not count if the patient gets up once or twice per night only to go to the bathroom and falls back asleep immediately)?","NPI - Get Up During the Night | NPI1-Get Up during Night | NPI1K02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279442","cyclophosphamide/doxorubicin/etoposide/fluorouracil","C10070","A regimen consisting of fluorouracil, doxorubicin, cyclophosphamide, vincristine, and prednisone that may be used in the treatment of breast cancer.","FACVP Regimen | CTX/DOX/5-FU/VP-16 | Cyclophosphamide/Doxorubicin/Etoposide/Fluorouracil | FACVP | Fluorouracil-Doxorubicin-Cyclophosphamide-Etoposide | Fluorouracil/Adriamycin/Cyclophosphamide/VP-16 | Fluorouracil/Doxorubicin/Cyclophosphamide/Etoposide | Fluorouracil/Doxorubicin/Cyclophosphamide/Etoposide Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639658","NPI - Wander, Pace or Get Involved in Inappropriate Activities at Night","C100710","Neuropsychiatric Inventory (NPI) Does the patient wander, pace or get involved in inappropriate activities at night?","NPI - Wander, Pace or Get Involved in Inappropriate Activities at Night | NPI1-Wander or Pace at Night | NPI1K03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639659","NPI - Awaken You During the Night","C100711","Neuropsychiatric Inventory (NPI) Does the patient awaken you during the night?","NPI - Awaken You During the Night | NPI1-Awaken Caregiver during Night | NPI1K04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639660","NPI - Wake Up at Night, Dress, and Plan to Go Out","C100712","Neuropsychiatric Inventory (NPI) Does the patient wake up at night, dress, and plan to go out thinking that it is morning and time to start the day?","NPI - Wake Up at Night, Dress, and Plan to Go Out | NPI1-Wake at Night and Think Morning | NPI1K05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639661","NPI - Awaken Too Early in Morning","C100713","Neuropsychiatric Inventory (NPI) Does the patient awaken too early in the morning (earlier than was his/her habit)?","NPI - Awaken Too Early in Morning | NPI1-Awaken Too Early in Morning | NPI1K06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639663","NPI - Any Other Nighttime Behaviors That Bother You","C100715","Neuropsychiatric Inventory (NPI) Does the patient have any other nighttime behaviors that bother you that we haven't talked about?","NPI - Any Other Nighttime Behaviors That Bother You | NPI1-Other Nighttime Behaviors | NPI1K08",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639664","NPI - Change in Appetite, Weight, or Eating Habits","C100716","Neuropsychiatric Inventory (NPI) Has he/she had any change in appetite, weight, or eating habits (count as NA if the patient is incapacitated and has to be fed)? Has there been any change in the type of food he/she prefers?","NPI - Change in Appetite, Weight, or Eating Habits | NPI1-Change in Appetite or Weight | NPI1L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639665","NPI - Loss of Appetite","C100717","Neuropsychiatric Inventory (NPI) Has he/she had a loss of appetite?","NPI - Loss of Appetite | NPI1-Loss of Appetite | NPI1L01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639666","NPI - Increase in Appetite","C100718","Neuropsychiatric Inventory (NPI) Has he/she had an increase in appetite?","NPI - Increase in Appetite | NPI1-Increase in Appetite | NPI1L02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639667","NPI - Loss of Weight","C100719","Neuropsychiatric Inventory (NPI) Has he/she had a loss of weight?","NPI - Loss of Weight | NPI1-Weight Loss | NPI1L03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639627","NPI - Less Interested in the Activities and Plans of Others","C100679","Neuropsychiatric Inventory (NPI) Does the patient seem less interested in the activities and plans of others?","NPI - Less Interested in the Activities and Plans of Others | NPI1-Less Interest in Activities | NPI1G05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639628","NPI - Lost Interest in Friends and Family Members","C100680","Neuropsychiatric Inventory (NPI) Has the patient lost interest in friends and family members?","NPI - Lost Interest in Friends and Family Members | NPI1-Lost Interest in Friends | NPI1G06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639629","NPI - Less Enthusiastic About His/Her Usual Interests","C100681","Neuropsychiatric Inventory (NPI) Is the patient less enthusiastic about his/her usual interests?","NPI - Less Enthusiastic About His/Her Usual Interests | NPI1-Less Enthusiastic | NPI1G07",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639630","NPI - Show Any Other Signs That He/She Doesn't Care About Doing New Things","C100682","Neuropsychiatric Inventory (NPI) Does the patient show any other signs that he/she doesn't care about doing new things?","NPI - Show Any Other Signs That He/She Doesn't Care About Doing New Things | NPI1-Other Signs of Not Caring | NPI1G08",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639631","NPI - Seem to Act Impulsively Without Thinking","C100683","Neuropsychiatric Inventory (NPI) Does the patient seem to act impulsively without thinking? Does he/she do or say things that are not usually done or said in public? Does he/she do things that are embarrassing to you or others?","NPI - Seem to Act Impulsively Without Thinking | NPI1-Act Impulsively | NPI1H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639632","NPI - Act Impulsively without Appearing to Consider the Consequences","C100684","Neuropsychiatric Inventory (NPI) Does the patient act impulsively without appearing to consider the consequences?","NPI - Act Impulsively without Appearing to Consider the Consequences | NPI1-Act Impulsively without Care | NPI1H01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639633","NPI - Talk to Total Strangers as if He/She Knew Them","C100685","Neuropsychiatric Inventory (NPI) Does the patient talk to total strangers as if he/she knew them?","NPI - Talk to Total Strangers as if He/She Knew Them | NPI1-Talk to Strangers | NPI1H02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639634","NPI - Say Things to People that are Insensitive","C100686","Neuropsychiatric Inventory (NPI) Does the patient say things to people that are insensitive or hurt their feelings?","NPI - Say Things to People that are Insensitive | NPI1-Say Insensitive Things | NPI1H03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639635","NPI - Say Crude Things or Make Sexual Remarks","C100687","Neuropsychiatric Inventory (NPI) Does the patient say crude things or make sexual remarks that he/she would not usually have said?","NPI - Say Crude Things or Make Sexual Remarks | NPI1-Make Crude Remarks | NPI1H04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639636","NPI - Talk Openly About Very Personal or Private Matters","C100688","Neuropsychiatric Inventory (NPI) Does the patient talk openly about very personal or private matters not usually discussed in public?","NPI - Talk Openly About Very Personal or Private Matters | NPI1-Talk Openly about Private Matters | NPI1H05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639637","NPI - Take Liberties or Touch or Hug Others","C100689","Neuropsychiatric Inventory (NPI) Does the patient take liberties or touch or hug others in a way that is out of character for him/her?","NPI - Take Liberties or Touch or Hug Others | NPI1-Take Liberties or Touch Others | NPI1H06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639638","NPI - Show Any Other Signs of Loss of Control of His/Her Impulses","C100690","Neuropsychiatric Inventory (NPI) Does the patient show any other signs of loss of control of his/her impulses?","NPI - Show Any Other Signs of Loss of Control of His/Her Impulses | NPI1-Other Signs of Impulses | NPI1H07",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639585","NPI - Describe Feeling Things on His/Her Skin","C100637","Neuropsychiatric Inventory (NPI) Does the patient describe feeling things on his/her skin or otherwise appear to be feeling things crawling or touching him/her?","NPI - Describe Feeling Things on His/Her Skin | NPI1-Feel Things on Skin | NPI1B05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639586","NPI - Describe Tastes That Are Without Any Known Cause","C100638","Neuropsychiatric Inventory (NPI) Does the patient describe tastes that are without any known cause?","NPI - Describe Tastes That Are Without Any Known Cause | NPI1-Taste without Known Cause | NPI1B06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639587","NPI - Describe Any Other Unusual Sensory Experiences","C100639","Neuropsychiatric Inventory (NPI) Does the patient describe any other unusual sensory experiences?","NPI - Describe Any Other Unusual Sensory Experiences | NPI1-Other Unusual Sensory Experience | NPI1B07",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639588","NPI - Periods When He/She Refuses to Cooperate","C100640","Neuropsychiatric Inventory (NPI) Does the patient have periods when he/she refuses to cooperate or won't let people help him/her? Is he/she hard to handle?","NPI - Periods When He/She Refuses to Cooperate | NPI1-Refuse to Cooperate | NPI1C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639589","NPI - Get Upset with Those Trying to Care for Him/Her","C100641","Neuropsychiatric Inventory (NPI) Does the patient get upset with those trying to care for him/her or resist activities such as bathing or changing clothes?","NPI - Get Upset with Those Trying to Care for Him/Her | NPI1-Get Upset with Caregiver | NPI1C01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639590","NPI - Stubborn","C100642","Neuropsychiatric Inventory (NPI) Is the patient stubborn, having to have things his/her way?","NPI - Stubborn | NPI1-Stubborn | NPI1C02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639591","NPI - Uncooperative","C100643","Neuropsychiatric Inventory (NPI) Is the patient uncooperative, resistive to help from others?","NPI - Uncooperative | NPI1-Uncooperative | NPI1C03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639592","NPI - Any Other Behaviors That Make Him/Her Hard to Handle","C100644","Neuropsychiatric Inventory (NPI) Does the patient have any other behaviors that make him/her hard to handle?","NPI - Any Other Behaviors That Make Him/Her Hard to Handle | NPI1-Other Behaviors Hard to Handle | NPI1C04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639593","NPI - Shout or Curse Angrily","C100645","Neuropsychiatric Inventory (NPI) Does the patient shout or curse angrily?","NPI - Shout or Curse Angrily | NPI1-Shout or Curse Angrily | NPI1C05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639594","NPI - Slam doors, Kick Furniture, Throw Things","C100646","Neuropsychiatric Inventory (NPI) Does the patient slam doors, kick furniture, throw things?","NPI - Slam doors, Kick Furniture, Throw Things | NPI1-Slam, Kick or Throw Things | NPI1C06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639595","NPI - Attempt to Hurt or Hit Others","C100647","Neuropsychiatric Inventory (NPI) Does the patient attempt to hurt or hit others?","NPI - Attempt to Hurt or Hit Others | NPI1-Hurt or Hit Others | NPI1C07",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639596","NPI - Any Other Aggressive or Agitated Behaviors","C100648","Neuropsychiatric Inventory (NPI) Does the patient have any other aggressive or agitated behaviors?","NPI - Any Other Aggressive or Agitated Behaviors | NPI1-Other Aggressive Behavior | NPI1C08",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639597","NPI - Seem Sad or Depressed","C100649","Neuropsychiatric Inventory (NPI) Does the patient seem sad or depressed? Does he/she say that he/she feels sad or depressed?","NPI - Seem Sad or Depressed | NPI1-Sad or Depressed | NPI1D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639598","NPI - Periods of Tearfulness or Sobbing","C100650","Neuropsychiatric Inventory (NPI) Does the patient have periods of tearfulness or sobbing that seem to indicate sadness?","NPI - Periods of Tearfulness or Sobbing | NPI1-Tearfulness or Sobbing | NPI1D01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639599","NPI - Say, or Act as if He/She is Sad or in Low Spirits","C100651","Neuropsychiatric Inventory (NPI) Does the patient say, or act as if he/she is sad or in low spirits?","NPI - Say, or Act as if He/She is Sad or in Low Spirits | NPI1-Say or Act in Low Spirits | NPI1D02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639600","NPI - Put Him/Herself Down or Say That He/She Feels Like a Failure","C100652","Neuropsychiatric Inventory (NPI) Does the patient put him/herself down or say that he/she feels like a failure?","NPI - Put Him/Herself Down or Say That He/She Feels Like a Failure | NPI1-Feel Like a Failure | NPI1D03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639601","NPI - Say That He/She is a Bad Person","C100653","Neuropsychiatric Inventory (NPI) Does the patient say that he/she is a bad person or deserves to be punished?","NPI - Say That He/She is a Bad Person | NPI1-Bad Person | NPI1D04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639602","NPI - Seem Very Discouraged","C100654","Neuropsychiatric Inventory (NPI) Does the patient seem very discouraged or say that he/she has no future?","NPI - Seem Very Discouraged | NPI1-Discouraged | NPI1D05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639604","NPI - Express a Wish for Death","C100656","Neuropsychiatric Inventory (NPI) Does the patient express a wish for death or talk about killing himself/herself?","NPI - Express a Wish for Death | NPI1-Wish for Death | NPI1D07",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639605","NPI - Show Any Other Signs of Depression or Sadness","C100657","Neuropsychiatric Inventory (NPI) Does the patient show any other signs of depression or sadness?","NPI - Show Any Other Signs of Depression or Sadness | NPI1-Other Signs of Depression | NPI1D08",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639606","NPI - Very Nervous, Worried, or Frightened for No Apparent Reason","C100658","Neuropsychiatric Inventory (NPI) Is the patient very nervous, worried, or frightened for no apparent reason? Does he/she seem very tense or fidgety? Is the patient afraid to be apart from you?","NPI - Very Nervous, Worried, or Frightened for No Apparent Reason | NPI1-Nervous or Worried | NPI1E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639607","NPI - Say That He/She is Worried About Planned Events","C100659","Neuropsychiatric Inventory (NPI) Does the patient say that he/she is worried about planned events?","NPI - Say That He/She is Worried About Planned Events | NPI1-Worried about Planned Event | NPI1E01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639608","NPI - Periods of Feeling Shaky, Unable to Relax, or Feeling Excessively Tense","C100660","Neuropsychiatric Inventory (NPI) Does the patient have periods of feeling shaky, unable to relax, or feeling excessively tense?","NPI - Periods of Feeling Shaky, Unable to Relax, or Feeling Excessively Tense | NPI1-Shaky or Unable to Relax | NPI1E02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639609","NPI - Periods of Shortness of Breath, Gasping, or Sighing for No Apparent Reason","C100661","Neuropsychiatric Inventory (NPI) Does the patient have periods of (or complain of) shortness of breath, gasping, or sighing for no apparent reason other than nervousness?","NPI - Periods of Shortness of Breath, Gasping, or Sighing for No Apparent Reason | NPI1-Short of Breath, Gasp, Sigh | NPI1E03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639610","NPI - Complain of Butterflies, Racing or Pounding Heart","C100662","Neuropsychiatric Inventory (NPI) Does the patient complain of butterflies in his/her stomach, or of racing or pounding of the heart in association with nervousness? (Symptoms not explained by ill health).","NPI - Complain of Butterflies, Racing or Pounding Heart | NPI1-Butterflies or Racing Heart | NPI1E04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639611","NPI - Avoid Certain Places or Situations That Make Him/Her More Nervous","C100663","Neuropsychiatric Inventory (NPI) Does the patient avoid certain places or situations that make him/her more nervous such as riding in the car, meeting with friends, or being in crowds?","NPI - Avoid Certain Places or Situations That Make Him/Her More Nervous | NPI1-Avoid Places or Situations | NPI1E05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639612","NPI - Become Nervous and Upset When Separated From You","C100664","Neuropsychiatric Inventory (NPI) Does the patient become nervous and upset when separated from you (or his/her caregiver)? (Does he/she cling to you to keep from being separated?).","NPI - Become Nervous and Upset When Separated From You | NPI1-Nervous when Separated | NPI1E06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639724","RDQ - Change Position Frequently","C100781","Roland Morris Disability Questionnaire (RDQ) I change position frequently to try and get my back comfortable.","RDQ - Change Position Frequently | RDQ01-Change Position Frequently | RDQ0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639725","RDQ - Walk More Slowly","C100782","Roland Morris Disability Questionnaire (RDQ) I walk more slowly than usual because of my back.","RDQ - Walk More Slowly | RDQ01-Walk More Slowly | RDQ0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639726","RDQ - Not Do Any Usual House Jobs","C100783","Roland Morris Disability Questionnaire (RDQ) Because of my back, I am not doing any of the jobs that I usually do around the house.","RDQ - Not Do Any Usual House Jobs | RDQ01-Not Do Any Usual Jobs | RDQ0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639727","RDQ - Use Handrail to Get Upstairs","C100784","Roland Morris Disability Questionnaire (RDQ) Because of my back, I use a handrail to get upstairs.","RDQ - Use Handrail to Get Upstairs | RDQ01-Use Handrail to Get Upstairs | RDQ0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639728","RDQ - Lie Down to Rest More Often","C100785","Roland Morris Disability Questionnaire (RDQ) Because of my back, I lie down to rest more often.","RDQ - Lie Down to Rest More Often | RDQ01-Lie Down to Rest More Often | RDQ0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639729","RDQ - Hold on to Get Out of a Chair","C100786","Roland Morris Disability Questionnaire (RDQ) Because of my back, I have to hold on to something to get out of an easy chair.","RDQ - Hold on to Get Out of a Chair | RDQ01-Hold on to Get Out of a Chair | RDQ0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639730","RDQ - Get Other People to Do Things","C100787","Roland Morris Disability Questionnaire (RDQ) Because of my back, I try to get other people to do things for me.","RDQ - Get Other People to Do Things | RDQ01-Get Other People to Do Things | RDQ0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639732","RDQ - Only Stand for Short Periods","C100789","Roland Morris Disability Questionnaire (RDQ) I only stand for short periods of time because of my back.","RDQ - Only Stand for Short Periods | RDQ01-Only Stand for Short Periods | RDQ0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639733","RDQ - Try Not to Bend or Kneel","C100790","Roland Morris Disability Questionnaire (RDQ) Because of my back, I try not to bend or kneel down.","RDQ - Try Not to Bend or Kneel | RDQ01-Try Not to Bend or Kneel | RDQ0111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639734","RDQ - Difficult to Get Out of a Chair","C100791","Roland Morris Disability Questionnaire (RDQ) I find it difficult to get out of a chair because of my back.","RDQ - Difficult to Get Out of a Chair | RDQ01-Difficult to Get Out of a Chair | RDQ0112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639764","SF36 v1.0 Standard - Physical: Accomplished Less","C100826","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) During the past 4 weeks, how much of the time have you had any problems with your work or other regular daily activities as a result of your physical health - accomplished less than you would like.","SF36 v1.0 Standard - Physical: Accomplished Less | SF361-Physical: Accomplished Less | SF36104B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639765","SF36 v1.0 Standard - Physical: Limited Kind of Work","C100827","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) During the past 4 weeks, how much of the time have you had any problems with your work or other regular daily activities as a result of your physical health - were limited in the kind of work or other activities.","SF36 v1.0 Standard - Physical: Limited Kind of Work | SF361-Physical: Limited Kind of Work | SF36104C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639766","SF36 v1.0 Standard - Physical: Difficulty Perform Work","C100828","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) During the past 4 weeks, how much of the time have you had any problems with your work or other regular daily activities as a result of your physical health - had difficulty performing the work or other activities (for example, it took extra effort).","SF36 v1.0 Standard - Physical: Difficulty Perform Work | SF361-Physical: Difficulty Perform Work | SF36104D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639767","SF36 v1.0 Standard - Emotional: Cut Down Time on Work","C100829","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) During the past 4 weeks, how much of the time have you had problems with your work or other regular daily activities as a result of any emotional problems (such as feeling depressed or anxious) - cut down on the amount of time you spent on work or other activities.","SF36 v1.0 Standard - Emotional: Cut Down Time on Work | SF361-Emotional: Cut Down Time on Work | SF36105A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639769","SF36 v1.0 Standard - Emotional: Did Work Less Carefully","C100831","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) During the past 4 weeks, how much of the time have you had problems with your work or other regular daily activities as a result of any emotional problems (such as feeling depressed or anxious) - did work or other activities less carefully than usual.","SF36 v1.0 Standard - Emotional: Did Work Less Carefully | SF361-Emotional: Did Work Less Carefully | SF36105C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639770","SF36 v1.0 Standard - Extent Phys/Emotional Interfered","C100832","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) During the past 4 weeks, to what extent has your physical health or emotional problems interfered with your normal social activities with family, friends, neighbors, or groups?","SF36 v1.0 Standard - Extent Phys/Emotional Interfered | SF361-Extent Phys/Emotional Interfered | SF36106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639771","SF36 v1.0 Standard - How Much Bodily Pain Have You Had","C100833","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) How much bodily pain have you had during the past 4 weeks?","SF36 v1.0 Standard - How Much Bodily Pain Have You Had | SF361-How Much Bodily Pain Have You Had | SF36107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639772","SF36 v1.0 Standard - Pain Interfere With Normal Work","C100834","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) During the past 4 weeks, how much did pain interfere with your normal work (including both work outside the home and housework)?","SF36 v1.0 Standard - Pain Interfere With Normal Work | SF361-Pain Interfere With Normal Work | SF36108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639773","SF36 v1.0 Standard - Did You Feel Full of Pep","C100835","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - did you feel full of pep.","SF36 v1.0 Standard - Did You Feel Full of Pep | SF361-Did You Feel Full of Pep | SF36109A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639774","SF36 v1.0 Standard - Have You Been Very Nervous Person","C100836","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - have you been a very nervous person.","SF36 v1.0 Standard - Have You Been Very Nervous Person | SF361-Have You Been Very Nervous Person | SF36109B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639775","SF36 v1.0 Standard - Felt Down Nothing Cheer You Up","C100837","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - have you felt so down in the dumps that nothing could cheer you up.","SF36 v1.0 Standard - Felt Down Nothing Cheer You Up | SF361-Felt Down Nothing Cheer You Up | SF36109C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639854","UPDRS - Motor Examination: Facial Expression","C100919","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination; facial expression.","UPDRS - Motor Examination: Facial Expression | UPD1-Motor:Facial Expression | UPD119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639855","UPDRS - Motor Examination: Tremor at Rest","C100920","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination; tremor at rest (head, upper and lower extremities).","UPDRS - Motor Examination: Tremor at Rest | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639857","UPDRS - Motor Examination: Rigidity","C100922","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination; rigidity (Judged on passive movement of major joints with patient relaxed in sitting position. Cogwheeling to be ignored.).","UPDRS - Motor Examination: Rigidity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639858","UPDRS - Motor Examination: Finger Taps","C100923","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination; finger taps (Patient taps thumb with index finger in rapid succession.).","UPDRS - Motor Examination: Finger Taps | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639859","UPDRS - Motor Examination: Hand Movements","C100924","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination; hand movements (Patient opens and closes hands in rapid succession.).","UPDRS - Motor Examination: Hand Movements | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639860","UPDRS - Motor Examination: Rapid Alternating Movements of Hands","C100925","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination; rapid alternating movements of hands (Pronation-supination movements of hands, vertically and horizontally, with as large an amplitude as possible, both hands simultaneously.).","UPDRS - Motor Examination: Rapid Alternating Movements of Hands | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639861","UPDRS - Motor Examination: Leg Agility","C100926","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination; leg agility (Patient taps heel on the ground in rapid succession picking up entire leg. Amplitude should be at least 3 inches.).","UPDRS - Motor Examination: Leg Agility | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639862","UPDRS - Motor Examination: Arising from Chair","C100927","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination; arising from chair (Patient attempts to rise from a straightbacked chair, with arms folded across chest.).","UPDRS - Motor Examination: Arising from Chair | UPD1-Motor:Arising from Chair | UPD127",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639863","UPDRS - Motor Examination: Posture","C100928","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination; posture.","UPDRS - Motor Examination: Posture | UPD1-Motor:Posture | UPD128",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639864","UPDRS - Motor Examination: Gait","C100929","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination; gait.","UPDRS - Motor Examination: Gait | UPD1-Motor:Gait | UPD129",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639865","UPDRS - Motor Examination: Postural Stability","C100930","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination; postural stability (Response to sudden, strong posterior displacement produced by pull on shoulders while patient erect with eyes open and feet slightly apart. Patient is prepared.).","UPDRS - Motor Examination: Postural Stability | UPD1-Motor:Postural Stability | UPD130",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639867","UPDRS - Complications of Therapy: Dyskinesias - Duration","C100932","Unified Parkinson's Disease Rating Scale (UPDRS) Complications of therapy (in the past week); dyskinesias, duration; what proportion of the waking day are dyskinesias present? (Historical information.).","UPDRS - Complications of Therapy: Dyskinesias - Duration | UPD1-Complications:Dyskinesias Duration | UPD132",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639868","UPDRS - Complications of Therapy: Dyskinesias - Disability","C100933","Unified Parkinson's Disease Rating Scale (UPDRS) Complications of therapy (in the past week); dyskinesias, disability; how disabling are the dyskinesias? (Historical information; may be modified by office examination.).","UPDRS - Complications of Therapy: Dyskinesias - Disability | UPD1-Complications:Dyskinesias Disable | UPD133",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639869","UPDRS - Complications of Therapy: Dyskinesias - Painful Dyskinesias","C100934","Unified Parkinson's Disease Rating Scale (UPDRS) Complications of therapy (in the past week); dyskinesias, painful dyskinesias; How painful are the dyskinesias?","UPDRS - Complications of Therapy: Dyskinesias - Painful Dyskinesias | UPD1-Complications:Dyskinesias Painful | UPD134",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279444","cyclophosphamide/mercaptopurine/prednisone/vincristine","C10071","A regimen consisting of vincristine, cyclophosphamide, mercaptopurine, and prednisone that may be used in the treatment of central nervous system (CNS) lymphoma.","Cyclophosphamide/Mercaptopurine/Prednisone/Vincristine Regimen | CTX/MP/PRED/VCR | Cyclophosphamide-Mercaptopurine-Prednisone-Vincristine | Cyclophosphamide/Mercaptopurine/Prednisone/Vincristine | VEMP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639668","NPI - Gained Weight","C100720","Neuropsychiatric Inventory (NPI) Has he/she gained weight?","NPI - Gained Weight | NPI1-Weight Gain | NPI1L04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639669","NPI - Change in Eating Behavior","C100721","Neuropsychiatric Inventory (NPI) Has he/she had a change in eating behavior such as putting too much food in his/her mouth at once?","NPI - Change in Eating Behavior | NPI1-Change in Eating Behavior | NPI1L05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639670","NPI - Change in Kind of Food He/She Likes","C100722","Neuropsychiatric Inventory (NPI) Has he/she had a change in the kind of food he/she likes such as eating too many sweets or other specific types of food?","NPI - Change in Kind of Food He/She Likes | NPI1-Change in Kind of Food | NPI1L06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639671","NPI - Developed Eating Behaviors Such as Eating Exactly the Same Types of Food","C100723","Neuropsychiatric Inventory (NPI) Has he/she developed eating behaviors such as eating exactly the same types of food each day or eating the food in exactly the same order?","NPI - Developed Eating Behaviors Such as Eating Exactly the Same Types of Food | NPI1-Develop Eating Behaviors | NPI1L07",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639673","PDQUALIF - Lightheadedness","C100725","Parkinson's Disease Quality of Life Scale (PDQUALIF) Changing position causes me to become lightheaded (lying to standing, or sitting to standing).","PDQUALIF - Lightheadedness | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639674","PDQUALIF - Imbalance","C100726","Parkinson's Disease Quality of Life Scale (PDQUALIF) When walking, I have trouble keeping my balance.","PDQUALIF - Imbalance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639675","PDQUALIF - Swallowing Difficulty","C100727","Parkinson's Disease Quality of Life Scale (PDQUALIF) When eating or drinking fluids, I have difficulty swallowing.","PDQUALIF - Swallowing Difficulty | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639676","PDQUALIF - Communication","C100728","Parkinson's Disease Quality of Life Scale (PDQUALIF) My Parkinson's symptoms affect my ability to communicate with people.","PDQUALIF - Communication | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639677","PDQUALIF - Nocturia","C100729","Parkinson's Disease Quality of Life Scale (PDQUALIF) The need to go to the bathroom keeps me up at night.","PDQUALIF - Nocturia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639678","PDQUALIF - Sexual Ability","C100730","Parkinson's Disease Quality of Life Scale (PDQUALIF) My Parkinson's symptoms affect my ability to show affection in intimate or sexual ways.","PDQUALIF - Sexual Ability | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639679","PDQUALIF - Neuropathy in Hands or Feet","C100731","Parkinson's Disease Quality of Life Scale (PDQUALIF) I have aching/burning/coldness/numbness in my hand/feet.","PDQUALIF - Neuropathy in Hands or Feet | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639680","PDQUALIF - Bladder Control Difficulty","C100732","Parkinson's Disease Quality of Life Scale (PDQUALIF) I have difficulty with bladder control (frequency, urgency, inability).","PDQUALIF - Bladder Control Difficulty | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639681","PDQUALIF - Constipation","C100733","Parkinson's Disease Quality of Life Scale (PDQUALIF) Constipation is a problem.","PDQUALIF - Constipation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639682","PDQUALIF - Trouble with Sleep Initiation or Waking Early","C100734","Parkinson's Disease Quality of Life Scale (PDQUALIF) My Parkinson's symptoms cause me to have trouble falling asleep, or waking early.","PDQUALIF - Trouble with Sleep Initiation or Waking Early | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639684","PDQUALIF - Positive Outlook Difficult","C100736","Parkinson's Disease Quality of Life Scale (PDQUALIF) My Parkinson's symptoms make it hard to maintain a positive outlook.","PDQUALIF - Positive Outlook Difficult | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639685","PDQUALIF - Burden to Others","C100737","Parkinson's Disease Quality of Life Scale (PDQUALIF) My Parkinson's symptoms cause me to feel like a burden to other people.","PDQUALIF - Burden to Others | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639686","PDQUALIF - Social Life Affected","C100738","Parkinson's Disease Quality of Life Scale (PDQUALIF) My Parkinson's symptoms have affected my social life.","PDQUALIF - Social Life Affected | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639687","PDQUALIF - Worry about Future","C100739","Parkinson's Disease Quality of Life Scale (PDQUALIF) I worry about what the future has in store.","PDQUALIF - Worry about Future | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639688","PDQUALIF - Difficulty in Asking for Help","C100740","Parkinson's Disease Quality of Life Scale (PDQUALIF) Asking others for help is difficult for me.","PDQUALIF - Difficulty in Asking for Help | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639689","PDQUALIF - Important to Maintain Independence","C100741","Parkinson's Disease Quality of Life Scale (PDQUALIF) Maintaining my independence is important to me.","PDQUALIF - Important to Maintain Independence | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639690","PDQUALIF - Difficulty in Adjusting to Change","C100742","Parkinson's Disease Quality of Life Scale (PDQUALIF) It has been difficult to adjust to the changes which have taken place in my body.","PDQUALIF - Difficulty in Adjusting to Change | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639691","PDQUALIF - Social Life Not Affected","C100743","Parkinson's Disease Quality of Life Scale (PDQUALIF) My Parkinson's symptoms have not affected my social life.","PDQUALIF - Social Life Not Affected | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639692","PDQUALIF - Travel Important","C100744","Parkinson's Disease Quality of Life Scale (PDQUALIF) Travel remains an important part of my leisure activities.","PDQUALIF - Travel Important | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639693","PDQUALIF - Family Relationship Affected","C100745","Parkinson's Disease Quality of Life Scale (PDQUALIF) My Parkinson's symptoms have affected my family role and responsibility.","PDQUALIF - Family Relationship Affected | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639694","PDQUALIF - Social Isolation","C100746","Parkinson's Disease Quality of Life Scale (PDQUALIF) My Parkinson's symptoms cause me to stay away from social gatherings.","PDQUALIF - Social Isolation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639695","PDQUALIF - Self Concept Change","C100747","Parkinson's Disease Quality of Life Scale (PDQUALIF) My spouse/children/friends' view of me has changed because of my illness.","PDQUALIF - Self Concept Change | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639696","PDQUALIF - Sexual Desirability","C100748","Parkinson's Disease Quality of Life Scale (PDQUALIF) I feel I am less sexually desirable because of my illness.","PDQUALIF - Sexual Desirability | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639697","PDQUALIF - Independent Hygiene in Past 7 Days","C100749","Parkinson's Disease Quality of Life Scale (PDQUALIF) In the past 7 days, in my personal hygiene (bathing, hair care, make up, shaving or toileting), I have been independent.","PDQUALIF - Independent Hygiene in Past 7 Days | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639698","PDQUALIF - Independent Food Preparation in Past 7 Days","C100750","Parkinson's Disease Quality of Life Scale (PDQUALIF) In the past 7 days, in food preparation or eating I am independent.","PDQUALIF - Independent Food Preparation in Past 7 Days | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639699","PDQUALIF - Problem with Communication in the Past 7 Days","C100751","Parkinson's Disease Quality of Life Scale (PDQUALIF) In the past 7 days, written or spoken communication is a problem for me.","PDQUALIF - Problem with Communication in the Past 7 Days | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639700","PDQUALIF - Fatigue in Past 7 Days","C100752","Parkinson's Disease Quality of Life Scale (PDQUALIF) In the past 7 days, fatigue makes participation in activities, household chores, shopping or yard work a problem for me.","PDQUALIF - Fatigue in Past 7 Days | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639702","PDQUALIF - Sleep with Partner in Past 7 Days","C100754","Parkinson's Disease Quality of Life Scale (PDQUALIF) In the past 7 days, my nighttime symptoms keep me from sleeping with my spouse/partner.","PDQUALIF - Sleep with Partner in Past 7 Days | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639703","PDQUALIF - Driving in Past 7 Days","C100755","Parkinson's Disease Quality of Life Scale (PDQUALIF) In the past 7 days, my Parkinson's symptoms have interfered with my driving ability.","PDQUALIF - Driving in Past 7 Days | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639704","PDQUALIF - Financial Strain in Past 7 Days","C100756","Parkinson's Disease Quality of Life Scale (PDQUALIF) In the past 7 days, my illness has caused a financial strain for me and my family.","PDQUALIF - Financial Strain in Past 7 Days | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639705","PDQUALIF - Parkinson's Symptoms","C100757","Parkinson's Disease Quality of Life Scale (PDQUALIF) Compared to 6 months ago, my Parkinson's symptoms are.","PDQUALIF - Parkinson's Symptoms | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639807","SF-MPQ-2 - Numbness","C100869","Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Numbness.","SF-MPQ-2 - Numbness | SFMP2-Numbness | SFMP222",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639809","SOAPP-R - Need Higher Doses of Medication","C100871","Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have you felt a need for higher doses of medication to treat your pain?","SOAPP-R - Need Higher Doses of Medication | SOAPR1-Need Higher Doses of Medication | SOAPR102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639810","SOAPP-R - Felt Impatient With Doctors","C100872","Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have you felt impatient with your doctors?","SOAPP-R - Felt Impatient With Doctors | SOAPR1-Felt Impatient With Doctors | SOAPR103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639811","SOAPP-R - Felt That Things Are Overwhelming","C100873","Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have you felt that things are just too overwhelming that you can't handle them?","SOAPP-R - Felt That Things Are Overwhelming | SOAPR1-Felt That Things Are Overwhelming | SOAPR104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639812","SOAPP-R - How Often Tension at Home","C100874","Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often is there tension in the home?","SOAPP-R - How Often Tension at Home | SOAPR1-How Often Tension at Home | SOAPR105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639813","SOAPP-R - How Often Counted Pain Pills","C100875","Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have you counted pain pills to see how many are remaining?","SOAPP-R - How Often Counted Pain Pills | SOAPR1-How Often Counted Pain Pills | SOAPR106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639814","SOAPP-R - Concerned People Will Judge You","C100876","Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have you been concerned that people will judge you for taking pain medication?","SOAPP-R - Concerned People Will Judge You | SOAPR1-Concerned People Will Judge You | SOAPR107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639815","SOAPP-R - How Often Feel Bored","C100877","Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often do you feel bored?","SOAPP-R - How Often Feel Bored | SOAPR1-How Often Feel Bored | SOAPR108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639816","SOAPP-R - How Often Taken More Pain Medication","C100878","Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have you taken more pain medication than you were supposed to?","SOAPP-R - How Often Taken More Pain Medication | SOAPR1-How Often Taken More Pain Med | SOAPR109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639818","SOAPP-R - Felt Craving for Medication","C100880","Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have you felt a craving for medication?","SOAPP-R - Felt Craving for Medication | SOAPR1-Felt Craving for Medication | SOAPR111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639819","SOAPP-R - Others Expressed Concern Over Medication Use","C100881","Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have others expressed concern over your use of medication?","SOAPP-R - Others Expressed Concern Over Medication Use | SOAPR1-Expressed Concern Over Med Use | SOAPR112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639820","SOAPP-R - How Often Friends Had Problem","C100882","Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have any of your close friends had a problem with alcohol or drugs?","SOAPP-R - How Often Friends Had Problem | SOAPR1-How Often Friends Had Problem | SOAPR113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639836","UPDRS - Mentation, Behavior and Mood: Intellectual Impairment","C100901","Unified Parkinson's Disease Rating Scale (UPDRS) Mentation, behavior and mood; intellectual impairment.","UPDRS - Mentation, Behavior and Mood: Intellectual Impairment | UPD1-Mentation:Intellectual Impairment | UPD101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639837","UPDRS - Mentation, Behavior and Mood: Thought Disorder","C100902","Unified Parkinson's Disease Rating Scale (UPDRS) Mentation, behavior and mood; thought disorder.","UPDRS - Mentation, Behavior and Mood: Thought Disorder | UPD1-Mentation:Thought Disorder | UPD102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639838","UPDRS - Mentation, Behavior and Mood: Depression","C100903","Unified Parkinson's Disease Rating Scale (UPDRS) Mentation, behavior and mood; depression.","UPDRS - Mentation, Behavior and Mood: Depression | UPD1-Mentation:Depression | UPD103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639840","UPDRS - Activities of Daily Living: Speech","C100905","Unified Parkinson's Disease Rating Scale (UPDRS) Activities of daily living (for both 'on' and 'off'); speech.","UPDRS - Activities of Daily Living: Speech | UPD1-Activities:Speech | UPD105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639841","UPDRS - Activities of Daily Living: Salivation","C100906","Unified Parkinson's Disease Rating Scale (UPDRS) Activities of daily living (for both 'on' and 'off'); salivation.","UPDRS - Activities of Daily Living: Salivation | UPD1-Activities:Salivation | UPD106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639842","UPDRS - Activities of Daily Living: Swallowing","C100907","Unified Parkinson's Disease Rating Scale (UPDRS) Activities of daily living (for both 'on' and 'off'); swallowing.","UPDRS - Activities of Daily Living: Swallowing | UPD1-Activities:Swallowing | UPD107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639843","UPDRS - Activities of Daily Living: Handwriting","C100908","Unified Parkinson's Disease Rating Scale (UPDRS) Activities of daily living (for both 'on' and 'off'); handwriting.","UPDRS - Activities of Daily Living: Handwriting | UPD1-Activities:Handwriting | UPD108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639844","UPDRS - Activities of Daily Living: Cutting Food and Handling Utensils","C100909","Unified Parkinson's Disease Rating Scale (UPDRS) Activities of daily living (for both 'on' and 'off'); cutting food and handling utensils.","UPDRS - Activities of Daily Living: Cutting Food and Handling Utensils | UPD1-Activities:Cut Food/Handle Utensil | UPD109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639845","UPDRS - Activities of Daily Living: Dressing","C100910","Unified Parkinson's Disease Rating Scale (UPDRS) Activities of daily living (for both 'on' and 'off'); dressing.","UPDRS - Activities of Daily Living: Dressing | UPD1-Activities:Dressing | UPD110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639846","UPDRS - Activities of Daily Living: Hygiene","C100911","Unified Parkinson's Disease Rating Scale (UPDRS) Activities of daily living (for both 'on' and 'off'); hygiene.","UPDRS - Activities of Daily Living: Hygiene | UPD1-Activities:Hygiene | UPD111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639847","UPDRS - Activities of Daily Living: Turning in Bed and Adjusting Bed Clothes","C100912","Unified Parkinson's Disease Rating Scale (UPDRS) Activities of daily living (for both 'on' and 'off'); turning in bed and adjusting bed clothes.","UPDRS - Activities of Daily Living: Turning in Bed and Adjusting Bed Clothes | UPD1-Activities:Turn Bed/Adj Clothes | UPD112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639848","UPDRS - Activities of Daily Living: Falling","C100913","Unified Parkinson's Disease Rating Scale (UPDRS) Activities of daily living (for both 'on' and 'off'); falling (unrelated to freezing).","UPDRS - Activities of Daily Living: Falling | UPD1-Activities:Falling | UPD113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639849","UPDRS - Activities of Daily Living: Freezing When Walking","C100914","Unified Parkinson's Disease Rating Scale (UPDRS) Activities of daily living (for both 'on' and 'off'); freezing when walking.","UPDRS - Activities of Daily Living: Freezing When Walking | UPD1-Activities:Freezing When Walking | UPD114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639851","UPDRS - Activities of Daily Living: Tremor","C100916","Unified Parkinson's Disease Rating Scale (UPDRS) Activities of daily living (for both 'on' and 'off'); tremor (Symptomatic complaint of tremor in any part of body.).","UPDRS - Activities of Daily Living: Tremor | UPD1-Activities:Tremor | UPD116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639852","UPDRS - Activities of Daily Living: Sensory Complaints Related to Parkinsonism","C100917","Unified Parkinson's Disease Rating Scale (UPDRS) Activities of daily living (for both 'on' and 'off'); sensory complaints related to Parkinsonism.","UPDRS - Activities of Daily Living: Sensory Complaints Related to Parkinsonism | UPD1-Activities:Sensory Complaints | UPD117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639853","UPDRS - Motor Examination: Speech","C100918","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination; speech.","UPDRS - Motor Examination: Speech | UPD1-Motor:Speech | UPD118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639751","SF36 v1.0 Standard - In General You Say Your Health Is","C100813","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) In general, would you say your health is.","SF36 v1.0 Standard - In General You Say Your Health Is | SF361-In General You Say Your Health Is | SF36101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639752","SF36 v1.0 Standard - Comp Year Ago Rate Gen Health Now","C100814","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) Compared to one year ago, how would you rate your health in general now?","SF36 v1.0 Standard - Comp Year Ago Rate Gen Health Now | SF361-Comp Year Ago Rate Gen Health Now | SF36102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639753","SF36 v1.0 Standard - Limit Vigorous Activities","C100815","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) How much does your health now limit you in - vigorous activities, such as running, lifting heavy objects, participating in strenuous sports.","SF36 v1.0 Standard - Limit Vigorous Activities | SF361-Limit Vigorous Activities | SF36103A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639754","SF36 v1.0 Standard - Limit Moderate Activities","C100816","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) How much does your health now limit you in - moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or playing golf.","SF36 v1.0 Standard - Limit Moderate Activities | SF361-Limit Moderate Activities | SF36103B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639755","SF36 v1.0 Standard - Limit Lifting or Carrying","C100817","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) How much does your health now limit you in - lifting or carrying groceries.","SF36 v1.0 Standard - Limit Lifting or Carrying | SF361-Limit Lifting or Carrying | SF36103C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639756","SF36 v1.0 Standard - Limit Climbing Several Flights","C100818","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) How much does your health now limit you in - climbing several flights of stairs.","SF36 v1.0 Standard - Limit Climbing Several Flights | SF361-Limit Climbing Several Flights | SF36103D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639757","SF36 v1.0 Standard - Limit Climbing One Flight Stairs","C100819","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) How much does your health now limit you in - climbing one flight of stairs.","SF36 v1.0 Standard - Limit Climbing One Flight Stairs | SF361-Limit Climbing One Flight Stairs | SF36103E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639759","SF36 v1.0 Standard - Limit Walking More Than a Mile","C100821","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) How much does your health now limit you in - walking more than a mile.","SF36 v1.0 Standard - Limit Walking More Than a Mile | SF361-Limit Walking More Than a Mile | SF36103G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639760","SF36 v1.0 Standard - Limit Walking Several Blocks","C100822","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) How much does your health now limit you in - walking several blocks.","SF36 v1.0 Standard - Limit Walking Several Blocks | SF361-Limit Walking Several Blocks | SF36103H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639761","SF36 v1.0 Standard - Limit Walking One Block","C100823","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) How much does your health now limit you in - walking one block.","SF36 v1.0 Standard - Limit Walking One Block | SF361-Limit Walking One Block | SF36103I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639762","SF36 v1.0 Standard - Limit Bathing or Dressing Yourself","C100824","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) How much does your health now limit you in - bathing or dressing yourself.","SF36 v1.0 Standard - Limit Bathing or Dressing Yourself | SF361-Limit Bathing or Dressing Yourself | SF36103J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639763","SF36 v1.0 Standard - Physical: Cut Down Time on Work","C100825","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) During the past 4 weeks, how much of the time have you had any problems with your work or other regular daily activities as a result of your physical health - cut down on the amount of time you spent on work or other activities.","SF36 v1.0 Standard - Physical: Cut Down Time on Work | SF361-Physical: Cut Down Time on Work | SF36104A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4012291","Ileal Atresia","C101026","A congenital malformation characterized by the absence of a normal opening in a part of the ileum.","Ileal Atresia | Atresia of Ileum | Congenital Atresia of Ileum | Congenital Ileal Atresia",,,,,,,,,,,,,,,"4093450","Congenital atresia of ileum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0266175","Jejunal Atresia","C101027","A congenital malformation characterized by the absence of a normal opening in a part of the jejunum.","Jejunal Atresia | Atresia of Jejunum | Congenital Atresia of Jejunum | Congenital Jejunal Atresia",,,,,,,,,,,,,,,"4235786","Congenital atresia of jejunum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0349470","Neonatal Aspiration of Amniotic Fluid","C101028","Inhalation of fluid from the amniotic sac into the lungs by the neonate.","Neonatal Aspiration of Amniotic Fluid | ",,,,,,,,,,,,,,,"433589","Neonatal aspiration of amniotic fluid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4230922","Atrioventricular Septal Defect","C101029","A congenital heart malformation characterized by abnormalities in the anatomic structures that relate to the endocardial cushions. These abnormalities can include defects in the lower part of the atrial septum and the ventricular septum and lack of separation of the mitral and tricuspid valves.","Atrioventricular Septal Defect | AV Septal Defect | Common AV Canal | Common Atrioventricular Canal | Endocardial Cushion Defect",,,,,,,,,,,,,,,"4100152","Atrioventricular septal defect and common atrioventricular junction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3639953","Complete Atrioventricular Canal Defect Balanced","C101030","Atrioventricular septal defect in which the atrioventricular junction is shared evenly between the left ventricle and right ventricle.","Complete Atrioventricular Canal Defect Balanced | CAVD, Balanced | Complete AV Canal Defect Balanced | Complete Atrioventricular Canal Defect (Balanced)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639954","Complete Atrioventricular Canal Defect Unbalanced","C101031","Atrioventricular septal defect in which there is usually a single dominant ventricle and a hypoplastic ventricle.","Complete Atrioventricular Canal Defect Unbalanced | CAVD, Unbalanced | Complete AV Canal Defect Unbalanced | Complete Atrioventricular Canal Defect (Unbalanced)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639821","SOAPP-R - Others Told You Bad Temper","C100883","Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have others told you that you had a bad temper?","SOAPP-R - Others Told You Bad Temper | SOAPR1-Others Told You Bad Temper | SOAPR114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639822","SOAPP-R - Felt Consumed to Get Pain Medication","C100884","Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have you felt consumed by the need to get pain medication?","SOAPP-R - Felt Consumed to Get Pain Medication | SOAPR1-Felt Consumed to Get Pain Med | SOAPR115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639823","SOAPP-R - Run Out of Pain Medication Early","C100885","Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have you run out of pain medication early?","SOAPP-R - Run Out of Pain Medication Early | SOAPR1-Run Out of Pain Med Early | SOAPR116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639824","SOAPP-R - Others Kept You From what You Deserve","C100886","Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have others kept you from getting what you deserve?","SOAPP-R - Others Kept You From what You Deserve | SOAPR1-Kept From What You Deserve | SOAPR117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639825","SOAPP-R - Legal Problems or Arrested","C100887","Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often, in your lifetime, have you had legal problems or been arrested?","SOAPP-R - Legal Problems or Arrested | SOAPR1-Legal Problems or Arrested | SOAPR118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639826","SOAPP-R - Attended AA or NA Meeting","C100888","Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have you attended an AA or NA meeting?","SOAPP-R - Attended AA or NA Meeting | SOAPR1-Attended AA or NA Meeting | SOAPR119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639827","SOAPP-R - Argument Where Someone Got Hurt","C100889","Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have you been in an argument that was so out of control that someone got hurt?","SOAPP-R - Argument Where Someone Got Hurt | SOAPR1-Argument Someone Got Hurt | SOAPR120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639828","SOAPP-R - How Often Sexually Abused","C100890","Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have you been sexually abused?","SOAPP-R - How Often Sexually Abused | SOAPR1-How Often Sexually Abused | SOAPR121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639829","SOAPP-R - Others Suggested Drug or Alcohol Problem","C100891","Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have others suggested that you have a drug or alcohol problem?","SOAPP-R - Others Suggested Drug or Alcohol Problem | SOAPR1-Suggested Drug or Alcohol Problem | SOAPR122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639830","SOAPP-R - How Often Borrowed Pain Medication","C100892","Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have you had to borrow pain medications from your family or friends?","SOAPP-R - How Often Borrowed Pain Medication | SOAPR1-How Often Borrowed Pain Meds | SOAPR123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639831","SOAPP-R - Treated for Alcohol or Drug Problem","C100893","Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have you been treated for an alcohol or drug problem?","SOAPP-R - Treated for Alcohol or Drug Problem | SOAPR1-Treated for Alcohol or Drug Prob | SOAPR124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639832","SOAPP-R - Any Additional Information","C100894","Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) Please include any additional information you wish about the above answers.","SOAPP-R - Any Additional Information | SOAPR1-Any Additional Information | SOAPR125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639833","SOAPP-R - Score","C100895","Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) Score.","SOAPP-R - Score | SOAPR1-Score | SOAPR126",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639776","SF36 v1.0 Standard - Have You Felt Calm and Peaceful","C100838","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - have you felt calm and peaceful.","SF36 v1.0 Standard - Have You Felt Calm and Peaceful | SF361-Have You Felt Calm and Peaceful | SF36109D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639777","SF36 v1.0 Standard - Did You Have a Lot of Energy","C100839","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - did you have a lot of energy.","SF36 v1.0 Standard - Did You Have a Lot of Energy | SF361-Did You Have a Lot of Energy | SF36109E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279468","cisplatin/doxorubicin/fluorouracil/vinblastine","C10083","A regimen consisting of fluorouracil, vinblastine, doxorubicin, and cyclophosphamide that may be used in the treatment of breast cancer.","FUVAC Regimen | CDDP/DOX/5-FU/VBL | FUVAC | Fluorouracil-Vinblastine-Doxorubicin-Cyclophosphamide | Fluorouracil/Vinblastine/Adriamycin/Cyclophosphamide | Fluorouracil/Vinblastine/Doxorubicin/Cyclophosphamide | Fluorouracil/Vinblastine/Doxorubicin/Cyclophosphamide Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639778","SF36 v1.0 Standard - You Felt Downhearted and Blue","C100840","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - have you felt downhearted and blue.","SF36 v1.0 Standard - You Felt Downhearted and Blue | SF361-You Felt Downhearted and Blue | SF36109F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639779","SF36 v1.0 Standard - Did You Feel Worn Out","C100841","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - did you feel worn out.","SF36 v1.0 Standard - Did You Feel Worn Out | SF361-Did You Feel Worn Out | SF36109G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639780","SF36 v1.0 Standard - Have You Been Happy Person","C100842","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - have you been a happy person.","SF36 v1.0 Standard - Have You Been Happy Person | SF361-Have You Been Happy Person | SF36109H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639781","SF36 v1.0 Standard - Did You Feel Tired","C100843","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - did you feel tired.","SF36 v1.0 Standard - Did You Feel Tired | SF361-Did You Feel Tired | SF36109I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639783","SF36 v1.0 Standard - Get Sick Little Easier Than Other","C100845","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) How TRUE or FALSE is the following statement for you - I seem to get sick a little easier than other people.","SF36 v1.0 Standard - Get Sick Little Easier Than Other | SF361-Get Sick Little Easier Than Other | SF36111A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639784","SF36 v1.0 Standard - I Am as Healthy as Anybody I Know","C100846","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) How TRUE or FALSE is the following statement for you - I am as healthy as anybody I know.","SF36 v1.0 Standard - I Am as Healthy as Anybody I Know | SF361-I Am as Healthy as Anybody I Know | SF36111B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639785","SF36 v1.0 Standard - I Expect My Health to Get Worse","C100847","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) How TRUE or FALSE is the following statement for you - I expect my health to get worse.","SF36 v1.0 Standard - I Expect My Health to Get Worse | SF361-I Expect My Health to Get Worse | SF36111C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639786","SF36 v1.0 Standard - My Health is Excellent","C100848","The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) How TRUE or FALSE is the following statement for you - my health is excellent","SF36 v1.0 Standard - My Health is Excellent | SF361-My Health is Excellent | SF36111D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639787","SF-MPQ-2 - Throbbing Pain","C100849","Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Throbbing pain.","SF-MPQ-2 - Throbbing Pain | SFMP2-Throbbing Pain | SFMP201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639788","SF-MPQ-2 - Shooting Pain","C100850","Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Shooting pain.","SF-MPQ-2 - Shooting Pain | SFMP2-Shooting Pain | SFMP202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639789","SF-MPQ-2 - Stabbing Pain","C100851","Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Stabbing pain.","SF-MPQ-2 - Stabbing Pain | SFMP2-Stabbing Pain | SFMP203",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639790","SF-MPQ-2 - Sharp Pain","C100852","Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Sharp pain.","SF-MPQ-2 - Sharp Pain | SFMP2-Sharp Pain | SFMP204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639791","SF-MPQ-2 - Cramping Pain","C100853","Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Cramping pain.","SF-MPQ-2 - Cramping Pain | SFMP2-Cramping Pain | SFMP205",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639792","SF-MPQ-2 - Gnawing Pain","C100854","Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Gnawing pain.","SF-MPQ-2 - Gnawing Pain | SFMP2-Gnawing Pain | SFMP206",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639793","SF-MPQ-2 - Hot-burning Pain","C100855","Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Hot-burning pain.","SF-MPQ-2 - Hot-burning Pain | SFMP2-Hot-burning Pain | SFMP207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639794","SF-MPQ-2 - Aching Pain","C100856","Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Aching pain.","SF-MPQ-2 - Aching Pain | SFMP2-Aching Pain | SFMP208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639796","SF-MPQ-2 - Tender","C100858","Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Tender.","SF-MPQ-2 - Tender | SFMP2-Tender | SFMP210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639797","SF-MPQ-2 - Splitting Pain","C100859","Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Splitting pain.","SF-MPQ-2 - Splitting Pain | SFMP2-Splitting Pain | SFMP211",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639798","SF-MPQ-2 - Tiring-Exhausting","C100860","Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Tiring-exhausting.","SF-MPQ-2 - Tiring-Exhausting | SFMP2-Tiring-Exhausting | SFMP212",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639799","SF-MPQ-2 - Sickening","C100861","Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Sickening.","SF-MPQ-2 - Sickening | SFMP2-Sickening | SFMP213",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639800","SF-MPQ-2 - Fearful","C100862","Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Fearful.","SF-MPQ-2 - Fearful | SFMP2-Fearful | SFMP214",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639801","SF-MPQ-2 - Punishing-Cruel","C100863","Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Punishing-cruel.","SF-MPQ-2 - Punishing-Cruel | SFMP2-Punishing-Cruel | SFMP215",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639802","SF-MPQ-2 - Electric-Shock Pain","C100864","Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Electric-shock pain.","SF-MPQ-2 - Electric-Shock Pain | SFMP2-Electric-Shock Pain | SFMP216",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639804","SF-MPQ-2 - Piercing","C100866","Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Piercing.","SF-MPQ-2 - Piercing | SFMP2-Piercing | SFMP218",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639805","SF-MPQ-2 - Pain Caused by Light Touch","C100867","Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Pain caused by light touch.","SF-MPQ-2 - Pain Caused by Light Touch | SFMP2-Pain Caused by Light Touch | SFMP219",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639806","SF-MPQ-2 - Itching","C100868","Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Itching.","SF-MPQ-2 - Itching | SFMP2-Itching | SFMP220",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639927","C-SSRS Baseline - Interrupted Suicide Attempt","C100995","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Has there been a time when you started to do something to try to end your life but someone or something stopped you before you actually did anything?","C-SSRS Baseline - Interrupted Suicide Attempt | CSS01-Interrupted Attempt | CSS0115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639928","C-SSRS Baseline - Number of Interrupted Suicide Attempts","C100996","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Total number of interrupted attempts.","C-SSRS Baseline - Number of Interrupted Suicide Attempts | CSS01-Number of Interrupted Attempts | CSS0116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639929","C-SSRS Baseline - Description of Interrupted Suicide Attempt","C100997","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Description of interrupted attempt.","C-SSRS Baseline - Description of Interrupted Suicide Attempt | CSS01-Interrupted Attempt, Describe | CSS0116A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639930","C-SSRS Baseline - Aborted Suicide Attempt","C100998","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Has there been a time when you started to do something to try to end your life but you stopped yourself before you actually did anything?","C-SSRS Baseline - Aborted Suicide Attempt | CSS01-Aborted Attempt | CSS0117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639931","C-SSRS Baseline - Number of Aborted Suicide Attempts","C100999","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Total number of aborted attempts.","C-SSRS Baseline - Number of Aborted Suicide Attempts | CSS01-Number of Aborted Attempts | CSS0118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0052794","Ethyleneimine","C1009","A monofunctional alkylating agent with potential antineoplastic activity.  Reacting with DNA mainly at guanine and adenine residues, ethylenimine alkylates DNA, thereby producing DNA interstrand crosslinks and DNA breaks, and interfering with DNA replication and cell division. (NCI04)","Ethyleneimine | AZIRIDINE | Aminoethylene | Azacyclopropane | Azirane | Aziridine | Dimethyleneimine | Dimethylenimine | Ethylenimine | Ethylimine",,,,,,,,,,,,,,,"4223542","Ethylenimine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3639932","C-SSRS Baseline - Description of Aborted Suicide Attempt","C101000","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Description of aborted attempt.","C-SSRS Baseline - Description of Aborted Suicide Attempt | CSS01-Aborted Attempt, Describe | CSS0118A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639933","C-SSRS Baseline - Preparatory Acts or Behaviors Toward Suicide Attempt","C101001","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Have you taken any steps toward making a suicide attempt or preparing to kill yourself (such as collecting pills, getting a gun, giving valuables away or writing a suicide note)?","C-SSRS Baseline - Preparatory Acts or Behaviors Toward Suicide Attempt | CSS01-Preparatory Acts/Behavior | CSS0119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639934","C-SSRS Baseline - Description of Preparatory Acts or Behaviors Toward Suicide Attempt","C101002","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Description of preparatory acts or behaviors.","C-SSRS Baseline - Description of Preparatory Acts or Behaviors Toward Suicide Attempt | CSS01-Preparatory Acts/Behavior, Descr | CSS0119A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639935","C-SSRS Baseline - Suicidal Behavior","C101003","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Suicidal behavior was present during the assessment period?","C-SSRS Baseline - Suicidal Behavior | CSS01-Suicidal Behavior | CSS0120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639936","C-SSRS Baseline - Most Recent Suicide Attempt Date","C101004","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Most recent actual attempt date.","C-SSRS Baseline - Most Recent Suicide Attempt Date | CSS01-Most Recent Attempt Date | CSS0121A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639937","C-SSRS Baseline - Most Recent Suicide Attempt Damage","C101005","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Most recent actual attempt lethality/medical damage.","C-SSRS Baseline - Most Recent Suicide Attempt Damage | CSS01-Most Recent Attempt Damage | CSS0121B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639940","C-SSRS Baseline - Most Lethal Suicide Attempt Damage","C101008","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Most lethal actual attempt lethality/medical damage.","C-SSRS Baseline - Most Lethal Suicide Attempt Damage | CSS01-Most Lethal Attempt Damage | CSS0122B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639941","C-SSRS Baseline - Most Lethal Suicide Attempt Potential","C101009","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Most lethal actual attempt potential lethality.","C-SSRS Baseline - Most Lethal Suicide Attempt Potential | CSS01-Most Lethal Attempt Potential | CSS0122C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279502","cyclophosphamide/fluorouracil/methotrexate/tamoxifen","C10100","A regimen consisting of cyclophosphamide, methotrexate, fluorouracil, and tamoxifen that may be used in the treatment of breast cancer.","CMFT Regimen | CMFT | CTX/5-FU/MTX/TMX | Cyclophosphamide-Methotrexate-Fluorouracil-Tamoxifen | Cyclophosphamide/Fluorouracil/Methotrexate/Tamoxifen | Cyclophosphamide/Methotrexate/Fluorouracil/Tamoxifen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639942","C-SSRS Baseline - First Suicide Attempt Date","C101010","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Initial/first actual attempt date.","C-SSRS Baseline - First Suicide Attempt Date | CSS01-First Attempt Date | CSS0123A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639943","C-SSRS Baseline - First Suicide Attempt Damage","C101011","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Initial/first actual attempt lethality/medical damage.","C-SSRS Baseline - First Suicide Attempt Damage | CSS01-First Attempt Damage | CSS0123B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639944","C-SSRS Baseline - First Suicide Attempt Potential","C101012","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Initial/first actual attempt potential lethality.","C-SSRS Baseline - First Suicide Attempt Potential | CSS01-First Attempt Potential | CSS0123C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639945","FPSR - How Much Do You Hurt","C101013","Faces Pain Scale Revised (FPSR) Point to the face that shows how much you hurt (right now).","FPSR - How Much Do You Hurt | FPSR1-How Much Do You Hurt | FPSR101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639946","C-SSRS Baseline - Ideation With Intent, No Plan","C101014","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Have you have these thoughts and had some intention of acting on them?","C-SSRS Baseline - Ideation With Intent, No Plan | CSS01-Ideation With Intent, No Plan | CSS0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639947","C-SSRS Baseline - Description of Ideation With Intent, No Plan","C101015","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Description of active suicidal ideation with some intent to act, without specific plan.","C-SSRS Baseline - Description of Ideation With Intent, No Plan | CSS01-Ideation With Intent No Plan Descr | CSS0104A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639948","MDS-UPDRS - Get Out of Bed, Car, or Deep Chair","C101018","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you usually had trouble getting out of bed, a car seat, or a deep chair?","MDS-UPDRS - Get Out of Bed, Car, or Deep Chair | UPD2-Get Out of Bed/Car/Deep Chair | UPD2211",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639949","MNSI - Right Foot Dry Skin, Callus","C101019","Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; appearance of right foot - dry skin, callus.","MNSI - Right Foot Dry Skin, Callus | MNSI1-Right Foot Dry Skin, Callus | MNSI119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639951","SF-MPQ-2 - Tingling or 'Pins and Needles'","C101021","Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Tingling or 'pins and needles'.","SF-MPQ-2 - Tingling or 'Pins and Needles' | SFMP2-Tingling or 'Pins and Needles' | SFMP221",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1290398","Cerebral Arterial Aneurysm","C101022","A balloon type pouch or bulge in the wall of a cerebral artery.","Cerebral Arterial Aneurysm | Aneurysm of Cerebral Artery | Cerebral Artery Aneurysm",,,,,,,,,,,,,,,"4029497","Cerebral arterial aneurysm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3639952","Cerebral Venous Aneurysm","C101023","A balloon type pouch or bulge in the wall of a cerebral vein.","Cerebral Venous Aneurysm | Aneurysm of Cerebral Vein | Cerebral Vein Aneurysm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0266190","Colon Atresia","C101024","A congenital malformation characterized by the absence of a normal opening in a part of the colon.","Colon Atresia | Atresia of Colon | Congenital Atresia of Colon",,,,,,,,,,,,,,,"4286282","Congenital atresia of colon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3279849","Duodenal Atresia","C101025","A congenital malformation characterized by the absence of a normal opening in a part of the duodenum.","Duodenal Atresia | Atresia of Duodenum | Congenital Atresia of Duodenum | Congenital Duodenal Atresia",,,,,,,,,,,,,,,"4196964","Congenital atresia of duodenum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3540640","FUS/CREB3L1 Fusion Protein","C101056","A predicted fusion protein encoded by the FUS/CREB3L1 fusion gene. This protein is comprised of approximately half the RNA-binding protein FUS fused to the DNA-binding basic domain and leucine zipper dimerization domain of the cyclic AMP-responsive element-binding protein 3-like protein 1.","FUS/CREB3L1 Fusion Protein | FUS-CREB3L1 Fusion Protein | FUS::CREB3L1 Fusion Protein | RNA-Binding Protein FUS/Cyclic AMP-Responsive Element-Binding Protein 3-Like Protein 1 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639968","MSN/ALK Fusion Gene","C101059","A fusion gene that results from a chromosomal translocation t(X;2)(q11;p23) which fuses most of the coding sequence of the MSN gene with the 3' portion of the ALK gene. This rearrangement is associated with rare cases of anaplastic large cell lymphoma.","MSN/ALK Fusion Gene | MSN-ALK Fusion Gene | MSN::ALK Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639969","MSN/ALK Fusion Protein","C101060","A fusion protein encoded by the MSN/ALK fusion gene. This protein is comprised of most of the moesin protein, including the band 4.1 region, fused to the cytoplasmic domain of the ALK tyrosine kinase receptor protein, including the tyrosine kinase domain.","MSN/ALK Fusion Protein | MSN-ALK Fusion Protein | MSN::ALK Fusion Protein | Moesin/ALK Tyrosine Kinase Receptor Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3279505","NONO/TFE3 Fusion Gene","C101061","A fusion gene that results from a chromosomal inversion inv(X)(p11.2;q12) which fuses exon 9 of the NONO gene with exon 6 of the TFE3 gene. This rearrangement is associated with one case of renal cell carcinoma.","NONO/TFE3 Fusion Gene | NONO-TFE3 Fusion Gene | NONO::TFE3 Fusion Gene | p54nrb/NONO-TFE3 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639970","NONO/TFE3 Fusion Protein","C101062","A fusion protein encoded by the NONO/TFE3 fusion gene. This protein is comprised of most of the non-POU domain-containing octamer-binding protein fused to the C-terminal basic helix-loop-helix DNA binding and leucine zipper dimerization domains of the transcription factor E3 protein.","NONO/TFE3 Fusion Protein | NONO-TFE3 Fusion Protein | NONO::TFE3 Fusion Protein | Non-POU Domain-Containing Octamer-Binding Protein/Transcription Factor E3 Fusion Protein | p54nrb/NONO-TFE3 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0265863","Dextrocardia Situs Solitus","C101032","A congenital heart defect in which the heart is located in the right side and the other organs are in their normal position.","Dextrocardia Situs Solitus | Dextrocardia Normal Situs | Dextrocardia, Normal Situs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0151737","Intentional Trauma","C101034","An injury that is not the result of an accident or natural causes.","Intentional Trauma | Non-accidental Trauma | Nonaccidental Trauma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639958","Retinopathy of Prematurity with Plus Disease","C101036","A stage of retinopathy of prematurity characterized by the presence of the following in at least two quadrants around the optic nerve: dilation and tortuosity of major retinal vasculature as a result of increased blood flow.","Retinopathy of Prematurity with Plus Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0158940","Transient Tachypnea of the Newborn","C101037","A respiratory disorder characterized by higher than normal respiratory rates among premature and cesarean section delivered neonates whose lungs have not fully matured. The cause is often excess fluid in the lungs, and resolution is aided by supplemental oxygen and sometimes, antibiotics.","Transient Tachypnea of the Newborn | Retained Fetal Lung Fluid | TTN | Transitory Tachypnea of Newborn | Type II Respiratory Distress Syndrome | Wet Lung Syndrome",,,,,,,,,,,,,,,"321683","Transitory tachypnea of newborn",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1854678","Lethal Multiple Pterygium Syndrome","C101038","A rare variant of multiple pterygium syndrome, characterized by severe athrogryposis, pterygium, akinesia and often hydrops fetalis and cystic hygroma. This variant is fatal, usually during the second or third trimester of pregnancy.","Lethal Multiple Pterygium Syndrome | ",,,,,,,,,,,,,,,"4244589","Lethal multiple pterygium syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265261","Escobar Syndrome","C101039","A rare congenital disorder, this is the non-lethal variant of multiple pterygium syndrome, characterized by orthopedic and craniofacial abnormalities, pterygium and akinethesia. The majority of cases are autosomal dominant.","Escobar Syndrome | ",,,,,,,,,,,,,,,"4214761","Escobar syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085758","Total Colonic Aganglionosis","C101040","The severe form of Hirschsprung disease, this is characterized by a complete lack of nerve cells in the large intestine, and often a partial lack in the small intestine. The bowel is not stimulated without innervation and obstruction ensues. Surgical intervention is necessary.","Total Colonic Aganglionosis | TCA",,,,,,,,,,,,,,,"4109786","Total colonic aganglionosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3639870","UPDRS - Complications of Therapy: Dyskinesias - Presence of Early Morning Dystonia","C100935","Unified Parkinson's Disease Rating Scale (UPDRS) Complications of therapy (in the past week); dyskinesias, presence of early morning dystonia (Historical information.).","UPDRS - Complications of Therapy: Dyskinesias - Presence of Early Morning Dystonia | UPD1-Complications:Dyskinesias Dystonia | UPD135",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639871","UPDRS - Complications of Therapy: Clinical Fluctuations - Off Periods Predictable","C100936","Unified Parkinson's Disease Rating Scale (UPDRS) Complications of therapy (in the past week); clinical fluctuations, are 'off' periods predictable?","UPDRS - Complications of Therapy: Clinical Fluctuations - Off Periods Predictable | UPD1-Complications:Fluct Predictable | UPD136",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639872","UPDRS - Complications of Therapy: Clinical Fluctuations - Off Periods Unpredictable","C100937","Unified Parkinson's Disease Rating Scale (UPDRS) Complications of therapy (in the past week); clinical fluctuations, are 'off' periods unpredictable?","UPDRS - Complications of Therapy: Clinical Fluctuations - Off Periods Unpredictable | UPD1-Complications:Fluct Unpredictable | UPD137",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639873","UPDRS - Complications of Therapy: Clinical Fluctuations - Off Periods Sudden","C100938","Unified Parkinson's Disease Rating Scale (UPDRS) Complications of therapy (in the past week); clinical fluctuations, do 'off' periods come on suddenly, within a few seconds?","UPDRS - Complications of Therapy: Clinical Fluctuations - Off Periods Sudden | UPD1-Complications:Fluct Suddenly | UPD138",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639874","UPDRS - Complications of Therapy: Clinical Fluctuations - Average Off Periods Per Day","C100939","Unified Parkinson's Disease Rating Scale (UPDRS) Complications of therapy (in the past week); clinical fluctuations, what proportion of the waking day is the patient 'off' on average?","UPDRS - Complications of Therapy: Clinical Fluctuations - Average Off Periods Per Day | UPD1-Complications:Fluct Average | UPD139",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639876","UPDRS - Complications of Therapy: Other Complications - Sleep Disturbances","C100941","Unified Parkinson's Disease Rating Scale (UPDRS) Complications of therapy (in the past week); other complications, any sleep disturbances, such as insomnia or hypersomnolence?","UPDRS - Complications of Therapy: Other Complications - Sleep Disturbances | UPD1-Complications:Insomnia Hypersomnol | UPD141",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639877","UPDRS - Complications of Therapy: Other Complications - Symptomatic Orthostasis","C100942","Unified Parkinson's Disease Rating Scale (UPDRS) Complications of therapy (in the past week); other complications, does the patient have symptomatic orthostasis? (Record the patient's blood pressure, height and weight on the scoring form).","UPDRS - Complications of Therapy: Other Complications - Symptomatic Orthostasis | UPD1-Complications:Symptom Orthostasis | UPD142",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639878","UPDRS - Modified Hoehn and Yahr Staging","C100943","Unified Parkinson's Disease Rating Scale (UPDRS) Modified Hoehn and Yahr Staging.","UPDRS - Modified Hoehn and Yahr Staging | UPD1-Modified Hoehn and Yahr Staging | UPD143",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639879","UPDRS - Schwab and England Activities of Daily Living Scale","C100944","Unified Parkinson's Disease Rating Scale (UPDRS) Schwab and England Activities of Daily Living Scale.","UPDRS - Schwab and England Activities of Daily Living Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639881","WPAI:SHP v2.0 - Currently Employed","C100949","Work Productivity and Activity Impairment Questionnaire-Specific Health Problem v2.0 (WPAI:SHP) Are you currently employed (working for pay)?","WPAI:SHP v2.0 - Currently Employed | WPAI01-Currently Employed | WPAI0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639882","WPAI:SHP v2.0 - Missed Work Hours Due to Problem","C100950","Work Productivity and Activity Impairment Questionnaire-Specific Health Problem v2.0 (WPAI:SHP) During the past seven days, how many hours did you miss from work because of problems associated with your problem?","WPAI:SHP v2.0 - Missed Work Hours Due to Problem | WPAI01-Missed Work Hours Due to Problem | WPAI0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639883","WPAI:SHP v2.0 - Missed Work Hours Due to Other Reasons","C100951","Work Productivity and Activity Impairment Questionnaire-Specific Health Problem v2.0 (WPAI:SHP) During the past seven days, how many hours did you miss from work because of any other reason, such as vacation, holidays, time off to participate in this study?","WPAI:SHP v2.0 - Missed Work Hours Due to Other Reasons | WPAI01-Missed Work Hours Due to Other | WPAI0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639884","WPAI:SHP v2.0 - Hours Actually Worked","C100952","Work Productivity and Activity Impairment Questionnaire-Specific Health Problem v2.0 (WPAI:SHP) During the past seven days, how many hours did you actually work?","WPAI:SHP v2.0 - Hours Actually Worked | WPAI01-Hours Actually Worked | WPAI0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639885","WPAI:SHP v2.0 - Problem Affects Productivity","C100953","Work Productivity and Activity Impairment Questionnaire-Specific Health Problem v2.0 (WPAI:SHP) During the past seven days, how much did your problem affect your productivity while you were working?","WPAI:SHP v2.0 - Problem Affects Productivity | WPAI01-Problem Affect Productivity | WPAI0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639886","WPAI:SHP v2.0 - Problem Affects Regular Daily Activity","C100954","Work Productivity and Activity Impairment Questionnaire-Specific Health Problem v2.0 (WPAI:SHP) During the past seven days, how much did your problem affect your ability to do your regular daily activities, other than work at a job?","WPAI:SHP v2.0 - Problem Affects Regular Daily Activity | WPAI01-Problem Affect Reg Daily Activity | WPAI0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639887","CGI - Severity of Illness","C100955","Clinical Global Impression (CGI) Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?","CGI - Severity of Illness | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639889","CGI - Efficacy Index","C100957","Clinical Global Impression (CGI) Rate this item on the basis of drug effect only. Select the terms which best describe the degrees of therapeutic effect and side effects and record the number in the box where the two items intersect.","CGI - Efficacy Index | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639891","COMM - Complaints Not Completing Tasks","C100959","Current Opioid Misuse Measure (COMM) In the past 30 days, how often do people complain that you are not completing necessary tasks? (i.e., doing things that need to be done, such as going to class, work or appointments)","COMM - Complaints Not Completing Tasks | COMM1-Complaints Not Completing Tasks | COMM102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639892","COMM - Other Sources for Pain Medication","C100960","Current Opioid Misuse Measure (COMM) In the past 30 days, how often have you had to go to someone other than your prescribing physician to get sufficient pain relief from medications? (i.e., another doctor, the Emergency Room, friends, street source)","COMM - Other Sources for Pain Medication | COMM1-Other Sources For Pain Medication | COMM103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639893","COMM - Taken Medications Other Than Prescribed","C100961","Current Opioid Misuse Measure (COMM) In the past 30 days, how often have you taken your medications differently from how they are prescribed?","COMM - Taken Medications Other Than Prescribed | COMM1-Taken Meds Other Than Prescribed | COMM104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639894","COMM - Seriously Thought of Hurting Self","C100962","Current Opioid Misuse Measure (COMM) In the past 30 days, how often have you seriously thought about hurting yourself?","COMM - Seriously Thought of Hurting Self | COMM1-Seriously Thought of Hurting Self | COMM105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639895","COMM - Time Spent Thinking About Opioids","C100963","Current Opioid Misuse Measure (COMM) In the past 30 days, how much of your time was spent thinking about opioid medications (having enough, taking them, dosing schedule, etc.)?","COMM - Time Spent Thinking About Opioids | COMM1-Time Spent Thinking About Opioids | COMM106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639896","COMM - Been in an Argument","C100964","Current Opioid Misuse Measure (COMM) In the past 30 days, how often have you been in an argument?","COMM - Been in an Argument | COMM1-Been in an Argument | COMM107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639897","COMM - Trouble Controlling Anger","C100965","Current Opioid Misuse Measure (COMM) In the past 30 days, how often have you had trouble controlling your anger (e.g., road rage, screaming, etc.)?","COMM - Trouble Controlling Anger | COMM1-Trouble Controlling Anger | COMM108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639898","COMM - Take Medications Belonging to Others","C100966","Current Opioid Misuse Measure (COMM) In the past 30 days, how often have you needed to take pain medications belonging to someone else?","COMM - Take Medications Belonging to Others | COMM1-Take Meds Belonging to Others | COMM109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639899","COMM - Worry About Handling Medications","C100967","Current Opioid Misuse Measure (COMM) In the past 30 days, how often have you been worried about how you're handling your medications?","COMM - Worry About Handling Medications | COMM1-Worry About Handling Meds | COMM110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639901","COMM - Emergency Phone Call or Clinic Visit","C100969","Current Opioid Misuse Measure (COMM) In the past 30 days, how often have you had to make an emergency phone call or show up at the clinic without an appointment?","COMM - Emergency Phone Call or Clinic Visit | COMM1-Emergency Phone Call/Clinic Visit | COMM112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639902","COMM - Gotten Angry With People","C100970","Current Opioid Misuse Measure (COMM) In the past 30 days, how often have you gotten angry with people?","COMM - Gotten Angry With People | COMM1-Gotten Angry With People | COMM113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639903","COMM - Take More Medication Than Prescribed","C100971","Current Opioid Misuse Measure (COMM) In the past 30 days, how often have you had to take more of your medication than prescribed?","COMM - Take More Medication Than Prescribed | COMM1-Take More Meds Than Prescribed | COMM114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639904","COMM - Borrowed Medication From Others","C100972","Current Opioid Misuse Measure (COMM) In the past 30 days, how often have you borrowed pain medication from someone else?","COMM - Borrowed Medication From Others | COMM1-Borrowed Meds From Others | COMM115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639905","COMM - Used Pain Medicine For Other Symptoms","C100973","Current Opioid Misuse Measure (COMM) In the past 30 days, how often have you used your pain medicine for symptoms other than for pain (e.g., to help you sleep, improve your mood, or relieve stress)?","COMM - Used Pain Medicine For Other Symptoms | COMM1-Used Pain Meds For Other Symptoms | COMM116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639906","COMM - Visit Emergency Room","C100974","Current Opioid Misuse Measure (COMM) In the past 30 days, how often have you had to visit the Emergency Room?","COMM - Visit Emergency Room | COMM1-Visit Emergency Room | COMM117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639907","COMM - Score","C100975","Current Opioid Misuse Measure (COMM) Score.","COMM - Score | COMM1-Score | COMM118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639908","C-SSRS Baseline - Wish to be Dead or go to Sleep and not Wake Up","C100976","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Have you wished you were dead or wished you could go to sleep and not wake up?","C-SSRS Baseline - Wish to be Dead or go to Sleep and not Wake Up | CSS01-Wish to be Dead | CSS0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639909","C-SSRS Baseline - Description of Wish to be Dead","C100977","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Description of wishing to be dead.","C-SSRS Baseline - Description of Wish to be Dead | CSS01-Wish to be Dead, Describe | CSS0101A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639910","C-SSRS Baseline - Non-Specific Suicidal Thought","C100978","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Have you actually had any thoughts of killing yourself?","C-SSRS Baseline - Non-Specific Suicidal Thought | CSS01-Non-Specific Suicidal Thought | CSS0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639912","C-SSRS Baseline - Suicidal Ideation-No Intent","C100980","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Have you been thinking about how you might do this?","C-SSRS Baseline - Suicidal Ideation-No Intent | CSS01-Suicidal Ideation-No Intent | CSS0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639913","C-SSRS Baseline - Description of Suicidal Ideation-No Intent","C100981","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Description of active suicidal ideation with any methods (not plan) without intent to act.","C-SSRS Baseline - Description of Suicidal Ideation-No Intent | CSS01-Suicidal Ideation-No Intent, Descr | CSS0103A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639914","C-SSRS Baseline - Ideation With Plan/Intent","C100982","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan?","C-SSRS Baseline - Ideation With Plan/Intent | CSS01-Ideation With Plan/Intent | CSS0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639915","C-SSRS Baseline - Description of Ideation With Plan and Intent","C100983","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Description of active suicidal ideation with specific plan and intent.","C-SSRS Baseline - Description of Ideation With Plan and Intent | CSS01-Ideation With Plan/Intent, Descr | CSS0105A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639916","C-SSRS Baseline - Most Severe Ideation","C100984","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Most severe ideation.","C-SSRS Baseline - Most Severe Ideation | CSS01-Most Severe Ideation | CSS0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639918","C-SSRS Baseline - Frequency of Most Severe Ideation","C100986","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) How many times have you had these thoughts?","C-SSRS Baseline - Frequency of Most Severe Ideation | CSS01-Most Severe Ideation, Frequency | CSS0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639919","C-SSRS Baseline - Duration of Most Severe Ideation","C100987","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) When you have these thoughts, how long do they last?","C-SSRS Baseline - Duration of Most Severe Ideation | CSS01-Most Severe Ideation, Duration | CSS0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639920","C-SSRS Baseline - Control over Most Severe Ideation","C100988","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Could/can you stop thinking about killing yourself or wanting to die if you want to?","C-SSRS Baseline - Control over Most Severe Ideation | CSS01-Most Severe Ideation, Control | CSS0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639921","C-SSRS Baseline - Deterrents to Most Severe Ideation","C100989","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Are there things - anyone or anything (e.g., family, religion, pain of death) - that stopped you from wanting to die or acting on thoughts of committing suicide?","C-SSRS Baseline - Deterrents to Most Severe Ideation | CSS01-Most Severe Ideation, Deterrents | CSS0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639922","C-SSRS Baseline - Reasons for Most Severe Ideation","C100990","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) What sort of reasons did you have for thinking about wanting to die or killing yourself? Was it to end the pain or stop the way you were feeling (in other words you couldn't go on living with this pain or how you were feeling) or was it to get attention, revenge or a reaction from others? Or both?","C-SSRS Baseline - Reasons for Most Severe Ideation | CSS01-Most Severe Ideation, Reasons | CSS0111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639923","C-SSRS Baseline - Actual Suicide Attempt","C100991","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Have you made a suicide attempt? Have you done anything to harm yourself? Have you done anything dangerous where you could have died?","C-SSRS Baseline - Actual Suicide Attempt | CSS01-Actual Attempt | CSS0112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639924","C-SSRS Baseline - Number of Actual Suicide Attempts","C100992","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Total number of actual attempts.","C-SSRS Baseline - Number of Actual Suicide Attempts | CSS01-Number of Actual Attempts | CSS0113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639925","C-SSRS Baseline - Description of Actual Suicide Attempts","C100993","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Description of actual attempt.","C-SSRS Baseline - Description of Actual Suicide Attempts | CSS01-Actual Attempt, Describe | CSS0113A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639926","C-SSRS Baseline - Non-suicidal Self-injurious Behavior","C100994","Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Has the subject engaged in non-suicidal self-injurious behavior.","C-SSRS Baseline - Non-suicidal Self-injurious Behavior | CSS01-Non-suicidal Self-injurious Behav | CSS0114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0345240","Total Intestinal Aganglionosis","C101074","A complete lack of ganglia in the intestine. This is an extremely severe form of Hirschsprung Disease.","Total Intestinal Aganglionosis | ",,,,,,,,,,,,,,,"4005775","Total intestinal aganglionosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3537318","TFG/ALK Fusion Gene","C101075","A fusion gene that results from a chromosomal translocation t(2;3)(p23;q21) which fuses a portion of the 5' part of the TFG gene to the last 10 exons of the ALK gene. This rearrangement is associated with anaplastic large cell lymphoma.","TFG/ALK Fusion Gene | TFG-ALK | TFG::ALK Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537317","TFG/ALK Fusion Protein","C101076","A fusion protein encoded by the TFG/ALK fusion gene. This protein is comprised of the N-terminus of protein TFG, including the coiled-coil oligomerization domain, fused to the cytoplasmic domain of the ALK tyrosine kinase receptor protein.","TFG/ALK Fusion Protein | Protein TFG/ALK Tyrosine Kinase Receptor Fusion Protein | TFG-ALK | TFG::ALK Fusion Protein | TRK-Fused Gene/Anaplastic Lymphoma Kinase (Ki-1) Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537362","TFG/ALK Short Form Fusion Gene","C101077","A fusion gene (~2.4 kb) that results from a chromosomal translocation t(2;3)(p23;q21) which fuses a third of the 5' portion of the TFG gene to the last 10 exons of the ALK gene. This rearrangement is associated with anaplastic large cell lymphoma.","TFG/ALK Short Form Fusion Gene | TFG-ALK(S) | TFG::ALK Short Form Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537364","TFG/ALK Long Form Fusion Gene","C101078","A fusion gene (~2.8 kb) that results from a chromosomal translocation t(2;3)(p23;q21) which fuses the 5' half of the TFG gene to the last 10 exons of the ALK gene. This rearrangement is associated with anaplastic large cell lymphoma.","TFG/ALK Long Form Fusion Gene | TFG-ALK(L) | TFG::ALK Long Form Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537366","TFG/ALK Extra Long Form Fusion Gene","C101079","A fusion gene (~2.6 kb) that results from a chromosomal translocation t(2;3)(p23;q21) which fuses the 5' half of the TFG gene to the last 10 exons of the ALK gene. This rearrangement is associated with anaplastic large cell lymphoma.","TFG/ALK Extra Long Form Fusion Gene | TFG-ALK XL | TFG-ALK(XL) | TFG::ALK Extra Long Form Fusion Gene | TRK-Fused Gene/Anaplastic Large Cell Lymphoma Kinase Extra Long Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537361","TFG/ALK Short Form Fusion Protein","C101080","A fusion protein (701 aa, ~78 kDa) encoded by the TFG/ALK short form fusion gene. This protein is comprised of about one third of the N-terminal sequence of protein TFG, including the coiled-coil oligomerization domain, fused to the cytoplasmic domain of the ALK tyrosine kinase receptor protein.","TFG/ALK Short Form Fusion Protein | Protein TFG/ALK Tyrosine Kinase Receptor Short Form Fusion Protein | TFG-ALK(S) | TFG::ALK Short Form Fusion Protein | TRK-Fused Gene/Anaplastic Lymphoma Kinase (Ki-1) Short Form Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537363","TFG/ALK Long Form Fusion Protein","C101081","A fusion protein (756 aa, ~84 kDa) encoded by the TFG/ALK long form fusion gene. This protein is comprised of the N-terminal third of protein TFG, including the coiled-coil oligomerization domain, fused to the cytoplasmic domain of the ALK tyrosine kinase receptor protein.","TFG/ALK Long Form Fusion Protein | Protein TFG/ALK Tyrosine Kinase Receptor Fusion Protein Long Form | TFG-ALK(L) | TFG::ALK Long Form Fusion Protein | TRK-Fused Gene/Anaplastic Lymphoma Kinase (Ki-1) Fusion Protein Long Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537365","TFG/ALK Extra Long Form Fusion Protein","C101082","A fusion protein (803 aa, ~89 kDa) encoded by the TFG/ALK extra long form fusion gene. This protein is comprised of the N-terminal half of protein TFG, including the coiled-coil oligomerization domain, fused to the cytoplasmic domain of the ALK tyrosine kinase receptor protein.","TFG/ALK Extra Long Form Fusion Protein | Protein TFG/ALK Tyrosine Kinase Receptor Extra Long Form Fusion Protein | TFG-ALK XL | TFG-ALK(XL) | TFG::ALK Extra Long Form Fusion Protein | TRK-Fused Gene/Anaplastic Large Cell Lymphoma Kinase Extra Long Form Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639982","TPM3/ALK Fusion Gene","C101083","A fusion gene that results from a chromosomal translocation t(1;2)(q25;p23) which fuses most of the coding sequence of the TPM3 gene to the last 10 exons of the ALK gene. This rearrangement is associated with anaplastic large cell lymphoma and inflammatory myofibroblastic tumor.","TPM3/ALK Fusion Gene | TPM3-ALK Fusion Gene | TPM3::ALK Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639983","TPM3/ALK Fusion Protein","C101084","A fusion protein encoded by the TPM3/ALK fusion gene. This protein is comprised of most of the tropomyosin alpha-3 chain protein fused to the cytoplasmic domain of the ALK tyrosine kinase receptor protein.","TPM3/ALK Fusion Protein | TPM3-ALK Fusion Protein | TPM3::ALK Fusion Protein | Tropomyosin Alpha-3 Chain/ALK Tyrosine Kinase Receptor Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1620114","Cyclin-Dependent Kinase 12, Human","C101097","Cyclin-dependent kinase 12 (1490 aa, ~164 kDa) is encoded by the human CDK12 gene. This protein is involved in the regulation of both RNA splicing and transcription elongation through the mediation of serine/threonine phosphorylation.","Cyclin-Dependent Kinase 12 | CDC2-Related Protein Kinase 7 | Cdc2-Related Kinase with an Arginine/Serine-Rich Domain | Cdc2-Related Kinase, Arginine/Serine-Rich | Cell Division Cycle 2-Related Protein Kinase 7 | Cell Division Protein Kinase 12 | CrkRS | EC 2.7.11.22 | EC 2.7.11.23 | hCDK12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542481","KIAA2020","C101099","Human NUTM2A wild-type allele is located in the vicinity of 10q23.2 and is approximately 14 kb in length. This allele, which encodes NUT family member 2A protein, has an unknown function. A translocation t(10;17)(q22-23;p13) that fuses this gene with the YWHAE gene is associated with high-grade uterine endometrial stromal sarcoma.","NUTM2A wt Allele | FAM22A | Family with Sequence Similarity 22, Member A Gene | KIAA2020 | NUT Family Member 2A wt Allele | RP11-322M19.3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0053025","Nafazatrom","C1010","A pyrazolinone derivative with potential antimetastatic activities. Nafazatrom, originally developed as an antithrombotic agent, inhibits the key prostaglandin catabolic enzyme, 15-hydroxyprostaglandin dehydrogenase, which prolongs the biological half-life of prostacyclin (prostaglandin I2; PGI2) and prevents intravascular coagulation. This agent also serves as a reducing cofactor with the hydroperoxidase moiety of cyclooxygenase and accelerates the conversion of arachidonic acid into precursors of PGI2. An elevated level of PGI2 prevents aggregation of platelets; subsequently it decreases the formation of tumor cell-platelet aggregates as well as their sequestration in blood vessels, which is an important initiating step in the development of metastasis.","Nafazatrom | 1-(2-(beta-naphthyloxy)ethyl)-3-methyl-2-pyrazolin-5-one | 3H-pyrazol-3-one,2,4-dihydro-5-methyl-2-(2-(2-naphthalenyloxy)ethyl) | Bay g 6575 | Bay-g 6575 | NAFAZATROM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639987","Protein KIAA2020","C101100","NUT family member 2A (878 aa, ~94 kDa) is encoded by the human NUTM2A gene. This protein has an unknown function.","NUT Family Member 2A | Hypothetical Protein LOC728118 | NUTM2A | Protein FAM22A | Protein KIAA2020",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542482","NUTM2B wt Allele","C101102","Human NUTM2B wild-type allele is located in the vicinity of 10q22.3 and is approximately 16 kb in length. This allele, which encodes NUT family member 2B protein, has no known function. A translocation t(10;17)(q22-23;p13) that fuses this gene with the YWHAE gene is associated with high-grade uterine endometrial stromal sarcoma.","NUTM2B wt Allele | FAM22B | Family with Sequence Similarity 22, Member B Gene | NUT Family Member 2B wt Allele | bA119F19.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639989","NUT Family Member 2B","C101103","NUT family member 2B (878 aa, ~94 kDa) is encoded by the human NUTM2B gene. This protein has a function that is unknown.","NUT Family Member 2B | NUTM2B | Protein FAM22B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539778","FBXO11 wt Allele","C101105","Human FBXO11 wild-type allele is located in the vicinity of 2p16.3 and is approximately 116 kb in length. This allele, which encodes F-box only protein 11, is involved in the regulation of protein ubiquitination. Polymorphism of the gene is associated with otitis media.","FBXO11 wt Allele | F-Box Protein 11 wt Allele | FBX11 | MGC44383 | PRMT9 | UBR6 | UG063H01 | Ubiquitin Protein Ligase E3 Component N-Recognin 6 Gene | VIT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539832","F-Box Only Protein 11","C101106","F-box only protein 11 (927 aa, ~104 kDa) is encoded by the human FBXO11 gene. This protein plays a role in substrate recognition for the ubiquitin ligase complex.","F-Box Only Protein 11 | FBXO11 | Protein Arginine N-Methyltransferase 9 | Ubiquitin Protein Ligase E3 Component N-Recognin 6 | VIT-1 | Vitiligo-Associated Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539571","HEY1 wt Allele","C101108","Human HEY1 wild-type allele is located in the vicinity of 8q21 and is approximately 4 kb in length. This allele, which encodes hairy/enhancer-of-split related with YRPW motif protein 1, plays a role in protein dimerization and the negative regulation of transcription.","HEY1 wt Allele | BHLHb31 | CHF-2 | CHF2 | HERP2 | HESR-1 | HESR1 | HRT-1 | HRT1 | Hairy/Enhancer-of-Split Related with YRPW Motif 1 Gene | Hes Related Family BHLH Transcription Factor With YRPW Motif 1 wt Allele | MGC1274 | OAF1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279512","cytarabine/daunorubicin/prednisone/thioguanine","C10110","A regimen consisting of cytarabine, daunorubicin, prednisone, and thioguanine that may be used in the treatment of acute myeloid leukemia (AML).","Cytarabine/Daunorubicin/Prednisone/Thioguanine Regimen | ARA-C/DNR/PRED/TG | TRAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538866","Serine/Arginine-Rich Splicing Factor 2, Human","C101112","Serine/arginine-rich splicing factor 2 (221 aa, ~25 kDa) is encoded by the human SRSF2 gene. This protein plays a role in the modulation of mRNA processing.","Serine/Arginine-Rich Splicing Factor 2 | Protein PR264 | SC-35 | SR Splicing Factor 2 | SRSF2 | Splicing Component, 35 kDa | Splicing Factor SC35 | Splicing Factor, Arginine/Serine-Rich 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540639","U2AF1 wt Allele","C101114","Human U2AF1 wild-type allele is located in the vicinity of 21q22.3 and is approximately 15 kb in length. This allele, which encodes splicing factor U2AF 35 kDa subunit protein, plays a role in the mediation of messenger RNA processing. A missense mutation may be associated with myelodysplastic syndrome.","U2AF1 wt Allele | DKFZp313J1712 | FP793 | RN | RNU2AF1 | U2 Small Nuclear RNA Auxiliary Factor 1 wt Allele | U2AF35 | U2AFBP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639990","Splicing Factor U2AF 35 kDa Subunit","C101115","Splicing factor U2AF 35 kDa subunit (240 aa, ~28 kDa) is encoded by the human U2AF1 gene. This protein is involved in the regulation of mRNA splicing.","Splicing Factor U2AF 35 kDa Subunit | U2 Auxiliary Factor 35 kDa Subunit | U2 snRNP Auxiliary Factor Small Subunit | U2(RNU2) Small Nuclear RNA Auxiliary Factor Binding Protein | U2AF1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539662","YWHAE wt Allele","C101117","Human YWHAE wild-type allele is located in the vicinity of 17p13.3 and is approximately 56 kb in length. This allele, which encodes 14-3-3 protein epsilon, is involved in the modulation of signal transduction.","YWHAE wt Allele | 14-3-3 Epsilon Gene | 14-3-3E | FLJ45465 | KCIP-1 | MDCR | MDS | Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein, Epsilon Polypeptide wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1144015","YWHAE protein, human","C101118","14-3-3 protein epsilon (255 aa, ~29 kDa) is encoded by the human YWHAE gene. This protein plays a role in signal transduction.","14-3-3 Protein Epsilon | 14-3-3E | Mitochondrial Import Stimulation Factor L Subunit | Protein Kinase C Inhibitor Protein-1 | YWHAE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540647","ZRSR2 wt Allele","C101121","Human ZRSR2 wild-type allele is located in the vicinity of Xp22.1 and is approximately 33 kb in length. This allele, which encodes U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2, plays a role in the regulation of RNA splicing.","ZRSR2 wt Allele | MGC142014 | MGC142040 | U2AF1-RS2 | U2AF1L2 | U2AF1RS2 | URP | ZC3H22 | Zinc Finger (CCCH type), RNA-Binding Motif And Serine/Arginine Rich 2 Gene | Zinc Finger CCCH-type, RNA Binding Motif and Serine/Arginine Rich 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1435016","U2 Small Nuclear Ribonucleoprotein Auxiliary Factor 35 kDa Subunit-Related Protein 2, Human","C101122","U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2 (482 aa, ~58 kDa) is encoded by the human ZRSR2 gene. This protein is involved in the modulation of messenger RNA maturation.","U2 Small Nuclear Ribonucleoprotein Auxiliary Factor 35 kDa Subunit-Related Protein 2 | CCCH Type Zinc Finger, RNA-Binding Motif And Serine/Arginine Rich Protein 2 | Renal Carcinoma Antigen NY-REN-20 | U2 Small Nuclear Ribonucleoprotein Auxiliary Factor, Small Subunit 2 | U2(RNU2) Small Nuclear RNA Auxiliary Factor 1-Like 2 | U2AF35-Related Protein | URP | ZRSR2 | Zinc Finger-, CCCH Domain-, and RNA-Binding Motif-Containing Serine/Arginine-Rich Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538862","STIL wt Allele","C101127","Human STIL wild-type allele is located in the vicinity of 1p32 and is approximately 64 kb in length. This allele, which encodes SCL-interrupting locus protein, is involved in signaling that promotes cellular proliferation and modulates embryonic development. A chromosomal deletion at 1p32 between this gene and the TAL1 gene is associated with T-cell acute lymphoblastic leukemia. Mutation of the gene is associated with microcephaly primary type 7.","STIL wt Allele | MCPH7 | RP1-18D14.8 | SCL-Interrupting Locus Gene | SCL/TAL1 Interrupting Locus Gene | SCL/TAL1 Interrupting Locus wt Allele | SCL/TAL1-Interrupting Locus Gene | SIL | STIL Centriolar Assembly Protein wt Allele | TAL1 (SCL) Interrupting Locus Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639995","STIL protein, human","C101128","SCL-interrupting locus protein (1287 aa, ~143 kDa) is encoded by the human STIL gene. This protein plays a role in both the progression of embryonic development and the modulation of cell proliferation.","SCL-Interrupting Locus Protein | STIL | STIL Centriolar Assembly Protein | TAL-1-Interrupting Locus Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433981","Guarana Supplement","C101130","An herbal supplement containing an extract from guarana (Paullinia cupana), a climbing plant of the Sapindaceae family which is native to the Amazon basin, with stimulant, antioxidant and potential chemoprotective activities. Guarana supplement contains various phytochemicals, including caffeine, theobromine, theophylline, tannins, saponins, catechins, epicatechins, proanthocyanidols and other compounds in minor concentrations. Caffeine is a central nervous system stimulant and may reduce chemotherapy-related fatigue. Tannins and other polyphenols may have chemopreventive activity. Intake of the guarana supplement may prevent cancer-related anorexia. In addition, animal studies have demonstrated that the ingestion of guarana resulted in decreased proliferation and increased apoptosis of tumor cells.","Guarana Supplement | Paullinia cupana Supplement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639984","TPM4/ALK Fusion Gene","C101085","A fusion gene that results from a chromosomal translocation t(1;2)(q25;p23) which fuses most of the coding sequence of the TPM4 gene to the last 10 exons of the ALK gene. This rearrangement is associated with inflammatory myofibroblastic tumor.","TPM4/ALK Fusion Gene | TPM4-ALK Fusion Gene | TPM4::ALK Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639985","TPM4/ALK Fusion Protein","C101086","A fusion protein encoded by the TPM4/ALK fusion gene. This protein is comprised of most of the tropomyosin alpha-4 chain protein fused to the cytoplasmic domain of the ALK tyrosine kinase receptor protein.","TPM4/ALK Fusion Protein | TPM4-ALK Fusion Protein | TPM4::ALK Fusion Protein | Tropomyosin Alpha-4 Chain/ALK Tyrosine Kinase Receptor Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435313","Kukui Nut","C101087","No value exists.","Kukui Nut | Candleberry Seed | Candlenut Seed | Indian Walnut Seed | KUKUI NUT | Kemiri Seed | Kukui Nut Tree Seed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540624","ARID2 wt Allele","C101089","Human ARID2 wild-type allele is located in the vicinity of 12q12 and is approximately 178 kb in length. This allele, which encodes AT-rich interactive domain-containing protein 2, plays a role in both the modulation of chromatin remodeling and transcriptional regulation.","ARID2 wt Allele | AT Rich Interactive Domain 2 (ARID, RFX-Like) Gene | AT-Rich Interactive Domain 2 wt Allele | BAF200 | BRG1-Associated Factor, 200-kD Gene | CSS6 | DKFZp686G052 | FLJ30619 | KIAA1557 | p200",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539872","AT-Rich Interactive Domain-Containing Protein 2","C101090","AT-rich interactive domain-containing protein 2 (1835 aa, ~197 kDa) is encoded by the human ARID2 gene. This protein is involved in the mediation of chromatin remodeling.","AT-Rich Interactive Domain-Containing Protein 2 | ARID Domain-Containing Protein 2 | ARID2 | BAF200 | BRG1-Associated Factor 200 | Zinc Finger Protein with Activation Potential | Zipzap/p200",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541257","BCOR wt Allele","C101092","Human BCOR wild-type allele is located in the vicinity of Xp11.4 and is approximately 128 kb in length. This allele, which encodes BCL-6 corepressor protein, is involved in transcriptional regulation. Mutation of the gene is associated with microphthalmia syndromic type 2.","BCOR wt Allele | ANOP2 | BCL6 Co-Repressor Gene | BCL6 Corepressor wt Allele | FLJ20285 | KIAA1575 | MAA2 | MCOPS2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3543414","BCL-6 Corepressor","C101093","BCL-6 corepressor (1755 aa, ~192 kDa) is encoded by the human BCOR gene. This protein plays a role in the negative regulation of transcription.","BCL-6 Corepressor | BCL-6 Interacting Corepressor | BCL6 Co-Repressor | BCoR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1311943","FluMist","C101094","A weakened live virus vaccine containing three seasonal influenza reassortants with prophylactic activity against influenza subtypes A and B. The trivalent live-attenuated influenza vaccine (LAIV) contains 2 strains of the influenza subtype A, one for H1N1 and one for H3N2, and one strain of subtype B. Upon intranasal administration by sprayer of the trivalent LAIV, the live viruses replicate in the upper respiratory tract and induce an immune response leading to active immunization against influenza subtypes A and B.","Trivalent Live-Attenuated Influenza Vaccine | FluMist | Fluenz | Trivalent Intranasal Influenza Vaccine, Live",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539634","CDK12 wt Allele","C101096","Human CDK12 wild-type allele is located in the vicinity of 17q12 and is approximately 73 kb in length. This allele, which encodes cyclin-dependent kinase 12 protein, plays a role in the modulation of protein phosphorylation. Chromosomal deletions within the 17q12 region can lead to out of frame fusions of this gene and the ERBB2 gene and may be associated with gastric cancer.","CDK12 wt Allele | CDC2 Related Protein Kinase 7 Gene | CRK7 | CRKR | CRKRS | Cdc2-Related Kinase, Arginine/Serine-Rich Gene | Cyclin Dependent Kinase 12 wt Allele | Cyclin-Dependent Kinase 12 Gene | KIAA0904 | hCDK12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639971","NPM1/RARA Short Fusion Gene","C101063","A fusion gene (~1.9 kb) that results from a chromosomal translocation t(5;17)(q35;q21) which fuses the first 442 nucleotides of the NPM1 gene to exon 3 of the RARA gene. This rearrangement is rare and is associated with acute myeloid leukemia.","NPM1/RARA Short Fusion Gene | NPM-RAR Short Form | NPM1-RARA Short Fusion Gene | NPM1::RARA Short Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639972","NPM1/RARA Long Fusion Gene","C101064","A fusion gene (~2.1 kb) that results from a chromosomal translocation t(5;17)(q35;q21) which fuses the first 484 nucleotides of the NPM1 gene to exon 3 of the RARA gene. This rearrangement is rare and is associated with acute myeloid leukemia.","NPM1/RARA Long Fusion Gene | NPM-RAR Long Form | NPM1-RARA Long Fusion Gene | NPM1::RARA Long Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639973","NPM1/RARA Short Fusion Protein","C101065","A fusion protein (520 aa, ~57 kDa) encoded by the NPM1/RARA short fusion gene. This protein is comprised of the N-terminus of the nucleophosmin protein fused to the DNA-binding domain, ligand binding domain and coactivator recognition site from the retinoic acid receptor alpha protein.","NPM1/RARA Short Fusion Protein | NPM1-RARA Short Fusion Protein | NPM1::RARA Short Fusion Protein | Nucleophosmin/Retinoic Acid Receptor Alpha Short Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639974","NPM1/RARA Long Fusion Protein","C101066","A fusion protein (563 aa, ~63 kDa) encoded by the NPM1/RARA long fusion gene. This protein is comprised of the N-terminus of the nucleophosmin protein fused to the DNA-binding domain, ligand binding domain and coactivator recognition site from the retinoic acid receptor alpha protein.","NPM1/RARA Long Fusion Protein | NPM1-RARA Long Fusion Protein | NPM1::RARA Long Fusion Protein | Nucleophosmin/Retinoic Acid Receptor Alpha Long Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639975","PAX3/FOXO4 Fusion Gene","C101067","A fusion gene that results from a rearrangement involving chromosome 2 and the X chromosome which fuses the 5' portion of the PAX3 gene to the 3' portion of the FOXO4 gene. This rearrangement is associated with rare variants of alveolar rhabdomyosarcoma.","PAX3/FOXO4 Fusion Gene | PAX3-AFX Fusion Gene | PAX3-FOXO4 Fusion Gene | PAX3/AFX Fusion Gene | PAX3::FOXO4 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433986","Zirconium Zr 89 Desferrioxamine B Monoclonal Antibody huJ591","C101133","A radioimmunoconjugate comprised of the recombinant humanized monoclonal antibody J591 against prostate-specific membrane antigen (PSMA) conjugated to chelator desferrioxamine B (DFO-B) and labeled with the radioisotope zirconium Zr 89 with potential imaging property used in positron emission tomography (PET) imaging. Upon administration of zirconium Zr 89 desferrioxamine B monoclonal antibody huJ591, the antibody moiety binds to the extracellular domain of PSMA, and the radioisotope moiety may be detected using PET, thereby allowing the imaging and quantification of PSMA-expressing tumor cells. PSMA, or folate hydrolase, is a cell surface peptidase highly expressed by malignant prostate epithelial cells and vascular endothelial cells of numerous solid tumor malignancies. In addition, upon PET imaging this agent provides high tumor:background tissue ratios.","Zirconium Zr 89 Desferrioxamine B Monoclonal Antibody huJ591 | 89Zr-DFO-huJ591",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640005","Lysozyme Immunohistochemistry","C101141","An immunohistochemical diagnostic test utilizing an antibody to detect lysozyme in tissues.","Lysozyme Immunohistochemistry | Muramidase Immunohistochemistry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539703","SYP wt Allele","C101145","Human SYP wild-type allele is located within Xp11.23-p11.22 and is approximately 12 kb in length. This allele, which encodes synaptophysin protein, plays a role in synaptic functions. Mutation of the gene is associated with SYP-related mental retardation X-linked.","SYP wt Allele | MRX96 | MRXSYP | Synaptophysin wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639976","PAX3/FOXO4 Fusion Protein","C101068","A fusion protein encoded by the PAX3/FOXO4 fusion gene. This protein is comprised of the N-terminal DNA binding domain of paired box protein Pax-3 and the C-terminal transactivation domain of forkhead box protein O4.","PAX3/FOXO4 Fusion Protein | PAX3-FOXO4 Fusion Protein | PAX3::FOXO4 Fusion Protein | Paired Box Protein Pax-3/Forkhead Box Protein O4 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639977","PAX3/NCOA1 Fusion Gene","C101069","A fusion gene that results from a rearrangement of chromosome 2 which fuses exon 6 of the PAX3 gene to either exon 12 of the NCOA1 gene. This rearrangement is associated with rare variants of alveolar rhabdomyosarcoma.","PAX3/NCOA1 Fusion Gene | PAX3-NCOA1 Fusion Gene | PAX3::NCOA1 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639978","PAX3/NCOA1 Fusion Protein","C101070","A fusion protein encoded by the PAX3/NCOA1 fusion gene. This protein is comprised of the N-terminal DNA binding domain of paired box protein Pax-3 and the C-terminal transactivation domain of nuclear receptor coactivator 1.","PAX3/NCOA1 Fusion Protein | PAX3-NCOA1 Fusion Protein | PAX3::NCOA1 Fusion Protein | Paired Box Protein Pax-3/ Nuclear Receptor Coactivator 1 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639980","SS18L1/SSX1 Fusion Gene","C101072","A fusion gene that results from a chromosomal translocation t(X;20)(p11;q13.3) which fuses exon 10 of the SS18L1 gene to exon 6 of the SSX1 gene. This rearrangement is associated with synovial sarcoma.","SS18L1/SSX1 Fusion Gene | SS18L1-SSX1 Fusion Gene | SS18L1::SSX1 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639981","SS18L1/SSX1 Fusion Protein","C101073","A fusion protein encoded by the SS18L1/SSX1 fusion gene. This protein is comprised of all but the last 8 amino acids of the calcium-responsive transactivator protein fused to 78 amino acids from the C-terminus of protein SSX1.","SS18L1/SSX1 Fusion Protein | Calcium-Responsive Transactivator/Protein SSX1 Fusion Protein | SS18L1-SSX1 Fusion Protein | SS18L1::SSX1 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3277059","Congenital Bilateral Cataracts","C101194","Cataract in both eyes that are present at birth.","Congenital Bilateral Cataracts | Cataract, Congenital, Bilateral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640029","Congenital Ventricular Tachycardia","C101196","An electrocardiographic finding of a tachycardia that originates in the ventricles that is present at birth.","Congenital Ventricular Tachycardia | Congenital VT | Congenital VTach",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640030","Congenital Supraventricular Tachycardia","C101197","A disorder present at birth characterized by an electrocardiographic finding of a tachycardia that originates above the ventricles.","Congenital Supraventricular Tachycardia | Congenital SVT | Supraventricular Tachycardia (SVT), Congenital | Supraventricular Tachycardia (SVT), Congential",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0393791","Congenital Facial Nerve Palsy","C101198","Partial or complete paralysis of the facial muscles of one side of an individual's face that is present at birth. It is caused by damage to the seventh cranial nerve.","Congenital Facial Nerve Palsy | ",,,,,,,,,,,,,,,"4048018","Congenital facial nerve palsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640031","Congenital Phrenic Nerve Palsy","C101199","Damage to the phrenic nerve that results in paralysis of the hemidiaphragm at birth.","Congenital Phrenic Nerve Palsy | Phrenic Nerve Palsy, Congenital",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0473780","Neonatal Alloimmune Thrombocytopenia","C101200","Thrombocytopenia that occurs in neonates as a consequence of transplacental passage of maternal alloantibodies directed against fetal platelet antigens.","Neonatal Alloimmune Thrombocytopenia | NAIT | Neonatal Thrombocytopenia due to Platelet Alloimmunization",,,,,,,,,,,,,,,"4345345","Neonatal alloimmune thrombocytopenia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0266504","Myelomeningocele","C101201","A congenital abnormality in which the spinal cord and meninges protrude through a defect in the spinal column. The protrusion is above the skin surface.","Myelomeningocele | Meningomyelocele | Spina Bifida Cystica",,,,,,,,,,,,,,,"4212197","Meningomyelocele",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0431307","Lumbar Myelomeningocele","C101203","A congenital abnormality in the lumbar region of the spine, in which the spinal cord and meninges protrude through a defect in the spinal column. The protrusion is above the skin surface.","Lumbar Myelomeningocele | Lumbar Meningomyelocele",,,,,,,,,,,,,,,"4069672|4070070","Lumbar myelocystocele|Lumbar meningomyelocele",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL435478","Sacral Myelomeningocele","C101207","A congenital abnormality in the sacral region of the spine, in which the spinal cord and meninges protrude through a defect in the spinal column. The protrusion is above the skin surface.","Sacral Myelomeningocele | Congenital Sacral Meningocele | Sacral Meningomyelocele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0431308","Thoracic Myelomeningocele","C101208","A congenital abnormality in the thoracic region of the spine, in which the spinal cord and meninges protrude through a defect in the spinal column. The protrusion is above the skin surface.","Thoracic Myelomeningocele | Thoracic Meningomyelocele",,,,,,,,,,,,,,,"4070069|4070074","Thoracic meningomyelocele|Thoracic myelocystocele",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0266506","Spinal Meningocele","C101209","A congenital abnormality in which the meninges protrude through a defect in the spinal column.","Spinal Meningocele | Meningocele",,,,,,,,,,,,,,,"4275103","Congenital spinal meningocele",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640034","Cervical Meningocele","C101210","A congenital abnormality in the cervical region of the spine in which the meninges protrude through a defect in the spinal column.","Cervical Meningocele | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640035","Lumbar Meningocele","C101211","A congenital abnormality in the lumbar region of the spine in which the meninges protrude through a defect in the spinal column.","Lumbar Meningocele | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521556","Sacral Meningocele","C101212","A congenital abnormality in the sacral region of the spine in which the meninges protrude through a defect in the spinal column.","Sacral Meningocele | ",,,,,,,,,,,,,,,"4316231","Congenital sacral meningocele",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640036","Thoracic Meningocele","C101213","A congenital abnormality in the thoracic region of the spine in which the meninges protrude through a defect in the spinal column.","Thoracic Meningocele | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2749822","Spina Bifida","C101214","A congenital neural tube defect in which vertebrae are not fully formed. It results in the protrusion of the spinal cord through the opening of the vertebrae.","Spina Bifida | Rachischisis | SPINA BIFIDA | Spinal Meningocele | Spinal Myelocele | Spinal Myelomeningocele",,,,,,,,,,,,,,,"4283381","Spina bifida",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0271629","Mullerian Inhibiting Factor Deficiency","C101215","A deficiency of the Mullerian inhibiting substance, which is secreted by the Sertoli cells during embryogenesis. It can result in unilateral or bilateral cryptorchidism, testicular regression syndrome and sterility.","Mullerian Inhibiting Factor Deficiency | MIS Deficiency | Mullerian Inhibiting Substance Deficiency | Müllerian Inhibiting Factor Deficiency | Müllerian Inhibiting Substance Deficiency",,,,,,,,,,,,,,,"4283801","Mullerian inhibiting factor deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3552487","Myopathy","C101216","A non-neoplastic disorder that affects the muscles. Representative examples include muscular dystrophy, metabolic myopathies, muscular atrophies, and dermatomyositis.","Myopathy | ",,,,,,,,,,,,,,,"137275","Disorder of muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640037","Retinal Examination","C101217","An examination of the retina of the eye using an ophthalmoscope.","Retinal Examination | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0272031","Hemolytic Anemia due to Membrane Defect","C101218","A group of inherited hemolytic anemias caused by erythrocyte membrane defects. This includes hereditary pyropoikilocytosis, hereditary spherocytosis and hereditary elliptocytosis.","Hemolytic Anemia due to Membrane Defect | Anemia due to Membrane Defect | Hemolytic Anemia due to Erythrocyte Membrane Defect",,,,,,,,,,,,,,,"4009785","Anemia due to membrane defect",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1609433","Bilateral Renal Agenesis","C101219","A congenital abnormality characterized by the absence of both kidneys.","Bilateral Renal Agenesis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3276950","Unilateral Renal Agenesis","C101220","A congenital abnormality characterized by the presence of only one kidney.","Unilateral Renal Agenesis | Congenital Single Kidney | Congenital Solitary Kidney",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0419406","Birth Head Circumference","C101221","The measurement around a neonate's head at birth.","Birth Head Circumference | Head Circumference at Birth | Head Circumference at Initial Disposition",,,,,,,,,,,,,,,"4015277","Birth head circumference",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL435606","Complete Trisomy 21 Syndrome","C101222","A syndrome characterized by the presence of three complete copies of genetic material for chromosome 21, instead of the normal two. It leads to a variety of abnormalities that include mental retardation, macroglossia, microgenia, epicanthic eyelids, and a single transverse palmar crease.","Complete Trisomy 21 Syndrome | Down Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152095","Complete Trisomy 13 Syndrome","C101223","A syndrome characterized by the presence of three complete copies of genetic material for chromosome 13, instead of the normal two. It leads to a variety of abnormalities that include mental retardation, microcephaly, low-set ears, eye structural defects, polydactyly, and limb abnormalities.","Complete Trisomy 13 Syndrome | Patau Syndrome",,,,,,,,,,,,,,,"436802","Complete trisomy 13 syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0857112","Bilateral Glaucoma","C101228","Increased pressure in both eyeballs due to obstruction of the outflow of aqueous humor.","Bilateral Glaucoma | ",,,,,,,,,,,,,,,"760891","Bilateral glaucoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1850544","Hypernatremic Dehydration","C101229","Dehydration resulting from abnormally high levels of sodium in the blood. Infants and individuals that are intubated are at highest risk.","Hypernatremic Dehydration | ",,,,,,,,,,,,,,,"4322552","Hypernatremic dehydration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0279769","lomustine/mitolactol/procarbazine/thioguanine/vincristine","C10122","A regimen consisting of thioguanine, procarbazine, mitolactol (dibromodulcitol), lomustine, and vincristine that may be used in the treatment of malignant glioma.","TPDCV Regimen | CCNU/DBD/PCB/TG/VCR | TPDCV | Thioguanine-Procarbazine-Mitolactol-Lomustine-Vincristine | Thioguanine/Procarbazine/Mitolactol /CCNU/Vincristine | Thioguanine/Procarbazine/Mitolactol /Lomustine/Vincristine Thioguanine/Procarbazine/Mitolactol l/Lomustine/Vincristine Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538930","Triage Status","C101230","The degree of urgency in which a medical procedure must be performed. (ACC)","Triage Status | PRUSTAT | Procedure Urgency Status Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640039","Medical Device Deployment","C101231","The act of instantiating, positioning or activating a medical device inside of the body. (ACC)","Medical Device Deployment | DEPLOYED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640040","Intracoronary Device","C101232","A device for use within the coronary anatomy. (ACC)","Intracoronary Device | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640041","Coronary Vessel Bifurcation Lesion","C101233","A lesion found in the division of a vessel into at least two branches, each of which is 1.5 mm or greater in diameter. (ACC)","Coronary Vessel Bifurcation Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700431","Cardiac Rehabilitation","C101234","A medically supervised program to improve the health and well-being of people who have heart problems. This may include exercise training, education on heart healthy living, and/or counseling to reduce stress. (ACC)","Cardiac Rehabilitation | ",,,,,,,,,,,,,,,"4209116","Cardiac rehabilitation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0375886","Exercise Counseling","C101235","A process by which a health professional creates a regimen of physical activity intended to maintain or improve the health of a subject. (ACC)","Exercise Counseling | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640043","Upper Limit of Vulnerability for Induction of Ventricular Fibrillation","C101237","Stimulus strength above which electrical stimulation from a cardiac device cannot induce ventricular fibrillation even when the stimulus occurs during the vulnerable period of the cardiac cycle. (ACC)","Upper Limit of Vulnerability for Induction of Ventricular Fibrillation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640044","Cardiac Lead Function Indicator","C101238","An indicator to describe whether the electrical lead device is performing as intended. (ACC)","Cardiac Lead Function Indicator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433984","Elsiglutide","C101131","A synthetic glucagon-like peptide-2 (GLP-2) analogue with potential antidiarrheal and intestinotrophic activities. Upon subcutaneous administration, elsiglutide, a 39 amino acid polypeptide, binds to GLP-2 receptors and thereby promotes proliferation of epithelial cells. Regeneration of endothelial cells damaged during chemotherapy may prevent or decrease chemotherapy-induced diarrhea. In addition, elsiglutide may prevent chemotherapy-induced intestinal injury. GLP-2, a peptide hormone primarily produced in the small intestines in response to food, plays a key role in intestinal epithelial growth, metabolism and regeneration of epithelial cells.","Elsiglutide | ELSIGLUTIDE | ZP1846",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639999","mTOR1/2 Kinase Inhibitor ME-344","C101132","An active metabolite of NV-128, a novel flavonoid small molecule inhibitor of the mammalian Target of Rapamycin (mTOR), with potential antineoplastic activity. Upon administration, mTOR1/2 Kinase inhibitor ME-344 downregulates the PIK3/AKT/mTOR pathway and results in chromatin condensation in the absence of caspase activation. Consequently, this agent induces caspase-independent cell death in tumor cells with a de-regulated PIK3/AKT/mTOR pathway or chemotherapeutic resistant cells.","mTOR1/2 Kinase Inhibitor ME-344 | ME-344",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0345237","Short Segment Hirschsprung Disease","C101041","The most common form of Hirschsprung Disease, this is characterized by a lack of nerve cells in the sigmoid colon and rectum. The bowel is not stimulated without innervation and obstruction ensues. Surgical intervention is necessary.","Short Segment Hirschsprung Disease | Short Segment Hirschsprung's Disease",,,,,,,,,,,,,,,"4002470","Short segment Hirschsprung's disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268287","Steroid 21-Monooxygenase Deficiency","C101042","Less than necessary amount of the enzyme steroid 21-monooxygenase; which is necessary to synthesize cortisol.","Steroid 21-Monooxygenase Deficiency | ",,,,,,,,,,,,,,,"4051375|4200860","Deficiency of steroid 21-monooxygenase|Steroid 21-monooxygenase deficiency, simple virilizing type",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C4228268","Spina Bifida Occulta","C101044","The mildest form of spina bifida, characterized by any of several neural tube defects which may go undetected until an x-ray is performed. Treatment is symptomatic.","Spina Bifida Occulta | ",,,,,,,,,,,,,,,"381677","Spina bifida occulta",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0472781","Drug Induced Methemoglobinemia","C101045","Methemoglobinemia that is caused by exposure to certain drugs (xylocaine and benzene).","Drug Induced Methemoglobinemia | Drug-Induced Methemoglobinemia",,,,,,,,,,,,,,,"4098157","Drug-induced methemoglobinemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3639959","ATIC/ALK Fusion Gene","C101046","A fusion gene that results from a chromosomal inversion inv(2)(p23q35) which fuses the first 7 exons of the ATIC gene with exon 20 of the ALK gene. This rearrangement is associated with rare cases of anaplastic large cell lymphoma.","ATIC/ALK Fusion Gene | ATIC-ALK Fusion Gene | ATIC::ALK Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1309988","ATIC/ALK Fusion Protein, Human","C101047","A fusion protein encoded by the ATIC/ALK fusion gene. This protein is comprised of the IMPCH and the dimerization domains of the bifunctional purine biosynthesis protein PURH fused to the cytoplasmic domain of the ALK tyrosine kinase receptor protein, including the tyrosine kinase domain.","ATIC/ALK Fusion Protein | ATIC-ALK Fusion Protein | ATIC::ALK Fusion Protein | Bifunctional Purine Biosynthesis Protein PURH/ALK Tyrosine Kinase Receptor Fusion Protein | Bifunctional Purine Biosynthesis Protein PURH::ALK Tyrosine Kinase Receptor Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639961","BCR/JAK2 Fusion Gene","C101048","A fusion gene that results from a chromosomal translocation t(9;22)(p24;q11.2) which fuses the 5' portion of the BCR gene with the 3' part of the JAK2 gene. This rearrangement is associated with myeloproliferative disorder.","BCR/JAK2 Fusion Gene | BCR-JAK2 Fusion Gene | BCR::JAK2 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639962","BCR/JAK2 Fusion Protein","C101049","A fusion protein encoded by the BCR/JAK2 fusion gene. This protein is comprised of the N-terminal coiled-coil domain of breakpoint cluster region protein fused to the C-terminal JH1 tyrosine kinase domain of tyrosine-protein kinase JAK2.","BCR/JAK2 Fusion Protein | BCR-JAK2 Fusion Protein | BCR::JAK2 Fusion Protein | Breakpoint Cluster Region Protein/Tyrosine-Protein Kinase JAK2 Fusion Protein | Breakpoint Cluster Region Protein::Tyrosine-Protein Kinase JAK2 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639963","COL1A2/PLAG1 Fusion Gene","C101053","A fusion gene that results from a chromosomal translocation t(7;8)(p22;q13) which fuses the 5' promoter region of the COL1A2 gene upstream of the entire coding region of the PLAG1 gene. This rearrangement is associated with both aberrant expression of the transcription factor zinc finger protein PLAG1 and lipoblastoma.","COL1A2/PLAG1 Fusion Gene | COL1A2-PLAG1 Fusion Gene | COL1A2::PLAG1 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639964","HAS2/PLAG1 Fusion Gene","C101054","A fusion gene that results from an intrachromosomal rearrangement of the q arm of chromosome 8 which fuses the 5' promoter region of the HAS2 gene upstream of the entire coding region of the PLAG1 gene. This rearrangement is associated with both aberrant expression of the transcription factor zinc finger protein PLAG1 and lipoblastoma.","HAS2/PLAG1 Fusion Gene | HAS2-PLAG1 Fusion Gene | HAS2::PLAG1 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3639965","FUS/CREB3L1 Fusion Gene","C101055","A fusion gene that results from a chromosomal rearrangement involving chromosomes 11 and 16 which fuses the first 6 or 9 exons of the FUS gene with exon 5 of the CREB3L1 gene. This rearrangement is associated with fibrosarcoma.","FUS/CREB3L1 Fusion Gene | FUS-CREB3L1 Fusion Gene | FUS::CREB3L1 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435505","IGF-1R antisense oligodeoxynucleotide-treated autologous glioma cells","C101257","A preparation of irradiated autologous glioma cells treated ex vivo with IMV-001, an antisense oligodeoxynucleotide of insulin-like growth factor receptor 1 (IGF-1R/AS ODN), and encapsulated within bio-diffusion chambers, with potential antineoplastic activity. The IGF-1R/AS ODN IMV-001-treated autologous glioma cells IGV-001 are encapsulated within implantable and removable bio-diffusion chambers with additional IMV-001, irradiated, and implanted into the patient. The IGF-1R/AS ODN binds to IGF-1R mRNA in glioma cells, and shuts down the translation of IGF-1R in the glioma cells. Downregulation of IGF-1R, in addition to irradiation, induces apoptosis and causes the release of exosomes, which contain tumor-associated antigens (TAAs). The diffusion of exosomes together with the additional IMV-001 from the bio-diffusion chambers may activate the patient's immune system and mount a cytotoxic T-lymphocyte (CTL) response against cells expressing these TAAs. IGF-1R, a receptor tyrosine kinase, is overexpressed in a variety of tumor cell types and is essential for tumor cell growth, transformation and survival.","IGF-1R Antisense Oligodeoxynucleotide-treated Autologous Glioma Cells IGV-001 | IGF-1R/AS ODN-treated Autologous Glioma Cells IGV-001 | IGV 001 | IGV-001 | IGV001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435506","CD19CAR-CD3zeta-4-1BB-expressing Allogeneic T-lymphocyte Cells","C101258","Allogeneic T-lymphocytes transduced with a modified lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. Upon transfusion, CD19CAR-CD3zeta-4-1BB-expressing allogeneic T-lymphocyte cells direct the T-lymphocytes to CD19-expressing tumor cells, thereby inducing a selective toxicity in CD19-expressing tumor cells. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19 and the inclusion of this signaling domain may increase the antitumor activity compared to the inclusion of the CD3-zeta chain alone. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.","CD19CAR-CD3zeta-4-1BB-expressing Allogeneic T-lymphocyte Cells | CART-19 Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435508","Multifunctional/Multitargeted Anticancer Agent OMN54","C101260","An orally available, multivalent herbal formulation containing a novel mixture of whole extracts from three commonly used Chinese medicinal herbs Ganoderma lucidum (lingzhi mushroom), Salvia miltiorrhiza (Chinese sage, or danshen) and Scutellaria barbata (ban zhi lian), with potential immunomodulating, antiangiogenic, anti-inflammatory, antiproliferative and antiviral activities. Although the exact mechanism of action remains to be fully elucidated due to the complexity of the multiple phytochemicals, multifunctional/multitargeted anticancer agent OMN54 appears to work in an additive and synergistic manner by acting on a variety of signaling pathways and on multiple targets, such as vascular endothelial growth factor, nuclear factor kappa B, interleukin-1beta, fibroblast growth factor, and epidermal growth factor.","Multifunctional/Multitargeted Anticancer Agent OMN54 | Aneustat | MFMT OMN54 | OMN54",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435509","Bevacizumab-IRDye 800CW","C101261","An immunoconjugate and a fluorescent tracer consisting of the recombinant humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab conjugated to the N-hydroxysuccinamide (NHS) ester form of the near-infrared (NIR) fluorescent dye IRDye 800CW, that may be used for VEGF-specific tumor imaging. Upon administration, the bevacizumab moiety of bevacizumab-IRDye 800CW binds to VEGF and the fluorescent signal can be visualized using NIR fluorescence imaging (700-1,000 nm).","Bevacizumab-IRDye 800CW | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435510","liposomal MUC1/PET-lipid A vaccine","C101262","A cancer vaccine comprised of a 43 amino acid epitope from glycoprotein MUC1 (mucin 1) and the synthetic Toll-like receptor 4 (TLR-4) agonist PET lipid A encapsulated in cholesterol/dipalmitoylphosphatidylcholine (DPPC)/dimyristoylphosphatidylglycerol (DMPG) liposomes, with potential immunostimulatory and antineoplastic activities. The MUC1 epitope is composed of two 20 amino glycosylated VNTR (various number tandem repeats) from human MUC1A and including 6 glycosylated sites modified by Tn (alfa-N-acetyl-D-galactosamine). Immunization of liposomal MUC1/PET-lipid A vaccine ONT-10 results in an antibody as well as a cytotoxic T-lymphocyte (CTL) response against hypoglycosylated MUC1 expressing tumor cells. The tumor associated antigen MUC1, a type I transmembrane protein, is overexpressed and aberrantly glycosylated in a variety of tumor cells. As a vaccine adjuvant, PET lipid A, also known as penta erythritol lipid A, stimulates both cellular and humoral responses to the vaccine antigen.","Liposomal MUC1/PET-lipid A Vaccine ONT-10 | ONT-10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2976303","Sofosbuvir","C101263","An orally available nucleotide prodrug and a hepatitis C virus (HCV) NS5B polymerase inhibitor with potential HCV inhibiting activity. Upon oral administration, sofosbuvir is metabolized to 2'-deoxy-2'-alpha-fluoro-beta-C-methyluridine-5'-monophosphate, which is then converted into the active triphosphate nucleotide that inhibits the NS5B polymerase, thereby preventing viral replication. The HCV NS5B protein, an RNA-dependent RNA polymerase, is essential for the replication of the viral HCV RNA genome.","Sofosbuvir | GS-7977 | L-Alanine, N-[[P(S),2'R]-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, 1-methylethyl Ester | PSI-7977 | SOFOSBUVIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054965","CD57 Antigen","C101147","A carbohydrate molecule that contains a sulfoglucuronyl residue and found predominantly on the surface of natural killer cells. It is involved in the modulation of cell-cell and cell-matrix interactions.","CD57 Antigen | CD57 | HNK-1 | HNK1 | Human Natural Killer-1 Antigen | L2/HNK-1 | Leu7",,,,,,,,,,,,,,,"4049486","Lymphocyte antigen CD57",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1414170","DSG3 Gene","C101148","This gene plays a role in cell-cell adhesion.","DSG3 Gene | DSG3 | Desmoglein 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538809","DSG3 wt Allele","C101149","Human DSG3 wild-type allele is located in the vicinity of 18q12.1 and is approximately 31 kb in length. This allele, which encodes desmoglein-3 protein, is involved in the modulation of cell-cell adhesion.","DSG3 wt Allele | ABOLM | CDHF6 | Desmoglein 3 (Pemphigus Vulgaris Antigen) Gene | Desmoglein 3 wt Allele | PVA | Pemphigus Vulgaris Antigen Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0113222","Desmoglein 3","C101150","Desmoglein-3 (999 aa, ~108 kDa) is encoded by the human DSG3 gene. This protein plays a role in desmosome-mediated cell-cell adhesion.","Desmoglein-3 | 130 kDa Pemphigus Vulgaris Antigen | Cadherin Family Member 6 | DESMOGLEIN 3 | DSG3 | Desmoglein 3 | PVA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538777","SPN wt Allele","C101152","Human SPN wild-type allele is located in the vicinity of 16p11.2 and is approximately 8 kb in length. This allele, which encodes leukosialin protein, plays a role in both chemotaxis and leukocyte migration.","SPN wt Allele | CD43 | GPL115 | LSN | Leukosialin Gene | Sialophorin wt Allele | gpL115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539699","CD9 wt Allele","C101155","Human CD9 wild-type allele is located in the vicinity of 12p13.3 and is approximately 39 kb in length. This allele, which encodes CD9 antigen protein, plays a role in platelet degranulation, sperm-egg fusion and cell adhesion.","CD9 wt Allele | BA2 | BTCC-1 | CD9 Molecule wt Allele | DRAP-27 | MIC3 | MRP-1 | Motility Related Protein-1 Gene | P24 | TSPAN-29 | TSPAN29",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054970","CD9 Antigen","C101156","CD9 antigen (228 aa, ~25 kDa) is encoded by the human CD9 gene. This protein is involved in both sperm-egg fusion and platelet degranulation.","CD9 Antigen | 5H9 Antigen | Antigen CD9 | CD9 | Cell Growth-Inhibiting Gene 2 Protein | Leukocyte Antigen MIC3 | MRP-1 | Motility-Related Protein | Motility-Related Protein -1 | Tetraspanin-29 | Tspan-29 | p24",,,,,,,,,,,,,,,"4180399","Lymphocyte antigen CD9",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1415575","HLA-DRA Gene","C101157","This gene plays a role in antigen presentation.","HLA-DRA Gene | HLA-DRA | Major Histocompatibility Complex, Class II, DR Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538701","HLA-DRA wt Allele","C101158","Human HLA-DRA wild-type allele is located in the vicinity of 6p21.3 and is approximately 5 kb in length. This allele, which encodes HLA class II histocompatibility antigen, DR alpha chain protein, is involved in the mediation of antigen presentation.","HLA-DRA wt Allele | DASS-397D15.1 | HLA-DRA1 | MLRW | Major Histocompatibility Complex, Class II, DR Alpha wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019763","HLA-DR alpha-Chains","C101159","HLA class II histocompatibility antigen, DR alpha chain (254 aa, ~29 kDa) is encoded by the human HLA-DRA gene. This protein plays a role in the presentation of antigen for recognition by CD4 T-cells.","HLA Class II Histocompatibility Antigen, DR Alpha Chain | Histocompatibility Antigen HLA-DR Alpha | MHC Class II Antigen DRA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640019","Dextro-Transposition of the Great Vessels with Intact Ventricular Septum","C101185","A congenital heart defect in which there is an abnormal arrangement of any of the primary blood vessels of the heart in conjunction with the notable absence of any pathologic opening between the cardiac ventricles.","Dextro-Transposition of the Great Vessels with Intact Ventricular Septum | D-Transposition of the Great Vessels with Intact Ventricular Septum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640020","Dextro-Transposition of the Great Vessels with Ventricular Septal Defect","C101186","A congenital heart defect in which there is an abnormal arrangement of any of the primary blood vessels of the heart in conjunction with a pathologic opening between the cardiac ventricles.","Dextro-Transposition of the Great Vessels with Ventricular Septal Defect | D-Transposition of the Great Vessels with Ventricular Septal Defect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640022","Unilateral Anophthalmos","C101188","A rare congenital abnormality characterized by the complete absence of ocular tissue in one orbit.","Unilateral Anophthalmos | Anophthalmos, Unilateral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3551307","Bilateral Microphthalmos","C101189","A congenital abnormality characterized by the presence of two abnormally small eye globes.","Bilateral Microphthalmos | Microphthalmos, Bilateral",,,,,,,,,,,,,,,"3657819","Bilateral microphthalmos",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640024","Unilateral Microphthalmos","C101190","A congenital abnormality characterized by the presence of one abnormally small eye globe and one normally sized eye globe.","Unilateral Microphthalmos | Microphthalmos, Unilateral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640025","Acquired Bilateral Cataracts","C101191","Cataracts in both eyes that result from the aging process, an injury, or as a manifestation of a systemic disorder.","Acquired Bilateral Cataracts | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640026","Acquired Unilateral Cataract","C101192","A cataract in one eye that results from the aging process, an injury, or as a manifestation of a systemic disorder.","Acquired Unilateral Cataract | Cataract, Acquired, Unilateral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541321","ATM Interactor","C101292","ATM interactor (823 aa, ~88 kDa) is encoded by the human ATMIN gene. This protein plays a role in the modulation of both cell survival and the response to DNA damage.","ATM Interactor | ASCIZ | ATM INteracting Protein | ATM Substrate CHK2-Interacting Zinc Finger Protein | ATM/ATR-Substrate CHEK2-Interacting Zinc Finger Protein | ATM/ATR-Substrate CHK2-Interacting Zinc Finger Protein | ATM/ATR-Substrate Chk2-Interacting Zn++-Finger Protein | Zinc Finger Protein 822",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435549","Gallium Ga 68-Edotreotide","C101369","A radioconjugate consisting of the octreotide derivative edotreotide labeled with gallium 68 (Ga-68) with potential application in somatostatin receptor (SSTR) imaging in conjunction with positron emission tomography (PET). Similar to octreotide, gallium Ga 68-edotreotide binds to SSTRs, especially type 2 receptors, present on the cell membranes of many types of neuroendocrine tumor cells and their metastases, thereby allowing for imaging of SSTR-expressing cells upon PET. Gallium Ga 68-edotreotide is produced by substituting tyrosine for phenylalanine at the 3 position of the somatostatin analogue octreotide (Tyr3-octreotide or TOC) and chelating the substituted octreotide to Ga-68 via the macrocyclic chelating agent dodecanetetraacetic acid (DOTA).","Gallium Ga 68-Edotreotide | 68Ga-DOTA-TOC | 68Ga-DOTA-d-Phe1-Tyr3-octreotide | EDOTREOTIDE GALLIUM GA-68 | Ga-68 DOTA0-Tyr3-octreotide | Ga-68 DOTATOC | Ga-68-DOTA-TOC | Ga-68-DOTA-Tyr(3)-octreotide | Gallium Ga 68-DOTATOC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279848","CDDP/DHAD/TMX/VP-16","C10136","A regimen consisting of tamoxifen, etoposide, mitoxantrone, and cisplatin that may be used in the treatment of breast cancer.","TEMP Regimen | CDDP/DHAD/TMX/VP-16 | Cisplatin/Etoposide/Mitoxantrone/Tamoxifen | TEMP | Tamoxifen/Etoposide/Mitoxantrone/Cisplatin | Tamoxifen/Etoposide/Mitoxantrone/Cisplatin Regimen | Tamoxifen/Etoposide/Mitoxantrone/Platinol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435550","Immunomodulatory Agent CC-11006","C101370","A proprietary, orally available, small molecule and thalidomide analog, with potential immunomodulating and antineoplastic activity. CC-11006 appears to have a similar mechanism to thalidomide and may modulate the expression of proinflammatory and regulatory cytokines.","Immunomodulatory Agent CC-11006 | CC-11006 | CC-11006-MDS-001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435551","Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Progenitor Cells","C101371","Autologous, CD34-positive hematopoietic progenitor cells (HPCs) transduced with rHIV7-shI-TAR-CCR5RZ, a lentiviral vector encoding three anti-human immunodeficiency virus (HIV) RNA genes, with potential antineoplastic activity. The 3 RNA products produced by the lentilvirus are: a short hairpin RNA (shRNA) targeted to an exon of the HIV-1 genes tat/rev, designated as shI; a decoy for the HIV TAT reactive element, designated as TAR; a ribozyme targeting the host cells CCR5 chemokine receptor, designated as CCR5RZ. Upon administration, lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells expressing the 3 species of RNAs display 3 seperate mechanims of action: the shRNA blocks the transcription of tat/rev, the TAR decoy binds to the TAT protein that is essential for HIV replication, and CCR5RZ catalyzes CCR5 which is needed for viral attachment and entry into the host cells. Altogether, infusion of these HPCs may ultimately inhibit HIV replication and suppress HIV infection.","Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Progenitor Cells | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537281","TIAF1 protein, human","C101374","Putative TGFB1-induced anti-apoptotic factor 1 (115 aa, ~12 kDa) is encoded by the human MYO18A gene. This protein plays a role in the modulation of apoptosis.","Putative TGFB1-Induced Anti-Apoptotic Factor 1 | 12 kDa TGF-Beta-1-Induced Antiapoptotic Factor | TGF-Beta-1-Induced Antiapoptotic Factor 1 | TGFB1-Induced Anti-Apoptotic Factor 1 | TGFB1-Induced Anti-Apoptotic Factor 1 | TIAF1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540505","Ubiquitin-Conjugating Enzyme E2 R1","C101303","Ubiquitin-conjugating enzyme E2 R1 (236 aa, ~27 kDa) is encoded by the human CDC34 gene. This protein plays a role in the processing of ubiquitin for protein modification.","Ubiquitin-Conjugating Enzyme E2 R1 | (E3-Independent) E2 Ubiquitin-Conjugating Enzyme R1 | CDC34 | Cell Division Cycle 34 | E2 Ubiquitin-Conjugating Enzyme R1 | EC 2.3.2.23 | EC 2.3.2.24 | EC 6.3.2.19, Formerly | Ubiquitin-Conjugating Enzyme E2-32 kDa Complementing | Ubiquitin-Conjugating Enzyme E2-CDC34 | Ubiquitin-Protein Ligase R1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014761","Hemolytic Disease of the Newborn","C101304","A disorder of the fetus or newborn that occurs when fetal cells that are coated with IgG alloantibodies from the mother attack antigens inherited from the father. Severity can range from absence of symptoms to death.","Hemolytic Disease of the Newborn | Erythroblastosis Fetalis | HDFN | Hemolytic Disease of the Fetus or Newborn | Isoimmune Hemolytic Disease of the Newborn",,,,,,,,,,,,,,,"440218","Hemolytic disease of fetus OR newborn due to isoimmunization",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640079","Colonic Band","C101305","A pathologic fibrous band that impedes passage of intestinal contents through the colon.","Colonic Band | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826439","NLRP6 Gene","C101306","This gene may be involved in inflammation.","NLRP6 Gene | NLR Family, Pyrin Domain Containing 6 Gene | NLRP6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640080","NACHT, LRR and PYD Domains-Containing Protein 6","C101308","NACHT, LRR and PYD domains-containing protein 6 (892 aa, ~99 kDa) is encoded by the human NLRP6 gene. This protein may be involved in the activation of the inflammatory response.","NACHT, LRR and PYD Domains-Containing Protein 6 | Angiotensin II/Vasopressin Receptor | NLRP6 | PYRIN-Containing APAF1-Like Protein 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825552","HTRA1 Gene","C101309","This gene plays a role in proteolysis.","HTRA1 Gene | HTRA1 | HtrA Serine Peptidase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540561","HTRA1 wt Allele","C101310","Human HTRA1 wild-type allele is located in the vicinity of 10q26.3 and is approximately 53 kb in length. This allele, which encodes serine protease HTRA1 protein, is involved in the mediation of proteolysis. Variations in the promoter of the gene are associated with age-related macular degeneration type 7. Mutation of the gene is associated with cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy.","HTRA1 wt Allele | ARMD7 | HtrA | HtrA Serine Peptidase 1 wt Allele | L56 | ORF480 | PRSS11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1258300","Serine Protease HTRA1, Human","C101311","Serine protease HTRA1 (480 aa, ~51 kDa) is encoded by the human HTRA1 gene. This protein plays a role in the proteolysis of IGF-binding proteins.","Serine Protease HTRA1 | EC 3.4.21.- | HTRA1 | High-Temperature Requirement A Serine Peptidase 1 | IGFBP5-Protease | L56 | Serine Protease 11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640081","Immature Retinopathy of Prematurity","C101312","An immature state in which retinopathy of prematurity cannot be established.","Immature Retinopathy of Prematurity | ROP | Retinopathy of Prematurity, Immature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0431698","Bilateral Renal Dysplasia","C101313","A finding of congenital malformations in both kidneys characterized by the presence of cysts of various sizes, primitive ducts, islands of metaplastic cartilage and undifferentiated mesenchyme, and the absence of cortico-medullary demarcation.","Bilateral Renal Dysplasia | ",,,,,,,,,,,,,,,"4003489","Bilateral renal dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640082","Coronary Anomaly","C101314","Any deviation from normal in the coronary vasculature.","Coronary Anomaly | Coronary Anomalies (includes aneurysm, anomalous)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640083","Colonic Web","C101315","A pathologic fibrous net that impedes passage of intestinal contents through the colon.","Colonic Web | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899086","Fracture of Long Bone Related to Birth","C101317","An injury sustained during the birthing process in which the continuity is broken in any bone that is longer in length than width.","Fracture of Long Bone Related to Birth | Fracture of Long Bone Related to Birth Trauma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897062","Fracture of Skull Related to Birth","C101318","An injury sustained during the birthing process in which the continuity is broken in the skull.","Fracture of Skull Related to Birth | Fracture of Skull Related to Birth Trauma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3536761","Transient Leukemoid Reaction of the Newborn","C101319","Increased white blood cell count and increased neutrophil precursors resembling leukemia in a neonate or fetus. Often, this is a response to medications received, infection or Down syndrome.","Transient Leukemoid Reaction of the Newborn | Leukemoid Reaction of the Newborn | Transient Leukemoid Reaction of Newborn",,,,,,,,,,,,,,,"4101586","Leukemoid reaction of the newborn",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640085","Perinatal Blood Aspiration Syndrome","C101320","Respiratory distress in the newborn due to inhalation of blood; this is an unusual event and is sometimes linked to the non passage of meconium before delivery or mothers with antepartum hemorrhage.","Perinatal Blood Aspiration Syndrome | Perinatal Aspiration of Blood",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540839","Neonatal Drug Withdrawal","C101321","A constellation of neurobehavioral features observed following cessation or reduction of antenatal or postnatal drug exposure.","Neonatal Drug Withdrawal | DWN | Drug Withdrawal Syndrome in Newborn",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640086","Complete Atrioventricular Septal Defect with Tetralogy of Fallot","C101322","A rare congenital heart anomaly in which there is coexistence of tetralogy of Fallot and complete atrioventricular septal defect. The latter is characterized by defects in the atrial and ventricular septa and a common atrioventricular valve.","Complete Atrioventricular Septal Defect with Tetralogy of Fallot | Tetralogy of Fallot - Complete AV Canal Defect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0270191","Perinatal Intraventricular Hemorrhage","C101324","Bleeding within the cerebral ventricles occurring around the time of birth.","Perinatal Intraventricular Hemorrhage | ",,,,,,,,,,,,,,,"436519","Perinatal intraventricular hemorrhage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640087","Heterotaxy Syndrome with Polysplenia","C101325","A congenital defect in which there is an abnormal spatial arrangement of the internal thoraco-abdominal organs; this manifestation of the disorder presents with many accessory spleens instead of one.","Heterotaxy Syndrome with Polysplenia | Heterotaxy, Polysplenia",,,,,,,,,,,,,,,"45769886","Polysplenia heterotaxy syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0345138","Pericardial Anomaly","C101327","Any abnormality involving the pericardium.","Pericardial Anomaly | ",,,,,,,,,,,,,,,"4262309","Pericardial anomaly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162670","Mitochondrial Myopathy","C101328","Myopathy caused by mitochondrial abnormalities.","Mitochondrial Myopathy | ",,,,,,,,,,,,,,,"4059379","Mitochondrial myopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0452132","Congenital Malformation Syndrome Related to Known Exogenous Cause","C101329","A syndrome characterized by the presence of structural malformations that are present at birth and can be attributed to an exogenous cause.","Congenital Malformation Syndrome Related to Known Exogenous Cause | Congenital Malformation Syndrome due to Known Exogenous Cause",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642481","Neonatal Resuscitation","C101330","Measures applied for the restoration of life to a newborn.","Neonatal Resuscitation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640089","Respiratory Failure Related to Neuromuscular Disorder","C101331","Impaired gas exchange by the respiratory system resulting in hypoxemia and decreased oxygenation of the tissues that may be associated with increased arterial levels of carbon dioxide; the respiratory failure is due to a neuromuscular disorder.","Respiratory Failure Related to Neuromuscular Disorder | Respiratory Failure due to Neuromuscular Disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640090","Respiratory Failure Related to Central Nervous System Disorder","C101332","Impaired gas exchange by the respiratory system resulting in hypoxemia and decreased oxygenation of the tissues that may be associated with increased arterial levels of carbon dioxide; the respiratory failure is due to a central nervous system disorder.","Respiratory Failure Related to Central Nervous System Disorder | Respiratory Failure due to CNS Disorder | Respiratory Failure due to Central Nervous System Disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0272271","Coagulation Disorder Related to Liver Dysfunction","C101333","A disorder of blood clotting that is attributable to a deficiency in liver function.","Coagulation Disorder Related to Liver Dysfunction | Blood Coagulation Disorder due to Liver Disease | Coagulation Defects due to Liver Disease",,,,,,,,,,,,,,,"4290259","Blood coagulation disorder due to liver disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1263739","Organic Acid Metabolism Disorder","C101334","An inherited disorder that affects the metabolism of any acidic compound containing carbon in a covalent linkage.","Organic Acid Metabolism Disorder | Disorder of Organic Acid Metabolism",,,,,,,,,,,,,,,"4021042","Disorder of organic acid metabolism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3539775","RNASEL wt Allele","C101336","Human RNASEL wild-type allele is located in the vicinity of 1q25 and is approximately 16 kb in length. This allele, which encodes 2-5A-dependent ribonuclease protein, is involved in the antiviral response. Mutation of the gene is associated with prostate cancer hereditary type 1.","RNASEL wt Allele | PRCA1 | Prostate Cancer Hereditary Type 1 Gene | RNS4 | Ribonuclease L (2',5'-Oligoisoadenylate Synthetase-Dependent) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640091","Arterial Thrombosis Related to Vascular Access Complication","C101338","The formation of a thrombus in the artery as a direct result of an activity associated with vascular access.","Arterial Thrombosis Related to Vascular Access Complication | Acquired Secondary Arterial Thrombosis due to Catheter Complication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640092","Venous Thrombosis Related to Vascular Access Complication","C101339","The formation of a thrombus in the vein as a direct result of an activity associated with vascular access.","Venous Thrombosis Related to Vascular Access Complication | Acquired Secondary Venous Thrombosis due to Catheter Complication | Venous Thrombosis due to Vascular Access Complication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412567","ARVCF Gene","C101340","This gene is involved in cell adhesion and mRNA splicing.","ARVCF Gene | ARVCF | ARVCF Delta Catenin Family Member Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542483","ARVCF wt Allele","C101341","Human ARVCF wild-type allele is located in the vicinity of 22q11.21 and is approximately 47 kb in length. This allele, which encodes splicing regulator ARVCF protein, plays a role in mRNA splicing and cell-cell adhesion. Mutation of the gene is associated with velo-cardio-facial syndrome.","ARVCF wt Allele | ARVCF Delta Catenin Family Member wt Allele | Armadillo Repeat Gene Deleted In Velocardiofacial Syndrome Gene | Armadillo Repeat Gene Deleted in VCFS | Armadillo Repeat Gene Deleted in Velocardiofacial Syndrome Gene | FLJ35345",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640093","Armadillo Repeat Protein Deleted In Velo-Cardio-Facial Syndrome","C101342","Splicing regulator ARVCF (962 aa, ~105 kDa) is encoded by the human ARVCF gene. This protein is involved in cell adhesion and mRNA splicing.","Splicing Regulator ARVCF | ARVCF | Armadillo Repeat Protein Deleted In Velo-Cardio-Facial Syndrome | Armadillo Repeat Protein Deleted In Velo-Cardio-Facial Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413724","CRY1 Gene","C101343","This gene plays a role in circadian rhythm.","CRY1 Gene | CRY1 | Cryptochrome 1 (Photolyase-Like) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538840","CRY1 wt Allele","C101344","Human CRY1 wild-type allele is located within 12q23-q24.1 and is approximately 103 kb in length. This allele, which encodes cryptochrome-1 protein, is involved in the regulation of circadian rhythm.","CRY1 wt Allele | Cryptochrome 1 (Photolyase-Like) wt Allele | PHLL1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0288450","cryptochrome 1","C101345","Cryptochrome-1 (586 aa, ~66 kDa) is encoded by the human CRY1 gene. This protein plays a role in the circadian rhythm process.","Cryptochrome-1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541915","STAG2 wt Allele","C101347","Human STAG2 wild-type allele is located in the vicinity of Xq25 and is approximately 462 kb in length. This allele, which encodes cohesin subunit SA-2, plays a role in sister chromatid adhesion.","STAG2 wt Allele | HPE13 | MKMS | NEDXCF | SA-2 | SA2 | SA2 Stromalin Gene | SCC3B | STAG2 Cohesin Complex Component wt Allele | Sister Chromatid Cohesion 3 Homolog (S. cerevisiae) B Gene | Sister Chromatid Cohesion 3 Homolog B Gene | Stromal Antigen 2 Gene | Stromal Antigen 2 wt Allele | bA517O1.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421305","UBQLN2 Gene","C101349","This gene may play a role in protein turnover.","UBQLN2 Gene | UBQLN2 | Ubiquilin 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420024","SH3BP5 Gene","C101375","This gene is involved in the regulation of signaling.","SH3BP5 Gene | SH3-Domain Binding Protein 5 (BTK-Associated) Gene | SH3BP5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541916","SH3BP5 wt Allele","C101376","Human SH3BP5 wild-type allele is located in the vicinity of 3p24.3 and is approximately 87 kb in length. This allele, which encodes SH3 domain-binding protein 5, plays a role in the modulation of intracellular communication.","SH3BP5 wt Allele | SAB | SH3-Domain Binding Protein 5 (BTK-Associated) wt Allele | Sab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538855","SH3 Domain-Binding Protein 5","C101377","SH3 domain-binding protein 5 (455 aa, ~50 kDa) is encoded by the human SH3BP5 gene. This protein is involved in the inhibition of protein kinases.","SH3 Domain-Binding Protein 5 | SH3 Domain-Binding Protein That Preferentially Associates with BTK | SH3BP-5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540468","THBD wt Allele","C101379","Human THBD wild-type allele is located in the vicinity of 20p11.2 and is approximately 4 kb in length. This allele, which encodes thrombomodulin protein, is involved in the regulation of both blood coagulation and thrombolysis. Mutation of the gene is associated with both thrombophilia and hemolytic uremic syndrome atypical type 6.","THBD wt Allele | AHUS6 | BDCA3 | CD141 | THPH12 | THRM | TM | Thrombomodulin wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1540100","TSPYL2 Gene","C101297","This gene is involved in chromatin remodeling.","TSPYL2 Gene | TSPY-Like 2 Gene | TSPYL2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539724","TSPYL2 wt Allele","C101298","Human TSPYL2 wild-type allele is located in the vicinity of Xp11.2 and is approximately 6 kb in length. This allele, which encodes testis-specific Y-encoded-like protein 2, plays a role in the remodeling of chromatin.","TSPYL2 wt Allele | CDA1 | CINAP | CTCL | DENTT | HRIHFB2216 | NP79 | SE204 | TSPX | TSPY-Like 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537388","Testis-Specific Y-Encoded-Like Protein 2","C101299","Testis-specific Y-encoded-like protein 2 (693 aa, ~79 kDa) is encoded by the human TSPYL2 gene. This protein is involved in the assembly of nucleosomes.","Testis-Specific Y-Encoded-Like Protein 2 | CASK-Interacting Nucleosome Assembly Protein | CTCL-Associated Antigen se20-4 | Cell Division Autoantigen 1 | Cutaneous T-Cell Lymphoma-Associated Antigen se20-4 | Differentially-Expressed Nucleolar TGF-Beta1 Target Protein | NP79 | Nuclear Protein of 79 kDa | TSPY-Like Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413263","CDC34 Gene","C101300","This gene plays a role in protein ubiquitination.","CDC34 Gene | CDC34 | Cell Division Cycle 34 Homolog (S. cerevisiae) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540496","CDC34 wt Allele","C101301","Human CDC34 wild-type allele is located in the vicinity of 19p13.3 and is approximately 10 kb in length. This allele, which encodes ubiquitin-conjugating enzyme E2 R1 protein, is involved in the modification of ubiquitin.","CDC34 wt Allele | Cell Division Cycle 34 Gene | Cell Division Cycle 34 Homolog (S. cerevisiae) wt Allele | E2-CDC34 | UBC3 | UBCH3 | UBE2R1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640045","In Situ Existing Lead","C101239","An insulated electrical conductor designed to connect to an electrical device for which the lead is in situ. (ACC)","In Situ Existing Lead | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539918","In Situ Lead Status","C101240","The state of an insulated wire designed to conduct energy from an electrical device to an anatomic site. (ACC)","In Situ Lead Status | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1868842","Lead Dislodgement","C101241","Movement of a lead away from the original implantation site. (ACC)","Lead Dislodgement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035139","Reimplantation","C101242","A surgical procedure that places something in the body that was previously lost or removed.","Reimplantation | ",,,,,,,,,,,,,,,"4151924","Reimplantation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640046","Substance Adverse Event","C101243","An unexpected or dangerous reaction to a substance (e.g., food, environmental agent). (ACC)","Substance Adverse Event | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541332","Tobacco Cessation Counseling","C101244","A process by which a health professional provides education, recommendations, or interventions to help clients stop using tobacco products. (ACC)","Tobacco Cessation Counseling | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640047","Antitachycardia Pacing","C101245","Delivery of electrical impulses to the heart at a faster rate than the intrinsic rate during an episode of tachycardia, in an attempt to terminate the abnormal tachycardia. (ACC)","Antitachycardia Pacing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640049","Appropriate Treatment","C101247","Correct activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects. (ACC)","Appropriate Treatment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0561946","Explantation","C101248","A surgical procedure that removes something that was implanted in the body.","Explantation | ",,,,,,,,,,,,,,,"4154603","Removal of implant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640051","Peripheral Embolus","C101249","Acute occlusion of a peripheral blood vessel resulting from intravascular migration of material. Examples of embolic material include thrombus, fat, bone marrow, air, and amniotic fluid. (ACC)","Peripheral Embolus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640052","Cardioverter Defibrillator Shock Therapy","C101251","Delivery of strong electrical impulses by a cardioverter defibrillator to return the electrical activity of the heart to normal. (ACC)","Cardioverter Defibrillator Shock Therapy | Cardiac Defibrillator Procedure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0241669","Venous Obstruction","C101252","Partial or total occlusion of a vein. (ACC)","Venous Obstruction | ",,,,,,,,,,,,,,,"4145867","Venous occlusion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640053","Renal Artery Disease","C101254","Pathology involving the main renal arteries or extrarenal arterial branches. (ACC)","Renal Artery Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3536833","Aldosterone Receptor Antagonist","C101255","A class of agents that act by selectively inhibiting aldosterone receptor activation with diuretic activity. Aldosterone receptor antagonists bind to and block the activation of aldosterone (mineralocorticoid) receptors on the epithelial cells in the late distal tubule and collecting duct of the kidney, thus preventing the synthesis of aldosterone-induced proteins which enhance Na+ retention and K+ and H+ secretion. The enhanced excretion of Na+ produces diuresis ultimately resulting in a reduction in blood pressure without the loss of K+.","Aldosterone Receptor Antagonist | Aldosterone inhibitor (mineralocorticoid receptor antagonist) | Antimineralocorticoid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640054","Glycoprotein IIb/IIIa Antagonist","C101256","A class of agents that act by selectively inhibiting glycoprotein IIb/IIIa with anticoagulant activity. Glycoprotein IIb/IIIa antagonists bind to and block the activation of the platelet-surface integrin glycoprotein IIb/IIIa, thus preventing the binding of fibrinogen and von Willebrand factor leading to the inhibition of platelet activation and aggregation.","Glycoprotein IIb/IIIa Antagonist | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640075","Has_Data_Element","C101281","An association created to relate a data element concept to the codelist term that is used to bundle its subset of valid value concepts.","Has_Data_Element | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541313","PIK3R2 wt Allele","C101284","Human PIK3R2 wild-type allele is located within 19q13.2-q13.4 and is approximately 17 kb in length. This allele, which encodes phosphatidylinositol 3-kinase regulatory subunit beta protein, plays a role in the modulation of tyrosine phosphorylation.","PIK3R2 wt Allele | MPPH | MPPH1 | P85B | Phosphatidylinositol 3-Kinase, Regulatory Subunit 2 Gene | Phosphatidylinositol 3-Kinase, Regulatory Subunit, 85-kD, Beta Gene | Phosphoinositide-3-Kinase Regulatory Subunit 2 wt Allele | Phosphoinositide-3-Kinase, Regulatory Subunit 2 (Beta) Gene | p85 | p85-BETA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537330","phosphoinositol-3 kinase regulatory subunit 2, human","C101285","Phosphatidylinositol 3-kinase regulatory subunit beta (728 aa, ~82 kDa) is encoded by the human PIK3R2 gene. This protein is involved in the modulation of both tyrosine phosphorylation and signal transduction.","Phosphatidylinositol 3-Kinase Regulatory Subunit Beta | PI3-Kinase Regulatory Subunit Beta | PI3-Kinase Subunit p85-Beta | PI3K Regulatory Subunit Beta | PIK3R2 | Phosphatidylinositol 3-Kinase 85 kDa Regulatory Subunit Beta | Phosphatidylinositol 3-Kinase, Regulatory Subunit, Polypeptide 2 | PtdIns-3-Kinase Regulatory Subunit Beta | PtdIns-3-Kinase Regulatory Subunit p85-Beta | p85-Beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419253","RALBP1 Gene","C101286","This gene is involved in the regulation of small GTPase activity.","RALBP1 Gene | RALBP1 | ralA Binding Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539807","RALBP1 wt Allele","C101287","Human RALBP1 wild-type allele is located in the vicinity of 18p11.3 and is approximately 63 kb in length. This allele, which encodes ralA-binding protein 1, plays a role in the modulation of signaling and small molecule transport.","RALBP1 wt Allele | RIP | RIP1 | RLIP1 | RLIP76 | ralA Binding Protein 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1448943","RALBP1 protein, human","C101288","RalA-binding protein 1 (655 aa, ~76 kDa) is encoded by the human RALBP1 gene. This protein is involved in the regulation of small molecule transport and signaling.","RalA-Binding Protein 1 | 76 kDa Ral-Interacting Protein | DNP-SG ATPase | Dinitrophenyl S-Glutathione ATPase | EC 7.6.2.2 | EC 7.6.2.3 | Ral-Interacting Protein 1 | RalBP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435599","Integrin AlphaM/Beta2","C101289","Integrin alpha-M/beta2 is a protein complex comprised of a heterodimer of integrin alpha M and integrin beta 2. This complex is involved in anti-bacterial defense and complement internalization.","Integrin AlphaM/Beta2 | CD11b/CD18 | CR3 | Complement Receptor 3 | Integrin Alpha-M/Beta-2 | Mac-1 | Macrophage-1 Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2239910","ATMIN Gene","C101290","This gene plays a role in the response to DNA damage.","ATMIN Gene | ATM Interactor Gene | ATMIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540552","ATMIN wt Allele","C101291","Human ATMIN wild-type allele is located in the vicinity of 16q23.2 and is approximately 11 kb in length. This allele, which encodes ATM interactor protein, is involved in both DNA damage response and cell survival.","ATMIN wt Allele | ASCIZ | ATM Interactor wt Allele | KIAA0431 | ZNF822",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640104","Cation Channel Sperm-Associated Protein Subunit Zeta","C101397","Cation channel sperm-associated protein subunit zeta (200 aa, ~23 kDa) is encoded by the human CATSPERZ gene. This protein is involved in sperm capacitation.","Cation Channel Sperm-Associated Protein Subunit Zeta | CATSPERZ | CatSper-Zeta | CatSperzeta | Hypothetical Protein LOC25858 | Testis-Expressed Protein 40 | Testis-Expressed Sequence 40 Protein | Uncharacterized Protein C11orf20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428691","C9orf72 Gene","C101398","This gene plays a role in the regulation of both cellular stress responses and autophagy.","C9orf72 Gene | C9orf72 | C9orf72-SMCR8 Complex Subunit Gene | Chromosome 9 Open Reading Frame 72 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538797","C9orf72 wt Allele","C101399","Human C9orf72 wild-type allele is located in the vicinity of 9p21.2 and is approximately 27 kb in length. This allele, which encodes guanine nucleotide exchange factor C9orf72 protein, is involved in guanyl-nucleotide exchange activity that mediates cellular stress responses and regulates autophagy. An expanded GGGGCC hexanucleotide repeat in the non-coding region of the C9orf72 gene is associated with amyotrophic lateral sclerosis and frontotemporal dementia.","C9orf72 wt Allele | ALSFTD | C9orf72-SMCR8 Complex Subunit wt Allele | Chromosome 9 Open Reading Frame 72 Gene | Chromosome 9 Open Reading Frame 72 wt Allele | DENND9 | DENNL72 | FTDALS | Guanine Nucleotide Exchange C9orf72 Gene | MGC23980 | RP11-27J8.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0053230","Benznidazole","C1013","A nitroimidazole derivative having an antiprotozoal activity by interfering with parasite protein biosynthesis, influencing cytokines production and stimulating host phagocytosis. (NCI)","Benznidazole | 2-Nitro-N-(phenylmethyl)-1H-imidazole-1-acetamide | BENZNIDAZOLE | N-Benzyl-2-nitroimidazole-1-acetamide | N-benzyl-2-nitroimidazole-1-acetamide | Radanil | Ro-7-1051 | Rochagan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640105","C9orf72 protein, human","C101400","Guanine nucleotide exchange factor C9orf72 (481 aa, ~54 kDa) is encoded by the human C9orf72 gene. This protein plays a role in cellular stress responses, autophagy and guanyl-nucleotide exchange activity.","Guanine Nucleotide Exchange Factor C9orf72 | C9orf72 | Hypothetical Protein LOC203228 | Protein C9orf72 | Uncharacterized Protein C9orf72 | Uncharacterized Protein C9orf72",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539613","GRN wt Allele","C101402","Human GRN wild-type allele is located in the vicinity of 17q21.32 and is approximately 8 kb in length. This allele, which encodes progranulin protein, plays a role in wound healing, lysosome acidification and the modulation of inflammation. Mutation of the gene is associated with primary progressive aphasia, neuronal ceroid lipofuscinosis type 11 and ubiquitin-positive frontotemporal dementia.","GRN wt Allele | CLN11 | GEP | GP88 | Glycoprotein, 88-kD Gene | Granulin Gene | Granulin Precursor wt Allele | Granulin wt Allele | Granulin-Epithelin Gene | PCDGF | PEPI | PGRN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1453193","Granulins, Human","C101403","Progranulin (593 aa, ~64 kDa) is encoded by the human GRN gene. This protein is involved in lysosome acidification, inflammation and wound healing.","Progranulin | Epithelin Precursor | GP88 | GRN | Glycoprotein 88 | Glycoprotein of 88 kDa | Granulin Precursor | Granulins | Granulins | PC Cell-Derived Growth Factor | PCDGF | PEPI | PGRN | Proepithelin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415198","GPC6 Gene","C101404","This gene plays a role in protein binding.","GPC6 Gene | GPC6 | Glypican 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542972","GPC6 wt Allele","C101405","Human GPC6 wild-type allele is located in the vicinity of 13q32 and is approximately 1181 kb in length. This allele, which encodes glypican-6 protein, is involved in cell-protein interactions. Mutation of the gene is associated with omodysplasia type 1.","GPC6 wt Allele | Glypican 6 wt Allele | MGC126288 | OMIMD1 | UNQ369/PRO705",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1438417","Glypican-6, Human","C101406","Glypican-6 (555 aa, ~63 kDa) is encoded by the human GPC6 gene. This protein plays a role in the mediation of cell-protein interactions.","Glypican-6 | GPC6 | Glypican Proteoglycan 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420758","TLL1 Gene","C101407","This gene plays a role in both collagen processing and skeletal development.","TLL1 Gene | TLL1 | Tolloid-Like 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542925","TLL1 wt Allele","C101408","Human TLL1 wild-type allele is located within 4q32-q33 and is approximately 231 kb in length. This allele, which encodes tolloid-like protein 1, is involved in both skeletal development and the modification of collagen.","TLL1 wt Allele | ASD6 | TLL | Tolloid-Like 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1969616","FOXO6 Gene","C101410","This gene may play a role in transcriptional activation.","FOXO6 Gene | FOXO6 | Forkhead Box O6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542973","FOXO6 wt Allele","C101411","Human FOXO6 wild-type allele is located in the vicinity of 1p34.2 and is approximately 22 kb in length. This allele, which encodes forkhead box protein O6, may be involved in the activation of transcription.","FOXO6 wt Allele | Forkhead Box O6 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540469","AICDA wt Allele","C101414","Human AICDA wild-type allele is located in the vicinity of 12p13 and is approximately 11 kb in length. This allele, which encodes single-stranded DNA cytidine deaminase protein, is involved in both DNA methylation and B-cell differentiation. Mutation of the gene is associated with immunodeficiency with hyper-IgM type 2.","AICDA wt Allele | AID | ARP2 | Activation Induced Cytidine Deaminase wt Allele | CDA2 | HEL-S-284 | HIGM2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538973","activation-induced cytidine deaminase, human","C101415","Single-stranded DNA cytosine deaminase (198 aa, ~24 kDa) is encoded by the human AICDA gene. This protein plays a role in both B-cell functioning and DNA modification.","Single-Stranded DNA Cytosine Deaminase | AICDA | AID | Activation-Induced Cytidine Deaminase | Cytidine Aminohydrolase | EC 3.5.4.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825819","LIN28B Gene","C101416","This gene plays a role in the suppression of miRNA processing.","LIN28B Gene | LIN28B | Lin-28 Homolog B (C. elegans) Gene | Lin-28 Homolog B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540511","LIN28B wt Allele","C101417","Human LIN28B wild-type allele is located in the vicinity of 6q21 and is approximately 126 kb in length. This allele, which encodes protein lin-28 homolog B, is involved in the regulation of pre-miRNA degradation.","LIN28B wt Allele | CSDD2 | FLJ16517 | LIN28, C. elegans, Homolog of, B Gene | Lin-28 Homolog B (C. elegans) Gene | Lin-28 Homolog B (C. elegans) wt Allele | Lin-28 Homolog B wt Allele | Lin-28.2 | RP3-522O2.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640107","Protein Lin-28 Homolog B","C101418","Protein lin-28 homolog B (250 aa, ~27 kDa) is encoded by the human LIN28B gene. This protein plays a role in the degradation of pre-miRNA.","Protein Lin-28 Homolog B | LIN28B | Lin-28B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539233","RIGI Gene","C101419","This gene plays a role in the antiviral response.","RIGI Gene | DDX58 | DDX58 Gene | DDX58 Gene | DExD/H-Box Helicase 58 Gene | RIG-I | RIGI | RNA Sensor RIG-I Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1310468","Probable ATP-Dependent RNA Helicase DDX58, Human","C101421","Antiviral innate immune response receptor RIG-I (925 aa, ~107 kDa) is encoded by the human RIGI gene. This protein is involved in the activation of antiviral responses.","Antiviral Innate Immune Response Receptor RIG-I | ATP-Dependent RNA Helicase DDX58 | DDX58 | DEAD Box Protein 58 | EC 3.6.4.13 | Probable ATP-Dependent RNA Helicase DDX58 | RIG-1 | RIG-I | RIG-I-Like Receptor 1 | RIGI | RLR-1 | RNA Helicase RIG-I | RNA Sensor RIG-I | Retinoic Acid-Inducible Gene 1 Protein | Retinoic Acid-Inducible Gene I Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541307","POSTN wt Allele","C101423","Human POSTN wild-type allele is located in the vicinity of 13q13.3 and is approximately 47 kb in length. This allele, which encodes periostin protein, is involved in the regulation of cell adhesion.","POSTN wt Allele | OSF-2 | OSF2 | Osteoblast Specific Factor 2 (Fasciclin I-Like) Gene | PDLPOSTN | PN | Periostin Gene | Periostin, Osteoblast Specific Factor wt Allele | RP11-412K4.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0219433","Periostin, Human","C101424","Periostin (836 aa, ~93 kDa) is encoded by the human POSTN gene. This protein plays a role in cell adhesion.","Periostin | OSF-2 | Osteoblast-Specific Factor 2 | PN | Periodontal Ligament-Specific Periostin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541331","KIF5B wt Allele","C101426","Human KIF5B wild-type allele is located in the vicinity of 10p11.22 and is approximately 47 kb in length. This allele, which encodes kinesin-1 heavy chain protein, plays a role in vesicle transport. A chromosomal inversion involving this gene and the RET gene may be associated with lung adenocarcinoma.","KIF5B wt Allele | HEL-S-61 | KINH | KNS | KNS1 | Kinesin 1 Heavy Chain Gene | Kinesin Family Member 5B wt Allele | Kinesin, Heavy Chain, Ubiquitous Gene | UKHC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541330","Kinesin-1 Heavy Chain, Human","C101427","Kinesin-1 heavy chain (963 aa, ~110 kDa) is encoded by the human KIF5B gene. This protein is involved in organelle and vesicle transport.","Kinesin-1 Heavy Chain | Conventional Kinesin Heavy Chain | KIF5B | Kinesin 1 Heavy Chain | Kinesin Heavy Chain | UKHC | Ubiquitous Kinesin Heavy Chain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541883","FLJ21945","C101429","Human WDCP wild-type allele is located in the vicinity of 2p23.3 and is approximately 20 kb in length. This allele, which encodes WD repeat and coiled-coil-containing protein, is involved in binding to tyrosine-protein kinase HCK. A tandem duplication that fuses this gene and the ALK gene may be associated with colorectal cancer.","WDCP wt Allele | C2orf44 | Chromosome 2 Open Reading Frame 44 Gene | FLJ21945 | PP384 | WD Repeat and Coiled Coil Containing wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640108","Chromosome 2 Open Reading Frame 44 Protein","C101430","WD repeat and coiled-coil-containing protein (721 aa, ~79 kDa) is encoded by the human WDCP gene. This protein plays a role in tyrosine-protein kinase HCK binding.","WD Repeat and Coiled-Coil-Containing Protein | Chromosome 2 Open Reading Frame 44 Protein | WD Repeat and Coiled-Coil-Containing Protein C2orf44 | WD Repeat- and Coiled-Coil-Containing Protein | WD Repeat-Containing Protein C2orf44",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540636","SDC4 wt Allele","C101432","Human SDC4 wild-type allele is located in the vicinity of 20q12 and is approximately 23 kb in length. This allele, which encodes syndecan-4 protein, plays a role in heparan sulfate binding.","SDC4 wt Allele | MGC22217 | SYND4 | Syndecan 4 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539710","SLC34A2 wt Allele","C101435","Human SLC34A2 wild-type allele is located in the vicinity of 4p15.2 and is approximately 23 kb in length. This allele, which encodes sodium-dependent phosphate transport protein 2B, is involved in sodium/phosphate co-transport. Mutation of the gene is associated with pulmonary alveolar microlithiasis. A chromosomal aberration involving this gene and the ROS1 gene may be associated with non-small cell lung cancer.","SLC34A2 wt Allele | FLJ90534 | NAPI-3B | NAPI-IIb | NPTIIb | PULAM | Solute Carrier Family 34 (Sodium Phosphate), Member 2 Gene | Solute Carrier Family 34 (Type II Sodium/Phosphate Cotransporter), Member 2 Gene | Solute Carrier Family 34 Member 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539711","SLC34A2 protein, human","C101436","Sodium-dependent phosphate transport protein 2B (690 aa, ~76 kDa) is encoded by the human SLC34A2 gene. This protein plays a role in pH-sensitive sodium-dependent phosphate transport.","Sodium-Dependent Phosphate Transport Protein 2B | Na(+)-Dependent Phosphate Cotransporter 2B | Na(+)/Pi Cotransporter 2B | NaPi-2b | NaPi2b | NaPi3b | SLC34A2 | Sodium-Phosphate Transport Protein 2B | Sodium/Phosphate Cotransporter 2B | Solute Carrier Family 34 Member 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538755","UBQLN2 wt Allele","C101350","Human UBQLN2 wild-type allele is located in the vicinity of Xp11.21 and is approximately 3 kb in length. This allele, which encodes ubiquilin-2 protein, may be involved in the regulation of proteasome activity. Mutation of the gene is associated with amyotrophic lateral sclerosis type 15.","UBQLN2 wt Allele | ALS15 | CHAP1 | CHAP1/DSK2 | DSK2 | Dsk2 | HRIHFB2157 | LIC-2 | N4BP4 | NEDD4 Binding Protein 4 Gene | PLIC-2 | PLIC2 | RIHFB2157 | Ubiquilin 2 wt Allele | Ubiquilin 2 wt Allele Chap1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539718","Ubiquilin-2","C101351","Ubiquilin-2 (624 aa, ~66 kDa) is encoded by the human UBQLN2 gene. This protein may play a role in the modulation of proteasome-mediated protein degradation.","Ubiquilin-2 | Chap1 | DSK2 Homolog | NEDD4 Binding Protein 4 | PLIC-2 | Protein Linking IAP with Cytoskeleton 2 | Ubiquitin-Like Product Chap1/Dsk2 | hPLIC-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414233","GPR183 Gene","C101352","This gene is involved in humoral immunity.","GPR183 Gene | G Protein-Coupled Receptor 183 Gene | GPR183",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540502","Epstein-Barr Virus-Induced Gene 2","C101353","Human GPR183 wild-type allele is located in the vicinity of 13q32.3 and is approximately 13 kb in length. This allele, which encodes G-protein coupled receptor 183 protein, plays a role in the modulation of humoral immunity. Aberrant expression of this gene is induced by Epstein-Barr virus and may be associated with virally-induced neoplasms.","GPR183 wt Allele | EBI2 | Epstein-Barr Virus Induced Gene 2 (Lymphocyte-Specific G Protein-Coupled Receptor) Gene | Epstein-Barr Virus-Induced Gene 2 | G Protein-Coupled Receptor 183 wt Allele | RP11-461N23.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540501","G-Protein Coupled Receptor 183","C101354","G-protein coupled receptor 183 (361 aa, ~41 kDa) is encoded by the human GPR183 gene. This protein is involved in both B-cell maturation and localization.","G-Protein Coupled Receptor 183 | EBI2 | EBV-Induced G-Protein Coupled Receptor 2 | Epstein-Barr Virus-Induced G-Protein Coupled Receptor 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538841","PHLPP1 wt Allele","C101356","Human PHLPP1 wild-type allele is located in the vicinity of 18q21.32 and is approximately 265 kb in length. This allele, which encodes PH domain leucine-rich repeat-containing protein phosphatase 1 protein, is involved in both signaling and protein dephosphorylation.","PHLPP1 wt Allele | KIAA0606 | PH Domain and Leucine Rich Repeat Protein Phosphatase 1 wt Allele | PHLPP | PLEKHE1 | SCOP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539067","Oat (plant)","C101357","No value exists.","Oat | Avena Grain | Avena sativa Kernel | Common Oat Grain | OAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824198","ARHGAP29 Gene","C101359","This gene is involved in Rho-mediated signal transduction.","ARHGAP29 Gene | ARHGAP29 | Rho GTPase Activating Protein 29 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541905","ARHGAP29 wt Allele","C101360","Human ARHGAP29 wild-type allele is located in the vicinity of 1p22.1 and is approximately 126 kb in length. This allele, which encodes Rho GTPase-activating protein 29, plays a role in the modulation of signaling.","ARHGAP29 wt Allele | PARG1 | RP11-255E17.1 | Rho GTPase Activating Protein 29 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538892","Rho GTPase-Activating Protein 29, Human","C101361","Rho GTPase-activating protein 29 (1261 aa, ~142 kDa) is encoded by the human ARHGAP29 gene. This protein is involved in the regulation of Rho protein-mediated signaling.","Rho GTPase-Activating Protein 29 | PTPL1-Associated RhoGAP 1 | PTPL1-Associated RhoGAP Protein 1 | Rho-Type GTPase-Activating Protein 29",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152096","Complete Trisomy 18 Syndrome","C101362","A constellation of symptoms that occur as a result of the presence of a complete third copy of the 18th chromosome. Characteristics include profound mental retardation and severe malformations. Individuals with this syndrome rarely live past one year.","Complete Trisomy 18 Syndrome | Edwards Syndrome | Trisomy 18",,,,,,,,,,,,,,,"438865","Complete trisomy 18 syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1416602","KCNMA1 Gene","C101363","This gene plays a role in potassium transport.","KCNMA1 Gene | KCNMA1 | Potassium Large Conductance Calcium-Activated Channel, Subfamily M, Alpha Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539661","KCNMA1 wt Allele","C101364","Human KCNMA1 wild-type allele is located in the vicinity of 10q22.3 and is approximately 769 kb in length. This allele, which encodes calcium-activated potassium channel subunit alpha-1 protein, is involved in the regulation of potassium transport. Aberrant expression of the gene may play a role in melanoma.","KCNMA1 wt Allele | BKTM | KCa1.1 | MaxiK | Potassium Large Conductance Calcium-Activated Channel, Subfamily M, Alpha Member 1 wt Allele | RP11-443A13.1 | SAKCA | SLO | SLO-ALPHA | SLO1 | bA205K10.1 | mSLO1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537389","KCNMA1 protein, human","C101365","Calcium-activated potassium channel subunit alpha-1 (1236 aa, ~138 kDa) is encoded by the human KCNMA1 gene. This protein plays a role in calcium-dependent potassium transport.","Calcium-Activated Potassium Channel Subunit Alpha-1 | BK Channel | BKCA Alpha | Calcium-Activated Potassium Channel, Subfamily M Subunit Alpha-1 | K(VCA)Alpha | KCNMA1 | KCa1.1 | Maxi K Channel | MaxiK | Slo Homolog | Slo-Alpha | Slo1 | Slowpoke Homolog | Stretch-Activated Kca Channel | hSlo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435546","Anti-CD40 Monoclonal Antibody Chi Lob 7/4","C101366","An IgG1 chimeric monoclonal antibody agonist of the cell surface receptor CD40 with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, anti-CD40 monoclonal antibody Chi Lob 7/4 binds to CD40 on a variety of immune cell types, triggering the cellular proliferation and activation of antigen-presenting cells (APCs), activating B cells and T cells, and enhancing the immune response; in addition, this agent binds to the CD40 antigen present on the surfaces of some solid tumor cells, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cytotoxicity (ADCC) eventually resulting in decreased tumor growth. CD40, a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells, many B-cell malignancies, and many solid tumors, mediating both indirect tumor cell death through the activation of the immune system and direct tumor cell apoptosis.","Anti-CD40 Monoclonal Antibody Chi Lob 7/4 | Chi Lob 7/4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435547","CD-expressing Bifidobacterium APS001F","C101367","A recombinant anaerobic bacterium, Bifidobacterium longum, encoding the cytosine deaminase (CD) gene with potential antineoplastic adjuvant activity. Upon injection, the CD-expressing bifidobacterium preferentially localizes and grows in the hypoxic environment of the tumor and expresses CD, an enzyme that catalyzes the intracellular conversion of the prodrug flucytosine (5-FC) into the antineoplastic agent 5-fluorouracil (5-FU). Upon administration of 5-FC, and subsequent localized conversion into 5-FU and its cytotoxic active metabolites, the tumor is specifically exposed to cytotoxic agents while the exposure to normal tissues is minimal.","CD-expressing Bifidobacterium APS001F | APS001F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435548","STAT3 antisense oligonucleotide ISIS 481464","C101368","An antisense oligonucleotide targeting signal transducer and activator of transcription 3 (STAT3) with potential antitumor activity. Danvatirsen binds to STAT3 mRNA, thereby inhibiting translation of the transcript. Suppression of STAT3 expression induces tumor cell apoptosis and decreases tumor cell growth. STAT3, a protein overexpressed in a variety of human cancers, plays a critical role in tumor cell growth and survival.","Danvatirsen | AZD9150 | DANVATIRSEN | ISIS 481464 | ISIS-STAT3rx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2974542","tubulin polymerization inhibitor CKD-516","C101264","A benzophenone derivative and water soluble valine prodrug of the tubulin binding agent S516, with potential tubulin-inhibiting, vascular-disrupting and antineoplastic activity. Upon administration, valecobulin is converted into its active metabolite S-516 that binds to tubulin and prevents its polymerization in tumor blood vessel endothelial cells and tumor cells. This blocks the formation of the mitotic spindle and leads to cell cycle arrest at the G2/M phase. As a result, this agent disrupts the tumor vasculature and tumor blood flow, deprives tumor cells of nutrients and induces tumor cell apoptosis. In addition, this agent has a direct cytotoxic effect on tumor cells by inhibiting tubulin polymerization.","Valecobulin | (S)-N-(4-(3-(1H-1,2,4-Triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide Hydrochloride | CKD-516 | Tubulin Polymerization Inhibitor CKD-516 | VALECOBULIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435511","Bovine Lactoferrin Supplement","C101265","A supplement containing lactoferrin derived from bovine milk with potential chemopreventive, immunostimulating, and antimicrobial activity. Upon administration, lactoferrin binds to metal in the oral cavity and may prevent metal-induced oxidation of lipids. This may reduce the metallic taste and taste disturbances induced by certain metal-containing chemotherapeutics; metal-induced lipid oxidation, and the subsequent production of aldehydes and ketones attribute to the metallic smell. Lactoferrin, a glycoprotein belonging to the transferrin family of metal-binding proteins, can be found in milk and other secretory fluids as well as in polymorphonuclear cells and leukocytes; lactoferrin plays a role in the innate defense of mucosal surfaces and its iron-binding activity is associated with the antibacterial activity.","Bovine Lactoferrin Supplement | bLF Supplement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640067","Hormone Receptor Positive","C101267","A finding indicating that the neoplastic cells in a tissue sample test positive for hormone receptors.","Hormone Receptor Positive | ER and/or PR + | ER and/or PR Positive | Estrogen Receptor and/or Progesterone Receptor Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1833797","Bilateral Optic Nerve Hypoplasia","C101268","A congenital abnormality characterized by the underdevelopment of both optic nerves.","Bilateral Optic Nerve Hypoplasia | Bilateral Hypoplasia of the Optic Nerve | Hypoplasia of the Optic Nerve, Bilateral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640068","Unilateral Optic Nerve Hypoplasia","C101269","A congenital abnormality characterized by the underdevelopment of one optic nerve.","Unilateral Optic Nerve Hypoplasia | Hypoplasia of the Optic Nerve, Unilateral | Unilateral Hypoplasia of the Optic Nerve",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0270204","Kernicterus Related to Isoimmunization","C101270","Encephalopathy in infants due to high levels of unconjugated bilirubin that are a result of Rh incompatibility between the mother and the fetus.","Kernicterus Related to Isoimmunization | Kernicterus due to Isoimmunization | Kernicterus related to Isoimmunization",,,,,,,,,,,,,,,"437681","Kernicterus due to isoimmunization",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640069","Perinatal Central Nervous System Depression","C101271","Generalized depression of the central nervous system of an infant during the perinatal period.","Perinatal Central Nervous System Depression | Difficult Transition to Extrauterine Life",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640071","Suspected Necrotizing Enterocolitis","C101273","The diagnosis assigned when a health care practitioner feels strongly the patient has necrotizing enterocolitis, but lacks definitive proof.","Suspected Necrotizing Enterocolitis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0340016","Traumatic Chylothorax","C101274","Accumulation of lymph fluid in the pleural cavity as a result of thoracic trauma.","Traumatic Chylothorax | ",,,,,,,,,,,,,,,"4052557","Traumatic chylothorax",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1855352","Duodenal Band","C101275","A pathologic fibrous band that impedes passage of intestinal contents through the duodenum.","Duodenal Band | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640072","Ileal Band","C101276","A pathologic fibrous band that impedes passage of intestinal contents through the ileum.","Ileal Band | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640073","Jejunal Band","C101277","A pathologic fibrous band that impedes passage of intestinal contents through the jejunum.","Jejunal Band | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640074","Spinal Injury Related to Birth","C101278","An injury to the spine sustained during the birthing process.","Spinal Injury Related to Birth | Spinal Cord Injury Related to Birth | Spinal Injury Related to Birth Trauma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1261566","Laryngeal Agenesis","C101279","A congenital deformity in which there is no laryngeal structure.","Laryngeal Agenesis | Agenesis of Larynx",,,,,,,,,,,,,,,"4005619","Agenesis of larynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3540551","SEC16A wt Allele","C101473","Human SEC16A wild-type allele is located in the vicinity of 9q34.3 and is approximately 43 kb in length. This allele, which encodes protein transport protein Sec16A, plays a role in protein trafficking.","SEC16A wt Allele | KIAA0310 | RP11-413M3.10 | RP11-413M3.10-002 | SEC16 Homolog A (S. cerevisiae) wt Allele | SEC16L | p250",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640114","Protein Transport Protein Sec16A","C101474","Protein transport protein Sec16A (2179 aa, ~234 kDa) is encoded by the human SEC16A gene. This protein is involved in the regulation of intracellular protein transport.","Protein Transport Protein Sec16A | SEC16 Homolog A | SEC16A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1822669","SEC31A Gene","C101475","This gene plays a role in anterograde transport.","SEC31A Gene | SEC31 Homolog A, COPII Coat Complex Component Gene | SEC31A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540556","SEC31A wt Allele","C101476","Human SEC31A wild-type allele is located in the vicinity of 4q21.3 and is approximately 83 kb in length. This allele, which encodes protein transport protein Sec31A, is involved in protein trafficking.","SEC31A wt Allele | ABP125 | ABP130 | HPBKS | HSPC275 | HSPC334 | KIAA0905 | NEDSOSB | SEC31 Homolog A (S. cerevisiae) wt Allele | SEC31 Homolog A, COPII Coat Complex Component wt Allele | SEC31 Homolog A, COPII Coating Complex Component Gene | SEC31-Like 1 (S. cerevisiae) Gene | SEC31L1 | Yeast Sec31p Homolog Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541855","Protein Transport Protein Sec31A","C101477","Protein transport protein Sec31A (1220 aa, ~133 kDa) is encoded by the human SEC31A gene. This protein plays a role in the mediation of protein transport between the endoplasmic reticulum and the Golgi apparatus.","Protein Transport Protein Sec31A | ABP125 | ABP130 | SEC31-Like Protein 1 | SEC31-Related Protein A | SEC31A | Web1-Like Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419924","SEC22B Gene","C101478","This gene is involved in protein transport.","SEC22B Gene | SEC22 Vesicle Trafficking Protein Homolog B (S. cerevisiae) (gene/pseudogene) Gene | SEC22B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541272","SEC22B wt Allele","C101479","Human SEC22B wild-type allele is located in the vicinity of 1q21.1 and is approximately 21 kb in length. This allele, which encodes vesicle-trafficking protein SEC22b, plays a role in protein trafficking.","SEC22B wt Allele | ERS-24 | SEC22 Vesicle Trafficking Protein Homolog B (S. cerevisiae) (gene/pseudogene) wt Allele | SEC22L1 | sec22b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537287","Vesicle-Trafficking Protein SEC22b","C101480","Vesicle-trafficking protein SEC22b (215 aa, ~25 kDa) is encoded by the human SEC22B gene. This protein is involved in anterograde transport.","Vesicle-Trafficking Protein SEC22b | ER-Golgi SNARE of 24 kDa | ERS-24 | ERS24 | SEC22 | SEC22 Vesicle-Trafficking Protein-Like 1 | Vesicle-Trafficking Protein Homolog B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1846414","GABBR2 Gene","C101481","This gene plays a role in signaling.","GABBR2 Gene | GABBR2 | Gamma-Aminobutyric Acid (GABA) B Receptor, 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539627","GABBR2 wt Allele","C101482","Human GABBR2 wild-type allele is located within 9q22.1-q22.3 and is approximately 421 kb in length. This allele, which encodes gamma-aminobutyric acid type B receptor subunit 2 protein, is involved in gamma-aminobutyric acid-mediated signaling.","GABBR2 wt Allele | GABABR2 | GPR51 | GPRC3B | Gamma-Aminobutyric Acid (GABA) B Receptor, 2 wt Allele | HG20 | HRIHFB2099",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538681","Gamma-Aminobutyric Acid Type B Receptor Subunit 2, Human","C101483","Gamma-aminobutyric acid type B receptor subunit 2 (941 aa, ~106 kDa) is encoded by the human GABBR2 gene. This protein plays a role in the mediation of GABA-dependent signaling.","Gamma-Aminobutyric Acid Type B Receptor Subunit 2 | G-Protein Coupled Receptor 51 | GABA-B Receptor 2 | GABA-B-R2 | GABA-BR2 | GABABR2 | Gb2 | HG20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539626","LGR5 wt Allele","C101485","Human LGR5 wild-type allele is located within 12q22-q23 and is approximately 147 kb in length. This allele, which encodes leucine-rich repeat-containing G-protein coupled receptor 5 protein, is involved in signaling.","LGR5 wt Allele | FEX | GPR49 | GPR67 | GRP49 | HG38 | Leucine-Rich Repeat Containing G Protein-Coupled Receptor 5 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640115","Leucine-Rich Repeat-Containing G-Protein Coupled Receptor 5","C101486","Leucine-rich repeat-containing G-protein coupled receptor 5 (907 aa, ~100 kDa) is encoded by the human LGR5 gene. This protein plays a role in signal transduction.","Leucine-Rich Repeat-Containing G-Protein Coupled Receptor 5 | G Protein-Coupled Receptor 49 | G-Protein Coupled Receptor 49 | G-Protein Coupled Receptor 67 | G-Protein Coupled Receptor HG38 | LGR5 | Leucine-Rich Repeat-Containing G Protein-Coupled Receptor 5 | Orphan G Protein-Coupled Receptor HG38",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428908","NUP107 Gene","C101487","This gene is involved in the assembly of the nuclear pore complex.","NUP107 Gene | NUP107 | Nucleoporin 107kDa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2744539","Thrombomodulin, Human","C101380","Thrombomodulin (575 aa, ~60 kDa) is encoded by the human THBD gene. This protein plays a role in thrombin binding, fibrinolysis and coagulation.","Thrombomodulin | Antigen CD141 | BDCA-3 | CD141 | CD141 Antigen | Fetomodulin | TM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425233","NISCH Gene","C101381","This gene is involved in imidazoline binding and signaling.","NISCH Gene | NISCH | Nischarin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540559","NISCH wt Allele","C101382","Human NISCH wild-type allele is located in the vicinity of 3p21.1 and is approximately 38 kb in length. This allele, which encodes nischarin protein, plays a role in imidazoline-mediated signaling.","NISCH wt Allele | I-1 | IR1 | IRAS | KIAA0975 | Nischarin wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0915731","NISCH protein, human","C101383","Nischarin (1504 aa, ~167 kDa) is encoded by the human NISCH gene. This protein is involved in the regulation of signal transduction.","Nischarin | I-1 | I-1 Receptor Candidate Protein | I1R | I1R Candidate Protein | IR1 | Imidazoline Receptor 1 | Imidazoline Receptor Antisera-Selected Protein | Imidazoline-1 Receptor | Imidazoline-1 Receptor Candidate Protein | hIRAS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2351986","Delcasertib","C101384","No value exists.","Delcasertib | BMS-875944 | DELCASERTIB | KAI-9803",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823598","UNC45A Gene","C101385","This gene plays a role in the modulation of protein folding.","UNC45A Gene | UNC45A | Unc-45 Homolog A (C. elegans) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539610","UNC45A wt Allele","C101386","Human UNC45A wild-type allele is located in the vicinity of 15q26.1 and is approximately 24 kb in length. This allele, which encodes protein unc-45 homolog A, is involved in both cell differentiation and muscle development.","UNC45A wt Allele | FLJ10043 | GC-UNC45 | GCUNC-45 | GCUNC45 | IRO039700 | SMAP-1 | SMAP1 | Unc-45 Homolog A (C. elegans) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537368","Protein Unc-45 Homolog A, Human","C101387","Protein unc-45 homolog A (944 aa, ~103 kDa) is encoded by the human UNC45A gene. This protein plays a role as a chaperone for both progesterone receptor and myosin.","Protein Unc-45 Homolog A | GCUNC-45 | SMAP-1 | Smooth Muscle Cell-Associated Protein 1 | UNC45A | Unc-45A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1100850","Translationally-Controlled Tumor Protein, Human","C101391","Translationally-controlled tumor protein (172 aa, ~20 kDa) is encoded by the human TPT1 gene. This protein is involved in both calcium binding and microtubule polymerization.","Translationally-Controlled Tumor Protein | Fortilin | HRF | Histamine-Releasing Factor | TCTP | Translationally Controlled Tumor Protein | p23",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414463","ESRRA Gene","C101392","This gene plays a role in transcriptional regulation and DNA binding.","ESRRA Gene | ESRRA | Estrogen-Related Receptor Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540540","ESRRA wt Allele","C101393","Human ESRRA wild-type allele is located in the vicinity of 11q12 and is approximately 11 kb in length. This allele, which encodes steroid hormone receptor ERR1 protein, is involved in DNA binding and transcriptional activation.","ESRRA wt Allele | ERR1 | ERRa | ESRL1 | Estrogen-Related Receptor Alpha wt Allele | NR3B1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0388148","ERR1 protein","C101394","Steroid hormone receptor ERR1 (423 aa, ~46 kDa) is encoded by the human ESRRA gene. This protein plays a role in steroid-dependent transcriptional regulation.","Steroid Hormone Receptor ERR1 | ERR-Alpha | ESRRA | Estrogen Receptor-Like 1 | Estrogen-Related Receptor Alpha | NR3B1 | Nuclear Receptor Subfamily 3 Group B Member 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700596","CATSPERZ Gene","C101395","This gene is involved in sperm motility.","CATSPERZ Gene | CATSPERZ | Catsper Channel Auxiliary Subunit Zeta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542484","DKFZP566E164","C101396","Human CATSPERZ wild-type allele is located in the vicinity of 11q13.1 and is approximately 4 kb in length. This allele, which encodes cation channel sperm-associated protein subunit zeta, plays a role in sperm maturation.","CATSPERZ wt Allele | C11orf20 | Cation Channel, Sperm-Associated, Auxiliary Subunit Zeta Gene | Catsper Channel Auxiliary Subunit Zeta wt Allele | Chromosome 11 Open Reading Frame 20 Gene | DKFZP566E164 | TEX40 | Testis Expressed 40 Gene | Testis-Expressed Gene 40",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640111","Procedure_Uses_Manufactured_Object","C101462","A role used to assert that a procedure or technical method requires use of specific artifacts or pieces of equipment. The domain and range for this role are 'Activity' and 'Manufactured Object', respectively.","Procedure_Uses_Manufactured_Object | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823999","ZNF700 Gene","C101463","This gene plays a role in the regulation of transcription.","ZNF700 Gene | ZNF700 | Zinc Finger Protein 700 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542917","ZNF700 wt Allele","C101464","Human ZNF700 wild-type allele is located in the vicinity of 19p13.2 and is approximately 26 kb in length. This allele, which encodes zinc finger protein 700, is involved in transcriptional regulation.","ZNF700 wt Allele | DKFZp434I1610 | Zinc Finger Protein 700 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537288","Zinc Finger Protein 700","C101465","Zinc finger protein 700 (742 aa, ~86 kDa) is encoded by the human ZNF700 gene. This protein plays a role in transcriptional regulation.","Zinc Finger Protein 700 | ZNF700",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541907","GPBP1L1 wt Allele","C101467","Human GPBP1L1 wild-type allele is located in the vicinity of 1p34.1 and is approximately 61 kb in length. This allele, which encodes vasculin-like protein 1, may play a role in the regulation of transcription.","GPBP1L1 wt Allele | GC-Rich Promoter Binding Protein 1-Like 1 wt Allele | RP11-767N6.1 | SP192",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640112","Vasculin-Like Protein 1","C101468","Vasculin-like protein 1 (474 aa, ~52 kDa) is encoded by the human GPBP1L1 gene. This protein may be involved in the modulation of transcription.","Vasculin-Like Protein 1 | GC-Rich Promoter-Binding Protein 1-Like 1 | GPBP1L1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420568","TADA2A Gene","C101469","This gene plays a role in both histone acetylation and transcriptional regulation.","TADA2A Gene | TADA2A | Transcriptional Adaptor 2A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540524","TADA2A wt Allele","C101470","Human TADA2A wild-type allele is located within 17q12-q21 and is approximately 71 kb in length. This allele, which encodes transcriptional adapter 2-alpha protein, is involved in the modulation of both histone modification and transcription.","TADA2A wt Allele | ADA2 | ADA2A | KL04P | TADA2L | Transcriptional Adaptor 2A wt Allele | hADA2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0385910","TADA2A protein, human","C101471","Transcriptional adapter 2-alpha (443 aa, ~52 kDa) is encoded by the human TADA2A gene. This protein plays a role in the modulation of transcription by histone acetylation.","Transcriptional Adapter 2-Alpha | ADA2-Like Protein | TADA2A | Transcriptional Adapter 2-Like",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2239919","SEC16A Gene","C101472","This gene is involved in intracellular protein transport.","SEC16A Gene | SEC16 Homolog A (S. cerevisiae) Gene | SEC16A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1121065","Type-1 Angiotensin II Receptor-Associated Protein, Human","C101502","Type-1 angiotensin II receptor-associated protein (159 aa, ~17 kDa) is encoded by the human AGTRAP gene. This protein plays a role in the negative regulation of angiotensin receptor signaling.","Type-1 Angiotensin II Receptor-Associated Protein | AT1 Receptor-Associated Protein | ATI Receptor-Associated Protein | Angiotensin II, Type I Receptor-Associated Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541906","SSBP2 wt Allele","C101504","Human SSBP2 wild-type allele is located in the vicinity of 5q14.1 and is approximately 339 kb in length. This allele, which encodes single-stranded DNA-binding protein 2, may play a role in the stabilization of genomic DNA.","SSBP2 wt Allele | HSPC116 | SOSS-B2 | SSDP2 | Single-Stranded DNA Binding Protein 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537375","Single-Stranded DNA-Binding Protein 2, Human","C101505","Single-stranded DNA-binding protein 2 (361 aa, ~38 kDa) is encoded by the human SSBP2 gene. This protein may be involved in genome stability.","Single-Stranded DNA-Binding Protein 2 | SSBP2 | Sequence-Specific Single-Stranded-DNA-Binding Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3543431","TDG wt Allele","C101584","Human TDG wild-type allele is located in the vicinity of 12q24.1 and is approximately 23 kb in length. This allele, which encodes G/T mismatch-specific thymine DNA glycosylase protein, plays a role in DNA repair.","TDG wt Allele | CD3G | Thymine-DNA Glycosylase wt Allele | hTDG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0145822","Thymine DNA Glycosylase","C101585","G/T mismatch-specific thymine DNA glycosylase (410 aa, ~46 kDa) is encoded by the human TDG gene. This protein is involved in DNA repair.","G/T Mismatch-Specific Thymine DNA Glycosylase | CD3G | EC 3.2.2.29 | TDG | Thymine-DNA Glycosylase | hTDG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538738","ERIS","C101587","Human STING1 wild-type allele is located in the vicinity of 5q31.2 and is approximately 7 kb in length. This allele, which encodes stimulator of interferon genes protein, is involved in both signaling and immunity. Mutation of the gene is associated with infantile-onset STING-associated vasculopathy.","STING1 wt Allele | ERIS | FLJ38577 | MITA | MPYS | NET23 | SAVI | STING | Stimulator of Interferon Response cGAMP Interactor 1 wt Allele | TMEM173 | Transmembrane Protein 173 Gene | hMITA | hSTING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539068","transmembrane protein 173, human","C101588","Stimulator of interferon genes protein (379 aa, ~42 kDa) is encoded by the human STING1 gene. This protein plays a role in the modulation of both innate immune responses and signal transduction.","Stimulator of Interferon Genes Protein | ERIS | Endoplasmic Reticulum IFN Stimulator | Endoplasmic Reticulum Interferon Stimulator | Mediator of IRF3 Activation | Mitochondrial Mediator of IRF3 Activation | N-Terminal Methionine-Proline-Tyrosine-Serine Plasma Membrane Tetraspanner | STING | STING1 | Stimulator of Interferon Genes | Stimulator of Interferon Protein | TMEM173 | Transmembrane Protein 173 | hMITA | hSTING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415672","HOXB9 Gene","C101590","This gene is involved in both embryonic development and transcriptional regulation.","HOXB9 Gene | HOXB9 | Homeobox B9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541286","HOXB9 wt Allele","C101591","Human HOXB9 wild-type allele is located in the vicinity of 17q21.3 and is approximately 5 kb in length. This allele, which encodes homeobox protein Hox-B9, plays a role in pattern formation.","HOXB9 wt Allele | HOX-2.5 | HOX2 | HOX2E | Homeo Box B9 Gene | Homeobox B9 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640146","Homeobox Protein Hox-B9","C101592","Homeobox protein Hox-B9 (250 aa, ~28 kDa) is encoded by the human HOXB9 gene. This protein is involved in transcriptional regulation during embryonic development.","Homeobox Protein Hox-B9 | Homeobox Protein Hox-2.5 | Homeobox Protein Hox-2E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427808","DEPTOR Gene","C101593","This gene plays a role in mTOR-mediated signaling.","DEPTOR Gene | DEP Domain Containing MTOR-Interacting Protein Gene | DEPTOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540549","DEPTOR wt Allele","C101594","Human DEPTOR wild-type allele is located in the vicinity of 8q24.12 and is approximately 177 kb in length. This allele, which encodes DEP domain-containing mTOR-interacting protein, is involved in the modulation of the mTOR signaling pathway.","DEPTOR wt Allele | DEP Domain Containing 6 Gene | DEP Domain Containing MTOR-Interacting Protein wt Allele | DEP.6 | DEPDC6 | DKFZp564B1778 | FLJ12341 | FLJ12428 | FLJ13854",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435775","Tocotrienol-rich Fraction","C101518","An orally available nutritional supplement containing high amounts of the vitamin E family member tocotrienol with antioxidant, hypolipidemic and potential immunomodulating and antiproliferative activity. Upon oral administration, tocotrienol-rich fraction (TRF) accumulates in tumor cells and induces cell cycle arrest, programmed cell death, and inhibits tumor cell proliferation. In addition, this agent suppresses 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase activity and inhibits angiogenesis. Rice bran oil, palm oil and annatto seed oil are common sources of TRF.","Tocotrienol-rich Fraction | TRF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640124","FMS inhibitor JNJ-40346527","C101519","A small molecule and orally available inhibitor of colony-stimulating factor-1 receptor (CSF1R; FMS) with potential antineoplastic activity. Edicotinib blocks the receptor-ligand interaction between FMS and its ligand CSF1, thereby preventing autophosphorylation of FMS. As a result, unphosphorylated FMS can not activate FMS-mediated signaling pathways, thus potentially inhibiting cell proliferation in FMS-overexpressed tumor cells. FMS, a tyrosine kinase receptor, is overexpressed in certain tumor cell types and plays an essential role in macrophage differentiation, recruitment, and activation as well as the regulation of cell proliferation.","Edicotinib | 1H-Imidazole-2-carboxamide, 5-Cyano-N-(2-(4,4-dimethyl-1-cyclohexen-1-yl)-6-(tetrahydro-2,2,6,6-tetramethyl-2H-pyran-4-yl)-3-pyridinyl)- | 4-Cyano-1H-imidazole-2-carboxylic acid N-(2-(4,4-dimethylcyclohex-1-enyl)-6-(2,2,6,6-tetramethyltetrahydropyran-4-yl)pyridin-3-yl)amide | 4-Cyano-N-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyl-tetrahydro-2H-pyran-4-yl)pyridin-3-yl)-1H-imidazole-2-carboxamide | EDICOTINIB | JNJ-40346527",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435778","Anti-DLL4 Monoclonal Antibody MEDI0639","C101521","An immunoglobulin G1 lambda monoclonal antibody directed against the Notch ligand delta-like 4 (DLL4) with potential antineoplastic activity. Anti-DLL4 monoclonal antibody MEDI0639 specifically binds to DLL4 and prevents its interaction with Notch receptors, thereby inhibiting Notch-mediated signaling and gene transcription, which may block tumor angiogenesis and eventually the inhibition of tumor cell growth. Activation of Notch receptors by DLL4 stimulates proteolytic cleavage of the Notch intracellular domain (NICD); after cleavage, NICD is translocated to the nucleus and mediates the transcriptional regulation of a variety of genes involved in vascular development. The expression of DLL4 is highly restricted to the vascular endothelium; DLL4/Notch signaling is required for the development of functional tumor blood vessels.","Anti-DLL4 Monoclonal Antibody MEDI0639 | MEDI-0639 | MEDI0639",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435779","Indium In 111 Anti-CD45 Monoclonal Antibody BC8","C101522","A radioimmunoconjugate containing the murine IgG1 anti-CD45 monoclonal antibody (MoAb) BC8 labeled with the gamma-emitting isotope indium 111 (In 111), with potential radioimaging application. Upon administration, indium In 111 anti-CD45 monoclonal antibody BC8 binds to CD45 antigen, a receptor protein tyrosine phosphatase expressed on the surface of most of the normal and malignant hematopoietic cells. After binding and internalization by CD45-expressing tumor cells, radioactive In 111 allows for the detection of BC8 distribution and tumor localization using gamma scintigraphy.","Indium In 111 Anti-CD45 Monoclonal Antibody BC8 | In 111 MOAB BC8 | In 111 Monoclonal Antibody BC8 | Indium In 111 Monoclonal Antibody BC8 | monoclonal antibody BC8, indium In 111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435780","Hypoxia-activated Prodrug TH-4000","C101523","A proprietary, hypoxia-activated prodrug with potential antineoplastic activity. Upon administration, the hypoxia-activated prodrug TH-4000 is activated in the hypoxic cells within tumors into an irreversible pan-HER inhibitor via a mechanism of action not yet fully elucidated. As a result, this agent inhibits cellular proliferation and differentiation of tumor cells overexpressing HER kinases, which belong to the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. Healthy, normal tissues may be spared due to the hypoxia-specific activity of this agent, potentially reducing systemic toxicity.","Hypoxia-activated Prodrug TH-4000 | Hypoxin | PR610 | TH-4000",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435781","anti-GCC antibody-drug conjugate MLN0264","C101524","An antibody-drug conjugate (ADC) containing a monoclonal antibody directed against guanylyl cyclase C (GCC or GUCY2C) conjugated to monomethylauristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity. The monoclonal antibody moiety of indusatumab vedotin selectively binds to GCC, a transmembrane receptor normally found on intestinal cells and dopamine neurons in the brain, but is also overexpressed on the surface of gastrointestinal cancers. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis in GCC-expressing tumor cells.","Indusatumab Vedotin | INDUSATUMAB VEDOTIN | MLN0264",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435782","TRPV6 Calcium Channel Inhibitor SOR-C13","C101525","An inhibitor of transient receptor potential cation channel vanilloid family member 6 (TRPV6, CaT1 or CATL) with potential antineoplastic activity. TRPV6 calcium channel inhibitor SOR-C13 binds to TRPV6 and prevents the influx of calcium ions into TRPV6-expressing tumor cells. This inhibits the activation of nuclear factor of activated T-cell (NFAT) transcription complex which may result in an inhibition of calcium-dependent cancer cell proliferation and an induction of apoptosis in tumor cells overexpressing TRPV6. The TRPV6 ion channel plays a key role in calcium homeostasis and is highly selective for calcium compared to other cations; it is overexpressed in a variety of tumors and initiates tumor cell growth, proliferation and metastases.","TRPV6 Calcium Channel Inhibitor SOR-C13 | SOR-C13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1563055","Interphalangeal Joint","C101527","Hinge joints between the phalanges of the hand or foot.","Interphalangeal Joint | ",,,,,,,,,,,,,,,"4211925","Interphalangeal joint structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0932508","Proximal Interphalangeal Joint","C101528","Interphalangeal joint located between the first and second phalanges.","Proximal Interphalangeal Joint | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0932510","Distal Interphalangeal Joint","C101529","Interphalangeal joint located between the second and third phalanges.","Distal Interphalangeal Joint | ",,,,,,,,,,,,,,,"37110887","Structure of distal interphalangeal joint",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL435783","Folate Binding Protein E39 Peptide Vaccine","C101530","A cancer vaccine comprised of human leukocyte antigen (HLA) A2 restricted folate binding protein (FBP) epitope E39 (amino acids 191 to 199), with potential immunostimulatory and antineoplastic activity. Upon intradermal injection, FBP E39 peptide vaccine may induce a specific cytotoxic T-lymphocyte (CTL) response against FBP-expressing tumor cell types. FBP is a membrane-bound, tumor-associated antigen highly overexpressed in various tumor cell types, such as in breast, ovarian and endometrial cancers; E 39 is a strong immunogenic peptide.","Folate Binding Protein E39 Peptide Vaccine | E39 Peptide Vaccine | FBP E39 Peptide Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435784","MEK Inhibitor WX-554","C101532","An orally available small molecule mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK) inhibitor, with potential antineoplastic activity. MEK inhibitor WX-554 selectively binds to and inhibits the activity of MEK, thereby preventing the activation of MEK-dependent effector proteins including some transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a dual-specificity threonine/tyrosine kinase that plays a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway, is frequently upregulated in a variety of tumor cell types.","MEK Inhibitor WX-554 | WX-554",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640134","Unapproved Drug for Use in Drug Shortage","C101533","A category of drug products that are not officially approved by the responsible agency. Drugs in this category have been processed according to standards set forth by the approving agency, and can be considered potential substitutes when the approved medication is unavailable.","Unapproved Drug for Use in Drug Shortage | UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1530416","Cicletanine Hydrochloride","C101534","The hydrochloride salt of a dihydropyridine derivative with diuretic and antihypertensive activity. Cicletanine exerts thiazide-like diuretic activity. In addition, this agent inhibits protein kinase C (PKC) and is able to reverse vasoconstriction through the inhibition of PKC-mediated inhibition of Na/K-ATPase phosphorylation.","Cicletanine Hydrochloride | CICLETANINE HYDROCHLORIDE | Furo(3,4-c)pyridin-7-ol, 3-(4-chlorophenyl)-1,3-dihydro-6-methyl-, Hydrochloride | WIN-90000 HCl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0952503","Ketobemidone Hydrochloride","C101535","No value exists.","Ketobemidone Hydrochloride | 1-(4-(3-hydroxyphenyl)-1-methyl-4-piperidinyl)-1-propanone Hydrochloride | Cymidon | Hoechst 10720 | KETOBEMIDONE HYDROCHLORIDE | Ketodur | WIN-1539",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539509","FCHSD1 Gene","C101506","This gene may be involved in signal transduction.","FCHSD1 Gene | FCH and Double SH3 Domains 1 Gene | FCHSD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540543","FCHSD1 wt Allele","C101507","Human FCHSD1 wild-type allele is located in the vicinity of 5q31.3 and is approximately 12 kb in length. This allele, which encodes F-BAR and double SH3 domains protein 1, may play a role in signaling.","FCHSD1 wt Allele | FCH and Double SH3 Domains 1 wt Allele | FLJ00007 | NWK2 | Nervous Wreck Homolog 2 Gene | Nervous Wreck, Drosophila, Homolog of, 2 Gene | UNQ737/PRO1431",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1531225","F-BAR and Double SH3 Domains Protein 1, Human","C101508","F-BAR and double SH3 domains protein 1 (690 aa, ~77 kDa) is encoded by the human FCHSD1 gene. This protein may be involved in signaling.","F-BAR and Double SH3 Domains Protein 1 | FCH and Double SH3 Domains Protein 1 | FCHSD1 | NWK2 | Protein Nervous Wreck 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640118","API/FDF Analytical Testing Site","C101509","Sites that perform testing of the characteristics and attributes of active pharmaceutical ingredients or finished dosage forms.","API/FDF Analytical Testing Site | API/FDF ANALYTICAL TESTING | API/FDF Analytical Testing | Active Pharmaceutical Ingredient / Finished Dosage Form Analytical Testing Site | Analytical Testing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640119","FDF Manufacture","C101510","The act of making a product as ready to be utilized or consumed by the end user.","FDF Manufacture | FDF MANUFACTURE | Finished Dosage Form Manufacture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640120","Clinical Bioequivalence or Bioavailability Study","C101511","All the activities included in the process of conducting clinical bioequivalence or bioavailability studies.","Clinical Bioequivalence or Bioavailability Study | CLINICAL BIOEQUIVALENCE OR BIOAVALABILITY STUDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640121","In Vitro Bioequivalence or Bioanalytical Testing","C101512","Bioequivalence or bioanalytical testing performed in vitro.","In Vitro Bioequivalence or Bioanalytical Testing | IN VITRO BIOEQUIVALENCE OR BIOANALYTICAL TESTING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640122","Glucurolactone","C101515","No value exists.","Glucurolactone | GLUCUROLACTONE | Gamma-lactone of D-Glucofuranuronic Acid | Guronsan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435774","Gamma-delta Tocotrienol","C101517","An orally available nutritional supplement containing the gamma and delta forms of the vitamin E family member tocotrienol, with hypocholesterolemic, antithrombotic, antioxidant, and potential antineoplastic activity. Upon oral administration, gamma-delta tocotrienol accumulates in cancer cells and may exert their anti-cancer activity in part through 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase downregulation and/or degradation, cell cycle arrest, and induction of caspase-mediated apoptosis. In addition, this agent may inhibit angiogenesis partially through the blockage of vascular endothelial growth factor receptor (VEGFR) and the inhibition of tumor cell-induced vessel formation. Altogether, this may result in the inhibition of tumor cell growth. Further, this agent prevents free radical formation and inhibits lipid peroxidation. Tocotrienols contain 3 double bonds, absent in tocopherols, on its farnesyl isoprenoid side chain that likely contribute to its anti-cancer activities.","Gamma-delta Tocotrienol | GDT | gdT3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538717","FOXM1 wt Allele","C101581","Human FOXM1 wild-type allele is located in the vicinity of 12p13 and is approximately 19 kb in length. This allele, which encodes forkhead box protein M1, plays a role in the modulation of the expression of genes involved in DNA replication. Aberrant expression of the gene is associated with a large number of neoplastic diseases.","FOXM1 wt Allele | FKHL16 | FOXM1B | Forkhead Box M1 wt Allele | HFH-11 | HFH11 | HNF-3 | INS-1 | MPHOSPH2 | MPP-2 | MPP2 | PIG29 | TGT3 | TRIDENT | Trident Gene | WIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539737","Forkhead Box Protein M1","C101582","Forkhead box protein M1 (763 aa, ~84 kDa) is encoded by the human FOXM1 gene. This protein is involved in the regulation of both mitosis and transcription.","Forkhead Box Protein M1 | FOXM1 | Forkhead Box M1B Transcription Factor | Forkhead, Drosophila, Homolog-Like 16 | Forkhead-Related Protein FKHL16 | HFH-11 | HNF-3/Fork-Head Homolog 11 | Hepatocyte Nuclear Factor 3 Forkhead Homolog 11 | M-Phase Phosphoprotein 2 | MPM-2 Reactive Phosphoprotein 2 | Transcription Factor Trident | Trident | Winged-Helix Factor From INS-1 Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420022","SH3BP2 Gene","C101437","This gene plays a role in signal transduction.","SH3BP2 Gene | SH3 Domain Binding Protein 2 Gene | SH3-Domain Binding Protein 2 Gene | SH3BP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539607","SH3BP2 wt Allele","C101438","Human SH3BP2 wild-type allele is located 4p16.3 and is approximately 48 kb in length. This allele, which encodes SH3 domain-binding protein 2, is involved in the modulation of signaling. Mutation of the gene is associated with cherubism.","SH3BP2 wt Allele | 3BP-2 | 3BP2 | CRBM | CRPM | Cherubism Gene | FLJ42079 | FLJ54978 | RES4-23 | SH3 Domain Binding Protein 2 wt Allele | SH3-Domain Binding Protein 2 Gene | SH3-Domain Binding Protein 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537390","SH3 Domain-Binding Protein 2, Human","C101439","SH3 domain-binding protein 2 (561 aa, ~62 kDa) is encoded by the human SH3BP2 gene. This protein plays a role in intracellular signaling.","SH3 Domain-Binding Protein 2 | 3BP-2 | Abl-SH3 Binding Protein 2 | TNFAIP3 Interacting Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540555","CAMTA1 wt Allele","C101441","Human CAMTA1 wild-type allele is located within 1p36.31-p36.23 and is approximately 984 kb in length. This allele, which encodes calmodulin-binding transcription activator 1 protein, plays a role in transcriptional regulation. A chromosomal translocation involving this gene and the WWTR gene may be associated with epithelioid hemangioendothelioma.","CAMTA1 wt Allele | CANPMR | Calmodulin Binding Transcription Activator 1 wt Allele | KIAA0833 | MSTP023 | RP3-467L1.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537303","Calmodulin-binding transcription activator 1","C101442","Calmodulin-binding transcription activator 1 (1673 aa, ~184 kDa) is encoded by the human CAMTA1 gene. This protein is involved in the modulation of gene transcription.","Calmodulin-Binding Transcription Activator 1 | CAMTA1 | Calmodulin Binding Transcription Activator 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540522","H3.3A","C101444","Human H3-3A wild-type allele is located in the vicinity of 1q42.12 and is approximately 10 kb in length. This allele, which encodes histone H3.3 protein, plays a role in both nucleosome assembly and transcriptional regulation.","H3-3A wt Allele | H3 Histone Family Member 3A Gene | H3.3 Histone A wt Allele | H3.3A | H3F3 | H3F3A | H3F3A wt Allele | LOC347376 | MGC87782 | MGC87783 | PP781 | RP11-396C23.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541290","LRIG3 wt Allele","C101447","Human LRIG3 wild-type allele is located in the vicinity of 12q14.1 and is approximately 48 kb in length. This allele, which encodes leucine-rich repeats and immunoglobulin-like domains protein 3, may play a role in signaling.","LRIG3 wt Allele | FLJ90440 | KIAA3016 | LIG3 | Leucine-Rich Repeats and Immunoglobulin-Like Domains 3 wt Allele | UNQ287/PRO326/PRO335",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640109","Leucine-Rich Repeats and Immunoglobulin-Like Domains Protein 3","C101448","Leucine-rich repeats and immunoglobulin-like domains protein 3 (1119 aa, ~123 kDa) is encoded by the human LRIG3 gene. This protein may be involved in signal transduction.","Leucine-Rich Repeats and Immunoglobulin-Like Domains Protein 3 | LIG-3 | LRIG3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538790","PHF6 wt Allele","C101450","Human PHF6 wild-type allele is located in the vicinity of Xq26.2 and is approximately 56 kb in length. This allele, which encodes PHD finger protein 6, is involved in the regulation of transcription. Mutation of the gene is associated with Borjeson-Forssman-Lehmann syndrome.","PHF6 wt Allele | BFLS | BORJ | Borjeson-Forssman-Lehmann Syndrome Gene | CENP-31 | Centromere Protein 31 Gene | KIAA1823 | MGC14797 | PHD Finger Protein 6 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539552","PHD Finger Protein 6","C101451","PHD finger protein 6 (365 aa, ~41 kDa) is encoded by the human PHF6 gene. This protein plays a role in transcriptional regulation.","PHD Finger Protein 6 | Centromere Protein 31 | PHD-Like Zinc Finger Protein | PHF6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542420","ECT2L wt Allele","C101453","Human ECT2L wild-type allele is located in the vicinity of 6q24.1 and is approximately 108 kb in length. This allele, which encodes epithelial cell-transforming sequence 2 oncogene-like protein, may play a role in the regulation of small GTPase-mediated signaling.","ECT2L wt Allele | ARHGEF32 | C6orf91 | Chromosome 6 Open Reading Frame 91 Gene | Epithelial Cell Transforming Sequence 2 Oncogene-Like wt Allele | F-Box Protein 49 Gene | FBXO49 | LFDH | RP3-509I19.3 | dJ509I19.2 | dJ509I19.3 | dJ509I19.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542418","Epithelial Cell-Transforming Sequence 2 Oncogene-Like","C101454","Epithelial cell-transforming sequence 2 oncogene-like (904 aa, ~105 kDa) is encoded by the human ECT2L gene. This protein may be involved in signal transduction.","Epithelial Cell-Transforming Sequence 2 Oncogene-Like | F-Box Protein 49 | Lung-Specific F-Box and DH Domain-Containing Protein | Putative Guanine Nucleotide Exchange Factor LFDH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537669","MAST1 Gene","C101455","This gene plays a role in cytoskeletal organization.","MAST1 Gene | MAST1 | Microtubule Associated Serine/Threonine Kinase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540558","MAST1 wt Allele","C101456","Human MAST1 wild-type allele is located in the vicinity of 19p13.2 and is approximately 37 kb in length. This allele, which encodes microtubule-associated serine/threonine-protein kinase 1 protein, is involved in both protein phosphorylation and cytoskeletal structure.","MAST1 wt Allele | KIAA0973 | Microtubule Associated Serine/Threonine Kinase 1 wt Allele | SAST | SAST170",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542416","EC 2.7.11.1","C101457","Microtubule-associated serine/threonine-protein kinase 1 (1570 aa, ~180 kDa) is encoded by the human MAST1 gene. This protein plays a role in serine/threonine phosphorylation of cytoskeletal proteins.","Microtubule-Associated Serine/Threonine-Protein Kinase 1 | EC 2.7.11.1 | MAST1 | Syntrophin-Associated Serine/Threonine-Protein Kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425969","MAST2 Gene","C101458","This gene is involved in serine/threonine phosphorylation.","MAST2 Gene | MAST2 | Microtubule Associated Serine/Threonine Kinase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540554","MAST2 wt Allele","C101459","Human MAST2 wild-type allele is located in the vicinity of 1p34.1 and is approximately 249 kb in length. This allele, which encodes microtubule-associated serine/threonine-protein kinase 2 protein, plays a role in the modulation of serine/threonine phosphorylation of cytoskeleton-associated proteins.","MAST2 wt Allele | FLJ39200 | KIAA0807 | MAST205 | MTSSK | Microtubule Associated Serine/Threonine Kinase 2 wt Allele | RP4-533D7.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1610407","Microtubule-Associated Serine/Threonine-Protein Kinase 2, Human","C101460","Microtubule-associated serine/threonine-protein kinase 2 (1798 aa, ~196 kDa) is encoded by the human MAST2 gene. This protein is involved in both cytoskeletal organization and protein phosphorylation.","Microtubule-Associated Serine/Threonine-Protein Kinase 2 | EC 2.7.11.1 | MAST2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640110","Procedure_Has_Target_Disease","C101461","A role used to assert that a procedure or technical method detects, diagnoses, or treats a specified disease state. The domain and range for this role are 'Activity' and 'Disease, Disorder or Finding', respectively.","Procedure_Has_Target_Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829358","Labeler Regulatory Contact for FDA","C101701","The representative of a labeler company who is the authorized channel for communication between the company and the FDA.","Labeler Regulatory Contact for FDA | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640190","Secondary Identifier","C101703","No value exists.","Secondary Identifier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539931","Third Party Submitter","C101710","An outside party delegated to submit regulatory information.","Third Party Regulatory Information Submitter | Third Party",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640197","To Be Marketed","C101711","Indicates that a product is intended to be promoted for use at a future time.","To Be Marketed | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541243","DEP Domain-Containing mTOR-Interacting Protein, Human","C101595","DEP domain-containing mTOR-interacting protein (409 aa, ~46 kDa) is encoded by the human DEPTOR gene. This protein plays a role in the regulation of mTOR signaling.","DEP Domain-Containing mTOR-Interacting Protein | DEP Domain-Containing Protein 6 | DEPTOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640147","Silent Myocardial Infarction by ECG Finding","C101598","An electrocardiographic finding that a myocardial infarction has occurred concurrently with the absence of clinical symptoms.","Silent Myocardial Infarction by ECG Finding | Silent Myocardial Infarction by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279993","cyclophosphamide/dacarbazine/dactinomycin/doxorubicin/vincristine","C10159","A regimen consisting of vincristine, actinomycin, cyclophosphamide, doxorubicin, and dacarbazine that may be used in the treatment of metastatic or unresectable pediatric soft tissue sarcomas.","VACAD Regimen | Actinomycin-D/Cyclophosphamide/Dacarbazine/Doxorubicin/Vincristine | CTX/DACT/DOX/DTIC/VCR | VACAD | Vincristine-Actinomycin-D-Cyclophosphamide-Doxorubicin-Dacarbazine | Vincristine/Actinomycin-D/Cyclophosphamide/Adriamycin/Dacarbazine | Vincristine/Actinomycin-D/Cyclophosphamide/Doxorubicin/Dacarbazine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0053355","Ubenimex","C1015","A microbial metabolite and dipeptide with potential immunomodulatory and antitumor activities. Ubenimex competitively inhibits many aminopeptidases, including B, N and leucine aminopeptidases. Aminopeptidases has been implicated in the process of cell adhesion and invasion of tumor cells. Therefore, inhibiting aminopeptidases may partially attribute to the antitumor effect of ubenimex. This agent also activates T lymphocyte, macrophage and bone marrow stem cell as well as stimulates release of interleukin-1 and -2, thus further enhances its antitumor activity.","Ubenimex | Bestatin | L-Leucine, N-(3-amino-2-hydroxy-1-oxo-4-phenylbutyl)-, [S-(R*,S*)]- | N-[(2S,3R)-4-phenyl-3-amino-2-hydroxybutyryl]-L-leucine | NK 421 | UBENIMEX | [(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]-L-leucine | [S-(R*,S*)]-N-(3-amino-2-hydroxy-1-oxo-4-phenylbutyl)-L-leucine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3543405","ATF5 wt Allele","C101600","Human ATF5 wild-type allele is located in the vicinity of 19q13.3 and is approximately 5 kb in length. This allele, which encodes cyclic AMP-dependent transcription factor ATF-5 protein, plays a role in the modulation of transcription.","ATF5 wt Allele | ATFX | Activating Transcription Factor 5 wt Allele | FLJ34666 | HMFN0395",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542400","Cyclic AMP-Dependent Transcription Factor ATF-5, Human","C101601","Cyclic AMP-dependent transcription factor ATF-5 (282 aa, ~30 kDa) is encoded by the human ATF5 gene. This protein is involved in the positive regulation of gene transcription.","Cyclic AMP-Dependent Transcription Factor ATF-5 | ATF5 | Activating Transcription Factor 5 | Transcription Factor ATFx | cAMP-Dependent Transcription Factor ATF-5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826843","RNH1 Gene","C101602","This gene plays a role in enzyme inhibition.","RNH1 Gene | RNH1 | Ribonuclease/Angiogenin Inhibitor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539762","RNH1 wt Allele","C101603","Human RNH1 wild-type allele is located in the vicinity of 11p15.5 and is approximately 13 kb in length. This allele, which encodes ribonuclease inhibitor protein, is involved in the negative regulation of ribonuclease activity.","RNH1 wt Allele | MGC18200 | MGC4569 | MGC54054 | PRI | RAI | RNH | Ribonuclease/Angiogenin Inhibitor 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539761","Ribonuclease Inhibitor","C101604","Ribonuclease inhibitor (461 aa, ~50 kDa) is encoded by the human RNH1 gene. This protein plays a role in the inhibition of ribonucleases.","Ribonuclease Inhibitor | PRI | Placental RNase Inhibitor | Placental Ribonuclease Inhibitor | RAI | Ribonuclease/Angiogenin Inhibitor 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435947","Fascin","C101607","Fascin (493 aa, ~55 kDa) is encoded by the human FSCN1 gene. This protein is involved in the formation of actin filaments.","Fascin | 55 kDa Actin-Bundling Protein | FSCN1 | Singed-Like Protein | p55",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824983","DTL Gene","C101608","This gene plays a role in protein ubiquitination.","DTL Gene | DTL | Denticleless E3 Ubiquitin Protein Ligase Homolog (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538817","DTL wt Allele","C101609","Human DTL wild-type allele is located in the vicinity of 1q32 and is approximately 72 kb in length. This allele, which encodes denticleless protein homolog, is involved in the modulation of ubiquitination.","DTL wt Allele | CDT2 | CDW1 | DCAF2 | Denticleless E3 Ubiquitin Protein Ligase Homolog (Drosophila) wt Allele | L2DTL | RAMP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540508","Denticleless Protein Homolog","C101610","Denticleless protein homolog (730 aa, ~79 kDa) is encoded by the human DTL gene. This protein plays a role in the regulation of E3 ubiquitin ligase activity.","Denticleless Protein Homolog | DDB1- and CUL4-Associated Factor 2 | Lethal(2) Denticleless Protein Homolog | Retinoic Acid-Regulated Nuclear Matrix-Associated Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1822714","SHARPIN Gene","C101611","This gene is involved in polyubiquitination.","SHARPIN Gene | SHANK-Associated RH Domain Interactor Gene | SHARPIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539782","SHARPIN wt Allele","C101612","Human SHARPIN wild-type allele is located in the vicinity of 8q24.3 and is approximately 9 kb in length. This allele, which encodes sharpin protein, plays a role in ubiquitin polymerization.","SHARPIN wt Allele | DKFZp434N1923 | PSEC0216 | SHANK-Associated RH Domain Interactor wt Allele | SIPL1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3502026","SHARPIN protein, human","C101613","Sharpin (387 aa, ~40 kDa) is encoded by the human SHARPIN gene. This protein is involved in the formation of linear polyubiquitin chains.","Sharpin | Shank-Associated RH Domain-Interacting Protein | Shank-Interacting Protein-Like 1 | hSIPL1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539671","AKT1S1 wt Allele","C101615","Human AKT1S1 wild-type allele is located in the vicinity of 19q13.33 and is approximately 9 kb in length. This allele, which encodes proline-rich AKT1 substrate 1 protein, is involved in the mTOR signaling pathway.","AKT1S1 wt Allele | AKT1 Substrate 1 (Proline-Rich) Gene | AKT1 Substrate 1 (Proline-Rich) wt Allele | AKT1 Substrate 1 wt Allele | AKT1 Substrate 1, Proline-Rich Gene | Lobe | MGC2865 | PRAS40 | Proline-Rich Akt Substrate, 40 kDa Gene | Proline-Rich Akt Substrate, 40-kD Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1450880","AKT1S1 protein, human","C101616","Proline-rich AKT1 substrate 1 (256 aa, ~27 kDa) is encoded by the human AKT1S1 gene. This protein plays a role in mTOR-dependent signaling.","Proline-Rich AKT1 Substrate 1 | 40 kDa Proline-Rich AKT Substrate | AKT1S1 | PRAS40",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538750","ZMYM3 wt Allele","C101618","Human ZMYM3 wild-type allele is located in the vicinity of Xq13.1 and is approximately 16 kb in length. This allele, which encodes zinc finger MYM-type protein 3, plays a role in the regulation of chromatin remodeling, cell morphology and cytoskeletal organization. A chromosomal translocation (X;13) involving this gene is associated with X-linked mental retardation.","ZMYM3 wt Allele | DXS6673E | KIAA0385 | MYM | XFIM | ZNF198L2 | ZNF261 | Zinc Finger, MYM-Type 3 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826724","PRRT2 Gene","C101620","This gene may play a role in brain and spine development.","PRRT2 Gene | PRRT2 | Proline-Rich Transmembrane Protein 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539645","PRRT2 wt Allele","C101621","Human PRRT2 wild-type allele is located in the vicinity of 16p11.2 and is approximately 4 kb in length. This allele, which encodes proline-rich transmembrane protein 2, may be involved in the development of the brain and spinal cord. Mutation of the gene is associated with both episodic kinesigenic dyskinesia-1 and infantile convulsion and choreoathetosis syndrome.","PRRT2 wt Allele | DKFZp547J199 | DYT10 | EKD1 | FLJ25513 | IFITMD1 | Interferon Induced Transmembrane Protein Domain Containing 1 Gene | PKC | Proline-Rich Transmembrane Protein 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3252543","PRRT2 protein, human","C101622","Proline-rich transmembrane protein 2 (340 aa, ~35 kDa) is encoded by the human PRRT2 gene. This protein may play a role in central nervous system development.","Proline-Rich Transmembrane Protein 2 | DSPB3 | Dispanin Subfamily B Member 3 | Interferon Induced Transmembrane Protein Domain Containing 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0117901","Flumedroxone Acetate","C101536","No value exists.","Flumedroxone Acetate | 6alpha-trifluoromethyl-17alpha-acetoxyprogesterone | FLUMEDROXONE ACETATE | WG-537",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640139","Spinosad Factor A","C101537","No value exists.","Spinosad Factor A | SPINOSAD FACTOR A | Spinosyns",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2975231","BET inhibitor GSK525762","C101538","A small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins with potential antineoplastic activity. Upon administration, molibresib binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histone peptides. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomain at the N-terminus, BET proteins, comprising of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.","Molibresib | GSK-525762A | GSK525762 | I-BET 762 | MOLIBRESIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412925","EGLN1 Gene","C101543","This gene plays a role in both protein modification and oxygen homeostasis.","EGLN1 Gene | EGLN1 | Egl Nine Homolog 1 (C. elegans) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540628","EGLN1 wt Allele","C101544","Human EGLN1 wild-type allele is located in the vicinity of 1q42.1 and is approximately 61 kb in length. This allele, which encodes egl nine homolog 1 protein, is involved in the response to hypoxia. Mutation of the gene is associated with familial erythrocytosis type 3.","EGLN1 wt Allele | C1orf12 | DKFZp761F179 | ECYT3 | Egl Nine Homolog 1 (C. elegans) wt Allele | HIF Prolyl Hydroxylase 2 Gene | HIF-PH2 | HIFPH2 | HPH-2 | HPH2 | PHD2 | PNAS-118 | PNAS-137 | SM-20 | SM20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540623","Egl Nine Homolog 1, Human","C101545","Egl nine homolog 1 (426 aa, ~46 kDa) is encoded by the human EGLN1 gene. This protein plays a role in the modification of hypoxia-inducible factor alpha proteins in response to hypoxic conditions.","Egl Nine Homolog 1 | EC 1.14.11.29 | EGLN1 | HIF-PH2 | HIF-Prolyl Hydroxylase 2 | HPH-2 | Hypoxia-Inducible Factor Prolyl Hydroxylase 2 | PHD2 | Prolyl Hydroxylase Domain-Containing Protein 2 | SM-20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539656","TYK2 wt Allele","C101547","Human TYK2 wild-type allele is located in the vicinity of 19p13.2 and is approximately 30 kb in length. This allele, which encodes non-receptor tyrosine-protein kinase TYK2 protein, plays a role in the mediation of both type I interferon signaling and tyrosine phosphorylation.","TYK2 wt Allele | IMD35 | JTK1 | Tyrosine Kinase 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1448662","Non-Receptor Tyrosine-Protein Kinase TYK2, Human","C101548","Non-receptor tyrosine-protein kinase TYK2 (1187 aa, ~134 kDa) is encoded by the human TYK2 gene. This protein is involved in both tyrosine phosphorylation and signal transduction.","Non-Receptor Tyrosine-Protein Kinase TYK2 | EC 2.7.10.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418223","P4HA2 Gene","C101549","This gene is involved in collagen metabolism.","P4HA2 Gene | P4HA2 | Prolyl 4-Hydroxylase, Alpha Polypeptide II Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542975","P4HA2 wt Allele","C101550","Human P4HA2 wild-type allele is located in the vicinity of 5q31 and is approximately 103 kb in length. This allele, which encodes prolyl 4-hydroxylase subunit alpha-2 protein, plays a role in procollagen processing.","P4HA2 wt Allele | 4-PH Alpha 2 Gene | C-P4Halpha(II) Gene | Collagen Prolyl 4-Hydroxylase Alpha(II)Gene | Prolyl 4-Hydroxylase, Alpha Polypeptide II wt Allele | UNQ290/PRO330",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542409","Prolyl 4-Hydroxylase Subunit Alpha-2","C101551","Prolyl 4-hydroxylase subunit alpha-2 (535 aa, ~62 kDa) is encoded by the human P4HA2 gene. This protein is involved in collagen maturation.","Prolyl 4-Hydroxylase Subunit Alpha-2 | 4-PH Alpha-2 | C-P4H Alpha(II) | Collagen Prolyl 4-Hydroxylase Alpha(II) | EC 1.14.11.2 | P4HA2 | Procollagen-Proline, 2-Oxoglutarate 4-Dioxygenase, Alpha Polypeptide II | Procollagen-Proline,2-Oxoglutarate-4-Dioxygenase Subunit Alpha-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417511","MX2 Gene","C101552","This gene plays a role in GTP hydrolysis.","MX2 Gene | MX2 | Myxovirus (Influenza Virus) Resistance 2 (Mouse) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540578","MX2 wt Allele","C101553","Human MX2 wild-type allele is located in the vicinity of 21q22.3 and is approximately 46 kb in length. This allele, which encodes interferon-induced GTP-binding protein Mx2, is involved in both binding and hydrolysis of GTP.","MX2 wt Allele | MXB | Myxovirus (Influenza Virus) Resistance 2 (Mouse) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537352","Interferon-Induced GTP-Binding Protein Mx2, Human","C101554","Interferon-induced GTP-binding protein Mx2 (715 aa, ~82 kDa) is encoded by the human MX2 gene. This protein plays a role in both GTP binding and hydrolysis.","Interferon-Induced GTP-Binding Protein Mx2 | Interferon-Regulated Resistance GTP-Binding Protein MxB | MX2 | Myxovirus Resistance Protein 2 | Second Interferon-Induced Protein p78 | p78-Related Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423495","LGALS13 Gene","C101555","This gene is involved in lipid metabolism.","LGALS13 Gene | LGALS13 | Lectin, Galactoside-Binding, Soluble, 13 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538844","LGALS13 wt Allele","C101556","Human LGALS13 wild-type allele is located in the vicinity of 19q13.1 and is approximately 5 kb in length. This allele, which encodes galactoside-binding soluble lectin 13 protein, plays a role in phospholipid metabolism.","LGALS13 wt Allele | GAL13 | Galectin 13 Gene | Lectin, Galactoside-Binding, Soluble, 13 wt Allele | PLAC8 | PP13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0607430","Galactose Binding Lectin","C101557","Galactoside-binding soluble lectin 13 (139 aa, ~16 kDa) is encoded by the human LGALS13 gene. This protein is involved in lysophospholipase activity.","Galactoside-Binding Soluble Lectin 13 | Beta-Galactoside-Binding Lectin | EC 3.1.1.5 | Gal-13 | Galectin-13 | LGALS13 | PP13 | Placental Protein 13 | Placental Tissue Protein 13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538853","SGK1 wt Allele","C101560","Human SGK1 wild-type allele is located in the vicinity of 6q23 and is approximately 149 kb in length. This allele, which encodes serine/threonine-protein kinase Sgk1 protein, is involved in the modulation of both protein phosphorylation and signaling. Aberrant expression of the gene may be associated with hypertension and diabetic nephropathy.","SGK1 wt Allele | RP1-188K17.1 | SGK | Serum/Glucocorticoid Regulated Kinase 1 wt Allele | Serum/Glucocorticoid Regulated Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1528301","Serine/Threonine-Protein Kinase Sgk1, Human","C101561","Serine/threonine-protein kinase Sgk1 (431 aa, ~49 kDa) is encoded by the human SGK1 gene. This protein plays a role in both signaling in response to cellular stress and serine/threonine phosphorylation.","Serine/Threonine-Protein Kinase Sgk1 | EC 2.7.11.1 | Serine/Threonine-Protein Kinase Sgk | Serum/Glucocorticoid-Regulated Kinase 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539783","SIRT2 wt Allele","C101563","Human SIRT2 wild-type allele is located in the vicinity of 19q13 and is approximately 21 kb in length. This allele, which encodes NAD-dependent deacetylase sirtuin-2 protein, is involved in the regulation of protein acetylation.","SIRT2 wt Allele | FLJ35621 | FLJ37491 | SIR2 | SIR2L | SIR2L2 | Sirtuin (Silent Mating Type Information Regulation 2 Homolog) 2 (S. cerevisiae) Gene | Sirtuin 2 wt Allele | Sirtuin Type 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539589","SIRT2 protein, human","C101564","NAD-dependent deacetylase sirtuin-2 (389 aa, ~43 kDa) is encoded by the human SIRT2 gene. This protein plays a role in the deacetylation of tubulin.","NAD-Dependent Deacetylase Sirtuin-2 | EC 3.5.1.- | SIR2-Like Protein 2 | SIRT2 | Silent Information Regulator 2 | Sir2-Related Protein Type 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538709","DDX3X wt Allele","C101566","Human DDX3X wild-type allele is located within Xp11.3-p11.23 and is approximately 31 kb in length. This allele, which encodes ATP-dependent RNA helicase DDX3X protein, plays a role in the modulation of RNA structure.","DDX3X wt Allele | CAP-Rf | DBX | DDX14 | DDX3 | DEAD (Asp-Glu-Ala-Asp) Box Helicase 3, X-Linked Gene | DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 3, X-Linked Gene | DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 3, X-Linked wt Allele | DEAD-Box Helicase 3 X-Linked wt Allele | DEAD-Box Helicase 3, X-Linked Gene | DEAD/H (Asp-Glu-Ala-Asp/His) Box Polypeptide 3 Gene | DEAD/H Box-3, X-Linked Gene | HLP2 | MRX102 | MRXSSB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1309084","ATP-Dependent RNA Helicase DDX3X, Human","C101567","ATP-dependent RNA helicase DDX3X (662 aa, ~73 kDa) is encoded by the human DDX3X gene. This protein is involved in the regulation of RNA structure, localization and metabolism.","ATP-Dependent RNA Helicase DDX3X | CAP-Rf | DBX | DDX3X | DEAD Box Protein 3, X-Chromosomal | DEAD Box, X Isoform | EC 3.6.4.13 | HLP2 | Helicase-Like Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826967","UBA2 Gene","C101568","This gene plays a role in protein modification.","UBA2 Gene | UBA2 | Ubiquitin-Like Modifier Activating Enzyme 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541278","UBA2 wt Allele","C101569","Human UBA2 wild-type allele is located in the vicinity of 19q12 and is approximately 42 kb in length. This allele, which encodes SUMO-activating enzyme subunit 2 protein, is involved in the regulation of sumoylation.","UBA2 wt Allele | ARX | FLJ13058 | HRIHFB2115 | SAE2 | UBLE1B | Ubiquitin-Like Modifier Activating Enzyme 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1306952","SUMO-Activating Enzyme Subunit 2, Human","C101570","SUMO-activating enzyme subunit 2 (640 aa, ~71 kDa) is encoded by the human UBA2 gene. This protein plays a role in post-translational protein modification.","SUMO-Activating Enzyme Subunit 2 | Anthracycline-Associated Resistance ARX | EC 6.3.2.- | SAE2 | SUMO-1 Activating Enzyme Subunit 2 | SUMO-ACTIVATING ENZYME SUBUNIT 2 | UBA2 | Ubiquitin-Like Activating Enzyme E1B | Ubiquitin-Like-Activating Enzyme E1B | Ubiquitin-like 1-activating enzyme E1B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826966","SAE1 Gene","C101571","This gene is involved in post-translational protein modification.","SAE1 Gene | SAE1 | SUMO1 Activating Enzyme Subunit 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539796","SAE1 wt Allele","C101572","Human SAE1 wild-type allele is located in the vicinity of 19q13.32 and is approximately 80 kb in length. This allele, which encodes SUMO-activating enzyme subunit 1 protein, plays a role in the promotion of sumoylation.","SAE1 wt Allele | AOS1 | Activator of SUMO1 Gene | FLJ3091 | HSPC140 | SUA1 | SUMO1 Activating Enzyme Subunit 1 wt Allele | UBLE1A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1306951","SUMO-Activating Enzyme Subunit 1, Human","C101573","SUMO-activating enzyme subunit 1 (346 aa, ~38 kDa) is encoded by the human SAE1 gene. This protein is involved in the regulation of sumoylation.","SUMO-Activating Enzyme Subunit 1 | SAE1 | SUA1 | SUMO-1 Activating Enzyme E1 N Subunit | SUMO-1 Activating Enzyme Subunit 1 | SUMO-ACTIVATING ENZYME SUBUNIT 1 | Sentrin/SUMO-Activating Protein AOS1 | Ubiquitin-Like -Activating Enzyme E1A | Ubiquitin-like 1-activating enzyme E1A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541878","USP9X wt Allele","C101575","Human USP9X wild-type allele is located in the vicinity of Xp11.4 and is approximately 151 kb in length. This allele, which encodes probable ubiquitin carboxyl-terminal hydrolase FAF-X protein, is involved in the modulation of protein ubiquitination.","USP9X wt Allele | DFFRX | Drosophila Fat Facets Related, X-Linked Gene | FAF | FAM | Fat Facets Protein Related, X-Linked Gene | MRX99 | MRXS99F | Ubiquitin Specific Peptidase 9 X-Linked wt Allele | Ubiquitin Specific Peptidase 9, X-Linked (Fat Facets-Like, Drosophila) Gene | Ubiquitin Specific Peptidase 9, X-Linked wt Allele | Ubiquitin Specific Protease 9, X Chromosome (Fat Facets-Like Drosophila) Gene | Ubiquitin Specific Protease 9, X-Linked (Fat Facets-Like, Drosophila) Gene | XLID99 | hFAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540488","CCR2 wt Allele","C101578","Human CCR2 wild-type allele is located in the vicinity of 3p21.31 and is approximately 7 kb in length. This allele, which encodes C-C chemokine receptor type 2 protein, is involved in both chemokine binding and signaling.","CCR2 wt Allele | CC-CKR-2 | CCR-2 | CCR2A | CCR2B | CD192 | CKR2 | CKR2A | CKR2B | CMKBR2 | Chemokine (C-C Motif) Receptor 2 wt Allele | FLJ78302 | MCP-1-R | MGC103828 | MGC111760 | MGC168006 | hCG_14621",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0253486","CCR2 Receptors","C101579","C-C chemokine receptor type 2 (374 aa, ~42 kDa) is encoded by the human CCR2 gene. This protein plays a role in both cytokine binding and receptor signaling.","C-C Chemokine Receptor Type 2 | Antigen CD192 | C-C CKR-2 | CC-CKR-2 | CCR-2 | CCR2 | CD192 | CD192 Antigen | MCP-1 Receptor | MCP-1-R | Monocyte Chemoattractant Protein 1 Receptor | Monocyte Chemotactic Protein 1 Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540590","NUP107 wt Allele","C101488","Human NUP107 wild-type allele is located in the vicinity of 12q15 and is approximately 56 kb in length. This allele, which encodes nuclear pore complex protein Nup107, plays a role in nuclear transport.","NUP107 wt Allele | NUP84 | Nucleoporin 107kDa wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640116","Nuclear Pore Complex Protein Nup107","C101489","Nuclear pore complex protein Nup107 (925 aa, ~106 kDa) is encoded by the human NUP107 gene. This protein is involved in nuclear pore assembly.","Nuclear Pore Complex Protein Nup107 | 107 kDa Nucleoporin | Nucleoporin Nup107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539537","SQSTM1 wt Allele","C101492","Human SQSTM1 wild-type allele is located 5q35 and is approximately 32 kb in length. This allele, which encodes sequestosome-1 protein, plays a role in signal transduction. Mutation of the gene is associated with Paget disease of bone.","SQSTM1 wt Allele | A170 | OSIL | PDB3 | Sequestosome 1 wt Allele | ZIP3 | p60 | p62 | p62B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1137054","Sequestosome-1","C101493","Sequestosome-1 (440 aa, ~48 kDa) is encoded by the human SQSTM1 gene. This protein is involved in signaling.","Sequestosome-1 | EBI3-Associated Protein Of 60 kDa | EBIAP | Phosphotyrosine-Independent Ligand for the Lck SH2 Domain Of 62 kDa | Ubiquitin-Binding Protein p62 | p60",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538854","PPFIBP1 wt Allele","C101495","Human PPFIBP1 wild-type allele is located in the vicinity of 12p12.1 and is approximately 172 kb in length. This allele, which encodes liprin-beta-1 protein, is involved in the modulation of protein-protein interactions.","PPFIBP1 wt Allele | KIAA1230 | L2 | PTPRF Interacting Protein, Binding Protein 1 (Liprin Beta 1) wt Allele | SGT2 | hSGT2 | hSgt2p",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538802","Liprin-Beta-1","C101496","Liprin-beta-1 (1011 aa, ~114 kDa) is encoded by the human PPFIBP1 gene. This protein plays a role in the mediation of protein-protein interactions.","Liprin-Beta-1 | PPFIBP1 | PTPRF-Interacting Protein-Binding Protein 1 | Protein Tyrosine Phosphatase Receptor Type f Polypeptide-Interacting Protein-Binding Protein 1 | hSGT2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538825","ESRP1 wt Allele","C101498","Human ESRP1 wild-type allele is located in the vicinity of 8q22.1 and is approximately 66 kb in length. This allele, which encodes epithelial splicing regulatory protein 1, plays a role in the regulation of RNA splicing.","ESRP1 wt Allele | Epithelial Splicing Regulatory Protein 1 wt Allele | FLJ20171 | RBM35A | RMB35A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537358","Epithelial Splicing Regulatory Protein 1, Human","C101499","Epithelial splicing regulatory protein 1 (681 aa, ~76 kDa) is encoded by the human ESRP1 gene. This protein is involved in the mediation of mRNA splicing.","Epithelial Splicing Regulatory Protein 1 | RNA-Binding Motif Protein 35A | RNA-Binding Protein 35A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279933","bleomycin/cisplatin/mitomycin/vindesine","C10149","A regimen consisting of bleomycin, vindesine, mitomycin and cisplatin that may be used in the treatment of disseminated squamous-cell carcinoma of the cervix.","BEMP Regimen | BEMP | BLEO/CDDP/DAVA/MITO | Bleomycin-Vindesine-Mitomycin-Platinol | Bleomycin/Eldisine/Mitomycin/Platinol | Bleomycin/Eldisine/Mitomycin/Platinol Regimen | Bleomycin/Vindesine/Mitomycin/Cisplatin | Bleomycin/Vindesine/Mitomycin/Cisplatin Regimen | Bleomycin/Vindesine/Mitomycin/Platinol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0387288","Verteporfin","C1014","A synthetic light-activated agent with photodynamic activity. Upon systemic administration, verteporfin accumulates in neovessels in the eye and, once stimulated by nonthermal red light in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to neovascular endothelium and blood vessel occlusion. (NCI04)","Verteporfin | BPD-MA | Benzoporphyrin Derivative Monoacid Ring A | VERTEPORFIN | Visudyne",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422049","AGTRAP Gene","C101500","This gene plays a role in angiotensin signaling.","AGTRAP Gene | AGTRAP | Angiotensin II Receptor-Associated Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640186","Primary Identifier","C101698","No value exists.","Primary Identifier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280488","VAB-6 regimen","C10234","A regimen consisting of vinblastine, dactinomycin, bleomycin, cyclophosphamide and cisplatin that may be used in the treatment of testicular cancer.","VAB-6 Regimen | BLEO/CDDP/CTX/DACT/VBL | Bleomycin-Cisplatin-Cyclophosphamide-Dactinomycin-Vinblastine | Bleomycin/Cisplatin/Cyclophosphamide/Dactinomycin/Vinblastine | Bleomycin/Cisplatin/Cyclophosphamide/Dactinomycin/Vinblastine Regimen | VAB-6 | VAB-V",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539617","Digestive System Findings Domain","C102640","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to digestive system findings.","Digestive System Findings Domain | GI | Gastrointestinal System Findings | Gastrointestinal System Findings Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538713","Hematopoietic System Findings Domain","C102641","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to hematopoietic system findings.","Hematopoietic System Findings Domain | HM | Hematopoietic System Findings",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640859","High-priority Tuberculosis Subject","C102644","An individual that has tested positive for pulmonary, laryngeal, or pleural tuberculosis and may or may not present with cavitary disease.","High-priority Tuberculosis Subject | HIGH-PRIORITY TUBERCULOSIS CONTACT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640861","Household Contact","C102646","A way of contracting a disease through interactions with an infected person in the same residence.","Household Contact | HOUSEHOLD CONTACT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640862","Household Environment","C102647","The area in which an individual lives.","Household Environment | HOUSEHOLD ENVIRONMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640863","Immigrant From High Tuberculosis Prevalent Area","C102648","An individual that has migrated from a country with a high occurrence of tuberculosis.","Immigrant From High Tuberculosis Prevalent Area | IMMIGRANT FROM HIGH TUBERCULOSIS PREVALENT AREA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539078","Immune System Findings Domain","C102649","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to immune system findings.","Immune System Findings Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541296","Integumentary System Findings Domain","C102651","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to integumentary system findings.","Integumentary System Findings Domain | IG | Integumentary System Findings",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640559","SF-36 v1.0 Acute - My Health is Excellent","C102160","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) How TRUE or FALSE is the following statement for you - my health is excellent","SF-36 v1.0 Acute - My Health is Excellent | SF362-My Health is Excellent | SF36211D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640560","SF-36 v2.0 Acute - In General You Say Your Health Is","C102161","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) In general, would you say your health is.","SF-36 v2.0 Acute - In General You Say Your Health Is | SF364-In General You Say Your Health Is | SF36401",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640561","SF-36 v2.0 Acute - Comp Week Ago Rate Gen Health Now","C102162","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) Compared to one week ago, how would you rate your health in general now?","SF-36 v2.0 Acute - Comp Week Ago Rate Gen Health Now | SF364-Comp Week Ago Rate Gen Health Now | SF36402",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538721","MTCH2 wt Allele","C102899","Human MTCH2 wild-type allele is located in the vicinity of 11p11.2 and is approximately 25 kb in length. This allele, which encodes mitochondrial carrier homolog 2 protein, plays a role in mitochondrial polarization.","MTCH2 wt Allele | 2310034D24Rik | HSPC032 | MIMP | Mitochondrial Carrier 2 wt Allele | Mitochondrial Carrier Homolog 2 (C. elegans) Gene | SLC25A50 | Solute Carrier Family 25, Member 50 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054245","Butein","C1028","A flavonoid obtained from the seed of Cyclopia subternata. It is a specific protein tyrosine kinase inhibitor that induces apoptosis. (NCI)","Butein | 2',3,4,4'-Tetrahydroxy-chalcone | BUTEIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538739","Mitochondrial Carrier Homolog 2","C102900","Mitochondrial carrier homolog 2 (303 aa, ~33 kDa) is encoded by the human MTCH2 gene. This protein is involved in the modulation of mitochondrial polarization.","Mitochondrial Carrier Homolog 2 | MTCH2 | Met-Induced Mitochondrial Protein | Solute Carrier Family 25 Member 50",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538845","PPP6C wt Allele","C102902","Human PPP6C wild-type allele is located in the vicinity of 9q33.3 and is approximately 43 kb in length. This allele, which encodes serine/threonine-protein phosphatase 6 catalytic subunit protein, is involved in protein dephosphorylation, signal transduction and cell cycle regulation.","PPP6C wt Allele | PP6 | PP6C | Protein Phosphatase 6, Catalytic Subunit wt Allele | RP11-366O20.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2001938","Serine/Threonine-Protein Phosphatase 6 Catalytic Subunit, Human","C102903","Serine/threonine-protein phosphatase 6 catalytic subunit (305 aa, ~35 kDa) is encoded by the human PPP6C gene. This protein plays a role in protein dephosphorylation, cell cycle progression and receptor signaling.","Serine/Threonine-Protein Phosphatase 6 Catalytic Subunit | EC 3.1.3.16 | PP6C | PPP6C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539745","SNX31 wt Allele","C102907","Human SNX31 wild-type allele is located in the vicinity of 8q22.3 and is approximately 91 kb in length. This allele, which encodes sorting nexin-31 protein, plays a role in intracellular transport.","SNX31 wt Allele | MGC39715 | Sorting Nexin 31 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539863","Sorting Nexin-31, Human","C102908","Sorting nexin-31 (440 aa, ~51 kDa) is encoded by the human SNX31 gene. This protein is involved in the mediation of intracellular transport.","Sorting Nexin-31 | SNX31 | Sorting Nexin 31",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420471","STK19 Gene","C102909","This gene plays a role in protein phosphorylation.","STK19 Gene | STK19 | Serine/Threonine Kinase 19 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538702","STK19 wt Allele","C102910","Human STK19 wild-type allele is located in the vicinity of 6p21.33 and is approximately 10 kb in length. This allele, which encodes serine/threonine-protein kinase 19 protein, is involved in phosphorylation of serine/threonine residues.","STK19 wt Allele | D6S60 | D6S60E | DADB-112B14.2 | G11 | HLA-RP1 | RP1 | Serine/Threonine Kinase 19 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL436816","Beta-hydroxy-beta-methylbutyrate Supplement","C102547","A nutritional supplement containing the active metabolite of the essential amino acid leucine, with potential anti-catabolic and anabolic activities. Upon oral administration of beta-hydroxy-beta-methylbutyrate (HMB), this leucine metabolite may decrease protein breakdown and increase protein synthesis thereby increasing muscle strength and mass. Although the exact mechanisms remain to be fully elucidated, multiple mechanisms have been proposed: 1) HMB is a precursor of cholesterol synthesis in skeletal muscle cells thereby increasing sarcolemmal integrity; 2) HMB may inhibit the ubiquitin-proteasome proteolytic pathway responsible for the specific degradation of intracellular proteins, thereby preventing muscular proteolysis; and/or 3) HMB may stimulate protein synthesis through a mammalian target of rapamycin (mTOR)-mediated mechanism.","Beta-hydroxy-beta-methylbutyrate Supplement | HMB Supplement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425478","PADI4 Gene","C102548","This gene is involved in arginine modification.","PADI4 Gene | PADI4 | Peptidyl Arginine Deiminase, Type IV Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540603","PADI4 wt Allele","C102549","Human PADI4 wild-type allele is located in the vicinity of 1p36.13 and is approximately 56 kb in length. This allele, which encodes protein-arginine deiminase type-4 protein, plays a role in the post-translational protein modification. Mutation of the gene is associated with susceptibility to rheumatoid arthritis.","PADI4 wt Allele | PAD | PAD4 | PADI5 | PDI4 | PDI5 | Peptidyl Arginine Deiminase, Type IV wt Allele | Peptidyl Arginine Deiminase, Type V Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280523","etoposide/mitoxantrone/thiotepa","C10254","A regimen consisting of mitoxantrone, etoposide, and thiotepa that may be used in the treatment of relapsed breast cancer.","MVT Regimen | DHAD/TSPA/VP-16 | Etoposide/Mitoxantrone/Thiotepa | MVT | Mitoxantrone-Etoposide-Thiotepa | Mitoxantrone/Etoposide/Thiotepa | Mitoxantrone/Etoposide/Thiotepa Regimen | Mitoxantrone/VePesid/Thiotepa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1434089","Protein-Arginine Deiminase Type-4","C102550","Protein-arginine deiminase type-4 (663 aa, ~74 kDa) is encoded by the human PADI4 gene. This protein is involved in the deimination of arginine residues in histones.","Protein-Arginine Deiminase Type-4 | EC 3.5.3.15 | HL-60 PAD | PADI-H Protein | PADI4 | Peptidyl Arginine Deiminase, Type V | Peptidylarginine Deiminase IV | Protein-Arginine Deiminase Type IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426035","HS6ST2 Gene","C102551","This gene plays a role in the modification of heparan sulfate.","HS6ST2 Gene | HS6ST2 | Heparan Sulfate 6-O-Sulfotransferase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540805","HS6ST2 wt Allele","C102552","Human HS6ST2 wild-type allele is located in the vicinity of Xq26.2 and is approximately 335 kb in length. This allele, which encodes heparan-sulfate 6-O-sulfotransferase 2 protein, is involved in proteoglycan modification.","HS6ST2 wt Allele | Heparan Sulfate 6-O-Sulfotransferase 2 wt Allele | MGC130022 | MGC130023 | PSEC0092 | RP3-435D1.3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640465","COWS - Bone or Joint Aches","C102060","Clinical Opiate Withdrawal Scale (COWS) Bone or joint aches.","COWS - Bone or Joint Aches | COWS1-Bone or Joint Aches | COWS105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640466","COWS - Runny Nose or Tearing","C102061","Clinical Opiate Withdrawal Scale (COWS) Runny nose or tearing.","COWS - Runny Nose or Tearing | COWS1-Runny Nose or Tearing | COWS106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640467","COWS - GI Upset","C102062","Clinical Opiate Withdrawal Scale (COWS) GI upset.","COWS - GI Upset | COWS1-GI Upset | COWS107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640468","COWS - Tremor","C102063","Clinical Opiate Withdrawal Scale (COWS) Tremor.","COWS - Tremor | COWS1-Tremor | COWS108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640469","COWS - Yawning","C102064","Clinical Opiate Withdrawal Scale (COWS) Yawning.","COWS - Yawning | COWS1-Yawning | COWS109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640470","COWS - Anxiety or Irritability","C102065","Clinical Opiate Withdrawal Scale (COWS) Anxiety or irritability.","COWS - Anxiety or Irritability | COWS1-Anxiety or Irritability | COWS110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640471","COWS - Gooseflesh Skin","C102066","Clinical Opiate Withdrawal Scale (COWS) Gooseflesh skin.","COWS - Gooseflesh Skin | COWS1-Gooseflesh Skin | COWS111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640472","EQ-5D-5L - Mobility","C102067","The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Mobility.","EQ-5D-5L - Mobility | EQ5D02-Mobility | EQ5D0201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640276","ADNI-AVLT Questionnaire Question","C101870","A question associated with the ADNI version of the AVLT questionnaire.","ADNI-AVLT Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640277","BARS Clinical Classification Question","C101871","A question associated with the BARS questionnaire.","BARS Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640279","COWS Questionnaire Question","C101873","A question associated with the COWS questionnaire.","COWS Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640280","ECOG Clinical Classification Question","C101874","A question associated with the ECOG performance status questionnaire.","ECOG Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640281","EQ-5D-5L Questionnaire Question","C101875","A question associated with the EQ-5D-5L questionnaire.","EQ-5D-5L Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640282","HAMA Questionnaire Question","C101876","A question associated with the HAMA questionnaire.","HAMA Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642477","HAMD 21 Questionnaire Question","C101877","A question associated with the HAMD 21 questionnaire.","HAMD 21 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640283","SF36 v1 0 Acute Questionnaire Question","C101878","A question associated with the SF36 v1.0 Acute questionnaire.","SF36 v1 0 Acute Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640285","SF36 v2 0 Acute Questionnaire Question","C101880","A question associated with the SF36 v2.0 Acute questionnaire.","SF36 v2 0 Acute Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640286","SOWS Subjective Questionnaire Question","C101881","A question associated with the SOWS questionnaire.","SOWS Subjective Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640287","YMRS Questionnaire Question","C101882","A question associated with the YMRS questionnaire.","YMRS Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640288","Lead Event Finding","C101883","No value exists.","Lead Event Finding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640289","CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology","C101884","Test codes of questionnaire questions associated with the Short Form 36 Health Survey Acute, US Version 2.0 (SF36 v2.0 Acute) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology | QS-SF36 v2.0 Acute TESTCD | SF364TC | The Short Form 36 Health Survey Acute, US Version 2.0 Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640562","SF-36 v2.0 Acute - Limit Vigorous Activities","C102163","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) How much does your health now limit you in - vigorous activities, such as running, lifting heavy objects, participating in strenuous sports.","SF-36 v2.0 Acute - Limit Vigorous Activities | SF364-Limit Vigorous Activities | SF36403A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640563","SF-36 v2.0 Acute - Limit Moderate Activities","C102164","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) How much does your health now limit you in - moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or playing golf.","SF-36 v2.0 Acute - Limit Moderate Activities | SF364-Limit Moderate Activities | SF36403B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640564","SF-36 v2.0 Acute - Limit Lifting or Carrying","C102165","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) How much does your health now limit you in - lifting or carrying groceries.","SF-36 v2.0 Acute - Limit Lifting or Carrying | SF364-Limit Lifting or Carrying | SF36403C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640565","SF-36 v2.0 Acute - Limit Climbing Several Flights","C102166","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) How much does your health now limit you in - climbing several flights of stairs.","SF-36 v2.0 Acute - Limit Climbing Several Flights | SF364-Limit Climbing Several Flights | SF36403D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640566","SF-36 v2.0 Acute - Limit Climbing One Flight Stairs","C102167","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) How much does your health now limit you in - climbing one flight of stairs.","SF-36 v2.0 Acute - Limit Climbing One Flight Stairs | SF364-Limit Climbing One Flight Stairs | SF36403E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640567","SF36403F","C102168","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) How much does your health now limit you in - bending, kneeling, or stooping.","SF-36 v2.0 Acute - Limit Bending/Kneeling/Stooping | SF364-Limit Bending/Kneeling/Stooping | SF36403F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640568","SF-36 v2.0 Acute - Limit Walking More Than a Mile","C102169","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) How much does your health now limit you in - walking more than a mile.","SF-36 v2.0 Acute - Limit Walking More Than a Mile | SF364-Limit Walking More Than a Mile | SF36403G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640569","SF-36 v2.0 Acute - Limit Walking Several Hundred Yds","C102170","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) How much does your health now limit you in - walking several hundred yards.","SF-36 v2.0 Acute - Limit Walking Several Hundred Yds | SF364-Limit Walking Several Hundred Yds | SF36403H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640570","SF-36 v2.0 Acute - Limit Walking One Hundred Yards","C102171","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) How much does your health now limit you in - walking one hundred yards.","SF-36 v2.0 Acute - Limit Walking One Hundred Yards | SF364-Limit Walking One Hundred Yards | SF36403I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640571","SF-36 v2.0 Acute - Limit Bathing or Dressing Yourself","C102172","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) How much does your health now limit you in - bathing or dressing yourself.","SF-36 v2.0 Acute - Limit Bathing or Dressing Yourself | SF364-Limit Bathing or Dressing Yourself | SF36403J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640572","SF-36 v2.0 Acute - Physical: Cut Down Time on Work","C102173","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) During the past week, how much of the time have you had any problems with your work or other regular daily activities as a result of your physical health - cut down on the amount of time you spent on work or other activities.","SF-36 v2.0 Acute - Physical: Cut Down Time on Work | SF364-Physical: Cut Down Time on Work | SF36404A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640766","SOWS Subjective (Handelsman) - I Feel Anxious","C102409","Subjective Opiate Withdrawal Scale (SOWS Subjective) I feel anxious.","SOWS Subjective (Handelsman) - I Feel Anxious | SOWSA1-I Feel Anxious | SOWSA101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1430075","Serine/Threonine-Protein Kinase 19, Human","C102911","Serine/threonine-protein kinase 19 (368 aa, ~41 kDa) is encoded by the human STK19 gene. This protein plays a role in post-translational protein phosphorylation.","Serine/Threonine-Protein Kinase 19 | EC 2.7.11.1 | Protein G11 | Protein RP1 | STK19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426652","USP44 Gene","C102912","This gene is involved in both cell cycle and protein deubiquitination.","USP44 Gene | USP44 | Ubiquitin Specific Peptidase 44 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539066","NCI CTEP SDC Mediastinal Cancer Sub-Category Terminology","C103088","Mediastinal Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Mediastinal Cancer Sub-Category Terminology | Mediastinal Cancer | NCI CTEP Simple Disease Classification Mediastinal Cancer Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538785","NCI CTEP SDC Mesothelioma Sub-Category Terminology","C103089","Mesothelioma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Mesothelioma Sub-Category Terminology | Mesothelioma | NCI CTEP Simple Disease Classification Mesothelioma Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539721","NCI CTEP SDC Non-Small Cell Lung Cancer Sub-Category Terminology","C103090","Non-Small Cell Lung Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Non-Small Cell Lung Cancer Sub-Category Terminology | NCI CTEP Simple Disease Classification Non-Small Cell Lung Cancer Sub-Category Terminology | Non-Small Cell Lung Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540630","NCI CTEP SDC Small Cell Lung Cancer Sub-Category Terminology","C103091","Small Cell Lung Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Small Cell Lung Cancer Sub-Category Terminology | NCI CTEP Simple Disease Classification Small Cell Lung Cancer Sub-Category Terminology | Small Cell Lung Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538737","NCI CTEP SDC Miscellaneous Neoplasm Sub-Category Terminology","C103094","Miscellaneous Neoplasm is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Miscellaneous Neoplasm Sub-Category Terminology | Miscellaneous Neoplasm | NCI CTEP Simple Disease Classification Miscellaneous Neoplasm Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640473","EQ-5D-5L - Self-Care","C102068","The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Self-care.","EQ-5D-5L - Self-Care | EQ5D02-Self-Care | EQ5D0202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640474","EQ-5D-5L - Usual Activities","C102069","The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Usual activities.","EQ-5D-5L - Usual Activities | EQ5D02-Usual Activities | EQ5D0203",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640475","EQ-5D-5L - Pain or Discomfort","C102070","The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Pain or discomfort.","EQ-5D-5L - Pain or Discomfort | EQ5D02-Pain/Discomfort | EQ5D0204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640476","EQ-5D-5L - Anxiety or Depression","C102071","The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Anxiety or depression.","EQ-5D-5L - Anxiety or Depression | EQ5D02-Anxiety/Depression | EQ5D0205",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640477","EQ-5D-5L - EQ VAS Score","C102072","The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Mark an X on the scale to indicate how your health is today and write the number you marked on the scale in the box below.","EQ-5D-5L - EQ VAS Score | EQ5D02-EQ VAS Score | EQ5D0206",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640478","HAMA - Anxious Mood","C102073","Hamilton Anxiety Rating Scale (HAMA) Anxious mood; worries, anticipation of the worst, fearful anticipation, irritability.","HAMA - Anxious Mood | HAMA1-Anxious Mood | HAMA101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640479","HAMA - Tension","C102074","Hamilton Anxiety Rating Scale (HAMA) Tension; feelings of tension, fatigability, startle response, moved to tears easily, trembling, feelings of restlessness, inability to relax.","HAMA - Tension | HAMA1-Tension | HAMA102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640481","HAMA - Insomnia","C102076","Hamilton Anxiety Rating Scale (HAMA) Insomnia; difficulty falling asleep, broken sleep, unsatisfying sleep and fatigue on waking, dreams, nightmares, night terrors.","HAMA - Insomnia | HAMA1-Insomnia | HAMA104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640482","HAMA - Intellectual","C102077","Hamilton Anxiety Rating Scale (HAMA) Intellectual; difficulty in concentration, poor memory.","HAMA - Intellectual | HAMA1-Intellectual | HAMA105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640483","HAMA - Depressed Mood","C102078","Hamilton Anxiety Rating Scale (HAMA) Depressed mood; loss of interest, lack of pleasure in hobbies, depression, early waking, diurnal swing.","HAMA - Depressed Mood | HAMA1-Depressed Mood | HAMA106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640290","SPL Business Operation Qualifier Terminology","C101885","Terminology used to qualify the information on business operations concerned with medical product development, manufacturing, and marketing in the framework of the Structured Product Labeling documents.","SPL Business Operation Qualifier Terminology | Business Operation Qualifier | Structured Product Labeling Business Operation Qualifier Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640291","Manufactures Non-Generics","C101886","A business that makes brand name products.","Manufactures Non-Generics | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL436272","EphA2-targeting DOPC-encapsulated siRNA","C101889","A liposomal formulation consisting of short-interfering RNAs (siRNAs) directed against ephrin type-A receptor 2 (EphA2) and encapsulated into 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) neutral liposomes, with potential antineoplastic activity. Upon internalization, EphA2-targeting DOPC-encapsulated siRNA can hybridize to EphA2 DNA and mRNA, thereby interfering with both the transcription and translation of EphA2, and thus inhibiting tumor cell growth. The cell-surface receptor EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) involved in mammalian development, is overexpressed by a variety of different cancer cell types and plays an important role in tumor growth.","EphA2-targeting DOPC-encapsulated siRNA | siRNA-EphA2-DOPC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539007","CDISC SDTM Vaccination Evidence Source Terminology","C102590","Terminology associated with the vaccination evidence source codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Vaccination Evidence Source Terminology | SDTM-VCNEVD | VCNEVD | Vaccination Evidence Source",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640767","SOWS Subjective (Handelsman) - I Feel Like Yawning","C102410","Subjective Opiate Withdrawal Scale (SOWS Subjective) I feel like yawning.","SOWS Subjective (Handelsman) - I Feel Like Yawning | SOWSA1-I Feel Like Yawning | SOWSA102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640768","SOWS Subjective (Handelsman) - I'm Perspiring","C102411","Subjective Opiate Withdrawal Scale (SOWS Subjective) I'm perspiring.","SOWS Subjective (Handelsman) - I'm Perspiring | SOWSA1-I'm Perspiring | SOWSA103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640769","SOWS Subjective (Handelsman) - My Eyes Are Tearing","C102412","Subjective Opiate Withdrawal Scale (SOWS Subjective) My eyes are tearing.","SOWS Subjective (Handelsman) - My Eyes Are Tearing | SOWSA1-My Eyes Are Tearing | SOWSA104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640771","SOWS Subjective (Handelsman) - I Have Goose Flesh","C102414","Subjective Opiate Withdrawal Scale (SOWS Subjective) I have goose flesh.","SOWS Subjective (Handelsman) - I Have Goose Flesh | SOWSA1-I Have Goose Flesh | SOWSA106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640772","SOWS Subjective (Handelsman) - I Am Shaking","C102415","Subjective Opiate Withdrawal Scale (SOWS Subjective) I am shaking.","SOWS Subjective (Handelsman) - I Am Shaking | SOWSA1-I Am Shaking | SOWSA107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640774","SOWS Subjective (Handelsman) - I Have Cold Flashes","C102417","Subjective Opiate Withdrawal Scale (SOWS Subjective) I have cold flashes.","SOWS Subjective (Handelsman) - I Have Cold Flashes | SOWSA1-I Have Cold Flashes | SOWSA109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640775","SOWS Subjective (Handelsman) - My Bones and Muscles Ache","C102418","Subjective Opiate Withdrawal Scale (SOWS Subjective) My bones and muscles ache.","SOWS Subjective (Handelsman) - My Bones and Muscles Ache | SOWSA1-My Bones and Muscles Ache | SOWSA110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640776","SOWS Subjective (Handelsman) - I Feel Restless","C102419","Subjective Opiate Withdrawal Scale (SOWS Subjective) I feel restless.","SOWS Subjective (Handelsman) - I Feel Restless | SOWSA1-I Feel Restless | SOWSA111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640777","SOWS Subjective (Handelsman) - I Feel Nauseous","C102420","Subjective Opiate Withdrawal Scale (SOWS Subjective) I feel nauseous.","SOWS Subjective (Handelsman) - I Feel Nauseous | SOWSA1-I Feel Nauseous | SOWSA112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640778","SOWS Subjective (Handelsman) - I Feel Like Vomiting","C102421","Subjective Opiate Withdrawal Scale (SOWS Subjective) I feel like vomiting.","SOWS Subjective (Handelsman) - I Feel Like Vomiting | SOWSA1-I Feel Like Vomiting | SOWSA113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640779","SOWS Subjective (Handelsman) - My Muscles Twitch","C102422","Subjective Opiate Withdrawal Scale (SOWS Subjective) My muscles twitch.","SOWS Subjective (Handelsman) - My Muscles Twitch | SOWSA1-My Muscles Twitch | SOWSA114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640780","SOWS Subjective (Handelsman) - I Have Cramps in My Stomach","C102423","Subjective Opiate Withdrawal Scale (SOWS Subjective) I have cramps in my stomach.","SOWS Subjective (Handelsman) - I Have Cramps in My Stomach | SOWSA1-I Have Cramps in My Stomach | SOWSA115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0597369","Religious Group","C103282","A group of people characterized by the practice of a common religion.","Religious Group | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280677","cytarabine/hydroxyurea","C10328","A regimen consisting of cytarabine and hydroxyurea that may be used in the treatment of acute myeloid leukemia (AML).","Cytarabine/Hydroxyurea Regimen | ARA-C/HU | Cytarabine-Hydroxyurea | Cytarabine/Hydroxyurea | Hydroxyurea-Cytarabine | Hydroxyurea/Cytarabine | ara-C-HU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0053902","Emitefur","C1022","An orally available antimetabolite composed of the 1-ethoxymethyl derivative of 5-fluorouracil (5-FU) and the dihydropyrimidine dehydrogenase (DPYD) inhibitor 3-cyano-2,6-dihydroxypyridine (CNDP) in a 1:1 molar ratio, with antineoplastic activity.  Upon administration, the prodrug emitefur is converted into 5-FU, while CNDP prevents the degradation of 5-FU by inhibiting DPYD and thereby prolonging the half-life of 5-FU. This increases 5-FU's concentration and thus its antitumor activity through inhibition of DNA and RNA synthesis, as well as inhibition of thymidylate synthase activity. In addition, by inhibiting the formation of 5-FU metabolites, some toxic effects associated with these metabolites may be reduced. DPYD is the rate-limiting enzyme in the catabolism of 5-FU.","Emitefur | (2) m-[[3-(Ethoxymethyl)-5-fluoro-3,6-dihydro-2,6-dioxo-1(2H)-pyrimidinyl]carbonyl]benzoic Acid, 2-Ester with 2,6-Dihydroxynicotinonitrile Benzoate (Ester) | 3-((3-(Ethoxymethyl)-5-fluoro-3,6-dihydro-2,6-dioxo-1(2H)-pyrimidinyl)carbonyl)benzoic acid, 6-(benzoyloxy)-3-cyano-2-pyridinyl ester | 3-[3-(6-Benzoyloxy-3-cyrano-2-pyridyloxycarbonyl)benzoyl]-1-(ethoxymethyl)-5-fluorouracil | BOF-A2 | EMITEFUR | Last-F | [[Ethoxymethyl-5-fluoro-3,6-dihydro-2,6-dioxo-1(2H)-pyrimidinyl]carbonyl]benzoic Acid, 6-(Benzoyloxy)-3-cyano-2-pyridinyl Ester | emitefur",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640244","CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology","C101825","Test names of questionnaire questions associated with the Short Form 36 Health Survey Acute, US Version 2.0 (SF36 v2.0 Acute) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology | QS-SF36 v2.0 Acute TEST | SF364TN | The Short Form 36 Health Survey Acute, US Version 2.0 Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054160","Bruceantin","C1025","A triterpene quassinoid antineoplastic antibiotic isolated from the plant Brucea antidysenterica.  Bruceantin inhibits the peptidyl transferase elongation reaction, resulting in decreased protein and DNA synthesis.  Bruceantin also has antiamoebic and antimalarial activity. (NCI04)","Bruceantin | 2H-3, 11c-(Epoxymethano)phenanthro[10,1-bc]pyran, Picras-3-en-21-oic Acid Derivative | BRUCEANTIN | Picras-3-en-21-oic Acid, 15-[(3,4-dimethyl-1-oxo-2-pentenyl)oxy]-13,20-epoxy-3,11, 12-trihydroxy-2,16-dioxo-, Methyl Ester, (11beta,12alpha,15beta(E)) | Picras-3-en-21-oic acid, 15-[(3, 4-dimethyl-1-oxo-2-pentenyl)oxy]-13,20-epoxy-3,11,12-trihydroxy-2, 16-dioxo-, methyl ester [11.beta.,12.alpha.,15.beta.(E)]- | Picras-3-en-21-oic acid, 15-[(3, 4-dimethyl-1-oxo-2-pentenyl)oxy]-13,20-epoxy-3,11,12-trihydroxy-2, 16-dioxo-, methyl ester, [11.beta.,12.alpha.,15.beta.(E)]- | [11Beta,12alpha,15beta(E)]-15-[(3,4-dimethyl-1-oxo-2-pentenyl)oxy]-13,20-epoxy-3,11,12-trihydroxy-2,16-dioxopicras-3-en-21-oic Acid Methyl Ester",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640835","Bacteriological Cure","C102600","There are no indicators of bacterial infection in an individual who previously had an infection.","Bacteriological Cure | BACTERIOLOGICAL CURE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640524","SF-36 v1.0 Acute - In General You Say Your Health Is","C102125","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) In general, would you say your health is.","SF-36 v1.0 Acute - In General You Say Your Health Is | SF362-In General You Say Your Health Is | SF36201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640525","SF-36 v1.0 Acute - Comp Week Ago Rate Gen Health Now","C102126","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) Compared to one week ago, how would you rate your health in general now?","SF-36 v1.0 Acute - Comp Week Ago Rate Gen Health Now | SF362-Comp Week Ago Rate Gen Health Now | SF36202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640526","SF-36 v1.0 Acute - Limit Vigorous Activities","C102127","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) How much does your health now limit you in - vigorous activities, such as running, lifting heavy objects, participating in strenuous sports.","SF-36 v1.0 Acute - Limit Vigorous Activities | SF362-Limit Vigorous Activities | SF36203A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437177","HPV-16 E6 Peptides Vaccine/Candida albicans Extract","C102874","A human papillomavirus (HPV) type 16 vaccine containing four E6 peptides in combination with an extract of Candida albicans, with potential immunomodulating and antineoplastic activities. Upon administration of HPV-16 E6 peptides vaccine/Candida albicans extract, the four HPV-16 E6 peptides and the Candida albicans may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against cells expressing the E6 oncoprotein, resulting in tumor cell lysis. The HPV 16 transforming protein E6 is expressed in precancerous and malignant cervical lesions, and HPV may be a cause of some head and neck squamous cell carcinomas (HNSCCs). Candida albicans allergenic extract may be used as a recall antigen to stimulate the immune system against HPV.","HPV-16 E6 Peptides Vaccine/Candida albicans Extract | HPV-16 E6 Peptides Vaccine/Candin | PepCan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437178","Nanoparticle-encapsulated Doxorubicin Hydrochloride","C102875","A formulation of nanoparticles encapsulating the hydrochloride salt form of the anthracycline antibiotic doxorubicin, with potential antitumor activity. Upon intravenous administration, doxorubicin intercalates DNA, interferes with the activity of topoisomerase II, and causes DNA adducts and other DNA damage, resulting in tumor cell growth inhibition and apoptosis. This agent also interacts with cell membrane lipids causing lipid peroxidation. Delivery of doxorubicin in nanoparticles may improve drug penetration into tumors and may circumvent the tumor cells multidrug resistance mechanisms and may therefore be effective in chemoresistant tumor cells.","Nanoparticle-encapsulated Doxorubicin Hydrochloride | BA-003 | Doxorubicin Transdrug | Livatag",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541337","NCI CTEP Simple Disease Classification Thyroid Cancer Sub-Category Terminology","C103059","Thyroid Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Thyroid Cancer Sub-Category Terminology | NCI CTEP Simple Disease Classification Thyroid Cancer Sub-Category Terminology | Thyroid Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540616","NCI CTEP SDC Retinoblastoma Sub-Category Terminology","C103061","Retinoblastoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Retinoblastoma Sub-Category Terminology | NCI CTEP Simple Disease Classification Retinoblastoma Sub-Category Terminology | Retinoblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641180","Serious Clinical Event Type","C103294","A category of clinical events regarded as having similar characteristics considered crucial and consequential.","Serious Clinical Event Type | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641181","Clinical Event Pattern Type","C103295","A category of clinical events which have a recurrent characteristic feature.","Clinical Event Pattern Type | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641345","ESS - As a Passenger in a Car for an Hour Without a Break","C103539","Epworth Sleepiness Scale (ESS) As a passenger in a car for an hour without a break.","ESS - As a Passenger in a Car for an Hour Without a Break | ESS01-Passenger for Hour Without Break | ESS0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641346","ESS - Lying Down to Rest in the Afternoon When Circumstances Permit","C103540","Epworth Sleepiness Scale (ESS) Lying down to rest in the afternoon when circumstances permit.","ESS - Lying Down to Rest in the Afternoon When Circumstances Permit | ESS01-Lying Down to Rest In Afternoon | ESS0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641348","ESS - Sitting Quietly After a Lunch without Alcohol","C103542","Epworth Sleepiness Scale (ESS) Sitting quietly after a lunch without alcohol.","ESS - Sitting Quietly After a Lunch without Alcohol | ESS01-Sitting Quietly After Lunch | ESS0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641349","ESS - In a car, While Stopped for a Few Minutes in the Traffic","C103543","Epworth Sleepiness Scale (ESS) In a car, while stopped for a few minutes in the traffic.","ESS - In a car, While Stopped for a Few Minutes in the Traffic | ESS01-In Car Stopped Few Minutes Traffic | ESS0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641350","FIQR - Brush or Comb Your Hair","C103544","Revised Fibromyalgia Impact Questionnaire (FIQR) Brush or comb your hair.","FIQR - Brush or Comb Your Hair | FIQR01-Brush or Comb Your Hair | FIQR0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641351","FIQR - Walk Continuously for 20 Minutes","C103545","Revised Fibromyalgia Impact Questionnaire (FIQR) Walk continuously for 20 minutes.","FIQR - Walk Continuously for 20 Minutes | FIQR01-Walk Continuously for 20 Minutes | FIQR0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641352","FIQR - Prepare a Homemade Meal","C103546","Revised Fibromyalgia Impact Questionnaire (FIQR) Prepare a homemade meal.","FIQR - Prepare a Homemade Meal | FIQR01-Prepare a Homemade Meal | FIQR0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641353","FIQR - Vacuum Scrub or Sweep Floors","C103547","Revised Fibromyalgia Impact Questionnaire (FIQR) Vacuum, scrub or sweep floors.","FIQR - Vacuum Scrub or Sweep Floors | FIQR01-Vacuum Scrub or Sweep Floors | FIQR0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641354","FIQR - Lift and Carry a Bag Full of Groceries","C103548","Revised Fibromyalgia Impact Questionnaire (FIQR) Lift and carry a bag full of groceries.","FIQR - Lift and Carry a Bag Full of Groceries | FIQR01-Lift/Carry Bag Full of Groceries | FIQR0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641355","FIQR - Climb One Flight of Stairs","C103549","Revised Fibromyalgia Impact Questionnaire (FIQR) Climb one flight of stairs.","FIQR - Climb One Flight of Stairs | FIQR01-Climb One Flight of Stairs | FIQR0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640245","CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology","C101826","Test codes of questionnaire questions associated with the Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology | QS-SF36 v2.0 Standard TESTCD | SF363TC | The Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640246","CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology","C101827","Test names of questionnaire questions associated with the Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology | QS-SF36 v2.0 Standard TEST | SF363TN | The Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640247","CDISC Questionnaire SOWS Subjective Test Code Terminology","C101828","Test codes of questionnaire questions associated with the Subjective Opiate Withdrawal Scale (SOWS Subjective) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire SOWS Subjective Test Code Terminology | QS-SOWS Subjective TESTCD | SOWSA1TC | Subjective Opiate Withdrawal Scale Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640248","CDISC Questionnaire SOWS Subjective Test Name Terminology","C101829","Test names of questionnaire questions associated with the Subjective Opiate Withdrawal Scale (SOWS Subjective) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire SOWS Subjective Test Name Terminology | QS-SOWS Subjective TEST | SOWSA1TN | Subjective Opiate Withdrawal Scale Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640249","CDISC Questionnaire YMRS Test Code Terminology","C101830","Test codes of questionnaire questions associated with the Young Mania Rating Scale (YMRS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire YMRS Test Code Terminology | QS-YMRS TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640250","CDISC Questionnaire YMRS Test Name Terminology","C101831","Test names of questionnaire questions associated with the Young Mania Rating Scale (YMRS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire YMRS Test Name Terminology | QS-YMRS TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538917","CDISC SDTM Findings About Test Name Terminology","C101833","Terminology associated with the findings about test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Findings About Test Name Terminology | FATEST | Findings About Test Name | SDTM-FATEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640252","CDISC SDTM Findings About Object Terminology","C101835","Terminology associated with the findings about the object of the observation codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC SDTM Findings About Object Terminology | SDTM-FAOBJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640253","CDISC Clinical Data Element Glossary Terminology","C101836","The terminology subset that includes the Clinical Data Element Glossary of terms for the Clinical Data Interchange Standards Consortium (CDISC).","CDISC Clinical Data Element Glossary Terminology | CDISC-CLINDE | CLINDE | Clinical Data Element Glossary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640254","CDISC SDTM Consensus Cardiac Classification Systems Test Name Terminology","C101837","Terminology associated with the consensus cardiac classification systems codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Consensus Cardiac Classification Systems Test Name Terminology | CCRCLS | Consensus Cardiac Classification System Test Name | SDTM-CCRCLS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640255","CDISC SDTM Consensus Cardiac Classification Systems Test Code Terminology","C101838","Terminology associated with the consensus cardiac classification systems codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Consensus Cardiac Classification Systems Test Code Terminology | CCRCLSCD | Consensus Cardiac Classification System Test Code | SDTM-CCRCLSCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640527","SF-36 v1.0 Acute - Limit Moderate Activities","C102128","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) How much does your health now limit you in - moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or playing golf.","SF-36 v1.0 Acute - Limit Moderate Activities | SF362-Limit Moderate Activities | SF36203B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640528","SF-36 v1.0 Acute - Limit Lifting or Carrying","C102129","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) How much does your health now limit you in - lifting or carrying groceries.","SF-36 v1.0 Acute - Limit Lifting or Carrying | SF362-Limit Lifting or Carrying | SF36203C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640529","SF-36 v1.0 Acute - Limit Climbing Several Flights","C102130","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) How much does your health now limit you in - climbing several flights of stairs.","SF-36 v1.0 Acute - Limit Climbing Several Flights | SF362-Limit Climbing Several Flights | SF36203D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640530","SF-36 v1.0 Acute - Limit Climbing One Flight Stairs","C102131","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) How much does your health now limit you in - climbing one flight of stairs.","SF-36 v1.0 Acute - Limit Climbing One Flight Stairs | SF362-Limit Climbing One Flight Stairs | SF36203E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640531","SF36203F","C102132","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) How much does your health now limit you in - bending, kneeling, or stooping.","SF-36 v1.0 Acute - Limit Bending/Kneeling/Stooping | SF362-Limit Bending/Kneeling/Stooping | SF36203F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640532","SF-36 v1.0 Acute - Limit Walking More Than a Mile","C102133","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) How much does your health now limit you in - walking more than a mile.","SF-36 v1.0 Acute - Limit Walking More Than a Mile | SF362-Limit Walking More Than a Mile | SF36203G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640533","SF-36 v1.0 Acute - Limit Walking Several Blocks","C102134","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) How much does your health now limit you in - walking several blocks.","SF-36 v1.0 Acute - Limit Walking Several Blocks | SF362-Limit Walking Several Blocks | SF36203H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640534","SF-36 v1.0 Acute - Limit Walking One Block","C102135","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) How much does your health now limit you in - walking one block.","SF-36 v1.0 Acute - Limit Walking One Block | SF362-Limit Walking One Block | SF36203I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542412","NCI CTEP Simple Disease Classification Colorectal Cancer Sub-Category Terminology","C103063","Colorectal Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Colorectal Cancer Sub-Category Terminology | Colorectal Cancer | NCI CTEP Simple Disease Classification Colorectal Cancer Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641050","NCI CTEP SDC Liver and Hepatobiliary Cancer Sub-Category Terminology","C103066","Liver and Hepatobiliary Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Liver and Hepatobiliary Cancer Sub-Category Terminology | Liver and Hepatobiliary Cancer | NCI CTEP Simple Disease Classification Liver and Hepatobiliary Cancer Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539935","NCI CTEP SDC Small Intestine Cancer Sub-Category Terminology","C103068","Small Intestine Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Small Intestine Cancer Sub-Category Terminology | NCI CTEP Simple Disease Classification Small Intestine Cancer Sub-Category Terminology | Small Intestine Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641150","Mixture Component","C103243","A substance that occurs as part of a mixture substance.","Mixture Component | MIXTURE COMPONENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641152","Chemical Moiety","C103246","A single entity that can be represented as a set of atoms usually connected through a continuous set of covalent bonds.","Chemical Moiety | CHEMICAL MOIETY | moiety",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641356","FIQR - Change Bed Sheets","C103550","Revised Fibromyalgia Impact Questionnaire (FIQR) Change bed sheets.","FIQR - Change Bed Sheets | FIQR01-Change Bed Sheets | FIQR0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641358","FIQR - Go Shopping for Groceries","C103552","Revised Fibromyalgia Impact Questionnaire (FIQR) Go shopping for groceries.","FIQR - Go Shopping for Groceries | FIQR01-Go Shopping for Groceries | FIQR0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641359","FIQR - Fibromyalgia Prevented Me from Accomplishing Goals for the Week","C103553","Revised Fibromyalgia Impact Questionnaire (FIQR) Fibromyalgia prevented me from accomplishing goals for the week.","FIQR - Fibromyalgia Prevented Me from Accomplishing Goals for the Week | FIQR01-Fibromyalgia Prevented Goals | FIQR0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641360","FIQR - I was Completely Overwhelmed by My Fibromyalgia Symptoms","C103554","Revised Fibromyalgia Impact Questionnaire (FIQR) I was completely overwhelmed by my fibromyalgia symptoms.","FIQR - I was Completely Overwhelmed by My Fibromyalgia Symptoms | FIQR01-Overwhelmed by Fibromyalgia | FIQR0111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641361","FIQR - Pain","C103555","Revised Fibromyalgia Impact Questionnaire (FIQR) Please rate your level of pain.","FIQR - Pain | FIQR01-Pain | FIQR0112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641362","FIQR - Energy","C103556","Revised Fibromyalgia Impact Questionnaire (FIQR) Please rate your level of energy.","FIQR - Energy | FIQR01-Energy | FIQR0113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541255","USP44 wt Allele","C102913","Human USP44 wild-type allele is located in the vicinity of 12q22 and is approximately 35 kb in length. This allele, which encodes ubiquitin carboxyl-terminal hydrolase 44 protein, plays a role in both anaphase and the removal of ubiquitin from protein substrates.","USP44 wt Allele | FLJ14528 | Ubiquitin Specific Peptidase 44 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3669265","USP44 protein, human","C102914","Ubiquitin carboxyl-terminal hydrolase 44 (712 aa, ~81 kDa) is encoded by the human USP44 gene. This protein is involved in the proteolytic removal of ubiquitin.","Ubiquitin Carboxyl-Terminal Hydrolase 44 | Deubiquitinating Enzyme 44 | EC 3.4.19.12 | USP44 | Ubiquitin Specific Peptidase 44 | Ubiquitin Specific Protease 44 | Ubiquitin Thioesterase 44 | Ubiquitin-Specific-Processing Protease 44",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419420","RNF20 Gene","C102915","This gene plays a role in polyubiquitination, histone modification and transcriptional regulation.","RNF20 Gene | RNF20 | Ring Finger Protein 20, E3 Ubiquitin Protein Ligase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539659","RNF20 wt Allele","C102916","Human RNF20 wild-type allele is located in the vicinity of 9q22 and is approximately 29 kb in length. This allele, which encodes E3 ubiquitin-protein ligase BRE1A protein, is involved in the modulation of transcription, polyubiquitination and histone modification.","RNF20 wt Allele | BRE1 | BRE1 E3 Ubiquitin Ligase Homolog (S. cerevisiae) Gene | BRE1A | FLJ11189 | FLJ20382 | KAIA2779 | Ring Finger Protein 20, E3 Ubiquitin Protein Ligase wt Allele | hBRE1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1680604","E3 Ubiquitin-Protein Ligase BRE1A, Human","C102917","E3 ubiquitin-protein ligase BRE1A (975 aa, ~114 kDa) is encoded by the human RNF20 gene. This protein plays a role in the ubiquitination of histones.","E3 Ubiquitin-Protein Ligase BRE1A | BRE1-A | EC 2.3.2.27 | EC 6.3.2.-, Formerly | RING Finger Protein 20 | hBRE1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540602","SPDEF wt Allele","C102919","Human SPDEF wild-type allele is located in the vicinity of 6p21.3 and is approximately 19 kb in length. This allele, which encodes SAM pointed domain-containing Ets transcription factor, plays a role in transcriptional regulation.","SPDEF wt Allele | PDEF | PSE | RP11-375E1 A.3 | RP11-375E1__A.3 | SAM Pointed Domain Containing ets Transcription Factor wt Allele | bA375E1.3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1433154","Heparan-Sulfate 6-O-Sulfotransferase 2, Human","C102553","Heparan-sulfate 6-O-sulfotransferase 2 (605 aa, ~69 kDa) is encoded by the human HS6ST2 gene. This protein plays a role in the sulfation of proteoglycans.","Heparan-Sulfate 6-O-Sulfotransferase 2 | EC 2.8.2.- | HS6ST-2 | HS6ST2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL436819","R1 Cooling Gel Plus R2 Moisturizing/Sun Protecting Lotion","C102555","A skin care treatment system consisting of a cytokine-containing milk-based cooling gel and a cytokine-containing milk-based soothing lotion with hydrating and potential protective activity against radiation-induced dermatitis. Application of the R1 cooling gel immediately upon radiation treatment may hydrate the skin, provide cooling relief, and may protect the skin against radiation-induced dermatitis. The subsequent application of the R2 lotion moisturizes the skin while also protecting the skin against inflammation. In addition, R2 contains avobenzone, homosalate, octinoxate and octocrylene, which exert UVA and UVB skin protective activity.","R1 Cooling Gel Plus R2 Moisturizing/Sun Protecting Lotion | R1/R2 Waterjel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640810","Low Interval Point in Time Date Data Type","C102556","A data type comprised of a set of consecutive low values of an ordered point in time date datatype.","Low Interval Point in Time Date Data Type | IVL.LOW<TS.DATE>",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640812","Visit End Time","C102558","The stop time of the visit.","Visit End Time | VISENTIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640813","Performed Medical Condition Result","C102559","The result of an actual line of questioning about a sign, symptom, disease, or other medical occurrence.","Performed Medical Condition Result | PerformedMedicalConditionResult",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL436273","Epidermal Growth Factor Ointment","C101890","A topical ointment containing a recombinant form of human epidermal growth factor (EGF) with potential protective activity against EGF receptor (EGFR/HER1) inhibitor-induced cutaneous toxicities. Upon topical application of the EGF ointment, EGF locally activates EGFR, thereby abrogating EGFR inhibition in the skin caused by systemic EGFR inhibiting agents. This may help inhibit the skin rash induced by EGFR antagonists. EGFR, a tyrosine kinase, plays a key role in maintaining epidermal integrity.","Epidermal Growth Factor Ointment | EGF Ointment | Sesal Yeongo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL436274","Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo","C101891","An allogeneic cancer vaccine composed of lethally irradiated, whole pancreatic cancer cells transfected with a plasmid carrying the gene for cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Allogeneic GM-CSF-secreting tumor vaccine PANC 6.03 pcDNA-1/GM-Neo secretes GM-CSF thereby activating dendritic cells, promoting antigen presentation to B- and T-cells, and promoting a cytotoxic T-lymphocyte (CTL) response. This may eventually kill tumor cells. The pancreatic tumor cells are derived from the PANC 6.03 tumor cell line.","Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo | PANC 6.03 pcDNA-1/GM-Neo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641312","OAB-q Questionnaire Question","C103498","A question associated with the OAB-q questionnaire.","OAB-q Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641313","OAB-q Short Form Questionnaire Question","C103499","A question associated with the OAB-q Short Form questionnaire.","OAB-q Short Form Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054452","Heparin Calcium","C1034","The calcium salt form of heparin.  As a glycosaminoglycan anticoagulant, heparin calcium binds to antithrombin III to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin. (NCI)","Heparin Calcium | Calciparine | HEPARIN CALCIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641314","ODI v2.1a Questionnaire Question","C103500","A question associated with the ODI v2.1a questionnaire.","ODI v2.1a Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537378","SAM Pointed Domain-Containing Ets Transcription Factor, Human","C102920","SAM pointed domain-containing Ets transcription factor (335 aa, ~38 kDa) is encoded by the human SPDEF gene. This protein is involved in transcriptional regulation and may modulate both prostate development and prostate cancer progression.","SAM Pointed Domain-Containing Ets Transcription Factor | Prostate Epithelium-Specific Ets Transcription Factor | Prostate-Derived Ets Factor | Prostate-Specific Ets | SPDEF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417202","MMP13 Gene","C102921","This gene plays a role in proteolysis of collagen.","MMP13 Gene | MMP13 | Matrix Metallopeptidase 13 (Collagenase 3) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540596","MMP13 wt Allele","C102922","Human MMP13 wild-type allele is located in the vicinity of 11q22.3 and is approximately 13 kb in length. This allele, which encodes collagenase 3 protein, is involved in collagen catabolism. Mutation of the gene is associated with both spondyloepimetaphyseal dysplasia Missouri type and metaphyseal anadysplasia type 1.","MMP13 wt Allele | CLG3 | MANDP1 | Matrix Metallopeptidase 13 (Collagenase 3) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1567335","MMP13 protein, human","C102923","Collagenase 3 (471 aa, ~54 kDa) is encoded by the human MMP13 gene. This protein plays a role in the proteolysis of the extracellular matrix.","Collagenase 3 | Collagenase-3 | EC 3.4.24.- | MMP-13 | MMP13 | Matrix Metalloprotease 13 | Matrix Metalloprotease-13 | Matrix Metalloproteinase 13 | Matrix Metalloproteinase-13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420602","TBR1 Gene","C102924","This gene is involved in both brain development and transcriptional regulation.","TBR1 Gene | T-Box, Brain, 1 Gene | TBR1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541323","TBR1 wt Allele","C102925","Human TBR1 wild-type allele is located in the vicinity of 2q24 and is approximately 10 kb in length. This allele, which encodes T-box brain protein 1, plays a role in DNA binding, gene transcription and brain development.","TBR1 wt Allele | T-Box, Brain, 1 wt Allele | TBR-1 | TES-56",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537392","T-Box Brain Protein 1","C102926","T-box brain protein 1 (682 aa, ~74 kDa) is encoded by the human TBR1 gene. This protein is involved in both transcriptional regulation and brain development.","T-Box Brain Protein 1 | T-Brain-1 | TBR-1 | TES-56",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640445","AIMS - Neck, Shoulders, Hips","C102040","Abnormal Involuntary Movement Scale (AIMS) Trunk Movements, Neck, shoulders, hips, e.g., rocking, twisting, squirming, pelvic gyrations. Include diaphragmatic movements.","AIMS - Neck, Shoulders, Hips | AIMS01-Neck, Shoulders, Hips | AIMS0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640446","AIMS - Severity of Abnormal Movements","C102041","Abnormal Involuntary Movement Scale (AIMS) Global Judgments, Severity of abnormal movements, based on the highest single score on the above items.","AIMS - Severity of Abnormal Movements | AIMS01-Severity of Abnormal Movements | AIMS0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640447","AIMS - Incapacitation Due to Abnormal Movements","C102042","Abnormal Involuntary Movement Scale (AIMS) Global Judgments, Incapacitation due to abnormal movements.","AIMS - Incapacitation Due to Abnormal Movements | AIMS01-Incapacitation due Abn Movements | AIMS0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640448","AIMS - Patient's Awareness of Abnormal Movements","C102043","Abnormal Involuntary Movement Scale (AIMS) Global Judgments, Patient's awareness of abnormal movements.","AIMS - Patient's Awareness of Abnormal Movements | AIMS01-Patient Awareness Abn Movements | AIMS0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640449","AIMS - Current Teeth/Dentures Problems","C102044","Abnormal Involuntary Movement Scale (AIMS) Dental Status, Current problems with teeth and/or dentures.","AIMS - Current Teeth/Dentures Problems | AIMS01-Current Problems Teeth/Dentures | AIMS0111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640451","BARS - Objective","C102046","Barnes Akathisia Rating Scale (BARS) Objective.","BARS - Objective | BARS01-Objective | BARS0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640452","BARS - Subjective, Awareness","C102047","Barnes Akathisia Rating Scale (BARS) Subjective, awareness of restlessness.","BARS - Subjective, Awareness | BARS01-Subjective, Awareness | BARS0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640484","HAMA - Somatic (Muscular)","C102079","Hamilton Anxiety Rating Scale (HAMA) Somatic (muscular); pains and aches, twitching, stiffness, myoclonic jerks, grinding of teeth, unsteady voice, increased muscular tone.","HAMA - Somatic (Muscular) | HAMA1-Somatic (Muscular) | HAMA107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640485","HAMA - Somatic (Sensory)","C102080","Hamilton Anxiety Rating Scale (HAMA) Somatic (sensory); tinnitus, blurring of vision, hot and cold flushes, feelings of weakness, pricking sensation.","HAMA - Somatic (Sensory) | HAMA1-Somatic (Sensory) | HAMA108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640486","HAMA - Cardiovascular Symptoms","C102081","Hamilton Anxiety Rating Scale (HAMA) Cardiovascular symptoms; tachycardia, palpitations, pain in chest, throbbing of vessels, fainting feelings, missing beat.","HAMA - Cardiovascular Symptoms | HAMA1-Cardiovascular Symptoms | HAMA109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640487","HAMA - Respiratory Symptoms","C102082","Hamilton Anxiety Rating Scale (HAMA) Respiratory symptoms; pressure or constriction in chest, choking feelings, sighing, dyspnea.","HAMA - Respiratory Symptoms | HAMA1-Respiratory Symptoms | HAMA110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640489","HAMA - Genitourinary Symptoms","C102084","Hamilton Anxiety Rating Scale (HAMA) Genitourinary symptoms; frequency of micturition, urgency of micturition, amenorrhea, menorrhagia, development of frigidity, premature ejaculation, loss of libido, impotence.","HAMA - Genitourinary Symptoms | HAMA1-Genitourinary Symptoms | HAMA112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640490","HAMA - Autonomic Symptoms","C102085","Hamilton Anxiety Rating Scale (HAMA) Autonomic symptoms; dry mouth, flushing, pallor, tendency to sweat, giddiness, tension, headache, raising of hair.","HAMA - Autonomic Symptoms | HAMA1-Autonomic Symptoms | HAMA113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640491","HAMA - Behavior at Interview","C102086","Hamilton Anxiety Rating Scale (HAMA) Behavior at interview; fidgeting, restlessness or pacing, tremor of hands, furrowed brow, strained face, sighing or rapid respiration, facial pallor, swallowing, etc.","HAMA - Behavior at Interview | HAMA1-Behavior at Interview | HAMA114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640493","HAMD-21 - Feelings of Guilt","C102088","Hamilton Depression Rating Scale 21 Item (HAMD-21) Feelings of guilt.","HAMD-21 - Feelings of Guilt | HAMD2-Feelings of Guilt | HAMD202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640494","HAMD-21 - Suicide","C102089","Hamilton Depression Rating Scale 21 Item (HAMD-21) Suicide.","HAMD-21 - Suicide | HAMD2-Suicide | HAMD203",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640495","HAMD-21 - Insomnia Early","C102090","Hamilton Depression Rating Scale 21 Item (HAMD-21) Insomnia early.","HAMD-21 - Insomnia Early | HAMD2-Insomnia Early | HAMD204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640496","HAMD-21 - Insomnia Middle","C102091","Hamilton Depression Rating Scale 21 Item (HAMD-21) Insomnia middle.","HAMD-21 - Insomnia Middle | HAMD2-Insomnia Middle | HAMD205",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL436275","Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo","C101892","An allogeneic cancer vaccine composed of lethally irradiated, whole pancreatic cancer cells transfected with a plasmid carrying the gene for cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Allogeneic GM-CSF-secreting tumor vaccine PANC 10.05 pcDNA-1/GM-Neo secretes GM-CSF thereby activating dendritic cells, promoting antigen presentation to B- and T-cells, and promoting a cytotoxic T-lymphocyte (CTL) response. This may eventually kill tumor cells. The pancreatic tumor cells are derived from the PANC 10.05 tumor cell line.","Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo | PANC 10.05 pcDNA-1/GM-Neo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL436276","HLA-A*2402-Restricted Multipeptide Vaccine S-488410","C101893","A cancer vaccine composed of HLA-*2402-restricted epitopic peptides derived from three cancer/testis (CT) antigens, with potential antineoplastic activity. Upon subcutaneous administration, HLA-A*2402-restricted multipeptide vaccine S-488410 may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing these CT antigens. CT antigens, normally expressed only in germ cells of the testis, are overexpressed in a wide variety of human cancers.","HLA-A*2402-Restricted Multipeptide Vaccine S-488410 | S-488410",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL436277","Poly-alendronate Dextran-Guanidine Conjugate","C101894","A polybisphosphonate dextran-guanidine conjugate with potential anti-resorptive and antineoplastic activities. Alendronic acid and aminoguanidine were conjugated sequentially to oxidized dextran resulting in an average of 8 alendronate and 50 guanidine groups coupled to the dextran backbone. Upon administration, the poly-alendronate dextran-guanidine conjugate inhibits the mevalonate pathway by inhibiting farnesyl diphosphate synthase (FDPS) which leads to a reduction in protein prenylation and to the loss of downstream metabolites essential for osteoclast function. This eventually leads to the induction of apoptosis in osteoclasts. Also, by preventing osteoclast-mediated bone resorption, this agent decreases bone turnover and stabilizes the bone matrix. The guanidine moiety increases the nitrogen content and possibly the activity of the bisphosphonate and its ability to inhibit FDPS. In addition, the guanidine moiety facilitates cell internalization and may contribute to this agent's cytotoxicity.","Poly-alendronate Dextran-Guanidine Conjugate | Dextran/Alendronate/Guanidine-containing Polybisphosphonate | ODX | Osteodex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL436278","anti-HER3 monoclonal antibody LJM716","C101895","A human monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3) with potential antineoplastic activity. Elgemtumab binds to and locks HER3 in the inactive conformation and does not interfere with its interaction with neuregulin (NRG). The inactivated form of HER3 blocks the PI3K/Akt signaling pathway, thereby inhibiting cellular proliferation in HER2 or NRG expressing tumor cells. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors; it has no active kinase domain but is activated through heterodimerization with other members of the EGFR receptor family, such as HER2.","Elgemtumab | ELGEMTUMAB | LJM-716 | LJM716",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640301","ADNI AVLT - List A Recall 1 Word 1","C101896","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 1, Word 1.","ADNI AVLT - List A Recall 1 Word 1 | AVL01-List A Recall 1 Word 1 | AVL01001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640302","ADNI AVLT - List A Recall 1 Word 2","C101897","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 1, Word 2.","ADNI AVLT - List A Recall 1 Word 2 | AVL01-List A Recall 1 Word 2 | AVL01002",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640303","ADNI AVLT - List A Recall 1 Word 3","C101898","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 1, Word 3.","ADNI AVLT - List A Recall 1 Word 3 | AVL01-List A Recall 1 Word 3 | AVL01003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640304","ADNI AVLT - List A Recall 1 Word 4","C101899","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 1, Word 4.","ADNI AVLT - List A Recall 1 Word 4 | AVL01-List A Recall 1 Word 4 | AVL01004",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640836","Bacteriological Failure","C102601","There are indicators of bacterial infection in the individual who previously had an infection.","Bacteriological Failure | BACTERIOLOGICAL FAILURE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640837","Bacteriological Finding","C102602","Objective evidence of bacterial infection perceptible to the examiner by laboratory procedure.","Bacteriological Finding | BACTERIOLOGICAL FINDING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641315","PHQ-9 Questionnaire Question","C103501","A question associated with the PHQ-9 questionnaire.","PHQ-9 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641316","PHQ-15 Questionnaire Question","C103502","A question associated with the PHQ-15 questionnaire.","PHQ-15 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641317","SIQR Questionnaire Question","C103503","A question associated with the SIQR questionnaire.","SIQR Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641318","SOWS Short Questionnaire Question","C103504","A question associated with the SOWS Short questionnaire.","SOWS Short Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642469","UPS Questionnaire Question","C103505","A question associated with the UPS questionnaire.","UPS Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640989","BTK inhibitor ONO-4059","C102876","An orally available formulation containing an inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity. Upon administration, tirabrutinib covalently binds to BTK within B cells, thereby preventing B cell receptor signaling and impeding B cell development. As a result, this agent may inhibit the proliferation of B cell malignancies. BTK, a cytoplasmic tyrosine kinase and member of the Tec family of kinases, plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.","Tirabrutinib | 6-Amino-9-((3R)-1-(2-butynoyl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one | 8H-Purin-8-one,6-amino-7,9-dihydro-9-((3R)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl) | GS 4059 | GS-4059 | GS4059 | ONO-4059 | ONO4059 | TIRABRUTINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640453","BARS - Subjective, Distress","C102048","Barnes Akathisia Rating Scale (BARS) Subjective, distress related to restlessness.","BARS - Subjective, Distress | BARS01-Subjective, Distress | BARS0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640454","BARS - Global Clinical Assessment","C102049","Barnes Akathisia Rating Scale (BARS) Global clinical assessment of akathisia.","BARS - Global Clinical Assessment | BARS01-Global Clinical Assessment | BARS0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640455","CDR - Memory","C102050","Clinical Dementia Rating (CDR) Memory.","CDR - Memory | CDR01-Memory | CDR0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640456","CDR - Orientation","C102051","Clinical Dementia Rating (CDR) Orientation.","CDR - Orientation | CDR01-Orientation | CDR0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640457","CDR - Judgment and Problem Solving","C102052","Clinical Dementia Rating (CDR) Judgment and problem solving.","CDR - Judgment and Problem Solving | CDR01-Judgment and Problem Solving | CDR0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640458","CDR - Community Affairs","C102053","Clinical Dementia Rating (CDR) Community affairs.","CDR - Community Affairs | CDR01-Community Affairs | CDR0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640459","CDR - Home and Hobbies","C102054","Clinical Dementia Rating (CDR) Home and hobbies.","CDR - Home and Hobbies | CDR01-Home and Hobbies | CDR0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640460","CDR - Personal Care","C102055","Clinical Dementia Rating (CDR) Personal care.","CDR - Personal Care | CDR01-Personal Care | CDR0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640462","COWS - Sweating","C102057","Clinical Opiate Withdrawal Scale (COWS) Sweating.","COWS - Sweating | COWS1-Sweating | COWS102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640463","COWS - Restlessness","C102058","Clinical Opiate Withdrawal Scale (COWS) Restlessness.","COWS - Restlessness | COWS1-Restlessness | COWS103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640464","COWS - Pupil Size","C102059","Clinical Opiate Withdrawal Scale (COWS) Pupil size.","COWS - Pupil Size | COWS1-Pupil Size | COWS104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL601883","PARP 1/2 inhibitor E7449","C102746","An orally available small molecule inhibitor of the nuclear enzymes poly (ADP-ribose) polymerase (PARP) 1 and 2, with potential antineoplastic activity. Upon administration, E7449 selectively binds to PARP 1 and 2, thereby preventing the repair of damaged DNA via the base excision repair (BER) pathway. This agent enhances the accumulation of single and double strand DNA breaks and promotes genomic instability eventually leading to apoptosis. PARP 1/2 inhibitor E7449 may enhance the cytotoxicity of DNA-damaging agents and of radiotherapy. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA.","PARP/Tankyrase Inhibitor 2X-121  | 2X-121 | E-7449 | E7449 | PARP/TNKS Inhibitor 2X-121 | PARP/Tankyrase Inhibitor 2X-121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437004","PLED-based MnSOD Mimetic","C102747","A derivative of pyridoxyl ethyldiamine (PLED) and mimetic of the human mitochondrial manganese superoxide dismutase (MnSOD), with antioxidant, metal chelating and potential chemoprotective activities. Upon administration, PLED-based MnSOD mimetic mimics MnSOD and scavenges oxygen free radicals such as superoxide anion, hydrogen peroxide, and hydroxyl radical, thereby preventing oxygen free radical damage to macromolecules such as DNA and minimizing oxygen free radical-related chemotoxicity in normal tissues. In addition, this agent is able to strongly bind to iron.","PLED-based MnSOD Mimetic | CALMANGAFODIPIR | PLEDOx | PP-095",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640497","HAMD-21 - Insomnia Late","C102092","Hamilton Depression Rating Scale 21 Item (HAMD-21) Insomnia late.","HAMD-21 - Insomnia Late | HAMD2-Insomnia Late | HAMD206",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640498","HAMD-21 - Work and Activities","C102093","Hamilton Depression Rating Scale 21 Item (HAMD-21) Work and activities.","HAMD-21 - Work and Activities | HAMD2-Work and Activities | HAMD207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640499","HAMD-21 - Retardation","C102094","Hamilton Depression Rating Scale 21 Item (HAMD-21) Retardation; psychomotor (slowness of thought and speech, impaired ability to concentrate, decreased motor activity).","HAMD-21 - Retardation | HAMD2-Retardation | HAMD208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640500","HAMD-21 - Agitation","C102095","Hamilton Depression Rating Scale 21 Item (HAMD-21) Agitation.","HAMD-21 - Agitation | HAMD2-Agitation | HAMD209",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640501","HAMD-21 - Anxiety Psychological","C102096","Hamilton Depression Rating Scale 21 Item (HAMD-21) Anxiety psychological.","HAMD-21 - Anxiety Psychological | HAMD2-Anxiety Psychological | HAMD210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831332","Blocked Ventricular Premature Complex by ECG Finding","C102604","An electrocardiographic finding of a premature ventricular complex which occurs between two normal QRS complexes which have normal timing. (CDISC)","Blocked Ventricular Premature Complex by ECG Finding | Blocked Ventricular Premature Complex | Blocked Ventricular Premature Complex by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640840","Clinical Cure","C102607","The absence of signs or symptoms of disease in an individual who previously had a disease.","Clinical Cure | CLINICAL CURE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640841","Clinical Failure","C102608","The occurrence or recurrence of disease signs or symptoms after treatment.","Clinical Failure | CLINICAL FAILURE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640842","Contact With Exposure During Medical Procedure","C102609","A way of contracting a disease by interacting with an individual that has been exposed to the disease while undergoing a medical procedure.","Contact With Exposure During Medical Procedure | CONTACT WITH EXPOSURE DURING MEDICAL PROCEDURE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640843","Contact With Exposure In Crowd Setting","C102610","A way of contracting a disease by physically associating with an infected group of individuals.","Contact With Exposure In Crowd Setting | CONTACT WITH EXPOSURE IN CROWD SETTING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640846","Current or Recent Employee or Volunteer in Homeless Shelter","C102613","An individual who is presently or not long ago worked or offered to assist without pay at a temporary housing facility for persons without a stable or permanent residence.","Current or Recent Employee or Volunteer in Homeless Shelter | CURRENT OR RECENT EMPLOYEE OR VOLUNTEER IN HOMELESS SHELTER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640847","Current or Recent Employee or Volunteer in Jail or Prison","C102614","An individual who is presently or not long ago worked or offered to assist without pay at an institution where persons are confined for punishment and to protect the public.","Current or Recent Employee or Volunteer in Jail or Prison | CURRENT OR RECENT EMPLOYEE OR VOLUNTEER IN JAIL OR PRISON",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640848","Current or Recent Employee or Volunteer in Nursing Home","C102615","An individual who is presently or not long ago worked or offered to assist without pay at a residential health care facility for persons with chronic illness or disability.","Current or Recent Employee or Volunteer in Nursing Home | CURRENT OR RECENT EMPLOYEE OR VOLUNTEER IN NURSING HOME",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538936","Device Exposure Domain","C102617","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to device exposure.","Device Exposure Domain | DX | Device Exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3490677","tanibirumab","C102877","A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, olinvacimab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression.","Olinvacimab | OLINVACIMAB | TTAC-0001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437181","Boanmycin Hydrochloride","C102878","The hydrochloride salt form of boanmycin (aka bleomycin A6), a component of the antibiotic bleomycin produced by Streptomyces species, with potential antineoplastic activity. Upon administration, boanmycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals. This causes single- and double-stranded DNA breaks which eventually leads to cell death. Compared to bleomycin, boanmycin appears to have a more favorable toxicity profile.","Boanmycin Hydrochloride | BAM HCl | BLEOMYCIN A6 HYDROCHLORIDE | Bleomycin A6 Hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437182","hTERT/Survivin/CMV Multipeptide Vaccine","C102879","A vaccine containing multiple peptides derived from the human telomerase reverse transcriptase (hTERT), survivin and cytomegalovirus (CMV), with potential immunostimulating and antineoplastic activities. Upon administration, hTERT/survivin/CMV multipeptide vaccine may elicit a cytotoxic T cell (CTL) response against tumor cells espressing hTERT, survivin and CMV. hTERT, the catalytic subunit of telomerase, and the inhibitor of apoptosis (IAP) family member survivin, both often upregulated in tumor cells, play key roles in tumor cell growth and survival. Further, CMV expression is correlated with certain types of cancer.","hTERT/Survivin/CMV Multipeptide Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437183","Everolimus Tablets for Oral Suspension","C102880","Tablets for oral suspension containing everolimus, a derivative of the natural macrocyclic lactone sirolimus, with immunosuppressive and antineoplastic activities. After suspension of the everolimus tablets in water and oral administration, this agent inhibits the activation of the serine/threonine kinase mammalian target of rapamycin (mTOR) by binding to mTOR's cytosolic receptor immunophilin FK Binding Protein-12 (FKBP-12). Inhibition of the mTOR complex may result in the inhibition of the phosphatidylinositol 3 kinase/Akt/mTOR pathway and an inhibition in the expression of vascular endothelial cell growth factor (VEGF) and hypoxia-inducible factor. Ultimately, this may result in decreased tumor cell proliferation and tumor angiogenesis. This pediatric formulation can dissolve easily in a small volume of water making it easier to swallow and is available in smaller dose increments thereby allowing for greater dosing flexibility.","Everolimus Tablets for Oral Suspension | Afinitor Disperz",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437184","Thioureidobutyronitrile","C102881","A water-soluble, small molecule and activator of the tumor suppressor protein p53, with potential antineoplastic activity. Upon intravenous administration, thioureidobutyronitrile activates p53 which in turn induces the expressions of p21 and PUMA (p53 up-regulated modulator of apoptosis), thereby inhibiting cancer cell growth and causing tumor cell apoptosis. Thioureidobutyronitrile may be effective in drug-resistant cancers with mutated p53. p53 tumor suppressor, a transcription factor regulating the expression of many stress response genes and mediating various anti-proliferative processes, is often mutated in cancer cells.","Thioureidobutyronitrile | 4-ISOTHIOUREIDOBUTYRONITRILE | 4-Isothioureidobutyronitrile | Carbamimidothioic Acid, 3-Cyanopropyl Ester | Kevetrin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437185","uniformly-labeled [U-13C] glucose","C102882","A non-radioactive, naturally occurring carbon 13 (13C) glucose isotopomer in which all six carbons are 13C, with potential imaging application. Upon administration of uniformly-labeled [U-13C] glucose, the glucose is taken up and metabolized by tumors and the 13C-containing metabolites can be imaged by 13C nuclear magnetic resonance (NMR) spectroscopy. Since tumor cells take up and metabolize glucose in higher amounts and through different pathways than normal cells, this agent may help assess the metabolic phenotype of the tumor.","Uniformly-labeled [13C]glucose | U-13C-Glucose | [U-13C] Glucose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437005","Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia Extract Granules","C102748","A proprietary suspension formulation prepared from granules of standardized extracts from the fruits of Vaccinium myrtillus, the aerial parts of Macleaya cordata and the roots of Echinacea angustifolia, with potential anti-mucositis, anti-inflammatory, and analgesic activities. The main active ingredients of this formulation include anthocyanosides and procyanidins, benzophenanthridinic alkaloids, and alkylamides from V. myrtillus, M. cordata and E. angustifolia extracts, respectively. Upon administration in the mucosal cavity, the anthocyanosides scavenge free radicals, form a protective barrier on the mucosa, and protect the integrity of the capillary vessels; the benzophenanthridine alkaloids prevent the production of pro-inflammatory cytokines by inhibiting NF-kB and may halt the growth of microorganisms; the alkylamides inhibit cyclooxygenase and 5-lipoxygenase thereby blocking productions of prostaglandin and leukotriene. Furthermore, alkylamides modulate the expression of tumor necrosis factor alpha and other cytokines involved in inflammation processes through cannabinoid type 2 receptors and as cannabinomimetics they may also exert analgesic activity.","Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia Extract Granules | Samital Granules | V. myrtillus/M. cordata/E. angustfolia Extract Granules",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640931","Zirconium Zr 89-labeled Anti-PlGF Monoclonal Antibody RO5323441","C102750","A radioimmunoconjugate comprised of the humanized IgG1 monoclonal antibody directed against placental growth factor (PlGF) and labeled with zirconium Zr 89 (Zr 89), with potential radiotracer activity upon positron emission tomography (PET) imaging. The monoclonal antibody moiety of RO5323441 binds to both PlGF-1 and -2, thereby preventing the binding of PlGF-1 and -2 to the vascular endothelial growth factor receptor-1 (VEGFR-1) and the subsequent activation of VEGFR-1. The radioisotope moiety of RO5323441 may be detected using PET, thereby allowing for visualization of the antibody's distribution and PlGF expression. PlGF, a member of the VEGF sub-family and a key molecule in angiogenesis and vasculogenesis, is upregulated in many cancers.","Zirconium Zr 89-labeled Anti-PlGF Monoclonal Antibody RO5323441 | 89Zr-RO5323441",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437008","WT1 Peptide Vaccine WT2725","C102751","A peptide cancer vaccine comprised of a peptide derived from Wilms tumor gene 1 (WT1) protein, with potential immunomodulating and antineoplastic activities. Upon administration, WT2725 may induce a specific cytotoxic T-lymphocyte (CTL) response against WT1-overexpressing tumor cells. WT1 protein, a zinc finger DNA-binding protein, is overexpressed in leukemic cells and in a vast number of non-hematological solid tumors.","WT1 Peptide Vaccine WT2725 | WT2725",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640933","Gemictabine ProTide","C102752","A pyrimidine analogue and a proprietary prodrug based on an aryloxy phosphoramidate derivative of gemcitabine with potential antineoplastic activity. Upon intravenous administration and cellular uptake, fosgemcitabine palabenamide is converted into the active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP). dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA replication; dFdCTP is incorporated into DNA, resulting in premature termination of DNA replication and eventually induction of apoptosis. With the phosphoramidate moiety on the gemcitabine monophosphate group, NUC-1031 has improved properties over its parent molecule: 1) is more lipophilic and accumulates in cancer cells by passive diffusion and does not require a nucleoside transporter, 2) as the agent is delivered in the monophosphate form, the first phosphorylation step by deoxycytidine kinase is not required, 3) this agent is not susceptible to deactivation by cytidine deaminase cleavage of the monophosphorylated form. Altogether, this may help overcome resistance to gemcitabine.","Fosgemcitabine Palabenamide | Acelarin | FOSGEMCITABINE PALABENAMIDE | Gemictabine ProTide | NUC 1031 | NUC-1031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640256","CDISC SDTM New York Heart Association Class Responses Terminology","C101839","Terminology associated with the New York Heart Association class responses codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM New York Heart Association Class Responses Terminology | NYHAC | New York Heart Association Classification | SDTM-NYHAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640257","CDISC SDTM Killip Class Responses Terminology","C101840","Terminology associated with the Killip class responses codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Killip Class Responses Terminology | KILLIPC | Killip Class Responses | SDTM-KILLIPC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539103","CDISC SDTM Thrombolysis in Myocardial Infarction Flow Responses Terminology","C101841","Terminology associated with the time flow responses codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Thrombolysis in Myocardial Infarction Flow Responses Terminology | SDTM-TIMIFLRS | TIMI Flow Responses | TIMIFLRS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640258","CDISC SDTM Canadian Cardiovascular Society Classification Terminology","C101842","Terminology associated with the Canadian Cardiovascular Society classification codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Canadian Cardiovascular Society Classification Terminology | CACRDSC | Canadian Cardiovascular Society Classification | SDTM-CACRDSC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640259","CDISC SDTM Coronary Artery Disease Presentation Terminology","C101843","Terminology associated with the coronary artery disease presentation codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Coronary Artery Disease Presentation Terminology | CADPRSN | Coronary Artery Disease Presentation | SDTM-CADPRSN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640260","CDISC SDTM Coronary Artery Disease Symptoms Terminology","C101844","Terminology associated with the coronary artery disease symptoms codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Coronary Artery Disease Symptoms Terminology | CADSYMP | Coronary Artery Disease Symptoms | SDTM-CADSYMP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539921","CDISC SDTM Mechanical Circulatory Support Placement Timing Terminology","C101845","Terminology associated with the mechanical circulatory support placement timing codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Mechanical Circulatory Support Placement Timing Terminology | MCRCSPTM | Mechanical Circulatory Support Placement Timing | SDTM-MCRCSPTM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640535","SF-36 v1.0 Acute - Limit Bathing or Dressing Yourself","C102136","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) How much does your health now limit you in - bathing or dressing yourself.","SF-36 v1.0 Acute - Limit Bathing or Dressing Yourself | SF362-Limit Bathing or Dressing Yourself | SF36203J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640536","SF-36 v1.0 Acute - Physical: Cut Down Time on Work","C102137","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) The Short Form 36 Health Survey Acute, US Version 1.0 (SF36 V1.0 ACUTE) -During the past week, have you had any of the following problems with your work or other regular daily activities as a result of your physical health - cut down on the amount of time you spent on work or other activities.","SF-36 v1.0 Acute - Physical: Cut Down Time on Work | SF362-Physical: Cut Down Time on Work | SF36204A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640537","SF-36 v1.0 Acute - Physical: Accomplished Less","C102138","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) During the past week, have you had any of the following problems with your work or other regular daily activities as a result of your physical health - accomplished less than you would like.","SF-36 v1.0 Acute - Physical: Accomplished Less | SF362-Physical: Accomplished Less | SF36204B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640538","SF-36 v1.0 Acute - Physical: Limited Kind of Work","C102139","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) During the past week, have you had any of the following problems with your work or other regular daily activities as a result of your physical health - were limited in the kind of work or other activities.","SF-36 v1.0 Acute - Physical: Limited Kind of Work | SF362-Physical: Limited Kind of Work | SF36204C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640539","SF-36 v1.0 Acute - Physical: Difficulty Perform Work","C102140","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) During the past week, have you had any of the following problems with your work or other regular daily activities as a result of your physical health - had difficulty performing the work or other activities (for example, it took extra effort).","SF-36 v1.0 Acute - Physical: Difficulty Perform Work | SF362-Physical: Difficulty Perform Work | SF36204D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640540","SF-36 v1.0 Acute - Emotional: Cut Down Time on Work","C102141","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) During the past week, have you had any of the following problems with your work or other regular daily activities as a result of any emotional problems (such as feeling depressed or anxious) - cut down on the amount of time you spent on work or other activities.","SF-36 v1.0 Acute - Emotional: Cut Down Time on Work | SF362-Emotional: Cut Down Time on Work | SF36205A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640541","SF-36 v1.0 Acute - Emotional: Accomplished Less","C102142","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) During the past week, have you had any of the following problems with your work or other regular daily activities as a result of any emotional problems (such as feeling depressed or anxious) - accomplished less than you would like.","SF-36 v1.0 Acute - Emotional: Accomplished Less | SF362-Emotional: Accomplished Less | SF36205B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640542","SF-36 v1.0 Acute - Emotional: Did Work Less Carefully","C102143","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) During the past week, have you had any of the following problems with your work or other regular daily activities as a result of any emotional problems (such as feeling depressed or anxious) - did work or other activities less carefully than usual.","SF-36 v1.0 Acute - Emotional: Did Work Less Carefully | SF362-Emotional: Did Work Less Carefully | SF36205C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640543","SF-36 v1.0 Acute - Extent Phys/Emotional Interfered","C102144","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) During the past week, to what extent has your physical health or emotional problems interfered with your normal social activities with family, friends, neighbors, or groups?","SF-36 v1.0 Acute - Extent Phys/Emotional Interfered | SF362-Extent Phys/Emotional Interfered | SF36206",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640545","SF-36 v1.0 Acute - Pain Interfere With Normal Work","C102146","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) During the past week, how much did pain interfere with your normal work (including both work outside the home and housework)?","SF-36 v1.0 Acute - Pain Interfere With Normal Work | SF362-Pain Interfere With Normal Work | SF36208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541900","NCI CTEP SDC Ovarian Germ Cell Cancer Sub-Category Terminology","C103071","Ovarian Germ Cell Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Ovarian Germ Cell Cancer Sub-Category Terminology | NCI CTEP Simple Disease Classification Ovarian Germ Cell Cancer Sub-Category Terminology | Ovarian Germ Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541914","NCI CTEP SDC Testicular Germ Cell Cancer Sub-Category Terminology","C103072","Testicular Germ Cell Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Testicular Germ Cell Cancer Sub-Category Terminology | NCI CTEP Simple Disease Classification Testicular Germ Cell Cancer Sub-Category Terminology | Testicular Germ Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641054","NCI CTEP SDC Head and Neck Neoplasm, Miscellaneous Sub-Category Terminology","C103073","Head and Neck Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Head and Neck Neoplasm, Miscellaneous Sub-Category Terminology | Head and Neck Neoplasm, Miscellaneous | NCI CTEP Simple Disease Classification Head and Neck Neoplasm, Miscellaneous Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540527","NCI CTEP SDC Head and Neck Precancerous Condition Sub-Category Terminology","C103074","Head and Neck Precancerous Condition is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Head and Neck Precancerous Condition Sub-Category Terminology | Head and Neck Precancerous Condition | NCI CTEP Simple Disease Classification Head and Neck Precancerous Condition Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538931","NCI CTEP SDC Head and Neck Squamous Cell Carcinoma Sub-Category Terminology","C103075","Head and Neck Squamous Cell Carcinoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Head and Neck Squamous Cell Carcinoma Sub-Category Terminology | Head and Neck Squamous Cell Carcinoma | NCI CTEP Simple Disease Classification Head and Neck Squamous Cell Carcinoma Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539713","NCI CTEP SDC Nasopharyngeal Cancer Sub-Category Terminology","C103076","Nasopharyngeal Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Nasopharyngeal Cancer Sub-Category Terminology | NCI CTEP Simple Disease Classification Nasopharyngeal Cancer Sub-Category Terminology | Nasopharyngeal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537461","PREX2 wt Allele","C102518","Human PREX2 wild-type allele is located in the vicinity of 8q13.2 and is approximately 285 kb in length. This allele, which encodes phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 2 protein, plays a role in the regulation of small GTPase-dependent signaling.","PREX2 wt Allele | 6230420N16Rik | DEP.2 | DEPDC2 | FLJ12987 | P-REX2 | Phosphatidylinositol-3,4,5-Trisphosphate-Dependent Rac Exchange Factor 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539808","CDISC SDTM Risk Assessment Terminology","C101848","Terminology associated with the protocol risk assessment response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Protocol Risk Assessment Response Codelist | CDISC SDTM Risk Assessment Terminology | Protocol Risk Assessment Response | RSKASMT | Risk Assessment | SDTM-RSKASMT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640264","CDISC SDTM Coronary Vessel Disease Extent Terminology","C101850","Terminology associated with the coronary vessel disease extent codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Coronary Vessel Disease Extent Terminology | CVSLDEXT | Coronary Vessel Disease Extent | SDTM-CVSLDEXT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640266","CDISC SDTM Sudden Death Syndrome Type Terminology","C101852","Terminology associated with the sudden death syndrome type codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Sudden Death Syndrome Type Terminology | SDTHSDTP | SDTM-SDTHSDTP | Sudden Death Syndrome Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539948","CDISC SDTM Cardiac Valvular Regurgitation Severity Terminology","C101853","Terminology associated with the cardiac valvular regurgitation severity codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Cardiac Valvular Regurgitation Severity Terminology | SDTM-CVLVRSEV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL436874","Saccharomyces boulardii Probiotic Supplement","C102567","A probiotic containing the non-pathogenic yeast Saccharomyces boulardii with antidiarrheal and potential anti-inflammatory, antimicrobial and immunomodulating activities. As a dietary supplement, S. boulardii may improve digestion and help maintain adequate colonization of the gastrointestinal (GI) tract by modulating the composition of the normal intestinal microflora. During colonization of the GI tract, S. boulardii forms a protective barrier that helps maintain the integrity of the epithelial barrier. This prevents attachment of pathogens to the intestinal mucosa. In addition, this probiotic secretes a protease that binds to and degrades toxins A and B produced by Clostridium difficile, thereby preventing their harmful effects. Dietary supplementation with this bacterium may reduce the secretion of proinflammatory cytokines and may potentiate natural and acquired immunity.","Saccharomyces boulardii Probiotic Supplement | Floratil | S. boulardii Probiotic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640546","SF-36 v1.0 Acute - Did You Feel Full of Pep","C102147","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - did you feel full of pep.","SF-36 v1.0 Acute - Did You Feel Full of Pep | SF362-Did You Feel Full of Pep | SF36209A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539927","NCI CTEP SDC Salivary Gland Cancer Sub-Category Terminology","C103077","Salivary Gland Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Salivary Gland Cancer Sub-Category Terminology | NCI CTEP Simple Disease Classification Salivary Gland Cancer Sub-Category Terminology | Salivary Gland Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0265881","Congenital Aortic Arch Hypoplasia","C103266","An underdeveloped aortic arch that is present at birth. This symptom is usually found in association with other cardiac defects that characterize left heart syndrome.","Congenital Aortic Arch Hypoplasia | Congenital Hypoplasia Aortic Arch | Congenital Hypoplasia of Aortic Arch",,,,,,,,,,,,,,,"4245636","Congenital hypoplasia of aortic arch",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL438123","Largetrifoliolious Bugbane Rhizome Supplement","C103271","A proprietary tablet formulation containing an extract from Largetrifoliolious Bugbane rhizome (Shengma), the dried root of Cimicifuga sp., with potential use for relieving menopausal symptoms. The Largetrifoliolious bugbane rhizome supplement contains total saponins, including phytoestrogens that can modulate estrogen receptor signaling. This supplement is used to reduce disease symptoms, such as sweating, toothache, headache, ulcers, and insomnia. In women, this supplement may be used to reduce symptoms related to menopause.","Largetrifoliolious Bugbane Rhizome Supplement | Ximingting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538772","Phosphatidylinositol 3,4,5-Trisphosphate-Dependent Rac Exchanger 2 Protein, Human","C102519","Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 2 protein (1606 aa, ~183 kDa) is encoded by the human PREX2 gene. This protein is involved in the activation of Rac family GTPases.","Phosphatidylinositol 3,4,5-Trisphosphate-Dependent Rac Exchanger 2 Protein | DEP Domain-Containing Protein 2 | P-Rex2 | PREX2 | PtdIns(3,4,5)-Dependent Rac Exchanger 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539536","ARID1B wt Allele","C102521","Human ARID1B wild-type allele is located in the vicinity of 6q25.1 and is approximately 433 kb in length. This allele, which encodes AT-rich interactive domain-containing protein 1B, is involved in both cell type-specific transcriptional regulation and chromatin remodeling.","ARID1B wt Allele | 6A3-5 | AT Rich Interactive Domain 1B (SWI1-Like) Gene | AT-Rich Interactive Domain 1B wt Allele | BAF-Associated Factor, 250-kD, B Gene | BAF250B | BAF250b | BRIGHT | CSS1 | DAN15 | ELD/OSA1 | KIAA1235 | MRD12 | OSA2 | P250R | RP11-419L10.1 | p250R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539849","AT-Rich Interactive Domain-Containing Protein 1B","C102522","AT-rich interactive domain-containing protein 1B (2236 aa, ~236 kDa) is encoded by the human ARID1B gene. This protein plays a role in transcriptional regulation mediated by chromatin remodeling.","AT-Rich Interactive Domain-Containing Protein 1B | ARID Domain-Containing Protein 1B | ARID1B | BAF250B | BRG1-Associated Factor 250b | BRG1-Binding Protein hELD/OSA1 | ELD (Eyelid)/OSA Protein | Osa Homolog 2 | hOsa2 | p250R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539690","MAP3K13 wt Allele","C102524","Human MAP3K13 wild-type allele is located in the vicinity of 3q27 and is approximately 206 kb in length. This allele, which encodes mitogen-activated protein kinase kinase kinase 13 protein, plays a role in the modulation of both JNK-dependent signaling and serine/threonine phosphorylation.","MAP3K13 wt Allele | LZK | MEKK13 | MGC133196 | MLK | Mitogen-Activated Protein Kinase Kinase Kinase 13 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1431040","Mitogen-Activated Protein Kinase Kinase Kinase 13, Human","C102525","Mitogen-activated protein kinase kinase kinase 13 (966 aa, ~108 kDa) is encoded by the human MAP3K13 gene. This protein is involved in the mediation of serine/threonine phosphorylation.","Mitogen-Activated Protein Kinase Kinase Kinase 13 | EC 2.7.11.25 | Leucine Zipper-Bearing Kinase | MAP3K13 | MLK | Mixed Lineage Kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640797","Doxycycline Phosphate","C102526","No value exists.","Doxycycline Phosphate | 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S-(4alpha,4aalpha,5alpha,5aalpha,6alpha,12aalpha))-, Phosphate (1:1) (Salt) | DOXYCYCLINE PHOSPHATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0344375","Stomach Cramp","C102529","An involuntary muscular contraction in the stomach. Often, this cramp is spasmodic and can be uncomfortable.","Stomach Cramp | Stomach Cramps",,,,,,,,,,,,,,,"4196986","Stomach cramps",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL436875","Docetaxel Lipid Microspheres","C102568","A lipid microsphere (LM)-based formulation containing the poorly water soluble taxane docetaxel, a semi-synthetic analogue of paclitaxel, with antineoplastic activity. Docetaxel binds specifically to the beta-tubulin subunit of the microtubule, stabilizing tubulin and inhibiting microtubule disassembly, which causes cell cycle arrest at the G2/M phase and leads to cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response. Compared to docetaxel alone, the LM formulation may enhance stability, improve efficacy and may reduce toxicity; this formulation does not contain toxic detergents needed to solubilize docetaxel which further improves its side effect profile.","Docetaxel Lipid Microspheres | DLE | DT-LM | Docetaxel Lipid Emulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL436876","Recombinant EphB4-HSA Fusion Protein","C102569","A recombinant fusion protein composed of the full-length extracellular domain (soluble) of human receptor tyrosine kinase ephrin type-B receptor 4 (sEphB4) and fused, at its C-terminus, to full-length human serum albumin (HSA), with potential antineoplastic and anti-angiogenic activities. sEphB4-HSA functions as a decoy receptor for the membrane-bound ligand Ephrin-B2 (Efnb2) and interferes with the binding of Efnb2 to its native receptors, including EphB4 and EphA3. This may result in a reduction of angiogenesis and a reduction in cell growth of Efnb2 and/or EphB4 over-expressing tumor cells. In addition, this agent also prevents the angiogenic effects of numerous growth factors due to interactions between Efnb2 and EphB4. Efnb2 and EphB4 are overexpressed in a variety of tumor cell types; the bi-directional signaling of Efnb2-EphB4 plays an important role in angiogenesis and tumor cell migration, invasion, and proliferation. Albumin reduces this agent's degradation, improves circulation time and may thus improve efficacy.","Recombinant EphB4-HSA Fusion Protein | SEPHB4-HSA | sEphB4-HSA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280525","mercaptopurine/methotrexate","C10256","A regimen consisting of mercaptopurine and methotrexate that may be used in the treatment of acute lymphoblastic leukemia (ALL).","Mercaptopurine/Methotrexate Regimen | Linker Regimen maintenance | MP/MTX | Mercaptopurine and Methotrexate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640823","Broad Ligament Adenosarcoma","C102570","An extremely rare adenosarcoma that arises from the broad ligament.","Broad Ligament Adenosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1997870","Epoetin Zeta","C102571","A recombinant form of the endogenous human cytokine erythropoietin (EPO) with erythropoiesis-stimulating activity. Similar to EPO, epoetin zeta binds to and activates erythropoietin receptors on the surface of committed erythroid progenitors in the bone marrow resulting in their proliferation and differentiation into functional erythrocytes. This may enhance red blood cell counts and hemoglobin levels. Epoetin zeta differs from other epoetins in its glycosylation profile. EPO is a glycosylated polypeptide primarily produced by renal peritubular cells and its synthesis is regulated by a serum oxygenation feedback mechanism.","Epoetin Zeta | Retacrit | SB309 | Silapo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640502","HAMD-21 - Anxiety Somatic","C102097","Hamilton Depression Rating Scale 21 Item (HAMD-21) Anxiety somatic; physiological concomitants of anxiety, (i.e., effects of autonomic overactivity, 'butterflies,' indigestion, stomach cramps, belching, diarrhea, palpitations, hyperventilation, paresthesia, sweating, flushing, tremor, headache, urinary frequency).","HAMD-21 - Anxiety Somatic | HAMD2-Anxiety Somatic | HAMD211",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640503","HAMD-21 - Somatic Symptoms Gastro-intestinal","C102098","Hamilton Depression Rating Scale 21 Item (HAMD-21) Somatic symptoms gastro-intestinal.","HAMD-21 - Somatic Symptoms Gastro-intestinal | HAMD2-Somatic Symptoms Gastro-intestinal | HAMD212",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640504","HAMD-21 - Somatic Symptoms General","C102099","Hamilton Depression Rating Scale 21 Item (HAMD-21) Somatic symptoms general.","HAMD-21 - Somatic Symptoms General | HAMD2-Somatic Symptoms General | HAMD213",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640505","HAMD-21 - Genital Symptoms","C102100","Hamilton Depression Rating Scale 21 Item (HAMD-21) Genital symptoms; symptoms such as loss of libido, impaired sexual performance, menstrual disturbances.","HAMD-21 - Genital Symptoms | HAMD2-Genital Symptoms | HAMD214",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0892377","Klebsiella pneumoniae Glycoprotein","C1018","A glycoprotein complex extracted from Klebsiella pneumoniae K2O1 strain with immunostimulating property. This glycoprotein complex consists of 2 repetitive glycoprotein subunits; P1 comes from the bacterial capsule about 95 kD in molecular mass and F1, having an lipopolysaccharide-related structure (350 kDa), is derived from bacterial external membrane. Although the mechanism of action is not fully elucidated, Klebsiella pneumoniae F1 fraction appears to suppress monocyte apoptosis, hence inducing the differentiation of monocytes into macrophages. Furthermore, this agent also enhances humoral and cell-mediated immune responses, and increases natural killer cell cytotoxicity functions. This glycoprotein has been shown to reduce the incidence of infection.","Klebsiella pneumoniae Glycoprotein | Biostim | RU 41.740 | RU- 41740",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640305","ADNI AVLT - List A Recall 1 Word 5","C101900","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 1, Word 5.","ADNI AVLT - List A Recall 1 Word 5 | AVL01-List A Recall 1 Word 5 | AVL01005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640306","ADNI AVLT - List A Recall 1 Word 6","C101901","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 1, Word 6.","ADNI AVLT - List A Recall 1 Word 6 | AVL01-List A Recall 1 Word 6 | AVL01006",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640307","ADNI AVLT - List A Recall 1 Word 7","C101902","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 1, Word 7.","ADNI AVLT - List A Recall 1 Word 7 | AVL01-List A Recall 1 Word 7 | AVL01007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640308","ADNI AVLT - List A Recall 1 Word 8","C101903","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 1, Word 8.","ADNI AVLT - List A Recall 1 Word 8 | AVL01-List A Recall 1 Word 8 | AVL01008",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640309","ADNI AVLT - List A Recall 1 Word 9","C101904","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 1, Word 9.","ADNI AVLT - List A Recall 1 Word 9 | AVL01-List A Recall 1 Word 9 | AVL01009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640311","ADNI AVLT - List A Recall 1 Word 11","C101906","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 1, Word 11.","ADNI AVLT - List A Recall 1 Word 11 | AVL01-List A Recall 1 Word 11 | AVL01011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640312","ADNI AVLT - List A Recall 1 Word 12","C101907","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 1, Word 12.","ADNI AVLT - List A Recall 1 Word 12 | AVL01-List A Recall 1 Word 12 | AVL01012",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640313","ADNI AVLT - List A Recall 1 Word 13","C101908","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 1, Word 13.","ADNI AVLT - List A Recall 1 Word 13 | AVL01-List A Recall 1 Word 13 | AVL01013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640314","ADNI AVLT - List A Recall 1 Word 14","C101909","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 1, Word 14.","ADNI AVLT - List A Recall 1 Word 14 | AVL01-List A Recall 1 Word 14 | AVL01014",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0699222","Nitroglycerin Transdermal Patch","C103272","A sustained release transdermal patch containing the organic nitrate nitroglycerin, with vasodilator and potential immunomodulating activities. Upon application to the skin, nitroglycerin is continuously released from the patch and absorbed. In turn, nitroglycerin is converted into nitric oxide (NO), which activates guanylyl cyclase, increasing cyclic guanosine monophosphate concentration thus resulting in smooth muscle relaxation. In addition, activation of NO-mediated signaling pathways may inhibit hypoxia-induced tumor cell invasiveness, chemoresistance, evasion of immune cell recognition and cancer cell progression. Particularly, reactivation of NO-mediated signaling appears to inhibit the increased tumor cell shedding of the major histocompatibility complex class I chain-related (MIC) molecules MICA and MICB as is seen in hypoxic tumor environments; MIC molecules play key roles in tumor cell immune surveillance through their interaction with the C-type lectin-like NKG2D receptor on natural killer, lymphokine-activated killer and effector T cells.","Nitroglycerin Transdermal Patch | GTN Transdermal Patch | Glyceryl Trinitrate Transdermal Patch | Minitran",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333997","Lymphoid Hyperplasia","C102532","A benign or malignant, diffuse and/or follicular lymphocytic proliferation.","Lymphoid Hyperplasia | ",,,,,,,,,,,,,,,"4028722|4195465","Lymphoid hyperplasia|Lymphoid hyperplasia",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C4013040","Myopia","C102533","The condition in which the individual does not see far distances clearly.","Myopia | Myopic | Nearsighted | Nearsightedness",,,,,,,,,,,,,,,"379805","Myopia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640798","Anti-ErbB3 Monoclonal Antibody AV-203","C102535","A humanized monoclonal antibody (MoAb) directed against the human receptor tyrosine-protein kinase ErbB-3 (HER3) with potential antineoplastic activity. Anti-ErbB3 MoAb AV-203 binds to and inhibits both ligand neuregulin-1 (NRG-1)-dependent and ligand-independent ErbB3 activation, which may result in inhibition of ErbB3-dependent PI3K/Akt signaling and may lead to inhibition of cellular proliferation and differentiation. ErbB3, a member of the epidermal growth factor receptor (EGFR) family, is frequently overexpressed in solid tumors and its overexpression generally correlates with poor prognosis and tumor resistance; it has no active kinase domain itself but is activated through heterodimerization with other members of the EGFR receptor family that do.","Anti-ErbB3 Monoclonal Antibody AV-203 | AV 203 | AV-203 | AV203 | Anti-ErbB3 MoAb AV-203 | CAN-017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL436809","Hyaluronic Acid-based Hydrating Vaginal Gel","C102536","A clear, colorless water-based vaginal gel containing the partial benzyl ester of hyaluronic acid (HA) with potential hydrating activity. Upon vaginal application, HA adheres to the vaginal mucosa where it retains water, provides moisture to the vagina and protects the vaginal mucosa. This gel may provide relief in vaginal dryness and may prevent sexual discomfort, itching and irritation. This HA derivative is less susceptible to enzymatic breakdown and provides longer lasting activity compared to HA. HA is naturally present in the vaginal epithelium.","Hyaluronic Acid-based Hydrating Vaginal Gel | Hyalo GYN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540803","SPOP wt Allele","C102537","Human SPOP wild-type allele is located in the vicinity of 17q21.33 and is approximately 79 kb in length. This allele, which encodes speckle-type POZ protein, plays a role in the regulation of protein ubiquitination. Mutation of the gene is associated with Nabais Sa-de Vries syndrome, types 1 and 2.","SPOP wt Allele | BTBD32 | NEDMACE | NEDMIDF | NSDVS1 | NSDVS2 | Speckle Type BTB/POZ Protein wt Allele | Speckle-Type BTB/POZ Protein Gene | Speckle-Type POZ Protein Gene | Speckle-Type POZ Protein wt Allele | TEF2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539844","Speckle-Type POZ Protein, Human","C102538","Speckle-type POZ protein (374 aa, ~42 kDa) is encoded by the human SPOP gene. This protein is involved the ubiquitination of proteins.","Speckle-Type POZ Protein | HIB Homolog 1 | Roadkill Homolog 1 | SPOP | Speckle-Type BTB/POZ Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL436811","Water-based Vaginal Lubricant","C102539","A water-based vaginal lubricant with hydration activity. Upon application to the vagina, the water-based vaginal lubricant provides moisture and may relieve dryness and sexual discomfort.","Water-based Vaginal Lubricant | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL436812","Lactoperoxidase/Lysozyme/Lactoferrin-based Prebiotic Vaginal Lubricant","C102540","A preservative-free, prebiotic vaginal lubricant with potential moisturizing and protective activities. Upon vaginal application, the lactoperoxidase/lysozyme/lactoferrin-based prebiotic vaginal lubricant moisturizes the vagina and may relieve and/or prevent dryness, itching, irritation, odor and infection. The vaginal lubricant contains anti-yeast proteins and enzymes, including lactoperoxidase, lysozyme and lactoferrin which are naturally found in vaginal fluid and help maintain the natural microflora in the vagina. The prebiotic glycogen helps restore and maintain the beneficial microorganisms in the vagina and maintains a healthy acidic pH. Altogether, this protects the vagina against the actions of harmful bacteria.","Lactoperoxidase/Lysozyme/Lactoferrin-based Prebiotic Vaginal Lubricant | Luvena",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL436813","Adenovirus-PSA Prostate Cancer Vaccine","C102541","A cancer vaccine composed of a genetically engineered, replication-deficient type 5 adenovirus carrying the human prostate-specific antigen (PSA), with potential immunostimulating and antineoplastic activities. Upon subcutaneous vaccination with the adenovirus-PSA prostate cancer vaccine, the adenovirus infects cells and expresses PSA. In turn, PSA may activate the immune system and may induce a cytotoxic T-lymphocyte response against PSA-expressing tumor cells. PSA, a tumor associated antigen, is expressed by prostate epithelial cells and is overexpressed in prostate cancer.","Adenovirus-PSA Prostate Cancer Vaccine | Ad/PSA Vaccine | Adenovirus/PSA Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640506","HAMD-21 - Hypochondriasis","C102101","Hamilton Depression Rating Scale 21 Item (HAMD-21) Hypochondriasis.","HAMD-21 - Hypochondriasis | HAMD2-Hypochondriasis | HAMD215",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640507","HAMD-21 - Loss of Weight by History","C102102","Hamilton Depression Rating Scale 21 Item (HAMD-21) Loss of weight when rating by history.","HAMD-21 - Loss of Weight by History | HAMD2-Loss of Weight by History | HAMD216A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640508","HAMD-21 - Loss of Weight Measured","C102103","Hamilton Depression Rating Scale 21 Item (HAMD-21) Loss of weight on weekly ratings by war psychiatrist, when actual weight changes are measured.","HAMD-21 - Loss of Weight Measured | HAMD2-Loss of Weight Measured | HAMD216B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640509","HAMD-21 - Insight","C102104","Hamilton Depression Rating Scale 21 Item (HAMD-21) Insight.","HAMD-21 - Insight | HAMD2-Insight | HAMD217",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640510","HAMD-21 - Diurnal Variation","C102105","Hamilton Depression Rating Scale 21 Item (HAMD-21) Diurnal variation.","HAMD-21 - Diurnal Variation | HAMD2-Diurnal Variation | HAMD218A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640511","HAMD-21 - Diurnal Variation Severity","C102106","Hamilton Depression Rating Scale 21 Item (HAMD-21) Diurnal variation severity.","HAMD-21 - Diurnal Variation Severity | HAMD2-Diurnal Variation Severity | HAMD218B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640512","HAMD-21 - Depersonalization and Derealization","C102107","Hamilton Depression Rating Scale 21 Item (HAMD-21) Depersonalization and derealization; such as feelings of unreality, nihilistic ideas.","HAMD-21 - Depersonalization and Derealization | HAMD2-Depersonalization/Derealization | HAMD219",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640513","HAMD-21 - Paranoid Symptoms","C102108","Hamilton Depression Rating Scale 21 Item (HAMD-21) Paranoid symptoms.","HAMD-21 - Paranoid Symptoms | HAMD2-Paranoid Symptoms | HAMD220",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640514","HAMD-21 - Obsessional and Compulsive Symptoms","C102109","Hamilton Depression Rating Scale 21 Item (HAMD-21) Obsessional and compulsive symptoms.","HAMD-21 - Obsessional and Compulsive Symptoms | HAMD2-Obsessional/Compulsive Symptoms | HAMD221",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640315","ADNI AVLT - List A Recall 1 Word 15","C101910","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 1, Word 15.","ADNI AVLT - List A Recall 1 Word 15 | AVL01-List A Recall 1 Word 15 | AVL01015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640316","ADNI AVLT - List A Recall 1 Total","C101911","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of words recalled from List A, first attempt.","ADNI AVLT - List A Recall 1 Total | AVL01-List A Recall 1 Total | AVL01016",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640317","ADNI AVLT - List A Intrusions 1","C101912","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of intrusions while recalling List A, first attempt.","ADNI AVLT - List A Intrusions 1 | AVL01-List A Intrusions 1 | AVL01017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640318","ADNI AVLT - List A Recall 2 Word 1","C101913","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 2, Word 1.","ADNI AVLT - List A Recall 2 Word 1 | AVL01-List A Recall 2 Word 1 | AVL01018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540849","Device to Subject Relationship Domain","C102620","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to device to subject relationship.","Device to Subject Relationship Domain | DR | Device-Subject Relationships",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542920","Device Tracking and Disposition Domain","C102621","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to device tracking and disposition.","Device Tracking and Disposition Domain | DT | Device Tracking and Disposition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0872145","Directly Observed Therapy","C102624","Medication is dispensed and consumed under the direct supervision of personnel at a clinical site.","Directly Observed Therapy | ",,,,,,,,,,,,,,,"4056964","Drug intake observed",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3542449","Drug Resistance Status","C102626","The determination of whether the microbe or lesion is resistant to drugs normally used in treatment.","Drug Resistance Status | DRSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416809","LDB1 Gene","C102885","This gene is involved in the modulation of transcription.","LDB1 Gene | LDB1 | LIM Domain Binding 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538767","LDB1 wt Allele","C102886","Human LDB1 wild-type allele is located within 10q24-q25 and is approximately 13 kb in length. This allele, which encodes LIM domain-binding protein 1, plays a role in the regulation of gene transcription.","LDB1 wt Allele | CLIM2 | LIM Domain Binding 1 wt Allele | NLI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1433433","LDB1 protein, human","C102887","LIM domain-binding protein 1 (411 aa, ~47 kDa) is encoded by the human LDB1 gene. This protein is involved in transcription factor regulation.","LIM Domain-Binding Protein 1 | CLIM-2 | Carboxyl Terminal LIM Domain-Binding Protein 2 | Carboxyl-Terminal LIM Domain-Binding Protein 2 | LDB-1 | LDB1 | LIM Domain-Binding Factor CLIM2 | LIM Domain-Binding Factor-1 | Nuclear LIM Interactor | hLdb1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540582","CTDNEP1 wt Allele","C102889","Human CTDNEP1 wild-type allele is located in the vicinity of 17p13 and is approximately 8 kb in length. This allele, which encodes CTD nuclear envelope phosphatase 1 protein, is involved in the modulation of fatty acid phosphatases.","CTDNEP1 wt Allele | CTD Nuclear Envelope Phosphatase 1 wt Allele | DULLARD | HSA011916 | NET56",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1432965","CTD Nuclear Envelope Phosphatase 1, Human","C102890","CTD nuclear envelope phosphatase 1 (244 aa, ~28 kDa) is encoded by the human CTDNEP1 gene. This protein plays a role in the dephosphorylation and regulation of fatty acid phosphatase proteins.","CTD Nuclear Envelope Phosphatase 1 | C-Terminal Domain Nuclear Envelope Phosphatase 1 | CTDNEP1 | EC 3.1.3.16 | Serine/Threonine-Protein Phosphatase Dullard",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414508","F2RL3 Gene","C102542","This gene plays a role in both receptor signaling and platelet activation.","F2RL3 Gene | Coagulation Factor II (Thrombin) Receptor-Like 3 Gene | F2RL3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540804","F2RL3 wt Allele","C102543","Human F2RL3 wild-type allele is located in the vicinity of 19p12 and is approximately 3 kb in length. This allele, which encodes proteinase-activated receptor 4 protein, is involved in the modulation of both platelet activation and receptor signaling.","F2RL3 wt Allele | Coagulation Factor II (Thrombin) Receptor-Like 3 wt Allele | PAR4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437010","Adenovirus Encoding Tyrosinase/MART-1/MAGEA6-transduced Autologous Dendritic Cell Vaccine","C102753","A cell-based cancer vaccine composed of autologous dendritic cells (DCs) transduced with a recombinant adenoviral vector encoding three full length human melanoma associated antigens (MAAs), tyrosinase, melan-A (MART-1) and the melanoma antigen A6 (MAGEA6), with potential antineoplastic activity. Upon intradermal administration, adenovirus encoding tyrosinase/MART-1/MAGEA6-transduced autologous DC vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tyrosinase/MART-1/MAGEA6-positive tumor cells, which may result in tumor cell death and decreased tumor growth. Tyrosinase, a melanoma-specific differentiation antigen, catalyzes the first step of melanin synthesis in melanocytes. Vaccination with multi-antigen modified DC may improve the efficacy of the DC immunotherapy.","Adenovirus Encoding Tyrosinase/MART-1/MAGEA6-transduced Autologous Dendritic Cell Vaccine | AdVTMM2-transduced Dendritic Cell Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2353772","TZP-101","C102755","The hydrochloride salt form of ulimorelin, a macrocyclic ghrelin peptidomimetic, with potential gastrointestinal (GI) prokinetic activity. Upon intravenous administration, ulimorelin binds to the ghrelin receptor in the GI tract and may stimulate GI motility. Ghrelin is a natural ligand for growth hormone secretagogue receptors and is normally localized in the proximal GI tract. The ghrelin receptor signaling pathway mediates multiple GI functions, including motility and gastric emptying.","Ulimorelin Hydrochloride | (2R,5S,8R,11R)-5-Cyclopropyl-11-((4-fluorophenyl)methyl)-2,7,8-trimethyl-2,3,4,5,7,8,10,11,13,14,15,16-dodecahydro-6H-1,4,7,10,13- benzoxatetraazacyclooctadecine-6,9,12-trione Hydrochloride Monohydrate | TZP-101 | ULIMORELIN HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0603925","Sheng-Mai San","C102756","A Chinese herbal medicine composed of extracts from the roots of Panax Ginseng (ren shen) and Ophiopogon japonicas (mai men dong), and the berries of Schisandra chinensis (wu wei zi) with potential protective activity. Ginseng contains a complex mixture of saponins, ginsenosides and panaxosides; homoisoflavonoids isolated from Ophiopogon show anti-inflammatory properties; Schisandra contains abundant amounts of phytoestrogen lignans with antioxidant activity. Although the mechanism of action maybe inexplicit or complex, these phytochemicals work synergistically and may improve symptoms such as shortness of breath, sweating, cough, thirst, dry mouth, and palpitations as well as have an effect on chemotherapy or radiotherapy-induced fatigue, weakness, and neutropenia.","Sheng-Mai San | Panax ginseng/Ophiopogon japonicus/Schisandra chinensis Herbal Supplement | Shengmai San",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437012","Allodepleted Haploidentical T Cells-expressing Inducible Caspase 9","C102757","Allodepleted haploidentical T-lymphocytes transduced with the Gal-V pseudotyped retrovirus vector encoding SFG.iCasp9-2A-deltaCD19, with potential immune reconstitution property. SFG.iCasp9-2A-deltaCD19 contains the suicide gene inducible caspase 9 (iCasp9) linked with a 2A-like cleavable peptide to the selectable marker, truncated human CD19 (deltaCD19). iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9 using a short linker (SGGGS). Donor T cell therapy may help control transplant-related viral infections following allogeneic hematopoietic stem cell transplantation. However, even the addition of allodepleted donor T cells can lead to graft-versus-host disease (GVHD). In the event that GVHD begins to develop, the chemical homodimerizer AP1903 can be administered, which binds to the FKBP12-F36V domain activating caspase 9. This results in the death of T cells causing GVHD while sparing the virus reactive T-cells.","Allodepleted Haploidentical T Cells-expressing Inducible Caspase 9 | iCasp9 Allogeneic T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538922","CDISC SDTM Cardiac Valvular Stenosis Severity Terminology","C101854","Terminology associated with the cardiac valvular stenosis severity codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Cardiac Valvular Stenosis Severity Terminology | SDTM-CVLSTSEV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640267","CDISC SDTM Non-system Reason for PCI Delay Terminology","C101855","Terminology associated with the non-system reason for PCI delay codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Non-system Reason for PCI Delay Terminology | NSYSPCID | Non-system Reason for PCI Delay | SDTM-NSYSPCID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538926","Endocrine System Findings Domain","C102630","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to endocrine system findings.","Endocrine System Findings Domain | ED | Endocrine System Findings",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640852","Extensively Drug Resistance Process","C102633","Resistance to nearly all known drugs, particularly the most efficacious or non-first line drugs, used in the treatment of a particular disease.","Extensively Drug Resistance Process | EXTENSIVE DRUG RESISTANCE | XDR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640547","SF-36 v1.0 Acute - Have You Been Very Nervous Person","C102148","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - have you been a very nervous person.","SF-36 v1.0 Acute - Have You Been Very Nervous Person | SF362-Have You Been Very Nervous Person | SF36209B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640548","SF-36 v1.0 Acute - Felt Down Nothing Cheer You Up","C102149","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - have you felt so down in the dumps that nothing could cheer you up.","SF-36 v1.0 Acute - Felt Down Nothing Cheer You Up | SF362-Felt Down Nothing Cheer You Up | SF36209C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280279","cyclophosphamide/fluorouracil/fluoxymesterone/methotrexate","C10214","A regimen consisting of cyclophosphamide, methotrexate, fluorouracil, and fluoxymesterone that may be used as maintenance therapy for breast cancer.","Cyclophosphamide/Fluorouracil/Fluoxymesterone/Methotrexate Regimen | CMF-FLU | CMFH | CTX/5-FU/FXM/MTX | Cyclophosphamide-Fluorouracil-Fluoxymesterone-Methotrexate Regimen | Cyclophosphamide/Fluorouracil/Fluoxymesterone/Methotrexate Cyclophosphamide-Fluorouracil-Fluoxymesterone-Methotrexate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640549","SF-36 v1.0 Acute - Have You Felt Calm and Peaceful","C102150","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - have you felt calm and peaceful.","SF-36 v1.0 Acute - Have You Felt Calm and Peaceful | SF362-Have You Felt Calm and Peaceful | SF36209D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640550","SF-36 v1.0 Acute - Did You Have a Lot of Energy","C102151","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - did you have a lot of energy.","SF-36 v1.0 Acute - Did You Have a Lot of Energy | SF362-Did You Have a Lot of Energy | SF36209E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640551","SF-36 v1.0 Acute - You Felt Downhearted and Blue","C102152","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - have you felt downhearted and blue.","SF-36 v1.0 Acute - You Felt Downhearted and Blue | SF362-You Felt Downhearted and Blue | SF36209F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640552","SF-36 v1.0 Acute - Did You Feel Worn Out","C102153","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - did you feel worn out.","SF-36 v1.0 Acute - Did You Feel Worn Out | SF362-Did You Feel Worn Out | SF36209G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539821","SOX10 wt Allele","C102892","Human SOX10 wild-type allele is located in the vicinity of 22q13.1 and is approximately 17 kb in length. This allele, which encodes transcription factor SOX-10 protein, plays a role in transcriptional activation. Mutation of the gene is associated with Waardenburg syndrome types 2E and 4C and with peripheral demyelinating neuropathy, central dysmyelinating leukodystrophy, Waardenburg syndrome, and Hirschsprung disease.","SOX10 wt Allele | DOM | Dominant Megacolon, Mouse, Human Homolog of Gene | PCWH | RP5-1039K5.9 | SRY (Sex Determining Region Y)-Box 10 wt Allele | SRY-Related HMG-Box Gene 10 | WS2E | WS4 | WS4C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1569837","SOX10 protein, human","C102893","Transcription factor SOX-10 (466 aa, ~50 kDa) is encoded by the human SOX10 gene. This protein is involved in the regulation of gene expression.","Transcription Factor SOX-10 | SOX10 | SRY-Related HMG-Box Gene 10 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823228","TASP1 Gene","C102894","This gene plays a role in both proteolysis and transcriptional regulation.","TASP1 Gene | TASP1 | Taspase, Threonine Aspartase, 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541256","TASP1 wt Allele","C102895","Human TASP1 wild-type allele is located in the vicinity of 20p12.1 and is approximately 373 kb in length. This allele, which encodes threonine aspartase 1 protein, is involved in proteolysis.","TASP1 wt Allele | C20orf13 | Chromosome 20 Open Reading Frame 13 Gene | FLJ20212 | Taspase, Threonine Aspartase, 1 wt Allele | dJ585I14.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541322","Threonine Aspartase","C102896","Threonine aspartase 1 (420 aa, ~44 kDa) is encoded by the human TASP1 gene. This protein plays a role in the proteolysis of histone-lysine N-methyltransferase MLL protein.","Threonine Aspartase 1 | EC 3.4.25.- | TASP1 | Taspase 1 | Taspase-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425005","MTCH2 Gene","C102898","This gene is involved in transport through the inner mitochondrial membrane.","MTCH2 Gene | MTCH2 | Mitochondrial Carrier 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641057","NCI CTEP SDC Immunodeficiency and Immunosuppression Disorder Sub-Category Terminology","C103081","Immunodeficiency and Immunosuppression Disorder is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Immunodeficiency and Immunosuppression Disorder Sub-Category Terminology | Immunodeficiency and Immunosuppression Disorder | NCI CTEP Simple Disease Classification Immunodeficiency and Immunosuppression Disorder Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541890","Extracted Lead","C102283","The lead has been removed from the body.","Extracted Lead | EXTRACTED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640667","Reused Lead","C102284","The lead has been left in situ and reused.","Reused Lead | REUSED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538929","CDISC SDTM Procedure Urgency Status Terminology","C101856","Terminology associated with the procedure urgency status codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Procedure Urgency Status Terminology | PRURGNCY | Procedure Urgency Status | SDTM-PRURGNCY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539779","CDISC SDTM Procedure Terminology","C101858","Terminology associated with the procedure codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Procedure Terminology | PROCEDUR | Procedure | SDTM-PROCEDUR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640268","CDISC SDTM Cardiac Procedure Indication Terminology","C101859","Terminology associated with the cardiac procedure indication codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Cardiac Procedure Indication Terminology | CVPRCIND | Cardiac Procedure Indication | SDTM-CVPRCIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539594","CDISC SDTM Coronary Artery Dominance Terminology","C101860","Terminology associated with the coronary artery dominance codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Coronary Artery Dominance Terminology | CARTDOM | Coronary Artery Dominance | SDTM-CARTDOM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640269","CDISC SDTM Lesion Complexity Terminology","C101861","Terminology associated with the lesion complexity codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Lesion Complexity Terminology | LSNCMPX | Lesion Complexity | SDTM-LSNCMPX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640270","CDISC SDTM Lead Abnormality Terminology","C101862","Terminology associated with the lead abnormality codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Lead Abnormality Terminology | LEADABN | Lead Abnormality | SDTM-LEADABN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640271","CDISC SDTM Reason Coronary Sinus Access or Left Ventricular Lead Not Implanted Terminology","C101864","Terminology associated with the reason coronary sinus access or left ventricular lead not implanted codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Reason Coronary Sinus Access or Left Ventricular Lead Not Implanted Terminology | CSLVLNIM | Reason CS/LV Lead Not Implanted | SDTM-CSLVLNIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640272","CDISC SDTM Acute Coronary Syndrome Presentation Category Terminology","C101865","Terminology associated with the acute coronary syndrome presentation category codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Acute Coronary Syndrome Presentation Category Terminology | ACSPCAT | Acute Coronary Syndrome Presentation Category | SDTM-ACSPCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640273","CDISC SDTM Cardiac Rhythm Device Failure Manifestation Terminology","C101866","Terminology associated with the cardiac rhythm device failure manifestation codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Cardiac Rhythm Device Failure Manifestation Terminology | CRYDFMAN | Cardiac Rhythm Device Failure Manifestation | SDTM-CRYDFMAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539917","CDISC SDTM Lead Status Terminology","C101867","Terminology associated with the lead status codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Lead Status Terminology | LEADSTAT | Lead Status | SDTM-LEADSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640275","AIMS Clinical Classification Question","C101869","A question associated with the AIMS questionnaire.","AIMS Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538954","Tuberculosis Contact","C102573","Any exposure to a suspected or confirmed tuberculosis causing agent.","Tuberculosis Contact | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640553","SF-36 v1.0 Acute - Have You Been a Happy Person","C102154","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - have you been a happy person.","SF-36 v1.0 Acute - Have You Been a Happy Person | SF362-Have You Been a Happy Person | SF36209H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640555","SF-36 v1.0 Acute - Time Phys/Emotional Interfered","C102156","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) During the past week, how much of the time has your physical health or emotional problems interfered with your social activities (like visiting friends, relatives, etc.)?","SF-36 v1.0 Acute - Time Phys/Emotional Interfered | SF362-Time Phys/Emotional Interfered | SF36210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640556","SF-36 v1.0 Acute - Get Sick Little Easier Than Other","C102157","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) How TRUE or FALSE is the following statement for you - I seem to get sick a little easier than other people.","SF-36 v1.0 Acute - Get Sick Little Easier Than Other | SF362-Get Sick Little Easier Than Other | SF36211A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640557","SF-36 v1.0 Acute - I Am as Healthy as Anybody I Know","C102158","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) How TRUE or FALSE is the following statement for you - I am as healthy as anybody I know.","SF-36 v1.0 Acute - I Am as Healthy as Anybody I Know | SF362-I Am as Healthy as Anybody I Know | SF36211B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640558","SF-36 v1.0 Acute - I Expect My Health to Get Worse","C102159","The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) How TRUE or FALSE is the following statement for you - I expect my health to get worse.","SF-36 v1.0 Acute - I Expect My Health to Get Worse | SF362-I Expect My Health to Get Worse | SF36211C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539079","NCI CTEP SDC Clear Cell Sarcoma of the Kidney Sub-Category Terminology","C103082","Clear Cell Sarcoma of the Kidney is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Clear Cell Sarcoma of the Kidney Sub-Category Terminology | Clear Cell Sarcoma of the Kidney | NCI CTEP Simple Disease Classification Clear Cell Sarcoma of the Kidney Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540608","NCI CTEP SDC Renal Cell Carcinoma Sub-Category Terminology","C103084","Renal Cell Carcinoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Renal Cell Carcinoma Sub-Category Terminology | NCI CTEP Simple Disease Classification Renal Cell Carcinoma Sub-Category Terminology | Renal Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538837","NCI CTEP SDC Rhabdoid Tumor of the Kidney Sub-Category Terminology","C103085","Rhabdoid Tumor of the Kidney is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Rhabdoid Tumor of the Kidney Sub-Category Terminology | NCI CTEP Simple Disease Classification Rhabdoid Tumor of the Kidney Sub-Category Terminology | Rhabdoid Tumor of the Kidney",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538905","NCI CTEP SDC Wilms Tumor Sub-Category Terminology","C103086","Wilms Tumor is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Wilms Tumor Sub-Category Terminology | NCI CTEP Simple Disease Classification Wilms Tumor Sub-Category Terminology | Wilms Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640232","CDISC Questionnaire CDR Test Name Terminology","C101812","Test names of clinical classification questions associated with the Clinical Dementia Rating (CDR) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification CDR Test Name Terminology | CDISC Questionnaire CDR Test Name Terminology | CDR01TN | Clinical Dementia Rating Clinical Classification Test Name | Clinical Dementia Rating Questionnaire Test Name | QS-CDR TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640233","CDISC Questionnaire COWS Test Code Terminology","C101813","Test codes of questionnaire questions associated with the Clinical Opiate Withdrawal Scale (COWS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire COWS Test Code Terminology | COWS1TC | Clinical Opiate Withdrawal Scale Questionnaire Test Code | QS-COWS TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640234","CDISC Questionnaire COWS Test Name Terminology","C101814","Test names of questionnaire questions associated with the Clinical Opiate Withdrawal Scale (COWS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire COWS Test Name Terminology | COWS1TN | Clinical Opiate Withdrawal Scale Questionnaire Test Name | QS-COWS TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640236","QS-ECOG TEST","C101816","Test names of clinical classification questions associated with the Eastern Cooperative Oncology Group (ECOG) Performance Status for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification ECOG Test Name Terminology | ECOG1TN | Eastern Cooperative Oncology Group Performance Status Clinical Classification Test Name | QS-ECOG TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640237","CDISC Questionnaire EQ-5D-5L Test Code Terminology","C101817","Test cods of questionnaire questions associated with the European Quality of Life Five Dimension Five Level Scale (EQ-5D-5L) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire EQ-5D-5L Test Code Terminology | EQ5D02TC | European Quality of Life Five Dimension Five Level Scale Questionnaire Test Code | QS-EQ-5D-5L TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640238","CDISC Questionnaire EQ-5D-5L Test Name Terminology","C101818","Test names of questionnaire questions associated with the European Quality of Life Five Dimension Five Level Scale (EQ-5D-5L) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire EQ-5D-5L Test Name Terminology | EQ5D02TN | European Quality of Life Five Dimension Five Level Scale Questionnaire Test Name | QS-EQ-5D-5L TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640239","CDISC Clinical Classification HAMA Test Code Terminology","C101819","Test codes of clinical classification questions associated with the Hamilton Anxiety Rating Scale (HAMA) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification HAMA Test Code Terminology | HAMA1TC | Hamilton Anxiety Rating Scale Clinical Classification Test Code | QS-HAMA TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640825","CDISC SDTM Contact Case Investigation Contact Type Terminology","C102575","Terminology associated with the contact case investigation contact type codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Contact Case Investigation Contact Type Terminology | CCINVTYP | Contact Case Investigation Contact Type | SDTM-CCINVTYP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640826","CDISC SDTM Directly Observed Therapy Location Terminology","C102576","Terminology associated with the directly observed therapy location codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Directly Observed Therapy Location Terminology | SDTM-DOBSTLOC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542450","CDISC SDTM Drug Resistance Status Terminology","C102577","Terminology associated with the drug resistance status codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Drug Resistance Status Terminology | DRSTAT | Drug Resistance Status | SDTM-DRSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542417","CDISC SDTM Disease Outcome Terminology","C102578","Terminology associated with the disease outcome codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Disease Outcome Terminology | DSSOUT | Disease Outcome | SDTM-DSSOUT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640827","CDISC SDTM Supporting Evidence for Re-Treatment Terminology","C102579","Terminology associated with the supporting evidence for re-treatment codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Supporting Evidence for Re-Treatment Terminology | EVDRETRT | SDTM-EVDRETRT | Supporting Evidence for Re-Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540597","CDISC SDTM Microbial Identification Certainty Terminology","C102581","Terminology associated with the microbial identification certainty codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Microbial Identification Certainty Terminology | MCIDCERT | Microbial Identification Certainty | SDTM-MCIDCERT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538831","CDISC SDTM Reason for Treatment Interruption Terminology","C102583","Terminology associated with the reason for treatment interruption codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Reason for Treatment Interruption Terminology | REASTINT | Reason for Treatment Interruption | SDTM-REASTINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538830","CDISC SDTM Reason For Treatment Terminology","C102584","Terminology associated with the reason for treatment codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Reason For Treatment Terminology | REASTRT | Reason For Treatment | SDTM-REASTRT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540847","CDISC SDTM Treatment Failure Reason Terminology","C102585","Terminology associated with the treatment failure reason codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Treatment Failure Reason Terminology | SDTM-REASTRTF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539763","CDISC SDTM Reason Treatment Not Administered Terminology","C102586","Terminology associated with the reason treatment not administered codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Reason Treatment Not Administered Terminology | SDTM-RSTRTNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538985","CDISC SDTM Social Risk Factor Terminology","C102587","Terminology associated with the social risk factor codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Social Risk Factor Terminology | RISKSOC | SDTM-RISKSOC | Social Risk Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539811","CDISC SDTM Contact Setting Terminology","C102588","Terminology associated with the contact setting codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Contact Setting Terminology | SDTM-SETCON",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640319","ADNI AVLT - List A Recall 2 Word 2","C101914","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 2, Word 2.","ADNI AVLT - List A Recall 2 Word 2 | AVL01-List A Recall 2 Word 2 | AVL01019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640320","ADNI AVLT - List A Recall 2 Word 3","C101915","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 2, Word 3.","ADNI AVLT - List A Recall 2 Word 3 | AVL01-List A Recall 2 Word 3 | AVL01020",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640321","ADNI AVLT - List A Recall 2 Word 4","C101916","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 2, Word 4.","ADNI AVLT - List A Recall 2 Word 4 | AVL01-List A Recall 2 Word 4 | AVL01021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640322","ADNI AVLT - List A Recall 2 Word 5","C101917","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 2, Word 5.","ADNI AVLT - List A Recall 2 Word 5 | AVL01-List A Recall 2 Word 5 | AVL01022",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640323","ADNI AVLT - List A Recall 2 Word 6","C101918","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 2, Word 6.","ADNI AVLT - List A Recall 2 Word 6 | AVL01-List A Recall 2 Word 6 | AVL01023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640324","ADNI AVLT - List A Recall 2 Word 7","C101919","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 2, Word 7.","ADNI AVLT - List A Recall 2 Word 7 | AVL01-List A Recall 2 Word 7 | AVL01024",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438126","Lactobacillus acidophilus/Streptococcus thermophilus/Bifidobacterium lactis/L. rhamnosus/B. longum/B. bifidum-based Probiotic Supplement","C103275","A nutritional supplement containing probiotic cultures of Lactobacillus acidophilus (L. acidophilus), L. rhamnosus Streptococcus thermophilus, Bifidobacterium lactis, (B. lactis), B. longum and B. bifidum, with gastrointestinal (GI) protective and immunomodulating activities. Upon oral administration, the bacteria in this probiotic supplement help maintain adequate colonization of the GI tract and modulate the composition of the normal microflora. Upon colonization of the GI tract, the probiotic bacteria form a protective barrier that helps maintain the integrity of the epithelial barrier. This will interfere with the attachment of pathogenic bacteria and other harmful substances, prevent inflammation and improve GI function.","Lactobacillus acidophilus/Streptococcus thermophilus/Bifidobacterium lactis/L. rhamnosus/B. longum/B. bifidum-based Probiotic Supplement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438127","Pegylated Liposomal Mitomycin C Lipid-based Prodrug","C103276","A pegylated liposomal formulation comprised of a lipophilic prodrug of the antineoplastic antibiotic mitomycin C containing a cleavable disulfide bond (PL-MLP), with potential antineoplastic activity. Upon administration of the pegylated liposomal mitomycin C lipid-based prodrug, the MLP moiety becomes activated upon thiolysis at the tumor site, thereby releasing mitomycin C. Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.  The thiolytic environment and upregulated expression of thioredoxins at the tumor site allow for the activation and release of mitomycin C. This prodrug formulation allows for greater circulation time, less systemic toxicity and increased accumulation of mitomycin C at the tumor site.","Pegylated Liposomal Mitomycin C Lipid-based Prodrug | JNJ-27548547 | PL-MLP | Promitil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438128","p110beta/delta PI3K Inhibitor GS-9820","C103277","An inhibitor of the beta and delta isoforms of the 110 kDa catalytic subunit of class IA phosphoinositide-3 kinases (PI3K) with potential immunomodulating and antineoplastic activities. Acalisib inhibits the activity of PI3K, thereby preventing the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), which decreases tumor cell proliferation and induces cell death. PI3K-mediated signaling is often dysregulated in cancer cells; the targeted inhibition of PI3K is designed to preserve PI3K signaling in normal, non-neoplastic cells.","Acalisib | 6-Fluoro-3-phenyl-2-((1S)-1-(7H-purin-6-ylamino)ethyl)quinazolin-4(3H)-one | ACALISIB | CAL-120 | GS-9820",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438129","Fluorine F 18 d-FMAU","C103278","A radioconjugate comprised of the synthetic pyrimidine analogue 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)thymine (d-FMAU) labeled with the radioisotope fluorine F 18 (18F-d-FMAU), that can potentially be used as an imaging agent upon positron emission tomography (PET). Upon administration, fluorine F 18 FMAU is distributed and taken up by cells based on the rate of the cell's DNA synthesis. Upon PET imaging, cell proliferation in tumors can be assessed as tumor cells have a higher rate of DNA synthesis than normal, healthy cells. This agent is not catabolized and has a long half-life compared to the radioconjugate carbon C 11 thymidine.","Fluorine F 18 d-FMAU | 1-(2'-Deoxy-2'-[18F]fluoro-beta-D-arabinofuranosyl)thymine | 18F-FMAU | 2'-Deoxy-2'-[18F]fluoro-5-methyl-1-beta-D-arabinofuranosyluracil | 5-METHYL-2'-FLUOROARAURACIL F-18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1815369","PEG-3350/Sodium Sulfate/Sodium Chloride/Potassium Chloride/Sodium Ascorbate/Ascorbic Acid-based Laxative","C103279","A preparation containing the nonabsorbable polymer polyethylene glycol (PEG or macrogol) 3350 and sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid with laxative activity. Upon oral administration, the PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid-based laxative promotes the retention of water in the bowel. This increases the water content of stool, which results in increased gastrointestinal motility and evacuation of colonic contents. This results in a complete cleansing of the colon. Compared to the 4 liter PEG-3350-based preparations, this PEG-based laxative is a low volume (2 liter) preparation, which improves patients' tolerance.","PEG-3350/Sodium Sulfate/Sodium Chloride/Potassium Chloride/Sodium Ascorbate/Ascorbic Acid-based Laxative | Moviprep | PEG-Asc",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541259","CDISC Questionnaire HAMA Test Name Terminology","C101820","Test names of clinical classification questions associated with the Hamilton Anxiety Rating Scale (HAMA) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification HAMA Test Name Terminology | HAMA1TN | Hamilton Anxiety Rating Scale Clinical Classification Test Name | QS-HAMA TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640240","CDISC Clinical Classification HAMD 21 Test Code Terminology","C101821","Test codes of clinical classification questions associated with the Hamilton Depression Rating Scale 21-Item (HAMD-21) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification HAMD 21 Test Code Terminology | HAMD2TC | Hamilton Depression Rating Scale 21-Item Clinical Classification Test Code | QS-HAMD 21 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640241","CDISC Clinical Classification HAMD 21 Test Name Terminology","C101822","Test names of clinical classification questions associated with the Hamilton Depression Rating Scale 21-Item (HAMD-21) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification HAMD 21 Test Name Terminology | HAMD2TN | Hamilton Depression Rating Scale 21-Item Clinical Classification Test Name | QS-HAMD 21 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640242","CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology","C101823","Test codes of questionnaire questions associated with the Short Form 36 Health Survey Acute, US Version 1.0 (SF36 v1.0 Acute) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology | QS-SF36 v1.0 Acute TESTCD | SF362TC | The Short Form 36 Health Survey Acute, US Version 1.0 Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640243","CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology","C101824","Test names of questionnaire questions associated with the Short Form 36 Health Survey Acute, US Version 1.0 (SF36 v1.0 Acute) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology | QS-SF36 v1.0 Acute TEST | SF362TN | The Short Form 36 Health Survey Acute, US Version 1.0 Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0676301","protease-activated receptor 4","C102544","Proteinase-activated receptor 4 (385 aa, ~41 kDa) is encoded by the human F2RL3 gene. This protein plays a role in both the mediation of receptor signaling and the promotion of platelet activation.","Proteinase-Activated Receptor 4 | Coagulation Factor II Receptor-Like 3 | PAR-4 | Protease-Activated Receptor-4 | Proteinase-Activated Receptor-4 | Thrombin Receptor-Like 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL436814","Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta","C102545","A recombinant, replicating oncolytic vesicular stomatitis virus (VSV) carrying the human interferon-beta (IFN-b) gene, with potential immunomodulating and antineoplastic activities. Upon intratumoral administration, recombinant VSV expressing IFN-b replicates in the tumor environment specifically, partially due to defective innate antiviral host defense mechanisms in tumor cells, involving type I IFNs, and exerts its cytolytic activity towards the tumor cells. By expressing human IFN-b, an INF-b-mediated antiviral immune response in surrounding normal cells is activated which protects normal cells against virus replication and VSV-mediated cell lysis. However, tumor cells have a defective IFN-b-mediated innate antiviral immune response allowing for VSV to replicate in these cells without interference. In addition, the IFN-b produced by VSV may activate an immune response in surrounding normal cells and may activate T-lymphocytes, dendritic cells and natural killer cells; thus, inducing an anti-tumor immune response against the tumor cells. VSV, a single-stranded RNA virus belonging to the genus Vesiculovirus of the family Rhabdoviridae, is relatively nonpathogenic to healthy humans.","Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta | Recombinant VSV-IFN-beta | VSV-hIFN-b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640325","ADNI AVLT - List A Recall 2 Word 8","C101920","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 2, Word 8.","ADNI AVLT - List A Recall 2 Word 8 | AVL01-List A Recall 2 Word 8 | AVL01025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640326","ADNI AVLT - List A Recall 2 Word 9","C101921","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 2, Word 9.","ADNI AVLT - List A Recall 2 Word 9 | AVL01-List A Recall 2 Word 9 | AVL01026",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640327","ADNI AVLT - List A Recall 2 Word 10","C101922","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 2, Word 10.","ADNI AVLT - List A Recall 2 Word 10 | AVL01-List A Recall 2 Word 10 | AVL01027",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640328","ADNI AVLT - List A Recall 2 Word 11","C101923","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 2, Word 11.","ADNI AVLT - List A Recall 2 Word 11 | AVL01-List A Recall 2 Word 11 | AVL01028",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640329","ADNI AVLT - List A Recall 2 Word 12","C101924","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 2, Word 12.","ADNI AVLT - List A Recall 2 Word 12 | AVL01-List A Recall 2 Word 12 | AVL01029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640330","ADNI AVLT - List A Recall 2 Word 13","C101925","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 2, Word 13.","ADNI AVLT - List A Recall 2 Word 13 | AVL01-List A Recall 2 Word 13 | AVL01030",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640331","ADNI AVLT - List A Recall 2 Word 14","C101926","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 2, Word 14.","ADNI AVLT - List A Recall 2 Word 14 | AVL01-List A Recall 2 Word 14 | AVL01031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640333","ADNI AVLT - List A Recall 2 Total","C101928","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of words recalled from List A, second attempt.","ADNI AVLT - List A Recall 2 Total | AVL01-List A Recall 2 Total | AVL01033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640334","ADNI AVLT - List A Intrusions 2","C101929","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of intrusions while recalling List A, second attempt.","ADNI AVLT - List A Intrusions 2 | AVL01-List A Intrusions 2 | AVL01034",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640854","Failure After First Treatment","C102635","A lack of response to the first cycle of therapy.","Failure After First Treatment | FAILURE AFTER FIRST TREATMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640855","Failure After Multiple Treatments","C102636","A lack of response to more than one cycle of therapy.","Failure After Multiple Treatments | FAILURE AFTER MULTIPLE TREATMENTS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539653","Fetal Findings Domain","C102637","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to fetal findings.","Fetal Findings Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641337","ADCS-CGIC - Clinical Impression of Change from Baseline","C103531","Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Clinical impression of change from baseline.","ADCS-CGIC - Clinical Impression of Change from Baseline | ACGC01-Clinical Impression of Change | ACGC0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641338","C-SSRS Since Last Visit - Suicide","C103532","C-SSRS Since Last Visit (C-SSRS Since Last Visit) Suicide.","C-SSRS Since Last Visit - Suicide | CSS02-Suicide | CSS0221",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641340","C-SSRS Since Last Visit - Most Lethal Actual Attempt Lethality/Medical Damage","C103534","C-SSRS Since Last Visit (C-SSRS Since Last Visit) Most lethal actual attempt lethality/medical damage.","C-SSRS Since Last Visit - Most Lethal Actual Attempt Lethality/Medical Damage | CSS02-Most Lethal Attempt Damage | CSS0222B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641341","C-SSRS Since Last Visit - Most Lethal Actual Attempt Potential Lethality","C103535","C-SSRS Since Last Visit (C-SSRS Since Last Visit) Most lethal actual attempt potential lethality.","C-SSRS Since Last Visit - Most Lethal Actual Attempt Potential Lethality | CSS02-Most Lethal Attempt Potential | CSS0222C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641342","ESS - Sitting and Reading","C103536","Epworth Sleepiness Scale (ESS) Sitting and reading.","ESS - Sitting and Reading | ESS01-Sitting and Reading | ESS0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641343","ESS - Watching TV","C103537","Epworth Sleepiness Scale (ESS) Watching TV.","ESS - Watching TV | ESS01-Watching TV | ESS0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641344","ESS - Sitting, Inactive in a Public Place","C103538","Epworth Sleepiness Scale (ESS) Sitting, inactive in a public place (e.g. a theatre or a meeting).","ESS - Sitting, Inactive in a Public Place | ESS01-Sitting Inactive in a Public Place | ESS0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0385181","Ginsenoside Rg3 Capsule","C103300","A capsule containing the steroidal saponin ginsenoside Rg3 isolated from the root of Panax ginseng, with potential cancer preventive and anti-angiogenic activities. Upon oral administration, ginsenoside Rg3 appears to inhibit endothelial cell proliferation, migration and tubular formation, and promotes cancer cell apoptosis. This agent also modulates the activities of certain growth factors, such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and matrix metalloproteinases (MMPs), on tumor angiogenesis. In addition, ginsenoside Rg3 may be able to sensitize cancer cells to some chemotherapeutic agents.","Ginsenoside Rg3 Capsule | Shen Yi Capsule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641363","FIQR - Stiffness","C103557","Revised Fibromyalgia Impact Questionnaire (FIQR) Please rate your level of stiffness.","FIQR - Stiffness | FIQR01-Stiffness | FIQR0114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641364","FIQR - Your Sleep","C103558","Revised Fibromyalgia Impact Questionnaire (FIQR) Please rate the quality of your sleep.","FIQR - Your Sleep | FIQR01-Your Sleep | FIQR0115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641365","FIQR - Depression","C103559","Revised Fibromyalgia Impact Questionnaire (FIQR) Please rate your level of depression.","FIQR - Depression | FIQR01-Depression | FIQR0116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641366","FIQR - Memory Problems","C103560","Revised Fibromyalgia Impact Questionnaire (FIQR) Please rate your level of memory problems.","FIQR - Memory Problems | FIQR01-Memory Problems | FIQR0117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641368","FIQR - Tenderness to Touch","C103562","Revised Fibromyalgia Impact Questionnaire (FIQR) Please rate your level of tenderness to touch.","FIQR - Tenderness to Touch | FIQR01-Tenderness to Touch | FIQR0119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641369","FIQR - Balance Problems","C103563","Revised Fibromyalgia Impact Questionnaire (FIQR) Please rate your level of balance problems.","FIQR - Balance Problems | FIQR01-Balance Problems | FIQR0120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641370","FIQR - Sensitivity to Loud Noises, Bright Lights, Odors and Cold","C103564","Revised Fibromyalgia Impact Questionnaire (FIQR) Please rate your level of sensitivity to loud noises, bright lights, odors and cold.","FIQR - Sensitivity to Loud Noises, Bright Lights, Odors and Cold | FIQR01-Sensitivity Noise/Light/Odor/Cold | FIQR0121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641371","GAD-7 - Feeling Nervous Anxious or On Edge","C103565","Generalized Anxiety Disorder - 7 (GAD-7) Feeling nervous, anxious or on edge.","GAD-7 - Feeling Nervous Anxious or On Edge | GAD01-Feeling Nervous Anxious or On Edge | GAD0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641047","NCI CTEP SDC Neuroendocrine Cancer Sub-Category Terminology","C103057","Neuroendocrine Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Neuroendocrine Cancer Sub-Category Terminology | NCI CTEP Simple Disease Classification Neuroendocrine Cancer Sub-Category Terminology | Neuroendocrine Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541904","NCI CTEP SDC Parathyroid Cancer Sub-Category Terminology","C103058","Parathyroid Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Parathyroid Cancer Sub-Category Terminology | NCI CTEP Simple Disease Classification Parathyroid Cancer Sub-Category Terminology | Parathyroid Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641145","Protein/Peptide Substance","C103227","A substance that may be described as a discrete sequence of alpha-amino-acids connected through peptide bonds.","Protein/Peptide Substance | PROTEIN/PEPTIDE SUBSTANCE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0270217","Perinatal Jaundice Related to Inspissated Bile Syndrome","C103228","Yellow pigmentation of the skin, mucous membranes and eyes due to hyperbilirubinemia caused by inspissated bile plugs in the bile ducts during the perinatal period.","Perinatal Jaundice Related to Inspissated Bile Syndrome | Perinatal Jaundice due to Inspissated Bile Syndrome",,,,,,,,,,,,,,,"4251487","Perinatal jaundice due to inspissated bile syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3256251","Phellodendron amurense bark extract","C103230","A proprietary formulation consisting of a Phellodendron amurense (Amur cork tree) bark extract, often used in traditional Chinese medicine, with anti-inflammatory, anti-oxidant and potential chemopreventive and antineoplastic activities. Phellodendron amurense bark extract contains certain isoquinoline alkaloids, flavone glycosides and phenolic compounds. Upon administration of Phellodendron amurense bark extract, the various phytochemicals in this formulation modulate multiple signal transduction pathways. This agent appears to block the activation of the transcription factor cAMP response binding protein (CREB) and inhibits Akt signaling, thereby inhibiting tumor cell growth and inducing apoptosis in Akt- and CREB-overexpressing cancer cells. In addition, this agent inhibits cyclooxygenase type 2 (COX-2), nuclear factor kappa b (NF-kB) and tumor necrosis factor alpha (TNF-a)-mediated signaling; COX-2, NF-kB and TNF-a are upregulated in certain types of cancer and during inflammation.","Phellodendron amurense Bark Extract | Nexrutine | PHELLODENDRON AMURENSE BARK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0161446","Brachial Plexus Injury","C103231","Damage to the nerves in the brachial plexus network. These nerves originate in the spinal column and innervate the shoulder, arm and hand. Often, damage is sustained from overstretching or motor vehicle accidents.","Brachial Plexus Injury | ",,,,,,,,,,,,,,,"374221","Injury of brachial plexus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0546982","Cystic Fibrosis with Meconium Ileus","C103233","A congenital metabolic detected in the neonatal period that is characterized by the presence of a meconium ileus. The disease affects the exocrine glands andis inherited as an autosomal trait. The secretions of exocrine glands are abnormal, resulting in excessively viscid mucus production which causes obstruction of passageways (including pancreatic and bile ducts, intestines, and bronchi). The sweat sodium and chloride content are increased. Symptoms usually appear in childhood and include meconium ileus, poor growth despite good appetite, malabsorption and foul bulky stools, chronic bronchitis with cough, recurrent pneumonia, bronchiectasis, emphysema, clubbing of the fingers, and salt depletion in hot weather.","Cystic Fibrosis with Meconium Ileus | ",,,,,,,,,,,,,,,"193174","Cystic fibrosis with meconium ileus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1413821","CTSS Gene","C103234","This gene is involved in the proteolysis of antigenic proteins.","CTSS Gene | CTSS | Cathepsin S Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541411","CTSS wt Allele","C103235","Human CTSS wild-type allele is located in the vicinity of 1q21 and is approximately 36 kb in length. This allele, which encodes cathepsin S protein, plays a role in antigen processing.","CTSS wt Allele | Cathepsin S wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539529","S-Adenosylmethionine Decarboxylase Proenzyme","C102775","S-adenosylmethionine decarboxylase proenzyme (334 aa, ~38 kDa) is encoded by the human AMD1 gene. This protein is involved in polyamine metabolism.","S-Adenosylmethionine Decarboxylase Proenzyme | AMD1 | AdoMetDC | EC 4.1.1.50 | S-Adenosyl-L-Methionine Carboxy-Lyase | S-Adenosyl-L-Methionine Decarboxylase | S-Adenosyl-Methionine Decarboxylase | S-Adenosylmethionine Decarboxylase 1 | SAMDC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540808","SCD wt Allele","C102777","Human SCD wild-type allele is located in the vicinity of 10q24.31 and is approximately 18 kb in length. This allele, which encodes acyl-CoA desaturase protein, is involved in fatty acid biosynthesis.","SCD wt Allele | FADS5 | MSTP008 | SCD1 | SCDOS | Stearoyl-CoA Desaturase (Delta-9-Desaturase) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2002916","SCD1 protein, human","C102778","Acyl-CoA desaturase (359 aa, ~42 kDa) is encoded by the human SCD gene. This protein plays a role in the synthesis of fatty acids.","Acyl-CoA Desaturase | Delta(9)-Desaturase | Delta-9 Desaturase | EC 1.14.19.1 | Fatty Acid Desaturase | SCD | Stearoyl-CoA Desaturase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424724","SARM1 Gene","C102779","This gene is involved in both signaling and immunity.","SARM1 Gene | SARM1 | Sterile Alpha and TIR Motif Containing 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540553","SARM1 wt Allele","C102780","Human SARM1 wild-type allele is located in the vicinity of 17q11 and is approximately 37 kb in length. This allele, which encodes sterile alpha and TIR motif-containing protein 1, plays a role in both immunity and signal transduction.","SARM1 wt Allele | KIAA0524 | SAMD2 | SARM | Sterile Alpha and TIR Motif Containing 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1097381","SARM1 protein, human","C102781","Sterile alpha and TIR motif-containing protein 1 (724 aa, ~79 kDa) is encoded by the human SARM1 gene. This protein is involved in immune responsive signaling.","Sterile Alpha and TIR Motif-Containing Protein 1 | SAM Domain-Containing Protein 2 | SARM1 | Sterile Alpha Motif Domain-Containing Protein 2 | Sterile Alpha and Armadillo Repeat Protein | Sterile Alpha and HEAT/Armadillo Motif Protein | Tir-1 Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640942","Recombinant Human MUC1-Oxidized Polymannose-pulsed Autologous Dendritic Cell Vaccine","C102782","A cancer vaccine containing autologous dendritic cells pulsed with a fusion product of an epitope of human tumor-associated epithelial mucin 1 (MUC1) antigen and the vaccine adjuvant mannan (oxidized mannose), with potential antineoplastic activity. When the modified dendritic cells are returned to the patient, they may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the MUC1 antigen, resulting in tumor cell lysis. Addition of manna in this vaccine, enhances immune recognition. MUC1 antigen, a high-molecular-weight transmembrane glycoprotein, is overexpressed on many tumor cells.","Recombinant Human MUC1-Oxidized Polymannose-pulsed Autologous Dendritic Cell Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539569","DNA-Binding Protein Inhibitor ID-3","C102970","DNA-binding protein inhibitor ID-3 (119 aa, ~12 kDa) is encoded by the human ID3 gene. This protein plays a role in the inhibition of transcription factor activity.","DNA-Binding Protein Inhibitor ID-3 | Class B Basic Helix-Loop-Helix Protein 25 | Helix-Loop-Helix Protein HEIR-1 | ID-Like Protein Inhibitor HLH 1R21 | ID3 | Inhibitor of DNA Binding 3 | bHLHb25",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007203","Cardiac Resuscitation","C102971","Measures performed to restore cardiac function.","Cardiac Resuscitation | ",,,,,,,,,,,,,,,"4320484","Cardiac resuscitation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641112","DOT1L inhibitor EPZ-5676","C103179","A small molecule inhibitor of histone methyltransferase with potential antineoplastic activity. Upon intravenous administration, pinometostat specifically blocks the activity of the histone lysine-methyltransferase DOT1L, thereby inhibiting the methylation of nucleosomal histone H3 on lysine 79 (H3K79) that is bound to the mixed lineage leukemia (MLL) fusion protein which targets genes and blocks the expression of leukemogenic genes. This eventually leads to an induction of apoptosis in the leukemic cells bearing the MLL gene translocations. DOT1L, a non-SET domain-containing histone methyltransferase, specifically methylates H3K79 and plays a key role in normal cell differentiation and in the development of leukemia with MLL gene rearrangement on chromosome 11 and promotes the expression of leukemia-causing genes.","Pinometostat | DOT1L Inhibitor EPZ-5676 | EPZ-5676 | PINOMETOSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641113","Data Standard","C103180","A statement that defines conventions, guidelines, characteristics or methods for consistent data handling to facilitate exchange or processing of the data. This set of criteria are reviewed by and agreed upon by the user community or a governing body before they are released and adopted for use.","Data Standard | data standards",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2744115","Soy Lecithin/Glycerol Dioleate-based Oral Spray","C103181","An oral spray containing soy phospholipid and glycerol dioleate, with protective, analgesic and anti-mucositic activities. Upon spraying onto the oral mucosal surface and contact with saliva, the soy lecithin/glycerol dioleate-based oral spray forms a gel and adheres to the mucosal surfaces thereby forming a lipid film. This provides a protective barrier and an analgesic effect within the oral cavity. In addition, the lipid barrier prevents bacterial growth at affected areas thereby decreasing infection risk.","Soy Lecithin/Glycerol Dioleate-based Oral Spray | Episil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537369","Sprouty-Related, EVH1 Domain-Containing Protein 1","C102823","Sprouty-related, EVH1 domain-containing protein 1 (444 aa, ~50 kDa) is encoded by the human SPRED1 gene. This protein plays a role in signal transduction regulation.","Sprouty-Related, EVH1 Domain-Containing Protein 1 | Spred-1 | Sprouty-Related EVH1 Domain-Containing Protein 1 | Suppressor of Ras/MAPK Activation | hSpred1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418943","PROC Gene","C102824","This gene is involved in the modulation of blood coagulation.","PROC Gene | PROC | Protein C (Inactivator Of Coagulation Factors Va and VIIIa) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540812","PROC wt Allele","C102825","Human PROC wild-type allele is located within 2q13-q14 and is approximately 11 kb in length. This allele, which encodes vitamin K-dependent protein C, plays a role in the negative regulation of blood coagulation. Mutation of the gene is associated with thrombophilia due to protein C deficiency.","PROC wt Allele | APC | PC | PROC1 | Protein C (Inactivator Of Coagulation Factors Va and VIIIa) wt Allele | THPH3 | THPH4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524129","Autoprothrombin IIA","C102826","Vitamin K-dependent protein C (461 aa, ~52 kDa) is encoded by the human PROC gene. This protein is involved in the degradation of factors Va and VIIIa.","Vitamin K-Dependent Protein C | Anticoagulant Protein C | Autoprothrombin IIA | Blood Coagulation Factor XIV | EC 3.4.21.69 | PROC | Protein C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539819","EIF2AK3 wt Allele","C102828","Human EIF2AK3 wild-type allele is located in the vicinity of 2p12 and is approximately 71 kb in length. This allele, which encodes eukaryotic translation initiation factor 2-alpha kinase 3 protein, is involved in both protein phosphorylation and the negative regulation of translation. Mutation of the gene is associated with Wolcott-Rallison syndrome.","EIF2AK3 wt Allele | Eukaryotic Translation Initiation Factor 2 Alpha Kinase 3 wt Allele | Eukaryotic Translation Initiation Factor 2-Alpha Kinase 3 Gene | Eukaryotic Translation Initiation Factor 2-Alpha Kinase 3 wt Allele | PEK | PERK | WRS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1137836","eukaryotic translation initiation factor 2-alpha kinase 3, human","C102829","Eukaryotic translation initiation factor 2-alpha kinase 3 (1116 aa, ~125 kDa) is encoded by the human EIF2AK3 gene. This protein plays a role in the inhibition of protein synthesis.","Eukaryotic Translation Initiation Factor 2-Alpha Kinase 3 | EC 2.7.11.1 | EIF2AK3 | Eukaryotic Translation Initiation Factor 2 Alpha Kinase 3 | HsPEK | PERK | PKR-Like ER Kinase | PRKR-Like Endoplasmic Reticulum Kinase | Pancreatic eIF2-Alpha Kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415638","HNRNPD Gene","C102830","This gene is involved in RNA catabolism.","HNRNPD Gene | HNRNPD | Heterogeneous Nuclear Ribonucleoprotein D (AU-Rich Element RNA Binding Protein 1, 37kDa) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540626","HNRNPD wt Allele","C102831","Human HNRNPD wild-type allele is located in the vicinity of 4q21 and is approximately 22 kb in length. This allele, which encodes heterogeneous nuclear ribonucleoprotein D0, plays a role in the catabolism of RNA.","HNRNPD wt Allele | AUF1 | AUF1A | HNRPD | Heterogeneous Nuclear Ribonucleoprotein D (AU-Rich Element RNA Binding Protein 1, 37kDa) wt Allele | P37 | hnRNPD0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540526","NCI CTEP SDC Head and Neck Neoplasm Category Terminology","C103019","Head and Neck Neoplasm is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Head and Neck Neoplasm Category Terminology | Head and Neck Neoplasm | NCI CTEP Simple Disease Classification Head and Neck Neoplasm Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641147","Fetal Neurodevelopmental Disorder","C103236","A fetal affliction that has a neurological basis and manifests as a developmental disability.","Fetal Neurodevelopmental Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0220807","Chemical Structure","C103240","A representation of the arrangement of atoms and bonds.","Chemical Structure | CHEMICAL STRUCTURE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641149","Substance Dispersity","C103241","A measure of the heterogeneity of sizes, shapes or masses of molecules or particles.","Substance Dispersity | DISPERSITY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641295","CDISC Questionnaire PHQ-9 Test Name Terminology","C103480","Test names of questionnaire questions associated with the 9 item patient health questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire PHQ-9 Test Name Terminology | PHQ01TN | Patient Health Questionnaire - 9 Item Questionnaire Test Name | QS-PHQ-9 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641297","CDISC Questionnaire PHQ-15 Test Name Terminology","C103482","Test names of questionnaire questions associated with the 15 item patient health questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire PHQ-15 Test Name Terminology | PHQ02TN | Patient Health Questionnaire - 15 Item Questionnaire Test Name | QS-PHQ-15 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641298","CDISC Questionnaire PHQ-15 Test Code Terminology","C103483","Test codes of questionnaire questions associated with the 15 item patient health questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire PHQ-15 Test Code Terminology | PHQ02TC | Patient Health Questionnaire - 15 Item Questionnaire Test Code | QS-PHQ-15 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641299","CDISC Questionnaire SIQR Test Name Terminology","C103484","Test names of questionnaire questions associated with the symptom impact questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire SIQR Test Name Terminology | QS-SIQR TEST | SIQR01TN | Symptom Impact Questionnaire Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641301","CDISC Questionnaire SOWS Short Test Name Terminology","C103486","Test names of questionnaire questions associated with the short opiate withdrawal scale questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire SOWS Short Test Name Terminology | QS-SOWS Short TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641302","CDISC Questionnaire SOWS Short Test Code Terminology","C103487","Test codes of questionnaire questions associated with the short opiate withdrawal scale questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire SOWS Short Test Code Terminology | QS-SOWS Short TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641303","CDISC Questionnaire UPS Test Name Terminology","C103488","Test names of questionnaire questions associated with the urgency perception scale questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire UPS Test Name Terminology | QS-UPS TEST | UPS01TN | Urgency Perception Scale Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641304","CDISC Questionnaire UPS Test Code Terminology","C103489","Test codes of questionnaire questions associated with the urgency perception scale questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire UPS Test Code Terminology | QS-UPS TESTCD | UPS01TC | Urgency Perception Scale Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424466","MRPL45 Gene","C102972","This gene is involved in mitochondrial RNA translation.","MRPL45 Gene | MRPL45 | Mitochondrial Ribosomal Protein L45 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539700","MRPL45 wt Allele","C102973","Human MRPL45 wild-type allele is located in the vicinity of 17q21.2 and is approximately 26 kb in length. This allele, which encodes 39S ribosomal protein L45, mitochondrial, plays a role in the translation of mitochondrial RNA.","MRPL45 wt Allele | L45mt | MRP-L45 | Mitochondrial Ribosomal Protein L45 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538740","39S Ribosomal Protein L45, Mitochondrial","C102974","39S ribosomal protein L45, mitochondrial (306 aa, ~35 kDa) is encoded by the human MRPL45 gene. This protein is involved in mitochondrial gene product expression.","39S Ribosomal Protein L45, Mitochondrial | L45mt | MRP-L45 | Mitochondrial Ribosomal Protein L45",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899089","Fracture of Clavicle Related to Birth","C102975","An injury sustained during the birthing process in which the continuity is broken in the clavicle.","Fracture of Clavicle Related to Birth | Fracture of Clavicle Related to Birth Trauma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437215","Src/Abl Kinase Inhibitor AZD0424","C102976","An orally bioavailable small molecule tyrosine kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Upon oral administration, AZD0424 selectively inhibits both Src and Abl kinase activity which may result in the inhibition of tumor growth in susceptible tumor cells. Src and Abl kinases are upregulated in certain tumor cells and play important roles in tumor cell proliferation and metastasis.","Src/Abl Kinase Inhibitor AZD0424 | AZD-0424 | AZD0424",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0270250","Meconium Peritonitis","C102977","Inflammation of the peritoneum caused by an intrauterine intestinal perforation leading to presence of meconium within the fetal peritoneal cavity. This is frequently seen as intra-abdominal calcifications on imaging.","Meconium Peritonitis | ",,,,,,,,,,,,,,,"4238980","Meconium peritonitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL437216","Apoptotic Autologous Tumor Cells-pulsed Alpha-type-1 Polarized Dendritic Cells","C102978","A cell based cancer vaccine composed of mature polarized dendritic cells (DCs) and pulsed with apoptotic autologous tumor cells that has potential immunostimulating and antineoplatic activities. Dendritic cells (DCs) were treated with interleukin-1beta, tumor necrosis factor alpha, interferon-alpha (IFN-a), IFN-gamma and polyinosinic:polycytidylic acid (p-I:C) to produce mature alpha type-1 polarized DCs (alphaDC1) that are capable of producing high levels of interleukin-12p70 (IL-12p70). The alphaDC1 are subsequently pulsed with apoptotic autologous tumor cells. Upon administration, these DCs are able to induce a potent cytotoxic T lymphocyte (CTL) response against tumor associated antigens (TAAs), resulting in tumor cell lysis and inhibition of tumor cell growth. Apoptotic tumor cells contain an array of TAAs.","Apoptotic Autologous Tumor Cells-pulsed Alpha-type-1 Polarized Dendritic Cells | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0266316","Congenital Hydronephrosis","C102979","Collection of urine in the renal pelvis that results in dilatation of the renal pelvis and calyces that is present at birth.","Congenital Hydronephrosis | ",,,,,,,,,,,,,,,"4037874","Congenital hydronephrosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL437217","Anti-ENPP3 Antibody-Drug Conjugate AGS-16C3F","C102980","An antibody-drug conjugate (ADC) containing a fully human monoclonal antibody (AGS-16C) directed to the ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3), conjugated via a non-cleavable linker to monomethyl auristatin F (MMAF), an auristatin derivative and a potent microtubule inhibitor, that has potential antineoplastic activity. Upon intravenous administration of ADC AGS-16C3F, the monoclonal antibody moiety of this conjugate selectively binds to ENPP3 then is internalized and undergoes proteolytic cleavage to release MMAF. MMAF binds to and inhibits tubulin polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. While normally expressed at low levels in the proximal tubules of the kidney, the type II transmembrane glycoprotein ENPP3 has been found to be overexpressed in renal neoplasms.","Anti-ENPP3 Antibody-Drug Conjugate AGS-16C3F | ADC AGS-16C3F | AGS-16C3F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1676077","Iodine I 131 Rituximab","C102981","A radioimmunoconjugate comprised of rituximab, a recombinant chimeric monoclonal antibody directed against the CD20 antigen, and labeled with iodine I 131 with potential antineoplastic activity. The antibody moiety of iodine I 131 rituximab binds to the CD20 antigen thereby delivering cytotoxic iodine I 131 specifically to cancer cells expressing CD20. The CD20 antigen, a hydrophobic transmembrane protein, is expressed on normal pre-B and mature B lymphocytes.","Iodine I 131 Rituximab | (131)I-Rituximab | 131I-Rituxan | RITUXIMAB I-131",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538824","TRIM36 wt Allele","C102818","Human TRIM36 wild-type allele is located in the vicinity of 5q22.3 and is approximately 56 kb in length. This allele, which encodes E3 ubiquitin-protein ligase TRIM36 protein, plays a role in both protein modification and the regulation of protein degradation.","TRIM36 wt Allele | HAPRIN | RBCC728 | RNF98 | Tripartite Motif Containing 36 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1505287","E3 Ubiquitin-Protein Ligase TRIM36, Human","C102819","E3 ubiquitin-protein ligase TRIM36 (728 aa, ~83 kDa) is encoded by the human TRIM36 gene. This protein is involved in the regulation of protein degradation.","E3 Ubiquitin-Protein Ligase TRIM36 | EC 2.3.2.27 | EC 6.3.2.-, Formerly | RING Finger Protein 98 | Tripartite Motif-Containing Protein 36 | Zinc-Binding Protein Rbcc728",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0238104","Chronic Endometritis","C102820","A non-granulomatous or granulomatous chronic inflammation of the endometrium. Causes include sexually transmitted pathogens and gynecological procedures. Patients may present with irregular bleeding.","Chronic Endometritis | ",,,,,,,,,,,,,,,"4273703","Chronic endometritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1426807","SPRED1 Gene","C102821","This gene plays a role in the modulation of signaling.","SPRED1 Gene | SPRED1 | Sprouty Related EVH1 Domain Containing 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540811","SPRED1 wt Allele","C102822","Human SPRED1 wild-type allele is located in the vicinity of 15q14 and is approximately 105 kb in length. This allele, which encodes sprouty-related, EVH1 domain-containing protein 1, is involved in the regulation of signal transduction.","SPRED1 wt Allele | FLJ33903 | LGSS | NFLS | PPP1R147 | Protein Phosphatase 1, Regulatory Subunit 147 Gene | Sprouty Related EVH1 Domain Containing 1 wt Allele | Sprouty-Related, EVH1 Domain Containing 1 Gene | hSpred1 | spred-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641027","NCI CTEP SDC Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma) Category Terminology","C103020","Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma) is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma) Category Terminology | Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma) | NCI CTEP Simple Disease Classification Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma) Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641028","NCI CTEP SDC Immune Disorder (excluding AIDS and malignancy) Category Terminology","C103021","Immune Disorder (excluding AIDS and malignancy) is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Immune Disorder (excluding AIDS and malignancy) Category Terminology | Immune Disorder (excluding AIDS and malignancy) | NCI CTEP Simple Disease Classification Immune Disorder (excluding AIDS and malignancy) Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641029","NCI CTEP SDC Lung, Mediastinal and Pleural Neoplasm Category Terminology","C103023","Lung, Mediastinal and Pleural Neoplasm is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Lung, Mediastinal and Pleural Neoplasm Category Terminology | Lung, Mediastinal and Pleural Neoplasm | NCI CTEP Simple Disease Classification Lung, Mediastinal and Pleural Neoplasm Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538736","NCI CTEP SDC Miscellaneous Neoplasm Category Terminology","C103024","Miscellaneous Neoplasm is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Miscellaneous Neoplasm Category Terminology | Miscellaneous Neoplasm | NCI CTEP Simple Disease Classification Miscellaneous Neoplasm Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538914","NCI CTEP SDC Non-neoplastic Disorder Category Terminology","C103025","Non-neoplastic Disorder is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Non-neoplastic Disorder Category Terminology | NCI CTEP Simple Disease Classification Non-neoplastic Disorder Category Terminology | Non-neoplastic Disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641030","NCI CTEP SDC Reproductive System Neoplasm, Female Category Terminology","C103026","Reproductive System Neoplasm, Female is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Reproductive System Neoplasm, Female Category Terminology | NCI CTEP Simple Disease Classification Reproductive System Neoplasm, Female Category Terminology | Reproductive System Neoplasm, Female",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641031","NCI CTEP SDC Reproductive System Neoplasm, Male Category Terminology","C103027","Reproductive System Neoplasm, Male is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Reproductive System Neoplasm, Male Category Terminology | NCI CTEP Simple Disease Classification Reproductive System Neoplasm, Male Category Terminology | Reproductive System Neoplasm, Male",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539785","NCI CTEP SDC Skin Neoplasm Category Terminology","C103028","Skin Neoplasm is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Skin Neoplasm Category Terminology | NCI CTEP Simple Disease Classification Skin Neoplasm Category Terminology | Skin Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641116","In Utero Drug Withdrawal","C103183","Drug withdrawal symptoms in a fetus following maternal discontinuation or reduction of use of one or more addictive substance(s) that have caused fetal physiological dependence.","In Utero Drug Withdrawal | In-utero Drug Withdrawal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641305","ADCS-CGIC Questionnaire Question","C103490","A question associated with the ADCS-CGIC questionnaire.","ADCS-CGIC Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641306","C-SSRS Since Last Visit Questionnaire Question","C103491","A question associated with the C-SSRS Since Last Visit questionnaire.","C-SSRS Since Last Visit Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641307","ESS Questionnaire Question","C103492","A question associated with the ESS questionnaire.","ESS Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641308","FIQR Questionnaire Question","C103493","A question associated with the FIQR questionnaire.","FIQR Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641309","GAD-7 Questionnaire Question","C103494","A question associated with the GAD-7 questionnaire.","GAD-7 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641310","HADS Questionnaire Question","C103495","A question associated with the HADS questionnaire.","HADS Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641311","IIEF Questionnaire Question","C103496","A question associated with the IIEF questionnaire.","IIEF Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642468","NPS Questionnaire Question","C103497","A question associated with the NPS questionnaire.","NPS Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1956193","Diammonium Glycyrrhizinate","C102865","The diammonium salt of glycyrrhizin and the active constituent in the traditional Chinese medicinal herb Glycyrrhiza uralensis (Chinese liquorice or Gan-Cao) with anti-inflammatory, antioxidant and hepatoprotective properties. Diammonium glycyrrhizinate (DG) is slowly metabolized within the cells into glycyrrhetic acid, which inhibits enzymes that control cortisol metabolism and contributes to this agent's anti-inflammatory effect. Although the exact mechanism of action remains to be fully elucidated, DG may prevent or reduce hepatotoxicity via the scavenging of free radicals. This agent also upregulates the expression of transcription coactivator PGC-1alpha and modulates hepatic enzymes such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), superoxide dismutase and glutathion peroxidase.","Diammonium Glycyrrhizinate | 18beta-Glycyrrhizic Acid Diammoniumsalt | DIAMMONIUM GLYCYRRHIZINATE | alpha-D-Glucopyranosiduronic acid, (3beta,20beta)-20-carboxy-11-oxo-30-norolean-12-en-3-yl 2-O-beta-D-Glucopyranuronosyl-, Diammonium Salt (9CI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437147","Aspirin/Simvastatin/Atenolol/Ramipril/Thiazide Capsule","C102868","An orally bioavailable combination pill containing aspirin, simvastatin, atenolol, ramipril and thiazide with preventive activity against cardiovascular disease (CVD). Aspirin is a cyclooxygenase inhibitor with antiplatelet, analgesic, antipyretic and anti-inflammatory activities; simvastatin is a statin with a cholesterol lowering effect; and the beta-blocker atenolol as well as the ACE inhibitor ramipril and the thiazide diuretic all have blood pressure lowering activity. Upon oral administration of aspirin/simvastatin/atenolol/ramipril/thiazide capsule, the combined effects of the active ingredients in this formulation lower the risk of CVD.","Aspirin/Simvastatin/Atenolol/Ramipril/Thiazide Capsule | Polycap | Quintapill",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641076","NCI CTEP SDC Leukemia, Miscellaneous Sub-Category Terminology","C103127","Leukemia, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Leukemia, Miscellaneous Sub-Category Terminology | Leukemia, Miscellaneous | NCI CTEP Simple Disease Classification Leukemia, Miscellaneous Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538995","NCI CTEP SDC Myelodysplastic Syndrome Sub-Category Terminology","C103128","Myelodysplastic Syndrome is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Myelodysplastic Syndrome Sub-Category Terminology | Myelodysplastic Syndrome | NCI CTEP Simple Disease Classification Myelodysplastic Syndrome Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538956","NCI CTEP SDC Myelodysplastic/Myeloproliferative Disease Sub-Category Terminology","C103129","Myelodysplastic/Myeloproliferative Disease is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Myelodysplastic/Myeloproliferative Disease Sub-Category Terminology | Myelodysplastic/Myeloproliferative Disease | NCI CTEP Simple Disease Classification Myelodysplastic/Myeloproliferative Disease Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538749","NCI CTEP SDC Myeloma Sub-Category Terminology","C103130","Myeloma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Myeloma Sub-Category Terminology | Myeloma | NCI CTEP Simple Disease Classification Myeloma Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641078","NCI CTEP SDC Urothelial Tract/Bladder Neoplasm, Miscellaneous Sub-Category Terminology","C103132","Urothelial Tract/Bladder Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Urothelial Tract/Bladder Neoplasm, Miscellaneous Sub-Category Terminology | NCI CTEP Simple Disease Classification Urothelial Tract/Bladder Neoplasm, Miscellaneous Sub-Category Terminology | Urothelial Tract/Bladder Neoplasm, Miscellaneous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539720","NCI CTEP SDC Non-Hodgkin Lymphoma Sub-Category Terminology","C103133","Non-Hodgkin Lymphoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Non-Hodgkin Lymphoma Sub-Category Terminology | NCI CTEP Simple Disease Classification Non-Hodgkin Lymphoma Sub-Category Terminology | Non-Hodgkin Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541281","NCI CTEP SDC Hodgkin Lymphoma Sub-Category Terminology","C103135","Hodgkin Lymphoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Hodgkin Lymphoma Sub-Category Terminology | Hodgkin Lymphoma | NCI CTEP Simple Disease Classification Hodgkin Lymphoma Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417327","MS4A2 Gene","C101623","This gene is involved in immunoglobulin binding.","MS4A2 Gene | MS4A2 | Membrane-Spanning 4-Domains, Subfamily A, Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539705","MS4A2 wt Allele","C101624","Human MS4A2 wild-type allele is located within 11q12-q13 and is approximately 10 kb in length. This allele, which encodes high affinity immunoglobulin epsilon receptor subunit beta protein, plays a role in both immunoglobulin binding and mast cell responses.","MS4A2 wt Allele | APY | ATOPY | FCER1B | FCERI | IGEL | IGER | IGHER | IgE Responsiveness (Atopic) Gene | MS4A1 | Membrane-Spanning 4-Domains, Subfamily A, Member 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540649","High Affinity Immunoglobulin Epsilon Receptor Subunit Beta","C101625","High affinity immunoglobulin epsilon receptor subunit beta (244 aa, ~27 kDa) is encoded by the human MS4A2 gene. This protein is involved in the response to allergens.","High Affinity Immunoglobulin Epsilon Receptor Subunit Beta | Fc Epsilon Receptor I Beta-Chain | FcERI | IgE Fc Receptor Subunit Beta | MS4A2 | Membrane-Spanning 4-Domains Subfamily A Member 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427271","PITPNC1 Gene","C101626","This gene plays a role in both signaling and lipid transport.","PITPNC1 Gene | PITPNC1 | Phosphatidylinositol Transfer Protein, Cytoplasmic 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538829","PITPNC1 wt Allele","C101627","Human PITPNC1 wild-type allele is located in the vicinity of 17q24.2 and is approximately 316 kb in length. This allele, which encodes cytoplasmic phosphatidylinositol transfer protein 1, is involved in phospholipid transport.","PITPNC1 wt Allele | Phosphatidylinositol Transfer Protein, Cytoplasmic 1 wt Allele | RDGB-BETA | RDGBB | RDGBB1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0665127","Cytoplasmic Phosphatidylinositol Transfer Protein 1, Human","C101628","Cytoplasmic phosphatidylinositol transfer protein 1 (332 aa, ~38 kDa) is encoded by the human PITPNC1 gene. This protein plays a role in the modulation of both phospholipid-mediated signaling and lipid transport.","Cytoplasmic Phosphatidylinositol Transfer Protein 1 | M-rdgB beta | Mammalian rdgB Homolog Beta | MrdgBbeta | PITPNC1 | RdgBbeta | Retinal Degeneration B Beta 1 | Retinal Degeneration B Homolog Beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414991","GAS6 Gene","C101629","This gene is involved in both receptor binding and signal transduction.","GAS6 Gene | GAS6 | Growth Arrest-Specific 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539526","GAS6 wt Allele","C101630","Human GAS6 wild-type allele is located in the vicinity of 13q34 and is approximately 44 kb in length. This allele, which encodes growth arrest-specific protein 6, plays a role in both ligand-mediated signaling and receptor tyrosine kinase binding.","GAS6 wt Allele | AXL Stimulatory Factor Gene | AXLLG | AXSF | DKFZp666G247 | FLJ34709 | Growth Arrest-Specific 6 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0218352","growth arrest-specific 6 protein, human","C101631","Growth arrest-specific protein 6 (721 aa, ~80 kDa) is encoded by the human GAS6 gene. This protein is involved in the modulation of receptor tyrosine kinase-dependent signaling.","Growth Arrest-Specific Protein 6 | AXL Receptor Tyrosine Kinase Ligand | AXL Stimulatory Factor | GAS-6 | GAS6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3469945","SWI5 Gene","C101632","This gene is involved in double-strand break repair by homologous recombination.","SWI5 Gene | SWI5 | SWI5 Homologous Recombination Repair Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542911","SWI5 wt Allele","C101633","Human SWI5 wild-type allele is located in the vicinity of 9q34.11 and is approximately 14 kb in length. This allele, which encodes DNA repair protein SWI5 homolog protein, plays a role in the modulation of DNA repair.","SWI5 wt Allele | C9orf119 | Chromosome 9 Open Reading Frame 119 Gene | RP11-395P17.9 | SAE3 | SAE3, S. cerevisiae, Homolog of Gene | SWI5 Homologous Recombination Repair Protein wt Allele | SWI5 Recombination Repair Homolog (Yeast) Gene | SWI5, S. pombe, Homolog of Gene | bA395P17.9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640150","DNA Repair Protein SWI5 Homolog","C101634","DNA repair protein SWI5 homolog (235 aa, ~27 kDa) is encoded by the human SWI5 gene. This protein is involved in DNA repair through homologous recombination.","DNA Repair Protein SWI5 Homolog | HBV DNAPTP1-Transactivated Protein A | Protein SAE3 Homolog | SWI5 | SWI5 Homologous Recombination Repair Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3808295","Genu Recurvatum","C103184","An abnormal alignment of the knee backwards that is due to a deformity in the knee joint.","Genu Recurvatum | Hyperextension Deformity of Knee | Hyperextension of Knee Deformity",,,,,,,,,,,,,,,"78241","Congenital genu recurvatum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641117","Congenital Reproductive System Abnormality","C103185","A disorder that affects the female or male reproductive system and is present at birth. Representative examples include ovarian agenesis, vaginal agenesis, and penile agenesis.","Congenital Reproductive System Abnormality | Congenital Abnormality of the Reproductive System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2930619","Sexual Differentiation Disorder","C103186","A congenital disorder characterized by abnormalities in the development of the sexual characteristics.","Sexual Differentiation Disorder | CARD | Conditions Affecting Reproductive Development | DSD | Differences of Sex Development | Disorder of Sexual Differentiation | Disorders of Sex Development | Intersex | Intersex Conditions",,,,,,,,,,,,,,,"4212927","Disorder of sexual differentiation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0475739","Perinatal Subependymal Hemorrhage with Intraventricular and Intracerebral Extension","C103187","A hemorrhage that involves the subependymal region, the lateral cerebral ventricles and the brain tissue occurring around the time of birth.","Perinatal Subependymal Hemorrhage with Intraventricular and Intracerebral Extension | ",,,,,,,,,,,,,,,"4171123","Perinatal subependymal hemorrhage with intraventricular and intracerebral extension",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641118","Acquired Phrenic Nerve Injury","C103188","Damage to the phrenic nerve that was not present at birth.","Acquired Phrenic Nerve Injury | Phrenic Nerve Injury, Acquired",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641119","Acquired Phrenic Nerve Palsy","C103189","Damage to the phrenic nerve that results in paralysis of the hemidiaphragm and was not present at birth.","Acquired Phrenic Nerve Palsy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0270149","Perinatal Respiratory Distress","C103190","A pathological increase in the effort and frequency or breathing movements during the perinatal period.","Perinatal Respiratory Distress | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0270148","Perinatal Cyanotic Attack","C103191","Episodes of cyanosis during the perinatal period.","Perinatal Cyanotic Attack | ",,,,,,,,,,,,,,,"134760","Perinatal cyanotic attacks",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL437432","Plasmacytoid Dendritic Cell Vaccine","C103192","A whole cell vaccine derived from a distinct subset of dendritic cells (DCs) with a plasma cell-like morphology that exhibits immunomodulating activity. Plasmacytoid dendritic cells (pDCs) express a characteristic set of surface markers, such as CD123 (interleukin-3 receptor alpha chain), BDCA-2 (blood dendritic cell antigen 2; CD303) and BDCA-4 (CD304), as well as intracellular toll-like receptors 7 and 9. Upon stimulation, the activated pDCs produce substantial amounts of interferon (IFN) alpha, and to a lesser degree IFN-beta, as well as other cytokines and chemokines, such as tumor necrosis factor alpha and interleukins 1, 6 and 8. In addition, these pDCs, directly or indirectly stimulate T-cells, B-cells and natural killer cells. This may potentially lead to increased immunity against tumor cells.","Plasmacytoid Dendritic Cell Vaccine | pDC Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2974969","Tumor-Cells Apoptosis Factor Hormone-Peptide","C103193","A synthetic 14-amino acid peptide derived from a novel human peptide hormone, Tumor-Cells Apoptosis Factor (TCApF), with potential antineoplastic activity. Upon intravenous administration, tumor-cells apoptosis factor hormone-peptide binds to the T1/ST2 receptor (IL1RL1) and activates both caspase 8 and Bcl-2 mediated apoptosis, in addition to the activation of p38 MAPK and JNK signaling cascades in tumor cells. Furthermore, this agent inhibits angiogenesis by suppressing the expressions of vascular endothelial growth factor A (VEGFA) and fms-related tyrosine kinase 1 (VEGFR1).  Tumor-cells apoptosis factor hormone-peptide also modulates immune system responses via increasing the expressions of interleukin-10 and anti-angiogenic interleukin. T1/ST2 receptor, a member of the toll/interleukin-1 receptor superfamily, is overexpressed in certain cancer cells.","Tumor-Cells Apoptosis Factor Hormone-Peptide | NEROFE | Nerofe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641372","GAD-7 - Not Being Able to Stop or Control Worrying","C103566","Generalized Anxiety Disorder - 7 (GAD-7) Not being able to stop or control worrying.","GAD-7 - Not Being Able to Stop or Control Worrying | GAD01-Not Able to Stop/Control Worrying | GAD0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641373","GAD-7 - Worrying Too Much About Different Things","C103567","Generalized Anxiety Disorder - 7 (GAD-7) Worrying too much about different things.","GAD-7 - Worrying Too Much About Different Things | GAD01-Worrying Too Much About Things | GAD0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641374","GAD-7 - Trouble Relaxing","C103568","Generalized Anxiety Disorder - 7 (GAD-7) Trouble relaxing.","GAD-7 - Trouble Relaxing | GAD01-Trouble Relaxing | GAD0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641376","GAD-7 - Becoming Easily Annoyed or Irritable","C103570","Generalized Anxiety Disorder - 7 (GAD-7) Becoming easily annoyed or irritable.","GAD-7 - Becoming Easily Annoyed or Irritable | GAD01-Becoming Easily Annoyed/Irritable | GAD0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641377","GAD-7 - Feel Afraid as if Something Awful Might Happen","C103571","Generalized Anxiety Disorder - 7 (GAD-7) Feeling afraid as if something awful might happen.","GAD-7 - Feel Afraid as if Something Awful Might Happen | GAD01-Feel Afraid/Something Awful Happen | GAD0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641378","GAD-7 - Problems Made it Difficult to Work, Take Care of Things, or Get Along with Other People","C103572","Generalized Anxiety Disorder - 7 (GAD-7) If you checked off any problems, how difficult have these problems made it for you to do your work, take care of things at home, or get along with other people?","GAD-7 - Problems Made it Difficult to Work, Take Care of Things, or Get Along with Other People | GAD01-Difficult to Work/Take Care Things | GAD0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641379","HADS - I Feel Tense or Wound Up","C103573","Hospital Anxiety and Depression Scale (HADS) I feel tense or 'wound up.'","HADS - I Feel Tense or Wound Up | HADS01-I Feel Tense or Wound Up | HADS0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641380","HADS - I Still Enjoy the Things I Used to Enjoy","C103574","Hospital Anxiety and Depression Scale (HADS) I still enjoy the things I used to enjoy.","HADS - I Still Enjoy the Things I Used to Enjoy | HADS01-Enjoy the Things I Used to Enjoy | HADS0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541324","EOMES wt Allele","C102928","Human EOMES wild-type allele is located 3p24.1 and is approximately 7 kb in length. This allele, which encodes eomesodermin homolog protein, is involved in both embryonic development and the regulation of gene transcription.","EOMES wt Allele | Eomesodermin (Xenopus laevis) Homolog Gene | Eomesodermin wt Allele | Eomesodermin, Xenopus, Homolog of Gene | T-Box, Brain, 2 Gene | TBR2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641001","Eomesodermin Homolog","C102929","Eomesodermin homolog (686 aa, ~73 kDa) is encoded by the human EOMES gene. This protein plays a role in transcriptional activation of genes involved in trophoblast differentiation, gastrulation, and brain development.","Eomesodermin Homolog | T-Box Brain Protein 2 | T-Box Brain2 | T-Brain-2 | TBR-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423027","DNAJB6 Gene","C102930","This gene is involved in protein chaperone activity.","DNAJB6 Gene | DNAJB6 | DnaJ (Hsp40) Homolog, Subfamily B, Member 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539697","DNAJB6 wt Allele","C102931","Human DNAJB6 wild-type allele is located in the vicinity of 7q36.3 and is approximately 82 kb in length. This allele, which encodes DnaJ homolog subfamily B member 6 protein, plays a role in the regulation of protein folding and aggregation. Mutation of the gene is associated with limb-girdle muscular dystrophy type 1E.","DNAJB6 wt Allele | DJ4 | DnaJ | DnaJ (Hsp40) Homolog, Subfamily B, Member 6 wt Allele | HHDJ1 | HSJ-2 | HSJ2 | LGMD1E | MRJ | MSJ-1 | tcag7.555",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1435323","DnaJ Homolog Subfamily B Member 6","C102932","DnaJ homolog subfamily B member 6 (326 aa, ~36 kDa) is encoded by the human DNAJB6 gene. This protein is involved in the mediation of protein folding and the inhibition of protein aggregation.","DnaJ Homolog Subfamily B Member 6 | DNAJB6 | HHDJ1 | HSJ-2 | Heat Shock Protein J2 | MRJ | MSJ-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3543834","CDISC Basic Data Structure Dataset","C103371","An ADaM BDS dataset contains one or more records per subject, per analysis parameter, per analysis time point. Variables include the value being analyzed (e.g., AVAL) and the description of the value being analyzed (e.g., PARAM). Other variables in the dataset provide more information about the value being analyzed (e.g., the subject identification) or describe and trace the derivation of it (e.g., DTYPE) or support the analysis of it (e.g., treatment variables, covariates).","CDISC Basic Data Structure Dataset | BASIC DATA STRUCTURE | BDS | Basic Data Structure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541888","CDISC Events Class","C103372","This SDTM class captures planned protocol milestones such as randomization and study completion, and occurrences, conditions, or incidents independent of planned study evaluations occurring during the trial (e.g., adverse events) or prior to the trial (e.g., medical history).","CDISC Events Class | EVENTS | Events",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542921","CDISC Interventions Class","C103374","This SDTM class captures investigational, therapeutic and other treatments that are administered to the subject (with some actual or expected physiological effect) either as specified by the study protocol (e.g., exposure to study drug), coincident with the study assessment period (e.g., concomitant medications), or self-administered by the subject (such as use of alcohol, tobacco, or caffeine).","CDISC Interventions Class | INTERVENTIONS | Interventions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641232","CDISC Other ADaM Dataset","C103375","An ADaM analysis dataset that doesn't conform to the ADSL or BDS structure.","CDISC Other ADaM Dataset | ADAM OTHER | ADaM Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540605","CDISC Relationship Class","C103376","This SDTM class provides a means to link related records between datasets. It includes the RELREC and SUPPQUAL datasets.","CDISC Relationship Class | RELATIONSHIP | Relationships",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640151","Protein Numb Homolog","C101637","Protein numb homolog (651 aa, ~71 kDa) is encoded by the human NUMB gene. This protein plays a role in the development of neurons.","Protein Numb Homolog | Protein S171 | h-Numb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539823","TBX3 wt Allele","C101639","Human TBX3 wild-type allele is located in the vicinity of 12q24.1 and is approximately 14 kb in length. This allele, which encodes T-box transcription factor TBX3 protein, plays a role in both transcriptional regulation and anterior/posterior axis development. Mutation of the gene is associated with ulnar-mammary syndrome.","TBX3 wt Allele | T-Box 3 wt Allele | TBX3-ISO | UMS | Ulnar Mammary Syndrome Gene | XHL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640152","T-Box Transcription Factor TBX3","C101640","T-box transcription factor TBX3 (743 aa, ~79 kDa) is encoded by the human TBX3 gene. This protein is involved in both the negative regulation of transcription and embryogenesis.","T-Box Transcription Factor TBX3 | T-Box Protein 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242939","Adjuvant Radiotherapy","C101642","Radiation therapy that is administered to augment or stimulate other treatment modalities or to minimize or prevent disease recurrence.","Adjuvant Radiotherapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540534","SERPINF1 wt Allele","C101644","Human SERPINF1 wild-type allele is located in the vicinity of 17p13.3 and is approximately 16 kb in length. This allele, which encodes pigment epithelium-derived factor protein, plays a role in both angiogenesis and cell proliferation. Mutation of the gene is associated with osteogenesis imperfecta type 12.","SERPINF1 wt Allele | EPC-1 | OI12 | OI6 | PEDF | PIG35 | Pigment Epithelium-Derived Factor Gene | Proliferation-Inducing Protein 35 Gene | Serpin Peptidase Inhibitor, Clade F (Alpha-2 Antiplasmin, Pigment Epithelium Derived Factor), Member 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0213321","serine (or cysteine) proteinase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 1 protein, human","C101645","Pigment epithelium-derived factor (418 aa, ~46 kDa) is encoded by the human SERPINF1 gene. This protein is involved in the regulation of both cell proliferation and angiogenesis.","Pigment Epithelium-Derived Factor | Cell Proliferation-Inducing Gene 35 Protein | EPC-1 | PEDF | Proliferation-Inducing Protein 35 | SERPINF1 | Serpin F1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538718","FOXA1 wt Allele","C101647","Human FOXA1 wild-type allele is located within 14q12-q13 and is approximately 10 kb in length. This allele, which encodes hepatocyte nuclear factor 3-alpha protein, is involved in transcriptional regulation. Aberrant expression of the gene is associated with several cancers.","FOXA1 wt Allele | Forkhead Box A1 wt Allele | HNF3A | Hepatocyte Nuclear Factor 3, Alpha Gene | MGC33105 | TCF3A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1506537","FOXA1 protein, human","C101648","Hepatocyte nuclear factor 3-alpha (472 aa, ~49 kDa) is encoded by the human FOXA1 gene. This protein plays a role in the modulation of transcription.","Hepatocyte Nuclear Factor 3-Alpha | Forkhead Box Protein A1 | FoxA1 | HNF-3-Alpha | HNF-3A | TCF-3A | Transcription Factor 3A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537626","LCLAT1 Gene","C102933","This gene plays a role in phospholipid metabolism.","LCLAT1 Gene | LCLAT1 | Lysocardiolipin Acyltransferase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540466","LCLAT1 wt Allele","C102934","Human LCLAT1 wild-type allele is located in the vicinity of 2p23.1 and is approximately 197 kb in length. This allele, which encodes lysocardiolipin acyltransferase 1 protein, is involved in the modification of phospholipids.","LCLAT1 wt Allele | 1AGPAT8 | AGPAT8 | ALCAT1 | HSRG1849 | LYCAT | Lysocardiolipin Acyltransferase 1 wt Allele | UNQ1849 | UNQ1849/PRO3579",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539733","Lysocardiolipin Acyltransferase 1, Human","C102935","Lysocardiolipin acyltransferase 1 (414 aa, ~49 kDa) is encoded by the human LCLAT1 gene. This protein plays a role in lipid acylation.","Lysocardiolipin Acyltransferase 1 | 1-AGP Acyltransferase 8 | 1-AGPAT 8 | 1-Acylglycerol-3-Phosphate O-Acyltransferase 8 | Acyl-CoA:Lysocardiolipin Acyltransferase 1 | EC 2.3.1.- | EC 2.3.1.51",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541909","Synphilin-1, Human","C102938","Synphilin-1 (919 aa, ~100 kDa) is encoded by the human SNCAIP gene. This protein is involved in the modulation of ubiquitin ligase activity.","Synphilin-1 | Alpha-Synuclein-Interacting Protein | Sph1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539707","CD99 wt Allele","C102940","Human CD99 wild-type allele is located in the vicinity of both Xp22.32 and Yp11.3 and is approximately 50 kb in length. This allele, which encodes CD99 antigen protein, is involved in cell adhesion.","CD99 wt Allele | Antigen Identified By Monoclonal Antibodies 12E7, F21 and O13 Gene | CD99 Molecule wt Allele | HBA71 | MIC2 | MIC2X | MIC2Y | MSK5X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539064","NCI CTEP Simple Disease Classification Cervical Cancer Sub-Category Terminology","C103098","Cervical Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Cervical Cancer Sub-Category Terminology | Cervical Cancer | NCI CTEP Simple Disease Classification Cervical Cancer Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541229","NCI CTEP SDC Cervical Intraepithelial Neoplasia (CIN) Sub-Category Terminology","C103099","Cervical Intraepithelial Neoplasia (CIN) is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Cervical Intraepithelial Neoplasia (CIN) Sub-Category Terminology | Cervical Intraepithelial Neoplasia (CIN) | NCI CTEP Simple Disease Classification Cervical Intraepithelial Neoplasia (CIN) Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054258","Butocin","C1030","A S-substituted analog of mercaptopurine and purine antagonist with cytostatic activity. Butocin inhibits purine nucleotide synthesis and DNA replication.","Butocin | BUTOCIN | Benin | Butocine | N-(5-(6-purinylthio)valeryl)glycine ethyl ester | benin | benin spofa | butocine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641233","CDISC Special Purpose Class","C103377","This SDTM class contains a set of domains which do not conform to the Findings, Events or Interventions observation classes. The domains included are DM, CO, SE and SV.","CDISC Special Purpose Class | SPECIAL PURPOSE | SPECIAL-PURPOSE | Special Purpose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437022","Talacotuzumab","C102784","A humanized IgG1 monoclonal antibody against CD123 (Interleukin-3 receptor alpha chain or IL3RA) with potential antineoplastic activity. Upon intravenous administration, talacotuzumab binds to and neutralizes CD123. This may inhibit IL-3-dependent signaling and may inhibit proliferation and differentiation in CD123-positive tumor cells. CSL362 contains an engineered Fc region which increases its binding affinity to Fc-gamma receptors on the surface of natural killer (NK) cells thereby initiating antibody-dependent cellular cytotoxicity (ADCC). CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with increased leukemic cell proliferation and aggressiveness.","Talacotuzumab | Anti-IL-3 Receptor Alpha Monoclonal Antibody CSL362 | CSL 362 | CSL362 | JNJ-56022473 | JNJ56022473 | TALACOTUZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437023","Iodine I 124 Anti-phosphatidylserine Monoclonal Antibody PGN650","C102785","A radioimmunoconjugate composed of the F(ab')2 fragment of human monoclonal antibody PGN650 against phosphatidylserine (PS) labeled with the radioisotope iodine I 124, with potential imaging activity upon positron-emission tomography (PET). Upon administration, the MoAb moiety of PGN650 binds to exposed PS on tumor cells, thereby allowing for the visualization of tumors upon PET. This may facilitate the assessment of the effectiveness of antitumor agents. The phospholipid PS is normally located on the inner leaflet of the plasma membrane of healthy cells but is flipped to the outer leaflet in the endothelial lining of the tumor vasculature and other tumor cells in response to chemo- or radio- treatments in addition to oxidative stress.","Iodine I 124 Anti-phosphatidylserine Monoclonal Antibody PGN650 | I-124 Anti-PS MoAb PNG650 | I-124 PGN650",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL777451","pan-selectin antagonist GMI-1070","C102786","A synthetic, glycomimetic molecule and pan-selectin antagonist, with potential use in a vaso-occlusive crisis. Upon administration, rivipansel prevents the interaction between leukocytes and the endothelium and may prevent cell activation and adhesion. By preventing selectin-mediated cell adhesion in sickle cell anemia, this agent may inhibit red blood cell-white blood cell interactions, normalize blood flow and reduce inflammation and vascular occlusive pain. GMI-1070 has the strongest antagonistic activity towards E-selectin but a sulfate-binding domain allows for interactions with P- and L-selectins. Selectins, containing lectin- and EGF-like domains, are a family of cell adhesion molecules implicated in inflammatory processes and cancer.","Rivipansel | GMI-1070 | PF-06460031 | RIVIPANSEL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437024","HPV E6/E7 DNA Vaccine GX-188E","C102787","A therapeutic DNA vaccine encoding the E6/E7 fusion protein of human papillomavirus (HPV) subtypes 16 and 18, plus the immune-enhancer, Fms-like tyrosine kinase-3 ligand (FLT3L), with potential immunostimulating and antineoplastic activities. DNA vaccine GX-188E is administered using a proprietary delivery system that electroporates the vaccine into cervical cells. Expression of the E6/E7 fusion product may elicit a cytotoxic T-lymphocyte (CTL) response against cervical cancer cells expressing E6 and E7 oncoproteins, resulting in tumor cell lysis. FLT3L is a ligand for the FLT3 tyrosine kinase receptor, which upon activation stimulates the proliferation of hematopoietic progenitor cells. HPV type 16 and 18 are the most common HPV types involved in cervical carcinogenesis.","HPV E6/E7 DNA Vaccine GX-188E | GX-188E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437025","Deuterated Phenanthrene","C102788","A noncarcinogenic and structural analogue of polycyclic aromatic hydrocarbon (PAH), phenanthrene labeled with deuterium ([D10]Phe) with potential use in assessing an individual's capacity for PAH metabolism by the diol epoxide pathway. Upon oral or inhalation administration, [D10]Phe is metabolized into the tetraol end product ([D10]PheT) via the diol epoxide pathway, and can be quantified in urine. [D10]PheT can be used as a biomarker to assess PAHs metabolic activation and may therefore determine an individual's susceptibility to carcinogenicity upon PAH exposure.","Deuterated Phenanthrene | Phenanthrene-D10 | [D10] phenanthrene | [D10]Phe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437026","Inducible CD4+CD25+ Regulatory T Cells","C102789","Inducible regulatory T-lymphocytes that express CD4, CD25 (the alpha chain of the interleukin 2 receptor) and forkhead box P3 (FOXP3), with potential immunomodulating activity. Inducible CD4+CD25+ T regulatory cells (iTregs) are a subset of CD4+ T lymphocytes that are induced from CD25- precursors in peripheral lymphoid organs with interleukin-2 and transforming growth factor-beta. These regulatory T cells are essential in maintaining immunologic homeostasis. They may also prevent autoimmunity by suppressing self-reactive T cells, and may induce tolerance to allogeneic organ transplants such as in hematopoietic stem cell transplants.","Inducible CD4+CD25+ Regulatory T Cells | iTregs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539664","GDF3 wt Allele","C101650","Human GDF3 wild-type allele is located in the vicinity of 12p13.1 and is approximately 6 kb in length. This allele, which encodes growth/differentiation factor 3 protein, plays a role in cellular differentiation in embryogenesis and during maturation. Mutation of the gene is associated with Klippel-Feil syndrome type 3, microphthalmia isolated with coloboma type 6 and microphthalmia isolated type 7.","GDF3 wt Allele | Growth Differentiation Factor 3 wt Allele | KFS3 | MCOP7 | MCOPCB6 | UNQ222/PRO248",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2003670","GDF3 protein, human","C101651","Growth/differentiation factor 3 (364 aa, ~41 kDa) is encoded by the human GDF3 gene. This protein is involved in the modulation of both cell growth and differentiation.","Growth/Differentiation Factor 3 | GDF-3 | Growth Differentiation Factor 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423494","GOLIM4 Gene","C101652","This gene plays a role in protein targeting.","GOLIM4 Gene | GOLIM4 | Golgi Integral Membrane Protein 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538775","GOLIM4 wt Allele","C101653","Human GOLIM4 wild-type allele is located in the vicinity of 3q26.2 and is approximately 87 kb in length. This allele, which encodes Golgi integral membrane protein 4, is involved in protein trafficking.","GOLIM4 wt Allele | GIMPC | GOLPH4 | GPP130 | Golgi Integral Membrane Protein 4 wt Allele | P138",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539619","Golgi Integral Membrane Protein 4, Human","C101654","Golgi integral membrane protein 4 (696 aa, ~82 kDa) is encoded by the human GOLIM4 gene. This protein plays a role in subcellular protein transport.","Golgi Integral Membrane Protein 4 | GIMPc | Golgi Integral Membrane Protein, cis | Golgi Phosphoprotein 4 | Golgi Phosphoprotein of 130 kDa | Golgi-Localized Phosphoprotein of 130 kDa | Type II Golgi Membrane Protein | cis Golgi-Localized Calcium-Binding Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419374","RGS4 Gene","C101655","This gene is involved in GTPase activation.","RGS4 Gene | RGS4 | Regulator of G-Protein Signaling 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538835","RGS4 wt Allele","C101656","Human RGS4 wild-type allele is located in the vicinity of 1q23.3 and is approximately 8 kb in length. This allele, which encodes regulator of G-protein signaling 4 protein, plays a role in the modulation of G-protein signaling. Mutation of the gene may be associated with both schizophrenia and Parkinson disease.","RGS4 wt Allele | DKFZp761F1924 | MGC2124 | MGC60244 | RGP4 | RP11-430G6.1 | Regulator of G-Protein Signaling 4 wt Allele | SCZD9 | Schizophrenia Disorder 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538836","Regulator of G-Protein Signaling 4","C101657","Regulator of G-protein signaling 4 (205 aa, ~23 kDa) is encoded by the human RGS4 gene. This protein is involved in the promotion of GTPase activity.","Regulator of G-Protein Signaling 4 | RGP4 | RGS4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823401","TMEM138 Gene","C101658","This gene plays a role in cilium formation.","TMEM138 Gene | TMEM138 | Transmembrane Protein 138 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542423","TMEM138 wt Allele","C101659","Human TMEM138 wild-type allele is located in the vicinity of 11q12.2 and is approximately 8 kb in length. This allele, which encodes transmembrane protein 138, is involved in ciliogenesis.","TMEM138 wt Allele | HSPC196 | HSPC198 | JBTS16 | Transmembrane Protein 138 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540654","Transmembrane Protein 138","C101660","Transmembrane protein 138 (162 aa, ~19 kDa) is encoded by the human TMEM138 gene. This protein plays a role in the formation of cilium.","Transmembrane Protein 138 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538789","TMEM216 wt Allele","C101662","Human TMEM216 wild-type allele is located in the vicinity of 11q13.1 and is approximately 7 kb in length. This allele, which encodes transmembrane protein 216, plays a role in the formation of cilium. Mutation of the gene is associated with Joubert syndrome type 2 and Meckel syndrome type 2.","TMEM216 wt Allele | Cerebello-Oculo-Renal Syndrome 2 Gene | HSPC244 | JBTS2 | MGC13379 | MKS2 | Meckel Syndrome, Type 2 Gene | Transmembrane Protein 216 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537386","Transmembrane Protein 216","C101663","Transmembrane protein 216 (138 aa, ~16 kDa) is encoded by the human TMEM216 gene. This protein is involved in cilium formation.","Transmembrane Protein 216 | TMEM216",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0377278","Heterogeneous Nuclear Ribonucleoprotein D0","C102832","Heterogeneous nuclear ribonucleoprotein D0 (355 aa, ~38 kDa) is encoded by the human HNRNPD gene. This protein is involved in both RNA transport and splicing.","Heterogeneous Nuclear Ribonucleoprotein D0 | AU-Rich Element RNA-Binding Protein 1 | HNRNPD | hnRNP D0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897483","SPL Combination Product Type Terminology","C102833","Terminology used for representation of the type of part 3 combination in the framework of the Structured Product Labeling documents.","SPL Combination Product Type Terminology | Combination Product Types | Structured Product Labeling Combination Product Type Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827741","Type 1: Convenience Kit or Co-Package","C102834","Products meeting the definition at 21 CFR 3.2(e)(2), such as surgical kits, first aid kits, or drugs co-packaged with delivery devices.","Type 1: Convenience Kit or Co-Package | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640953","Type 2: Prefilled Drug Delivery Device/System","C102835","Products meeting the definition at 21 CFR 3.2(e)(1) comprised of a delivery device containing a drug, such as a prefilled syringe.","Type 2: Prefilled Drug Delivery Device/System | Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640954","Type 3: Prefilled Biologic Delivery Device/System","C102836","Products meeting the definition at 21 CFR 3.2(e)(1) comprised of a delivery device containing a biological product, such as a prefilled syringe.","Type 3: Prefilled Biologic Delivery Device/System | Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640955","Type 4: Device Coated/Impregnated/Otherwise Combined with Drug","C102837","Products meeting the definition at 21 CFR 3.2(e)(1) comprised of a device coated or impregnated with a drug, such as a drug-eluting stent.","Type 4: Device Coated/Impregnated/Otherwise Combined with Drug | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640956","Type 5: Device Coated or Otherwise Combined with Biologic","C102838","Products meeting the definition at 21 CFR 3.2(e)(1) comprised of a device coated or otherwise combined with a biological product, such as a surgical implant.","Type 5: Device Coated or Otherwise Combined with Biologic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640957","Type 6: Drug/Biologic Combination","C102839","Products meeting the definition at 21 CFR 3.2(e)(1), comprised of a drug and a biological product that are chemically, physically, or otherwise combined to form a single entity, such as an antibody and a drug.","Type 6: Drug/Biologic Combination | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640958","Type 7: Separate Products Requiring Cross Labeling","C102840","Products meeting the definition at 21 CFR 3.2(e)(3) or (4) comprised of a separately marketed drug, device, and/ or biological product, such as certain light-activated drugs and associated light sources.","Type 7: Separate Products Requiring Cross Labeling | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640959","Type 8: Possible Combination Based on Cross Labeling of Separate Products","C102841","Investigational products that may meet the definition at 21 CFR 3.2(e)(3) or (4) but for which combination product status remains uncertain based on the information available at the stage of product development or evaluation, comprised of a separately marketed drug, device, and/or biological product.","Type 8: Possible Combination Based on Cross Labeling of Separate Products | Type 8: Possible Combination Based on Cross Labeling of Separate Products (Temporary Type)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640960","Type 9: Other Type of Part 3 Combination Product","C102842","Any products not falling within types 1 through 8 that satisfy the definition for combination product at 21 CFR 3.2(e), such as a single-entity product comprised of a drug, device, and a biological product.","Type 9: Other Type of Part 3 Combination Product | Type 9: Other Type of Part 3 Combination Product (e.g., Drug/Device/Biological Product)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539615","NCI CTEP SDC Gestational Trophoblastic Disease Sub-Category Terminology","C103101","Gestational Trophoblastic Disease is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Gestational Trophoblastic Disease Sub-Category Terminology | Gestational Trophoblastic Disease | NCI CTEP Simple Disease Classification Gestational Trophoblastic Disease Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641066","NCI CTEP SDC Ovarian Cancer (excluding Ovarian Germ Cell Cancer) Sub-Category Terminology","C103102","Ovarian Cancer (excluding Ovarian Germ Cell Cancer) is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Ovarian Cancer (excluding Ovarian Germ Cell Cancer) Sub-Category Terminology | NCI CTEP Simple Disease Classification Ovarian Cancer (excluding Ovarian Germ Cell Cancer) Sub-Category Terminology | Ovarian Cancer (excluding Ovarian Germ Cell Cancer)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542435","NCI CTEP SDC Uterine Cancer Sub-Category Terminology","C103103","Uterine Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Uterine Cancer Sub-Category Terminology | NCI CTEP Simple Disease Classification Uterine Cancer Sub-Category Terminology | Uterine Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539950","NCI CTEP SDC Vaginal Cancer Sub-Category Terminology","C103104","Vaginal Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Vaginal Cancer Sub-Category Terminology | NCI CTEP Simple Disease Classification Vaginal Cancer Sub-Category Terminology | Vaginal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538899","NCI CTEP SDC Vulvar Cancer Sub-Category Terminology","C103106","Vulvar Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Vulvar Cancer Sub-Category Terminology | NCI CTEP Simple Disease Classification Vulvar Cancer Sub-Category Terminology | Vulvar Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280591","DOX/MTX/VP-16","C10278","A regimen consisting of doxorubicin, etoposide and methotrexate that can be used for the treatment of small cell lung cancer (SCLC).","Doxorubicin/Etoposide/Methotrexate Regimen | AMV | DOX/MTX/VP-16 | Doxorubicin-Etoposide-Methotrexate | Doxorubicin/Etoposide/Methotrexate | VAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415467","HAND2 Gene","C102790","This gene plays a role in both transcriptional regulation and cardiac development.","HAND2 Gene | HAND2 | Heart and Neural Crest Derivatives Expressed 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539567","HAND2 wt Allele","C102791","Human HAND2 wild-type allele is located in the vicinity of 4q33 and is approximately 5 kb in length. This allele, which encodes heart- and neural crest derivatives-expressed protein 2, is involved in cardiac morphogenesis, DNA binding and transcriptional modulation.","HAND2 wt Allele | BHLHA26 | DHAND | DHAND2 | Heart and Neural Crest Derivatives Expressed 2 wt Allele | Hed | Thing2 | bHLHa26 | dHand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437219","Gag:267-274 Peptide Vaccine","C102982","A peptide vaccine containing the amino acids 267 through 274 of the human immunodeficiency virus type 1 (HIV-1) gag core protein (gag:267-274), with potential immunostimulating activity. Upon vaccination, the immune system may exert a potent cytotoxic T-lymphocyte (CTL) response against the xenoantigen gag:267-274 and produces pro-inflammatory cytokines. The concomitant administration of a cancer peptide vaccine may benefit from an already activated immune system and may augment an immune response against the administered tumor associated antigen(s). Gag:267-274 peptide is highly immunogenic and may potentially be used as a cancer immunoadjuvant.","Gag:267-274 Peptide Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0345198","Congenital Ileal Stenosis","C102984","Narrowing of the lumen of the ileum that is present at birth.","Congenital Ileal Stenosis | ",,,,,,,,,,,,,,,"4005769","Congenital ileal stenosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0345195","Congenital Jejunal Stenosis","C102985","Narrowing of the lumen of the jejunum that is present at birth.","Congenital Jejunal Stenosis | ",,,,,,,,,,,,,,,"4005768","Congenital jejunal stenosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4014127","Somatotropin deficiency","C102986","Abnormally low levels of circulating somatotropin.","Somatotropin Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342527","Testosterone Biosynthesis Deficiency","C102987","Inadequate production of circulating testosterone.","Testosterone Biosynthesis Deficiency | ",,,,,,,,,,,,,,,"4310743","Deficiency of testosterone biosynthesis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0411065","Brachial Plexus Palsy Related to Birth","C102990","Birth injury to the brachial plexus. It results in paralysis of the muscles of the shoulder, arm, and hand. It manifests as lack of mobility in the arm, usually in the first week of life. In the majority of cases there is spontaneous recovery.","Brachial Plexus Palsy Related to Birth | Brachial Plexus Palsy due to Birth Trauma",,,,,,,,,,,,,,,"4070527","Brachial plexus palsy due to birth trauma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3538734","MIR375 wt Allele","C101665","Human MIR375 wild-type allele is located in the vicinity of 2q35 and is approximately 70 bases in length. This allele, which encodes MIR375 pre-miRNA, is involved in the modulation of gene expression.","MIR375 wt Allele | MIRN375 | MicroRNA 375 wt Allele | hsa-mir-375 | miRNA375",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640154","MIR375 Pre-miRNA","C101666","MIR375 pre-miRNA (70 nucleotides) is encoded by the human MIR375 gene. This oligoribonucleotide plays a role in the regulation of gene silencing.","MIR375 Pre-miRNA | Pre-MicroRNA 375 | Pre-miRNA 375",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640155","Actively Marketed","C101667","Indicates that a product is currently being promoted for use.","Actively Marketed | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829141","Medical Device Brand Name Family","C101668","A grouping of medical devices items based upon brand name.","Medical Device Brand Name Family | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640157","Manufacturing Date Production Identifier","C101669","The production identifier is the date of manufacture.","Manufacturing Date Production Identifier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640172","Device Labeler","C101684","An individual that labels a device.","Device Labeler | Labeler",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541317","NCI CTEP SDC Soft Tissue Neoplasm Category Terminology","C103029","Soft Tissue Neoplasm is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Soft Tissue Neoplasm Category Terminology | NCI CTEP Simple Disease Classification Soft Tissue Neoplasm Category Terminology | Soft Tissue Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641032","NCI CTEP SDC Urothelial Tract Neoplasm Category Terminology","C103030","Urothelial Tract Neoplasm is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Urothelial Tract Neoplasm Category Terminology | NCI CTEP Simple Disease Classification Urothelial Tract Neoplasm Category Terminology | Urothelial Tract Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641033","NCI CTEP SDC Astrocytoma, High Grade Sub-Category Terminology","C103031","Astrocytoma, High Grade is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Astrocytoma, High Grade Sub-Category Terminology | Astrocytoma, High Grade | NCI CTEP Simple Disease Classification Astrocytoma, High Grade Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641034","NCI CTEP SDC AIDS-related Human Papillomavirus Sub-Category Terminology","C103032","AIDS-related Human Papillomavirus is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC AIDS-related Human Papillomavirus Sub-Category Terminology | AIDS-related Human Papillomavirus | NCI CTEP Simple Disease Classification AIDS-related Human Papillomavirus Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539883","NCI CTEP SDC AIDS-related Kaposi Sarcoma Sub-Category Terminology","C103033","AIDS-related Kaposi Sarcoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC AIDS-related Kaposi Sarcoma Sub-Category Terminology | AIDS-related Kaposi Sarcoma | NCI CTEP Simple Disease Classification AIDS-related Kaposi Sarcoma Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540470","NCI CTEP SDC AIDS-related Lymphoma Sub-Category Terminology","C103034","AIDS-related Lymphoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC AIDS-related Lymphoma Sub-Category Terminology | AIDS-related Lymphoma | NCI CTEP Simple Disease Classification AIDS-related Lymphoma Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641381","HADS - I Get a Frightened Feeling Something Awful is About to Happen","C103575","Hospital Anxiety and Depression Scale (HADS) I get a sort of frightened feeling as if something awful is about to happen.","HADS - I Get a Frightened Feeling Something Awful is About to Happen | HADS01-Something Awful About to Happen | HADS0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796113","Perlman Syndrome","C103144","A rare, autosomal recessive syndrome characterized by the presence of polyhydramnios, neonatal macrosomia, craniofacial abnormalities, nephroblastomatosis, and predisposition to Wilms tumor.  The prognosis is poor.","Perlman Syndrome | Renal Hamartomas, Nephroblastomatosis and Fetal Gigantism",,,,,,,,,,,,,,,"36716275","Perlman syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640176","Never Marketed","C101688","Indicates that a product was never promoted for use.","Never Marketed | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539766","ERBB Receptor Feedback Inhibitor 1, Human","C101731","ERBB receptor feedback inhibitor 1 (462 aa, ~51 kDa) is encoded by the human ERRFI1 gene. This protein plays a role in the regulation of ligand-dependent dimerization.","ERBB Receptor Feedback Inhibitor 1 | MIG-6 | Mitogen-Inducible Gene 6 Protein | Receptor-Associated Late Transducer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540523","H3/l","C101733","Human H3C2 wild-type allele is located in the vicinity of 6p22.1 and is approximately 1 kb in length. This allele, which encodes histone H3.1 protein, plays a role in the modulation of chromatin structure.","H3C2 wt Allele | H3 Clustered Histone 2 wt Allele | H3 Histone Family, Member L Gene | H3/l | H3FL | H3b | HIST1 Cluster, H3b Gene | HIST1H3B | HIST1H3B wt Allele | Histone 1, H3b Gene | Histone Cluster 1 H3 Family Member B Gene | Histone Cluster 1, H3b Gene | Histone Gene Cluster 1, H3 Histone Family, Member B Gene | Histone Gene Cluster 1, H3b Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538735","AMH wt Allele","C101736","Human AMH wild-type allele is located in the vicinity of 19p13.3 and is approximately 3 kb in length. This allele, which encodes Muellerian-inhibiting factor protein, is involved in the morphogenesis of the reproductive system. Mutation of the gene is associated with persistent Muellerian duct syndrome.","AMH wt Allele | Anti-Mullerian Hormone wt Allele | MIF | MIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641035","NCI CTEP SDC AIDS-related Malignancy and Condition, Miscellaneous Sub-Category Terminology","C103035","AIDS-related Malignancy and Condition, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC AIDS-related Malignancy and Condition, Miscellaneous Sub-Category Terminology | AIDS-related Malignancy and Condition, Miscellaneous | NCI CTEP Simple Disease Classification AIDS-related Malignancy and Condition, Miscellaneous Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541889","NCI CTEP SDC Ewing Sarcoma Sub-Category Terminology","C103038","Ewing Sarcoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Ewing Sarcoma Sub-Category Terminology | Ewing Sarcoma | NCI CTEP Simple Disease Classification Ewing Sarcoma Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL777881","PEG-linked L-RNA oligonucleotide hepcidin-targeting agent NOX-H94","C103195","A proprietary 44-nucleotide L-stereoisomer RNA oligonucleotide conjugated to a 40 kDa polyethylene glycol (PEG) that targets hepcidin with potential anti-anemic activity. Upon intravenous or subcutaneous administration, lexaptepid pegol binds to hepcidin and prevents it from binding to the iron channel ferroportin, located on the basolateral surface of gastrointestinal enterocytes and the plasma membrane of macrophages. This prevents hepcidin-induced internalization and degradation of ferroportin, thus decreasing macrophage iron retention. In turn, binding of NOX-H94 to hepcidin normalizes plasma iron levels and increases erythropoiesis. This may inhibit anemia caused by inflammation. Hepcidin, a peptide hormone that plays a key role in the homeostasis of systemic iron, is upregulated during acute and chronic inflammation in response to cytokines. The unique mirror-image configuration of this agent renders it resistant to hydrolysis and shows a low antigenicity profile. Pegylation increases the half-life of this agent.","Lexaptepid Pegol | LEXAPTEPID PEGOL | NOX-H94",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437435","Fluorine F 18 4-L-fluoroglutamine (2S,4R)","C103196","A radioconjugate and glutamine analog consisting of the fluorine F 18 labeled 2S, 4R stereoisomer of 4-fluoroglutamine with potential use as a metabolic tracer for tumor imaging. Upon intravenous administration, fluorine F 18 4-L-fluoroglutamine (2S,4R) is preferentially taken up by cancer cells, possibly driven by c-Myc upregulation. Upon positron emission tomography (PET), cancer cells can be imaged. Tumor cells use the amino acid glutamine for nutritional purposes necessary for energy production and growth; as tumor cells proliferate more rapidly than normal healthy cells, glutamine uptake is higher in certain cancer cells.","Fluorine F 18 4-L-fluoroglutamine (2S,4R) | 18F Fluoroglutamine | [18F] 4-L-fluoroglutamine (2S,4R)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641126","Racemate","C103198","An equimolar mixture of two enantiomers. A racemate is optically inactive.","Racemate | RACEMIC | Racemic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641127","Organism Part","C103199","A portion of an organism.","Organism Part | ORGANISM PART",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641128","Organism Part Location","C103200","Anatomical placement of a particular portion of an organism.","Organism Part Location | ORGANISM PART LOCATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029141","Optical Rotation","C103201","The ability of a chiral substance to rotate the plane of polarization of a beam of transmitted plane-polarized light, either clockwise (to the right) or counterclockwise (to the left).","Optical Rotation | OPTICAL ACTIVITY | Optical Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641383","HADS - Worrying Thoughts Go Through My Mind","C103577","Hospital Anxiety and Depression Scale (HADS) Worrying thoughts go through my mind.","HADS - Worrying Thoughts Go Through My Mind | HADS01-Worrying Thoughts Go Through Mind | HADS0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641384","HADS - I Feel Cheerful","C103578","Hospital Anxiety and Depression Scale (HADS) I feel cheerful.","HADS - I Feel Cheerful | HADS01-I Feel Cheerful | HADS0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641385","HADS - I Can Sit at Ease and Feel Relaxed","C103579","Hospital Anxiety and Depression Scale (HADS) I can sit at ease and feel relaxed.","HADS - I Can Sit at Ease and Feel Relaxed | HADS01-Sit at Ease and Feel Relaxed | HADS0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641386","HADS - I Feel as if I am Slowed Down","C103580","Hospital Anxiety and Depression Scale (HADS) I feel as if I am slowed down.","HADS - I Feel as if I am Slowed Down | HADS01-I Feel as if I am Slowed Down | HADS0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641387","HADS - I Get Frightened Feeling Like Butterflies in the Stomach","C103581","Hospital Anxiety and Depression Scale (HADS) I get a sort of frightened feeling like 'butterflies' in the stomach.","HADS - I Get Frightened Feeling Like Butterflies in the Stomach | HADS01-Butterflies in the Stomach | HADS0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641388","HADS - I Have Lost Interest in My Appearance","C103582","Hospital Anxiety and Depression Scale (HADS) I have lost interest in my appearance.","HADS - I Have Lost Interest in My Appearance | HADS01-Lost Interest in My Appearance | HADS0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641389","HADS - I Feel Restless as if I Have to be on the Move","C103583","Hospital Anxiety and Depression Scale (HADS) I feel restless as if I have to be on the move.","HADS - I Feel Restless as if I Have to be on the Move | HADS01-Feel Restless be on the Move | HADS0111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641390","HADS - I Look Forward with Enjoyment to Things","C103584","Hospital Anxiety and Depression Scale (HADS) I look forward with enjoyment to things.","HADS - I Look Forward with Enjoyment to Things | HADS01-Look Forward with Enjoyment | HADS0112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641391","HADS - I Get Sudden Feelings of Panic","C103585","Hospital Anxiety and Depression Scale (HADS) I get sudden feelings of panic.","HADS - I Get Sudden Feelings of Panic | HADS01-I Get Sudden Feelings of Panic | HADS0113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641392","HADS - I Can Enjoy a Good Book or Radio or Television Programme","C103586","Hospital Anxiety and Depression Scale (HADS) I can enjoy a good book or radio or television programme.","HADS - I Can Enjoy a Good Book or Radio or Television Programme | HADS01-Enjoy Good Book/Radio/Television | HADS0114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641394","IIEF - Erections Hard Enough for Penetration","C103588","International Index of Erectile Function (IIEF) Over the past four weeks when you had erections with sexual stimulation, how often were your erections hard enough for penetration?","IIEF - Erections Hard Enough for Penetration | IIEF01-Erection Firmness | IIEF01-Erection Hard Enough to Penetrate | IIEF0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641395","IIEF - Able to Penetrate Your Partner","C103589","International Index of Erectile Function (IIEF) Over the past four weeks when you attempted sexual intercourse, how often were you able to penetrate (enter) your partner?","IIEF - Able to Penetrate Your Partner | IIEF01-Able to Penetrate Your Partner | IIEF01-Penetration Ability | IIEF0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641396","IIEF - Able to Maintain Your Erection After You Had Penetrated Your Partner","C103590","International Index of Erectile Function (IIEF) Over the past four weeks during sexual intercourse, how often were you able to maintain your erection after you had penetrated (entered) your partner?","IIEF - Able to Maintain Your Erection After You Had Penetrated Your Partner | IIEF01-Maintain Erection After Penetrate | IIEF01-Maintenance Frequency | IIEF0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641234","CDISC Trial Design Class","C103379","This SDTM class describes the plan for the procedures to be followed in a clinical trial, including planned and actual timing of events, control group, method of allocating treatments, blinding methods, assignment of epochs that subjects pass through in the course of a trial.","CDISC Trial Design Class | TRIAL DESIGN | Trial Design",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1644065","Muellerian-Inhibiting Factor","C101737","Muellerian-inhibiting factor (560 aa, ~59 kDa) is encoded by the human AMH gene. This protein plays a role in the development of the male reproductive system.","Muellerian-Inhibiting Factor | AMH | Anti-Muellerian Hormone | Anti-Müllerian Hormone | MIS | Muellerian-Inhibiting Substance | Mullerian Inhibiting Factor | Mullerian Inhibiting Substance | Mullerian-Inhibiting Factor | Mullerian-Inhibiting Substance | Müllerian Inhibiting Factor | Müllerian Inhibiting Substance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417821","NR1D1 Gene","C101738","This gene plays a role in both transcriptional regulation and circadian rhythms.","NR1D1 Gene | NR1D1 | Nuclear Receptor Subfamily 1, Group D, Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537463","NR1D1 wt Allele","C101739","Human NR1D1 wild-type allele is located in the vicinity of 17q11.2 and is approximately 8 kb in length. This allele, which encodes nuclear receptor subfamily 1 group D member 1 protein, is involved in the regulation of metabolism.","NR1D1 wt Allele | EAR1 | Nuclear Receptor Subfamily 1, Group D, Member 1 wt Allele | REV-ERB-Alpha | Rev-ErbA-Alpha | Rev-ErbAalpha | THRA1 | THRAL | ear-1 | hRev",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1456353","NR1D1 protein, human","C101740","Nuclear receptor subfamily 1 group D member 1 (614 aa, ~67 kDa) is encoded by the human NR1D1 gene. This protein plays a role in transcriptional regulation of genes involved in metabolic processes and circadian rhythm.","Nuclear Receptor Subfamily 1 Group D Member 1 | EAR-1 | NR1D1 | Rev-erbA-Alpha | v-erbA-Related Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417822","NR1D2 Gene","C101741","This gene is involved in transcriptional regulation and metabolic processes.","NR1D2 Gene | NR1D2 | Nuclear Receptor Subfamily 1, Group D, Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540498","NR1D2 wt Allele","C101742","Human NR1D2 wild-type allele is located in the vicinity of 3p24.2 and is approximately 35 kb in length. This allele, which encodes nuclear receptor subfamily 1 group D member 2 protein, plays a role in the regulation of gene expression.","NR1D2 wt Allele | BD73 | EAR-1R | EAR-1r | HZF2 | Hs.37288 | Nuclear Receptor Subfamily 1, Group D, Member 2 wt Allele | REV-ERB-Beta | RVR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537391","Nuclear Receptor Subfamily 1 Group D Member 2","C101743","Nuclear receptor subfamily 1 group D member 2 (579 aa, ~65 kDa) is encoded by the human NR1D2 gene. This protein plays a role in circadian rhythms and transcriptional repression.","Nuclear Receptor Subfamily 1 Group D Member 2 | EAR-1R | NR1D2 | Orphan Nuclear Hormone Receptor BD73 | Rev-erb-Beta | v-erbA-Related Protein 1-Related",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426112","SNX18 Gene","C101744","This gene is involved in both endocytosis and protein trafficking.","SNX18 Gene | SNX18 | Sorting Nexin 18 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0053444","Glucuronidase Inhibitor","C1017","Any substance that inhibits glucuronidase, an enzyme involved in the hydrolysis of glucuronic acid from glucuronides. One of the key processes by which the human body eliminates toxic chemicals and hormones is by glucuronidation. When beta-glucuronidase deconjugates these glucuronides, it prolongs the stay of the hormone or toxic chemical in the body. Inhibition of glucuronidase can produce chemoprotective effects.","Glucuronidase Inhibitor | beta-D-Glucuronidase Inhibitors | beta-Glucuronidase Inhibitors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538776","TFCP2 wt Allele","C101801","Human TFCP2 wild-type allele is located in the vicinity of 12q13 and is approximately 79 kb in length. This allele, which encodes alpha-globin transcription factor CP2 protein, is involved in the modulation of gene expression.","TFCP2 wt Allele | LBP-1C | LBP1C | LSF | LSF1D | SEF | TFCP2C | Transcription Factor CP2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539874","Alpha-Globin Transcription Factor CP2, Human","C101802","Alpha-globin transcription factor CP2 (502 aa, ~57 kDa) is encoded by the human TFCP2 gene. This protein plays a role in transcriptional activation.","Alpha-Globin Transcription Factor CP2 | Late SV40 Factor | SAA3 Enhancer Factor | TFCP2 | Transcription Factor CP2 | Transcription Factor LSF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642462","F2 Gene Product","C101803","A protein encoded by the F2 gene.","F2 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641129","Dextrorotatory","C103202","The ability of an optically active substance to rotate the plane of polarized light clockwise (to the right).","Dextrorotatory | (+) | DEXTROROTATORY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641130","Levorotatory","C103203","The ability of an optically active substance to rotate the plane of polarized light counterclockwise (to the left).","Levorotatory | (-) | LEVOROTATORY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641131","Nonrotatory","C103204","The inability of a substance to rotate the plane of polarized light.","Nonrotatory | (+/-) | NONROTATORY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542408","Chemical Substance Excluding Protein or Nucleic Acid","C103205","A type of substance that may be described as a stoichiometric or non-stoichiometric single molecular entity and is not a protein or nucleic acid substance.","Chemical Substance Excluding Protein or Nucleic Acid | CHEMICAL SUBSTANCE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641132","Structurally Diverse Substance","C103206","A type of polydisperse substance isolated from a single source that is a complex mixture which cannot be described as a limited set of single substance.","Structurally Diverse Substance | STRUCTURALLY DIVERSE SUBSTANCE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0599473","enantiomer","C103207","An object or molecule that is not superimposable on its mirror image. The classic description of chirality is the comparison of the hand in a mirror, because the mirror image is the opposite. A chiral molecule has one or more chiral centers.","Chiral | CHIRAL | Chirality | enantiomer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641134","Epimeric","C103209","A particular kind of diastereoisomers that differ in their stereochemistry at only one chiral center; the stereochemistry at all other chiral centers is identical.","Epimeric | EPIMERIC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641273","CDISC Questionnaire ADCS-CGIC Test Name Terminology","C103458","Test names of questionnaire questions associated with the Alzheimer's disease cooperative study-clinical global impression of change questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire ADCS-CGIC Test Name Terminology | ACGC01TN | Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change Questionnaire Test Name | QS-ADCS-CGIC TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641274","CDISC Questionnaire ADCS-CGIC Test Code Terminology","C103459","Test codes of questionnaire questions associated with the Alzheimer's disease cooperative study-clinical global impression of change questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire ADCS-CGIC Test Code Terminology | ACGC01TC | Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change Questionnaire Test Code | QS-ADCS-CGIC TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539773","PIK3C2B wt Allele","C102943","Human PIK3C2B wild-type allele is located in the vicinity of 1q32 and is approximately 72 kb in length. This allele, which encodes phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta protein, plays a role in the regulation of phosphoinositol signaling.","PIK3C2B wt Allele | C2-PI3K | PI3K-C2beta | PI3KC2B | Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Beta wt Allele | Phosphatidylinositol-4-Phosphate 3-Kinase, Catalytic Subunit Type 2 Beta Gene | RP11-739N20.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1608572","PIK3C2B protein, human","C102944","Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta (1634 aa, ~185 kDa) is encoded by the human PIK3C2B gene. This protein is involved in both second messenger signaling and the phosphorylation of phosphoinositol.","Phosphatidylinositol 4-Phosphate 3-Kinase C2 Domain-Containing Subunit Beta | C2-PI3K | EC 2.7.1.154 | PI3K-C2-Beta | PIK3C2B | Phosphatidylinositol 3-Kinase C2 Domain-Containing Beta Polypeptide | Phosphoinositide 3-Kinase-C2-Beta | PtdIns-3-Kinase C2 Subunit Beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541408","PIK3C2G wt Allele","C102946","Human PIK3C2G wild-type allele is located in the vicinity of 12p12 and is approximately 401 kb in length. This allele, which encodes phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma protein, plays a role in both the phosphorylation of phospholipids and the modulation of second messenger signaling.","PIK3C2G wt Allele | PI3K-C2-Gamma | PI3K-C2GAMMA | Phosphatidylinositol 3-Kinase, Class 2, Gamma Gene | Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Gamma wt Allele | Phosphatidylinositol-4-Phosphate 3-Kinase, Catalytic Subunit Type 2 Gamma Gene | Phosphoinositide-3-Kinase, Class 2, Gamma Polypeptide Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2000042","PIK3C2G protein, human","C102947","Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma (1445 aa, ~166 kDa) is encoded by the human PIK3C2G gene. This protein is involved in the modulation of phosphoinositol signaling.","Phosphatidylinositol 4-Phosphate 3-Kinase C2 Domain-Containing Subunit Gamma | EC 2.7.1.154 | PI3K-C2-Gamma | PIK3C2G | PTDINS-3-Kinase C2 Gamma | Phosphatidylinositol 3-Kinase C2 Domain-Containing Gamma | Phosphatidylinositol 3-Kinase C2 Domain-Containing Gamma Polypeptide | Phosphatidylinositol-4-Phosphate 3-Kinase C2 Domain-Containing Gamma Polypeptide | Phosphatidylinositol-4-Phosphate 3-Kinase C2 Domain-Containing Subunit Gamma | Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Gamma | Phosphoinositide 3-Kinase-C2-Gamma | PtdIns-3-Kinase C2 Subunit Gamma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539599","CD109 wt Allele","C102949","Human CD109 wild-type allele is located in the vicinity of 6q13 and is approximately 133 kb in length. This allele, which encodes CD109 antigen protein, may play a role in the modulation of both proteolysis and signaling.","CD109 wt Allele | CD109 Antigen (Gov Platelet Alloantigens) Gene | CD109 Molecule wt Allele | CPAMD7 | DKFZp762L1111 | FLJ38569 | Gov Platelet Alloantigens Gene | RP11-525G3.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539854","CD109 Antigen, Human","C102950","CD109 antigen (1445 aa, ~162 kDa) is encoded by the human CD109 gene. This protein may be involved in both proteolysis and signaling.","CD109 Antigen | 150 kDa TGF-Beta-1-Binding Protein | Activated T-Cell Marker CD109 | C3 and PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 7 | CD109 | Platelet-Specific Gov Antigen | p180 | r150",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539601","OTX2 wt Allele","C102952","Human OTX2 wild-type allele is located in the vicinity of 14q22.3 and is approximately 10 kb in length. This allele, which encodes homeobox protein OTX2, plays a role in the positive regulation of gene expression during embryonic pattern formation. Mutation of the gene is associated with both microphthalmia syndromic type 5 and pituitary hormone deficiency combined type 6.","OTX2 wt Allele | CPHD6 | MCOPS5 | Orthodenticle Homeobox 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3543413","Experimental Organism Benign Basalioma","C103391","A benign epithelial neoplasm arising from primary epithelial germ cells of the piliary complex.","Experimental Organism Benign Basalioma | BASALIOMA, BENIGN | Basalioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641241","Experimental Organism Benign Bone Osteofibroma","C103392","A benign neoplasm, morphologically a fibroma with osseous components.","Experimental Organism Benign Bone Osteofibroma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641242","Experimental Organism Malignant Hepatocholangiocellular Carcinoma","C103393","A malignant mixed neoplasm of the liver comprising neoplastic hepatocytes and bile duct epithelial cells; both elements displaying evidence of malignancy.","Experimental Organism Malignant Hepatocholangiocellular Carcinoma | CARCINOMA, HEPATOCHOLANGIOCELLULAR, MALIGNANT | Hepatocholangiocellular Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641243","Experimental Organism Malignant Hibernoma","C103394","A malignant neoplasm arising from the brown adipose tissue in animals, usually in the subcutis and the thoracic cavity.","Experimental Organism Malignant Hibernoma | HIBERNOMA, MALIGNANT | Malignant Hibernoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537326","Heart- and Neural Crest Derivatives-Expressed Protein 2","C102792","Heart- and neural crest derivatives-expressed protein 2 (217 aa, ~24 kDa) is encoded by the human HAND2 gene. This protein plays a role in the regulation of gene expression during heart development.","Heart- and Neural Crest Derivatives-Expressed Protein 2 | Basic Helix-Loop-Helix Transcription Factor HAND2 | Class A Basic Helix-Loop-Helix Protein 26 | Deciduum, Heart, Autonomic Nervous System and Neural Crest Derivatives-Expressed Protein 2 | HAND2 | bHLHa26 | dHAND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416858","LILRB2 Gene","C102793","This gene is involved in immunity.","LILRB2 Gene | LILRB2 | Leukocyte Immunoglobulin-Like Receptor, Subfamily B (With TM and ITIM Domains), Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538733","LILRB2 wt Allele","C102794","Human LILRB2 wild-type allele is located in the vicinity of 19q13.4 and is approximately 7 kb in length. This allele, which encodes leukocyte immunoglobulin-like receptor subfamily B member 2 protein, plays a role in binding to class I MHC antigens and the regulation of T-cell responses.","LILRB2 wt Allele | CD85D | ILT4 | LILRA6 | LIR-2 | LIR2 | Leukocyte Immunoglobulin-Like Receptor, Subfamily B (With TM and ITIM Domains), Member 2 wt Allele | MIR-10 | MIR10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538732","LILRB2 protein, human","C102795","Leukocyte immunoglobulin-like receptor subfamily B member 2 (598 aa, ~65 kDa) is encoded by the human LILRB2 gene. This protein is involved in the regulation of class I MHC antigen responses.","Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 2 | Antigen CD85d | CD85 Antigen-Like Family Member D | CD85d | CD85d Antigen | ILT-4 | Immunoglobulin-Like Transcript 4 | LILRB2 | LIR-2 | Leukocyte Immunoglobulin-Like Receptor 2 | MIR-10 | Monocyte/Macrophage Immunoglobulin-Like Receptor 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540809","DNM2 wt Allele","C102797","Human DNM2 wild-type allele is located in the vicinity of 19p13.2 and is approximately 118 kb in length. This allele, which encodes dynamin-2 protein, is involved in both microtubule polymerization and GTPase activity. Mutation of the gene is associated with centronuclear myopathy type 1 and Charcot-Marie-Tooth disease types dominant intermediate B and 2M axonal.","DNM2 wt Allele | CMT2M | CMTDI1 | CMTDIB | DI-CMTB | DYN2 | DYNII | Dynamin 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640225","QS-AIMS TESTCD","C101805","Test codes of clinical classification questions associated with the Abnormal Involuntary Movement Scale (AIMS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification AIMS Test Code Terminology | AIMS01TC | Abnormal Involuntary Movement Scale Clinical Classification Test Code | QS-AIMS TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640226","QS-AIMS TEST","C101806","Test names of clinical classification questions associated with the Abnormal Involuntary Movement Scale (AIMS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification AIMS Test Name Terminology | AIMS01TN | Abnormal Involuntary Movement Scale Clinical Classification Test Name | QS-AIMS TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640227","CDISC Functional Test ADNI AVLT Test Code Terminology","C101807","Test codes of functional test questions associated with the Alzheimer's Disease Neuroimaging Initiative's (ADNI) version of the Auditory Verbal Learning Test (AVLT) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Functional Test ADNI AVLT Test Code Terminology | ADNI Auditory Verbal Learning Functional Test Test Code | AVL01TC | QS-ADNI AVLT TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640228","CDISC Functional Test ADNI AVLT Test Name Terminology","C101808","Test names of functional test questions associated with the Alzheimer's Disease Neuroimaging Initiative's (ADNI) version of the Auditory Verbal Learning Test (AVLT) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Functional Test ADNI AVLT Test Name Terminology | ADNI Auditory Verbal Learning Functional Test Test Name | AVL01TN | QS-ADNI AVLT TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640229","QS-BARS TESTCD","C101809","Test codes of clinical classification questions associated with the Barnes Akathisia Rating Scale (BARS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification BARS Test Code Terminology | BARS01TC | Barnes Akathisia Rating Scale Clinical Classification Test Code | QS-BARS TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640230","QS-BARS TEST","C101810","Test names of clinical classification questions associated with the Barnes Akathisia Rating Scale (BARS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification BARS Test Name Terminology | BARS01TN | Barnes Akathisia Rating Scale Clinical Classification Test Name | QS-BARS TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538856","SNX18 wt Allele","C101745","Human SNX18 wild-type allele is located in the vicinity of 5q11.2 and is approximately 29 kb in length. This allele, which encodes sorting nexin-18 protein, plays a role in both subcellular protein transport and endocytosis.","SNX18 wt Allele | FLJ11997 | FLJ32560 | FLJ61062 | MGC150827 | MGC150829 | SH3PX2 | SH3PXD3B | SNAG1 | Sorting Nexin 18 wt Allele | Sorting Nexin Associated Golgi Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2604442","Sorting Nexin-18, Human","C101746","Sorting nexin-18 (628 aa, ~96 kDa) is encoded by the human SNX18 gene. This protein is involved in both protein transport and endocytosis.","Sorting Nexin-18 | SH3 and PX Domain-Containing Protein 3B | SNX18 | Sorting Nexin 18 | Sorting Nexin-Associated Golgi Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825292","FFAR1 Gene","C101747","This gene plays a role in G protein signaling.","FFAR1 Gene | FFAR1 | Free Fatty Acid Receptor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539625","FFAR1 wt Allele","C101748","Human FFAR1 wild-type allele is located in the vicinity of 19q13.1 and is approximately 1 kb in length. This allele, which encodes free fatty acid receptor 1 protein, is involved in lipid binding, receptor signaling and the regulation of insulin secretion.","FFAR1 wt Allele | FFA1R | Free Fatty Acid Receptor 1 wt Allele | G Protein-Coupled Receptor 40 Gene | GPCR40 | GPR40",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641275","CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology","C103460","Test names of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Since Last Visit (C-SSRS Since Last Vist) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology | CSS02TN | Columbia-Suicide Severity Rating Scale Since Last Visit Questionnaire Test Name | QS-C-SSRS SINCE LAST VISIT TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641276","CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology","C103461","Test codes of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Since Last Visit (C-SSRS Since Last Vist) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology | CSS02TC | Columbia-Suicide Severity Rating Scale Since Last Visit Questionnaire Test Code | QS-C-SSRS SINCE LAST VISIT TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641277","CDISC Questionnaire ESS Test Name Terminology","C103462","Test names of questionnaire questions associated with the Epworth sleepiness scale questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire ESS Test Name Terminology | ESS01TN | Epworth Sleepiness Scale Questionnaire Test Name | QS-ESS TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641279","CDISC Questionnaire FIQR Test Name Terminology","C103464","Test names of questionnaire questions associated with the revised fibromyalgia impact questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire FIQR Test Name Terminology | FIQR01TN | QS-FIQR TEST | Revised Fibromyalgia Impact Questionnaire Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641280","CDISC Questionnaire FIQR Test Code Terminology","C103465","Test codes of questionnaire questions associated with the revised fibromyalgia impact questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire FIQR Test Code Terminology | FIQR01TC | QS-FIQR TESTCD | Revised Fibromyalgia Impact Questionnaire Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641281","CDISC Questionnaire GAD-7 Test Name Terminology","C103466","Test names of questionnaire questions associated with the generalized anxiety disorder 7 item questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire GAD-7 Test Name Terminology | GAD01TN | Generalized Anxiety Disorder - 7 Questionnaire Test Name | QS-GAD-7 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437131","Carmustine Sustained-Release Implant Wafer","C102847","A sustained release (SR) implant wafer containing the lipophilic nitrosourea carmustine (BCNU) with antineoplastic activity. Upon intracranial administration of the implant wafer and subsequent release of BCNU from the wafer, this agent alkylates and cross-links DNA during all phases of the cell cycle, resulting in the disruption of DNA function, cell cycle arrest, and apoptosis. This wafer contains the biodegradable copolymer PLGA (poly(lactide-co-glycolide) as the major drug delivery vehicle which is slowly degraded into water and carbon dioxide thereby continously releasing BCNU over approximately 3-4 weeks. Compared to systemic administration of BCNU alone, this local SR formulation is able to maintain higher drug concentrations locally over a longer period of time while minimizing exposure to other tissues.","Carmustine Sustained-Release Implant Wafer | CASANT Wafer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437132","Absorbable Adhesion Barrier Gel","C102848","An isotonic, sterile, absorbable adhesion barrier gel composed of polyethylene oxide and sodium carboxymethylcellulose, with protective activity. Upon application of a single layer into the uterine cavity at the end of any hysteroscopic surgery, the absorbable adhesion barrier gel may provide a protective barrier which protects the traumatized tissue and allows for healing. This gel may therefore prevent the formation of post-surgical intrauterine adhesions.","Absorbable Adhesion Barrier Gel | Oxiplex/AP Gel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2605865","CK2-targeting Synthetic Peptide CIGB-300","C102849","A synthetic peptide targeting the substrates of casein kinase 2 (CK2), with potential antineoplastic activity. Upon administration and nucleolar localization, CK2-targeting synthetic peptide CIGB-300 binds to phosphoacceptor sites on the CK2 substrates, in particular the oncoprotein nucleophosmin (B23 or NPM1). This blocks the activation of B23 and induces apoptosis, thereby inhibiting tumor cell growth in susceptible tumor cells. CK2, a protein kinase often overexpressed in a variety of cancer cell types, appears to be correlated with malignant transformation, tumor growth and survival. Overexpression of B23 has been correlated with increased cellular growth and proliferation as well as inhibition of differentiation and apoptosis.","CK2-targeting Synthetic Peptide CIGB-300 | CIBG-300 | CIGB-300 | CIGB-325 | P15-tat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1528381","OTX2 protein, human","C102953","Homeobox protein OTX2 (289 aa, ~32 kDa) is encoded by the human OTX2 gene. This protein is involved in both transcriptional regulation and embryonic development.","Homeobox Protein OTX2 | Orthodenticle Homolog 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541293","Systemic Arterial Hypertensive Disorder","C102954","Any condition resulting in systemically elevated blood pressure that is attributed to an arterial source.","Systemic Arterial Hypertensive Disorder | Hypertensive Disorder, Systemic Arterial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539940","NCI CTEP SDC Penile Cancer Sub-Category Terminology","C103108","Penile Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Penile Cancer Sub-Category Terminology | NCI CTEP Simple Disease Classification Penile Cancer Sub-Category Terminology | Penile Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541264","NCI CTEP Simple Disease Classification Prostate Cancer Sub-Category Terminology","C103109","Prostate Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Prostate Cancer Sub-Category Terminology | NCI CTEP Simple Disease Classification Prostate Cancer Sub-Category Terminology | Prostate Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641068","NCI CTEP SDC Prostatic Intraepithelial Neoplasia (PIN) Sub-Category Terminology","C103110","Prostatic Intraepithelial Neoplasia (PIN) is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Prostatic Intraepithelial Neoplasia (PIN) Sub-Category Terminology | NCI CTEP Simple Disease Classification Prostatic Intraepithelial Neoplasia (PIN) Sub-Category Terminology | Prostatic Intraepithelial Neoplasia (PIN)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641069","NCI CTEP SDC Testicular Cancer (excluding Testicular Germ Cell Cancer) Sub-Category Terminology","C103111","Testicular Cancer (excluding Testicular Germ Cell Cancer) is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Testicular Cancer (excluding Testicular Germ Cell Cancer) Sub-Category Terminology | NCI CTEP Simple Disease Classification Testicular Cancer (excluding Testicular Germ Cell Cancer) Sub-Category Terminology | Testicular Cancer (excluding Testicular Germ Cell Cancer)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539018","NCI CTEP SDC Melanoma Sub-Category Terminology","C103113","Melanoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Melanoma Sub-Category Terminology | Melanoma | NCI CTEP Simple Disease Classification Melanoma Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3884445","DNM2 protein, human","C102798","Dynamin-2 (870 aa, ~98 kDa) is encoded by the human DNM2 gene. This protein plays a role in both microtubule polymerization and GTP hydrolysis.","Dynamin-2 | DNM2 | EC 3.6.5.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419337","RELN Gene","C102799","This gene is involved in both proteolysis and signaling.","RELN Gene | RELN | Reelin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280592","doxorubicin/fluorouracil/mitomycin/vincristine protocol","C10279","A regimen consisting of fluorouracil, vincristine, doxorubicin, and mitomycin that may be used for the treatment of breast cancer.","FOAM Regimen | DOX/5-FU/MITO/VCR | Doxorubicin/Fluorouracil/Mitomycin/Vincristine | FOAM | Fluorouracil-Vincristine-Doxorubicin-Mitomycin | Fluorouracil-Vincristine-Doxorubicin-Mitomycin Regimen | Fluorouracil/Oncovin/Adriamycin/Mitomycin | Fluorouracil/Vincristine/Doxorubicin/Mitomycin | VFAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539667","RELN wt Allele","C102800","Human RELN wild-type allele is located in the vicinity of 7q22 and is approximately 518 kb in length. This allele, which encodes reelin protein, plays a role in extracellular matrix proteolysis, signal transduction and neuronal development. Mutation of the gene is associated with lissencephaly type 2.","RELN wt Allele | LIS2 | PRO1598 | RL | Reelin wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1568702","Reelin, Human","C102801","Reelin (3460 aa, ~388 kDa) is encoded by the human RELN gene. This protein is involved in both neuronal development and proteolysis.","Reelin | EC 3.4.21.- | RELN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054252","Buthionine Sulfoximine","C1029","A synthetic amino acid. Buthionine sulfoximine irreversibly inhibits gamma-glutamylcysteine synthase, thereby depleting cells of glutathione, a metabolite that plays a critical role in protecting cells against oxidative stress, and resulting in free radical-induced apoptosis. Elevated glutathione levels are associated with tumor cell resistance to alkylating agents and platinum compounds. By depleting cells of glutathione, this agent may enhance the in vitro and in vivo cytotoxicities of various chemotherapeutic agents in drug-resistant tumors. Buthionine sulfoximine may also exhibit antiangiogenesis activity. (NCI04)","Buthionine Sulfoximine | 2-Amino-4-(S-butylsulfonimidoyl) Butanoic Acid | BSO | BUTHIONINE SULFOXIMINE, L- | Butanoic Acid, 2-Amino-4-(S-butylsulfonimidoyl)- | Butanoic acid, 2-amino-4-(S-butylsulfonimidoyl)- | Buthionine Sulphoximine | L-Buthionine Sulfoximine | L-Buthionine sulfoximine | S-(3-Amino-3-carboxypropyl)-S-butylsulfoximine | S-(n-Butyl)homocysteine Sulfoximine | buthionine sulfoximine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539852","Free Fatty Acid Receptor 1, Human","C101749","Free fatty acid receptor 1 (300 aa, ~31 kDa) is encoded by the human FFAR1 gene. This protein plays a role in fatty acid-dependent receptor signaling.","Free Fatty Acid Receptor 1 | G-Protein Coupled Receptor 40",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2350498","KLRK1 protein, human","C101752","NKG2-D type II integral membrane protein (216 aa, ~25 kDa) is encoded by the human KLRK1 gene. This protein plays a role in ligand-mediated NK cell activation.","NKG2-D Type II Integral Membrane Protein | Antigen CD314 | CD Antigen CD314 | CD314 | CD314 Antigen | KLRK1 | Killer Cell Lectin-Like Receptor Subfamily K Member 1 | NK Cell Receptor D | NKG2-D-Activating NK Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541879","CDH23 wt Allele","C101754","Human CDH23 wild-type allele is located in the vicinity of 10q22.1 and is approximately 419 kb in length. This allele, which encodes cadherin-23 protein, plays a role in both cell adhesion and stereocilia organization. Mutation of the gene is associated with deafness autosomal recessive type 12 and Usher syndrome types 1D, digenic 1D/F and 3.","CDH23 wt Allele | CDHR23 | Cadherin-Related 23 wt Allele | DFNB12 | DKFZp434P2350 | FLJ00233 | FLJ36499 | KIAA1774 | KIAA1812 | MGC102761 | RP11-472K8.4 | UNQ1894/PRO4340 | USH1D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1310307","Cadherin-23","C101755","Cadherin-23 (3354 aa, ~370 kDa) is encoded by the human CDH23 gene. This protein is involved in the organization of stereocilia and cell-cell adhesion.","Cadherin-23 | Otocadherin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421222","TTN Gene","C101756","This gene plays a role in sarcomere structure.","TTN Gene | TTN | Titin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3711784","Titin, Human","C101758","Titin (34350 aa, ~3816 kDa) is encoded by the human TTN gene. This protein plays a role in muscle filament structure and contraction.","Titin | Connectin | EC 2.7.11.1 | Rhabdomyosarcoma antigen MU-RMS-40.14 | TITIN | TTN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538873","MMP10 wt Allele","C101760","Human MMP10 wild-type allele is located in the vicinity of 11q22.3 and is approximately 10 kb in length. This allele, which encodes stromelysin-2 protein, is involved in proteolysis of components of the extracellular matrix.","MMP10 wt Allele | Matrix Metallopeptidase 10 (Stromelysin 2) wt Allele | SL-2 | SL2 | ST2 | STMY2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1723259","Stromelysin-2","C101761","Stromelysin-2 (476 aa, ~54 kDa) is encoded by the human MMP10 gene. This protein plays a role in the metabolism of the extracellular matrix.","Stromelysin-2 | EC 3.4.24.22 | MMP-10 | MMP10 | Matrix Metalloprotease 10 | Matrix Metalloprotease-10 | Matrix Metalloproteinase 10 | Matrix Metalloproteinase-10 | SL-2 | Stromelysin-II | Transin-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2603824","Naphthalimide Analogue UNBS5162","C102850","An amonafide (naphthalimide) derivative and pan-antagonist of chemokine ligand (CXCL) expression, with potential anti-angiogenic activity. Although UNBS5162 is a derivative of amonafide, this agent appears to have a different profile to that of amonafide and its exact mechanism of action remains to be fully elucidated. This agent seems to decrease the expression of various proangiogenic CXCL chemokines in vitro and may have synergistic effects with radiotherapy or chemotherapy. CXCLs are small cytokines in the CXC chemokine family that are overexpressed in certain cancers; CXCL-mediated signaling plays a key role in angiogenesis and tumor progression.","Naphthalimide Analogue UNBS5162 | 1-(2-(2-(Dimethylamino)ethyl)-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-5-yl)urea | UNBS-5162 | UNBS5162",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0077906","urinastatin","C102851","A multivalent Kunitz-type serine protease inhibitor derived from human urine, with potential protective, anti-fibrinolytic and anticoagulant activities. Upon administration, ulinastatin (or urinary trypsinogen inhibitor) inhibits the activities of a variety of enzymes, including trypsin, chymotrypsin, thrombin, kallikrein, plasmin, elastase, cathepsin, lipase, hyaluronidase, factors IXa, Xa, XIa, and XlIa, and polymorphonuclear leukocyte elastase. In addition, ulinastatin inhibits the excessive release of proinflammatory mediators, such as tumor necrosis factor-alpha, interleukin-6 and -8, and chemokines. Altogether, this agent may improve the microcirculation, perfusion and function of tissues and may protect organ injury.","Ulinastatin | Bikunin | Trypsin Inhibitor, Bikunin | ULINASTATIN | UTI | Urinary Trypsin Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640967","Fruquintinib","C102852","An orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and antineoplastic activities. Upon oral administration, fruquintinib inhibits VEGF-induced phosphorylation of VEGFRs 1, 2, and 3 which may result in the inhibition of migration, proliferation and survival of endothelial cells, microvessel formation, the inhibition of tumor cell proliferation, and tumor cell death. Expression of VEGFRs may be upregulated in a variety of tumor cell types.","Fruquintinib | 6-(6,7-Dimethoxyquinazolin-4-yl)oxy-N,2-dimethyl-1-benzofuran-3-carboxamide | Elunate | FRUQUINTINIB | Fruzaqla | HMPL 013 | HMPL-013 | HMPL013 | VEGFR-1/2/3 Inhibitor HMPL-013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437134","Anti-TGF-beta RII Monoclonal Antibody IMC-TR1","C102853","A monoclonal antibody directed against transforming growth factor-beta receptor type II (TGF-beta RII) with potential antineoplastic activity. Anti-TGF-beta RII monoclonal antibody IMC-TR1 specifically targets and binds to TGF-beta R11, thereby preventing the activation of TGF-beta RII-mediated signaling pathways. TGF-beta RII is mutated in a number of cancer cell types and is involved in cancer cell proliferation and tumor progression.","Anti-TGF-beta RII Monoclonal Antibody IMC-TR1 | IMC-TR1 | LY3022859",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541899","NCI CTEP SDC Osteosarcoma Sub-Category Terminology","C103039","Osteosarcoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Osteosarcoma Sub-Category Terminology | NCI CTEP Simple Disease Classification Osteosarcoma Sub-Category Terminology | Osteosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280646","carmustine/cisplatin/dacarbazine","C10303","A regimen consisting of carmustine, cisplatin, and dacarbazine that may be used in the treatment of metastatic melanoma.","CDB Regimen | BCNU/CDDP/DTIC | CDB | Carmustine-Cisplatin-Dacarbazine | Carmustine/Cisplatin/Dacarbazine | Carmustine/Cisplatin/Dacarbazine Regimen | DTIC+BCNU+Cisplatin | DTIC-BCNU-Cisplatin Regimen | Dacarbazine-Carmustine-Cisplatin Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641037","NCI CTEP SDC Breast Cancer - In Situ Sub-Category Terminology","C103040","Breast Cancer - In Situ is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Breast Cancer - In Situ Sub-Category Terminology | Breast Cancer - In situ | NCI CTEP Simple Disease Classification Breast Cancer - In situ Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641038","NCI CTEP SDC Breast Cancer - Invasive Sub-Category Terminology","C103041","Breast Cancer - Invasive is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Breast Cancer - Invasive Sub-Category Terminology | Breast Cancer - Invasive | NCI CTEP Simple Disease Classification Breast Cancer - Invasive Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539924","NCI CTEP SDC Merkel Cell Tumor Sub-Category Terminology","C103114","Merkel Cell Tumor is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Merkel Cell Tumor Sub-Category Terminology | Merkel Cell Tumor | NCI CTEP Simple Disease Classification Merkel Cell Tumor Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542432","NCI CTEP SDC Squamous Cell Carcinoma of the Skin Sub-Category Terminology","C103116","Squamous Cell Carcinoma of the Skin is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Squamous Cell Carcinoma of the Skin Sub-Category Terminology | NCI CTEP Simple Disease Classification Squamous Cell Carcinoma of the Skin Sub-Category Terminology | Squamous Cell Carcinoma of the Skin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641214","GNRLOBSC","C103329","The terminology that includes concepts relevant to the Clinical Data Interchange Standards Consortium (CDISC) Define-XML standard general observation classes.","CDISC Define-XML General Observation Class Terminology | DEFINE-GNRLOBSC | GNRLOBSC | General Observation Class",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1623196","Lavandula angustifolia","C101763","A plant with aromatic leaves and flowers that is a member of the mint family. Oil from the flowers has been used in some cultures to treat certain medical problems, to keep insects away, and to wash in. It is also used in aromatherapy. Perillyl alcohol, a substance found in lavender, is being studied in cancer prevention and treatment.","Lavandula angustifolia | Common Lavender | English Lavender | English lavender | LAVANDULA ANGUSTIFOLIA WHOLE | lavender | true lavender",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539622","B3GAT1 wt Allele","C101764","Human B3GAT1 wild-type allele is located in the vicinity of 11q25 and is approximately 33 kb in length. This allele, which encodes galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 protein, is involved in the addition of carbohydrate to proteins.","B3GAT1 wt Allele | Beta-1,3-Glucuronyltransferase 1 (Glucuronosyltransferase P) wt Allele | CD57 | GLCATP | GLCUATP | HNK1 | LEU7 | NK-1 | NK1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1450412","Galactosylgalactosylxylosylprotein 3-Beta-Glucuronosyltransferase 1, Human","C101765","Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 (334 aa, ~38 kDa) is encoded by the human B3GAT1 gene. This protein plays a role in protein glycosylation.","Galactosylgalactosylxylosylprotein 3-Beta-Glucuronosyltransferase 1 | B3GAT1 | Beta-1,3-Glucuronyltransferase 1 | EC 2.4.1.135 | GlcAT-P | GlcUAT-P | Glucuronosyltransferase P | UDP-GlcUA:Glycoprotein Beta-1,3-Glucuronyltransferase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541271","PPARGC1B wt Allele","C101767","Human PPARGC1B wild-type allele is located in the vicinity of 5q32 and is approximately 125 kb in length. This allele, which encodes peroxisome proliferator-activated receptor gamma coactivator 1-beta protein, plays a role in both transcriptional regulation and estrogen receptor signaling.","PPARGC1B wt Allele | DKFZp686C1790 | ERRL1 | FLJ14284 | PERC | PGC-1(beta) | PGC1B | Peroxisome Proliferative Activated Receptor, Gamma, Coactivator 1, Beta Gene | Peroxisome Proliferator-Activated Receptor Gamma, Coactivator 1 Beta wt Allele | Peroxisome Proliferator-Activated Receptor-Gamma, Coactivator 1 Beta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1136465","Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-Beta, Human","C101768","Peroxisome proliferator-activated receptor gamma coactivator 1-beta (1023 aa, ~113 kDa) is encoded by the human PPARGC1B gene. This protein is involved in both estrogen receptor signaling and transcriptional activation.","Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-Beta | Estrogen Receptor-Related Receptor Ligand 1 | PGC-1-Beta | PGC-1-Related Estrogen Receptor Alpha Coactivator | PGC1-Beta | PGC1-Related Estrogen Receptor Coactivator | PPAR-Gamma Coactivator 1-Beta | PPARGC-1-Beta | PPARGC1B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280060","bleomycin/fluorouracil/methotrexate/vincristine","C10176","A regimen consisting of vincristine, bleomycin, methotrexate, and fluorouracil that may be used in the treatment of head and neck cancer.","VBMF Regimen | BLEO/5-FU/MTX/VCR | Bleomycin/Fluorouracil/Methotrexate/Vincristine | VBMF | Vincristine-Bleomycin-Methotrexate-Fluorouracil | Vincristine/Bleomycin/Methotrexate/Fluorouracil | Vincristine/Bleomycin/Methotrexate/Fluorouracil Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538698","TFF3 wt Allele","C101770","Human TFF3 wild-type allele is located in the vicinity of 21q22.3 and is approximately 4 kb in length. This allele, which encodes trefoil factor 3 protein, plays a role in cell motility and both repair and maintenance of the intestinal mucosa.","TFF3 wt Allele | HITF | ITF | P1B | TFI | Trefoil Factor 3 (Intestinal) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0660409","Trefoil Factor 3, Human","C101771","Trefoil factor 3 (80 aa, ~9 kDa) is encoded by the human TFF3 gene. This protein is involved in both digestion and gastrointestinal mucosa maintenance.","Trefoil Factor 3 | Human Intestinal Trefoil Factor | Intestinal Trefoil Factor | Polypeptide P1.B | TFF3 | hITF | hP1.B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541344","NCI CTEP SDC Astrocytoma, Low Grade Sub-Category Terminology","C103043","Astrocytoma, Low Grade is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Astrocytoma, Low Grade Sub-Category Terminology | Astrocytoma, Low Grade | NCI CTEP Simple Disease Classification Astrocytoma, Low Grade Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539082","NCI CTEP SDC Ependymal Tumors Sub-Category Terminology","C103047","Ependymal Tumors is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Ependymal Tumors Sub-Category Terminology | Ependymal Tumors | NCI CTEP Simple Disease Classification Ependymal Tumors Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641042","NCI CTEP SDC Germ Cell Tumors of the CNS Sub-Category Terminology","C103048","Germ Cell Tumors of the CNS is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Germ Cell Tumors of the CNS Sub-Category Terminology | Germ Cell Tumors of the CNS | NCI CTEP Simple Disease Classification Germ Cell Tumors of the CNS Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641135","Meso Compound","C103210","An achiral member of a set of diastereoisomers that is not optically active while the other isomers within the set are optically active.","Meso Compound | MESO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641136","Square Planar 1 Molecular Geometry","C103211","Square planar molecular geometry where the Cahn-Ingold-Prelog (CIP) priority of the donor atom directly across from the priority 1 donor atom is also 1.","Square Planar 1 Molecular Geometry | SP-4-1 | SQUARE PLANAR 1 | Square Planar 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641137","Square Planar 2 Molecular Geometry","C103212","Square planar molecular geometry where the Cahn-Ingold-Prelog (CIP) priority of the donor atom directly across from the priority 1 donor atom is 2.","Square Planar 2 Molecular Geometry | SP-4-2 | SQUARE PLANAR 2 | Square Planar 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641138","Square Planar 3 Molecular Geometry","C103213","Square planar molecular geometry where the Cahn-Ingold-Prelog (CIP) priority of the donor atom directly across from the priority 1 donor atom is 3.","Square Planar 3 Molecular Geometry | SP-4-3 | SQUARE PLANAR 3 | Square Planar 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437014","Lactobacillus plantarum 299v/Lactobacillus acidophilus/Bifidobacterium lactis Probiotic Supplement","C102759","A powder-based, probiotic supplement drink containing the non-pathogenic microorganisms Lactobacillus plantarum 299v, Lactobacillus acidophilus, and Bifidobacterium lactis, with potential immunomodulating and protective activities. Upon oral ingestion, the naturally-occurring bacterial components in this dietary supplement may improve digestion and help maintain adequate colonization of the gastrointestinal (GI) tract by modulating the composition of the normal microflora. During colonization in the GI tract, the bacteria may form a protective intestinal barrier which may prevent damage to the mucosal epithelia caused by toxins and attachment of potential pathogens, thereby protecting against infections. In addition, this agent may reduce the secretion of proinflammatory cytokines and may potentiate natural and acquired immunity.","Lactobacillus plantarum 299v/Lactobacillus acidophilus/Bifidobacterium lactis Probiotic Supplement | Goodbelly Probiotic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420412","SRPK1 Gene","C102760","This gene is involved in both protein phosphorylation and RNA splicing.","SRPK1 Gene | SRPK1 | SRSF Protein Kinase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539813","SRPK1 wt Allele","C102761","Human SRPK1 wild-type allele is located in the vicinity of 6p21.31 and is approximately 88 kb in length. This allele, which encodes SRSF protein kinase 1 protein, plays a role in phosphorylation of proteins involved in RNA splicing.","SRPK1 wt Allele | RP3-422H11.1 | SFRSK1 | SRSF Protein Kinase 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0255758","SRSF Protein Kinase 1, Human","C102762","SRSF protein kinase 1 (655 aa, ~74 kDa) is encoded by the human SRPK1 gene. This protein is involved in the phosphorylation of splicing factors.","SRSF Protein Kinase 1 | EC 2.7.11.1 | SFRS Protein Kinase 1 | SR-Protein-Specific Kinase 1 | Serine/Arginine-Rich Protein-Specific Kinase 1 | Serine/Arginine-Rich Splicing Factor Kinase 1 | Serine/Threonine-Protein Kinase SRPK1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540806","ZFPM2 wt Allele","C102765","Human ZFPM2 wild-type allele is located in the vicinity of 8q23 and is approximately 486 kb in length. This allele, which encodes zinc finger protein ZFPM2, is involved in transcriptional regulation during heart development. Mutation of the gene is associated with both diaphragmatic hernia 3 and tetralogy of Fallot. A complex chromosomal rearrangement fuses this gene and the RUNX1 gene and is associated with myelodysplasia.","ZFPM2 wt Allele | DIH3 | FOG2 | Modulator of Transcription Factor GATA4 Gene | ZNF89B | Zinc Finger Protein, Multitype 2 wt Allele | hFOG-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641093","Congenital Phrenic Nerve Injury","C103156","Damage to the phrenic nerve that is present at birth.","Congenital Phrenic Nerve Injury | Phrenic Nerve Injury, Congenital",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641095","Bioassay Measurement","C103158","The act of measuring or estimating a quantity resulting from a laboratory test or analysis of the biological activity of a substance performed by studying its effect on an organism or in a test tube under controlled conditions.","Bioassay Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641096","Subject Exclusion Reason","C103160","The explanation given as to why a subject was prevented from being allowed to participate in a study.","Subject Exclusion Reason | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641099","Study Treatment Causality","C103163","The principle that a relationship exists between a study treatment (cause) and the occurrence of an event (effect).","Study Treatment Causality | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642472","Subject Pool","C103164","The total group of study subjects that may participate in a study.","Subject Pool | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641100","Subject Visit Type","C103165","The kind of visit undertaken by the subject within a study, such as inpatient, outpatient, telephone, etc.","Subject Visit Type | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641102","Data Origin","C103167","The primary point where the data was generated or collected.","Data Origin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641103","FDA Toxicity Measure Type Terminology","C103168","Terminology codelist used to describe the kind of scale used to measure the toxicity of a substance.","FDA Toxicity Measure Type Terminology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641104","FDA Act Type Terminology","C103169","Terminology codelist used to describe the principal observations for human clinical and non-human non-clinical studies for the FDA CDA guide.","FDA Act Type Terminology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435898","Mesothelin-specific Chimeric Antigen Receptor-engineered Peripheral Blood Lymphocytes","C101773","A preparation of peripheral blood lymphocytes (PBLs) transduced with a retroviral vector encoding a T cell chimeric antigen receptor (CAR) specific for mesothelin with potential immunostimulatory and antineoplastic activities. After transduction, expansion in culture, and reintroduction into the patient, the mesothelin-specific chimeric antigen receptor-engineered PBLs bind to tumor cells expressing mesothelin. This may stimulate the secretion of cytokines and result in cell lysis of mesothelin-expressing cancer cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in many epithelial-derived cancers.","Mesothelin-specific Chimeric Antigen Receptor-engineered Peripheral Blood Lymphocytes | Anti-mesothelin CAR PBL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540586","IL33 wt Allele","C101775","Human IL33 wild-type allele is located in the vicinity of 9p24.1 and is approximately 42 kb in length. This allele, which encodes interleukin-33 protein, is involved in cytokine-mediated activation of inflammation.","IL33 wt Allele | C9orf26 | Chromosome 9 Open Reading Frame 26 Gene | DKFZp586H0523 | DVS27 | IL1F11 | Interleukin 33 wt Allele | NF-HEV | NFEHEV | RP11-575C20.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435900","Iobenguane I-124","C101776","A radioconjugate composed of the positron-emitting radioisotope iodine I 124 labeled to iobenguane, the synthetic aralkylguanidine analogue of the neurotransmitter norepinephrine (NE), with potential diagnostic imaging applications upon positron emitting tomography (PET) or computed tomography (CT). Upon administration, iobenguane I-124 is taken up and accumulates in the granules of adrenal medullary chromaffin cells and in the pre-synaptic granules of adrenergic neurons in a manner almost identical with that of NE. In turn, tumor cells can be imaged upon PET or CT.","Iobenguane I-124 | 124I-MIBG | 124I-metaiodobenzylguanidine | IOBENGUANE I-124 | Iodine I 124 Iobenguane | Iodine I 124 Metaiodobenzylguanidine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435901","Multi-epitope Folate Receptor Alpha Peptide Vaccine","C101777","A peptide vaccine containing five immunogenic peptide epitopes of the human folate receptor alpha (FR alpha or FOLR1), including FR30, FR56, FR76, FR113, and FR238, with potential immunomodulating and antineoplastic activity. Upon administration, the multi-epitope FR alpha peptide vaccine may induce a cytotoxic T-lymphocyte (CTL) response against FR alpha-overexpressing tumor cells. FR alpha is a high-affinity folate-binding protein and a member of the folate receptor family; this receptor is overexpressed in a majority of ovarian cancers and in about 50% of breast cancers.","Multi-epitope Folate Receptor Alpha Peptide Vaccine | FR Alpha Peptide Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640212","Lipegfilgrastim","C101778","A long acting glyco-pegylated recombinant form of human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Similar to G-CSF, lipegfilgrastim binds to and activates specific cell surface receptors, and stimulates neutrophil progenitor proliferation and differentiation. Therefore, this agent may prevent the duration and incidence of chemotherapy-induced neutropenia. Compared to filgrastim, lipegfilgrastim has a prolonged plasma half-life.","Lipegfilgrastim | LIPEGFILGRASTIM | Lonquest | Lonquex | Pegylated granulocyte colony stimulating factor (human short isoform) O(sup 3.137)-((3,5-dideoxy-5-((N-((omega-methoxypoly(oxyethylene))carbonyl)glycyl)amino)-D- glycero-alpha-D-galacto-non-2-ulopyranosylonic acid)-(2->6)-2-(acetylamino)-2-deoxy-alpha-D- galactopyranosyl)-des-(37-39)-(1-methionine)human granulocyte colony-stimulating factor (G-CSF, pluripoietin) | Poly(oxy-1,2-ethanediyl), alpha-hydro-omega-methoxy-, 133-ester with granulocyte colony-stimulating factor (methionyl,133-(O-(2-(acetylamino)-6-O-(N-((N- carboxyglycyl)amino)-alpha-neuraminosyl)-2-deoxy-alpha-D-galactopyranosyl)-L-threonine)) (human) | XM22",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1667752","Interleukin-33, Human","C101779","Interleukin-33 (270 aa, ~31 kDa) is encoded by the human IL33 gene. This protein plays a role in the positive regulation of inflammation.","Interleukin-33 | IL-1F11 | IL-33 | IL33 | Interleukin-1 Family Member 11 | NF-HEV | Nuclear Factor from High Endothelial Venules",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539611","ARHGEF2 wt Allele","C101781","Human ARHGEF2 wild-type allele is located within 1q21-q22 and is approximately 50 kb in length. This allele, which encodes Rho guanine nucleotide exchange factor 2 protein, plays a role in signaling, apoptosis, and cell proliferation.","ARHGEF2 wt Allele | DKFZp547L106 | DKFZp547P1516 | FLJ45440 | GEF | GEF-H1 | GEFH1 | KIAA0651 | LFP40 | P40 | Rho/Rac Guanine Nucleotide Exchange Factor (GEF) 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641139","Square Planar 4 Molecular Geometry","C103214","Square planar molecular geometry where the Cahn-Ingold-Prelog (CIP) priority of the donor atom directly across from the priority 1 donor atom is 4.","Square Planar 4 Molecular Geometry | SP-4-4 | SQUARE PLANAR 4 | Square Planar 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641140","Tetrahedral Molecular Geometry","C103215","A molecule in which the central atom is bound to four atoms that form the vertices of a tetrahedron.","Tetrahedral Molecular Geometry | T-4 | TETRAHEDRAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641141","Octahedral 12 Molecular Geometry","C103216","Octahedral molecular geometry where the Cahn-Ingold-Prelog (CIP) priority of the lowest priority donor atom directly across from (trans to) a priority 1 donor atom is also 1 and the priority of the donor atom across from (trans to) the highest priority atom in the plane perpendicular to this reference axis is 2.","Octahedral 12 Molecular Geometry | OC-6-12 | OCTAHEDRAL 12 | trans-octahedral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641142","Octahedral 22 Molecular Geometry","C103217","Octahedral molecular geometry where the Cahn-Ingold-Prelog (CIP) priority of the lowest priority donor atom directly across from (trans to) a priority 1 donor atom is 2 and the priority of the donor atom across from (trans to) the highest priority atom in the plane perpendicular to this reference axis is 2.","Octahedral 22 Molecular Geometry | OC-6-22 | OCTAHEDRAL 22 | mer-octahedral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641143","Octahedral 21 Molecular Geometry","C103218","Octahedral molecular geometry where the Cahn-Ingold-Prelog (CIP) priority of the lowest priority donor atom directly across from (trans to) a priority 1 donor atom is 2 and the priority of the donor atom across from (trans to) the highest priority atom in the plane perpendicular to this reference axis is 1.","Octahedral 21 Molecular Geometry | OC-6-21 | OCTAHEDRAL 21 | cis-octahedral | fac-octahedral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641144","Cahn-Ingold-Prelog Priority System","C103219","Rules created by Robert Sidney Cahn, Christopher Kelk Ingold and Vladimir Prelog to name stereoisomers in organic chemistry.","Cahn-Ingold-Prelog Priority System | CAHN-INGOLD-PRELOG PRIORITY SYSTEM | CIP System | Cahn-Ingold-Prelog Priority Rules",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539736","Axial S","C103221","Chirality axis based stereochemistry where, using the Cahn-Ingold-Prelog (CIP) priority rules, the priorities (from highest to lowest) of the substituent atoms exist in a counterclockwise direction.","Axial S | AXIAL S | LAMBDA | M | Sa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0953071","Bamipine Dihydrochloride","C103224","No value exists.","Bamipine Dihydrochloride | BAMIPINE DIHYDROCHLORIDE | Piperidine, 4-(N-benzyl-N-phenylamino)-1-methyl-, Dihydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524294","Ischemic Necrosis","C103225","Loss of vascularization and tissue death caused by the disruption in the arterial access. Common causes include trauma due to accidents, insect or reptile bites, severe cold exposure or pathological conditions such as infarctions or blood dyscrasias.","Ischemic Necrosis | Geographic (ischemic)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0345017","Pulmonary Trunk Hypoplasia","C103226","Underdeveloped pulmonary arteries.","Pulmonary Trunk Hypoplasia | ",,,,,,,,,,,,,,,"4112095","Pulmonary trunk hypoplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641282","CDISC Questionnaire GAD-7 Test Code Terminology","C103467","Test codes of questionnaire questions associated with the generalized anxiety disorder 7 item questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire GAD-7 Test Code Terminology | GAD01TC | Generalized Anxiety Disorder - 7 Questionnaire Test Code | QS-GAD-7 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641283","CDISC Questionnaire HADS Test Name Terminology","C103468","Test names of questionnaire questions associated with the hospital anxiety and depression scale questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire HADS Test Name Terminology | HADS01TN | Hospital Anxiety and Depression Scale Questionnaire Test Name | QS-HADS TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537374","Zinc Finger Protein ZFPM2","C102766","Zinc finger protein ZFPM2 (1151 aa, ~128 kDa) is encoded by the human ZFPM2 gene. This protein plays a role in DNA binding, transcriptional regulation and cardiac development.","Zinc Finger Protein ZFPM2 | FOG-2 | Friend of GATA 2 | Friend of GATA Protein 2 | Zinc Finger Protein 89B | Zinc Finger Protein Multitype 2 | hFOG-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413220","CD37 Gene","C102767","This gene is involved in the regulation of immunoglobulin production.","CD37 Gene | CD37 | CD37 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540807","CD37 wt Allele","C102768","Human CD37 wild-type allele is located in the vicinity of 19q13.3 and is approximately 5 kb in length. This allele, which encodes leukocyte antigen CD37 protein, plays a role in the modulation of immunoglobulin production.","CD37 wt Allele | CD37 Antigen Gene | CD37 Molecule wt Allele | GP52-40 | TSPAN26",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054955","Leukocyte Antigen CD37, Human","C102769","Leukocyte antigen CD37 (281 aa, ~32 kDa) is encoded by the human CD37 gene. This protein is involved in the regulation of humoral immunity.","Leukocyte Antigen CD37 | Antigen CD37 | CD37 | CD37 Antigen | Cell Differentiation Antigen 37 | Leukocyte Surface Antigen CD37 | Tetraspanin-26 | Tspan-26",,,,,,,,,,,,,,,"4307805","Lymphocyte antigen CD37",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1423067","SIRT7 Gene","C102770","This gene plays a role in post-translational protein modification.","SIRT7 Gene | SIRT7 | Sirtuin 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539784","SIRT7 wt Allele","C102771","Human SIRT7 wild-type allele is located in the vicinity of 17q25 and is approximately 6 kb in length. This allele, which encodes NAD-dependent protein deacetylase sirtuin-7 protein, is involved in the modulation of protein acetylation.","SIRT7 wt Allele | SIR2L7 | Sirtuin (Silent Mating Type Information Regulation 2 Homolog) 7 (S. cerevisiae) Gene | Sirtuin 7 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422622","HIPK2 Gene","C102956","This gene plays a role in the phosphorylation of transcription factors.","HIPK2 Gene | HIPK2 | Homeodomain Interacting Protein Kinase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541409","HIPK2 wt Allele","C102957","Human HIPK2 wild-type allele is located within 7q32-q34 and is approximately 231 kb in length. This allele, which encodes homeodomain-interacting protein kinase 2 protein, is involved in serine/threonine phosphorylation, cell cycle regulation and apoptosis.","HIPK2 wt Allele | Homeodomain Interacting Protein Kinase 2 wt Allele | PRO0593",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447702","Homeodomain-Interacting Protein Kinase 2, Human","C102958","Homeodomain-interacting protein kinase 2 (1198 aa, ~131 kDa) is encoded by the human HIPK2 gene. This protein plays a role in protein phosphorylation, transcriptional regulation and cell cycle progression.","Homeodomain-Interacting Protein Kinase 2 | EC 2.7.11.1 | Homeodomain Interacting Protein Kinase 2 | hHIPk2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823843","WRAP53 Gene","C102959","This gene is involved in telomerase activity.","WRAP53 Gene | WD Repeat Containing Antisense to TP53 Gene | WRAP53",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538903","WRAP53 wt Allele","C102960","Human WRAP53 wild-type allele is located in the vicinity of 17p13.1 and is approximately 17 kb in length. This allele, which encodes telomerase Cajal body protein 1, plays a role in telomere maintenance. Mutation of the gene is associated with dyskeratosis congenita autosomal recessive type 3.","WRAP53 wt Allele | DKCB3 | FLJ10385 | TCAB1 | WD Repeat Containing Antisense to TP53 wt Allele | WD Repeat Containing, Antisense to TP53 Gene | WD Repeat Domain 79 Gene | WD-Encoding RNA Antisense to P53 Gene | WDR79",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537359","Telomerase Cajal Body Protein 1, Human","C102961","Telomerase Cajal body protein 1 (548 aa, ~59 kDa) is encoded by the human WRAP53 gene. This protein is involved in the positive regulation of telomere synthesis.","Telomerase Cajal Body Protein 1 | WD Repeat-Containing Protein 79 | WD Repeat-Containing Protein WRAP53 | WD40 Protein Wrap53 | WD40 Repeat-Containing Protein Encoding RNA Antisense to p53 | WRAP53",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054436","Caffeine Citrate","C1033","Commercial citrate of caffeine, though not a definite salt.  It is the alkaloid caffeine, with a portion of adherent citric acid, as indicated by its pharmacopoeial name (citrated caffeine). Its general action and uses are the same as those given under caffeine. Caffeine citrate is used chiefly as a remedy for the idiopathic headache (migraine). This salt is very soluble in water, and is assimilated much more readily than pure caffeine when taken into the stomach. (NCI04)","Caffeine Citrate | CAFFEINE CITRATE | Caffeina Citrata | Citrated Caffeine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641248","FLT-Positron Emission Tomography","C103401","An imaging technique that utilizes positron emission tomography to produce a three-dimensional image of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced into the body on the biologically active molecule fluoro-L-thymidine (FLT). FLT when imaged will give tissue metabolic activity, in terms of cell proliferation.","FLT-Positron Emission Tomography | FLT-PET | Fluoro-L-Thymidine-Positron Emission Tomography",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539612","Rho Guanine Nucleotide Exchange Factor 2","C101782","Rho guanine nucleotide exchange factor 2 (986 aa, ~112 kDa) is encoded by the human ARHGEF2 gene. This protein is involved in the regulation of both guanine nucleotide exchange and signal transduction.","Rho Guanine Nucleotide Exchange Factor 2 | ARHGEF2 | GEF-H1 | Guanine Nucleotide Exchange Factor H1 | Microtubule-Regulated Rho-GEF | Proliferating Cell Nucleolar Antigen p40",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542906","ECT2 wt Allele","C101784","Human ECT2 wild-type allele is located within 3q26.1-q26.2 and is approximately 71 kb in length. This allele, which encodes protein ECT2, is involved in the modulation of apoptosis, cytokinesis and signal transduction.","ECT2 wt Allele | ARHGEF31 | Epithelial Cell Transforming Sequence 2 Oncogene wt Allele | FLJ10461 | MGC138291",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640214","Protein ECT2","C101785","Protein ECT2 (914 aa, ~104 kDa) is encoded by the human ECT2 gene. This protein plays a role in the regulation of GTPase-dependent signaling.","Protein ECT2 | Epithelial Cell-Transforming Sequence 2 Oncogene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640215","Multi-AGC Kinase Inhibitor AT13148","C101786","An orally available, small molecule inhibitor of AGC group kinases, with potential antineoplastic activity. AT13148 inhibits, in an ATP-competitive manner, the enzymatic activity of two AGC kinases, protein kinase B (PKB or AKT) and p70S6K which play key roles in the PI3K/PKB/mTOR signaling pathway. Blockade of this pathway leads to an inhibition of cell growth and the induction of apoptosis in susceptible tumor cells. PI3K/PKB/mTOR pathway is dysregulated in greater than 50% of tumors, and is often correlated with resistance and increased tumor survival. AGC group kinases are serine/threonine kinases that are regulated by secondary messengers such as cyclic AMP and lipids.","Multi-AGC Kinase Inhibitor AT13148 | AT-13148 | AT13148",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435906","TIL 1383I T Cell Receptor-Transduced Autologous T Cells","C101787","Autologous peripheral blood lymphocytes-derived T cells transduced with a retroviral encoding TIL 1383I, a T cell receptor (TCR) specific for melanoma antigen tyrosinase, with potential immunostimulating and antineoplastic activity. After transduction, expansion in culture, and reintroduction into the patient, TIL 1383I TCR-transduced autologous T cells bind to tumor cells expressing tyrosinase, which may induce cytokine expression, activation and proliferation of T-cells, and a specific cytotoxic T-lymphocyte (CTL) response against tyrosinase-expressing tumor cells. TIL 1383I TCR originated from a melanoma patient's CD4+ tumor-infiltrating lymphocytes and is reactive against a class I MHC (HLA-A2)-restricted epitope (368-376) of tyrosinase.","TIL 1383I T Cell Receptor-Transduced Autologous T Cells | TIL 1383I TCR Transduced Autologous T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435907","Adenoviral Transduced hIL-12-expressing Autologous Dendritic Cells INXN-3001 Plus Activator Ligand INXN-1001","C101789","Autologous dendritic cells tranduced with a replication incompetent adenovirus encoding human pro-inflammatory cytokine interleukin-12 (IL-12) (INXN-3001) in combination with the proprietary orally bioavailable, small molecule activator ligand INXN-1001, with potential immunomodulating and antineoplastic activities. Production of IL-12 is controlled by an inducible DNA element that allows transcription initiation only in the presence of the ligand inducer INXN-1001. Upon intratumoral injection of INXN-3001 and subsequent oral administration of activator ligand, INXN-1001 is able to induce expression of IL-12 in INXN-3001. IL-12 expressed by the adenovirus may activate the immune system by promoting the activation of natural killer cells, inducing the secretion of interferon-gamma and inducing a cytotoxic T lymphocyte response against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation. As INXN-1001 regulates both the timing and the levels of IL-12 expression, IL-12 toxicity can be reduced.","Adenoviral Transduced hIL-12-expressing Autologous Dendritic Cells INXN-3001 Plus Activator Ligand INXN-1001 | DC-RTS-IL-12 | INXN-3001/1001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641284","CDISC Questionnaire HADS Test Code Terminology","C103469","Test codes of questionnaire questions associated with the hospital anxiety and depression scale questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire HADS Test Code Terminology | HADS01TC | Hospital Anxiety and Depression Scale Questionnaire Test Code | QS-HADS TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641285","CDISC Questionnaire IIEF Test Name Terminology","C103470","Test names of questionnaire questions associated with the international index of erectile function questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire IIEF Test Name Terminology | IIEF01TN | International Index of Erectile Function Questionnaire Test Name | QS-IIEF TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641286","CDISC Questionnaire IIEF Test Code Terminology","C103471","Test codes of questionnaire questions associated with the international index of erectile function questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire IIEF Test Code Terminology | IIEF01TC | International Index of Erectile Function Questionnaire Test Code | QS-IIEF TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641288","CDISC Questionnaire NPS Test Code Terminology","C103473","Test codes of questionnaire questions associated with the neuropathic pain scale questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire NPS Test Code Terminology | NPS01TC | Neuropathic Pain Scale Questionnaire Test Code | QS-NPS TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641289","CDISC Questionnaire OAB-q Test Name Terminology","C103474","Test names of questionnaire questions associated with the overactive bladder questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire OAB-q Test Name Terminology | OABQ01TN | QS-OAB-q TEST | The Overactive Bladder Questionnaire Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641290","CDISC Questionnaire OAB-q Test Code Terminology","C103475","Test codes of questionnaire questions associated with the overactive bladder questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire OAB-q Test Code Terminology | OABQ01TC | QS-OAB-q TESTCD | The Overactive Bladder Questionnaire Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641291","CDISC Questionnaire OAB-q Short Form Test Name Terminology","C103476","Test names of questionnaire questions associated with the overactive bladder questionnaire short form for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire OAB-q Short Form Test Name Terminology | OABQ02TN | QS-OAB-q Short Form TEST | The Overactive Bladder Questionnaire Short Form Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641292","CDISC Questionnaire OAB-q Short Form Test Code Terminology","C103477","Test codes of questionnaire questions associated with the overactive bladder questionnaire short form for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire OAB-q Short Form Test Code Terminology | OABQ02TC | QS-OAB-q Short Form TESTCD | The Overactive Bladder Questionnaire Short Form Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641293","CDISC Questionnaire ODI v2.1a Test Name Terminology","C103478","Test names of questionnaire questions associated with the Oswestry disability index version 2.1a questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire ODI v2.1a Test Name Terminology | ODI01TN | QS-ODI v2.1a TEST | The Oswestry Disability Index Version 2.1a Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641294","CDISC Questionnaire ODI v2.1a Test Code Terminology","C103479","Test codes of questionnaire questions associated with the Oswestry disability index version 2.1a questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire ODI v2.1a Test Code Terminology | ODI01TC | QS-ODI v2.1a TESTCD | The Oswestry Disability Index Version 2.1a Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421571","ZFP36 Gene","C102962","This gene plays a role in RNA turnover.","ZFP36 Gene | ZFP36 | Zinc Finger Protein 36, C3H Type, Homolog (Mouse) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539814","ZFP36 wt Allele","C102963","Human ZFP36 wild-type allele is located in the vicinity of 19q13.1 and is approximately 3 kb in length. This allele, which encodes tristetraprolin protein, is involved in the regulation of RNA degradation.","ZFP36 wt Allele | G0S24 | GOS24 | NUP475 | RNF162A | TIS11 | TTP | Zinc Finger Protein 36, C3H Type, Homolog (Mouse) wt Allele | zfp-36",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1506603","ZFP36 protein, human","C102964","Tristetraprolin (326 aa, ~34 kDa) is encoded by the human ZFP36 gene. This protein plays a role in both RNA binding and metabolism.","Tristetraprolin | G0/G1 Switch Regulatory Protein 24 | Growth Factor-Inducible Nuclear Protein NUP475 | Protein TIS11A | TIS11 | TTP | Zfp-36 | Zinc Finger Protein 36 Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541410","WNT16 wt Allele","C102966","Human WNT16 wild-type allele is located in the vicinity of 7q31 and is approximately 16 kb in length. This allele, which encodes protein Wnt-16, plays a role in both receptor binding and ligand-mediated signaling.","WNT16 wt Allele | Wingless-Type MMTV Integration Site Family, Member 16 wt Allele | Wingless-Type MMTV Integration Site Family, Member 16b Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538906","Protein Wnt-16","C102967","Protein Wnt-16 (365 aa, ~41 kDa) is encoded by the human WNT16 gene. This protein is involved in ligand-dependent signaling.","Protein Wnt-16 | Wingless-Type MMTV Integration Site Family, Member 16 | Wingless-Type MMTV Integration Site Family, Member 16b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539568","ID3 wt Allele","C102969","Human ID3 wild-type allele is located within 1p36.13-p36.12 and is approximately 2 kb in length. This allele, which encodes DNA-binding protein inhibitor ID-3 protein, is involved in the negative regulation of gene expression.","ID3 wt Allele | 1R21 | BHLHB25 | HEIR-1 | Inhibitor of DNA Binding 3, Dominant Negative Helix-Loop-Helix Protein wt Allele | bHLHb25",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538838","NCI CTEP SDC Rhabdomyosarcoma Sub-Category Terminology","C103118","Rhabdomyosarcoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Rhabdomyosarcoma Sub-Category Terminology | NCI CTEP Simple Disease Classification Rhabdomyosarcoma Sub-Category Terminology | Rhabdomyosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1453749","SH2B Adapter Protein 3, Human","C102804","SH2B adapter protein 3 (575 aa, ~63 kDa) is encoded by the human SH2B3 gene. This protein plays a role in T-cell receptor signaling.","SH2B Adapter Protein 3 | Lymphocyte Adapter Protein | Lymphocyte Adaptor Protein | Lymphocyte-Specific Adapter Protein Lnk | SH2B3 | Signal Transduction Protein Lnk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825683","KANSL1 Gene","C102805","This gene is involved in histone acetylation.","KANSL1 Gene | KANSL1 | KAT8 Regulatory NSL Complex Subunit 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538716","KANSL1 wt Allele","C102806","Human KANSL1 wild-type allele is located in the vicinity of 17q21.31 and is approximately 195 kb in length. This allele, which encodes KAT8 regulatory NSL complex subunit 1 protein, plays a role in the modulation of histone acetylation. Mutation of the gene is associated with 17q21.31 microdeletion syndrome.","KANSL1 wt Allele | CENP-36 | KAT8 Regulatory NSL Complex Subunit 1 wt Allele | KIAA1267 | MSL1V1 | MSL1v1 | NSL1 | hMSL1v1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538715","KAT8 Regulatory NSL Complex Subunit 1, Human","C102807","KAT8 regulatory NSL complex subunit 1 (1105 aa, ~121 kDa) is encoded by the human KANSL1 gene. This protein is involved in the regulation of histone acetylation.","KAT8 Regulatory NSL Complex Subunit 1 | Centromere Protein 36 | KANSL1 | MLL1/MLL Complex Subunit KANSL1 | MSL1 Homolog 1 | NSL Complex Protein NSL1 | Non-Specific Lethal 1 Homolog | hMSL1v1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418489","PFKFB3 Gene","C102808","This gene plays a role in carbohydrate metabolism.","PFKFB3 Gene | 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 Gene | PFKFB3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540810","PFKFB3 wt Allele","C102809","Human PFKFB3 wild-type allele is located in the vicinity of 10p15.1 and is approximately 91 kb in length. This allele, which encodes 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3, is involved in both the synthesis and degradation of fructose 2,6-bisphosphate.","PFKFB3 wt Allele | 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 wt Allele | IPFK2 | PFK2 | RP11-298K24.3 | iPFK-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280593","doxorubicin/fluorouracil/semustine protocol","C10280","A regimen consisting of doxorubicin, fluorouracil, and semustine that may be used in the treatment of certain hepatic cancers.","Doxorubicin/Fluorouracil/Semustine Regimen | DOX/5-FU/MeCCNU | Doxorubicin-Fluorouracil-Semustine | Doxorubicin/Fluorouracil/Semustine | MEFA | MeCCNU/Fluorouracil/Adriamycin | MeFA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539535","6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3","C102810","6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (520 aa, ~60 kDa) is encoded by the human PFKFB3 gene. This protein plays a role in the metabolism of fructose.","6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 | 6PF-2-K/Fru-2,6-P2ase 3 | 6PF-2-K/Fru-2,6-P2ase Brain/Placenta-Type Isozyme | PFK/FBPase 3 | PFKFB3 | Renal Carcinoma Antigen NY-REN-56 | iPFK-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419069","PTGFRN Gene","C102811","This gene is involved in the inhibition of prostaglandin binding.","PTGFRN Gene | PTGFRN | Prostaglandin F2 Receptor Negative Regulator Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540631","PTGFRN wt Allele","C102812","Human PTGFRN wild-type allele is located in the vicinity of 1p13.1 and is approximately 80 kb in length. This allele, which encodes prostaglandin F2 receptor negative regulator protein, plays a role in inhibition of ligand-receptor interactions.","PTGFRN wt Allele | CD315 | CD9P-1 | CD9P1 | EWI-F | EWIF | FPRP | KIAA1436 | Prostaglandin F2 Receptor Negative Regulator wt Allele | SMAP-6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539828","Prostaglandin F2 Receptor Negative Regulator","C102813","Prostaglandin F2 receptor negative regulator (879 aa, ~99 kDa) is encoded by the human PTGFRN gene. This protein is involved in the inhibition of both prostaglandin F2-alpha binding to its receptor and any downstream signaling pathways.","Prostaglandin F2 Receptor Negative Regulator | Antigen CD315 | CD315 | CD315 Antigen | CD9 Partner 1 | CD9P-1 | EWI Motif-Containing Protein F | EWI-F | Glu-Trp-Ile EWI Motif-Containing Protein F | Prostaglandin F2-Alpha Receptor Regulatory Protein | Prostaglandin F2-Alpha Receptor-Associated Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539747","ZNF678 wt Allele","C102815","Human ZNF678 wild-type allele is located in the vicinity of 1q42.13 and is approximately 99 kb in length. This allele, which encodes zinc finger protein 678, may be involved in transcriptional regulation.","ZNF678 wt Allele | MGC42493 | Zinc Finger Protein 678 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541294","Zinc Finger Protein 678","C102816","Zinc finger protein 678 (525 aa, ~61 kDa) is encoded by the human ZNF678 gene. This protein may play a role in transcriptional regulation.","Zinc Finger Protein 678 | Hypothetical Protein MGC42493",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435910","linoleyl carbonate-paclitaxel","C101792","A formulation of the 6-omega fatty acid derivative 2'-linoleyl carbonate (LOC) conjugated to paclitaxel, a taxane compound extracted from the Pacific yew tree Taxus brevifolia, with potential antineoplastic activity. Paclitaxel binds to and stabilizes tubulin, thereby interfering with the dynamics of microtubule assembly/disassembly and resulting in the inhibition of cell division. LOC enhances the uptake of paclitaxel by tumor cells, thereby concentrating this agent in tumor cells compared to normal cells, and may decrease its toxicity profile; fatty acids serve as energy sources and biochemical precursors for the fast growing tumor cells.","Linoleyl Carbonate-Paclitaxel | 2-Linoleyl Carbonate-paclitaxel | LOC-paclitaxel | Linoleyl Carbonate-paclitaxel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435911","Topical Calcitriol","C101793","A topical formulation containing the hormonally active form of vitamin D3, with potential protective activity against chemotherapy-induced alopecia (CIA).  Upon topical application to the scalp, calcitriol may prevent keratinocyte apoptosis in anagen hair follicles. Therefore, this agent may protect against the damaging effects of certain chemotherapeutics to the hair follicles.","Topical Calcitriol | Topical Compound 31543",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435912","Aerosolized Aldesleukin","C101794","An aerosol formulation of aldesleukin, a recombinant form of interleukin-2 (IL-2), with potential immunostimulating activity. Upon IL-2 inhalation, this cytokine activates lymphokine-activated killer cells and natural killer cells, and induces expression of cytotoxic cytokines, such as interferon-gamma and transforming growth factor-beta. This may eventually halt tumor cell growth. Localized administration of IL-2 may decrease toxicity and increase efficacy.","Aerosolized Aldesleukin | Aerosolized Recombinant IL-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435913","TORC1/2 Kinase Inhibitor DS-3078a","C101795","An orally bioavailable inhibitor of raptor-mTOR protein complex (TORC1) and rictor-mTOR protein complex (TORC2) with potential antineoplastic activity. TORC1/2 inhibitor DS-3078a binds to and inhibits both TORC1 and TORC2, which may result in tumor cell apoptosis and a decrease in tumor cell proliferation. TORC1 and 2 are upregulated in some tumors and play an important role in the PI3K/Akt/mTOR signaling pathway, which is frequently dysregulated in human cancers.","TORC1/2 Kinase Inhibitor DS-3078a | DS-3078a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL435914","Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes","C101796","A population of allogeneic cytotoxic T-lymphocytes (CTLs) specifically reactive to human adenovirus (Ad) with potential immunomodulating and anti-adenoviral activities. Upon immunoprophylactic adoptive cell therapy, infusion of allogeneic Ad-specific CTLs may help reconstitute Ad-specific CTL responses in patients at risk of developing Ad infections after allogeneic stem cell transplant or in Ad-infected immunocompromised hosts. These allogeneic Ad-specific CTLs are prepared by multiple rounds of stimulation with donor peripheral blood mononuclear cells and lymphoblastoid cell lines that have been transduced with Ad5f35, a recombinant adenoviral vector carrying no transgene.","Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes | Allogeneic Adenovirus-specific CTLs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437135","benegrastim","C102854","A recombinant dimeric fusion peptide of the human granulocyte colony-stimulating factor (G-CSF; filgrastim), with immunomodulating and hematopoietic activities. Efbemalenograstim alfa binds to the cell surface G-CSF receptors (G-CSFRs) inducing receptor dimerization and activation of signaling cascades such as the Jak-STAT and mitogen-activated protein kinase pathways. This stimulates neutrophil progenitor proliferation and differentiation. Compared to other preparations of monomer recombinant G-CSF, dimeric filgrastim may allow for stronger activation of G-CSFRs and a faster myeloid precursor response thus enhancing neutrophil recovery upon myelosuppressive therapy.","Efbemalenograstim alfa | EFBEMALENOGRASTIM ALFA | F-627 | F627 | Recombinant Dimeric G-CSF Fusion Protein F627 | Rh G-CSF Fc Fusion Protein F-627",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3252354","Gemcitabine Prodrug LY2334737","C102856","An orally available valproic acid prodrug of gemcitabine, a broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine prodrug LY2334737 is hydrolyzed by carboxylesterase 2 (CES2) and releases gemcitabine systemically over a period of time consistent with formation rate-limited kinetics. In turn, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate and triphosphate (dFdCDP and dFdCTP) by deoxycytidine kinase. dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA replication; dFdCTP is incorporated into DNA, resulting in premature termination of DNA replication and eventually the induction of apoptosis. Compared to gemcitabine, this prodrug is able to avoid hydrolysis in enterocytes and the portal circulation thus avoiding first pass metabolism and increasing systemic gemcitabine availability. In addition, the slow release of gemcitabine may enhance efficacy while lowering toxicity. CES2, a serine ester hydrolase, is expressed in certain tumors which may allow for increased conversion of gemcitabine at the tumor site thus increases cytotoxicity.","Gemcitabine Prodrug LY2334737 | LY-2334737 | LY2334737",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640971","Low Interval Integer Data Type","C102858","A data type comprised of a set of consecutive low valued integers of an ordered base data type.","Low Interval Integer Data Type | IVL.LOW<INT>",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640972","Low Interval Point in Time Date and Time Data Type","C102859","A data type comprised of a set of consecutive low values, comprised of a date and time value that corresponds with a specific point in the time continuum, of an ordered base data type.","Low Interval Point in Time Date and Time Data Type | IVL.LOW<TS.DATETIME>",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640973","Interval Quantity Data Type","C102860","A data type comprised of a set of consecutive values of an ordered base, which is an abstract generalization for all value data types that have an order relationship.","Interval Quantity Data Type | IVL<QTY>",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641073","NCI CTEP SDC Hematopoietic Neoplasm/Lymphoma Category Terminology","C103120","Hematopoietic Neoplasm/Lymphoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Hematopoietic Neoplasm/Lymphoma Category Terminology | Hematopoietic Neoplasm/Lymphoma | NCI CTEP Simplified Disease Classification Hematopoietic Neoplasm/Lymphoma Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641074","NCI CTEP SDC Hematopoietic Neoplasm/Leukemia Category Terminology","C103121","Hematopoietic Neoplasm/Leukemia is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Hematopoietic Neoplasm/Leukemia Category Terminology | Hematopoietic Neoplasm/Leukemia | NCI CTEP Simple Disease Classification Hematopoietic Neoplasm/Leukemia Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641075","NCI CTEP SDC Hematopoietic Neoplasm/Myeloma Category Terminology","C103122","Hematopoietic Neoplasm/Myeloma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Hematopoietic Neoplasm/Myeloma Category Terminology | Hematopoietic Neoplasm/Myeloma | NCI CTEP Simple Disease Classification Hematopoietic Neoplasm/Myeloma Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542401","NCI CTEP SDC Acute Lymphoblastic Leukemia Sub-Category Terminology","C103123","Acute Lymphoblastic Leukemia is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Acute Lymphoblastic Leukemia Sub-Category Terminology | Acute Lymphoblastic Leukemia | NCI CTEP Simple Disease Classification Acute Lymphoblastic Leukemia Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539001","NCI CTEP SDC Chronic Lymphoid Leukemia Sub-Category Terminology","C103125","Chronic Lymphoid Leukemia is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Chronic Lymphoid Leukemia Sub-Category Terminology | Chronic Lymphoid Leukemia | NCI CTEP Simple Disease Classification Chronic Lymphoid Leukemia Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539559","NCI CTEP SDC Chronic Myeloproliferative Disease Sub-Category Terminology","C103126","Chronic Myeloproliferative Disease is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Chronic Myeloproliferative Disease Sub-Category Terminology | Chronic Myeloproliferative Disease | NCI CTEP Simple Disease Classification Chronic Myeloproliferative Disease Sub-Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424149","TRIM36 Gene","C102817","This gene is involved in protein modification.","TRIM36 Gene | TRIM36 | Tripartite Motif Containing 36 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641024","NCI CTEP SDC CNS Neoplasm (Primary Tumor) Category Terminology","C103010","CNS Neoplasm (Primary Tumor) is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC CNS Neoplasm (Primary Tumor) Category Terminology | CNS Neoplasm (Primary Tumor) | NCI CTEP Simple Disease Classification CNS Neoplasm (Primary Tumor) Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641025","NCI CTEP SDC AIDS-related Malignancy and Condition Category Terminology","C103011","AIDS-related Malignancy and Condition is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC AIDS-related Malignancy and Condition Category Terminology | AIDS-related Malignancy and Condition | NCI CTEP Simple Disease Classification AIDS-related Malignancy and Condition Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541234","NCI CTEP SDC Bone Neoplasm Category Terminology","C103012","Bone Neoplasm is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Bone Neoplasm Category Terminology | Bone Neoplasm | NCI CTEP Simple Disease Classification Bone Neoplasm Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641026","NCI CTEP SDC CNS-excluded Nervous System Neoplasm and Disorder Category Terminology","C103014","CNS-excluded Nervous System Neoplasm and Disorder is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC CNS-excluded Nervous System Neoplasm and Disorder Category Terminology | CNS-excluded Nervous System Neoplasm and Disorder | NCI CTEP Simple Disease Classification CNS-excluded Nervous System Neoplasm and Disorder Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539651","NCI CTEP SDC Endocrine Neoplasm Category Terminology","C103015","Endocrine Neoplasm is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Endocrine Neoplasm Category Terminology | Endocrine Neoplasm | NCI CTEP Simple Disease Classification Endocrine Neoplasm Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541891","NCI CTEP SDC Eye Neoplasm Category Terminology","C103016","Eye Neoplasm is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Eye Neoplasm Category Terminology | Eye Neoplasm | NCI CTEP Simple Disease Classification Eye Neoplasm Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541856","BRCA1-A Complex Subunit Abraxas, Human","C101799","BRCA1-A complex subunit Abraxas 1 (409 aa, ~47 kDa) is encoded by the human ABRAXAS1 gene. This protein is involved in both DNA repair and cell cycle regulation.","BRCA1-A Complex Subunit Abraxas 1 | ABRAXAS | ABRAXAS1 | Abraxas Protein | BRCA1-A Complex Subunit Abraxas | Coiled-Coil Domain-Containing Protein 98 | Protein FAM175A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826999","Global Unique Device Identification Database Submission","C101716","The submission of a global unique device identification record.","Global Unique Device Identification Database Submission | GUDID | GUDID Submission",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415700","HPN Gene","C101718","This gene is involved in protein metabolism.","HPN Gene | HPN | Hepsin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538884","HPN wt Allele","C101719","Human HPN wild-type allele is located within 19q11-q13.2 and is approximately 26 kb in length. This allele, which encodes serine protease hepsin protein, plays a role in proteolysis.","HPN wt Allele | Hepsin wt Allele | TMPRSS1 | Transmembrane Protease, Serine 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL933375","HPN protein, human","C101720","Serine protease hepsin (417 aa, ~45 kDa) is encoded by the human HPN gene. This protein is involved in proteolysis.","Serine Protease Hepsin | EC 3.4.21.106 | HPN | TMPRSS1 | Transmembrane Protease Serine 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538900","EED wt Allele","C101723","Human EED wild-type allele is located within 11q14.2-q22.3 and is approximately 34 kb in length. This allele, which encodes polycomb protein EED, is involved in both histone methylation and transcriptional regulation.","EED wt Allele | COGIS | EED, Mouse, Homolog of Gene | Embryonic Ectoderm Development Protein, Mouse, Homolog of Gene | Embryonic Ectoderm Development wt Allele | HEED | WAIT-1 | WAIT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537344","Polycomb Protein EED","C101725","Polycomb protein EED (441 aa, ~50 kDa) is encoded by the human EED gene. This protein plays a role in transcriptional repression mediated by histone methylation.","Polycomb Protein EED | EED | Embryonic Ectoderm Development Protein | WAIT-1 | WD Protein Associating With Integrin Cytoplasmic Tails 1 | hEED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641043","NCI CTEP SDC Oligodendroglial Tumors Sub-Category Terminology","C103050","Oligodendroglial Tumors is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Oligodendroglial Tumors Sub-Category Terminology | NCI CTEP Simple Disease Classification Oligodendroglial Tumors Sub-Category Terminology | Oligodendroglial Tumors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540583","NCI CTEP SDC Neuroblastoma Sub-Category Terminology","C103053","Neuroblastoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Neuroblastoma Sub-Category Terminology | NCI CTEP Simple Disease Classification Neuroblastoma Sub-Category Terminology | Neuroblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540584","NCI CTEP SDC Neurofibromatosis Sub-Category Terminology","C103054","Neurofibromatosis is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Neurofibromatosis Sub-Category Terminology | NCI CTEP Simple Disease Classification Neurofibromatosis Sub-Category Terminology | Neurofibromatosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539591","NAD-Dependent Protein Deacetylase Sirtuin-7","C102772","NAD-dependent protein deacetylase sirtuin-7 (400 aa, ~45 kDa) is encoded by the human SIRT7 gene. This protein plays a role in protein deacetylation.","NAD-Dependent Protein Deacetylase Sirtuin-7 | EC 3.5.1.- | Regulatory Protein SIR2 Homolog 7 | SIR2-Like Protein 7 | SIRT7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412379","AMD1 Gene","C102773","This gene is involved in polyamine biosynthesis.","AMD1 Gene | AMD1 | Adenosylmethionine Decarboxylase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539530","AMD1 wt Allele","C102774","Human AMD1 wild-type allele is located in the vicinity of 6q21 and is approximately 21 kb in length. This allele, which encodes S-adenosylmethionine decarboxylase proenzyme protein, plays a role in the synthesis of both spermine and spermidine.","AMD1 wt Allele | ADOMETDC | AMD | Adenosylmethionine Decarboxylase 1 wt Allele | RP11-397G5.3 | SAMDC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537452","NCI CTEP SDC Gastrointestinal Neoplasm Category Terminology","C103017","Gastrointestinal Neoplasm is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Gastrointestinal Neoplasm Category Terminology | Gastrointestinal Neoplasm | NCI CTEP Simple Disease Classification Gastrointestinal Neoplasm Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539614","NCI CTEP SDC Germ Cell Neoplasm Category Terminology","C103018","Germ Cell Neoplasm is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.","NCI CTEP SDC Germ Cell Neoplasm Category Terminology | Germ Cell Neoplasm | NCI CTEP Simple Disease Classification Germ Cell Neoplasm Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641105","Postnatal Drug Withdrawal","C103170","Withdrawal signs and symptoms that present during the postnatal period and are caused by drug use by the pregnant mother.","Postnatal Drug Withdrawal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641106","Congenital Bleeding Disorder","C103172","A bleeding disorder that is diagnosed during childhood, with the presenting symptom of excessive bleeding.","Congenital Bleeding Disorder | Congenital Bleeding Defect | Congenital Coagulation Defect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641107","Age at Time of Vaccination","C103173","The age of the subject at the time of the vaccination.","Age at Time of Vaccination | Age at the Time of Vaccination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642473","Equipment Qualification","C103174","The process by which a piece of equipment is verified that it performs according to its specifications.","Equipment Qualification | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641108","Unused Subset Concept","C103175","A terminology codelist concept that is not currently in use.","Unused Subset Concept | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641109","Requalification","C103176","The action of repeating the qualification or reconfirming that a person, process, product or piece of equipment is suitable for a particular postition or task.","Requalification | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1101268","Beta-elemene","C103177","One of the isomers of elemene, a lipid soluble sesquiterpene and the active component isolated from the Chinese medicinal herb Rhizoma zedoariae with potential antineoplastic and chemopreventive activities. Although the exact mechanism of action through which beta-elemene exerts its effect has yet to be fully elucidated, this agent appears to induce apoptosis through different mechanisms of action and induces cell cycle arrest at different stages based on the tumor cell type involved. Beta-elemene may sensitize cancer cells to other chemotherapeutic agents.","Beta-elemene | (1S,2S,4R)-2,4-diisopropenyl-1-methyl-1-vinylcyclohexane | (1alpha,2beta,4beta)-1-Methyl-2,4-bis(methylvinyl)-1- vinylcyclohexane",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437425","Modified Citrus Pectin Supplement","C103178","A dietary supplement containing the modified citrus pectin (MCP) derived from the soluble fiber of citrus fruit peels and a galectin-3 inhibitor with potential antioxidant, hypocholesterolemic, immunostimulatory, metal chelating, and anti-metastatic activities. MCP is a low molecular weight version of pectin composed of short, slightly-branched carbohydrate chains and is modified for enhanced absorbability. The bioactive fragments, most likely the galactan-containing portion, of pectin binds to galectin-3, a carbohydrate-binding protein involved in imflammation, heart disease and is upregulated on the surface of certain types of tumor cells. Binding of MCP may result in the suppression of cancer cell aggregation, adhesion, proliferation and metastasis. In addition, MCP decreases prostate specific antigen (PSA) levels and may remove heavy metals. Also, unsaturated oligogalacturonic acids in MCP may stimulate the immune system through the activation of natural killer cells, cytotoxic T-cells, and B-cells.","Modified Citrus Pectin Supplement | PectaSol-C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538823","NURF55","C101727","Human RBBP4 wild-type allele is located 1p35.1 and is approximately 35 kb in length. This allele, which encodes histone-binding protein RBBP4, plays a role in histone binding, transcriptional regulation and cell cycle progression.","RBBP4 wt Allele | NURF55 | RBAP48 | RbAp48 | Retinoblastoma Binding Protein 4 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2757047","Retinoblastoma-Binding Protein 4","C101728","Histone-binding protein RBBP4 (425 aa, ~48 kDa) is encoded by the human RBBP4 gene. This protein is involved in transcriptional regulation, cell proliferation and histone binding.","Histone-Binding Protein RBBP4 | CAF-1 Subunit C | CAF-I 48 kDa Subunit | CAF-I p48 | Chromatin Assembly Factor 1 Subunit C | Chromatin Assembly Factor I p48 Subunit | Nucleosome-Remodeling Factor Subunit RBAP48 | RBBP-4 | RBBP4 | Retinoblastoma Binding Protein 4 | Retinoblastoma-Binding Protein 4 | Retinoblastoma-Binding Protein p48",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538816","ERRFI1 wt Allele","C101730","Human ERRFI1 wild-type allele is located in the vicinity of 1p36 and is approximately 22 kb in length. This allele, which encodes ERBB receptor feedback inhibitor 1 protein, is involved in the regulation of EGF receptor signaling.","ERRFI1 wt Allele | ERBB Receptor Feedback Inhibitor 1 wt Allele | GENE-33 | MIG-6 | MIG6 | Mitogen-Inducible Gene 6 | RALT | Receptor-Associated Late Transducer Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641183","Nucleolin Antagonist IPP-204106N","C103297","A synthetic, multivalent, lysine-rich, pseudopeptide and nucleolin antagonist with potential anti-angiogenic, antineoplastic and pro-apoptotic activities. Upon administration, IPP-204106N antagonizes nucleolin leading to a downregulation of cell-surface nucleolin; preventing the binding of certain growth promoting ligands to nucleolin may suppress tumor cell proliferation and angiogenesis. In addition, IPP-204106N is able to translocate to the nucleolus and bind to nucleolar nucleolin. This prevents nucleolin from binding to and stabilizing mRNA of the anti-apoptotic Bcl2; destabilizing Bcl2 mRNA leads to a reduction in Bcl2 protein synthesis and induces apoptosis. Further, this agent can antagonize nucleophosmin. Nucleolin, a nucleolar phosphoprotein, is overexpressed on the cell surface of certain cancer cells and binds ligands involved in cell proliferation, adhesion and angiogenesis.","Nucleolin Antagonist IPP-204106N | IPP-204106 | N6L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641185","BET bromodomains 2/3/4 inhibitor MK-8628","C103298","A synthetic, small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins 2, 3 and 4 with potential antineoplastic activity. Upon administration, birabresib binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histone peptides. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes, including c-Myc-dependent target genes, may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomain at the N-terminus, the BET proteins BRD2, BRD3, BRD4 are transcriptional regulators that play an important role in cellular growth.","Birabresib | 6H-Thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-6-acetamide, 4-(4-Chlorophenyl)-N-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6S)- | BIRABRESIB | BRD 2/3/4 Inhibitor OTX015 | MK-8628 | OTX015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438136","PEG-based Laxative NER1006","C103299","A preparation containing the nonabsorbable polymer polyethylene glycol (PEG or macrogol) 3350 with laxative activity. Upon oral administration, the PEG-3350-based laxative NER1006 promotes the retention of water in the bowel. This increases both the water content and volume of stool, which results in increased gastrointestinal motility and the evacuation of colonic contents leading to a complete cleansing of the colon. Compared to the 4 liter PEG-3350-based preparations, this PEG-based laxative is a low volume (2 liter) preparation, which may improve tolerance.","PEG-based Laxative NER1006 | NER1006",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280678","Fluorouracil/Hydroxyurea","C10329","A regimen consisting of fluorouracil and hydroxyurea that may be used in the treatment of head and neck cancers.","Fluorouracil/Hydroxyurea Regimen | 5-FU/HU | Fluorouracil-Hydroxyurea | Fluorouracil-Hydroxyurea Regimen | Fluorouracil/Hydroxyurea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054404","Cactinomycin","C1032","A chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces chrysomallus.  Cactinomycin binds to DNA by intercalating between guanine and cytosine, forming stable antibiotic-DNA complexes that inhibit RNA and protein synthesis. (NCI04)","Cactinomycin | ACTINOMYCIN C | Actinomycin C | CACTINOMYCIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641655","SPI-2012","C103856","A long-acting, recombinant analog of the endogenous human granulocyte colony-stimulating factor (G-CSF) with hematopoietic activity. Similar to G-CSF, eflapegrastim binds to and activates specific cell surface receptors and stimulates neutrophil progenitor proliferation and differentiation, as well as selected neutrophil functions. Therefore, this agent may decrease the duration and incidence of chemotherapy-induced neutropenia. The long-acting G-CSF analog SPI-2012 extends the half-life of G-CSF, allowing for administration once every 3 weeks.","Eflapegrastim | EFLAPEGRASTIM | HM10460A | HNK460 | LAPS-GCSF | SPI-2012 | SPI2012",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438335","Anti-GRP78 Monoclonal Antibody PAT-SM6","C103857","A IgM monoclonal antibody (MoAb) against 78-kDa glucose-regulated protein (GRP78; also called BiP or HSPA5), with potential proapoptotic and antineoplastic activities. Upon intravenous administration of the anti-GRP78 monoclonal antibody PAT-SM6, the MoAb strongly binds to GRP78, thereby preventing the activation of multiple GRP78-mediated pathways and blocking the GRP78-induced suppression of apoptotic pathways. This eventually leads to the induction of tumor cell apoptosis and a reduction in tumor cell proliferation. GRP78, the endoplasmic reticulum (ER) chaperone and unfolded protein response (UPR) regulator, is overexpressed on the surface of a variety of cancer cell types; its expression is associated with increased tumor cell survival and proliferation, as well as angiogenesis and resistance to chemotherapy.","Anti-GRP78 Monoclonal Antibody PAT-SM6 | PAT-SM6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438336","tumor-homing peptide iRGD","C103858","A 9 amino acid-based cyclic, tumor specific homing, arginine-glycine-aspartic acid (RGD)-based peptide (CRGDKRGPDC), with tumor penetrating activity. The iRGD contains the RGD motif as well as the C-terminal end binding (CendR) motif that increases internalization. Upon administration, the RGD motif of the iRGD peptide is able to specifically target tumors by binding to alphavbeta3/alphavbeta5 integrins on tumor endothelium. In turn, iRGD is cleaved by specific tumor proteases, which exposes the positively charged CendR motif. This motif binds to neuropilin-1 (NRP-1), a receptor overexpressed on certain tumor cells. This increases vascular permeability of tumor blood vessels and promotes tumor penetration. Compared to other RGD peptides, this agent is able to both improve delivery and increase the accumulation of co-administered or conjugated chemotherapeutic agents in the tumor.","Internalized-arginylglycylaspartic Acid Cyclic Peptide | CEND 1 | CEND-1 | IRGD | L-Cysteine, L-Cysteinyl-L-Arginylglycyl-L-.Alpha.-Aspartyl-L-Lysylglycyl-L-Prolyl-L-.Alpha.-Aspartyl-, Cyclic (1->9)-Disulfide | LSTA 1 | LSTA-1 | LSTA1 | iRGD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539787","SLAMF1 wt Allele","C104060","Human SLAMF1 wild-type allele is located in the vicinity of 1q23.3 and is approximately 39 kb in length. This allele, which encodes signaling lymphocytic activation molecule protein, plays a role in initiating signal transduction networks in immune cells.","SLAMF1 wt Allele | CD150 | CDw150 | SLAMF1 | Signaling Lymphocytic Activation Molecule Family Member 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0299811","Signaling Lymphocytic Activation Molecule Family Member 1","C104061","Signaling lymphocytic activation molecule (335 aa, ~37 kDa) is encoded by the human SLAMF1 gene. This protein is involved in immune cell regulation and acts as a microbial sensor.","Signaling Lymphocytic Activation Molecule | CD150 | CDw150 | IPO-3 | Signaling Lymphocytic Activation Molecule Family Member 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539694","CD163 wt Allele","C104063","Human CD163 wild-type allele is located in the vicinity of 12p13.3 and is approximately 33 kb in length. This allele, which encodes scavenger receptor cysteine-rich type 1 protein M130, is involved in the clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages.","CD163 wt Allele | CD163 | CD163 Molecule wt Allele | M130 | MM130",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1570089","CD163 antigen protein, human","C104064","Scavenger receptor cysteine-rich type 1 protein M130 (1156 aa, ~125 kDa) is encoded by the human CD163 gene. This protein plays a role in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages.","Scavenger Receptor Cysteine-Rich Type 1 Protein M130 | Antigen CD163 | CD163 | CD163 Antigen | CD163 Molecule | Hemoglobin Scavenger Receptor | Macrophage-Associated Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641476","OAB-q - Frustrated Your Family and Friends","C103670","The Overactive Bladder Questionnaire (OAB-q) Frustrated your family and friends?","OAB-q - Frustrated Your Family and Friends | OABQ01-Frustrated Family and Friends | OABQ0118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641477","OAB-q - Caused You Anxiety or Worry","C103671","The Overactive Bladder Questionnaire (OAB-q) Caused you anxiety or worry?","OAB-q - Caused You Anxiety or Worry | OABQ01-Caused You Anxiety or Worry | OABQ0119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541897","IFNL1 wt Allele","C104351","Human IFNL1 wild-type allele is located in the vicinity of 19q13.13 and is approximately 2 kb in length. This allele, which encodes interferon lambda-1 protein, is involved in both cytokine-dependent signaling and host defense.","IFNL1 wt Allele | IL-29 | IL29 | Interferon, Lambda 1 wt Allele | Interleukin 29 Gene | ZCYTO21",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541295","Interferon Lambda-1, Human","C104352","Interferon lambda-1 (200 aa, ~22 kDa) is encoded by the human IFNL1 gene. This protein plays a role in both cytokine signaling and the response to viral infection.","Interferon Lambda-1 | Cytokine Zcyto21 | IFN-Lambda-1 | IFNL1 | IL-29 | Interferon Lambda 1 | Interferon-Lambda 1 | Interferon-Lambda-1 | Interleukin-29",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538708","GZMB wt Allele","C104354","Human GZMB wild-type allele is located in the vicinity of 14q11.2 and is approximately 3 kb in length. This allele, which encodes granzyme B protein, is involved in both proteolysis and cellular immune responses.","GZMB wt Allele | CCPI | CGL-1 | CGL1 | CSP-B | CSPB | CTLA1 | CTSGL1 | GRB | GranzB | Granzyme B (Granzyme 2, Cytotoxic T-Lymphocyte-Associated Serine Esterase 1) wt Allele | HLP | Protease, Serine, B Gene | SECT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541301","KIF2C wt Allele","C104357","Human KIF2C wild-type allele is located in the vicinity of 1p34.1 and is approximately 28 kb in length. This allele, which encodes kinesin-like protein KIF2C, plays a role in the regulation of microtubule depolymerization.","KIF2C wt Allele | KNSL6 | Kinesin Family Member 2C wt Allele | Kinesin-Like 6 (Mitotic Centromere-Associated Kinesin) Gene | MCAK | RP11-269F19.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537349","Kinesin-Like Protein KIF2C, Human","C104358","Kinesin-like protein KIF2C (725 aa, ~81 kDa) is encoded by the human KIF2C gene. This protein is involved in tubulin depolymerization.","Kinesin-Like Protein KIF2C | KIF2C | Kinesin-Like 6 | Kinesin-Like Protein 6 | MCAK | Mitotic Centromere-Associated Kinesin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540490","KIR3DL1 wt Allele","C104360","Human KIR3DL1 wild-type allele is located in the vicinity of 19q13.4 and is approximately 142 kb in length. This allele, which encodes killer cell immunoglobulin-like receptor 3DL1 protein, is involved in the regulation of natural killer cell activity.","KIR3DL1 wt Allele | AMB11 | CD158E | CD158E1 | CD158e1 | CD158e1/2 | CD158e2 | KIR | KIR3DL1/S1 | Killer Cell Immunoglobulin Like Receptor, Three Ig Domains and Long Cytoplasmic Tail 1 wt Allele | Killer Cell Immunoglobulin-Like Receptor, Three Domains, Long Cytoplasmic Tail, 1 Gene | NKAT3 | NKB1 | NKB1B | cl-11 | cl-2 | nkat3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1430234","KIR3DL1 protein, human","C104361","Killer cell immunoglobulin-like receptor 3DL1 (444 aa, ~49 kDa) is encoded by the human KIR3DL1 gene. This protein plays a role in the modulation of cell-mediated cytotoxicity.","Killer Cell Immunoglobulin-Like Receptor 3DL1 | CD158 Antigen-Like Family Member E | CD158e | CD158e Antigen | HLA-BW4-Specific Inhibitory NK Cell Receptor | KIR Antigen 3DL1 | KIR3DL1 | MHC Class I NK Cell Receptor | NK-receptor | NKAT-3 | Natural Killer-Associated Transcript 3 | p70 Killer Cell Inhibitory Receptor | p70 NK Receptor CL-2/CL-11 | p70 Natural Killer Cell Receptor Clones CL-2/CL-11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642098","ADCS-ADL - Left at Home for Less Than One Hour","C105319","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Was the subject left at home, for less than 1 hour, during the day?","ADCS-ADL - Left at Home for Less Than One Hour | ADL01-Left at Home for Less Than 1 Hour | ADL0118C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642099","ADCS-ADL - Talk About Current Events","C105320","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, did the subject talk about current events?","ADCS-ADL - Talk About Current Events | ADL01-Talk About Current Events | ADL0119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642101","ADCS-ADL - Talk About Events Outside of Home that Subject Took Part In","C105322","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Did the subject talk about events that he/she took part in outside home involving family, friends, or neighbors?","ADCS-ADL - Talk About Events Outside of Home that Subject Took Part In | ADL01-Talk About Outside Events | ADL0119B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642102","ADCS-ADL - Talk About Events at Home that Subject Took Part in or Watched","C105323","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Did the subject talk about events that occurred at home that he/she took part in or watched?","ADCS-ADL - Talk About Events at Home that Subject Took Part in or Watched | ADL01-Talk About at Home Events | ADL0119C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642103","ADCS-ADL - Read for More Than Five Minutes","C105324","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, did the subject read a magazine, newspaper or book for more than 5 minutes at a time?","ADCS-ADL - Read for More Than Five Minutes | ADL01-Read More Than 5 Minutes | ADL0120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642104","ADCS-ADL - Talk About What Subject Read Less Than One Hour After Reading","C105325","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Did the subject usually talk about details of what he/she read while or shortly (less than 1 hour) after reading?","ADCS-ADL - Talk About What Subject Read Less Than One Hour After Reading | ADL01-Talk Within 1 Hour After Reading | ADL0120A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539577","MST1L wt Allele","C104670","Human MST1L wild-type allele is located 1p36.13 and is approximately 15 kb in length. This allele encodes putative macrophage stimulating 1-like protein, a non-functional member of the peptidase S1 family.","MST1L wt Allele | BRF-1 | D1F15S1A | MSPL-7 | MSPL7 | MST1P9 | MSTP7 | MSTP9 | Macrophage Stimulating 1 (Hepatocyte Growth Factor-Like) Pseudogene 9 Gene | Macrophage Stimulating 1 Like (Pseudogene) wt Allele | Macrophage Stimulating 1 Like Gene | Macrophage Stimulating 1-Like Gene | Macrophage Stimulating 1-Like wt Allele | Macrophage Stimulating, Pseudogene 7 Gene | Macrophage Stimulating, Pseudogene 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539587","Putative Macrophage-Stimulating Protein MSTP9, human","C104671","Putative macrophage stimulating 1-like protein (715 aa, ~80 kDa) is encoded by the human MST1L gene. This protein is a non-functional member of the peptidase S1 family.","Putative Macrophage-Stimulating 1-Like Protein | BRF-1 | Brain Rescue Factor 1 | Brain-Rescue-Factor-1 | EC 3.4.21 | Hepatocyte Growth Factor-Like Protein Homolog | MST1L | Macrophage Stimulating 1 (Hepatocyte Growth Factor-Like) Pseudogene 9 | Macrophage Stimulating, Pseudogene 7 | Macrophage Stimulating, Pseudogene 9 | Putative Macrophage-Stimulating Protein MSTP9 | Putative Macrophage-Stimulating Protein MSTP9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0759658","Protein CBFA2T2","C104932","Protein CBFA2T2 (604 aa, ~67 kDa) is encoded by the human CBFA2T2 gene. This protein may be involved in tumor suppression.","Protein CBFA2T2 | Core-Binding Factor, Runt Domain, Alpha Subunit 2; Translocated to, 2 | ETO Homolog on Chromosome 20 | ETO Homologous on Chromosome 20 | MTG8-Like Protein | MTG8-Related Protein 1 | Myeloid Translocation Gene-Related Protein 1 | Myeloid Translocation-Related Protein 1 | p85",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539608","CRIP2 wt Allele","C104938","Human CRIP2 wild-type allele is located in the vicinity of 14q32.3 and is approximately 7 kb in length. This allele encodes cysteine-rich protein 2, a putative transcription factor that may be involved in smooth muscle tissue differentiation.","CRIP2 wt Allele | CRIP | CRP-2 | CRP2 | Cysteine-Rich Protein 2 wt Allele | ESP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0651363","Cysteine-Rich Protein 2, Human","C104940","Cysteine-rich protein 2 (208 aa, ~22 kDa) is encoded by the human CRIP2 gene. This putative transcription factor may play a role in differentiation of smooth muscle tissue.","Cysteine-Rich Protein 2 | CRIP2 | Cysteine-Rich Intestinal Protein | LIM Domain Protein ESP1/CRP2 | Protein ESP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641897","Scanning Proton Beam Therapy","C104941","Proton beam radiation therapy in which magnets deflect and steer the proton beam.  (Adapted from medicalphysicsweb)","Scanning Proton Beam Therapy | Spot Scanning",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641898","Scattering Proton Beam Therapy","C104942","Proton beam radiation therapy in which the proton beam is spread by placing scattering material in the path of the protons.  (Adapted from medicalphysicsweb)","Scattering Proton Beam Therapy | Passive Scattering",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541990","MTHFD2 wt Allele","C104944","Human MTHFD2 wild-type allele is located in the vicinity of 2p13.1 and is approximately 19 kb in length. This allele, which encodes bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial protein, plays a role in folic acid metabolism.","MTHFD2 wt Allele | Methylenetetrahydrofolate Dehydrogenase (NADP+ Dependent) 2, Methenyltetrahydrofolate Cyclohydrolase wt Allele | NMDMC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538800","CD226 wt Allele","C104066","Human CD226 wild-type allele is located in the vicinity of 18q22.3 and is approximately 96 kb in length. This allele, which encodes CD226 antigen protein, plays a role in cellular adhesion of platelets and megakaryocytic cells.","CD226 wt Allele | CD226 Antigen Gene | CD226 Molecule wt Allele | DNAM-1 | DNAM1 | PTA1 | TLiSA1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1432727","CD226 Antigen, Human","C104067","CD226 antigen (336 aa, ~38 kDa) is encoded by the human CD226 gene. This protein is involved in cellular adhesion of platelets and megakaryocytic cells and megakaryocytic cell maturation.","CD226 Antigen | CD226 Molecule | DNAM-1 | DNAX Accessory Molecule 1 | Platelet and T-Cell Activation Antigen 1 | T Lineage-Specific Activation Antigen 1 Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538766","CD244 wt Allele","C104069","Human CD244 wild-type allele is located in the vicinity of 1q23.1 and is approximately 32 kb in length. This allele, which encodes natural killer cell receptor 2B4 protein, is involved in non-MHC-restricted NK cell killing.","CD244 wt Allele | 2B4 | CD244 Molecule, Natural Killer Cell Receptor 2B4 wt Allele | NAIL | NKR2B4 | Nmrk | SLAMF4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1432728","Natural Killer Cell Receptor 2B4, Human","C104070","Natural killer cell receptor 2B4 (370 aa, ~42 kDa) is encoded by the human CD244 gene. This protein plays a role in natural killer cell immune function.","Natural Killer Cell Receptor 2B4 | CD244 Antigen | CD244 Molecule | NAIL | NK Cell Activation-inducing Ligand | NK Cell Type I Receptor Protein 2B4 | NKR2B4 | Natural Killer Cell Activation-Inducing Ligand | SLAM Family Member 4 | SLAMF4 | Signaling Lymphocytic Activation Molecule 4 | h2B4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538887","CD27 wt Allele","C104072","Human CD27 wild-type allele is located in the vicinity of 12p13 and is approximately 7 kb in length. This allele, which encodes CD27 antigen protein, plays a role in regulating B-cell activation and immunoglobulin synthesis.","CD27 wt Allele | CD27 | CD27 Molecule wt Allele | LPFS2 | S152 | S152. LPFS2 | T14 | TNFRSF7 | Tp55 | Tumor Necrosis Factor Receptor Superfamily, Member 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054949","CD27 Antigen","C104073","CD27 antigen (260 aa, ~29 kDa) is encoded by the human CD27 gene. This protein is involved in regulating B-cell activation, immunoglobulin synthesis, and apoptosis.","CD27 Antigen | CD27 Molecule | CD27L Receptor | T-Cell Activation Antigen CD27 | T-Cell Activation Antigen S152 | TNFRSF7 | Tumor Necrosis Factor Receptor Superfamily Member 7 | Tumor Necrosis Factor Receptor Superfamily, Member 7",,,,,,,,,,,,,,,"4239529","Lymphocyte antigen CD27",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641412","NPI - Hallucinations Severity","C103606","Neuropsychiatric Inventory (NPI) Severity of the hallucinations.","NPI - Hallucinations Severity | NPI1-Hallucinations Severity | NPI1B09",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641413","NPI - Hallucinations Distress","C103607","Neuropsychiatric Inventory (NPI) Hallucinations: How emotionally distressing do you find this behavior?","NPI - Hallucinations Distress | NPI1-Hallucinations Distress | NPI1B10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641414","NPI - Agitation/Aggression Frequency","C103608","Neuropsychiatric Inventory (NPI) Frequency of the agitation/aggression.","NPI - Agitation/Aggression Frequency | NPI1-Agitation/Aggression Frequency | NPI1C09",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641415","NPI - Agitation/Aggression Severity","C103609","Neuropsychiatric Inventory (NPI) Severity of the agitation/aggression.","NPI - Agitation/Aggression Severity | NPI1-Agitation/Aggression Severity | NPI1C10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538761","KLRC1 wt Allele","C104363","Human KLRC1 wild-type allele is located in the vicinity of 12p13 and is approximately 12 kb in length. This allele, which encodes NKG2-A/NKG2-B type II integral membrane protein, plays a role in the regulation of immune signaling pathways.","KLRC1 wt Allele | CD159A | Killer Cell Lectin-Like Receptor Subfamily C, Member 1 wt Allele | Killer Cell Lectin-Like Receptor, Subfamily C, Member 1 Gene | NKG2 | NKG2-A | NKG2-B | NKG2A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538762","NKG2-A/NKG2-B Type II Integral Membrane Protein, Human","C104364","NKG2-A/NKG2-B type II integral membrane protein (233 aa, ~26 kDa) is encoded by the human KLRC1 gene. This protein is involved in the modulation of cell-mediated immunity.","NKG2-A/NKG2-B Type II Integral Membrane Protein | C-Lectin Type II Protein | CD159 Antigen-Like Family Member A | CD159a | CD159a Antigen | KLRC1 | NK Cell Receptor A | NKG2-1/B Activating NK Receptor | NKG2-A/B Type II Integral Membrane Protein | NKG2-A/B-Activating NK Receptor | Natural Killer Cell Lectin | Natural Killer Group Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541219","ACER2 wt Allele","C103894","Human ACER2 wild-type allele is located 9p22.1 and is approximately 44 kb in length. This allele, which encodes alkaline ceramidase 2 protein, is involved in the catabolism of sphingolipid ceramides.","ACER2 wt Allele | ALKCDase2 | ASAH3L | Alkaline Ceramidase 2 wt Allele | N-Acylsphingosine Amidohydrolase 3-Like Gene | PP11646 | RP11-363E7.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537286","ACER2 protein, human","C103895","Alkaline ceramidase 2 (275 aa, ~31 kDa) is encoded by the human ACER2 gene. This protein plays a role in ceramide metabolism and sphingosine synthesis.","Alkaline Ceramidase 2 | ACER2 | Acylsphingosine Deacylase 3-Like | AlkCDase 2 | Alkaline CDase 2 | EC 3.5.1.23 | N-Acylsphingosine Amidohydrolase 3-Like | haCER2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540548","ACER3 wt Allele","C103897","Human ACER3 wild-type allele is located in the vicinity of 11q13.5 and is approximately 166 kb in length. This allele, which encodes alkaline ceramidase 3 protein, plays a role in phytoceramide metabolism.","ACER3 wt Allele | APHC | Alkaline Ceramidase 3 wt Allele | FLJ11238 | PHCA | Phytoceramidase, Alkaline Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539590","Alkaline Ceramidase 3","C103898","Alkaline ceramidase 3 (267 aa, ~32 kDa) is encoded by the human ACER3 gene. This protein is involved in the synthesis of phytosphingosine.","Alkaline Ceramidase 3 | ACER3 | AlkCDase 3 | Alkaline CDase 3 | Alkaline Dihydroceramidase SB89 | Alkaline Phytoceramidase | EC 3.5.1.- | aPHC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054692","Carbogen","C1038","An inhalant consisting of hyperoxic gas (95%-98% oxygen and 2%-5% carbon dioxide) with radiosensitizing properties.  Inhaled carbogen reduces diffusion-limited tumor hypoxia, increasing tumor radiosensitivity due to the increased availability of molecular oxygen for cytotoxic radiation-induced oxygen free radical production. (NCI04)","Carbogen | CARBOGEN | carbogen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539770","ASAH1 wt Allele","C103900","Human ASAH1 wild-type allele is located in the vicinity 8p22 of and is approximately 29 kb in length. This allele, which encodes acid ceramidase protein, is involved in ceramide metabolism. Mutation of the gene is associated with both Farber lipogranulomatosis and spinal muscular atrophy with progressive myoclonic epilepsy.","ASAH1 wt Allele | AC | ACDase | ASAH | FLJ21558 | N-Acylsphingosine Amidohydrolase (Acid Ceramidase) 1 wt Allele | PHP | PHP32 | SMAPME",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2000891","Acid Ceramidase, Human","C103901","Acid ceramidase (395 aa, ~45 kDa) is encoded by the human ASAH1 gene. This protein plays a role in sphingosine biosynthesis.","Acid Ceramidase | AC | ACDase | ASAH1 | Acid CDase | Acylsphingosine Deacylase | EC 3.5.1.23 | N-Acylsphingosine Amidohydrolase | PHP32 | Putative 32 kDa Heart Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538795","SERPINC1 wt Allele","C104682","Human SERPINC1 wild-type allele is located in the vicinity of 1q25.1 and is approximately 14 kb in length. This allele, which encodes antithrombin-III protein, plays a role in both protease inhibition and blood coagulation. Mutation of the gene is associated with antithrombin III deficiency.","SERPINC1 wt Allele | AT3 | AT3D | ATIII | MGC22579 | PRO0309 | Serpin Peptidase Inhibitor, Clade C (Antithrombin), Member 1 wt Allele | THPH7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1530588","S-Methylmethionine--Homocysteine S-Methyltransferase BHMT2, Human","C104884","S-methylmethionine-homocysteine S-methyltransferase BHMT2 (363 aa, ~40 kDa) is encoded by the human BHMT2 gene. This protein plays a role in the conversion of homocysteine to methionine.","S-Methylmethionine-Homocysteine S-Methyltransferase BHMT2 | BHMT2 | Betaine--Homocysteine S-Methyltransferase 2 | Betaine-Homocysteine Methyltransferase 2 | Betaine-Homocysteine S-Methyltransferase 2 | Betaine—Homocysteine S-Methyltransferase 2 | EC 2.1.1.5 | S-Methylmethionine--Homocysteine S-Methyltransferase BHMT2 | S-Methylmethionine—Homocysteine S-Methyltransferase BHMT2 | SMM-Hcy Methyltransferase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541871","CHAT wt Allele","C104886","Human CHAT wild-type allele is located in the vicinity of 10q11.2 and is approximately 85 kb in length. This allele, which encodes choline O-acetyltransferase protein, plays a role in the synthesis of acetylcholine. Mutation of the gene is associated with congenital myasthenic syndrome with episodic apnea (familial infantile myasthenia gravis 2).","CHAT wt Allele | CHOACTASE | CMS1A | CMS1A2 | Choline O-Acetyltransferase wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008407","Choline O-Acetyltransferase","C104887","Choline O-acetyltransferase (748 aa, ~83 kDa) is encoded by the human CHAT gene. This protein is involved in acetylcholine biosynthesis.","Choline O-Acetyltransferase | Acetyl CoA:Choline O-Acetyltransferase | CHAT | CHOACTase | ChAT | Choline Acetylase | Choline Acetyltransferase | EC 2.3.1.6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642470","MR-Based Treatment Machine","C104947","An instrument that integrates magnetic resonance imaging with delivery of radiation therapy.","MR-Based Treatment Machine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446112","Denintuzumab Mafodotin","C105150","An immunoconjugate consisting of an anti-CD19 monoclonal antibody conjugated to the auristatin derivative monomethyl auristatin F (MMAF), with potential antineoplastic activity. Upon administration of denintuzumab mafodotin, the antibody moiety targets the cell surface antigen CD19, found on a number of B-cell-derived cancers. Upon antibody/antigen binding and internalization, the immunoconjugate releases MMAF, which binds to tubulin and inhibits its polymerization. Inhibition of tubulin polymerization may result in G2/M phase arrest and tumor cell apoptosis. This causes inhibition of cell growth of CD19-expressing tumor cells. CD19, a B-cell antigen, is overexpressed by a variety of different cancer cell types.","Denintuzumab Mafodotin | ADC SGN-19A | DENINTUZUMAB MAFODOTIN | Denintuzumab mafodotin | Immunoglobulin G1-kappa Auristatin F Conjugate, Anti-(homosapiens CD19 (B Lymphocyte Surface Antigen B4, leu-12)), Humanized Monoclonal Antibody | SGN CD19A | SGN-19A | SGN-CD19A | SGNCD19A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1311002","17-Beta-Hydroxysteroid Dehydrogenase Type 3","C105151","Testosterone 17-beta-dehydrogenase 3 (310 aa, ~35 kDa) is encoded by the human HSD17B3 gene. This protein plays a role in the reduction of androstenedione to testosterone.","Testosterone 17-Beta-Dehydrogenase 3 | 17-Beta-HSD 3 | 17-Beta-HSD3 | 17-Beta-Hydroxysteroid Dehydrogenase Type 3 | EC 1.1.1.64 | HSD17B3 | Short Chain Dehydrogenase/Reductase Family 12C, Member 2 | Testicular 17-Beta-Hydroxysteroid Dehydrogenase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540642","HSD17B6 wt Allele","C105153","Human HSD17B6 wild-type allele is located in the vicinity of 12q13 and is approximately 36 kb in length. This allele, which encodes 17-beta-hydroxysteroid dehydrogenase type 6 protein, plays a role in androgen catabolism.","HSD17B6 wt Allele | HSE | Hydroxysteroid (17-Beta) Dehydrogenase 6 wt Allele | RODH | SDR9C6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0961431","EC 1.1.1.62","C105154","17-beta-hydroxysteroid dehydrogenase type 6 (317 aa, ~36 kDa) is encoded by the human HSD17B6 gene. This protein is involved in androgen catabolism.","17-Beta-Hydroxysteroid Dehydrogenase Type 6 | 17-Beta-HSD 6 | 17-Beta-HSD6 | 3(Alpha->Beta)-Hydroxysteroid Epimerase | 3(Alpha->Beta)-Hydroxysteroid Epimerase I | 3-Alpha->Beta-HSE | 3-Alpha->Beta-Hydroxysteroid Epimerase | 3-Hydroxysteroid Epimerase | EC 1.1.1.105 | EC 1.1.1.62 | EC 1.1.1.63 | HSD17B6 | Hydroxysteroid (17-Beta) Dehydrogenase 6 | Hydroxysteroid (17-Beta) Dehydrogenase 6 Homolog (Mouse) | NAD+ -Dependent 3 Alpha-Hydroxysteroid Dehydrogenase 3-Hydroxysteroid Epimerase | Oxidative 3-Alpha Hydroxysteroid Dehydrogenase | Oxidative 3-Alpha-Hydroxysteroid-Dehydrogenase | Retinol Dehydrogenase | Short Chain Dehydrogenase/Reductase Family 9C, Member 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542422","HSD3B2 wt Allele","C105156","Human HSD3B2 wild-type allele is located in the vicinity of 1p13.1 and is approximately 8 kb in length. This allele, which encodes 3 beta-hydroxysteroid dehydrogenase/delta 5->4-isomerase type 2 protein, is involved in the oxidative conversion of ketosteroids during the biosynthesis of hormonal steroids. Mutations in this gene are associated with 3-beta-hydroxysteroid dehydrogenase, type II, deficiency.","HSD3B2 wt Allele | HSD3B | HSDB | HSDB3B | Hydroxy-Delta-5-Steroid Dehydrogenase, 3 Beta- and Steroid Delta-Isomerase wt Allele | SDR11E2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2606868","3 beta-hydroxysteroid dehydrogenase type II","C105157","3 beta-hydroxysteroid dehydrogenase/Delta 5->4-isomerase type 2 (372 aa, ~42 kDa) is encoded by the human HSD3B2 gene. This protein plays an oxidative role in the biosynthesis of hormonal steroids.","3 Beta-Hydroxysteroid Dehydrogenase/Delta 5->4-Isomerase Type 2 | 3 Beta-Hydroxysteroid Dehydrogenase Type II | 3 Beta-Hydroxysteroid Dehydrogenase Type II, Delta 5-Delta 4-Isomerase Type II, 3 Beta-HSD Type II | 3 Beta-Hydroxysteroid Dehydrogenase/Delta 5-->4-Isomerase Type 2 | 3 Beta-Hydroxysteroid Dehydrogenase/Delta 5-->4-Isomerase Type II | 3 Beta-Hydroxysteroid Dehydrogenase/Delta 5->4-Isomerase Type II | 3 Beta-Hydroxysteroid Dehydrogenase/Delta 5—>4-Isomerase Type 2 | 3 Beta-Hydroxysteroid Dehydrogenase/Delta 5—>4-Isomerase Type II | 3-Beta-HSD Adrenal and Gonadal Type | 3-Beta-HSD II | 3-Beta-HSD Type II | 3-Beta-Hydroxy-5-Ene Steroid Dehydrogenase | 3-Beta-Hydroxy-Delta(5)-Steroid Dehydrogenase | Delta 5-Delta 4-Isomerase Type II | EC 1.1.1.145 | EC 5.3.3.1 | HSD3B2 | Progesterone Reductase | Short Chain Dehydrogenase/Reductase Family 11E, Member 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641416","NPI - Agitation/Aggression Distress","C103610","Neuropsychiatric Inventory (NPI) Agitation/Aggression: How emotionally distressing do you find this behavior?","NPI - Agitation/Aggression Distress | NPI1-Agitation/Aggression Distress | NPI1C11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641418","NPI - Depression/Dysphoria Severity","C103612","Neuropsychiatric Inventory (NPI) Severity of the depression/dysphoria.","NPI - Depression/Dysphoria Severity | NPI1-Depression/Dysphoria Severity | NPI1D10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641419","NPI - Depression/Dysphoria Distress","C103613","Neuropsychiatric Inventory (NPI) Depression/Dysphoria: How emotionally distressing do you find this behavior?","NPI - Depression/Dysphoria Distress | NPI1-Depression/Dysphoria Distress | NPI1D11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641420","NPI - Anxiety Frequency","C103614","Neuropsychiatric Inventory (NPI) Frequency of the anxiety.","NPI - Anxiety Frequency | NPI1-Anxiety Frequency | NPI1E08",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641421","NPI - Anxiety Severity","C103615","Neuropsychiatric Inventory (NPI) Severity of the anxiety.","NPI - Anxiety Severity | NPI1-Anxiety Severity | NPI1E09",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641423","NPI - Elation/Euphoria Frequency","C103617","Neuropsychiatric Inventory (NPI) Frequency of the elation/euphoria.","NPI - Elation/Euphoria Frequency | NPI1-Elation/Euphoria Frequency | NPI1F08",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641424","NPI - Elation/Euphoria Severity","C103618","Neuropsychiatric Inventory (NPI) Severity of the elation/euphoria.","NPI - Elation/Euphoria Severity | NPI1-Elation/Euphoria Severity | NPI1F09",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641425","NPI - Elation/Euphoria Distress","C103619","Neuropsychiatric Inventory (NPI) Elation/Euphoria: How emotionally distressing do you find this behavior?","NPI - Elation/Euphoria Distress | NPI1-Elation/Euphoria Distress | NPI1F10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641426","NPI - Apathy/Indifference Frequency","C103620","Neuropsychiatric Inventory (NPI) Frequency of the apathy/indifference.","NPI - Apathy/Indifference Frequency | NPI1-Apathy/Indifference Frequency | NPI1G09",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641428","NPI - Apathy/Indifference Distress","C103622","Neuropsychiatric Inventory (NPI) Apathy/Indifference: How emotionally distressing do you find this behavior?","NPI - Apathy/Indifference Distress | NPI1-Apathy/Indifference Distress | NPI1G11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641429","NPI - Disinhibition Frequency","C103623","Neuropsychiatric Inventory (NPI) Frequency of the disinhibition.","NPI - Disinhibition Frequency | NPI1-Disinhibition Frequency | NPI1H08",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641430","NPI - Disinhibition Severity","C103624","Neuropsychiatric Inventory (NPI) Severity of the disinhibition.","NPI - Disinhibition Severity | NPI1-Disinhibition Severity | NPI1H09",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538754","ASAH2 wt Allele","C103903","Human ASAH2 wild-type allele is located in the vicinity of 10q11.21 and is approximately 155 kb in length. This allele, which encodes neutral ceramidase protein, plays a role in sphingolipid metabolism.","ASAH2 wt Allele | BCDase | HNAC1 | LCDase | N-Acylsphingosine Amidohydrolase (Non-Lysosomal Ceramidase) 2 wt Allele | N-Cdase | NCDase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1570403","ASAH2 protein, human","C103904","Neutral ceramidase (780 aa, ~86 kDa) is encoded by the human ASAH2 gene. This protein is involved in ceramide hydrolysis.","Neutral Ceramidase | ASAH2 | Acylsphingosine Deacylase 2 | BCDase | EC 3.5.1.23 | LCDase | Mitochondrial Ceramidase | N-Acylsphingosine Amidohydrolase 2 | N-CDase | NCDase | Non-Lysosomal Ceramidase | hCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541414","ASAH2B wt Allele","C103906","Human ASAH2B wild-type allele is located in the vicinity of 10q11.23 and is approximately 77 kb in length. This allele, which encodes putative inactive neutral ceramidase B protein, may be involved in ceramide metabolism.","ASAH2B wt Allele | ASAH2-Like Gene | ASAH2C | ASAH2L | N-Acylsphingosine Amidohydrolase (Non-Lysosomal Ceramidase) 2B Gene | RP11-564C4.1 | bA449O16.3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537384","Putative Inactive Neutral Ceramidase B","C103907","Putative inactive neutral ceramidase B (165 aa, ~19 kDa) is encoded by the human ASAH2B gene. This protein may play a role in ceramide hydrolysis.","Putative Inactive Neutral Ceramidase B | ASAH2-Like Protein | ASAH2B | Putative Inactive N-Acylsphingosine Amidohydrolase 2B | Putative Inactive Non-Lysosomal Ceramidase B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540515","CEP55 wt Allele","C104120","Human CEP55 wild-type allele is located in the vicinity of 10q24.1 and is approximately 32 kb in length. This allele, which encodes centrosomal protein of 55 kDa, plays a role in mitotic exit and cytokinesis.","CEP55 wt Allele | C10orf3 | CT111 | Centrosomal Protein 55kDa wt Allele | Chromosome 10 Open Reading Frame 3 Gene | FLJ10540 | RP11-30E16.2 | URCC6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537289","Centrosomal Protein of 55 kDa","C104121","Centrosomal protein of 55 kDa (464 aa, ~54 kDa) is encoded by the human CEP55 gene. This protein is involved in mitotic exit and cytokinesis.","Centrosomal Protein of 55 kDa | Cancer/Testis Antigen 111 | Cep55 | Up-Regulated in Colon Cancer 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541981","CERKL wt Allele","C104123","Human CERKL wild-type allele is located in the vicinity of 2q31.3 and is approximately 144 kb in length. This allele, which encodes ceramide kinase-like protein, is involved in protecting cells from apoptosis in oxidative stress conditions.","CERKL wt Allele | Ceramide Kinase Like wt Allele | Ceramide Kinase-like Gene | RP26 | Retinitis Pigmentosa 26 (Autosomal Recessive) Gene | Retinitis Pigmentosa 26 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641725","Ceramide Kinase-like Protein","C104124","Ceramide kinase-like protein (558 aa, ~63 kDa) is encoded by the human CERKL gene. This protein plays a role in protecting cells from apoptosis in oxidative stress conditions.","Ceramide Kinase-like Protein | CERKL | Retinitis Pigmentosa 26 (Autosomal Recessive)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539748","CERS5 wt Allele","C104126","Human CERS5 wild-type allele is located in the vicinity of 12q13.12 and is approximately 38 kb in length. This allele, which encodes ceramide synthase 5 protein, plays a role in cell signaling and apoptosis.","CERS5 wt Allele | Ceramide Synthase 5 wt Allele | FLJ25304 | LAG1 Homolog, Ceramide Synthase 5 Gene | LAG1 Longevity Assurance Homolog 5 (S. cerevisiae) Gene | LAG1, S. cerevisiae, Homolog of 5 Gene | LASS5 | MGC45411 | TRAM Homolog 4 Gene | Trh4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1679756","Ceramide Synthase 5, Human","C104127","Ceramide synthase 5 (392 aa, ~46 kDa) is encoded by the human CERS5 gene. This protein is involved in apoptosis via the mitochondrial death pathway.","Ceramide Synthase 5 | CerS5 | EC 2.3.1.24 | LAG1 Longevity Assurance Homolog 5 | Sphingosine N-Acyltransferase CERS5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641877","CT on Rails","C104888","A system that improves the accuracy of radiation treatment by precisely identifying the location of the tumor.  It involves the pairing of the machine used to deliver external beam radiotherapy with a CT scanner.","CT on Rails | CT On Rails",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539739","DST wt Allele","C104890","Human DST wild-type allele is located in the vicinity of 6p12.1 and is approximately 497 kb in length. This allele, which encodes dystonin protein, is involved in the structure of cytoskeleton networks. Mutations in this gene are associated with Hereditary Sensory and Autonomic Neuropathy Type VI.","DST wt Allele | BP230 | BP240 | BPA | BPAG1 | CATX-15 | CATX15 | D6S1101 | DMH | DT | Dystonin wt Allele | FLJ13425 | FLJ21489 | FLJ30627 | FLJ32235 | HSAN6 | KIAA0728 | MACF2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1437025","Dystonin, Human","C104891","Dystonin (7570 aa, ~860 kDa) is encoded by the human DST gene. This protein plays a structural role in cytoskeleton networks.","Dystonin | 230 kDa Bullous Pemphigoid Antigen | 230/240 kDa Bullous Pemphigoid Antigen | BASEMENT MEMBRANE ZONE BP230 | BMZ BP230 | BP230 | BPAG1 | Bullous Pemphigoid Antigen | Bullous Pemphigoid Antigen 1 | Bullous Pemphigoid Antigen 1, 230/240kDa | DST | Dystonia Musculorum Protein | Hemidesmosomal Plaque Protein | Trabeculin-Beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540497","E2F6 wt Allele","C104894","Human E2F6 wild-type allele is located in the vicinity of 2p25.1 and is approximately 22 kb in length. This allele, which encodes transcription factor E2F6 protein, plays a role in entry into the cell cycle.","E2F6 wt Allele | E2F Transcription Factor 6 wt Allele | E2F-6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1450313","E2F6 protein, human","C104896","Transcription factor E2F6 (281 aa, ~32 kDa) is encoded by the human E2F6 gene. This protein is involved in entry into the cell cycle, but not cell cycle progression.","Transcription Factor E2F6 | E2F Transcription Factor 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541986","CHDH wt Allele","C104897","Human CHDH wild-type allele is located in the vicinity of 3p21.1 and is approximately 30 kb in length. This allele, which encodes choline dehydrogenase, mitochondrial protein, plays a role in the metabolism of choline.","CHDH wt Allele | Choline Dehydrogenase wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542407","Choline Dehydrogenase, Mitochondrial","C104898","Choline dehydrogenase, mitochondrial (594 aa, ~65 kDa) is encoded by the human CHDH gene. This protein is involved in the conversion of choline to betaine.","Choline Dehydrogenase, Mitochondrial | CDH | CHD | CHDH | EC 1.1.99.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0258439","TNF receptor-associated factor 1","C105110","TNF receptor-associated factor 1 (416 aa, ~46 kDa) is encoded by the human TRAF1 gene. This protein plays a role in the regulation of both protein ubiquitination and TNF receptor family-mediated signaling pathways.","TNF Receptor-Associated Factor 1 | Epstein-Barr Virus-Induced Protein 6 | TRAF1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541861","TNFRSF9 wt Allele","C105112","Human TNFRSF9 wild-type allele is located in the vicinity of 1p36 and is approximately 21 kb in length. This allele, which encodes tumor necrosis factor receptor superfamily member 9, is involved in T-cell development.","TNFRSF9 wt Allele | 4-1BB | 4-1BB, Mouse, Homolog of Gene | CD137 | CDw137 | Homolog of Mouse 4-1BB Gene | ILA | Induced By Lymphocyte Activation (ILA) Gene | Induced By Lymphocyte Activation Gene | Interleukin-Activated Receptor, Homolog of Mouse Ly63 Gene | Ly63, Mouse, Homolog of Gene | TNF Receptor Superfamily Member 9 wt Allele | Tumor Necrosis Factor Receptor Superfamily, Member 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3543429","SRD5A1 wt Allele","C105159","Human SRD5A1 wild-type allele is located 5p15 and is approximately 36 kb in length. This allele, which encodes 3-oxo-5-alpha-steroid 4-dehydrogenase 1 protein, plays a role in the conversion of testosterone into dihydrotestosterone.","SRD5A1 wt Allele | S5AR 1 | Steroid-5-Alpha-Reductase, Alpha Polypeptide 1 (3-Oxo-5 Alpha-Steroid Delta 4-Dehydrogenase Alpha 1) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541297","NGF wt Allele","C105375","Human NGF wild-type allele is located in the vicinity of 1p13.1 and is approximately 52 kb in length. This allele, which encodes beta-nerve growth factor protein, is involved in the modulation of both the growth and the differentiation of neurons. Mutation of the gene is associated with hereditary sensory and autonomic neuropathy type 5.","NGF wt Allele | Beta-NGF | HSAN5 | NGFB | Nerve Growth Factor (Beta Polypeptide) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538687","ANXA2 wt Allele","C105377","Human ANXA2 wild-type allele is located in the vicinity of 15q22.2 and is approximately 56 kb in length. This allele, which encodes annexin A2 protein, plays a role in both bone development and signaling.","ANXA2 wt Allele | ANX2 | ANX2L4 | Annexin A2 wt Allele | CAL1H | LIP2 | LPC2 | LPC2D | P36 | PAP-IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1175494","ANXA2 protein, human","C105378","Annexin A2 (339 aa, ~39 kDa) is encoded by the human ANXA2 gene. This protein is involved in ligand binding, signal transduction and bone development.","Annexin A2 | ANXA2 | Annexin II | Annexin-2 | Calpactin I Heavy Chain | Calpactin I Heavy Polypeptide | Calpactin-1 Heavy Chain | Chromobindin 8 | Chromobindin-8 | Lipocortin II | PAP-IV | Placental Anticoagulant Protein IV | Protein I | p36",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542415","C1QA wt Allele","C105380","Human C1QA wild-type allele is located in the vicinity of 1p36.12 and is approximately 3 kb in length. This allele, which encodes complement C1q subcomponent subunit A protein, is involved in the initiation of complement-mediated immunity. Mutation of the gene is associated with complement component C1q deficiency.","C1QA wt Allele | C1qA | Complement C1q A Chain wt Allele | Complement Component 1, Q Subcomponent, Alpha Polypeptide Gene | Complement Component 1, q Subcomponent, A Chain Gene | Complement Component 1, q Subcomponent, A Chain wt Allele | Complement Component C1q, A Chain Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539862","Complement C1q Subcomponent Subunit A","C105381","Complement C1q subcomponent subunit A (245 aa, ~26 kDa) is encoded by the human C1QA gene. This protein plays a role in the activation of the classical complement pathway.","Complement C1q Subcomponent Subunit A | C1QA | Complement Component 1, q Subcomponent, A Chain | Complement Component 1, q Subcomponent, Alpha Polypeptide | Complement Component C1q A Chain | Complement Component C1q, A Chain | Complement Subcomponent C1q Chain A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538851","REG3A wt Allele","C105383","Human REG3A wild-type allele is located in the vicinity of 2p12 and is approximately 3 kb in length. This allele, which encodes regenerating islet-derived protein 3-alpha, may play a role in both the proliferation and differentiation of islet cells.","REG3A wt Allele | HIP | HIP/PAP | Hepatocarcinoma-Intestine-Pancreas Gene | INGAP | PAP | PAP-H | PAP1 | PBCGF | REG-III | REG3 | Regenerating Islet-Derived 3 Alpha wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2714958","proIslet peptide, human","C105384","Regenerating islet-derived protein 3-alpha (175 aa, ~19 kDa) is encoded by the human REG3A gene. This protein may be involved in pancreatic inflammation.","Regenerating Islet-Derived Protein 3-Alpha | HIP/PAP | Hepatointestinal Pancreatic Protein | Human Proislet Peptide | INGAP | Islet Neogenesis Associated Protein | Islet Neogenesis-Associated Protein | PAP Homologous Protein | Pancreatic Beta Cell Growth Factor | Pancreatitis-Associated Protein | Pancreatitis-Associated Protein 1 | Proliferation-Inducing Protein 34 | Proliferation-Inducing Protein 42 | REG-3-Alpha | REG3A | Reg III-Alpha | Regenerating Islet-Derived Protein III-Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538706","EPAS1 wt Allele","C104305","Human EPAS1 wild-type allele is located within 2p21-p16 and is approximately 93 kb in length. This allele, which encodes endothelial PAS domain-containing protein 1, is involved in the regulation of transcription in response to oxygen. Mutation of the gene is associated with familial erythrocytosis type 4.","EPAS1 wt Allele | BHLHE73 | ECYT4 | Endothelial PAS Domain Protein 1 wt Allele | HIF2A | HLF | Hypoxia-Inducible Factor 2, Alpha Subunit Gene | MOP2 | Member of PAS Superfamily 2 Gene | PASD2 | bHLHe73",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1436532","Endothelial PAS Domain-Containing Protein 1, Human","C104306","Endothelial PAS domain-containing protein 1 (870 aa, ~96 kDa) is encoded by the human EPAS1 gene. This protein plays a role in both the response to hypoxia and transcriptional regulation.","Endothelial PAS Domain-Containing Protein 1 | Basic-Helix-Loop-Helix-PAS Protein MOP2 | Class E Basic Helix-Loop-Helix Protein 73 | EPAS-1 | EPAS1 | HIF-1 Alpha-Like Factor | HIF-1-Alpha-Like Factor | HIF-1alpha-Like Factor | HIF-2-Alpha | HIF2-Alpha | HLF | Hypoxia-Inducible Factor 2 Alpha | Hypoxia-Inducible Factor 2-Alpha | Member of PAS Protein 2 | PAS Domain-Containing Protein 2 | bHLHe73",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538700","HLA-G wt Allele","C104317","Human HLA-G wild-type allele is located in the vicinity 6p21.3 and is approximately 4 kb in length. This allele, which encodes HLA class I histocompatibility antigen, alpha chain G protein, plays a role in MHC class I-mediated immune responses.","HLA-G wt Allele | DADB-15K14.8 | HLA-6.0 | HLA-G Histocompatibility Antigen, Class I, G Gene | HLAG | MHC-G | Major Histocompatibility Complex, Class I, G wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642059","GCGI - Global Disease Status of Pain","C105280","General Clinical Global Impressions (GCGI v1) Global disease status of pain.","GCGI - Global Disease Status of Pain | GCGI01-Global Disease Status of Pain | GCGI0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642060","GCGI - Pain Treatment Preference","C105281","General Clinical Global Impressions (GCGI v1) Pain treatment preference.","GCGI - Pain Treatment Preference | GCGI01-Pain Treatment Preference | GCGI0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642062","ADCS-ADL - Description of Usual Performance of Eating","C105283","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Regarding eating: which best describes the subject's usual performance during the past 4 weeks?","ADCS-ADL - Description of Usual Performance of Eating | ADL01-Usual Eating Performance | ADL0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539734","Acyl-Protein Thioesterase 1","C104626","Acyl-protein thioesterase 1 (230 aa, ~25 kDa) is encoded by the human LYPLA1 gene. This protein plays a role in regulating membrane lysophospholipid levels.","Acyl-Protein Thioesterase 1 | Acyl-protein Thioesterase-1 | EC 3.1.2.- | LYPLA1 | LysoPLA I | Lysophospholipase I | Lysophospholipid-Specific Lysophospholipase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540818","LAMP1 wt Allele","C104628","Human LAMP1 wild-type allele is located in the vicinity of 13q34 and is approximately 27 kb in length. This allele, which encodes lysosome-associated membrane glycoprotein 1 protein, plays a role in selectin-mediated cell adhesion and may play a role in tumor cell metastasis.","LAMP1 wt Allele | CD107a | LAMP-1 | LAMPA | LGP120 | Lysosomal-Associated Membrane Protein 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0125271","Lysosome-Associated Membrane Glycoprotein 1","C104629","Lysosome-associated membrane glycoprotein 1 (417 aa, ~45 kDa) is encoded by the human LAMP1 gene. This membrane glycoprotein is involved in selectin-mediated cell adhesion and may be involved in tumor cell metastasis.","Lysosome-Associated Membrane Glycoprotein 1 | CD107 Antigen-Like Family Member A | CD107a Antigen | LAMP-1 | LAMP1 | Lysosomal-Associated Membrane Protein 1 | Lysosome-Associated Membrane Protein 1",,,,,,,,,,,,,,,"4012845","Lymphocyte antigen CD107A",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3538703","MR1 wt Allele","C104631","Human MR1 wild-type allele is located in the vicinity of 1q25.3 and is approximately 29 kb in length. This allele, which encodes major histocompatibility complex class I-related gene protein, is involved in antigen presentation in the gut.","MR1 wt Allele | HLALS | Major Histocompatibility Complex, Class I-Related wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540594","Major Histocompatibility Complex Class I-Related Gene Protein","C104632","Major histocompatibility complex class I-related gene protein (341 aa, ~39 kDa) is encoded by the human MR1 gene. This protein plays a role in gut antigen presentation.","Major Histocompatibility Complex Class I-Related Gene Protein | Class I Histocompatibility Antigen-Like Protein | MHC Class I-Like Antigen MR-1 | MHC Class I-Related Gene Protein | MHC Class-I Related-Gene Protein | Major Histocompatibility Complex, Class I-Like Sequence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538741","MRC1 wt Allele","C104634","Human MRC1 wild-type allele is located in the vicinity of 10p12.33 and is approximately 102 kb in length. This allele, which encodes macrophage mannose receptor 1 protein, plays a role in mediating endocytosis of glycoproteins by macrophages.","MRC1 wt Allele | CD206 | CLEC13D | CLEC13DL | MMR | MRC1L1 | Mannose Receptor, C Type 1 wt Allele | bA541I19.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3493301","Macrophage Mannose Receptor 1, Human","C104635","Macrophage mannose receptor 1 (1456 aa, ~166 kDa) is encoded by the human MRC1 gene. This protein is involved in mediating macrophage endocytosis of glycoproteins.","Macrophage Mannose Receptor 1 | C-Type Lectin Domain Family 13 Member D | C-Type Lectin Domain Family 13 Member D-Like | CD206 Antigen | Macrophage Mannose Receptor 1-Like Protein 1 | Mannose Receptor, C Type 1 | Mannose Receptor, C Type 1-Like 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425104","PTGES2 Gene","C105114","This gene plays a role in prostaglandin biosynthesis.","PTGES2 Gene | PTGES2 | Prostaglandin E Synthase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1571037","prostaglandin E synthase 2","C105116","Prostaglandin E synthase 2 (377 aa, ~42 kDa) is encoded by the human PTGES2 gene. This protein plays a role in both the synthesis of prostaglandin E2 and transcriptional activation.","Prostaglandin E Synthase 2 | EC 5.3.99.3 | GATE-Binding Factor 1 | Gamma-Interferon-Activated Transcriptional Element-Binding Factor 1 | Membrane-Associated Prostaglandin E Synthase 2 | Membrane-Associated Prostaglandin E Synthase-2 | Microsomal Prostaglandin E Synthase 2 | PTGES2 | Prostaglandin-H(2) E-Isomerase | mPGE Synthase-2 | mPGES-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539675","Target of Rapamycin Complex 2 Subunit MAPKAP1, Human","C105119","Target of rapamycin complex 2 subunit MAPKAP1 (522 aa, ~59 kDa) is encoded by the human MAPKAP1 gene. This protein is involved in the modulation of growth factor-dependent signaling.","Target of Rapamycin Complex 2 Subunit MAPKAP1 | MAPKAP1 | MEKK2-Interacting Protein 1 | Mitogen-Activated Protein Kinase 2-Associated Protein 1 | Mitogen-Activated Protein Kinase Associated Protein 1 | SAPK-Interacting Protein 1 | Stress-Activated Map Kinase-Interacting Protein 1 | TORC2 Subunit MAPKAP1 | mSIN1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538796","TNFAIP1 wt Allele","C105121","Human TNFAIP1 wild-type allele is located within 17q22-q23 and is approximately 11 kb in length. This allele, which encodes BTB/POZ domain-containing adapter for CUL3-mediated RhoA degradation protein 2, is involved in the modulation of the ubiquitination of transforming protein RhoA.","TNFAIP1 wt Allele | B12 | B61 | BACURD2 | BTBD34 | EDP1 | MGC2317 | Tumor Necrosis Factor, Alpha-Induced Protein 1 (Endothelial) wt Allele | hBACURD2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538886","BTB/POZ Domain-Containing Adapter For CUL3-Mediated RhoA Degradation Protein 2","C105122","BTB/POZ domain-containing adapter for CUL3-mediated RhoA degradation protein 2 (316 aa, ~36 kDa) is encoded by the human TNFAIP1 gene. This protein plays a role in substrate recognition for an E3 ubiquitin ligase complex.","BTB/POZ Domain-Containing Adapter for CUL3-Mediated RhoA Degradation Protein 2 | BTB/POZ Domain-Containing Adapter For CUL3-Mediated RhoA Degradation Protein 2 | BTB/POZ Domain-Containing Adapter For CUL3-Mediated RhoA Degradation Protein 2 | BTB/POZ Domain-Containing Protein TNFAIP1 | Protein B12 | TNFAIP1 | Tumor Necrosis Factor, Alpha-Induced Protein 1, Endothelial | hBACURD2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642105","ADCS-ADL - Talk About What Subject Read More Than One Hour After Reading","C105326","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Did the subject usually talk about what he/she read 1 hour or longer after reading?","ADCS-ADL - Talk About What Subject Read More Than One Hour After Reading | ADL01-Talk 1 Hour or More After Reading | ADL0120B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541328","UCHL1 wt Allele","C105387","Human UCHL1 wild-type allele is located in the vicinity of 4p13 and is approximately 12 kb in length. This allele, which encodes ubiquitin carboxyl-terminal hydrolase isozyme L1 protein, is involved in the deubiquitination of proteins. Mutation of the gene is associated with Parkinson disease type 5.","UCHL1 wt Allele | PARK5 | PGP 9.5 | PGP9.5 | PGP95 | Ubiquitin Carboxyl-Terminal Esterase L1 (Ubiquitin Thiolesterase) wt Allele | Uch-L1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1436157","Ubiquitin Carboxyl-Terminal Hydrolase Isozyme L1, Human","C105388","Ubiquitin carboxyl-terminal hydrolase isozyme L1 (223 aa, ~25 kDa) is encoded by the human UCHL1 gene. This protein plays a role in ubiquitin metabolism.","Ubiquitin Carboxyl-Terminal Hydrolase Isozyme L1 | EC 3.4.19.12 | Neuron Cytoplasmic Protein 9.5 | PGP 9.5 | PGP9.5 | UCH-L1 | UCHL1 | Ubiquitin Thioesterase L1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541419","RPP40 wt Allele","C104724","Human RPP40 wild-type allele is located in the vicinity of 6p25.1 and is approximately 9 kb in length. This allele, which encodes ribonuclease P protein subunit p40 protein, plays a role in the generation of tRNA molecules.","RPP40 wt Allele | RNASEP1 | Ribonuclease P/MRP 40kDa Subunit wt Allele | bA428J1.3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1308570","Ribonuclease P Protein Subunit p40, Human","C104725","Ribonuclease P protein subunit p40 (363 aa, ~42 kDa) is encoded by the human RPP40 gene. This protein is involved in cleavage of tRNA molecules.","Ribonuclease P Protein Subunit p40 | EC 3.1.26.5 | RNase P Subunit 1 | RNaseP Protein p40 | RPP40 | Ribonuclease P 40kDa Subunit | Ribonuclease P, 40kD Subunit | Ribonuclease P1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539648","RPS14 wt Allele","C104727","Human RPS14 wild-type allele is located within 5q31-q33 and is approximately 7 kb in length. This allele, which encodes 40S ribosomal protein S14, is involved in translation as a structural protein of the 40S ribosome subunit. Loss of this gene may be the cause of 5q deletion syndrome.","RPS14 wt Allele | EMTB | Ribosomal Protein S14 wt Allele | S14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0073315","ribosomal protein S14","C104728","40S ribosomal protein S14 (151 aa, ~16 kDa) is encoded by the human RPS14 gene. This protein plays a role in translation as a structural protein of the 40S ribosome subunit.","40S Ribosomal Protein S14 | Emetine Resistance | RPS14 | Ribosomal Protein S14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541420","PBXIP1 wt Allele","C104730","Human PBXIP1 wild-type allele is located in the vicinity of 1q21.3 and is approximately 12 kb in length. This allele, which encodes pre-B-cell leukemia transcription factor-interacting protein 1, is involved in the negative regulation of transcription factor activity.","PBXIP1 wt Allele | HPIP | Pre-B-Cell Leukemia Homeobox Interacting Protein 1 wt Allele | RP11-307C12.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL445806","Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2","C104731","A radioconjugate composed of the cytokine interleukin-2 (IL-2) conjugated to the bifunctional chelating agent succinimidyl-6-hydrazinopyridine-3-carboxylate (HYNIC-NHS) and co-ligand tricine and labeled with the radioisotope technetium Tc 99m (99mTc-HYNIC-IL2), that can potentially be used as a diagnostic agent to detect tumor inflammation. Upon intravenous administration, IL-2 selectively binds to the IL-2 receptor (IL-2R) expressed on tumor infiltrating lymphocytes (TILs); upon internalization, the Tc99m moiety can be visualized using radioimaging, which allows the quantification of TILs expressing IL-2R. This agent detects tumor enlargement due to invasion by TILs and not tumor progression.","Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2 | 99mTc-HYNIC-IL2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438337","anti-ErbB3 monoclonal antibody REGN1400","C103859","A human monoclonal antibody directed against the human epidermal growth factor receptor ErbB3 (Her3) with potential antineoplastic activity. Upon administration, anti-ErbB3 monoclonal antibody REGN1400 binds to ErbB3 and prevents neuregulin 1 ligand binding to ErbB3, which may result in an inhibition of ErbB3-dependent phosphatidylinositol-3 kinase (PI3K)/Akt signaling. This eventually leads to the inhibition of cellular proliferation and differentiation. ErbB3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in a variety of solid tumors and its overexpression generally correlates with poor prognosis and tumor resistance.","Anti-ErbB3 Monoclonal Antibody REGN1400 | REGN 1400 | REGN-1400 | REGN1400",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3530137","Anti-HLA-DR Monoclonal Antibody IMMU-114","C103860","A humanized IgG4 monoclonal antibody that targets the human leukocyte antigen HLA-DR, with potential antineoplastic activity. Upon administration, anti-HLA-DR monoclonal antibody IMMU-114 binds to HLA-DR on HLA-DR-expressing tumor cells and, although the exact mechanism has yet to be fully elucidated, appears to induce hyperactivation of ERK- and JNK-dependent mitogen activated protein kinase signaling pathways. This may lead to mitochondrial membrane depolarization and reactive oxygen species (ROS) generation. This eventually leads to an induction of tumor cell apoptosis and a reduction in tumor cell proliferation. IMMU-14 may be beneficial in the treatment of graft versus host disease (GVHD) as it appears to suppress T-lymphocyte proliferation and natural killer (NK) cell activation. As the Fc region of the orgnial IgG1 MoAb was replaced with the IgG4 isotype, IMMU-114 does not induce a complement cytotoxicity (CDC) or an antibody-dependent cell-mediated cytotoxicity (ADCC). HLA-DR, a MHC class II molecule, is found on various b-cell hematologic malignancies and in autoimmune diseases as well as on normal cells.","Anti-HLA-DR Monoclonal Antibody IMMU-114 | Anti-HLA-DR MoAb L243 | IMMU-114 | hL243gamma4P",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438339","PI3K Alpha/Beta Inhibitor BAY1082439","C103861","An orally bioavailable inhibitor of the class I phosphoinositide 3-kinase (PI3K) alpha and beta isoforms with potential antineoplastic activity. PI3K alpha/beta inhibitor BAY1082439 selectively inhibits both PI3K alpha, including mutated forms of PIK3CA, and PI3K beta in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K-expressing and/or PTEN-driven tumor cells. By specifically targeting class I PI3K alpha and beta, this agent may be more efficacious and less toxic than pan PI3K inhibitors. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and results in increased tumor cell growth, survival, and resistance to chemotherapy and radiotherapy. PIK3CA, one of the most highly mutated oncogenes, encodes the p110-alpha catalytic subunit of the class I PI3K. PTEN, a tumor suppressor protein and negative regulator of PI3K activity, is often mutated in a variety of cancer cells.","PI3K Alpha/Beta Inhibitor BAY1082439 | BAY-1082439 | BAY1082439",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438340","Allogeneic Irradiated Melanoma Cell Vaccine CSF470","C103862","An allogeneic cancer vaccine composed of a mixture of lethally irradiated whole melanoma cancer cells obtained from four different melanoma cell lines, with potential immunostimulating and antineoplastic activities. Upon intradermal injections, allogeneic irradiated melanoma cell vaccine may stimulate the body's immune system to exert a cytotoxic T-lymphocyte response and antibody-dependent cellular cytotoxicity (ADCC) against the melanoma cancer cells.","Allogeneic Irradiated Melanoma Cell Vaccine CSF470 | CSF 470 Vaccine | CSF470 Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641662","anti-ErbB3/anti-IGF-1R bispecific monoclonal antibody MM-141","C103863","A bispecific monoclonal antibody directed against the human epidermal growth factor receptor ErbB3 (Her3) and the human insulin-like growth factor-1 receptor (IGF-1R), with potential antineoplastic activity. The anti-IGF-1R targeting arm of Istiratumab binds to IGF-1R on tumor cells thereby preventing the binding of the natural ligands IGF-1, 2 and heregulin (HRG) to IGF-1R; the anti-ErbB3 therapeutic arm prevents the binding of neuregulin (NRG) to ErbB3. This prevents the activation of the PI3K/AKT signal transduction pathway and may result in both the induction of apoptosis and a decrease in cellular proliferation in IGF-1R and ErbB3-overexpressing tumor cells. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily, and ErB3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, are frequently overexpressed in solid tumors.","Istiratumab | ISTIRATUMAB | MM-005 | MM-141",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438342","Gallium Ga 68-labeled DOTA Di-HSG Peptide IMP-288","C103864","A radiolabeled divalent histamine-succinyl-glycine (HSG) hapten-peptide linked with the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to the radionuclide gallium (Ga) 68 with potential use in diagnostic imaging. After pretargeting with a bispecific monoclonal antibody (BiMoAB) directed against both a tumor associated antigen (TAA) and the HSG hapten-peptide, the HSG portion of administered gallium Ga 68-labeled di-HSG-DOTA peptide IMP-288 binds the anti-HSG portion of the BiMoAB; Ga-68 radioisotopic activity localized to tumor cells bearing the TAA can then be visualized upon positron emission tomography (PET).","Gallium Ga 68-labeled DOTA Di-HSG Peptide IMP-288 | Ga-68-IMP-288",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540819","MAP4 wt Allele","C104637","Human MAP4 wild-type allele is located in the vicinity of 3p21 and is approximately 239 kb in length. This allele, which encodes microtubule-associated protein 4, is involved in both microtubule assembly and cell cycle progression.","MAP4 wt Allele | MAP-4 | Microtubule-Associated Protein 4 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4077534","MAP4 protein, human","C104638","Microtubule-associated protein 4 (1152 aa, ~121 kDa) is encoded by the human MAP4 gene. This protein plays a role in both microtubule assembly and cell cycle progression.","Microtubule-Associated Protein 4 | MAP-4 | MAP4 | Microtubule Associated Protein 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539741","NEK3 wt Allele","C104844","Human NEK3 wild-type allele is located in the vicinity of 13q14.13 and is approximately 27 kb in length. This allele, which encodes serine/threonine-protein kinase Nek3 protein, is involved in neuronal morphogenesis and polarity.","NEK3 wt Allele | HSPK 36 | HSPK36 | MGC29949 | NIMA-Related Kinase 3 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538727","APBA2 wt Allele","C104845","Human APBA2 wild-type allele is located within 15q11-q12 and is approximately 281 kb in length. This allele, which encodes amyloid beta A4 precursor protein-binding family A member 2 protein, is involved in both amyloid beta A4 precursor protein processing and vesicle transport.","APBA2 wt Allele | Amyloid Beta (A4) Precursor Protein-Binding, Family A, Member 2 wt Allele | D15S1518E | HsT16821 | LIN-10 | MGC:14091 | MINT2 | X11-BETA | X11L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537353","NEK3 protein, human","C104846","Serine/threonine-protein kinase Nek3 (506 aa, ~58 kDa) is encoded by the human NEK3 gene. This protein plays a role in morphogenesis and polarity of neurons.","Serine/Threonine-Protein Kinase Nek3 | EC 2.7.11.1 | Glycogen Synthase A Kinase | NIMA (Never in Mitosis Gene A)-Related Kinase 3 | Never in Mitosis A-Related Kinase 3 | NimA-Related Protein Kinase 3 | Phosphorylase B Kinase Kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538960","Amyloid Beta A4 Precursor Protein-Binding Family A Member 2, Human","C104847","Amyloid beta A4 precursor protein-binding family A member 2 (749 aa, ~83 kDa) is encoded by the human APBA2 gene. This protein plays a role in the modulation of both vesicle transport and proteolytic processing of amyloid beta A4 precursor protein.","Amyloid Beta A4 Precursor Protein-Binding Family A Member 2 | APBA2 | Adapter Protein X11beta | Mint-2 | Munc18-1-Interacting Protein 2 | Neuron-Specific X11L Protein | Neuronal Munc18-1-Interacting Protein 2 | X11-Like Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538728","APBA3 wt Allele","C104849","Human APBA3 wild-type allele is located in the vicinity of 19p13.3 and is approximately 11 kb in length. This allele, which encodes amyloid beta A4 precursor protein-binding family A member 3 protein, plays a role in amyloid beta A4 precursor protein binding.","APBA3 wt Allele | Amyloid Beta (A4) Precursor Protein-Binding, Family A, Member 3 wt Allele | MGC:15815 | X11L2 | mint3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642106","ADCS-ADL - Write Things Down","C105327","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, did the subject ever write things down?","ADCS-ADL - Write Things Down | ADL01-Write Things Down | ADL0121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642107","ADCS-ADL - Description of Most Complicated Writings","C105328","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) If yes, which best describes the most complicated things that he/she wrote.","ADCS-ADL - Description of Most Complicated Writings | ADL01-Most Complicated Writings | ADL0121A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642108","ADCS-ADL - Perform Pastime, Hobby or Game","C105329","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, did the subject perform a pastime, hobby or game?","ADCS-ADL - Perform Pastime, Hobby or Game | ADL01-Perform Pastime | ADL0122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642109","ADCS-ADL - Pastime: Card or Board Games","C105330","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Which pastimes did he/she perform: Card or board games.","ADCS-ADL - Pastime: Card or Board Games | ADL01-Pastime: Card or Board Games | ADL0122A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642110","ADCS-ADL - Pastime: Bingo","C105331","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Which pastimes did he/she perform: bingo.","ADCS-ADL - Pastime: Bingo | ADL01-Pastime: Bingo | ADL0122B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642112","ADCS-ADL - Pastime: Art","C105333","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Which pastimes did he/she perform: art.","ADCS-ADL - Pastime: Art | ADL01-Pastime: Art | ADL0122D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642113","ADCS-ADL - Pastime: Musical Instrument","C105334","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Which pastimes did he/she perform: musical instrument.","ADCS-ADL - Pastime: Musical Instrument | ADL01-Pastime: Musical Instrument | ADL0122E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642114","ADCS-ADL - Pastime: Knitting","C105335","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Which pastimes did he/she perform: knitting.","ADCS-ADL - Pastime: Knitting | ADL01-Pastime: Knitting | ADL0122F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642115","ADCS-ADL - Pastime: Sewing","C105336","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Which pastimes did he/she perform: sewing.","ADCS-ADL - Pastime: Sewing | ADL01-Pastime: Sewing | ADL0122G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642116","ADCS-ADL - Pastime: Reading","C105337","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Which pastimes did he/she perform: reading.","ADCS-ADL - Pastime: Reading | ADL01-Pastime: Reading | ADL0122H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642117","ADCS-ADL - Pastime: Gardening","C105338","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Which pastimes did he/she perform: gardening.","ADCS-ADL - Pastime: Gardening | ADL01-Pastime: Gardening | ADL0122I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642118","ADCS-ADL - Pastime: Golf","C105339","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Which pastimes did he/she perform: golf.","ADCS-ADL - Pastime: Golf | ADL01-Pastime: Golf | ADL0122J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280991","melphalan/vincristine","C10533","A regimen consisting of vincristine and melphalan that may be used in combination with irradiation and combination in the treatment of pediatric metastatic rhabdomyosarcoma.","VM Regimen | L-PAM/VCR | Melphalan-Vincristine | Melphalan/Vincristine | VM | Vincristine-Melphalan | Vincristine/Melphalan | Vincristine/Melphalan Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642119","ADCS-ADL - Pastime: Tennis","C105340","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Which pastimes did he/she perform: tennis.","ADCS-ADL - Pastime: Tennis | ADL01-Pastime: Tennis | ADL0122K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538852","Pre-B-Cell Leukemia Transcription Factor-Interacting Protein 1, Human","C104733","Pre-B-cell leukemia transcription factor-interacting protein 1 (731 aa, ~81 kDa) is encoded by the human PBXIP1 gene. This protein plays a role in the repression of gene transcription.","Pre-B-Cell Leukemia Transcription Factor-Interacting Protein 1 | Hematopoietic PBX-Interacting Protein | Hematopoietic PBX1-Interacting Protein1 | PBX Homeobox-Interacting Protein 1 | PBXIP1 | Pre-B-Cell Leukemia Transcription Factor Interacting Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL445808","WT1 235-243 Peptide Vaccine","C104734","A synthetic peptide vaccine consisting of a HLA-A24-restricted human Wilms' Tumor protein-1 (WT1) peptide comprised of amino acids 235 through 243, a MHC class I-restricted peptide, with potential immunomodulating and antitumor activities. Vaccination with WT1 235-243 peptide may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation. WT1, a zinc finger DNA-binding protein, is overexpressed in most types of leukemia and in a variety of solid cancers.","WT1 235-243 Peptide Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438310","Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine","C103830","A recombinant chaperone-peptide complex-based vaccine composed of a complex between heat shock protein hsp110 and the human melanoma-associated antigen gp100, with potential antineoplastic activity. Upon vaccination, recombinant hsp110-gp100 chaperone complex activates the immune system to exert a cytotoxic T cell immune response and antigen-specific interferon-gamma production against gp100-overexpressing cancer cells. Gp100, is overexpressed in a variety of cancer cell types. Hsp110, binds to and chaperones full-length proteins during heat shock; as an immunoadjuvant it is able to enhance an immune response against antigen(s) and stimulate T-lymphocyte activation.","Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0966387","Fluorine F 18 FMDHT","C103831","A radioconjugate containing a derivative of the androgen testosterone (FMDHT) and labeled with the radioisotope fluorine F 18, with potential use as an imaging agent for positron emission tomography (PET). Upon administration, fluorine F 18 FMDHT binds to the androgen receptor (AR). Upon PET imaging, AR-expressing prostate tumor cells can be imaged and assessed.","Fluorine F 18 FMDHT | 18F FMDHT | [7Alpha-18F]fluoro-17alpha-methyl-5alpha-dihydrotestosterone | [F-18] FMDHT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540471","CD69 wt Allele","C104075","Human CD69 wild-type allele is located in the vicinity of 12p13 and is approximately 8 kb in length. This allele, which encodes early activation antigen CD69 protein, is involved in T-cell proliferation and signal transduction in natural killer cells and platelets.","CD69 wt Allele | AIM | AIM/CD69 | BL-AC/P26 | C-type Lectin Domain Family 2, Member C Gene | CD69 | CD69 Antigen (p60, Early T-Cell Activation Antigen) Gene | CD69 Molecule wt Allele | CLEC2C | EA1 | GP32/28 | MLR-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2744535","Early Activation Antigen CD69, Human","C104076","Early activation antigen CD69 (199 aa, ~23 kDa) is encoded by the human CD69 gene. This protein plays a role in signal transduction in natural killer cells and platelets.","Early Activation Antigen CD69 | AIM | Activation Inducer Molecule | C-type Lectin Domain Family 2 Member C | CD69 Antigen | CD69 Molecule | EA1 | Early Lymphocyte Activation Antigen | Early T-Cell Activation Antigen p60 | GP32/28 | Leukocyte Surface Antigen Leu-23 | MLR-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538888","CD70 wt Allele","C104078","Human CD70 wild-type allele is located in the vicinity of 19p13 and is approximately 8 kb in length. This allele, which encodes CD70 antigen protein, plays a role in T-cell activation and proliferation.","CD70 wt Allele | CD27L | CD27LG | CD70 | CD70 Molecule wt Allele | TNFSF7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1664176","CD70 protein, human","C104079","CD70 antigen (193 aa, ~21 kDa) is encoded by the human CD70 gene. This protein is involved in T-cell activation and proliferation and may also play a role in B-cell activation.","CD70 Antigen | CD27 Ligand | CD27L | CD70 Molecule | Ki-24 Antigen | Surface Antigen CD70 | TNFSF7 | Tumor Necrosis Factor (Ligand) Superfamily, Member 7 | Tumor Necrosis Factor Ligand Superfamily Member 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540634","NDRG2 wt Allele","C104085","Human NDRG2 wild-type allele is located in the vicinity of 14q11.2 and is approximately 54 kb in length. This allele, which encodes protein NDRG2, plays a role in the modulation of both Wnt signaling pathways and cell differentiation.","NDRG2 wt Allele | KIAA1248 | NDRG Family Member 2 wt Allele | SYLD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539717","Protein NDRG2","C104086","Protein NDRG2 (371 aa, ~41 kDa) is encoded by the human NDRG2 gene. This protein is involved in both dendritic cell differentiation and Wnt signaling.","Protein NDRG2 | N-myc Downstream-Regulated Gene 2 Protein | NDRG2 | Protein Syld709613",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537336","Amyloid Beta A4 Precursor Protein-Binding Family A Member 3, Human","C104850","Amyloid beta A4 precursor protein-binding family A member 3 (575 aa, ~61 kDa) is encoded by the human APBA3 gene. This protein is involved in the regulation of amyloid beta A4 precursor protein proteolysis.","Amyloid Beta A4 Precursor Protein-Binding Family A Member 3 | APBA3 | Adapter Protein X11gamma | Mint-3 | Munc18-1-Interacting Protein 3 | Neuron-Specific X11L2 Protein | Neuronal Munc18-1-Interacting Protein 3 | X11-Like 2 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539528","GGTB2 protein, human","C104853","Beta-1,4-galactosyltransferase 1 (398 aa, ~44 kDa) is encoded by the human B4GALT1 gene. This protein plays a role in the biosynthesis of lactose.","Beta-1,4-Galactosyltransferase 1 | B4GALT1 | Beta-1,4-GalTase 1 | Beta4Gal-T1 | EC 2.4.1.- | Glycoprotein-4-Beta-Galactosyltransferase 2 | UDP-Gal:Beta-GlcNAc Beta-1,4-Galactosyltransferase 1 | UDP-Galactose:Beta-N-Acetylglucosamine Beta-1,4-Galactosyltransferase 1 | b4Gal-T1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1571584","SLC4A1 protein, human","C105066","Band 3 anion transport protein (911 aa, ~102 kDa) is encoded by the human SLC4A1 gene. This protein plays a role in chloride/bicarbonate exchange.","Band 3 Anion Transport Protein | Anion Exchange Protein 1 | Anion Exchanger 1 | Anion Exchanger-1 | CD233 Antigen | Erythrocyte Membrane Protein Band 3 | Erythroid Anion Exchange Protein | Froese Blood Group | SLC4A1 | Solute Carrier Family 4 Member 1 | Solute Carrier Family 4, Anion Exchanger, Number 1 | Swann Blood Group | Waldner Blood Group | Wright Blood Group",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539534","SLC4A3 wt Allele","C105068","Human SLC4A3 wild-type allele is located in the vicinity of 2q36 and is approximately 15 kb in length. This allele, which encodes anion exchange protein 3, plays a role in chloride/bicarbonate exchange in cardiac myocytes.","SLC4A3 wt Allele | AE 3 | AE3 | CAE3/BAE3 | SLC2C | Solute Carrier Family 4, Anion Exchanger, Member 3 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1455357","SLC4A3 protein, human","C105069","Anion exchange protein 3 (1232 aa, ~136 kDa) is encoded by the human SLC4A3 gene. This protein is involved in chloride/bicarbonate exchange in cardiac myocytes.","Anion Exchange Protein 3 | Anion Exchanger 3 | Anion Exchanger 3, Neuronal | Cardiac/Brain Band 3-Like Protein | Neuronal Band 3-Like Protein | Solute Carrier Family 4 Member 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540632","SLC18A2 wt Allele","C105071","Human SLC18A2 wild-type allele is located in the vicinity of 10q25 and is approximately 38 kb in length. This allele, which encodes synaptic vesicular amine transporter protein, is involved in the subcellular localization of neurotransmitters.","SLC18A2 wt Allele | SVAT | SVMT | Solute Carrier Family 18 (Vesicular Monoamine), Member 2 wt Allele | VAT2 | VMAT2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539788","Synaptic Vesicular Amine Transporter","C105072","Synaptic vesicular amine transporter (514 aa, ~56 kDa) is encoded by the human SLC18A2 gene. This protein plays a role in pumping monoamine neurotransmitters into synaptic vesicles.","Synaptic Vesicular Amine Transporter | Monoamine Transporter | SLC18A2 | Solute Carrier Family 18 Member 2 | VAT2 | Vesicle Monoamine Transporter Type 2 | Vesicle Monoamine/H+ Antiporter | Vesicular Amine Transporter 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539712","CELF2 wt Allele","C104685","Human CELF2 wild-type allele is located in the vicinity of 10p13 and is approximately 331 kb in length. This allele, which encodes CUGBP Elav-like family member 2 protein, is involved in both RNA metabolism and heart contraction.","CELF2 wt Allele | BRUNOL3 | CUGBP, Elav-Like Family Member 2 wt Allele | CUGBP2 | ETR-3 | ETR3 | NAPOR | NAPOR-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537342","CUGBP Elav-Like Family Member 2, Human","C104686","CUGBP Elav-like family member 2 (508 aa, ~54 kDa) is encoded by the human CELF2 gene. This protein plays a role in both heart contraction and RNA processing.","CUGBP Elav-Like Family Member 2 | Bruno-Like Protein 3 | CELF-2 | CELF2 | CUG Triplet Repeat RNA-Binding Protein 2 | CUG Triplet Repeat, RNA Binding Protein 2 | CUG Triplet Repeat, RNA-Binding Protein 2 | CUG-BP- and ETR-3-Like Factor 2 | CUG-BP2 | ELAV-Type Rna-Binding Protein 3 | ETR-3 | Neuroblastoma Apoptosis-Related RNA-Binding Protein | RNA-Binding Protein BRUNOL-3 | hNAPOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539695","MEIS2 wt Allele","C104688","Human MEIS2 wild-type allele is located in the vicinity of 15q14 and is approximately 212 kb in length. This allele, which encodes homeobox protein Meis2, plays a role in transcriptional regulation.","MEIS2 wt Allele | HsT18361 | MRG1 | Meis (Mouse) Homolog 2 Gene | Meis Homeobox 2 wt Allele | Meis Homolog 2 Gene | Meis1, Myeloid Ecotropic Viral Integration Site 1 Homolog 2 Gene | Meis1-Related Gene 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542427","Homeobox Protein Meis2","C104689","Homeobox protein Meis2 (477 aa, ~52 kDa) is encoded by the human MEIS2 gene. This protein is involved in the modulation of gene transcription.","Homeobox Protein Meis2 | MEIS2 | Meis1-Related Protein 1 | TALE Homeobox Protein Meis2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540480","NFYA wt Allele","C104691","Human NFYA wild-type allele is located in the vicinity of 6p21.3 and is approximately 29 kb in length. This allele, which encodes nuclear transcription factor Y subunit alpha protein, is involved in binding to the CCAAT motif in gene promoters.","NFYA wt Allele | CBF-A | CBF-B | HAP2 | NF-YA | Nuclear Transcription Factor Y, Alpha wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537354","Nuclear Transcription Factor Y Subunit Alpha","C104692","Nuclear transcription factor Y subunit alpha (347 aa, ~37 kDa) is encoded by the human NFYA gene. This protein plays a role in both transcriptional regulation and gene promoter binding.","Nuclear Transcription Factor Y Subunit Alpha | CAAT Box DNA-Binding Protein Subunit A | CAAT-Box DNA Binding Protein Subunit A | CCAAT-Binding Transcription Factor Subunit B | HAP2 CCAAT-Binding Protein | NF-YA | NFYA | Nuclear Transcription Factor Y Subunit A | Transcription Factor NF-Y, A Subunit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540550","STRA6 wt Allele","C104694","Human STRA6 wild-type allele is located in the vicinity of 15q24.1 and is approximately 33 kb in length. This allele, which encodes stimulated by retinoic acid gene 6 protein homolog, plays a role in both retinol metabolism and organ development. Mutation of the gene is associated with both syndromic microphthalmia type 9 and isolated colobomatous microphthalmia.","STRA6 wt Allele | FLJ12541 | MCOPCB8 | MCOPS9 | PP14296 | Stimulated By Retinoic Acid 6 wt Allele | Stimulated By Retinoic Acid Gene 6 Homolog (Mouse) Gene | UNQ3126/PRO10282/PRO19578",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539791","Stimulated By Retinoic Acid Gene 6 Protein Homolog","C104695","Stimulated by retinoic acid gene 6 protein homolog (667 aa, ~74 kDa) is encoded by the human STRA6 gene. This protein is involved in retinoid metabolism.","Stimulated By Retinoic Acid Gene 6 Protein Homolog | STRA6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539635","HDAC10 wt Allele","C104507","Human HDAC10 wild-type allele is located in the vicinity of 22q13.31 and is approximately 6 kb in length. This allele, which encodes histone deacetylase 10 protein, is involved in both transcriptional regulation and histone deacetylation.","HDAC10 wt Allele | HD10 | Histone Deacetylase 10 wt Allele | RP3-402G11.7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539593","HDAC10 protein, human","C104508","Histone deacetylase 10 (669 aa, ~71 kDa) is encoded by the human HDAC10 gene. This protein plays a role in both the deacetylation of histones and transcriptional regulation.","Histone Deacetylase 10 | EC 3.5.1.98 | HD10 | HDAC10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539749","MAGEA1 wt Allele","C104510","Human MAGEA1 wild-type allele is located in the vicinity of Xq28 and is approximately 6 kb in length. This allele, which encodes melanoma-associated antigen 1 protein, may be involved in embryonal development, tumor transformation, or tumor progression.","MAGEA1 wt Allele | CT1.1 | MAGE1 | MGC9326 | Melanoma Antigen Family A, 1 (Directs Expression of Antigen MZ2-E) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1456426","Melanoma-Associated Antigen 1, Human","C104511","Melanoma-associated antigen 1 (309 aa, ~34 kDa) is encoded by the human MAGEA1 gene. This protein may play a role in embryonal development, tumor transformation, or tumor progression.","Melanoma-Associated Antigen 1 | Cancer/Testis Antigen 1.1 | Cancer/Testis Antigen Family 1, Member 1 | MAGE-1 Antigen | MAGE-A1 | MAGEA1 | Melanoma Antigen Family A 1 | Melanoma Antigen MAGE-1 | Melanoma-Associated Antigen MZ2-E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537322","Endothelial Cell-Specific Molecule 1, Human","C104089","Endothelial cell-specific molecule 1 (184 aa, ~20 kDa) is encoded by the human ESM1 gene. This protein may play a role in the modulation of leukocyte-endothelial cell interactions.","Endothelial Cell-Specific Molecule 1 | ESM-1 | ESM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641431","NPI - Disinhibition Distress","C103625","Neuropsychiatric Inventory (NPI) Disinhibition: How emotionally distressing do you find this behavior?","NPI - Disinhibition Distress | NPI1-Disinhibition Distress | NPI1H10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641432","NPI - Irritability/Lability Frequency","C103626","Neuropsychiatric Inventory (NPI) Frequency of the irritability/lability.","NPI - Irritability/Lability Frequency | NPI1-Irritability/Lability Frequency | NPI1I08",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641433","NPI - Irritability/Lability Severity","C103627","Neuropsychiatric Inventory (NPI) Severity of the irritability/lability.","NPI - Irritability/Lability Severity | NPI1-Irritability/Lability Severity | NPI1I09",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641434","NPI - Irritability/Lability Distress","C103628","Neuropsychiatric Inventory (NPI) Irritability/Lability: How emotionally distressing do you find this behavior?","NPI - Irritability/Lability Distress | NPI1-Irritability/Lability Distress | NPI1I10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641435","NPI - Aberrant Motor Behavior Frequency","C103629","Neuropsychiatric Inventory (NPI) Frequency of the aberrant motor behavior.","NPI - Aberrant Motor Behavior Frequency | NPI1-Aberrant Motor Behavior Frequency | NPI1J08",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641436","NPI - Aberrant Motor Behavior Severity","C103630","Neuropsychiatric Inventory (NPI) Severity of the aberrant motor behavior.","NPI - Aberrant Motor Behavior Severity | NPI1-Aberrant Motor Behavior Severity | NPI1J09",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641437","NPI - Aberrant Motor Behavior Distress","C103631","Neuropsychiatric Inventory (NPI) Aberrant Motor Behavior: How emotionally distressing do you find this behavior?","NPI - Aberrant Motor Behavior Distress | NPI1-Aberrant Motor Behavior Distress | NPI1J10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641438","NPI - Sleep and Nighttime Behavior Disorders Frequency","C103632","Neuropsychiatric Inventory (NPI) Frequency of the nighttime behavior.","NPI - Sleep and Nighttime Behavior Disorders Frequency | NPI1-Sleep/Nighttime Behavior Frequency | NPI1K09",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641440","NPI - Sleep and Nighttime Behavior Disorders Distress","C103634","Neuropsychiatric Inventory (NPI) Sleep and Nighttime Behavior Disorders: How emotionally distressing do you find this behavior?","NPI - Sleep and Nighttime Behavior Disorders Distress | NPI1-Sleep/Nighttime Behavior Distress | NPI1K11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641441","NPI - Appetite and Eating Disorders Frequency","C103635","Neuropsychiatric Inventory (NPI) Frequency of the changes in eating habits or appetite.","NPI - Appetite and Eating Disorders Frequency | NPI1-Appetite/Eating Disorder Frequency | NPI1L09",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641442","NPI - Appetite and Eating Disorders Severity","C103636","Neuropsychiatric Inventory (NPI) Severity of the changes in eating habits or appetite.","NPI - Appetite and Eating Disorders Severity | NPI1-Appetite/Eating Disorder Severity | NPI1L10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641443","NPI - Appetite and Eating Disorders Distress","C103637","Neuropsychiatric Inventory (NPI) Appetite and Eating Disorders: How emotionally distressing do you find this behavior?","NPI - Appetite and Eating Disorders Distress | NPI1-Appetite/Eating Disorder Distress | NPI1L11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641444","NPS - Tell Us How Intense Your Pain Is","C103638","Neuropathic Pain Scale (NPS) Please use the scale below to tell us how intense your pain is.","NPS - Tell Us How Intense Your Pain Is | NPS01-Tell Us How Intense Your Pain Is | NPS0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541280","SLC22A1 wt Allele","C105074","Human SLC22A1 wild-type allele is located in the vicinity of 6q25.3 and is approximately 37 kb in length. This allele, which encodes solute carrier family 22 member 1 protein, plays a role in the transport of organic cations.","SLC22A1 wt Allele | HOCT1 | OCT1 | Solute Carrier Family 22 (Organic Cation Transporter), Member 1 wt Allele | oct1_cds",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0291786","Organic Cation Transporter 1","C105075","Solute carrier family 22 member 1 (554 aa, ~61 kDa) is encoded by the human SLC22A1 gene. This protein is involved in bidirectional cation transport.","Solute Carrier Family 22 Member 1 | Organic Cation Transporter 1 | SLC22A1 | hOCT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542927","SOST wt Allele","C105077","Human SOST wild-type allele is located in the vicinity of 17q11.2 and is approximately 5 kb in length. This allele, which encodes sclerostin protein, is involved in the negative regulation of ossification. Mutation of the gene is associated with bone dysplasias including sclerosteosis type 1, van Buchem disease and craniodiaphyseal dysplasia autosomal dominant.","SOST wt Allele | CDD | Sclerosteosis Gene | Sclerostin wt Allele | UNQ2976/PRO7455/PRO7476 | VBCH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542926","Sclerostin","C105078","Sclerostin (213 aa, ~24 kDa) is encoded by the human SOST gene. This protein plays a role in the regulation of bone growth and Wnt signaling pathways.","Sclerostin | SOST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642063","ADCS-ADL - Description of Optimal Performance of Walking","C105284","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Regarding walking (or getting around in a wheelchair), in the past 4 weeks, which best describes his/her optimal performance.","ADCS-ADL - Description of Optimal Performance of Walking | ADL01-Optimal Walking Performance | ADL0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642064","ADCS-ADL - Usual Bowel and Bladder Function at Toilet","C105285","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Regarding bowel and bladder function at the toilet, which best describes his/her usual performance in the past 4 weeks.","ADCS-ADL - Usual Bowel and Bladder Function at Toilet | ADL01-Usual Bowel/Bladder Function | ADL0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642065","ADCS-ADL - Description of Usual Performance of Bathing","C105286","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Regarding bathing, in the past 4 weeks, which best describes his/her usual performance.","ADCS-ADL - Description of Usual Performance of Bathing | ADL01-Usual Bathing Performance | ADL0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642066","ADCS-ADL - Description of Optimal Performance of Grooming","C105287","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Regarding grooming, in the past 4 weeks, which best describes his/her optimal performance.","ADCS-ADL - Description of Optimal Performance of Grooming | ADL01-Optimal Grooming Performance | ADL0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642067","ADCS-ADL - Select First Clothes for the Day","C105288","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Regarding dressing in the past 4 weeks: Did the subject select his/her first set of clothes for the day?","ADCS-ADL - Select First Clothes for the Day | ADL01-Select First Clothes for the Day | ADL0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642068","ADCS-ADL - Description of Usual Performance of Dressing","C105289","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) If yes, which best describes usual performance.","ADCS-ADL - Description of Usual Performance of Dressing | ADL01-Usual Dressing Performance | ADL0106A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538891","TOB2 wt Allele","C104697","Human TOB2 wild-type allele is located in the vicinity of 22q13.2 and is approximately 14 kb in length. This allele, which encodes protein Tob2, is involved in both cell cycle arrest and the negative regulation of cell proliferation.","TOB2 wt Allele | CTA-223H9.7 | KIAA1663 | TOB4 | TOBL | TROB2 | Transducer of ERBB2, 2 wt Allele | bK223H9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0055390","Chloroaluminum Phthalocyanine","C1048","A rhodamine-based dye used as a photosensitizing agent in cytotoxic photodynamic therapy. (NCI)","Chloroaluminum Phthalocyanine | AlSPc | Aluminum Sulfonated Phthalocyanine | Non-Sulfonated Chloroaluminum Phthalocyanine | Sulfonated Aluminum Phthalocyanine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538791","PSMG2 wt Allele","C104900","Human PSMG2 wild-type allele is located in the vicinity of 18p11.21 and is approximately 23 kb in length. This allele, which encodes proteasome assembly chaperone 2 protein, plays a role in promoting assembly of the 20S proteasome.","PSMG2 wt Allele | CLAST3 | HCCA3 | HDCMC29P | HSPC260 | HsT1707 | MDS003 | MGC15092 | PAC-2 | PAC2 | Proteasome (Prosome, Macropain) Assembly Chaperone 2 wt Allele | TNFSF5IP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541262","Proteasome Assembly Chaperone 2, Human","C104901","Proteasome assembly chaperone 2 (264 aa, ~29 kDa) is encoded by the human PSMG2 gene. This protein plays a role in promoting assembly of the 20S proteasome.","Proteasome Assembly Chaperone 2 | CD40 Ligand-Activated Specific Transcript 3 | Hepatocellular Carcinoma Susceptibility Protein | Hepatocellular Carcinoma-Susceptibility Protein | Likely Ortholog of Mouse CD40 Ligand-Activated Specific Transcript 3 (Clast3) | PSMG2 | Proteasome (Prosome, Macropain) Assembly Chaperone 2 | Proteasome Assembling Chaperone 2 | Tumor Necrosis Factor Superfamily, Member 5-Induced Protein 1 | X 003 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541987","STRA8 wt Allele","C104904","Human STRA8 wild-type allele is located in the vicinity of 7q33 and is approximately 27 kb in length. This allele, which encodes stimulated by retinoic acid gene 8 protein, may play a role in spermatogenesis.","STRA8 wt Allele | Stimulated by Retinoic Acid 8 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1436114","Stimulated by Retinoic Acid Gene 8 Protein, Human","C104905","Stimulated by retinoic acid gene 8 protein (330 aa, ~37 kDa) is encoded by the human STRA8 gene. This protein may be involved in spermatogenesis.","Stimulated by Retinoic Acid Gene 8 Protein | Stimulated by Retinoic Acid Gene 8 Homolog (Mouse) | Stimulated by Retinoic Acid Gene 8 Protein Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641882","Radio Beacon Transponder System","C104907","A tracking system that monitors the position of the target organ or tissue in real-time in order to spare surrounding tissues from radiation exposure during treatment.","Radio Beacon Transponder System | RF Beacons",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538794","MAGEA4 wt Allele","C104513","Human MAGEA4 wild-type allele is located in the vicinity of Xq28 and is approximately 13 kb in length. This allele, which encodes melanoma-associated antigen 4 protein, may play a role in embryonal development, tumor transformation, or tumor progression.","MAGEA4 wt Allele | CT1.4 | MAGE-41 | MAGE-X2 | MAGE4 | MAGE4A | MAGE4B | MGC21336 | Melanoma Antigen Family A, 4 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539668","TNFRSF10C wt Allele","C104516","Human TNFRSF10C wild-type allele is located within 8p22-p21 and is approximately 48 kb in length. This allele, which encodes tumor necrosis factor receptor superfamily member 10C protein, plays a role in both apoptosis inhibition and ligand binding.","TNFRSF10C wt Allele | CD263 | DCR1 | DCR1-TNFR | LIT | TRAIL-R3 | TRAILR3 | TRID | Tumor Necrosis Factor Receptor Superfamily, Member 10c, Decoy without an Intracellular Domain wt Allele | UNQ321/PRO366",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542971","MAGEA6 wt Allele","C104518","Human MAGEA6 wild-type allele is located in the vicinity of Xq28 and is approximately 4 kb in length. This allele, which encodes melanoma-associated antigen 6 protein, may enhance ubiquitin ligase activity.","MAGEA6 wt Allele | MAGE-3b | MAGE3B | Melanoma Antigen Family A, 6 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1438062","Melanoma-Associated Antigen 6","C104519","Melanoma-associated antigen 6 (314 aa, ~35 kDa) is encoded by the human MAGEA6 gene. This protein may enhance ubiquitin ligase activity.","Melanoma-Associated Antigen 6 | Cancer/Testis Antigen 1.6 | Cancer/Testis Antigen Family 1, Member 6 | MAGE-6 Antigen | MAGE-A6 | MAGE3B Antigen | MAGEA6 | Melanoma Antigen Family A, 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1738873","Estradiol 17-Beta-Dehydrogenase 1, Human","C104037","Estradiol 17-beta-dehydrogenase 1 (328 aa, ~35 kDa) is encoded by the human HSD17B1 gene. This protein is involved in the conversion of both estrogens and androgens to their active intracellular forms.","Estradiol 17-Beta-Dehydrogenase 1 | 17-Beta-HSD 1 | 17-Beta-HSD I | 17-Beta-Hydroxysteroid Dehydrogenase I | 17-Beta-Hydroxysteroid Dehydrogenase Type 1 | 20 Alpha-Hydroxysteroid Dehydrogenase | 20-alpha-HSD | E2DH | Estradiol 17-Beta-Dehydrogenase-1 | HSD17B1 | Hydroxysteroid (17-Beta) Dehydrogenase 1 Isoform | Placental 17-Beta-Hydroxysteroid Dehydrogenase | Short Chain Dehydrogenase/Reductase Family 28CE, Member 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539564","BCL2A1 wt Allele","C104039","Human BCL2A1 wild-type allele is located in the vicinity of 15q24.3 and is approximately 14 kb in length. This allele, which encodes Bcl-2-related protein A1, is involved in the down-regulation of apoptosis and mediation of the inflammatory response.","BCL2A1 wt Allele | ACC-1 | ACC-2 | BCL2-Related Protein A1 wt Allele | BCL2L5 | BFL1 | GRS | HBPA1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0527108","BCL2-related protein A1, human","C104040","Bcl-2-related protein A1 (175 aa, ~20 kDa) is encoded by the human BCL2A1 gene. This protein plays a role in the regulation of inflammation.","BCL-2-Related Protein A1 | BCL-2-Like Protein 5 | BCL2-L-5 | BCL2-Related Protein A1 | BCL2-Related Protein A1 | BCL2A1 | BFL1 Protein | Hematopoietic BCL2-Related Protein A1 | Hemopoietic-Specific Early Response Protein | Potein BFL-1 | Protein GRS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641445","NPS - Tell Us How Sharp Your Pain Feels","C103639","Neuropathic Pain Scale (NPS) Please use the scale below to tell us how sharp your pain feels. Words used to describe 'sharp' feelings include 'like a knife,' 'like a spike,' 'jabbing,' or 'like jolts.'","NPS - Tell Us How Sharp Your Pain Feels | NPS01-Tell Us How Sharp Your Pain Feels | NPS0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641446","NPS - Tell Us How Hot Your Pain Feels","C103640","Neuropathic Pain Scale (NPS) Please use the scale below to tell us how hot your pain feels. Words used to describe very hot pain include 'burning' and 'on fire.'","NPS - Tell Us How Hot Your Pain Feels | NPS01-Tell Us How Hot Your Pain Feels | NPS0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0082920","HLA-G antigen","C104327","HLA class I histocompatibility antigen, alpha chain G (338 aa, ~38 kDa) is encoded by the human HLA-G gene. This protein is involved in the mediation of antigen presentation and processing.","HLA Class I Histocompatibility Antigen, Alpha Chain G | HLA G Antigen | HLA-G | MHC Class I Antigen G | b2 Microglobulin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642069","ADCS-ADL - Description of Usual Performance of Physically Getting Dressed","C105290","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Regarding physically getting dressed, which best describes his/her usual performance in the past 4 weeks.","ADCS-ADL - Description of Usual Performance of Physically Getting Dressed | ADL01-Usual Physically Dressing Perform | ADL0106B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642070","ADCS-ADL - Use a Telephone","C105291","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, did the subject use a telephone?","ADCS-ADL - Use a Telephone | ADL01-Use a Telephone | ADL0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642071","ADCS-ADL - Description of Highest Performance of Telephone Use","C105292","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) If yes, which best describes his/her highest level of performance.","ADCS-ADL - Description of Highest Performance of Telephone Use | ADL01-Highest Telephone Use Performance | ADL0107A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642072","ADCS-ADL - Watch Television","C105293","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, did the subject watch television?","ADCS-ADL - Watch Television | ADL01-Watch Television | ADL0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642073","ADCS-ADL - Select or Ask for Television Program","C105294","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Did the subject usually select or ask for different programs or his/her favorite show?","ADCS-ADL - Select or Ask for Television Program | ADL01-Select Television Program | ADL0108A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642075","ADCS-ADL - Talk About TV Content Within a Day After Watching","C105296","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Did the subject talk about the content of a program within a day (24 hours) after watching it?","ADCS-ADL - Talk About TV Content Within a Day After Watching | ADL01-Talk About TV Content Within a Day | ADL0108C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642076","ADCS-ADL - Pay Attention to Conversation","C105297","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, did the subject ever appear to pay attention to conversation or small talk for at least 5 minutes?","ADCS-ADL - Pay Attention to Conversation | ADL01-Pay Attention to Conversation | ADL0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540820","CAPG wt Allele","C104640","Human CAPG wild-type allele is located in the vicinity of 2p11.2 and is approximately 24 kb in length. This allele, which encodes macrophage-capping protein, plays a role in actin-based motility in non-muscle cells.","CAPG wt Allele | AFCP | Capping Protein (Actin Filament), Gelsolin-Like wt Allele | MCP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1429585","Macrophage-Capping Protein","C104641","Macrophage-capping protein (348 aa, ~39 kDa) is encoded by the human CAPG gene. This protein is involved in actin-based motility in non-muscle cells.","Macrophage-Capping Protein | Actin Regulatory Protein CAP-G | Actin-Regulatory Protein CAP-G | Gelsolin-Like Capping Protein | Macrophage Capping Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539646","MDC1 wt Allele","C104643","Human MDC1 wild-type allele is located in the vicinity of 6p21.3 and is approximately 18 kb in length. This allele, which encodes mediator of DNA damage checkpoint protein 1, is involved in checkpoint mediated cell cycle arrest.","MDC1 wt Allele | Em:AB023051.5 | KIAA0170 | Mediator of DNA Damage Checkpoint 1 wt Allele | Mediator of DNA-Damage Checkpoint 1 Gene | NFBD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537382","Mediator of DNA Damage Checkpoint Protein 1, Human","C104644","Mediator of DNA damage checkpoint protein 1 (2089 aa, ~227 kDa) is encoded by the human MDC1 gene. This protein plays a role in checkpoint mediated cell cycle arrest.","Mediator of DNA Damage Checkpoint Protein 1 | Homolog to Drosophila Photoreceptor Protein Calphotin | MDC1 | Mediator of DNA Damage Checkpoint 1 | Nuclear Factor with BRCT Domains 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539603","CHPT1 wt Allele","C104911","Human CHPT1 wild-type allele is located within 12q and is approximately 47 kb in length. This allele, which encodes cholinephosphotransferase 1 protein, is involved in phosphatidylcholine metabolism.","CHPT1 wt Allele | CPT | CPT1 | Choline Phosphotransferase 1 wt Allele | MSTP022",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539643","EIF4E wt Allele","C105124","Human EIF4E wild-type allele is located within 4q21-q25 and is approximately 59 kb in length. This allele, which encodes eukaryotic translation initiation factor 4E protein, plays a role in both mRNA cap recognition and ribosome recruitment.","EIF4E wt Allele | CBP | EIF4E1 | EIF4EL1 | EIF4F | Eukaryotic Translation Initiation Factor 4E wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0058988","Eukaryotic Initiation Factor-4E","C105125","Eukaryotic translation initiation factor 4E (217 aa, ~25 kDa) is encoded by the human EIF4E gene. This protein is involved in the initiation of mRNA translation.","Eukaryotic Translation Initiation Factor 4E | Eukaryotic Translation Initiation Factor 4E-Like 1 | eIF-4E | eIF-4F 25 kDa Subunit | eIF4E | mRNA Cap-Binding Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539708","MTRR wt Allele","C105127","Human MTRR wild-type allele is located in the vicinity of 5p15.31 and is approximately 55 kb in length. This allele, which encodes methionine synthase reductase protein, is involved in both B vitamin metabolism and methionine synthesis. Mutation of the gene is associated with both folate-sensitive neural tube defects and methylcobalamin deficiency type E.","MTRR wt Allele | 5-Methyltetrahydrofolate-Homocysteine Methyltransferase Reductase wt Allele | MSR | cblE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1453956","Methionine Synthase Reductase, Human","C105128","Methionine synthase reductase (725 aa, ~80 kDa) is encoded by the human MTRR gene. This protein plays a role in both methionine biosynthesis and B vitamin metabolism.","Methionine Synthase Reductase | 5-Methyltetrahydrofolate-Homocysteine Methyltransferase Reductase | EC 1.16.1.8 | MSR | MTRR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641925","CDISC Questionnaire DAD Test Name Terminology","C105129","Test names of questionnaire questions associated with the Disability Assessment for Dementia (DAD)for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire DAD Test Name Terminology | DAD01TN | Disability Assessment for Dementia Questionnaire Test Name | QS-DAD TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641926","CDISC Questionnaire DAD Test Code Terminology","C105130","Test codes of questionnaire questions associated with the Disability Assessment for Dementia (DAD)for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire DAD Test Code Terminology | DAD01TC | Disability Assessment for Dementia Questionnaire Test Code | QS-DAD TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641927","CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology","C105131","Test names of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale (C-SSRS) Baseline/Screening Version Phase 1 Study Version 1/14/09for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology | CSS03TN | Columbia-Suicide Severity Rating Scale Baseline/Screening Version Phase 1 Study Questionnaire Test Name | QS-C-SSRS BASELINE/SCREENING VERSION PHASE 1 STUDY TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541978","CAMK2N1 wt Allele","C104042","Human CAMK2N1 wild-type allele is located in the vicinity of 1p36.12 and is approximately 4 kb in length. This allele, which encodes calcium/calmodulin-dependent protein kinase II inhibitor 1 protein, plays a role in inhibition of calcium-dependent cell signaling.","CAMK2N1 wt Allele | Calcium/Calmodulin-Dependent Protein Kinase II Inhibitor 1 wt Allele | PRO1489 | RP11-401M16.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542913","Calcium/Calmodulin-Dependent Protein Kinase II Inhibitor 1","C104043","Calcium/calmodulin-dependent protein kinase II inhibitor 1 (78 aa, ~9 kDa) is encoded by the human CAMK2N1 gene. This protein is involved in inhibition of calcium-dependent cell signaling.","Calcium/Calmodulin-Dependent Protein Kinase II Inhibitor 1 | CAMK2N1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433840","ERK Inhibitor MK-8353","C104045","An orally available inhibitor of extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon oral administration, MK-8353 inhibits both ERK phosphorylation and activation of ERK-mediated signal transduction pathways; thereby, preventing ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is often upregulated in a variety of tumor cell types and plays a role in tumor cell proliferation, differentiation and survival.","ERK Inhibitor MK-8353 | MK-8353 | MK-8353-001 | SCH 900353",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541274","CTAG2 wt Allele","C104047","Human CTAG2 wild-type allele is located in the vicinity of Xq28 and is approximately 2 kb in length. This allele, which encodes cancer/testis antigen 2 protein, may be involved in tumorigenesis of melanomas, sarcomas, and other tumor types.","CTAG2 wt Allele | CAMEL | CTAG2 | Cancer/Testis Antigen 2 wt Allele | ESO2 | LAGE1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL439067","Itraconazole Dispersion In Polymer Matrix","C104048","A proprietary oral formulation composed of the poorly soluble, synthetic triazole agent, itraconazole, dispersed in a polymer matrix, with antifungal and potential anti-angiogenic activities. Upon oral administration, itraconazole inhibits the enzyme cytochrome P450 lanosterol 14 alpha-demethylase, resulting in a decrease in fungal ergosterol synthesis. Although the exact mechanism through which itraconazole inhibits angiogenesis has yet to be fully elucidated, this agent appears to inhibit the Hedgehog (Hh) signaling pathway, cholesterol synthesis and mammalian target of rapamycin (mTOR) signaling in endothelial cells. This agent may also prevent the activation of and signaling by various angiogenic growth factors. By decreasing the tumor vasculature and nutrient supply, itraconazole ultimately inhibits tumor cell growth. The solid dispersion of itraconazole in the polymer matrix enhances dissolution of itraconazole in the gastrointestinal tract and increases its bioavailability; this allows for the administration of a much lower dose compared to itraconazole alone.","Itraconazole Dispersion In Polymer Matrix | SUBA-Itraconazole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446652","Imalumab","C104260","A human, recombinant monoclonal antibody (MoAb) against macrophage migration inhibitory factor (MIF), with potential immunomodulating, anti-inflammatory and antineoplastic activities. Upon intravenous administration, imalumab binds to MIF, blocking its activity and preventing the MIF-mediated secretion of certain cytokines, including interleukin-1 beta and tumor necrosis factor-alpha. This may lead to an inhibition of cancer cell proliferation in MIF-overexpressing tumor cells. MIF, a pro-inflammatory cytokine overexpressed in some cancers, plays a key role in inflammation, immune responses and cancer cell proliferation.","Imalumab | BAX-69 | BAX069 | BAX69 | IMALUMAB | Immunoglobulin G1-kappa, Anti-(Homo sapiens MIF (Macrophage Migration Inhibitory Factor, Glycosylation-inhibiting Factor, GlIF, GIF)), Homo sapiens Monoclonal Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL445612","AK 3012","C104266","A proprietary topical formulation. Upon subcutaneous administration, the active ingredient in AK 3012 may inhibit actinic keratosis.","AK 3012 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1453599","Homeobox Protein Hox-A3","C104334","Homeobox protein Hox-A3 (443 aa, ~46 kDa) is encoded by the human HOXA3 gene. This protein plays a role in both the modulation of gene expression and anterior/posterior embryonic patterning.","Homeobox Protein Hox-A3 | HOXA3 | Homeo Box 1E | Homeo Box A3 | Homeobox Protein Hox-1E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438343","Autologous Bone Marrow-derived CD34/CXCR4-positive Stem Cells AMR-001","C103865","A cell-based product containing autologous bone marrow derived CD34 positive and C-X-C chemokine receptor type 4 (CXCR4) positive stem cells with potential antiapoptotic and proangiogenic activities. Upon intracoronary infusion after a myocardial infarction (MI), autologous bone marrow-derived CD34/CXCR4-positive stem cells may preserve cardiac muscle cells and prevent apoptosis; thus improving myocardial perfusion. CD34/CXCR4-positive stem cells are naturally mobilized upon cell injury through signaling by hypoxia inducing factor (HIF), which is secreted in response to hypoxia. In turn, HIF induces the synthesis of stromal-derived factor 1 (SDF-1) and vascular endothelial growth factor (VEGF) which mobilize CD34/CXCR4 positive stem cells; CXCR4 is the receptor for stromal-derived factor 1 (SDF-1).","Autologous Bone Marrow-derived CD34/CXCR4-positive Stem Cells AMR-001 | AMR-001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438344","High-titer RSV Immune Globulin RI-001","C103866","A plasma-derived, polyclonal, intravenous immunoglobulin formulation (IVIG) containing standardized high levels of antibodies against respiratory syncytial virus (RSV), a single-stranded, enveloped paramyxovirus, with potential immunomodulating activity. The high-titer RSV immune globulin RI-001 is derived from healthy donors with high amounts of RSV antibodies. Upon intravenous administration, the antibodies against RSV may provide passive immunization against RSV. This may prevent lower respiratory tract infections by RSV in immunocompromised patients. The polyclonal antibodies in RI-001 are able to target various viral epitopes.","High-titer RSV Immune Globulin RI-001 | RI-001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539650","MRC2 wt Allele","C104646","Human MRC2 wild-type allele is located in the vicinity of 17q23.2 and is approximately 66 kb in length. This allele, which encodes C-type mannose receptor 2, plays a role in extracellular matrix remodeling and may play a role in tumorigenesis and metastasis.","MRC2 wt Allele | CD280 | CLEC13E | ENDO180 | KIAA0709 | Mannose Receptor, C type 2 wt Allele | UPARAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0914341","Endo180","C104647","C-type mannose receptor 2 (1479 aa, ~167 kDa) is encoded by the human MRC2 gene. This protein is involved in remodeling of the extracellular matrix and may play a role in the tumorigenesis and metastasis.","C-Type Mannose Receptor 2 | C-Type Lectin Domain Family 13 Member E | CD280 Antigen | Endocytic Receptor (Macrophage Mannose Receptor Family) | Endocytic Receptor 180 | Macrophage Mannose Receptor 2 | UPAR-Associated Protein | Urokinase Receptor-Associated Protein | Urokinase-Type Plasminogen Activator Receptor-Associated Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540821","MICB wt Allele","C104649","Human MICB wild-type allele is located in the vicinity of 6p21.3 and is approximately 16 kb in length. This allele, which encodes MHC class I polypeptide-related sequence B protein, is involved in cytolytic activation of natural killer cells, CD8 alpha-beta T cells, and gamma-delta T cells.","MICB wt Allele | MHC Class I Polypeptide-Related Sequence B wt Allele | MIC-B | PERB11.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539750","MHC class I polypeptide-related sequence B protein, human","C104650","MHC class I polypeptide-related sequence B (383 aa, ~43 kDa) is encoded by the human MICB gene. This protein plays a role in activation of cytolysis by natural killer cells, CD8 alpha-beta T cells, and gamma-delta T cells.","MHC Class I Polypeptide-Related Sequence B | MIC-B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539751","MIB1 wt Allele","C104652","Human MIB1 wild-type allele is located in the vicinity of 18q11.2 and is approximately 130 kb in length. This allele, which encodes E3 ubiquitin-protein ligase MIB1 protein, plays a role in both ubiquitination and the regulation of Delta-mediated Notch signaling.","MIB1 wt Allele | DIP-1 | DIP1 | KIAA1323 | MIB | Mindbomb E3 Ubiquitin Protein Ligase 1 wt Allele | Mindbomb Homolog 1 (Drosophila) Gene | ZZANK2 | ZZZ6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1741198","E3 Ubiquitin-Protein Ligase MIB1, Human","C104653","E3 ubiquitin-protein ligase MIB1 (1006 aa, ~110 kDa) is encoded by the human MIB1 gene. This protein is involved in both ubiquitination and the regulation of Delta-mediated Notch signaling.","E3 Ubiquitin-Protein Ligase MIB1 | DAPK-Interacting Protein 1 | EC 2.3.2.27 | EC 6.3.2.-, Formerly | MIB1 | Mind Bomb Homolog 1 | Mindbomb Homolog 1 (Drosophila) | Ubiquitin Ligase Mind Bomb | Ubiquitin Ligase Protein MIB1 | Zinc Finger ZZ Type with Ankyrin Repeat Domain Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541984","SNURF wt Allele","C104855","Human SNURF wild-type allele is located in the vicinity of 15q12 and is approximately 45 kb in length. This allele, which encodes SNRPN upstream reading frame protein, may play a role in brain development. Splice variants or chromosomal translocation causing deletion of either the 5' untranslated region or the coding region of the gene is associated with either Angelman syndrome or Prader-Willi syndrome due to parental imprint switch failure.","SNURF wt Allele | SNRPN Upstream Reading Frame wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541315","SNRPN Upstream Reading Frame Protein, Human","C104856","SNRPN upstream reading frame protein (71 aa, ~8 kDa) is encoded by the human SNURF gene. This protein may be involved in the development of the brain.","SNRPN Upstream Reading Frame Protein | SNURF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539738","LGALS3 wt Allele","C104858","Human LGALS3 wild-type allele is located in the vicinity of 14q22.3 and is approximately 21 kb in length. This allele, which encodes galectin-3 protein, is involved in both carbohydrate recognition and immunity.","LGALS3 wt Allele | CBP35 | GAL3 | GALBP | GALIG | L31 | LGALS2 | Lectin, Galactoside-Binding, Soluble, 3 wt Allele | MAC-2 | MAC2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641928","CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology","C105132","Test codes of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale (C-SSRS) Baseline/Screening Version Phase 1 Study Version 1/14/09 for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology | CSS03TC | Columbia-Suicide Severity Rating Scale Baseline/Screening Version Phase 1 Study Questionnaire Test Code | QS-C-SSRS BASELINE/SCREENING VERSION PHASE 1 STUDY TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641929","CDISC Questionnaire PI v1 Test Name Terminology","C105133","Test names of questionnaire questions associated with the Pain Intensity (PI) version 1 for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire PI v1 Test Name Terminology | PI01TN | Pain Intensity Questionnaire Test Name | QS-PI TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641931","CDISC Questionnaire PR v1 Test Name Terminology","C105135","Test names of questionnaire questions associated with the Pain Relief (PR) version 1 for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire PR v1 Test Name Terminology | PR01TN | Pain Relief Questionnaire Test Name | QS-PR TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642121","ADCS-ADL - Pastime: Fishing","C105342","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Which pastimes did he/she perform: fishing.","ADCS-ADL - Pastime: Fishing | ADL01-Pastime: Fishing | ADL0122M",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642122","ADCS-ADL - Pastime: Other","C105343","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Which pastimes did he/she perform: other.","ADCS-ADL - Pastime: Other | ADL01-Pastime: Other | ADL0122N",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642123","ADCS-ADL - Pastime: Other Specify","C105344","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Which pastimes did he/she perform: other specify.","ADCS-ADL - Pastime: Other Specify | ADL01-Pastime: Other Specify | ADL0122O",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642124","ADCS-ADL - Performed Hobbies Only at Day Care","C105345","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) If the subject performs hobbies/pastimes only at day care, check here.","ADCS-ADL - Performed Hobbies Only at Day Care | ADL01-Hobbies Only at Day Care | ADL0122P",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642125","ADCS-ADL - Description of Usual Performance of Common Pastimes","C105346","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) If yes, how did the subject usually perform his/her most common pastimes.","ADCS-ADL - Description of Usual Performance of Common Pastimes | ADL01-Usual Common Pastimes Performance | ADL0122Q",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642126","ADCS-ADL - Use Household Appliance to do Chores","C105347","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, did the subject use a household appliance to do chores?","ADCS-ADL - Use Household Appliance to do Chores | ADL01-Use Household Appliance | ADL0123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642127","ADCS-ADL - Appliance: Washer","C105348","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Check all that were used: washer.","ADCS-ADL - Appliance: Washer | ADL01-Appliance: Washer | ADL0123A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642128","ADCS-ADL - Appliance: Dryer","C105349","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Check all that were used: dryer.","ADCS-ADL - Appliance: Dryer | ADL01-Appliance: Dryer | ADL0123B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642129","ADCS-ADL - Appliance: Vacuum","C105350","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Check all that were used: vacuum.","ADCS-ADL - Appliance: Vacuum | ADL01-Appliance: Vacuum | ADL0123C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL445613","pan FGFR inhibitor ARQ 087","C104267","An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. Derazantinib binds to and potently inhibits the activity of FGFR subtypes 1, 2 and 3. This may result in the inhibition of FGFR-mediated signal transduction pathways, tumor cell proliferation, tumor angiogenesis and tumor cell death in FGFR-overexpressing tumor cells. FGFR, a receptor tyrosine kinase, is upregulated in many tumor cell types and plays a key role in tumor cellular proliferation, differentiation, angiogenesis and survival.","Derazantinib | ARQ 087 | ARQ-087 | DERAZANTINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL445614","Fluorine F 18-labeled S-(3-Fluoropropyl)homocysteine Hydrochloride","C104269","The hydrochloride salt form of a radioconjugate composed of a synthetic derivative of the amino acid methionine radiolabeled with fluoride F 18, with potential use as a tumor imaging agent during positron emission tomography (PET). Upon administration, fluorine F 18-labeled S-(3-fluoropropyl) homocysteine is preferentially taken up by tumor cells through an amino acid transporter, which is overexpressed by cancer cells. As tumor cells have a higher rate of proliferation than normal cells, these cancer cells have increased rates of protein synthesis and thus an increased demand for amino acids. This allows for visualization of tumors cells upon PET.","Fluorine F 18-labeled S-(3-Fluoropropyl)homocysteine Hydrochloride | (18F)-D-FPHCYS | 18F-FPM | [(18)F]FPHCys",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541263","HAMP wt Allele","C104272","Human HAMP wild-type allele is located in the vicinity of 19q13.1 and is approximately 3 kb in length. This allele, which encodes hepcidin protein, plays a role in both antimicrobial activity and iron homeostasis. Mutation of the gene is associated with hemochromatosis type 2B.","HAMP wt Allele | HEPC | HFE2B | Hepcidin Antimicrobial Peptide wt Allele | LEAP-1 | LEAP1 | PLTR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3252719","Fish Oil/Glycerol/Egg Lecithin-based Emulsion","C104273","An injectable, nutritional lipid emulsion composed of 10% fish oil and high amounts of the fish oil-derived polyunsaturated omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Additionally, the fish oil/glycerol/egg lecithin-based emulsion contains, myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, octadecatetraenoic acid, eicosaenoic acid, arachidonic acid, docosaenoic acid, and docosapentaenoic acid. This agent supplies essential fatty acids that can be incorporated into cell membranes. The fatty acids may decrease the production of certain pro-inflammatory cytokines, including interleukin 1 (IL-1), IL-6 and tumor necrosis factor (TNF). In addition to fish oil, this lipid emulsion contains egg phospholipids to maintain membrane integrity; glycerol to provide energy through glycolysis; and the antioxidant alpha-tocopherol (vitamin E).","Fish Oil/Glycerol/Egg Lecithin-based Emulsion | FISH OIL TRIGLYCERIDES | Omegaven",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1722701","Licartin","C104275","An immunoradioconjugate containing metuximab, an antibody fragment targeting the hepatocellular cancer (HCC)-associated antigen HAb18G/CD147, that is conjugated to the radioisotope iodine I 131, with potential antineoplastic activity. Upon administration, the metuximab moiety of licartin targets and binds to HAb18G/CD147 on HCC cells; upon internalization, the radioisotope I 131 delivers a cytotoxic dose of gamma radiation, thereby causing selective destruction of HAb18G/CD147-expressing cells. HAb18G/CD147, a member of CD147 family, is overexpressed in HCC and fibroblasts and its expression is associated with cancer cell progression and increased adhesion, invasion and metastasis.","Licartin | (131)I-labeled HAb18 F(ab')(2) | Iodine I 131 Metuximab | Iodine[131I] Metuximab | [131I] mAb HAb18G/CD147",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541412","SDHA wt Allele","C103874","Human SDHA wild-type allele is located in the vicinity of 5p15 and is approximately 38 kb in length. This allele, which encodes succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial protein, plays a role in cellular respiration. Mutation of the gene is associated with both mitochondrial complex II deficiency and cardiomyopathy dilated type 1GG.","SDHA wt Allele | CMD1GG | FP | PGL5 | SDH1 | SDH2 | SDHF | Succinate Dehydrogenase Complex, Subunit A, Flavoprotein (Fp) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541238","SDHA protein, human","C103875","Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial (664 aa, ~73 kDa) is encoded by the human SDHA gene. This protein is involved in the mitochondrial electron transport chain.","Succinate Dehydrogenase [Ubiquinone] Flavoprotein Subunit, Mitochondrial | EC 1.3.5.1 | Flavoprotein Subunit of Complex II | Fp | SDHA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541277","ABCA5 wt Allele","C103877","Human ABCA5 wild-type allele is located in the vicinity of 17q24.3 and is approximately 83 kb in length. This allele, which encodes cholesterol transporter ABCA5 protein, plays a role in both the binding and metabolism of ATP.","ABCA5 wt Allele | ABC13 | ATP Binding Cassette Subfamily A, Member 5 wt Allele | ATP-Binding Cassette, Sub-Family A (ABC1), Member 5 Gene | ATP-Binding Cassette, Sub-Family A (ABC1), Member 5 wt Allele | ATP-Binding Cassette, Subfamily A, Member 5 Gene | EST90625 | HTC3 | KIAA1888",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539865","ATP-Binding Cassette Sub-Family A Member 5","C103878","Cholesterol transporter ABCA5 (1642 aa, ~187 kDa) is encoded by the human ABCA5 gene. This protein is involved in ATP hydrolysis.","Cholesterol Transporter ABCA5 | ABCA5 | ATP-Binding Cassette A5 | ATP-Binding Cassette Sub-Family A Member 5 | ATP-Binding Cassette Sub-Family A Member 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541913","PLXDC1 wt Allele","C104091","Human PLXDC1 wild-type allele is located in the vicinity of 17q21.1 and is approximately 90 kb in length. This allele, which encodes plexin domain-containing protein 1, plays a role in the capillary tube formation.","PLXDC1 wt Allele | Plexin Domain Containing 1 wt Allele | TEM3 | TEM7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537381","Plexin Domain-Containing Protein 1, Human","C104092","Plexin domain-containing protein 1 (500 aa, ~56 kDa) is encoded by the human PLXDC1 gene. This protein is involved in endothelial tube formation.","Plexin Domain-Containing Protein 1 | PLXDC1 | Tumor Endothelial Marker 3 | Tumor Endothelial Marker 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540546","ANTXR1 wt Allele","C104094","Human ANTXR1 wild-type allele is located in the vicinity of 2p13.1 and is approximately 236 kb in length. This allele, which encodes anthrax toxin receptor 1 protein, is involved in the modulation of cytoskeletal rearrangement, cellular adhesion and cell migration. Mutation of the gene is associated with hemangioma capillary infantile.","ANTXR1 wt Allele | ATR | Anthrax Toxin Receptor 1 wt Allele | FLJ10601 | FLJ21776 | TEM8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537387","Anthrax Toxin Receptor 1, Human","C104095","Anthrax toxin receptor 1 (564 aa, ~63 kDa) is encoded by the human ANTXR1 gene. This protein plays a role in the regulation of both cell adhesion and cellular motility.","Anthrax Toxin Receptor 1 | ANTXR1 | Tumor Endothelial Marker 8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539824","APLN wt Allele","C104097","Human APLN wild-type allele is located in the vicinity of Xq25 and is approximately 10 kb in length. This allele, which encodes apelin protein, plays a role in immunity and the negative regulation of HIV-1 infection.","APLN wt Allele | AGTRL1 Ligand Gene | APEL | Apelin wt Allele | UNQ471 | XNPEP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3710772","Galectin-3 internal gene protein, human","C104859","Galectin-3 (250 aa, ~26 kDa) is encoded by the human LGALS3 gene. This protein plays a role in both antibody-mediated immunity and carbohydrate binding.","Galectin-3 | 35 kDa Lectin | CBP 35 | Carbohydrate-Binding Protein 35 | GALBP | Gal-3 | Galactose-Specific Lectin 3 | Galactoside-Binding Protein | IgE-Binding Protein | L-31 | LGALS3 | Laminin-Binding Protein | Lectin L-29 | Mac-2 Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539628","TLE1 wt Allele","C104861","Human TLE1 wild-type allele is located in the vicinity of 9q21.32 and is approximately 106 kb in length. This allele, which encodes transducin-like enhancer protein 1, plays a role in the regulation of transcription.","TLE1 wt Allele | ESG | ESG1 | Enhancer of Split Groucho 1 Gene | GRG1 | RP11-203D19.1 | Transducin-Like Enhancer of Split 1 (E(Sp1) Homolog, Drosophila) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541273","Transducin-Like Enhancer Protein 1","C104862","Transducin-like enhancer protein 1 (770 aa, ~83 kDa) is encoded by the human TLE1 gene. This protein is involved in transcriptional regulation.","Transducin-Like Enhancer Protein 1 | E(Sp1) Homolog | ESG1 | Enhancer of Split Groucho-Like Protein 1 | TLE1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541917","AHCY wt Allele","C104864","Human AHCY wild-type allele is located in the vicinity of 20q11.22 and is approximately 32 kb in length. This allele, which encodes adenosylhomocysteinase protein, is involved in the metabolism of amino acids. Mutation of the gene is associated with hypermethioninemia with S-adenosylhomocysteine hydrolase deficiency.","AHCY wt Allele | Adenosylhomocysteinase wt Allele | SAHH | adoHcyase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0050795","Adenosylhomocysteinase","C104866","Adenosylhomocysteinase (432 aa, ~48 kDa) is encoded by the human AHCY gene. This protein plays a role in amino acid modification.","Adenosylhomocysteinase | AHCY | AdoHcyase | EC 3.3.1.1 | S-Adenosyl-L-Homocysteine Hydrolase | S-Adenosylhomocysteine Hydrolase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538898","SESN3 wt Allele","C104867","Human SESN3 wild-type allele is located in the vicinity of 11q21 and is approximately 67 kb in length. This allele, which encodes sestrin-3 protein, plays a role in regulating levels of intracellular reactive oxygen species.","SESN3 wt Allele | MGC29667 | SEST3 | Sestrin 3 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539809","Sestrin-3","C104868","Sestrin-3 (492 aa, ~57 kDa) is encoded by the human SESN3 gene. This protein is involved in regulating levels of intracellular reactive oxygen species.","Sestrin-3 | EC 1.11.1.- | SESN3 | Sestrin 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538868","SOX11 wt Allele","C105080","Human SOX11 wild-type allele is located in the vicinity of 2p25 and is approximately 9 kb in length. This allele, which encodes transcription factor SOX-11 protein, plays a role in the negative regulation of transcription.","SOX11 wt Allele | MRD27 | SRY (Sex Determining Region Y)-Box 11 Gene | SRY (Sex-Determining Region Y)-Box 11 Gene | SRY Box 11 Gene | SRY-Box 11 wt Allele | SRY-Related HMG-Box Gene 11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447404","SOX11 protein, human","C105081","Transcription factor SOX-11 (441 aa, ~47 kDa) is encoded by the human SOX11 gene. This protein is involved in transcriptional repression.","Transcription Factor SOX-11 | SOX11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642130","ADCS-ADL - Appliance: Dishwasher","C105351","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Check all that were used: dishwasher.","ADCS-ADL - Appliance: Dishwasher | ADL01-Appliance: Dishwasher | ADL0123D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642132","ADCS-ADL - Appliance: Toaster Oven","C105353","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Check all that were used: toaster oven.","ADCS-ADL - Appliance: Toaster Oven | ADL01-Appliance: Toaster Oven | ADL0123F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642133","ADCS-ADL - Appliance: Range","C105354","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Check all that were used: range.","ADCS-ADL - Appliance: Range | ADL01-Appliance: Range | ADL0123G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642134","ADCS-ADL - Appliance: Microwave","C105355","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Check all that were used: microwave.","ADCS-ADL - Appliance: Microwave | ADL01-Appliance: Microwave | ADL0123H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642135","ADCS-ADL - Appliance: Food Processor","C105356","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Check all that were used: food processor.","ADCS-ADL - Appliance: Food Processor | ADL01-Appliance: Food Processor | ADL0123I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642136","ADCS-ADL - Appliance: Other","C105357","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Check all that were used: other.","ADCS-ADL - Appliance: Other | ADL01-Appliance: Other | ADL0123J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642137","ADCS-ADL - Appliance: Other Specify","C105358","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Check all that were used: other specify.","ADCS-ADL - Appliance: Other Specify | ADL01-Appliance: Other Specify | ADL0123K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538890","Protein Tob2","C104698","Protein Tob2 (344 aa, ~37 kDa) is encoded by the human TOB2 gene. This protein plays a role in cell cycle arrest.","Protein Tob2 | Protein Tob4 | TOB2 | Transducer of ErbB-2 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0055268","Chaparrinone","C1046","A quassinoid phytochemical isolated from Ailanthus integrifolia sp. calycina and other plant species with potential antineoplastic activity.  Chaparrinone inhibits protein synthesis, has antimalarial properties, and is cytotoxic to some tumor cells. (NCI04)","Chaparrinone | Picras-3-ene-2,16-dione, 11,20-epoxy-1,11,12-trihydroxy-, (1beta,11beta,12alpha)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540475","CXADR wt Allele","C104700","Human CXADR wild-type allele is located in the vicinity of 21q21.1 and is approximately 81 kb in length. This allele, which encodes coxsackievirus and adenovirus receptor protein, plays a role in both viral infection and tight junction formation.","CXADR wt Allele | CAR | CAR4/6 | Coxsackie Virus and Adenovirus Receptor wt Allele | HCAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539542","Coxsackievirus and Adenovirus Receptor","C104701","Coxsackievirus and adenovirus receptor (365 aa, ~40 kDa) is encoded by the human CXADR gene. This protein is involved in both the formation of the epithelial apical junction complex and viral infection.","Coxsackievirus and Adenovirus Receptor | 46 kD Coxsackievirus and Adenovirus Receptor (CAR) Protein | CAR | CVB3-Binding Protein | CXADR | Coxsackievirus B-Adenovirus Receptor | HCVADR | hCAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540560","MVP wt Allele","C104703","Human MVP wild-type allele is located in the vicinity of 16p11.2 and is approximately 28 kb in length. This allele, which encodes major vault protein, is involved in vault ribonucleoprotein complex structure and function.","MVP wt Allele | LRP | Major Vault Protein wt Allele | VAULT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541254","HAVCR2 wt Allele","C104277","Human HAVCR2 wild-type allele is located in the vicinity of 5q33.3 and is approximately 57 kb in length. This allele, which encodes hepatitis A virus cellular receptor 2 protein, is involved in the activation of macrophages and helper T cells.","HAVCR2 wt Allele | CD366 | FLJ14428 | HAVcr-2 | Hepatitis A Virus Cellular Receptor 2 wt Allele | KIM-3 | TIM3 | TIMD-3 | TIMD3 | Tim-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1120826","HAVCR2 protein, human","C104278","Hepatitis A virus cellular receptor 2 (301 aa, ~33 kDa) is encoded by the human HAVCR2 gene. This protein plays a role in the regulation of T helper cell and macrophage activation.","Hepatitis A Virus Cellular Receptor 2 | CD366 | CD366 Antigen | HAVCR2 | HAVcr-2 | Kidney Injury Molecule-3 | T Cell Immunoglobulin Mucin 3 | T Cell Immunoglobulin Mucin-3 | T-Cell Immunoglobulin And Mucin Domain-Containing Protein 3 | T-Cell Membrane Protein 3 | TIM-3 | TIMD-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641741","Trouble Doing Strenuous Activities Like Carrying a Heavy Shopping Bag or Suitcase","C104279","A question about whether an individual has or had trouble performing strenuous activities, such as carrying a heavy shopping bag or a suitcase.","Trouble Doing Strenuous Activities Like Carrying a Heavy Shopping Bag or Suitcase | Do you have trouble doing strenuous activities, like carrying a heavy shopping bag or a suitcase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641742","p53/HDM2 Interaction Inhibitor CGM097","C104280","An orally bioavailable HDM2 (human homolog of double minute 2) antagonist with potential antineoplastic activity. Upon oral administration, p53/HDM2 interaction inhibitor CGM097 inhibits the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited, which may result in the restoration of p53 signaling and, thus, the p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger nuclear phosphoprotein, is a negative regulator of the p53 pathway, often overexpressed in cancer cells and has been implicated in cancer cell proliferation and survival.","p53/HDM2 Interaction Inhibitor CGM097 | CGM-097 | CGM097 | HDM2/p53 Inhibitor CGM097",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1621918","TNFRSF10C protein, human","C104520","Tumor necrosis factor receptor superfamily member 10C (259 aa, ~27 kDa) is encoded by the human TNFRSF10C gene. This protein is involved in both binding to tumor necrosis factor ligand superfamily member 10 and the inhibition of apoptosis.","Tumor Necrosis Factor Receptor Superfamily Member 10C | Antagonist Decoy Receptor For TRAIL/Apo-2L | CD263 | CD263 Antigen | DcR1 | Decoy Receptor 1 | Decoy TRAIL Receptor Without Death Domain | Lymphocyte Inhibitor of TRAIL | TNF-Related Apoptosis-Inducing Ligand Receptor 3 | TNFRSF10C | TRAIL Receptor 3 | TRAIL Receptor without an Intracellular Domain | TRAIL-R3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542402","Apelin, Human","C104098","Apelin (77 aa, ~9 kDa) is encoded by the human APLN gene. This protein is involved in both the inhibition of HIV-1 entry into cells and in immune responses.","Apelin | AGTRL1 Ligand | APJ Endogenous Ligand | APLN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054841","carzinophilin","C1040","An ethylenimine antineoplastic antibiotic isolated from the bacterium Streptomyces sahachiroi.  Carzinophilin forms interstrand DNA cross-links, thereby inhibiting DNA synthesis. (NCI04)","Carzinophilin | CARZINOPHILIN | CARZINOPHILIN A | CZP | Cardinophillin | Cardinophyllin | Carzinophyllin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641723","PARP1 Gene Product","C104101","A protein encoded by the PARP1 gene.","PARP1 Gene Product | PARP Gene Product",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641447","NPS - Tell Us How Dull Your Pain Feels","C103641","Neuropathic Pain Scale (NPS) Please use the scale below to tell us how dull your pain feels. Words used to describe very dull pain include 'like a dull toothache,' 'dull pain,' and 'like a bruise.'","NPS - Tell Us How Dull Your Pain Feels | NPS01-Tell Us How Dull Your Pain Feels | NPS0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641448","NPS - Tell Us How Cold Your Pain Feels","C103642","Neuropathic Pain Scale (NPS) Please use the scale below to tell us how cold your pain feels. Words used to describe very cold pain included 'like ice' and 'freezing.'","NPS - Tell Us How Cold Your Pain Feels | NPS01-Tell Us How Cold Your Pain Feels | NPS0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641449","NPS - Tell Us How Sensitive Your Skin is to Light Touch or Clothing","C103643","Neuropathic Pain Scale (NPS) Please use the scale below to tell us how sensitive your skin is to light touch or clothing. Words used to describe sensitive skin include 'like sunburned skin,' and 'raw skin.'","NPS - Tell Us How Sensitive Your Skin is to Light Touch or Clothing | NPS01-Sensitiv Skin to Light Touch/Cloth | NPS0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641451","NPS - Describe the Time Quality Of Your Pain","C103645","Neuropathic Pain Scale (NPS) Which of the following best describes the time quality of your pain? Please check only one answer.","NPS - Describe the Time Quality Of Your Pain | NPS01-Describe Time Quality Of Your Pain | NPS0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641452","NPS - Describe the Background Pain","C103646","Neuropathic Pain Scale (NPS) I feel a background pain all of the time and occasional flare-ups (break-through pain) some of the time. Describe the background pain.","NPS - Describe the Background Pain | NPS01-Describe the Background Pain | NPS0108A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641453","NPS - Describe the Flare-up Pain","C103647","Neuropathic Pain Scale (NPS) I feel a background pain all of the time and occasional flare-ups (break-through pain) some of the time. Describe the flare-up (break-through) pain.","NPS - Describe the Flare-up Pain | NPS01-Describe the Flare-up Pain | NPS0108B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3543428","SPRY4 wt Allele","C105083","Human SPRY4 wild-type allele is located in the vicinity of 5q31.3 and is approximately 16 kb in length. This allele, which encodes protein sprouty homolog 4, is involved in the negative regulation of signaling.","SPRY4 wt Allele | HH17 | Sprouty Homolog 4 (Drosophila) Gene | Sprouty Homolog 4 (Drosophila) wt Allele | Sprouty Homolog 4 Gene | Sprouty RTK Signaling Antagonist 4 wt Allele | Sprouty, Drosophila, Homolog of, 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542431","SPRY4 protein, human","C105084","Protein sprouty homolog 4 (299 aa, ~33 kDa) is encoded by the human SPRY4 gene. This protein plays a role in the inhibition of receptor-mediated signaling pathways.","Protein Sprouty Homolog 4 | SPRY4 | Spry-4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538602","SREBF1 wt Allele","C105086","Human SREBF1 wild-type allele is located in the vicinity of 17p11.2 and is approximately 26 kb in length. This allele, which encodes sterol regulatory element-binding protein 1, plays a role in both lipid homeostasis and the positive regulation of transcription.","SREBF1 wt Allele | BHLHD1 | SREBP-1c | SREBP1 | Sterol Regulatory Element Binding Transcription Factor 1 wt Allele | bHLHd1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1528373","SREBF1 protein, human","C105087","Sterol regulatory element-binding protein 1 (1147 aa, ~122 kDa) is encoded by the human SREBF1 gene. This protein is involved in both transcriptional activation and cholesterol homeostasis.","Sterol Regulatory Element-Binding Protein 1 | Class D Basic Helix-Loop-Helix Protein 1 | SREBF1 | SREBP-1 | Sterol Regulatory Element-Binding Transcription Factor 1 | bHLHd1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539797","SULF2 wt Allele","C105089","Human SULF2 wild-type allele is located within 20q13.12-q13.13 and is approximately 130 kb in length. This allele, which encodes extracellular sulfatase Sulf-2 protein, is involved in the modulation of proteoglycan binding specificity.","SULF2 wt Allele | HSULF-2 | KIAA1247 | RP5-1049G16.1 | SULF-2 | Sulfatase 2 wt Allele | UNQ559/PRO1120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539798","SULF2 protein, human","C105090","Extracellular sulfatase Sulf-2 (870 aa, ~100 kDa) is encoded by the human SULF2 gene. This protein plays a role in the removal of O-sulfate groups from heparan sulfate proteoglycans.","Extracellular Sulfatase Sulf-2 | EC 3.1.6.- | SULF2 | hSulf-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540644","TBXA2R wt Allele","C105092","Human TBXA2R wild-type allele is located in the vicinity of 19p13.3 and is approximately 12 kb in length. This allele, which encodes thromboxane A2 receptor protein, plays a role in both receptor signaling and platelet aggregation. Mutation of the gene is associated with bleeding disorder platelet-type 13.","TBXA2R wt Allele | BDPLT13 | TXA2-R | Thromboxane A2 Receptor wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540547","TDP1 wt Allele","C105095","Human TDP1 wild-type allele is located in the vicinity of 14q32.11 and is approximately 90 kb in length. This allele, which encodes tyrosyl-DNA phosphodiesterase 1 protein, is involved in DNA repair. Mutation of the gene is associated with spinocerebellar ataxia autosomal recessive with axonal neuropathy.","TDP1 wt Allele | FLJ11090 | SCAN1 | Tyrosyl-DNA Phosphodiesterase 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642077","ADCS-ADL - Usual Conversation Participation","C105298","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) If yes, which best describes his/her usual degree of participation.","ADCS-ADL - Usual Conversation Participation | ADL01-Usual Conversation Participation | ADL0109A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0293442","major vault protein, human","C104704","Major vault protein (893 aa, ~100 kDa) is encoded by the human MVP gene. This protein plays a role in both the structure and function of vault ribonucleoprotein complexes.","Major Vault Protein | Lung Resistance-Related Protein | MVP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540557","CAMK2A wt Allele","C104706","Human CAMK2A wild-type allele is located in the vicinity of 5q32 and is approximately 71 kb in length. This allele, which encodes calcium/calmodulin-dependent protein kinase type II subunit alpha protein, plays a role in both signal transduction and serine/threonine phosphorylation.","CAMK2A wt Allele | CAMKA | Calcium/Calmodulin-Dependent Protein Kinase II Alpha wt Allele | KIAA0968",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542912","Calcium/Calmodulin-Dependent Protein Kinase Type II Subunit Alpha, Human","C104707","Calcium/calmodulin-dependent protein kinase type II subunit alpha (478 aa, ~54 kDa) is encoded by the human CAMK2A gene. This protein is involved in both serine/threonine phosphorylation and neurotransmission.","Calcium/Calmodulin-Dependent Protein Kinase Type II Subunit Alpha | CAMK2A | CaM Kinase II Alpha Subunit | CaM Kinase II Subunit Alpha | CaM-Kinase II Alpha Chain | CaMK-II Alpha Subunit | CaMK-II Subunit Alpha | CaMKIINalpha | Calcium/Calmodulin-Dependent Protein Kinase (CaM Kinase) II Alpha | Calcium/Calmodulin-Dependent Protein Kinase II Alpha-B Subunit | Calcium/Calmodulin-Dependent Protein Kinase Type II Alpha Chain | EC 2.7.11.17",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539714","RAD50 wt Allele","C104709","Human RAD50 wild-type allele is located in the vicinity of 5q31 and is approximately 89 kb in length. This allele, which encodes DNA repair protein RAD50, is involved in DNA double-strand break repair, cell cycle checkpoint activation, telomere maintenance, and meiotic recombination. Mutations in this gene are associated with Nijmegen breakage syndrome-like disorder.","RAD50 wt Allele | NBSLD | RAD50 (S. cerevisiae) Homolog Gene | RAD50 Double Strand Break Repair Protein wt Allele | RAD50 Homolog (S. cerevisiae) Gene | RAD50 Homolog, Double Strand Break Repair Protein Gene | RAD50, S. cerevisiae, Homolog of Gene | RAD50-2 | RAD502 | hRad50",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541988","FOLR2 wt Allele","C104915","Human FOLR2 wild-type allele is located within 11q13.3-q14.1 and is approximately 5 kb in length. This allele, which encodes folate receptor beta protein, plays a role in the internalization of folic acid.","FOLR2 wt Allele | BETA-HFR | FBP | FBP/PL-1 | FR-BETA | FR-P3 | Folate Receptor 2 (Fetal) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL599528","FOLR2 protein, human","C104916","Folate receptor beta (255 aa, ~29 kDa) is encoded by the human FOLR2 gene. This protein is involved in folic acid transport.","Folate Receptor Beta | FBP | FOLR2 | FR-Beta | Folate Receptor 2 | Folate Receptor, Fetal/Placental | Folate-Binding Protein, Fetal/Placental | Placental Folate-Binding Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641887","Cobalt-60 Radiation Therapy","C104919","Radiation therapy using gamma radiation generated from cobalt-60.","Cobalt-60 Radiation Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539743","MAGEB18 wt Allele","C104522","Human MAGEB18 wild-type allele is located in the vicinity of Xp21.3 and is approximately 2 kb in length. This allele, which encodes melanoma-associated antigen B18 protein, may enhance ubiquitin ligase activity.","MAGEB18 wt Allele | MAGE Family Member B18 wt Allele | MGC33889 | Melanoma Antigen Family B, 18 Gene | Melanoma Antigen Family B, 18 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542428","Melanoma-Associated Antigen B18","C104523","Melanoma-associated antigen B18 (343 aa, ~39 kDa) is encoded by the human MAGEB18 gene. This protein may enhance ubiquitin ligase activity.","Melanoma-Associated Antigen B18 | MAGE-B18 | MAGE-B18 Antigen | MAGEB18 | Melanoma Antigen Family B, 18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539744","MAGEC1 wt Allele","C104525","Human MAGEC1 wild-type allele is located in the vicinity of Xq26 and is approximately 6 kb in length. This allele, which encodes melanoma-associated antigen C1 protein, may be involved in embryonal development, tumor transformation, or tumor progression.","MAGEC1 wt Allele | CT7 | CT7.1 | MAGE Family Member C1 wt Allele | MAGE-C1 | MGC39366 | Melanoma Antigen Family C, 1 Gene | Melanoma Antigen, Family C, 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537328","MAGEC1 protein, human","C104526","Melanoma-associated antigen C1 (1142 aa, ~124 kDa) is encoded by the human MAGEC1 gene. This protein may play a role in embryonal development, tumor transformation, or tumor progression.","Melanoma-Associated Antigen C1 | CT7 | CT7.1 | Cancer/Testis Antigen 7.1 | Cancer/Testis Antigen Family 7, Member 1 | MAGE-C1 Antigen | MAGEC1 | Melanoma Antigen Family C, 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540514","MAGEC2 wt Allele","C104528","Human MAGEC2 wild-type allele is located in the vicinity of Xq27 and is approximately 3 kb in length. This allele, which encodes melanoma-associated antigen C2 protein, may enhance ubiquitin ligase activity. The gene is frequently expressed in head and neck carcinomas, breast carcinomas, non-small-cell lung carcinomas, and sarcomas.","MAGEC2 wt Allele | CT10 | HCA587 | MAGE-C2 | MAGEE1 | Melanoma Antigen Family C, 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539847","Melanoma-Associated Antigen C2, Human","C104529","Melanoma-associated antigen C2 (373 aa, ~41 kDa) is encoded by the human MAGEC2 gene. This protein may enhance ubiquitin ligase activity.","Melanoma-Associated Antigen C2 | CT10 | Cancer/Testis Antigen 10 | Hepatocellular Cancer Antigen 587 | Hepatocellular Carcinoma-Associated Antigen 587 | MAGE-C2 Antigen | MAGE-E1 Antigen | MAGEC2 | Melanoma Antigen Family C, 2 | Melanoma Antigen, Family E, 1, Cancer/Testis Specific, Cancer/Testis Antigen 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280873","cyclophosphamide/doxorubicin/fluorouracil/methotrexate/prednisone","C10452","A regimen consisting of prednisone, methotrexate, fluorouracil, doxorubicin, and cyclophosphamide that may be used in the treatment of breast cancer.","PMFAC Regimen | CTX/DOX/5-FU/MTX/PRED | Cyclophosphamide/Doxorubicin/Fluorouracil/Methotrexate/Prednisone | PMFAC | Prednisone-Methotrexate-Fluorouracil-Doxorubicin-Cyclophosphamide | Prednisone/Methotrexate/Fluorouracil/Adriamycin/Cyclophosphamide | Prednisone/Methotrexate/Fluorouracil/Doxorubicin/Cyclophosphamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540492","HES3 wt Allele","C104531","Human HES3 wild-type allele is located in the vicinity of 1p36.31 and is approximately 1 kb in length. This allele, which encodes transcription factor HES-3 protein, is involved in the negative regulation of transcription.","HES3 wt Allele | BHLHB43 | Hairy and Enhancer of Split 3 (Drosophila) wt Allele | RP1-120G22.7 | bHLHb43",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641454","NPS - Describe the Single Type of Pain All Time","C103648","Neuropathic Pain Scale (NPS) I feel a single type of pain all the time. Describe this pain.","NPS - Describe the Single Type of Pain All Time | NPS01-Describe Single Type Pain All Time | NPS0108C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641455","NPS - Describe the Occasional Pain","C103649","Neuropathic Pain Scale (NPS) I fee a single type of pain only sometimes. Other times, I am pain free. Describe the occasional pain.","NPS - Describe the Occasional Pain | NPS01-Describe the Occasional Pain | NPS0108D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641456","NPS - Tell Us Overall How Unpleasant Your Pain is to You","C103650","Neuropathic Pain Scale (NPS) Now that you have told us the different physical aspects of your pain, the different types of sensations, we want you to tell us overall how unpleasant your pain is to you. Words used to describe very unpleasant pain include 'miserable' and intolerable.' Remember, pain can have a low intensity, buy still feel extremely unpleasant, and some kinds of pain can have a high intensity but be very tolerable. With this scale, please tell us how unpleasant your pain feels.","NPS - Tell Us Overall How Unpleasant Your Pain is to You | NPS01-Tell How Unpleasant Your Pain Feel | NPS0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641457","NPS - How Intense is Your Deep Pain","C103651","Neuropathic Pain Scale (NPS) Lastly, we want you to give us an estimate of the severity of your deep versus surface pain. We want your to rate each location of pain separately. We realize that it can be difficult to make these estimates, and most likely it will be a 'best guess,' but please give us your best estimate. How intense is your deep pain?","NPS - How Intense is Your Deep Pain | NPS01-How Intense is Your Deep Pain | NPS0110A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641458","NPS - How Intense is Your Surface Pain","C103652","Neuropathic Pain Scale (NPS) Lastly, we want you to give us an estimate of the severity of your deep versus surface pain. We want your to rate each location of pain separately. We realize that it can be difficult to make these estimates, and most likely it will be a 'best guess,' but please give us your best estimate. How intense is your surface pain?","NPS - How Intense is Your Surface Pain | NPS01-How Intense is Your Surface Pain | NPS0110B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641459","OAB-q - Frequent Urination During the Daytime","C103653","The Overactive Bladder Questionnaire (OAB-q) Frequent urination during the daytime hours?","OAB-q - Frequent Urination During the Daytime | OABQ01-Frequent Urination During Daytime | OABQ0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641460","OAB-q - Uncomfortable Urge to Urinate","C103654","The Overactive Bladder Questionnaire (OAB-q) An uncomfortable urge to urinate?","OAB-q - Uncomfortable Urge to Urinate | OABQ01-Uncomfortable Urge to Urinate | OABQ0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540565","HOXB6 wt Allele","C104336","Human HOXB6 wild-type allele is located in the vicinity of 17q21.32 and is approximately 11 kb in length. This allele, which encodes homeobox protein Hox-B6, plays a role in transcription of patterning genes.","HOXB6 wt Allele | HOX2 | HOX2B | HU-2 | Homeobox B6 wt Allele | Hox-2.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538965","Homeobox Protein Hox-B6","C104337","Homeobox protein Hox-B6 (224 aa, ~25 kDa) is encoded by the human HOXB6 gene. This protein is involved in embryonic pattern formation.","Homeobox Protein Hox-B6 | HOXB6 | Homeo Box 2B | Homeo Box B6 | Homeobox Protein Hox-2.2 | Homeobox Protein Hox-2B | Homeobox Protein Hu-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538704","HSPD1 wt Allele","C104339","Human HSPD1 wild-type allele is located in the vicinity of 2q33.1 and is approximately 30 kb in length. This allele, which encodes 60 kDa heat shock protein, mitochondrial, is involved in both import and folding of mitochondrial proteins. Mutation of the gene is associated with spastic paraplegia 13 and leukodystrophy hypomyelinating type 4.","HSPD1 wt Allele | CPN60 | GROEL | GroEL | HLD4 | HSP-60 | HSP60 | HSP65 | Heat Shock 60kDa Protein 1 (Chaperonin) wt Allele | HuCHA60 | SPG13 | Spastic Paraplegia 13 (Autosomal Dominant) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642078","ADCS-ADL - Clear Dishes After Meal or Snack","C105299","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Standard Version (ADCS-ADL Standard) Did the subject clear the dishes from the table after a meal or snack?","ADCS-ADL - Clear Dishes After Meal or Snack | ADL01-Clear Dishes | ADL0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0055843","CL 246738","C1052","An immunomodulator, 3,6-bis(2-piperidinoethoxy) acridine trihydrochloride, used in a phase I study for possible immunostimulatory effects in colorectal cancer. (NCI)","CL 246738 | 3,6-bis-(2-piperidinoethoxyl)acridine trihydrochloride | CL 246,738",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642080","ADCS-ADL - Find Personal Belongings at Home","C105301","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, did the subject usually manage to find his/her personal belongings at home?","ADCS-ADL - Find Personal Belongings at Home | ADL01-Find Belongings | ADL0111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642081","ADCS-ADL - Description of Usual Performance of Finding Personal Belonging at Home","C105302","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) If yes, which best describes how he/she usually performed.","ADCS-ADL - Description of Usual Performance of Finding Personal Belonging at Home | ADL01-Find Belongings Usual Performance | ADL0111A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642082","ADCS-ADL - Obtain Beverage for Self","C105303","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, did the subject obtain a hot or cold beverage for him/herself?","ADCS-ADL - Obtain Beverage for Self | ADL01-Obtain Beverage | ADL0112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642083","ADCS-ADL - Description of Highest Performance of Obtaining Beverage","C105304","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) If yes, which best describes his/her highest level of performance.","ADCS-ADL - Description of Highest Performance of Obtaining Beverage | ADL01-Obtain Beverage Highest Perform | ADL0112A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642085","ADCS-ADL - Highest Level of Food Preparation","C105306","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) If yes, which best describes his/her highest level of food preparation.","ADCS-ADL - Highest Level of Food Preparation | ADL01-Highest Level of Food Preparation | ADL0113A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642086","ADCS-ADL - Dispose of Garbage in Appropriate Place at Home","C105307","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, did the subject dispose of garbage or litter in an appropriate place or container at home?","ADCS-ADL - Dispose of Garbage in Appropriate Place at Home | ADL01-Dispose of Garbage | ADL0114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642087","ADCS-ADL - Description of Usual Performance of Garbage Disposal","C105308","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) If yes, which best describes how he/she usually performed.","ADCS-ADL - Description of Usual Performance of Garbage Disposal | ADL01-Dispose Garbage Usual Performance | ADL0114A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642088","ADCS-ADL - Get Around Outside Home","C105309","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, did the subject get around (or travel) outside of his/her home?","ADCS-ADL - Get Around Outside Home | ADL01-Get Around Outside Home | ADL0115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642089","ADCS-ADL - Description of Optimal Performance of Getting Around Outside of Home","C105310","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) If yes, which best describes his/her optimal performance.","ADCS-ADL - Description of Optimal Performance of Getting Around Outside of Home | ADL01-Get Around Optimal Performance | ADL0115A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541989","MTHFD1 wt Allele","C104922","Human MTHFD1 wild-type allele is located in the vicinity of 14q24 and is approximately 72 kb in length. This allele, which encodes C-1-tetrahydrofolate synthase, cytoplasmic protein, is involved in the metabolism of folic acid. Mutation of the gene is associated with susceptibility to folate-sensitive neural tube defects.","MTHFD1 wt Allele | MTHFC | MTHFD | Methylenetetrahydrofolate Dehydrogenase (NADP+ Dependent) 1, Methenyltetrahydrofolate Cyclohydrolase, Formyltetrahydrofolate Synthetase wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539606","CRABP2 wt Allele","C104926","Human CRABP2 wild-type allele is located in the vicinity of 1q21.3 and is approximately 6 kb in length. This allele, which encodes cellular retinoic acid-binding protein 2, is involved in both retinoic acid binding and retinoic acid signaling.","CRABP2 wt Allele | CRABP-II | Cellular Retinoic Acid Binding Protein 2 wt Allele | RBP6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0219579","retinoic acid binding protein II, cellular","C104927","Cellular retinoic acid-binding protein 2 (138 aa, ~16 kDa) is encoded by the human CRABP2 gene. This protein plays a role in retinoic acid signaling.","Cellular Retinoic Acid-Binding Protein 2 | Cellular Retinoic Acid Binding Protein 2 | Cellular Retinoic Acid-Binding Protein II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540573","CBFA2T2 wt Allele","C104930","Human CBFA2T2 wild-type allele is located in the vicinity of 20q11 and is approximately 160 kb in length. This allele, which encodes protein CBFA2T2, may play a role in tumor suppression. This gene is frequently fused to RUNX1 by the t(8;21)(q22;q22) translocation in acute myeloid leukemia.","CBFA2T2 wt Allele | Core-Binding Factor, Runt Domain, Alpha Subunit 2; Translocated to, 2 wt Allele | EHT | MTGR1 | ZMYND3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641932","CDISC Questionnaire PR v1 Test Code Terminology","C105136","Test codes of questionnaire questions associated with the Pain Relief (PR) version 1 for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire PR v1 Test Code Terminology | PR01TC | Pain Relief Questionnaire Test Code | QS-PR TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641933","CDISC Questionnaire GCGI v1 Test Name Terminology","C105137","Test names of questionnaire questions associated with the General Clinical Global Impressions (GCGI) version 1 for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire GCGI v1 Test Name Terminology | GCGI01TN | General Clinical Global Impressions Questionnaire Test Name | QS-GCGI TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641934","CDISC Questionnaire GCGI v1 Test Code Terminology","C105138","Test codes of questionnaire questions associated with the General Clinical Global Impressions (GCGI) version 1 for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire GCGI v1 Test Code Terminology | GCGI01TC | General Clinical Global Impressions Questionnaire Test Code | QS-GCGI TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826964","CDISC Questionnaire ADCS-ADL Test Name Terminology","C105139","Test names of questionnaire questions associated with the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire ADCS-ADL Test Name Terminology | ADL01TN | Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory Questionnaire Test Name | QS-ADCS-ADL TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0963312","Cancer/Testis Antigen 2","C104049","Cancer/testis antigen 2 (210 aa, ~21 kDa) is encoded by the human CTAG2 gene. This protein may play a role in tumorigenesis of several tissues.","Cancer/Testis Antigen 2 | Autoimmunogenic Cancer/Testis Antigen NY-ESO-2 | CT6.2 | CT6.2b | CTAG2 | Cancer/Testis Antigen 2 Isoform LAGE-1B | Cancer/Testis Antigen 6.2 | Cancer/Testis Antigen 6.2b | Isoform LAGE-1B | L Antigen Family Member 1 | L Antigen Family Member 1 Isoform B | LAGE-1 | LAGE-1L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541979","CA9 wt Allele","C104051","Human CA9 wild-type allele is located in the vicinity of 9p13.3 and is approximately 7 kb in length. This allele, which encodes carbonic anhydrase 9 protein, plays a role in intracellular pH balance.","CA9 wt Allele | CA9 | CAIX | Carbonic Anhydrase IX wt Allele | G250",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0258855","Carbonic Anhydrase 9, Human","C104052","Carbonic anhydrase 9 (459 aa, ~50 kDa) is encoded by the human CA9 gene. This protein is involved in intracellular pH balance and may be involved in cell proliferation and transformation.","Carbonic Anhydrase 9 | CA-IX | CA9 | Carbonic Anhydrase IX | Carbonic Dehydratase IX | Membrane Antigen MN | P54/58N | RCC-Associated Protein G250 | Renal Cell Carcinoma-Associated Protein G250 | pMW1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540479","CTSG wt Allele","C104054","Human CTSG wild-type allele is located in the vicinity of 14q12 and is approximately 3 kb in length. This allele, which encodes cathepsin G protein, is involved in protein processing and degradation.","CTSG wt Allele | CATG | CG | CTSG | Cathepsin G wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3501648","Telapristone Acetate","C104055","The acetate form of the 21-substituted-19-nor-progestin telapristone, an orally available selective progesterone receptor modulator (SPRM), with potential anti-progesterone and antineoplastic activities. Upon oral administration, CDB-4124 competitively binds to the progesterone receptor (PR) in progesterone-responsive tissue and inhibits PR-mediated gene expression. This interferes with progesterone activity in the reproductive system. As a result, this agent may suppress ovulation and inhibit proliferation of endometrial tissue. Also, this agent may prevent cell growth and induce apoptosis in estrogen receptor (ER) and PR-positive breast cancer cells through a reduction in progesterone levels, ER downregulation and a suppression of the expression of cyclin-dependent kinases (CDK) 2 and 4, ultimately leading to G1/S cell cycle arrest. Unlike some other SPRMs, this agent does not exert any estrogenic, androgenic, anti-estrogenic, and anti-androgenic activities.","Telapristone Acetate | (8S,11R,13S,14S,17R)-11-(4-(Dimethylamino)phenyl)-17-(2-methoxyacetyl)-13-methyl-3-oxo-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl Acetate | CDB-4124 | Proellex | Progenta | TELAPRISTONE ACETATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1567075","Cathepsin G, Human","C104056","Cathepsin G (255 aa, ~29 kDa) is encoded by the human CTSG gene. This protein plays a role in protein processing and may be involved in connective tissue remodeling at sites of infection.","Cathepsin G | CG | CTSG | EC 3.4.21",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1568861","60 kDa Heat Shock Protein, Mitochondrial, Human","C104340","60 kDa heat shock protein, mitochondrial (573 aa, ~61 kDa) is encoded by the human HSPD1 gene. This protein plays a role in mitochondrial protein folding.","60 kDa Heat Shock Protein, Mitochondrial | 60 kDa Chaperonin | CPN60 | Chaperonin 60 | HSP-60 | HSPD1 | Heat Shock Protein 60 | Heat Shock Protein 65 | Hsp60 | HuCHA60 | Mitochondrial Matrix Protein P1 | P60 Lymphocyte Protein | Short Heat Shock Protein 60 Hsp60s1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540651","IL20 wt Allele","C104342","Human IL20 wild-type allele is located in the vicinity of 1q32 and is approximately 4 kb in length. This allele, which encodes interleukin-20 protein, plays a role in cytokine signaling through activation of signal transducer and activator of transcription 3.","IL20 wt Allele | IL-20 | IL10D | Interleukin 20 wt Allele | UNQ852/PRO1801 | ZCYTO10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1700504","Interleukin-20","C104343","Interleukin-20 (176 aa, ~20 kDa) is encoded by the human IL20 gene. This protein is involved in the regulation of signal transducer and activator of transcription 3-mediated signaling.","Interleukin-20 | Cytokine Zcyto10 | Four Alpha Helix Cytokine | IL-20 | IL20 | Interleukin 20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540650","IL21 wt Allele","C104345","Human IL21 wild-type allele is located within 4q26-q27 and is approximately 8 kb in length. This allele, which encodes interleukin-21 protein, is involved in both immunity and signaling.","IL21 wt Allele | IL-21 | Interleukin 21 wt Allele | Za11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0962190","interleukin 21 protein, human","C104346","Interleukin-21 (155 aa, ~18 kDa) is encoded by the human IL21 gene. This protein plays a role in both receptor-mediated signaling and the inflammatory response.","Interleukin-21 | IL-21 | IL21 | Za11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541896","IFNL2 wt Allele","C104348","Human IFNL2 wild-type allele is located in the vicinity of 19q13.13 and is approximately 2 kb in length. This allele, which encodes interferon lambda-2 protein, plays a role in both the response to viral infection and cytokine signaling.","IFNL2 wt Allele | IL-28A | IL28A | Interferon, Lambda 2 wt Allele | Interleukin 28A Gene | ZCYTO20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539861","Interferon Lambda-2, Human","C104349","Interferon lambda-2 (200 aa, ~22 kDa) is encoded by the human IFNL2 gene. This protein is involved in both cytokine-mediated signaling and antiviral activity.","Interferon Lambda-2 | Cytokine Zcyto20 | IFN-Lambda-2 | IFNL2 | IL-28A | Interferon Lambda 2 | Interferon-Lambda 2 | Interferon-Lambda-2 | Interleukin-28A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538744","ABCC4 wt Allele","C103880","Human ABCC4 wild-type allele is located in the vicinity of 13q32 and is approximately 282 kb in length. This allele, which encodes multidrug resistance-associated protein 4, is involved in ATP hydrolysis, anion transport and platelet activation.","ABCC4 wt Allele | ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 4 wt Allele | Canalicular Multispecific Organic Anion Transporter (ABC Superfamily) Gene | EST170205 | MOAT-B | MOATB | MRP4 | bA464I2.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538745","Multidrug Resistance-Associated Protein 4, Human","C103881","Multidrug resistance-associated protein 4 (1325 aa, ~150 kDa) is encoded by the human ABCC4 gene. This protein plays a role in platelet degranulation, ATP hydrolysis and organic anion transport.","Multidrug Resistance-Associated Protein 4 | ABCC4 | ATP-Binding Cassette Sub-Family C Member 4 | Canalicular Multispecific Organic Anion Transporter | MOAT-B | MRP/cMOAT-Related ABC Transporter | Multi-Specific Organic Anion Transporter B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642090","ADCS-ADL - Go Shopping","C105311","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, did the subject ever go shopping?","ADCS-ADL - Go Shopping | ADL01-Go Shopping | ADL0116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540822","IRF9 wt Allele","C104655","Human IRF9 wild-type allele is located in the vicinity of 14q11.2 and is approximately 6 kb in length. This allele, which encodes interferon regulatory factor 9 protein, is involved in both transcription regulation and signaling by type I interferons.","IRF9 wt Allele | IRF-9 | ISGF3 | ISGF3G | Interferon Regulatory Factor 9 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1506531","IRF9 protein, human","C104656","Interferon regulatory factor 9 (393 aa, ~44 kDa) is encoded by the human IRF9 gene. This protein plays a role in activating transcription via type I interferon signaling.","Interferon Regulatory Factor 9 | IFN-Alpha-Responsive Transcription Factor Subunit | IRF9 | ISGF-3 Gamma | ISGF3 p48 Subunit | Interferon-Stimulated Gene Factor 3 Gamma | Interferon-Stimulated Transcription Factor 3, Gamma (48kD) | Interferon-Stimulated Transcription Factor 3, Gamma 48kDa | Transcriptional Regulator ISGF3 Subunit Gamma | p48",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540823","ISG15 wt Allele","C104658","Human ISG15 wild-type allele is located in the vicinity of 1p36.33 and is approximately 1 kb in length. This allele, which encodes ubiquitin-like protein ISG15, plays a role in type I interferon signaling.","ISG15 wt Allele | G1P2 | IFI15 | IP17 | ISG15 Ubiquitin-Like Modifier wt Allele | UCRP | hUCRP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0385884","Ubiquitin-Like Protein ISG15, Human","C104659","Ubiquitin-like protein ISG15 (165 aa, ~18 kDa) is encoded by the human ISG15 gene. This protein is involved in type I interferon-mediated signaling.","Ubiquitin-Like Protein ISG15 | Interferon, Alpha-Inducible Protein (Clone IFI-15K) | Interferon-Induced 15 kDa Protein | Interferon-Induced 17 kDa Protein | Interferon-Induced 17-kDa/15-kDa Protein | Interferon-Stimulated Protein, 15 kDa | Ubiquitin Cross-Reactive Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540824","EIF5 wt Allele","C104661","Human EIF5 wild-type allele is located in the vicinity of 14q32.32 and is approximately 11 kb in length. This allele, which encodes eukaryotic translation initiation factor 5 protein, is involved in both GTP hydrolysis and the association of the 40S and 60S ribosomal subunits.","EIF5 wt Allele | EIF-5 | EIF-5A | Eukaryotic Translation Initiation Factor 5 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0058991","Eukaryotic Initiation Factor-5","C104662","Eukaryotic translation initiation factor 5 (431 aa, ~49 kDa) is encoded by the human EIF5 gene. This protein plays a role in the interaction between the 40S and 60S ribosomal subunits.","Eukaryotic Translation Initiation Factor 5 | EIF5 | eIF-5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826963","CDISC Questionnaire ADCS-ADL Test Code Terminology","C105140","Test codes of questionnaire questions associated with the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire ADCS-ADL Test Code Terminology | ADL01TC | Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory Questionnaire Test Code | QS-ADCS-ADL TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641937","C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Questionnaire Question","C105141","A question associated with the C-SSRS Baseline/Screening Version Phase 1 Study version 1/14/09 questionnaire.","C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641938","DAD Questionnaire Question","C105142","A question associated with the DAD questionnaire.","DAD Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641939","PI Questionnaire Question","C105143","A question associated with the PI version 1 questionnaire.","PI Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641940","PR Questionnaire Question","C105144","A question associated with the PR version 1 questionnaire.","PR Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641941","GCGI Questionnaire Question","C105145","A question associated with the GCGI version 1 questionnaire.","GCGI Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831645","ADCS-ADL Questionnaire Question","C105146","A question associated with the ADCS-ADL questionnaire.","ADCS-ADL Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541886","HSD17B3 wt Allele","C105149","Human HSD17B3 wild-type allele is located in the vicinity of 9q22 and is approximately 67 kb in length. This allele, which encodes testosterone 17-beta-dehydrogenase 3 protein, is involved in the conversion of androstenedione to testosterone. Deficiency can result in male pseudohermaphroditism with gynecomastia.","HSD17B3 wt Allele | EDH17B3 | Hydroxysteroid (17-Beta) Dehydrogenase 3 wt Allele | SDR12C2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642138","ADCS-ADL - Description of Usual Use of Commonly Used Appliances","C105359","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) If yes, for the most commonly used appliances, which best describes how the subject usually used them.","ADCS-ADL - Description of Usual Use of Commonly Used Appliances | ADL01-Use Common Used Appliances | ADL0123L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642139","ADCS-ADL - Total Score","C105360","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Total score.","ADCS-ADL - Total Score | ADL01-Total ADCS-ADL Score | ADL0124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642140","ADCS-ADL - Number of 'Don't Know' Responses","C105361","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Number of 'Don't Know' responses.","ADCS-ADL - Number of 'Don't Know' Responses | ADL01-Number Don't Know Responses | ADL0125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433954","immunoconjugate RO5479599","C104058","An immunoconjugate containing a glycoengineered, humanized monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3), with potential antineoplastic activity. Upon administration,  lumretuzumab binds to the extracellular domain of HER3 and inhibits HER3 dimerization; thereby, preventing EGFR-dependent signaling. In addition, RO5479599 stimulates the immune system to exert antibody-dependent cellular cytotoxicity (ADCC). This may decrease proliferation of HER3-overexpressing tumor cells. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors; it has no active kinase domain but is activated through heterodimerization with other members of the EGFR receptor family, such as HER2.","Lumretuzumab | LUMRETUZUMAB | RO5479599",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641397","IIEF - Maintain Your Erection to Completion of Intercourse","C103591","International Index of Erectile Function (IIEF) Over the past four weeks during sexual intercourse, how difficult was it to maintain your erection to completion of intercourse?","IIEF - Maintain Your Erection to Completion of Intercourse | IIEF01-Maintain Erection to Completion | IIEF01-Maintenance Ability | IIEF0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641398","IIEF - How Many Times Have You Attempted Sexual Intercourse","C103592","International Index of Erectile Function (IIEF) Over the past four weeks how many times have you attempted sexual intercourse?","IIEF - How Many Times Have You Attempted Sexual Intercourse | IIEF01-Intercourse Frequency | IIEF01-Times Attempted Sexual Intercours | IIEF0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641400","IIEF - How Much Have You Enjoyed Sexual Intercourse","C103594","International Index of Erectile Function (IIEF) Over the past four weeks how much have you enjoyed sexual intercourse?","IIEF - How Much Have You Enjoyed Sexual Intercourse | IIEF01-Enjoyed Sexual Intercourse | IIEF01-Intercourse Enjoyment | IIEF0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641401","IIEF - How Often Did You Ejaculate","C103595","International Index of Erectile Function (IIEF) Over the past four weeks when you had sexual stimulation or intercourse, how often did you ejaculate?","IIEF - How Often Did You Ejaculate | IIEF01-Ejaculation Frequency | IIEF01-How Often Did You Ejaculate | IIEF0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641402","IIEF - Did You Have Feeling of Orgasm With or Without Ejaculation","C103596","International Index of Erectile Function (IIEF) Over the past four weeks when you had sexual stimulation or intercourse, how often did you have the feeling of orgasm with our without ejaculation?","IIEF - Did You Have Feeling of Orgasm With or Without Ejaculation | IIEF01-Did You Have Feeling of Orgasm | IIEF01-Orgasm Frequency | IIEF0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641403","IIEF - How Often Have You Felt Sexual Desire","C103597","International Index of Erectile Function (IIEF) Over the past four weeks how often have you felt sexual desire?","IIEF - How Often Have You Felt Sexual Desire | IIEF01-Desire Frequency | IIEF01-Have You Felt Sexual Desire | IIEF0111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641404","IIEF - Rate Your Level of Sexual Desire","C103598","International Index of Erectile Function (IIEF) Over the past four weeks how would you rate your level of sexual desire?","IIEF - Rate Your Level of Sexual Desire | IIEF01-Desire Level | IIEF01-Rate Your Level of Sexual Desire | IIEF0112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641405","IIEF - Satisfied with Overall Sex Life","C103599","International Index of Erectile Function (IIEF) Over the past four weeks how satisfied have you been with your overall sex life?","IIEF - Satisfied with Overall Sex Life | IIEF01-Overall Satisfaction | IIEF01-Satisfied with Overall Sex Life | IIEF0113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054506","Calicheamicin Gamma 1I","C1035","An oligosaccharide enediyne antitumor antibiotic isolated from Micromonospora echinospora ssp. Calichensis.  Calicheamicin Gamma 1I binds to the minor groove of DNA, resulting in site-specific double-strand breaks and apoptosis. (NCI04)","Calicheamicin Gamma 1I | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539701","ABCC2 wt Allele","C103883","Human ABCC2 wild-type allele is located in the vicinity of 10q24 and is approximately 69 kb in length. This allele, which encodes canalicular multispecific organic anion transporter 1 protein, plays a role in both multidrug resistance and organic anion transport. Mutation of the gene is associated with Dubin-Johnson syndrome.","ABCC2 wt Allele | ABC30 | ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 2 wt Allele | CMOAT | CMOAT1 | CMRP | Canalicular Multispecific Organic Anion Transporter 1 Gene | DJS | MRP2 | cMRP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0525410","multidrug resistance-associated protein 2","C103884","Canalicular multispecific organic anion transporter 1 (1545 aa, ~174 kDa) is encoded by the human ABCC2 gene. This protein is involved in both anion transport and multidrug resistance.","Canalicular Multispecific Organic Anion Transporter 1 | ABCC2 | ATP-Binding Cassette Sub-Family C Member 2 | Canalicular Multidrug Resistance Protein | Multidrug Resistance-Associated Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541413","ACACA wt Allele","C103886","Human ACACA wild-type allele is located in the vicinity of 17q21 and is approximately 325 kb in length. This allele, which encodes acetyl-CoA carboxylase 1 protein, is involved in long-chain fatty acid biosynthesis. Mutation of the gene is associated with acetyl-CoA carboxylase 1 deficiency.","ACACA wt Allele | ACAC | ACACAD | ACACalpha | ACC | ACC1 | ACCA | ACCalpha | Acac1 | Acetyl-CoA Carboxylase Alpha wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541857","Acetyl-CoA Carboxylase 1","C103887","Acetyl-CoA carboxylase 1 (2346 aa, ~266 kDa) is encoded by the human ACACA gene. This protein plays a role in the modulation of long-chain fatty acid biosynthesis.","Acetyl-CoA Carboxylase 1 | ACACA | ACC | ACC-Alpha | ACC1 | Acetyl-Coenzyme A Carboxylase Alpha | EC 6.4.1.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641672","TNFRSF8 Gene Product","C103889","A protein encoded by the TNFRSF8 gene.","TNFRSF8 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641673","Soluble Tumor Necrosis Factor Receptor Superfamily Member 8","C103890","Soluble tumor necrosis factor receptor superfamily member 8 (~85 kDa) is encoded by the human TNFRSF8 gene. This enzymatically processed protein may be involved in the inhibition of tumor necrosis factor ligand superfamily member 8 (CD30 ligand) binding to its cell surface-localized receptor.","Soluble Tumor Necrosis Factor Receptor Superfamily Member 8 | Soluble Ber-H2 | Soluble CD30 | Soluble CD30L Receptor | Soluble Ki-1 | Soluble Ki-1 Antigen | sCD30",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541218","ACER1 wt Allele","C103891","Human ACER1 wild-type allele is located in the vicinity of 19p13.3 and is approximately 27 kb in length. This allele, which encodes alkaline ceramidase 1 protein, plays a role in the conversion of ceramides to sphingosine.","ACER1 wt Allele | ALKCDase1 | ASAH3 | Alkaline Ceramidase 1 wt Allele | N-Acylsphingosine Amidohydrolase (Alkaline Ceramidase) 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539592","Alkaline Ceramidase 1, Human","C103892","Alkaline ceramidase 1 (264 aa, ~31 kDa) is encoded by the human ACER1 gene. This protein is involved in the catabolism of sphingolipid ceramides.","Alkaline Ceramidase 1 | ACER1 | Acylsphingosine Deacylase 3 | AlkCDase 1 | Alkaline CDase 1 | EC 3.5.1.23 | N-Acylsphingosine Amidohydrolase 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541329","UGT1A7 wt Allele","C104105","Human UGT1A7 wild-type allele is located in the vicinity of 2q37 and is approximately 91 kb in length. This allele, which encodes UDP-glucuronosyltransferase 1-7 protein, is involved in the metabolism of drugs and xenobiotics. Variation of the gene is associated with decreased metabolic activity.","UGT1A7 wt Allele | 1-7 | UDP Glucuronosyltransferase 1 Family, Polypeptide A7 wt Allele | UDP Glycosyltransferase 1 Family, Polypeptide A6 Gene | UDPGT | UGT-1G | UGT1-07 | UGT1.7 | UGT1G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540825","MIR382 wt Allele","C104666","Human MIR382 wild-type allele is located in the vicinity of 14q32.31 and is approximately 76 bp in length. This allele, which encodes MIR382 pre-microRNA, is involved in the regulation of transcription.","MIR382 wt Allele | MIRN382 | MicroRNA 382 wt Allele | hsa-mir-382 | mir-382",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641848","MIR382 Pre-miRNA","C104667","MIR382 pre-microRNA (76 bases) is encoded by the human MIR382 gene. This oligoribonucleotide plays a role in the regulation of transcription.","MIR382 Pre-miRNA | Pre-miRNA MIR382 | Pre-microRNA MIR382",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540494","BHMT wt Allele","C104870","Human BHMT wild-type allele is located in the vicinity of 5q14.1 and is approximately 21 kb in length. This allele, which encodes betaine-homocysteine S-methyltransferase 1 protein, plays a role in amino acid metabolism.","BHMT wt Allele | BHMT1 | Betaine--Homocysteine S-Methyltransferase wt Allele | Betaine-Homocysteine S-Methyltransferase Gene | HEL-S-61p",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641871","Megavoltage Planar Imaging","C104871","Planar imaging that includes megavoltage images.","Megavoltage Planar Imaging | MV - radiography | MV Planar Imaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1530585","Betaine-Homocysteine S-Methyltransferase 1, Human","C104872","Betaine-homocysteine S-methyltransferase 1 (406 aa, ~45 kDa) is encoded by the human BHMT gene. This protein is involved in the metabolism of homocysteine.","Betaine-Homocysteine S-Methyltransferase 1 | BHMT | BHMT1 | Betaine--Homocysteine Methyltransferase | Betaine--Homocysteine S-Methyltransferase 1 | Betaine—Homocysteine S-Methyltransferase | EC 2.1.1.5 | Epididymis Secretory Sperm Binding Protein Li 61p",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641872","Kilovoltage Planar Imaging","C104873","Planar imaging that includes kilovoltage images.","Kilovoltage Planar Imaging | KV Planar Imaging | kV - radiography | kV Planar Imaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538839","CYP26B1 wt Allele","C104875","Human CYP26B1 wild-type allele is located in the vicinity of 2p13.2 and is approximately 19 kb in length. This allele, which encodes cytochrome P450 26B1 protein, is involved in the specific inactivation of all-trans-retinoic acid. Mutations in this gene are associated with craniofacial and other skeletal anomalies.","CYP26B1 wt Allele | CYP26A2 | Cytochrome P450, Family 26, Subfamily B, Polypeptide 1 wt Allele | Cytochrome P450, Subfamily XXVIA, Polypeptide 2 Gene | Cytochrome P450, Subfamily XXVIB, Polypeptide 1 Gene | P450, Retinoic Acid-Inactivating, 2 Gene | P450RAI-2 | P450RAI2 | RHFCA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641873","Cytochrome P450 26B1","C104876","Cytochrome P450 26B1 (512 aa, ~58 kDa) is encoded by the human CYP26B1 gene. This protein plays a role in the metabolism of all-trans-retinoic acid.","Cytochrome P450 26B1 | CYP26B1 | Cytochrome P450 26A2 | Cytochrome P450 Retinoic Acid-Inactivating 2 | Cytochrome P450 Retinoid Metabolizing Protein | Cytochrome P450RAI-2 | EC 1.14.-.- | Retinoic Acid-Metabolizing Cytochrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641874","Megavoltage Cone Beam Computed Tomography","C104877","Cone beam computed tomography that includes megavoltage images.","Megavoltage Cone Beam Computed Tomography | Cone Beam Megavoltage CT | Cone Beam Megavoltage CT Imaging | Cone Beam Megavoltage Computed Tomography | Cone Beam Megavoltage Computed Tomography Imaging | Cone Beam Megavoltage Imaging | Conebeam CT - MV | MV Cone Beam CT | Megavoltage Computed Tomography",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538826","DND1 wt Allele","C104879","Human DND1 wild-type allele is located in the vicinity of 5q31.3 and is approximately 3 kb in length. This allele, which encodes dead end protein homolog 1 protein, plays a role in regulating gene expression by prohibiting miRNA-mediated gene suppression. Reduced expression of this gene has been implicated in tongue squamous cell carcinoma.","DND1 wt Allele | Dead End Homolog 1 (Zebrafish) wt Allele | MGC34750 | RBMS4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642141","APOE*4 Allele","C105362","Human APOE*4 allele is located in the vicinity of 19q13.2 and is approximately 4 kb in length. This allele, which encodes apolipoprotein E4 protein, plays a role in triglyceride metabolism. The allele is associated with increased occurrence of both Alzheimer disease and coronary artery disease.","APOE*4 Allele | APOE*E4 | APOE-epsilon4 Allele | APOE4 Allele | ApoE4 | Apolipoprotein E*4 Allele | Apolipoprotein E4 Allele | NM_000041.2:c.388T>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642142","APOE Gene Product","C105363","A protein encoded by the APOE gene.","APOE Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642145","NTRK1 Gene Product","C105367","A protein encoded by the NTRK1 gene.","NTRK1 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642147","MIR518E Pre-miRNA","C105373","MIR518E pre-miRNA (88 nucleotides) is encoded by the human MIR518E gene. This oligoribonucleotide may be involved in gene silencing.","MIR518E Pre-miRNA | Pre-MicroRNA 518e | Pre-miRNA 518e",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0674683","DNA Repair Protein RAD50, Human","C104710","DNA repair protein RAD50 (1312 aa, ~154 kDa) is encoded by the human RAD50 gene. This protein plays a role in DNA double-strand break repair, cell cycle checkpoint activation, telomere maintenance, and meiotic recombination.","DNA Repair Protein RAD50 | EC 3.6.1.15 | EC 3.6.3.27 | RAD50 | hRAD50",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641406","IIEF - Satisfied with Your Sexual Relationship with Your Partner","C103600","International Index of Erectile Function (IIEF) Over the past four weeks how satisfied have you been with your sexual relationship with your partner?","IIEF - Satisfied with Your Sexual Relationship with Your Partner | IIEF01-Relationship Satisfaction | IIEF01-Satisfy with Sexual Relationship | IIEF0114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641407","IIEF - Your Confidence to Get and Keep an Erection","C103601","International Index of Erectile Function (IIEF) Over the past four weeks how do you rate your confidence that you could get and keep an erection?","IIEF - Your Confidence to Get and Keep an Erection | IIEF01-Confidence to Get/Keep Erection | IIEF01-Erection Confidence | IIEF0115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641408","NPI - Delusions Frequency","C103602","Neuropsychiatric Inventory (NPI) Frequency of the delusions.","NPI - Delusions Frequency | NPI1-Delusions Frequency | NPI1A10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641409","NPI - Delusions Severity","C103603","Neuropsychiatric Inventory (NPI) Severity of the delusions.","NPI - Delusions Severity | NPI1-Delusions Severity | NPI1A11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641410","NPI - Delusions Distress","C103604","Neuropsychiatric Inventory (NPI) Delusion: How emotionally distressing do you find this behavior?","NPI - Delusions Distress | NPI1-Delusions Distress | NPI1A12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539636","HDAC11 wt Allele","C104288","Human HDAC11 wild-type allele is located in the vicinity of 3p25.1 and is approximately 27 kb in length. This allele, which encodes histone deacetylase 11 protein, plays a role in the epigenetic regulation of transcription.","HDAC11 wt Allele | HD11 | Histone Deacetylase 11 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538129","Histone Deacetylase 11, Human","C104289","Histone deacetylase 11 (347 aa, ~39 kDa) is encoded by the human HDAC11 gene. This protein is involved in both histone deacetylation and transcriptional regulation.","Histone Deacetylase 11 | EC 3.5.1.98 | HD11 | HDAC11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL445626","Anti-Tissue Factor Monoclonal Antibody MORAb-066","C104291","A humanized monoclonal antibody against human tissue factor (TF), with potential antiangiogenic, anticoagulant and anti-inflammatory activities. Upon administration, anti-TF monoclonal antibody MORAb-066 binds to TF and prevents Factor VIIa (FVIIa) from binding, thereby interfering with the activation of Factor X (FX) into FXa. This may prevent thrombin formation and cancer-associated venous thromboembolism, and may inhibit angiogenesis and tumor cell proliferation. TF, a transmembrane protein and initiator of the coagulation cascade, is overexpressed in many tumor cells and tumor endothelial cells; its expression is correlated with metastasis, angiogenesis, tumor cell growth and tumor-associated thrombosis.","Anti-Tissue Factor Monoclonal Antibody MORAb-066 | Anti-TF Monoclonal Antibody MORAb-066 | MORAb-066",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL445627","PI3K/mTOR/ALK-1/DNA-PK inhibitor P7170","C104292","An orally bioavailable inhibitor of phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR), activin receptor-like kinase 1 (ALK-1) and DNA-dependent protein kinase (DNA-PK), with potential anti-angiogenic and antineoplastic activities. Upon oral administration, panulisib inhibits the activity of all four kinases. This prevents PI3K/mTOR and ALK-1-mediated signaling pathways and may lead to the inhibition of cancer cell growth in PI3K/mTOR-overexpressing tumor cells and angiogenesis in ALK-1-overexpressing endothelial cells. Also, by inhibiting DNA-PK, this agent inhibits the ability of tumor cells to repair damaged DNA. The PI3K/mTOR pathway is upregulated in a variety of tumors and plays an important role in regulating cancer cell proliferation, growth, and survival. ALK-1, a member of the transforming growth factor beta (TGF-b) type I receptor family, is overexpressed on endothelial cells in a variety of tumor types and increases endothelial cell proliferation and migration. DNA-PK is activated upon DNA damage and plays a key role in repairing double-stranded DNA breaks.","Panulisib | AK15176 | P7170 | PANULISIB | PI3K/mTOR/ALK-1/DNA-PK Inhibitor P7170",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537334","UDP-Glucuronosyltransferase 1-7","C104106","UDP-glucuronosyltransferase 1-7 (530 aa, ~60 kDa) is encoded by the human UGT1A7 gene. This protein is involved in the conjugation and elimination of toxins.","UDP-Glucuronosyltransferase 1-7 | EC 2.4.1.17 | UDP-Glucuronosyltransferase 1-G | UDP-Glucuronosyltransferase 1A7 | UDPGT 1-7 | UGT-1G | UGT1*7 | UGT1-07 | UGT1.7 | UGT1A7 | UGT1G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540595","CD8A wt Allele","C104108","Human CD8A wild-type allele is located in the vicinity of 2p11.2 and is approximately 24 kb in length. This allele, which encodes T-cell surface glycoprotein CD8 alpha chain protein, plays a role in antigen recognition by T-cells.","CD8A wt Allele | CD8 | CD8a Molecule wt Allele | Leu2 | MAL | p32",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1721291","T-Cell Surface Glycoprotein CD8 Alpha Chain, Human","C104109","T-cell surface glycoprotein CD8 alpha chain (235 aa, ~26 kDa) is encoded by the human CD8A gene. This protein is involved in cell-cell interactions during antigen recognition by T-cells.","T-Cell Surface Glycoprotein CD8 Alpha Chain | CD8a Molecule | Leu2 T-Lymphocyte Antigen | OKT8 T-Cell Antigen | T-Cell Antigen Leu2 | T-Lymphocyte Differentiation Antigen T8/Leu-2 | p32",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541310","CDC20 wt Allele","C104111","Human CDC20 wild-type allele is located in the vicinity of 1p34.1 and is approximately 4 kb in length. This allele, which encodes cell division cycle protein 20 homolog protein, is involved in spindle assembly checkpoint and metaphase arrest.","CDC20 wt Allele | CDC20A | Cell Division Cycle 20 Homolog (S. cerevisiae) wt Allele | bA276H19.3 | p55CDC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539866","Cell Division Cycle Protein 20 Homolog","C104112","Cell division cycle protein 20 homolog (499 aa, ~55 kDa) is encoded by the human CDC20 gene. This protein plays a role in metaphase arrest.","Cell Division Cycle Protein 20 Homolog | CDC20 | p55CDC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539566","CEACAM1 wt Allele","C104114","Human CEACAM1 wild-type allele is located in the vicinity of 19q13.2 and is approximately 21 kb in length. This allele, which encodes carcinoembryonic antigen-related cell adhesion molecule 1 protein, plays a role in cell-cell interactions in differentiation, angiogenesis, apoptosis, immune response, and tumorigenesis.","CEACAM1 wt Allele | BGP | BGP1 | BGPI | CD66a | Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (Biliary Glycoprotein) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0378910","Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1","C104115","Carcinoembryonic antigen-related cell adhesion molecule 1 (526 aa, ~58 kDa) is encoded by the human CEACAM1 gene. This protein is involved in differentiation, angiogenesis, apoptosis, immune response, and tumorigenesis.","Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 | BGP-1 | Biliary Glycoprotein 1 | CD66a Antigen | CEACAM1",,,,,,,,,,,,,,,"4011785","Lymphocyte antigen CD66A",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2743373","CEBPB protein, human","C104118","CCAAT/enhancer-binding protein beta (345 aa, ~36 kDa) is encoded by the human CEBPB gene. This protein plays a role in the regulation of acute-phase reaction, inflammation and hemopoiesis.","CCAAT/Enhancer Binding Protein Beta | CEBPB | Interleukin 6-Dependent DNA-Binding Protein | Liver Activator Protein | Nuclear Factor of Interleukin 6 | TCF-5 | Transcription Factor 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641875","Kilovoltage Cone Beam Computed Tomography","C104880","Cone beam computed tomography that includes kilovoltage images.","Kilovoltage Cone Beam Computed Tomography | Cone Beam Kilovoltage CT Imaging | Cone Beam Kilovoltage Computed Tomography | Cone Beam Kilovoltage Computed Tomography Imaging | Cone Beam Kilovoltage Imaging | Conebeam CT - kV | KV Cone Beam CT | kV Cone Beam CT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541985","BHMT2 wt Allele","C104883","Human BHMT2 wild-type allele is located in the vicinity of 5q13 and is approximately 20 kb in length. This allele, which encodes S-methylmethionine-homocysteine S-methyltransferase BHMT2 protein, is involved in methionine synthesis.","BHMT2 wt Allele | Betaine--Homocysteine S-Methyltransferase 2 wt Allele | Betaine-Homocysteine S-Methyltransferase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540645","Tyrosyl-DNA Phosphodiesterase 1","C105096","Tyrosyl-DNA phosphodiesterase 1 (608 aa, ~68 kDa) is encoded by the human TDP1 gene. This protein plays a role in single and double strand break repair of DNA.","Tyrosyl-DNA Phosphodiesterase 1 | EC 3.1.4.- | TDP1 | Tyr-DNA Phosphodiesterase 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540579","NELFCD wt Allele","C105098","Human NELFCD wild-type allele is located in the vicinity of 20q13 and is approximately 14 kb in length. This allele, which encodes negative elongation factor C/D protein, plays a role in the inhibition of transcriptional elongation.","NELFCD wt Allele | HSPC130 | NELF-C | NELF-D | NELFD | Negative Elongation Factor Complex Member C/D wt Allele | TH1 | TH1-Like (Drosophila) Gene | TH1L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1451170","Negative Elongation Factor C/D","C105099","Negative elongation factor C/D (590 aa, ~66 kDa) is encoded by the human NELFCD gene. This protein is involved in transcriptional pausing.","Negative Elongation Factor C/D | NELF-C/D | NELFCD | Negative Elongation Factor Proteins C and D | TH1-Like Protein | Trihydrophobin 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0130561","Asulacrine Isethionate","C1050","The isethionate salt of an amsacrine analogue with antineoplastic properties. Asulacrine inhibits the enzyme topoisomerase ll, thereby blocking DNA replication and RNA and protein synthesis.","Asulacrine Isethionate | 9-(2-Methoxy-4-(methylsulfonylamino)phenylamino)-N,5-dimethyl-4-acridinecarboxamide 2-hydroxyethanesulfonate | ASULACRINE ISETHIONATE | CI-921",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541334","TMPO wt Allele","C105101","Human TMPO wild-type allele is located in the vicinity of 12q22 and is approximately 34 kb in length. This allele, which encodes both lamina-associated polypeptide 2, isoform alpha and lamina-associated polypeptide 2, isoforms beta/gamma proteins, is involved in the maintenance of nuclear structure. Mutation of the gene is associated with cardiomyopathy dilated type 1T.","TMPO wt Allele | CMD1T | LAP2 | LEMD4 | PRO0868 | TP | Thymopoietin wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538883","Lamina-Associated Polypeptide 2, Isoform Alpha","C105102","Lamina-associated polypeptide 2, isoform alpha (694 aa, ~75 kDa) is encoded by the human TMPO gene. This protein plays a role in the structure of the nucleus.","Lamina-Associated Polypeptide 2, Isoform Alpha | LEM Domain Containing 4 | Lamina-Associated Polypeptide 2 | TMPO | TP Alpha | TPRP Isoform Alpha | Thymopoietin | Thymopoietin Isoform Alpha | Thymopoietin-Related Peptide Isoform Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539698","RAD51 wt Allele","C104712","Human RAD51 wild-type allele is located in the vicinity of 15q15.1 and is approximately 37 kb in length. This allele, which encodes DNA repair protein RAD51 homolog 1 protein, plays a role in both DNA repair and homologous recombination.","RAD51 wt Allele | BRCC5 | FANCR | HRAD51 | HsRad51 | HsT16930 | MRMV2 | RAD51 Homolog (S. cerevisiae) Gene | RAD51 Recombinase wt Allele | RAD51, S. cerevisiae, Homolog of A Gene | RAD51, S. cerevisiae, Homolog of Gene | RAD51A | RECA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539765","DNA Repair Protein RAD51 Homolog 1","C104713","DNA repair protein RAD51 homolog 1 (339 aa, ~37 kDa) is encoded by the human RAD51 gene. This protein is involved in both homologous recombination and DNA repair.","DNA Repair Protein RAD51 Homolog 1 | BRCA1/BRCA2-Containing Complex, Subunit 5 | RAD51 | RAD51 (S. cerevisiae) Homolog (E coli RecA Homolog) | RAD51 Homolog (RecA Homolog, E. coli) | RAD51 Homolog (RecA Homolog, E. coli) (S. cerevisiae) | RAD51 Homolog A | RecA, E. coli, Homolog of | RecA-Like Protein | Recombination Protein A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541418","PARK7 wt Allele","C104715","Human PARK7 wild-type allele is located in the vicinity of 1p36.23 and is approximately 31 kb in length. This allele, which encodes protein DJ-1, is involved in the negative regulation of apoptosis. Mutation of the gene is associated with Parkinson disease type 7.","PARK7 wt Allele | CTA-215D11.1 | DJ-1 | DJ1 | Parkinson Disease (Autosomal Recessive, Early Oonset) 7 Gene | Parkinson Protein 7 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0537311","PARK7 protein, human","C104716","Protein DJ-1 (189 aa, ~20 kDa) is encoded by the human PARK7 gene. This protein plays a role in the downregulation of apoptosis.","Protein DJ-1 | EC 3.4.-.- | Oncogene DJ1 | PARK7 | Parkinson Disease Protein 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539531","PARP2 wt Allele","C104718","Human PARP2 wild-type allele is located within 14q11.2-q12 and is approximately 14 kb in length. This allele, which encodes poly [ADP-ribose] polymerase 2 protein, plays a role in DNA repair through base excision.","PARP2 wt Allele | ADP-Ribosyltransferase (NAD+; Poly(ADP-Ribose) Polymerase)-Like 2 Gene | ADPRT2 | ADPRTL2 | ADPRTL3 | ARTD2 | PARP-2 | Poly (ADP-Ribose) Polymerase 2 Gene | Poly (ADP-Ribose) Polymerase Family, Member 2 Gene | Poly(ADP-Ribose) Polymerase 2 wt Allele | pADPRT-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1436356","Poly [ADP-Ribose] Polymerase 2, Human","C104720","Poly [ADP-ribose] polymerase 2 (583 aa, ~66 kDa) is encoded by the human PARP2 gene. This protein is involved in the initiation of DNA repair.","Poly [ADP-Ribose] Polymerase 2 | ADP-Ribosyltransferase 2 | ADP-Ribosyltransferase Diphtheria Toxin-Like 2 | ADP-Ribosyltransferase-Like 2 | ADPRT-2 | ARTD2 | EC 2.4.2.30 | NAD(+) ADP-Ribosyltransferase 2 | PARP-2 | PARP2 | Poly (ADP-Ribose) Polymerase 2 | Poly (ADP-Ribosyl) Transferase-Like 2 | Poly(ADP-Ribose) Synthase 2 | Poly[ADP-Ribose] Synthase 2 | hPARP-2 | pADPRT-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538820","RASSF5 wt Allele","C104721","Human RASSF5 wild-type allele is located in the vicinity of 1q32.1 and is approximately 82 kb in length. This allele, which encodes RAS association domain-containing protein 5, is involved in both tumor suppression and lymphocyte adhesion.","RASSF5 wt Allele | Maxp1 | NORE1 | NORE1A | NORE1B | RAPL | RAS Association (RalGDS/AF-6) Domain Family Member 5 Gene wt Allele | RASSF3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1122251","Ras Association Domain-Containing Protein 5, Human","C104722","RAS association domain-containing protein 5 (418 aa, ~47 kDa) is encoded by the human RASSF5 gene. This protein plays a role in both lymphocyte adhesion and tumor suppression.","Ras Association Domain-Containing Protein 5 | New RAS Effector 1 | Novel RAS Effector 1 | RAS Association (RalGDS/AF-6) Domain Family 5 | RAS Association Domain-Containing Protein 5 | RAS Effector-Like Protein | Rap1-Binding Protein | Regulator for Cell Adhesion and Polarization Enriched in Lymphoid Tissue | Tumor Suppressor RASSF3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280837","cisplatin/cyclophosphamide/doxorubicin/prednisone","C10429","A regimen consisting of cisplatin, cyclophosphamide, doxorubicin and prednisone that can be used for the treatment of thymomas and thymic carcinomas.","Cisplatin/Cyclophosphamide/Doxorubicin/Prednisone Regimen | CAPPr | CDDP/CTX/DOX/PRED | Cisplatin-Cyclophosphamide-Doxorubicin-Prednisone | Cisplatin/Cyclophosphamide/Doxorubicin/Prednisone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641645","Hemoglobin Variant Measurement","C103845","A test to measure the variants of hemoglobin.","Hemoglobin Variant Measurement | HGBVAR | Hemoglobin Variants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641652","Cycled Drug Stability Study-Complex","C103853","No value exists.","Cycled Drug Stability Study-Complex | Cycled-Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641461","OAB-q - Sudden Urge to Urinate with Little or No Warning","C103655","The Overactive Bladder Questionnaire (OAB-q) A sudden urge to urinate with little or no warning?","OAB-q - Sudden Urge to Urinate with Little or No Warning | OABQ01-Sudden Urge to Urinate No Warning | OABQ0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641462","OAB-q - Accidental Loss of Urine","C103656","The Overactive Bladder Questionnaire (OAB-q) Accidental loss of small amounts of urine?","OAB-q - Accidental Loss of Urine | OABQ01-Accidental Loss of Urine | OABQ0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641463","OAB-q - Nighttime Urination","C103657","The Overactive Bladder Questionnaire (OAB-q) Nighttime urination?","OAB-q - Nighttime Urination | OABQ01-Nighttime Urination | OABQ0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641464","OAB-q - Waking Up at Night Because You had to Urinate","C103658","The Overactive Bladder Questionnaire (OAB-q) Waking up at night because you had to urinate?","OAB-q - Waking Up at Night Because You had to Urinate | OABQ01-Waking Up at Night had to Urinate | OABQ0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641465","OAB-q - Uncontrollable Urge to Urinate","C103659","The Overactive Bladder Questionnaire (OAB-q) An uncontrollable urge to urinate?","OAB-q - Uncontrollable Urge to Urinate | OABQ01-Uncontrollable Urge to Urinate | OABQ0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641466","OAB-q - Urine Loss Associated with a Strong Desire to Urinate","C103660","The Overactive Bladder Questionnaire (OAB-q) Urine loss associated with a strong desire to urinate?","OAB-q - Urine Loss Associated with a Strong Desire to Urinate | OABQ01-Urine Loss Strong Desire Urinate | OABQ0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641467","OAB-q - Carefully Plan Your Commute","C103661","The Overactive Bladder Questionnaire (OAB-q) Made you carefully plan your commute?","OAB-q - Carefully Plan Your Commute | OABQ01-Carefully Plan Your Commute | OABQ0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641468","OAB-q - Feel Drowsy or Sleepy During the Day","C103662","The Overactive Bladder Questionnaire (OAB-q) Caused you to feel drowsy or sleepy during the day?","OAB-q - Feel Drowsy or Sleepy During the Day | OABQ01-Feel Drowsy or Sleepy During Day | OABQ0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641470","OAB-q - Caused You Distress","C103664","The Overactive Bladder Questionnaire (OAB-q) Caused you distress?","OAB-q - Caused You Distress | OABQ01-Caused You Distress | OABQ0112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641471","OAB-q - Frustrated You","C103665","The Overactive Bladder Questionnaire (OAB-q) Frustrated you?","OAB-q - Frustrated You | OABQ01-Frustrated You | OABQ0113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641472","OAB-q - Feel Like There is Something Wrong with You","C103666","The Overactive Bladder Questionnaire (OAB-q) Made you feel like there is something wrong with you?","OAB-q - Feel Like There is Something Wrong with You | OABQ01-Feel Something Wrong with You | OABQ0114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641473","OAB-q - Interfered with a Good Night's Rest","C103667","The Overactive Bladder Questionnaire (OAB-q) Interfered with your ability to get a good night's rest?","OAB-q - Interfered with a Good Night's Rest | OABQ01-Interfered with Good Night's Rest | OABQ0115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641474","OAB-q - Decrease Your Physical Activities","C103668","The Overactive Bladder Questionnaire (OAB-q) Caused you to decrease your physical activities (exercising, sports, etc.)?","OAB-q - Decrease Your Physical Activities | OABQ01-Decrease Your Physical Activities | OABQ0116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641475","OAB-q - Prevented You From Feeling Rested Upon Waking","C103669","The Overactive Bladder Questionnaire (OAB-q) Prevented you from feeling rested upon waking in the morning?","OAB-q - Prevented You From Feeling Rested Upon Waking | OABQ01-Prevented From Feeling Rested | OABQ0117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538882","Lamina-Associated Polypeptide 2, Isoforms Beta/Gamma","C105103","Lamina-associated polypeptide 2, isoforms beta/gamma (694 aa, ~75 kDa) is encoded by the human TMPO gene. This protein is involved in the mediation of nuclear structure.","Lamina-Associated Polypeptide 2, Isoforms Beta/Gamma | LEM Domain Containing 4 | Lamina-Associated Polypeptide 2 | TMPO | TP Beta/Gamma | TPRP Isoforms Beta/Gamma | Thymopoietin | Thymopoietin, Isoforms Beta/Gamma | Thymopoietin-Related Peptide Isoforms Beta/Gamma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541230","TMEM204 wt Allele","C105106","Human TMEM204 wild-type allele is located in the vicinity of 16p13.3 and is approximately 27 kb in length. This allele, which encodes transmembrane protein 204, plays a role in the regulation of cell-cell adhesion.","TMEM204 wt Allele | C16orf30 | CLP24 | Chromosome 16 Open Reading Frame 30 Gene | Transmembrane Protein 204 wt Allele | UNQ6509/PRO21434",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538881","Transmembrane Protein 204, Human","C105107","Transmembrane protein 204 (226 aa, ~25 kDa) is encoded by the human TMEM204 gene. This protein is involved in cellular permeability.","Transmembrane Protein 204 | Claudin-Like Protein 24 | TMEM204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540503","TRAF1 wt Allele","C105109","Human TRAF1 wild-type allele is located within 9q33-q34 and is approximately 27 kb in length. This allele, which encodes TNF receptor-associated factor 1 protein, is involved in both the modulation of TNF receptor family-mediated signal transduction and the regulation of protein ubiquitination.","TRAF1 wt Allele | EBI6 | MGC:10353 | TNF Receptor-Associated Factor 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642091","ADCS-ADL - How Subject Usually Selects Items","C105312","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Which one best describes how the subject usually selects items.","ADCS-ADL - How Subject Usually Selects Items | ADL01-How Usually Selects Items | ADL0116A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642092","ADCS-ADL - Pay for Items Without Supervision or Physical Help","C105313","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Did the subject usually pay for items without supervision or physical help?","ADCS-ADL - Pay for Items Without Supervision or Physical Help | ADL01-Pay Without Supervision | ADL0116B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642093","ADCS-ADL - Keep Appointments or Meetings with Others","C105314","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, did the subject keep appointments or meetings with other people, such as relatives, a doctor, the hairdresser, etc.?","ADCS-ADL - Keep Appointments or Meetings with Others | ADL01-Keep Appointments | ADL0117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642094","ADCS-ADL - Description of Awareness of Appointment Ahead of Time","C105315","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) If yes, which best describes his/her awareness of the meeting ahead of time.","ADCS-ADL - Description of Awareness of Appointment Ahead of Time | ADL01-Aware of Appointment Ahead of Time | ADL0117A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642095","ADCS-ADL - Subject Left on Their Own","C105316","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, was the subject ever left on his/her own?","ADCS-ADL - Subject Left on Their Own | ADL01-Left On His/Her Own | ADL0118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642096","ADCS-ADL - Left Away From Home for Fifteen Minutes or Longer","C105317","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Was the subject left away from home, for 15 minutes or longer, during the day?","ADCS-ADL - Left Away From Home for Fifteen Minutes or Longer | ADL01-Left Away From Home | ADL0118A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642097","ADCS-ADL - Left at Home for One Hour or Longer","C105318","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Was the subject left: at home, for an hour or longer, during the day?","ADCS-ADL - Left at Home for One Hour or Longer | ADL01-Left at Home for 1 Hour or Longer | ADL0118B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640394","ADNI AVLT - List A Recall 6 (After B) Word 9","C101989","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 6 (after B Recall), Word 9.","ADNI AVLT - List A Recall 6 (After B) Word 9 | AVL01-List A Recall 6 (After B) Word 9 | AVL01094",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640395","ADNI AVLT - List A Recall 6 (After B) Word 10","C101990","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 6 (after B Recall), Word 10.","ADNI AVLT - List A Recall 6 (After B) Word 10 | AVL01-List A Recall 6 (After B) Word 10 | AVL01095",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640396","ADNI AVLT - List A Recall 6 (After B) Word 11","C101991","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 6 (after B Recall), Word 11.","ADNI AVLT - List A Recall 6 (After B) Word 11 | AVL01-List A Recall 6 (After B) Word 11 | AVL01096",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640397","ADNI AVLT - List A Recall 6 (After B) Word 12","C101992","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 6 (after B Recall), Word 12.","ADNI AVLT - List A Recall 6 (After B) Word 12 | AVL01-List A Recall 6 (After B) Word 12 | AVL01097",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640398","ADNI AVLT - List A Recall 6 (After B) Word 13","C101993","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 6 (after B Recall), Word 13.","ADNI AVLT - List A Recall 6 (After B) Word 13 | AVL01-List A Recall 6 (After B) Word 13 | AVL01098",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640399","ADNI AVLT - List A Recall 6 (After B) Word 14","C101994","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 6 (after B Recall), Word 14.","ADNI AVLT - List A Recall 6 (After B) Word 14 | AVL01-List A Recall 6 (After B) Word 14 | AVL01099",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640894","Previous Patient Noncompliance","C102698","A previous episode of failure by a patient to follow medical advice, take medication as directed, or adhere to a prescribed course of treatment.","Previous Patient Noncompliance | PREVIOUS PATIENT NONCOMPLIANCE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1443309","Reason for Treatment","C102702","The reason the treatment was administered.","Reason for Treatment | ",,,,,,,,,,,,,,,"4256917","Reasons for treatment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3538938","Amyloid Beta A4 Precursor Protein-Binding Family A Member 1, Human","C104829","Amyloid beta A4 precursor protein-binding family A member 1 (837 aa, ~93 kDa) is encoded by the human APBA1 gene. This protein is involved in both the proteolytic processing of amyloid beta A4 precursor protein and neuronal vesicle exocytosis.","Amyloid Beta A4 Precursor Protein-Binding Family A Member 1 | APBA1 | Adapter Protein X11alpha | Mint-1 | Neuron-Specific X11 Protein | Neuronal Munc18-1-Interacting Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541430","CAMK2B wt Allele","C104831","Human CAMK2B wild-type allele is located within 7p14.3-p14.1 and is approximately 117 kb in length. This allele, which encodes calcium/calmodulin-dependent protein kinase type II subunit beta protein, is involved in calcium signaling and neuron function.","CAMK2B wt Allele | CAM2 | CAMK2 | CAMKB | Calcium/Calmodulin-Dependent Protein Kinase II Beta wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1869377","Calcium/Calmodulin-Dependent Protein Kinase Type II Subunit Beta, Human","C104832","Calcium/calmodulin-dependent protein kinase type II subunit beta (666 aa, ~73 kDa) is encoded by the human CAMK2B gene. This protein plays a role in calcium signaling in the central nervous system.","Calcium/Calmodulin-Dependent Protein Kinase Type II Subunit Beta | CaM Kinase II Beta Subunit | CaM Kinase II Subunit Beta | CaM-Kinase II Beta Chain | CaMK-II Subunit Beta | Calcium/Calmodulin-Dependent Protein Kinase (CaM Kinase) II Beta | EC 2.7.11.1 | Proline Rich Calmodulin-Dependent Protein Kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541431","CAMK2G wt Allele","C104834","Human CAMK2G wild-type allele is located in the vicinity of 10q22 and is approximately 62 kb in length. This allele, which encodes calcium/calmodulin-dependent protein kinase type II subunit gamma protein, plays a role in calcium signaling.","CAMK2G wt Allele | CAMK | CAMK-II | CAMKG | Calcium/Calmodulin-Dependent Protein Kinase II Gamma wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006776","Calcium/Calmodulin-Dependent Protein Kinase Type II Subunit Gamma","C104835","Calcium/calmodulin-dependent protein kinase type II subunit gamma (558 aa, ~63 kDa) is encoded by the human CAMK2G gene. This protein is involved in calcium signaling.","Calcium/Calmodulin-Dependent Protein Kinase Type II Subunit Gamma | CAMK2G | CaM Kinase II Subunit Gamma | CaMK-II Subunit Gamma | Calcium/Calmodulin-Dependent Protein Kinase (CaM Kinase) II Gamma | EC 2.7.11.17",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541983","CDC25B wt Allele","C104837","Human CDC25B wild-type allele is located in the vicinity of 20p13 and is approximately 19 kb in length. This allele, which encodes M-phase inducer phosphatase 2 protein, is involved in control of progression through the cell cycle.","CDC25B wt Allele | CDC25HU2 | Cell Division Cycle 25B wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1563402","M-Phase Inducer Phosphatase 2, Human","C104838","M-phase inducer phosphatase 2 (580 aa, ~65 kDa) is encoded by the human CDC25B gene. This protein plays a role in progression through the mitotic cell cycle.","M-Phase Inducer Phosphatase 2 | CDC25B | Cell Division Cycle 25 Homolog B (S. cerevisiae) | Cell Division Cycle 25 Homolog B (S. pombe) | Dual Specificity Phosphatase Cdc25B | EC 3.1.3.48",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539709","NANOS3 wt Allele","C104840","Human NANOS3 wild-type allele is located in the vicinity of 19p13.13 and is approximately 4 kb in length. This allele, which encodes nanos homolog 3 protein, plays a role in maintaining germ cells in an undifferentiated state.","NANOS3 wt Allele | NANOS1L | NOS-3 | NOS3 | Nanos Homolog 3 (Drosophila) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641870","NANOS3 protein, human","C104841","Nanos homolog 3 (173 aa, ~19 kDa) is encoded by the human NANOS3 gene. This protein is involved in maintaining germ cells in an undifferentiated state.","Nanos Homolog 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541279","SRD5A3 wt Allele","C105162","Human SRD5A3 wild-type allele is located 4q12 and is approximately 27 kb in length. This allele, which encodes probable polyprenol reductase protein, is involved in both the metabolism of testosterone and the early steps of protein N-linked glycosylation.  Mutations in this gene are associated with congenital disorder of glycosylation type Iq.","SRD5A3 wt Allele | CDG1P | CDG1Q | FLJ13352 | KRIZI | S5AR 3 | SRD5A2L | SRD5A2L1 | Steroid 5 Alpha-Reductase 3 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538879","Probable Polyprenol Reductase, Human","C105163","Probable polyprenol reductase (318 aa, ~37 kDa) is encoded by the human SRD5A3 gene. This protein plays a role in the metabolism of testosterone and maintenance of the androgen-androgen receptor activation pathway.","Probable Polyprenol Reductase | 3-Oxo-5-Alpha-Steroid 4-Dehydrogenase 3 | EC 1.3.1.30 | SR Type 3 | SRD5A3 | Steroid 5-Alpha-Reductase 2-Like | Steroid 5-Alpha-Reductase 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641949","DAD - Decide to Wash or Take a Bath or Shower","C105170","Disability Assessment for Dementia (DAD) Decide to wash himself/herself or to take a bath or shower?","DAD - Decide to Wash or Take a Bath or Shower | DAD01-Decide to Wash | DAD0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641951","DAD - Decide to Care for His/Her Hair","C105172","Disability Assessment for Dementia (DAD) Decide to care for his/her hair (wash and comb)?","DAD - Decide to Care for His/Her Hair | DAD01-Decide to Care For Hair | DAD0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539673","S1PR4 wt Allele","C104780","Human S1PR4 wild-type allele is located in the vicinity of 19p13.3 and is approximately 2 kb in length. This allele, which encodes sphingosine 1-phosphate receptor 4 protein, may play a role in cell migration processes in lymphocytes.","S1PR4 wt Allele | EDG6 | LPC1 | S1P4 | SLP4 | Sphingosine-1-Phosphate Receptor 4 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541911","Sphingosine 1-Phosphate Receptor 4","C104781","Sphingosine 1-phosphate receptor 4 (384 aa, ~42 kDa) is encoded by the human S1PR4 gene. This G protein-coupled receptor may be involved in cell migration processes in lymphocytes.","Sphingosine 1-Phosphate Receptor 4 | Endothelial Differentiation G-Protein Coupled Receptor 6 | Endothelial Differentiation, G Protein Coupled Receptor 6 | Endothelial Differentiation, G-Protein-Coupled Receptor 6 | Endothelial Differentiation, Lysophosphatidic Acid G-Protein-Coupled Receptor, 6 | S1P Receptor 4 | S1P Receptor EDG-6 | Sphingosine 1-Phosphate Receptor EDG6 | Sphingosine-1-Phosphate Receptor 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641907","Rectal Balloon","C104992","An air filled rectal balloon that is used for prostate immobilization in patients receiving radiation therapy for prostate cancer.","Rectal Balloon | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641909","Electronic Portal Imaging (device)","C104994","The acquisition of images of an anatomic area that is being irradiated using radiotherapy beams and an electronic detector.","Electronic Portal Imaging | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538781","SCGB3A1 wt Allele","C104996","Human SCGB3A1 wild-type allele is located within 5q35-qter and is approximately 1 kb in length. This allele encodes secretoglobin family 3A member 1 protein, a secreted protein of unknown function.","SCGB3A1 wt Allele | HIN-1 | HIN1 | LU105 | PnSP-2 | Secretoglobin, Family 3A, Member 1 wt Allele | UGRP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539574","Secretoglobin Family 3A Member 1, Human","C104997","Secretoglobin family 3A member 1 (104 aa, ~10 kDa) is encoded by the human SCGB3A1 gene. This is a secreted protein of unknown function.","Secretoglobin Family 3A Member 1 | Cytokine HIN-1 | Cytokine High in Normal-1 | High in Normal 1 | Pneumo Secretory Protein 2 | Uteroglobin-Related Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540635","SDC2 wt Allele","C104999","Human SDC2 wild-type allele is located within 8q22-q23 and is approximately 118 kb in length. This allele, which encodes syndecan-2 protein, plays a role in cell-matrix interactions, cell migration, and cell proliferation.","SDC2 wt Allele | CD362 | HSPG | HSPG1 | SYND2 | Syndecan 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0055465","chlorozotocin","C1049","A glucose-linked chloroethylnitrosourea with potential antineoplastic activity.  Chlorozotocin alkylates DNA and proteins, induces the formation of interstrand DNA and DNA-protein crosslinks, and causes DNA strand breakage, thereby damaging DNA and resulting in cell death.  This agent has been shown to exhibit antitumor and immunomodulatory effects in cell lines and animal models.  Chlorozotocin is a mutagen and is less myelotoxic than other nitrosoureas. (NCI04)","Chlorozotocin | 1-(2-chloroethyl)-1-nitroso-3-(D-glucos-2-yl)urea | 2-[3-(2-chloroethyl)-3-nitrosoureido]-2-deoxy-D-glucopyranose | 2-[[[(2-chloroethyl)nitrosamino]carbonyl]amino]-2-deoxy-D-glucose | CHLOROZOTOCIN | CHLZ | CZT | Chlorozotocyna | D-Glucopyranose, 2-[[[(2-chloroethyl)nitrosoamino]carbonyl]amino]-2-deoxy- | D-Glucose, 2-[[[(2-chloroethyl)nitrosoamino]carbonyl]amino]-2-deoxy- (9CI) | D-glucopyranose, 2-[[[(2-chloroethyl)nitrosoamino]carbonyl]amino]-2-deoxy | D-glucose, 2-[[[(2-chloroethyl)nitrosoamino]carbonyl]amino]-2-deoxy- (9CI) | DCNU | Dome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642004","C-SSRS Baseline/Screening Version Phase 1 Study - Most Severe Ideation (Lifetime)","C105225","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Most severe ideation. (Lifetime).","C-SSRS Baseline/Screening Version Phase 1 Study - Most Severe Ideation (Lifetime) | CSS03-Most Severe Idea-Life | CSS0306A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642005","C-SSRS Baseline/Screening Version Phase 1 Study - Describe Most Severe Ideation (Lifetime)","C105226","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Description of ideation. (Lifetime).","C-SSRS Baseline/Screening Version Phase 1 Study - Describe Most Severe Ideation (Lifetime) | CSS03-Most Severe Idea, Desc-Life | CSS0306B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642006","C-SSRS Baseline/Screening Version Phase 1 Study - Most Severe Ideation (Past 6 Months)","C105227","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Most severe ideation. (Past 6 Months).","C-SSRS Baseline/Screening Version Phase 1 Study - Most Severe Ideation (Past 6 Months) | CSS03-Most Severe Idea-P6M | CSS0306C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642007","C-SSRS Baseline/Screening Version Phase 1 Study - Describe Most Severe Ideation (Past 6 Months)","C105228","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Description of ideation. (Past 6 Months).","C-SSRS Baseline/Screening Version Phase 1 Study - Describe Most Severe Ideation (Past 6 Months) | CSS03-Most Severe Idea, Desc-P6M | CSS0306D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642008","C-SSRS Baseline/Screening Version Phase 1 Study - Frequency of Most Severe Ideation (Lifetime)","C105229","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) How many times have you had these thoughts? (Lifetime).","C-SSRS Baseline/Screening Version Phase 1 Study - Frequency of Most Severe Ideation (Lifetime) | CSS03-Most Severe Idea, Frequency-Life | CSS0307A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539752","Ras-Related Protein Rab-40B","C104560","Ras-related protein Rab-40B (278 aa, ~31 kDa) is encoded by the human RAB40B gene. This protein may be involved in the regulation of ubiquitination and vesicle transport.","Ras-Related Protein Rab-40B | GTP-Binding Protein Homologous To Saccharomyces Cerevisiae SEC4 | Protein Rar | RAB40B | SOCS Box-Containing Protein RAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541882","NES wt Allele","C104561","Human NES wild-type allele is located in the vicinity of 1q23.1 and is approximately 7 kb in length. This allele, which encodes nestin protein, plays a role in mitosis.","NES wt Allele | FLJ21841 | Nestin wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3711758","NES protein, human","C104562","Nestin (1621 aa, ~177 kDa) is encoded by the human NES gene. This protein is involved in mitosis.","Nestin | NES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539723","NCF2 wt Allele","C104564","Human NCF2 wild-type allele is located in the vicinity of 1q25 and is approximately 35 kb in length. This allele, which encodes neutrophil cytosol factor 2 protein, is involved in the generation of superoxide in neutrophils. Mutations in this gene are associated with chronic granulomatous disease.","NCF2 wt Allele | Chronic Granulomatous Disease, Autosomal 2 Gene | NCF-2 | NOXA2 | Neutrophil Cytosolic Factor 2 (65kD, Chronic Granulomatous Disease, Autosomal 2) Gene | Neutrophil Cytosolic Factor 2 wt Allele | P67-PHOX | P67PHOX | p67 PHOX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0213574","neutrophil cytosol factor 67K","C104565","Neutrophil cytosol factor 2 (526 aa, ~60 kDa) is encoded by the human NCF2 gene. This protein plays a role in the generation of superoxide in neutrophils.","Neutrophil Cytosol Factor 2 | 67 kDa Neutrophil Oxidase Factor | NADPH Oxidase Activator 2 | NCF-2 | NCF2 | Neutrophil Cytosolic Factor 2 | Neutrophil NADPH Oxidase Factor 2 | p67phox",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538783","SLAMF6 wt Allele","C105056","Human SLAMF6 wild-type allele is located in the vicinity of 1q23.2 and is approximately 38 kb in length. This allele, which encodes SLAM family member 6 protein, plays a role as a coreceptor in natural killer cell activation.","SLAMF6 wt Allele | CD352 | KALI | KALIb | Ly108 | NTB-A | NTBA | SF2000 | SLAM Family Member 6 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539786","SLAM Family Member 6","C105057","SLAM family member 6 (332 aa, ~37 kDa) is encoded by the human SLAMF6 gene. This protein acts as a coreceptor in the process of natural killer cell activation.","SLAM Family Member 6 | Activating NK Receptor | CD352 Antigen | NK-T-B-Antigen | NTBA Receptor | Natural Killer-, T- and B-Cell Antigen | SLAMF6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542433","SLC1A4 wt Allele","C105059","Human SLC1A4 wild-type allele is located within 2p15-p13 and is approximately 35 kb in length. This allele, which encodes neutral amino acid transporter A protein, is involved in sodium-dependent transport of alanine, serine, cysteine, and threonine.","SLC1A4 wt Allele | ASCT-1 | ASCT1 | SATT | Solute Carrier Family 1 (Glutamate/Neutral Amino Acid Transporter), Member 4 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641923","Neutral Amino Acid Transporter A","C105060","Neutral amino acid transporter A (532 aa, ~56 kDa) is encoded by the human SLC1A4 gene. This protein plays a role in transporting alanine, serine, cysteine, and threonine.","Neutral Amino Acid Transporter A | Alanine/Serine/Cysteine/Threonine Transporter 1 | Glutamate/Neutral Amino Acid Transporter | Solute Carrier Family 1 Member 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540530","SLC29A1 wt Allele","C105062","Human SLC29A1 wild-type allele is located in the vicinity of 6p21.1 and is approximately 15 kb in length. This allele, which encodes equilibrative nucleoside transporter 1 protein, plays a role in mediating both influx and efflux of nucleosides across the plasma membrane.","SLC29A1 wt Allele | ENT1 | Solute Carrier Family 29 (Equilibrative Nucleoside Transporter), Member 1 Gene | Solute Carrier Family 29 (Nucleoside Transporter), Member 1 Gene | Solute Carrier Family 29 (Nucleoside Transporters), Member 1 Gene | Solute Carrier Family 29 Member 1 (Augustine Blood Group) wt Allele | hENT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0533642","Equilibrative Nucleoside Transporter 1","C105063","Equilibrative nucleoside transporter 1 (456 aa, ~50 kDa) is encoded by the human SLC29A1 gene. This protein is involved in mediating nucleoside influx and efflux.","Equilibrative Nucleoside Transporter 1 | Equilibrative NBMPR-Sensitive Nucleoside Transporter | Equilibrative Nitrobenzylmercaptopurine Riboside (NBMPR)-Sensitive Nucleoside Transporter | Equilibrative Nitrobenzylmercaptopurine Riboside-Sensitive Nucleoside Transporter | Nucleoside Transporter, ES-Type | SLC29A1 | Solute Carrier Family 29 Member 1 | hENT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537449","PI3 wt Allele","C105390","Human PI3 wild-type allele is located in the vicinity of 20q13.12 and is approximately 2 kb in length. This allele, which encodes elafin protein, is involved in the regulation of connective tissue proteolysis.","PI3 wt Allele | Cementoin | ESI | Peptidase Inhibitor 3, Skin-Derived wt Allele | SKALP | WAP3 | WFDC14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0142580","PI3 protein, human","C105391","Elafin (117 aa, ~12 kDa) is encoded by the human PI3 gene. This protein plays a role in the inhibition of neutrophil and pancreatic elastase proteinase activity.","Elafin | ESI | Elastase-Specific Inhibitor | PI-3 | PI3 | Peptidase Inhibitor 3 | Protease Inhibitor WAP3 | SKALP | Skin-Derived Antileukoproteinase | Trappin-2 | WAP Four-Disulfide Core Domain Protein 14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446318","Phenethyl Isothiocyanate-containing Watercress Juice","C105392","A juice extracted from watercress containing high amounts of phenethyl isothiocyanate (PEITC), with potential chemopreventive and antitumor activities. Although the mechanism(s) of action through which PEITC exerts its effect(s) has yet to be fully elucidated, PEITC is able to induce apoptosis in tumor cells through the induction of reactive oxygen species (ROS). Additionally, PEITC is able to modulate extracellular signal-regulated kinases (ERK), c-Jun N-terminal kinase (JNK) and mitogen-activated protein kinase (MAPK) signal transduction pathways, activating the expression of stress-responsive genes and eventually inducing apoptosis. PEITC also inhibits the expression of genes involved in tumor progression such as HIF, STAT-3, HER2, BCL-XL, and XIAP and induces the expression of genes involved in tumor suppression such as p53, ATF-2, and p57. Furthermore, this agent has been shown to reactivate the gene expression of certain detoxification enzymes.","Phenethyl Isothiocyanate-containing Watercress Juice | PEITC-containing Watercress Juice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3543430","CCNC wt Allele","C105394","Human CCNC wild-type allele is located in the vicinity of 6q21 and is approximately 27 kb in length. This allele, which encodes cyclin-C protein, is involved in the regulation of transcription.","CCNC wt Allele | CycC | Cyclin C wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446320","allogeneic T lymphocytes BPX-501","C105395","Allogeneic, T-lymphocytes with potential immune reconstitution activity. Donor T-lymphocytes are transduced with a retroviral vector (BPZ-1001) encoding the inducible suicide gene caspase 9 (iCasp9) and linked to a drug binding domain. Donor T-cell therapy may help control transplant-related infections following allogeneic hematopoietic stem cell transplantation. However, the addition of donor T-cells can lead to graft-versus-host disease (GVHD). In the event that GVHD begins to develop, the chemical homodimerizer AP1903 can be administered, which binds to the drug binding domain and induces caspase 9 expression. This activates apoptosis in the T-cells causing GVHD.","Rivogenlecleucel | BPX-501 | RIVOGENLECLEUCEL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1611475","cyclin C protein, human","C105396","Cyclin-C (283 aa, ~33 kDa) is encoded by the human CCNC gene. This protein plays a role in the regulation of the Mediator transcriptional coactivator complex.","Cyclin-C | CCNC | SRB11 Homolog | hSRB11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540571","MT1G wt Allele","C105398","Human MT1G wild-type allele is located in the vicinity of 16q13 and is approximately 1 kb in length. This allele, which encodes metallothionein-1G protein, plays a role in both binding and transport of trace metals.","MT1G wt Allele | MT1 | MT1K | Metallothionein 1G wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642150","Monocarboxylate Transporter 1 Inhibitor AZD3965","C105399","An orally available inhibitor of monocarboxylate transporter 1 (MCT1), with potential antineoplastic activity. Upon oral administration, MCT1 inhibitor AZD3965 binds to MCT1 and prevents the transport of lactate into and out of the cell. This leads to an accumulation of lactate, intracellular acidification, and eventually cancer cell death. MCT1, a protein overexpressed on tumor cells, is responsible for the transport of monocarboxylates across the cell membrane and plays a key role in cell metabolism.","Monocarboxylate Transporter 1 Inhibitor AZD3965 | AZD-3965 | AZD3965 | MCT1 Inhibitor AZD3965",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1610496","SDC2 protein, human","C105000","Syndecan-2 (201 aa, ~22 kDa) is encoded by the human SDC2 gene. This protein is involved in cell migration, cell proliferation, and cell-matrix interactions. In addition, this protein acts as a receptor for HIV-1.","Syndecan-2 | CD362 Antigen | Cell Surface-Associated Heparan Sulfate Proteoglycan 1 | Fibroglycan | Heparan Sulfate Proteoglycan 1, Cell Surface-Associated | Heparan Sulfate Proteoglycan Core Protein | SDC2 | Syndecan Proteoglycan 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541991","SFRP2 wt Allele","C105002","Human SFRP2 wild-type allele is located in the vicinity of 4q31.3 and is approximately 9 kb in length. This allele, which encodes secreted frizzled-related protein 2, plays a role in modulating Wnt signaling of cell growth and differentiation.","SFRP2 wt Allele | FRP-2 | FRP2 | SARP-1 | SARP1 | SDF-5 | Secreted Frizzled-Related Protein 2 wt Allele | sFRP-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541992","SFRP5 wt Allele","C105005","Human SFRP5 wild-type allele is located in the vicinity of 10q24.1 and is approximately 5 kb in length. This allele, which encodes secreted frizzled-related protein 5, a signaling protein that may be involved in determining the polarity of photoreceptor cells in the retina.","SFRP5 wt Allele | FRP-1b | FRP1B | SARP-3 | SARP3 | Secreted Frizzled-Related Protein 5 wt Allele | sFRP-5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641998","C-SSRS Baseline/Screening Version Phase 1 Study - Active Suicidal Ideation with Some Intent to Act, without Specific Plan (Lifetime)","C105219","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Have you had these thoughts and had some intention of acting on them? (Lifetime).","C-SSRS Baseline/Screening Version Phase 1 Study - Active Suicidal Ideation with Some Intent to Act, without Specific Plan (Lifetime) | CSS03-Idea, Intent, No Plan-Life | CSS0304A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641999","C-SSRS Baseline/Screening Version Phase 1 Study - Active Suicidal Ideation with Some Intent to Act, without Specific Plan (Past 6 Months)","C105220","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Have you had these thoughts and had some intention of acting on them? (Past 6 Months).","C-SSRS Baseline/Screening Version Phase 1 Study - Active Suicidal Ideation with Some Intent to Act, without Specific Plan (Past 6 Months) | CSS03-Idea, Intent, No Plan-P6M | CSS0304B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642001","C-SSRS Baseline/Screening Version Phase 1 Study - Active Suicidal Ideation with Specific Plan and Intent (Lifetime)","C105222","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan? (Lifetime).","C-SSRS Baseline/Screening Version Phase 1 Study - Active Suicidal Ideation with Specific Plan and Intent (Lifetime) | CSS03-Idea, Plan, Intent-Life | CSS0305A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642002","C-SSRS Baseline/Screening Version Phase 1 Study - Active Suicidal Ideation with Specific Plan and Intent (Past 6 Months)","C105223","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan? (Past 6 Months).","C-SSRS Baseline/Screening Version Phase 1 Study - Active Suicidal Ideation with Specific Plan and Intent (Past 6 Months) | CSS03-Idea, Plan, Intent-P6M | CSS0305B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3543427","NNMT wt Allele","C104567","Human NNMT wild-type allele is located in the vicinity of 11q23.1 and is approximately 55 kb in length. This allele, which encodes nicotinamide N-methyltransferase protein, plays a role in the detoxification of metabolism of xenobiotic compounds.","NNMT wt Allele | Nicotinamide N-Methyltransferase wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1530470","NNMT protein, human","C104568","Nicotinamide N-methyltransferase (264 aa, ~30 kDa) is encoded by the human NNMT gene. This protein is involved in the detoxification of xenobiotic compounds.","Nicotinamide N-Methyltransferase | EC 2.1.1.1 | NNMT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540613","NOX4 wt Allele","C104571","Human NOX4 wild-type allele is located in the vicinity of 11q14.3 and is approximately 265 kb in length. This allele, which encodes NADPH oxidase 4 protein, is involved as an oxygen sensor in signal transduction, cell differentiation, and tumor cell growth.","NOX4 wt Allele | KOX | KOX-1 | NADPH Oxidase 4 wt Allele | RENOX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1454287","NOX4 protein, human","C104572","NADPH oxidase 4 (578 aa, ~67 kDa) is encoded by the human NOX4 gene. This protein plays a role as an oxygen sensor in cell differentiation and signal transduction.","NADPH Oxidase 4 | EC 1.6.3.- | Kidney Oxidase-1 | Kidney Superoxide-Producing NADPH Oxidase | NOX4 | Renal NAD(P)H-Oxidase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540813","HOMER3 wt Allele","C104573","Human HOMER3 wild-type allele is located in the vicinity of 19p13.11 and is approximately 12 kb in length. This allele, which encodes homer protein homolog 3 protein, is involved in protein localization at the postsynaptic density.","HOMER3 wt Allele | HOMER-3 | Homer Homolog 3 (Drosophila) wt Allele | Homer, Neuronal Immediate Early Gene, 3 | VESL3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0893390","Homer Protein Homolog 3","C104574","Homer protein homolog 3 (361 aa, ~40 kDa) is encoded by the human HOMER3 gene. This protein plays a role in protein-protein interactions.","Homer Protein Homolog 3 | HOMER3 | Homer-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541426","S1PR5 wt Allele","C104783","Human S1PR5 wild-type allele is located in the vicinity of 19p13.2 and is approximately 11 kb in length. This allele, which encodes sphingosine 1-phosphate receptor 5 protein, is involved in the regulation of cell proliferation, apoptosis, motility, and neurite retraction.","S1PR5 wt Allele | EDG-8 | EDG8 | S1P5 | SPPR-1 | SPPR-2 | Sphingosine-1-Phosphate Receptor 5 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541912","Sphingosine 1-Phosphate Receptor 5","C104784","Sphingosine 1-phosphate receptor 5 (398 aa, ~42 kDa) is encoded by the human S1PR5 gene. This protein plays a role in the regulation of cell proliferation and motility, apoptosis, and neurite retraction.","Sphingosine 1-Phosphate Receptor 5 | Endothelial Differentiation G-Protein-Coupled Receptor 8 | Endothelial Differentiation, Sphingolipid G-Protein-Coupled Receptor, 8 | S1P Receptor 5 | S1P Receptor EDG-8 | Sphingosine 1-Phosphate Receptor EDG-8 | Sphingosine 1-Phosphate Receptor EDG8 | Sphingosine-1-Phosphate Receptor 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540465","PDPN wt Allele","C104786","Human PDPN wild-type allele is located in the vicinity of 1p36.21 and is approximately 34 kb in length. This allele, which encodes podoplanin protein, is involved in the modulation of cell shape.","PDPN wt Allele | AGGRUS | CTA-520D8.1 | GP36 | GP40 | Gp38 | HT1A-1 | Lung Type-I Cell Membrane-Associated Glycoprotein Gene | OTS8 | PA2.26 | PSEC0003 | PSEC0025 | Podoplanin wt Allele | T1A | T1A-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537357","Podoplanin","C104787","Podoplanin (162 aa, ~17 kDa) is encoded by the human PDPN gene. This protein plays a role in the determination of cell shape.","Podoplanin | Aggrus | Glycoprotein 36 | Gp36 | PA2.26 Antigen | PDPN | T1-Alpha | hT1alpha-1 | hT1alpha-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538902","SLC4A1 wt Allele","C105065","Human SLC4A1 wild-type allele is located in the vicinity of 17q21.31 and is approximately 20 kb in length. This allele, which encodes band 3 anion transport protein, is involved in elimination of carbon dioxide from tissues. Mutations in this gene are associated with both hereditary spherocytosis and distal renal tubular acidosis. Other mutations result in novel blood group antigens.","SLC4A1 wt Allele | AE 1 | AE1 | BND3 | CD233 | DI | EMPB3 | EPB | FR | RTA1A | SW | Solute Carrier Family 4, Anion Exchanger, Member 1 (Erythrocyte Membrane Protein Band 3, Diego Blood Group) wt Allele | WD | WD1 | WR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642045","PI - Worst Pain Intensity For Various Time Periods of Evaluation","C105266","Pain Intensity (PI v1) Worst pain intensity for various time periods of evaluation.","PI - Worst Pain Intensity For Various Time Periods of Evaluation | PI01-Worst Pain Intensity | PI0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642047","PR - Average Pain Relief For Various Time Periods of Evaluation","C105268","Pain Intensity (PR v1) Average pain relief for various time periods of evaluation.","PR - Average Pain Relief For Various Time Periods of Evaluation | PR01-Average Pain Relief | PR0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642048","PR - Minimum Pain Relief For Various Time Periods of Evaluation","C105269","Pain Intensity (PR v1) Minimum pain relief for various time periods of evaluation.","PR - Minimum Pain Relief For Various Time Periods of Evaluation | PR01-Minimum Pain Relief | PR0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642049","PR - Maximum Pain Relief For Various Time Periods of Evaluation","C105270","Pain Intensity (PR v1) Maximum pain relief for various time periods of evaluation.","PR - Maximum Pain Relief For Various Time Periods of Evaluation | PR01-Maximum Pain Relief | PR0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642050","PR - Least Pain Relief For Various Time Periods of Evaluation","C105271","Pain Intensity (PR v1) Least pain relief for various time periods of evaluation.","PR - Least Pain Relief For Various Time Periods of Evaluation | PR01-Least Pain Relief | PR0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642052","PR - Starting Pain Half Gone","C105273","Pain Intensity (PR v1) Starting pain at least 1/2 gone?","PR - Starting Pain Half Gone | PR01-Starting Pain at Least 1/2 Gone | PR0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642053","PR - Was There Perceptible Pain Relief","C105274","Pain Intensity (PR v1) Was there perceptible pain relief?","PR - Was There Perceptible Pain Relief | PR01-Was there Perceptible Pain Relief | PR0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642054","PR - Time to Perceptible Pain Relief","C105275","Pain Intensity (PR v1) Time to perceptible pain relief.","PR - Time to Perceptible Pain Relief | PR01-Time to Perceptible Pain Relief | PR0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642055","PR - Was There Meaningful Pain Relief","C105276","Pain Intensity (PR v1) Was there meaningful pain relief?","PR - Was There Meaningful Pain Relief | PR01-Was there Meaningful Pain Relief | PR0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642056","PR - Time to Meaningful Pain Relief","C105277","Pain Intensity (PR v1) Time to meaningful pain relief.","PR - Time to Meaningful Pain Relief | PR01-Time to Meaningful Pain Relief | PR0111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642057","GCGI - Global Severity of Pain","C105278","General Clinical Global Impressions (GCGI v1) Global severity of pain.","GCGI - Global Severity of Pain | GCGI01-Global Severity of Pain | GCGI0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642058","GCGI - Global Improvement of Pain","C105279","General Clinical Global Impressions (GCGI v1) Global improvement of pain.","GCGI - Global Improvement of Pain | GCGI01-Global Improvement of Pain | GCGI0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0055849","Zeniplatin","C1053","A third-generation, water-soluble platinum compound. (NCI)","Zeniplatin | CL 286,558 | ZENIPLATIN | cis-(2,2-Bis(aminomethyl)-1,3-propanediol)(1,1-cyclobutanedicarboxylato)platinum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539869","Metallothionein-1G","C105400","Metallothionein-1G (62 aa, ~6 kDa) is encoded by the human MT1G gene. This protein is involved in trace metal binding.","Metallothionein-1G | MT-1G | MT-1K | MT-IG | MT1G | Metallothionein-1K | Metallothionein-IG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539746","RICTOR wt Allele","C104736","Human RICTOR wild-type allele is located in the vicinity of 5p13.1 and is approximately 136 kb in length. This allele, which encodes rapamycin-insensitive companion of mTOR protein, plays a role in nutrient-dependent regulation of cell growth.","RICTOR wt Allele | AVO3 | KIAA1999 | MGC39830 | PIA | RPTOR Independent Companion of MTOR, Complex 2 wt Allele | hAVO3 | mAVO3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL445810","WT1 247-261 Peptide Vaccine","C104737","A synthetic peptide vaccine consisting of a HLA-DRw53-restricted human Wilms' Tumor protein-1 (WT1) peptide comprised of amino acids 247 through 261, a HLA class II-restricted WT1 peptide, with potential immunomodulating and antitumor activities. Vaccination with WT1 247-261 peptide may stimulate a CD4-positive helper T-lymphocyte-mediated immune response against WT1 expressing cells. Activated helper T-cells stimulate dendritic cells, and activate the proliferation of other T-lymphoctes and B-lymphocytes. This causes tumor cell lysis and inhibition of cancer cell proliferation in WT1-overexpressing tumor cells. WT1, a zinc finger DNA-binding protein, is overexpressed in most types of leukemia and in a variety of solid cancers.","WT1 247-261 Peptide Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL445811","WT1 124-138 Peptide Vaccine","C104738","A synthetic peptide vaccine consisting of a HLA-DR15-restricted human Wilms' Tumor protein-1 (WT1) peptide comprised of amino acids 124 through 138, a HLA class II-restricted WT1 peptide, with potential immunomodulating and antitumor activities. Vaccination with WT1 124-138 peptide may stimulate a CD4-positive helper T-lymphocyte-mediated immune response against WT1 expressing cells. Activated helper T-cells stimulate dendritic cells, and activate the proliferation of other T-lymphoctes and B-lymphocytes. This causes tumor cell lysis and inhibition of cancer cell proliferation in WT1-overexpressing tumor cells. WT1, a zinc finger DNA-binding protein, is overexpressed in most types of leukemia and in a variety of solid cancers.","WT1 124-138 Peptide Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537313","Rapamycin-Insensitive Companion of mTOR","C104740","Rapamycin-insensitive companion of mTOR (1708 aa, ~192 kDa) is encoded by the human RICTOR gene. This protein is involved in regulation of cell growth in response to nutrients and growth factors.","Rapamycin-Insensitive Companion of mTOR | AVO3 Homolog | Pianissimo | RICTOR | RPTOR Independent Companion of MTOR, Complex 2 | TORC2-Specific Protein AVO3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541421","PDE2A wt Allele","C104741","Human PDE2A wild-type allele is located in the vicinity of 11q13.4 and is approximately 98 kb in length. This allele, which encodes cGMP-dependent 3',5'-cyclic phosphodiesterase protein, plays a role in the metabolism of both cyclic AMP and cyclic GMP.","PDE2A wt Allele | CGS-PDE | PDE2A1 | PED2A4 | Phosphodiesterase 2A, cGMP-Stimulated wt Allele | cGSPDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1869260","PDE2A protein, human","C104742","cGMP-dependent 3',5'-cyclic phosphodiesterase (941 aa, ~106 kDa) is encoded by the human PDE2A gene. This protein is involved in the catabolism of both cyclic GMP and cyclic AMP.","cGMP-Dependent 3',5'-Cyclic Phosphodiesterase | CGS-PDE | Cyclic GMP-Stimulated Phosphodiesterase | EC 3.1.4.17 | PDE2A | cGMP-Dependent 3,5-Cyclic Phosphodiesterase | cGMP-Stimulated Phosphodiesterase 1 | cGMP-Stimulated Phosphodiesterase 4 | cGSPDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640335","ADNI AVLT - List A Recall 3 Word 1","C101930","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 3, Word 1.","ADNI AVLT - List A Recall 3 Word 1 | AVL01-List A Recall 3 Word 1 | AVL01035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640336","ADNI AVLT - List A Recall 3 Word 2","C101931","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 3, Word 2.","ADNI AVLT - List A Recall 3 Word 2 | AVL01-List A Recall 3 Word 2 | AVL01036",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640337","ADNI AVLT - List A Recall 3 Word 3","C101932","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 3, Word 3.","ADNI AVLT - List A Recall 3 Word 3 | AVL01-List A Recall 3 Word 3 | AVL01037",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640338","ADNI AVLT - List A Recall 3 Word 4","C101933","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 3, Word 4.","ADNI AVLT - List A Recall 3 Word 4 | AVL01-List A Recall 3 Word 4 | AVL01038",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640339","ADNI AVLT - List A Recall 3 Word 5","C101934","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 3, Word 5.","ADNI AVLT - List A Recall 3 Word 5 | AVL01-List A Recall 3 Word 5 | AVL01039",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640341","ADNI AVLT - List A Recall 3 Word 7","C101936","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 3, Word 7.","ADNI AVLT - List A Recall 3 Word 7 | AVL01-List A Recall 3 Word 7 | AVL01041",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640342","ADNI AVLT - List A Recall 3 Word 8","C101937","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 3, Word 8.","ADNI AVLT - List A Recall 3 Word 8 | AVL01-List A Recall 3 Word 8 | AVL01042",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640343","ADNI AVLT - List A Recall 3 Word 9","C101938","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 3, Word 9.","ADNI AVLT - List A Recall 3 Word 9 | AVL01-List A Recall 3 Word 9 | AVL01043",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640344","ADNI AVLT - List A Recall 3 Word 10","C101939","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 3, Word 10.","ADNI AVLT - List A Recall 3 Word 10 | AVL01-List A Recall 3 Word 10 | AVL01044",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640345","ADNI AVLT - List A Recall 3 Word 11","C101940","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 3, Word 11.","ADNI AVLT - List A Recall 3 Word 11 | AVL01-List A Recall 3 Word 11 | AVL01045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640346","ADNI AVLT - List A Recall 3 Word 12","C101941","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 3, Word 12.","ADNI AVLT - List A Recall 3 Word 12 | AVL01-List A Recall 3 Word 12 | AVL01046",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640347","ADNI AVLT - List A Recall 3 Word 13","C101942","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 3, Word 13.","ADNI AVLT - List A Recall 3 Word 13 | AVL01-List A Recall 3 Word 13 | AVL01047",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640348","ADNI AVLT - List A Recall 3 Word 14","C101943","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 3, Word 14.","ADNI AVLT - List A Recall 3 Word 14 | AVL01-List A Recall 3 Word 14 | AVL01048",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640349","ADNI AVLT - List A Recall 3 Word 15","C101944","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 3, Word 15.","ADNI AVLT - List A Recall 3 Word 15 | AVL01-List A Recall 3 Word 15 | AVL01049",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539630","PFKM wt Allele","C104790","Human PFKM wild-type allele is located in the vicinity of 12q13.11 and is approximately 41 kb in length. This allele, which encodes 6-phosphofructokinase, muscle type protein, plays a role in muscle cell metabolism of glucose. Mutation of the gene is associated with glycogen storage disease type 7.","PFKM wt Allele | GSD7 | PFK-1 | PFK1 | PFKA | PFKX | Phosphofructokinase, Muscle wt Allele | Phosphofructokinase, Polypeptide X Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1448495","6-Phosphofructokinase, Muscle Type, Human","C104791","6-phosphofructokinase, muscle type (780 aa, ~85 kDa) is encoded by the human PFKM gene. This protein is involved in the mediation of muscle cell glycolysis.","6-Phosphofructokinase, Muscle Type | 6-Phosphofructo-1-Kinase | EC 2.7.1.11 | PFK-A | PFKM | Phosphofructo-1-Kinase Isozyme A | Phosphofructokinase 1 | Phosphofructokinase-M | Phosphohexokinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541427","PIGF wt Allele","C104793","Human PIGF wild-type allele is located within 2p21-p16 and is approximately 36 kb in length. This allele, which encodes phosphatidylinositol-glycan biosynthesis class F protein, is involved in protein lipidation.","PIGF wt Allele | Phosphatidylinositol Glycan Anchor Biosynthesis, Class F wt Allele | Phosphatidylinositol Glycan, Class F Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447425","Phosphatidylinositol-Glycan Biosynthesis Class F Protein","C104794","Phosphatidylinositol-glycan biosynthesis class F protein (219 aa, ~25 kDa) is encoded by the human PIGF gene. This protein plays a role in glycophosphatidyl inositol anchor biosynthesis.","Phosphatidylinositol-Glycan Biosynthesis Class F Protein | GPI11 Homolog | PIG-F | PIGF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538684","PIAS1 wt Allele","C104796","Human PIAS1 wild-type allele is located in the vicinity of 15q23 and is approximately 137 kb in length. This allele, which encodes E3 SUMO-protein ligase PIAS1 protein, plays a role in both protein sumoylation and signaling.","PIAS1 wt Allele | DDXBP1 | GBP | GU/RH-II | Protein Inhibitor of Activated STAT, 1 wt Allele | ZMIZ3 | Zinc Finger, MIZ-Type Containing 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0765997","Secreted Frizzled-Related Protein 5, Human","C105006","Secreted frizzled-related protein 5 (317 aa, ~36 kDa) is encoded by the human SFRP5 gene. This protein may play a role in determining the polarity of photoreceptor cells in the retina.","Secreted Frizzled-Related Protein 5 | FRP-1b | Frizzled-Related Protein 1b | SARP-3 | Secreted Apoptosis Related Protein 3 | Secreted Apoptosis-Related Protein 3 | sFRP-5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538894","SEL1L wt Allele","C105008","Human SEL1L wild-type allele is located in the vicinity of 14q31 and is approximately 62 kb in length. This allele, which encodes protein Sel-1 homolog 1 protein, plays a role in degradation of misfolded proteins.","SEL1L wt Allele | IBD2 | PRO1063 | SEL1-Like | SEL1L1 | Sel-1 Suppressor of Lin-12-Like (C. elegans) wt Allele | Sel-1L | TSA305",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1449232","Protein Sel-1 Homolog 1","C105009","Protein Sel-1 homolog 1 (794 aa, ~89 kDa) is encoded by the human SEL1L gene. This protein is involved in degradation of misfolded endoplasmic reticulum proteins.","Protein Sel-1 Homolog 1 | SEL1-Like | Sel-1 (Suppressor of Lin-12, C.elegans)-Like | Sel-1 Suppressor of Lin-12-Like 1 | Suppressor of Lin 12 (Sel-1), C. elegans, Homolog of | Suppressor of Lin-12-Like Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640897","Refugee From High Tuberculosis Prevalent Area","C102705","An individual that has fled a country for their own safety which has a high occurrence of tuberculosis.","Refugee From High Tuberculosis Prevalent Area | REFUGEE FROM HIGH TUBERCULOSIS PREVALENT AREA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280560","cyclophosphamide/cytarabine/prednisone/thioguanine/vincristine","C10270","A regimen consisting of prednisone, cytarabine, 6-thioguanine, cyclophosphamide, and vincristine that may be used in the treatment of childhood acute myeloid leukemia (AML).","PATCO Regimen | ARA-C/CTX/PRED/TG/VCR | Cyclophosphamide/Cytarabine/Prednisone/Thioguanine/Vincristine | PATCO | Prednisone-Cytarabine-Thioguanine-Cyclophosphamide-Vincristine | Prednisone/Ara-C/Thioguanine/Cyclophosphamide/Oncovin | Prednisone/Cytarabine/Thioguanine/Cyclophosphamide/Vincristine | Prednisone/Cytarabine/Thioguanine/Cyclophosphamide/Vincristine Regimen | T-COAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640900","Site of Directly Observed Therapy","C102710","The physical location at which the medication or therapy was observed, by the healthcare provider, as being taken by the subject.","Site of Directly Observed Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640611","SF-36 v2.0 Standard - Physical: Difficulty Perform Work","C102212","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) During the past 4 weeks, how much of the time have you had any problems with your work or other regular daily activities as a result of your physical health - had difficulty performing the work or other activities (for example, it took extra effort).","SF-36 v2.0 Standard - Physical: Difficulty Perform Work | SF363-Physical: Difficulty Perform Work | SF36304D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640612","SF-36 v2.0 Standard - Emotional: Cut Down Time on Work","C102213","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) During the past 4 weeks, how much of the time have you had problems with your work or other regular daily activities as a result of any emotional problems (such as feeling depressed or anxious) - cut down on the amount of time you spent on work or other activities.","SF-36 v2.0 Standard - Emotional: Cut Down Time on Work | SF363-Emotional: Cut Down Time on Work | SF36305A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640613","SF-36 v2.0 Standard - Emotional: Accomplished Less","C102214","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) During the past 4 weeks, how much of the time have you had problems with your work or other regular daily activities as a result of any emotional problems (such as feeling depressed or anxious) - accomplished less than you would like.","SF-36 v2.0 Standard - Emotional: Accomplished Less | SF363-Emotional: Accomplished Less | SF36305B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL445815","Ulixertinib","C104744","An orally available inhibitor of extracellular signal-regulated kinase (ERK) 1 and 2, with potential antineoplastic activity. Upon oral administration, ulixertinib inhibits both ERK 1 and 2, thereby preventing the activation of ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.","Ulixertinib | 1H-Pyrrole-2-carboxamide, 4-(5-chloro-2-((1-methylethyl)amino)-4-pyridinyl)-N-((1S)-1-(3-chlorophenyl)-2-hydroxyethyl)- | BVD-523 | ULIXERTINIB | VRT752271",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539704","MTR wt Allele","C104948","Human MTR wild-type allele is located in the vicinity of 1q43 and is approximately 109 kb in length. This allele, which encodes methionine synthase protein, is involved in the synthesis of methionine. Mutation of the gene is associated with both methylcobalamin deficiency type G and susceptibility to folate-sensitive neural tube defects.","MTR wt Allele | 5-Methyltetrahydrofolate-Homocysteine Methyltransferase wt Allele | MS | cblG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039676","Methionine Synthase","C104949","Methionine synthase (1265 aa, ~141 kDa) is encoded by the human MTR gene. This protein plays a role in the methylation of homocysteine.","Methionine Synthase | 5-Methyltetrahydrofolate--Homocysteine Methyltransferase | 5-Methyltetrahydrofolate-Homocysteine Methyltransferase 1 | 5-Methyltetrahydrofolate—Homocysteine Methyltransferase | Cobalamin-Dependent Methionine Synthase | EC 2.1.1.13 | MS | MTR | Vitamin-B12 Dependent Methionine Synthase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540486","CRLF1 wt Allele","C104951","Human CRLF1 wild-type allele is located in the vicinity of 19p12 and is approximately 14 kb in length. This allele, which encodes cytokine receptor-like factor 1 protein, may play roles in nervous system development and immune function. Mutations in this gene are associated with cold-induced sweating syndrome and Crisponi syndrome.","CRLF1 wt Allele | CISS | CISS1 | CLF | CLF-1 | Cytokine Receptor-Like Factor 1 wt Allele | NR6 | ZcytoR5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0755506","Cytokine Receptor-Like Factor 1","C104952","Cytokine receptor-like factor 1 (422 aa, ~46 kDa) is encoded by the human CRLF1 gene. This protein may be involved in both immune function and nervous system development.","Cytokine Receptor-Like Factor 1 | Class I Cytokine Receptor | Cytokine Type 1 Receptor CRLP-1 | Cytokine-Like Factor 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540513","PCYT1A wt Allele","C104954","Human PCYT1A wild-type allele is located in the vicinity of 3q29 and is approximately 74 kb in length. This allele, which encodes choline-phosphate cytidylyltransferase A protein, plays a role in phospholipid biosynthesis.","PCYT1A wt Allele | CCTA | CT | CTA | CTPCT | Cytidylyltransferase, CTP-Phosphocholine Gene | PCYT1 | Phosphate Cytidylyltransferase 1, Choline Gene | Phosphate Cytidylyltransferase 1, Choline, Alpha Isoform Gene | Phosphate Cytidylyltransferase 1, Choline, Alpha wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539600","LHX3 wt Allele","C104956","Human LHX3 wild-type allele is located in the vicinity of 9q34.3 and is approximately 9 kb in length. This allele, which encodes LIM/homeobox protein LHX3, is a transcription factor involved in motor neuron specification and pituitary development. Mutations in this gene are associated with combined pituitary hormone deficiency 3.","LHX3 wt Allele | CPHD3 | LIM Homeobox 3 wt Allele | LIM3 | M2-LHX3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538970","PCYT1A protein, human","C104957","Choline-phosphate cytidylyltransferase A (367 aa, ~42 kDa) is encoded by the human PCYT1A gene. This protein is involved in the biosynthesis of phosphatidylcholine.","Choline-Phosphate Cytidylyltransferase A | CCT A | CCT-alpha | CT A | CTP:Phosphocholine Cytidylyltransferase A | EC 2.7.7.15 | PCYT1A | Phosphorylcholine Transferase A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640350","ADNI AVLT - List A Recall 3 Total","C101945","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of words recalled from List A, third attempt.","ADNI AVLT - List A Recall 3 Total | AVL01-List A Recall 3 Total | AVL01050",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0519097","Left Ventricular Aneurysm","C102654","A bulge or ballooning in the wall of the left ventricle of the heart.","Left Ventricular Aneurysm | ",,,,,,,,,,,,,,,"4182190","Left ventricular aneurysm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3640866","Lived in Refugee Camp","C102657","An individual that resided in a camp for those displaced from their homeland.","Lived in Refugee Camp | LIVED IN REFUGEE CAMP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640869","Long-term Facility Resident","C102660","An individual that lives at a healthcare facility that provides rehabilitative, restorative, and/or ongoing skilled nursing care to patients or residents in need of assistance with activities of daily living.","Long-term Facility Resident | LONG-TERM FACILITY RESIDENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640870","Low-priority Tuberculosis Subject","C102662","An individual that has had limited exposure to an individual with tuberculosis and has a low probability of having had a recent infection.","Low-priority Tuberculosis Subject | LOW-PRIORITY TUBERCULOSIS CONTACT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640872","Medication Misplaced","C102664","Medications that were lost because they were put in the wrong place.","Medication Misplaced | MEDICATION MISPLACED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640873","Medium-priority Tuberculosis Subject","C102665","An individual that has tested negative for pulmonary, laryngeal, or pleural tuberculosis but has had a non-cavitary chest x-ray that is consistent with tuberculosis.","Medium-priority Tuberculosis Subject | MEDIUM-PRIORITY TUBERCULOSIS CONTACT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540598","Microbial Identification Certainty","C102667","A qualification that describes the degree of certainty of the correctness of a microbial identification test result.","Microbial Identification Certainty | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537219","SERPINA1 wt Allele","C105011","Human SERPINA1 wild-type allele is located in the vicinity of 14q32.1 and is approximately 14 kb in length. This allele, which encodes alpha-1-antitrypsin protein, is involved in both the regulation of proteolysis and coagulation. Mutations in this gene are associated with pulmonary disease, emphysema, and bleeding disorders.","SERPINA1 wt Allele | A1A | A1AT | AAT | Alpha1AT | PI | PI1 | PRO2275 | Protease Inhibitor 1 (Anti-Elastase), Alpha-1-Antitrypsin Gene | Serine (Or Cysteine) Proteinase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 1 Gene | Serine (Or Cysteine) Proteinase Inhibitor, Clade A, Member 1 Gene | Serine (or Cysteine) Proteinase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 1 Gene | Serpin Family A Member 1 wt Allele | Serpin Peptidase Inhibitor Clade A (Alpha-1antiproteinase, Antitrypsin) Member 1 Gene | Serpin Peptidase Inhibitor Clade A Member 1 Gene | Serpin Peptidase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 1 Gene | nNIF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1455316","Alpha-1-Antitrypsin, Human","C105012","Alpha-1-antitrypsin (418 aa, ~47 kDa) is encoded by the human SERPINA1 gene. This protein plays a role in regulation of proteolysis.","Alpha-1-Antitrypsin | Alpha-1 Antitrypsin | Alpha-1 Protease Inhibitor | Alpha-1-Antiproteinase | Alpha1AT | Anti-Elastase | Protease Inhibitor 1 | SERPINA1 | Serine (or Cysteine) Proteinase Inhibitor, Clade A, Member 1 | Serpin A1 | Serpin Family A Member 1 | Serpin Peptidase Inhibitor Clade A Member 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541993","SETMAR wt Allele","C105014","Human SETMAR wild-type allele is located in the vicinity of 3p26.1 and is approximately 14 kb in length. This allele, which encodes histone-lysine N-methyltransferase SETMAR protein, plays a role in epigenetic transcriptional activation and may be involved in mediating genomic integration of foreign DNA.","SETMAR wt Allele | SET Domain and Mariner Transposase Fusion Gene wt Allele | hsMar1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1723767","Histone-Lysine N-Methyltransferase SETMAR, Human","C105015","Histone-lysine N-methyltransferase SETMAR (671 aa, ~77 kDa) is encoded by the human SETMAR gene. This protein is involved in epigenetic transcriptional activation.","Histone-Lysine N-Methyltransferase SETMAR | EC 2.1.1.43 | Metnase | SET Domain and Mariner Transposase Fusion Gene-Containing Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541903","Phosphatidylcholine:Ceramide Cholinephosphotransferase 1, Human","C105018","Phosphatidylcholine:ceramide cholinephosphotransferase 1 (419 aa, ~49 kDa) is encoded by the human SGMS1 gene. This protein plays a role in apoptosis.","Phosphatidylcholine:Ceramide Cholinephosphotransferase 1 | EC 2.7.8.27 | Medulla Oblongata-Derived Protein | Protein MOB | SGMS1 | Sphingomyelin Synthase 1 | Transmembrane Protein 23",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642009","C-SSRS Baseline/Screening Version Phase 1 Study - Frequency of Most Severe Ideation (Past 6 Months)","C105230","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) How many times have you had these thoughts? (Past 6 Months).","C-SSRS Baseline/Screening Version Phase 1 Study - Frequency of Most Severe Ideation (Past 6 Months) | CSS03-Most Severe Idea, Frequency-P6M | CSS0307B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642011","C-SSRS Baseline/Screening Version Phase 1 Study - Duration of Most Severe Ideation (Past 6 Months)","C105232","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) When you have these thoughts, how long do they last? (Past 6 Months).","C-SSRS Baseline/Screening Version Phase 1 Study - Duration of Most Severe Ideation (Past 6 Months) | CSS03-Most Severe Idea, Duration-P6M | CSS0308B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640614","SF-36 v2.0 Standard - Emotional: Did Work Less Carefully","C102215","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) During the past 4 weeks, how much of the time have you had problems with your work or other regular daily activities as a result of any emotional problems (such as feeling depressed or anxious) - did work or other activities less carefully than usual.","SF-36 v2.0 Standard - Emotional: Did Work Less Carefully | SF363-Emotional: Did Work Less Carefully | SF36305C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640615","SF-36 v2.0 Standard - Extent Phys/Emotional Interfered","C102216","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) During the past 4 weeks, to what extent has your physical health or emotional problems interfered with your normal social activities with family, friends, neighbors, or groups?","SF-36 v2.0 Standard - Extent Phys/Emotional Interfered | SF363-Extent Phys/Emotional Interfered | SF36306",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640616","SF-36 v2.0 Standard - How Much Bodily Pain Have You Had","C102217","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) How much bodily pain have you had during the past 4 weeks?","SF-36 v2.0 Standard - How Much Bodily Pain Have You Had | SF363-How Much Bodily Pain Have You Had | SF36307",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640617","SF-36 v2.0 Standard - Pain Interfere With Normal Work","C102218","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) During the past 4 weeks, how much did pain interfere with your normal work (including both work outside the home and housework)?","SF-36 v2.0 Standard - Pain Interfere With Normal Work | SF363-Pain Interfere With Normal Work | SF36308",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640618","SF-36 v2.0 Standard - Did You Feel Full of Life","C102219","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - did you feel full of life.","SF-36 v2.0 Standard - Did You Feel Full of Life | SF363-Did You Feel Full of Life | SF36309A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640620","SF-36 v2.0 Standard - Felt Down Nothing Cheer You Up","C102221","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - have you felt so down in the dumps that nothing could cheer you up.","SF-36 v2.0 Standard - Felt Down Nothing Cheer You Up | SF363-Felt Down Nothing Cheer You Up | SF36309C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640621","SF-36 v2.0 Standard - Have You Felt Calm and Peaceful","C102222","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - have you felt calm and peaceful.","SF-36 v2.0 Standard - Have You Felt Calm and Peaceful | SF363-Have You Felt Calm and Peaceful | SF36309D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640622","SF-36 v2.0 Standard - Did You Have a Lot of Energy","C102223","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - did you have a lot of energy.","SF-36 v2.0 Standard - Did You Have a Lot of Energy | SF363-Did You Have a Lot of Energy | SF36309E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0903890","YY1 Transcription Factor","C102473","Transcriptional repressor protein YY1 (414 aa, ~45 kDa) is encoded by the human YY1 gene. This protein is involved in both DNA repair and the repression of transcription.","Transcriptional Repressor Protein YY1 | Delta Transcription Factor | INO80 Complex Subunit S | NF-E1 | YY-1 | Yin and Yang 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826259","MLXIPL Gene","C102474","This gene plays a role in both DNA binding and transcriptional regulation.","MLXIPL Gene | MLX Interacting Protein-Like Gene | MLXIPL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538729","MLXIPL wt Allele","C102475","Human MLXIPL wild-type allele is located in the vicinity of 7q11.23 and is approximately 31 kb in length. This allele, which encodes carbohydrate-responsive element-binding protein, is involved in the regulation of transcription. Deletion of the gene is associated with Williams-Beuren syndrome.","MLXIPL wt Allele | BHLHD14 | CHREBP | MIO | MLX Interacting Protein-Like wt Allele | MONDOB | WBSCR14 | WS-bHLH | Williams Beuren Syndrome Chromosome Region 14 Gene | bHLHd14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0300290","LIM homeobox 3 protein, human","C104958","LIM/homeobox protein LHX3 (397 aa, ~43 kDa) is encoded by the human LHX3 gene. This transcription factor plays a role in pituitary development.","LIM/Homeobox Protein LHX3 | LIM Homeobox 3 | LIM Homeobox Protein 3 | LIM/Homeodomain Protein LHX3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539726","ZNF423 wt Allele","C104960","Human ZNF423 wild-type allele is located in the vicinity of 16q12 and is approximately 370 kb in length. This allele, which encodes zinc finger protein 423, plays a role in differentiation and maturation of olfactory receptor neurons. Mutations in this gene are associated with Joubert syndrome 19 and nephronophthisis 14.","ZNF423 wt Allele | Ebfaz | KIAA0760 | NPHP14 | OAZ | Roaz | ZFP104 | ZFP423 | Zinc Finger Protein 423 wt Allele | hOAZ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641953","DAD - Wash and Dry All Parts of Body Safely and Completely","C105174","Disability Assessment for Dementia (DAD) Wash and dry all parts of his/her body safely and completely?","DAD - Wash and Dry All Parts of Body Safely and Completely | DAD01-Wash and Dry Body Safely | DAD0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641954","DAD - Brush Teeth or Take Care of Dentures Appropriately","C105175","Disability Assessment for Dementia (DAD) Brush his/her teeth or take care of his/her dentures appropriately?","DAD - Brush Teeth or Take Care of Dentures Appropriately | DAD01-Brush Teeth Take Care of Dentures | DAD0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641956","DAD - Decide to Dress Himself/Herself","C105177","Disability Assessment for Dementia (DAD) Decide to dress himself/herself?","DAD - Decide to Dress Himself/Herself | DAD01-Decide to Dress | DAD0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641957","DAD - Choose Appropriate Clothing","C105178","Disability Assessment for Dementia (DAD) Choose appropriate clothing (with regard to the occasion, neatness, the weather and color combination)?","DAD - Choose Appropriate Clothing | DAD01-Choose Appropriate Clothing | DAD0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641958","DAD - Dress in the Appropriate Order","C105179","Disability Assessment for Dementia (DAD) Dress himself/herself in the appropriate order (undergarments, pant/dress, shoes)?","DAD - Dress in the Appropriate Order | DAD01-Dress in Appropriate Order | DAD0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641959","DAD - Dress Himself/Herself Completely","C105180","Disability Assessment for Dementia (DAD) Dress himself/herself completely?","DAD - Dress Himself/Herself Completely | DAD01-Dress Completely | DAD0111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641960","DAD - Undress Himself/Herself Completely","C105181","Disability Assessment for Dementia (DAD) Undress himself/herself completely?","DAD - Undress Himself/Herself Completely | DAD01-Undress Completely | DAD0112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641961","DAD - Decide to Use the Toilet at Appropriate Times","C105182","Disability Assessment for Dementia (DAD) Decide to use the toilet at appropriate times?","DAD - Decide to Use the Toilet at Appropriate Times | DAD01-Use Toilet at Appropriate Times | DAD0113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641962","DAD - Use the Toilet Without Accidents","C105183","Disability Assessment for Dementia (DAD) Use the toilet without 'accidents'?","DAD - Use the Toilet Without Accidents | DAD01-Use Toilet Without Accidents | DAD0114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641963","DAD - Decide That He/She Needs to Eat","C105184","Disability Assessment for Dementia (DAD) Decide that he/she needs to eat?","DAD - Decide That He/She Needs to Eat | DAD01-Decide That He/She Needs to Eat | DAD0115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640573","SF-36 v2.0 Acute - Physical: Accomplished Less","C102174","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) During the past week, how much of the time have you had any problems with your work or other regular daily activities as a result of your physical health - accomplished less than you would like.","SF-36 v2.0 Acute - Physical: Accomplished Less | SF364-Physical: Accomplished Less | SF36404B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640574","SF-36 v2.0 Acute - Physical: Limited Kind of Work","C102175","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) During the past week, how much of the time have you had any problems with your work or other regular daily activities as a result of your physical health - were limited in the kind of work or other activities.","SF-36 v2.0 Acute - Physical: Limited Kind of Work | SF364-Physical: Limited Kind of Work | SF36404C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640575","SF-36 v2.0 Acute - Physical: Difficulty Perform Work","C102176","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) During the past week, how much of the time have you had any problems with your work or other regular daily activities as a result of your physical health - had difficulty performing the work or other activities (for example, it took extra effort).","SF-36 v2.0 Acute - Physical: Difficulty Perform Work | SF364-Physical: Difficulty Perform Work | SF36404D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640576","SF-36 v2.0 Acute - Emotional: Cut Down Time on Work","C102177","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) During the past week, how much of the time have you had problems with your work or other regular daily activities as a result of any emotional problems (such as feeling depressed or anxious) - cut down on the amount of time you spent on work or other activities.","SF-36 v2.0 Acute - Emotional: Cut Down Time on Work | SF364-Emotional: Cut Down Time on Work | SF36405A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640577","SF-36 v2.0 Acute - Emotional: Accomplished Less","C102178","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) During the past week, how much of the time have you had problems with your work or other regular daily activities as a result of any emotional problems (such as feeling depressed or anxious) - accomplished less than you would like.","SF-36 v2.0 Acute - Emotional: Accomplished Less | SF364-Emotional: Accomplished Less | SF36405B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640578","SF-36 v2.0 Acute - Emotional: Did Work Less Carefully","C102179","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) During the past week, how much of the time have you had problems with your work or other regular daily activities as a result of any emotional problems (such as feeling depressed or anxious) - did work or other activities less carefully than usual.","SF-36 v2.0 Acute - Emotional: Did Work Less Carefully | SF364-Emotional: Did Work Less Carefully | SF36405C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640579","SF-36 v2.0 Acute - Extent Phys/Emotional Interfered","C102180","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) During the past week, to what extent has your physical health or emotional problems interfered with your normal social activities with family, friends, neighbors, or groups?","SF-36 v2.0 Acute - Extent Phys/Emotional Interfered | SF364-Extent Phys/Emotional Interfered | SF36406",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640580","SF-36 v2.0 Acute - How Much Bodily Pain Have You Had","C102181","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) How much bodily pain have you had during the past week?","SF-36 v2.0 Acute - How Much Bodily Pain Have You Had | SF364-How Much Bodily Pain Have You Had | SF36407",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642012","C-SSRS Baseline/Screening Version Phase 1 Study - Controllability of Most Severe Ideation (Lifetime)","C105233","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Could/can you stop thinking about killing yourself or wanting to die if you want to? (Lifetime).","C-SSRS Baseline/Screening Version Phase 1 Study - Controllability of Most Severe Ideation (Lifetime) | CSS03-Most Severe Idea, Control-Life | CSS0309A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642013","C-SSRS Baseline/Screening Version Phase 1 Study - Controllability of Most Severe Ideation (Past 6 Months)","C105234","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Could/can you stop thinking about killing yourself or wanting to die if you want to? (Past 6 Months).","C-SSRS Baseline/Screening Version Phase 1 Study - Controllability of Most Severe Ideation (Past 6 Months) | CSS03-Most Severe Idea, Control-P6M | CSS0309B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642014","C-SSRS Baseline/Screening Version Phase 1 Study - Deterrents to Most Severe Ideation (Lifetime)","C105235","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Are there things-anyone or anything (e.g., family, religion, pain of death) that stopped you from wanting to die or acting on thoughts of committing suicide? (Lifetime).","C-SSRS Baseline/Screening Version Phase 1 Study - Deterrents to Most Severe Ideation (Lifetime) | CSS03-Most Severe Idea, Deterrents-Life | CSS0310A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642015","C-SSRS Baseline/Screening Version Phase 1 Study - Deterrents to Most Severe Ideation (Past 6 Months)","C105236","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Are there things-anyone or anything (e.g., family, religion, pain of death) that stopped you from wanting to die or acting on thoughts of committing suicide? (Past 6 Months).","C-SSRS Baseline/Screening Version Phase 1 Study - Deterrents to Most Severe Ideation (Past 6 Months) | CSS03-Most Severe Idea, Deterrents-P6M | CSS0310B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642016","C-SSRS Baseline/Screening Version Phase 1 Study - Reasons for Most Severe Ideation (Lifetime)","C105237","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) What sort of reasons did you have for thinking about wanting to die or killing yourself? Was it to end the pain or stop the way you were feeling (in other words you couldn't go on living with this pain or how you were feeling) or was it to get attention, revenge or a reaction from others? Or both? (Lifetime).","C-SSRS Baseline/Screening Version Phase 1 Study - Reasons for Most Severe Ideation (Lifetime) | CSS03-Most Severe Idea, Reasons-Life | CSS0311A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642017","C-SSRS Baseline/Screening Version Phase 1 Study - Reasons for Most Severe Ideation (Past 6 Months)","C105238","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) What sort of reasons did you have for thinking about wanting to die or killing yourself? Was it to end the pain or stop the way you were feeling (in other words you couldn't go on living with this pain or how you were feeling) or was it to get attention, revenge or a reaction from others? Or both? (Past 6 Months).","C-SSRS Baseline/Screening Version Phase 1 Study - Reasons for Most Severe Ideation (Past 6 Months) | CSS03-Most Severe Idea, Reasons-P6M | CSS0311B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642018","C-SSRS Baseline/Screening Version Phase 1 Study - Actual Suicide Attempt","C105239","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Have you made a suicide attempt? Have you done anything to harm yourself? Have you done anything dangerous where you could have died?","C-SSRS Baseline/Screening Version Phase 1 Study - Actual Suicide Attempt | CSS03-Actual Attempt | CSS0312",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539629","TRIB2 wt Allele","C104576","Human TRIB2 wild-type allele is located in the vicinity of 2p24.3 and is approximately 26 kb in length. This allele, which encodes tribbles homolog 2 protein, plays a role in the modulation of MAP kinase-dependent signaling.","TRIB2 wt Allele | C5FW | GS3955 | TRB2 | Tribbles Homolog 2 (Drosophila) Gene | Tribbles Pseudokinase 2 wt Allele | Tribbles, Drosophila, Homolog of, 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541919","Tribbles Homolog 2","C104577","Tribbles homolog 2 (343 aa, ~39 kDa) is encoded by the human TRIB2 gene. This protein is involved in the modulation of MAP kinase activation.","Tribbles Homolog 2 | TRB-2 | TRIB2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539691","Carbohydrate-Responsive Element-Binding Protein","C102476","Carbohydrate-responsive element-binding protein (852 aa, ~93 kDa) is encoded by the human MLXIPL gene. This protein plays a role in transcriptional regulation.","Carbohydrate-Responsive Element-Binding Protein | ChREBP | Class D Basic Helix-Loop-Helix Protein 14 | MLX Interactor | MLX-Interacting Protein-Like | MLXIPL | WS Basic-Helix-Loop-Helix Leucine Zipper Protein | WS-bHLH | Williams-Beuren Syndrome Chromosomal Region 14 Protein | bHLHd14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825986","MGAT4C Gene","C102477","This gene is involved in protein glycosylation.","MGAT4C Gene | MGAT4C | Mannosyl (Alpha-1,3-)-Glycoprotein Beta-1,4-N-Acetylglucosaminyltransferase, Isozyme C (Putative) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540520","MGAT4C wt Allele","C102478","Human MGAT4C wild-type allele is located in the vicinity of 12q21 and is approximately 860 kb in length. This allele, which encodes alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase C protein, plays a role in post-translational protein modification.","MGAT4C wt Allele | GNT-IV-H | GNTIVH | HGNT-IV-H | Mannosyl (Alpha-1,3-)-Glycoprotein Beta-1,4-N-Acetylglucosaminyltransferase, Isozyme C (Putative) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3543839","Alpha-1,3-Mannosyl-Glycoprotein 4-Beta-N-Acetylglucosaminyltransferase C","C102479","Alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase C (478 aa, ~56 kDa) is encoded by the human MGAT4C gene. This protein is involved in protein glycosylation.","Alpha-1,3-Mannosyl-Glycoprotein 4-Beta-N-Acetylglucosaminyltransferase C | EC 2.4.1.145 | GlcNAc-T IVc | GnT-IVc | MGAT4C | N-Acetylglucosaminyltransferase IV Homolog | N-Acetylglucosaminyltransferase IVc | N-Glycosyl-Oligosaccharide-Glycoprotein N-Acetylglucosaminyltransferase IVc | UDP-N-Acetylglucosamine: Alpha-1,3-D-Mannoside Beta-1,4-N-Acetylglucosaminyltransferase IVc | hGnT-IV-H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421355","UNC119 Gene","C102480","This gene plays a role in protein trafficking.","UNC119 Gene | UNC119 | Unc-119 Homolog (C. elegans) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538691","UNC119 wt Allele","C102481","Human UNC119 wild-type allele is located in the vicinity of 17q11.2 and is approximately 6 kb in length. This allele, which encodes protein unc-119 homolog A, is involved in the modulation of subcellular protein localization. Mutation of the gene is associated with cone-rod dystrophy.","UNC119 wt Allele | HRG4 | POC7 | POC7A | RG4 | Unc-119 Homolog (C. elegans) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541892","Protein Unc-119 Homolog A","C102482","Protein unc-119 homolog A (240 aa, ~27 kDa) is encoded by the human UNC119 gene. This protein plays a role in subcellular protein localization.","Protein Unc-119 Homolog A | Retinal Protein 4 | UNC119 | hRG4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538849","FKBP1A wt Allele","C102484","Human FKBP1A wild-type allele is located in the vicinity of 20p13 and is approximately 24 kb in length. This allele, which encodes peptidyl-prolyl cis-trans isomerase FKBP1A protein, plays a role in the regulation of both signal transduction and protein folding.","FKBP1A wt Allele | FK506 Binding Protein 1A, 12kDa Gene | FK506 Binding Protein, 12-kD Gene | FK506 Binding Protein, T-Cell Gene | FK506-Binding Protein 1 Gene | FK506-Binding Protein 1A (12kD) Gene | FK506-Binding Protein, T-Cell, 12-kD Gene | FKBP Prolyl Isomerase 1A wt Allele | FKBP-12 | FKBP-1A | FKBP1 | FKBP12 | PKC12 | PKCI2 | PPIASE | RP11-314N13.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2934980","Peptidyl-Prolyl Cis-Trans Isomerase FKBP1A, Human","C102485","Peptidyl-prolyl cis-trans isomerase FKBP1A (108 aa, ~12 kDa) is encoded by the human FKBP1A gene. This protein is involved in both protein folding and the modulation of TGF-beta signaling.","Peptidyl-Prolyl Cis-Trans Isomerase FKBP1A | 12 kDa FK506-Binding Protein | 12 kDa FKBP | Calstabin 1 | Calstabin-1 | Calstabin1 | EC 5.2.1.8 | FK506-Binding Protein 1A | FKBP Prolyl Isomerase 1A | FKBP-12 | FKBP-1A | FKBP1A | Immunophilin FKBP12 | PPIase FKBP1A | Protein Kinase C Inhibitor 2 | Rotamase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640400","ADNI AVLT - List A Recall 6 (After B) Word 15","C101995","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 6 (after B Recall), Word 15.","ADNI AVLT - List A Recall 6 (After B) Word 15 | AVL01-List A Recall 6 (After B) Word 15 | AVL01100",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641965","DAD - Eat Meals at a Normal Pace and with Appropriate Manners","C105186","Disability Assessment for Dementia (DAD) Eat his/her meals at a normal pace and with appropriate manners?","DAD - Eat Meals at a Normal Pace and with Appropriate Manners | DAD01-Eat at Normal Pace With Manners | DAD0117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641966","DAD - Decide to Prepare a Light Meal or Snack for Himself/Herself","C105187","Disability Assessment for Dementia (DAD) Decide to prepare a light meal or snack for himself/herself?","DAD - Decide to Prepare a Light Meal or Snack for Himself/Herself | DAD01-Decide to Prepare Meal Snack | DAD0118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641967","DAD - Adequately Plan a Light Meal or Snack","C105188","Disability Assessment for Dementia (DAD) Adequately plan a light meal or snack (ingredients, cookware)?","DAD - Adequately Plan a Light Meal or Snack | DAD01-Adequately Plan Light Meal Snack | DAD0119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641968","DAD - Safely Prepare or Cook a Light Meal or Snack","C105189","Disability Assessment for Dementia (DAD) Prepare or cook a light meal or a snack safely?","DAD - Safely Prepare or Cook a Light Meal or Snack | DAD01-Prepare or Cook Light Meal Snack | DAD0120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1566317","2-hydroxyoleic acid","C105401","An orally bioavailable, synthetic analog of the fatty acid oleic acid, with potential antitumor activity. Upon administration,idroxioleic acid activates sphingomyelin synthase (SMS), thereby increasing the concentration of sphingomyelin (SM) and diacylglycerol (DAG) in the tumor cell membrane and decreasing membrane levels of phosphatidylethanolamine (PE) and phosphatidylcholine (PC). This restores the normal, healthy levels and ratios of membrane lipids. By restoring normal membrane lipid structure and composition, this agent inhibits membrane-protein associated signaling and the aberrant activity of signaling pathways in certain tumor cells, including the Ras/MAPK and PI3K/AKt pathways. This inhibits tumor cell proliferation, induces tumor cell differentiation, and eventually can cause cell death.","Idroxioleic Acid | 2-Hydroxyoleic Acid | 2-OHOA | 2OHOA | IDROXIOLEIC ACID | LAM 561 | LAM-561 | LAM561 | Minerval | NFX88 | SML-0256",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642151","Entospletinib","C105402","An orally available inhibitor of spleen tyrosine kinase (Syk), with potential antineoplastic activity. Upon oral administration of entospletinib, this agent may inhibit the activity of Syk, which inhibits B-cell receptor (BCR) signaling and leads to an inhibition of tumor cell activation, migration, adhesion and proliferation. Syk, a non-receptor cytoplasmic, BCR-associated tyrosine kinase, is expressed in hematopoietic tissues and is often overexpressed in hematopoeitic malignancies.","Entospletinib | 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine | ENTO | ENTOSPLETINIB | GS 9973 | GS-9973 | GS9973 | Imidazo(1,2-a)pyrazin-8-amine, 6-(1H-indazol-6-yl)-N-(4-(4-morpholinyl)phenyl)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3659253","Lutetium Lu 177 DOTA-Tetulomab","C105403","A radioimmunoconjugate, which consists of a monoclonal antibody against the cell-surface antigen CD37 covalently linked, via the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. The antibody moiety of lutetium Lu 177 DOTA-tetulomab binds to CD37 on tumor B-cells. Upon internalization, the radioisotope moiety delivers a cytotoxic dose of beta radiation to CD37-expressing tumor cells. CD37, a transmembrane glycoprotein, is overexpressed in B-cell malignancies.","Lutetium Lu 177 DOTA-Tetulomab | 177Lu-DOTA-HH1 | 177Lu-Dota-Tetulomab | 177Lu-HH1 | TETULOMAB TETRAXETAN LU-177",,,,,,,,,,,,,,,"35622684","Lilotomab satetraxetan (177-Lu)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3539730","NPY1R wt Allele","C105405","Human NPY1R wild-type allele is located within 4q31.3-q32 and is approximately 21 kb in length. This allele, which encodes neuropeptide Y receptor type 1 protein, plays a role in diverse physiological functions as a receptor for neuropeptide Y.","NPY1R wt Allele | NPY1-R | NPYR | NPYY1 | Neuropeptide Y Receptor Y1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642153","Neuropeptide Y Receptor Type 1, human","C105406","Neuropeptide Y receptor type 1 (384 aa, ~44 kDa) is encoded by the human NPY1R gene. This protein is involved in diverse physiological functions as a receptor for neuropeptide Y.","Neuropeptide Y Receptor Type 1 | NPY1-R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640581","SF-36 v2.0 Acute - Pain Interfere With Normal Work","C102182","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) During the past week, how much did pain interfere with your normal work (including both work outside the home and housework)?","SF-36 v2.0 Acute - Pain Interfere With Normal Work | SF364-Pain Interfere With Normal Work | SF36408",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640582","SF-36 v2.0 Acute - Did You Feel Full of Life","C102183","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - did you feel full of life.","SF-36 v2.0 Acute - Did You Feel Full of Life | SF364-Did You Feel Full of Life | SF36409A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640584","SF-36 v2.0 Acute - Felt Down Nothing Cheer You Up","C102185","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - have you felt so down in the dumps that nothing could cheer you up.","SF-36 v2.0 Acute - Felt Down Nothing Cheer You Up | SF364-Felt Down Nothing Cheer You Up | SF36409C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541312","KHDRBS1 wt Allele","C102428","Human KHDRBS1 wild-type allele is located in the vicinity of 1p32 and is approximately 47 kb in length. This allele, which encodes KH domain-containing, RNA-binding, signal transduction-associated protein 1, plays a role in the modulation of Wnt-dependent signaling, cell cycle progression, RNA processing and apoptosis regulation.","KHDRBS1 wt Allele | FLJ34027 | KH Domain Containing, RNA Binding, Signal Transduction Associated 1 wt Allele | SAM68 | Sam68 | p62 | p68",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539665","KH Domain-Containing, RNA-Binding, Signal Transduction-Associated Protein 1","C102429","KH domain-containing, RNA-binding, signal transduction-associated protein 1 (443 aa, ~48 kDa) is encoded by the human KHDRBS1 gene. This protein is involved in signaling pathway modulation and the mediation of alternative RNA splicing that regulates apoptosis.","KH Domain-Containing, RNA-Binding, Signal Transduction-Associated Protein 1 | GAP-Associated Tyrosine Phosphoprotein p62 | KHDRBS1 | Sam68 | Src-Associated in Mitosis 68 kDa Protein | p21 Ras GTPase-Activating Protein-Associated p62 | p68",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640784","Vaccine Provider","C102430","A person or organization that is licensed, certified or otherwise authorized or permitted by law to administer vaccinations in the ordinary course of business or practice of a profession.","Vaccine Provider | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640785","Funding Source for Product","C102431","Source of money used to acquire the product.","Funding Source for Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640786","Private Funding","C102432","Money available for projects or products in the private sector that does not include government contribution, grants or contracts.","Private Funding | Private Funds",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640787","Military Funding","C102433","Government funds available to support military operations.","Military Funding | Military Funds",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640788","Public Funding","C102434","Money available in the public sector, including the local, city, county, state and federal government.","Public Funding | Public Funds",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640789","Required Emergency Room or Doctor Visit","C102436","An event in which a visit to the emergency room or to the doctor is considered essential to prevent permanent impairment or damage.","Required Emergency Room or Doctor Visit | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539541","S100A4 wt Allele","C102438","Human S100A4 wild-type allele is located in the vicinity of 1q21 and is approximately 7 kb in length. This allele, which encodes protein S100-A4, plays a role in calcium binding, cell differentiation and signaling.","S100A4 wt Allele | 18A2 | 42A | CAPL | FSP1 | MTS1 | Malignant Transformation Suppression 1 Gene | P9KA | PEL98 | S100 Calcium Binding Protein A4 wt Allele | S100 Calcium-Binding Protein A4 (Calcium Protein, Calvasculin, Metastasin, Murine Placental Homolog) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539540","SERPINB9 wt Allele","C104579","Human SERPINB9 wild-type allele is located in the vicinity of 6p25 and is approximately 16 kb in length. This allele, which encodes serpin B9 protein, is involved in the negative regulation of serine protease activity.","SERPINB9 wt Allele | CAP-3 | CAP3 | PI-9 | PI9 | Serpin Peptidase Inhibitor, Clade B (Ovalbumin), Member 9 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537272","Serpin B9, Human","C104580","Serpin B9 (376 aa, ~42 kDa) is encoded by the human SERPINB9 gene. This protein plays a role in the inhibition of granzyme B.","Serpin B9 | CAP-3 | CAP3 | Cytoplasmic Antiproteinase 3 | PI-9 | Peptidase Inhibitor 9 | SERPINB9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540814","PELO wt Allele","C104582","Human PELO wild-type allele is located in the vicinity of 5q11.2 and is approximately 16 kb in length. This allele, which encodes protein pelota homolog, may play a role in RNA degradation and cell division.","PELO wt Allele | CGI-17 | PRO1770 | Pelota (Drosophila) Homolog Gene | Pelota Homolog (Drosophila) Gene | Pelota Homolog (Drosophila) wt Allele | Pelota Homolog Gene | Pelota mRNA Surveillance and Ribosome Rescue Factor wt Allele | Pelota, Drosophila, Homolog of Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540643","Protein Pelota Homolog, Human","C104583","Protein pelota homolog (385 aa, ~43 kDa) is encoded by the human PELO gene. This protein may be involved in endoribonuclease activity and chromosomal segregation during mitosis.","Protein Pelota Homolog | EC 3.1.-.- | PELO | Protein Dom34 homolog | hPelota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540815","NSMAF wt Allele","C104585","Human NSMAF wild-type allele is located within 8q12-q13 and is approximately 76 kb in length. This allele, which encodes protein FAN, plays a role in regulating TNF-induced cellular responses.","NSMAF wt Allele | FAN | Neutral Sphingomyelinase (N-SMase) Activation Associated Factor wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538969","Protein FAN","C104586","Protein FAN (917 aa, ~104 kDa) is encoded by the human NSMAF gene. This protein is involved in cell signaling via the TNF pathway.","Protein FAN | Factor Associated with N-SMase Activation | Factor Associated with Neutral Sphingomyelinase Activation | NSMAF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540519","NT5C2 wt Allele","C104588","Human NT5C2 wild-type allele is located in the vicinity of 10q24.32 and is approximately 107 kb in length. This allele, which encodes cytosolic purine 5'-nucleotidase protein, is involved in the cellular metabolism of purines.","NT5C2 wt Allele | 5'-Nucleotidase (Purine), Cytosolic Type B Gene | 5'-Nucleotidase, Cytosolic II wt Allele | 5-Prime-Nucleotidase, Cytosolic II Gene | GMP | NT5B | NT5CP | Nucleotidase, 5-Prime, Cytosolic II Gene | Nucleotidase, 5-Prime, Type B Gene | PNT5 | Purine 5-Prime-Nucleotidase Gene | Spastic Paraplegia 45 (Autosomal Recessive) Gene | cN-II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1701467","Cytosolic Purine 5'-Nucleotidase, Human","C104589","Cytosolic purine 5'-nucleotidase (561 aa, ~65 kDa) is encoded by the human NT5C2 gene. This protein plays a role in the maintenance of intracellular purine pools.","Cytosolic Purine 5'-Nucleotidase | 5'-Nucleotidase (Purine), Cytosolic Type B | Cytosolic 5'-Nucleotidase II | Cytosolic Purine 5-Nucleotidase | EC 3.1.3.5 | IMP-Specific 5'-NT | NT5C2 | Purine 5' Nucleotidase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640401","ADNI AVLT - List A Recall 6 (After B) Total","C101996","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of words recalled from List A, sixth attempt (after List B recall).","ADNI AVLT - List A Recall 6 (After B) Total | AVL01-List A Recall 6 (After B) Total | AVL01101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640402","ADNI AVLT - List A Intrusions 6","C101997","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of intrusions while recalling List A, sixth attempt (after List B recall).","ADNI AVLT - List A Intrusions 6 | AVL01-List A Intrusions 6 | AVL01102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640403","ADNI AVLT - List B Recall Word 1","C101998","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List B, Word 1.","ADNI AVLT - List B Recall Word 1 | AVL01-List B Recall Word 1 | AVL01103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640404","ADNI AVLT - List B Recall Word 2","C101999","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List B, Word 2.","ADNI AVLT - List B Recall Word 2 | AVL01-List B Recall Word 2 | AVL01104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640405","ADNI AVLT - List B Recall Word 3","C102000","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List B, Word 3.","ADNI AVLT - List B Recall Word 3 | AVL01-List B Recall Word 3 | AVL01105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640406","ADNI AVLT - List B Recall Word 4","C102001","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List B, Word 4.","ADNI AVLT - List B Recall Word 4 | AVL01-List B Recall Word 4 | AVL01106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640407","ADNI AVLT - List B Recall Word 5","C102002","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List B, Word 5.","ADNI AVLT - List B Recall Word 5 | AVL01-List B Recall Word 5 | AVL01107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640408","ADNI AVLT - List B Recall Word 6","C102003","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List B, Word 6.","ADNI AVLT - List B Recall Word 6 | AVL01-List B Recall Word 6 | AVL01108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640409","ADNI AVLT - List B Recall Word 7","C102004","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List B, Word 7.","ADNI AVLT - List B Recall Word 7 | AVL01-List B Recall Word 7 | AVL01109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640410","ADNI AVLT - List B Recall Word 8","C102005","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List B, Word 8.","ADNI AVLT - List B Recall Word 8 | AVL01-List B Recall Word 8 | AVL01110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640411","ADNI AVLT - List B Recall Word 9","C102006","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List B, Word 9.","ADNI AVLT - List B Recall Word 9 | AVL01-List B Recall Word 9 | AVL01111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640412","ADNI AVLT - List B Recall Word 10","C102007","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List B, Word 10.","ADNI AVLT - List B Recall Word 10 | AVL01-List B Recall Word 10 | AVL01112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640413","ADNI AVLT - List B Recall Word 11","C102008","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List B, Word 11.","ADNI AVLT - List B Recall Word 11 | AVL01-List B Recall Word 11 | AVL01113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640414","ADNI AVLT - List B Recall Word 12","C102009","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List B, Word 12.","ADNI AVLT - List B Recall Word 12 | AVL01-List B Recall Word 12 | AVL01114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3543845","NPY2R wt Allele","C105409","Human NPY2R wild-type allele is located in the vicinity of 4q31 and is approximately 8 kb in length. This allele, which encodes neuropeptide Y receptor type 2 protein, is involved in diverse physiological functions as a receptor for neuropeptide Y.","NPY2R wt Allele | NPY2-R | Neuropeptide Y Receptor Y2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0382066","Neuropeptide Y Receptor Type 2","C105410","Neuropeptide Y receptor type 2 (381 aa, ~43 kDa) is encoded by the human NPY2R gene. This protein plays a role in diverse physiological functions as a receptor for neuropeptide Y.","Neuropeptide Y Receptor Type 2 | NPY-Y2 Receptor | Y2 Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539731","NPY5R wt Allele","C105412","Human NPY5R wild-type allele is located within 4q31-q32 and is approximately 8 kb in length. This allele, which encodes neuropeptide Y receptor type 5 protein, plays a role in diverse physiological functions as a receptor for neuropeptide Y.","NPY5R wt Allele | NPY5-R | NPYR5 | NPYY5-R | Neuropeptide Y Receptor Y5 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0391255","Neuropeptide Y Receptor Type 5","C105413","Neuropeptide Y receptor type 5 (445 aa, ~51 kDa) is encoded by the human NPY5R gene. This protein is involved in diverse physiological functions as a receptor for neuropeptide Y.","Neuropeptide Y Receptor Type 5 | NPY-Y5 Receptor | Y5 Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL445817","IGF-1R Inhibitor PL225B","C104746","An orally bioavailable inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. IGF-1R inhibitor PL225B selectively binds to and inhibits the activities of IGF-1R, which may result in both the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis in IGF-1R-overexpressing tumor cells. IGF-1R, a receptor tyrosine kinase overexpressed in a variety of human cancers, plays a significant role in the stimulation of cellular proliferation, oncogenic transformation, and suppression of apoptosis.","IGF-1R Inhibitor PL225B | PL225B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL445818","UV1 Telomerase Peptide Vaccine","C104747","A synthetic, peptide cancer vaccine directed against the human telomerase reverse transcriptase catalytic subunit (hTERT) with potential immunomodulating activity. Vaccination with the UV1 telomerase peptide may stimulate cytotoxic T-cells to recognize and kill telomerase-expressing cells. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation.","UV1 Telomerase Peptide Vaccine | UV1/hTERT Peptide Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0287850","Protein S100-A4, Human","C102439","Protein S100-A4 (101 aa, ~12 kDa) is encoded by the human S100A4 gene. This protein is involved in both the positive regulation of signaling and calcium binding.","Protein S100-A4 | Calcium Placental Protein | Calvasculin | Fibroblast-Specific Protein-1 | Leukemia Multidrug Resistance Associated Protein | Malignant Transformation Suppression 1 | Metastasin | Placental Calcium-Binding Protein | Protein Mts1 | S100 Calcium-Binding Protein A4 | S100A4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538450","CHD8 Gene","C102440","This gene plays a role in both chromatin remodeling and transcriptional regulation.","CHD8 Gene | CHD8 | Chromodomain Helicase DNA Binding Protein 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540049","CHD8 wt Allele","C102441","Human CHD8 wild-type allele is located in the vicinity of 14q11.2 and is approximately 71 kb in length. This allele, which encodes chromodomain-helicase-DNA-binding protein 8, is involved in both transcriptional regulation and chromatin modification.","CHD8 wt Allele | Axis Duplication Inhibitor Gene | Chromodomain Helicase DNA Binding Protein 8 wt Allele | DKFZp686N17164 | DUPLIN | HELSNF1 | KIAA1564",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640790","Number of Hospitalization Days","C102443","The number of inpatient hospital days.","Number of Hospitalization Days | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419858","SCN2A Gene","C102444","This gene is involved in neuronal excitation.","SCN2A Gene | SCN2A | Sodium Voltage-Gated Channel Alpha Subunit 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640352","ADNI AVLT - List A Recall 4 Word 1","C101947","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 4, Word 1.","ADNI AVLT - List A Recall 4 Word 1 | AVL01-List A Recall 4 Word 1 | AVL01052",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640353","ADNI AVLT - List A Recall 4 Word 2","C101948","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 4, Word 2.","ADNI AVLT - List A Recall 4 Word 2 | AVL01-List A Recall 4 Word 2 | AVL01053",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640354","ADNI AVLT - List A Recall 4 Word 3","C101949","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 4, Word 3.","ADNI AVLT - List A Recall 4 Word 3 | AVL01-List A Recall 4 Word 3 | AVL01054",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640355","ADNI AVLT - List A Recall 4 Word 4","C101950","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 4, Word 4.","ADNI AVLT - List A Recall 4 Word 4 | AVL01-List A Recall 4 Word 4 | AVL01055",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640356","ADNI AVLT - List A Recall 4 Word 5","C101951","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 4, Word 5.","ADNI AVLT - List A Recall 4 Word 5 | AVL01-List A Recall 4 Word 5 | AVL01056",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640357","ADNI AVLT - List A Recall 4 Word 6","C101952","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 4, Word 6.","ADNI AVLT - List A Recall 4 Word 6 | AVL01-List A Recall 4 Word 6 | AVL01057",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640358","ADNI AVLT - List A Recall 4 Word 7","C101953","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 4, Word 7.","ADNI AVLT - List A Recall 4 Word 7 | AVL01-List A Recall 4 Word 7 | AVL01058",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640359","ADNI AVLT - List A Recall 4 Word 8","C101954","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 4, Word 8.","ADNI AVLT - List A Recall 4 Word 8 | AVL01-List A Recall 4 Word 8 | AVL01059",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539609","E3 SUMO-Protein Ligase PIAS1, Human","C104797","E3 SUMO-protein ligase PIAS1 (651 aa, ~72 kDa) is encoded by the human PIAS1 gene. This protein is involved in the mediation of protein sumoylation.","E3 SUMO-Protein Ligase PIAS1 | AR Interacting Protein | DEAD/H (Asp-Glu-Ala-Asp/His) Box Binding Protein 1 | DEAD/H Box-Binding Protein 1 | E3 SUMO-Protein Transferase PIAS1 | EC 2.3.2.- | GBP | Gu-Binding Protein | PIAS1 | Protein Inhibitor of Activated STAT Protein 1 | Protein Inhibitor of Activated STAT-1 | RNA Helicase II-Binding Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541428","PIM2 wt Allele","C104799","Human PIM2 wild-type allele is located in the vicinity of Xp11.23 and is approximately 6 kb in length. This allele, which encodes serine/threonine-protein kinase pim-2 protein, is involved in the modulation of cell proliferation, serine/threonine phosphorylation and apoptosis.","PIM2 wt Allele | Pim-2 Oncogene wt Allele | Proto-Oncogene Pim-2 (Serine Threonine Kinase) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0055377","Chlornaphazine","C1047","An alkylating antineoplastic agent no longer used in the United States, because it induces chromosomal aberration and causes cancer. (NCI)","Chlornaphazine | CHLORNAPHAZINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1453189","Serine/Threonine-Protein Kinase Pim-2, Human","C104800","Serine/threonine-protein kinase pim-2 (311 aa, ~34 kDa) is encoded by the human PIM2 gene. This protein plays a role in apoptosis regulation, protein phosphorylation and cell proliferation.","Serine/Threonine-Protein Kinase Pim-2 | EC 2.7.11.1 | PIM2 | Pim-2h | Serine/Threonine Protein Kinase Pim-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539729","PRKCI wt Allele","C104802","Human PRKCI wild-type allele is located in the vicinity of 3q26.3 and is approximately 84 kb in length. This allele, which encodes protein kinase C iota type protein, is involved in both apoptosis and protein phosphorylation.","PRKCI wt Allele | DXS1179E | PKCI | Protein Kinase C, Iota wt Allele | nPKC-iota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1568202","Protein Kinase C Iota Type, Human","C104803","Protein kinase C iota type (596 aa, ~68 kDa) is encoded by the human PRKCI gene. This protein plays a role in serine/threonine phosphorylation.","Protein Kinase C Iota Type | Atypical Protein Kinase C-Lambda/Iota | EC 2.7.11.13 | PRKC-Lambda/Iota | PRKCI | aPKC-Lambda/Iota | nPKC-Iota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540442","PRUNE2 wt Allele","C104805","Human PRUNE2 wild-type allele is located in the vicinity of 9q21.2 and is approximately 295 kb in length. This allele, which encodes protein prune homolog 2, may play a role in apoptosis regulation.","PRUNE2 wt Allele | A214N16.3 | BMCC1 | BNIPXL | C9orf65 | Chromosome 9 Open Reading Frame 65 Gene | KIAA0367 | Prune Homolog 2 (Drosophila) wt Allele | RP11-214N16.3 | RP11-58J3.2 | bA214N16.3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537283","Protein Prune Homolog 2, Human","C104806","Protein prune homolog 2 (3088 aa, ~341 kDa) is encoded by the human PRUNE2 gene. This protein may be involved in the regulation of apoptosis.","Protein Prune Homolog 2 | BCH Motif-Containing Molecule at the Carboxyl Terminal Region 1 | BNIP2 Motif-Containing Molecule at the C-Terminal Region 1 | PRUNE2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541303","PSENEN wt Allele","C104808","Human PSENEN wild-type allele is located in the vicinity of 19q13.12 and is approximately 1 kb in length. This allele, which encodes gamma-secretase subunit PEN-2 protein, is involved in the regulation of both Notch-dependent signaling and intramembrane proteolysis.","PSENEN wt Allele | MDS033 | MSTP064 | PEN-2 | PEN2 | Presenilin Enhancer 2 Homolog (C. elegans) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640902","Subject in Contact With Tuberculosis Source","C102714","An individual that came into contact with a source of tuberculosis.","Subject in Contact With Tuberculosis Source | CONTACT WITH TUBERCULOSIS SOURCE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640904","Supporting Evidence for Retreatment","C102717","Clinical evidence to support reason for re-treatment of disease.","Supporting Evidence for Retreatment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640905","Travel To High Burden Tuberculosis Country","C102719","Entry into one or more of the 22 countries that have a relatively high prevalence of tuberculosis cases.","Travel To High Burden Tuberculosis Country | TRAVEL TO HIGH BURDEN COUNTRY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539004","Treatment Episode Indicator","C102720","An indication of whether this is the individual's first time being treated for a disease or that they are receiving a subsequent treatment.","Treatment Episode Indicator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539006","Vaccination Evidence Source","C102727","Source of information regarding the subject's vaccination status.","Vaccination Evidence Source | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541422","PDGFC wt Allele","C104750","Human PDGFC wild-type allele is located in the vicinity of 4q23 and is approximately 211 kb in length. This allele, which encodes platelet-derived growth factor C protein, is involved in both embryonic development and growth factor signaling.","PDGFC wt Allele | FALLOTEIN | Platelet Derived Growth Factor C wt Allele | SCDGF | UNQ174/PRO200",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1571527","Platelet-Derived Growth Factor C, human","C104751","Platelet-derived growth factor C (345 aa, ~39 kDa) is encoded by the human PDGFC gene. This protein plays a role in both growth factor receptor binding and embryonic development.","Platelet-Derived Growth Factor C | Fallotein | PDGF-C | PDGFC | SCDGF | Secretory Growth Factor-Like Protein | Spinal Cord-Derived Growth Factor | VEGF-E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541423","RLF wt Allele","C104753","Human RLF wild-type allele is located in the vicinity of 1p32 and is approximately 80 kb in length. This allele, which encodes zinc finger protein RLF, may be involved in DNA binding and transcriptional regulation.","RLF wt Allele | Rearranged L-myc Fusion wt Allele | ZNF292L | Zn-15L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1313665","Zinc Finger Protein RLF","C104754","Zinc finger protein RLF (1914 aa, ~218 kDa) is encoded by the human RLF gene. This protein may play a role in DNA binding and transcriptional regulation.","Zinc Finger Protein RLF | Rearranged L-myc Fusion Gene Protein | Rearranged L-myc Fusion Sequence | Zn-15 Related | Zn-15-Related Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538833","RPA1 wt Allele","C104756","Human RPA1 wild-type allele is located in the vicinity of 17p13.3 and is approximately 70 kb in length. This allele, which encodes replication protein A 70 kDa DNA-binding subunit protein, plays a role in stabilizing single-stranded DNA structures.","RPA1 wt Allele | HSSB | MST075 | MSTP075 | REPA1 | RF-A | RP-A | RPA70 | Replication Protein A1, 70kDa wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037183","RPA1 protein, human","C104757","Replication protein A 70 kDa DNA-binding subunit (616 aa, ~68 kDa) is encoded by the human RPA1 gene. This protein is involved in stabilizing single-stranded DNA structures.","Replication Protein A 70 kDa DNA-Binding Subunit | RF-A Protein 1 | RP-A p70 | RPA1 | Replication Factor A Protein 1 | Replication Protein A1 70kDa | Replication Protein A1, 70kDa | Single-Stranded DNA-Binding Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540499","Zinc Finger Protein 423","C104961","Zinc finger protein 423 (1284 aa, ~145 kDa) is encoded by the human ZNF423 gene. This protein is involved in differentiation of olfactory receptor neurons.","Zinc Finger Protein 423 | Early B-cell Factor Associated Zinc Finger Protein | Olf1/EBF-Associated Zinc Finger Protein | Smad- and Olf-Interacting Zinc Finger Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541260","ATG5 wt Allele","C104963","Human ATG5 wild-type allele is located in the vicinity of 6q21 and is approximately 141 kb in length. This allele, which encodes autophagy protein 5, is involved in autophagy and may be involved in apoptosis.","ATG5 wt Allele | APG5 | APG5L | ASP | Autophagy Related 5 wt Allele | hAPG5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537312","Autophagy Protein 5","C104964","Autophagy protein 5 (275 aa, ~32 kDa) is encoded by the human ATG5 gene. This protein plays a role in autophagy and may play a role in apoptosis.","Autophagy Protein 5 | APG5 (Autophagy 5, S. cerevisiae)-Like | APG5 Autophagy 5-Like (S. cerevisiae) | APG5-Like | ATG5 Autophagy Related 5 Homolog | ATG5 Autophagy Related 5 Homolog (S. cerevisiae) | Apoptosis Specific Protein | Apoptosis-Specific Protein | Autophagy Related 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541302","PEMT wt Allele","C104966","Human PEMT wild-type allele is located in the vicinity of 17p11.2 and is approximately 86 kb in length. This allele, which encodes phosphatidylethanolamine N-methyltransferase protein, is involved in phosphatidylcholine biosynthesis.","PEMT wt Allele | PEAMT | PEMPT | PEMT2 | PNMT | Phosphatidylethanolamine N-Methyltransferase wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640361","ADNI AVLT - List A Recall 4 Word 10","C101956","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 4, Word 10.","ADNI AVLT - List A Recall 4 Word 10 | AVL01-List A Recall 4 Word 10 | AVL01061",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640362","ADNI AVLT - List A Recall 4 Word 11","C101957","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 4, Word 11.","ADNI AVLT - List A Recall 4 Word 11 | AVL01-List A Recall 4 Word 11 | AVL01062",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640363","ADNI AVLT - List A Recall 4 Word 12","C101958","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 4, Word 12.","ADNI AVLT - List A Recall 4 Word 12 | AVL01-List A Recall 4 Word 12 | AVL01063",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640365","ADNI AVLT - List A Recall 4 Word 14","C101960","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 4, Word 14.","ADNI AVLT - List A Recall 4 Word 14 | AVL01-List A Recall 4 Word 14 | AVL01065",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640366","ADNI AVLT - List A Recall 4 Word 15","C101961","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 4, Word 15.","ADNI AVLT - List A Recall 4 Word 15 | AVL01-List A Recall 4 Word 15 | AVL01066",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640367","ADNI AVLT - List A Recall 4 Total","C101962","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of words recalled from List A, fourth attempt.","ADNI AVLT - List A Recall 4 Total | AVL01-List A Recall 4 Total | AVL01067",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0474715","Myocardial Ischemia by ECG Finding","C102675","An electrocardiographic finding of ST and T wave changes consistent with impaired myocardial perfusion.","Myocardial Ischemia by ECG Finding | Myocardial Ischemia by EKG Finding",,,,,,,,,,,,,,,"4064346","EKG myocardial ischemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2350390","Myocardial Perfusion Imaging","C102676","A procedure that captures pictures of blood flow throughout the heart muscle.","Myocardial Perfusion Imaging | Myocardial perfusion imaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539725","SMPD1 wt Allele","C105020","Human SMPD1 wild-type allele is located within 11p15.4-p15.1 and is approximately 5 kb in length. This allele, which encodes sphingomyelin phosphodiesterase protein, is involved in ceramide biosynthesis. Mutation of the gene is associated with Niemann-Pick disease type A and type B.","SMPD1 wt Allele | ASM | ASMASE | NPD | Sphingomyelin Phosphodiesterase 1, Acid Lysosomal wt Allele | Sphingomyelinase, Acid Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL340955","sphingomyelin phosphodiesterase 1, acid lysosomal, human","C105021","Sphingomyelin phosphodiesterase (629 aa, ~70 kDa) is encoded by the human SMPD1 gene. This protein plays a role in sphingomyelin catabolism.","Sphingomyelin Phosphodiesterase | Acid Sphingomyelinase | EC 3.1.4.12 | SMPD1 | Sphingomyelinase, Acid | aSMase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540588","SMPD2 wt Allele","C105023","Human SMPD2 wild-type allele is located in the vicinity of 6q21 and is approximately 3 kb in length. This allele, which encodes sphingomyelin phosphodiesterase 2 protein, plays a role in ceramide metabolism.","SMPD2 wt Allele | ISC1 | NSMASE | NSMASE1 | RP5-919F19.2 | Sphingomyelin Phosphodiesterase 2, Neutral Membrane (Neutral Sphingomyelinase) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539740","SGMS2 wt Allele","C105025","Human SGMS2 wild-type allele is located in the vicinity of 4q25 and is approximately 90 kb in length. This allele, which encodes phosphatidylcholine:ceramide cholinephosphotransferase 2 protein, plays a role in cell growth.","SGMS2 wt Allele | MGC26963 | SMS2 | Sphingomyelin Synthase 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539580","Sphingomyelin Phosphodiesterase 2","C105026","Sphingomyelin phosphodiesterase 2 (423 aa, ~48 kDa) is encoded by the human SMPD2 gene. This protein is involved in phospholipid metabolism.","Sphingomyelin Phosphodiesterase 2 | EC 3.1.4.12 | Lyso-PAF-PLC | Lyso-Platelet-Activating Factor-Phospholipase C | N-SMase | Neutral Sphingomyelinase | SMPD2 | nSMase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641910","Phosphatidylcholine:Ceramide Cholinephosphotransferase 2","C105027","Phosphatidylcholine:ceramide cholinephosphotransferase 2 (365 aa, ~42 kDa) is encoded by the human SGMS2 gene. This protein is involved in cell growth.","Phosphatidylcholine:Ceramide Cholinephosphotransferase 2 | EC 2.7.8.27 | SGMS2 | Sphingomyelin Synthase 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542429","SGPL1 wt Allele","C105030","Human SGPL1 wild-type allele is located in the vicinity of 10q21 and is approximately 65 kb in length. This allele, which encodes sphingosine-1-phosphate lyase 1 protein, is involved in both the metabolism of phosphorylated sphingoid bases and apoptosis.","SGPL1 wt Allele | KIAA1252 | S1PL | SPL | SPL 1 | Sphingosine-1-Phosphate Lyase 1 wt Allele | hSPL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540589","SMPD3 wt Allele","C105031","Human SMPD3 wild-type allele is located in the vicinity of 16q22.1 and is approximately 90 kb in length. This allele, which encodes sphingomyelin phosphodiesterase 3 protein, is involved in sphingomyelin metabolism.","SMPD3 wt Allele | NSMASE2 | Sphingomyelin Phosphodiesterase 3, Neutral Membrane (Neutral Sphingomyelinase II) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640623","SF-36 v2.0 Standard - You Felt Downhearted and Depressed","C102224","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - have you felt downhearted and depressed.","SF-36 v2.0 Standard - You Felt Downhearted and Depressed | SF363-You Felt Downhearted and Depressed | SF36309F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640624","SF-36 v2.0 Standard - Did You Feel Worn Out","C102225","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - did you feel worn out.","SF-36 v2.0 Standard - Did You Feel Worn Out | SF363-Did You Feel Worn Out | SF36309G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640625","SF-36 v2.0 Standard - Have You Been Happy","C102226","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - have you been happy.","SF-36 v2.0 Standard - Have You Been Happy | SF363-Have You Been Happy | SF36309H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640626","SF-36 v2.0 Standard - Did You Feel Tired","C102227","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - did you feel tired.","SF-36 v2.0 Standard - Did You Feel Tired | SF363-Did You Feel Tired | SF36309I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640627","SF-36 v2.0 Standard - Time Phys/Emotional Interfered","C102228","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your social activities (like visiting friends, relatives, etc.)?","SF-36 v2.0 Standard - Time Phys/Emotional Interfered | SF363-Time Phys/Emotional Interfered | SF36310",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640628","SF-36 v2.0 Standard - Get Sick Little Easier Than Other","C102229","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) How TRUE or FALSE is the following statement for you - I seem to get sick a little easier than other people.","SF-36 v2.0 Standard - Get Sick Little Easier Than Other | SF363-Get Sick Little Easier Than Other | SF36311A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640630","SF-36 v2.0 Standard - I Expect My Health to Get Worse","C102231","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) How TRUE or FALSE is the following statement for you - I expect my health to get worse.","SF-36 v2.0 Standard - I Expect My Health to Get Worse | SF363-I Expect My Health to Get Worse | SF36311C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640631","SF-36 v2.0 Standard - My Health is Excellent","C102232","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) How TRUE or FALSE is the following statement for you - my health is excellent","SF-36 v2.0 Standard - My Health is Excellent | SF363-My Health is Excellent | SF36311D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640632","YMRS - Elevated Mood","C102233","Young Mania Rating Scale (YMRS) Elevated mood.","YMRS - Elevated Mood | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640633","YMRS - Increased Motor Activity-Energy","C102234","Young Mania Rating Scale (YMRS) Increased motor activity-energy.","YMRS - Increased Motor Activity-Energy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640634","YMRS - Sexual Interest","C102235","Young Mania Rating Scale (YMRS) Sexual interest.","YMRS - Sexual Interest | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640635","YMRS - Sleep","C102236","Young Mania Rating Scale (YMRS) Sleep.","YMRS - Sleep | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640636","YMRS - Irritability","C102237","Young Mania Rating Scale (YMRS) Irritability.","YMRS - Irritability | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1530535","PEMT protein, human","C104967","Phosphatidylethanolamine N-methyltransferase (199 aa, ~22 kDa) is encoded by the human PEMT gene. This protein plays a role in the methylation of phosphatidylethanolamine to synthesize phosphatidylcholine.","Phosphatidylethanolamine N-Methyltransferase | EC 2.1.1.17 | EC 2.1.1.71 | PEAMT | PEMT | PEMT2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538792","SHMT1 wt Allele","C104969","Human SHMT1 wild-type allele is located in the vicinity of 17p11.2 and is approximately 36 kb in length. This allele, which encodes serine hydroxymethyltransferase, cytosolic protein, plays a role in the metabolism of both amino acids and folate.","SHMT1 wt Allele | CSHMT | MGC15229 | MGC24556 | SHMT | Serine Hydroxymethyltransferase 1 (Soluble) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036725","Serine Hydroxymethyltransferase, Cytosolic","C104970","Serine hydroxymethyltransferase, cytosolic (483 aa, ~53 kDa) is encoded by the human SHMT1 gene. This protein is involved in the conversion of glycine to serine.","Serine Hydroxymethyltransferase, Cytosolic | EC 2.1.2.1 | Glycine Hydroxymethyltransferase | SHMT | SHMT1 | Serine Methylase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1137282","Phospholipase A2","C104973","Phospholipase A2 (148 aa, ~16 kDa) is encoded by the human PLA2G1B gene. This protein plays a role in fatty acid metabolism.","Phospholipase A2 | EC 3.1.1.4 | Group IB Phospholipase A2 | PLA2G1B | Phosphatidylcholine 2-Acylhydrolase 1B | Phospholipase A2 Group IB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539632","GSTA1 wt Allele","C104975","Human GSTA1 wild-type allele is located in the vicinity of 6p12.2 and is approximately 13 kb in length. This allele, which encodes glutathione S-transferase A1, plays a role in the metabolism of glutathione.","GSTA1 wt Allele | GST2 | GSTA1-1 | GTH1 | Glutathione S-Transferase Alpha 1 wt Allele | RP11-392A23.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1436224","Glutathione S-Transferase A1, Human","C104976","Glutathione S-transferase A1 (222 aa, ~26 kDa) is encoded by the human GSTA1 gene. This protein is involved in glutathione metabolism.","Glutathione S-Transferase A1 | EC 2.5.1.18 | GST Class-Alpha Member 1 | GST HA Subunit 1 | GST-Epsilon | GSTA1 | GSTA1-1 | GTH1 | Glutathione S-Alkyltransferase A1 | Glutathione S-Aryltransferase A1 | S-(Hydroxyalkyl)Glutathione Lyase A1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641969","DAD - Attempt to Telephone Someone at a Suitable Time","C105190","Disability Assessment for Dementia (DAD) Attempt to telephone someone at a suitable time?","DAD - Attempt to Telephone Someone at a Suitable Time | DAD01-Telephone Someone at Suitable Time | DAD0121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641971","DAD - Carry Out an Appropriate Telephone Conversation","C105192","Disability Assessment for Dementia (DAD) Carry out an appropriate telephone conversation?","DAD - Carry Out an Appropriate Telephone Conversation | DAD01-Carry Out Telephone Conversation | DAD0123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641972","DAD - Write and Convey a Telephone Message Adequately","C105193","Disability Assessment for Dementia (DAD) Write and convey a telephone message adequately?","DAD - Write and Convey a Telephone Message Adequately | DAD01-Write Convey Telephone Message | DAD0124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641973","DAD - Decide to Go Out at an Appropriate Time","C105194","Disability Assessment for Dementia (DAD) Decide to go out (walk, visit, shop) at an appropriate time?","DAD - Decide to Go Out at an Appropriate Time | DAD01-Decide to Go Out | DAD0125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538810","Nonclinical Pregnancy Results Domain","C102678","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to nonclinical pregnancy results.","Nonclinical Pregnancy Results Domain | Nonclinical Pregnancy Results | PY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640878","Non-household Environment","C102679","An area outside of that in which an individual lives.","Non-household Environment | NON-HOUSEHOLD ENVIRONMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640585","SF-36 v2.0 Acute - Have You Felt Calm and Peaceful","C102186","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - have you felt calm and peaceful.","SF-36 v2.0 Acute - Have You Felt Calm and Peaceful | SF364-Have You Felt Calm and Peaceful | SF36409D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640586","SF-36 v2.0 Acute - Did You Have a Lot of Energy","C102187","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - did you have a lot of energy.","SF-36 v2.0 Acute - Did You Have a Lot of Energy | SF364-Did You Have a Lot of Energy | SF36409E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640588","SF-36 v2.0 Acute - Did You Feel Worn Out","C102189","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - did you feel worn out.","SF-36 v2.0 Acute - Did You Feel Worn Out | SF364-Did You Feel Worn Out | SF36409G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640589","SF-36 v2.0 Acute - Have You Been Happy","C102190","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - have you been happy.","SF-36 v2.0 Acute - Have You Been Happy | SF364-Have You Been Happy | SF36409H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539582","Sphingomyelin Phosphodiesterase 3","C105032","Sphingomyelin phosphodiesterase 3 (655 aa, ~71 kDa) is encoded by the human SMPD3 gene. This protein plays a role in ceramide biosynthesis.","Sphingomyelin Phosphodiesterase 3 | EC 3.1.4.12 | Neutral Sphingomyelinase II | SMPD3 | nSMase-2 | nSMase2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642019","C-SSRS Baseline/Screening Version Phase 1 Study - Number of Actual Suicide Attempts","C105240","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Total number of actual attempts.","C-SSRS Baseline/Screening Version Phase 1 Study - Number of Actual Suicide Attempts | CSS03-Number of Actual Attempts | CSS0313",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642020","C-SSRS Baseline/Screening Version Phase 1 Study - Description of Actual Suicide Attempt","C105241","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Description of actual attempt.","C-SSRS Baseline/Screening Version Phase 1 Study - Description of Actual Suicide Attempt | CSS03-Actual Attempt, Describe | CSS0313A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642022","C-SSRS Baseline/Screening Version Phase 1 Study - Interrupted Suicide Attempt","C105243","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Has there been a time when you started to do something to try to end your life but someone or something stopped you before you actually did anything?","C-SSRS Baseline/Screening Version Phase 1 Study - Interrupted Suicide Attempt | CSS03-Interrupted Attempt | CSS0315",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642023","C-SSRS Baseline/Screening Version Phase 1 Study - Number of Interrupted Suicide Attempts","C105244","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Total number of interrupted.","C-SSRS Baseline/Screening Version Phase 1 Study - Number of Interrupted Suicide Attempts | CSS03-Number of Interrupted Attempts | CSS0316",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642024","C-SSRS Baseline/Screening Version Phase 1 Study - Description of Interrupted Suicide Attempt","C105245","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Description of interrupted attempt.","C-SSRS Baseline/Screening Version Phase 1 Study - Description of Interrupted Suicide Attempt | CSS03-Interrupted Attempt, Describe | CSS0316A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642025","C-SSRS Baseline/Screening Version Phase 1 Study - Aborted Suicide Attempt","C105246","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Has there been a time when you started to do something to try to end your life but you stopped yourself before you actually did anything?","C-SSRS Baseline/Screening Version Phase 1 Study - Aborted Suicide Attempt | CSS03-Aborted Attempt | CSS0317",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642026","C-SSRS Baseline/Screening Version Phase 1 Study - Number of Aborted Suicide Attempts","C105247","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Total number of aborted.","C-SSRS Baseline/Screening Version Phase 1 Study - Number of Aborted Suicide Attempts | CSS03-Number of Aborted Attempts | CSS0318",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642027","C-SSRS Baseline/Screening Version Phase 1 Study - Description of Aborted Suicide Attempt","C105248","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Description of aborted attempt.","C-SSRS Baseline/Screening Version Phase 1 Study - Description of Aborted Suicide Attempt | CSS03-Aborted Attempt, Describe | CSS0318A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642028","C-SSRS Baseline/Screening Version Phase 1 Study - Preparatory Acts or Behaviors Toward Suicide Attempt","C105249","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Have you taken any steps toward making a suicide attempt or preparing to kill yourself (such as collecting pills, getting a gun, giving valuables away or writing a suicide note)?","C-SSRS Baseline/Screening Version Phase 1 Study - Preparatory Acts or Behaviors Toward Suicide Attempt | CSS03-Preparatory Acts/Behavior | CSS0319",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640637","YMRS - Speech (Rate and Amount)","C102238","Young Mania Rating Scale (YMRS) Speech (Rate and Amount).","YMRS - Speech (Rate and Amount) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640638","YMRS - Language-Thought Disorder","C102239","Young Mania Rating Scale (YMRS) Language-thought disorder.","YMRS - Language-Thought Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540563","TRPC4 wt Allele","C102487","Human TRPC4 wild-type allele is located in the vicinity of 13q13.3 and is approximately 234 kb in length. This allele, which encodes short transient receptor potential channel 4 protein, is involved in the modulation of cellular calcium.","TRPC4 wt Allele | HTRP-4 | HTRP4 | MGC119570 | MGC119571 | MGC119572 | MGC119573 | TRP4 | Transient Receptor Potential Cation Channel, Subfamily C, Member 4 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540562","Short Transient Receptor Potential Channel 4","C102488","Short transient receptor potential channel 4 (977 aa, ~112 kDa) is encoded by the human TRPC4 gene. This protein plays a role in the transport of calcium.","Short Transient Receptor Potential Channel 4 | Trp-Related Protein 4 | TrpC4 | hTrp-4 | hTrp4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539638","HDAC7 wt Allele","C102490","Human HDAC7 wild-type allele is located in the vicinity of 12q13.1 and is approximately 50 kb in length. This allele, which encodes histone deacetylase 7 protein, plays a role in histone modification.","HDAC7 wt Allele | DKFZP586J0917 | DKFZp586J0917 | FLJ99588 | HD7A | HDAC7A | Histone Deacetylase 7 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537454","HDAC7 protein, human","C102491","Histone deacetylase 7 (952 aa, ~103 kDa) is encoded by the human HDAC7 gene. This protein is involved in chromatin remodeling.","Histone Deacetylase 7 | EC 3.5.1.98 | HD7 | HD7a | HDAC7 | Histone Deacetylase 7A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539637","HDAC9 wt Allele","C102493","Human HDAC9 wild-type allele is located in the vicinity of 7p21.1 and is approximately 910 kb in length. This allele, which encodes histone deacetylase 9 protein, is involved in the modification of histones.","HDAC9 wt Allele | DKFZp779K1053 | HD7 | HD7b | HD9 | HDAC | HDAC7 | HDAC7B | HDAC9B | HDAC9FL | HDRP | Histone Deacetylase 9 wt Allele | KIAA0744 | MITR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538688","Histone Deacetylase 9, Human","C102494","Histone deacetylase 9 (1011 aa, ~111 kDa) is encoded by the human HDAC9 gene. This protein plays a role in the modification of chromatin structure.","Histone Deacetylase 9 | EC 3.5.1.98 | HD7 | HD7b | HD9 | HDAC9 | Histone Deacetylase 7B | Histone Deacetylase-Related Protein | MEF2-Interacting Transcription Repressor MITR | MITR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413285","CDK5R1 Gene","C102495","This gene is involved in neuronal differentiation.","CDK5R1 Gene | CDK5R1 | Cyclin-Dependent Kinase 5, Regulatory Subunit 1 (p35) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539715","CDK5R1 wt Allele","C102496","Human CDK5R1 wild-type allele is located in the vicinity of 17q11.2 and is approximately 5 kb in length. This allele, which encodes cyclin-dependent kinase 5 activator 1 protein, plays a role in the regulation of neurite outgrowth.","CDK5R1 wt Allele | CDK5P35 | CDK5R | Cyclin-Dependent Kinase 5, Regulatory Subunit 1 (p35) wt Allele | MGC33831 | NCK5A | p23 | p25 | p35 | p35nck5a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640794","Cyclin-Dependent Kinase 5 Activator 1","C102497","Cyclin-dependent kinase 5 activator 1 (307 aa, ~34 kDa) is encoded by the human CDK5R1 gene. This protein is involved in the modulation of both kinase activity and neuronal development.","Cyclin-Dependent Kinase 5 Activator 1 | CDK5 Activator 1 | Cyclin-Dependent Kinase 5 Regulatory Subunit 1 | TPKII Regulatory Subunit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641974","DAD - Adequately Organize an Outing with Respect to Transportation, Keys, Destination, Weather, Money, Shopping List","C105195","Disability Assessment for Dementia (DAD) Adequately organize an outing with respect to transportation, keys, destination, weather, necessary money, shopping list?","DAD - Adequately Organize an Outing with Respect to Transportation, Keys, Destination, Weather, Money, Shopping List | DAD01-Adequately Organize an Outing | DAD0126",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641975","DAD - Go Out and Reach a Familiar Destination Without Getting Lost","C105196","Disability Assessment for Dementia (DAD) Go out and reach a familiar destination without getting lost?","DAD - Go Out and Reach a Familiar Destination Without Getting Lost | DAD01-Go Out Without Getting Lost | DAD0127",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641976","DAD - Safely Take the Adequate Mode of Transportation","C105197","Disability Assessment for Dementia (DAD) Safely take the adequate mode of transportation (car, bus, taxi)?","DAD - Safely Take the Adequate Mode of Transportation | DAD01-Safely Take Transportation | DAD0128",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641977","DAD - Return From the Store with Appropriate Items","C105198","Disability Assessment for Dementia (DAD) Return from the store with the appropriate items?","DAD - Return From the Store with Appropriate Items | DAD01-Return From Store With Items | DAD0129",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641978","DAD - Show an Interest in Personal Affairs such as Finances and Written Correspondence","C105199","Disability Assessment for Dementia (DAD) Show an interest in his/her personal affairs such as his/her finances and written correspondence?","DAD - Show an Interest in Personal Affairs such as Finances and Written Correspondence | DAD01-Show Interest in Personal Affairs | DAD0130",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641979","DAD - Organize Finances to Pay Bills","C105200","Disability Assessment for Dementia (DAD) Organize his/her finances to pay his/her bills (checks, bank statement, bills)?","DAD - Organize Finances to Pay Bills | DAD01-Organize Finances to Pay Bills | DAD0131",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641981","DAD - Handle Money Adequately","C105202","Disability Assessment for Dementia (DAD) Handle his/her money adequately (deal with cash)?","DAD - Handle Money Adequately | DAD01-Handle Money Adequately | DAD0133",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641982","DAD - Decide to Take Medications at the Correct Time","C105203","Disability Assessment for Dementia (DAD) Decide to take his/her medications at the correct time?","DAD - Decide to Take Medications at the Correct Time | DAD01-Take Medications at Correct Time | DAD0134",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641983","DAD - Take Medications as Prescribed","C105204","Disability Assessment for Dementia (DAD) Take his/her medications as prescribed (according to the right dosage)?","DAD - Take Medications as Prescribed | DAD01-Take Medications as Prescribed | DAD0135",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537302","Transcription Cofactor HES-6","C104535","Transcription cofactor HES-6 (224 aa, ~24 kDa) is encoded by the human HES6 gene. This protein plays a role in the modulation of transcription factor activity.","Transcription Cofactor HES-6 | C-HAIRY1 | Class B Basic Helix-Loop-Helix Protein 41 | HES6 | Hairy and Enhancer of Split 6 | bHLHb41",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640590","SF-36 v2.0 Acute - Did You Feel Tired","C102191","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - did you feel tired.","SF-36 v2.0 Acute - Did You Feel Tired | SF364-Did You Feel Tired | SF36409I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640591","SF-36 v2.0 Acute - Time Phys/Emotional Interfered","C102192","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) During the past week, how much of the time has your physical health or emotional problems interfered with your social activities (like visiting friends, relatives, etc.)?","SF-36 v2.0 Acute - Time Phys/Emotional Interfered | SF364-Time Phys/Emotional Interfered | SF36410",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640592","SF-36 v2.0 Acute - Get Sick Little Easier Than Other","C102193","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) How TRUE or FALSE is the following statement for you - I seem to get sick a little easier than other people.","SF-36 v2.0 Acute - Get Sick Little Easier Than Other | SF364-Get Sick Little Easier Than Other | SF36411A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640593","SF-36 v2.0 Acute - I Am as Healthy as Anybody I Know","C102194","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) How TRUE or FALSE is the following statement for you - I am as healthy as anybody I know.","SF-36 v2.0 Acute - I Am as Healthy as Anybody I Know | SF364-I Am as Healthy as Anybody I Know | SF36411B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640594","SF-36 v2.0 Acute - I Expect My Health to Get Worse","C102195","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) How TRUE or FALSE is the following statement for you - I expect my health to get worse.","SF-36 v2.0 Acute - I Expect My Health to Get Worse | SF364-I Expect My Health to Get Worse | SF36411C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640595","SF-36 v2.0 Acute - My Health is Excellent","C102196","The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) How TRUE or FALSE is the following statement for you - my health is excellent","SF-36 v2.0 Acute - My Health is Excellent | SF364-My Health is Excellent | SF36411D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640596","SF-36 v2.0 Standard - In General You Say Your Health Is","C102197","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) In general, would you say your health is.","SF-36 v2.0 Standard - In General You Say Your Health Is | SF363-In General You Say Your Health Is | SF36301",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640597","SF-36 v2.0 Standard - Comp Year Ago Rate Gen Health Now","C102198","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) Compared to one year ago, how would you rate your health in general now?","SF-36 v2.0 Standard - Comp Year Ago Rate Gen Health Now | SF363-Comp Year Ago Rate Gen Health Now | SF36302",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640598","SF-36 v2.0 Standard - Limit Vigorous Activities","C102199","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) How much does your health now limit you in - vigorous activities, such as running, lifting heavy objects, participating in strenuous sports.","SF-36 v2.0 Standard - Limit Vigorous Activities | SF363-Limit Vigorous Activities | SF36303A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538758","SCN2A wt Allele","C102445","Human SCN2A wild-type allele is located in the vicinity of 2q24.3 and is approximately 153 kb in length. This allele, which encodes sodium channel protein type 2 subunit alpha protein, plays a role in both sodium transport and membrane potential. Mutation of the gene is associated with both benign familial infantile type 3 seizures and epileptic encephalopathy early infantile type 11.","SCN2A wt Allele | BFIC3 | BFIS3 | BFNIS | EIEE11 | HBA | HBSCI | HBSCII | NAC2 | Na(v)1.2 | Nav1.2 | SCN2A1 | SCN2A2 | Sodium Channel, Brain Type II, Alpha Subunit Gene | Sodium Channel, Neuronal Type II, Alpha Subunit Gene | Sodium Channel, Neuronal Type II, Alpha Subunit-1 Gene | Sodium Channel, Voltage Gated, Type II, Alpha Subunit Gene | Sodium Channel, Voltage-Gated, Type II, Alpha 1 Polypeptide Gene | Sodium Channel, Voltage-Gated, Type II, Alpha 2 Polypeptide Gene | Sodium Channel, Voltage-Gated, Type II, Alpha Polypeptide Gene | Sodium Channel, Voltage-Gated, Type II, Alpha Subunit Gene | Sodium Voltage-Gated Channel Alpha Subunit 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1740160","Sodium Channel Protein Type 2 Subunit Alpha, Human","C102446","Sodium channel protein type 2 subunit alpha (2005 aa, ~228 kDa) is encoded by the human SCN2A gene. This protein is involved in membrane polarization.","Sodium Channel Protein Type 2 Subunit Alpha | HBSC II | SCN2A | Sodium Channel Protein Brain II Subunit Alpha | Sodium Channel Protein Type II Subunit Alpha | Voltage-Gated Sodium Channel Subunit Alpha Nav1.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642029","C-SSRS Baseline/Screening Version Phase 1 Study - Description of Preparatory Acts or Behaviors Toward Suicide Attempt","C105250","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Description of preparatory acts or behaviors.","C-SSRS Baseline/Screening Version Phase 1 Study - Description of Preparatory Acts or Behaviors Toward Suicide Attempt | CSS03-Preparatory Acts/Behavior, Descr | CSS0319A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642030","C-SSRS Baseline/Screening Version Phase 1 Study - Suicidal Behavior","C105251","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Suicidal behavior was present during the assessment period?","C-SSRS Baseline/Screening Version Phase 1 Study - Suicidal Behavior | CSS03-Suicidal Behavior | CSS0320",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539565","BGLAP wt Allele","C104591","Human BGLAP wild-type allele is located within 1q25-q31 and is approximately 1 kb in length. This allele, which encodes osteocalcin protein, plays a role in the regulation of bone formation.","BGLAP wt Allele | BGP | Bone Gamma-Carboxyglutamate (Gla) Protein (Osteocalcin) Gene | Bone Gamma-Carboxyglutamate (Gla) Protein Gene | Bone Gamma-Carboxyglutamate (Gla) Protein wt Allele | Bone Gamma-Carboxyglutamate Protein wt Allele | OC | OCN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0752226","Chamomile","C1045","The flower-heads of either the plant Anthemis nobilis or the plant Matricaria chamomilla.  Chamomile has a warm aromatic odour and a very bitter taste and contains volatile oils which are a mixture of butyl and amyl angelates and valerates.  Due to its coumarin constituents, large doses may interfere with coagulation. (NCI04)","Chamomile | chamomile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414253","S1PR1 Gene","C102498","This gene plays a role in lipid binding.","S1PR1 Gene | S1PR1 | Sphingosine-1-Phosphate Receptor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054150","bropirimine","C1024","An oral immunostimulant that causes the body to produce interferon and other substances.","Bropirimine | 2-Amino-5-bromo-6-phenyl-4(3H)-pyrimidone | 2-amino-5-bromo-6-phenyl-4-(3H)-pyrimidinone | 4(3H)-Pyrimidinone, 2-amino-5-bromo-6-phenyl- | 4-Pyrimidinol, 2-amino-5-bromo-6-phenyl- | ABPP | BROPIRIMINE | Remisar | U-54,461",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640415","ADNI AVLT - List B Recall Word 13","C102010","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List B, Word 13.","ADNI AVLT - List B Recall Word 13 | AVL01-List B Recall Word 13 | AVL01115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640416","ADNI AVLT - List B Recall Word 14","C102011","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List B, Word 14.","ADNI AVLT - List B Recall Word 14 | AVL01-List B Recall Word 14 | AVL01116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640417","ADNI AVLT - List B Recall Word 15","C102012","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List B, Word 15.","ADNI AVLT - List B Recall Word 15 | AVL01-List B Recall Word 15 | AVL01117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640418","ADNI AVLT - List B Recall Total","C102013","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of words recalled from List B.","ADNI AVLT - List B Recall Total | AVL01-List B Recall Total | AVL01118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640419","ADNI AVLT - List B Intrusions","C102014","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of intrusions while recalling List B.","ADNI AVLT - List B Intrusions | AVL01-List B Intrusions | AVL01119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640420","ADNI AVLT - List A 30 Min Delay Recall Word 1","C102015","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, 30 Minute Delay Recall, Word 1.","ADNI AVLT - List A 30 Min Delay Recall Word 1 | AVL01-List A 30 Min Delay Recall Word 1 | AVL01120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640421","ADNI AVLT - List A 30 Min Delay Recall Word 2","C102016","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, 30 Minute Delay Recall, Word 2.","ADNI AVLT - List A 30 Min Delay Recall Word 2 | AVL01-List A 30 Min Delay Recall Word 2 | AVL01121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640422","ADNI AVLT - List A 30 Min Delay Recall Word 3","C102017","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, 30 Minute Delay Recall, Word 3.","ADNI AVLT - List A 30 Min Delay Recall Word 3 | AVL01-List A 30 Min Delay Recall Word 3 | AVL01122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640423","ADNI AVLT - List A 30 Min Delay Recall Word 4","C102018","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, 30 Minute Delay Recall, Word 4.","ADNI AVLT - List A 30 Min Delay Recall Word 4 | AVL01-List A 30 Min Delay Recall Word 4 | AVL01123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539572","HEY2 wt Allele","C104537","Human HEY2 wild-type allele is located in the vicinity of 6q21 and is approximately 14 kb in length. This allele, which encodes hairy/enhancer-of-split related with YRPW motif protein 2, plays a role in both Notch signal transduction and transcriptional repression.","HEY2 wt Allele | CHF1 | GRIDLOCK | GRL | HERP | HERP1 | HESR2 | HRT2 | Hairy/Enhancer-Of-Split Related With YRPW Motif 2 wt Allele | RP1-293L8.3 | bHLHb32",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538756","NLRP1 wt Allele","C104539","Human NLRP1 wild-type allele is located in the vicinity of 17p13.2 and is approximately 120 kb in length. This allele, which encodes NACHT, LRR and PYD domains-containing protein 1, is involved in apoptosis induction. Mutations in the gene are associated with vitiligo-associated multiple autoimmune disease susceptibility 1.","NLRP1 wt Allele | AIADK | CARD7 | CIDED | CLR17.1 | DEFCAP | DEFCAP-L/S | DKFZp586O1822 | KIAA0926 | MSPC | NAC | NALP1 | NLR Family Pyrin Domain Containing 1 wt Allele | NLR Family, Pyrin Domain Containing 1 Gene | NLRP1A | NLRP1A, Mouse, Homolog of Gene | PP1044 | SLEV1 | Systemic Lupus Erythematosus, Vitiligo-Related 1 Gene | VAMAS1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538964","Hairy/Enhancer-Of-Split Related With YRPW Motif Protein 2, Human","C104540","Hairy/enhancer-of-split related with YRPW motif protein 2 (337 aa, ~36 kDa) is encoded by the human HEY2 gene. This protein is involved in both the negative regulation of gene expression and Notch-dependent signaling.","Hairy/Enhancer-of-Split Related With YRPW Motif Protein 2 | Cardiovascular Helix-Loop-Helix Factor 1 | Class B Basic Helix-Loop-Helix Protein 32 | HES-Related Repressor Protein 2 | HEY2 | HRT-2 | Hairy and Enhancer of Split-Related Protein 2 | Hairy-Related Transcription Factor 2 | Hairy/Enhancer-Of-Split Related With YRPW Motif Protein 2 | Hairy/Enhancer-Of-Split Related With YRPW Motif Protein 2 | Protein Gridlock Homolog | bHLHb32 | hCHF1 | hHRT2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538768","NACHT, LRR and PYD Domains-Containing Protein 1, Human","C104541","NACHT, LRR and PYD domains-containing protein 1 (1473 aa, ~166 kDa) is encoded by the human NLRP1 gene. This protein plays a role in the induction of apoptosis.","NACHT, LRR and PYD Domains-Containing Protein 1 | Caspase Recruitment Domain Protein 7 | Caspase Recruitment Domain-Containing Protein 7 | Death Effector Filament-Forming CED4-Like Apoptosis Protein | Death Effector Filament-Forming ced-4-Like Apoptosis Protein | NACHT Domain-, Leucine-Rich Repeat-, and PYD-Containing Protein 1 | NACHT, LRR and PYD Containing Protein 1 | NACHT, Leucine Rich Repeat and PYD (Pyrin Domain) Containing 1 | NACHT, Leucine Rich Repeat and PYD Containing 1 | NLR Family, Pyrin Domain Containing 1 | NLRP1 | Nucleotide-Binding Domain and Caspase Recruitment Domain | Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat and Pyrin Domain Containing 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538765","NCR2 wt Allele","C104544","Human NCR2 wild-type allele is located in the vicinity of 6p21.1 and is approximately 15 kb in length. This allele, which encodes natural cytotoxicity triggering receptor 2 protein plays a role in natural killer cell function.","NCR2 wt Allele | CD336 | LY95 | Lymphocyte Antigen 95, Mouse, Homolog of Gene | NK-p44 | NKp44 | Natural Cytotoxicity Triggering Receptor 2 wt Allele | dJ149M18.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540531","SLC29A2 wt Allele","C104545","Human SLC29A2 wild-type allele is located in the vicinity of 11q13 and is approximately 10 kb in length. This allele, which encodes equilibrative nucleoside transporter 2, is involved in nucleoside equilibration.","SLC29A2 wt Allele | DER12 | ENT2 | HNP36 | Solute Carrier Family 29 (Nucleoside Transporters), Member 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541424","PDK1 wt Allele","C104759","Human PDK1 wild-type allele is located in the vicinity of 2q31.1 and is approximately 70 kb in length. This allele, which encodes [pyruvate dehydrogenase [lipoamide]] kinase isozyme 1, mitochondrial protein, plays a role in carbohydrate metabolism.","PDK1 wt Allele | PDHK1 | Pyruvate Dehydrogenase Kinase, Isozyme 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538757","SCN1A wt Allele","C102448","Human SCN1A wild-type allele is located in the vicinity of 2q24.3 and is approximately 84 kb in length. This allele, which encodes sodium channel protein type 1 subunit alpha, plays a role in voltage-gated sodium transport. Mutation of the gene is associated with generalized epilepsy with febrile seizures plus type 2, Dravet syndrome, intractable childhood epilepsy with generalized tonic-clonic seizures, familial hemiplegic migraine type 3 and familial febrile convulsions type 3A.","SCN1A wt Allele | EIEE6 | FEB3 | FEB3A | FHM3 | Febrile Convulsions 3 Gene | GEFSP2 | HBSCI | NAC1 | NAV1.1 | Nav1.1 | SCN1 | SMEI | Sodium Channel, Brain Type I, Alpha Subunit Gene | Sodium Channel, Neuronal Type I, Alpha Subunit Gene | Sodium Channel, Voltage Gated, Type I, Alpha Subunit Gene | Sodium Channel, Voltage-Gated, Type I, Alpha Subunit Gene | Sodium Voltage-Gated Channel Alpha Subunit 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537394","SCN1A protein, human","C102449","Sodium channel protein type 1 subunit alpha (2009 aa, ~229 kDa) is encoded by the human SCN1A gene. This protein is involved in the modulation of sodium transport.","Sodium Channel Protein Type 1 Subunit Alpha | Nav1.1 | SCN1A | Sodium Channel Protein Brain I Subunit Alpha | Sodium Channel Protein Type I Subunit Alpha | Voltage-Gated Sodium Channel Subunit Alpha Nav1.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640791","Resulted in Prolongation of Hospitalization","C102450","An indication or description that an extended period of hospitalization is necessary.","Resulted in Prolongation of Hospitalization | Resulted in prolongation of hospitalization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640792","Disability or Permanent Damage","C102451","A sustained and substantial impairment or disruption of a person's ability to conduct normal life functions for the remainder of his/her life.","Disability or Permanent Damage | Resulted in permanent disability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537433","KATNAL2 Gene","C102452","This gene plays a role in ATP hydrolysis.","KATNAL2 Gene | KATNAL2 | Katanin Catalytic Subunit A1 Like 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539742","KATNAL2 wt Allele","C102453","Human KATNAL2 wild-type allele is located in the vicinity of 18q21.1 and is approximately 102 kb in length. This allele, which encodes katanin p60 ATPase-containing subunit A-like 2 protein, is involved in both ATP hydrolysis and microtubule depolymerization.","KATNAL2 wt Allele | DKFZp667C165 | Katanin Catalytic Subunit A Like 2 Gene | Katanin Catalytic Subunit A1 Like 2 wt Allele | Katanin p60 Subunit A Like 2 Gene | Katanin p60 Subunit A-Like 2 Gene | MGC33211",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539660","Katanin p60 ATPase-Containing Subunit A-Like 2","C102454","Katanin p60 ATPase-containing subunit A-like 2 (538 aa, ~61 kDa) is encoded by the human KATNAL2 gene. This protein plays a role in both hydrolysis of ATP and microtubule dynamics.","Katanin p60 ATPase-Containing Subunit A-Like 2 | EC 3.6.4.3 | KATNA-Like 2 | KATNAL2 | Katanin p60 Subunit A-Like 2 | p60 Katanin-Like 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428031","NTNG1 Gene","C102455","This gene is involved in axon formation.","NTNG1 Gene | NTNG1 | Netrin G1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1142712","Netrin-G1, Human","C102457","Netrin-G1 (539 aa, ~61 kDa) is encoded by the human NTNG1 gene. This protein is involved in axonogenesis.","Netrin-G1 | Laminet 1 | Laminet-1 | Netrin G1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415300","GRIN2B Gene","C102458","This gene plays a role in both neurotransmitter binding and ion transport.","GRIN2B Gene | GRIN2B | Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 2B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640368","ADNI AVLT - List A Intrusions 4","C101963","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of intrusions while recalling List A, fourth attempt.","ADNI AVLT - List A Intrusions 4 | AVL01-List A Intrusions 4 | AVL01068",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640369","ADNI AVLT - List A Recall 5 Word 1","C101964","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 5, Word 1.","ADNI AVLT - List A Recall 5 Word 1 | AVL01-List A Recall 5 Word 1 | AVL01069",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641841","Constant Concern","C104606","A response that indicates a state of continual concern.","Constant Concern | Constant concerns",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641843","Highest Level of Support","C104608","An answer confirming the highest level of support.","Highest Level of Support | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538812","PYY wt Allele","C104811","Human PYY wild-type allele is located in the vicinity of 17q21.1 and is approximately 52 kb in length. This allele, which encodes peptide YY protein, plays a role in signaling that modulates digestion. Genetic variations in this gene may contribute to obesity.","PYY wt Allele | PYY-I | PYY1 | Peptide YY wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0070358","Peptide YY","C104812","Peptide YY (97 aa, ~11 kDa) is encoded by the human PYY gene. This protein is involved in hormone signaling to regulate gastrointestinal processes.","Peptide YY | PYY | PYY-I | Peptide Tyrosine Tyrosine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539754","RAB5C wt Allele","C104815","Human RAB5C wild-type allele is located in the vicinity of 17q21.2 and is approximately 30 kb in length. This allele, which encodes Ras-related protein Rab-5C, is involved in GTP metabolism and may be involved in vesicle transport.","RAB5C wt Allele | L1880 | RAB5C, Member RAS Oncogene Family wt Allele | RAB5CL | RAB5L | RABL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539753","Ras-Related Protein Rab-5C","C104816","Ras-related protein Rab-5C (216 aa, ~23 kDa) is encoded by the human RAB5C gene. This protein plays a role in GTPase activity.","Ras-Related Protein Rab-5C | L1880 | RAB5C | RAB5L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541429","RAC3 wt Allele","C104818","Human RAC3 wild-type allele is located in the vicinity of 17q25.3 and is approximately 3 kb in length. This allele, which encodes Ras-related C3 botulinum toxin substrate 3 protein, plays a role in both GTP hydrolysis and the formation of cell protrusions.","RAC3 wt Allele | Ras-Related C3 Botulinum Toxin Substrate 3 (Rho Family, Small GTP Binding Protein Rac3) wt Allele | Rho Family, Small GTP Binding Protein Rac3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538822","Ras-Related C3 Botulinum Toxin Substrate 3","C104819","Ras-related C3 botulinum toxin substrate 3 (192 aa, ~21 kDa) is encoded by the human RAC3 gene. This protein is involved in the formation of lamellipodia and membrane ruffles.","Ras-Related C3 Botulinum Toxin Substrate 3 | RAC3 | p21-Rac3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640425","ADNI AVLT - List A 30 Min Delay Recall Word 6","C102020","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, 30 Minute Delay Recall, Word 6.","ADNI AVLT - List A 30 Min Delay Recall Word 6 | AVL01-List A 30 Min Delay Recall Word 6 | AVL01125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640426","ADNI AVLT - List A 30 Min Delay Recall Word 7","C102021","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, 30 Minute Delay Recall, Word 7.","ADNI AVLT - List A 30 Min Delay Recall Word 7 | AVL01-List A 30 Min Delay Recall Word 7 | AVL01126",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640427","ADNI AVLT - List A 30 Min Delay Recall Word 8","C102022","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, 30 Minute Delay Recall, Word 8.","ADNI AVLT - List A 30 Min Delay Recall Word 8 | AVL01-List A 30 Min Delay Recall Word 8 | AVL01127",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640428","ADNI AVLT - List A 30 Min Delay Recall Word 9","C102023","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, 30 Minute Delay Recall, Word 9.","ADNI AVLT - List A 30 Min Delay Recall Word 9 | AVL01-List A 30 Min Delay Recall Word 9 | AVL01128",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640429","ADNI AVLT - List A 30 Min Delay Recall Word 10","C102024","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, 30 Minute Delay Recall, Word 10.","ADNI AVLT - List A 30 Min Delay Recall Word 10 | AVL01-List A 30 Min Delay Recall Word 10 | AVL01129",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2000212","[Pyruvate Dehydrogenase [Lipoamide]] Kinase Isozyme 1, Mitochondrial, Human","C104761","[Pyruvate dehydrogenase [lipoamide]] kinase isozyme 1, mitochondrial (436 aa, ~49 kDa) is encoded by the human PDK1 gene. This protein is involved in pyruvate and glucose metabolism.","[Pyruvate Dehydrogenase [Lipoamide]] Kinase Isozyme 1, Mitochondrial | EC 2.7.11.2 | Mitochondrial Pyruvate Dehydrogenase, Lipoamide, Kinase Isoenzyme 1 | PDK1 | Pyruvate Dehydrogenase Kinase Isoform 1 | Pyruvate Dehydrogenase Kinase, Isoenzyme 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541425","RPL13A wt Allele","C104762","Human RPL13A wild-type allele is located in the vicinity of 19q13.3 and is approximately 8 kb in length. This allele, which encodes 60S ribosomal protein L13a, is involved in translation as a structural protein of the 60S ribosome subunit.","RPL13A wt Allele | L13A | Ribosomal Protein L13a wt Allele | TSTA1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641868","60S Ribosomal Protein L13a","C104763","60S ribosomal protein L13a (203 aa, ~24 kDa) is encoded by the human RPL13A gene. This protein plays a role in translation as a structural protein of the 60S ribosome subunit.","60S Ribosomal Protein L13a | 23 kDa Highly Basic Protein | Large Ribosomal Subunit Protein uL13 | RPL13A | Tissue Specific Transplantation Antigen 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540564","RPS6KA1 wt Allele","C104765","Human RPS6KA1 wild-type allele is located in the vicinity of 1p36.11 and is approximately 45 kb in length. This allele, which encodes ribosomal protein S6 kinase alpha-1 protein, plays a role in regulating transcription, cellular proliferation, differentiation, and survival.","RPS6KA1 wt Allele | HU-1 | MAPKAPK-1a | MAPKAPK1A | RSK | RSK-1 | RSK1 | Ribosomal Protein S6 Kinase A1 wt Allele | Ribosomal Protein S6 Kinase, 90-kD, 1 Gene | Ribosomal Protein S6 Kinase, 90kD, Polypeptide 1 Gene | Ribosomal Protein S6 Kinase, 90kDa, Polypeptide 1 Gene | dJ590P13.1 | dJ590P13.1 (Ribosomal Protein S6 Kinase, 90kD, Polypeptide 1) Gene | p90Rsk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539803","90 kDa Ribosomal Protein S6 Kinase 1","C104766","Ribosomal protein S6 kinase alpha-1 (735 aa, ~83 kDa) is encoded by the human RPS6KA1 gene. This protein is involved in MAPK signaling and regulation of cell growth, proliferation, and differentiation.","Ribosomal Protein S6 Kinase Alpha-1 | 90 kDa Ribosomal Protein S6 Kinase 1 | EC 2.7.11.1 | MAP Kinase-Activated Protein Kinase 1a | MAPK-Activated Protein Kinase 1a | MAPKAP Kinase 1a | MAPKAPK-1a | Mitogen-Activated Protein Kinase-Activated Protein Kinase 1a | RPS6KA1 | RSK-1 | Ribosomal Protein S6 Kinase 1 | Ribosomal Protein S6 Kinase Alpha 1 | Ribosomal S6 Kinase 1 | S6K-Alpha 1 | S6K-Alpha-1 | p90-RSK 1 | p90RSK1 | p90S6K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538731","RPTOR wt Allele","C104768","Human RPTOR wild-type allele is located in the vicinity of 17q25.3 and is approximately 422 kb in length. This allele, which encodes regulatory-associated protein of mTOR protein, plays a role in regulating cell growth in response to nutrient and insulin levels.","RPTOR wt Allele | KIAA1303 | KOG1 | Mip1 | Raptor Gene | Regulatory Associated Protein of mTOR Complex 1 wt Allele | Regulatory Associated Protein of mTOR, Complex 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538725","Regulatory-Associated Protein of mTOR, Human","C104769","Regulatory-associated protein of mTOR (1335 aa, ~149 kDa) is encoded by the human RPTOR gene. This protein is involved in regulating cell growth and survival in response to nutrient and hormonal signals.","Regulatory-Associated Protein of mTOR | RPTOR | Raptor | p150 Target of Rapamycin (TOR)-Scaffold Protein | p150 Target of Rapamycin (TOR)-Scaffold Protein Containing WD-Repeats",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640370","ADNI AVLT - List A Recall 5 Word 2","C101965","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 5, Word 2.","ADNI AVLT - List A Recall 5 Word 2 | AVL01-List A Recall 5 Word 2 | AVL01070",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640371","ADNI AVLT - List A Recall 5 Word 3","C101966","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 5, Word 3.","ADNI AVLT - List A Recall 5 Word 3 | AVL01-List A Recall 5 Word 3 | AVL01071",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640372","ADNI AVLT - List A Recall 5 Word 4","C101967","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 5, Word 4.","ADNI AVLT - List A Recall 5 Word 4 | AVL01-List A Recall 5 Word 4 | AVL01072",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640373","ADNI AVLT - List A Recall 5 Word 5","C101968","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 5, Word 5.","ADNI AVLT - List A Recall 5 Word 5 | AVL01-List A Recall 5 Word 5 | AVL01073",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640375","ADNI AVLT - List A Recall 5 Word 7","C101970","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 5, Word 7.","ADNI AVLT - List A Recall 5 Word 7 | AVL01-List A Recall 5 Word 7 | AVL01075",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640376","ADNI AVLT - List A Recall 5 Word 8","C101971","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 5, Word 8.","ADNI AVLT - List A Recall 5 Word 8 | AVL01-List A Recall 5 Word 8 | AVL01076",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640377","ADNI AVLT - List A Recall 5 Word 9","C101972","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 5, Word 9.","ADNI AVLT - List A Recall 5 Word 9 | AVL01-List A Recall 5 Word 9 | AVL01077",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640378","ADNI AVLT - List A Recall 5 Word 10","C101973","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 5, Word 10.","ADNI AVLT - List A Recall 5 Word 10 | AVL01-List A Recall 5 Word 10 | AVL01078",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640379","ADNI AVLT - List A Recall 5 Word 11","C101974","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 5, Word 11.","ADNI AVLT - List A Recall 5 Word 11 | AVL01-List A Recall 5 Word 11 | AVL01079",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640380","ADNI AVLT - List A Recall 5 Word 12","C101975","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 5, Word 12.","ADNI AVLT - List A Recall 5 Word 12 | AVL01-List A Recall 5 Word 12 | AVL01080",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640381","ADNI AVLT - List A Recall 5 Word 13","C101976","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 5, Word 13.","ADNI AVLT - List A Recall 5 Word 13 | AVL01-List A Recall 5 Word 13 | AVL01081",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640382","ADNI AVLT - List A Recall 5 Word 14","C101977","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 5, Word 14.","ADNI AVLT - List A Recall 5 Word 14 | AVL01-List A Recall 5 Word 14 | AVL01082",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640383","ADNI AVLT - List A Recall 5 Word 15","C101978","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 5, Word 15.","ADNI AVLT - List A Recall 5 Word 15 | AVL01-List A Recall 5 Word 15 | AVL01083",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640384","ADNI AVLT - List A Recall 5 Total","C101979","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of words recalled from List A, fifth attempt.","ADNI AVLT - List A Recall 5 Total | AVL01-List A Recall 5 Total | AVL01084",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641869","Wireless Communication Problem","C104820","Problems with the RF wireless technology characteristics and performance (e.g., frequency, output power, range, reception), wireless quality of service, wireless coexistence, security of wireless signals and data, and electromagnetic compatibility.","Wireless Communication Problem | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539716","PLCG1 wt Allele","C104822","Human PLCG1 wild-type allele is located within 20q12-q13.1 and is approximately 39 kb in length. This allele, which encodes 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 protein, plays a role in second messenger production.","PLCG1 wt Allele | NCKAP3 | PLC-II | PLC1 | PLC148 | PLCgamma1 | Phospholipase C, Gamma 1 (Formerly Subtype 148) Gene | Phospholipase C, Gamma 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1959510","PLCG1 protein, human","C104824","1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 (1290 aa, ~149 kDa) is encoded by the human PLCG1 gene. This protein is involved in the intracellular propagation of signals from ligand-dependent receptor-type tyrosine kinases.","1-Phosphatidylinositol 4,5-Bisphosphate Phosphodiesterase Gamma-1 | EC 3.1.4.11 | Inositoltrisphosphohydrolase Monophosphatidylinositol Phosphodiesterase | PLC-148 | PLC-Gamma-1 | PLC-II | PLCG1 | Phosphatidylinositol Phospholipase C | Phosphoinositidase C | Phosphoinositide Phospholipase C | Phosphoinositide Phospholipase C-Gamma-1 | Phospholipase C-148 | Phospholipase C-Gamma-1 | Phospholipase C-II | Triphosphoinositide Phosphodiesterase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1253907","Primula veris","C104825","No value exists.","Primula veris | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0330255","Pulsatilla vulgaris","C104826","No value exists.","Pulsatilla vulgaris | PULSATILLA VULGARIS WHOLE",,,,,,,,,,,,,,,"4099519","Anemone pulsatilla",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3540581","SMPD4 wt Allele","C105036","Human SMPD4 wild-type allele is located in the vicinity of 2q21.1 and is approximately 31 kb in length. This allele, which encodes sphingomyelin phosphodiesterase 4 protein, plays a role in phospholipid metabolism.","SMPD4 wt Allele | FLJ20297 | FLJ20756 | KIAA1418 | NET13 | NSMASE-3 | NSMASE3 | Sphingomyelin Phosphodiesterase 4, Neutral Membrane (Neutral Sphingomyelinase-3) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542430","SGPP1 wt Allele","C105038","Human SGPP1 wild-type allele is located in the vicinity of 14q23.2 and is approximately 44 kb in length. This allele, which encodes sphingosine-1-phosphate phosphatase 1 protein, plays a role in intracellular and extracellular sphingosine-1-phosphate levels.","SGPP1 wt Allele | Sphingosine-1-Phosphate Phosphatase 1 wt Allele | Spp1 | hSPP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539581","Sphingomyelin Phosphodiesterase 4","C105039","Sphingomyelin phosphodiesterase 4 (827 aa, ~93 kDa) is encoded by the human SMPD4 gene. This protein is involved in sphingomyelin catabolism.","Sphingomyelin Phosphodiesterase 4 | EC 3.1.4.12 | Neutral Sphingomyelinase III | SMPD4 | nSMase-3 | nSMase3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1434623","Sphingosine-1-Phosphate Phosphatase 1, Human","C105040","Sphingosine-1-phosphate phosphatase 1 (441 aa, ~49 kDa) is encoded by the human SGPP1 gene. This protein is involved in regulating intracellular and extracellular sphingosine-1-phosphate levels.","Sphingosine-1-Phosphate Phosphatase 1 | EC 3.1.3.- | SGPP1 | SPPase1 | Sphingosine-1-Phosphatase 1 | hSPPase1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640920","Clinical Observation Subcategory","C102740","A subdivision of clinical observational data.","Clinical Observation Subcategory | CLSCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640921","Clinical Observation Result Category","C102741","A classification of a clinical observation result.","Clinical Observation Result Category | CLRESCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL437002","Extended Release Bupivacaine Hydrochloride Resorbable Matrix Formulation","C102745","An extended release (ER) injectable formulation composed of the hydrochloride salt form of bupivacaine, an amide-type, long-acting local anesthetic, in a resorbable sucrose acetate isobutyrate-based matrix, with analgesic activity. Following administration in or around a specific site, ER bupivacaine is released from the matrix over an extended period of time. Upon release, bupivacaine reversibly binds to specific voltage-gated sodium ion channels in the neuronal membrane, resulting in a decrease in the voltage-dependent membrane permeability to sodium ions, membrane destabilization, and depolarization inhibition thus disrupting nerve impulse conduction. This eventually leads to a reversible loss of sensation. This formulation may provide pain relief up to 72 hours.","Extended Release Bupivacaine Hydrochloride Resorbable Matrix Formulation | ER Bupivacaine HCl | SABER-Bupivacaine Hydrochloride | Sustained Release Bupivacaine Hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640639","YMRS - Content","C102240","Young Mania Rating Scale (YMRS) Content.","YMRS - Content | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640641","YMRS - Appearance","C102242","Young Mania Rating Scale (YMRS) Appearance.","YMRS - Appearance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640642","YMRS - Insight","C102243","Young Mania Rating Scale (YMRS) Insight.","YMRS - Insight | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640644","Short Term General Hospital","C102248","The patient will remain in a basic hospital environment for a brief time.","Short Term General Hospital | SHORT TERM GENERAL HOSPITAL | Short Term Hospitalization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640645","Median Heart Rate","C102249","A measurement of the median number of cycles of contraction and subsequent relaxation of the heart, usually expressed as beats per minute, obtained from a set of measurements of the heart rate.","Median Heart Rate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539604","CR2 wt Allele","C104978","Human CR2 wild-type allele is located in the vicinity of 1q32 and is approximately 36 kb in length. This allele, which encodes complement receptor type 2 protein, is involved in the activation of both B-cells and complement-mediated immunity. Mutation of the gene is associated with systemic lupus erythematosus type 9.","CR2 wt Allele | C3DR | CD21 | CR | CVID7 | Complement Component (3d/Epstein Barr Virus) Receptor 2 wt Allele | RP11-78B10.1 | SLEB9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540489","CKS1B wt Allele","C104981","Human CKS1B wild-type allele is located in the vicinity of 1q21.3 and is approximately 5 kb in length. This allele, which encodes cyclin-dependent kinases regulatory subunit 1 protein, is involved in cell cycle progression.","CKS1B wt Allele | CDC28 Protein Kinase Regulatory Subunit 1B wt Allele | CKS1 | PNAS-16 | PNAS-18 | ckshs1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641900","INPP5D Gene Product","C104985","A protein encoded by the INPP5D gene.","INPP5D Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641903","Palliative Radiation Therapy for Metastatic Cancer","C104988","Radiation therapy given as palliative treatment to a patient with metastatic cancer.","Palliative Radiation Therapy for Metastatic Cancer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641904","Retreatment of Progressive Local Disease with External Beam Radiation","C104989","External beam radiation therapy given as retreatment of locally progressive cancer.","Retreatment of Progressive Local Disease with External Beam Radiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641905","Retreatment of Progressive Local Disease with Brachytherapy","C104990","Brachytherapy given as retreatment of locally progressive cancer.","Retreatment of Progressive Local Disease with Brachytherapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641906","Retreatment of Progressive Local Disease with Cryotherapy and HIFU","C104991","Cryotherapy and high intensity focused ultrasound given as retreatment of locally progressive cancer.","Retreatment of Progressive Local Disease with Cryotherapy and HIFU | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541314","Pairing Events Domain","C102694","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to pairing events.","Pairing Events Domain | PA | Pairing Events",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541884","SGPP2 wt Allele","C105045","Human SGPP2 wild-type allele is located in the vicinity of 2q36.1 and is approximately 136 kb in length. This allele, which encodes sphingosine-1-phosphate phosphatase 2 protein, is involved in intracellular and extracellular sphingosine-1-phosphate levels.","SGPP2 wt Allele | FLJ39004 | SPP2 | Sphingosine-1-Phosphate Phosphatase 2 wt Allele | hSPP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1434624","Sphingosine-1-Phosphate Phosphatase 2, Human","C105047","Sphingosine-1-phosphate phosphatase 2 (399 aa, ~48 kDa) is encoded by the human SGPP2 gene. This protein plays a role in regulating intracellular and extracellular sphingosine-1-phosphate levels.","Sphingosine-1-Phosphate Phosphatase 2 | EC 3.1.3.- | SGPP2 | SPPase2 | Sphingosine 1-Phosphate Phosphohydrolase 2 | Sphingosine-1-Phosphatase 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642031","C-SSRS Baseline/Screening Version Phase 1 Study - Most Recent Suicide Attempt Date","C105252","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Most recent attempt date.","C-SSRS Baseline/Screening Version Phase 1 Study - Most Recent Suicide Attempt Date | CSS03-Most Recent Attempt Date | CSS0321A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642032","C-SSRS Baseline/Screening Version Phase 1 Study - Most Recent Suicide Attempt Actual Lethality/Medical Damage","C105253","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Most recent attempt actual lethality/medical damage.","C-SSRS Baseline/Screening Version Phase 1 Study - Most Recent Suicide Attempt Actual Lethality/Medical Damage | CSS03-Most Recent Attempt Damage | CSS0321B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642033","C-SSRS Baseline/Screening Version Phase 1 Study - Most Recent Suicide Attempt Potential Lethality","C105254","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Most recent attempt potential lethality.","C-SSRS Baseline/Screening Version Phase 1 Study - Most Recent Suicide Attempt Potential Lethality | CSS03-Most Recent Attempt Potential | CSS0321C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642034","C-SSRS Baseline/Screening Version Phase 1 Study - Most Lethal Suicide Attempt Date","C105255","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Most lethal attempt date.","C-SSRS Baseline/Screening Version Phase 1 Study - Most Lethal Suicide Attempt Date | CSS03-Most Lethal Attempt Date | CSS0322A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640646","Median PR Duration","C102250","A measurement of the median duration (time) of the PR interval, obtained from a set of measurements of the PR interval. The PR interval is defined as the time from the beginning of the P wave (representing the onset of atrial depolarization) to the beginning of the R wave (representing the onset of ventricular depolarization). In some cases, a Q wave will precede the R wave, in which case the PR interval is measured from the beginning of the P wave to the beginning of the Q wave.","Median PR Duration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640647","Median QRS Duration","C102251","A measurement of the median duration (time) of the QRS interval, obtained from a set of measurements of the QRS interval. The QRS interval is defined as the time from the beginning of the QRS complex to the end of the QRS complex, representing the time it takes for the ventricles to depolarize.","Median QRS Duration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640648","Median QT Duration","C102252","A measurement of the median duration (time) of the QT interval, obtained from a set of measurements of the QT interval. The QT interval is defined as the time from the beginning of the QRS complex to the end of the T wave, representing the time it takes for the ventricles to depolarize and subsequently repolarize. In some cases, the Q wave will be absent, in which case the QT interval is measured from the beginning of the R wave to the end of the T wave.","Median QT Duration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640649","Median QTcF","C102253","A measurement of the median duration (time) of the QTc interval, obtained from a set of measurements of the QT interval and corrected using the Fridericia's correction formula.","Median QTcF | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640650","Median RR Duration","C102254","A measurement of the median duration (time) of the RR interval, obtained from a set of measurements of the RR interval. The RR interval is defined as the time between successive peaks of the R wave and can be used to measure the ventricular rate.","Median RR Duration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416661","KLF5 Gene","C102501","This gene plays a role in the positive regulation of transcription.","KLF5 Gene | KLF5 | Kruppel-Like Factor 5 (Intestinal) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540487","KLF5 wt Allele","C102502","Human KLF5 wild-type allele is located in the vicinity of 13q22.1 and is approximately 23 kb in length. This allele, which encodes Krueppel-like factor 5 protein, is involved in the regulation of transcription.","KLF5 wt Allele | BTEB2 | CKLF | IKLF | Kruppel-Like Factor 5 (Intestinal) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538966","Krueppel-Like Factor 5","C102503","Krueppel-like factor 5 (457 aa, ~51 kDa) is encoded by the human KLF5 gene. This protein plays a role in transcriptional activation.","Krueppel-Like Factor 5 | BTE-Binding Protein 2 | Basic Transcription Element-Binding Protein 2 | Colon Krueppel-Like Factor | GC-Box-Binding Protein 2 | Intestinal-Enriched Krueppel-Like Factor | KLF5 | Transcription Factor BTEB2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419183","QPCT Gene","C102504","This gene is involved in protein modification.","QPCT Gene | Glutaminyl-Peptide Cyclotransferase Gene | QPCT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538813","QPCT wt Allele","C102505","Human QPCT wild-type allele is located in the vicinity of 2p22.2 and is approximately 29 kb in length. This allele, which encodes glutaminyl-peptide cyclotransferase protein, plays a role in the post-translational protein modification.","QPCT wt Allele | GCT | Glutaminyl-Peptide Cyclotransferase wt Allele | QC | sQC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641984","DAD - Show an Interest in Leisure Activities","C105205","Disability Assessment for Dementia (DAD) Show an interest in leisure activity(ies)?","DAD - Show an Interest in Leisure Activities | DAD01-Show Interest in Leisure Activity | DAD0136",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641985","DAD - Take an Interest in Household Chores as in the Past","C105206","Disability Assessment for Dementia (DAD) Take an interest in household chores that he/she used to perform in the past?","DAD - Take an Interest in Household Chores as in the Past | DAD01-Take Interest in Household Chores | DAD0137",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641986","DAD - Plan and Organize Adequately Household Chores as in the Past","C105207","Disability Assessment for Dementia (DAD) Plan and organize adequately household chores that he/she used to perform in the past?","DAD - Plan and Organize Adequately Household Chores as in the Past | DAD01-Plan Organize Household Chores | DAD0138",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641988","DAD - Stay Safely at Home When Needed","C105209","Disability Assessment for Dementia (DAD) Stay safely at home by himself/herself when needed?","DAD - Stay Safely at Home When Needed | DAD01-Stay Safely at Home When Needed | DAD0140",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641989","C-SSRS Baseline/Screening Version Phase 1 Study - Wish to be Dead (Lifetime)","C105210","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study (C-SSRS Baseline/Screening Version Phase 1) Have you wished you were dead or wished you could go to sleep and not wake up? (Lifetime).","C-SSRS Baseline/Screening Version Phase 1 Study - Wish to be Dead (Lifetime) | CSS03-Wish to be Dead-Life | CSS0301A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641990","C-SSRS Baseline/Screening Version Phase 1 Study - Wish to be Dead (Past 6 Months)","C105211","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study (C-SSRS Baseline/Screening Version Phase 1) Have you wished you were dead or wished you could go to sleep and not wake up? (Past 6 Months).","C-SSRS Baseline/Screening Version Phase 1 Study - Wish to be Dead (Past 6 Months) | CSS03-Wish to be Dead-P6M | CSS0301B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641991","C-SSRS Baseline/Screening Version Phase 1 Study - Description of Wish to be Dead (Lifetime)","C105212","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study (C-SSRS Baseline/Screening Version Phase 1) Description of wishing to be dead.","C-SSRS Baseline/Screening Version Phase 1 Study - Description of Wish to be Dead (Lifetime) | CSS03-Wish to be Dead, Describe | CSS0301C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641992","C-SSRS Baseline/Screening Version Phase 1 Study - Non-Specific Active Suicidal Thoughts (Lifetime)","C105213","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Have you actually had any thoughts of killing yourself? (Lifetime).","C-SSRS Baseline/Screening Version Phase 1 Study - Non-Specific Active Suicidal Thoughts (Lifetime) | CSS03-Non-Spec Suicid Thought-Life | CSS0302A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641993","C-SSRS Baseline/Screening Version Phase 1 Study - Non-Specific Active Suicidal Thoughts (Past 6 Months)","C105214","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Have you actually had any thoughts of killing yourself? (Past 6 Months).","C-SSRS Baseline/Screening Version Phase 1 Study - Non-Specific Active Suicidal Thoughts (Past 6 Months) | CSS03-Non-Spec Suicid Thought-P6M | CSS0302B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641994","C-SSRS Baseline/Screening Version Phase 1 Study - Description of Non-Specific Active Suicidal Thoughts (Lifetime)","C105215","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Description of non-specific active suicidal thoughts.","C-SSRS Baseline/Screening Version Phase 1 Study - Description of Non-Specific Active Suicidal Thoughts (Lifetime) | CSS03-Non-Spec Suicid Thought, Describe | CSS0302C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641995","C-SSRS Baseline/Screening Version Phase 1 Study - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act (Lifetime)","C105216","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Have you been thinking about how you might do this? (Lifetime).","C-SSRS Baseline/Screening Version Phase 1 Study - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act (Lifetime) | CSS03-Idea, No Intent, No Plan-Life | CSS0303A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640893","Presumptive","C102697","Supplying or being a probable or reasonable settlement or result.","Presumptive | PRESUMPTIVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0053879","Batanopride","C1021","A serotonin antagonist having antiemetic properties.","Batanopride | BATANOPRIDE | BMY-25801",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640599","SF-36 v2.0 Standard - Limit Moderate Activities","C102200","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) How much does your health now limit you in - moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or playing golf.","SF-36 v2.0 Standard - Limit Moderate Activities | SF363-Limit Moderate Activities | SF36303B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640600","SF-36 v2.0 Standard - Limit Lifting or Carrying","C102201","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) How much does your health now limit you in - lifting or carrying groceries.","SF-36 v2.0 Standard - Limit Lifting or Carrying | SF363-Limit Lifting or Carrying | SF36303C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640601","SF-36 v2.0 Standard - Limit Climbing Several Flights","C102202","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) How much does your health now limit you in - climbing several flights of stairs.","SF-36 v2.0 Standard - Limit Climbing Several Flights | SF363-Limit Climbing Several Flights | SF36303D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640602","SF-36 v2.0 Standard - Limit Climbing One Flight Stairs","C102203","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) How much does your health now limit you in - climbing one flight of stairs.","SF-36 v2.0 Standard - Limit Climbing One Flight Stairs | SF363-Limit Climbing One Flight Stairs | SF36303E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640603","SF36303F","C102204","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) How much does your health now limit you in - bending, kneeling, or stooping.","SF-36 v2.0 Standard - Limit Bending/Kneeling/Stooping | SF363-Limit Bending/Kneeling/Stooping | SF36303F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640604","SF-36 v2.0 Standard - Limit Walking More Than a Mile","C102205","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) How much does your health now limit you in - walking more than a mile.","SF-36 v2.0 Standard - Limit Walking More Than a Mile | SF363-Limit Walking More Than a Mile | SF36303G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640605","SF-36 v2.0 Standard - Limit Walking Several Hundred Yds","C102206","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) How much does your health now limit you in - walking several hundred yards.","SF-36 v2.0 Standard - Limit Walking Several Hundred Yds | SF363-Limit Walking Several Hundred Yds | SF36303H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640606","SF-36 v2.0 Standard - Limit Walking One Hundred Yards","C102207","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) How much does your health now limit you in - walking one hundred yards.","SF-36 v2.0 Standard - Limit Walking One Hundred Yards | SF363-Limit Walking One Hundred Yards | SF36303I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640607","SF-36 v2.0 Standard - Limit Bathing or Dressing Yourself","C102208","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) How much does your health now limit you in - bathing or dressing yourself.","SF-36 v2.0 Standard - Limit Bathing or Dressing Yourself | SF363-Limit Bathing or Dressing Yourself | SF36303J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640608","SF-36 v2.0 Standard - Physical: Cut Down Time on Work","C102209","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) During the past 4 weeks, how much of the time have you had any problems with your work or other regular daily activities as a result of your physical health - cut down on the amount of time you spent on work or other activities.","SF-36 v2.0 Standard - Physical: Cut Down Time on Work | SF363-Physical: Cut Down Time on Work | SF36304A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280444","bleomycin/vinblastine","C10220","A regimen consisting of bleomycin and vinblastine that can be used for the treatment of testicular cancer.","Bleomycin/Vinblastine Regimen | BLEO/VBL | Bleomycin and Vinblastine | Bleomycin-Vinblastine | Bleomycin/Vinblastine | VB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642035","C-SSRS Baseline/Screening Version Phase 1 Study - Most Lethal Suicide Attempt Actual Lethality/Medical Damage","C105256","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Most lethal attempt actual lethality/medical damage.","C-SSRS Baseline/Screening Version Phase 1 Study - Most Lethal Suicide Attempt Actual Lethality/Medical Damage | CSS03-Most Lethal Attempt Damage | CSS0322B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642036","C-SSRS Baseline/Screening Version Phase 1 Study - Most Lethal Suicide Attempt Potential Lethality","C105257","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Most lethal attempt potential lethality.","C-SSRS Baseline/Screening Version Phase 1 Study - Most Lethal Suicide Attempt Potential Lethality | CSS03-Most Lethal Attempt Potential | CSS0322C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642038","C-SSRS Baseline/Screening Version Phase 1 Study - First Suicide Attempt Actual Lethality/Medical Damage","C105259","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Initial/first attempt actual lethality/medical damage.","C-SSRS Baseline/Screening Version Phase 1 Study - First Suicide Attempt Actual Lethality/Medical Damage | CSS03-First Attempt Damage | CSS0323B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642039","C-SSRS Baseline/Screening Version Phase 1 Study - First Suicide Attempt Potential Lethality","C105260","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Initial/first attempt potential lethality.","C-SSRS Baseline/Screening Version Phase 1 Study - First Suicide Attempt Potential Lethality | CSS03-First Attempt Potential | CSS0323C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642040","PI - Pain Intensity For Various Time Periods of Evaluation","C105261","Pain Intensity (PI v1) Pain intensity for various time periods of evaluation.","PI - Pain Intensity For Various Time Periods of Evaluation | PI01-Pain Intensity | PI0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642041","PI - Average Pain Intensity For Various Time Periods of Evaluation","C105262","Pain Intensity (PI v1) Average pain intensity for various time periods of evaluation.","PI - Average Pain Intensity For Various Time Periods of Evaluation | PI01-Average Pain Intensity | PI0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642043","PI - Maximum Pain Intensity For Various Time Periods of Evaluation","C105264","Pain Intensity (PI v1) Maximum pain intensity for various time periods of evaluation.","PI - Maximum Pain Intensity For Various Time Periods of Evaluation | PI01-Maximum Pain Intensity | PI0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642044","PI - Least Pain Intensity For Various Time Periods of Evaluation","C105265","Pain Intensity (PI v1) Least pain intensity for various time periods of evaluation.","PI - Least Pain Intensity For Various Time Periods of Evaluation | PI01-Least Pain Intensity | PI0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540816","MAP1LC3A wt Allele","C104612","Human MAP1LC3A wild-type allele is located in the vicinity of 20q11.22 and is approximately 13 kb in length. This allele, which encodes microtubule-associated proteins 1A/1B light chain 3A protein, is involved in microtubule function and autophagocytosis.","MAP1LC3A wt Allele | ATG8 | LC3 | LC3A | MAP1ALC3 | MAP1BLC3 | Microtubule-Associated Protein 1 Light Chain 3 Alpha wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL436829","Glutaminyl-Peptide Cyclotransferase, Human","C102506","Glutaminyl-peptide cyclotransferase (361 aa, ~41 kDa) is encoded by the human QPCT gene. This protein is involved in the synthesis of cyclic glutamyl peptides.","Glutaminyl-Peptide Cyclotransferase | EC 2.3.2.5 | Glutaminyl Cyclase | Glutaminyl-tRNA Cyclotransferase | Glutamyl Cyclase | QC | sQC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415628","FOXA3 Gene","C102507","This gene plays a role in the activation of transcription.","FOXA3 Gene | FOXA3 | Forkhead Box A3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538719","FOXA3 wt Allele","C102508","Human FOXA3 wild-type allele is located within 19q13.2-q13.4 and is approximately 10 kb in length. This allele, which encodes hepatocyte nuclear factor 3-gamma protein, is involved in transcriptional activation.","FOXA3 wt Allele | FKHH3 | Forkhead Box A3 wt Allele | HNF3G | Hepatocyte Nuclear Factor 3, Gamma Gene | MGC10179 | TCF3G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1565825","FOXA3 protein, human","C102509","Hepatocyte nuclear factor 3-gamma (350 aa, ~37 kDa) is encoded by the human FOXA3 gene. This protein plays a role in the positive regulation of transcription.","Hepatocyte Nuclear Factor 3-Gamma | Fork head-Related Protein FKH H3 | Forkhead Box Protein A3 | HNF-3-Gamma | HNF-3G | TCF-3G | Transcription Factor 3G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413784","NKX2-5 Gene","C102510","This gene plays a role in both transcriptional regulation and heart development.","NKX2-5 Gene | NK2 Homeobox 5 Gene | NKX2-5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538707","NKX2-5 wt Allele","C102511","Human NKX2-5 wild-type allele is located in the vicinity of 5q34 and is approximately 3 kb in length. This allele, which encodes homeobox protein Nkx-2.5, is involved in both heart development and the modulation of transcription. Mutation of the gene is associated with atrial septal defect type 7, tetralogy of Fallot, and congenital hypothyroidism non-goitrous type 5.","NKX2-5 wt Allele | CHNG5 | CSX | CSX1 | FLJ52202 | FLJ97166 | FLJ97195 | FLJ97197 | FLJ99536 | HLHS2 | NK2 Homeobox 5 wt Allele | NKX2.5 | NKX2E | NKX4-1 | Tinman Paralog (Drosophila) Gene | VSD3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640795","Homeobox Protein Nkx-2.5, human","C102512","Homeobox protein Nkx-2.5 (324 aa, ~35 kDa) is encoded by the human NKX2-5 gene. This protein plays a role in myocardial differentiation.","Homeobox Protein Nkx-2.5 | Cardiac-Specific Homeobox | Homeobox Protein CSX | Homeobox Protein NK-2 Homolog E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537460","SLC12A2 wt Allele","C102514","Human SLC12A2 wild-type allele is located in the vicinity of 5q23.3 and is approximately 106 kb in length. This allele, which encodes solute carrier family 12 member 2 protein, plays a role in cellular homeostasis.","SLC12A2 wt Allele | BSC | BSC2 | MGC104233 | NKCC1 | Solute Carrier Family 12 (Sodium/Potassium/Chloride Transporters), Member 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3711655","SLC12A2 protein, human","C102515","Solute carrier family 12 member 2 (1212 aa, ~131 kDa) is encoded by the human SLC12A2 gene. This protein is involved in ion reabsorption.","Solute Carrier Family 12 Member 2 | Basolateral Na-K-Cl Symporter | Bumetanide-Sensitive Sodium-(Potassium)-Chloride Cotransporter 1 | SLC12A2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640430","ADNI AVLT - List A 30 Min Delay Recall Word 11","C102025","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, 30 Minute Delay Recall, Word 11.","ADNI AVLT - List A 30 Min Delay Recall Word 11 | AVL01-List A 30 Min Delay Recall Word 11 | AVL01130",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640431","ADNI AVLT - List A 30 Min Delay Recall Word 12","C102026","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, 30 Minute Delay Recall, Word 12.","ADNI AVLT - List A 30 Min Delay Recall Word 12 | AVL01-List A 30 Min Delay Recall Word 12 | AVL01131",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640432","ADNI AVLT - List A 30 Min Delay Recall Word 13","C102027","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, 30 Minute Delay Recall, Word 13.","ADNI AVLT - List A 30 Min Delay Recall Word 13 | AVL01-List A 30 Min Delay Recall Word 13 | AVL01132",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641996","C-SSRS Baseline/Screening Version Phase 1 Study - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act (Past 6 Months)","C105217","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Have you been thinking about how you might do this? (Past 6 Months).","C-SSRS Baseline/Screening Version Phase 1 Study - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act (Past 6 Months) | CSS03-Idea, No Intent, No Plan-P6M | CSS0303B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2350724","Natural Cytotoxicity Triggering Receptor 2, Human","C104546","Natural cytotoxicity triggering receptor 2 (276 aa, ~30 kDa) is encoded by the human NCR2 gene. This protein is involved in natural killer cell function.","Natural Cytotoxicity Triggering Receptor 2 | Activating NK Receptor NKp44 | CD336 Antigen | Lymphocyte Antigen 95 Homolog | NK Cell-Activating Receptor | NK-p44 | NKp44 | Natural Killer Cell p44-Related Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0669846","Equilibrative-Nucleoside Transporter 2","C104547","Equilibrative nucleoside transporter 2 (456 aa, ~50 kDa) is encoded by the human SLC29A2 gene. This protein plays a role in nucleoside transport for nucleotide salvage.","Equilibrative Nucleoside Transporter 2 | 36 kDa Nucleolar Protein HNP36 | Delayed-Early Response Protein 12 | Equilibrative NBMPR-Insensitive Nucleoside Transporter | Equilibrative Nitrobenzylmercaptopurine Riboside-Insensitive Nucleoside Transporter | Hydrophobic Nucleolar Protein, 36 kDa | Nucleoside Transporter, Ei-Type | SLC29A2 | Solute Carrier Family 29 Member 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538764","NCR3 wt Allele","C104549","Human NCR3 wild-type allele is located in the vicinity of 6p21.3 and is approximately 4 kb in length. This allele, which encodes natural cytotoxicity triggering receptor 3 protein, is involved in natural killer cell function.","NCR3 wt Allele | 1C7 | CD337 | LY117 | MALS | NK-p30 | NKp30 | Natural Cytotoxicity Triggering Receptor 3 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1432202","NCR3 protein, human","C104550","Natural cytotoxicity triggering receptor 3 (201 aa, ~22 kDa) is encoded by the human NCR3 gene. This protein plays a role in natural killer cell function.","Natural Cytotoxicity Triggering Receptor 3 | Activating NK-A1 Receptor | Activating Natural Killer Receptor p30 | CD337 Antigen | Lymphocyte Antigen 117 | NCR3 | Natural Killer Cell p30-Related Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538901","TBL2 wt Allele","C104552","Human TBL2 wild-type allele is located in the vicinity of 7q11.23 and is approximately 10 kb in length. This allele, which encodes transducin beta-like protein 2, may play a role in signal transduction. In Williams-Beuren syndrome, the chromosomal region this gene is located in is deleted.","TBL2 wt Allele | Transducin (Beta)-Like 2 wt Allele | UNQ563/PRO1125 | WBSCR13 | WS-betaTRP | Williams-Beuren Syndrome Chromosome Region 13 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539820","Transducin Beta-Like Protein 2","C104553","Transducin beta-like protein 2 (447 aa, ~50 kDa) is encoded by the human TBL2 gene. This protein may be involved in signal transduction.","Transducin Beta-Like Protein 2 | TBL2 | WS Beta-Transducin Repeats Protein | WS-betaTRP | Williams-Beuren Syndrome Chromosomal Region 13 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540521","IRF8 wt Allele","C104555","Human IRF8 wild-type allele is located in the vicinity of 16q24.1 and is approximately 24 kb in length. This allele, which encodes interferon regulatory factor 8 protein, is involved in the modulation of interferon and interferon-inducible gene expression.","IRF8 wt Allele | H-ICSBP | ICSBP | ICSBP1 | IRF-8 | Interferon Regulatory Factor 8 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0082978","IRF-8 protein, human","C104556","Interferon regulatory factor 8 (426 aa, ~48 kDa) is encoded by the human IRF8 gene. This protein plays a role in the regulation of gene transcription.","Interferon Regulatory Factor 8 | H-ICSBP | ICSBP | IRF-8 | IRF8 | Interferon Consensus Sequence-Binding Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640609","SF-36 v2.0 Standard - Physical: Accomplished Less","C102210","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) During the past 4 weeks, how much of the time have you had any problems with your work or other regular daily activities as a result of your physical health - accomplished less than you would like.","SF-36 v2.0 Standard - Physical: Accomplished Less | SF363-Physical: Accomplished Less | SF36304B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640610","SF-36 v2.0 Standard - Physical: Limited Kind of Work","C102211","The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) During the past 4 weeks, how much of the time have you had any problems with your work or other regular daily activities as a result of your physical health - were limited in the kind of work or other activities.","SF-36 v2.0 Standard - Physical: Limited Kind of Work | SF363-Physical: Limited Kind of Work | SF36304C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538769","GRIN2B wt Allele","C102459","Human GRIN2B wild-type allele is located in the vicinity of 12p12 and is approximately 419 kb in length. This allele, which encodes glutamate receptor ionotropic, NMDA 2B protein, is involved in both glutamate binding and calcium transport. Mutation of the gene and chromosomal translocations involving the gene, t(9;12)(p23;p13.1) and t(10;12)(q21.1;p13.1), are associated with mental retardation.","GRIN2B wt Allele | EIEE27 | GluN2B | Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 2B wt Allele | Glutamate Receptor, Ionotropic, N-Methyl-D-Aspartate 2B Gene | MGC142178 | MGC142180 | MRD6 | NMDAR2B | NR2B | hNR3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1738978","Glutamate Receptor Ionotropic, NMDA 2B, Human","C102460","Glutamate receptor ionotropic, NMDA 2B (1484 aa, ~166 kDa) is encoded by the human GRIN2B gene. This protein plays a role in both calcium transport and glutamate binding.","Glutamate Receptor Ionotropic, NMDA 2B | GRIN2B | GluN2B | Glutamate Receptor Subunit Epsilon-2 | Glutamate [NMDA] Receptor Subunit Epsilon-2 | N-Methyl D-Aspartate Receptor Subtype 2B | N-Methyl-D-Aspartate Receptor Channel, Subunit Epsilon-2 | N-Methyl-D-Aspartate Receptor Subunit 2B | N-Methyl-D-Aspartate Receptor Subunit 3 | NMDAR2B | NR2B | NR3 | hNR3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540050","SCARB1 wt Allele","C102462","Human SCARB1 wild-type allele is located in the vicinity of 12q24.31 and is approximately 106 kb in length. This allele, which encodes scavenger receptor class B member 1 protein, plays a role in both binding and import of lipids and lipoproteins.","SCARB1 wt Allele | CD36 Antigen (Collagen Type I Receptor, Thrombospondin Receptor)-Like 1 Gene | CD36 Antigen-Like 1 Gene | CD36L1 | CLA-1 | CLA1 | HDLQTL6 | MGC138242 | SR-B1 | SR-BI | SRB1 | Scavenger Receptor Class B, Member 1 wt Allele | Scavenger Receptor, Class B, Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537338","Scavenger Receptor Class B Member 1, Human","C102463","Scavenger receptor class B member 1 (552 aa, ~61 kDa) is encoded by the human SCARB1 gene. This protein is involved in the import of lipoproteins.","Scavenger Receptor Class B Member 1 | CD36 Antigen-Like 1 | CD36 and LIMPII Analogous 1 | CD36L1 | CLA-1 | Collagen Type I Receptor, Thrombospondin Receptor-Like 1 | SCARB1 | SR-BI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413203","CD151 Gene","C102464","This gene plays a role in cell-matrix adhesion.","CD151 Gene | CD151 | CD151 Molecule (Raph Blood Group) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538819","CD151 wt Allele","C102465","Human CD151 wild-type allele is located in the vicinity of 11p15.5 and is approximately 7 kb in length. This allele, which encodes CD151 antigen protein, is involved in both signaling and epithelial cell adhesion to the basal lamina. Mutation of the gene is associated with nephropathy with pretibial epidermolysis bullosa and deafness.","CD151 wt Allele | CD151 Antigen Gene | CD151 Molecule (Raph Blood Group) wt Allele | GP27 | MER2 | PETA-3 | PETA3 | RAPH | SFA-1 | SFA1 | TSPAN24",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1621248","Antigens, CD151","C102466","CD151 antigen (253 aa, ~28 kDa) is encoded by the human CD151 gene. This protein plays a role in both cell adhesion and signal transduction.","CD151 Antigen | Antigen CD151 | CD151 | GP27 | Membrane Glycoprotein SFA-1 | PETA-3 | Platelet-Endothelial Tetraspan Antigen 3 | Tetraspanin-24 | Tspan-24",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640793","Other Vaccinations Given within Four Weeks","C102467","Vaccines that the patient received within four weeks prior to the current vaccine administration date being reported.","Other Vaccinations Given within Four Weeks | Other Vaccinations Given within 4 Weeks | Other vaccinations given within 4 weeks",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540599","Microtubule-Associated Proteins 1A/1B Light Chain 3A, Human","C104613","Microtubule-associated proteins 1A/1B light chain 3A (121 aa, ~14 kDa) is encoded by the human MAP1LC3A gene. This protein plays a role in autophagocytosis and microtubule function.","Microtubule-Associated Proteins 1A/1B Light Chain 3A | Autophagy-Related Protein LC3 A | Autophagy-Related Ubiquitin-Like Modifier LC3 A | MAP1 Light Chain 3-Like Protein 1 | MAP1A/1B Light Chain 3 A | MAP1A/MAP1B LC3 A | MAP1A/MAP1B Light Chain 3 A | Microtubule-Associated Protein 1 Light Chain 3 Alpha | Microtubule-Associated Proteins 1A/1B Light Chain 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540529","LPL wt Allele","C104615","Human LPL wild-type allele is located in the vicinity of 8p21.3 and is approximately 66 kb in length. This allele, which encodes lipoprotein lipase, plays a role in both triglyceride metabolism and lipoprotein uptake. Mutations in this gene are associated with several disorders of lipoprotein metabolism.","LPL wt Allele | HDLCQ11 | LIPD | Lipoprotein Lipase wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2932881","LPL protein, human","C104616","Lipoprotein lipase (475 aa, ~53 kDa) is encoded by the human LPL gene. This protein is involved in the metabolism of triglycerides.","Lipoprotein Lipase | 3.1.1.34 | LPL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540817","LRRC19 wt Allele","C104618","Human LRRC19 wild-type allele is located in the vicinity of 9p21.2 and is approximately 13 kb in length. This allele, which encodes leucine-rich repeat-containing protein 19, may be involved in inducing innate immune responses in kidney and other tissues.","LRRC19 wt Allele | FLJ21302 | Leucine Rich Repeat Containing 19 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539850","Leucine-Rich Repeat-Containing Protein 19","C104619","Leucine-rich repeat-containing protein 19 (370 aa, ~42 kDa) is encoded by the human LRRC19 gene. This protein may play a role in inducing innate immune responses in kidney and other tissues.","Leucine-Rich Repeat-Containing Protein 19 | LRRC19 | Leucine Rich Repeat Containing 19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539652","LAG3 wt Allele","C104621","Human LAG3 wild-type allele is located in the vicinity of 12p13.32 and is approximately 6 kb in length. This allele, which encodes lymphocyte activation gene 3 protein, plays a role in the activation of natural killer cells and T-cells.","LAG3 wt Allele | CD223 | FDC | LAG-3 | Lymphocyte Activating 3 wt Allele | Lymphocyte-Activation Gene 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1456336","Lymphocyte Activation Gene 3 Protein","C104623","Lymphocyte activation gene 3 protein (525 aa, ~57 kDa) is encoded by the human LAG3 gene. This protein is involved in the activation of T-cells and natural killer cells.","Lymphocyte Activation Gene 3 Protein | CD223 Antigen | LAG-3 | LAG3 | Protein FDC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539674","LYPLA1 wt Allele","C104625","Human LYPLA1 wild-type allele is located in the vicinity of 8q11.23 and is approximately 56 kb in length. This allele, which encodes acyl-protein thioesterase 1 protein, is involved in regulating the level of lysophospholipids in membranes.","LYPLA1 wt Allele | APT-1 | APT1 | LPL-I | LPL1 | Lysophospholipase I wt Allele | hAPT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538726","APBA1 wt Allele","C104828","Human APBA1 wild-type allele is located within 9q13-q21.1 and is approximately 245 kb in length. This allele, which encodes amyloid beta A4 precursor protein-binding family A member 1 protein, plays a role in both the exocytosis of synaptic vesicles and amyloid beta A4 precursor protein proteolysis.","APBA1 wt Allele | Amyloid Beta (A4) Precursor Protein-Binding, Family A, Member 1 wt Allele | D9S411E | LIN10 | MINT1 | X11 | X11A | X11ALPHA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640433","ADNI AVLT - List A 30 Min Delay Recall Word 14","C102028","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, 30 Minute Delay Recall, Word 14.","ADNI AVLT - List A 30 Min Delay Recall Word 14 | AVL01-List A 30 Min Delay Recall Word 14 | AVL01133",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640434","ADNI AVLT - List A 30 Min Delay Recall Word 15","C102029","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, 30 Minute Delay Recall, Word 15.","ADNI AVLT - List A 30 Min Delay Recall Word 15 | AVL01-List A 30 Min Delay Recall Word 15 | AVL01134",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640435","ADNI AVLT - List A 30 Min Delay Recall Total","C102030","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of words recalled from List A, 30 Minute Delay recall.","ADNI AVLT - List A 30 Min Delay Recall Total | AVL01-List A 30 Min Delay Recall Total | AVL01135",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640437","ADNI AVLT - List A Recognition Total","C102032","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of words correct on recognition test.","ADNI AVLT - List A Recognition Total | AVL01-List A Recognition Total | AVL01137",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640439","AIMS - Muscles of Facial Expression","C102034","Abnormal Involuntary Movement Scale (AIMS) Facial and Oral Movements, Muscles of facial expression, e.g., movements of forehead, eyebrows, periorbital area, cheeks. Include frowning, blinking, grimacing of upper face.","AIMS - Muscles of Facial Expression | AIMS01-Muscles of Facial Expression | AIMS0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640440","AIMS - Lips and Perioral Area","C102035","Abnormal Involuntary Movement Scale (AIMS) Facial and Oral Movements, Lips and perioral area, e.g., puckering, pouting, smacking.","AIMS - Lips and Perioral Area | AIMS01-Lips and Perioral Area | AIMS0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640441","AIMS - Jaw","C102036","Abnormal Involuntary Movement Scale (AIMS) Facial and Oral Movements, Jaw, e.g., biting, clenching, chewing, mouth opening, lateral movement.","AIMS - Jaw | AIMS01-Jaw | AIMS0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640442","AIMS - Tongue","C102037","Abnormal Involuntary Movement Scale (AIMS) Facial and Oral Movements, Tongue. Rate only increase in movement both in and out of mouth, not inability to sustain movement.","AIMS - Tongue | AIMS01-Tongue | AIMS0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640443","AIMS - Upper Extremities","C102038","Abnormal Involuntary Movement Scale (AIMS) Extremity Movements, Upper (arms, wrists, hands, fingers). Include movements that are choreic (rapid, objectively purposeless, irregular, spontaneous) or athetoid (slow, irregular, complex, serpentine). Do not include tremor (repetitive, regular, rhythmic movements).","AIMS - Upper Extremities | AIMS01-Upper Extremities | AIMS0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640444","AIMS - Lower Extremities","C102039","Abnormal Involuntary Movement Scale (AIMS) Extremity Movements, Lower (legs, knees, ankles, toes), e.g., lateral knee movement, foot tapping, heel dropping, foot squirming, inversion and eversion of foot.","AIMS - Lower Extremities | AIMS01-Lower Extremities | AIMS0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538878","3-Oxo-5-Alpha-Steroid 4-Dehydrogenase 1","C105160","3-oxo-5-alpha-steroid 4-dehydrogenase 1 (259 aa, ~29 kDa) is encoded by the human SRD5A1 gene. This protein is involved in sexual differentiation and androgen physiology.","3-Oxo-5-Alpha-Steroid 4-Dehydrogenase 1 | 3-Oxo-5 Alpha-Steroid Delta 4-Dehydrogenase Alpha 1 | 5-Alpha Reductase | EC 1.3.1.30 | EC 1.3.99.5 | SR Type 1 | SRD5A1 | Steroid 5-Alpha-Reductase 1 | Steroid 5-Alpha-Reductase Type I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280876","bleomycin/cisplatin/etoposide/ifosfamide","C10455","A regimen consisting of etoposide, ifosfamide, cisplatin, and bleomycin that may be used in the treatment of certain germ cell tumors.","VIP-B Regimen | BLEO/CDDP/IFF/VP-16 | Bleomycin/Cisplatin/Etoposide/Ifosfamide | Etoposide-Ifosfamide-Cisplatin-Bleomycin | Etoposide-Ifosfamide-Cisplatin-Bleomycin Regimen | Etoposide/Ifosfamide/Cisplatin/Bleomycin | VIP-B | VePesid/Ifosfamide/Platinol/Bleomycin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540572","RRM2B wt Allele","C104771","Human RRM2B wild-type allele is located in the vicinity of 8q23.1 and is approximately 35 kb in length. This allele, which encodes ribonucleoside-diphosphate reductase subunit M2 B protein, is involved in generation of deoxyribonucleoside diphosphates. Mutations in this gene have been associated with autosomal recessive mitochondrial DNA depletion syndrome, autosomal dominant progressive external ophthalmoplegia-5, and mitochondrial neurogastrointestinal encephalopathy.","RRM2B wt Allele | MTDPS8A | MTDPS8B | P53R2 | PEOA5 | Ribonucleotide Reductase M2 B (TP53 Inducible) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539802","Ribonucleoside-Diphosphate Reductase Subunit M2 B","C104772","Ribonucleoside-diphosphate reductase subunit M2 B (351 aa, ~41 kDa) is encoded by the human RRM2B gene. This protein plays a role in the metabolism of deoxyribonucleoside diphosphates.","Ribonucleoside-Diphosphate Reductase Subunit M2 B | EC 1.17.4.1 | RRM2B | Ribonucleotide Reductase M2 B (TP53 Inducible) | TP53-Inducible Ribonucleotide Reductase M2 B | p53-Inducible Ribonucleotide Reductase Short Form Beta | p53-Inducible Ribonucleotide Reductase Small Subunit 2 Homolog | p53-Inducible Ribonucleotide Reductase Small Subunit 2-Like Protein | p53R2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540467","S1PR2 wt Allele","C104774","Human S1PR2 wild-type allele is located in the vicinity of 19p13.2 and is approximately 10 kb in length. This allele, which encodes sphingosine 1-phosphate receptor 2 protein, plays a role in cell proliferation, cell survival, and transcriptional activation.","S1PR2 wt Allele | AGR16 | EDG-5 | EDG5 | Gpcr13 | H218 | LPB2 | S1P2 | Sphingosine-1-Phosphate Receptor 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538962","Sphingosine 1-Phosphate Receptor 2, Human","C104775","Sphingosine 1-phosphate receptor 2 (353 aa, ~39 kDa) is encoded by the human S1PR2 gene. This protein is involved in transcriptional activation, cell proliferation and cell survival.","Sphingosine 1-Phosphate Receptor 2 | Endothelial Differentiation G-Protein Coupled Receptor 5 | Endothelial Differentiation, Sphingolipid G-Protein-Coupled Receptor, 5 | S1P Receptor 2 | S1P Receptor EDG-5 | S1P Receptor EDG5 | Sphingosine 1-Phosphate Receptor EDG-5 | Sphingosine-1-Phosphate Receptor 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541270","S1PR3 wt Allele","C104777","Human S1PR3 wild-type allele is located within 9q22.1-q22.2 and is approximately 14 kb in length. This allele, which encodes sphingosine 1-phosphate receptor 3 protein, may be involved in regulating angiogenesis and vascular endothelial cell function.","S1PR3 wt Allele | EDG-3 | EDG3 | LPB3 | S1P3 | Sphingosine-1-Phosphate Receptor 3 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541910","sphingosine-1-phosphate receptor-3, human","C104778","Sphingosine 1-phosphate receptor 3 (378 aa, ~42 kDa) is encoded by the human S1PR3 gene. This G protein-coupled receptor may play a role in vascular endothelial cell function and regulation of angiogenesis.","Sphingosine 1-Phosphate Receptor 3 | Endothelial Differentiation G-Protein Coupled Receptor 3 | Endothelial Differentiation, Sphingolipid G-Protein-Coupled Receptor, 3 | G Protein-Coupled Receptor, Endothelial Differentiation Gene-3 | S1P Receptor 3 | S1P Receptor EDG-3 | S1P Receptor EDG3 | Sphingosine 1-Phosphate Receptor EDG-3 | Sphingosine-1-Phosphate Receptor 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1115580","Illness at Time of Vaccination","C102468","Illnesses that exist and/or were observed in a patient at the time the patient received vaccination.","Illness at Time of Vaccination | Illness at time of vaccination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0557094","Number of Siblings","C102469","An individual's total number of brothers and sisters.","Number of Siblings | ",,,,,,,,,,,,,,,"4072485","Number of siblings",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2721654","Adverse Event Following Immunization","C102470","Any unfavorable or unintended symptom, sign, or disease including an abnormal laboratory finding) temporally associated with the previous administration of vaccine(s) that may or may not be considered related to the vaccine administration. Such events can be intervention related, dose related, route related, patient related, or caused by an interaction with other product(s) or procedure(s).","Adverse Event Following Immunization | AEFI | Adverse event following prior vaccination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540585","YY1 wt Allele","C102472","Human YY1 wild-type allele is located within 14q and is approximately 44 kb in length. This allele, which encodes transcriptional repressor protein YY1, plays a role in both transcriptional repression and DNA repair.","YY1 wt Allele | DELTA | INO80S | NF-E1 | UCRBP | YIN-YANG-1 | YY1 Transcription Factor wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640385","ADNI AVLT - List A Intrusions 5","C101980","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of intrusions while recalling List A, fifth attempt.","ADNI AVLT - List A Intrusions 5 | AVL01-List A Intrusions 5 | AVL01085",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640386","ADNI AVLT - List A Recall 6 (After B) Word 1","C101981","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 6 (after B Recall), Word 1.","ADNI AVLT - List A Recall 6 (After B) Word 1 | AVL01-List A Recall 6 (After B) Word 1 | AVL01086",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640387","ADNI AVLT - List A Recall 6 (After B) Word 2","C101982","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 6 (after B Recall), Word 2.","ADNI AVLT - List A Recall 6 (After B) Word 2 | AVL01-List A Recall 6 (After B) Word 2 | AVL01087",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640389","ADNI AVLT - List A Recall 6 (After B) Word 4","C101984","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 6 (after B Recall), Word 4.","ADNI AVLT - List A Recall 6 (After B) Word 4 | AVL01-List A Recall 6 (After B) Word 4 | AVL01089",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640390","ADNI AVLT - List A Recall 6 (After B) Word 5","C101985","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 6 (after B Recall), Word 5.","ADNI AVLT - List A Recall 6 (After B) Word 5 | AVL01-List A Recall 6 (After B) Word 5 | AVL01090",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640391","ADNI AVLT - List A Recall 6 (After B) Word 6","C101986","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 6 (after B Recall), Word 6.","ADNI AVLT - List A Recall 6 (After B) Word 6 | AVL01-List A Recall 6 (After B) Word 6 | AVL01091",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640392","ADNI AVLT - List A Recall 6 (After B) Word 7","C101987","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 6 (after B Recall), Word 7.","ADNI AVLT - List A Recall 6 (After B) Word 7 | AVL01-List A Recall 6 (After B) Word 7 | AVL01092",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3640393","ADNI AVLT - List A Recall 6 (After B) Word 8","C101988","Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 6 (after B Recall), Word 8.","ADNI AVLT - List A Recall 6 (After B) Word 8 | AVL01-List A Recall 6 (After B) Word 8 | AVL01093",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831616","ADCS-ADL Severe Dementia - Talk About TV Content While Watching","C106989","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) If yes, did subject usually talk about the content of a program while watching it?","ADCS-ADL Severe Dementia - Talk About TV Content While Watching | ADL02-Talk About TV Content While Watch | ADL0208B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831615","ADCS-ADL Severe Dementia - Talk About TV Content Within a Day After Watching","C106990","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) If yes, did subject talk about the content of a program within a day (24 hours) after watching it?","ADCS-ADL Severe Dementia - Talk About TV Content Within a Day After Watching | ADL02-Talk About TV Content Within a Day | ADL0208C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831625","ADCS-ADL Severe Dementia - Pay Attention to Conversation","C106991","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) In the past 4 weeks, did subject ever appear to pay attention to conversation or small talk for at least 5 minutes?","ADCS-ADL Severe Dementia - Pay Attention to Conversation | ADL02-Pay Attention to Conversation | ADL0209",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831607","ADCS-ADL Severe Dementia - Usual Conversation Participation","C106992","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) If yes, which best describes subject's usual degree of participation.","ADCS-ADL Severe Dementia - Usual Conversation Participation | ADL02-Usual Conversation Participation | ADL0209A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831641","ADCS-ADL Severe Dementia - Clear Dishes After Meal or Snack","C106993","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) Did subject clear the dishes from the table after a meal or snack?","ADCS-ADL Severe Dementia - Clear Dishes After Meal or Snack | ADL02-Clear Dishes | ADL0210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831634","ADCS-ADL Severe Dementia - Description of Usual Performance of Clearing Dishes","C106994","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) If yes, which best describes how subject usually performed.","ADCS-ADL Severe Dementia - Description of Usual Performance of Clearing Dishes | ADL02-Clear Dishes Usual Performance | ADL0210A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831628","ADCS-ADL Severe Dementia - Find Personal Belongings at Home","C106995","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) In the past 4 weeks, did subject usually manage to find his or her personal belongings at home?","ADCS-ADL Severe Dementia - Find Personal Belongings at Home | ADL02-Find Belongings | ADL0211",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831632","ADCS-ADL Severe Dementia - Description of Usual Performance of Finding Personal Belonging at Home","C106996","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) If yes, which best describes how subject usually performed.","ADCS-ADL Severe Dementia - Description of Usual Performance of Finding Personal Belonging at Home | ADL02-Find Belongings Usual Performance | ADL0211A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449448","Mucoadhesive Paclitaxel Formulation","C107188","An orally available, mucoadhesive lipid preparation consisting of paclitaxel, a compound extracted from the Pacific yew tree Taxus brevifolia, in a formulation that is comprised of a mixture of monoolein, tricarprylin, and Tween 80, with potential antineoplastic activity. Upon oral administration, DHP107 forms droplets and micelles in the intestine; these adhere to mucoepithelial cells in the gastrointestinal tract and are absorbed through lipid-based uptake mechanisms. Upon absorption, paclitaxel binds to and stabilizes tubulin molecules, which results in the inhibition of both microtubule depolymerization and cell division. This agent also induces apoptosis by both binding to and blocking the function of the apoptosis inhibitor protein B-cell Leukemia 2 (Bcl-2).The mucoadhesive paclitaxel formulation does not contain P-glycoprotein inhibitors, the solvent cremophor or any other toxic solvent.","Mucoadhesive Paclitaxel Formulation | DHP107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541284","HOXA7 wt Allele","C105433","Human HOXA7 wild-type allele is located in the vicinity of 7p15.2 and is approximately 4 kb in length. This allele, which encodes homeobox protein Hox-A7, plays a role in anterior-posterior regulation of gene expression during embryonic development.","HOXA7 wt Allele | ANTP | HOX1 | HOX1.1 | HOX1A | Homeobox A7 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642157","Homeobox Protein Hox-A7","C105434","Homeobox protein Hox-A7 (230 aa, ~25 kDa) is encoded by the human HOXA7 gene. This protein is involved in anterior-posterior patterning during embryonic development.","Homeobox Protein Hox-A7 | Homeo Box A7 | Homeobox Protein Hox 1.1 | Homeobox Protein Hox-1A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541285","HOXB4 wt Allele","C105436","Human HOXB4 wild-type allele is located in the vicinity of 17q21.32 and is approximately 5 kb in length. This allele, which encodes homeobox protein Hox-B4, is involved in anterior-posterior regulation of gene expression during embryonic development.","HOXB4 wt Allele | HOX-2.6 | HOX2 | HOX2F | Homeobox B4 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642158","Homeobox Protein Hox-B4","C105437","Homeobox protein Hox-B4 (251 aa, ~28 kDa) is encoded by the human HOXB4 gene. This protein plays a role in anterior-posterior patterning during embryonic development.","Homeobox Protein Hox-B4 | Homeo Box 2F | Homeo Box B4 | Homeobox Protein Hox-2.6 | Homeobox Protein Hox-2F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042479","Venom","C106130","A concentrated fluid of poisonous and biologically active substances secreted by a variety of animals that can be injected or in some other way introduced into another animal or human, usually by a bite or a sting.","Venom | ",,,,,,,,,,,,,,,"4291945","Venom",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3830064","Fungus-based Natural Product","C106131","Any mixture of substances or products derived from fungi.","Fungus-based Natural Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827659","Venom Protein","C106132","Protein isolated from venom.","Venom Protein | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830171","FDA Classified Non-traditional Sterilization Method","C106133","Sterilization methods that do not have a long history of safe and effective use and for which there are no FDA-recognized standards, but for which published information on validation of these methods exists and for which FDA has previously evaluated data as part of a QS evaluation and determined the methods to be adequate.","FDA Classified Non-traditional Sterilization Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812373","CHAF1A wt Allele","C106137","Human CHAF1A wild-type allele is located in the vicinity of 19p13.3 and is approximately 42 kb in length. This allele, which encodes chromatin assembly factor 1 subunit A protein, is involved in both histone complex assembly and transcriptional regulation.","CHAF1A wt Allele | CAF | CAF-1 | CAF1 | CAF1B | CAF1P150 | Chromatin Assembly Factor 1, Subunit A (p150) wt Allele | MGC71229 | P150",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828815","NID2 wt Allele","C107105","Human NID2 wild-type allele is located in the vicinity of 14q22.1 and is approximately 64 kb in length. This allele, which encodes nidogen-2 protein, is involved inmaintaining the structure of the basement membrane.","NID2 wt Allele | NID-2 | Nidogen 2 (Osteonidogen) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0758040","Nidogen-2, Human","C107106","Nidogen-2 (1375 aa, ~151 kDa) is encoded by the human NID2 gene. This protein plays a role in both basement membrane structure and cell adhesion.","Nidogen-2 | NID2 | Nidogen 2 | Osteonidogen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811061","ACLY wt Allele","C107108","Human ACLY wild-type allele is located in the vicinity of 17q21.2 and is approximately 63 kb in length. This allele, which encodes ATP-citrate synthase protein, plays a role in both acetyl-CoA metabolism and de novo lipid synthesis.","ACLY wt Allele | ACL | ATP Citrate Lyase wt Allele | ATPCL | CLATP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004199","ATP-Citrate Synthase","C107109","ATP-citrate synthase (1101 aa, ~121 kDa) is encoded by the human ACLY gene. This protein is involved in both the synthesis of cytosolic acetyl-CoA and the de novo lipid synthesis.","ATP-Citrate Synthase | ACLY | ATP Citrate Lyase | ATP-Citrate (Pro-S-)-Lyase | Citrate Cleavage Enzyme | EC 2.3.3.8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810679","MGST2 wt Allele","C107111","Human MGST2 wild-type allele is located in the vicinity of 4q28.3 and is approximately 75 kb in length. This allele, which encodes microsomal glutathione S-transferase 2 protein, is involved in both the metabolism of leukotriene C4 and the inflammation process.","MGST2 wt Allele | GST2 | Glutathione S-Transferase, Microsomal, 2 Gene | MGST-II | Microsomal Glutathione S-Transferase 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1701621","Microsomal Glutathione S-Transferase 2, Human","C107112","Microsomal glutathione S-transferase 2 (147 aa, ~17 kDa) is encoded by the human MGST2 gene. This protein plays a role in both the regulation of inflammation and the synthesis of leukotriene C4.","Microsomal Glutathione S-Transferase 2 | EC 2.5.1.18 | Microsomal GST-2 | Microsomal GST-II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831433","PBTL CD19CAR-28/CD137/zeta","C106429","Peripheral blood T-lymphocytes (PBTLs) transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) coupled to the costimulatory signaling domain CD28, the signaling domain of 4-1BB (CD137), and the zeta chain of the T-cell receptor (TCR), with potential immunomodulating and antineoplastic activities. Upon transfusion, PBTL CD19CAR-28/CD137zeta directs the T-lymphocytes to CD19-expressing tumor cells and induces selective toxicity in CD19-expressing tumor cells. CD28, a T-cell surface-associated co-stimulatory molecule, is required for full T-cell activation, proliferation, and survival. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19. Furthermore, inclusion of the 4-1BB signaling domain may increase the antitumor activity compared to the inclusion of the CD28 costimulatory domain and TCR zeta chain alone. CD19 antigen is a B-cell specific cell surface antigen, which is expressed in all B-cell lineage malignancies.","PBTL CD19CAR-28/CD137/zeta | CD19CAR/28137-bearing ATLs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811382","ANGPT4 wt Allele","C106489","Human ANGPT4 wild-type allele is located in the vicinity of 20p13 and is approximately 44 kb in length. This allele, which encodes angiopoietin-4 protein, is involved in both vascular development and angiogenesis.","ANGPT4 wt Allele | AGP4 | ANG-3 | ANG-4 | ANG3 | ANG4 | Angiopoietin 4 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830869","C-SSRS Baseline/Screening Version - Most Severe Ideation (Lifetime)","C106719","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Most severe ideation. (Lifetime).","C-SSRS Baseline/Screening Version - Most Severe Ideation (Lifetime) | CSS04-Most Severe Idea-Life | CSS0406A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830897","C-SSRS Baseline/Screening Version - Describe Most Severe Ideation (Lifetime)","C106720","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Description of most severe Ideation. (Lifetime).","C-SSRS Baseline/Screening Version - Describe Most Severe Ideation (Lifetime) | CSS04-Most Severe Idea, Desc-Life | CSS0406B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830868","C-SSRS Baseline/Screening Version - Most Severe Ideation (Past X Months)","C106721","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Most severe ideation. (Past X Months).","C-SSRS Baseline/Screening Version - Most Severe Ideation (Past X Months) | CSS04-Most Severe Idea-P_M | CSS0406C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830896","C-SSRS Baseline/Screening Version - Describe Most Severe Ideation (Past X Months)","C106722","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Description of most severe ideation. (Past X Months).","C-SSRS Baseline/Screening Version - Describe Most Severe Ideation (Past X Months) | CSS04-Most Severe Idea, Desc-P_M | CSS0406D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830879","C-SSRS Baseline/Screening Version - Frequency of Most Severe Ideation (Lifetime)","C106723","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) How many times have you had these thoughts? (Lifetime).","C-SSRS Baseline/Screening Version - Frequency of Most Severe Ideation (Lifetime) | CSS04-Most Severe Idea, Frequency-Life | CSS0407A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830884","C-SSRS Baseline/Screening Version - Duration of Most Severe Ideation (Lifetime)","C106725","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) When you have the thoughts, how long do they last? (Lifetime).","C-SSRS Baseline/Screening Version - Duration of Most Severe Ideation (Lifetime) | CSS04-Most Severe Idea, Duration-Life | CSS0408A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830883","C-SSRS Baseline/Screening Version - Duration of Most Severe Ideation (Past X Months)","C106726","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) When you have the thoughts, how long do they last? (Past X Months).","C-SSRS Baseline/Screening Version - Duration of Most Severe Ideation (Past X Months) | CSS04-Most Severe Idea, Duration-P_M | CSS0408B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830899","C-SSRS Baseline/Screening Version - Controllability of Most Severe Ideation (Lifetime)","C106727","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Could/can you stop thinking about killing yourself or wanting to die if you want to? (Lifetime).","C-SSRS Baseline/Screening Version - Controllability of Most Severe Ideation (Lifetime) | CSS04-Most Severe Idea, Control-Life | CSS0409A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830898","C-SSRS Baseline/Screening Version - Controllability of Most Severe Ideation (Past X Months)","C106728","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Could/can you stop thinking about killing yourself or wanting to die if you want to? (Past X Months).","C-SSRS Baseline/Screening Version - Controllability of Most Severe Ideation (Past X Months) | CSS04-Most Severe Idea, Control-P_M | CSS0409B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449450","CD33CAR-CD3zeta-4-1BB-expressing Autologous T-Lymphocytes","C107190","Autologous T-lymphocytes transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD33 scFv (single chain variable fragment) coupled to the signaling domain of 4-1BB (CD137) and the zeta chain of the T-cell receptor (TCRzeta), with potential immunomodulating and antineoplastic activities. Upon transfusion, CD33-specific CAR retroviral vector-transduced autologous T lymphocytes target CD33-expressing tumor cells and induce selective toxicity in CD33-expressing tumor cells. Following binding to CD33, the 4-1BB co-stimulatory molecule signaling domain enhances both activation and signaling. Inclusion of the 4-1BB signaling domain may also increase the antitumor activity when compared to the inclusion of the CD3-zeta chain alone. CD33 is expressed on normal non-pluripotent hematopoietic stem cells as well as on myeloid leukemia cells.","CD33CAR-CD3zeta-4-1BB-expressing Autologous T-Lymphocytes | Anti-CD33 TCR zeta:CD137 CAR T Cells | CART-33 TCR zeta:CD137 Cells | CART33 TCR zeta:CD137 Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449451","EGFR CAR-CD3zeta-4-1BB-expressing Autologous T-Lymphocytes","C107191","Autologous human T-lymphocytes transduced with a retroviral vector encoding an anti-epidermal growth factor receptor (EGFR) chimeric T cell receptor (chimeric antigen receptor or CAR) gene coupled to the signaling domains from both CD3 zeta and CD137 (4-1BB), with potential immunostimulatory and antineoplastic activities. Upon administration, the chimeric EGFR antigen receptor-modified autologous T lymphocytes bind to the EGFR antigen on tumor cell surfaces; subsequently, EGFR-expressing tumor cells may be lysed. Following binding to EGFR, the 4-1BB co-stimulatory molecule signaling domain enhances both activation and signaling. Inclusion of the 4-1BB signaling domain may also increase the antitumor activity when compared to the inclusion of the CD3-zeta chain alone. EGFR, a receptor tyrosine kinase (RTK) overexpressed by a variety of cancer cell types, plays key roles in tumor cell proliferation and tumor angiogenesis.","EGFR CAR-CD3zeta-4-1BB-expressing Autologous T-Lymphocytes | CART-EGFR TCR zeta:CD137 Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814378","Chromatin Assembly Factor 1 Subunit A, Human","C106138","Chromatin assembly factor 1 subunit A (956 aa, ~107 kDa) is encoded by the human CHAF1A gene. This protein plays a role in replication-dependent nucleosome assembly.","Chromatin Assembly Factor 1 Subunit A | CAF-1 Subunit A | CAF-I 150 kDa Subunit | CAF-I p150 | CHAF1A | Chromatin Assembly Factor I (150 kDa) | Chromatin Assembly Factor I p150 Subunit | hp150",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830974","CRY2 wt Allele","C106140","Human CRY2 wild-type allele is located in the vicinity of 11p11.2 and is approximately 36 kb in length. This allele, which encodes cryptochrome-2 protein, plays a role in the regulation of circadian rhythms.","CRY2 wt Allele | Cryptochrome 2 (Photolyase-Like) wt Allele | HCRY2 | KIAA0658 | PHLL2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813555","Cryptochrome-2","C106141","Cryptochrome-2 (593 aa, ~67 kDa) is encoded by the human CRY2 gene. This protein is involved in blue light-dependent regulation of the circadian feedback loop.","Cryptochrome-2 | CRY2 | Growth-Inhibiting Protein 37",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811214","DCLRE1A wt Allele","C106143","Human DCLRE1A wild-type allele is located in the vicinity of 10q25.1 and is approximately 20 kb in length. This allele, which encodes DNA cross-link repair 1A protein, is involved in both interstrand DNA repair and cell cycle progression.","DCLRE1A wt Allele | DNA Cross-Link Repair 1A (PSO2 Homolog, S. cerevisiae) Gene | DNA Cross-Link Repair 1A wt Allele | DNA-Crosslink Repair Gene SNM1 | KIAA0086 | PSO2 | PSO2 Homolog (S. cerevisiae) Gene | SNM1 | SNM1A | hSNM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0759317","DCLRE1A protein, human","C106144","DNA cross-link repair 1A protein (1040 aa, ~116 kDa) is encoded by the human DCLRE1A gene. This protein plays a role in both the mitotic spindle cell cycle checkpoint and DNA repair.","DNA Cross-Link Repair 1A Protein | DCLRE1A | SNM1 Homolog A | hSNM1 | hSNM1A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829109","Mexican State","C106145","Any of the 31 states that comprise the United Mexican States.","Mexican State | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828956","MOSAIQ Oncology Information Management System","C105668","A proprietary information management system designed as a vendor-neutral platform that collects radiation oncology and medical oncology patient data into a single user interface.","MOSAIQ Oncology Information Management System | MOSAIQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828710","ONCOCHART Management Tool","C105669","A proprietary charge capture, documentation and electronic medical record system for radiation oncology.","ONCOCHART Management Tool | ONCOCHART",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829134","MEDITECH Health Record System","C105670","Any of the electronic health record systems and solutions developed by the MEDITECH corporation.","MEDITECH Health Record System | MEDITECH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829154","McKesson Health Record System","C105671","Any of the electronic health record systems and solutions developed by the McKesson corporation.","McKesson Health Record System | McKesson",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810536","Epic Health Record System","C105672","Any of the electronic health record systems and solutions developed by the Epic corporation.","Epic Health Record System | Epic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828820","NextGen Healthcare Record System","C105673","Any of the electronic health record systems and solutions developed by the NextGen corporation.","NextGen Healthcare Record System | NextGen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827105","Protein Phosphatase 2A Inhibitor LB-100","C106430","A water soluble inhibitor of the protein phosphatase 2A (PP2A), with potential chemo- and radiotherapy enhancing activity. Upon injection, PP2A inhibitor LB-100 inhibits the removal of phosphate groups from proteins essential for cell cycle progression. When used with radio- or chemotherapy treatment, this agent prevents the activation of PP2A-mediated repair mechanisms and allows for malignant cells to progress through the cell cycle without having their damaged DNA repaired. This enhances the cytotoxic effect of the chemotherapeutic or radiotherapeutic agent and results in tumor cell apoptosis. PP2A, a serine/threonine phosphatase that plays a key role in the control of cell growth and DNA damage repair.","Protein Phosphatase 2A Inhibitor LB-100 | LB-100 | PP2A Inhibitor LB-100",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1251984","Topical Menthol Cream","C106431","A topical cream containing menthol that both causes a localized cooling sensation and has analgesic activities. Upon topical application, menthol acts on the cold-sensitive transient receptor potential cation channel subfamily M member 8 (TMPR8), which provides a cooling sensation. This treatment also provides an analgesic effect through the activation of the inhibitory Group II/III metabotropic glutamate receptors (mGluRs). This may decrease neuropathic pain from chemotherapy. In addition, the topical application of menthol causes vasodilation.","Topical Menthol Cream | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426628","DDX52 Gene","C106433","This gene plays a role in both RNA binding and ATP hydrolysis.","DDX52 Gene | DDX52 | DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 52 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813716","DDX52 wt Allele","C106434","Human DDX52 wild-type allele is located in the vicinity of 17q21.1 and is approximately 34 kb in length. This allele, which encodes probable ATP-dependent RNA helicase DDX52 protein, is involved in both ATP hydrolysis and RNA binding.","DDX52 wt Allele | DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 52 wt Allele | HUSSY-19 | HUSSY19 | Human Sequence Similar to Yeast 19 Gene | ROK1 | ROK1, S. cerevisiae, Homolog of, Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815137","Probable ATP-Dependent RNA Helicase DDX52","C106435","Probable ATP-dependent RNA helicase DDX52 (599 aa, ~67 kDa) is encoded by the human DDX52 gene. This protein plays a role in both RNA binding and ATPase activity.","Probable ATP-Dependent RNA Helicase DDX52 | ATP-Dependent RNA Helicase ROK1-Like | DDX52 | DEAD Box Protein 52 | EC 3.6.4.13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813553","NOTCH3 wt Allele","C106437","Human NOTCH3 wild-type allele is located within 19p13.2-p13.1 and is approximately 41 kb in length. This allele, which encodes neurogenic locus notch homolog protein 3, is involved in both cell-cell signaling and cell differentiation. Mutation of the gene is associated with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).","NOTCH3 wt Allele | CADASIL | CASIL | IMF2 | Notch (Drosophila) Homolog 3 Gene | Notch 3 wt Allele | Notch Homolog 3 (Drosophila) Gene | Notch Homolog 3 Gene | Notch, Drosophila, Homolog of, 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831624","ADCS-ADL Severe Dementia Questionnaire Question","C106673","A question associated with the ADCS-ADL Severe Dementia questionnaire.","ADCS-ADL Severe Dementia Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831385","BDI Clinical Classification Question","C106674","A question associated with the BDI questionnaire.","BDI Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827850","TDI Clinical Classification Question","C106675","A question associated with the TDI questionnaire.","TDI Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830886","C-SSRS Baseline/Screening Version - Deterrents to Most Severe Ideation (Lifetime)","C106729","No value exists.","C-SSRS Baseline/Screening Version - Deterrents to Most Severe Ideation (Lifetime) | CSS04-Most Severe Idea, Deterrents-Life | CSS0410A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830885","C-SSRS Baseline/Screening Version - Deterrents to Most Severe Ideation (Past X Months)","C106730","No value exists.","C-SSRS Baseline/Screening Version - Deterrents to Most Severe Ideation (Past X Months) | CSS04-Most Severe Idea, Deterrents-P_M | CSS0410B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830854","C-SSRS Baseline/Screening Version - Reasons for Most Severe Ideation (Lifetime)","C106731","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) What sort of reasons did you have for thinking about wanting to die or killing yourself? Was it to end the pain or stop the way you were feeling (in other words you couldn't go on living with this pain or how you were feeling) or was it to get attention, revenge or a reaction from others? Or both? (Lifetime).","C-SSRS Baseline/Screening Version - Reasons for Most Severe Ideation (Lifetime) | CSS04-Most Severe Idea, Reasons-Life | CSS0411A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831654","ADCS-ADL MCI - Use Household Appliance: Other","C106939","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check household appliances that apply: other.","ADCS-ADL MCI - Use Household Appliance: Other | ADL03-Appliance: Other | ADL0317J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281340","cisplatin/fluorouracil/paclitaxel","C10693","A regimen consisting of cisplatin, fluorouracil and paclitaxel that may be used in the treatment of squamous cell carcinoma of the head and neck.","Cisplatin/Fluorouracil/Paclitaxel Regimen | CDDP/5-FU/TAX | Cisplatin-Fluorouracil-Paclitaxel | Cisplatin-Fluorouracil-Paclitaxel Regimen | Platinol/Fluorouracil/Taxol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831653","ADCS-ADL MCI - Use Household Appliance: Other Specify","C106940","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check household appliances that apply: other specify.","ADCS-ADL MCI - Use Household Appliance: Other Specify | ADL03-Appliance: Other Specify | ADL0317K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831717","ADCS-ADL MCI - Description of Usual Use of Commonly Used Appliances","C106941","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, for the 1 or 2 most commonly used appliances, which best describes how subject usually used them.","ADCS-ADL MCI - Description of Usual Use of Commonly Used Appliances | ADL03-Use Common Used Appliances (q17a) | ADL0317L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831700","ADCS-ADL MCI - Perform Pastime, Hobby or Game","C106942","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject perform a pastime, hobby or game?","ADCS-ADL MCI - Perform Pastime, Hobby or Game | ADL03-Perform Pastime | ADL0318",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831699","ADCS-ADL MCI - Perform Pastime, Hobby or Game: Card or Board Games","C106943","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check pastimes that apply: card or board games.","ADCS-ADL MCI - Perform Pastime, Hobby or Game: Card or Board Games | ADL03-Pastime: Card or Board Games | ADL0318A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831701","ADCS-ADL MCI - Perform Pastime, Hobby or Game: Bingo","C106944","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check pastimes that apply: Bingo.","ADCS-ADL MCI - Perform Pastime, Hobby or Game: Bingo | ADL03-Pastime: Bingo | ADL0318B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831698","ADCS-ADL MCI - Perform Pastime, Hobby or Game: Crosswords","C106945","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check pastimes that apply: crosswords.","ADCS-ADL MCI - Perform Pastime, Hobby or Game: Crosswords | ADL03-Pastime: Crosswords | ADL0318C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831702","ADCS-ADL MCI - Perform Pastime, Hobby or Game: Art","C106946","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check pastimes that apply: art.","ADCS-ADL MCI - Perform Pastime, Hobby or Game: Art | ADL03-Pastime: Art | ADL0318D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828814","NIH Minipig","C106549","An inbred strain of miniature swine developed by Sachs et al at the NIH in 1976 from a cross between a Hormel pig and a Vita Vet miniature pig.","NIH Minipig | NIH SLA MINIATURE SWINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831281","BrainLab iPlan","C105674","A proprietary treatment planning system that uses template-based workflow to facilitate the planning for Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiotherapy (SBRT).","BrainLab iPlan | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827224","Nucletron Oncentra","C105676","A proprietary DICOM-compliant treatment planning software system.","Nucletron Oncentra | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830323","Elekta Xio","C105678","A proprietary 3D intensity-modulated radiation therapy treatment planning platform developed by the Elekta corporation.","Elekta Xio | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810570","KRT5 wt Allele","C105680","Human KRT5 wild-type allele is located in the vicinity of 12q13.13 and is approximately 6 kb in length. This allele, which encodes keratin, type II cytoskeletal 5 protein, plays a role in the formation of the epidermis. Mutation of the gene is associated with Dowling-Degos disease and several subtypes of epidermolysis bullosa simplex.","KRT5 wt Allele | CK5 | DDD | DDD1 | EBS2 | Epidermolysis Bullosa Simplex 2 Dowling-Meara/Kobner/Weber-Cockayne Types Gene | K5 | KRT5A | Keratin 5 (Epidermolysis Bullosa Simplex, Dowling-Meara/Kobner/Weber-Cockayne Types) Gene | Keratin 5 wt Allele | Keratin 5, Type II Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1620063","KRT5 protein, human","C105681","Keratin, type II cytoskeletal 5 (590 aa, ~62 kDa) is encoded by the human KRT5 gene. This protein is involved in the structure of the epidermis.","Keratin, Type II Cytoskeletal 5 | 58 kDa Cytokeratin | CK-5 | Cytokeratin-5 | K5 | KRT5 | Keratin-5 | Type-II Keratin Kb5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810571","KRT72 wt Allele","C105683","Human KRT72 wild-type allele is located in the vicinity of 12q13.13 and is approximately 16 kb in length. This allele, which encodes keratin, type II cytoskeletal 72 protein, is involved in the formation of hair.","KRT72 wt Allele | CK6 | Cytokeratin 72 Gene | K6IRS2 | K6irs | KB35 | KRT6 | KRT6IRS2 | Keratin 6, Inner Root Sheath, 2 Gene | Keratin 72 wt Allele | Keratin 72, Type II Gene | Keratin, Type II Cytoskeletal 72 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811158","Keratin, Type II Cytoskeletal 72, Human","C105684","Keratin, type II cytoskeletal 72 (511 aa, ~56 kDa) is encoded by the human KRT72 gene. This protein plays a role in hair formation.","Keratin, Type II Cytoskeletal 72 | CK-6 | CK-72 | Cytokeratin 72 | Cytokeratin-72 | K72 | KRT72 | Keratin 6, Inner Root Sheath, 2 | Keratin 72 | Keratin Protein K6irs | Keratin-72 | Type II Inner Root Sheath-Specific Keratin-K6irs2 | Type-II Keratin Kb35",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027621","Neonatology","C105686","A branch of pediatric medicine focused on the diagnosis and treatment of newborns.","Neonatology | ",,,,,,,,,,,,,,,"4235267","Neonatology",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829477","JAK2 NM_004972.3:c.2792A>G","C105911","A nucleotide substitution at position 2792 of the coding sequence of the JAK2 gene where adenine has been mutated to guanine.","JAK2 NM_004972.3:c.2792A>G | JAK-2 c.2792A>G | JAK2 c.2792A>G | JTK10 c.2792A>G | Janus Kinase 2 c.2792A>G | NM_004972.3:c.2792A>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830916","C-SSRS Already Enrolled Subjects Questionnaire Question","C106676","A question associated with the C-SSRS Already Enrolled Subjects questionnaire.","C-SSRS Already Enrolled Subjects Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830855","C-SSRS Baseline/Screening Version Questionnaire Question","C106677","A question associated with the C-SSRS Baseline/Screening Version questionnaire.","C-SSRS Baseline/Screening Version Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827306","GDS Questionnaire Question","C106678","A question associated with the GDS questionnaire.","GDS Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830004","Geriatric Depression Scale Short Form Questionnaire Question","C106679","A question associated with the Geriatric Depression Scale Short Form questionnaire.","Geriatric Depression Scale Short Form Questionnaire Question | GDS-SF Questionnaire Question | GDS-SF Questionnaire Question",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829852","HAQ-DI Questionnaire Question","C106680","A question associated with the HAQ-DI questionnaire.","HAQ-DI Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828999","MMRC Questionnaire Question","C106681","A question associated with the MMRC questionnaire.","MMRC Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828155","SGRQ-C Questionnaire Question","C106682","A question associated with the SGRQ-C questionnaire.","SGRQ-C Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831693","ADCS-ADL MCI - Perform Pastime, Hobby or Game: Musical Instrument","C106947","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check pastimes that apply: musical instrument.","ADCS-ADL MCI - Perform Pastime, Hobby or Game: Musical Instrument | ADL03-Pastime: Musical Instrument | ADL0318E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831689","ADCS-ADL MCI - Perform Pastime, Hobby or Game: Sewing","C106949","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check pastimes that apply: sewing.","ADCS-ADL MCI - Perform Pastime, Hobby or Game: Sewing | ADL03-Pastime: Sewing | ADL0318G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831690","ADCS-ADL MCI - Perform Pastime, Hobby or Game: Reading","C106950","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check pastimes that apply: reading.","ADCS-ADL MCI - Perform Pastime, Hobby or Game: Reading | ADL03-Pastime: Reading | ADL0318H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831696","ADCS-ADL MCI - Perform Pastime, Hobby or Game: Gardening","C106951","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check pastimes that apply: gardening.","ADCS-ADL MCI - Perform Pastime, Hobby or Game: Gardening | ADL03-Pastime: Gardening | ADL0318I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831695","ADCS-ADL MCI - Perform Pastime, Hobby or Game: Golf","C106952","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check pastimes that apply: golf.","ADCS-ADL MCI - Perform Pastime, Hobby or Game: Golf | ADL03-Pastime: Golf | ADL0318J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449420","MART-1/gp100/Tyrosinase/MAGE-A3 Peptides-loaded Irradiated Allogeneic Plasmacytoid Dendritic Cells","C107159","Irradiated allogeneic, HLA-A*0201 positive, plasmacytoid dendritic cells (pDCs) loaded with 4 melanoma peptides derived from the tumor associated antigens (TAAs) MelA/MART-1, gp100/pmel17, tyrosinase, and MAGE-A3, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the irradiated allogeneic pDCs may trigger functional multi-specific T cells from peripheral blood mononuclear cells and tumor-infiltrating lymphocytes, and activate the immune system to mount a cytotoxic T-lymphocyte response against HLA-A*0201 positive melanoma cancer cells expressing the TAAs MelA/MART-1, gp100/pmel17, tyrosinase, and MAGE-A3. These TAAs are upregulated in a variety of tumor cells. The pDCs are derived from a distinct subset of dendritic cells (DCs) with a plasma cell-like morphology and express a characteristic set of surface markers and may increase the anti-tumor immune responses.","MART-1/gp100/Tyrosinase/MAGE-A3 Peptides-loaded Irradiated Allogeneic Plasmacytoid Dendritic Cells | GeniusVac-Mel4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0694651","Left gluteus medius","C105638","One of the three gluteal muscles on the lateral surface of the pelvic bone that abducts and rotates the thigh located on the left side of the body.","Left Gluteus Medius | LG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0694668","Right gluteus medius","C105639","One of the three gluteal muscles on the lateral surface of the pelvic bone that abducts and rotates the thigh located on the right side of the body.","Right Gluteus Medius | RG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0694662","Left Vastus Lateralis","C105640","The largest muscle in the quadriceps femoris that is responsible for extending and stabilizing the knee located on the left side of the body.","Left Vastus Lateralis | LVL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0694678","Right Vastus Lateralis","C105641","The largest muscle in the quadriceps femoris that is responsible for extending and stabilizing the knee located on the right side of the body.","Right Vastus Lateralis | RVL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0694654","Left Lower Forearm","C105642","The distal half of the left upper limb between the elbow and the wrist.","Left Lower Forearm | LLFA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0694671","Right Lower Forearm","C105643","The distal half of the right upper limb between the elbow and the wrist.","Right Lower Forearm | RLFA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642281","MLL/MLLT11 Fusion Protein","C105647","A fusion protein encoded by the MLL/MLLT11 fusion gene. This protein is comprised of the N-terminal half of the histone-lysine N-methyltransferase MLL protein, including the AT hook DNA binding domain and the DNA methyltransferase domain, fused to the N-terminus of the entire protein AF1q.","MLL/MLLT11 Fusion Protein | Histone-Lysine N-Methyltransferase MLL/Protein AF1q Fusion Protein | KMT2A::MLLT11 Fusion Protein | MLL-AF1q Fusion Protein | MLL-MLLT11 Fusion Protein | MLL/AF1q Fusion Protein | MLL::MLLT11 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830972","C-SSRS Already Enrolled Subjects - Aborted Suicide Attempt (Prior to Study Entry)","C107068","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Has there been a time when you started to do something to try to end your life but you stopped yourself before you actually did anything? (Prior to Study Entry).","C-SSRS Already Enrolled Subjects - Aborted Suicide Attempt (Prior to Study Entry) | CSS05-Aborted Attempt-Prior | CSS0517A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830971","C-SSRS Already Enrolled Subjects - Aborted Suicide Attempt (Since Study Start)","C107069","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Has there been a time when you started to do something to try to end your life but you stopped yourself before you actually did anything? (Since Study Start).","C-SSRS Already Enrolled Subjects - Aborted Suicide Attempt (Since Study Start) | CSS05-Aborted Attempt-Since | CSS0517B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830924","C-SSRS Already Enrolled Subjects - Number of Aborted Suicide Attempts (Prior to Study Entry)","C107070","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Total number of aborted. (Prior to Study Entry).","C-SSRS Already Enrolled Subjects - Number of Aborted Suicide Attempts (Prior to Study Entry) | CSS05-Number of Aborted Attempts-Prior | CSS0518A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831736","ADCS-ADL MCI - Balance Checkbook","C106898","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject balance his or her checkbook or a credit card statement?","ADCS-ADL MCI - Balance Checkbook | ADL03-Balance Checkbook | ADL0305",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831724","ADCS-ADL MCI - Description of Usual Performance of Balancing Checkbook","C106899","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, which best describes how he or she usually performed.","ADCS-ADL MCI - Description of Usual Performance of Balancing Checkbook | ADL03-Balance Checkbook Performance | ADL0305A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0057671","Anguidine","C1068","A trichothecene mycotoxin and potent teratogen. Anguidine inhibits initiation of protein synthesis, resulting in the death of rapidly proliferating cells.  Anguidine also has been shown to both potentiate and protect against the cytotoxic effects of other drugs.  (NCI04)","Anguidine | 3Alpha,4Beta, 15-triol, 12, 13-epoxy-,4, 15-diacetate (8CI) | 4, 15-Diacetoxyscirpen-3-ol | 4Beta, 15-diacetoxy-3alpha-hydroxy-12, 13-epoxytrichothec-9-ene | ANGUIDINE | Anguidin | DAS | DIACETOXYSCIRPENOL | Diacetoxyscirpenol | MM 4462 | Trichothec-9-ene-3, 4, 15-triol, 12, 13-epoxy-, 4, 15-diacetate (3alpha, 4beta)-(9CI) | Trichothec-9-ene-3, 4,15-triol, 12,13-epoxy-, 4,15-diacetate, (3.alpha.,4.beta.)- (9CI) | Trichothec-9-ene-3,4, 15-triol, 12,13-epoxy-, 4,15-diacetate | Trichothec-9-ene-3,4, 15-triol, 12,13-epoxy-, 4,15-diacetate, (3.alpha.,4.beta.)- (9CI) | Trichothec-9-ene-3,4,15-triol, 12,13-epoxy-, 4, 15-diacetate | Trichothec-9-ene-3,4,15-triol, 12,13-epoxy-, 4,15-diacetate | Trichothec-9-ene-3,4,15-triol, 12,13-epoxy-, 4,15-diacetate, (3.alpha.,4.beta.)- (9CI)",,,,,,,,,,,,,,,"4174224","Diacetoxyscirpenol",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3831646","ADCS-ADL MCI - Write Things Down","C106900","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject ever write things down?","ADCS-ADL MCI - Write Things Down | ADL03-Write Things Down | ADL0306",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831734","ADCS-ADL MCI - Clean Laundry","C106902","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject clean a load of laundry?","ADCS-ADL MCI - Clean Laundry | ADL03-Clean Laundry | ADL0307",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831722","ADCS-ADL MCI - Description of Usual Performance of Clean Laundry","C106903","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, which best describes how he or she usually performed.","ADCS-ADL MCI - Description of Usual Performance of Clean Laundry | ADL03-Laundry Cleaning Performance | ADL0307A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831710","ADCS-ADL MCI - Keep Appointments","C106904","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject keep appointments or meetings with other people, such as relatives, a doctor, the hairdresser, etc.?","ADCS-ADL MCI - Keep Appointments | ADL03-Keep Appointments | ADL0308",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831731","ADCS-ADL MCI - Description of Awareness of the Meeting Ahead of Time","C106905","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, which best describes his or her awareness of the meeting ahead of time.","ADCS-ADL MCI - Description of Awareness of the Meeting Ahead of Time | ADL03-Aware of Appointment Ahead of Time | ADL0308A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831660","ADCS-ADL MCI - Use a Telephone","C106906","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject use a telephone?","ADCS-ADL MCI - Use a Telephone | ADL03-Use a Telephone | ADL0309",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831728","ADCS-ADL MCI - Description of Highest Level of Performance of Telephone Use","C106907","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, which best describes his or her highest level of performance.","ADCS-ADL MCI - Description of Highest Level of Performance of Telephone Use | ADL03-Highest Telephone Use Performance | ADL0309A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831704","ADCS-ADL MCI - Make a Meal or Snack","C106908","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject make him or herself a meal or snack at home?","ADCS-ADL MCI - Make a Meal or Snack | ADL03-Make a Meal | ADL0310",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449421","Oncolytic Adenovirus ICOVIR5-infected Autologous Mesenchymal Stem Cells","C107160","Bone marrow-derived autologous mesenchymal stem cells (MSCs) infected with the oncolytic, replication-competent adenovirus ICOVIR5, with potential antineoplastic activity. Upon infusion of the oncolytic adenovirus ICOVIR5-infected autologous MSCs, these cells target the adenovirus to tumors. The oncolytic virus then selectively transfects and replicates in the tumor cells causing a direct cytotoxic effect and lysis of the tumor cells. In addition, the viral infection may stimulate an immune response against the virally-infected tumor cells. This may lead to an inhibition of cancer cell proliferation. ICOVIR-5, a virus derived from wild-type human adenovirus serotype 5 (Had5), has been modified to selectively replicate in tumor cells that have a deregulated retinoblastoma/E2F pathway.","Oncolytic Adenovirus ICOVIR5-infected Autologous Mesenchymal Stem Cells | Celyvir",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449422","Heparan Sulfate Glycosaminoglycan Mimetic Nanopolymer Mouthwash","C107161","A nanopolymer-based mouthwash formulation containing a mimetic of the glycosaminoglycan (GAG) heparan sulfate, with potential anti-mucositic and protective activities. Upon rinsing with the mouthwash, GAGs bind to heparan sulfate binding sites on macromolecules within the extracellular matrix (EMC), which prevents the destruction of the ECM and protects both growth factors and cytokines from being degraded. By replacing the GAGs damaged by chemotherapy and/or radiation, this mouthwash may protect healthy tissue against the cytotoxic effects of chemotherapy and radiation and may prevent against radio-chemotherapy-induced mucositis.","Heparan Sulfate Glycosaminoglycan Mimetic Nanopolymer Mouthwash | MUCIPLIQ Mouthwash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0765152","angiopoietin 4","C106491","Angiopoietin-4 (503 aa, ~57 kDa) is encoded by the human ANGPT4 gene. This protein plays a role in both vascular development and angiogenesis.","Angiopoietin-4 | ANGPT4 | Angiopoietin-3 | DJ824F16.2 (Angiopoietin 4)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814524","CD1D wt Allele","C106494","Human CD1D wild-type allele is located within 1q22-q23 and is approximately 6 kb in length. This allele, which encodes antigen-presenting glycoprotein CD1d, plays a role in glycolipid antigen presentation.","CD1D wt Allele | CD1A | CD1d Molecule wt Allele | R3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2351710","CD1D protein, human","C106495","Antigen-presenting glycoprotein CD1d (335 aa, ~38 kDa) is encoded by the human CD1D gene. This protein is involved in lipid antigen presentation.","Antigen-Presenting Glycoprotein CD1d | Antigen CD1d | CD1D | CD1d | CD1d Antigen | Differentiation Antigen CD1-Alpha-3 | HMC Class I Antigen-Like Glycoprotein CD1D | R3G1 | T-Cell Surface Glycoprotein CD1d | Thymocyte Antigen CD1D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813166","WRNIP1 wt Allele","C106310","Human WRNIP1 wild-type allele is located in the vicinity of 6p25.2 and is approximately 21 kb in length. This allele, which encodes ATPase WRNIP1 protein, plays a role in both DNA replication and ATP hydrolysis.","WRNIP1 wt Allele | FLJ22526 | RP11-420G6.2 | WHIP | Werner Helicase Interacting Protein 1 wt Allele | bA420G6.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813625","ATPase WRNIP1, Human","C106311","ATPase WRNIP1 (665 aa, ~72 kDa) is encoded by the human WRNIP1 gene. This protein is involved in both ATP hydrolysis and DNA replication.","ATPase WRNIP1 | Putative Helicase RUVBL | WRNIP1 | Werner Helicase-Interacting Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828300","RORC Gene Product","C106313","A protein encoded by the RORC gene.","RORC Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420614","TBX4 Gene","C106321","This gene plays a role in skeletal development.","TBX4 Gene | T-Box 4 Gene | TBX4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813609","TBX4 wt Allele","C106322","Human TBX4 wild-type allele is located within 17q21-q22 and is approximately 33 kb in length. This allele, which encodes T-box transcription factor TBX4 protein, is involved in both transcriptional regulation and limb formation. Mutation of the gene is associated with small patella syndrome.","TBX4 wt Allele | SPS | T-Box 4 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1434641","Dual Specificity Mitogen-Activated Protein Kinase Kinase 2, Human","C106633","Dual specificity mitogen-activated protein kinase kinase 2 (400 aa, ~44 kDa) is encoded by the human MAP2K2 gene. This protein plays a role in protein phosphorylation.","Dual Specificity Mitogen-Activated Protein Kinase Kinase 2 | EC 2.7.12.2 | ERK Activator Kinase 2 | MAP Kinase Kinase 2 | MAP2K2 | MAPK/ERK Kinase 2 | MAPKK 2 | MEK 2 | Mitogen-Activated Protein Kinase Kinase 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815268","SETBP1 wt Allele","C106636","Human SETBP1 wild-type allele is located in the vicinity of 18q21.1 and is approximately 388 kb in length. This allele, which encodes SET-binding protein, may play a role in the regulation of protein SET activity. Mutation of the gene is associated with Schinzel-Giedion midface retraction syndrome. A chromosomal translocation, t(11;18)(p15;q12), involving this gene and the NUP98 gene is involved in T-cell acute lymphoblastic leukemia.","SETBP1 wt Allele | KIAA0437 | MRD29 | SEB | SET Binding Protein 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1309881","SET-Binding Protein, Human","C106637","SET-binding protein (1596 aa, ~175 kDa) is encoded by the human SETBP1 gene. This protein is involved in binding to protein SET.","SET-Binding Protein | SEB | SET-Binding Protein 1 | SETBP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3147783","CGAS Gene","C106638","This gene plays a role in the biosynthesis of cyclic dinucleotides.","CGAS Gene | CGAS | Cyclic GMP-AMP Synthase Gene | MB21D1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831729","ADCS-ADL MCI - Description of Highest Level of Food Preparation","C106909","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, which best describes his or her highest level of food preparation.","ADCS-ADL MCI - Description of Highest Level of Food Preparation | ADL03-Highest Level of Food Preparation | ADL0310A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811113","COL7A1 wt Allele","C107114","Human COL7A1 wild-type allele is located in the vicinity of 3p21.1 and is approximately 31 kb in length. This allele, which encodes collagen alpha-1(VII) chain protein, plays a role in interactions between squamous epithelia and the basement membrane. Mutations in this gene are associated with all forms of dystrophic epidermolysis bullosa.","COL7A1 wt Allele | Collagen Type VII Alpha 1 Chain wt Allele | Collagen, Type VII, Alpha 1 Gene | EBD1 | EBDCT | EBR1 | NDNC8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812182","Collagen Alpha-1(VII) Chain","C107115","Collagen alpha-1(VII) chain (2944 aa, ~295 kDa) is encoded by the human COL7A1 gene. This protein is involved in interactions between squamous epithelia and the basement membrane.","Collagen Alpha-1(VII) Chain | COL7A1 | Collagen VII, Alpha-1 Polypeptide | Epidermolysis Bullosa, Dystrophic, Dominant And Recessive | LC Collagen | Long-Chain Collagen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814518","GABARAPL2 wt Allele","C107117","Human GABARAPL2 wild-type allele is located in the vicinity of 16q22.1 and is approximately 12 kb in length. This allele, which encodes gamma-aminobutyric acid receptor-associated protein-like 2, is involved in the regulation of intra-Golgi transport.","GABARAPL2 wt Allele | ATG8 | ATG8C | FLC3A | GABA(A) Receptor-Associated Protein-Like 2 wt Allele | GATE-16 | GATE16 | GATE16, Bovine, Homolog of Gene | GEF-2 | GEF2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1452406","Gamma-Aminobutyric Acid Receptor-Associated Protein-Like 2, Human","C107118","Gamma-aminobutyric acid receptor-associated protein-like 2 (117 aa, ~14 kDa) is encoded by the human GABARAPL2 gene. This protein plays a role in the regulation of intra-Golgi transport.","Gamma-Aminobutyric Acid Receptor-Associated Protein-Like 2 | GABA-A Receptor-Associated Protein-Like Protein 2 | GABARAPL2 | Ganglioside Expression Factor 2 | General Protein Transport Factor P16 | Golgi-Associated ATPase Enhancer of 16 Kda | MAP1 Light Chain 3 Related Protein | MAP1 Light Chain 3-Related Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831131","CHD1 wt Allele","C107120","Human CHD1 wild-type allele is located within 5q15-q21 and is approximately 71 kb in length. This allele, which encodes chromodomain-helicase-DNA-binding protein 1, plays a role in the regulation of transcription by the modification of chromatin structure.","CHD1 wt Allele | CHD-1 | Chromodomain Helicase DNA Binding Protein 1 wt Allele | PILBOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1448753","Chromodomain-Helicase-DNA-Binding Protein 1, Human","C107121","Chromodomain-helicase-DNA-binding protein 1 (1710 aa, ~197 kDa) is encoded by the human CHD1 gene. This protein is involved in the regulation of transcription by the modification of chromatin structure.","Chromodomain-Helicase-DNA-Binding Protein 1 | ATP-Dependent Helicase CHD1 | CHD1 | Chromodomain Helicase DNA Binding Protein 1 | Chromodomain Helicase DNA-Binding Protein 1 | EC 3.6.1 | EC 3.6.4.12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812153","DAB2IP wt Allele","C107123","Human DAB2IP wild-type allele is located within 9q33.1-q33.3 and is approximately 218 kb in length. This allele, which encodes disabled homolog 2-interacting protein, may be involved in tumor suppression.","DAB2IP wt Allele | AF9Q34 | AIP1 | DAB2 Interacting Protein wt Allele | DIP1/2 | KIAA1743",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831538","Anesthetized Exsanguination and Perfusion Euthanasia","C106500","A method of euthanasia whereby a subject is anesthetized and the blood of the body is replaced by a perfusate.","Anesthetized Exsanguination and Perfusion Euthanasia | ANESTHETIZED EXSANGUINATION AND PERFUSION | Anesthetized Perfusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830853","C-SSRS Baseline/Screening Version - Reasons for Most Severe Ideation (Past X Months)","C106732","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) What sort of reasons did you have for thinking about wanting to die or killing yourself? Was it to end the pain or stop the way you were feeling (in other words you couldn't go on living with this pain or how you were feeling) or was it to get attention, revenge or a reaction from others? Or both? (Past X Months).","C-SSRS Baseline/Screening Version - Reasons for Most Severe Ideation (Past X Months) | CSS04-Most Severe Idea, Reasons-P_M | CSS0411B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830901","C-SSRS Baseline/Screening Version - Actual Suicide Attempt (Lifetime)","C106733","No value exists.","C-SSRS Baseline/Screening Version - Actual Suicide Attempt (Lifetime) | CSS04-Actual Attempt-Life | CSS0412A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830900","C-SSRS Baseline/Screening Version - Actual Suicide Attempt (Past X Years)","C106734","No value exists.","C-SSRS Baseline/Screening Version - Actual Suicide Attempt (Past X Years) | CSS04-Actual Attempt-P_Y | CSS0412B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830861","C-SSRS Baseline/Screening Version - Number of Actual Suicide Attempts (Lifetime)","C106735","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Total number of attempts. (Lifetime).","C-SSRS Baseline/Screening Version - Number of Actual Suicide Attempts (Lifetime) | CSS04-Number of Actual Attempts-Life | CSS0413A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830860","C-SSRS Baseline/Screening Version - Number of Actual Suicide Attempts (Past X Years)","C106736","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Total number of attempts. (Past X Years).","C-SSRS Baseline/Screening Version - Number of Actual Suicide Attempts (Past X Years) | CSS04-Number of Actual Attempts-P_Y | CSS0413B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830891","C-SSRS Baseline/Screening Version - Description of Actual Suicide Attempt","C106737","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Description of actual attempt.","C-SSRS Baseline/Screening Version - Description of Actual Suicide Attempt | CSS04-Actual Attempt, Describe | CSS0413C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827909","Structured Product Labeling Lot Distribution Data - Distribution Codes","C106324","Terminology to support Structured Product Labeling with lot distribution data and distribution codes.","SPL Lot Distribution Data - Distribution Codes Terminology | SPL Lot Distribution Data - Distribution Codes | Structured Product Labeling Lot Distribution Data - Distribution Codes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828428","Quantity Distributed per Reporting Interval","C106325","Quantity of items distributed in a reporting period.","Quantity Distributed per Reporting Interval | Distributed per reporting interval",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827330","Quantity Distributed Anticipated Total","C106326","Anticipated quantity of items distributed.","Quantity Distributed Anticipated Total | Distributed - anticipated total",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812168","LBP wt Allele","C105866","Human LBP wild-type allele is located in the vicinity of 20q11.23 and is approximately 31 kb in length. This allele, which encodes lipopolysaccharide-binding protein, is involved in binding to lipopolysaccharide.","LBP wt Allele | BPI Fold Containing Family D, Member 2 Gene | BPIFD2 | Lipopolysaccharide Binding Protein wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1505993","Lipopolysaccharide-Binding Protein, Human","C105867","Lipopolysaccharide-binding protein (481 aa, ~53 kDa) is encoded by the human LBP gene. This protein plays a role in lipopolysaccharide binding.","Lipopolysaccharide-Binding Protein | LBP | LPS-BP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814801","HTR1A wt Allele","C105869","Human HTR1A wild-type allele is located within 5q11.2-q13 and is approximately 2 kb in length. This allele, which encodes 5-hydroxytryptamine receptor 1A protein, plays a role in both neurotransmitter binding and G protein-coupled receptor signaling. Mutation of the gene is associated with menstrual cycle-dependent periodic fevers.","HTR1A wt Allele | 5-HT-1A | 5-HT1A | 5-Hydroxytryptamine (Serotonin) Receptor 1A Gene | 5-Hydroxytryptamine (Serotonin) Receptor 1A, G Protein-Coupled wt Allele | 5HT1a | ADRB2RL1 | ADRBRL1 | G-21 | PFMCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3712806","5-Hydroxytryptamine Receptor 1A, human","C105870","5-hydroxytryptamine receptor 1A (422 aa, ~46 kDa) is encoded by the human HTR1A gene. This protein is involved in both serotonin binding and neurotransmitter-mediated signal transduction.","5-Hydroxytryptamine Receptor 1A | 5-HT-1A | 5-HT1A | 5-HT1a Receptor | Beta-2-Adrenergic Receptor-Like Protein G-21 | G-21 | HTR1A | Serotonin 5-HT-1A Receptor | Serotonin Receptor 1A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815636","TPH1 wt Allele","C105872","Human TPH1 wild-type allele is located within 11p15.3-p14 and is approximately 25 kb in length. This allele, which encodes tryptophan 5-hydroxylase 1 protein, is involved in tryptophan metabolism.","TPH1 wt Allele | TPH | TPRH | TRPH | Tryptophan Hydroxylase (Tryptophan 5-Monooxygenase) Gene | Tryptophan Hydroxylase 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1566598","TPH1 protein, human","C105873","Tryptophan 5-hydroxylase 1 (444 aa, ~51 kDa) is encoded by the human TPH1 gene. This protein plays a role in the metabolism of tryptophan.","Tryptophan 5-Hydroxylase 1 | EC 1.14.16.4 | TPH1 | Tryptophan 5-Monooxygenase | Tryptophan 5-Monooxygenase 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813551","cGAS","C106639","Human CGAS wild-type allele is located in the vicinity of 6q13 and is approximately 39 kb in length. This allele, which encodes cyclic GMP-AMP synthase protein, is involved in both immunity and cyclic nucleotide synthesis.","CGAS wt Allele | C6orf150 | Chromosome 6 Open Reading Frame 150 Gene | Cyclic GMP-AMP Synthase wt Allele | D4 | MB21D1 | Mab-21 Domain Containing 1 Gene | cGAS | h-cGAS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425525","NAXE Gene","C106641","This gene is involved in both apolipoprotein A-I binding and nicotinamide-adenine dinucleotide metabolism.","NAXE Gene | APOA1BP | NAD(P)HX Epimerase Gene | NAXE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812155","AIBP","C106642","Human NAXE wild-type allele is located in the vicinity of 1q22 and is approximately 3 kb in length. This allele, which encodes NAD(P)H-hydrate epimerase protein, is involved in both NAD metabolism and apolipoprotein A-I binding.","NAXE wt Allele | AIBP | APOA1BP | Apolipoprotein A-I Binding Protein Gene | MGC119143 | MGC119144 | MGC119145 | NAD(P)HX Epimerase  wt Allele | NAD(P)HX Epimerase wt Allele | PEBEL | RP11-284F21.3 | YJEFN1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829589","Human Prescription Drug Manufacturing","C106643","The process of manufacturing prescription medications for humans by a pharmaceutical company.","Human Prescription Drug Manufacturing | Manufactures human prescription drug products",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1306969","NAD(P)H-Hydrate Epimerase, Human","C106644","NAD(P)H-hydrate epimerase (288 aa, ~32 kDa) is encoded by the human NAXE gene. This protein is involved in both lipoprotein binding and nucleotide metabolism.","NAD(P)H-Hydrate Epimerase | AI-BP | APOA1BP | ApoA-I Binding Protein | ApoA-I-Binding Protein | ApoA1-Binding Protein | Apolipoprotein A-I-Binding Protein | EC 5.1.99.6 | NAD(P)HX Epimerase | NAXE | YjeF N-Terminal Domain-Containing Protein 1 | YjeF_N1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829591","Human Over-the-Counter Drug Manufacturing","C106645","The process of manufacturing non-prescription medications for humans by a pharmaceutical company.","Human Over-the-Counter Drug Manufacturing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828162","SGRQ-C - Have Attacks of Wheezing","C106857","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Please check one box for each question: I have attacks of wheezing.","SGRQ-C - Have Attacks of Wheezing | SGRQC1-I Have Attacks of Wheezing | SGRQC105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828156","SGRQ-C - Number of Respiratory Attacks Last Year","C106858","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Please check one box for each question: How many respiratory attacks did you have during the last year?","SGRQ-C - Number of Respiratory Attacks Last Year | SGRQC1-How Many Respiratory Attacks | SGRQC106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828163","SGRQ-C - Good Days with Few Respiratory Problems","C106859","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Please check one box for each question: How often do you have good days (with few respiratory problems)?","SGRQ-C - Good Days with Few Respiratory Problems | SGRQC1-How Often Do You Have Good Days | SGRQC107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828143","SGRQ-C - Wheezing Worse In the Morning","C106860","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Please check one box for each question: If you wheeze, is it worse when you get up in the morning?","SGRQ-C - Wheezing Worse In the Morning | SGRQC1-Wheeze Worse in the Morning | SGRQC108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828173","SGRQ-C - Description of Your Respiratory Problems","C106861","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) How would you describe your respiratory problems?","SGRQ-C - Description of Your Respiratory Problems | SGRQC1-Describe Your Resp Problems | SGRQC109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1138356","Disabled Homolog 2-Interacting Protein","C107124","Disabled homolog 2-interacting protein (1189 aa, ~132 kDa) is encoded by the human DAB2IP gene. This protein may play a role in tumor suppression.","Disabled Homolog 2-Interacting Protein | ASK-Interacting Protein 1 | ASK1-Interacting Protein 1 | DAB2 Interaction Protein | DAB2-Interacting Protein | DOC-2/DAB2 Interactive Protein | NGAP-Like Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815263","PHLPP2 wt Allele","C107126","Human PHLPP2 wild-type allele is located in the vicinity of 16q22.2 and is approximately 87 kb in length. This allele, which encodes PH domain leucine-rich repeat-containing protein phosphatase 2 protein, plays a role in the regulation of apoptosis and may act as a tumor suppressor.","PHLPP2 wt Allele | KIAA0931 | PH Domain and Leucine Rich Repeat Protein Phosphatase 2 wt Allele | PHLPPL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1452875","Neurogenic Locus Notch Homolog Protein 3, Human","C106438","Neurogenic locus notch homolog protein 3 (2321 aa, ~244 kDa) is encoded by the human NOTCH3 gene. This protein plays a role in both cell fate commitment and cell-cell signaling.","Neurogenic Locus Notch Homolog Protein 3 | NOTCH3 | Notch 3 | Notch Homolog 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1867717","PSAP Gene","C106439","This gene is involved in the promotion of lipid degradation.","PSAP Gene | PSAP | Prosaposin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811239","PSAP wt Allele","C106440","Human PSAP wild-type allele is located within 10q21-q22 and is approximately 35 kb in length. This allele, which encodes prosaposin protein, plays a role in the positive regulation of lipid hydrolysis. Mutation of the gene is associated with combined saposin deficiency, leukodystrophy metachromatic due to saposin-B deficiency, Gaucher disease, atypical, due to saposin C deficiency, Krabbe disease, atypical, due to saposin A deficiency and Tay-Sachs disease.","PSAP wt Allele | GLBA | PARK24 | PSAPD | Prosaposin wt Allele | SAP1 | SAP2 | Variant Gaucher Disease and Variant Metachromatic Leukodystrophy Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475344","PSAP protein, human","C106441","Prosaposin (524 aa, ~58 kDa) is encoded by the human PSAP gene. This protein is involved in sphingolipid catabolism.","Prosaposin | PSAP | Proactivator Polypeptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811698","DHH wt Allele","C106443","Human DHH wild-type allele is located in the vicinity of 12q13.12 and is approximately 5 kb in length. This allele, which encodes desert hedgehog protein, is involved in the regulation of both male gonadal differentiation and perineurial development. Mutations in this gene are associated with both 46XY partial gonadal dysgenesis, with minifascicular neuropathy, and 46XY sex reversal 7.","DHH wt Allele | Desert Hedgehog wt Allele | GDXYM | HHG-3 | MGC35145 | SRXY7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1701852","Desert Hedgehog Protein, Human","C106444","Desert hedgehog protein (396 aa, ~344 kDa) is encoded by the human DHH gene. This protein plays a role in the regulation of male gonadal morphogenesis.","Desert Hedgehog Protein | Desert Hedgehog (Drosophila) Homolog | Desert Hedgehog Homolog | Mutant Desert Hedgehog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811699","IHH wt Allele","C106446","Human IHH wild-type allele is located within 2q33-q35 and is approximately 6 kb in length. This allele, which encodes indian hedgehog protein, plays a role in both bone growth and differentiation. Mutations in this gene are associated with acrocapitofemoral dysplasia and brachydactyly, type A1.","IHH wt Allele | BDA1 | HHG-2 | HHG2 | Indian Hedgehog wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830865","C-SSRS Baseline/Screening Version - Non-suicidal Self-injurious Behavior (Lifetime)","C106738","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Has subject engage in non-suicidal self-injurious behavior? (Lifetime).","C-SSRS Baseline/Screening Version - Non-suicidal Self-injurious Behavior (Lifetime) | CSS04-Non-suicidal Self-injur Behav-Life | CSS0414A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830877","C-SSRS Baseline/Screening Version - Interrupted Suicide Attempt (Lifetime)","C106740","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Has there been a time when you started to do something to end your life but someone or something stopped you before you actually did anything? (Lifetime).","C-SSRS Baseline/Screening Version - Interrupted Suicide Attempt (Lifetime) | CSS04-Interrupted Attempt-Life | CSS0415A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830876","C-SSRS Baseline/Screening Version - Interrupted Suicide Attempt (Past X Years)","C106741","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Has there been a time when you started to do something to end your life but someone or something stopped you before you actually did anything? (Past X Years)","C-SSRS Baseline/Screening Version - Interrupted Suicide Attempt (Past X Years) | CSS04-Interrupted Attempt-P_Y | CSS0415B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830858","C-SSRS Baseline/Screening Version - Number of Interrupted Suicide Attempts (Past X Years)","C106743","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Total number of interrupted. (Past X Years).","C-SSRS Baseline/Screening Version - Number of Interrupted Suicide Attempts (Past X Years) | CSS04-Number of Interrupt Attempts-P_Y | CSS0416B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830890","C-SSRS Baseline/Screening Version - Description of Interrupted Suicide Attempt","C106744","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Description of interrupted attempt.","C-SSRS Baseline/Screening Version - Description of Interrupted Suicide Attempt | CSS04-Interrupted Attempt, Describe | CSS0416C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830909","C-SSRS Baseline/Screening Version - Aborted Suicide Attempt (Lifetime)","C106745","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Has there been a time when you started to do something to try to end your life but you stopped yourself before you actually did anything? (Lifetime).","C-SSRS Baseline/Screening Version - Aborted Suicide Attempt (Lifetime) | CSS04-Aborted Attempt-Life | CSS0417A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831687","ADCS-ADL MCI - Perform Pastime, Hobby or Game: Workshop","C106954","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check pastimes that apply: workshop.","ADCS-ADL MCI - Perform Pastime, Hobby or Game: Workshop | ADL03-Pastime: Workshop | ADL0318L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831697","ADCS-ADL MCI - Perform Pastime, Hobby or Game: Fishing","C106955","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check pastimes that apply: fishing.","ADCS-ADL MCI - Perform Pastime, Hobby or Game: Fishing | ADL03-Pastime: Fishing | ADL0318M",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831692","ADCS-ADL MCI - Perform Pastime, Hobby or Game: Other","C106956","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check pastimes that apply: other.","ADCS-ADL MCI - Perform Pastime, Hobby or Game: Other | ADL03-Pastime: Other | ADL0318N",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831683","ADCS-ADL MCI - Require Help to Perform Hobbies","C106958","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Did subject require supervision, or help, to perform any of these hobbies?","ADCS-ADL MCI - Require Help to Perform Hobbies | ADL03-Hobbies Needed Help (Q18a) | ADL0318P",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831705","ADCS-ADL MCI - List Hobbies Lost Ability to Perform","C106959","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) List any hobby(ies) that the subject has lost the ability to perform.","ADCS-ADL MCI - List Hobbies Lost Ability to Perform | ADL03-Hobbies Unable to Perform (Q18b) | ADL0318Q",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814032","SLC6A4 wt Allele","C105875","Human SLC6A4 wild-type allele is located in the vicinity of 17q11.2 and is approximately 42 kb in length. This allele, which encodes sodium-dependent serotonin transporter protein, plays a role in serotonin uptake. Polymorphism in the promoter region affects gene expression and lower gene expression is associated with depression. Coding region variations are associated with genetic susceptibility to both obsessive-compulsive disorder and alcoholism.","SLC6A4 wt Allele | 5-HTT | 5-HTTLPR | 5HTT | HTT | OCD1 | SERT | SERT1 | Solute Carrier Family 6 (Neurotransmitter Transporter, Serotonin), Member 4 wt Allele | hSERT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1456457","Sodium-Dependent Serotonin Transporter, Human","C105876","Sodium-dependent serotonin transporter (630 aa, ~70 kDa) is encoded by the human SLC6A4 gene. This protein is involved in serotonin internalization.","Sodium-Dependent Serotonin Transporter | 5-Hydroxytryptamine Transporter | 5HT Transporter | 5HTT | Na+/Cl- Dependent Serotonin Transporter | SLC6A4 | Solute Carrier Family 6 Member 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811087","CLCN7 wt Allele","C105878","Human CLCN7 wild-type allele is located in the vicinity of 16p13 and is approximately 31 kb in length. This allele, which encodes H(+)/Cl(-) exchange transporter 7 protein, is involved in chloride ion transport. Mutation of the gene is associated with both osteopetrosis autosomal dominant type 2 and osteopetrosis autosomal recessive type 4.","CLCN7 wt Allele | CLC-7 | CLC7 | Chloride Channel 7 Gene | Chloride Channel, Voltage-Sensitive 7 wt Allele | OPTA2 | OPTB4 | PPP1R63 | Protein Phosphatase 1, Regulatory Subunit 63 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825161","FAM83A Gene","C106098","This gene may be involved in tumor resistance.","FAM83A Gene | FAM83A | Family with Sequence Similarity 83 Member A Gene | Family with Sequence Similarity 83, Member A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811655","FAM83A wt Allele","C106099","Human FAM83A wild-type allele is located in the vicinity of 8q24.13 and is approximately 31 kb in length. This allele, which encodes protein FAM83A, may play a role in chemotherapy-resistant tumors.","FAM83A wt Allele | BJ-TSA-9 | Family with Sequence Similarity 83 Member A wt Allele | Family with Sequence Similarity 83, Member A Gene | Family with Sequence Similarity 83, Member A wt Allele | MGC14128 | TSGP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0057090","Daidzein","C1060","An isoflavone extract from soy, which is an inactive analog of the tyrosine kinase inhibitor genistein. It has antioxidant and phytoestrogenic properties. (NCI)","Daidzein | 4',7-Dihydroxyisoflavone | 7-Hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one | DAIDZEIN | daidzein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2355192","Protein FAM83A, Human","C106100","Protein FAM83A (434 aa, ~47 kDa) is encoded by the human FAM83A gene. This protein may be involved in tumor drug resistance.","Protein FAM83A | Tumor Antigen BJ-TSA-9 | Tumor-Specific Gene Expressed In Prostate Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828542","Plant-based Natural Product","C106104","Any mixture of substances or products derived from a plant or from part of a plant.","Plant-based Natural Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828541","Plant or Plant Part Extract","C106105","Any extract from a plant or from part of a plant.","Plant or Plant Part Extract | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424635","CIB1 Gene","C106107","This gene plays a role in cell adhesion, megakaryocyte differentiation, apoptosis regulation and calcium binding.","CIB1 Gene | CIB1 | Calcium and Integrin Binding 1 (Calmyrin) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810618","CIB1 wt Allele","C106108","Human CIB1 wild-type allele is located within 15q25.3-q26 and is approximately 4 kb in length. This allele, which encodes calcium and integrin-binding protein 1, is involved in megakaryocyte differentiation, integrin regulation, calcium binding and apoptosis.","CIB1 wt Allele | CALMYRIN | CIB | CIBP | Calcium and Integrin Binding 1 (Calmyrin) wt Allele | KIP | KIP1 | PRKDCIP | SIP2-28",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828165","SGRQ-C - Feel Breathless Washing or Dressing Yourself","C106862","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Questions about what activities usually make you feel breathless: Washing or dressing yourself.","SGRQ-C - Feel Breathless Washing or Dressing Yourself | SGRQC1-Washing or Dressing Yourself | SGRQC110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828169","SGRQ-C - Feel Breathless Walking Around the House","C106863","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Questions about what activities usually make you feel breathless: Walking around the house.","SGRQ-C - Feel Breathless Walking Around the House | SGRQC1-Walking Around the House | SGRQC111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828167","SGRQ-C - Feel Breathless Walking Up a Flight of Stairs","C106865","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Questions about what activities usually make you feel breathless: Walking up a flight of stairs.","SGRQ-C - Feel Breathless Walking Up a Flight of Stairs | SGRQC1-Walking Up a Flight of Stairs | SGRQC113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828166","SGRQ-C - Feel Breathless Walking Up Hills","C106866","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Questions about what activities usually make you feel breathless: Walking up hills.","SGRQ-C - Feel Breathless Walking Up Hills | SGRQC1-Walking Up Hills | SGRQC114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828177","SGRQ-C - Coughing Hurts","C106867","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Some more questions about your cough and breathlessness: Coughing hurts.","SGRQ-C - Coughing Hurts | SGRQC1-Coughing Hurts | SGRQC115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828176","SGRQ-C - Coughing Makes Me Tired","C106868","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Some more questions about your cough and breathlessness: Coughing makes me tired.","SGRQ-C - Coughing Makes Me Tired | SGRQC1-Coughing Makes Me Tired | SGRQC116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828147","SGRQ-C - Short of Breath When Talk","C106869","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Some more questions about your cough and breathlessness: I am short of breath when I talk.","SGRQ-C - Short of Breath When Talk | SGRQC1-Short of Breath When Talk | SGRQC117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828148","SGRQ-C - Short of Breath When Bend Over","C106870","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Some more questions about your cough and breathlessness: I am short of breath when I bend over.","SGRQ-C - Short of Breath When Bend Over | SGRQC1-Short of Breath When Bend Over | SGRQC118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828178","SGRQ-C - Coughing Disturbs My Sleep","C106871","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Some more questions about your cough and breathlessness: My coughing or breathing disturbs my sleep.","SGRQ-C - Coughing Disturbs My Sleep | SGRQC1-Coughing Disturbs My Sleep | SGRQC119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830923","C-SSRS Already Enrolled Subjects - Number of Aborted Suicide Attempts (Since Study Start)","C107071","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Total number of aborted. (Since Study Start).","C-SSRS Already Enrolled Subjects - Number of Aborted Suicide Attempts (Since Study Start) | CSS05-Number of Aborted Attempts-Since | CSS0518B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830956","C-SSRS Already Enrolled Subjects - Description of Aborted Suicide Attempt","C107072","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Description of aborted attempt.","C-SSRS Already Enrolled Subjects - Description of Aborted Suicide Attempt | CSS05-Aborted Attempt, Describe | CSS0518C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830917","C-SSRS Already Enrolled Subjects - Preparatory Acts or Behaviors Toward Suicide Attempt (Since Study Start)","C107074","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Have you taken any steps towards making a suicide attempt or preparing to kill yourself (such as collecting pills, getting a gun, giving valuables away or writing a suicide note)? (Since Study Start).","C-SSRS Already Enrolled Subjects - Preparatory Acts or Behaviors Toward Suicide Attempt (Since Study Start) | CSS05-Preparatory Acts/Behavior-Since | CSS0519B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0662932","IHH protein, human","C106448","Indian hedgehog protein (411 aa, ~45 kDa) is encoded by the human IHH gene. This protein is involved in both bone growth patterning and morphogenesis.","Indian Hedgehog Protein | Indian Hedgehog (Drosophila) Homolog | Indian Hedgehog Homolog | Indian Hedgehog Homolog (Drosophila)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0540463","Podocalyxin, Human","C106450","Podocalyxin (558 aa, ~59 kDa) is encoded by the human PODXL gene. This protein plays a role in both cell migration and cell-cell adhesion.","Podocalyxin | GCTM-2 Antigen | Gp200 | PC | PCLP-1 | PODXL | Podocalyxin-Like Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815277","GAS1 wt Allele","C106452","Human GAS1 wild-type allele is located within 9q21.3-q22 and is approximately 3 kb in length. This allele, which encodes growth arrest-specific protein 1, is involved in cell growth suppression through cell cycle arrest. Mutations in this gene play a role in holoprosencephaly.","GAS1 wt Allele | GAS-1 | Growth Arrest-Specific 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823486","TRIAP1 Gene","C106453","This gene is involved in the inhibition of apoptosis.","TRIAP1 Gene | TP53 Regulated Inhibitor of Apoptosis 1 Gene | TRIAP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831716","ADCS-ADL MCI - Drive a Car","C106960","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject drive a car?","ADCS-ADL MCI - Drive a Car | ADL03-Drive Car | ADL0319",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831727","ADCS-ADL MCI - Description of Optimal Performance of Driving Car","C106961","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, which best describes his or her optimal performance.","ADCS-ADL MCI - Description of Optimal Performance of Driving Car | ADL03-Drive Car Optimal Performance | ADL0319A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831671","ADCS-ADL MCI - Take Medications Regularly","C106962","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) During the past 4 weeks, did subject take his or her medications regularly?","ADCS-ADL MCI - Take Medications Regularly | ADL03-Take Medications Regularly | ADL0320",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831725","ADCS-ADL MCI - Description of Taking Medications Regularly","C106963","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, was this.","ADCS-ADL MCI - Description of Taking Medications Regularly | ADL03-Take Medications Performance | ADL0320A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831735","ADCS-ADL MCI - Carry Through Complex Activities to Completion","C106964","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) During the past 4 weeks, did subject usually carry through complex or time-consuming activities to completion?","ADCS-ADL MCI - Carry Through Complex Activities to Completion | ADL03-Complete Complex Activities | ADL0321",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831730","ADCS-ADL MCI - Description of Extent Needing Reminder","C106965","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, which best describes extent to which he or she needed reminders.","ADCS-ADL MCI - Description of Extent Needing Reminder | ADL03-Extent Needed Reminders | ADL0321A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831711","ADCS-ADL MCI - Initiate Complex Daily Activities","C106966","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) During the past 4 weeks, to what extent did subject initiate complex daily activities or projects (e.g., hobbies, travel)?","ADCS-ADL MCI - Initiate Complex Daily Activities | ADL03-Initiate Complex Activities | ADL0322",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831662","ADCS-ADL MCI - Time Taken to Complete Complex Activities","C106967","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) During the past 4 weeks, how long did it usually take subject to complete complex or time-consuming tasks or activities?","ADCS-ADL MCI - Time Taken to Complete Complex Activities | ADL03-Time to Complete Complex Tasks | ADL0323",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831714","ADCS-ADL MCI - Extenuating Circumstance","C106968","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Has an extenuating circumstance (such as a physical health problem, change in residence, change in support network, death of a family member, etc.) contributed to a recent alteration in the subject's activities of daily living?","ADCS-ADL MCI - Extenuating Circumstance | ADL03-Extenuating Circumstances | ADL0324",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449424","Gallium Ga 68-labeled Affibody ABY-025","C107163","A radioconjugate composed of an optimized affibody conjugated, via its C-terminal cysteine, to maleimide-DOTA, and linked to the radioisotope gallium Ga 68, with potential use as a tracer for human epidermal growth factor receptor type 2 (HER2; ErbB2)-expressing tumors using positron emission tomography (PET). Upon intravenous administration of the gallium Ga 68-labeled affibody ABY-025, the affibody targets HER2-expressing tumor cells. This facilitates both detection of HER2-expressing tumor cells and assessment of responses to HER2-targeting chemotherapeutic agents during PET imaging. The affibody is an optimized antibody mimetic based on a 6.5-kDa 3-helical bundle Z domain derived from the staphylococcal protein A (Z her2:342); the nonbinding surface of the Z domain is reengineered (Z her2:2891) to increase binding affinity for HER2 and to improve tumor imaging. HER2 is overexpressed in many cancer cell types.","Gallium Ga 68-labeled Affibody ABY-025 | Gallium Ga 68-[maleimide-DOTA-Cys61]-ZHER2:2891-Cys | [68Ga]ABY-025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447592","Calcium and Integrin-Binding Protein 1, Human","C106109","Calcium and integrin-binding protein 1 (191 aa, ~22 kDa) is encoded by the human CIB1 gene. This protein plays a role in calcium binding, integrin activity regulation, apoptosis modulation and megakaryocyte differentiation.","Calcium and Integrin-Binding Protein 1 | CIB | CIB1 | CIBP | Calcium- and Integrin-Binding Protein | Calmyrin | DNA-Dependent Protein Kinase Interacting Protein | DNA-PKcs-Interacting Protein | KIP | Kinase-Interacting Protein | SIP2-28 | SNK-Interacting Protein 2-28",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813176","PTPRD wt Allele","C106111","Human PTPRD wild-type allele is located within 9p23-p24.3 and is approximately 2298 kb in length. This allele, which encodes receptor-type tyrosine-protein phosphatase delta protein, plays a role in both phosphotyrosine dephosphorylation and dendrite morphogenesis.","PTPRD wt Allele | HPTP | HPTPD | HPTPDELTA | PTPD | Protein Tyrosine Phosphatase, Receptor Type, D wt Allele | Protein-Tyrosine Phosphatase, Receptor-Type, D Gene | Protein-Tyrosine Phosphatase, Receptor-Type, Delta Gene | RPTPDELTA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1448876","Receptor-Type Tyrosine-Protein Phosphatase Delta, Human","C106112","Receptor-type tyrosine-protein phosphatase delta (1912 aa, ~215 kDa) is encoded by the human PTPRD gene. This protein is involved in both dendrite morphogenesis and phosphotyrosine dephosphorylation.","Receptor-Type Tyrosine-Protein Phosphatase Delta | EC 3.1.3.48 | PTPRD | Protein Tyrosine Phosphatase, Receptor Type, Delta Polypeptide | Protein-Tyrosine Phosphatase Delta | Protein-Tyrosine Phosphatase-Delta | R-PTP-Delta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814147","PTPRK wt Allele","C106114","Human PTPRK wild-type allele is located within 6q22.2-q22.3 and is approximately 552 kb in length. This allele, which encodes receptor-type tyrosine-protein phosphatase kappa protein, plays a role in cell-cell adhesion, cell migration and receptor signaling.","PTPRK wt Allele | PTPK | Protein Tyrosine Phosphatase, Receptor Type, K wt Allele | R-PTP-Kappa | RP3-480J14.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1452493","Receptor-Type Tyrosine-Protein Phosphatase Kappa, Human","C106115","Receptor-type tyrosine-protein phosphatase kappa (1439 aa, ~162 kDa) is encoded by the human PTPRK gene. This protein is involved in protein dephosphorylation, cell migration, receptor signaling and cell-cell contact.","Receptor-Type Tyrosine-Protein Phosphatase Kappa | EC 3.1.3.48 | PTPRK | Protein Tyrosine Phosphatase Kappa | Protein Tyrosine Phosphatase, Receptor Type, K | Protein-Tyrosine Phosphatase Kappa | Protein-Tyrosine Phosphatase, Receptor Type, Kappa | R-PTP-Kappa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447355","anti-CD70 monoclonal antibody ARGX-110","C106116","A defucosylated, humanized IgG1 monoclonal antibody directed against the extracellular domain of the human CD70 molecule with potential antineoplastic activity. Upon administration, cusatuzumab selectively binds to, and neutralizes the activity of CD70, which may also induce an antibody-dependent cellular cytotoxicity (ADCC) response against CD70-expressing tumor cells. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on a number of solid and hematological tumors. Its overexpression may play an important role in evasion of immune surveillance.","Cusatuzumab | ARGX-110 | Anti-CD70 Monoclonal Antibody ARGX-110 | CUSATUZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447356","T1E28z CAR-expressing Autologous CD4-positive T Lymphocytes","C106117","Autologous CD4 positive T-lymphocytes engineered to express the chimeric antigen receptor (CAR) T1E28z containing the ErbB ligand, T1E, fused to the hinge region, transmembrane domain and endodomain of CD28 and the CD3zeta endodomain, with potential immunomodulating and antineoplastic activities. T1E, a chimeric polypeptide containing the N-terminus of human transforming growth factor (TGF)-alpha fused to the C-terminus of epidermal growth factor (EGF), binds to ErbB1 homodimers and heterodimers as well as ErbB2/3 heterodimers, but not to ErbB2 or erbB3 alone. Upon intratumoral administration, the promiscuous ErbB ligand T1E of the T1E28z CAR-expressing autologous CD4-positive T lymphocytes binds to the specific ErbB homo- and heterodimers on tumor cells. This induces selective toxicity in ErbB-expressing tumor cells resulting in tumor cell lysis. ErbB1, ErbB2 and ErbB3, members of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, are frequently overexpressed in solid tumors and play key roles in tumor cell proliferation and tumor angiogenesis.","T1E28z CAR-expressing Autologous CD4-positive T Lymphocytes | 4ab T1E28z Positive T-cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830949","C-SSRS Already Enrolled Subjects - Description of Preparatory Acts or Behaviors Toward Suicide Attempt","C107075","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Description of preparatory acts or behavior.","C-SSRS Already Enrolled Subjects - Description of Preparatory Acts or Behaviors Toward Suicide Attempt | CSS05-Preparatory Acts/Behavior, Descr | CSS0519C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830913","C-SSRS Already Enrolled Subjects - Suicidal Behavior (Prior to Study Entry)","C107076","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Suicidal behavior was present during the assessment period? (Prior to Study Entry).","C-SSRS Already Enrolled Subjects - Suicidal Behavior (Prior to Study Entry) | CSS05-Suicidal Behavior-Prior | CSS0520A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830912","C-SSRS Already Enrolled Subjects - Suicidal Behavior (Since Study Start)","C107077","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Suicidal behavior was present during the assessment period? (Since Study Start).","C-SSRS Already Enrolled Subjects - Suicidal Behavior (Since Study Start) | CSS05-Suicidal Behavior-Since | CSS0520B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830962","C-SSRS Already Enrolled Subjects - Completed Suicide (Prior to Study Entry)","C107078","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Completed suicide? (Prior to Study Entry)","C-SSRS Already Enrolled Subjects - Completed Suicide (Prior to Study Entry) | CSS05-Completed Suicide-Prior | CSS0521A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830961","C-SSRS Already Enrolled Subjects - Completed Suicide (Since Study Start)","C107079","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Completed suicide? (Since Study Start)","C-SSRS Already Enrolled Subjects - Completed Suicide (Since Study Start) | CSS05-Completed Suicide-Since | CSS0521B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830933","C-SSRS Already Enrolled Subjects - Most Recent Suicide Attempt Actual Lethality/Medical Damage","C107081","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Most recent attempt actual lethality/medical damage.","C-SSRS Already Enrolled Subjects - Most Recent Suicide Attempt Actual Lethality/Medical Damage | CSS05-Most Recent Attempt Damage | CSS0522B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830931","C-SSRS Already Enrolled Subjects - Most Recent Suicide Attempt Potential Lethality","C107082","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Most recent attempt potential lethality.","C-SSRS Already Enrolled Subjects - Most Recent Suicide Attempt Potential Lethality | CSS05-Most Recent Attempt Potential | CSS0522C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830935","C-SSRS Already Enrolled Subjects - Most Lethal Suicide Attempt Date","C107083","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Most lethal attempt date.","C-SSRS Already Enrolled Subjects - Most Lethal Suicide Attempt Date | CSS05-Most Lethal Attempt Date | CSS0523A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830936","C-SSRS Already Enrolled Subjects - Most Lethal Suicide Attempt Actual Lethality/Medical Damage","C107084","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Most lethal attempt actual lethality/medical damage.","C-SSRS Already Enrolled Subjects - Most Lethal Suicide Attempt Actual Lethality/Medical Damage | CSS05-Most Lethal Attempt Damage | CSS0523B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0057256","Defensins","C1063","Highly conserved cysteine-rich peptides that play a role in host defense, and may be produced in response to microbial products or proinflammatory cytokines. Defensins bind to microbial cell membranes and can become aggregate either to form pore-like structures or to encapsulate the microbe. These peptide aggregates lead to destabilization of the cell membrane and, subsequently, to lysis of the microbe.","Defensins | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827376","BDI - Functional Impairment","C106701","Baseline Dyspnea Index (BDI) Functional impairment.","BDI - Functional Impairment | BDI01-Functional Impairment | BDI0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831386","BDI - Magnitude of Task","C106702","Baseline Dyspnea Index (BDI) Magnitude of task.","BDI - Magnitude of Task | BDI01-Magnitude of Task | BDI0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831387","BDI - Magnitude of Effort","C106703","Baseline Dyspnea Index (BDI) Magnitude of effort.","BDI - Magnitude of Effort | BDI01-Magnitude of Effort | BDI0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827853","TDI - Change in Functional Impairment","C106704","Transition Dyspnea Index (TDI) Change in functional impairment.","TDI - Change in Functional Impairment | TDI01-Change in Functional Impairment | TDI0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827851","TDI - Change in Magnitude of Task","C106705","Transition Dyspnea Index (TDI) Change in magnitude of task.","TDI - Change in Magnitude of Task | TDI01-Change in Magnitude of Task | TDI0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831661","ADCS-ADL MCI - Travel Outside Home","C106910","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject get around (or travel) outside of his or her home?","ADCS-ADL MCI - Travel Outside Home | ADL03-Get Around Outside Home | ADL0311",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831726","ADCS-ADL MCI - Description of Optimal Performance of Travelling Outside Home","C106911","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, which best describes his or her optimal performance.","ADCS-ADL MCI - Description of Optimal Performance of Travelling Outside Home | ADL03-Get Around Optimal Performance | ADL0311A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831667","ADCS-ADL MCI - Talk About Current Events","C106912","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject talk about current events?","ADCS-ADL MCI - Talk About Current Events | ADL03-Talk About Current Events | ADL0312",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831665","ADCS-ADL MCI - Talk About Regional, National or International Events","C106913","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, did subject talk about regional, national, or international events?","ADCS-ADL MCI - Talk About Regional, National or International Events | ADL03-Regional, National, International | ADL0312A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831666","ADCS-ADL MCI - Talk About Outside Home Events","C106914","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, did subject talk about events outside home involving family, friends, or neighbors?","ADCS-ADL MCI - Talk About Outside Home Events | ADL03-Talk About Outside Events | ADL0312B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831670","ADCS-ADL MCI - Talk About at Home Events","C106915","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, did subject talk about events that occurred at home that he or she took part in or watched?","ADCS-ADL MCI - Talk About at Home Events | ADL03-Talk About at Home Events | ADL0312C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831732","ADCS-ADL MCI - Converse Without Repeating","C106916","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, did subject converse without repeating him or herself, or asking the same questions repeatedly?","ADCS-ADL MCI - Converse Without Repeating | ADL03-Talk Without Repeating | ADL0312D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3661349","DMS612","C107164","A dimethane sulfonate derivative and alkylating agent with a structure similar to other alkylating agents such as chlorambucil, busulfan and melphalan, with potential antineoplastic activity. Although the exact mechanism of action has yet to be fully elucidated, benzaldehyde dimethane sulfonate alkylates DNA, which results in DNA double strand breaks, inhibition of DNA replication, cell cycle arrest and cell death. In addition, this agent is metabolized by the enzyme aldehyde dehydrogenase (ALDH) into the active carboxylic acid metabolite benzoic acid dimethane sulfonate (BA), which further contributes to its alkylating activity. Unlike other alkylating agents, benzaldehyde dimethane sulfonate has demonstrated antitumor activity in renal cell carcinoma.","Benzaldehyde Dimethane Sulfonate | BEN | DMS-612 | DMS612 | NSC 281612",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449425","Carbohydrate Supplement Drink","C107165","A nutritional supplement drink containing 12.5% carbohydrates, which may enhance recovery following gastrointestinal (GI) surgery. Oral intake of the carbohydrate drink before surgery may prevent insulin resistance and associated hyperglycemia. It may also maintain adequate protein balance and muscle function. Ultimately, giving carbohydrates immediately before surgery may improve overall recovery time and return of GI function. It may also decrease muscle loss.","Carbohydrate Supplement Drink | Carbohydrate Drink",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449426","pBCAR3 Phosphopeptide-tetanus Peptide Vaccine","C107166","A vaccine composed of a phosphorylated peptide from the tumor associated antigen breast cancer anti-estrogen resistance-3 (BCAR3) and a tetanus-derived peptide, with potential immunomodulating and antineoplastic activities. Upon administration of pBCAR3 phosphopeptide-tetanus peptide vaccine, the pBCAR3 phosphopeptide may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against phosphopeptide-containing tumor cells. The tetanus peptide serves as an immunoadjuvant and induces a helper T-cell response, which may help stimulate an immune response against the pBCAR3-expressing melanoma tumor cells. BCAR3 is upregulated in a variety of cancer cells.","pBCAR3 Phosphopeptide-tetanus Peptide Vaccine | pBCAR3-phosphopeptide Plus Tet Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449427","pIRS2 Phosphopeptide-tetanus Peptide Vaccine","C107167","A vaccine composed of a phosphorylated peptide from the tumor associated antigen insulin receptor substrate-2 (IRS2) and a tetanus-derived peptide, with potential immunomodulating and antineoplastic activities. Upon administration of pIRS2 phosphopeptide-tetanus peptide vaccine, the pIRS2 phosphopeptide may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against phosphopeptide-containing tumor cells. The tetanus peptide serves as an immunoadjuvant and induces a helper T-cell response which may help stimulate an immune response against the pIRS2-expressing melanoma tumor cells. IRS2 is upregulated in a variety of cancer cells.","pIRS2 Phosphopeptide-tetanus Peptide Vaccine | pIRS2-phosphopeptide Plus Tet Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449428","pBCAR3/pIRS2-Phosphopeptide-tetanus Peptide Vaccine","C107168","A vaccine composed of phosphorylated peptides from the tumor associated antigens breast cancer anti-estrogen resistance-3 (BCAR3) and insulin receptor substrate-2 (IRS2) and a tetanus-derived peptide, with potential immunomodulating and antineoplastic activities. Upon administration of pBCAR3/pIRS2 phosphopeptide-tetanus peptide vaccine, the pBCAR3/pIRS2 phosphopeptide may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing either phosphopeptide. The tetanus peptide serves as an immunoadjuvant and induces a helper T-cell response which may help stimulate an immune response against pBCAR3 and pIRS2-expressing melanoma tumor cells. BCAR3 and IRS2 are upregulated in a variety of cancer cells.","pBCAR3/pIRS2-Phosphopeptide-tetanus Peptide Vaccine | 2-MpP Phosphopeptide-tetanus Peptide Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449429","Allogeneic HLA-A2/4-1BB ligand-expressing Melanoma Vaccine","C107169","An allogeneic melanoma cell vaccine derived from a cell line with high expression of melanoma associated antigens and genetically modified to express both HLA-A2 and 4-1BB ligand, with potential immunostimulating and antineoplastic activities. Upon administration, the 4-1BB ligand of the allogeneic HLA-A2/4-1BB ligand-expressing melanoma vaccine binds to 4-1BB on activated T-lymphocytes, which induces a strong immune response against HLA-A2 positive melanoma cells.","Allogeneic HLA-A2/4-1BB ligand-expressing Melanoma Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831203","Captive Bolt and Exsanguination Euthanasia","C106506","A method of euthanasia whereby a subject is shot in the brain with a captive bolt pistol causing immediate and permanent unconsciousness or death, followed by draining the body of blood.","Captive Bolt and Exsanguination Euthanasia | CAPTIVE BOLT EXSANGUINATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827152","Xentuzumab","C106118","A humanized IgG1 insulin-like growth factor (IGF) monoclonal antibody targeting the IGF ligands 1 (IGF-1) and 2 (IGF-2), with potential antineoplastic activity. Upon administration, xentuzumab binds to both IGF-1 and IGF-2 and inhibits the binding of these ligands to their receptor, IGF-1R. This blocks the insulin growth factor (IGF) signaling pathway, which is upregulated in a number of cancer cell types and plays a key role in cancer cell proliferation and chemoresistance. In addition, BI 836845 prevents the binding of IGF-2 to insulin receptor variant A (IR-A), preventing its activation.","Xentuzumab | BI 836845 | Immunoglobulin G1, Anti-(Human Insulin-like Growth Factor I) (Human Monoclonal PS05388 Heavy Chain), Disulfide with Human Monoclonal PS05388 Light Chain, Dimer | XENTUZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433830","MUC16-targeted antibody-drug conjugate DMUC5754A","C106119","An antibody drug conjugate (ADC) consisting of a humanized IgG1 monoclonal antibody targeting the MUC16 protein (CA-125) conjugated to, via a cleavable linker, the antimicrotubulin agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. The monoclonal antibody moiety of sofituzumab vedotin selectively binds to MUC16. After internalization of the drug conjugate and proteolytic cleavage of the linker, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M-phase growth arrest and tumor cell apoptosis. MUC16, a transmembrane protein, is overexpressed on the cell surface of more than 80 percent of ovarian cancer cells but not on healthy cells.","Sofituzumab Vedotin | DMUC5754A | SOFITUZUMAB VEDOTIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3853940","p53-HDM2 Interaction Inhibitor MI-773","C106120","An orally available spiro-oxindole HDM2 (human double minute 2) antagonist with potential antineoplastic activity. Upon oral administration, the p53-HDM2 protein-protein interaction inhibitor MI-773 binds to HDM2, preventing the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored, which may result in the restoration of p53 signaling and lead to the p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger protein and a negative regulator of the p53 pathway, is often overexpressed in cancer cells. It has been implicated in cancer cell proliferation and survival.","p53-HDM2 Interaction Inhibitor MI-773 | MI-773 | SAR-405838 | SAR405838 | p53-MDM2 Interaction Inhibitor MI-773",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714905","Quantity Final Containers Returned","C106328","Quantity of final containers returned.","Quantity Final Containers Returned | Returned",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829538","INPP4B wt Allele","C106329","Human INPP4B wild-type allele is located in the vicinity of 4q31.21 and is approximately 824 kb in length. This allele, which encodes inositol polyphosphate 4-phosphatase type II protein, plays a role in the regulation of phosphatidylinositol signaling and metabolism.","INPP4B wt Allele | Inositol Polyphosphate-4-Phosphatase Type II B wt Allele | Inositol Polyphosphate-4-Phosphatase, Type II, 105-kD Gene | Inositol Polyphosphate-4-Phosphatase, Type II, 105kD Gene | Inositol Polyphosphate-4-Phosphatase, Type II, 105kDa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2002106","Type II Inositol 3,4-Bisphosphate 4-Phosphatase, Human","C106330","Inositol polyphosphate 4-phosphatase type II (924 aa, ~105 kDa) is encoded by the human INPP4B gene. This protein is involved in the modulation of phosphatidylinositol metabolism and signaling.","Inositol Polyphosphate 4-Phosphatase Type II | 4-Phosphatase II | EC 3.1.3.66 | INPP4B | Inositol Polyphosphate 4-Phosphatase II | Inositol Polyphosphate-4-Phosphatase Type II | Type II Inositol 3,4-Bisphosphate 4-Phosphatase | Type II Inositol-3,4-Bisphosphate 4-Phosphatase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420165","SLC27A3 Gene","C106331","This gene plays a role in fatty acid metabolism.","SLC27A3 Gene | SLC27A3 | Solute Carrier Family 27 (Fatty Acid Transporter), Member 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811062","SLC27A3 wt Allele","C106332","Human SLC27A3 wild-type allele is located in the vicinity of 1q21.3 and is approximately 6 kb in length. This allele, which encodes long-chain fatty acid transport protein 3, is involved in fatty acid-acyl-CoA synthesis.","SLC27A3 wt Allele | ACSVL3 | FATP3 | PSEC0067 | Solute Carrier Family 27 (Fatty Acid Transporter), Member 3 wt Allele | UNQ367/PRO703 | VLCS-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1955972","Non-Receptor Type Protein Tyrosine Phosphatase","C106408","A group of cytosolic enzymes that specifically remove tyrosine-bound phosphate groups from many phosphoproteins, including many enzymes phosphorylated by a tyrosine kinase. These proteins play a role in the modulation of tyrosine phosphorylation and dephosphorylation in cellular signaling pathways.","Non-Receptor Type Protein Tyrosine Phosphatase | Cytosolic Protein Tyrosine Phosphatase | Non-Receptor PTPase | Non-Receptor Protein Tyrosine Phosphatase | PTPN | Protein Tyrosine Phosphatase Non-Receptor Type | Tyrosine-Protein Phosphatase Non-Receptor Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828359","Receptor-Type Protein Tyrosine Phosphatase Gene","C106409","A family of genes that encode transmembrane receptors, which also have protein tyrosine phosphatase activity. These genes are involved in both the removal of phosphate groups from tyrosine residues and the modulation of signaling pathways.","Receptor-Type Protein Tyrosine Phosphatase Gene | Receptor Type PTP Gene | Receptor Tyrosine Phosphatase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828443","PTPRE Gene Product","C106411","A protein encoded by the PTPRE gene.","PTPRE Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830987","CPE Gene Product","C106412","A protein encoded by the CPE gene.","CPE Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2243119","ATRIP Gene","C106413","This gene is involved in the DNA damage checkpoint.","ATRIP Gene | ATR Interacting Protein Gene | ATRIP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813162","ATRIP wt Allele","C106414","Human ATRIP wild-type allele is located in the vicinity of 3p21.31 and is approximately 19 kb in length. This allele, which encodes ATR-interacting protein, plays a role in cell cycle checkpoint signaling.","ATRIP wt Allele | ATR Interacting Protein wt Allele | ATR-Interacting Protein Gene | FLJ12343 | MGC20625 | MGC21482 | MGC26740 | hCG_1997849",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831684","ADCS-ADL MCI - Read More Than 5 Minutes","C106917","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject read a magazine, newspaper or book for more than 5 minutes at a time?","ADCS-ADL MCI - Read More Than 5 Minutes | ADL03-Read More Than 5 Minutes | ADL0313",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831664","ADCS-ADL MCI - Talk Within 1 Hour After Reading","C106919","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, did subject usually talk about what he or she read while or shortly after reading (less than 1 hour)?","ADCS-ADL MCI - Talk Within 1 Hour After Reading | ADL03-Talk Within 1 Hour After Reading | ADL0313B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831663","ADCS-ADL MCI - Talk Within 24 Hours After Reading","C106920","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, did subject usually talk about what he or she read 1-24 hours after reading?","ADCS-ADL MCI - Talk Within 24 Hours After Reading | ADL03-Talk Within 1 Day After Reading | ADL0313C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831647","ADCS-ADL MCI - Watch Television","C106921","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject watch television?","ADCS-ADL MCI - Watch Television | ADL03-Watch Television | ADL0314",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831668","ADCS-ADL MCI - Talk About Content of Program While Watching","C106923","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, did subject usually talk about the content of a program while watching it?","ADCS-ADL MCI - Talk About Content of Program While Watching | ADL03-Talk About TV Content While Watch | ADL0314B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2716679","PH Domain Leucine-Rich Repeat-Containing Protein Phosphatase 2, Human","C107127","PH domain leucine-rich repeat-containing protein phosphatase 2 (1323 aa, ~147 kDa) is encoded by the human PHLPP2 gene. This protein is involved in the regulation of apoptosis and may act as a tumor suppressor.","PH Domain Leucine-Rich Repeat-Containing Protein Phosphatase 2 | EC 3.1.3.16 | PH Domain Leucine-Rich Repeat-Containing Protein Phosphatase-Like | PH Domain and Leucine Rich Repeat Protein Phosphatase-Like | PH Domain and Leucine-Rich Repeat Protein Phosphatase-Like | PHLPP-Like | PHLPP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814435","ITGAE wt Allele","C107129","Human ITGAE wild-type allele is located in the vicinity of 17p13 and is approximately 87 kb in length. This allele, which encodes integrin alpha-E protein, is involved in cell adhesion and may play a role in activation of intestinal intraepithelial lymphocytes.","ITGAE wt Allele | CD103 | HUMINAE | Human Mucosal Lymphocyte Antigen 1, Alpha Subunit Gene | Integrin, Alpha E (Antigen CD103, Human Mucosal Lymphocyte Antigen 1; Alpha Polypeptide) wt Allele | Integrin, Alpha-E Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831198","Carbon Dioxide and Exsanguination Euthanasia","C106507","A method of euthanasia whereby a subject inhales carbon dioxide until asphyxiation occurs and then the body is immediately drained of blood.","Carbon Dioxide and Exsanguination Euthanasia | Asphyxia Exsanguination | CARBON DIOXIDE EXSANGUINATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831057","Coil Strength","C106510","The maximum voltage allowable to pass through an electromagnetic coil.","Coil Strength | COILSTR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810626","Long-Chain Fatty Acid Transport Protein 3","C106333","Long-chain fatty acid transport protein 3 (730 aa, ~79 kDa) is encoded by the human SLC27A3 gene. This protein plays a role in the metabolism of fatty acids.","Long-Chain Fatty Acid Transport Protein 3 | EC 6.2.1.- | FATP-3 | Fatty Acid Transport Protein 3 | SLC27A3 | Solute Carrier Family 27 Member 3 | VLCS-3 | Very Long-Chain Acyl-CoA Synthetase Homolog 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420166","SLC27A4 Gene","C106334","This gene is involved in both fatty acid transport and metabolism.","SLC27A4 Gene | SLC27A4 | Solute Carrier Family 27 (Fatty Acid Transporter), Member 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811063","SLC27A4 wt Allele","C106335","Human SLC27A4 wild-type allele is located in the vicinity of 9q34.11 and is approximately 21 kb in length. This allele, which encodes long-chain fatty acid transport protein 4, plays a role in both the transport and metabolism of fatty acids.","SLC27A4 wt Allele | ACSVL4 | FATP4 | IPS | Solute Carrier Family 27 (Fatty Acid Transporter), Member 4 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421286","UBE2L3 Gene","C106337","This gene plays a role in protein ubiquitination.","UBE2L3 Gene | UBE2L3 | Ubiquitin-Conjugating Enzyme E2L 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812289","UBE2L3 wt Allele","C106338","Human UBE2L3 wild-type allele is located in the vicinity of 22q11.2 and is approximately 75 kb in length. This allele, which encodes ubiquitin-conjugating enzyme E2 L3 protein, is involved in the ubiquitination of proteins.","UBE2L3 wt Allele | E2-F1 | L-UBC | UBCH7 | UbcM4 | Ubiquitin-Conjugating Enzyme E2L 3 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0753687","Ubiquitin-Conjugating Enzyme E2 L3, Human","C106339","Ubiquitin-conjugating enzyme E2 L3 (154 aa, ~18 kDa) is encoded by the human UBE2L3 gene. This protein plays a role in E2 ubiquitin ligase activity.","Ubiquitin-Conjugating Enzyme E2 L3 | E2 Ubiquitin-Conjugating Enzyme L3 | EC 2.3.2.23 | EC 6.3.2.19, Formerly | L-UBC | UBE2L3 | UbcH7 | Ubiquitin Carrier Protein L3 | Ubiquitin-Conjugating Enzyme E2-F1 | Ubiquitin-Conjugating Enzyme UBCH7 | Ubiquitin-Protein Ligase L3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815266","FAM131B wt Allele","C106341","Human FAM131B wild-type allele is located in the vicinity of 7q34 and is approximately 9 kb in length. This allele, which encodes protein FAM131B, has not been characterized.","FAM131B wt Allele | Family with Sequence Similarity 131 Member B wt Allele | Family with Sequence Similarity 131, Member B Gene | KIAA0773",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447410","H(+)/Cl(-) Exchange Transporter 7, Human","C105879","H(+)/Cl(-) exchange transporter 7 (805 aa, ~89 kDa) is encoded by the human CLCN7 gene. This protein plays a role in proton-coupled, chloride anion transport.","H(+)/Cl(-) Exchange Transporter 7 | CLCN7 | Chloride Channel 7 Alpha Subunit | Chloride Channel Protein 7 | ClC-7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826967","CDISC Questionnaire ADCS-ADL MCI Test Name Terminology","C106650","Test names of questionnaire questions associated with the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory MCI (ADCS-ADL MCI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire ADCS-ADL MCI Test Name Terminology | ADL03TN | Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory MCI Version Questionnaire Test Name | QS-ADCS-ADL MCI TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826966","CDISC Questionnaire ADCS-ADL MCI Test Code Terminology","C106651","Test codes of questionnaire questions associated with the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory MCI (ADCS-ADL MCI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire ADCS-ADL MCI Test Code Terminology | ADL03TC | Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory MCI Version Questionnaire Test Code | QS-ADCS-ADL MCI TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826856","CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology","C106652","Test names of questionnaire questions associated with the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory Severe Dementia (ADCS-ADL Severe Dementia) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology | ADL02TN | Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory Severe Dementia Version Questionnaire Test Name | QS-ADCS-ADL Severe Dementia TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826965","CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology","C106653","Test codes of questionnaire questions associated with the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory Severe Dementia (ADCS-ADL Severe Dementia) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology | ADL02TC | Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory Severe Dementia Version Questionnaire Test Code | QS-ADCS-ADL Severe Dementia TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826960","QS-BDI TEST","C106654","Test names of clinical classification questions associated with the Baseline Dyspnea Index (BDI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification BDI Test Name Terminology | BDI01TN | Baseline Dyspnea Index Clinical Classification Test Name | QS-BDI TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826959","QS-BDI TESTCD","C106655","Test codes of clinical classification questions associated with the Baseline Dyspnea Index (BDI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification BDI Test Code Terminology | BDI01TC | Baseline Dyspnea Index Clinical Classification Test Code | QS-BDI TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826898","QS-TDI TEST","C106656","Test names of clinical classification questions associated with the Transition Dyspnea Index (TDI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification TDI Test Name Terminology | QS-TDI TEST | TDI01TN | Transition Dyspnea Index Clinical Classification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826897","QS-TDI TESTCD","C106657","Test codes of clinical classification questions associated with the Transition Dyspnea Index (TDI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification TDI Test Code Terminology | QS-TDI TESTCD | TDI01TC | Transition Dyspnea Index Clinical Classification Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826952","CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology","C106658","Test names of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology | CSS05TN | Columbia-Suicide Severity Rating Scale Already Enrolled Subjects Questionnaire Test Name | QS-C-SSRS Already Enrolled Subjects TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826951","CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology","C106659","Test codes of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology | CSS05TC | Columbia-Suicide Severity Rating Scale Already Enrolled Subjects Questionnaire Test Code | QS-C-SSRS Already Enrolled Subjects TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814419","FST wt Allele","C107132","Human FST wild-type allele is located in the vicinity of 5q11.2 and is approximately 7 kb in length. This allele, which encodes follistatin protein, plays a role in inhibiting both follicle-stimulating hormone release and activin-mediated cell growth.","FST wt Allele | FS | Follistatin wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1609759","FST protein, human","C107133","Follistatin (344 aa, ~38 kDa) is encoded by the human FST gene. This protein is involved in inhibiting both activin-mediated cell growth and follicle-stimulating hormone release.","Follistatin | Activin-Binding Protein | FS | FST | Follistatin Isoform FST317",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813582","NDN wt Allele","C107135","Human NDN wild-type allele is located in the vicinity of 15q11.2 and is approximately 2 kb in length. This allele, which encodes necdin protein, is involved in suppression of cell growth in postmitotic neurons. Mutations in this gene are associated with Prader-Willi syndrome.","NDN wt Allele | HsT16328 | Necdin (Mouse) Homolog Gene | Necdin Homolog (Mouse) Gene | Necdin Homolog Gene | Necdin, MAGE Family Member wt Allele | Necdin, Melanoma Antigen (MAGE) Family Member Gene | Necdin, Melanoma Antigen (MAGE) Family Member wt Allele | PWCR | Prader-Willi Syndrome Chromosome Region Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448164","Necdin","C107136","Necdin (321 aa, ~36 kDa) is encoded by the human NDN gene. This protein plays a role in suppression of cell growth in postmitotic neurons.","Necdin | NDN | Necdin (Mouse) Homolog | Necdin Homolog | Necdin Homolog (Mouse) | Prader-Willi Syndrome Chromosome Region",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829378","Kinome","C107139","The set of all kinases expressed in a cell or contained in a genome.","Kinome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829930","GAS1 protein, human","C106454","Growth arrest-specific protein 1 (345 aa, ~36 kDa) is encoded by the human GAS1 gene. This protein plays a role in both cell cycle arrest and cell growth suppression.","Growth Arrest-Specific Protein 1 | GAS-1 | GAS1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812245","TRIAP1 wt Allele","C106455","Human TRIAP1 wild-type allele is located in the vicinity of 12q24.31 and is approximately 2 kb in length. This allele, which encodes TP53-regulated inhibitor of apoptosis 1, plays a role in the negative regulation of apoptosis.","TRIAP1 wt Allele | 15E1.1 | HSPC132 | MDM35 | Mitochondrial Distribution and Morphology 35 Homolog (S. cerevisiae) Gene | P53CSV | TP53 Regulated Inhibitor of Apoptosis 1 wt Allele | WF-1 | p53CSV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1567287","TP53-Regulated Inhibitor of Apoptosis 1, Human","C106456","TP53-regulated inhibitor of apoptosis 1 (76 aa, ~9 kDa) is encoded by the human TRIAP1 gene. This protein is involved in cell survival.","TP53-Regulated Inhibitor of Apoptosis 1 | Protein 15E1.1 | TRIAP1 | WF-1 | p53-Inducible Cell-Survival Factor | p53CSV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828421","RAB23 wt Allele","C106458","Human RAB23 wild-type allele is located in the vicinity of 6p11 and is approximately 33 kb in length. This allele, which encodes ras-related protein Rab-23, plays a role in both intracellular signaling and intracellular membrane trafficking. Mutations in this gene are associated with Carpenter syndrome.","RAB23 wt Allele | HSPC137 | RAB23, Member RAS Oncogene Family wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815109","Fetal Measurements Domain","C106522","A findings domain that captures individual fetal body and tissue weights, as well as growth measurements.","Fetal Measurements Domain | FM | Fetal Measurements",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830908","C-SSRS Baseline/Screening Version - Aborted Suicide Attempt (Past X Years)","C106746","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Has there been a time when you started to do something to try to end your life but you stopped yourself before you actually did anything? (Past X Years).","C-SSRS Baseline/Screening Version - Aborted Suicide Attempt (Past X Years) | CSS04-Aborted Attempt-P_Y | CSS0417B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830863","C-SSRS Baseline/Screening Version - Number of Aborted Suicide Attempts (Lifetime)","C106747","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Total number of aborted. (Lifetime).","C-SSRS Baseline/Screening Version - Number of Aborted Suicide Attempts (Lifetime) | CSS04-Number of Aborted Attempts-Life | CSS0418A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830895","C-SSRS Baseline/Screening Version - Description of Aborted Suicide Attempt","C106749","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Description of aborted attempt.","C-SSRS Baseline/Screening Version - Description of Aborted Suicide Attempt | CSS04-Aborted Attempt, Describe | CSS0418C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830857","C-SSRS Baseline/Screening Version - Preparatory Acts or Behaviors Toward Suicide Attempt (Lifetime)","C106750","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Have you taken any steps towards making a suicide attempt or preparing to kill yourself (such as collecting pills, getting a gun, giving valuables away or writing a suicide note)? (Lifetime).","C-SSRS Baseline/Screening Version - Preparatory Acts or Behaviors Toward Suicide Attempt (Lifetime) | CSS04-Preparatory Acts/Behavior-Life | CSS0419A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830856","C-SSRS Baseline/Screening Version - Preparatory Acts or Behaviors Toward Suicide Attempt (Past X Years)","C106751","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Have you taken any steps towards making a suicide attempt or preparing to kill yourself (such as collecting pills, getting a gun, giving valuables away or writing a suicide note)? (Past X Years).","C-SSRS Baseline/Screening Version - Preparatory Acts or Behaviors Toward Suicide Attempt (Past X Years) | CSS04-Preparatory Acts/Behavior-P_Y | CSS0419B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830888","C-SSRS Baseline/Screening Version - Description of Preparatory Acts or Behaviors Toward Suicide Attempt","C106752","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Description of preparatory acts or behavior.","C-SSRS Baseline/Screening Version - Description of Preparatory Acts or Behaviors Toward Suicide Attempt | CSS04-Preparatory Acts/Behav, Descr | CSS0419C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830852","C-SSRS Baseline/Screening Version - Suicidal Behavior (Lifetime)","C106753","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Suicidal behavior was present during the assessment period? (Lifetime).","C-SSRS Baseline/Screening Version - Suicidal Behavior (Lifetime) | CSS04-Suicidal Behavior-Life | CSS0420A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830851","C-SSRS Baseline/Screening Version - Suicidal Behavior (Past X Years)","C106754","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Suicidal behavior was present during the assessment period? (Past X Years).","C-SSRS Baseline/Screening Version - Suicidal Behavior (Past X Years) | CSS04-Suicidal Behavior-P_Y | CSS0420B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830871","C-SSRS Baseline/Screening Version - Most Recent Suicide Attempt Date","C106755","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Most recent attempt date.","C-SSRS Baseline/Screening Version - Most Recent Suicide Attempt Date | CSS04-Most Recent Attempt Date | CSS0421A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830872","C-SSRS Baseline/Screening Version - Most Recent Suicide Attempt Actual Lethality/Medical Damage","C106756","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Most recent attempt actual lethality/medical damage.","C-SSRS Baseline/Screening Version - Most Recent Suicide Attempt Actual Lethality/Medical Damage | CSS04-Most Recent Attempt Damage | CSS0421B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538774","S100A10 wt Allele","C105415","Human S100A10 wild-type allele is located in the vicinity of 1q21 and is approximately 11 kb in length. This allele, which encodes protein S100-A10, is involved in cell cycle progression and cell differentiation and may be involved in exocytosis and endocytosis.","S100A10 wt Allele | 42C | ANX2L | ANX2LG | CAL1L | CLP11 | GP11 | P11 | S100 Calcium Binding Protein A10 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0966870","CAL1L protein, human","C105416","Protein S100-A10 (97 aa, ~11 kDa) is encoded by the human S100A10 gene. This protein plays a role in cell cycle progression and cell differentiation and may be involved in exocytosis and endocytosis.","Protein S100-A10 | Annexin II Ligand, Calpactin I, Light Polypeptide | Annexin II Tetramer (AIIt) p11 Subunit | Calpactin I Light Chain | Calpactin-I Light Chain | Cellular Ligand of Annexin II | S100 Calcium Binding Protein A10 (Annexin II Ligand, Calpactin I, Light Polypeptide (p11)) | S100 Calcium-Binding Protein A10 | S100 Calcium-Binding Protein A10 (Annexin II Ligand, Calpactin I, Light Polypeptide (p11)) | S100A10 | p10 | p10 Protein | p11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828164","SGRQ-C - Get Exhausted Easily","C106872","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Some more questions about your cough and breathlessness: I get exhausted easily.","SGRQ-C - Get Exhausted Easily | SGRQC1-Get Exhausted Easily | SGRQC120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828175","SGRQ-C - Cough Is Embarrassing in Public","C106873","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Questions about other effects that your respiratory problems may have on you: My cough or breathing is embarrassing in public.","SGRQ-C - Cough Is Embarrassing in Public | SGRQC1-Cough Is Embarrassing in Public | SGRQC121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828183","SGRQ-C - Afraid or Panic When Cannot Catch Breath","C106874","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Questions about other effects that your respiratory problems may have on you: I get afraid or panic when I cannot catch my breath.","SGRQ-C - Afraid or Panic When Cannot Catch Breath | SGRQC1-Afraid When Cannot Catch Breath | SGRQC123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828157","SGRQ-C - Not in Control of Respiratory Problems","C106875","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Questions about other effects that your respiratory problems may have on you: I feel that I am not in control of my respiratory problems.","SGRQ-C - Not in Control of Respiratory Problems | SGRQC1-Not in Control of Resp Problems | SGRQC124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828182","SGRQ-C - Become Frail Because of Respiratory Problems","C106876","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Questions about other effects that your respiratory problems may have on you: I have become frail or an invalid because of my respiratory problems.","SGRQ-C - Become Frail Because of Respiratory Problems | SGRQC1-Frail Because of Resp Problems | SGRQC125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827215","SGRQ-C - Exercise Is Not Safe for Me","C106877","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Questions about other effects that your respiratory problems may have on you: Exercise is not safe for me.","SGRQ-C - Exercise Is Not Safe for Me | SGRQC1-Exercise Is Not Safe for Me | SGRQC126",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828146","SGRQ-C - Take a Long Time to Get Washed or Dressed","C106879","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) These are questions about how your activities might be affected by your respiratory problems: I take a long time to get washed or dressed.","SGRQ-C - Take a Long Time to Get Washed or Dressed | SGRQC1-Take a Long Time to Get Washed | SGRQC128",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828180","SGRQ-C - Cannot Take a Bath or Shower","C106880","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) These are questions about how your activities might be affected by your respiratory problems: I cannot take a bath or shower, or I take a long time to do it.","SGRQ-C - Cannot Take a Bath or Shower | SGRQC1-Cannot Take a Bath or Shower | SGRQC129",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828145","SGRQ-C - Walk Slower Than Other People My Age","C106881","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) These are questions about how your activities might be affected by your respiratory problems: I walk slower than other people my age, or I stop to rest.","SGRQ-C - Walk Slower Than Other People My Age | SGRQC1-Walk Slow Than Others My Age | SGRQC130",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828158","SGRQ-C - Jobs Take a Long Time","C106882","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) These are questions about how your activities might be affected by your respiratory problems: Jobs such as household chores take a long time, or I have to stop to rest.","SGRQ-C - Jobs Take a Long Time | SGRQC1-Jobs Take a Long Time | SGRQC131",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828144","SGRQ-C - Walk Up Flight of Stairs Slowly","C106883","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) These are questions about how your activities might be affected by your respiratory problems: If I walk up one flight of stairs, I have to go slowly or stop.","SGRQ-C - Walk Up Flight of Stairs Slowly | SGRQC1-Walk Up Flight of Stairs Slowly | SGRQC132",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828368","Ras-Related Protein Rab-23","C106459","Ras-related protein Rab-23 (237 aa, ~27 kDa) is encoded by the human RAB23 gene. This protein is involved in both intracellular signaling and intracellular membrane trafficking.","Ras-Related Protein Rab-23 | RAB Family Small GTP Binding Protein RAB 23 | RAB23",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412822","BRDT Gene","C106460","This gene plays a role in both chromatin remodeling and spermatogenesis.","BRDT Gene | BRDT | Bromodomain Testis-Specific Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812649","BRDT wt Allele","C106462","Human BRDT wild-type allele is located in the vicinity of 1p22.1 and is approximately 65 kb in length. This allele, which encodes bromodomain testis-specific protein, is involved in both spermatogenesis and chromatin remodeling.","BRDT wt Allele | BRD6 | Bromodomain Testis-Specific wt Allele | CT9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813717","DTX2 wt Allele","C106466","Human DTX2 wild-type allele is located in the vicinity of 7q11.23 and is approximately 44 kb in length. This allele, which encodes probable E3 ubiquitin-protein ligase DTX2 protein, is involved in regulation of Notch signaling.","DTX2 wt Allele | Deltex Homolog 2 (Drosophila) wt Allele | HDTX2 | KIAA1528 | RNF58",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1872738","Probable E3 Ubiquitin-Protein Ligase DTX2, Human","C106468","Probable E3 ubiquitin-protein ligase DTX2 (622 aa, ~67 kDa) is encoded by the human DTX2 gene. This protein plays a role in regulation of cell-cell communication during cell fate determination.","Probable E3 Ubiquitin-Protein Ligase DTX2 | DTX2 | Deltex (Drosophila) Homolog 2 | Deltex2 | EC 2.3.2.27 | EC 6.3.2.-, Formerly | Protein Deltex-2 | RING Finger Protein 58 | RING-Type E3 Ubiquitin Transferase DTX2 | Zinc Ion Binding Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827852","TDI - Change in Magnitude of Effort","C106706","Transition Dyspnea Index (TDI) Change in magnitude of effort.","TDI - Change in Magnitude of Effort | TDI01-Change in Magnitude of Effort | TDI0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830850","C-SSRS Baseline/Screening Version - Wish to be Dead (Lifetime)","C106707","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Have you wished you were dead or wished you could go to sleep and not wake up? (Lifetime).","C-SSRS Baseline/Screening Version - Wish to be Dead (Lifetime) | CSS04-Wish to be Dead-Life | CSS0401A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830849","C-SSRS Baseline/Screening Version - Wish to be Dead (Past X Months)","C106708","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Have you wished you were dead or wished you could go to sleep and not wake up? (Past X Months).","C-SSRS Baseline/Screening Version - Wish to be Dead (Past X Months) | CSS04-Wish to be Dead-P_M | CSS0401B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830870","C-SSRS Baseline/Screening Version - Most Recent Suicide Attempt Potential Lethality","C106757","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Most recent attempt potential lethality.","C-SSRS Baseline/Screening Version - Most Recent Suicide Attempt Potential Lethality | CSS04-Most Recent Attempt Potential | CSS0421C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830874","C-SSRS Baseline/Screening Version - Most Lethal Suicide Attempt Date","C106758","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Most lethal attempt date.","C-SSRS Baseline/Screening Version - Most Lethal Suicide Attempt Date | CSS04-Most Lethal Attempt Date | CSS0422A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831715","ADCS-ADL MCI - Explain Extenuating Circumstance","C106969","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, explain.","ADCS-ADL MCI - Explain Extenuating Circumstance | ADL03-Explain Circumstance | ADL0324A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831674","ADCS-ADL MCI - Subscore for Items 1 to 3","C106970","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Subscore for page 1. (Range = 0-10).","ADCS-ADL MCI - Subscore for Items 1 to 3 | ADL03-Subscore for Items 1 to 3 | ADL0326",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831673","ADCS-ADL MCI - Subscore for Items 4 to 7","C106971","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Subscore for page 2. (Range = 0-8).","ADCS-ADL MCI - Subscore for Items 4 to 7 | ADL03-Subscore for Items 4 to 7 | ADL0327",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831672","ADCS-ADL MCI - Subscore for Items 8 to 10","C106972","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Subscore for page 3. (Range = 0-10).","ADCS-ADL MCI - Subscore for Items 8 to 10 | ADL03-Subscore for Items 8 to 10 | ADL0328",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827206","ADCS-ADL MCI - Subscore for Items 11 to 12","C106973","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Subscore for page 4. (Range = 0-7).","ADCS-ADL MCI - Subscore for Items 11 to 12 | ADL03-Subscore for Items 11 to 12d | ADL0329",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831676","ADCS-ADL MCI - Subscore for Items 13 to 14","C106974","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Subscore for page 5. (Range = 0-6).","ADCS-ADL MCI - Subscore for Items 13 to 14 | ADL03-Subscore for Items 13 to 14c | ADL0330",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831675","ADCS-ADL MCI - Subscore for Items 15 to 16","C106975","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Subscore for page 6. (Range = 0-5).","ADCS-ADL MCI - Subscore for Items 15 to 16 | ADL03-Subscore for Items 15 to 16c | ADL0331",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831678","ADCS-ADL MCI - Subscore for Item 17","C106976","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Subscore for page 7. (Range = 0-4).","ADCS-ADL MCI - Subscore for Item 17 | ADL03-Subscore for Item 17 | ADL0332",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831677","ADCS-ADL MCI - Subscore for Item 18","C106977","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Subscore for page 8. (Range = 0-3).","ADCS-ADL MCI - Subscore for Item 18 | ADL03-Subscore for Item 18 | ADL0333",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831737","ADCS-ADL MCI - ADL Total Score","C106978","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) ADL total score: sum the page subscores for pages 1-8 of the ADL (items 1-18). (Range = 0-53).","ADCS-ADL MCI - ADL Total Score | ADL03-Total ADCS-ADL Score | ADL0334",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831633","ADCS-ADL Severe Dementia - Description of Usual Performance of Eating","C106979","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) Regarding eating, which best describes subject's usual performance during the last 4 weeks?","ADCS-ADL Severe Dementia - Description of Usual Performance of Eating | ADL02-Usual Eating Performance | ADL0201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540507","AKR1C1 wt Allele","C105418","Human AKR1C1 wild-type allele is located within 10p15-p14 and is approximately 91 kb in length. This allele, which encodes aldo-keto reductase family 1 member C1 protein, plays a role in the conversion of progesterone to its inactive form, 20-alpha-dihydroxyprogesterone, and may have a role in the transport of bile.","AKR1C1 wt Allele | Aldo-Keto Reductase Family 1, Member C1 wt Allele | C9 | DD1 | DD1/DD2 | DDH | DDH1 | H-37 | HAKRC | HBAB | MBAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1721278","AKR1C1 protein, human","C105419","Aldo-keto reductase family 1 member C1 (323 aa, ~37 kDa) is encoded by the human AKR1C1 gene. This protein is involved in the conversion of progesterone to its inactive form and may have a role in the transport of bile.","Aldo-Keto Reductase Family 1 Member C1 | 2-Alpha-HSD | 20 Alpha-Hydroxysteroid Dehydrogenase | 20-Alpha-HSD | 20-Alpha-Hydroxysteroid Dehydrogenase | AKR1C1 | Aldo-Keto Reductase C | Aldo-Keto Reductase Family 1, Member C1 (Dihydrodiol Dehydrogenase 1; 20-Alpha (3-Alpha)-Hydroxysteroid Dehydrogenase) | Chlordecone Reductase Homolog HAKRC | Dihydrodiol Dehydrogenase 1 | Dihydrodiol Dehydrogenase 1/2 | Dihydrodiol Dehydrogenase Isoform DD1 | EC 1.1.1.112 | EC 1.1.1.149 | EC 1.3.1.20 | Hepatic Dihydrodiol Dehydrogenase | High-Affinity Hepatic Bile Acid-Binding Protein | Indanol Dehydrogenase | Trans-1,2-Dihydrobenzene-1,2-Diol Dehydrogenase | Type II 3-Alpha-Hydroxysteroid Dehydrogenase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538711","UGT2B15 wt Allele","C105421","Human UGT2B15 wild-type allele is located in the vicinity of 4q13 and is approximately 24 kb in length. This allele, which encodes UDP-glucuronosyltransferase 2B15 protein, plays a role in the detoxification of xenobiotics and steroids.","UGT2B15 wt Allele | HLUG4 | UDP Glucuronosyltransferase 2 Family, Polypeptide B15 wt Allele | UDPGT 2B8 | UDPGT2B15 | UDPGTH3 | UGT2B8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537396","UDP-Glucuronosyltransferase 2B15, Human","C105422","UDP-glucuronosyltransferase 2B15 (530 aa, ~61 kDa) is encoded by the human UGT2B15 gene. This protein is involved in the catabolism of xenobiotics and steroids.","UDP-Glucuronosyltransferase 2B15 | EC 2.4.1.17 | HLUG4 | UDP Glycosyltransferase 2 Family, Member B15 | UDP Glycosyltransferase 2 Family, Polypeptide B15 | UDP Glycosyltransferase 2B15 | UDP-Glucuronosyltransferase 2B8 | UDP-Glucuronosyltransferase UGT2B15 | UDP-Glucuronyltransferase, Family 2, Beta-15 | UDPGT 2B15 | UDPGT 2B8 | UDPGTh-3 | UGT2B15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3543846","UGT2B17 wt Allele","C105424","Human UGT2B17 wild-type allele is located in the vicinity of 4q13 and is approximately 31 kb in length. This allele, which encodes UDP-glucuronosyltransferase 2B17 protein, is involved in the catabolism of xenobiotics and steroids. Copy number variation of the gene is associated with aberrant bone mineral density quantitative trait which can lead to osteoporosis.","UGT2B17 wt Allele | UDP Glucuronosyltransferase 2 Family, Polypeptide B17 wt Allele | UDPGT2B17",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537397","UDP-Glucuronosyltransferase 2B17, Human","C105425","UDP-glucuronosyltransferase 2B17 (530 aa, ~61 kDa) is encoded by the human UGT2B17 gene. This protein plays a role in the metabolism of steroids and xenobiotics.","UDP-Glucuronosyltransferase 2B17 | C19-Steroid-Specific UDP-Glucuronosyltransferase | C19-Steroid-Specific UDPGT | EC 2.4.1.17 | UDP Glycosyltransferase 2 Family, Member B17 | UDP Glycosyltransferase 2 Family, Polypeptide B17 | UDP-Glucuronyltransferase, Family 2, Beta-17 | UDPGT 2B17 | UGT2B17",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828159","SGRQ-C - If Walk Fast Have to Stop","C106884","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) These are questions about how your activities might be affected by your respiratory problems: If I hurry or walk fast, I have to stop or slow down.","SGRQ-C - If Walk Fast Have to Stop | SGRQC1-If I Hurry, I Have to Stop | SGRQC133",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828171","SGRQ-C - Difficult to Walk Up Hills","C106885","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) These are questions about how your activities might be affected by your respiratory problems: My breathing makes it difficult to do things such as walk up hills, carry things up stairs, light gardening such as weeding, dance, bowl or play golf.","SGRQ-C - Difficult to Walk Up Hills | SGRQC1-Difficult to Walk Up Hills | SGRQC134",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830934","C-SSRS Already Enrolled Subjects - Most Lethal Suicide Attempt Potential Lethality","C107085","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Most lethal attempt potential lethality.","C-SSRS Already Enrolled Subjects - Most Lethal Suicide Attempt Potential Lethality | CSS05-Most Lethal Attempt Potential | CSS0523C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830943","C-SSRS Already Enrolled Subjects - First Suicide Attempt Actual Lethality/Medical Damage","C107087","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Initial/first attempt actual lethality/medical damage.","C-SSRS Already Enrolled Subjects - First Suicide Attempt Actual Lethality/Medical Damage | CSS05-First Attempt Damage | CSS0524B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830941","C-SSRS Already Enrolled Subjects - First Suicide Attempt Potential Lethality","C107088","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Initial/first attempt potential lethality.","C-SSRS Already Enrolled Subjects - First Suicide Attempt Potential Lethality | CSS05-First Attempt Potential | CSS0524C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831648","ADCS-ADL MCI - Use Household Appliance: Washer","C107089","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check household appliances that apply: washer.","ADCS-ADL MCI - Use Household Appliance: Washer | ADL03-Appliance: Washer | ADL0317A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831657","ADCS-ADL MCI - Use Household Appliance: Dryer","C107090","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check household appliances that apply: dryer.","ADCS-ADL MCI - Use Household Appliance: Dryer | ADL03-Appliance: Dryer | ADL0317B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831649","ADCS-ADL MCI - Use Household Appliance: Vacuum","C107091","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check household appliances that apply: vacuum.","ADCS-ADL MCI - Use Household Appliance: Vacuum | ADL03-Appliance: Vacuum | ADL0317C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831686","ADCS-ADL MCI - Points for Questions (1-18) Answered 'Don't Know'","C107092","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Were any questions (1-18) answered 'Don't Know'? If yes, calculate total points for 'Don't Know'.","ADCS-ADL MCI - Points for Questions (1-18) Answered 'Don't Know' | ADL03-Total Points for 'Don't Know' | ADL0325",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829869","HAQ-DI With VAS - Aids or Devices For Hygiene/Reach/Grip/Act-Other","C107093","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Other (for hygiene, reach, grip and activities).","HAQ-DI With VAS - Aids or Devices For Hygiene/Reach/Grip/Act-Other | HAQ01-Othr Aid (Hygiene/Reach/Grip/Act) | HAQ0140",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829868","HAQ-DI With VAS - Aids or Devices For Hygiene/Reach/Grip/Act-Specify","C107094","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Specify (for hygiene, reach, grip and activities).","HAQ-DI With VAS - Aids or Devices For Hygiene/Reach/Grip/Act-Specify | HAQ01-Spec Aid (Hygiene/Reach/Grip/Act) | HAQ0141",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830887","C-SSRS Baseline/Screening Version - Description of Wish to be Dead","C106709","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Description of wishing to be dead.","C-SSRS Baseline/Screening Version - Description of Wish to be Dead | CSS04-Wish to be Dead, Describe | CSS0401C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830867","C-SSRS Baseline/Screening Version - Non-Specific Active Suicidal Thoughts (Lifetime)","C106710","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Have you actually had any thoughts of killing yourself? (Lifetime).","C-SSRS Baseline/Screening Version - Non-Specific Active Suicidal Thoughts (Lifetime) | CSS04-Non-Spec Suicid Thought-Life | CSS0402A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830889","C-SSRS Baseline/Screening Version - Description of Non-Specific Active Suicidal Thoughts","C106712","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Description of non-specific active suicidal thoughts.","C-SSRS Baseline/Screening Version - Description of Non-Specific Active Suicidal Thoughts | CSS04-Non-Spec Suicid Thought, Describe | CSS0402C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830907","C-SSRS Baseline/Screening Version - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act (Lifetime)","C106713","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Have you been thinking about how you might do this? (Lifetime).","C-SSRS Baseline/Screening Version - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act (Lifetime) | CSS04-Idea, No Intent, No Plan-Life | CSS0403A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830906","C-SSRS Baseline/Screening Version - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act (Past X Months)","C106714","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Have you been thinking about how you might do this? (Past X Months).","C-SSRS Baseline/Screening Version - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act (Past X Months) | CSS04-Idea, No Intent, No Plan-P_M | CSS0403B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830894","C-SSRS Baseline/Screening Version - Description of Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act","C106715","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Description of active suicidal ideation with any methods (not plan) without intent to act.","C-SSRS Baseline/Screening Version - Description of Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act | CSS04-Idea, No Intent, No Plan, Describe | CSS0403C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830903","C-SSRS Baseline/Screening Version - Active Suicidal Ideation with Specific Plan and Intent (Lifetime)","C106716","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Have you started to work out or worked out the details of how to kill yourself? Do you intent to carry out this plan? (Lifetime).","C-SSRS Baseline/Screening Version - Active Suicidal Ideation with Specific Plan and Intent (Lifetime) | CSS04-Idea, Plan, Intent-Life | CSS0405A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830902","C-SSRS Baseline/Screening Version - Active Suicidal Ideation with Specific Plan and Intent (Past X Months)","C106717","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Have you started to work out or worked out the details of how to kill yourself? Do you intent to carry out this plan? (Past X Months).","C-SSRS Baseline/Screening Version - Active Suicidal Ideation with Specific Plan and Intent (Past X Months) | CSS04-Idea, Plan, Intent-P_M | CSS0405B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831669","ADCS-ADL MCI - Talk About Content of Program After Watching Within a Day","C106924","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, did subject talk about the content of a program within a day (24 hours) after watching it?","ADCS-ADL MCI - Talk About Content of Program After Watching Within a Day | ADL03-Talk About TV Content Within a Day | ADL0314C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831636","ADCS-ADL Severe Dementia - Description of Optimal Performance of Walking","C106980","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) Regarding walking (or getting around in a wheelchair) in the past 4 weeks, which best describes subject's optimal performance?","ADCS-ADL Severe Dementia - Description of Optimal Performance of Walking | ADL02-Optimal Walking Performance | ADL0202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831608","ADCS-ADL Severe Dementia - Usual Bowel and Bladder Function at Toilet","C106981","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) Regarding bowel and bladder function at the toilet, which best describes subject's usual performance during the past 4 weeks?","ADCS-ADL Severe Dementia - Usual Bowel and Bladder Function at Toilet | ADL02-Usual Bowel/Bladder Function | ADL0203",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827174","Glutathione Pegylated Liposomal Doxorubicin Hydrochloride Formulation 2B3-101","C106121","A glutathione (GSH) pegylated, liposome-encapsulated preparation of the hydrochloride salt form of the anthracycline antineoplastic antibiotic doxorubicin, with potential anetineoplastic activity. Upon administration, the glutathione pegylated liposomal formulation 2B3-101 specifically delivers doxorubicin into the brain. Doxorubicin intercalates between DNA base pairs and interferes with topoisomerase II activity, which inhibits both DNA replication and RNA synthesis, resulting in cancer cell death and tumor regression. Doxorubicin also generates reactive oxygen species, which causes cell membrane lipid peroxidation leading to cytotoxicity. The pegylated liposomal delivery of doxorubicin improves drug penetration into tumors and prolongs circulation time, thereby increasing doxorubicin's efficacy and decreasing its toxicity. Conjugation of GSH to the PEG molecules directs the liposomes to the GSH transporters on the blood brain barrier (BBB) and improves the delivery of doxorubicin into the brain.","Glutathione Pegylated Liposomal Doxorubicin Hydrochloride Formulation 2B3-101 | 2B3-101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447359","iC9-GD2-CD28-OX40-expressing T Lymphocytes","C106123","Modified T-lymphocytes expressing a 3rd generation chimeric antigen receptor (CAR) specific for the disialoganglioside GD2, which contains the CD3zeta chain, the signaling domains of the co-stimulatory molecules CD28 and CD134 (OX-40) and the suicide gene inducible caspase 9 (iCasp9), with potential immunomodulating and antineoplastic activities. Upon administration, iC9-GD2-CD28-OX40-expressing T lymphocytes target the GD2 antigen on tumor cells, thereby providing selective toxicity towards GD2-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered, which binds to the drug binding FKBP12-F36V domain and activates caspase 9, resulting in the apoptosis of the administered T-cells. The tumor associated antigen GD2 is overexpressed on the surface of almost all tumors of neuroectodermal origin. OX40 and CD28, both T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation.","iC9-GD2-CD28-OX40-expressing T Lymphocytes | iC9-GD2 T Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1723263","Poly-gamma Glutamic Acid","C106124","A water-soluble and biodegradable polymer naturally synthesized by various strains of Bacillus and composed of D- and L-glutamic acid polymerized via gamma-amide linkages, with potential antineoplastic activity. Upon administration, poly-gamma glutamic acid may augment the immune response by increasing the production of interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) and inducing the activation of macrophage and natural killer (NK) cells. IFN-gamma is a major mediator of innate and adaptive immunity against viral and intracellular bacterial infections as well as for tumor control. TNF-alpha is a cytokine involved in systemic inflammation, which is capable of inducing apoptotic cell death and exhibits anti-tumoral effects.","Poly-gamma Glutamic Acid | Gamma-polyglutamic Acid | Poly-gamma-glutamate | gamma-PGA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827151","MEK/Aurora Kinase Inhibitor BI 847325","C106126","An orally available dual inhibitor of mitogen-activated protein kinase kinase (MEK) and Aurora kinases, with potential antineoplastic activity. Upon oral administration, MEK/Aurora kinase inhibitor BI 847325 selectively binds to and inhibits the activity of MEK, which both prevents the activation of MEK-dependent effector proteins and inhibits growth factor-mediated cell signaling. BI 847325 also binds to and inhibits the activity of the Aurora kinases A, B and C which may disrupt the assembly of the mitotic spindle apparatus, prevent chromosome segregation, and inhibit both cellular division and proliferation in Aurora kinase-overexpressing tumor cells.  Altogether, this leads to the inhibition of cell proliferation and tumor growth as well as the induction of tumor regression. MEK, a dual-specificity threonine/tyrosine kinase that plays a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway, is frequently upregulated in a variety of tumor cell types. Aurora kinases are serine-threonine kinases that play essential roles in mitotic checkpoint control and are overexpressed by a wide variety of cancer cell types.","MEK/Aurora Kinase Inhibitor BI 847325 | BI 847325",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831536","Animal-based Natural Product","C106128","Any substance or product derived from an animal.","Animal-based Natural Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1958487","ATR-Interacting Protein, Human","C106415","ATR-interacting protein (791 aa, ~86 kDa) is encoded by the human ATRIP gene. This protein is involved in signaling during the DNA damage checkpoint of the cell cycle.","ATR-Interacting Protein | ATM and Rad3-Related-Interacting Protein | ATR Interacting Protein | ATRIP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412638","ATP2A2 Gene","C106416","This gene plays a role in cardiac muscle contraction.","ATP2A2 Gene | ATP2A2 | ATPase, Ca++ Transporting, Cardiac Muscle, Slow Twitch 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814791","ATP2A2 wt Allele","C106417","Human ATP2A2 wild-type allele is located in the vicinity of 12q24.11 and is approximately 70 kb in length. This allele, which encodes sarcoplasmic/endoplasmic reticulum calcium ATPase 2 protein, is involved in the modulation of cardiac muscle contractility. Mutation of the gene is associated with both Darier disease and acrokeratosis verruciformis.","ATP2A2 wt Allele | ATP2B | ATPase, Ca++ Dependent, Slow-Twitch, Cardiac Muscle-2 Gene | ATPase, Ca++ Transporting, Cardiac Muscle, Slow Twitch 2 wt Allele | DAR | DD | SERCA2 | Sarcoplasmic Reticulum Ca(2+)-ATPase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1567357","Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase 2, Human","C106418","Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (1042 aa, ~115 kDa) is encoded by the human ATP2A2 gene. This protein plays a role in both heart contraction and ATP hydrolysis.","Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase 2 | ATP2A2 | Calcium Pump 2 | Calcium-Transporting ATPase Sarcoplasmic Reticulum Type, Slow Twitch Skeletal Muscle Isoform | Cardiac Ca2+ ATPase | EC 3.6.3.8, Formerly | EC 7.2.2.10 | Endoplasmic Reticulum Class 1/2 Ca(2+) ATPase | SERCA2 | SR Ca(2+)-ATPase 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415500","HCRT Gene","C106419","This gene is involved in neuropeptide signaling.","HCRT Gene | HCRT | Hypocretin (Orexin) Neuropeptide Precursor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811761","HCRT wt Allele","C106420","Human HCRT wild-type allele is located in the vicinity of 17q21 and is approximately 1 kb in length. This allele, which encodes orexin protein, plays a role in both G-protein coupled receptor signaling and feeding behavior. Mutation of the gene is associated with narcolepsy 1.","HCRT wt Allele | Hypocretin (Orexin) Neuropeptide Precursor wt Allele | NRCLP1 | OX | PPOX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527908","HCRT protein, human","C106421","Orexin (131 aa, ~13 kDa) is encoded by the human HCRT gene. This protein is involved in neuropeptide-dependent signaling and feeding behavior.","Orexin | Hcrt | Hypocretin | Prepro-Orexin | Preproorexin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414964","GAN Gene","C106422","This gene plays a role in both neurofilament structure and ubiquitination.","GAN Gene | GAN | Gigaxonin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814805","GAN wt Allele","C106423","Human GAN wild-type allele is located in the vicinity of 16q24.1 and is approximately 65 kb in length. This allele, which encodes gigaxonin protein, is involved in both ubiquitination and neurofilament structure. Mutation of the gene is associated with giant axonal neuropathy.","GAN wt Allele | GAN1 | Giant Axonal Neuropathy (Gigaxonin) Gene | Gigaxonin wt Allele | KLHL16",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831712","ADCS-ADL MCI - Go Shopping At a Store","C106925","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject ever go shopping at a store?","ADCS-ADL MCI - Go Shopping At a Store | ADL03-Go Shopping | ADL0315",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831682","ADCS-ADL MCI - Select Correct Items Without Help","C106926","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, did subject usually select correct items without supervision or help?","ADCS-ADL MCI - Select Correct Items Without Help | ADL03-Select Items Without Help | ADL0315A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831703","ADCS-ADL MCI - Pay for Items on His or Her Own","C106927","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, did subject usually pay for items on his or her own?","ADCS-ADL MCI - Pay for Items on His or Her Own | ADL03-Pay Items On His/Her Own | ADL0315B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831706","ADCS-ADL MCI - Left on His or Her Own","C106928","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, was subject ever left on his or her own?","ADCS-ADL MCI - Left on His or Her Own | ADL03-Left On His/Her Own | ADL0316",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831707","ADCS-ADL MCI - Left Away From Home Longer Than 15 Minutes","C106929","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, was subject left away from home, for 15 minutes or longer, during the day?","ADCS-ADL MCI - Left Away From Home Longer Than 15 Minutes | ADL03-Left Away From Home | ADL0316A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831708","ADCS-ADL MCI - Left at Home Longer Than an Hour","C106930","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, was subject left at home, for an hour or longer, during the day?","ADCS-ADL MCI - Left at Home Longer Than an Hour | ADL03-Left at Home for 1 Hour or Longer | ADL0316B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831709","ADCS-ADL MCI - Left at Home Less Than an Hour","C106931","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, was subject left at home, for less than 1 hour, during the day?","ADCS-ADL MCI - Left at Home Less Than an Hour | ADL03-Left at Home for Less Than 1 Hour | ADL0316C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831658","ADCS-ADL MCI - Use Household Appliance: Dishwasher","C106933","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check household appliances that apply: dishwasher.","ADCS-ADL MCI - Use Household Appliance: Dishwasher | ADL03-Appliance: Dishwasher | ADL0317D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831652","ADCS-ADL MCI - Use Household Appliance: Power Tools","C106934","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check household appliances that apply: power tool(s).","ADCS-ADL MCI - Use Household Appliance: Power Tools | ADL03-Appliance: Power Tools | ADL0317E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831650","ADCS-ADL MCI - Use Household Appliance: Toaster Oven","C106935","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check household appliances that apply: toaster oven.","ADCS-ADL MCI - Use Household Appliance: Toaster Oven | ADL03-Appliance: Toaster Oven | ADL0317F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831651","ADCS-ADL MCI - Use Household Appliance: Range","C106936","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check household appliances that apply: range.","ADCS-ADL MCI - Use Household Appliance: Range | ADL03-Appliance: Range | ADL0317G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831655","ADCS-ADL MCI - Use Household Appliance: Microwave","C106937","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check household appliances that apply: microwave.","ADCS-ADL MCI - Use Household Appliance: Microwave | ADL03-Appliance: Microwave | ADL0317H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831656","ADCS-ADL MCI - Use Household Appliance: Food Processor","C106938","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check household appliances that apply: food processor.","ADCS-ADL MCI - Use Household Appliance: Food Processor | ADL03-Appliance: Food Processor | ADL0317I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829196","Marine-based Natural Product","C106129","Any substance or product derived from any organism that lives in bodies of fresh or salt water.","Marine-based Natural Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540545","DIABLO wt Allele","C105652","Human DIABLO wild-type allele is located in the vicinity of 12q24.31 and is approximately 20 kb in length. This allele, which encodes diablo IAP-binding mitochondrial protein, is involved in the promotion of caspase-mediated apoptosis. Mutation of the gene is associated with deafness autosomal dominant type 64.","DIABLO wt Allele | DFNA64 | DIABLO-S | Diablo IAP-Binding Mitochondrial Protein wt Allele | Diablo, IAP-Binding Mitochondrial Protein Gene | Diablo, IAP-Binding Mitochondrial Protein wt Allele | FLJ10537 | FLJ25049 | SMAC | SMAC3 | hCG_1782202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540629","second mitochondria-derived activator of caspase, human","C105653","Diablo IAP-binding mitochondrial protein (239 aa, ~27 kDa) is encoded by the human DIABLO gene. This protein plays a role in the activation of caspase-dependent apoptosis.","Diablo IAP-Binding Mitochondrial Protein | DIABLO | Diablo Homolog, Mitochondrial | Diablo Homolog, Mitochondrial | Direct IAP-Binding Protein with Low pI | Second Mitochondria-Derived Activator of Caspase | Smac",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541275","LAGE3 wt Allele","C105655","Human LAGE3 wild-type allele is located in the vicinity of Xq28 and is approximately 2 kb in length. This allele, which encodes L antigen family member 3 protein, has no known function.","LAGE3 wt Allele | CVG5 | DNA Segment on Chromosome X (Unique) 9879 Expressed Sequence Gene | DXS9879E | DXS9951E | ESO3 | ITBA2 | L Antigen Family, Member 3 wt Allele | XX-FW81657B9.4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542424","L Antigen Family Member 3","C105656","L antigen family member 3 (143 aa, ~15 kDa) is encoded by the human LAGE3 gene. This protein has no known function.","L Antigen Family Member 3 | LAGE3 | Protein ESO-3 | Protein ITBA2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815274","ITSN1 wt Allele","C105658","Human ITSN1 wild-type allele is located within 21q22.1-q22.2 and is approximately 257 kb in length. This allele, which encodes intersectin-1 protein, is involved in both vesicle endocytosis and small GTPase-mediated signaling.","ITSN1 wt Allele | Human Intersectin-SH3 Domain-Containing Protein SH3P17 Gene | ITSN | Intersectin 1 (SH3 Domain Protein) wt Allele | SH3D1A | SH3P17",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0760530","intersectin 1","C105659","Intersectin-1 (1721 aa, ~195 kDa) is encoded by the human ITSN1 gene. This protein plays a role in the regulation of both small GTPase activity and clathrin-dependent endocytosis.","Intersectin-1 | ITSN1 | SH3 Domain-Containing Protein 1A | SH3P17",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813550","NCL wt Allele","C105662","Human NCL wild-type allele is located in the vicinity of 2q37.1 and is approximately 30 kb in length. This allele, which encodes nucleolin protein, plays a role in both ribosomal assembly and chromosome decondensation.","NCL wt Allele | C23 | Nucleolin wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1451903","Nucleolin, Human","C105663","Nucleolin (710 aa, ~77 kDa) is encoded by the human NCL gene. This protein is involved in both chromatin decondensation and ribosome assembly.","Nucleolin | NCL | Protein C23",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810578","Gigaxonin, human","C106424","Gigaxonin (597 aa, ~68 kDa) is encoded by the human GAN gene. This protein plays a role in the modulation of both protein ubiquitination and neurofilament structure.","Gigaxonin | GAN | Kelch-Like Family Member 16 | Kelch-Like Protein 16",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421977","PDCD11 Gene","C106425","This gene is involved in RNA processing.","PDCD11 Gene | PDCD11 | Programmed Cell Death 11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3715022","PDCD11 wt Allele","C106426","Human PDCD11 wild-type allele is located in the vicinity of 10q24.33 and is approximately 50 kb in length. This allele, which encodes protein RRP5 homolog, plays a role in ribosomal RNA processing.","PDCD11 wt Allele | ALG-4 | ALG4 | Apoptosis-Linked Gene 4 | KIAA0185 | NFBP | Programmed Cell Death 11 wt Allele | RRP5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1611930","Protein RRP5 Homolog, Human","C106427","Protein RRP5 homolog (1871 aa, ~209 kDa) is encoded by the human PDCD11 gene. This protein is involved in rRNA biosynthesis.","Protein RRP5 Homolog | NF-Kappa-B-Binding Protein | NFBP | PDCD11 | Programmed Cell Death Protein 11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447782","anlotinib hydrochloride","C106428","The hydrochloride salt form of catequentinib, a receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities. Upon administration, catequentinib targets multiple RTKs, including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt tumor cell growth.","Catequentinib Hydrochloride | 1-((4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolyl)oxymethyl)cyclopropanamine, Dihydrochloride | ALTN HCl | Anlotinib Hydrochloride | Anlotinib Hydrochloride | CATEQUENTINIB DIHYDROCHLORIDE | CATEQUENTINIB HYDROCHLORIDE | Cyclopropanamine, 1-(((4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-, Hydrochloride (1:2) | Fukewei",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826950","CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology","C106660","Test names of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology | CSS04TN | Columbia-Suicide Severity Rating Scale Baseline/Screening Version Questionnaire Test Name | QS-C-SSRS Baseline/Screening Version TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826949","CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology","C106661","Test codes of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology | CSS04TC | Columbia-Suicide Severity Rating Scale Baseline/Screening Version Questionnaire Test Code | QS-C-SSRS Baseline/Screening Version TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826926","CDISC Questionnaire GDS Test Name Terminology","C106662","Test names of questionnaire questions associated with the Geriatric Depression Scale (GDS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire GDS Test Name Terminology | GDS01TN | Geriatric Depression Scale Questionnaire Test Name | QS-GDS TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826925","CDISC Questionnaire GDS Test Code Terminology","C106663","Test codes of questionnaire questions associated with the Geriatric Depression Scale (GDS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire GDS Test Code Terminology | GDS01TC | Geriatric Depression Scale Questionnaire Test Code | QS-GDS TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826927","CDISC Questionnaire GDS-SF Test Code Terminology","C106665","Test codes of questionnaire questions associated with the Geriatric Depression Scale Short Form (GDS-SF) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire GDS-SF Test Code Terminology | GDS02TC | Geriatric Depression Scale Short Form Questionnaire Test Code | QS-GDS-SF TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826924","CDISC Questionnaire HAQ-DI With VAS Test Name Terminology","C106666","Test names of questionnaire questions associated with the Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire HAQ-DI With VAS Test Name Terminology | HAQ01TN | Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale Questionnaire Test Name | QS-HAQ-DI TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829567","Image Acquisition Matrix Size","C106533","A measurement of the number of data fields, pixels or data points assigned to each linear dimension in a digital image.","Image Acquisition Matrix Size | AQMTRXSZ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829290","Lewis, Rat Strain","C106538","Derived from Wistar stock by the laboratory of Dr. Lewis at the Wistar Institute in the 1940s and 1950s, the Lewis is a white albino rat with genotype a, TyrC. The Lewis rat has a MHC haplotype of RT1A'.","Lewis, Rat Strain | LEW | LEWIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830873","C-SSRS Baseline/Screening Version - Most Lethal Suicide Attempt Potential Lethality","C106760","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Most lethal attempt potential lethality.","C-SSRS Baseline/Screening Version - Most Lethal Suicide Attempt Potential Lethality | CSS04-Most Lethal Attempt Potential | CSS0422C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830881","C-SSRS Baseline/Screening Version - First Suicide Attempt Date","C106761","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Initial/first attempt date.","C-SSRS Baseline/Screening Version - First Suicide Attempt Date | CSS04-First Attempt Date | CSS0423A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830882","C-SSRS Baseline/Screening Version - First Suicide Attempt Actual Lethality/Medical Damage","C106762","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Initial/first attempt actual lethality/medical damage.","C-SSRS Baseline/Screening Version - First Suicide Attempt Actual Lethality/Medical Damage | CSS04-First Attempt Damage | CSS0423B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830880","C-SSRS Baseline/Screening Version - First Suicide Attempt Potential Lethality","C106763","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Initial/first attempt potential lethality.","C-SSRS Baseline/Screening Version - First Suicide Attempt Potential Lethality | CSS04-First Attempt Potential | CSS0423C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830043","GDS - Basically Satisfied With Life","C106764","Geriatric Depression Scale (GDS) Are you basically satisfied with your life?","GDS - Basically Satisfied With Life | GDS01-Satisfied With Life | GDS0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830041","GDS - Dropped Activities and Interests","C106765","Geriatric Depression Scale (GDS) Have you dropped many of your activities and interests?","GDS - Dropped Activities and Interests | GDS01-Dropped Activities and Interests | GDS0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830035","GDS - Feel Life Is Empty","C106766","Geriatric Depression Scale (GDS) Do you feel that your life is empty?","GDS - Feel Life Is Empty | GDS01-Life Is Empty | GDS0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1743883","Glutathione S-Transferase Mu 4, Human","C105666","Glutathione S-transferase Mu 4 (218 aa, ~26 kDa) is encoded by the human GSTM4 gene. This protein plays a role in the metabolism of glutathione, 1-chloro-2,4-dinitrobenzene and other xenobiotics.","Glutathione S-Transferase Mu 4 | EC 2.5.1.18 | GST Class-Mu 4 | GST-Mu2 | GSTM4 | GSTM4-4 | Glutathione S-Alkyltransferase M4 | Glutathione S-Aralkyltransferase M4 | Glutathione S-Aryltransferase M4 | Glutathione S-Transferase M4 | S-(Hydroxyalkyl)Glutathione Lyase M4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3715043","ARIA Oncology Information System","C105667","A proprietary information and image management system designed to oversee oncology care.","ARIA Oncology Information System | ARIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539573","GLIS2 Gene","C105900","This gene is involved in transcriptional regulation and signaling pathway modulation.","GLIS2 Gene | GLIS Family Zinc Finger 2 Gene | GLIS2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811757","GLIS2 wt Allele","C105901","Human GLIS2 wild-type allele is located in the vicinity of 16p13.3 and is approximately 25 kb in length. This allele, which encodes zinc finger protein GLIS2, plays a role in the modulation of both signaling and transcription. Mutation of the gene is associated with type 7 nephronophthisis.","GLIS2 wt Allele | GLI-Similar 2 Gene | GLIS Family Zinc Finger 2 wt Allele | NKL | NPHP7 | Nephrocystin-7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815567","Zinc Finger Protein GLIS2, Human","C105902","Zinc finger protein GLIS2 (524 aa, ~56 kDa) is encoded by the human GLIS2 gene. This protein is involved in the regulation of transcription and the repression of signaling pathways.","Zinc Finger Protein GLIS2 | GLI-Similar 2 | GLI-Similar Protein 2 | GLIS2 | Kruppel-Like Zinc Finger Protein GLIS2 | Neuronal Krueppel-Like Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828496","PPBP Gene Product","C105903","A protein encoded by the PPBP gene.","PPBP Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0752521","Cytochrome P450 2A6","C105905","Cytochrome P450 2A6 (494 aa, ~57 kDa) is encoded by the human CYP2A6 gene. This protein is involved in the metabolism of xenobiotics.","Cytochrome P450 2A6 | 1,4-Cineole 2-Exo-Monooxygenase | CYP2A6 | CYPIIA6 | Coumarin 7-Hydroxylase | Cytochrome P450 IIA3 | Cytochrome P450(I) | EC 1.14.13.-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829469","JAK2 Protein Variant","C105906","A variation in the amino acid sequence for the tyrosine-protein kinase JAK2 protein.","JAK2 Protein Variant | JAK-2 Protein Variant | Janus Kinase 2 Protein Variant | Tyrosine-Protein Kinase JAK2 Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826923","CDISC Questionnaire HAQ-DI With VAS Test Code Terminology","C106667","Test codes of questionnaire questions associated with the Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire HAQ-DI With VAS Test Code Terminology | HAQ01TC | Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale Questionnaire Test Code | QS-HAQ-DI TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826914","CDISC Questionnaire MMRC Test Name Terminology","C106668","Test names of questionnaire questions associated with the Modified Medical Research Council Dyspnea Scale (MMRC) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire MMRC Test Name Terminology | MMRC01TN | Modified Medical Research Council Dyspnea Scale Questionnaire Test Name | QS-MMRC TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826913","CDISC Questionnaire MMRC Test Code Terminology","C106669","Test codes of questionnaire questions associated with the Modified Medical Research Council Dyspnea Scale (MMRC) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire MMRC Test Code Terminology | MMRC01TC | Modified Medical Research Council Dyspnea Scale Questionnaire Test Code | QS-MMRC TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826903","CDISC Questionnaire SGRQ-C Test Name Terminology","C106670","Test names of questionnaire questions associated with the St.George's Respiratory Questionnaire for COPD Patients (SGRQ-C) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire SGRQ-C Test Name Terminology | QS-SGRQ-C TEST | SGRQC1TN | St. George's Respiratory Questionnaire for COPD Patients Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826902","CDISC Questionnaire SGRQ-C Test Code Terminology","C106671","Test codes of questionnaire questions associated with the St.George's Respiratory Questionnaire for COPD Patients (SGRQ-C) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire SGRQ-C Test Code Terminology | QS-SGRQ-C TESTCD | SGRQC1TC | St. George's Respiratory Questionnaire for COPD Patients Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831685","ADCS-ADL MCI Questionnaire Question","C106672","A question associated with the ADCS-ADL MCI questionnaire.","ADCS-ADL MCI Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828172","SGRQ-C - Difficult to Carry Heavy Loads","C106886","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) These are questions about how your activities might be affected by your respiratory problems: My breathing makes it difficult to do things such as carry heavy loads, dig in the garden or shovel snow, jog or walk briskly (5 miles per hour), play tennis or swim.","SGRQ-C - Difficult to Carry Heavy Loads | SGRQC1-Difficult to Carry Heavy Loads | SGRQC135",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828160","SGRQ-C - How Respiratory Problems Affect You","C106887","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) How do your respiratory problems affect you?","SGRQ-C - How Respiratory Problems Affect You | SGRQC1-How Resp Problems Affect You | SGRQC141",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714920","ANGPTL1 wt Allele","C106474","Human ANGPTL1 wild-type allele is located in the vicinity of 1q25.2 and is approximately 22 kb in length. This allele, which encodes angiopoietin-related protein 1, plays a role in the regulation of hematopoietic stem cells.","ANGPTL1 wt Allele | ANG-3 | ANG3 | ANGPT3 | ARP1 | AngY | Angiopoietin-Like 1 wt Allele | DJ595C2.2 | UNQ162",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714828","Angiopoietin-Related Protein 1, Human","C106475","Angiopoietin-related protein 1 (491 aa, ~57 kDa) is encoded by the human ANGPTL1 gene. This protein is involved in the regulation of hematopoietic stem cells.","Angiopoietin-Related Protein 1 | ANGPTL1 | Angioarrestin | Angiopoietin 3 | Angiopoietin Y1 | Angiopoietin-3 | Angiopoietin-Like Protein 1 | DJ595C2.2 (Angiopoietin Y1)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826887","CDISC SDTM Device Identifier Parameter Long Name Terminology","C106480","Terminology associated with the device identifier long name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Device Identifier Parameter Long Name Terminology | DIPARM | Device Identifier Long Name | SDTM-DIPARM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826862","CDISC SDTM Device-In-Use Test Name Terminology","C106482","Terminology associated with the device-in-use test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Device-In-Use Test Name Terminology | DUTEST | Device-In-Use Test Name | SDTM-DUTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826882","CDISC SDTM Device-In-Use Test Code Terminology","C106483","Terminology associated with the device-in-use test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Device-In-Use Test Code Terminology | DUTESTCD | Device-In-Use Test Code | SDTM-DUTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829540","Infranatant","C106484","The liquid, solid or semi-solid lying below a liquid residue, which is separated by crystallization, precipitation or centrifugation of a biological sample.","Infranatant | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830021","GDS - Often Get Bored","C106767","Geriatric Depression Scale (GDS) Do you often get bored?","GDS - Often Get Bored | GDS01-Bored Often | GDS0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830025","GDS - Hopeful About Future","C106768","Geriatric Depression Scale (GDS) Are you hopeful about the future?","GDS - Hopeful About Future | GDS01-Hopeful About Future | GDS0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830042","GDS - Bothered by Thoughts","C106769","Geriatric Depression Scale (GDS) Are you bothered by thoughts you can't get out of your head?","GDS - Bothered by Thoughts | GDS01-Bothered by Thoughts | GDS0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830028","GDS - Good Spirits Most of Time","C106770","Geriatric Depression Scale (GDS) Are you in good spirits most of the time?","GDS - Good Spirits Most of Time | GDS01-Good Spirits Most of Time | GDS0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830044","GDS - Afraid of Something Bad Happening","C106771","Geriatric Depression Scale (GDS) Are you afraid that something bad is going to happen to you?","GDS - Afraid of Something Bad Happening | GDS01-Afraid of Something Bad Happening | GDS0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830036","GDS - Feel Happy Most of Time","C106772","Geriatric Depression Scale (GDS) Do you feel happy most of the time?","GDS - Feel Happy Most of Time | GDS01-Feel Happy Most of Time | GDS0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830029","GDS - Get Restless and Fidgety","C106774","Geriatric Depression Scale (GDS) Do you often get restless and fidgety?","GDS - Get Restless and Fidgety | GDS01-Get Restless and Fidgety | GDS0111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830018","GDS - Prefer to Stay Home","C106775","Geriatric Depression Scale (GDS) Do you prefer to stay at home, rather than going out and doing new things?","GDS - Prefer to Stay Home | GDS01-Prefer to Stay Home | GDS0112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830030","GDS - Frequently Worry About Future","C106776","Geriatric Depression Scale (GDS) Do you frequently worry about the future?","GDS - Frequently Worry About Future | GDS01-Worry About Future | GDS0113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831630","ADCS-ADL Severe Dementia - Description of Usual Performance of Physically Getting Dressed","C106984","No value exists.","ADCS-ADL Severe Dementia - Description of Usual Performance of Physically Getting Dressed | ADL02-Usual Physically Dressing Perform | ADL0206",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831609","ADCS-ADL Severe Dementia - Use a Telephone","C106985","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) In the past 4 weeks, did subject use a telephone?","ADCS-ADL Severe Dementia - Use a Telephone | ADL02-Use a Telephone | ADL0207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831639","ADCS-ADL Severe Dementia - Description of Highest Performance of Telephone Use","C106986","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) If yes, which best describes subject's highest level of performance.","ADCS-ADL Severe Dementia - Description of Highest Performance of Telephone Use | ADL02-Highest Telephone Use Performance | ADL0207A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831623","ADCS-ADL Severe Dementia - Select or Ask for Television Program","C106988","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) If yes, did subject usually select or ask for different programs or subject's favorite show?","ADCS-ADL Severe Dementia - Select or Ask for Television Program | ADL02-Select Television Program | ADL0208A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538867","AKR1C2 wt Allele","C105427","Human AKR1C2 wild-type allele is located within 10p15-p14 and is approximately 30 kb in length. This allele, which encodes aldo-keto reductase family 1 member C2 protein, is involved in the metabolism of steroid hormones and the inactivation of androgens. Mutations in this gene are associated with 46XY sex reversal 8.","AKR1C2 wt Allele | Aldo-Keto Reductase Family 1, Member C2 (Dihydrodiol Dehydrogenase 2; Bile Acid Binding Protein; 3-Alpha Hydroxysteroid Dehydrogenase, Type III) Gene | Aldo-Keto Reductase Family 1, Member C2 wt Allele | BABP | DD | DD-2 | DD/BABP | DD2 | DDH2 | HAKRD | HBAB | MCDR2 | SRXY8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1456345","AKR1C2 protein, human","C105428","Aldo-keto reductase family 1 member C2 (323 aa, ~37 kDa) is encoded by the human AKR1C2 gene. This protein plays a role in the metabolism of steroid hormones and the inactivation of androgens.","Aldo-Keto Reductase Family 1 Member C2 | 3-Alpha-HSD3 | AKR1C-Pseudo | AKR1C2 | Aldo-Keto Reductase Family 1, Member C2 (Dihydrodiol Dehydrogenase 2; Bile Acid Binding Protein; 3-Alpha Hydroxysteroid Dehydrogenase, Type III) | Chlordecone Reductase Homolog HAKRD | Dihydrodiol Dehydrogenase 2 | Dihydrodiol Dehydrogenase/Bile Acid-Binding Protein | EC 1.1.1.213 | EC 1.3.1.20 | Pseudo-Chlordecone Reductase | Trans-1,2-Dihydrobenzene-1,2-Diol Dehydrogenase | Type II Dihydrodiol Dehydrogenase | Type III 3-Alpha-Hydroxysteroid Dehydrogenase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541299","SLCO2B1 wt Allele","C105430","Human SLCO2B1 wild-type allele is located in the vicinity of 11q13 and is approximately 106 kb in length. This allele, which encodes solute carrier organic anion transporter family member 2B1, plays a role in transport of organic anions and may function in regulation of placental uptake of sulfated steroids.","SLCO2B1 wt Allele | KIAA0880 | OATP-B | OATP-RP2 | OATP2B1 | OATPB | OATPRP2 | SLC21A9 | Solute Carrier Organic Anion Transporter Family, Member 2B1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539845","Solute Carrier Organic Anion Transporter Family Member 2B1","C105431","Solute carrier organic anion transporter family member 2B1 (709 aa, ~77 kDa) is encoded by the human SLCO2B1 gene. This protein is involved in transport of organic anions and may function in regulation of placental uptake of sulfated steroids.","Solute Carrier Organic Anion Transporter Family Member 2B1 | Organic Anion Transporter B | Organic Anion Transporter Polypeptide-Related Protein 2 | SLCO2B1 | Solute Carrier Family 21 (Organic Anion Transporter), Member 9 | Solute Carrier Family 21 Member 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831713","ADCS-ADL MCI - Find Personal Belongings","C106891","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject usually manage to find his or her personal belongings at home?","ADCS-ADL MCI - Find Personal Belongings | ADL03-Find Personal Belongings | ADL0301",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831681","ADCS-ADL MCI - Select First Clothes for the Day","C106893","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject select his or her first set of clothes for the day?","ADCS-ADL MCI - Select First Clothes for the Day | ADL03-Select First Clothes for the Day | ADL0302",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831718","ADCS-ADL MCI - Description of Usual Performance of Selecting First Clothes for the Day","C106894","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, which best describes his or her usual performance.","ADCS-ADL MCI - Description of Usual Performance of Selecting First Clothes for the Day | ADL03-Usual Dressing Performance | ADL0302A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831719","ADCS-ADL MCI - Description of Usual Performance of Physically Getting Dressed","C106895","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Regarding physically getting dressed, which best describes his or her usual performance in the past 4 weeks.","ADCS-ADL MCI - Description of Usual Performance of Physically Getting Dressed | ADL03-Usual Physically Dressing Perform | ADL0303",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831733","ADCS-ADL MCI - Clean Room","C106896","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject clean a living-, sitting-, or family room?","ADCS-ADL MCI - Clean Room | ADL03-Clean Room | ADL0304",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831723","ADCS-ADL MCI - Description of Usual Performance of Cleaning Room","C106897","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, which best describes how he or she usually performed.","ADCS-ADL MCI - Description of Usual Performance of Cleaning Room | ADL03-Clean Room Performance | ADL0304A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0057856","Iproplatin","C1070","A synthetic second-generation platinum-containing compound related to cisplatin. Iproplatin binds to and forms DNA crosslinks and platinum-DNA adducts, resulting in DNA replication failure and cell death.  Although less prone to glutathione inactivation compared to cisplatin, resistance to this agent has been observed in vitro due to repair of platination damage by tumor cells. (NCI04)","Iproplatin | (OC-6-33)-dichlorodihydroxybis(2-propanamine)platinum | CHIP | Diisopropylammine-trans-dihydroxymalonatoplatinum(IV) | IPROPLATIN | JM-9 | Platinum, dichlorodihydroxybis(2-propanamine)-, (oc-6-33)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0702094","Agranulocytosis","C107102","A marked decrease in the number of mature granulocytes (most often neutrophils) in the peripheral blood.","Agranulocytosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4015676","Sudden Death","C107103","An unexpected death without warning.","Sudden Death | Sudden Death, NOS",,,,,,,,,,,,,,,"4132309","Sudden death",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3641535","PHQ-15 - Trouble Sleeping","C103729","Patient Health Questionnaire - 15 (PHQ-15) Trouble sleeping.","PHQ-15 - Trouble Sleeping | PHQ02-Trouble Sleeping | PHQ0215",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641536","SIQR - Brush or Comb Your Hair","C103730","Symptom Impact Questionnaire (SIQR) Brush or comb your hair.","SIQR - Brush or Comb Your Hair | SIQR01-Brush or Comb Your Hair | SIQR0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641537","SIQR - Walk Continuously for 20 Minutes","C103731","Symptom Impact Questionnaire (SIQR) Walk continuously for 20 minutes.","SIQR - Walk Continuously for 20 Minutes | SIQR01-Walk Continuously for 20 Minutes | SIQR0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641538","SIQR - Prepare a Homemade Meal","C103732","Symptom Impact Questionnaire (SIQR) Prepare a homemade meal.","SIQR - Prepare a Homemade Meal | SIQR01-Prepare a Homemade Meal | SIQR0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641540","SIQR - Lift and Carry a Bag Full of Groceries","C103734","Symptom Impact Questionnaire (SIQR) Lift and carry a bag full of groceries.","SIQR - Lift and Carry a Bag Full of Groceries | SIQR01-Lift/Carry Bag Full of Groceries | SIQR0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641541","SIQR - Climb One Flight of Stairs","C103735","Symptom Impact Questionnaire (SIQR) Climb one flight of stairs.","SIQR - Climb One Flight of Stairs | SIQR01-Climb One Flight of Stairs | SIQR0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641542","SIQR - Change Bed Sheets","C103736","Symptom Impact Questionnaire (SIQR) Change bed sheets.","SIQR - Change Bed Sheets | SIQR01-Change Bed Sheets | SIQR0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641543","SIQR - Sit in a Chair for 45 Minutes","C103737","Symptom Impact Questionnaire (SIQR) Sit in a chair for 45 minutes.","SIQR - Sit in a Chair for 45 Minutes | SIQR01-Sit in a Chair for 45 Minutes | SIQR0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641544","SIQR - Go Shopping for Groceries","C103738","Symptom Impact Questionnaire (SIQR) Go shopping for groceries.","SIQR - Go Shopping for Groceries | SIQR01-Go Shopping for Groceries | SIQR0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641545","SIQR - My Medical Problem Prevented Me from Accomplishing Goals for the Week","C103739","Symptom Impact Questionnaire (SIQR) My medical problems prevented me from accomplishing goals for week.","SIQR - My Medical Problem Prevented Me from Accomplishing Goals for the Week | SIQR01-Prevent from Accomplishing Goals | SIQR0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0252524","LGALS1 protein, human","C104408","Galectin-1 (135 aa, ~15 kDa) is encoded by the human LGALS1 gene. This protein may play a role in modulating cell-cell and cell-matrix interactions and may regulate apoptosis, cell proliferation and cell differentiation.","Galectin-1 | 14 kDa Laminin-Binding Protein | 14 kDa Lectin | Beta-Galactoside-Binding Lectin L-14-I | Beta-Galactoside-Binding Protein 14kDa | Galaptin | Galectin 1 | LGALS1 | Lactose-Binding Lectin 1 | Putative MAPK-Activating Protein PM12 | S-Lac Lectin 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542967","GAPDH wt Allele","C104410","Human GAPDH wild-type allele is located in the vicinity of 12p13.31 and is approximately 4 kb in length. This allele, which encodes glyceraldehyde-3-phosphate dehydrogenase protein, plays a role in carbohydrate metabolism.","GAPDH wt Allele | G3PD | GAPD | Glyceraldehyde-3-Phosphate Dehydrogenase wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812258","SLCO1B3 wt Allele","C106618","Human SLCO1B3 wild-type allele is located in the vicinity of 12p12 and is approximately 279 kb in length. This allele, which encodes solute carrier organic anion transporter family member 1B3 protein, is involved in both bile acid and bilirubin transport and sodium-independent uptake of endogenous and xenobiotic compounds. Mutations in this gene are associated with hyperbilirubinemia, Rotor type, digenic.","SLCO1B3 wt Allele | HBLRR | LST-2 | LST-3TM13 | LST2 | LST3 | OATP-8 | OATP1B3 | OATP8 | SLC21A8 | Solute Carrier Organic Anion Transporter Family, Member 1B3 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447762","SLCO1B3 protein, human","C106619","Solute carrier organic anion transporter family member 1B3 (702 aa, ~74 kDa) is encoded by the human SLCO1B3 gene. This protein plays a role in both the uptake of endogenous and xenobiotic compounds in the liver and bile acid and bilirubin transport.","Solute Carrier Organic Anion Transporter Family Member 1B3 | Liver-Specific Organic Anion Transporter 2 | Liver-Specific Organic Anion Transporter 3TM13 | Organic Anion Transporter 8 | Organic Anion Transporter LST-3c | Organic Anion-Transporting Polypeptide 8 | SLCO1B3 | Solute Carrier Family 21 Member 8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811165","MAP3K5 wt Allele","C106622","Human MAP3K5 wild-type allele is located in the vicinity of 6q22.33 and is approximately 235 kb in length. This allele, which encodes mitogen-activated protein kinase kinase kinase 5 protein, plays a role in mediating cell signaling during cell fate determination.","MAP3K5 wt Allele | ASK-1 | ASK1 | MAPKKK5 | MEKK 5 | MEKK5 | Mitogen-Activated Protein Kinase Kinase Kinase 5 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1436155","Mitogen-Activated Protein Kinase Kinase Kinase 5, Human","C106623","Mitogen-activated protein kinase kinase kinase 5 (1374 aa, ~155 kDa) is encoded by the human MAP3K5 gene. This protein is involved in the apoptosis signal transduction pathway through mitochondria-dependent caspase activation.","Mitogen-Activated Protein Kinase Kinase Kinase 5 | ASK1 | Apoptosis Signal Regulating Kinase 1 | Apoptosis Signal-Regulating Kinase 1 | EC 2.7.11.25 | MAP/ERK Kinase Kinase 5 | MAP3K5 | MAPK/ERK Kinase Kinase 5 | MEK Kinase 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641598","C-SSRS Since Last Visit - Description of Interrupted Suicide Attempt","C103792","Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Description of interrupted attempt.","C-SSRS Since Last Visit - Description of Interrupted Suicide Attempt | CSS02-Interrupted Attempt, Describe | CSS0216A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641599","C-SSRS Since Last Visit - Aborted Suicide Attempt","C103793","Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Has there been a time when you started to do something to try to end your life but you stopped yourself before you actually did anything?","C-SSRS Since Last Visit - Aborted Suicide Attempt | CSS02-Aborted Attempt | CSS0217",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641818","BID Gene Product","C104459","A protein encoded by the human BID gene.","BID Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541253","GAGE8 wt Allele","C104463","Human GAGE8 wild-type allele is located in the vicinity of Xp11 and is approximately 7 kb in length. This allele, which encodes G antigen 2D protein, may play a role in tumor progression.","GAGE8 wt Allele | CT4.8 | Cancer/Testis Antigen Family 4, Member 8 Gene | G Antigen 8 wt Allele | GAGE-8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324140","Suffolk sheep (organism)","C106572","A strain of sheep originally derived in England in the 1880s from a cross between a Southdown ram and a Norfolk Horned ewe. The Suffolk sheep has a white-colored body, black face and legs, and has a wool type of medium.","Suffolk Sheep | SUFFOLK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3805302","Swiss Webster mouse breed","C106573","Derived from inbreeding of Swiss mice at the Rockefeller Institute in 1926 by Dr. Leslie Webster, the Swiss Webster is a white albino mouse with genotype TyrC. The superior nurturing ability of the Swiss Webster makes it ideal for embryo transfers.","Swiss Webster Mouse | SW | SWISS WEBSTER | SWR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830023","GDS - More Memory Problems Than Most","C106777","Geriatric Depression Scale (GDS) Do you feel you have more problems with memory than most?","GDS - More Memory Problems Than Most | GDS01-Memory Problems | GDS0114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830000","GDS - Think Wonderful to Be Alive","C106778","Geriatric Depression Scale (GDS) Do you think it is wonderful to be alive now?","GDS - Think Wonderful to Be Alive | GDS01-Wonderful to Be Alive | GDS0115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830038","GDS - Feel Downhearted and Blue","C106779","Geriatric Depression Scale (GDS) Do you often feel downhearted and blue?","GDS - Feel Downhearted and Blue | GDS01-Feel Downhearted and Blue | GDS0116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830033","GDS - Feel Worthless","C106780","Geriatric Depression Scale (GDS) Do you feel pretty worthless the way you are now?","GDS - Feel Worthless | GDS01-Feel Worthless | GDS0117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829999","GDS - Worry About the Past","C106781","Geriatric Depression Scale (GDS) Do you worry a lot about the past?","GDS - Worry About the Past | GDS01-Worry About the Past | GDS0118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830032","GDS - Find Life Exciting","C106782","Geriatric Depression Scale (GDS) Do you find life very exciting?","GDS - Find Life Exciting | GDS01-Find Life Exciting | GDS0119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830027","GDS - Hard to Start New Projects","C106783","Geriatric Depression Scale (GDS) Is it hard for you to get started on new projects?","GDS - Hard to Start New Projects | GDS01-Hard to Start New Projects | GDS0120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830037","GDS - Feel Full of Energy","C106784","Geriatric Depression Scale (GDS) Do you feel full of energy?","GDS - Feel Full of Energy | GDS01-Feel Full of Energy | GDS0121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831621","ADCS-ADL Severe Dementia - Sum of Items 13-15","C107014","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) Sum of items 13-15. (Range is 0-10).","ADCS-ADL Severe Dementia - Sum of Items 13-15 | ADL02-Sum 13 to 15 | ADL0223",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831619","ADCS-ADL Severe Dementia - Sum of Items 16-19","C107015","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) Sum of items 16-19. (Range is 0-4).","ADCS-ADL Severe Dementia - Sum of Items 16-19 | ADL02-Sum 16 to 19 | ADL0224",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831614","ADCS-ADL Severe Dementia - Total Score","C107016","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) Total score. (Range is 0-54).","ADCS-ADL Severe Dementia - Total Score | ADL02-Total ADCS-ADL Score | ADL0225",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830905","C-SSRS Baseline/Screening Version - Active Suicidal Ideation with Some Intent to Act, without Specific Plan (Lifetime)","C107017","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Have you had these thoughts and had some intention of acting on them? (Lifetime).","C-SSRS Baseline/Screening Version - Active Suicidal Ideation with Some Intent to Act, without Specific Plan (Lifetime) | CSS04-Idea, Intent, No Plan-Life | CSS0404A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830904","C-SSRS Baseline/Screening Version - Active Suicidal Ideation with Some Intent to Act, without Specific Plan (Past X Months)","C107018","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Have you had these thoughts and had some intention of acting on them? (Past X Months).","C-SSRS Baseline/Screening Version - Active Suicidal Ideation with Some Intent to Act, without Specific Plan (Past X Months) | CSS04-Idea, Intent, No Plan-P_M | CSS0404B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830893","C-SSRS Baseline/Screening Version - Description of Active Suicidal Ideation with Some Intent to Act, without Specific Plan","C107019","Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Description of active suicidal ideation with some intent to act, without specific plan.","C-SSRS Baseline/Screening Version - Description of Active Suicidal Ideation with Some Intent to Act, without Specific Plan | CSS04-Idea, Intent, No Plan, Describe | CSS0404C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281352","bicalutamide/leuprolide","C10701","A regimen consisting of bicalutamide and leuprolide acetate that may be used in the treatment of certain types of prostate cancer.","Bicalutamide/Leuprolide Regimen | Bicalutamide and Leuprolide | Bicalutamide-Leuprolide | Bicalutamide/Leuprolide | CDX/LEUP | Casidex/Lupron",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829867","HAQ-DI With VAS - Aids or Devices - Jar Opener (Jars Previously Opened)","C107020","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Jar opener (for jars previously opened).","HAQ-DI With VAS - Aids or Devices - Jar Opener (Jars Previously Opened) | HAQ01-Aid: Jar Opener (Previously Open) | HAQ0136",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828149","SGRQ-C - Respiratory Problems a Nuisance to Family, Friends or Neighbours","C107021","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Questions about other effects that your respiratory problems may have on you: My respiratory problems are a nuisance to my family, friends or neighbors.","SGRQ-C - Respiratory Problems a Nuisance to Family, Friends or Neighbours | SGRQC1-Respiratory Problems a Nuisance | SGRQC122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829893","HAQ-DI With VAS - Able to Do Chores - Vacuuming or Yardwork","C106841","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Activities: are you able to do chores such as vacuuming or yardwork?","HAQ-DI With VAS - Able to Do Chores - Vacuuming or Yardwork | HAQ01-Able to Do Chores | HAQ0133",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829864","HAQ-DI With VAS - Aids or Devices - Raised Toilet Seat","C106842","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Raised toilet seat.","HAQ-DI With VAS - Aids or Devices - Raised Toilet Seat | HAQ01-Aid: Raised Toilet Seat | HAQ0134",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829875","HAQ-DI With VAS - Aids or Devices - Bathtub Seat","C106843","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Bathtub seat.","HAQ-DI With VAS - Aids or Devices - Bathtub Seat | HAQ01-Aid: Bathtub Seat | HAQ0135",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829876","HAQ-DI With VAS - Aids or Devices - Bathtub Bar","C106844","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Bathtub bar.","HAQ-DI With VAS - Aids or Devices - Bathtub Bar | HAQ01-Aid: Bathtub Bar | HAQ0137",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829866","HAQ-DI With VAS - Aids or Devices - Long-Handled Appliances for Reach","C106845","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Long-handled appliances for reach.","HAQ-DI With VAS - Aids or Devices - Long-Handled Appliances for Reach | HAQ01-Aid: Long-Handled Appl Reach | HAQ0138",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829865","HAQ-DI With VAS - Aids or Devices - Long-Handled Appliances in Bathroom","C106846","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Long-handled appliances in bathroom.","HAQ-DI With VAS - Aids or Devices - Long-Handled Appliances in Bathroom | HAQ01-Aid: Long-Handled Appl Bathroom | HAQ0139",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829855","HAQ-DI With VAS - Help From Another Person - Hygiene","C106847","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Categories usually need help from another person - Hygiene.","HAQ-DI With VAS - Help From Another Person - Hygiene | HAQ01-Help: Hygiene | HAQ0142",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829854","HAQ-DI With VAS - Help From Another Person - Reach","C106848","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Categories usually need help from another person - Reach.","HAQ-DI With VAS - Help From Another Person - Reach | HAQ01-Help: Reach | HAQ0143",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829856","HAQ-DI With VAS - Help From Another Person - Gripping and Opening Things","C106849","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Categories usually need help from another person - Gripping and opening things.","HAQ-DI With VAS - Help From Another Person - Gripping and Opening Things | HAQ01-Help: Gripping and Opening Things | HAQ0144",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829851","HAQ-DI With VAS - Severity of Pain in the Past Week","C106851","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) How much pain have you had because of your illness in the past week.","HAQ-DI With VAS - Severity of Pain in the Past Week | HAQ01-Severity of Pain | HAQ0146",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829000","MMRC - Description of Level of Breathlessness","C106852","No value exists.","MMRC - Description of Level of Breathlessness | MMRC01-Description of Breathlessness | MMRC0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3267032","Congenital Hematological Disorder","C104003","A disorder of the blood that is present at birth.","Congenital Hematological Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438387","Topical Cocaine Hydrochloride","C104004","A topical formulation of the hydrochloride salt of the tropane alkaloid cocaine, with local anesthetic activity. Upon topical application of the cocaine hydrochloride solution to nasal mucous membranes, cocaine reversibly binds to and blocks the voltage-gated sodium channels in the neuronal cell membranes. By stabilizing neuronal membranes, cocaine inhibits the initiation and conduction of nerve impulses and produces a reversible loss of sensation.","Topical Cocaine Hydrochloride | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433964","Pegfilgrastim Biosimilar LA-EP2006","C104005","A biosimilar of pegfilgrastim, a long-acting pegylated form of recombinant human granulocyte colony-stimulating factor (G-CSF) filgrastim, with hematopoietic activity. In a similar manner to G-CSF, pegfilgrastim biosimilar LA-EP2006 binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. Therefore, this agent may prevent the incidence and shorten the duration of chemotherapy-induced neutropenia. Conjugation of the cytokine with a branched polyethylene glycol molecule significantly increases this agent's therapeutic half-life compared to filgrastim.","Pegfilgrastim Biosimilar LA-EP2006 | LA-EP2006",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438388","Anti-CD20-CAR-CD3zeta-4-1BB-expressing Autologous T-lymphocyte Cells","C104006","A preparation of autologous blood T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) consisting of an anti-CD20 scFv (single chain variable fragment); the cytoplasmic portion of the human TCR-[zeta] molecule; and the co-stimulatory molecule 4-1BB (CD137), with potential immunostimulating and antineoplastic activities. Upon transfusion, anti-CD20-CAR-CD3zeta-4-1BB-expressing autologous T-lymphocyte cells direct T-cells to CD20-expressing tumor cells. This results in cytotoxic T lymphocyte (CTL) and antibody responses against CD20-expressing tumor cells, causing tumor cell lysis. The CD20 antigen, a non-glycosylated cell surface phosphoprotein, is a B-cell specific cell surface antigen expressed in B-cell lineage malignancies. CD3 zeta is one of several membrane-bound polypeptides found in the T-cell receptor (TCR)/CD3 complex and regulates the assembly of complete TCR complexes and their expression on the cell surface. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD20; the inclusion of this signaling domain may increase the antitumor activity compared to the inclusion of the CD3-zeta chain alone.","Anti-CD20-CAR-CD3zeta-4-1BB-expressing Autologous T-lymphocyte Cells | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830034","GDS - Feel Situation Is Hopeless","C106785","Geriatric Depression Scale (GDS) Do you feel that your situation is hopeless?","GDS - Feel Situation Is Hopeless | GDS01-Feel Hopeless | GDS0122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830020","GDS - Often Upset Over Little Things","C106787","Geriatric Depression Scale (GDS) Do you frequently get upset over little things?","GDS - Often Upset Over Little Things | GDS01-Often Upset Over Little Things | GDS0124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830031","GDS - Frequently Feel Like Crying","C106788","Geriatric Depression Scale (GDS) Do you frequently feel like crying?","GDS - Frequently Feel Like Crying | GDS01-Frequently Feel Like Crying | GDS0125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830026","GDS - Have Trouble Concentrating","C106789","Geriatric Depression Scale (GDS) Do you have trouble concentrating?","GDS - Have Trouble Concentrating | GDS01-Trouble Concentrating | GDS0126",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830039","GDS - Enjoy Getting Up in the Morning","C106790","Geriatric Depression Scale (GDS) Do you enjoy getting up in the morning?","GDS - Enjoy Getting Up in the Morning | GDS01-Enjoy Getting Up in the Morning | GDS0127",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830019","GDS - Prefer to Avoid Social Gatherings","C106791","Geriatric Depression Scale (GDS) Do you prefer to avoid social gatherings?","GDS - Prefer to Avoid Social Gatherings | GDS01-Avoid Social Gatherings | GDS0128",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830040","GDS - Easy to Make Decisions","C106792","Geriatric Depression Scale (GDS) Is it easy for you to make decisions?","GDS - Easy to Make Decisions | GDS01-Easy to Make Decisions | GDS0129",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830024","GDS - Mind as Clear as It Used to Be","C106793","Geriatric Depression Scale (GDS) Is your mind as clear as it used to be?","GDS - Mind as Clear as It Used to Be | GDS01-Mind as Clear as It Used to Be | GDS0130",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830016","GDS-SF - Basically Satisfied With Life","C106794","Geriatric Depression Scale, Short Form (GDS-SF) Are you basically satisfied with your life?","GDS-SF - Basically Satisfied With Life | GDS02-Satisfied With Life | GDS0201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830015","GDS-SF - Dropped Activities and Interests","C106795","Geriatric Depression Scale, Short Form (GDS-SF) Have you dropped many of your activities and interests?","GDS-SF - Dropped Activities and Interests | GDS02-Dropped Activities and Interests | GDS0202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831610","ADCS-ADL Severe Dementia - Turn On Light Without Help Entering Room","C107009","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) In the past 4 weeks, did subject usually turn on a light without help when entering a dark room or area?","ADCS-ADL Severe Dementia - Turn On Light Without Help Entering Room | ADL02-Turn On Light | ADL0218",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831612","ADCS-ADL Severe Dementia - Turn Off Light Without Help Leaving Room","C107010","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) In the past 4 weeks, did subject usually turn off lights without help when leaving a room or going to sleep?","ADCS-ADL Severe Dementia - Turn Off Light Without Help Leaving Room | ADL02-Turn Off Light | ADL0219",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831620","ADCS-ADL Severe Dementia - Sum of Items 1-5","C107011","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) Sum of items 1-5. (Range is 0-15).","ADCS-ADL Severe Dementia - Sum of Items 1-5 | ADL02-Sum 1 to 5 | ADL0220",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831618","ADCS-ADL Severe Dementia - Sum of Items 6-8","C107012","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) Sum of items 6-8. (Range is 0-13).","ADCS-ADL Severe Dementia - Sum of Items 6-8 | ADL02-Sum 6 to 8 | ADL0221",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828174","SGRQ-C - Description of Your Current Health","C106853","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Before completing the rest of the questionnaire: please check one box to show how you describe your current health.","SGRQ-C - Description of Your Current Health | SGRQC1-Describe Your Current Health | SGRQC101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828179","SGRQ-C - Cough","C106854","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Please check one box for each question: I cough.","SGRQ-C - Cough | SGRQC1-I Cough | SGRQC102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828181","SGRQ-C - Bring Up Phlegm","C106855","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Please check one box for each question: I bring up phlegm (sputum).","SGRQ-C - Bring Up Phlegm | SGRQC1-I Bring Up Phlegm | SGRQC103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830921","C-SSRS Already Enrolled Subjects - Number of Actual Suicide Attempts (Since Study Start)","C107059","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Total number of actual attempts. (Since Study Start).","C-SSRS Already Enrolled Subjects - Number of Actual Suicide Attempts (Since Study Start) | CSS05-Number of Actual Attempts-Since | CSS0513B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830952","C-SSRS Already Enrolled Subjects - Description of Actual Suicide Attempt","C107060","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Description of actual attempt.","C-SSRS Already Enrolled Subjects - Description of Actual Suicide Attempt | CSS05-Actual Attempt, Describe | CSS0513C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830926","C-SSRS Already Enrolled Subjects - Non-suicidal Self-injurious Behavior (Prior to Study Entry)","C107061","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Has subject engaged in non-suicidal self-injurious behavior? (Prior to Study Entry).","C-SSRS Already Enrolled Subjects - Non-suicidal Self-injurious Behavior (Prior to Study Entry) | CSS05-Non-suicid Self-injur Behav-Prior | CSS0514A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830938","C-SSRS Already Enrolled Subjects - Interrupted Suicide Attempt (Prior to Study Entry)","C107063","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Has there been a time when you started to do something to end your life but someone or something stopped you before you actually did anything? (Prior to Study Entry).","C-SSRS Already Enrolled Subjects - Interrupted Suicide Attempt (Prior to Study Entry) | CSS05-Interrupted Attempt-Prior | CSS0515A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830937","C-SSRS Already Enrolled Subjects - Interrupted Suicide Attempt (Since Study Start)","C107064","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Has there been a time when you started to do something to end your life but someone or something stopped you before you actually did anything? (Since Study Start).","C-SSRS Already Enrolled Subjects - Interrupted Suicide Attempt (Since Study Start) | CSS05-Interrupted Attempt-Since | CSS0515B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830920","C-SSRS Already Enrolled Subjects - Number of Interrupted Suicide Attempts (Prior to Study Entry)","C107065","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Total number of interrupted. (Prior to Study Entry).","C-SSRS Already Enrolled Subjects - Number of Interrupted Suicide Attempts (Prior to Study Entry) | CSS05-Num of Interrupted Attempts-Prior | CSS0516A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830919","C-SSRS Already Enrolled Subjects - Number of Interrupted Suicide Attempts (Since Study Start)","C107066","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Total number of interrupted. (Since Study Start).","C-SSRS Already Enrolled Subjects - Number of Interrupted Suicide Attempts (Since Study Start) | CSS05-Num of Interrupted Attempts-Since | CSS0516B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830951","C-SSRS Already Enrolled Subjects - Description of Interrupted Suicide Attempt","C107067","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Description of interrupted attempt.","C-SSRS Already Enrolled Subjects - Description of Interrupted Suicide Attempt | CSS05-Interrupted Attempt, Describe | CSS0516C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438389","Technetium Tc 99m-3PRGD2","C104007","A radiopharmaceutical agent comprised of a pegylated arginine-glycine-aspartic acid (RGD) dimer (PRGD2) labeled with technetium Tc 99m, with potential alphaVbeta3 integrin imaging activity when used with single photon emission computed tomography (SPECT). After intravenous administration of technetium Tc 99m-3PRGD2, the RGD moiety binds to alphaVbeta3 integrin on the cell membrane via the cyclic RGD motif. Upon PET imaging, alphaVbeta3 integrin-expressing tumor cells can be visualized and expression levels can be quantified. Compared to other radiolabeled RGD-containing peptides, this agent shows an increased affinity for alphaVbeta3 integrin, enhanced tumor uptake as well as improved pharmacokinetics. AlphaVbeta3 integrin, a member of the integrin receptor family, is overexpressed on certain tumor cells and tumor endothelial cells while minimally or not expressed on healthy, normal cells; this receptor plays a key role in angiogenesis, tumor proliferation and survival.","Technetium Tc 99m-3PRGD2 | (99m)Tc-PEG(4)-E[PEG(4)-c(RGDfK)](2) ((99m)Tc-3PRGD2) | 99mTc-3PRGD2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3530053","PI3K/HDAC inhibitor CUDC-907","C104008","An orally bioavailable inhibitor of both phosphoinositide 3-kinase (PI3K) class I and pan histone deacetylase (HDAC) enzymes, with potential antineoplastic activity. Upon oral administration, fimepinostat inhibits the activity of both PI3K class I isoforms and HDAC, thereby preventing the activation of the PI3K-AKT-mTOR signal transduction pathway that is often overactivated in many cancer cell types. This may prevent growth of PI3K and/or HDAC-expressing tumor cells. CUDC-907 shows an increased inhibition of tumor cell growth and induction of apoptosis when compared to inhibitors that target either PI3K or HDAC.","Fimepinostat | CUDC-907 | FIMEPINOSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540525","F12 wt Allele","C104217","Human F12 wild-type allele is located within 5q33-qter and is approximately 8 kb in length. This allele, which encodes coagulation factor XII protein, plays a role in coagulation, fibrinolysis, and the generation of bradykinin and angiotensin. Mutations in the F12 gene are associated with angioedema, hereditary, type III.","F12 wt Allele | Coagulation Factor XII (Hageman Factor) wt Allele | HAE3 | HAEX | HAF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538782","TNNT2 wt Allele","C104218","Human TNNT2 wild-type allele is located in the vicinity of 1q32.1 and is approximately 19 kb in length. This allele, which encodes troponin T, cardiac muscle, is involved in muscle contraction.","TNNT2 wt Allele | CMD1D | CMH2 | CMPD2 | Cardiomyopathy, Dilated 1D (Autosomal Dominant) Gene | Cardiomyopathy, Hypertrophic 2 Gene | LVNC6 | RCM3 | TnTC | Troponin T Type 2 (Cardiac) Gene | Troponin T Type 2 (Cardiac) wt Allele | Troponin T2, Cardiac Type wt Allele | cTnT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015525","Coagulation Factor XII","C104219","Coagulation factor XII (615 aa, ~68 kDa) is encoded by the human F12 gene. This protein is involved in blood coagulation and fibrinolysis.","Coagulation Factor XII | Beta-Factor XIIa Part 1 | Beta-Factor XIIa Part 2 | Coagulation Factor XIIa Heavy Chain | Coagulation Factor XIIa Light Chain | EC 3.4.21.38 | F12 | Hageman Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538889","Troponin T, Cardiac Muscle","C104220","Troponin T, cardiac muscle (298 aa, ~36 kDa) is encoded by the human TNNT2 gene. This protein plays a role in cardiac muscle contraction.","Troponin T, Cardiac Muscle | Cardiac Muscle Troponin T | Cardiac Troponin T | TNNT2 | TnTc | cTnT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538828","TNNI3 wt Allele","C104224","Human TNNI3 wild-type allele is located in the vicinity of 19q13.4 and is approximately 6 kb in length. This allele, which encodes troponin I, cardiac muscle, plays a role in muscle filament sliding.","TNNI3 wt Allele | CMD1FF | CMD2A | CMH7 | RCM1 | TNNC1 | Troponin I Type 3 (Cardiac) wt Allele | cTnI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540500","CCR7 wt Allele","C104129","Human CCR7 wild-type allele is located within 17q12-q21.2 and is approximately 12 kb in length. This allele, which encodes C-C chemokine receptor type 7 protein, is involved in lymphocyte activation.","CCR7 wt Allele | BLR2 | CD197 | CDw197 | CMKBR7 | Chemokine (C-C motif) Receptor 7 wt Allele | EBI1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0214153","CCR7 protein, human","C104130","C-C chemokine receptor type 7 (378 aa, ~43 kDa) is encoded by the human CCR7 gene. This protein plays a role in memory T-cell migration and dendritic cell maturation.","C-C Chemokine Receptor Type 7 | CD197 Antigen | Epstein-Barr Virus-Induced G-Protein Coupled Receptor 1 | Lymphocyte-Specific G Protein-Coupled Peptide Receptor | MIP-3 Beta Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540528","CLEC4C wt Allele","C104132","Human CLEC4C wild-type allele is located within 12p13.2-p12.3 and is approximately 22 kb in length. This allele, which encodes c-type lectin domain family 4 member C protein, plays a role in antigen processing and presentation.","CLEC4C wt Allele | BDCA2 | C-type Lectin Domain Family 4, Member C wt Allele | CD303 | CLECSF11 | CLECSF7 | DLEC | HECL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542406","C-Type Lectin Domain Family 4 Member C, Human","C104133","C-type lectin domain family 4 member C (213 aa, ~25 kDa) is encoded by the human CLEC4C gene. This protein is involved in antigen processing and presentation to T-cells.","C-Type Lectin Domain Family 4 Member C | Blood Dendritic Cell Antigen 2 Protein | C-Type (Calcium Dependent, Carbohydrate-Recognition Domain) 11 | C-Type (Calcium Dependent, Carbohydrate-Recognition Domain) Lectin, Superfamily Member 7 | CD303 Antigen | CLEC4C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641478","OAB-q - Stay Home More Often Than You Would Prefer","C103672","The Overactive Bladder Questionnaire (OAB-q) Caused you to stay home more often than you would prefer?","OAB-q - Stay Home More Often Than You Would Prefer | OABQ01-Stay Home More Often Than Prefer | OABQ0120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641479","OAB-q - Adjust Your Travel Plans so That You are Always Near a Restroom","C103673","The Overactive Bladder Questionnaire (OAB-q) Caused you to adjust your travel plans so that you are always near a restroom?","OAB-q - Adjust Your Travel Plans so That You are Always Near a Restroom | OABQ01-Adjust Travel Plans Near Restroom | OABQ0121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641480","OAB-q - Avoid Activities Away From Restrooms","C103674","The Overactive Bladder Questionnaire (OAB-q) Made you avoid activities away from restrooms (i.e., walks, running, hiking)?","OAB-q - Avoid Activities Away From Restrooms | OABQ01-Avoid Act Away From Restroom | OABQ0122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641481","OAB-q - Frustrated or Annoyed About the Amount of Time You Spend in the Restroom","C103675","The Overactive Bladder Questionnaire (OAB-q) Made you frustrated or annoyed about the amount of time you spend in the restroom?","OAB-q - Frustrated or Annoyed About the Amount of Time You Spend in the Restroom | OABQ01-Amount of Time Spend in Restroom | OABQ0123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641482","OAB-q - Awakened You During Sleep","C103676","The Overactive Bladder Questionnaire (OAB-q) Awakened you during sleep?","OAB-q - Awakened You During Sleep | OABQ01-Awakened You During Sleep | OABQ0124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641483","OAB-q - Made You Worry About Odor or Hygiene","C103677","The Overactive Bladder Questionnaire (OAB-q) Made you worry about odor or hygiene?","OAB-q - Made You Worry About Odor or Hygiene | OABQ01-Worry About Odor or Hygiene | OABQ0125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641484","OAB-q - Uncomfortable While Traveling With Others","C103678","The Overactive Bladder Questionnaire (OAB-q) Made you uncomfortable while traveling with others because of needing to stop for a restroom?","OAB-q - Uncomfortable While Traveling With Others | OABQ01-Uncomfortable Travel with Others | OABQ0126",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827723","Unplanned Terminal Sacrifice","C106580","An indication that the subject was sacrificed prior to the end of the planned treatment period, and the subject was not otherwise moribund.","Unplanned Terminal Sacrifice | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3476815","VR - Veterans Rand Health Survey","C106581","A findings domain that captures information regarding the genetics of viral drug resistance. It contains the reference sequence used to validate the observed genetic mutation of interest.","Viral Resistance Domain | Viral Resistance Findings Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815532","DLL1 wt Allele","C106583","Human DLL1 wild-type allele is located in the vicinity of 6q27 and is approximately 8 kb in length. This allele, which encodes delta-like protein 1, plays a role in notch signaling during hematopoietic cell fate determination.","DLL1 wt Allele | DELTA1 | DL1 | Delta-Like 1 (Drosophila) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823180","ALKBH7 Gene","C106584","This gene plays a role in oxidation.","ALKBH7 Gene | ALKBH7 | AlkB, Alkylation Repair Homolog 7 (E. Coli) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815527","Delta-Like Protein 1, human","C106586","Delta-like protein 1 (723 aa, ~78 kDa) is encoded by the human DLL1 gene. This protein is involved in cell fate decisions during hematopoiesis.","Delta-Like Protein 1 | Delta | Delta (Drosophila)-Like 1 | Delta1 | Drosophila Delta Homolog 1 | H-Delta-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812637","ALKBH7 protein, human","C106587","Alpha-ketoglutarate-dependent dioxygenase alkB homolog 7 (221 aa, ~25 kDa) is encoded by the human ALKBH7 gene. This protein plays a role in oxidoreductase activity.","Alpha-Ketoglutarate-Dependent Dioxygenase AlkB Homolog 7 | ALKBH7 | Alkylated DNA Repair Protein AlkB Homolog 7 | EC 1.14.11.- | Spermatogenesis Cell Proliferation-Related Protein | Spermatogenesis-Associated Protein 11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811108","SLC7A5 wt Allele","C106589","Human SLC7A5 wild-type allele is located in the vicinity of 16q24.3 and is approximately 39 kb in length. This allele, which encodes large neutral amino acids transporter small subunit 1 protein, is involved in cellular uptake of large neutral amino acids.","SLC7A5 wt Allele | 4F2 LC | 4F2LC | Antigen Defined By Monoclonal Antibody 4F2, Light Chain Gene | CD98 | CD98LC | D16S469E | E16 | HLAT1 | LAT1 | MPE16 | Solute Carrier Family 7 (Amino Acid Transporter Light Chain, L System), Member 5 Gene | Solute Carrier Family 7 (Amino Acid Transporter Light Chain, L System), Member 5 wt Allele | Solute Carrier Family 7 (Cationic Amino Acid Transporter, Y+ System), Member 5 | Solute Carrier Family 7 Member 5 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0293237","SLC7A5 protein, human","C106590","Large neutral amino acids transporter small subunit 1 (507 aa, ~55 kDa) is encoded by the human SLC7A5 gene. This protein plays a role in both neutral amino acid transport and neurogenesis in the brain.","Large Neutral Amino Acids Transporter Small Subunit 1 | 4F2 LC | 4F2 Light Chain | 4F2LC | CD98 Light Chain | E16 | Integral Membrane Protein E16 | L-Type Amino Acid Transporter 1 | Large Neutral Amino Acids Transporter 1 | Membrane Protein E16 | SLC7A5 | Sodium-Independent Neutral Amino Acid Transporter LAT1 | Solute Carrier Family 7 (Cationic Amino Acid Transporter, Y+ System), Member 5 | Solute Carrier Family 7 Member 5 | Y+ System Cationic Amino Acid Transporter | hLAT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3536868","Glyceraldehyde-3-Phosphate Dehydrogenase","C104411","Glyceraldehyde-3-phosphate dehydrogenase (335 aa, ~36 kDa) is encoded by the human GAPDH gene. This protein is involved in carbohydrate metabolism.","Glyceraldehyde-3-Phosphate Dehydrogenase | Aging-Associated Gene 9 Protein | EC 1.2.1.12 | GAPDH | Peptidyl-Cysteine S-Nitrosylase GAPDH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3177718","Heparin Derivative SST0001","C104412","An N-acetylated, glycol-split form of heparin that is devoid of anticoagulant activity and is an inhibitor of heparanase with antineoplastic and antiangiogenic activities. Upon subcutaneous administration, roneparstat inhibits the activity of heparanase. This prevents the heparanase-mediated cleavage of heparan sulfate (HS) proteoglycans on cell surfaces and within the extracellular matrix. In addition, this agent prevents the heparanase-induced production of a number of angiogenic growth factors, including matrix metalloproteinase-9, hepatocyte growth factor and vascular endothelial growth factor. Altogether, this leads to an inhibition of both tumor cell growth and angiogenesis. Heparanase, an enzyme that is responsible for the proteolytic cleavage of proteoglycans, is upregulated in a variety of tumor cell types and promotes tumor cell growth; it plays a key role in tumor cell invasion, metastasis and angiogenesis.","Roneparstat | 100NA,RO-H | RONEPARSTAT | SST0001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL445680","Umbralisib","C104413","An orally bioavailable, selective inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinases (PI3K) with potential antineoplastic activity.  PI3K-delta inhibitor TGR-1202 inhibits PI3K and prevents the activation of the PI3K/AKT kinase signaling pathway. This decreases proliferation and induces cell death in susceptible tumor cells.  Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in tumor cells and cells of the hematopoietic lineage. The targeted inhibition of PI3K-delta allows for PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.","Umbralisib | 2-((1S)-1-(4-Amino-3-(3-fluoro-4-(1-methylethoxy)phenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-1-benzopyran-4-one | RP-5264 | RP5264 | TGR 1202 | TGR-1202 | TGR1202 | UMBRALISIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL445681","Geranylgeranyltransferase I Inhibitor","C104414","A substance that inhibits protein geranylgeranyltransferase type 1 (GGTase-I), with potential antineoplastic activity. GGTase-I is involved in the posttranslational modification of a number of oncogenic GTPases, including K-Ras, N-Ras, RhoA, RhoC, Cdc42, RalA, RalB and Rac1. Inhibition of the prenylation of these oncogenic proteins inhibits both their oncogenic activity and membrane localization. This may result in cell cycle arrest and apoptosis. Protein geranylgeranylation, catayzed by GGTase-I, plays a critical role in malignant transformation and cancer cell proliferation, migration and invasion.","Geranylgeranyltransferase I Inhibitor | GGTI-I | GGTase-I Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL445682","Gene-Modified HIV-Protected Hematopoietic Stem Cells","C104415","Autologous hematopoietic stem cells (HSCs) genetically modified to be resistant to infection by human immunodeficiency virus (HIV). Allogeneic human autologous HSCs are isolated and transduced ex vivo with three different anti-HIV genes. Upon infusion into the HIV-infected lymphoma patient, the gene-modified HIV-protected HSCs are resistant to HIV entry and replication thereby preventing HIV infection in these proliferating stem cells and any differentiated cells that they give rise to. This results in the formation of immune cells resistant to HIV which also may be able to destroy HIV-infected cells.","Gene-Modified HIV-Protected Hematopoietic Stem Cells | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542968","GATA6 wt Allele","C104417","Human GATA6 wild-type allele is located within 18q11-q12 and is approximately 33 kb in length. This allele, which encodes transcription factor GATA-6 protein, is involved in regulation of cellular differentiation and organogenesis during development. Mutations in this gene are associated with several congenital defects.","GATA6 wt Allele | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541333","BCCIP wt Allele","C103957","Human BCCIP wild-type allele is located in the vicinity of 10q26.1 and is approximately 30 kb in length. This allele, which encodes BRCA2 and CDKN1A-interacting protein, may play a role in both DNA damage repair and the cell cycle.","BCCIP wt Allele | BRCA2 and CDKN1A Interacting Protein wt Allele | TOK-1 | TOK1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540625","BRCA2 and CDKN1A-Interacting Protein, Human","C103958","BRCA2 and CDKN1A-interacting protein (314 aa, ~36 kDa) is encoded by the human BCCIP gene. This protein may be involved in the regulation of both cell cycle progression and DNA repair.","BRCA2 and CDKN1A-Interacting Protein | BCCIP | BRCA2 and Cip1/p21 Interacting Protein | Cdk Inhibitor P21 Binding Protein | P21- and CDK-Associated Protein 1 | Protein TOK-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539871","F-Box Only Protein 32, Human","C104225","F-box only protein 32 (355 aa, ~42 kDa) is encoded by the human FBXO32 gene. This protein plays a role in protein ubiquitination and degradation.","F-Box Only Protein 32 | Atrogin 1 | Atrogin-1 | F-Box Protein 32 | FBXO32 | Muscle Atrophy F-Box Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1305957","Troponin I, Cardiac Muscle","C104226","Troponin I, cardiac muscle (210 aa, ~24 kDa) is encoded by the human TNNI3 gene. This protein is involved in muscle filament movement in cardiac cells.","Troponin I, Cardiac Muscle | Cardiac Troponin I | TNNI3 | cTnI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542478","CCNA1 wt Allele","C104228","Human CCNA1 wild-type allele is located within 13q12.3-q13 and is approximately 11 kb in length. This allele, which encodes cyclin-A1 protein, plays a role in the control of the cell cycle at the G1/S and G2/M transitions.","CCNA1 wt Allele | Cyclin A1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2720171","CCNA1 protein, human","C104229","Cyclin-A1 (465 aa, ~52 kDa) is encoded by the human CCNA1 gene. This protein is involved in the G1/S and G2/M cell cycle transitions.","Cyclin-A1 | CCNA1 | Cyclin A1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641600","C-SSRS Since Last Visit - Number of Aborted Suicide Attempts","C103794","Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Total number of aborted attempts.","C-SSRS Since Last Visit - Number of Aborted Suicide Attempts | CSS02-Number of Aborted Attempts | CSS0218",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641601","C-SSRS Since Last Visit - Description of Aborted Suicide Attempt","C103795","Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Description of interrupted attempt.","C-SSRS Since Last Visit - Description of Aborted Suicide Attempt | CSS02-Aborted Attempt, Describe | CSS0218A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641602","C-SSRS Since Last Visit - Preparatory Acts or Behaviors Toward Suicide Attempt","C103796","Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Have you taken any steps toward making a suicide attempt or preparing to kill yourself (such as collecting pills, getting a gun, giving valuables away or writing a suicide note)?","C-SSRS Since Last Visit - Preparatory Acts or Behaviors Toward Suicide Attempt | CSS02-Preparatory Acts/Behavior | CSS0219",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641603","C-SSRS Since Last Visit - Description of Preparatory Acts or Behaviors Toward Suicide Attempt","C103797","Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Description of preparatory acts or behaviors.","C-SSRS Since Last Visit - Description of Preparatory Acts or Behaviors Toward Suicide Attempt | CSS02-Preparatory Acts/Behavior, Descr | CSS0219A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641604","C-SSRS Since Last Visit - Suicidal Behavior","C103798","Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Suicidal behavior was present during the assessment period?","C-SSRS Since Last Visit - Suicidal Behavior | CSS02-Suicidal Behavior | CSS0220",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641605","C-SSRS Since Last Visit - Ideation With Intent, No Plan","C103799","Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Have you have these thoughts and had some intention of acting on them?","C-SSRS Since Last Visit - Ideation With Intent, No Plan | CSS02-Ideation With Intent, No Plan | CSS0204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054633","Caracemide","C1037","An agent derived from acetohydroxamic acid with potential antineoplastic activity.  Caracemide inhibits ribonuclease reductase, resulting in decreased DNA synthesis and tumor growth; it also inhibits acetylcholinesterase.  In vivo, caracemide contributes to the formation of the neurotoxin methyl isocyanate; this effect, along with the agent's acetylcholinesterase activity, may be responsible for the severe central nervous system toxicity observed in clinical trials. (NCI04)","Caracemide | Acetamide, N-[(Methylamino)carbonyl]-N-[[(methylamino)carbonyl]oxy]-(9CI) | Acetamide, N-[(methylamino)carbonyl]-N-[[(methylamino)carbonyl]oxy]- (9CI) | CARACEMIDE | N-Acetyl-N-(methylcarbamoyloxy)-N'-methylurea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641485","OAB-q - Affected Your Relationships with Family and Friends","C103679","The Overactive Bladder Questionnaire (OAB-q) Affected your relationships with family and friends?","OAB-q - Affected Your Relationships with Family and Friends | OABQ01-Affected Relationships | OABQ0127",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641486","OAB-q - Decrease Participating in Social Gatherings","C103680","The Overactive Bladder Questionnaire (OAB-q) Caused you to decrease participating in social gatherings, such as parties or visits with family or friends?","OAB-q - Decrease Participating in Social Gatherings | OABQ01-Decrease Participating Gatherings | OABQ0128",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641488","OAB-q - Interfered with Getting Sleep","C103682","The Overactive Bladder Questionnaire (OAB-q) Interfered with getting the amount of sleep you needed?","OAB-q - Interfered with Getting Sleep | OABQ01-Interfered with Getting Sleep | OABQ0130",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641489","OAB-q - Caused Problems with Your Partner or Spouse","C103683","The Overactive Bladder Questionnaire (OAB-q) Caused you to have problems with your partner or spouse?","OAB-q - Caused Problems with Your Partner or Spouse | OABQ01-Caused Problems Partner/Spouse | OABQ0131",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641490","OAB-q - Plan Activities More Carefully","C103684","The Overactive Bladder Questionnaire (OAB-q) Caused you to plan activities more carefully?","OAB-q - Plan Activities More Carefully | OABQ01-Plan Activities More Carefully | OABQ0132",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641491","OAB-q - Locate Closest Restroom as Soon as You Arrive","C103685","The Overactive Bladder Questionnaire (OAB-q) Caused you to locate the closest restroom as soon as you arrive at a place you have never been?","OAB-q - Locate Closest Restroom as Soon as You Arrive | OABQ01-Locate Closest Restroom | OABQ0133",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641492","OAB-q Short Form - Uncomfortable Urge to Urinate","C103686","The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) An uncomfortable urge to urinate?","OAB-q Short Form - Uncomfortable Urge to Urinate | OABQ02-Uncomfortable Urge to Urinate | OABQ0201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641494","OAB-q Short Form - Accidental Loss of Urine","C103688","The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Accidental loss of small amounts of urine?","OAB-q Short Form - Accidental Loss of Urine | OABQ02-Accidental Loss of Urine | OABQ0203",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830012","GDS-SF - Feel Life Is Empty","C106796","Geriatric Depression Scale, Short Form (GDS-SF) Do you feel that your life is empty?","GDS-SF - Feel Life Is Empty | GDS02-Life Is Empty | GDS0203",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830006","GDS-SF - Often Get Bored","C106797","Geriatric Depression Scale, Short Form (GDS-SF) Do you often get bored?","GDS-SF - Often Get Bored | GDS02-Bored Often | GDS0204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830009","GDS-SF - Good Spirits Most of Time","C106798","Geriatric Depression Scale, Short Form (GDS-SF) Are you in good spirits most of the time?","GDS-SF - Good Spirits Most of Time | GDS02-Good Spirits Most of Time | GDS0205",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830017","GDS-SF - Afraid of Something Bad Happening","C106799","Geriatric Depression Scale, Short Form (GDS-SF) Are you afraid that something bad is going to happen to you?","GDS-SF - Afraid of Something Bad Happening | GDS02-Afraid of Something Bad Happening | GDS0206",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0057598","Dexamethasone Acetate","C1067","The acetate salt form of Dexamethasone, a synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","Dexamethasone Acetate, Unspecified | DEXAMETHASONE ACETATE, UNSPECIFIED FORM | Dalalone DP | Dalalone LA | Decadron LA | Dexamethasone Acetate | Dexamethasone Acetate | Dexamethasone acetate | Dexasone LA | Solurex LA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830013","GDS-SF - Feel Happy Most of Time","C106800","Geriatric Depression Scale, Short Form (GDS-SF) Do you feel happy most of the time?","GDS-SF - Feel Happy Most of Time | GDS02-Feel Happy Most of Time | GDS0207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830005","GDS-SF - Prefer to Stay Home","C106802","Geriatric Depression Scale, Short Form (GDS-SF) Do you prefer to stay at home, rather than going out and doing new things?","GDS-SF - Prefer to Stay Home | GDS02-Prefer to Stay Home | GDS0209",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830008","GDS-SF - More Memory Problems Than Most","C106803","Geriatric Depression Scale, Short Form (GDS-SF) Do you feel you have more problems with memory than most?","GDS-SF - More Memory Problems Than Most | GDS02-Memory Problems | GDS0210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830002","GDS-SF - Think Wonderful to Be Alive","C106804","Geriatric Depression Scale, Short Form (GDS-SF) Do you think it is wonderful to be alive now?","GDS-SF - Think Wonderful to Be Alive | GDS02-Wonderful to Be Alive | GDS0211",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830010","GDS-SF - Feel Worthless","C106805","Geriatric Depression Scale, Short Form (GDS-SF) Do you feel pretty worthless the way you are now?","GDS-SF - Feel Worthless | GDS02-Feel Worthless | GDS0212",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830014","GDS-SF - Feel Full of Energy","C106806","Geriatric Depression Scale, Short Form (GDS-SF) Do you feel full of energy?","GDS-SF - Feel Full of Energy | GDS02-Feel Full of Energy | GDS0213",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830011","GDS-SF - Feel Situation is Hopeless","C106807","Geriatric Depression Scale, Short Form (GDS-SF) Do you feel that your situation is hopeless?","GDS-SF - Feel Situation is Hopeless | GDS02-Feel Hopeless | GDS0214",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830003","GDS-SF - Think Most People Better Off Than You","C106808","Geriatric Depression Scale, Short Form (GDS-SF) Do you think that most people are better off than you are?","GDS-SF - Think Most People Better Off Than You | GDS02-Most People Better Off Than You | GDS0215",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829892","HAQ-DI With VAS - Able to Dress Yourself","C106809","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Dressing and grooming: are you able to dress yourself, including tying shoelaces and doing buttons?","HAQ-DI With VAS - Able to Dress Yourself | HAQ01-Dress Yourself | HAQ0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541973","ATF3 wt Allele","C103960","Human ATF3 wild-type allele is located in the vicinity of 1q32.3 and is approximately 55 kb in length. This allele, which encodes cyclic AMP-dependent transcription factor ATF-3 protein, is involved in both transcriptional repression and DNA binding.","ATF3 wt Allele | Activating Transcription Factor 3 wt Allele | RP11-338C15.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0253596","activating transcription factor 3","C103961","Cyclic AMP-dependent transcription factor ATF-3 (181 aa, ~21 kDa) is encoded by the human ATF3 gene. This protein plays a role in both DNA binding and the repression of gene expression.","Cyclic AMP-Dependent Transcription Factor ATF-3 | ATF-3 | ATF3 | Activating Transcription Factor 3 | cAMP-Dependent Transcription Factor ATF-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541860","ANLN wt Allele","C103963","Human ANLN wild-type allele is located within 7p15-p14 and is approximately 64 kb in length. This allele, which encodes anillin, plays a role in cleavage furrow dynamics.","ANLN wt Allele | ANILLIN | Anillin (Drosophila Scraps Homolog), Actin Binding Protein Gene | Anillin Actin Binding Protein wt Allele | Anillin, Actin Binding Protein (Scraps Homolog, Drosophila) Gene | Anillin, Actin Binding Protein Gene | FSGS8 | Scraps | scra",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3884130","anillin protein, human","C103964","Anillin (1124 aa, ~124 kDa) is encoded by the human ANLN gene. This protein plays a role in in maintaining the structural integrity of the cleavage furrow and in the completion of cell cleavage.","Anillin | ANLN | Actin-Binding Protein Anillin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541874","ACTB wt Allele","C103966","Human ACTB wild-type allele is located in the vicinity of 7p22 and is approximately 37 kb in length. This allele, which encodes actin, cytoplasmic 1 protein, plays a role in the modulation of both cell motility and cell shape. Mutation of the gene is associated with dystonia juvenile-onset and Baraitser-Winter syndrome type 1.","ACTB wt Allele | Actin Beta wt Allele | Actin, Beta Gene | Actin, Beta wt Allele | BRWS1 | PS1TP5BP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034345","Pyruvate Dehydrogenase Deficiency","C103968","A genetic disorder caused by mutations in the genes that are responsible for production of protein components of the pyruvate dehydrogenase complex. It may present with lactic acidosis. Signs and symptoms include developmental delays, seizures and hypotonia.","Pyruvate Dehydrogenase Deficiency | PDH",,,,,,,,,,,,,,,"4262820","Pyruvate dehydrogenase complex deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005186","beta-Actin","C103969","Actin, cytoplasmic 1 (375 aa, ~42 kDa) is encoded by the human ACTB gene. This protein is involved in both cell motility and morphology.","Actin, Cytoplasmic 1 | ACTB | Beta-Actin | PS1TP5-Binding Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0665744","DEGS1 protein, human","C104177","Sphingolipid delta(4)-desaturase DES1 (323 aa, ~38 kDa) is encoded by the human DEGS1 gene. This protein plays a role in fatty acid biosynthesis.","Sphingolipid Delta(4)-Desaturase DES1 | Cell Migration-Inducing Gene 15 Protein | DEGS1 | DES1 | Degenerative Spermatocyte Homolog 1 | Delta(4)-Desaturase, Sphingolipid 1 | Dihydroceramide Desaturase | Dihydroceramide Desaturase 1 | Membrane Fatty Acid (Lipid) Desaturase | Membrane Lipid Desaturase | Sphingolipid Delta(4)-Desaturase 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641606","C-SSRS Since Last Visit - Description of Ideation With Intent, No Plan","C103800","Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Description of active suicidal ideation with some intent to act, without specific plan.","C-SSRS Since Last Visit - Description of Ideation With Intent, No Plan | CSS02-Ideation With Intent No Plan Descr | CSS0204A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641607","C-SSRS Since Last Visit - Ideation With Plan/Intent","C103801","Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan?","C-SSRS Since Last Visit - Ideation With Plan/Intent | CSS02-Ideation With Plan/Intent | CSS0205",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541320","G Antigen 2D","C104469","G antigen 2D (116 aa, ~13 kDa) is encoded by both the human GAGE2D and GAGE8 genes. This protein may be involved in tumor antigenicity.","G Antigen 2D | CT4.8 | Cancer/Testis Antigen 4.8 | G Antigen 8 | GAGE-2D | GAGE-8 | GAGE2D | GAGE8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541252","GAGE7 wt Allele","C104471","Human GAGE7 wild-type allele is located within Xp11.4-p11.2 and is approximately 7 kb in length. This allele, which encodes G antigen 7 protein, may be involved in tumor antigenicity.","GAGE7 wt Allele | AL4 | CT4.7 | Cancer/Testis Antigen Family 4, Member 7 Gene | G Antigen 7 wt Allele | GAGE-7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537325","G Antigen 7","C104472","G antigen 7 (117 aa, ~13 kDa) is encoded by the human GAGE7 gene. This protein may play a role in tumor recognition.","G Antigen 7 | CT4.7 | Cancer/Testis Antigen 4.7 | GAGE-12I | GAGE-7 | GAGE-7B | GAGE-8 | GAGE7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541250","GAGE6 wt Allele","C104474","Human GAGE6 wild-type allele is located within Xp11.4-p11.2 and is approximately 7 kb in length. This allele, which encodes G antigen 6 protein, may play a role in tumor transformation.","GAGE6 wt Allele | CT4.6 | Cancer/Testis Antigen Family 4, Member 6 Gene | G Antigen 6 wt Allele | GAGE-6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539539","G Antigen 2A","C104378","G antigen 2A (116 aa, ~13 kDa) is encoded by the human GAGE2A gene. This protein may be involved in tumorigenesis.","G Antigen 2A | Cancer/Testis Antigen 4.2 | Cancer/Testis Antigen Family 4, Member 2 | G Antigen 2 | G Antigen 2A/2B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540652","FGD4 wt Allele","C104380","Human FGD4 wild-type allele is located in the vicinity of 12p11.21 and is approximately 246 kb in length. This allele, which encodes FYVE, RhoGEF and PH domain-containing protein 4, is involved in regulation of the actin cytoskeleton and cell shape. Mutations in this gene are associated with Charcot-Marie-Tooth disease type 4H (CMT4H).","FGD4 wt Allele | CMT4H | FGD1 Family, Member 4 Gene | FRABP | FYVE, RhoGEF and PH Domain Containing 4 wt Allele | Frabin Gene | ZFYVE6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541415","ASAH2C wt Allele","C103909","Human ASAH2C wild-type allele is located in the vicinity of 10q11.22 and is approximately 56 kb in length. This allele, which encodes putative neutral ceramidase C protein, may play a role in sphingolipid metabolism.","ASAH2C wt Allele | ASAH2L | Ceramidase, Nonlysosomal, C Gene | N-Acylsphingosine Amidohydrolase (Non-Lysosomal Ceramidase) 2C Gene | N-Acylsphingosine Amidohydrolase (Non-Lysosomal Ceramidase) 2C wt Allele | RP11-98I6.3 | bA98I6.3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538753","Putative Neutral Ceramidase C","C103910","Putative neutral ceramidase C (622 aa, ~69 kDa) is encoded by the human ASAH2C gene. This protein may be involved in sphingosine synthesis.","Putative Neutral Ceramidase C | ASAH2C | EC 3.5.1.23 | N-Acylsphingosine Amidohydrolase 2C | Non-Lysosomal Ceramidase C | Nonlysosomal Ceramidase C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829881","HAQ-DI With VAS - Able to Stand Up From Chair","C106811","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Arising: are you able to stand up from a straight chair?","HAQ-DI With VAS - Able to Stand Up From Chair | HAQ01-Stand Up From a Straight Chair | HAQ0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828150","SGRQ-C - Respiratory Problems Affect Daily Life: Cannot Play Sports","C107022","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) We would like to know how your respiratory problems usually affect your daily life: I cannot play sports or do other physical activities.","SGRQ-C - Respiratory Problems Affect Daily Life: Cannot Play Sports | SGRQC1-Cannot Play Sports | SGRQC136",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828153","SGRQ-C - Respiratory Problems Affect Daily Life: Cannot Go Out for Entertainment","C107023","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) We would like to know how your respiratory problems usually affect your daily life: I cannot go out for entertainment or recreation.","SGRQ-C - Respiratory Problems Affect Daily Life: Cannot Go Out for Entertainment | SGRQC1-Cannot Go Out for Entertainment | SGRQC137",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828152","SGRQ-C - Respiratory Problems Affect Daily Life: Cannot Go Out to Do Shopping","C107024","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) We would like to know how your respiratory problems usually affect your daily life: I cannot go out of the house to do the shopping.","SGRQ-C - Respiratory Problems Affect Daily Life: Cannot Go Out to Do Shopping | SGRQC1-Cannot Go Out to Do Shopping | SGRQC138",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828154","SGRQ-C - Respiratory Problems Affect Daily Life: Cannot Do Household Chores","C107025","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) We would like to know how your respiratory problems usually affect your daily life: I cannot do household chores.","SGRQ-C - Respiratory Problems Affect Daily Life: Cannot Do Household Chores | SGRQC1-Cannot Do Household Chores | SGRQC139",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828151","SGRQ-C - Respiratory Problems Affect Daily Life: Cannot Move Far From Bed","C107026","St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) We would like to know how your respiratory problems usually affect your daily life: I cannot move far from my bed or chair.","SGRQ-C - Respiratory Problems Affect Daily Life: Cannot Move Far From Bed | SGRQC1-Cannot Move Far From My Bed | SGRQC140",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830911","C-SSRS Already Enrolled Subjects - Wish to Be Dead (Prior to Study Entry)","C107027","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects) Have you wished you were dead or wished you could go to sleep and not wake up? (Prior to Study Entry).","C-SSRS Already Enrolled Subjects - Wish to Be Dead (Prior to Study Entry) | CSS05-Wish to be Dead-Prior | CSS0501A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830910","C-SSRS Already Enrolled Subjects - Wish to Be Dead (Since Study Start)","C107028","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects) Have you wished you were dead or wished you could go to sleep and not wake up? (Since Study Start).","C-SSRS Already Enrolled Subjects - Wish to Be Dead (Since Study Start) | CSS05-Wish to be Dead-Since | CSS0501B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830948","C-SSRS Already Enrolled Subjects - Description of Wish to Be Dead","C107029","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Description of wishing to be dead.","C-SSRS Already Enrolled Subjects - Description of Wish to Be Dead | CSS05-Wish to be Dead, Describe | CSS0501C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281353","bicalutamide/goserelin","C10702","A regimen consisting of bicalutamide and goserelin that can be used for the treatment of prostate cancer.","Bicalutamide/Goserelin Regimen | Bicalutamide and Goserelin | Bicalutamide-Goserelin | Bicalutamide-Goserelin Regimen | Bicalutamide/Goserelin | CDX/ZDX | Goserelin/Bicalutamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830928","C-SSRS Already Enrolled Subjects - Non-Specific Active Suicidal Thoughts (Prior to Study Entry)","C107030","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Have you actually had any thoughts of killing yourself? (Prior to Study Entry).","C-SSRS Already Enrolled Subjects - Non-Specific Active Suicidal Thoughts (Prior to Study Entry) | CSS05-Non-Spec Suicid Thought-Prior | CSS0502A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541876","DEGS2 wt Allele","C104179","Human DEGS2 wild-type allele is located in the vicinity of 14q32.2 and is approximately 14 kb in length. This allele, which encodes sphingolipid delta(4)-desaturase/C4-hydroxylase DES2 protein, plays a role in sphingolipid biosynthesis.","DEGS2 wt Allele | C14orf66 | Chromosome 14 Open Reading Frame 66 | DES2 | Delta(4)-Desaturase, Sphingolipid 2 wt Allele | FADS8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641732","Sphingolipid Delta(4)-Desaturase/C4-Hydroxylase DES2","C104180","Sphingolipid delta(4)-desaturase/C4-hydroxylase DES2 (323 aa, ~37 kDa) is encoded by the human DEGS2 gene. This protein is involved in sphingolipid biosynthesis.","Sphingolipid Delta(4)-Desaturase/C4-Hydroxylase DES2 | DEGS2 | DES2 | Degenerative Spermatocyte Homolog 2 | Degenerative Spermatocyte Homolog 2, Lipid Desaturase | Degenerative Spermatocyte Homolog 2, Lipid Desaturase (Drosophila) | Sphingolipid C4-Hydroxylase/Delta 4-Desaturase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540633","DCAF7 wt Allele","C104182","Human DCAF7 wild-type allele is located in the vicinity of 17q23.3 and is approximately 44 kb in length. This allele, which encodes DDB1- and CUL4-associated factor 7 protein, may be involved in regulation of transcription.","DCAF7 wt Allele | AN11 | AN11, Petunia, Homolog of Gene | DDB1 and CUL4 Associated Factor 7 wt Allele | HAN11 | SWAN-1 | WDR68",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539812","DDB-1 and CUL4-Associated Factor 7","C104183","DDB1- and CUL4-associated factor 7 (342 aa, ~39 kDa) is encoded by the human DCAF7 gene. This protein may play a role in regulation of transcription.","DDB1- and CUL4-Associated Factor 7 | DCAF7 | Human Anthocyanin | Seven-WD-Repeat Protein of the AN11 Family-1 | WD Repeat Domain 68 | WD Repeat-Containing Protein 68 | WD Repeat-Containing Protein An11 Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539767","DDIT4 wt Allele","C104185","Human DDIT4 wild-type allele is located in the vicinity of 10q22.1 and is approximately 2 kb in length. This allele, which encodes DNA damage-inducible transcript 4 protein, plays a role in responses to cellular stress and regulates apoptosis in response to DNA damage.","DDIT4 wt Allele | DNA-Damage-Inducible Transcript 4 wt Allele | Dig2 | FLJ20500 | REDD-1 | REDD1 | RTP801",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539835","DNA Damage-Inducible Transcript 4 Protein","C104186","DNA damage-inducible transcript 4 protein (232 aa, ~25 kDa) is encoded by the human DDIT4 gene. This protein is involved in responses to cellular stress and regulates apoptosis in response to DNA damage.","DNA Damage-Inducible Transcript 4 Protein | HIF-1 Responsive Protein | Protein Regulated in Development and DNA Damage Response 1 | RTP801",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539639","EIF2S1 wt Allele","C104188","Human EIF2S1 wild-type allele is located in the vicinity of 14q21.3 and is approximately 27 kb in length. This allele, which encodes eukaryotic translation initiation factor 2 subunit 1 protein, is involved in the initiation of protein translation.","EIF2S1 wt Allele | EIF-2-alpha | EIF2 | EIF2A | Eukaryotic Translation Initiation Factor 2, Subunit 1 Alpha, 35kDa wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013733","Eukaryotic Initiation Factor-2, alpha Subunit","C104189","Eukaryotic translation initiation factor 2 subunit 1 (315 aa, ~36 kDa) is encoded by the human EIF2S1 gene. This protein plays a role in the initiation of protein translation.","Eukaryotic Translation Initiation Factor 2 Subunit 1 | EIF2S1 | Eukaryotic Translation Initiation Factor 2 Subunit Alpha | eIF-2-alpha | eIF-2A | eIF-2alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541251","G Antigen 6","C104477","G antigen 6 (117 aa, ~13 kDa) is encoded by the human GAGE6 gene. This protein may be involved in tumor malignancy.","G Antigen 6 | CT4.6 | Cancer/Testis Antigen 4.6 | GAGE-6 | GAGE6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537271","G Antigen 5","C104482","G antigen 5 (117 aa, ~13 kDa) is encoded by the human GAGE5 gene. This protein may play a role in tumor formation.","G Antigen 5 | CT4.5 | Cancer/Testis Antigen 4.5 | GAGE-5 | GAGE5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537324","G Antigen 4","C104484","G antigen 4 (117 aa, ~13 kDa) is encoded by the human GAGE4 gene. This protein may be involved in tumor transformation.","G Antigen 4 | CT4.4 | Cancer/Testis Antigen 4.4 | GAGE-4 | GAGE4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541248","GAGE4 wt Allele","C104485","Human GAGE4 wild-type allele is located within Xp11.4-p11.2 and is approximately 6 kb in length. This allele, which encodes G antigen 4 protein, may play a role in tumor formation.","GAGE4 wt Allele | CT4.4 | Cancer/Testis Antigen Family 4, Member 4 Gene | G Antigen 4 wt Allele | GAGE-4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541245","G Antigen 1","C104491","G antigen 1 (139 aa, ~16 kDa) is encoded by the human GAGE1 gene. This protein may be involved in tumor formation.","G Antigen 1 | Antigen MZ2-F | CT4.1 | Cancer/Testis Antigen 4.1 | GAGE-1 | GAGE1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438391","MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells","C104009","A preparation of polyclonal autologous CD8 positive T-lymphocytes specific for the Merkel cell polyomavirus (MCPyV) T antigen (TAg) with potential antineoplastic activity. Peripheral blood lymphocytes from a Merkel cell carcinoma (MCC) patient were obtained and antigen-specific CD8+ T cells targeting a specific MCPyV TAg epitope were derived and expanded ex vivo. Upon infusion of the MCPyV TAg-specific polyclonal autologous CD8-positive T cell vaccine, the T cells recognize the MCPyV antigen and exert a cytotoxic T-lymphocyte response against the MCPyV TAg-expressing MCC cells. MCPyV is expressed in about 80% of MCC and is not expressed in normal, human tissue; the MCPyVTag oncoprotein plays a key role in MCC survival and tumor cell proliferation.","MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438392","Zirconium Zr 89-labeled RO5479599","C104010","A radioimmunoconjugate containing a glycoengineered, humanized monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3) and labeled with the radioisotope zirconium Zr 89, with radioisotopic activity and potential use as an imaging agent as well as potential antineoplastic activity. Upon administration, the RO5479599 moiety of zirconium Zn 89-labeled RO5479599 binds to the extracellular domain of HER3 and inhibits HER3 dimerization, thereby preventing EGFR-dependent signaling. In addition, RO5479599 elicits enhanced antibody-dependent cellular cytotoxicity (ADCC). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER3-expressing tumor cells. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors; it has no active kinase domain but is activated through heterodimerization with other members of the EGFR receptor family, such as HER2.","Zirconium Zr 89-labeled RO5479599 | 89Zr-RO5479599 | 89Zr-labeled RO5479599",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2677367","Right Aortic Arch","C103917","An anatomic abnormality that occurs during embryonic development, in which the aortic arch is right-sided.","Right Aortic Arch | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0266312","Microcystic Renal Disease","C103918","A congenital renal disorder characterized by the presence of small cysts in the renal cortex and/or renal medulla.","Microcystic Renal Disease | ",,,,,,,,,,,,,,,"4237290","Microcystic renal disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0431719","Solitary Multilocular Kidney Cyst","C103919","A single cyst in the kidney with several compartments.","Solitary Multilocular Kidney Cyst | Solitary Multilocular Renal Cyst",,,,,,,,,,,,,,,"4312856","Solitary multilocular renal cyst",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3539063","Bart's Hemoglobinopathy","C103920","A severe and rare form of alpha thalassemia characterized by the absence of alpha globin chains. It results in hydrops fetalis, severe anemia, hepatosplenomegaly, heart defects, and genitourinary abnormalities. It leads to death in utero or shortly thereafter.","Hemoglobin Barts | Bart's Hemoglobinopathy | Hemoglobin Bart's Hydrops",,,,,,,,,,,,,,,"4200254","Hemoglobin Bart's hydrops syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4014043","Lissencephaly","C103921","A rare genetic brain malformation characterized by smooth folds and grooves in the brain. There are approximately 20 different types of lissencephaly that are identified by various symptoms.","Lissencephaly | ",,,,,,,,,,,,,,,"4070082","Lissencephaly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0266323","Congenital Hydroureter","C103922","Dilatation of the ureter caused by obstruction of urine flow that is present at birth.","Congenital Hydroureter | ",,,,,,,,,,,,,,,"4151274","Congenital hydroureter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265675","Congenital Postural Scoliosis","C103923","Abnormal sideways curvature of the spine that is present at birth.","Congenital Postural Scoliosis | ",,,,,,,,,,,,,,,"4049645","Congenital postural scoliosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3539672","ALOX12 wt Allele","C103925","Human ALOX12 wild-type allele is located in the vicinity of 17p13.1 and is approximately 15 kb in length. This allele, which encodes arachidonate 12-lipoxygenase, 12S-type protein, is involved in leukotriene synthesis.","ALOX12 wt Allele | 12-LOX | 12S-LOX | Arachidonate 12-Lipoxygenase wt Allele | LOG12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538850","CDC25C wt Allele","C104135","Human CDC25C wild-type allele is located in the vicinity of 5q31 and is approximately 53 kb in length. This allele, which encodes m-phase inducer phosphatase 3 protein, is involved in mitotic control and cell cycle progression.","CDC25C wt Allele | CDC25 | Cell Division Cycle 25 Homolog C wt Allele | PPP1R60",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0213045","Cdc25C protein","C104136","M-phase inducer phosphatase 3 (473 aa, ~53 kDa) is encoded by the human CDC25C gene. This protein plays a role in cell cycle progression through the G1/S checkpoint.","M-Phase Inducer Phosphatase 3 | CDC25C | Cell Division Cycle 25 Homolog C | Dual Specificity Phosphatase Cdc25C | EC 3.1.3.48 | Protein Phosphatase 1, Regulatory Subunit 60",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830950","C-SSRS Already Enrolled Subjects - Description of Non-Specific Active Suicidal Thoughts","C107032","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Description of non-specific active suicidal Thoughts.","C-SSRS Already Enrolled Subjects - Description of Non-Specific Active Suicidal Thoughts | CSS05-Non-Spec Suicid Thought, Describe | CSS0502C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830969","C-SSRS Already Enrolled Subjects - Active Suicidal Ideation With Any Methods (Not Plan) Without Intent to Act (Since Study Start)","C107034","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Have you been thinking about how you might do this? (Since Study Start).","C-SSRS Already Enrolled Subjects - Active Suicidal Ideation With Any Methods (Not Plan) Without Intent to Act (Since Study Start) | CSS05-Idea, No Intent, No Plan-Since | CSS0503B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828459","Protein FAM131B","C106342","Protein FAM131B (332 aa, ~36 kDa) is encoded by the human FAM131B gene. This protein has no known function.","Protein FAM131B | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416692","KLC1 Gene","C106343","This gene plays a role in microtubule-based movement.","KLC1 Gene | KLC1 | Kinesin Light Chain 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812221","KLC1 wt Allele","C106344","Human KLC1 wild-type allele is located in the vicinity of 14q32.3 and is approximately 140 kb in length. This allele, which encodes kinesin light chain 1 protein, is involved in organelle transport.","KLC1 wt Allele | KLC | KNS2 | KNS2A | Kinesin 2 Gene | Kinesin Light Chain 1 wt Allele | hKLC1B | hKLC1G | hKLC1J | hKLC1N | hKLC1P | hKLC1R | hKLC1S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1505128","Kinesin Light Chain 1, Human","C106345","Kinesin light chain 1 (573 aa, ~65 kDa) is encoded by the human KLC1 gene. This protein plays a role in microtubule motor activity.","Kinesin Light Chain 1 | KLC 1 | KLC1 | Kinesin 2 60/70kDa | Medulloblastoma Antigen MU-MB-2.50",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810646","EFEMP1 wt Allele","C106347","Human EFEMP1 wild-type allele is located in the vicinity of 2p16 and is approximately 58 kb in length. This allele, which encodes EGF-containing fibulin-like extracellular matrix protein 1, plays a role in cell surface receptor binding. Aberrant expression of the gene is associated with glioma. Mutation of the gene is associated with Doyne honeycomb retinal dystrophy.","EFEMP1 wt Allele | DHRD | DRAD | EGF Containing Fibulin Like Extracellular Matrix Protein 1 wt Allele | EGF Containing Fibulin-Like Extracellular Matrix Protein 1 Gene | FBLN3 | FBNL | FIBL-3 | Fibrillin-Like Gene | Fibulin 3 Gene | MLVT | MTLV | S1-5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447731","EGF-Containing Fibulin-Like Extracellular Matrix Protein 1, Human","C106348","EGF-containing fibulin-like extracellular matrix protein 1 (493 aa, ~55 kDa) is encoded by the human EFEMP1 gene. This protein is involved in receptor binding.","EGF-Containing Fibulin-Like Extracellular Matrix Protein 1 | EFEMP1 | EGF Containing Fibulin-Like Extracellular Matrix Protein 1 | Extracellular Protein S1-5 | FIBL-3 | Fibrillin-Like Protein | Fibulin 3 | Fibulin-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424515","CIZ1 Gene","C106349","This gene plays a role in the regulation of DNA replication.","CIZ1 Gene | CDKN1A Interacting Zinc Finger Protein 1 Gene | CIZ1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811756","CIZ1 wt Allele","C106350","Human CIZ1 wild-type allele is located in the vicinity of 9q34.1 and is approximately 38 kb in length. This allele, which encodes Cip1-interacting zinc finger protein, is involved in the positive regulation of DNA replication.","CIZ1 wt Allele | CDKN1A Interacting Zinc Finger Protein 1 wt Allele | LSFR1 | NP94 | ZNF356",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813547","Cip1-Interacting Zinc Finger Protein, Human","C106351","Cip1-interacting zinc finger protein (898 aa, ~100 kDa) is encoded by the human CIZ1 gene. This protein plays a role in the modulation of both cyclin-dependent kinase inhibitor 1 protein localization and DNA replication.","Cip1-Interacting Zinc Finger Protein | CDKN1A-Interacting Zinc Finger Protein 1 | CIZ1 | Nuclear Protein NP94 | Zinc Finger Protein 356",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419895","SDCBP Gene","C106352","This gene is involved in protein-protein interactions.","SDCBP Gene | SDCBP | Syndecan Binding Protein (Syntenin) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641546","SIQR - I was Completely Overwhelmed by My Medical Problem","C103740","Symptom Impact Questionnaire (SIQR) I was completely overwhelmed by my medical problems.","SIQR - I was Completely Overwhelmed by My Medical Problem | SIQR01-Overwhelmed by Medical Problems | SIQR0111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641547","SIQR - Pain","C103741","Symptom Impact Questionnaire (SIQR) Please rate your level of pain.","SIQR - Pain | SIQR01-Pain | SIQR0112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641548","SIQR - Energy","C103742","Symptom Impact Questionnaire (SIQR) Please rate your level of energy.","SIQR - Energy | SIQR01-Energy | SIQR0113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641549","SIQR - Stiffness","C103743","Symptom Impact Questionnaire (SIQR) Please rate your level of stiffness.","SIQR - Stiffness | SIQR01-Stiffness | SIQR0114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641550","SIQR - Your Sleep","C103744","Symptom Impact Questionnaire (SIQR) Please rate the quality of your sleep.","SIQR - Your Sleep | SIQR01-Your Sleep | SIQR0115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641551","SIQR - Depression","C103745","Symptom Impact Questionnaire (SIQR) Please rate your level of depression.","SIQR - Depression | SIQR01-Depression | SIQR0116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641552","SIQR - Memory Problems","C103746","Symptom Impact Questionnaire (SIQR) Please rate your level of memory problems.","SIQR - Memory Problems | SIQR01-Memory Problems | SIQR0117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641554","SIQR - Tenderness to Touch","C103748","Symptom Impact Questionnaire (SIQR) Please rate your level of tenderness to touch.","SIQR - Tenderness to Touch | SIQR01-Tenderness to Touch | SIQR0119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641555","SIQR - Balance Problems","C103749","Symptom Impact Questionnaire (SIQR) Please rate your level of balance problems.","SIQR - Balance Problems | SIQR01-Balance Problems | SIQR0120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641556","SIQR - Sensitivity to Loud Noises, Bright Lights, Odors and Cold","C103750","Symptom Impact Questionnaire (SIQR) Please rate your level of sensitivity to loud noises, bright lights, odors and cold.","SIQR - Sensitivity to Loud Noises, Bright Lights, Odors and Cold | SIQR01-Sensitivity Noise/Light/Odor/Cold | SIQR0121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641557","SOWS Short - Feeling Sick","C103751","Short Opiate Withdrawal Scale (SOWS Short) Feeling sick.","SOWS Short - Feeling Sick | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641558","SOWS Short - Stomach Cramps","C103752","Short Opiate Withdrawal Scale (SOWS Short) Stomach cramps.","SOWS Short - Stomach Cramps | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641559","SOWS Short - Muscle Spasms/Twitching","C103753","Short Opiate Withdrawal Scale (SOWS Short) Muscle spasms/twitching.","SOWS Short - Muscle Spasms/Twitching | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641560","SOWS Short - Feelings of Coldness","C103754","Short Opiate Withdrawal Scale (SOWS Short) Feelings of coldness.","SOWS Short - Feelings of Coldness | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641562","SOWS Short - Muscular Tension","C103756","Short Opiate Withdrawal Scale (SOWS Short) Muscular tension.","SOWS Short - Muscular Tension | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641563","SOWS Short - Aches and Pains","C103757","Short Opiate Withdrawal Scale (SOWS Short) Aches and pains.","SOWS Short - Aches and Pains | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641564","SOWS Short - Yawning","C103758","Short Opiate Withdrawal Scale (SOWS Short) Yawning.","SOWS Short - Yawning | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641565","SOWS Short - Runny Eyes","C103759","Short Opiate Withdrawal Scale (SOWS Short) Runny eyes.","SOWS Short - Runny Eyes | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2932888","Alkaline Phosphatase, Tissue-Nonspecific Isozyme, Human","C104232","Alkaline phosphatase, tissue-nonspecific isozyme (524 aa, ~57 kDa) is encoded by the human ALPL gene. This protein may play a role in matrix mineralization.","Alkaline Phosphatase, Tissue-Nonspecific Isozyme | ALPL | AP-TNAP | Alkaline Phosphatase Liver/Bone/Kidney Isozyme | Alkaline Phosphomonoesterase | EC 3.1.3.1 | Liver/Bone/Kidney-Type Alkaline Phosphatase | TNSALP | Tissue Non-Specific Alkaline Phosphatase | Tissue-Nonspecific ALP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539597","CYP1B1 wt Allele","C104235","Human CYP1B1 wild-type allele is located in the vicinity of 2p22.2 and is approximately 43 kb in length. This allele, which encodes cytochrome P450 1B1 protein, is involved in both the development of the eye and the metabolism of xenobiotics and steroids. Mutation of the gene is associated with primary congenital glaucoma type 3A, primary open angle glaucoma and Peters anomaly.","CYP1B1 wt Allele | CP1B | CYPIB1 | Cytochrome P450, Family 1, Subfamily B, Polypeptide 1 wt Allele | Cytochrome P450, Subfamily I (Dioxin-Inducible), Polypeptide 1 (Glaucoma 3, Primary Infantile) Gene | GLC3A | P4501B1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539596","CP wt Allele","C104138","Human CP wild-type allele is located within 3q23-q25 and is approximately 60 kb in length. This allele, which encodes ceruloplasmin protein, plays a role in iron homeostasis and neuronal survival. Mutations cause aceruloplasminemia, which results in iron accumulation and tissue damage, and is associated with diabetes and neurologic abnormalities.","CP wt Allele | CP-2 | Ceruloplasmin (Ferroxidase) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647982","Ceruloplasmin","C104139","Ceruloplasmin (1065 aa, ~122 kDa) is encoded by the human CP gene. This protein is involved in iron homeostasis.","Ceruloplasmin | CP | Ferroxidase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539702","CRBN wt Allele","C104141","Human CRBN wild-type allele is located in the vicinity of 3p26.3 and is approximately 31 kb in length. This allele, which encodes protein cereblon protein, is involved in ubiquitin-mediated protein degradation. Mutations are associated with autosomal recessive nonsyndromic mental retardation.","CRBN wt Allele | Cereblon wt Allele | MRT2A | Mental Retardation, Non-Syndromic, Autosomal Recessive, 2A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641726","CRBN protein, human","C104142","Protein cereblon (442 aa, ~51 kDa) is encoded by the human CRBN gene. This protein plays a role in assembly and regulation of calcium-activated potassium channels in brain.","Protein Cereblon | CRBN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538864","CXCL16 wt Allele","C104144","Human CXCL16 wild-type allele is located in the vicinity of 17p13 and is approximately 6 kb in length. This allele, which encodes C-X-C motif chemokine 16 protein, may play a role in lymphocyte chemotaxis and scavenger receptor for oxidized low density lipoprotein.","CXCL16 wt Allele | CXCLG16 | Chemokine (C-X-C motif) Ligand 16 wt Allele | SR-PSOX | SRPSOX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3543836","C-X-C Motif Chemokine 16","C104145","C-X-C motif chemokine 16 (254 aa, ~28 kDa) is encoded by the human CXCL16 gene. This protein may be involved in lymphocyte chemotaxis.","C-X-C Motif Chemokine 16 | CXC Chemokine Ligand 16 | CXCL16 | Scavenger Receptor for Phosphatidylserine and Oxidized Low Density Lipoprotein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541982","CYP24A1 wt Allele","C104147","Human CYP24A1 wild-type allele is located in the vicinity of 20q13.2 and is approximately 21 kb in length. This allele, which encodes 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial protein, is involved in vitamin D3 metabolism and calcium homeostasis. Mutations in CYP24A1 are associated with infantile hypercalcemia.","CYP24A1 wt Allele | CP24 | CYP24 | Cytochrome P450 Family 24 Subfamily A Member 1 wt Allele | Cytochrome P450, Family 24, Subfamily A, Polypeptide 1 Gene | Cytochrome P450, Subfamily XXIV (Vitamin D 24-Hydroxylase) Gene | Cytochrome P450, Subfamily XXIV Gene | Exo-Mitochondrial Protein Gene | HCAI | HCINF1 | LncBCAS1-4_1 | P450-CC24 | Vitamin D 24-Hydroxylase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0283470","CYP24A1 protein, human","C104148","1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (514 aa, ~59 kDa) is encoded by the human CYP24A1 gene. This protein plays a role in calcium homeostasis.","1,25-Dihydroxyvitamin D(3) 24-Hydroxylase, Mitochondrial | 1,25-Dihydroxyvitamin D3 24-Hydroxylase | 24-OHase | CYP24A1 | Cytochrome P450 24A1 | Cytochrome P450 Family 24 Subfamily A Member 1 | Cytochrome P450-CC24 | EC 1.14.13.126 | EC 1.14.13.16 | Exo-Mitochondrial Protein | Vitamin D 24-Hydroxylase | Vitamin D(3) 24-Hydroxylase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641495","OAB-q Short Form - Nighttime Urination","C103689","The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Nighttime urination?","OAB-q Short Form - Nighttime Urination | OABQ02-Nighttime Urination | OABQ0204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812243","SDCBP wt Allele","C106353","Human SDCBP wild-type allele is located in the vicinity of 8q12 and is approximately 30 kb in length. This allele, which encodes syntenin-1 protein, plays a role in the mediation of syndecan coupling to the cytoskeleton.","SDCBP wt Allele | MDA-9 | ST1 | SYCL | Syndecan Binding Protein (Syntenin) wt Allele | TACIP18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1308361","Melanoma Differentiation Associated Protein 9, human","C106354","Syntenin-1 (298 aa, ~32 kDa) is encoded by the human SDCBP gene. This protein is involved in mediating intracellular protein-protein interactions.","Syntenin-1 | MDA-9 | Melanoma Differentiation Associated Protein 9 | Melanoma Differentiation-Associated Protein 9 | Pro-TGF-Alpha Cytoplasmic Domain-Interacting Protein 18 | SDCBP | Scaffold Protein Pbp1 | Syndecan-Binding Protein 1 | TACIP18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425475","IFNL3 Gene","C106355","This gene plays a role in cytokine signaling.","IFNL3 Gene | IFNL3 | Interferon, Lambda 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815173","IFNL3 wt Allele","C106356","Human IFNL3 wild-type allele is located in the vicinity of 19q13.13 and is approximately 1 kb in length. This allele, which encodes interferon lambda-3 protein, is involved in both cytokine receptor binding and immunomodulation.","IFNL3 wt Allele | IL-28B | IL28B | IL28C | Interferon, Lambda 3 wt Allele | Interleukin 28B (Interferon, Lambda 3) Gene | Interleukin 28B Gene | ZCYTO22",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811252","CD63 wt Allele","C106592","Human CD63 wild-type allele is located within 12q12-q13 and is approximately 4 kb in length. This allele, which encodes CD63 antigen protein, plays a role in signal transduction and may play a role in growth regulation. Mutation of this gene is associated with tumor progression and deficiency of the protein is associated with Hermansky-Pudlak syndrome.","CD63 wt Allele | CD63 Molecule wt Allele | LAMP-3 | ME491 | MLA1 | OMA81H | TSPAN30",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0083298","CD63 Antigen","C106593","CD63 antigen (238 aa, ~256 kDa) is encoded by the human CD63 gene. This protein is involved in signal transduction and may play a role in growth regulation.","CD63 Antigen | CD63 Antigen (Melanoma 1 Antigen) | Granulophysin | Lysosomal-Associated Membrane Protein 3 | Lysosome-Associated Membrane Glycoprotein 3 | Melanoma-Associated Antigen ME491 | Melanoma-Associated Antigen MLA1 | Ocular Melanoma-Associated Antigen | Tetraspanin-30 | Tspan-30",,,,,,,,,,,,,,,"4267886","Lymphocyte antigen CD63",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3811755","CYBB wt Allele","C106595","Human CYBB wild-type allele is located in the vicinity of Xp21.1 and is approximately 33 kb in length. This allele, which encodes cytochrome B-245 heavy chain protein, is involved in the microbicidal oxidase system of phagocytes. Mutations in this gene are associated with both atypical mycobacteriosis, familial, X-linked 2 and chronic granulomatous disease, X-linked.","CYBB wt Allele | AMCBX2 | CGD | CGDX | Cytochrome B-245 Beta Chain wt Allele | Cytochrome B-245, Beta Polypeptide Gene | Cytochrome b(-245), Beta Subunit Gene | Cytochrome b(588), Beta Subunit Gene | GP91-1 | GP91-PHOX | NOX2 | gp91 phox",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1429424","Cytochrome B-245 Heavy Chain","C106596","Cytochrome B-245 heavy chain (570 aa, ~65 kDa) is encoded by the human CYBB gene. This protein plays a role in the microbicidal activity of phagocytes.","Cytochrome B-245 Heavy Chain | CGD91-Phox | CYBB | Cytochrome B(558) Subunit Beta | Cytochrome B558 Subunit Beta | EC 1.6.3 | Heme-Binding Membrane Glycoprotein Gp91phox | NADPH Oxidase 2 | Neutrophil Cytochrome B 91 kDa Polypeptide | Superoxide-Generating NADPH Oxidase Heavy Chain Subunit | gp91 phox | gp91-1 | gp91-phox | p22 Phagocyte B-Cytochrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417830","NR2C2 Gene","C106597","This gene is involved in hormone-dependent transcriptional regulation.","NR2C2 Gene | NR2C2 | Nuclear Receptor Subfamily 2, Group C, Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812805","NR2C2 wt Allele","C106598","Human NR2C2 wild-type allele is located in the vicinity of 3p25 and is approximately 106 kb in length. This allele, which encodes nuclear receptor subfamily 2 group C member 2 protein, plays a role in hormone-mediated transcriptional regulation. Aberrant expression of the gene may be associated with corticotrophic malignancies and Cushing disease.","NR2C2 wt Allele | Nuclear Receptor Subfamily 2, Group C, Member 2 wt Allele | TAK1 | TR2R1 | TR4 | hTAK1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1505532","NR2C2 protein, human","C106599","Nuclear receptor subfamily 2 group C member 2 (596 aa, ~65 kDa) is encoded by the human NR2C2 gene. This protein is involved in both hormone binding and transcriptional regulation.","Nuclear Receptor Subfamily 2 Group C Member 2 | NR2C2 | Nuclear Hormone Receptor TR4 | Orphan Nuclear Receptor TAK1 | Orphan Nuclear Receptor TR4 | TR4 Nuclear Hormone Receptor | Testicular Nuclear Receptor 4 | Testicular Receptor 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641566","SOWS Short - Insomnia/Problems Sleeping","C103760","Short Opiate Withdrawal Scale (SOWS Short) Insomnia/problems sleeping.","SOWS Short - Insomnia/Problems Sleeping | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641567","UPS - Describe Your Experience When You Desire to Urinate","C103761","Urgency Perception Scale (UPS) Which of the following would typically describe your experience when you have a desire to urinate.","UPS - Describe Your Experience When You Desire to Urinate | UPS01-Describe Your Desire to Urinate | UPS0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1530758","GATA6 protein, human","C104418","Transcription factor GATA-6 (595 aa, ~60 kDa) is encoded by the human GATA6 gene. This protein plays a role in regulation of cellular differentiation and organogenesis during development.","Transcription Factor GATA-6 | GATA-Binding Factor 6 | GATA-Binding Protein 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL445684","autologous GM-CSF-secreting lethally irradiated leukemia cell vaccine","C104419","An autologous cancer vaccine composed of lethally irradiated leukemia cells that are genetically modified to secrete the immunostimulatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Upon intradermal injection, the autologous GM-CSF-secreting lethally irradiated leukemia cell vaccine secretes GM-CSF. In turn, GM-CSF may stimulate the immune system to attack tumor cells by enhancing the activation of dendritic cells (DCs) and promoting antigen presentation to both B- and T-lymphocytes. In addition, GM-CSF promotes antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function.","Autologous GM-CSF-secreting Lethally Irradiated Leukemia Cell Vaccine | Autologous GVAX Leukemia Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL445685","Zirconium Zr 89 DFO-MSTP2109A","C104420","A radioimmunoconjugate composed of the radioisotope zirconium Zr 89 conjugated to an antibody that targets six transmembrane epithelial antigen of the prostate 1 (STEAP1) that can potentially be used as a prostate cancer tracer during positron emission tomography (PET). Upon administration of zirconium Zr 89 DFO-MSTP2109A, the antibody moiety DFO-MSTP2109A binds to STEAP1 on prostate cancer cells. In turn, Zr 89 allows for the visualization of those cells using PET. STEAP1, a six-transmembrane domain protein, is overexpressed on the surface of prostate cancer cells.","Zirconium Zr 89 DFO-MSTP2109A | 89Zr-DFO-MSTP2109A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537453","GBA wt Allele","C104422","Human GBA1 wild-type allele is located in the vicinity of 1q22 and is approximately 10 kb in length. This allele, which encodes lysosomal acid glucosylceramidase protein, is involved in the production of ceramides from glucosylceramides. Mutations in this gene are associated with Gaucher disease and with increased susceptibility to Lewy body dementia or late-onset Parkinson disease.","GBA1 wt Allele | Beta-Glucosidase, Acid Gene | GBA | GBA wt Allele | GBA wt Allele | GBA1 | GC | GCB | GLUC | Glucosidase, Beta, Acid Gene | Glucosidase, Beta, Acid wt Allele | Glucosidase, Beta; Acid (includes Glucosylceramidase) Gene | Glucosylceramidase Beta 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1375381","GBA protein, human","C104423","Lysosomal acid glucosylceramidase (536 aa, ~60 kDa) is encoded by the human GBA1 gene. This protein plays a role in the hydrolysis of glucosylceramides yielding free ceramide.","Lysosomal Acid Glucosylceramidase | Acid Beta-Glucosidase | Alglucerase | Beta-GC | Beta-Glucocerebrosidase | Beta-Glucosylceramidase 1 | Cholesterol Glucosyltransferase | Cholesteryl-Beta-Glucosidase | D-Glucosyl-N-Acylsphingosine Glucohydrolase | EC 3.2.1.45 | GBA | GBA1 | Glucocerebrosidase | Glucosidase, Beta; Acid (includes Glucosylceramidase) | Glucosylceramidase | Glucosylceramidase | Glucosylceramidase Beta | Glucosylceramidase Beta 1 | Imiglucerase | Lysosomal Acid GCase | Lysosomal Cholesterol Glycosyltransferase | Lysosomal Galactosylceramidase | Lysosomal Glucocerebrosidase | Lysosomal Glycosylceramidase | SGTase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541289","GBA2 wt Allele","C104425","Human GBA2 wild-type allele is located in the vicinity of 9p13.3 and is approximately 13 kb in length. This allele, which encodes non-lysosomal glucosylceramidase protein, is involved in the generation and prevention of glycolipid accumulation and bile acid hydrolysis.","GBA2 wt Allele | AD035 | DKFZp762K054 | Glucosidase, Beta (Bile Acid) 2 Gene | Glucosidase, Beta (Bile Acid) 2 wt Allele | Glucosylceramidase Beta 2 wt Allele | KIAA1605",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539583","Non-Lysosomal Glucosylceramidase, Human","C104426","Non-lysosomal glucosylceramidase (927, ~105 kDa) is encoded by the human GBA2 gene. This protein plays a role in the generation and prevention of glycolipid accumulation.","Non-Lysosomal Glucosylceramidase | Beta-Glucocerebrosidase 2 | Beta-Glucosidase 2 | Bile Acid Beta-Glucosidase | EC 3.2.1.45 | GBA2 | Glucosylceramidase 2 | NLGase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541895","FCGR1A wt Allele","C104236","Human FCGR1A wild-type allele is located within 1q21.2-q21.3 and is approximately 10 kb in length. This allele, which encodes high affinity immunoglobulin gamma Fc receptor I protein, plays a role in both innate and adaptive immune responses.","FCGR1A wt Allele | CD64A | FCG1 | FCGR1 | FCRI | Fc Fragment of IgG, High Affinity Ia, Receptor (CD64) wt Allele | IGFR1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1450093","Cytochrome P450 1B1, Human","C104237","Cytochrome P450 1B1 (543 aa, ~61 kDa) is encoded by the human CYP1B1 gene. This protein plays a role in the metabolism of steroids and xenobiotics.","Cytochrome P450 1B1 | CYP1B1 | CYPIB1 | EC 1.14.14.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541311","RAD23B wt Allele","C104240","Human RAD23B wild-type allele is located in the vicinity of 9q31.2 and is approximately 49 kb in length. This allele, which encodes UV excision repair protein RAD23 homolog B protein, plays a role in the repair of DNA damage.","RAD23B wt Allele | HHR23B | HR23B | P58 | RAD23 Homolog B (S. cerevisiae) wt Allele | RP11-131A5.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539756","UV Excision Repair Protein RAD23 Homolog B","C104241","UV excision repair protein RAD23 homolog B (409 aa, ~43 kDa) is encoded by the human RAD23B gene. This protein is involved in nucleotide-excision repair of DNA damage.","UV Excision Repair Protein RAD23 Homolog B | HR23B | RAD23B | XP-C Repair Complementing Complex 58 kDa | XP-C Repair Complementing Protein | XP-C Repair-Complementing Complex 58 kDa Protein | hHR23B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537404","Tubulin Beta-3 Chain, Human","C104244","Tubulin beta-3 chain (450 aa, ~50 kDa) is encoded by the human TUBB3 gene. This protein is involved in both axonal guidance and microtubule structure.","Tubulin Beta-3 Chain | Class III Beta-Tubulin | TUBB3 | Tubulin Beta-4 Chain | Tubulin Beta-III | Tuj-1 Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539732","RORC wt Allele","C104246","Human RORC wild-type allele is located in the vicinity of 1q21 and is approximately 26 kb in length. This allele, which encodes nuclear receptor ROR-gamma protein, is involved in transcriptional activation.","RORC wt Allele | IMD42 | NR1F3 | RAR Related Orphan Receptor C wt Allele | RAR-Related Orphan Receptor C Gene | RAR-Related Orphan Receptor C wt Allele | RAR-Related Orphan Receptor Gamma Gene | RORG | RZR-GAMMA | RZRG | TOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641496","OAB-q Short Form - Waking Up at Night Because You had to Urinate","C103690","The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Waking up at night because you had to urinate?","OAB-q Short Form - Waking Up at Night Because You had to Urinate | OABQ02-Waking Up at Night had to Urinate | OABQ0205",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641497","OAB-q Short Form - Urine Loss Associated with a Strong Desire to Urinate","C103691","The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Urine loss associated with strong desire to urinate?","OAB-q Short Form - Urine Loss Associated with a Strong Desire to Urinate | OABQ02-Urine Loss Strong Desire Urinate | OABQ0206",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641498","OAB-q Short Form - Plan 'Escape Routes' to Restrooms","C103692","The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Caused you to plan 'escape routes' to restrooms in public places?","OAB-q Short Form - Plan 'Escape Routes' to Restrooms | OABQ02-Plan 'Escape Routes' to Restrooms | OABQ0207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641499","OAB-q Short Form - Feel Like There is Something Wrong with You","C103693","The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Made you feel like there is something wrong with you?","OAB-q Short Form - Feel Like There is Something Wrong with You | OABQ02-Feel Something is Wrong with You | OABQ0208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641500","OAB-q Short Form - Interfered with a Good Night's Rest","C103694","The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Interfered with your ability to get a good night's rest?","OAB-q Short Form - Interfered with a Good Night's Rest | OABQ02-Interfered with Good Night's Rest | OABQ0209",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641501","OAB-q Short Form - Frustrated or Annoyed About the Amount of Time You Spend in the Restroom","C103695","The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Made you frustrated or annoyed about the amount of time you spend in the restroom?","OAB-q Short Form - Frustrated or Annoyed About the Amount of Time You Spend in the Restroom | OABQ02-Frustrated about Time in Restroom | OABQ0210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641502","OAB-q Short Form - Avoid Activities Away From Restrooms","C103696","The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Made you avoid activities away from restrooms (i.e., walks, running, hiking)?","OAB-q Short Form - Avoid Activities Away From Restrooms | OABQ02-Avoid Activ Away From Restroom | OABQ0211",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641503","OAB-q Short Form - Awakened You During Sleep","C103697","The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Awakened you during sleep?","OAB-q Short Form - Awakened You During Sleep | OABQ02-Awakened You During Sleep | OABQ0212",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641505","OAB-q Short Form - Caused Problems with Your Partner or Spouse","C103699","The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Caused you to have problems with your partner or spouse?","OAB-q Short Form - Caused Problems with Your Partner or Spouse | OABQ02-Caused Problems Partner/Spouse | OABQ0214",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054599","Canola Oil","C1036","Vegetable oil developed from rapeseed plant.","Canola Oil | CANOLA OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641506","OAB-q Short Form - Uncomfortable While Traveling With Others","C103700","The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Made you uncomfortable while travelling with others because of needing to stop for a restroom?","OAB-q Short Form - Uncomfortable While Traveling With Others | OABQ02-Uncomfortable Travel with Others | OABQ0215",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641507","OAB-q Short Form - Affected Your Relationships with Family and Friends","C103701","The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Affected your relationships with family and friends?","OAB-q Short Form - Affected Your Relationships with Family and Friends | OABQ02-Affected Relationships | OABQ0216",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641508","OAB-q Short Form - Interfered with Getting Sleep","C103702","The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Interfered with getting the amount of sleep you needed?","OAB-q Short Form - Interfered with Getting Sleep | OABQ02-Interfered with Getting Sleep | OABQ0217",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0057545","Desmethylmisonidazole","C1065","A radiosensitizer that targets hypoxic cells and act as oxygen substitute making tumor cells sensitive to radiation damage.","Desmethylmisonidazole | 1,2-propanediol, 3-(2-nitro-1h-imidazol-1-yl)- | DESMETHYLMISONIDAZOLE | Demethylmisonidazole | Ro 05-9963 | SR-1530",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812167","BPI wt Allele","C106601","Human BPI wild-type allele is located in the vicinity of 20q11.23 and is approximately 77 kb in length. This allele, which encodes bactericidal permeability-increasing protein, plays a role in defense against gram-negative bacterial infections.","BPI wt Allele | BPIFD1 | Bactericidal/Permeability-Increasing Protein wt Allele | CAP 57 | RBPI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0052897","Bactericidal Permeability-Increasing Protein","C106602","Bactericidal permeability-increasing protein (487 aa, ~54 kDa) is encoded by the human BPI gene. This protein is involved in both defense against gram-negative bacterial infections and lipopolysaccharide binding.","Bactericidal Permeability-Increasing Protein | BACTERICIDAL PERMEABILITY-INCREASING PROTEIN | BPI | BPI Fold Containing Family D, Member 1 | Bactericidal/Permeability-Increasing Protein | RBPI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829894","HAQ-DI With VAS - Able to Cut Meat","C106813","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Eating: are you able to cut your meat?","HAQ-DI With VAS - Able to Cut Meat | HAQ01-Cut Your Meat | HAQ0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829888","HAQ-DI With VAS - Able to Lift Cup or Glass to Mouth","C106814","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Eating: are you able to lift a full cup or glass to your mouth?","HAQ-DI With VAS - Able to Lift Cup or Glass to Mouth | HAQ01-Lift a Full Cup or Glass to Mouth | HAQ0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829886","HAQ-DI With VAS - Able to Open Milk Carton","C106815","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Eating: are you able to open a new milk carton?","HAQ-DI With VAS - Able to Open Milk Carton | HAQ01-Open a New Milk Carton | HAQ0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829878","HAQ-DI With VAS - Able to Walk Outdoors On Flat Ground","C106816","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Walking: are you able to walk outdoors on flat ground?","HAQ-DI With VAS - Able to Walk Outdoors On Flat Ground | HAQ01-Walk Outdoors on Flat Ground | HAQ0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829895","HAQ-DI With VAS - Able to Climb Up Steps","C106817","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Walking: are you able to climb up five steps?","HAQ-DI With VAS - Able to Climb Up Steps | HAQ01-Climb Up Five Steps | HAQ0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829873","HAQ-DI With VAS - Aids or Devices - Cane","C106818","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Cane.","HAQ-DI With VAS - Aids or Devices - Cane | HAQ01-Aid: Cane | HAQ0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829861","HAQ-DI With VAS - Aids or Devices - Walker","C106819","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Walker.","HAQ-DI With VAS - Aids or Devices - Walker | HAQ01-Aid: Walker | HAQ0111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1870739","GHRL protein, human","C104429","Appetite-regulating hormone (117 aa, ~13 kDa) is encoded by the human GHRL gene. This protein is involved in satiety, thirst and anxiety and regulating growth hormone release.","Appetite-Regulating Hormone | Ghrelin | Ghrelin, Growth Hormone Secretagogue Receptor Ligand | Growth Hormone Secretagogue | Growth Hormone-Releasing Peptide | Motilin-Related Peptide | Obestatin | Protein M46",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538751","ACTA2 wt Allele","C103971","Human ACTA2 wild-type allele is located in the vicinity of 10q23.3 and is approximately 56 kb in length. This allele, which encodes actin, aortic smooth muscle protein, is involved in smooth muscle cell contraction. Mutations of this gene predispose patients to a variety of diffuse and diverse vascular diseases, including premature onset coronary artery disease, premature ischemic strokes, familial aortic aneurysm thoracic type 6, Moyamoya disease type 5 and multisystemic smooth muscle dysfunction syndrome.","ACTA2 wt Allele | AAT6 | ACTSA | ACTVS | Actin Alpha 2, Smooth Muscle wt Allele | Actin, Alpha 2, Smooth Muscle, Aorta Gene | Actin, Alpha 2, Smooth Muscle, Aorta wt Allele | Actin, Alpha, Smooth Muscle, Aortic Gene | Actin, Alpha-2, Smooth Muscle, Aorta Gene | Actin, Vascular Smooth Muscle | GIG46 | MYMY5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2716282","Actin, Aortic Smooth Muscle, Human","C103972","Actin, aortic smooth muscle (377 aa, ~42 kDa) is encoded by the human ACTA2 gene. This protein plays a role in the contraction of smooth muscle.","Actin, Aortic Smooth Muscle | ACTA2 | Alpha-Actin-2 | Alpha-Cardiac Actin | Alpha-SMA | Alpha-Smooth Muscle Actin | Cell Growth-Inhibiting Gene 46 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541226","ADIPOR1 wt Allele","C103974","Human ADIPOR1 wild-type allele is located in the vicinity of 1q32.1 and is approximately 18 kb in length. This allele, which encodes adiponectin receptor protein 1, plays a role in adiponectin-mediated signaling.","ADIPOR1 wt Allele | ACDCR1 | Adiponectin Receptor 1 wt Allele | CGI-45 | CGI45 | PAQR1 | TESBP1A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537284","Adiponectin Receptor Protein 1, Human","C103975","Adiponectin receptor protein 1 (375 aa, ~43 kDa) is encoded by the human ADIPOR1 gene. This protein is involved in adiponectin binding and signal transduction.","Adiponectin Receptor Protein 1 | ADIPOR1 | Adiponectin Receptor 1 | Progestin and AdipoQ Receptor Family Member I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541858","ADIPOR2 wt Allele","C103977","Human ADIPOR2 wild-type allele is located in the vicinity of 12p13.31 and is approximately 100 kb in length. This allele, which encodes adiponectin receptor protein 2, is involved in hormone-mediated signaling.","ADIPOR2 wt Allele | ACDCR2 | Adiponectin Receptor 2 wt Allele | PAQR2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537285","Adiponectin Receptor Protein 2, Human","C103978","Adiponectin receptor protein 2 (386 aa, ~44 kDa) is encoded by the human ADIPOR2 gene. This protein plays a role in adiponectin-mediated signal transduction.","Adiponectin Receptor Protein 2 | ADIPOR2 | Adiponectin Receptor 2 | Progestin and AdipoQ Receptor Family Member II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539623","ZGLP1 wt Allele","C103980","Human ZGLP1 wild-type allele is located in the vicinity of 19p13.2 and is approximately 5 kb in length. This allele, which encodes GATA-type zinc finger protein 1, plays a role in the negative regulation of transcription.","ZGLP1 wt Allele | GLP-1 | GLP1 | Zinc Finger, GATA-Like Protein 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438302","Carbon C 11 Erlotinib Hydrochloride","C103819","The hydrochloride salt form of the quinazoline derivative erlotinib labeled with the positron-emitting isotope carbon C 11, with potential use in imaging.  Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic tyrosine kinase domain of the epidermal growth factor receptor (EGFR). Following exposure to this agent, EGFR expression status can be determined and EGFR overexpressing tumor cells can be visualized using positron emission tomography (PET) imaging. This may be useful in determining the tumor cell response to a particular EGFR kinase inhibitor in individual patients. EGFR, a receptor tyrosine kinase, is overexpressed in numerous cancer cell types, and plays a significant role in tumor cell progression.","Carbon C 11 Erlotinib Hydrochloride | C11-Erlotinib Hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438303","Lirilumab","C103820","A fully human monoclonal antibody against killer-cell immunoglobulin-like receptors (KIR), with potential antineoplastic activity. Upon administration, lirilumab binds to KIR, thereby preventing the binding of KIR ligands to KIR on natural killer (NK) cells. By blocking these inhibitory receptors, NK cells become activated and attack cancer cells leading to tumor cell death. KIR, a member of the immunoglobulin superfamily, is expressed on the surface of NK cells.","Lirilumab | BMS-986015 | IPH2102 | LIRILUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438304","Amnion-derived Cellular Cytokine Solution","C103821","A topical cellular cytokine solution containing a distinct combination of growth factors and cytokines secreted by and released from amnion-derived multipotent progenitor (AMP) cells, with potential immunomodulating and skin healing activities. The amnion-derived cellular cytokine solution (ACCS) contains near physiological levels of transforming growth factor beta, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2, as well as the angiogenesis factors platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF) and angiogenin that are normally found in healing wounds. Upon spraying the solution onto affected areas, the cytokines and growth factors in ACCS appear to increase the migration, proliferation and differentiation of both keratinocytes and fibroblasts; enhance the migration and phagocytosis of macrophages in wounds; and increase epithelialization. Together these processes may accelerate skin healing and tissue repair. Also, ACCS may be beneficial in the treatment of radiation burns of the skin.","Amnion-derived Cellular Cytokine Solution | ACSS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438305","Injectable Astragalus membranaceus Polysaccharide","C103822","An injectable form of a polysaccharide isolated from the radix of Astragalus membranaceus (PG2), used in traditional Chinese medicine, with potential hematopoiesis inducing and immunomodulating activities. Upon injection, APS may be able to relieve certain chemotherapy-induced side effects, including myelosuppression, fatigue, mucositis, pain, nausea and vomiting, as well as loss of appetite and body weight. Also, APS may exert immunostimulatory activities by stimulating B-lymphocytes, activating T-lymphocytes, inducing cytokine production, and activating macrophages and natural killer cells through as of yet unidentified mechanism(s). APS may improve compliance of radiotherapy and/or chemotherapy.","Injectable Astragalus membranaceus Polysaccharide | ASTRAGALUS MONGHOLICUS ROOT POLYSACCHARIDES | Injectable APS | Injectable PG2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540516","BAGE wt Allele","C104493","Human BAGE wild-type allele is located in the vicinity of 21p11.1 and is approximately 2 kb in length. This allele, which encodes B melanoma antigen 1 protein, may be involved in melanoma progression.","BAGE wt Allele | B Melanoma Antigen wt Allele | BAGE1 | CT2.1 | Cancer/Testis Antigen Family 2, Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539527","B Melanoma Antigen 1, Human","C104494","B melanoma antigen 1 (43 aa, ~5 kDa) is encoded by the human BAGE gene. This protein may play a role in melanoma tumorigenesis.","B Melanoma Antigen 1 | Antigen MZ2-BA | B Melanoma Antigen | BAGE | CT2.1 | Cancer/Testis Antigen 2.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537294","FGD4 protein, human","C104381","FYVE, RhoGEF and PH domain-containing protein 4 (766 aa, ~87 kDa) is encoded by the human FGD4 gene. This protein plays a role in regulation of the actin cytoskeleton and cell shape.","FYVE, RhoGEF and PH Domain-Containing Protein 4 | Actin Filament-Binding Protein Frabin | Actin-Filament Binding Protein Frabin | FGD1 Family, Member 4 | FGD1-Related F-Actin-Binding Protein | FGD4 | Frabin | Zinc Finger FYVE Domain-Containing Protein 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539654","FGF23 wt Allele","C104383","Human FGF23 wild-type allele is located in the vicinity of 12p13.3 and is approximately 12 kb in length. This allele, which encodes fibroblast growth factor 23 protein, plays a role in regulation of phosphate homeostasis. Mutations in this gene are associated with autosomal dominant hypophosphatemic rickets (ADHR) and familial tumoral calcinosis with hyperphosphatemia. It is overexpressed in oncogenic hypophosphatemic osteomalacia (OHO).","FGF23 wt Allele | ADHR | FGF-23 | FGFN | Fibroblast Growth Factor 23 wt Allele | HPDR2 | HYPF | PHPTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1431973","Fibroblast Growth Factor 23, Human","C104384","Fibroblast growth factor 23 (251 aa, ~28 kDa) is encoded by the human FGF23 gene. This protein is involved in inhibition of renal tubular phosphate transport.","Fibroblast Growth Factor 23 | FGF-23 | Phosphatonin | Tumor-Derived Hypophosphatemia Inducing Factor | Tumor-Derived Hypophosphatemia-Inducing Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542929","VEGF-D","C104386","Human VEGFD wild-type allele is located in the vicinity of Xp22.2 and is approximately 39 kb in length. This allele, which encodes vascular endothelial growth factor D, is involved in endothelial cell growth, angiogenesis, and lymphangiogenesis.","VEGFD wt Allele | FIGF | VEGF-D | VEGFD | Vascular Endothelial Growth Factor D wt Allele | c-Fos Induced Growth Factor (Vascular Endothelial Growth Factor D) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3656951","Vascular Endothelial Growth Factor D, Human","C104387","Vascular endothelial growth factor D (354 aa, ~40 kDa) is encoded by the human VEGFD gene. This protein plays a role in angiogenesis, lymphangiogenesis, and endothelial cell growth, and also has effects on the permeability of blood vessels.","Vascular Endothelial Growth Factor D | FIGF | Fos-Induced Growth Factor | VEGF-D | VEGFD | c-Fos-Induced Growth Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540541","FKBP8 wt Allele","C104389","Human FKBP8 wild-type allele is located in the vicinity of 19p12 and is approximately 12 kb in length. This allele, which encodes peptidyl-prolyl cis-trans isomerase FKBP8 protein, plays a role in immunoregulation, protein folding, and protein trafficking.","FKBP8 wt Allele | FK506 Binding Protein 8, 38kDa wt Allele | FKBP-38 | FKBP-8 | FKBP38 | FKBPr38 | PPIase FKBP8 | hFKBP38",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1174216","Peptidyl-Prolyl Cis-Trans Isomerase FKBP8, Human","C104390","Peptidyl-prolyl cis-trans isomerase FKBP8 (412 aa, ~45 kDa) is encoded by the human FKBP8 gene. This protein is involved in immunoregulation, protein folding, and protein trafficking and may play a role in neurons associated with memory.","Peptidyl-Prolyl Cis-Trans Isomerase FKBP8 | 38 kDa FK506-Binding Protein | EC 5.2.1.8 | FK506-Binding Protein 8 | FKBP8 | Rotamase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540627","FMOD wt Allele","C104392","Human FMOD wild-type allele is located in the vicinity of 1q32 and is approximately 11 kb in length. This allele, which encodes fibromodulin protein, may be involved in the assembly of the extracellular matrix.","FMOD wt Allele | FM | Fibromodulin wt Allele | SLRR2E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0060375","fibromodulin","C104393","Fibromodulin (376 aa, ~43 kDa) is encoded by the human FMOD gene. This protein may play a role in the assembly of the extracellular matrix.","Fibromodulin | Collagen-Binding 59 kDa Protein | Fibromodulin Proteoglycan | KSPG Fibromodulin | Keratan Sulfate Proteoglycan Fibromodulin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829872","HAQ-DI With VAS - Aids or Devices - Crutches","C106820","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Crutches.","HAQ-DI With VAS - Aids or Devices - Crutches | HAQ01-Aid: Crutches | HAQ0112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827354","HAQ-DI With VAS - Aids or Devices - Wheelchair","C106821","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Wheelchair.","HAQ-DI With VAS - Aids or Devices - Wheelchair | HAQ01-Aid: Wheelchair | HAQ0113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829862","HAQ-DI With VAS - Aids or Devices - Used For Dressing","C106822","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Devices used for dressing (button hook, zipper pull, long-handled shoe horn, etc.).","HAQ-DI With VAS - Aids or Devices - Used For Dressing | HAQ01-Aid: Devices Used for Dressing | HAQ0114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829874","HAQ-DI With VAS - Aids or Devices - Built Up or Special Utensils","C106823","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Built up or special utensils.","HAQ-DI With VAS - Aids or Devices - Built Up or Special Utensils | HAQ01-Aid: Built Up or Special Utensils | HAQ0115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829863","HAQ-DI With VAS - Aids or Devices - Special or Built Up Chair","C106824","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Special or built up chair.","HAQ-DI With VAS - Aids or Devices - Special or Built Up Chair | HAQ01-Aid: Special or Built Up Chair | HAQ0116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830955","C-SSRS Already Enrolled Subjects - Description of Active Suicidal Ideation With Any Methods (Not Plan) Without Intent to Act","C107035","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Description of active suicidal ideation with any methods (not plan) without intent to act.","C-SSRS Already Enrolled Subjects - Description of Active Suicidal Ideation With Any Methods (Not Plan) Without Intent to Act | CSS05-Idea, No Intent, No Plan, Describe | CSS0503C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830967","C-SSRS Already Enrolled Subjects - Active Suicidal Ideation With Some Intent to Act, Without Specific Plan (Since Study Start)","C107037","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Have you had these thoughts and had some intention of acting on them? (Since Study Start).","C-SSRS Already Enrolled Subjects - Active Suicidal Ideation With Some Intent to Act, Without Specific Plan (Since Study Start) | CSS05-Idea, Intent, No Plan-Since | CSS0504B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830954","C-SSRS Already Enrolled Subjects - Description of Active Suicidal Ideation With Some Intent to Act, Without Specific Plan","C107038","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Description of active suicidal ideation with some intent to act, without specific plan.","C-SSRS Already Enrolled Subjects - Description of Active Suicidal Ideation With Some Intent to Act, Without Specific Plan | CSS05-Idea, Intent, No Plan, Describe | CSS0504C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830966","C-SSRS Already Enrolled Subjects - Active Suicidal Ideation With Specific Plan and Intent (Prior to Study Entry)","C107039","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan? (Prior to Study Entry).","C-SSRS Already Enrolled Subjects - Active Suicidal Ideation With Specific Plan and Intent (Prior to Study Entry) | CSS05-Idea, Plan, Intent-Prior | CSS0505A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830965","C-SSRS Already Enrolled Subjects - Active Suicidal Ideation With Specific Plan and Intent (Since Study Start)","C107040","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan? (Since Study Start).","C-SSRS Already Enrolled Subjects - Active Suicidal Ideation With Specific Plan and Intent (Since Study Start) | CSS05-Idea, Plan, Intent-Since | CSS0505B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539624","GATA-Type Zinc Finger Protein 1","C103981","GATA-type zinc finger protein 1 (271 aa, ~30 kDa) is encoded by the human ZGLP1 gene. This protein is involved in the inhibition of transcription by GATA family transcription factors.","GATA-Type Zinc Finger Protein 1 | GATA Like Protein 1 | GATA Like Protein-1 | GATA-Like Protein 1 | GLP-1 | ZGLP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3543419","Voluntary Report","C103982","A type of report that is voluntary.","Voluntary Report | Voluntary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538770","NQO2 wt Allele","C103985","Human NQO2 wild-type allele is located in the vicinity of 6p25.2 and is approximately 32 kb in length. This allele, which encodes ribosyldihydronicotinamide dehydrogenase [quinone] protein, plays a role in both vitamin metabolism and detoxification.","NQO2 wt Allele | DHQV | DIA6 | NAD(P)H Dehydrogenase, Quinone 2 wt Allele | NAD(P)H Menadione Oxidoreductase 2, Dioxin-Inducible Gene | NMOR2 | QR2 | RP1-90J20.3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0963926","NRH - quinone oxidoreductase2","C103986","Ribosyldihydronicotinamide dehydrogenase [quinone] (231 aa, ~26 kDa) is encoded by the human NQO2 gene. This protein is involved in the metabolism of quinone-containing compounds.","Ribosyldihydronicotinamide Dehydrogenase [Quinone] | EC 1.10.99.2 | NQO2 | NRH Dehydrogenase [Quinone] 2 | NRH:Quinone Oxidoreductase 2 | QR2 | Quinone Reductase 2 | Ribosyldihydronicotinamide Dehydrogenase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539640","EIF4A1 wt Allele","C104191","Human EIF4A1 wild-type allele is located in the vicinity of 17p13 and is approximately 6 kb in length. This allele, which encodes eukaryotic initiation factor 4A-I, plays a role in translation initiation.","EIF4A1 wt Allele | DDX2A | EIF-4A | EIF4A | Eukaryotic Translation Initiation Factor 4A1 wt Allele | eIF-4A-I | eIF4A-I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539641","Eukaryotic Initiation Factor 4A-I, human","C104192","Eukaryotic initiation factor 4A-I (406 aa, ~46 kDa) is encoded by the human EIF4A1 gene. This protein is involved in translation initiation.","Eukaryotic Initiation Factor 4A-I | ATP-Dependent RNA Helicase eIF4A-1 | EC 3.6.4.13 | Eukaryotic Translation Initiation Factor 4A, Isoform 1 | eIF-4A-I | eIF4A-I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538705","ELANE wt Allele","C104196","Human ELANE wild-type allele is located in the vicinity of 19p13.3 and is approximately 4 kb in length. This allele, which encodes neutrophil elastase protein, is involved in innate host defense and tissue remodeling.","ELANE wt Allele | ELA2 | Elastase 2, Neutrophil Gene | Elastase, Leukocyte Gene | Elastase, Neutrophil Expressed wt Allele | Elastase, Neutrophil Gene | Elastase, Neutrophil-Expressed Gene | GE | HLE | HNE | NE | PMN-E | Protease, Serine, Bone Marrow Gene | SCN1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0065866","Medullasin","C104198","Neutrophil elastase (267 aa, ~29 kDa) is encoded by the human ELANE gene. This protein plays a role in innate host defense and tissue remodeling.","Neutrophil Elastase | Bone Marrow Serine Protease | EC 3.4.21.37 | ELANE | Elastase 2 | Elastase 2, Neutrophil | Elastase, Neutrophil Expressed | Granulocyte-Derived Elastase | Human Leukocyte Elastase | Leukocyte Elastate | Medullasin | PMN Elastase | Polymorphonuclear Elastase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538788","MAGEA10 wt Allele","C104497","Human MAGEA10 wild-type allele is located in the vicinity of Xq28 and is approximately 5 kb in length. This allele, which encodes melanoma-associated antigen 10 protein, may plays a role in tumorigenesis.","MAGEA10 wt Allele | CT1.10 | Cancer/Testis Antigen Family 1, Member 10 Gene | MAGE10 | MGC10599 | Melanoma Antigen Family A, 10 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0917743","Fadrozole Hydrochloride","C1044","The hydrochloride salt of the nonsteroidal aromatase inhibitor fadrozole with potential antineoplastic activity. Fadrozole specifically inhibits aromatase, blocking the aromatization of androstenedione and testosterone into estrone and estradiol, respectively, the final step in estrogen biosynthesis; the reduction in estrogen levels may inhibit growth in estrogen-dependent cancers. Aromatase, a member of the cytochrome P-450 superfamily, is found in many tissues; overexpression has been linked to the development of preneoplastic and neoplastic changes in breast tissue.","Fadrozole Hydrochloride | (+/-)-p-(5,6,7,8-Tetrahydroimidazo(1,5-a)pyridin-5-yl)benzonitrile Monohydrochloride | 4-(5,6,7,8-Tetrahydroimidazo(1,5-a)pyridin-5-yl)benzonitrile Hydrochloride | 4-(5,6,7,8-Tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Monohydrochloride | Afema | Arensin | CGS 16949A | CGS-16949A | CGS16949A | FADROZOLE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542970","MAGEA2 wt Allele","C104500","Human MAGEA2 wild-type allele is located in the vicinity of Xq28 and is approximately 4 kb in length. This allele, which encodes melanoma-associated antigen 2 protein, is involved in the regulation of p53-dependent signal transduction.","MAGEA2 wt Allele | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539826","Melanoma-Associated Antigen 2","C104501","Melanoma-associated antigen 2 (314 aa, ~35 kDa) is encoded by the human MAGEA2 and MAGEA2B genes. This protein plays a role in the modulation of p53-dependent signaling pathways.","Melanoma-Associated Antigen 2 | CT1.2 | Cancer/Testis Antigen 1.2 | MAGE-2 Antigen | MAGE-A2 | MAGEA2 | Melanoma Antigen 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538895","ARTS","C104503","Human SEPTIN4 wild-type allele is located in the vicinity of 17q22 and is approximately 20 kb in length. This allele, which encodes septin-4 protein, plays a role in both GTP hydrolysis and the structure of the cytoskeleton.","SEPTIN4 wt Allele | ARTS | BRADEION | C17orf47 | CE5B3 | Chromosome 17 Open Reading Frame 47 Gene | FLJ40121 | H5 | MART | PNUTL2 | Peanut-Like 2 Gene | SEP4 | SEPT4 | SEPT4 wt Allele | Septin 4 wt Allele | hCDCREL-2 | hucep-7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538896","Septin-4","C104505","Septin-4 (478 aa, ~55 kDa) is encoded by the human SEPTIN4 gene. This protein is involved in both cytoskeletal structure and GTP hydrolysis.","Septin-4 | ARTS | Apoptosis-Related Protein In The TGF-Beta Signaling Pathway | Bradeion Beta | Brain Protein H5 | CE5B3 Beta | Cell Division Control-Related Protein 2 | Cerebral Protein 7 | Peanut-Like Protein 2 | SEPT4 | SEPTIN4 | Septin-M | hCDCREL-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003691","Arachidonate 12-Lipoxygenase, 12S-Type","C103926","Arachidonate 12-lipoxygenase, 12S-type (663 aa, ~76 kDa) is encoded by the human ALOX12 gene. This protein plays a role in both fatty acid oxidation and leukotriene biosynthesis.","Arachidonate 12-Lipoxygenase, 12S-Type | 12S-LOX | 12S-Lipoxygenase | ALOX12 | EC 1.13.11.31 | Platelet-Type Lipoxygenase 12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541416","ARG1 wt Allele","C103928","Human ARG1 wild-type allele is located 6q23 and is approximately 11 kb in length. This allele, which encodes arginase-1 protein, is involved in the metabolism of both amino acids and urea. Mutation of the gene is associated with argininemia.","ARG1 wt Allele | Arginase, Liver wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3500855","Arginase-1, human","C103929","Arginase-1 (322 aa, ~35 kDa) is encoded by the human ARG1 gene. This protein plays a role in the cleavage of L-arginine to L-ornithine and urea.","Arginase-1 | ARG1 | Arginase A1 | EC 3.5.3.1 | L-Arginine Amidinohydrolase | L-Arginine Ureahydrolase | Liver-Type Arginase | Type I Arginase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539689","ARSA wt Allele","C103931","Human ARSA wild-type allele is located in the vicinity of 22q13.33 and is approximately 3 kb in length. This allele, which encodes arylsulfatase A protein, plays a role in the catabolism of cerebroside sulfate. Mutation of the gene is associated with leukodystrophy metachromatic.","ARSA wt Allele | Arylsulfatase A wt Allele | MLD | Metachromatic Leucodystrophy Gene | Metachromatic Leukodystrophy Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007804","Arylsulfatase A","C103932","Arylsulfatase A (507 aa, ~54 kDa) is encoded by the human ARSA gene. This protein is involved in the hydrolysis of cerebroside sulfate.","Arylsulfatase A | ARSA | ASA | Cerebroside 3-Sulfatase | Cerebroside-Sulfatase | EC 3.1.6.8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641679","Automotive Occupations","C103933","A class of professional or vocational positions of employment that involve work with automobiles.","Automotive Occupations | Automotive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0158617","Congenital Aortic Valve Insufficiency","C103936","Dysfunction of the aortic valve characterized by incomplete valve closure that is present at birth.","Congenital Aortic Valve Insufficiency | Congenital Aortic Insufficiency | Congenital Insufficiency of Aortic Valve | Congenital insufficiency of aortic valve | Congential Aortic Valve Insufficiency",,,,,,,,,,,,,,,"321107","Congenital insufficiency of aortic valve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3539562","B4GALT6 wt Allele","C103938","Human B4GALT6 wild-type allele is located in the vicinity of 18q11 and is approximately 62 kb in length. This allele, which encodes beta-1,4-galactosyltransferase 6 protein, is involved in ceramide metabolism.","B4GALT6 wt Allele | B4Gal-T6 | UDP-Gal:BetaGlcNAc Beta 1,4- Galactosyltransferase, Polypeptide 6 wt Allele | beta4Gal-T6 | beta4GalT-VI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0061433","Beta-1,4-Galactosyltransferase 6","C103939","Beta-1,4-galactosyltransferase 6 (382 aa, ~45 kDa) is encoded by the human B4GALT6 gene. This protein plays a role in the glycosylation of ceramides.","Beta-1,4-Galactosyltransferase 6 | B4GALT6 | Beta-1,4-GalTase 6 | Beta4Gal-T6 | EC 2.4.1.- | EC 2.4.1.274 | Glucosylceramide Beta-1,4-Galactosyltransferase | LacCer Synthase | Lactosylceramide Synthase | UDP-Gal:Beta-GlcNAc Beta-1,4-Galactosyltransferase 6 | UDP-Gal:Glucosylceramide Beta-1,4-Galactosyltransferase | UDP-Galactose:Beta-N-Acetylglucosamine Beta-1,4-Galactosyltransferase 6 | b4Gal-T6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830953","C-SSRS Already Enrolled Subjects - Description of Active Suicidal Ideation With Specific Plan and Intent","C107041","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Description of active suicidal ideation with specific plan and intent.","C-SSRS Already Enrolled Subjects - Description of Active Suicidal Ideation With Specific Plan and Intent | CSS05-Idea, Plan, Intent, Describe | CSS0505C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830958","C-SSRS Already Enrolled Subjects - Describe Most Severe Ideation (Prior to Study Entry)","C107043","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Description of most severe Ideation. (Prior to Study Entry).","C-SSRS Already Enrolled Subjects - Describe Most Severe Ideation (Prior to Study Entry) | CSS05-Most Severe Idea, Desc-Prior | CSS0506B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830929","C-SSRS Already Enrolled Subjects - Most Severe Ideation (Since Study Start)","C107044","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Most severe ideation. (Since Study Start).","C-SSRS Already Enrolled Subjects - Most Severe Ideation (Since Study Start) | CSS05-Most Severe Idea-Since | CSS0506C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830957","C-SSRS Already Enrolled Subjects - Describe Most Severe Ideation (Since Study Start)","C107045","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Description of most severe Ideation. (Since Study Start).","C-SSRS Already Enrolled Subjects - Describe Most Severe Ideation (Since Study Start) | CSS05-Most Severe Idea, Desc-Since | CSS0506D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830940","C-SSRS Already Enrolled Subjects - Frequency of Most Severe Ideation (Prior to Study Entry)","C107046","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) How many times have you had these thoughts? (Prior to Study Entry).","C-SSRS Already Enrolled Subjects - Frequency of Most Severe Ideation (Prior to Study Entry) | CSS05-Most Severe Idea, Frequency-Prior | CSS0507A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830939","C-SSRS Already Enrolled Subjects - Frequency of Most Severe Ideation (Since Study Start)","C107047","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) How many times have you had these thoughts? (Since Study Start).","C-SSRS Already Enrolled Subjects - Frequency of Most Severe Ideation (Since Study Start) | CSS05-Most Severe Idea, Frequency-Since | CSS0507B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1174094","Interferon Lambda-3, Human","C106357","Interferon lambda-3 (196 aa, ~22 kDa) is encoded by the human IFNL3 gene. This protein plays a role in cytokine signaling.","Interferon Lambda-3 | Cytokine Zcyto22 | IFN-Lambda-3 | IFN-Lambda-4 | IFNL3 | IL-28B | IL-28C | Interferon Lambda 3 | Interferon Lambda-4 | Interferon-Lambda 3 | Interferon-Lambda-3 | Interleukin-28B | Interleukin-28C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811690","ZNF444 wt Allele","C106359","Human ZNF444 wild-type allele is located in the vicinity of 19q13.43 and is approximately 28 kb in length. This allele, which encodes zinc finger protein 444, plays a role in transcriptional activation, DNA binding and LDL metabolism.","ZNF444 wt Allele | EZF-2 | EZF2 | FLJ11137 | ZSCAN17 | Zinc Finger Protein 444 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811689","Zinc Finger Protein 444","C106360","Zinc finger protein 444 (327 aa, ~35 kDa) is encoded by the human ZNF444 gene. This protein is involved in both LDL metabolism and the positive regulation of transcription.","Zinc Finger Protein 444 | EZF-2 | Endothelial Zinc Finger Protein 2 | ZNF444 | Zinc Finger and SCAN domain-Containing Protein 17",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424571","SCARF1 Gene","C106361","This gene plays a role in cholesterol metabolism.","SCARF1 Gene | SCARF1 | Scavenger Receptor Class F, Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813611","SCARF1 wt Allele","C106362","Human SCARF1 wild-type allele is located in the vicinity of 17p13.3 and is approximately 12 kb in length. This allele, which encodes scavenger receptor class F member 1 protein, is involved in the metabolism of acetylated LDL.","SCARF1 wt Allele | KIAA0149 | SREC | SREC-I | SREC1 | Scavenger Receptor Class F, Member 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641568","ODI v2.1a - Pain Intensity","C103762","The Oswestry Disability Index Version 2.1a (ODI v2.1a) Section 1: Pain intensity.","ODI v2.1a - Pain Intensity | ODI01-Pain Intensity | ODI0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641569","ODI v2.1a - Personal Care","C103763","The Oswestry Disability Index Version 2.1a (ODI v2.1a) Section 2: Personal care (washing, dressing, etc.).","ODI v2.1a - Personal Care | ODI01-Personal Care | ODI0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641570","ODI v2.1a - Lifting","C103764","The Oswestry Disability Index Version 2.1a (ODI v2.1a) Section 3: Lifting.","ODI v2.1a - Lifting | ODI01-Lifting | ODI0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641571","ODI v2.1a - Walking","C103765","The Oswestry Disability Index Version 2.1a (ODI v2.1a) Section 4: Walking.","ODI v2.1a - Walking | ODI01-Walking | ODI0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641573","ODI v2.1a - Standing","C103767","The Oswestry Disability Index Version 2.1a (ODI v2.1a) Section 6: Standing.","ODI v2.1a - Standing | ODI01-Standing | ODI0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641574","ODI v2.1a - Sleeping","C103768","The Oswestry Disability Index Version 2.1a (ODI v2.1a) Section 7: Sleeping.","ODI v2.1a - Sleeping | ODI01-Sleeping | ODI0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641575","ODI v2.1a - Sex Life","C103769","The Oswestry Disability Index Version 2.1a (ODI v2.1a) Section 8: Sex life (if applicable).","ODI v2.1a - Sex Life | ODI01-Sex Life | ODI0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641576","ODI v2.1a - Social Life","C103770","The Oswestry Disability Index Version 2.1a (ODI v2.1a) Section 9: Social life.","ODI v2.1a - Social Life | ODI01-Social Life | ODI0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641577","ODI v2.1a - Travelling","C103771","The Oswestry Disability Index Version 2.1a (ODI v2.1a) Section 10: Travelling.","ODI v2.1a - Travelling | ODI01-Travelling | ODI0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415738","HSD17B1 Gene","C104035","This gene is involved in estrogen biosynthesis.","HSD17B1 Gene | HSD17B1 | Hydroxysteroid 17-Beta Dehydrogenase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541417","FPGS wt Allele","C103941","Human FPGS wild-type allele is located in the vicinity of 9q34.1 and is approximately 20 kb in length. This allele, which encodes folylpolyglutamate synthase, mitochondrial protein, is involved in the metabolism of folates.","FPGS wt Allele | Folylpolyglutamate Synthase wt Allele | RP11-228B15.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539598","CYP27A1 wt Allele","C104150","Human CYP27A1 wild-type allele is located within 2q35 and is approximately 34 kb in length. This allele, which encodes sterol 26-hydroxylase, mitochondrial protein, plays a role in bile synthesis and cholesterol homeostasis. Mutations in CYP27A1 are associated with cerebrotendinous xanthomatosis.","CYP27A1 wt Allele | CP27 | CTX | CYP27 | Cytochrome P450, Family 27, Subfamily A, Polypeptide 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1312672","CYP27A1 protein, human","C104151","Sterol 26-hydroxylase, mitochondrial (531 aa, ~60 kDa) is encoded by the human CYP27A1 gene. This protein is involved in cholesterol homeostasis and bile synthesis.","Sterol 26-Hydroxylase, Mitochondrial | 5-beta-cholestane-3-alpha, 7-alpha, 12-alpha-triol 26-Hydroxylase | CYP27A1 | Cholestanetriol 26-Monooxygenase | Cytochrome P-450C27/25 | Cytochrome P450 27 | Cytochrome P450 27A1 | EC 1.14.13.15 | Sterol 27-hydroxylase | Vitamin D(3) 25-Hydroxylase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542475","CLLU1 wt Allele","C104156","Human CLLU1 wild-type allele is located in the vicinity of 12q22 and is approximately 70 kb in length. This allele, which encodes chronic lymphocytic leukemia up-regulated protein 1, may play a role in chronic lymphocytic leukemia.","CLLU1 wt Allele | Chronic Lymphocytic Leukemia Up-Regulated 1 wt Allele | Chronic Lymphocytic Leukemia Upregulated Gene 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539851","Chronic Lymphocytic Leukemia Up-Regulated Protein 1","C104157","Chronic lymphocytic leukemia up-regulated protein 1 (121 aa, ~14 kDa) is encoded by the human CLLU1 gene. This protein may be involved in chronic lymphocytic leukemia.","Chronic Lymphocytic Leukemia Up-Regulated Protein 1 | CLLU1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540544","BMF wt Allele","C104159","Human BMF wild-type allele is located in the vicinity of 15q14 and is approximately 21 kb in length. This allele, which encodes bcl-2-modifying factor protein, is involved in the regulation of apoptosis.","BMF wt Allele | Bcl2 Modifying Factor wt Allele | FLJ00065",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1434616","SCARF1 protein, human","C106363","Scavenger receptor class F member 1 (830 aa, ~87 kDa) is encoded by the human SCARF1 gene. This protein plays a role in both the internalization and degradation of acetylated LDL.","Scavenger Receptor Class F Member 1 | Acetyl LDL Receptor | Endothelial Cells Scavenger Receptor | SCARF1 | SREC-I | Scavenger Receptor Expressed By Endothelial Cells 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538314","BAIAP2L1 Gene","C106364","This gene plays a role in both signaling and cytoskeletal modeling.","BAIAP2L1 Gene | BAI1-Associated Protein 2-Like 1 Gene | BAIAP2L1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815928","BAIAP2L1 wt Allele","C106365","Human BAIAP2L1 wild-type allele is located in the vicinity of 7q22.1 and is approximately 109 kb in length. This allele, which encodes brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 1, is involved in both cytoskeletal modeling and signal transduction.","BAIAP2L1 wt Allele | BAI1-Associated Protein 2-Like 1 wt Allele | IRTKS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815878","Brain-Specific Angiogenesis Inhibitor 1-Associated Protein 2-Like Protein 1","C106366","Brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 1 (511 aa, ~57 kDa) is encoded by the human BAIAP2L1 gene. This protein plays a role in cytoskeletal remodeling.","Brain-Specific Angiogenesis Inhibitor 1-Associated Protein 2-Like Protein 1 | BAI1-Associated Protein 2-Like Protein 1 | BAIAP2L1 | Insulin Receptor Tyrosine Kinase Substrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447734","Zirconium Zr 89-labeled Monoclonal Antibody MMOT0530A","C106367","A radioimmunoconjugate composed of a monoclonal antibody that targets an antigen overexpressed in pancreatic and ovarian cancer and labeled with the radioisotope zirconium Zr 89, with potential use for assessing tumor antigen expression using positron emission tomography (PET). Upon administration of zirconium Zr 89-labeled monoclonal antibody MMOT0530A, this agent targets an antigen expressed on certain tumor cells and is internalized.  Following tumor cell uptake, the radioisotope moiety can be visualized using PET imaging. This may result in both the quantification of tumor antigen expression and an assessment of the response to treatment with therapeutics targeting the antigen.","Zirconium Zr 89-labeled Monoclonal Antibody MMOT0530A | 89Zr-MMOT | 89Zr-MMOT0530A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1570777","KRP-203","C106368","The hydrochloride salt form of mocravimod, a sphingosine 1-phosphate (S1P) receptor agonist, with potential immunosuppressive activity. Upon administration of mocravimod, this agent binds to S1P receptors on lymphocytes, which prevents binding of serum S1P to S1P receptors and leads to S1P receptor internalization. This reduces the number of circulating blood leukocytes and accelerates lymphocyte homing into peripheral lymph nodes, thereby preventing their infiltration into peripheral inflammatory sites. This agent also decreases the production of inflammatory cytokines by lymphocytes, such as interferon gamma (IFN-g), interleukin-12 (IL-12), and tumor necrosis factor (TNF).","Mocravimod Hydrochloride | 2-Amino-2-propanediol Hydrochloride | KRP-203 | KRP203 | MOCRAVIMOD HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813710","MACC1 wt Allele","C106604","Human MACC1 wild-type allele is located in the vicinity of 7p21.1 and is approximately 83 kb in length. This allele, which encodes metastasis-associated in colon cancer protein 1, is involved in promoting both cell motility and cell proliferation. Expression of this gene in colon cancers is a prognostic indicator for metastasis formation.","MACC1 wt Allele | 7A5 | Metastasis Associated in Colon Cancer 1 wt Allele | SH3BP4L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829117","MACC1 protein, human","C106605","Metastasis-associated in colon cancer protein 1 (852 aa, ~97 kDa) is encoded by the human MACC1 gene. This protein plays a role in both cell proliferation and cell motility.","Metastasis-Associated in Colon Cancer Protein 1 | MACC1 | Putative Binding Protein 7a5 | SH3 Domain-Containing Protein 7a5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811164","MAP2K2 wt Allele","C106607","Human MAP2K2 wild-type allele is located in the vicinity of 19p13.3 and is approximately 34 kb in length. This allele, which encodes dual specificity mitogen-activated protein kinase kinase 2 protein, is involved in both MAPK and toll-like receptor signaling pathways. Mutation of the gene is associated with cardiofaciocutaneous syndrome.","MAP2K2 wt Allele | MAPKK2 | MEK2 | MKK2 | Mitogen-Activated Protein Kinase Kinase 2 wt Allele | PRKMK2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641579","C-SSRS Since Last Visit - Description of Wish to be Dead","C103773","Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Description of wishing to be dead.","C-SSRS Since Last Visit - Description of Wish to be Dead | CSS02-Wish to be Dead, Describe | CSS0201A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641581","C-SSRS Since Last Visit - Description of Non-Specific Suicide Thought","C103775","Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Description of non-specific active suicidal thoughts.","C-SSRS Since Last Visit - Description of Non-Specific Suicide Thought | CSS02-Non-Specific Suicid Thought, Descr | CSS0202A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641582","C-SSRS Since Last Visit - Suicidal Ideation-No Intent","C103776","Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Have you been thinking about how you might do this?","C-SSRS Since Last Visit - Suicidal Ideation-No Intent | CSS02-Suicidal Ideation-No Intent | CSS0203",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641583","C-SSRS Since Last Visit - Description of Suicidal Ideation-No Intent","C103777","Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Description of active suicidal ideation with any methods (not plan) without intent to act.","C-SSRS Since Last Visit - Description of Suicidal Ideation-No Intent | CSS02-Suicidal Ideation-No Intent, Descr | CSS0203A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641584","C-SSRS Since Last Visit - Description of Ideation With Plan and Intent","C103778","Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Description of active suicidal ideation with specific plan and intent.","C-SSRS Since Last Visit - Description of Ideation With Plan and Intent | CSS02-Ideation With Plan/Intent, Descr | CSS0205A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641585","C-SSRS Since Last Visit - Most Severe Ideation","C103779","Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Most severe ideation.","C-SSRS Since Last Visit - Most Severe Ideation | CSS02-Most Severe Ideation | CSS0206",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542969","GIP wt Allele","C104431","Human GIP wild-type allele is located within 17q21.3-q22 and is approximately 10 kb in length. This allele, which encodes gastric inhibitory polypeptide, is involved in insulin secretion and glucose homeostasis.","GIP wt Allele | Gastric Inhibitory Polypeptide wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017132","Gastric Inhibitory Polypeptide","C104432","Gastric inhibitory polypeptide (153 aa, ~17 kDa) is encoded by the human GIP gene. This protein plays a role in insulin secretion and glucose homeostasis.","Gastric Inhibitory Polypeptide | GIP | Glucose-Dependent Insulinotropic Polypeptide | Incretin Hormone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538959","GPX2 protein, human","C104433","Glutathione peroxidase 2 (190 aa, ~22 kDa) is encoded by the human GPX2 gene. This protein is involved in detoxification and digestion.","Glutathione Peroxidase 2 | EC 1.11.1.9 | GPX2 | Gastrointestinal Glutathione Peroxidase | Glutathione Peroxidase-Gastrointestinal | Glutathione Peroxidase-Related Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539631","GPX2 wt Allele","C104435","Human GPX2 wild-type allele is located in the vicinity of 14q23.3 and is approximately 4 kb in length. This allele, which encodes glutathione peroxidase 2 protein, plays a role in digestion and detoxification.","GPX2 wt Allele | GI-GPx | GPRP | GPRP-2 | GPx-2 | GPx-GI | GSHPX-GI | GSHPx-2 | Glutathione Peroxidase 2 (Gastrointestinal) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541885","HSD17B1 wt Allele","C104036","Human HSD17B1 wild-type allele is located in the vicinity of 17q21.2 and is approximately 4 kb in length. This allele, which encodes estradiol 17-beta-dehydrogenase 1 protein, plays a role in converting both estrogens and androgens to their active forms.","HSD17B1 wt Allele | E17KSR | EDH17B2 | EDHB17 | HSD17 | Hydroxysteroid (17-Beta) Dehydrogenase 1 Gene | Hydroxysteroid 17-Beta Dehydrogenase 1 wt Allele | MGC138140 | SDR28C1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2720178","Nuclear Receptor Subfamily 1 Group F Member 3","C104247","Nuclear receptor ROR-gamma (518 aa, ~58 kDa) is encoded by the human RORC gene. This protein plays a role in ligand-mediated transcriptional regulation.","Nuclear Receptor ROR-Gamma | NR1F3 | Nuclear Receptor RZR-Gamma | Nuclear Receptor Subfamily 1 Group F Member 3 | RAR-Related Orphan Receptor C | RAR-Related Orphan Receptor Gamma | RORC | RZR-Gamma | Retinoic Acid-Binding Receptor Gamma | Retinoid-Related Orphan Receptor Gamma | Retinoid-Related Orphan Receptor-Gamma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540638","TBX21 wt Allele","C104249","Human TBX21 wild-type allele is located in the vicinity of 17q21.32 and is approximately 13 kb in length. This allele, which encodes T-box transcription factor TBX21 protein, plays a role in the transcriptional regulation of interferon-gamma. Genetic variation is associated with susceptibility to asthma with nasal polyps and aspirin intolerance.","TBX21 wt Allele | T-Box 21 wt Allele | T-PET | T-bet | TBET | TBLYM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542479","ITGB7 wt Allele","C104252","Human ITGB7 wild-type allele is located in the vicinity of 12q13.13 and is approximately 16 kb in length. This allele, which encodes integrin beta-7 protein, is involved in the regulation of both integrin-mediated signaling and cell-matrix adhesion.","ITGB7 wt Allele | Integrin, Beta 7 wt Allele | Integrin, Beta-7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542480","DLL3 wt Allele","C104255","Human DLL3 wild-type allele is located in the vicinity of 19q13 and is approximately 10 kb in length. This allele, which encodes delta-like protein 3, plays a role in both neural cell differentiation and somitogenesis. Mutation of the gene is associated with spondylocostal dysostosis type 1.","DLL3 wt Allele | Delta (Drosophila)-Like 3 Gene | Delta Like Canonical Notch Ligand 3 wt Allele | Delta, Drosophila, Homolog of, 3 Gene | Delta-Like 3 (Drosophila) Gene | SCDO1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542919","Delta-Like Protein 3, Human","C104256","Delta-like protein 3 (618 aa, ~65 kDa) is encoded by the human DLL3 gene. This protein is involved in binding to notch proteins, mesoderm development and neurogenesis.","Delta-Like Protein 3 | DLL3 | Delta 3 | Delta-Like 3 | Delta3 | Drosophila Delta Homolog 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540491","HES4 wt Allele","C104258","Human HES4 wild-type allele is located in the vicinity of 1p36.33 and is approximately 1 kb in length. This allele, which encodes transcription factor HES-4 protein, is involved in the negative regulation of transcription.","HES4 wt Allele | BHLHB42 | Hairy and Enhancer of Split 4 (Drosophila) wt Allele | bHLHb42",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537383","Bcl-2-Modifying Factor","C104160","Bcl-2-modifying factor (184 aa, ~21 kDa) is encoded by the human BMF gene. This protein plays a role in the positive regulation of pro-apoptotic gene products.","Bcl-2-Modifying Factor | BMF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539680","KIF23 wt Allele","C104162","Human KIF23 wild-type allele is located in the vicinity of 15q23 and is approximately 34 kb in length. This allele, which encodes kinesin-like protein KIF23, plays a role in microtubule motor activity, mitotic spindle formation and cytokinesis.","KIF23 wt Allele | CHO1 | KNSL5 | Kinesin Family Member 23 wt Allele | Kinesin-Like 5 (Mitotic Kinesin-Like Protein 1) Gene | MKLP-1 | MKLP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641510","OAB-q Short Form - Locate Closest Restroom as Soon as You Arrive","C103704","The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Caused you to locate the closest restroom as soon as you arrive at a place you have never been?","OAB-q Short Form - Locate Closest Restroom as Soon as You Arrive | OABQ02-Locate Closest Restroom | OABQ0219",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641511","PHQ-9 - Little Interest or Pleasure in Doing Things","C103705","Patient Health Questionnaire - 9 (PHQ-9) Over the last 2 weeks, how often have you been bothered by: Little interest or pleasure in doing things.","PHQ-9 - Little Interest or Pleasure in Doing Things | PHQ01-Little Interest/Pleasure in Things | PHQ0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641513","PHQ-9 - Trouble Falling or Staying Asleep, or Sleeping Too Much","C103707","Patient Health Questionnaire - 9 (PHQ-9) Over the last 2 weeks, how often have you been bothered by: Trouble falling or staying asleep, or sleeping too much.","PHQ-9 - Trouble Falling or Staying Asleep, or Sleeping Too Much | PHQ01-Trouble Falling or Staying Asleep | PHQ0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641514","PHQ-9 - Feeling Tired or Having Little Energy","C103708","Patient Health Questionnaire - 9 (PHQ-9) Over the last 2 weeks, how often have you been bothered by: Feeling tired or having little energy.","PHQ-9 - Feeling Tired or Having Little Energy | PHQ01-Feeling Tired or Little Energy | PHQ0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641515","PHQ-9 - Poor Appetite or Overeating","C103709","Patient Health Questionnaire - 9 (PHQ-9) Over the last 2 weeks, how often have you been bothered by: Poor appetite or overeating.","PHQ-9 - Poor Appetite or Overeating | PHQ01-Poor Appetite or Overeating | PHQ0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641516","PHQ-9 - Feeling Bad About Yourself","C103710","Patient Health Questionnaire - 9 (PHQ-9) Over the last 2 weeks, how often have you been bothered by: Feeling bad about yourself - or that you are a failure or have let yourself or your family down.","PHQ-9 - Feeling Bad About Yourself | PHQ01-Feeling Bad About Yourself | PHQ0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641517","PHQ-9 - Trouble Concentrating on Things","C103711","Patient Health Questionnaire - 9 (PHQ-9) Over the last 2 weeks, how often have you been bothered by: Trouble concentrating on things, such as reading the newspaper or watching television.","PHQ-9 - Trouble Concentrating on Things | PHQ01-Trouble Concentrating on Things | PHQ0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641518","PHQ-9 - Moving or Speaking Slowly or the Opposite being Fidgety or Restless","C103712","Patient Health Questionnaire - 9 (PHQ-9) Over the last 2 weeks, how often have you been bothered by: Moving or speaking so slowly that other people could have noticed? Or the opposite - being so fidgety or restless that you have been moving around a lot more than usual.","PHQ-9 - Moving or Speaking Slowly or the Opposite being Fidgety or Restless | PHQ01-Moving Slowly or Fidgety/Restless | PHQ0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641519","PHQ-9 - Thoughts That You Would be Better Off Dead","C103713","Patient Health Questionnaire - 9 (PHQ-9) Over the last 2 weeks, how often have you been bothered by: Thoughts that you would be better off dead or of hurting yourself in some way.","PHQ-9 - Thoughts That You Would be Better Off Dead | PHQ01-Thoughts You Be Better Off Dead | PHQ0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641520","PHQ-9 - How Difficult have Problems Made it for You to Work, Take Care of Things, or Get Along with Other People","C103714","Patient Health Questionnaire - 9 (PHQ-9) If you checked off any problems, how difficult have these problems made it for you to do your work, take care of things at home, or get along with other people?","PHQ-9 - How Difficult have Problems Made it for You to Work, Take Care of Things, or Get Along with Other People | PHQ01-Difficult to Work/Take Care Things | PHQ0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812180","SEMA4D wt Allele","C106609","Human SEMA4D wild-type allele is located in the vicinity of 9q22.2 and is approximately 137 kb in length. This allele, which encodes semaphorin-4D protein, plays a role in both axonal growth cone guidance and cell-cell signaling.","SEMA4D wt Allele | A8 | BB18 | CD100 | Coll-4 | FLJ39737 | GR3 | SEMAJ | Sema Domain, Immunoglobulin Domain (Ig), Transmembrane Domain (TM) and Short Cytoplasmic Domain, (semaphorin) 4D wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0296790","Semaphorin-4D","C106610","Semaphorin-4D (862 aa, ~96 kDa) is encoded by the human SEMA4D gene. This protein is involved in both axonal growth cone guidance in the developing central nervous system and cell-cell signaling.","Semaphorin-4D | C9orf164 | CD100 Antigen | Chromosome 9 Open Reading Frame 164 | M-Sema-G | SEMA4D",,,,,,,,,,,,,,,"4012390","Lymphocyte antigen CD100",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3810564","SMAD1 wt Allele","C106612","Human SMAD1 wild-type allele is located in the vicinity of 4q31.21 and is approximately 78 kb in length. This allele, which encodes mothers against decapentaplegic homolog 1 protein, is involved in the regulation of cell growth, apoptosis, morphogenesis, development and immune responses.","SMAD1 wt Allele | BSP-1 | BSP1 | HSMAD1 | JV4-1 | JV41 | MADH1 | MADR1 | SMAD Family Member 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0528559","SMAD1 protein, human","C106613","Mothers against decapentaplegic homolog 1 (465 aa, ~52 kDa) is encoded by the human SMAD1 gene. This protein plays a role in regulating the action of bone morphogenic proteins in cell growth, apoptosis, morphogenesis, development and immune responses.","Mothers Against Decapentaplegic Homolog 1 | MAD Homolog 1 | MAD, Mothers Against Decapentaplegic Homolog 1 | MAD, Mothers Against Decapentaplegic Homolog 1 (Drosophila) | Mad-Related Protein 1 | Mothers Against DPP Homolog 1 | SMAD, Mothers Against DPP Homolog 1 (Drosophila) | TGF-Beta Signaling Protein 1 | Transforming Growth Factor-Beta Signaling Protein 1 | Transforming Growth Factor-Beta-Signaling Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1612086","Solute Carrier Organic Anion Transporter Family Member 1B1, Human","C106616","Solute carrier organic anion transporter family member 1B1 (691 aa, ~76 kDa) is encoded by the human SLCO1B1 gene. This protein is involved in the sodium-independent uptake of endogenous compounds in the liver.","Solute Carrier Organic Anion Transporter Family Member 1B1 | Liver-Specific Organic Anion Transporter 1 | SLCO1B1 | Sodium-Independent Organic Anion-Transporting Polypeptide 2 | Solute Carrier Family 21 (Organic Anion Transporter), Member 6 | Solute Carrier Family 21 Member 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829870","HAQ-DI With VAS - Aids or Devices For Dress/Arising/Eat/Walk-Specify","C106826","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Specify (for dressing and grooming, arising, eating and walking).","HAQ-DI With VAS - Aids or Devices For Dress/Arising/Eat/Walk-Specify | HAQ01-Spec Aid (Dress/Arising/Eat/Walk) | HAQ0118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829859","HAQ-DI With VAS - Help From Another Person - Dressing and Grooming","C106827","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Categories usually need help from another person - Dressing and grooming.","HAQ-DI With VAS - Help From Another Person - Dressing and Grooming | HAQ01-Help: Dressing and Grooming | HAQ0119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829860","HAQ-DI With VAS - Help From Another Person - Arising","C106828","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Categories usually need help from another person - Arising.","HAQ-DI With VAS - Help From Another Person - Arising | HAQ01-Help: Arising | HAQ0120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829858","HAQ-DI With VAS - Help From Another Person - Eating","C106829","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Categories usually need help from another person - Eating.","HAQ-DI With VAS - Help From Another Person - Eating | HAQ01-Help: Eating | HAQ0121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541974","CBR3 wt Allele","C103988","Human CBR3 wild-type allele is located in the vicinity of 21q22.2 and is approximately 12 kb in length. This allele, which encodes carbonyl reductase [NADPH] 3 protein, is involved in the metabolism of carbonyl-containing compounds.","CBR3 wt Allele | Carbonyl Reductase 3 wt Allele | SDR21C2 | Short Chain Dehydrogenase/Reductase Family 21C, Member 2 Gene | hCBR3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538941","Carbonyl Reductase [NADPH] 3, Human","C103989","Carbonyl reductase [NADPH] 3 (277 aa, ~31 kDa) is encoded by the human CBR3 gene. This protein plays a role in the reduction of metabolically active carbonyl compounds.","Carbonyl Reductase [NADPH] 3 | CBR3 | Carbonyl Reductase 3 | EC 1.1.1.184 | NADPH-Dependent Carbonyl Reductase 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539876","Transcription Factor HES-4","C104259","Transcription factor HES-4 (221 aa, ~24 kDa) is encoded by the human HES4 gene. This protein plays a role in transcriptional repression.","Transcription Factor HES-4 | Class B Basic Helix-Loop-Helix Protein 42 | HES4 | Hairy and Enhancer of Split 4 | bHLH Factor Hes4 | bHLHb42 | hHES4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438306","XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410","C103823","A cancer vaccine containing immunogenic, HLA-A2-specific epitopes derived from X-box-binding protein 1-unspliced (XBP1-US), XBP1-spliced (SP), syndecan-1 (CD138), and CS1 (CD2 subset 1, CRACC, SLAMF7, CD319) with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, XBP1-US/XBP1-SP/CD138/CS1 multipeptide vaccine PVX-410 may stimulate the immune system to induce a cytotoxic T-lymphocyte response against the four myeloma-specific antigens.  The tumor associated antigens (TAAs) XBP1-US, XBP1-SP, CD138 and CS1, are overexpressed on the surface of multiple myeloma (MM) cells.","XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410 | PVX-410",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3180499","Oxycodone Hydrochloride/Naloxone Hydrochloride Prolonged-release Tablet","C103824","A prolonged-release tablet formulation composed of the hydrochloride salt form of the opioid receptor agonist oxycodone and the hydrochloride salt form of the opioid receptor antagonist naloxone which may produce analgesia while relieving opioid-mediated gastrointestinal (GI) side effects. Upon oral administration, oxycodone binds to opioid receptors, thereby mimicking the effects of endogenous opiates to provide analgesia. As naloxone is very poorly absorbed, this agent binds locally to opiate receptors in the GI tract, thereby preventing oxycodone from binding to these receptors. This relieves the opioid-related side effects on the GI tract, including opioid-induced constipation.","Oxycodone Hydrochloride/Naloxone Hydrochloride Prolonged-release Tablet | Targin | Targinact",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433733","Smac Mimetic GDC-0917","C103825","An orally available, monovalent mimetic of second mitochondrial-derived activator of caspases (Smac/DIABLO) and inhibitor of IAPs (Inhibitor of Apoptosis Proteins) with potential antineoplastic activity. Smac mimetic GDC-0917 binds to the Smac binding groove on IAPs, including the direct caspase inhibitor X chromosome-linked IAP (XIAP) and the cellular IAPs 1 and 2. This inhibits the activities of these IAPs and promotes the induction of apoptosis through apoptotic signaling pathways.  IAPs are overexpressed by many cancer cell types and suppress apoptosis by binding to and inhibiting active caspases-3, -7 and -9 via their baculoviral lAP repeat (BIR) domains.","Smac Mimetic GDC-0917 | CUDC 427 | CUDC-427 | CUDC427 | GDC-0917 | IAP Antagonist GDC-0917 | L-Prolinamide, N-methyl-L-alanyl-(2S)-2-cyclohexylglycyl-N-(2-(2-oxazolyl)-4-phenyl-5-thiazolyl)- | RG 7459 | RG-7459 | RG7459 | SMAC/DIABLO Mimetic GDC-0917",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641628","Taladegib","C103826","An orally bioavailable small molecule antagonist of the Hedgehog (Hh)-ligand cell surface receptor smoothened (Smo) with potential antineoplastic activity. Taladegib inhibits signaling that is mediated by the Hh pathway protein Smo, which may result in a suppression of the Hh signaling pathway and may lead to the inhibition of the proliferation of tumor cells in which this pathway is abnormally activated. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair; constitutive activation of this pathway is associated with uncontrolled cellular proliferation and has been observed in a variety of cancers.","Taladegib | 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide | Benzamide, 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)- | LY-2940680 | LY2940680 | TALADEGIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438307","anti-PSMA/CD3 BiTE monoclonal antibody MT112","C103827","A recombinant T-cell engaging bispecific monoclonal antibody (BiTE) directed against human prostate specific membrane antigen (PSMA) and the CD3 epsilon subunit of the T cell receptor complex, with potential immunostimulating and antineoplastic activities.  Pasotuxizumab possesses two antigen-recognition sites, one for PSMA, and one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR). This bispecific monoclonal antibody brings PSMA-expressing tumor cells and cytotoxic T lymphocytes (CTLs) together, which may result in the CTL-mediated cell death of PSMA-expressing cells. PSMA, a tumor associated antigen, is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.","Pasotuxizumab | AMG-212 | BAY2010112 | MT112 | PASOTUXIZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641630","Galectin-1 Inhibitor OTX008","C103828","A calixarene-based compound and galectin-1 (Gal-1) inhibitor with potential anti-angiogenic and antineoplastic activities. Upon subcutaneous administration, galectin-1 inhibitor OTX008 binds Gal-1 which leads to Gal-1 oxidation and proteasomal degradation, through an as of yet not fully elucidated mechanism, and eventually downregulation of Gal-1. This decreases tumor cell growth and inhibits angiogenesis. Gal-1, a multifunctional carbohydrate-binding protein, is often overexpressed on tumor cells and plays a key role in cancer cell proliferation, apoptosis, tumor angiogenesis and evasion of immune responses.","Galectin-1 Inhibitor OTX008 | Gal-1 Inhibitor OTX008 | KM-0118 | OTX-008 | OTX008",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641521","PHQ-15 - Stomach Pain","C103715","Patient Health Questionnaire - 15 (PHQ-15) Stomach pain.","PHQ-15 - Stomach Pain | PHQ02-Stomach Pain | PHQ0201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641523","PHQ-15 - Pain In Your Arms, Legs, or Joints","C103717","Patient Health Questionnaire - 15 (PHQ-15) Pain in your arms, legs, or joints (knees, hips, etc.).","PHQ-15 - Pain In Your Arms, Legs, or Joints | PHQ02-Pain In Your Arms, Legs, or Joints | PHQ0203",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641524","PHQ-15 - Menstrual Cramp or Other Problems with Your Periods","C103718","Patient Health Questionnaire - 15 (PHQ-15) Menstrual cramps or other problems with your periods [Women only].","PHQ-15 - Menstrual Cramp or Other Problems with Your Periods | PHQ02-Menstrual Cramp/Problem Periods | PHQ0204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641525","PHQ-15 - Headaches","C103719","Patient Health Questionnaire - 15 (PHQ-15) Headaches.","PHQ-15 - Headaches | PHQ02-Headaches | PHQ0205",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641526","PHQ-15 - Chest Pain","C103720","Patient Health Questionnaire - 15 (PHQ-15) Chest pain.","PHQ-15 - Chest Pain | PHQ02-Chest Pain | PHQ0206",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539774","FOXP3 wt Allele","C104395","Human FOXP3 wild-type allele is located in the vicinity of Xp11.23 and is approximately 14 kb in length. This allele, which encodes forkhead box protein P3, plays a role in transcription regulation and the immune response. Mutations in this gene are associated with immunodeficiency polyendocrinopathy, enteropathy, X-linked syndrome (IPEX).","FOXP3 wt Allele | AIID | DIETER | Forkhead Box P3 wt Allele | IPEX | JM2 | PIDX | SCURFIN | XPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1504797","Forkhead Box Protein P3","C104396","Forkhead box protein P3 (431 aa, ~47 kDa) is encoded by the human FOXP3 gene. This protein is involved in transcription regulation and the immune response.","Forkhead Box Protein P3 | FOXP3 | FOXP3delta7 | Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked | Scurfin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542965","FSHB wt Allele","C104398","Human FSHB wild-type allele is located in the vicinity of 11p13 and is approximately 4 kb in length. This allele, which encodes follitropin subunit beta protein, is involved in induction of sperm and egg production. Mutations in this gene are associated with follicle-stimulating hormone deficiency, isolated.","FSHB wt Allele | FSH-B | Follicle Stimulating Hormone, Beta Polypeptide wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4082585","Follitropin Subunit Beta","C104399","Follitropin subunit beta (129 aa, ~15 kDa) is encoded by the human FSHB gene. This protein plays a role in induction of egg and sperm production.","Follitropin Subunit Beta | FSH-beta | Follicle Stimulating Hormone Beta Subunit | Follicle Stimulating Hormone, Beta Polypeptide | Follitropin Beta Chain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0055205","CGP-6809","C1043","A water-soluble nitrosourea that cross-links with DNA, causing inhibition of DNA synthesis.","CGP-6809 | EDMN | ethyl-6-deoxy-3,5-di-O-methyl-6-(3-methyl-3-nitrosoureido)-alpha-D-glucofuranoside",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538869","FUT4 wt Allele","C104401","Human FUT4 wild-type allele is located in the vicinity of 11q21 and is approximately 6 kb in length. This allele, which encodes alpha-(1,3)-fucosyltransferase 4 protein, plays a role in the generation of fucosylated carbohydrate structures.","FUT4 wt Allele | Alpha (1,3) Fucosyltransferase, Myeloid-Specific Gene | CD15 | CD15 Fucosyltransferase Gene | ELFT | FCT3A | FUC-TIV | FUTIV | Fucosyltransferase 4 (Alpha (1,3) Fucosyltransferase, Myeloid-Specific) Gene | Fucosyltransferase 4 (Alpha (1,3) Fucosyltransferase, Myeloid-Specific) wt Allele | Fucosyltransferase 4 wt Allele | LeX | LeX Fucosyltransferase Gene | SSEA-1 | SSEA-1 Fucosyltransferase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829853","HAQ-DI With VAS - Help From Another Person - Walking","C106830","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Categories usually need help from another person - Walking.","HAQ-DI With VAS - Help From Another Person - Walking | HAQ01-Help: Walking | HAQ0122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829877","HAQ-DI With VAS - Able to Wash and Dry Body","C106831","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Hygiene: are you able to wash and dry your body?","HAQ-DI With VAS - Able to Wash and Dry Body | HAQ01-Wash and Dry Your Body | HAQ0123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829880","HAQ-DI With VAS - Able to Take Tub Bath","C106832","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Hygiene: are you able to take a tub bath?","HAQ-DI With VAS - Able to Take Tub Bath | HAQ01-Take a Tub Bath | HAQ0124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829889","HAQ-DI With VAS - Able to Get On and Off Toilet","C106833","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Hygiene: are you able to get on and off the toilet?","HAQ-DI With VAS - Able to Get On and Off Toilet | HAQ01-Get On and Off The Toilet | HAQ0125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829896","HAQ-DI With VAS - Able to Bend Down and Pick Up Clothing From Floor","C106835","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Reach: are you able to bend down and pick up clothing from the floor?","HAQ-DI With VAS - Able to Bend Down and Pick Up Clothing From Floor | HAQ01-Bend Down Pick Up Clothing - Floor | HAQ0127",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829887","HAQ-DI With VAS - Able to Open Car Doors","C106836","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Grip: are you able to open car doors?","HAQ-DI With VAS - Able to Open Car Doors | HAQ01-Open Car Doors | HAQ0128",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829885","HAQ-DI With VAS - Able to Open Previously Opened Jars","C106837","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Grip: are you able to open jars which have been previously opened?","HAQ-DI With VAS - Able to Open Previously Opened Jars | HAQ01-Open Jars Previously Opened | HAQ0129",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829879","HAQ-DI With VAS - Able to Turn Faucets On and Off","C106838","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Grip: are you able to turn faucets on and off?","HAQ-DI With VAS - Able to Turn Faucets On and Off | HAQ01-Turn Faucets On And Off | HAQ0130",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829890","HAQ-DI With VAS - Able to Get In and Out of Car","C106840","Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Activities: are you able to get in and out of a car?","HAQ-DI With VAS - Able to Get In and Out of Car | HAQ01-Get In and Out of a Car | HAQ0132",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830945","C-SSRS Already Enrolled Subjects - Duration of Most Severe Ideation (Prior to Study Entry)","C107048","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) When you have the thoughts, how long do they last? (Prior to Study Entry).","C-SSRS Already Enrolled Subjects - Duration of Most Severe Ideation (Prior to Study Entry) | CSS05-Most Severe Idea, Duration-Prior | CSS0508A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830944","C-SSRS Already Enrolled Subjects - Duration of Most Severe Ideation (Since Study Start)","C107049","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) When you have the thoughts, how long do they last? (Since Study Start).","C-SSRS Already Enrolled Subjects - Duration of Most Severe Ideation (Since Study Start) | CSS05-Most Severe Idea, Duration-Since | CSS0508B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541975","BAALC wt Allele","C103992","Human BAALC wild-type allele is located in the vicinity of 8q22.3 and is approximately 90 kb in length. This allele, which encodes brain and acute leukemia cytoplasmic protein, may play a role in the functioning of neurons and hematopoietic cells. Aberrant expression may be associated with acute myeloid leukemia.","BAALC wt Allele | Brain and Acute Leukemia, Cytoplasmic wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538974","Brain and Acute Leukemia Cytoplasmic Protein","C103993","Brain and acute leukemia cytoplasmic protein (180 aa, ~19 kDa) is encoded by the human BAALC gene. This protein may be involved in synapse function or hematopoiesis.","Brain and Acute Leukemia Cytoplasmic Protein | BAALC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539706","MTAP wt Allele","C103995","Human MTAP wild-type allele is located in the vicinity of 9p21 and is approximately 230 kb in length. This allele, which encodes S-methyl-5'-thioadenosine phosphorylase protein, is involved in the metabolism of both polyamines and purines. Mutation of the gene is associated with diaphyseal medullary stenosis with malignant fibrous histiocytoma.","MTAP wt Allele | BDMF | DMSFH | DMSMFH | LGMBF | MSAP | Methylthioadenosine Phosphorylase wt Allele | c86fus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0048820","S-Methyl-5'-Thioadenosine Phosphorylase","C103996","S-methyl-5'-thioadenosine phosphorylase (283 aa, ~31 kDa) is encoded by the human MTAP gene. This protein plays a role in amino acid, nucleotide and polyamine metabolism.","S-Methyl-5'-Thioadenosine Phosphorylase | 5'-Methylthioadenosine Phosphorylase | EC 2.4.2.28 | MTA Phosphorylase | MTAP | MTAPase | MeSAdo Phosphorylase | S-Methyl-5-Thioadenosine Phosphorylase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415755","HSPA1A Gene","C103997","This gene is involved in protein folding.","HSPA1A Gene | HSPA1A | Heat Shock 70 kDa Protein 1A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415756","HSPA1B Gene","C103998","This gene plays a role in protein chaperone activity.","HSPA1B Gene | HSPA1B | Heat Shock 70 kDa Protein 1B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541976","HSPA1A wt Allele","C103999","Human HSPA1A wild-type allele is located in the vicinity of 6p21.3 and is approximately 2 kb in length. This allele, which encodes heat shock 70 kDa protein 1A/1B, plays a role in protein chaperone activity.","HSPA1A wt Allele | DAQB-147D11.1 | HSP70-1 | HSP70-1A | HSP70I | HSP72 | HSPA1 | Heat Shock 70 kDa Protein 1A wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0054727","Carbovir","C1039","A nucleoside reverse transcriptase inhibitor analog of guanosine. Carbovir decreases HIV viral loads, retards or prevents the damage to the immune system, and reduces the risk of developing AIDS.","Carbovir | (+ -)-Carbovir | 2',3'-didehydro-2',3'-dideoxyguanosine | CARBOVIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541977","HSPA1B wt Allele","C104000","Human HSPA1B wild-type allele is located in the vicinity of 6p21.3 and is approximately 3 kb in length. This allele, which encodes heat shock 70 kDa protein 1A/1B, is involved in protein folding.","HSPA1B wt Allele | HSP70-1B | HSP70-2 | Heat Shock 70 kDa Protein 1B wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL438309","FAP-specific CD8-positive T Cells","C103829","A preparation of CD8-positive T cells specific for human fibroblast activating protein (FAP) with potential immunopotentiating activity. T cells have been genetically modified to express a chimeric antigen receptor specific for FAP. Upon infusion, the FAP-specific CD8-positive T cells bind to FAP-expressing tumor cells and exhibit a selective toxicity to tumor cells. This may result in both tumor cell lysis and inhibition of tumor cell growth. FAP, a cell surface glycoprotein, is overexpressed on tumor-associated fibroblasts but minimally expressed on normal, healthy cells.","FAP-specific CD8-positive T Cells | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831626","ADCS-ADL Severe Dementia - Obtain Beverage for Self","C106997","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) In the past 4 weeks, did subject obtain a hot or cold beverage for him or herself?","ADCS-ADL Severe Dementia - Obtain Beverage for Self | ADL02-Obtain Beverage | ADL0212",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831640","ADCS-ADL Severe Dementia - Description of Highest Performance of Obtaining Beverage","C106998","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) If yes, which best describes subject highest level of performance.","ADCS-ADL Severe Dementia - Description of Highest Performance of Obtaining Beverage | ADL02-Obtain Beverage Highest Perform | ADL0212A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831629","ADCS-ADL Severe Dementia - Dispose of Garbage in Appropriate Place at Home","C106999","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) In the past 4 weeks, did subject dispose of garbage or litter in an appropriate place or container at home?","ADCS-ADL Severe Dementia - Dispose of Garbage in Appropriate Place at Home | ADL02-Dispose of Garbage | ADL0213",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0057769","Dibenzo (a,l) pyrene","C1069","A yellowish-reddish, carcinogenic aromatic hydrocarbon consisting of six fused rings and produced by the incomplete combustion of organic matter. Dibenzo[a,e]pyrene is primarily found in coal gasification products, cigarette smoke and fossil fuels. This substance is used only for research purposes to induce tumorigenesis. Dibenzo[a,e]pyrene is a mutagen and is reasonably anticipated to be a human carcinogen.","Dibenzo (a,l) pyrene | 1,2,3,4-Dibenzopyrene | DB(a,l)P | DIBENZO(A,L)PYRENE | Dibenzo(def,p)chrysene | Dibenzo[a,l]pyrene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831627","ADCS-ADL Severe Dementia - Get Around Outside Home","C107001","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) In the past 4 weeks, did subject get around (or travel) outside of his or her home?","ADCS-ADL Severe Dementia - Get Around Outside Home | ADL02-Get Around Outside Home | ADL0214",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831638","ADCS-ADL Severe Dementia - Description of Optimal Performance of Getting Around Outside of Home","C107002","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) If yes, which best describes subject subject's optimal performance.","ADCS-ADL Severe Dementia - Description of Optimal Performance of Getting Around Outside of Home | ADL02-Get Around Optimal Performance | ADL0214A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831622","ADCS-ADL Severe Dementia - Subject Left on Their Own","C107003","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) In the past 4 weeks, was subject ever left on his or her own?","ADCS-ADL Severe Dementia - Subject Left on Their Own | ADL02-Left On His/Her Own | ADL0215",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831642","ADCS-ADL Severe Dementia - Alone Away From Home for Fifteen Minutes or Longer","C107004","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) If yes, was subject left away from home for 15 minutes or longer during the day?","ADCS-ADL Severe Dementia - Alone Away From Home for Fifteen Minutes or Longer | ADL02-Left Away From Home | ADL0215A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831643","ADCS-ADL Severe Dementia - Alone at Home for One Hour or Longer","C107005","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) If yes, was subject left at home for an hour or longer during the day?","ADCS-ADL Severe Dementia - Alone at Home for One Hour or Longer | ADL02-Left at Home for 1 Hour or Longer | ADL0215B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1429589","Alpha-(1,3)-Fucosyltransferase 4, Human","C104402","Alpha-(1,3)-fucosyltransferase 4 (530 aa, ~60 kDa) is encoded by the human FUT4 gene. This protein is involved in the generation of fucosylated carbohydrate structures.","Alpha-(1,3)-Fucosyltransferase 4 | 4-Galactosyl-N-Acetylglucosaminide 3-Alpha-L-Fucosyltransferase | Alpha-(1,3)-Fucosyltransferase | Alpha-3-Fucosyltransferase | CD15 Fucosyltransferase | EC 2.4.1.152 | EC 2.4.1.65 | EC 2.4.1.65, Formerly | ELAM Ligand Fucosyltransferase | ELAM-1 Ligand Fucosyltransferase | FUT4 | Fuc-TIV | FucT-IV | Fucosyltransferase 4 | Fucosyltransferase IV | Galactoside 3-L-Fucosyltransferase | LeX Fucosyltransferase | Lewis X | Lewis X Fucosyltransferase | SSEA-1 Fucosyltransferase | Stage-Specific Embryonic Antigen 1 | Stage-Specific Embryonic Antigen 1 Fucosyltransferase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542966","FZD8 wt Allele","C104404","Human FZD8 wild-type allele is located in the vicinity of 10p11.2 and is approximately 3 kb in length. This allele, which encodes frizzled-8 protein, is involved in beta-catenin signaling.","FZD8 wt Allele | FZ-8 | Frizzled (Drosophila) Homolog 8 Gene | Frizzled 8, Seven Transmembrane Spanning Receptor Gene | Frizzled Class Receptor 8 wt Allele | Frizzled Family Receptor 8 Gene | Frizzled Homolog 8 (Drosophila) Gene | Frizzled, Drosophila, Homolog of, 8 Gene | hFZ8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2354682","Frizzled-8, Human","C104405","Frizzled-8 (694 aa, ~73 kDa) is encoded by the human FZD8 gene. This protein plays a role in beta-catenin signaling.","Frizzled-8 | FZ-8 | Frizzled 8 | Frizzled Family Receptor 8 | Frizzled Homolog 8 | hFZ8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538683","LGALS1 wt Allele","C104407","Human LGALS1 wild-type allele is located in the vicinity of 22q13.1 and is approximately 4 kb in length. This allele, which encodes galectin-1 protein, may be involved in modulating cell-cell and cell-matrix interactions and in regulating apoptosis.","LGALS1 wt Allele | GAL1 | GBP | HBL | HLBP14 | HPL | Lectin, Galactoside-Binding, Soluble, 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0060626","Folylpolyglutamate Synthase, Mitochondrial","C103942","Folylpolyglutamate synthase, mitochondrial (587 aa, ~65 kDa) is encoded by the human FPGS gene. This protein plays a role in the conversion of folates to polyglutamate derivatives.","Folylpolyglutamate Synthase, Mitochondrial | EC 6.3.2.17 | FPGS | Folylpoly-Gamma-Glutamate Synthetase | Tetrahydrofolate Synthase | Tetrahydrofolylpolyglutamate Synthase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539616","GGH wt Allele","C103944","Human GGH wild-type allele is located in the vicinity of 8q12.3 and is approximately 24 kb in length. This allele, which encodes gamma-glutamyl hydrolase protein, plays a role in glutamine metabolism.","GGH wt Allele | GH | Gamma-Glutamyl Hydrolase (Conjugase, Folylpolygammaglutamyl Hydrolase) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033993","Gamma-Glutamyl Hydrolase","C103945","Gamma-glutamyl hydrolase (318 aa, ~36 kDa) is encoded by the human GGH gene. This protein is involved in the hydrolysis of gamma-linked glutamate bonds.","Gamma-Glutamyl Hydrolase | Conjugase | EC 3.4.19.9 | GGH | GH | Gamma-Glu-X Carboxypeptidase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538834","SLC19A1 wt Allele","C103947","Human SLC19A1 wild-type allele is located in the vicinity of 21q22.3 and is approximately 51 kb in length. This allele, which encodes folate transporter 1 protein, is involved in folic acid metabolism.","SLC19A1 wt Allele | CHMD | FOLT | IFC-1 | IFC1 | MEGAF | REFC | RFC | RFC1 | RFT-1 | Solute Carrier Family 19 (Folate Transporter), Member 1 Gene | Solute Carrier Family 19 Member 1 wt Allele | hRFC | hSLC19A1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830960","C-SSRS Already Enrolled Subjects - Controllability of Most Severe Ideation (Prior to Study Entry)","C107050","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Could/can you stop thinking about killing yourself or wanting to die if you want to? (Prior to Study Entry).","C-SSRS Already Enrolled Subjects - Controllability of Most Severe Ideation (Prior to Study Entry) | CSS05-Most Severe Idea, Control-Prior | CSS0509A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830959","C-SSRS Already Enrolled Subjects - Controllability of Most Severe Ideation (Since Study Start)","C107051","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Could/can you stop thinking about killing yourself or wanting to die if you want to? (Since Study Start).","C-SSRS Already Enrolled Subjects - Controllability of Most Severe Ideation (Since Study Start) | CSS05-Most Severe Idea, Control-Since | CSS0509B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830946","C-SSRS Already Enrolled Subjects - Deterrents to Most Severe Ideation (Since Study Start)","C107053","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Are there things-anyone or anything (e.g., family, religion, pain of death) that stopped you from wanting to die or acting on thoughts of committing suicide? (Since Study Start).","C-SSRS Already Enrolled Subjects - Deterrents to Most Severe Ideation (Since Study Start) | CSS05-Most Severe Idea, Deterrents-Since | CSS0510B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830914","C-SSRS Already Enrolled Subjects - Reasons For Most Severe Ideation (Since Study Start)","C107055","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) What sort of reasons did you have for thinking about wanting to die or killing yourself? Was it to end the pain or stop the way you were feeling (in other words you couldn't go on living with this pain or how you were feeling) or was it to get attention, revenge or a reaction from others? Or both? (Since Study Start).","C-SSRS Already Enrolled Subjects - Reasons For Most Severe Ideation (Since Study Start) | CSS05-Most Severe Idea, Reasons-Since | CSS0511B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830964","C-SSRS Already Enrolled Subjects - Actual Suicide Attempt (Prior to Study Entry)","C107056","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Have you made a suicide attempt? Have you done anything to harm yourself? Have you done anything dangerous where you could have died? (Prior to Study Entry).","C-SSRS Already Enrolled Subjects - Actual Suicide Attempt (Prior to Study Entry) | CSS05-Actual Attempt-Prior | CSS0512A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830963","C-SSRS Already Enrolled Subjects - Actual Suicide Attempt (Since Study Start)","C107057","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Have you made a suicide attempt? Have you done anything to harm yourself? Have you done anything dangerous where you could have died? (Since Study Start).","C-SSRS Already Enrolled Subjects - Actual Suicide Attempt (Since Study Start) | CSS05-Actual Attempt-Since | CSS0512B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830922","C-SSRS Already Enrolled Subjects - Number of Actual Suicide Attempts (Prior to Study Entry)","C107058","Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Total number of actual attempts. (Prior to Study Entry).","C-SSRS Already Enrolled Subjects - Number of Actual Suicide Attempts (Prior to Study Entry) | CSS05-Number of Actual Attempts-Prior | CSS0513A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447735","Simmitecan Hydrochloride","C106369","The hydrochloride salt form of simmitecan, an ester prodrug of chimmitecan, a 9-alkyl substituted camptothecin derivative with potential antineoplastc activity. Upon intravenous administration, simmitecan is hydrolyzed by carboxylesterase and the activated form, chimmitecan, is produced. Chimmitecan inhibits topoisomerase I, stabilizes covalent topoisomerase I-DNA complexes, and inhibits the religation of topoisomerase I-mediated single-strand DNA breaks. Futhermore, the covalent topoisomerase I-DNA complexes interfere and block the DNA replication machinery, resulting in the production of potentially lethal double-strand DNA breaks. This leads to an inhibition of DNA replication and the induction of apoptosis. The modification at position 9 yields improved cytotoxicity compared to some other camptothecin analogues.","Simmitecan Hydrochloride | SIMMITECAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538771","ENO1 wt Allele","C104204","Human ENO1 wild-type allele is located in the vicinity of 1p36.2 and is approximately 18 kb in length. This allele, which encodes alpha-enolase protein, plays a role in glycolysis and tumor suppression, and acts as a structural lens protein.","ENO1 wt Allele | ENO1L1 | Enolase 1, (Alpha) wt Allele | MBP-1 | MPB1 | NNE | PPH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2364020","ENO1 protein, human","C104205","Alpha-enolase (434 aa, ~47 kDa) is encoded by the human ENO1 gene. This protein is involved in glycolysis and tumor suppression, and acts as a structural lens protein.","Alpha-Enolase | 2-phospho-D-glycerate Hydro-lyase | Alpha Enolase Like 1 | EC 4.2.1.1 | Enolase 1 | Enolase-Alpha | MYC Promoter-Binding Protein 1 | Non-Neural Enolase | Phosphopyruvate Hydratase | Plasminogen-Binding Protein | Tau-Crystallin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542477","PXN wt Allele","C104207","Human PXN wild-type allele is located in the vicinity of 12q24.31 and is approximately 55 kb in length. This allele, which encodes paxillin protein, is involved in focal adhesions, cytoskeletal structure and integrin-mediated signaling.","PXN wt Allele | PAX | Paxillin wt Allele | hCG_1778014",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0135575","PXN protein, human","C104208","Paxillin (591 aa, ~65 kDa) is encoded by the human PXN gene. This protein plays a role in cell adhesion, integrin-mediated signal transduction and actin remodeling.","Paxillin | PXN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540601","ENPP2 wt Allele","C104210","Human ENPP2 wild-type allele is located in the vicinity of 8q24.1 and is approximately 116 kb in length. This allele, which encodes ectonucleotide pyrophosphatase/phosphodiesterase family member 2 protein, is involved in cell growth, survival, migration and angiogenesis. Expression is upregulated in several kinds of carcinomas.","ENPP2 wt Allele | ATX | ATX-X | E-NPP2 | Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 wt Allele | NPP2 | PD-IALPHA | PDNP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537321","PDNP2 protein, human","C104211","Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (863 aa, ~99 kDa) is encoded by the human ENPP2 gene. This protein plays a role in cell growth, survival, migration and angiogenesis.","Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 | Autotaxin | Autotaxin-T | EC 3.1.4.39 | ENPP2 | Extracellular Lysophospholipase D | Phosphodiesterase I/Nucleotide Pyrophosphatase 2 | Plasma Lysophospholipase D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538801","PTPN13 wt Allele","C104213","Human PTPN13 wild-type allele is located in the vicinity of 4q21.3 and is approximately 221 kb in length. This allele, which encodes tyrosine-protein phosphatase non-receptor type 13 protein, plays a role in both signaling and dephosphorylation of phosphotyrosine.","PTPN13 wt Allele | FAP-1 | PNP1 | PTP-BAS | PTP-BL | PTP1E | PTPL1 | PTPLE | Protein Tyrosine Phosphatase, Non-Receptor Type 13 (APO-1/CD95 (Fas)-Associated Phosphatase) wt Allele | hPTP1E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1437837","PTPN13 protein, human","C104214","Tyrosine-protein phosphatase non-receptor type 13 (2485 aa, ~277 kDa) is encoded by the human PTPN13 gene. This protein is involved in both the regulation of signaling and the mediation of protein phosphatase activity.","Tyrosine-Protein Phosphatase Non-Receptor Type 13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831644","ADCS-ADL Severe Dementia - Alone at Home for Less Than One Hour","C107006","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) If yes, was subject left at home for less than 1 hour during the day?","ADCS-ADL Severe Dementia - Alone at Home for Less Than One Hour | ADL02-Left at Home for Less Than 1 Hour | ADL0215C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831611","ADCS-ADL Severe Dementia - Turn On Faucet to Wash Without Help","C107007","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) In the past 4 weeks, did subject usually run water from a faucet to wash subject's hands or face without help?","ADCS-ADL Severe Dementia - Turn On Faucet to Wash Without Help | ADL02-Run Water Faucet to Wash | ADL0216",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831613","ADCS-ADL Severe Dementia - Turn Off Faucet After Wash Without Help","C107008","Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) In the past 4 weeks, did subject usually turn off the faucet after finishing running water without help?","ADCS-ADL Severe Dementia - Turn Off Faucet After Wash Without Help | ADL02-Turn Off Faucet | ADL0217",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524033","Porfimer Sodium","C1071","The sodium salt of a mixture of oligomers formed by ether and ester linkages of up to eight porphyrin units with photodynamic activity. Absorbed selectively by tumor cells, porfimer produces oxygen radicals after activation by 630 nm wavelength laser light, resulting in tumor cell cytotoxicity. In addition, tumor cell death may occur due to ischemic necrosis secondary to vascular occlusion that appears to be partly mediated by the release of thromboxane A2.","Porfimer Sodium | CL-184116 | DHE | Dihematoporphyrin Ester | Dihematoporphyrin Ether | HPD | Hematoporphyrin Derivative | Hematoporphyrin derivative | PORFIMER SODIUM | Photobarr | Photofrin II | dihematoporphyrin ether | hematoporphyrin derivative | photofrin | porfimer sodium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538746","ABCC5 wt Allele","C103950","Human ABCC5 wild-type allele is located in the vicinity of 3q27 and is approximately 98 kb in length. This allele, which encodes multidrug resistance-associated protein 5, is involved in the transport of cyclic nucleotides.","ABCC5 wt Allele | ABC33 | ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 5 wt Allele | EST277145 | MOAT-C | MOATC | MRP5 | SMRP | pABC11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537370","Multidrug Resistance-Associated Protein 5, Human","C103951","Multidrug resistance-associated protein 5 (1437 aa, ~161 kDa) is encoded by the human ABCC5 gene. This protein plays a role in the export of cyclic nucleotides.","Multidrug Resistance-Associated Protein 5 | ABCC5 | ATP-Binding Cassette Sub-Family C Member 5 | MOAT-C | Multi-Specific Organic Anion Transporter C | SMRP | pABC11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538808","PLVAP wt Allele","C103953","Human PLVAP wild-type allele is located in the vicinity of 19p13.2 and is approximately 26 kb in length. This allele, which encodes plasmalemma vesicle-associated protein, may play a role in the formation of caveolae.","PLVAP wt Allele | FELS | PV-1 | PV1 | Plasmalemma Vesicle Associated Protein wt Allele | gp68",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537282","Plasmalemma Vesicle-Associated Protein, Human","C103954","Plasmalemma vesicle-associated protein (442 aa, ~51 kDa) is encoded by the human PLVAP gene. This protein is involved in the structure of caveolae in endothelial cells.","Plasmalemma Vesicle-Associated Protein | Fenestrated Endothelial-Linked Structure Protein | Fenestrated-Endothelial Linked Structure Protein | PLVAP | PV-1 | PV-1 Protein | Plasmalemma Vesicle Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3807882","Coloboma of the Retina","C103956","A congenital or acquired defect characterized by the presence of a hole in the retina.","Coloboma of the Retina | Coloboma of Retina",,,,,,,,,,,,,,,"35625845|40403234|438859","Coloboma of choroid and retina|Coloboma of retina|Fundus coloboma",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C3541291","Kinesin-Like Protein KIF23, Human","C104163","Kinesin-like protein KIF23 (960 aa, ~110 kDa) is encoded by the human KIF23 gene. This protein is involved in mitotic spindle assembly, cytokinesis and microtubule-dependent motor activity.","Kinesin-Like Protein KIF23 | KIF23 | Kinesin-Like Protein 5 | Mitotic Kinesin-Like Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538793","TUBB wt Allele","C104165","Human TUBB wild-type allele is located in the vicinity of 6p21.33 and is approximately 5 kb in length. This allele, which encodes tubulin beta chain protein, is involved in microtubule dynamics.","TUBB wt Allele | DAAP-285E11.4 | M40 | MGC16435 | OK/SW-cl.56 | TUBB1 | TUBB5 | Tubb5 | Tubulin, Beta Class I wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539817","Tubulin Beta Chain, Human","C104166","Tubulin beta chain (444 aa, ~50 kDa) is encoded by the human TUBB gene. This protein plays a role in both the structure and functioning of microtubules.","Tubulin Beta Chain | Beta 5-Tubulin | Beta Ib Tubulin | Beta1-Tubulin | Class I Beta-Tubulin | TUBB | Tubulin Beta Polypeptide | Tubulin Beta-5 Chain | Tubulin, Beta | Tubulin, Beta Polypeptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641731","anti-CD22 monoclonal antibody-MMAE conjugate DCDT2980S","C104167","An antibody-drug conjugate (ADC) composed of MCDT2219A, a humanized IgG1 anti-CD22 monoclonal antibody covalently linked, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of pinatuzumab vedotin binds to B cell-specific CD22 receptors and is rapidly internalized, thereby delivering MMAE intracellularly. Upon proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. CD22, a cell surface glycoprotein, is expressed on mature B-cells and on most malignant B-cells.","Pinatuzumab Vedotin | ADC DCDT2980S | Antibody-Drug Conjugate DCDT2980S | DCDT2980S | PINATUZUMAB VEDOTIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281256","doxorubicin/vinorelbine","C10636","A regimen consisting of doxorubicin and vinorelbine that may be used in the treatment of advanced breast cancer.","Doxorubicin/Vinorelbine Regimen | DOX/VNB | Doxorubicin and Vinorelbine | Doxorubicin-Vinorelbine | Doxorubicin/Vinorelbine | NA | NA Regimen | Navelbine/Adriamycin | Vinorelbine-Doxorubicin | Vinorelbine/Doxorubicin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447737","Alpha-lipoic Acid-Palladium/Vitamin/Mineral Supplement","C106371","A proprietary water- and lipid-soluble polymer-based nutritional supplement composed of a complex mixture of alpha-lipoic acid bound to palladium (Palladium Lipoic Acid Complex (PdLA)) and other minerals, vitamins and amino acids, including vitamins B1, B2 and B12, formylmethionine, acetyl cysteine, and trace amounts of molybdinum, rhodium, and ruthenium, with potential anti-oxidant and cytoprotective activities. Upon oral administration, the alpha-lipoic acid-palladium/vitamin/mineral supplement acts as a free radical scavenger, crosses the cell membrane and is able to transfer electrons from fatty acids to DNA via the electron transport chain in mitochondria, which protects against DNA damage. This could protect non-cancerous cells from the oxidative damage caused by radiation and chemotherapy. In addition, in the hypoxic conditions found within tumors, the excess electrons can generate free radicals within mitochondria and could induce both cytochrome c release and apoptosis.","Alpha-lipoic Acid-Palladium/Vitamin/Mineral Supplement | LAPd | Palladium Lipoic Complex | PolyMVA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641586","C-SSRS Since Last Visit - Describe Most Severe Ideation","C103780","Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Description of most severe ideation.","C-SSRS Since Last Visit - Describe Most Severe Ideation | CSS02-Most Severe Ideation, Description | CSS0206A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641587","C-SSRS Since Last Visit - Frequency of Most Severe Ideation","C103781","Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) How many times have you had these thoughts?","C-SSRS Since Last Visit - Frequency of Most Severe Ideation | CSS02-Most Severe Ideation, Frequency | CSS0207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641588","C-SSRS Since Last Visit - Duration of Most Severe Ideation","C103782","Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) When you have these thoughts, how long do they last?","C-SSRS Since Last Visit - Duration of Most Severe Ideation | CSS02-Most Severe Ideation, Duration | CSS0208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641589","C-SSRS Since Last Visit - Control over Most Severe Ideation","C103783","Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Could/can you stop thinking about killing yourself or wanting to die if you want to?","C-SSRS Since Last Visit - Control over Most Severe Ideation | CSS02-Most Severe Ideation, Control | CSS0209",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641590","C-SSRS Since Last Visit - Deterrents to Most Severe Ideation","C103784","Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Are there things - anyone or anything (e.g., family, religion, pain of death) - that stopped you from wanting to die or acting on thoughts of committing suicide?","C-SSRS Since Last Visit - Deterrents to Most Severe Ideation | CSS02-Most Severe Ideation, Deterrents | CSS0210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641592","C-SSRS Since Last Visit - Actual Suicide Attempt","C103786","Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Have you made a suicide attempt? Have you done anything to harm yourself? Have you done anything dangerous where you could have died?","C-SSRS Since Last Visit - Actual Suicide Attempt | CSS02-Actual Attempt | CSS0212",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641593","C-SSRS Since Last Visit - Number of Actual Suicide Attempts","C103787","Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Total number of actual attempts.","C-SSRS Since Last Visit - Number of Actual Suicide Attempts | CSS02-Number of Actual Attempts | CSS0213",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641594","C-SSRS Since Last Visit - Description of Actual Suicide Attempts","C103788","Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Description of suicidal or self-injurious behaviors.","C-SSRS Since Last Visit - Description of Actual Suicide Attempts | CSS02-Actual Attempt, Describe | CSS0213A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641595","C-SSRS Since Last Visit - Non-suicidal Self-injurious Behavior","C103789","Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Has the subject engaged in non-suicidal self-injurious behavior.","C-SSRS Since Last Visit - Non-suicidal Self-injurious Behavior | CSS02-Non-suicidal Self-injurious Behav | CSS0214",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641596","C-SSRS Since Last Visit - Interrupted Suicide Attempt","C103790","Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Has there been a time when you started to do something to try to end your life but someone or something stopped you before you actually did anything?","C-SSRS Since Last Visit - Interrupted Suicide Attempt | CSS02-Interrupted Attempt | CSS0215",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641597","C-SSRS Since Last Visit - Number of Interrupted Suicide Attempts","C103791","Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Total number of interrupted attempts.","C-SSRS Since Last Visit - Number of Interrupted Suicide Attempts | CSS02-Number of Interrupted Attempts | CSS0216",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828438","Pulse Sequence","C106562","A serially recurrent arrangement of radiofrequency pulses that are applied to the sample.","Pulse Sequence | PULSSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828362","Receiver Bandwidth","C106563","The range between the minimum and maximum cut-off frequencies for a particular receiver, commonly measured in Hertz.","Receiver Bandwidth | RCBDWDTH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828357","Reconstruction Filter Type","C106564","A classification of the reconstruction filter used to suppress noise, enhance edges, perform resolution recovery and smooth an image.","Reconstruction Filter Type | RCFLTRTP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539815","TUBA3C wt Allele","C104169","Human TUBA3C wild-type allele is located in the vicinity of 13q12.11 and is approximately 8 kb in length. This allele, which encodes tubulin alpha-3C/D chain protein, plays a role in microtubule structure and function.","TUBA3C wt Allele | TUBA2 | Tubulin, Alpha 2 Gene | Tubulin, Alpha 3c wt Allele | bA408E5.3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539816","Tubulin Alpha-3C/D Chain, human","C104170","Tubulin alpha-3C/D chain (450 aa, ~50 kDa) is encoded by the human TUBA3C gene. This protein is involved in microtubule structural dynamics.","Tubulin Alpha-3C/D Chain | Alpha-Tubulin 2 | Alpha-Tubulin 3C/D | TUBA3C | Tubulin Alpha-2 Chain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542476","CRTAM wt Allele","C104173","Human CRTAM wild-type allele is located in the vicinity of 11q24.1 and is approximately 34 kb in length. This allele, which encodes cytotoxic and regulatory T-cell molecule protein, plays a role in promoting natural killer (NK) cell cytotoxicity.","CRTAM wt Allele | CD355 | Cytotoxic and Regulatory T-Cell Molecule wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0914468","class-I restricted T cell-associated molecule","C104174","Cytotoxic and regulatory T-cell molecule (393 aa, ~47 kDa) is encoded by the human CRTAM gene. This protein is involved in promoting natural killer (NK) cell cytotoxicity and may promote interferon-gamma (IFN-gamma) secretion by CD8+ cells.","Cytotoxic and Regulatory T-Cell Molecule | CD355 Antigen | CRTAM | Class I MHC Restricted T Cell Associated Molecule | Class-I MHC-Restricted T-Cell-Associated Molecule | Cytotoxic and Regulatory T Cell Molecule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539688","DEGS1 wt Allele","C104176","Human DEGS1 wild-type allele is located within 1q41-q42.12 and is approximately 18 kb in length. This allele, which encodes sphingolipid delta(4)-desaturase DES1 protein, is involved in fatty acid biosynthesis.","DEGS1 wt Allele | DEGS | DEGS-1 | DES1 | Degenerative Spermatocyte Homolog 1, Lipid Desaturase (Drosophila) Gene | Delta 4-Desaturase, Sphingolipid 1 wt Allele | Delta(4)-Desaturase, Sphingolipid 1 Gene | Des-1 | FADS7 | MLD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641527","PHQ-15 - Dizziness","C103721","Patient Health Questionnaire - 15 (PHQ-15) Dizziness.","PHQ-15 - Dizziness | PHQ02-Dizziness | PHQ0207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641528","PHQ-15 - Fainting Spells","C103722","Patient Health Questionnaire - 15 (PHQ-15) Fainting spells.","PHQ-15 - Fainting Spells | PHQ02-Fainting Spells | PHQ0208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641529","PHQ-15 - Feeling Your Heart Pound or Race","C103723","Patient Health Questionnaire - 15 (PHQ-15) Feeling your heart pound or race.","PHQ-15 - Feeling Your Heart Pound or Race | PHQ02-Feeling Your Heart Pound or Race | PHQ0209",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641531","PHQ-15 - Pain or Problems During Sexual Intercourse","C103725","Patient Health Questionnaire - 15 (PHQ-15) Pain or problems during sexual intercourse.","PHQ-15 - Pain or Problems During Sexual Intercourse | PHQ02-Pain/Problems During Intercourse | PHQ0211",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641532","PHQ-15 - Constipation, Loose Bowels, or Diarrhea","C103726","Patient Health Questionnaire - 15 (PHQ-15) Constipation, loose bowels, or diarrhea.","PHQ-15 - Constipation, Loose Bowels, or Diarrhea | PHQ02-Constipation/Loose Bowels/Diarrhea | PHQ0212",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641533","PHQ-15 - Nausea, Gas, or Indigestion","C103727","Patient Health Questionnaire - 15 (PHQ-15) Nausea, gas, or indigestion.","PHQ-15 - Nausea, Gas, or Indigestion | PHQ02-Nausea, Gas, or Indigestion | PHQ0213",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3641534","PHQ-15 - Feeling Tired or Having Low Energy","C103728","Patient Health Questionnaire - 15 (PHQ-15) Feeling tired or having low energy.","PHQ-15 - Feeling Tired or Having Low Energy | PHQ02-Feeling Tired or Having Low Energy | PHQ0214",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829153","McKinley County, NM","C109500","No value exists.","McKinley County, NM | McKinley County | McKinley County, New Mexico | NM031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828962","Mora County, NM","C109501","No value exists.","Mora County, NM | Mora County | Mora County, New Mexico | NM033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812815","Otero County, NM","C109502","No value exists.","Otero County, NM | NM035 | Otero County | Otero County, New Mexico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828323","Rio Arriba County, NM","C109504","No value exists.","Rio Arriba County, NM | NM039 | Rio Arriba County | Rio Arriba County, New Mexico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813307","Roosevelt County, NM","C109505","No value exists.","Roosevelt County, NM | NM041 | Roosevelt County | Roosevelt County, New Mexico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828257","Sandoval County, NM","C109506","No value exists.","Sandoval County, NM | NM043 | Sandoval County | Sandoval County, New Mexico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811229","San Juan County, NM","C109507","No value exists.","San Juan County, NM | NM045 | San Juan County | San Juan County, New Mexico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811232","San Miguel County, NM","C109508","No value exists.","San Miguel County, NM | NM047 | San Miguel County | San Miguel County, New Mexico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831091","Clarion County, PA","C109947","No value exists.","Clarion County, PA | Clarion County | Clarion County, Pennsylvania | PA031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831083","Clearfield County, PA","C109948","No value exists.","Clearfield County, PA | Clearfield County | Clearfield County, Pennsylvania | PA033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812189","Columbia County, PA","C109950","No value exists.","Columbia County, PA | Columbia County | Columbia County, Pennsylvania | PA037",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812864","Crawford County, PA","C109951","No value exists.","Crawford County, PA | Crawford County | Crawford County, Pennsylvania | PA039",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813312","Cumberland County, PA","C109952","No value exists.","Cumberland County, PA | Cumberland County | Cumberland County, Pennsylvania | PA041",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830600","Dauphin County, PA","C109953","No value exists.","Dauphin County, PA | Dauphin County | Dauphin County, Pennsylvania | PA043",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815524","Delaware County, PA","C109954","No value exists.","Delaware County, PA | Delaware County | Delaware County, Pennsylvania | PA045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810546","Erie County, PA","C109956","No value exists.","Erie County, PA | Erie County | Erie County, Pennsylvania | PA049",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812204","Fayette County, PA","C109957","No value exists.","Fayette County, PA | Fayette County | Fayette County, Pennsylvania | PA051",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814001","Forest County, PA","C109958","No value exists.","Forest County, PA | Forest County | Forest County, Pennsylvania | PA053",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814022","Franklin County, PA","C109959","No value exists.","Franklin County, PA | Franklin County | Franklin County, Pennsylvania | PA055",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814399","Greene County, PA","C109961","No value exists.","Greene County, PA | Greene County | Greene County, Pennsylvania | PA059",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829585","Huntingdon County, PA","C109962","No value exists.","Huntingdon County, PA | Huntingdon County | Huntingdon County, Pennsylvania | PA061",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811082","Clay County, MS","C109101","No value exists.","Clay County, MS | Clay County | Clay County, Mississippi | MS025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831070","Coahoma County, MS","C109102","No value exists.","Coahoma County, MS | Coahoma County | Coahoma County, Mississippi | MS027",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831009","Copiah County, MS","C109103","No value exists.","Copiah County, MS | Copiah County | Copiah County, Mississippi | MS029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812676","Covington County, MS","C109104","No value exists.","Covington County, MS | Covington County | Covington County, Mississippi | MS031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815534","DeSoto County, MS","C109105","No value exists.","DeSoto County, MS | DeSoto County | DeSoto County, Mississippi | MS033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814008","Franklin County, MS","C109107","No value exists.","Franklin County, MS | Franklin County | Franklin County, Mississippi | MS037",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829991","George County, MS","C109108","No value exists.","George County, MS | George County | George County, Mississippi | MS039",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814403","Greene County, MS","C109109","No value exists.","Greene County, MS | Greene County | Greene County, Mississippi | MS041",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829934","Grenada County, MS","C109110","No value exists.","Grenada County, MS | Grenada County | Grenada County, Mississippi | MS043",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815160","Hancock County, MS","C109111","No value exists.","Hancock County, MS | Hancock County | Hancock County, Mississippi | MS045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829694","Hinds County, MS","C109113","No value exists.","Hinds County, MS | Hinds County | Hinds County, Mississippi | MS049",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812697","Holmes County, MS","C109114","No value exists.","Holmes County, MS | Holmes County | Holmes County, Mississippi | MS051",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814437","Humphreys County, MS","C109115","No value exists.","Humphreys County, MS | Humphreys County | Humphreys County, Mississippi | MS053",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829490","Issaquena County, MS","C109116","No value exists.","Issaquena County, MS | Issaquena County | Issaquena County, Mississippi | MS055",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829488","Itawamba County, MS","C109117","No value exists.","Itawamba County, MS | Itawamba County | Itawamba County, Mississippi | MS057",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810764","Jasper County, MS","C109119","No value exists.","Jasper County, MS | Jasper County | Jasper County, Mississippi | MS061",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810771","Jefferson County, MS","C109120","No value exists.","Jefferson County, MS | Jefferson County | Jefferson County, Mississippi | MS063",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829463","Jefferson Davis County, MS","C109121","No value exists.","Jefferson Davis County, MS | Jefferson Davis County | Jefferson Davis County, Mississippi | MS065",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810790","Jones County, MS","C109122","No value exists.","Jones County, MS | Jones County | Jones County, Mississippi | MS067",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829415","Kemper County, MS","C109123","No value exists.","Kemper County, MS | Kemper County | Kemper County, Mississippi | MS069",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813647","Lamar County, MS","C109125","No value exists.","Lamar County, MS | Lamar County | Lamar County, Mississippi | MS073",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813655","Lauderdale County, MS","C109126","No value exists.","Lauderdale County, MS | Lauderdale County | Lauderdale County, Mississippi | MS075",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813665","Lawrence County, MS","C109127","No value exists.","Lawrence County, MS | Lawrence County | Lawrence County, Mississippi | MS077",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829308","Leake County, MS","C109128","No value exists.","Leake County, MS | Leake County | Leake County, Mississippi | MS079",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831045","Columbiana County, OH","C109745","No value exists.","Columbiana County, OH | Columbiana County | Columbiana County, Ohio | OH029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831001","Coshocton County, OH","C109746","No value exists.","Coshocton County, OH | Coshocton County | Coshocton County, Ohio | OH031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812863","Crawford County, OH","C109747","No value exists.","Crawford County, OH | Crawford County | Crawford County, Ohio | OH033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830627","Cuyahoga County, OH","C109748","No value exists.","Cuyahoga County, OH | Cuyahoga County | Cuyahoga County, Ohio | OH035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830547","Defiance County, OH","C109750","No value exists.","Defiance County, OH | Defiance County | Defiance County, Ohio | OH039",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815525","Delaware County, OH","C109751","No value exists.","Delaware County, OH | Delaware County | Delaware County, Ohio | OH041",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810544","Erie County, OH","C109752","No value exists.","Erie County, OH | Erie County | Erie County, Ohio | OH043",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811692","Fairfield County, OH","C109753","No value exists.","Fairfield County, OH | Fairfield County | Fairfield County, Ohio | OH045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814026","Franklin County, OH","C109755","No value exists.","Franklin County, OH | Franklin County | Franklin County, Ohio | OH049",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814422","Fulton County, OH","C109756","No value exists.","Fulton County, OH | Fulton County | Fulton County, Ohio | OH051",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830055","Gallia County, OH","C109757","No value exists.","Gallia County, OH | Gallia County | Gallia County, Ohio | OH053",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831398","Bastrop County, TX","C110221","No value exists.","Bastrop County, TX | Bastrop County | Bastrop County, Texas | TX021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831390","Baylor County, TX","C110222","No value exists.","Baylor County, TX | Baylor County | Baylor County, Texas | TX023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831376","Bee County, TX","C110223","No value exists.","Bee County, TX | Bee County | Bee County, Texas | TX025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816207","Bell County, TX","C110224","No value exists.","Bell County, TX | Bell County | Bell County, Texas | TX027",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831341","Blanco County, TX","C110226","No value exists.","Blanco County, TX | Blanco County | Blanco County, Texas | TX031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831316","Borden County, TX","C110227","No value exists.","Borden County, TX | Borden County | Borden County, Texas | TX033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831313","Bosque County, TX","C110228","No value exists.","Bosque County, TX | Bosque County | Bosque County, Texas | TX035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831287","Bowie County, TX","C110229","No value exists.","Bowie County, TX | Bowie County | Bowie County, Texas | TX037",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831275","Brazos County, TX","C110231","No value exists.","Brazos County, TX | Brazos County | Brazos County, Texas | TX041",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831264","Brewster County, TX","C110232","No value exists.","Brewster County, TX | Brewster County | Brewster County, Texas | TX043",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831263","Briscoe County, TX","C110233","No value exists.","Briscoe County, TX | Briscoe County | Briscoe County, Texas | TX045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812652","Brooks County, TX","C110234","No value exists.","Brooks County, TX | Brooks County | Brooks County, Texas | TX047",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812657","Brown County, TX","C110235","No value exists.","Brown County, TX | Brown County | Brown County, Texas | TX049",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831242","Burnet County, TX","C110237","No value exists.","Burnet County, TX | Burnet County | Burnet County, Texas | TX053",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813952","Caldwell County, TX","C110238","No value exists.","Caldwell County, TX | Caldwell County | Caldwell County, Texas | TX055",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814027","Frederick County, MD","C108890","No value exists.","Frederick County, MD | Frederick County | Frederick County, Maryland | MD021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830049","Garrett County, MD","C108891","No value exists.","Garrett County, MD | Garrett County | Garrett County, Maryland | MD023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812714","Howard County, MD","C108893","No value exists.","Howard County, MD | Howard County | Howard County, Maryland | MD027",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810792","Kent County, MD","C108894","No value exists.","Kent County, MD | Kent County | Kent County, Maryland | MD029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811271","Montgomery County, MD","C108895","No value exists.","Montgomery County, MD | MD031 | Montgomery County | Montgomery County, Maryland",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816738","Prince George's County, MD","C108896","No value exists.","Prince George's County, MD | MD033 | Prince George's County | Prince George's County, Maryland",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828425","Queen Anne's County, MD","C108897","No value exists.","Queen Anne's County, MD | MD035 | Queen Anne's County | Queen Anne's County, Maryland",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813220","Somerset County, MD","C108899","No value exists.","Somerset County, MD | MD039 | Somerset County | Somerset County, Maryland",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815202","Talbot County, MD","C108900","No value exists.","Talbot County, MD | MD041 | Talbot County | Talbot County, Maryland",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813241","Washington County, MD","C108901","No value exists.","Washington County, MD | MD043 | Washington County | Washington County, Maryland",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827465","Wicomico County, MD","C108902","No value exists.","Wicomico County, MD | MD045 | Wicomico County | Wicomico County, Maryland",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831419","Baltimore City, MD","C108904","No value exists.","Baltimore City, MD | Baltimore City | Baltimore City, Maryland | MD510",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831409","Barnstable County, MA","C108905","No value exists.","Barnstable County, MA | Barnstable County | Barnstable County, Massachusetts | MA001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831361","Berkshire County, MA","C108906","No value exists.","Berkshire County, MA | Berkshire County | Berkshire County, Massachusetts | MA003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811876","Bristol County, MA","C108907","No value exists.","Bristol County, MA | Bristol County | Bristol County, Massachusetts | MA005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830375","Dukes County, MA","C108908","No value exists.","Dukes County, MA | Dukes County | Dukes County, Massachusetts | MA007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814024","Franklin County, MA","C108910","No value exists.","Franklin County, MA | Franklin County | Franklin County, Massachusetts | MA011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829906","Hampden County, MA","C108911","No value exists.","Hampden County, MA | Hampden County | Hampden County, Massachusetts | MA013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815159","Hampshire County, MA","C108912","No value exists.","Hampshire County, MA | Hampshire County | Hampshire County, Massachusetts | MA015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813168","Howard County, NE","C109388","No value exists.","Howard County, NE | Howard County | Howard County, Nebraska | NE093",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810774","Jefferson County, NE","C109389","No value exists.","Jefferson County, NE | Jefferson County | Jefferson County, Nebraska | NE095",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829546","Indiana County, PA","C109963","No value exists.","Indiana County, PA | Indiana County | Indiana County, Pennsylvania | PA063",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810779","Jefferson County, PA","C109964","No value exists.","Jefferson County, PA | Jefferson County | Jefferson County, Pennsylvania | PA065",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829442","Juniata County, PA","C109965","No value exists.","Juniata County, PA | Juniata County | Juniata County, Pennsylvania | PA067",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813649","Lancaster County, PA","C109967","No value exists.","Lancaster County, PA | Lancaster County | Lancaster County, Pennsylvania | PA071",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813666","Lawrence County, PA","C109968","No value exists.","Lawrence County, PA | Lawrence County | Lawrence County, Pennsylvania | PA073",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829306","Lebanon County, PA","C109969","No value exists.","Lebanon County, PA | Lebanon County | Lebanon County, Pennsylvania | PA075",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829301","Lehigh County, PA","C109970","No value exists.","Lehigh County, PA | Lehigh County | Lehigh County, Pennsylvania | PA077",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829240","Luzerne County, PA","C109971","No value exists.","Luzerne County, PA | Luzerne County | Luzerne County, Pennsylvania | PA079",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829156","McKean County, PA","C109973","No value exists.","McKean County, PA | McKean County | McKean County, Pennsylvania | PA083",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810677","Mercer County, PA","C109974","No value exists.","Mercer County, PA | Mercer County | Mercer County, Pennsylvania | PA085",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829072","Mifflin County, PA","C109975","No value exists.","Mifflin County, PA | Mifflin County | Mifflin County, Pennsylvania | PA087",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811259","Monroe County, PA","C109976","No value exists.","Monroe County, PA | Monroe County | Monroe County, Pennsylvania | PA089",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811277","Montgomery County, PA","C109977","No value exists.","Montgomery County, PA | Montgomery County | Montgomery County, Pennsylvania | PA091",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827675","Uvalde County, TX","C110442","No value exists.","Uvalde County, TX | TX463 | Uvalde County | Uvalde County, Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827668","Val Verde County, TX","C110443","No value exists.","Val Verde County, TX | TX465 | Val Verde County | Val Verde County, Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827665","Van Zandt County, TX","C110444","No value exists.","Van Zandt County, TX | TX467 | Van Zandt County | Van Zandt County, Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827560","Victoria County, TX","C110445","No value exists.","Victoria County, TX | TX469 | Victoria County | Victoria County, Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812768","Walker County, TX","C110446","No value exists.","Walker County, TX | TX471 | Walker County | Walker County, Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827518","Waller County, TX","C110447","No value exists.","Waller County, TX | TX473 | Waller County | Waller County, Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811314","Washington County, TX","C110449","No value exists.","Washington County, TX | TX477 | Washington County | Washington County, Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827290","Webb County, TX","C110450","No value exists.","Webb County, TX | TX479 | Webb County | Webb County, Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827481","Wharton County, TX","C110451","No value exists.","Wharton County, TX | TX481 | Wharton County | Wharton County, Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810720","Wheeler County, TX","C110452","No value exists.","Wheeler County, TX | TX483 | Wheeler County | Wheeler County, Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810727","Wichita County, TX","C110453","No value exists.","Wichita County, TX | TX485 | Wichita County | Wichita County, Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827462","Willacy County, TX","C110455","No value exists.","Willacy County, TX | TX489 | Willacy County | Willacy County, Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814100","Lincoln County, MS","C109131","No value exists.","Lincoln County, MS | Lincoln County | Lincoln County, Mississippi | MS085",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815620","Lowndes County, MS","C109132","No value exists.","Lowndes County, MS | Lowndes County | Lowndes County, Mississippi | MS087",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376900","Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6, human","C107471","Carcinoembryonic antigen-related cell adhesion molecule 6 (344 aa, ~37 kDa) is encoded by the human CEACAM6 gene. This plays a probable role in both cell-cell signaling and cell adhesion.","Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6 | CD66c | CD66c Antigen | CEA-Like Protein | CEACAM6 | Cluster Of Differentiation 66c | Non-Specific Cross Reacting Antigen | Non-Specific Crossreacting Antigen | Nonspecific Crossreacting Antigen | Normal Cross-Reacting Antigen | Normal Crossreacting Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811749","NR1I3 wt Allele","C107473","Human NR1I3 wild-type allele is located in the vicinity of 1q23.3 and is approximately 9 kb in length. This allele, which encodes nuclear receptor subfamily 1 group I member 3 protein, plays a role in the regulation of xenobiotic and endobiotic metabolism.","NR1I3 wt Allele | CAR | CAR1 | MB67 | Nuclear Receptor Subfamily 1, Group I, Member 3 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0914906","constitutive androstane receptor","C107474","Nuclear receptor subfamily 1 group I member 3 (352 aa, ~40 kDa) is encoded by the human NR1I3 gene. This protein is involved in the regulation of xenobiotic and endobiotic metabolism.","Nuclear Receptor Subfamily 1 Group I Member 3 | Constitutive Activator of Retinoid Response | Constitutive Active Receptor | Constitutive Active Response | Constitutive Androstane Nuclear Receptor Variant 2 | Constitutive Androstane Nuclear Receptor Variant 3 | Constitutive Androstane Nuclear Receptor Variant 4 | Constitutive Androstane Nuclear Receptor Variant 5 | Constitutive Androstane Receptor | NR1I3 | Orphan Nuclear Hormone Receptor | Orphan Nuclear Receptor MB67",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812730","ELAVL1 wt Allele","C107476","Human ELAVL1 wild-type allele is located in the vicinity of 19p13.2 and is approximately 47 kb in length. This allele, which encodes ELAV-like protein 1, is involved in the regulation of mRNA stability.","ELAVL1 wt Allele | ELAV (Embryonic Lethal, Abnormal Vision, Drosophila)-Like 1 (Hu Antigen R) wt Allele | ELAV1 | HUR | Hua | MelG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1743508","ELAV-Like Protein 1, Human","C107477","ELAV-like protein 1 (326 aa, ~36 kDa) is encoded by the human ELAVL1 gene. This protein plays a role in the regulation of gene expression by stabilizing AU-rich element-containing mRNAs.","ELAV-Like Protein 1 | ELAV Like RNA Binding Protein 1 | Embryonic Lethal, Abnormal Vision, Drosophila, Homolog-Like 1 | Hu Antigen R | Hu-Antigen R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813957","Calhoun County, TX","C110239","No value exists.","Calhoun County, TX | Calhoun County | Calhoun County, Texas | TX057",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831222","Callahan County, TX","C110240","No value exists.","Callahan County, TX | Callahan County | Callahan County, Texas | TX059",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814385","Cameron County, TX","C110241","No value exists.","Cameron County, TX | Cameron County | Cameron County, Texas | TX061",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831189","Carson County, TX","C110243","No value exists.","Carson County, TX | Carson County | Carson County, Texas | TX065",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815123","Cass County, TX","C110244","No value exists.","Cass County, TX | Cass County | Cass County, Texas | TX067",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827248","Castro County, TX","C110245","No value exists.","Castro County, TX | Castro County | Castro County, Texas | TX069",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814379","Chambers County, TX","C110246","No value exists.","Chambers County, TX | Chambers County | Chambers County, Texas | TX071",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831114","Childress County, TX","C110248","No value exists.","Childress County, TX | Childress County | Childress County, Texas | TX075",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811076","Clay County, TX","C110249","No value exists.","Clay County, TX | Clay County | Clay County, Texas | TX077",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831063","Cochran County, TX","C110250","No value exists.","Cochran County, TX | Cochran County | Cochran County, Texas | TX079",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827211","Coke County, TX","C110251","No value exists.","Coke County, TX | Coke County | Coke County, Texas | TX081",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831055","Coleman County, TX","C110252","No value exists.","Coleman County, TX | Coleman County | Coleman County, Texas | TX083",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813245","Washington County, KY","C108795","No value exists.","Washington County, KY | KY229 | Washington County | Washington County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813613","Wayne County, KY","C108796","No value exists.","Wayne County, KY | KY231 | Wayne County | Wayne County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810725","Whitley County, KY","C108798","No value exists.","Whitley County, KY | KY235 | Whitley County | Whitley County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827278","Wolfe County, KY","C108799","No value exists.","Wolfe County, KY | KY237 | Wolfe County | Wolfe County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0095568","Apaziquone","C1087","An indolequinone bioreductive prodrug and analog of mitomycin C with potential antineoplastic and radiosensitization activities. Apaziquone is converted to active metabolites in hypoxic cells by intracellular reductases, which are present in greater amounts in hypoxic tumor cells. The active metabolites alkylate DNA, resulting in apoptotic cell death. This agent displays selectivity activity towards both hypoxic solid tumors, which exhibits higher expression of cytochrome P450 reductase, and well-oxygenated malignant cells that overexpress the bioreductive enzyme NQO1 (NAD(P)H: quinone oxidoreductase). Apaziquone may selectively sensitize hypoxic tumor cells to radiocytotoxicity.","Apaziquone | 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione) prop-beta-en-alpha-ol | APAZIQUONE | E O9 | EO9 | Eoquin | Neoquin | Qapzola",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810752","Woodford County, KY","C108800","No value exists.","Woodford County, KY | KY239 | Woodford County | Woodford County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831746","Acadia Parish, LA","C108801","No value exists.","Acadia Parish, LA | Acadia Parish | Acadia Parish, Louisiana | LA001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831468","Ascension Parish, LA","C108803","No value exists.","Ascension Parish, LA | Ascension Parish | Ascension Parish, Louisiana | LA005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810786","Johnson County, NE","C109390","No value exists.","Johnson County, NE | Johnson County | Johnson County, Nebraska | NE097",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829418","Kearney County, NE","C109391","No value exists.","Kearney County, NE | Kearney County | Kearney County, Nebraska | NE099",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829416","Keith County, NE","C109392","No value exists.","Keith County, NE | Keith County | Keith County, Nebraska | NE101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829388","Kimball County, NE","C109394","No value exists.","Kimball County, NE | Kimball County | Kimball County, Nebraska | NE105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813272","Knox County, NE","C109395","No value exists.","Knox County, NE | Knox County | Knox County, Nebraska | NE107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813648","Lancaster County, NE","C109396","No value exists.","Lancaster County, NE | Lancaster County | Lancaster County, Nebraska | NE109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714849","Lincoln County, NE","C109397","No value exists.","Lincoln County, NE | Lincoln County | Lincoln County, Nebraska | NE111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815610","Logan County, NE","C109398","No value exists.","Logan County, NE | Logan County | Logan County, Nebraska | NE113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0059874","Etoposide Phosphate","C1093","A phosphate salt of a semisynthetic derivative of podophyllotoxin. Etoposide binds to the enzyme topoisomerase II, inducing double-strand DNA breaks, inhibiting DNA repair, and resulting in decreased DNA synthesis and tumor cell proliferation. Cells in the S and G2 phases of the cell cycle are most sensitive to this agent. (NCI04)","Etoposide Phosphate | ETOPOSIDE PHOSPHATE | Etopophos | etoposide phosphate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812240","McPherson County, NE","C109400","No value exists.","McPherson County, NE | McPherson County | McPherson County, Nebraska | NE117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815918","Madison County, NE","C109401","No value exists.","Madison County, NE | Madison County | Madison County, Nebraska | NE119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829124","Merrick County, NE","C109402","No value exists.","Merrick County, NE | Merrick County | Merrick County, Nebraska | NE121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828958","Morrill County, NE","C109403","No value exists.","Morrill County, NE | Morrill County | Morrill County, Nebraska | NE123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812332","Nemaha County, NE","C109405","No value exists.","Nemaha County, NE | NE127 | Nemaha County | Nemaha County, Nebraska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828749","Nuckolls County, NE","C109406","No value exists.","Nuckolls County, NE | NE129 | Nuckolls County | Nuckolls County, Nebraska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828689","Otoe County, NE","C109407","No value exists.","Otoe County, NE | NE131 | Otoe County | Otoe County, Nebraska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813694","Pawnee County, NE","C109408","No value exists.","Pawnee County, NE | NE133 | Pawnee County | Pawnee County, Nebraska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814118","Phelps County, NE","C109410","No value exists.","Phelps County, NE | NE137 | Phelps County | Phelps County, Nebraska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814128","Pierce County, NE","C109411","No value exists.","Pierce County, NE | NE139 | Pierce County | Pierce County, Nebraska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811216","Platte County, NE","C109412","No value exists.","Platte County, NE | NE141 | Platte County | Platte County, Nebraska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811777","Polk County, NE","C109413","No value exists.","Polk County, NE | NE143 | Polk County | Polk County, Nebraska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828350","Red Willow County, NE","C109414","No value exists.","Red Willow County, NE | NE145 | Red Willow County | Red Willow County, Nebraska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813301","Rock County, NE","C109416","No value exists.","Rock County, NE | NE149 | Rock County | Rock County, Nebraska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810734","Williamson County, TX","C110456","No value exists.","Williamson County, TX | TX491 | Williamson County | Williamson County, Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810737","Wilson County, TX","C110457","No value exists.","Wilson County, TX | TX493 | Wilson County | Wilson County, Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827457","Winkler County, TX","C110458","No value exists.","Winkler County, TX | TX495 | Winkler County | Winkler County, Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810745","Wise County, TX","C110459","No value exists.","Wise County, TX | TX497 | Wise County | Wise County, Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827403","Yoakum County, TX","C110461","No value exists.","Yoakum County, TX | TX501 | Yoakum County | Yoakum County, Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827401","Young County, TX","C110462","No value exists.","Young County, TX | TX503 | Young County | Young County, Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827396","Zapata County, TX","C110463","No value exists.","Zapata County, TX | TX505 | Zapata County | Zapata County, Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827395","Zavala County, TX","C110464","No value exists.","Zavala County, TX | TX507 | Zavala County | Zavala County, Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831284","Box Elder County, UT","C110466","No value exists.","Box Elder County, UT | Box Elder County | Box Elder County, Utah | UT003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831229","Cache County, UT","C110467","No value exists.","Cache County, UT | Cache County | Cache County, Utah | UT005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814774","Carbon County, UT","C110468","No value exists.","Carbon County, UT | Carbon County | Carbon County, Utah | UT007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830610","Daggett County, UT","C110469","No value exists.","Daggett County, UT | Daggett County | Daggett County, Utah | UT009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815129","Davis County, UT","C110470","No value exists.","Davis County, UT | Davis County | Davis County, Utah | UT011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827317","Emery County, UT","C110472","No value exists.","Emery County, UT | Emery County | Emery County, Utah | UT015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814499","Garfield County, UT","C110473","No value exists.","Garfield County, UT | Garfield County | Garfield County, Utah | UT017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813971","Grand County, UT","C110474","No value exists.","Grand County, UT | Grand County | Grand County, Utah | UT019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831326","Blue Earth County, MN","C109008","No value exists.","Blue Earth County, MN | Blue Earth County | Blue Earth County, Minnesota | MN013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811885","Brown County, MN","C109009","No value exists.","Brown County, MN | Brown County | Brown County, Minnesota | MN015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831193","Carlton County, MN","C109010","No value exists.","Carlton County, MN | Carlton County | Carlton County, Minnesota | MN017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812365","Cass County, MN","C109012","No value exists.","Cass County, MN | Cass County | Cass County, Minnesota | MN021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812847","Chippewa County, MN","C109013","No value exists.","Chippewa County, MN | Chippewa County | Chippewa County, Minnesota | MN023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827256","Chisago County, MN","C109014","No value exists.","Chisago County, MN | Chisago County | Chisago County, Minnesota | MN025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811080","Clay County, MN","C109015","No value exists.","Clay County, MN | Clay County | Clay County, Minnesota | MN027",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811089","Clearwater County, MN","C109016","No value exists.","Clearwater County, MN | Clearwater County | Clearwater County, Minnesota | MN029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830997","Cottonwood County, MN","C109018","No value exists.","Cottonwood County, MN | Cottonwood County | Cottonwood County, Minnesota | MN033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810702","Mitchell County, KS","C108637","No value exists.","Mitchell County, KS | KS123 | Mitchell County | Mitchell County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811269","Montgomery County, KS","C108638","No value exists.","Montgomery County, KS | KS125 | Montgomery County | Montgomery County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811295","Morris County, KS","C108639","No value exists.","Morris County, KS | KS127 | Morris County | Morris County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811300","Morton County, KS","C108640","No value exists.","Morton County, KS | KS129 | Morton County | Morton County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812331","Nemaha County, KS","C108641","No value exists.","Nemaha County, KS | KS131 | Nemaha County | Nemaha County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828835","Neosho County, KS","C108642","No value exists.","Neosho County, KS | KS133 | Neosho County | Neosho County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828833","Ness County, KS","C108643","No value exists.","Ness County, KS | KS135 | Ness County | Ness County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812808","Osage County, KS","C108645","No value exists.","Osage County, KS | KS139 | Osage County | Osage County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828695","Osborne County, KS","C108646","No value exists.","Osborne County, KS | KS141 | Osborne County | Osborne County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812818","Ottawa County, KS","C108647","No value exists.","Ottawa County, KS | KS143 | Ottawa County | Ottawa County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813693","Pawnee County, KS","C108648","No value exists.","Pawnee County, KS | KS145 | Pawnee County | Pawnee County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812271","Pottawatomie County, KS","C108650","No value exists.","Pottawatomie County, KS | KS149 | Pottawatomie County | Pottawatomie County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828495","Pratt County, KS","C108651","No value exists.","Pratt County, KS | KS151 | Pratt County | Pratt County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828366","Rawlins County, KS","C108652","No value exists.","Rawlins County, KS | KS153 | Rawlins County | Rawlins County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828344","Reno County, KS","C108653","No value exists.","Reno County, KS | KS155 | Reno County | Reno County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828337","Republic County, KS","C108654","No value exists.","Republic County, KS | KS157 | Republic County | Republic County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828326","Riley County, KS","C108656","No value exists.","Riley County, KS | KS161 | Riley County | Riley County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828302","Rooks County, KS","C108657","No value exists.","Rooks County, KS | KS163 | Rooks County | Rooks County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810633","Rush County, KS","C108658","No value exists.","Rush County, KS | KS165 | Rush County | Rush County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831428","Avoyelles Parish, LA","C108805","No value exists.","Avoyelles Parish, LA | Avoyelles Parish | Avoyelles Parish, Louisiana | LA009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831382","Beauregard Parish, LA","C108806","No value exists.","Beauregard Parish, LA | Beauregard Parish | Beauregard Parish, Louisiana | LA011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831355","Bienville Parish, LA","C108807","No value exists.","Bienville Parish, LA | Bienville Parish | Bienville Parish, Louisiana | LA013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831227","Caddo Parish, LA","C108809","No value exists.","Caddo Parish, LA | Caddo Parish | Caddo Parish, Louisiana | LA017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831225","Calcasieu Parish, LA","C108810","No value exists.","Calcasieu Parish, LA | Calcasieu Parish | Calcasieu Parish, Louisiana | LA019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831224","Caldwell Parish, LA","C108811","No value exists.","Caldwell Parish, LA | Caldwell Parish | Caldwell Parish, Louisiana | LA021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831216","Cameron Parish, LA","C108812","No value exists.","Cameron Parish, LA | Cameron Parish | Cameron Parish, Louisiana | LA023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831184","Catahoula Parish, LA","C108813","No value exists.","Catahoula Parish, LA | Catahoula Parish | Catahoula Parish, Louisiana | LA025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831028","Concordia Parish, LA","C108815","No value exists.","Concordia Parish, LA | Concordia Parish | Concordia Parish, Louisiana | LA029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830529","De Soto Parish, LA","C108816","No value exists.","De Soto Parish, LA | De Soto Parish | De Soto Parish, Louisiana | LA031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830358","East Baton Rouge Parish, LA","C108817","No value exists.","East Baton Rouge Parish, LA | East Baton Rouge Parish | East Baton Rouge Parish, Louisiana | LA033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830357","East Carroll Parish, LA","C108818","No value exists.","East Carroll Parish, LA | East Carroll Parish | East Carroll Parish, Louisiana | LA035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827337","East Feliciana Parish, LA","C108819","No value exists.","East Feliciana Parish, LA | East Feliciana Parish | East Feliciana Parish, Louisiana | LA037",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830080","Franklin Parish, LA","C108821","No value exists.","Franklin Parish, LA | Franklin Parish | Franklin Parish, Louisiana | LA041",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831108","Chouteau County, MT","C109293","No value exists.","Chouteau County, MT | Chouteau County | Chouteau County, Montana | MT015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813316","Custer County, MT","C109294","No value exists.","Custer County, MT | Custer County | Custer County, Montana | MT017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830606","Daniels County, MT","C109295","No value exists.","Daniels County, MT | Daniels County | Daniels County, Montana | MT019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815130","Dawson County, MT","C109296","No value exists.","Dawson County, MT | Dawson County | Dawson County, Montana | MT021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830548","Deer Lodge County, MT","C109297","No value exists.","Deer Lodge County, MT | Deer Lodge County | Deer Lodge County, Montana | MT023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830261","Fallon County, MT","C109298","No value exists.","Fallon County, MT | Fallon County | Fallon County, Montana | MT025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0059682","Etanidazole","C1092","A 2-nitroimidazole with radiosensitizing properties. Etanidazole depletes glutathione and inhibits glutathione transferase, thereby enhancing the cytotoxicity of ionizing radiation. This agent may also be useful as an imaging agent for identifying hypoxic, drug-resistant regions of primary tumors or metastases.  (NCI04)","Etanidazole | 1H-Imidazole-1-acetamide, N-(2-hydroxyethyl)-2-nitro- | 2-Nitroimidazole-1-acetamide, N-(2-hydroxyethyl)- | ETANIDAZOLE | SR-2508 | etanidazole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830102","Flathead County, MT","C109300","No value exists.","Flathead County, MT | Flathead County | Flathead County, Montana | MT029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811227","Saline County, NE","C109417","No value exists.","Saline County, NE | NE151 | Saline County | Saline County, Nebraska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810789","Johnston County, OK","C109853","No value exists.","Johnston County, OK | Johnston County | Johnston County, Oklahoma | OK069",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829419","Kay County, OK","C109854","No value exists.","Kay County, OK | Kay County | Kay County, Oklahoma | OK071",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829384","Kingfisher County, OK","C109855","No value exists.","Kingfisher County, OK | Kingfisher County | Kingfisher County, Oklahoma | OK073",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829313","Latimer County, OK","C109857","No value exists.","Latimer County, OK | Latimer County | Latimer County, Oklahoma | OK077",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829303","Le Flore County, OK","C109858","No value exists.","Le Flore County, OK | Le Flore County | Le Flore County, Oklahoma | OK079",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815579","Lincoln County, OK","C109859","No value exists.","Lincoln County, OK | Lincoln County | Lincoln County, Oklahoma | OK081",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815612","Logan County, OK","C109860","No value exists.","Logan County, OK | Logan County | Logan County, Oklahoma | OK083",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829166","McClain County, OK","C109862","No value exists.","McClain County, OK | McClain County | McClain County, Oklahoma | OK087",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829159","McCurtain County, OK","C109863","No value exists.","McCurtain County, OK | McCurtain County | McCurtain County, Oklahoma | OK089",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829217","Major County, OK","C109865","No value exists.","Major County, OK | Major County | Major County, Oklahoma | OK093",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811731","Marshall County, OK","C109866","No value exists.","Marshall County, OK | Marshall County | Marshall County, Oklahoma | OK095",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811304","Murray County, OK","C109868","No value exists.","Murray County, OK | Murray County | Murray County, Oklahoma | OK099",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811818","Muskogee County, OK","C109869","No value exists.","Muskogee County, OK | Muskogee County | Muskogee County, Oklahoma | OK101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811201","Noble County, OK","C109870","No value exists.","Noble County, OK | Noble County | Noble County, Oklahoma | OK103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828766","Nowata County, OK","C109871","No value exists.","Nowata County, OK | Nowata County | Nowata County, Oklahoma | OK105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828722","Oklahoma County, OK","C109873","No value exists.","Oklahoma County, OK | OK109 | Oklahoma County | Oklahoma County, Oklahoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828721","Okmulgee County, OK","C109874","No value exists.","Okmulgee County, OK | OK111 | Okmulgee County | Okmulgee County, Oklahoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812810","Osage County, OK","C109875","No value exists.","Osage County, OK | OK113 | Osage County | Osage County, Oklahoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812821","Ottawa County, OK","C109876","No value exists.","Ottawa County, OK | OK115 | Ottawa County | Ottawa County, Oklahoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813695","Pawnee County, OK","C109877","No value exists.","Pawnee County, OK | OK117 | Pawnee County | Pawnee County, Oklahoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828546","Pittsburg County, OK","C109879","No value exists.","Pittsburg County, OK | OK121 | Pittsburg County | Pittsburg County, Oklahoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812264","Pontotoc County, OK","C109880","No value exists.","Pontotoc County, OK | OK123 | Pontotoc County | Pontotoc County, Oklahoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830975","Crow Wing County, MN","C109019","No value exists.","Crow Wing County, MN | Crow Wing County | Crow Wing County, Minnesota | MN035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814785","Dakota County, MN","C109020","No value exists.","Dakota County, MN | Dakota County | Dakota County, Minnesota | MN037",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811821","Dodge County, MN","C109021","No value exists.","Dodge County, MN | Dodge County | Dodge County, Minnesota | MN039",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830180","Faribault County, MN","C109023","No value exists.","Faribault County, MN | Faribault County | Faribault County, Minnesota | MN043",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812689","Fillmore County, MN","C109024","No value exists.","Fillmore County, MN | Fillmore County | Fillmore County, Minnesota | MN045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827312","Freeborn County, MN","C109025","No value exists.","Freeborn County, MN | Freeborn County | Freeborn County, Minnesota | MN047",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829965","Goodhue County, MN","C109026","No value exists.","Goodhue County, MN | Goodhue County | Goodhue County, Minnesota | MN049",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813977","Grant County, MN","C109027","No value exists.","Grant County, MN | Grant County | Grant County, Minnesota | MN051",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812711","Houston County, MN","C109029","No value exists.","Houston County, MN | Houston County | Houston County, Minnesota | MN055",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829601","Hubbard County, MN","C109030","No value exists.","Hubbard County, MN | Hubbard County | Hubbard County, Minnesota | MN057",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829496","Isanti County, MN","C109031","No value exists.","Isanti County, MN | Isanti County | Isanti County, Minnesota | MN059",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829489","Itasca County, MN","C109032","No value exists.","Itasca County, MN | Itasca County | Itasca County, Minnesota | MN061",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816466","Jackson County, MN","C109033","No value exists.","Jackson County, MN | Jackson County | Jackson County, Minnesota | MN063",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829435","Kandiyohi County, MN","C109035","No value exists.","Kandiyohi County, MN | Kandiyohi County | Kandiyohi County, Minnesota | MN067",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829373","Kittson County, MN","C109036","No value exists.","Kittson County, MN | Kittson County | Kittson County, Minnesota | MN069",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829368","Koochiching County, MN","C109037","No value exists.","Koochiching County, MN | Koochiching County | Koochiching County, Minnesota | MN071",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829350","Lac qui Parle County, MN","C109038","No value exists.","Lac qui Parle County, MN | Lac qui Parle County | Lac qui Parle County, Minnesota | MN073",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813639","Lake County, MN","C109039","No value exists.","Lake County, MN | Lake County | Lake County, Minnesota | MN075",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815261","Sierra County, NM","C109510","No value exists.","Sierra County, NM | NM051 | Sierra County | Sierra County, New Mexico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827998","Socorro County, NM","C109511","No value exists.","Socorro County, NM | NM053 | Socorro County | Socorro County, New Mexico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827858","Taos County, NM","C109512","No value exists.","Taos County, NM | NM055 | Taos County | Taos County, New Mexico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813229","Union County, NM","C109514","No value exists.","Union County, NM | NM059 | Union County | Union County, New Mexico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827669","Valencia County, NM","C109515","No value exists.","Valencia County, NM | NM061 | Valencia County | Valencia County, New Mexico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812157","Albany County, NY","C109516","No value exists.","Albany County, NY | Albany County | Albany County, New York | NY001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816196","Clay County, TN","C110129","No value exists.","Clay County, TN | Clay County | Clay County, Tennessee | TN027",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831062","Cocke County, TN","C110130","No value exists.","Cocke County, TN | Cocke County | Cocke County, Tennessee | TN029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813156","Crockett County, TN","C110132","No value exists.","Crockett County, TN | Crockett County | Crockett County, Tennessee | TN033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813960","Cumberland County, TN","C110133","No value exists.","Cumberland County, TN | Cumberland County | Cumberland County, Tennessee | TN035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814793","Davidson County, TN","C110134","No value exists.","Davidson County, TN | Davidson County | Davidson County, Tennessee | TN037",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815139","Decatur County, TN","C110135","No value exists.","Decatur County, TN | Decatur County | Decatur County, Tennessee | TN039",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830514","Dickson County, TN","C110137","No value exists.","Dickson County, TN | Dickson County | Dickson County, Tennessee | TN043",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830366","Dyer County, TN","C110138","No value exists.","Dyer County, TN | Dyer County | Dyer County, Tennessee | TN045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812206","Fayette County, TN","C110139","No value exists.","Fayette County, TN | Fayette County | Fayette County, Tennessee | TN047",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830155","Fentress County, TN","C110140","No value exists.","Fentress County, TN | Fentress County | Fentress County, Tennessee | TN049",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814014","Franklin County, TN","C110141","No value exists.","Franklin County, TN | Franklin County | Franklin County, Tennessee | TN051",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814506","Giles County, TN","C110143","No value exists.","Giles County, TN | Giles County | Giles County, Tennessee | TN055",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829956","Grainger County, TN","C110144","No value exists.","Grainger County, TN | Grainger County | Grainger County, Tennessee | TN057",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814406","Greene County, TN","C110145","No value exists.","Greene County, TN | Greene County | Greene County, Tennessee | TN059",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814414","Grundy County, TN","C110146","No value exists.","Grundy County, TN | Grundy County | Grundy County, Tennessee | TN061",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829908","Hamblen County, TN","C110147","No value exists.","Hamblen County, TN | Hamblen County | Hamblen County, Tennessee | TN063",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815161","Hancock County, TN","C110149","No value exists.","Hancock County, TN | Hancock County | Hancock County, Tennessee | TN067",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815542","Hardeman County, TN","C110150","No value exists.","Hardeman County, TN | Hardeman County | Hardeman County, Tennessee | TN069",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815544","Hardin County, TN","C110151","No value exists.","Hardin County, TN | Hardin County | Hardin County, Tennessee | TN071",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827341","Hawkins County, TN","C110152","No value exists.","Hawkins County, TN | Hawkins County | Hawkins County, Tennessee | TN073",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815564","Haywood County, TN","C110153","No value exists.","Haywood County, TN | Haywood County | Haywood County, Tennessee | TN075",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811148","Henry County, TN","C110155","No value exists.","Henry County, TN | Henry County | Henry County, Tennessee | TN079",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811706","Hickman County, TN","C110156","No value exists.","Hickman County, TN | Hickman County | Hickman County, Tennessee | TN081",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812712","Houston County, TN","C110157","No value exists.","Houston County, TN | Houston County | Houston County, Tennessee | TN083",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814494","Gallatin County, MT","C109301","No value exists.","Gallatin County, MT | Gallatin County | Gallatin County, Montana | MT031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814496","Garfield County, MT","C109302","No value exists.","Garfield County, MT | Garfield County | Garfield County, Montana | MT033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829978","Glacier County, MT","C109303","No value exists.","Glacier County, MT | Glacier County | Glacier County, Montana | MT035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829952","Granite County, MT","C109305","No value exists.","Granite County, MT | Granite County | Granite County, Montana | MT039",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811716","Hill County, MT","C109306","No value exists.","Hill County, MT | Hill County | Hill County, Montana | MT041",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810773","Jefferson County, MT","C109307","No value exists.","Jefferson County, MT | Jefferson County | Jefferson County, Montana | MT043",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829448","Judith Basin County, MT","C109308","No value exists.","Judith Basin County, MT | Judith Basin County | Judith Basin County, Montana | MT045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813640","Lake County, MT","C109309","No value exists.","Lake County, MT | Lake County | Lake County, Montana | MT047",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814087","Liberty County, MT","C109311","No value exists.","Liberty County, MT | Liberty County | Liberty County, Montana | MT051",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814101","Lincoln County, MT","C109312","No value exists.","Lincoln County, MT | Lincoln County | Lincoln County, Montana | MT053",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829165","McCone County, MT","C109313","No value exists.","McCone County, MT | MT055 | McCone County | McCone County, Montana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815916","Madison County, MT","C109314","No value exists.","Madison County, MT | MT057 | Madison County | Madison County, Montana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829144","Meagher County, MT","C109315","No value exists.","Meagher County, MT | MT059 | Meagher County | Meagher County, Montana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810695","Mineral County, MT","C109316","No value exists.","Mineral County, MT | MT061 | Mineral County | Mineral County, Montana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828875","Musselshell County, MT","C109318","No value exists.","Musselshell County, MT | MT065 | Musselshell County | Musselshell County, Montana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813689","Park County, MT","C109319","No value exists.","Park County, MT | MT067 | Park County | Park County, Montana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828575","Petroleum County, MT","C109320","No value exists.","Petroleum County, MT | MT069 | Petroleum County | Petroleum County, Montana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814122","Phillips County, MT","C109321","No value exists.","Phillips County, MT | MT071 | Phillips County | Phillips County, Montana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829997","Geauga County, OH","C109758","No value exists.","Geauga County, OH | Geauga County | Geauga County, Ohio | OH055",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814408","Greene County, OH","C109759","No value exists.","Greene County, OH | Greene County | Greene County, Ohio | OH057",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829922","Guernsey County, OH","C109760","No value exists.","Guernsey County, OH | Guernsey County | Guernsey County, Ohio | OH059",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815150","Hamilton County, OH","C109761","No value exists.","Hamilton County, OH | Hamilton County | Hamilton County, Ohio | OH061",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815163","Hancock County, OH","C109762","No value exists.","Hancock County, OH | Hancock County | Hancock County, Ohio | OH063",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815548","Hardin County, OH","C109763","No value exists.","Hardin County, OH | Hardin County | Hardin County, Ohio | OH065",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811317","Pottawatomie County, OK","C109881","No value exists.","Pottawatomie County, OK | OK125 | Pottawatomie County | Pottawatomie County, Oklahoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828436","Pushmataha County, OK","C109882","No value exists.","Pushmataha County, OK | OK127 | Pushmataha County | Pushmataha County, Oklahoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828305","Rogers County, OK","C109884","No value exists.","Rogers County, OK | OK131 | Rogers County | Rogers County, Oklahoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815232","Seminole County, OK","C109885","No value exists.","Seminole County, OK | OK133 | Seminole County | Seminole County, Oklahoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810759","Lamar County, TX","C110349","No value exists.","Lamar County, TX | Lamar County | Lamar County, Texas | TX277",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829341","Lamb County, TX","C110350","No value exists.","Lamb County, TX | Lamb County | Lamb County, Texas | TX279",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829337","Lampasas County, TX","C110351","No value exists.","Lampasas County, TX | Lampasas County | Lampasas County, Texas | TX281",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829310","Lavaca County, TX","C110353","No value exists.","Lavaca County, TX | Lavaca County | Lavaca County, Texas | TX285",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813677","Lee County, TX","C110354","No value exists.","Lee County, TX | Lee County | Lee County, Texas | TX287",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814077","Leon County, TX","C110355","No value exists.","Leon County, TX | Leon County | Leon County, Texas | TX289",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814088","Liberty County, TX","C110356","No value exists.","Liberty County, TX | Liberty County | Liberty County, Texas | TX291",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814090","Limestone County, TX","C110357","No value exists.","Limestone County, TX | Limestone County | Limestone County, Texas | TX293",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829266","Live Oak County, TX","C110359","No value exists.","Live Oak County, TX | Live Oak County | Live Oak County, Texas | TX297",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829263","Llano County, TX","C110360","No value exists.","Llano County, TX | Llano County | Llano County, Texas | TX299",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829247","Lubbock County, TX","C110362","No value exists.","Lubbock County, TX | Lubbock County | Lubbock County, Texas | TX303",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829234","Lynn County, TX","C110363","No value exists.","Lynn County, TX | Lynn County | Lynn County, Texas | TX305",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829152","McLennan County, TX","C110365","No value exists.","McLennan County, TX | McLennan County | McLennan County, Texas | TX309",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829149","McMullen County, TX","C110366","No value exists.","McMullen County, TX | McMullen County | McMullen County, Texas | TX311",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815922","Madison County, TX","C110367","No value exists.","Madison County, TX | Madison County | Madison County, Texas | TX313",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811180","Marion County, TX","C110368","No value exists.","Marion County, TX | Marion County | Marion County, Texas | TX315",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811735","Martin County, TX","C110369","No value exists.","Martin County, TX | Martin County | Martin County, Texas | TX317",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829178","Matagorda County, TX","C110371","No value exists.","Matagorda County, TX | Matagorda County | Matagorda County, Texas | TX321",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829170","Maverick County, TX","C110372","No value exists.","Maverick County, TX | Maverick County | Maverick County, Texas | TX323",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812717","Medina County, TX","C110373","No value exists.","Medina County, TX | Medina County | Medina County, Texas | TX325",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812638","Allegany County, NY","C109517","No value exists.","Allegany County, NY | Allegany County | Allegany County, New York | NY003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827325","Bronx County, NY","C109518","No value exists.","Bronx County, NY | Bronx County | Bronx County, New York | NY005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831178","Cattaraugus County, NY","C109520","No value exists.","Cattaraugus County, NY | Cattaraugus County | Cattaraugus County, New York | NY009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831175","Cayuga County, NY","C109521","No value exists.","Cayuga County, NY | Cayuga County | Cayuga County, New York | NY011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812377","Chautauqua County, NY","C109522","No value exists.","Chautauqua County, NY | Chautauqua County | Chautauqua County, New York | NY013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831125","Chemung County, NY","C109523","No value exists.","Chemung County, NY | Chemung County | Chemung County, New York | NY015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831124","Chenango County, NY","C109524","No value exists.","Chenango County, NY | Chenango County | Chenango County, New York | NY017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812186","Columbia County, NY","C109526","No value exists.","Columbia County, NY | Columbia County | Columbia County, New York | NY021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831003","Cortland County, NY","C109527","No value exists.","Cortland County, NY | Cortland County | Cortland County, New York | NY023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815523","Delaware County, NY","C109528","No value exists.","Delaware County, NY | Delaware County | Delaware County, New York | NY025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830367","Dutchess County, NY","C109529","No value exists.","Dutchess County, NY | Dutchess County | Dutchess County, New York | NY027",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810545","Erie County, NY","C109530","No value exists.","Erie County, NY | Erie County | Erie County, New York | NY029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814009","Franklin County, NY","C109532","No value exists.","Franklin County, NY | Franklin County | Franklin County, New York | NY033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814423","Fulton County, NY","C109533","No value exists.","Fulton County, NY | Fulton County | Fulton County, New York | NY035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814502","Genesee County, NY","C109534","No value exists.","Genesee County, NY | Genesee County | Genesee County, New York | NY037",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813999","Greene County, NY","C109535","No value exists.","Greene County, NY | Greene County | Greene County, New York | NY039",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829706","Herkimer County, NY","C109537","No value exists.","Herkimer County, NY | Herkimer County | Herkimer County, New York | NY043",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810775","Jefferson County, NY","C109538","No value exists.","Jefferson County, NY | Jefferson County | Jefferson County, New York | NY045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810795","Kings County, NY","C109539","No value exists.","Kings County, NY | Kings County | Kings County, New York | NY047",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814081","Lewis County, NY","C109540","No value exists.","Lewis County, NY | Lewis County | Lewis County, New York | NY049",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815603","Livingston County, NY","C109541","No value exists.","Livingston County, NY | Livingston County | Livingston County, New York | NY051",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811204","Northampton County, PA","C109979","No value exists.","Northampton County, PA | Northampton County | Northampton County, Pennsylvania | PA095",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811206","Northumberland County, PA","C109980","No value exists.","Northumberland County, PA | Northumberland County | Northumberland County, Pennsylvania | PA097",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814436","Humphreys County, TN","C110158","No value exists.","Humphreys County, TN | Humphreys County | Humphreys County, Tennessee | TN085",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816197","Jackson County, TN","C110159","No value exists.","Jackson County, TN | Jackson County | Jackson County, Tennessee | TN087",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1617068","Toxic Shock Syndrome Toxin-1","C1086","Staphylococcal toxic shock syndrome toxin 1.  A superantigen with the potential to suppress plasma cell differentiation and antibody responsiveness. Potent pyrogen, induces T lymphocyte proliferation, requiring interleukin 1 release from macrophages, suppresses immunoglobulin production, enhances endotoxin shock, and enhances hypersensitivity skin reactions. Causes staphylococcal toxic shock syndrome (TSS).","Toxic Shock Syndrome Toxin-1 | TSST-1",,,,,,,,,,,,,,,"4136105","TSST-1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3831194","Carlisle County, KY","C108700","No value exists.","Carlisle County, KY | Carlisle County | Carlisle County, Kentucky | KY039",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811359","Carroll County, KY","C108701","No value exists.","Carroll County, KY | Carroll County | Carroll County, Kentucky | KY041",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811360","Carter County, KY","C108702","No value exists.","Carter County, KY | Carter County | Carter County, Kentucky | KY043",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831187","Casey County, KY","C108703","No value exists.","Casey County, KY | Casey County | Casey County, Kentucky | KY045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811361","Christian County, KY","C108704","No value exists.","Christian County, KY | Christian County | Christian County, Kentucky | KY047",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811362","Clark County, KY","C108705","No value exists.","Clark County, KY | Clark County | Clark County, Kentucky | KY049",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811081","Clay County, KY","C108706","No value exists.","Clay County, KY | Clay County | Clay County, Kentucky | KY051",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811103","Clinton County, KY","C108707","No value exists.","Clinton County, KY | Clinton County | Clinton County, Kentucky | KY053",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811364","Cumberland County, KY","C108709","No value exists.","Cumberland County, KY | Cumberland County | Cumberland County, Kentucky | KY057",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815127","Daviess County, KY","C108710","No value exists.","Daviess County, KY | Daviess County | Daviess County, Kentucky | KY059",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827335","Edmonson County, KY","C108711","No value exists.","Edmonson County, KY | Edmonson County | Edmonson County, Kentucky | KY061",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830321","Elliott County, KY","C108712","No value exists.","Elliott County, KY | Elliott County | Elliott County, Kentucky | KY063",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830304","Estill County, KY","C108713","No value exists.","Estill County, KY | Estill County | Estill County, Kentucky | KY065",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830101","Fleming County, KY","C108715","No value exists.","Fleming County, KY | Fleming County | Fleming County, Kentucky | KY069",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813572","Floyd County, KY","C108716","No value exists.","Floyd County, KY | Floyd County | Floyd County, Kentucky | KY071",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814021","Franklin County, KY","C108717","No value exists.","Franklin County, KY | Franklin County | Franklin County, Kentucky | KY073",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814425","Fulton County, KY","C108718","No value exists.","Fulton County, KY | Fulton County | Fulton County, Kentucky | KY075",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814493","Gallatin County, KY","C108719","No value exists.","Gallatin County, KY | Gallatin County | Gallatin County, Kentucky | KY077",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813984","Grant County, KY","C108721","No value exists.","Grant County, KY | Grant County | Grant County, Kentucky | KY081",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811147","Henry County, OH","C109765","No value exists.","Henry County, OH | Henry County | Henry County, Ohio | OH069",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811711","Highland County, OH","C109766","No value exists.","Highland County, OH | Highland County | Highland County, Ohio | OH071",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829678","Hocking County, OH","C109767","No value exists.","Hocking County, OH | Hocking County | Hocking County, Ohio | OH073",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812696","Holmes County, OH","C109768","No value exists.","Holmes County, OH | Holmes County | Holmes County, Ohio | OH075",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814440","Huron County, OH","C109769","No value exists.","Huron County, OH | Huron County | Huron County, Ohio | OH077",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810776","Jefferson County, OH","C109771","No value exists.","Jefferson County, OH | Jefferson County | Jefferson County, Ohio | OH081",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813273","Knox County, OH","C109772","No value exists.","Knox County, OH | Knox County | Knox County, Ohio | OH083",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813641","Lake County, OH","C109773","No value exists.","Lake County, OH | Lake County | Lake County, Ohio | OH085",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810760","Lawrence County, OH","C109774","No value exists.","Lawrence County, OH | Lawrence County | Lawrence County, Ohio | OH087",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829287","Licking County, OH","C109775","No value exists.","Licking County, OH | Licking County | Licking County, Ohio | OH089",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829258","Lorain County, OH","C109777","No value exists.","Lorain County, OH | Lorain County | Lorain County, Ohio | OH093",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815622","Lucas County, OH","C109778","No value exists.","Lucas County, OH | Lucas County | Lucas County, Ohio | OH095",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815920","Madison County, OH","C109779","No value exists.","Madison County, OH | Madison County | Madison County, Ohio | OH097",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829218","Mahoning County, OH","C109780","No value exists.","Mahoning County, OH | Mahoning County | Mahoning County, Ohio | OH099",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812718","Medina County, OH","C109782","No value exists.","Medina County, OH | Medina County | Medina County, Ohio | OH103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812719","Meigs County, OH","C109783","No value exists.","Meigs County, OH | Meigs County | Meigs County, Ohio | OH105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810676","Mercer County, OH","C109784","No value exists.","Mercer County, OH | Mercer County | Mercer County, Ohio | OH107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810682","Miami County, OH","C109785","No value exists.","Miami County, OH | Miami County | Miami County, Ohio | OH109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811258","Monroe County, OH","C109786","No value exists.","Monroe County, OH | Monroe County | Monroe County, Ohio | OH111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811291","Morgan County, OH","C109788","No value exists.","Morgan County, OH | Morgan County | Morgan County, Ohio | OH115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811298","Morrow County, OH","C109789","No value exists.","Morrow County, OH | Morrow County | Morrow County, Ohio | OH117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831049","Collingsworth County, TX","C110254","No value exists.","Collingsworth County, TX | Collingsworth County | Collingsworth County, Texas | TX087",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831047","Colorado County, TX","C110255","No value exists.","Colorado County, TX | Colorado County | Colorado County, Texas | TX089",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831042","Comal County, TX","C110256","No value exists.","Comal County, TX | Comal County | Comal County, Texas | TX091",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812190","Comanche County, TX","C110257","No value exists.","Comanche County, TX | Comanche County | Comanche County, Texas | TX093",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813182","Menard County, TX","C110374","No value exists.","Menard County, TX | Menard County | Menard County, Texas | TX327",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810688","Midland County, TX","C110375","No value exists.","Midland County, TX | Midland County | Midland County, Texas | TX329",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810693","Mills County, TX","C110377","No value exists.","Mills County, TX | Mills County | Mills County, Texas | TX333",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810704","Mitchell County, TX","C110378","No value exists.","Mitchell County, TX | Mitchell County | Mitchell County, Texas | TX335",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828970","Montague County, TX","C110379","No value exists.","Montague County, TX | Montague County | Montague County, Texas | TX337",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811279","Montgomery County, TX","C110380","No value exists.","Montgomery County, TX | Montgomery County | Montgomery County, Texas | TX339",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810684","Middlesex County, MA","C108913","No value exists.","Middlesex County, MA | MA017 | Middlesex County | Middlesex County, Massachusetts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828863","Nantucket County, MA","C108914","No value exists.","Nantucket County, MA | MA019 | Nantucket County | Nantucket County, Massachusetts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828789","Norfolk County, MA","C108915","No value exists.","Norfolk County, MA | MA021 | Norfolk County | Norfolk County, Massachusetts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811219","Plymouth County, MA","C108916","No value exists.","Plymouth County, MA | MA023 | Plymouth County | Plymouth County, Massachusetts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810754","Worcester County, MA","C108918","No value exists.","Worcester County, MA | MA027 | Worcester County | Worcester County, Massachusetts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831578","Alcona County, MI","C108919","No value exists.","Alcona County, MI | Alcona County | Alcona County, Michigan | MI001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831572","Alger County, MI","C108920","No value exists.","Alger County, MI | Alger County | Alger County, Michigan | MI003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827203","Allegan County, MI","C108921","No value exists.","Allegan County, MI | Allegan County | Allegan County, Michigan | MI005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816498","Antrim County, MI","C108923","No value exists.","Antrim County, MI | Antrim County | Antrim County, Michigan | MI009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831478","Arenac County, MI","C108924","No value exists.","Arenac County, MI | Arenac County | Arenac County, Michigan | MI011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831412","Baraga County, MI","C108925","No value exists.","Baraga County, MI | Baraga County | Baraga County, Michigan | MI013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811854","Barry County, MI","C108926","No value exists.","Barry County, MI | Barry County | Barry County, Michigan | MI015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811857","Bay County, MI","C108927","No value exists.","Bay County, MI | Bay County | Bay County, Michigan | MI017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831280","Branch County, MI","C108930","No value exists.","Branch County, MI | Branch County | Branch County, Michigan | MI023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812346","Calhoun County, MI","C108931","No value exists.","Calhoun County, MI | Calhoun County | Calhoun County, Michigan | MI025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812364","Cass County, MI","C108932","No value exists.","Cass County, MI | Cass County | Cass County, Michigan | MI027",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831137","Charlevoix County, MI","C108933","No value exists.","Charlevoix County, MI | Charlevoix County | Charlevoix County, Michigan | MI029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814115","Perry County, PA","C109981","No value exists.","Perry County, PA | PA099 | Perry County | Perry County, Pennsylvania",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828569","Philadelphia County, PA","C109982","No value exists.","Philadelphia County, PA | PA101 | Philadelphia County | Philadelphia County, Pennsylvania",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814140","Pike County, PA","C109983","No value exists.","Pike County, PA | PA103 | Pike County | Pike County, Pennsylvania",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812273","Potter County, PA","C109984","No value exists.","Potter County, PA | PA105 | Potter County | Potter County, Pennsylvania",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828215","Schuylkill County, PA","C109985","No value exists.","Schuylkill County, PA | PA107 | Schuylkill County | Schuylkill County, Pennsylvania",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827999","Snyder County, PA","C109986","No value exists.","Snyder County, PA | PA109 | Snyder County | Snyder County, Pennsylvania",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814831","Sullivan County, PA","C109988","No value exists.","Sullivan County, PA | PA113 | Sullivan County | Sullivan County, Pennsylvania",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827887","Susquehanna County, PA","C109989","No value exists.","Susquehanna County, PA | PA115 | Susquehanna County | Susquehanna County, Pennsylvania",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815222","Tioga County, PA","C109990","No value exists.","Tioga County, PA | PA117 | Tioga County | Tioga County, Pennsylvania",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813236","Union County, PA","C109991","No value exists.","Union County, PA | PA119 | Union County | Union County, Pennsylvania",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827355","Venango County, PA","C109992","No value exists.","Venango County, PA | PA121 | Venango County | Venango County, Pennsylvania",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812797","Washington County, PA","C109994","No value exists.","Washington County, PA | PA125 | Washington County | Washington County, Pennsylvania",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813260","Wayne County, PA","C109995","No value exists.","Wayne County, PA | PA127 | Wayne County | Wayne County, Pennsylvania",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813627","Westmoreland County, PA","C109996","No value exists.","Westmoreland County, PA | PA129 | Westmoreland County | Westmoreland County, Pennsylvania",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811328","Wyoming County, PA","C109997","No value exists.","Wyoming County, PA | PA131 | Wyoming County | Wyoming County, Pennsylvania",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812651","Bristol County, RI","C109999","No value exists.","Bristol County, RI | Bristol County | Bristol County, Rhode Island | RI001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811155","Kent County, RI","C110000","No value exists.","Kent County, RI | Kent County | Kent County, Rhode Island | RI003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828824","Newport County, RI","C110001","No value exists.","Newport County, RI | Newport County | Newport County, Rhode Island | RI005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828454","Providence County, RI","C110002","No value exists.","Providence County, RI | Providence County | Providence County, Rhode Island | RI007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831764","Abbeville County, SC","C110004","No value exists.","Abbeville County, SC | Abbeville County | Abbeville County, South Carolina | SC001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831586","Aiken County, SC","C110005","No value exists.","Aiken County, SC | Aiken County | Aiken County, South Carolina | SC003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816178","Iron County, UT","C110475","No value exists.","Iron County, UT | Iron County | Iron County, Utah | UT021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829946","Graves County, KY","C108722","No value exists.","Graves County, KY | Graves County | Graves County, Kentucky | KY083",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813992","Grayson County, KY","C108723","No value exists.","Grayson County, KY | Grayson County | Grayson County, Kentucky | KY085",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813995","Green County, KY","C108724","No value exists.","Green County, KY | Green County | Green County, Kentucky | KY087",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815168","Hancock County, KY","C108726","No value exists.","Hancock County, KY | Hancock County | Hancock County, Kentucky | KY091",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815546","Hardin County, KY","C108727","No value exists.","Hardin County, KY | Hardin County | Hardin County, Kentucky | KY093",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815549","Harlan County, KY","C108728","No value exists.","Harlan County, KY | Harlan County | Harlan County, Kentucky | KY095",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811335","Harrison County, KY","C108729","No value exists.","Harrison County, KY | Harrison County | Harrison County, Kentucky | KY097",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812862","Crawford County, MO","C109198","No value exists.","Crawford County, MO | Crawford County | Crawford County, Missouri | MO055",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814782","Dade County, MO","C109199","No value exists.","Dade County, MO | Dade County | Dade County, Missouri | MO057",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814787","Dallas County, MO","C109200","No value exists.","Dallas County, MO | Dallas County | Dallas County, Missouri | MO059",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815125","Daviess County, MO","C109201","No value exists.","Daviess County, MO | Daviess County | Daviess County, Missouri | MO061",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815516","DeKalb County, MO","C109202","No value exists.","DeKalb County, MO | DeKalb County | DeKalb County, Missouri | MO063",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811831","Douglas County, MO","C109204","No value exists.","Douglas County, MO | Douglas County | Douglas County, Missouri | MO067",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830373","Dunklin County, MO","C109205","No value exists.","Dunklin County, MO | Dunklin County | Dunklin County, Missouri | MO069",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814005","Franklin County, MO","C109206","No value exists.","Franklin County, MO | Franklin County | Franklin County, Missouri | MO071",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830047","Gasconade County, MO","C109207","No value exists.","Gasconade County, MO | Gasconade County | Gasconade County, Missouri | MO073",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829992","Gentry County, MO","C109208","No value exists.","Gentry County, MO | Gentry County | Gentry County, Missouri | MO075",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814412","Grundy County, MO","C109210","No value exists.","Grundy County, MO | Grundy County | Grundy County, Missouri | MO079",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815556","Harrison County, MO","C109211","No value exists.","Harrison County, MO | Harrison County | Harrison County, Missouri | MO081",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811140","Henry County, MO","C109212","No value exists.","Henry County, MO | Henry County | Henry County, Missouri | MO083",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829701","Hickory County, MO","C109213","No value exists.","Hickory County, MO | Hickory County | Hickory County, Missouri | MO085",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813171","Howard County, MO","C109215","No value exists.","Howard County, MO | Howard County | Howard County, Missouri | MO089",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829614","Howell County, MO","C109216","No value exists.","Howell County, MO | Howell County | Howell County, Missouri | MO091",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816179","Iron County, MO","C109217","No value exists.","Iron County, MO | Iron County | Iron County, Missouri | MO093",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831030","Concho County, TX","C110258","No value exists.","Concho County, TX | Concho County | Concho County, Texas | TX095",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831002","Coryell County, TX","C110260","No value exists.","Coryell County, TX | Coryell County | Coryell County, Texas | TX099",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830999","Cottle County, TX","C110261","No value exists.","Cottle County, TX | Cottle County | Cottle County, Texas | TX101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830984","Crane County, TX","C110262","No value exists.","Crane County, TX | Crane County | Crane County, Texas | TX103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813155","Crockett County, TX","C110263","No value exists.","Crockett County, TX | Crockett County | Crockett County, Texas | TX105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830635","Culberson County, TX","C110265","No value exists.","Culberson County, TX | Culberson County | Culberson County, Texas | TX109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830608","Dallam County, TX","C110266","No value exists.","Dallam County, TX | Dallam County | Dallam County, Texas | TX111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814786","Dallas County, TX","C110267","No value exists.","Dallas County, TX | Dallas County | Dallas County, Texas | TX113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815133","Dawson County, TX","C110268","No value exists.","Dawson County, TX | Dawson County | Dawson County, Texas | TX115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830553","Deaf Smith County, TX","C110269","No value exists.","Deaf Smith County, TX | Deaf Smith County | Deaf Smith County, Texas | TX117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830539","Denton County, TX","C110271","No value exists.","Denton County, TX | Denton County | Denton County, Texas | TX121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830522","DeWitt County, TX","C110272","No value exists.","DeWitt County, TX | DeWitt County | DeWitt County, Texas | TX123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827286","Dickens County, TX","C110273","No value exists.","Dickens County, TX | Dickens County | Dickens County, Texas | TX125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830480","Dimmit County, TX","C110274","No value exists.","Dimmit County, TX | Dimmit County | Dimmit County, Texas | TX127",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830404","Donley County, TX","C110275","No value exists.","Donley County, TX | Donley County | Donley County, Texas | TX129",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830355","Eastland County, TX","C110277","No value exists.","Eastland County, TX | Eastland County | Eastland County, Texas | TX133",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827336","Ector County, TX","C110278","No value exists.","Ector County, TX | Ector County | Ector County, Texas | TX135",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811842","Edwards County, TX","C110279","No value exists.","Edwards County, TX | Edwards County | Edwards County, Texas | TX137",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812832","Ellis County, TX","C110280","No value exists.","Ellis County, TX | Ellis County | Ellis County, Texas | TX139",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830306","Erath County, TX","C110282","No value exists.","Erath County, TX | Erath County | Erath County, Texas | TX143",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830258","Falls County, TX","C110283","No value exists.","Falls County, TX | Falls County | Falls County, Texas | TX145",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812200","Fannin County, TX","C110284","No value exists.","Fannin County, TX | Fannin County | Fannin County, Texas | TX147",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812208","Fayette County, TX","C110285","No value exists.","Fayette County, TX | Fayette County | Fayette County, Texas | TX149",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830111","Fisher County, TX","C110286","No value exists.","Fisher County, TX | Fisher County | Fisher County, Texas | TX151",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829951","Grant Parish, LA","C108822","No value exists.","Grant Parish, LA | Grant Parish | Grant Parish, Louisiana | LA043",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812846","Chippewa County, MI","C108935","No value exists.","Chippewa County, MI | Chippewa County | Chippewa County, Michigan | MI033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831093","Clare County, MI","C108936","No value exists.","Clare County, MI | Clare County | Clare County, Michigan | MI035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811099","Clinton County, MI","C108937","No value exists.","Clinton County, MI | Clinton County | Clinton County, Michigan | MI037",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812861","Crawford County, MI","C108938","No value exists.","Crawford County, MI | Crawford County | Crawford County, Michigan | MI039",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815530","Delta County, MI","C108939","No value exists.","Delta County, MI | Delta County | Delta County, Michigan | MI041",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830354","Eaton County, MI","C108941","No value exists.","Eaton County, MI | Eaton County | Eaton County, Michigan | MI045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812837","Emmet County, MI","C108942","No value exists.","Emmet County, MI | Emmet County | Emmet County, Michigan | MI047",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814501","Genesee County, MI","C108943","No value exists.","Genesee County, MI | Genesee County | Genesee County, Michigan | MI049",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829976","Gladwin County, MI","C108944","No value exists.","Gladwin County, MI | Gladwin County | Gladwin County, Michigan | MI051",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829969","Gogebic County, MI","C108945","No value exists.","Gogebic County, MI | Gogebic County | Gogebic County, Michigan | MI053",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828233","Sarpy County, NE","C109418","No value exists.","Sarpy County, NE | NE153 | Sarpy County | Sarpy County, Nebraska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828213","Scotts Bluff County, NE","C109420","No value exists.","Scotts Bluff County, NE | NE157 | Scotts Bluff County | Scotts Bluff County, Nebraska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815240","Seward County, NE","C109421","No value exists.","Seward County, NE | NE159 | Seward County | Seward County, Nebraska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815253","Sheridan County, NE","C109422","No value exists.","Sheridan County, NE | NE161 | Sheridan County | Sheridan County, Nebraska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815257","Sherman County, NE","C109423","No value exists.","Sherman County, NE | NE163 | Sherman County | Sherman County, Nebraska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810615","Sioux County, NE","C109424","No value exists.","Sioux County, NE | NE165 | Sioux County | Sioux County, Nebraska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827835","Thayer County, NE","C109426","No value exists.","Thayer County, NE | NE169 | Thayer County | Thayer County, Nebraska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815217","Thomas County, NE","C109427","No value exists.","Thomas County, NE | NE171 | Thomas County | Thomas County, Nebraska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815218","Thurston County, NE","C109428","No value exists.","Thurston County, NE | NE173 | Thurston County | Thurston County, Nebraska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811341","Valley County, NE","C109429","No value exists.","Valley County, NE | NE175 | Valley County | Valley County, Nebraska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813248","Washington County, NE","C109430","No value exists.","Washington County, NE | NE177 | Washington County | Washington County, Nebraska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813619","Webster County, NE","C109432","No value exists.","Webster County, NE | NE181 | Webster County | Webster County, Nebraska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810718","Wheeler County, NE","C109433","No value exists.","Wheeler County, NE | NE183 | Wheeler County | Wheeler County, Nebraska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811331","York County, NE","C109434","No value exists.","York County, NE | NE185 | York County | York County, Nebraska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810573","Kane County, UT","C110477","No value exists.","Kane County, UT | Kane County | Kane County, Utah | UT025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829070","Millard County, UT","C110478","No value exists.","Millard County, UT | Millard County | Millard County, Utah | UT027",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827383","Piute County, UT","C110480","No value exists.","Piute County, UT | Piute County | Piute County, Utah | UT031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828329","Rich County, UT","C110481","No value exists.","Rich County, UT | Rich County | Rich County, Utah | UT033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828269","Salt Lake County, UT","C110482","No value exists.","Salt Lake County, UT | Salt Lake County | Salt Lake County, Utah | UT035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811231","San Juan County, UT","C110483","No value exists.","San Juan County, UT | San Juan County | San Juan County, Utah | UT037",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815238","Sevier County, UT","C110485","No value exists.","Sevier County, UT | Sevier County | Sevier County, Utah | UT041",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814834","Summit County, UT","C110486","No value exists.","Summit County, UT | Summit County | Summit County, Utah | UT043",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827812","Tooele County, UT","C110487","No value exists.","Tooele County, UT | Tooele County | Tooele County, Utah | UT045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827738","Uintah County, UT","C110488","No value exists.","Uintah County, UT | UT047 | Uintah County | Uintah County, Utah",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827679","Utah County, UT","C110489","No value exists.","Utah County, UT | UT049 | Utah County | Utah County, Utah",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812790","Washington County, UT","C110491","No value exists.","Washington County, UT | UT053 | Washington County | Washington County, Utah",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813261","Wayne County, UT","C110492","No value exists.","Wayne County, UT | UT055 | Wayne County | Wayne County, Utah",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827493","Weber County, UT","C110493","No value exists.","Weber County, UT | UT057 | Weber County | Weber County, Utah",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831605","Addison County, VT","C110494","No value exists.","Addison County, VT | Addison County | Addison County, Vermont | VT001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831367","Bennington County, VT","C110495","No value exists.","Bennington County, VT | Bennington County | Bennington County, Vermont | VT003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831110","Chittenden County, VT","C110497","No value exists.","Chittenden County, VT | Chittenden County | Chittenden County, Vermont | VT007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811124","Essex County, VT","C110498","No value exists.","Essex County, VT | Essex County | Essex County, Vermont | VT009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814012","Franklin County, VT","C110499","No value exists.","Franklin County, VT | Franklin County | Franklin County, Vermont | VT011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4048314","Fluosol-DA","C1104","A perfluorocarbon blood substitute in trials for the treatment of severe anemia","Fluosol-DA | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829954","Grand Isle County, VT","C110500","No value exists.","Grand Isle County, VT | Grand Isle County | Grand Isle County, Vermont | VT013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812748","Orange County, VT","C110502","No value exists.","Orange County, VT | Orange County | Orange County, Vermont | VT017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812807","Orleans County, VT","C110503","No value exists.","Orleans County, VT | Orleans County | Orleans County, Vermont | VT019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828288","Rutland County, VT","C110504","No value exists.","Rutland County, VT | Rutland County | Rutland County, Vermont | VT021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816462","Jackson County, MO","C109218","No value exists.","Jackson County, MO | Jackson County | Jackson County, Missouri | MO095",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810765","Jasper County, MO","C109219","No value exists.","Jasper County, MO | Jasper County | Jasper County, Missouri | MO097",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810785","Johnson County, MO","C109221","No value exists.","Johnson County, MO | Johnson County | Johnson County, Missouri | MO101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813271","Knox County, MO","C109222","No value exists.","Knox County, MO | Knox County | Knox County, Missouri | MO103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829351","Laclede County, MO","C109223","No value exists.","Laclede County, MO | Laclede County | Laclede County, Missouri | MO105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813631","Lafayette County, MO","C109224","No value exists.","Lafayette County, MO | Lafayette County | Lafayette County, Missouri | MO107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813664","Lawrence County, MO","C109225","No value exists.","Lawrence County, MO | Lawrence County | Lawrence County, Missouri | MO109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814099","Lincoln County, MO","C109227","No value exists.","Lincoln County, MO | Lincoln County | Lincoln County, Missouri | MO113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815581","Linn County, MO","C109228","No value exists.","Linn County, MO | Linn County | Linn County, Missouri | MO115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827740","Tyrrell County, NC","C109666","No value exists.","Tyrrell County, NC | NC177 | Tyrrell County | Tyrrell County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813231","Union County, NC","C109667","No value exists.","Union County, NC | NC179 | Union County | Union County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827357","Vance County, NC","C109668","No value exists.","Vance County, NC | NC181 | Vance County | Vance County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827526","Wake County, NC","C109669","No value exists.","Wake County, NC | NC183 | Wake County | Wake County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812779","Warren County, NC","C109670","No value exists.","Warren County, NC | NC185 | Warren County | Warren County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812795","Washington County, NC","C109671","No value exists.","Washington County, NC | NC187 | Washington County | Washington County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827502","Watauga County, NC","C109672","No value exists.","Watauga County, NC | NC189 | Watauga County | Watauga County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810729","Wilkes County, NC","C109674","No value exists.","Wilkes County, NC | NC193 | Wilkes County | Wilkes County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810736","Wilson County, NC","C109675","No value exists.","Wilson County, NC | NC195 | Wilson County | Wilson County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827416","Yadkin County, NC","C109676","No value exists.","Yadkin County, NC | NC197 | Yadkin County | Yadkin County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827411","Yancey County, NC","C109677","No value exists.","Yancey County, NC | NC199 | Yancey County | Yancey County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811638","Adams County, ND","C109678","No value exists.","Adams County, ND | Adams County | Adams County, North Dakota | ND001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831366","Benson County, ND","C109680","No value exists.","Benson County, ND | Benson County | Benson County, North Dakota | ND005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831352","Billings County, ND","C109681","No value exists.","Billings County, ND | Billings County | Billings County, North Dakota | ND007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831291","Bottineau County, ND","C109682","No value exists.","Bottineau County, ND | Bottineau County | Bottineau County, North Dakota | ND009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829576","Iberia Parish, LA","C108823","No value exists.","Iberia Parish, LA | Iberia Parish | Iberia Parish, Louisiana | LA045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829575","Iberville Parish, LA","C108824","No value exists.","Iberville Parish, LA | Iberville Parish | Iberville Parish, Louisiana | LA047",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829479","Jackson Parish, LA","C108825","No value exists.","Jackson Parish, LA | Jackson Parish | Jackson Parish, Louisiana | LA049",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829462","Jefferson Davis Parish, LA","C108827","No value exists.","Jefferson Davis Parish, LA | Jefferson Davis Parish | Jefferson Davis Parish, Louisiana | LA053",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829347","Lafayette Parish, LA","C108828","No value exists.","Lafayette Parish, LA | LA055 | Lafayette Parish | Lafayette Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829346","Lafourche Parish, LA","C108829","No value exists.","Lafourche Parish, LA | LA057 | Lafourche Parish | Lafourche Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829323","La Salle Parish, LA","C108830","No value exists.","La Salle Parish, LA | LA059 | La Salle Parish | La Salle Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829276","Lincoln Parish, LA","C108831","No value exists.","Lincoln Parish, LA | LA061 | Lincoln Parish | Lincoln Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829225","Madison Parish, LA","C108833","No value exists.","Madison Parish, LA | LA065 | Madison Parish | Madison Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828961","Morehouse Parish, LA","C108834","No value exists.","Morehouse Parish, LA | LA067 | Morehouse Parish | Morehouse Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828858","Natchitoches Parish, LA","C108835","No value exists.","Natchitoches Parish, LA | LA069 | Natchitoches Parish | Natchitoches Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828697","Orleans Parish, LA","C108836","No value exists.","Orleans Parish, LA | LA071 | Orleans Parish | Orleans Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828686","Ouachita Parish, LA","C108837","No value exists.","Ouachita Parish, LA | LA073 | Ouachita Parish | Ouachita Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828523","Pointe Coupee Parish, LA","C108839","No value exists.","Pointe Coupee Parish, LA | LA077 | Pointe Coupee Parish | Pointe Coupee Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828371","Rapides Parish, LA","C108840","No value exists.","Rapides Parish, LA | LA079 | Rapides Parish | Rapides Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828351","Red River Parish, LA","C108841","No value exists.","Red River Parish, LA | LA081 | Red River Parish | Red River Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828328","Richland Parish, LA","C108842","No value exists.","Richland Parish, LA | LA083 | Richland Parish | Richland Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828283","Sabine Parish, LA","C108843","No value exists.","Sabine Parish, LA | LA085 | Sabine Parish | Sabine Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827945","St. Charles Parish, LA","C108845","No value exists.","St. Charles Parish, LA | LA089 | St. Charles Parish | St. Charles Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827932","St. Helena Parish, LA","C108846","No value exists.","St. Helena Parish, LA | LA091 | St. Helena Parish | St. Helena Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827930","St. James Parish, LA","C108847","No value exists.","St. James Parish, LA | LA093 | St. James Parish | St. James Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827927","St. John the Baptist Parish, LA","C108848","No value exists.","St. John the Baptist Parish, LA | LA095 | St. John the Baptist Parish | St. John the Baptist Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827926","St. Landry Parish, LA","C108849","No value exists.","St. Landry Parish, LA | LA097 | St. Landry Parish | St. Landry Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831105","Churchill County, NV","C109435","No value exists.","Churchill County, NV | Churchill County | Churchill County, Nevada | NV001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811833","Douglas County, NV","C109437","No value exists.","Douglas County, NV | Douglas County | Douglas County, Nevada | NV005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830322","Elko County, NV","C109438","No value exists.","Elko County, NV | Elko County | Elko County, Nevada | NV007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830305","Esmeralda County, NV","C109439","No value exists.","Esmeralda County, NV | Esmeralda County | Esmeralda County, Nevada | NV009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830302","Eureka County, NV","C109440","No value exists.","Eureka County, NV | Eureka County | Eureka County, Nevada | NV011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814434","Humboldt County, NV","C109441","No value exists.","Humboldt County, NV | Humboldt County | Humboldt County, Nevada | NV013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815201","Lincoln County, NV","C109443","No value exists.","Lincoln County, NV | Lincoln County | Lincoln County, Nevada | NV017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815627","Lyon County, NV","C109444","No value exists.","Lyon County, NV | Lyon County | Lyon County, Nevada | NV019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810696","Mineral County, NV","C109445","No value exists.","Mineral County, NV | Mineral County | Mineral County, Nevada | NV021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828742","Nye County, NV","C109446","No value exists.","Nye County, NV | NV023 | Nye County | Nye County, Nevada",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828578","Pershing County, NV","C109447","No value exists.","Pershing County, NV | NV027 | Pershing County | Pershing County, Nevada",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827504","Washoe County, NV","C109449","No value exists.","Washoe County, NV | NV031 | Washoe County | Washoe County, Nevada",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828191","Sequoyah County, OK","C109886","No value exists.","Sequoyah County, OK | OK135 | Sequoyah County | Sequoyah County, Oklahoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814462","Stephens County, OK","C109887","No value exists.","Stephens County, OK | OK137 | Stephens County | Stephens County, Oklahoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815215","Texas County, OK","C109888","No value exists.","Texas County, OK | OK139 | Texas County | Texas County, Oklahoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827830","Tillman County, OK","C109889","No value exists.","Tillman County, OK | OK141 | Tillman County | Tillman County, Oklahoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827756","Tulsa County, OK","C109890","No value exists.","Tulsa County, OK | OK143 | Tulsa County | Tulsa County, Oklahoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827308","Wagoner County, OK","C109891","No value exists.","Wagoner County, OK | OK145 | Wagoner County | Wagoner County, Oklahoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827505","Washita County, OK","C109893","No value exists.","Washita County, OK | OK149 | Washita County | Washita County, Oklahoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810753","Woods County, OK","C109894","No value exists.","Woods County, OK | OK151 | Woods County | Woods County, Oklahoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827447","Woodward County, OK","C109895","No value exists.","Woodward County, OK | OK153 | Woodward County | Woodward County, Oklahoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811386","Baker County, OR","C109896","No value exists.","Baker County, OR | Baker County | Baker County, Oregon | OR001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811866","Benton County, OR","C109897","No value exists.","Benton County, OR | Benton County | Benton County, Oregon | OR003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831086","Clatsop County, OR","C109899","No value exists.","Clatsop County, OR | Clatsop County | Clatsop County, Oregon | OR007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813250","Washington County, VT","C110505","No value exists.","Washington County, VT | VT023 | Washington County | Washington County, Vermont",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810739","Windham County, VT","C110506","No value exists.","Windham County, VT | VT025 | Windham County | Windham County, Vermont",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829342","Lake of the Woods County, MN","C109040","No value exists.","Lake of the Woods County, MN | Lake of the Woods County | Lake of the Woods County, Minnesota | MN077",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829295","Le Sueur County, MN","C109041","No value exists.","Le Sueur County, MN | Le Sueur County | Le Sueur County, Minnesota | MN079",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815626","Lyon County, MN","C109043","No value exists.","Lyon County, MN | Lyon County | Lyon County, Minnesota | MN083",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829151","McLeod County, MN","C109044","No value exists.","McLeod County, MN | MN085 | McLeod County | McLeod County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829219","Mahnomen County, MN","C109045","No value exists.","Mahnomen County, MN | MN087 | Mahnomen County | Mahnomen County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811733","Martin County, MN","C109047","No value exists.","Martin County, MN | MN091 | Martin County | Martin County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829133","Meeker County, MN","C109048","No value exists.","Meeker County, MN | MN093 | Meeker County | Meeker County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829069","Mille Lacs County, MN","C109049","No value exists.","Mille Lacs County, MN | MN095 | Mille Lacs County | Mille Lacs County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828957","Morrison County, MN","C109050","No value exists.","Morrison County, MN | MN097 | Morrison County | Morrison County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828946","Mower County, MN","C109051","No value exists.","Mower County, MN | MN099 | Mower County | Mower County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828816","Nicollet County, MN","C109053","No value exists.","Nicollet County, MN | MN103 | Nicollet County | Nicollet County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812804","Nobles County, MN","C109054","No value exists.","Nobles County, MN | MN105 | Nobles County | Nobles County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828787","Norman County, MN","C109055","No value exists.","Norman County, MN | MN107 | Norman County | Norman County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828711","Olmsted County, MN","C109056","No value exists.","Olmsted County, MN | MN109 | Olmsted County | Olmsted County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813698","Pennington County, MN","C109058","No value exists.","Pennington County, MN | MN113 | Pennington County | Pennington County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828553","Pine County, MN","C109059","No value exists.","Pine County, MN | MN115 | Pine County | Pine County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828551","Pipestone County, MN","C109060","No value exists.","Pipestone County, MN | MN117 | Pipestone County | Pipestone County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811779","Polk County, MN","C109061","No value exists.","Polk County, MN | MN119 | Polk County | Polk County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812267","Pope County, MN","C109062","No value exists.","Pope County, MN | MN121 | Pope County | Pope County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812308","Ramsey County, MN","C109063","No value exists.","Ramsey County, MN | MN123 | Ramsey County | Ramsey County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828349","Redwood County, MN","C109065","No value exists.","Redwood County, MN | MN127 | Redwood County | Redwood County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831286","Bowman County, ND","C109683","No value exists.","Bowman County, ND | Bowman County | Bowman County, North Dakota | ND011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812337","Burke County, ND","C109684","No value exists.","Burke County, ND | Burke County | Burke County, North Dakota | ND013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812367","Cass County, ND","C109686","No value exists.","Cass County, ND | Cass County | Cass County, North Dakota | ND017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831177","Cavalier County, ND","C109687","No value exists.","Cavalier County, ND | Cavalier County | Cavalier County, North Dakota | ND019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830515","Dickey County, ND","C109688","No value exists.","Dickey County, ND | Dickey County | Dickey County, North Dakota | ND021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830416","Divide County, ND","C109689","No value exists.","Divide County, ND | Divide County | Divide County, North Dakota | ND023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810526","Dunn County, ND","C109690","No value exists.","Dunn County, ND | Dunn County | Dunn County, North Dakota | ND025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830316","Emmons County, ND","C109692","No value exists.","Emmons County, ND | Emmons County | Emmons County, North Dakota | ND029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830085","Foster County, ND","C109693","No value exists.","Foster County, ND | Foster County | Foster County, North Dakota | ND031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814845","Golden Valley County, ND","C109694","No value exists.","Golden Valley County, ND | Golden Valley County | Golden Valley County, North Dakota | ND033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829955","Grand Forks County, ND","C109695","No value exists.","Grand Forks County, ND | Grand Forks County | Grand Forks County, North Dakota | ND035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829933","Griggs County, ND","C109697","No value exists.","Griggs County, ND | Griggs County | Griggs County, North Dakota | ND039",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816198","Jefferson County, TN","C110160","No value exists.","Jefferson County, TN | Jefferson County | Jefferson County, Tennessee | TN089",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816199","Johnson County, TN","C110161","No value exists.","Johnson County, TN | Johnson County | Johnson County, Tennessee | TN091",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813274","Knox County, TN","C110162","No value exists.","Knox County, TN | Knox County | Knox County, Tennessee | TN093",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813644","Lake County, TN","C110163","No value exists.","Lake County, TN | Lake County | Lake County, Tennessee | TN095",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813668","Lawrence County, TN","C110165","No value exists.","Lawrence County, TN | Lawrence County | Lawrence County, Tennessee | TN099",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814082","Lewis County, TN","C110166","No value exists.","Lewis County, TN | Lewis County | Lewis County, Tennessee | TN101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815576","Lincoln County, TN","C110167","No value exists.","Lincoln County, TN | Lincoln County | Lincoln County, Tennessee | TN103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829253","Loudon County, TN","C110168","No value exists.","Loudon County, TN | Loudon County | Loudon County, Tennessee | TN105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829150","McMinn County, TN","C110169","No value exists.","McMinn County, TN | McMinn County | McMinn County, Tennessee | TN107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815904","Macon County, TN","C110171","No value exists.","Macon County, TN | Macon County | Macon County, Tennessee | TN111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815921","Madison County, TN","C110172","No value exists.","Madison County, TN | Madison County | Madison County, Tennessee | TN113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811171","Marion County, TN","C110173","No value exists.","Marion County, TN | Marion County | Marion County, Tennessee | TN115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811729","Marshall County, TN","C110174","No value exists.","Marshall County, TN | Marshall County | Marshall County, Tennessee | TN117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829171","Maury County, TN","C110175","No value exists.","Maury County, TN | Maury County | Maury County, Tennessee | TN119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827921","St. Mary Parish, LA","C108851","No value exists.","St. Mary Parish, LA | LA101 | St. Mary Parish | St. Mary Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827905","St. Tammany Parish, LA","C108852","No value exists.","St. Tammany Parish, LA | LA103 | St. Tammany Parish | St. Tammany Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828517","Pondera County, MT","C109322","No value exists.","Pondera County, MT | MT073 | Pondera County | Pondera County, Montana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828500","Powder River County, MT","C109323","No value exists.","Powder River County, MT | MT075 | Powder River County | Powder River County, Montana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812278","Powell County, MT","C109324","No value exists.","Powell County, MT | MT077 | Powell County | Powell County, Montana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828367","Ravalli County, MT","C109326","No value exists.","Ravalli County, MT | MT081 | Ravalli County | Ravalli County, Montana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813282","Richland County, MT","C109327","No value exists.","Richland County, MT | MT083 | Richland County | Richland County, Montana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813306","Roosevelt County, MT","C109328","No value exists.","Roosevelt County, MT | MT085 | Roosevelt County | Roosevelt County, Montana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828296","Rosebud County, MT","C109329","No value exists.","Rosebud County, MT | MT087 | Rosebud County | Rosebud County, Montana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828259","Sanders County, MT","C109330","No value exists.","Sanders County, MT | MT089 | Sanders County | Sanders County, Montana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828021","Silver Bow County, MT","C109332","No value exists.","Silver Bow County, MT | MT093 | Silver Bow County | Silver Bow County, Montana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827931","Stillwater County, MT","C109333","No value exists.","Stillwater County, MT | MT095 | Stillwater County | Stillwater County, Montana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827879","Sweet Grass County, MT","C109334","No value exists.","Sweet Grass County, MT | MT097 | Sweet Grass County | Sweet Grass County, Montana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815212","Teton County, MT","C109335","No value exists.","Teton County, MT | MT099 | Teton County | Teton County, Montana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827811","Toole County, MT","C109336","No value exists.","Toole County, MT | MT101 | Toole County | Toole County, Montana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811340","Valley County, MT","C109338","No value exists.","Valley County, MT | MT105 | Valley County | Valley County, Montana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827473","Wheatland County, MT","C109339","No value exists.","Wheatland County, MT | MT107 | Wheatland County | Wheatland County, Montana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827466","Wibaux County, MT","C109340","No value exists.","Wibaux County, MT | MT109 | Wibaux County | Wibaux County, Montana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810811","Yellowstone County, Montana","C109341","No value exists.","Yellowstone County, MT | MT111 | Yellowstone County | Yellowstone County, Montana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811640","Adams County, NE","C109342","No value exists.","Adams County, NE | Adams County | Adams County, Nebraska | NE001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831471","Arthur County, NE","C109344","No value exists.","Arthur County, NE | Arthur County | Arthur County, Nebraska | NE005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831414","Banner County, NE","C109345","No value exists.","Banner County, NE | Banner County | Banner County, Nebraska | NE007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811659","Blaine County, NE","C109346","No value exists.","Blaine County, NE | Blaine County | Blaine County, Nebraska | NE009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811880","Boone County, NE","C109347","No value exists.","Boone County, NE | Boone County | Boone County, Nebraska | NE011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831285","Box Butte County, NE","C109348","No value exists.","Box Butte County, NE | Box Butte County | Box Butte County, Nebraska | NE013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812183","Columbia County, OR","C109900","No value exists.","Columbia County, OR | Columbia County | Columbia County, Oregon | OR009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812671","Coos County, OR","C109901","No value exists.","Coos County, OR | Coos County | Coos County, Oregon | OR011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812865","Crook County, OR","C109902","No value exists.","Crook County, OR | Crook County | Crook County, Oregon | OR013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830534","Deschutes County, OR","C109904","No value exists.","Deschutes County, OR | Deschutes County | Deschutes County, Oregon | OR017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811834","Douglas County, OR","C109905","No value exists.","Douglas County, OR | Douglas County | Douglas County, Oregon | OR019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829980","Gilliam County, OR","C109906","No value exists.","Gilliam County, OR | Gilliam County | Gilliam County, Oregon | OR021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813976","Grant County, OR","C109907","No value exists.","Grant County, OR | Grant County | Grant County, Oregon | OR023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829669","Hood River County, OR","C109909","No value exists.","Hood River County, OR | Hood River County | Hood River County, Oregon | OR027",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816464","Jackson County, OR","C109910","No value exists.","Jackson County, OR | Jackson County | Jackson County, Oregon | OR029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810778","Jefferson County, OR","C109911","No value exists.","Jefferson County, OR | Jefferson County | Jefferson County, Oregon | OR031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829451","Josephine County, OR","C109912","No value exists.","Josephine County, OR | Josephine County | Josephine County, Oregon | OR033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829372","Klamath County, OR","C109913","No value exists.","Klamath County, OR | Klamath County | Klamath County, Oregon | OR035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811283","Moore County, TX","C110381","No value exists.","Moore County, TX | Moore County | Moore County, Texas | TX341",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811297","Morris County, TX","C110382","No value exists.","Morris County, TX | Morris County | Morris County, Texas | TX343",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828952","Motley County, TX","C110383","No value exists.","Motley County, TX | Motley County | Motley County, Texas | TX345",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828868","Nacogdoches County, TX","C110384","No value exists.","Nacogdoches County, TX | Nacogdoches County | Nacogdoches County, Texas | TX347",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828847","Navarro County, TX","C110385","No value exists.","Navarro County, TX | Navarro County | Navarro County, Texas | TX349",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828809","Nolan County, TX","C110387","No value exists.","Nolan County, TX | Nolan County | Nolan County, Texas | TX353",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828747","Nueces County, TX","C110388","No value exists.","Nueces County, TX | Nueces County | Nueces County, Texas | TX355",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827210","Ochiltree County, TX","C110389","No value exists.","Ochiltree County, TX | Ochiltree County | Ochiltree County, Texas | TX357",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812736","Oldham County, TX","C110390","No value exists.","Oldham County, TX | Oldham County | Oldham County, Texas | TX359",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812744","Orange County, TX","C110391","No value exists.","Orange County, TX | Orange County | Orange County, Texas | TX361",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812838","Renville County, MN","C109066","No value exists.","Renville County, MN | MN129 | Renville County | Renville County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813280","Rice County, MN","C109067","No value exists.","Rice County, MN | MN131 | Rice County | Rice County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813300","Rock County, MN","C109068","No value exists.","Rock County, MN | MN133 | Rock County | Rock County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814056","St. Louis County, MN","C109070","No value exists.","St. Louis County, MN | MN137 | St. Louis County | St. Louis County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814850","Scott County, MN","C109071","No value exists.","Scott County, MN | MN139 | Scott County | Scott County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815919","Madison County, NY","C109542","No value exists.","Madison County, NY | Madison County | Madison County, New York | NY053",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810717","Monroe County, NY","C109543","No value exists.","Monroe County, NY | Monroe County | Monroe County, New York | NY055",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812327","Nassau County, NY","C109545","No value exists.","Nassau County, NY | NY059 | Nassau County | Nassau County, New York",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828821","New York County, NY","C109546","No value exists.","New York County, NY | NY061 | New York County | New York County, New York",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828818","Niagara County, NY","C109547","No value exists.","Niagara County, NY | NY063 | Niagara County | Niagara County, New York",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828705","Onondaga County, NY","C109549","No value exists.","Onondaga County, NY | NY067 | Onondaga County | Onondaga County, New York",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828703","Ontario County, NY","C109550","No value exists.","Ontario County, NY | NY069 | Ontario County | Ontario County, New York",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812750","Orange County, NY","C109551","No value exists.","Orange County, NY | NY071 | Orange County | Orange County, New York",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812806","Orleans County, NY","C109552","No value exists.","Orleans County, NY | NY073 | Orleans County | Orleans County, New York",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828692","Oswego County, NY","C109553","No value exists.","Oswego County, NY | NY075 | Oswego County | Oswego County, New York",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812302","Putnam County, NY","C109555","No value exists.","Putnam County, NY | NY079 | Putnam County | Putnam County, New York",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816497","Queens County, NY","C109556","No value exists.","Queens County, NY | NY081 | Queens County | Queens County, New York",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828343","Rensselaer County, NY","C109557","No value exists.","Rensselaer County, NY | NY083 | Rensselaer County | Rensselaer County, New York",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813288","Richmond County, NY","C109558","No value exists.","Richmond County, NY | NY085 | Richmond County | Richmond County, New York",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827925","St. Lawrence County, NY","C109560","No value exists.","St. Lawrence County, NY | NY089 | St. Lawrence County | St. Lawrence County, New York",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828235","Saratoga County, NY","C109561","No value exists.","Saratoga County, NY | NY091 | Saratoga County | Saratoga County, New York",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828220","Schenectady County, NY","C109562","No value exists.","Schenectady County, NY | NY093 | Schenectady County | Schenectady County, New York",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828217","Schoharie County, NY","C109563","No value exists.","Schoharie County, NY | NY095 | Schoharie County | Schoharie County, New York",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811791","Schuyler County, NY","C109564","No value exists.","Schuyler County, NY | NY097 | Schuyler County | Schuyler County, New York",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811260","Monroe County, TN","C110177","No value exists.","Monroe County, TN | Monroe County | Monroe County, Tennessee | TN123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811278","Montgomery County, TN","C110178","No value exists.","Montgomery County, TN | Montgomery County | Montgomery County, Tennessee | TN125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811282","Moore County, TN","C110179","No value exists.","Moore County, TN | Moore County | Moore County, Tennessee | TN127",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811292","Morgan County, TN","C110180","No value exists.","Morgan County, TN | Morgan County | Morgan County, Tennessee | TN129",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828739","Obion County, TN","C110181","No value exists.","Obion County, TN | Obion County | Obion County, Tennessee | TN131",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814116","Perry County, TN","C110183","No value exists.","Perry County, TN | Perry County | Perry County, Tennessee | TN135",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828559","Pickett County, TN","C110184","No value exists.","Pickett County, TN | Pickett County | Pickett County, Tennessee | TN137",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811776","Polk County, TN","C110185","No value exists.","Polk County, TN | Polk County | Polk County, Tennessee | TN139",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812304","Putnam County, TN","C110186","No value exists.","Putnam County, TN | Putnam County | Putnam County, Tennessee | TN141",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828333","Rhea County, TN","C110187","No value exists.","Rhea County, TN | Rhea County | Rhea County, Tennessee | TN143",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813298","Robertson County, TN","C110189","No value exists.","Robertson County, TN | Robertson County | Robertson County, Tennessee | TN147",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810642","Rutherford County, TN","C110190","No value exists.","Rutherford County, TN | Rutherford County | Rutherford County, Tennessee | TN149",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814851","Scott County, TN","C110191","No value exists.","Scott County, TN | Scott County | Scott County, Tennessee | TN151",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828192","Sequatchie County, TN","C110192","No value exists.","Sequatchie County, TN | Sequatchie County | Sequatchie County, Tennessee | TN153",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815560","Hart County, KY","C108730","No value exists.","Hart County, KY | Hart County | Hart County, Kentucky | KY099",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811138","Henderson County, KY","C108731","No value exists.","Henderson County, KY | Henderson County | Henderson County, Kentucky | KY101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811705","Hickman County, KY","C108733","No value exists.","Hickman County, KY | Hickman County | Hickman County, Kentucky | KY105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812704","Hopkins County, KY","C108734","No value exists.","Hopkins County, KY | Hopkins County | Hopkins County, Kentucky | KY107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816473","Jackson County, KY","C108735","No value exists.","Jackson County, KY | Jackson County | Jackson County, Kentucky | KY109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810770","Jefferson County, KY","C108736","No value exists.","Jefferson County, KY | Jefferson County | Jefferson County, Kentucky | KY111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829456","Jessamine County, KY","C108737","No value exists.","Jessamine County, KY | Jessamine County | Jessamine County, Kentucky | KY113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829410","Kenton County, KY","C108739","No value exists.","Kenton County, KY | KY117 | Kenton County | Kenton County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827313","Knott County, KY","C108740","No value exists.","Knott County, KY | KY119 | Knott County | Knott County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811886","Brown County, NE","C109350","No value exists.","Brown County, NE | Brown County | Brown County, Nebraska | NE017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812335","Buffalo County, NE","C109351","No value exists.","Buffalo County, NE | Buffalo County | Buffalo County, Nebraska | NE019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831240","Burt County, NE","C109352","No value exists.","Burt County, NE | Burt County | Burt County, Nebraska | NE021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812339","Butler County, NE","C109353","No value exists.","Butler County, NE | Butler County | Butler County, Nebraska | NE023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828876","Muskingum County, OH","C109790","No value exists.","Muskingum County, OH | Muskingum County | Muskingum County, Ohio | OH119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811199","Noble County, OH","C109791","No value exists.","Noble County, OH | Noble County | Noble County, Ohio | OH121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812820","Ottawa County, OH","C109792","No value exists.","Ottawa County, OH | OH123 | Ottawa County | Ottawa County, Ohio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813692","Paulding County, OH","C109793","No value exists.","Paulding County, OH | OH125 | Paulding County | Paulding County, Ohio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814114","Perry County, OH","C109794","No value exists.","Perry County, OH | OH127 | Perry County | Perry County, Ohio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814139","Pike County, OH","C109796","No value exists.","Pike County, OH | OH131 | Pike County | Pike County, Ohio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812268","Portage County, OH","C109797","No value exists.","Portage County, OH | OH133 | Portage County | Portage County, Ohio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828494","Preble County, OH","C109798","No value exists.","Preble County, OH | OH135 | Preble County | Preble County, Ohio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812303","Putnam County, OH","C109799","No value exists.","Putnam County, OH | OH137 | Putnam County | Putnam County, Ohio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828294","Ross County, OH","C109801","No value exists.","Ross County, OH | OH141 | Ross County | Ross County, Ohio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828256","Sandusky County, OH","C109802","No value exists.","Sandusky County, OH | OH143 | Sandusky County | Sandusky County, Ohio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828214","Scioto County, OH","C109803","No value exists.","Scioto County, OH | OH145 | Scioto County | Scioto County, Ohio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815234","Seneca County, OH","C109804","No value exists.","Seneca County, OH | OH147 | Seneca County | Seneca County, Ohio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815248","Shelby County, OH","C109805","No value exists.","Shelby County, OH | OH149 | Shelby County | Shelby County, Ohio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814832","Summit County, OH","C109807","No value exists.","Summit County, OH | OH153 | Summit County | Summit County, Ohio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827760","Trumbull County, OH","C109808","No value exists.","Trumbull County, OH | OH155 | Trumbull County | Trumbull County, Ohio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827747","Tuscarawas County, OH","C109809","No value exists.","Tuscarawas County, OH | OH157 | Tuscarawas County | Tuscarawas County, Ohio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813238","Union County, OH","C109810","No value exists.","Union County, OH | OH159 | Union County | Union County, Ohio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813687","Panola County, TX","C110393","No value exists.","Panola County, TX | Panola County | Panola County, Texas | TX365",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828661","Parker County, TX","C110394","No value exists.","Parker County, TX | Parker County | Parker County, Texas | TX367",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828660","Parmer County, TX","C110395","No value exists.","Parmer County, TX | Parmer County | Parmer County, Texas | TX369",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828622","Pecos County, TX","C110396","No value exists.","Pecos County, TX | Pecos County | Pecos County, Texas | TX371",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811782","Polk County, TX","C110397","No value exists.","Polk County, TX | Polk County | Polk County, Texas | TX373",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828483","Presidio County, TX","C110399","No value exists.","Presidio County, TX | Presidio County | Presidio County, Texas | TX377",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828413","Rains County, TX","C110400","No value exists.","Rains County, TX | Rains County | Rains County, Texas | TX379",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828374","Randall County, TX","C110401","No value exists.","Randall County, TX | Randall County | Randall County, Texas | TX381",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828363","Real County, TX","C110403","No value exists.","Real County, TX | Real County | Real County, Texas | TX385",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828352","Red River County, TX","C110404","No value exists.","Red River County, TX | Red River County | Red River County, Texas | TX387",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828348","Reeves County, TX","C110405","No value exists.","Reeves County, TX | Reeves County | Reeves County, Texas | TX389",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828347","Refugio County, TX","C110406","No value exists.","Refugio County, TX | Refugio County | Refugio County, Texas | TX391",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813296","Roberts County, TX","C110407","No value exists.","Roberts County, TX | Roberts County | Roberts County, Texas | TX393",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828307","Rockwall County, TX","C110409","No value exists.","Rockwall County, TX | Rockwall County | Rockwall County, Texas | TX397",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829953","Grand Traverse County, MI","C108946","No value exists.","Grand Traverse County, MI | Grand Traverse County | Grand Traverse County, Michigan | MI055",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829947","Gratiot County, MI","C108947","No value exists.","Gratiot County, MI | Gratiot County | Gratiot County, Michigan | MI057",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829695","Hillsdale County, MI","C108948","No value exists.","Hillsdale County, MI | Hillsdale County | Hillsdale County, Michigan | MI059",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814439","Huron County, MI","C108950","No value exists.","Huron County, MI | Huron County | Huron County, Michigan | MI063",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829539","Ingham County, MI","C108951","No value exists.","Ingham County, MI | Ingham County | Ingham County, Michigan | MI065",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829505","Ionia County, MI","C108952","No value exists.","Ionia County, MI | Ionia County | Ionia County, Michigan | MI067",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829504","Iosco County, MI","C108953","No value exists.","Iosco County, MI | Iosco County | Iosco County, Michigan | MI069",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814465","Steuben County, NY","C109566","No value exists.","Steuben County, NY | NY101 | Steuben County | Steuben County, New York",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814824","Suffolk County, NY","C109567","No value exists.","Suffolk County, NY | NY103 | Suffolk County | Suffolk County, New York",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814826","Sullivan County, NY","C109568","No value exists.","Sullivan County, NY | NY105 | Sullivan County | Sullivan County, New York",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815221","Tioga County, NY","C109569","No value exists.","Tioga County, NY | NY107 | Tioga County | Tioga County, New York",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827813","Tompkins County, NY","C109570","No value exists.","Tompkins County, NY | NY109 | Tompkins County | Tompkins County, New York",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812775","Warren County, NY","C109572","No value exists.","Warren County, NY | NY113 | Warren County | Warren County, New York",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813253","Washington County, NY","C109573","No value exists.","Washington County, NY | NY115 | Washington County | Washington County, New York",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831567","Allendale County, SC","C110006","No value exists.","Allendale County, SC | Allendale County | Allendale County, South Carolina | SC005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813130","Anderson County, SC","C110007","No value exists.","Anderson County, SC | Anderson County | Anderson County, South Carolina | SC007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831417","Bamberg County, SC","C110008","No value exists.","Bamberg County, SC | Bamberg County | Bamberg County, South Carolina | SC009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831408","Barnwell County, SC","C110009","No value exists.","Barnwell County, SC | Barnwell County | Barnwell County, South Carolina | SC011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813678","Beaufort County, SC","C110010","No value exists.","Beaufort County, SC | Beaufort County | Beaufort County, South Carolina | SC013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813680","Calhoun County, SC","C110012","No value exists.","Calhoun County, SC | Calhoun County | Calhoun County, South Carolina | SC017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831138","Charleston County, SC","C110013","No value exists.","Charleston County, SC | Charleston County | Charleston County, South Carolina | SC019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813681","Cherokee County, SC","C110014","No value exists.","Cherokee County, SC | Cherokee County | Cherokee County, South Carolina | SC021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813682","Chester County, SC","C110015","No value exists.","Chester County, SC | Chester County | Chester County, South Carolina | SC023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831052","Colleton County, SC","C110018","No value exists.","Colleton County, SC | Colleton County | Colleton County, South Carolina | SC029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830602","Darlington County, SC","C110019","No value exists.","Darlington County, SC | Darlington County | Darlington County, South Carolina | SC031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830482","Dillon County, SC","C110020","No value exists.","Dillon County, SC | Dillon County | Dillon County, South Carolina | SC033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811825","Dorchester County, SC","C110021","No value exists.","Dorchester County, SC | Dorchester County | Dorchester County, South Carolina | SC035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830338","Edgefield County, SC","C110022","No value exists.","Edgefield County, SC | Edgefield County | Edgefield County, South Carolina | SC037",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813567","Florence County, SC","C110024","No value exists.","Florence County, SC | Florence County | Florence County, South Carolina | SC041",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829990","Georgetown County, SC","C110025","No value exists.","Georgetown County, SC | Georgetown County | Georgetown County, South Carolina | SC043",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813269","Knox County, KY","C108741","No value exists.","Knox County, KY | KY121 | Knox County | Knox County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829326","Larue County, KY","C108742","No value exists.","Larue County, KY | KY123 | Larue County | Larue County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829312","Laurel County, KY","C108743","No value exists.","Laurel County, KY | KY125 | Laurel County | Laurel County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813673","Lee County, KY","C108745","No value exists.","Lee County, KY | KY129 | Lee County | Lee County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829296","Leslie County, KY","C108746","No value exists.","Leslie County, KY | KY131 | Leslie County | Leslie County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829294","Letcher County, KY","C108747","No value exists.","Letcher County, KY | KY133 | Letcher County | Letcher County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814079","Lewis County, KY","C108748","No value exists.","Lewis County, KY | KY135 | Lewis County | Lewis County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814096","Lincoln County, KY","C108749","No value exists.","Lincoln County, KY | KY137 | Lincoln County | Lincoln County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815608","Logan County, KY","C108751","No value exists.","Logan County, KY | KY141 | Logan County | Logan County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815625","Lyon County, KY","C108752","No value exists.","Lyon County, KY | KY143 | Lyon County | Lyon County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829162","McCracken County, KY","C108753","No value exists.","McCracken County, KY | KY145 | McCracken County | McCracken County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829161","McCreary County, KY","C108754","No value exists.","McCreary County, KY | KY147 | McCreary County | McCreary County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812236","McLean County, KY","C108755","No value exists.","McLean County, KY | KY149 | McLean County | McLean County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829221","Magoffin County, KY","C108757","No value exists.","Magoffin County, KY | KY153 | Magoffin County | Magoffin County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811172","Marion County, KY","C108758","No value exists.","Marion County, KY | KY155 | Marion County | Marion County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811728","Marshall County, KY","C108759","No value exists.","Marshall County, KY | KY157 | Marshall County | Marshall County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811734","Martin County, KY","C108760","No value exists.","Martin County, KY | KY159 | Martin County | Martin County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815602","Livingston County, MO","C109229","No value exists.","Livingston County, MO | Livingston County | Livingston County, Missouri | MO117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827364","McDonald County, MO","C109230","No value exists.","McDonald County, MO | MO119 | McDonald County | McDonald County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815902","Macon County, MO","C109231","No value exists.","Macon County, MO | MO121 | Macon County | Macon County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815914","Madison County, MO","C109232","No value exists.","Madison County, MO | MO123 | Madison County | Madison County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829198","Maries County, MO","C109233","No value exists.","Maries County, MO | MO125 | Maries County | Maries County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811185","Marion County, MO","C109234","No value exists.","Marion County, MO | MO127 | Marion County | Marion County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810691","Miller County, MO","C109236","No value exists.","Miller County, MO | MO131 | Miller County | Miller County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810699","Mississippi County, MO","C109237","No value exists.","Mississippi County, MO | MO133 | Mississippi County | Mississippi County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827554","Vinton County, OH","C109812","No value exists.","Vinton County, OH | OH163 | Vinton County | Vinton County, Ohio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812778","Warren County, OH","C109813","No value exists.","Warren County, OH | OH165 | Warren County | Warren County, Ohio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813243","Washington County, OH","C109814","No value exists.","Washington County, OH | OH167 | Washington County | Washington County, Ohio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813254","Wayne County, OH","C109815","No value exists.","Wayne County, OH | OH169 | Wayne County | Wayne County, Ohio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810732","Williams County, OH","C109816","No value exists.","Williams County, OH | OH171 | Williams County | Williams County, Ohio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811325","Wyandot County, OH","C109818","No value exists.","Wyandot County, OH | OH175 | Wyandot County | Wyandot County, Ohio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811630","Adair County, OK","C109819","No value exists.","Adair County, OK | Adair County | Adair County, Oklahoma | OK001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813570","Floyd County, TX","C110287","No value exists.","Floyd County, TX | Floyd County | Floyd County, Texas | TX153",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830092","Foard County, TX","C110288","No value exists.","Foard County, TX | Foard County | Foard County, Texas | TX155",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830086","Fort Bend County, TX","C110289","No value exists.","Fort Bend County, TX | Fort Bend County | Fort Bend County, Texas | TX157",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814023","Franklin County, TX","C110290","No value exists.","Franklin County, TX | Franklin County | Franklin County, Texas | TX159",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830078","Freestone County, TX","C110291","No value exists.","Freestone County, TX | Freestone County | Freestone County, Texas | TX161",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830076","Frio County, TX","C110292","No value exists.","Frio County, TX | Frio County | Frio County, Texas | TX163",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830056","Gaines County, TX","C110293","No value exists.","Gaines County, TX | Gaines County | Gaines County, Texas | TX165",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827307","Garza County, TX","C110295","No value exists.","Garza County, TX | Garza County | Garza County, Texas | TX169",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829981","Gillespie County, TX","C110296","No value exists.","Gillespie County, TX | Gillespie County | Gillespie County, Texas | TX171",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829974","Glasscock County, TX","C110297","No value exists.","Glasscock County, TX | Glasscock County | Glasscock County, Texas | TX173",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829968","Goliad County, TX","C110298","No value exists.","Goliad County, TX | Goliad County | Goliad County, Texas | TX175",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829967","Gonzales County, TX","C110299","No value exists.","Gonzales County, TX | Gonzales County | Gonzales County, Texas | TX177",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813988","Gray County, TX","C110300","No value exists.","Gray County, TX | Gray County | Gray County, Texas | TX179",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813991","Grayson County, TX","C110301","No value exists.","Grayson County, TX | Grayson County | Grayson County, Texas | TX181",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829936","Gregg County, TX","C110302","No value exists.","Gregg County, TX | Gregg County | Gregg County, Texas | TX183",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829932","Grimes County, TX","C110303","No value exists.","Grimes County, TX | Grimes County | Grimes County, Texas | TX185",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814796","Guadalupe County, TX","C110304","No value exists.","Guadalupe County, TX | Guadalupe County | Guadalupe County, Texas | TX187",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815144","Hale County, TX","C110305","No value exists.","Hale County, TX | Hale County | Hale County, Texas | TX189",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816176","Iron County, MI","C108954","No value exists.","Iron County, MI | Iron County | Iron County, Michigan | MI071",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816469","Jackson County, MI","C108956","No value exists.","Jackson County, MI | Jackson County | Jackson County, Michigan | MI075",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829440","Kalamazoo County, MI","C108957","No value exists.","Kalamazoo County, MI | Kalamazoo County | Kalamazoo County, Michigan | MI077",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829438","Kalkaska County, MI","C108958","No value exists.","Kalkaska County, MI | Kalkaska County | Kalkaska County, Michigan | MI079",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810793","Kent County, MI","C108959","No value exists.","Kent County, MI | Kent County | Kent County, Michigan | MI081",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829402","Keweenaw County, MI","C108960","No value exists.","Keweenaw County, MI | Keweenaw County | Keweenaw County, Michigan | MI083",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829332","Lapeer County, MI","C108962","No value exists.","Lapeer County, MI | Lapeer County | Lapeer County, Michigan | MI087",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829305","Leelanau County, MI","C108963","No value exists.","Leelanau County, MI | Leelanau County | Leelanau County, Michigan | MI089",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829299","Lenawee County, MI","C108964","No value exists.","Lenawee County, MI | Lenawee County | Lenawee County, Michigan | MI091",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815601","Livingston County, MI","C108965","No value exists.","Livingston County, MI | Livingston County | Livingston County, Michigan | MI093",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829246","Luce County, MI","C108966","No value exists.","Luce County, MI | Luce County | Luce County, Michigan | MI095",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829231","Macomb County, MI","C108968","No value exists.","Macomb County, MI | MI099 | Macomb County | Macomb County, Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829211","Manistee County, MI","C108969","No value exists.","Manistee County, MI | MI101 | Manistee County | Manistee County, Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811190","Marquette County, MI","C108970","No value exists.","Marquette County, MI | MI103 | Marquette County | Marquette County, Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811741","Mason County, MI","C108971","No value exists.","Mason County, MI | MI105 | Mason County | Mason County, Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829142","Mecosta County, MI","C108972","No value exists.","Mecosta County, MI | MI107 | Mecosta County | Mecosta County, Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810687","Midland County, MI","C108974","No value exists.","Midland County, MI | MI111 | Midland County | Midland County, Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829006","Missaukee County, MI","C108975","No value exists.","Missaukee County, MI | MI113 | Missaukee County | Missaukee County, Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810714","Monroe County, MI","C108976","No value exists.","Monroe County, MI | MI115 | Monroe County | Monroe County, Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828969","Montcalm County, MI","C108977","No value exists.","Montcalm County, MI | MI117 | Montcalm County | Montcalm County, Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828966","Montmorency County, MI","C108978","No value exists.","Montmorency County, MI | MI119 | Montmorency County | Montmorency County, Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827472","White Pine County, NV","C109450","No value exists.","White Pine County, NV | NV033 | White Pine County | White Pine County, Nevada",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831374","Belknap County, NH","C109452","No value exists.","Belknap County, NH | Belknap County | Belknap County, New Hampshire | NH001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812359","Carroll County, NH","C109453","No value exists.","Carroll County, NH | Carroll County | Carroll County, New Hampshire | NH003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829938","Greenville County, SC","C110026","No value exists.","Greenville County, SC | Greenville County | Greenville County, South Carolina | SC045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813684","Greenwood County, SC","C110027","No value exists.","Greenwood County, SC | Greenwood County | Greenwood County, South Carolina | SC047",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813685","Jasper County, SC","C110030","No value exists.","Jasper County, SC | Jasper County | Jasper County, South Carolina | SC053",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829405","Kershaw County, SC","C110031","No value exists.","Kershaw County, SC | Kershaw County | Kershaw County, South Carolina | SC055",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813650","Lancaster County, SC","C110032","No value exists.","Lancaster County, SC | Lancaster County | Lancaster County, South Carolina | SC057",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813658","Laurens County, SC","C110033","No value exists.","Laurens County, SC | Laurens County | Laurens County, South Carolina | SC059",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813676","Lee County, SC","C110034","No value exists.","Lee County, SC | Lee County | Lee County, South Carolina | SC061",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829163","McCormick County, SC","C110036","No value exists.","McCormick County, SC | McCormick County | McCormick County, South Carolina | SC065",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827279","Windsor County, VT","C110507","No value exists.","Windsor County, VT | VT027 | Windsor County | Windsor County, Vermont",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831744","Accomack County, VA","C110508","No value exists.","Accomack County, VA | Accomack County | Accomack County, Virginia | VA001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831580","Albemarle County, VA","C110509","No value exists.","Albemarle County, VA | Albemarle County | Albemarle County, Virginia | VA003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831552","Amelia County, VA","C110511","No value exists.","Amelia County, VA | Amelia County | Amelia County, Virginia | VA007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831550","Amherst County, VA","C110512","No value exists.","Amherst County, VA | Amherst County | Amherst County, Virginia | VA009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831504","Appomattox County, VA","C110513","No value exists.","Appomattox County, VA | Appomattox County | Appomattox County, Virginia | VA011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831476","Arlington County, VA","C110514","No value exists.","Arlington County, VA | Arlington County | Arlington County, Virginia | VA013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831449","Augusta County, VA","C110515","No value exists.","Augusta County, VA | Augusta County | Augusta County, Virginia | VA015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816496","Bedford County, VA","C110517","No value exists.","Bedford County, VA | Bedford County | Bedford County, Virginia | VA019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831340","Bland County, VA","C110518","No value exists.","Bland County, VA | Bland County | Bland County, Virginia | VA021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812661","Brunswick County, VA","C110520","No value exists.","Brunswick County, VA | Brunswick County | Brunswick County, Virginia | VA025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831253","Buckingham County, VA","C110522","No value exists.","Buckingham County, VA | Buckingham County | Buckingham County, Virginia | VA029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814387","Campbell County, VA","C110523","No value exists.","Campbell County, VA | Campbell County | Campbell County, Virginia | VA031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828979","Moniteau County, MO","C109238","No value exists.","Moniteau County, MO | MO135 | Moniteau County | Moniteau County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810715","Monroe County, MO","C109239","No value exists.","Monroe County, MO | MO137 | Monroe County | Monroe County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811290","Morgan County, MO","C109241","No value exists.","Morgan County, MO | MO141 | Morgan County | Morgan County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828825","New Madrid County, MO","C109242","No value exists.","New Madrid County, MO | MO143 | New Madrid County | New Madrid County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810594","Newton County, MO","C109243","No value exists.","Newton County, MO | MO145 | Newton County | Newton County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827267","Nodaway County, MO","C109244","No value exists.","Nodaway County, MO | MO147 | Nodaway County | Nodaway County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828698","Oregon County, MO","C109245","No value exists.","Oregon County, MO | MO149 | Oregon County | Oregon County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828677","Ozark County, MO","C109247","No value exists.","Ozark County, MO | MO153 | Ozark County | Ozark County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828616","Pemiscot County, MO","C109248","No value exists.","Pemiscot County, MO | MO155 | Pemiscot County | Pemiscot County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814112","Perry County, MO","C109249","No value exists.","Perry County, MO | MO157 | Perry County | Perry County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828574","Pettis County, MO","C109250","No value exists.","Pettis County, MO | MO159 | Pettis County | Pettis County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814137","Pike County, MO","C109252","No value exists.","Pike County, MO | MO163 | Pike County | Pike County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811217","Platte County, MO","C109253","No value exists.","Platte County, MO | MO165 | Platte County | Platte County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811778","Polk County, MO","C109254","No value exists.","Polk County, MO | MO167 | Polk County | Polk County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812295","Pulaski County, MO","C109255","No value exists.","Pulaski County, MO | MO169 | Pulaski County | Pulaski County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812301","Putnam County, MO","C109256","No value exists.","Putnam County, MO | MO171 | Putnam County | Putnam County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812315","Randolph County, MO","C109258","No value exists.","Randolph County, MO | MO175 | Randolph County | Randolph County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828365","Ray County, MO","C109259","No value exists.","Ray County, MO | MO177 | Ray County | Ray County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829702","Hettinger County, ND","C109698","No value exists.","Hettinger County, ND | Hettinger County | Hettinger County, North Dakota | ND041",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829389","Kidder County, ND","C109699","No value exists.","Kidder County, ND | Kidder County | Kidder County, North Dakota | ND043",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815148","Hall County, TX","C110306","No value exists.","Hall County, TX | Hall County | Hall County, Texas | TX191",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815154","Hamilton County, TX","C110307","No value exists.","Hamilton County, TX | Hamilton County | Hamilton County, Texas | TX193",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829899","Hansford County, TX","C110308","No value exists.","Hansford County, TX | Hansford County | Hansford County, Texas | TX195",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815541","Hardeman County, TX","C110309","No value exists.","Hardeman County, TX | Hardeman County | Hardeman County, Texas | TX197",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815547","Hardin County, TX","C110310","No value exists.","Hardin County, TX | Hardin County | Hardin County, Texas | TX199",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815553","Harris County, TX","C110311","No value exists.","Harris County, TX | Harris County | Harris County, Texas | TX201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815557","Harrison County, TX","C110312","No value exists.","Harrison County, TX | Harrison County | Harrison County, Texas | TX203",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829840","Hartley County, TX","C110313","No value exists.","Hartley County, TX | Hartley County | Hartley County, Texas | TX205",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815563","Haskell County, TX","C110314","No value exists.","Haskell County, TX | Haskell County | Haskell County, Texas | TX207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827859","Tangipahoa Parish, LA","C108853","No value exists.","Tangipahoa Parish, LA | LA105 | Tangipahoa Parish | Tangipahoa Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827846","Tensas Parish, LA","C108854","No value exists.","Tensas Parish, LA | LA107 | Tensas Parish | Tensas Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827841","Terrebonne Parish, LA","C108855","No value exists.","Terrebonne Parish, LA | LA109 | Terrebonne Parish | Terrebonne Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827725","Union Parish, LA","C108856","No value exists.","Union Parish, LA | LA111 | Union Parish | Union Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827650","Vernon Parish, LA","C108858","No value exists.","Vernon Parish, LA | LA115 | Vernon Parish | Vernon Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827506","Washington Parish, LA","C108859","No value exists.","Washington Parish, LA | LA117 | Washington Parish | Washington Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827492","Webster Parish, LA","C108860","No value exists.","Webster Parish, LA | LA119 | Webster Parish | Webster Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827490","West Baton Rouge Parish, LA","C108861","No value exists.","West Baton Rouge Parish, LA | LA121 | West Baton Rouge Parish | West Baton Rouge Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827489","West Carroll Parish, LA","C108862","No value exists.","West Carroll Parish, LA | LA123 | West Carroll Parish | West Carroll Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827455","Winn Parish, LA","C108864","No value exists.","Winn Parish, LA | LA127 | Winn Parish | Winn Parish, Louisiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831539","Androscoggin County, ME","C108865","No value exists.","Androscoggin County, ME | Androscoggin County | Androscoggin County, Maine | ME001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831475","Aroostook County, ME","C108866","No value exists.","Aroostook County, ME | Aroostook County | Aroostook County, Maine | ME003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812372","Cumberland County, ME","C108867","No value exists.","Cumberland County, ME | Cumberland County | Cumberland County, Maine | ME005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814019","Franklin County, ME","C108868","No value exists.","Franklin County, ME | Franklin County | Franklin County, Maine | ME007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815167","Hancock County, ME","C108869","No value exists.","Hancock County, ME | Hancock County | Hancock County, Maine | ME009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827272","Cheshire County, NH","C109454","No value exists.","Cheshire County, NH | Cheshire County | Cheshire County, New Hampshire | NH005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812670","Coos County, NH","C109455","No value exists.","Coos County, NH | Coos County | Coos County, New Hampshire | NH007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829957","Grafton County, NH","C109456","No value exists.","Grafton County, NH | Grafton County | Grafton County, New Hampshire | NH009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827238","Merrimack County, NH","C109458","No value exists.","Merrimack County, NH | Merrimack County | Merrimack County, New Hampshire | NH013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813303","Rockingham County, NH","C109459","No value exists.","Rockingham County, NH | NH015 | Rockingham County | Rockingham County, New Hampshire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827913","Strafford County, NH","C109460","No value exists.","Strafford County, NH | NH017 | Strafford County | Strafford County, New Hampshire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814827","Sullivan County, NH","C109461","No value exists.","Sullivan County, NH | NH019 | Sullivan County | Sullivan County, New Hampshire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL450213","Atlantic County, NJ","C109462","No value exists.","Atlantic County, NJ | Atlantic County | Atlantic County, New Jersey | NJ001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831243","Burlington County, NJ","C109464","No value exists.","Burlington County, NJ | Burlington County | Burlington County, New Jersey | NJ005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812350","Camden County, NJ","C109465","No value exists.","Camden County, NJ | Camden County | Camden County, New Jersey | NJ007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831204","Cape May County, NJ","C109466","No value exists.","Cape May County, NJ | Cape May County | Cape May County, New Jersey | NJ009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813311","Cumberland County, NJ","C109467","No value exists.","Cumberland County, NJ | Cumberland County | Cumberland County, New Jersey | NJ011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811122","Essex County, NJ","C109468","No value exists.","Essex County, NJ | Essex County | Essex County, New Jersey | NJ013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829600","Hudson County, NJ","C109470","No value exists.","Hudson County, NJ | Hudson County | Hudson County, New Jersey | NJ017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829586","Hunterdon County, NJ","C109471","No value exists.","Hunterdon County, NJ | Hunterdon County | Hunterdon County, New Jersey | NJ019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810675","Mercer County, NJ","C109472","No value exists.","Mercer County, NJ | Mercer County | Mercer County, New Jersey | NJ021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810685","Middlesex County, NJ","C109473","No value exists.","Middlesex County, NJ | Middlesex County | Middlesex County, New Jersey | NJ023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828978","Monmouth County, NJ","C109474","No value exists.","Monmouth County, NJ | Monmouth County | Monmouth County, New Jersey | NJ025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828734","Ocean County, NJ","C109476","No value exists.","Ocean County, NJ | NJ029 | Ocean County | Ocean County, New Jersey",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828655","Passaic County, NJ","C109477","No value exists.","Passaic County, NJ | NJ031 | Passaic County | Passaic County, New Jersey",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828273","Salem County, NJ","C109478","No value exists.","Salem County, NJ | NJ033 | Salem County | Salem County, New Jersey",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813221","Somerset County, NJ","C109479","No value exists.","Somerset County, NJ | NJ035 | Somerset County | Somerset County, New Jersey",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815194","Sussex County, NJ","C109480","No value exists.","Sussex County, NJ | NJ037 | Sussex County | Sussex County, New Jersey",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813642","Lake County, OR","C109914","No value exists.","Lake County, OR | Lake County | Lake County, Oregon | OR037",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814779","Caroline County, VA","C110524","No value exists.","Caroline County, VA | Caroline County | Caroline County, Virginia | VA033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815116","Carroll County, VA","C110525","No value exists.","Carroll County, VA | Carroll County | Carroll County, Virginia | VA035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831141","Charles City County, VA","C110526","No value exists.","Charles City County, VA | Charles City County | Charles City County, Virginia | VA036",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814769","Chesterfield County, VA","C110528","No value exists.","Chesterfield County, VA | Chesterfield County | Chesterfield County, Virginia | VA041",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815510","Clarke County, VA","C110529","No value exists.","Clarke County, VA | Clarke County | Clarke County, Virginia | VA043",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813148","Craig County, VA","C110530","No value exists.","Craig County, VA | Craig County | Craig County, Virginia | VA045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827321","Culpeper County, VA","C110531","No value exists.","Culpeper County, VA | Culpeper County | Culpeper County, Virginia | VA047",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813961","Cumberland County, VA","C110532","No value exists.","Cumberland County, VA | Cumberland County | Cumberland County, Virginia | VA049",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830479","Dinwiddie County, VA","C110534","No value exists.","Dinwiddie County, VA | Dinwiddie County | Dinwiddie County, Virginia | VA053",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811125","Essex County, VA","C110535","No value exists.","Essex County, VA | Essex County | Essex County, Virginia | VA057",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830263","Fairfax County, VA","C110536","No value exists.","Fairfax County, VA | Fairfax County | Fairfax County, Virginia | VA059",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454467","Fauquier County, VA","C110537","No value exists.","Fauquier County, VA | Fauquier County | Fauquier County, Virginia | VA061",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813571","Floyd County, VA","C110538","No value exists.","Floyd County, VA | Floyd County | Floyd County, Virginia | VA063",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828031","Sherburne County, MN","C109072","No value exists.","Sherburne County, MN | MN141 | Sherburne County | Sherburne County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828026","Sibley County, MN","C109073","No value exists.","Sibley County, MN | MN143 | Sibley County | Sibley County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827942","Stearns County, MN","C109074","No value exists.","Stearns County, MN | MN145 | Stearns County | Stearns County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814459","Steele County, MN","C109075","No value exists.","Steele County, MN | MN147 | Steele County | Steele County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814468","Stevens County, MN","C109076","No value exists.","Stevens County, MN | MN149 | Stevens County | Stevens County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827877","Swift County, MN","C109077","No value exists.","Swift County, MN | MN151 | Swift County | Swift County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815227","Todd County, MN","C109078","No value exists.","Todd County, MN | MN153 | Todd County | Todd County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827787","Traverse County, MN","C109079","No value exists.","Traverse County, MN | MN155 | Traverse County | Traverse County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827530","Wadena County, MN","C109081","No value exists.","Wadena County, MN | MN159 | Wadena County | Wadena County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827509","Waseca County, MN","C109082","No value exists.","Waseca County, MN | MN161 | Waseca County | Waseca County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813247","Washington County, MN","C109083","No value exists.","Washington County, MN | MN163 | Washington County | Washington County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827500","Watonwan County, MN","C109084","No value exists.","Watonwan County, MN | MN165 | Watonwan County | Watonwan County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829338","LaMoure County, ND","C109700","No value exists.","LaMoure County, ND | LaMoure County | LaMoure County, North Dakota | ND045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815609","Logan County, ND","C109701","No value exists.","Logan County, ND | Logan County | Logan County, North Dakota | ND047",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812231","McHenry County, ND","C109702","No value exists.","McHenry County, ND | McHenry County | McHenry County, North Dakota | ND049",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829155","McKenzie County, ND","C109704","No value exists.","McKenzie County, ND | McKenzie County | McKenzie County, North Dakota | ND053",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812238","McLean County, ND","C109705","No value exists.","McLean County, ND | McLean County | McLean County, North Dakota | ND055",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811301","Morton County, ND","C109707","No value exists.","Morton County, ND | Morton County | Morton County, North Dakota | ND059",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828950","Mountrail County, ND","C109708","No value exists.","Mountrail County, ND | Mountrail County | Mountrail County, North Dakota | ND061",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812329","Nelson County, ND","C109709","No value exists.","Nelson County, ND | ND063 | Nelson County | Nelson County, North Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828712","Oliver County, ND","C109710","No value exists.","Oliver County, ND | ND065 | Oliver County | Oliver County, North Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827239","Pembina County, ND","C109711","No value exists.","Pembina County, ND | ND067 | Pembina County | Pembina County, North Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812309","Ramsey County, ND","C109713","No value exists.","Ramsey County, ND | ND071 | Ramsey County | Ramsey County, North Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828372","Ransom County, ND","C109714","No value exists.","Ransom County, ND | ND073 | Ransom County | Ransom County, North Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812839","Renville County, ND","C109715","No value exists.","Renville County, ND | ND075 | Renville County | Renville County, North Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813283","Richland County, ND","C109716","No value exists.","Richland County, ND | ND077 | Richland County | Richland County, North Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828304","Rolette County, ND","C109717","No value exists.","Rolette County, ND | ND079 | Rolette County | Rolette County, North Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815254","Sheridan County, ND","C109719","No value exists.","Sheridan County, ND | ND083 | Sheridan County | Sheridan County, North Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810613","Sioux County, ND","C109720","No value exists.","Sioux County, ND | ND085 | Sioux County | Sioux County, North Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828002","Slope County, ND","C109721","No value exists.","Slope County, ND | ND087 | Slope County | Slope County, North Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814064","Stark County, ND","C109722","No value exists.","Stark County, ND | ND089 | Stark County | Stark County, North Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814067","Steele County, ND","C109723","No value exists.","Steele County, ND | ND091 | Steele County | Steele County, North Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813270","Knox County, ME","C108871","No value exists.","Knox County, ME | Knox County | Knox County, Maine | ME013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814097","Lincoln County, ME","C108872","No value exists.","Lincoln County, ME | Lincoln County | Lincoln County, Maine | ME015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828679","Oxford County, ME","C108873","No value exists.","Oxford County, ME | ME017 | Oxford County | Oxford County, Maine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828612","Penobscot County, ME","C108874","No value exists.","Penobscot County, ME | ME019 | Penobscot County | Penobscot County, Maine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828549","Piscataquis County, ME","C108875","No value exists.","Piscataquis County, ME | ME021 | Piscataquis County | Piscataquis County, Maine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813219","Somerset County, ME","C108877","No value exists.","Somerset County, ME | ME025 | Somerset County | Somerset County, Maine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827524","Waldo County, ME","C108878","No value exists.","Waldo County, ME | ME027 | Waldo County | Waldo County, Maine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812789","Washington County, ME","C108879","No value exists.","Washington County, ME | ME029 | Washington County | Washington County, Maine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811330","York County, ME","C108880","No value exists.","York County, ME | ME031 | York County | York County, Maine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831534","Anne Arundel County, MD","C108882","No value exists.","Anne Arundel County, MD | Anne Arundel County | Anne Arundel County, Maryland | MD003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831418","Baltimore County, MD","C108883","No value exists.","Baltimore County, MD | Baltimore County | Baltimore County, Maryland | MD005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827298","Calvert County, MD","C108884","No value exists.","Calvert County, MD | Calvert County | Calvert County, Maryland | MD009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813319","Cedar County, NE","C109355","No value exists.","Cedar County, NE | Cedar County | Cedar County, Nebraska | NE027",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812375","Chase County, NE","C109356","No value exists.","Chase County, NE | Chase County | Chase County, Nebraska | NE029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831123","Cherry County, NE","C109357","No value exists.","Cherry County, NE | Cherry County | Cherry County, Nebraska | NE031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812844","Cheyenne County, NE","C109358","No value exists.","Cheyenne County, NE | Cheyenne County | Cheyenne County, Nebraska | NE033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812179","Colfax County, NE","C109360","No value exists.","Colfax County, NE | Colfax County | Colfax County, Nebraska | NE037",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830632","Cuming County, NE","C109361","No value exists.","Cuming County, NE | Cuming County | Cuming County, Nebraska | NE039",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813317","Custer County, NE","C109362","No value exists.","Custer County, NE | Custer County | Custer County, Nebraska | NE041",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814784","Dakota County, NE","C109363","No value exists.","Dakota County, NE | Dakota County | Dakota County, Nebraska | NE043",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827329","Dawes County, NE","C109364","No value exists.","Dawes County, NE | Dawes County | Dawes County, Nebraska | NE045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815537","Deuel County, NE","C109366","No value exists.","Deuel County, NE | Deuel County | Deuel County, Nebraska | NE049",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830414","Dixon County, NE","C109367","No value exists.","Dixon County, NE | Dixon County | Dixon County, Nebraska | NE051",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811822","Dodge County, NE","C109368","No value exists.","Dodge County, NE | Dodge County | Dodge County, Nebraska | NE053",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811832","Douglas County, NE","C109369","No value exists.","Douglas County, NE | Douglas County | Douglas County, Nebraska | NE055",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813653","Lane County, OR","C109915","No value exists.","Lane County, OR | Lane County | Lane County, Oregon | OR039",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815574","Lincoln County, OR","C109916","No value exists.","Lincoln County, OR | Lincoln County | Lincoln County, Oregon | OR041",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815583","Linn County, OR","C109917","No value exists.","Linn County, OR | Linn County | Linn County, Oregon | OR043",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829216","Malheur County, OR","C109918","No value exists.","Malheur County, OR | Malheur County | Malheur County, Oregon | OR045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811299","Morrow County, OR","C109920","No value exists.","Morrow County, OR | Morrow County | Morrow County, Oregon | OR049",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828880","Multnomah County, OR","C109921","No value exists.","Multnomah County, OR | Multnomah County | Multnomah County, Oregon | OR051",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811784","Polk County, OR","C109922","No value exists.","Polk County, OR | OR053 | Polk County | Polk County, Oregon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815258","Sherman County, OR","C109923","No value exists.","Sherman County, OR | OR055 | Sherman County | Sherman County, Oregon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827831","Tillamook County, OR","C109924","No value exists.","Tillamook County, OR | OR057 | Tillamook County | Tillamook County, Oregon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813228","Union County, OR","C109926","No value exists.","Union County, OR | OR061 | Union County | Union County, Oregon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827517","Wallowa County, OR","C109927","No value exists.","Wallowa County, OR | OR063 | Wallowa County | Wallowa County, Oregon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827510","Wasco County, OR","C109928","No value exists.","Wasco County, OR | OR065 | Wasco County | Wasco County, Oregon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813249","Washington County, OR","C109929","No value exists.","Washington County, OR | OR067 | Washington County | Washington County, Oregon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827412","Yamhill County, OR","C109931","No value exists.","Yamhill County, OR | OR071 | Yamhill County | Yamhill County, Oregon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811644","Adams County, PA","C109932","No value exists.","Adams County, PA | Adams County | Adams County, Pennsylvania | PA001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816740","Allegheny County, PA","C109933","No value exists.","Allegheny County, PA | Allegheny County | Allegheny County, Pennsylvania | PA003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3715045","Armstrong County, PA","C109934","No value exists.","Armstrong County, PA | Armstrong County | Armstrong County, Pennsylvania | PA005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811860","Beaver County, PA","C109935","No value exists.","Beaver County, PA | Beaver County | Beaver County, Pennsylvania | PA007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831362","Berks County, PA","C109937","No value exists.","Berks County, PA | Berks County | Berks County, Pennsylvania | PA011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831342","Blair County, PA","C109938","No value exists.","Blair County, PA | Blair County | Blair County, Pennsylvania | PA013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811882","Bradford County, PA","C109939","No value exists.","Bradford County, PA | Bradford County | Bradford County, Pennsylvania | PA015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831252","Bucks County, PA","C109940","No value exists.","Bucks County, PA | Bucks County | Bucks County, Pennsylvania | PA017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812341","Butler County, PA","C109941","No value exists.","Butler County, PA | Butler County | Butler County, Pennsylvania | PA019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812351","Cameron County, PA","C109943","No value exists.","Cameron County, PA | Cameron County | Cameron County, Pennsylvania | PA023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812353","Carbon County, PA","C109944","No value exists.","Carbon County, PA | Carbon County | Carbon County, Pennsylvania | PA025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827463","Wilkin County, MN","C109085","No value exists.","Wilkin County, MN | MN167 | Wilkin County | Wilkin County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810756","Wright County, MN","C109087","No value exists.","Wright County, MN | MN171 | Wright County | Wright County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827404","Yellow Medicine County, MN","C109088","No value exists.","Yellow Medicine County, MN | MN173 | Yellow Medicine County | Yellow Medicine County, Minnesota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811639","Adams County, MS","C109089","No value exists.","Adams County, MS | Adams County | Adams County, Mississippi | MS001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831577","Alcorn County, MS","C109090","No value exists.","Alcorn County, MS | Alcorn County | Alcorn County, Mississippi | MS003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831452","Attala County, MS","C109092","No value exists.","Attala County, MS | Attala County | Attala County, Mississippi | MS007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811865","Benton County, MS","C109093","No value exists.","Benton County, MS | Benton County | Benton County, Mississippi | MS009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831324","Bolivar County, MS","C109094","No value exists.","Bolivar County, MS | Bolivar County | Bolivar County, Mississippi | MS011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812347","Calhoun County, MS","C109095","No value exists.","Calhoun County, MS | Calhoun County | Calhoun County, Mississippi | MS013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812358","Carroll County, MS","C109096","No value exists.","Carroll County, MS | Carroll County | Carroll County, Mississippi | MS015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812848","Choctaw County, MS","C109098","No value exists.","Choctaw County, MS | Choctaw County | Choctaw County, Mississippi | MS019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812851","Claiborne County, MS","C109099","No value exists.","Claiborne County, MS | Claiborne County | Claiborne County, Mississippi | MS021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0059623","Estradiol Valerate","C1090","The parenterally-administered synthetic valerate ester of estradiol, a steroid sex hormone vital to the maintenance of fertility and secondary sexual characteristics in females.  As the primary, most potent estrogen hormone produced by the ovaries, estradiol binds to and activates specific nuclear receptors.  This agent exhibits mild anabolic and metabolic properties, and increases blood coagulability. (NCI04)","Estradiol Valerate | Delestrogen | ESTRADIOL VALERATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812855","Clarke County, MS","C109100","No value exists.","Clarke County, MS | Clarke County | Clarke County, Mississippi | MS023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813257","Wayne County, NY","C109574","No value exists.","Wayne County, NY | NY117 | Wayne County | Wayne County, New York",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827488","Westchester County, NY","C109575","No value exists.","Westchester County, NY | NY119 | Westchester County | Westchester County, New York",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811327","Wyoming County, NY","C109576","No value exists.","Wyoming County, NY | NY121 | Wyoming County | Wyoming County, New York",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827409","Yates County, NY","C109577","No value exists.","Yates County, NY | NY123 | Yates County | Yates County, New York",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831583","Alamance County, NC","C109578","No value exists.","Alamance County, NC | Alamance County | Alamance County, North Carolina | NC001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812634","Alexander County, NC","C109579","No value exists.","Alexander County, NC | Alexander County | Alexander County, North Carolina | NC003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831531","Anson County, NC","C109581","No value exists.","Anson County, NC | Anson County | Anson County, North Carolina | NC007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831467","Ashe County, NC","C109582","No value exists.","Ashe County, NC | Ashe County | Ashe County, North Carolina | NC009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815237","Sevier County, TN","C110193","No value exists.","Sevier County, TN | Sevier County | Sevier County, Tennessee | TN155",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815249","Shelby County, TN","C110194","No value exists.","Shelby County, TN | Shelby County | Shelby County, Tennessee | TN157",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811208","Smith County, TN","C110195","No value exists.","Smith County, TN | Smith County | Smith County, Tennessee | TN159",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814469","Stewart County, TN","C110196","No value exists.","Stewart County, TN | Stewart County | Stewart County, Tennessee | TN161",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814828","Sullivan County, TN","C110197","No value exists.","Sullivan County, TN | Sullivan County | Sullivan County, Tennessee | TN163",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814836","Sumner County, TN","C110198","No value exists.","Sumner County, TN | Sumner County | Sumner County, Tennessee | TN165",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815224","Tipton County, TN","C110199","No value exists.","Tipton County, TN | TN167 | Tipton County | Tipton County, Tennessee",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827763","Trousdale County, TN","C110200","No value exists.","Trousdale County, TN | TN169 | Trousdale County | Trousdale County, Tennessee",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827726","Unicoi County, TN","C110201","No value exists.","Unicoi County, TN | TN171 | Unicoi County | Unicoi County, Tennessee",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813235","Union County, TN","C110202","No value exists.","Union County, TN | TN173 | Union County | Union County, Tennessee",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812786","Warren County, TN","C110204","No value exists.","Warren County, TN | TN177 | Warren County | Warren County, Tennessee",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813242","Washington County, TN","C110205","No value exists.","Washington County, TN | TN179 | Washington County | Washington County, Tennessee",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813256","Wayne County, TN","C110206","No value exists.","Wayne County, TN | TN181 | Wayne County | Wayne County, Tennessee",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827495","Weakley County, TN","C110207","No value exists.","Weakley County, TN | TN183 | Weakley County | Weakley County, Tennessee",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813629","White County, TN","C110208","No value exists.","White County, TN | TN185 | White County | White County, Tennessee",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814071","Williamson County, TN","C110209","No value exists.","Williamson County, TN | TN187 | Williamson County | Williamson County, Tennessee",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814072","Wilson County, TN","C110210","No value exists.","Wilson County, TN | TN189 | Wilson County | Wilson County, Tennessee",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813129","Anderson County, TX","C110211","No value exists.","Anderson County, TX | Anderson County | Anderson County, Texas | TX001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816206","Andrews County, TX","C110212","No value exists.","Andrews County, TX | Andrews County | Andrews County, Texas | TX003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831537","Angelina County, TX","C110213","No value exists.","Angelina County, TX | Angelina County | Angelina County, Texas | TX005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831483","Aransas County, TX","C110214","No value exists.","Aransas County, TX | Aransas County | Aransas County, Texas | TX007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831481","Archer County, TX","C110215","No value exists.","Archer County, TX | Archer County | Archer County, Texas | TX009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3715046","Armstrong County, TX","C110216","No value exists.","Armstrong County, TX | Armstrong County | Armstrong County, Texas | TX011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831461","Atascosa County, TX","C110217","No value exists.","Atascosa County, TX | Atascosa County | Atascosa County, Texas | TX013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812690","Fillmore County, NE","C109371","No value exists.","Fillmore County, NE | Fillmore County | Fillmore County, Nebraska | NE059",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814010","Franklin County, NE","C109372","No value exists.","Franklin County, NE | Franklin County | Franklin County, Nebraska | NE061",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830075","Frontier County, NE","C109373","No value exists.","Frontier County, NE | Frontier County | Frontier County, Nebraska | NE063",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830063","Furnas County, NE","C109374","No value exists.","Furnas County, NE | Furnas County | Furnas County, Nebraska | NE065",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830057","Gage County, NE","C109375","No value exists.","Gage County, NE | Gage County | Gage County, Nebraska | NE067",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814497","Garfield County, NE","C109377","No value exists.","Garfield County, NE | Garfield County | Garfield County, Nebraska | NE071",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829960","Gosper County, NE","C109378","No value exists.","Gosper County, NE | Gosper County | Gosper County, Nebraska | NE073",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813978","Grant County, NE","C109379","No value exists.","Grant County, NE | Grant County | Grant County, Nebraska | NE075",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813993","Greeley County, NE","C109380","No value exists.","Greeley County, NE | Greeley County | Greeley County, Nebraska | NE077",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815151","Hamilton County, NE","C109382","No value exists.","Hamilton County, NE | Hamilton County | Hamilton County, Nebraska | NE081",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815550","Harlan County, NE","C109383","No value exists.","Harlan County, NE | Harlan County | Harlan County, Nebraska | NE083",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829734","Hayes County, NE","C109384","No value exists.","Hayes County, NE | Hayes County | Hayes County, Nebraska | NE085",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829682","Hitchcock County, NE","C109385","No value exists.","Hitchcock County, NE | Hitchcock County | Hitchcock County, Nebraska | NE087",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829668","Hooker County, NE","C109387","No value exists.","Hooker County, NE | Hooker County | Hooker County, Nebraska | NE091",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831573","Alfalfa County, OK","C109820","No value exists.","Alfalfa County, OK | Alfalfa County | Alfalfa County, Oklahoma | OK003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831457","Atoka County, OK","C109821","No value exists.","Atoka County, OK | Atoka County | Atoka County, Oklahoma | OK005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811859","Beaver County, OK","C109822","No value exists.","Beaver County, OK | Beaver County | Beaver County, Oklahoma | OK007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831380","Beckham County, OK","C109823","No value exists.","Beckham County, OK | Beckham County | Beckham County, Oklahoma | OK009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811658","Blaine County, OK","C109824","No value exists.","Blaine County, OK | Blaine County | Blaine County, Oklahoma | OK011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811889","Bryan County, OK","C109825","No value exists.","Bryan County, OK | Bryan County | Bryan County, Oklahoma | OK013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831211","Canadian County, OK","C109827","No value exists.","Canadian County, OK | Canadian County | Canadian County, Oklahoma | OK017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812363","Carter County, OK","C109828","No value exists.","Carter County, OK | Carter County | Carter County, Oklahoma | OK019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812841","Cherokee County, OK","C109829","No value exists.","Cherokee County, OK | Cherokee County | Cherokee County, Oklahoma | OK021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812849","Choctaw County, OK","C109830","No value exists.","Choctaw County, OK | Choctaw County | Choctaw County, Oklahoma | OK023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831152","Centre County, PA","C109945","No value exists.","Centre County, PA | Centre County | Centre County, Pennsylvania | PA027",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812842","Chester County, PA","C109946","No value exists.","Chester County, PA | Chester County | Chester County, Pennsylvania | PA029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827258","Runnels County, TX","C110410","No value exists.","Runnels County, TX | Runnels County | Runnels County, Texas | TX399",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810636","Rusk County, TX","C110411","No value exists.","Rusk County, TX | Rusk County | Rusk County, Texas | TX401",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828263","San Augustine County, TX","C110413","No value exists.","San Augustine County, TX | San Augustine County | San Augustine County, Texas | TX405",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828251","San Jacinto County, TX","C110414","No value exists.","San Jacinto County, TX | San Jacinto County | San Jacinto County, Texas | TX407",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828245","San Patricio County, TX","C110415","No value exists.","San Patricio County, TX | San Patricio County | San Patricio County, Texas | TX409",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828243","San Saba County, TX","C110416","No value exists.","San Saba County, TX | San Saba County | San Saba County, Texas | TX411",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828211","Scurry County, TX","C110418","No value exists.","Scurry County, TX | Scurry County | Scurry County, Texas | TX415",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828040","Shackelford County, TX","C110419","No value exists.","Shackelford County, TX | Shackelford County | Shackelford County, Texas | TX417",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815250","Shelby County, TX","C110420","No value exists.","Shelby County, TX | Shelby County | Shelby County, Texas | TX419",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815259","Sherman County, TX","C110421","No value exists.","Sherman County, TX | Sherman County | Sherman County, Texas | TX421",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811211","Smith County, TX","C110422","No value exists.","Smith County, TX | Smith County | Smith County, Texas | TX423",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827951","Starr County, TX","C110424","No value exists.","Starr County, TX | Starr County | Starr County, Texas | TX427",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814461","Stephens County, TX","C110425","No value exists.","Stephens County, TX | Stephens County | Stephens County, Texas | TX429",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827936","Sterling County, TX","C110426","No value exists.","Sterling County, TX | Sterling County | Sterling County, Texas | TX431",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827917","Stonewall County, TX","C110427","No value exists.","Stonewall County, TX | Stonewall County | Stonewall County, Texas | TX433",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827883","Sutton County, TX","C110428","No value exists.","Sutton County, TX | Sutton County | Sutton County, Texas | TX435",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827856","Tarrant County, TX","C110430","No value exists.","Tarrant County, TX | TX439 | Tarrant County | Tarrant County, Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815205","Taylor County, TX","C110431","No value exists.","Taylor County, TX | TX441 | Taylor County | Taylor County, Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815210","Terrell County, TX","C110432","No value exists.","Terrell County, TX | TX443 | Terrell County | Terrell County, Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827839","Terry County, TX","C110433","No value exists.","Terry County, TX | TX445 | Terry County | Terry County, Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827833","Throckmorton County, TX","C110434","No value exists.","Throckmorton County, TX | TX447 | Throckmorton County | Throckmorton County, Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827814","Tom Green County, TX","C110436","No value exists.","Tom Green County, TX | TX451 | Tom Green County | Tom Green County, Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831430","Avery County, NC","C109583","No value exists.","Avery County, NC | Avery County | Avery County, North Carolina | NC011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811858","Beaufort County, NC","C109584","No value exists.","Beaufort County, NC | Beaufort County | Beaufort County, North Carolina | NC013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831359","Bertie County, NC","C109585","No value exists.","Bertie County, NC | Bertie County | Bertie County, North Carolina | NC015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811888","Brunswick County, NC","C109587","No value exists.","Brunswick County, NC | Brunswick County | Brunswick County, North Carolina | NC019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831247","Buncombe County, NC","C109588","No value exists.","Buncombe County, NC | Buncombe County | Buncombe County, North Carolina | NC021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812336","Burke County, NC","C109589","No value exists.","Burke County, NC | Burke County | Burke County, North Carolina | NC023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831232","Cabarrus County, NC","C109590","No value exists.","Cabarrus County, NC | Cabarrus County | Cabarrus County, North Carolina | NC025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812344","Caldwell County, NC","C109591","No value exists.","Caldwell County, NC | Caldwell County | Caldwell County, North Carolina | NC027",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827250","Carteret County, NC","C109593","No value exists.","Carteret County, NC | Carteret County | Carteret County, North Carolina | NC031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831185","Caswell County, NC","C109594","No value exists.","Caswell County, NC | Caswell County | Caswell County, North Carolina | NC033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827247","Catawba County, NC","C109595","No value exists.","Catawba County, NC | Catawba County | Catawba County, North Carolina | NC035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812376","Chatham County, NC","C109596","No value exists.","Chatham County, NC | Chatham County | Chatham County, North Carolina | NC037",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812840","Cherokee County, NC","C109597","No value exists.","Cherokee County, NC | Cherokee County | Cherokee County, North Carolina | NC039",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812857","Clay County, NC","C109599","No value exists.","Clay County, NC | Clay County | Clay County, North Carolina | NC043",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700599","Pyrimethamine-Sulfadoxine","C1095","A combination product containing pyrimethamine and sulfadoxine.  Pyrimethamine is a competitive inhibitor of dihydrofolate reductase (DHFR).  DHFR is a key enzyme in the redox cycle for production of tetrahydrofolate, a cofactor that is required for the synthesis of DNA and proteins.  Sulfadoxine competitively antagonizes paraaminobenzoic acid (PABA), resulting in disruption of folic acid synthesis and ultimately DNA synthesis. Sulfadoxine acts synergistically with pyrimethamine. (NCI04)","Pyrimethamine-Sulfadoxine | Fansidar | Pyrimethamine Sulfadoxine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811093","Cleveland County, NC","C109600","No value exists.","Cleveland County, NC | Cleveland County | Cleveland County, North Carolina | NC045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831044","Columbus County, NC","C109601","No value exists.","Columbus County, NC | Columbus County | Columbus County, North Carolina | NC047",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811175","Marion County, SC","C110037","No value exists.","Marion County, SC | Marion County | Marion County, South Carolina | SC067",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829193","Marlboro County, SC","C110038","No value exists.","Marlboro County, SC | Marlboro County | Marlboro County, South Carolina | SC069",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828830","Newberry County, SC","C110039","No value exists.","Newberry County, SC | Newberry County | Newberry County, South Carolina | SC071",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812259","Oconee County, SC","C110040","No value exists.","Oconee County, SC | Oconee County | Oconee County, South Carolina | SC073",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828700","Orangeburg County, SC","C110041","No value exists.","Orangeburg County, SC | Orangeburg County | Orangeburg County, South Carolina | SC075",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831446","Austin County, TX","C110218","No value exists.","Austin County, TX | Austin County | Austin County, Texas | TX015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831423","Bailey County, TX","C110219","No value exists.","Bailey County, TX | Bailey County | Bailey County, Texas | TX017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831416","Bandera County, TX","C110220","No value exists.","Bandera County, TX | Bandera County | Bandera County, Texas | TX019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812246","Meade County, KY","C108762","No value exists.","Meade County, KY | KY163 | Meade County | Meade County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829130","Menifee County, KY","C108763","No value exists.","Menifee County, KY | KY165 | Menifee County | Menifee County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810672","Mercer County, KY","C108764","No value exists.","Mercer County, KY | KY167 | Mercer County | Mercer County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829115","Metcalfe County, KY","C108765","No value exists.","Metcalfe County, KY | KY169 | Metcalfe County | Metcalfe County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810713","Monroe County, KY","C108766","No value exists.","Monroe County, KY | KY171 | Monroe County | Monroe County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811289","Morgan County, KY","C108768","No value exists.","Morgan County, KY | KY175 | Morgan County | Morgan County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828883","Muhlenberg County, KY","C108769","No value exists.","Muhlenberg County, KY | KY177 | Muhlenberg County | Muhlenberg County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812328","Nelson County, KY","C108770","No value exists.","Nelson County, KY | KY179 | Nelson County | Nelson County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810602","Nicholas County, KY","C108771","No value exists.","Nicholas County, KY | KY181 | Nicholas County | Nicholas County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812733","Ohio County, KY","C108772","No value exists.","Ohio County, KY | KY183 | Ohio County | Ohio County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812735","Oldham County, KY","C108773","No value exists.","Oldham County, KY | KY185 | Oldham County | Oldham County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828681","Owsley County, KY","C108775","No value exists.","Owsley County, KY | KY189 | Owsley County | Owsley County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814111","Perry County, KY","C108777","No value exists.","Perry County, KY | KY193 | Perry County | Perry County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814136","Pike County, KY","C108778","No value exists.","Pike County, KY | KY195 | Pike County | Pike County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812294","Pulaski County, KY","C108780","No value exists.","Pulaski County, KY | KY199 | Pulaski County | Pulaski County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813297","Robertson County, KY","C108781","No value exists.","Robertson County, KY | KY201 | Robertson County | Robertson County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828311","Rockcastle County, KY","C108782","No value exists.","Rockcastle County, KY | KY203 | Rockcastle County | Rockcastle County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813308","Rowan County, KY","C108783","No value exists.","Rowan County, KY | KY205 | Rowan County | Rowan County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810638","Russell County, KY","C108784","No value exists.","Russell County, KY | KY207 | Russell County | Russell County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815246","Shelby County, KY","C108786","No value exists.","Shelby County, KY | KY211 | Shelby County | Shelby County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815262","Simpson County, KY","C108787","No value exists.","Simpson County, KY | KY213 | Simpson County | Simpson County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831101","Cimarron County, OK","C109831","No value exists.","Cimarron County, OK | Cimarron County | Cimarron County, Oklahoma | OK025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831068","Coal County, OK","C109833","No value exists.","Coal County, OK | Coal County | Coal County, Oklahoma | OK029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812191","Comanche County, OK","C109834","No value exists.","Comanche County, OK | Comanche County | Comanche County, Oklahoma | OK031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830998","Cotton County, OK","C109835","No value exists.","Cotton County, OK | Cotton County | Cotton County, Oklahoma | OK033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812860","Craig County, OK","C109836","No value exists.","Craig County, OK | Craig County | Craig County, Oklahoma | OK035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830982","Creek County, OK","C109837","No value exists.","Creek County, OK | Creek County | Creek County, Oklahoma | OK037",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815521","Delaware County, OK","C109839","No value exists.","Delaware County, OK | Delaware County | Delaware County, Oklahoma | OK041",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815538","Dewey County, OK","C109840","No value exists.","Dewey County, OK | Dewey County | Dewey County, Oklahoma | OK043",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812831","Ellis County, OK","C109841","No value exists.","Ellis County, OK | Ellis County | Ellis County, Oklahoma | OK045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814498","Garfield County, OK","C109842","No value exists.","Garfield County, OK | Garfield County | Garfield County, Oklahoma | OK047",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813967","Grady County, OK","C109844","No value exists.","Grady County, OK | Grady County | Grady County, Oklahoma | OK051",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813973","Grant County, OK","C109845","No value exists.","Grant County, OK | Grant County | Grant County, Oklahoma | OK053",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829937","Greer County, OK","C109846","No value exists.","Greer County, OK | Greer County | Greer County, Oklahoma | OK055",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829845","Harmon County, OK","C109847","No value exists.","Harmon County, OK | Harmon County | Harmon County, Oklahoma | OK057",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815552","Harper County, OK","C109848","No value exists.","Harper County, OK | Harper County | Harper County, Oklahoma | OK059",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814034","Hughes County, OK","C109850","No value exists.","Hughes County, OK | Hughes County | Hughes County, Oklahoma | OK063",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816467","Jackson County, OK","C109851","No value exists.","Jackson County, OK | Jackson County | Jackson County, Oklahoma | OK065",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810777","Jefferson County, OK","C109852","No value exists.","Jefferson County, OK | Jefferson County | Jefferson County, Oklahoma | OK067",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829733","Hays County, TX","C110315","No value exists.","Hays County, TX | Hays County | Hays County, Texas | TX209",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829716","Hemphill County, TX","C110316","No value exists.","Hemphill County, TX | Hemphill County | Hemphill County, Texas | TX211",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811707","Hidalgo County, TX","C110318","No value exists.","Hidalgo County, TX | Hidalgo County | Hidalgo County, Texas | TX215",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811715","Hill County, TX","C110319","No value exists.","Hill County, TX | Hill County | Hill County, Texas | TX217",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829677","Hockley County, TX","C110320","No value exists.","Hockley County, TX | Hockley County | Hockley County, Texas | TX219",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827234","Hood County, TX","C110321","No value exists.","Hood County, TX | Hood County | Hood County, Texas | TX221",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812705","Hopkins County, TX","C110322","No value exists.","Hopkins County, TX | Hopkins County | Hopkins County, Texas | TX223",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827786","Travis County, TX","C110437","No value exists.","Travis County, TX | TX453 | Travis County | Travis County, Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810664","Trinity County, TX","C110438","No value exists.","Trinity County, TX | TX455 | Trinity County | Trinity County, Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811812","Tyler County, TX","C110439","No value exists.","Tyler County, TX | TX457 | Tyler County | Tyler County, Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813240","Upshur County, TX","C110440","No value exists.","Upshur County, TX | TX459 | Upshur County | Upshur County, Texas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828877","Muskegon County, MI","C108979","No value exists.","Muskegon County, MI | MI121 | Muskegon County | Muskegon County, Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281620","leuprolide/tamoxifen","C10897","A regimen consisting of leuprolide and tamoxifen that may be used in the treatment of breast cancer.","Leuprolide/Tamoxifen Regimen | LEUP/TMX | Leuprolide-Tamoxifen | Leuprolide-Tamoxifen Regimen | Leuprolide/Tamoxifen | Tamoxifen/Leuprolide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828831","Newaygo County, MI","C108980","No value exists.","Newaygo County, MI | MI123 | Newaygo County | Newaygo County, Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827222","Oakland County, MI","C108981","No value exists.","Oakland County, MI | MI125 | Oakland County | Oakland County, Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828735","Oceana County, MI","C108982","No value exists.","Oceana County, MI | MI127 | Oceana County | Oceana County, Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828702","Ontonagon County, MI","C108984","No value exists.","Ontonagon County, MI | MI131 | Ontonagon County | Ontonagon County, Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812813","Osceola County, MI","C108985","No value exists.","Osceola County, MI | MI133 | Osceola County | Osceola County, Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828694","Oscoda County, MI","C108986","No value exists.","Oscoda County, MI | MI135 | Oscoda County | Oscoda County, Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812816","Otsego County, MI","C108987","No value exists.","Otsego County, MI | MI137 | Otsego County | Otsego County, Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828482","Presque Isle County, MI","C108989","No value exists.","Presque Isle County, MI | MI141 | Presque Isle County | Presque Isle County, Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828298","Roscommon County, MI","C108990","No value exists.","Roscommon County, MI | MI143 | Roscommon County | Roscommon County, Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828278","Saginaw County, MI","C108991","No value exists.","Saginaw County, MI | MI145 | Saginaw County | Saginaw County, Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814051","St. Clair County, MI","C108992","No value exists.","St. Clair County, MI | MI147 | St. Clair County | St. Clair County, Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814054","St. Joseph County, MI","C108993","No value exists.","St. Joseph County, MI | MI149 | St. Joseph County | St. Joseph County, Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828216","Schoolcraft County, MI","C108995","No value exists.","Schoolcraft County, MI | MI153 | Schoolcraft County | Schoolcraft County, Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828030","Shiawassee County, MI","C108996","No value exists.","Shiawassee County, MI | MI155 | Shiawassee County | Shiawassee County, Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827746","Tuscola County, MI","C108997","No value exists.","Tuscola County, MI | MI157 | Tuscola County | Tuscola County, Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811344","Van Buren County, MI","C108998","No value exists.","Van Buren County, MI | MI159 | Van Buren County | Van Buren County, Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827503","Washtenaw County, MI","C108999","No value exists.","Washtenaw County, MI | MI161 | Washtenaw County | Washtenaw County, Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813285","Richland County, SC","C110043","No value exists.","Richland County, SC | Richland County | Richland County, South Carolina | SC079",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828268","Saluda County, SC","C110044","No value exists.","Saluda County, SC | SC081 | Saluda County | Saluda County, South Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827965","Spartanburg County, SC","C110045","No value exists.","Spartanburg County, SC | SC083 | Spartanburg County | Spartanburg County, South Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814838","Sumter County, SC","C110046","No value exists.","Sumter County, SC | SC085 | Sumter County | Sumter County, South Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813232","Union County, SC","C110047","No value exists.","Union County, SC | SC087 | Union County | Union County, South Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811319","York County, SC","C110049","No value exists.","York County, SC | SC091 | York County | York County, South Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831447","Aurora County, SD","C110050","No value exists.","Aurora County, SD | Aurora County | Aurora County, South Dakota | SD003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831384","Beadle County, SD","C110051","No value exists.","Beadle County, SD | Beadle County | Beadle County, South Dakota | SD005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831368","Bennett County, SD","C110052","No value exists.","Bennett County, SD | Bennett County | Bennett County, South Dakota | SD007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831320","Bon Homme County, SD","C110053","No value exists.","Bon Homme County, SD | Bon Homme County | Bon Homme County, South Dakota | SD009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812656","Brown County, SD","C110055","No value exists.","Brown County, SD | Brown County | Brown County, South Dakota | SD013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831254","Brule County, SD","C110056","No value exists.","Brule County, SD | Brule County | Brule County, South Dakota | SD015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813137","Buffalo County, SD","C110057","No value exists.","Buffalo County, SD | Buffalo County | Buffalo County, South Dakota | SD017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813141","Butte County, SD","C110058","No value exists.","Butte County, SD | Butte County | Butte County, South Dakota | SD019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814389","Campbell County, SD","C110059","No value exists.","Campbell County, SD | Campbell County | Campbell County, South Dakota | SD021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831139","Charles Mix County, SD","C110060","No value exists.","Charles Mix County, SD | Charles Mix County | Charles Mix County, South Dakota | SD023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814853","Clay County, SD","C110062","No value exists.","Clay County, SD | Clay County | Clay County, South Dakota | SD027",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831059","Codington County, SD","C110063","No value exists.","Codington County, SD | Codington County | Codington County, South Dakota | SD029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831005","Corson County, SD","C110064","No value exists.","Corson County, SD | Corson County | Corson County, South Dakota | SD031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813964","Custer County, SD","C110065","No value exists.","Custer County, SD | Custer County | Custer County, South Dakota | SD033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830597","Day County, SD","C110067","No value exists.","Day County, SD | Day County | Day County, South Dakota | SD037",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815536","Deuel County, SD","C110068","No value exists.","Deuel County, SD | Deuel County | Deuel County, South Dakota | SD039",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830094","Fluvanna County, VA","C110539","No value exists.","Fluvanna County, VA | Fluvanna County | Fluvanna County, Virginia | VA065",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814011","Franklin County, VA","C110540","No value exists.","Franklin County, VA | Franklin County | Franklin County, Virginia | VA067",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813602","Spencer County, KY","C108788","No value exists.","Spencer County, KY | KY215 | Spencer County | Spencer County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815204","Taylor County, KY","C108789","No value exists.","Taylor County, KY | KY217 | Taylor County | Taylor County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827770","Trigg County, KY","C108791","No value exists.","Trigg County, KY | KY221 | Trigg County | Trigg County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827769","Trimble County, KY","C108792","No value exists.","Trimble County, KY | KY223 | Trimble County | Trimble County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813237","Union County, KY","C108793","No value exists.","Union County, KY | KY225 | Union County | Union County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812782","Warren County, KY","C108794","No value exists.","Warren County, KY | KY227 | Warren County | Warren County, Kentucky",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828334","Reynolds County, MO","C109260","No value exists.","Reynolds County, MO | MO179 | Reynolds County | Reynolds County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813292","Ripley County, MO","C109261","No value exists.","Ripley County, MO | MO181 | Ripley County | Ripley County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814050","St. Clair County, MO","C109263","No value exists.","St. Clair County, MO | MO185 | St. Clair County | St. Clair County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827941","Ste. Genevieve County, MO","C109264","No value exists.","Ste. Genevieve County, MO | MO186 | Ste. Genevieve County | Ste. Genevieve County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827935","St. Francois County, MO","C109265","No value exists.","St. Francois County, MO | MO187 | St. Francois County | St. Francois County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814057","St. Louis County, MO","C109266","No value exists.","St. Louis County, MO | MO189 | St. Louis County | St. Louis County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811223","Saline County, MO","C109267","No value exists.","Saline County, MO | MO195 | Saline County | Saline County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811793","Schuyler County, MO","C109268","No value exists.","Schuyler County, MO | MO197 | Schuyler County | Schuyler County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811799","Scott County, MO","C109270","No value exists.","Scott County, MO | MO201 | Scott County | Scott County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815241","Shannon County, MO","C109271","No value exists.","Shannon County, MO | MO203 | Shannon County | Shannon County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815247","Shelby County, MO","C109272","No value exists.","Shelby County, MO | MO205 | Shelby County | Shelby County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827919","Stoddard County, MO","C109273","No value exists.","Stoddard County, MO | MO207 | Stoddard County | Stoddard County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827860","Taney County, MO","C109276","No value exists.","Taney County, MO | MO213 | Taney County | Taney County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815214","Texas County, MO","C109277","No value exists.","Texas County, MO | MO215 | Texas County | Texas County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811345","Vernon County, MO","C109278","No value exists.","Vernon County, MO | MO217 | Vernon County | Vernon County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812785","Warren County, MO","C109279","No value exists.","Warren County, MO | MO219 | Warren County | Warren County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813262","Wayne County, MO","C109281","No value exists.","Wayne County, MO | MO223 | Wayne County | Wayne County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813617","Webster County, MO","C109282","No value exists.","Webster County, MO | MO225 | Webster County | Webster County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813170","Howard County, TX","C110324","No value exists.","Howard County, TX | Howard County | Howard County, Texas | TX227",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829599","Hudspeth County, TX","C110325","No value exists.","Hudspeth County, TX | Hudspeth County | Hudspeth County, Texas | TX229",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829587","Hunt County, TX","C110326","No value exists.","Hunt County, TX | Hunt County | Hunt County, Texas | TX231",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814442","Hutchinson County, TX","C110327","No value exists.","Hutchinson County, TX | Hutchinson County | Hutchinson County, Texas | TX233",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829480","Jack County, TX","C110329","No value exists.","Jack County, TX | Jack County | Jack County, Texas | TX237",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816208","Jackson County, TX","C110330","No value exists.","Jackson County, TX | Jackson County | Jackson County, Texas | TX239",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816209","Jasper County, TX","C110331","No value exists.","Jasper County, TX | Jasper County | Jasper County, Texas | TX241",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816210","Jeff Davis County, TX","C110332","No value exists.","Jeff Davis County, TX | Jeff Davis County | Jeff Davis County, Texas | TX243",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816211","Jefferson County, TX","C110333","No value exists.","Jefferson County, TX | Jefferson County | Jefferson County, Texas | TX245",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829453","Jim Wells County, TX","C110335","No value exists.","Jim Wells County, TX | Jim Wells County | Jim Wells County, Texas | TX249",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816212","Johnson County, TX","C110336","No value exists.","Johnson County, TX | Johnson County | Johnson County, Texas | TX251",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816213","Jones County, TX","C110337","No value exists.","Jones County, TX | Jones County | Jones County, Texas | TX253",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829433","Karnes County, TX","C110338","No value exists.","Karnes County, TX | Karnes County | Karnes County, Texas | TX255",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829420","Kaufman County, TX","C110339","No value exists.","Kaufman County, TX | Kaufman County | Kaufman County, Texas | TX257",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829413","Kenedy County, TX","C110341","No value exists.","Kenedy County, TX | Kenedy County | Kenedy County, Texas | TX261",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811157","Kent County, TX","C110342","No value exists.","Kent County, TX | Kent County | Kent County, Texas | TX263",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829406","Kerr County, TX","C110343","No value exists.","Kerr County, TX | Kerr County | Kerr County, Texas | TX265",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829387","Kimble County, TX","C110344","No value exists.","Kimble County, TX | Kimble County | Kimble County, Texas | TX267",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816214","King County, TX","C110345","No value exists.","King County, TX | King County | King County, Texas | TX269",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829371","Kleberg County, TX","C110347","No value exists.","Kleberg County, TX | Kleberg County | Kleberg County, Texas | TX273",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813275","Knox County, TX","C110348","No value exists.","Knox County, TX | Knox County | Knox County, Texas | TX275",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812354","Caroline County, MD","C108885","No value exists.","Caroline County, MD | Caroline County | Caroline County, Maryland | MD011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812356","Carroll County, MD","C108886","No value exists.","Carroll County, MD | Carroll County | Carroll County, Maryland | MD013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831140","Charles County, MD","C108888","No value exists.","Charles County, MD | Charles County | Charles County, Maryland | MD017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811824","Dorchester County, MD","C108889","No value exists.","Dorchester County, MD | Dorchester County | Dorchester County, Maryland | MD019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813265","Wayne County, MI","C109000","No value exists.","Wayne County, MI | MI163 | Wayne County | Wayne County, Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827482","Wexford County, MI","C109001","No value exists.","Wexford County, MI | MI165 | Wexford County | Wexford County, Michigan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827205","Aitkin County, MN","C109002","No value exists.","Aitkin County, MN | Aitkin County | Aitkin County, Minnesota | MN001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831532","Anoka County, MN","C109003","No value exists.","Anoka County, MN | Anoka County | Anoka County, Minnesota | MN003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831381","Becker County, MN","C109004","No value exists.","Becker County, MN | Becker County | Becker County, Minnesota | MN005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831372","Beltrami County, MN","C109005","No value exists.","Beltrami County, MN | Beltrami County | Beltrami County, Minnesota | MN007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811863","Benton County, MN","C109006","No value exists.","Benton County, MN | Benton County | Benton County, Minnesota | MN009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831353","Big Stone County, MN","C109007","No value exists.","Big Stone County, MN | Big Stone County | Big Stone County, Minnesota | MN011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813234","Union County, NJ","C109481","No value exists.","Union County, NJ | NJ039 | Union County | Union County, New Jersey",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812777","Warren County, NJ","C109482","No value exists.","Warren County, NJ | NJ041 | Warren County | Warren County, New Jersey",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831360","Bernalillo County, NM","C109483","No value exists.","Bernalillo County, NM | Bernalillo County | Bernalillo County, New Mexico | NM001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831179","Catron County, NM","C109484","No value exists.","Catron County, NM | Catron County | Catron County, New Mexico | NM003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831132","Chaves County, NM","C109485","No value exists.","Chaves County, NM | Chaves County | Chaves County, New Mexico | NM005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831103","Cibola County, NM","C109486","No value exists.","Cibola County, NM | Cibola County | Cibola County, New Mexico | NM006",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813313","Curry County, NM","C109488","No value exists.","Curry County, NM | Curry County | Curry County, New Mexico | NM009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830551","De Baca County, NM","C109489","No value exists.","De Baca County, NM | De Baca County | De Baca County, New Mexico | NM011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830407","Dona Ana County, NM","C109490","No value exists.","Dona Ana County, NM | Dona Ana County | Dona Ana County, New Mexico | NM013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811838","Eddy County, NM","C109491","No value exists.","Eddy County, NM | Eddy County | Eddy County, New Mexico | NM015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814797","Guadalupe County, NM","C109493","No value exists.","Guadalupe County, NM | Guadalupe County | Guadalupe County, New Mexico | NM019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811334","Harding County, NM","C109494","No value exists.","Harding County, NM | Harding County | Harding County, New Mexico | NM021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811708","Hidalgo County, NM","C109495","No value exists.","Hidalgo County, NM | Hidalgo County | Hidalgo County, New Mexico | NM023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829309","Lea County, NM","C109496","No value exists.","Lea County, NM | Lea County | Lea County, New Mexico | NM025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815200","Lincoln County, NM","C109497","No value exists.","Lincoln County, NM | Lincoln County | Lincoln County, New Mexico | NM027",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829244","Luna County, NM","C109499","No value exists.","Luna County, NM | Luna County | Luna County, New Mexico | NM029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814028","Frederick County, VA","C110541","No value exists.","Frederick County, VA | Frederick County | Frederick County, Virginia | VA069",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814843","Gloucester County, VA","C110543","No value exists.","Gloucester County, VA | Gloucester County | Gloucester County, Virginia | VA073",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829966","Goochland County, VA","C110544","No value exists.","Goochland County, VA | Goochland County | Goochland County, Virginia | VA075",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813990","Grayson County, VA","C110545","No value exists.","Grayson County, VA | Grayson County | Grayson County, Virginia | VA077",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814398","Greene County, VA","C110546","No value exists.","Greene County, VA | Greene County | Greene County, Virginia | VA079",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829940","Greensville County, VA","C110547","No value exists.","Greensville County, VA | Greensville County | Greensville County, Virginia | VA081",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829900","Hanover County, VA","C110549","No value exists.","Hanover County, VA | Hanover County | Hanover County, Virginia | VA085",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829711","Henrico County, VA","C110550","No value exists.","Henrico County, VA | Henrico County | Henrico County, Virginia | VA087",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811141","Henry County, VA","C110551","No value exists.","Henry County, VA | Henry County | Henry County, Virginia | VA089",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811712","Highland County, VA","C110552","No value exists.","Highland County, VA | Highland County | Highland County, Virginia | VA091",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829494","Isle of Wight County, VA","C110553","No value exists.","Isle of Wight County, VA | Isle of Wight County | Isle of Wight County, Virginia | VA093",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829385","King and Queen County, VA","C110555","No value exists.","King and Queen County, VA | King and Queen County | King and Queen County, Virginia | VA097",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829383","King George County, VA","C110556","No value exists.","King George County, VA | King George County | King George County, Virginia | VA099",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829380","King William County, VA","C110557","No value exists.","King William County, VA | King William County | King William County, Virginia | VA101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813651","Lancaster County, VA","C110558","No value exists.","Lancaster County, VA | Lancaster County | Lancaster County, Virginia | VA103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814075","Lee County, VA","C110559","No value exists.","Lee County, VA | Lee County | Lee County, Virginia | VA105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815615","Louisa County, VA","C110561","No value exists.","Louisa County, VA | Louisa County | Louisa County, Virginia | VA109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829243","Lunenburg County, VA","C110562","No value exists.","Lunenburg County, VA | Lunenburg County | Lunenburg County, Virginia | VA111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815923","Madison County, VA","C110563","No value exists.","Madison County, VA | Madison County | Madison County, Virginia | VA113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827365","Mathews County, VA","C110564","No value exists.","Mathews County, VA | Mathews County | Mathews County, Virginia | VA115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810686","Middlesex County, VA","C110566","No value exists.","Middlesex County, VA | Middlesex County | Middlesex County, Virginia | VA119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811280","Montgomery County, VA","C110567","No value exists.","Montgomery County, VA | Montgomery County | Montgomery County, Virginia | VA121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812330","Nelson County, VA","C110568","No value exists.","Nelson County, VA | Nelson County | Nelson County, Virginia | VA125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828827","New Kent County, VA","C110569","No value exists.","New Kent County, VA | New Kent County | New Kent County, Virginia | VA127",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811322","Worth County, MO","C109283","No value exists.","Worth County, MO | MO227 | Worth County | Worth County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811324","Wright County, MO","C109284","No value exists.","Wright County, MO | MO229 | Wright County | Wright County, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827924","St. Louis City, MO","C109285","No value exists.","St. Louis City, MO | MO510 | St. Louis City | St. Louis City, Missouri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811651","Big Horn County, MT","C109287","No value exists.","Big Horn County, MT | Big Horn County | Big Horn County, Montana | MT003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811657","Blaine County, MT","C109288","No value exists.","Blaine County, MT | Blaine County | Blaine County, Montana | MT005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831260","Broadwater County, MT","C109289","No value exists.","Broadwater County, MT | Broadwater County | Broadwater County, Montana | MT007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812352","Carbon County, MT","C109290","No value exists.","Carbon County, MT | Carbon County | Carbon County, Montana | MT009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812362","Carter County, MT","C109291","No value exists.","Carter County, MT | Carter County | Carter County, Montana | MT011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827798","Towner County, ND","C109725","No value exists.","Towner County, ND | ND095 | Towner County | Towner County, North Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827795","Traill County, ND","C109726","No value exists.","Traill County, ND | ND097 | Traill County | Traill County, North Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827516","Walsh County, ND","C109727","No value exists.","Walsh County, ND | ND099 | Walsh County | Walsh County, North Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812773","Ward County, ND","C109728","No value exists.","Ward County, ND | ND101 | Ward County | Ward County, North Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813623","Wells County, ND","C109729","No value exists.","Wells County, ND | ND103 | Wells County | Wells County, North Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810731","Williams County, ND","C109730","No value exists.","Williams County, ND | ND105 | Williams County | Williams County, North Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811636","Adams County, OH","C109731","No value exists.","Adams County, OH | Adams County | Adams County, Ohio | OH001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811383","Ashland County, OH","C109733","No value exists.","Ashland County, OH | Ashland County | Ashland County, Ohio | OH005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831465","Ashtabula County, OH","C109734","No value exists.","Ashtabula County, OH | Ashtabula County | Ashtabula County, Ohio | OH007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827218","Athens County, OH","C109735","No value exists.","Athens County, OH | Athens County | Athens County, Ohio | OH009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831450","Auglaize County, OH","C109736","No value exists.","Auglaize County, OH | Auglaize County | Auglaize County, Ohio | OH011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811887","Brown County, OH","C109738","No value exists.","Brown County, OH | Brown County | Brown County, Ohio | OH015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812360","Carroll County, OH","C109740","No value exists.","Carroll County, OH | Carroll County | Carroll County, Ohio | OH019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812374","Champaign County, OH","C109741","No value exists.","Champaign County, OH | Champaign County | Champaign County, Ohio | OH021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812854","Clark County, OH","C109742","No value exists.","Clark County, OH | Clark County | Clark County, Ohio | OH023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811104","Clinton County, OH","C109744","No value exists.","Clinton County, OH | Clinton County | Clinton County, Ohio | OH027",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3715025","TNFSF13 wt Allele","C105968","Human TNFSF13 wild-type allele is located in the vicinity of 17p13.1 and is approximately 3 kb in length. This allele, which encodes tumor necrosis factor ligand superfamily member 13 protein, plays a role in the regulation of both B cell development and apoptosis.","TNFSF13 wt Allele | APRIL | CD256 | TALL-2 | TALL2 | TRDL-1 | Tumor Necrosis Factor (Ligand) Family, Member 13A Gene | Tumor Necrosis Factor (Ligand) Superfamily, Member 13 wt Allele | Tumor Necrosis Factor Ligand Superfamily, Member 13 Gene | Tumor Necrosis Factor Ligand Superfamily, Member 13A Gene | ZTNF2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831377","Bedford City, VA","C110604","No value exists.","Bedford City, VA | Bedford City | Bedford City, Virginia | VA515",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831261","Bristol City, VA","C110605","No value exists.","Bristol City, VA | Bristol City | Bristol City, Virginia | VA520",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831136","Charlottesville City, VA","C110607","No value exists.","Charlottesville City, VA | Charlottesville City | Charlottesville City, Virginia | VA540",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831122","Chesapeake City, VA","C110608","No value exists.","Chesapeake City, VA | Chesapeake City | Chesapeake City, Virginia | VA550",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831048","Colonial Heights City, VA","C110609","No value exists.","Colonial Heights City, VA | Colonial Heights City | Colonial Heights City, Virginia | VA570",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830993","Covington City, VA","C110610","No value exists.","Covington City, VA | Covington City | Covington City, Virginia | VA580",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830605","Danville City, VA","C110611","No value exists.","Danville City, VA | Danville City | Danville City, Virginia | VA590",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830264","Fairfax City, VA","C110613","No value exists.","Fairfax City, VA | Fairfax City | Fairfax City, Virginia | VA600",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830259","Falls Church City, VA","C110614","No value exists.","Falls Church City, VA | Falls Church City | Falls Church City, Virginia | VA610",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830081","Franklin City, VA","C110615","No value exists.","Franklin City, VA | Franklin City | Franklin City, Virginia | VA620",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830079","Fredericksburg City, VA","C110616","No value exists.","Fredericksburg City, VA | Fredericksburg City | Fredericksburg City, Virginia | VA630",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829905","Hampton City, VA","C110618","No value exists.","Hampton City, VA | Hampton City | Hampton City, Virginia | VA650",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829842","Harrisonburg City, VA","C110619","No value exists.","Harrisonburg City, VA | Harrisonburg City | Harrisonburg City, Virginia | VA660",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829666","Hopewell City, VA","C110620","No value exists.","Hopewell City, VA | Hopewell City | Hopewell City, Virginia | VA670",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829289","Lexington City, VA","C110621","No value exists.","Lexington City, VA | Lexington City | Lexington City, Virginia | VA678",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829235","Lynchburg City, VA","C110622","No value exists.","Lynchburg City, VA | Lynchburg City | Lynchburg City, Virginia | VA680",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829214","Manassas Park City, VA","C110624","No value exists.","Manassas Park City, VA | Manassas Park City | Manassas Park City, Virginia | VA685",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829189","Martinsville City, VA","C110625","No value exists.","Martinsville City, VA | Martinsville City | Martinsville City, Virginia | VA690",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828823","Newport News City, VA","C110626","No value exists.","Newport News City, VA | Newport News City | Newport News City, Virginia | VA700",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828790","Norfolk City, VA","C110627","No value exists.","Norfolk City, VA | Norfolk City | Norfolk City, Virginia | VA710",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811315","Wayne County, MS","C109165","No value exists.","Wayne County, MS | MS153 | Wayne County | Wayne County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813615","Webster County, MS","C109166","No value exists.","Webster County, MS | MS155 | Webster County | Webster County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810730","Wilkinson County, MS","C109167","No value exists.","Wilkinson County, MS | MS157 | Wilkinson County | Wilkinson County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827413","Yalobusha County, MS","C109169","No value exists.","Yalobusha County, MS | MS161 | Yalobusha County | Yalobusha County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541335","TPI1 wt Allele","C105558","Human TPI1 wild-type allele is located in the vicinity of 12p13.31 and is approximately 4 kb in length. This allele, which encodes triosephosphate isomerase protein, is involved in the isomerization of both glyceraldehyde 3-phosphate (G3P) and dihydroxy-acetone phosphate (DHAP) in both glycolysis and gluconeogenesis. Mutations in this gene are associated with triosephosphate isomerase deficiency.","TPI1 wt Allele | TIM | TPI | Triosephosphate Isomerase 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814143","POLI wt Allele","C106238","Human POLI wild-type allele is located in the vicinity of 18q21.1 and is approximately 52 kb in length. This allele, which encodes DNA polymerase iota protein, is involved in DNA repair.","POLI wt Allele | Polymerase (DNA Directed) Iota wt Allele | Polymerase, DNA, Iota Gene | RAD30, S. cerevisiae, Homolog of, B Gene | RAD30B | RAD3OB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0961834","DNA Polymerase Iota","C106239","DNA polymerase iota (740 aa, ~83 kDa) is encoded by the human POLI gene. This protein plays a role in the repair of DNA damage during DNA replication.","DNA Polymerase Iota | EC 2.7.7.7 | Eta2 | POLI | RAD30 Homolog B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811786","POLK wt Allele","C106241","Human POLK wild-type allele is located in the vicinity of 5q13 and is approximately 89 kb in length. This allele, which encodes DNA polymerase kappa protein, plays a role in the repair of DNA damage during DNA replication.","POLK wt Allele | DINB1 | DINP | POLQ | Polymerase (DNA Directed) Kappa wt Allele | Polymerase (DNA-Directed) Kappa Gene | Polymerase, DNA, Kappa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1620161","BGN protein, human","C105840","Biglycan (368 aa, ~42 kDa) is encoded by the human BGN gene. This protein plays a role in connective tissue structure.","Biglycan | BGN | Biglycan Proteoglycan | Bone/Cartilage Proteoglycan I | Bone/Cartilage Proteoglycan-I | Dermatan Sulphate Proteoglycan I | PG-S1 | Proteoglycan-I | Small Leucine-Rich Protein 1A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810539","EFNB2 wt Allele","C105842","Human EFNB2 wild-type allele is located in the vicinity of 13q33 and is approximately 45 kb in length. This allele, which encodes ephrin-B2 protein, plays a role in intercellular signal transduction.","EFNB2 wt Allele | EPLG5 | Ephrin-B2 wt Allele | HTKL | Htk-L | LERK5 | MGC126226 | MGC126227 | MGC126228 | RP11-272L14.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0386040","EFNB2 protein, human","C105843","Ephrin-B2 (333 aa, ~37 kDa) is encoded by the human EFNB2 gene. This protein is involved in cell-cell communication.","Ephrin-B2 | EFNB2 | EPH-Related Receptor Tyrosine Kinase Ligand 5 | HTK Ligand | HTK-L | LERK-5 | Ligand of Eph-Related Kinase 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830411","DNase-Seq","C106052","A molecular genetic technique where genome-wide sequencing is performed on DNA regions that are super sensitive to cleavage by DNase I to identify putative DNA regulatory sequences.","DNase-Seq | DNase I Hypersensitive Sites Sequencing | DNase-Hypersensitivity (sequencing of hypersensitive sites or segments of open chromatin that are more readily cleaved by DNaseI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828807","NOMe-Seq","C106053","A DNA sequencing technique that can both determine DNA methylation status and distinguish non-nucleosomal DNA from nucleosome-associated DNA. This technique subjects samples to both bisulfite treatment to modify unmethylated cytosines and GpC methyltransferase treatment to identify non-nucleosomal DNA regions. The treated samples are then analyzed using next-generation sequencing techniques.","NOMe-Seq | NOME-Seq | Nucleosome Occupancy and Methylome Sequencing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829112","Methylome","C106057","The characterization of all of the nucleic acid methylation modifications in a particular cell or in the genome of an organism.","Methylome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538633","PHF20 Gene","C106058","This gene plays a role in both histone acetylation and transcriptional regulation.","PHF20 Gene | PHD Finger Protein 20 Gene | PHF20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810549","PHF20 wt Allele","C106059","Human PHF20 wild-type allele is located within 20q11.22-q11.23 and is approximately 178 kb in length. This allele, which encodes PHD finger protein 20, is involved in transcriptional regulation and histone acetylation.","PHF20 wt Allele | C20orf104 | Chromosome 20 Open Reading Frame 104 Gene | GLEA2 | HCA58 | NZF | PHD Finger Protein 20 wt Allele | RP5-1121G12.1 | TZP | dJ1121G12.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1448193","PHD Finger Protein 20, Human","C106060","PHD finger protein 20 (1012 aa, ~115 kDa) is encoded by the human PHF20 gene. This protein plays a role in the acetylation of histones and transcriptional regulation.","PHD Finger Protein 20 | Glioma-Expressed Antigen 2 | Hepatocellular Carcinoma-Associated Antigen 58 | Novel Zinc Finger Protein | PHF20 | Transcription Factor TZP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539755","ZMYND8 wt Allele","C105609","Human ZMYND8 wild-type allele is located in the vicinity of 20q13.12 and is approximately 148 kb in length. This allele, which encodes protein kinase C-binding protein 1, is involved in the function of protein kinase C. The encoded protein is also a cutaneous T-cell lymphoma-associated antigen.","ZMYND8 wt Allele | KIAA1125 | PRKCBP1 | PRO2893 | RACK7 | Zinc Finger, MYND-Type Containing 8 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1309710","Protein Kinase C-Binding Protein 1","C105610","Protein kinase C-binding protein 1 (1186 aa, ~132 kDa) is encoded by the human ZMYND8 gene. This protein plays a role in protein kinase C function and may be a transcriptional regulator.","Protein Kinase C-Binding Protein 1 | CTCL Tumor Antigen se14-3 | CTCL-Associated Antigen se14-3 | Cutaneous T-Cell Lymphoma Associated Antigen se14-3 | Cutaneous T-Cell Lymphoma-Associated Antigen se14-3 | Predicted Protein of HQ2893 | Protein Kinase C Binding Protein 1 | ZMYND8 | Zinc Finger MYND Domain Containing Protein 8 | Zinc Finger MYND Domain-Containing Protein 8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446448","Copper Cu 62 Ethylglyoxal Bis(thiosemicarbazone)","C105611","A radiopharmaceutical composed of the nonspecific perfusion agent ethylglyoxal bis(thiosemicarbazone) (ETS) linked to the beta-emitting, radioisotope copper Cu 62, with potential tumor imaging activity upon positron emitting tomography (PET). Upon injection, copper Cu 62-ETS distributes to various organs, especially the kidneys and the myocardium. Upon PET imaging, tumor blood flow can be visualized and the efficacy of antineoplastic and anti-angiogenic chemotherapeutics can be assessed. Cu62-ETS has a short half life of 9.74 minutes. ETS has an enhanced hyperemic response compared to other perfusion agents.","Copper Cu 62 Ethylglyoxal Bis(thiosemicarbazone) | 62Cu-ETS | 62Cu-Ethylglyoxal Bis | 62Cu-Ethylglyoxal Bis(thiosemicarbazone)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446449","EGFR inhibitor ABT-414","C105612","An epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon intravenous infusion, depatuxizumab mafodotin inhibits the activity of EGFR, thereby preventing EGFR-mediated signaling. This may inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase overexpressed in certain tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","Depatuxizumab Mafodotin | ABT-414 | DEPATUXIZUMAB MAFODOTIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813566","RAD9B wt Allele","C106281","Human RAD9B wild-type allele is located in the vicinity of 12q24.11 and is approximately 30 kb in length. This allele, which encodes cell cycle checkpoint control protein RAD9B, plays a role in DNA repair-dependent cell cycle checkpoint control.","RAD9B wt Allele | FLJ40346 | RAD9 Homolog B (S. pombe) wt Allele | RAD9, S. pombe, Homolog of, B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815185","Cell Cycle Checkpoint Control Protein RAD9B","C106282","Cell cycle checkpoint control protein RAD9B (426 aa, ~48 kDa) is encoded by the human RAD9B gene. This protein is involved in the modulation of both cell cycle progression and DNA repair.","Cell Cycle Checkpoint Control Protein RAD9B | Cell Cycle Checkpoint Control Protein RAD9B Homolog | DNA Repair Exonuclease rad9 Homolog B | RAD9B | hRAD9B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814867","REV1 wt Allele","C106284","Human REV1 wild-type allele is located within 2q11.1-q11.2 and is approximately 90 kb in length. This allele, which encodes DNA repair protein REV1, is involved in the repair of replicating DNA.","REV1 wt Allele | REV1 (Yeast Homolog)- Like Gene | REV1 (Yeast Homolog)-Like Gene | REV1 Homolog (S. cerevisiae) Gene | REV1, Polymerase (DNA Directed) wt Allele | REV1, S. cerevisiae, Homolog of Gene | REV1-Like (Yeast) Gene | REV1L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813122","DNA Repair Protein REV1","C106285","DNA repair protein REV1 (1251 aa, ~138 kDa) is encoded by the human REV1 gene. This protein plays a role in translesion DNA synthesis.","DNA Repair Protein REV1 | AIBP80 | Alpha Integrin-Binding Protein 80 | Alpha-Integrin-Binding Protein 80 | EC 2.7.7.- | REV1 | REV1 Homolog | REV1- Like | REV1-Like | Rev1-Like Terminal Deoxycytidyl Transferase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827406","Yazoo County, MS","C109170","No value exists.","Yazoo County, MS | MS163 | Yazoo County | Yazoo County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811633","Adair County, MO","C109171","No value exists.","Adair County, MO | Adair County | Adair County, Missouri | MO001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811381","Andrew County, MO","C109172","No value exists.","Andrew County, MO | Andrew County | Andrew County, Missouri | MO003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811384","Atchison County, MO","C109173","No value exists.","Atchison County, MO | Atchison County | Atchison County, Missouri | MO005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811855","Barry County, MO","C109175","No value exists.","Barry County, MO | Barry County | Barry County, Missouri | MO009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811856","Barton County, MO","C109176","No value exists.","Barton County, MO | Barton County | Barton County, Missouri | MO011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831397","Bates County, MO","C109177","No value exists.","Bates County, MO | Bates County | Bates County, Missouri | MO013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811864","Benton County, MO","C109178","No value exists.","Benton County, MO | Benton County | Benton County, Missouri | MO015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831323","Bollinger County, MO","C109179","No value exists.","Bollinger County, MO | Bollinger County | Bollinger County, Missouri | MO017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811890","Buchanan County, MO","C109181","No value exists.","Buchanan County, MO | Buchanan County | Buchanan County, Missouri | MO021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812338","Butler County, MO","C109182","No value exists.","Butler County, MO | Butler County | Butler County, Missouri | MO023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812343","Caldwell County, MO","C109183","No value exists.","Caldwell County, MO | Caldwell County | Caldwell County, Missouri | MO025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831221","Callaway County, MO","C109184","No value exists.","Callaway County, MO | Callaway County | Callaway County, Missouri | MO027",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831205","Cape Girardeau County, MO","C109186","No value exists.","Cape Girardeau County, MO | Cape Girardeau County | Cape Girardeau County, Missouri | MO031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812357","Carroll County, MO","C109187","No value exists.","Carroll County, MO | Carroll County | Carroll County, Missouri | MO033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812361","Carter County, MO","C109188","No value exists.","Carter County, MO | Carter County | Carter County, Missouri | MO035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812366","Cass County, MO","C109189","No value exists.","Cass County, MO | Cass County | Cass County, Missouri | MO037",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813706","Cedar County, MO","C109190","No value exists.","Cedar County, MO | Cedar County | Cedar County, Missouri | MO039",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812850","Christian County, MO","C109192","No value exists.","Christian County, MO | Christian County | Christian County, Missouri | MO043",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812852","Clark County, MO","C109193","No value exists.","Clark County, MO | Clark County | Clark County, Missouri | MO045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812856","Clay County, MO","C109194","No value exists.","Clay County, MO | Clay County | Clay County, Missouri | MO047",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811098","Clinton County, MO","C109195","No value exists.","Clinton County, MO | Clinton County | Clinton County, Missouri | MO049",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812859","Cole County, MO","C109196","No value exists.","Cole County, MO | Cole County | Cole County, Missouri | MO051",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815903","Macon County, NC","C109634","No value exists.","Macon County, NC | Macon County | Macon County, North Carolina | NC113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815917","Madison County, NC","C109635","No value exists.","Madison County, NC | Madison County | Madison County, North Carolina | NC115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811736","Martin County, NC","C109636","No value exists.","Martin County, NC | Martin County | Martin County, North Carolina | NC117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447413","Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201","C106242","A genetically-modified, dendritic cell-based (DCs) vaccine in which the autologous cells are transduced with an adenoviral vector expressing the tumor antigen prostate-specific membrane antigen (PSMA) and a fusion protein composed of synthetic ligand inducible adjuvant iMC composed of a drug-inducible costimulatory CD40 receptor (iCD40) and the adaptor protein MyD88, with potential immunomodulating and antineoplastic activities. The iCD40 contains a membrane-localized cytoplasmic CD40 domain fused to the FK506 modified drug-binding protein 12 (FKBP12). Upon intradermal administration of BPX-201, these DCs accumulate in local draining lymph nodes. Twenty-four hours after vaccination, the dimerizing agent AP1903 is administered. AP1903 binds to the drug binding domain, leading to iMC oligomerization and activation of iCD40 and MyD88-mediated signaling in iMC-expressing DCs. This signaling pathway activates the DCs and stimulates a cytotoxic T-lymphocyte (CTL) response against host tumor cells that express PSMA. PSMA, a glycoprotein secreted by prostatic epithelial and ductal cells, is overexpressed in prostate cancer cells and is used as a tumor marker for both diagnosis and treatment evaluation. MyD88 is involved in interleukin 1 receptor (IL1R) and toll-like receptor (TLR) signaling.","Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201 | Adenovector-transduced AP1903-inducible iMC-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201 | BPX-201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811773","DNA Polymerase Kappa, Human","C106243","DNA polymerase kappa (870 aa, ~99 kDa) is encoded by the human POLK gene. This protein is involved in DNA damage repair.","DNA Polymerase Kappa | DINB Protein | DINP | EC 2.7.7.7 | POLK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814525","RAD18 wt Allele","C106245","Human RAD18 wild-type allele is located within 3p25-p24 and is approximately 188 kb in length. This allele, which encodes E3 ubiquitin-protein ligase RAD18 protein, is involved in both repair of UV-damaged DNA and protein ubiquitination.","RAD18 wt Allele | RAD18 Homolog (S. cerevisiae) wt Allele | RAD18, S. cerevisiae, Homolog Gene | RNF73",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1434353","E3 Ubiquitin-Protein Ligase RAD18, Human","C106246","E3 ubiquitin-protein ligase RAD18 (495 aa, ~56 kDa) is encoded by the human RAD18 gene. This protein plays a role in both ubiquitination and postreplication repair of UV-damaged DNA.","E3 Ubiquitin-Protein Ligase RAD18 | EC 2.3.2.27 | EC 6.3.2.-, Formerly | Postreplication Repair Protein RAD18 | RAD18 | RING Finger Protein 73 | hHR18 | hRAD18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447416","Autologous CD19-28z Chimeric Antigen Receptor-expressing T-lymphocytes","C106247","Genetically modified autologous T-lymphocytes transduced with a replication incompetent retroviral vector expressing a chimeric T cell antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment), fused to the extracellular, transmembrane and intracellular signaling domains of the T cell co-stimulatory receptor CD28 and the cytoplasmic signaling domain of the zeta chain of the TCR/CD3 complex (CD3-zeta) (CAR19-28z), with potential antineoplastic activities. Upon intravenous administration, autologous CD19-28z CAR-expressing T-lymphocytes are directed to CD19-expressing tumor cells, which induces selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. The CD28 co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19. The inclusion of the CD28 signaling domain may increase proliferation of T-cells and antitumor activity compared to the inclusion of the CD3-zeta chain alone.","Autologous CD19-28z Chimeric Antigen Receptor-expressing T-lymphocytes | CAR 19-28z T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425629","NEK9 Gene","C106061","This gene is involved in protein phosphorylation and cell division.","NEK9 Gene | NEK9 | NIMA (Never In Mitosis Gene A)-Related Kinase 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814037","NEK9 wt Allele","C106062","Human NEK9 wild-type allele is located in the vicinity of 14q24.3 and is approximately 45 kb in length. This allele, which encodes serine/threonine-protein kinase Nek9 protein, plays a role in the modulation of protein phosphorylation, mitosis and cell division.","NEK9 wt Allele | DKFZp434D0935 | MGC16714 | NERCC | NERCC1 | NIMA (Never In Mitosis Gene A)-Related Kinase 9 wt Allele | Nek8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1138216","NEK9 protein, human","C106063","Serine/threonine-protein kinase Nek9 (979 aa, ~107 kDa) is encoded by the human NEK9 gene. This protein is involved in the progression of mitosis and the mediation of protein phosphorylation.","Serine/Threonine-Protein Kinase Nek9 | EC 2.7.11.1 | NIMA-Related Kinase Nek8 | Nek8 | Nercc1 Kinase | NimA-Related Kinase 8 | NimA-Related Protein Kinase 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827966","SPARCL1 wt Allele","C106065","Human SPARCL1 wild-type allele is located in the vicinity of 4q22.1 and is approximately 58 kb in length. This allele, which encodes SPARC-like protein 1, may play a role in both endothelium structure and leukocyte migration.","SPARCL1 wt Allele | MAST 9 | MAST9 | PIG33 | SC1 | SPARC-Like 1 (Hevin) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1608638","SPARC-Like Protein 1, Human","C106066","SPARC-like protein 1 (664 aa, ~75 kDa) is encoded by the human SPARCL1 gene. This protein may be involved in both leukocyte extravasation and endothelial cell-cell adhesion.","SPARC-Like Protein 1 | Hevin | High Endothelial Venule Protein | MAST 9 | Mast9 | Proliferation-Inducing Protein 33",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538798","WNK1 wt Allele","C105603","Human WNK1 wild-type allele is located in the vicinity of 12p13.3 and is approximately 159 kb in length. This allele, which encodes serine/threonine-protein kinase WNK1 protein, is involved in regulation of blood pressure by controlling the transport of both sodium and chloride ions. Mutations in this gene are associated with both pseudohypoaldosteronism type II and hereditary sensory neuropathy type II.","WNK1 wt Allele | HSAN2 | HSN2 | Hereditary Sensory Neuropathy, Type II Gene | KDP | KIAA0344 | PHA2C | PPP1R167 | PRKWNK1 | PSK | Protein Kinase, Lysine Deficient 1 Gene | Protein Kinase, Lysine-Deficient 1 | Protein Phosphatase 1, Regulatory Subunit 167 Gene | WNK Lysine Deficient Protein Kinase 1 wt Allele | hWNK1 | p65",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1453853","Serine/Threonine-Protein Kinase WNK1, Human","C105604","Serine/threonine-protein kinase WNK1 (2382 aa, ~251 kDa) is encoded by the human WNK1 gene. This protein plays a role in controling sodium and chloride ion transport.","Serine/Threonine-Protein Kinase WNK1 | EC 2.7.11.1 | Erythrocyte 65 kDa Protein | Hereditary Sensory Neuropathy, Type I | Kinase Deficient Protein | Prostate-Derived Sterile 20-Like Kinase | Protein Kinase Lysine-Deficient 1 | Protein Kinase with No Lysine 1 | Protein Kinase, Lysine Deficient 1 | WNK Lysine Deficient Protein Kinase 1 Isoform | WNK1 | hWNK1 | p65",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538848","ZEB1 wt Allele","C105606","Human ZEB1 wild-type allele is located in the vicinity of 10p11.2 and is approximately 214 kb in length. This allele, which encodes zinc finger E-box-binding homeobox 1 protein, plays a role in the transcriptional repression of interleukin-2 gene expression. Mutations in this gene are associated with both posterior polymorphous corneal dystrophy-3 and late-onset Fuchs endothelial corneal dystrophy.","ZEB1 wt Allele | AREB6 | BZP | DELTAEF1 | FECD6 | NIL-2-A | NIL2A | PPCD3 | Posterior Polymorphous Corneal Dystrophy 3 Gene | T-Lymphocyte-Specific Interleukin 2 Inhibitor Gene | TCF-8 | TCF8 | Transcription Factor 8 (Represses Interleukin 2 Expression) Gene | ZEB | ZFHEP | ZFHX1A | Zinc Finger E-Box Binding Homeobox 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3537279","Zinc Finger E-Box-Binding Homeobox 1, Human","C105607","Zinc finger E-box-binding homeobox 1 (1124 aa, ~124 kDa) is encoded by the human ZEB1 gene. This protein is involved in both the transcriptional repression of interleukin 2 and the positive regulation of neuronal differentiation.","Zinc Finger E-Box-Binding Homeobox 1 | Delta-Crystallin Enhancer Binding Factor 1 | NIL-2-A Zinc Finger Protein | Negative Regulator of IL2 | Posterior Polymorphous Corneal Dystrophy 3 | TCF-8 | Transcription Factor 8 | Transcription Factor 8 (Represses Interleukin 2 Expression) | ZEB1 | Zinc Finger Homeodomain Enhancer-Binding Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811169","NPRL3 wt Allele","C106287","Human NPRL3 wild-type allele is located in the vicinity of 16p13.3 and is approximately 55 kb in length. This allele, which encodes nitrogen permease regulator 3-like protein, has no known function.","NPRL3 wt Allele | C16orf35 | CGTHBA | Chromosome 16 Open Reading Frame 35 Gene | Conserved Gene Telomeric to Alpha Globin Cluster Gene | HS-40 | MARE | NPR3 | Nitrogen Permease Regulator-Like 3 (S. cerevisiae) wt Allele | RMD11 | Z69666.1-003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811759","Nitrogen Permease Regulator 3-Like Protein","C106288","GATOR complex protein NPRL3 (569 aa, ~64 kDa) is encoded by the human NPRL3 gene. This protein has no known function.","GATOR Complex Protein NPRL3 | -14 Gene Protein | Alpha-Globin Regulatory Element-Containing Gene Protein | NPRL3 | Nitrogen Permease Regulator 3-Like Protein | Protein CGTHBA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811212","SUMO1 wt Allele","C106290","Human SUMO1 wild-type allele is located in the vicinity of 2q33 and is approximately 32 kb in length. This allele, which encodes small ubiquitin-related modifier 1 protein, is involved in the post-translational modification of proteins.","SUMO1 wt Allele | DAP1 | GMP1 | OFC10 | OK/SW-cl.43 | PIC1 | SENP2 | SMT3 | SMT3 Suppressor of Mif Two 3 Homolog 1 (S. cerevisiae) wt Allele | SMT3 Suppressor of Mif Two 3 Homolog 1 (Yeast) Gene | SMT3C | SMT3H3 | UBL1 | Ubiquitin-Like 1 (Sentrin) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1564958","SUMO1 protein, human","C106291","Small ubiquitin-related modifier 1 (101 aa, ~12 kDa) is encoded by the human SUMO1 gene. This protein plays a role in post-translational protein modification.","Small Ubiquitin-Related Modifier 1 | GAP Modifying Protein 1 | GAP-Modifying Protein 1 | GMP1 | SMT3 Homolog 3 | SUMO-1 | SUMO1 | Sentrin | Smt3C | Ubiquitin-Homology Domain Protein PIC1 | Ubiquitin-Like Protein SMT3C | Ubiquitin-Like Protein UBL1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815225","TNP1 wt Allele","C106293","Human TNP1 wild-type allele is located within 2q35-q36 and is approximately 1 kb in length. This allele, which encodes spermatid nuclear transition protein 1, plays a role in sperm morphology.","TNP1 wt Allele | TP1 | Transition Protein 1 (During Histone to Protamine Replacement) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814151","GADD45B wt Allele","C105845","Human GADD45B wild-type allele is located in the vicinity of 19p13.3 and is approximately 2 kb in length. This allele, which encodes growth arrest and DNA damage-inducible protein GADD45 beta, is involved in the modulation of apoptosis, signaling and cell growth.","GADD45B wt Allele | DKFZP566B133 | GADD45BETA | Growth Arrest and DNA-Damage-Inducible, Beta wt Allele | MYD118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814411","Growth Arrest and DNA Damage-Inducible Protein GADD45 Beta, Human","C105846","Growth arrest and DNA damage-inducible protein GADD45 beta (160 aa, ~18 kDa) is encoded by the human GADD45B gene. This protein plays a role in the regulation of cell growth, apoptosis and signaling.","Growth Arrest and DNA Damage-Inducible Protein GADD45 Beta | GADD45B | Growth Arrest and DNA-Damage-Inducible Beta | Myeloid Differentiation Primary Response Protein MyD118 | Negative Growth Regulatory Protein MyD118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813576","MAD2L1 wt Allele","C105848","Human MAD2L1 wild-type allele is located in the vicinity of 4q27 and is approximately 8 kb in length. This allele, which encodes mitotic spindle assembly checkpoint protein MAD2A, plays a role in the regulation of mitotic progression.","MAD2L1 wt Allele | HSMAD2 | MAD2 | MAD2 Mitotic Arrest Deficient-Like 1 (Yeast) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812249","Mecklenburg County, NC","C109637","No value exists.","Mecklenburg County, NC | Mecklenburg County | Mecklenburg County, North Carolina | NC119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811281","Moore County, NC","C109640","No value exists.","Moore County, NC | Moore County | Moore County, North Carolina | NC125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828860","Nash County, NC","C109641","No value exists.","Nash County, NC | NC127 | Nash County | Nash County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828829","New Hanover County, NC","C109642","No value exists.","New Hanover County, NC | NC129 | New Hanover County | New Hanover County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811203","Northampton County, NC","C109643","No value exists.","Northampton County, NC | NC131 | Northampton County | Northampton County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812745","Orange County, NC","C109645","No value exists.","Orange County, NC | NC135 | Orange County | Orange County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828663","Pamlico County, NC","C109646","No value exists.","Pamlico County, NC | NC137 | Pamlico County | Pamlico County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828656","Pasquotank County, NC","C109647","No value exists.","Pasquotank County, NC | NC139 | Pasquotank County | Pasquotank County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828615","Pender County, NC","C109648","No value exists.","Pender County, NC | NC141 | Pender County | Pender County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828579","Perquimans County, NC","C109649","No value exists.","Perquimans County, NC | NC143 | Perquimans County | Perquimans County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828547","Pitt County, NC","C109651","No value exists.","Pitt County, NC | NC147 | Pitt County | Pitt County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811785","Polk County, NC","C109652","No value exists.","Polk County, NC | NC149 | Polk County | Polk County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812316","Randolph County, NC","C109653","No value exists.","Randolph County, NC | NC151 | Randolph County | Randolph County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813289","Richmond County, NC","C109654","No value exists.","Richmond County, NC | NC153 | Richmond County | Richmond County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828315","Robeson County, NC","C109655","No value exists.","Robeson County, NC | NC155 | Robeson County | Robeson County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813309","Rowan County, NC","C109657","No value exists.","Rowan County, NC | NC159 | Rowan County | Rowan County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810641","Rutherford County, NC","C109658","No value exists.","Rutherford County, NC | NC161 | Rutherford County | Rutherford County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828264","Sampson County, NC","C109659","No value exists.","Sampson County, NC | NC163 | Sampson County | Sampson County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811794","Scotland County, NC","C109660","No value exists.","Scotland County, NC | NC165 | Scotland County | Scotland County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827953","Stanly County, NC","C109661","No value exists.","Stanly County, NC | NC167 | Stanly County | Stanly County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815189","Surry County, NC","C109663","No value exists.","Surry County, NC | NC171 | Surry County | Surry County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827881","Swain County, NC","C109664","No value exists.","Swain County, NC | NC173 | Swain County | Swain County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827788","Transylvania County, NC","C109665","No value exists.","Transylvania County, NC | NC175 | Transylvania County | Transylvania County, North Carolina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447155","anti-MMP-9 monoclonal antibody GS-5745","C105803","A humanized monoclonal antibody against matrix metalloproteinase 9 (MMP-9), with potential antineoplastic activity. Upon administration, andecaliximab binds to MMP-9 and inhibits its enzymatic activity. This results in an inhibition of extracellular matrix protein degradation and, potentially, the inhibition of angiogenesis, tumor growth, invasion, and metastasis. MMP-9, a protein belonging to the MMP family, plays a key role in the degradation of collagens and proteoglycans; increased activity of MMP-9 has been associated with increased invasion and metastasis of cancer.","Andecaliximab | ANDECALIXIMAB | GS-5745",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830093","Fms/Trk Tyrosine Kinase Inhibitor PLX7486 Tosylate","C105804","The tosylate salt form of PLX7486, a selective inhibitor of the receptor tyrosine kinases colony-stimulating factor-1 receptor (CSF1R; fms) and neurotrophic tyrosine kinase receptor types 1, 2 and 3 (TrkA, TrkB, and TrkC, respectively) with potential antineoplastic activity. Upon administration, PLX7486 binds to and inhibits the activity of these tyrosine kinases. This inhibits Fms and Trk-mediated signaling transduction pathways that are upregulated in certain cancer cell types. This may eventually halt tumor cell proliferation in Fms and TrkA, TrkB, and/or TrkC-overexpressing tumor cells. Fms and TrkA, TrkB, and TrkC are receptor tyrosine kinases that are upregulated or mutated in a variety of tumors and promote tumor cell proliferation and survival.","Fms/Trk Tyrosine Kinase Inhibitor PLX7486 Tosylate | PLX7486-TsOH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447157","Anti-CD19 Monoclonal Antibody DI-B4","C105805","A low-fucosylated, humanized, IgG1 isotype, monoclonal antibody directed against the B-cell-specific membrane protein CD19 with potential immunostimulating and antineoplastic activities. Anti-CD19 monoclonal antibody DI-B4 binds to CD19, which may result in a strong antibody-dependent cellular cytotoxicity (ADCC) directed at CD19-expressing B-cells but with minimal complement dependent cytotoxicity. DI-B4 contains low levels of fucose, which contributes to its enhanced ADCC activity. CD19 is a B-cell specific membrane antigen that is widely expressed during B-cell development and in all B-cell lineage malignancies.","Anti-CD19 Monoclonal Antibody DI-B4 | DI-B4 | anti-CD19 MoAb DI-B4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447158","Autologous Sarcoma Lysate-pulsed Dendritic Cell Vaccine","C105806","A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from sarcoma cells with potential immunostimulatory and antineoplastic activities. Upon administration, the autologous sarcoma lysate-pulsed dendritic cell vaccine exposes the immune system to an undefined amount of sarcoma-type tumor associated antigens (TAA), which may result in the induction of both specific anti-tumoral cytotoxic T lymphocytes (CTL) and antibody-dependent responses against the sarcoma TAA-expressing cells, resulting in sarcoma cell lysis.","Autologous Sarcoma Lysate-pulsed Dendritic Cell Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447159","Autologous Sarcoma Cell Lysate","C105807","A cell lysate derived from sarcoma cells with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, the autologous sarcoma cell lysate exposes the immune system to an undefined amount of sarcoma-type tumor associated antigens (TAA), which may result in the induction of both specific anti-tumoral cytotoxic T lymphocytes (CTL) and antibody-dependent responses against the sarcoma TAA-expressing cells, resulting in sarcoma cell lysis.","Autologous Sarcoma Cell Lysate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447160","Indium In 111 Pertuzumab","C105808","A radioimmunoconjugate composed of a humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the tyrosine kinase receptor human epidermal growth factor-2 (HER-2) and linked to the gamma-emitting radioisotope indium In 111, with potential use in radioimaging. Upon administration, indium In 111 pertuzumab binds to HER-2. After binding and internalization into HER-2-expressing tumor cells, radioactive In 111 facilitates the detection of HER-2-expressing tumor cells using single photon emission computed tomography (SPECT). This may predict or evaluate the tumor's response to certain HER-2-targeting chemotherapeutics.","Indium In 111 Pertuzumab | 111In-pertuzumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812692","IL1RL1 wt Allele","C106009","Human IL1RL1 wild-type allele is located in the vicinity of 2q12 and is approximately 41 kb in length. This allele, which encodes interleukin-1 receptor-like 1, is involved in immune response signal transduction.","IL1RL1 wt Allele | DER4 | FIT-1 | Growth Stimulation-Expressed Gene | Growth Stimulation-Expressed Gene Mouse, Homolog of Gene | Homolog of Mouse Growth Stimulation-Expressed Gene | IL33R | Interleukin 1 Receptor Like 1 wt Allele | Interleukin 1 Receptor-Like 1 Gene | Interleukin 1 Receptor-Like 1 wt Allele | Interleukin 1 Receptor-Related Protein Gene | Interleukin 33 Receptor Gene | ST2 | ST2, Mouse, Homolog of Gene | ST2L | ST2V | T1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0389551","semaphorin IV","C106010","Semaphorin-3F (785 aa, ~88 kDa) is encoded by the human SEMA3F gene. This protein is involved in both cell signaling and axon guidance.","Semaphorin-3F | SEMA3F | Sema III/F | Sema IV | Semaphorin III/F | Semaphorin IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812635","EPGN wt Allele","C105919","Human EPGN wild-type allele is located in the vicinity of 4q13.3 and is approximately 7 kb in length. This allele, which encodes epigen protein, is involved in epidermal cell survival, proliferation, and migration.","EPGN wt Allele | ALGV3072 | EPG | Epithelial Mitogen Homolog (Mouse) Gene | Epithelial Mitogen wt Allele | PRO9904",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3884530","Epigen, Human","C105920","Epigen (154 aa, ~17 kDa) is encoded by the human EPGN gene. This protein plays a role in survival, proliferation, and migration of epidermal cells.","Epigen | EPG | Epithelial Mitogen | Epithelial Mitogen Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810651","A2M wt Allele","C105923","Human A2M wild-type allele is located in the vicinity of 12p13.31 and is approximately 49 kb in length. This allele, which encodes alpha-2-macroglobulin protein, plays a role in various processes as a protease inhibitor. Mutations in this gene are associated with alpha-2-macroglobulin deficiency and susceptibility to Alzheimer disease.","A2M wt Allele | A2MD | Alpha-2-Macroglobulin wt Allele | CPAMD5 | FWP007 | S863-7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813577","Mitotic Spindle Assembly Checkpoint Protein MAD2A","C105849","Mitotic spindle assembly checkpoint protein MAD2A (205 aa, ~24 kDa) is encoded by the human MAD2L1 gene. This protein is involved in the mitotic spindle-assembly checkpoint.","Mitotic Spindle Assembly Checkpoint Protein MAD2A | HsMAD2 | MAD2-Like Protein 1 | MAD2L1 | Mitotic Arrest Deficient 2-Like Protein 1 | Mitotic Arrest Deficient, Yeast, Homolog-Like 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447178","[18F]L-FMAC","C105850","A radioconjugate composed of 2'-deoxy-2'-18F-fluoro-5-methyl-beta-L-arabinofuranosylcytosine ([18F]L-FMAC), a L-deoxycytidine analog and high-affinity substrate for deoxycytidine kinase (DCK), labeled with fluorine F 18, with potential diagnostic activity during positron emission tomography (PET) imaging. Upon administration, [18F]L-FMAC is preferentially taken up by and accumulated in cells with high DCK levels, including tumor cells with dysregulated nucleoside metabolism. After phosphorylation by DCK, the 18F moiety can be visualized by PET imaging. As many nucleoside analog prodrugs are chemotherapeutic agents that require DCK for their phosphorylation and activation, [18F]L-FMAC can potentially be used as a marker to measure DCK activity and to predict the chemotherapeutic efficacy of DCK-dependent prodrugs. DCK, a rate-limiting enzyme in the deoxyribonucleoside salvage pathway for DNA synthesis, is overexpressed in certain solid tumors, lymphoid and myeloid malignancies and certain immune cells, such as proliferating T-lymphocytes. The L-enantiomer is less susceptible to deamination by cytidine deaminase (CDA) than the D-enantiomer and increases the stability of this radioconjugate.","[18F]L-FMAC | 2'-Deoxy-2'-18F-fluoro-5-methyl-beta-L-arabinofuranosylcytosine | L-FMAC F-18 | L-fluorine F 18-FMAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447179","CDKs/JAK2/FLT3 inhibitor TG02 citrate","C105851","An orally bioavailable citrate salt form of zotiraciclib a multi-kinase inhibitor for cyclin dependent kinase (CDK) subtypes 1, 2, 7 and 9, Janus-associated kinase 2 (JAK2), FMS-related tyrosine kinase 3 (FLT3, FLK2, STK1), with potential antineoplastic activity. Upon oral administration, CDK/JAK2/FLT3 Inhibitor TG02 binds to and inhibits the CDK subtypes, JAK2, and FLT3. TG02 also inhibits, to a lesser extent, TYK2, TYRO3, STAT5 and P38delta. This may result in both an induction of apoptosis and an inhibition of tumor cell proliferation in cancer cells that overexpress these kinases. JAK2, often upregulated or mutated in a variety of cancer cells, mediates STAT3 activation and plays a key role in tumor cell proliferation and survival. CDKs are serine/threonine kinases that play key roles in the regulation of the cell cycle and cellular proliferation. FLT3, a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias.","Zotiraciclib Citrate | 20-Oxa-5,7,14,27-tetraazatetracyclo(19.3.1.12,6.18,12)heptacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene, 14-Methyl-, 2-Hydroxy-1,2,3-propanetricarboxylate (1:1) | SB1317 Citrate | TG02 Citrate | ZOTIRACICLIB CITRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813154","RSPO2 wt Allele","C106068","Human RSPO2 wild-type allele is located in the vicinity of 8q23.1 and is approximately 184 kb in length. This allele, which encodes R-spondin-2 protein, is involved in both signal transduction and embryonic limb formation.","RSPO2 wt Allele | CRISTIN2 | HHRRD | MGC35555 | R-Spondin 2 wt Allele | R-Spondin Family, Member 2 Gene | TETAMS2 | UNQ9384/PRO34209",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828290","R-Spondin-2","C106069","R-spondin-2 (243 aa, ~28 kDa) is encoded by the human RSPO2 gene. This protein plays a role in beta-catenin-mediated signaling and bone, limb and lung development.","R-Spondin-2 | Roof Plate-Specific Spondin-2 | hRspo2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419756","RRAS Gene","C106070","This gene is involved in both axon guidance and the promotion of angiogenesis.","RRAS Gene | RAS Related Gene | RRAS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812738","RRAS wt Allele","C106071","Human RRAS wild-type allele is located within 19q13.3-qter and is approximately 5 kb in length. This allele, which encodes Ras-related protein R-Ras, plays a role in both cytoskeletal rearrangement and angiogenesis.","RRAS wt Allele | Oncogene RRAS | R-Ras | RAS Related wt Allele | Related RAS Viral (R-Ras) Oncogene Homolog Gene | Related RAS Viral Oncogene Homolog Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642207","Milliequivalent Per Gram of Creatinine","C105501","A unit of relative amount of substance concentration defined as the concentration of milliequivalents per gram of creatinine.","Milliequivalent Per Gram of Creatinine | mEq/g Creatinine | meq/g{Creatinine}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439324","Milligram Per Gram of Creatinine","C105502","A unit of substance concentration defined as the number of milligrams per gram of creatinine.","Milligram Per Gram of Creatinine | mg/g Creatinine | mg/g{Creatinine} | ug/mg Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827141","Crenolanib Besylate","C106204","The besylate salt form of crenolanib, an orally bioavailable benzimidazole targeting the platelet-derived growth factor receptor (PDGFR) subtypes alpha and beta and FMS-related tyrosine kinase 3 (Flt3), with potential antineoplastic activity. Upon oral administration, crenolanib binds to and inhibits both wild-type and mutated forms of PDGFR and Flt3, which may result in the inhibition of PDGFR- and Flt3-related signal transduction pathways. This results in inhibition of tumor angiogenesis and tumor cell proliferation in PDGFR and/or Flt3 overexpressing tumor cells. PDGFR and Flt3, class III receptor tyrosine kinases, are upregulated or mutated in many tumor cell types.","Crenolanib Besylate | 4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-, Benzenesulfonate (1:1) | CP-868,596-26 | CP-86859626 | CRENOLANIB BESYLATE | [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine Monobenzenesulfonate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1696294","Drospirenone/Ethinyl Estradiol","C106205","A combination of two steroid sex hormones, the estrogen ethinyl estradiol and a progestin drospirenone, used for contraceptive purposes.  The combination of ethinyl estradiol with drospirenone suppresses the hypothalamic-pituitary system, leading to an inhibition of the release of gonadotropin hormones follicle stimulating hormone (FSH) and luteinizing hormone (LH). The inhibition of FSH release suppresses the development of ovarian follicle. The decreased release of LH inhibits ovulation. In addition, thickening of the cervical mucus and the endometrium is promoted, thereby altering the endometrium in such a way as to discourage implantation.","Drospirenone/Ethinyl Estradiol | Yasmin | Yaz",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814416","LDHA wt Allele","C106207","Human LDHA wild-type allele is located in the vicinity of 11p15.4 and is approximately 14 kb in length. This allele, which encodes L-lactate dehydrogenase A chain protein, plays a role in fermentation. Mutation of the gene is associated with glycogen storage disease 11.","LDHA wt Allele | GSD11 | LDH, Subunit M Gene | LDH1 | LDHM | Lactate Dehydrogenase A wt Allele | PIG19 | Proliferation-Inducing Gene 19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0915024","EC 1.1.1.27","C106208","L-lactate dehydrogenase A chain (332 aa, ~37 kDa) is encoded by the human LDHA gene. This protein is involved in the metabolism of lactate and pyruvate.","L-Lactate Dehydrogenase A Chain | Cell Proliferation-Inducing Gene 19 Protein | EC 1.1.1.27 | LDH Muscle Subunit | LDH-A | LDH-M | LDHA | Lactate Dehydrogenase A | Lactate Dehydrogenase M | Renal Carcinoma Antigen NY-REN-59",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3715179","ATP6AP1 wt Allele","C106210","Human ATP6AP1 wild-type allele is located in the vicinity of Xq28 and is approximately 8 kb in length. This allele, which encodes V-type proton ATPase subunit S1 protein, is involved in vacuolar acidification.","ATP6AP1 wt Allele | 16A | ATP6IP1 | ATP6S1 | ATPase H+ Transporting Accessory Protein 1 wt Allele | ATPase, H+ Transporting, Lysosomal (Vacuolar Proton Pump), Subunit 1 wt Allele | ATPase, H+ Transporting, Lysosomal Accessory Protein 1 Gene | ATPase, H+ Transporting, Lysosomal Interacting Protein 1 Gene | Ac45 | CF2 | H-ATPase Subunit Gene | MGC129781 | VATPS1 | XAP-3 | XAP3 | XX-FW83563B9.4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0212532","IL1RL1 protein, human","C106011","Interleukin-1 receptor-like 1 (556 aa, ~63 kDa) is encoded by the human IL1RL1 gene. This protein plays a role in binding interleukin-33 and immune response signaling.","Interleukin-1 Receptor-Like 1 | IL1RL1 | Interleukin 1 Receptor-Related Protein | Protein ST2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813709","LRRC32 wt Allele","C106013","Human LRRC32 wild-type allele is located within 11q13.5-q14 and is approximately 13 kb in length. This allele, which encodes leucine-rich repeat-containing protein 32, is involved in the regulation of immune cell function.","LRRC32 wt Allele | D11S833E | GARP | Leucine Rich Repeat Containing 32 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815177","LRRC32 protein, human","C106014","Leucine-rich repeat-containing protein 32 (662 aa, ~72 kDa) is encoded by the human LRRC32 gene. This protein plays a role in the regulation of immune cell function.","Leucine-Rich Repeat-Containing Protein 32 | GARP | Garpin | Glycoprotein A Repetitions Predominant | LRRC32",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815170","SERPINA9 wt Allele","C106016","Human SERPINA9 wild-type allele is located in the vicinity of 14q32.13 and is approximately 17 kb in length. This allele, which encodes Serpin A9 protein, plays a role in the regulation of trypsin activity.","SERPINA9 wt Allele | CENTERIN | GCET1 | Germinal Center B Cell-Expressed Transcript 1 Gene | Germinal Center B-Cell-Expressed Transcript 1 Gene | SERPINA11 | SERPINA11b | Serine (or Cysteine) Proteinase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 9 Gene | Serpin Family A Member 9 wt Allele | Serpin Peptidase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 9 Gene | Serpin Peptidase Inhibitor, Clade A, Member 9 Gene | UNQ692/PRO1337",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1571681","SERPINA9 protein, human","C106017","Serpin A9 (417 aa, ~47 kDa) is encoded by the human SERPINA9 gene. This protein is involved in trypsin activity regulation.","Serpin A9 | Centerin | Germinal Center B-Cell-Expressed Transcript 1 Protein | Serine Proteinase Inhibitor A11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811242","SPTBN2 wt Allele","C106019","Human SPTBN2 wild-type allele is located in the vicinity of 11q13.2 and is approximately 44 kb in length. This allele, which encodes spectrin beta chain, non-erythrocytic 2 protein, is involved in the regulation of actin filament function. Mutations in this gene are associated with spinocerebellar ataxia 5.","SPTBN2 wt Allele | GTRAP41 | KIAA0302 | SCA5 | Spectrin, Beta, Non-Erythrocytic 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1531080","Spectrin Beta Chain, Non-Erythrocytic 2, Human","C106020","Spectrin beta chain, non-erythrocytic 2 (2390 aa, ~271 kDa) is encoded by the human SPTBN2 gene. This protein plays a role in the regulation of actin filament function.","Spectrin Beta Chain, Non-Erythrocytic 2 | Beta-III Spectrin | Glutamate Transporter EAAT4-Associated Protein 41 | Spectrin Beta Chain, Brain 2 | Spectrin, Non-Erythroid Beta Chain 2 | Spinocerebellar Ataxia 5 | Spinocerebellar Ataxia 5 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811130","ABCC3 wt Allele","C106022","Human ABCC3 wild-type allele is located in the vicinity of 17q22 and is approximately 57 kb in length. This allele, which encodes canalicular multispecific organic anion transporter 2 protein, plays a role in bile metabolism and transport.","ABCC3 wt Allele | ABC31 | ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 3 wt Allele | EST90757 | MLP2 | MOAT-D | MRP3 | cMOAT2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813592","RRAS protein, human","C106072","Ras-related protein R-Ras (218 aa, ~23 kDa) is encoded by the human RRAS gene. This protein is involved in both the positive regulation of angiogenesis and cytoskeletal modeling in axons.","Ras-Related Protein R-Ras | EC 3.6.5.- | RRAS | Ras Family Small GTP Binding Protein R-Ras | p23",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3715042","RHOJ wt Allele","C106081","Human RHOJ wild-type allele is located in the vicinity of 14q23.2 and is approximately 89 kb in length. This allele, which encodes Rho-related GTP-binding protein RhoJ, is involved in both cellular morphology and GTP metabolism.","RHOJ wt Allele | ARHJ | FLJ14445 | RAS-Like, Family 7, Member B Gene | RASL7B | RHOI | Ras Homolog Family Member J wt Allele | Ras Homolog Gene Family, Member J Gene | TC10B | TCL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447820","Rho-Related GTP-Binding Protein RhoJ","C106082","Rho-related GTP-binding protein RhoJ (214 aa, ~24 kDa) is encoded by the human RHOJ gene. This protein plays a role in the regulation of both GTP hydrolysis and cellular morphology.","Rho-Related GTP-Binding Protein RhoJ | RAS-Like, Family 7, Member B | RHOJ | Ras Homolog Gene Family, Member J | Ras-Like Protein Family Member 7B | TC10-Like Rho GTPase | Tc10-Like GTP-Binding Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446450","Gemcitabine Hydrochloride Emulsion","C105613","An orally available nanoparticle-based formulation containing the hydrochloride salt form of gemcitabine, a broad-spectrum antimetabolite and deoxycytidine analogue, with antineoplastic activity. The formulation consists of an oil-in-water emulsion in which gemicitabine is solubilized in the excipient matrix containing a mixture of oil and (co)surfactants. Upon oral administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA, resulting in premature termination of DNA replication and the induction of apoptosis. Further, dFdCDP inhibits ribonucleotide reductase and reduces the deoxynucleotide pool available for DNA synthesis. Compared to gemcitabine alone, the emulsion allows for increased oral bioavailability and decreases its susceptibility to deamination and deactivation by cytidine deaminase.","Gemcitabine Hydrochloride Emulsion | D07001-F4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1435858","V-Type Proton ATPase Subunit S1","C106211","V-type proton ATPase subunit S1 (470 aa, ~52 kDa) is encoded by the human ATP6AP1 gene. This protein plays a role in the acidification of vacuoles.","V-Type Proton ATPase Subunit S1 | ATP6AP1 | ATPase H+ Transporting Accessory Protein 1 | Protein XAP-3 | V-ATPase Ac45 Subunit | V-ATPase S1 Accessory Protein | V-ATPase Subunit S1 | Vacuolar ATPase Subunit 1 | Vacuolar Proton Pump Subunit S1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815186","AGER wt Allele","C106213","Human AGER wild-type allele is located in the vicinity of 6p21.3 and is approximately 3 kb in length. This allele, which encodes advanced glycosylation end product-specific receptor protein, plays a role in both advanced glycation end product recognition and inflammatory signaling.","AGER wt Allele | Advanced Glycosylation End Product-Specific Receptor wt Allele | DAMA-358M23.4 | RAGE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812151","Advanced Glycosylation End Product-Specific Receptor, human","C106214","Advanced glycosylation end product-specific receptor (404 aa, ~43 kDa) is encoded by the human AGER gene. This protein is involved in advanced glycation end product binding, inflammatory responses and receptor-mediated signaling.","Advanced Glycosylation End Product-Specific Receptor | AGER | RAGE | Receptor For Advanced Glycosylation End Products",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828806","Non-Academic Hospital","C105742","A hospital that is not affiliated with a university.","Non-Academic Hospital | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812827","Study Element","C105752","An artifact that is one of the individual components of the study.","Study Element | ELEMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827796","Toxicity Grade Scale Type Terminology","C105753","Terminology codelist containing values associated with identifiable classes of grading scales used to classify toxicity.","Toxicity Grade Scale Type Terminology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540641","TRDMT1 wt Allele","C105561","Human TRDMT1 wild-type allele is located in the vicinity of 10p15.1 and is approximately 60 kb in length. This allele, which encodes tRNA (cytosine(38)-C(5))-methyltransferase protein, plays a role in methylation of aspartic acid transfer RNA but also has DNA-(cytosine-C5) methyltransferase activity.","TRDMT1 wt Allele | DMNT2 | DNMT2 | M.HsaIIP | MHSAIIP | PUMET | RNMT1 | tRNA Aspartic Acid Methyltransferase 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0077333","tRNA (Cytosine(38)-C(5))-Methyltransferase, Human","C105562","tRNA (Cytosine(38)-C(5))-Methyltransferase (391 aa, ~46 kDa) is encoded by the human TRDMT1 gene. This protein is involved in the specific methylation of cytosine 38 in the anticodon loop of tRNA(Asp).","tRNA (Cytosine(38)-C(5))-Methyltransferase | DNA (Cytosine-5)-Methyltransferase-Like Protein 2 | DNA (Cytosine-5-)-Methyltransferase 2 | DNA MTase Homolog HsaIIP | DNA Methyltransferase Homolog HsaIIP | DNA Methyltransferase-2 | EC 2.1.1.204 | EC 2.1.1.29 | PuMet | TRDMT1 | tRNA (Cytosine-5-)-Methyltransferase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539618","TSC22D3 wt Allele","C105564","Human TSC22D3 wild-type allele is located in the vicinity of Xq22.3 and is approximately 64 kb in length. This allele, which encodes TSC22 domain family protein 3, is involved in both the transcriptional regulation of apoptotic genes and immunosuppression.","TSC22D3 wt Allele | DIP | DSIPI | GILZ | TSC-22R | TSC22 Domain Family, Member 3 wt Allele | hDIP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0661256","TSC22D3 protein, human","C105565","TSC22 domain family protein 3 (134 aa, ~15 kDa) is encoded by the human TSC22D3 gene. This protein plays a role in both apoptosis in T-cells and immunosuppression in macrophages.","TSC22 Domain Family Protein 3 | DSIP-Immunoreactive Leucine Zipper Protein | DSIP-Immunoreactive Peptide | Delta Sleep Inducing Peptide, Immunoreactor | Delta Sleep-Inducing Peptide Immunoreactor | Glucocorticoid-Induced Leucine Zipper Protein | Protein DIP | TSC-22 Related Protein | TSC-22-Like Protein | TSC-22-Related Protein | TSC22D3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539620","TNFRSF18 wt Allele","C105567","Human TNFRSF18 wild-type allele is located in the vicinity of 1p36.3 and is approximately 3 kb in length. This allele, which encodes tumor necrosis factor receptor superfamily member 18 protein, plays a role in dominant immunological self-tolerance and may play a role in both T-cell activation and T-cell programmed cell death.","TNFRSF18 wt Allele | AITR | CD357 | ENERGEN | GITR | GITR-D | Glucocorticoid-Induced TNFR-Related Gene | Tumor Necrosis Factor Receptor Superfamily Member 18 wt Allele | Tumor Necrosis Factor Receptor Superfamily, Member 18 Gene | Tumor Necrosis Factor Receptor Superfamily, Member 18 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1455126","TNFRSF18 protein, human","C105568","Tumor necrosis factor receptor superfamily member 18 (241 aa, ~26 kDa) is encoded by the human TNFRSF18 gene. This protein is involved in T-cell-mediated immune function.","Tumor Necrosis Factor Receptor Superfamily Member 18 | Activation-Inducible TNFR Family Member | Activation-Inducible TNFR Family Receptor | CD357 Antigen | GITR | Glucocorticoid-Induced TNFR-Related Protein | TNF Receptor Superfamily Activation-Inducible Protein | TNFRSF18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542907","TNFRSF21 wt Allele","C105570","Human TNFRSF21 wild-type allele is located in the vicinity of 6p21.1 and is approximately 78 kb in length. This allele, which encodes tumor necrosis factor receptor superfamily member 21 protein, is involved in the induction of apoptosis and may be involved in both inflammation and immune regulation.","TNFRSF21 wt Allele | BM-018 | CD358 | DR6 | Tumor Necrosis Factor Receptor Superfamily, Member 21 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541241","Tumor Necrosis Factor Receptor Superfamily Member 21","C105571","Tumor necrosis factor receptor superfamily member 21 (655 aa, ~72 kDa) is encoded by the human TNFRSF21 gene. This protein plays a role in the induction of apoptosis and may play a role in T-helper cell activation.","Tumor Necrosis Factor Receptor Superfamily Member 21 | CD358 Antigen | Death Receptor 6 | TNFR-Related Death Receptor 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812251","MBD4 wt Allele","C106164","Human MBD4 wild-type allele is located in the vicinity of 3q21.3 and is approximately 9 kb in length. This allele, which encodes methyl-CpG-binding domain protein 4, plays a role in DNA mismatch repair.","MBD4 wt Allele | G/5-Fluorouracil Mismatch Glycosylase With Biphasic Kinetics Gene | MED1 | Methyl-CpG Binding Domain 4, DNA Glycosylase wt Allele | Methyl-CpG Binding Domain Protein 4 Gene | Methyl-CpG Binding Domain Protein 4 wt Allele | TPDS2 | UVM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446451","Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T Cells","C105614","A preparation of genetically modified autologous central memory (Tcm) enriched T-cells transduced with a replication incompetent lentiviral vector expressing a chimeric antigen receptor (CAR), containing a CD28 signaling domain fused to both CD3 zeta, which targets the CD19 antigen, and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells are directed to CD19-expressing tumor cells, thereby inducing a selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.  Devoid of both ligand binding domains and tyrosine kinase activity, EGFRt both facilitates in vivo detection of the administered T-cells and can promote elimination of those cells upon a cetuximab-induced antibody dependent cellular cytotoxicity response. The costimulatory signaling domain enhances proliferation of T cells and antitumor activity.","Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T Cells | Autologous CD19R:CD28:lentiviral/EGFRt+ T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446453","Astragalus-based Formulation Qing Shu Yi Qi Tang","C105616","An herbal remedy containing Astragalus membranaceus, Panax ginseng, Atractylodes chinensis Koidz, Cimicifuga foetida, A. macrocephala Koidz, Alisma orientale Juzep, and Citrus reticulata Blanco, with potential immunomodulating, anti-oxidant and anticachexia activities. Upon oral consumption, the ingredients in this herbal supplement may modulate the activity of the immune system through a decrease in both the expression of nuclear factor-kappa B (NF-kappa B) and the production of pro-inflammatory cytokines such as interleukin-1beta (Il-1b), IL-6, and tumor necrosis factor-alpha (TNF-alpha). Increased levels of pro-inflammatory cytokines are correlated with decreased appetite and weight loss; thus, this herbal remedy may improve immune function, appetite and weight gain, which could prevent cachexia.","Astragalus-based Formulation Qing Shu Yi Qi Tang | QSYQT | Qing-Shu-Yi-Qi-Tang",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1958566","Magnesium Isoglycyrrhizinate","C105617","The magnesium salt form of the saponin, isoglycyrrhizinate, a derivative of glycyrrhizic acid extracted from the roots of the plant Glycyrrhiza glabra, with potential anti-inflammatory, antioxidant and hepatoprotective activities. Although the exact mechanism of action remains to be fully elucidated, magnesium isoglycyrrhizinate may prevent or reduce hepatotoxicity through the scavenging of free radicals. This agent also modulates the activity of hepatic enzymes such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), superoxide dismutase (SOD) and glutathione peroxidase.","Magnesium Isoglycyrrhizinate | MAGNESIUM ISOGLYCYRRHIZINATE | Tianqingganmei",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1689829","Therapeutic Hepatitis C Immune Globulin","C105618","A human plasma-derived, polyclonal, intravenous immunoglobulin G (IgG) formulation containing high levels of antibodies against hepatitis C virus (HCV), a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family, with potential immunomodulating and antiviral activities. The hepatitis C IgG is isolated from donors expressing high amounts of HCV antibodies. Upon intravenous administration, the anti-HCV antibodies bind to the virus and provide passive immunization against HCV. This may prevent both infection by HCV in immunocompromised patients and hepatitis C-related liver disease. The polyclonal anti-HCV antibodies are able to target various viral epitopes.","Therapeutic Hepatitis C Immune Globulin | Anti-HCV Immunoglobulin | Biotest-HCIG | Civacir | HCIG | HEPATITIS C IMMUNE GLOBULIN (HUMAN)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642270","Alvin J Siteman Cancer Center","C105620","The Alvin J Siteman Cancer Center is dedicated to advancing new approaches to cancer prevention, diagnosis, and treatment through research. It became an NCI-designated cancer center in 2001 and achieved Comprehensive Cancer Center status in 2004. Parent institutions include Barnes-Jewish Hospital and Washington University School of Medicine. Partner institutions include St. Louis Children's Hospital and BJC Healthcare.","Alvin J Siteman Cancer Center | Siteman | Siteman Cancer Center",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642271","Dan L Duncan Cancer Center","C105622","The Dan L Duncan Cancer Center focuses on cancer research, patient care, training, and education. It became an NCI-designated cancer center in 2007. It is a consortium made up of Baylor College of Medicine and its three primary teaching hospital affiliates: Ben Taub Hospital, Michael E DeBakey Veterans Affairs Medical Center, and Texas Children's Hospital.","Dan L Duncan Cancer Center | DLDCC | Dan L Duncan Cancer Center at the Baylor College of Medicine | Duncan Cancer Center at BCM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0146524","transition protein 1 (during histone to protamine replacement), human","C106294","Spermatid nuclear transition protein 1 (55 aa, ~6 kDa) is encoded by the human TNP1 gene. This protein is involved in the maturation of sperm.","Spermatid Nuclear Transition Protein 1 | STP-1 | TNP1 | TP-1 | Transition Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829594","Human Clinical Subject Data Section","C105754","A section within the study document pertaining to data collected from human clinical study subjects.","Human Clinical Subject Data Section | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828804","Non-human Clinical Subject Data Section","C105755","A section within the study document pertaining to data collected from non-human clinical study subjects.","Non-human Clinical Subject Data Section | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828190","Serious Adverse Event Reason","C105756","The rationale for why the adverse event was reported as being serious.","Serious Adverse Event Reason | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828189","Serious Adverse Event Reason Type Terminology","C105757","Terminology codelist containing values associated with the rationale for why the adverse event was reported as being serious.","Serious Adverse Event Reason Type Terminology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827903","Subject Trial Set","C105759","The collection of subjects that have a common set of parameters defined in the protocol (could be experimental parameters, treatment parameters, or sponsor-defined attributes).","Subject Trial Set | TRIAL SET",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827762","True False Response Terminology","C105761","Terminology codelist used for any True False responses.","True False Response Terminology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229873","Anterior Tonsillar Pillar","C105762","The anterior border of the tonsillar fossa.  It is composed of the palatoglossus muscle.","Anterior Tonsillar Pillar | ",,,,,,,,,,,,,,,"4102925","Glossopalatine arch",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0757844","TNFSF13 protein, human","C105969","Tumor necrosis factor ligand superfamily member 13 (250 aa, ~27 kDa) is encoded by the human TNFSF13 gene. This protein is involved in the regulation of both apoptosis and B cell development.","Tumor Necrosis Factor Ligand Superfamily Member 13 | A Proliferation-Inducing Ligand | APRIL | CD256 Antigen | TNF- and APOL-Related Leukocyte Expressed Ligand 2 | TNF-Related Death Ligand 1 | TNFSF13 | Tumor Necrosis Factor-Like Protein ZTNF2 | Tumor Necrosis Factor-Related Death Ligand-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813558","IL13RA2 wt Allele","C105973","Human IL13RA2 wild-type allele is located within Xq13.1-q28 and is approximately 16 kb in length. This allele, which encodes interleukin-13 receptor subunit alpha-2 protein, is involved in both the maturation and differentiation of B-cells.","IL13RA2 wt Allele | CD213a2 | CT19 | IL-13R | IL-13RA2 | IL13BP | IL13R | Interleukin 13 Receptor Subunit Alpha 2 wt Allele | Interleukin 13 Receptor, Alpha 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811700","RAD23A wt Allele","C106251","Human RAD23A wild-type allele is located in the vicinity of 19p13.2 and is approximately 8 kb in length. This allele, which encodes UV excision repair protein RAD23 homolog A, plays a role in both proteasome-dependent protein degradation and nucleotide excision repair.","RAD23A wt Allele | HHR23A | HR23A | MGC111083 | RAD23 (S. cerevisiae) Homolog A Gene | RAD23 Homolog A (S. cerevisiae) wt Allele | RAD23, Yeast Homolog, A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811701","UV Excision Repair Protein RAD23 Homolog A","C106252","UV excision repair protein RAD23 homolog A (363 aa, ~40 kDa) is encoded by the human RAD23A gene. This protein is involved in both DNA repair and the targeting of ubiquitinated proteins to the proteasome.","UV Excision Repair Protein RAD23 Homolog A | HR23A | RAD23A | hHR23A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827103","CXCR4 Peptide Antagonist LY2510924","C106253","An inhibitor of CXC chemokine receptor 4 (CXCR4), with potential antineoplastic activity. Upon subcutaneous administration, CXCR4 inhibitor LY2510924 binds to the chemokine receptor CXCR4, thereby preventing CXCR4 binding to its ligand, stromal derived factor-1 (SDF-1), and subsequent receptor activation. This may result in decreased tumor cell proliferation and migration. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types.","CXCR4 Peptide Antagonist LY2510924 | LY2510924",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433881","pan-RAF kinase inhibitor TAK-580","C106254","An orally available inhibitor of wild-type and certain mutant forms of A-Raf, B-Raf and C-Raf protein kinases, with potential antineoplastic activity. Upon administration, tovorafenib inhibits Raf-mediated signal transduction pathways, which may lead to an inhibition of tumor cell growth. Raf protein kinases play a key role in the RAF/MEK/ERK signaling pathway, which is often deregulated in human cancers and plays a key role in tumor cell proliferation and survival.","Tovorafenib | (R)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-N-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide | BIIB 024 | BIIB-024 | BIIB024 | DAY 101 | DAY-101 | DAY101 | MLN 2480 | MLN-2480 | MLN2480 | Ojemda | TAK 580 | TAK-580 | TAK580 | TOVORAFENIB | pan-RAF Kinase Inhibitor DAY101 | pan-RAF Kinase Inhibitor DAY101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433882","Antibody-Drug Conjugate DFRF4539A","C106256","An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) Fc receptor-like protein 5 (FcRH5; CD307; FCRL5; IRTA2; BXMAS1) and conjugated to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, via the protease-labile linker maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (MC-VC-PABC), with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of anti-FcRH5 ADC DFRF4539A selectively binds to FcRH5 expressed on the surface of myeloma cells. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and tumor cell apoptosis. FcRH5, an immune receptor translocation-associated protein/Fc receptor homolog (IRTA/FCRH) family member and a B-cell lineage marker, is overexpressed on myeloma cells.","Anti-FcRH5 Antibody-drug Conjugate DFRF4539A | ADC DFRF4539A | Anti-FcRH5 ADC DFRF4539A | Antibody-Drug Conjugate DFRF4539A | DFRF4539A | RG 7598 | RG-7598 | RG7598",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027926","Neurosurgery","C105687","A surgical specialty concerned with surgical treatment of the nervous system.","Neurosurgery | Neurological Surgery",,,,,,,,,,,,,,,"4215133","Neurosurgery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1274104","Obstetrics and Gynecology","C105688","A medical specialty concerned with the female reproductive organs in their pregnant and non-pregnant states.","Obstetrics and Gynecology | OBG/GYN | OBGYN",,,,,,,,,,,,,,,"4215122","Obstetrics and gynecology",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031813","Physical Medicine and Rehabilitation","C105689","A medical specialty focused on restoring functional ability and quality of life to people with physical impairments or disabilities.","Physical Medicine and Rehabilitation | Physiatry | Rehabilitation Medicine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032331","Podiatry","C105690","A medical specialty concerned with care and treatment of human feet in health and disease.","Podiatry | ",,,,,,,,,,,,,,,"36716230","Podiatry",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1555771","Internal Medicine - Sports Medicine","C105693","A medical specialty concerned with the diagnosis and treatment or injuries or illness resulting from athletic activities.","Sports Medicine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1274039","General Surgery","C105694","A surgical specialty that focuses on surgical management of diseases of the abdominal organs.","General Surgery | ",,,,,,,,,,,,,,,"4214575","General surgery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1610819","PDZ and LIM Domain Protein 2, Human","C105697","PDZ and LIM domain protein 2 (352 aa, ~37 kDa) is encoded by the human PDLIM2 gene. This protein is involved in actin binding, cell migration and cell adhesion.","PDZ and LIM Domain Protein 2 | PDLIM2 | PDZ-LIM Protein Mystique | STAT-Interacting LIM Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555886","Hand Surgery","C105698","A surgical specialty concerned with the surgical management of disease, disability, or injury of the upper extremity.","Hand Surgery | ",,,,,,,,,,,,,,,"37158949","Hand surgery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3714645","Vascular Surgery","C105699","A surgical specialty that focuses on diagnosis and management of disorders of the arterial, venous and lymphatic systems, other than the intracranial vessels and the heart.","Vascular Surgery | ",,,,,,,,,,,,,,,"4235388","Vascular surgery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0056285","Copovithane","C1056","A synthetic polymer (copolymer of 1,3-bis(methylaminocarboxyl)-2-methylenepropanecarbamate and N-vinyl pyrrolidone) of low molecular weight which acts as a nonspecific immune modulator and has been shown to have significant antitumor activity in vitro and in vivo in preclinical and some early clinical studies. The mechanism of action is unknown. Immunologic evaluation revealed some improvement in helper and suppressor T cell ratio, in vitro cytotoxicity tests, and lymphocyte blastogenic response. (NCI)","Copovithane | BAY I 7433 | COPOVITHANE | CPV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827686","Urological Surgery","C105700","A surgical specialty concerned with surgical treatment of the diseases of the urinary tract and urogenital system.","Urological Surgery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831077","Clinical Classification for Oncology","C106297","Tumor classification based on pre-treatment information obtained from the physical examination, radiology tests, and biopsies.","Clinical Classification for Oncology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831508","Any T","C106299","No specification on the details of the primary tumor growth.","Any T | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0057159","Duborimycin","C1062","An anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Duborimycin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis. (NCI04)","Duborimycin | 13-Hydroxydaunomycin | 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(1-hydroxyethyl)-1-methoxy-, (8S-cis)-, hydrochloride | DAUNORUBICINOL | Daunomycinol | Daunomycinol HCl | Daunorubicineal | Daunorubicinol | Duborimycin Hydrochloride | Duborimycine | Duborimycine, Hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811703","UBE2A wt Allele","C106300","Human UBE2A wild-type allele is located in the vicinity of Xq24 and is approximately 10 kb in length. This allele, which encodes ubiquitin-conjugating enzyme E2 A protein, plays a role in histone modification.","UBE2A wt Allele | HHR6A | MRXS30 | MRXSN | RAD6, Yeast, Homolog of, Type A Gene | RAD6A | UBC2 | Ubiquitin-Conjugating Enzyme E2A wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0526543","Ubiquitin-Conjugating Enzyme E2 A","C106302","Ubiquitin-conjugating enzyme E2 A (152 aa, ~17 kDa) is encoded by the human UBE2A gene. This protein is involved in the monoubiquitination of histone H2B.","Ubiquitin-Conjugating Enzyme E2 A | E2 Ubiquitin-Conjugating Enzyme A | EC 2.3.2.23 | EC 6.3.2.19, Formerly | HR6A | RAD6 Homolog A | UBE2A | Ubiquitin Carrier Protein A | Ubiquitin-Protein Ligase A | hHR6A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828527","Pleural/Elastic Layer Invasion","C106305","A pathologic finding indicating the extent of visceral pleural invasion by a malignant neoplasm.","Pleural/Elastic Layer Invasion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814391","Interleukin-13 Receptor Subunit Alpha-2, Human","C105975","Interleukin-13 receptor subunit alpha-2 (380 aa, ~44 kDa) is encoded by the human IL13RA2 gene. This protein plays a role in both B-cell differentiation and maturation.","Interleukin-13 Receptor Subunit Alpha-2 | CD213a2 Antigen | Cancer/Testis Antigen 19 | IL-13 Receptor Subunit Alpha-2 | IL-13R Subunit Alpha-2 | IL-13R-Alpha-2 | IL13RA2 | Interleukin 13 Binding Protein | Interleukin 13 Receptor Alpha 2 Chain | Interleukin-13-Binding Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810569","KRT17 wt Allele","C105978","Human KRT17 wild-type allele is located in the vicinity of 17q21.2 and is approximately 5 kb in length. This allele, which encodes keratin, type I cytoskeletal 17 protein, is involved in the formation of hair follicles and sebaceous glands. Mutations in this gene are associated with Jackson-Lawler type pachyonychia congenita and steatocystoma multiplex.","KRT17 wt Allele | 39.1 | CK-17 | K17 | Keratin 17 wt Allele | PC | PC2 | PCHC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524627","Keratin-17","C105980","Keratin, type I cytoskeletal 17 (432 aa, ~48 kDa) is encoded by the human KRT17 gene. This protein plays a role in the development of hair follicles and other skin appendages.","Keratin, Type I Cytoskeletal 17 | Cytokeratin-17 | KRT17 | Keratin 17 | Keratin 17 Epitope S1 | Keratin 17 Epitope S2 | Keratin 17 Epitope S4 | Keratin-17",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433890","WT1 Peptide Vaccine OCV-501","C106257","A peptide cancer vaccine comprised of a peptide derived from Wilms tumor gene 1 (WT1) protein, with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, WT1 peptide vaccine OCV-501 may stimulate a CD4-positive helper T-lymphocyte-mediated immune response against WT1 expressing cells. WT1 protein, a zinc finger DNA-binding protein, is overexpressed in leukemic cells and in some solid tumors.","WT1 Peptide Vaccine OCV-501 | OCV-501",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447161","AdGMCAIX-transduced Autologous Dendritic Cells","C105809","Autologous dendritic cells (DCs) transduced with a recombinant, replication-defective adenoviral vector expressing the fusion gene granulocyte-macrophage colony-stimulating factor (GM-CSF) and carbonic anhydrase IX (CA-IX or CA9) (GMCA-9), with potential immunomodulating activity. The autologous DCs are transduced ex vivo and express the GMCA-9 fusion protein on the cell surface. Upon intradermal administration of the AdGMCAIX-transduced autologous DCs back into the patient, the DCs activate the immune system to both mount a cytotoxic T lymphocyte-mediated response against tumor cells positive for the CA9 antigen, and generate memory T cells. This may result in decreased tumor growth. CA9, also known as G250, is a renal cell carcinoma (RCC)-associated antigen and a member of the carbonic anhydrase family that contains a human leukocyte antigen (HLA)-A2.1-restricted epitope; it is found in a majority of renal cell carcinomas while absent in most normal tissues. The cytokine GM-CSF enhances the immunogenicity of CA9-based DC vaccines.","AdGMCAIX-transduced Autologous Dendritic Cells | DC-AdGMCAIX | DCs expressing CMCA9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447162","Autologous Glioma Cell Lysate","C105810","A cell lysate derived from glioma cells with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, the autologous glioma cell lysate exposes the immune system to an undefined amount of glioma-type tumor associated antigens (TAA), which may result in the induction of both specific anti-tumoral cytotoxic T lymphocytes (CTL) and antibody-dependent responses against the glioma TAA-expressing cells, resulting in glioma cell lysis.","Autologous Glioma Cell Lysate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447163","Ad-hCMV-TK","C105811","A human serotype 5, replication-defective, first generation adenoviral vector, with the viral E1a and E3 protein encoding regions deleted, which is engineered to express the herpes simplex virus thymidine kinase (HSV-tk) gene under the transcriptional control of the CMV promoter. This agent, when administered in conjunction with a synthetic acyclic guanosine analogue, possesses potential antineoplastic activity. Upon administration into the peritumoral region after tumor resection, adenoviral vector encoding HSV thymidine kinase is transduced into tumor cells, and HSV-tk is expressed. Tumor cells expressing HSV-tk are sensitive to synthetic acyclic guanosine analogues. Subsequent administration of a synthetic acyclic guanosine analogue, such as valacyclovir (VCV) or ganciclovir (GCV), kills the tumor cells expressing HSV-tk. The release of tumor-associated antigens (TAA) by dying tumor cells may then stimulate an antitumor cytotoxic T lymphocyte (CTL) response, directed aganst any remaining tumor cells.","Ad-hCMV-TK | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447164","Ad-hCMV-Flt3L","C105813","A human serotype 5, replication-defective, first generation adenoviral vector, with the viral E1a and E3 protein encoding regions deleted, which is engineered to express the soluble, immune-mediated stimulatory gene human fms-like tyrosine kinase 3 ligand (Flt3L), under the transcriptional control of the CMV promoter, with potential immunostimulating activity. Upon administration, Ad-hCMV-Flt3L is transduced into tumor cells and Flt3L is expressed. Flt3L stimulates both the proliferation of dendritic cells (DCs) and their migration to the tumor site. Upon exposure to the tumor-associated antigens (TAA) released from dying glioma cells, which were killed by thymidine kinase-mediated valacyclovir-induced tumor cell death, the DCs initiate a specific immune response against any remaining TAA-expressing tumor cells. Flt3L is a hematopoietic growth factor and ligand for the Flt3 tyrosine kinase receptor.","Ad-hCMV-Flt3L | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813161","PGBD5 wt Allele","C105703","Human PGBD5 wild-type allele is located in the vicinity of 1q42.13 and is approximately 104 kb in length. This allele, which encodes piggyBac transposable element-derived protein 5, may involved in transposition.","PGBD5 wt Allele | DKFZp761A0620 | FLJ11413 | PiggyBac Transposable Element Derived 5 wt Allele | PiggyBac Transposable Element-Derived Gene 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002198","Alpha-2-Macroglobulin","C105924","Alpha-2-macroglobulin (1474 aa, ~163 kDa) is encoded by the human A2M gene. This protein has activity as a protease inhibitor.","Alpha-2-Macroglobulin | A2M | Alpha-2-M | C3 and PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3715038","TMTC1 wt Allele","C105926","Human TMTC1 wild-type allele is located in the vicinity of 12p11.22 and is approximately 284 kb in length. This allele, which encodes transmembrane and TPR repeat-containing protein 1, a mitochondrial integral membrane protein of unknown function.","TMTC1 wt Allele | ARG99 | FLJ31400 | FLJ41625 | OLF | TMTC1A | Transmembrane O-Mannosyltransferase Targeting Cadherins 1 wt Allele | Transmembrane and Tetratricopeptide Repeat Containing 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3884507","Transmembrane and TPR Repeat-Containing Protein 1, Human","C105927","Protein O-mannosyl-transferase TMTC1 (882 aa, ~99 kDa) is encoded by the human TMTC1 gene. This protein is involved in protein mannosylation.","Protein O-Mannosyl-Transferase TMTC1 | EC 2.4.1.109 | Transmembrane and TPR Repeat-Containing Protein 1 | Transmembrane and Tetratricopeptide Repeat Containing 1A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811132","EDNRB wt Allele","C105929","Human EDNRB wild-type allele is located in the vicinity of 13q22 and is approximately 24 kb in length. This allele, which encodes endothelin receptor type B protein, plays a role in vasoconstriction, vasodilation, bronchoconstriction and cell proliferation. Mutations in this gene are associated with ABCD syndrome, Waardenburg syndrome, type 4A, and susceptibility to Hirschsprung disease 2.","EDNRB wt Allele | ABCDS | ET-B | ET-BR | ETB | ETB1 | ETBR | ETRB | Endothelin Receptor Type B wt Allele | HSCR | HSCR2 | WS4A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3852390","EDNRB protein, human","C105930","Endothelin receptor type B (442 aa, ~50 kDa) is encoded by the human EDNRB gene. This protein is involved in vasoconstriction and vasodilation.","Endothelin Receptor Type B | EDNRB | ET-B | ET-BR | Endothelin B Receptor | Endothelin Receptor Non-Selective Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813160","FGD5 wt Allele","C105932","Human FGD5 wild-type allele is located in the vicinity of 3p25.1 and is approximately 116 kb in length. This allele, which encodes FYVE, RhoGEF and PH domain-containing protein 5, is involved in both signal transduction and the reorganization of the actin cytoskeleton.","FGD5 wt Allele | FLJ00274 | FLJ39957 | FYVE, RhoGEF and PH Domain Containing 5 wt Allele | ZFYVE23",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830062","FGD5 protein, human","C105933","FYVE, RhoGEF and PH domain-containing protein 5 (1462 aa, ~160 kDa) is encoded by the human FGD5 gene. This protein plays a role in both signal transduction and the reorganization of the actin cytoskeleton.","FYVE, RhoGEF and PH Domain-Containing Protein 5 | FGD5 | Zinc Finger FYVE Domain-Containing Protein 23",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3659483","Ralimetinib Mesylate","C105853","The dimesylate salt form of LY2228820, a tri-substituted imidazole derivative and orally available, p38 mitogen-activated protein kinase (MAPK) inhibitor with potential anti-inflammatory and antineoplastic activities. Upon administration, ralimetinib inhibits the activity of p38, particularly the alpha and beta isoforms, thereby inhibiting MAPKAPK2 phosphorylation and preventing p38 MAPK-mediated signaling. This may inhibit the production of a variety of cytokines involved in inflammation, cellular proliferation and angiogenesis such as tumor necrosis factor alpha (TNFa), interleukin (IL)-1, -6 and -8, vascular endothelial growth factor, and macrophage inflammatory protein-1 alpha. Ultimately this induces apoptosis and reduces tumor cell proliferation. In addition, inhibition of the p38 MAPK pathway by LY2228820 increases the antineoplastic activity of certain chemotherapeutic agents. p38 MAPK, a serine/threonine protein kinase that is often upregulated in cancer cells, plays a crucial role in tumor cell proliferation, angiogenesis and metastasis.","Ralimetinib Mesylate | 3H-Imidazo(4,5-b)pyridin-2-amine, 5-(2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-(2,2-dimethylpropyl)-, Methanesulfonate (1:2) | LY-2228820 | LY2228820 | LY2228820 Dimesylate | RALIMETINIB MESYLATE | Ralimetinib Dimesylate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814869","PGK1 wt Allele","C105854","Human PGK1 wild-type allele is located in the vicinity of Xq13.3 and is approximately 64 kb in length. This allele, which encodes phosphoglycerate kinase 1 protein, is involved in both glycolysis and gluconeogenesis. Mutation of the gene is associated with phosphoglycerate kinase 1 deficiency.","PGK1 wt Allele | MIG10 | OK/SW-cl.110 | PGKA | Phosphoglycerate Kinase 1 wt Allele | RP4-570L12.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814452","Phosphoglycerate Kinase 1, Human","C105855","Phosphoglycerate kinase 1 (417 aa, ~45 kDa) is encoded by the human PGK1 gene. This protein plays a role in glycolysis.","Phosphoglycerate Kinase 1 | Cell Migration-Inducing Gene 10 Protein | EC 2.7.2.3 | PGK1 | PRP 2 | Primer Recognition Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815512","CACNA1G wt Allele","C105857","Human CACNA1G wild-type allele is located in the vicinity of 17q22 and is approximately 66 kb in length. This allele, which encodes voltage-dependent T-type calcium channel subunit alpha-1G protein, plays a role in both calcium transport and membrane depolarization.","CACNA1G wt Allele | Ca(V)T.1 | Calcium Channel, Voltage-Dependent, T Type, Alpha 1G Subunit wt Allele | Cav3.1 | KIAA1123 | NBR13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813552","Voltage-Dependent T-Type Calcium Channel Subunit Alpha-1G","C105858","Voltage-dependent T-type calcium channel subunit alpha-1G (2377 aa, ~262 kDa) is encoded by the human CACNA1G gene. This protein is involved in both membrane depolarization and calcium import.","Voltage-Dependent T-Type Calcium Channel Subunit Alpha-1G | CACNA1G | Cav3.1c | NBR13 | Voltage-Dependent Calcium Channel Alpha 1G Subunit | Voltage-Gated Calcium Channel Subunit Alpha Cav3.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810598","NEUROG1 wt Allele","C105860","Human NEUROG1 wild-type allele is located within 5q23-q31 and is approximately 2 kb in length. This allele, which encodes neurogenin-1 protein, is involved in both transcriptional regulation and neuronal differentiation.","NEUROG1 wt Allele | AKA | BHLHA6 | Math4C | NEUROD3 | NGN | NGN1 | Neurogenic Differentiation 3 Gene | Neurogenin 1 wt Allele | bHLHa6 | ngn1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0537839","Neurogenin-1, Human","C105861","Neurogenin-1 (237 aa, ~26 kDa) is encoded by the human NEUROG1 gene. This protein plays a role in both neuron differentiation and the regulation of gene expression.","Neurogenin-1 | Class A Basic Helix-Loop-Helix Protein 6 | NEUROG1 | NGN-1 | NeuroD3 | Neurogenic Basic-Helix-Loop-Helix Protein | Neurogenic Differentiation Factor 3 | bHLHa6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812222","UGT1A9 wt Allele","C105863","Human UGT1A9 wild-type allele is located in the vicinity of 2q37 and is approximately 101 kb in length. This allele, which encodes UDP-glucuronosyltransferase 1-9 protein, plays a role in the detoxification of phenolic compounds.","UGT1A9 wt Allele | GNT1 | HLUGP4 | LUGP4 | UDP Glucuronosyltransferase 1 Family, Polypeptide A9 wt Allele | UDPGT | UDPGT 1-9 | UGT-1I | UGT1-09 | UGT1-9 | UGT1.9 | UGT1AI | UGT1I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642213","Millimole Per Gram of Creatinine","C105510","A unit of substance concentration defined as the concentration of millimoles of solute per gram of creatinine.","Millimole Per Gram of Creatinine | mmol/g Creatinine | mmol/g{Creatinine}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642216","Per Deciliter","C105514","A volume unit equal to one deciliter used as a denominator to build a derived unit expressed as a ratio.","Per Deciliter | /dL | /dl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814074","WT1-AS wt Allele","C106216","Human WT1-AS wild-type allele is located in the vicinity of 11p13 and is approximately 23 kb in length. This allele, which encodes Wilms tumor-associated antisense RNA, may be involved in the regulation of WT1 gene expression. This gene is imprinted in the kidney, displays preferential expression from the paternal allele, and imprinting defects at chromosome 11p13 may be associated with Wilms tumor.","WT1-AS wt Allele | WIT-1 | WIT1 | WT1 Antisense RNA (Non-Protein Coding) Gene | WT1 Antisense RNA wt Allele | WT1-AS1 | WT1AS | Wilms Tumor Upstream Neighbor 1 Gene | Wilms Tumor-Associated Antisense RNA Gene | dJ74J1.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814073","Wilms Tumor-Associated Antisense RNA","C106217","Wilms tumor-associated antisense RNA (~23 kb) is encoded by the human WT1-AS gene. This large non-coding RNA may play a role in the expression of the WT1 gene.","Wilms Tumor-Associated Antisense RNA | WIT-1 | WT1-AS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828743","NUP98/KDM5A Fusion Protein","C105816","A fusion protein encoded by the NUP98/KDM5A fusion gene. This protein is comprised of the N-terminal nucleoporin GLFG repeat domains of the nuclear pore complex protein Nup98-Nup96 protein fused to the C-terminal PHD domain of the lysine-specific demethylase 5A protein.","NUP98/KDM5A Fusion Protein | NUP98-JARID1A Fusion Protein | NUP98-KDM5A Fusion Protein | NUP98-RBBP2 Fusion Protein | NUP98/JARID1A Fusion Protein | NUP98/RBBP2 Fusion Protein | NUP98::KDM5A Fusion Protein | Nuclear Pore Complex Protein Nup98-Nup96/Jumonji/ARID Domain-Containing Protein 1A Fusion Protein | Nuclear Pore Complex Protein Nup98-Nup96/Lysine-Specific Demethylase 5A Fusion Protein | Nuclear Pore Complex Protein Nup98-Nup96/Retinoblastoma-Binding Protein 2 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0757457","MOAT-D protein, human","C106023","Canalicular multispecific organic anion transporter 2 (1527 aa, ~169 kDa) is encoded by the human ABCC3 gene. This protein is involved in both the transport and metabolism of bile.","Canalicular Multispecific Organic Anion Transporter 2 | ABCC3 | ATP-Binding Cassette Sub-Family C Member 3 | MOAT-D | Multi-Specific Organic Anion Transporter D | Multidrug Resistance-Associated Protein 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812225","DUSP6 wt Allele","C106025","Human DUSP6 wild-type allele is located within 12q22-q23 and is approximately 6 kb in length. This allele, which encodes dual specificity protein phosphatase 6 protein, is involved in protein dephosphorylation and the negative regulation of mitogen-activated protein kinase-dependent signaling.","DUSP6 wt Allele | Dual Specificity Phosphatase 6 wt Allele | HH19 | MKP3 | PYST1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1608529","Dual Specificity Protein Phosphatase 6, Human","C106026","Dual specificity protein phosphatase 6 (381 aa, ~42 kDa) is encoded by the human DUSP6 gene. This protein plays a role in both dephosphorylation and inactivation of mitogen-activated protein kinases.","Dual Specificity Protein Phosphatase 6 | DUSP6 | Dual Specificity Protein Phosphatase PYST1 | Dual-Specificity Protein Phosphatase 6 | EC 3.1.3.16 | EC 3.1.3.48 | MAP Kinase Phosphatase 3 | MKP-3 | Mitogen-Activated Protein Kinase Phosphatase 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813581","SPRY2 wt Allele","C106028","Human SPRY2 wild-type allele is located in the vicinity of 13q31.1 and is approximately 5 kb in length. This allele, which encodes protein sprouty homolog 2, plays a role in modulation of growth factor signaling pathways.","SPRY2 wt Allele | Sprouty Homolog 2 (Drosophila) wt Allele | hSPRY2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813608","Protein Sprouty Homolog 2","C106029","Protein sprouty homolog 2 (315 aa, ~35 kDa) is encoded by the human SPRY2 gene. This protein is involved in antagonism of growth factor signaling pathways.","Protein Sprouty Homolog 2 | SPRY2 | Sprouty 2 | Spry-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814817","APOB wt Allele","C106031","Human APOB wild-type allele is located within 2p24-p23 and is approximately 43 kb in length. This allele, which encodes apolipoprotein B-100 protein, is involved in both transport and cellular binding of lipoprotein particles. Mutation of the gene is associated with both familial ligand-defective apolipoprotein B-100 and familial hypobetalipoproteinemia type 1.","APOB wt Allele | Apolipoprotein B (Including Ag(x) Antigen) Gene | Apolipoprotein B wt Allele | FLDB | LDLCQ4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0103839","Apolipoprotein B-100, Human","C106032","Apolipoprotein B-100 (4563 aa, ~516 kDa) is encoded by the human APOB gene. This protein plays a role in both transport and cellular uptake of LDL particles.","Apolipoprotein B-100 | APOB | Apo B-100 | ApoB-100",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829284","LIM domain binding 2 protein, human","C105936","LIM domain-binding protein 2 (373 aa, ~43 kDa) is encoded by the human LDB2 gene. This protein is involved in transcription factor regulation.","LIM Domain-Binding Protein 2 | Carboxyl-Terminal LIM Domain-Binding Protein 1 | LDB2 | LIM Binding Domain 2 | LIM Domain-Binding Factor CLIM1 | LIM Domain-Binding Factor-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813164","PALMD wt Allele","C105938","Human PALMD wild-type allele is located in the vicinity of 1p22-p21 and is approximately 49 kb in length. This allele, which encodes palmdelphin protein, may be involved in plasma membrane dynamics.","PALMD wt Allele | C1orf11 | FLJ20271 | PALML | Palmdelphin wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447296","PALMD protein, human","C105939","Palmdelphin (551 aa, ~63 kDa) is encoded by the human PALMD gene. This protein may play a role in plasma membrane dynamics.","Palmdelphin | Paralemnin-Like Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1622228","UDP-Glucuronosyltransferase 1-9, Human","C105864","UDP-glucuronosyltransferase 1-9 (530 aa, ~60 kDa) is encoded by the human UGT1A9 gene. This protein is involved in the metabolism of phenolic compounds.","UDP-Glucuronosyltransferase 1-9 | EC 2.4.1.17 | UDP Glycosyltransferase 1 Family, Polypeptide A9 | UDP-Glucuronosyltransferase 1-I | UDP-Glucuronosyltransferase 1A9 | UDPGT 1-9 | UGT-1I | UGT1*9 | UGT1-09 | UGT1.9 | UGT1A9 | UGT1I | lugP4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539428","PIEZO1 Gene","C106083","This gene plays a role in ion transport.","PIEZO1 Gene | PIEZO1 | Piezo-Type Mechanosensitive Ion Channel Component 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811160","PIEZO1 wt Allele","C106084","Human PIEZO1 wild-type allele is located in the vicinity of 16q24.3 and is approximately 70 kb in length. This allele, which encodes piezo-type mechanosensitive ion channel component 1 protein, is involved in mechanically regulated ion transport.","PIEZO1 wt Allele | FAM38A | Family with Sequence Similarity 38, Member A Gene | KIAA0233 | Mib | Piezo-Type Mechanosensitive Ion Channel Component 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1872588","Piezo-Type Mechanosensitive Ion Channel Component 1, Human","C106085","Piezo-type mechanosensitive ion channel component 1 (2521 aa, ~287 kDa) is encoded by the human PIEZO1 gene. This protein plays a role in detection of mechanical stimuli.","Piezo-Type Mechanosensitive Ion Channel Component 1 | Membrane Protein Induced By Beta-Amyloid Treatment | Mib | Protein FAM38A | Protein PIEZO1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448201","PIEZO2 Gene","C106086","This gene is involved in the response to mechanical stimuli.","PIEZO2 Gene | PIEZO2 | Piezo-Type Mechanosensitive Ion Channel Component 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811695","PIEZO2 wt Allele","C106087","Human PIEZO2 wild-type allele is located in the vicinity of 18p11.21 and is approximately 479 kb in length. This allele, which encodes piezo-type mechanosensitive ion channel component 2 protein, plays a role in the conduction of mechanical impulses.","PIEZO2 wt Allele | C18orf30 | C18orf58 | Chromosome 18 Open Reading Frame 30 Gene | Chromosome 18 Open Reading Frame 58 Gene | FAM38B | FAM38B2 | FLJ23144 | FLJ23403 | FLJ34907 | Family with Sequence Similarity 38, Member B Gene | HsT748 | HsT771 | Piezo-Type Mechanosensitive Ion Channel Component 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814819","Piezo-Type Mechanosensitive Ion Channel Component 2","C106088","Piezo-type mechanosensitive ion channel component 2 (2752 aa, ~318 kDa) is encoded by the human PIEZO2 gene. This protein is involved in ion transport.","Piezo-Type Mechanosensitive Ion Channel Component 2 | Protein FAM38B | Protein PIEZO2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419021","PSMC2 Gene","C106089","This gene is involved in the regulation of proteasomal activity.","PSMC2 Gene | PSMC2 | Proteasome 26S Subunit, ATPase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810650","PSMC2 wt Allele","C106090","Human PSMC2 wild-type allele is located within 7q22.1-q22.3 and is approximately 25 kb in length. This allele, which encodes 26S proteasome regulatory subunit 7 protein, plays a role in both ATP hydrolysis and the modulation of proteasomal activity.","PSMC2 wt Allele | MSS1 | Mammalian Suppressor of sgv-1 of Yeast Gene | Nbla10058 | Protease 26S, Subunit 7 Gene | Proteasome (Prosome, Macropain) 26S Subunit, ATPase, 2 Gene | Proteasome 26S Subunit, ATPase 2 wt Allele | Proteasome 26S Subunit, ATPase, 2 Gene | RPT1 | S7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1448710","proteasome (prosome, macropain) 26S subunit, ATPase, 2 protein, human","C106091","26S proteasome regulatory subunit 7 (433 aa, ~49 kDa) is encoded by the human PSMC2 gene. This protein is involved in both the regulation of proteasome-mediated degradation of ubiquitinated proteins and ATP hydrolysis.","26S Proteasome Regulatory Subunit 7 | 26S Protease Regulatory Subunit 7 | 26S Proteasome AAA-ATPase Subunit RPT1 | PSMC2 | Protease 26S Subunit 7 | Proteasome 26S Subunit ATPase 2 | Protein MSS1 | Putative Protein Product of Nbla10058 | Testis Secretory Sperm-Binding Protein Li 197a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1565573","Killer Cell Immunoglobulin-Like Receptor 2DS1, Human","C106094","Killer cell immunoglobulin-like receptor 2DS1 (304 aa, ~34 kDa) is encoded by the human KIR2DS1 gene. This protein plays a role in natural killer cell-mediated immunity.","Killer Cell Immunoglobulin-Like Receptor 2DS1 | CD158 Antigen-Like Family Member H | CD158h | CD158h Antigen | KIR2DS1 | Killer Cell Immunoglobulin-Like Receptor KIRDS1 | MHC Class I NK Cell Receptor Eb6 ActI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810583","TAOK3 wt Allele","C106219","Human TAOK3 wild-type allele is located within 12q and is approximately 223 kb in length. This allele, which encodes serine/threonine-protein kinase TAO3 protein, plays a role in both signal transduction and serine/threonine phosphorylation.","TAOK3 wt Allele | DPK | JIK | KDS | MAP3K18 | TAO Kinase 3 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814066","TAOK3 protein, human","C106220","Serine/threonine-protein kinase TAO3 (898 aa, ~105 kDa) is encoded by the human TAOK3 gene. This protein is involved in both serine/threonine phosphorylation and mitogen-activated kinase signaling pathway regulation.","Serine/Threonine-Protein Kinase TAO3 | CTCL-Associated Antigen HD-CL-09 | Cutaneous T-Cell Lymphoma-Associated Antigen HD-CL-09 | Dendritic Cell-Derived Protein Kinase | EC 2.7.11.1 | JNK/SAPK-Inhibitory Kinase | Jun Kinase-Inhibitory Kinase | Kinase from Chicken Homolog A | STE20-Like Kinase | TAOK3 | Thousand and One Amino Acid Protein 3 | hKFC-A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813165","VTCN1 wt Allele","C106222","Human VTCN1 wild-type allele is located in the vicinity of 1p13.1 and is approximately 67 kb in length. This allele, which encodes V-set domain-containing T-cell activation inhibitor 1 protein, is involved in the negative regulation of T-cell-mediated immunity.","VTCN1 wt Allele | B7 Family Member, H4 Gene | B7 Superfamily Member 1 Gene | B7-H4 | B7H4 | B7S1 | B7X | B7h.5 | FLJ22418 | PRO1291 | RP11-229A19.4 | UNQ659/PRO1291 | V-Set Domain Containing T Cell Activation Inhibitor 1 wt Allele | VCTN1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1259813","VTCN1 protein, human","C106223","V-set domain-containing T-cell activation inhibitor 1 (282 aa, ~31 kDa) is encoded by the human VTCN1 gene. This protein plays a role in the inhibition of T-cell functions.","V-Set Domain-Containing T-Cell Activation Inhibitor 1 | B7 Homolog 4 | B7h.5 | Immune Costimulatory Protein B7-H4 | Protein B7S1 | T-Cell Costimulatory Molecule B7x | VTCN1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811768","POLD1 wt Allele","C106225","Human POLD1 wild-type allele is located in the vicinity of 19q13.3 and is approximately 34 kb in length. This allele, which encodes DNA polymerase delta catalytic subunit protein, plays a role in DNA replication. Mutation of the gene may be associated with increased susceptibility to colorectal malignancies.","POLD1 wt Allele | CDC2 | CDC2 Homolog (S. cerevisiae) Gene | CRCS10 | DNA Polymerase Delta 1, Catalytic Subunit wt Allele | MDPL | POLD | Polymerase (DNA Directed), Delta 1, Catalytic Subunit (125kD) Gene | Polymerase (DNA Directed), Delta 1, Catalytic Subunit Gene | Polymerase (DNA) Delta 1, Catalytic Subunit Gene | Polymerase (DNA-Directed), Delta 1, Catalytic Subunit Gene | Polymerase, DNA, Delta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811769","POLD1 protein, human","C106226","DNA polymerase delta catalytic subunit (1107 aa, ~124 kDa) is encoded by the human POLD1 gene. This protein is involved in both DNA leading strand synthesis and Okazaki fragment completion.","DNA Polymerase Delta Catalytic Subunit | CDC2 Homolog | DNA Polymerase Subunit Delta p125 | EC 2.7.7.7 | POLD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814043","POLD3 wt Allele","C106228","Human POLD3 wild-type allele is located in the vicinity of 11q14 and is approximately 175 kb in length. This allele, which encodes DNA polymerase delta subunit 3 protein, is involved in the positive regulation of DNA replication. Somatic mutation of the gene may be associated with renal cell carcinoma.","POLD3 wt Allele | KIAA0039 | P66 | P68 | Pol Delta C Subunit (p66) Gene | Polymerase (DNA Directed), Delta 3, Accessory Subunit wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1308940","Tripartite Motif-Containing Protein 16, Human","C106035","Tripartite motif-containing protein 16 (564 aa, ~64 kDa) is encoded by the human TRIM16 gene. This protein is involved in histone acetylation, keratinocyte differentiation and retinoic acid signaling.","Tripartite Motif-Containing Protein 16 | E3 Ubiquitin-Protein Ligase TRIM16 | EC 2.3.2.27 | Estrogen-Responsive B Box Protein | TRIM16",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538712","UGT1A6 wt Allele","C105573","Human UGT1A6 wild-type allele is located in the vicinity of 2q37 and is approximately 82 kb in length. This allele, which encodes UDP-glucuronosyltransferase 1-6 protein, plays a role in both the conjugation and excretion of phenols.","UGT1A6 wt Allele | GNT1 | HLUGP | HLUGP1 | UDP Glucuronosyltransferase 1 Family, Polypeptide A6 wt Allele | UDPGT | UDPGT 1-6 | UGT-1F | UGT1 | UGT1*6 | UGT1-06 | UGT1.6 | UGT1A6S | UGT1F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541875","UDP-Glucuronosyltransferase 1-6, Human","C105574","UDP-glucuronosyltransferase 1-6 (532 aa, ~61 kDa) is encoded by the human UGT1A6 gene. This protein is involved in the elimination of phenolic metabolites.","UDP-Glucuronosyltransferase 1-6 | EC 2.4.1.17 | Phenol-Metabolizing UDP-Glucuronosyltransferase | UDP Glycosyltransferase 1 Family, Polypeptide A6 | UDP-Glucuronosyltransferase 1 Family Polypeptide A6s | UDP-Glucuronosyltransferase 1-F | UDP-Glucuronosyltransferase 1A6 | UGT1A6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541239","UGT2B7 wt Allele","C105576","Human UGT2B7 wild-type allele is located in the vicinity of 4q13 and is approximately 62 kb in length. This allele, which encodes UDP-glucuronosyltransferase 2B7 protein, is involved in regulating levels of estrogens and estradiols.","UGT2B7 wt Allele | EC 2.4.1.17 | UDP Glucuronosyltransferase 2 Family, Polypeptide B7 wt Allele | UDPGT 2B7 | UDPGT 2B9 | UDPGT2B7 | UDPGTH2 | UDPGTh-2 | UGT2B9 | UGTB2B9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1504898","UDP-Glucuronosyltransferase 2B7, Human","C105577","UDP-glucuronosyltransferase 2B7 (529 aa, ~61 kDa) is encoded by the human UGT2B7 gene. This protein plays a role in regulating the metabolism of estrogen metabolites.","UDP-Glucuronosyltransferase 2B7 | 3,4-Catechol Estrogen Specific | 3,4-Catechol Estrogen-Specific UDPGT | EC 2.4.1.17 | UDP Glucuronosyltransferase 2B7 | UDP Glycosyltransferase 2 Family, Polypeptide B7 | UDP-Glucuronosyltransferase 2B9 | UDP-Glucuronyltransferase, Family 2, Beta-7 | UGT2B17 | UGT2B7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0766421","MBD4 protein, human","C106168","Methyl-CpG-binding domain protein 4 (580 aa, ~66 kDa) is encoded by the human MBD4 gene. This protein is involved in the DNA mismatch-specific glycosylase activity.","Methyl-CpG-Binding Domain Protein 4 | 3,N(4)-Ethenocytosine Glycosylase | EC 3.2.2.- | G/5-Fluorouracil Mismatch Glycosylase with Biphasic Kinetics | G/T Mismatch Glycosylase | G/U Mismatch Glycosylase | MBD4 | Methyl-CpG-Binding Endonuclease 1 | Methyl-CpG-Binding Protein MBD4 | Mismatch-Specific DNA N-Glycosylase | Putative Methyl-CpG Binding Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829111","Mexican City","C106174","A named municipality within a Mexican state.","Mexican City | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421418","VAMP1 Gene","C106095","This gene is involved in neurotransmitter secretion.","VAMP1 Gene | VAMP1 | Vesicle-Associated Membrane Protein 1 (Synaptobrevin 1) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811805","VAMP1 wt Allele","C106096","Human VAMP1 wild-type allele is located within 12p and is approximately 9 kb in length. This allele, which encodes vesicle-associated membrane protein 1, plays a role in the secretion of neurotransmitters.","VAMP1 wt Allele | SYB1 | VAMP-1 | Vesicle-Associated Membrane Protein 1 (Synaptobrevin 1) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1505736","Vesicle-Associated Membrane Protein 1, human","C106097","Vesicle-associated membrane protein 1 (118 aa, ~13 kDa) is encoded by the human VAMP1 gene. This protein is involved in neurotransmitter secretion.","Vesicle-Associated Membrane Protein 1 | Synaptobrevin 1 | Synaptobrevin-1 | VAMP-1 | VAMP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642272","Harold C Simmons Cancer Center","C105623","The Harold C Simmons Cancer Center is focused on translational cancer research. It became an NCI-designated cancer center in 2010. It is part of University of Texas Southwestern Medical Center.","Harold C Simmons Cancer Center | Harold C Simmons Cancer Center at the University of Texas Southwestern Medical Center | Harold C Simmons Comprehensive Cancer Center | Simmons Cancer Center",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539633","Hollings Cancer Center","C105624","The mission of the Hollings Cancer Center is to reduce the cancer burden in South Carolina through high-quality patient care, research, professional education, and cancer prevention programs with a focus on reaching underserved populations. It became an NCI-designated cancer center in 2009. It is a Medical University of South Carolina center.","Hollings Cancer Center | HCC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642274","The University of Kansas Cancer Center","C105627","The University of Kansas Cancer Center is focused on using drug discovery, delivery, and development to transform the delivery of clinical care in Kansas and Missouri. It became an NCI-designated cancer center in 2012. Its partners include University of Kansas, University of Kansas Medical Center, University of Kansas Hospital, KU School of Pharmacy, University of Kansas School of Medicine, Wichita, and Stowers Institute for Medical Research.","The University of Kansas Cancer Center | KUCC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642275","University of Maryland Marlene and Stewart Greenebaum Cancer Center","C105628","The mission of the University of Maryland Marlene and Stewart Greenebaum Cancer Center is to conduct innovative basic and clinical research that will impact the understanding and treatment of cancer around the world and to provide state-of-the-art clinical care to cancer patients in Maryland and beyond. It became an NCI-designated cancer center in 2008. Its parent institutions include University of Maryland School of Medicine and University of Maryland Medical System.","University of Maryland Marlene and Stewart Greenebaum Cancer Center | UMGCC | University of Maryland Greenebaum Cancer Center",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642276","University of New Mexico Cancer Center","C105629","The mission of the University of New Mexico Cancer Center is to reduce the burden of cancer incidence and mortality by discovering the genetic, environmental, social, and behavioral factors that contribute to the distinct cancer patterns and disparities in the American Southwest; translate its scientific discoveries to novel diagnostic, screening, prevention, and therapeutic tools and clinical trials; and assure that all New Mexicans have access to outstanding cancer treatment and clinical trials. It became an NCI-designated cancer center in 2005. It is a University of New Mexico center.","University of New Mexico Cancer Center | UNM Cancer Center | UNMCC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642277","Winship Cancer Institute","C105630","Winship Cancer Institute is dedicated to the integration of innovative clinical and basic science research with patient care for the prevention, treatment, and control of cancer. It became an NCI-designated cancer center in 2009. It is a component of the Robert W. Woodruff Health Sciences Center of Emory University.","Winship Cancer Institute | Winship | Winship Cancer Institute of Emory University",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642278","SPL Substance Indexing Terminology","C105631","Terminology used for representation of the information with substance indexing in the framework of the Structured Product Labeling documents.","SPL Substance Indexing Terminology | Structured Product Labeling Substance Indexing Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539758","ULBP1 wt Allele","C105581","Human ULBP1 wild-type allele is located in the vicinity of 6q25.1 and is approximately 10 kb in length. This allele, which encodes UL16-binding protein 1, plays a role in the production of both cytokines and chemokines by natural killer cells.","ULBP1 wt Allele | Alcan-Beta Gene | MULT1 | N2DL-1 | N2DL1 | NKG2DL1 | RAET1I | Retinoic Acid Early Transcript 1I Gene | UL16 Binding Protein 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642258","NKG2D Ligand 1","C105582","UL16-binding protein 1 (244 aa, ~28 kDa) is encoded by the human ULBP1 gene. This protein is involved in activation of multiple signaling pathways in primary NK cells.","UL16-Binding Protein 1 | ALCAN-Beta | N2DL-1 | NKG2D Ligand 1 | NKG2D Ligand 1 | NKG2DL1 | Retinoic Acid Early Transcript 1I | ULBP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539757","ULBP2 wt Allele","C105584","Human ULBP2 wild-type allele is located in the vicinity of 6q25.1 and is approximately 7 kb in length. This allele, which encodes UL16-binding protein 2, is involved in the activation of multiple signaling pathways in primary NK cells.","ULBP2 wt Allele | ALCAN-Alpha Gene | N2DL-2 | N2DL2 | NKG2DL2 | RAET1H | Retinoic Acid Early Transcript 1H Gene | UL16 Binding Protein 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814449","RBM4 wt Allele","C106258","Human RBM4 wild-type allele is located in the vicinity of 11q13 and is approximately 28 kb in length. This allele, which encodes RNA-binding protein 4, is involved in muscle cell differentiation, translation of mRNA and alternative splicing.","RBM4 wt Allele | LARK | RBM4A | RNA Binding Motif Protein 4 wt Allele | ZCCHC21 | ZCRB3A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433893","PIM Kinase Inhibitor LGH447","C106259","An orally available pan-PIM protein kinase inhibitor with potential antineoplastic activity. PIM kinase inhibitor LGH447 binds to and inhibits the activities of PIM-1, -2 and -3 serine/threonine kinases, which may result in the interruption of the G1/S phase cell cycle transition, the expression of the pro-apoptotic Bcl2 protein and tumor cell apoptosis in cells that overexpress PIMs. PIM kinases, downstream effectors of many cytokine and growth factor signaling pathways, play key roles in cell cycle progression and apoptosis inhibition and may be overexpressed in various malignancies.","PIM Kinase Inhibitor LGH447 | LGH-447 | LGH447 | PIM 447 | PIM-447 | PIM447",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815596","RNA-Binding Protein 4, Human","C106260","RNA-binding protein 4 (364 aa, ~40 kDa) is encoded by the human RBM4 gene. This protein plays a role in alternative splicing, muscle cell differentiation and translation.","RNA-Binding Protein 4 | Lark Homolog | RBM4 | RNA-Binding Motif Protein 4 | RNA-Binding Motif Protein 4a | Zinc Finger CCHC-Type and RNA Binding Motif 3A | hLark",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433894","PI3K-beta Inhibitor GSK2636771","C106261","An orally bioavailable, substituted benzimidazole inhibitor of the class I phosphoinositide 3-kinase (PI3K) beta isoform with potential antineoplastic activity. PI3K beta inhibitor GSK2636771 selectively inhibits PI3K beta kinase activity in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K beta-expressing and/or PTEN-driven tumor cells. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and results in the promotion of tumor cell growth, survival, and resistance to both chemotherapy and radiotherapy. PI3K beta is the p110-beta catalytic subunit of the class I PI3K. PTEN, a tumor suppressor protein and negative regulator of PI3K activity, is often mutated in a variety of cancer cells.","PI3K-beta Inhibitor GSK2636771 | GSK-2636771 | GSK2636771",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714658","Month of the Year","C106179","Any of the 12 major divisions of the year, each lasting approximately 30 days.","Month of the Year | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828980","Molecular Density","C105704","The number of molecules contained in a specific volume.","Molecular Density | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447073","Unit Density","C105705","The number of arbitrary units of something contained in a specific volume.","Unit Density | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815180","PiggyBac Transposable Element-Derived Protein 5","C105708","PiggyBac transposable element-derived protein 5 (455 aa, ~52 kDa) is encoded by the human PGBD5 gene. This protein may play a role in transposable DNA element movement.","PiggyBac Transposable Element-Derived Protein 5 | PGBD5 | PiggyBac Domain-Related Protein 5 | PiggyBac Transposase 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815539","Dewey County, SD","C110069","No value exists.","Dewey County, SD | Dewey County | Dewey County, South Dakota | SD041",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830337","Edmunds County, SD","C110071","No value exists.","Edmunds County, SD | Edmunds County | Edmunds County, South Dakota | SD045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830260","Fall River County, SD","C110072","No value exists.","Fall River County, SD | Fall River County | Fall River County, South Dakota | SD047",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830174","Faulk County, SD","C110073","No value exists.","Faulk County, SD | Faulk County | Faulk County, South Dakota | SD049",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813981","Grant County, SD","C110074","No value exists.","Grant County, SD | Grant County | Grant County, South Dakota | SD051",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829935","Gregory County, SD","C110075","No value exists.","Gregory County, SD | Gregory County | Gregory County, South Dakota | SD053",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829907","Hamlin County, SD","C110077","No value exists.","Hamlin County, SD | Hamlin County | Hamlin County, South Dakota | SD057",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829903","Hand County, SD","C110078","No value exists.","Hand County, SD | Hand County | Hand County, South Dakota | SD059",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829898","Hanson County, SD","C110079","No value exists.","Hanson County, SD | Hanson County | Hanson County, South Dakota | SD061",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814854","Harding County, SD","C110080","No value exists.","Harding County, SD | Harding County | Harding County, South Dakota | SD063",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814033","Hughes County, SD","C110081","No value exists.","Hughes County, SD | Hughes County | Hughes County, South Dakota | SD065",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814446","Hyde County, SD","C110083","No value exists.","Hyde County, SD | Hyde County | Hyde County, South Dakota | SD069",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814855","Jackson County, SD","C110084","No value exists.","Jackson County, SD | Jackson County | Jackson County, South Dakota | SD071",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829459","Jerauld County, SD","C110085","No value exists.","Jerauld County, SD | Jerauld County | Jerauld County, South Dakota | SD073",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814856","Jones County, SD","C110086","No value exists.","Jones County, SD | Jones County | Jones County, South Dakota | SD075",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829381","Kingsbury County, SD","C110087","No value exists.","Kingsbury County, SD | Kingsbury County | Kingsbury County, South Dakota | SD077",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813667","Lawrence County, SD","C110089","No value exists.","Lawrence County, SD | Lawrence County | Lawrence County, South Dakota | SD081",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815577","Lincoln County, SD","C110090","No value exists.","Lincoln County, SD | Lincoln County | Lincoln County, South Dakota | SD083",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810568","KRT14 wt Allele","C105982","Human KRT14 wild-type allele is located within 17q12-q21 and is approximately 5 kb in length. This allele, which encodes keratin, type I cytoskeletal 14 protein, plays a role in the regulation of cell morphology. Mutations in this gene are associated with dermatopathia pigmentosa reticularis, Naegeli-Franceschetti-Jadassohn syndrome, and several types of epidermolysis bullosa simplex.","KRT14 wt Allele | CK-14 | CK14 | EBS3 | EBS4 | K14 | Keratin 14 wt Allele | NFJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1611622","Keratin, Type I Cytoskeletal 14, Human","C105983","Keratin, type I cytoskeletal 14 (472 aa, ~52 kDa) is encoded by the human KRT14 gene. This protein is involved in cell morphology regulation.","Keratin, Type I Cytoskeletal 14 | CK-14 | Cytokeratin 14 | Cytokeratin-14 | K14 | KRT14 | Keratin 14 | Keratin-14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811719","MIR150 wt Allele","C105986","Human MIR150 wild-type allele is located in the vicinity of 19q13.33 and is 84 bases in length. This allele, which encodes MIR150 pre-miRNA, may play a role in the regulation of gene transcription.","MIR150 wt Allele | MIRN150 | MicroRNA 150 wt Allele | hsa-mir-150 | miR-150 | miRNA 150 | miRNA150 | mir-150",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829010","MIR150 Pre-miRNA","C105987","MIR150 pre-miRNA (84 bases) is encoded by the human MIR150 gene. This ribonucleotide may be involved in the regulation of transcription.","MIR150 Pre-miRNA | MIR150 pre-miRNA | Pre-MicroRNA 150 | Pre-miRNA 150 | Pre-miRNA MIR150",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811722","MIR191 wt Allele","C105989","Human MIR191 wild-type allele is located in the vicinity of 3p21.31 and is 92 bases in length. This allele, which encodes MIR191 pre-miRNA, may play a role in the regulation of transcription.","MIR191 wt Allele | MIRN191 | MicroRNA 191 wt Allele | hsa-mir-191 | miR-191 | miRNA 191 | miRNA191 | mir-191",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829009","MIR191 Pre-miRNA","C105990","MIR191 pre-miRNA (92 bases) is encoded by the human MIR191 gene. This ribonucleotide may be involved in the regulation of gene transcription.","MIR191 Pre-miRNA | MIR191 pre-miRNA | Pre-MicroRNA 191 | Pre-miRNA 191 | Pre-miRNA MIR191",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811127","SULT1E1 wt Allele","C105992","Human SULT1E1 wild-type allele is located in the vicinity of 4q13.1 and is approximately 49 kb in length. This allele, which encodes estrogen sulfotransferase protein, is involved in the metabolism of estrogen.","SULT1E1 wt Allele | EST | EST-1 | ST1E1 | STE | Sulfotransferase Family 1E, Estrogen-Preferring, Member 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0059669","sulfotransferase family 1E, estrogen-preferring, member 1 protein, human","C105993","Estrogen sulfotransferase (294 aa, ~35 kDa) is encoded by the human SULT1E1 gene. This protein plays a role in the conjugation of sulfate to estrogens.","Estrogen Sulfotransferase | EC 2.8.2.4 | EST-1 | Estrone Sulfotransferase | ST1E1 | SULT1E1 | Sulfotransferase 1E1 | Sulfotransferase, Estrogen-Preferring",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433934","anti-c-Met monoclonal antibody ABT-700","C106262","An immunoglobulin G1 (IgG1) humanized monoclonal antibody directed against human hepatocyte growth factor receptor (HGFR or c-Met), with potential antineoplastic activity. Telisotuzumab binds to c-Met, thereby preventing both c-Met binding to its ligand, HGF and the subsequent activation of the HGF/c-Met signaling pathway. This may cause cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.","Telisotuzumab | ABT-700 | Anti-c-Met Monoclonal Antibody ABT-700 | TELISOTUZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814526","RAD52 wt Allele","C106264","Human RAD52 wild-type allele is located within 12p13-p12.2 and is approximately 79 kb in length. This allele, which encodes DNA repair protein RAD52 homolog, plays a role in both homologous recombination and DNA repair.","RAD52 wt Allele | RAD52 (S. cerevisiae) Homolog Gene | RAD52 Homolog (S. cerevisiae) Gene | RAD52 Homolog, DNA Repair Protein wt Allele | RAD52, Yeast Homolog of Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0663124","DNA Repair Protein RAD52 Homolog, Human","C106265","DNA repair protein RAD52 homolog (418 aa, ~46 kDa) is encoded by the human RAD52 gene. This protein is involved in both homologous recombination and double-strand break repair.","DNA Repair Protein RAD52 Homolog | RAD52 | Recombination Protein RAD52 | Rhabdomyosarcoma Antigen MU-RMS-40.23",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433957","Anti-CD27L Antibody-Drug Conjugate AMG 172","C106266","An immunoconjugate consisting of a human IgG1 monoclonal antibody directed against CD27L conjugated, via a non-cleavable linker, to the cytotoxic agent maytansinoid DM1, with potential antineoplastic activity. The monoclonal antibody moiety of this immunoconjugate binds to CD27L on tumor cell surfaces. After internalization, the DM1 moiety binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting both cell division and proliferation of cancer cells that express CD27L. CD27L, a type II transmembrane protein and member of the tumor necrosis factor family, is a co-stimulatory molecule constitutively expressed on a subset of activated T-cells, B-cells, and dendritic cells, which is overexpressed in certain tumor cell types.","Anti-CD27L Antibody-Drug Conjugate AMG 172 | AMG 172 | AMG-172",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827381","MNX1/ETV6 Fusion Protein","C105818","A fusion protein encoded by the MNX1/ETV6 fusion gene. This protein is comprised of the N-terminal portion of the motor neuron and pancreas homeobox protein 1 protein, including the polyalanine repeat domain, fused to most of the transcription factor ETV6 protein, including the helix-loop-helix and ETS domains.","MNX1/ETV6 Fusion Protein | HLXB9-ETV6 Fusion Protein | HLXB9/ETV6 Fusion Protein | Homeobox Protein HB9/Transcription Factor ETV6 Fusion Protein | MNX1-ETV6 Fusion Protein | MNX1::ETV6 Fusion Protein | Motor Neuron and Pancreas Homeobox Protein 1/Transcription Factor ETV6 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3530154","CBFA2T3/GLIS2 Fusion Protein, Human","C105820","A fusion protein encoded by the CBFA2T3/GLIS2 fusion gene. This protein is comprised of the N-terminal TAFH domain of the protein CBFA2T3 protein fused to the zinc finger protein GLIS2 protein.","CBFA2T3/GLIS2 Fusion Protein | CBFA2T3-GLIS2 Fusion Protein | CBFA2T3::GLIS2 Fusion Protein | Protein CBFA2T3/Zinc Finger Protein GLIS2 Fusion Protein | Protein CBFA2T3::Zinc Finger Protein GLIS2 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814790","DACT2 wt Allele","C105719","Human DACT2 wild-type allele is located in the vicinity of 6q27 and is approximately 27 kb in length. This allele, which encodes dapper homolog 2 protein, plays a role in the negative regulation of signal transduction.","DACT2 wt Allele | C6orf116 | Chromosome 6 Open Reading Frame 116 Gene | DAPPER2 | DPR2 | Dapper, Antagonist of Beta-Catenin, Homolog 2 (Xenopus laevis) wt Allele | PP13671 | RP11-503C24.7 | bA503C24.7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814455","PAP-2b","C105942","Human PLPP3 wild-type allele is located in the vicinity of 1p32.2 and is approximately 151 kb in length. This allele, which encodes phospholipid phosphatase 3 protein, plays a role in both diacylglycerol metabolism and phospholipase D cell signaling.","PLPP3 wt Allele | Dri42 | LPP3 | PAP-2b | PAP2B | PPAP2B | Phosphatidic Acid Phosphatase Type 2B Gene | Phospholipid Phosphatase 3 wt Allele | VCIP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816452","PPAP2B protein, human","C105943","Phospholipid phosphatase 3 (311 aa, ~35 kDa) is encoded by the human PLPP3 gene. This protein is involved in both cell signaling and diacylglycerol metabolism.","Phospholipid Phosphatase 3 | EC 3.1.3.4 | Lipid Phosphate Phosphohydrolase 3 | PAP2 Beta | PAP2-Beta | PLPP3 | Phosphatidate Phosphohydrolase Type 2b | Phosphatidic Acid Phosphatase 2b | Phosphatidic Acid Phosphatase Type 2B | Type-2 Phosphatidic Acid Phosphatase-Beta | VCIP | Vascular Endothelial Growth Factor and Type I Collagen Inducible | Vascular Endothelial Growth Factor and Type I Collagen-Inducible Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829237","Lyman County, SD","C110091","No value exists.","Lyman County, SD | Lyman County | Lyman County, South Dakota | SD085",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829164","McCook County, SD","C110092","No value exists.","McCook County, SD | McCook County | McCook County, South Dakota | SD087",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812241","McPherson County, SD","C110093","No value exists.","McPherson County, SD | McPherson County | McPherson County, South Dakota | SD089",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812247","Meade County, SD","C110095","No value exists.","Meade County, SD | Meade County | Meade County, South Dakota | SD093",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829132","Mellette County, SD","C110096","No value exists.","Mellette County, SD | Mellette County | Mellette County, South Dakota | SD095",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829062","Miner County, SD","C110097","No value exists.","Miner County, SD | Miner County | Miner County, South Dakota | SD097",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829056","Minnehaha County, SD","C110098","No value exists.","Minnehaha County, SD | Minnehaha County | Minnehaha County, South Dakota | SD099",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828963","Moody County, SD","C110099","No value exists.","Moody County, SD | Moody County | Moody County, South Dakota | SD101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811205","Northampton County, VA","C110570","No value exists.","Northampton County, VA | Northampton County | Northampton County, Virginia | VA131",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811207","Northumberland County, VA","C110571","No value exists.","Northumberland County, VA | Northumberland County | Northumberland County, Virginia | VA133",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828768","Nottoway County, VA","C110572","No value exists.","Nottoway County, VA | Nottoway County | Nottoway County, Virginia | VA135",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812749","Orange County, VA","C110573","No value exists.","Orange County, VA | Orange County | Orange County, Virginia | VA137",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812825","Page County, VA","C110574","No value exists.","Page County, VA | Page County | Page County, Virginia | VA139",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828636","Patrick County, VA","C110575","No value exists.","Patrick County, VA | Patrick County | Patrick County, Virginia | VA141",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828545","Pittsylvania County, VA","C110576","No value exists.","Pittsylvania County, VA | Pittsylvania County | Pittsylvania County, Virginia | VA143",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828497","Powhatan County, VA","C110577","No value exists.","Powhatan County, VA | Powhatan County | Powhatan County, Virginia | VA145",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828475","Prince Edward County, VA","C110578","No value exists.","Prince Edward County, VA | Prince Edward County | Prince Edward County, Virginia | VA147",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816737","Prince George County, VA","C110579","No value exists.","Prince George County, VA | Prince George County | Prince George County, Virginia | VA149",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812296","Pulaski County, VA","C110581","No value exists.","Pulaski County, VA | Pulaski County | Pulaski County, Virginia | VA155",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828370","Rappahannock County, VA","C110582","No value exists.","Rappahannock County, VA | Rappahannock County | Rappahannock County, Virginia | VA157",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813290","Richmond County, VA","C110583","No value exists.","Richmond County, VA | Richmond County | Richmond County, Virginia | VA159",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828316","Roanoke County, VA","C110584","No value exists.","Roanoke County, VA | Roanoke County | Roanoke County, Virginia | VA161",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828312","Rockbridge County, VA","C110585","No value exists.","Rockbridge County, VA | Rockbridge County | Rockbridge County, Virginia | VA163",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813305","Rockingham County, VA","C110586","No value exists.","Rockingham County, VA | Rockingham County | Rockingham County, Virginia | VA165",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811800","Scott County, VA","C110588","No value exists.","Scott County, VA | Scott County | Scott County, Virginia | VA169",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811385","BAG3 wt Allele","C105995","Human BAG3 wild-type allele is located within 10q25.2-q26.2 and is approximately 26 kb in length. This allele, which encodes BAG family molecular chaperone regulator 3 protein, plays a role in the modulation of both apoptosis and protein folding. Mutation of the gene is associated with both myopathy myofibrillar type 6 and cardiomyopathy dilated type 1HH.","BAG3 wt Allele | BAG-3 | BCL2-Associated Athanogene 3 wt Allele | BIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816451","BAG Family Molecular Chaperone Regulator 3, human","C105996","BAG family molecular chaperone regulator 3 (575 aa, ~62 kDa) is encoded by the human BAG3 gene. This protein is involved in both protein chaperone activity modulation and the negative regulation of apoptosis.","BAG Family Molecular Chaperone Regulator 3 | BAG-3 | BAG-Family Molecular Chaperone Regulator-3 | BAG3 | Bcl-2-Associated Athanogene 3 | Bcl-2-Binding Protein Bis | Docking Protein CAIR-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642224","Unit Per Gram of Creatinine","C105523","A unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one unit per gram of creatinine.","Unit Per Gram of Creatinine | U/g Creatinine | U/g{creatinine}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642226","RET Gene Product","C105525","A protein encoded by the RET gene.","RET Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3642227","EGFR Gene Product","C105526","A protein encoded by the EGFR gene.","EGFR Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830172","FDA CDRH GUDID Terminology","C106039","A set of terminology created to support the efforts of the FDA CDRH Global Unique Device Identification Database project.","FDA CDRH GUDID Terminology | FDA Center for Devices and Radiological Health Global Unique Device Identification Database Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035918","Natural Rubber","C106043","The natural extract of tropical rubber plants.","Natural Rubber | NATURAL LATEX RUBBER | Natural Rubber Latex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813580","SPRY1 wt Allele","C105945","Human SPRY1 wild-type allele is located in the vicinity of 4q28.1 and is approximately 7 kb in length. This allele, which encodes protein sprouty homolog 1, may act as an antagonist of fibroblast growth factor signaling in organogenesis.","SPRY1 wt Allele | Sprouty Homolog 1, Antagonist of FGF Signaling (Drosophila) Gene wt Allele | Spry-1 | hSPRY1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828456","Protein Sprouty Homolog 1","C105946","Protein sprouty homolog 1 (319 aa, ~35 kDa) is encoded by the human SPRY1 gene. This protein may play a role in fibroblast growth factor signaling in organogenesis.","Protein Sprouty Homolog 1 | Sprouty (Drosophila) Homolog 1 (Antagonist of FGF Signaling) | Sprouty, Drosophila, Homolog of, 1 (Antagonist of FGF Signaling)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828032","Shenandoah County, VA","C110589","No value exists.","Shenandoah County, VA | Shenandoah County | Shenandoah County, Virginia | VA171",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828001","Smyth County, VA","C110590","No value exists.","Smyth County, VA | Smyth County | Smyth County, Virginia | VA173",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827969","Southampton County, VA","C110591","No value exists.","Southampton County, VA | Southampton County | Southampton County, Virginia | VA175",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814058","Stafford County, VA","C110593","No value exists.","Stafford County, VA | Stafford County | Stafford County, Virginia | VA179",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815190","Surry County, VA","C110594","No value exists.","Surry County, VA | Surry County | Surry County, Virginia | VA181",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815192","Sussex County, VA","C110595","No value exists.","Sussex County, VA | Sussex County | Sussex County, Virginia | VA183",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815209","Tazewell County, VA","C110596","No value exists.","Tazewell County, VA | Tazewell County | Tazewell County, Virginia | VA185",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812783","Warren County, VA","C110597","No value exists.","Warren County, VA | VA187 | Warren County | Warren County, Virginia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812798","Washington County, VA","C110598","No value exists.","Washington County, VA | VA191 | Washington County | Washington County, Virginia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815915","Madison County, MS","C109133","No value exists.","Madison County, MS | MS089 | Madison County | Madison County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811183","Marion County, MS","C109134","No value exists.","Marion County, MS | MS091 | Marion County | Marion County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811192","Marshall County, MS","C109135","No value exists.","Marshall County, MS | MS093 | Marshall County | Marshall County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810716","Monroe County, MS","C109136","No value exists.","Monroe County, MS | MS095 | Monroe County | Monroe County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811273","Montgomery County, MS","C109137","No value exists.","Montgomery County, MS | MS097 | Montgomery County | Montgomery County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810591","Newton County, MS","C109139","No value exists.","Newton County, MS | MS101 | Newton County | Newton County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828765","Noxubee County, MS","C109140","No value exists.","Noxubee County, MS | MS103 | Noxubee County | Noxubee County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828720","Oktibbeha County, MS","C109141","No value exists.","Oktibbeha County, MS | MS105 | Oktibbeha County | Oktibbeha County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813686","Panola County, MS","C109142","No value exists.","Panola County, MS | MS107 | Panola County | Panola County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814113","Perry County, MS","C109144","No value exists.","Perry County, MS | MS111 | Perry County | Perry County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814138","Pike County, MS","C109145","No value exists.","Pike County, MS | MS113 | Pike County | Pike County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812263","Pontotoc County, MS","C109146","No value exists.","Pontotoc County, MS | MS115 | Pontotoc County | Pontotoc County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828487","Prentiss County, MS","C109147","No value exists.","Prentiss County, MS | MS117 | Prentiss County | Prentiss County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812307","Quitman County, MS","C109148","No value exists.","Quitman County, MS | MS119 | Quitman County | Quitman County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828373","Rankin County, MS","C109149","No value exists.","Rankin County, MS | MS121 | Rankin County | Rankin County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1448128","DNA Polymerase Delta Subunit 3, Human","C106229","DNA polymerase delta subunit 3 (466 aa, ~51 kDa) is encoded by the human POLD3 gene. This protein plays a role in DNA replication.","DNA Polymerase Delta Subunit 3 | DNA Polymerase Subunit Delta p66 | POLD3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447406","cMet CAR-mRNA Electroporated Autologous T Lymphocytes","C106230","A preparation of autologous T-lymphocytes that have been electroporated with an mRNA encoding a chimeric antigen receptor (CAR) consisting of an anti-human hepatocyte growth factor receptor (HGFR or cMet) scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta) coupled to the co-stimulatory molecule 4-1BB (CD137), with potential antineoplastic activities. Upon intratumoral administration, cMet CAR-mRNA electroporated autologous T lymphocytes direct T-cells to cMet-expressing tumor cells, which induces a selective toxicity in cMet-expressing tumor cells and causes tumor cell lysis. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of cMet. The inclusion of the 4-1BB signaling domain may increase the antitumor activity as compared to the inclusion of the CD3-zeta chain alone. The mRNA CAR is expressed for a limited amount of time, which can prevent serious, unforeseen side effects. cMet, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.","cMet CAR-mRNA Electroporated Autologous T Lymphocytes | cMet RNA CAR T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447407","mRNA-derived Prostate Cancer Vaccine CV9104","C106231","A prostate cancer vaccine containing six messenger RNAs (mRNAs) encoding for antigens upregulated in prostate cancer, including mRNAs for prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), prostatic acid phosphatase (PAP), and mucin 1 (MUC1), with potential antineoplastic and immunomodulating activities. Upon intradermal administration of mRNA-derived prostate cancer vaccine CV9104, this agent enters cells, the mRNAs are translated into the respective prostate specific antigens and may cause the immune system to mount a cytotoxic T lymphocyte response (CTL) against PSA-, PSMA-, PAP- and MUC1-expressing prostate tumor cells. The mRNAs used in this vaccine are modified to have enhanced translational potency and adjuvant activities. PSA, PSMA, PAP and MUC1 are frequently upregulated in prostate cancer cells; their expression in prostate cancer has been correlated with disease progression.","mRNA-derived Prostate Cancer Vaccine CV9104 | CV9104 | RNActive-derived Prostate Cancer Vaccine CV9104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811772","POLE wt Allele","C106233","Human POLE wild-type allele is located in the vicinity of 12q24.3 and is approximately 213 kb in length. This allele, which encodes DNA polymerase epsilon catalytic subunit A protein, plays a role in both DNA base-excision repair and DNA replication. Mutation of the gene may be associated with both increased susceptibility to colorectal malignancies and facial dysmorphism, immunodeficiency, livedo, and short stature (FILS) syndrome.","POLE wt Allele | CRCS12 | DNA Polymerase Epsilon, Catalytic Subunit wt Allele | FILS | IMAGEI | POLE1 | Polymerase (DNA Directed), Epsilon Gene | Polymerase (DNA Directed), Epsilon, Catalytic Subunit Gene | Polymerase (DNA Directed), Epsilon-1 Gene | Polymerase, DNA, Epsilon Gene | Polymerase, DNA, Epsilon-1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829223","Magnetic Resonance Safe","C106045","The device poses no known hazards resulting from exposure to any MR environment. MR Safe items are composed of materials that are electrically nonconductive, nonmetallic, and nonmagnetic. See ASTM F2503.","Magnetic Resonance Safe | MR Safe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827379","Magnetic Resonance Conditional","C106046","A device with demonstrated safety in the MR environment within defined conditions. At a minimum, address the conditions of the static magnetic field, the switched gradient magnetic field and the radiofrequency fields.  Additional conditions, including specific configurations of the item, may be required. See ASTM F2503.","Magnetic Resonance Conditional | MR Conditional",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829222","Magnetic Resonance Unsafe","C106047","The device which poses unacceptable risks to the patient, medical staff or other persons within the MR environment. See ASTM F2503","Magnetic Resonance Unsafe | MR Unsafe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540617","NKG2D Ligand 2, Human","C105591","UL16-binding protein 2 (246 aa, ~27 kDa) is encoded by the human ULBP2 gene. This protein plays a role in the production of both cytokines and chemokines by natural killer cells.","UL16-Binding Protein 2 | Alcan-Alpha | N2DL-2 | NKG2D Ligand 2 | NKG2D Ligand 2 | NKG2DL2 | Retinoic Acid Early Transcript 1H | UL16 Binding Protein 2 | UL16-Binding Protein 2 | ULBP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1634526","Gram Per Gram of Creatinine","C105485","A unit of substance concentration defined as the number of grams per gram of creatinine.","Gram Per Gram of Creatinine | g/g Creatinine | g/g{Creatinine} | mg/mg Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1629844","Gram Per Mole of Creatinine","C105486","A unit of substance concentration defined as the number of grams per mole quantity of creatinine.","Gram Per Mole of Creatinine | g/mol Creatinine | g/mol{creatinine} | mg/mmol Creatinine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828038","Sharkey County, MS","C109151","No value exists.","Sharkey County, MS | MS125 | Sharkey County | Sharkey County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810609","Simpson County, MS","C109152","No value exists.","Simpson County, MS | MS127 | Simpson County | Simpson County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811209","Smith County, MS","C109153","No value exists.","Smith County, MS | MS129 | Smith County | Smith County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814472","Stone County, MS","C109154","No value exists.","Stone County, MS | MS131 | Stone County | Stone County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827865","Tallahatchie County, MS","C109156","No value exists.","Tallahatchie County, MS | MS135 | Tallahatchie County | Tallahatchie County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827855","Tate County, MS","C109157","No value exists.","Tate County, MS | MS137 | Tate County | Tate County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827826","Tippah County, MS","C109158","No value exists.","Tippah County, MS | MS139 | Tippah County | Tippah County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827824","Tishomingo County, MS","C109159","No value exists.","Tishomingo County, MS | MS141 | Tishomingo County | Tishomingo County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827750","Tunica County, MS","C109160","No value exists.","Tunica County, MS | MS143 | Tunica County | Tunica County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827515","Walthall County, MS","C109162","No value exists.","Walthall County, MS | MS147 | Walthall County | Walthall County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812780","Warren County, MS","C109163","No value exists.","Warren County, MS | MS149 | Warren County | Warren County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812796","Washington County, MS","C109164","No value exists.","Washington County, MS | MS151 | Washington County | Washington County, Mississippi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830983","Craven County, NC","C109602","No value exists.","Craven County, NC | Craven County | Craven County, North Carolina | NC049",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812866","Cumberland County, NC","C109603","No value exists.","Cumberland County, NC | Cumberland County | Cumberland County, North Carolina | NC051",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830628","Currituck County, NC","C109604","No value exists.","Currituck County, NC | Currituck County | Currituck County, North Carolina | NC053",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830604","Dare County, NC","C109605","No value exists.","Dare County, NC | Dare County | Dare County, North Carolina | NC055",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814792","Davidson County, NC","C109606","No value exists.","Davidson County, NC | Davidson County | Davidson County, North Carolina | NC057",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830599","Davie County, NC","C109607","No value exists.","Davie County, NC | Davie County | Davie County, North Carolina | NC059",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830368","Durham County, NC","C109609","No value exists.","Durham County, NC | Durham County | Durham County, North Carolina | NC063",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830339","Edgecombe County, NC","C109610","No value exists.","Edgecombe County, NC | Edgecombe County | Edgecombe County, North Carolina | NC065",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814003","Forsyth County, NC","C109611","No value exists.","Forsyth County, NC | Forsyth County | Forsyth County, North Carolina | NC067",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814018","Franklin County, NC","C109612","No value exists.","Franklin County, NC | Franklin County | Franklin County, North Carolina | NC069",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830046","Gaston County, NC","C109613","No value exists.","Gaston County, NC | Gaston County | Gaston County, North Carolina | NC071",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813968","Graham County, NC","C109615","No value exists.","Graham County, NC | Graham County | Graham County, North Carolina | NC075",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL447409","Olive Oil Extract/Curcumin-based Capsule","C106234","A capsule containing an extract of olive oil, rich in polyphenols, and curcumin, the polyphenol derived from the plant Curcuma longa, also known as turmeric, with potential anti-neoplastic, -angiogenic, -inflammatory, -oxidant and chemopreventive activities. The olive oil extract/curcumin-based capsule is rich in phytonutrients, especially polyphenols. Upon oral administration, the polyphenols, and other active ingredients in this supplement may exert anti-inflammatory activity by decreasing the production of inflammation mediators, such as TNF-alpha, interleukin (IL) 1-beta, IL-6, IL-10, interferon gamma, thromboxane B2, and leukotriene B4. They also inhibit a variety of pro-inflammatory enzymes, such as cyclooxygenase 1 (COX-1) and COX-2, block the formation of reactive-oxygen species and neutralize free radicals. In addition, curcumin and some other polyphenols disrupt cell signal transduction pathways involved in carcinogenesis. Specifically, curcumin inhibits cell invasion by inhibiting matrix metalloproteinase-9 (MMP-9) expression by suppressing NF-kB and AP-1 activation.","Olive Oil Extract/Curcumin-based Capsule | PhytoMed Medical Food Suppement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827161","selective estrogen receptor degrader ARN-810","C106235","An orally available, nonsteroidal selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, brilanestrant binds to the estrogen receptor and induces a conformational change that results in the degradation of the receptor. This may inhibit the growth and survival of ER-expressing cancer cells.","Brilanestrant | ARN-810 | BRILANESTRANT | GDC-0810 | RO7056118 | SERD ARN-810",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1431890","DNA Polymerase Epsilon Catalytic Subunit A","C106236","DNA polymerase epsilon catalytic subunit A (2286 aa, ~262 kDa) is encoded by the human POLE gene. This protein is involved in both DNA repair and DNA replication.","DNA Polymerase Epsilon Catalytic Subunit A | DNA Polymerase II Subunit A | EC 2.7.7.7 | POLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831427","Axillary Lymph Node Dissection without Prior Sentinel Lymph Node Biopsy","C105784","A surgical procedure in which the axillary lymph node group is dissected and removed without prior removal and examination of the sentinel lymph node.","Axillary Lymph Node Dissection without Prior Sentinel Lymph Node Biopsy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3539759","ULBP3 wt Allele","C105593","Human ULBP3 wild-type allele is located in the vicinity of 6q25.1 and is approximately 8 kb in length. This allele, which encodes UL16-binding protein 3, plays a role in the production of both cytokines and chemokines by natural killer cells.","ULBP3 wt Allele | ALCAN-Gamma Gene | N2DL-3 | N2DL3 | NKG2DL3 | RAET1N | Retinoic Acid Early Transcript 1N Gene | UL16 Binding Protein 3 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540618","NKG2D Ligand 3, Human","C105594","UL16-binding protein 3 (244 aa, ~28 kDa) is encoded by the human ULBP3 gene. This protein is involved in activation of multiple signaling pathways in primary NK cells.","UL16-Binding Protein 3 | Alcan-Gamma | N2DL-3 | NKG2D Ligand 3 | NKG2D Ligand 3 | NKG2DL3 | Retinoic Acid Early Transcript 1N | UL16 Binding Protein 3 | UL16-Binding Protein 3 | ULBP3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1261470","Meningocele","C105595","A congenital abnormality in which the meninges protrude through a defect in the spinal column or the cranium.","Meningocele | Central Nervous System Meningocele",,,,,,,,,,,,,,,"4065454","Congenital meningocele",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3542928","VEGFB wt Allele","C105597","Human VEGFB wild-type allele is located in the vicinity of 11q13 and is approximately 4 kb in length. This allele, which encodes vascular endothelial growth factor B protein, is involved in both endothelial cell proliferation and angiogenesis.","VEGFB wt Allele | VEGF-B | VEGFL | VRF | Vascular Endothelial Growth Factor B wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1171893","Vascular Endothelial Growth Factor B","C105598","Vascular endothelial growth factor B (207 aa, ~22 kDa) is encoded by the human VEGFB gene. This protein plays a role in both the formation of blood vessels and endothelial cell physiology.","Vascular Endothelial Growth Factor B | VEGF-Related Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3541288","VPS18 wt Allele","C105600","Human VPS18 wild-type allele is located within 15q14-q15 and is approximately 10 kb in length. This allele, which encodes vacuolar protein sorting-associated protein 18, plays a role in the segregation of intracellular molecules into distinct organelles.","VPS18 wt Allele | KIAA1475 | PEP3 | VPS18, CORVET/HOPS Core Subunit Gene | Vacuolar Protein Sorting 18 Homolog (S. cerevisiae) wt Allele | Vacuolar Protein Sorting 18, Yeast, Homolog of Gene | hVPS18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0965631","Vacuolar Protein Sorting-Associated Protein 18, Human","C105601","Vacuolar protein sorting-associated protein 18 (973 aa, ~110 kDa) is encoded by the human VPS18 gene. This protein is involved in vesicle-mediated protein trafficking.","Vacuolar Protein Sorting-Associated Protein 18 | Vacuolar Protein Sorting Protein 18 | Vacuolar Protein Sorting-Associated Protein 18 Homolog | hVPS18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811763","NTHL1 wt Allele","C106193","Human NTHL1 wild-type allele is located in the vicinity of 16p13.3 and is approximately 8 kb in length. This allele, which encodes endonuclease III-like protein 1, is involved in DNA repair by nucleotide-excision.","NTHL1 wt Allele | Endonuclease III, E. coli, Homolog of Gene | NTH1 | Nth (E.Coli Endonuclease III)-Like 1 Gene | Nth Endonuclease III-Like 1 (E. coli) Gene | Nth Like DNA Glycosylase 1 wt Allele | OCTS3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1306916","Endonuclease III-Like Protein 1, Human","C106194","Endonuclease III-like protein 1 (312 aa, ~34 kDa) is encoded by the human NTHL1 gene. This protein plays a role in nucleotide-excision repair.","Endonuclease III-Like Protein 1 | Bifunctional DNA N-Glycosylase/DNA-(Apurinic or Apyrimidinic Site) Lyase | DNA Glycosylase/AP Lyase | EC 4.2.99.18 | Endonuclease III-Like Protein | NTHL1 | Nth (E.coli Endonuclease III)-Like 1 | Nth Endonuclease III-Like 1 | Nth-Like 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810521","mER","C106199","Human GPER1 wild-type allele is located in the vicinity of 7p22.3 and is approximately 12 kb in length. This allele, which encodes G-protein coupled estrogen receptor 1 protein, is involved in both G protein-coupled receptor signaling and estrogen binding.","GPER1 wt Allele | CEPR | CMKRL2 | DRY12 | FEG-1 | G Protein-Coupled Estrogen Receptor 1 wt Allele | G Protein-Coupled Receptor 30 Gene | GPCR-Br | GPER | GPR30 | LERGU | LERGU2 | LyGPR | mER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0057158","Daunorubicin-DNA Complex","C1061","A complex comprised of Daunorubicin linked to DNA to enhance the topoisomerase II-mediated interaction with the DNA base pairs and reduce cardiotoxicity associated with anthracyclines. (NCI)","Daunorubicin-DNA Complex | DNR-DNA complex | Daunomycin-DNA Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0673013","G-Protein Coupled Estrogen Receptor 1, Human","C106200","G-protein coupled estrogen receptor 1 (375 aa, ~42 kDa) is encoded by the human GPER1 gene. This protein plays a role in estrogen-dependent G protein-coupled receptor signaling.","G-Protein Coupled Estrogen Receptor 1 | Chemoattractant Receptor-Like 2 | Chemokine Receptor-Like 2 | Constitutively Expressed Peptide-Like Receptor | FEG-1 | Flow-Induced Endothelial G-Protein Coupled Receptor 1 | G Protein-Coupled Estrogen Receptor 1 | G Protein-Coupled Receptor 30 | G-Protein Coupled Receptor 30 | GPCR-BR | GPER | Heptahelix Receptor | IL8-Related Receptor DRY12 | LYGPR | Lymphocyte-Derived G-Protein Coupled Receptor | Membrane Estrogen Receptor | mER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829531","Interdigital Region","C106201","The space between the digits of the hand or foot.","Interdigital Region | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227680","Ureteropelvic Junction","C106203","The area where the ureter joins the renal pelvis.","Ureteropelvic Junction | UPJ",,,,,,,,,,,,,,,"4137954","Structure of ureteropelvic junction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829949","Granville County, NC","C109616","No value exists.","Granville County, NC | Granville County | Granville County, North Carolina | NC077",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814404","Greene County, NC","C109617","No value exists.","Greene County, NC | Greene County | Greene County, North Carolina | NC079",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829920","Guilford County, NC","C109618","No value exists.","Guilford County, NC | Guilford County | Guilford County, North Carolina | NC081",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829844","Harnett County, NC","C109620","No value exists.","Harnett County, NC | Harnett County | Harnett County, North Carolina | NC085",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815565","Haywood County, NC","C109621","No value exists.","Haywood County, NC | Haywood County | Haywood County, North Carolina | NC087",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811137","Henderson County, NC","C109622","No value exists.","Henderson County, NC | Henderson County | Henderson County, North Carolina | NC089",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829703","Hertford County, NC","C109623","No value exists.","Hertford County, NC | Hertford County | Hertford County, North Carolina | NC091",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829675","Hoke County, NC","C109624","No value exists.","Hoke County, NC | Hoke County | Hoke County, North Carolina | NC093",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829503","Iredell County, NC","C109626","No value exists.","Iredell County, NC | Iredell County | Iredell County, North Carolina | NC097",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816461","Jackson County, NC","C109627","No value exists.","Jackson County, NC | Jackson County | Jackson County, North Carolina | NC099",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810788","Johnston County, NC","C109628","No value exists.","Johnston County, NC | Johnston County | Johnston County, North Carolina | NC101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810791","Jones County, NC","C109629","No value exists.","Jones County, NC | Jones County | Jones County, North Carolina | NC103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813675","Lee County, NC","C109630","No value exists.","Lee County, NC | Lee County | Lee County, North Carolina | NC105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714832","Lincoln County, NC","C109632","No value exists.","Lincoln County, NC | Lincoln County | Lincoln County, North Carolina | NC109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812230","McDowell County, NC","C109633","No value exists.","McDowell County, NC | McDowell County | McDowell County, North Carolina | NC111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813699","Pennington County, SD","C110100","No value exists.","Pennington County, SD | Pennington County | Pennington County, South Dakota | SD103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813702","Perkins County, SD","C110101","No value exists.","Perkins County, SD | Perkins County | Perkins County, South Dakota | SD105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812274","Potter County, SD","C110102","No value exists.","Potter County, SD | Potter County | Potter County, South Dakota | SD107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813295","Roberts County, SD","C110103","No value exists.","Roberts County, SD | Roberts County | Roberts County, South Dakota | SD109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828260","Sanborn County, SD","C110104","No value exists.","Sanborn County, SD | SD111 | Sanborn County | Sanborn County, South Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814857","Shannon County, SD","C110105","No value exists.","Shannon County, SD | SD113 | Shannon County | Shannon County, South Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827963","Spink County, SD","C110106","No value exists.","Spink County, SD | SD115 | Spink County | Spink County, South Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0056331","Cordycepin","C1057","A purine nucleoside antimetabolite and antibiotic isolated from the fungus Cordyceps militaris with potential antineoplastic, antioxidant, and anti-inflammatory activities. Cordycepin is an inhibitor of polyadenylation, activates AMP-activated protein kinase (AMPK) and reduces mammalian target of rapamycin (mTOR) signaling, which may result in both the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase belonging to the phosphatidylinositol 3-kinase (PI3K)-related kinase (PIKK) family, plays an important role in the PI3K/AKT/mTOR signaling pathway that regulates cell growth and proliferation, and its expression or activity is frequently dysregulated in human cancers.","Cordycepin | 3'-Deoxyadenosine | 3'-dA-CE Phosphoramidite | 3-dAdenosine | 9-Cordyceposidoadenine | COR | CORDYCEPIN | Cordycepine | Kordicepin | cordycepin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814807","RELB wt Allele","C105998","Human RELB wild-type allele is located in the vicinity of 19q13.32 and is approximately 37 kb in length. This allele, which encodes transcription factor RelB protein, plays a role in transcriptional regulation of immune processes.","RELB wt Allele | I-REL | IREL | REL-B | v-rel Reticuloendotheliosis Viral Oncogene Homolog B wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0167957","Transcription Factor RelB","C105999","Transcription factor RelB (579 aa, ~62 kDa) is encoded by the human RELB gene. This protein is involved in transcriptional regulation of immune processes.","Transcription Factor RelB | v-rel Avian Reticuloendotheliosis Viral Oncogene Homolog B (Nuclear Factor of Kappa Light Polypeptide Gene Enhancer in B-cells 3) | v-rel Avian Reticuloendotheliosis Viral Oncogene Homolog B, Nuclear Factor of Kappa Light Polypeptide Gene Enhancer in B-cells 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433965","Brachyury-expressing Yeast Vaccine GI-6301","C106267","A cancer vaccine composed of a heat-killed, recombinant form of the yeast Saccharomyces cerevisiae that is genetically modified to express the transcription factor brachyury protein, with potential antineoplastic activity. Upon subcutaneous administration, the brachyury-expressing yeast vaccine GI-6301 is recognized by dendritic cells, processed, and presented by Class I and II MHC molecules on the dendritic cell surface. This elicits a targeted CD4+ and CD8+ T-lymphocyte-mediated immune response. This process kills brachyury-expressing tumor cells. Brachyury is overexpressed in a variety of tumor types and plays an important role in cancer progression and metastasis.","Brachyury-expressing Yeast Vaccine GI-6301 | GI-6301",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811251","CADM1 wt Allele","C106270","Human CADM1 wild-type allele is located in the vicinity of 11q23.2 and is approximately 336 kb in length. This allele, which encodes cell adhesion molecule 1 protein, is involved in the modulation of cell-cell adhesion.","CADM1 wt Allele | BL2 | Cell Adhesion Molecule 1 wt Allele | IGSF4 | IGSF4A | NECL2 | Necl-2 | RA175 | ST17 | SYNCAM | TSLC1 | sTSLC-1 | sgIGSF | synCAM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433963","Liposome-encapsulated RB94 Plasmid DNA Gene Therapy Agent SGT-94","C106271","A systemic gene therapy anti-cancer agent composed of cationic liposomes, which encapsulates plasmid DNA encoding for the tumor suppressor gene RB94 and is complexed with anti-transferrin receptor single chain antibody fragment (TfRscFv), with potential antineoplastic activity. Upon systemic administration of liposome-encapsulated RB94 plasmid DNA gene therapy agent SGT-94, the TfRscFv portion of this agent selectively targets the tumor cells expressing transferrin receptors. TfRscFv binding to the transferrin receptor allows receptor-mediated endocytosis and transfection, followed by the expression of RB94 gene. This induces tumor cell apoptosis through an as of yet unknown pathway. RB94 is a modified, N-terminal truncated form of the full-length protein retinoblastoma gene RB110, and exerts enhanced antitumor activity. The transferrin receptor (TfR) functions in cellular iron uptake through its interaction with transferrin, and is overexpressed in a variety of tumor types.","Liposome-encapsulated RB94 Plasmid DNA Gene Therapy Agent SGT-94 | SGT-94 | TfRscFv/Lip/RB94",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1309370","Cell Adhesion Molecule 1, Human","C106272","Cell adhesion molecule 1 (442 aa, ~49 kDa) is encoded by the human CADM1 gene. This protein plays a role in calcium-dependent cell-cell adhesion.","Cell Adhesion Molecule 1 | CADM1 | IgSF4 | Immunoglobulin Superfamily Member 4 | NECL-2 | Nectin-Like 2 | Nectin-Like Protein 2 | SgIgSF | Spermatogenic Immunoglobulin Superfamily | SynCAM | Synaptic Cell Adhesion Molecule | TSLC-1 | Tumor Suppressor in Lung Cancer 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0270202","ABO Hemolytic Disease of the Newborn","C106273","A condition of the newborn characterized by the destruction of red blood cells initiated by the transmission of anti-A or anti-B antibodies from a mother to the child via the placenta against A or B antigens of the newborn's blood.","ABO Hemolytic Disease of the Newborn | ABO Hemolytic Disease of Newborn | ABO Isoimmunization | Hemolytic Disease due to ABO Isoimmunization",,,,,,,,,,,,,,,"437090","Hemolytic disease of fetus OR newborn due to ABO immunization",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3814047","PAX1 wt Allele","C106275","Human PAX1 wild-type allele is located in the vicinity of 20p11.2 and is approximately 10 kb in length. This allele, which encodes paired box protein Pax-1, plays a role in transcriptional regulation.","PAX1 wt Allele | HUP48 | Paired Box 1 wt Allele | Paired Box Gene 1 | Paired Domain Gene HuP48 | RP5-1065O2.3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1571217","paired box protein 1, human","C106276","Paired box protein Pax-1 (534 aa, ~55 kDa) is encoded by the human PAX1 gene. This protein is involved in the regulation of transcription during both skeletal development and T-cell differentiation.","Paired Box Protein Pax-1 | HuP48 | PAX1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814780","Dapper Homolog 2","C105724","Dapper homolog 2 (774 aa, ~83 kDa) is encoded by the human DACT2 gene. This protein is involved in the inhibition of signal transduction.","Dapper Homolog 2 | DACT2 | Dapper Antagonist of Catenin 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813202","DAD1 wt Allele","C105730","Human DAD1 wild-type allele is located 14q11.2 and is approximately 24 kb in length. This allele, which encodes dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit DAD1 protein, is involved in the glycosylation of proteins.","DAD1 wt Allele | Defender Against Cell Death 1 wt Allele | OST2 | Oligosaccharyltransferase 2 Homolog (S. cerevisiae) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829259","Loose Seed Implant","C105732","A radioactive implant consisting of individual pellets.","Loose Seed Implant | Loose Seed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827467","Whole-Pelvis","C105733","All of the tissues and organs within the pelvic cavity considered together. This is generally taken to mean the prostate gland, seminal vesicles, and pelvic lymph nodes.","Whole-Pelvis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0220374","Dolichyl-Diphosphooligosaccharide-Protein Glycosyltransferase Subunit DAD1, Human","C105734","Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit DAD1 (113 aa, ~12 kDa) is encoded by the human DAD1 gene. This protein plays a role in the addition of high-mannose oligosaccharides to asparagine residues.","Dolichyl-Diphosphooligosaccharide-Protein Glycosyltransferase Subunit DAD1 | DAD-1 | DAD1 | Defender Against Cell Death 1 | Dolichyl-Diphosphooligosaccharide--Protein Glycosyltransferase Subunit DAD1 | Dolichyl-Diphosphooligosaccharide—Protein Glycosyltransferase Subunit DAD1 | EC 2.4.99.18 | Oligosaccharyl Transferase Subunit DAD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831745","Accidents and Adverse Effects","C105736","Causes of death attributable to accidents or their adverse events.","Accidents and Adverse Effects | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815271","SELP","C105738","Human SELENOP wild-type allele is located in the vicinity of 5q12 and is approximately 88 kb in length. This allele, which encodes selenoprotein P, plays a role in selenium distribution.","SELENOP wt Allele | SELP | SEPP | SEPP1 | SeP | Selenoprotein P wt Allele | Selenoprotein P, Plasma, 1 Gene | Selenoprotein P, Plasma,1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0141947","Selenoprotein P","C105739","Selenoprotein P (381 aa, ~43 kDa) is encoded by the human SELENOP gene. This protein is involved in the modulation of selenium metabolism.","Selenoprotein P | SELENOP | SEPP1 | SeP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827954","Stanley County, SD","C110107","No value exists.","Stanley County, SD | SD117 | Stanley County | Stanley County, South Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814858","Todd County, SD","C110109","No value exists.","Todd County, SD | SD121 | Todd County | Todd County, South Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827768","Tripp County, SD","C110110","No value exists.","Tripp County, SD | SD123 | Tripp County | Tripp County, South Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811808","Turner County, SD","C110111","No value exists.","Turner County, SD | SD125 | Turner County | Turner County, South Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813223","Union County, SD","C110112","No value exists.","Union County, SD | SD127 | Union County | Union County, South Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812772","Walworth County, SD","C110113","No value exists.","Walworth County, SD | SD129 | Walworth County | Walworth County, South Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827394","Ziebach County, SD","C110115","No value exists.","Ziebach County, SD | SD137 | Ziebach County | Ziebach County, South Dakota",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813131","Anderson County, TN","C110116","No value exists.","Anderson County, TN | Anderson County | Anderson County, Tennessee | TN001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816194","Bedford County, TN","C110117","No value exists.","Bedford County, TN | Bedford County | Bedford County, Tennessee | TN003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816195","Benton County, TN","C110118","No value exists.","Benton County, TN | Benton County | Benton County, Tennessee | TN005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811662","Blount County, TN","C110120","No value exists.","Blount County, TN | Blount County | Blount County, Tennessee | TN009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812170","Bradley County, TN","C110121","No value exists.","Bradley County, TN | Bradley County | Bradley County, Tennessee | TN011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814388","Campbell County, TN","C110122","No value exists.","Campbell County, TN | Campbell County | Campbell County, Tennessee | TN013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831208","Cannon County, TN","C110123","No value exists.","Cannon County, TN | Cannon County | Cannon County, Tennessee | TN015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831130","Cheatham County, TN","C110126","No value exists.","Cheatham County, TN | Cheatham County | Cheatham County, Tennessee | TN021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814768","Chester County, TN","C110127","No value exists.","Chester County, TN | Chester County | Chester County, Tennessee | TN023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815505","Claiborne County, TN","C110128","No value exists.","Claiborne County, TN | Claiborne County | Claiborne County, Tennessee | TN025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810746","Wise County, VA","C110600","No value exists.","Wise County, VA | VA195 | Wise County | Wise County, Virginia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827419","Wythe County, VA","C110601","No value exists.","Wythe County, VA | VA197 | Wythe County | Wythe County, Virginia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811333","York County, VA","C110602","No value exists.","York County, VA | VA199 | York County | York County, Virginia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831574","Alexandria City, VA","C110603","No value exists.","Alexandria City, VA | Alexandria City | Alexandria City, Virginia | VA510",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814048","STEAP1 wt Allele","C106002","Human STEAP1 wild-type allele is located in the vicinity of 7q21 and is approximately 10 kb in length. This allele, which encodes metalloreductase STEAP1 protein, plays a role at cell-cell junctions.","STEAP1 wt Allele | PRSS24 | STEAP | Six Transmembrane Epithelial Antigen of the Prostate 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829118","STEAP1 protein, human","C106003","Metalloreductase STEAP1 (339 aa, ~40 kDa) is encoded by the human STEAP1 gene. This protein plays a role at cell-cell junctions.","Metalloreductase STEAP1 | EC 1.16.1.- | STEAP1 | Six-Transmembrane Epithelial Antigen of the Prostate 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814864","SERPINA7 wt Allele","C106004","Human SERPINA7 wild-type allele is located in the vicinity of Xq22.2 and is approximately 6 kb in length. This allele, which encodes thyroxine-binding globulin protein, is involved in thyroid hormone transport. Mutation of the gene is associated with thyroxine-binding globulin deficiency.","SERPINA7 wt Allele | Serine (Or Cysteine) Proteinase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 7 Gene | Serpin Peptidase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 7 wt Allele | TBG | TBG, Serum Gene | Thyroxine-Binding Globulin of Serum Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2713677","Thyroxine-Binding Globulin","C106005","Thyroxine-binding globulin (415 aa, ~46 kDa) is encoded by the human SERPINA7 gene. This protein plays a role in both binding to and transport of both thyroxine and triiodothyroxine.","Thyroxine-Binding Globulin | SERPINA7 | Serpin A7 | T4-Binding Globulin | Thyroxin-Binding Globulin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815272","SEMA3F wt Allele","C106008","Human SEMA3F wild-type allele is located in the vicinity of 3p21.3 and is approximately 34 kb in length. This allele, which encodes semaphorin-3F protein, plays a role in both axon guidance and cell signaling.","SEMA3F wt Allele | SEMA4 | SEMAK | Sema Domain, Immunoglobulin Domain (Ig), Short Basic Domain, Secreted, (Semaphorin) 3F wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814527","RAD9A wt Allele","C106278","Human RAD9A wild-type allele is located within 11q13.1-q13.2 and is approximately 7 kb in length. This allele, which encodes cell cycle checkpoint control protein RAD9A, is involved in the regulation of both DNA repair and cell cycle progression.","RAD9A wt Allele | RAD9 | RAD9 (S. pombe) Homolog Gene | RAD9 Homolog A (S. pombe) wt Allele | RAD9, S. pombe, Homolog of Gene | RAD9, S. pombe, Homolog of, A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1448657","Cell Cycle Checkpoint Control Protein RAD9A, Human","C106279","Cell cycle checkpoint control protein RAD9A (391 aa, ~43 kDa) is encoded by the human RAD9A gene. This protein plays a role in DNA repair-dependent cell cycle checkpoint control.","Cell Cycle Checkpoint Control Protein RAD9A | DNA Repair Exonuclease rad9 Homolog A | EC 3.1.11.2 | RAD9A | hRAD9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812281","FKBP5 wt Allele","C105830","Human FKBP5 wild-type allele is located in the vicinity of 6p21.31 and is approximately 155 kb in length. This allele, which encodes peptidyl-prolyl cis-trans isomerase FKBP5 protein, is involved in the modulation of protein folding.","FKBP5 wt Allele | AIG6 | FK506 Binding Protein 5 wt Allele | FKBP51 | FKBP54 | P54 | PPIase | Ptg-10 | RP3-340B19.6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1741214","FKBP5 protein, human","C105831","Peptidyl-prolyl cis-trans isomerase FKBP5 (457 aa, ~51 kDa) is encoded by the human FKBP5 gene. This protein plays a role in the mediation of protein folding.","Peptidyl-Prolyl Cis-Trans Isomerase FKBP5 | 51 kDa FK506-Binding Protein | 51 kDa FK506-Binding Protein 5 | 51 kDa FKBP | 54 kDa Progesterone Receptor-Associated Immunophilin | Androgen-Regulated Protein 6 | EC 5.2.1.8 | FF1 Antigen | FK506-Binding Protein 5 | FKBP-5 | FKBP-51 | FKBP5 | FKBP54 | HSP90-Binding Immunophilin | PPIase FKBP5 | Rotamase | T-Cell FK506-Binding Protein | p54",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811153","NEIL3 wt Allele","C105833","Human NEIL3 wild-type allele is located in the vicinity of 4q34.3 and is approximately 53 kb in length. This allele, which encodes endonuclease 8-like 3 protein, is involved in DNA binding and repair.","NEIL3 wt Allele | FGP2 | FLJ10858 | FPG2 | NEI3 | Nei Endonuclease VIII-Like 3 (E. coli) wt Allele | hFPG2 | hNEI3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1172441","Endonuclease 8-Like 3, Human","C105834","Endonuclease 8-like 3 (605 aa, ~68 kDa) is encoded by the human NEIL3 gene. This protein plays a role in binding and repair of single-stranded DNA.","Endonuclease 8-Like 3 | DNA Glycosylase FPG2 | DNA Glycosylase hFPG2 | DNA Glycosylase/AP Lyase Neil3 | EC 3.2.2.- | EC 4.2.99.18 | Endonuclease VIII-Like 3 | NEIL3 | Nei-Like Protein 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812228","ATPE","C105836","Human ATP5F1E wild-type allele is located in the vicinity of 20q13.32 and is approximately 7 kb in length. This allele, which encodes ATP synthase subunit epsilon, mitochondrial protein, plays a role in ATP biosynthesis. Mutation of the gene is associated with mitochondrial complex V (ATP synthase) deficiency nuclear type 3.","ATP5F1E wt Allele | ATP Synthase F1 Subunit Epsilon wt Allele | ATP Synthase, H+ Transporting, Mitochondrial F1 Complex, Epsilon Subunit Gene | ATP5E | ATP5E wt Allele | ATPE | MC5DN3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815864","ATP Synthase Subunit Epsilon, Mitochondrial","C105837","ATP synthase subunit epsilon, mitochondrial (51 aa, ~6 kDa) is encoded by the human ATP5F1E gene. This protein is involved in the biosynthesis of ATP.","ATP Synthase Subunit Epsilon, Mitochondrial | ATP Synthase F1 Subunit Epsilon | ATP5E | ATP5F1E | ATPase Subunit Epsilon | Mitochondrial ATP Synthase Epsilon Chain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810522","BGN wt Allele","C105839","Human BGN wild-type allele is located in the vicinity of Xq28 and is approximately 15 kb in length. This allele, which encodes biglycan protein, is involved in the composition of the extracellular matrix.","BGN wt Allele | Biglycan wt Allele | DSPG1 | PG-S1 | PGI | SLRR1A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815634","SYNPO wt Allele","C105954","Human SYNPO wild-type allele is located in the vicinity of 5q33.1 and is approximately 58 kb in length. This allele, which encodes synaptopodin protein, plays a role in actin-mediated cell motility and cell morphology.","SYNPO wt Allele | KIAA1029 | Synaptopodin wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1611526","Synaptopodin, Human","C105955","Synaptopodin (929 aa, ~94 kDa) is encoded by the human SYNPO gene. This protein is involved in actin-mediated cell morphology and cell motility.","Synaptopodin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811072","TCF4 wt Allele","C105957","Human TCF4 wild-type allele is located 18q21.1 and is approximately 442 kb in length. This allele, which encodes transcription factor 4 protein, is involved in transcriptional regulation of immunoglobulin genes. Mutations in this gene are associated with Pitt-Hopkins syndrome.","TCF4 wt Allele | E2-2 | ITF-2 | ITF2 | PTHS | SEF-2 | SEF2 | SEF2-1 | SEF2-1A | SEF2-1B | TCF-4 | Transcription Factor 4 wt Allele | bHLHb19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2746081","Transcription Factor 4, Human","C105958","Transcription factor 4 (667 aa, ~71 kDa) is encoded by the human TCF4 gene. This protein plays a role in the regulation of immunoglobulin transcription.","Transcription Factor 4 | Class B Basic Helix-Loop-Helix Protein 19 | Immunoglobulin Transcription Factor 2 | SL3-3 Enhancer Factor 2 | TCF4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814041","IL22 wt Allele","C105962","Human IL22 wild-type allele is located in the vicinity of 12q15 and is approximately 5 kb in length. This allele, which encodes interleukin-22, plays a role in both cell signaling and regulation of the immune response.","IL22 wt Allele | IL-21 | IL-D110 | IL-TIF | IL21 | ILTIF | Interleukin 22 wt Allele | MGC79382 | MGC79384 | TIFIL-23 | TIFa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0961814","interleukin 22 protein, human","C105963","Interleukin-22 (179 aa, ~20 kDa) is encoded by the human IL22 gene. This protein is involved in both cell signaling and the immune response.","Interleukin-22 | Cytokine Zcyto18 | IL-10-Related T-Cell-Derived Inducible Factor | IL-10-Related T-Cell-Derived-Inducible Factor | IL-22 | IL22 | Zcyto18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814519","RWDD3 wt Allele","C105965","Human RWDD3 wild-type allele is located in the vicinity of 1p21.3 and is approximately 13 kb in length. This allele, which encodes RWD domain-containing protein 3, is involved in the regulation of protein sumoylation.","RWDD3 wt Allele | DKFZP566K023 | RSUME | RWD Domain Containing 3 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828287","RWD Domain-Containing Protein 3, human","C105966","RWD domain-containing protein 3 (267 aa, ~31 kDa) is encoded by the human RWDD3 gene. This protein plays a role in the sumoylation of proteins.","RWD Domain-Containing Protein 3 | RSUME1 | RWD Domain-Containing Sumoylation Enhancer | RWD-Containing Sumoylation Enhancer | RWDD3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1439200","Stress-Induced-Phosphoprotein 1, Human","C112068","Stress-induced-phosphoprotein 1 (543 aa, ~63 kDa) is encoded by the human STIP1 gene. This protein plays a role in chaperone protein function.","Stress-Induced-Phosphoprotein 1 | Hsc70/Hsp90-Organizing Protein | Hsp70/Hsp90-Organizing Protein | IEF-SSP-3521 | NY-REN-11 Antigen | P60 | Renal Carcinoma Antigen NY-REN-11 | STIP1 | Stress-Induced Phosphoprotein 1 | Transformation-Sensitive Protein IEF SSP 3521",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830636","CTHRC1 wt Allele","C112070","Human CTHRC1 wild-type allele is located in the vicinity of 8q22.3 and is approximately 11 kb in length. This allele, which encodes collagen triple helix repeat-containing protein 1, plays a role in the cellular response to arterial injury through involvement in vascular remodeling. Mutations in this gene are associated with Barrett esophagus/esophageal adenocarcinoma.","CTHRC1 wt Allele | Collagen Triple Helix Repeat Containing 1 wt Allele | UNQ762/PRO1550",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812181","Collagen Triple Helix Repeat-Containing Protein 1, Human","C112071","Collagen triple helix repeat-containing protein 1 (243 aa, ~26 kDa) is encoded by the human CTHRC1 gene. This protein is involved in the cellular response to arterial injury.","Collagen Triple Helix Repeat-Containing Protein 1 | Collagen Triple Helix Repeat Containing 1 | Collagen Triple-Helix Repeat-Containing Protein 1 | Protein NMTC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814417","GSTM3 wt Allele","C112073","Human GSTM3 wild-type allele is located in the vicinity of 1p13.3 and is approximately 8 kb in length. This allele, which encodes glutathione S-transferase Mu 3 protein, plays a role in both nitrogen detoxification and glutathione metabolism.","GSTM3 wt Allele | GST5 | GSTB | GSTM3-3 | GTM3 | Glutathione S-Transferase M3 (Brain) Gene | Glutathione S-Transferase Mu 3 (Brain) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1524023","Recombinant Hepatocyte Growth Factor","C1122","A recombinant therapeutic agent which is chemically identical to or similar to the endogenous glycoprotein cytokine hepatocyte growth factor (HGF), which is produced by the liver and the pancreas.  Endogenous HGF synthesis is stimulated by injuries affecting liver tissues.  This agent, a potent angiogenic and neurotrophic factor and a multifunctional cytokine that acts as a mitogen, motogen and a morphogen, is important for organogenesis and tissue regeneration.  Therapeutic HGF has been shown to attenuate brain ischemic injury in animal models through angiogenic and neuroprotective actions. (NCI04)","Recombinant Hepatocyte Growth Factor | HEPATOPOIETIN-A | HGF | HGF/SF | Hepatopoietin | Scatter Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919881","Angiotensin Converting Enzyme Inhibitor Fetopathy","C111908","Fetal embryopathy associated with maternal angiotensis converting enzyme (ACE) inhibitor use during pregnancy that may include fetal acute renal failure, growth restriction, oligohydramnios, calvaria abnormalities, preterm birth, and pulmonary hypoplasia with respiratory distress.","Angiotensin Converting Enzyme Inhibitor Fetopathy | ACE Fetopathy | ACE Inhibitor Fetopathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1167662","Diabetic Fetopathy","C111909","A constellation of features seen in the hyperinsulinemic fetus of a diabetic mother that include macrosomia, postnatal hypoglycemia and polycythemia.","Diabetic Fetopathy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0235987","Fetal Virilization","C111910","Inappropriate secondary sex characteristics in the neonate usually due to in utero androgen exposure.","Fetal Virilization | Fetal Virilism",,,,,,,,,,,,,,,"4318554","Fetal virilism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013927","Amniotic Fluid Embolism","C111911","Acute hypotension or cardiac arrest, acute hypoxia or coagulopathy in the absence of any other potential explanation related to the presence of amniotic fluid or the fetal debris within the maternal vascular system during the antepartum or intrapartum period.","Amniotic Fluid Embolism | Amniotic Fluid Embolism Syndrome",,,,,,,,,,,,,,,"435616","Amniotic fluid embolism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2717841","Chromatin Assembly Factor I","C111912","A heterotrimeric protein complex that mediates chromatin assembly by promoting histone H3 and H4 deposition onto newly synthesized DNA during replication or DNA repair. This complex is comprised of chromatin assembly factor 1 subunit A, chromatin assembly factor 1 subunit B and histone-binding protein RBBP4.","Chromatin Assembly Factor I | CAF-1 | CAF-1 Complex | CAF-I | CAF1 | Chromatin Assembly Factor 1 | Chromatin Assembly Factor 1 Complex | Chromatin Assembly Factor I Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828492","Pre-Gestational Diabetes","C111913","Diabetes diagnosed before current pregnancy. (reVITALize)","Pre-Gestational Diabetes | Pregestational Diabetes | Unspecified pre-existing diabetes mellitus in pregnancy, unspecified trimester",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1719672","Severe Sepsis","C111915","Clinical syndrome defined by the presence of both infection and a systemic inflammatory response that progresses to multi-organ failure.","Severe Sepsis | Sepsis with Organ Dysfunction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427798","NLRP4 Gene","C111916","This gene may be involved in inflammation.","NLRP4 Gene | NLR Family, Pyrin Domain Containing 4 Gene | NLRP4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811664","NLRP4 wt Allele","C111917","Human NLRP4 wild-type allele is located in the vicinity of 19q13.43 and is approximately 45 kb in length. This allele, which encodes NACHT, LRR and PYD domains-containing protein 4, may play a role in the negative regulation of signaling by type I interferon.","NLRP4 wt Allele | CLR19.5 | CT58 | NACHT, Leucine Rich Repeat and PYD Containing 4 Gene | NLR Family, Pyrin Domain Containing 4 wt Allele | NLR Family, Pyrin Domain-Containing 4 Gene | Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat and Pyrin Domain Containing 4 Gene | PAN2 | PYPAF4 | RNH2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813560","NACHT, LRR and PYD Domains-Containing Protein 4, Human","C111918","NACHT, LRR and PYD domains-containing protein 4 (994 aa, ~113 kDa) is encoded by the human NLRP4 gene. This protein may be involved in the modulation of signaling in inflammation.","NACHT, LRR and PYD Domains-Containing Protein 4 | CT58 | Cancer/Testis Antigen 58 | NACHT Domain-, Leucine-Rich Repeat-, and PYD-Containing Protein 4 | NACHT, LRR and PYD Containing Protein 4 | NLRP4 | PAAD and NACHT-Containing Protein 2 | PYRIN Domain- and NACHT Domain-Containing Protein 2 | PYRIN Domain-Containing APAF1-Like Protein 4 | PYRIN and NACHT-Containing Protein 2 | PYRIN-Containing APAF1-Like Protein 4 | Ribonuclease Inhibitor 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0149797","Umbilical Granuloma","C112119","Excessive granulation tissue at the base of the umbilicus after separation.","Umbilical Granuloma | ",,,,,,,,,,,,,,,"4066378","Umbilical granuloma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0239343","Acral Erythema","C112180","Reddening of the palmar and plantar regions of the body with occasional involvement of the distal extremities.","Acral Erythema | Erythema of the palms and/or soles",,,,,,,,,,,,,,,"4033054","Acral erythema",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040247","Tinea Infection","C112181","A skin infection caused by a fungus.","Tinea Infection | Tinea",,,,,,,,,,,,,,,"135473","Dermatophytosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3827209","Toxic Erythema of Chemotherapy","C112182","Painful red or purple patches, edematous plaques or blisters on the hands, feet, extremities or intertriginous regions; the onset can occur days to months after receiving chemotherapy.","Toxic Erythema of Chemotherapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0686366","Blepharitis","C112183","Inflammation of the eyelids near the eyelashes.","Blepharitis | ",,,,,,,,,,,,,,,"378425","Blepharitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014583","Bulbar Conjunctivitis","C112189","Inflammation of the thin layer of tissue lining the sclera of the eye characterized by redness in the white portion of the eye.","Bulbar Conjunctivitis | Episcleritis",,,,,,,,,,,,,,,"4218083","Episcleritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3826908","CDISC Questionnaire PDDS Test Code Terminology","C112447","Test codes of questionnaire questions associated with the Patient Determined Disease Steps (PDDS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire PDDS Test Code Terminology | PDDS01TC | Patient Determined Disease Steps Questionnaire Test Code | QS-PDDS TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826901","CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology","C112448","Test names of questionnaire questions associated with the St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology | QS-SGRQ Past 3 Months Version TEST | SGRQ01TN | St. George's Respiratory Questionnaire Past 3 Months Version Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1136749","Transcriptional Repressor CTCFL, Human","C111823","Transcriptional repressor CTCFL (663 aa, ~76 kDa) is encoded by the human CTCFL gene. This protein plays a role in gene regulation through transcriptional repression.","Transcriptional Repressor CTCFL | BORIS-Like Protein | Brother of the Regulator of Imprinted Sites | CCCTC-Binding Factor | CTCF Paralog | CTCF-Like Protein | Cancer/Testis Antigen 27 | Putative High Mobility Group Protein 1-Like 1 | Putative High Mobility Group Protein B1-Like 1 | Zinc Finger Protein CTCF-T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811648","ADH1C wt Allele","C111824","Human ADH1C wild-type allele is located in the vicinity of 4q23 and is approximately 17 kb in length. This allele, which encodes alcohol dehydrogenase 1C protein, plays a role in alcohol oxidation.","ADH1C wt Allele | ADH3 | Alcohol Dehydrogenase 1C (Class I), Gamma Polypeptide wt Allele | Alcohol Dehydrogenase 3 (Class I), Gamma Polypeptide Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1312457","Alcohol Dehydrogenase 1C, Human","C111826","Alcohol dehydrogenase 1C (375 aa, ~40 kDa) is encoded by the human ADH1C gene. This protein is involved in the oxidation of alcohols.","Alcohol Dehydrogenase 1C | ADH, Gamma Subunit | ADH1C | Alcohol Dehydrogenase 1C, Gamma Polypeptide | Alcohol Dehydrogenase 3 | Alcohol Dehydrogenase 3, Gamma Polypeptide | Alcohol Dehydrogenase Subunit Gamma | EC 1.1.1.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828460","chromosome 11 open reading frame 30 protein, human","C111828","Protein EMSY (1322 aa, ~141 kDa) is encoded by the human EMSY gene. This protein is involved in transcription repression and may be involved in DNA repair.","Protein EMSY | BRCA2-Interacting Transcriptional Repressor EMSY | EMSY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811647","ADH4 wt Allele","C111831","Human ADH4 wild-type allele is located in the vicinity of 4q22 and is approximately 34 kb in length. This allele, which encodes alcohol dehydrogenase 4 protein, is involved in the metabolism of alcohols.","ADH4 wt Allele | ADH-2 | Alcohol Dehydrogenase 4 (Class II), Pi Polypeptide wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813708","LRP1B wt Allele","C111832","Human LRP1B wild-type allele is located in the vicinity of 2q21.2 and is approximately 1900 kb in length. This allele, which encodes low-density lipoprotein receptor-related protein 1B, is involved in both the metabolism of low density lipoproteins and receptor-mediated endocytosis.","LRP1B wt Allele | LRP-1B | LRP-DIT | LRPDIT | Low Density Lipoprotein Receptor-Related Protein 1B wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0538164","alcohol dehydrogenase IV","C111833","Alcohol dehydrogenase 4 (380 aa, ~40 kDa) is encoded by the human ADH4 gene. This protein plays a role in alcohol oxidation.","Alcohol Dehydrogenase 4 | ADH, Class II | ADH4 | Alcohol Dehydrogenase Class II Pi Chain | Alcohol Dehydrogenase, Pi Isozyme | EC 1.1.1.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205725","Human Herpesvirus 5","C112314","A species of enveloped and spherical viruses with a capsid with T=16 icosahedral symmetry and surrounded by amorphous tegument, in the Herpesviridae family and Cytomegalovirus genus. The genome is composed of monopartite, linear double-stranded DNA. Human herpesvirus 5 is found in humans and causes mononucleosis-like symptoms in healthy individuals and pneumonia, hepatitis, encephalitis, myelitis, colitis, retinitis, neuropathy, mucoepidermoid carcinoma as well as other malignancies in immunocompromised persons, organ transplant recipients and newborn infants. Human herpesvirus 5 is transmitted congenitally or via direct person-to-person contact.","Human Herpesvirus 5 | HCMV | HHV-5 | HUMAN CYTOMEGALOVIRUS | HUMAN HERPESVIRUS 5 | Human Betaherpesvirus 5 | Human Cytomegalovirus",,,,,,,,,,,,,,,"4085595","Human cytomegalovirus 5",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3831498","AQ20 - Feel Breathless When Trying to Sleep","C112535","Airway Questionnaire 20 (AQ20) Do you feel breathless when trying to sleep?","AQ20 - Feel Breathless When Trying to Sleep | AQ01-Breathless When Trying to Sleep | AQ0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831486","AQ20 - Worry About Long Term Effects of Drugs for Chest Trouble","C112536","Airway Questionnaire 20 (AQ20) Do you worry about the long term effects of the drugs you take for your chest trouble?","AQ20 - Worry About Long Term Effects of Drugs for Chest Trouble | AQ01-Long Term Effects of Drugs | AQ0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831499","AQ20 - Difficulty Getting Around the House Because of Chest Trouble","C112538","Airway Questionnaire 20 (AQ20) Are there times when you have difficulty getting around the house because of your chest trouble?","AQ20 - Difficulty Getting Around the House Because of Chest Trouble | AQ01-Difficulty Getting Around the House | AQ0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831503","AQ20 - Chest Problem Make You Breathless at Work","C112539","Airway Questionnaire 20 (AQ20) Does your chest problem make you breathless when you do things at work? (Paid employment).","AQ20 - Chest Problem Make You Breathless at Work | AQ01-Breathless Carry out Work Activity | AQ0111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831487","AQ20 - Walking Upstairs Make You Breathless","C112540","Airway Questionnaire 20 (AQ20) Does walking upstairs make you breathless?","AQ20 - Walking Upstairs Make You Breathless | AQ01-Breathless Walking Upstairs | AQ0112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810542","PDIA3 wt Allele","C112120","Human PDIA3 wild-type allele is located in the vicinity of 15q15 and is approximately 27 kb in length. This allele, which encodes protein disulfide-isomerase A3 protein, plays a role in both the rearrangement of protein disulfide bonds and antigen presentation.","PDIA3 wt Allele | ER60 | ERp57 | ERp60 | ERp61 | GRP57 | GRP58 | Glucose Regulated Protein, 58kDa Gene | Glucose-Regulated Protein, 58kD Gene | HsT17083 | P58 | PI-PLC | Protein Disulfide Isomerase Family A, Member 3 wt Allele | Protein Disulfide Isomerase-Associated 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0251914","Protein Disulfide-Isomerase A3, Human","C112121","Protein disulfide-isomerase A3 (505 aa, ~57 kDa) is encoded by the human PDIA3 gene. This protein is involved in both the activity of the MHC class I peptide-loading complex and post-translational disulfide bond formation.","Protein Disulfide-Isomerase A3 | 58 kDa Glucose-Regulated Protein | 58 kDa Microsomal Protein | Disulfide Isomerase ER-60 | EC 5.3.4.1 | ER Protein 57 | ER Protein 60 | ERp57 | ERp60 | Endoplasmic Reticulum Resident Protein 57 | Endoplasmic Reticulum Resident Protein 60 | Endoplasmic Reticulum p58 | PDIA3 | Protein Disulfide Isomerase-Associated 3 | p58",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0877055","Acute Generalized Exanthematous Pustulosis","C112122","A widespread acute rash characterized by fever and multiple small pustules on a reddish background.","Acute Generalized Exanthematous Pustulosis | ",,,,,,,,,,,,,,,"45773387","Acute generalized exanthematous pustulosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0521616","Pseudoporphyria","C112124","A drug-induced photodermatosis characterized by skin fragility, erythema, and the appearance of tense bullae, erosions and scarring in the absence of abnormalities in porphyrin metabolism.","Pseudoporphyria | ",,,,,,,,,,,,,,,"4316363","Pseudoporphyria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3813707","LGALS9 wt Allele","C112125","Human LGALS9 wild-type allele is located in the vicinity of 17q11.2 and is approximately 20 kb in length. This allele, which encodes galectin-9 protein, is involved in carbohydrate binding and may be an eosinophil chemoattractant. Overexpression of the gene may be associated with Hodgkin lymphoma.","LGALS9 wt Allele | HUAT | LGALS9A | Lectin, Galactoside-Binding, Soluble, 9 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0537111","Galectin-9, Human","C112126","Galectin-9 (355 aa, ~40 kDa) is encoded by the human LGALS9 gene. This protein plays a role in galactoside binding and as an eosinophil chemoattractant.","Galectin-9 | Ecalectin | Gal-9 | Galectin 9 | LGALS9 | Tumor Antigen HOM-HD-21 | Urate Transporter/Channel Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811813","DUSP4 wt Allele","C112128","Human DUSP4 wild-type allele is located within 8p12-p11 and is approximately 18 kb in length. This allele, which encodes dual specificity protein phosphatase 4 protein, plays a role in the dephosphorylation of MAP kinases.","DUSP4 wt Allele | Dual Specificity Phosphatase 4 wt Allele | HVH2 | MKP-2 | MKP2 | TYP | VH2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0298690","Dual Specificity Protein Phosphatase 4, Human","C112129","Dual specificity protein phosphatase 4 (394 aa, ~43 kDa) is encoded by the human DUSP4 gene. This protein is involved in the dephosphorylation of mitogen-activated protein kinase-1 and -3.","Dual Specificity Protein Phosphatase 4 | DUSP4 | Dual Specificity Protein Phosphatase HVH2 | Dual-Specificity Phosphatase 4 | Dual-Specificity Protein Phosphatase 4 | EC 3.1.3.16 | EC 3.1.3.48 | MAP Kinase Phosphatase 2 | MKP-2 | Mitogen-Activated Protein Kinase Phosphatase 2 | VH1 Homologous Phosphatase 2 | VH1-Like Phosphatase 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813588","MYH1 wt Allele","C112131","Human MYH1 wild-type allele is located in the vicinity of 17p13.1 and is approximately 26 kb in length. This allele, which encodes myosin-1 protein, is involved in the contraction of skeletal muscles.","MYH1 wt Allele | MGC133384 | MHC IIx/d | MYH2X/D | MYHC IIx/d | MYHC2X/D | MYHSA1 | MYHa | MyHC-2X/D | MyHC-2x | Myosin, Heavy Chain 1, Skeletal Muscle, Adult wt Allele | Myosin, Heavy Polypeptide 1, Skeletal Muscle, Adult Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826900","CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology","C112449","Test codes of questionnaire questions associated with the St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology | QS-SGRQ Past 3 Months Version TESTCD | SGRQ01TC | St. George's Respiratory Questionnaire Past 3 Months Version Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826851","CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology","C112450","Test names of questionnaire questions associated with the St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology | QS-SGRQ Past 4 Weeks Version TEST | SGRQ02TN | St. George's Respiratory Questionnaire Past 4 Weeks Version Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826899","CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology","C112451","Test codes of questionnaire questions associated with the St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology | QS-SGRQ Past 4 Weeks Version TESTCD | SGRQ02TC | St. George's Respiratory Questionnaire Past 4 Weeks Version Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826895","CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology","C112453","Test codes of questionnaire questions associated with the Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology | National Eye Institute Visual Functioning Questionnaire - 25 Version 2000 Interviewer-Administered Format Questionnaire Test Code | QS-VFQ25-Interviewer Administered Format TESTCD | VFQ1TC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826894","CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology","C112454","Test names of questionnaire questions associated with the Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology | National Eye Institute Visual Functioning Questionnaire - 25 Version 2000 Self-Administered Format Questionnaire Test Name | QS-VFQ25-Self Administered Format TEST | VFQ2TN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826893","CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology","C112455","Test codes of questionnaire questions associated with the Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology | National Eye Institute Visual Functioning Questionnaire - 25 Version 2000 Self-Administered Format Questionnaire Test Code | QS-VFQ25-Self Administered Format TESTCD | VFQ2TC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831489","AQ20 Questionnaire Question","C112456","A question associated with the AQ20 questionnaire.","AQ20 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830382","DS Clinical Classification Question","C112457","A question associated with the DS questionnaire.","DS Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830335","EDSS Clinical Classification Question","C112458","A question associated with the EDSS clinical classification.","EDSS Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827390","FAMS Questionnaire Question","C112459","A question associated with the FAMS questionnaire.","FAMS Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831528","Antepartum Obstetric Air Embolism","C111780","Presence of a large air bubble in the maternal vascular system which originated from a distant site during the antepartum period.","Antepartum Obstetric Air Embolism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828507","Postpartum Obstetric Air Embolism","C111781","Presence of a large air bubble in the maternal vascular system which originated from a distant site during the postpartum period.","Postpartum Obstetric Air Embolism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816181","Low-Density Lipoprotein Receptor-Related Protein 1B, Human","C111834","Low-density lipoprotein receptor-related protein 1B (4599 aa, ~515 kDa) is encoded by the human LRP1B gene. This protein plays a role in the metabolism of low density lipoproteins.","Low-Density Lipoprotein Receptor-Related Protein 1B | EC 1.1.1.94 | EC 3.4.21.9 | LRP-1B | LRP-DIT | LRP-Deleted In Tumors | LRP1B | Low Density Lipoprotein Receptor Related Protein-Deleted In Tumor | Low Density Lipoprotein-Related Protein 1B (Deleted In Tumors) | Low Density Lipoprotein-Related Protein 1B Deleted In Tumors | Low-Density Lipoprotein Receptor Related Protein 1B | Low-Density Lipoprotein Receptor-Related Protein-Deleted In Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829180","Mass Measurement","C112025","No value exists.","Mass Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035414","Rhabdoviridae","C112027","A family of bullet-shaped, negative-sense viruses capable of infect a broad range of hosts in both the animal and plant kingdoms.","Rhabdoviridae | ",,,,,,,,,,,,,,,"4234350","Family Rhabdoviridae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006395","Bunyaviridae","C112028","A family of negative-sense, enveloped RNA viruses that infect arthropods or rodents, but that can be transmitted to humans.","Bunyaviridae | ",,,,,,,,,,,,,,,"4085759","Family Bunyaviridae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0949921","Sapovirus","C112029","A genus of non-enveloped viruses with a capsid with T=3 icosahedral symmetry, in the family Caliciviridae. The genome is composed of a linear, single-strand of positive sense RNA. Sapoviruses are found in humans and swine and cause gastroenteritis in humans.","Sapovirus | SAPOVIRUS",,,,,,,,,,,,,,,"4248368","Genus Sapovirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002331","Alphavirus","C112030","A genus of enveloped, spherical, or pleomorphic viruses with T=4 icosahedral symmetry, in the family Togaviridae. The genome is composed of a linear, single-strand of positive sense RNA. Alphaviruses are spread by insect vector, able to infect vertebrates and invertebrates, and cause arthritis, encephalitis, rashes and fever in humans.","Alphavirus | ALPHAVIRUS | Arboviruses Group A",,,,,,,,,,,,,,,"4085601","Alphavirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085150","Filoviridae","C112031","A family of filamentous viruses with helical capsids and glycoprotein projections on their surface. The virus may have a branched morphology of varying length. The genome is composed of a linear single-strand of negative sense RNA. Filoviridae infect primates, pigs and bats in nature and are a causitive agent of viral hemorrhagic fevers in humans and primates.","Filoviridae | FILOVIRIDAE | Filovirus",,,,,,,,,,,,,,,"4248249","Family Filoviridae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3831493","AQ20 - Get Breathless Doing Housework","C112541","Airway Questionnaire 20 (AQ20) Do you get breathless doing housework?","AQ20 - Get Breathless Doing Housework | AQ01-Get Breathless Doing Housework | AQ0113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831501","AQ20 - Chest Trouble Make You Go Home Sooner Than Others","C112542","Airway Questionnaire 20 (AQ20) Does your chest trouble make you go home sooner than others after a night out?","AQ20 - Chest Trouble Make You Go Home Sooner Than Others | AQ01-Go Home Sooner Than Others | AQ0114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831488","AQ20 - Suffer From Breathlessness When Laugh","C112543","Airway Questionnaire 20 (AQ20) Do you suffer from breathlessness when you laugh?","AQ20 - Suffer From Breathlessness When Laugh | AQ01-Breathlessness When Laugh | AQ0115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831502","AQ20 - Chest Trouble Make You Feel Impatient","C112544","Airway Questionnaire 20 (AQ20) Does your chest trouble often make you feel impatient?","AQ20 - Chest Trouble Make You Feel Impatient | AQ01-Impatient Due to Chest Trouble | AQ0116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831495","AQ20 - Fullness of Life is Limited by Chest Trouble","C112545","Airway Questionnaire 20 (AQ20) Do you think the fullness of your life is limited by your chest trouble?","AQ20 - Fullness of Life is Limited by Chest Trouble | AQ01-Full Life Limited by Chest Trouble | AQ0117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831497","AQ20 - Feel Drained After a Cold Because of Chest Trouble","C112546","Airway Questionnaire 20 (AQ20) Do you feel drained after a cold because of your chest trouble?","AQ20 - Feel Drained After a Cold Because of Chest Trouble | AQ01-Drained After a Cold | AQ0118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827346","DS - Disease Steps Classification","C112549","Disease Steps (DS) Methods: For Disease Steps, classification of a patient is determined by history and neurologic examination as well as course of MS.","DS - Disease Steps Classification | DS01-Disease Steps Classification | DS0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830336","EDSS - Expanded Disability Score","C112550","Kurtzke Expanded Disability Status Scale (EDSS) Expanded disability score.","EDSS - Expanded Disability Score | EDSS01-Expanded Disability Score | EDSS0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830235","FAMS - Have Trouble Meeting Needs of Family Because of My Condition","C112551","Functional Assessment of Multiple Sclerosis (FAMS) Mobility: Because of my physical condition, I have trouble meeting the needs of my family.","FAMS - Have Trouble Meeting Needs of Family Because of My Condition | FAMS01-Trouble Meeting Needs of Family | FAMS0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814142","DKK4 wt Allele","C111882","Human DKK4 wild-type allele is located within 8p11.2-p11.1 and is approximately 3 kb in length. This allele, which encodes dickkopf-related protein 4, plays a role in the modulation of Wnt signaling.","DKK4 wt Allele | DKK-4 | Dickkopf (Xenopus Laevis) Homolog 4 Gene | Dickkopf 4 Homolog (Xenopus Laevis) Gene | Dickkopf Homolog 4 Gene | Dickkopf, Xenopus, Homolog of, 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816454","Dickkopf-Related Protein 4","C111883","Dickkopf-related protein 4 (224 aa, ~25 kDa) is encoded by the human DKK4 gene. This protein is involved in the negative regulation of Wnt signaling.","Dickkopf-Related Protein 4 | Dickkopf 4 | Dickkopf Related Protei-42 | Dickkopf-4 | Dkk-4 | hDkk-4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454222","Exanthem","C111884","A widespread, acute rash.","Exanthem | ",,,,,,,,,,,,,,,"4109438","Eruption",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0343065","Dermatographism","C111885","A raised, inflamed skin reaction to pressure from rubbing or scratching.","Dermatographism | ",,,,,,,,,,,,,,,"132983","Dermatographic urticaria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3831527","Antepartum Obstetric Septic Embolism","C111782","Presence of bacterially-infected tissue in the maternal vascular system which originated from a distant site during the antepartum period.","Antepartum Obstetric Septic Embolism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831526","Antepartum Obstetric Thromboembolism","C111783","Presence of a blood clot in the maternal vascular system which originated from a distant site during the antepartum period.","Antepartum Obstetric Thromboembolism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828573","PGP wt Allele","C111792","Human PGP wild-type allele is located in the vicinity of 16p13.3 and is approximately 3 kb in length. This allele, which encodes phosphoglycolate phosphatase protein, may play a role in the regulation of oxygen transport by red blood cells.","PGP wt Allele | Phosphoglycolate Phosphatase wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814453","PGPase","C111793","Phosphoglycolate phosphatase (321 aa, ~34 kDa) is encoded by the human PGP gene. This protein may be involved in regulating oxygen transport by red blood cells.","Phosphoglycolate Phosphatase | EC 3.1.3.18 | PGP | PGPase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826883","CDISC SDTM Device Tracking and Disposition Event Dictionary Derived Term Terminology","C112037","Terminology associated with the Device Tracking and Disposition Event Dictionary Derived Term codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Device Tracking and Disposition Event Dictionary Derived Term Terminology | DTDECOD | Device Tracking and Disposition Event Dictionary Derived Term | SDTM-DTDECOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009401","Colorado Tick Fever Virus","C112240","A species of non-enveloped, spherical viruses with an icosahedral symmetry of triple capsid structure in the Reoviridae family and Coltivirus genus. The genome is composed of segmented, double-stranded RNA. Colorado tick fever viruses are found in adult wood ticks, humans and mammals, and cause Colorado tick fever in humans. Colorado tick fever viruses are transmitted mainly via the bite of infected Rocky Mountain wood ticks (Dermacentor andersoni).","Colorado Tick Fever Virus | COLORADO TICK FEVER VIRUS | CTFV",,,,,,,,,,,,,,,"4145287","Colorado tick fever virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4049886","Coxsackie A Virus","C112242","A species of non-enveloped, spherical viruses with a capsid with T=3 icosahedral symmetry in the Picornaviridae family and Enterovirus genus. The genome is composed of single-stranded, positive-sense RNA. Coxsackie A viruses are found in humans and cause hand, foot, and mouth disease, acute hemorrhagic conjunctivitis and herpangina via fecal-oral contamination.","Coxsackie A Virus | COXSACKIE A VIRUS | Coxsackie Virus A | Coxsackievirus A | Enterovirus A | Enterovirus EV-A | Human Coxsackievirus A | Human Enterovirus A",,,,,,,,,,,,,,,"4201875","Human coxsackievirus A",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0010243","Coxsackieviruses B","C112243","A species of non-enveloped, spherical viruses with a capsid with T=3 icosahedral symmetry in the Picornaviridae family and Enterovirus genus. The genome is composed of single-stranded, positive-sense RNA. Coxsackie B viruses are found in humans and cause aseptic meningitis, Bornholm disease, arrhythmias and heart failure via fecal-oral contamination.","Coxsackie B Virus | COXSACKIE B VIRUS | Coxsackie Virus B | Enterovirus B | Enterovirus EV-B | Human Enterovirus B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011974","Diaper Dermatitis","C111886","An inflammatory skin condition in the diaper area that may be caused by irritation or infection.","Diaper Dermatitis | Diaper Rash | Nappy Rash",,,,,,,,,,,,,,,"200164","Diaper rash",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0343874","Candida Diaper Dermatitis","C111887","An inflammatory skin condition in the diaper area superimposed with Candida infection, characterized by a bright red rash with a sharply demarcated edge and satellite lesions. Skin folds are often involved.","Candida Diaper Dermatitis | Candida Diaper Rash | Candida Nappy Rash",,,,,,,,,,,,,,,"4080744","Diaper candidiasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4012362","Seborrheic Dermatitis","C111888","A chronic, inflammatory skin disorder that affects the scalp, central face and skin folds; it is characterized by scaling and itching.","Seborrheic Dermatitis | Cradle Cap | Seborrhea | Seborrheic Eczema",,,,,,,,,,,,,,,"137053","Seborrheic dermatitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL454225","Carbon C 14 Telotristat Etiprate","C111891","An orally bioavailable, tryptophan hydroxylase (TPH) inhibitor prodrug labeled with carbon C 14, which could be used to evaluate the pharmacokinetic profile of telotristat etiprate. Upon administration, telotristat etiprate is converted to its active moiety, telotristat (LP-778902), which binds to and blocks the activity of TPH. This may result in a reduction in peripheral serotonin (5-HT) production and improvement of serotonin-mediated gastrointestinal adverse side effects, such as severe diarrhea. TPH, the rate-limiting enzyme in serotonin biosynthesis, is overexpressed in carcinoid tumor cells. Telotristat radiolabeled with carbon C 14 facilitates the evaluation of the pharmacokinetic characteristics of this agent, including its absorption, distribution, metabolism, and excretion (ADME).","Carbon C 14 Telotristat Etiprate | 14C-telotristat Etiprate | [14C]-LX1606 | [14C]-telotristat Etiprate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827091","PEG-proline-interferon alpha-2b","C111892","A long-acting formulation of recombinant interferon alpha subtype 2b (IFN-a2b), in which IFN-a2b is coupled, via proline, to polyethylene glycol (PEG), with antiviral, immunomodulating and antineoplastic activities. Upon administration of ropeginterferon alfa-2b, IFN-a2b targets and binds to specific IFN cell-surface receptors. This activates IFN-mediated signal transduction pathways and induces the transcription and translation of genes with IFN-specific response elements (ISREs). Their protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety inhibits proteolytic breakdown and clearance of IFN-a2b, which prolongs its half-life, extends the duration of its therapeutic effects and allows less frequent dosing. The proline linker facilitates the synthesis of a single positional isomer which further increases its stability and half-life.","Ropeginterferon Alfa-2B | AOP 2014 | AOP-2014 | AOP2014 | Besremi | P-1101 | P1101 | PEG-P-IFN-Alfa-2b | PEG-P-IFN-Alpha-2b | PEG-Proline-Interferon Alfa-2b | ROPEGINTERFERON ALFA-2B | Ropeginterferon alfa-2b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1436312","Glutathione S-Transferase Mu 3, Human","C112074","Glutathione S-transferase Mu 3 (225 aa, ~27 kDa) is encoded by the human GSTM3 gene. This protein is involved in cellular detoxification of glutathione, nitrogenous compounds and other xenobiotics.","Glutathione S-Transferase Mu 3 | Brain GST | Brain Type Mu-Glutathione S-Transferase | EC 2.5.1.18 | GST Class-Mu 3 | GSTM3-3 | Glutathione S-Aralkyltransferase M3 | Glutathione S-Aryltransferase M3 | Glutathione S-Transferase 5 | Glutathione S-Transferase M3 | Glutathione S-Transferase, Mu-3 | S-(Hydroxyalkyl)Glutathione Lyase M3 | hGSTM3-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816725","67 kDa Laminin Receptor","C107450","67 kDa laminin receptor is a homodimer of 40S ribosomal protein SA. This cell surface receptor binds laminin and may interact with major prion protein.","67 kDa Laminin Receptor | 67 kD Laminin Receptor | 67LR | 67kD Laminin Receptor | 67kD, Ribosomal Protein SA | Colon Carcinoma Laminin-Binding Protein | LAMBR | LAMR1 | LR | LamR | Laminin Receptor | Laminin Receptor 1 | Laminin Receptor, 67-kD | Laminin Receptor-1 | Laminin Receptor-1 (67kD)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812754","DDX31 wt Allele","C107452","Human DDX31 wild-type allele is located in the vicinity of 9q34.13 and is approximately 77 kb in length. This allele, which encodes probable ATP-dependent RNA helicase DDX31 protein, is involved in the regulation of RNA secondary structure.","DDX31 wt Allele | DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 31 Gene | DEAD-Box Helicase 31 wt Allele | FLJ13633 | FLJ14578 | FLJ23349 | PPP1R25",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3657902","DDX31 protein, human","C107453","Probable ATP-dependent RNA helicase DDX31 (851 aa, ~94 kDa) is encoded by the human DDX31 gene. This protein plays a role in the regulation of RNA secondary structure.","Probable ATP-Dependent RNA Helicase DDX31 | DDX31 | DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 31 | DEAD Box Protein 31 | DEAD/DEXH Helicase DDX31 | DEAD/H (Asp-Glu-Ala-Asp/His) Box Polypeptide 31 | EC 3.6.4.13 | G2 Helicase | Helicain | Protein Phosphatase 1, Regulatory Subunit 25",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830061","GAB1 wt Allele","C107455","Human GAB1 wild-type allele is located in the vicinity of 4q31.21 and is approximately 138 kb in length. This allele, which encodes GRB2-associated-binding protein 1, plays a role in the intracellular signaling pathways of several growth factor receptors.","GAB1 wt Allele | DFNB26 | Deafness, Autosomal Recessive 26 Gene | GRB2 Associated Binding Protein 1 wt Allele | GRB2-Associated Binding Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814000","Ford County, KS","C108604","No value exists.","Ford County, KS | Ford County | Ford County, Kansas | KS057",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814017","Franklin County, KS","C108605","No value exists.","Franklin County, KS | Franklin County | Franklin County, Kansas | KS059",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829998","Geary County, KS","C108606","No value exists.","Geary County, KS | Geary County | Geary County, Kansas | KS061",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829959","Gove County, KS","C108607","No value exists.","Gove County, KS | Gove County | Gove County, Kansas | KS063",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813975","Grant County, KS","C108609","No value exists.","Grant County, KS | Grant County | Grant County, Kansas | KS067",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813989","Gray County, KS","C108610","No value exists.","Gray County, KS | Gray County | Gray County, Kansas | KS069",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813994","Greeley County, KS","C108611","No value exists.","Greeley County, KS | Greeley County | Greeley County, Kansas | KS071",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814409","Greenwood County, KS","C108612","No value exists.","Greenwood County, KS | Greenwood County | Greenwood County, Kansas | KS073",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815551","Harper County, KS","C108614","No value exists.","Harper County, KS | Harper County | Harper County, Kansas | KS077",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829837","Harvey County, KS","C108615","No value exists.","Harvey County, KS | Harvey County | Harvey County, Kansas | KS079",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815561","Haskell County, KS","C108616","No value exists.","Haskell County, KS | Haskell County | Haskell County, Kansas | KS081",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829676","Hodgeman County, KS","C108617","No value exists.","Hodgeman County, KS | Hodgeman County | Hodgeman County, Kansas | KS083",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816459","Jackson County, KS","C108618","No value exists.","Jackson County, KS | Jackson County | Jackson County, Kansas | KS085",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454281","TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes","C111992","A preparation of tumor infiltrating lymphocytes (TILs) that are transduced with a retroviral vector encoding a gene for a dominant-negative form of the transforming growth factor beta (TGFb) receptor, TGFbDNRII, with potential immunomodulating activity. Upon administration, the TGFbDNRII-transduced autologous TILs recognize and kill tumor cells. The expression of TGFbDNRII allows for the TILs to be resistant to TGF-b-mediated inhibition of T cell proliferation and activation, which allows optimal TIL activity. The immunosuppressant TGF-b is produced by tumor cells and plays a key role in the repression of the immune system.","TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes | TGFbDNRII-transduced Autologous TILs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454282","ATR kinase inhibitor AZD6738","C111993","An orally available morpholino-pyrimidine-based inhibitor of ataxia telangiectasia and rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration, Ceralasertib selectively inhibits ATR activity by blocking the downstream phosphorylation of the serine/threonine protein kinase CHK1. This prevents ATR-mediated signaling, and results in the inhibition of DNA damage checkpoint activation, disruption of DNA damage repair, and the induction of tumor cell apoptosis. In addition, AZD6738 sensitizes tumor cells to chemo- and radiotherapy. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression and survival; it is activated by DNA damage caused during DNA replication-associated stress.","Ceralasertib | AZD6738 | CERALASERTIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454283","P-glycoprotein inhibitor HM30181AK","C111994","An inhibitor of the adenosine triphosphate (ATP)-binding cassette (ABC) transporter P-glycoprotein (P-gp), with adjuvant activity. Upon oral administration, encequidar selectively binds to and inhibits the multidrug resistance (MDR) efflux pump P-gp, which prevents the efflux of various chemotherapeutic agents from intestinal epithelial cells to the gastrointestinal tract. This leads to an increase in both oral bioavailability and therapeutic efficacy. P-gp prevents the intestinal uptake and intracellular accumulation of various cytotoxic agents. Encequidar is not systemically absorbed.","Encequidar | 4-Oxo-4H-chromene-2-carboxylic acid [2-(2-4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl]-phenyl-2H-tetrazol-5-yl)-4,5-dimethoxy-phenyl]-amide | ENCEQUIDAR | HM30181A | HM30181AK | Pgp Inhibitor HM30181AK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454285","Autologous Cultured Acute Myeloid Leukemia-specific Cytotoxic T Lymphocytes","C111996","A preparation of cytotoxic, autologous acute myelogenous leukemia (AML)-reactive T lymphocytes (CTL), with potential immunomodulating and antineoplastic activities. The autologous cultured AML-specific CTLs are prepared using a specific AML-CTL culture method. Autologous peripheral blood lymphocytes are taken from an AML patient and the autologous AML blasts are treated with granulocyte macrophage colony-stimulating factor (GM-CSF) and interleukin 4 (IL-4), both of which promote ex vivo differentiation of AML blasts into dendritic cells (DCs). In the same culture, T cells are treated and activated by low-dose interleukin 2 (IL-2), and expanded using anti-CD3. This results in cultured AML-reactive CTLs which are administered back into the patient after autologous hematopoietic stem cell transplant (AHSCT). The autologous cultured AML-specific CTLs may eradicate residual AML cells.","Autologous Cultured Acute Myeloid Leukemia-specific Cytotoxic T Lymphocytes | Autologous AML-reactive Cultured CTL | Autologous AML-specific CTLs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454286","Anti-HER3 Monoclonal Antibody GSK2849330","C111997","A monoclonal antibody directed against the human epidermal growth factor receptor 3 (HER3; ERBB3) with potential antineoplastic activity. Anti-HER3 monoclonal antibody GSK2849330 binds to HER3 and inhibits its activation. This may prevent HER3-mediated signaling and inhibit HER3-dependent tumor cell proliferation and differentiation. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors and is associated with poor prognosis and drug resistance; it has no active kinase domain but is activated through heterodimerization with other members of the EGFR receptor family, such as HER2.","Anti-HER3 Monoclonal Antibody GSK2849330 | GSK2849330",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454287","Live-attenuated Listeria monocytogenes-encoding EGFRvIII-NY-ESO-1 Vaccine ADU-623","C111998","A live-attenuated, double-deleted strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding a mutant form of the tumor associated antigens, epidermal growth factor receptor (EGFRvIII) and the cancer/testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, live-attenuated Listeria monocytogenes encoding EGFRvIII-NY-ESO-1 vaccine targets dendritic cells and expresses EGFRvIII and NY-ESO-1. This promotes both a potent innate immune response and an adaptive immune response involving the recruitment and activation of T lymphocytes against EGFRvIII and NY-ESO-1-expressing tumor cells, which results in tumor cell lysis.","Live-attenuated Listeria monocytogenes-encoding EGFRvIII-NY-ESO-1 Vaccine ADU-623 | ADU-623",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454674","BET Inhibitor RO6870810","C112500","A small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins with potential antineoplastic activity. Upon administration, the BET inhibitor RO6870810 binds to the acetylated lysine recognition motifs found in the bromodomain of BET proteins, which prevents the interaction between BET proteins and acetylated histones. This interaction disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomains at the N-terminus, BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during cellular development and growth.","BET Inhibitor RO6870810 | Bromodomain and Extra-Terminal Protein Inhibitor RO6870810 | RG 6146 | RG6146 | RO-6870810 | RO6870810 | TEN 010 | TEN-010",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414029","DGKA Gene","C112501","This gene is involved in phospholipid metabolism.","DGKA Gene | DGKA | Diacylglycerol Kinase, Alpha 80kDa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813712","DGKA wt Allele","C112502","Human DGKA wild-type allele is located in the vicinity of 12q13.3 and is approximately 27 kb in length. This allele, which encodes diacylglycerol kinase alpha protein, plays a role in lipid phosphorylation and the attenuation of second messenger signaling.","DGKA wt Allele | DAGK | DAGK1 | DGK-alpha | Diacylglycerol Kinase, Alpha 80kDa wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815868","Diacylglycerol Kinase Alpha","C112503","Diacylglycerol kinase alpha (735 aa, ~83 kDa) is encoded by the human DGKA gene. This protein is involved in the negative regulation of second messenger signaling through lipid phosphorylation.","Diacylglycerol Kinase Alpha | 80 kDa Diacylglycerol Kinase | DAG Kinase Alpha | DGKA | Diacylglycerol Kinase, Alpha | Diglyceride Kinase Alpha | EC 2.7.1.107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811244","MSR1 wt Allele","C112505","Human MSR1 wild-type allele is located in the vicinity of 8p22 and is approximately 450 kb in length. This allele, which encodes macrophage scavenger receptor types I and II protein, is involved in the modulation of cholesterol and lipoprotein transport. Mutation of the gene is associated with Barrett esophagus and prostate cancer.","MSR1 wt Allele | CD204 | Macrophage Scavenger Receptor 1 wt Allele | Macrophage Scavenger Receptor Gene | SCARA1 | SR-A | SRA | phSR1 | phSR2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0212576","Macrophage Scavenger Receptor Types I and II","C112507","Macrophage scavenger receptor types I and II (451 aa, ~50 kDa) is encoded by the human MSR1 gene. This protein plays a role in cholesterol and lipoprotein transport.","Macrophage Scavenger Receptor Types I and II | CD204 Antigen | Macrophage Acetylated LDL Receptor I and II | Macrophage Scavenger Receptor | Macrophage Scavenger Receptor Type III | Scavenger Receptor Class A Member 1 | Scavenger Receptor Class A, Member 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811068","PSMB8 wt Allele","C112076","Human PSMB8 wild-type allele is located in the vicinity of 6p21.3 and is approximately 4 kb in length. This allele, which encodes proteasome subunit beta type-8 protein, is involved in both antigen processing and protein catabolism. Mutation of the gene is associated with Nakajo syndrome and chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome (CANDLE syndrome).","PSMB8 wt Allele | ALDD | D6S216 | D6S216E | JMP | LMP7 | Large Multifunctional Peptidase 7 Gene | Large Multifunctional Protease 7 Gene | NKJO | PSMB5i | Proteasome (Prosome, Macropain) Subunit, Beta Type, 8 (Large Multifunctional Peptidase 7) Gene | Proteasome (Prosome, Macropain) Subunit, Beta Type, 8 (Large Multifunctional Protease 7) Gene | Proteasome (Prosome, Macropain) Subunit, Beta Type, 8 wt Allele | Proteasome-Related Gene 7 | RING10 | Y2 | beta5i",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527848","Proteasome Subunit Beta Type-8, Human","C112077","Proteasome subunit beta type-8 (276 aa, ~30 kDa) is encoded by the human PSMB8 gene. This protein plays a role in both protein metabolism and the generation of MHC class I-binding peptides.","Proteasome Subunit Beta Type-8 | EC 3.4.25.1 | Large Multifunctional Peptidase 7 | Large Multifunctional Protease 7 | Low Molecular Mass Protein 7 | Low Molecular Weight Protein 7 | Macropain Subunit C13 | Multicatalytic Endopeptidase Complex Subunit C13 | PSMB8 | Protease Component C13 | Proteasome Component C13 | Proteasome Subunit Beta 5i | Proteasome Subunit Beta-5i | Proteasome Subunit Y2 | Really Interesting New Gene 10 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811067","PSMB10 wt Allele","C112079","Human PSMB10 wild-type allele is located in the vicinity of 16q22.1 and is approximately 3 kb in length. This allele, which encodes proteasome subunit beta type-10 protein, plays a role in proteasomal protein catabolism.","PSMB10 wt Allele | LMP10 | MECL1 | MGC1665 | Proteasome (Prosome, Macropain) Subunit, Beta Type, 10 wt Allele | beta2i",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0388576","Proteasome Subunit Beta Type-10, Human","C112080","Proteasome subunit beta type-10 (273 aa, ~29 kDa) is encoded by the human PSMB10 gene. This protein is involved in the formation of peptide antigens by the immunoproteasome.","Proteasome Subunit Beta Type-10 | EC 3.4.25.1 | Low Molecular Mass Protein 10 | Macropain Subunit MECl-1 | Multicatalytic Endopeptidase Complex Subunit MECl-1 | PSMB10 | Proteasome Catalytic Subunit 2i | Proteasome MECl-1 | Proteasome Subunit Beta-2i | Proteasome Subunit MECL1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813546","SLC44A1 wt Allele","C112082","Human SLC44A1 wild-type allele is located in the vicinity of 9q31.2 and is approximately 195 kb in length. This allele, which encodes choline transporter-like protein 1, is involved in choline transporter and may be involved in membrane synthesis and myelin production.","SLC44A1 wt Allele | CD92 | CDW92 | CHTL1 | CTL1 | Solute Carrier Family 44 (Choline Transporter), Member 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1099413","SLC44A1 protein, human","C112083","Choline transporter-like protein 1 (657 aa, ~73 kDa) is encoded by the human SLC44A1 gene. This protein plays a role in choline transport.","Choline Transporter-Like Protein 1 | CD92 Antigen | CDW92 Antigen | RP11-287A8.1 | SLC44A1 | Solute Carrier Family 44 Member 1 | Solute Carrier Family 44, Member 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812695","LPAR3 wt Allele","C112085","Human LPAR3 wild-type allele is located in the vicinity of 1p22.3 and is approximately 82 kb in length. This allele, which encodes lysophosphatidic acid receptor 3 protein, plays a role as a cellular receptor for lysophosphatidic acid and mediates lysophosphatidic acid-evoked calcium mobilization.","LPAR3 wt Allele | EDG7 | Edg-7 | Endothelial Cell Differentiation Gene 7 | Endothelial Differentiation Gene 7 | GPCR | HOFNH30 | LP-A3 | LPA-3 | LPA3 | Lysophosphatidic Acid Receptor 3 wt Allele | RP4-678I3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829455","Jewell County, KS","C108620","No value exists.","Jewell County, KS | Jewell County | Jewell County, Kansas | KS089",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810783","Johnson County, KS","C108621","No value exists.","Johnson County, KS | Johnson County | Johnson County, Kansas | KS091",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829417","Kearny County, KS","C108622","No value exists.","Kearny County, KS | KS093 | Kearny County | Kearny County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829382","Kingman County, KS","C108623","No value exists.","Kingman County, KS | KS095 | Kingman County | Kingman County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829355","Labette County, KS","C108625","No value exists.","Labette County, KS | KS099 | Labette County | Labette County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813652","Lane County, KS","C108626","No value exists.","Lane County, KS | KS101 | Lane County | Lane County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829307","Leavenworth County, KS","C108627","No value exists.","Leavenworth County, KS | KS103 | Leavenworth County | Leavenworth County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814095","Lincoln County, KS","C108628","No value exists.","Lincoln County, KS | KS105 | Lincoln County | Lincoln County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815584","Linn County, KS","C108629","No value exists.","Linn County, KS | KS107 | Linn County | Linn County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815624","Lyon County, KS","C108631","No value exists.","Lyon County, KS | KS111 | Lyon County | Lyon County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812239","McPherson County, KS","C108632","No value exists.","McPherson County, KS | KS113 | McPherson County | McPherson County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811176","Marion County, KS","C108633","No value exists.","Marion County, KS | KS115 | Marion County | Marion County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811191","Marshall County, KS","C108634","No value exists.","Marshall County, KS | KS117 | Marshall County | Marshall County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810681","Miami County, KS","C108636","No value exists.","Miami County, KS | KS121 | Miami County | Miami County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815638","IRF2BP2 wt Allele","C107665","Human IRF2BP2 wild-type allele is located in the vicinity of 1q42.3 and is approximately 5 kb in length. This allele, which encodes interferon regulatory factor 2-binding protein 2, is involved in the repression of interferon gene expression.","IRF2BP2 wt Allele | IRF-2BP2 | Interferon Regulatory Factor 2 Binding Protein 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1259223","Interferon Regulatory Factor 2-Binding Protein 2, Human","C107666","Interferon regulatory factor 2-binding protein 2 (587 aa, ~61 kDa) is encoded by the human IRF2BP2 gene. This protein plays a role in the negative regulation of interferon expression.","Interferon Regulatory Factor 2-Binding Protein 2 | IRF-2-Binding Protein 2 | IRF-2BP2 | IRF2-Binding Protein 2 | IRF2BP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413301","CDX1 Gene","C107667","This gene is involved in gene expression in the intestine.","CDX1 Gene | CDX1 | Caudal Type Homeobox 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831165","CDX1 wt Allele","C107668","Human CDX1 wild-type allele is located in the vicinity of 5q32 and is approximately 19 kb in length. This allele, which encodes homeobox protein CDX-1, plays a role in the regulation of intestinal gene expression.","CDX1 wt Allele | CDX-1 | Caudal Type Homeobox 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1505660","Homeobox Protein CDX-1, Human","C107669","Homeobox protein CDX-1 (265 aa, ~28 kDa) is encoded by the human CDX1 gene. This protein is involved in the modulation of gene expression in the intestine.","Homeobox Protein CDX-1 | CDX1 | Caudal Type Homeo Box Transcription Factor 1 | Caudal Type Homeobox Transcription Factor 1 | Caudal-Type Homeobox Protein 1 | Caudal-Type Homeobox Protein CDX1 | Caudal-Type Homeobox Transcription Factor 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454288","anti-LAG-3 monoclonal antibody BMS-986016","C111999","A monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with potential immunomodulating and antineoplastic activities. Upon administration, relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs). This may activate antigen-specific T-lymphocytes and enhance cytotoxic T cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG-3 is a member of the immunoglobulin superfamily (IgSF) and binds to major histocompatibility complex (MHC) class II. LAG-3 expression on TILs is associated with tumor-mediated immune suppression.","Relatlimab | BMS 986016 | BMS-986016 | BMS986016 | Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer | RELATLIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085160","Hidradenitis","C112190","Inflammation of the apocrine sweat glands, characterized by redness, itching, pain or swelling of the sweat glands, usually in the axillae or groin.","Hidradenitis | ",,,,,,,,,,,,,,,"434119","Hidradenitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014034","Enanthem","C112197","An acute eruption of ulcerative lesions on the mucous membrane of the oropharynx.","Enanthem | ",,,,,,,,,,,,,,,"4239322","Mucous membrane eruption",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221237","Angular Cheilitis","C112198","Inflammation of the skin at the corners of the mouth characterized by redness, fissures or crusts.","Angular Cheilitis | Cheilosis | Perleche | Perlèche",,,,,,,,,,,,,,,"4144108","Angular cheilitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017675","Glossitis","C112199","Inflammation of the tongue.","Glossitis | ",,,,,,,,,,,,,,,"436147","Glossitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0263518","Telogen Effluvium","C112200","A scalp hair loss condition characterized by excessive shedding of hair in the resting phase of growth, usually following a fever or major body stress.","Telogen Effluvium | ",,,,,,,,,,,,,,,"140173","Telogen effluvium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031736","Polymorphous Light Eruption","C112201","A red, edematous rash that occurs on areas of the skin with recent exposure to sunlight.","Polymorphous Light Eruption | ",,,,,,,,,,,,,,,"4080921","Polymorphous light eruption",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1306792","Red Man Syndrome","C112202","An abrupt onset drug reaction characterized by a red rash that involves the face, neck, and upper torso.","Red Man Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417839","NR5A2 Gene","C112510","This gene is involved in ligand-dependent transcriptional regulation.","NR5A2 Gene | NR5A2 | Nuclear Receptor Subfamily 5, Group A, Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813144","NR5A2 wt Allele","C112511","Human NR5A2 wild-type allele is located in the vicinity of 1q32.1 and is approximately 150 kb in length. This allele, which encodes nuclear receptor subfamily 5 group A member 2 protein, plays a role in ligand-dependent regulation of gene transcription.","NR5A2 wt Allele | B1F | B1F2 | CPF | FTF | FTZ-F1 | FTZ-F1beta | LRH-1 | LRH1 | Nuclear Receptor Subfamily 5, Group A, Member 2 wt Allele | hB1 | hB1F-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1429901","NR5A2 protein, human","C112512","Nuclear receptor subfamily 5 group A member 2 (541 aa, ~61 kDa) is encoded by the human NR5A2 gene. This protein is involved in both transcriptional regulation and hormone binding.","Nuclear Receptor Subfamily 5 Group A Member 2 | Alpha-1-Fetoprotein Transcription Factor | B1-Binding Factor | B1-Binding Factor, Hepatocyte Transcription Factor which Activates Enhancer II of Hepatitis B Virus | CYP7A Promoter-Binding Factor | Fetoprotein Transcription Factor | Fetoprotein-Alpha 1 (AFP) Transcription Factor | Hepatocytic Transcription Factor | Human B1-Binding Factor | LRH-1 | Liver Receptor Homolog 1 | Liver Receptor Homolog-1 | NR5A2 | Nuclear Receptor NR5A2 | hB1F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417810","NPR1 Gene","C112513","This gene plays a role in ligand-dependent cyclic GMP synthesis.","NPR1 Gene | NPR1 | Natriuretic Peptide Receptor A/Guanylate Cyclase A (Atrionatriuretic Peptide Receptor A) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811241","PRKCG wt Allele","C111836","Human PRKCG wild-type allele is located in the vicinity of 19q13.4 and is approximately 28 kb in length. This allele, which encodes Protein kinase C gamma type protein, plays a role in the regulation of cellular signaling pathways. Mutations in this gene are associated with spinocerebellar ataxia 14.","PRKCG wt Allele | MGC57564 | PKCC | PKCG | Protein Kinase C, Gamma wt Allele | SCA14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0256015","protein kinase C gamma","C111837","Protein kinase C gamma type (697 aa, ~78 kDa) is encoded by the human PRKCG gene. This protein is involved in cellular signaling.","Protein Kinase C Gamma Type | EC 2.7.11.13 | PKC-Gamma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811198","NDRG4 wt Allele","C111839","Human NDRG4 wild-type allele is located within 16q21-q22.1 and is approximately 51 kb in length. This allele, which encodes protein NDRG4, plays a role in both vascular smooth muscle cell growth and neuronal survival.","NDRG4 wt Allele | BDM1 | KIAA1180 | NDRG Family Member wt Allele | NMYC Downstream-Regulated Gene 4 | SMAP-8 | SMAP8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1448047","NDRG4 protein, human","C111840","Protein NDRG4 (352 aa, ~38 kDa) is encoded by the human NDRG4 gene. This protein is involved in the inhibition of neuronal cell death and the growth of vascular smooth muscle cell.","Protein NDRG4 | Brain Development-Related Molecule 1 | N-Myc Downstream-Regulated Gene 4 Protein | SMAP-8 | Smooth Muscle Associated Protein 8 | Smooth Muscle-Associated Protein 8 | Vascular Smooth Muscle Cell-Associated Protein 8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810559","EPHA7 wt Allele","C111843","Human EPHA7 wild-type allele is located in the vicinity of 6q16.1 and is approximately 180 kb in length. This allele, which encodes ephrin type-A receptor 7 protein, is involved in regulation of developmental processes.","EPHA7 wt Allele | EHK-3 | EHK3 | EK11 | EPH Receptor A7 wt Allele | HEK11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815882","Lost Medical Device","C112329","A finding referring to a medical device that is no longer held or possessed; incapable of being recovered or regained.","Lost Medical Device | LOST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206546","Lyssavirus","C112330","A genus of enveloped, bullet or cylindrical shaped viruses in the family Rhabdoviridae. The genome is composed of a linear single-strand of negative sense RNA. Lyssavirus species 1 can be carried by any warm-blooded mammal while species 2-7 have specific hosts. Species in the genus Lyssavirus cause Rabies in humans.","Lyssavirus | LYSSAVIRUS",,,,,,,,,,,,,,,"4011227","Genus Lyssavirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0949889","Marburgvirus","C112331","A genus of filamentous, enveloped viruses with glycoprotein surface spikes, in the family Filoviridae. The genome is composed of a linear single-strand of negative sense RNA. The primary product of the fourth gene is the GP1,2 glycoprotein, which does not require cotranscriptional editing. Marburgviruses humans and primates and cause hemorrhagic fevers in humans.","Marburgvirus | MARBURGVIRUS",,,,,,,,,,,,,,,"4314612","Genus Marburgvirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3831599","Adjustable Dose Pre-filled Pen Syringe","C107670","A syringe with a measured dose of medication that has an apparatus that enables the user to specify the amount of the medication to deliver in an injection.","Adjustable Dose Pre-filled Pen Syringe | Adjustable Dose Pre-Filled Drug Pen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828884","Mucin-Depleted Foci of the Mouse Intestinal Tract","C107671","Precancerous dysplastic lesions depleted of mucin in the colonic mucosa of the mouse.","Mucin-Depleted Foci of the Mouse Intestinal Tract | MDF of the Mouse Intestinal Tract",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829516","Intramucosal Carcinoma of the Mouse Intestinal Tract","C107672","Infiltration of malignant glandular epithelial cells into the lamina propria of the intestine of the mouse without involvement of the submucosa.","Intramucosal Carcinoma of the Mouse Intestinal Tract | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829116","Metastatic Carcinoma of the Mouse Intestinal Tract","C107674","A carcinoma that arises from the intestinal tract of the mouse and has spread to other anatomic sites.","Metastatic Carcinoma of the Mouse Intestinal Tract | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827908","SPL Race Terminology","C107675","Terminology used for representation of the race designation in the framework of the Structured Product Labeling documents.","SPL Race Terminology | Structured Product Labeling Race Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815135","Dicycloplatin","C107676","A third-generation, supramolecular platinum-based compound composed of carboplatin linked, by a strong hydrogen bond, to 1,1-cyclobutane dicarboxylate (CBDCA), with potential antineoplastic activity. Although the exact mechanism of action has yet to be fully elucidated, dicycloplatin appears to have a mechanism of action similar to that of other platinum-based compounds, which involves both DNA binding and the formation of DNA crosslinks. This mechanism results in the induction of apoptosis and cell growth inhibition. Compared to carboplatin alone, dicycloplatin shows enhanced solubility and stability in aqueous solution and appears to have a more favorable toxicity profile.","Dicycloplatin | DCP | DICYCLOPLATIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831134","Chattahoochee County, GA","C108100","No value exists.","Chattahoochee County, GA | Chattahoochee County | Chattahoochee County, Georgia | GA053",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831133","Chattooga County, GA","C108101","No value exists.","Chattooga County, GA | Chattooga County | Chattooga County, Georgia | GA055",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814106","Cherokee County, GA","C108102","No value exists.","Cherokee County, GA | Cherokee County | Cherokee County, Georgia | GA057",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814107","Clarke County, GA","C108103","No value exists.","Clarke County, GA | Clarke County | Clarke County, Georgia | GA059",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811079","Clay County, GA","C108104","No value exists.","Clay County, GA | Clay County | Clay County, Georgia | GA061",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811084","Clayton County, GA","C108105","No value exists.","Clayton County, GA | Clayton County | Clayton County, Georgia | GA063",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830391","Drug Induced Cutaneous Lupus Erythematosus","C112203","A reaction to a drug characterized by skin findings common to lupus including photosensitivity and butterfly rash; typically it resolves after drug discontinuation.","Drug Induced Cutaneous Lupus Erythematosus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812646","Drug Induced Cutaneous Vasculitis","C112204","A skin hypersensitivity reaction due to exposure to a pharmacologic substance that is characterized by raised purpuric lesions, red macules, hemorrhagic blisters and ulcerations.","Drug Induced Cutaneous Vasculitis | Drug Induced Vasculitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454405","pan-FGFR tyrosine kinase inhibitor BAY1163877","C112205","A pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. Rogaratinib inhibits the activities of FGFRs, which may result in the inhibition of both tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. FGFRs are a family of receptor tyrosine kinases, which may be upregulated in various tumor cell types and may be involved in tumor cell differentiation and proliferation, tumor angiogenesis, and tumor cell survival.","Rogaratinib | 4-((4-Amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo(2,1-f)(1,2,4)triazin-7-yl)methyl)piperazin-2-one | BAY-1163877 | BAY1163877 | ROGARATINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829081","MHIS-NACC Questionnaire Question","C112461","A question associated with the MHIS-NACC questionnaire.","MHIS-NACC Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828629","PDDS Questionnaire Question","C112462","A question associated with the PDDS questionnaire.","PDDS Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827934","St George's Respiratory Questionnaire Past 3 Months Version Questionnaire Question","C112463","A question associated with the SGRQ Past 3 Months Version questionnaire.","St George's Respiratory Questionnaire Past 3 Months Version Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827933","St George's Respiratory Questionnaire Past 4 Weeks Version Questionnaire Question","C112464","A question associated with the SGRQ Past 4 Weeks Version questionnaire.","St George's Respiratory Questionnaire Past 4 Weeks Version Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827609","VFQ25-Interviewer Administered Format Questionnaire Question","C112465","A question associated with the VFQ25-Interviewer Administered Format questionnaire.","VFQ25-Interviewer Administered Format Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827567","VFQ25-Self Administered Format Questionnaire Question","C112466","A question associated with the VFQ25-Self Administered Format questionnaire.","VFQ25-Self Administered Format Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830989","COWS - Total Score","C112468","Clinical Opiate Withdrawal Scale (COWS) Total score.","COWS - Total Score | COWS1-Total Score | COWS112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828760","NPI - Delusions FxS Score","C112469","Neuropsychiatric Inventory (NPI) Delusions: (frequency score x severity score).","NPI - Delusions FxS Score | NPI1-Delusions FxS Score | NPI1AFS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828756","NPI - Hallucinations FxS Score","C112470","Neuropsychiatric Inventory (NPI) Hallucinations: (frequency score x severity score).","NPI - Hallucinations FxS Score | NPI1-Hallucinations FxS Score | NPI1BFS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828764","NPI - Agitation/Aggression FxS Score","C112471","Neuropsychiatric Inventory (NPI) Agitation/Aggression: (frequency score x severity score).","NPI - Agitation/Aggression FxS Score | NPI1-Agitation/Aggression FxS Score | NPI1CFS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828759","NPI - Depression/Dysphoria FxS Score","C112472","Neuropsychiatric Inventory (NPI) Depression/Dysphoria: (frequency score x severity score).","NPI - Depression/Dysphoria FxS Score | NPI1-Depression/Dysphoria FxS Score | NPI1DFS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810532","Ephrin Type-A Receptor 7, human","C111844","Ephrin type-A receptor 7 (998 aa, ~112 kDa) is encoded by the human EPHA7 gene. This protein plays a role in development.","Ephrin Type-A Receptor 7 | EC 2.7.10.1 | EPH Homology Kinase 3 | EPH-Like Kinase 11 | Eph Homology Kinase-3 | Ephrin Receptor EphA7 | Receptor Protein-Tyrosine Kinase HEK11 | Tyrosine-Protein Kinase Receptor EHK-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812280","TFPI2 wt Allele","C111845","Human TFPI2 wild-type allele is located in the vicinity of 7q22 and is approximately 6 kb in length. This allele, which encodes tissue factor pathway inhibitor 2 protein, is involved in the negative regulation of serine proteinase activity.","TFPI2 wt Allele | PP5 | REF1 | TFPI-2 | Tissue Factor Pathway Inhibitor 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1453587","Tissue Factor Pathway Inhibitor 2, Human","C111846","Tissue factor pathway inhibitor 2 (235 aa, ~27 kDa) is encoded by the human TFPI2 gene. This protein plays a role in the inhibition of serine proteinases.","Tissue Factor Pathway Inhibitor 2 | PP5 | Placental Protein 5 | Retinal Pigment Epithelium Cell Factor 1 | TFPI-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811213","SLC38A3 wt Allele","C111848","Human SLC38A3 wild-type allele is located in the vicinity of 3p21.31 and is approximately 16 kb in length. This allele, which encodes sodium-coupled neutral amino acid transporter 3 protein, plays a role in neutral amino acid transport and may play a role in both synaptic transmission and nitrogen metabolism.","SLC38A3 wt Allele | G17 | NAT1 | SN1 | SNAT3 | Solute Carrier Family 38 (Amino Acid Transporter), Member 3 Gene | Solute Carrier Family 38, Member 3 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810658","SLC38A3 protein, human","C111849","Sodium-coupled neutral amino acid transporter 3 (504 aa, ~56 kDa) is encoded by the human SLC38A3 gene. This protein is involved in neutral amino acid transport.","Sodium-Coupled Neutral Amino Acid Transporter 3 | N-System Amino Acid Transporter 1 | Na(+)-Coupled Neutral Amino Acid Transporter 3 | SLC38A3 | Solute Carrier Family 38 Member 3 | System N Amino Acid Transporter 1 | System N1 Na+ And H+-Coupled Glutamine Transporter | Transport System N, Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830232","FAMS - I Am Able to Work","C112552","Functional Assessment of Multiple Sclerosis (FAMS) Mobility: I am able to work (include work at home).","FAMS - I Am Able to Work | FAMS01-I Am Able to Work | FAMS0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830219","FAMS - I Have Trouble Walking","C112553","Functional Assessment of Multiple Sclerosis (FAMS) Mobility: I have trouble walking.","FAMS - I Have Trouble Walking | FAMS01-I Have Trouble Walking | FAMS0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830218","FAMS - Limit Social Activity Because of Condition","C112554","Functional Assessment of Multiple Sclerosis (FAMS) Mobility: I have to limit my social activity because of my condition.","FAMS - Limit Social Activity Because of Condition | FAMS01-Limit My Social Activity | FAMS0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830220","FAMS - I Have Strength in My Legs","C112555","Functional Assessment of Multiple Sclerosis (FAMS) Mobility: I have strength in my legs.","FAMS - I Have Strength in My Legs | FAMS01-I Have Strength in My Legs | FAMS0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830207","FAMS - Trouble Getting Around in Public Places","C112556","Functional Assessment of Multiple Sclerosis (FAMS) Mobility: I have trouble getting around in public places.","FAMS - Trouble Getting Around in Public Places | FAMS01-Trouble Getting Around in Public | FAMS0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830236","FAMS - Have to Take Condition Into Account When Making Plans","C112557","Functional Assessment of Multiple Sclerosis (FAMS) Mobility: I have to take my condition into account when making plans.","FAMS - Have to Take Condition Into Account When Making Plans | FAMS01-Take My Condition Into Account | FAMS0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830223","FAMS - I Have Nausea","C112558","Functional Assessment of Multiple Sclerosis (FAMS) Symptoms: I have nausea.","FAMS - I Have Nausea | FAMS01-I Have Nausea | FAMS0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830222","FAMS - I Have Pain","C112559","Functional Assessment of Multiple Sclerosis (FAMS) Symptoms: I have pain.","FAMS - I Have Pain | FAMS01-I Have Pain | FAMS0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830230","FAMS - I Feel Ill","C112560","Functional Assessment of Multiple Sclerosis (FAMS) Symptoms: I feel ill.","FAMS - I Feel Ill | FAMS01-I Feel Ill | FAMS0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830221","FAMS - I Have Pain in My Joints","C112562","Functional Assessment of Multiple Sclerosis (FAMS) Symptoms: I have pain in my joints.","FAMS - I Have Pain in My Joints | FAMS01-I Have Pain in My Joints | FAMS0112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830255","FAMS - Bothered by Headaches","C112563","Functional Assessment of Multiple Sclerosis (FAMS) Symptoms: I am bothered by headaches.","FAMS - Bothered by Headaches | FAMS01-I Am Bothered by Headaches | FAMS0113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827220","FAMS - Bothered by Muscle Pains","C112564","Functional Assessment of Multiple Sclerosis (FAMS) Symptoms: I am bothered by muscle pains.","FAMS - Bothered by Muscle Pains | FAMS01-I Am Bothered by Muscle Pains | FAMS0114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830228","FAMS - I Feel Sad","C112565","Functional Assessment of Multiple Sclerosis (FAMS) Emotional Well-Being: I feel sad.","FAMS - I Feel Sad | FAMS01-I Feel Sad | FAMS0115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830217","FAMS - Losing Hope in Fight Against My Illness","C112566","Functional Assessment of Multiple Sclerosis (FAMS) Emotional Well-Being: I am losing hope in the fight against my illness.","FAMS - Losing Hope in Fight Against My Illness | FAMS01-Losing Hope Against Illness | FAMS0116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830233","FAMS - I Am Able to Enjoy Life","C112567","Functional Assessment of Multiple Sclerosis (FAMS) Emotional Well-Being: I am able to enjoy life.","FAMS - I Am Able to Enjoy Life | FAMS01-I Am Able to Enjoy Life | FAMS0117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831065","Cobb County, GA","C108107","No value exists.","Cobb County, GA | Cobb County | Cobb County, Georgia | GA067",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812175","Coffee County, GA","C108108","No value exists.","Coffee County, GA | Coffee County | Coffee County, Georgia | GA069",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831046","Colquitt County, GA","C108109","No value exists.","Colquitt County, GA | Colquitt County | Colquitt County, Georgia | GA071",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812184","Columbia County, GA","C108110","No value exists.","Columbia County, GA | Columbia County | Columbia County, Georgia | GA073",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830992","Coweta County, GA","C108112","No value exists.","Coweta County, GA | Coweta County | Coweta County, Georgia | GA077",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813151","Crawford County, GA","C108113","No value exists.","Crawford County, GA | Crawford County | Crawford County, Georgia | GA079",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830980","Crisp County, GA","C108114","No value exists.","Crisp County, GA | Crisp County | Crisp County, Georgia | GA081",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814783","Dade County, GA","C108115","No value exists.","Dade County, GA | Dade County | Dade County, Georgia | GA083",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815131","Dawson County, GA","C108116","No value exists.","Dawson County, GA | Dawson County | Dawson County, Georgia | GA085",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815515","DeKalb County, GA","C108118","No value exists.","DeKalb County, GA | DeKalb County | DeKalb County, Georgia | GA089",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811820","Dodge County, GA","C108119","No value exists.","Dodge County, GA | Dodge County | Dodge County, Georgia | GA091",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830402","Dooly County, GA","C108120","No value exists.","Dooly County, GA | Dooly County | Dooly County, Georgia | GA093",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830398","Dougherty County, GA","C108121","No value exists.","Dougherty County, GA | Dougherty County | Dougherty County, Georgia | GA095",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811827","Douglas County, GA","C108122","No value exists.","Douglas County, GA | Douglas County | Douglas County, Georgia | GA097",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810810","Echols County, GA","C108124","No value exists.","Echols County, GA | Echols County | Echols County, Georgia | GA101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811843","Effingham County, GA","C108125","No value exists.","Effingham County, GA | Effingham County | Effingham County, Georgia | GA103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811847","Elbert County, GA","C108126","No value exists.","Elbert County, GA | Elbert County | Elbert County, Georgia | GA105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830318","Emanuel County, GA","C108127","No value exists.","Emanuel County, GA | Emanuel County | Emanuel County, Georgia | GA107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812201","Fannin County, GA","C108129","No value exists.","Fannin County, GA | Fannin County | Fannin County, Georgia | GA111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813153","ATF4 wt Allele","C107458","Human ATF4 wild-type allele is located in the vicinity of 22q13.1 and is approximately 3 kb in length. This allele, which encodes cyclic AMP-dependent transcription factor ATF-4 protein, is involved in the regulation of gene transcription.","ATF4 wt Allele | Activating Transcription Factor 4 wt Allele | CREB-2 | CREB2 | TAXREB67 | TXREB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1566322","Cyclic AMP-Dependent Transcription Factor ATF-4, Human","C107459","Cyclic AMP-dependent transcription factor ATF-4 (351 aa, ~39 kDa) is encoded by the human ATF4 gene. This protein plays a role in the regulation of gene transcription.","Cyclic AMP-Dependent Transcription Factor ATF-4 | ATF4 | CAMP Response Element-Binding Protein 2 | CAMP-Dependent Transcription Factor ATF-4 | CAMP-Responsive Element-Binding Protein 2 | Cyclic AMP-Responsive Element-Binding Protein 2 | DNA-Binding Protein TAXREB67 | Tax-Responsive Enhancer Element-Binding Protein 67",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828763","NPI - Anxiety FxS Score","C112473","Neuropsychiatric Inventory (NPI) Anxiety: (frequency score x severity score).","NPI - Anxiety FxS Score | NPI1-Anxiety FxS Score | NPI1EFS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828757","NPI - Elation/Euphoria FxS Score","C112474","Neuropsychiatric Inventory (NPI) Elation/Euphoria: (frequency score x severity score).","NPI - Elation/Euphoria FxS Score | NPI1-Elation/Euphoria FxS Score | NPI1FFS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828762","NPI - Apathy/Indifference FxS Score","C112475","Neuropsychiatric Inventory (NPI) Apathy/Indifference: (frequency score x severity score).","NPI - Apathy/Indifference FxS Score | NPI1-Apathy/Indifference FxS Score | NPI1GFS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828758","NPI - Disinhibition FxS Score","C112476","Neuropsychiatric Inventory (NPI) Disinhibition: (frequency score x severity score).","NPI - Disinhibition FxS Score | NPI1-Disinhibition FxS Score | NPI1HFS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827227","NPI - Aberrant Motor Behavior FxS Score","C112478","Neuropsychiatric Inventory (NPI) Aberrant Motor Behavior: (frequency score x severity score).","NPI - Aberrant Motor Behavior FxS Score | NPI1-Aberrant Motor Behavior FxS Score | NPI1JFS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827226","NPI - Sleep/Night Behavior Disorder FxS Score","C112479","Neuropsychiatric Inventory (NPI) Sleep and Nighttime Behavior Disorders: (frequency score x severity score).","NPI - Sleep/Night Behavior Disorder FxS Score | NPI1-Sleep/Night Behav Disord FxS Score | NPI1KFS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813965","TNFRSF13C wt Allele","C111796","Human TNFRSF13C wild-type allele is located within 22q13.1-q13.31 and is approximately 2 kb in length. This allele, which encodes tumor necrosis factor receptor superfamily member 13C protein, is involved in promoting peripheral B-cell survival. Mutations in this gene are associated with common variable immunodeficiency-4.","TNFRSF13C wt Allele | BAFF-R | BAFFR | BR3 | BROMIX | CD268 | CVID4 | Prolixin Gene | TNF Receptor Superfamily Member 13C wt Allele | Tumor Necrosis Factor Receptor Superfamily, Member 13C Gene | Tumor Necrosis Factor Receptor Superfamily, Member 13C wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0061751","Glycyrrhizin","C1117","A saponin-like compound that provides the main sweet flavor for Glycyrrhiza glabra (licorice), with potential immunomodulating, anti-inflammatory, hepato- and neuro-protective, and antineoplastic activities. Glycyrrhizin modulates certain enzymes involved in inflammation and oxidative stress, and downregulates certain pro-inflammatory mediators, thereby protecting against inflammation- and reactive oxygen species (ROS)-induced damage. Glycerrhizin may also suppress the growth of susceptible tumor cells.","Glycyrrhizin | (3beta,20beta)-20-Carboxy-11-oxo-30-norolean-12-en-3-yl-2-O-beta-D-glucopyranuronosyl-alpha-D-glucopyranosiduronic Acid | Dipotassium Glycyrrhizate | GLYCYRRHIZIN | Glycyrrhizic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011313","Dengue Virus 1","C112266","The serotype labeled 1 of the viral species Dengue virus, which is a single-stranded, positive-sense RNA virus of the Flaviviridae family and Flavivirus genus, and causes dengue fever.","Dengue Virus 1 | DEN-1 | DENGUE VIRUS 1 | DENV-1 | Dengue Virus Type 1",,,,,,,,,,,,,,,"4244879","Dengue virus, type 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3830241","FAMS - Feel Trapped by My Condition","C112568","Functional Assessment of Multiple Sclerosis (FAMS) Emotional Well-Being: I feel trapped by my condition.","FAMS - Feel Trapped by My Condition | FAMS01-I Feel Trapped by My Condition | FAMS0118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830251","FAMS - Depressed About My Condition","C112569","Functional Assessment of Multiple Sclerosis (FAMS) Emotional Well-Being: I am depressed about my condition.","FAMS - Depressed About My Condition | FAMS01-I Am Depressed About My Condition | FAMS0119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454226","Oncolytic Herpes Simplex Virus-1-encoding GM-CSF","C111893","An ICP34.5-, ICP47-deleted, oncolytic herpes simplex type-1 virus (HSV-1) isolated from the mouth of an HSV-1-infected patient of Chinese Han ethnicity, and encoding the immunostimulating factor cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with potential immunostimulating and antineoplastic activities. Upon administration, the recombinant human GM-CSF HSV-1 selectively infects and replicates in tumor cells, thereby inducing tumor cell lysis. In addition, GM-CSF attracts dendritic cells (DCs) and may stimulate a cytotoxic T cell response against tumor cells, which results in immune-mediated tumor cell death. Deletion of the gene encoding for ICP34.5 provides tumor selectivity and prevents replication in healthy cells. As ICP47 blocks antigen presentation in HSV-infected cells, deletion of this gene may induce a more potent antitumor immune response in the tumor cells. Additionally, deletion of ICP47 causes increased expression of the HSV US11 gene and allows US11 to be expressed as an immediate early and not a late gene. This further enhances the degree of viral replication and oncolysis of tumor cells. Interruption of the ICP6 gene, which encodes the large subunit of the viral ribonucleotide reductase, in the viral vector also enhances selective replication in tumor cells.","Oncolytic Herpes Simplex Virus-1-encoding GM-CSF | HSV-encoding GM-CSF | OrienX010 | Recombinant hGM-CSF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454227","Donor Regulatory T-lymphocytes","C111894","Donor-derived regulatory T-cells (Tregs), with potential immunomodulating activity.  Tregs are a subset of CD4+ T cells that express high levels of CD25 (interleukin 2 receptor) and the transcription factor Foxp3. The donor CD4+CD25+ Tregs modulate immune responses and may induce tolerance to allogeneic organ transplants, such as hematopoietic stem cell transplants (HSCTs), thereby preventing graft-versus-host disease (GVHD).","Donor Regulatory T-lymphocytes | Donor CD4+CD25+FoxP3+ T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454228","Pyrotinib","C111895","An orally bioavailable, dual kinase inhibitor of the epidermal growth factor receptor (EGFR or HER-1) and the human epidermal growth factor receptor 2 (ErbB2 or HER-2), with potential antineoplastic activity. Upon oral administration, pyrotinib binds to and inhibits both EGFR and HER2, which may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumor cells. EGFR and HER2 are receptor tyrosine kinases that are upregulated in various tumor cell types and play major roles in tumor cell proliferation and tumor vascularization.","Pyrotinib | PYROTINIB | SHR 1258 | SHR-1258 | SHR1258",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3252721","Olive Oil/Soya Oil/Egg Lecithin-based Emulsion","C111896","An injectable, isotonic, nutritional lipid emulsion composed of approximately 80% refined olive oil and 20% refined soybean oil, used for parenteral nutrition. The olive oil/soya oil/egg lecithin emulsion provides about 15% of saturated fatty acids (SFA), 65% of mono-unsaturated fatty acids (MUFA) and 20% of essential poly-unsaturated fatty acids (EPUFA). Upon parenteral administration, the emulsion supplies calories, for energy, and essential fatty acids that can be incorporated into cell membranes. The fatty acids may decrease the production of certain pro-inflammatory cytokines, including interleukin 1 (IL-1), IL-6 and tumor necrosis factor (TNF). In addition to olive oil and soya oil, this lipid emulsion contains egg lecithin and provides phosphorus and choline, which are needed to maintain cell membrane integrity.","Olive Oil/Soya Oil/Egg Lecithin-based Emulsion | ClinOleic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827131","Yangzheng Xiaoji Extract","C111897","A traditional Chinese medicine (TCM)-based formulation containing the Yangzheng Xiaoji (YZXJ) extract, consisting of various components, with potential antineoplastic and anti-angiogenic activities. Some of the main components in Yangzheng Xiaoji are Radix Astragali, Fructus Ligustri Lucidi, Radix Ginseng, Ganoderma, Rhizoma Curcumac, Fried Rhizoma Atractylodis, Macrocephalae and Herba Hedyotidis. Although the exact mechanism(s) through which Yangzheng Xiaoji exerts its effects have yet to be fully elucidated, this agent, upon administration, inhibits the activation of various signaling protein kinases, such as focal adhesion kinase (FAK) and paxillin. This prevents signal transduction pathways that are upregulated in cancer, prevents the adhesion and migration of tumor cells and inhibits tumor cell growth.","Yangzheng Xiaoji Extract | DME25 | YZXJ Extract",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811697","SLC16A1 wt Allele","C107461","Human SLC16A1 wild-type allele is located in the vicinity of 1p12 and is approximately 45 kb in length. This allele, which encodes monocarboxylate transporter 1 protein, plays a role in the transport of monocarboxylates across the plasma membrane. Mutations in this gene are associated with erythrocyte lactate transporter defect and hyperinsulinemic hypoglycemia, familial, 7.","SLC16A1 wt Allele | HHF7 | MCT | MCT 1 | MCT1 | Solute Carrier Family 16 (Monocarboxylate Transporter), Member 1 Gene | Solute Carrier Family 16 (Monocarboxylate Transporter), Member 1 wt Allele | Solute Carrier Family 16 (Monocarboxylic Acid Transporters), Member 1 Gene | Solute Carrier Family 16 Member 1 wt Allele | Solute Carrier Family 16, Member 1 (Monocarboxylic Acid Transporter 1) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812715","Monocarboxylate Transporter 1, Human","C107462","Monocarboxylate transporter 1 (500 aa, ~54 kDa) is encoded by the human SLC16A1 gene. This protein is involved in monocarboxylate transport across the plasma membrane.","Monocarboxylate Transporter 1 | MCT 1 | MCT1 | SLC16A1 | Solute Carrier Family 16 (Monocarboxylic Acid Transporters), Member 1 | Solute Carrier Family 16 Member 1 | Solute Carrier Family 16, Member 1 (Monocarboxylic Acid Transporter 1)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812242","SLC16A4 wt Allele","C107464","Human SLC16A4 wild-type allele is located in the vicinity of 1p13.3 and is approximately 28 kb in length. This allele, which encodes monocarboxylate transporter 5 protein, is involved in monocarboxylate transport across the plasma membrane.","SLC16A4 wt Allele | MCT 4 | MCT 5 | MCT4 | MCT5 | Solute Carrier Family 16, Member 4 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0913710","SLC16A4 protein, human","C107465","Monocarboxylate transporter 5 (487 aa, ~54 kDa) is encoded by the human SLC16A4 gene. This protein plays a role in the transport of monocarboxylates across the plasma membrane.","Monocarboxylate Transporter 5 | Monocarboxylate Transporter 4 | SLC16A4 | Solute Carrier Family 16 (Monocarboxylic Acid Transporters), Member 4 | Solute Carrier Family 16 Member 4 | Solute Carrier Family 16, Member 4 (Monocarboxylic Acid Transporter 5)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810555","SLC46A1 wt Allele","C107467","Human SLC46A1 wild-type allele is located in the vicinity of 17q11.2 and is approximately 13 kb in length. This allele, which encodes proton-coupled folate transporter protein, is involved in transport of both folate and antifolate across the plasma membrane, and heme transport in duodenal enterocytes. Mutations in this gene are associated with hereditary folate malabsorption.","SLC46A1 wt Allele | G21 | HCP1 | HsPCFT | MGC9564 | PCFT | PCFT/HCP1 | Solute Carrier Family 46 (Folate Transporter), Member 1 wt Allele | hPCFT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813543","CEACAM6 wt Allele","C107470","Human CEACAM6 wild-type allele is located in the vicinity of 19q13.2 and is approximately 17 kb in length. This allele, which encodes carcinoembryonic antigen-related cell adhesion molecule 6 protein, plays a probable role in both cell adhesion and cell-cell signaling.","CEACAM6 wt Allele | CD66c | CEAL | Carcinoembryonic Antigen Related Cell Adhesion Molecule 6 wt Allele | Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6 (Non-Specific Cross Reacting Antigen) Gene | NCA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828022","Signal Width","C112418","A measurement of the range of values seen in the time interval between the beginning and end of the pulse wave. This is usually calculated at the point where the amplitude is at 50% of the wave peak.","Signal Width | SIGW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828009","SIX2 wt Allele","C111803","Human SIX2 wild-type allele is located in the vicinity of 2p21 and is approximately 4 kb in length. This allele, which encodes Homeobox protein SIX2, plays a role in the regulation of transcription and may be involved in limb or eye development.","SIX2 wt Allele | SIX Homeobox 2 wt Allele | Sine Oculis Homeobox (Drosophila) Homolog 2 Gene | Sine Oculis Homeobox Homolog 2 (Drosophila) Gene | Sine Oculis Homeobox, Drosophila, Homolog of, 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829674","Homeobox Protein SIX2","C111804","Homeobox protein SIX2 (291 aa, ~32 kDa) is encoded by the human SIX2 gene. This protein is involved in the regulation of transcription.","Homeobox Protein SIX2 | Sine Oculis Homeobox (Drosophila) Homolog 2 | Sine Oculis Homeobox Homolog 2 | Sine Oculis Homeobox Homolog 2 (Drosophila)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3715037","SIX4 wt Allele","C111807","Human SIX4 wild-type allele is located in the vicinity of 14q23.1 and is approximately 15 kb in length. This allele, which encodes homeobox protein SIX4, is involved in the regulation of transcription and may play a role in the differentiation and maturation of neuronal cells.","SIX4 wt Allele | AREC3 | SIX Homeobox 4 wt Allele | Sine Oculis Homeobox, Drosophila, Homolog of, 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454289","Oraxol","C112000","A combination formulation composed of a capsule containing the taxane compound paclitaxel and a tablet containing the multidrug resistance (MDR) efflux pump P-glycoprotein (P-gp) inhibitor HM30181A, with potential antineoplastic activity. Upon oral administration of oraxol, the HM30181A moiety binds to and inhibits P-gp, which prevents P-gp-mediated efflux of paclitaxel, therefore enhancing its oral bioavailability. In turn, paclitaxel binds to and stabilizes microtubules, preventing their depolymerization, which results in the inhibition of cellular motility, mitosis, and replication. Altogether, this may result in greater intracellular concentration of paclitaxel, and enhanced cytotoxicity against tumor cells, when compared to the administration of paclitaxel alone.  P-gp, encoded by the MDR-1 gene, is a member of the ATP-binding cassette (ABC) superfamily of transmembrane transporters; it prevents the intestinal uptake and intracellular accumulation of various cytotoxic agents.","Oraxol | Paclitaxel-HM30181 Methanesulfonate Monohydrate | Paclitaxel/HM30181A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827076","anti-LIV-1 monoclonal antibody-MMAE conjugate SGN-LIV1A","C112001","An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the anti-solute carrier family 39 zinc transporter member 6 (SLC39A6; LIV-1; ZIP6) protein that is conjugated, via a protease-cleavable linker, to the cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration and internalization by LIV-1-positive tumor cells, ladiratuzumab vedotin undergoes enzymatic cleavage to release MMAE into the cytosol. In turn, MMAE binds to and inhibits tubulin polymerization, which may result in G2/M phase cell cycle arrest and apoptosis in LIV-1-expressing tumor cells. LIV-1, a member of the zinc transporter family, is expressed in several types of solid tumors and plays a key role in tumor cell progression and metastasis. The linkage system in ladiratuzumab vedotin is highly stable in plasma, resulting in cytotoxic specificity against LIV-1-positive cells.","Ladiratuzumab Vedotin | LADIRATUZUMAB VEDOTIN | SGN-LIV1A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0318759","Dengue Virus 2","C112267","The serotype labeled 2 of the viral species Dengue virus, which is a single-stranded, positive-sense RNA virus of the Flaviviridae family and Flavivirus genus, and causes dengue fever.","Dengue Virus 2 | DEN-2 | DENGUE VIRUS 2 | DENV-2 | Dengue Virus Type 2",,,,,,,,,,,,,,,"4187627","Dengue virus, type 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0318760","Dengue Virus 3","C112268","The serotype labeled 3 of the viral species Dengue virus, which is a single-stranded, positive-sense RNA virus of the Flaviviridae family and Flavivirus genus, and causes dengue fever.","Dengue Virus 3 | DEN-3 | DENGUE VIRUS 3 | DENV-3 | Dengue Virus Type 3",,,,,,,,,,,,,,,"4223974","Dengue virus, type 3",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0318761","Dengue Virus 4","C112269","The serotype labeled 4 of the viral species Dengue virus, which is a single-stranded, positive-sense RNA virus of the Flaviviridae family and Flavivirus genus, and causes dengue fever.","Dengue Virus 4 | DEN-4 | DENGUE VIRUS 4 | DENV-4 | Dengue Virus Type 4",,,,,,,,,,,,,,,"4273619","Dengue virus, type 4",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0949892","Ebola Virus","C112271","A genus of filamentous, enveloped viruses with glycoprotein surface spikes, in the family Filoviridae. The genome is composed of a linear single-strand of negative sense RNA. The primary product of gene transcription of the fourth gene is a small glycoprotein (sGP), while RNA editing allows expression of full length glycoprotein. The Ebolavirus natural reservoir is considered to be fruit bats of the Pteropodidae family and cause severe hemorrhagic fevers in humans.","Ebola Virus | EBOLA VIRUS | EBOV",,,,,,,,,,,,,,,"4314470","Ebolavirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013534","Echovirus","C112272","A species of non-enveloped, spherical and icosahedral viruses in the Picornaviridae family and Enterovirus genus. The genome is composed of single-stranded, positive-sense RNA. Echoviruses are found in humans and cause aseptic meningitis, encephalitis, paralysis and myocarditis via direct fecal-oral contamination, respiration and oral secretions, or indirect routes.","Echovirus | ECHOVIRUS",,,,,,,,,,,,,,,"4193958","Human echovirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0747742","Experimental Organism Benign Polyp","C112275","A benign polypoid neoplasm of an epithelial lining projecting into a lumen or cavity. (CDISC)","Experimental Organism Benign Polyp | POLYP, BENIGN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830294","Experimental Organism Benign Seminoma","C112276","A benign germ cell neoplasm of the testis. (CDISC)","Experimental Organism Benign Seminoma | SEMINOMA, BENIGN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1529723","Atrial Natriuretic Peptide Receptor 1, Human","C112515","Atrial natriuretic peptide receptor 1 (1061 aa, ~119 kDa) is encoded by the human NPR1 gene. This protein plays a role in both guanylate cyclase activity and natriuretic peptide binding.","Atrial Natriuretic Peptide Receptor 1 | ANP-A | ANPR-A | Atrial Natriuretic Peptide Receptor Type A | Atrial Natriuretic Peptide Receptor, Type A | Atrionatriuretic Peptide Receptor A | Atrionatriuretic Peptide Receptor, Type A | EC 4.6.1.2 | GC-A | Guanylate Cyclase 2A | Guanylate Cyclase A | NPR-A | Natriuretic Peptide A Type Receptor | Natriuretic Peptide Receptor A | Natriuretic Peptide Receptor A/Guanylate Cyclase A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454230","pan-PI3K/mTOR inhibitor PQR309","C111898","An orally bioavailable pan inhibitor of phosphoinositide-3-kinases (PI3K) and inhibitor of the mammalian target of rapamycin (mTOR), with potential antineoplastic activity. Bimiralisib inhibits the PI3K kinase isoforms alpha, beta, gamma and delta and, to a lesser extent, mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to both chemotherapy and radiotherapy. As mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K, this agent may potentially be more potent than an agent that inhibits either PI3K kinase or mTOR kinase. By inhibiting mTOR to a lesser extent than PI3K, PQR309 does not interfere with the mTOR-mediated negative feedback loop on PI3K signaling. Blocking the negative feedback loop would potentially increase PI3K signaling and decrease therapeutic efficacy.","Bimiralisib | 2-Pyridinamine, 5-(4,6-Di-4-morpholinyl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)- | BIMIRALISIB | PQR-309 | PQR309",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816180","Lysophosphatidic Acid Receptor 3, human","C112086","Lysophosphatidic acid receptor 3 (353 aa, ~40 kDa) is encoded by the human LPAR3 gene. This protein is involved in the regulation of calcium mobilization.","Lysophosphatidic Acid Receptor 3 | Calcium-Mobilizing Lysophosphatidic Acid Receptor LP-A3 | Endothelial Cell Differentiation Gene 7 Protein | Endothelial Differentiation, Lysophosphatidic Acid G-Protein-Coupled Receptor, 7 | LPA Receptor 3 | LPA Receptor EDG7 | Lysophosphatidic Acid Receptor Edg-7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829534","Intent to Compound 506E Drug","C112087","A compounder intends to produce a drug classified as 506E.","Intent to Compound 506E Drug | Intent to compound 506E (drug shortage) drugs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812159","L1","C112089","Human CYRIB wild-type allele is located in the vicinity of 8q24.21 and is approximately 178 kb in length. This allele, which encodes CYFIP-related Rac1 interactor B protein, is involved in the modulation of RAC1-dependent signaling and cytoskeletal remodeling.","CYRIB wt Allele | BM-009 | CYFIP Related Rac1 Interactor B wt Allele | CYRI | CYRI-B | FAM49B | FAM49B wt Allele | Family with Sequence Similarity 49 Member B Gene | Family with Sequence Similarity 49, Member B Gene | L1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1374516","Protein FAM49B","C112090","CYFIP-related Rac1 interactor B (324 aa, ~37 kDa) is encoded by the human CYRIB gene. This protein plays a role in the downregulation of RAC1-dependent signaling and cytoskeletal remodeling.","CYFIP-Related Rac1 Interactor B | CYFIP Related Rac1 Interactor B | CYRIB | L1 | Protein FAM49B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828810","No Intent to Compound 506E Drug","C112091","A compounder does not intend to produce a drug classified as 506E.","No Intent to Compound 506E Drug | No intent to compound 506E (drug shortage) drugs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831038","Compounding from Bulk Ingredient","C112092","A compounder produces a drug with bulk ingredients.","Compounding from Bulk Ingredient | Compounding from bulk ingredient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828776","Not Compounding from Bulk Ingredient","C112093","A compounder produces a drug without bulk ingredients.","Not Compounding from Bulk Ingredient | Not compounding from bulk ingredient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831037","Compounding Sterile Product","C112094","A compounder produces a sterile product.","Compounding Sterile Product | Compounding sterile products",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828775","Not Compounding Sterile Product","C112095","A compounder does not produce a sterile product.","Not Compounding Sterile Product | Not compounding sterile products",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813589","UTP23 wt Allele","C112097","Human UTP23 wild-type allele is located in the vicinity of 8q24.11 and is approximately 83 kb in length. This allele, which encodes rRNA-processing protein UTP23 homolog, plays a role in rRNA-processing and ribosome biogenesis.","UTP23 wt Allele | C8orf53 | MGC14595 | UTP23, Small Subunit (SSU) Processome Component, Homolog (Yeast) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827893","Surgical Mesh Open Area","C112421","A quantitative or qualitative measurement of the physical dimensions of the open spaces in a loosely woven sheet of inorganic or biological materials, which is used to physically support organs or tissue during a surgical procedure.","Surgical Mesh Open Area | SRGMSHOA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0702091","Tick-Borne Encephalitis Virus","C112422","A species of enveloped, spherical and icosahedral viruses in the Flaviviridae family and Flavivirus genus. The genome is composed of non-segmented, single-stranded, positive-sense RNA. Tick-borne encephalitis viruses are found in ticks of the Ixodes species and humans and cause tick-borne encephalitis in humans. Tick-borne encephalitis viruses are transmitted via the bite of infected ticks, primarily Ixodes ricinus or Ixodes persulcatus.","Tick-Borne Encephalitis Virus | FSME virus | TBEV | TICK-BORNE ENCEPHALITIS VIRUS",,,,,,,,,,,,,,,"4138406","Tick-borne encephalitis virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1299725","Tympanic Bulla","C112425","The bony cavities located on the posterior ventral portion of the skull, which house the sensory receptors of the middle and inner ear.","Tympanic Bulla | TYMPANIC BULLA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206559","Varicellovirus","C112426","A genus of enveloped, spherical or pleomorphic viruses with a capsid with T=16 icosahedral symmetry and surrounded by amorphous tegument, in the family Herpesviridae. The genome is composed of monopartite, linear double-stranded DNA. Varicelloviruses are found in mammals and cause chickenpox and shingles in humans.","Varicellovirus | VARICELLOVIRUS | Varicellavirus",,,,,,,,,,,,,,,"4214140","Varicellovirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829293","Levator Ani/Bulbospongiosus","C112430","A laboratory specimen consisting of the bulbocavernosus and the levator ani.","Levator Ani/Bulbospongiosus | MUSCLE, LEVATOR ANI/BULBOSPONGIOSUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828709","Oncogenicity","C112431","A measurement of the cell immortalization potential of an agent.","Oncogenicity | ONCOGENICITY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827125","Cebranopadol","C112002","An orally available benzenoid that acts as an opioid peptide receptor agonist for the nociceptin/orphanin FQ peptide receptor (opioid receptor like -1; OPRL1; ORL-1; NOP; kappa-type 3 opioid receptor) and the classical opioid receptors, mu, delta and kappa, with potential anti-nociceptive activity. Upon oral administration, cebranopadol binds to NOP and the mu, delta and kappa opioid receptors, which enhances NOP- and opioid receptor-mediated signaling, interferes with the sensation of pain and results in an analgesic effect. NOP, a member of the opioid receptor family, and its endogenous ligand nociceptin play key roles in the regulation of various brain activities including pain, and some inflammatory and immune responses.","Cebranopadol | CEBRANOPADOL | GRT 6005 | GRT-6005 | GRT6005 | Spiro[cyclohexane-1,1'(3'H)-pyrano[3,4-b]indol]-4-amine, 6'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenyl-, (1alpha,4beta)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454292","Neoantigen-based Melanoma-Poly-ICLC Vaccine","C112003","A peptide-based melanoma cancer vaccine consisting of neoantigens and peptides derived from patient-specific melanoma immunogenic epitopes, combined with the immunostimulant poly-ICLC with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-based melanoma vaccine stimulates the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. The adjuvant poly-ICLC, composed of double-stranded RNA molecules of polyinosinic-polycytidylic acid stabilized with poly L-lysine in carboxymethylcellulose, is a ligand for toll-like receptor-3 (TLR3) and induces the release of cytokines which may help to boost the immune response against the selected neoantigens.","Neoantigen-based Melanoma-Poly-ICLC Vaccine | NeoVax Melanoma Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454293","p70S6K/Akt inhibitor MSC2363318A","C112004","An orally available inhibitor of the serine/threonine protein kinases ribosomal protein S6 Kinase (p70S6K) and Akt (protein kinase B), with potential antineoplastic activity. Upon administration, rupitasertib binds to and inhibits the activity of p70S6K and Akt. This prevents the activation of the PI3K/Akt/p70S6K signaling pathway and inhibits tumor cell proliferation in cancer cells that have an overactivated PI3K/Akt/p70S6K signaling pathway. Constitutive activation and dysregulated signaling of the PI3K/Akt/p70S6K pathway are frequently associated with tumorigenesis of many tumor types; targeting multiple kinases in this pathway is more efficacious than targeting a single kinase.","Rupitasertib | M-2698 | MSC-2363318A | MSC2363318A | RUPITASERTIB | p70S6K/Akt Inhibitor M-2698 | p70S6K/Akt Inhibitor M-2698 | p70S6K/Akt Inhibitor MSC2363318A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454406","Autologous Tumor Cell Proteoliposome Chronic Lymphocytic Leukemia Vaccine","C112206","An autologous chronic lymphocytic leukemia cancer vaccine consisting of patient-specific membrane proteins directly extracted from patient autologous tumor cells and incorporated into liposomes along with Interleukin 2 (IL-2) to produce membrane-patched proteoliposomes, with potential immunostimulating and antineoplastic activities. After subcutaneous injection of the autologous tumor cell proteoliposomes chronic lymphocytic leukemia vaccine, liposomes deliver the encapsulated tumor antigens into the cytosol of antigen presenting cells (APCs). Subsequently, the APCs process the antigens and present antigen-derived peptides to the immune system. This may enhance recognition of tumors by the immune system, and activate both cytotoxic CD8+ T cells and CD4+ helper T cells against tumor cells. IL-2 is incorporated into the vaccine to leverage its ability to expand activated T cells.","Autologous Tumor Cell Proteoliposome Chronic Lymphocytic Leukemia Vaccine | Oncoquest-CLL Vaccine | Oncoquest-L Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454407","Bivalent HPV16/18 Therapeutic Cervical Cancer Vaccine","C112207","A bivalent human papillomavirus (HPV) therapeutic vaccine containing recombinant inactivated adenylate cyclase (CyaA) from Bordetella pertussis carrying a sequence encoding the E7 antigen of both HPV16 and 18, with potential immunostimulatory and antiviral properties. Upon administration of bivalent HPV16/18 therapeutic cervical cancer vaccine, the expressed proteins may activate cell-mediated immunity and induce both cytotoxic CD8+ T cells and CD4+ helper T cells against the target antigens HPV16-E7 and HPV18-E7, which leads to HPV viral clearance. Adenylate cyclase is a virulence factor of Bordetella pertussis. Its ability to bind to CD11b-expressing dendritic cells and deliver antigens directly to the cytosol allows the activation and induction of T-cell immunity. CyaA may also induce a B cell response.","Bivalent HPV16/18 Therapeutic Cervical Cancer Vaccine | ProCervix",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810813","Anticonvulsant Hypersensitivity Syndrome","C112209","A form of drug hypersensitivity syndrome caused by anti-convulsants.","Anticonvulsant Hypersensitivity Syndrome | Anti-Convulsant Hypersensitivity Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811318","ZMYND10 wt Allele","C111851","Human ZMYND10 wild-type allele is located in the vicinity of 3p21.3 and is approximately 6 kb in length. This allele, which encodes zinc finger MYND domain-containing protein 10, is involved in motile ciliary function. Mutations in this gene are associated with primary ciliary dyskinesia-22.","ZMYND10 wt Allele | BLU | CILD22 | FLU | LUCA12.4 | Zinc Finger, MYND-Type Containing 10 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815198","Zinc Finger MYND Domain-Containing Protein 10","C111852","Zinc finger MYND domain-containing protein 10 (440 aa, ~50 kDa) is encoded by the human ZMYND10 gene. This protein plays a role in ciliary function.","Zinc Finger MYND Domain-Containing Protein 10 | Protein Blu | ZMYND10 | Zinc Finger, MYND Domain Containing 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814825","Sudden Unexplained Infant Death","C111853","Unexpected death of an infant less than one year of age, whose cause of death is not immediately obvious prior to investigation.","Sudden Unexplained Infant Death | SUID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827273","Sudden Unexplained Death in Childhood","C111854","Unexpected death of a child over one year of age, which remains unexplained when all known and possible causes of death have been ruled out.","Sudden Unexplained Death in Childhood | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828292","rRNA-Processing Protein UTP23 Homolog","C112098","rRNA-processing protein UTP23 homolog (249 aa, ~28 kDa) is encoded by the human UTP23 gene. This protein is involved in rRNA-processing and ribosome biogenesis.","rRNA-Processing Protein UTP23 Homolog | C8orf53 | Chromosome 8 Open Reading Frame 53",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811670","CANX wt Allele","C112100","Human CANX wild-type allele is located in the vicinity of 5q35 and is approximately 53 kb in length. This allele, which encodes calnexin protein, is involved in both antigen presentation and protein folding.","CANX wt Allele | CNX | Calnexin wt Allele | IP90 | P90",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0392993","gp100 Antigen/MART-1 Antigen","C11233","No value exists.","gp100 Antigen/MART-1 Antigen | gp100/MART-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828132","SGRQ Past 3 Months Version - Coughing Disturbs My Sleep","C112649","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are more questions about your cough and shortness of breath these days: My coughing or breathing disturbs my sleep.","SGRQ Past 3 Months Version - Coughing Disturbs My Sleep | SGRQ01-Coughing Disturbs My Sleep | SGRQ0123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828117","SGRQ Past 3 Months Version - I Get Exhausted Easily","C112650","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are more questions about your cough and shortness of breath these days: I get exhausted easily.","SGRQ Past 3 Months Version - I Get Exhausted Easily | SGRQ01-I Get Exhausted Easily | SGRQ0124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828111","SGRQ Past 3 Months Version - My Cough is Embarrassing in Public","C112651","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about other effects that your respiratory problems may have on you these days: My cough or breathing is embarrassing in public.","SGRQ Past 3 Months Version - My Cough is Embarrassing in Public | SGRQ01-Cough Is Embarrassing in Public | SGRQ0125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828107","SGRQ Past 3 Months Version - Respiratory Problems a Nuisance to Family","C112652","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about other effects that your respiratory problems may have on you these days: My respiratory problems are a nuisance to my family, friends or neighbors.","SGRQ Past 3 Months Version - Respiratory Problems a Nuisance to Family | SGRQ01-Respiratory Problems a Nuisance | SGRQ0126",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828124","SGRQ Past 3 Months Version - Get Afraid When Cannot Catch My Breath","C112653","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about other effects that your respiratory problems may have on you these days: I get afraid or panic when I cannot catch my breath.","SGRQ Past 3 Months Version - Get Afraid When Cannot Catch My Breath | SGRQ01-Afraid When Cannot Catch Breath | SGRQ0127",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828110","SGRQ Past 3 Months Version - Not Expect Respiratory Problems Get Better","C112655","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about other effects that your respiratory problems may have on you these days: I do not expect my respiratory problems to get any better.","SGRQ Past 3 Months Version - Not Expect Respiratory Problems Get Better | SGRQ01-Not Expect Probs to Get Better | SGRQ0129",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828142","SGRQ Past 3 Months Version - Become Frail or Invalid Because of My Respiratory Problems","C112656","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about other effects that your respiratory problems may have on you these days: I have become frail or an invalid because of my respiratory problems.","SGRQ Past 3 Months Version - Become Frail or Invalid Because of My Respiratory Problems | SGRQ01-I Have Become Frail | SGRQ0130",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828125","SGRQ Past 3 Months Version - Exercise Is Not Safe for Me","C112657","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about other effects that your respiratory problems may have on you these days: Exercise is not safe for me.","SGRQ Past 3 Months Version - Exercise Is Not Safe for Me | SGRQ01-Exercise Is Not Safe for Me | SGRQ0131",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828126","SGRQ Past 3 Months Version - Everything Too Much Effort","C112658","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about other effects that your respiratory problems may have on you these days: Everything seems too much of an effort.","SGRQ Past 3 Months Version - Everything Too Much Effort | SGRQ01-Everything Too Much Effort | SGRQ0132",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828101","SGRQ Past 3 Months Version - Treatment Does Not Help Me Much","C112659","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about your respiratory treatment: My treatment does not help me very much.","SGRQ Past 3 Months Version - Treatment Does Not Help Me Much | SGRQ01-Treatment Does Not Help Me Much | SGRQ0133",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0262988","Cutaneous Vasculitis","C112210","Inflammation of the blood vessel wall characterized by palpable purpura.","Cutaneous Vasculitis | ",,,,,,,,,,,,,,,"4182711","Vasculitis of the skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162504","Neutrophilic Eccrine Hidradenitis","C112211","Painful red or pink edematous nodules most commonly found on the palmar and/or plantar regions.","Neutrophilic Eccrine Hidradenitis | ",,,,,,,,,,,,,,,"4081091","Neutrophilic eccrine hidradenitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085661","Onycholysis","C112212","A nail condition characterized by spontaneous separation of a fingernail or toenail from its nail bed.","Onycholysis | ",,,,,,,,,,,,,,,"4328079","Onycholysis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040261","Onychomycosis","C112214","Fungal infection of a fingernail or toenail.","Onychomycosis | Tinea Unguium",,,,,,,,,,,,,,,"4215978","Onychomycosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3854365","Paronychial Inflammation","C112215","Swelling and redness of the nail folds.","Paronychial Inflammation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828761","NPI - Appetite/Eating Disorders FxS Score","C112480","Neuropsychiatric Inventory (NPI) Appetite and Eating Disorders: (frequency score x severity score).","NPI - Appetite/Eating Disorders FxS Score | NPI1-Appetite/Eating Disorders FxS Score | NPI1LFS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828753","NPI - NPI Total Score","C112481","Neuropsychiatric Inventory (NPI) Total of (Frequency Sub-total) x (Severity Sub-total).","NPI - NPI Total Score | NPI1-NPI Total Score | NPI1TOT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828754","NPI - NPI Total Distress Score","C112482","Neuropsychiatric Inventory (NPI) Sub-total of distress score.","NPI - NPI Total Distress Score | NPI1-NPI Total Distress Score | NPI1DIST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537720","MIR22 Gene","C112483","This gene may be involved in the regulation of target gene transcription.","MIR22 Gene | MIR22 | MicroRNA 22 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811720","MIR22 wt Allele","C112484","Human MIR22 wild-type allele is located in the vicinity of 17p13.3 and is approximately 5 kb in length. This allele, which encodes MIR22 pre-miRNA, may play a role in the negative regulation of gene expression.","MIR22 wt Allele | MIRN22 | MicroRNA 22 wt Allele | hsa-mir-22 | miR-22 | miRNA22",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829008","MIR22 Pre-miRNA","C112485","MIR22 pre-miRNA (85 bases) is encoded by the human MIR22 gene. This ribonucleotide may be involved in the regulation of transcription.","MIR22 Pre-miRNA | Pre-MIR22 | Pre-MicroRNA 22 | Pre-miRNA 22 | Pre-miRNA MIR22 | Pre-miRNA22",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418219","P2RY2 Gene","C112486","This gene plays a role in nucleotide receptor signaling.","P2RY2 Gene | P2RY2 | Purinergic Receptor P2Y, G-Protein Coupled, 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0543693","Neonatal Neutropenia","C111855","A condition characterized by a decrease in the number of neutrophils in the blood below established reference ranges in a newborn.","Neonatal Neutropenia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0158992","Disseminated Intravascular Coagulation in Newborn","C111856","A clotting condition characterized as a disruption in the homeostatic balance of the coagulation and fibrinolytic systems presenting as a pathological activation of coagulation mechanisms leading to the formation of small clots inside the blood vessels throughout the body of the newborn.","Disseminated Intravascular Coagulation in Newborn | Neonatal Disseminated Intravascular Coagulation",,,,,,,,,,,,,,,"432443","Disseminated intravascular coagulation in newborn",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019088","Hemorrhagic Disease of Newborn","C111857","A condition characterized as a coagulation disturbance in newborns due to vitamin K deficiency resulting in impaired production of coagulation factors II, VII, IX, and X, and proteins C and S by the liver.","Hemorrhagic Disease of Newborn | Vitamin K Deficiency Bleeding in Newborn",,,,,,,,,,,,,,,"435358","Hemorrhagic disease of the newborn due to vitamin K deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0405327","Direct Maternal Death","C111858","Death resulting from conditions or complications which are unique to pregnancy and occur during the antepartum, intrapartum, or postpartum period.","Direct Maternal Death | ",,,,,,,,,,,,,,,"4028784","Direct maternal death",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3697906","Indirect Maternal Death","C111859","Death resulting from previously existing disease or a disease developing during pregnancy which was not associated with gestation, but which was aggravated by the unique physiologic changes of pregnancy. Examples of indirect deaths include those associated with epilepsy, diabetes, cardiac disease and hormone-dependent malignancies.","Indirect Maternal Death | ",,,,,,,,,,,,,,,"44784548","Indirect maternal death",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024923","Maternal Mortality","C111860","The death of a woman while pregnant or within 42 days of the end of the pregnancy, irrespective of the duration or anatomic site of the pregnancy, due to any cause related to or aggravated by the pregnancy or its management, but not from accidental or incidental causes.","Maternal Mortality | Maternal Death",,,,,,,,,,,,,,,"4244279","Maternal death",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828506","Postpartum Obstetric Septic Embolism","C111861","Presence of bacterially-infected tissue in the maternal vascular system which originated from a distant site during the postpartum period.","Postpartum Obstetric Septic Embolism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1432368","Dual Specificity Protein Phosphatase 5, Human","C111864","Dual specificity protein phosphatase 5 (384 aa, ~42 kDa) is encoded by the human DUSP5 gene. This protein is involved in the dephosphorylation of MAP kinase family proteins.","Dual Specificity Protein Phosphatase 5 | DUSP5 | Dual Specificity Protein Phosphatase HVH3 | Dual Specificity Protein Phosphatase hVH3 | Dual-Specificity Protein Phosphatase 5 | EC 3.1.3.16 | EC 3.1.3.48 | VH1-Like Phosphatase 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828505","Postpartum Obstetric Thromboembolism","C111865","Presence of a blood clot in the maternal vascular system which originated from a distant site during the postpartum period.","Postpartum Obstetric Thromboembolism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206598","Molluscipoxvirus","C112356","A genus of enveloped, brick-shaped viruses in the family Poxviridae. The genome is composed of linear, double-stranded DNA and the virus is capable of infection either with or without its external membrane envelope. Molluscipoxviruses may be sexually transmitted and cause molluscum contagiosum in humans.","Molluscipoxvirus | MOLLUSCIPOXVIRUS | Molluscipox Virus",,,,,,,,,,,,,,,"4307115","Molluscipoxvirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3830226","FAMS - I Feel Useless","C112570","Functional Assessment of Multiple Sclerosis (FAMS) Emotional Well-Being: I feel useless.","FAMS - I Feel Useless | FAMS01-I Feel Useless | FAMS0120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830243","FAMS - Feel Overwhelmed by My Condition","C112571","Functional Assessment of Multiple Sclerosis (FAMS) Emotional Well-Being: I feel overwhelmed by my condition.","FAMS - Feel Overwhelmed by My Condition | FAMS01-Feel Overwhelmed by My Condition | FAMS0121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830215","FAMS - My Work is Fulfilling","C112572","Functional Assessment of Multiple Sclerosis (FAMS) General Contentment: My work (include work at home) is fulfilling.","FAMS - My Work is Fulfilling | FAMS01-My Work Is Fulfilling | FAMS0122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830224","FAMS - I Have Accepted My Illness","C112573","Functional Assessment of Multiple Sclerosis (FAMS) General Contentment: I have accepted my illness.","FAMS - I Have Accepted My Illness | FAMS01-I Have Accepted My Illness | FAMS0123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830250","FAMS - Enjoying Things I Usually Do for Fun","C112574","Functional Assessment of Multiple Sclerosis (FAMS) General Contentment: I am enjoying the things I usually do for fun.","FAMS - Enjoying Things I Usually Do for Fun | FAMS01-Enjoy Things I Usually Do for Fun | FAMS0124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830252","FAMS - Content With Quality of My Life Now","C112575","Functional Assessment of Multiple Sclerosis (FAMS) General Contentment: I am content with the quality of my life right now.","FAMS - Content With Quality of My Life Now | FAMS01-Content With Quality of My Life | FAMS0125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830231","FAMS - I Am Frustrated by My Condition","C112576","Functional Assessment of Multiple Sclerosis (FAMS) General Contentment: I am frustrated by my condition.","FAMS - I Am Frustrated by My Condition | FAMS01-I Am Frustrated by My Condition | FAMS0126",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830242","FAMS - Feel Sense of Purpose in My Life","C112577","Functional Assessment of Multiple Sclerosis (FAMS) General Contentment: I feel a sense of purpose in my life.","FAMS - Feel Sense of Purpose in My Life | FAMS01-Feel Sense of Purpose in My Life | FAMS0127",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830244","FAMS - Feel Motivated to Do Things","C112578","Functional Assessment of Multiple Sclerosis (FAMS) General Contentment: I feel motivated to do things.","FAMS - Feel Motivated to Do Things | FAMS01-I Feel Motivated to Do Things | FAMS0128",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830237","FAMS - Have a Lack of Energy","C112579","Functional Assessment of Multiple Sclerosis (FAMS) Thinking and Fatigue: I have a lack of energy.","FAMS - Have a Lack of Energy | FAMS01-I Have a Lack of Energy | FAMS0129",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828127","SGRQ Past 3 Months Version - Embarrassed Using Medication in Public","C112660","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about your respiratory treatment: I get embarrassed using my medication in public.","SGRQ Past 3 Months Version - Embarrassed Using Medication in Public | SGRQ01-Embarrassed Using Med in Public | SGRQ0134",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027822","Neurodermatitis","C111963","Skin findings arising from repeated rubbing, picking or scratching of a real or imagined irritation of the skin.","Neurodermatitis | Lichen Simplex Chronicus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827885","Sustained Engraftment","C111964","Sustained donor-derived neutrophil recovery with achievement of donor chimerism equal or greater than 90%.","Sustained Engraftment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085641","Pustular Eruption","C111967","A diffuse or generalized outbreak of numerous pustules.","Pustular Eruption | ",,,,,,,,,,,,,,,"4167338","Pustular rash",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL454452","Bulla","C111970","A large (greater than 5-10 mm) intraepidermal/subepidermal cavity filled with clear, serosanguineous or cloudy fluid.","Bulla | Bullae",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023653","Lichenification","C111974","Thickening and hardening of the skin associated with chronic inflammation or irritation.","Lichenification | ",,,,,,,,,,,,,,,"4063179","Lichenification",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3810652","MBTD1 wt Allele","C111975","Human MBTD1 wild-type allele is located in the vicinity of 17q21.33 and is approximately 83 kb in length. This allele, which encodes MBT domain-containing protein 1, may be involved in transcriptional regulation. A fusion of this gene and the CXorf67 gene may be associated with low-grade endometrial stromal sarcomas.","MBTD1 wt Allele | FLJ20055 | Mbt Domain Containing 1 wt Allele | SA49P01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2744260","MBT Domain-Containing Protein 1, Human","C111976","MBT domain-containing protein 1 (628 aa, ~71 kDa) is encoded by the human MBTD1 gene. This protein may play a role in the regulation of gene transcription.","MBT Domain-Containing Protein 1 | MBTD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2829198","EZHIP Gene","C111977","This gene is involved in the negative regulation of histone-lysine N-methyltransferase EZH2 activity.","EZHIP Gene | CXorf67 | CXorf67 Gene | EZH Inhibitory Protein Gene | EZHIP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830626","MGC47837","C111978","Human EZHIP wild-type allele is located in the vicinity of Xp11.22 and is approximately 2 kb in length. This allele, which encodes EZH inhibitory protein, plays a role in the modulation of histone H3-K27 methylation. A fusion of this gene and the MBTD1 gene may be associated with low-grade endometrial stromal sarcomas.","EZHIP wt Allele | CATACOMB | CXorf67 | CXorf67 wt Allele | Catalytic Antagonist of Polycomb Gene | Chromosome X Open Reading Frame 67 Gene | EZH Inhibitory Protein wt Allele | KIP75 | MGC47837",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813593","P2RY2 wt Allele","C112487","Human P2RY2 wild-type allele is located within 11q13.5-q14.1 and is approximately 18 kb in length. This allele, which encodes P2Y purinoceptor 2, is involved in both purine binding and signal transduction.","P2RY2 wt Allele | HP2U | P2RU1 | P2U | P2U1 | P2UR | P2Y2 | P2Y2R | Purinergic Receptor P2Y, G Protein-Coupled, 2 Gene | Purinergic Receptor P2Y, G-Protein Coupled, 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2745815","P2Y Purinoceptor 2, Human","C112488","P2Y purinoceptor 2 (377 aa, ~42 kDa) is encoded by the human P2RY2 gene. This protein plays a role in ligand-dependent activation of second messenger signaling pathways.","P2Y Purinoceptor 2 | ATP Receptor | P2U Nucleotide Receptor | P2U Purinoceptor 1 | P2U Receptor 1 | P2U1 | P2Y2 | Purinergic Receptor | Purinergic Receptor P2Y2 | Purinoceptor P2Y2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2829370","CCSER1 Gene","C112489","This gene may be involved in mitosis.","CCSER1 Gene | CCSER1 | Coiled-Coil Serine-Rich Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815265","CCSER1 wt Allele","C112490","Human CCSER1 wild-type allele is located 4q22.1 and is approximately 1475 kb in length. This allele, which encodes serine-rich coiled-coil domain-containing protein 1, may play a role in mitosis. Deletion mutation of the gene is associated with various neoplasms.","CCSER1 wt Allele | Coiled-Coil Serine-Rich Protein 1 wt Allele | FAM190A | Family With Sequence Similarity 190, Member A Gene | KIAA1680",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812177","Serine-Rich Coiled-Coil Domain-Containing Protein 1","C112491","Serine-rich coiled-coil domain-containing protein 1 (900 aa, ~100 kDa) is encoded by the human CCSER1 gene. This protein may be involved in mitosis.","Serine-Rich Coiled-Coil Domain-Containing Protein 1 | CCSER1 | Coiled-Coil Serine-Rich Protein 1 | Protein FAM190A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421313","UCP1 Gene","C112492","This gene plays a role in proton transport.","UCP1 Gene | UCP1 | Uncoupling Protein 1 (Mitochondrial, Proton Carrier) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810625","UCP1 wt Allele","C112493","Human UCP1 wild-type allele is located within 4q28-q31 and is approximately 9 kb in length. This allele, which encodes mitochondrial brown fat uncoupling protein 1, is involved in thermogenic proton transport. Polymorphism in the gene is associated with susceptibility to both obesity and type II diabetes mellitus.","UCP1 wt Allele | SLC25A7 | UCP | Uncoupling Protein 1 (Mitochondrial, Proton Carrier) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0107264","Mitochondrial Brown Fat Uncoupling Protein 1","C112494","Mitochondrial brown fat uncoupling protein 1 (307 aa, ~33 kDa) is encoded by the human UCP1 gene. This protein plays a role in thermogenesis.","Mitochondrial Brown Fat Uncoupling Protein 1 | Brown Adipose Tissue Uncoupling Protein | Solute Carrier Family 25 Member 7 | Thermogenin | UCP 1 | UCP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829673","Homeobox Protein SIX4","C111810","Homeobox protein SIX4 (781 aa, ~83 kDa) is encoded by the human SIX4 gene. This protein plays a role in both transcription regulation and eye development.","Homeobox Protein SIX4 | Sine Oculis Homeobox (Drosophila) Homolog 4 | Sine Oculis Homeobox Homolog 4 | Sine Oculis Homeobox Homolog 4 (Drosophila)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428880","DNAI7 Gene","C112053","This gene plays a role in cellular processes involving the axonemal dynein complex.","DNAI7 Gene | CASC1 | CASC1 Gene | CFAP94 | DNAI7 | Dynein Axonemal Intermediate Chain 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812755","FLJ10921","C112054","Human DNAI7 wild-type allele is located in the vicinity of 12p12.1 and is approximately 88 kb in length. This allele, which encodes dynein axonemal intermediate chain 7 protein, is involved in axonemal dynein complex activities.","DNAI7 wt Allele | CASC1 wt Allele | CFAP94 | Cancer Susceptibility 1 Gene | Cancer Susceptibility Candidate 1 Gene | Dynein Axonemal Intermediate Chain 7 wt Allele | FLJ10921 | LAS1 | Lung Adenoma Susceptibility Gene 1 | PPP1R54 | Protein Phosphatase 1, Regulatory Subunit 54 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813600","Cancer Susceptibility Candidate Protein 1","C112056","Dynein axonemal intermediate chain 7 (716 aa, ~83 kDa) is encoded by the human DNAI7 gene. This protein plays a role in microtubule processes that depend on axonemal dynein activity.","Dynein Axonemal Intermediate Chain 7 | Cancer Susceptibility Candidate Gene 1 Protein | Cancer Susceptibility Candidate Protein 1 | Cilia and Flagella Associated Protein 94 | DNAI7 | Dynein Intermediate Chain CFAP94, Axonemal | Lung Adenoma Susceptibility 1-Like Protein | Protein CASC1 | Protein Phosphatase 1 Regulatory Subunit 54 | Protein Phosphatase 1, Regulatory Subunit 54",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830227","FAMS - I Feel Tired","C112580","Functional Assessment of Multiple Sclerosis (FAMS) Thinking and Fatigue: I feel tired.","FAMS - I Feel Tired | FAMS01-I Feel Tired | FAMS0130",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830204","FAMS - Trouble Starting Things Because I Am Tired","C112581","Functional Assessment of Multiple Sclerosis (FAMS) Thinking and Fatigue: I have trouble starting things because I am tired.","FAMS - Trouble Starting Things Because I Am Tired | FAMS01-Trouble Starting Things | FAMS0131",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830208","FAMS - Trouble Finishing Things Because I Am Tired","C112582","Functional Assessment of Multiple Sclerosis (FAMS) Thinking and Fatigue: I have trouble finishing things because I am tired.","FAMS - Trouble Finishing Things Because I Am Tired | FAMS01-Trouble Finishing Things | FAMS0132",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830205","FAMS - Trouble Remembering Things","C112584","Functional Assessment of Multiple Sclerosis (FAMS) Thinking and Fatigue: I have trouble remembering things.","FAMS - Trouble Remembering Things | FAMS01-I Have Trouble Remembering Things | FAMS0134",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830216","FAMS - My Thinking is Slower Than Before","C112586","Functional Assessment of Multiple Sclerosis (FAMS) Thinking and Fatigue: My thinking is slower than before.","FAMS - My Thinking is Slower Than Before | FAMS01-My Thinking Is Slower Than Before | FAMS0136",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454231","Liposomal Eribulin Mesylate","C111899","A liposome-encapsulated formulation of the mesylate salt form of eribulin, a synthetic, macrocyclic ketone analogue of halichondrin B, a substance derived from the marine sponge genus Halichondria, with potential antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits both the polymerization of tubulin and the assembly of microtubules. This results in the inhibition of mitotic spindle assembly, the induction of cell cycle arrest at G2/M phase, as well as tumor cell apoptosis. Compared to the administration of eribulin alone, liposomal delivery of eribulin allows for a longer half-life, which allows increased drug concentration in target tissues while decreasing systemic toxicity.","Liposomal Eribulin Mesylate | E7389 Liposomal Formulation | E7389-LF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0061824","Gossypol Acetic Acid","C1118","The naturally occurring acetic acid form of gossypol, and an orally available polyphenolic aldehyde derived mostly from cottonseed with potential antineoplastic activity.  The biologic activities of gossypol acetic acid are similar to those of gossypol and include suppression of DNA replication, inhibition of tumor cell proliferation, and male contraceptive effects. (NCI04)","Gossypol Acetic Acid | GOSSYPOL ACETIC ACID | Gossypol Acetate | gossypol acetic acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454232","Autologous Melanoma Lysate/NY-ESO-1-pulsed Autologous Dendritic Cell Vaccine","C111900","A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with both a lysate from autologous melanoma cells containing tumor associated antigens (TAAs) and a synthetic peptide derived from the tumor associated antigen human cancer-testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon administration, autologous melanoma lysate/NY-ESO-1-pulsed autologous DC vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody-mediated immune responses against melanoma cells, which may result in melanoma cell lysis. NY-ESO-1 is expressed in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival.","Autologous Melanoma Lysate/NY-ESO-1-pulsed Autologous Dendritic Cell Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454233","BET inhibitor CPI-0610","C111901","The anhydrous form of pelabresib, a small molecule inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, pelabresib binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histone peptides. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of two bromodomains at the N-terminus, the BET proteins (BRD2, BRD3, BRD4 and BRDT) are transcriptional regulators that play an important role during development and cellular growth.","Pelabresib Anhydrous | BET Inhibitor CPI-0610 | CPI-0610 | CPI-0610 Anhydrous | CPI-232 | CPI-267232 | PELABRESIB | PELABRESIB ANHYDROUS | Pelabresib | Pelabresib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814393","Uncharacterized Protein CXorf67","C111979","EZH inhibitory protein (503 aa, ~52 kDa) is encoded by the human EZHIP gene. This protein is involved in the inhibition of histone H3-K27 methylation by histone-lysine N-methyltransferase EZH2.","EZH Inhibitory Protein | CXorf67 | Catalytic Antagonist of Polycomb | EZHIP | Uncharacterized Protein CXorf67",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812164","SIX5 wt Allele","C111813","Human SIX5 wild-type allele is located in the vicinity of 19q13.32 and is approximately 4 kb in length. This allele, which encodes homeobox protein SIX5, plays a role in both the regulation of transcription and the regulation of organogenesis. Mutations in this gene are associated with branchiootorenal syndrome type 2.","SIX5 wt Allele | BOR2 | DMAHP | SIX Homeobox 5 wt Allele | Sine Oculis Homeobox, Drosophila, Homolog of, 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0392703","Shakes","C111815","Unsteadiness or trembling movements of the whole body or a body part.","Shakes | Shakiness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816455","Homeobox Protein SIX5, Human","C111816","Homeobox protein SIX5 (739 aa, ~75 kDa) is encoded by the human SIX5 gene. This protein is involved in both transcription regulation and organogenesis regulation.","Homeobox Protein SIX5 | DM Locus-Associated Homeodomain Protein | Dystrophia Myotonica-Associated Homeodomain Protein | Sine Oculis Homeobox (Drosophila) Homolog 5 | Sine Oculis Homeobox Homolog 5 | Sine Oculis Homeobox Homolog 5 (Drosophila)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812165","CTCFL wt Allele","C111819","Human CTCFL wild-type allele is located in the vicinity of 20q13.31 and is approximately 30 kb in length. This allele, which encodes transcriptional repressor CTCFL protein, is involved in both gene regulation and X-chromosome inactivation.","CTCFL wt Allele | BORIS | CCCTC-Binding Factor (Zinc Finger Protein)-Like wt Allele | CT27 | CTCF-T | DJ579F20.2 | HMG-1L1 | HMGB1L1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454294","Adenovirus 5-Human Guanylyl Cyclase C-PADRE Vaccine","C112005","A replication-defective, recombinant adenoviral serotype 5 (Ad5) encoding human guanylyl cyclase C (hGCC) and the synthetic Pan DR epitope (PADRE), with potential antineoplastic and immunomodulating activities. Upon intramuscular administration, the Ad5-hGCC-PADRE vaccine expresses hGCC, which may induce both humoral and cellular immune responses against tumor cells expressing the hGCC antigen. This results in the immune-mediated inhibition of tumor cell proliferation, and leads to tumor death. The hGCC protein is normally restricted to intestinal epithelial cells but is overexpressed by metastatic colorectal tumors. PADRE is a helper T-lymphocyte epitope that is able to augment the magnitude and duration of the cytotoxic T-lymphocyte (CTL) response.","Adenovirus 5-Human Guanylyl Cyclase C-PADRE Vaccine | Ad5-hGCC-PADRE Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830170","FDA Device Classification","C112278","The class of medical device as determined by the US Food and Drug Administration, based upon the level of control necessary to ensure safety and effectiveness (21 CFR 860).","FDA Device Classification | FDADEVCL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1258015","Henipavirus","C112290","A genus of enveloped, pleomorphically spherical viruses in the family Paramyxoviridae. The genome is composed of a linear single-strand of negative sense RNA. The Henipavirus natural reservoir is considered to be fruit bats of the Pteropodidae family and cause influenza-like illness in humans.","Henipavirus | HENIPAVIRUS",,,,,,,,,,,,,,,"4231386","Genus Henipavirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL454234","Lenti-D/ABCD1-transduced Autologous Hematopoietic Stem Cells","C111902","Autologous CD34+ hematopoietic stem cells transduced with Lenti-D lentiviral vector encoding the human ATP-binding cassette, sub-family D, member 1 (ABCD1) cDNA, for the potential treatment of childhood cerebral adrenoleukodystrophy (CCALD). Upon administration of the lenti-D/ABCD1-transduced autologous hematopoietic stem cells, the cells proliferate, and some travel to the brain and differentiate into microglial cells. The expressed ABCD1 restores the function of ALD protein (ALDP) and aids in the treatment of CCALD.  In CCALD, the ABCD1 gene is mutated, leading to the inability of patients to metabolize very long chain fatty acids in cells of the brain.","Lenti-D/ABCD1-transduced Autologous Hematopoietic Stem Cells | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454235","CMVpp65/gB Plasmid Vaccine ASP0113","C111903","A poloxamer-formulated, bivalent DNA vaccine containing two plasmids encoding both the human cytomegaloviral (CMV) tegument phosphoprotein 65 (pp65), a major internal matrix protein, and glycoprotein B (gB), an important CMV component responsible for attachment and entry into cells, with potential immunostimulatory properties. Upon intramuscular injection of CMVpp65/gB plasmid vaccine ASP0113, the expressed proteins may activate the immune system to mount both cellular and humoral immune responses against CMV-positive cells. This results in cell lysis of CMV-infected cells and prevents both viral replication and the development of CMV disease. This vaccine also provides active immunization and protective immunity against CMV infection in CMV-negative patients exposed to infected donor cells or tissues in transplant recipients. CMV infection can cause serious complications in patients receiving either allogeneic hematopoietic cell transplants (HCT) or solid organ transplants. The poloxamer-based delivery system enhances DNA delivery.","CMVpp65/gB Plasmid Vaccine ASP0113 | ASP0113 | TransVax",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0455990","Immune Hydrops Fetalis","C111904","Fluid accumulation in multiple fetal anatomic cavities attributable to a maternal immune response against fetal blood cell antigens.","Immune Hydrops Fetalis | ",,,,,,,,,,,,,,,"77662","Hydrops fetalis due to isoimmunization",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1835252","Non-Immune Hydrops Fetalis","C111905","Fluid accumulation in multiple fetal anatomic cavities that is of non-immune origin.","Non-Immune Hydrops Fetalis | ",,,,,,,,,,,,,,,"76533","Non-immune hydrops fetalis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3715044","AKR1A1 wt Allele","C112102","Human AKR1A1 wild-type allele is located within 1p33-p32 and is approximately 20 kb in length. This allele, which encodes alcohol dehydrogenase [NADP(+)] protein, is involved in the reduction of biogenic and xenobiotic aldehydes.","AKR1A1 wt Allele | ALDR1 | ALR | ARM | Aldo-Keto Reductase Family 1, Member A1 (Aldehyde Reductase) wt Allele | DD3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0108187","CANX protein, human","C112103","Calnexin (592 aa, ~68 kDa) is encoded by the human CANX gene. This protein plays a role in antigen presentation, protein folding and complex assembly.","Calnexin | CANX | IP90 | Major Histocompatibility Complex Class I Antigen-Binding Protein p88 | p90",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0051115","Alcohol Dehydrogenase [NADP(+)]","C112104","Alcohol dehydrogenase [NADP(+)] (325 aa, ~37 kDa) is encoded by the human AKR1A1 gene. This protein plays a role in the reduction of biogenic and xenobiotic aldehydes.","Alcohol Dehydrogenase [NADP(+)] | AKR1A1 | Alcohol Dehydrogenase | Aldehyde Reductase | Aldo-Keto Reductase Family 1 Member A1 | Aldo-Keto Reductase Family 1, Member A1 | Dihydrodiol Dehydrogenase 3 | EC 1.1.1.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813587","KEAP1 wt Allele","C112106","Human KEAP1 wild-type allele is located in the vicinity of 19p13.2 and is approximately 18 kb in length. This allele, which encodes kelch-like ECH-associated protein 1, plays a role in targeting NFE2L2/NRF2 for ubiquitin-mediated protein degradation.","KEAP1 wt Allele | INRF2 | INrf2 | KIAA0132 | KLHL19 | Kelch-Like ECH-Associated Protein 1 wt Allele | MGC10630 | MGC1114 | MGC20887 | MGC4407 | MGC9454",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0967993","Kelch-Like ECH-Associated Protein 1, Human","C112107","Kelch-like ECH-associated protein 1 (624 aa, ~70 kDa) is encoded by the human KEAP1 gene. This protein is involved in ubiquitin-mediated protein degradation.","Kelch-Like ECH-Associated Protein 1 | Cytosolic Inhibitor Of Nrf2 | KEAP1 | Kelch-Like Family Member 19 | Kelch-Like Protein 19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812660","Skin Bruise","C112174","Extravasation of blood into the subcutaneous space.","Skin Bruise | Bruise | Ecchymosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002994","Angioedema","C112175","Rapid swelling of the deep layers of the skin due to transient vascular leakage of serous fluid.","Angioedema | ",,,,,,,,,,,,,,,"3661528|432791","Angioedema|Angioedema",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0277941","Blanching","C112176","Transient pallor of the skin caused by reduced blood flow to the affected region.","Blanching | ",,,,,,,,,,,,,,,"4260836","Blanching of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3826962","CDISC Questionnaire AQ20 Test Name Terminology","C112434","Test names of questionnaire questions associated with the Airway Questionnaire 20 (AQ20) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire AQ20 Test Name Terminology | AQ01TN | Airway Questionnaire 20 Questionnaire Test Name | QS-AQ20 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826961","CDISC Questionnaire AQ20 Test Code Terminology","C112435","Test codes of questionnaire questions associated with the Airway Questionnaire 20 (AQ20) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire AQ20 Test Code Terminology | AQ01TC | Airway Questionnaire 20 Questionnaire Test Code | QS-AQ20 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826939","QS-DS TEST","C112436","Test names of clinical classification questions associated with the Disease Steps (DS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification DS Test Name Terminology | DS01TN | Disease Steps Clinical Classification Test Name | QS-DS TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826938","QS-DS TESTCD","C112437","Test codes of clinical classification questions associated with the Disease Steps (DS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification DS Test Code Terminology | DS01TC | Disease Steps Clinical Classification Test Code | QS-DS TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826937","QS-EDSS TEST","C112438","Test names of clinical classification questions associated with the Kurtzke Expanded Disability Status Scale (EDSS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification EDSS Test Name Terminology | EDSS01TN | Kurtzke Expanded Disability Status Scale Clinical Classification Test Name | QS-EDSS TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826936","QS-EDSS TESTCD","C112439","Test codes of clinical classification questions associated with the Kurtzke Expanded Disability Status Scale (EDSS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification EDSS Test Code Terminology | EDSS01TC | Kurtzke Expanded Disability Status Scale Clinical Classification Test Code | QS-EDSS TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826935","CDISC Questionnaire FAMS Test Name Terminology","C112440","Test names of questionnaire questions associated with the Functional Assessment of Multiple Sclerosis (FAMS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire FAMS Test Name Terminology | FAMS01TN | Functional Assessment of Multiple Sclerosis Version 4 Questionnaire Test Name | QS-FAMS TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826934","CDISC Questionnaire FAMS Test Code Terminology","C112441","Test codes of questionnaire questions associated with the Functional Assessment of Multiple Sclerosis (FAMS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire FAMS Test Code Terminology | FAMS01TC | Functional Assessment of Multiple Sclerosis Version 4 Questionnaire Test Code | QS-FAMS TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831500","AQ20 - Cough Often During the Day","C112529","Airway Questionnaire 20 (AQ20) Do you cough often during the day?","AQ20 - Cough Often During the Day | AQ01-Cough Often During Day | AQ0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0393027","ethynyluracil/fluorouracil","C11252","A combination tablet of ethynyluracil and fluorouracil. Fluorouracil is an antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Ethynyluracil is an orally-active fluoropyrimidine analog that inhibits dihydropyrimidine dehydrogenase, the rate-limiting enzyme that catabolizes and inactivates 5-fluorouracil in the liver. This may lead to an increase in the bioavailability and, effectiveness of fluorouracil.","Eniluracil/5-FU Combination Tablet | 776C85/5-FU | Ethynyluracil/Fluorouracil | GW776/5-FU | GW776/5-Fluorouracil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827219","AQ20 - Chest Trouble Make You Feel Restless","C112530","Airway Questionnaire 20 (AQ20) Does your chest trouble often make you feel restless?","AQ20 - Chest Trouble Make You Feel Restless | AQ01-Feel Restless Due to Chest Trouble | AQ0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831494","AQ20 - Gardening Make You Breathless","C112531","Airway Questionnaire 20 (AQ20) Does gardening make you breathless?","AQ20 - Gardening Make You Breathless | AQ01-Gardening Make You Breathless | AQ0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813583","PTGES wt Allele","C112109","Human PTGES wild-type allele is located in the vicinity of 9q34.3 and is approximately 15 kb in length. This allele, which encodes prostaglandin E synthase protein, may be involved in TP53 induced apoptosis.","PTGES wt Allele | MGST-IV | MGST1-L1 | MGST1L1 | MPGES | MPGES-1 | MPGES1 | PGES | PIG12 | PP102 | PP1294 | Prostaglandin E Synthase wt Allele | TP53I12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0392962","docetaxel/epirubicin","C11210","A regimen consisting of docetaxel and epirubicin that can be used for the treatment of breast cancer.","Docetaxel/Epirubicin Regimen | Docetaxel and Epirubicin (DE) | Docetaxel-Epirubicin | Docetaxel/Epirubicin | EPI/TXT | ET",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454356","Skin Sloughing","C112110","Peeling or shedding of skin in sheets.","Skin Sloughing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1571038","Prostaglandin E Synthase, Human","C112111","Prostaglandin E synthase (152 aa, ~17 kDa) is encoded by the human PTGES gene. This protein may play a role in TP53 induced apoptosis.","Prostaglandin E Synthase | EC 5.3.99.3 | Glutathione Peroxidase PTGES | Glutathione S-Transferase 1-Like 1 | Glutathione Transferase PTGES | MGST1-Like 1 | Microsomal Glutathione S-Transferase 1-Like 1 | Microsomal Prostaglandin E Synthase 1 | Microsomal Prostaglandin E Synthase-1 | P53-Induced Apoptosis Protein 12 | P53-Induced Gene 12 Protein | PTGES | Tumor Protein P53 Inducible Protein 12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030326","Panniculitis","C112112","Inflammation of the subcutaneous adipose tissue.","Panniculitis | ",,,,,,,,,,,,,,,"432719","Panniculitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829593","Human Drug Compounding Outsourcing Facility","C112113","A site designated as an establishment for outsourcing of human drug compounding.","Human Drug Compounding Outsourcing Facility | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815112","Chronic Decubitus","C112115","A longstanding lesion caused by death of tissue due to external pressure.","Chronic Decubitus | Chronic Decubitus Ulcer | Chronic Pressure Sore | Chronic Pressure Ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0264005","Eosinophilic Fasciitis","C112116","Inflammation and induration of the fascia related to an accumulation of white blood cells, including eosinophils.","Eosinophilic Fasciitis | Shulman Syndrome",,,,,,,,,,,,,,,"4083100","Fasciitis with eosinophilia syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085381","Nairovirus","C112358","A genus of enveloped, spherical viruses in the family Bunyaviridae. The genome is composed of a circular single-strand of negative sense RNA. Nairoviruses are tick-borne with human and animal hosts and cause hemorrhagic fevers and gastroenteritis in humans.","Nairovirus | NAIROVIRUS",,,,,,,,,,,,,,,"4085760","Genus Nairovirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0751673","Nipah Virus","C112359","A species of enveloped and pleomorphic viruses in the Paramyxoviridae family and Henipavirus genus. The genome is composed of non-segmented, negative-sense, single-stranded RNA. Nipah viruses are found naturally in Pteropid fruit bats, and are zoonotic pathogens in domestic animals (mainly in pigs) and humans. Nipah viruses cause respiratory diseases, relapse and fatal encephalitis in humans.","Nipah Virus | NIPAH VIRUS | NiV",,,,,,,,,,,,,,,"4020200","Nipah virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828795","Non-Study Device Issue","C112361","Issue associated with any deviations from specifications relating to non-study device or equipment operations.","Non-Study Device Issue | NON-STUDY EQUIPMENT ISSUE | Non-Study Equipment Malfunction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826920","QS-KFSS TEST","C112442","Test names of clinical classification questions associated with the Kurtzke Functional Systems Scores (KFSS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification KFSS Test Name Terminology | KFSS1TN | Kurtzke Functional Systems Scores Clinical Classification Test Name | QS-KFSS TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826919","QS-KFSS TESTCD","C112443","Test codes of clinical classification questions associated with the Kurtzke Functional Systems Scores (KFSS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification KFSS Test Code Terminology | KFSS1TC | Kurtzke Functional Systems Scores Clinical Classification Test Code | QS-KFSS TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826916","CDISC Questionnaire MHIS-NACC Test Name Terminology","C112444","Test names of questionnaire questions associated with the Modified Hachinski Ischemic Scale-NACC Version (MHIS-NACC) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire MHIS-NACC Test Name Terminology | MHIS01TN | Modified Hachinski Ischemic Scale-NACC Version Questionnaire Test Name | QS-MHIS-NACC TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826909","CDISC Questionnaire PDDS Test Name Terminology","C112446","Test names of questionnaire questions associated with the Patient Determined Disease Steps (PDDS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire PDDS Test Name Terminology | PDDS01TN | Patient Determined Disease Steps Questionnaire Test Name | QS-PDDS TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828099","SGRQ Past 3 Months Version - Unpleasant Side Effects From Medication","C112661","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about your respiratory treatment: I have unpleasant side effects from my medication.","SGRQ Past 3 Months Version - Unpleasant Side Effects From Medication | SGRQ01-Unpleasant Side Effect From Med | SGRQ0135",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828100","SGRQ Past 3 Months Version - Treatment Interferes With My Life","C112662","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about your respiratory treatment: My treatment interferes with my life a lot.","SGRQ Past 3 Months Version - Treatment Interferes With My Life | SGRQ01-Treatment Interferes With Life | SGRQ0136",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828103","SGRQ Past 3 Months Version - Take Long Time to Get Washed or Dressed","C112663","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about how your activities might be affected by your respiratory problems: I take a long time to get washed or dressed.","SGRQ Past 3 Months Version - Take Long Time to Get Washed or Dressed | SGRQ01-Take a Long Time to Get Washed | SGRQ0137",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828133","SGRQ Past 3 Months Version - Cannot Take a Bath or Shower","C112664","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about how your activities might be affected by your respiratory problems: I cannot take a bath or shower, or I take a long time to do it.","SGRQ Past 3 Months Version - Cannot Take a Bath or Shower | SGRQ01-I Cannot Take a Bath or Shower | SGRQ0138",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828094","SGRQ Past 3 Months Version - Walk Slower Than Other People My Age","C112665","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about how your activities might be affected by your respiratory problems: I walk slower than other people my age, or I stop to rest.","SGRQ Past 3 Months Version - Walk Slower Than Other People My Age | SGRQ01-I Walk Slower Than Other People | SGRQ0139",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828112","SGRQ Past 3 Months Version - Jobs Take Long Time or I Have to Stop","C112666","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about how your activities might be affected by your respiratory problems: Jobs such as household chores take a long time, or I have to stop to rest.","SGRQ Past 3 Months Version - Jobs Take Long Time or I Have to Stop | SGRQ01-Jobs Take a Long Time | SGRQ0140",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828118","SGRQ Past 3 Months Version - If Walk Up One Flight of Stairs I Have to Go Slow","C112667","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about how your activities might be affected by your respiratory problems: If I walk up one flight of stairs, I have to go slowly or stop.","SGRQ Past 3 Months Version - If Walk Up One Flight of Stairs I Have to Go Slow | SGRQ01-Walk Up Flight of Stairs Slowly | SGRQ0141",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016515","Aphthovirus","C112229","A genus of non-enveloped, spherical viruses with T=pseudo3 icosahedral capsid, in the family Picornaviridae. The genome is composed of a linear, single-strand of positive sense, naked RNA. Aphthoviruses are found in cloven-hooved animals and cause foot-and-mouth disease in humans.","Aphthovirus | APHTHOVIRUS",,,,,,,,,,,,,,,"4234356","Genus Aphthovirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003725","Arbovirus","C112230","A non-taxonomic grouping of viruses that are transmitted through an arthropod vector and replicate in a vertebrate host. These include a variety of species from the families Bunyaviridae, Flaviviridae and Reoviridae.","Arbovirus | ARBOVIRUS | Arthropod-borne Virus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004120","Astroviridae","C112231","A family of non-enveloped, spherical-shaped, capsid-enclosed viruses. The virus is icosahedral in shape with characteristic star-like surface projections. The genome is composed of a linear, non-segmented single-strand of positive sense RNA. Astroviridae infect vertebrates and are a causative agent of gastroenteritis in humans.","Astroviridae | ASTROVIRIDAE | Astrovirus",,,,,,,,,,,,,,,"4310596","Astroviridae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205660","Barmah Forest Virus","C112232","A species of enveloped, spherical or pleomorphic viruses with a capsid with T=4 icosahedral symmetry in the Togaviridae family and Alphavirus genus. The genome is composed of single-stranded, positive-sense RNA. Barmah forest viruses are found in both vertebrates and invertebrates, and cause infectious arthritis, encephalitis, rashes and fever in humans. Barmah forest viruses are transmitted mainly via the bite of infected mosquitoes.","Barmah Forest Virus | BARMAH FOREST VIRUS",,,,,,,,,,,,,,,"4211514","Barmah Forest virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0224400","Bulbospongiosus","C112234","A superficial muscle located in the midline of the perineum and anterior to the anus. It covers the bulb of the penis in males and the vestibular bulb in females. The origin and insertion differs between males and females.","Bulbospongiosus | Bulbocavernosus | MUSCLE, BULBOSPONGIOSUS",,,,,,,,,,,,,,,"4325431","Structure of bulbospongiosus muscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3831484","AQ20 - Worry When Going to Friend House Something Will Upset Your Chest","C112532","Airway Questionnaire 20 (AQ20) Do you worry when going to a friend's house that there might be something there that will upset your chest?","AQ20 - Worry When Going to Friend House Something Will Upset Your Chest | AQ01-Chest Upset at Friend House | AQ0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831492","AQ20 - Get Chest Problems When Contact With Strong Smells","C112533","Airway Questionnaire 20 (AQ20) Do you get chest problems when you come into contact with strong smells, exhaust fumes, cigarette smoke, perfume etc?","AQ20 - Get Chest Problems When Contact With Strong Smells | AQ01-Chest Prob Smell/Fume/Smoke/Perfume | AQ0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831490","AQ20 - Partner Find Your Chest Trouble Upsetting","C112534","Airway Questionnaire 20 (AQ20) Does your partner find your chest trouble upsetting?","AQ20 - Partner Find Your Chest Trouble Upsetting | AQ01-Partner Upset by Your Chest Trouble | AQ0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829362","KRT18 wt Allele","C111867","Human KRT18 wild-type allele is located in the vicinity of 12q13 and is approximately 4 kb in length. This allele, which encodes keratin, type I cytoskeletal 18 protein, is involved in both the negative regulation of apoptosis and intermediate filament structure. Mutations in the gene are associated with cryptogenic cirrhosis.","KRT18 wt Allele | CK18 | CYK18 | Cell Proliferation-Inducing Gene 46 | K18 | Keratin 18 wt Allele | PIG46",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1455201","Keratin, Type I Cytoskeletal 18, Human","C111868","Keratin, type I cytoskeletal 18 (430 aa, ~48 kDa) is encoded by the human KRT18 gene. This protein plays a role in both intermediate filament structure and the inhibition of apoptosis.","Keratin, Type I Cytoskeletal 18 | CK-18 | Cell Proliferation-Inducing Gene 46 Protein | Cell Proliferation-Inducing Protein 46 | Cytokeratin 18 | Cytokeratin-18 | K18 | KRT18 | Keratin-18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812760","SEC14L1 wt Allele","C111870","Human SEC14L1 wild-type allele is located in the vicinity of 17q25.2 and is approximately 130 kb in length. This allele, which encodes SEC14-like protein 1, may play a role in intracellular transport. Aberrant elevated expression of the gene may be associated with a poor prognosis for prostate adenocarcinoma.","SEC14L1 wt Allele | PRELID4A | SEC14 (S. cerevisiae)-Like 1 Gene | SEC14, S. cerevisiae, Homolog of, 1 Gene | SEC14-Like 1 (S. cerevisiae) wt Allele | SEC14-Like 1 Gene | SEC14L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815886","SEC14-Like Protein 1","C111871","SEC14-like protein 1 (715 aa, ~81 kDa) is encoded by the human SEC14L1 gene. This protein may be involved in intracellular transport.","SEC14-Like Protein 1 | SEC14L1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812156","ALAS1 wt Allele","C111873","Human ALAS1 wild-type allele is located in the vicinity of 3p21.1 and is approximately 16 kb in length. This allele, which encodes 5-aminolevulinate synthase, nonspecific, mitochondrial protein, is involved in both heme biosynthesis and lipid metabolism.","ALAS1 wt Allele | ALAS | ALAS, Housekeeping Type Gene | ALAS3 | ALASH | Aminolevulinate, Delta-, Synthase 1 wt Allele | MIG4 | OK/SW-cl.121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815531","5-Aminolevulinate Synthase, Nonspecific, Mitochondrial","C111874","5-aminolevulinate synthase, nonspecific, mitochondrial (640 aa, ~71 kDa) is encoded by the human ALAS1 gene. This protein plays a role in both protoporphyrin biosynthesis and lipid metabolism.","5-Aminolevulinate Synthase, Nonspecific, Mitochondrial | 5-Aminolevulinic Acid Synthase 1 | ALAS-H | ALAS1 | Delta-ALA Synthase 1 | Delta-Aminolevulinate Synthase 1 | EC 2.3.1.37 | Migration-Inducing Protein 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831458","ATOH1 wt Allele","C111876","Human ATOH1 wild-type allele is located in the vicinity of 4q22 and is approximately 1 kb in length. This allele, which encodes protein atonal homolog 1, plays a role in the modulation of E-box dependent transcription.","ATOH1 wt Allele | ATH1 | Atonal Homolog 1 (Drosophila) wt Allele | Atonal, Drosophila, Homolog of, 1 Gene | BHLHA14 | HATH1 | MATH-1 | MATH1, Mouse, Homolog of Gene | bHLHa14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827223","Number of Coil Channels","C112364","The number of channels, or elements, in the head coil component of the device.","Number of Coil Channels | COILNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206592","Orbivirus","C112365","A genus of non-enveloped, non-turreted viruses with a triple capsid structure, in the family Reoviridae. The genome is composed of linear, segmented double-stranded RNA. Orbiviruses are infective in a wide range of arthropod and vertebrate hosts and primarily cause disease in animals.","Orbivirus | ORBIVIRUS",,,,,,,,,,,,,,,"4259134","Genus Orbivirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085377","Orthobunyavirus","C112366","A genus of enveloped, spherical viruses in the family Bunyaviridae. The genome is composed of three linear, segmented single-strands of negative sense RNA. Orthobunyaviruses are mostly transmitted by gnats and cause encephalitis in humans.","Orthobunyavirus | Bunyavirus | ORTHOBUNYAVIRUS",,,,,,,,,,,,,,,"4231380","Genus Orthobunyavirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206583","Parapoxvirus","C112367","A genus of enveloped, oval-shaped virions with surface filaments, in the family Poxviridae. The genome is composed of non-segmented, double-stranded DNA. Two distinct infection virus particles exist for Parapoxviruses and cause non-serious infection in humans.","Parapoxvirus | PARAPOXVIRUS",,,,,,,,,,,,,,,"4289935","Parapoxvirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828607","Percent Change From Baseline in Sum of Area","C112369","The most recently recorded sum of areas minus the baseline sum of areas divided by the baseline sum of areas, multiplied by 100.","Percent Change From Baseline in Sum of Area | Percent Change Baseline in Sum of Area",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830206","FAMS - Trouble Learning New Tasks or Directions","C112587","Functional Assessment of Multiple Sclerosis (FAMS) Thinking and Fatigue: I have trouble learning new tasks or directions.","FAMS - Trouble Learning New Tasks or Directions | FAMS01-I Have Trouble Learning New Tasks | FAMS0137",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830247","FAMS - Feel Close to My Friends","C112588","Functional Assessment of Multiple Sclerosis (FAMS) Family/Social Well-Being: I feel close to my friends.","FAMS - Feel Close to My Friends | FAMS01-I Feel Close to My Friends | FAMS0138",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830239","FAMS - Get Emotional Support From Family","C112589","Functional Assessment of Multiple Sclerosis (FAMS) Family/Social Well-Being: I get emotional support from my family.","FAMS - Get Emotional Support From Family | FAMS01-Get Emotional Support From Family | FAMS0139",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830238","FAMS - Get Support From Friends","C112590","Functional Assessment of Multiple Sclerosis (FAMS) Family/Social Well-Being: I get support from my friends.","FAMS - Get Support From Friends | FAMS01-I Get Support From My Friends | FAMS0140",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828119","SGRQ Past 3 Months Version - If Walk Fast I Have to Stop or Slow Down","C112668","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about how your activities might be affected by your respiratory problems: If I hurry or walk fast, I have to stop or slow down.","SGRQ Past 3 Months Version - If Walk Fast I Have to Stop or Slow Down | SGRQ01-If I Hurry, I Have to Stop | SGRQ0142",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828139","SGRQ Past 3 Months Version - Breathing Makes Difficult to Walk Up Hills","C112669","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about how your activities might be affected by your respiratory problems: My breathing makes it difficult to do things such as walk up hills, carry things up stairs, light gardening such as weeding, dance, bowl or play golf.","SGRQ Past 3 Months Version - Breathing Makes Difficult to Walk Up Hills | SGRQ01-Difficult to Walk Up Hills | SGRQ0143",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828141","SGRQ Past 3 Months Version - Breathing Makes Difficult to Carry Heavy Loads","C112670","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about how your activities might be affected by your respiratory problems: My breathing makes it difficult to do things such as carry heavy loads, dig in the garden or shovel snow, jog or walk briskly (5 miles per hour), play tennis or swim.","SGRQ Past 3 Months Version - Breathing Makes Difficult to Carry Heavy Loads | SGRQ01-Difficult to Carry Heavy Loads | SGRQ0144",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828140","SGRQ Past 3 Months Version - Breathing Makes Difficult to Do Heavy Manual Work","C112671","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about how your activities might be affected by your respiratory problems: My breathing makes it difficult to do things such as very heavy manual work, ride a bike, run, swim fast, or play competitive sports.","SGRQ Past 3 Months Version - Breathing Makes Difficult to Do Heavy Manual Work | SGRQ01-Difficult to Do Very Heavy Work | SGRQ0145",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813163","ZC3H7B wt Allele","C111981","Human ZC3H7B wild-type allele is located in the vicinity of 22q13.2 and is approximately 59 kb in length. This allele, which encodes zinc finger CCCH domain-containing protein 7B, is involved in binding to non-structural protein NSP3. A fusion of this gene and the BCOR gene may be associated with low-grade endometrial stromal sarcomas.","ZC3H7B wt Allele | DKFZp434K0920 | FLJ13787 | KIAA1031 | ROXAN1 | RoXaN | Zinc Finger CCCH-Type Containing 7B wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1450933","Zinc Finger CCCH Domain-Containing Protein 7B, Human","C111982","Zinc finger CCCH domain-containing protein 7B (993 aa, ~112 kDa) is encoded by the human ZC3H7B gene. This protein plays a role in binding to rotavirus protein NSP3.","Zinc Finger CCCH Domain-Containing Protein 7B | RoXaN | Rotavirus 'X' Associated Non-Structural Protein | Rotavirus 'X'-Associated Non-Structural Protein | Rotavirus X Protein Associated With NSP3 | Rotavirus X Protein Associated With NSP3 1 | Ubiquitous Tetratricopeptide Containing Protein RoXaN | ZC3H7B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1302813","Fixed Drug Eruption","C111986","Round areas of red-purple reaction in the skin that result after drug exposure; these recur in the same location when the medication is readministered.","Fixed Drug Eruption | ",,,,,,,,,,,,,,,"4249310","Fixed drug eruption",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221245","Skin Fissure","C111987","A narrow break in the skin.","Skin Fissure | Fissuring",,,,,,,,,,,,,,,"4316082","Fissure in skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL454669","Autologous Lymphoid Effector Cells Specific Against Tumor Cells","C112495","A preparation of cytotoxic, autologous lymphoid effector cells specifically targeted towards tumor cells, with potential immunomodulating and antineoplastic activities. The autologous lymphoid effector cells are prepared by drawing a blood sample containing the required precursors for CD4+ helper T-cells, CD8+ cytotoxic T-cells, and natural killer (NK) cells from a cancer patient. The precursor cells are activated, selected and expanded to generate mature autologous lymphoid effector cells with the potential for enhanced tumor recognition. Upon readministration into the patient, the autologous lymphoid effector cells may induce both humoral and cellular immune responses against tumor cells. This may result in the immune-mediated inhibition of tumor cell proliferation, which leads to tumor cell death.","Autologous Lymphoid Effector Cells Specific Against Tumor Cells | ALECSAT | AUTOLOGOUS EX VIVO EXPANDED CD4+-ENRICHED LEUKOCYTES TREATED WITH THE DE-METHYLATING AGENT 5-AZA-DEOXYCYTIDINE | Autologous Activated Cytotoxic T Lymphocytes/Natural Killer Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454670","Fluorine F 18 FDHT","C112496","A radioconjugate containing a derivative of the androgen testosterone, 16-beta-fluoro-5-alpha-dihydrotestosterone (FDHT), labeled with the radioisotope fluorine F18 (18F-FDHT), with potential use as an imaging agent for positron emission tomography (PET). Upon administration, 18F-FDHT binds to the androgen receptor (AR). Upon PET imaging, AR-expressing prostate tumor cells can be imaged and assessed.","Fluorine F 18 FDHT | (18)F-16beta-Fluoro-5alpha-Dihydrotestosterone | (18)F-FDHT | 16Beta-18F-Fluoro-5alpha-Dihydrotestosterone | 18F-FDHT | Fluorine F 18 16-Beta-Fluoro-5-Alpha-Dihydrotestosterone | Fluorine F 18-FDHT | Fluorine F18 16-Beta-Fluoro-5-Alpha-Dihydrotestosterone | Fluorine F18-FDHT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3711165","PI3K/mTOR Kinase Inhibitor VS-5584","C112497","A potent and selective inhibitor of both phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinase in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. PI3K/mTOR kinase inhibitor VS-5584 inhibits mTOR kinase and all class I PI3K isoforms. Consequently, this disrupts phosphorylation of substrates downstream of PI3K and mTOR and may result in apoptosis and growth inhibition in susceptible tumor cells. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy. mTOR is a serine/threonine kinase downstream of PI3K, which also has PI3K-independent activity. Consequently, this agent may potentially be more potent than an agent that inhibits either PI3K kinase or mTOR kinase.","PI3K/mTOR Kinase Inhibitor VS-5584 | 2-Pyrimidinamine, 5-[8-Methyl-9-(1-Methylethyl)-2-(4-Morpholinyl)-9H-Purin-6-Yl]-2- | 5-[8-Methyl-9-(1-Methylethyl)-2-(4-Morpholinyl)-9H-Purin-6-Yl]-2-Pyrimidinamine | PI3K/mTOR Inhibitor VS-5584 | SB 2343 | SB-2343 | SB2343 | VS 5584 | VS-5584 | VS5584",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454672","Extended Release Flucytosine","C112498","An extended release (ER) oral tablet that contains flucytosine (5-FC), a fluorinated cytosine analog, with antifungal activity and potential anti-cancer activity. Following oral administration of ER 5-FC, the 5-FC is deaminated to its active metabolite 5-fluorouracil (5-FU). 5-FU replaces uracil during RNA synthesis, which consequently inhibits downstream protein synthesis. In addition, 5-FU is metabolized further to 5-fluorodeoxyuridylic acid monophosphate, which inhibits thymidylate synthetase. Inhibition of this enzyme interrupts nucleotide synthesis, DNA replication and cell proliferation. Negative regulation of protein synthesis, DNA replication and cell proliferation can lead to cell death. Following ingestion of ER 5-FC, intravenous injection of a retroviral vector encoding cytosine deaminase (TC 511) at a tumor site may result in higher local concentrations of 5-FU and its metabolites, and increased tumor cell death than other 5-FU treatment regimens.","Extended Release Flucytosine | Extended Release 5-FC | Extended Release 5-Fluorocytosine | Extended-Release 5-FC | Extended-Release 5-Fluorocytosine | Extended-Release Flucytosine | Toca FC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454673","Cetuximab-IRDye 800CW","C112499","An immunoconjugate comprised of the recombinant chimeric monoclonal antibody cetuximab conjugated to the N-hydroxysuccinamide (NHS) ester form of the near-infrared (NIR) fluorescent dye IRDye 800CW (cetuximab-IRDye 800) with potential imaging use. The antibody moiety of cetuximab-IRDye 800 binds to the extracellular domain of the epidermal growth factor receptor (EGFR). Upon binding, IRDye 800 may be detected using NIR imaging, which facilitates the visualization and quantification of EGFR-expressing tumor cells. EGFR is a receptor tyrosine kinase that may be overexpressed on the cell surfaces of various tumor types.","Cetuximab-IRDye 800CW | Cetuximab-IRDye 800 | Cetuximab-IRDye800 | Cetuximab-IRDye800CW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0062565","Herbimycin","C1124","A benzoquinone antineoplastic antibiotic isolated from the bacterium Streptomyces hygroscopicus.  Herbimycin binds to and inhibits the cytosolic chaperone functions of heat shock protein 90 (HSP90).  HSP90 maintains the stability and functional shape of many oncogenic signaling proteins; the inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins that may be over-expressed or overactive in tumor cells. (NCI04)","Herbimycin | 17-Demethoxy-15-methoxy-11-O-methylgeldanamycin, (15R)- | HERBIMYCIN A | Herbimycin A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811070","Protein Atonal Homolog 1, human","C111877","Protein atonal homolog 1 (354 aa, ~38 kDa) is encoded by the human ATOH1 gene. This protein is involved in the activation of E-box dependent gene expression.","Protein Atonal Homolog 1 | Class A Basic Helix-Loop-Helix Protein 14 | Helix-Loop-Helix Protein HATH-1 | bHLHa14 | hATH1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814141","DKK2 wt Allele","C111879","Human DKK2 wild-type allele is located in the vicinity of 4q25 and is approximately 362 kb in length. This allele, which encodes dickkopf-related protein 2, is involved in the negative regulation of Wnt signaling.","DKK2 wt Allele | DKK-2 | Dickkopf (Xenopus Laevis) Homolog 2 Gene | Dickkopf 2 Homolog (Xenopus Laevis) Gene | Dickkopf Homolog 2 Gene | Dickkopf WNT Signaling Pathway Inhibitor 2 wt Allele | Dickkopf, Xenopus, Homolog of, 2 Gene | UNQ682/PRO1316",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831147","CFLAR Gene Product","C112061","A protein encoded by the CFLAR gene.","CFLAR Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813605","KIAA0196","C112063","Human WASHC5 wild-type allele is located in the vicinity of 8q24.13 and is approximately 68 kb in length. This allele, which encodes WASH complex subunit strumpellin protein, plays a role in the induction of actin polymerization. Mutations in this gene are associated with autosomal dominant spastic paraplegia 8.","WASHC5 wt Allele | KIAA0196 | RTSC | RTSC1 | SPG8 | Spastic Paraplegia 8 (Autosomal Dominant) Gene | WASH Complex Subunit 5 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1872106","WASH complex subunit strumpellin, Human","C112065","WASH complex subunit strumpellin (1159 aa, ~134 kDa) is encoded by the human WASHC5 gene. This protein is involved in actin polymerization.","WASH Complex Subunit Strumpellin | Strumpellin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812703","STIP1 wt Allele","C112067","Human STIP1 wild-type allele is located in the vicinity of 11q13 and is approximately 19 kb in length. This allele, which encodes stress-induced-phosphoprotein 1, is involved in chaperone protein function as a bridge between HSP70 and HSP90.","STIP1 wt Allele | HOP | STI1 | STI1, Yeast, Homologe of Gene | STI1L | Stress-Induced-Phosphoprotein 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830249","FAMS - Family Has Accepted My Illness","C112591","Functional Assessment of Multiple Sclerosis (FAMS) Family/Social Well-Being: My family has accepted my illness.","FAMS - Family Has Accepted My Illness | FAMS01-My Family Has Accepted My Illness | FAMS0141",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830213","FAMS - Satisfied With Family Communication About My Illness","C112592","Functional Assessment of Multiple Sclerosis (FAMS) Family/Social Well-Being: I am satisfied with family communication about my illness.","FAMS - Satisfied With Family Communication About My Illness | FAMS01-Satisfied Communication Illness | FAMS0142",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830248","FAMS - Family Has Trouble Understanding When My Condition Gets Worse","C112593","Functional Assessment of Multiple Sclerosis (FAMS) Family/Social Well-Being: My family has trouble understanding when my condition gets worse.","FAMS - Family Has Trouble Understanding When My Condition Gets Worse | FAMS01-Trouble Understanding Worsening | FAMS0143",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830245","FAMS - Feel Left Out of Things","C112594","Functional Assessment of Multiple Sclerosis (FAMS) Family/Social Well-Being: I feel 'left out' of things.","FAMS - Feel Left Out of Things | FAMS01-I Feel Left Out of Things | FAMS0144",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830253","FAMS - Bothered by Side Effects of Treatment","C112595","Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: I am bothered by side effects of treatment.","FAMS - Bothered by Side Effects of Treatment | FAMS01-Bothered by Treatment Side Effect | FAMS0145",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830240","FAMS - Forced to Spend Time in Bed","C112596","Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: I am forced to spend time in bed.","FAMS - Forced to Spend Time in Bed | FAMS01-I Am Forced to Spend Time in Bed | FAMS0146",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830246","FAMS - Feel Close to My Partner","C112597","Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: I feel close to my partner (or the person who is my main support).","FAMS - Feel Close to My Partner | FAMS01-I Feel Close to My Partner | FAMS0147",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830211","FAMS - Satisfied With My Sex Life","C112598","Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: I am satisfied with my sex life.","FAMS - Satisfied With My Sex Life | FAMS01-I Am Satisfied With My Sex Life | FAMS0148",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830212","FAMS - Satisfied With How I Am Coping With Illness","C112599","Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: I am satisfied with how I am coping with my illness.","FAMS - Satisfied With How I Am Coping With Illness | FAMS01-Satisfied With How I Am Coping | FAMS0149",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830229","FAMS - I Feel Nervous","C112600","Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: I feel nervous.","FAMS - I Feel Nervous | FAMS01-I Feel Nervous | FAMS0150",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454236","anti-EGFR TAP antibody-drug conjugate IMGN289","C111906","A targeted antibody payload (TAP)-based immunoconjugate consisting of a human monoclonal antibody directed against the epidermal growth factor receptor (EGFR) conjugated, via a nonreducible thioether linker (succinimidyl trans-4-(maleimidylmethyl)cyclohexane-1-carboxylate or SMCC), to the cytotoxic agent maytansinoid mertansine (DM1), with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of laprituximab emtansine binds to and inhibits EGFR on tumor cell surfaces. Inhibition of EGFR prevents EGFR-mediated signaling and may inhibit tumor cell proliferation. After internalization, the mertansine moiety binds to tubulin and interferes with microtubule assembly/disassembly dynamics. This inhibits both cell division and the proliferation of cancer cells that express EGFR. EGFR, overexpressed by a variety of cancers, plays a key role in tumor cell proliferation and survival. Linkage of the antibody and drug, through a nonreducible linker, appears to contribute to the improved efficacy and reduced toxicity of this antibody-drug conjugate (ADC) compared to similar ADCs constructed with reducible linkers.","Laprituximab Emtansine | Anti-EGFR-SMCC-DM1 | IMGN289 | LAPRITUXIMAB EMTANSINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454237","HO/02/02","C111907","A topical formulation that can be used to relieve radiation dermatitis.","HO/02/02 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454278","Autologous iC9-GD2-CAR-expressing VZV-specific T Lymphocytes","C111989","Genetically modified, autologous varicella zoster virus (VZV)-specific T-lymphocytes transduced with a retroviral vector encoding a chimeric antigen receptor (CAR) specific for the disialoganglioside GD2, which contains the signaling domains for the co-stimulatory molecules CD28 and CD134 (OX-40), and the suicide gene, inducible caspase 9 (iCasp9 or iC9), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, iC9-GD2-CD28-OX40-expressing T lymphocytes target the GD2 antigen on tumor cells for selective toxicity against GD2-expressing tumor cells. iCasp9 consists of a full-length caspase 9, including its caspase recruitment domain, linked to a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V). If the administered T cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered, which binds to the FKBP12-F36V drug binding domain, activates caspase 9, and results in apoptosis of the administered T-cells. Expression of the iCasp9 gene in T cells for adoptive transfer increases safety and broadens the scope for their clinical applications. The tumor associated antigen GD2 is overexpressed on the surface of almost all tumors of neuroectodermal origin. OX40 and CD28, both T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation. An additional VZV vaccine can be administered to increase T-cell activity.","Autologous iC9-GD2-CAR-expressing VZV-specific T Lymphocytes | Autologous iC9-GD2-CAR-VZV-CTLs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454279","Polo-like kinase 4 inhibitor CFI-400945 fumarate","C111990","An orally available fumarate salt form of CFI-400945, a polo-like kinase 4 (PLK4) inhibitor with potential antineoplastic activity. Upon oral administration, polo-like kinase 4 inhibitor CFI-400945 selectively inhibits PLK4, which results in the disruption of mitosis and the induction of apoptosis. PLK4 inhibition also prevents cell division and inhibits proliferation of PLK4-overexpressing tumor cells. PLK4, a member of the polo family of serine/threonine kinases overexpressed in a variety of cancer cell types, plays a crucial role in the regulation of centriole duplication during the cell cycle.","Ocifisertib Fumarate | CFI 400945 Fumarate | CFI-400945 | CFI-400945 Fumarate | OCIFISERTIB FUMARATE | PLK4 Inhibitor CFI-400945 Fumarate | Polo-like Kinase 4 Inhibitor CFI-400945 Fumarate | Polo-like Kinase 4 Inhibitor CFI-400945 Fumarate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454280","Autologous GM-CSF-secreting Lethally Irradiated Colorectal Cancer Cell Vaccine","C111991","A lethally irradiated, autologous colorectal cancer vaccine consisting of patient-specific colorectal cancer cells genetically modified to secrete the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Upon vaccination, the autologous GM-CSF-secreting lethally irradiated colorectal cancer cell vaccine releases GM-CSF. In turn, GM-CSF may increase the body's immune response against tumor cells by promoting the maturation and activation of dendritic cells (DCs), and enhancing tumor-specific antigen presentation to both B- and T-cells, which leads to better recognition of tumors by the immune system. In addition, GM-CSF promotes antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function.","Autologous GM-CSF-secreting Lethally Irradiated Colorectal Cancer Cell Vaccine | GVAX Colorectal Cancer Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0965384","Fluorine F 18 Galacto-RGD Peptide","C112178","A radiotracer composed of a cyclic Arg-Gly-Asp (RGD) peptide that is conjugated with galactose and radiolabeled with fluorine 18, for potential noninvasive positron emission tomography (PET) imaging of alphaVbeta3 integrin expression. Upon administration, the RGD moiety of the fluorine 18 galacto-RGD peptide selectively binds to alphaVbeta3 integrin. During PET imaging, alphaVbeta3-expressing tumor cells can be visualized and the degree of tumor angiogenesis can be determined. Use of a hydrophilic glycopeptide-based agent may increase retention in the blood and reduce clearance by the liver. This leads to both increased uptake of fluorine 18 galacto-RGD peptide by tumor cells and enhanced PET imaging efficiency, when compared to other agents that are constructed using lipophilic conjugates. AlphaVbeta3 integrin, a cell adhesion and signaling receptor, is upregulated in tumor vessel endothelial cells and has been associated with proliferation of tumor cells, tumor angiogenesis and metastasis.","Fluorine F 18 Galacto-RGD Peptide | 18F-Galacto-RGD | Fluorine F 18 Glycosylated RGD Peptide | [18F]Galacto-RGD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814123","Pickens County, AL","C107741","No value exists.","Pickens County, AL | AL107 | Pickens County | Pickens County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814131","Pike County, AL","C107742","No value exists.","Pike County, AL | AL109 | Pike County | Pike County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812310","Randolph County, AL","C107743","No value exists.","Randolph County, AL | AL111 | Randolph County | Randolph County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810640","Russell County, AL","C107744","No value exists.","Russell County, AL | AL113 | Russell County | Russell County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815242","Shelby County, AL","C107746","No value exists.","Shelby County, AL | AL117 | Shelby County | Shelby County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814837","Sumter County, AL","C107747","No value exists.","Sumter County, AL | AL119 | Sumter County | Sumter County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827866","Talladega County, AL","C107748","No value exists.","Talladega County, AL | AL121 | Talladega County | Talladega County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827864","Tallapoosa County, AL","C107749","No value exists.","Tallapoosa County, AL | AL123 | Tallapoosa County | Tallapoosa County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827748","Tuscaloosa County, AL","C107750","No value exists.","Tuscaloosa County, AL | AL125 | Tuscaloosa County | Tuscaloosa County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813251","Washington County, AL","C107752","No value exists.","Washington County, AL | AL129 | Washington County | Washington County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810728","Wilcox County, AL","C107753","No value exists.","Wilcox County, AL | AL131 | Wilcox County | Wilcox County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810743","Winston County, AL","C107754","No value exists.","Winston County, AL | AL133 | Winston County | Winston County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831576","Aleutians East Borough, AK","C107755","No value exists.","Aleutians East Borough, AK | AK013 | Aleutians East Borough | Aleutians East Borough, Alaska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831575","Aleutians West Census Area, AK","C107756","No value exists.","Aleutians West Census Area, AK | AK016 | Aleutians West Census Area | Aleutians West Census Area, Alaska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831357","Bethel Census Area, AK","C107758","No value exists.","Bethel Census Area, AK | AK050 | Bethel Census Area | Bethel Census Area, Alaska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831262","Bristol Bay Borough, AK","C107759","No value exists.","Bristol Bay Borough, AK | AK060 | Bristol Bay Borough | Bristol Bay Borough, Alaska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830541","Denali Borough, AK","C107760","No value exists.","Denali Borough, AK | AK068 | Denali Borough | Denali Borough, Alaska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0102271","Almond Oil","C107259","The oil extracted from the seed fruits of Prunus amygdalus. Almond oil is typically used as a skin emollient and for massage.","Almond Oil | ALMOND OIL | Sweet Almond Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827200","Ambrette Seed Oil","C107260","The oil extracted from the seeds of Abelmoschus moschatus. Ambrette seed oil is used for aches and stiffness and for its aromatic properties.","Ambrette Seed Oil | AMBRETTE SEED OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831548","Amomum villosum Leaf Oil","C107261","The essential oil of Amomum villosum. Black cardamom oil is used for treatment of the digestive tract.","Amomum villosum Leaf Oil | AMOMUM VILLOSUM LEAF OIL | Black Cardamom Oil | WURFBAINIA VILLOSA LEAF OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3256343","Angelica Root Oil","C107262","The oil extracted from the roots of Angelica archangelica. Angelica root oil is used in aromatherapy and to stimulate the immune system.","Angelica Root Oil | ANGELICA ROOT OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811841","Edwards County, KS","C108599","No value exists.","Edwards County, KS | Edwards County | Edwards County, Kansas | KS047",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812828","Elk County, KS","C108600","No value exists.","Elk County, KS | Elk County | Elk County, Kansas | KS049",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812830","Ellis County, KS","C108601","No value exists.","Ellis County, KS | Ellis County | Ellis County, Kansas | KS051",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830320","Ellsworth County, KS","C108602","No value exists.","Ellsworth County, KS | Ellsworth County | Ellsworth County, Kansas | KS053",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830114","Finney County, KS","C108603","No value exists.","Finney County, KS | Finney County | Finney County, Kansas | KS055",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811801","RNF43 wt Allele","C107650","Human RNF43 wild-type allele is located in the vicinity of 17q23.2 and is approximately 65 kb in length. This allele, which encodes E3 ubiquitin-protein ligase RNF43 protein, plays a role in both signaling and protein ubiquitination.","RNF43 wt Allele | DKFZp781H0392 | FLJ20315 | RNF124 | Ring Finger Protein 43 wt Allele | SSPCS | URCC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1566185","E3 Ubiquitin-Protein Ligase RNF43, Human","C107651","E3 ubiquitin-protein ligase RNF43 (783 aa, ~86 kDa) is encoded by the human RNF43 gene. This protein is involved in the modulation of both Wnt signaling and protein ubiquitination.","E3 Ubiquitin-Protein Ligase RNF43 | EC 2.3.2.27 | EC 6.3.2.-, Formerly | RING Finger Protein 124 | RING-Type E3 Ubiquitin Transferase RNF43 | Ring Finger Protein 43",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813714","RPL5 wt Allele","C107653","Human RPL5 wild-type allele is located in the vicinity of 1p22.1 and is approximately 10 kb in length. This allele, which encodes 60S ribosomal protein L5, is involved in the formation of the 60S ribosome. Mutation of the gene is associated with Diamond-Blackfan anemia 6.","RPL5 wt Allele | DBA6 | L5 | MSTP030 | PPP1R135 | Protein Phosphatase 1, Regulatory Subunit 135 Gene | Ribosomal Protein L5 wt Allele | uL18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2933718","ribosomal protein L5, human","C107654","60S ribosomal protein L5 (297 aa, ~34 kDa) is encoded by the human RPL5 gene. This protein plays a role in both ribosome formation and RNA binding.","60S Ribosomal Protein L5 | Large Ribosomal Subunit Protein uL18 | RPL5 | Ribosomal Protein L5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813175","POT1 wt Allele","C107656","Human POT1 wild-type allele is located in the vicinity of 7q31.33 and is approximately 108 kb in length. This allele, which encodes protection of telomeres protein 1, is involved in the positive regulation of telomerase.","POT1 wt Allele | CMM10 | DKFZp586D211 | GLM9 | HPOT1 | Protection of Telomeres 1 Homolog (S. pombe) Gene | Protection of Telomeres 1 wt Allele | hPot1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813174","POT1 protein, human","C107657","Protection of telomeres protein 1 (634 aa, ~71 kDa) is encoded by the human POT1 gene. This protein plays a role in telomere maintenance.","Protection of Telomeres Protein 1 | POT1 | POT1-Like Telomere End-Binding Protein | Protection of Telomeres 1 Homolog | hPot1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811752","CNOT3 wt Allele","C107659","Human CNOT3 wild-type allele is located in the vicinity of 19q13.4 and is approximately 18 kb in length. This allele, which encodes CCR4-NOT transcription complex subunit 3 protein, plays a role in RNA processing, translational regulation and transcriptional regulation.","CNOT3 wt Allele | CCR4-NOT Transcription Complex, Subunit 3 wt Allele | KIAA0691 | LENG2 | NOT3 | NOT3 (Negative Regulator of Transcription 3, Yeast) Homolog Gene | NOT3H | Negative Regulator of Transcription 3, S. cerevisiae, Homolog of, Gene | XXbac-BCX105G6.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828687","Ouachita County, AR","C107850","No value exists.","Ouachita County, AR | AR103 | Ouachita County | Ouachita County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0304138","Hops Oil","C107315","The essential oil of Humulus lupulus. Hops oil has antimicrobial and antiseptic properties and is also reported to have diuretic and sedative effect.","Hops Oil | HOPS OIL | Hops Flower Essential Oil",,,,,,,,,,,,,,,"4031688","Oil of hops",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829665","Horehound Oil","C107316","The essential oil of Marrubium vulgare. Horehound oil is used typically in expectorants and cough suppressants.","Horehound Oil | HOREHOUND OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829545","BOSWELLIA SERRATA RESIN OIL","C107317","The oil extracted from the resin of various Boswellia species. Frankincense oil is used in perfumes, cosmetics, and pharmaceuticals.","Indian Frankincense Oil | INDIAN FRANKINCENSE OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0064161","Jojoba Oil","C107318","The oil extracted from the seeds of Simmondsia chinensis. Jojoba oil is used primarily in cosmetics.","Jojoba Oil | JOJOBA OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829434","Kanuka Oil","C107319","The essential oil of Leptospermum (Kunzea) ericoides. Kanuka oil has anti-fungal and anti-inflammatory properties and is used in skincare preparations.","Kanuka Oil | KANUKA OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0991843","Lanolin Oil","C107320","The liquid phase oil separated from lanolin. Lanolin oil is used primarily in skin care products.","Lanolin Oil | LANOLIN OIL | Wool Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0304108","Lemon Oil","C107321","The oil extracted from the fruit peel of Citrus limon. Lemon oil is used as a flavoring and for its aromatic qualities. It is also said to have many medicinal purposes.","Lemon Oil | LEMON OIL, COLD PRESSED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3255847","Levant Cottonseed Oil","C107322","The oil extracted from the seeds of Gossypium herbaceum. Levant cottonseed oil is a source of gossypol and has antispermacidal activity.","Levant Cottonseed Oil | LEVANT COTTONSEED OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1533371","Lime Oil","C107323","The oil extracted from the fruit peel of Citrus aurantifolia. Lime oil can be taken as an antioxidant and may help support immune health. Additionally, it is used as a flavoring agent.","Lime Oil | LIME OIL, COLD PRESSED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023754","Linseed Oil","C107324","The oil extracted from the seeds of Linum usitatissimum. Linseed oil is used as a nutritional supplement and as a polymerizing resin.","Linseed Oil | Flaxseed Oil | LINSEED OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3255699","Lovage Oil","C107325","The essential oil of Levisticum officinale or the oil extracted from its roots. The leaf oil is used for the treatment of digestive ailments and in skincare.","Lovage Oil | LOVAGE OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829233","Mace Oil","C107326","The essential oil of the nutmeg (Myristica fragrans). Mace oil is used as a flavoring and in pharmaceuticals for its analgesic, antispasmodic, laxative, and stimulant activities.","Mace Oil | MACE OIL | Mace Essential Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3255955","Mango Seed Oil","C107327","The oil extracted from the kernel of Mangifera indica. Mango seed oil is typically used in skincare preparations.","Mango Seed Oil | MANGO SEED OIL | Mango Butter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3486642","Manuka Oil","C107328","The essential oil of Leptospermum scoparium. Manuka oil has anti-fungal and anti-inflammatory properties and is used in skincare preparations.","Manuka Oil | MANUKA OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3256058","Melaleuca quinquenervia leaf oil","C107329","The essential oil of Melaleuca quinquenervia. Melaleuca quinquenervia oil has antiseptic and antibacterial properties and is used in cosmetic products.","Melaleuca quinquenervia Leaf Oil | Cajeput Oil | MELALEUCA QUINQUENERVIA LEAF OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0065939","Menhaden Oil","C107330","The oil extracted from various Brevoortia and Ethmidium species. Menhaden oil is used industrially in paint production and the tanning of leather as was as in livestock feeds.","Menhaden Oil | MENHADEN OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830141","FGFR2 NM_000141.4:c.1647T>A","C107598","A nucleotide substitution at position 1647 of the coding sequence of the FGFR2 gene where thymine has been mutated to adenine.","FGFR2 NM_000141.4:c.1647T>A | BEK c.1647T>A | CD332 c.1647T>A | ECT1 c.1647T>A | FGFR2 c.1647T>A | Fibroblast Growth Factor Receptor 2 c.1647T>A | K-SAM c.1647T>A | KGFR c.1647T>A | NM_000141.4:c.1647T>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830140","FGFR2 NM_000141.4:c.1647T>G","C107599","A nucleotide substitution at position 1647 of the coding sequence of the FGFR2 gene where thymine has been mutated to guanine.","FGFR2 NM_000141.4:c.1647T>G | BEK c.1647T>G | CD332 c.1647T>G | ECT1 c.1647T>G | FGFR2 c.1647T>G | Fibroblast Growth Factor Receptor 2 c.1647T>G | K-SAM c.1647T>G | KGFR c.1647T>G | NM_000141.4:c.1647T>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0058725","Doxorubicin-DNA Complex","C1075","A complex comprised of Doxorubicin linked to DNA to enhance the topoisomerase II-mediated interaction with the DNA base pairs and reduce cardiotoxicity associated with anthracyclines. (NCI)","Doxorubicin-DNA Complex | Adriamycin-DNA Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0438971","Other Asian","C107601","A person having origins in the original peoples of Asia, but not China, India, Korea, the Philippine Islands or Vietnam.","Other Asian | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830142","FGFR2 NM_000141.4:c.1645A>C","C107603","A nucleotide substitution at position 1645 of the coding sequence of the FGFR2 gene where cytosine has been mutated to guanine.","FGFR2 NM_000141.4:c.1645A>C | BEK c.1645A>C | CD332 c.1645A>C | ECT1 c.1645A>C | FGFR2 c.1645A>C | Fibroblast Growth Factor Receptor 2 c.1645A>C | K-SAM c.1645A>C | KGFR c.1645A>C | NM_000141.4:c.1645A>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830976","Crowley County, CO","C107945","No value exists.","Crowley County, CO | CO025 | Crowley County | Crowley County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813315","Custer County, CO","C107946","No value exists.","Custer County, CO | CO027 | Custer County | Custer County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830538","Denver County, CO","C107948","No value exists.","Denver County, CO | CO031 | Denver County | Denver County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830408","Dolores County, CO","C107949","No value exists.","Dolores County, CO | CO033 | Dolores County | Dolores County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811826","Douglas County, CO","C107950","No value exists.","Douglas County, CO | CO035 | Douglas County | Douglas County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830365","Eagle County, CO","C107951","No value exists.","Eagle County, CO | CO037 | Eagle County | Eagle County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811307","El Paso County, CO","C107953","No value exists.","El Paso County, CO | CO041 | El Paso County | El Paso County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814030","Fremont County, CO","C107954","No value exists.","Fremont County, CO | CO043 | Fremont County | Fremont County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449599","Anti-5T4 Antibody-Drug Conjugate PF-06263507","C107388","An antibody-drug conjugate composed of an antibody directed against 5T4 and conjugated, via the stable linker maleimidocaproyl (mc), to the microtubule inhibitor monomethyl auristatin phenylalanine (MMAF), with potential antineoplastic activity. Upon administration, the antibody moiety of PF-06263507 selectively binds to cells expressing the 5T4 oncofetal antigen. After internalization and enzymatic cleavage of the immunoconjugate within the tumor cell cytosol, free MMAF binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. 5T4, a transmembrane glycoprotein, is overexpressed by a variety of cancer cell types; its expression is correlated with increased invasiveness.","Anti-5T4 Antibody-Drug Conjugate PF-06263507 | PF-06263507",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016895","Monosialotetrahexosylganglioside","C107389","A glycosphingolipid containing a sialic acid residue found in neuronal cell membranes, with potential neuroprotective and neuroregenerative activities. Upon administration, monosialotetrahexosylganglioside, also called GM-1, is able to both prevent neurologic damage and induce regeneration of damaged neurons through neurotrophic repair mechanisms, enhancement of the production of neutrophins, and augmenting neurite outgrowth. In addition, GM-1 exerts anti-excitotoxic activity, prevents necrosis, and improves neuronal recovery and function.","Monosialotetrahexosylganglioside | GANGLIOSIDE GM1 | GM-1 | GM1 | Ganglioside GM-1 | Monosialoanglioside GM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831568","Allamakee County, IA","C108479","No value exists.","Allamakee County, IA | Allamakee County | Allamakee County, Iowa | IA005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831506","Appanoose County, IA","C108480","No value exists.","Appanoose County, IA | Appanoose County | Appanoose County, Iowa | IA007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831172","CCR4-NOT Transcription Complex Subunit 3","C107660","CCR4-NOT transcription complex subunit 3 (753 aa, ~82 kDa) is encoded by the human CNOT3 gene. This protein is involved in transcriptional regulation, RNA processing and translational regulation.","CCR4-NOT Transcription Complex Subunit 3 | CCR4-Associated Factor 3 | CNOT3 | Leukocyte Receptor Cluster Member 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815273","STRN wt Allele","C107662","Human STRN wild-type allele is located in the vicinity of 2p22.2 and is approximately 123 kb in length. This allele, which encodes striatin protein, maybe involved in calcium signaling or cell junction formation.","STRN wt Allele | SG2NA | Striatin, Calmodulin Binding Protein wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814475","Striatin, Human","C107663","Striatin (780 aa, ~86 kDa) is encoded by the human STRN gene. This protein may play a role in calcium-mediated signaling.","Striatin | STRN | Striatin, Calmodulin Binding Protein | Striatin, Calmodulin-Binding Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814517","Taylor County, FL","C108069","No value exists.","Taylor County, FL | FL123 | Taylor County | Taylor County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813226","Union County, FL","C108070","No value exists.","Union County, FL | FL125 | Union County | Union County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827542","Volusia County, FL","C108071","No value exists.","Volusia County, FL | FL127 | Volusia County | Volusia County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827525","Wakulla County, FL","C108072","No value exists.","Wakulla County, FL | FL129 | Wakulla County | Wakulla County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812769","Walton County, FL","C108073","No value exists.","Walton County, FL | FL131 | Walton County | Walton County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813246","Washington County, FL","C108074","No value exists.","Washington County, FL | FL133 | Washington County | Washington County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831505","Appling County, GA","C108075","No value exists.","Appling County, GA | Appling County | Appling County, Georgia | GA001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831459","Atkinson County, GA","C108076","No value exists.","Atkinson County, GA | Atkinson County | Atkinson County, Georgia | GA003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831424","Bacon County, GA","C108077","No value exists.","Bacon County, GA | Bacon County | Bacon County, Georgia | GA005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815632","Baldwin County, GA","C108079","No value exists.","Baldwin County, GA | Baldwin County | Baldwin County, Georgia | GA009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831415","Banks County, GA","C108080","No value exists.","Banks County, GA | Banks County | Banks County, Georgia | GA011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831402","Bartow County, GA","C108082","No value exists.","Bartow County, GA | Bartow County | Bartow County, Georgia | GA015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831369","Ben Hill County, GA","C108083","No value exists.","Ben Hill County, GA | Ben Hill County | Ben Hill County, Georgia | GA017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814102","Berrien County, GA","C108084","No value exists.","Berrien County, GA | Berrien County | Berrien County, Georgia | GA019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811074","Bibb County, GA","C108085","No value exists.","Bibb County, GA | Bibb County | Bibb County, Georgia | GA021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831334","Bleckley County, GA","C108086","No value exists.","Bleckley County, GA | Bleckley County | Bleckley County, Georgia | GA023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3256062","Mentha arvensis Flower Oil","C107331","The essential oil of Mentha arvensis, the field mint. Mentha arvensis flower oil is used as a flavoring and can also be used for the treatment of skin problems.","Mentha arvensis Flower Oil | MENTHA ARVENSIS FLOWER OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0066969","Mustard Oil","C107332","The vegetable oil pressed from seeds or the essential oil extracted from the seeds of Brassica nigra, Brassica juncea, or Brassica hirta. Mustard oil is used as a cooking oil, a source of omega-3 fatty acids, and in various medicinal preparations.","Mustard Oil | MUSTARD OIL",,,,,,,,,,,,,,,"4096922","Oil of mustard",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828728","Ogle County, IL","C108353","No value exists.","Ogle County, IL | IL141 | Ogle County | Ogle County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828610","Peoria County, IL","C108354","No value exists.","Peoria County, IL | IL143 | Peoria County | Peoria County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814109","Perry County, IL","C108355","No value exists.","Perry County, IL | IL145 | Perry County | Perry County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828561","Piatt County, IL","C108356","No value exists.","Piatt County, IL | IL147 | Piatt County | Piatt County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812265","Pope County, IL","C108358","No value exists.","Pope County, IL | IL151 | Pope County | Pope County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811851","Pulaski County, IL","C108359","No value exists.","Pulaski County, IL | IL153 | Pulaski County | Pulaski County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812299","Putnam County, IL","C108360","No value exists.","Putnam County, IL | IL155 | Putnam County | Putnam County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812313","Randolph County, IL","C108361","No value exists.","Randolph County, IL | IL157 | Randolph County | Randolph County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828309","Rock Island County, IL","C108363","No value exists.","Rock Island County, IL | IL161 | Rock Island County | Rock Island County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814052","St. Clair County, IL","C108364","No value exists.","St. Clair County, IL | IL163 | St. Clair County | St. Clair County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811225","Saline County, IL","C108365","No value exists.","Saline County, IL | IL165 | Saline County | Saline County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828254","Sangamon County, IL","C108366","No value exists.","Sangamon County, IL | IL167 | Sangamon County | Sangamon County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811792","Schuyler County, IL","C108367","No value exists.","Schuyler County, IL | IL169 | Schuyler County | Schuyler County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815243","Shelby County, IL","C108369","No value exists.","Shelby County, IL | IL173 | Shelby County | Shelby County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814063","Stark County, IL","C108370","No value exists.","Stark County, IL | IL175 | Stark County | Stark County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827939","Stephenson County, IL","C108371","No value exists.","Stephenson County, IL | IL177 | Stephenson County | Stephenson County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815208","Tazewell County, IL","C108372","No value exists.","Tazewell County, IL | IL179 | Tazewell County | Tazewell County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827653","Vermilion County, IL","C108374","No value exists.","Vermilion County, IL | IL183 | Vermilion County | Vermilion County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812765","Wabash County, IL","C108375","No value exists.","Wabash County, IL | IL185 | Wabash County | Wabash County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812776","Warren County, IL","C108376","No value exists.","Warren County, IL | IL187 | Warren County | Warren County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811313","Washington County, IL","C108377","No value exists.","Washington County, IL | IL189 | Washington County | Washington County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814495","Garfield County, CO","C107955","No value exists.","Garfield County, CO | CO045 | Garfield County | Garfield County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829979","Gilpin County, CO","C107956","No value exists.","Gilpin County, CO | CO047 | Gilpin County | Gilpin County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813972","Grand County, CO","C107957","No value exists.","Grand County, CO | CO049 | Grand County | Grand County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829693","Hinsdale County, CO","C107959","No value exists.","Hinsdale County, CO | CO053 | Hinsdale County | Hinsdale County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829598","Huerfano County, CO","C107960","No value exists.","Huerfano County, CO | CO055 | Huerfano County | Huerfano County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816474","Jackson County, CO","C107961","No value exists.","Jackson County, CO | CO057 | Jackson County | Jackson County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810768","Jefferson County, CO","C107962","No value exists.","Jefferson County, CO | CO059 | Jefferson County | Jefferson County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810796","Kiowa County, CO","C107963","No value exists.","Kiowa County, CO | CO061 | Kiowa County | Kiowa County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813635","Lake County, CO","C107965","No value exists.","Lake County, CO | CO065 | Lake County | Lake County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829331","La Plata County, CO","C107966","No value exists.","La Plata County, CO | CO067 | La Plata County | La Plata County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829327","Larimer County, CO","C107967","No value exists.","Larimer County, CO | CO069 | Larimer County | Larimer County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829322","Las Animas County, CO","C107968","No value exists.","Las Animas County, CO | CO071 | Las Animas County | Las Animas County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814092","Lincoln County, CO","C107969","No value exists.","Lincoln County, CO | CO073 | Lincoln County | Lincoln County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829123","Mesa County, CO","C107971","No value exists.","Mesa County, CO | CO077 | Mesa County | Mesa County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810694","Mineral County, CO","C107972","No value exists.","Mineral County, CO | CO079 | Mineral County | Mineral County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828983","Moffat County, CO","C107973","No value exists.","Moffat County, CO | CO081 | Moffat County | Moffat County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828967","Montezuma County, CO","C107974","No value exists.","Montezuma County, CO | CO083 | Montezuma County | Montezuma County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828964","Montrose County, CO","C107975","No value exists.","Montrose County, CO | CO085 | Montrose County | Montrose County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812814","Otero County, CO","C107977","No value exists.","Otero County, CO | CO089 | Otero County | Otero County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449598","BP-Cx1-Platinum Complex BP-C1","C107387","A combination agent composed of the benzo-poly-carbonic-acid polymer BP-Cx1 chelated to platinum with potential antineoplastic activity. Upon intramuscular injection, the polymer moiety of BP-Cx1-Platinum Complex BP-C1 (BP-C1) alters the permeability of the cell membranes, which allows for increased penetration of platinum into tumor cells. In turn, platinum binds to nucleophilic groups such as GC-rich sites in DNA and induces intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition. In addition, the BP-Cx1 ligand is able to stimulate the innate immune system and upregulates a variety of cytokines including interferon, tumor necrosis factor-alpha (TNF-alpha), granulocyte macrophage-colony stimulating factor (GM-CSF), and various interleukins (ILs) such as IL-6 and IL-25. In comparison to cisplatin and other platinum-based compounds, treatment with BP-C1 allows for less platinum administration, which reduces platinum-associated systemic toxicity and side effects, and enhances the safety profile while maintaining or improving its efficacy.","BP-Cx1-Platinum Complex BP-C1 | BP-C1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827214","Audubon County, IA","C108481","No value exists.","Audubon County, IA | Audubon County | Audubon County, Iowa | IA009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815926","Benton County, IA","C108482","No value exists.","Benton County, IA | Benton County | Benton County, Iowa | IA011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831344","Black Hawk County, IA","C108483","No value exists.","Black Hawk County, IA | Black Hawk County | Black Hawk County, Iowa | IA013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812161","Boone County, IA","C108484","No value exists.","Boone County, IA | Boone County | Boone County, Iowa | IA015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813135","Buchanan County, IA","C108486","No value exists.","Buchanan County, IA | Buchanan County | Buchanan County, Iowa | IA019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831250","Buena Vista County, IA","C108487","No value exists.","Buena Vista County, IA | Buena Vista County | Buena Vista County, Iowa | IA021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813139","Butler County, IA","C108488","No value exists.","Butler County, IA | Butler County | Butler County, Iowa | IA023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813955","Calhoun County, IA","C108489","No value exists.","Calhoun County, IA | Calhoun County | Calhoun County, Iowa | IA025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815115","Carroll County, IA","C108490","No value exists.","Carroll County, IA | Carroll County | Carroll County, Iowa | IA027",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813705","Cedar County, IA","C108492","No value exists.","Cedar County, IA | Cedar County | Cedar County, Iowa | IA031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831149","Cerro Gordo County, IA","C108493","No value exists.","Cerro Gordo County, IA | Cerro Gordo County | Cerro Gordo County, Iowa | IA033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814766","Cherokee County, IA","C108494","No value exists.","Cherokee County, IA | Cherokee County | Cherokee County, Iowa | IA035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814770","Chickasaw County, IA","C108495","No value exists.","Chickasaw County, IA | Chickasaw County | Chickasaw County, Iowa | IA037",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815927","Clay County, IA","C108497","No value exists.","Clay County, IA | Clay County | Clay County, Iowa | IA041",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811083","Clayton County, IA","C108498","No value exists.","Clayton County, IA | Clayton County | Clayton County, Iowa | IA043",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811101","Clinton County, IA","C108499","No value exists.","Clinton County, IA | Clinton County | Clinton County, Iowa | IA045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0059386","enterotoxin B, staphylococcal","C1084","A bacterial enterotoxin with potential immunostimulatory activity. Staphylococcal enterotoxin B (SEB), a gram positive superantigen produced by Staphylococcus aureus, is a potent stimulator of T-cell activation. SEB binds directly to class II major histocompatibility complex (MHC) molecules and the V beta region of the T-cell receptor (TCR), leading to an amplified T-cell response. In response to SEB, both CD4+ and CD8+ cells proliferate, secrete cytokines and demonstrate enhanced cytotoxic activity against a broad range of antigens. Co-administration of SEB with interleukin-2 (IL-2) by direct injection into tumor cells, may induce clonal T-cell expansion and potentiate apoptosis of tumor cells, resulting in decreased tumor growth.","Staphylococcal Enterotoxin B | SEB | STAPHYLOCOCCAL ENTEROTOXIN B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813149","Crawford County, IA","C108500","No value exists.","Crawford County, IA | Crawford County | Crawford County, Iowa | IA047",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815128","Davis County, IA","C108502","No value exists.","Davis County, IA | Davis County | Davis County, Iowa | IA051",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811305","Decatur County, IA","C108503","No value exists.","Decatur County, IA | Decatur County | Decatur County, Iowa | IA053",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815526","Delaware County, IA","C108504","No value exists.","Delaware County, IA | Delaware County | Delaware County, Iowa | IA055",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830530","Des Moines County, IA","C108505","No value exists.","Des Moines County, IA | Des Moines County | Des Moines County, Iowa | IA057",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812653","Brooks County, GA","C108088","No value exists.","Brooks County, GA | Brooks County | Brooks County, Georgia | GA027",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812662","Bryan County, GA","C108089","No value exists.","Bryan County, GA | Bryan County | Bryan County, Georgia | GA029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831249","Bulloch County, GA","C108090","No value exists.","Bulloch County, GA | Bulloch County | Bulloch County, Georgia | GA031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813138","Burke County, GA","C108091","No value exists.","Burke County, GA | Burke County | Burke County, Georgia | GA033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831239","Butts County, GA","C108092","No value exists.","Butts County, GA | Butts County | Butts County, Georgia | GA035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814103","Camden County, GA","C108094","No value exists.","Camden County, GA | Camden County | Camden County, Georgia | GA039",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831210","Candler County, GA","C108095","No value exists.","Candler County, GA | Candler County | Candler County, Georgia | GA043",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814104","Carroll County, GA","C108096","No value exists.","Carroll County, GA | Carroll County | Carroll County, Georgia | GA045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831180","Catoosa County, GA","C108097","No value exists.","Catoosa County, GA | Catoosa County | Catoosa County, Georgia | GA047",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827282","Charlton County, GA","C108098","No value exists.","Charlton County, GA | Charlton County | Charlton County, Georgia | GA049",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1452189","Sulfotransferase 1A1, Human","C107443","Sulfotransferase 1A1 (295 aa, ~34 kDa) is encoded by the human SULT1A1 gene. This protein is involved in the sulfate conjugation of catecholamines, phenolic drugs and neurotransmitters.","Sulfotransferase 1A1 | Aryl Sulfotransferase 1 | EC 2.8.2.1 | HAST1/HAST2 | P-PST | Phenol Sulfotransferase 1 | Phenol-Sulfating Phenol Sulfotransferase 1 | ST1A3 | SULT1A1 | Thermostable Phenol Sulfotransferase | Thermostable Phenol Sulfotransferase1 | Ts-PST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815276","CSNK2B wt Allele","C107445","Human CSNK2B wild-type allele is located in the vicinity of 6p21.33 and is approximately 5 kb in length. This allele, which encodes casein kinase II subunit beta protein, is involved in the regulation of casein kinase II.","CSNK2B wt Allele | CK2B | CK2N | CSK2B | Casein Kinase 2, Beta Polypeptide wt Allele | G5A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814454","Casein Kinase II Subunit Beta","C107446","Casein kinase II subunit beta (215 aa, ~25 kDa) is encoded by the human CSNK2B gene. This protein plays a role in the regulation of casein kinase II.","Casein Kinase II Subunit Beta | CK II Beta | Casein Kinase II Beta Subunit | G5a, Phosvitin | Phosvitin | Protein G5a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830060","GABRG1 wt Allele","C107448","Human GABRG1 wild-type allele is located in the vicinity of 4p12 and is approximately 88 kb in length. This allele, which encodes gamma-aminobutyric acid receptor subunit gamma-1 protein, plays a role in mediating neuronal inhibition.","GABRG1 wt Allele | Gamma-Aminobutyric Acid (GABA) A Receptor, Gamma 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2353676","Gamma-Aminobutyric Acid Receptor Subunit Gamma-1, Human","C107449","Gamma-aminobutyric acid receptor subunit gamma-1 (465 aa, ~54 kDa) is encoded by the human GABRG1 gene. This protein is involved in mediating neuronal inhibition.","Gamma-Aminobutyric Acid Receptor Subunit Gamma-1 | GABA(A) Receptor Subunit Gamma-1 | GABA(A) Receptor, Gamma | Gamma-1 Polypeptide | Gamma-Aminobutyric Acid Receptor Subunit Gamma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810722","White County, IL","C108379","No value exists.","White County, IL | IL193 | White County | White County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827471","Whiteside County, IL","C108380","No value exists.","Whiteside County, IL | IL195 | Whiteside County | Whiteside County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827461","Will County, IL","C108381","No value exists.","Will County, IL | IL197 | Will County | Will County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810733","Williamson County, IL","C108382","No value exists.","Williamson County, IL | IL199 | Williamson County | Williamson County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810741","Winnebago County, IL","C108383","No value exists.","Winnebago County, IL | IL201 | Winnebago County | Winnebago County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810639","Russell County, KS","C108659","No value exists.","Russell County, KS | KS167 | Russell County | Russell County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811226","Saline County, KS","C108660","No value exists.","Saline County, KS | KS169 | Saline County | Saline County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814860","Sedgwick County, KS","C108662","No value exists.","Sedgwick County, KS | KS173 | Sedgwick County | Sedgwick County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815239","Seward County, KS","C108663","No value exists.","Seward County, KS | KS175 | Seward County | Seward County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828034","Shawnee County, KS","C108664","No value exists.","Shawnee County, KS | KS177 | Shawnee County | Shawnee County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815251","Sheridan County, KS","C108665","No value exists.","Sheridan County, KS | KS179 | Sheridan County | Sheridan County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811210","Smith County, KS","C108667","No value exists.","Smith County, KS | KS183 | Smith County | Smith County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814061","Stanton County, KS","C108669","No value exists.","Stanton County, KS | KS187 | Stanton County | Stanton County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL451868","Rovalpituzumab Tesirine","C107678","An antibody-drug conjugate (ADC) containing a humanized IgG1 monoclonal antibody (MAb) directed against the delta-like protein 3 (DLL3), conjugated to the cytotoxic pyrrolobenzodiazepine (PBD) dimer D6.5 (SC-DR002) via a maleimide-containing linker with an eight-carbon polyethylene glycol spacer and a cathepsin B-cleavable valine-alanine dipeptide, with potential antineoplastic activity. The MAb moiety of rovalpituzumab tesirine selectively binds to DLL3 on tumor cell surfaces. Upon internalization of the ADC, the dipeptide linker is cleaved and D6.5 is released. Then the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of DLL3-overexpressing tumor cells. DLL3, a membrane protein that binds to Notch receptors and regulates Notch-mediated signaling and gene transcription, is overexpressed by certain cancers but is rarely expressed by normal, healthy cells.","Rovalpituzumab Tesirine | ROVALPITUZUMAB TESIRINE | Rova-T | SC16LD6.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL451869","Liposomal Rhenium Re 186",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1435750","Melphalan Flufenamide","C107680","A peptide-drug conjugate composed of a peptide conjugated, via an aminopeptidase-targeting linkage, to the alkylating agent melphalan, with potential antineoplastic and anti-angiogenic activities. Upon administration, the highly lipophilic melphalan flufenamide penetrates cell membranes and enters cells. In aminopeptidase-positive tumor cells, melphalan flufenamide is hydrolyzed by peptidases to release the hydrophilic alkylating agent melphalan. This results in the specific release and accumulation of melphalan in aminopeptidase-positive tumor cells. Melphalan alkylates DNA at the N7 position of guanine residues and induces DNA intra- and inter-strand cross-linkages. This results in the inhibition of DNA and RNA synthesis and the induction of apoptosis, thereby inhibiting tumor cell proliferation. Peptidases are overexpressed by certain cancer cells. The administration of melphalan flufenamide allows for enhanced efficacy and reduced toxicity compared to melphalan.","Melphalan Flufenamide | Ethyl (2S)-2-((2S)-2-Amino-3-(4-(bis(2-chloroethyl)amino)phenyl)propanamido)-3-(4-fluorophenyl)propanoate | J-1 | J1 | L-melphalanyl-p-L-fluorophenylalanine Ethyl Ester | MELPHALAN FLUFENAMIDE | Melflufen | Melphalan flufenamide | Prodrug J1 | Ygalo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830139","FGFR2 NM_000141.4:c.1975A>G","C107605","A nucleotide substitution at position 1975 of the coding sequence of the FGFR2 gene where adenine has been mutated to guanine.","FGFR2 NM_000141.4:c.1975A>G | BEK c.1975A>G | CD332 c.1975A>G | ECT1 c.1975A>G | FGFR2 c.1975A>G | Fibroblast Growth Factor Receptor 2 c.1975A>G | K-SAM c.1975A>G | KGFR c.1975A>G | NM_000141.4:c.1975A>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829110","Mexican or Mexican American","C107607","A person of Mexican or Mexican American culture or origin, regardless of race.","Mexican or Mexican American | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828691","Other Hispanic or Latino(a)","C107609","A person of Spanish culture or origin, but not Cuban, Mexican, Puerto Rican, South or Central American, regardless of race.","Other Hispanic or Latino(a) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810580","SPINT1 wt Allele","C107611","Human SPINT1 wild-type allele is located in the vicinity of 15q15.1 and is approximately 14 kb in length. This allele, which encodes Kunitz-type protease inhibitor 1 protein, is involved in both the inhibition of proteolysis and the modulation of growth factor signaling.","SPINT1 wt Allele | HAI | HAI1 | MANSC2 | Serine Peptidase Inhibitor, Kunitz Type 1 wt Allele | UNQ223/PRO256",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0668015","Kunitz-Type Protease Inhibitor 1, Human","C107612","Kunitz-type protease inhibitor 1 (529 aa, ~58 kDa) is encoded by the human SPINT1 gene. This protein plays a role in both growth factor signaling and the regulation of protease activity.","Kunitz-Type Protease Inhibitor 1 | Hepatocyte Growth Factor Activator Inhibitor | Hepatocyte Growth Factor Activator Inhibitor Type 1 | SPINT1 | Serine Protease Inhibitor, Kunitz Type 1 | Serine Protease Inhibitor, Kunitz-Type, 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811649","ADRA2C wt Allele","C107614","Human ADRA2C wild-type allele is located in the vicinity of 4p16 and is approximately 2 kb in length. This allele, which encodes alpha-2C adrenergic receptor protein, plays a role in the inhibition of G protein-coupled receptor-mediated adenylate cyclase activity.","ADRA2C wt Allele | ADRA2L2 | ADRA2RL2 | ADRARL2 | ALPHA2CAR | Adrenergic, Alpha-2C-, Receptor Gene | Adrenoceptor Alpha 2C wt Allele | Alpha2-AR-C4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2932445","Alpha-2C Adrenergic Receptor, human","C107615","Alpha-2C adrenergic receptor (462 aa, ~50 kDa) is encoded by the human ADRA2C gene. This protein is involved in catecholamine-induced regulation of adenylate cyclase signaling.","Alpha-2C Adrenergic Receptor | Alpha-2 Adrenergic Receptor Subtype C4 | Alpha-2C Adrenoceptor | Alpha-2C Adrenoreceptor | Alpha-2C-Adrenergic Receptor | Alpha-2CAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3473403","Angelica Seed Oil","C107263","The oil extracted from the seeds of Angelica archangelica. Angelica seed oil is used primarily in aromatherapy.","Angelica Seed Oil | ANGELICA SEED OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449517","Apricot Kernel Oil","C107264","The oil cold-pressed from the dried seeds of the fruit of the apricot tree. Apricot kernel oil is used for frying and cooking, in the cosmetic industry, and for skin care.","Apricot Kernel Oil | APRICOT KERNEL OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2975054","Argan Oil","C107265","The oil extracted from the kernels of Argania spinosa. Moroccan oil is used as a food ingredient and for cosmetic purposes.","Argan Oil | ARGAN OIL | Moroccan Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831470","Asafetida Oil","C107266","The oily resin obtained from the rhizomes of Ferula species, especially Ferula asafoetida. Asafetida oil is used as a flavoring and in medicinal preparations.","Asafetida Oil | Asant | Devil's Dung | FERULA ASSA-FOETIDA OIL | Giant Fennel Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3265002","Avocado Oil","C107267","The oil extracted from the fruits of Persea americana. Avocado oil is used is used as a food ingredient, as a cooking oil, and for lubrication and in cosmetics.","Avocado Oil | AVOCADO OIL",,,,,,,,,,,,,,,"35621799","Avocado oil unsaponifiables",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3831425","Backhousia citriodora Leaf Oil","C107268","The essential oil of Backhousia citriodora. One form of lemonmyrtle oil is used as a flavoring or for its aromatic properties. The other form of lemon myrtle oil is used in the production of citronella.","Backhousia citriodora Leaf Oil | BACKHOUSIA CITRIODORA LEAF OIL | Lemon Myrtle Oil | Sweet Verbena Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1178058","Balsam Peru Oil","C107269","The essentail oil of Myroxylon balsamum. Balsam peru oil is used primarily in parfumery and skin care preparations.","Balsam Peru Oil | BALSAM PERU OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831391","Bay Fruit Oil","C107270","The oil extracted from the fruit of Laurus nobilis. Bay fruit oil can be used for its anti-rheumatism effects.","Bay Fruit Oil | BAY FRUIT OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0301250","Bitter Almond Oil","C107272","The oil extracted from the seed press-cake of Prunus amygdalus var. amara. Bitter almond oil is used as a flavoring and sweetener.","Bitter Almond Oil | BITTER ALMOND OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831346","Bitter Fennel Fruit Oil","C107273","The oil extracted from the fruit of Foeniculum vulgare. Bitter fennel fruit oil can be used as treatment for digestive complaints.","Bitter Fennel Fruit Oil | FOENICULUM VULGARE FRUIT OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0072982","Brassica napus Oil","C107274","The oil extracted from the seeds of Brassica napus. Rapeseed oil was traditionally used as an industrial lubricant but newer varieties are used for animal feed, vegetable oil for human consumption, and biodiesel.","Brassica napus Oil | BRASSICA NAPUS SUBSP. NAPUS OIL | Rapeseed Oil",,,,,,,,,,,,,,,"4037233","Rapeseed oil",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3474157","Camelina sativa Seed Oil","C107275","The oil extracted from the seeds of Camelina sativa. Camelina oil is used as vegetable oil and animal feed and was also used as a lamp oil.","Camelina sativa Seed Oil | CAMELINA SATIVA SEED OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0439966","Canaga Oil","C107276","The essential oil of Cananga odorata. Cananga oil is used primarily in aromatherapy preparations.","Canaga Oil | Cananga Oil | YLANG-YLANG OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3256827","Carapa guianensis Seed Oil","C107277","The oil extracted from the seed kernels of Carapa guianensis. Carapa oil is used as a lamp oil, in the making of soap, and for topical skin application.","Carapa guianensis Seed Oil | Brazilian Mahogany Oil | CARAPA GUIANENSIS SEED OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812834","Elmore County, ID","C108258","No value exists.","Elmore County, ID | Elmore County | Elmore County, Idaho | ID039",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814006","Franklin County, ID","C108259","No value exists.","Franklin County, ID | Franklin County | Franklin County, Idaho | ID041",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814031","Fremont County, ID","C108260","No value exists.","Fremont County, ID | Fremont County | Fremont County, Idaho | ID043",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829996","Gem County, ID","C108261","No value exists.","Gem County, ID | Gem County | Gem County, Idaho | ID045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813704","Perry County, AR","C107851","No value exists.","Perry County, AR | AR105 | Perry County | Perry County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814119","Phillips County, AR","C107852","No value exists.","Phillips County, AR | AR107 | Phillips County | Phillips County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814132","Pike County, AR","C107853","No value exists.","Pike County, AR | AR109 | Pike County | Pike County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828524","Poinsett County, AR","C107854","No value exists.","Poinsett County, AR | AR111 | Poinsett County | Poinsett County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812266","Pope County, AR","C107856","No value exists.","Pope County, AR | AR115 | Pope County | Pope County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812756","Prairie County, AR","C107857","No value exists.","Prairie County, AR | AR117 | Prairie County | Prairie County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811849","Pulaski County, AR","C107858","No value exists.","Pulaski County, AR | AR119 | Pulaski County | Pulaski County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812311","Randolph County, AR","C107859","No value exists.","Randolph County, AR | AR121 | Randolph County | Randolph County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811224","Saline County, AR","C107861","No value exists.","Saline County, AR | AR125 | Saline County | Saline County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811798","Scott County, AR","C107862","No value exists.","Scott County, AR | AR127 | Scott County | Scott County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828203","Searcy County, AR","C107863","No value exists.","Searcy County, AR | AR129 | Searcy County | Searcy County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828202","Sebastian County, AR","C107864","No value exists.","Sebastian County, AR | AR131 | Sebastian County | Sebastian County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815236","Sevier County, AR","C107865","No value exists.","Sevier County, AR | AR133 | Sevier County | Sevier County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814471","Stone County, AR","C107867","No value exists.","Stone County, AR | AR137 | Stone County | Stone County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813230","Union County, AR","C107868","No value exists.","Union County, AR | AR139 | Union County | Union County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811342","Van Buren County, AR","C107869","No value exists.","Van Buren County, AR | AR141 | Van Buren County | Van Buren County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL451870","tumor cell-derived DRibbles vaccine","C107681","An off-the-shelf (OTS) autophagosome-enriched tumor vaccine composed of dendritic cell (DC)-targeting microvesicles containing short lived proteins (SLiPs) and defective ribosomal products (DRiPs) derived from tumor cells, with potential immunostimulating and antineoplastic activities. The DriPs- and SLiPs-filled autophagosome microvesicles are made by treating two human non-small cell lung cancer (NSCLC) cell lines, UbiLT3 (non-specific histopathology) and UbiLT6 (adenocarcinoma-like) with both a proteasome inhibitor, to prevent protein degradation, and an autophagy inducer. DPV-001 contains a wide variety of NSCLC-derived TAAs, many as immunogenic altered-peptide ligands (APL), and numerous damage-associated molecular pattern molecules (DAMPs) with Toll-like receptor (TLR) 2, 3, 4, 7 and 9 agonist activities. Upon administration of allogeneic autophagosome-enriched vaccine DPV-001, the proteins in the vaccine target DCs and may stimulate the immune system to mount cytotoxic T-lymphocyte (CTL) and helper T-lymphocyte responses against the TAAs. The TAAs are overexpressed in a variety of cancer cell types other than NSCLC. The tumor-associated SLiPS and DRiPs are highly unstable and normally degraded by tumor cell proteasomes. They are typically not processed and cross-presented by antigen-presenting cells (APCs).","Allogeneic Autophagosome-enriched Vaccine DPV-001 | Allogeneic DRibble Vaccine DPV-001 | DPV 001 | DPV-001 | DPV-001 Vaccine | DPV001 | DRiPs and SLiPs-containing Blebs Vaccine DPV-001 | DRibble Vaccine DPV-001 | Dribble Cancer Vaccine DPV-001 | Dribbles Vaccine DPV-001 | Tumor-derived Autophagosomes Vaccine DPV-001 | Vaccine DPV-001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1172252","Substance P-Saporin","C107682","An agent composed of substance P (SP) conjugated to the ribosome-inactivating protein and neurotoxin saporin (SAP), isolated from the seeds of the plant Saponaria officinalis (SP-SAP), with potential analgesic activity. Upon administration, SP-SAP targets the SP receptor, neurokinin-1 receptor (NK-1R), located on neurons. When SP-SAP binds NK-1R and the receptor/conjugate complex internalizes, the saporin moiety inactivates ribosomes and prevents protein synthesis, which causes cell death, destroys NK-1R-expressing nerves and decreases pain perception.","Substance P-Saporin | SP-SAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812207","Fayette County, GA","C108130","No value exists.","Fayette County, GA | Fayette County | Fayette County, Georgia | GA113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813569","Floyd County, GA","C108131","No value exists.","Floyd County, GA | Floyd County | Floyd County, Georgia | GA115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811308","Forsyth County, GA","C108132","No value exists.","Forsyth County, GA | Forsyth County | Forsyth County, Georgia | GA117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814424","Fulton County, GA","C108134","No value exists.","Fulton County, GA | Fulton County | Fulton County, Georgia | GA121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814108","Gilmer County, GA","C108135","No value exists.","Gilmer County, GA | GA123 | Gilmer County | Gilmer County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829975","Glascock County, GA","C108136","No value exists.","Glascock County, GA | GA125 | Glascock County | Glascock County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829972","Glynn County, GA","C108137","No value exists.","Glynn County, GA | GA127 | Glynn County | Glynn County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829963","Gordon County, GA","C108138","No value exists.","Gordon County, GA | GA129 | Gordon County | Gordon County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813998","Greene County, GA","C108140","No value exists.","Greene County, GA | GA133 | Greene County | Greene County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829915","Gwinnett County, GA","C108141","No value exists.","Gwinnett County, GA | GA135 | Gwinnett County | Gwinnett County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829912","Habersham County, GA","C108142","No value exists.","Habersham County, GA | GA137 | Habersham County | Habersham County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814478","Hall County, GA","C108143","No value exists.","Hall County, GA | GA139 | Hall County | Hall County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829850","Haralson County, GA","C108145","No value exists.","Haralson County, GA | GA143 | Haralson County | Haralson County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814480","Harris County, GA","C108146","No value exists.","Harris County, GA | GA145 | Harris County | Harris County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814481","Hart County, GA","C108147","No value exists.","Hart County, GA | GA147 | Hart County | Hart County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811249","TXNRD1 wt Allele","C107617","Human TXNRD1 wild-type allele is located within 12q23-q24.1 and is approximately 135 kb in length. This allele, which encodes thioredoxin reductase 1, cytoplasmic protein, is involved in the modulation of oxidative stress.","TXNRD1 wt Allele | GRIM-12 | GRIM12 | KDRF | TR | TR1 | TRXR1 | TXNR | Thioredoxin Reductase 1 wt Allele | Trxr1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828685","Ouray County, CO","C107978","No value exists.","Ouray County, CO | CO091 | Ouray County | Ouray County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813688","Park County, CO","C107979","No value exists.","Park County, CO | CO093 | Park County | Park County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814120","Phillips County, CO","C107980","No value exists.","Phillips County, CO | CO095 | Phillips County | Phillips County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828548","Pitkin County, CO","C107981","No value exists.","Pitkin County, CO | CO097 | Pitkin County | Pitkin County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828453","Prowers County, CO","C107982","No value exists.","Prowers County, CO | CO099 | Prowers County | Prowers County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828322","Rio Blanco County, CO","C107984","No value exists.","Rio Blanco County, CO | CO103 | Rio Blanco County | Rio Blanco County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828321","Rio Grande County, CO","C107985","No value exists.","Rio Grande County, CO | CO105 | Rio Grande County | Rio Grande County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828293","Routt County, CO","C107986","No value exists.","Routt County, CO | CO107 | Routt County | Routt County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828277","Saguache County, CO","C107987","No value exists.","Saguache County, CO | CO109 | Saguache County | Saguache County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811228","San Juan County, CO","C107988","No value exists.","San Juan County, CO | CO111 | San Juan County | San Juan County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814859","Sedgwick County, CO","C107990","No value exists.","Sedgwick County, CO | CO115 | Sedgwick County | Sedgwick County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814833","Summit County, CO","C107991","No value exists.","Summit County, CO | CO117 | Summit County | Summit County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827847","Teller County, CO","C107992","No value exists.","Teller County, CO | CO119 | Teller County | Teller County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812792","Washington County, CO","C107993","No value exists.","Washington County, CO | CO121 | Washington County | Washington County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827491","Weld County, CO","C107994","No value exists.","Weld County, CO | CO123 | Weld County | Weld County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811693","Fairfield County, CT","C107996","No value exists.","Fairfield County, CT | CT001 | Fairfield County | Fairfield County, Connecticut",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829841","Hartford County, CT","C107997","No value exists.","Hartford County, CT | CT003 | Hartford County | Hartford County, Connecticut",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829269","Litchfield County, CT","C107998","No value exists.","Litchfield County, CT | CT005 | Litchfield County | Litchfield County, Connecticut",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810683","Middlesex County, CT","C107999","No value exists.","Middlesex County, CT | CT007 | Middlesex County | Middlesex County, Connecticut",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829964","Gooding County, ID","C108262","No value exists.","Gooding County, ID | Gooding County | Gooding County, Idaho | ID047",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829572","Idaho County, ID","C108263","No value exists.","Idaho County, ID | ID049 | Idaho County | Idaho County, Idaho",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816205","Jefferson County, ID","C108264","No value exists.","Jefferson County, ID | ID051 | Jefferson County | Jefferson County, Idaho",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829458","Jerome County, ID","C108265","No value exists.","Jerome County, ID | ID053 | Jerome County | Jerome County, Idaho",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829317","Latah County, ID","C108267","No value exists.","Latah County, ID | ID057 | Latah County | Latah County, Idaho",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829300","Lemhi County, ID","C108268","No value exists.","Lemhi County, ID | ID059 | Lemhi County | Lemhi County, Idaho",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814078","Lewis County, ID","C108269","No value exists.","Lewis County, ID | ID061 | Lewis County | Lewis County, Idaho",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814094","Lincoln County, ID","C108270","No value exists.","Lincoln County, ID | ID063 | Lincoln County | Lincoln County, Idaho",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815910","Madison County, ID","C108271","No value exists.","Madison County, ID | ID065 | Madison County | Madison County, Idaho",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828819","Nez Perce County, ID","C108273","No value exists.","Nez Perce County, ID | ID069 | Nez Perce County | Nez Perce County, Idaho",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812740","Oneida County, ID","C108274","No value exists.","Oneida County, ID | ID071 | Oneida County | Oneida County, Idaho",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828680","Owyhee County, ID","C108275","No value exists.","Owyhee County, ID | ID073 | Owyhee County | Owyhee County, Idaho",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828634","Payette County, ID","C108276","No value exists.","Payette County, ID | ID075 | Payette County | Payette County, Idaho",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828499","Power County, ID","C108277","No value exists.","Power County, ID | ID077 | Power County | Power County, Idaho",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815211","Teton County, ID","C108279","No value exists.","Teton County, ID | ID081 | Teton County | Teton County, Idaho",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827744","Twin Falls County, ID","C108280","No value exists.","Twin Falls County, ID | ID083 | Twin Falls County | Twin Falls County, Idaho",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811339","Valley County, ID","C108281","No value exists.","Valley County, ID | ID085 | Valley County | Valley County, Idaho",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812633","Alexander County, IL","C108284","No value exists.","Alexander County, IL | Alexander County | Alexander County, Illinois | IL003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831322","Bond County, IL","C108285","No value exists.","Bond County, IL | Bond County | Bond County, Illinois | IL005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812163","Boone County, IL","C108286","No value exists.","Boone County, IL | Boone County | Boone County, Illinois | IL007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812658","Brown County, IL","C108287","No value exists.","Brown County, IL | Brown County | Brown County, Illinois | IL009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831246","Bureau County, IL","C108288","No value exists.","Bureau County, IL | Bureau County | Bureau County, Illinois | IL011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812794","Washington County, AR","C107870","No value exists.","Washington County, AR | AR143 | Washington County | Washington County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810721","White County, AR","C107871","No value exists.","White County, AR | AR145 | White County | White County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827405","Yell County, AR","C107873","No value exists.","Yell County, AR | AR149 | Yell County | Yell County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831582","Alameda County, CA","C107874","No value exists.","Alameda County, CA | Alameda County | Alameda County, California | CA001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831555","Alpine County, CA","C107875","No value exists.","Alpine County, CA | Alpine County | Alpine County, California | CA003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831553","Amador County, CA","C107876","No value exists.","Amador County, CA | Amador County | Amador County, California | CA005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812342","Butte County, CA","C107877","No value exists.","Butte County, CA | Butte County | Butte County, California | CA007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831043","Colusa County, CA","C107879","No value exists.","Colusa County, CA | CA011 | Colusa County | Colusa County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827344","Contra Costa County, CA","C107880","No value exists.","Contra Costa County, CA | CA013 | Contra Costa County | Contra Costa County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830543","Del Norte County, CA","C107881","No value exists.","Del Norte County, CA | CA015 | Del Norte County | Del Norte County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830330","El Dorado County, CA","C107882","No value exists.","El Dorado County, CA | CA017 | El Dorado County | El Dorado County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830077","Fresno County, CA","C107883","No value exists.","Fresno County, CA | CA019 | Fresno County | Fresno County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0781149","NEATSFOOT OIL","C107334","The oil rendered from the shin bones and feet of cattle. Neatsfoot oil is used primarily as a conditioning, softening, and preservative agent for leather.","Neatsfoot Oil | NEATSFOOT OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3651714","Nigella sativa Seed Oil","C107335","The oil extracted from the seeds of Nigella sativa. Blackseed oil is used primarily for its nutritive properties.","Nigella sativa Seed Oil | NIGELLA SATIVA SEED OIL | Nigella sativa Blackseed Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0301248","Nutmeg Oil","C107336","The essential oil obtained from ground nutmeg. Nutmeg oil is typically used as a food flavoring but also has analgesic properties.","Nutmeg Oil | NUTMEG OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0254751","Orange Oil Extract","C107337","The oil extracted from the fruit peel of Citrus sinensis. Orange oil is used as a flavoring, a solvent and for its aromatic properties.","Orange Oil Extract | ORANGE OIL, COLD PRESSED | Orange Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3497608","Oregano Leaf Oil","C107338","The essential oil of Origanum vulgare. Oregano oil has antibacterial and antifungal properties.","Oregano Leaf Oil | OREGANO LEAF OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3255979","Origanum majorana Leaf Extract","C107339","The essential oil of Origanum marjorana. Marjoram oil is reported to have sedative effects and to be useful in calming asthma and other respiratory symptoms.","Origanum majorana Leaf Extract | SWEET MARJORAM OIL | Sweet Marjoram Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1445784","Orris Root Extract","C107340","The oil extracted from the roots of Iris germanica, Iris florentina, and Iris pallida. Orris root oil is used as a perfume ingredient and as an ingredient in gin.","Orris Root Extract | IRIS PALLIDA ROOT OIL | Orris Root Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1656676","Palmarosa Oil","C107341","The essential oil of Cymbopogon martini. Palmarosa oil is used in treatments for the skin, nervous, and digestive systems.","Palmarosa Oil | PALMAROSA OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829730","Heard County, GA","C108148","No value exists.","Heard County, GA | GA149 | Heard County | Heard County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811139","Henry County, GA","C108149","No value exists.","Henry County, GA | GA151 | Henry County | Henry County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829499","Irwin County, GA","C108151","No value exists.","Irwin County, GA | GA155 | Irwin County | Irwin County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814482","Jackson County, GA","C108152","No value exists.","Jackson County, GA | GA157 | Jackson County | Jackson County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814483","Jasper County, GA","C108153","No value exists.","Jasper County, GA | GA159 | Jasper County | Jasper County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814484","Jeff Davis County, GA","C108154","No value exists.","Jeff Davis County, GA | GA161 | Jeff Davis County | Jeff Davis County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814485","Jefferson County, GA","C108155","No value exists.","Jefferson County, GA | GA163 | Jefferson County | Jefferson County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814486","Johnson County, GA","C108157","No value exists.","Johnson County, GA | GA167 | Johnson County | Johnson County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814487","Jones County, GA","C108158","No value exists.","Jones County, GA | GA169 | Jones County | Jones County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813646","Lamar County, GA","C108159","No value exists.","Lamar County, GA | GA171 | Lamar County | Lamar County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829334","Lanier County, GA","C108160","No value exists.","Lanier County, GA | GA173 | Lanier County | Lanier County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813657","Laurens County, GA","C108161","No value exists.","Laurens County, GA | GA175 | Laurens County | Laurens County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810761","Lee County, GA","C108162","No value exists.","Lee County, GA | GA177 | Lee County | Lee County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814086","Liberty County, GA","C108163","No value exists.","Liberty County, GA | GA179 | Liberty County | Liberty County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814093","Lincoln County, GA","C108164","No value exists.","Lincoln County, GA | GA181 | Lincoln County | Lincoln County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829261","Long County, GA","C108165","No value exists.","Long County, GA | GA183 | Long County | Long County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815619","Lowndes County, GA","C108166","No value exists.","Lowndes County, GA | GA185 | Lowndes County | Lowndes County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829245","Lumpkin County, GA","C108167","No value exists.","Lumpkin County, GA | GA187 | Lumpkin County | Lumpkin County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812234","McIntosh County, GA","C108169","No value exists.","McIntosh County, GA | GA191 | McIntosh County | McIntosh County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815629","Macon County, GA","C108170","No value exists.","Macon County, GA | GA193 | Macon County | Macon County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815908","Madison County, GA","C108171","No value exists.","Madison County, GA | GA195 | Madison County | Madison County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811187","Marion County, GA","C108172","No value exists.","Marion County, GA | GA197 | Marion County | Marion County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810690","Miller County, GA","C108174","No value exists.","Miller County, GA | GA201 | Miller County | Miller County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810700","Mitchell County, GA","C108175","No value exists.","Mitchell County, GA | GA205 | Mitchell County | Mitchell County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810709","Monroe County, GA","C108176","No value exists.","Monroe County, GA | GA207 | Monroe County | Monroe County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0058837","Dynemicin A","C1079","An enediyne antineoplastic antibiotic hybrid containing an anthraquinone moiety isolated from the bacterium Micromonospora chersina.  The anthraquinone moiety intercalates into DNA and the benzene diradical intermediate of the enediyne core binds to the minor groove of DNA, resulting in double-strand breaks in DNA, inhibition of DNA replication and apoptosis. (NCI04)","Dynemicin A | DYNEMICIN A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828826","New London County, CT","C108001","No value exists.","New London County, CT | CT011 | New London County | New London County, Connecticut",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827815","Tolland County, CT","C108002","No value exists.","Tolland County, CT | CT013 | Tolland County | Tolland County, Connecticut",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810738","Windham County, CT","C108003","No value exists.","Windham County, CT | CT015 | Windham County | Windham County, Connecticut",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811156","Kent County, DE","C108004","No value exists.","Kent County, DE | DE001 | Kent County | Kent County, Delaware",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827268","New Castle County, DE","C108005","No value exists.","New Castle County, DE | DE003 | New Castle County | New Castle County, Delaware",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0058272","dimethylbusulfan","C1073","An aliphatic analogue of busulfan with potential antineoplastic activity.  As an alkylating agent, dimethylbusulfan induces neutropenia and has been shown to exhibit antitumor effects in some animal models.  Alkylating agents exert cytotoxic and chemotherapeutic effects by transferring alkyl groups to DNA, thereby damaging DNA and interfering with DNA synthesis and cell division. (NCI04)","Dimethylmyleran | 2,5-Dimethanesulfonoxyhexane | DMB | DMM | Dimethyl-Myleran | Dimethylbusulfan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827128","Tazemetostat","C107506","An orally available, small molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone methyl transferase EZH2, with potential antineoplastic activity. Upon oral administration, tazemetostat selectively inhibits the activity of both wild-type and mutated forms of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased tumor cell proliferation in EZH2 mutated cancer cells. EZH2, which belongs to the class of histone methyltransferases (HMTs), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation.","Tazemetostat | E 7438 | E-7438 | E7438 | EPZ 6438 | EPZ-6438 | EPZ6438 | N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide | N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide | TAZEMETOSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3665328","Parsley Seed Oil","C107342","The oil extracted from the seeds of Petroselinum sativum. Parsley seed oil is used primarily for the treatment of digestive issues.","Parsley Seed Oil | PARSLEY SEED OIL",,,,,,,,,,,,,,,"4195583","Oil of parsley",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828620","Pelargonium capitatum Oil","C107343","The essential oil of Pelargonium capitatum. Pelargonium capitatum oil is used for its aromatic properties and as an ingredient in skincare preparations.","Pelargonium capitatum Oil | PELARGONIUM CAPITATUM OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828619","Pelargonium odoratissimum Oil","C107344","The essential oil of Pelargonium odoratissimum. Pelargonium odoratissimum oil is used for its aromatic properties and as an ingredient in skincare preparations.","Pelargonium odoratissimum Oil | PELARGONIUM ODORATISSIMUM OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828618","Pelargonium radens Oil","C107345","The essential oil of Pelargonium radens. Pelargonium radens oil is used for its aromatic properties and as an ingredient in skincare preparations.","Pelargonium radens Oil | PELARGONIUM RADENS OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3256244","Perilla frutescens Leaf Oil","C107347","The essential oil of Perilla frutescens. (note: the seed oil is the more common, traditionally used as a lamp oil and as drying oil finish)","Perilla frutescens Leaf Oil | PERILLA FRUTESCENS LEAF OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3527641","Pine Needle Oil Pinus mugo","C107348","The essential oil of Pinus mugo. Mugo pine oil is used primarily for its aroma but is also used in massage oils.","Pine Needle Oil Pinus mugo | Mugo Pine Oil | PINE NEEDLE OIL (PINUS MUGO)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3474165","Pistachio Oil","C107349","The oil extracted from the fruit of Pistacia vera. Pistachio oil is used as a food oil.","Pistachio Oil | PISTACHIO OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3256645","Pomegranate Seed Oil","C107350","The oil extracted from the seeds of Punica granatum. Pomegranite seed oil is a source of antioxidants and is used in skincare preparations.","Pomegranate Seed Oil | POMEGRANATE SEED OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1445804","Pumpkin Seed Oil","C107351","The oil extracted from the seeds of Cucurbita pepo var. styriaca. Pumpkin seed oil is used primarily as a food flavoring.","Pumpkin Seed Oil | PUMPKIN SEED OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828332","Rhododendron dauricum Leaf Oil","C107352","The essential oil of Rhododendron dauricum.","Rhododendron dauricum Leaf Oil | RHODODENDRON DAURICUM LEAF OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3256268","Ribes nigurm Seed","C107353","The oil extracted from the seeds of Ribes nigurm. Black currant oil is a source of gamma-linoleic acid and may have immune-enhancing effects.","Ribes nigurm Seed | Black Currant Seed Oil | RIBES NIGRUM SEED OIL | Ribes nigurm Seed Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811634","Adams County, IN","C108385","No value exists.","Adams County, IN | Adams County | Adams County, Indiana | IN001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812644","Allen County, IN","C108386","No value exists.","Allen County, IN | Allen County | Allen County, Indiana | IN003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831403","Bartholomew County, IN","C108387","No value exists.","Bartholomew County, IN | Bartholomew County | Bartholomew County, Indiana | IN005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816491","Benton County, IN","C108388","No value exists.","Benton County, IN | Benton County | Benton County, Indiana | IN007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831345","Blackford County, IN","C108389","No value exists.","Blackford County, IN | Blackford County | Blackford County, Indiana | IN009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812659","Brown County, IN","C108391","No value exists.","Brown County, IN | Brown County | Brown County, Indiana | IN013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815114","Carroll County, IN","C108392","No value exists.","Carroll County, IN | Carroll County | Carroll County, Indiana | IN015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815121","Cass County, IN","C108393","No value exists.","Cass County, IN | Cass County | Cass County, Indiana | IN017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815508","Clark County, IN","C108394","No value exists.","Clark County, IN | Clark County | Clark County, Indiana | IN019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811265","Montgomery County, GA","C108177","No value exists.","Montgomery County, GA | GA209 | Montgomery County | Montgomery County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811286","Morgan County, GA","C108178","No value exists.","Morgan County, GA | GA211 | Morgan County | Morgan County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811817","Muscogee County, GA","C108180","No value exists.","Muscogee County, GA | GA215 | Muscogee County | Muscogee County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810593","Newton County, GA","C108181","No value exists.","Newton County, GA | GA217 | Newton County | Newton County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812260","Oconee County, GA","C108182","No value exists.","Oconee County, GA | GA219 | Oconee County | Oconee County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828727","Oglethorpe County, GA","C108183","No value exists.","Oglethorpe County, GA | GA221 | Oglethorpe County | Oglethorpe County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813691","Paulding County, GA","C108184","No value exists.","Paulding County, GA | GA223 | Paulding County | Paulding County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814124","Pickens County, GA","C108186","No value exists.","Pickens County, GA | GA227 | Pickens County | Pickens County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814126","Pierce County, GA","C108187","No value exists.","Pierce County, GA | GA229 | Pierce County | Pierce County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814133","Pike County, GA","C108188","No value exists.","Pike County, GA | GA231 | Pike County | Pike County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811783","Polk County, GA","C108189","No value exists.","Polk County, GA | GA233 | Polk County | Polk County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811850","Pulaski County, GA","C108190","No value exists.","Pulaski County, GA | GA235 | Pulaski County | Pulaski County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812306","Quitman County, GA","C108192","No value exists.","Quitman County, GA | GA239 | Quitman County | Quitman County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828420","Rabun County, GA","C108193","No value exists.","Rabun County, GA | GA241 | Rabun County | Rabun County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812312","Randolph County, GA","C108194","No value exists.","Randolph County, GA | GA243 | Randolph County | Randolph County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814466","Stevens County, KS","C108670","No value exists.","Stevens County, KS | KS189 | Stevens County | Stevens County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814835","Sumner County, KS","C108671","No value exists.","Sumner County, KS | KS191 | Sumner County | Sumner County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815216","Thomas County, KS","C108672","No value exists.","Thomas County, KS | KS193 | Thomas County | Thomas County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827776","Trego County, KS","C108673","No value exists.","Trego County, KS | KS195 | Trego County | Trego County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827532","Wabaunsee County, KS","C108674","No value exists.","Wabaunsee County, KS | KS197 | Wabaunsee County | Wabaunsee County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827520","Wallace County, KS","C108675","No value exists.","Wallace County, KS | KS199 | Wallace County | Wallace County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810726","Wichita County, KS","C108677","No value exists.","Wichita County, KS | KS203 | Wichita County | Wichita County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810735","Wilson County, KS","C108678","No value exists.","Wilson County, KS | KS205 | Wilson County | Wilson County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830379","Dubuque County, IA","C108507","No value exists.","Dubuque County, IA | Dubuque County | Dubuque County, Iowa | IA061",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812836","Emmet County, IA","C108508","No value exists.","Emmet County, IA | Emmet County | Emmet County, Iowa | IA063",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812205","Fayette County, IA","C108509","No value exists.","Fayette County, IA | Fayette County | Fayette County, Iowa | IA065",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811309","Franklin County, IA","C108511","No value exists.","Franklin County, IA | Franklin County | Franklin County, Iowa | IA069",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811310","Fremont County, IA","C108512","No value exists.","Fremont County, IA | Fremont County | Fremont County, Iowa | IA071",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814401","Greene County, IA","C108513","No value exists.","Greene County, IA | Greene County | Greene County, Iowa | IA073",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814413","Grundy County, IA","C108514","No value exists.","Grundy County, IA | Grundy County | Grundy County, Iowa | IA075",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815153","Hamilton County, IA","C108516","No value exists.","Hamilton County, IA | Hamilton County | Hamilton County, Iowa | IA079",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815162","Hancock County, IA","C108517","No value exists.","Hancock County, IA | Hancock County | Hancock County, Iowa | IA081",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815543","Hardin County, IA","C108518","No value exists.","Hardin County, IA | Hardin County | Hardin County, Iowa | IA083",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815555","Harrison County, IA","C108519","No value exists.","Harrison County, IA | Harrison County | Harrison County, Iowa | IA085",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811143","Henry County, IA","C108520","No value exists.","Henry County, IA | Henry County | Henry County, Iowa | IA087",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814433","Humboldt County, IA","C108522","No value exists.","Humboldt County, IA | Humboldt County | Humboldt County, Iowa | IA091",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829573","Ida County, IA","C108523","No value exists.","Ida County, IA | IA093 | Ida County | Ida County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816174","Iowa County, IA","C108524","No value exists.","Iowa County, IA | IA095 | Iowa County | Iowa County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827221","Fairbanks North Star Borough, AK","C107762","No value exists.","Fairbanks North Star Borough, AK | AK090 | Fairbanks North Star Borough | Fairbanks North Star Borough, Alaska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829909","Haines Borough, AK","C107763","No value exists.","Haines Borough, AK | AK100 | Haines Borough | Haines Borough, Alaska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829667","Hoonah-Angoon Census Area, AK","C107764","No value exists.","Hoonah-Angoon Census Area, AK | AK105 | Hoonah-Angoon Census Area | Hoonah-Angoon Census Area, Alaska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829445","Juneau City and Borough, AK","C107765","No value exists.","Juneau City and Borough, AK | AK110 | Juneau City and Borough | Juneau City and Borough, Alaska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829414","Kenai Peninsula Borough, AK","C107766","No value exists.","Kenai Peninsula Borough, AK | AK122 | Kenai Peninsula Borough | Kenai Peninsula Borough, Alaska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829369","Kodiak Island Borough, AK","C107768","No value exists.","Kodiak Island Borough, AK | AK150 | Kodiak Island Borough | Kodiak Island Borough, Alaska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829343","Lake and Peninsula Borough, AK","C107769","No value exists.","Lake and Peninsula Borough, AK | AK164 | Lake and Peninsula Borough | Lake and Peninsula Borough, Alaska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829177","Matanuska-Susitna Borough, AK","C107770","No value exists.","Matanuska-Susitna Borough, AK | AK170 | Matanuska-Susitna Borough | Matanuska-Susitna Borough, Alaska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828808","Nome Census Area, AK","C107771","No value exists.","Nome Census Area, AK | AK180 | Nome Census Area | Nome Census Area, Alaska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828785","North Slope Borough, AK","C107772","No value exists.","North Slope Borough, AK | AK185 | North Slope Borough | North Slope Borough, Alaska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828784","Northwest Arctic Borough, AK","C107773","No value exists.","Northwest Arctic Borough, AK | AK188 | Northwest Arctic Borough | Northwest Arctic Borough, Alaska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828474","Prince of Wales-Hyder Census Area, AK","C107775","No value exists.","Prince of Wales-Hyder Census Area, AK | AK198 | Prince of Wales-Hyder Census Area | Prince of Wales-Hyder Census Area, Alaska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828014","Sitka City and Borough, AK","C107776","No value exists.","Sitka City and Borough, AK | AK220 | Sitka City and Borough | Sitka City and Borough, Alaska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828006","Skagway Municipality, AK","C107777","No value exists.","Skagway Municipality, AK | AK230 | Skagway Municipality | Skagway Municipality, Alaska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827968","Southeast Fairbanks Census Area, AK","C107778","No value exists.","Southeast Fairbanks Census Area, AK | AK240 | Southeast Fairbanks Census Area | Southeast Fairbanks Census Area, Alaska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827670","Valdez-Cordova Census Area, AK","C107779","No value exists.","Valdez-Cordova Census Area, AK | AK261 | Valdez-Cordova Census Area | Valdez-Cordova Census Area, Alaska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827531","Wade Hampton Census Area, AK","C107780","No value exists.","Wade Hampton Census Area, AK | AK270 | Wade Hampton Census Area | Wade Hampton Census Area, Alaska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827414","Yakutat City and Borough, AK","C107782","No value exists.","Yakutat City and Borough, AK | AK282 | Yakutat City and Borough | Yakutat City and Borough, Alaska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827398","Yukon-Koyukuk Census Area, AK","C107783","No value exists.","Yukon-Koyukuk Census Area, AK | AK290 | Yukon-Koyukuk Census Area | Yukon-Koyukuk Census Area, Alaska",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811075","Clay County, IN","C108395","No value exists.","Clay County, IN | Clay County | Clay County, Indiana | IN021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813150","Crawford County, IN","C108397","No value exists.","Crawford County, IN | Crawford County | Crawford County, Indiana | IN025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815126","Daviess County, IN","C108398","No value exists.","Daviess County, IN | Daviess County | Daviess County, Indiana | IN027",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830552","Dearborn County, IN","C108399","No value exists.","Dearborn County, IN | Dearborn County | Dearborn County, Indiana | IN029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0059385","Staphylococcal enterotoxin A","C1083","A bacterial enterotoxin with potential immunostimulatory activity. Staphylococcal enterotoxin A (SEA), a gram positive bacterial superantigen (SAg), is a potent stimulator of T-cell activation. SEA superantigen binds directly to class II major histocompatibility complex (MHC) molecules and to the V beta region of the T-cell receptor (TCR), leading to an amplified T-cell response. In response to SEA, both CD4+ and CD8+ cells proliferate, secrete cytokines, and demonstrate enhanced cytotoxic activity against a broad range of antigens. Vaccination with the SEA protein, administered by direct transfection into tumor cells, may elicit a non-specific cytotoxic T-cell (CTL) response and result in decreased tumor cell growth.","Staphylococcal Enterotoxin A | SEA | STAPHYLOCOCCAL ENTEROTOXIN A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815519","DeKalb County, IN","C108401","No value exists.","DeKalb County, IN | DeKalb County | DeKalb County, Indiana | IN033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815522","Delaware County, IN","C108402","No value exists.","Delaware County, IN | Delaware County | Delaware County, Indiana | IN035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830380","Dubois County, IN","C108403","No value exists.","Dubois County, IN | Dubois County | Dubois County, Indiana | IN037",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827318","Elkhart County, IN","C108404","No value exists.","Elkhart County, IN | Elkhart County | Elkhart County, Indiana | IN039",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812211","Fayette County, IN","C108405","No value exists.","Fayette County, IN | Fayette County | Fayette County, Indiana | IN041",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830084","Fountain County, IN","C108407","No value exists.","Fountain County, IN | Fountain County | Fountain County, Indiana | IN045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814004","Franklin County, IN","C108408","No value exists.","Franklin County, IN | Franklin County | Franklin County, Indiana | IN047",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814427","Fulton County, IN","C108409","No value exists.","Fulton County, IN | Fulton County | Fulton County, Indiana | IN049",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814503","Gibson County, IN","C108410","No value exists.","Gibson County, IN | Gibson County | Gibson County, Indiana | IN051",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813982","Grant County, IN","C108411","No value exists.","Grant County, IN | Grant County | Grant County, Indiana | IN053",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827448","Woodson County, KS","C108679","No value exists.","Woodson County, KS | KS207 | Woodson County | Woodson County, Kansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811632","Adair County, KY","C108681","No value exists.","Adair County, KY | Adair County | Adair County, Kentucky | KY001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812643","Allen County, KY","C108682","No value exists.","Allen County, KY | Allen County | Allen County, Kentucky | KY003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811350","Anderson County, KY","C108683","No value exists.","Anderson County, KY | Anderson County | Anderson County, Kentucky | KY005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831420","Ballard County, KY","C108684","No value exists.","Ballard County, KY | Ballard County | Ballard County, Kentucky | KY007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831406","Barren County, KY","C108685","No value exists.","Barren County, KY | Barren County | Barren County, Kentucky | KY009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811352","Bell County, KY","C108687","No value exists.","Bell County, KY | Bell County | Bell County, Kentucky | KY013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811353","Boone County, KY","C108688","No value exists.","Boone County, KY | Boone County | Boone County, Kentucky | KY015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811354","Bourbon County, KY","C108689","No value exists.","Bourbon County, KY | Bourbon County | Bourbon County, Kentucky | KY017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811355","Boyd County, KY","C108690","No value exists.","Boyd County, KY | Boyd County | Boyd County, Kentucky | KY019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831282","Bracken County, KY","C108692","No value exists.","Bracken County, KY | Bracken County | Bracken County, Kentucky | KY023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831268","Breathitt County, KY","C108693","No value exists.","Breathitt County, KY | Breathitt County | Breathitt County, Kentucky | KY025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831267","Breckinridge County, KY","C108694","No value exists.","Breckinridge County, KY | Breckinridge County | Breckinridge County, Kentucky | KY027",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827300","Bullitt County, KY","C108695","No value exists.","Bullitt County, KY | Bullitt County | Bullitt County, Kentucky | KY029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811356","Butler County, KY","C108696","No value exists.","Butler County, KY | Butler County | Butler County, Kentucky | KY031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831220","Calloway County, KY","C108698","No value exists.","Calloway County, KY | Calloway County | Calloway County, Kentucky | KY035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811358","Campbell County, KY","C108699","No value exists.","Campbell County, KY | Campbell County | Campbell County, Kentucky | KY037",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL451871","anti-FGFR2 antibody BAY1179470","C107683","An antibody against the fibroblast growth factor receptor type 2 (FGFR2), with potential antineoplastic activity. Upon administration, aprutumab binds to and inhibits FGFR2, which may result in the inhibition of both FGFR2 phosphorylation and FGFR2-mediated signal transduction pathways. This results in the inhibition of cell proliferation and the induction of cell death of FGFR2-expressing tumor cells. FGFR2, upregulated in many tumor cell types, is a receptor tyrosine kinase, which is essential to tumor cellular proliferation, differentiation and survival.","Aprutumab | AGC-2500 | APRUTUMAB | BAY-1179470 | BAY1179470",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827157","PI3Kbeta Inhibitor AZD8186","C107684","An inhibitor of the beta isoform of phosphoinositide-3 kinase (PI3K), with potential antineoplastic activity. Upon administration, PI3Kbeta inhibitor AZD8186 selectively inhibits the activity of PI3Kbeta in the PI3K/Akt/mTOR signaling pathway, which may result in a decrease of tumor cell proliferation and induces cell death in PI3K-expressing cancer cells. By specifically targeting class I PI3K beta, this agent may be more efficacious and less toxic than pan PI3K inhibitors. PI3K-mediated signaling is often dysregulated in cancer cells and contributes to increased tumor cell growth, survival, and tumor resistance to a variety of antineoplastic agents.","PI3Kbeta Inhibitor AZD8186 | AZD-8186 | AZD8186",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816200","Jackson County, IA","C108525","No value exists.","Jackson County, IA | IA097 | Jackson County | Jackson County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816202","Jefferson County, IA","C108527","No value exists.","Jefferson County, IA | IA101 | Jefferson County | Jefferson County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816203","Johnson County, IA","C108528","No value exists.","Johnson County, IA | IA103 | Johnson County | Johnson County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816204","Jones County, IA","C108529","No value exists.","Jones County, IA | IA105 | Jones County | Jones County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829409","Keokuk County, IA","C108530","No value exists.","Keokuk County, IA | IA107 | Keokuk County | Keokuk County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829365","Kossuth County, IA","C108531","No value exists.","Kossuth County, IA | IA109 | Kossuth County | Kossuth County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815582","Linn County, IA","C108533","No value exists.","Linn County, IA | IA113 | Linn County | Linn County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815614","Louisa County, IA","C108534","No value exists.","Louisa County, IA | IA115 | Louisa County | Louisa County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815621","Lucas County, IA","C108535","No value exists.","Lucas County, IA | IA117 | Lucas County | Lucas County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815623","Lyon County, IA","C108536","No value exists.","Lyon County, IA | IA119 | Lyon County | Lyon County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829220","Mahaska County, IA","C108538","No value exists.","Mahaska County, IA | IA123 | Mahaska County | Mahaska County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811184","Marion County, IA","C108539","No value exists.","Marion County, IA | IA125 | Marion County | Marion County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811250","TXNRD2 wt Allele","C107620","Human TXNRD2 wild-type allele is located in the vicinity of 22q11.21 and is approximately 66 kb in length. This allele, which encodes thioredoxin reductase 2, mitochondrial protein, plays a role in thioredoxin redox potential.","TXNRD2 wt Allele | SELZ | TR | TR-BETA | TR3 | TRXR2 | Thioredoxin Reductase 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815867","TXNRD2 protein, human","C107621","Thioredoxin reductase 2, mitochondrial (524 aa, ~57 kDa) is encoded by the human TXNRD2 gene. This protein is involved in thioredoxin reduction.","Thioredoxin Reductase 2, Mitochondrial | EC 1.8.1.9 | SelZ | Selenoprotein Z | TR-Beta | TXNRD2 | Thioredoxin Reductase 3 | Thioredoxin Reductase Beta | Thioredoxin Reductase TR3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811254","TTF1 wt Allele","C107623","Human TTF1 wild-type allele is located in the vicinity of 9q34.13 and is approximately 31 kb in length. This allele, which encodes transcription termination factor 1 protein, is involved in both transcriptional termination and replication fork arrest.","TTF1 wt Allele | TTF-1 | TTF-I | Transcription Termination Factor, RNA Polymerase I wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831507","Apache County, AZ","C107784","No value exists.","Apache County, AZ | AZ001 | Apache County | Apache County, Arizona",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831064","Cochise County, AZ","C107785","No value exists.","Cochise County, AZ | AZ003 | Cochise County | Cochise County, Arizona",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831061","Coconino County, AZ","C107786","No value exists.","Coconino County, AZ | AZ005 | Coconino County | Coconino County, Arizona",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813969","Graham County, AZ","C107788","No value exists.","Graham County, AZ | AZ009 | Graham County | Graham County, Arizona",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829941","Greenlee County, AZ","C107789","No value exists.","Greenlee County, AZ | AZ011 | Greenlee County | Greenlee County, Arizona",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829333","La Paz County, AZ","C107790","No value exists.","La Paz County, AZ | AZ012 | La Paz County | La Paz County, Arizona",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0304098","Cardamom Oil","C107279","The essential oil from Elettaria cardomomum. Cardamom oil is used for its aromatic properties, in cooking, and in medicinal preparations.","Cardamom Oil | CARDAMOM OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3488988","Carrot Seed Oil","C107280","The oil extracted from the seeds of Daucus carota. Carrot seed oil is primarily used in skin treatment preparations.","Carrot Seed Oil | CARROT SEED OIL | Wild Carrot Seed Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3474158","Cashew Oil","C107281","The oil extracted from the nut fruit of Anacardium occidentale. Cashew oil is primarily used as a cooking oil.","Cashew Oil | CASHEW OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831163","Cedrus deodara Seed Oil","C107282","The essential oil of Cedrus deodara. Cedar oil is used in cleaning products and for aromatherapy.","Cedrus deodara Seed Oil | CEDRUS DEODARA SEED OIL | Himalayan Cedar Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3488429","Cervus elaphus Horn Oil","C107283","An extract obtained from deer antler velvet. Deer antler extract contains insulin-like growth factor-1, estrone and estradiol. It is used for its growth hormone activities and is considered a performance-enhancing drug.","Cervus elaphus Horn Oil | CERVUS ELAPHUS HORN OIL | Deer Antler Extract",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3255743","Chamaecyparis obtusa Wood Oil","C107284","The oil extracted from the wood of Chamaecyparis obtusa. Hinoki wood oil has anti-bacterial properties and is used in perfumes, toothpaste, and hair tonic as well as for aromatherapy.","Chamaecyparis obtusa Wood Oil | CHAMAECYPARIS OBTUSA WOOD OIL | Hinoki Wood Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3255746","Chamaemelum nobile Flower Oil","C107285","The oil extracted from the petals of Chamaemelum nobile. Chamomile oil has anti-inflammatory properties.","Chamaemelum nobile Flower Oil | CHAMAEMELUM NOBILE FLOWER OIL | Chamomile Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3474159","Chilean Hazelnut Oil","C107286","The oil extracted from the nuts of Gevuina avellana. Hazelnut oil is a good source of vitamin E and is typically used in skincare preparations.","Chilean Hazelnut Oil | CHILEAN HAZELNUT OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831100","Cinnamomum loureirii Bark Extract","C107288","The oil extracted from the bark of Cinnamomum loureiroi. Saigon cinnamon bark oil is used primarily in aromatherapy.","Cinnamomum loureirii Bark Extract | Cinnamomum loureiroi Bark Extract | SAIGON CINNAMON BARK OIL | Saigon Cinnamon Bark Oil | Vietnamese Cassia Oil | Vietnamese Cinnamon Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1721512","Cinnamomum zeylanicum Bark Extract","C107289","The oil extracted from the bark of Cinnamomum zeylanicum. Cinnamon bark oil has antibacterial and antifungal properties but is an irritant to skin. It is used primarily in aromatherapy.","Cinnamomum zeylanicum Bark Extract | CINNAMON BARK OIL | Cinnamon Bark Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828626","PDGFRA Protein Variant","C107569","A variation in the amino acid sequence for the platelet-derived growth factor receptor alpha protein.","PDGFRA Protein Variant | CD140a Antigen Protein Variant | PDGFR-Alpha Protein Variant | Platelet-Derived Growth Factor Receptor Alpha Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813209","PROS1 wt Allele","C107572","Human PROS1 wild-type allele is located in the vicinity of 3q11.2 and is approximately 101 kb in length. This allele, which encodes vitamin K-dependent protein S, is involved in the regulation of coagulation. Mutations in this gene are associated with both autosomal dominant and autosomal recessive thrombophilia due to protein S deficiency.","PROS1 wt Allele | PROS | PS21 | PS22 | PS23 | PS24 | PS25 | PSA | Protein S (Alpha) wt Allele | Protein S, Alpha Gene | THPH5 | THPH6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2002622","Vitamin K-Dependent Protein S, Human","C107573","Vitamin K-dependent protein S (676 aa, ~75 kDa) is encoded by the human PROS1 gene. This protein plays a role in coagulation regulation.","Vitamin K-Dependent Protein S | PROS1 | Protein Sa | Vitamin K-Dependent Plasma Protein S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812261","SLC22A2 wt Allele","C107575","Human SLC22A2 wild-type allele is located in the vicinity of 6q25.3 and is approximately 107 kb in length. This allele, which encodes solute carrier family 22 member 2 protein, plays a role in mediating tubular uptake of organic compounds from the circulation.","SLC22A2 wt Allele | HOCT2 | OCT2 | Solute Carrier Family 22 (Organic Cation Transporter), Member 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1453694","Solute Carrier Family 22 Member 2","C107576","Solute carrier family 22 member 2 (555 aa, ~63 kDa) is encoded by the human SLC22A2 gene. This protein is involved in mediating tubular uptake of organic compounds from the circulation.","Solute Carrier Family 22 Member 2 | Organic Cation Transporter 2 | SLC22A2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811806","SLC18A1 wt Allele","C107578","Human SLC18A1 wild-type allele is located in the vicinity of 8p21.3 and is approximately 38 kb in length. This allele, which encodes chromaffin granule amine transporter protein, plays a role in the accumulation of cytosolic monoamines in secretory vesicles.","SLC18A1 wt Allele | CGAT | Solute Carrier Family 18 (Vesicular Monoamine Transporter), Member 1 wt Allele | VAT1 | VMAT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829973","Glenn County, CA","C107884","No value exists.","Glenn County, CA | CA021 | Glenn County | Glenn County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814035","Humboldt County, CA","C107885","No value exists.","Humboldt County, CA | CA023 | Humboldt County | Humboldt County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829557","Imperial County, CA","C107886","No value exists.","Imperial County, CA | CA025 | Imperial County | Imperial County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829506","Inyo County, CA","C107887","No value exists.","Inyo County, CA | CA027 | Inyo County | Inyo County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829407","Kern County, CA","C107888","No value exists.","Kern County, CA | CA029 | Kern County | Kern County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL451873","BC-819 Plasmid/Polyethylenimine Complex","C107685","A plasmid DNA encoding for the A fragment of Diphtheria Toxin (DTA) under the control of the H19 gene promoter (BC-819 or DTA-H19) and mixed with the transfectant polyethylenimine (PEI), with potential antineoplastic activity. Upon administration, the PEI moiety enhances the entry of the agent into rapidly dividing cells. Upon cell entry, activation of the H19 gene promoter-containing plasmids and DTA expression are limited to tumor cells, as high levels of H19 expression are only found in tumor cells. DTA disrupts protein synthesis. Tumor-cell selective expression of this toxin leads to the selective destruction of the tumor while sparing healthy, normal cells. H19, an oncofetal, regulatory RNA, is overexpressed in certain cancer cells while its expression in normal cells is minimal or absent; it plays a key role in cancer progression, angiogenesis and metastasis.","BC-819 Plasmid/Polyethylenimine Complex | BC-819/PEI | DTA-H19/PEI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL451874","PI3Kdelta inhibitor INCB040093","C107686","An orally bioavailable, selective inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinases (PI3K) with potential antineoplastic activity. Dezapelisib specifically inhibits PI3Kdelta, which prevents both the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and the activation of the PI3K/AKT kinase signaling pathway. This decreases proliferation and induces cell death in PI3K-overexpressing tumor cells. Unlike other isoforms of PI3K, PI3Kdelta is often overexpressed in tumor cells, especially those of hematologic origin, and plays a crucial role in tumor cell regulation and survival. The targeted inhibition of PI3Kdelta allows for PI3K signaling in normal, non-neoplastic cells.","Dezapelisib | 5H-Thiazolo(3,2-a)pyrimidin-5-one, 6-(3-Fluorophenyl)-3-methyl-7-((1S)-1-(9H-purin-6-ylamino)ethyl)- | DEZAPELISIB | INCB040093",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827684","US County","C107687","A region in the United States created by territorial division for the purpose of local government.","US County | United States County",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831441","Autauga County, AL","C107688","No value exists.","Autauga County, AL | AL001 | Autauga County | Autauga County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811387","Baldwin County, AL","C107689","No value exists.","Baldwin County, AL | AL003 | Baldwin County | Baldwin County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811853","Barbour County, AL","C107690","No value exists.","Barbour County, AL | AL005 | Barbour County | Barbour County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811073","Bibb County, AL","C107691","No value exists.","Bibb County, AL | AL007 | Bibb County | Bibb County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811661","Blount County, AL","C107692","No value exists.","Blount County, AL | AL009 | Blount County | Blount County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831248","Bullock County, AL","C107693","No value exists.","Bullock County, AL | AL011 | Bullock County | Bullock County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811868","Butler County, AL","C107694","No value exists.","Butler County, AL | AL013 | Butler County | Butler County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811869","Calhoun County, AL","C107695","No value exists.","Calhoun County, AL | AL015 | Calhoun County | Calhoun County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811871","Cherokee County, AL","C107697","No value exists.","Cherokee County, AL | AL019 | Cherokee County | Cherokee County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831113","Chilton County, AL","C107698","No value exists.","Chilton County, AL | AL021 | Chilton County | Chilton County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811872","Choctaw County, AL","C107699","No value exists.","Choctaw County, AL | AL023 | Choctaw County | Choctaw County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1610981","Transcription Termination Factor 1, Human","C107624","Transcription termination factor 1 (905 aa, ~103 kDa) is encoded by the human TTF1 gene. This protein plays a role in transcription arrest.","Transcription Termination Factor 1 | RNA Polymerase I Termination Factor | TTF-1 | TTF1 | Transcription Termination Factor I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810567","KRT13 wt Allele","C107626","Human KRT13 wild-type allele is located in the vicinity of 17q21.2 and is approximately 5 kb in length. This allele, which encodes keratin, type I cytoskeletal 13 protein, plays a role in epidermal development. Mutation of the gene is associated with white sponge nevus.","KRT13 wt Allele | CK13 | K13 | Keratin 13 wt Allele | MGC161462 | MGC3781",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1673263","KRT13 protein, human","C107627","Keratin, type I cytoskeletal 13 (458 aa, ~50 kDa) is encoded by the human KRT13 gene. This protein is involved in the development of the epidermal endothelium.","Keratin, Type I Cytoskeletal 13 | CK-13 | Cytokeratin 13 | Cytokeratin-13 | K13 | KRT13 | Keratin-13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831584","Alachua County, FL","C108008","No value exists.","Alachua County, FL | Alachua County | Alachua County, Florida | FL001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814508","Baker County, FL","C108009","No value exists.","Baker County, FL | Baker County | Baker County, Florida | FL003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814509","Bay County, FL","C108010","No value exists.","Bay County, FL | Bay County | Bay County, Florida | FL005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812169","Bradford County, FL","C108011","No value exists.","Bradford County, FL | Bradford County | Bradford County, Florida | FL007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831265","Brevard County, FL","C108012","No value exists.","Brevard County, FL | Brevard County | Brevard County, Florida | FL009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831256","Broward County, FL","C108013","No value exists.","Broward County, FL | Broward County | Broward County, Florida | FL011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814381","Charlotte County, FL","C108015","No value exists.","Charlotte County, FL | Charlotte County | Charlotte County, Florida | FL015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1721515","Cinnamon Leaf Oil","C107290","The oil extracted from the leaves of Cinnamomum zeylanicum. Cinnamon leaf oil is used primarily in aromatherapy.","Cinnamon Leaf Oil | CINNAMON LEAF OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3255928","Citrus sinensis Flower Oil","C107292","The essential oil from the flower of Citrus sinensis. Orange blossom oil is used primarily for aromatherapy.","Citrus sinensis Flower Oil | CITRUS SINENSIS FLOWER OIL | Neroli | Orange Blossom Essential Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1366079","Clary Sage Oil","C107293","The essential oil of Salvia sclarea. Clary sage oil is used in the treatment of depression, stress, insomnia and deep seated tension.","Clary Sage Oil | CLARY SAGE OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3531209","Coix lacryma-jobi Oil","C107294","The oil extracted from the seeds of Coix lacryma-jobi. Coix lacryma-jobi oil is used primarily in skincare preparations.","Coix lacryma-jobi Oil | COIX LACRYMA-JOBI SEED OIL | Job's Tears Seed Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3695977","Cucumber Seed Oil","C107295","The oil extracted from the seeds of Cucumis sativus. Cucumber seed oil is used primarily in skincare preparations.","Cucumber Seed Oil | CUCUMBER SEED OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0304132","Cumin Oil","C107296","The oil extracted from the seeds of Cuminum cyminum. Cumin oil is used in treatments of the digestive system.","Cumin Oil | CUMIN OIL",,,,,,,,,,,,,,,"4049145","Oil of cumin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3830629","CURCUMA AROMATICA ROOT OIL","C107297","The oil extracted from the root tuber of Curcuma wenyujin.","Curcuma Aromatica Root Oil | CURCUMA AROMATICA ROOT OIL | Curcuma wenyujin Rhizome Oil | Curcuma wenyujin Root Oil | White Turmeric Root Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815118","Carroll County, IL","C108290","No value exists.","Carroll County, IL | Carroll County | Carroll County, Illinois | IL015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814380","Champaign County, IL","C108292","No value exists.","Champaign County, IL | Champaign County | Champaign County, Illinois | IL019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815110","Christian County, IL","C108293","No value exists.","Christian County, IL | Christian County | Christian County, Illinois | IL021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815506","Clark County, IL","C108294","No value exists.","Clark County, IL | Clark County | Clark County, Illinois | IL023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816488","Clay County, IL","C108295","No value exists.","Clay County, IL | Clay County | Clay County, Illinois | IL025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811097","Clinton County, IL","C108296","No value exists.","Clinton County, IL | Clinton County | Clinton County, Illinois | IL027",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812667","Cook County, IL","C108298","No value exists.","Cook County, IL | Cook County | Cook County, Illinois | IL031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813152","Crawford County, IL","C108299","No value exists.","Crawford County, IL | Crawford County | Crawford County, Illinois | IL033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0059364","Enocitabine","C1082","A pyrimidine antimetabolite converted to Cytarabine in the body. (NCI)","Enocitabine | BHAC | Behenoyl Cytarabine | Behenoyl cytarabine | ENOCITABINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813962","Cumberland County, IL","C108300","No value exists.","Cumberland County, IL | Cumberland County | Cumberland County, Illinois | IL035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830523","De Witt County, IL","C108302","No value exists.","De Witt County, IL | De Witt County | De Witt County, Illinois | IL039",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811828","Douglas County, IL","C108303","No value exists.","Douglas County, IL | Douglas County | Douglas County, Illinois | IL041",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830372","DuPage County, IL","C108304","No value exists.","DuPage County, IL | DuPage County | DuPage County, Illinois | IL043",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830340","Edgar County, IL","C108305","No value exists.","Edgar County, IL | Edgar County | Edgar County, Illinois | IL045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810794","Kings County, CA","C107889","No value exists.","Kings County, CA | CA031 | Kings County | Kings County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813634","Lake County, CA","C107890","No value exists.","Lake County, CA | CA033 | Lake County | Lake County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829318","Lassen County, CA","C107891","No value exists.","Lassen County, CA | CA035 | Lassen County | Lassen County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829226","Madera County, CA","C107893","No value exists.","Madera County, CA | CA039 | Madera County | Madera County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829197","Marin County, CA","C107894","No value exists.","Marin County, CA | CA041 | Marin County | Marin County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829194","Mariposa County, CA","C107895","No value exists.","Mariposa County, CA | CA043 | Mariposa County | Mariposa County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829131","Mendocino County, CA","C107896","No value exists.","Mendocino County, CA | CA045 | Mendocino County | Mendocino County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829126","Merced County, CA","C107897","No value exists.","Merced County, CA | CA047 | Merced County | Merced County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828976","Mono County, CA","C107899","No value exists.","Mono County, CA | CA051 | Mono County | Mono County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0058809","Brequinar Sodium","C1078","The sodium salt form of Brequinar.  Brequinar inhibits the enzyme dihydroorotate dehydrogenase, thereby blocking de novo pyrimidine biosynthesis.  This agent may also enhance the in vivo antitumor effect of antineoplastic agents such as 5-FU. (NCI04)","Brequinar Sodium | BREQUINAR SODIUM | Brequinar sodium | DUP-785 | DUP785 | Sodium 6-Fluoro-2-(2'-fluoro-4-biphenylyl)-3-methyl-4-quinolinecarboxylate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828968","Monterey County, CA","C107900","No value exists.","Monterey County, CA | CA053 | Monterey County | Monterey County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828862","Napa County, CA","C107901","No value exists.","Napa County, CA | CA055 | Napa County | Napa County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812746","Orange County, CA","C107903","No value exists.","Orange County, CA | CA059 | Orange County | Orange County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828543","Placer County, CA","C107904","No value exists.","Placer County, CA | CA061 | Placer County | Placer County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827198","Plumas County, CA","C107905","No value exists.","Plumas County, CA | CA063 | Plumas County | Plumas County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828318","Riverside County, CA","C107906","No value exists.","Riverside County, CA | CA065 | Riverside County | Riverside County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828281","Sacramento County, CA","C107907","No value exists.","Sacramento County, CA | CA067 | Sacramento County | Sacramento County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828261","San Bernardino County, CA","C107909","No value exists.","San Bernardino County, CA | CA071 | San Bernardino County | San Bernardino County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828258","San Diego County, CA","C107910","No value exists.","San Diego County, CA | CA073 | San Diego County | San Diego County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828255","San Francisco County, CA","C107911","No value exists.","San Francisco County, CA | CA075 | San Francisco County | San Francisco County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828250","San Joaquin County, CA","C107912","No value exists.","San Joaquin County, CA | CA077 | San Joaquin County | San Joaquin County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3256183","rice germ oil","C107354","The oil extracted from the germ and inner husk of Oryza sativa grains. Rice bran oil is used as a cooking oil and as a substitute for carnauba wax in cosmetics, confectionery, shoe creams and polishing compounds.","Rice Germ Oil | RICE GERM OIL | Rice Bran Extract | Rice Bran Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3177516","FAK Inhibitor VS-4718","C107238","An orally bioavailable focal adhesion kinase (FAK) inhibitor with potential antineoplastic activity. Upon administration, VS-4718 inhibits FAK, blocks fibronectin-stimulated FAK autophosphorylation of Tyr397, and may prevent the integrin-mediated activation of several downstream signal transduction pathways, including ERK, JNK/MAPK and PI3K/Akt. This results in the reduction of the number of cancer stem cells (CSCs) and inhibits tumor cell migration, proliferation and survival. The cytoplasmic tyrosine kinase FAK is a signal transducer for integrins and is constitutively activated in various tumor cell types; it is involved in tumor cell invasion, migration and proliferation and plays a key role in the development, function and survival of CSCs.","FAK Inhibitor VS-4718 | VS-4718",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827145","FACT Complex-targeting Curaxin CBL0137","C107239","An orally available curaxin-based agent targeting the Facilitates Chromatin Transcription (FACT) complex, with potential antineoplastic activity. Upon administration, CBL0137 binds to FACT and sequesters the FACT complex on chromatin, which inhibits its activity. This prevents transcription of certain genes involved in cancer-associated signaling pathways; it specifically inhibits the transcription of both NF-kappa B and heat shock transcription factor 1 (HSF1) and simultaneously activates p53. This causes an increase in tumor cell apoptosis and a decrease in tumor cell proliferation, in FACT-positive cancers. In addition, this agent is able to sensitize FACT-positive tumor cells to the cytotoxic effects of other chemotherapeutic agents. FACT, a transcription and replication factor composed of the Structure Specific Recognition Protein (SSRP1) and suppressor of Ty 16 (Spt16) proteins, is expressed in a variety of tumor cells while almost absent in normal cells; its expression is associated with increased tumor aggressiveness and poor prognosis.","FACT Complex-targeting Curaxin CBL0137 | CBL0137",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449496","CD19CAR-CD28zeta-4-1BB-expressing Allogeneic T Lymphocytes","C107242","Allogeneic T-lymphocytes transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) coupled to the costimulatory signaling domain CD28, the signaling domain of 4-1BB (CD137), and the zeta chain of the T-cell receptor (TCR), with potential immunomodulating and antineoplastic activities. Upon transfusion, CD19CAR-CD28 zeta-4-1BB-expressing allogeneic T lymphocytes directs the T-lymphocytes to and induces selective toxicity in CD19-expressing tumor cells. CD28, a T-cell surface-associated co-stimulatory molecule, is required for T-cell activation, proliferation, and survival. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19. Furthermore, inclusion of the 4-1BB signaling domain may increase the antitumor activity compared to the inclusion of the CD28 costimulatory domain and TCR zeta chain alone. CD19 antigen is a B-cell specific cell surface antigen, which is expressed in all B-cell lineage malignancies.","CD19CAR-CD28zeta-4-1BB-expressing Allogeneic T Lymphocytes | Allogeneic CD19.CAR/28137zeta T-lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449497","PEP-CMV Vaccine","C107243","A peptide vaccine derived from cytomegalovirus (CMV) antigens with potential immunostimulating activity. Intradermal administration of the PEP-CMV vaccine may stimulate the immune system to mount a specific helper and cytotoxic T-lymphocyte (CTL) response against CMV-infected tumor cells. Infection with the herpesvirus CMV may play a significant role in tumor cell initiation and progression as well as chemoresistance.","PEP-CMV Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813287","Richmond County, GA","C108195","No value exists.","Richmond County, GA | GA245 | Richmond County | Richmond County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828310","Rockdale County, GA","C108196","No value exists.","Rockdale County, GA | GA247 | Rockdale County | Rockdale County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828218","Schley County, GA","C108197","No value exists.","Schley County, GA | GA249 | Schley County | Schley County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831097","Citrus County, FL","C108016","No value exists.","Citrus County, FL | Citrus County | Citrus County, Florida | FL017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814510","Clay County, FL","C108017","No value exists.","Clay County, FL | Clay County | Clay County, Florida | FL019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831051","Collier County, FL","C108018","No value exists.","Collier County, FL | Collier County | Collier County, Florida | FL021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812188","Columbia County, FL","C108019","No value exists.","Columbia County, FL | Columbia County | Columbia County, Florida | FL023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815535","DeSoto County, FL","C108020","No value exists.","DeSoto County, FL | DeSoto County | DeSoto County, Florida | FL027",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830415","Dixie County, FL","C108021","No value exists.","Dixie County, FL | Dixie County | Dixie County, Florida | FL029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810529","Duval County, FL","C108022","No value exists.","Duval County, FL | Duval County | Duval County, Florida | FL031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811120","Escambia County, FL","C108023","No value exists.","Escambia County, FL | Escambia County | Escambia County, Florida | FL033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830109","Flagler County, FL","C108024","No value exists.","Flagler County, FL | FL035 | Flagler County | Flagler County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814016","Franklin County, FL","C108025","No value exists.","Franklin County, FL | FL037 | Franklin County | Franklin County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830058","Gadsden County, FL","C108026","No value exists.","Gadsden County, FL | FL039 | Gadsden County | Gadsden County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829982","Gilchrist County, FL","C108027","No value exists.","Gilchrist County, FL | FL041 | Gilchrist County | Gilchrist County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829919","Gulf County, FL","C108029","No value exists.","Gulf County, FL | FL045 | Gulf County | Gulf County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814511","Hamilton County, FL","C108030","No value exists.","Hamilton County, FL | FL047 | Hamilton County | Hamilton County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829849","Hardee County, FL","C108031","No value exists.","Hardee County, FL | FL049 | Hardee County | Hardee County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829705","Hernando County, FL","C108033","No value exists.","Hernando County, FL | FL053 | Hernando County | Hernando County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814512","Highlands County, FL","C108034","No value exists.","Highlands County, FL | FL055 | Highlands County | Highlands County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812218","Hillsborough County, FL","C108035","No value exists.","Hillsborough County, FL | FL057 | Hillsborough County | Hillsborough County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810608","Nitrogen Dioxide Sterilization","C107416","A sterilization process that uses nitrogen dioxide to kill microorganisms.","Nitrogen Dioxide Sterilization | Nitrogen Dioxide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827894","Supercritical Carbon Dioxide Sterilization","C107417","A sterilization process that uses supercritical carbon dioxide to kill microorganisms.","Supercritical Carbon Dioxide Sterilization | Supercritical Carbon Dioxide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829272","Liquid Chemical Sterilization","C107418","A sterilization process to kill microorganisms using a liquid sterilant.","Liquid Chemical Sterilization | Liquid Chemical Sterilant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811306","Effingham County, IL","C108307","No value exists.","Effingham County, IL | Effingham County | Effingham County, Illinois | IL049",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812212","Fayette County, IL","C108308","No value exists.","Fayette County, IL | Fayette County | Fayette County, Illinois | IL051",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813575","Ford County, IL","C108309","No value exists.","Ford County, IL | Ford County | Ford County, Illinois | IL053",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814007","Franklin County, IL","C108310","No value exists.","Franklin County, IL | Franklin County | Franklin County, Illinois | IL055",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814428","Fulton County, IL","C108311","No value exists.","Fulton County, IL | Fulton County | Fulton County, Illinois | IL057",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814405","Greene County, IL","C108313","No value exists.","Greene County, IL | Greene County | Greene County, Illinois | IL061",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814415","Grundy County, IL","C108314","No value exists.","Grundy County, IL | Grundy County | Grundy County, Illinois | IL063",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815149","Hamilton County, IL","C108315","No value exists.","Hamilton County, IL | Hamilton County | Hamilton County, Illinois | IL065",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815166","Hancock County, IL","C108316","No value exists.","Hancock County, IL | Hancock County | Hancock County, Illinois | IL067",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815545","Hardin County, IL","C108317","No value exists.","Hardin County, IL | Hardin County | Hardin County, Illinois | IL069",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811142","Henry County, IL","C108319","No value exists.","Henry County, IL | Henry County | Henry County, Illinois | IL073",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828299","Rosa alba Flower Extract","C107355","The oil extracted from the flower petals of Rosa alba. Rosa alba oil is used for its aromatic properties.","Rosa alba Flower Extract | ROSA X ALBA FLOWER OIL | Rosa alba Flower Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3256256","ROSA CENTIFOLIA FLOWER OIL","C107356","The oil extracted from the flowers of Rosa centifolia. Rose oil is used as a frangrance component.","Rosa centifolia Flower Oil | ROSA CENTIFOLIA FLOWER OIL | Rose Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3256258","Rosa damascena Flower Oil","C107357","The oil extracted from the flowers of Rosa damascena. Rose oil is used as a frangrance component.","Rosa damascena Flower Oil | ROSA X DAMASCENA FLOWER OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3473990","Rosa gallica Flower Oil","C107358","The oil extracted from the flowers of Rosa gallica. Rose oil is used as a frangrance component.","Rosa gallica Flower Oil | ROSA GALLICA FLOWER OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3256271","Rosa moschata Oil","C107359","The oil extracted from the flowers of Rosa moschata. Rose oil is used in skincare preparations.","Rosa moschata Oil | ROSA MOSCHATA OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828280","Saffron Oil","C107361","The oil extracted from the stigmas of the Crocus sativus flower. Saffron oil is used for external application in uterine sores.","Saffron Oil | SAFFRON OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828276","Saigon Cinnamon Leaf Oil","C107362","The essential oil of Cinnamomum loureiroi. Saigon cinnamon leaf oil is used primarily in aromatherapy.","Saigon Cinnamon Leaf Oil | SAIGON CINNAMON LEAF OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827257","Sambucus canadensis Flower Oil","C107363","The oil extracted from the flowers of Sambucus canadensis. Elder flower oil can be taken as a natural laxitive or used externally for skin conditions.","Sambucus canadensis Flower Oil | Elder Flower Oil | Elderberry Flower Oil | SAMBUCUS CANADENSIS FLOWER OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0304115","Sandalwood Oil","C107365","The oil extracted from the heartwood of Santalum album. Sandalwood oil is used in perfumery, aromatherapy and skin care.","Sandalwood Oil | Indian Sandalwood Oil | SANDALWOOD OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3256723","Santalum spicatum Oil","C107366","The oil extracted from the heartwood of Santalum spicatum. Australian sandalwood oil is used as a substitute for Inidan sandalwood oil in perfumery, aromatherapy and skin care.","Santalum spicatum Oil | Australian Sandalwood Oil | SANTALUM SPICATUM OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0304119","Thyme Oil","C107367","The essential oil of Thymus vulgaris. Thyme oil is used for its antibiotic and antifungal activities.","Thyme Oil | THYME OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538555","turmeric oil","C107368","The oil extracted from the rhizomes of Curcuma longa. Turmerica oil is used for aromatherapy and can be used for its antioxidant and anti-inflammatory properties.","Turmeric Oil | TURMERIC OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811809","Turpentine Oil","C107369","The oily fluid obtained by the distillation of various pine resins. Turpentine is used as a solvent, industrial ingredient, and medicinal ingredient.","Turpentine Oil | Spirit of Turpentine | TURPENTINE OIL | Turpentine | Wood Turpentine",,,,,,,,,,,,,,,"4115902","Oil of turpentine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0458162","Walnut Oil","C107370","The oil pressed from English walnut seeds, Juglans regia. Walnut oil is most often used as a flavoring ingredient in cooking.","Walnut Oil | WALNUT OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3256877","West Indian lemongrass oil","C107371","The essential oil of Cymbopogon citratus. Lemongrass oils have been used as a pesticide or preservative and may have antifungal properties.","West Indian Lemongrass Oil | Lemongrass Oil | WEST INDIAN LEMONGRASS OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0244994","Wheat Germ Oil","C107372","The oil extracted from the germ of the wheat kernel. Wheat germ oil can be used as a source of vitamin E and for the treatment of skin conditions.","Wheat Germ Oil | WHEAT GERM OIL",,,,,,,,,,,,,,,"4047289","Wheatgerm oil",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828212","Screven County, GA","C108198","No value exists.","Screven County, GA | GA251 | Screven County | Screven County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827967","Spalding County, GA","C108200","No value exists.","Spalding County, GA | GA255 | Spalding County | Spalding County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814460","Stephens County, GA","C108201","No value exists.","Stephens County, GA | GA257 | Stephens County | Stephens County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814470","Stewart County, GA","C108202","No value exists.","Stewart County, GA | GA259 | Stewart County | Stewart County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814488","Sumter County, GA","C108203","No value exists.","Sumter County, GA | GA261 | Sumter County | Sumter County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827233","Taliaferro County, GA","C108205","No value exists.","Taliaferro County, GA | GA265 | Taliaferro County | Taliaferro County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827854","Tattnall County, GA","C108206","No value exists.","Tattnall County, GA | GA267 | Tattnall County | Tattnall County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814490","Taylor County, GA","C108207","No value exists.","Taylor County, GA | GA269 | Taylor County | Taylor County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827848","Telfair County, GA","C108208","No value exists.","Telfair County, GA | GA271 | Telfair County | Telfair County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814492","Thomas County, GA","C108210","No value exists.","Thomas County, GA | GA275 | Thomas County | Thomas County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827832","Tift County, GA","C108211","No value exists.","Tift County, GA | GA277 | Tift County | Tift County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827810","Toombs County, GA","C108212","No value exists.","Toombs County, GA | GA279 | Toombs County | Toombs County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827797","Towns County, GA","C108213","No value exists.","Towns County, GA | GA281 | Towns County | Towns County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827774","Treutlen County, GA","C108214","No value exists.","Treutlen County, GA | GA283 | Treutlen County | Treutlen County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811807","Turner County, GA","C108216","No value exists.","Turner County, GA | GA287 | Turner County | Turner County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827745","Twiggs County, GA","C108217","No value exists.","Twiggs County, GA | GA289 | Twiggs County | Twiggs County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813233","Union County, GA","C108218","No value exists.","Union County, GA | GA291 | Union County | Union County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827690","Upson County, GA","C108219","No value exists.","Upson County, GA | GA293 | Upson County | Upson County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281514","cytarabine/topotecan","C10821","A regimen consisting of cytarabine and topotecan that may be used in certain types of acute myeloid leukemia (AML).","Cytarabine/Topotecan Regimen | ARA-C/TOPO | AraC/Topotecan | Cytarabine-Topotecan | Cytarabine/Topotecan | Cytosar-U/Hycamtin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812770","Walton County, GA","C108221","No value exists.","Walton County, GA | GA297 | Walton County | Walton County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827513","Ware County, GA","C108222","No value exists.","Ware County, GA | GA299 | Ware County | Ware County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812787","Warren County, GA","C108223","No value exists.","Warren County, GA | GA301 | Warren County | Warren County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812791","Washington County, GA","C108224","No value exists.","Washington County, GA | GA303 | Washington County | Washington County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829698","High-level Disinfectant Sterilization","C107419","A sterilization method that uses a disinfectant for a period of time to kill all microorganisms except small numbers of bacterial spores.","High-level Disinfectant Sterilization | High Level Disinfectant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813586","RIP","C107421","Human DCAF1 wild-type allele is located in the vicinity of 3p21.2 and is approximately 110 kb in length. This allele, which encodes DDB1- and CUL4-associated factor 1 protein, is involved in both substrate recognition by the E3 ubiquitin-protein ligase complex and serine-threonine phosphorylation.","DCAF1 wt Allele | DDB1 and CUL4 Associated Factor 1 wt Allele | KIAA0800 | MGC102804 | RIP | VPRBP | Vpr (HIV-1) Binding Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2355557","VprBP protein, human","C107422","DDB1- and CUL4-associated factor 1 (1507 aa, ~169 kDa) is encoded by the human DCAF1 gene. This protein plays a role in both serine/threonine-protein kinase activity and E3 ubiquitin-protein ligase complex substrate recognition.","DDB1- and CUL4-Associated Factor 1 | DCAF1 | DDB1 and CUL4 Associated Factor 1 | EC 2.7.11.1 | HIV-1 Vpr-Binding Protein | Protein VPRBP | Serine/Threonine-Protein Kinase VPRBP | Vpr-Binding Protein | Vpr-Interacting Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813559","MAGEB2 wt Allele","C107425","Human MAGEB2 wild-type allele is located in the vicinity of Xp21.3 and is approximately 5 kb in length. This allele, which encodes melanoma-associated antigen B2 protein, plays a role in regulating ubiquitin ligase activity.","MAGEB2 wt Allele | CT3.2 | DAM6 | MAGE-XP-2 | MGC26438 | Melanoma Antigen Family B, 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810524","Melanoma-Associated Antigen B2, Human","C107428","Melanoma-associated antigen B2 (319 aa, ~35 kDa) is encoded by the human MAGEB2 gene. This protein is involved in enhancing ubiquitin ligase activity.","Melanoma-Associated Antigen B2 | Cancer/Testis Antigen 3.2 | Cancer/Testis Antigen Family 3, Member 2 | DSS-AHC Critical Interval MAGE Superfamily 6 | DSS/AHC Critical Interval MAGE Superfamily 6 | MAGE XP-2 Antigen | MAGE-B2 Antigen | MAGEB2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811193","Marshall County, IA","C108540","No value exists.","Marshall County, IA | IA127 | Marshall County | Marshall County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810692","Mills County, IA","C108541","No value exists.","Mills County, IA | IA129 | Mills County | Mills County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810701","Mitchell County, IA","C108542","No value exists.","Mitchell County, IA | IA131 | Mitchell County | Mitchell County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828972","Monona County, IA","C108543","No value exists.","Monona County, IA | IA133 | Monona County | Monona County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810710","Monroe County, IA","C108544","No value exists.","Monroe County, IA | IA135 | Monroe County | Monroe County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811266","Montgomery County, IA","C108545","No value exists.","Montgomery County, IA | IA137 | Montgomery County | Montgomery County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829199","Maricopa County, AZ","C107791","No value exists.","Maricopa County, AZ | AZ013 | Maricopa County | Maricopa County, Arizona",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828982","Mohave County, AZ","C107792","No value exists.","Mohave County, AZ | AZ015 | Mohave County | Mohave County, Arizona",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828848","Navajo County, AZ","C107793","No value exists.","Navajo County, AZ | AZ017 | Navajo County | Navajo County, Arizona",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828555","Pima County, AZ","C107794","No value exists.","Pima County, AZ | AZ019 | Pima County | Pima County, Arizona",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811237","Santa Cruz County, AZ","C107796","No value exists.","Santa Cruz County, AZ | AZ023 | Santa Cruz County | Santa Cruz County, Arizona",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827407","Yavapai County, AZ","C107797","No value exists.","Yavapai County, AZ | AZ025 | Yavapai County | Yavapai County, Arizona",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810757","Yuma County, AZ","C107798","No value exists.","Yuma County, AZ | AZ027 | Yuma County | Yuma County, Arizona",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831477","Arkansas County, AR","C107799","No value exists.","Arkansas County, AR | AR001 | Arkansas County | Arkansas County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0058758","Dromostanolone Propionate","C1077","The propionate salt form of dromostanolone, a synthetic anabolic steroid related to dihydrotestosterone that has antiestrogenic effects.  Dromostanolone inhibits the growth of estrogen receptor-presenting breast cancers; its virilizing effects limit its clinical usefulness. (NCI)","Dromostanolone Propionate | 2 Alpha-Methyldihydrotestosterone Propionate | 2-Alpha-Methyldihydrotestosterone Propionate | 2.alpha.-Methyldihydrotestosterone propionate | Compound 32379 | DROMOSTANOLONE PROPIONATE | Drolban | Drostanolone Propionate | Drostanolone propionate | Emdisterone | Masterid | Masteril | Masteron | Masterone | Permastril",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3474474","White Pine Oil","C107373","The essential oil of Pinus strobus. White pine oil may be used for skincare preparations and aromatherapy. It is also used commonly in household cleaning products.","White Pine Oil | WHITE PINE OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815156","Hamilton County, IN","C108413","No value exists.","Hamilton County, IN | Hamilton County | Hamilton County, Indiana | IN057",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815165","Hancock County, IN","C108414","No value exists.","Hancock County, IN | Hancock County | Hancock County, Indiana | IN059",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815558","Harrison County, IN","C108415","No value exists.","Harrison County, IN | Harrison County | Harrison County, Indiana | IN061",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829714","Hendricks County, IN","C108416","No value exists.","Hendricks County, IN | Hendricks County | Hendricks County, Indiana | IN063",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811146","Henry County, IN","C108417","No value exists.","Henry County, IN | Henry County | Henry County, Indiana | IN065",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827213","Huntington County, IN","C108419","No value exists.","Huntington County, IN | Huntington County | Huntington County, Indiana | IN069",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816465","Jackson County, IN","C108420","No value exists.","Jackson County, IN | IN071 | Jackson County | Jackson County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816475","Jasper County, IN","C108421","No value exists.","Jasper County, IN | IN073 | Jasper County | Jasper County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829465","Jay County, IN","C108422","No value exists.","Jay County, IN | IN075 | Jay County | Jay County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829460","Jennings County, IN","C108424","No value exists.","Jennings County, IN | IN079 | Jennings County | Jennings County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816493","Johnson County, IN","C108425","No value exists.","Johnson County, IN | IN081 | Johnson County | Johnson County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813268","Knox County, IN","C108426","No value exists.","Knox County, IN | IN083 | Knox County | Knox County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829366","Kosciusko County, IN","C108427","No value exists.","Kosciusko County, IN | IN085 | Kosciusko County | Kosciusko County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829345","LaGrange County, IN","C108428","No value exists.","LaGrange County, IN | IN087 | LaGrange County | LaGrange County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829330","LaPorte County, IN","C108430","No value exists.","LaPorte County, IN | IN091 | LaPorte County | LaPorte County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813662","Lawrence County, IN","C108431","No value exists.","Lawrence County, IN | IN093 | Lawrence County | Lawrence County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815912","Madison County, IN","C108432","No value exists.","Madison County, IN | IN095 | Madison County | Madison County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811177","Marion County, IN","C108433","No value exists.","Marion County, IN | IN097 | Marion County | Marion County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811194","Marshall County, IN","C108434","No value exists.","Marshall County, IN | IN099 | Marshall County | Marshall County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810712","Monroe County, IN","C108437","No value exists.","Monroe County, IN | IN105 | Monroe County | Monroe County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811268","Montgomery County, IN","C108438","No value exists.","Montgomery County, IN | IN107 | Montgomery County | Montgomery County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811288","Morgan County, IN","C108439","No value exists.","Morgan County, IN | IN109 | Morgan County | Morgan County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828879","Muscatine County, IA","C108546","No value exists.","Muscatine County, IA | IA139 | Muscatine County | Muscatine County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812812","Osceola County, IA","C108548","No value exists.","Osceola County, IA | IA143 | Osceola County | Osceola County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812824","Page County, IA","C108549","No value exists.","Page County, IA | IA145 | Page County | Page County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827373","Palo Alto County, IA","C108550","No value exists.","Palo Alto County, IA | IA147 | Palo Alto County | Palo Alto County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811220","Plymouth County, IA","C108551","No value exists.","Plymouth County, IA | IA149 | Plymouth County | Plymouth County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811766","Pocahontas County, IA","C108552","No value exists.","Pocahontas County, IA | IA151 | Pocahontas County | Pocahontas County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828502","Pottawattamie County, IA","C108554","No value exists.","Pottawattamie County, IA | IA155 | Pottawattamie County | Pottawattamie County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828498","Poweshiek County, IA","C108555","No value exists.","Poweshiek County, IA | IA157 | Poweshiek County | Poweshiek County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828324","Ringgold County, IA","C108556","No value exists.","Ringgold County, IA | IA159 | Ringgold County | Ringgold County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828282","Sac County, IA","C108557","No value exists.","Sac County, IA | IA161 | Sac County | Sac County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815245","Shelby County, IA","C108559","No value exists.","Shelby County, IA | IA165 | Shelby County | Shelby County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810614","Sioux County, IA","C108560","No value exists.","Sioux County, IA | IA167 | Sioux County | Sioux County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827914","Story County, IA","C108561","No value exists.","Story County, IA | IA169 | Story County | Story County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827863","Tama County, IA","C108562","No value exists.","Tama County, IA | IA171 | Tama County | Tama County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813224","Union County, IA","C108564","No value exists.","Union County, IA | IA175 | Union County | Union County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811343","Van Buren County, IA","C108565","No value exists.","Van Buren County, IA | IA177 | Van Buren County | Van Buren County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827514","Wapello County, IA","C108566","No value exists.","Wapello County, IA | IA179 | Wapello County | Wapello County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812774","Warren County, IA","C108567","No value exists.","Warren County, IA | IA181 | Warren County | Warren County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813259","Wayne County, IA","C108569","No value exists.","Wayne County, IA | IA185 | Wayne County | Wayne County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813616","Webster County, IA","C108570","No value exists.","Webster County, IA | IA187 | Webster County | Webster County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810740","Winnebago County, IA","C108571","No value exists.","Winnebago County, IA | IA189 | Winnebago County | Winnebago County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827456","Winneshiek County, IA","C108572","No value exists.","Winneshiek County, IA | IA191 | Winneshiek County | Winneshiek County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831395","Baxter County, AR","C107801","No value exists.","Baxter County, AR | AR005 | Baxter County | Baxter County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811862","Benton County, AR","C107802","No value exists.","Benton County, AR | AR007 | Benton County | Benton County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811878","Boone County, AR","C107803","No value exists.","Boone County, AR | AR009 | Boone County | Boone County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811883","Bradley County, AR","C107804","No value exists.","Bradley County, AR | AR011 | Bradley County | Bradley County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812345","Calhoun County, AR","C107805","No value exists.","Calhoun County, AR | AR013 | Calhoun County | Calhoun County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831119","Chicot County, AR","C107807","No value exists.","Chicot County, AR | AR017 | Chicot County | Chicot County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812369","Clark County, AR","C107808","No value exists.","Clark County, AR | AR019 | Clark County | Clark County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811077","Clay County, AR","C107809","No value exists.","Clay County, AR | AR021 | Clay County | Clay County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811092","Cleburne County, AR","C107810","No value exists.","Cleburne County, AR | AR023 | Cleburne County | Cleburne County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811094","Cleveland County, AR","C107811","No value exists.","Cleveland County, AR | AR025 | Cleveland County | Cleveland County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827343","Conway County, AR","C107813","No value exists.","Conway County, AR | AR029 | Conway County | Conway County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830985","Craighead County, AR","C107814","No value exists.","Craighead County, AR | AR031 | Craighead County | Craighead County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812370","Crawford County, AR","C107815","No value exists.","Crawford County, AR | AR033 | Crawford County | Crawford County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812371","Crittenden County, AR","C107816","No value exists.","Crittenden County, AR | AR035 | Crittenden County | Crittenden County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810762","Dallas County, AR","C107818","No value exists.","Dallas County, AR | AR039 | Dallas County | Dallas County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830532","Desha County, AR","C107819","No value exists.","Desha County, AR | AR041 | Desha County | Desha County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2954886","Curcuma xanthorrhiza Oil","C107298","The oil extracted from the root tuber of Curcuma xanthorrhiza. Curcuma xanthorrhiza oil is used primarily in skincare preparations.","Curcuma xanthorrhiza Oil | CURCUMA ZANTHORRHIZA OIL | Curcuma xanthorrhiza Root Oil | Curcuma zanthorrhiza Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3256220","CYMBOPOGON SCHOENANTHUS OIL","C107299","The essential oil of Cymbopogon schoenanthus. Cymbopogon schoenanthus oil is used for its aromatic properties.","Cymbopogon schoenanthus Oil | CYMBOPOGON SCHOENANTHUS OIL | Camel Grass Oil | Lemongrass Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3710068","Davana Oil","C107300","The essential oil of Artemisia pallens. Davana oil is used in making perfumes and can be processed to yield the anthelmintic chemical santonin.","Davana Oil | DAVANA OIL | Dhavanam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810595","Newton County, IN","C108440","No value exists.","Newton County, IN | IN111 | Newton County | Newton County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812734","Ohio County, IN","C108442","No value exists.","Ohio County, IN | IN115 | Ohio County | Ohio County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812747","Orange County, IN","C108443","No value exists.","Orange County, IN | IN117 | Orange County | Orange County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812822","Owen County, IN","C108444","No value exists.","Owen County, IN | IN119 | Owen County | Owen County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828662","Parke County, IN","C108445","No value exists.","Parke County, IN | IN121 | Parke County | Parke County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1529241","SLC18A1 protein, human","C107580","Chromaffin granule amine transporter (525 aa, ~56 kDa) is encoded by the human SLC18A1 gene. This protein is involved in the transport of biogenic monoamines into secretory vesicles.","Chromaffin Granule Amine Transporter | Solute Carrier Family 18 Member 1 | Vesicular Amine Transporter 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830129","FGFR2 Protein Variant","C107581","A variation in the amino acid sequence for the fibroblast growth factor receptor 2 protein.","FGFR2 Protein Variant | CD332 Antigen Protein Variant | FGFR-2 Protein Variant | Fibroblast Growth Factor Receptor 2 Protein Variant | KGFR Protein Variant | Keratinocyte Growth Factor Receptor Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830138","FGFR2 NM_000141.4:c.755C>G","C107583","A nucleotide substitution at position 755 of the coding sequence of the FGFR2 gene where cytosine has been mutated to guanine.","FGFR2 NM_000141.4:c.755C>G | BEK c.755C>G | CD332 c.755C>G | ECT1 c.755C>G | FGFR2 c.755C>G | Fibroblast Growth Factor Receptor 2 c.755C>G | K-SAM c.755C>G | KGFR c.755C>G | NM_000141.4:c.755C>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811714","IL10RA wt Allele","C107584","Human IL10RA wild-type allele is located in the vicinity of 11q23.3 and is approximately 15 kb in length. This allele, which encodes interleukin-10 receptor subunit alpha protein, is involved in the regulation of immunosuppression. Mutations in this gene are associated with inflammatory bowel disease 28, early onset, autosomal recessive.","IL10RA wt Allele | CD210 | CD210a | CDW210A | HIL-10R | IBD28 | IL-10R1 | IL-10RA | IL10R | Interleukin 10 Receptor, Alpha wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1721051","Interleukin-10 Receptor alpha Subunit","C107586","Interleukin-10 receptor subunit alpha (578 aa, ~63 kDa) is encoded by the human IL10RA gene. This protein plays a role in the regulation of immunosuppression.","Interleukin-10 Receptor Subunit Alpha | CD210 Antigen | IL-10R Subunit 1 | IL-10R Subunit Alpha | Interleukin-10 Receptor Alpha Chain | Interleukin-10 Receptor Subunit 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0058753","Dromostanolone","C1076","A synthetic anabolic steroid related to dihydrotestosterone that has antiestrogenic effects. Dromostanolone inhibits the growth of estrogen receptor-presenting breast cancers; its virilizing effects limit its clinical usefulness. (NCI04)","Dromostanolone | 17 Beta-hydroxy-2 alpha-methyl-5 alpha-androstan-3-one | 2 Alpha-5 alpha-17 beta-17-hydroxy-2-methyl-androstan-3-one | 2 Alpha-methylandrostan-17 beta-ol-3-one | 2 Alpha-methyldihydrotestosterone | 2.alpha.-Methyldihydrotestosterone | 5.alpha.-Androstan-3-one, 17.beta.-hydroxy-2.alpha.-methyl- | DROMOSTANOLONE | Drostanolone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811873","Clarke County, AL","C107700","No value exists.","Clarke County, AL | AL025 | Clarke County | Clarke County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811078","Clay County, AL","C107701","No value exists.","Clay County, AL | AL027 | Clay County | Clay County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811091","Cleburne County, AL","C107702","No value exists.","Cleburne County, AL | AL029 | Cleburne County | Cleburne County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811874","Coffee County, AL","C107703","No value exists.","Coffee County, AL | AL031 | Coffee County | Coffee County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831027","Conecuh County, AL","C107705","No value exists.","Conecuh County, AL | AL035 | Conecuh County | Conecuh County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831010","Coosa County, AL","C107706","No value exists.","Coosa County, AL | AL037 | Coosa County | Coosa County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811875","Covington County, AL","C107707","No value exists.","Covington County, AL | AL039 | Covington County | Covington County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830981","Crenshaw County, AL","C107708","No value exists.","Crenshaw County, AL | AL041 | Crenshaw County | Crenshaw County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830609","Dale County, AL","C107710","No value exists.","Dale County, AL | AL045 | Dale County | Dale County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814789","Dallas County, AL","C107711","No value exists.","Dallas County, AL | AL047 | Dallas County | Dallas County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815520","DeKalb County, AL","C107712","No value exists.","DeKalb County, AL | AL049 | DeKalb County | DeKalb County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812833","Elmore County, AL","C107713","No value exists.","Elmore County, AL | AL051 | Elmore County | Elmore County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811121","Escambia County, AL","C107714","No value exists.","Escambia County, AL | AL053 | Escambia County | Escambia County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812210","Fayette County, AL","C107716","No value exists.","Fayette County, AL | AL057 | Fayette County | Fayette County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814025","Franklin County, AL","C107717","No value exists.","Franklin County, AL | AL059 | Franklin County | Franklin County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829993","Geneva County, AL","C107718","No value exists.","Geneva County, AL | AL061 | Geneva County | Geneva County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814407","Greene County, AL","C107719","No value exists.","Greene County, AL | AL063 | Greene County | Greene County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815143","Hale County, AL","C107720","No value exists.","Hale County, AL | AL065 | Hale County | Hale County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814040","TRAF7 wt Allele","C107647","Human TRAF7 wild-type allele is located in the vicinity of 16p13.3 and is approximately 22 kb in length. This allele, which encodes E3 ubiquitin-protein ligase TRAF7 protein, plays a role in the positive regulation of both protein ubiquitination and MAPK signaling pathways.","TRAF7 wt Allele | CAFDADD | DKFZp586I021 | MGC7807 | RFWD1 | RNF119 | TNF Receptor Associated Factor 7 wt Allele | TNF Receptor-Associated Factor 7, E3 Ubiquitin Protein Ligase wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1452015","TRAF7 protein, human","C107648","E3 ubiquitin-protein ligase TRAF7 (670 aa, ~75 kDa) is encoded by the human TRAF7 gene. This protein is involved in both protein ubiquitination and MAPK signaling.","E3 Ubiquitin-Protein Ligase TRAF7 | EC 2.3.2.27 | EC 6.3.2.-, Formerly | RING Finger Protein 119 | RING Finger and WD Repeat Domains-Containing Protein 1 | RING Finger and WD Repeat-Containing Protein 1 | RING-Type E3 Ubiquitin Transferase TRAF7 | Ring Finger and WD Repeat Domain 1 | TNF Receptor-Associated Factor 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830517","Dianthus caryophyllus Flower Oil","C107301","The oil extracted from the flowers of Dianthus caryophyllus. Carnation flower oil is used as a fragrance component.","Dianthus caryophyllus Flower Oil | Carnation Flower Oil | DIANTHUS CARYOPHYLLUS FLOWER OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0790018","Dill Seed Oil","C107302","The oil extracted from the seeds of Anethum graveolens. Dill seed oil is believed to sooth the nerves and is also used for digestive issues.","Dill Seed Oil | DILL SEED OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1815743","Dill Weed Oil","C107303","The essential oil of Anethum graveolens. Dill weed oil is used as treatment for digestive complaints.","Dill Weed Oil | DILLWEED OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3488915","East Indian Lemongrass Oil","C107304","The essential oil of Cymbopogon flexuosus. East Indian lemongrass oil has antifungal activity.","East Indian Lemongrass Oil | EAST INDIAN LEMONGRASS OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1337244","EMU OIL","C107305","An oil rendered from the fat of the emu, Dromaius novaehollandiae. Emu oil is used for its anti-inflammatory and wound healing properties.","Emu Oil | EMU OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3256043","European Hazelnut Oil","C107306","The oil extracted from the nuts of Corylus avellana. Hazelnut oil is used as a food ingredient and flavoring.","European Hazelnut Oil | EUROPEAN HAZELNUT OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830154","Fenugreek Seed Oil","C107307","The oil pressed or distilled from the seeds of trigonella foenum gracecum. Fenugreek seed oil has activity as a phytoestrogen and topical activity as an antimicrobial agent.","Fenugreek Seed Oil | FENUGREEK SEED OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016156","Fish Liver Oil","C107308","The oil extracted from fish such as cod, salmon, and shark. Fish liver oils typically contain high levels of omega-3 fatty acids, EPA and DHA, and vitamins A and D. It is used as a dietary supplement.","Fish Liver Oil | FISH LIVER OIL",,,,,,,,,,,,,,,"4054623","Fish liver oil",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0304137","Ginger Oil","C107310","The essential oil of Zingiber officinale. Ginger oil has been used for digestive health.","Ginger Oil | GINGER OIL | Ginger Root Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0458160","Grape Seed Oil","C107311","The oil extracted from the seeds of grapes. Grape seed oil is used in cooking and cosmetics and for medicinal purposes.","Grape Seed Oil | GRAPE SEED OIL | Grape Oil | Grapeseed Oil",,,,,,,,,,,,,,,"4044602","Grapeseed oil",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3256844","GRAPEFRUIT SEED OIL","C107312","The oil extracted from the seeds, pulp, and white membranes of Citrus paradisi. Grapefruit seed oil is used as a food supplement and in cosmetics.","Grapefruit Seed Oil | GRAPEFRUIT SEED OIL | Grapefruit Seed Extract",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0304889","Halibut Liver Oil","C107313","The oil extracted from the liver of Hippoglossus species. Halibut liver oil is taken as a supplement for vitamins A and D.","Halibut Liver Oil | HALIBUT LIVER OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3255685","Hippophae rhamnoides Fruit Oil","C107314","The oil extracted from the fruit of Hippophae rhamnoides. Sea buckhorn fruit oil is used primarily in skincare preparations.","Hippophae rhamnoides Fruit Oil | HIPPOPHAE RHAMNOIDES FRUIT OIL | Sea Buckthorn Fruit Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829501","Iroquois County, IL","C108320","No value exists.","Iroquois County, IL | IL075 | Iroquois County | Iroquois County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816476","Jasper County, IL","C108322","No value exists.","Jasper County, IL | IL079 | Jasper County | Jasper County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816477","Jefferson County, IL","C108323","No value exists.","Jefferson County, IL | IL081 | Jefferson County | Jefferson County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829457","Jersey County, IL","C108324","No value exists.","Jersey County, IL | IL083 | Jersey County | Jersey County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829452","Jo Daviess County, IL","C108325","No value exists.","Jo Daviess County, IL | IL085 | Jo Daviess County | Jo Daviess County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816490","Johnson County, IL","C108326","No value exists.","Johnson County, IL | IL087 | Johnson County | Johnson County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827291","Kankakee County, IL","C108328","No value exists.","Kankakee County, IL | IL091 | Kankakee County | Kankakee County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830137","FGFR2 NM_000141.4:c.758C>G","C107590","A nucleotide substitution at position 758 of the coding sequence of the FGFR2 gene where cytosine has been mutated to guanine.","FGFR2 NM_000141.4:c.758C>G | BEK c.758C>G | CD332 c.758C>G | ECT1 c.758C>G | FGFR2 c.758C>G | Fibroblast Growth Factor Receptor 2 c.758C>G | K-SAM c.758C>G | KGFR c.758C>G | NM_000141.4:c.758C>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830145","FGFR2 NM_000141.4:c.1115C>G","C107592","A nucleotide substitution at position 1115 of the coding sequence of the FGFR2 gene where cytosine has been mutated to guanine.","FGFR2 NM_000141.4:c.1115C>G | BEK c.1115C>G | CD332 c.1115C>G | ECT1 c.1115C>G | FGFR2 c.1115C>G | Fibroblast Growth Factor Receptor 2 c.1115C>G | K-SAM c.1115C>G | KGFR c.1115C>G | NM_000141.4:c.1115C>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827246","San Luis Obispo County, CA","C107913","No value exists.","San Luis Obispo County, CA | CA079 | San Luis Obispo County | San Luis Obispo County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828246","San Mateo County, CA","C107914","No value exists.","San Mateo County, CA | CA081 | San Mateo County | San Mateo County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828240","Santa Clara County, CA","C107916","No value exists.","Santa Clara County, CA | CA085 | Santa Clara County | Santa Clara County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828036","Shasta County, CA","C107918","No value exists.","Shasta County, CA | CA089 | Shasta County | Shasta County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815260","Sierra County, CA","C107919","No value exists.","Sierra County, CA | CA091 | Sierra County | Sierra County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828015","Siskiyou County, CA","C107920","No value exists.","Siskiyou County, CA | CA093 | Siskiyou County | Siskiyou County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827994","Solano County, CA","C107921","No value exists.","Solano County, CA | CA095 | Solano County | Solano County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827955","Stanislaus County, CA","C107923","No value exists.","Stanislaus County, CA | CA099 | Stanislaus County | Stanislaus County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827884","Sutter County, CA","C107924","No value exists.","Sutter County, CA | CA101 | Sutter County | Sutter County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827849","Tehama County, CA","C107925","No value exists.","Tehama County, CA | CA103 | Tehama County | Tehama County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810665","Trinity County, CA","C107926","No value exists.","Trinity County, CA | CA105 | Trinity County | Trinity County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827757","Tulare County, CA","C107927","No value exists.","Tulare County, CA | CA107 | Tulare County | Tulare County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827655","Ventura County, CA","C107929","No value exists.","Ventura County, CA | CA111 | Ventura County | Ventura County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827402","Yolo County, CA","C107930","No value exists.","Yolo County, CA | CA113 | Yolo County | Yolo County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827399","Yuba County, CA","C107931","No value exists.","Yuba County, CA | CA115 | Yuba County | Yuba County, California",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811642","Adams County, CO","C107932","No value exists.","Adams County, CO | Adams County | Adams County, Colorado | CO001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812708","Houston County, AL","C107722","No value exists.","Houston County, AL | AL069 | Houston County | Houston County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816460","Jackson County, AL","C107723","No value exists.","Jackson County, AL | AL071 | Jackson County | Jackson County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810766","Jefferson County, AL","C107724","No value exists.","Jefferson County, AL | AL073 | Jefferson County | Jefferson County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813645","Lamar County, AL","C107725","No value exists.","Lamar County, AL | AL075 | Lamar County | Lamar County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813659","Lawrence County, AL","C107727","No value exists.","Lawrence County, AL | AL079 | Lawrence County | Lawrence County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3853559","Lee County, AL","C107728","No value exists.","Lee County, AL | AL081 | Lee County | Lee County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814089","Limestone County, AL","C107729","No value exists.","Limestone County, AL | AL083 | Limestone County | Limestone County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449498","Topical Sirolimus","C107244","A topical formulation containing the macrolide sirolimus (rapamycin), which is produced by the organism Streptomyces hygroscopicus, with potential anti-proliferative activity. Upon application of topical sirolimus, this agent migrates into the skin and is internalized by the affected cells. In turn, sirolimus binds to the immunophilin FK binding protein-12 (FKBP-12) and forms a sirolimus:FKBP-12 complex. This complex binds to and inhibits the activity of the serine/threonine kinase mammalian target of rapamycin (mTOR).  It also decreases the production of vascular endothelial growth factor (VEGF) and results in the suppression of cellular proliferation.","Topical Sirolimus | NPC-12G | NPC-12G Gel | Rapamune Topical Formulation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550786","BRAF(V600E) inhibitor CEP-32496","C107245","An orally available v-raf murine sarcoma viral oncogene homolog B1 (B-raf) serine/threonine protein kinase inhibitor with potential antineoplastic activity. Agerafenib specifically and selectively inhibits the activity of the mutated form (V600E) of B-raf kinase. This inhibits the activation of the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway and may result in a decrease in the proliferation of tumor cells expressing the mutated B-raf gene. The Raf mutation BRAF V600E, in which valine is substituted for glutamic acid at residue 600, is frequently found in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival.","Agerafenib | 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Hydrochloride | AC013773 | AGERAFENIB | CEP-32496 | RXDX-105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812698","Holmes County, FL","C108036","No value exists.","Holmes County, FL | FL059 | Holmes County | Holmes County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814513","Jackson County, FL","C108038","No value exists.","Jackson County, FL | FL063 | Jackson County | Jackson County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814514","Jefferson County, FL","C108039","No value exists.","Jefferson County, FL | FL065 | Jefferson County | Jefferson County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813278","Lafayette County, FL","C108040","No value exists.","Lafayette County, FL | FL067 | Lafayette County | Lafayette County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810758","Lake County, FL","C108041","No value exists.","Lake County, FL | FL069 | Lake County | Lake County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813670","Lee County, FL","C108042","No value exists.","Lee County, FL | FL071 | Lee County | Lee County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829292","Levy County, FL","C108044","No value exists.","Levy County, FL | FL075 | Levy County | Levy County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814085","Liberty County, FL","C108045","No value exists.","Liberty County, FL | FL077 | Liberty County | Liberty County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815907","Madison County, FL","C108046","No value exists.","Madison County, FL | FL079 | Madison County | Madison County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829213","Manatee County, FL","C108047","No value exists.","Manatee County, FL | FL081 | Manatee County | Manatee County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811173","Marion County, FL","C108048","No value exists.","Marion County, FL | FL083 | Marion County | Marion County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827235","Miami-Dade County, FL","C108050","No value exists.","Miami-Dade County, FL | FL086 | Miami-Dade County | Miami-Dade County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810708","Monroe County, FL","C108051","No value exists.","Monroe County, FL | FL087 | Monroe County | Monroe County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812326","Nassau County, FL","C108052","No value exists.","Nassau County, FL | FL089 | Nassau County | Nassau County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828726","Okaloosa County, FL","C108053","No value exists.","Okaloosa County, FL | FL091 | Okaloosa County | Okaloosa County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812751","Orange County, FL","C108055","No value exists.","Orange County, FL | FL095 | Orange County | Orange County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812811","Osceola County, FL","C108056","No value exists.","Osceola County, FL | FL097 | Osceola County | Osceola County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828665","Palm Beach County, FL","C108057","No value exists.","Palm Beach County, FL | FL099 | Palm Beach County | Palm Beach County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828657","Pasco County, FL","C108058","No value exists.","Pasco County, FL | FL101 | Pasco County | Pasco County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828552","Pinellas County, FL","C108059","No value exists.","Pinellas County, FL | FL103 | Pinellas County | Pinellas County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812297","Putnam County, FL","C108061","No value exists.","Putnam County, FL | FL107 | Putnam County | Putnam County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827928","St. Johns County, FL","C108062","No value exists.","St. Johns County, FL | FL109 | St. Johns County | St. Johns County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827923","St. Lucie County, FL","C108063","No value exists.","St. Lucie County, FL | FL111 | St. Lucie County | St. Lucie County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828237","Santa Rosa County, FL","C108064","No value exists.","Santa Rosa County, FL | FL113 | Santa Rosa County | Santa Rosa County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811154","Kendall County, IL","C108329","No value exists.","Kendall County, IL | IL093 | Kendall County | Kendall County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813267","Knox County, IL","C108330","No value exists.","Knox County, IL | IL095 | Knox County | Knox County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813636","Lake County, IL","C108331","No value exists.","Lake County, IL | IL097 | Lake County | Lake County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829325","LaSalle County, IL","C108332","No value exists.","LaSalle County, IL | IL099 | LaSalle County | LaSalle County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813672","Lee County, IL","C108334","No value exists.","Lee County, IL | IL103 | Lee County | Lee County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815599","Livingston County, IL","C108335","No value exists.","Livingston County, IL | IL105 | Livingston County | Livingston County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815606","Logan County, IL","C108336","No value exists.","Logan County, IL | IL107 | Logan County | Logan County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829158","McDonough County, IL","C108337","No value exists.","McDonough County, IL | IL109 | McDonough County | McDonough County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812232","McHenry County, IL","C108338","No value exists.","McHenry County, IL | IL111 | McHenry County | McHenry County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815630","Macon County, IL","C108340","No value exists.","Macon County, IL | IL115 | Macon County | Macon County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829230","Macoupin County, IL","C108341","No value exists.","Macoupin County, IL | IL117 | Macoupin County | Macoupin County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815911","Madison County, IL","C108342","No value exists.","Madison County, IL | IL119 | Madison County | Madison County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811186","Marion County, IL","C108343","No value exists.","Marion County, IL | IL121 | Marion County | Marion County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811744","Mason County, IL","C108345","No value exists.","Mason County, IL | IL125 | Mason County | Mason County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829181","Massac County, IL","C108346","No value exists.","Massac County, IL | IL127 | Massac County | Massac County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813183","Menard County, IL","C108347","No value exists.","Menard County, IL | IL129 | Menard County | Menard County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810671","Mercer County, IL","C108348","No value exists.","Mercer County, IL | IL131 | Mercer County | Mercer County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810711","Monroe County, IL","C108349","No value exists.","Monroe County, IL | IL133 | Monroe County | Monroe County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811287","Morgan County, IL","C108351","No value exists.","Morgan County, IL | IL137 | Morgan County | Morgan County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828951","Moultrie County, IL","C108352","No value exists.","Moultrie County, IL | IL139 | Moultrie County | Moultrie County, Illinois",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827204","Alamosa County, CO","C107933","No value exists.","Alamosa County, CO | Alamosa County | Alamosa County, Colorado | CO003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831480","Archuleta County, CO","C107935","No value exists.","Archuleta County, CO | Archuleta County | Archuleta County, Colorado | CO007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831426","Baca County, CO","C107936","No value exists.","Baca County, CO | Baca County | Baca County, Colorado | CO009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831365","Bent County, CO","C107937","No value exists.","Bent County, CO | Bent County | Bent County, Colorado | CO011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831290","Boulder County, CO","C107938","No value exists.","Boulder County, CO | Boulder County | Boulder County, Colorado | CO013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831257","Broomfield County, CO","C107939","No value exists.","Broomfield County, CO | Broomfield County | Broomfield County, Colorado | CO014",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812843","Cheyenne County, CO","C107941","No value exists.","Cheyenne County, CO | CO017 | Cheyenne County | Cheyenne County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831084","Clear Creek County, CO","C107942","No value exists.","Clear Creek County, CO | CO019 | Clear Creek County | Clear Creek County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831026","Conejos County, CO","C107943","No value exists.","Conejos County, CO | CO021 | Conejos County | Conejos County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831000","Costilla County, CO","C107944","No value exists.","Costilla County, CO | CO023 | Costilla County | Costilla County, Colorado",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827280","Wild Thyme Oil","C107374","The essential oil of Thymus serpyllum. Wild thyme oil is primarily used in skincare preparations.","Wild Thyme Oil | WILD THYME OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827260","Zedoary Oil","C107375","The oil extracted from the rhizomes of Curcuma zedoaria. Zedoary oil is typically used in treatments for digestive complaints.","Zedoary Oil | CURCUMA ZEDOARIA OIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828621","Pediatric Non-Congenital Ventricular Tachycardia","C107376","A disorder characterized by an electrocardiographic finding of three or more consecutive complexes of ventricular origin that was not present at birth in an individual under age 21. The QRS complexes are wide and have an abnormal morphology.","Pediatric Non-Congenital Ventricular Tachycardia | Pediatric Non-congenital Ventricular Tachycardia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3256492","Abies sibirica Leaf Oil","C107256","The essential oil of Abies sibirica. Siberian fir oil is used in aromatherapy and perfumes.","Abies sibirica Leaf Oil | ABIES SIBIRICA LEAF OIL | Siberian Fir Oil | Siberian Pine Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831742","Achillea millefolium Oil","C107257","The essential oil of Achillea millefolium, the yarrow plant. Yarrow oil has activities that can be beneficial to the nervous, genitourinary and digestive systems, and can be used topically for skin care.","Achillea millefolium Oil | ACHILLEA MILLEFOLIUM OIL | Yarrow Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449512","Aesculus hippocastanum Seed Fluid Extract","C107258","The oil extracted from the seeds of Aesculus hippocastanum. Horse chestnut oil is used topically as a treatment for rheumatism and phlebitis.","Aesculus hippocastanum Seed Fluid Extract | AESCULUS HIPPOCASTANUM SEED OIL | Aesculus hippocastanum Seed Oil | Horse Chestnut Seed Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813255","Wayne County, GA","C108225","No value exists.","Wayne County, GA | GA305 | Wayne County | Wayne County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813618","Webster County, GA","C108226","No value exists.","Webster County, GA | GA307 | Webster County | Webster County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813628","Wheeler County, GA","C108227","No value exists.","Wheeler County, GA | GA309 | Wheeler County | Wheeler County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813630","White County, GA","C108228","No value exists.","White County, GA | GA311 | White County | White County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827281","Whitfield County, GA","C108229","No value exists.","Whitfield County, GA | GA313 | Whitfield County | Whitfield County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814069","Wilkes County, GA","C108231","No value exists.","Wilkes County, GA | GA317 | Wilkes County | Wilkes County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814070","Wilkinson County, GA","C108232","No value exists.","Wilkinson County, GA | GA319 | Wilkinson County | Wilkinson County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811320","Worth County, GA","C108233","No value exists.","Worth County, GA | GA321 | Worth County | Worth County, Georgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829735","Hawaii County, HI","C108234","No value exists.","Hawaii County, HI | HI001 | Hawaii County | Hawaii County, Hawaii",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829439","Kalawao County, HI","C108236","No value exists.","Kalawao County, HI | HI005 | Kalawao County | Kalawao County, Hawaii",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829421","Kauai County, HI","C108237","No value exists.","Kauai County, HI | HI007 | Kauai County | Kauai County, Hawaii",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829173","Maui County, HI","C108238","No value exists.","Maui County, HI | HI009 | Maui County | Maui County, Hawaii",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831738","Ada County, ID","C108239","No value exists.","Ada County, ID | Ada County | Ada County, Idaho | ID001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811643","Adams County, ID","C108240","No value exists.","Adams County, ID | Adams County | Adams County, Idaho | ID003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831383","Bear Lake County, ID","C108242","No value exists.","Bear Lake County, ID | Bear Lake County | Bear Lake County, Idaho | ID007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831370","Benewah County, ID","C108243","No value exists.","Benewah County, ID | Benewah County | Benewah County, Idaho | ID009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814516","Sumter County, FL","C108067","No value exists.","Sumter County, FL | FL119 | Sumter County | Sumter County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827882","Suwannee County, FL","C108068","No value exists.","Suwannee County, FL | FL121 | Suwannee County | Suwannee County, Florida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811114","GLB1 wt Allele","C107437","Human GLB1 wild-type allele is located in the vicinity of 3p22.3 and is approximately 101 kb in length. This allele, which encodes beta-galactosidase protein, is involved in the hydrolysis of the terminal beta-galactose from ganglioside substrates.","GLB1 wt Allele | BGAL | EBP | ELNR1 | Galactosidase, Beta 1 wt Allele | MPS4B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1256865","GLB1 protein, human","C107438","Beta-galactosidase (677 aa, ~76 kDa) is encoded by the human GLB1 gene. This protein plays a role in the hydrolysis of the terminal beta-galactose from ganglioside substrates.","Beta-Galactosidase | Acid Beta-Galactosidase | EC 3.2.1.23 | Elastin Receptor 1 | Elastin Receptor 1 (67kD) | Elastin Receptor 1, 67kDa | GLB1 | Lactase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812647","ALPP wt Allele","C107553","Human ALPP wild-type allele is located in the vicinity of 2q37 and is approximately 4 kb in length. This allele, which encodes alkaline phosphatase, placental type protein, is involved in placental alkaline phosphatase activity.","ALPP wt Allele | ALP | Alkaline Phosphatase, Placental (Regan Isozyme) Gene | Alkaline Phosphatase, Placental wt Allele | PALP | PLAP | PLAP-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0740201","Alkaline Phosphatase, Placental Type","C107554","Alkaline phosphatase, placental type (535 aa, ~58 kDa) is encoded by the human ALPP gene. This protein plays a role in phosphate metabolism.","Alkaline Phosphatase, Placental Type | ALPP | Alkaline Phosphatase Regan Isozyme | Alkaline Phosphomonoesterase | EC 3.1.3.1 | PLAP-1 | Placental Alkaline Phosphatase 1 | Regan Isozyme",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830396","Drew County, AR","C107820","No value exists.","Drew County, AR | AR043 | Drew County | Drew County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830173","Faulkner County, AR","C107821","No value exists.","Faulkner County, AR | AR045 | Faulkner County | Faulkner County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449595","MDM2 inhibitor DS-3032b","C107384","The tosylate form of milademetan, an orally available MDM2 (murine double minute 2) antagonist with potential antineoplastic activity. Upon oral administration, milademetan binds to, and prevents the binding of MDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This results in the restoration of p53 signaling and leads to the p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein and a negative regulator of the p53 pathway, is overexpressed in cancer cells; it has been implicated in cancer cell proliferation and survival.","Milademetan Tosylate | DS-3032 Tosylate | DS-3032b | DS-3032b Tosylate | MILADEMETAN TOSYLATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449597","PI3K Inhibitor WX-037","C107386","A phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor WX-037 specifically inhibits PI3K, which prevents the activation of the PI3K/protein kinase B-mediated signaling pathway. This may result in the inhibition of both tumor cell growth and survival in PI3K-overexpressing tumor cells. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","PI3K Inhibitor WX-037 | WX-037",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814110","Perry County, IN","C108446","No value exists.","Perry County, IN | IN123 | Perry County | Perry County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814135","Pike County, IN","C108447","No value exists.","Pike County, IN | IN125 | Pike County | Pike County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828513","Porter County, IN","C108448","No value exists.","Porter County, IN | IN127 | Porter County | Porter County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828511","Posey County, IN","C108449","No value exists.","Posey County, IN | IN129 | Posey County | Posey County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812300","Putnam County, IN","C108451","No value exists.","Putnam County, IN | IN133 | Putnam County | Putnam County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812314","Randolph County, IN","C108452","No value exists.","Randolph County, IN | IN135 | Randolph County | Randolph County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813291","Ripley County, IN","C108453","No value exists.","Ripley County, IN | IN137 | Ripley County | Ripley County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810634","Rush County, IN","C108454","No value exists.","Rush County, IN | IN139 | Rush County | Rush County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814055","St. Joseph County, IN","C108455","No value exists.","St. Joseph County, IN | IN141 | St. Joseph County | St. Joseph County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815244","Shelby County, IN","C108457","No value exists.","Shelby County, IN | IN145 | Shelby County | Shelby County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813603","Spencer County, IN","C108458","No value exists.","Spencer County, IN | IN147 | Spencer County | Spencer County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827952","Starke County, IN","C108459","No value exists.","Starke County, IN | IN149 | Starke County | Starke County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814464","Steuben County, IN","C108460","No value exists.","Steuben County, IN | IN151 | Steuben County | Steuben County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814830","Sullivan County, IN","C108461","No value exists.","Sullivan County, IN | IN153 | Sullivan County | Sullivan County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831351","Bingham County, ID","C108244","No value exists.","Bingham County, ID | Bingham County | Bingham County, Idaho | ID011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811656","Blaine County, ID","C108245","No value exists.","Blaine County, ID | Blaine County | Blaine County, Idaho | ID013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831325","Boise County, ID","C108246","No value exists.","Boise County, ID | Boise County | Boise County, Idaho | ID015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831318","Bonneville County, ID","C108248","No value exists.","Bonneville County, ID | Bonneville County | Bonneville County, Idaho | ID019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831289","Boundary County, ID","C108249","No value exists.","Boundary County, ID | Boundary County | Boundary County, Idaho | ID021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813140","Butte County, ID","C108250","No value exists.","Butte County, ID | Butte County | Butte County, Idaho | ID023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831218","Camas County, ID","C108251","No value exists.","Camas County, ID | Camas County | Camas County, Idaho | ID025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831195","Caribou County, ID","C108253","No value exists.","Caribou County, ID | Caribou County | Caribou County, Idaho | ID029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831186","Cassia County, ID","C108254","No value exists.","Cassia County, ID | Cassia County | Cassia County, Idaho | ID031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815509","Clark County, ID","C108255","No value exists.","Clark County, ID | Clark County | Clark County, Idaho | ID033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811090","Clearwater County, ID","C108256","No value exists.","Clearwater County, ID | Clearwater County | Clearwater County, Idaho | ID035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813963","Custer County, ID","C108257","No value exists.","Custer County, ID | Custer County | Custer County, Idaho | ID037",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0058310","Dinoprost Tromethamine","C1074","A synthetic analogue of the naturally occurring prostaglandin F2 alpha.  Prostaglandin F2 alpha stimulates myometrial activity, relaxes the cervix, inhibits corpus luteal steroidogenesis, and induces luteolysis by direct action on the corpus luteum. (NCI04)","Dinoprost Tromethamine | DINOPROST TROMETHAMINE | Dinoprost tromethamine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL451747","Aloe/Anise/Ascorbic Acid/Clove/Peppermint/Spearmint/Thyme-based Mouthwash","C107501","A herbal-based mouthrinse containing aloe, anise, ascorbic acid, clove, peppermint, spearmint and thyme, with potential anti-mucositic activity. When aloe/anise/ascorbic acid/clove/peppermint/spearmint/thyme-based mouthwash is used as a rinse, the ingredients in this agent may prevent or decrease inflammation and bacterial infections.This may prevent or inhibit radiotherapy- or chemotherapy-induced mucositis and decreases the pain associated with mucositis.","Aloe/Anise/Ascorbic Acid/Clove/Peppermint/Spearmint/Thyme-based Mouthwash | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL451748","Glioblastoma Cancer Vaccine ERC1671","C107502","A cancer vaccine composed of a combination of autologous glioblastoma (GBM) tumor cells, allogeneic GBM tumor cells, generated from three different GBM donor cancer patients, and the lysates of all of these cells, with potential antineoplastic activity. Upon intradermal administration of GBM cancer vaccine ERC1671, the mixture of the autologous and allogeneic cells and lysates stimulates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against GBM-associated antigens, which leads to the destruction of glioblastoma cells.","Glioblastoma Cancer Vaccine ERC1671 | ERC-1671 | ERC1671 | Gliovac",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813590","SULT1A1 wt Allele","C107442","Human SULT1A1 wild-type allele is located in the vicinity of 16p12.1 and is approximately 18 kb in length. This allele, which encodes sulfotransferase 1A1 protein, plays a role in the sulfate conjugation of catecholamines, phenolic drugs and neurotransmitters.","SULT1A1 wt Allele | HAST1/HAST2 | P-PST | P-PST 1 | PST | ST1A1 | ST1A3 | STP | STP1 | Sulfotransferase Family, Cytosolic, 1A, Phenol-Preferring, Member 1 wt Allele | TSPST1 | Ts-PST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827450","Woodbury County, IA","C108573","No value exists.","Woodbury County, IA | IA193 | Woodbury County | Woodbury County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811321","Worth County, IA","C108574","No value exists.","Worth County, IA | IA195 | Worth County | Worth County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811323","Wright County, IA","C108575","No value exists.","Wright County, IA | IA197 | Wright County | Wright County, Iowa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812642","Allen County, KS","C108576","No value exists.","Allen County, KS | Allen County | Allen County, Kansas | KS001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810800","Atchison County, KS","C108578","No value exists.","Atchison County, KS | Atchison County | Atchison County, Kansas | KS005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827377","Barber County, KS","C108579","No value exists.","Barber County, KS | Barber County | Barber County, Kansas | KS007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810801","Barton County, KS","C108580","No value exists.","Barton County, KS | Barton County | Barton County, Kansas | KS009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810802","Bourbon County, KS","C108581","No value exists.","Bourbon County, KS | Bourbon County | Bourbon County, Kansas | KS011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810803","Brown County, KS","C108582","No value exists.","Brown County, KS | Brown County | Brown County, Kansas | KS013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810805","Chase County, KS","C108584","No value exists.","Chase County, KS | Chase County | Chase County, Kansas | KS017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810806","Chautauqua County, KS","C108585","No value exists.","Chautauqua County, KS | Chautauqua County | Chautauqua County, Kansas | KS019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810807","Cherokee County, KS","C108586","No value exists.","Cherokee County, KS | Cherokee County | Cherokee County, Kansas | KS021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810808","Cheyenne County, KS","C108587","No value exists.","Cheyenne County, KS | Cheyenne County | Cheyenne County, Kansas | KS023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810809","Clark County, KS","C108588","No value exists.","Clark County, KS | Clark County | Clark County, Kansas | KS025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831072","Cloud County, KS","C108590","No value exists.","Cloud County, KS | Cloud County | Cloud County, Kansas | KS029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831058","Coffey County, KS","C108591","No value exists.","Coffey County, KS | Coffey County | Coffey County, Kansas | KS031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811348","Comanche County, KS","C108592","No value exists.","Comanche County, KS | Comanche County | Comanche County, Kansas | KS033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827322","Cowley County, KS","C108593","No value exists.","Cowley County, KS | Cowley County | Cowley County, Kansas | KS035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815138","Decatur County, KS","C108595","No value exists.","Decatur County, KS | Decatur County | Decatur County, Kansas | KS039",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815869","Dickinson County, KS","C108596","No value exists.","Dickinson County, KS | Dickinson County | Dickinson County, Kansas | KS041",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830405","Doniphan County, KS","C108597","No value exists.","Doniphan County, KS | Doniphan County | Doniphan County, Kansas | KS043",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811829","Douglas County, KS","C108598","No value exists.","Douglas County, KS | Douglas County | Douglas County, Kansas | KS045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814015","Franklin County, AR","C107822","No value exists.","Franklin County, AR | AR047 | Franklin County | Franklin County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830051","Garland County, AR","C107824","No value exists.","Garland County, AR | AR051 | Garland County | Garland County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813980","Grant County, AR","C107825","No value exists.","Grant County, AR | AR053 | Grant County | Grant County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814402","Greene County, AR","C107826","No value exists.","Greene County, AR | AR055 | Greene County | Greene County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829715","Hempstead County, AR","C107827","No value exists.","Hempstead County, AR | AR057 | Hempstead County | Hempstead County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815924","Hot Spring County, AR","C107828","No value exists.","Hot Spring County, AR | AR059 | Hot Spring County | Hot Spring County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829549","Independence County, AR","C107830","No value exists.","Independence County, AR | AR063 | Independence County | Independence County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829481","Izard County, AR","C107831","No value exists.","Izard County, AR | AR065 | Izard County | Izard County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816471","Jackson County, AR","C107832","No value exists.","Jackson County, AR | AR067 | Jackson County | Jackson County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810767","Jefferson County, AR","C107833","No value exists.","Jefferson County, AR | AR069 | Jefferson County | Jefferson County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810782","Johnson County, AR","C107834","No value exists.","Johnson County, AR | AR071 | Johnson County | Johnson County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813660","Lawrence County, AR","C107836","No value exists.","Lawrence County, AR | AR075 | Lawrence County | Lawrence County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813669","Lee County, AR","C107837","No value exists.","Lee County, AR | AR077 | Lee County | Lee County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814091","Lincoln County, AR","C107838","No value exists.","Lincoln County, AR | AR079 | Lincoln County | Lincoln County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829267","Little River County, AR","C107839","No value exists.","Little River County, AR | AR081 | Little River County | Little River County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829260","Lonoke County, AR","C107841","No value exists.","Lonoke County, AR | AR085 | Lonoke County | Lonoke County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815906","Madison County, AR","C107842","No value exists.","Madison County, AR | AR087 | Madison County | Madison County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811178","Marion County, AR","C107843","No value exists.","Marion County, AR | AR089 | Marion County | Marion County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810689","Miller County, AR","C107844","No value exists.","Miller County, AR | AR091 | Miller County | Miller County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810707","Monroe County, AR","C107846","No value exists.","Monroe County, AR | AR095 | Monroe County | Monroe County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811264","Montgomery County, AR","C107847","No value exists.","Montgomery County, AR | AR097 | Montgomery County | Montgomery County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812333","Nevada County, AR","C107848","No value exists.","Nevada County, AR | AR099 | Nevada County | Nevada County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810590","Newton County, AR","C107849","No value exists.","Newton County, AR | AR101 | Newton County | Newton County, Arkansas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827825","Tippecanoe County, IN","C108463","No value exists.","Tippecanoe County, IN | IN157 | Tippecanoe County | Tippecanoe County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815223","Tipton County, IN","C108464","No value exists.","Tipton County, IN | IN159 | Tipton County | Tipton County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812803","Union County, IN","C108465","No value exists.","Union County, IN | IN161 | Union County | Union County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827667","Vanderburgh County, IN","C108466","No value exists.","Vanderburgh County, IN | IN163 | Vanderburgh County | Vanderburgh County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827651","Vermillion County, IN","C108467","No value exists.","Vermillion County, IN | IN165 | Vermillion County | Vermillion County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812764","Wabash County, IN","C108469","No value exists.","Wabash County, IN | IN169 | Wabash County | Wabash County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812784","Warren County, IN","C108470","No value exists.","Warren County, IN | IN171 | Warren County | Warren County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827512","Warrick County, IN","C108471","No value exists.","Warrick County, IN | IN173 | Warrick County | Warrick County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813212","Washington County, IN","C108472","No value exists.","Washington County, IN | IN175 | Washington County | Washington County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813624","Wells County, IN","C108474","No value exists.","Wells County, IN | IN179 | Wells County | Wells County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810723","White County, IN","C108475","No value exists.","White County, IN | IN181 | White County | White County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810724","Whitley County, IN","C108476","No value exists.","Whitley County, IN | IN183 | Whitley County | Whitley County, Indiana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811631","Adair County, IA","C108477","No value exists.","Adair County, IA | Adair County | Adair County, Iowa | IA001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811641","Adams County, IA","C108478","No value exists.","Adams County, IA | Adams County | Adams County, Iowa | IA003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830143","FGFR2 NM_000141.4:c.1144T>C","C107596","A nucleotide substitution at position 1144 of the coding sequence of the FGFR2 gene where thymine has been mutated to cytosine.","FGFR2 NM_000141.4:c.1144T>C | BEK c.1144T>C | CD332 c.1144T>C | ECT1 c.1144T>C | FGFR2 c.1144T>C | Fibroblast Growth Factor Receptor 2 c.1144T>C | K-SAM c.1144T>C | KGFR c.1144T>C | NM_000141.4:c.1144T>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL451750","Recombinant Human Adenovirus Type 5 H101","C107504","A replication selective, recombinant, E1B and partial E3 gene deleted form of human adenovirus type 5, with potential antineoplastic activity. Upon intratumoral injection of recombinant human adenovirus type 5, the adenovirus selectively replicates in cancer cells while preventing viral replication in normal, healthy cells. This induces a selective adenovirus-mediated cytotoxicity in cancer cells, which leads to cancer cell lysis. In addition, viral spread to adjacent cells, following lysis of infected cells, may activate the immune system to kill the infected tumor cells. The E1B protein causes p53 inactivation, which promotes viral replication; deletion of E1B allows for p53 activation in normal cells, which prevents viral replication in normal, healthy cells. The mutation and subsequent inactivation of p53 in cancer cells enables the E1B-deleted adenovirus to selectively replicate in cancer cells. Partial deletion of E3, encoding the adenovirus death protein, enhances the safety profile of the administered adenovirus.","Recombinant Human Adenovirus Type 5 H101 | H-101 | H101 | Oncorine | rAd5 H101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL451751","CD138CAR-CD137/TCRzeta-expressing T Lymphocytes","C107505","T-lymphocytes transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) specific for syndecan-1 (CD138) (CART-138 T cells) coupled to the signaling domain of 4-1BB (CD137), and the zeta chain of the T-cell receptor (TCRzeta), with potential immunomodulating and antineoplastic activities. Upon transfusion, CD138CAR- CD137/TCRzeta -expressing T lymphocytes directs the T-lymphocytes to syndecan-1-expressing tumor cells and induces selective toxicity in those tumor cells. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of syndecan-1. Syndecan-1, a type 1 transmembrane proteoglycan and tumor associated antigen, is overexpressed in a variety of cancer cells. It plays a key role in the regulation of cell growth, differentiation, and adhesion, and its expression is correlated with poor prognosis.","CD138CAR-CD137/TCRzeta-expressing T Lymphocytes | CART-138 TCR zeta:CD137",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815618","Lowndes County, AL","C107730","No value exists.","Lowndes County, AL | AL085 | Lowndes County | Lowndes County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815628","Macon County, AL","C107731","No value exists.","Macon County, AL | AL087 | Macon County | Macon County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815905","Madison County, AL","C107732","No value exists.","Madison County, AL | AL089 | Madison County | Madison County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829201","Marengo County, AL","C107733","No value exists.","Marengo County, AL | AL091 | Marengo County | Marengo County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811726","Marshall County, AL","C107735","No value exists.","Marshall County, AL | AL095 | Marshall County | Marshall County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828996","Mobile County, AL","C107736","No value exists.","Mobile County, AL | AL097 | Mobile County | Mobile County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810706","Monroe County, AL","C107737","No value exists.","Monroe County, AL | AL099 | Monroe County | Monroe County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811263","Montgomery County, AL","C107738","No value exists.","Montgomery County, AL | AL101 | Montgomery County | Montgomery County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813703","Perry County, AL","C107740","No value exists.","Perry County, AL | AL105 | Perry County | Perry County, Alabama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831166","CDR - Global CDR","C113881","Clinical Dementia Rating (CDR) Global CDR.","CDR - Global CDR | CDR01-Global CDR | CDR0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829145","MDS-UPDRS - Postural Tremor of Left Hand","C113882","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Postural Tremor of the Left Hand.","MDS-UPDRS - Postural Tremor of Left Hand | UPD2-Postural Tremor of Left Hand | UPD2315B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829146","MDS-UPDRS - Kinetic Tremor of Right Hand","C113883","The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Kinetic Tremor of the Right Hand.","MDS-UPDRS - Kinetic Tremor of Right Hand | UPD2-Kinetic Tremor of Right Hand | UPD2316A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829396","KFSS - Other Functions","C113884","Kurtzke Functional Systems Scores (KFSS) Other functions.","KFSS - Other Functions | KFSS1-Other Functions | KFSS108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829395","KFSS - Other Functions Specify","C113885","Kurtzke Functional Systems Scores (KFSS) Any other neurologic findings attributed to MS (specify).","KFSS - Other Functions Specify | KFSS1-Other Functions Specify | KFSS108A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830059","GAD-7 - Total Score","C113886","Generalized Anxiety Disorder - 7 (GAD-7) Total score.","GAD-7 - Total Score | GAD01-Total Score | GAD0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828403","RAND-36 - Expect Health to Get Worse","C114077","RAND 36-Item Health Survey 1.0 (RAND-36) How true or false is each of the following statements for you: I expect my health to get worse.","RAND-36 - Expect Health to Get Worse | R3601-I Expect My Health to Get Worse | R360135",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828384","RAND-36 - My Health is Excellent","C114078","RAND 36-Item Health Survey 1.0 (RAND-36) How true or false is each of the following statements for you: My health is excellent.","RAND-36 - My Health is Excellent | R3601-My Health Is Excellent | R360136",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0412564","Fetal Echocardiography","C114079","An antenatal ultrasonographic procedure used to evaluate the structure and function of the fetal heart.","Fetal Echocardiography | ",,,,,,,,,,,,,,,"4334808","Fetal echocardiography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2052183","Fetal Doppler Velocimetry","C114080","An antenatal ultrasonographic method that measures blood flow velocity through either maternal or fetal vessels.","Fetal Doppler Velocimetry | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827010","Fetal Doppler Monitoring","C114081","A technique that utilizes a Doppler transducer to monitor fetal heart rate. The transducer is placed on the maternal abdomen and detects fetal cardiac motion using ultrasound.","Fetal Doppler Monitoring | EFM | External Fetal Heart Rate Monitoring",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002032","Chlorophyta","C114082","A phylum of paraphyletic, photosynthetic and autotrophic green algae.","Chlorophyta | ",,,,,,,,,,,,,,,"44783572","Chlorophyta",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL473442","Internal Fetal Heart Rate Monitoring","C114083","A technique that utilizes a wire attached to the fetal scalp to monitor fetal heart rate. The wire detects fetal cardiac electrical activity to determine the baseline fetal heart rate and variability.","Internal Fetal Heart Rate Monitoring | FSE | Fetal Scalp Electrode Monitoring",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829515","Intrapartum Fetal Stimulation","C114084","Any method used to elicit a fetal heart rate acceleration response during labor.","Intrapartum Fetal Stimulation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826968","PSN","C113719","A term that refers to a pulmonary nodule in which part of the ground-glass opacity completely obscures the parenchyma on CT scan examination.","Part-Solid Ground-Glass Pulmonary Nodule | PSN | Part Solid Nodule | Partly Solid Ground-Glass Pulmonary Nodule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831752","Abnormal Colorectal Exam, Suspicious for Malignancy","C113720","A clinical finding indicating the presence of a firm, indurated, or nodular lesion, which is suspicious for malignancy, during colorectal examination.","Abnormal Colorectal Exam, Suspicious for Malignancy | Abnormal Colorectal Exam, Suspicious for Cancer | Abnormal Colorectal Examination, Suspicious for Malignancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831753","Abnormal Colorectal Exam, Highly Suspicious for Malignancy","C113721","A clinical finding indicating the presence of a lesion, which is highly suspicious for malignancy, during colorectal examination.","Abnormal Colorectal Exam, Highly Suspicious for Malignancy | Abnormal Colorectal Exam, Highly Suspicious for Cancer | Abnormal Colorectal Examination, Highly Suspicious for Malignancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827195","Colorectal Examination Finding","C113722","No value exists.","Colorectal Examination Finding | Colorectal Exam Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2103575","Scleroderma Polymyositis Overlap Syndrome","C113723","A rare autoimmune disorder in which patients present with overlapping symptoms of systemic scleroderma and polymyositis or dermatomyositis.","Scleroderma Polymyositis Overlap Syndrome | Scleroderma Polymyositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1408353","Undiagnosed","C113725","Refers to an underlying pathologic process that has not been identified.","Undiagnosed | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0194794","Transurethral Incision of the Prostate","C113727","A surgical procedure performed in patients with benign prostatic hyperplasia.  An instrument is inserted in the urethra that generates electric current or laser beam, which create incisions in the bladder neck. The incisions result in decreased resistance to the flow of the urine out of the urinary bladder.","Transurethral Incision of the Prostate | TIBN | TUIP | Transurethral Incision of Bladder Neck | Transurethral Incision of the Bladder Neck",,,,,,,,,,,,,,,"4209601","Prostatotomy by transurethral approach",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3810541","Adverse Event Emergency Room Visit","C111737","The situation that occurs when an individual must visit the Emergency Room or Department because of an adverse event.","Adverse Event Emergency Room Visit | ER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831596","Adverse Event Doctor Visit","C111738","The situation that occurs when an individual must visit a physician because of an adverse event.","Adverse Event Doctor Visit | Doctor Visit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714973","PIK3CD wt Allele","C113629","Human PIK3CD wild-type allele is located in the vicinity of 1p36.2 and is approximately 77 kb in length. This allele, which encodes phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform protein, is involved in both immunity and second messenger signaling.","PIK3CD wt Allele | APDS | IMD14 | P110DELTA | PI3K | PI3K-DELTA | PIK3-DELTA | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Delta wt Allele | Phosphoinositide-3-Kinase, Catalytic, 110-kD Delta Gene | Phosphoinositide-3-Kinase, Catalytic, Delta Gene | Phosphoinositide-3-Kinase, Catalytic, Delta Polypeptide Gene | RP11-558F24.3 | p110-DELTA | p110D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813591","PIK3CD protein, human","C113631","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (1044 aa, ~119 kDa) is encoded by the human PIK3CD gene. This protein plays a role in both signal transduction and cell-mediated immunity.","Phosphatidylinositol 4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta Isoform | EC 2.7.1.153 | PI3-Kinase Subunit Delta | PI3-Kinase p110 Subunit Delta | PI3K-Delta | PI3Kdelta | PIK3 Delta | PIK3CD | Phosphatidylinositol 4,5-Bisphosphate 3-Kinase 110 kDa Catalytic Subunit Delta | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 110 kDa Catalytic Subunit Delta | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta Isoform | Phosphoinositide-3-Kinase C | PtdIns-3-Kinase Subunit Delta | PtdIns-3-Kinase Subunit p110-Delta | p110-Delta | p110delta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812293","UGT1A4 wt Allele","C113633","Human UGT1A4 wild-type allele is located in the vicinity of 2q37 and is approximately 55 kb in length. This allele, which encodes UDP-glucuronosyltransferase 1-4 protein, plays a role in the catabolism of xenobiotics. Mutation of the gene is associated with Gilbert syndrome and Crigler-Najjar syndrome types 1 and 2.","UGT1A4 wt Allele | HUG-BR2 | UDP Glucuronosyltransferase 1 Family, Polypeptide A4 wt Allele | UDP Glycosyltransferase 1 Family, Polypeptide A4 Gene | UDP-Glycosyltransferase 1 Family, Polypeptide A4 Gene | UDPGT | UDPGT 1-4 | UGT-1D | UGT1-04 | UGT1.4 | UGT1D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0053593","UDP-Glucuronosyltransferase 1-4","C113634","UDP-glucuronosyltransferase 1-4 (534 aa, ~60 kDa) is encoded by the human UGT1A4 gene. This protein is involved in glucuronidation of toxins.","UDP-Glucuronosyltransferase 1-4 | Bilirubin UDP-Glucuronosyltransferase Isozyme 2 | Bilirubin-Specific UDPGT Isozyme 2 | EC 2.4.1.17 | UDP-Glucuronosyltransferase 1-D | UDP-Glucuronosyltransferase 1A4 | UDPGT 1-4 | UGT-1D | UGT1*4 | UGT1-04 | UGT1.4 | UGT1A4 | UGT1D | hUG-BR2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827561","Vibroacoustic Stimulation","C114085","A fetal stimulation technique that uses vibratory sound applied to the maternal abdomen to elicit a fetal heart rate acceleration response before or during labor.","Vibroacoustic Stimulation | VAS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831564","Allis Clamp Fetal Scalp Stimulation","C114086","A fetal stimulation technique that uses an Allis clamp applied transvaginally to the fetal head to elicit a fetal heart rate acceleration response during labor.","Allis Clamp Fetal Scalp Stimulation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830484","Digital Fetal Scalp Stimulation","C114087","A fetal stimulation technique that uses transvaginal digital pressure or rubbing to the fetal head to elicit a fetal heart rate acceleration response during labor.","Digital Fetal Scalp Stimulation | Scalp Stim",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831006","Corrected Age","C114089","Chronological age reduced by the number of weeks born before 40 weeks of gestation; most appropriately used to describe children up to 3 years of age who were born preterm.","Corrected Age | Adjusted Age | Corrected Gestational Age",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828508","Postmenstrual Age","C114090","Best estimate of the first day of last menstrual period to birth plus time elapsed from day of birth.","Postmenstrual Age | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829315","Late Preterm Birth","C114092","Birth when a fetus is between 34 weeks and 0 days through 36 weeks and 6 days gestational age.","Late Preterm Birth | Late Pre-Term",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0233324","Term Birth","C114093","Birth at greater than or equal to 37 weeks using best estimated due date.","Term Birth | Term",,,,,,,,,,,,,,,"4054968","Term birth of newborn",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3830361","Early Term Birth","C114094","Birth at 37 weeks and 0 days through 38 weeks and 6 days.","Early Term Birth | Early Term",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0064695","Lavendustin A","C1142","A compound isolated from strains of Streptomyces griseolavendus that may exert antitumor activity by inhibition of protein tyrosine kinase and tubulin polymerization. (NCI)","Lavendustin A | 5-(((2,5-Dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxy Benzoic Acid | Benzoic acid, 5-[[(2, 5-dihydroxyphenyl)methyl][(2-hydroxyphenyl)methyl]amino]-2-hydroxy - | LAVENDUSTIN A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830682","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Self-injurious Behavior, Intent Unknown (Past 3 Months)","C113919","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Has subject engaged in self-injurious behavior, intent unknown? (Past 3 Months).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Self-injurious Behavior, Intent Unknown (Past 3 Months) | CSS10-Self-injur Behav, Intent Unk-P3M | CSS1011B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830706","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Interrupted Suicide Attempt (Lifetime)","C113920","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Has there been a time when you started to do something to make yourself not alive anymore (end your life or kill yourself) but someone or something stopped you before you actually did anything? What did you do? (Lifetime).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Interrupted Suicide Attempt (Lifetime) | CSS10-Interrupted Attempt-Life | CSS1012A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830705","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Interrupted Suicide Attempt (Past 3 Months)","C113921","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Has there been a time when you started to do something to make yourself not alive anymore (end your life or kill yourself) but someone or something stopped you before you actually did anything? What did you do? (Past 3 Months).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Interrupted Suicide Attempt (Past 3 Months) | CSS10-Interrupted Attempt-P3M | CSS1012B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830688","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Number of Interrupted Suicide Attempts (Lifetime)","C113922","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Total number of interrupted. (Lifetime).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Number of Interrupted Suicide Attempts (Lifetime) | CSS10-Number of Interrupt Attempts-Life | CSS1013A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830687","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Number of Interrupted Suicide Attempts (Past 3 Months)","C113923","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Total number of interrupted. (Past 3 Months).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Number of Interrupted Suicide Attempts (Past 3 Months) | CSS10-Number of Interrupt Attempts-P3M | CSS1013B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830716","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Description of Interrupted Suicide Attempt","C113924","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Description of interrupted attempt.","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Description of Interrupted Suicide Attempt | CSS10-Interrupted Attempt, Describe | CSS1013C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830733","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Aborted or Self-interrupted Suicide Attempt (Lifetime)","C113925","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Has there been a time when you started to do something to make yourself not alive anymore (end your life or kill yourself) but you changed your mind (stopped yourself) before you actually did anything? What did you do? (Lifetime).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Aborted or Self-interrupted Suicide Attempt (Lifetime) | CSS10-Aborted Attempt-Life | CSS1014A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830691","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Number of Aborted or Self-interrupted Suicide Attempt (Past 3 Months)","C113928","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Total number of aborted or self-interrupted. (Past 3 Months).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Number of Aborted or Self-interrupted Suicide Attempt (Past 3 Months) | CSS10-Number of Aborted Attempts-P3M | CSS1015B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830721","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Description of Aborted Suicide Attempt","C113929","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Description of aborted or self-interrupted attempt.","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Description of Aborted Suicide Attempt | CSS10-Aborted Attempt, Describe | CSS1015C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810551","SERPIND1 wt Allele","C113636","Human SERPIND1 wild-type allele is located in the vicinity of 22q11.21 and is approximately 14 kb in length. This allele, which encodes heparin cofactor 2 protein, is involved in heparin-dependent inhibition of thrombin. Mutation of the gene is associated with thrombophilia due to heparin cofactor 2 deficiency.","SERPIND1 wt Allele | D22S673 | HC2 | HCF2 | HCII | HLS2 | LS2 | Serine (Or Cysteine) Proteinase Inhibitor, Clade D (Heparin Cofactor), Member 1 Gene | Serpin Peptidase Inhibitor, Clade D (Heparin Cofactor), Member 1 wt Allele | THPH10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2713376","SERPIND1 protein, human","C113637","Heparin cofactor 2 (499 aa, ~57 kDa) is encoded by the human SERPIND1 gene. This protein plays a role in the glycosaminoglycan-dependent inhibition of thrombin.","Heparin Cofactor 2 | HC-II | HLS2 | Heparin Cofactor II | Leuserpin 2 | Leuserpin-2 | Protease Inhibitor Leuserpin-2 | Serpin D1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814773","BASP1 wt Allele","C113639","Human BASP1 wild-type allele is located in the vicinity of 5p15.1 and is approximately 211 kb in length. This allele, which encodes brain acid soluble protein 1, may play a role in signal transduction.","BASP1 wt Allele | Brain Abundant, Membrane Attached Signal Protein 1 wt Allele | Brain-Abundant Signal Protein, Membrane-Attached, 1 Gene | CAP-23 | CAP23 | CAP23, Chicken, Homolog of Gene | NAP-22 | NAP22 | NAP22, Rat, Homolog of Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2609166","Discordant Twin","C113829","A twin whose estimated fetal weight is determined to have 20% or greater difference from its sibling.","Discordant Twin | Discordant Growth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811816","EPHB4 wt Allele","C113831","Human EPHB4 wild-type allele is located in the vicinity of 7q22 and is approximately 25 kb in length. This allele, which encodes ephrin type-B receptor 4 protein, is involved in ligand-dependent signaling pathways.","EPHB4 wt Allele | EPH Receptor B4 wt Allele | EphB4 | HTK | MYK, Mouse, Homolog of Gene | MYK1 | TYRO11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810533","Ephrin Type-B Receptor 4, human","C113832","Ephrin type-B receptor 4 (987 aa, ~108 kDa) is encoded by the human EPHB4 gene. This protein plays a role in ephrin-B binding, tyrosine phosphorylation, and signal transduction.","Ephrin Type-B Receptor 4 | EC 2.7.10.1 | EphB4 | Ephrin Receptor EphB4 | Tyrosine-Protein Kinase Receptor HTK | Tyrosine-Protein Kinase TYRO11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830149","Fetal Hypoxemia","C113833","Abnormally low arterial blood oxygen concentration in a fetus.","Fetal Hypoxemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816448","4-Hydroxytestosterone","C113835","No value exists.","4-Hydroxytestosterone | 4-HYDROXYTESTOSTERONE | 4-Hydroxyandrost-4-ene-3,17-dione | 4-Hydroxyandrostenedione | CR1447",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815175","IL31 wt Allele","C113836","Human IL31 wild-type allele is located in the vicinity of 12q24.31 and is approximately 2 kb in length. This allele, which encodes interleukin-31 protein, plays a role in both signal transduction and immunity.","IL31 wt Allele | IL-31 | Interleukin 31 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1571097","Interleukin-31, Human","C113837","Interleukin-31 (164 aa, ~18 kDa) is encoded by the human IL31 gene. This protein is involved in signaling during the immune response.","Interleukin-31 | IL-31 | IL31 | Interleukin 31",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813959","CTSV wt Allele","C114304","Human CTSV wild-type allele is located in the vicinity of 9q22.2 and is approximately 10 kb in length. This allele, which encodes cathepsin L2 protein, is involved in proteolysis.","CTSV wt Allele | CATL2 | CTSL2 | CTSU | Cathepsin V wt Allele | UNQ268/PRO305",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0764137","cathepsin V","C114305","Cathepsin L2 (334 aa, ~37 kDa) is encoded by the human CTSV gene. This protein plays a role in proteolysis.","Cathepsin L2 | CTSV | Cathepsin U | Cathepsin V | EC 3.4.22.43",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813948","SCUBE2 wt Allele","C114307","Human SCUBE2 wild-type allele is located in the vicinity of 11p15.3 and is approximately 119 kb in length. This allele, which encodes signal peptide, CUB and EGF-like domain-containing protein 2, may play a role in both cell-cell adhesion and cell proliferation.","SCUBE2 wt Allele | CEGB1 | CEGF1 | CEGP1 | Signal Peptide, CUB Domain, EGF-Like 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827208","Signal Peptide, CUB and EGF-Like Domain-Containing Protein 2","C114308","Signal peptide, CUB and EGF-like domain-containing protein 2 (999 aa, ~110 kDa) is encoded by the human SCUBE2 gene. This protein may be involved in the modulation of both cell-cell adhesion and cell proliferation.","Signal Peptide, CUB and EGF-Like Domain-Containing Protein 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829660","HOTS wt Allele","C114310","Human HOTS wild-type allele is located in the vicinity of 11p15 and is approximately 6 kb in length. This allele, which encodes H19 opposite tumor suppressor protein, may be involved in tumor suppression.","HOTS wt Allele | H19 Opposite Tumor Suppressor wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL458373","Folate Binding Protein J65 Peptide Vaccine","C113660","A cancer vaccine comprised of human leukocyte antigen (HLA)-A2-restricted folate binding protein (FBP) epitope J65 (9 amino acids; EIWTFSTKV), with potential immunostimulatory and antineoplastic activities. Upon intradermal injection, FBP J65 peptide vaccine may induce a specific cytotoxic T-lymphocyte (CTL) response against J65 FBP-expressing tumor cell types. FBP is a membrane-bound, tumor-associated antigen overexpressed in various tumor types, including breast, ovarian and endometrial cancers. J65 is a strongly immunogenic peptide.","Folate Binding Protein J65 Peptide Vaccine | FBP J65 Peptide Vaccine | J65 Peptide Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL458375","Coffee Dietary Supplement","C113662","A dietary supplement containing coffee, with potential gastrointestinal (GI) tract stimulating activity. Following consumption of the dietary supplement, the coffee may both stimulate peristalsis and may increase bowel movement. The supplement also may also stimulate the central nervous system, suppress appetite and cause weight loss.","Coffee Dietary Supplement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813585","msdRNA","C111278","The RNA portion of the msDNA molecule, which contains two stem-loop structures and varies widely in length across bacterial species.","msdRNA | MSR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0066880","Multicopy Single-stranded DNA","C111279","A DNA/RNA chimera comprised of a single-stranded DNA molecule covalently bound to an internal guanosine of a RNA molecule.","Multicopy Single-stranded DNA | msDNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828901","MSQOL-54 - Others Notice Your Problems With Memory or Concentration","C114032","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Have others, such as family members or friends, noticed that you have trouble with your memory or problems with your concentration?","MSQOL-54 - Others Notice Your Problems With Memory or Concentration | MSQL1-Others Notice Your Memory Trouble | MSQL145",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828902","MSQOL-54 - Lack of Sexual Interest","C114033","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of a problem was each of the following for you during the past 4 weeks: Lack of sexual interest.","MSQOL-54 - Lack of Sexual Interest | MSQL1-Lack of Sexual Interest | MSQL146",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828903","MSQOL-54 - Inadequate Lubrication","C114035","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of a problem was each of the following for you during the past 4 weeks: Inadequate lubrication.","MSQOL-54 - Inadequate Lubrication | MSQL1-Inadequate Lubrication | MSQL147W",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828934","MSQOL-54 - Difficulty Having Orgasm","C114036","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of a problem was each of the following for you during the past 4 weeks: Difficulty having orgasm.","MSQOL-54 - Difficulty Having Orgasm | MSQL1-Difficulty Having Orgasm | MSQL148",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828942","MSQOL-54 - Ability to Satisfy Sexual Partner","C114037","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of a problem was each of the following for you during the past 4 weeks: Ability to satisfy sexual partner.","MSQOL-54 - Ability to Satisfy Sexual Partner | MSQL1-Ability to Satisfy Sexual Partner | MSQL149",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827367","MSQOL-54 - Satisfied With Sexual Function","C114038","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) Overall, how satisfied were you with your sexual function during the past 4 weeks?","MSQOL-54 - Satisfied With Sexual Function | MSQL1-Satisfied With Sexual Function | MSQL150",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831279","Branch Duct","C113668","A small duct that originates from the main duct.","Branch Duct | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1405308","Vaccine-Associated Paralytic Poliomyelitis","C113671","A rare, paralytic poliomyelitis associated with the orally administered live attenuated strain of the poliovirus, OPV.","Vaccine-Associated Paralytic Poliomyelitis | OPV associated Paralytic Poliomyelitis | VAPP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830466","Disseminated Oka Varicella Zoster Virus Infection","C113672","A rare systemic and life-threatening infection associated with vaccination with the live attenuated strain of the Varicella-zoster virus, Oka.","Disseminated Oka Varicella Zoster Virus Infection | Disseminated Oka VZV Infection | Disseminated Varicella Zoster Vaccine Virus Infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1550099","Sediment","C113677","Material that has settled out of solution.","Sediment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828565","PHQ-9 - Total Score","C113887","Patient Health Questionnaire - 9 (PHQ-9) Total score.","PHQ-9 - Total Score | PHQ01-Total Score | PHQ0111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831314","Borg CR10 - Rating","C113888","Borg Category-Ratio10 Scale (Borg CR10) Rating.","Borg CR10 - Rating | BCR101-Rating | BCR10101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1287748","Plantar Grasp Reflex","C110939","A newborn reflex that is characterized by flexion of the toes when the sole of the foot is stroked.","Plantar Grasp Reflex | PLTGRRFX | Plantar Grasp Reflex Finding",,,,,,,,,,,,,,,"4175530","Plantar grasp reflex",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4227838","Panhypopituitarism","C110940","Insufficient production of all the anterior pituitary hormones.","Panhypopituitarism | Complete Hypopituitarism",,,,,,,,,,,,,,,"30365","Panhypopituitarism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL451680","Allantoic Cyst","C110941","An umbilical cyst that arises from allantoic tissue that did not regress during gestational development. Most cases involve a patent urachus that allows for communication to the urinary bladder.","Allantoic Cyst | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0265914","Congenital Anomaly of Pulmonary Veins","C110942","Aberrant drainage of one or more of the pulmonary veins which causes the return of oxygen-rich blood to the right atrium.","Congenital Anomaly of Pulmonary Veins | ",,,,,,,,,,,,,,,"4006984","Congenital anomaly of pulmonary veins",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL451681","Musculoskeletal Injury","C110943","Damage to the muscles, bones and their supportive structural attachments.","Musculoskeletal Injury | Muscle/Tendon Damage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454078","Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101","C111688","A liposomal nanoparticle-based therapeutic vaccine composed of the cationic lipid R-DOTAP (R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride) encapsulating six human papillomavirus 16 (HPV-16) E6 and E7 peptides, with potential immunostimulating activity. Upon subcutaneous administration of the liposomal HPV-16 E6 and E7 multipeptide vaccine, the nanoparticles are taken up by antigen presenting cells (APCs), specifically dendritic cells (DCs), which may stimulate the immune system to induce a cytotoxic T-lymphocyte response (CTL) against HPV-16 E6 and E7-expressing tumor cells. HPV-16 E6 and E7 are oncoproteins that play a key role in the tumorigenesis of a variety of cancers.","Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101 | PDS0101 | mmunoMAPK-RDOTAP /HPV-16 E6/E7 Peptide Antigen Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1958472","HLA-A*0201 Restricted TERT(572Y)/TERT(572) Peptides Vaccine Vx-001","C111689","A peptide-based cancer vaccine consisting of two human leukocyte antigen (HLA)-A*0201 restricted 9-mer epitopes derived from the human telomerase reverse transcriptase (hTERT), TERT 572Y (YLFFYRKSV; TYR-Vx001) and TERT 572 (RLFFYRKSV; ARG-Vx001), with potential immunostimulating and antineoplastic activities. Subcutaneous injection of TERT(572Y) peptide followed by subcutaneous administration of the TERT(572) peptide may elicit a specific and possibly optimal cytotoxic T cell (CTL) response against hTERT-expressing tumor cells. hTERT, the catalytic subunit of human telomerase, is an human leukocyte antigen-A*0201-restricted cryptic epitope of telomerase. TERT is expressed in the majority of human cancer cells, is not expressed or is expressed at very low levels in normal cells and plays a key role in tumorigenesis. TERT572Y is the optimized variant of the native cryptic peptide TERT572 in which tyrosine has been substituted for an arginine at position 1; TERT572Y shows increased HLA-A*0201 binding affinity compared to TERT572.","HLA-A*0201 Restricted TERT(572Y)/TERT(572) Peptides Vaccine Vx-001 | HLA-A*0201 Restricted Telomerase-specific Vaccine Vx-001 | Vx-001 | Vx001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830652","C-SSRS Screening - Most Lethal Suicide Attempt Potential Lethality","C111495","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Most lethal attempt potential lethality.","C-SSRS Screening - Most Lethal Suicide Attempt Potential Lethality | CSS09-Most Lethal Attempt Potential | CSS0922C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830658","C-SSRS Screening - First Suicide Attempt Date","C111496","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Initial/first attempt date.","C-SSRS Screening - First Suicide Attempt Date | CSS09-First Attempt Date | CSS0923A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830657","C-SSRS Screening - First Suicide Attempt Potential Lethality","C111498","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Initial/first attempt potential lethality.","C-SSRS Screening - First Suicide Attempt Potential Lethality | CSS09-First Attempt Potential | CSS0923C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830181","FAQ - Write checks, Pay bills, Balance checkbook","C111499","Functional Activities Questionnaire (FAQ) Writing checks, paying bills, balancing checkbook.","FAQ - Write checks, Pay bills, Balance checkbook | FAQ01-Write Checks/Pay Bills/Checkbook | FAQ0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830202","FAQ - Assemble","C111500","Functional Activities Questionnaire (FAQ) Assembling tax records, business affairs, or papers.","FAQ - Assemble | FAQ01-Assembling | FAQ0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830184","FAQ - Shop Alone","C111501","Functional Activities Questionnaire (FAQ) Shopping alone for clothes, household necessities, or groceries.","FAQ - Shop Alone | FAQ01-Shopping Alone | FAQ0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830188","FAQ - Play Game of Skill, Work on Hobby","C111502","Functional Activities Questionnaire (FAQ) Playing a game of skill, working on a hobby.","FAQ - Play Game of Skill, Work on Hobby | FAQ01-Playing a Game of Skill | FAQ0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830201","FAQ - Heat water, Make Coffee, Turn Off Stove","C111503","Functional Activities Questionnaire (FAQ) Heating water, making a cup of coffee, turning off stove after use.","FAQ - Heat water, Make Coffee, Turn Off Stove | FAQ01-Heat Water/Make Coffee/Stove Off | FAQ0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830187","FAQ - Prepare a Meal","C111504","Functional Activities Questionnaire (FAQ) Preparing a balanced meal.","FAQ - Prepare a Meal | FAQ01-Preparing a Balanced Meal | FAQ0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830200","FAQ - Keep Track of Current Events","C111505","Functional Activities Questionnaire (FAQ) Keeping track of current events.","FAQ - Keep Track of Current Events | FAQ01-Keeping Track of Current Events | FAQ0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830189","FAQ - Pay Attention, Understand, Discuss","C111506","Functional Activities Questionnaire (FAQ) Paying attention to, understanding, discussing TV, book, magazine.","FAQ - Pay Attention, Understand, Discuss | FAQ01-Paying Attention | FAQ0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830185","FAQ - Remember","C111507","Functional Activities Questionnaire (FAQ) Remembering appointments, family occasions, holidays, medications.","FAQ - Remember | FAQ01-Remembering | FAQ0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830182","FAQ - Travel","C111508","Functional Activities Questionnaire (FAQ) Traveling out of neighborhood, driving, arranging to take buses.","FAQ - Travel | FAQ01-Traveling | FAQ0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828937","MSQOL-54 - Bowel or Bladder Function Interfere With Social Activities","C114039","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) During the past 4 weeks, to what extent have problems with your bowel or bladder function interfered with your normal social activities with family, friends, neighbors, or groups?","MSQOL-54 - Bowel or Bladder Function Interfere With Social Activities | MSQL1-Bowel/Bladder Interfered Activity | MSQL151",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828900","MSQOL-54 - Pain Interfere Enjoyment of Life","C114040","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) During the past 4 weeks, how much did pain interfere with your enjoyment of life?","MSQOL-54 - Pain Interfere Enjoyment of Life | MSQL1-Pain Interfere Enjoyment of Life | MSQL152",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828893","MSQOL-54 - Rate Your Own Quality of Life","C114041","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) Overall, how would you rate your own quality-of-life?","MSQOL-54 - Rate Your Own Quality of Life | MSQL1-Rate Your Own Quality-of-Life | MSQL153",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828936","MSQOL-54 - Describe How You Feel About Your Life","C114042","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) Which best describes how you feel about your life as a whole?","MSQOL-54 - Describe How You Feel About Your Life | MSQL1-Describe How Feel About Your Life | MSQL154",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828377","RAND-36 - Rate Your Health","C114043","RAND 36-Item Health Survey 1.0 (RAND-36) In general, would you say your health is:","RAND-36 - Rate Your Health | R3601-Would You Say Your Health Is | R360101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828376","RAND-36 - Rate Your Health Compared to One Year Ago","C114044","RAND 36-Item Health Survey 1.0 (RAND-36) Compared to one year ago, how would you rate your health in general now?","RAND-36 - Rate Your Health Compared to One Year Ago | R3601-Health Now Compared to 1 Year Ago | R360102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828387","RAND-36 - Health Limit Vigorous Activities","C114045","RAND 36-Item Health Survey 1.0 (RAND-36) Does your health now limit you in these activities: Vigorous activities, such as running, lifting heavy objects, participating in strenuous sports.","RAND-36 - Health Limit Vigorous Activities | R3601-Health Limit Vigorous Activities | R360103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828388","RAND-36 - Health Limit Moderate Activities","C114046","RAND 36-Item Health Survey 1.0 (RAND-36) Does your health now limit you in these activities: Moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or playing golf.","RAND-36 - Health Limit Moderate Activities | R3601-Health Limit Moderate Activities | R360104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011609","Drug Skin Rash","C114280","An eruption in the skin due to exposure to a pharmacologic substance.","Drug Skin Rash | Drug Rash | Drug-Induced Rash",,,,,,,,,,,,,,,"4103376|4295465","Eruption due to drug|Drug-induced dermatosis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0030583","Parotitis","C114281","Inflammation of the parotid glands.","Parotitis | ",,,,,,,,,,,,,,,"4032796","Parotitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL449121","Uterine Dehiscence","C114282","Asymptomatic separation of the uterine wall, usually at the site of a prior uterine scar, that does not include the overlying serosa.","Uterine Dehiscence | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830679","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Wish to be Dead (Lifetime)","C113889","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Have you thought about being dead or what it would be like to be dead? Have you wished you were dead or wished you could go to sleep and never wake up? Do you ever wish you weren't alive anymore? (Lifetime).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Wish to be Dead (Lifetime) | CSS10-Wish to be Dead-Life | CSS1001A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830678","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Wish to be Dead (Past 1 Month)","C113890","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Have you thought about being dead or what it would be like to be dead? Have you wished you were dead or wished you could go to sleep and never wake up? Do you ever wish you weren't alive anymore? (Past 1 Month).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Wish to be Dead (Past 1 Month) | CSS10-Wish to be Dead-P1M | CSS1001B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830713","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Description of Wish to be Dead","C113891","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Description of wishing to be dead.","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Description of Wish to be Dead | CSS10-Wish to be Dead, Describe | CSS1001C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830696","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Non-Specific Active Suicidal Thoughts (Lifetime)","C113892","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Have you thought about doing something to make yourself not alive anymore? Have you had any thoughts about killing yourself? (Lifetime).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Non-Specific Active Suicidal Thoughts (Lifetime) | CSS10-Non-Spec Suicid Thought-Life | CSS1002A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830695","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Non-Specific Active Suicidal Thoughts (Past 1 Month)","C113893","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Have you thought about doing something to make yourself not alive anymore? Have you had any thoughts about killing yourself? (Past 1 Month).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Non-Specific Active Suicidal Thoughts (Past 1 Month) | CSS10-Non-Spec Suicid Thought-P1M | CSS1002B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830715","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Description of Non-Specific Active Suicidal Thoughts","C113894","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Description of non-specific active suicidal thoughts.","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Description of Non-Specific Active Suicidal Thoughts | CSS10-Non-Spec Suicid Thought, Describe | CSS1002C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830731","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Active Suicidal Ideation With Any Methods (Not Plan) Without Intent to Act (Lifetime)","C113895","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Have you thought about how you would do that or how you would make yourself not alive anymore (kill yourself)? What did you think about? (Lifetime).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Active Suicidal Ideation With Any Methods (Not Plan) Without Intent to Act (Lifetime) | CSS10-Idea, No Intent, No Plan-Life | CSS1003A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830730","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Active Suicidal Ideation With Any Methods (Not Plan) Without Intent to Act (Past 1 Month)","C113896","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Have you thought about how you would do that or how you would make yourself not alive anymore (kill yourself)? What did you think about? (Past 1 Month).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Active Suicidal Ideation With Any Methods (Not Plan) Without Intent to Act (Past 1 Month) | CSS10-Idea, No Intent, No Plan-P1M | CSS1003B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827194","Glioblastoma by Gene Expression Profile","C111691","Classification of glioblastoma into molecular subtypes as defined by gene expression profiling.","Glioblastoma by Gene Expression Profile | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828464","Proneural Glioblastoma","C111692","A molecular subtype of glioblastoma that is associated with younger age at presentation and is characterized by p53 mutations and PDGFRa amplifications.","Proneural Glioblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828832","Neural Glioblastoma","C111693","A molecular subtype of glioblastoma characterized by the expression of the neural markers NEFL, GABRA1, SYT1, and SLC12A5.","Neural Glioblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827253","Classical Glioblastoma","C111694","A molecular subtype of glioblastoma characterized by lack of p53 mutations, chromosome 7 amplifications or deletions, and high levels of EGFR amplification.","Classical Glioblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829122","Mesenchymal Glioblastoma","C111695","A molecular subtype of glioblastoma characterized by the presence of NF1 mutations.","Mesenchymal Glioblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0061688","Glycosylphosphatidylinositols","C1116","A glycolipid that functions as a protein modifier and has a core structure composed of a phosphatidylinositol (PI) bound, through a carbohydrate linker comprised of glucosamine and three mannose residues, to an ethanolamine phosphate (EtNP), which can be covalently linked to the carboxy-terminal amino acid of the modified protein. Glycosylphosphatidylinositol moieties anchor extracellular proteins to the cell surface by insertion of the PI fatty acid chains into the membrane bilayer.","Glycosylphosphatidylinositol | GPI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830190","FAQ-NACC UDS Version 2.0 - Write checks, Pay bills, Balance checkbook","C111510","Functional Assessment Questionnaire-NACC UDS Version 2.0 (FAQ-NACC UDS Version 2.0) Writing checks, paying bills, balancing checkbook.","FAQ-NACC UDS Version 2.0 - Write checks, Pay bills, Balance checkbook | FAQNA1-Write Checks/Pay Bills/Checkbook | FAQNA101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830199","FAQ-NACC UDS Version 2.0 - Assemble","C111511","Functional Assessment Questionnaire-NACC UDS Version 2.0 (FAQ-NACC UDS Version 2.0) Assembling tax records, business affairs, or papers.","FAQ-NACC UDS Version 2.0 - Assemble | FAQNA1-Assembling | FAQNA102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471791","FGFR inhibitor TAS-120","C114283","An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. Futibatinib selectively and irreversibly binds to and inhibits FGFR, which may result in the inhibition of both the FGFR-mediated signal transduction pathway and tumor cell proliferation, and increased cell death in FGFR-overexpressing tumor cells. FGFR is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival and its expression is upregulated in many tumor cell types.","Futibatinib | 2-Propen-1-one, 1-((3S)-3-(4-Amino-3-(2-(3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)-1-pyrrolidinyl)- | FUTIBATINIB | Lytgobi | TAS 120 | TAS-120 | TAS120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471792","H1299 Tumor Cell Lysate Vaccine","C114284","A cell lysate derived from a lung cancer cell line, H1299, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration, the H1299 tumor cell lysate exposes the immune system to an undefined amount of tumor associated antigens (TAA), particularly cancer testis antigens (CTAs), which may result in the induction of both anti-tumoral cytotoxic T-lymphocytes (CTL) and antibody-dependent responses against TAA-expressing cells, leading to tumor cell lysis. CTAs, such as MAGE, are selectively expressed in a variety of cancers but are not expressed in normal, healthy cells outside the testis.","H1299 Tumor Cell Lysate Vaccine | H1299 Lysate Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471793","Survivin/p53/HER2 Antigen-loaded Autologous Dendritic Cell Vaccine","C114285","An autologous dendritic cell (DC) vaccine loaded with tumor-associated antigens (TAAs) derived from survivin, p53 and human epidermal growth factor receptor 2 (HER2 or ERBB2), with immunostimulating and antineoplastic activities. Upon administration, this DC vaccine may elicit a potent cytotoxic T-cell (CTL) response against tumor cells expressing these TAAs, resulting in tumor cell death. Survivin, p53 and HER2 are essential in neoplastic growth, and are considered to be universal tumor antigens.","Survivin/p53/HER2 Antigen-loaded Autologous Dendritic Cell Vaccine | Survivin/p53/HER2 Antigen-loaded Autologous DC Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471794","anti-CLDN6 monoclonal antibody IMAB027","C114286","A monoclonal antibody directed against the cell surface protein claudin 6 (CLDN6), with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CLDN6 monoclonal antibody ASP1650 binds to CLDN-6 and may stimulate the immune system to exert both an antibody-dependent cellular cytotoxicity (ADCC) and a complement-dependent cytotoxicity (CDC) mediated immune response against CLDN-6-expressing tumor cells. This may inhibit tumor cell growth. CLDN-6, a tight-junction protein and embryonic antigen, is expressed on a variety of tumor cells but is not expressed on normal, healthy adult cells.","Anti-CLDN6 Monoclonal Antibody ASP1650 | ASP 1650 | ASP-1650 | ASP1650 | Anti-Claudin 6 Monoclonal Antibody ASP1650 | IMAB027",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471796","ALK/TRK Inhibitor TSR-011","C114287","An orally available inhibitor of both the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the tropomyosin-related kinases (TRK) TRKA, TRKB, and TRKC, with potential antineoplastic activity. Upon administration, ALK/TRK inhibitor TSR-011 binds to and inhibits both ALK and TRK kinases. The inhibition leads to disruption of ALK- and TRK-mediated signaling and impedes tumor cell growth in ALK/TRK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. TRK, a family of receptor tyrosine kinases activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.","ALK/TRK Inhibitor TSR-011 | TSR-011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812173","Brain Acid Soluble Protein 1, Human","C113640","Brain acid soluble protein 1 (227 aa, ~23 kDa) is encoded by the human BASP1 gene. This protein may be involved in both signal transduction and neurite outgrowth.","Brain Acid Soluble Protein 1 | 22 kDa Neuronal Tissue-Enriched Acidic Protein | Brain Acid-Soluble Protein 1 | Neuronal Axonal Membrane Protein NAP-22 | Neuronal Tissue-Enriched Acidic Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810632","RETN wt Allele","C113642","Human RETN wild-type allele is located in the vicinity of 19p13.2 and is approximately 1 kb in length. This allele, which encodes resistin protein, is involved in the regulation of glucose metabolism. Mutation of the gene is associated with increased susceptibility to both non-insulin dependent diabetes mellitus and insulin resistance-related hypertension.","RETN wt Allele | ADSF | FIZZ3 | Found In Inflammatory Zone 3 Gene | HXCP1 | RETN1 | RSTN | Resistin wt Allele | UNQ407/PRO1199 | XCP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1432227","Resistin, Human","C113643","Resistin (108 aa, ~11 kDa) is encoded by the human RETN gene. This protein plays a role in the regulation of insulin-mediated glucose metabolism.","Resistin | Adipose Tissue-Specific Secretory Factor | C/EBP-Epsilon Regulated Myeloid-Specific Secreted Cysteine-Rich Protein Precursor 1 | C/EBP-Epsilon-Regulated Myeloid-Specific Secreted Cysteine-Rich Protein | Cysteine-Rich Secreted Protein A12-Alpha-Like 2 | Cysteine-Rich Secreted Protein FIZZ3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830720","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Description of Active Suicidal Ideation With Any Methods (Not Plan) Without Intent to Act","C113897","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Description of active suicidal ideation with any methods (not plan) without intent to act.","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Description of Active Suicidal Ideation With Any Methods (Not Plan) Without Intent to Act | CSS10-Idea, No Intent, No Plan, Describe | CSS1003C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829314","Late Term Birth","C114096","Birth at 41 weeks and 0 days through 41 weeks and 6 days.","Late Term Birth | Late Term",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1398117","Post Term Birth","C114097","Birth at greater than or equal to 42 weeks and 0 days.","Post Term Birth | Post Term | Postterm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829528","Intermittent Auscultation","C114098","A method of assessing intrapartum fetal heart rate during set intervals using an external device, such as a Doppler, fetoscope or stethoscope.","Intermittent Auscultation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829511","Intrauterine Resuscitation","C114099","Treatments or maneuvers applied to the mother to improve uterine perfusion or oxygen delivery to the fetus in response to abnormal fetal heart rate patterns.","Intrauterine Resuscitation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0064443","KW-2149","C1140","A semisynthetic water-soluble disulfide derivative of the antineoplastic antibiotic mitomycin C.  Activated by serum and glutathione, KW-2149 causes interstrand DNA cross-links and DNA-protein cross-links, resulting in single-strand DNA breaks and inhibition of DNA synthesis. (NCI04)","Mitomycin C Analog KW-2149 | 7-N-(2-((2-(gamma-L-Glutamylamino)ethyl)dithio)ethyl)mitomycin C | KT6149 | KW 2149 | KW-2149",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830148","Fetal Scalp Sampling","C114100","A technique used to evaluate fetal acid-base status during labor by obtaining a capillary blood specimen from the fetus.","Fetal Scalp Sampling | Fetal Scalp pH Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471816","OFF Regimen","C114101","A regimen that includes leucovorin, 5-fluorouracil and oxaliplatin that can be used in the treatment of ampullary and pancreatic adenocarcinoma, and esophageal and esophagogastric junction and gastric cancer, and mucinous neoplasms of the ovary.","OFF Regimen | Fluorouracil/Leucovorin Calcium/Oxaliplatin Regimen | Fluorouracil/Leucovorin/Oxaliplatin | OLF | OLF Regimen | Oxaliplatin/Folinic Acid/Fluorouracil Regimen | Oxaliplatin/Leucovorin/Fluorouracil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827962","Spontaneous Labor and Birth","C114102","Initiation of labor without the use of pharmacological and/or mechanical interventions, resulting in a non-operative vaginal birth. (reVITALize)","Spontaneous Labor and Birth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0269863","First Degree Perineal Laceration","C114104","Injury to perineal skin only. (reVITALize)","First Degree Perineal Laceration | ",,,,,,,,,,,,,,,"197343","First degree perineal laceration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0269870","Second Degree Perineal Laceration","C114105","Injury to perineum involving perineal muscles but not involving anal sphincter. (reVITALize)","Second Degree Perineal Laceration | ",,,,,,,,,,,,,,,"198492","Second degree perineal laceration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0269874","Third Degree Perineal Laceration","C114106","Injury to perineum involving anal sphincter complex. (adapted from reVITALize)","Third Degree Perineal Laceration | ",,,,,,,,,,,,,,,"193830","Third degree perineal laceration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1275806","Fourth Degree Perineal Laceration","C114107","Injury to perineum involving anal sphincter complex and internal anal sphincter and anal epithelium. (reVITALize)","Fourth Degree Perineal Laceration | ",,,,,,,,,,,,,,,"198495","Fourth degree perineal laceration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3813158","Experimental Organism Islet Cell Adenoma Neoplasm","C114108","A benign neoplasm arising from the islet cells of the pancreas.","Experimental Organism Islet Cell Adenoma Neoplasm | ADENOMA, ISLET CELL, BENIGN | Islet Cell Adenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714935","Experimental Organism Acidophil Carcinoma Neoplasm","C114109","A malignant epithelial neoplasm of the anterior pituitary gland in which the neoplastic cells stain positive with acidic dyes.","Experimental Organism Acidophil Carcinoma | Acidophil Adenocarcinoma | Acidophil Carcinoma | CARCINOMA, ACIDOPHIL, MALIGNANT | Eosinophil Adenocarcinoma | Eosinophil Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830742","C-SSRS Children's Since Last Visit - Number of Aborted or Self-interrupted Suicide Attempts","C111451","Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Total number of aborted or self-interrupted.","C-SSRS Children's Since Last Visit - Number of Aborted or Self-interrupted Suicide Attempts | CSS08-Number of Aborted Attempts | CSS0815",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830760","C-SSRS Children's Since Last Visit - Description of Aborted or Self-interrupted Suicide Attempt","C111452","Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Description of aborted attempt or self-interrupted attempt.","C-SSRS Children's Since Last Visit - Description of Aborted or Self-interrupted Suicide Attempt | CSS08-Aborted Attempt, Describe | CSS0815A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830739","C-SSRS Children's Since Last Visit - Preparatory Acts or Behaviors Toward Suicide Attempt","C111453","Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Have you done anything to get ready to make yourself not alive anymore (to end your life or kill yourself) - like giving things away, writing a goodbye note, getting things you need to kill yourself?","C-SSRS Children's Since Last Visit - Preparatory Acts or Behaviors Toward Suicide Attempt | CSS08-Preparatory Acts/Behavior | CSS0816",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830281","Extrascleral Extension of Uveal Melanoma","C111028","Spread of uveal melanoma beyond the sclera.","Extrascleral Extension of Uveal Melanoma | extrascleral extension | extrascleral_extension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1630218","Alistipes shahii","C114246","A species of strictly anaerobic, Gram negative, pigment-producing, rod shaped bacteria assigned to the phylum Bacteroidetes. This bacteria is non-motile, non-spore forming, bile-resistant, indole positive, catalase negative, hydrolyzes esculin, and does not reduce nitrate. A. shahii is a commensal organism of the human gastrointestinal tract.","Alistipes shahii | ALISTIPES SHAHII",,,,,,,,,,,,,,,"46271537","Alistipes shahii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2278479","Megamonas funiformis","C114247","A species of anaerobic, Gram negative, rod shaped bacteria assigned to the phylum Firmicutes. This bacteria is non-motile, non-spore forming, filamentous, weakly hemolytic, indole positive, negative for oxidase and catalase, hydrolyzes esculin and gelatin, and does not reduce nitrate. M. funiformis has been isolated from human feces and is a normal part of the human intestinal flora.","Megamonas funiformis | MEGAMONAS FUNIFORMIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1074952","Arthrobacter cumminsii","C114248","A species of obligately aerobic, Gram positive, irregular shaped bacteria assigned to the phylum Actinobacteria. This bacteria is non-motile, non-spore forming, catalase positive, hydrolyzes gelatin, and does not reduce nitrate. A. cumminsii is widely distributed in the environment, especially in soil. It may cause opportunistic infections in humans.","Arthrobacter cumminsii | ARTHROBACTER CUMMINSII",,,,,,,,,,,,,,,"4013796","Pseudoglutamicibacter cumminsii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1007427","Corynebacterium tuberculostearicum","C114249","A species of aerobic, Gram positive, rod shaped bacteria assigned to the phylum Actinobacteria. This bacteria is non-motile, non-spore forming, lipophilic, catalase positive, produces tuberculostearic acid, reduces nitrate and ferments saccharose. C. tuberculostearicum is a part of the normal human skin flora, but may also be involved in the development of inflammatory breast diseases.","Corynebacterium tuberculostearicum | CORYNEBACTERIUM TUBERCULOSTEARICUM",,,,,,,,,,,,,,,"4219544","Corynebacterium tuberculostearicum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1224919","Clostridium bolteae","C114250","A species of obligately anaerobic, Gram positive, rod shaped bacteria assigned to the phylum Firmicutes. This bacteria is non-motile, non-spore forming, negative for indole, lecithinase, lipase, catalase and urease, does not hydrolyze esculin or gelatin, does not reduce nitrate, and ferments carbohydrate to produce acetic acid and lactic acid. C. bolteae is a part of the normal human intestinal microflora, but may also be involved in the development of autism and bacteremia.","Clostridium bolteae | CLOSTRIDIUM BOLTEAE",,,,,,,,,,,,,,,"4188983","Enterocloster bolteae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1482117","Clostridium hathewayi","C114251","A species of strictly anaerobic, Gram negative, rod shaped bacteria assigned to the phylum Firmicutes. This bacteria is spore forming, negative for indole, catalase, lecithinase and lipase, hydrolyzes esculin and starch, but not gelatin, does not reduce nitrate, ferments carbohydrate to produce acetate, ethanol, carbon dioxide and hydrogen, and exhibits variable motility. C. hathewayi is a part of the normal human intestinal microflora, but may also be involved in the development of acute appendicitis and bacteremia.","Clostridium hathewayi | CLOSTRIDIUM HATHEWAYI",,,,,,,,,,,,,,,"4214301","Hungatella hathewayi",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0317552","Fusobacterium naviforme","C114252","A species of obligately anaerobic, Gram negative, rod shaped bacteria assigned to the phylum Fusobacteria. This bacteria is non-spore forming, indole positive, non-fermentative, and characteristically produce butyrate as a major end product of its metabolism. F. naviforme has been isolated in human clinical samples and may cause infections in humans.","Fusobacterium naviforme | Bacillus naviformis | FUSOBACTERIUM NAVIFORME | Fusibacterium naviforme | Pseudobacterium naviformis | Ristella naviformis",,,,,,,,,,,,,,,"4140362","Fusobacterium naviforme",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL458358","Lactobacillus rhamnosus/L. jensenii/L. crispatus/L. gasseri Oral Supplement","C113645","A A nutritional supplement containing the probiotic Lactobacillus strains, L. rhamnosus, L. jensenii, L. crispatus and L. gasseri, with protective and immunomodulating activities. The bacteria in this probiotic supplement colonize the vaginal tract and help to maintain as well as restore the composition of the normal, healthy vaginal flora. The four Lactobacillus species form a protective barrier that helps both to maintain the integrity of the vaginal tract and prevent the attachment of pathogenic bacteria and other harmful substances, thereby protecting against genitourinary infections.","Lactobacillus rhamnosus/L. jensenii/L. crispatus/L. gasseri Oral Supplement | L. rhamnosus/L. jensenii/L. crispatus/L. gasseri Oral Supplement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827120","LSD1 Inhibitor GSK2879552","C113646","An orally available, irreversible, inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity. Upon administration, GSK2879552 binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the dimethylated form of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor-suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. LSD1, overexpressed in certain tumor cells, plays a key role in tumor cell growth and survival.","LSD1 Inhibitor GSK2879552 | GSK2879552",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL458360","Alpha-1,3-galactosyltransferase-expressing Allogeneic Renal Cell Carcinoma Vaccine","C113647","An allogeneic renal cell cancer (RCC) vaccine composed of cell line-derived RCCs that are genetically engineered to express the murine alpha-1,3-galactosyltransferase (GalT), with potential immunostimulatory and antineoplastic activities. Not naturally occurring in humans, GalT catalyzes the expression of foreign alpha-1,3-galactosyl (alpha-gal) carbohydrate epitopes on the cell membranes of the allogeneic RCCs present in the vaccine. This induces a hyperacute rejection reaction involving pre-existing human anti-alpha-gal antibodies, which bind to the foreign alpha-gal epitopes expressed by the allogeneic RCCs. This results in complement-mediated cytotoxicity (CMC) and antibody-dependent cell-mediated cytotoxicity (ADCC) towards endogenous RCCs with unmodified carbohydrate epitopes.","Alpha-1,3-galactosyltransferase-expressing Allogeneic Renal Cell Carcinoma Vaccine | HAR | HyperAcute Renal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL458361","Contrast Agent CS-1000","C113648","An aqueous colloidal nanoemulsion containing perfluorocarbon (PFC) polymers that can be used as a tracer for cell tracking purposes during fluorine-19 (19F) magnetic resonance imaging (MRI). Upon administration of the contrast agent CS-1000 to cells ex vivo, this agent freely enters the cells. Upon introduction of these cells into the patient and subsequent 19F MRI, the amount of fluorine can be detected and cellular persistence, survival and distribution of the treated cells can be assessed. The emulsion allows for fast entry of the fluorinated polymers into cells; the polymers do not degrade and remain in the cells.","Contrast Agent CS-1000 | CS-1000",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829357","Labeling does not Contain MRI Safety Information","C113844","Information on the safety of using a device in a magnetic resonance (MR) environment has not been provided in the labeling by the labeler.","Labeling does not Contain MRI Safety Information | Labeling does not contain MRI Safety Information",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826956","CDISC Questionnaire Borg CR10 Test Name Terminology","C113845","Test names of questionnaire questions associated with the Borg CR10 Scale for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire Borg CR10 Test Name Terminology | BCR101TN | Borg CR10 Scale Questionnaire Test Name | QS-Borg CR10 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826955","CDISC Questionnaire Borg CR10 Test Code Terminology","C113846","Test codes of questionnaire questions associated with the Borg CR10 Scale for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire Borg CR10 Test Code Terminology | BCR101TC | Borg CR10 Scale Questionnaire Test Code | QS-Borg CR10 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830292","Experimental Organism Histiocytic Lymphoma Neoplasm","C114110","A malignant neoplasm of large lymphocytes, which resemble histiocytes.","Experimental Organism Histiocytic Lymphoma Neoplasm | LYMPHOMA, HISTIOCYTIC, MALIGNANT | Lymphoma, Large Cell, Malignant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816170","Experimental Organism Mixed Lymphoma Neoplasm","C114111","A malignant neoplasm composed of a mixed lymphocyte population.","Experimental Organism Mixed Lymphoma Neoplasm | LYMPHOMA, MIXED, MALIGNANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3253439","H19 Opposite Tumor Suppressor, Human","C114311","H19 opposite tumor suppressor (151 aa, ~17 kDa) is encoded by the human HOTS gene. This protein may play a role in tumor suppression.","H19 Opposite Tumor Suppressor | HOTS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814813","IGF2-AS wt Allele","C114313","Human IGF2-AS wild-type allele is located in the vicinity of 11p15.5 and is approximately 8 kb in length. This allele, which encodes IGF2 Antisense RNA and may encode putative insulin-like growth factor 2 antisense gene protein, plays a role in Wilms tumor and may be involved in embryotic kidney development.","IGF2-AS wt Allele | IGF2 Antisense RNA (Non-Protein Coding) Gene | IGF2 Antisense RNA 1 (Non-Protein Coding) Gene | IGF2 Antisense RNA wt Allele | IGF2, Antisense Gene | IGF2-AS1 | IGF2AS | Insulin-Like Growth Factor 2 Antisense 1 (Non-Protein Coding) Gene | Insulin-Like Growth Factor 2, Antisense Gene | Insulin-Like Growth Factor II, Antisense Gene | PEG8 | hCG_1995804",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814812","Putative Insulin-Like Growth Factor 2 Antisense Gene Protein","C114314","Putative insulin-like growth factor 2 antisense gene protein (168 aa, ~18 kDa) is encoded by the human IGF2-AS gene. This protein may play a role in Wilms tumor formation.","Putative Insulin-Like Growth Factor 2 Antisense Gene Protein | IGF2 Antisense Gene Protein 1 | IGF2-AS1 | PEG8/IGF2AS Protein | Putative Insulin-Like Growth Factor 2 Antisense Gene Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0914288","IGF2 Antisense RNA, Human","C114315","IGF2 Antisense RNA (~2 kb) is encoded by the human IGF2-AS gene. This non-coding RNA is involved in Wilms tumor and may play a role in renal development.","IGF2 Antisense RNA | IGF2 Antisense RNA 1 | IGF2-AS | IGF2AS | Insulin-Like Growth Factor 2 Antisense | Insulin-Like Growth Factor 2 Antisense 1 | Insulin-Like Growth Factor 2, Antisense | PEG8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810575","KCNQ1OT1 wt Allele","C114317","Human KCNQ1OT1 wild-type allele is located in the vicinity of 11p15 and is approximately 92 kb in length. This allele, which encodes KCNQ1 opposite strand/antisense transcript 1 non-coding RNA, is involved in the regulation of gene transcription through epigenetic modification of DNA. Aberrant expression of the gene is associated with Beckwith-Wiedemann syndrome.","KCNQ1OT1 wt Allele | KCNQ1 Antisense RNA 2 (Non-Protein Coding) Gene | KCNQ1 Opposite Strand/Antisense Transcript 1 (Non-Protein Coding) wt Allele | KCNQ1 Overlapping Transcript 1 (Non-Protein Coding) Gene | KCNQ1-AS2 | KCNQ10T1 | KvDMR1 | KvLQT1-AS | LIT1 | NCRNA00012 | Non-Protein Coding RNA 12 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1436653","KCNQ1 Opposite Strand/Antisense Transcript 1, Human","C114318","KCNQ1 opposite strand/antisense transcript 1 (~92 kb) is encoded by the human KCNQ1OT1 gene. This non-coding RNA plays a role in epigenetic processes.","KCNQ1 Opposite Strand/Antisense Transcript 1 | KCNQ1 Antisense RNA 2 | KCNQ1 Overlapping Transcript 1 | KCNQ1OT1 | LIT1 | Long QT Intronic Transcript 1 | NCRNA00012 | Non-Protein Coding RNA 12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830736","C-SSRS Children's Since Last Visit - Suicidal Behavior","C111455","Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Suicidal behavior was present during the assessment period?","C-SSRS Children's Since Last Visit - Suicidal Behavior | CSS08-Suicidal Behavior | CSS0817",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830735","C-SSRS Children's Since Last Visit - Suicide","C111456","Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Suicide.","C-SSRS Children's Since Last Visit - Suicide | CSS08-Suicide | CSS0818",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830747","C-SSRS Children's Since Last Visit - Most Lethal Suicide Attempt Date","C111457","Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Most lethal attempt date.","C-SSRS Children's Since Last Visit - Most Lethal Suicide Attempt Date | CSS08-Most Lethal Attempt Date | CSS0819A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830748","C-SSRS Children's Since Last Visit - Most Lethal Suicide Attempt Actual Lethality/Medical Damage","C111458","Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Most lethal attempt actual lethality/medical damage.","C-SSRS Children's Since Last Visit - Most Lethal Suicide Attempt Actual Lethality/Medical Damage | CSS08-Most Lethal Attempt Damage | CSS0819B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830746","C-SSRS Children's Since Last Visit - Most Lethal Suicide Attempt Potential Lethality","C111459","Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Most lethal attempt potential lethality.","C-SSRS Children's Since Last Visit - Most Lethal Suicide Attempt Potential Lethality | CSS08-Most Lethal Attempt Potential | CSS0819C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830638","C-SSRS Screening - Wish to be Dead","C111460","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Have you wished you were dead or wished you could go to sleep and not wake up?","C-SSRS Screening - Wish to be Dead | CSS09-Wish to be Dead | CSS0901",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830662","C-SSRS Screening - Description of Wish to be Dead","C111461","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Description of wishing to be dead.","C-SSRS Screening - Description of Wish to be Dead | CSS09-Wish to be Dead, Describe | CSS0901A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830647","C-SSRS Screening - Non-Specific Active Suicidal Thoughts","C111462","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Have you actually had any thoughts of killing yourself?","C-SSRS Screening - Non-Specific Active Suicidal Thoughts | CSS09-Non-Spec Suicid Thought | CSS0902",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830664","C-SSRS Screening - Description of Non-Specific Active Suicidal Thoughts","C111463","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Description of non-specific active suicidal thoughts.","C-SSRS Screening - Description of Non-Specific Active Suicidal Thoughts | CSS09-Non-Spec Suicid Thought, Describe | CSS0902A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830676","C-SSRS Screening - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act","C111464","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Have you been thinking about how you might do this?","C-SSRS Screening - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act | CSS09-Idea, No Intent, No Plan | CSS0903",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1013217","Tsukamurella pulmonis","C114253","A species of aerobic, Gram positive, slightly acid-alcohol-fast, rod shaped bacteria assigned to the phylum Actinobacteria. This bacteria is non-motile, non-spore forming, catalase and urease positive, resistant to streptomycin, rifampin and capreomycin, utilizes glucose, hydrolyzes esculin but not gelatin, and does not reduce nitrate. T. pulmonis has been isolated from patients with pulmonary tuberculosis and is an opportunistic pathogen which may cause pulmmonary infections in immunosuppressed indiviuals.","Tsukamurella pulmonis | TSUKAMURELLA PULMONIS",,,,,,,,,,,,,,,"4014395","Tsukamurella pulmonis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319880","Candida rugosa","C114254","A dimorphic yeast in the phylum Ascomycota. This species is ovoid, ellipsoidal or cylindrical shaped, and forms pseudohyphae. The lipase produced by this yeast is used commercially in biotransformation to catalyze hydrolysis reactions, especially for the production of ricinoleic acid. C. rugosa is also a human pathogen and can cause fungemia, with reduced susceptibility to the azole antifungal agents.","Candida rugosa | C. rugosa | CANDIDA RUGOSA",,,,,,,,,,,,,,,"4028804","Diutina rugosa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1010126","Candida dubliniensis","C114255","A dimorphic yeast consisting of ovoid or spherical blastospores in the phylum Ascomycota. This species is germ-tube positive, produces thick-walled blastospores arranged in triplets or contiguous pairs, and pseudohyphae with short unilateral, bilateral or multilateral branches at the septa, assimilates carbohydrates, hydrolyzes esculin, and does not utilize potassium nitrate. C. dubliniensis is an opportunistic pathogen and has been isolated from immunocompromised individuals and the oral cavities of HIV-infected patients. It can cause candidosis and systematic fungemia in humans.","Candida dubliniensis | C. dubliniensis | CANDIDA DUBLINIENSIS",,,,,,,,,,,,,,,"4018997","Candida dubliniensis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1424343","SEPTIN8 Gene","C114430","This gene plays a role in cytoskeletal filament formation.","SEPTIN8 Gene | SEPT8 | SEPT8 Gene | SEPTIN8 | Septin 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816190","Septin-8, Human","C114432","Septin-8 (483 aa, ~56 kDa) is encoded by the human SEPTIN8 gene. This protein plays a role in cytoskeletal filament dynamics.","Septin-8 | SEPT8 | SEPTIN8 | Septin 8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420069","GEMIN2 Gene","C114433","This gene is involved in spliceosome formation.","GEMIN2 Gene | GEMIN2 | Gem (Nuclear Organelle) Associated Protein 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810617","GEMIN2 wt Allele","C114434","Human GEMIN2 wild-type allele is located in the vicinity of 14q13 and is approximately 23 kb in length. This allele, which encodes gem-associated protein 2, plays a role in the formation of the spliceosome.","GEMIN2 wt Allele | Gem (Nuclear Organelle) Associated Protein 2 wt Allele | SIP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0666285","GEMIN2 protein, human","C114435","Gem-associated protein 2 (280 aa, ~32 kDa) is encoded by the human GEMIN2 gene. This protein is involved in the assembly of small nuclear ribonucleoproteins that build the spliceosome.","Gem-Associated Protein 2 | Component of Gems 2 | Gemin-2 | SMN Interacting Protein 1 | SMN-Interacting Protein 1 | Survival of Motor Neuron Protein Interacting Protein 1 | Survival of Motor Neuron Protein-Interacting Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419599","PTBP3 Gene","C114436","This gene plays a role in RNA splicing, cellular differentiation and erythropoiesis.","PTBP3 Gene | PTBP3 | Polypyrimidine Tract Binding Protein 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814145","PTBP3 wt Allele","C114437","Human PTBP3 wild-type allele is located in the vicinity of 9q32 and is approximately 115 kb in length. This allele, which encodes polypyrimidine tract-binding protein 3, is involved in the modulation of both RNA splicing and erythropoiesis.","PTBP3 wt Allele | DKFZp781I1117 | Polypyrimidine Tract Binding Protein 3 wt Allele | ROD1 | ROD1 Regulator of Differentiation 1 (S. pombe) Gene | RP11-165N19.1 | Regulator of Differentiation (In S. pombe) 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815597","Polypyrimidine Tract-Binding Protein 3, Human","C114438","Polypyrimidine tract-binding protein 3 (552 aa, ~60 kDa) is encoded by the human PTBP3 gene. This protein plays a role in both erythropoiesis and RNA splicing.","Polypyrimidine Tract-Binding Protein 3 | Fission Yeast Differentiation Regulator | PTBP3 | ROD1 Regulator Of Differentiation 1 | Regulator of Differentiation 1 | Rod1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1864963","RNF216 Gene","C114439","This gene is involved in promoting the degradation of substrates by the proteasome.","RNF216 Gene | RNF216 | Ring Finger Protein 216 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826942","CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology","C113847","Test names of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology | CSS10TN | Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent Questionnaire Test Name | QS-C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826941","CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology","C113848","Test codes of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology | CSS10TC | Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent Questionnaire Test Code | QS-C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826930","CDISC Questionnaire Fatigue Severity Scale Test Name Terminology","C113849","Test names of questionnaire questions associated with the Fatigue Severity Scale for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire Fatigue Severity Scale Test Name Terminology | FSS01TN | Fatigue Severity Scale Questionnaire Test Name | QS-FSS TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826929","CDISC Questionnaire Fatigue Severity Scale Test Code Terminology","C113850","Test codes of questionnaire questions associated with the Fatigue Severity Scale for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire Fatigue Severity Scale Test Code Terminology | FSS01TC | Fatigue Severity Scale Questionnaire Test Code | QS-FSS TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826958","CDISC Questionnaire Bladder Control Scale Test Name Terminology","C113851","Test names of questionnaire questions associated with the Bladder Control Scale for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire Bladder Control Scale Test Name Terminology | BLCS01TN | Bladder Control Scale Questionnaire Test Name | QS-BLCS TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826954","CDISC Questionnaire Bowel Control Scale Test Name Terminology","C113853","Test names of questionnaire questions associated with the Bowel Control Scale for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire Bowel Control Scale Test Name Terminology | BWCS01TN | Bowel Control Scale Questionnaire Test Name | QS-BWCS TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826953","CDISC Questionnaire Bowel Control Scale Test Code Terminology","C113854","Test codes of questionnaire questions associated with the Bowel Control Scale for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire Bowel Control Scale Test Code Terminology | BWCS01TC | Bowel Control Scale Questionnaire Test Code | QS-BWCS TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826922","CDISC Questionnaire Impact of Visual Impairment Scale Test Name Terminology","C113855","Test names of questionnaire questions associated with the Impact of Visual Impairment Scale for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire Impact of Visual Impairment Scale Test Name Terminology | IVIS01TN | Impact of Visual Impairment Scale Questionnaire Test Name | QS-IVIS TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828389","RAND-36 - Health Limit Lifting Groceries","C114047","RAND 36-Item Health Survey 1.0 (RAND-36) Does your health now limit you in these activities: Lifting or carrying groceries.","RAND-36 - Health Limit Lifting Groceries | R3601-Health Limit Carrying Groceries | R360105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828390","RAND-36 - Health Limit Climbing Several Flights","C114048","RAND 36-Item Health Survey 1.0 (RAND-36) Does your health now limit you in these activities: Climbing several flights of stairs.","RAND-36 - Health Limit Climbing Several Flights | R3601-Health Limit Climb Several Flights | R360106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714974","AIRE wt Allele","C114320","Human AIRE wild-type allele is located in the vicinity of 21q22.3 and is approximately 12 kb in length. This allele, which encodes autoimmune regulator protein, plays a role in both transcriptional activation and the negative regulation of autoimmune responses. Mutation of the gene is associated with autoimmune polyendocrine syndrome 1.","AIRE wt Allele | AIRE1 | APECED | APS1 | APSI | Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy Gene | Autoimmune Regulator (Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy) Gene | Autoimmune Regulator wt Allele | PGA1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1741275","Autoimmune Regulator, Human","C114321","Autoimmune regulator (545 aa, ~58 kDa) is encoded by the human AIRE gene. This protein is involved in both the activation of gene transcription and the inhibition of autoimmunity.","Autoimmune Regulator | AIRE | APECED Protein | Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy Protein | Autoimmune Regulator (APECED Protein)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3694424","Indwelling Device","C113684","A device designed to be left in the body for an extended time.","Indwelling Device | Indwelling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823588","HAUS7 Gene","C113686","This gene is involved in cell division.","HAUS7 Gene | HAUS Augmin-Like Complex, Subunit 7 Gene | HAUS7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812291","HAUS7 wt Allele","C113688","Human HAUS7 wild-type allele is located in the vicinity of Xq28 and is approximately 48 kb in length. This allele, which encodes HAUS augmin-like complex subunit 7 protein, plays a role in mitotic spindle assembly, centrosome integrity and cytokinesis.","HAUS7 wt Allele | HAUS Augmin-Like Complex, Subunit 7 wt Allele | UCHL5IP | UIP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3715067","HAUS Augmin-Like Complex Subunit 7, human","C113689","HAUS augmin-like complex subunit 7 (368 aa, ~41 kDa) is encoded by the human HAUS7 gene. This protein is involved in centrosome maintenance, mitotic spindle assembly and cytokinesis.","HAUS Augmin-Like Complex Subunit 7 | 26S Proteasome-Associated UCH Interacting Protein 1 | 26S Proteasome-Associated UCH37-Interacting Protein 1 | Three Prime Repair Exonuclease 2 Isoform UIP1 | UCH37 Interacting Protein 1 | UCH37-Interacting Protein 1 | UCHL5 Interacting Protein | UCHL5-Interacting Protein | UIP1 | X-Linked Protein STS1769",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810661","RNF216 wt Allele","C114440","Human RNF216 wild-type allele is located in the vicinity of 7p22.1 and is approximately 162 kb in length. This allele, which encodes E3 ubiquitin-protein ligase RNF216 protein, plays a role in both protein ubiquitination and catabolism. Mutation of the protein is associated with cerebellar ataxia and hypogonadotropic hypogonadism.","RNF216 wt Allele | CAHH | Ring Finger Protein 216 wt Allele | TRIAD3 | U7I1 | UBCE7IP1 | ZIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1310520","E3 Ubiquitin-Protein Ligase RNF216, Human","C114441","E3 ubiquitin-protein ligase RNF216 (866 aa, ~99 kDa) is encoded by the human RNF216 gene. This protein is involved in ubiquitination and degradation of proteins.","E3 Ubiquitin-Protein Ligase RNF216 | EC 2.3.2.27 | EC 6.3.2.-, Formerly | Ring Finger Protein 216 | Triad Domain-Containing Protein 3 | Ubiquitin-Conjugating Enzyme 7-Interacting Protein 1 | Zinc Finger Protein Inhibiting NF-Kappa-B | Zinc Finger Protein Inhibiting NFKB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538837","RGS22 Gene","C114442","This gene plays a role in the inhibition of G-protein coupled receptor signaling.","RGS22 Gene | RGS22 | Regulator of G-Protein Signaling 22 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813557","RGS22 wt Allele","C114443","Human RGS22 wild-type allele is located in the vicinity of 8q22.2 and is approximately 170 kb in length. This allele, which encodes regulator of G-protein signaling 22 protein, is involved in the positive regulation of GTPase activity and the negative regulation of receptor signaling.","RGS22 wt Allele | CT145 | DKFZP434I092 | PRTD-NY2 | Regulator of G-Protein Signaling 22 wt Allele | Regulator of G-Protein Signalling 22 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815896","Regulator of G-Protein Signaling 22, Human","C114444","Regulator of G-protein signaling 22 (1264 aa, ~147 kDa) is encoded by the human RGS22 gene. This protein plays a role in the modulation of both GTPase activity and signal transduction.","Regulator of G-Protein Signaling 22 | RGS22",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471785","Sulforaphane-cyclodextrin Complex","C113804","An orally available, stable powder formulation composed of sulforaphane, a naturally-occurring phytochemical belonging to the class of isothiocyanates, encapsulated within alpha-cyclodextrin, with chemopreventive activity. Upon administration of sulforaphane/alpha-cyclodextrin complex SFX-01, sulforaphane activates the transcription factor NF-E2-related factor 2 (Nrf2; NFE2L2), a member of the basic leucine zipper family, which binds to and activates antioxidant-response elements (AREs). Subsequently, activated AREs mediate the transcription of various cytoprotective genes and antioxidant enzymes, particularly phase II detoxification enzymes, such as glutathione-S-transferase and quinone oxidoreductase, resulting in the detoxification of highly reactive carcinogens. Cyclodextrin is able to prevent sulforaphane's rapid breakdown, which improves its stability and half-life.","Sulforaphane-cyclodextrin Complex | SFX-01 | Stabilized Sulforaphane | Sulforadex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471786","Gallium Ga 68-labeled MLN6907","C113805","A radioconjugate containing a monoclonal antibody directed against guanylyl cyclase C (GCC) labeled with the radioisotope gallium Ga 68, with positron emission tomography (PET) imaging activity. The monoclonal antibody moiety of MLN6907 selectively binds to GCC, a transmembrane receptor normally found on intestinal cells and dopaminergic neurons in the brain, that is also overexpressed on the surface of a variety of cancer cells. Upon internalization of the agent and PET, tumors expressing GCC can be visualized.","Gallium Ga 68-labeled MLN6907 | [68Ga]MLN6907",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471788","Carbon C11 Temozolomide","C113806","A radioconjugate composed of temozolomide, a imidazotetrazine analog of dacarbazine, labeled with the radioisotope carbon C11, with potential positron emission tomography (PET) imaging activity. As a cytotoxic alkylating agent, temozolomide is hydrolyzed at physiologic pH to the pharmacologically active compound, 5-(3-methyl-(triazen-1-yl)-imidazole)-4-carboxamide (MTIC). MTIC is further hydrolyzed to 5-aminoimidazole-4-carboxamide (AIC) and a methyldiazonium cation. The cation is able to methylate DNA, particularly at the O6 and N7 positions of guanine residues, resulting in cell cycle arrest, inhibition of DNA replication and the induction of apoptosis. Temozolomide is metabolized to MITC at all sites, crosses the blood-brain-barrier and penetrates well into the central nervous system. Upon PET, the biodistribution, uptake in cancer cells and the efficacy of temozolomide can be assessed.","Carbon C11 Temozolomide | [11C] Temozolomide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828392","RAND-36 - Health Limit Bending or Stooping","C114050","RAND 36-Item Health Survey 1.0 (RAND-36) Does your health now limit you in these activities: Bending, kneeling, or stooping.","RAND-36 - Health Limit Bending or Stooping | R3601-Health Limit Bending or Kneeling | R360108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828386","RAND-36 - Health Limit Walking More Than A Mile","C114051","RAND 36-Item Health Survey 1.0 (RAND-36) Does your health now limit you in these activities: Walking more than a mile.","RAND-36 - Health Limit Walking More Than A Mile | R3601-Health Limit Walk More Than Mile | R360109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828385","RAND-36 - Health Limit Walking Several Blocks","C114052","RAND 36-Item Health Survey 1.0 (RAND-36) Does your health now limit you in these activities: Walking several blocks.","RAND-36 - Health Limit Walking Several Blocks | R3601-Health Limit Walk Several Blocks | R360110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827288","RAND-36 - Health Limit Walking One Block","C114053","RAND 36-Item Health Survey 1.0 (RAND-36) Does your health now limit you in these activities: Walking one block.","RAND-36 - Health Limit Walking One Block | R3601-Health Limit Walk One Block | R360111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828393","RAND-36 - Health Limit Bathing or Dressing","C114054","RAND 36-Item Health Survey 1.0 (RAND-36) Does your health now limit you in these activities: Bathing or dressing yourself.","RAND-36 - Health Limit Bathing or Dressing | R3601-Health Limit Bathing/Dressing Self | R360112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828381","RAND-36 - Physical Health Cut Down Time Spent on Work","C114055","RAND 36-Item Health Survey 1.0 (RAND-36) During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of your physical health: Cut down the amount of time you spent on work or other activities.","RAND-36 - Physical Health Cut Down Time Spent on Work | R3601-Phys Health: Cut Work Time | R360113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828382","RAND-36 - Physical Health Accomplished Less","C114056","RAND 36-Item Health Survey 1.0 (RAND-36) During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of your physical health: Accomplished less than you would like.","RAND-36 - Physical Health Accomplished Less | R3601-Phys Health: Accomplish Less | R360114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828379","RAND-36 - Physical Health Limited in the Kind of Work","C114057","RAND 36-Item Health Survey 1.0 (RAND-36) During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of your physical health: Were limited in the kind of work or other activities.","RAND-36 - Physical Health Limited in the Kind of Work | R3601-Phys Health: Limit Kind of Work | R360115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828380","RAND-36 - Physical Health Difficulty Performing Work","C114058","RAND 36-Item Health Survey 1.0 (RAND-36) During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of your physical health: Had difficulty performing the work or other activities.","RAND-36 - Physical Health Difficulty Performing Work | R3601-Phys Health: Difficulty Performing | R360116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828405","RAND-36 - Emotional Problem Cut Down Time Spent on Work","C114059","RAND 36-Item Health Survey 1.0 (RAND-36) During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of any emotional problems: Cut down the amount of time you spent on work or other activities.","RAND-36 - Emotional Problem Cut Down Time Spent on Work | R3601-Emotional Problem: Cut Work Time | R360117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827225","NPPB Gene Product","C113693","A protein encoded by the NPPB gene.","NPPB Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830729","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Active Suicidal Ideation With Some Intent to Act, Without Specific Plan (Lifetime)","C113898","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) When you thought about making yourself not alive anymore (or killing yourself), did you think that this was something you might actually do? This is different from (as opposed to) having the thoughts but knowing you wouldn't do anything about it. (Lifetime).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Active Suicidal Ideation With Some Intent to Act, Without Specific Plan (Lifetime) | CSS10-Idea, Intent, No Plan-Life | CSS1004A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830728","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Active Suicidal Ideation With Some Intent to Act, Without Specific Plan (Past 1 Month)","C113899","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) When you thought about making yourself not alive anymore (or killing yourself), did you think that this was something you might actually do? This is different from (as opposed to) having the thoughts but knowing you wouldn't do anything about it. (Past 1 Month).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Active Suicidal Ideation With Some Intent to Act, Without Specific Plan (Past 1 Month) | CSS10-Idea, Intent, No Plan-P1M | CSS1004B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830719","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Description of Active Suicidal Ideation With Some Intent to Act, Without Specific Plan","C113900","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Description of active suicidal ideation with some intent to act, without specific plan.","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Description of Active Suicidal Ideation With Some Intent to Act, Without Specific Plan | CSS10-Idea, Intent, No Plan, Describe | CSS1004C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830727","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Active Suicidal Ideation With Specific Plan and Intent (Lifetime)","C113901","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Have you ever decided how or when you would make yourself not alive anymore/kill yourself? Have you ever planned out (worked out the details of) how you would do it? What was your plan? When you made this plan (or worked out these details), was any part of you thinking about actually doing it? (Lifetime).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Active Suicidal Ideation With Specific Plan and Intent (Lifetime) | CSS10-Idea, Plan, Intent-Life | CSS1005A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471790","DLK1/EPHA2/HBB/NRP1/RGS5/TEM1 Peptide-pulsed Alpha-type-1 Polarized Dendritic Cell Vaccine","C113807","A cell based cancer vaccine composed of mature polarized dendritic cells (alphaDC1) pulsed with six human leukocyte antigen (HLA)-A2-presented tumor blood vessel antigen (TBVA)-derived peptides, with potential immunostimulatory and antineoplastic activities. Dendritic cells (DCs) were treated with a 'type-1 polarizing cytokine cocktail', including interleukin-1beta, tumor necrosis factor alpha (TNF-a), interferon-alpha (IFN-a), IFN-gamma and polyinosinic:polycytidylic acid (pI:C) to produce mature alpha type-1 polarized DCs (alphaDC1) that are capable of producing high levels of interleukin-12p70 (IL-12p70). The alphaDC1 are subsequently pulsed with TBVA-derived peptides, including delta-like homologue 1 (DLK1) 310-318, EPH receptor A2 (EPHA2) 883-891, beta-globin (HBB) 31-39, neuropilin-1 (NRP1) 433-441, regulator of G-protein signaling 5 (RGS5) 5-13 and tumor endothelial marker 1 (TEM1) 691-700. Upon administration, these DCs are able to induce a potent cytotoxic T-lymphocyte (CTL) response against the TBVAs expressed on tumor-associated stromal cells, which results in stromal cell lysis and inhibition of angiogenesis. Disrupting the surrounding tumor vasculature inhibits tumor cell growth and survival. alphaDC1 are able to induce a potent tumor antigen-specific CTL response due to their high co-stimulatory activity and the secretion of anti-cancer cytokines, such as IL-12p70.","DLK1/EPHA2/HBB/NRP1/RGS5/TEM1 Peptide-pulsed Alpha-type-1 Polarized Dendritic Cell Vaccine | Tumor Blood Vessel Antigen Peptide-pulsed Alpha-type-1 Polarized Dendritic Cell Vaccine | alphaDC1-TBVA Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828896","MSQOL-54 - Physical Health Difficulty Perform Work","C114003","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of your physical health: Had difficulty performing the work or other activities.","MSQOL-54 - Physical Health Difficulty Perform Work | MSQL1-Phys Health: Difficulty Performing | MSQL116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828931","MSQOL-54 - Emotional Problem Cut Down Time on Work","C114004","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of any emotional problems: Cut down on the amount of time you could spend on work or other activities.","MSQOL-54 - Emotional Problem Cut Down Time on Work | MSQL1-Emotional Problem: Cut Work Time | MSQL117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828932","MSQOL-54 - Emotional Problem Accomplish Less","C114005","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of any emotional problems: Accomplished less than you would like.","MSQOL-54 - Emotional Problem Accomplish Less | MSQL1-Emotional Problem: Accomplish Less | MSQL118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828930","MSQOL-54 - Emotional Problem Did Not Do Work Carefully","C114006","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of any emotional problems: Didn't do work or other activities as carefully as usual.","MSQOL-54 - Emotional Problem Did Not Do Work Carefully | MSQL1-Emotional Problem: Less Careful | MSQL119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471797","Bifidobacterium lactis/Lactobacillus acidophilus/L. plantarum/L. salivarius Probiotic Supplement","C114288","An orally available, probiotic supplement containing the non-pathogenic microorganisms Lactobacillus acidophilus, L. plantarum, L. salivarius and Bifidobacterium lactis, with potential anti-inflammatory, immunomodulating and protective activities. Upon oral ingestion, the naturally-occurring bacterial components in this dietary supplement may improve digestion and help maintain adequate colonization of the gastrointestinal (GI) tract by modulating the composition of the normal microflora. During colonization in the GI tract, the bacteria may form a protective intestinal barrier that may prevent both damage to the mucosal epithelia caused by toxins and attachment of potential pathogens, which protects against bacterial translocation and infections. In addition, this agent may both reduce the secretion of pro-inflammatory cytokines, including interleukin-10, and potentiate natural and acquired immunity.","Bifidobacterium lactis/Lactobacillus acidophilus/L. plantarum/L. salivarius Probiotic Supplement | Lactibiane Tolerance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471798","PSA/IL-2/GM-CSF Vaccine","C114289","A prostate cancer vaccine containing prostate specific antigen (PSA) combined with the cytokines, interleukin-2 (IL-2) and granulocyte macrophage-colony-stimulating factor (GM-CSF), with potential antineoplastic activity. Upon intradermal vaccination, PSA/IL-2/GM-CSF vaccine may activate the immune system to induce a cytotoxic T-cell (CTL) response against prostate cancer cells expressing this antigen, thereby decreasing tumor cell growth. PSA, a glycoprotein secreted by prostatic epithelial and ductal cells, is overexpressed by prostate cancer cells. IL-2 stimulates natural killer (NK) cells and cytotoxic T-cells against the PSA-expressing tumor cells. GM-CSF promotes antigen presentation to dendritic cells and further stimulates a tumor-specific cytotoxic T-lymphocyte (CTL) response.","PSA/IL-2/GM-CSF Vaccine | ProscaVax | Prostatac",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472221","Pronase Oral Solution","C114290","An oral solution containing a mixture of proteinases, which are produced by Streptomyces griseus, with mucolytic activity and potential diagnostic applications. Upon oral administration, pronase is able to cleave peptide chains of polypeptides into individual amino acids, thereby dissolving mucus. The removal of mucus may improve the visibility of parts of the digestive tract, such as the esophagus and the stomach, during endoscopy. Pre-treatment with pronase before endoscopic examination may help in the detection of certain cancers, such as esophageal and gastric cancer.","Pronase Oral Solution | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471799","Concentrated Beet Crystals","C114291","A formulation containing concentrated beetroot crystals, with potential antioxidant and protective activities. Concentrated beetroot crystals contain antioxidants, including betacyanin, which scavenge free radicals, and high levels of nitrates and folic acid. Intake of concentrated beetroot crystals leads to the conversion of nitrate to nitric oxide (NO). This may have a beneficial effect on blood flow and blood pressure through the stimulation of NO-mediated vasodilation. Additionally, this agent may decrease fatigue and increase physical performance.","Concentrated Beet Crystals | BEETELITE NeoShot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0065234","Lugol's solution","C114292","A solution composed of iodine and potassium iodide, which can be used as a reagent and antiseptic, with potential use in cancer diagnosis. The iodine in Lugol's solution selectively binds to alpha-1,4 glucans found in polysaccharides, such as glycogen. Lugol's solution reacts with glycogen in normal, healthy non-keratinized, squamous epithelium and the iodine-glucan complex stains the glycogen-containing cells dark brown. Cancer cells are devoid of glycogen, so these cells will stay unstained. The presence of cancer cells can be detected by the degree of staining and the neoplastic cells can be surgically removed. High-grade intraepitheial neoplasia has almost no glycogen-containing epithelium.","Lugol's Solution | Lugol's Iodine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472222","HER2-pulsed Autologous Type-1 Polarized Dendritic Cell Vaccine","C114293","A dendritic cell (DC)-based cancer vaccine composed of autologous, type-1 polarized dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A2-restricted HER-2-derived peptides, with potential immunomodulatory and antineoplastic activities. Autologous DCs were treated with GM-CSF, interleukin-4, interferon-gamma and bacterial lipopolysaccharide (LPS), a toll-like receptor type 4 agonist, to produce highly polarized DCs (alphaDC1) that are capable of producing high levels of interleukin-12p70 (IL-12p70). Upon administration, HER2-pulsed autologous DC vaccine may stimulate a potent cytotoxic T-lymphocyte (CTL) response against HER-2-positive tumor cells, which may result in tumor cell death and decreased tumor growth. HER-2, a tyrosine kinase receptor for epidermal growth factor (EGF) (also known as neu and ErbB2), is overexpressed by a variety of cancers.","HER2-pulsed Autologous Type-1 Polarized Dendritic Cell Vaccine | HER-2 pulsed DC1 Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830726","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Active Suicidal Ideation With Specific Plan and Intent (Past 1 Month)","C113902","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Have you ever decided how or when you would make yourself not alive anymore/kill yourself? Have you ever planned out (worked out the details of) how you would do it? What was your plan? When you made this plan (or worked out these details), was any part of you thinking about actually doing it? (Past 1 Month).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Active Suicidal Ideation With Specific Plan and Intent (Past 1 Month) | CSS10-Idea, Plan, Intent-P1M | CSS1005B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830718","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Description of Active Suicidal Ideation With Specific Plan and Intent","C113903","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Description of active suicidal ideation with specific plan and intent.","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Description of Active Suicidal Ideation With Specific Plan and Intent | CSS10-Idea, Plan, Intent, Describe | CSS1005C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830698","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Most Severe Ideation (Lifetime)","C113904","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Most severe Ideation. (Lifetime).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Most Severe Ideation (Lifetime) | CSS10-Most Severe Idea-Life | CSS1006A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830723","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Describe Most Severe Ideation (Lifetime)","C113905","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Description of most severe ideation. (Lifetime).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Describe Most Severe Ideation (Lifetime) | CSS10-Most Severe Idea, Desc-Life | CSS1006B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830291","Experimental Organism Lymphosarcoma Neoplasm","C114112","An antiquated term referring to a malignant lymphoma that is diffused and composed of small and large lymphocytes.","Experimental Organism Lymphosarcoma Neoplasm | LYMPHOSARCOMA, MALIGNANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830293","Experimental Organism Benign Stromal Tumor Neoplasm","C114113","A benign neoplasm composed of mesenchymal stromal cells.","Experimental Organism Benign Stromal Tumor Neoplasm | STROMAL TUMOR, BENIGN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816482","Experimental Organism Benign Thymoma Neoplasm","C114115","A benign neoplasm of the thymus, originating from epithelial thymus cells.","Experimental Organism Benign Thymoma Neoplasm | THYMOMA, BENIGN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826880","CDISC SDTM Morphology Test Name Terminology","C114116","Terminology associated with the morphology test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Morphology Test Name Terminology | SDTM-MOTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826879","CDISC SDTM Morphology Test Code Terminology","C114117","Terminology associated with the morphology test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Morphology Test Code Terminology | SDTM-MOTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811897","CDISC SDTM Protocol Milestone Terminology","C114118","Terminology associated with the protocol milestone codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Protocol Milestone Terminology | PROTMLST | Protocol Milestone | SDTM-PROTMLST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826861","CDISC SDTM Pharmacogenomics Biomarker Medical Statement Terminology","C114119","Terminology associated with the pharmacogenomics biomarker medical statement codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Pharmacogenomics Biomarker Medical Statement Terminology | SDTM-PBSTMT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830348","ECG Recording Quality","C114120","A finding pertaining to the quality of an ECG recording.","ECG Recording Quality | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828928","MSQOL-54 - Extend Physical Health or Emotional Problem Interfere With Social Activities","C114007","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) During the past 4 weeks, to what extent has your physical health or emotional problems interfered with your normal social activities with family, friends, neighbors, or groups?","MSQOL-54 - Extend Physical Health or Emotional Problem Interfere With Social Activities | MSQL1-Extent Interfered Social Activity | MSQL120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828938","MSQOL-54 - Bodily Pain","C114008","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much bodily pain have you had during the past 4 weeks?","MSQOL-54 - Bodily Pain | MSQL1-How Much Bodily Pain Have You Had | MSQL121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828899","MSQOL-54 - Pain Interfere With Normal Work","C114009","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) During the past 4 weeks, how much did pain interfere with your normal work?","MSQOL-54 - Pain Interfere With Normal Work | MSQL1-Did Pain Interfere With Your Work | MSQL122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828927","MSQOL-54 - Feel Full of Pep","C114010","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Did you feel full of pep?","MSQOL-54 - Feel Full of Pep | MSQL1-Did You Feel Full of Pep | MSQL123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828939","MSQOL-54 - Been a Nervous Person","C114011","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Have you been a very nervous person?","MSQOL-54 - Been a Nervous Person | MSQL1-Have Been a Very Nervous Person | MSQL124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828920","MSQOL-54 - Felt So Down Nothing Could Cheer You Up","C114012","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Have you felt so down in the dumps that nothing could cheer you up?","MSQOL-54 - Felt So Down Nothing Could Cheer You Up | MSQL1-Have Felt So Down in the Dumps | MSQL125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828917","MSQOL-54 - Have a Lot of Energy","C114014","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Did you have a lot of energy?","MSQOL-54 - Have a Lot of Energy | MSQL1-Did You Have a Lot of Energy | MSQL127",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828921","MSQOL-54 - Felt Downhearted and Blue","C114015","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Have you felt downhearted and blue?","MSQOL-54 - Felt Downhearted and Blue | MSQL1-Have Felt Downhearted and Blue | MSQL128",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828923","MSQOL-54 - Feel Worn Out","C114016","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Did you feel worn out?","MSQOL-54 - Feel Worn Out | MSQL1-Did You Feel Worn Out | MSQL129",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0319600","Kluyveromyces marxianus","C114256","A dimorphic, homothallic and hemiascomycetous yeast in the phylum Ascomycota. This species is respiro-fermentative, Crabtree negative, thermotolerant, and assimilate lactose and insulin. This species also has a characteristically high growth rate and secretory capacity. K. marxianus is a biocatalyst and used industrially to produce beta-galactosidase, beta-glucosidase, inulinase, and polygalacturonases. It is also used as baker's yeast and an anticholesterolemic agent.","Kluyveromyces marxianus | C. pseudotropicalis | Candida pseudotropicalis | K. cicerisporus | K. fragilis | KLUYVEROMYCES MARXIANUS | Kluyveromyces cicerisporus | Kluyveromyces fragilis",,,,,,,,,,,,,,,"4352748","Kluyveromyces marxianus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319876","Yarrowia lipolytica","C114257","A dimorphic yeast in the phylum Ascomycota. This species is strictly aerobic, degrades hydrophobic substrates, assimilates glucose, fructose and mannose, and utilizes ethanol and glycerol as carbon sources. Y. lipolytica is a biocatalyst and used commercially in biotransformation to catalyze hydrolysis, esterification, interesterification and transesterification reactions. It is also used for the production of citric acid.","Yarrowia lipolytica | Candida lipolytica | M. lipolytica | Mycotorula lipolytica | Y. lipolytica | YARROWIA LIPOLYTICA",,,,,,,,,,,,,,,"45766066","Yarrowia lipolytica",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1014572","Candida pararugosa","C114258","A yeast in the phylum Ascomycota. This species assimilates glucose, xylitol, galactose and sorbitol. C. pararugosa has been isolated from human feces and is a normal part of the oral microflora.","Candida pararugosa | C. pararugosa | CANDIDA PARARUGOSA",,,,,,,,,,,,,,,"45765397","Wickerhamiella pararugosa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL458362","TLR4 agonist GLA-SE","C113649","A synthetic lipid A derivative and selective toll-like receptor 4 (TLR4) agonist composed of glucopyranosyl lipid-A (GLA) in a stable, oil-in-water emulsion (GLA-SE), with potential immunostimulating and antineoplastic activities. Upon intratumoral administration into the immunosuppressed tumor microenvironment (TME), TLR4 agonist G100 binds to and activates TLR4 on various immune cells, thereby stimulating dendritic cells (DCs), monocytes and macrophages. This activation results in the production of pro-inflammatory cytokines and chemokines. This induces a T helper cell-1 (Th1) immune response and activates a cytotoxic T-lymphocyte (CTL) response against tumor-associated antigens (TAAs) that were released in the TME by tumor cells lysed during cytotoxic treatments, such as radiotherapy. TLR4, a member of the TLR family, plays a key role in the activation of innate immunity.","TLR4 Agonist G100 | G100 | GLA-SE | Glucopyranosyl Lipid A Stable Emulsion | Glucopyranosyl Lipid Adjuvant-Stable Emulsion | TLR 4 Agonist G100 | TLR-4 Agonist G100 | TLR-4 Agonist GLA-SE | Toll-like Receptor 4 Agonist G100 | Toll-like Receptor 4 Agonist GLA-SE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL458363","IVAC Mutanome Vaccine","C113650","An individualized, poly-neo-epitopic encoding, ribonucleic acid (RNA)-based cancer vaccine that targets a variety of patient-specific, immunogenic mutant epitopes, with potential immunostimulatory and antineoplastic activities. Upon intranodal administration, the RNA in the individualized mutanome vaccine is translated by antigen presenting cells (APCs) and the expressed protein is presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL) and memory T-cell immune responses against the patient-specific neoantigens.","IVAC Mutanome Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL458364","Ovapuldencel-T","C113651","A cancer vaccine consisting of autologous dendritic cells (DCs) loaded with autologous, lethally irradiated cancer cells and mixed with the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulatory and antineoplastic activities. Upon vaccination, ovapuldencel-T may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against the repertoire of tumor associated antigens (TAAs) found in the irradiated cancer cells. GM-CSF enhances the activation of dendritic cells (DCs) and promotes antigen presentation to both B- and T-lymphocytes.","Ovapuldencel-T | OVAPULDENCEL-T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL458366","gp96-secreting allogeneic bladder cancer cell vaccine HS-410","C113653","An allogeneic urothelial bladder cancer cell vaccine expressing a recombinant secretory form of the immunoadjuvant heat shock protein gp96 fused with an immunoglobulin Fc domain (gp96-Ig) protein, with potential antineoplastic activity. Upon administration of vesigenurtucel-L, the live, irradiated tumor cells continuously secrete gp96-Ig along with its chaperoned tumor associated antigens (TAAs). This enhances antigen cross presentation to cytotoxic T-lymphocytes (CTLs) and, upon expansion, leads to the induction of a potent CTL response against the TAAs on the endogenous bladder cancer cells. This vaccine also induces a memory T cell response that could fight recurring cancer cells. gp96-Ig is constructed by replacing the KDEL endoplasmic reticulum (ER) retention sequence of gp96 with the Fc portion of the IgG1 protein. This allows for gp96, normally an ER-resident chaperone peptide, to be released from cells.","Vesigenurtucel-L | HS-410 | VESIGENURTUCEL-L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL458367","Midazolam-containing Buccal Liquid","C113654","An oromucosal solution containing the maleate salt form of midazolam, a short-acting benzodiazepine derivative, with anxiolytic, hypnotic, anticonvulsant and sedative activities. Upon administration of the solution into the buccal cavity, midazolam exerts its effect by binding to the benzodiazepine receptor at the gamma-aminobutyric acid (GABA) receptor-chloride ionophore complex in the central nervous system (CNS). This leads to an increase in the permeability of chloride channels, membrane hyperpolarization and enhances the inhibitory effect of GABA in the CNS. Midazolam may also interfere with the reuptake of GABA, thereby causing accumulation of GABA in the synaptic cleft. The oromucosal formulation facilitates administration to patients that are unable to swallow. The ethanol in this formulation improves the buccal absorption of midazolam.","Midazolam-containing Buccal Liquid | Epistatus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022741","Kluyveromyces","C114123","A genus of yeasts in the family Saccharomycetaceae and phylum Ascomycota.","Kluyveromyces | ",,,,,,,,,,,,,,,"4301749","Kluyveromyces",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0949682","Yarrowia","C114124","A genus of yeasts in the family Dipodascaceae and phylum Ascomycota.","Yarrowia | ",,,,,,,,,,,,,,,"45766065","Yarrowia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3397314","Magnusiomyces","C114126","A genus of yeasts in the family Dipodascaceae and phylum Ascomycota.","Magnusiomyces | ",,,,,,,,,,,,,,,"37016453","Magnusiomyces",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0997510","Filobasidium","C114127","A genus of yeasts in the family Filobasidiaceae and phylum Basidiomycota.","Filobasidium | ",,,,,,,,,,,,,,,"4308305","Filobasidium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033734","Prototheca","C114128","A genus of green algae in the family Chlorellaceae and phylum Chlorophyta.","Prototheca | ",,,,,,,,,,,,,,,"4293013","Prototheca",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242669","Placental Retention","C114130","After delivery of neonate, placental retention that requires clinical intervention such as manual extraction, curettage or uterotonic medications.","Placental Retention | Retained Placenta",,,,,,,,,,,,,,,"4003030","Retained placenta",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0473305","Augmentation of Labor","C114132","The stimulation of uterine contractions using pharmacologic methods or artificial rupture of membranes (AROM) to increase their frequency and/or strength following the onset of spontaneous labor or contractions following spontaneous rupture of membranes. Does not apply if induction of labor is performed. (reVITALize)","Augmentation of Labor | ",,,,,,,,,,,,,,,"4127260","Augmentation of labor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3810601","PDZK1 wt Allele","C114323","Human PDZK1 wild-type allele is located in the vicinity of 1q21 and is approximately 37 kb in length. This allele, which encodes Na(+)/H(+) exchange regulatory cofactor NHE-RF3 protein, is involved in the modulation of ion channel and signaling protein localization. Variations and aberrant expression of this gene may be associated with metabolic syndrome and drug resistance of multiple myeloma, respectively.","PDZK1 wt Allele | CAP70 | CLAMP | NHERF-3 | NHERF3 | PDZ Domain Containing 1 wt Allele | PDZ Domain-Containing 1 Gene | PDZD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810600","Na(+)/H(+) Exchange Regulatory Cofactor NHE-RF3","C114324","Na(+)/H(+) exchange regulatory cofactor NHE-RF3 (519 aa, ~57 kDa) is encoded by the human PDZK1 gene. This protein plays a role in the localization of ion transporters and signaling proteins.","Na(+)/H(+) Exchange Regulatory Cofactor NHE-RF3 | C-Terminal Linking and Modulating Protein | CFTR-Associated Protein of 70 kDa | CFTR-Associated Protein, 70 kDa | NHERF-3 | Na(+)/H(+) Exchanger Regulatory Factor 3 | Na/Pi Cotransporter C-Terminal-Associated Protein 1 | NaPi-Cap1 | PDZ Domain-Containing Protein 1 | PDZ-Containing Kidney Protein 1 | Sodium-Hydrogen Exchanger Regulatory Factor 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3715214","RHOU wt Allele","C114326","Human RHOU wild-type allele is located within 1q42.11-q42.3 and is approximately 102 kb in length. This allele, which encodes Rho-related GTP-binding protein RhoU, plays a role in signal transduction that modulates cytoskeletal organization and cell migration.","RHOU wt Allele | 2310026M05Rik | ARHU | CDC42L1 | DJ646B12.2 | FLJ10616 | Ras Homolog Family Member U wt Allele | Ras Homolog Gene Family, Member U Gene | Ras-Like Gene Family Member U Gene | WRCH1 | fJ646B12.2 | hG28K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0968598","Rho-Related GTP-Binding Protein RhoU, Human","C114327","Rho-related GTP-binding protein RhoU (258 aa, ~28 kDa) is encoded by the human RHOU gene. This protein is involved in the regulation of cell migration.","Rho-Related GTP-Binding Protein RhoU | CDC42-Like GTPase | CDC42-Like GTPase 1 | GTP-Binding Protein Like 1 | GTP-Binding Protein SB128 | GTP-Binding Protein-Like 1 | Rho GTPase-Like Protein ARHU | Ryu GTPase | WRCH-1 | Wnt-1 Responsive Cdc42 Homolog | Wnt-1 Responsive Cdc42 Homolog 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830669","C-SSRS Screening - Description of Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act","C111465","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Description of active suicidal ideation with any methods (not plan) without intent to act.","C-SSRS Screening - Description of Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act | CSS09-Idea, No Intent, No Plan, Describe | CSS0903A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830668","C-SSRS Screening - Description of Active Suicidal Ideation with Some Intent to Act, without Specific Plan","C111467","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Description of active suicidal ideation with some intent to act, without specific plan.","C-SSRS Screening - Description of Active Suicidal Ideation with Some Intent to Act, without Specific Plan | CSS09-Idea, Intent, No Plan, Describe | CSS0904A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830674","C-SSRS Screening - Active Suicidal Ideation with Specific Plan and Intent","C111468","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan?","C-SSRS Screening - Active Suicidal Ideation with Specific Plan and Intent | CSS09-Idea, Plan, Intent | CSS0905",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830667","C-SSRS Screening - Description of Active Suicidal Ideation with Specific Plan and Intent","C111469","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Description of active suicidal ideation with specific plan and intent.","C-SSRS Screening - Description of Active Suicidal Ideation with Specific Plan and Intent | CSS09-Idea, Plan, Intent, Describe | CSS0905A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830648","C-SSRS Screening - Most Severe Ideation","C111470","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Most severe ideation.","C-SSRS Screening - Most Severe Ideation | CSS09-Most Severe Idea | CSS0906",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830671","C-SSRS Screening - Describe Most Severe Ideation","C111471","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Description of most severe ideation.","C-SSRS Screening - Describe Most Severe Ideation | CSS09-Most Severe Idea, Desc | CSS0906A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830656","C-SSRS Screening - Frequency of Most Severe Ideation","C111472","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) How many times have you had these thoughts?","C-SSRS Screening - Frequency of Most Severe Ideation | CSS09-Most Severe Idea, Frequency | CSS0907",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830660","C-SSRS Screening - Duration of Most Severe Ideation","C111473","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) When you have the thoughts, how long do they last?","C-SSRS Screening - Duration of Most Severe Ideation | CSS09-Most Severe Idea, Duration | CSS0908",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0446038","Pichia norvegensis","C114259","A dimorphic yeast in the phylum Ascomycota. This species is ovoid or ellipsoidal shaped, arranged in single or pairs, ferments glucose and assimilates cellobiose but not galactose, sucrose, maltose, lactose, D-mannitol and D-glucitol, produces ascospores and utilizes thiamine, biotin and pyridoxine. P. norvegensis has been isolated from the normal vaginal flora.","Pichia norvegensis | C. mycoderma var. annulata | Candida mycoderma var. annulata | P. norvegensis | PICHIA NORVEGENSIS",,,,,,,,,,,,,,,"37018624","Pichia norvegensis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1478347","Candida orthopsilosis","C114260","A yeast in the phylum Ascomycota. This species is oval, round, or cylindrical shaped, ferments glucose, does not form true hyphae and exists in either a yeast phase or a pseudohyphal form. C. orthopsilosis a commensal of human skin, and an opportunistic human pathogen which may cause superficial cutaneous infections.","Candida orthopsilosis | C. orthopsilosis | CANDIDA ORTHOPSILOSIS | Candida parapsilosis group II",,,,,,,,,,,,,,,"37016373","Candida orthopsilosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0446045","Candida zeylanoides","C114261","A yeast in the phylum Ascomycota. This species is urease-negative, forms feather-like pseudohyphae consisting of chains of cells with oval blastospores, assimilates glucose, and does not grow in the presence of cycloheximide. C. zeylanoides is an opportunistic human pathogen which may cause fungemia and arthritis.","Candida zeylanoides | C. krissii | C. zeylanoides | CANDIDA ZEYLANOIDES | Candida krissii",,,,,,,,,,,,,,,"4352755","Candida zeylanoides",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0561725","Wickerhamomyces anomalus","C114262","A yeast in the phylum Ascomycota. This species is spheroidal to elongate shaped, forms pseudohyphae and produces hat-shaped ascospores, can grow anaerobically, ferments glucose and sucrose, assimilates glucose, galactose, fructose, raffinose and mannose but not formic acid and methanol, and utilizes nitrate and urea. W. anomalus is used in food and feed processing and functions as a biopreservation agent, phytase producer, and for folate biofortification. It is also the causative agent of opportunistic mycoses that develop in immunocompromised individuals as well as neonates.","Wickerhamomyces anomalus | C. pelliculosa | Candida pelliculosa | H. anomala | Hansenula anomala | P. anomala | Pichia anomala | W. anomalus | WICKERHAMOMYCES ANOMALUS",,,,,,,,,,,,,,,"4145969","Wickerhamomyces anomalus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3397315","Magnusiomyces capitatus","C114263","A yeast in the phylum Ascomycota. This species forms branched hyphae, and hyaline, ellipsoidal ascospores, and assimilates glucose, galactose, ethanol and glycerol. M. capitatus is an opportunistic pathogen and has been isolated from the human digestive and respiratory tracts as well as the blood of immunocompromised hosts.","Magnusiomyces capitatus | Blastoschizomyces capitatus | Dipodascus capitatus | Geotrichum capitatum | M. capitatus | MAGNUSIOMYCES CAPITATUS | Saprochaete capitata | Trichosporon capitatum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0319895","Rhodotorula glutinis","C114264","A yeast in the phylum Basidiomycota. This species is globose to ovoid, or cylindrical to fusiform shaped, forms distinctive orange/red colonies, assimilates glucose, ethanol and glycerol, and utilizes nitrate. R. glutinis is a common environmental inhabitant and an opportunistic pathogen which may cause meningitis, fungemia, and sepsis.","Rhodotorula glutinis | R. glutinis | RHODOTORULA GLUTINIS",,,,,,,,,,,,,,,"4239686","Rhodotorula glutinis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319891","Filobasidium uniguttulatum","C114265","A heterothallic yeast in the phylum Basidiomycota. This species is basidia hyaline, urease-positive, produces hyphae and smooth, ovate or kidney shaped basidiospores, and assimilates glucose, sucrose and maltose. F. uniguttulatum may cause meningitis.","Filobasidium uniguttulatum | C. neoformans var. uniguttulatus | C. uniguttulatus | Cryptococcus neoformans var. uniguttulatus | Cryptococcus uniguttulatus | E. uniguttulata | Eutorulopsis uniguttulata | F. uniguttulatum | FILOBASIDIUM UNIGUTTULATUM",,,,,,,,,,,,,,,"35622972","Filobasidium uniguttulatum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1670664","Cryptococcus randhawii","C114266","An anamorphic yeast in the phylum Basidiomycota. This species is globose to ovoid shaped, assimilates glucose, galactose, xylose, arabinose, sucrose and maltose, does not produce hyphae or pseudohyphae, and utilizes nitrate. C. randhawii is originally isolated from the decaying wood samples in North-western India.","Cryptococcus randhawii | C. randhawii | CRYPTOCOCCUS RANDHAWII",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419305","RBMS1 Gene","C114445","This gene is involved in both DNA replication and single-stranded DNA binding.","RBMS1 Gene | RBMS1 | RNA Binding Motif, Single Stranded Interacting Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810550","RBMS1 wt Allele","C114446","Human RBMS1 wild-type allele is located in the vicinity of 2q24.2 and is approximately 222 kb in length. This allele, which encodes RNA-binding motif, single-stranded-interacting protein 1, plays a role in DNA replication.","RBMS1 wt Allele | C2orf12 | Cervical Cancer Oncogene 4 | Chromosome 2 Open Reading Frame 12 Gene | HCC-4 | MSSP | MSSP-1 | MSSP-2 | MSSP-3 | RNA Binding Motif, Single Stranded Interacting Protein 1 wt Allele | RNA-Binding Motif, Single Strand-Interacting Protein, 1 Gene | SCR2 | Suppressor of Cdc 2 (Cdc13) With RNA Binding Motif 2 Gene | YC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826921","CDISC Questionnaire Impact of Visual Impairment Scale Test Code Terminology","C113856","Test codes of questionnaire questions associated with the Impact of Visual Impairment Scale for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire Impact of Visual Impairment Scale Test Code Terminology | IVIS01TC | Impact of Visual Impairment Scale Questionnaire Test Code | QS-IVIS TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826918","CDISC Questionnaire Modified Fatigue Impact Scale Test Name Terminology","C113857","Test names of questionnaire questions associated with the Modified Fatigue Impact Scale for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire Modified Fatigue Impact Scale Test Name Terminology | MFIS01TN | Modified Fatigue Impact Scale Questionnaire Test Name | QS-MFIS TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826852","CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology","C113859","Test names of questionnaire questions associated with the Multiple Sclerosis Quality of Life-54 Instrument for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology | MSQL1TN | Multiple Sclerosis Quality of Life-54 Instrument Questionnaire Test Name | QS-MSQOL-54 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826910","CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology","C113860","Test codes of questionnaire questions associated with the Multiple Sclerosis Quality of Life-54 Instrument for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology | MSQL1TC | Multiple Sclerosis Quality of Life-54 Instrument Questionnaire Test Code | QS-MSQOL-54 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826907","CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology","C113861","Test names of questionnaire questions associated with the RAND 36-Item Health Survey 1.0 for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology | QS-RAND-36 V1.0 TEST | R3601TN | RAND 36-Item Health Survey 1.0 Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826906","CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology","C113862","Test names of questionnaire questions associated with the RAND 36-Item Health Survey 1.0 for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology | QS-RAND-36 V1.0 TESTCD | R3601TC | RAND 36-Item Health Survey 1.0 Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831315","Borg CR10 Questionnaire Question","C113863","A question associated with the Borg CR10 questionnaire.","Borg CR10 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830684","C-SSRS Pediatric Cognitively Impaired Lifetime Recent Questionnaire Question","C113864","A question associated with the C-SSRS Pediatric Cognitively Impaired Lifetime Recent questionnaire.","C-SSRS Pediatric Cognitively Impaired Lifetime Recent Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830066","FSS Questionnaire Question","C113865","A question associated with the FSS questionnaire.","FSS Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831335","BLCS Questionnaire Question","C113866","A question associated with the BLCS questionnaire.","BLCS Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831233","BWCS Questionnaire Question","C113867","A question associated with the BWCS questionnaire.","BWCS Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827294","IVIS Questionnaire Question","C113868","A question associated with the IVIS questionnaire.","IVIS Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829089","MFIS Questionnaire Question","C113869","A question associated with the MFIS questionnaire.","MFIS Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828894","MSQOL-54 Questionnaire Question","C113870","A question associated with the MSQOL-54 questionnaire.","MSQOL-54 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829970","GNG2 wt Allele","C114329","Human GNG2 wild-type allele is located in the vicinity of 14q21 and is approximately 153 kb in length. This allele, which encodes guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2 protein, is involved in G protein-dependent signal transduction.","GNG2 wt Allele | Guanine Nucleotide Binding Protein (G Protein), Gamma 2 wt Allele | Guanine Nucleotide-Binding Protein, Gamma-2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814431","Guanine Nucleotide-Binding Protein G(I)/G(S)/G(O) Subunit Gamma-2, Human","C114330","Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2 (71 aa, ~8 kDa) is encoded by the human GNG2 gene. This protein plays a role in G protein GTPase activity.","Guanine Nucleotide-Binding Protein G(I)/G(S)/G(O) Subunit Gamma-2 | G Gamma-I | G Protein Gamma-2 Subunit | Guanine Nucleotide Binding Protein Gamma 2 | Guanine Nucleotide-Binding Protein G(I)/G(O) | Guanine Nucleotide-Binding Protein G(I)/G(O) Gamma-2 Subunit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815633","GNG11 wt Allele","C114332","Human GNG11 wild-type allele is located in the vicinity of 7q21 and is approximately 5 kb in length. This allele, which encodes guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-11 protein, plays a role in the mediation of G protein-dependent signaling.","GNG11 wt Allele | GNGT11 | Guanine Nucleotide Binding Protein (G Protein), Gamma 11 wt Allele | Guanine Nucleotide-Binding Protein, Gamma-11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814430","Guanine Nucleotide-Binding Protein G(I)/G(S)/G(O) Subunit Gamma-11, human","C114333","Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-11 (73 aa, ~8 kDa) is encoded by the human GNG11 gene. This protein is involved in GTPase-dependent signal transduction.","Guanine Nucleotide-Binding Protein G(I)/G(S)/G(O) Subunit Gamma-11 | G Protein Gamma-11 Subunit | Guanine Nucleotide-Binding Protein G(I)/G(S)/G(O) Gamma-11 Subunit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829971","GNG12 wt Allele","C114335","Human GNG12 wild-type allele is located in the vicinity of 1p31.3 and is approximately 132 kb in length. This allele, which encodes guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-12 protein, is involved in GTPase-dependent signaling.","GNG12 wt Allele | Guanine Nucleotide Binding Protein (G Protein), Gamma 12 wt Allele | Guanine Nucleotide-Binding Protein, Gamma-12 Gene | RP5-975D15.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0063555","Inosine Dialdehyde","C1136","A toxic purine analogue. Inosine dialdehyde inhibits ribonucleotide reductase, resulting in decreased synthesis of DNA, RNA, and proteins, and G2/M-phase cell cycle arrest.  This agent also forms stable covalent crosslinks in proteins, thereby inhibiting the activity of enzymes involved in nucleic acid synthesis. (NCI04)","Inosine Dialdehyde | 9H-Purine-9-acetaldehyde, .alpha.-(1-formyl-2-hydroxyethoxy)-1,6-dihydro-6-oxo-, (R,R)- (8CI) | 9H-Purine-9-acetaldehyde, .alpha.-(1-formyl-2-hydroxyethoxy)-1,6-dihydro-6-oxo-, (R-(R*, R*))- (9CI) | 9H-purine-9-acetaldehyde, alpha-(1-formyl-2-hydroxyethoxy)-1,6-dihydro-6-oxo-, (R,R)- (8CI) | 9H-purine-9-acetaldehyde, alpha-(1-formyl-2-hydroxyethoxy)-1,6-dihydro-6-oxo-, (R-(R*, R*))- (9CI) | Diglycoaldehyde | Diglycolaldehyde, .alpha.-(hydroxymethyl)-.alpha.'-(6-hydroxy-9H-purin-9-yl)- | INOSINE DIALDEHYDE | IdA | Inosine dialdehyde | Inox | Wy-5321 | diglycolaldehyde, alpha-(hydroxymethyl)-alpha'-(6-hydroxy-9H-purin-9-yl)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830672","C-SSRS Screening - Controllability of Most Severe Ideation","C111474","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Could/can you stop thinking about killing yourself or wanting to die if you want to?","C-SSRS Screening - Controllability of Most Severe Ideation | CSS09-Most Severe Idea, Controllability | CSS0909",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830661","C-SSRS Screening - Deterrents to Most Severe Ideation","C111475","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Are there things-anyone or anything (e.g., family, religion, pain of death) - that stopped you from wanting to die or acting on thoughts of committing suicide?","C-SSRS Screening - Deterrents to Most Severe Ideation | CSS09-Most Severe Idea, Deterrents | CSS0910",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830673","C-SSRS Screening - Actual Suicide Attempt","C111477","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Have you made a suicide attempt? Have you done anything to harm yourself? Have you done anything dangerous where you could have died?","C-SSRS Screening - Actual Suicide Attempt | CSS09-Actual Attempt | CSS0912",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830666","C-SSRS Screening - Description of Actual Suicide Attempt","C111479","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Description of actual attempt.","C-SSRS Screening - Description of Actual Suicide Attempt | CSS09-Actual Attempt, Describe | CSS0913A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0252967","RNA-Binding Motif, Single-Stranded-Interacting Protein 1, Human","C114447","RNA-binding motif, single-stranded-interacting protein 1 (406 aa, ~45 kDa) is encoded by the human RBMS1 gene. This protein is involved in both single-stranded DNA binding and DNA replication.","RNA-Binding Motif, Single-Stranded-Interacting Protein 1 | Single-Stranded DNA-Binding Protein MSSP-1 | Suppressor of CDC2 With RNA-Binding Motif 2 | c-Myc Gene Single Strand Binding Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422492","RBM14 Gene","C114448","This gene plays a role in transcriptional modulation.","RBM14 Gene | RBM14 | RNA Binding Motif Protein 14 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810616","RBM14 wt Allele","C114449","Human RBM14 wild-type allele is located in the vicinity of 11q13.2 and is approximately 22 kb in length. This allele, which encodes RNA-binding protein 14, is involved in the modulation of gene transcription.","RBM14 wt Allele | COAA | DKFZp779J0927 | PSP2 | RNA Binding Motif Protein 14 wt Allele | SIP | SYTIP1 | TMEM137",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1448135","RNA-Binding Protein 14, Human","C114450","RNA-binding protein 14 (669 aa, ~69 kDa) is encoded by the human RBM14 gene. This protein plays a role in the modulation of gene expression.","RNA-Binding Protein 14 | Coactivator Activator | PSP2 | Paraspeckle Protein 2 | RBM14 | RNA Binding Motif Protein 14 | RNA-Binding Motif Protein 14 | RRM-Containing Coactivator Activator/Modulator | SYT Interacting Protein | SYT-Interacting Protein | Synaptotagmin-Interacting Protein | Transmembrane Protein 137",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828369","Rare Childhood Malignant Neoplasm","C114451","An infrequent malignant neoplasm that occurs during childhood.","Rare Childhood Malignant Neoplasm | Rare Malignant Childhood Neoplasm | Rare Malignant Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811248","RANBP2 wt Allele","C114453","Human RANBP2 wild-type allele is located in the vicinity of 2q12.3 and is approximately 66 kb in length. This allele, which encodes E3 SUMO-protein ligase RanBP2 protein, plays a role in both nuclear transport and protein SUMOylation. Mutation of the gene is associated with acute infection-induced encephalopathy 3. A chromosomal translocation t(2;2)(p23;q13) involving this gene and the ALK gene is associated with both inflammatory myofibroblastic tumor and, more rarely, myeloproliferative disorders.","RANBP2 wt Allele | ADANE | ANE1 | IIAE3 | NUP358 | RAN Binding Protein 2 wt Allele | TRP1 | TRP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889654","Content Classification System Term Indicator","C114455","An indicator of a particular meaning of a term in relation to the Content Classification System.","Content Classification System Term Indicator | Term Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827842","Term Uniform Resource Locator","C114456","The unique address of a terminology entity on the world wide internet.","Term Uniform Resource Locator | Term Source URL | Term URL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831533","Annotation Property","C114458","An attribute that can be used with an entity to relate it to a value.","Annotation Property | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831020","Content Model","C114459","A structured representation of a collection of data.","Content Model | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830324","electronic Trial Master File Code","C114460","The symbol assigned to terms in the eTMF Content Model.","electronic Trial Master File Code | eTMF Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828378","RAND-36 Questionnaire Question","C113871","A question associated with the RAND-36 questionnaire.","RAND-36 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828404","RAND-36 - Emotional Problem Did Not Do Work as Carefully","C114061","RAND 36-Item Health Survey 1.0 (RAND-36) During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of any emotional problems: Didn't do work or other activities as carefully as usual.","RAND-36 - Emotional Problem Did Not Do Work as Carefully | R3601-Emotional Problem: Less Careful | R360119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828402","RAND-36 - Extend Physical Health or Emotional Problems Interfere With Social Activities","C114062","RAND 36-Item Health Survey 1.0 (RAND-36) During the past 4 weeks, to what extent has your physical health or emotional problems interfered with your normal social activities with family, friends, neighbors, or groups?","RAND-36 - Extend Physical Health or Emotional Problems Interfere With Social Activities | R3601-Extent Interfered Social Activity | R360120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828407","RAND-36 - Bodily Pain","C114063","RAND 36-Item Health Survey 1.0 (RAND-36) How much bodily pain have you had during the past 4 weeks?","RAND-36 - Bodily Pain | R3601-How Much Bodily Pain Have You Had | R360121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828383","RAND-36 - Pain Interfere With Normal Work","C114064","RAND 36-Item Health Survey 1.0 (RAND-36) During the past 4 weeks, how much did pain interfere with your normal work?","RAND-36 - Pain Interfere With Normal Work | R3601-Did Pain Interfere With Your Work | R360122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828401","RAND-36 - Feel Full of Pep","C114065","RAND 36-Item Health Survey 1.0 (RAND-36) How much of the time during the past 4 weeks: Did you feel full of pep?","RAND-36 - Feel Full of Pep | R3601-Did You Feel Full of Pep | R360123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828408","RAND-36 - Been a Nervous Person","C114066","RAND 36-Item Health Survey 1.0 (RAND-36) How much of the time during the past 4 weeks: Have you been a very nervous person?","RAND-36 - Been a Nervous Person | R3601-Have Been a Very Nervous Person | R360124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828396","RAND-36 - Felt Nothing Could Cheer You Up","C114067","RAND 36-Item Health Survey 1.0 (RAND-36) How much of the time during the past 4 weeks: Have you felt so down in the dumps that nothing could cheer you up?","RAND-36 - Felt Nothing Could Cheer You Up | R3601-Have Felt So Down in the Dumps | R360125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828394","RAND-36 - Have a Lot of Energy","C114069","RAND 36-Item Health Survey 1.0 (RAND-36) How much of the time during the past 4 weeks: Did you have a lot of energy?","RAND-36 - Have a Lot of Energy | R3601-Did You Have a Lot of Energy | R360127",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828397","RAND-36 - Felt Downhearted and Blue","C114070","RAND 36-Item Health Survey 1.0 (RAND-36) How much of the time during the past 4 weeks: Have you felt downhearted and blue?","RAND-36 - Felt Downhearted and Blue | R3601-Have Felt Downhearted and Blue | R360128",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828399","RAND-36 - Feel Worn Out","C114071","RAND 36-Item Health Survey 1.0 (RAND-36) How much of the time during the past 4 weeks: Did you feel worn out?","RAND-36 - Feel Worn Out | R3601-Did You Feel Worn Out | R360129",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828409","RAND-36 - Been a Happy Person","C114072","RAND 36-Item Health Survey 1.0 (RAND-36) How much of the time during the past 4 weeks: Have you been a happy person?","RAND-36 - Been a Happy Person | R3601-Have You Been a Happy Person | R360130",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828400","RAND-36 - Feel Tired","C114073","RAND 36-Item Health Survey 1.0 (RAND-36) How much of the time during the past 4 weeks: Did you feel tired?","RAND-36 - Feel Tired | R3601-Did You Feel Tired | R360131",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828375","RAND-36 - Time Physical Health or Emotional Problems Interfere With Social Activities","C114074","RAND 36-Item Health Survey 1.0 (RAND-36) During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your social activities?","RAND-36 - Time Physical Health or Emotional Problems Interfere With Social Activities | R3601-Amt Time Interfere Social Activity | R360132",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831763","Abbott Diagnostics","C113705","A manufacturer of in vitro diagnostic instrument systems.","Abbott Diagnostics | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831379","Beckman Coulter, Inc","C113706","A manufacturer of biomedical laboratory instruments.","Beckman Coulter, Inc | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828314","Roche Diagnostics","C113707","A manufacturer of instruments and assay systems for clinical analysis and diagnosis.","Roche Diagnostics | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0858867","Reticulocytopenia","C113710","Abnormally low level of immature red blood cells in the blood.","Reticulocytopenia | ",,,,,,,,,,,,,,,"4051681","Reticulocytopenia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1527405","Erythrocytosis","C113711","Abnormally high level of red blood cells in the blood.","Erythrocytosis | ",,,,,,,,,,,,,,,"4130681","Erythrocytosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0272195","Eosinophilopenia","C113712","Abnormally low level of eosinophils in the blood.","Eosinophilopenia | ",,,,,,,,,,,,,,,"4184190","Eosinopenia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1719331","Basophilopenia","C113713","Abnormally low level of basophils in the blood.","Basophilopenia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830722","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Describe Most Severe Ideation (Past 1 Month)","C113907","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Description of most severe ideation. (Past 1 Month).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Describe Most Severe Ideation (Past 1 Month) | CSS10-Most Severe Idea, Desc-P1M | CSS1006D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830709","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Frequency (Lifetime)","C113908","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) How many times have you had these thoughts? (Lifetime).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Frequency (Lifetime) | CSS10-Most Severe Idea, Frequency-Life | CSS1007A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830708","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Frequency (Past 1 Month)","C113909","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) How many times have you had these thoughts? (Past 1 Month).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Frequency (Past 1 Month) | CSS10-Most Severe Idea, Frequency-P1M | CSS1007B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0271737","Autoimmune Primary Adrenal Insufficiency","C113814","Diminished production of adrenocortical hormones due to autoimmune destruction of the adrenal glands.","Autoimmune Primary Adrenal Insufficiency | Autoimmune Addison's Disease | Autoimmune Adrenalitis",,,,,,,,,,,,,,,"4298436","Addison's disease due to autoimmunity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3814444","HPX wt Allele","C113819","Human HPX wild-type allele is located within 11p15.5-p15.4 and is approximately 12 kb in length. This allele, which encodes hemopexin protein, is involved in the metabolism of both iron and hemoglobin.","HPX wt Allele | HX | Hemopexin wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019067","Hemopexin","C113820","Hemopexin (462 aa, ~52 kDa) is encoded by the human HPX gene. This protein plays a role in iron and heme metabolism.","Hemopexin | Beta-1B-Glycoprotein | HPX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812154","AHSG wt Allele","C113822","Human AHSG wild-type allele is located in the vicinity of 3q27 and is approximately 8 kb in length. This allele, which encodes alpha-2-HS-glycoprotein, plays a role in the modulation of bone formation.","AHSG wt Allele | A2HS | AHS | Alpha-2-HS-Glycoprotein wt Allele | FETUA | Feutin, Mouse, Homolog of Gene | HSGA | PRO2743",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1138314","alpha-2-HS-glycoprotein, human","C113823","Alpha-2-HS-glycoprotein (367 aa, ~39 kDa) is encoded by the human AHSG gene. This protein is involved in the regulation of bone mineralization.","Alpha-2-HS-Glycoprotein | Alpha-2-Z-Globulin | Ba-Alpha-2-Glycoprotein | Fetuin A | Fetuin-A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0404852","Vanishing Twin Syndrome","C113825","A multiple pregnancy that over time is spontaneously reduced by one or more embryos which are then resorbed.","Vanishing Twin Syndrome | Vanishing Twin",,,,,,,,,,,,,,,"4129025","Vanishing twin syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828395","RAND-36 - Get Sick Easier Than Other","C114075","RAND 36-Item Health Survey 1.0 (RAND-36) How true or false is each of the following statements for you: I seem to get sick a little easier than other people.","RAND-36 - Get Sick Easier Than Other | R3601-Get Sick Easier Than Other People | R360133",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828410","RAND-36 - As Healthy as Anybody","C114076","RAND 36-Item Health Survey 1.0 (RAND-36) How true or false is each of the following statements for you: I am as healthy as anybody I know.","RAND-36 - As Healthy as Anybody | R3601-I Am as Healthy as Anybody I Know | R360134",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471805","genetically engineered HSV-1 expressing IL-12","C114294","A genetically engineered, replication selective, infected cell protein (ICP) 34.5 gene-deleted, oncolytic human simplex virus type 1 (HSV-1) expressing the human immunostimulating cytokine interleukin-12 (IL-12), with potential antineoplastic activity. Upon intratumoral administration of HSV-1 expressing IL-12 NSC 733972, the IL-12-expressing HSV-1 preferentially infects and replicates in tumor cells of neuronal origin causing viral-mediated tumor cell lysis. The released virus particles, in turn, infect and replicate in neighboring tumor cells. In addition, the IL-12-expressing HSV-1 promotes the secretion of IL-12 by the tumor cells. IL-12 promotes the activation of natural killer cells, which induces both the secretion of interferon-gamma and a cytotoxic T-lymphocyte (CTL) response against the tumor cells. This results in both immune-mediated tumor cell death and further inhibition of tumor cell proliferation. Deletion of the gene encoding for ICP34.5 imparts tumor selectivity by preventing replication in healthy cells.","IL-12-expressing HSV-1 NSC 733972 | M032 | NSC 733972",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472223","Anti-NY-ESO1 TCR-transduced Autologous CD62L+-derived T-Lymphocytes","C114295","Human autologous CD62L-positive T-lymphocytes transduced with a retroviral vector encoding a T cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1, with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and reintroduction into the patient, the anti-NY-ESO1 TCR-transduced autologous CD62L+-derived T-Lymphocytes bind to NY-ESO-1-overexpressing tumor cells. This may result in cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1-positive cancer cells. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types. CD62L, also called L-selectin, is a lymphoid homing receptor and differentiation marker and is expressed on a subset of CD8-positive T-lymphocytes; it is involved in the migration of T-lymphocytes to lymph nodes and may improve the efficacy for ex vivo-expanded T-cells following adoptive cell therapy.","Anti-NY-ESO1 TCR-transduced Autologous CD62L+-derived T-Lymphocytes | Autologous CD62L+-derived T Lymphocytes Transduced With NY-ESO-1-specific TCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471807","Opebacan","C114296","An injectable formulation composed of opebacan, a 21 kDa recombinant fragment of human bactericidal/permeability-increasing protein (BPI), with potential anti-infective activity. Upon intravenous administration, opebacan is able to mimic BPI and binds to and neutralizes lipopolysaccharides (LPS or endotoxins), which are components of the cell wall of gram-negative bacteria that induce a potent innate immune response. This may prevent an endotoxin-mediated inflammatory response and may prevent graft-versus-host-disease (GvHD) after myeloablative allogeneic hematopoietic stem cell transplantation (aHSCT). BPI, a host-defense protein against microbial infection, is naturally produced by neutrophils. Chemo- and radio-therapy induce neutropenia and depletion of endogenous BPI. These therapies also cause intestinal damage and release of bacterial endotoxins into the bloodstream, which initiate a systemic inflammatory response, activate donor T-lymphocytes and possibly cause GvHD following aHSCT.","Opebacan | 132-L-Alanine-1-193-bactericidal/Permeability-increasing Protein (Human) | Neuprex | OPEBACAN | Recombinant BPI 21 Fragment | rBPI 21 | rBPI- 21",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1095905","Beet Juice","C114297","The juice of the beetroot, with potential antioxidant and protective activities. Beetroot juice contains antioxidants, including betacyanin, which scavenge free radicals. In addition, beetroot contains high levels of nitrates and folic acid. Consumption of beetroot juice leads to the conversion of nitrate to nitric oxide (NO) in the body. This juice may have a beneficial effect on blood flow and blood pressure through the induction of NO-mediated vasodilation. Additionally, this agent may decrease fatigue and increase physical performance.","Beetroot Juice | BEET JUICE | Beet Juice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830707","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Frequency Write Response","C113910","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Frequency, write response.","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Frequency Write Response | CSS10-Frequency, Write Response | CSS1007C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830725","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Actual Suicide Attempt (Lifetime)","C113911","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Did you ever do anything to try to kill yourself or make yourself not alive anymore? What did you do? Did you ever hurt yourself on purpose? Why did you do that? (Lifetime).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Actual Suicide Attempt (Lifetime) | CSS10-Actual Attempt-Life | CSS1008A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830724","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Actual Suicide Attempt (Past 3 Month)","C113912","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Did you ever do anything to try to kill yourself or make yourself not alive anymore? What did you do? Did you ever hurt yourself on purpose? Why did you do that? (Past 3 Month).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Actual Suicide Attempt (Past 3 Month) | CSS10-Actual Attempt-P3M | CSS1008B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830690","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Number of Actual Suicide Attempts (Lifetime)","C113913","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Total number of actual attempts. (Lifetime).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Number of Actual Suicide Attempts (Lifetime) | CSS10-Number of Actual Attempts-Life | CSS1009A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830689","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Number of Actual Suicide Attempts (Past 3 Months)","C113914","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Total number of actual attempts. (Past 3 Months).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Number of Actual Suicide Attempts (Past 3 Months) | CSS10-Number of Actual Attempts-P3M | CSS1009B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830717","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Description of Actual Suicide Attempt","C113915","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Description of actual attempt.","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Description of Actual Suicide Attempt | CSS10-Actual Attempt, Describe | CSS1009C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830694","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Non-suicidal Self-injurious Behavior (Lifetime)","C113916","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Has subject engaged in non-suicidal self-injurious behavior? (Lifetime)","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Non-suicidal Self-injurious Behavior (Lifetime) | CSS10-Non-suicidal Self-injur Behav-Life | CSS1010A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830693","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Non-suicidal Self-injurious Behavior (Past 3 Months)","C113917","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Has subject engaged in non-suicidal self-injurious behavior? (Past 3 Months).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Non-suicidal Self-injurious Behavior (Past 3 Months) | CSS10-Non-suicidal Self-injur Behav-P3M | CSS1010B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829205","Manual Fetal Rotation","C114133","A procedure during labor in which the occiput is manually rotated from posterior to anterior.","Manual Fetal Rotation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677662","Spontaneous Vertex Delivery","C114134","The birth of a cephalically presenting fetus without operative instrumentation or assistance.","Spontaneous Vertex Delivery | ",,,,,,,,,,,,,,,"4205240","Spontaneous vertex delivery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0269704","Spontaneous Breech Delivery","C114135","The birth of a breech-presenting fetus without operative instrumentation or assistance.","Spontaneous Breech Delivery | Spontaneous Vaginal Breech Birth",,,,,,,,,,,,,,,"4073422","Spontaneous breech delivery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828940","MSQOL-54 - Been a Happy Person","C114017","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Have you been a happy person?","MSQOL-54 - Been a Happy Person | MSQL1-Have You Been a Happy Person | MSQL130",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828925","MSQOL-54 - Feel Tired","C114018","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Did you feel tired?","MSQOL-54 - Feel Tired | MSQL1-Did You Feel Tired | MSQL131",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828926","MSQOL-54 - Feel Rested Waking in the Morning","C114019","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Did you feel rested on waking in the morning?","MSQOL-54 - Feel Rested Waking in the Morning | MSQL1-Did You Feel Rested on Waking | MSQL132",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828892","MSQOL-54 - Time Physical Health or Emotional Problem Interfere With Social Activities","C114020","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your social activities?","MSQOL-54 - Time Physical Health or Emotional Problem Interfere With Social Activities | MSQL1-Amt Time Interfere Social Activity | MSQL133",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828918","MSQOL-54 - Get Sick Easier Than Other","C114021","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How true or false is each of the following statements for you: I seem to get sick a little easier than other people.","MSQOL-54 - Get Sick Easier Than Other | MSQL1-Get Sick Easier Than Other People | MSQL134",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828941","MSQOL-54 - As Healthy as Anybody","C114022","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How true or false is each of the following statements for you: I am as healthy as anybody I know.","MSQOL-54 - As Healthy as Anybody | MSQL1-I Am as Healthy as Anybody I Know | MSQL135",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828915","MSQOL-54 - Health is Excellent","C114024","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How true or false is each of the following statements for you: My health is excellent.","MSQOL-54 - Health is Excellent | MSQL1-My Health Is Excellent | MSQL137",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828933","MSQOL-54 - Discouraged by Health Problem","C114025","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Were you discouraged by your health problems?","MSQOL-54 - Discouraged by Health Problem | MSQL1-Discouraged by Health Problems | MSQL138",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828919","MSQOL-54 - Frustrated With Health","C114026","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Were you frustrated about your health?","MSQOL-54 - Frustrated With Health | MSQL1-Were Frustrated About Your Health | MSQL139",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828916","MSQOL-54 - Health a Worry in Life","C114027","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Was your health a worry in your life? Was your health a worry in your life?","MSQOL-54 - Health a Worry in Life | MSQL1-Was Health a Worry in Your Life | MSQL140",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828924","MSQOL-54 - Feel Weighed Down by Health Problem","C114028","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Did you feel weighed down by your health problems?","MSQOL-54 - Feel Weighed Down by Health Problem | MSQL1-Weighed Down by Health Problems | MSQL141",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828935","MSQOL-54 - Difficulty Concentrating and Thinking","C114029","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Have you had difficulty concentrating and thinking?","MSQOL-54 - Difficulty Concentrating and Thinking | MSQL1-Difficulty Concentrating/Thinking | MSQL142",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472224","10-carboxymethyl-9-acridanone, sodium salt","C114298","The sodium salt form of cridanimod, a small molecule that can increase progesterone receptor (PR) expression, with potential antineoplastic adjuvant activity. Upon intramuscular administration, cridanimod is able to induce the expression of PR in endometrial cancer. This could increase the sensitivity of endometrial cancer cells to progestin monotherapy. In combination with a progestin, cancer cells could be eradicated through increased PR-mediated signaling, leading to an inhibition of luteinizing hormone (LH) release from the pituitary gland, via a negative feedback mechanism, and, eventually, an inhibition of estrogen release from the ovaries. This leads to an inhibition of cellular growth in estrogen-dependent tumor cells. In addition, this agent is able to increase the production and release of interferon (IFN) alpha and beta. PR is often downregulated in endometrial cancer and makes it resistant to progestin-mediated hormone therapy.","Cridanimod Sodium | CRIDANIMOD SODIUM | Sodium 2-(9-Oxoacridin-10yl) Acetate | Virexxa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830697","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Most Severe Ideation (Past 1 Month)","C113906","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Most severe Ideation. (Past 1 Month).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Most Severe Ideation (Past 1 Month) | CSS10-Most Severe Idea-P1M | CSS1006C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL458369","Long-acting Release Pasireotide","C113656","A long-acting release (LAR) formulation containing pasireotide, a synthetic long-acting cyclohexapeptide, with somatostatin-like activity. Upon intramuscular administration of the LAR formulation of pasireotide, this somatostatin analog strongly binds to and activates somatostatin receptor (SSTR) subtypes 1, 2, 3, and 5. This leads to an inhibition in the secretion of human growth hormone (hGH) and results in decreased production of insulin-like growth factor (IGF-1), which may inhibit IGF-1-mediated cell signaling pathways. This may lead to an inhibition in tumor cell growth and an increase in apoptosis in IGF-1-overexpressing tumor cells. In addition, this agent causes a reduction in adrenocorticotropic hormone (ACTH), which leads to an inhibition of cortisol secretion. ACTH-producing tumors cause hypersecretion of cortisol which results in many unwanted symptoms. This agent may also block other key survival pathways such as the phosphatidylinositol 3-kinase (PI3K) and the mitogen-activated protein kinase (MAPK) signaling pathways. Pasireotide also inhibits vascular endothelial growth factor (VEGF) secretion, thereby decreasing angiogenesis and tumor cell growth in VEGF-overexpressing tumor cells. The long-acting form of pasireotide allows for less frequent administration as compared to the original form of this agent. SSTRs are overexpressed by some neuroendocrine and non-neuroendocrine tumor cells.","Long-acting Release Pasireotide | LAR Pasireotide | SOM230 LAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL458370","Carboxylesterase-expressing Allogeneic Neural Stem Cells","C113657","A preparation of allogeneic neural stem cells (NSC), derived from a human fetal cell line, that are adenovirally-transduced to express a modified form of the human enzyme carboxylesterase (CE) hCE1m6, with potential adjuvant activity. Upon intracranial administration, NSCs localize to tumor sites, due to their tumor-trophic nature, and transiently express hCE1m6. Intravenous co-administration of the prodrug irinotecan allows for the selective conversion by hCE1m6 to its active metabolite and topoisomerase I inhibitor, SN-38, in the vicinity of tumor sites. This leads to a local anti-neoplastic effect and causes reduced toxicity and increased therapeutic efficacy of irinotecan. Since NSCs freely cross the blood-brain barrier, these cells can also be intravenously administered to target brain tumor cells. hCE1m6 shows increased activity as compared to unmodified human CE.","Carboxylesterase-expressing Allogeneic Neural Stem Cells | CE-secreting Allogeneic NSCs | hCE1m6-NSC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0341970","Assisted Breech Delivery","C114137","The birth of a breech-presenting fetus with operative instrumentation or assistance.","Assisted Breech Delivery | ",,,,,,,,,,,,,,,"4075168","Assisted breech delivery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3827773","Trial of Birth Labor after Cesarean","C114138","Trial of labor in a woman with a previous cesarean delivery regardless of ultimate route of delivery.","Trial of Birth Labor after Cesarean | TOLAC | Trial of Birth Labor after Caesarean | Trial of Labor after Caesarean | Trial of Labor after Cesarean | Trial of Labor after Cesarean Delivery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828478","Primary Cesarean Birth","C114139","The first surgical delivery of one or more intrauterine fetuses though an abdominal incision in a woman without prior cesarean delivery.","Primary Cesarean Birth | Primary Caesarean Birth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828341","Repeat Cesarean Birth","C114140","The surgical delivery of one or more intrauterine fetuses though an abdominal incision in a woman who has had prior cesarean delivery(ies).","Repeat Cesarean Birth | Repeat Caesarean Birth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0473296","Elective Cesarean Delivery","C114141","A cesarean delivery scheduled at a patient's request or provider preference without medical or obstetric indications.","Elective Cesarean Delivery | Elective Caesarean Delivery | Elective Caesarean Section | Elective Cesarean Section",,,,,,,,,,,,,,,"4075182","Elective cesarean section",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829544","Indicated Cesarean Delivery","C114142","A cesarean delivery that is performed for specific, medical or obstetric indications, which may be scheduled or unscheduled.","Indicated Cesarean Delivery | Indicated Caesarean Delivery | Indicated Caesarean Section | Indicated Cesarean Section",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0495285","Delivery by Destructive Operation","C114143","Extraction of a fetus through the cervix using destructive surgical techniques.","Delivery by Destructive Operation | DELIVERY BY DESTRUCTIVE OPERATION | Destructive Procedure",,,,,,,,,,,,,,,"4066113","Deliveries by destructive operation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3830328","Electrical Stimulation Electrode Type","C114145","The type of electrode used on the subject during electrical stimulation of the body or organ.","Electrical Stimulation Electrode Type | STIMPARM | Stimulation Parameter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830290","Explanted Medical Device","C114146","A finding referring to a medical device that has been removed from the body, usually during a surgical procedure.","Explanted Medical Device | Device Explantation | EXPLANTED | Inactive (Removed)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0678088","carboplatin/gemcitabine/paclitaxel","C11414","A regimen consisting of carboplatin, gemcitabine, and paclitaxel that may be used in the treatment of advanced ovarian carcinoma and non-small cell lung cancer (NSCLC).","Carboplatin/Gemcitabine/Paclitaxel Regimen | CBDCA/dFdC/TAX | Carboplatin and Gemcitabine (GCb) and Paclitaxel | Carboplatin-Gemcitabine-Paclitaxel | Carboplatin/Gemcitabine/Paclitaxel | GCP | PCG (Carboplatin)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829926","Guanine Nucleotide-Binding Protein G(I)/G(S)/G(O) Subunit Gamma-12","C114336","Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-12 (72 aa, ~8 kDa) is encoded by the human GNG12 gene. This protein plays a role in G protein-mediated signal transduction.","Guanine Nucleotide-Binding Protein G(I)/G(S)/G(O) Subunit Gamma-12 | G Protein Gamma-12 Subunit | Guanine Nucleotide-Binding Protein G(I)/G(S)/G(O) Gamma-12 Subunit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830646","C-SSRS Screening - Non-suicidal Self-injurious Behavior","C111480","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Has subject engaged in non-suicidal self-injurious behavior?","C-SSRS Screening - Non-suicidal Self-injurious Behavior | CSS09-Non-suicidal Self-injur Behav | CSS0914",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830655","C-SSRS Screening - Interrupted Suicide Attempt","C111481","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Has there been a time when you started to do something to end your life but someone or something stopped you before you actually did anything?","C-SSRS Screening - Interrupted Suicide Attempt | CSS09-Interrupted Attempt | CSS0915",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830665","C-SSRS Screening - Description of Interrupted Suicide Attempt","C111483","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Description of interrupted attempt.","C-SSRS Screening - Description of Interrupted Suicide Attempt | CSS09-Interrupted Attempt, Describe | CSS0916A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830677","C-SSRS Screening - Aborted Suicide Attempt","C111484","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Has there been a time when you started to do something to try to end your life but you stopped yourself before you actually did anything?","C-SSRS Screening - Aborted Suicide Attempt | CSS09-Aborted Attempt | CSS0917",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830645","C-SSRS Screening - Number of Aborted Suicide Attempts","C111485","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Total number of aborted.","C-SSRS Screening - Number of Aborted Suicide Attempts | CSS09-Number of Aborted Attempts | CSS0918",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828891","MSQOL-54 - Trouble Keep Attention for Long","C114030","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Did you have trouble keeping your attention on an activity for long?","MSQOL-54 - Trouble Keep Attention for Long | MSQL1-Trouble Keep Attention for Long | MSQL143",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828890","MSQOL-54 - Trouble With Memory","C114031","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Have you had trouble with your memory?","MSQOL-54 - Trouble With Memory | MSQL1-Have Had Trouble With Your Memory | MSQL144",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0319886","Cryptococcus albidus","C114267","A yeast in the phylum Basidiomycota. This species is globose to ovoid shaped, urease- and nitrate-positive, does not produce hyphae or pseudohyphae, assimilates glucose and sucrose. C. albidus is a common transient on human skin, and may cause cutaneous, pulmonary, CNS and vaginal infections.","Cryptococcus albidus | C. albidus | CRYPTOCOCCUS ALBIDUS | R. albida | Rhodotorula albida | T. albida | T. nadaensis | T. neoformans var. albida | Torula albida | Torulopsis albida | Torulopsis nadaensis | Torulopsis neoformans var. albida",,,,,,,,,,,,,,,"4250183","Naganishia albida",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319888","Cryptococcus laurentii","C114269","An encapsulated yeast in the phylum Basidiomycota. This species is spherical and elongate shaped, urease-positive, pseudohyphae- and nitrate-negative, does not ferment sugars, and assimilates glucose, galactose, maltose, sucrose, trehalose and lactose. C. laurentii is isolated from palm wine and may cause pulmonary and cutaneous infection and CAPD associated peritonitis in humans.","Cryptococcus laurentii | C. laurentii | CRYPTOCOCCUS LAURENTII",,,,,,,,,,,,,,,"4218775","Papiliotrema laurentii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1005990","Pichia kluyveri","C114270","A yeast in the phylum Ascomycota. This species is ovoidal to cylindroidal shaped, produces pseudohyphae, ferments glucose and does not assimilate nitrate. P. kluyveri is used in alcoholic fermentation to boost fruit flavors in wine.","Pichia kluyveri | P. kluyveri | PICHIA KLUYVERI",,,,,,,,,,,,,,,"37016550","Pichia kluyveri",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0331711","Prototheca wickerhamii","C114271","A species of achlorophyllous, spherular green alga that grows in aggregates with multiple internal cleavages, in the phylum Chlorophyta. This alga is non-spore forming, non-fermentative, metabolizes glucose, galactose and trehalose, does not utilize potassium nitrate, and reproduces asexually by internal septation and cleavage. P. wickerhamii are found saprophytically on decaying organic matters and can cause protothecosis and systemic algaemia in humans.","Prototheca wickerhamii | P. wickerhamii | PROTOTHECA WICKERHAMII",,,,,,,,,,,,,,,"4320922","Prototheca wickerhamii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0446051","Trichosporon asahii","C114272","A yeast in the phylum Basidiomycota. This species is round to oval shaped, with budding yeast-like cells, produces true hyphae forming cylindrical arthroconidia, and hydrolyzes urea. T. asahii is a common soil inhabitant and colonizes the skin and gastrointestinal tract of humans. It may cause superficial infections, disseminated trichosporonosis in immunocompromised individuals, fungemia and fatal septic shock.","Trichosporon asahii | T. asahii | TRICHOSPORON ASAHII",,,,,,,,,,,,,,,"4352756","Trichosporon asahii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL458371","Immediate-release Tablet Afuresertib","C113658","An immediate-release (IR) tablet formulation containing afuresertib, an inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Upon oral administration of the IR formulation, afuresertib binds to and inhibits the activity of Akt, which may result in the inhibition of PI3K/Akt signaling pathway, decreased tumor cell proliferation and the induction of tumor cell apoptosis in Akt-expressing tumor cells. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","Immediate-release Tablet Afuresertib | GSK2110183 IR Tablet | IR Afuresertib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL458372","Anti-CD98 Monoclonal Antibody IGN523","C113659","A humanized, monoclonal antibody targeting the CD98 (gp125) antigen, with potential immunomodulatory and antineoplastic activities. Upon intravenous administration, IGN523 binds to CD98 expressed on the tumor cell surface and elicits both natural killer (NK)-cell mediated antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity towards CD98-expressing tumor cells. In addition, IGN523 inhibits essential amino acid uptake by rapidly proliferating tumor cells. CD98, a type II transmembrane glycoprotein, is involved in both integrin signaling and amino acid transport processes; it is overexpressed in certain cancer cells and plays a key role in the proliferation, survival and metastasis of tumor cells.","Anti-CD98 Monoclonal Antibody IGN523 | IGN-523 | IGN523",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811758","PRKCE wt Allele","C114338","Human PRKCE wild-type allele is located in the vicinity of 2p21 and is approximately 537 kb in length. This allele, which encodes protein kinase C epsilon type protein, is involved in diacylglycerol-dependent protein phosphorylation and signal transduction.","PRKCE wt Allele | PKCE | Protein Kinase C, Epsilon wt Allele | nPKC-Epsilon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1566340","Protein Kinase C Epsilon Type, Human","C114339","Protein kinase C epsilon type (737 aa, ~84 kDa) is encoded by the human PRKCE gene. This protein plays a role in diacylglycerol-dependent serine/threonine phosphorylation.","Protein Kinase C Epsilon Type | EC 2.7.11.13 | nPKC-Epsilon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814144","POLR2L wt Allele","C114341","Human POLR2L wild-type allele is located in the vicinity of 11p15 and is approximately 5 kb in length. This allele, which encodes DNA-directed RNA polymerases I, II, and III subunit RPABC5 protein, is involved in the DNA-directed biosynthesis of RNA.","POLR2L wt Allele | Polymerase (RNA) II (DNA Directed) Polypeptide L, 7.6kDa wt Allele | RBP10 | RPABC5 | RPB10 | RPB7.6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829270","LIS, Rat Strain","C114342","This rat comes from Lister stock at the Lister Institute in the 1920s, but the derivation origin is unknown. It has a white body coat color and black coat color over the head.","LIS, Rat Strain | LISTER HOODED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816481","DNA-Directed RNA Polymerases I, II, and III Subunit RPABC5","C114343","DNA-directed RNA polymerases I, II, and III subunit RPABC5 (67 aa, ~8 kDa) is encoded by the human POLR2L gene. This protein plays a role in the synthesis of RNA from a DNA template.","DNA-Directed RNA Polymerases I, II, and III Subunit RPABC5 | DNA-Directed RNA Polymerase III Subunit L | POLR2L | RNA Polymerase II 7.6 KDa Subunit | RNA Polymerase II, 7.6-kD Subunit | RNA Polymerases I, II, and III Subunit ABC5 | RPB10 Homolog | RPB7.6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472248","New Zealand Rabbit","C114344","One of the larger rabbit breeds, the New Zealand was derived by Don Johnson in 1916 by crossing unknown breeds. This rabbit weighs between 9-12 lbs. fully grown and may come in a variety of coat colors.","New Zealand Rabbit | NEW ZEALAND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1096189","Type II Hypersensitivity","C114345","A hypersensitivity reaction mediated by antibodies formed against cell surface antigens.","Type II Hypersensitivity | Type 2 Hypersensitivity Reaction | Type II Hypersensitivity Reaction",,,,,,,,,,,,,,,"4234087","Hypersensitivity reaction mediated by antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020951","Type III Hypersensitivity","C114346","A hypersensitivity reaction resulting from the deposition of antigen-antibody immune complexes in tissues, which trigger activation of the complement system.","Type III Hypersensitivity | Type 3 Hypersensitivity Reaction | Type III Hypersensitivity Reaction",,,,,,,,,,,,,,,"4309036","Hypersensitivity reaction mediated by immune complex",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0409676","Juvenile Spondyloarthritis","C114347","A group of chronic, inflammatory childhood diseases characterized by arthritis and enthesitis. This disorder can affect the axial skeleton in late childhood or young adulthood.","Juvenile Spondyloarthritis | JSpA | Juvenile Spondyloarthropathy",,,,,,,,,,,,,,,"4079735","Juvenile spondyloarthropathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3830670","C-SSRS Screening - Description of Aborted Suicide Attempt","C111486","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Description of aborted attempt.","C-SSRS Screening - Description of Aborted Suicide Attempt | CSS09-Aborted Attempt, Describe | CSS0918A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830642","C-SSRS Screening - Preparatory Acts or Behaviors Toward Suicide Attempt","C111487","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Have you taken any steps towards making a suicide attempt or preparing to kill yourself (such as collecting pills, getting a gun, giving valuables away or writing a suicide note)?","C-SSRS Screening - Preparatory Acts or Behaviors Toward Suicide Attempt | CSS09-Preparatory Acts/Behavior | CSS0919",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830663","C-SSRS Screening - Description of Preparatory Acts or Behaviors Toward Suicide Attempt","C111488","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Description of preparatory acts or behavior.","C-SSRS Screening - Description of Preparatory Acts or Behaviors Toward Suicide Attempt | CSS09-Preparatory Acts/Behavior, Descr | CSS0919A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830639","C-SSRS Screening - Suicidal Behavior","C111489","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Suicidal behavior was present during the assessment period?","C-SSRS Screening - Suicidal Behavior | CSS09-Suicidal Behavior | CSS0920",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830650","C-SSRS Screening - Most Recent Suicide Attempt Date","C111490","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Most recent attempt date.","C-SSRS Screening - Most Recent Suicide Attempt Date | CSS09-Most Recent Attempt Date | CSS0921A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830651","C-SSRS Screening - Most Recent Suicide Attempt Actual Lethality/Medical Damage","C111491","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Most recent attempt actual lethality/medical damage.","C-SSRS Screening - Most Recent Suicide Attempt Actual Lethality/Medical Damage | CSS09-Most Recent Attempt Damage | CSS0921B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830649","C-SSRS Screening - Most Recent Suicide Attempt Potential Lethality","C111492","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Most recent attempt potential lethality.","C-SSRS Screening - Most Recent Suicide Attempt Potential Lethality | CSS09-Most Recent Attempt Potential | CSS0921C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830653","C-SSRS Screening - Most Lethal Suicide Attempt Date","C111493","Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Most lethal attempt date.","C-SSRS Screening - Most Lethal Suicide Attempt Date | CSS09-Most Lethal Attempt Date | CSS0922A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714755","Pharmacogenomics Trial Characteristics Domain","C111290","A special purpose domain that contains design parameters used in performing pharmacogenomic assessments.","Pharmacogenomics Trial Characteristics Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026661","mRNA Precursor","C111298","A primary RNA transcript synthesized from a DNA template in eukaryotic nuclei which is post-transcriptionally modified and spliced to produce a mature mRNA.","Precursor mRNA | pre-mRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830192","FAQ-NACC UDS Version 2.0 - Shop Alone","C111512","Functional Assessment Questionnaire-NACC UDS Version 2.0 (FAQ-NACC UDS Version 2.0) Shopping alone for clothes, household necessities, or groceries.","FAQ-NACC UDS Version 2.0 - Shop Alone | FAQNA1-Shopping Alone | FAQNA103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827388","FAQ-NACC UDS Version 2.0 - Play Game of Skill, Work on Hobby","C111513","Functional Assessment Questionnaire-NACC UDS Version 2.0 (FAQ-NACC UDS Version 2.0) Playing a game of skill, working on a hobby.","FAQ-NACC UDS Version 2.0 - Play Game of Skill, Work on Hobby | FAQNA1-Playing a Game of Skill | FAQNA104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830198","FAQ-NACC UDS Version 2.0 - Heat water, Make Coffee, Turn Off Stove","C111514","Functional Assessment Questionnaire-NACC UDS Version 2.0 (FAQ-NACC UDS Version 2.0) Heating water, making a cup of coffee, turning off stove after use.","FAQ-NACC UDS Version 2.0 - Heat water, Make Coffee, Turn Off Stove | FAQNA1-Heat Water/Make Coffee/Stove Off | FAQNA105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830195","FAQ-NACC UDS Version 2.0 - Prepare a Meal","C111515","Functional Assessment Questionnaire-NACC UDS Version 2.0 (FAQ-NACC UDS Version 2.0) Preparing a balanced meal.","FAQ-NACC UDS Version 2.0 - Prepare a Meal | FAQNA1-Preparing a Balanced Meal | FAQNA106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830197","FAQ-NACC UDS Version 2.0 - Keep Track of Current Events","C111516","Functional Assessment Questionnaire-NACC UDS Version 2.0 (FAQ-NACC UDS Version 2.0) Keeping track of current events.","FAQ-NACC UDS Version 2.0 - Keep Track of Current Events | FAQNA1-Keeping Track of Current Events | FAQNA107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454076","ALK-FAK Inhibitor CEP-37440","C111685","An orally available dual kinase inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and focal adhesion kinase (FAK), with potential antineoplastic activity. Upon administration, ALK-FAK inhibitor CEP-37440 selectively binds to and inhibits ALK kinase and FAK kinase. The inhibition leads to disruption of ALK- and FAK-mediated signal transduction pathways and eventually inhibits tumor cell growth in ALK- and FAK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; its dysregulation and gene rearrangements are associated with a variety of tumors. The cytoplasmic tyrosine kinase FAK, a signal transducer for integrins, is upregulated and constitutively activated in various tumor types; it plays a key role in tumor cell migration, proliferation, survival, and tumor angiogenesis.","ALK-FAK Inhibitor CEP-37440 | CEP-37440",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810876","Rice Bran","C111686","The nutrient-rich hard outer layer of the rice cereal grain, with potential chemopreventive, antioxidant, iron chelating, anticholesterol and anti-inflammatory activities. Rice bran is rich in fiber, such as beta-glucan, pectin and gum; it also comprises vitamins and minerals, such as iron, magnesium and phosphorus, and essential fatty acids. In addition, Rice bran contains various bioactive components, including ferulic acid, tricin, beta-sitosterol, gamma-oryzanol, phytic acid, and inositol hexaphosphate (IP6). The potential anticancer activity of rice bran may be due to the synergistic effects of these phytochemicals on their ability to induce apoptosis, inhibit cell proliferation, and alter cell cycle progression in cancer cells. Rice bran's bioactive components also protect against tissue damage by scavenging free radicals and blocking chronic inflammatory responses. In addition, they are able to modulate the gut microflora and carcinogen-metabolizing enzymes, thereby further exerting a chemopreventive effect.","Rice Bran | RICE BRAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454077","Navy Bean Powder","C111687","The powder form of the cooked navy bean with potential antioxidant and chemopreventive activities. Navy beans are rich in fiber, minerals, vitamins, and phytochemicals such as flavonoids and phytosterols. They appear to prevent carcinogenesis by inducing tumor cell apoptosis. Intake of navy bean powder may have a beneficial effect on intestinal microflora.","Navy Bean Powder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL453658","Electrocauterization","C111192","To destroy tissue using an electrical current. This process may be used to kill certain types of small tumors or to seal off blood vessels to stop bleeding.","Electrocauterization | ELECTROCAUTERIZATION",,,,,,,,,,,,,,,"4045079|4144920","Galvanocauterization - action|Electrocautery operation",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3829943","Greenbrier County, WV","C110693","No value exists.","Greenbrier County, WV | Greenbrier County | Greenbrier County, West Virginia | WV025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815158","Hampshire County, WV","C110694","No value exists.","Hampshire County, WV | Hampshire County | Hampshire County, West Virginia | WV027",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815164","Hancock County, WV","C110695","No value exists.","Hancock County, WV | Hancock County | Hancock County, West Virginia | WV029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829848","Hardy County, WV","C110696","No value exists.","Hardy County, WV | Hardy County | Hardy County, West Virginia | WV031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816463","Jackson County, WV","C110698","No value exists.","Jackson County, WV | Jackson County | Jackson County, West Virginia | WV035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810780","Jefferson County, WV","C110699","No value exists.","Jefferson County, WV | Jefferson County | Jefferson County, West Virginia | WV037",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0060696","Fotemustine","C1106","A chloroethylating nitrosourea with antineoplastic activity. Fotemustine alkylates guanine by forming chloroethyl adducts at the 6 position of guanine, resulting in N1-guanine and N3-cytosine cross linkages, inhibition of DNA synthesis, cell cycle arrest, and finally apoptosis. This agent is lipophilic and crosses the blood-brain barrier.","Fotemustine | 1-[N-(2-chloroethyl)-N-nitrosoureido]ethylphosphonic acid diethyl ester | FOTEMUSTINE | Muphoran | S 10036 | [1-[[[(2-chloroethyl)nitrosamino]-carbonyl]amino]ethyl]phosphonic acid diethyl ester | diethyl[1-[3-(2-chloroethyl)-3-nitrosoureido]ethyl]phosphonate | fotemustine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829436","Kanawha County, WV","C110700","No value exists.","Kanawha County, WV | Kanawha County | Kanawha County, West Virginia | WV039",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814084","Lewis County, WV","C110701","No value exists.","Lewis County, WV | Lewis County | Lewis County, West Virginia | WV041",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815613","Logan County, WV","C110703","No value exists.","Logan County, WV | Logan County | Logan County, West Virginia | WV045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812229","McDowell County, WV","C110704","No value exists.","McDowell County, WV | McDowell County | McDowell County, West Virginia | WV047",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811174","Marion County, WV","C110705","No value exists.","Marion County, WV | Marion County | Marion County, West Virginia | WV049",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811725","Marshall County, WV","C110706","No value exists.","Marshall County, WV | Marshall County | Marshall County, West Virginia | WV051",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811739","Mason County, WV","C110707","No value exists.","Mason County, WV | Mason County | Mason County, West Virginia | WV053",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810697","Mineral County, WV","C110709","No value exists.","Mineral County, WV | Mineral County | Mineral County, West Virginia | WV057",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829061","Mingo County, WV","C110710","No value exists.","Mingo County, WV | Mingo County | Mingo County, West Virginia | WV059",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828971","Monongalia County, WV","C110711","No value exists.","Monongalia County, WV | Monongalia County | Monongalia County, West Virginia | WV061",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811262","Monroe County, WV","C110712","No value exists.","Monroe County, WV | Monroe County | Monroe County, West Virginia | WV063",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811294","Morgan County, WV","C110713","No value exists.","Morgan County, WV | Morgan County | Morgan County, West Virginia | WV065",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812732","Ohio County, WV","C110715","No value exists.","Ohio County, WV | Ohio County | Ohio County, West Virginia | WV069",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813697","Pendleton County, WV","C110716","No value exists.","Pendleton County, WV | Pendleton County | Pendleton County, West Virginia | WV071",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828528","Pleasants County, WV","C110717","No value exists.","Pleasants County, WV | Pleasants County | Pleasants County, West Virginia | WV073",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811767","Pocahontas County, WV","C110718","No value exists.","Pocahontas County, WV | Pocahontas County | Pocahontas County, West Virginia | WV075",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3809620","AV Block Second Degree","C111119","Intermittent failure of atrial electrical impulse conduction to the ventricles.","AV Block Second Degree | Atrioventricular Block Second Degree | Atrioventricular Block, Second Degree | Second Degree AV Block | Second Degree Atrioventricular Block",,,,,,,,,,,,,,,"318448","Second degree atrioventricular block",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162512","Neostriatum","C111122","The brain area that is composed of the caudate nucleus and putamen.","Neostriatum | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830798","C-SSRS Children's Baseline/Screening - Description of Non-Specific Active Suicidal Thoughts","C111390","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Description of non-specific active suicidal thoughts.","C-SSRS Children's Baseline/Screening - Description of Non-Specific Active Suicidal Thoughts | CSS07-Non-Spec Suicid Thought, Describe | CSS0702C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814029","Fremont County, WY","C110814","No value exists.","Fremont County, WY | Fremont County | Fremont County, Wyoming | WY013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829962","Goshen County, WY","C110815","No value exists.","Goshen County, WY | Goshen County | Goshen County, Wyoming | WY015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815925","Hot Springs County, WY","C110816","No value exists.","Hot Springs County, WY | Hot Springs County | Hot Springs County, Wyoming | WY017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810787","Johnson County, WY","C110817","No value exists.","Johnson County, WY | Johnson County | Johnson County, Wyoming | WY019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0338207","bleomycin/dacarbazine/lomustine/vincristine","C11081","A regimen consisting of bleomycin, vincristine, lomustine, and dacarbazine for the treatment of melanoma.","BOLD Regimen | BLEO/CCNU/DTIC/VCR | BOLD | Bleomycin-Vincristine-Lomustine-Dacarbazine | Bleomycin/Dacarbazine/Lomustine/Vincristine | Bleomycin/Oncovin/Lomustine/Dacarbazine | Bleomycin/Vincristine/Lomustine/Dacarbazine | Bleomycin/Vincristine/Lomustine/Dacarbazine Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828857","Natrona County, WY","C110820","No value exists.","Natrona County, WY | Natrona County | Natrona County, Wyoming | WY025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828812","Niobrara County, WY","C110821","No value exists.","Niobrara County, WY | Niobrara County | Niobrara County, Wyoming | WY027",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813690","Park County, WY","C110822","No value exists.","Park County, WY | Park County | Park County, Wyoming | WY029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811215","Platte County, WY","C110823","No value exists.","Platte County, WY | Platte County | Platte County, Wyoming | WY031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827902","Sublette County, WY","C110825","No value exists.","Sublette County, WY | Sublette County | Sublette County, Wyoming | WY035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827878","Sweetwater County, WY","C110826","No value exists.","Sweetwater County, WY | Sweetwater County | Sweetwater County, Wyoming | WY037",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815213","Teton County, WY","C110827","No value exists.","Teton County, WY | Teton County | Teton County, Wyoming | WY039",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827739","Uinta County, WY","C110828","No value exists.","Uinta County, WY | Uinta County | Uinta County, Wyoming | WY041",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827508","Washakie County, WY","C110829","No value exists.","Washakie County, WY | WY043 | Washakie County | Washakie County, Wyoming",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830356","Eastern District, AS","C110831","No value exists.","Eastern District, AS | AS010 | Eastern District | Eastern District, American Samoa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829209","Manu'a District, AS","C110832","No value exists.","Manu'a District, AS | AS020 | Manu'a District | Manu'a District, American Samoa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828295","Rose Island, AS","C110833","No value exists.","Rose Island, AS | AS030 | Rose Island | Rose Island, American Samoa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827880","Swains Island, AS","C110834","No value exists.","Swains Island, AS | AS040 | Swains Island | Swains Island, American Samoa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814798","Guam, GU","C110836","No value exists.","Guam, GU | GU010 | Guam | Guam, Guam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828786","Northern Islands Municipality, MP","C110837","No value exists.","Northern Islands Municipality, MP | MP085 | Northern Islands Municipality | Northern Islands Municipality, Northern Mariana Islands",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813180","Rota Municipality, Northern Mariana Islands","C110838","No value exists.","Rota Municipality, MP | MP100 | Rota Municipality | Rota Municipality, Northern Mariana Islands",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828275","Saipan Municipality, MP","C110839","No value exists.","Saipan Municipality, MP | MP110 | Saipan Municipality | Saipan Municipality, Northern Mariana Islands",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816727","Benign basal cell tumor","C111198","A benign epithelial neoplasm with a uniform, monomorphic appearance that is dominated by basal cells. (SEND)","Experimental Organism Basal Cell Adenoma | Adenoma, Basal Cell, Benign | BASAL CELL TUMOR, BENIGN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811653","Experimental Organism Basal Cell Carcinoma","C111199","A malignant epithelial neoplasm arising from basal cells. (SEND)","Experimental Organism Basal Cell Carcinoma | BCC | Basal Cell Cancer | Basal Cell Carcinoma | Basal Cell Epithelioma | Basal Cell Skin Carcinoma | CARCINOMA, BASAL CELL, MALIGNANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830761","C-SSRS Children's Since Last Visit - Describe Most Severe Ideation","C111439","Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Description of most severe ideation.","C-SSRS Children's Since Last Visit - Describe Most Severe Ideation | CSS08-Most Severe Ideation, Description | CSS0806A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830751","C-SSRS Children's Since Last Visit - Frequency of Most Severe Ideation","C111440","Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) How many times have you had these thoughts?","C-SSRS Children's Since Last Visit - Frequency of Most Severe Ideation | CSS08-Most Severe Ideation, Frequency | CSS0807",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830750","C-SSRS Children's Since Last Visit - Frequency, Write Response","C111441","Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Frequency, write response.","C-SSRS Children's Since Last Visit - Frequency, Write Response | CSS08-Frequency, Write Response | CSS0807A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830762","C-SSRS Children's Since Last Visit - Actual Suicide Attempt","C111442","Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Did you do anything to try to kill yourself or make yourself not alive anymore? What did you do? Did you hurt yourself on purpose? Why did you do that?","C-SSRS Children's Since Last Visit - Actual Suicide Attempt | CSS08-Actual Attempt | CSS0808",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830741","C-SSRS Children's Since Last Visit - Number of Actual Suicide Attempts","C111443","Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Total number of actual attempts.","C-SSRS Children's Since Last Visit - Number of Actual Suicide Attempts | CSS08-Number of Actual Attempts | CSS0809",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828480","Preston County, WV","C110719","No value exists.","Preston County, WV | Preston County | Preston County, West Virginia | WV077",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL453977","MELK Inhibitor OTS167","C111569","An orally available inhibitor of maternal embryonic leucine zipper kinase (MELK) with potential antineoplastic activity. Upon administration, OTS167 binds to MELK, which prevents both MELK phosphorylation and activation; thus inhibiting the phosphorylation of downstream MELK substrates. This may lead to an inhibition of both cell proliferation and survival in MELK-expressing tumor cells. MELK, a serine/threonine kinase, is involved in cancer cell survival, invasiveness and cancer-stem cell formation and maintenance; it is highly upregulated in various types of cancer cells and absent in normal, healthy cells.","MELK Inhibitor OTS167 | OTS-167 | OTS167",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL453978","Nanosomal Docetaxel Lipid Suspension","C111570","A lipid-based nanosomal formulation of the poorly soluble, semi-synthetic, second-generation taxane docetaxel, with potential antineoplastic activity. Upon intravenous injection, docetaxel binds to and stabilizes tubulin, which inhibits microtubule disassembly and results in both cell cycle arrest at the G2/M phase and cell death. This liposomal formulation solubilizes docetaxel without the use of toxic solvents, such as polysorbate 80. This permits the administration of larger doses of docetaxel and improves the drug's safety profile by avoiding solvent-associated toxicities, such as hypersensitivity reactions and neurotoxicity. In addition, the nanosomal lipid-based delivery of docetaxel improves drug penetration into tumors and decreases drug clearance, all of which prolong the duration of docetaxel's therapeutic effects.","Nanosomal Docetaxel Lipid Suspension | DTX-LNS | NDLS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL453979","expanded umbilical cord blood product HSC835","C111571","A preparation of allogeneic umbilical cord blood (UCB)-derived hematopoietic stem and progenitor cells (HSPCs) expanded in culture with the stimulatory cytokines stem cell factor (SCF; Kit ligand; mast cell growth factor; MGF), FMS-like tyrosine kinase 3 ligand (Flt3L), interleukin 6 (IL-6), and thrombopoietin, in the presence of an aryl hydrocarbon receptor (AHR) antagonist LHD221 (StemRegenin-1; SR-1), with potential to improve hematopoietic recovery following myeloablative conditioning. Upon administration of Spanlecortemlocel, these cells increase and restore the number of HSPCs, which may prevent or decrease the risk of infection and other complications of chemotherapy-induced neutropenia (CIN) or cord blood transplantation. LHD221, an AHR antagonist facilitates the expansion of CD34-positive hematopoietic progenitors and impedes HSPC differentiation during cytokine-driven expansion in culture.","Spanlecortemlocel | Allogeneic UCB-derived HSPCs MGTA 456 | Allogeneic Umbilical Cord Blood-derived Hematopoietic Stem and Progenitor Cells MGTA-456 | Expanded Umbilical Cord Blood Product HSC835 | HSC 835 | HSC835 | MGTA 456 | MGTA-456 | SPANLECORTEMLOCEL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL453980","Carbon C 14 Oxaliplatin","C111572","A radioconjugate composed of the platinum agent oxaliplatin labeled with the isotope carbon C 14, that can be used to predict the response to oxaliplatin therapy using accelerator mass spectrometry (AMS). Upon intravenous administration of a microdose of carbon C 14 oxaliplatin, the oxaliplatin moiety covalently links to DNA and forms mono- and di-DNA adducts. The platinum-DNA adduct formation can be measured through quantification of C14-labeled drug-DNA adducts by using AMS. By measuring the microdose-induced DNA damage, the response to oxaliplatin-based chemotherapy can be assessed and predicted. Measurements that indicate either low drug-DNA adduct formation or increased DNA repair (C14 removal from DNA) are correlated with increased resistance to platinum-based chemotherapeutics.","Carbon C 14 Oxaliplatin | [14C] Oxaliplatin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830812","C-SSRS Children's Baseline/Screening - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act (Lifetime)","C111391","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Have you thought about how you would do that or how you would make yourself not alive anymore (kill yourself)? What did you think about? (Lifetime).","C-SSRS Children's Baseline/Screening - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act (Lifetime) | CSS07-Idea, No Intent, No Plan-Life | CSS0703A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830803","C-SSRS Children's Baseline/Screening - Description of Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act","C111393","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Description of active suicidal ideation with any methods (not plan) without intent to act.","C-SSRS Children's Baseline/Screening - Description of Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act | CSS07-Idea, No Intent, No Plan, Describe | CSS0703C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830810","C-SSRS Children's Baseline/Screening - Active Suicidal Ideation with Some Intent to Act, without Specific Plan (Lifetime)","C111394","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) When you thought about making yourself not alive anymore (or killing yourself), did you think that this was something you might actually do? This is different from (as opposed to) having the thoughts but knowing you wouldn't do anything about it. (Lifetime).","C-SSRS Children's Baseline/Screening - Active Suicidal Ideation with Some Intent to Act, without Specific Plan (Lifetime) | CSS07-Idea, Intent, No Plan-Life | CSS0704A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830809","C-SSRS Children's Baseline/Screening - Active Suicidal Ideation with Some Intent to Act, without Specific Plan (Past 6 Months)","C111395","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) When you thought about making yourself not alive anymore (or killing yourself), did you think that this was something you might actually do? This is different from (as opposed to) having the thoughts but knowing you wouldn't do anything about it. (Past 6 Months).","C-SSRS Children's Baseline/Screening - Active Suicidal Ideation with Some Intent to Act, without Specific Plan (Past 6 Months) | CSS07-Idea, Intent, No Plan-P6M | CSS0704B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830802","C-SSRS Children's Baseline/Screening - Description of Active Suicidal Ideation with Some Intent to Act, without Specific Plan","C111396","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Description of active suicidal ideation with some intent to act, without specific plan.","C-SSRS Children's Baseline/Screening - Description of Active Suicidal Ideation with Some Intent to Act, without Specific Plan | CSS07-Idea, Intent, No Plan, Describe | CSS0704C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830808","C-SSRS Children's Baseline/Screening - Active Suicidal Ideation with Specific Plan and Intent (Lifetime)","C111397","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Have you ever decided how or when you would make yourself not alive anymore/kill yourself? Have you ever planned out (worked out the details of) how you would do it? What was your plan? When you made this plan (or worked out these details), was any part of you thinking about actually doing it? (Lifetime).","C-SSRS Children's Baseline/Screening - Active Suicidal Ideation with Specific Plan and Intent (Lifetime) | CSS07-Idea, Plan, Intent-Life | CSS0705A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830807","C-SSRS Children's Baseline/Screening - Active Suicidal Ideation with Specific Plan and Intent (Past 6 Months)","C111398","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Have you ever decided how or when you would make yourself not alive anymore/kill yourself? Have you ever planned out (worked out the details of) how you would do it? What was your plan? When you made this plan (or worked out these details), was any part of you thinking about actually doing it? (Past 6 Months).","C-SSRS Children's Baseline/Screening - Active Suicidal Ideation with Specific Plan and Intent (Past 6 Months) | CSS07-Idea, Plan, Intent-P6M | CSS0705B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830801","C-SSRS Children's Baseline/Screening - Description of Active Suicidal Ideation with Specific Plan and Intent","C111399","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Description of active suicidal ideation with specific plan and intent.","C-SSRS Children's Baseline/Screening - Description of Active Suicidal Ideation with Specific Plan and Intent | CSS07-Idea, Plan, Intent, Describe | CSS0705C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811380","Crook County, WY","C110813","No value exists.","Crook County, WY | Crook County | Crook County, Wyoming | WY011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827827","Tinian Municipality, MP","C110840","No value exists.","Tinian Municipality, MP | MP120 | Tinian Municipality | Tinian Municipality, Northern Mariana Islands",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831591","Aguada Municipio, PR","C110842","No value exists.","Aguada Municipio, PR | Aguada Municipio | Aguada Municipio, Puerto Rico | PR003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830756","C-SSRS Children's Since Last Visit - Description of Actual Suicide Attempt","C111444","Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Description of actual attempt.","C-SSRS Children's Since Last Visit - Description of Actual Suicide Attempt | CSS08-Actual Attempt, Describe | CSS0809A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830743","C-SSRS Children's Since Last Visit - Non-suicidal Self-injurious Behavior","C111445","Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Has subject engaged in non-suicidal self-injurious behavior?","C-SSRS Children's Since Last Visit - Non-suicidal Self-injurious Behavior | CSS08-Non-suicidal Self-injurious Behav | CSS0810",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830737","C-SSRS Children's Since Last Visit - Self-injurious Behavior, Intent Unknown","C111446","Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Has subject engaged in self-injurious behavior, intent unknown?","C-SSRS Children's Since Last Visit - Self-injurious Behavior, Intent Unknown | CSS08-Self-injur Behav, Intent Unknown | CSS0811",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830749","C-SSRS Children's Since Last Visit - Interrupted Suicide Attempt","C111447","Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Has there been a time when you started to do something to make yourself not alive anymore (end your life or kill yourself) but someone or something stopped you before you actually did anything? What did you do?","C-SSRS Children's Since Last Visit - Interrupted Suicide Attempt | CSS08-Interrupted Attempt | CSS0812",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830740","C-SSRS Children's Since Last Visit - Number of Interrupted Suicide Attempts","C111448","Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Total number of interrupted.","C-SSRS Children's Since Last Visit - Number of Interrupted Suicide Attempts | CSS08-Number of Interrupt Attempts | CSS0813",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830755","C-SSRS Children's Since Last Visit - Description of Interrupted Suicide Attempt","C111449","Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Description of interrupted attempt.","C-SSRS Children's Since Last Visit - Description of Interrupted Suicide Attempt | CSS08-Interrupted Attempt, Describe | CSS0813A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1263992","Toxic Methemoglobinemia with Cyanosis","C110936","Blue skin coloration due to elevated blood levels of methemoglobin. The degree of cyanosis is directly correlated to the concentration of methemoglobin in the blood. As methemoglobin is not suitable for carrying oxygen, hypoxemia becomes a serious sequela.","Toxic Methemoglobinemia with Cyanosis | ",,,,,,,,,,,,,,,"4131911","Toxic methemoglobinemia with cyanosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0080203","Tachyarrhythmia","C110938","A disorder characterized by an arrhythmia with an above normal rate.","Tachyarrhythmia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL453982","mRNA-derived lung cancer vaccine CV9202","C111574","A non-small cell lung cancer (NSCLC) vaccine containing six modified mRNAs, which encode six different NSCLC associated antigens, with potential antitumor and immunomodulatory activities. Upon intradermal administration, mRNA-derived lung cancer vaccine BI 1361849 may stimulate the immune system to mount both humoral and cellular responses against NSCLC cells. The six tumor-associated antigens (TAAs) encoded by these mRNAs are frequently expressed by NSCLC cells and are minimally expressed or absent in normal, healthy cells.","mRNA-derived Lung Cancer Vaccine BI 1361849 | BI 1361849 | BI1361849 | CV9202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811161","Micro (prefix)","C111074","A prefix meaning very small in scale or scope.","Micro | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831474","Arrhythmia by ECG Finding","C111075","An arrhythmia that is detected on an electrocardiograph.","Arrhythmia by ECG Finding | Arrhythmia by EKG Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827685","US Counties Terminology","C111076","A list of all the counties in the United States, and the states in which they are located.","US Counties Terminology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829590","Human Prescription Drug Distribution","C111077","The process of distributing prescription medications for human use.","Human Prescription Drug Distribution | Distributes human prescription drug products",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829592","Human Over-the-Counter Drug Distribution","C111078","The process of distributing non-prescription medications for human use.","Human Over-the-Counter Drug Distribution | Distributes human over-the-counter drug products",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827389","FAMS - Worry My Condition Will Get Worse","C112601","Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: I worry that my condition will get worse.","FAMS - Worry My Condition Will Get Worse | FAMS01-Worry My Condition Will Get Worse | FAMS0151",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827391","FAMS - I Am Sleeping Well","C112602","Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: I am sleeping well.","FAMS - I Am Sleeping Well | FAMS01-I Am Sleeping Well | FAMS0152",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830234","FAMS - Heat Worsens My Symptoms","C112603","Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: Heat worsens my symptoms.","FAMS - Heat Worsens My Symptoms | FAMS01-Heat Worsens My Symptoms | FAMS0153",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830209","FAMS - Trouble Controlling My Urine","C112604","Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: I have trouble controlling my urine.","FAMS - Trouble Controlling My Urine | FAMS01-Have Trouble Controlling My Urine | FAMS0154",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830203","FAMS - Urinate More Frequently Than Usual","C112605","Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: I urinate more frequently than usual.","FAMS - Urinate More Frequently Than Usual | FAMS01-I Urinate More Frequently | FAMS0155",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830257","FAMS - Bothered by Chills","C112606","Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: I am bothered by the chills.","FAMS - Bothered by Chills | FAMS01-I Am Bothered by the Chills | FAMS0156",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830254","FAMS - Bothered by Muscle Spasms","C112608","Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: I am bothered by muscle spasms.","FAMS - Bothered by Muscle Spasms | FAMS01-I Am Bothered by Muscle Spasms | FAMS0158",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829393","KFSS - Pyramidal Functions","C112609","Kurtzke Functional Systems Scores (KFSS) Pyramidal functions.","KFSS - Pyramidal Functions | KFSS1-Pyramidal Functions | KFSS101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829398","KFSS - Cerebellar Functions","C112610","Kurtzke Functional Systems Scores (KFSS) Cerebellar functions.","KFSS - Cerebellar Functions | KFSS1-Cerebellar Functions | KFSS102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829390","KFSS - Weakness Interferes With Testing","C112611","Kurtzke Functional Systems Scores (KFSS) Record number 1 in small box when weakness (grade 3 or worse on pyramidal) interferes with testing.","KFSS - Weakness Interferes With Testing | KFSS1-Weakness Interferes With Testing | KFSS102A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829399","KFSS - Brain Stem Functions","C112612","Kurtzke Functional Systems Scores (KFSS) Brainstem functions.","KFSS - Brain Stem Functions | KFSS1-Brain Stem Functions | KFSS103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829391","KFSS - Sensory Functions","C112613","Kurtzke Functional Systems Scores (KFSS) Sensory function.","KFSS - Sensory Functions | KFSS1-Sensory Functions | KFSS104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829400","KFSS - Bowel and Bladder Functions","C112614","Kurtzke Functional Systems Scores (KFSS) Bowel and bladder function.","KFSS - Bowel and Bladder Functions | KFSS1-Bowel and Bladder Functions | KFSS105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827261","KFSS - Visual (or Optic) Functions","C112615","Kurtzke Functional Systems Scores (KFSS) Visual function.","KFSS - Visual (or Optic) Functions | KFSS1-Visual or Optic Functions | KFSS106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830526","Device Embolization","C111642","Movement of a medical device to an unintended location within the body with resulting obstruction of an organ or vessel.","Device Embolization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013580","Ectopia Cordis","C111643","A rare congenital anomaly where the heart is formed outside of the thoracic cavity. It is associated with intracardiac lesions and other structural malformations.","Ectopia Cordis | ",,,,,,,,,,,,,,,"4302306","Ectopia cordis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1915475","Bacteroides dorei","C111133","A species of anaerobic, gram-negative, rod shaped bacteria assigned to the phylum Bacteroidetes. This specis is non-spore forming, non-motile, does not hydrolyze esculin, is indole negative and nitrate is not reduced.","Bacteroides dorei | BACTEROIDES DOREI",,,,,,,,,,,,,,,"42872962","Phocaeicola dorei",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2796430","Bacteroides faecis","C111134","A species of anaerobic, gram-negative, rod shaped bacteria assigned to the phylum Bacteroidetes. This species is non-motile, spore forming, oxidase, urease and catalase negative, indole positive and hydrolyzes esculin. B. faecis was originally isolated from human feces.","Bacteroides faecis | BACTEROIDES FAECIS",,,,,,,,,,,,,,,"37399352","Bacteroides faecis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006440","Bursa Of Fabricius","C111141","An epithelial outgrowth of lymphoid tissue in the cloaca of young birds, responsible for B-lymphocyte maturation. It undergoes atrophy and involution at six months of age.","Bursa of Fabricius | BURSA OF FABRICIUS | Bursa Of Fabricius",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830196","FAQ-NACC UDS Version 2.0 - Pay Attention, Understand, Discuss","C111517","Functional Assessment Questionnaire-NACC UDS Version 2.0 (FAQ-NACC UDS Version 2.0) Paying attention to, understanding, discussing TV, book, magazine.","FAQ-NACC UDS Version 2.0 - Pay Attention, Understand, Discuss | FAQNA1-Paying Attention | FAQNA108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830193","FAQ-NACC UDS Version 2.0 - Remember","C111518","Functional Assessment Questionnaire-NACC UDS Version 2.0 (FAQ-NACC UDS Version 2.0) Remembering appointments, family occasions, holidays, medications.","FAQ-NACC UDS Version 2.0 - Remember | FAQNA1-Remembering | FAQNA109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830191","FAQ-NACC UDS Version 2.0 - Travel","C111519","Functional Assessment Questionnaire-NACC UDS Version 2.0 (FAQ-NACC UDS Version 2.0) Traveling out of neighborhood, driving, arranging to take buses.","FAQ-NACC UDS Version 2.0 - Travel | FAQNA1-Traveling | FAQNA110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828204","SDS - Symptoms Disrupted Work/School Work","C111521","Sheehan Disability Scale (SDS) The symptoms have disrupted your work/school work.","SDS - Symptoms Disrupted Work/School Work | SDS01-Work/School | SDS0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828208","SDS - Not Worked/Studied in Past Week for Reason Unrelated to Disorder","C111522","Sheehan Disability Scale (SDS) I have not worked/studied at all during the past week for reasons unrelated to the disorder.","SDS - Not Worked/Studied in Past Week for Reason Unrelated to Disorder | SDS01-No Work/Study - Unrelated Disorder | SDS0101A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828205","SDS - Symptoms Disrupted Social Life/Leisure Activities","C111523","Sheehan Disability Scale (SDS) The symptoms have disrupted your social life/leisure activities.","SDS - Symptoms Disrupted Social Life/Leisure Activities | SDS01-Social Life | SDS0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828206","SDS - Symptoms Disrupted Family Life/Home Responsibilities","C111524","Sheehan Disability Scale (SDS) The symptoms have disrupted your family life/home responsibilities.","SDS - Symptoms Disrupted Family Life/Home Responsibilities | SDS01-Family Life/Home Responsibilities | SDS0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828210","SDS - Days Lost","C111525","Sheehan Disability Scale (SDS) On how many days in the last week did your symptoms cause you to miss school or work or leave you unable to carry out your normal daily responsibilities?","SDS - Days Lost | SDS01-Days Lost | SDS0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828209","SDS0105","C111526","Sheehan Disability Scale (SDS) On how many days in the last week did you feel so impaired by your symptoms, that even though you went to school or work or had other daily responsibilities, your productivity was reduced?","SDS - Days Underproductive | SDS - Days Unproductive | SDS01-Days Underproductive | SDS01-Days Underproductive | SDS01-Days Unproductive | SDS0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830767","C-SSRS Children's Baseline - Wish to be Dead","C111527","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Have you thought about being dead or what it would be like to be dead? Have you wished you were dead or wished you could go to sleep and never wake up? Do you ever wish you weren't alive anymore?","C-SSRS Children's Baseline - Wish to be Dead | CSS06-Wish to be Dead | CSS0601",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830834","C-SSRS Children's Baseline - Description of Wish to be Dead","C111528","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Description of wishing to be dead.","C-SSRS Children's Baseline - Description of Wish to be Dead | CSS06-Wish to be Dead, Describe | CSS0601A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830820","C-SSRS Children's Baseline - Non-Specific Active Suicidal Thoughts","C111529","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Have you thought about doing something to make yourself not alive anymore? Have you had any thoughts about killing yourself?","C-SSRS Children's Baseline - Non-Specific Active Suicidal Thoughts | CSS06-Non-Specific Suicidal Thought | CSS0602",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826912","CDISC Questionnaire MRS Test Name Terminology","C111347","Test names of clinical classification questions associated with the Modified Rankin Scale (MRS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification MRS Test Name Terminology | CDISC Questionnaire MRS Test Name Terminology | MRS01TN | Modified Rankin Scale Clinical Classification Test Name | Modified Rankin Scale Questionnaire Test Name | QS-MRS TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826911","CDISC Questionnaire MRS Test Code Terminology","C111348","Test codes of clinical classification questions associated with the Modified Rankin Scale (MRS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification MRS Test Code Terminology | CDISC Questionnaire MRS Test Code Terminology | MRS01TC | Modified Rankin Scale Clinical Classification Test Code | Modified Rankin Scale Questionnaire Test Code | QS-MRS TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826905","CDISC Questionnaire SDS Test Name Terminology","C111349","Test names of questionnaire questions associated with the Sheehan Disability Scale (SDS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire SDS Test Name Terminology | QS-SDS TEST | SDS01TN | Sheehan Disability Scale Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0338289","letrozole/tamoxifen","C11134","A regimen consisting of tamoxifen and letrozole that may be used in the treatment of breast cancer.","Tamoxifen/Letrozole Regimen | Letrozole-Tamoxifen | Letrozole/Tamoxifen | Tam Letrozole | Tamoxifen-Letrozole | Tamoxifen/Letrozole | letrozole/TMX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826904","CDISC Questionnaire SDS Test Code Terminology","C111350","Test codes of questionnaire questions associated with the Sheehan Disability Scale (SDS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire SDS Test Code Terminology | QS-SDS TESTCD | SDS01TC | Sheehan Disability Scale Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830814","C-SSRS Children's Baseline Questionnaire Question","C111351","A question associated with the C-SSRS Children's Baseline questionnaire.","C-SSRS Children's Baseline Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830774","C-SSRS Children's Baseline/Screening Questionnaire Question","C111352","A question associated with the C-SSRS Children's Baseline/Screening questionnaire.","C-SSRS Children's Baseline/Screening Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830738","C-SSRS Children's Since Last Visit Questionnaire Question","C111353","A question associated with the C-SSRS Children's Since Last Visit questionnaire.","C-SSRS Children's Since Last Visit Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830186","FAQ Questionnaire Question","C111355","A question associated with the FAQ questionnaire.","FAQ Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830194","FAQ-NACC UDS Version 2.0 Clinical Classification Question","C111356","A question associated with the FAQ-NACC UDS Version 2.0 clinical classification.","FAQ-NACC UDS Version 2.0 Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828943","MRS Questionnaire Question","C111357","A question associated with the MRS clinical classification.","MRS Clinical Classification Question | MRS Questionnaire Question",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829394","KFSS - Presence of Temporal Pallor","C112616","Kurtzke Functional Systems Scores (KFSS) Record number 1 in small box for presence of temporal pallor.","KFSS - Presence of Temporal Pallor | KFSS1-Presence of Temporal Pallor | KFSS106A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829397","KFSS - Cerebral (or Mental) Functions","C112617","Kurtzke Functional Systems Scores (KFSS) Cerebral (or mental) functions.","KFSS - Cerebral (or Mental) Functions | KFSS1-Cerebral or Mental Functions | KFSS107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427803","NLRP2 Gene","C111919","This gene plays a role in the modulation of apoptotic signaling.","NLRP2 Gene | NLR Family, Pyrin Domain Containing 2 Gene | NLRP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811665","NLRP2 wt Allele","C111920","Human NLRP2 wild-type allele is located in the vicinity of 19q13.42 and is approximately 48 kb in length. This allele, which encodes NACHT, LRR and PYD domains-containing protein 2, is involved in the regulation of signaling.","NLRP2 wt Allele | CLR19.9 | FLJ20510 | NACHT, Leucine Rich Repeat and PYD Containing 2 Gene | NALP2 | NBS1 | NLR Family, Pyrin Domain Containing 2 wt Allele | NLR Family, Pyrin Domain-Containing 2 Gene | Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat and Pyrin Domain Containing 2 Gene | PAN1 | PYPAF2 | XXbac-BPG230H20.8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814821","NACHT, LRR and PYD Domains-Containing Protein 2","C111921","NACHT, LRR and PYD domains-containing protein 2 (1062 aa, ~121 kDa) is encoded by the human NLRP2 gene. This protein plays a role in signaling pathways involved in apoptosis and inflammation.","NACHT, LRR and PYD Domains-Containing Protein 2 | NACHT Domain-, Leucine-Rich Repeat-, and PYD-Containing Protein 2 | NACHT, LRR and PYD Containing Protein 2 | NLRP2 | Nucleotide-Binding Site Protein 1 | PYRIN Domain and NACHT Domain-Containing Protein 1 | PYRIN Domain- and NACHT Domain-Containing Protein 1 | PYRIN Domain-Containing APAF1-Like Protein 2 | PYRIN-Containing APAF1-Like Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423060","TSGA10 Gene","C111922","This gene plays a role in spermatogenesis.","TSGA10 Gene | TSGA10 | Testis Specific, 10 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813561","TSGA10 wt Allele","C111923","Human TSGA10 wild-type allele is located in the vicinity of 2q11.2 and is approximately 158 kb in length. This allele, which encodes testis-specific gene 10 protein, may be involved in the formation of the fibrous sheath of the sperm tail.","TSGA10 wt Allele | CEP4L | CT79 | Cancer/Testis Antigen 79 Gene | Testis Specific, 10 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814392","Testis-Specific Gene 10 Protein","C111924","Testis-specific gene 10 protein (698 aa, ~81 kDa) is encoded by the human TSGA10 gene. This protein may play a role in sperm tail morphogenesis.","Testis-Specific Gene 10 Protein | Cancer/Testis Antigen 79 | Testis Development Protein NYD-SP7 | Testis-Specific Protein 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413365","CFTR Gene","C111925","This gene is involved in ion transport.","CFTR Gene | CFTR | Cystic Fibrosis Transmembrane Conductance Regulator (ATP-Binding Cassette Sub-Family C, Member 7) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811819","CFTR wt Allele","C111926","Human CFTR wild-type allele is located in the vicinity of 7q31.2 and is approximately 203 kb in length. This allele, which encodes cystic fibrosis transmembrane conductance regulator protein, plays a role in the transport of chloride ions. Mutation of the gene is associated with cystic fibrosis and congenital bilateral absence of the vas deferens.","CFTR wt Allele | ABC35 | ABCC7 | CF | CFTR/MRP | Cystic Fibrosis Transmembrane Conductance Regulator (ATP-Binding Cassette Sub-Family C, Member 7) wt Allele | Cystic Fibrosis Transmembrane Conductance Regulator, ATP-Binding Cassette (Sub-Family C, Member 7) Gene | MRP7 | TNR-CFTR | dJ760C5.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0056889","CFTR protein, human","C111927","Cystic fibrosis transmembrane conductance regulator (1480 aa, ~168 kDa) is encoded by the human CFTR gene. This protein is involved in chloride transport and the regulation of other ion transport pathways.","Cystic Fibrosis Transmembrane Conductance Regulator | ATP-Binding Cassette Sub-Family C Member 7 | CFTR | Channel Conductance-Controlling ATPase | EC 3.6.3.49, Formerly | EC 5.6.1.6 | cAMP-Dependent Chloride Channel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0061202","Genistein","C1113","A soy-derived isoflavone and phytoestrogen with antineoplastic activity. Genistein binds to and inhibits protein-tyrosine kinase, thereby disrupting signal transduction and inducing cell differentiation.  This agent also inhibits topoisomerase-II, leading to DNA fragmentation and apoptosis, and induces G2/M cell cycle arrest.  Genistein exhibits antioxidant, antiangiogenic, and immunosuppressive activities. (NCI04)","Genistein | 4',5, 7-Trihydroxyisoflavone | 4',5,7-Trihydroxyisoflavone | 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one | GENISTEIN | Genestein | Genisteol | Prunetol | genistein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830782","C-SSRS Children's Baseline/Screening - Most Severe Ideation","C111400","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Most severe ideation.","C-SSRS Children's Baseline/Screening - Most Severe Ideation | CSS07-Most Severe Idea | CSS0706A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830805","C-SSRS Children's Baseline/Screening - Describe Most Severe Ideation","C111401","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Description of most severe ideation.","C-SSRS Children's Baseline/Screening - Describe Most Severe Ideation | CSS07-Most Severe Idea, Desc | CSS0706B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830792","C-SSRS Children's Baseline/Screening - Frequency of Most Severe Ideation (Lifetime)","C111402","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) How many times have you had these thoughts? (Lifetime).","C-SSRS Children's Baseline/Screening - Frequency of Most Severe Ideation (Lifetime) | CSS07-Most Severe Idea, Frequency-Life | CSS0707A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830790","C-SSRS Children's Baseline/Screening - Frequency, Write Response","C111404","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Frequency, write response.","C-SSRS Children's Baseline/Screening - Frequency, Write Response | CSS07-Frequency, Write Response | CSS0707C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830806","C-SSRS Children's Baseline/Screening - Actual Suicide Attempt","C111405","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Did you ever do anything to try to kill yourself or make yourself not alive anymore? What did you do? Did you ever hurt yourself on purpose? Why did you do that?","C-SSRS Children's Baseline/Screening - Actual Suicide Attempt | CSS07-Actual Attempt | CSS0708",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830777","C-SSRS Children's Baseline/Screening - Number of Actual Suicide Attempts","C111406","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Total number of actual attempts.","C-SSRS Children's Baseline/Screening - Number of Actual Suicide Attempts | CSS07-Number of Actual Attempts | CSS0709",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830836","C-SSRS Children's Baseline - Description of Non-Specific Active Suicidal Thoughts","C111530","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Description of non-specific active suicidal thoughts.","C-SSRS Children's Baseline - Description of Non-Specific Active Suicidal Thoughts | CSS06-Non-Specific Suicid Thought, Descr | CSS0602A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830847","C-SSRS Children's Baseline - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act","C111531","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Have you thought about how you would do that or how you would make yourself not alive anymore (kill yourself)? What did you think about?","C-SSRS Children's Baseline - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act | CSS06-Idea, No Intent, No Plan | CSS0603",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830846","C-SSRS Children's Baseline - Active Suicidal Ideation with Some Intent to Act, without Specific Plan","C111533","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) When you thought about making yourself not alive anymore (or killing yourself), did you think that this was something you might actually do? This is different from (as opposed to) having the thoughts but knowing you wouldn't do anything about it.","C-SSRS Children's Baseline - Active Suicidal Ideation with Some Intent to Act, without Specific Plan | CSS06-Ideation With Intent, No Plan | CSS0604",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830840","C-SSRS Children's Baseline - Description of Active Suicidal Ideation with Some Intent to Act, without Specific Plan","C111534","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Description of active suicidal ideation with some intent to act, without specific plan.","C-SSRS Children's Baseline - Description of Active Suicidal Ideation with Some Intent to Act, without Specific Plan | CSS06-Ideation With Intent No Plan Descr | CSS0604A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830845","C-SSRS Children's Baseline - Active Suicidal Ideation with Specific Plan and Intent","C111535","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Have you ever decided how or when you would make yourself not alive anymore/kill yourself? Have you ever planned out (worked out the details of) how you would do it? What was your plan? When you made this plan (or worked out these details), was any part of you thinking about actually doing it?","C-SSRS Children's Baseline - Active Suicidal Ideation with Specific Plan and Intent | CSS06-Ideation With Plan/Intent | CSS0605",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830839","C-SSRS Children's Baseline - Description of Active Suicidal Ideation with Specific Plan and Intent","C111536","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Description of active suicidal ideation with specific plan and intent.","C-SSRS Children's Baseline - Description of Active Suicidal Ideation with Specific Plan and Intent | CSS06-Ideation With Plan/Intent, Descr | CSS0605A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830843","C-SSRS Children's Baseline - Describe Most Severe Ideation","C111538","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Description of most severe ideation.","C-SSRS Children's Baseline - Describe Most Severe Ideation | CSS06-Most Severe Ideation, Description | CSS0606A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830830","C-SSRS Children's Baseline - Frequency of Most Severe Ideation","C111539","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) How many times have you had these thoughts?","C-SSRS Children's Baseline - Frequency of Most Severe Ideation | CSS06-Most Severe Ideation, Frequency | CSS0607",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830829","C-SSRS Children's Baseline - Frequency, Write Response","C111540","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Frequency, write response.","C-SSRS Children's Baseline - Frequency, Write Response | CSS06-Frequency, Write Response | CSS0607A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454151","Selatinib Ditosilate","C111764","An orally bioavailable ditosilate salt form of selatinib, an analog of the quinazoline lapatinib and dual inhibitor of epidermal growth factor receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (ErbB-2 or HER-2), with potential antineoplastic activity. Upon administration, selatinib reversibly blocks phosphorylation of both EGFR and ErbB2, thereby suppressing tumor growth in EGFR/ErbB-2-overexpressing tumor cells. The tyrosine kinases EGFR and ErbB2 have been implicated in the growth of various tumor types.","Selatinib Ditosilate | SELATINIB DITOSILATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828207","SDS Questionnaire Question","C111358","A question associated with the SDS questionnaire.","SDS Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812305","Putnam County, WV","C110720","No value exists.","Putnam County, WV | Putnam County | Putnam County, West Virginia | WV079",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828412","Raleigh County, WV","C110721","No value exists.","Raleigh County, WV | Raleigh County | Raleigh County, West Virginia | WV081",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812317","Randolph County, WV","C110722","No value exists.","Randolph County, WV | Randolph County | Randolph County, West Virginia | WV083",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813294","Roane County, WV","C110724","No value exists.","Roane County, WV | Roane County | Roane County, West Virginia | WV087",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827896","Summers County, WV","C110725","No value exists.","Summers County, WV | Summers County | Summers County, West Virginia | WV089",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815207","Taylor County, WV","C110726","No value exists.","Taylor County, WV | Taylor County | Taylor County, West Virginia | WV091",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827758","Tucker County, WV","C110727","No value exists.","Tucker County, WV | Tucker County | Tucker County, West Virginia | WV093",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811811","Tyler County, WV","C110728","No value exists.","Tyler County, WV | Tyler County | Tyler County, West Virginia | WV095",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813612","Wayne County, WV","C110730","No value exists.","Wayne County, WV | WV099 | Wayne County | Wayne County, West Virginia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813621","Webster County, WV","C110731","No value exists.","Webster County, WV | WV101 | Webster County | Webster County, West Virginia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827483","Wetzel County, WV","C110732","No value exists.","Wetzel County, WV | WV103 | Wetzel County | Wetzel County, West Virginia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827453","Wirt County, WV","C110733","No value exists.","Wirt County, WV | WV105 | Wirt County | Wirt County, West Virginia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810750","Wood County, WV","C110734","No value exists.","Wood County, WV | WV107 | Wood County | Wood County, West Virginia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811645","Adams County, WI","C110736","No value exists.","Adams County, WI | Adams County | Adams County, Wisconsin | WI001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813715","UBR5 wt Allele","C111929","Human UBR5 wild-type allele is located in the vicinity of 8q22 and is approximately 161 kb in length. This allele, which encodes E3 ubiquitin-protein ligase UBR5 protein, is involved in the initiation of protein degradation.","UBR5 wt Allele | DD5 | E3 Identified By Differential Display Gene | E3 Ubiquitin Protein Ligase, HECT Domain Containing, 1 Gene | E3 Ubiquitin Protein Ligase, HECT Domain-Containing, 1 Gene | EDD | EDD1 | HYD | Hyperplastic Discs, Drosophila, Homolog of Gene | KIAA0896 | Ubiquitin Protein Ligase E3 Component N-Recognin 5 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0965793","E3 Ubiquitin-Protein Ligase UBR5, Human","C111930","E3 ubiquitin-protein ligase UBR5 (2799 aa, ~309 kDa) is encoded by the human UBR5 gene. This protein plays a role in the promotion of both protein ubiquitination and protein catabolism.","E3 Ubiquitin-Protein Ligase UBR5 | E3 Identified By Differential Display | E3 Ubiquitin-Protein Ligase, HECT Domain-Containing 1 | EC 2.3.2.26 | EC 6.3.2.-, Formerly | HECT-Type E3 Ubiquitin Transferase UBR5 | Hyperplastic Discs Protein Homolog | Progestin Induced Protein | Progestin-Induced Protein | UBR5 | hHYD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425417","RNF130 Gene","C111931","This gene is involved in the ubiquitination of proteins.","RNF130 Gene | RNF130 | Ring Finger Protein 130 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815884","Myosin-1","C112132","Myosin-1 (1939 aa, ~223 kDa) is encoded by the human MYH1 gene. This protein plays a role in skeletal muscle contraction.","Myosin-1 | MyHC-2x | MyHC-IIx/D | Myosin Heavy Chain 1 | Myosin Heavy Chain 2x | Myosin Heavy Chain IIx/D | Myosin Heavy Chain, Skeletal Muscle, Adult 1 | Myosin, Heavy Chain, IIx/D | Myosin, Skeletal, Heavy Chain, Adult 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814150","MYH2 wt Allele","C112134","Human MYH2 wild-type allele is located in the vicinity of 17p13.1 and is approximately 85 kb in length. This allele, which encodes myosin-2 protein, plays a role in muscle contraction.","MYH2 wt Allele | MHC IIa | MYH2A | MYHC IIa | MYHC2A | MYHSA2 | MYHas8 | MyHC-2A | MyHC-IIa | Myosin, Heavy Chain 2, Skeletal Muscle, Adult wt Allele | Myosin, Heavy Polypeptide 2, Skeletal Muscle, Adult Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815883","Myosin-2","C112135","Myosin-2 (1941 aa, ~223 kDa) is encoded by the human MYH2 gene. This protein is involved in the contraction of skeletal muscles.","Myosin-2 | Fast 2a Myosin Heavy Chain | MyHC-2a | MyHC-IIa | Myosin Heavy Chain 2 | Myosin Heavy Chain 2a | Myosin Heavy Chain IIa | Myosin Heavy Chain, Skeletal Muscle, Adult 2 | Myosin, Heavy Chain, IIa | Myosin, Skeletal, Heavy Chain, Adult 2 | Type IIA Myosin Heavy Chain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0950625","L1CAM protein, human","C112138","Neural cell adhesion molecule L1 (1257 aa, ~140 kDa) is encoded by the human L1CAM gene. This protein plays a role in neurogenesis.","Neural Cell Adhesion Molecule L1 | CD171 | CD171 Antigen | L1-CAM | L1CAM | N-CAM-L1 | NCAM-L1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813711","TAPBP wt Allele","C112140","Human TAPBP wild-type allele is located in the vicinity of 6p21.3 and is approximately 15 kb in length. This allele, which encodes tapasin protein, plays a role in antigen presentation. Variation of the gene is associated with bare lymphocyte syndrome, type I.","TAPBP wt Allele | DADB-159G18.7 | NGS17 | TAP Binding Protein (Tapasin) wt Allele | TAPA | TPN | TPSN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830800","C-SSRS Children's Baseline/Screening - Description of Actual Suicide Attempt","C111407","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Description of actual attempt.","C-SSRS Children's Baseline/Screening - Description of Actual Suicide Attempt | CSS07-Actual Attempt, Describe | CSS0709A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830779","C-SSRS Children's Baseline/Screening - Non-suicidal Self-injurious Behavior","C111408","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Has subject engaged in non-suicidal self-injurious behavior?","C-SSRS Children's Baseline/Screening - Non-suicidal Self-injurious Behavior | CSS07-Non-suicidal Self-injur Behav | CSS0710",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830773","C-SSRS Children's Baseline/Screening - Self-injurious Behavior, Intent Unknown","C111409","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Has subject engaged in self-injurious behavior, intent unknown?","C-SSRS Children's Baseline/Screening - Self-injurious Behavior, Intent Unknown | CSS07-Self-injur Behav, Intent Unknown | CSS0711",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830789","C-SSRS Children's Baseline/Screening - Interrupted Suicide Attempt","C111410","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Has there been a time when you started to do something to make yourself not alive anymore (end your life or kill yourself) but someone or something stopped you before you actually did anything? What did you do?","C-SSRS Children's Baseline/Screening - Interrupted Suicide Attempt | CSS07-Interrupted Attempt | CSS0712",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830776","C-SSRS Children's Baseline/Screening - Number of Interrupted Suicide Attempts","C111411","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Total number of interrupted.","C-SSRS Children's Baseline/Screening - Number of Interrupted Suicide Attempts | CSS07-Number of Interrupt Attempts | CSS0713",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831589","Aguas Buenas Municipio, PR","C110844","No value exists.","Aguas Buenas Municipio, PR | Aguas Buenas Municipio | Aguas Buenas Municipio, Puerto Rico | PR007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831587","Aibonito Municipio, PR","C110845","No value exists.","Aibonito Municipio, PR | Aibonito Municipio | Aibonito Municipio, Puerto Rico | PR009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827263","Anasco Municipio, PR","C110846","No value exists.","Anasco Municipio, PR | Anasco Municipio | Anasco Municipio, Puerto Rico | PR011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831479","Arecibo Municipio, PR","C110847","No value exists.","Arecibo Municipio, PR | Arecibo Municipio | Arecibo Municipio, Puerto Rico | PR013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831473","Arroyo Municipio, PR","C110848","No value exists.","Arroyo Municipio, PR | Arroyo Municipio | Arroyo Municipio, Puerto Rico | PR015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831407","Barranquitas Municipio, PR","C110850","No value exists.","Barranquitas Municipio, PR | Barranquitas Municipio | Barranquitas Municipio, Puerto Rico | PR019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831394","Bayamon Municipio, PR","C110851","No value exists.","Bayamon Municipio, PR | Bayamon Municipio | Bayamon Municipio, Puerto Rico | PR021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831230","Cabo Rojo Municipio, PR","C110852","No value exists.","Cabo Rojo Municipio, PR | Cabo Rojo Municipio | Cabo Rojo Municipio, Puerto Rico | PR023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827299","Caguas Municipio, PR","C110853","No value exists.","Caguas Municipio, PR | Caguas Municipio | Caguas Municipio, Puerto Rico | PR025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831212","Camuy Municipio, PR","C110854","No value exists.","Camuy Municipio, PR | Camuy Municipio | Camuy Municipio, Puerto Rico | PR027",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831207","Canovanas Municipio, PR","C110855","No value exists.","Canovanas Municipio, PR | Canovanas Municipio | Canovanas Municipio, Puerto Rico | PR029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831183","Catano Municipio, PR","C110857","No value exists.","Catano Municipio, PR | Catano Municipio | Catano Municipio, Puerto Rico | PR033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3805220","Marked Baseline Fetal Heart Rate Variability","C111765","A baseline fetal heart rate with an amplitude range that is greater than 25 beats per minute.","Marked Baseline Fetal Heart Rate Variability | Exaggerated Baseline Variability | Hypervariability | Marked Baseline Variability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0455991","Fetal Arrhythmia","C111766","A variation from the normal heart rhythm in a fetus.","Fetal Arrhythmia | ",,,,,,,,,,,,,,,"4172863","Fetal dysrhythmia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3805221","Minimal Baseline Fetal Heart Rate Variability","C111767","A baseline fetal heart rate with a detectable amplitude range that is greater than undetectable but less than or equal to five beats per minute.","Minimal Baseline Fetal Heart Rate Variability | Minimal Baseline Variability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3805063","Sinusoidal Fetal Heart Rate Pattern","C111768","A fetal heart rate pattern characterized by a smooth, sine wave-like undulating pattern with a cycle frequency of 3 to 5 beats per minute that continues for at least 20 minutes or more.","Sinusoidal Fetal Heart Rate Pattern | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830147","Fetal Tachyarrhythmia","C111769","An abnormality in the fetal heart rhythm associated with an increase in fetal heart rate above 160 beats per minute.","Fetal Tachyarrhythmia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830151","Fetal Bradyarrhythmia","C111770","An abnormality in the fetal heart rhythm associated with a decrease in fetal heart rate below 110 beats per minute.","Fetal Bradyarrhythmia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829548","Indeterminate Continuous Cardiotocography Pattern","C111772","Indeterminate fetal heart rate pattern. Not predictive of abnormal acid-base status at time of observation but insufficient to classify pattern as Category I or III. Example patterns include: minimal or marked variability, absent variability without recurrent decelerations, absence of induced accelerations after fetal stimulation, recurrent variable decelerations with minimal or moderate variability, prolonged decelerations, recurrent late decelerations with moderate variability and variable decelerations with slow return to baseline, overshoots or shoulders.","Indeterminate Continuous Cardiotocography Pattern | Category II Tracing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831751","Abnormal Continuous Cardiotocography Pattern","C111773","Abnormal fetal heart rate pattern. Predictive of abnormal acid-base status at time of observation. Patterns include sinusoidal pattern or absent fetal heart rate variability with any of the following: recurrent late decelerations, recurrent variable decelerations, or bradycardia.","Abnormal Continuous Cardiotocography Pattern | Category III Tracing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830150","Fetal Heart Rate Pattern","C111774","The sequence of a fetal heart rhythm and rate.","Fetal Heart Rate Pattern | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828582","Periodic Fetal Heart Rate Pattern","C111775","Fetal heart rate patterns associated with maternal uterine contractions.","Periodic Fetal Heart Rate Pattern | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830310","Episodic Fetal Heart Rate Pattern","C111776","Fetal heart rate patterns not associated with maternal uterine contractions.","Episodic Fetal Heart Rate Pattern | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828993","Moderate Baseline Fetal Heart Rate Variability","C111777","A baseline fetal heart rate with a detectable amplitude range that is greater than or equal to 6 but less than or equal to 25 beats per minute.","Moderate Baseline Fetal Heart Rate Variability | Moderate Baseline Variability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3805223","Recurrent Variable Fetal Heart Rate Deceleration","C111778","Variable decelerations that occur with greater than or equal to 50 percent of uterine contractions. They are usually associated with umbilical cord compression.","Recurrent Variable Fetal Heart Rate Deceleration | Recurrent Variable Deceleration | Recurrent Variable Fetal Heart Rate Decelerations",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2363934","Ductus Venosus Agenesis","C111779","Congenital absence of the fetal ductus venosus.","Ductus Venosus Agenesis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811365","Ashland County, WI","C110737","No value exists.","Ashland County, WI | Ashland County | Ashland County, Wisconsin | WI003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831405","Barron County, WI","C110738","No value exists.","Barron County, WI | Barron County | Barron County, Wisconsin | WI005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831392","Bayfield County, WI","C110739","No value exists.","Bayfield County, WI | Bayfield County | Bayfield County, Wisconsin | WI007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811367","Buffalo County, WI","C110741","No value exists.","Buffalo County, WI | Buffalo County | Buffalo County, Wisconsin | WI011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831241","Burnett County, WI","C110742","No value exists.","Burnett County, WI | Burnett County | Burnett County, Wisconsin | WI013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831219","Calumet County, WI","C110743","No value exists.","Calumet County, WI | Calumet County | Calumet County, Wisconsin | WI015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811368","Chippewa County, WI","C110744","No value exists.","Chippewa County, WI | Chippewa County | Chippewa County, Wisconsin | WI017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811369","Clark County, WI","C110745","No value exists.","Clark County, WI | Clark County | Clark County, Wisconsin | WI019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811371","Crawford County, WI","C110747","No value exists.","Crawford County, WI | Crawford County | Crawford County, Wisconsin | WI023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830607","Dane County, WI","C110748","No value exists.","Dane County, WI | Dane County | Dane County, Wisconsin | WI025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811823","Dodge County, WI","C110749","No value exists.","Dodge County, WI | Dodge County | Dodge County, Wisconsin | WI027",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830401","Door County, WI","C110750","No value exists.","Door County, WI | Door County | Door County, Wisconsin | WI029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL453983","AKT 1/2 Inhibitor BAY1125976","C111575","An orally bioavailable inhibitor of the serine/threonine protein kinase AKT (protein kinase B) isoforms 1 and 2 (AKT1/2) with potential antineoplastic activity. AKT1/2 inhibitor BAY1125976 selectively binds to and inhibits the phosphorylation and activity of AKT1/2 in a non-ATP competitive manner, which may result in the inhibition of the phosphatidylinositol 3 (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway. This may lead to both the reduction of cell proliferation and the induction of cell apoptosis in AKT-overexpressing tumor cells. The AKT signaling pathway is often deregulated in cancer and is associated with tumor cell proliferation, survival and migration.","AKT 1/2 Inhibitor BAY1125976 | BAY-1125976 | BAY1125976",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL453984","fluorine F 18 SKI-249380","C111576","A radioconjugate composed of a derivative of the multi-targeted kinase inhibitor dasatinib conjugated to the radioisotope fluorine F 18, with potential imaging activity during positron emission tomography (PET). Upon administration of fluorine F 18 dasatinib, dasatinib targets and binds to Bcr/Abl, SRC-family protein-tyrosine kinases, c-Kit and platelet-derived growth factor receptor (PDGFR). Upon binding, the fluorine F 18 moiety allows PET imaging of tumor cells and can be used as a tracer for the biodistribution of dasatinib.","Fluorine F 18 Dasatinib | F-SKI249380 | FLUORO-DASATINIB F-18 | Fluorine F 18 SKI-249380 | Fluoro(F18)-Dasatinib | SKI-249380 F-18 | [18F] SKI-249380 | [18F]-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-fluoroethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830616","DAD - Sub-Total Initiation","C111577","Disability Assessment for Dementia (DAD) Sub-total initiation.","DAD - Sub-Total Initiation | DAD01-Sub-Total Initiation | DAD0141",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830614","DAD - Total Initiation Number of Applicable Items","C111578","Disability Assessment for Dementia (DAD) Total initiation number of applicable items.","DAD - Total Initiation Number of Applicable Items | DAD01-Initiation Num Applic Items | DAD0142",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830615","DAD - Sub-Total Planning and Organization","C111579","Disability Assessment for Dementia (DAD) Sub-total planning and organization.","DAD - Sub-Total Planning and Organization | DAD01-Sub-Total Planning & Organization | DAD0143",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1313790","Tapasin, Human","C112141","Tapasin (448 aa, ~48 kDa) is encoded by the human TAPBP gene. This protein is involved in activity of the MHC class I peptide-loading complex.","Tapasin | NGS-17 | TAP-Associated Protein | TAP-Binding Protein | TPN | TPSN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827356","VASP wt Allele","C112143","Human VASP wild-type allele is located in the vicinity of 19q13.32 and is approximately 20 kb in length. This allele, which encodes vasodilator-stimulated phosphoprotein, plays a role in cell adhesion, motility, and regulation of platelet aggregation.","VASP wt Allele | Vasodilator-Stimulated Phosphoprotein wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829257","LRN","C112146","Human LORICRIN wild-type allele is located in the vicinity of 1q21.3 and is approximately 2 kb in length. This allele, which encodes loricrin protein, is involved in the cell envelope structure of mature keratinocytes. Mutations in this gene are associated with progressive symmetric erythrokeratoderma and Vohwinkel syndrome with ichthyosis.","LORICRIN wt Allele | LOR | LOR wt Allele | LRN | Loricrin Cornified Envelope Precursor Protein wt Allele | Loricrin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1457865","Phlebovirus","C112397","A genus of enveloped, spherical shaped viruses with surface glycoproteins that are arranged in a T=12 icosahedral symmetrical lattice, in the family Bunyaviridae. The genome is composed of three linear, segmented single-strands of negative sense RNA.  Phelboviruses are mosquito-borne and humans, ruminants and camels are natural hosts. This genus causes influenza-like illness and rarely hemorrhagic fevers in humans.","Phlebovirus | PHLEBOVIRUS",,,,,,,,,,,,,,,"4307684","Genus Phlebovirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3831176","Cayey Municipio, PR","C110858","No value exists.","Cayey Municipio, PR | Cayey Municipio | Cayey Municipio, Puerto Rico | PR035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831162","Ceiba Municipio, PR","C110859","No value exists.","Ceiba Municipio, PR | Ceiba Municipio | Ceiba Municipio, Puerto Rico | PR037",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831104","Ciales Municipio, PR","C110860","No value exists.","Ciales Municipio, PR | Ciales Municipio | Ciales Municipio, Puerto Rico | PR039",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831102","Cidra Municipio, PR","C110861","No value exists.","Cidra Municipio, PR | Cidra Municipio | Cidra Municipio, Puerto Rico | PR041",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831041","Comerio Municipio, PR","C110863","No value exists.","Comerio Municipio, PR | Comerio Municipio | Comerio Municipio, Puerto Rico | PR045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831007","Corozal Municipio, PR","C110864","No value exists.","Corozal Municipio, PR | Corozal Municipio | Corozal Municipio, Puerto Rico | PR047",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830634","Culebra Municipio, PR","C110865","No value exists.","Culebra Municipio, PR | Culebra Municipio | Culebra Municipio, Puerto Rico | PR049",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830400","Dorado Municipio, PR","C110866","No value exists.","Dorado Municipio, PR | Dorado Municipio | Dorado Municipio, Puerto Rico | PR051",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830262","Fajardo Municipio, PR","C110867","No value exists.","Fajardo Municipio, PR | Fajardo Municipio | Fajardo Municipio, Puerto Rico | PR053",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829927","Guanica Municipio, PR","C110869","No value exists.","Guanica Municipio, PR | Guanica Municipio | Guanica Municipio, Puerto Rico | PR055",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829925","Guayama Municipio, PR","C110870","No value exists.","Guayama Municipio, PR | Guayama Municipio | Guayama Municipio, Puerto Rico | PR057",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829924","Guayanilla Municipio, PR","C110871","No value exists.","Guayanilla Municipio, PR | Guayanilla Municipio | Guayanilla Municipio, Puerto Rico | PR059",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829923","Guaynabo Municipio, PR","C110872","No value exists.","Guaynabo Municipio, PR | Guaynabo Municipio | Guaynabo Municipio, Puerto Rico | PR061",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829917","Gurabo Municipio, PR","C110873","No value exists.","Gurabo Municipio, PR | Gurabo Municipio | Gurabo Municipio, Puerto Rico | PR063",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019064","Hemopericardium","C111644","An accumulation of blood within the pericardial sac.","Hemopericardium | ",,,,,,,,,,,,,,,"258449","Hemopericardium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0340757","Inferior Vena Cava Stenosis","C111645","Abnormal narrowing of the lumen of the inferior vena cava.","Inferior Vena Cava Stenosis | ",,,,,,,,,,,,,,,"4124860","Inferior vena cava stenosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039235","Junctional Ectopic Tachycardia","C111646","A tachycardia originating in or adjacent to the AV junction.","Junctional Ectopic Tachycardia | ",,,,,,,,,,,,,,,"4091899","Junctional ectopic tachycardia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023569","Levocardia","C111647","A condition where the heart is in the correct anatomic position but some or all of the other thoracoabdominal viscera are in the opposite lateral orientation.","Levocardia | LEVOCARDIA",,,,,,,,,,,,,,,"4007736","Situs inversus with levocardia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0344432","Polymorphic Ventricular Tachycardia","C111648","A ventricular tachycardia that is irregular in rate and rhythm.","Polymorphic Ventricular Tachycardia | ",,,,,,,,,,,,,,,"4088349","Ventricular tachycardia, polymorphic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032805","Post-Pericardiotomy Syndrome","C111649","An inflammatory disorder of the pericardium and pleura seen as a post-operative complication of cardiovascular surgery.","Post-Pericardiotomy Syndrome | ",,,,,,,,,,,,,,,"4150305","Post-pericardiotomy syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3544105","Prosthetic Valve Dysfunction","C111650","Malfunction of a surgically-placed cardiac valve related to the valve itself or the area around the valve.","Prosthetic Valve Dysfunction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0061179","Geldanamycin","C1112","A benzoquinone antineoplastic antibiotic isolated from the bacterium Streptomyces hygroscopicus.  Geldanamycin binds to and inhibits the cytosolic chaperone functions of heat shock protein 90 (HSP90).  HSP90 maintains the stability and functional shape of many oncogenic signaling proteins; the inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins that may be over-expressed or overactive in tumor cells. (NCI04)","Geldanamycin | Antibiotic (U-29,135) | Antibiotic U 29135 | GELDANAMYCIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811898","Protocol Summary for Pharmacogenomic Assessments Domain","C111300","A special purpose domain that contains the protocol summary information for pharmacogenomics assessments.","Protocol Summary for Pharmacogenomic Assessments Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033745","Proventriculus","C111301","A portion of the digestive system of birds, insects and invertebrates lying between the crop and the gizzard. It is responsible for the secretion of gastric enzymes and moving food into the gizzard.","Proventriculus | PROVENTRICULUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1048786","Ralstonia mannitolilytica","C111302","A species of xaerobic, gram-negative, rod shaped bacteria assigned to the phylum Proteobacteria. This species is urease, catalase and oxidase positive, does not reduce nitrate and acidifies D-arabitol and mannitol. This species was formerly, incorrectly identified as R. pickettii and is associated with nosocomial infections.","Ralstonia mannitolilytica | Pseudomonas thomasii | RALSTONIA MANNITOLILYTICA | Ralstonia pickettii biovar 3",,,,,,,,,,,,,,,"4216294","Ralstonia mannitolilytica",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828356","Reconstruction of Raw Data Type","C111303","The type of mathematical process used to produce the displayed image from the raw k-space data obtained from the receiver circuitry.","Reconstruction of Raw Data Type | RECONDAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL453740","Scapulohumeral Joint","C111308","The synovial ball and socket joint involving the articulation of the glenoid fossa of the scapula and the head of the humerus.","Scapulohumeral Joint | JOINT, SCAPULOHUMERAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012935","Single-stranded DNA","C111311","A long linear single-stranded polymer formed from nucleotides attached to a deoxyribose backbone.","Single-stranded DNA | SINGLE STRANDED DNA | ssDNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1036499","Slackia exigua","C111313","A species of obligately anaerobic, gram-positive, rod shaped bacteria assigned to the phylum Actinobacteria. This species is non-motile, non-spore forming, indole, urease and catalase negative, non-hemolytic, does not hydrolyze esculin and nitrate is note reduced. S. exigua was previously classified as Eubacterium exiguum.","Slackia exigua | Eubacterium exiguum | SLACKIA EXIGUA",,,,,,,,,,,,,,,"4200621","Slackia exigua",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3830617","DAD - Sub-Total Effective Performance Number of Applicable Items","C111581","Disability Assessment for Dementia (DAD) Sub-total effective performance number of applicable items.","DAD - Sub-Total Effective Performance Number of Applicable Items | DAD01-Effective Perf Num Applic Items | DAD0146",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830611","DAD - Total Score","C111582","Disability Assessment for Dementia (DAD) Total score.","DAD - Total Score | DAD01-Total Score | DAD0147",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830613","DAD - Total Number of Applicable Items","C111583","Disability Assessment for Dementia (DAD) Total number of applicable items.","DAD - Total Number of Applicable Items | DAD01-Total Num of Applic Items | DAD0148",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830612","DAD - Total Percent","C111584","Disability Assessment for Dementia (DAD) DAD total in percent.","DAD - Total Percent | DAD01-Total % | DAD0149",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827703","UPDRS - Motor Examination: Tremor at Rest, Face, Lips, Chin","C111585","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: tremor at rest, face, lips, chin.","UPDRS - Motor Examination: Tremor at Rest, Face, Lips, Chin | UPD1-Motor:Tremor at Rest:Face Lips Chin | UPD120A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827699","UPDRS - Motor Examination: Tremor at Rest, Hands, Right","C111586","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: tremor at rest, hands, right.","UPDRS - Motor Examination: Tremor at Rest, Hands, Right | UPD1-Motor:Tremor at Rest:Hands: Right | UPD120B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827700","UPDRS - Motor Examination: Tremor at Rest, Hands, Left","C111587","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: tremor at rest, hands, Left.","UPDRS - Motor Examination: Tremor at Rest, Hands, Left | UPD1-Motor:Tremor at Rest:Hands: Left | UPD120C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827701","UPDRS - Motor Examination: Tremor at Rest, Feet, Right","C111588","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: tremor at rest, feet, right.","UPDRS - Motor Examination: Tremor at Rest, Feet, Right | UPD1-Motor:Tremor at Rest:Feet: Right | UPD120D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827702","UPDRS - Motor Examination: Tremor at Rest, Feet, Left","C111589","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: tremor at rest, feet, left.","UPDRS - Motor Examination: Tremor at Rest, Feet, Left | UPD1-Motor:Tremor at Rest:Feet: Left | UPD120E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206543","Pneumovirus","C112398","A genus of enveloped, spherical viruses in the family Paramyxoviridae. The genome is composed of a linear single-strand of negative sense RNA.  Pneumoviruses are found in human, cattle and rodents and cause disease of the respiratory tract in humans.","Pneumovirus | PNEUMOVIRUS",,,,,,,,,,,,,,,"4309211","Genus Pneumovirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0062540","Hepsulfam","C1123","A bisulfamic ester which is similar in structure to busulfan and belongs to the family of drugs known as alkylsulfonate alkylating agents.  Hepsulfam forms covalent linkages with nucleophilic centers in DNA, resulting in depurination, base miscoding, strand scission, DNA-DNA and DNA-protein cross-linking, and cytotoxicity. (NCI04)","Hepsulfam | 1,7-Heptanediyl Ester Sulfamic Acid | HEPSULFAM | Sulfamic acid, 1,7-heptanediyl ester",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030531","Pseudocowpox Virus","C112401","A species of viruses in the Poxviridae family and Parapoxvirus genus. Pseudocowpox viruses are mainly found in cattle and cause mild sores on cow teats and udders. Pseudocowpox viruses can also infect humans via direct contact with infected dairy cattle during the milking process, and cause the skin disease milker's nodule.","Pseudocowpox Virus | PSEUDOCOWPOX VIRUS | Paravaccinia virus | Pseudocowpoxvirus",,,,,,,,,,,,,,,"4209576","Pseudocowpox virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829086","MHIS-NACC - Emotional Incontinence","C112620","Modified Hachinski Ischemic Scale-NACC Version (MHIS-NACC) Emotional incontinence.","MHIS-NACC - Emotional Incontinence | MHIS01-Emotional Incontinence | MHIS0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829082","MHIS-NACC - History or Presence of Hypertension","C112621","Modified Hachinski Ischemic Scale-NACC Version (MHIS-NACC) History or presence of hypertension.","MHIS-NACC - History or Presence of Hypertension | MHIS01-History or Presence Hypertension | MHIS0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829083","MHIS-NACC - History of Stroke","C112622","Modified Hachinski Ischemic Scale-NACC Version (MHIS-NACC) History of stroke.","MHIS-NACC - History of Stroke | MHIS01-History of Stroke | MHIS0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829084","MHIS-NACC - Focal Neurological Symptoms","C112623","Modified Hachinski Ischemic Scale-NACC Version (MHIS-NACC) Focal neurological symptoms.","MHIS-NACC - Focal Neurological Symptoms | MHIS01-Focal Neurological Symptoms | MHIS0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829085","MHIS-NACC - Focal Neurological Signs","C112624","Modified Hachinski Ischemic Scale-NACC Version (MHIS-NACC) Focal neurological signs.","MHIS-NACC - Focal Neurological Signs | MHIS01-Focal Neurological Signs | MHIS0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829078","MHIS-NACC - Total Score","C112625","Modified Hachinski Ischemic Scale-NACC Version (MHIS-NACC) Sum all circled answers for a total score.","MHIS-NACC - Total Score | MHIS01-Total Score | MHIS0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828630","PDDS - Category Describing Situation","C112626","Patient Determined Disease Steps (PDDS) This scale focuses mainly on how well you walk. You might not find a description that reflects your condition exactly, but please mark the one category that describes your situation the closest.","PDDS - Category Describing Situation | PDDS01-Category Describing Situation | PDDS0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3805222","Pulmonary Vein Obstruction","C111651","Blockage of the lumen of the pulmonary vein.","Pulmonary Vein Obstruction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1142175","Vascular Shunt Thrombosis","C111652","The presence of a thrombus within a vascular shunt.","Vascular Shunt Thrombosis | Shunt Thrombosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0340758","Superior Vena Cava Stenosis","C111653","Abnormal narrowing of the lumen of the superior vena cava.","Superior Vena Cava Stenosis | ",,,,,,,,,,,,,,,"4124861","Superior vena cava stenosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0340726","Venous Embolism","C111654","The passage of an embolus from its site of formation to another location within the venous system.","Venous Embolism | ",,,,,,,,,,,,,,,"318775","Venous embolism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242973","Ventricular Dysfunction","C111655","Impairment of the ventricle to either fill or eject adequately.","Ventricular Dysfunction | Ventricular functional abnormalities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0231246","Poor Weight Gain","C111659","Slower than normal rate of weight increase.","Poor Weight Gain | Failure to Gain Weight | Inadequate Weight Gain | Low Weight Gain",,,,,,,,,,,,,,,"4270276","Failure to gain weight",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3827910","SPL Equivalence Codes Terminology","C111660","Terminology used for representation of the information on pharmaceutical product equivalence codes in the framework of the Structured Product Labeling documents.","SPL Equivalence Codes Terminology | Equivalence Codes | Structured Product Labeling Equivalence Codes Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827911","SPL Contributing Factor-General Terminology","C111661","Terminology used for representation of the information on pharmaceutical product contributing factors in the framework of the Structured Product Labeling documents.","SPL Contributing Factor-General Terminology | Structured Product Labeling Contributing Factor-General Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0751969","Small Nucleolar RNA","C111316","Small RNA molecules that are present in the nucleolus. They associate with proteins to form small nucleolar ribonucleoprotein particles that are involved in modification of other RNAs.","Small Nucleolar RNA | SMALL NUCLEOLAR RNA | snoRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827385","Petersburg City, VA","C110629","No value exists.","Petersburg City, VA | Petersburg City | Petersburg City, Virginia | VA730",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828514","Poquoson City, VA","C110630","No value exists.","Poquoson City, VA | Poquoson City | Poquoson City, Virginia | VA735",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828512","Portsmouth City, VA","C110631","No value exists.","Portsmouth City, VA | Portsmouth City | Portsmouth City, Virginia | VA740",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828418","Radford City, VA","C110632","No value exists.","Radford City, VA | Radford City | Radford City, Virginia | VA750",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828317","Roanoke City, VA","C110634","No value exists.","Roanoke City, VA | Roanoke City | Roanoke City, Virginia | VA770",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828274","Salem City, VA","C110635","No value exists.","Salem City, VA | Salem City | Salem City, Virginia | VA775",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827948","Staunton City, VA","C110636","No value exists.","Staunton City, VA | Staunton City | Staunton City, Virginia | VA790",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827901","Suffolk City, VA","C110637","No value exists.","Suffolk City, VA | Suffolk City | Suffolk City, Virginia | VA800",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827323","Virginia Beach City, VA","C110638","No value exists.","Virginia Beach City, VA | VA810 | Virginia Beach City | Virginia Beach City, Virginia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827460","Williamsburg City, VA","C110640","No value exists.","Williamsburg City, VA | VA830 | Williamsburg City | Williamsburg City, Virginia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827458","Winchester City, VA","C110641","No value exists.","Winchester City, VA | VA840 | Winchester City | Winchester City, Virginia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811635","Adams County, WA","C110642","No value exists.","Adams County, WA | Adams County | Adams County, Washington | WA001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831463","Asotin County, WA","C110643","No value exists.","Asotin County, WA | Asotin County | Asotin County, Washington | WA003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816739","Benton County, WA","C110644","No value exists.","Benton County, WA | Benton County | Benton County, Washington | WA005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831094","Clallam County, WA","C110646","No value exists.","Clallam County, WA | Clallam County | Clallam County, Washington | WA009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815507","Clark County, WA","C110647","No value exists.","Clark County, WA | Clark County | Clark County, Washington | WA011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812187","Columbia County, WA","C110648","No value exists.","Columbia County, WA | Columbia County | Columbia County, Washington | WA013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830991","Cowlitz County, WA","C110649","No value exists.","Cowlitz County, WA | Cowlitz County | Cowlitz County, Washington | WA015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830152","Ferry County, WA","C110651","No value exists.","Ferry County, WA | Ferry County | Ferry County, Washington | WA019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814013","Franklin County, WA","C110652","No value exists.","Franklin County, WA | Franklin County | Franklin County, Washington | WA021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814500","Garfield County, WA","C110653","No value exists.","Garfield County, WA | Garfield County | Garfield County, Washington | WA023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1036498","Slackia","C111098","A genus of obligate anaerobic, Gram positive, cocci, coccobacilli or short bacilli shaped bacterium assigned to the phylum Actinobacteria and the family Coriobacteriaceae.","Slackia | ",,,,,,,,,,,,,,,"4161131","Slackia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828129","SGRQ Past 3 Months Version - Describe Your Current Health","C112627","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) Please check one box to show how you describe your current health.","SGRQ Past 3 Months Version - Describe Your Current Health | SGRQ01-Describe Your Current Health | SGRQ0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828115","SGRQ Past 3 Months Version - I Have Coughed","C112628","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) Over the past 3 months, I have coughed.","SGRQ Past 3 Months Version - I Have Coughed | SGRQ01-I Have Coughed | SGRQ0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828116","SGRQ Past 3 Months Version - I Have Brought Up Phlegm","C112629","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) Over the past 3 months, I have brought up phlegm (sputum).","SGRQ Past 3 Months Version - I Have Brought Up Phlegm | SGRQ01-I Have Brought Up Phlegm | SGRQ0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828113","SGRQ Past 3 Months Version - I Have Had Wheezing Attacks","C112631","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) Over the past 3 months, I have had wheezing attacks.","SGRQ Past 3 Months Version - I Have Had Wheezing Attacks | SGRQ01-I Have Had Wheezing Attacks | SGRQ0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828102","SGRQ Past 3 Months Version - Times Suffered From Severe Respiratory Attacks","C112632","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) How many times during the past 3 months have you suffered from severe or very unpleasant respiratory attacks?","SGRQ Past 3 Months Version - Times Suffered From Severe Respiratory Attacks | SGRQ01-Times Suffered Sev Resp Attacks | SGRQ0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828122","SGRQ Past 3 Months Version - How Long Did Worst Respiratory Attack Last","C112633","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) How long did the worst respiratory attack last?","SGRQ Past 3 Months Version - How Long Did Worst Respiratory Attack Last | SGRQ01-How Long Worst Resp Attack Last | SGRQ0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828121","SGRQ Past 3 Months Version - How Many Good Days You Had","C112634","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) Over the past 3 months, in a typical week, how many good days (with few respiratory problems) have you had?","SGRQ Past 3 Months Version - How Many Good Days You Had | SGRQ01-How Many Good Days Have You Had | SGRQ0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811116","RNF130 wt Allele","C111932","Human RNF130 wild-type allele is located in the vicinity of 5q35.3 and is approximately 153 kb in length. This allele, which encodes E3 ubiquitin-protein ligase RNF130 protein, plays a role in protein ubiquitylation. A fusion of this gene and the BRAF gene may be associated with pilocytic astrocytoma.","RNF130 wt Allele | G1RP | G1RZFP | GOLIATH | GP | Ring Finger Protein 130 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1723424","E3 Ubiquitin-Protein Ligase RNF130, Human","C111933","E3 ubiquitin-protein ligase RNF130 (419 aa, ~46 kDa) is encoded by the human RNF130 gene. This protein is involved in post-translational protein ubiquitination.","E3 Ubiquitin-Protein Ligase RNF130 | EC 2.3.2.27 | EC 6.3.2.-, Formerly | G1-Related Protein | G1-Related Zinc Finger Protein | Goliath | Goliath Homolog | H-Goliath | Ring Finger Protein 130",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417177","MKRN1 Gene","C111934","This gene is involved in ubiquitylation.","MKRN1 Gene | MKRN1 | Makorin Ring Finger Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814148","MKRN1 wt Allele","C111935","Human MKRN1 wild-type allele is located in the vicinity of 7q34 and is approximately 27 kb in length. This allele, which encodes E3 ubiquitin-protein ligase makorin-1 protein, plays a role in post-translational protein ubiquitination. A fusion of this gene and the BRAF gene may be associated with pilocytic astrocytoma.","MKRN1 wt Allele | Makorin Ring Finger Protein 1 wt Allele | RING Finger Protein 61 Gene | RNF61",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0915691","Makorin ring finger protein 1","C111936","E3 ubiquitin-protein ligase makorin-1 (482 aa, ~53 kDa) is encoded by the human MKRN1 gene. This protein is involved in the ubiquitination of proteins that regulate both cell survival and gene expression.","E3 Ubiquitin-Protein Ligase Makorin-1 | EC 2.3.2.27 | EC 6.3.2.-, Formerly | Makorin 1 | Makorin Ring Finger Protein 1 | Makorin-1 | RING Finger Protein 61",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226919","Cheek Pouch","C111156","An evagination of the oral mucosa within the cheek of some mammals, which forms a pocket.","Cheek Pouch | CHEEK POUCH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0441474","Chemical Ablation","C111157","Removal, separation, detachment, extirpation, or eradication of a body part, pathway, or function by chemical means.","Chemical Ablation | ABLATION, CHEMICAL",,,,,,,,,,,,,,,"4117508","Chemical destruction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242962","Chloroplast DNA","C111158","The DNA that is located in the photosynthetic, chlorophyll-containing organelle in the cells of young leaves and stems of higher plants.","Chloroplast DNA | cpDNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010352","Avian crop","C111162","A saccular diverticulum of the esophagus in bird species that is used for food storage prior to digestion.","Crop | CROP | Ingluvies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830799","C-SSRS Children's Baseline/Screening - Description of Interrupted Suicide Attempt","C111412","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Description of interrupted attempt.","C-SSRS Children's Baseline/Screening - Description of Interrupted Suicide Attempt | CSS07-Interrupted Attempt, Describe | CSS0713A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830813","C-SSRS Children's Baseline/Screening - Aborted Suicide Attempt","C111413","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Has there been a time when you started to do something to make yourself not alive anymore (end your life or kill yourself) but you changed your mind (stopped yourself) before you actually did anything? What did you do?","C-SSRS Children's Baseline/Screening - Aborted Suicide Attempt | CSS07-Aborted Attempt | CSS0714",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829945","Grays Harbor County, WA","C110655","No value exists.","Grays Harbor County, WA | Grays Harbor County | Grays Harbor County, Washington | WA027",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816730","Jefferson County, WA","C110657","No value exists.","Jefferson County, WA | Jefferson County | Jefferson County, Washington | WA031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816458","King County, WA","C110658","No value exists.","King County, WA | King County | King County, Washington | WA033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829375","Kitsap County, WA","C110659","No value exists.","Kitsap County, WA | Kitsap County | Kitsap County, Washington | WA035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830844","C-SSRS Children's Baseline - Actual Suicide Attempt","C111541","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Did you ever do anything to try to kill yourself or make yourself not alive anymore? What did you do? Did you ever hurt yourself on purpose? Why did you do that?","C-SSRS Children's Baseline - Actual Suicide Attempt | CSS06-Actual Attempt | CSS0608",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830817","C-SSRS Children's Baseline - Number of Actual Suicide Attempts","C111542","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Total number of actual attempts.","C-SSRS Children's Baseline - Number of Actual Suicide Attempts | CSS06-Number of Actual Attempts | CSS0609",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830819","C-SSRS Children's Baseline - Non-suicidal Self-injurious Behavior","C111544","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Has subject engaged in non-suicidal self-injurious behavior?","C-SSRS Children's Baseline - Non-suicidal Self-injurious Behavior | CSS06-Non-suicidal Self-injurious Behav | CSS0610",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830769","C-SSRS Children's Baseline - Self-injurious Behavior, Intent Unknown","C111545","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Has subject engaged in self-injurious behavior, intent unknown?","C-SSRS Children's Baseline - Self-injurious Behavior, Intent Unknown | CSS06-Self-injur Behav, Intent Unknown | CSS0611",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830828","C-SSRS Children's Baseline - Interrupted Suicide Attempt","C111546","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Has there been a time when you started to do something to make yourself not alive anymore (end your life or kill yourself) but someone or something stopped you before you actually did anything? What did you do?","C-SSRS Children's Baseline - Interrupted Suicide Attempt | CSS06-Interrupted Attempt | CSS0612",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830816","C-SSRS Children's Baseline - Number of Interrupted Suicide Attempts","C111547","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Total number of interrupted.","C-SSRS Children's Baseline - Number of Interrupted Suicide Attempts | CSS06-Number of Interrupt Attempts | CSS0613",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830837","C-SSRS Children's Baseline - Description of Interrupted Suicide Attempt","C111548","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Description of interrupted attempt.","C-SSRS Children's Baseline - Description of Interrupted Suicide Attempt | CSS06-Interrupted Attempt, Describe | CSS0613A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830848","C-SSRS Children's Baseline - Aborted Suicide Attempt","C111549","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Has there been a time when you started to do something to make yourself not alive anymore (end your life or kill yourself) but you changed your mind (stopped yourself) before you actually did anything? What did you do?","C-SSRS Children's Baseline - Aborted Suicide Attempt | CSS06-Aborted Attempt | CSS0614",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830818","C-SSRS Children's Baseline - Number of Aborted Suicide Attempts","C111550","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Total number of aborted.","C-SSRS Children's Baseline - Number of Aborted Suicide Attempts | CSS06-Number of Aborted Attempts | CSS0615",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811837","Douglas County, WI","C110751","No value exists.","Douglas County, WI | Douglas County | Douglas County, Wisconsin | WI031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810527","Dunn County, WI","C110752","No value exists.","Dunn County, WI | Dunn County | Dunn County, Wisconsin | WI033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814822","QKI wt Allele","C111938","Human QKI wild-type allele is located in the vicinity of 6q26 and is approximately 165 kb in length. This allele, which encodes protein quaking, plays a role in mRNA biosynthesis, mRNA splicing, mRNA stabilization, oligodendrocyte differentiation and myelination. A fusion of this gene and the NTRK2 gene may be associated with non-cerebellar pilocytic astrocytoma.","QKI wt Allele | HKQ | Hqk | QK | QK1 | QK3 | QKI, KH Domain Containing, RNA Binding wt Allele | Quaking Homolog, KH Domain RNA Binding (Mouse) Gene | Quaking, Mouse, Homolog of Gene | hqkI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828457","Protein Quaking","C111939","Protein quaking (341 aa, ~38 kDa) is encoded by the human QKI gene. This protein is involved in mRNA biosynthesis, mRNA splicing, mRNA stabilization and protein translation.","Protein Quaking | Homolog Of Mouse Quaking QKI (KH Domain RNA Binding Protein) | Quaking Homolog, KH Domain RNA Binding | RNA Binding Protein HQK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428294","NACC2 Gene","C111940","This gene plays a role in the modulation of cell proliferation.","NACC2 Gene | NACC Family Member 2 Gene | NACC2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812663","NACC2 wt Allele","C111941","Human NACC2 wild-type allele is located in the vicinity of 9q34.3 and is approximately 89 kb in length. This allele, which encodes nucleus accumbens-associated protein 2, is involved in the regulation of cell proliferation. A fusion of this gene and the NTRK2 gene may be associated with non-cerebellar pilocytic astrocytoma.","NACC2 wt Allele | BEND9 | BTB (POZ) Domain Containing 14A Gene | BTBD14 | BTBD14A | BTBD31 | MGC23427 | NACC Family Member 2 wt Allele | NACC Family Member 2, BEN and BTB (POZ) Domain Containing Gene | NACC Family Member 2, BEN and BTB/POZ Domains-Containing Gene | RBB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816960","Nucleus Accumbens-Associated Protein 2","C111942","Nucleus accumbens-associated protein 2 (587 aa, ~63 kDa) is encoded by the human NACC2 gene. This protein plays a role in the regulation of both cell proliferation and mitosis.","Nucleus Accumbens-Associated Protein 2 | BEN Domain Containing 9 | BTB/POZ Domain-Containing Protein 14A | NAC-2 | NACC2 | Repressor with BTB Domain and BEN Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831078","Clinical Chorioamnionitis","C111943","Inflammation of the fetal sac membranes, characterized by otherwise unexplained fever (at or above 38 degree C (100.4F)) with one or more of the following: uterine tenderness and/or irritability, leukocytosis, fetal tachycardia, maternal tachycardia, or malodorous vaginal discharge.","Clinical Chorioamnionitis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3875499","Histologic Chorioamnionitis","C111944","Inflammation of the fetal sac membranes that is characterized by neutrophilic infiltration of the amnion and chorion.","Histologic Chorioamnionitis | Acute Amnionitis | Acute Chorioamnionitis | Acute Choriodeciduitis | Acute Chorionitis | Microscopic Chorioamnionitis",,,,,,,,,,,,,,,"45766910","Acute chorioamnionitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0235842","Deciduitis","C111945","Acute inflammation characterized by neutrophilic infiltration of the decidua.","Deciduitis | ",,,,,,,,,,,,,,,"4327175","Decidual endometritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0083258","loricrin","C112147","Loricrin (312 aa, 26 kDa) is encoded by the human LORICRIN gene. This protein plays a role in the cell envelope structure of terminally differentiated epidermal cells.","Loricrin | LOR | Loricrin Cornified Envelope Precursor Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815267","FLG wt Allele","C112149","Human FLG wild-type allele is located in the vicinity of 1q21.3 and is approximately 23 kb in length. This allele, which encodes filaggrin protein, plays a role in promoting disulfide-bond formation in intermediate filaments. Mutations in this gene are associated with ichthyosis vulgaris and with susceptibility to atopic dermatitis type 2.","FLG wt Allele | ATOD2 | Filaggrin wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1399375","Filaggrin","C112150","Filaggrin (4061 aa, ~435 kDa) is encoded by the human FLG gene. This protein is involved in the structure of intermediate filaments.","Filaggrin | Epidermal Filaggrin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830778","C-SSRS Children's Baseline/Screening - Number of Aborted Suicide Attempts","C111414","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Total number of aborted.","C-SSRS Children's Baseline/Screening - Number of Aborted Suicide Attempts | CSS07-Number of Aborted Attempts | CSS0715",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830804","C-SSRS Children's Baseline/Screening - Description of Aborted Suicide Attempt","C111415","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Description of aborted attempt.","C-SSRS Children's Baseline/Screening - Description of Aborted Suicide Attempt | CSS07-Aborted Attempt, Describe | CSS0715A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830775","C-SSRS Children's Baseline/Screening - Preparatory Acts or Behaviors Toward Suicide Attempt","C111416","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Have you done anything to get ready to make yourself not alive anymore (to end your life or kill yourself) - like giving things away, writing a goodbye note, getting things you need to kill yourself?","C-SSRS Children's Baseline/Screening - Preparatory Acts or Behaviors Toward Suicide Attempt | CSS07-Preparatory Acts/Behavior | CSS0716",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830772","C-SSRS Children's Baseline/Screening - Suicidal Behavior","C111418","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Suicidal behavior was present during the assessment period?","C-SSRS Children's Baseline/Screening - Suicidal Behavior | CSS07-Suicidal Behavior | CSS0717",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830784","C-SSRS Children's Baseline/Screening - Most Recent Suicide Attempt Date","C111419","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Most recent attempt date.","C-SSRS Children's Baseline/Screening - Most Recent Suicide Attempt Date | CSS07-Most Recent Attempt Date | CSS0718A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830785","C-SSRS Children's Baseline/Screening - Most Recent Suicide Attempt Actual Lethality/Medical Damage","C111420","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Most recent attempt actual lethality/medical damage.","C-SSRS Children's Baseline/Screening - Most Recent Suicide Attempt Actual Lethality/Medical Damage | CSS07-Most Recent Attempt Damage | CSS0718B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830787","C-SSRS Children's Baseline/Screening - Most Lethal Suicide Attempt Date","C111422","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Most lethal attempt date.","C-SSRS Children's Baseline/Screening - Most Lethal Suicide Attempt Date | CSS07-Most Lethal Attempt Date | CSS0719A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830788","C-SSRS Children's Baseline/Screening - Most Lethal Suicide Attempt Actual Lethality/Medical Damage","C111423","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Most lethal attempt actual lethality/medical damage.","C-SSRS Children's Baseline/Screening - Most Lethal Suicide Attempt Actual Lethality/Medical Damage | CSS07-Most Lethal Attempt Damage | CSS0719B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830786","C-SSRS Children's Baseline/Screening - Most Lethal Suicide Attempt Potential Lethality","C111424","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Most lethal attempt potential lethality.","C-SSRS Children's Baseline/Screening - Most Lethal Suicide Attempt Potential Lethality | CSS07-Most Lethal Attempt Potential | CSS0719C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830794","C-SSRS Children's Baseline/Screening - First Suicide Attempt Date","C111425","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Initial/first attempt date.","C-SSRS Children's Baseline/Screening - First Suicide Attempt Date | CSS07-First Attempt Date | CSS0720A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829818","Hatillo Municipio, PR","C110874","No value exists.","Hatillo Municipio, PR | Hatillo Municipio | Hatillo Municipio, Puerto Rico | PR065",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829597","Humacao Municipio, PR","C110876","No value exists.","Humacao Municipio, PR | Humacao Municipio | Humacao Municipio, Puerto Rico | PR069",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829498","Isabela Municipio, PR","C110877","No value exists.","Isabela Municipio, PR | Isabela Municipio | Isabela Municipio, Puerto Rico | PR071",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830842","C-SSRS Children's Baseline - Description of Aborted Suicide Attempt","C111551","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Description of aborted attempt.","C-SSRS Children's Baseline - Description of Aborted Suicide Attempt | CSS06-Aborted Attempt, Describe | CSS0615A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830815","C-SSRS Children's Baseline - Preparatory Acts or Behaviors Toward Suicide Attempt","C111552","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Have you done anything to get ready to make yourself not alive anymore (to end your life or kill yourself) - like giving things away, writing a goodbye note, getting things you need to kill yourself?","C-SSRS Children's Baseline - Preparatory Acts or Behaviors Toward Suicide Attempt | CSS06-Preparatory Acts/Behavior | CSS0616",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830835","C-SSRS Children's Baseline - Description of Preparatory Acts or Behaviors Toward Suicide Attempt","C111553","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Description of preparatory acts or behaviors.","C-SSRS Children's Baseline - Description of Preparatory Acts or Behaviors Toward Suicide Attempt | CSS06-Preparatory Acts/Behavior, Descr | CSS0616A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830768","C-SSRS Children's Baseline - Suicidal Behavior","C111554","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Suicidal behavior was present during the assessment period?","C-SSRS Children's Baseline - Suicidal Behavior | CSS06-Suicidal Behavior | CSS0617",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL453547","Zirconium Zr 89 Df-IAB2M","C111040","A radioimmunoconjugate comprised of an antibody fragment (IAB2M) against prostate-specific membrane antigen (PSMA), conjugated to the chelator desferrioxamine (Df) and labeled with the radioisotope zirconium Zr 89, with potential positron emission tomography (PET) imaging activity. Upon administration of zirconium Zr 89 Df-IAB2M, the antibody moiety binds to the extracellular domain of PSMA expressed on cancer cells. This may enable PET detection of the radioisotope moiety, and allows the imaging and quantification of PSMA-expressing tumor cells. PSMA is a cell surface peptidase highly expressed by malignant prostate epithelial cells and vascular endothelial cells in various solid tumor malignancies.","Zirconium Zr 89 Df-IAB2M | [89Zr]Df-IAB2M",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL453548","Anti-CD19-CAR FMC63-28Z Retroviral Vector-transduced Allogeneic T-lymphocytes","C111041","Allogeneic T-lymphocytes derived from peripheral blood mononuclear cells (PBMC) transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) consisting of both the light and heavy chain variable regions of anti-CD19 monoclonal antibody FMC63, coupled to the molecule CD28 and the signaling domain of the zeta chain of the T-cell receptor (TCR) (FMC63-28Z), with potential immunomodulating and antineoplastic activities. Upon transfusion, the anti-CD19-CAR FMC63-28Z retroviral vector-transduced allogeneic T lymphocytes specifically recognize and kill CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen, which is expressed in all B-cell lineage malignancies and normal B-cells.","Anti-CD19-CAR FMC63-28Z Retroviral Vector-transduced Allogeneic T-lymphocytes | FMC63-28Z CAR-transduced Allogeneic T-lymphocytes | MSGV1-FMC63-28Z Anti-CD19 CAR-transduced Allogeneic T-lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1957161","JAK2 inhibitor WP1066","C111042","An orally bioavailable, small molecule inhibitor of signaling transducer and activator 3 (STAT3), with potential antineoplastic and immunomodulatory activities. Upon administration, STAT3 inhibitor WP1066 blocks the intranuclear translocation of p-STAT, thereby suppressing STAT3 signaling and decreasing the levels of downstream products including c-Myc. Additionally, WP1066 may upregulate costimulatory molecules including CD80 and CD86 on human microglia, and reverse glioma cancer stem cell (gCSC)-mediated innate and adaptive immune suppression allowing for the restoration of antitumor effector immune responses. The STAT3 pathway is overly active in many cancer types and is implicated in CSC-mediated growth, recurrence and resistance to conventional chemotherapies.","STAT3 Inhibitor WP1066 | (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide | WP 1066 | WP-1066 | WP1066",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830353","Eau Claire County, WI","C110753","No value exists.","Eau Claire County, WI | Eau Claire County | Eau Claire County, Wisconsin | WI035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830089","Fond du Lac County, WI","C110755","No value exists.","Fond du Lac County, WI | Fond du Lac County | Fond du Lac County, Wisconsin | WI039",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814002","Forest County, WI","C110756","No value exists.","Forest County, WI | Forest County | Forest County, Wisconsin | WI041",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813974","Grant County, WI","C110757","No value exists.","Grant County, WI | Grant County | Grant County, Wisconsin | WI043",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813996","Green County, WI","C110758","No value exists.","Green County, WI | Green County | Green County, Wisconsin | WI045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829942","Green Lake County, WI","C110759","No value exists.","Green Lake County, WI | Green Lake County | Green Lake County, Wisconsin | WI047",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816177","Iron County, WI","C110761","No value exists.","Iron County, WI | Iron County | Iron County, Wisconsin | WI051",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810763","Jackson County, WI","C110762","No value exists.","Jackson County, WI | Jackson County | Jackson County, Wisconsin | WI053",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810781","Jefferson County, WI","C110763","No value exists.","Jefferson County, WI | Jefferson County | Jefferson County, Wisconsin | WI055",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829444","Juneau County, WI","C110764","No value exists.","Juneau County, WI | Juneau County | Juneau County, Wisconsin | WI057",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829403","Kewaunee County, WI","C110766","No value exists.","Kewaunee County, WI | Kewaunee County | Kewaunee County, Wisconsin | WI061",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829349","La Crosse County, WI","C110767","No value exists.","La Crosse County, WI | La Crosse County | La Crosse County, Wisconsin | WI063",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813633","Lafayette County, WI","C110768","No value exists.","Lafayette County, WI | Lafayette County | Lafayette County, Wisconsin | WI065",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829335","Langlade County, WI","C110769","No value exists.","Langlade County, WI | Langlade County | Langlade County, Wisconsin | WI067",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815580","Lincoln County, WI","C110770","No value exists.","Lincoln County, WI | Lincoln County | Lincoln County, Wisconsin | WI069",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829203","Marathon County, WI","C110772","No value exists.","Marathon County, WI | Marathon County | Marathon County, Wisconsin | WI073",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829195","Marinette County, WI","C110773","No value exists.","Marinette County, WI | Marinette County | Marinette County, Wisconsin | WI075",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811189","Marquette County, WI","C110774","No value exists.","Marquette County, WI | Marquette County | Marquette County, Wisconsin | WI077",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813186","Menominee County, WI","C110775","No value exists.","Menominee County, WI | Menominee County | Menominee County, Wisconsin | WI078",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829064","Milwaukee County, WI","C110776","No value exists.","Milwaukee County, WI | Milwaukee County | Milwaukee County, Wisconsin | WI079",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828733","Oconto County, WI","C110778","No value exists.","Oconto County, WI | Oconto County | Oconto County, Wisconsin | WI083",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812741","Oneida County, WI","C110779","No value exists.","Oneida County, WI | Oneida County | Oneida County, Wisconsin | WI085",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828684","Outagamie County, WI","C110780","No value exists.","Outagamie County, WI | Outagamie County | Outagamie County, Wisconsin | WI087",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828676","Ozaukee County, WI","C110781","No value exists.","Ozaukee County, WI | Ozaukee County | Ozaukee County, Wisconsin | WI089",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810565","KRT10 wt Allele","C112152","Human KRT10 wild-type allele is located in the vicinity of 17q21 and is approximately 4 kb in length. This allele, which encodes keratin, type I cytoskeletal 10 protein, is involved in the intermediate filament structure of terminally differentiated epidermal cells. Mutations in this gene are associated with epidermolytic hyperkeratosis, ichthyosis with confetti, and cyclic ichthyosis with epidermolytic hyperkeratosis.","KRT10 wt Allele | BCIE | BIE | CK-10 | CK10 | EHK | Epidermolytic Hyperkeratosis Gene | K10 | KPP | Keratin 10 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0170518","Keratin-10","C112153","Keratin, type I cytoskeletal 10 (584 aa, ~59 kDa) is encoded by the human KRT10 gene. This protein plays a role in the structure of intermediate filaments.","Keratin, Type I Cytoskeletal 10 | Cytokeratin 10 | Cytokeratin-10 | KRT10 | Keratin-10 | Keratosis Palmaris Et Plantaris",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813549","C1GALT1 wt Allele","C112155","Human C1GALT1 wild-type allele is located in the vicinity of 7p21.3 and is approximately 92 kb in length. This allele, which encodes glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 protein, plays a role in mucin-type O-glycan metabolism.","C1GALT1 wt Allele | C1GALT | Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine 3-beta-Galactosyltransferase, 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1621701","Glycoprotein-N-Acetylgalactosamine 3-beta-Galactosyltransferase 1, Human","C112156","Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (363 aa, ~42 kDa) is encoded by the human C1GALT1 gene. This protein is involved in mucin-type O-glycan metabolism.","Glycoprotein-N-Acetylgalactosamine 3-Beta-Galactosyltransferase 1 | B3Gal-T8 | Beta-1,3-Galactosyltransferase | C1GALT1 | Core 1 Beta1,3-Galactosyltransferase 1 | Core 1 Beta3-Gal-T | Core 1 Beta3-Gal-T1 | Core 1 O-Glycan T-Synthase | Core 1 UDP-Galactose:N-Acetylgalactosamine-Alpha-R Beta 1,3-Galactosyltransferase 1 | EC 2.4.1.122 | T Synthase | T-Synthase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812675","C1GALT1C1 wt Allele","C112158","Human C1GALT1C1 wild-type allele is located in the vicinity of Xq24 and is approximately 4 kb in length. This allele, which encodes C1GALT1-specific chaperone 1 protein, plays a chaperone role in mucin-type O-glycan metabolism. Mutations in this gene are associated with somatic Tn polyagglutination syndrome.","C1GALT1C1 wt Allele | C1GALT1-Specific Chaperone 1 wt Allele | C1GALT2 | C1Gal-T2 | C38H2-L1 | COSMC | MST143 | TNPS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812673","C1GALT1-Specific Chaperone 1","C112159","C1GALT1-specific chaperone 1 (318 aa, ~36 kDa) is encoded by the human C1GALT1C1 gene. This protein plays a chaperone role in mucin-type O-glycan metabolism.","C1GALT1-Specific Chaperone 1 | Beta 1,3-Galactosyltransferase 2 | C1GALT1C1 | C38H2-Like Protein 1 | Core 1 Beta-3-Galactosyltransferase-Specific Molecular Chaperone | Core 1 Beta1,3-Galactosyltransferase 2 | Core 1 Beta3-Gal-T2 | Core 1 Beta3-Galactosyltransferase-Specific Molecular Chaperone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827742","Type 0: Not a Combination Product","C112160","A designation assigned when a product is not manufactured as a combination product.","Type 0: Not a Combination Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829464","Jayuya Municipio, PR","C110878","No value exists.","Jayuya Municipio, PR | Jayuya Municipio | Jayuya Municipio, Puerto Rico | PR073",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829449","Juana Diaz Municipio, PR","C110879","No value exists.","Juana Diaz Municipio, PR | Juana Diaz Municipio | Juana Diaz Municipio, Puerto Rico | PR075",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829446","Juncos Municipio, PR","C110880","No value exists.","Juncos Municipio, PR | Juncos Municipio | Juncos Municipio, Puerto Rico | PR077",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829328","Lares Municipio, PR","C110882","No value exists.","Lares Municipio, PR | Lares Municipio | Lares Municipio, Puerto Rico | PR081",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829320","Las Marias Municipio, PR","C110883","No value exists.","Las Marias Municipio, PR | Las Marias Municipio | Las Marias Municipio, Puerto Rico | PR083",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829319","Las Piedras Municipio, PR","C110884","No value exists.","Las Piedras Municipio, PR | Las Piedras Municipio | Las Piedras Municipio, Puerto Rico | PR085",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829262","Loiza Municipio, PR","C110885","No value exists.","Loiza Municipio, PR | Loiza Municipio | Loiza Municipio, Puerto Rico | PR087",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829242","Luquillo Municipio, PR","C110886","No value exists.","Luquillo Municipio, PR | Luquillo Municipio | Luquillo Municipio, Puerto Rico | PR089",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829200","Maricao Municipio, PR","C110888","No value exists.","Maricao Municipio, PR | Maricao Municipio | Maricao Municipio, Puerto Rico | PR093",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829172","Maunabo Municipio, PR","C110889","No value exists.","Maunabo Municipio, PR | Maunabo Municipio | Maunabo Municipio, Puerto Rico | PR095",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829168","Mayaguez Municipio, PR","C110890","No value exists.","Mayaguez Municipio, PR | Mayaguez Municipio | Mayaguez Municipio, Puerto Rico | PR097",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828995","Moca Municipio, PR","C110891","No value exists.","Moca Municipio, PR | Moca Municipio | Moca Municipio, Puerto Rico | PR099",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828959","Morovis Municipio, PR","C110892","No value exists.","Morovis Municipio, PR | Morovis Municipio | Morovis Municipio, Puerto Rico | PR101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828861","Naranjito Municipio, PR","C110894","No value exists.","Naranjito Municipio, PR | Naranjito Municipio | Naranjito Municipio, Puerto Rico | PR105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828696","Orocovis Municipio, PR","C110895","No value exists.","Orocovis Municipio, PR | Orocovis Municipio | Orocovis Municipio, Puerto Rico | PR107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828637","Patillas Municipio, PR","C110896","No value exists.","Patillas Municipio, PR | PR109 | Patillas Municipio | Patillas Municipio, Puerto Rico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828611","Penuelas Municipio, PR","C110897","No value exists.","Penuelas Municipio, PR | PR111 | Penuelas Municipio | Penuelas Municipio, Puerto Rico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828518","Ponce Municipio, PR","C110898","No value exists.","Ponce Municipio, PR | PR113 | Ponce Municipio | Ponce Municipio, Puerto Rico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828325","Rincon Municipio, PR","C110900","No value exists.","Rincon Municipio, PR | PR117 | Rincon Municipio | Rincon Municipio, Puerto Rico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828320","Rio Grande Municipio, PR","C110901","No value exists.","Rio Grande Municipio, PR | PR119 | Rio Grande Municipio | Rio Grande Municipio, Puerto Rico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049135","opioid agonist GIC-1001","C111045","A sulfonate-based salt form of a trimebutine derivative, an orally available, peripherally-acting opioid agonist and muscarinic antagonist, with potential visceral analgesic activity. Upon oral administration of GIC-1001, this agent may exert its therapeutic effects through the potential mechanisms of action for the trimebutine and sulfonate moieties: The trimebutine moiety can act as a motility enhancer in the gastrointestinal (GI) tract, as an antispasmodic agent to reduce colonic spasms, as an agonist of colonic mu and kappa opioid receptors, which could provide an analgesic effect, and blocks sodium channels and the release of a variety of GI peptides, which modulates the activity of visceral afferents. The sulfonate moiety releases hydrogen sulfide (H2S), which is involved, through an as of yet not fully elucidated mechanism of action, in the modulation of visceral perception and pain, possibly through the activation of ATP-sensitive potassium (KATP) ion channels and mu opioid receptors. Altogether, administration of this agent may both facilitate the insertion of the colonoscope during a colonoscopy and reduce colonic spasms and pain.","Trimebutine 3-Thiocarbamoylbenzenesulfonate | Benzoic Acid, 3,4,5-Trimethoxy-, 2-(Dimethylamino)-2-phenylbutyl Ester, 3-(Aminothioxomethyl)benzenesulfonate (1:1) | GIC-1001 | TB-905-02 | TRIMEBUTINE 3-THIOCARBAMOYLBENZENESULFONATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278423","Tracheal syrinx","C111323","The vocal organ of a bird that is located in the lower portion of the larynx.","Syrinx | SYRINX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827718","UPDRS - Motor Examination: Action Tremor, Hand, Right","C111590","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: action tremor, hand, right.","UPDRS - Motor Examination: Action Tremor, Hand, Right | UPD1--Motor:Action Tremor:Hand: Right | UPD121A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827719","UPDRS - Motor Examination: Action Tremor, Hand, Left","C111591","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: action tremor, hand, left.","UPDRS - Motor Examination: Action Tremor, Hand, Left | UPD1--Motor:Action Tremor:Hand: Left | UPD121B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827707","UPDRS - Motor Examination: Rigidity Neck","C111592","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: rigidity neck.","UPDRS - Motor Examination: Rigidity Neck | UPD1-Motor:Rigidity Neck | UPD122A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827705","UPDRS - Motor Examination: Rigidity Upper Extremity, Right","C111593","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: rigidity upper extremity, right.","UPDRS - Motor Examination: Rigidity Upper Extremity, Right | UPD1-Motor:Rigidity Upper Extrem: Right | UPD122B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827706","UPDRS - Motor Examination: Rigidity Upper Extremity, Left","C111594","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: rigidity upper extremity, left.","UPDRS - Motor Examination: Rigidity Upper Extremity, Left | UPD1-Motor:Rigidity Upper Extrem: Left | UPD122C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827708","UPDRS - Motor Examination: Rigidity Lower Extremity, Right","C111595","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: rigidity lower extremity, right.","UPDRS - Motor Examination: Rigidity Lower Extremity, Right | UPD1-Motor:Rigidity Lower Extrem: Right | UPD122D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827716","UPDRS - Motor Examination: Finger Taps, Right","C111597","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: finger taps, right.","UPDRS - Motor Examination: Finger Taps, Right | UPD1-Motor:Finger Taps: Right | UPD123A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827717","UPDRS - Motor Examination: Finger Taps, Left","C111598","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: finger taps, left.","UPDRS - Motor Examination: Finger Taps, Left | UPD1-Motor:Finger Taps: Left | UPD123B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827714","UPDRS - Motor Examination: Hand Grips, Right","C111599","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: hand grips, right.","UPDRS - Motor Examination: Hand Grips, Right | UPD1-Motor:Hand Grips: Right | UPD124A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827715","UPDRS - Motor Examination: Hand Grips, Left","C111600","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: hand grips, left.","UPDRS - Motor Examination: Hand Grips, Left | UPD1-Motor:Hand Grips: Left | UPD124B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827712","UPDRS - Motor Examination: Hand Pronate/Supinate, Right","C111601","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: hand pronate/supinate, right.","UPDRS - Motor Examination: Hand Pronate/Supinate, Right | UPD1-Motor:Hand Pronate/Supinate: Right | UPD125A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827713","UPDRS - Motor Examination: Hand Pronate/Supinate, Left","C111602","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: hand pronate/supinate, left.","UPDRS - Motor Examination: Hand Pronate/Supinate, Left | UPD1-Motor:Hand Pronate/Supinate: Left | UPD125B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034497","Rabies Virus","C112405","A species of enveloped, rod- or bullet-shaped viruses in the Rhabdoviridae family and Lyssavirus genus. The genome is composed of single-stranded, negative-sense RNA. Rabies viruses are neurotropic and zoonotic. They are found in mammals and humans and causes acute infection of the central nervous system, neural degeneration, and fatal encephalitis in humans. Rabies viruses are transmitted via direct contact with saliva from infected animal or human bites.","Rabies Virus | RABIES VIRUS",,,,,,,,,,,,,,,"4245970","Rabies virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1622354","Reagent Lot Number","C112406","The lot number of the reagent.","Reagent Lot Number | REAGLOT | Reagent Lot | Reagent_Lot_Number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1071061","Rhinovirus A","C112407","A species of non-enveloped, spherical viruses with a capsid with quasi T=3 icosahedral symmetry in the Picornaviridae family and Enterovirus genus. The genome is composed of single-stranded, positive-sense RNA. Rhinovirus A is found in humans and causes respiratory infections and the common cold. Rhinovirus A is transmitted via direct person-to-person contact and aerosols of respiratory droplets.","Rhinovirus A | Human Rhinovirus A | RHINOVIRUS A",,,,,,,,,,,,,,,"4226361","Human rhinovirus A",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1071062","Rhinovirus B","C112408","A species of non-enveloped, spherical viruses with a capsid with quasi T=3 icosahedral symmetry in the Picornaviridae family and Enterovirus genus. The genome is composed of single-stranded, positive-sense RNA. Rhinovirus B is found in humans and causes respiratory infections and the common cold. Rhinovirus B is transmitted via direct person-to-person contact and aerosols of respiratory droplets.","Rhinovirus B | Human Rhinovirus B | RHINOVIRUS B",,,,,,,,,,,,,,,"42872874","Human rhinovirus B",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2290915","Rhinovirus C","C112409","A species of non-enveloped, spherical viruses with a capsid with quasi T=3 icosahedral symmetry in the Picornaviridae family and Enterovirus genus. The genome is composed of single-stranded, positive-sense RNA. Rhinovirus C is found in humans and causes respiratory infections and the common cold. Rhinovirus C is transmitted via direct person-to-person contact and aerosols of respiratory droplets.","Rhinovirus C | Human Rhinovirus C | RHINOVIRUS C",,,,,,,,,,,,,,,"42872875","Human rhinovirus C",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0376477","Roseolovirus","C112410","A genus of enveloped, spherical or pleomorphic viruses with a capsid that is surrounded by an amorphous tegument, in the family Herpesviridae. The genome is composed of monopartite, linear double-stranded DNA. Roseoloviruses are found in humans and cause Roseola in humans.","Roseolovirus | ROSEOLOVIRUS",,,,,,,,,,,,,,,"4234498","Roseolovirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035866","Ross River Virus","C112411","A species of enveloped, spherical viruses with a capsid with T=4 icosahedral symmetry in the Togaviridae family and Alphavirus genus. The genome is composed of monopartite, single-stranded, positive-sense RNA. Ross river viruses are found in both vertebrates and invertebrates, and cause Ross River Fever in humans. Ross river viruses are transmitted via the bite of infected mosquitoes.","Ross River Virus | ROSS RIVER VIRUS | RRV",,,,,,,,,,,,,,,"4138375","Ross River virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206555","Rubivirus","C112414","A genus of enveloped, spherical viruses with a capsid with T=4 icosahedral symmetry, in the family Togaviridae. The genome is composed of a linear, single-strand of positive sense RNA. Rubiviruses are found in humans and cause respiratory disease in humans.","Rubivirus | RUBIVIRUS",,,,,,,,,,,,,,,"4165879","Rubivirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0949922","Sapporo Virus","C112415","A species of non-enveloped viruses in the Caliciviridae family and Sapovirus genus that have characteristic cup-shaped depressions on their spherical capsid surface and a distinctive structure of 'Star-of-David' configuration. The genome is composed of single-stranded, positive-sense RNA. Sapporo viruses are found in humans and cause gastroenteritis mainly in young children. Sapporo viruses are transmitted via oral ingestion.","Sapporo Virus | Human Calicivirus SLV | Human Calicivirus Sapporo-like Virus | SAPPORO VIRUS",,,,,,,,,,,,,,,"4310570","Sapporo virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828024","Signal Amplitude","C112416","A measurement of the height of the signal such as a magnetic pulse.","Signal Amplitude | SIGAMP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1899097","Wautersiella falsenii","C111334","A species of aerobic, gram-negative, rod shaped bacteria assigned to the phylum Bacteroidetes. This species is urease and indole positive, does not reduce nitrates, Citrate negative and alkaline phosphatase positive. W. falsenii has only been isolated in the clinical setting.","Wautersiella falsenii | Empedobacter falsenii | WAUTERSIELLA FALSENII",,,,,,,,,,,,,,,"42872461","Wautersiella falsenii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829374","Kittitas County, WA","C110660","No value exists.","Kittitas County, WA | Kittitas County | Kittitas County, Washington | WA037",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829370","Klickitat County, WA","C110661","No value exists.","Klickitat County, WA | Klickitat County | Klickitat County, Washington | WA039",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814083","Lewis County, WA","C110662","No value exists.","Lewis County, WA | Lewis County | Lewis County, Washington | WA041",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815575","Lincoln County, WA","C110663","No value exists.","Lincoln County, WA | Lincoln County | Lincoln County, Washington | WA043",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811740","Mason County, WA","C110664","No value exists.","Mason County, WA | Mason County | Mason County, Washington | WA045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828675","Pacific County, WA","C110666","No value exists.","Pacific County, WA | Pacific County | Pacific County, Washington | WA049",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828614","Pend Oreille County, WA","C110667","No value exists.","Pend Oreille County, WA | Pend Oreille County | Pend Oreille County, Washington | WA051",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814129","Pierce County, WA","C110668","No value exists.","Pierce County, WA | Pierce County | Pierce County, Washington | WA053",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811230","San Juan County, WA","C110669","No value exists.","San Juan County, WA | San Juan County | San Juan County, Washington | WA055",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828007","Skagit County, WA","C110670","No value exists.","Skagit County, WA | Skagit County | Skagit County, Washington | WA057",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828000","Snohomish County, WA","C110672","No value exists.","Snohomish County, WA | Snohomish County | Snohomish County, Washington | WA061",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827710","UPDRS - Motor Examination: Leg Agility, Right","C111603","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: leg agility, right.","UPDRS - Motor Examination: Leg Agility, Right | UPD1-Motor:Leg Agility: Right | UPD126A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827711","UPDRS - Motor Examination: Leg Agility, Left","C111604","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: leg agility, left.","UPDRS - Motor Examination: Leg Agility, Left | UPD1-Motor:Leg Agility: Left | UPD126B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827697","UPDRS - Symptomatic Orthostasis: Blood Pressure, Seated","C111605","Unified Parkinson's Disease Rating Scale (UPDRS) Symptomatic orthostasis: blood pressure, seated.","UPDRS - Symptomatic Orthostasis: Blood Pressure, Seated | UPD1-Blood Pressure: Seated | UPD142A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0344424","Ventricular Arrhythmia by ECG Finding","C111101","An electrocardiographic finding of an atypical cardiac rhythm resulting from a pathologic process in the cardiac ventricles.","Ventricular Arrhythmia by ECG Finding | Ventricular Arrhythmia | Ventricular Arrhythmia by EKG Finding | Ventricular arrhythmia",,,,,,,,,,,,,,,"4064453","EKG: ventricular arrhythmia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL455347","CDISC SDTM Employment Status Terminology","C111108","Terminology associated with the employment status codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Employment Status Terminology | EMPSTAT | Employment Status | SDTM-EMPSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826888","CDISC SDTM Device Events Category Terminology","C111109","Terminology associated with the device events category codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Device Events Category Terminology | Category of Device Events | DECAT | SDTM-DECAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828092","SGRQ Past 3 Months Version - Wheeze Worse When Get Up in the Morning","C112635","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) If you wheeze, is it worse when you get up in the morning?","SGRQ Past 3 Months Version - Wheeze Worse When Get Up in the Morning | SGRQ01-Wheeze Worse in the Morning | SGRQ0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828128","SGRQ Past 3 Months Version - Describe Your Respiratory Condition","C112636","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) How would you describe your respiratory condition?","SGRQ Past 3 Months Version - Describe Your Respiratory Condition | SGRQ01-Describe Your Resp Condition | SGRQ0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828123","SGRQ Past 3 Months Version - Held a Job","C112637","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) If you have ever held a job.","SGRQ Past 3 Months Version - Held a Job | SGRQ01-If You Have Ever Held a Job | SGRQ0111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828104","SGRQ Past 3 Months Version - Sitting or Lying Still","C112638","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about what activities usually make you feel short of breath these days: Sitting or lying still.","SGRQ Past 3 Months Version - Sitting or Lying Still | SGRQ01-Sitting or Lying Still | SGRQ0112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828098","SGRQ Past 3 Months Version - Walking Around the House","C112640","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about what activities usually make you feel short of breath these days: Walking around the house.","SGRQ Past 3 Months Version - Walking Around the House | SGRQ01-Walking Around the House | SGRQ0114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828097","SGRQ Past 3 Months Version - Walking Outside on Level Ground","C112641","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about what activities usually make you feel short of breath these days: Walking outside on level ground.","SGRQ Past 3 Months Version - Walking Outside on Level Ground | SGRQ01-Walking Outside on Level Ground | SGRQ0115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828096","SGRQ Past 3 Months Version - Walking Up a Flight of Stairs","C112642","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about what activities usually make you feel short of breath these days: Walking up a flight of stairs.","SGRQ Past 3 Months Version - Walking Up a Flight of Stairs | SGRQ01-Walking Up a Flight of Stairs | SGRQ0116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828095","SGRQ Past 3 Months Version - Walking Up Hills","C112643","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about what activities usually make you feel short of breath these days: Walking up hills.","SGRQ Past 3 Months Version - Walking Up Hills | SGRQ01-Walking Up Hills | SGRQ0117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828108","SGRQ Past 3 Months Version - Playing Sports or Other Physical Activities","C112644","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about what activities usually make you feel short of breath these days: Playing sports or other physical activities.","SGRQ Past 3 Months Version - Playing Sports or Other Physical Activities | SGRQ01-Playing Sports | SGRQ0118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828131","SGRQ Past 3 Months Version - Coughing Hurts","C112645","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are more questions about your cough and shortness of breath these days: Coughing hurts.","SGRQ Past 3 Months Version - Coughing Hurts | SGRQ01-Coughing Hurts | SGRQ0119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828130","SGRQ Past 3 Months Version - Coughing Makes Me Tired","C112646","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are more questions about your cough and shortness of breath these days: Coughing makes me tired.","SGRQ Past 3 Months Version - Coughing Makes Me Tired | SGRQ01-Coughing Makes Me Tired | SGRQ0120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828105","SGRQ Past 3 Months Version - Short of Breath When I Talk","C112647","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are more questions about your cough and shortness of breath these days: I am short of breath when I talk.","SGRQ Past 3 Months Version - Short of Breath When I Talk | SGRQ01-Short of Breath When I Talk | SGRQ0121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454073","Sorghum bicolor Supplement","C111681","An herbal-based nutritional supplement containing the leaf sheaths of the plant Sorghum bicolor, with potential antioxidant, anti-inflammatory, chemopreventive and immunomodulating activities. Sorghum bicolor supplement contains various phytochemicals, including phenolic acids and polyphenols such as proanthocyanidins. Sorghum bicolor supplement is particularly rich in 3-deoxyanthocyanins, such as luteolinidin and apigeninidin, and appears to induce apoptosis and inhibit cell proliferation in cancer cells through the stimulation of various apoptosis promoter genes and the downregulation of certain apoptosis inhibitor genes. In addition, due to the strong antioxidant nature of the phytochemicals, these compounds are able to scavenge free radicals and prevent tissue damage. Also, intake of this supplement modulates the immune system by both increasing the activity of natural killer (NK) cells and initiating the activation of macrophages.","Sorghum bicolor Supplement | Jobelyn | Sorghum bicolor Extract",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827207","Spokane County, WA","C110673","No value exists.","Spokane County, WA | Spokane County | Spokane County, Washington | WA063",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814467","Stevens County, WA","C110674","No value exists.","Stevens County, WA | Stevens County | Stevens County, Washington | WA065",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815219","Thurston County, WA","C110675","No value exists.","Thurston County, WA | Thurston County | Thurston County, Washington | WA067",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827529","Wahkiakum County, WA","C110676","No value exists.","Wahkiakum County, WA | WA069 | Wahkiakum County | Wahkiakum County, Washington",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827480","Whatcom County, WA","C110678","No value exists.","Whatcom County, WA | WA073 | Whatcom County | Whatcom County, Washington",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827470","Whitman County, WA","C110679","No value exists.","Whitman County, WA | WA075 | Whitman County | Whitman County, Washington",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827415","Yakima County, WA","C110680","No value exists.","Yakima County, WA | WA077 | Yakima County | Yakima County, Washington",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811372","Barbour County, WV","C110681","No value exists.","Barbour County, WV | Barbour County | Barbour County, West Virginia | WV001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811373","Berkeley County, WV","C110682","No value exists.","Berkeley County, WV | Berkeley County | Berkeley County, West Virginia | WV003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831277","Braxton County, WV","C110684","No value exists.","Braxton County, WV | Braxton County | Braxton County, West Virginia | WV007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831259","Brooke County, WV","C110685","No value exists.","Brooke County, WV | Brooke County | Brooke County, West Virginia | WV009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831231","Cabell County, WV","C110686","No value exists.","Cabell County, WV | Cabell County | Cabell County, West Virginia | WV011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811375","Calhoun County, WV","C110687","No value exists.","Calhoun County, WV | Calhoun County | Calhoun County, West Virginia | WV013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811376","Clay County, WV","C110688","No value exists.","Clay County, WV | Clay County | Clay County, West Virginia | WV015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812209","Fayette County, WV","C110690","No value exists.","Fayette County, WV | Fayette County | Fayette County, West Virginia | WV019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830823","C-SSRS Children's Baseline - Most Recent Suicide Attempt Date","C111555","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Most recent attempt date.","C-SSRS Children's Baseline - Most Recent Suicide Attempt Date | CSS06-Most Recent Attempt Date | CSS0618A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830822","C-SSRS Children's Baseline - Most Recent Suicide Attempt Potential Lethality","C111557","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Most recent attempt potential lethality.","C-SSRS Children's Baseline - Most Recent Suicide Attempt Potential Lethality | CSS06-Most Recent Attempt Potential | CSS0618C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830826","C-SSRS Children's Baseline - Most Lethal Suicide Attempt Date","C111558","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Most lethal attempt date.","C-SSRS Children's Baseline - Most Lethal Suicide Attempt Date | CSS06-Most Lethal Attempt Date | CSS0619A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830827","C-SSRS Children's Baseline - Most Lethal Suicide Attempt Actual Lethality/Medical Damage","C111559","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Most lethal attempt actual lethality/medical damage.","C-SSRS Children's Baseline - Most Lethal Suicide Attempt Actual Lethality/Medical Damage | CSS06-Most Lethal Attempt Damage | CSS0619B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826884","CDISC SDTM Device Properties Test Code Terminology","C111111","Terminology associated with the device properties test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Device Properties Test Code Terminology | DOTESTCD | Device Properties Test Code | SDTM-DOTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826885","CDISC SDTM Device Properties Test Name Terminology","C111112","Terminology associated with the device properties test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Device Properties Test Name Terminology | DOTEST | Device Properties Test Name | SDTM-DOTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826873","CDISC SEND Domain Abbreviation Terminology","C111113","Terminology associated with the SEND domain abbreviation codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).","CDISC SEND Domain Abbreviation Terminology | SDOMAIN | SEND Domain Abbreviation | SEND-SDOMAIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826881","CDISC SDTM Genetic Sample Type Terminology","C111114","Terminology associated with the genetic sample type codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC SDTM Genetic Sample Type Terminology | GENSMP | Genetic Sample Type | SDTM-GENSMP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828106","SGRQ Past 3 Months Version - Short of Breath When Bend Over","C112648","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are more questions about your cough and shortness of breath these days: I am short of breath when I bend over.","SGRQ Past 3 Months Version - Short of Breath When Bend Over | SGRQ01-Short of Breath When Bend Over | SGRQ0122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829931","Group B Streptococcus Risk","C111946","Categorization for likelihood of perinatal transmission of group B Streptococcus to neonate.","Group B Streptococcus Risk | GBS Risk Status | Group B Streptococcus Risk Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828510","Positive GBS Risk Status","C111947","Rectal/vaginal culture positive for group B Streptococcus (GBS) within 5 weeks.","Positive GBS Risk Status | Positive Group B Streptococcus Risk Status | Positive Group B Streptococcus Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828840","Negative GBS Risk Status","C111948","Rectal/vaginal culture negative for group B Streptococcus (GBS) within 5 weeks.","Negative GBS Risk Status | Negative Group B Streptococcus Risk Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827724","Unknown GBS Risk Status","C111949","Rectal/vaginal culture not taken within 5 weeks prior to birth, or urine GBS culture not taken.","Unknown GBS Risk Status | Unknown Group B Streptococcus Risk Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0522157","Pregnancy with Intrauterine Device","C111950","Co-existence of an intrauterine pregnancy with an intrauterine device.","Pregnancy with Intrauterine Device | IUD Pregnancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0425979","Nulliparous","C111951","A woman with a parity of zero.","Nulliparous | ",,,,,,,,,,,,,,,"4012561","Nulliparous",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1413455","CLCN6 Gene","C111952","This gene plays a role in chloride ion transport.","CLCN6 Gene | CLCN6 | Chloride Channel, Voltage-Sensitive 6 Gene | Chloride Voltage-Gated Channel 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811085","CLCN6 wt Allele","C111953","Human CLCN6 wild-type allele is located in the vicinity of 1p36 and is approximately 37 kb in length. This allele, which encodes H(+)/Cl(-) exchange transporter 6 protein, is involved in the antiport of chloride. A fusion of this gene and the BRAF gene may be associated with pilocytic astrocytoma.","CLCN6 wt Allele | CLC-6 | CLC6 | CONRIBA | Chloride Channel, Voltage-Sensitive 6 Gene | Chloride Channel, Voltage-Sensitive 6 wt Allele | Chloride Voltage-Gated Channel 6 wt Allele | ClC-6 | KIAA0046 | RP5-934G17.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811086","CLCN6 protein, human","C111954","H(+)/Cl(-) exchange transporter 6 (869 aa, ~97 kDa) is encoded by the human CLCN6 gene. This protein plays a role in ion exchange-based transport.","H(+)/Cl(-) Exchange Transporter 6 | CLCN6 | Chloride Channel 6 | Chloride Channel Protein 6 | Chloride Transport Protein 6 | Chloride Transport Protein 6 | ClC-6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426501","EPC1 Gene","C111955","This gene plays a role in both transcriptional regulation and histone acetylation.","EPC1 Gene | EPC1 | Enhancer of Polycomb Homolog 1 (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810538","EPC1 wt Allele","C111956","Human EPC1 wild-type allele is located in the vicinity of 10p11 and is approximately 111 kb in length. This allele, which encodes enhancer of polycomb homolog 1 protein, is involved in both the regulation of histone acetylation and gene transcription. A fusion of this gene and the PHF1 gene may be associated with low-grade endometrial stromal sarcomas.","EPC1 wt Allele | Enhancer of Polycomb Homolog 1 (Drosophila) wt Allele | Enhancer of Polycomb, Drosophila, Homolog of, 1 Gene | Epl1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152151","Triplet Pregnancy","C111957","A pregnancy involving three fetuses.","Triplet Pregnancy | ",,,,,,,,,,,,,,,"432375","Triplet pregnancy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3816729","Enhancer of Polycomb Homolog 1","C111958","Enhancer of polycomb homolog 1 (836 aa, ~93 kDa) is encoded by the human EPC1 gene. This protein plays a role in both histone acetyltransferase activity and transcriptional regulation.","Enhancer of Polycomb Homolog 1 | EPC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152152","Quadruplet Pregnancy","C111959","A pregnancy involving four fetuses.","Quadruplet Pregnancy | ",,,,,,,,,,,,,,,"442594","Quadruplet pregnancy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3830795","C-SSRS Children's Baseline/Screening - First Suicide Attempt Actual Lethality/Medical Damage","C111426","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Initial/first attempt actual lethality/medical damage.","C-SSRS Children's Baseline/Screening - First Suicide Attempt Actual Lethality/Medical Damage | CSS07-First Attempt Damage | CSS0720B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830793","C-SSRS Children's Baseline/Screening - First Suicide Attempt Potential Lethality","C111427","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Initial/first attempt potential lethality.","C-SSRS Children's Baseline/Screening - First Suicide Attempt Potential Lethality | CSS07-First Attempt Potential | CSS0720C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830734","C-SSRS Children's Since Last Visit - Wish to be Dead","C111428","Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Have you thought about being dead or what it would be like to be dead? Have you wished you were dead or wished you could go to sleep and never wake up? Do you ever wish you weren't alive anymore?","C-SSRS Children's Since Last Visit - Wish to be Dead | CSS08-Wish to be Dead | CSS0801",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830752","C-SSRS Children's Since Last Visit - Description of Wish to be Dead","C111429","Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Description of wishing to be dead.","C-SSRS Children's Since Last Visit - Description of Wish to be Dead | CSS08-Wish to be Dead, Describe | CSS0801A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830744","C-SSRS Children's Since Last Visit - Non-Specific Active Suicidal Thoughts","C111430","Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Have you thought about doing something to make yourself not alive anymore? Have you had any thoughts about killing yourself?","C-SSRS Children's Since Last Visit - Non-Specific Active Suicidal Thoughts | CSS08-Non-Specific Suicidal Thought | CSS0802",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830754","C-SSRS Children's Since Last Visit - Description of Non-Specific Active Suicidal Thoughts","C111431","Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Description of non-specific active suicidal thoughts.","C-SSRS Children's Since Last Visit - Description of Non-Specific Active Suicidal Thoughts | CSS08-Non-Specific Suicid Thought, Descr | CSS0802A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830765","C-SSRS Children's Since Last Visit - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act","C111432","Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Have you thought about how you would do that or how you would make yourself not alive anymore (kill yourself)? What did you think about?","C-SSRS Children's Since Last Visit - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act | CSS08-Idea, No Intent, No Plan | CSS0803",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830825","C-SSRS Children's Baseline - Most Lethal Suicide Attempt Potential Lethality","C111560","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Most lethal attempt potential lethality.","C-SSRS Children's Baseline - Most Lethal Suicide Attempt Potential Lethality | CSS06-Most Lethal Attempt Potential | CSS0619C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830833","C-SSRS Children's Baseline - First Suicide Attempt Actual Lethality/Medical Damage","C111562","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Initial/first attempt actual lethality/medical damage.","C-SSRS Children's Baseline - First Suicide Attempt Actual Lethality/Medical Damage | CSS06-First Attempt Damage | CSS0620B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830831","C-SSRS Children's Baseline - First Suicide Attempt Potential Lethality","C111563","Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Initial/first attempt potential lethality.","C-SSRS Children's Baseline - First Suicide Attempt Potential Lethality | CSS06-First Attempt Potential | CSS0620C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL453973","Anti-EGFRvIII CAR-transduced Allogeneic T-lymphocytes","C111565","Allogeneic human T-lymphocytes transduced with a retroviral vector encoding an anti-epidermal growth factor receptor (EGFR) variant III (EGFRvIII) mutant chimeric T cell receptor (chimeric antigen receptor or CAR) gene coupled to the signaling domains from CD8, CD28, 4-1BB (CD137) and CD3 zeta, with potential immunostimulatory and antineoplastic activities. Upon administration, the anti-EGFRvIII CAR-transduced allogeneic T lymphocytes bind to the EGFRvIII antigen on tumor cell surfaces; subsequently, EGFRvIII-expressing tumor cells may be lysed. EGFRvIII, an in-frame deletion of exons 2-7 in the EGFR gene, is overexpressed by a variety of cancer cell types and absent in normal, healthy cells; it plays a key role in tumor cell proliferation, tumor angiogenesis and radio- and chemoresistance.","Anti-EGFRvIII CAR-transduced Allogeneic T-lymphocytes | Anti-EGFRvIII CAR PG13-139-CD8-CD28BBZ- transduced T-lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL453974","Carbon C 14-labeled Ixazomib","C111566","A radioconjugate comprised of the orally available reversible 20S proteasome inhibitor ixazomib and labeled with the isotope carbon C 14. Upon administration, the ixazomib moiety hydrolyzes and generates its active form, MLN2238, which inhibits the activity of the 20S catalytic core subunit of the proteasome. This blocks the targeted proteolysis normally performed by the proteasome, which results in an accumulation of unwanted or misfolded proteins. The accumulation of protein may disrupt various cell signaling pathways, induce apoptosis, and inhibit tumor growth. In addition, this agent targets tumor suppressor microRNA-33b (miR-33b). Labeling with the radioactive tracer carbon C 14 allows for evaluation of ixazomib's absorption, distribution, metabolism and excretion (ADME).","Carbon C 14-labeled Ixazomib | [14C]-1,4-(R,S)-(carboxymethyl)-2-((R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-6-oxo-1,3,2-dioxaborinane-4-carboxylic Acid | [14C]-Ixazomib | [14C]-MLN9708",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830770","C-SSRS Children's Baseline/Screening - Wish to be Dead (Past 6 Months)","C111386","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Have you thought about being dead or what it would be like to be dead? Have you wished you were dead or wished you could go to sleep and never wake up? Do you ever wish you weren't alive anymore? (Past 6 Months).","C-SSRS Children's Baseline/Screening - Wish to be Dead (Past 6 Months) | CSS07-Wish to be Dead-P6M | CSS0701B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830796","C-SSRS Children's Baseline/Screening - Description of Wish to be Dead","C111387","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Description of wishing to be dead.","C-SSRS Children's Baseline/Screening - Description of Wish to be Dead | CSS07-Wish to be Dead, Describe | CSS0701C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830781","C-SSRS Children's Baseline/Screening - Non-Specific Active Suicidal Thoughts (Lifetime)","C111388","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Have you thought about doing something to make yourself not alive anymore? Have you had any thoughts about killing yourself? (Lifetime).","C-SSRS Children's Baseline/Screening - Non-Specific Active Suicidal Thoughts (Lifetime) | CSS07-Non-Spec Suicid Thought-Life | CSS0702A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830780","C-SSRS Children's Baseline/Screening - Non-Specific Active Suicidal Thoughts (Past 6 Months)","C111389","Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Have you thought about doing something to make yourself not alive anymore? Have you had any thoughts about killing yourself? (Past 6 Months).","C-SSRS Children's Baseline/Screening - Non-Specific Active Suicidal Thoughts (Past 6 Months) | CSS07-Non-Spec Suicid Thought-P6M | CSS0702B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814130","Pierce County, WI","C110783","No value exists.","Pierce County, WI | Pierce County | Pierce County, Wisconsin | WI093",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811774","Polk County, WI","C110784","No value exists.","Polk County, WI | Polk County | Polk County, Wisconsin | WI095",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828479","Price County, WI","C110786","No value exists.","Price County, WI | Price County | Price County, Wisconsin | WI099",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828419","Racine County, WI","C110787","No value exists.","Racine County, WI | Racine County | Racine County, Wisconsin | WI101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813286","Richland County, WI","C110788","No value exists.","Richland County, WI | Richland County | Richland County, Wisconsin | WI103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813302","Rock County, WI","C110789","No value exists.","Rock County, WI | Rock County | Rock County, Wisconsin | WI105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810635","Rusk County, WI","C110790","No value exists.","Rusk County, WI | Rusk County | Rusk County, Wisconsin | WI107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828229","Sauk County, WI","C110792","No value exists.","Sauk County, WI | Sauk County | Sauk County, Wisconsin | WI111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828227","Sawyer County, WI","C110793","No value exists.","Sawyer County, WI | Sawyer County | Sawyer County, Wisconsin | WI113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828035","Shawano County, WI","C110794","No value exists.","Shawano County, WI | Shawano County | Shawano County, Wisconsin | WI115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828033","Sheboygan County, WI","C110795","No value exists.","Sheboygan County, WI | Sheboygan County | Sheboygan County, Wisconsin | WI117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815206","Taylor County, WI","C110796","No value exists.","Taylor County, WI | Taylor County | Taylor County, Wisconsin | WI119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811346","Vernon County, WI","C110798","No value exists.","Vernon County, WI | Vernon County | Vernon County, Wisconsin | WI123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827556","Vilas County, WI","C110799","No value exists.","Vilas County, WI | Vilas County | Vilas County, Wisconsin | WI125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823768","MEAF6 Gene","C111960","This gene is involved in chromatin modification.","MEAF6 Gene | MEAF6 | MYST/Esa1-Associated Factor 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813950","Chromatin Modification-Related Protein MEAF6, human","C111962","Chromatin modification-related protein MEAF6 (191 aa, ~22 kDa) is encoded by the human MEAF6 gene. This protein is involved in histone acetylation.","Chromatin Modification-Related Protein MEAF6 | Centromere Protein 28 | Esa1-Associated Factor 6 Homolog | MEAF6 | Protein EAF6 Homolog | Sarcoma Antigen NY-SAR-91 | hEAF6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827193","Uveal Melanoma by Gene Expression Profile","C111030","No value exists.","Uveal Melanoma by Gene Expression Profile | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230355","Antecubital Region","C111032","The area of the body that is anterior to the elbow.","Antecubital Region | Antecubital Space",,,,,,,,,,,,,,,"4236336","Antecubital region structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829059","Minimal Aneuploidy","C111034","A numerical chromosomal abnormality characterized by the presence of copy number variations in less than five percent of chromosomal arms.","Minimal Aneuploidy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL455350","Oral Rehydration Solution OS-1","C111035","An aqueous solution composed of glucose and electrolytes, including sodium, potassium, chloride, magnesium, and phosphorus, with dehydration preventative and rehydration activities. Upon oral administration of the oral rehydration solution (ORS), water, electrolytes and glucose are absorbed from the gastrointestinal (GI) tract into the systemic circulation.  This replenishes the body's supply of water, carbohydrates and electrolytes, and prevents both dehydration and renal dysfunction.","Oral Rehydration Solution OS-1 | OS-1 | OS1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL453543","Multi-peptide CMV-Modified Vaccinia Ankara Vaccine","C111036","A vaccine consisting of an inactivated, Modified Vaccinia Ankara (MVA) viral vector encoding three herpes virus cytomegalovirus (CMV) tumor-associated antigens (TAAs), including UL83 (pp65), UL123 (IE1) and UL122 (IE2), with potential immunostimulating activity. The viral peptides expressed after administration of the multi-peptide CMV-MVA vaccine, may stimulate the immune system to mount both cytotoxic T-lymphocyte (CTL) and helper T-cell responses against CMV-infected cells. This results in cell lysis and prevents viral replication and the development of CMV disease. This vaccine also provides active immunization and protective immunity against CMV infection in CMV-negative patients. CMV infection can cause serious complications in patients receiving either allogeneic hematopoietic cell transplants (HCT) or solid organ transplants.","Multi-peptide CMV-Modified Vaccinia Ankara Vaccine | CMV-MVA Triplex Vaccine | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL453544","Synthetic Long E6/E7 Peptides Vaccine HPV-01","C111037","A therapeutic peptide vaccine consisting of thirteen synthetic long peptides (SLPs), which are 25-35 amino acids in size, derived from the human papillomavirus (HPV) type 16 oncoproteins E6 and E7, with potential immunostimulating and antitumor activities. Upon administration, synthetic long E6/E7 peptides vaccine HPV-01 is taken up and degraded into small pieces by dendritic cells. The processed viral epitopes are presented by dendritic cells, which may stimulate the host immune system to mount both cytotoxic T-cell lymphocyte (CTL) and helper T cell responses against HPV E6/E7-expressing tumor cells. This results in the destruction of tumor cells and leads to decreased tumor growth. The E6 and E7 oncoproteins are implicated in the tumorigenesis in a variety of cancers. The SLPs allow for optimal presentation by antigen-presenting cells.","Synthetic Long E6/E7 Peptides Vaccine HPV-01 | HPV-01 | ISA101 | SLP-HPV-01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830759","C-SSRS Children's Since Last Visit - Description of Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act","C111433","Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Description of active suicidal ideation with any methods (not plan) without intent to act.","C-SSRS Children's Since Last Visit - Description of Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act | CSS08-Idea, No Intent, No Plan, Describe | CSS0803A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830764","C-SSRS Children's Since Last Visit - Active Suicidal Ideation with Some Intent to Act, without Specific Plan","C111434","Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) When you thought about making yourself not alive anymore (or killing yourself), did you think that this was something you might actually do? This is different from (as opposed to) having the thoughts but knowing you wouldn't do anything about it.","C-SSRS Children's Since Last Visit - Active Suicidal Ideation with Some Intent to Act, without Specific Plan | CSS08-Ideation With Intent, No Plan | CSS0804",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830763","C-SSRS Children's Since Last Visit - Active Suicidal Ideation with Specific Plan and Intent","C111436","Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Have you decided how or when you would make yourself not alive anymore/kill yourself? Have you planned out (worked out the details of) how you would do it? What was your plan? When you made this plan (or worked out these details), was any part of you thinking about actually doing it?","C-SSRS Children's Since Last Visit - Active Suicidal Ideation with Specific Plan and Intent | CSS08-Ideation With Plan/Intent | CSS0805",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828285","Sabana Grande Municipio, PR","C110902","No value exists.","Sabana Grande Municipio, PR | PR121 | Sabana Grande Municipio | Sabana Grande Municipio, Puerto Rico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828272","Salinas Municipio, PR","C110903","No value exists.","Salinas Municipio, PR | PR123 | Salinas Municipio | Salinas Municipio, Puerto Rico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828253","San German Municipio, PR","C110904","No value exists.","San German Municipio, PR | PR125 | San German Municipio | San German Municipio, Puerto Rico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828249","San Juan Municipio, PR","C110905","No value exists.","San Juan Municipio, PR | PR127 | San Juan Municipio | San Juan Municipio, Puerto Rico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828248","San Lorenzo Municipio, PR","C110906","No value exists.","San Lorenzo Municipio, PR | PR129 | San Lorenzo Municipio | San Lorenzo Municipio, Puerto Rico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828238","Santa Isabel Municipio, PR","C110908","No value exists.","Santa Isabel Municipio, PR | PR133 | Santa Isabel Municipio | Santa Isabel Municipio, Puerto Rico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827817","Toa Alta Municipio, PR","C110909","No value exists.","Toa Alta Municipio, PR | PR135 | Toa Alta Municipio | Toa Alta Municipio, Puerto Rico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827816","Toa Baja Municipio, PR","C110910","No value exists.","Toa Baja Municipio, PR | PR137 | Toa Baja Municipio | Toa Baja Municipio, Puerto Rico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827761","Trujillo Alto Municipio, PR","C110911","No value exists.","Trujillo Alto Municipio, PR | PR139 | Trujillo Alto Municipio | Trujillo Alto Municipio, Puerto Rico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827676","Utuado Municipio, PR","C110912","No value exists.","Utuado Municipio, PR | PR141 | Utuado Municipio | Utuado Municipio, Puerto Rico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827660","Vega Baja Municipio, PR","C110914","No value exists.","Vega Baja Municipio, PR | PR145 | Vega Baja Municipio | Vega Baja Municipio, Puerto Rico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827559","Vieques Municipio, PR","C110915","No value exists.","Vieques Municipio, PR | PR147 | Vieques Municipio | Vieques Municipio, Puerto Rico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827555","Villalba Municipio, PR","C110916","No value exists.","Villalba Municipio, PR | PR149 | Villalba Municipio | Villalba Municipio, Puerto Rico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827417","Yabucoa Municipio, PR","C110917","No value exists.","Yabucoa Municipio, PR | PR151 | Yabucoa Municipio | Yabucoa Municipio, Puerto Rico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827408","Yauco Municipio, PR","C110918","No value exists.","Yauco Municipio, PR | PR153 | Yauco Municipio | Yauco Municipio, Puerto Rico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826945","CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology","C111336","Test codes of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology | CSS06TC | Columbia-Suicide Severity Rating Scale Children's Baseline Questionnaire Test Code | QS-C-SSRS Children's Baseline TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812771","Walworth County, WI","C110800","No value exists.","Walworth County, WI | WI127 | Walworth County | Walworth County, Wisconsin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827507","Washburn County, WI","C110801","No value exists.","Washburn County, WI | WI129 | Washburn County | Washburn County, Wisconsin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827499","Waukesha County, WI","C110803","No value exists.","Waukesha County, WI | WI133 | Waukesha County | Waukesha County, Wisconsin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827498","Waupaca County, WI","C110804","No value exists.","Waupaca County, WI | WI135 | Waupaca County | Waupaca County, Wisconsin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827497","Waushara County, WI","C110805","No value exists.","Waushara County, WI | WI137 | Waushara County | Waushara County, Wisconsin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810742","Winnebago County, WI","C110806","No value exists.","Winnebago County, WI | WI139 | Winnebago County | Winnebago County, Wisconsin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810749","Wood County, WI","C110807","No value exists.","Wood County, WI | WI141 | Wood County | Wood County, Wisconsin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811377","Big Horn County, WY","C110809","No value exists.","Big Horn County, WY | Big Horn County | Big Horn County, Wyoming | WY003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811378","Campbell County, WY","C110810","No value exists.","Campbell County, WY | Campbell County | Campbell County, Wyoming | WY005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811379","Carbon County, WY","C110811","No value exists.","Carbon County, WY | Carbon County | Carbon County, Wyoming | WY007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831014","Converse County, WY","C110812","No value exists.","Converse County, WY | Converse County | Converse County, Wyoming | WY009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827695","UPDRS - Symptomatic Orthostasis: Blood Pressure, Supine","C111606","Unified Parkinson's Disease Rating Scale (UPDRS) Symptomatic orthostasis: blood pressure, supine.","UPDRS - Symptomatic Orthostasis: Blood Pressure, Supine | UPD1-Blood Pressure: Supine | UPD142B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827696","UPDRS - Symptomatic Orthostasis: Blood Pressure, Standing","C111607","Unified Parkinson's Disease Rating Scale (UPDRS) Symptomatic orthostasis: blood pressure, standing.","UPDRS - Symptomatic Orthostasis: Blood Pressure, Standing | UPD1-Blood Pressure: Standing | UPD142C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827692","UPDRS - Symptomatic Orthostasis: Weight","C111608","Unified Parkinson's Disease Rating Scale (UPDRS) Symptomatic orthostasis: weight.","UPDRS - Symptomatic Orthostasis: Weight | UPD1-Weight | UPD142D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827694","UPDRS - Symptomatic Orthostasis: Pulse, Seated","C111609","Unified Parkinson's Disease Rating Scale (UPDRS) Symptomatic orthostasis: pulse, seated.","UPDRS - Symptomatic Orthostasis: Pulse, Seated | UPD1-Pulse: Seated | UPD142E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827693","UPDRS - Symptomatic Orthostasis: Pulse, Standing","C111610","Unified Parkinson's Disease Rating Scale (UPDRS) Symptomatic orthostasis: pulse, standing.","UPDRS - Symptomatic Orthostasis: Pulse, Standing | UPD1-Pulse: Standing | UPD142F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827698","UPDRS - Schwab and England % ADL Score (PD)","C111611","Unified Parkinson's Disease Rating Scale (UPDRS) Schwab and England % ADL score (PD).","UPDRS - Schwab and England % ADL Score (PD) | UPD1-Schwab/England % ADL Score (PD) | UPD144A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL453545","Anti-VEGFR2-CAR Retroviral Vector-transduced Autologous T-lymphocytes","C111038","Autologous human CD8-positive T-lymphocytes transduced with a recombinant retroviral vector encoding a chimeric T cell receptor (chimeric antigen receptor or CAR) consisting of an anti-vascular endothelial growth factor receptor type 2 (VEGFR2) scFv (single chain variable fragment), linked to the transmembrane domain of human CD8alpha and coupled to the costimulatory signaling domains of both CD28 and 4-1BB (CD137), and the CD3 zeta chain of the T-cell receptor (TCR), with potential immunostimulating and antineoplastic activities. Autologous peripheral blood lymphocytes (PBLs) from a patient with VEGFR2-positive cancer are pulsed with a retroviral vector that encodes the CAR gene specific for VEGFR2. After expansion in culture and reintroduction into the patient, the anti-VEGFR2 CAR-gene engineered CD8+ lymphocytes express anti-VEGFR2-CAR on their cell surfaces and bind to the VEGFR2 antigen on tumor cell surfaces. Subsequently, VEGFR2-expressing tumor cells are lysed. VEGFR2, a receptor tyrosine kinase (RTK) overexpressed by a variety of cancer cell types, belongs to the VEGFR superfamily and plays key roles in tumor cell proliferation, survival, invasion and tumor angiogenesis. The co-stimulatory molecules are required for optimal T-cell activation.","Anti-VEGFR2-CAR Retroviral Vector-transduced Autologous T-lymphocytes | Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL453546","Vadastuximab Talirine","C111039","An immunoconjugate consisting of a humanized monoclonal antibody that is engineered to contain cysteine residues that are conjugated to the synthetic, DNA cross-linking, pyrrolobenzodiazepine dimer SGD-1882, via the protease-cleavable linker maleimidocaproyl-valine-alanine dipeptide, with potential antineoplastic activity. The monoclonal antibody portion of vadastuximab talirine specifically binds to the cell surface antigen CD33. This causes the internalization of SGN-CD33A, and the release of the cytotoxic moiety SGD-1882. SGD-1882 binds to and crosslinks DNA, which results in both cell cycle arrest and the induction of apoptosis in CD33-expressing tumor cells. CD33, a transmembrane receptor, is expressed on myeloid leukemia cells.","Vadastuximab Talirine | SGN CD33A | SGN-CD33A | SGNCD33A | VADASTUXIMAB TALIRINE | Vadastuximab talirine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1959930","Absent Fetal Heart Rate Variability","C111756","A baseline fetal heart rate with an undetectable amplitude range.","Absent Fetal Heart Rate Variability | Absent Baseline Variability | Absent FHR Variability",,,,,,,,,,,,,,,"4143856","Absent fetal heart rate variability",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3820263","Mercaptopurine Oral Suspension","C111757","An oral suspension containing the thiopurine-derivative antimetabolite 6-mercaptopurine, with potential antineoplastic activity. Upon oral administration, mercaptopurine is metabolized by hypoxanthine-guanine phosphoribosyltransferase (HGPRTase) to its active metabolite 6-thioinosine monophosphate (TIMP); TIMP inhibits nucleotide interconversions and de novo purine ribonucleotide synthesis, which both blocks the formation of purine nucleotides and inhibits DNA synthesis. This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. By blocking DNA synthesis and replication, cancer cells are unable to proliferate. Compared to the tablet formulation, the liquid is easier to swallow and offers more flexibility and accuracy in dosing, which is beneficial for use in pediatric patients.","Mercaptopurine Oral Suspension | 6-MP Oral Suspension | Purixan | Xaluprine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454145","Mitochondrial Oxidative Phosphorylation Inhibitor ATR-101","C111758","An orally bioavailable inhibitor of mitochondrial oxidative phosphorylation with potential antineoplastic activity. Upon administration, ATR-101 inhibits the activity of F1F0-ATP synthase, elevates the mitochondrial membrane potential and depletes ATP in adrenocortical cells. The mitochondrial dysfunction caused by the release of reactive oxygen and triggered cytochrome c release leads to caspase-mediated cell death. ATR-101 may be useful in treating certain types of adrenocortical carcinoma.","Mitochondrial Oxidative Phosphorylation Inhibitor ATR-101 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454146","Activated Marrow Infiltrating Lymphocytes","C111759","A preparation of cells, which consists of autologous marrow infiltrating lymphocytes (MILs), that are manipulated in vitro, with potential antitumor and immune stimulating activities. MILs are harvested from autologous bone marrow from multiple myeloma patients and, in vitro, are exposed to and activated by anti-CD3/anti-CD28 monoclonal antibodies covalently attached to super-paramagnetic microbeads. After removal of the beads and expansion of the cells in culture, the activated MILs (aMILs) are re-introduced into the patient. The aMILs possess enhanced myeloma specificity, and are able to infiltrate the tumor microenvironment and initiate tumor cell lysis. CD3 and CD28, co-stimulatory molecules expressed on the surface of T-lymphocytes, play a key role in the activation of T-cells.","Activated Marrow Infiltrating Lymphocytes | aMIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026080","Midway Islands","C110919","An atoll in the North Pacific Ocean near the end of the Hawaiian Archipelago.","Midway Islands, UM | 925 | MIDWAY ISLANDS | Midway Islands | Midway Islands, U.S. Minor Outlying Islands | QM | UM300 | XMW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827929","St. John Island, VI","C110921","No value exists.","St. John Island, VI | St. John Island | St. John Island, Virgin Islands | VI020",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827275","St. Thomas Island, VI","C110922","No value exists.","St. Thomas Island, VI | St. Thomas Island | St. Thomas Island, Virgin Islands | VI030",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1867031","Chorioretinitis","C110923","Inflammation of the distal posterior uveal tract (choroid) and its structural and vascular attachments to the retina. It is usually caused by infection and though rare, it is clinically significant due to its most serious sequela: loss of vision.","Chorioretinitis | ",,,,,,,,,,,,,,,"434033","Chorioretinitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0473118","Physiologic Hyperbilirubinemia","C110927","Elevated bilirubin levels in the blood of a newborn infant. It is a normal response due to the limited ability to excrete bilirubin until the maturation of the neonatal liver is complete.","Physiologic Hyperbilirubinemia | Physiological Hyperbilirubinemia",,,,,,,,,,,,,,,"4340949","Physiological hyperbilirubinemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL454074","Fluorine F 18 5-Fluoro-2-deoxycytidine","C111682","A radioconjugate composed of a fluorinated pyrimidine analog, linked to the radioisotope fluorine F 18 with potential imaging activity using positron emission tomography/computed tomography (PET/CT). Upon administration of fluorine F 18 5-fluoro-2-deoxycytidine ([F-18]-FdCyd), the FdCyd moiety is phosphorylated by deoxycytidine kinase to 5-fluoro-2'-deoxycytidylate (FdCMP) and deaminated by deoxycytidylate (dCMP) deaminase, an enzyme overexpressed by tumor cells, to 5-fluoro-2-deoxyuridine monophosphate (FdUMP). Eventually, FdUMP is metabolized to the triphosphate forms 5-fluoro-2'-deoxycytidine-triphosphate (FdCTP) and fluorodeoxyuridine triphosphate (FdUTP). FdCTP and FdUTP inhibit DNA methyltransferase (DNMT) and DNA methylation, and induce DNA strand breaks, respectively. FdCyd is coadministered with tetrahydrouridine (THU), an inhibitor of cytidine/deoxycytidine deaminase, which prevents FdCyd breakdown and increases its efficacy. The fluorine F 18 moiety can be imaged upon PET/CT, thereby allowing for the evaluation of the biodistribution of FdCyd and its uptake by tumor cells.","Fluorine F 18 5-Fluoro-2-deoxycytidine | [F-18]-5-fluoro-2'-deoxycytidine | [F-18]-FdCyd",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829190","MART-1 Reactive CD8+ T-lymphocytes","C111683","Human CD8-positive T-lymphocytes that are engineered to recognize melanoma tumor associated antigen MART-1 (Melanoma Antigen Recognized by T cells, also called Melan-A) in a human leukocyte antigen (HLA)-A2-restricted manner, with potential antineoplastic activity. Human peripheral blood lymphocytes (PBLs) are isolated from a melanoma patient, exposed to the MART-1:27-35(27L) peptide and MART-1 specific T-lymphocytes are isolated and expanded. Upon infusion, these lymphocytes recognize and exert a cytotoxic T-cell-mediated immune response against MART-1-expressing melanoma cells. The synthetic MART-1:27-35 HLA-A2-restricted peptide has an amino acid substitution, leucine to alanine at position 27, to increase its immunogenicity.","MART-1 Reactive CD8+ T-lymphocytes | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3502536","Imisopasem Manganese","C111684","A manganese-based non-peptidyl mimetic of the human mitochondrial manganese superoxide dismutase (MnSOD), with potential antioxidant and chemo/radioprotective activities. Upon administration, imisopasem manganese mimics the activity of MnSOD and scavenges reactive oxygen species (ROS), such as superoxide anion, which prevents oxygen free radical damage to macromolecules such as DNA. This reduces ROS-mediated lipid peroxidation, prevents apoptosis and protects against oxygen free radical-induced toxicity in normal tissues.","Imisopasem Manganese | GC4403 | IMISOPASEM MANGANESE | M40403 | Manganese, dichloro[(4aR,13aR,17aR,21aR)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7Hdibenzo[b,h][1,4,7,10]tetraazacycloheptadecine-kN5,kN13,kN18,kN21,kN22]-, (PB-7-11-2344'3')- | SC-72325",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826948","CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology","C111337","Test names of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology | CSS07TN | Columbia-Suicide Severity Rating Scale Children's Baseline/Screening Questionnaire Test Name | QS-C-SSRS Children's Baseline/Screening TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826947","CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology","C111338","Test codes of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology | CSS07TC | Columbia-Suicide Severity Rating Scale Children's Baseline/Screening Questionnaire Test Code | QS-C-SSRS Children's Baseline/Screening TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826944","CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology","C111339","Test names of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology | CSS08TN | Columbia-Suicide Severity Rating Scale Children's Since Last Visit Questionnaire Test Name | QS-C-SSRS Children's Since Last Visit TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826943","CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology","C111340","Test codes of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology | CSS08TC | Columbia-Suicide Severity Rating Scale Children's Since Last Visit Questionnaire Test Code | QS-C-SSRS Children's Since Last Visit TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826854","CDISC Questionnaire C-SSRS Screening Test Name Terminology","C111341","Test names of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Screening (C-SSRS Screening) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire C-SSRS Screening Test Name Terminology | CSS09TN | Columbia-Suicide Severity Rating Scale Screening Questionnaire Test Name | QS-C-SSRS Screening TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826940","CDISC Questionnaire C-SSRS Screening Test Code Terminology","C111342","Test codes of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Screening (C-SSRS Screening) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire C-SSRS Screening Test Code Terminology | CSS09TC | Columbia-Suicide Severity Rating Scale Screening Questionnaire Test Code | QS-C-SSRS Screening TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826853","QS-FAQ TEST","C111343","Test names of clinical classification questions associated with the Functional Activities Questionnaire (FAQ) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification FAQ Test Name Terminology | FAQ01TN | Functional Activities Questionnaire Clinical Classification Test Name | QS-FAQ TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826931","QS-FAQ TESTCD","C111344","Test codes of clinical classification questions associated with the Functional Activities Questionnaire (FAQ) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification FAQ Test Code Terminology | FAQ01TC | Functional Activities Questionnaire Clinical Classification Test Code | QS-FAQ TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826932","QS-FAQ-NACC Version TESTCD","C111346","Test codes of clinical classification questions associated with the Functional Activities Questionnaire-NACC UDS Version 2.0 (FAQ-NACC UDS Version 2.0) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification FAQ-NACC UDS Version 2.0 Test Code Terminology | FAQNA1TC | Functional Assessment Questionnaire-NACC UDS V2.0 Clinical Classification Test Code | QS-FAQ-NACC Version TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814841","Gilmer County, WV","C110691","No value exists.","Gilmer County, WV | Gilmer County | Gilmer County, West Virginia | WV021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813979","Grant County, WV","C110692","No value exists.","Grant County, WV | Grant County | Grant County, West Virginia | WV023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827720","UPDRS - Mentation, Behavior and Mood Sub-total","C111613","Unified Parkinson's Disease Rating Scale (UPDRS) Mentation, behavior and mood sub-total.","UPDRS - Mentation, Behavior and Mood Sub-total | UPD1-Mentation, Behavior, Mood Sub-Total | UPD145",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827721","UPDRS - Activities of Daily Living Sub-total","C111614","Unified Parkinson's Disease Rating Scale (UPDRS) Activities of daily living sub-total.","UPDRS - Activities of Daily Living Sub-total | UPD1-Activities Daily Living Sub-Total | UPD146",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827704","UPDRS - Motor Examination Sub-total","C111615","Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination sub-total.","UPDRS - Motor Examination Sub-total | UPD1-Motor Examination Sub-Total | UPD147",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827691","UPDRS - UPDRS Total","C111616","Unified Parkinson's Disease Rating Scale (UPDRS) UPDRS total.","UPDRS - UPDRS Total | UPD1-UPDRS Total | UPD148",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830619","DAD - Plan and Organize Number of Applicable Items","C111617","Disability Assessment for Dementia (DAD) Sub-Total Planning and Organization Number of Applicable Items.","DAD - Plan and Organize Number of Applicable Items | DAD01-Plan & Org Num Applic Items | DAD0144",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0549124","Arterial Embolus","C111117","The passage of an embolus from its site of formation in the arterial system to another location within the circulatory system.","Arterial Embolus | Arterial Embolism",,,,,,,,,,,,,,,"312339","Arterial embolism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0340517","Atrial Thrombus","C111118","Presence of a blood clot in the atria of the heart.","Atrial Thrombus | Atrial thrombosis",,,,,,,,,,,,,,,"4108352","Atrial thrombosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL454147","Fentanyl Citrate-containing Nasal Spray","C111760","A nasal spray containing a phosphate-buffered solution of the citrate salt form of fentanyl, a short-acting, synthetic, lipophilic anilidopiperidine opioid, with analgesic activity. Upon applying one puff in the nostril, the fentanyl is rapidly absorbed through the nasal mucosa and selectively binds to and activates mu-opioid receptors in the central nervous system (CNS), mimicking the effects of endogenous opiates. Due to its quick onset and short duration of action, the administration of fentanyl nasal spray may relieve breakthrough pain in adults already receiving maintenance opioid therapy for chronic pain.","Fentanyl Citrate-containing Nasal Spray | Instanyl | Intranasal Fentanyl Spray",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3657815","Triptolide Analog","C111762","A water soluble analog of the diterpenoid triepoxide triptolide isolated from the Chinese herb Tripterygium wilfordii Hook.f., with potential antineoplastic activity. Upon intravenous administration, the triptolide analog inhibits heat shock protein 70 (HSP70) and prevents HSP70-mediated inhibition of apoptosis. This leads to both the induction of apoptosis and a reduction of cancer cell growth. HSP70, a molecular chaperone upregulated in various cancer cells, plays a key role in the inhibition of caspase-dependent and -independent apoptosis.","Triptolide Analog | MINNELIDE | Minnelide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL454150","Carbon C 14 Selumetinib","C111763","A radioconjugate containing the orally available selumetinib, an inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) types 1 and 2, labeled with the radioisotope carbon C 14. Upon oral administration, selumetinib selectively inhibits MEK1/2, which prevents the activation of MEK1/2 dependent effector proteins and transcription factors. This leads to an inhibition of cellular proliferation in MEK1/2-overexpressing tumor cells. MEK 1 and 2 are dual specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in various cancer cells. Selumetinib radiolabeled with carbon C-14 may be used as a radiotracer for pharmacokinetic studies of this agent, including its absorption, distribution, metabolism and excretion (ADME).","Carbon C 14 Selumetinib | [14C] Selumetinib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714936","Non-Compliant ADaM Datasets Domain","C111282","An analysis domain that contains analyses done on non-compliant ADaM datasets.","Non-Compliant ADaM Datasets Domain | AX | Non-Compliant ADaM Dataset",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899595","Clinical Trial Centralized Testing Documentation","C115642","The Trial Master File Reference Model zone that contains the collection of documents relating to testing vendors and sample management, including central and local testing facilities for the clinical trial.","TMF-RM Central and Local Testing Zone | Central and Local Testing | Centralized Testing Category | Centralz Test Cat | Clinical Trial Centralized Testing Documentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899616","Clinical Data Capture Document","C115643","The Trial Master File Reference Model section that contains a collection of documents related to data capture for the clinical trial.","TMF-RM Data Capture Section | Clinical Data Capture Document | DC Subcat | Data Capture | Data Capture Subcategory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896994","Clinical Trial Adjudication Committee Document","C115644","Records describing the Adjudication Committee's evaluation process of key events in a clinical trial.","Clinical Trial Adjudication Committee Document | Adju Cmte | Adjudication Committee Document | End Point Committee Document",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899596","Clinical Trial Central Laboratory Certification Document","C115645","The Trial Master File Reference Model section that contains a collection of documents related to the testing facilities participating in the clinical trial.","TMF-RM Facility Documentation Section | Clinical Trial Central Laboratory Certification Document | Facility Documentation | Facility Documentation Subcategory | Faclty Docn Subcat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899594","Clinical Trial Core Documentation","C115646","Records pertaining to the core trial of a clinical trial.","Clinical Trial Core Documentation | Core Trial Doc Subcat | Core Trial Documents Subcategory | Trial Documents",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899592","Clinical Trial Dose Escalation Document","C115647","Records detailing the correspondence and decisions regarding dose escalation during a clinical trial.","Clinical Trial Dose Escalation Document | Dose Esc | Dose Escalation Documents",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899588","Clinical Trial Financial Document","C115648","Documentation containing information pertaining to the finances of the clinical trial.","Clinical Trial Financial Documentation | Clinical Trial Financial Document | Finan Doc | Financial Documentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899586","Clinical Trial Indemnity Document","C115649","Documentation certifying legal protection in the event of any unforeseen adverse circumstance arising during the course of the clinical trial.","Clinical Trial Indemnity Documentation | Clinical Trial Indemnity Document | Indemnity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890715","Clinical Trial Insurance Documentation","C115651","Documentation confirming appropriate insurance coverage is available for the clinical trial.","Clinical Trial Insurance Documentation | Ins | Insurance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890944","Clinical Trial Interactive Response Technology Documentation","C115652","The Trial Master File Reference Model section that contains a collection of documents related to the interactive response technology used for the clinical trial.","TMF-RM Interactive Response Technology Section | Clinical Trial Interactive Response Technology Documentation | IRT | IRT Subcat | IVR | IVRT | IWR | IWRT | Interactive Response Technology | Interactive Response Technology Subcategory | Interactive Voice Response Technology | Interactive Web Response Technology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889639","Clinical Trial Interfacility Standardization Method Document","C115653","Documentation confirming the ability of two or more testing facilities to achieve consistent results when performing the same test or procedure for the clinical trial.","Clinical Trial Interfacility Standardization Methods Documentation | Clinical Trial Interfacility Standardization Method Document | IFSM | Interfacility Standardization Methods | Interlaboratory Comparison Testing | Proficiency Testing | Standardization Methods",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899580","Clinical Trial Investigator Site Documentation","C115654","Records pertaining to an investigator site in a clinical trial.","Clinical Trial Investigator Site Documentation | Investigator Documents Subcategory | Invstgr Doc Subcat | Site Set-up Documentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899578","Clinical Trial Laboratory Sample Detail Documentation","C115655","The Trial Master File Reference Model section that contains a collection of documents related to the management of the samples collected for the clinical trial.","TMF-RM Sample Documentation Section | Clinical Trial Laboratory Sample Detail Documentation | Lab Sample Detl | Laboratory Sample Details Subcategory | Sample Documentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898508","MPAI-4 - Participation: Self-Care","C115876","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Self-care: Eating, dressing, bathing, hygiene.","MPAI-4 - Participation: Self-Care | MPAI1-Self-Care | MPAI125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897740","Recurrent Combined Thymic Epithelial Neoplasm","C115444","The reemergence of combined thymus epithelial neoplasm after a period of remission.","Recurrent Combined Thymus Epithelial Neoplasm | Recurrent Combined Thymic Carcinoma | Recurrent Combined Thymic Epithelial Neoplasm | Recurrent Combined Thymic Epithelial Neoplasm | Recurrent Combined Thymic Epithelial Tumor | Recurrent Composite Thymoma-Thymic Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897743","Recurrent Childhood Kidney Neoplasm","C115445","The reemergence of renal neoplasm in childhood after a period of remission.","Recurrent Childhood Kidney Neoplasm | Recurrent Childhood Renal Neoplasm | Recurrent Kidney Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827578","VFQ25-Self Administered Format - Feel Frustrated Because of Eyesight","C112795","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Responses to Vision Problems: I feel frustrated a lot of the time because of my eyesight.","VFQ25-Self Administered Format - Feel Frustrated Because of Eyesight | VFQ2-I Feel Frustrated a Lot of the Time | VFQ221",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827577","VFQ25-Self Administered Format - Have Less Control Because of Eyesight","C112796","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Responses to Vision Problems: I have much less control over what I do, because of my eyesight.","VFQ25-Self Administered Format - Have Less Control Because of Eyesight | VFQ2-Much Less Control Over What I Do | VFQ222",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827576","VFQ25-Self Administered Format - Have to Rely On Other People Because of Eyesight","C112797","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Responses to Vision Problems: Because of my eyesight, I have to rely too much on what other people tell me.","VFQ25-Self Administered Format - Have to Rely On Other People Because of Eyesight | VFQ2-Rely Too Much on What Others Tell | VFQ223",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827573","VFQ25-Self Administered Format - Need Help From Others Because of Eyesight","C112798","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Responses to Vision Problems: I need a lot of help from others because of my eyesight.","VFQ25-Self Administered Format - Need Help From Others Because of Eyesight | VFQ2-I Need a Lot of Help From Others | VFQ224",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827562","VFQ25-Self Administered Format - Worry About Embarrass Myself or Others Because of Eyesight","C112799","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Responses to Vision Problems: I worry about doing things that will embarrass myself or others, because of my eyesight.","VFQ25-Self Administered Format - Worry About Embarrass Myself or Others Because of Eyesight | VFQ2-Worry I'll Do Embarrassing Things | VFQ225",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827565","VFQ25-Self Administered Format - Rate Your Overall Health","C112800","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) General Health: How would you rate your overall health, on a scale where zero is as bad as death and 10 is best possible health?","VFQ25-Self Administered Format - Rate Your Overall Health | VFQ2-Rate Your Overall Health | VFQ2A01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827566","VFQ25-Self Administered Format - Rate Your Eyesight Now","C112801","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) General Vision: How would you rate your eyesight now (with glasses or contact lens on, if you wear them), on a scale of from 0 to 10, where zero means the worst possible eyesight, as bad or worse than being blind, and 10 means the best possible eyesight?","VFQ25-Self Administered Format - Rate Your Eyesight Now | VFQ2-Rate Your Eyesight Now | VFQ2A02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827590","VFQ25-Self Administered Format - Difficulty Reading Small Print","C112802","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Near Vision: Wearing glasses, how much difficulty do you have reading the small print in a telephone book, on a medicine bottle, or on legal forms? Would you say:","VFQ25-Self Administered Format - Difficulty Reading Small Print | VFQ2-Difficulty Reading Small Print | VFQ2A03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814866","EIF2AK4 wt Allele","C113596","Human EIF2AK4 wild-type allele is located in the vicinity of 15q13.1 and is approximately 101 kb in length. This allele, which encodes eukaryotic translation initiation factor 2-alpha kinase 4 protein, is involved in both protein phosphorylation and the negative regulation of protein synthesis.","EIF2AK4 wt Allele | Eukaryotic Translation Initiation Factor 2 Alpha Kinase 4 wt Allele | GCN2 | General Control Nonderepressible 2 Gene | KIAA1338",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2354171","Eukaryotic Translation Initiation Factor 2-Alpha Kinase 4, Human","C113597","Eukaryotic translation initiation factor 2-alpha kinase 4 (1649 aa, ~187 kDa) is encoded by the human EIF2AK4 gene. This protein plays a role in both translational regulation and protein phosphorylation.","Eukaryotic Translation Initiation Factor 2-Alpha Kinase 4 | EC 2.7.11.1 | GCN2 EIF2alpha Kinase | GCN2-Like Protein | eIF-2-Alpha Kinase GCN2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811685","EXOC7 wt Allele","C113128","Human EXOC7 wild-type allele is located in the vicinity of 17q25.3 and is approximately 41 kb in length. This allele, which encodes exocyst complex component 7 protein, plays a role in the mediation of exocytosis.","EXOC7 wt Allele | 2-5-3p | EX070 | EXO70 | EXO70, S. cerevisiae, Homolog of Gene | EXOC1 | Exo70p | Exocyst Complex Component 7 wt Allele | KIAA1067 | YJL085W",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811686","exocyst component of 70kDa, human","C113129","Exocyst complex component 7 (735 aa, ~83 kDa) is encoded by the human EXOC7 gene. This protein is involved in the regulation of exocytosis.","Exocyst Complex Component 7 | EXOC7 | Exocyst Complex Component Exo70",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2239772","NAF1 Gene","C113130","This gene plays a role in the assembly of ribosomes and other riboproteins.","NAF1 Gene | NAF1 | Nuclear Assembly Factor 1 Ribonucleoprotein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828867","NAF1 wt Allele","C113131","Human NAF1 wild-type allele is located in the vicinity of 4q32.2 and is approximately 57 kb in length. This allele, which encodes H/ACA ribonucleoprotein complex non-core subunit NAF1 protein, is involved in riboprotein assembly.","NAF1 wt Allele | NAF1, S. cerevisiae, Homolog of Gene | Nuclear Assembly Factor 1 Homolog (S. cerevisiae) Gene | Nuclear Assembly Factor 1 Ribonucleoprotein wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2975216","H/ACA Ribonucleoprotein Complex Non-Core Subunit NAF1, Human","C113132","H/ACA ribonucleoprotein complex non-core subunit NAF1 (494 aa, ~54 kDa) is encoded by the human NAF1 gene. This protein plays a role in riboprotein formation.","H/ACA Ribonucleoprotein Complex Non-Core Subunit NAF1 | NAF1 | Nuclear Assembly Factor 1 Homolog | Nuclear Assembly Factor 1 Ribonucleoprotein | hNAF1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823935","CISD1 Gene","C113133","This gene is involved in both iron-sulfur cluster binding and electron transport.","CISD1 Gene | CDGSH Iron Sulfur Domain 1 Gene | CISD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898509","MPAI-4 - Participation: Residence","C115877","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Residence: Responsibilities of independent living and homemaking (such as, meal preparation, home repairs and maintenance, personal health maintenance beyond basic hygiene including medication management) but not including managing money.","MPAI-4 - Participation: Residence | MPAI1-Residence | MPAI126",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898506","MPAI-4 - Participation: Transportation","C115878","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Transportation.","MPAI-4 - Participation: Transportation | MPAI1-Transportation | MPAI127",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898510","MPAI-4 - Participation: Paid Employment","C115879","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Hours per week at paid employment when primary desired social role is paid employment. 'Support' means special help from another person with responsibilities (such as, a job coach or shadow, tutor, helper) or reduced responsibilities. Modifications to the physical environment that facilitate employment are not considered as support.","MPAI-4 - Participation: Paid Employment | MPAI1-Paid Employment | MPAI128A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897037","MPAI-4 - Participation: Other Employment","C115880","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Hours per week involved in constructive, role-appropriate activity other than paid employment when primary desired social role is not paid employment. 'Support' means special help from another person with responsibilities (such as, a job coach or shadow, tutor, helper) or reduced responsibilities. Modifications to the physical environment that facilitate employment are not considered as support.","MPAI-4 - Participation: Other Employment | MPAI1-Other Employment | MPAI128B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898511","MPAI-4 - Participation: Other Employment-Social Role","C115881","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Primary social role when paid employment is not primary desired social role.","MPAI-4 - Participation: Other Employment-Social Role | MPAI1-Other Employment-Social Role | MPAI128C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898512","MPAI-4 - Participation: Managing Money and Finances","C115882","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Managing money and finances: Shopping, keeping a check book or other bank account, managing personal income and investments.","MPAI-4 - Participation: Managing Money and Finances | MPAI1-Managing Money and Finances | MPAI129",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898523","MPAI-4 - Alcohol Use Pre-Injury","C115883","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Pre-Injury use of alcoholic beverages.","MPAI-4 - Alcohol Use Pre-Injury | MPAI1-Alcohol Use-Pre-Injury | MPAI130A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898524","MPAI-4 - Alcohol Use Post-Injury","C115884","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Post-Injury use of alcoholic beverages.","MPAI-4 - Alcohol Use Post-Injury | MPAI1-Alcohol Use-Post-Injury | MPAI130B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898521","MPAI-4 - Drug Use Pre-Injury","C115885","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Pre-Injury use of illegal drugs or abuse of prescription drugs.","MPAI-4 - Drug Use Pre-Injury | MPAI1-Drug Use-Pre-Injury | MPAI131A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898522","MPAI-4 - Drug Use Post-Injury","C115886","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Post-Injury use of illegal drugs or abuse of prescription drugs.","MPAI-4 - Drug Use Post-Injury | MPAI1-Drug Use-Post-Injury | MPAI131B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898505","MPAI-4 - Psychotic Symptoms Post-Injury","C115888","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Post-injury hallucinations, delusions, other persistent severely distorted perceptions of reality.","MPAI-4 - Psychotic Symptoms Post-Injury | MPAI1-Psychotic Symptoms-Post-Injury | MPAI132B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898519","MPAI-4 - Law Violations Pre-Injury","C115889","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Pre-injury history before and after injury.","MPAI-4 - Law Violations Pre-Injury | MPAI1-Law Violations-Pre-Injury | MPAI133A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816480","Probable G-Protein Coupled Receptor 110","C113545","Adhesion G-protein coupled receptor F1 (910 aa, ~101 kDa) is encoded by the human ADGRF1 gene. This protein is involved in G protein-coupled receptor signaling, which may be dependent on the removal of its extracellular domain.","Adhesion G Protein-Coupled Receptor F1 | ADGRF1 | G Protein-Coupled Receptor 110 | G Protein-Coupled Receptor PGR19 | G-Protein Coupled Receptor 110 | G-Protein Coupled Receptor KPG_012 | G-Protein Coupled Receptor PGR19 | Probable G-Protein Coupled Receptor 110 | Seven Transmembrane Helix Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3715041","CHN2 wt Allele","C113548","Human CHN2 wild-type allele is located in the vicinity of 7p15.3 and is approximately 392 kb in length. This allele, which encodes beta-chimaerin protein, plays a role in both the proliferation and migration of smooth muscle cells. Decreased expression of this gene is associated with high-grade gliomas and breast tumors, and increased expression of this gene is associated with lymphomas. Mutations in this gene have been associated with schizophrenia in men.","CHN2 wt Allele | ARHGAP3 | BCH | CHN2-3 | Chimerin 2 wt Allele | RHOGAP3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814377","UGT8 wt Allele","C113549","Human UGT8 wild-type allele is located in the vicinity of 4q26 and is approximately 80 kb in length. This allele, which encodes 2-hydroxyacylsphingosine 1-beta-galactosyltransferase protein, plays a role in the synthesis of galactocerebrosides.","UGT8 wt Allele | CGT | UDP Glycosyltransferase 8 wt Allele | UGT4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1570475","2-Hydroxyacylsphingosine 1-Beta-Galactosyltransferase, Human","C113550","2-hydroxyacylsphingosine 1-beta-galactosyltransferase (541 aa, ~61 kDa) is encoded by the human UGT8 gene. This protein is involved in the transfer of galactose to ceramide.","2-Hydroxyacylsphingosine 1-Beta-Galactosyltransferase | Ceramide UDP-Galactosyltransferase | Cerebroside Synthase | EC 2.4.1.45 | UDP-Galactose Ceramide Galactosyltransferase | UDP-Galactose-Ceramide Galactosyltransferase | UGT8 | Uridine Diphosphate Glycosyltransferase 8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3884572","Beta-Chimaerin, Human","C113551","Beta-chimaerin (468 aa, ~54 kDa) is encoded by the human CHN2 gene. This protein is involved in both the proliferation and migration of smooth muscle cells.","Beta-Chimaerin | Beta Chimerin | Beta-Chimerin | Beta3-Chimaerin | Chimaerin 2 | Chimerin (Chimaerin) 2 | Chimerin, Beta-2 | GTPase-Activating Protein, Rho, 3 | Rho GTPase-Activating Protein 3 | Rho-GTPase-Activating Protein 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812285","SEMA6A wt Allele","C113553","Human SEMA6A wild-type allele is located in the vicinity of 5q23.1 and is approximately 131 kb in length. This allele, which encodes semaphorin-6A protein, is involved in cell-cell signaling and axon guidance in the developing central nervous system. Mutations in this gene are associated with both neuroaxonal dystrophy and mouth disease.","SEMA6A wt Allele | HT018 | KIAA1368 | SEMA | SEMA6A-1 | SEMA6A1 | SEMAQ | Sema Domain, Transmembrane Domain (TM), and Cytoplasmic Domain, (Semaphorin) wt Allele | VIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816189","Semaphorin-6A, Human","C113554","Semaphorin-6A (1030 aa, ~114 kDa) is encoded by the human SEMA6A gene. This protein plays a role in axon guidance in the developing central nervous system.","Semaphorin-6A | SEMA6A | Sema VIA | Semaphorin 6A | Semaphorin 6A-1 | Semaphorin VIA | Semaphorin-6A-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828519","PON2 wt Allele","C113556","Human PON2 wild-type allele is located in the vicinity of 7q21.3 and is approximately 30 kb in length. This allele, which encodes serum paraoxonase/arylesterase 2 protein, may play a role as a cellular antioxidant.","PON2 wt Allele | PON 2 | Paraoxonase 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811724","CISD1 wt Allele","C113134","Human CISD1 wild-type allele is located in the vicinity of 10q21.1 and is approximately 21 kb in length. This allele, which encodes CDGSH iron-sulfur domain-containing protein 1, plays a role in the modulation of both cellular respiration and iron-sulfur cluster-dependent redox reactions.","CISD1 wt Allele | C10orf70 | CDGSH Iron Sulfur Domain 1 wt Allele | Chromosome 10 Open Reading Frame 70 Gene | MDS029 | ZCD1 | Zinc Finger, CDGSH-Type Domain 1 Gene | mitoNEET",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2003363","CDGSH Iron-Sulfur Domain-Containing Protein 1, Human","C113135","CDGSH iron-sulfur domain-containing protein 1 (108 aa, ~12 kDa) is encoded by the human CISD1 gene. This protein is involved in both iron-sulfur cluster binding and the regulation of cell respiration.","CDGSH Iron-Sulfur Domain-Containing Protein 1 | CDGSH Iron Sulfur Domain-Containing Protein 1 | CISD1 | MitoNEET | Mitochondrial Asn-Glu-Glu-Thr (NEET) | Zinc Finger CDGSH-Type Domain 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810560","HELQ wt Allele","C113138","Human HELQ wild-type allele is located in the vicinity of 4q21.23 and is approximately 49 kb in length. This allele, which encodes helicase POLQ-like protein, is involved in the modulation of DNA duplex unwinding.","HELQ wt Allele | HEL308 | Helicase, POLQ-Like wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1310456","Helicase POLQ-Like, Human","C113139","Helicase POLQ-like (1101 aa, ~124 kDa) is encoded by the human HELQ gene. This protein plays a role in ATP-dependent DNA helicase activity.","Helicase POLQ-Like | DNA Helicase HEL308 | EC 3.6.4.12 | HELQ | Mus308-Like Helicase | POLQ-Like Helicase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826267","MORC3 Gene","C113140","This gene is involved in binding to both RNA and nuclear matrix proteins.","MORC3 Gene | MORC Family CW-Type Zinc Finger 3 Gene | MORC3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812256","MORC3 wt Allele","C113141","Human MORC3 wild-type allele is located in the vicinity of 21q22.13 and is approximately 66 kb in length. This allele, which encodes MORC family CW-type zinc finger protein 3, plays a role in binding to both nuclear matrix proteins and RNA.","MORC3 wt Allele | KIAA0136 | MORC Family CW-Type Zinc Finger 3 wt Allele | NXP2 | ZCW5 | ZCWCC3 | Zinc Finger, CW Type With Coiled-Coil Domain 3 Gene | Zinc Finger, CW-Type With Coiled-Coil Domain 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0256204","MORC Family CW-Type Zinc Finger Protein 3","C113142","MORC family CW-type zinc finger protein 3 (939 aa, ~107 kDa) is encoded by the human MORC3 gene. This protein is involved in both RNA binding and nuclear matrix protein binding.","MORC Family CW-Type Zinc Finger Protein 3 | MJ ANTIGEN | MORC3 | NXP-2 | NXP2 | Nuclear Matrix Protein 2 | Nuclear Matrix Protein NXP-2 | Nuclear Matrix Protein NXP2 | Zinc Finger CW-Type Coiled-Coil Domain Protein 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827232","Testosterone Excess","C113349","Abnormally high level of testosterone.","Testosterone Excess | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827907","SPL Sex Terminology","C113350","Terminology used in the framework of Structured Product Labeling documents to distinguish the sex of an individual.","SPL Sex Terminology | Structured Product Labeling Sex Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3277370","Primary Ovarian Failure","C113352","Absent or premature cessation of ovarian function due to a pathologic process originating within the ovaries.","Primary Ovarian Failure | Hypergonadotropic Hypogonadism (Female) | primary ovarian insufficiency",,,,,,,,,,,,,,,"4279913","Primary ovarian failure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3830289","Exposure Planned Occurrence","C113353","An instance of an exposure event or incident that is intended to take place.","Exposure Planned Occurrence | EXPOCCUR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898520","MPAI-4 - Law Violations Post-Injury","C115890","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Post-injury history before and after injury.","MPAI-4 - Law Violations Post-Injury | MPAI1-Law Violations-Post-Injury | MPAI133B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889635","Uncharacterized Protein C10orf107, human","C116101","Ciliary-associated calcium-binding coiled-coil protein 1 (208 aa, ~24 kDa) is encoded by the human CABCOCO1 gene. This protein may play a role in blood pressure regulation.","Ciliary-Associated Calcium-Binding Coiled-Coil Protein 1 | CABCOCO1 | Calcium Binding Coiled-Coil Protein 1 | Calcium Binding Coiled-Coil Protein-1 | Ciliary-Associated Calcium-Binding Coiled-Coil 1 | Uncharacterized Protein C10orf107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896592","CDISC SDTM Pharmacogenomics Findings Test Name Terminology","C116105","Terminology associated with the pharmacogenomics findings test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Pharmacogenomics Findings Test Name Terminology | SDTM-PFTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896575","CDISC SDTM Viral Resistance Findings Test Name Terminology","C116109","Terminology associated with the viral resistance findings test name of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Viral Resistance Findings Test Name Terminology | SDTM-VRTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896588","CDISC SDTM Viral Resistance Findings Test Code Terminology","C116110","Terminology associated with the viral resistance findings test code of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Viral Resistance Findings Test Code Terminology | SDTM-VRTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889678","Institutional Review Board Independent Ethics Committee Subject Information Document","C115700","Records approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) that provides a subject with information about a clinical trial.","Institutional Review Board Independent Ethics Committee Subject Information Document | IRB-IEC Approved Subject Information | Institutional Review Board Independent Ethics Committee Approved Subject Information | Subj Info Sheet | Subject Information Sheet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890585","Institutional Review Board Independent Ethics Committee Subject Participation Document","C115701","Records approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC), and used by a subject to record participation in a clinical trial.","Institutional Review Board Independent Ethics Committee Subject Participation Document | IRB-IEC Approved Subject Participation | Institutional Review Board Independent Ethics Committee Approved Subject Participation | Subj Partic Card | Subject Participation Card",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898691","Investigational Medicinal Product Documentation","C115702","The Trial Master File Reference Model section that contains a collection of documents related to the regulatory import and/or export of investigational medicinal product(s) for the clinical trial.","TMF-RM Investigational Medicinal Product Section | Investigational Medicinal Product | Investigational Medicinal Product Documentation | Investigational Medicinal Product Subcategory | Invstgtl Med Prod Subcat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898669","Investigational Product and Trial Supplies Tracking Documentation","C115703","The Trial Master File Reference Model zone that contains the collection of documents relating to the management, shipping, storage, dispensing, and destruction of both Investigational Product(s) and supplies for the clinical trial.","TMF-RM Investigational Products and Trial Supplies Zone | IP Trial Suppl Cat | IP and Trial Supplies | IP and Trial Supplies Category | Investigational Product and Trial Supplies | Investigational Product and Trial Supplies Tracking Documentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898671","Investigational Product and Clinical Trial Supplies Tracking Document","C115704","Records that tracks the investigational product, and associated trial supplies, used during the course of the clinical trial.","Investigational Product and Clinical Trial Supplies Tracking Document | General Investigational Product and Trial Supplies Tracking Document | IP Trial Suppl Track Doc | IP and Trial Supplies Tracking Document",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898670","Investigational Product and Trial Supplies Shipping Handling and Labeling Documentation","C115705","The Trial Master File Reference Model section that contains a collection of documents related to the management of investigational product(s) and trial supplies for the clinical trial.","TMF-RM IP Documentation Section | IP Docn Subcat | IP Documentation | IP Documentation Subcategory | Investigational Product Documentation | Investigational Product and Trial Supplies Shipping Handling and Labeling Documentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898687","Investigational Product Communications and Tracking Documentation","C115706","Records pertaining to the tracking of, and communications about, the investigational product.","Investigational Product Communications and Tracking Documentation | General Investigational Product Documents | IP Doc Comm Track | IP Documents Communications and Tracking Subcategory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898684","Investigational Product Randomization Documentation","C115707","Records pertaining to the blinding and randomization of an investigational product (IP) and supplies.","Investigational Product Randomization Documentation | IP Allocation Documentation | IP Random Subcat | IP Randomization Subcategory | Investigational Product Randomization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898681","Investigational Product Regulatory Release Document","C115708","Documentation detailing the regulatory release of the investigational product(s) for the clinical trial.","Clinical Trial Investigational Product Regulatory Release Documentation | IP Reg Release | IP Regulatory Release | IP Regulatory Release Documentation | Investigational Product Regulatory Release | Investigational Product Regulatory Release Document",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898675","Investigational Product Site Release Document","C115710","Documentation approving the clinical trial site to receive a supply of investigational product(s).","Investigational Product Clinical Trial Site Release Documentation | Authorization to Ship Clinical Trial Materials | Drug Release Document | Drug Shipment Approval | IP Site Release Doc | IP Site Release Documentation | Investigational Product Site Release Document | Investigational Product Site Release Documentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433953","Untreated Childhood Oligoastrocytoma","C115949","A finding of oligoastrocytoma in childhood that has not been treated.","Untreated Childhood Oligoastrocytoma | Untreated Oligoastrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433936","Untreated Childhood Oligodendroglioma","C115950","A finding of oligodendroglioma in childhood that has not been treated.","Untreated Childhood Oligodendroglioma | Untreated Oligodendroglioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433938","Untreated Childhood Pilocytic Astrocytoma","C115951","A finding of pilocytic astrocytoma in childhood that has not been treated.","Untreated Childhood Pilocytic Astrocytoma | Untreated Pilocytic Astrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0755726","Serum Paraoxonase/Arylesterase 2, Human","C113557","Serum paraoxonase/arylesterase 2 (354 aa, ~39 kDa) is encoded by the human PON2 gene. This protein may play a role as a cellular antioxidant.","Serum Paraoxonase/Arylesterase 2 | A-Esterase 2 | Aromatic Esterase 2 | EC 3.1.1.2 | EC 3.1.1.81 | PON2 | Paraoxonase 2 | Paraoxonase Nirs | Serum Aryldialkylphosphatase 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830535","Derivation, Not Otherwise Specified","C113073","The synthesis of a material of interest using a process that is not otherwise specified.","Derivation, Not Otherwise Specified | Derivation, Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828715","Oligonucleotide Synthesis","C113074","The process of producing oligonucleotides by the union of simpler chemical compounds.","Oligonucleotide Synthesis | Synthesis, Oligonucleotide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3178925","Synthetic Peptide Synthesis","C113075","The process of producing peptides by the polymerization of amino acids.","Synthetic Peptide Synthesis | Peptide Synthesis, Synthetic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831541","Analytical Laboratory Testing, Not Otherwise Specified","C113076","Any analytical testing operation not otherwise specified.","Analytical Laboratory Testing, Not Otherwise Specified | Analytical Laboratory Testing, Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831328","Blood Products Laboratory Testing","C113077","In vitro testing of donor blood for safety prior to use in patients.","Blood Products Laboratory Testing | Laboratory Testing, Blood Products | Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831127","Chemical Laboratory Testing","C113078","Testing of specimens or materials for various chemical properties.","Chemical Laboratory Testing | Laboratory Testing, Chemical",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831060","Code Writing of Software Platform or Architecture for in Vitro Diagnostics Device","C113080","The act of writing code for the software of an in vitro diagnostic device.","Code Writing of Software Platform or Architecture for in Vitro Diagnostics Device | Write Code, Software Platform/Architecture, in Vitro Diagnostics Device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417029","MAPKAPK5 Gene","C113081","This gene is involved in protein phosphorylation, mTORC1-mediated signaling and tumor suppression.","MAPKAPK5 Gene | MAPKAPK5 | Mitogen-Activated Protein Kinase-Activated Protein Kinase 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811163","MAPKAPK5 wt Allele","C113082","Human MAPKAPK5 wild-type allele is located in the vicinity of 12q24.13 and is approximately 55 kb in length. This allele, which encodes MAP kinase-activated protein kinase 5 protein, plays a role in both the inhibition of mTORC1 signaling and serine/threonine phosphorylation.","MAPKAPK5 wt Allele | MAPKAP-K5 | MK-5 | MK5 | Mitogen-Activated Protein Kinase-Activated Protein Kinase 5 wt Allele | PRAK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1431394","MAP kinase-activated protein kinase 5, human","C113083","MAP kinase-activated protein kinase 5 (473 aa, ~54 kDa) is encoded by the human MAPKAPK5 gene. This protein is involved in serine/threonine phosphorylation, tumor growth suppression and signaling regulation.","MAP Kinase-Activated Protein Kinase 5 | EC 2.7.11.1 | MAPK-Activated Protein Kinase 5 | MAPKAP Kinase 5 | MAPKAP-K5 | MAPKAPK-5 | MK-5 | MK5 | PRAK | p38-Regulated/Activated Kinase | p38-Regulated/Activated Protein Kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826448","NOD1 Gene","C113086","This gene plays a role in both apoptosis and immunity.","NOD1 Gene | NOD1 | Nucleotide-Binding Oligomerization Domain Containing 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830121","Findings About Events or Interventions Collection Date Time","C113360","The date and time that a finding about an event or intervention was collected.","Findings About Events or Interventions Collection Date Time | FADTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3531930","Monochorionic Monoamniotic Twin Pregnancy","C112853","A pregnancy involving two fetuses that share both the chorion and amniotic sac. These twins are invariably identical.","Monochorionic Monoamniotic Twin Pregnancy | ",,,,,,,,,,,,,,,"43021952","Monochorionic monoamniotic twin pregnancy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2977401","Monochorionic Diamniotic Twin Pregnancy","C112854","A pregnancy involving two fetuses that share the same chorion but have separate amniotic sacs.","Monochorionic Diamniotic Twin Pregnancy | ",,,,,,,,,,,,,,,"43021951","Monochorionic diamniotic twin pregnancy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828805","Non-Cesarean Uterine Surgical Scarring","C112856","A scar/healing of the myometrium that occurs after uterine injury or after non-cesarean surgery.","Non-Cesarean Uterine Surgical Scarring | Non-Caesarean Uterine Surgical Scarring | Non-Cesarean Uterine Surgery Scar | Non-Cesarean Uterine Surgical Scar",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0000821","Threatened Abortion","C112857","Vaginal bleeding preceding the 20th week of gestation.","Threatened Abortion | ",,,,,,,,,,,,,,,"440457","Threatened miscarriage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3896591","CDISC SDTM Species Terminology","C116111","Terminology associated with the SDTM species codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Species Terminology | SDTM-SPCIES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473728","Lethal Injection Euthanasia","C116113","A method of euthanasia whereby a subject is given a lethal injection to induce death.","Lethal Injection Euthanasia | LETHAL INJECTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896664","CDISC Functional Test SDMT Test Code Terminology","C115396","Test codes of functional test questions associated with the Symbol Digit Modalities Test (SDMT) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Functional Test SDMT Test Code Terminology | FT- SDMT TESTCD | SDMT01TC | Symbol Digit Modalities Test Functional Test Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896661","CDISC Functional Test T25FW Test Name Terminology","C115397","Test names of functional test questions associated with the Timed 25-Foot Walk Test (T25FW) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Functional Test T25FW Test Name Terminology | FT- T25FW TEST | T25FW1TN | Timed 25-Foot Walk Test Functional Test Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896662","CDISC Functional Test T25FW Test Code Terminology","C115398","Test codes of functional test questions associated with the Timed 25-Foot Walk Test (T25FW) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Functional Test T25FW Test Code Terminology | FT- T25FW TESTCD | T25FW1TC | Timed 25-Foot Walk Test Functional Test Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896659","CDISC Functional Test TUG Test Name Terminology","C115399","Test names of functional test questions associated with the Timed Up and Go Test (TUG) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Functional Test TUG Test Name Terminology | FT- TUG TEST | TUG01TN | Timed Up and Go Test Functional Test Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896660","CDISC Functional Test TUG Test Code Terminology","C115400","Test codes of functional test questions associated with the Timed Up and Go Test (TUG) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Functional Test TUG Test Code Terminology | FT- TUG TESTCD | TUG01TC | Timed Up and Go Test Functional Test Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896622","QS-DRS TEST","C115401","Test names of clinical classification questions associated with the Disability Rating Scale (DRS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification DRS Test Name Terminology | DRS01TN | Disability Rating Scale Clinical Classification Test Name | QS-DRS TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896623","QS-DRS TESTCD","C115402","Test codes of clinical classification questions associated with the Disability Rating Scale (DRS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification DRS Test Code Terminology | DRS01TC | Disability Rating Scale Clinical Classification Test Code | QS-DRS TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896618","CDISC Questionnaire GOSE Test Name Terminology","C115403","Test names of questionnaire questions associated with the Extended Glasgow Outcome Scale (GOSE) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire GOSE Test Name Terminology | Extended Glasgow Outcome Scale Questionnaire Test Name | GOSE1TN | QS-GOSE TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827631","VFQ25-Interviewer Administered Format - Difficulty Recognizing People You Know","C112763","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Distance Vision: Because of your eyesight, how much difficulty do you have recognizing people you know from across a room?","VFQ25-Interviewer Administered Format - Difficulty Recognizing People You Know | VFQ1-Difficulty Recognizing People | VFQ1A06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827627","VFQ25-Interviewer Administered Format - Difficulty Taking Part in Sports or Outdoor Activities","C112764","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Distance Vision: Because of your eyesight, how much difficulty do you have taking part in active sports or other outdoor activities that you enjoy (like golf, bowling, jogging, or walking)?","VFQ25-Interviewer Administered Format - Difficulty Taking Part in Sports or Outdoor Activities | VFQ1-Difficulty Taking Part in Sports | VFQ1A07",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827630","VFQ25-Interviewer Administered Format - Difficulty Seeing and Enjoying Programs on TV","C112765","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Distance Vision: Because of your eyesight, how much difficulty do you have seeing and enjoying programs on TV?","VFQ25-Interviewer Administered Format - Difficulty Seeing and Enjoying Programs on TV | VFQ1-Difficulty Seeing Programs on TV | VFQ1A08",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827624","VFQ25-Interviewer Administered Format - Do You Have More Help From Others","C112767","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Role Limitations: Do you have more help from others because of your vision?","VFQ25-Interviewer Administered Format - Do You Have More Help From Others | VFQ1-Do You Have More Help From Others | VFQ1A11A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827617","VFQ25-Interviewer Administered Format - Limited in Kinds of Things Can Do","C112768","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Role Limitations: Are you limited in the kinds of things you can do because of your vision?","VFQ25-Interviewer Administered Format - Limited in Kinds of Things Can Do | VFQ1-Limited in Kinds of Things Can Do | VFQ1A11B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0768857","Nucleotide-Binding Oligomerization Domain-Containing Protein 1, Human","C113088","Nucleotide-binding oligomerization domain-containing protein 1 (953 aa, ~108 kDa) is encoded by the human NOD1 gene. This protein plays a role in both apoptosis and host-defense responses.","Nucleotide-Binding Oligomerization Domain-Containing Protein 1 | Caspase Recruitment Domain-Containing Protein 4 | NOD1 | Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat and CARD Domain Containing 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1870145","E3 Ubiquitin-Protein Ligase MARCH9, Human","C113308","E3 ubiquitin-protein ligase MARCH9 (346 aa, ~38 kDa) is encoded by the human MARCHF9 gene. This protein is involved in the ubiquitination of plasma membrane proteins.","E3 Ubiquitin-Protein Ligase MARCH9 | EC 2.3.2.27 | EC 6.3.2.-, Formerly | MARCH-IX | Membrane Associated Ring Finger 9 | Membrane Associated Ring-CH-Type Finger 9 | Membrane-Associated RING Finger Protein 9 | Membrane-Associated RING-CH Finger Protein 9 | Membrane-Associated RING-CH Protein IX | RING Finger Protein 179 | RING-Type E3 Ubiquitin Transferase MARCH9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814149","MX1 wt Allele","C113310","Human MX1 wild-type allele is located in the vicinity of 21q22.3 and is approximately 39 kb in length. This allele, which encodes interferon-induced GTP-binding protein Mx1, is involved in the regulation of apoptosis, hydrolysis of GTP, the modulation of interferon-regulated signaling.","MX1 wt Allele | IFI-78K | IFI78 | MX | MxA | Myxovirus (Influenza Virus) Resistance 1, Interferon-Inducible Protein p78 (Mouse) wt Allele | Myxovirus (Influenza) Resistance 1, Homolog of Murine (Interferon-Inducible Protein p78) Gene | Myxovirus Resistance 1, Mouse, Homolog of Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814808","Interferon-Induced GTP-Binding Protein Mx1","C113311","Interferon-induced GTP-binding protein Mx1 (662 aa, ~76 kDa) is encoded by the human MX1 gene. This protein plays a role in GTP hydrolysis, apoptosis regulation and interferon signaling.","Interferon-Induced GTP-Binding Protein Mx1 | Human Interferon-Regulated Resistance GTP-Binding Protein MXA | IFI-78K | Interferon-Inducible Protein p78 | Interferon-Regulated Resistance GTP-Binding Protein MxA | MX1 | Myxoma Resistance Protein 1 | Myxovirus Resistance Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812276","POU5F1B wt Allele","C113313","Human POU5F1B wild-type allele is located in the vicinity of 8q24.21 and is approximately 6 kb in length. This allele, which encodes putative POU domain, class 5, transcription factor 1B protein, plays a role in the regulation of transcription.","POU5F1B wt Allele | OCT4-PG1 | OCT4PG1 | OTF3C | OTF3P1 | Octamer Binding Protein 3-Like Sequence Gene | Octamer Binding Protein 3_like Sequence Gene | POU Class 5 Homeobox 1 Pseudogene 1 | POU Class 5 Homeobox 1B wt Allele | POU Domain Class 5, Transcription Factor 1 Pseudogene 1 | POU Domain Transcription Factor OCT4-Pg1 Gene | POU Domain, Class 5, Transcription Factor 1B Gene | POU5F1P1 | POU5F1P4 | POU5FLC20 | POU5FLC8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812275","Putative POU Domain, Class 5, Transcription Factor 1B, human","C113314","Putative POU domain, class 5, transcription factor 1B (359 aa, ~39 kDa) is encoded by the human POU5F1B gene. This protein is involved in the regulation of target gene expression.","Putative POU Domain, Class 5, Transcription Factor 1B | Oct4-pg1 | Octamer-Binding Protein 3-Like | Octamer-Binding Transcription Factor 3-Like | POU Domain, Class 5, Transcription Factor 1B | POU5F1B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0948915","Early Pregnancy Loss","C112858","Pregnancy loss before 10th week of gestation with documentation of a confirmed pregnancy.","Early Pregnancy Loss | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2919902","Peri-Implantational Loss","C112859","Pregnancy loss before 5th week of gestation with no gestational sac visible on ultrasonogram.","Peri-Implantational Loss | Chemical Pregnancy | Peri-Implantational Failure",,,,,,,,,,,,,,,"40482050","Chemical pregnancy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0266648","Pre-Embryonic Loss","C112860","Pregnancy loss with visible gestational sac or yolk sac or both but no visible embryo on ultrasonogram.","Pre-Embryonic Loss | Anembryonic Pregnancy",,,,,,,,,,,,,,,"4262136","Blighted ovum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3830317","Embryonic Loss","C112861","Pregnancy loss at 6 weeks, 0 days to 9 weeks, 6 days of gestation of an embryo with crown-rump length less than 10 mm and no cardiac activity visible on ultrasonogram.","Embryonic Loss | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830363","Early Fetal Death","C112862","Death of a fetus at 10 weeks, 0 days to 15 weeks, 6 days of gestation.","Early Fetal Death | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829316","Late Fetal Death","C112863","Death of a fetus at 16 weeks, 0 days to 19 weeks, 6 days of gestation.","Late Fetal Death | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0349467","Transient Myocardial Ischemia of Newborn","C112865","A condition characterized by a temporary imbalance between the oxygen supply and demand of the heart muscle in the newborn.","Transient Myocardial Ischemia of Newborn | ",,,,,,,,,,,,,,,"4172865","Transient myocardial ischemia of newborn",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1421584","ZIM2 Gene","C112867","This gene may play a role in transcriptional regulation.","ZIM2 Gene | ZIM2 | Zinc Finger, Imprinted 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815199","ZIM2 wt Allele","C112868","Human ZIM2 wild-type allele is located in the vicinity of 19q13.4 and is approximately 66 kb in length. This allele, which encodes zinc finger imprinted 2 protein, may be involved in the regulation of transcription.","ZIM2 wt Allele | ZNF656 | Zinc Finger, Imprinted 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827392","Zinc Finger Imprinted 2","C112869","Zinc finger imprinted 2 (527 aa, ~61 kDa) is encoded by the human ZIM2 gene. This protein may play a role in gene expression.","Zinc Finger Imprinted 2 | ZIM2 | Zinc Finger Protein 656",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418452","PEG3 Gene","C112870","This gene is involved in both tumor suppression and apoptosis.","PEG3 Gene | PEG3 | Paternally Expressed 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814457","PEG3 wt Allele","C112871","Human PEG3 wild-type allele is located in the vicinity of 19q13.4 and is approximately 31 kb in length. This allele, which encodes paternally-expressed gene 3 protein, plays a role in both apoptosis and tumor suppression.","PEG3 wt Allele | KIAA0287 | PW1 | Paternally Expressed 3 wt Allele | Paternally Expressed Gene 3 | Paternally-Expressed Gene 3 | ZKSCAN22 | ZNF904 | ZSCAN24 | hCG_1685807",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1455044","Paternally-Expressed Gene 3 Protein, Human","C112872","Paternally-expressed gene 3 protein (1588 aa, ~181 kDa) is encoded by the human PEG3 gene. This protein is involved in both tumor suppression and the regulation of apoptosis.","Paternally-Expressed Gene 3 Protein | PEG3 | Paternally Expressed Gene 3 Protein | Zinc Finger and SCAN Domain-Containing Protein 24",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473485","Sulfatinib","C116066","An orally bioavailable, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, and the fibroblast growth factor receptor type 1 (FGFR1), with potential antineoplastic and anti-angiogenic activities. Upon oral administration, sulfatinib binds to and inhibits VEGFRs and FGFR1 thereby inhibiting VEGFR- and FGFR1-mediated signal transduction pathways. This leads to a reduction of angiogenesis and tumor cell proliferation in VEGFR/FGFR1-overexpressing tumor cells. Expression of VEGFRs and FGFR1 may be upregulated in a variety of tumor cell types.","Sulfatinib | HMPL-012 | SURUFATINIB | Surufatinib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896619","CDISC Questionnaire GOSE Test Code Terminology","C115404","Test codes of questionnaire questions associated with the Extended Glasgow Outcome Scale (GOSE) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire GOSE Test Code Terminology | Extended Glasgow Outcome Scale Questionnaire Test Code | GOSE1TC | QS-GOSE TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896616","CDISC Questionnaire MPAI-4 Test Name Terminology","C115405","Test names of questionnaire questions associated with the Mayo-Portland Adaptability Inventory-4 (MPAI-4) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire MPAI-4 Test Name Terminology | MPAI1TN | Mayo-Portland Adaptability Inventory-4 Questionnaire Test Name | QS-MPAI-4 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896617","CDISC Questionnaire MPAI-4 Test Code Terminology","C115406","Test codes of questionnaire questions associated with the Mayo-Portland Adaptability Inventory-4 (MPAI-4) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire MPAI-4 Test Code Terminology | MPAI1TC | Mayo-Portland Adaptability Inventory-4 Questionnaire Test Code | QS-MPAI-4 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889413","Clinical Trial Management Tracking Documentation","C115658","Records detailing the progress of clinical trial activities.","Clinical Trial Management Tracking Documentation | Tracking Document | Trial Management Tracking Documents | Trial Mgmt Track",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899572","Clinical Trial Member Detail Documentation","C115659","Documentation defining the structure, roles and contact details of the clinical trial team (both sponsor and vendors).","Clinical Trial Team Details Documentation | Clinical Trial Member Detail Documentation | Members List | Team Roster | Team Structure | Trial Team Details | Trial Team Log | Trial Team Roles and Responsibilities | Trial Tm Detl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899568","Clinical Trial Non-Investigational Product Documentation","C115660","The Trial Master File Reference Model section that contains a collection of documents related to the management of non-investigational product(s) for the clinical trial.","TMF-RM Non-IP Documentation Section | Clinical Trial Non-Investigational Product Documentation | Non-IP Docn | Non-IP Documentation | Non-IP Documentation Subcategory | Non-Investigational Product Documentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899567","Clinical Trial Non-Investigational Product Supplies Documentation of Return","C115661","Documentation providing information regarding the return of the non-investigational product(s) and supplies for the clinical trial.","Clinical Trial Non-Investigational Product Supplies Documentation of Return | Non-IP Docn Return | Non-IP Documentation of Return | Non-IP Return Documentation | Non-Investigational Product Documentation of Return",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890410","Clinical Trial Notification of Termination Document","C115662","Documentation detailing the communications to regulatory authorities regarding the termination or closure of the clinical trial.","Clinical Trial Regulatory Notification of Termination or Closure Documentation | Clinical Trial Notification of Termination Document | Notification of Discontinuation of Clinical Trial | Reg Notf Trial Termin | Regulatory Notification of Trial Termination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899564","Clinical Trial Notification to Investigators of Safety Information Document","C115663","Documentation verifying distribution and receipt of the communications related to the safety of the clinical trial to the investigators.","Clinical Trial Notification to Investigators of Safety Information Documentation | Clinical Trial Notification to Investigators of Safety Information Document | Notf Invstgr Safe Info | Notification to Investigators of Safety Information | SUSAR Notification | Safety Letter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889412","Clinical Trial Protocol Deviation Document","C115664","Documentation detailing any non-compliance or deviations from the clinical study protocol.","Clinical Study Protocol Deviation Documentation | Clinical Trial Protocol Deviation Document | Deviation Log | Prot Deviate | Protocol Deviation Report | Protocol Deviations | Protocol Violation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899556","Clinical Trial Regulatory Approval Documentation","C115665","The Trial Master File Reference Model section that contains a collection of documents related to the regulatory trial approval for the clinical trial.","TMF-RM Trial Regulatory Approval Section | Clinical Trial Regulatory Approval Documentation | Trial Approv Subcat | Trial Approval | Trial Approval Subcategory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889409","Clinical Trial Regulatory Tracking Document","C115666","Records that track the regulatory activities during the course of a clinical trial.","Clinical Trial Regulatory Tracking Document | Reg Track Doc | Regulatory Tracking Document | Tracking Document",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829681","HLA-A Gene Product","C113513","A protein encoded by the human HLA-A gene.","HLA-A Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829697","High Shear Granulation","C113011","The use of a series of integrated steps whereby a dry powder is conditioned by wetting, or is melted, to form a plasticized mass that with the aid of high shear forces yields relatively dense particles.","High Shear Granulation | Granulation, High Shear",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829249","Low Shear Granulation","C113012","The use of a series of integrated steps whereby a dry powder is conditioned by wetting or is melted to form a plasticized mass that with the aid of low shear forces, yields particles possessing characteristic dimensions and density.","Low Shear Granulation | Granulation, Low Shear",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827959","Spray Granulation","C113013","Granulation involving the atomization of a slurry of fine particles that are bound as they are suspended and conveyed by a flowing hot gas stream, resulting in dry granules suitable for filling or compression.","Spray Granulation | Granulation, Spray",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830126","Final Harvest and Pooling of Viral Vectors","C113014","Procedures for extraction and collection of viral vectors from cultured cells.","Final Harvest and Pooling of Viral Vectors | Harvest/Pooling, Viral Vectors Final",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829595","Human Cell or Tissue Harvest","C113015","The process by which human donor cells or tissues are obtained for use in human implantation, transplantation, infusion, or transfer.","Human Cell or Tissue Harvest | Recovery, Human Cell/Tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829356","Labeling, Not Otherwise Specified","C113017","Any labeling operation not elsewhere described.","Labeling, Not Otherwise Specified | Labeling Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814505","GIG1","C113316","Human CCN1 wild-type allele is located in the vicinity of 1p22.3 and is approximately 3 kb in length. This allele, which encodes CCN family member 1 protein, is involved in heart morphogenesis, angiogenesis, cell proliferation, cell adhesion and the positive regulation of apoptosis.","CCN1 wt Allele | CCN Family, Member 1 Gene | CYR61 | CYR61 wt Allele | Cellular Communication Network Factor 1 wt Allele | Cysteine Rich, Angiogenic Inducer 61 Gene | Cysteine-Rich Protein 61, Mouse, Homolog of Gene | Cysteine-Rich, Angiogenic Inducer, 61 Gene | GIG1 | IGFBP10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1137456","CYR61 protein, human","C113317","CCN family member 1 (381 aa, ~42 kDa) is encoded by the human CCN1 gene. This protein plays a role in cell adhesion, cell proliferation, angiogenesis, heart morphogenesis and apoptosis.","CCN Family Member 1 | CCN1 | Cellular Communication Network Factor 1 | Cysteine-Rich Angiogenic Inducer 61 | Cysteine-Rich Heparin-Binding Protein 61 | Cysteine-Rich Protein 61 | IBP-10 | IGF-Binding Protein 10 | IGFBP-10 | Insulin-Like Growth Factor-Binding Protein 10 | Protein CYR61 | Protein GIG1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827597","VFQ25-Self Administered Format - Difficulty Figure Out Bill Accuracy","C112803","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Near Vision: Because of your eyesight, how much difficulty do you have figuring out whether bills you receive are accurate?","VFQ25-Self Administered Format - Difficulty Figure Out Bill Accuracy | VFQ2-Difficulty Figure Out Bill Accuracy | VFQ2A04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827585","VFQ25-Self Administered Format - Difficulty Shaving or Styling Hair or Putting On Makeup","C112804","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Near Vision: Because of your eyesight, how much difficulty do you have doing things like shaving, styling your hair, or putting on makeup?","VFQ25-Self Administered Format - Difficulty Shaving or Styling Hair or Putting On Makeup | VFQ2-Difficulty Shaving or Styling Hair | VFQ2A05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827588","VFQ25-Self Administered Format - Difficulty Recognizing People You Know","C112805","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Distance Vision: Because of your eyesight, how much difficulty do you have recognizing people you know from across a room?","VFQ25-Self Administered Format - Difficulty Recognizing People You Know | VFQ2-Difficulty Recognizing People | VFQ2A06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827587","VFQ25-Self Administered Format - Difficulty Seeing and Enjoying Programs on TV","C112807","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Distance Vision: Because of your eyesight, how much difficulty do you have seeing and enjoying programs on TV?","VFQ25-Self Administered Format - Difficulty Seeing and Enjoying Programs on TV | VFQ2-Difficulty Seeing Programs on TV | VFQ2A08",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827598","VFQ25-Self Administered Format - Difficulty Entertaining Friends and Family in Home","C112808","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Social Function: Because of your eyesight, how much difficulty do you have entertaining friends and family in your home?","VFQ25-Self Administered Format - Difficulty Entertaining Friends and Family in Home | VFQ2-Difficulty Entertaining Friends | VFQ2A09",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827581","VFQ25-Self Administered Format - Do You Have More Help From Others","C112809","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Role Limitations: Do you have more help from others because of your vision?","VFQ25-Self Administered Format - Do You Have More Help From Others | VFQ2-Do You Have More Help From Others | VFQ2A11A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827324","VFQ25-Self Administered Format - Limited in Kinds of Things Can Do","C112810","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Role Limitations: Are you limited in the kinds of things you can do because of your vision?","VFQ25-Self Administered Format - Limited in Kinds of Things Can Do | VFQ2-Limited in Kinds of Things Can Do | VFQ2A11B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473486","Long Peptide Vaccine 7","C116067","A peptide vaccine consisting of a combination of seven synthetic long peptides (SLPs), which are each about 30 amino acids in size, and derived from cancer-testis antigens (CTA) and melanocytic differentiation proteins (MDP), with potential immunostimulating and antitumor activities. Upon administration, long peptide vaccine 7 may stimulate the host immune system to mount a cytotoxic T-cell lymphocyte (CTL) response against tumor cells expressing these peptides. CTA and MDP are overexpressed in a variety of cancer cell types.","Long Peptide Vaccine 7 | LPV7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473487","Aurora A kinase inhibitor TAS-119","C116068","An orally bioavailable inhibitor of the serine/threonine protein kinase aurora A, with potential antimitotic and antineoplastic activities. Upon intravenous administration, aurora A kinase inhibitor VIC-1911 binds to and inhibits aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, inhibition of cell division and the induction of apoptosis in cells overexpressing aurora A kinase. Aurora A kinase localizes to the spindle poles and to spindle microtubules during mitosis; it plays an essential role in the regulation of spindle assembly. Aurora kinase A is overexpressed in a wide variety of cancers.","Aurora A Kinase Inhibitor VIC-1911 | Aurora A Kinase Inhibitor TAS-119 | TAS-119 | TAS-2104 | VIC 1911 | VIC-1911 | VIC1911",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473488","CD19CAR-CD3zeta-4-1BB-CD28-expressing Autologous T-Lymphocytes","C116069","Autologous T-lymphocytes transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) coupled to three co-stimulatory signaling domains derived from CD28, 4-1BB (CD137), and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3-zeta), with potential immunomodulating and antineoplastic activities. Upon transfusion, the CD19CAR-CD3zeta-4-1BB-CD28-expressing autologous T-lymphocytes direct the T-lymphocytes to CD19-expressing tumor cells and induce their selective toxicity. CD28, a T-cell surface-associated co-stimulatory molecule, is required for T-cell activation, proliferation, and survival. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19. CD3-zeta is a transmembrane signaling adaptor polypeptide that regulates the assembly of TCR complexes, modulates the expression of the complex on the cell surface and plays a key role in antigen recognition. CD19 antigen, a B-cell specific cell surface antigen, is expressed in all B-cell lineage malignancies.","CD19CAR-CD3zeta-4-1BB-CD28-expressing Autologous T-Lymphocytes | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473489","anti-C4.4a antibody-drug conjugate BAY1129980","C116070","An antibody-drug conjugate (ADC) composed of an antibody against a structural homolog of the urokinase-type plasminogen activator receptor (uPAR) and tumor-associated antigen, C4.4a, and conjugated with a cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, lupartumab amadotin targets and binds to C4.4a-expressing tumor cells. Upon binding and cell entry, the cytotoxic agent kills the tumor cell. C4.4a, a glycolipid-anchored membrane protein and a member of the Ly-6 family, is overexpressed by a variety of cancer cell types whereas it is minimally expressed on healthy cells.","Lupartumab Amadotin | BAY112-9980 | BAY1129980 | LUPARTUMAB AMADOTIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473490","Iodine I 124 CPD-1028","C116071","A radioconjugate composed of the insulin-like growth factor 1 receptor (IGF-1R) binding agent CPD-1028 and conjugated to the radionuclide iodine I 124, with potential tumor imaging upon positron emission tomography/computed tomography (PET/CT). Upon administration, iodine I 124 CPD-1028 targets and binds to IGF-1R-expressing tumor cells. Upon PET/CT imaging, the iodine I 124 moiety can be visualized and the quantity of IGF-1R-expressing tumor cells can be assessed. IGF-1R, a receptor tyrosine kinase overexpressed in a variety of human cancers, plays a significant role in the stimulation of cellular proliferation, oncogenic transformation, and the suppression of apoptosis.","Iodine I 124 CPD-1028 | [I-124]-CPD-1028",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473491","Autologous CD8+ Melanoma Specific T Cells","C116072","Autologous CD8 T-lymphocytes against melanoma-associated antigens, with potential immunomodulating and antineoplastic activities. Following leukapheresis and the ex vivo expansion of cytotoxic T-lymphocytes, the autologous CD8+ melanoma specific T-cells are re-introduced into the melanoma patient. These cytotoxic T-cells recognize and kill the patient's own melanoma cells.","Autologous CD8+ Melanoma Specific T Cells | Autologous Melanoma Specific Cytotoxic T Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2712370","Apparent Life Threatening Event","C116310","An episode during which the patient, usually a child less than one year, experiences a combination of apnea, color change, alteration in muscle tone, choking or gagging. This event can be frightening to the observer.","Apparent Life Threatening Event | ALTE",,,,,,,,,,,,,,,"36715345|46272970","Brief resolved unexplained event|Apparent life-threatening event in infant",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3899553","Clinical Trial Safety Reporting Documentation","C115667","The Trial Master File Reference Model zone that contains the collection of documents relating to safety and pharmacovigilance management for the clinical trial.","TMF-RM Safety Reporting Zone | Clinical Trial Safety Reporting Documentation | Safe Rept Cat | Safety Reporting | Safety Reporting Category",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899551","Clinical Trial Site Feasibility Document","C115668","Documentation describing site feasibility for the clinical study protocol.","Clinical Trial Site Feasibility Documentation | Clinical Trial Site Feasibility Document | Feas Doc | Feasibility Documentation | Site Selection Documentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890384","Clinical Trial Site Management Tracking Document","C115670","Records that track the site management activities during the course of a clinical trial.","Clinical Trial Site Management Tracking Document | Site Management Tracking Document | Site Mgmt Track Doc | Tracking Document",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899548","Clinical Trial Site Personnel Contact Document","C115671","Documentation detailing the contact information of the clinical trial site personnel.","Clinical Trial Site Personnel Contact Detail Documentation | Clinical Trial Site Personnel Contact Document | Site Contact Details | Study Site Pers Detl | Study Site Personnel Details",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899546","Clinical Trial Site Selection Documentation","C115672","The Trial Master File Reference Model section that contains a collection of documents related to site selection for the clinical trial.","TMF-RM Site Selection Section | Clinical Trial Site Selection Documentation | Site Select Mgmt | Site Selection | Site Selection Subcategory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898515","MPAI-4 - Other Condition Causing Physical Impairment Pre-Injury","C115891","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Pre-injury physical disability due to medical conditions other than brain injury, such as, spinal cord injury, amputation.","MPAI-4 - Other Condition Causing Physical Impairment Pre-Injury | MPAI1-Other Physical Cond-Pre-Injury | MPAI134A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898516","MPAI-4 - Other Condition Causing Physical Impairment Post-Injury","C115892","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Post-injury physical disability due to medical conditions other than brain injury, such as, spinal cord injury, amputation.","MPAI-4 - Other Condition Causing Physical Impairment Post-Injury | MPAI1-Other Physical Cond-Post-Injury | MPAI134B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898518","MPAI-4 - Other Condition Causing Cognitive Impairment Post-Injury","C115894","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Post-injury cognitive disability due to nonpsychiatric medical conditions other than brain injury, such as, dementia, stroke, developmental disability.","MPAI-4 - Other Condition Causing Cognitive Impairment Post-Injury | MPAI1-Other Cognitive Cond-Post-Injury | MPAI135B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897664","SWLS - My Life is Close to Ideal","C115895","Satisfaction With Life Scale (SWLS) In most ways my life is close to my ideal.","SWLS - My Life is Close to Ideal | SWLS01-My Life is Close to Ideal | SWLS0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897666","SWLS - Life Conditions are Excellent","C115896","Satisfaction With Life Scale (SWLS) The conditions of my life are excellent.","SWLS - Life Conditions are Excellent | SWLS01-My Life Conditions are Excellent | SWLS0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897663","SWLS - Satisfied with My Life","C115897","Satisfaction With Life Scale (SWLS) I am satisfied with my life.","SWLS - Satisfied with My Life | SWLS01-I Am Satisfied with My Life | SWLS0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897667","SWLS - Have Gotten Important Things","C115898","Satisfaction With Life Scale (SWLS) So far I have gotten the important things I want in life.","SWLS - Have Gotten Important Things | SWLS01-Have Gotten Important Things | SWLS0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897665","SWLS - Live Life Over Change Nothing","C115899","Satisfaction With Life Scale (SWLS) If I could live my life over, I would change almost nothing.","SWLS - Live Life Over Change Nothing | SWLS01-Live Life Over Change Nothing | SWLS0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830525","Device or Device Component Manufacturing","C113018","A process that involves designing, fabrication, assembly and/or processing of a device or device component.","Device or Device Component Manufacturing | Manufacture/Assemble, Device or Device Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829204","Manufacture or Assemble Software Platform or Architecture for in Vitro Diagnostics Device","C113019","Fabrication of the physical structure of an in vitro diagnostic device.","Manufacture or Assemble Software Platform or Architecture for in Vitro Diagnostics Device | Manufacture/Assemble, Software Platform/Architecture, in Vitro Diagnostics Device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828358","Recombinant Protein Manufacture","C113020","In vivo synthesis of recombinant proteins through recombinant DNA techniques, followed by purification.","Recombinant Protein Manufacture | Manufacture, Recombinant Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829353","Laboratory Testing for Bacteria, Virus, or Mycoplasma","C113021","Testing of specimens or materials for the presence of microbial contamination.","Laboratory Testing for Bacteria, Virus, or Mycoplasma | Laboratory Testing, Bacterial, Viral and Mycoplasma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827446","Working Cell Bank Release Laboratory Testing","C113022","Testing of cell bank specimens for microbial contamination.","Working Cell Bank Release Laboratory Testing | Laboratory Testing, Working Cell Bank Release Testing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830388","Dry Powder Conditioning Mixing","C113024","Mixing of dry ingredients with the addition of a small amount of liquid, done to increase binding capability.","Dry Powder Conditioning Mixing | Mixing, Dry Powder, Conditioning",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830387","Dry Powder Convection Mixing","C113025","Mixing of dry ingredients by mechanical agitation within a containment zone.","Dry Powder Convection Mixing | Mixing, Dry Powder, Convection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830386","Dry Powder Diffusion Mixing","C113026","Mixing of dry ingredients by repetitive tumbling.","Dry Powder Diffusion Mixing | Mixing, Dry Powder, Diffusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830385","Dry Powder Pneumatic Mixing","C113027","Mixing of dry ingredients by dispersion and turbulence within a flowing stream of gas.","Dry Powder Pneumatic Mixing | Mixing, Dry Powder, Pneumatic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829696","High Shear Wet Milling Mixing","C113028","Mixing of solids into liquid or of immiscible liquids by shear and impact within high velocity streams.","High Shear Wet Milling Mixing | Mixing, High Shear/Wet Milling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829248","Low Shear Mixing","C113029","Mixing of solids into liquid, without appreciable size reduction, to form a stable suspension.","Low Shear Mixing | Mixing, Low Shear",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815598","LIPG wt Allele","C113270","Human LIPG wild-type allele is located in the vicinity of 18q21.1 and is approximately 32 kb in length. This allele, which encodes endothelial lipase protein, plays a role in the catabolism of phospholipids, high density lipoproteins and triglycerides.","LIPG wt Allele | EDL | EL | Lipase, Endothelial wt Allele | PRO719 | UNQ387/PRO719",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829068","milliGray-Centimeter","C113271","A derived unit of measure for dose length product calculated by multiplying the radiation dose in milliGrays by the travel length in centimeters.","milliGray-Centimeter | mGy x cm | mGy-cm | mGyCm | milligray x centimeter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447747","Endothelial Lipase, Human","C113272","Endothelial lipase (500 aa, ~57 kDa) is encoded by the human LIPG gene. This protein is involved in the hydrolysis of triglycerides, phospholipids and high density lipoproteins.","Endothelial Lipase | EC 3.1.1.3 | EDL | EL | Endothelial Cell-Derived Lipase | LIPG | Lipoprotein Lipase H | Phospholipase A1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827582","VFQ25-Self Administered Format - Don't Go Out of Home Alone Because of Eyesight","C112812","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Dependency: I don't go out of my home alone, because of my eyesight.","VFQ25-Self Administered Format - Don't Go Out of Home Alone Because of Eyesight | VFQ2-I Don't Go Out of My Home Alone | VFQ2A13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829080","MHIS-NACC - Somatic Complaints","C112813","Modified Hachinski Ischemic Scale-NACC Version (MHIS-NACC) Somatic complaints.","MHIS-NACC - Somatic Complaints | MHIS01- Somatic Complaints | MHIS0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0263534","Horizontal Nail Ridging","C112814","Linear transverse/horizontal groove of one or more nail plates that migrate distally from the proximal nail fold with nail growth, usually secondary to illness, trauma or malnutrition.","Horizontal Nail Ridging | Beau's Lines",,,,,,,,,,,,,,,"4185564","Beau's lines",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3551315","Leukonychia","C112815","Any white discoloration of the nails or nail plates.","Leukonychia | ",,,,,,,,,,,,,,,"4006158","Leukonychia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0262977","Depigmentation","C112817","Loss of all color from the skin.","Depigmentation | ",,,,,,,,,,,,,,,"4048466","Achromia of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3814871","S100Z wt Allele","C113559","Human S100Z wild-type allele is located in the vicinity of 5q13.3 and is approximately 72 kb in length. This allele, which encodes protein S100-Z, is involved in calcium ion binding. Mutations in this gene are associated with ulcerative colitis.","S100Z wt Allele | Gm625 | S100 Calcium Binding Protein Z wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1100803","Protein S100-Z, Human","C113560","Protein S100-Z (99 aa, ~116 kDa) is encoded by the human S100Z gene. This protein plays a role in calcium ion binding.","Protein S100-Z | S100 Calcium Binding Protein, Zeta | S100 Calcium-Binding Protein Z | S100 Calcium-Binding Protein, Zeta | S100-zeta | S100Z",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812262","SLC22A3 wt Allele","C113562","Human SLC22A3 wild-type allele is located in the vicinity of 6q25.3 and is approximately 107 kb in length. This allele, which encodes Solute carrier family 22 member 3 protein, plays a role in the disposition of cationic neurotoxins and neurotransmitters in the brain. Mutations in this gene are associated with extragonadal seminoma and placental choriocarcinoma.","SLC22A3 wt Allele | EMT | EMTH | OCT3 | Solute Carrier Family 22 (Organic Cation Transporter), Member 3 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1314663","solute carrier family 22 (extraneuronal monoamine transporter), member 3, human","C113563","Solute carrier family 22 member 3 (556 aa, ~61 kDa) is encoded by the human SLC22A3 gene. This protein is involved in mediating membrane potential-dependent transport of organic cations and may play a role in the disposition of cationic neurotoxins and neurotransmitters in the brain.","Solute Carrier Family 22 Member 3 | EMT | Extraneuronal Monoamine Transporter | Organic Cation Transporter 3 | SLC22A3 | Solute Carrier Family 22 (Extraneuronal Monoamine Transporter), Member 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0217396","SOS1 Protein","C116311","Son of sevenless homolog 1 (1333 aa, ~152 kDa) is encoded by the human SOS1 gene. This protein is involved in the mediation of guanine nucleotide exchange for RAS superfamily proteins.","Son of Sevenless Homolog 1 | Guanine Nucleotide Exchange Factor SOS1 | SOS-1 | SOS1 Guanine Nucleotide Exchange Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887661","Stertor","C116312","The sound produced by tissue vibrations in the nasopharynx and pharynx secondary to partial obstruction of the upper airway.","Stertor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0235063","Respiratory Depression","C116314","A decrease in ventilation secondary to impaired signals from the central nervous system.","Respiratory Depression | ",,,,,,,,,,,,,,,"4214898","Decreased respiratory function",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037384","Snoring","C116315","A harsh inspiratory sound during sleep.","Snoring | ",,,,,,,,,,,,,,,"4248728","Snoring",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898709","Enteric-Type Sinonasal Adenocarcinoma","C116316","An adenocarcinoma that arises from the nasal cavity and paranasal sinuses. Histologically it resembles intestinal adenocarcinoma. It is associated with lengthy occupational exposure to dust.","Sinonasal Adenocarcinoma, Intestinal-Type | Enteric-Type Sinonasal Adenocarcinoma | Intestinal-Type Sinonasal Adenocarcinoma | Nasal Cavity and Paranasal Sinus Adenocarcinoma, Intestinal-Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2212425","Renal Small Cell Carcinoma","C116317","A very rare small cell neuroendocrine carcinoma that arises from the kidney.","Kidney Small Cell Neuroendocrine Carcinoma | Kidney Small Cell Carcinoma | Renal Small Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898157","Nasal Cavity and Paranasal Sinus Small Cell Neuroendocrine Cancer","C116318","A rare neuroendocrine carcinoma that arises from the nose and paranasal sinuses and is composed of malignant small cells. The mitotic count is more than 10 per 2 mm2 and/or the Ki-67 index is more than 20%.","Sinonasal Small Cell Neuroendocrine Carcinoma | Nasal Cavity and Paranasal Sinus Small Cell Carcinoma | Nasal Cavity and Paranasal Sinus Small Cell Neuroendocrine Cancer | Nasal Cavity and Paranasal Sinus Small Cell Neuroendocrine Carcinoma | Sinonasal Small Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2930917","Trisomy 14 Mosaicism","C116319","A rare chromosomal disorder characterized by trisomy of chromosome 14 in some cells in the body.  It manifests with intrauterine growth retardation, craniofacial abnormalities, failure to thrive, psychomotor delays, and mental retardation.","Trisomy 14 Mosaicism | ",,,,,,,,,,,,,,,"35608007","Mosaic trisomy 14 syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL473654","Insulin Sensitizer S-707106","C116320","An orally available protein and insulin sensitizer with anti-hyperglycemic activity. Upon oral administration, S-707106 increases the sensitivity of target organs to insulin, through an as of yet not fully elucidated mechanism. This agent may lower blood glucose levels.","Insulin Sensitizer S-707106 | S-707106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473655","CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine","C116321","A plasmid DNA vaccine containing the mammalian expression vector pUMVC3 (pNGVL3) encoding epitopes of CD105 (Endoglin), Y-box binding protein 1 (Yb-1), SRY-box 2 (SOX2), cadherin 3 (CDH3), and murine double minute 2 (MDM2) proteins, with potential immunomodulating and antineoplastic activities. Upon intradermal administration of pUMVC3-CD105/Yb-1/SOX2/CDH3/MDM2-epitopes plasmid DNA vaccine, the plasmid transfects cells and the peptides are expressed. This generates a specific memory Th1 (T-helper) cell immune response, stimulates secretion of cytokines by the T cells and leads to a cytotoxic T-lymphocyte (CTL) response against CD105/Yb-1/SOX2/CDH3/MDM2-expressing tumor cells. CD105/Yb-1/SOX2/CDH3/MDM2 proteins are highly immunogenic tumor associated antigens that are overexpressed in breast cancer. Additionally, these antigens are associated with breast cancer stem cells and with epithelial to mesenchymal transformation (EMT).","CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine | CD105/Yb-1/SOX2/CDH3/MDM2 Plasmid Vaccine | STEMVAC | STEMVAC Th1 Polyepitope Plasmid-based Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899543","Clinical Trial Site Training Material","C115604","Documentation used to train site personnel involved in the conduct of the clinical trial.","Clinical Trial Site Training Material Documentation | Clinical Trial Site Training Material | Site Traing Matl | Site Training Material",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0065964","Mepitiostane","C1158","An anabolic ether-modified form of the steroid epitiostanol. It has anti-estrogenic effect, which inhibits the progression of estrogen-stimulated cancers by competitive inhibition of estrogen binding to estrogen receptors. (NCI)","Mepitiostane | MEPITIOSTANE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279778","Untreated Hairy Cell Leukemia","C115905","A finding of hairy cell leukemia that has not been treated.","Untreated Hairy Cell Leukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897493","Stent Thrombosis","C116115","The formation of a blood clot of a vessel or heart chamber after and due to the placement of a stent.","Stent Thrombosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0500459","Arterial Segment","C116116","A segment of a blood vessel that is part of the arterial system.","Arterial Segment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898759","Inhibitory Concentration Test","C116117","A laboratory test to determine the concentration of a substance that will inhibit a biological or biochemical function, such as microorganism growth or enzymatic activity.","Inhibitory Concentration Test | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898217","Multiplex Probe Parameter","C116118","A description of the number of unique molecular probes used in each assay well or tube.","Multiplex Probe Parameter | MULTPLEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898502","MRI Coil Type","C116119","The classification of the coil that is used in an magnetic resonance imaging procedure. Usually refers to the anatomical location for where the coil is placed such as head, body or breast.","MRI Coil Type | MRICTYPE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897650","Scintillation Crystal Type","C116120","The classification of the crystalline material, which emits light in response to radiation exposure, used in the imaging procedure.","Scintillation Crystal Type | SCRYSTYP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899448","Data Storage Failure","C116121","Issue associated with the failure of the software to store collected data.","Data Storage Failure | DATA STORAGE FAILURE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898809","Image Weighting Type","C116122","A classification of the technique used to enhance image contrast based on differences in magnetic resonance tissue properties. This can be achieved by changing the echo time or repetition time after the tissue has returned to its equilibrium state.","Image Weighting Type | IMWGTTYP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814038","MGC33630","C113274","Human CFAP251 wild-type allele is located in the vicinity of 12q24.31 and is approximately 86 kb in length. This allele, which encodes cilia- and flagella-associated protein 251, is involved in cilia assembly and sperm motility. Mutation of the gene is associated with spermatogenic failure 33 and polymorphisms in the gene have been associated with variance in mean platelet volume.","CFAP251 wt Allele | CaM-IP4 | Cilia and Flagella Associated Protein 251 wt Allele | MGC33630 | SPGF33 | WD Repeat Domain 66 Gene | WDR66",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3501037","WD Repeat-Containing Protein 66, Human","C113275","Cilia- and flagella-associated protein 251 (1149 aa, ~130 kDa) is encoded by the human CFAP251 gene. This protein plays a role in cilium assembly.","Cilia- and Flagella-Associated Protein 251 | CFAP251 | Cilia and Flagella Associated Protein 251 | WD Repeat-Containing Protein 66 | WDR66",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810537","PSAT1 wt Allele","C113277","Human PSAT1 wild-type allele is located in the vicinity of 9q21.2 and is approximately 33 kb in length. This allele, which encodes phosphoserine aminotransferase protein, plays a role in the biosynthesis of amino acids. Mutation of the gene is associated with phosphoserine aminotransferase deficiency.","PSAT1 wt Allele | EPIP | PSA | PSAT | Phosphoserine Aminotransferase 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0070942","PSAT1 protein, human","C113278","Phosphoserine aminotransferase (370 aa, ~40 kDa) is encoded by the human PSAT1 gene. This protein is involved in amino acid biosynthesis.","Phosphoserine Aminotransferase | EC 2.6.1.52 | PSAT | Phosphohydroxythreonine Aminotransferase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812227","B9D2 wt Allele","C113280","Human B9D2 wild-type allele is located in the vicinity of 19q13.2 and is approximately 10 kb in length. This allele, which encodes B9 domain-containing protein 2, is involved in ciliogenesis. Mutation of the gene is associated with Meckel syndrome 10.","B9D2 wt Allele | B9 Protein Domain 2 wt Allele | ICIS-1 | MGC4093 | MKS10 | MKSR2 | Stumpy, Mouse, Homolog of Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812226","B9 Domain-Containing Protein 2","C113281","B9 domain-containing protein 2 (175 aa, ~19 kDa) is encoded by the human B9D2 gene. This protein plays a role in the maintenance of cilia.","B9 Domain-Containing Protein 2 | Involved In Cilia Stability-1 | MKS1-Related Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812742","WBP1L wt Allele","C113283","Human WBP1L wild-type allele is located in the vicinity of 10q24.32 and is approximately 72 kb in length. This allele, which encodes WW domain binding protein 1-like, may play a role in heme binding.","WBP1L wt Allele | C10orf26 | Chromosome 10 Open Reading Frame 26 Gene | FLJ20154 | OPA1L | OPAL1 | RP11-753C18.10-001 | WW Domain Binding Protein 1-Like wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813205","WW Domain Binding Protein 1-Like","C113284","WW domain binding protein 1-like (342 aa, ~38 kDa) is encoded by the human WBP1L gene. This protein may be involved in binding to heme.","WW Domain Binding Protein 1-Like | Chromosome 10 Open Reading Frame 26 | Outcome Predictor In Acute Leukemia 1 | WBP1L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827613","VFQ25-Interviewer Administered Format - Often Irritable Because of Eyesight","C112769","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Well-Being or Distress: I am often irritable because of my eyesight.","VFQ25-Interviewer Administered Format - Often Irritable Because of Eyesight | VFQ1-Often Irritable Because Eyesight | VFQ1A12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1959210","Multidrug and Toxin Extrusion Protein 1, Human","C113566","Multidrug and toxin extrusion protein 1 (570 aa, ~62 kDa) is encoded by the human SLC47A1 gene. This protein plays a role in transport of cationic drugs across membranes.","Multidrug and Toxin Extrusion Protein 1 | MATE-1 | Multidrug And Toxin Extrusion 1 | SLC47A1 | Solute Carrier Family 47 Member 1 | Solute Carrier Family 47, Member 1 | hMATE-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3253592","hMATE2-K protein, human","C113569","Multidrug and toxin extrusion protein 2 (602 aa, ~65 kDa) is encoded by the human SLC47A2 gene. This protein is involved in both excretion of toxic electrolytes and secretion of cationic drugs.","Multidrug and Toxin Extrusion Protein 2 | H+/Organic Cation Antiporter | Kidney-Specific H(+)/Organic Cation Antiporter | MATE-2 | Multidrug And Toxin Extrusion 2 | SLC47A2 | Solute Carrier Family 47 Member 2 | Solute Carrier Family 47, Member 2 | hMATE-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811221","SLC29A4 wt Allele","C113571","Human SLC29A4 wild-type allele is located 7p22.1 and is approximately 30 kb in length. This allele, which encodes equilibrative nucleoside transporter 4 protein, is involved in reuptake of monoamines into presynaptic neurons. Mutations in this gene are associated with desmoplastic small round cell tumor.","SLC29A4 wt Allele | ENT4 | PMAT | Solute Carrier Family 29 (Equilibrative Nucleoside Transporter), Member 4 wt Allele | hENT4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896993","Clinical Trial Startup Material","C115605","A collection of agendas, presentation materials, and other documents related to a clinical trial startup.","Clinical Trial Startup Material | Trial Start Up Subcategory | Trial Startup",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899532","Clinical Trial Team Training Material","C115606","Documentation pertaining to the training materials for the clinical trial team.","Clinical Trial Team Training Material Documentation | Clinical Trial Team Training Material | Trial Team Training Material | Trial Tm Training Matl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890566","Data Management Meeting Material","C115607","A collection of agendas, presentation materials, and other documents that are generated for attendees during a data management meeting.","Data Management Meeting Material | DM Mtng Matl | Meeting Material",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890412","Institutional Review Board - Independent Ethics Committee Meeting Material","C115609","A collection of agendas, presentation materials, and other documents generated for attendees during an Institutional Review Board - Independent Ethics Committee (IRB-IEC) meeting.","Institutional Review Board - Independent Ethics Committee Meeting Material | IRB-IEC Meeting Material | IRB-IEC Mtng Matl | Meeting Material",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898672","Investigational Product and Clinical Trial Supplies Meeting Material","C115610","A collection of agendas, presentations, and other documents generated for attendees during a meeting regarding the investigational product and associated trial supplies used in a clinical trial.","Investigational Product and Clinical Trial Supplies Meeting Material | General Investigational Product and Trial Supplies Meeting Material | IP Trial Suppl Mtng Matl | IP and Trial Supplies Meeting Material",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889395","Regulatory Communication Material","C115611","A collection of regulatory-related communications, agreements, significant discussions, or relevant information.","Regulatory Communication Material | Correspondence | Reg Comm | Regulatory Communications | Relevant Communications",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890894","Regulatory Meeting Material","C115612","A collection of agendas, presentation materials, and other documents generated for attendees during a regulatory meeting.","Regulatory Meeting Material | Meeting Material | Reg Mtng Matl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890892","Safety Meeting Material","C115613","A collection of agendas, presentation materials, and other documents generated for attendees during a safety report meeting.","Safety Meeting Material | Meeting Material | Safe Mtng Matl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890891","Statistic Meeting Material","C115614","A collection of agendas, presentation materials, and other documents generated for attendees during a statistics meeting.","Statistic Meeting Material | Meeting Material | Statistics Meeting Material | Stats Mtng Matl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890889","Vendor Meeting Material","C115615","A collection of agendas, presentation materials, and other documents generated for attendees during a vendor meeting.","Vendor Meeting Material | Meeting Material | Vend Mtng Matl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898749","Institutional Review Board Independent Ethics Committee Submission","C115616","Documentation submitted to an Institutional Review Board (IRB) or Independent Ethics Committee (IEC) for approval of the details of a clinical trial, and any changes or updates made to that trial.","Institutional Review Board Independent Ethics Committee Submission Documentation | IRB or IEC Submission | IRB-IEC Subm | IRB-IEC Submission | IRB/IEC Submission | Institutional Review Board Independent Ethics Committee Submission | Institutional Review Board Independent Ethics Committee Submission",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899534","Clinical Trial Team Documentation","C115617","The Trial Master File Reference Model section that contains a collection of documents related to the trial team for the clinical trial.","TMF-RM Trial Team Section | Clinical Trial Team Documentation | Trial Team | Trial Team Subcategory | Trial Tm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899701","Category Type","C115618","A description of a category.","Category Type | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897454","Study Subject Ultrasound Image","C115619","A ultrasound image taken of a study participant for use in a clinical trial.","Study Subject Ultrasound Image | Study Subj US | Study Subject Ultrasound",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898713","Interslice Distance Measurement","C116123","A measurement of the distance between slices within an image sequence, calculated by subtracting the nominal slice thickness from the couch increment.","Interslice Distance Measurement | INTDISTM | Interslice Distance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898692","Inversion Time","C116124","The time between the inversion and excitation pulses in an inversion recovery pulse sequence. (CDISC)","Inversion Time | INVRTIME",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889666","Number of Slices","C116125","The total number of image slices that are recorded during an imaging procedure.","Number of Slices | NUMSLICE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898810","Image Acquisition Dimensionality","C116126","The number of dimensions that the acquired image(s) are presented in.","Image Acquisition Dimensionality | IMAQDIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899406","Decay Correction Indicator","C116127","An indication as to whether the image reconstruction took into account the time-activity curve during which the radiolabeled tracer decayed as it spread through the body during the image acquisition.","Decay Correction Indicator | DECCORR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896614","CDISC Questionnaire SWLS Test Code Terminology","C115408","Test codes of questionnaire questions associated with the Satisfaction With Life Scale (SWLS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire SWLS Test Code Terminology | QS-SWLS TESTCD | SWLS01TC | Satisfaction With Life Scale Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900189","6MWT Functional Test Question","C115409","A question associated with the 6MWT functional test.","6MWT Functional Test Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899002","HAI Functional Test Question","C115410","A question associated with the HAI functional test.","HAI Functional Test Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898194","NHPT Functional Test Question","C115411","A question associated with the NHPT functional test.","NHPT Functional Test Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898053","PASAT Functional Test Question","C115412","A question associated with the PASAT functional test.","PASAT Functional Test Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897114","SDMT Functional Test Question","C115413","A question associated with the SDMT functional test.","SDMT Functional Test Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827570","VFQ25-Self Administered Format - Overall Health","C112771","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) General Health and Vision: In general, would you say your overall health is:","VFQ25-Self Administered Format - Overall Health | VFQ2-Your Overall Health Is | VFQ201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827579","VFQ25-Self Administered Format - Eyesight Using Both Eyes","C112772","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) General Health and Vision: At the present time, would you say your eyesight using both eyes (with glasses or contact lenses, if you wear them) is excellent, good, fair, poor, or very poor or are you completely blind?","VFQ25-Self Administered Format - Eyesight Using Both Eyes | VFQ2-Eyesight Using Both Eyes Is | VFQ202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827563","VFQ25-Self Administered Format - Time Spent Worry About Eyesight","C112773","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) General Health and Vision: How much of the time do you worry about your eyesight?","VFQ25-Self Administered Format - Time Spent Worry About Eyesight | VFQ2-How Often You Worry About Eyesight | VFQ203",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827568","VFQ25-Self Administered Format - Pain or Discomfort You Had in and Around Eyes","C112774","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) General Health and Vision: How much pain or discomfort have you had in and around your eyes (for example, burning, itching, or aching)? Would you say it is:","VFQ25-Self Administered Format - Pain or Discomfort You Had in and Around Eyes | VFQ2-How Much Pain in and Around Eyes | VFQ204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827591","VFQ25-Self Administered Format - Difficulty Reading Ordinary Print in Newspapers","C112775","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: How much difficulty do you have reading ordinary print in newspapers? Would you say you have:","VFQ25-Self Administered Format - Difficulty Reading Ordinary Print in Newspapers | VFQ2-Difficulty Reading Newspapers | VFQ205",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827601","VFQ25-Self Administered Format - Difficulty Doing Work or Hobbies","C112776","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: How much difficulty do you have doing work or hobbies that require you to see well up close, such as cooking, sewing, fixing things around the house, or using hand tools? Would you say:","VFQ25-Self Administered Format - Difficulty Doing Work or Hobbies | VFQ2-Difficulty Doing Work/Hobbies | VFQ206",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827596","VFQ25-Self Administered Format - Difficulty Finding Something On a Shelf","C112777","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: Because of your eyesight, how much difficulty do you have finding something on a crowded shelf?","VFQ25-Self Administered Format - Difficulty Finding Something On a Shelf | VFQ2-Difficulty Finding on Crowded Shelf | VFQ207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827589","VFQ25-Self Administered Format - Difficulty Reading Street Signs","C112778","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: How much difficulty do you have reading street signs or the names of stores?","VFQ25-Self Administered Format - Difficulty Reading Street Signs | VFQ2-Difficulty Reading Street Signs | VFQ208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827595","VFQ25-Self Administered Format - Difficulty Going Down Steps at Night","C112779","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: Because of your eyesight, how much difficulty do you have going down steps, stairs, or curbs in dim light or at night?","VFQ25-Self Administered Format - Difficulty Going Down Steps at Night | VFQ2-Difficulty Going Down Step at Night | VFQ209",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827593","VFQ25-Self Administered Format - Difficulty Noticing Objects Off to the Side While Walking","C112780","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: Because of your eyesight, how much difficulty do you have noticing objects off to the side while you are walking along?","VFQ25-Self Administered Format - Difficulty Noticing Objects Off to the Side While Walking | VFQ2-Difficulty Noticing Objects to Side | VFQ210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0063146","Hydroxyl Radical","C1130","A monovalent radical consisting of one hydrogen and oxygen atom found in bases, carboxylic acids, and alcohols.","Hydroxyl Radical | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3554809","Insulin Resistance","C113101","Decreased sensitivity to circulating insulin which may result in acanthosis nigicrans, elevated insulin level or hyperglycemia.","Insulin Resistance | ",,,,,,,,,,,,,,,"35622016","Insulin resistance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0342218","Hyperglucagonemia","C113102","Abnormally high levels of glucagon in the blood, which may manifest as hyperglycemia and/or necrolytic migratory erythema.","Hyperglucagonemia | ",,,,,,,,,,,,,,,"4099656","Excessive glucagon secretion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4015533","Hyperinsulinemia","C113104","Abnormally high levels of insulin in the blood.","Hyperinsulinemia | ",,,,,,,,,,,,,,,"4307509","Hyperinsulinism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3696412","Injectable Foam Dosage Form","C113106","A foam intended for parenteral administration.","Injectable Foam Dosage Form | INJECTABLE FOAM | Injectable Foam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814044","UBASH3B wt Allele","C113108","Human UBASH3B wild-type allele is located in the vicinity of 11q24.1 and is approximately 159 kb in length. This allele, which encodes ubiquitin-associated and SH3 domain-containing protein B, is involved in both the modulation of receptor half-life and protein tyrosine phosphatase activity.","UBASH3B wt Allele | KIAA1959 | STS-1 | STS1 | TULA-2 | Ubiquitin Associated and SH3 Domain Containing B wt Allele | p70",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1506130","Ubiquitin-Associated and SH3 Domain-Containing Protein B, Human","C113109","Ubiquitin-associated and SH3 domain-containing protein B (649 aa, ~73 kDa) is encoded by the human UBASH3B gene. This protein plays a role in the dephosphorylation of tyrosine kinases.","Ubiquitin-Associated and SH3 Domain-Containing Protein B | Cbl-Interacting Protein Sts-1 | Cbl-Interacting Protein p70 | EC 3.1.3.48 | Nm23-Phosphorylated Unknown Substrate | SH3 Domain-Containing 70 kDa Protein | STS1 | Suppressor of T-Cell Receptor Signaling 1 | T-Cell Ubiquitin Ligand 2 | TULA2 | Tyrosine-Protein Phosphatase STS1/TULA2 | UBASH3B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810554","SLC28A2 wt Allele","C113319","Human SLC28A2 wild-type allele is located in the vicinity of 15q15 and is approximately 24 kb in length. This allele, which encodes sodium/nucleoside cotransporter 2 protein, plays a role in the transport of purine nucleosides.","SLC28A2 wt Allele | CNT2 | HCNT2 | HsT17153 | SPNT1 | Solute Carrier Family 28 (Concentrative Nucleoside Transporter), Member 2 wt Allele | Solute Carrier Family 28 (Sodium-Coupled Nucleoside Transporter), Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810553","CNT2 protein, human","C113320","Sodium/nucleoside cotransporter 2 (658 aa, ~72 kDa) is encoded by the human SLC28A2 gene. This protein is involved in purine nucleoside transport.","Sodium/Nucleoside Cotransporter 2 | CNT 2 | Concentrative Nucleoside Transporter 2 | Na(+)/Nucleoside Cotransporter 2 | SLC28A2 | SPNT | Sodium-Coupled Nucleoside Transporter 2 | Sodium/Purine Nucleoside Co-Transporter | Solute Carrier Family 28 Member 2 | hCNT2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899440","Database Validation Plan","C115620","A proposed method that defines edit checks, the process of edit checks, and validation tests for database specification.","Database Validation Plan | Data Valid Plan | Data Validation Plan | Data Validation Specification | Data integration | EDC Validation including Validation Test Plan | Edit Check and Logic Check Specifications",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899064","GOSE - Family and Friendships: Problems with Family or Friends Before Injury","C115844","Extended Glasgow Outcome Scale (GOSE) Were there problems with family or friends before the injury?","GOSE - Family and Friendships: Problems with Family or Friends Before Injury | GOSE1-Family/Friends Probs Before Injury | GOSE107C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899056","GOSE - Return to Normal Life: Other Current Problems Relating to Injury","C115845","Extended Glasgow Outcome Scale (GOSE) Are there any other current problems relating to the injury which affect daily life?","GOSE - Return to Normal Life: Other Current Problems Relating to Injury | GOSE1-Other Problems Related to Injury | GOSE108A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899055","GOSE - Return to Normal Life: Similar Problems Before Injury","C115846","Extended Glasgow Outcome Scale (GOSE) Were similar problems present before the injury?","GOSE - Return to Normal Life: Similar Problems Before Injury | GOSE1-Similar Problems Before Injury | GOSE108B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897024","GOSE - Epilepsy: Since Injury Any Epileptic Fits","C115847","Extended Glasgow Outcome Scale (GOSE) Since the injury has the head injured person had any epileptic fits?","GOSE - Epilepsy: Since Injury Any Epileptic Fits | GOSE1-Since Injury Any Epileptic Fits | GOSE109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899067","GOSE - Epilepsy: Most Important Factor in Outcome","C115849","Extended Glasgow Outcome Scale (GOSE) What is the most important factor in outcome?","GOSE - Epilepsy: Most Important Factor in Outcome | GOSE1-Most Important Factor in Outcome | GOSE111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899063","GOSE - GOSE Overall Score","C115850","Extended Glasgow Outcome Scale (GOSE) Scoring: The patient's overall rating is based on the lowest outcome category indicated on the scale.","GOSE - GOSE Overall Score | GOSE1-GOSE Overall Score | GOSE112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898540","MPAI-4 - Abilities: Mobility","C115851","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Mobility: Problems walking or moving; balance problems that interfere with moving about.","MPAI-4 - Abilities: Mobility | MPAI1-Mobility | MPAI101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898536","MPAI-4 - Abilities: Use of Hands","C115852","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Use of hands: impaired strength or coordination in one or both hands.","MPAI-4 - Abilities: Use of Hands | MPAI1-Use of Hands | MPAI102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898534","MPAI-4 - Abilities: Vision","C115853","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Vision: Problems seeing; double vision; eye; brain, or nerve injuries that interfere with seeing.","MPAI-4 - Abilities: Vision | MPAI1-Vision | MPAI103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898544","MPAI-4 - Abilities: Audition","C115854","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Audition: Problems hearing; ringing in the ears.","MPAI-4 - Abilities: Audition | MPAI1-Audition | MPAI104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898543","MPAI-4 - Abilities: Dizziness","C115855","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Dizziness: Feeling unsteady, dizzy, light-headed.","MPAI-4 - Abilities: Dizziness | MPAI1-Dizziness | MPAI105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898539","MPAI-4 - Abilities: Motor Speech","C115856","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Motor speech: Abnormal clearness or rate of speech; stuttering.","MPAI-4 - Abilities: Motor Speech | MPAI1-Motor Speech | MPAI106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897395","T25FW Functional Test Question","C115414","A question associated with the T25FW functional test.","T25FW Functional Test Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897374","TUG Functional Test Question","C115415","A question associated with the TUG functional test.","TUG Functional Test Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899456","DRS Questionnaire Question","C115416","A question associated with the DRS questionnaire.","DRS Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899048","GOSE Questionnaire Question","C115417","A question associated with the GOSE questionnaire.","GOSE Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898503","MPAI-4 Questionnaire Question","C115418","A question associated with the MPAI-4 questionnaire.","MPAI-4 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897662","SWLS Questionnaire Question","C115419","A question associated with the SWLS questionnaire.","SWLS Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890779","SIII","C115422","Human ELOC wild-type allele is located in the vicinity of 8q21.11 and is approximately 33 kb in length. This allele, which encodes elongin-C protein, is involved in the promotion of transcriptional elongation.","ELOC wt Allele | Elongin C wt Allele | Elongin, 15-kD Subunit Gene | SIII | TCEB1 | Transcription Elongation Factor B (SIII), Polypeptide 1 (15kD, Elongin C) Gene | Transcription Elongation Factor B (SIII), Polypeptide 1 (15kDa, Elongin C) Gene | Transcription Elongation Factor B, Polypeptide 1 Gene | eloC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1612054","Transcription Elongation Factor B Polypeptide 1, Human","C115423","Elongin-C (112 aa, ~12 kDa) is encoded by the human ELOC gene. This protein plays a role in the positive regulation of transcriptional elongation.","Elongin-C | EloC | Elongin 15 kDa Subunit | Elongin C | RNA Polymerase II Transcription Factor SIII Subunit C | SIII p15 | Transcription Elongation Factor B Polypeptide 1 | Transcription Elongation Factor B Subunit 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447137","Zinc Finger Homeobox Protein 3, Human","C115426","Zinc finger homeobox protein 3 (3703 aa, ~404 kDa) is encoded by the human ZFHX3 gene. This protein is involved in cellular differentiation and transcriptional repression.","Zinc Finger Homeobox Protein 3 | AT Motif-Binding Factor 1 | AT-Binding Transcription Factor 1 | Alpha-Fetoprotein Enhancer Binding Protein | Alpha-Fetoprotein Enhancer-Binding Protein | ZFH-3 | Zinc Finger Homeodomain Protein 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899545","Clinical Trial Site Task Assignment Document","C115673","Documentation tracking the task delegation made by the principal investigator to the site personnel conducting the clinical trial.","Clinical Trial Site Task Assignment Documentation | Clinical Trial Site Task Assignment Document | Delegation of Authority | Site Sig Sheet | Site Signature Sheet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899544","Clinical Trial Site Training Completion Document","C115674","Documentation verifying the completion of training of the clinical trial site personnel.","Clinical Trial Site Training Completion Documentation | Clinical Trial Site Training Completion Document | Site Evidence of Training | Site Traing Docn | Site Training Documentation | Training completion documentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899540","Clinical Trial Subject Document Form","C115675","Records used to document data on a specific trial subject.","Clinical Trial Subject Document Form | Subj Doc Form Subcat | Subject Document Forms Subcategory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899537","Clinical Trial Supply Storage Condition Document","C115676","Records that contain the description of the setting and circumstances for storing supplies used in a clinical trial.","Clinical Trial Supply Storage Condition Document | Storage Condition Documentation | Trial Supl Stor Condit | Trial Supply Storage Conditions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829537","INS Gene Product","C113516","A protein encoded by the human INS gene.","INS Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812800","SCGB2A2 wt Allele","C113520","Human SCGB2A2 wild-type allele is located in the vicinity of 11q13 and is approximately 3 kb in length. This allele, which encodes mammaglobin-A protein, may play a role in mammary gland development and differentiation.","SCGB2A2 wt Allele | MGB1 | Secretoglobin Family 2A Member 2 wt Allele | Secretoglobin, Family 2A, Member 2 Gene | UGB2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1609207","SCGB2A2 protein, human","C113521","Mammaglobin-A (93 aa, ~10 kDa) is encoded by the human SCGB2A2 gene. This protein may be involved in the development of mammary glands.","Mammaglobin-A | Mammaglobin 1 | Mammaglobin A | Mammaglobin-1 | SCGB2A2 | Secretoglobin 2A2 | Secretoglobin Family 2A Member 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814810","IGCJ","C113523","Human JCHAIN wild-type allele is located the vicinity of 4q13.3 and is approximately 23 kb in length. This allele, which encodes immunoglobulin J chain protein, is involved in the joining of antibody monomer chains. Mutations in this gene are associated with both renal artery obstruction and fibromuscular dysplasia.","JCHAIN wt Allele | IGCJ | IGJ | Immunoglobulin J Polypeptide, Linker Protein for Immunoglobulin Alpha and Mu Polypeptides Gene | JCH | Joining Chain of Multimeric IgA and IgM wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021035","Immunoglobulin J Chain","C113525","Immunoglobulin J chain (159 aa, ~18 kDa) is encoded by the human JCHAIN gene. This protein plays a role in the joining of antibody structures.","Immunoglobulin J Chain | IgJ Chain | J Chain | JCHAIN | Joining Chain of Multimeric IgA and IgM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813713","SLC6A3 wt Allele","C113527","Human SLC6A3 wild-type allele is located in the vicinity of 5p15.3 and is approximately 53 kb in length. This allele, which encodes sodium-dependent dopamine transporter protein, is involved in sodium-dependent internalization of dopamine. Mutation of the gene is associated with infantile Parkinsonism-dystonia.","SLC6A3 wt Allele | DAT | DAT1 | PKDYS | Solute Carrier Family 6 (Neurotransmitter Transporter), Member 3 wt Allele | Solute Carrier Family 6 (Neurotransmitter Transporter, Dopamine), Member 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814521","SPATS2L wt Allele","C113528","Human SPATS2L wild-type allele is located in the vicinity of 2q33.1 and is approximately 201 kb in length. This allele, which encodes SPATS2-like protein, plays a role in protecting myoblasts from oxidative stress.","SPATS2L wt Allele | DNAPTP6 | SGNP | Spermatogenesis Associated, Serine-Rich 2-Like wt Allele | Spermatogenesis-Associated, Serine-Rich 2-Like Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811669","SLC28A3 wt Allele","C113322","Human SLC28A3 wild-type allele is located in the vicinity of 9q22.2 and is approximately 93 kb in length. This allele, which encodes solute carrier family 28 member 3 protein, is involved in sodium-mediated transport of nucleobases.","SLC28A3 wt Allele | CNT3 | Solute Carrier Family 28 (Concentrative Nucleoside Transporter), Member 3 wt Allele | Solute Carrier Family 28 (Sodium-Coupled Nucleoside Transporter), Member 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1098642","Solute Carrier Family 28 Member 3, Human","C113323","Solute carrier family 28 member 3 (691 aa, ~77 kDa) is encoded by the human SLC28A3 gene. This protein plays a role in the mediation of sodium dependent transport of nucleosides.","Solute Carrier Family 28 Member 3 | CNT 3 | Concentrative Na(+)-Nucleoside Cotransporter 3 | Concentrative Na+-Nucleoside Cotransporter 3 | Concentrative Nucleoside Transporter 3 | Na(+)/Nucleoside Cotransporter 3 | SLC28A3 | Sodium/Nucleoside Cotransporter 3 | hCNT3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813548","CALD1 wt Allele","C113325","Human CALD1 wild-type allele is located in the vicinity of 7q33 and is approximately 226 kb in length. This allele, which encodes caldesmon protein, plays a role in actin filament stability.","CALD1 wt Allele | CAD | CDM | Caldesmon 1 wt Allele | H-CAD | HCAD | L-CAD | LCAD | NAG22",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006746","Caldesmon","C113326","Caldesmon (793 aa, ~93 kDa) is encoded by the human CALD1 gene. This protein is involved in binding to and stabilization of filamentous actin.","Caldesmon | CALD1 | CDM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811129","ABCF2 wt Allele","C113328","Human ABCF2 wild-type allele is located in the vicinity of 7q36 and is approximately 19 kb in length. This allele, which encodes ATP-binding cassette sub-family F member 2 protein, is involved in ATP hydrolysis.","ABCF2 wt Allele | ABC28 | ATP-Binding Cassette, Sub-Family F (GCN20), Member 2 wt Allele | EST133090 | HUSSY-18 | HUSSY18 | Human Sequence Similar to Yeast 18 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831456","ATP-Binding Cassette Sub-Family F Member 2","C113329","ATP-binding cassette sub-family F member 2 (623 aa, ~71 kDa) is encoded by the human ABCF2 gene. This protein plays a role in ATP metabolism.","ATP-Binding Cassette Sub-Family F Member 2 | ABCF2 | ATP-Binding Cassette, Sub-Family F, Member 2 | Iron-Inhibited ABC Transporter 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827086","BRAF inhibitor PLX8394","C113330","An orally bioavailable inhibitor and specific dimer breaker of the serine/threonine-protein kinase B-raf (BRAF) protein, with potential antineoplastic activity. Upon oral administration, plixorafenib selectively binds to and inhibits the activity of dimeric BRAF mutants, including BRAF fusions and splice variants, and BRAFV600 monomers, while sparing RAF function in normal cells. This inhibits the proliferation of tumor cells which express these mutated forms of BRAF. BRAF, a member of the raf family of serine/threonine protein kinases, plays a role in the regulation of mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK) signaling pathways, which may be constitutively activated due to BRAF gene mutations. Mutated forms and fusions of BRAF are associated with a number of neoplastic diseases.","Plixorafenib | BRAF Inhibitor FORE8394 | BRAF Inhibitor FORE8394 | BRAF Inhibitor PLX8394 | BRAF Inhibitor PLX8394 | FORE 8394 | FORE-8394 | FORE8394 | PL -8394 | PLIXORAFENIB | PLX-8394 | PLX8394",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714505","Leukoderma","C112821","Localized loss of skin pigmentation, often in patches.","Leukoderma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898538","MPAI-4 - Abilities: Nonverbal Communication","C115858","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Nonverbal communication: Restricted or unusual gestures or facial expressions; talking too much or not enough; missing nonverbal cues from others.","MPAI-4 - Abilities: Nonverbal Communication | MPAI1-Nonverbal Communication | MPAI107B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898541","MPAI-4 - Abilities: Memory","C115860","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Memory: Problems learning and recalling new information.","MPAI-4 - Abilities: Memory | MPAI1-Memory | MPAI109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008240","Acid, Chlorogenic","C116073","A polyphenol and the ester of caffeic acid and quinic acid that is found in coffee and black tea, with potential antioxidant and chemopreventive activities. Chlorogenic acid scavenges free radicals, which inhibits DNA damage and may protect against the induction of carcinogenesis. In addition, this agent may upregulate the expression of genes involved in the activation of the immune system and enhances activation and proliferation of cytotoxic T-lymphocytes, macrophages, and natural killer cells. Chlorogenic acid also inhibits the activity of matrix metalloproteinases.","Chlorogenic Acid | 3-Caffeoylquinic Acid | 5-O-(3,4-Dihydroxycinnamoyl)-L-quinic Acid | CHLOROGENIC ACID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473492","Mps1 kinase inhibitor BAY1161909","C116074","An orally bioavailable, selective inhibitor of the serine/threonine monopolar spindle 1 (Mps1) kinase, with potential antineoplastic activity. Upon administration, empesertib binds to and inhibits the activity of Mps1. This causes inactivation of the spindle assembly checkpoint (SAC), accelerated mitosis, chromosomal misalignment, chromosomal missegregation, mitotic checkpoint complex destabilization, and increased aneuploidy. This leads to the induction of cell death in cancer cells overexpressing Mps1. Mps1, a kinase expressed in proliferating normal tissues and aberrantly overexpressed in a wide range of human tumors, is activated during mitosis and is essential for SAC functioning and controls chromosome alignment.","Empesertib | (2R)-2-(4-Fluorophenyl)-N-(4-(2-((2-methoxy-4-(methylsulfonyl)phenyl)amino)(1,2,4)triazolo(1,5-a)pyridin-6-yl)phenyl)propanamide | BAY116-1909 | BAY1161909 | EMPESERTIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473493","Copper Cu 64-DOTA-AE105","C116075","A radiotracer composed of AE105, a urokinase-type plasminogen activator receptor (uPAR) peptide antagonist, conjugated with DOTA and labeled with the radionuclide copper Cu 64, with potential imaging activity upon positron emission tomography (PET). Upon administration, the AE105 moiety of copper Cu 64-DOTA-AE105 targets and binds to uPAR-expressing tumor cells. Upon PET imaging, the copper Cu 64 moiety can be visualized, uPAR-expressing tumor cells can be quantified and the degree of tumor aggressiveness can be assessed. uPAR expression is correlated with increased tumor invasiveness and aggressiveness as well as a poor prognosis.","Copper Cu 64-DOTA-AE105 | 64Cu-DOTA-AE105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824715","CEP76 Gene","C116078","This gene is involved in centriole duplication.","CEP76 Gene | CEP76 | Centrosomal Protein 76 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889441","CEP76 wt Allele","C116079","Human CEP76 wild-type allele is located in the vicinity of 18p11.21 and is approximately 41 kb in length. This allele, which encodes centrosomal protein of 76 kDa, plays a role in the regulation of centriole duplication.","CEP76 wt Allele | C18orf9 | Centrosomal Protein 76 wt Allele | Centrosomal Protein 76kDa Gene | Centrosomal Protein, 76-kD Gene | Chromosome 18 Open Reading Frame 9 Gene | FLJ12542 | HsT1705",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2716207","Centrosomal Protein of 76 kDa, Human","C116080","Centrosomal protein of 76 kDa (659 aa, ~74 kDa) is encoded by the human CEP76 gene. This protein is involved in the regulation of centriole duplication.","Centrosomal Protein of 76 kDa | Cep76",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899386","Dialysis Access Complication","C116081","Any issue that arises as a consequence of a problem with a patient's dialysis access.","Dialysis Access Complication | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899535","Clinical Trial Supply Storage Excursion Document","C115678","Records that describe deviations from the clinical trial supply storage plan.","Clinical Trial Supply Storage Excursion Document | Storage Condition Excursion Documentation | Trial Supl Stor Condit Excur | Trial Supply Storage Condition Excursions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899453","Data Definitions for Analysis Dataset Document","C115679","Records that define and describe the programming logic required to transform a raw dataset to an analysis dataset.","Data Definitions for Analysis Dataset Document | Data Definitions for Analysis Datasets | Data Defs Subcat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889394","Data Management Communication Document","C115680","Records of communications pertaining to data management.","Data Management Communication Document | Correspondence | DM Comm | Data Management Communications | Relevant Communications",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899450","Data Management Document","C115681","Records pertaining to data management.","Data Management Document | Data Management Communications and Tracking Subcategory | Data Mgmt Comm Trk SubCat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899451","Data Management Documentation","C115682","The Trial Master File Reference Model zone that contains the collection of documents relating to data management activities for the clinical trial.","TMF-RM Data Management Zone | DM Cat | Data Management | Data Management Category | Data Management Documentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891561","Data Management Oversight Documentation","C115683","The Trial Master File Reference Model section that contains a collection of documents related to data management oversight for the clinical trial.","TMF-RM Data Management Oversight Section | DM Ovrsgt Subcat | Data Management | Data Management Oversight | Data Management Oversight Documentation | Data Management Oversight Subcategory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890386","Data Management Tracking Document","C115684","Records pertaining to any activities logged that relate to data management during the course of a clinical trial.","Data Management Tracking Document | DM Track Doc | Tracking Document",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899447","Data Validation Certification Document","C115685","Records pertaining to the certification by an authorized accrediting body confirming the successful implantation, and accurate functionality of a data validation program.","Data Validation Certification Document | DVC | Data Validation Certification | EDC UAT Sign Off | EDC Validation Certification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899446","Data Validation Test Document","C115686","Records pertaining to the completion of a data validation test.","Data Validation Test Document | DVT | Data Validation Database Specification QC | Data Validation Testing | Edit Check Validation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899442","Database Management Documentation","C115688","The Trial Master File Reference Model section that contains a collection of documents related to the database used for the Electronic Data Capture system for the clinical trial.","TMF-RM Database Section | DB Subcat | Database | Database Management Documentation | Database Subcategory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899270","Electronic Data Capture Management Team Documentation","C115689","The Trial Master File Reference Model section that contains a collection of documents related to the management of the Electronic Data Capture system for the clinical trial.","TMF-RM EDC Management Section | EDC Management | EDC Management Subcategory | EDC Mgmt Subcat | Electronic Data Capture Management | Electronic Data Capture Management Team Documentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889977","Evidence of Contractor Compliance Document","C115690","Documentation confirming that a vendor meets all criteria to fulfill a contractual obligation for the clinical trial.","Clinical Trial Vendor Qualification and Compliance Documentation | Audit Certificate | Documentation of Decision to Utilize Third Party | ECC | Evidence of Contractor Compliance | Evidence of Contractor Compliance Document | Qualification and Compliance | Qualification of Vendor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814474","SPATS2-Like Protein","C113529","SPATS2-Like protein (558 aa, ~62 kDa) is encoded by the human SPATS2L gene. This protein is involved in oxidative stress protection in myoblasts.","SPATS2-Like Protein | DNA Polymerase Transactivated Protein 6 | DNA Polymerase-Transactivated Protein 6 | Stress Granule And Nucleolar Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829002","Mixing, Not Otherwise Specified","C113031","Any mixing operation not otherwise specified.","Mixing, Not Otherwise Specified | Mixing, Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828701","Operation, Not Otherwise Specified","C113032","Performance of a practical work or of something involving the practical application of principles or processes that is not otherwise specified.","Operation, Not Otherwise Specified | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828674","Packaging Other","C113034","Any packaging operation not elsewhere described.","Packaging Other | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828342","Repackaging","C113035","Placement of an already-marketed product from its original primary container or closure system into a new container or closure system.","Repackaging | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828200","Secondary Packaging","C113036","The process of placing a finished product within an additional container or closure system.","Secondary Packaging | Packaging, Secondary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831585","Air Classification Particle Sizing","C113037","Separation of dry particles into size-differentiated fraction by conveying the particles in a stream of gas.","Air Classification Particle Sizing | Particle Sizing, Air Classification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828658","Particle Sizing, Not Otherwise Specified","C113039","A particle sizing operation not otherwise specified.","Particle Sizing, Not Otherwise Specified | Particle Sizing, Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828008","Size Reduction Particle Sizing","C113041","A process to reduce the particle size of a material by mechanical grinding, attrition, or impact.","Size Reduction Particle Sizing | Particle Sizing, Size Reduction (Coarse or Fine)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827484","Wet Milling Particle Sizing","C113042","A process to reduce the particle size of a slurry material by attrition using either grinding or mechanical shear.","Wet Milling Particle Sizing | Particle Sizing, Wet Milling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828538","Plasmapheresis for Human Source Plasma","C113043","Collection of the fluid portion of human blood for use in blood products by plasmapheresis.","Plasmapheresis for Human Source Plasma | Collection, Human Source Plasma for Further Manufacture, Blood Products",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827251","Coating of Solid Phase with Antigen, Antibody, or Nucleic Acid for in Vitro Diagnostics Device","C113044","The act of immobilizing one or more detection agents to a solid-phase support for an in vitro diagnostic device.","Coating of Solid Phase with Antigen, Antibody, or Nucleic Acid for in Vitro Diagnostics Device | Coating, Solid Phase Antigen/Antibody/Nucleic Acid for in Vitro Diagnostic Device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828864","Nanoparticle Production","C113045","The production of small, stable particles whose size is measured in nanometers.","Nanoparticle Production | Production, Nanoparticle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827199","Plasmid Production","C113046","The production of DNA plasmids.","Plasmid Production | Production, Plasmid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828520","Polysaccharide Preparation from Bacterial Cells","C113047","Separation and purification of bacterial membrane polysaccharides from target bacterial cultures.","Polysaccharide Preparation from Bacterial Cells | Preparation, Polysaccharide from Bacterial Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829602","HOXB13 wt Allele","C112823","Human HOXB13 wild-type allele is located in the vicinity of 17q21.32 and is approximately 4 kb in length. This allele, which encodes homeobox protein Hox-B13, plays a role in transcriptional regulation.","HOXB13 wt Allele | HPC9 | Homeo Box B13 Gene | Homeobox B13 wt Allele | PSGD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025218","Melasma","C112824","Symmetrical patches of tan or brown discoloration on the skin of the face that darken with sun exposure.","Melasma | ",,,,,,,,,,,,,,,"4264234","Chloasma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1436058","Homeobox Protein Hox-B13, Human","C112826","Homeobox protein Hox-B13 (284 aa, ~31 kDa) is encoded by the human HOXB13 gene. This protein is involved in both transcriptional regulation and anterior-posterior axis formation.","Homeobox Protein Hox-B13 | HOXB13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334013","Phrynoderma","C112827","Rough, dry, hypertrophic eruption of the skin associated with vitamin A deficiency.","Phrynoderma | ",,,,,,,,,,,,,,,"4031654","Phrynoderma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1413675","CPNE1 Gene","C112828","This gene plays a role in both calcium binding and vesicle transport.","CPNE1 Gene | CPNE1 | Copine I Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3854364","Harlequin Reaction","C112829","Transient blanching of the lower half of the body while in the lateral recumbent position, most commonly seen in premature or low birth weight infants.","Harlequin Reaction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813145","CPNE1 wt Allele","C112830","Human CPNE1 wild-type allele is located in the vicinity of 20q11.22 and is approximately 39 kb in length. This allele, which encodes copine-1 protein, is involved in both vesicle transport and calcium binding.","CPNE1 wt Allele | COPN1 | CPN1 | Copine I wt Allele | RP1-309K20.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0263386","Ichthyosis Acquisita","C112831","A non-hereditary form of ichthyosis characterized by plate-like scales on the legs, arms and occasionally the torso.","Ichthyosis Acquisita | Acquired Ichthyosis",,,,,,,,,,,,,,,"4313149","Acquired ichthyosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3812672","Copine-1","C112832","Copine-1 (537 aa, ~59 kDa) is encoded by the human CPNE1 gene. This protein plays a role in both calcium binding and vesicle trafficking.","Copine-1 | Copine I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040262","Tinea Versicolor","C112833","A skin condition characterized by hypopigmented, pink or tan, confetti-like, discrete and confluent scaly macules distributed on the chest, shoulders and upper back.","Tinea Versicolor | ",,,,,,,,,,,,,,,"134870","Pityriasis versicolor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2751021","Growth Hormone Excess","C112834","Overproduction of growth hormone, a protein-based peptide that stimulates growth, cell reproduction, and cell regeneration.","Growth Hormone Excess | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814523","QPRT wt Allele","C112838","Human QPRT wild-type allele is located in the vicinity of 16p11.2 and is approximately 20 kb in length. This allele, which encodes nicotinate-nucleotide pyrophosphorylase [carboxylating] protein, plays a role in NAD biosynthesis.","QPRT wt Allele | QPRTase | Quinolinate Phosphoribosyltransferase wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1565377","Equilibrative Nucleoside Transporter 4, Human","C113572","Equilibrative nucleoside transporter 4 (530 aa, ~58 kDa) is encoded by the human SLC29A4 gene. This protein plays a role in regulating homeostasis of monoamine neurotransmitters in the central nervous system.","Equilibrative Nucleoside Transporter 4 | Plasma Membrane Monoamine Transporter | SLC29A4 | Solute Carrier Family 29 (Monoamine Transporter), Member 4 | Solute Carrier Family 29 (Nucleoside Transporters), Member 4 | Solute Carrier Family 29 Member 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890353","TPX2 wt Allele","C116083","Human TPX2 wild-type allele is located in the vicinity of 20q11.2 and is approximately 63 kb in length. This allele, which encodes targeting protein for Xklp2, is involved in mitotic spindle assembly. Aberrant expression is associated with lung carcinoma.","TPX2 wt Allele | C20orf1 | C20orf2 | Chromosome 20 Open Reading Frame 1 Gene | DIL-2 | DIL2 | FLS353 | GD:C20orf1 | HCA519 | HCA90 | HCTP4 | REPP86 | RP11-243J16.10-002 | TPX2 Microtubule Nucleation Factor wt Allele | TPX2, Microtubule-Associated Gene | TPX2, Microtubule-Associated, Homolog (Xenopus Laevis) Gene | TPX2, Xenopus, Homolog of Gene | p100",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473698","Targeting Protein for Xklp2","C116084","Targeting protein for Xklp2 (747 aa, ~86 kDa) is encoded by the human TPX2 gene. This protein plays a role in the formation of mitotic spindles.","Targeting Protein for Xklp2 | DIL-2 | Differentially Expressed In Cancerous and Non-Cancerous Lung Cells 2 | Differentially Expressed In Lung Cells | Hepatocellular Carcinoma-Associated Antigen 519 | Preferentially Expressed In Colorectal Cancer | Protein Fls353 | Restricted Expression Proliferation Associated Protein 100 | Restricted Expression Proliferation-Associated Protein 100 | TPX2 | TPX2, Microtubule-Associated Protein Homolog | p100",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538254","ZRANB3 Gene","C116085","This gene is involved in both DNA damage response and DNA rewinding.","ZRANB3 Gene | ZRANB3 | Zinc Finger RANBP2-Type Containing 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473656","Liposomal Curcumin","C116322","A liposomal formulation containing curcumin, a poorly water-soluble polylphenol pigment isolated from the plant Curcuma longa, with potential antineoplastic, chemopreventive, antioxidant, anti-angiogenic and anti-inflammatory activities. Upon intravenous administration of liposomal curcumin, this agent blocks the formation of reactive-oxygen species, neutralizes free radicals, and exhibits anti-inflammatory properties as a result of inhibition of cyclooxygenases (COX) and other enzymes involved in inflammation. In addition, curcumin disrupts various cell signal transduction pathways involved in carcinogenesis, inhibits the activity of nuclear factor-kappa B (NF-kB), SRC, and annexin A2 (ANXA2), and reduces the expression of both matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor receptor 2 (VEGFR2). This prevents and/or inhibits tumor cell formation and proliferation. Liposome encapsulation of curcumin improves its efficacy, when compared to the administration of unencapsulated curcumin.","Liposomal Curcumin | Curcumin Liposome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473659","HDM2 inhibitor HDM201","C116325","An orally bioavailable human double minute 2 homolog (HDM2) inhibitor with potential antineoplastic activity. Siremadlin inhibits the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited, which may result in the restoration of both p53 signaling and p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger protein and negative regulator of the p53 pathway, is often overexpressed in cancer cells and has been implicated in cancer cell proliferation and survival.","Siremadlin | HDM201 | NVP-HDM 201 | SIREMADLIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473660","Androgen Receptor Antisense Oligonucleotide AZD5312","C116326","An antisense oligonucleotide targeting the androgen receptor (AR) mRNA, with potential antineoplastic activity. Upon intravenous administration, AZD5312 hybridizes with AR mRNA, which blocks translation of the AR protein. This both inhibits AR-induced tumor cell growth and promotes apoptosis in AR-overexpressing tumor cells. AR is overexpressed in certain breast and prostate cancers and is involved in tumor cell proliferation and survival.","Androgen Receptor Antisense Oligonucleotide AZD5312 | AZD-5312 | AZD5312 | ISIS-ARRx | ISIS-AZ1Rx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473661","Tangerine Tomato Juice","C116327","Tomato juice derived from the tangerine tomato, with potential antioxidant and chemopreventive activities. Tangerine tomato juice contains higher levels of the cis-isomer of lycopene (cis-LYC) compared to the trans-isomer (trans-LYC). Lycopene, a linear, unsaturated hydrocarbon carotenoid, is the major red pigment in certain fruits such as tomatoes, pink grapefruit, apricots, red oranges, watermelon, rosehips, and guava. As an antioxidant, lycopene scavenges free radicals, which may both inhibit cellular oxidation and prevent free radical damage to cells. cis-LYC is better absorbed than its trans form.","Tangerine Tomato Juice | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473662","Red Tomato Juice","C116328","Tomato juice derived from red tomatoes, with potential antioxidant and chemopreventive activities. Red tomato juice contains higher levels of the trans-isomer of lycopene (trans-LYC) compared to the cis-isomer (cis-LYC). Lycopene, a linear, unsaturated hydrocarbon carotenoid, is the major red pigment in certain fruits such as tomatoes, pink grapefruit, apricots, red oranges, watermelon, rosehips, and guava. As an antioxidant, lycopene scavenges free radicals which may both inhibit cellular oxidation and prevent free radical damage to cells. cis-LYC is better absorbed than its trans form.","Red Tomato Juice | Tangerine Tomato Juice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279088","Untreated Adult Acute Lymphoblastic Leukemia","C115910","A finding of acute lymphoblastic leukemia in adulthood that has not been treated.","Untreated Adult Acute Lymphoblastic Leukemia | Untreated Acute Lymphoblastic Leukemia (ALL)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279089","Untreated Adult Acute Myeloid Leukemia","C115912","A finding of acute myeloid leukemia in adulthood that has not been treated.","Untreated Adult Acute Myeloid Leukemia | Untreated Acute Myeloid Leukemia (AML)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279091","Untreated Childhood Acute Lymphoblastic Leukemia","C115914","A finding of acute lymphoblastic leukemia in childhood that has not been treated.","Untreated Childhood Acute Lymphoblastic Leukemia | Untreated Acute Lymphoblastic Leukemia (ALL)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897226","Untreated Childhood Myeloid Neoplasm","C115915","A finding of myeloid neoplasm in childhood that has not been treated.","Untreated Childhood Myeloid Neoplasm | Untreated Myeloid Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897217","Untreated Metastatic Squamous Cell Carcinoma to Neck with Occult Primary","C115917","A finding of metastatic squamous cell carcinoma to neck with occult primary that has not been treated.","Untreated Metastatic Squamous Cell Carcinoma to Neck with Occult Primary | Untreated Metastatic Squamous Cell Cancer to Neck with Occult Primary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433922","Untreated Childhood Anaplastic Astrocytoma","C115919","A finding of anaplastic astrocytoma in childhood that has not been treated.","Untreated Childhood Anaplastic Astrocytoma | Untreated Anaplastic Astrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433950","Untreated Childhood Anaplastic Oligoastrocytoma","C115920","A finding of anaplastic oligoastrocytoma in childhood that has not been treated.","Untreated Childhood Anaplastic Oligoastrocytoma | Untreated Anaplastic Oligoastrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0338327","Untreated Childhood Brain Stem Glioma","C115923","A finding of brain stem glioma in childhood that has not been treated.","Untreated Childhood Brain Stem Glioma | Untreated Brain Stem Glioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827196","Production of Immunoassay Detection Reagent","C113048","The production of antigen and antibody detection components.","Production of Immunoassay Detection Reagent | Immunoassay Detection Reagent Production | Production, Immunoassay Detection Reagent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828470","Production of Individual Vaccine Component","C113050","The preparation of material from one virus or bacteria strain for use as a component of a vaccine.","Production of Individual Vaccine Component | Individual Vaccine Component Production | Production, Individual Vaccine Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828468","Production of Nucleic Acid Detection Reagent","C113051","The production of nucleic acid probes and reagents to detect the presence of specific nucleic acids.","Production of Nucleic Acid Detection Reagent | Production, Nucleic Acid Detection Reagent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811845","ELAC2 wt Allele","C113286","Human ELAC2 wild-type allele is located in the vicinity of 17p11.2 and is approximately 27 kb in length. This allele, which encodes zinc phosphodiesterase ELAC protein 2, is involved in tRNA maturation. Mutation of the gene is associated with combined oxidative phosphorylation deficiency 17 and susceptibility to hereditary prostate cancer 2.","ELAC2 wt Allele | COXPD17 | ELAC, E. coli, Homolog of, 2 Gene | ELC2 | ElaC (E. coli) Homolog 2 Gene | ElaC Homolog 2 (E. coli) Gene | ElaC Ribonuclease Z 2 wt Allele | FLJ10530 | HPC2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447900","Zinc Phosphodiesterase ELAC Protein 2, Human","C113287","Zinc phosphodiesterase ELAC protein 2 (826 aa, ~92 kDa) is encoded by the human ELAC2 gene. This protein plays a role in endoribonuclease activity.","Zinc Phosphodiesterase ELAC Protein 2 | EC 3.1.26.11 | ELAC2 | ElaC Homolog Protein 2 | Heredity Prostate Cancer Protein 2 | Putative Prostate Cancer Susceptibility Protein HPC2/ELAC2 | RNase Z 2 | RNase ZL | Ribonuclease Z 2 | Ribonuclease Z, Long Form | tRNA 3 Endonuclease 2 | tRNase Z (Long Form) | tRNase Z 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813177","EXOSC5 wt Allele","C113291","Human EXOSC5 wild-type allele is located in the vicinity of 19q13.1 and is approximately 11 kb in length. This allele, which encodes exosome complex component RRP46 protein, plays a role in RNA metabolism.","EXOSC5 wt Allele | CML28 | Exosome Component 5 wt Allele | MGC12901 | RRP41B | RRP46 | Ribosomal RNA-Processing Protein 46, S. cerevisiae, Homolog of Gene | Rrp46p | hRrp46p | p12B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827081","P-p68 Inhibitor RX-5902","C113293","An orally bioavailable small molecule inhibitor of phosphorylated-p68 RNA helicase (P-p68), with potential anti-proliferative and antineoplastic activity. Upon oral administration, P-p68 inhibitor RX-5902 may both inhibit the activity of the anti-apoptotic B-cell lymphoma 2 (Bcl-2) protein and facilitate the induction of cyclin-dependent kinase inhibitor 1 (p21). This may prevent G2/M cell cycle progression and lead to growth inhibition in tumor cells. P-p68 is overexpressed in various types of solid tumors but absent in normal tissues, and plays a role in tumor progression and metastasis. p21 is a potent cyclin-dependent kinase inhibitor which regulates cell cycle progression and mediates both growth arrest and cellular senescence.","P-p68 Inhibitor RX-5902 | RX-5902 | SUPINOXIN | Supinoxin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812693","CD177 wt Allele","C113574","Human CD177 wild-type allele is located in the vicinity of 19q13.31 and is approximately 10 kb in length. This allele, which encodes CD177 antigen protein, plays a role in platelet function and coagulation. Mutations in this gene are associated with polycythemia and hemorrhagic thrombocythemia.","CD177 wt Allele | CD177 Molecule wt Allele | HNA-2a | HNA2A | NB1 | PRV-1 | PRV1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0913852","CD177 Antigen, Human","C113575","CD177 antigen (437 aa, ~46 kDa) is encoded by the human CD177 gene. This protein is involved in coagulation.","CD177 Antigen | Human Neutrophil Alloantigen 2a | NB1 GP | NB1 Glycoprotein | Neutrophil-Specific Antigen 1 | Polycythemia Rubra Vera 1 | Polycythemia Rubra Vera Protein 1 | Polycythemia Rubra Vera-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814528","RGL4 wt Allele","C113577","Human RGL4 wild-type allele is located in the vicinity of 22q11.23 and is approximately 11 kb in length. This allele, which encodes ral-GDS-related protein, is involved in guanyl-nucleotide metabolism.","RGL4 wt Allele | RALGDS-Related, Rabbit, Homolog of Gene | RGR | Ral Guanine Nucleotide Dissociation Stimulator-Like 4 wt Allele | hRGR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815187","Ral-GDS-Related Protein, human","C113578","Ral-GDS-related protein (473 aa, ~52 kDa) is encoded by the human RGL4 gene. This protein plays a role in in the metabolism of guanine nucleotides.","Ral-GDS-Related Protein | RGL4 | Ral-GDS Related Protein | Ral-GDS Related Protein Rgr | RalGDS Related Oncogene | RalGDS-Like 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811765","ENTPD1 wt Allele","C113580","Human ENTPD1 wild-type allele is located in the vicinity of 10q24.1 and is approximately 165 kb in length. This allele, which encodes ectonucleoside triphosphate diphosphohydrolase 1 protein, plays a role in modulating hemostasis and thrombotic reactions.","ENTPD1 wt Allele | ATP-DPH | ATPDase | CD39 | Ectonucleoside Triphosphate Diphosphohydrolase 1 wt Allele | NTPDase-1 | SPG64",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
,,"C113581","Ectonucleoside triphosphate diphosphohydrolase 1 (510 aa, ~58 kDa) is encoded by the human ENTPD1 gene. This protein is involved in the activation of platelets.","Ectonucleoside Triphosphate Diphosphohydrolase 1 | ATP Diphosphohydrolase | ATPDase | Apyrase | CD39 | CD39 Antigen | EC 3.6.1.5 | ENTPD1 | Ecto-ATP Diphosphohydrolase 1 | Ecto-ATPDase 1 | Ecto-ATPase 1 | Ecto-apyrase | Lymphoid Cell Activation Antigen | NTPDase 1 | NTPDase-1 | NTPDase1 | Nucleoside Triphosphate Diphosphohydrolase 1 | Vascular ATP Diphosphohydrolase",,,,,,,,,,,,,,,"4210635","Lymphocyte antigen CD39",,,,,,,,,,,,,,,,,,,,,,"--"
"C3812677","CPA1 wt Allele","C113583","Human CPA1 wild-type allele is located in the vicinity of 7q32 and is approximately 8 kb in length. This allele, which encodes carboxypeptidase A1 protein, is involved in enzyme metabolism.","CPA1 wt Allele | CPA | Carboxypeptidase A1 (Pancreatic) wt Allele | Procarboxypeptidase A1, Pancreatic Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1137931","Carboxypeptidase A1","C113584","Carboxypeptidase A1 (419 aa, ~47 kDa) is encoded by the human CPA1 gene. This protein plays a role in enzyme metabolism.","Carboxypeptidase A1 | CPA1 | EC 3.4.17.1 | Pancreatic Carboxypeptidase A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473663","Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes","C116329","A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a hinge-optimized, chimeric antigen receptor (CAR), containing a CD28 co-stimulatory signaling domain fused to CD3 zeta, the single-chain variable fragment of CD123 (Interleukin-3 receptor alpha chain or IL3RA) antigen, and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes are directed to and induce selective toxicity in CD123-expressing tumor cells. CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with increased leukemic cell proliferation and aggressiveness. Devoid of both ligand binding domains and tyrosine kinase activity, EGFRt both facilitates detection of the administered T-cells in vivo and can promote elimination of those cells following a cetuximab-induced antibody-dependent cellular cytotoxicity response. The costimulatory signaling domain enhances both proliferation of T-cells and antitumor activity. Hinge optimization prevents recognition of the CAR by Fc receptors (FcRs).","Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes | Anti CD123-CAR/CD28-costimulatory Lentiviral Vector-transduced Autologous T Lymphocytes | CD123R(EQ)28zeta/EGFRt+ T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889272","Randomization Validation","C115621","Documentation verifying the correct randomization number and treatment assignment have been generated by the randomization program being used in the clinical trial.","Clinical Trial Randomization Validation Documentation | RV | Randomization Sign Off | Randomization Validation | Randomization Validation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899443","Database Lock and Unlock Approval","C115626","Records that confirm the completion and satisfaction of all the requirements for a database release.","Database Lock and Unlock Approval | DB LUL Approv",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889961","Clinical Trial Protocol Amendment Summary","C115627","A synopsis of changes to, or formal clarification of, a clinical study protocol.","Clinical Trial Protocol Amendment Summary | Prot Amend | Protocol Amendment | Study Amendment Summary | Summary of Changes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899559","Clinical Trial Protocol Synopsis","C115628","Documentation summarizing the key points of the clinical study protocol.","Clinical Study Protocol Synopsis Documentation | Clinical Trial Protocol Synopsis | Prot Synop | Protocol Profile | Protocol Scientific Summary | Protocol Summary | Protocol Synopsis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899597","Clinical Study Report Synopsis","C115629","A summary of the results from the clinical study report.","Clinical Study Report Synopsis | CSR Synopsis | result synopsis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899555","Clinical Trial Safety Documentation","C115630","The Trial Master File Reference Model section that contains a collection of documents related to the safety management and reporting for the clinical trial.","TMF-RM Safety Documentation Section | Clinical Trial Safety Documentation | Safe Docn Subcat | Safety Documentation | Safety Documentation Subcategory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900048","Analysis Documentation","C115632","The Trial Master File Reference Model section that contains a collection of documents related to the statistical analysis of the clinical trial.","TMF-RM Statistics Analysis Section | Analysis | Analysis Documentation | Analysis Subcat | Analysis Subcategory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL458141","Metatinib Tromethamine","C113294","An orally bioavailable tyrosine kinase inhibitor of the BCR-ABL fusion oncoprotein, with potential antineoplastic activity. Upon oral administration, BCR-ABL tyrosine kinase inhibitor BL001 may inhibit the BCL-ABL protein, which may lead to decreased proliferation and enhanced apoptosis in tumor cells. BCR-ABL oncoprotein is generated by a reciprocal translocation between chromosome 9 and 22 specifically t(9;22)(q34;q11). The resulting fusion gene produces proteins with constitutively active tyrosine kinase activity, which stimulate both abnormal cell division and increased cellular proliferation. This fusion is associated with both chronic myeloid leukemia and acute lymphoblastic leukemia.","Metatinib Tromethamine | BCR-ABL Tyrosine Kinase Inhibitor BL001 | BL001 | Metatinib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL458142","pegylated recombinant human interleukin-10 AM0010","C113295","A covalent conjugate of recombinant human interleukin-10 (IL-10) and polyethylene glycol (PEG), with potential anti-fibrotic, anti-inflammatory, immunomodulating and antineoplastic activities. Upon subcutaneous administration, pegilodecakin may activate cell-mediated immunity against cancer cells by stimulating the differentiation and expansion of tumor specific cytotoxic CD8+ T cells. This agent may also lower serum cholesterol levels and reduce atherosclerotic plaques by inhibiting the synthesis of pro-inflammatory cytokines, such as Interferon-gamma, IL-2, IL-3, TNF-alpha, and GM-CSF. The PEG moiety inhibits proteolytic breakdown and clearance of AM0010, which prolongs its half-life, extends the duration of its therapeutic effects and allows less frequent dosing.","Pegilodecakin | AM-0010 | AM0010 | PEG-rHuIL-10 AM0010 | PEGILODECAKIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827586","VFQ25-Self Administered Format - Difficulty Seeing How People React","C112781","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: Because of your eyesight, how much difficulty do you have seeing how people react to things you say?","VFQ25-Self Administered Format - Difficulty Seeing How People React | VFQ2-Difficulty Seeing How People React | VFQ211",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827592","VFQ25-Self Administered Format - Difficulty Picking Out and Matching Own Clothes","C112782","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: Because of your eyesight, how much difficulty do you have picking out and matching your own clothes?","VFQ25-Self Administered Format - Difficulty Picking Out and Matching Own Clothes | VFQ2-Difficulty Picking Out Own Clothes | VFQ212",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827583","VFQ25-Self Administered Format - Difficulty Visiting People","C112783","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: Because of your eyesight, how much difficulty do you have visiting with people in their homes, at parties, or in restaurants?","VFQ25-Self Administered Format - Difficulty Visiting People | VFQ2-Difficulty Visiting With People | VFQ213",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827594","VFQ25-Self Administered Format - Difficulty Going Out to See Movies","C112784","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: Because of your eyesight, how much difficulty do you have going out to see movies, plays, or sports events?","VFQ25-Self Administered Format - Difficulty Going Out to See Movies | VFQ2-Difficulty Going Out to See Movies | VFQ214",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827602","VFQ25-Self Administered Format - Are You Currently Driving","C112785","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: Are you currently driving, at least once in a while?","VFQ25-Self Administered Format - Are You Currently Driving | VFQ2-Are You Currently Driving | VFQ215",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827572","VFQ25-Self Administered Format - Never Driven or Given Up Driving","C112786","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: If no: Have you never driven a car or have you given up driving?","VFQ25-Self Administered Format - Never Driven or Given Up Driving | VFQ2-Never Driven or Given Up Driving | VFQ215A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827574","VFQ25-Self Administered Format - Main Reason You Gave Up Driving","C112787","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: If you gave up driving: Was that mainly because of your eyesight, mainly for some other reason, or because of both your eyesight and other reasons?","VFQ25-Self Administered Format - Main Reason You Gave Up Driving | VFQ2-Main Reason You Gave Up Driving | VFQ215B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810599","FLNA wt Allele","C113586","Human FLNA wild-type allele is located in the vicinity of Xq28 and is approximately 26 kb in length. This allele, which encodes filamin-A protein, plays a role in actin structure and function. Mutations in this gene are associated with several syndromes, including periventricular nodular heterotopias, otopalatodigital syndrome type 1 and type 2, frontometaphyseal dysplasia, Melnick-Needles syndrome, and X-linked congenital idiopathic intestinal pseudoobstruction.","FLNA wt Allele | ABP-280 | ABPX | CSBS | CVD1 | FLN | FLN-A | FLN1 | FMD | Filamin A, Alpha wt Allele | MNS | NHBP | OPD | OPD1 | OPD2 | XLVD | XMVD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2239498","CPTP Gene","C113110","This gene is involved in sphingolipid transport.","CPTP Gene | CPTP | Ceramide-1-Phosphate Transfer Protein Gene | GLTPD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813146","MGC10334","C113111","Human CPTP wild-type allele is located in the vicinity of 1p36.33 and is approximately 4 kb in length. This allele, which encodes ceramide-1-phosphate transfer protein, plays a role in glycolipid transport.","CPTP wt Allele | CPTP | Ceramide-1-Phosphate Transfer Protein wt Allele | GLTPD1 | Glycolipid Transfer Protein Domain Containing 1 Gene | MGC10334",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3710858","GLTPD1 protein, human","C113112","Ceramide-1-phosphate transfer protein (214 aa, ~24 kDa) is encoded by the human CPTP gene. This protein is involved in intercellular transport of sphingolipids.","Ceramide-1-Phosphate Transfer Protein | CPTP | GLTP Domain-Containing Protein 1 | Glycolipid Transfer Protein Domain-Containing Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811197","GPNMB wt Allele","C113115","Human GPNMB wild-type allele is located in the vicinity of 7p15 and is approximately 39 kb in length. This allele, which encodes transmembrane glycoprotein NMB, may be involved in the modulation of cell proliferation. Aberrant expression of the gene is associated with glioblastoma multiforme and other neoplasms.","GPNMB wt Allele | Glycoprotein (Transmembrane) Nmb Gene | Glycoprotein Nmb wt Allele | Glycoprotein Nonmetastatic Melanoma Protein B Gene | HGFIN | Hematopoietic Growth Factor Inducible Neurokinin-1 Gene | NMB | UNQ1725/PRO9925",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813203","Transmembrane Glycoprotein NMB, Human","C113116","Transmembrane glycoprotein NMB (572 aa, ~64 kDa) is encoded by the human GPNMB gene. This protein may play a role in cell proliferation.","Transmembrane Glycoprotein NMB | Glycoprotein NMB | Glycoprotein Nmb-Like Protein | Glycoprotein Nonmetastatic B | Osteoactivin | Transmembrane Glycoprotein HGFIN | gpNMB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423717","OGFR Gene","C113117","This gene is involved in binding to Met-enkephalin.","OGFR Gene | OGFR | Opioid Growth Factor Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814863","OGFR wt Allele","C113118","Human OGFR wild-type allele is located in the vicinity of 20q13.3 and is approximately 9 kb in length. This allele, which encodes opioid growth factor receptor protein, plays a role in Met-enkephalin-dependent signaling.","OGFR wt Allele | 7-60 | Opioid Growth Factor Receptor wt Allele | RP5-885L7.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812731","Opioid Growth Factor Receptor, human","C113119","Opioid growth factor receptor (677 aa, ~73 kDa) is encoded by the human OGFR gene. This protein is involved in Met-enkephalin binding and downstream effects.","Opioid Growth Factor Receptor | 7-60 Protein | OGFr | Protein 7-60 | Zeta-Type Opioid Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420872","TPM1 Gene","C113121","This gene plays a role in muscle contraction.","TPM1 Gene | TPM1 | Tropomyosin 1 (Alpha) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900046","Analysis Quality Control Document","C115633","Records of the quality control (QC) procedures planned for the analysis programs, and the outputs of said QC procedures.","Analysis Quality Control Document | Analysis QC Docn | Analysis QC Documentation | Analysis Quality Control Documentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900016","Approval for Database Activation Document","C115634","Records of the completion of all requirements for a database activation specification.","Approval for Database Activation Document | Approv DB Activn | Approval for Database Activation | Approval for Database Go Live | Database Release Approval",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899940","Biological Sample Export Document","C115635","Documentation pertaining to the importation or exportation of specimens for the clinical trial.","Clinical Trial Biological Sample Import or Export Documentation | Biological Sample Export Document | Sample Export Documentation | Sample Expt Docn | Sample Import or Export Documentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899696","Central Clinical Trial Study Documentation","C115636","The Trial Master File Reference Model zone that contains the collection of documents relating to the clinical study protocol, investigator's brochure, key subject documentation and study reports for the clinical trial.","TMF-RM Central Trial Documents Zone | CTrial Doc Cat | Central Clinical Trial Study Documentation | Central Trial Documents | Central Trial Documents Category",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899694","Central Trial Documentation","C115637","Records of communications, tracking documents, templates, and forms related to the central trial of a clinical trial.","Central Trial Documentation | CTrial Doc Comm Track Subcat | Central Trial Documents Communications and Tracking Subcategory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889992","Central Trial Tracking Document","C115638","Records of the central trial activities during the course of a clinical trial.","Central Trial Tracking Document | CTrial Track | Tracking Document",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889398","Centralized Testing Communication Document","C115639","Records of communications related to a centralized test.","Centralized Testing Communication Document | Centralized Testing Communications | Centralz Test Comm | Correspondence | Relevant Communications",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898542","MPAI-4 - Abilities: Fund of Information","C115861","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Fund of Information: Problems remembering information learned in school or on the job; difficulty remembering information about self and family from years ago.","MPAI-4 - Abilities: Fund of Information | MPAI1-Fund of Information | MPAI110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898537","MPAI-4 - Abilities: Novel Problem-Solving","C115862","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Novel problem-solving: Problems thinking up solutions or picking the best solution to new problems.","MPAI-4 - Abilities: Novel Problem-Solving | MPAI1-Novel Problem-Solving | MPAI111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898533","MPAI-4 - Abilities: Visuospatial Abilities","C115863","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Visuospatial abilities: Problems drawing, assembling things, route-finding, being visually aware on both the left and right sides.","MPAI-4 - Abilities: Visuospatial Abilities | MPAI1-Visuospatial Abilities | MPAI112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898532","MPAI-4 - Adjustment: Anxiety","C115864","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Anxiety: Tense, nervous, fearful, phobias, nightmares, flashbacks of stressful events.","MPAI-4 - Adjustment: Anxiety | MPAI1-Anxiety | MPAI113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898531","MPAI-4 - Adjustment: Depression","C115865","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Depression: Sad, blue, hopeless, poor appetite, poor sleep, worry, self-criticism.","MPAI-4 - Adjustment: Depression | MPAI1-Depression | MPAI114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898526","MPAI-4 - Adjustment: Irritability, Anger, Aggression","C115866","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Irritability, anger, aggression: Verbal or physical expressions of anger.","MPAI-4 - Adjustment: Irritability, Anger, Aggression | MPAI1-Irritablity, Anger, Aggression | MPAI115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897038","MPAI-4 - Adjustment: Pain and Headache","C115867","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Pain and headache: Verbal and nonverbal expressions of pain; activities limited by pain.","MPAI-4 - Adjustment: Pain and Headache | MPAI1-Pain and Headache | MPAI116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898529","MPAI-4 - Adjustment: Fatigue","C115868","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Fatigue: Feeling tired; lack of energy; tiring easily.","MPAI-4 - Adjustment: Fatigue | MPAI1-Fatigue | MPAI117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897735","Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell Tumor","C115427","The reemergence of a malignant extragonadal nongerminomatous germ cell tumor after a period of remission.","Recurrent Malignant Extragonadal Nongerminomatous Germ Cell Tumor | Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL376163","Recurrent Extragonadal Seminoma","C115428","The reemergence of extragonadal seminoma after a period of remission.","Recurrent Extragonadal Seminoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433821","Recurrent Fallopian Tube Carcinoma","C115429","The reemergence of fallopian tube carcinoma after a period of remission.","Recurrent Fallopian Tube Carcinoma | Recurrent Fallopian Tube Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1541448","Recurrent Grade I Lymphomatoid Granulomatosis","C115430","The reemergence of grade I lymphomatoid granulomatosis after a period of remission.","Recurrent Grade I Lymphomatoid Granulomatosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897737","Recurrent Inverted Schneiderian Papilloma","C115432","The reemergence of inverted Schneiderian papilloma after a period of remission.","Recurrent Sinonasal Inverted Papilloma | Recurrent Inverted Schneiderian Papilloma | Recurrent Sinonasal Inverted Schneiderian Papilloma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897732","Recurrent Pancreatic Neuroendocrine Carcinoma","C115433","The reemergence of pancreatic neuroendocrine carcinoma after a period of remission.","Recurrent Pancreatic Neuroendocrine Carcinoma | Recurrent Pancreatic Neuroendocrine Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889699","AJUBA wt Allele","C115437","Human AJUBA wild-type allele is located in the vicinity 14q11.2 and is approximately 11 kb in length. This allele, which encodes LIM domain-containing protein ajuba, is involved in protein complex formation.","AJUBA wt Allele | Ajuba LIM Protein wt Allele | Ajuba, Mouse, Homolog of Gene | JUB | Jub, Ajuba Homolog (Xenopus Laevis) Gene | Jub, Ajuba Homolog Gene | MGC15563",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1433250","LIM Domain-Containing Protein Ajuba, Human","C115438","LIM domain-containing protein ajuba (538 aa, ~57 kDa) is encoded by the human AJUBA gene. This protein plays a role in the formation of protein complexes.","LIM Domain-Containing Protein Ajuba | Protein Ajuba",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0862200","Recurrent Mycosis Fungoides and Sezary Syndrome","C115439","The reemergence of mycosis fungoides/Sezary syndrome after a period of remission.","Recurrent Mycosis Fungoides and Sezary Syndrome | Recurrent Mycosis Fungoides and Sézary Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL343405","Recurrent Merkel Cell Carcinoma","C115440","The reemergence of Merkel cell carcinoma after a period of remission.","Recurrent Merkel Cell Carcinoma | Recurrent Merkel Cell Cancer | Recurrent Neuroendocrine Carcinoma of the Skin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827599","VFQ25-Self Administered Format - Difficulty Driving During Daytime","C112788","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: If currently driving: How much difficulty do you have driving during the daytime in familiar places? Would you say you have:","VFQ25-Self Administered Format - Difficulty Driving During Daytime | VFQ2-Difficulty Driving During Daytime | VFQ215C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827580","VFQ25-Self Administered Format - Driving in Difficult Condition","C112790","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: How much difficulty do you have driving in difficult conditions, such as in bad weather, during rush hour, on the freeway, or in city traffic? Would you say you have:","VFQ25-Self Administered Format - Driving in Difficult Condition | VFQ2-Driving in Difficult Conditions | VFQ216A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827603","VFQ25-Self Administered Format - Accomplish Less Because of Vision","C112791","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Responses to Vision Problems: Do you accomplish less than you would like because of your vision?","VFQ25-Self Administered Format - Accomplish Less Because of Vision | VFQ2-Accomplish Less Than You Would Like | VFQ217",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827575","VFQ25-Self Administered Format - Limited in How Long You Can Work Because of Vision","C112792","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Responses to Vision Problems: Are you limited in how long you can work or do other activities because of your vision?","VFQ25-Self Administered Format - Limited in How Long You Can Work Because of Vision | VFQ2-Limited in How Long You Can Work | VFQ218",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1439340","SLC6A3 protein, human","C113530","Sodium-dependent dopamine transporter (620 aa, ~68 kDa) is encoded by the human SLC6A3 gene. This protein plays a role in the downregulation of dopamine signaling.","Sodium-Dependent Dopamine Transporter | DA Transporter | DAT | Dopamine Transporter | Dopamine Transporter 1 | SLC6A3 | Solute Carrier Family 6 Member 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814799","CA6 wt Allele","C113532","Human CA6 wild-type allele is located in the vicinity of 1p36.2 and is approximately 29 kb in length. This allele, which encodes carbonic anhydrase 6 protein, is involved in the reversible hydration of carbon dioxide. Mutations in this gene are associated with both multilocular clear cell renal cell carcinoma and herpangina.","CA6 wt Allele | CA-VI | Carbonic Anhydrase VI wt Allele | GUSTIN | RP3-477M7.7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1311420","carbonic anhydrase VI, human","C113534","Carbonic anhydrase 6 (308 aa, ~35 kDa) is encoded by the human CA6 gene. This protein plays a role in the reversible hydration of carbon dioxide.","Carbonic Anhydrase 6 | CA-IV | CA6 | Carbonate Dehydratase VI | Carbonic Anhydrase IV | Carbonic Anhydrase, Secreted | EC 4.2.1.1 | GUSTIN | Salivary Carbonic Anhydrase | Secreted Carbonic Anhydrase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815270","SCGB1D2 wt Allele","C113535","Human SCGB1D2 wild-type allele is located in the vicinity of 11q13 and is approximately 3 kb in length. This allele, which encodes secretoglobin family 1D member 2 protein, plays a role in androgen binding.","SCGB1D2 wt Allele | LIPB | LIPHB | LPHB | LPNB | Lipophilin B (Uteroglobin Family Member), Prostatein-Like Gene | Secretoglobin, Family 1D, Member 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1434618","Secretoglobin Family 1D Member 2, Human","C113537","Secretoglobin family 1D member 2 (90 aa, ~10 kDa) is encoded by the human SCGB1D2 gene. This protein is involved in binding to androgens and other steroids.","Secretoglobin Family 1D Member 2 | Lipophilin B | Lipophilin-B | Prostatein-Like Lipophilin B | Secretoglobin 1D2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811667","TPM1 wt Allele","C113123","Human TPM1 wild-type allele is located in the vicinity of 15q22.1 and is approximately 29 kb in length. This allele, which encodes tropomyosin alpha-1 chain protein, is involved in the regulation of muscle contraction. Mutation of the gene is associated with left ventricular non-compaction 9 and cardiomyopathy types familial hypertrophic 3 and dilated 1Y.","TPM1 wt Allele | C15orf13 | CMD1Y | CMH3 | Cardiomyopathy, Hypertrophic 3 Gene | Chromosome 15 Open Reading Frame 13 Gene | HTM-alpha | LVNC9 | TMSA | Tropomyosin 1 (Alpha) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811682","Evacuated Blood Specimen Collection Tube","C113124","A blood collection tube that contains a vacuum, allowing it to draw blood through a needle to fill the tube.","Evacuated Blood Specimen Collection Tube | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0384723","Tropomyosin Alpha-1 Chain, Human","C113125","Tropomyosin alpha-1 chain (284 aa, ~33 kDa) is encoded by the human TPM1 gene. This protein plays a role in muscle contraction.","Tropomyosin Alpha-1 Chain | Alpha-Tropomyosin | Sarcomeric Tropomyosin Kappa | TPM1 | Tropomyosin, Skeletal Muscle Alpha | Tropomyosin-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427993","EXOC7 Gene","C113126","This gene is involved in vesicle exocytosis.","EXOC7 Gene | EXOC7 | Exocyst Complex Component 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL458160","Anti-PD-1 Monoclonal Antibody MEDI0680","C113332","A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody MEDI0680 binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the Ig superfamily expressed on T cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","Anti-PD-1 Monoclonal Antibody MEDI0680 | AMP-514 | MEDI0680",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL458161","anti-ErbB3 monoclonal antibody KTN3379","C113333","A human monoclonal antibody directed against the human epidermal growth factor receptor ErbB3 (HER3), with potential antineoplastic activity. Upon administration, the anti-ErbB3 monoclonal antibody CDX-3379 targets and binds to a unique epitope on ErbB3, thereby preventing ErbB3 phosphorylation and both ligand-dependent and ligand-independent ErbB3 signaling. This inhibits cellular proliferation and survival of ErbB3-expressing tumor cells. ErbB3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in a variety of tumors and its overexpression generally correlates with poor prognosis and tumor resistance.","Anti-ErbB3 Monoclonal Antibody CDX-3379 | CDX 3379 | CDX-3379 | CDX3379 | KTN 3379 | KTN-3379 | KTN3379",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL458162","Histone-Lysine N-Methyltransferase EZH2 Inhibitor GSK2816126","C113334","A small molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone-lysine N-methyltransferase EZH2, with potential antineoplastic activity. Upon administration, histone-lysine N-methyltransferase EZH2 inhibitor GSK2816126 inhibits the activity of EZH2 and specifically prevents the methylation of histone H3 lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased tumor cell proliferation in cancer cells that overexpress this enzyme. EZH2, which belongs to the class of histone methyltransferases (HMTs), is overexpressed or mutated in a variety of cancers and plays a key role in tumor cell proliferation.","Histone-Lysine N-Methyltransferase EZH2 Inhibitor GSK2816126 | EZH2 Inhibitor GSK2816126 | GSK2816126",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020503","Secondary Hyperparathyroidism","C113335","Overproduction of parathyroid hormone in response to influence external to the parathyroid glands.","Secondary Hyperparathyroidism | ",,,,,,,,,,,,,,,"138388","Secondary hyperparathyroidism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828442","Pubertal Failure","C113336","Abnormally absent or incomplete sexual development.","Pubertal Failure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342546","Premature Adrenarche","C113337","Premature onset of adrenal androgen-mediated secondary sexual characteristics.","Premature Adrenarche | ",,,,,,,,,,,,,,,"4011770","Premature adrenarche",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0342548","Premature Menarche","C113338","Occurrence of the first menstrual period in a female before the usual or expected age.","Premature Menarche | ",,,,,,,,,,,,,,,"4185404","Early menarche",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898527","MPAI-4 - Adjustment: Inappropriate Social Interaction","C115870","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Inappropriate social interaction: Acting childish, silly, rude, behavior not fitting for time and place.","MPAI-4 - Adjustment: Inappropriate Social Interaction | MPAI1-Inappropriate Social Interaction | MPAI119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898528","MPAI-4 - Adjustment: Impaired Self-Awareness","C115871","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Impaired self-awareness: Lack of recognition of personal limitations and disabilities and how they interfere with everyday activities and work or school.","MPAI-4 - Adjustment: Impaired Self-Awareness | MPAI1-Impaired Self-Awareness | MPAI120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898530","MPAI-4 - Adjustment: Family or Significant Relationships","C115872","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Family or significant relationships: Interactions with close others; describe stress within the family or those closest to the person with brain injury; 'family functioning' means cooperating to accomplish those tasks that need to be done to keep the household running.","MPAI-4 - Adjustment: Family or Significant Relationships | MPAI1-Family/Significant Relationships | MPAI121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898514","MPAI-4 - Participation: Initiation","C115873","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Initiation: Problems getting started on activities without prompting.","MPAI-4 - Participation: Initiation | MPAI1-Initiation | MPAI122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898507","MPAI-4 - Participation: Social Contact with Fiends, Work Associates and Others","C115874","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Social contact with friends, work associates, and other people who are not family, significant others, or professionals.","MPAI-4 - Participation: Social Contact with Fiends, Work Associates and Others | MPAI1-Social Contact-Friends/Coworkers | MPAI123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898513","MPAI-4 - Participation: Leisure and Recreational Activities","C115875","Mayo-Portland Adaptability Inventory-4 (MPAI-4) Leisure and recreational activities.","MPAI-4 - Participation: Leisure and Recreational Activities | MPAI1-Leisure and Recreation Activities | MPAI124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889461","ZRANB3 wt Allele","C116086","Human ZRANB3 wild-type allele is located in the vicinity of 2q21.3 and is approximately 394 kb in length. This allele, which encodes DNA annealing helicase and endonuclease ZRANB3 protein, plays a role in both DNA rewinding and the response to DNA damage.","ZRANB3 wt Allele | 4933425L19Rik | AH2 | DKFZP434B1727 | Zinc Finger RANBP2-Type Containing 3 wt Allele | Zinc Finger, RAN-Binding Domain Containing 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2975114","DNA Annealing Helicase and Endonuclease ZRANB3, Human","C116087","DNA annealing helicase and endonuclease ZRANB3 (1079 aa, ~123 kDa) is encoded by the human ZRANB3 gene. This protein is involved in both the modification of DNA topology and the response to DNA damage.","DNA Annealing Helicase and Endonuclease ZRANB3 | AH2 | Annealing Helicase 2 | DNA Annealing Helicase ZRANB3 | EC 3.1.-.- | EC 3.6.4.- | Endonuclease ZRANB3 | ZRANB3 | Zinc Finger RANBP2-Type Domain-Containing Protein 3 | Zinc Finger Ran-Binding Domain-Containing Protein 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823140","STX2 Gene","C116088","This gene plays a role in epithelial morphogenesis.","STX2 Gene | STX2 | Syntaxin 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889714","STX2 wt Allele","C116089","Human STX2 wild-type allele is located in the vicinity of 12q24.33 and is approximately 50 kb in length. This allele, which encodes syntaxin-2 protein, is involved in both vesicular transport and epithelial morphogenesis.","STX2 wt Allele | EPM | STX2A | STX2B | STX2C | Syntaxin 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1612113","Syntaxin-2, Human","C116090","Syntaxin-2 (288 aa, ~33 kDa) is encoded by the human STX2 gene. This protein plays a role in both epithelial morphogenesis and vesicle trafficking.","Syntaxin-2 | Epimorphin | STX2 | Syntaxin 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1540057","TRIM23 Gene","C116091","This gene is involved in the modulation of ubiquitination.","TRIM23 Gene | TRIM23 | Tripartite Motif Containing 23 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280363","Recurrent Lip and Oral Cavity Squamous Cell Carcinoma","C115442","The reemergence of lip and oral cavity squamous cell carcinoma after a period of remission.","Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280419","nasal cavity and paranasal sinus squamous cell carcinoma, recurrent","C115443","The reemergence of nasal cavity and paranasal sinus squamous cell carcinoma after a period of remission.","Recurrent Sinonasal Squamous Cell Carcinoma | Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Cancer | Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890567","Institutional Review Board - Independent Ethics Committee Shared Documentation","C115691","The Trial Master File Reference Model zone that contains the collection of documents relating to the interactions with the Institutional Review Board (IRB)/Independent Ethics Committee (IEC), including submissions, decisions, acknowledgments, and oversight information about the IRB/IEC for the clinical trial.","TMF-RM Institutional Review Board or Independent Ethics Committee and Other Approvals Zone | General IRB/IEC | IRB or IEC and Other Approvals | IRB-IEC Comm Cat | IRB-IEC Sponsor Communication Category | IRB/IEC and other Approvals | Institutional Review Board - Independent Ethics Committee | Institutional Review Board - Independent Ethics Committee Shared Documentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890388","Institutional Review Board - Independent Ethics Committee Tracking Document","C115692","Records maintained by the regulatory affairs staff or designee, that track the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) activities during the course of a clinical trial.","Institutional Review Board - Independent Ethics Committee Tracking Document | IRB-IEC Track Doc | IRB-IEC Tracking Document | Tracking Document",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890351","Institutional Review Board Independent Ethics Committee Additional Subject Information Document","C115693","Records by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) that provide a subject with additional information regarding to requirements or concepts of a clinical trial.","Institutional Review Board Independent Ethics Committee Additional Subject Information Document | IRB-IEC Approved Other Subject Information | Institutional Review Board Independent Ethics Committee Approved Other Subject Information | Other Written Information Given to Subjects | Subj Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898755","Institutional Review Board Independent Ethics Committee Composition Document","C115694","Documentation pertaining to the membership of the Institutional Review Board or Independent Ethics Committee regarding their qualifications and experience to review and evaluate the science, medical aspects, and ethics of the clinical trial.","Institutional Review Board Independent Ethics Committee Composition Documentation | Assurance Number | IRB Membership List | IRB Roster | IRB or IEC Composition | IRB-IEC Comp | IRB-IEC Composition | IRB/IEC Composition | Institutional Review Board Independent Ethics Committee Composition | Institutional Review Board Independent Ethics Committee Composition Document | Reviewer Participant List",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898752","Institutional Review Board Independent Ethics Committee Human Subject in Research Approval Documentation","C115696","The Trial Master File Reference Model section that contains a collection of documents related to the Institutional Review Board or Independent Ethics Committee decisions for the clinical trial.","TMF-RM IRB or IEC Trial Approval Section | IRB or IEC Trial Approval | IRB-IEC Doc Subcat | IRB-IEC Documents Subcategory | IRB/IEC Trial Approval | Institutional Review Board Independent Ethics Committee Documents | Institutional Review Board Independent Ethics Committee Human Subject in Research Approval Documentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814862","NRXN3 wt Allele","C113538","Human NRXN3 wild-type allele is located in the vicinity of 14q31 and is approximately 1622 kb in length. This allele, which encodes neurexin-3 protein, plays a role in cell adhesion and cell recognition. Genetic variations at this locus have been associated with alcohol dependence and autism spectrum disorder.","NRXN3 wt Allele | C14orf60 | Chromosome 14 Open Reading Frame 60 Gene | KIAA0743 | Neurexin 3 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816733","Neurexin-3, Human","C113539","Neurexin-3 (1643 aa, ~181 kDa) is encoded by the human NRXN3 gene. This protein is involved in cell recognition and cell adhesion.","Neurexin-3 | Neurexin III | Neurexin III-Alpha | Neurexin-3-Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829958","GPR101 wt Allele","C113541","Human GPR101 wild-type allele is located in the vicinity of Xq26.3 and is approximately 2 kb in length. This allele, which encodes probable G-protein coupled receptor 101 protein, may be involved in G protein-coupled receptor signaling.","GPR101 wt Allele | G Protein-Coupled Receptor 101 wt Allele | GPCR6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3883897","Probable G-Protein Coupled Receptor 101, Human","C113542","Probable G-protein coupled receptor 101 (508 aa, ~57 kDa) is encoded by the human GPR101 gene. This protein may play a role in neuronal G protein-coupled receptor signaling pathways.","Probable G-Protein Coupled Receptor 101 | G Protein-Coupled Receptor 101 | G-Protein Coupled Receptor 101 | GPR101 | Probable G Protein-Coupled Receptor 101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811696","hGPCR36","C113544","Human ADGRF1 wild-type allele is located in the vicinity of 6p12.3 and is approximately 45 kb in length. This allele, which encodes adhesion G-protein coupled receptor F1 protein, has an unknown cellular function. Mutations in this gene are associated with both prostate cancer and prostatitis.","ADGRF1 wt Allele | Adhesion G Protein-Coupled Receptor F1 wt Allele | G Protein-Coupled Receptor 110 Gene | GPR110 | KPG_012 | PGR19 | RP11-39C2.1 | hGPCR36",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828467","Production of Nucleic Acid Extraction Reagent","C113052","The production of chemical agents to purify specific nucleic acids.","Production of Nucleic Acid Extraction Reagent | Production, Nucleic Acid Extraction Reagent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827940","Stem Cell Isolation","C113053","Recovery and purification of stem cells from human sources, including umbilical cord blood.","Stem Cell Isolation | Isolation, Stem Cell | Stem Cell Collection | Stem Cell Recovery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827873","Synthetic Scaffold Production","C113054","Creation of a synthetic, biocompatible scaffold for the generation of bioengineered structures.","Synthetic Scaffold Production | Production, Scaffold Synthetic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827552","Viral Vector Preparation","C113055","Cloning and isolation of viral vectors from producer cell lines or transiently infected cells.","Viral Vector Preparation | Banking, Viral Vectors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827553","Viral Vector Expansion and Production","C113057","The use of cell culture techniques to expand a cell line in the production of viral vectors.","Viral Vector Expansion and Production | Expansion/Production, Viral Vectors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831331","Blood or Viral Antigen Purification","C113058","Purification of either blood-grouping antigens or viral proteins.","Blood or Viral Antigen Purification | Purification, Blood or Viral Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830973","Crystallization Purification","C113059","Separation of a product from a saturated solution by cooling the liquid or adding precipitants which lower the solubility of the desired product so that it forms crystals.","Crystallization Purification | Purification, Crystallization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4015004","Primary Amenorrhea","C113339","Abnormally late or absent menarche in a female with normal secondary sexual characteristics.","Primary Amenorrhea | Delayed Menarche",,,,,,,,,,,,,,,"4230947|764494","Primary physiologic amenorrhea|Delayed menarche",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C4013511","Secondary Amenorrhea","C113340","The cessation of menstruation for six months or more in a female that is not pregnant, breastfeeding or menopausal.","Secondary Amenorrhea | ",,,,,,,,,,,,,,,"40318195","Secondary amenorrhea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4227518","Premature Thelarche","C113342","Isolated breast development prior to the normal age of pubertal onset in females.","Premature Thelarche | ",,,,,,,,,,,,,,,"4011616","Premature development of the breasts",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3665358","Galactorrhea","C113343","Excessive secretion of breast milk.","Galactorrhea | Nipple Discharge",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0154209","Hyperestrogenism","C113344","Abnormally high level of estrogen.","Hyperestrogenism | Estrogen Excess",,,,,,,,,,,,,,,"200677","Hyperestrogenism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829579","Hyperprogesteronism","C113345","Abnormally high level of progesterone.","Hyperprogesteronism | Progesterone Excess",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829577","Hypoprogesteronism","C113346","Abnormally low level of progesterone.","Hypoprogesteronism | Progesterone Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4013694","Hypergonadotropic Hypogonadism","C113348","Ovarian or testicular dysfunction associated with high levels of gonadotropins.","Hypergonadotropic Hypogonadism | Primary Gonadal Failure",,,,,,,,,,,,,,,"4153218","Primary hypogonadism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1531278","Nicotinate-Nucleotide Pyrophosphorylase (Carboxylating), Human","C112839","Nicotinate-nucleotide pyrophosphorylase [carboxylating] (297 aa, ~31 kDa) is encoded by the human QPRT gene. This protein is involved in the synthesis of nicotinamide adenine dinucleotide.","Nicotinate-Nucleotide Pyrophosphorylase [Carboxylating] | EC 2.4.2.19 | Nicotinate-Nucleotide Pyrophosphorylase (Carboxylating) | QAPRTase | QPRTase | Quinolinate Phosphoribosyltransferase [Decarboxylating]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0151467","Adrenal Crisis","C112840","A life threatening condition due to inadequate levels of glucocorticoids in an individual with adrenal insufficiency.","Adrenal Crisis | Acute Adrenal Insufficiency | Addisonian Crisis",,,,,,,,,,,,,,,"35624320","Acute adrenal insufficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3827254","Chronic Maternal Hypertension","C112841","Hypertension that predates pregnancy.","Chronic Maternal Hypertension | Pre-existing essential hypertension complicating pregnancy, unspecified trimester | Unspecified pre-existing hypertension complicating pregnancy, unspecified trimester",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831106","Chronic Maternal Hypertension with Superimposed Preeclampsia","C112842","Chronic hypertension in association with preeclampsia.","Chronic Maternal Hypertension with Superimposed Preeclampsia | Pre-existing hypertension with pre-eclampsia, unspecified trimester",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4228546","Severe Preeclampsia","C112843","Preeclampsia with a systolic blood pressure of 160 mmHg or higher, or a diastolic blood pressure of 110 mmHg or higher on two occasions at least 4 hours apart while on bedrest. It is associated with thrombocytopenia (platelets less than 100,000 per microliter), impaired liver function (twice normal elevation of hepatic transaminases; severe, persistent right upper quadrant or epigastric pain), progressive renal insufficiency (serum creatinine greater than 1.1 mg/dL or doubling of baseline in the absence of other renal disease), pulmonary edema, or new-onset cerebral or visual disturbances.","Severe Preeclampsia | Preeclampsia with Severe Features",,,,,,,,,,,,,,,"433536","Severe pre-eclampsia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0271662","Gestational Diabetes Mellitus, A1","C112844","Carbohydrate intolerance first diagnosed during pregnancy. Diagnosis from abnormal oral glucose tolerance test (OGTT) but normal glucose levels when fasting and two hours post-prandial. Euglycemia achieved with diet and/or exercise.","Gestational Diabetes Mellitus, A1 | Gestational Diabetes Mellitus, A1 White Classification | Gestational Diabetes, A1 White Classification",,,,,,,,,,,,,,,"4326434","Gestational diabetes mellitus class A1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0271663","Gestational Diabetes Mellitus, A2","C112845","Carbohydrate intolerance first diagnosed during pregnancy. Diagnosis from abnormal oral glucose tolerance test (OGTT) and abnormal fasting or post-prandial glucose levels. Euglycemia achieved with medication.","Gestational Diabetes Mellitus, A2 | Gestational Diabetes Mellitus, A2 White Classification | Gestational Diabetes, A2 White Classification",,,,,,,,,,,,,,,"4263902","Gestational diabetes mellitus class A2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3890199","TRIM23 wt Allele","C116092","Human TRIM23 wild-type allele is located in the vicinity of 5q12.3 and is approximately 36 kb in length. This allele, which encodes E3 ubiquitin-protein ligase TRIM23 protein, plays a role in both protein ubiquitination and viral processes.","TRIM23 wt Allele | ARD1 | ARFD1 | RNF46 | Tripartite Motif Containing 23 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1314904","E3 Ubiquitin-Protein Ligase TRIM23, Human","C116093","E3 ubiquitin-protein ligase TRIM23 (574 aa, ~64 kDa) is encoded by the human TRIM23 gene. This protein is involved in both viral processes and the ubiquitination of proteins.","E3 Ubiquitin-Protein Ligase TRIM23 | ADP-Ribosylation Factor Domain Protein 1 | ADP-Ribosylation Factor Domain Protein 1, 64kDa | ADP-Ribosylation Factor Domain-Containing Protein 1 | ARF Domain Protein 1 | EC 2.3.2.27 | EC 6.3.2.-, Formerly | GTP-Binding Protein ARD-1 | RING Finger Protein 46 | TRIM23 | Tripartite Motif Protein TRIM23 | Tripartite Motif-Containing 23 | Tripartite Motif-Containing Protein 23",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899175","FDG-PET Scanning Finding","C116094","A nuclear medicine finding obtained using FDG-PET imaging technique.","FDG-PET Scanning Finding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538407","CABCOCO1 Gene","C116097","This gene may play a role in the regulation of blood pressure.","CABCOCO1 Gene | C10orf107 | CABCOCO1 | Ciliary Associated Calcium Binding Coiled-Coil 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889134","bA63A2.1","C116099","Human CABCOCO1 wild-type allele is located in the vicinity of 10q21.2 and is approximately 104 kb in length. This allele, which encodes ciliary-associated calcium-binding coiled-coil protein 1, may be involved in the modulation of blood pressure. Variation in the gene is associated with dichotomous hypertension.","CABCOCO1 wt Allele | C10orf107 | Chromosome 10 Open Reading Frame 107 Gene | Ciliary Associated Calcium Binding Coiled-Coil 1 wt Allele | Em:AC022398.2 | MGC44593 | RP11-63A2.1 | bA63A2.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL343504","Recurrent Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified","C115381","The reemergence of supratentorial embryonal tumor, not otherwise specified in childhood after a period of remission.","Recurrent Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified | Recurrent Childhood Supratentorial Embryonal Tumor, NOS | Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor | Recurrent Supratentorial Embryonal Tumor, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897734","Recurrent Olfactory Neuroblastoma","C115384","The reemergence of olfactory neuroblastoma after a period of remission.","Recurrent Olfactory Neuroblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897736","Recurrent Malignant Extragonadal Germ Cell Tumor","C115385","The reemergence of malignant extragonadal germ cell tumor after a period of remission.","Recurrent Malignant Extragonadal Germ Cell Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1741235","RNA-Binding Protein 10, Human","C115386","RNA-binding protein 10 (930 aa, ~104 kDa) is encoded by the human RBM10 gene. This protein is involved in RNA metabolism.","RNA-Binding Protein 10 | G Patch Domain-Containing Protein 9 | G-Patch Domain-Containing Protein 9 | RNA Binding Motif Protein 10 | RNA-Binding Motif Protein 10 | RNA-Binding Protein S1-1 | S1-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889273","Institutional Review Board Independent Ethics Committee Notification of Safety Information Document","C115698","Documentation submitted to the Institutional Review Board or Independent Ethics Committee detailing the safety of subjects in the clinical trial.","Institutional Review Board Independent Ethics Committee Notification of Safety Information Documentation | Institutional Review Board Independent Ethics Committee Notification of Safety Information Document | Notf IRB-IEC Safe Info | Notification to IRB or IEC of Safety Information | Notification to IRB-IEC of Safety Information | Notification to Institutional Review Board Independent Ethics Committee of Safety Information | Notification to Regulatory Authority of Safety/Trial Information | Safety Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889683","Institutional Review Board Independent Ethics Committee Notification of Trial Termination Document","C115699","Documentation detailing the communications to the Institutional Review Board or Independent Ethics Committee regarding the termination or closure of the clinical trial.","Institutional Review Board Independent Ethics Committee Notification of Trial Termination or Closure Documentation | IRB or IEC Notification of Trial Termination | IRB-IEC Notf Termin | IRB-IEC Notification of Trial Termination | IRB/IEC Notification of Trial Termination | Institutional Review Board Independent Ethics Committee Notification of Trial Termination | Institutional Review Board Independent Ethics Committee Notification of Trial Termination Document | Notification of Discontinuation of Clinical Trial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0338337","Untreated Childhood Cerebellar Astrocytoma","C115929","A finding of cerebellar astrocytoma in childhood that has not been treated.","Untreated Childhood Cerebellar Astrocytoma | Untreated Cerebellar Astrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388360","Untreated Childhood Cerebral Astrocytoma","C115930","A finding of cerebral astrocytoma in childhood that has not been treated.","Untreated Childhood Cerebral Astrocytoma | Untreated Cerebral Astrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433916","Untreated Childhood Diffuse Astrocytoma","C115932","A finding of diffuse astrocytoma in childhood that has not been treated.","Untreated Childhood Diffuse Astrocytoma | Untreated Diffuse Astrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433905","Untreated Childhood Fibrillary Astrocytoma","C115934","A finding of fibrillary astrocytoma in childhood that has not been treated.","Untreated Childhood Fibrillary Astrocytoma | Untreated Fibrillary Astrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433908","Untreated Childhood Gemistocytic Astrocytoma","C115937","A finding of gemistocytic astrocytoma in childhood that has not been treated.","Untreated Childhood Gemistocytic Astrocytoma | Untreated Gemistocytic Astrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830282","Extraction Purification","C113061","Isolation of materials from solution based on their differential solubility in different liquids.","Extraction Purification | Purification, Extraction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829139","Medical Gas Purification","C113062","Separation of a gas mixture into purified component gases for medical use.","Medical Gas Purification | Purification, Medical Gas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828716","Oligonucleotide Purification","C113063","The processing of separating full-length oligonucleotides from incomplete chains and reagents.","Oligonucleotide Purification | Purification, Oligonucleotide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828521","Polyclonal Antisera Purification","C113064","Antibody purification through immobilization, washing, and release.","Polyclonal Antisera Purification | Purification, Polyclonal Antisera",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815102","Protein Precipitation","C113065","The process of precipitating proteins from solution. Protein precipitation may be bulk and general or specific.","Protein Precipitation | Precipitation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0597301","Protein Purification","C113066","Separation of protein fractions by precipitation, chromatography, or other methods.","Protein Purification | Purification, Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828437","Purification, Not Otherwise Specified","C113067","Any isolation method not otherwise specified.","Purification, Not Otherwise Specified | Purification, Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827468","Whole Organism Lysate Purification","C113069","Lysis of whole organisms for the collection and purification of specific target fractions or molecules.","Whole Organism Lysate Purification | Purification, Whole Organism Lysate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828354","Red Blood Cell Reagent Preparation","C113070","Preparation of human red blood cells used to detect or identify blood-group antibodies for blood group determination.","Red Blood Cell Reagent Preparation | Preparation, Blood Products Red Blood Cell Reagent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827844","Terminal Sterilization","C113071","Sterilization of a finished product.","Terminal Sterilization | Sterilization, Terminal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL458143","Allogeneic Glioblastoma Stem-like Cell Line Lysate-pulsed Autologous Dendritic Cell Vaccine","C113296","A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from an allogeneic glioblastoma (GBM) stem-like cell line, with potential immunostimulatory and antineoplastic activities. Upon administration allogeneic glioblastoma stem-like cell line lysate-pulsed autologous dendritic cell vaccine exposes the immune system to GBM stem cell antigens, which may result in cytotoxic T lymphocyte (CTL) and antibody responses against GBM cells. This leads to GBM cell lysis. GBM stem-like cells contain a specific range of antigens that are essential for the neoplastic growth and survival of GBM cells.","Allogeneic Glioblastoma Stem-like Cell Line Lysate-pulsed Autologous Dendritic Cell Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471832","Radix Angelicae Sinensis/Radix Astragali Herbal Supplement","C113297","A traditional Chinese medicine comprising of Radix Angelicae Sinensis (RAS) and Radix Astragali (RA), with potential anti-inflammatory, immunostimulatory, neuroprotective, anti-hepatotoxic and antineoplastic activities. The main chemical constituents of RAS include ferulic acid, Z-ligustilide, butylidenephthalide and various polysaccharides. RA is the dried root of Astragalus membranaceus with primary constituents such polysaccharides, triterpenoids as well as isoflavones. Though their mechanisms of action remain largely elusive, Radix Angelicae Sinensis/Radix Astragali herbal supplements are commonly used for the treatment of various health conditions affecting women including premenstrual syndrome, dysmenorrhea, pelvic pain, recovery from childbirth and menopausal symptoms. These agents are also used for alleviating constipation, preventing and treating anemia and allergic attacks, and for the management of hypertension, joint pain and ulcers.","Radix Angelicae Sinensis/Radix Astragali Herbal Supplement | DB1 | Danggui Buxue Decoction No.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1300128","Chronic Villitis","C112846","T-cell immune response with diffuse perivillous fibrin deposition associated with intrauterine growth restriction, pre-term birth and recurrent fetal loss.","Chronic Villitis | VUE | Villitis of Unknown Etiology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829174","Maternal Weight Gain in Pregnancy","C112847","The last recorded maternal weight prior to birth minus the last recorded weight immediately prior to pregnancy. (reVITALize)","Maternal Weight Gain in Pregnancy | Maternal Weight Gain During Pregnancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0269672","Excessive Weight Gain in Pregnancy","C112848","In a woman with a normal weight pre-pregnancy body mass index (BMI), i.e. 18.5-24.9, the weight gained during pregnancy exceeds a total weight gain of 35 lbs. In a woman with an underweight pre-pregnancy body mass index (BMI), i.e. less than 18.5, the weight gained during pregnancy exceeds a total weight gain of 40 lbs. In a woman with an overweight pre-pregnancy body mass index (BMI), i.e. 25.0-29.9, the weight gained during pregnancy exceeds a total weight gain of 25 lbs. In a woman with an obese pre-pregnancy body mass index (BMI), i.e. greater than 30, the weight gained during pregnancy exceeds a total weight gain of 20 lbs. These standards are supported for the whole population irrespective of height, race or ethnicity.","Excessive Weight Gain in Pregnancy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2609259","Symphysis Pubis Dysfunction","C112850","Pelvic pain due to physiological pelvic ligament relaxation and increased joint mobility.","Symphysis Pubis Dysfunction | SPD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032993","Post Term Pregnancy","C112851","A gestation that lasts greater than or equal to 42 weeks and 0 days.","Post Term Pregnancy | Prolonged Pregnancy",,,,,,,,,,,,,,,"432695","Post-term pregnancy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152150","Twin Pregnancy","C112852","A pregnancy involving two fetuses.","Twin Pregnancy | ",,,,,,,,,,,,,,,"441919","Twin pregnancy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3711159","Filamin-A, Human","C113587","Filamin-A (2647 aa, ~281 kDa) is encoded by the human FLNA gene. This protein is involved in cytoskeletal remodeling.","Filamin-A | Actin Binding Protein 280 | Actin-Binding Protein 280 | Alpha-Filamin | EC 2.1.1.43 | EC 6.3.4.4 | Endothelial Actin-Binding Protein | Filamin 1 | Filamin A | Filamin A, Alpha (Actin Binding Protein 280) | Filamin, Alpha | Filamin-1 | Non-Muscle Filamin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0267071","Oropharyngeal Dysphagia","C113588","Difficulty in swallowing due to an abnormality in the mouth or throat.","Oropharyngeal Dysphagia | ",,,,,,,,,,,,,,,"440530","Oropharyngeal dysphagia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3812694","REN wt Allele","C113590","Human REN wild-type allele is located in the vicinity of 1q32 and is approximately 12 kb in length. This allele, which encodes renin protein, is involved in angiotensin activation and blood pressure homeostasis. Mutations in this gene are associated with both familial juvenile hyperuricemic nephropathy 2 and renal tubular dysgenesis.","REN wt Allele | HNFJ2 | Renin wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035094","Renin","C113591","Renin (406 aa, ~45 kDa) is encoded by the human REN gene. This protein plays a role in activation of angiotensin.","Renin | Angiotensin-Forming Enzyme | Angiotensinogenase | EC 3.4.23.15 | REN | Renin Precursor, Renal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812737","OLFM4 wt Allele","C113593","Human OLFM4 wild-type allele is located in the vicinity of 13q14.3 and is approximately 23 kb in length. This allele, which encodes olfactomedin-4 protein, plays a role in apoptosis inhibition.","OLFM4 wt Allele | GC1 | GCSF-Stimulated Clone 1 Gene | GW112 | OLM4 | OlfD | Olfactomedin 4 wt Allele | UNQ362 | hGC-1 | hOLfD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1122298","Olfactomedin-4, Human","C113594","Olfactomedin-4 (510 aa, ~57 kDa) is encoded by the human OLFM4 gene. This protein is involved in regulation of apoptosis.","Olfactomedin-4 | Antiapoptotic Protein GW112 | G-CSF-Stimulated Clone 1 Protein | bA209J19.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896670","CDISC Functional Test 6MWT Test Name Terminology","C115387","Test names of functional test questions associated with the 6 Minute Walk Test (6MWT) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Functional Test 6MWT Test Name Terminology | 6 Minute Walk Functional Test Test Name | FT- 6MWT TEST | SIXMW1TN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896671","CDISC Functional Test 6MWT Test Code Terminology","C115388","Test codes of functional test questions associated with the 6 Minute Walk Test (6MWT) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Functional Test 6MWT Test Code Terminology | 6 Minute Walk Functional Test Test Code | FT- 6MWT TESTCD | SIXMW1TC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891827","CDISC Functional Test HAI Test Name Terminology","C115389","Test names of functional test questions associated with the Hauser Ambulation Index (HAI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Functional Test HAI Test Name Terminology | FT- HAI TEST | HAI01TN | Hauser Ambulation Index Functional Test Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896669","CDISC Functional Test HAI Test Code Terminology","C115390","Test codes of functional test questions associated with the Hauser Ambulation Index (HAI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Functional Test HAI Test Code Terminology | FT- HAI TESTCD | HAI01TC | Hauser Ambulation Index Functional Test Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896667","CDISC Functional Test NHPT Test Name Terminology","C115391","Test names of functional test questions associated with the Nine-Hole Peg Test (NHPT) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Functional Test NHPT Test Name Terminology | FT- NHPT TEST | NHPT01TN | Nine-Hole Peg Test Functional Test Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896668","CDISC Functional Test NHPT Test Code Terminology","C115392","Test codes of functional test questions associated with the Nine-Hole Peg Test (NHPT) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Functional Test NHPT Test Code Terminology | FT- NHPT TESTCD | NHPT01TC | Nine-Hole Peg Test Functional Test Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896665","CDISC Functional Test PASAT Test Name Terminology","C115393","Test names of functional test questions associated with the Paced Auditory Serial Addition Test (PASAT) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Functional Test PASAT Test Name Terminology | FT- PASAT TEST | PASAT1TN | Paced Auditory Serial Addition Test Functional Test Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896666","CDISC Functional Test PASAT Test Code Terminology","C115394","Test codes of functional test questions associated with the Paced Auditory Serial Addition Test (PASAT) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Functional Test PASAT Test Code Terminology | FT- PASAT TESTCD | PASAT1TC | Paced Auditory Serial Addition Test Functional Test Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896663","CDISC Functional Test SDMT Test Name Terminology","C115395","Test names of functional test questions associated with the Symbol Digit Modalities Test (SDMT) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Functional Test SDMT Test Name Terminology | FT- SDMT TEST | SDMT01TN | Symbol Digit Modalities Test Functional Test Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899693","Centralized Testing Documentation","C115640","Records containing information related to a centralized test.","Centralized Testing Documentation | Centralized Testing Communications and Tracking Subcategory | Centralz Test Comm Track | General Centralized Testing documents otherwise unspecified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890387","Centralized Testing Tracking Document","C115641","Records pertaining to activities logged during a centralized test.","Centralized Testing Tracking Document | Centralz Test Doc | Tracking Document",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433911","Untreated Childhood Glioblastoma","C115942","A finding of glioblastoma in childhood that has not been treated.","Untreated Childhood Glioblastoma | Untreated Glioblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433933","Untreated Childhood Gliomatosis Cerebri","C115944","A finding of gliomatosis cerebri in childhood that has not been treated.","Untreated Childhood Gliomatosis Cerebri | Untreated Gliomatosis Cerebri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433919","Untreated Childhood Gliosarcoma","C115946","A finding of gliosarcoma in childhood that has not been treated.","Untreated Childhood Gliosarcoma | Untreated Gliosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0338341","Untreated Childhood Medulloblastoma","C115948","A finding of medulloblastoma in childhood that has not been treated.","Untreated Childhood Medulloblastoma | Untreated Medulloblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897943","Peripheral Vascular Intervention","C116150","A catheter-based or open surgical procedure designed to improve arterial or venous blood flow or otherwise modify or revise vascular conduits.","Peripheral Vascular Intervention | PERIPHERAL VASCULAR INTERVENTION | PVI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0063442","IMREG-1","C1132","A low molecular weight fraction of human leukocyte dialysates with potential immunostimulatory activity. IMREG-1 is shown to augment and accelerate human delayed type hypersensitivity (DTH) to recall antigen in vivo, potentiate production of interleukin-2 (IL-2) and interferon gamma, and induce expression of IL-2 receptor in peripheral blood mononuclear cells. These effects are attributed to the peptides Tyr-Gly and Tyr-Gly-Gly, which are identical to the N-terminal end of the enkephalins. Studies in HIV patients have shown that this agent may delay progression to more serious disease and improve laboratory markers.","IMREG-1 | IMREG 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811119","LRP2 wt Allele","C113300","Human LRP2 wild-type allele is located in the vicinity of 2q31.1 and is approximately 236 kb in length. This allele, which encodes low-density lipoprotein receptor-related protein 2, is involved in the endocytosis of lipoproteins, extracellular matrix proteins and secreted proteases. Mutation of the gene is associated with Donnai-Barrow syndrome.","LRP2 wt Allele | DBS | GP330 | Low Density Lipoprotein Receptor-Related Protein 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714574","low-density lipoprotein receptor-related protein 2, human","C113302","Low-density lipoprotein receptor-related protein 2 (4655 aa, ~200 kDa) is encoded by the human LRP2 gene. This protein plays a role in receptor-mediated endocytosis.","Low-Density Lipoprotein Receptor-Related Protein 2 | Glycoprotein 330 | Heymann Nephritis Antigen Homolog | LRP-2 | Low Density Lipoprotein Receptor-Related Protein 2 | Megalin | gp330",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811167","RNF179","C113306","Human MARCHF9 wild-type allele is located in the vicinity of 12q14.1 and is approximately 5 kb in length. This allele, which encodes E3 ubiquitin-protein ligase MARCH9 protein, plays a role in protein ubiquitination and may mediate the internalization of plasma membrane proteins.","MARCHF9 wt Allele | FLJ36578 | MARCH IX | MARCH-IX | MARCH9 | MARCH9 wt Allele | Membrane Associated Ring-CH-Type Finger 9 wt Allele | Membrane-Associated Ring Finger (C3HC4) 9 Gene | RNF179",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827569","VFQ25-Self Administered Format - Pain in Eyes Keep You From Doing What You Like","C112793","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Responses to Vision Problems: How much does pain or discomfort in or around your eyes, for example, burning, itching, or aching, keep you from doing what you'd like to be doing? Would you say:","VFQ25-Self Administered Format - Pain in Eyes Keep You From Doing What You Like | VFQ2-Eye Pain Keep From Doing What Like | VFQ219",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827564","VFQ25-Self Administered Format - Stay Home Because of Eyesight","C112794","Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Responses to Vision Problems: I stay home most of the time because of my eyesight.","VFQ25-Self Administered Format - Stay Home Because of Eyesight | VFQ2-I Stay Home Most of the Time | VFQ220",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811710","Kininogen-1, human","C114390","Kininogen-1 (644 aa, ~72 kDa) is encoded by the human KNG1 gene. This protein is involved in the positive regulation of fibrinolysis.","Kininogen-1 | Alpha-2-Thiol Proteinase Inhibitor | Fitzgerald Factor | HMWK | High Molecular Weight Kininogen | KNG1 | Kininogen | Kininogen 1 | Williams-Fitzgerald-Flaujeac Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811188","MARK4 wt Allele","C114392","Human MARK4 wild-type allele is located in the vicinity of 19q13.3 and is approximately 226 kb in length. This allele, which encodes MAP/microtubule affinity-regulating kinase 4 protein, is involved in the phosphorylation of microtubule-associated proteins. Aberrant overexpression of the gene is associated with hepatocellular carcinoma.","MARK4 wt Allele | FLJ90097 | KIAA1860 | MAP/Microtubule Affinity-Regulating Kinase 4 wt Allele | MARK4L | MARK4S | MARKL1 | MARKL1L | Nbla00650 | PAR-1D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1436363","MAP/Microtubule Affinity-Regulating Kinase 4, Human","C114393","MAP/microtubule affinity-regulating kinase 4 (752 aa, ~83 kDa) is encoded by the human MARK4 gene. This protein plays a role in microtubule-associated protein phosphorylation.","MAP/Microtubule Affinity-Regulating Kinase 4 | EC 2.7.11.1 | MAP/Microtubule Affinity-Regulating Kinase Like 1 | MAP/Microtubule Affinity-Regulating Kinase-Like 1 | MARK4 | MARK4 Serine/Threonine Protein Kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1970019","RRP15 Gene","C114394","This gene is involved in ribosomal RNA processing.","RRP15 Gene | RRP15 | Ribosomal RNA Processing 15 Homolog (S. cerevisiae) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814376","RRP15 wt Allele","C114395","Human RRP15 wild-type allele is located in the vicinity of 1q41 and is approximately 53 kb in length. This allele, which encodes RRP15-like protein, plays a role in the processing of ribosomal RNAs.","RRP15 wt Allele | CGI-115 | KIAA0507 | Ribosomal RNA Processing 15 Homolog (S. cerevisiae) wt Allele | Ribosomal RNA-Processing 15, S. cerevisiae, Homolog of Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828291","RRP15-Like Protein","C114396","RRP15-like protein (282 aa, ~31 kDa) is encoded by the human RRP15 gene. This protein is involved in ribosomal RNA maturation.","RRP15-Like Protein | Ribosomal RNA-Processing Protein 15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812701","SYCP1 wt Allele","C114399","Human SYCP1 wild-type allele is located within 1p13-p12 and is approximately 141 kb in length. This allele, which encodes synaptonemal complex protein 1, is involved in the formation of the synaptonemal complex in meiosis.","SYCP1 wt Allele | CT8 | HOM-TES-14 | RP11-109G4.1 | SCP-1 | SCP1 | Synaptonemal Complex Protein 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471767","Enadenotucirev","C113786","A complex, replication-selective, chimeric adenovirus type 11p (Ad11p)/Ad3 oncolytic virus vaccine, with potential antineoplastic and immunomodulating activities. Enadenotucirev has the Ad11p backbone with a large deletion in the E3-region and a small E4-domain (E4orf4) deleted, in addition to a partial E2B substitution by the Ad3 E2B genes. Upon intravenous administration of enadenotucirev, the adenovirus selectively reaches the tumor cells due to the leaky tumor vasculature and replicates in cancer cells; however, it is unable to replicate in normal, healthy cells. This induces a selective adenovirus-mediated cytotoxicity in cancer cells, which leads to cancer lysis. Following the lysis of infected cells, the replicated virus is released and can infect adjacent cells, which both induces further tumor cell oncolysis and may activate, through the release of tumor-associated antigens (TAAs) and inflammatory mediators from the lysed tumor cells, the immune system to mount an anti-tumor immune response. This further kills tumor cells. This may also stimulate long-term anti-tumor immunity. Although the cancer-selectivity of enadenotucirev is not entirely understood, the virus does not efficiently infect normal cells.","Enadenotucirev | Chimeric Oncolytic Adenovirus Ad3/Ad11p Containing Two Deletions in the Viral Genome in the E3 Region (2444 bp) and in the E4 Region (24 bp) and 197 Non-homologous Nucleotides in the E2B Region | ColoAd-1 | ColoAd1 | ColoAd1 Oncolytic Virus | ENADENOTUCIREV | EnAd",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828797","Non-Sterile Vibratory Powder Filling Method","C112996","A process that fills a dosage unit using a vibrating perforated plate to deliver a powder, which is not performed under sterile conditions.","Non-Sterile Vibratory Powder Filling Method | Filling, Powder, Nonsterile, Vibratory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828501","Powder Filling Method, Not Otherwise Specified","C112998","A process that fills a dosage unit with a powder in a method not otherwise specified.","Powder Filling Method, Not Otherwise Specified | Filling, Powder, Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828481","Pressurized Liquid Filling Method","C112999","A process that fills a dosage unit with a pressurized liquid, which is not performed under sterile conditions.","Pressurized Liquid Filling Method | Filling, Nonsterile, Liquid, Pressure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677756","estramustine/etoposide/paclitaxel","C11299","A regimen consisting of estramustine, etoposide, and paclitaxel that may be used in the treatment of hormone-refractory prostate cancer.","Estramustine/Etoposide/Paclitaxel Regimen | EM/TAX/VP-16 | Estramustine/Etoposide/Paclitaxel | TEE | TEE regimen | Taxol-Estramustine-Etoposide | Taxol/Estramustine/Etoposide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0063067","Hydrazine Sulfate","C1129","The synthetic sulfate salt of hydrazine, a derivative of ammonia. Hydrazine inhibits the enzyme phosphoenol pyruvate carboxykinase, thereby blocking gluconeogenesis. This agent has been reported to decrease the excessive energy needs and cachexia of cancer patients.  Classified as a likely human carcinogen, hydrazine sulfate is also a weak inhibitor of mono-amine oxidase (MAO). (NCI04)","Hydrazine Sulfate | HYDRAZINE SULFATE | Sehydrin | hydrazine sulfate",,,,,,,,,,,,,,,"4115781","Hydrazine sulfate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3831151","Centrifugal Filtration","C113000","The use of a spinning filter mounted in a drum periphery to purify a slurry.","Centrifugal Filtration | Filtration, Centrifugal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828948","Moving Filter Filtration","C113001","The use of a rotary drum, belt, or other moving filter to purify a slurry.","Moving Filter Filtration | Filtration, Moving Filter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829559","Immunological Flow Cytometry","C113003","A technique for counting, examining or sorting microscopic particles suspended in a stream of fluid based on tagging the population of interest with antibody-based reagents.","Immunological Flow Cytometry | Flow Cytometry - Difference-from-Normal | Sorting, Flow Cytometry/Immunological, Cell Products",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828415","Radioisotope Formation","C113004","The formation of radioactive compounds by the use of a cyclotron or nuclear reactor.","Radioisotope Formation | Formation, Radioisotope",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830384","Dry Roller Compaction Granulation","C113005","The act of forming granules by mechanically applying pressure by rollers to form a compact that is subsequently milled and screened resulting in dry granules.","Dry Roller Compaction Granulation | Granulation, Dry, Roller Compaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830383","Dry Slugging Granulation","C113006","The act of forming granules by mechanically applying pressure by punch and die to form a compact that is subsequently milled and screened resulting in dry granules.","Dry Slugging Granulation | Granulation, Dry, Slugging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831525","Antepartum Stillbirth","C113381","Fetal death greater than or equal to 20 weeks of gestation prior to labor with Apgar scores of 0 at 1 minute, 5 minutes and beyond.","Antepartum Stillbirth | ",,,,,,,,,,,,,,,"37017027","Antepartum stillbirth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829512","Intrapartum Stillbirth","C113382","Fetal death greater than or equal to 20 weeks of gestation during labor with Apgar scores of 0 at 1 minute, 5 minutes and beyond.","Intrapartum Stillbirth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829543","Indicated Preterm Birth","C113383","Preterm birth from 20 weeks to 36 weeks, and 6 days of gestation that is necessitated by the medical condition of the mother or fetus.","Indicated Preterm Birth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0266765","Placenta Increta","C113385","Histologically-confirmed deep attachment of the placenta into the myometrium that does not cross the serosa.","Placenta Increta | ",,,,,,,,,,,,,,,"4037762","Placenta increta",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0266766","Placenta Percreta","C113386","Histologically-confirmed deep attachment of the placenta into the myometrium and serosa. It may further extend into an adjacent organ such as the bladder.","Placenta Percreta | ",,,,,,,,,,,,,,,"4103298","Placenta percreta",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3830369","Duration of Rupture of Membrane","C113389","Duration from rupture of membranes to birth (in hours and minutes). (reVITALize)","Duration of Rupture of Membrane | Duration of Rupture of Membranes | Latency Interval",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828745","Number of Centimeters Dilated on Admission","C113390","The last documented cervical dilation, in centimeters, when the provider orders admission. (reVITALize)","Number of Centimeters Dilated on Admission | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831154","Cell Separation by Density Gradient Centrifugation","C112934","A method of separating cells by either their differential rate of sedimentation in a centrifugal gradient or their differential buoyancy in a density gradient.","Cell Separation by Density Gradient Centrifugation | Centrifugation, Cell Product Buoyant Density",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831053","Collection of Non-Human Source Plasma","C112935","The collection of the fluid portion of non-human blood intended as a source material for further manufacture.","Collection of Non-Human Source Plasma | Production, Non-Human Source Plasma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829838","Harvest of Product from Whole Cell Lysate","C112937","Collection of a material of interest from a cell lysate.","Harvest of Product from Whole Cell Lysate | Cell Culture, Harvest/Recovery, Extraction- Cells/Inclusion Bodies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829596","Human Blood Product-Derived Intermediate Paste Production","C112938","The production of concentrated proteins from human plasma during a protein purification process.","Human Blood Product-Derived Intermediate Paste Production | Production/Fractionation, Intermediate Paste/Human Blood, Blood Products",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828061","SGRQ Past 4 Weeks Version - Jobs Take Long Time or I Have to Stop","C112717","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about how your activities might be affected by your respiratory problems: Jobs such as household chores take a long time, or I have to stop to rest.","SGRQ Past 4 Weeks Version - Jobs Take Long Time or I Have to Stop | SGRQ02-Jobs Take a Long Time | SGRQ0240",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828067","SGRQ Past 4 Weeks Version - If Walk Up One Flight of Stairs I Have to Go Slow","C112718","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about how your activities might be affected by your respiratory problems: If I walk up one flight of stairs, I have to go slowly or stop.","SGRQ Past 4 Weeks Version - If Walk Up One Flight of Stairs I Have to Go Slow | SGRQ02-Walk Up Flight of Stairs Slowly | SGRQ0241",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828068","SGRQ Past 4 Weeks Version - If Walk Fast I Have to Stop or Slow Down","C112719","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about how your activities might be affected by your respiratory problems: If I hurry or walk fast, I have to stop or slow down.","SGRQ Past 4 Weeks Version - If Walk Fast I Have to Stop or Slow Down | SGRQ02-If I Hurry, I Have to Stop | SGRQ0242",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828088","SGRQ Past 4 Weeks Version - Breathing Makes Difficult to Walk Up Hills","C112720","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about how your activities might be affected by your respiratory problems: My breathing makes it difficult to do things such as walk up hills, carry things up stairs, light gardening such as weeding, dance, bowl or play golf.","SGRQ Past 4 Weeks Version - Breathing Makes Difficult to Walk Up Hills | SGRQ02-Difficult to Walk Up Hills | SGRQ0243",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828090","SGRQ Past 4 Weeks Version - Breathing Makes Difficult to Carry Heavy Loads","C112721","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about how your activities might be affected by your respiratory problems: My breathing makes it difficult to do things such as carry heavy loads, dig in the garden or shovel snow, jog or walk briskly (5 miles per hour), play tennis or swim.","SGRQ Past 4 Weeks Version - Breathing Makes Difficult to Carry Heavy Loads | SGRQ02-Difficult to Carry Heavy Loads | SGRQ0244",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827059","Nrf2 activator RTA 408","C113443","A member of the synthetic oleanane triterpenoid class of compounds and an activator of nuclear factor erythroid 2 [NF-E2]-related factor 2 (Nrf2, Nfe2l2), with potential chemopreventive activity. Upon administration, omaveloxolone activates the cytoprotective transcription factor Nrf2. In turn, Nrf2 translocates to the nucleus, dimerizes with a small Maf protein (sMaf), and binds to the antioxidant response element (ARE). This induces the expression of a number of cytoprotective genes, including NAD(P)H quinone oxidoreductase 1 (NQO1), sulfiredoxin 1 (Srxn1), heme oxygenase-1 (HO1, HMOX1), superoxide dismutase 1 (SOD1), gamma-glutamylcysteine synthetase (gamma-GCS), thioredoxin reductase-1 (TXNRD1), glutathione S-transferase (GST), glutamate-cysteine ligase catalytic subunit (Gclc) and glutamate-cysteine ligase regulatory subunit (Gclm), and increases the synthesis of the antioxidant glutathione (GSH). Nrf2, a leucine zipper transcription factor, plays a key role in the maintenance of redox balance and cytoprotection against oxidative stress.","Omaveloxolone | OMAVELOXOLONE | Propanamide, N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoro- | RTA 408 | RTA-408",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3834251","RX-3117","C113444","An orally available small molecule and nucleoside antimetabolite with potential antineoplastic activity. Upon administration, roducitabine is taken up by cells through a carrier-mediated transporter, phosphorylated by uridine cytidine kinase (UCK) and then further phosphorylated to its diphosphate (RX-DP) and triphosphate forms (RX-TP). The triphosphate form is incorporated into RNA and inhibits RNA synthesis. The diphosphate RX-DP is reduced by ribonucleotide reductase (RR) to dRX-DP; its triphosphate form (dRX-TP) is incorporated into DNA. In addition, roducitabine also inhibits DNA methyltransferase 1 (DNMT1). This eventually leads to cell cycle arrest and the induction of apoptosis. UCK is the rate-limiting enzyme in the pyrimidine-nucleotide salvage pathway.","Roducitabine | 4-Amino-1-((1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl)pyrimidin-2(1H)-one | Cytidine Analog RX-3117 | Fluorocyclopentenylcytosine | RODUCITABINE | RX-3117 | TV-1360",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830275","Extrusion Granulation","C113007","The use of a series of integrated steps whereby a dry powder is conditioned to form a plasticized mass that is forced through a screen and cut into sections, ultimately to yield granules possessing characteristic dimensions and density.","Extrusion Granulation | Granulation, Extrusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830097","Fluid Bed Granulation","C113008","The process of forming granules involving the addition of liquid to bind particles as they are suspended in a fluidized state by a flowing gas stream, resulting in dry granules suitable for filling or compression.","Fluid Bed Granulation | Granulation, Fluid Bed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830095","Fluidized Hot Melt Granulation","C113009","The process of forming granules using meltable binders to agglomerate dry powders under elevated temperatures resulting in granules suitable for filling or compression.","Fluidized Hot Melt Granulation | Granulation, Fluidized Hot Melt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829950","Granulation, Not Otherwise Specified","C113010","The act of forming something into grains.","Granulation, Not Otherwise Specified | Granulation, Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1721201","KLRC2 protein, human","C113254","NKG2-C type II integral membrane protein (231 aa, ~26 kDa) is encoded by the human KLRC2 gene. This protein plays a role in the recognition of MHC class I antigens by natural killer cells.","NKG2-C Type II Integral Membrane Protein | CD159 Antigen-Like Family Member C | CD159c | CD159c Antigen | KLRC2 | NK Cell Receptor C | NKG2-C-Activating NK Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810519","ECI2 wt Allele","C113256","Human ECI2 wild-type allele is located in the vicinity of 6p24.3 and is approximately 20 kb in length. This allele, which encodes enoyl-CoA delta isomerase 2, mitochondrial protein, plays a role in fatty acid metabolism.","ECI2 wt Allele | ACBD2 | DBI-Related Sequence 1 Gene | DRS-1 | DRS1 | Diazepam-Binding Inhibitor-Related Sequence 1 Gene | Enoyl-CoA Delta Isomerase 2 wt Allele | HCA88 | PECI | RP5-1013A10.1 | dJ1013A10.3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1309116","Enoyl-CoA Delta Isomerase 2, Mitochondrial, Human","C113257","Enoyl-CoA delta isomerase 2, mitochondrial (394 aa, ~44 kDa) is encoded by the human ECI2 gene. This protein is involved in enoyl-CoA metabolism.","Enoyl-CoA Delta Isomerase 2, Mitochondrial | Acyl-Coenzyme A Binding Domain Containing | D3,D2-Enoyl-CoA Isomerase | DBI-Related Protein 1 | DRS-1 | Delta(3),Delta(2)-Enoyl-CoA Isomerase | Diazepam-Binding Inhibitor-Related Protein 1 | Dodecenoyl-CoA Isomerase | EC 5.3.3.8 | ECI2 | Hepatocellular Carcinoma-Associated Antigen 88 | Peroxisomal 3,2-Trans-Enoyl-CoA Isomerase | Peroxisomal D3,D2-Enoyl-CoA Isomerase | Renal Carcinoma Antigen NY-REN-1 | pECI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811684","ARTN wt Allele","C113259","Human ARTN wild-type allele is located within 1p33-p32 and is approximately 4 kb in length. This allele, which encodes artemin protein, is involved in both the morphogenesis of Peyer patches and neuroblast proliferation.","ARTN wt Allele | Artemin wt Allele | ENOVIN | EVN | NBN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0911525","enovin","C113260","Artemin (220 aa, ~23 kDa) is encoded by the human ARTN gene. This protein plays a role in the development of both lymphoid tissue and the peripheral nervous system.","Artemin | Enovin | Neublastin | Neurotrophic Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810548","VCAN wt Allele","C113262","Human VCAN wild-type allele is located in the vicinity of 5q14.3 and is approximately 111 kb in length. This allele, which encodes versican core protein, plays a role in both proteoglycan metabolism and cell-matrix signaling.","VCAN wt Allele | CSPG2 | ERVR | GHAP | PG-M | Versican wt Allele | WGN | WGN1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1820738","Feeding Intolerance","C113395","Inability to achieve a full feeding volume.","Feeding Intolerance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813607","Infantile Gastroesophageal Reflux","C113396","Effortless regurgitation of gastric contents that commonly occurs in infants, usually right after feeding or burping.","Infantile Gastroesophageal Reflux | Gastroesophageal Reflux | Infant Reflux | Infant Regurgitation | Spilling | Spitting Up",,,,,,,,,,,,,,,"36716723","Infant gastrointestinal regurgitation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0338465","Sandifer's Syndrome","C113397","A condition associated with gastro-esophageal reflux disease that presents in infancy and early childhood and is characterized by spastic torticollis and dystonic body movements.","Sandifer's Syndrome | Sandifer Syndrome",,,,,,,,,,,,,,,"4046097","Sandifer syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0475598","Melena Neonatorum","C113398","Abnormally dark tarry feces containing blood, usually due to gastrointestinal bleeding or swallowed maternal blood in neonates.","Melena Neonatorum | Melena Neonatal | Neonatal Melena",,,,,,,,,,,,,,,"4048608","Neonatal melena",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0063444","ImuVert","C1133","A membrane vesicle/ribosome preparation derived from the bacterium Serratia marcescens with immunomodulatory activity. ImuVert triggers interferon (IFN) gamma production through binding the low affinity IgG Fc receptor type III (CD16) on natural killer (NK) cells. This agent works synergistically with interleukin-2 further enhancing IFN gamma production. In addition, ImuVert is capable of inducing peripheral blood mononuclear cells (PBMC), from the cord blood of newborn infants lacking NK activity, to exhibit NK activity.","ImuVert | Serratia Marcescens Extract",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019212","Hepatorenal Syndrome","C113400","A syndrome characterized by progressive kidney failure in a patient with cirrhosis or fulminant liver failure.","Hepatorenal Syndrome | Hepatorenal syndrome",,,,,,,,,,,,,,,"196455","Hepatorenal syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0063322","Tropisetron","C1131","An indole derivative with antiemetic activity.  As a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy-and radiotherapy-induced nausea and vomiting. (NCI04)","Tropisetron | ICS 205 930 | ICS 205-930 | ICS 205930 | TROPISETRON | tropisetron",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206510","Flaviviridae","C113201","A family of enveloped viruses with a genome consisting of a single molecule of linear positive-sense single-stranded RNA. They infect molluscs, mammals, and birds and some are transmitted by arthropod vectors. The family includes the hepatitis C and hepatitis G viruses.","Flaviviridae | ",,,,,,,,,,,,,,,"4085603","Family Flaviviridae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0079500","Hepacivirus","C113202","A genus a Flaviviridae with the Hepatitis C virus as its type species.","Hepacivirus | ",,,,,,,,,,,,,,,"4086089","Hepacivirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3831598","Adrenal Androgen Deficiency","C113203","Abnormally low or absent secretion of the androgen precursor hormones dehydroepiandrosterone (DHEA), DHEA sulfate, and androstenedione, from the adrenal gland.","Adrenal Androgen Deficiency | Adrenal Hypoandrogenism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010076","Coronaviridae","C113205","A family of positive sense ssRNA viruses of zoonotic origin. They are the cause of respiratory, enteric, hepatic, and neurological diseases of varying severity in humans and animals. Bats, birds, and pigs act as major reservoirs of coronaviruses.","Coronaviridae | CORONAVIRIDAE",,,,,,,,,,,,,,,"4087743","Family Coronaviridae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828050","SGRQ Past 4 Weeks Version - Treatment Does Not Help Me Much","C112710","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about your respiratory treatment: My treatment does not help me very much.","SGRQ Past 4 Weeks Version - Treatment Does Not Help Me Much | SGRQ02-Treatment Does Not Help Me Much | SGRQ0233",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828076","SGRQ Past 4 Weeks Version - Embarrassed Using Medication in Public","C112711","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about your respiratory treatment: I get embarrassed using my medication in public.","SGRQ Past 4 Weeks Version - Embarrassed Using Medication in Public | SGRQ02-Embarrassed Using Med in Public | SGRQ0234",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828048","SGRQ Past 4 Weeks Version - Unpleasant Side Effects From Medication","C112712","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about your respiratory treatment: I have unpleasant side effects from my medication.","SGRQ Past 4 Weeks Version - Unpleasant Side Effects From Medication | SGRQ02-Unpleasant Side Effect From Med | SGRQ0235",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828049","SGRQ Past 4 Weeks Version - Treatment Interferes With My Life","C112713","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about your respiratory treatment: My treatment interferes with my life a lot.","SGRQ Past 4 Weeks Version - Treatment Interferes With My Life | SGRQ02-Treatment Interferes With Life | SGRQ0236",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828052","SGRQ Past 4 Weeks Version - Take Long Time to Get Washed or Dressed","C112714","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about how your activities might be affected by your respiratory problems: I take a long time to get washed or dressed.","SGRQ Past 4 Weeks Version - Take Long Time to Get Washed or Dressed | SGRQ02-Take a Long Time to Get Washed | SGRQ0237",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828043","SGRQ Past 4 Weeks Version - Walk Slower Than Other People My Age","C112716","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about how your activities might be affected by your respiratory problems: I walk slower than other people my age, or I stop to rest.","SGRQ Past 4 Weeks Version - Walk Slower Than Other People My Age | SGRQ02-I Walk Slower Than Other People | SGRQ0239",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0317721","Megamonas","C113447","A genus of anaerobic, Gram negative, rod shaped bacteria assigned to the phylum Firmicutes and the family Veillonellaceae.","Megamonas | MEGAMONAS",,,,,,,,,,,,,,,"4185735","Megamonas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828537","Plasma Protein Cold Ethanol Fractionation","C112939","A multistep purification process that isolates plasma proteins based upon the differential solubility of proteins in ethanol solutions.","Plasma Protein Cold Ethanol Fractionation | Fractionation, Blood Products Cold Ethanol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828486","Preparation of Blood Products Grouping Reagent","C112941","A procedure to isolate blood group antigens for use in serological testing.","Preparation of Blood Products Grouping Reagent | Preparation, Blood Products Grouping Reagent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828471","Production of Blood Serological Test Device","C112942","A procedure to manufacture devices or components used in blood serological testing.","Production of Blood Serological Test Device | Production, Agglutination or Gel or Column Test, Blood Serological Testing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1429719","Versican Core Protein, Human","C113263","Versican core protein (3396 aa, ~373 kDa) is encoded by the human VCAN gene. This protein is involved in both environmental signaling and proteoglycan metabolism.","Versican Core Protein | Chondroitin Sulfate Proteoglycan Core Protein 2 | Chondroitin Sulfate Proteoglycan Core Protein, Cartilage | GHAP | Glial Hyaluronate-Binding Protein | Large Fibroblast Proteoglycan | PG-M",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813124","ADM wt Allele","C113265","Human ADM wild-type allele is located in the vicinity of 11p15.4 and is approximately 3 kb in length. This allele, which encodes ADM protein, is involved in both vasodilation and hormone-mediated signaling. Aberrant high levels of expression are associated with pheochromocytoma.","ADM wt Allele | AM | Adrenomedullin wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1313329","ADM protein, human","C113266","ADM (185 aa, ~20 kDa) is encoded by the human ADM gene. This protein plays a role in both signal transduction and vasodilation.","ADM | ADM Precursor | Adrenomedullin | PreproAM | Preproadrenomedullin | ProAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826865","Volume Doubling Time","C113268","The number of days that it takes for a nodule to double in volume.","Volume Doubling Time | VDT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827607","VFQ25-Interviewer Administered Format - Rate Your Overall Health","C112758","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) General Health: How would you rate your overall health, on a scale where zero is as bad as death and 10 is best possible health?","VFQ25-Interviewer Administered Format - Rate Your Overall Health | VFQ1-Rate Your Overall Health | VFQ1A01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827608","VFQ25-Interviewer Administered Format - Rate Your Eyesight Now","C112759","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) General Vision: How would you rate your eyesight now (with glasses or contact lens on, if you wear them), on a scale of from 0 to 10, where zero means the worst possible eyesight, as bad or worse than being blind, and 10 means the best possible eyesight?","VFQ25-Interviewer Administered Format - Rate Your Eyesight Now | VFQ1-Rate Your Eyesight Now | VFQ1A02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827633","VFQ25-Interviewer Administered Format - Difficulty Reading Small Print","C112760","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Near Vision: Wearing glasses, how much difficulty do you have reading the small print in a telephone book, on a medicine bottle, or on legal forms? Would you say:","VFQ25-Interviewer Administered Format - Difficulty Reading Small Print | VFQ1-Difficulty Reading Small Print | VFQ1A03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827640","VFQ25-Interviewer Administered Format - Difficulty Figure Out Bill Accuracy","C112761","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Near Vision: Because of your eyesight, how much difficulty do you have figuring out whether bills you receive are accurate?","VFQ25-Interviewer Administered Format - Difficulty Figure Out Bill Accuracy | VFQ1-Difficulty Figure Out Bill Accuracy | VFQ1A04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827628","VFQ25-Interviewer Administered Format - Difficulty Shaving or Styling Hair or Putting On Makeup","C112762","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Near Vision: Because of your eyesight, how much difficulty do you have doing things like shaving, styling your hair, or putting on makeup?","VFQ25-Interviewer Administered Format - Difficulty Shaving or Styling Hair or Putting On Makeup | VFQ1-Difficulty Shaving or Styling Hair | VFQ1A05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2353079","Serine/Threonine-Protein Kinase/Endoribonuclease IRE1, Human","C113614","Serine/threonine-protein kinase/endoribonuclease IRE1 (977 aa, ~110 kDa) is encoded by the human ERN1 gene. This protein is involved in both protein phosphorylation and mRNA processing in response to endoplasmic reticulum stress-dependent signaling.","Serine/Threonine-Protein Kinase/Endoribonuclease IRE1 | ERN1 | Endoplasmic Reticulum-To-Nucleus Signaling 1 | IRE1a | Inositol-Requiring Enzyme 1 | Inositol-Requiring Protein 1 | Ire1-alpha | hIRE1p",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0423738","Proctalgia Fugax","C113615","Recurrent episodes of pain localized to the anus or lower rectum which lasts seconds to minutes. There is no pain between episodes.","Proctalgia Fugax | ",,,,,,,,,,,,,,,"4266830","Painful spasm of anus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3831460","ATF6 wt Allele","C113617","Human ATF6 wild-type allele is located within 1q22-q23 and is approximately 198 kb in length. This allele, which encodes cyclic AMP-dependent transcription factor ATF-6 alpha protein, is involved in the activation of unfolded protein responsive genes.","ATF6 wt Allele | Activating Transcription Factor 6 wt Allele | Activating Transcription Factor 6, Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1571641","Cyclic AMP-Dependent Transcription Factor ATF-6 Alpha","C113618","Cyclic AMP-dependent transcription factor ATF-6 alpha (670 aa, ~75 kDa) is encoded by the human ATF6 gene. This protein plays a role in the expression of unfolded protein responsive genes.","Cyclic AMP-Dependent Transcription Factor ATF-6 Alpha | ATF6 | ATF6-Alpha | Activating Transcription Factor 6 | Activating Transcription Factor 6 Alpha | cAMP-Dependent Transcription Factor ATF-6 Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811202","DKC1 wt Allele","C113620","Human DKC1 wild-type allele is located in the vicinity of Xq28 and is approximately 15 kb in length. This allele, which encodes H/ACA ribonucleoprotein complex subunit 4 protein, plays a role in the stabilization and maintenance of telomerase and H/ACA small nucleolar RNA ribonucleoprotein biogenesis. Mutation of the gene is associated with both Hoyeraal-Hreidarsson syndrome and X-linked dyskeratosis congenita.","DKC1 wt Allele | CBF5 | DKC | DKCX | Dyskeratosis Congenita 1, Dyskerin Gene | Dyskerin Pseudouridine Synthase 1 wt Allele | NAP57 | NOLA4 | XAP101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811106","H/ACA Ribonucleoprotein Complex Subunit 4, human","C113621","H/ACA ribonucleoprotein complex subunit 4 (514 aa, ~58 kDa) is encoded by the human DKC1 gene. This protein is involved in telomerase stabilization and maintenance and the processing of ribosomal RNA.","H/ACA Ribonucleoprotein Complex Subunit 4 | CBF5 Homolog | Cbf5p Homolog | DKC1 | Dyskerin | EC 5.4.99.- | NOPP140-Associated Protein, 57-kD | Nopp140-Associated Protein of 57 kDa | Nucleolar Protein Family A Member 4 | Nucleolar Protein NAP57 | SnoRNP Protein DKC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814451","macroH2A1.2","C113623","Human MACROH2A1 wild-type allele is located in the vicinity of 5q31.1 and is approximately 66 kb in length. This allele, which encodes core histone macro-H2A.1 protein, is involved in both chromatin modification and nucleosome assembly.","MACROH2A1 wt Allele | H2A Histone Family Member Y Gene | H2A Histone Family, Member Y Gene | H2A.y | H2A/y | H2A1.1 | H2AF12M | H2AFJ | H2AFY | H2AFY wt Allele | MACRO H2A | MACRO H2A1 | MACROH2A1.1 | MH2A1 | MacroH2A.1 Histone wt Allele | mH2A1 | macroH2A1.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814450","Core Histone Macro-H2A.1, human","C113624","Core histone macro-H2A.1 (372 aa, ~40 kDa) is encoded by the human MACROH2A1 gene. This protein plays a role in chromatin modification.","Core Histone Macro-H2A.1 | H2A/y | H2A1.1 | Histone H2A.Y | Histone MacroH2A1 | Histone MacroH2A1.1 | Histone MacroH2A1.2 | MACROH2A1 | MACROH2A1.1 | Medulloblastoma Antigen MU-MB-50.205 | mH2A.1 | mH2A1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814802","Guanine Nucleotide-Binding Protein G(o) Subunit Alpha","C114350","Guanine nucleotide-binding protein G(o) subunit alpha (354 aa, ~40 kDa) is encoded by the human GNAO1 gene. This protein is involved in the regulation of G protein signaling.","Guanine Nucleotide-Binding Protein G(o) Subunit Alpha | G-ALPHA-o | GNAO1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3715026","TGFB1I1 wt Allele","C114352","Human TGFB1I1 wild-type allele is located in the vicinity of 16p11.2 and is approximately 6 kb in length. This allele, which encodes transforming growth factor beta-1-induced transcript 1 protein, is involved in the modulation of both signaling and nuclear receptor-dependent gene expression.","TGFB1I1 wt Allele | ARA55 | Androgen Receptor Coactivator Gene | HIC-5 | HIC5 | TSC-5 | Transforming Growth Factor Beta 1 Induced Transcript 1 wt Allele | Transforming Growth Factor, Beta-1-Induced 1 Gene | Transforming Growth Factor, Beta-Induced, 55-kD Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811704","Transforming Growth Factor Beta-1-Induced Transcript 1 Protein, Human","C114353","Transforming growth factor beta-1-induced transcript 1 protein (461 aa, ~50 kDa) is encoded by the human TGFB1I1 gene. This protein plays a role in the regulation of both nuclear receptor-dependent transcription and signal transduction.","Transforming Growth Factor Beta-1-Induced Transcript 1 Protein | Androgen Receptor Coactivator 55 kDa Protein | Androgen Receptor Coactivator ARA55 | Androgen Receptor-Associated Protein of 55 kDa | Hic-5 | Hydrogen Peroxide-Inducible Clone 5 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0263591","Drug Induced Lupus Erythematosus","C114354","An autoimmune disorder, similar to systemic lupus erythematosus, that is caused by certain drugs.","Drug Induced Lupus Erythematosus | Drug Induced Lupus | Drug-Induced Lupus | Drug-induced systemic lupus erythematosus",,,,,,,,,,,,,,,"4063581|4198217","Drug-induced systemic lupus erythematosus|Drug-induced lupus erythematosus",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3811162","MAPKAPK2 wt Allele","C114356","Human MAPKAPK2 wild-type allele is located in the vicinity of 1q32 and is approximately 49 kb in length. This allele, which encodes MAP kinase-activated protein kinase 2 protein, plays a role in MAPK-dependent signaling.","MAPKAPK2 wt Allele | MAPKAP-K2 | MK-2 | MK2 | Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4227547","Juvenile Idiopathic Arthritis","C114357","A group of chronic, inflammatory childhood disorders of unknown etiology that primarily involve joints.","Juvenile Idiopathic Arthritis | JIA",,,,,,,,,,,,,,,"4259507","Juvenile idiopathic arthritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3826988","Juvenile Polymyositis","C114358","An idiopathic inflammatory myopathy of childhood resulting in muscle weakness.","Juvenile Polymyositis | JPM",,,,,,,,,,,,,,,"42538014","Juvenile polymyositis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0248446","MAPKAPK2 protein, human","C114359","MAP kinase-activated protein kinase 2 (400 aa, ~46 kDa) is encoded by the human MAPKAPK2 gene. This protein is involved in stress responsive signaling.","MAP Kinase-Activated Protein Kinase 2 | EC 2.7.11.1 | MAPK-Activated Protein Kinase 2 | MAPKAP Kinase 2 | MAPKAP-K2 | MAPKAPK-2 | MK-2 | MK2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828266","Sample Purification from Cell Culture","C112943","A process that isolates a material of interest from a cell culture using a biomolecular separation technique.","Sample Purification from Cell Culture | Cell Culture, Purification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828265","Sample Recovery from Cell Culture, Not Otherwise Specified","C112944","A cell culture sample collection process that is not otherwise specified.","Sample Recovery from Cell Culture, Not Otherwise Specified | Cell Culture, Harvest/Recovery, Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828198","Sedimentation Sample Separation from Cell Culture","C112945","A process that collects a material of interest from a cell culture sample by allowing the materials harvested from the culture to separate by sedimentation.","Sedimentation Sample Separation from Cell Culture | Cell Culture, Harvest/Recovery, Sedimentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827937","Sterile Cell Culture Product Processing","C112946","Cell culture techniques done under aseptic conditions.","Sterile Cell Culture Product Processing | Processing, Sterile Cell Culture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827823","Tissue Decellularization","C112947","The physical, chemical and/or enzymatic processing of tissue samples to remove cells and leave behind the extracellular matrix or natural scaffold made up of collagen and other fibers and proteins.","Tissue Decellularization | Processing, Decellularized Tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827287","Recovery of Plasma from Blood Products","C112948","A process that derives plasma from single units of whole blood or as a by-product from the preparation of blood components from whole blood.","Recovery of Plasma from Blood Products | Recovery, Blood Products Human Plasma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829063","Mineral Sources","C112949","Indicates that a product is derived from a specified mineral material.","Mineral Sources | Derivation, Extraction, Mineral Source",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831160","Cell Bank Maintenance","C112951","A process that generates and maintains a single pool of cells prepared from a selected cell clone under specific conditions. This involves dispensing the cell sample into multiple containers and storing the sample under specific conditions.","Cell Bank Maintenance | Cell Banking, Master and Working Cell Bank Preparation and/or Maintenance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827229","Cell Culture Pooling","C112952","The expansion of a cell line in multiple vessels followed by the harvesting and pooling of the expanded culture into one vessel for holding or storage.","Cell Culture Pooling | Harvest/Pooling, Cell Product Final",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830468","Disposable Bag Culture","C112953","A type of culture in which cells are grown in single use bags.","Disposable Bag Culture | Cell Culture, Expansion, Disposable Bags",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830103","Flask or Bottle Culture","C112954","A type of culture in which cells are grown in flasks or bottles.","Flask or Bottle Culture | Cell Culture, Expansion, Flask or Bottle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828583","Perfusion Culture","C112955","A type of culture in which cells are grown and are continuously fed new culture media.","Perfusion Culture | Cell Culture, Perfusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828225","Scaffold Seeding","C112956","Addition of living cells to a biocompatible scaffold.","Scaffold Seeding | Seeding, Scaffold",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2806453","Betacoronavirus","C113207","A genus of enveloped and spherical positive sense ssRNA viruses in the subfamily Coronavirinae of the family Coronaviridae with a diameter of about 120 nm. Betacoronaviruses have a nonopartite, linear genome of 27-32 kb. Bats are the most common reservoir for betacoronaviruses.","Betacoronavirus | BETACORONAVIRUS | Beta-CoV | Coronavirus Group 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471768","6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatases Isoform 3 Inhibitor ACT-PFK-158","C113787","An inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases (PFK-2/FBPase) isoform 3 (PFKFB3) and derivative of 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), with potential antineoplastic activity. Upon administration, PFKFB3 inhibitor PFK-158 binds to and inhibits the activity of PFKFB3, which leads to the inhibition of both the glycolytic pathway in and glucose uptake by cancer cells. This prevents the production of macromolecules and energy that causes the enhanced cellular proliferation in cancer cells as compared to that of normal, healthy cells. Depriving cancer cells of nutrients and energy leads to the inhibition of cancer cell growth. PFKFB3, an enzyme that catalyzes the conversion of fructose-6-phosphate to fructose-2,6-bisphosphate, is highly expressed and active in human cancer cells; it plays a key role in increasing both glycolytic flux in and proliferation of cancer cells.","6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatases Isoform 3 Inhibitor ACT-PFK-158 | ACT-PFK-158 | PFK-158 | PFKFB3 Inhibitor PFK-158",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471769","UAE Inhibitor TAK-243","C113788","A small molecule inhibitor of ubiquitin-activating enzyme (UAE), with potential antineoplastic activity. UAE inhibitor TAK-243 binds to and inhibits UAE, which prevents both protein ubiquitination and subsequent protein degradation by the proteasome. This results in an excess of proteins in the cells and may lead to endoplasmic reticulum (ER) stress-mediated apoptosis. This inhibits tumor cell proliferation and survival. UAE, also called ubiquitin E1 enzyme (UBA1; E1), is more active in cancer cells than in normal, healthy cells.","UAE Inhibitor TAK-243 | AOB87172 | MLN7243 | TAK-243 | UAE Inhibitor  TAK-243",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471770","IGF-methotrexate Conjugate","C113789","A conjugate containing the antimetabolite and antifolate agent methotrexate conjugated to insulin-like growth factor (IGF), with potential antineoplastic activity. After intravenous administration, the IGF moiety of the IGF-methotrexate conjugate binds to and is internalized by IGF receptors (IGFR) on the surface of tumor cells. Following cell entry, the methotrexate then binds to and inhibits the enzyme dihydrofolate reductase, which catalyzes the conversion of dihydrofolate to tetrahydrofolate. This results in both the inhibition of DNA and RNA synthesis and the induction of death in rapidly dividing cells. Binding to IGFR can localize the cytotoxic effect of methotrexate in tumor cells. This may increase its efficacy while decreasing its toxicity to normal, healthy cells. IGFR is overexpressed on many types of cancer cells and has been implicated in metastasis and resistance to apoptosis.","IGF-methotrexate Conjugate | 765IGF-MTX | IGF/MTX | IGF/MTX Conjugate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471771","PH20 Hyaluronidase-expressing Adenovirus VCN-01","C113790","An oncolytic, replication-competent adenovirus encoding the human glycosylphosphatidylinositol-anchored enzyme PH20 hyaluronidase with potential antitumor activity. After intratumoral administration, PH20 hyaluronidase-expressing adenovirus VCN-01 selectively replicates in tumor cells, which may both cause oncolytic virus-induced cell death and induce the infection of adjacent tumor cells. In addition, the virus expresses hyaluronidase, which hydrolyzes and degrades the hyaluronic acid (HA) that coats tumor cells. The degradation of HA may result in a decrease for both the viscosity of the interstitial space and the tumor's interstitial fluid pressure (IFP). This increases viral spread and may result in the inhibition of tumor cell growth. In addition, HA degradation facilitates the penetration of chemotherapeutic agents into the tumor. HA is a glycosaminoglycan found in the extracellular matrix (ECM) and is frequently overproduced by various tumor cell types. The presence of HA in tumors correlates with increases in tumor cell growth, metastatic potential, tumor progression and resistance to chemotherapeutic agents.","PH20 Hyaluronidase-expressing Adenovirus VCN-01 | Genetically Modified Adenovirus-encoding Human PH20 Hyaluronidase VCN-01 | VCN-01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829095","MFIS - Less Motivated to Participate in Social Activities","C113974","Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have been less motivated to participate in social activities.","MFIS - Less Motivated to Participate in Social Activities | MFIS01-Less Motivated, Social Activity | MFIS0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829094","MFIS - Limited in My Abilities to Do Things Away From Home","C113975","Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have been limited in my ability to do things away from home.","MFIS - Limited in My Abilities to Do Things Away From Home | MFIS01-Limited in Ability Away From Home | MFIS0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827236","MFIS - Have Trouble Maintain Physical Effort","C113976","Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have had trouble maintaining physical effort for long periods.","MFIS - Have Trouble Maintain Physical Effort | MFIS01-Trouble Maintain Physical Effort | MFIS0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812286","Plexin-C1, Human","C113627","Plexin-C1 (1568 aa, ~176 kDa) is encoded by the human PLXNC1 gene. This protein is involved in ligand binding, signal transduction and cytoskeletal remodeling.","Plexin-C1 | CD232 Antigen | Plexin (Semaphorin Receptor) | Receptor For Viral Semaphorin Protein | Receptor For Virally-Encoded Semaphorin | Virus-Encoded Semaphorin Protein Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL455235","Autologous Peripheral Blood Lymphocytes Cotransduced with Retroviral Vectors Encoding Inducible IL-12 and Anti-NY-ESO-1 TCR","C113161","Human autologous peripheral blood lymphocytes (PBLs) transduced with two retroviral vectors, one encoding a T-cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1 and a second that encodes an inducible single chain form of interleukin-12 (IL-12) driven by a nuclear factor of activated T-cells (NFAT)-responsive promoter, with potential immunomodulating and antineoplastic activities. Following isolation of lymphocytes, retroviral vector transduction, and expansion of the cells ex vivo, the inducible IL-12/anti-NY-ESO-1 TCR-expressing autologous PBLs are re-administered into the patient by intravenous injection. As the transduced PBLs traverse the patient's circulation, they can bind to NY-ESO-1-overexpressing tumor cells. This binding activates the TCR signaling pathway in the transduced PBLs, which promotes NFAT-dependent gene transcription and induces expression of the cotransduced IL-12. IL-12 expression activates the immune system by promoting the secretion of interferon-gamma, activating natural killer cells (NKs), and inducing cytotoxic T-cell responses, which may result in both decreased cell proliferation and increased cell death for the NY-ESO-1-overexpressing tumor cells. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types. NFAT, a family of transcription factors involved in immune responses, is activated by calcium signaling, which can occur downstream of TCR activation. Use of a retroviral vector to express an inducible IL-12 may remove the requirement for concomitant administration of interleukin-2 (IL-2) as is the case for conventional cell transfer immunotherapies.","Autologous Peripheral Blood Lymphocytes Cotransduced with Retroviral Vectors Encoding Inducible IL-12 and Anti-NY-ESO-1 TCR | Autologous Lymphocytes Cotransduced with Genes Encoding IL-12 and Anti-NY-ESO-1 TCR | Autologous PBL Cotransduced with Retroviral Vectors Encoding Inducible IL-12 and Anti-NY-ESO-1 TCR | IL-12 Plus anti-ESO-1 TCR PBL | IL-12/Anti-NY-ESO-1 TCR-Expressing Autologous PBL | IL-12/Anti-NY-ESO-1 TCR-Expressing Autologous Peripheral Blood Lymphocytes | Inducible IL-12/Anti-NY-ESO-1 TCR-Expressing Autologous PBL | Inducible IL-12/Anti-NY-ESO-1 TCR-Expressing Autologous Peripheral Blood Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL455236","spleen tyrosine kinase inhibitor TAK-659","C113162","An inhibitor of spleen tyrosine kinase (syk), with potential anti-inflammatory, immunomodulating, and antineoplastic activities. Upon administration, mivavotinib may inhibit the activity of syk, which abrogates downstream B-cell receptor (BCR) signaling and leads to an inhibition of B-cell activation, chemotaxis, adhesion and proliferation. Syk, a BCR-associated non-receptor tyrosine kinase that mediates diverse cellular responses, including proliferation, differentiation, and phagocytosis, is expressed in hematopoietic tissues and is often overexpressed in hematopoietic malignancies.","Mivavotinib | 3H-Pyrrolo(3,4-C)pyridin-3-one, 6-(((1R,2S)-2-aminocyclohexyl)amino)-7-fluoro-1,2-dihydro-4-(1-methyl-1H-pyrazol-4-yl)- | MIVAVOTINIB | Spleen Tyrosine Kinase Inhibitor TAK-659 | Spleen Tyrosine Kinase Inhibitor TAK659 | TAK-659 | TAK-659 Free Base | TAK659 | TAK659 Free Base | syk Inhibitor TAK-659 | syk Inhibitor TAK659 | syk-Inhibitor TAK-659 | syk-Inhibitor TAK659",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2003387","recombinant cell-surface anchored sialidase DAS181","C113163","A recombinant sialidase fusion protein composed of a sialidase catalytic domain derived from Actinomyces viscosus, a constituent of the normal oral and gastrointestinal flora in humans, fused to a cell surface-anchoring domain, with potential anti-viral activity. Following administration by oral inhalation, oplunofusp proteolytically removes sialic acid from the airway epithelium, which inhibits viral binding to and internalization by cells of the respiratory epithelium and prevents viral replication. The cell surface anchoring-domain of this agent may increase retention time and drug potency. Sialic acids in the respiratory tract are used by influenza and parainfluenza viruses to invade airway epithelial cells.","Oplunofusp | 273-666-Neuraminidase [273-Methionine] (Actinomyces viscosus Clone DAS181) Fusion Protein With 125-145-Preproamphiregulin (Human) | DAS181 | DAS181-F02 | Fludase | OPLUNOFUSP | Recombinant Cell-Surface Anchored Sialidase DAS181",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL455237","anti-TF monoclonal antibody-MMAE conjugate","C113164","An antibody-drug conjugate (ADC) comprised of tisotumab, a monoclonal antibody against human tissue factor (TF) covalently coupled, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and potent microtubule disrupting agent, with potential antiangiogenic, anticoagulant and antineoplastic activities. Upon administration of tisotumab vedotin, the tisotumab moiety binds to cell surface TF and is internalized. Tisotumab binds to factor VIIa (FVIIa), which interferes with the activation of factor X (FX) into FXa. This may prevent thrombin formation and cancer-associated venous thromboembolism, and may inhibit angiogenesis and tumor cell proliferation. After internalization of the agent, the MMAE moiety is released by proteolytic cleavage. It then binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and apoptosis. TF, a transmembrane protein and initiator of the coagulation cascade, is overexpressed in many tumor cells and tumor-resident endothelial cells. Expression of TF is correlated with metastasis, angiogenesis, tumor cell growth and tumor-associated thrombosis.","Tisotumab Vedotin | HuMax-TF-ADC | TISOTUMAB VEDOTIN | Tisotumab Vedotin-tftv | Tisotumab vedotin | Tivdak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714758","Juvenile Psoriatic Arthritis","C114361","Childhood arthritis typically associated with psoriasis.","Juvenile Psoriatic Arthritis | JPsA",,,,,,,,,,,,,,,"4079733","Juvenile psoriatic arthritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3812287","PIK3C3 wt Allele","C114362","Human PIK3C3 wild-type allele is located in the vicinity of 18q12.3 and is approximately 133 kb in length. This allele, which encodes phosphatidylinositol 3-kinase catalytic subunit type 3 protein, is involved in second messenger molecule metabolism.","PIK3C3 wt Allele | Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3 wt Allele | Phosphatidylinositol 3-Kinase, Catalytic Subunit Type 3 Gene | Phosphatidylinositol 3-Kinase, Class 3 Gene | Phosphoinositide-3-Kinase, Class 3 Gene | VPS34 | VPS34, Yeast, Homolog of Gene | hVps34",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2936442","Class III Phosphatidylinositol 3-Kinase Catalytic Subunit","C114363","Phosphatidylinositol 3-kinase catalytic subunit type 3 (887 aa, ~102 kDa) is encoded by the human PIK3C3 gene. This protein plays a role in the phosphorylation of second messengers.","Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3 | EC 2.7.1.137 | PI3-Kinase Type 3 | PI3K Type 3 | PIK3C3 | Phosphatidylinositol 3-Kinase p100 Subunit | Phosphoinositide-3-Kinase Class 3 | PtdIns-3-Kinase Type 3 | hVps34",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919890","Hyperfibrinogenemia","C113740","Abnormally high level of fibrinogen in the blood.","Hyperfibrinogenemia | Fibrinogenemia",,,,,,,,,,,,,,,"4230568","Hyperfibrinogenemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3827549","Vitros ECi","C113741","A proprietary immunodiagnostic chemiluminescent system manufactured by Ortho Clinical Diagnostics.","Vitros ECi | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1735359","Excessive Bleeding","C113742","Abnormally heavy or prolonged loss of blood.","Excessive Bleeding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830299","Excessive Bruising","C113743","Bruising that is disproportionately high to the amount of trauma received or reported.","Excessive Bruising | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829671","Homogenate","C113744","Material that has been treated so as to be largely uniform throughout.","Homogenate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1833054","Hypocortisolemia","C113211","Abnormally low level of cortisol in the blood.","Hypocortisolemia | Hypocortisolism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3806978","Hyperaldosteronemia","C113212","Abnormally high levels of aldosterone in the blood.","Hyperaldosteronemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020428","Hyperaldosteronism","C113213","Overproduction of aldosterone by the adrenal glands, which may lead to hypokalemia and/or hypernatremia.","Hyperaldosteronism | Aldosteronism",,,,,,,,,,,,,,,"195213","Hyperaldosteronism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828476","Primary Hypoparathyroidism","C113214","Abnormally low levels of parathyroid hormone due to a disorder originating within the parathyroid glands.","Primary Hypoparathyroidism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206081","Androgen Excess","C113215","Excessive secretion of androgens from the adrenal glands or gonads. Clinical manifestations may include virilization.","Androgen Excess | Hyperandrogenism",,,,,,,,,,,,,,,"4029582","Hyperandrogenization syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3811128","TXNIP wt Allele","C113218","Human TXNIP wild-type allele is located in the vicinity of 1q21.1 and is approximately 4 kb in length. This allele, which encodes thioredoxin-interacting protein, is involved in the modulation of immunity and oxidative stress responses.","TXNIP wt Allele | EST01027 | HHCPA78 | RP11-315I20.4 | THIF | Thioredoxin Interacting Protein wt Allele | Upregulated By 1,25-Dihydroxyvitamin D-3 Gene | VDUP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278090","Gonadotropin-Independent Precocious Puberty","C113219","Premature development of secondary sexual characteristics due to the presence of sex steroids independent of pituitary gonadotropin release.","Gonadotropin-Independent Precocious Puberty | Peripheral Precocious Puberty | Pseudoprecocious Puberty",,,,,,,,,,,,,,,"42537283","Gonadotropin independent precocious puberty",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1450344","Thioredoxin-Interacting Protein","C113220","Thioredoxin-interacting protein (391 aa, ~44 kDa) is encoded by the human TXNIP gene. This protein plays a role in the immune response and oxidative stress-stimulated signaling.","Thioredoxin-Interacting Protein | TXNIP | Thioredoxin Binding Protein 2 | Thioredoxin-Binding Protein 2 | Vitamin D3 Up-Regulated Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421416","UVRAG Gene","C113221","This gene is involved in both autophagy and DNA repair.","UVRAG Gene | UV Radiation Resistance Associated Gene | UVRAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811802","UVRAG wt Allele","C113222","Human UVRAG wild-type allele is located in the vicinity of 11q13.5 and is approximately 329 kb in length. This allele, which encodes UV radiation resistance-associated gene protein, plays a role in the modulation of both DNA repair and autophagy. A chromosomal inversion inv(11)(q13.5;q25), which involves the gene, is associated with heterotaxy.","UVRAG wt Allele | DHTX | Disrupted In Heterotaxy Gene | UV Radiation Resistance Associated wt Allele | UV Radiation Resistance-Associated Gene | VPS38 | p63",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1438950","UV Radiation Resistance-Associated Gene Protein, Human","C113223","UV radiation resistance-associated gene protein (699 aa, ~78 kDa) is encoded by the human UVRAG gene. This protein is involved in both DNA repair and the positive regulation of autophagy.","UV Radiation Resistance-Associated Gene Protein | Beclin 1 Binding Protein | p63",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829096","MFIS - Less Motivated to Do Anything That Requires Thinking","C113978","Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have been less motivated to do anything that requires thinking.","MFIS - Less Motivated to Do Anything That Requires Thinking | MFIS01-Less Motivated, Thinking | MFIS0112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829093","MFIS - Muscles Have Felt Weak","C113979","Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks my muscles have felt weak.","MFIS - Muscles Have Felt Weak | MFIS01-My Muscles Have Felt Weak | MFIS0113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829108","MFIS - Been Physically Uncomfortable","C113980","Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have been physically uncomfortable.","MFIS - Been Physically Uncomfortable | MFIS01-Been Physically Uncomfortable | MFIS0114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829099","MFIS - Have Trouble Finishing Tasks That Require Thinking","C113981","Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have had trouble finishing tasks that require thinking.","MFIS - Have Trouble Finishing Tasks That Require Thinking | MFIS01-Trouble Finishing Thinking Tasks | MFIS0115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829107","MFIS - Difficulty Organizing My Thoughts","C113982","Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have had difficulty organizing my thoughts when doing things at home or at work.","MFIS - Difficulty Organizing My Thoughts | MFIS01-Difficulty Organizing My Thoughts | MFIS0116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829098","MFIS - Less Able to Complete Tasks That Require Physical Effort","C113983","Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have been less able to complete tasks that require physical effort.","MFIS - Less Able to Complete Tasks That Require Physical Effort | MFIS01-Less Able Complete Physical Tasks | MFIS0117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829092","MFIS - My Thinking Has Been Slowed Down","C113984","Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks my thinking has been slowed down.","MFIS - My Thinking Has Been Slowed Down | MFIS01-My Thinking Has Been Slowed Down | MFIS0118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829100","MFIS - Have Trouble Concentrating","C113985","Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have had trouble concentrating.","MFIS - Have Trouble Concentrating | MFIS01-I Have Had Trouble Concentrating | MFIS0119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829101","MFIS - Have Limited My Physical Activities","C113986","Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have limited my physical activities.","MFIS - Have Limited My Physical Activities | MFIS01-Have Limited My Physical Activity | MFIS0120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829091","MFIS - Need to Rest More Often or Longer","C113987","Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have needed to rest more often or for longer periods.","MFIS - Need to Rest More Often or Longer | MFIS01-Need to Rest More Often or Longer | MFIS0121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828889","MSQOL-54 - Would You Say Your Health Is","C113988","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) In general, would you say your health is:","MSQOL-54 - Would You Say Your Health Is | MSQL1-Would You Say Your Health Is | MSQL101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415736","HSD11B1 Gene","C113165","This gene is involved in corticosteroid metabolism.","HSD11B1 Gene | HSD11B1 | Hydroxysteroid (11-Beta) Dehydrogenase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828134","SGRQ Past 3 Months Version - Cannot Play Sports or Do Physical Activities","C112672","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) We would like to know how your respiratory problems usually affect your daily life: I cannot play sports or do other physical activities.","SGRQ Past 3 Months Version - Cannot Play Sports or Do Physical Activities | SGRQ01-I Cannot Play Sports | SGRQ0146",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828137","SGRQ Past 3 Months Version - Cannot Go Out for Entertainment","C112673","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) We would like to know how your respiratory problems usually affect your daily life: I cannot go out for entertainment or recreation.","SGRQ Past 3 Months Version - Cannot Go Out for Entertainment | SGRQ01-Cannot Go Out for Entertainment | SGRQ0147",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828136","SGRQ Past 3 Months Version - Cannot Go Out to Do Shopping","C112674","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) We would like to know how your respiratory problems usually affect your daily life: I cannot go out of the house to do the shopping.","SGRQ Past 3 Months Version - Cannot Go Out to Do Shopping | SGRQ01-Cannot Go Out to Do Shopping | SGRQ0148",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828138","SGRQ Past 3 Months Version - Cannot Do Household Chores","C112675","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) We would like to know how your respiratory problems usually affect your daily life: I cannot do household chores.","SGRQ Past 3 Months Version - Cannot Do Household Chores | SGRQ01-I Cannot Do Household Chores | SGRQ0149",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828120","SGRQ Past 3 Months Version - How Respiratory Problems Affect You","C112677","St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) Best describe how your respiratory problems affect you.","SGRQ Past 3 Months Version - How Respiratory Problems Affect You | SGRQ01-How Resp Problems Affect You | SGRQ0151",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828078","SGRQ Past 4 Weeks Version - Describe Your Current Health","C112678","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) Please check one box to show how you describe your current health.","SGRQ Past 4 Weeks Version - Describe Your Current Health | SGRQ02-Describe Your Current Health | SGRQ0201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828064","SGRQ Past 4 Weeks Version - I Have Coughed","C112679","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) Over the past 4 weeks, I have coughed.","SGRQ Past 4 Weeks Version - I Have Coughed | SGRQ02-I Have Coughed | SGRQ0202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828065","SGRQ Past 4 Weeks Version - I Have Brought Up Phlegm","C112680","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) Over the past 4 weeks, I have brought up phlegm (sputum).","SGRQ Past 4 Weeks Version - I Have Brought Up Phlegm | SGRQ02-I Have Brought Up Phlegm | SGRQ0203",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828063","SGRQ Past 4 Weeks Version - I Have Had Shortness of Breath","C112681","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) Over the past 4 weeks, I have had shortness of breath.","SGRQ Past 4 Weeks Version - I Have Had Shortness of Breath | SGRQ02-I Have Had Shortness of Breath | SGRQ0204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828062","SGRQ Past 4 Weeks Version - I Have Had Wheezing Attacks","C112682","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) Over the past 4 weeks, I have had wheezing attacks.","SGRQ Past 4 Weeks Version - I Have Had Wheezing Attacks | SGRQ02-I Have Had Wheezing Attacks | SGRQ0205",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828051","SGRQ Past 4 Weeks Version - Times Suffered From Severe Respiratory Attacks","C112683","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) How many times during the past 4 weeks have you suffered from severe or very unpleasant respiratory attacks?","SGRQ Past 4 Weeks Version - Times Suffered From Severe Respiratory Attacks | SGRQ02-Times Suffered Sev Resp Attacks | SGRQ0206",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085681","Hyperphosphatemia","C113750","Abnormally high level of phosphate in the blood.","Hyperphosphatemia | ",,,,,,,,,,,,,,,"4065502","Hyperphosphatemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0521173","Granulomatosis","C113754","A general term that refers to non-neoplastic and neoplastic disorders characterized by the presence of granulomas in various anatomic sites.","Granulomatosis | ",,,,,,,,,,,,,,,"40480130|4185897","Granulomatosis|Granulomatosis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0151479","Hyperamylasemia (finding)","C113755","Abnormally high level of amylase in the blood.","Hyperamylasemia | Elevated Amylase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0151857","Pleocytosis","C113756","Abnormally high cell count in a body fluid.","Pleocytosis | ",,,,,,,,,,,,,,,"4240184","Pleocytosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3830686","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Preparatory Acts or Behaviors Toward Suicide Attempt (Lifetime)","C113930","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Have you done anything to get ready to make yourself not alive anymore (to end your life or kill yourself) - like giving things away, writing a goodbye note, getting things you need to kill yourself? (Lifetime).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Preparatory Acts or Behaviors Toward Suicide Attempt (Lifetime) | CSS10-Preparatory Acts/Behavior-Life | CSS1016A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830685","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Preparatory Acts or Behaviors Toward Suicide Attempt (Past 3 Months)","C113931","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Have you done anything to get ready to make yourself not alive anymore (to end your life or kill yourself) - like giving things away, writing a goodbye note, getting things you need to kill yourself? (Past 3 Months).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Preparatory Acts or Behaviors Toward Suicide Attempt (Past 3 Months) | CSS10-Preparatory Acts/Behavior-P3M | CSS1016B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830714","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Description of Preparatory Acts or Behaviors Toward Suicide Attempt","C113932","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Description of preparatory acts or behaviors.","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Description of Preparatory Acts or Behaviors Toward Suicide Attempt | CSS10-Preparatory Acts/Behavior, Descr | CSS1016C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830681","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Suicidal Behavior (Lifetime)","C113933","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Suicidal behavior was present during the assessment period? (Lifetime).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Suicidal Behavior (Lifetime) | CSS10-Suicidal Behavior-Life | CSS1017A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830680","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Suicidal Behavior (Past 3 Months)","C113934","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Suicidal behavior was present during the assessment period? (Past 3 Months).","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Suicidal Behavior (Past 3 Months) | CSS10-Suicidal Behavior-P3M | CSS1017B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830700","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Most Recent Suicide Attempt Date","C113935","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Most recent attempt date.","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Most Recent Suicide Attempt Date | CSS10-Most Recent Attempt Date | CSS1018A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828089","SGRQ Past 4 Weeks Version - Breathing Makes Difficult to Do Heavy Manual Work","C112722","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about how your activities might be affected by your respiratory problems: My breathing makes it difficult to do things such as very heavy manual work, ride a bike, run, swim fast, or play competitive sports.","SGRQ Past 4 Weeks Version - Breathing Makes Difficult to Do Heavy Manual Work | SGRQ02-Difficult to Do Very Heavy Work | SGRQ0245",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828083","SGRQ Past 4 Weeks Version - Cannot Play Sports or Do Physical Activities","C112723","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) We would like to know how your respiratory problems usually affect your daily life: I cannot play sports or do other physical activities.","SGRQ Past 4 Weeks Version - Cannot Play Sports or Do Physical Activities | SGRQ02-I Cannot Play Sports | SGRQ0246",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828086","SGRQ Past 4 Weeks Version - Cannot Go Out for Entertainment","C112724","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) We would like to know how your respiratory problems usually affect your daily life: I cannot go out for entertainment or recreation.","SGRQ Past 4 Weeks Version - Cannot Go Out for Entertainment | SGRQ02-Cannot Go Out for Entertainment | SGRQ0247",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828085","SGRQ Past 4 Weeks Version - Cannot Go Out to Do Shopping","C112725","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) We would like to know how your respiratory problems usually affect your daily life: I cannot go out of the house to do the shopping.","SGRQ Past 4 Weeks Version - Cannot Go Out to Do Shopping | SGRQ02-Cannot Go Out to Do Shopping | SGRQ0248",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828087","SGRQ Past 4 Weeks Version - Cannot Do Household Chores","C112726","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) We would like to know how your respiratory problems usually affect your daily life: I cannot do household chores.","SGRQ Past 4 Weeks Version - Cannot Do Household Chores | SGRQ02-I Cannot Do Household Chores | SGRQ0249",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828084","SGRQ Past 4 Weeks Version - Cannot Move Far From Bed or Chair","C112727","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) We would like to know how your respiratory problems usually affect your daily life: I cannot move far from my bed or chair.","SGRQ Past 4 Weeks Version - Cannot Move Far From Bed or Chair | SGRQ02-I Cannot Move Far From My Bed | SGRQ0250",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828069","SGRQ Past 4 Weeks Version - How Respiratory Problems Affect You","C112728","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) Best describe how your respiratory problems affect you.","SGRQ Past 4 Weeks Version - How Respiratory Problems Affect You | SGRQ02-How Resp Problems Affect You | SGRQ0251",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827612","VFQ25-Interviewer Administered Format - Overall Health","C112729","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) General Heath and Vision: In general, would you say your overall health is:","VFQ25-Interviewer Administered Format - Overall Health | VFQ1-Your Overall Health Is | VFQ101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827622","VFQ25-Interviewer Administered Format - Eyesight Using Both Eyes","C112730","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) General Heath and Vision: at the present time, would you say your eyesight using both eyes (with glasses or contact lenses, if you wear them) is excellent, good, fair, poor, or very poor or are you completely blind?","VFQ25-Interviewer Administered Format - Eyesight Using Both Eyes | VFQ1-Eyesight Using Both Eyes Is | VFQ102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827610","VFQ25-Interviewer Administered Format - Pain or Discomfort You Had in and Around Eyes","C112732","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) General Heath and Vision: How much pain or discomfort have you had in and around your eyes (for example, burning, itching, or aching)? Would you say it is:","VFQ25-Interviewer Administered Format - Pain or Discomfort You Had in and Around Eyes | VFQ1-How Much Pain in and Around Eyes | VFQ104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828336","Reticulocyte Distribution Width (procedure)","C114218","The determination of the range of reticulocyte sizes in a blood specimen.","Reticulocyte Distribution Width | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828071","SGRQ Past 4 Weeks Version - How Long Did Worst Respiratory Attack Last","C112684","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) How long did the worst respiratory attack last?","SGRQ Past 4 Weeks Version - How Long Did Worst Respiratory Attack Last | SGRQ02-How Long Worst Resp Attack Last | SGRQ0207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828070","SGRQ Past 4 Weeks Version - How Many Good Days You Had","C112685","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) Over the past 4 weeks, in a typical week, how many good days (with few respiratory problems) have you had?","SGRQ Past 4 Weeks Version - How Many Good Days You Had | SGRQ02-How Many Good Days Have You Had | SGRQ0208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0597336","Quantitative Trait Locus","C113414","A stretch of DNA at a particular chromosomal location that contains or is linked to genes that are associated with the expression of a variable phenotypic trait.","Quantitative Trait Locus | QTL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3826857","Expression Quantitative Trait Locus","C113415","A stretch of DNA at a particular chromosomal location that is able to regulate the expression of a specific mRNA or protein.","Expression Quantitative Trait Locus | eQTL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829617","Housemate","C113419","A person who shares a house with another person.","Housemate | Roommate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3816732","Nerve-Sparing Surgery","C113420","Any surgery that attempts to preserve nerve function near the surgery site.","Nerve-Sparing Surgery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0270276","Gray Baby Syndrome","C113421","A disorder observed in a newborn who was exposed to chloramphenicol. Manifestations include hypotension, cyanosis, cardiovascular collapse and/or death.","Gray Baby Syndrome | Gray Syndrome | Grey Syndrome",,,,,,,,,,,,,,,"4296735","Gray syndrome from chloramphenicol administration in newborn",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0853695","Diethylstilbestrol Syndrome","C113422","A disorder likely to occur in children and grandchildren of a woman treated with diethylstilbestrol during pregnancy. Manifestations include vaginal adenosis, cervical malformations, vaginal septae, genital tract anomalies or Fallopian tube anomalies causing subsequent fertility problems.","Diethylstilbestrol Syndrome | Fetal Diethylstilbestrol Syndrome",,,,,,,,,,,,,,,"37396259","Fetal diethylstilbestrol syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3813276","Labor After Cesarean","C113423","Labor in a woman who has had one or more previous cesarean births.","Labor After Cesarean | LAC | Labor After Caesarean",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0473390","Threatened Preterm Labor","C113424","Frequent painful contractions prior to 37 weeks of gestation without cervical change.","Threatened Preterm Labor | Threatened Premature Labor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830701","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Most Recent Suicide Attempt Actual Lethality/Medical Damage","C113936","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Most recent attempt actual lethality/medical damage.","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Most Recent Suicide Attempt Actual Lethality/Medical Damage | CSS10-Most Recent Attempt Damage | CSS1018B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830699","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Most Recent Suicide Attempt Potential Lethality","C113937","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Most recent attempt potential lethality.","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Most Recent Suicide Attempt Potential Lethality | CSS10-Most Recent Attempt Potential | CSS1018C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830703","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Most Lethal Suicide Attempt Date","C113938","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Most lethal attempt date.","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Most Lethal Suicide Attempt Date | CSS10-Most Lethal Attempt Date | CSS1019A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830704","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Most Lethal Suicide Attempt Actual Lethality/Medical Damage","C113939","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Most lethal attempt actual lethality/medical damage.","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Most Lethal Suicide Attempt Actual Lethality/Medical Damage | CSS10-Most Lethal Attempt Damage | CSS1019B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830711","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - First Suicide Attempt Date","C113941","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Initial/first attempt date.","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - First Suicide Attempt Date | CSS10-First Attempt Date | CSS1020A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827634","VFQ25-Interviewer Administered Format - Difficulty Reading Ordinary Print in Newspapers","C112733","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Difficulty With Activities: How much difficulty do you have reading ordinary print in newspapers? Would you say you have:","VFQ25-Interviewer Administered Format - Difficulty Reading Ordinary Print in Newspapers | VFQ1-Difficulty Reading Newspapers | VFQ105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0267072","Esophageal Dysphagia","C113469","Difficulty in swallowing due to an abnormality in the esophagus.","Esophageal Dysphagia | ",,,,,,,,,,,,,,,"4254223","Esophageal dysphagia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1515385","Recombinant Leukoregulin","C1143","A formulated therapeutic analog of the endogenous lymphokine leukoregulin with potential antineoplastic activity.  Leukoregulin displays direct and indirect cytotoxicity through tumor cell lysis and enhancing tumor cell susceptibility to natural killer cell-mediated cytotoxicity.  This agent enhances membrane permeability and decreases p-glycoprotein expression, thereby promoting cytotoxic drug uptake into tumor cells.  Leukoregulin also induces the synthesis of collagenase and hyaluronan, expression and secretion of interleukin-8, and upregulates stromelysin-1 gene expression in human fibroblasts, thereby regulating extracellular matrix degradation. (NCI04)","Recombinant Leukoregulin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1313659","Synaptonemal Complex Protein 1, Human","C114400","Synaptonemal complex protein 1 (976 aa, ~114 kDa) is encoded by the human SYCP1 gene. This protein plays a role in the structure of the synaptonemal complex during meiotic prophase.","Synaptonemal Complex Protein 1 | CT8 | Cancer/Testis Antigen 8 | SCP-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428482","SUSD1 Gene","C114401","This gene is involved in calcium binding.","SUSD1 Gene | SUSD1 | Sushi Domain Containing 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827890","SUSD1 wt Allele","C114402","Human SUSD1 wild-type allele is located within 9q31.3-q33.1 and is approximately 135 kb in length. This allele, which encodes sushi domain-containing protein 1, plays a role in calcium binding.","SUSD1 wt Allele | RP11-4O1.1 | Sushi Domain Containing 1 wt Allele | UNQ2438/PRO4999",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815191","Sushi Domain-Containing Protein 1","C114403","Sushi domain-containing protein 1 (747 aa, ~83 kDa) is encoded by the human SUSD1 gene. This protein is involved in calcium binding.","Sushi Domain-Containing Protein 1 | SUSD1 | Sushi Domain Containing 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828504","Postpartum Shock","C114404","Severe loss of blood pressure leading to inadequate tissue perfusion after the delivery of the fetus.","Postpartum Shock | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1331543","Postpartum Pyrexia","C114405","A sustained temperature of 38C (100.4F) or greater beyond the first 24 hours following birth, or a temperature of 39C (102.2F) within the first 24 hours following birth. (adapted from ACOG)","Postpartum Pyrexia | Postpartum Fever",,,,,,,,,,,,,,,"4034154|4094003","Puerperal pyrexia|Postpartum fever",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3714952","USH1G wt Allele","C114407","Human USH1G wild-type allele is located in the vicinity of 17q25.1 and is approximately 7 kb in length. This allele, which encodes Usher syndrome type-1G protein, is involved in the development of both the retina and cochlear hair cells. Mutation of the gene is associated with Usher syndrome 1G.","USH1G wt Allele | ANKS4A | FLJ33924 | SANS | Sans | Usher Syndrome 1G (Autosomal Recessive) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811243","Usher Syndrome Type-1G Protein, Human","C114408","Usher syndrome type-1G protein (461 aa, ~51 kDa) is encoded by the human USH1G gene. This protein plays a role in retinal and cochlear development.","Usher Syndrome Type-1G Protein | Scaffold Protein Containing Ankyrin Repeats and SAM Domain | USH1G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152158","Agalactia","C114409","Lack of production or secretion of breast milk.","Agalactia | Agalactorrhea",,,,,,,,,,,,,,,"81088","Failure of lactation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1418668","PLXND1 Gene","C114410","This gene is involved in semaphorin binding and signaling.","PLXND1 Gene | PLXND1 | Plexin D1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815264","PLXND1 wt Allele","C114411","Human PLXND1 wild-type allele is located in the vicinity of 3q22.1 and is approximately 52 kb in length. This allele, which encodes plexin-D1 protein, plays a role in semaphorin-mediated signaling.","PLXND1 wt Allele | KIAA0620 | PLEXD1 | Plexin D1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811218","Plexin-D1","C114412","Plexin-D1 (1925 aa, ~212 kDa) is encoded by the human PLXND1 gene. This protein is involved in the mediation of semaphorin-dependent signal transduction.","Plexin-D1 | Plexin D1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539979","TMCC1 Gene","C114413","This gene has no known function.","TMCC1 Gene | TMCC1 | Transmembrane and Coiled-Coil Domain Family 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812648","BACE2 wt Allele","C112891","Human BACE2 wild-type allele is located in the vicinity of 21q22.3 and is approximately 108 kb in length. This allele, which encodes beta-secretase 2 protein, plays a role in protein cleavage.","BACE2 wt Allele | AEPLC | ALP56 | ASP1 | ASP21 | BAE2 | Beta-Site APP-Cleaving Enzyme 2 wt Allele | CDA13 | CEAP1 | DRAP | UNQ418/PRO852",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811065","Beta-Secretase 2, human","C112892","Beta-secretase 2 (518 aa, ~56 kDa) is encoded by the human BACE2 gene. This protein is involved in the cleavage of membrane bound proteins.","Beta-Secretase 2 | 56 kDa Aspartic-Like Protease | ASP1 | Asp 1 | Aspartic-Like Protease 56 kDa | Aspartic-Like Protease, 56 kD | Aspartyl Protease 1 | BACE2 | Beta-Site Amyloid Beta A4 Precursor Protein-Cleaving Enzyme 2 | Beta-Site Amyloid Precursor Protein Cleaving Enzyme 2 | DRAP | Down Region Aspartic Protease | Down Syndrome Region Aspartic Protease | EC 3.4.23.45 | Memapsin 1 | Memapsin-1 | Membrane-Associated Aspartic Protease 1 | Theta-Secretase | Transmembrane Aspartic Proteinase Asp1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412727","BACE1 Gene","C112893","This gene plays a role in protein cleavage.","BACE1 Gene | BACE1 | Beta-Site APP-Cleaving Enzyme 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815269","BACE1 wt Allele","C112894","Human BACE1 wild-type allele is located within 11q23.2-q23.3 and is approximately 31 kb in length. This allele, which encodes beta-secretase 1 protein, is involved in proteolytic processing.","BACE1 wt Allele | ASP2 | BACE | Beta-Site APP-Cleaving Enzyme 1 wt Allele | Beta-Site APP-Cleaving Enzyme Gene | HSPC104 | KIAA1149 | Secretase, Beta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1569775","Beta-Secretase 1, Human","C112895","Beta-secretase 1 (501 aa, ~56 kDa) is encoded by the human BACE1 gene. This protein plays a role in the proteolysis of ectodomains of membrane proteins.","Beta-Secretase 1 | APP Beta-Secretase | ASP2 | Asp 2 | Aspartyl Protease 2 | BACE1 | Beta-Site APP Cleaving Enzyme 1 | Beta-Site Amyloid Beta A4 Precursor Protein-Cleaving Enzyme | Beta-Site Amyloid Beta A4 Precursor Protein-Cleaving Enzyme 1 | Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 | EC 3.4.23.46 | Memapsin 2 | Memapsin-2 | Membrane-Associated Aspartic Protease 2 | Transmembrane Aspartic Proteinase Asp2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426113","TERF2IP Gene","C112896","This gene is involved in both telomere maintenance and gene transcription.","TERF2IP Gene | TERF2IP | Telomeric Repeat Binding Factor 2, Interacting Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814146","TERF2IP wt Allele","C112897","Human TERF2IP wild-type allele is located in the vicinity of 16q23.1 and is approximately 113 kb in length. This allele, which encodes telomeric repeat-binding factor 2-interacting protein 1, plays a role in both the regulation of gene expression and the modulation of telomere recombination.","TERF2IP wt Allele | DRIP5 | PP8000 | RAP1 | RAP1, Yeast, Homolog Gene | Telomeric Repeat Binding Factor 2, Interacting Protein wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810659","Telomeric Repeat-Binding Factor 2-Interacting Protein 1, Human","C112898","Telomeric repeat-binding factor 2-interacting protein 1 (399 aa, ~44 kDa) is encoded by the human TERF2IP gene. This protein is involved in both the negative regulation of telomere recombination and the modulation of gene transcription.","Telomeric Repeat-Binding Factor 2-Interacting Protein 1 | Dopamine Receptor Interacting Protein 5 | Dopamine Receptor-Interacting Protein 5 | RAP1 Homolog | Repressor/Activator Protein 1 Homolog | TERF2-Interacting Telomeric Protein | TERF2-Interacting Telomeric Protein 1 | TRF2-Interacting Telomeric Protein | TRF2-Interacting Telomeric Protein 1 | TRF2-Interacting Telomeric RAP1 Protein | hRap1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813197","HSD17B4 wt Allele","C114365","Human HSD17B4 wild-type allele is located in the vicinity of 5q21 and is approximately 185 kb in length. This allele, which encodes peroxisomal multifunctional enzyme type 2 protein, plays a role in the oxidation of fatty acids. Mutation of the gene is associated with D-bifunctional protein deficiency and Perrault syndrome 1.","HSD17B4 wt Allele | DBP | EDH17B4 | Hydroxysteroid (17-Beta) Dehydrogenase 4 wt Allele | MFE-2 | MPF-2 | PRLTS1 | SDR8C1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0536221","Peroxisomal Multifunctional Enzyme Type 2, Human","C114366","Peroxisomal multifunctional enzyme type 2 (736 aa, ~80 kDa) is encoded by the human HSD17B4 gene. This protein is involved in the peroxisomal beta-oxidation pathway for fatty acids.","Peroxisomal Multifunctional Enzyme Type 2 | 17-Beta-HSD 4 | 17-Beta-HSD IV | 17-Beta-Hydroxysteroid Dehydrogenase 4 | 17beta-Estradiol Dehydrogenase Type IV | 3-Alpha,7-Alpha,12-Alpha-Trihydroxy-5-Beta-Cholest-24-Enoyl-CoA Hydratase | Beta-Hydroxyacyl Dehydrogenase | Beta-Keto-Reductase | D-3-Hydroxyacyl-CoA Dehydratase | D-3-Hydroxyacyl-CoA Dehydratase/D-3-Hydroxyacyl-CoA Dehydrogenase Bifunctional Protein | D-Bifunctional Protein, Peroxisomal | DBP | DBP, Peroxisomal | HSD17B4 | MFE-2 | MPF-2 | Multifunctional Protein 2 | Peroxisomal Multifunctional Protein 2 | Short Chain Dehydrogenase/Reductase Family 8C, Member 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831350","Bioreactor Culture Biosynthesis","C112958","A process that synthesizes a material of interest using a large scale cell culture that is grown in a bioreactor.","Bioreactor Culture Biosynthesis | Derivation, Fermentation, Bioreactor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831158","Cell Culture-Based Biosynthesis, Not Otherwise Specified","C112959","A process that synthesizes a material of interest using cell culture that is not otherwise specified.","Cell Culture-Based Biosynthesis, Not Otherwise Specified | Derivation, Fermentation/Culture, Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830469","Disposable Bag Culture Biosynthesis","C112960","A process that synthesizes a material of interest using a disposable bag cell culture.","Disposable Bag Culture Biosynthesis | Derivation, Fermentation, Disposable Bags",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828584","Perfusion Culture Biosynthesis","C112961","A process that synthesizes a material of interest using a continuously fed cell culture.","Perfusion Culture Biosynthesis | Derivation, Fermentation, Perfusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831157","Cell or Vector Cryopreservation","C112963","Preservation of cells or genetic vectors by storage at low temperatures.","Cell or Vector Cryopreservation | Production, Cryopreserved Cell/Gene Therapy Intermediate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830531","Design and Specification of Software Platform or Architecture for in Vitro Diagnostics Device","C112964","The act of specifying the operational and physical requirements, respectively, for the software and hardware of an in vitro diagnostic device.","Design and Specification of Software Platform or Architecture for in Vitro Diagnostics Device | Design/Specification, Software Platform/Architecture, in Vitro Diagnostics Device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831329","Blood Product Distribution","C112965","The shipment of blood products under controlled conditions.","Blood Product Distribution | Distribution, Blood Products",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831155","Cell Product Encapsulation","C112966","A method that coats a cellular product with a layer of another material.","Cell Product Encapsulation | Encapsulation, Cell Product",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831066","Coating of Device with Immunologic Reagents","C112967","A procedure used to immobilize antigens or immunoglobulins on a device.","Coating of Device with Immunologic Reagents | Coating/Application, Biological Reagent Device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831036","Compression Formulation Process","C112968","A process that forms a solid dosage unit by applying mechanical forces to bind the formulation.","Compression Formulation Process | Dosage Formation, Compression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830496","Die Cutting Formulation Process","C112969","A process that forms a solid dosage unit by continuously cutting a uniform material into equally sized segments.","Die Cutting Formulation Process | Dosage Formation, Die Cutting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471772","Wheatgrass Juice","C113791","The juice extracted from the mature sprouts of wheatgrass, Triticum aestivum, which is a member of the Poaceae family, with potential anti-inflammatory, immunomodulating and chemopreventive activities. Wheatgrass juice contains many vitamins, including A, B vitamins, C and E, minerals, including selenium, iron, magnesium, calcium, manganese, copper and zinc, amino acids, chlorophyll and a number of antioxidant enzymes, including superoxide dismutase and cytochrome oxidase. Although the exact mechanism(s) of action through which wheatgrass juice exerts its effect(s) has yet to be fully elucidated, the components in the juice may scavenge free radicals, reduce chemotherapy-induced myelotoxicity, neutralize toxins and carcinogens and modulate the levels of certain pro-inflammatory cytokines, such as interleukin (IL)- 6, IL-8, IL-10 and IL-12.","Wheatgrass Juice | TRITICUM AESTIVUM IMMATURE TOP JUICE | Wheat Germ Juice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3710983","Akt/ERK inhibitor ONC201","C113792","A water soluble, orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) and extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon administration, dordaviprone binds to and inhibits the activity of Akt and ERK, which may result in inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt signal transduction pathway as well as the mitogen-activated protein kinase (MAPK)/ERK-mediated pathway. This may lead to the induction of tumor cell apoptosis mediated by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)/TRAIL death receptor type 5 (DR5) signaling in AKT/ERK-overexpressing tumor cells. The PI3K/Akt signaling pathway and MAPK/ERK pathway are upregulated in a variety of tumor cell types and play a key role in tumor cell proliferation, differentiation and survival by inhibiting apoptosis. In addition, ONC201 is able to cross the blood-brain barrier.","Dordaviprone | Akt/ERK Inhibitor ONC201 | Akt/ERK Inhibitor ONC201 | DORDAVIPRONE | ONC-201 | ONC201 | TIC10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471774","IDO inhibitor NLG919","C113793","An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon administration, navoximod targets and binds to IDO1, a cytosolic enzyme responsible for the oxidation of the essential amino acid tryptophan into kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, this agent increases tryptophan levels, restores the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes, and causes a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL) response against the IDO1-expressing tumor cells. IDO1 is overexpressed by a variety of tumor cell types and plays an important role in immunosuppression. Tryptophan depletion is associated with immunosuppression caused by T-cell suppression.","Navoximod | 5H-Imidazo(5,1-a)isoindole-5-ethanol, 6-Fluoro-alpha-(trans-4-hydroxycyclohexyl)-, (AlphaR,5S)- | GDC-0919 | NAVOXIMOD | NLG-919 | NLG919 | RG6078 | RO7077339-001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471775","CD133 Antigen Peptide-pulsed Autologous Dendritic Cell Vaccine","C113794","A cell-based cancer vaccine comprised of autologous dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A2-restricted peptides derived from the CD133 antigen, with potential antineoplastic activity. Upon intradermal administration, the CD133 antigen peptide-pulsed autologous DC vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against CD133-expressing tumor cells, resulting in tumor cell lysis. CD133, a cancer stem cell marker, is expressed on hematopoietic stem and progenitor cells and overexpressed on many types of cancer cells; it is associated with resistance to chemotherapy and increased cancer survival. HLA-A2 is an MHC class I molecule that presents antigenic peptides to CD8+ T-cells. Epitope design that is restricted to those epitopes that bind most efficiently to HLA-A2 may improve antigenic peptide immunogenicity.","CD133 Antigen Peptide-pulsed Autologous Dendritic Cell Vaccine | CD-133 Dendritic Cell Vaccine | CD133 DC Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471777","Immediate-release Onapristone","C113795","An immediate-release (IR) formulation of onapristone, an orally bioavailable progesterone receptor (PR) antagonist, with antineoplastic activity. Onapristone binds to the PR and inhibits both PR activation and the associated expression of PR-responsive genes. This may inhibit PR-mediated proliferative effects in cancer cells overexpressing PR. PR is expressed on certain cancer cell types and plays a key role in proliferation and survival.","Immediate-release Onapristone | IR Onapristone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471778","Anti-von Willebrand Factor Nanobody","C113796","A humanized, bivalent anti-von Willebrand factor (VWF) nanobody with potential anti-platelet activity. Anti-von Willebrand factor nanobody specifically binds to the A1 domain of the VWF molecule, thereby inhibiting and neutralizing VWF activity. This prevents the interaction of VWF with the platelet glycoprotein (Gp)Ib-IX-V receptor and prevents VWF-mediated platelet aggregation. VWF is a glycoprotein and plays a key role in blood coagulation. Increased VWF, which is seen in a number of diseases, is associated with an increased risk in thrombosis. The nanobody formulation allows for rapid distribution, onset of action and clearance. The nanobody is based on the smallest functional fragments of single-chain antibodies that naturally occur in the Camelidae family.","Anti-von Willebrand Factor Nanobody | Anti-vWf Nanobody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1540252","PAGR1 Gene","C112899","This gene plays a role in both transcriptional regulation and histone methylation.","PAGR1 Gene | PAGR1 | PAXIP1 Associated Glutamate-Rich Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0063041","Leflunomide","C1128","A derivative of isoxazole used for its immunosuppressive and anti-inflammatory properties.  As a prodrug, leflunomide is converted to an active metabolite, A77 1726, which blocks dihydroorotate dehydrogenase, a key enzyme of de novo pyrimidine synthesis, thereby preventing the expansion of activated T lymphocytes.  This agent also inhibits various protein tyrosine kinases, such as protein kinase C (PKC), thereby inhibiting cell proliferation. (NCI04)","Leflunomide | 4-Isoxazolecarboxamide, 5-Methyl-N-(4-(trifluoromethyl)phenyl)- | Arava | LEFLUNOMIDE | SU101 | leflunomide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812826","PAGR1 wt Allele","C112900","Human PAGR1 wild-type allele is located in the vicinity of 16p11.2 and is approximately 6 kb in length. This allele, which encodes PAXIP1-associated glutamate-rich protein 1, is involved in the regulation of both gene transcription and histone methylation.","PAGR1 wt Allele | C16orf53 | Chromosome 16 Open Reading Frame 53 Gene | GAS | PA1 | PAXIP1 Associated Glutamate-Rich Protein 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814458","PAXIP1-Associated Glutamate-Rich Protein 1, Human","C112901","PAXIP1-associated glutamate-rich protein 1 (254 aa, ~28 kDa) is encoded by the human PAGR1 gene. This protein plays a role in the modulation of both histone methyltransferase activity and gene expression.","PAXIP1-Associated Glutamate-Rich Protein 1 | Glutamate-Rich Coactivator Associated With SRC1 | Glutamate-Rich Coactivator Interacting With SRC1/NCOA1 | PAGR1 | PAXIP1-Associated Protein 1 | PTIP-Associated 1 Protein | PTIP-Associated Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3715113","HSD11B1 wt Allele","C113166","Human HSD11B1 wild-type allele is located within 1q32-q41 and is approximately 49 kb in length. This allele, which encodes 11-beta-hydroxysteroid dehydrogenase 1 protein, plays a role in the metabolism of cortisol. Mutation of the gene is associated with cortisone reductase deficiency.","HSD11B1 wt Allele | 11-DH | 11-beta-HSD1 | CORTRD2 | HDL | HSD11 | HSD11B | HSD11L | Hydroxysteroid (11-Beta) Dehydrogenase 1 wt Allele | SDR26C1 | Short Chain Dehydrogenase/Reductase Family 26C, Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3715112","Corticosteroid 11-Beta-Dehydrogenase Isozyme 1, human","C113167","11-beta-hydroxysteroid dehydrogenase 1 (292 aa, ~32 kDa) is encoded by the human HSD11B1 gene. This protein is involved in cortisone metabolism.","11-Beta-Hydroxysteroid Dehydrogenase 1 | 11-Beta-HSD1 | 11-Beta-Hydroxysteroid Dehydrogenase 1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 | 11-Beta-Hydroxysteroid Dehydrogenase, Type I | 11-DH | 7-Oxosteroid Reductase | Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 | Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 | EC 1.1.1.146 | EC 1.1.1.201 | HSD11B1 | Short Chain Dehydrogenase/Reductase Family 26C Member 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020514","Hyperprolactinemia","C113168","Abnormally high level of prolactin in the blood.","Hyperprolactinemia | ",,,,,,,,,,,,,,,"4030186","Hyperprolactinemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3714619","Insulin Resistance Syndrome","C113169","A cluster of closely related metabolic abnormalities associated with insulin resistance that confer an increased risk of the development of type 2 diabetes and cardiovascular disease. These abnormalities may include obesity, high blood pressure, abnormal cholesterol levels, proteinuria, and/or polycystic ovary syndrome.","Insulin Resistance Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015190","Sick Euthyroid Syndrome","C113170","Abnormal thyroid function tests, low triiodothyronine with elevated reverse triiodothyronine, in the setting of non-thyroidal illness.","Sick Euthyroid Syndrome | Euthyroid Sick Syndrome",,,,,,,,,,,,,,,"137991","Sick-euthyroid syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3827793","Transient Hypothyroxinemia of Prematurity","C113171","A common, self-limiting thyroid disorder seen in preterm infants that is characterized by abnormally low serum levels of thyroxine and free thyroxine with normal serum levels of thyroid stimulating hormone.","Transient Hypothyroxinemia of Prematurity | Hypothyroxinemia of Prematurity | THOP | Transient Congenital Hypothyroidism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887896","Primary Adrenal Insufficiency","C113172","A hormonal disorder that occurs when the adrenal glands fail to release adequate amounts of glucocorticoids (cortisol), mineralocorticoids (aldosterone, 11-deoxycorticosterone), and androgens (dehydroepiandrosterone) to meet physiologic needs, despite release of ACTH from the pituitary.","Primary Adrenal Insufficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813310","HSD3B1 wt Allele","C114368","Human HSD3B1 wild-type allele is located in the vicinity of 1p13.1 and is approximately 8 kb in length. This allele, which encodes 3 beta-hydroxysteroid dehydrogenase/delta 5->4-isomerase type 1 protein, is involved in both oxidative conversion of ketosteroids and the biosynthesis of hormonal steroids.","HSD3B1 wt Allele | 3-Beta-HSD, Placental Type Gene | 3-Beta-Hydroxysteroid Dehydrogenase 1 Gene | 3-Beta-Hydroxysteroid Dehydrogenase/Delta-Isomerase, Type I Gene | 3BETAHSD | 3BETAHSDI | 3BH | HSD3B | HSDB3 | HSDB3A | Hydroxy-Delta-5-Steroid Dehydrogenase, 3 Beta- and Steroid Delta-Isomerase 1 wt Allele | RP5-920G3.4 | SDR11E1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3489584","3 Beta-Hydroxysteroid Dehydrogenase/Delta 5->4-Isomerase Type 1, Human","C114369","3 beta-hydroxysteroid dehydrogenase/Delta 5->4-isomerase type 1 (373 aa, ~42 kDa) is encoded by the human HSD3B1 gene. This protein plays a role in both the biosynthesis of hormonal steroids and the oxidative conversion of ketosteroids.","3 Beta-Hydroxysteroid Dehydrogenase/Delta 5->4-Isomerase Type 1 | 3 Beta-Hydroxysteroid Dehydrogenase/Delta 5-->4-Isomerase Type 1 | 3 Beta-Hydroxysteroid Dehydrogenase/Delta 5-->4-Isomerase Type I | 3 Beta-Hydroxysteroid Dehydrogenase/Delta 5->4-Isomerase Type I | 3 Beta-Hydroxysteroid Dehydrogenase/Delta 5—>4-Isomerase Type 1 | 3 Beta-Hydroxysteroid Dehydrogenase/Delta 5—>4-Isomerase Type I | 3-Beta-HSD I | 3-Beta-Hydroxy-5-Ene Steroid Dehydrogenase | 3-Beta-Hydroxy-Delta(5)-Steroid Dehydrogenase | 3-Beta-Hydroxysteroid 3-Dehydrogenase | Delta-5-3-Ketosteroid Isomerase | EC 1.1.1.145 | EC 5.3.3.1 | HSD3B1 | Hydroxy-Delta-5-Steroid Dehydrogenase, 3 Beta-and Steroid Delta-Isomerase 1 | Progesterone Reductase | Short Chain Dehydrogenase/Reductase Family 11E | Short Chain Dehydrogenase/Reductase Family 11E, Member 1 | Steroid Delta-Isomerase | Trophoblast Antigen FDO161G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831524","Antepartum Uterine Rupture","C114370","An acute symptomatic tearing of the uterine wall prior to the onset of labor.","Antepartum Uterine Rupture | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0269608","Antepartum Hemorrhage","C114371","Excessive blood loss prior to onset of labor.","Antepartum Hemorrhage | Antenatal Bleeding",,,,,,,,,,,,,,,"434089","Antepartum hemorrhage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898700","Intrapartum Uterine Rupture","C114372","An acute symptomatic tearing of the uterine wall after the onset of labor.","Intrapartum Uterine Rupture | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829513","Intrapartum Shock","C114373","Severe loss of blood pressure leading to inadequate tissue perfusion after the onset of labor but prior to the delivery of the fetus.","Intrapartum Shock | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829514","Intrapartum Pyrexia","C114374","Elevated body temperature greater than or equal to 38C (100.4F) after the onset of labor but prior to the delivery of the fetus.","Intrapartum Pyrexia | Intrapartum Fever",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0269899","Early Postpartum Hemorrhage","C114375","Cumulative blood loss of greater than or equal to 1000 ML or blood loss accompanied by signs or symptoms of hypovolemia within 24 hours following the birth process (includes intrapartum loss). (reVITALize)","Early Postpartum Hemorrhage | Primary Postpartum Hemorrhage",,,,,,,,,,,,,,,"196488","Atonic postpartum hemorrhage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0473508","Late Postpartum Hemorrhage","C114376","Excessive blood loss between 24 hours after delivery through four weeks that requires intervention.","Late Postpartum Hemorrhage | Delayed Postpartum Hemorrhage | Secondary Postpartum Hemorrhage",,,,,,,,,,,,,,,"194109","Delayed AND/OR secondary postpartum hemorrhage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828503","Postpartum Uterine Inversion","C114377","Protrusion of the uterine fundus through the cervix when the placenta fails to detach from the uterus as it exits.","Postpartum Uterine Inversion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811247","PRSS1 wt Allele","C113758","Human PRSS1 wild-type allele is located in the vicinity of 7q34 and is approximately 4 kb in length. This allele, which encodes trypsin-1 protein, plays a role in proteolysis and digestion. Mutations in this gene are associated with both hereditary pancreatitis and trypsinogen deficiency.","PRSS1 wt Allele | Protease, Serine, 1 (Trypsin 1) wt Allele | Protease, Serine, 1 Gene | TRP1 | TRY1 | TRY4 | TRYP1 | Trypsinogen, Cationic Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041244","Trypsin-1","C113759","Trypsin-1 (247 aa, ~27 kDa) is encoded by the human PRSS1 gene. This protein is involved in proteolysis.","Trypsin-1 | Beta-trypsin | Cationic Trypsinogen | Digestive Zymogen | EC 3.4.21.4 | Nonfunctional Trypsin 1 | PRSS1 | Serine Protease 1 | Trypsin 1 | Trypsin I | Trypsinogen 1 | Trypsinogen A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830392","Drug Formulation Process, Not Otherwise Specified","C112970","A process that forms a dosage that is not otherwise specified.","Drug Formulation Process, Not Otherwise Specified | Dosage Formation, Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830096","Fluidized Bed Coating Method","C112971","A method that suspends a substrate in a fluidized bed while it is sprayed with a layer of coating material.","Fluidized Bed Coating Method | Coating, Fluid Bed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829321","Laser Drill Formulation Process","C112973","A process that uses a laser to drill holes in a tablet.","Laser Drill Formulation Process | Dosage Formation, Drilling, Laser",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828981","Molded Formulation Process","C112974","A process that forms a solid dosage unit by pouring or casting a melted agent into a prefabricated form.","Molded Formulation Process | Dosage Formation, Molding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828303","Roller Coating Method","C112975","A method that rolls a substrate such that it comes into contact with the coating material.","Roller Coating Method | Coating, Roller",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827259","Rotating Pan Coating Method","C112976","A method that agitates a substrate in a rotating pan while it is sprayed with a layer of coating material.","Rotating Pan Coating Method | Coating, Pan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421482","WASL Gene","C113224","This gene plays a role in actin polymerization.","WASL Gene | WASL | Wiskott-Aldrich Syndrome-Like Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812255","WASL wt Allele","C113225","Human WASL wild-type allele is located in the vicinity of 7q31.3 and is approximately 67 kb in length. This allele, which encodes neural Wiskott-Aldrich syndrome protein, is involved in the regulation of actin polymerization.","WASL wt Allele | N-WASP | NWASP | Wiskott-Aldrich Syndrome Gene-Like Gene | Wiskott-Aldrich Syndrome-Like wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1565159","Neural Wiskott-Aldrich Syndrome Protein, Human","C113226","Neural Wiskott-Aldrich syndrome protein (505 aa, ~55 kDa) is encoded by the human WASL gene. This protein plays a role in the modulation of actin fibril formation.","Neural Wiskott-Aldrich Syndrome Protein | N-WASP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424611","MFN2 Gene","C113227","This gene is involved in mitochondrial fusion.","MFN2 Gene | MFN2 | Mitofusin 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811170","MFN2 wt Allele","C113228","Human MFN2 wild-type allele is located in the vicinity of 1p36.22 and is approximately 33 kb in length. This allele, which encodes mitofusin-2 protein, plays a role in both GTP hydrolysis and mitochondrial fusion. Mutation of the gene is associated with Charcot-Marie-Tooth disease types 2A2 and 6.","MFN2 wt Allele | CMT2A | CMT2A2 | CPRP1 | HSG | Hyperplasia Suppressor Gene | KIAA0214 | MARF | Mitofusin 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1173198","MFN2 protein, human","C113229","Mitofusin-2 (757 aa, ~86 kDa) is encoded by the human MFN2 gene. This protein is involved in both mitochondrial fusion and GTP hydrolysis.","Mitofusin-2 | EC 3.6.5.- | MFN2 | Mitochondrial Assembly Regulatory Factor | Transmembrane GTPase MFN2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537742","MIR31 Gene","C113230","This gene may play a role in both the regulation of gene expression and tumor suppression.","MIR31 Gene | MIR31 | MicroRNA 31 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811721","MIR31 wt Allele","C113231","Human MIR31 wild-type allele is located in the vicinity of 9p21.3 and is approximately 0.1 kb in length. This allele, which encodes MIR31 pre-miRNA, may be involved in both tumor suppression and the modulation of transcription.","MIR31 wt Allele | MIRN31 | MicroRNA 31 wt Allele | hsa-mir-31 | miR-31 | miRNA31",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827382","MIR31 Pre-miRNA","C113232","MIR31 pre-miRNA (71 bases) is encoded by the human MIR31 gene. This ribonucleotide may play a role in both the regulation of gene transcription and tumor suppression.","MIR31 Pre-miRNA | Pre-MicroRNA 31 | Pre-miRNA 31 | Pre-miRNA MIR31",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826336","MYSM1 Gene","C113233","This gene is involved in both the deubiquitination of histone 2A and transcriptional regulation.","MYSM1 Gene | MYSM1 | Myb-Like, SWIRM and MPN Domains 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471779","Extended-release Onapristone","C113797","An extended-release (ER) formulation of onapristone, an orally bioavailable progesterone receptor (PR) antagonist, with antineoplastic activity. Onapristone binds to the PR and inhibits both PR activation and the associated expression of PR-responsive genes. This may inhibit PR-mediated proliferative effects in cancer cells overexpressing PR. PR is expressed on certain cancer cell types and plays a key role in proliferation and survival.","Extended-release Onapristone | ER Onapristone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828908","MSQOL-54 - Health Limit Vigorous Activities","C113990","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) Does your health limit you in these activities: Vigorous activities, such as running, lifting heavy objects, participating in strenuous sports.","MSQOL-54 - Health Limit Vigorous Activities | MSQL1-Health Limit Vigorous Activities | MSQL103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828909","MSQOL-54 - Health Limit Moderate Activities","C113991","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) Does your health limit you in these activities: Moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or playing golf.","MSQOL-54 - Health Limit Moderate Activities | MSQL1-Health Limit Moderate Activities | MSQL104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828911","MSQOL-54 - Health Limit Climbing Several Stairs","C113993","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) Does your health limit you in these activities: Climbing several flights of stairs.","MSQOL-54 - Health Limit Climbing Several Stairs | MSQL1-Health Limit Climb Several Flights | MSQL106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828912","MSQOL-54 - Health Limit Climbing One Stair","C113994","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) Does your health limit you in these activities: Climbing one flight of stairs.","MSQOL-54 - Health Limit Climbing One Stair | MSQL1-Health Limit Climb One Flight | MSQL107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828913","MSQOL-54 - Health Limit Bending, Kneeling or Stooping","C113995","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) Does your health limit you in these activities: Bending, kneeling, or Stooping.","MSQOL-54 - Health Limit Bending, Kneeling or Stooping | MSQL1-Health Limit Bending or Kneeling | MSQL108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828907","MSQOL-54 - Health Limit Walking More than A Mile","C113996","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) Does your health limit you in these activities: Walking more than a mile.","MSQOL-54 - Health Limit Walking More than A Mile | MSQL1-Health Limit Walk More Than Mile | MSQL109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828905","MSQOL-54 - Health Limit Walking Several Blocks","C113997","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) Does your health limit you in these activities: Walking several blocks.","MSQOL-54 - Health Limit Walking Several Blocks | MSQL1-Health Limit Walk Several Blocks | MSQL110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828906","MSQOL-54 - Health Limit Walking One Block","C113998","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) Does your health limit you in these activities: Walking One Block.","MSQOL-54 - Health Limit Walking One Block | MSQL1-Health Limit Walk One Block | MSQL111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828914","MSQOL-54 - Health Limit Bathing and Dressing Yourself","C113999","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) Does your health limit you in these activities: Bathing and dressing yourself.","MSQOL-54 - Health Limit Bathing and Dressing Yourself | MSQL1-Health Limit Bathing/Dressing Self | MSQL112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827083","Syk/JAK Inhibitor PRT062070","C113173","An orally bioavailable dual inhibitor of spleen tyrosine kinase (Syk) and Janus-associated kinases (JAK), with potential anti-inflammatory and antineoplastic activity. Upon oral administration, cerdulatinib specifically binds to and inhibits the activity of Syk, JAK1, and JAK3 with preferential inhibition of JAK1 and JAK3-dependent cytokine-mediated signaling and functional responses. This negatively affects the downstream JAK-STAT (signal transducer and activator of transcription) pathway, and leads to both reduced inflammation in various animal models and enhanced antiproliferative activity towards non-Hodgkin's lymphoma (NHL) cell lines. Syk is a non-receptor cytoplasmic tyrosine kinase involved in signal transduction in cells of hematopoietic origin including B cells, macrophages, basophils and neutrophils. Abnormal function of Syk has been implicated in several hematopoietic malignancies including NHL and chronic lymphocytic leukemia (CLL). The JAK-STAT pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","Cerdulatinib | CERDULATINIB | PRT-062070 | PRT062070 | Syk-JAK Inhibitor PRT062070 | Syk/JAK Inhibitor PRT062070",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL455245","Autologous CT7/MAGE-A3/WT1 mRNA-Electroporated Langerhans-Type Dendritic Cells","C113174","An autologous tumor cell vaccine containing CD34+ hematopoietic progenitor cell (HPC)-derived Langerhans-type dendritic cells (LCs) electroporated with mRNA encoding the full-length cancer-testis antigens, CT7 and melanoma-associated antigen 3 (MAGE-A3), and the self-differentiation tumor antigen, Wilms tumor 1 (WT1) with potential immunomodulating and antineoplastic activity. The autologous CT7/MAGE-A3/WT1 mRNA-electroporated Langerhans-type dendritic cells are prepared by drawing a blood sample containing the CD34+ HPCs from a cancer patient. The CD34+ HPCs are treated with a combination of cytokines which specifically support LC development, and the LC population is enriched and expanded ex vivo. The cultured LCs are allowed to mature for one day and then electroporated separately with CT7, MAGE-A3 or WT1 mRNA before final maturation. Upon intradermal administration into the patient, the mature LCs may activate cell-mediated immunity and induce both cytotoxic CD8+ T cells and CD4+ helper T cells against cancer cells expressing CT7, MAGE-A3 and WT1 tumor antigens. This may result in the immune-mediated inhibition of tumor cell proliferation, leading to tumor cell death. CT7 and MAGE-A3 are tumor-specific proteins overexpressed in a number of cancers but not in healthy tissues other than testis and placenta. WT1 is a transcription factor important in development and cancer pathogenesis, which is overexpressed in a variety of cancers, including multiple myeloma, leukemia, ovarian cancer, malignant mesothelioma, neural tumors and renal carcinoma.","Autologous CT7/MAGE-A3/WT1 mRNA-Electroporated Langerhans-Type Dendritic Cells | CT7/MAGE-A3/WT1 mRNA-Electroporated LCs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828041","SGRQ Past 4 Weeks Version - Wheeze Worse When Get Up in the Morning","C112686","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) If you wheeze, is it worse when you get up in the morning?","SGRQ Past 4 Weeks Version - Wheeze Worse When Get Up in the Morning | SGRQ02-Wheeze Worse in the Morning | SGRQ0209",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828077","SGRQ Past 4 Weeks Version - Describe Your Respiratory Condition","C112687","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) How would you describe your respiratory condition?","SGRQ Past 4 Weeks Version - Describe Your Respiratory Condition | SGRQ02-Describe Your Resp Condition | SGRQ0210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828072","SGRQ Past 4 Weeks Version - Held a Job","C112688","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) If you have ever held a job.","SGRQ Past 4 Weeks Version - Held a Job | SGRQ02-If You Have Ever Held a Job | SGRQ0211",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828053","SGRQ Past 4 Weeks Version - Sitting or Lying Still","C112689","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about what activities usually make you feel short of breath these days: Sitting or lying still.","SGRQ Past 4 Weeks Version - Sitting or Lying Still | SGRQ02-Sitting or Lying Still | SGRQ0212",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828047","SGRQ Past 4 Weeks Version - Walking Around the House","C112691","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about what activities usually make you feel short of breath these days: Walking around the house.","SGRQ Past 4 Weeks Version - Walking Around the House | SGRQ02-Walking Around the House | SGRQ0214",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815142","H3.3B","C113761","Human H3-3B wild-type allele is located in the vicinity of 17q25.1 and is approximately 9 kb in length. This allele, which encodes histone H3.3 protein, is involved in nucleosomal structure.","H3-3B wt Allele | H3 Histone Family Member 3B Gene | H3 Histone, Family 3B (H3.3B) Gene | H3 Histone, Family 3B Gene | H3.3 Histone B wt Allele | H3.3B | H3F3B | H3F3B wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814870","ATP1A1 wt Allele","C113763","Human ATP1A1 wild-type allele is located in the vicinity of 1p21 and is approximately 38 kb in length. This allele, which encodes sodium/potassium-transporting ATPase subunit alpha-1 protein, plays a role in both ATP metabolism and cation transport.","ATP1A1 wt Allele | ATPase Na+/K+ Transporting Subunit Alpha 1 wt Allele | ATPase, Na+/K+ Transporting, Alpha 1 Polypeptide Gene | ATPase, Na+/K+ Transporting, Alpha-1 Polypeptide Gene | CMT2DD | RP4-655J12.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813215","Sodium/Potassium-Transporting ATPase Subunit Alpha-1","C113764","Sodium/potassium-transporting ATPase subunit alpha-1 (1023 aa, ~113 kDa) is encoded by the human ATP1A1 gene. This protein is involved in both cation transport and ATP hydrolysis.","Sodium/Potassium-Transporting ATPase Subunit Alpha-1 | ATP1A1 | EC 3.6.3.9 | Na(+)/K(+) ATPase Alpha-1 Subunit | Na+, K+ ATPase Alpha Subunit | Na+/K+ ATPase 1 | Na, K-ATPase, Alpha-A Catalytic Polypeptide | Na,K-ATPase Alpha-1 Subunit | Na,K-ATPase Catalytic Subunit Alpha-A Protein | Sodium Pump 1 | Sodium Pump Subunit Alpha-1 | Sodium-Potassium ATPase Catalytic Subunit Alpha-1 | Sodium-Potassium-ATPase, Alpha 1 Polypeptide | Sodium-Potassium-ATPase, Alpha-1 Polypeptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811222","ATP2B3 wt Allele","C113766","Human ATP2B3 wild-type allele is located within Xq28 and is approximately 65 kb in length. This allele, which encodes plasma membrane calcium-transporting ATPase 3 protein, is involved in both cation transport and ATP hydrolysis. Mutation of the gene is associated with spinocerebellar ataxia, X-linked type 1.","ATP2B3 wt Allele | ATPase Plasma Membrane Ca2+ Transporting 3 wt Allele | ATPase, Ca(2+)-Transporting, Plasma Membrane, 3 Gene | ATPase, Ca++ Transporting, Plasma Membrane 3 Gene | CLA2 | Cerebellar Ataxia 2 (X-Linked) Gene | OPCA | PMCA3 | PMCA3a | Plasma Membrane Ca(2+)-ATPase, Type 3 Gene | SCAX1 | Spinocerebellar Ataxia, X-Linked 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1568751","ATP2B3 protein, human","C113767","Plasma membrane calcium-transporting ATPase 3 (1220 aa, ~134 kDa) is encoded by the human ATP2B3 gene. This protein plays a role in both ATP hydrolysis and calcium transport.","Plasma Membrane Calcium-Transporting ATPase 3 | ATP2B3 | Cilia and Flagella Associated Protein 39 | EC 3.6.3.8, Formerly | EC 7.2.2.10 | PMCA3 | Plasma Membrane Calcium ATPase | Plasma Membrane Calcium ATPase Isoform 3 | Plasma Membrane Calcium Pump | Plasma Membrane Calcium Pump Isoform 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268307","Direct Hyperbilirubinemia","C113768","Abnormally high level of conjugated bilirubin in the blood.","Direct Hyperbilirubinemia | Conjugated Hyperbilirubinemia",,,,,,,,,,,,,,,"4245547","Conjugated hyperbilirubinemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3830712","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - First Suicide Attempt Actual Lethality/Medical Damage","C113942","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Initial/first attempt actual lethality/medical damage.","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - First Suicide Attempt Actual Lethality/Medical Damage | CSS10-First Attempt Damage | CSS1020B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3715069","MYSM1 wt Allele","C113234","Human MYSM1 wild-type allele is located in the vicinity of 1p32.1 and is approximately 45 kb in length. This allele, which encodes deubiquitinase MYSM1 protein, plays a role in histone 2A deubiquitination and chromatin remodeling.","MYSM1 wt Allele | 2A-DUB | 2ADUB | KIAA1915 | Myb-Like, SWIRM and MPN Domains 1 wt Allele | RP4-592A1.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1958029","Histone H2A Deubiquitinase MYSM1, Human","C113235","Deubiquitinase MYSM1 (828 aa, ~95 kDa) is encoded by the human MYSM1 gene. This protein is involved in the deubiquitination of histone 2A, which leads to chromatin remodeling and transcriptional activation.","Deubiquitinase MYSM1 | 2A-DUB | EC 3.4.19.- | Histone H2A Deubiquitinase MYSM1 | MYSM1 | Myb-Like, SWIRM and MPN Domain-Containing Protein 1 | Myb-Like, SWIRM and MPN Domains-Containing Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827639","VFQ25-Interviewer Administered Format - Difficulty Finding Something On a Shelf","C112735","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Difficulty With Activities: Because of your eyesight, how much difficulty do you have finding something on a crowded shelf?","VFQ25-Interviewer Administered Format - Difficulty Finding Something On a Shelf | VFQ1-Difficulty Finding on Crowded Shelf | VFQ107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827632","VFQ25-Interviewer Administered Format - Difficulty Reading Street Signs","C112736","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Difficulty With Activities: How much difficulty do you have reading street signs or the names of stores?","VFQ25-Interviewer Administered Format - Difficulty Reading Street Signs | VFQ1-Difficulty Reading Street Signs | VFQ108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827638","VFQ25-Interviewer Administered Format - Difficulty Going Down Steps at Night","C112737","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Difficulty With Activities: Because of your eyesight, how much difficulty do you have going down steps, stairs, or curbs in dim light or at night?","VFQ25-Interviewer Administered Format - Difficulty Going Down Steps at Night | VFQ1-Difficulty Going Down Step at Night | VFQ109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827636","VFQ25-Interviewer Administered Format - Difficulty Noticing Objects Off to the Side While Walking","C112738","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Difficulty With Activities: Because of your eyesight, how much difficulty do you have noticing objects off to the side while you are walking along?","VFQ25-Interviewer Administered Format - Difficulty Noticing Objects Off to the Side While Walking | VFQ1-Difficulty Noticing Objects to Side | VFQ110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827629","VFQ25-Interviewer Administered Format - Difficulty Seeing How People React","C112739","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Difficulty With Activities: Because of your eyesight, how much difficulty do you have seeing how people react to things you say?","VFQ25-Interviewer Administered Format - Difficulty Seeing How People React | VFQ1-Difficulty Seeing How People React | VFQ111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828897","MSQOL-54 - Physical Health Cut Down Time on Work","C114000","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of your physical health: Cut down on the amount of time you could spend on work or other activities.","MSQOL-54 - Physical Health Cut Down Time on Work | MSQL1-Phys Health: Cut Work Time | MSQL113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828898","MSQOL-54 - Physical Health Accomplish Less","C114001","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of your physical health: Accomplished less than you would like.","MSQOL-54 - Physical Health Accomplish Less | MSQL1-Phys Health: Accomplish Less | MSQL114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828895","MSQOL-54 - Physical Health Limited in the Kind of Work","C114002","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of your physical health: Were limited in the kind of work or other activities.","MSQOL-54 - Physical Health Limited in the Kind of Work | MSQL1-Phys Health: Limit Kind of Work | MSQL115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830295","Experimental Organism Benign Nephroblastoma Neoplasm","C114235","A benign embryonal neoplasm of the kidney.","Experimental Organism Benign Nephroblastoma Neoplasm | NEPHROBLASTOMA, BENIGN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472211","Ventriculus","C114236","A thick-walled muscular pouch located beneath the proventriculus that is responsible for digestion in birds, insects and invertebrates.","Ventriculus | VENTRICULUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828046","SGRQ Past 4 Weeks Version - Walking Outside on Level Ground","C112692","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about what activities usually make you feel short of breath these days: Walking outside on level ground.","SGRQ Past 4 Weeks Version - Walking Outside on Level Ground | SGRQ02-Walking Outside on Level Ground | SGRQ0215",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828045","SGRQ Past 4 Weeks Version - Walking Up a Flight of Stairs","C112693","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about what activities usually make you feel short of breath these days: Walking up a flight of stairs.","SGRQ Past 4 Weeks Version - Walking Up a Flight of Stairs | SGRQ02-Walking Up a Flight of Stairs | SGRQ0216",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828044","SGRQ Past 4 Weeks Version - Walking Up Hills","C112694","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about what activities usually make you feel short of breath these days: Walking up hills.","SGRQ Past 4 Weeks Version - Walking Up Hills | SGRQ02-Walking Up Hills | SGRQ0217",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828057","SGRQ Past 4 Weeks Version - Playing Sports or Other Physical Activities","C112695","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about what activities usually make you feel short of breath these days: Playing sports or other physical activities.","SGRQ Past 4 Weeks Version - Playing Sports or Other Physical Activities | SGRQ02-Playing Sports | SGRQ0218",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828080","SGRQ Past 4 Weeks Version - Coughing Hurts","C112696","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are more questions about your cough and shortness of breath these days: Coughing hurts.","SGRQ Past 4 Weeks Version - Coughing Hurts | SGRQ02-Coughing Hurts | SGRQ0219",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828079","SGRQ Past 4 Weeks Version - Coughing Makes Me Tired","C112697","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are more questions about your cough and shortness of breath these days: Coughing makes me tired.","SGRQ Past 4 Weeks Version - Coughing Makes Me Tired | SGRQ02-Coughing Makes Me Tired | SGRQ0220",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828054","SGRQ Past 4 Weeks Version - Short of Breath When I Talk","C112698","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are more questions about your cough and shortness of breath these days: I am short of breath when I talk.","SGRQ Past 4 Weeks Version - Short of Breath When I Talk | SGRQ02-Short of Breath When I Talk | SGRQ0221",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828055","SGRQ Past 4 Weeks Version - Short of Breath When Bend Over","C112699","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are more questions about your cough and shortness of breath these days: I am short of breath when I bend over.","SGRQ Past 4 Weeks Version - Short of Breath When Bend Over | SGRQ02-Short of Breath When Bend Over | SGRQ0222",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL458226","NY-ESO-1/GLA-SE Vaccine ID-G305","C113432","A cancer vaccine composed of a recombinant form of the tumor antigen NY-ESO-1 and glucopyranosyl lipid adjuvant (GLA)-stable emulsion (GLA-SE), with potential antineoplastic and immunomodulating activities. Upon intramuscular injection, the adjuvant portion of the NY-ESO-1/GLA-SE vaccine ID-G30 binds to toll-like receptor subtype 4 (TLR-4) expressed on dendritic cells (DCs), monocytes, macrophages and B cells. The activated DCs present the NY-ESO-1 antigen to Th1 CD4 T-lymphocytes. This leads to the induction of cytotoxic T lymphocytes (CTLs) and the killing of NY-ESO-1-expressing tumor cells. This vaccine also induces specific antibody responses and increases the production of inflammatory cytokines.","NY-ESO-1/GLA-SE Vaccine ID-G305 | ID-G305 | IDC-G305",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL458227","PI3K delta/gamma inhibitor RP6530","C113433","An orally active, highly selective, small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. Upon administration, tenalisib inhibits the PI3K delta and gamma isoforms and prevents the activation of the PI3K/AKT-mediated signaling pathway. This may lead to a reduction in cellular proliferation in PI3K delta/gamma-expressing tumor cells. In addition, this agent modulates inflammatory responses through various mechanisms, including the inhibition of both the release of reactive oxygen species (ROS) from neutrophils and tumor necrosis factor (TNF)-alpha activity. Unlike other isoforms of PI3K, the delta and gamma isoforms are overexpressed primarily in hematologic malignancies and in inflammatory and autoimmune diseases. By selectively targeting these isoforms, PI3K signaling in normal, non-neoplastic cells is minimally impacted or not affected at all, which minimizes the side effect profile for this agent.","Tenalisib | 3-(3-Fluorophenyl)-2-((1S)-1-((7H-purin-6-yl)amino)propyl)-4H-1-benzopyran-4-one | 4H-1-Benzopyran-4-one, 3-(3-fluorophenyl)-2-((1S)-1-(9H-purin-6-ylamino)propyl)- | RP 6530 | RP-6530 | RP6530 | TENALISIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830710","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - First Suicide Attempt Potential Lethality","C113943","Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Initial/first attempt potential lethality.","C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - First Suicide Attempt Potential Lethality | CSS10-First Attempt Potential | CSS1020C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827311","FSS - Motivation is Lower When Fatigued","C113944","Fatigue Severity Scale (FSS) My motivation is lower when I am fatigued.","FSS - Motivation is Lower When Fatigued | FSS01-Motivation Is Lower When Fatigued | FSS0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830067","FSS - I Am Easily Fatigued","C113946","Fatigue Severity Scale (FSS) I am easily fatigued.","FSS - I Am Easily Fatigued | FSS01-I Am Easily Fatigued | FSS0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830071","FSS - Fatigue Interferes With Physical Functioning","C113947","Fatigue Severity Scale (FSS) Fatigue interferes with my physical functioning.","FSS - Fatigue Interferes With Physical Functioning | FSS01-Interferes With Phys Function | FSS0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830073","FSS - Fatigue Causes Frequent Problems","C113948","Fatigue Severity Scale (FSS) Fatigue causes frequent problems for me.","FSS - Fatigue Causes Frequent Problems | FSS01-Fatigue Causes Frequent Problems | FSS0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830068","FSS - Fatigue Prevents Sustained Physical Functioning","C113949","Fatigue Severity Scale (FSS) My fatigue prevents sustained physical functioning.","FSS - Fatigue Prevents Sustained Physical Functioning | FSS01-Prevents Sustained Phys Function | FSS0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830072","FSS - Fatigue Interferes With Carrying Out Duties","C113950","Fatigue Severity Scale (FSS) Fatigue interferes with carrying out certain duties and responsibilities.","FSS - Fatigue Interferes With Carrying Out Duties | FSS01-Fatigue Interferes With Duties | FSS0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830069","FSS - Fatigue is Among Most Disabling Symptoms","C113951","Fatigue Severity Scale (FSS) Fatigue is among my three most disabling symptoms.","FSS - Fatigue is Among Most Disabling Symptoms | FSS01-Among My 3 Most Disabling Symptoms | FSS0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830070","FSS - Fatigue Interferes With Work","C113952","Fatigue Severity Scale (FSS) Fatigue interferes with my work, family, or social life.","FSS - Fatigue Interferes With Work | FSS01-Fatigue Interferes With My Life | FSS0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831336","BLCS - Lost Control of Your Bladder","C113953","Bladder Control Scale (BLCS) During the past 4 weeks, how often have you lost control of your bladder or had an accident?","BLCS - Lost Control of Your Bladder | BLCS01-Lost Control of Bladder | BLCS0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831339","BLCS - Almost Lost Control of Your Bladder","C113954","Bladder Control Scale (BLCS) During the past 4 weeks, how often have you almost lost control of your bladder or had an accident?","BLCS - Almost Lost Control of Your Bladder | BLCS01-Almost Lost Control of Bladder | BLCS0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831337","BLCS - Bladder Problems Restrict Overall Lifestyle","C113956","Bladder Control Scale (BLCS) During the past 4 weeks, how much have bladder problems restricted your overall lifestyle?","BLCS - Bladder Problems Restrict Overall Lifestyle | BLCS01-Bladder Restricted Lifestyle | BLCS0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831236","BWCS - Been Constipated","C113957","Bowel Control Scale (BWCS) During the past 4 weeks, how often have you been constipated?","BWCS - Been Constipated | BWCS01-Been Constipated | BWCS0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831234","BWCS - Lost Control of Your Bowels","C113958","Bowel Control Scale (BWCS) During the past 4 weeks, how often have you lost control of your bowels or had an accident?","BWCS - Lost Control of Your Bowels | BWCS01-Lost Control of Bowels | BWCS0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827635","VFQ25-Interviewer Administered Format - Difficulty Picking Out and Matching Own Clothes","C112740","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Difficulty With Activities: Because of your eyesight, how much difficulty do you have picking out and matching your own clothes?","VFQ25-Interviewer Administered Format - Difficulty Picking Out and Matching Own Clothes | VFQ1-Difficulty Picking Out Own Clothes | VFQ112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827626","VFQ25-Interviewer Administered Format - Difficulty Visiting People","C112741","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Difficulty With Activities: Because of your eyesight, how much difficulty do you have visiting with people in their homes, at parties, or in restaurants?","VFQ25-Interviewer Administered Format - Difficulty Visiting People | VFQ1-Difficulty Visiting With People | VFQ113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827637","VFQ25-Interviewer Administered Format - Difficulty Going Out to See Movies","C112742","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Difficulty With Activities: Because of your eyesight, how much difficulty do you have going out to see movies, plays, or sports events?","VFQ25-Interviewer Administered Format - Difficulty Going Out to See Movies | VFQ1-Difficulty Going Out to See Movies | VFQ114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827645","VFQ25-Interviewer Administered Format - Are You Currently Driving","C112743","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Difficulty With Activities: Are you currently driving, at least once in a while?","VFQ25-Interviewer Administered Format - Are You Currently Driving | VFQ1-Are You Currently Driving | VFQ115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827616","VFQ25-Interviewer Administered Format - Main Reason You Gave Up Driving","C112745","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Difficulty With Activities: If gave up driving, was that mainly because of your eyesight, mainly for some other reason, or because of both your eyesight and other reasons?","VFQ25-Interviewer Administered Format - Main Reason You Gave Up Driving | VFQ1-Main Reason You Gave Up Driving | VFQ115B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2274020","Enterococcus thailandicus","C114243","A species of facultatively anaerobic, Gram-positive, spherical or ovoid shaped bacteria arranged in pairs or chains, in the phylum Firmicutes. This species is nonmotile, non-spore forming, catalase negative, hydrolyzes arginine and esculin, but not starch or gelatin, weakly positive for blood hemolysis, does not reduce nitrate, and ferments glucose. E. thailandicus has been isolated from fermented sausages produced in Thailand and is not yet known to be pathogenic to humans.","Enterococcus thailandicus | ENTEROCOCCUS THAILANDICUS | Enterococcus sanguinicola",,,,,,,,,,,,,,,"40486671","Enterococcus thailandicus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0445726","Atopobium rimae","C114244","A species of strictly anaerobic, Gram-positive, rod or elliptical shaped bacteria arranged in single element, pairs or chains, in the phylum Actinobacteria. This species is nonmotile, non-spore forming, negative for indole production and nitrate reduction, ferments glucose to yield lactic acid, acetic acid and formic acid, and does not produce gas from glucose fermentation. A. rimae is found in the normal gingival flora but can cause odontogenic infection, chronic periodontitis and bacteremia in humans.","Atopobium rimae | ATOPOBIUM RIMAE | Lactobacillus rimae",,,,,,,,,,,,,,,"4015384","Atopobium rimae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1017763","Peptoniphilus harei","C114245","A species of obligately anaerobic, Gram-positive, cocci shaped bacteria arranged in pairs, short chains, tetrads or small clusters, in the phylum Firmicutes. This species is nonmotile, non-spore forming, indole positive, produce butyric acid and gas in peptone yeast extract medium with glucose, negative for urease and nitrate reduction, produces coagulase, and does not ferment carbohydrates. P. harei is an opportunistic pathogen and has been isolated from antral washout specimens, pus from the peritoneal cavity, infected sacral sores, and abscesses of the face, neck, breast, and thigh.","Peptoniphilus harei | PEPTONIPHILUS HAREI | Peptostreptococcus harei | Schleiferella harei",,,,,,,,,,,,,,,"4334944","Peptoniphilus harei",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3810657","Transmembrane and Coiled-Coil Domains Protein 1, Human","C114415","Transmembrane and coiled-coil domains protein 1 (653 aa, ~72 kDa) is encoded by the human TMCC1 gene. This protein has no known function.","Transmembrane and Coiled-Coil Domains Protein 1 | TMCC1 | Transmembrane and Coiled-Coil Domains 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420683","TECTA Gene","C114416","This gene plays a role in hearing.","TECTA Gene | TECTA | Tectorin Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813718","TECTA wt Allele","C114417","Human TECTA wild-type allele is located within 11q22-q24 and is approximately 90 kb in length. This allele, which encodes alpha-tectorin protein, is involved in the structure of the tectorial membrane. Mutation of the gene is associated with autosomal dominant deafness 8/12 and autosomal recessive deafness 21.","TECTA wt Allele | DFNA12 | DFNA8 | DFNB21 | Tectorin Alpha wt Allele | Tectorin, Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815899","Alpha-Tectorin","C114418","Alpha-tectorin (2155 aa, ~240 kDa) is encoded by the human TECTA gene. This protein plays a role in hearing.","Alpha-Tectorin | Tectorin Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0546981","Lactation Suppression","C114419","Active suspension of lactation using a medical or physical intervention.","Lactation Suppression | ",,,,,,,,,,,,,,,"4182281","Inhibition of lactation procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1823249","TBCEL Gene","C114421","This gene is involved in tubulin turnover.","TBCEL Gene | TBCEL | Tubulin Folding Cofactor E-Like Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811848","TBCEL wt Allele","C114422","Human TBCEL wild-type allele is located in the vicinity of 11q23.3 and is approximately 67 kb in length. This allele, which encodes tubulin-specific chaperone cofactor E-like protein, plays a role in the modulation of tubulin metabolism.","TBCEL wt Allele | EL | El | LRRC35 | Leucine Rich Repeat Containing 35 Gene | MGC10233 | Tubulin Folding Cofactor E-Like wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL458228","PI3K-delta inhibitor INCB050465","C113434","An inhibitor of the delta isoform of phosphoinositide-3 kinase (PI3K) with potential antineoplastic activity. Parsaclisib inhibits the delta isoform of PI3K and prevents the activation of the PI3K/AKT signaling pathway. This both decreases proliferation and induces cell death in PI3K-delta-overexpressing tumor cells. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic disease and cell lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.","Parsaclisib | (4R)-4-(3-((1S)-1-(4-Amino-3-methyl-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one | IBI376 | INCB 50465 | INCB-50465 | INCB050465 | INCB50465 | PARSACLISIB | WHO 10589",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL458229","Wnt-5a Mimic Hexapeptide Foxy-5","C113435","A formylated, six amino acid, Wnt5a-derived peptide and wnt-5a mimetic with potential anti-metastatic activity. Upon intravenous administration, Wnt-5a mimic hexapeptide foxy-5 binds to and activates the wnt-5a receptors, Frizzled-2 and -5, which activates wnt-5a-mediated signaling. Increased wnt-5a signaling may inhibit endothelial tumor cell migration and invasion. This may decrease metastasis of susceptible tumor cells. However, foxy-5 does not affect tumor cell proliferation or apoptosis. Foxy-5 lacks a heparan sulfate-binding domain and contains a formyl group on its NH2-terminal methionine residue which decreases in vivo degradation. Decreased expression of wnt-5a protein is associated with increased motility of certain tumor cell types.","Wnt-5a Mimic Hexapeptide Foxy-5 | FOXY-5 | Foxy-5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL458231","innate defense regulator SGX942","C113437","A synthetic, 5-amino acid peptide and Innate Defense Regulator (IDR), with immunomodulating, anti-inflammatory, anti-infective and anti-mucositis activities. Upon intravenous administration, dusquetide binds to the ZZ domain of sequestosome-1, also called p62, and activates regulatory signaling transduction pathways involved in the modulation of the innate immune system, such as those mediated by mitogen-activated protein kinase (MAPK) p38 and CCAAT-enhancer-binding protein. This agent promotes monocyte and macrophage recruitment to, and accelerates healing in damaged and infected tissue; it suppresses inflammation through the regulation of the expression of multiple cytokines. This agent may prevent or decrease chemo- or radiotherapy-induced mucositis as well as other types of infection. p62, an intracellular adaptor protein that functions downstream of certain signaling receptors, plays a key role in the activation of the innate immune system.","Dusquetide | DUSQUETIDE | IMX 942 | Innate Defense Regulator SGX942 | L-Alaninamide, L-arginyl-L-isoleucyl-L-valyl-L-prolyl- | SGX942",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813554","PAXIP1 wt Allele","C112903","Human PAXIP1 wild-type allele is located in the vicinity of 7q36 and is approximately 59 kb in length. This allele, which encodes PAX-interacting protein 1, plays a role in the modulation of both gene transcription and the response to DNA damage.","PAXIP1 wt Allele | CAGF28 | CAGF29 | PACIP1 | PAX Interacting (With Transcription-Activation Domain) Protein 1 wt Allele | PAXIP1L | PTIP | TNRC2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1436935","PAX-Interacting Protein 1, Human","C112904","PAX-interacting protein 1 (1069 aa, ~121 kDa) is encoded by the human PAXIP1 gene. This protein is involved in both DNA damage responses and transcription regulation.","PAX-Interacting Protein 1 | PAX Transactivation Activation Domain-Interacting Protein | PAX Transactivation Domain-Interacting Protein | PAX Transcription Activation Domain Interacting Protein 1 Like | PAXIP1 | Protein Encoded By CAG Trinucleotide Repeats",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830168","FDA eManufacturing Terminology","C112906","Terminology developed to support manufacturing efforts of the FDA.","FDA eManufacturing Terminology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221151","Projectile Vomiting","C113480","Forceful expulsion of the contents of the stomach through the mouth.","Projectile Vomiting | ",,,,,,,,,,,,,,,"4312477","Projectile vomiting",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0266836","Infantile Colic","C113481","Paroxysms of irritability, fussing or crying that starts and stops without obvious cause in an infant up to four months of age without failure to thrive. Episodes last three or more hours per day for at least three days per week for at least on week.","Infantile Colic | Colic | Infant Colic",,,,,,,,,,,,,,,"4146835","Infantile colic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0270858","Abdominal Migraine","C113482","Paroxysmal episodes of intense, acute periumbilical pain that lasts for one or more hours with intervening periods of usual health lasting weeks to months, with no evidence of an inflammatory, anatomic, metabolic, or neoplastic process that explains the symptoms. The pain interferes with normal activities and is associated with at least two of the following symptoms: anorexia, nausea, vomiting, headache, photophobia, and/or pallor.","Abdominal Migraine | ",,,,,,,,,,,,,,,"4294246","Abdominal migraine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0021933","Intussusception","C113484","Telescoping or invagination of a part of the intestine into an adjacent segment.","Intussusception | INTUSSUSCEPTION",,,,,,,,,,,,,,,"197034","Intussusception of intestine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015938","Fetal Macrosomia","C113486","A fetus exceeding 4500 grams.","Fetal Macrosomia | ",,,,,,,,,,,,,,,"434758","Exceptionally large at birth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828803","Non-Rh Blood Group Isoimmunization","C113487","The mother develops antibodies against red blood cell non-Rhesus antigens. This may lead to potential fetal adverse outcomes such as anemia.","Non-Rh Blood Group Isoimmunization | Blood Group Isoimmunization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827231","Time of Onset of Labor","C113489","The time when regular uterine contractions began that resulted in labor with or without the use of pharmacological and/or mechanical interventions. (reVITALize)","Time of Onset of Labor | Time of the Onset of Labor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827664","Vapor Disposition Coating Method","C112977","A method that condenses a vaporized coating material onto a substrate.","Vapor Disposition Coating Method | Coating, Vapor Disposition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830389","Drying Method, Not Otherwise Specified","C112978","A process that is not otherwise specified, which removes water or a volatile solvent by evaporation.","Drying Method, Not Otherwise Specified | Drying, Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830104","Flash Drying Method","C112979","A process that removes water or volatile solvents from a bed of solids by relying on absorption of heat radiation by those solvents.","Flash Drying Method | Drying, Flash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828949","Moving Bed Drying Method","C112981","A process that removes water or volatile solvents from an agitated or tumbling bed of solids by relying on heat transfer from the equipment surface or a hot gas to the solid sample.","Moving Bed Drying Method | Drying, Moving Bed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828417","Radiant Heating Drying Method","C112982","A process that removes water or volatile solvents from a bed of solids by relying on absorption of heat radiation by those solvents","Radiant Heating Drying Method | Drying, Radiant Heating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827958","Spray Heating Drying Method","C112983","A process that removes water or volatile solvents from a bed of solids or a slurry using a large volumetric flow of hot air","Spray Heating Drying Method | Drying, Spray",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811107","Tubulin-Specific Chaperone Cofactor E-Like Protein, Human","C114423","Tubulin-specific chaperone cofactor E-like protein (424 aa, ~48 kDa) is encoded by the human TBCEL gene. This protein is involved in the regulation of microtubule dynamics through the modulation of tubulin degradation.","Tubulin-Specific Chaperone Cofactor E-Like Protein | Catastrophin | E-Like | E-Like Protein | EL | Leucine-Rich Repeat-Containing Protein 35 | TBCEL | Tubulin-Specific Chaperone E-Like",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539856","SSH2 Gene","C114424","This gene plays a role in both actin filament dynamics and protein dephosphorylation.","SSH2 Gene | SSH2 | Slingshot Protein Phosphatase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1999624","Protein Phosphatase Slingshot Homolog 2, Human","C114426","Protein phosphatase Slingshot homolog 2 (1423 aa, ~158 kDa) is encoded by the human SSH2 gene. This protein plays a role in both the regulation of actin polymerization and the dephosphorylation of proteins.","Protein Phosphatase Slingshot Homolog 2 | EC 3.1.3.16 | EC 3.1.3.48 | SSH-2L | SSH-Like Protein 2 | SSH2 | Slingshot Homolog 2 | hSSH-2L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422678","SLC26A6 Gene","C114427","This gene is involved in acid-base homeostasis.","SLC26A6 Gene | SLC26A6 | Solute Carrier Family 26 (Anion Exchanger), Member 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814520","SLC26A6 wt Allele","C114428","Human SLC26A6 wild-type allele is located in the vicinity of 3p21.3 and is approximately 10 kb in length. This allele, which encodes solute carrier family 26 member 6 protein, plays a role in the modulation of chloride transport.","SLC26A6 wt Allele | DKFZp586E1422 | Solute Carrier Family 26 (Anion Exchanger), Member 6 wt Allele | Solute Carrier Family 26, Member 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1434701","Solute Carrier Family 26 Member 6, Human","C114429","Solute carrier family 26 member 6 (759 aa, ~83 kDa) is encoded by the human SLC26A6 gene. This protein is involved in chloride exchange activity.","Solute Carrier Family 26 Member 6 | Anion Exchange Transporter | Anion Transporter 1 | Pendrin L1 | Pendrin-L1 | Pendrin-Like Protein 1 | SLC26A6 | SLC26A6b | Sulfate Anion Transporter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796324","irinotecan/oxaliplatin","C11442","A regimen consisting of irinotecan and oxaliplatin that can be used in the treatment of pancreatic and colorectal cancers, and appendiceal adenocarcinoma.","IROX Regimen | CPT-11/L-OHP | IROX | Irinotecan-Oxaliplatin | Irinotecan-Oxaliplatin Regimen | Irinotecan/Oxaliplatin | Irinotecan/Oxaliplatin Regimen | Oxaliplatin-Irinotecan | Oxaliplatin/Irinotecan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0530774","Recombinant Globulin Component Macrophage-activating Factor","C113798","A recombinant form of naturally-occurring GC (group-specific component) protein-derived macrophage-activating factor (GC-MAF). GC is also known as vitamin D binding protein (VDBP). GC-MAF promotes macrophage activation.","Recombinant Globulin Component Macrophage-activating Factor | Recombinant GC Protein-derived Macrophage-activating Factor | Recombinant GC-MAF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0939876","Uncaria tomentosa Extract","C113799","An extract of Uncaria tomentosa (U. tomentosa), also called Cat's claw, a native Amazonian plant belonging to the Rubiaceae species, with potential anti-inflammatory, immunomodulating, antioxidant and antineoplastic activities. Although the exact mechanism(s) by which U. tomentosa extract exerts its effect(s) has yet to be fully elucidated, this extract may inhibit the proliferation of certain types of cancer cells. This extract may modulate inflammatory and immune responses through the stimulation of T- and B-lymphocytes and certain cytokines, including interleukin (IL)-1, IL-6 and tumor necrosis factor-alpha (TNF-a). Components in U. tomentosa may both induce repair of chemically-induced DNA damage and scavenge free radicals, which may protect against reactive oxygen species (ROS)-mediated cellular damage. In addition, this extract stimulates myelopoiesis, which may prevent chemotherapy-induced neutropenia.","Uncaria tomentosa Extract | CAT'S CLAW | Cat's Claw Herbal Extract",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471781","Oxidized Avidin","C113800","An oxidized form of the glycoprotein avidin, that can be used as a linking agent for tissue-pretargeted radionuclide therapy. Upon intralesional administration, the aldehyde groups of oxidized avidin strongly bind to the amino groups on tissue proteins, via the formation of Schiff bases.  As avidin is able to strongly bind to biotin, intravenous administration of radiolabeled biotin may lead to the selective eradication of the pre-targeted tumor cells.","Oxidized Avidin | AvidinOX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810518","SALL4 wt Allele","C112907","Human SALL4 wild-type allele is located in the vicinity of 20q13.2 and is approximately 18 kb in length. This allele, which encodes Sal-like protein 4, is involved in both the positive and negative regulation of transcription. Mutation of the gene is associated with Duane-radial ray syndrome.","SALL4 wt Allele | DRRS | HSAL4 | IVIC | Sal (Drosophila)-Like 4 Gene | Sal-Like 4 (Drosophila) Gene | Sal-Like 4 Gene | Spalt Like Transcription Factor 4 wt Allele | Spalt-Like Transcription Factor 4 Gene | Spalt-Like Transcription Factor 4 wt Allele | ZNF797 | dJ1112F19.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL372759","SALL4 protein, human","C112908","Sal-like protein 4 (1053 aa, ~112 kDa) is encoded by the human SALL4 gene. This protein plays a role in self-renewal and maintenance of both embryonic and hematopoietic stem cells.","Sal-Like Protein 4 | SALL4 | Spalt-Like Transcription Factor 4 | Zinc Finger Protein 797 | Zinc Finger Protein SALL4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825463","HEXIM1 Gene","C112915","This gene is involved in the modulation of gene transcription.","HEXIM1 Gene | HEXIM1 | Hexamethylene Bis-Acetamide Inducible 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811166","HEXIM1 wt Allele","C112916","Human HEXIM1 wild-type allele is located in the vicinity of 17q21.31 and is approximately 5 kb in length. This allele, which encodes protein HEXIM1, plays a role in transcriptional repression.","HEXIM1 wt Allele | CLP-1 | CLP1 | EDG1 | HIS1 | Hexamethylene Bis-Acetamide Inducible 1 wt Allele | Hexamethylene-Bis-Acetamide-Inducible Transcript 1 Gene | MAQ1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL455246","DACH-Platin Micelle NC-4016","C113175","Polymeric micellar nanoparticles containing diaminocyclohexane platinum (DACH-platin or DACH-Pt) with potential antineoplastic activity. DACH-platin micelle NC-4016 is prepared through the formation of a polymer-metal complex between DACH-platin and the polyethylene glycol-poly (glutamic acid) block copolymer, PEG-P(Glu). DACH-platin, an active metabolite of the platinum-based antineoplastic agent oxaliplatin, is highly hydrophobic and toxic when administered systemically. The use of polymeric micelles incorporating DACH-platin may both increase cell permeability and enhance the retention of the agent. This allows an extended half-life in the blood circulation and a selective and high accumulation of DACH-platin at tumor sites. This results in increased anticancer efficacy while reducing side effects due to DACH-platin toxicity. Upon intravenous administration and internalization by tumor cells, DACH-platin binds to and causes both inter- and intra-strand cross-links in DNA, forming platinum adducts and triggering tumor cell apoptosis.","DACH-Platin Micelle NC-4016 | DACH-Pt/m NC-4016 | Dach-Platin Micelle NC-4016 | Diaminocyclohexane Platinum Micelle NC-4016 | NC-4016",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471809","DNR-expressing Nasopharyngeal Carcinoma-specific Cytotoxic T-Lymphocytes","C114378","A preparation of autologous, dominant-negative receptor (DNR)-expressing nasopharyngeal carcinoma (NPC)-specific cytotoxic T-lymphocytes (CTLs), with potential antineoplastic activity. The DNR-expressing NPC-specific CTLs specifically target Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1), latent membrane proteins (LMP) and BamHIA rightward frame 1 (BARF1), and are transduced with a retroviral vector expressing DNR, a dominant-negative form of the transforming growth factor beta (TGFb) receptor, which blocks TGF-beta-mediated signaling. Upon administration, the CTLs recognize and target NPC cells, which may result in both CTL-mediated cell lysis and the inhibition of tumor cell proliferation. Tumor-expressed TGF-beta inhibits T-lymphocyte activation and expansion; resistance to TGF-beta allows for optimal CTL activity. EBV infection plays a key role in NPC tumorigenesis.","DNR-expressing Nasopharyngeal Carcinoma-specific Cytotoxic T-Lymphocytes | DNR NPC-specific CTLs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471810","Copper Cu 64 Plerixafor","C114379","A radioconjugate labeled with the positron-emitting radioisotope, copper Cu 64, and also composed of plerixafor, a bicyclam and hematopoietic stem cell-mobilizing agent that targets the chemokine receptor CXCR4, with tumor imaging potential using positron emission tomography (PET)/computed tomography (CT). Upon administration, the plerixafor moiety blocks the binding of stromal cell-derived factor-1alpha (SDF-1alpha or CXCL12) to the cellular receptor CXCR4. In turn, the CXCR4-expressing tumor cells can be visualized using PET/CT and the resulting images could be used to predict a tumor's response to certain treatments. The expression of CXCR4 on cancer cells has been correlated with increased tumor cell survival, tumor progression, and increased metastatic potential.","Copper Cu 64 Plerixafor | 64-Cu-plerixafor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471814","NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine","C114380","A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with a peptide derived from the tumor associated antigen human cancer-testis antigen NY-ESO-1 (NY-ESO-1(157-165)), with potential immunostimulatory and antineoplastic activities. Upon administration, the NY-ESO-1(157-165) peptide-pulsed autologous dendritic cell vaccine may stimulate the immune system to mount both an anti-tumoral cytotoxic T-lymphocyte (CTL)- and an antibody-mediated immune response against NY-ESO-1-expressing tumor cells, which may result in tumor cell lysis. NY-ESO-1 is expressed both in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival.","NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine | Autologous NY-ESO-1 (157-165) Peptide-pulsed DC Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471817","photosensitizer LUZ 11","C114382","A bacteriochlorin-based photosensitizer, with antineoplastic activity upon photodynamic therapy (PDT). Following intravenous administration, redaporfin preferentially accumulates in hyperproliferative tissues, such as tumors. Local application of laser light at the tumor site results in the absorption of light by this agent and a photodynamic reaction between LUZ 11 and oxygen. This results in the production of reactive oxygen species (ROS), which includes singlet oxygen molecules, the superoxide ion, and other cytotoxic free radicals. The formation of ROS induces free radical-mediated DNA damage and cell death.","Redaporfin | LUZ 11 | REDAPORFIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827950","Stationary Bed Heating Drying Method","C112984","A process that removes water or volatile solvents from a bed of solids by relying on heat transfer from the equipment surface or a hot gas to the solid sample.","Stationary Bed Heating Drying Method | Drying, Stationary Bed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827821","Tissue Protein Extraction","C112985","The isolation of proteins or protein solutions from a biological source material.","Tissue Protein Extraction | Extraction, Tissue Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829493","Isolated Aseptic Liquid Filling Method","C112986","A process that fills a dosage unit with a liquid, which is performed in a closed environment under sterile conditions and without human intervention.","Isolated Aseptic Liquid Filling Method | Filling, Aseptic, Liquid, Isolator Process",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829492","Isolated Aseptic Powder Filling Method","C112987","A process that fills a dosage unit with a powder, which is performed in a closed environment under sterile conditions and without human intervention.","Isolated Aseptic Powder Filling Method | Filling, Aseptic, Powder, Isolator Process",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829271","Liquid Filling Method, Not Otherwise Specified","C112988","A process that fills a dosage unit with a liquid in a method not otherwise specified.","Liquid Filling Method, Not Otherwise Specified | Filling, Liquid, Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829207","Manual Aseptic Powder Filling Method","C112990","A process that fills a dosage unit with a powder, which is performed under sterile conditions and is likely to involve human intervention.","Manual Aseptic Powder Filling Method | Filling, Aseptic, Powder, Manual Process",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828802","Non-Sterile Augur Powder Filling Method","C112991","A process that fills a dosage unit using an augur to deliver the powder, which is not performed under sterile conditions.","Non-Sterile Augur Powder Filling Method | Filling, Powder, Nonsterile, Augur",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828801","Non-Sterile Dosing Disk Powder Filling Method","C112992","A process that fills a dosage unit using a dosing disk to deliver the powder, which is not performed under sterile conditions.","Non-Sterile Dosing Disk Powder Filling Method | Filling, Powder, Nonsterile, Dosing Disk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828800","Non-Sterile Medical Gas Filling Method","C112993","A process that fills a container with a purified medical gas, which is not performed under sterile conditions.","Non-Sterile Medical Gas Filling Method | Filling, Nonsterile, Medical Gas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828799","Non-Sterile Piston Powder Filling Method","C112994","A process that fills a dosage unit using a piston to deliver the powder, which is not performed under sterile conditions.","Non-Sterile Piston Powder Filling Method | Filling, Powder, Nonsterile, Dosator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828798","Non-Sterile Vacuum Powder Filling Method","C112995","A process that fills a dosage unit using a vacuum to deliver a powder, which is not performed under sterile conditions.","Non-Sterile Vacuum Powder Filling Method | Filling, Powder, Nonsterile, Vacuum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471782","Lutetium Lu 177 DOTA-biotin","C113801","A radioconjugate of biotin conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and labeled with the beta-emitting isotope lutetium Lu 177 (Lu-177) that can be used for radioimmunotherapeutic purposes.  Lutetium Lu 177 DOTA-biotin could be used in pre-targeting radioimmunotherapy, which pretreats the lesion with oxidized avidin that binds to protein amino groups on cells. As avidin binds to biotin, the radioisotope can be selectively delivered to cancer cells leading to tumor cell eradication.","Lutetium Lu 177 DOTA-biotin | 177Lu-ST2210 | CABIOTRAXETAN LUTETIUM LU-177 | [177Lu]DOTA-biotin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471784","Autologous Mesenchymal Stem Cells Apceth_101","C113803","Human autologous mesenchymal stem cells (MSCs) harvested from the bone marrow of a patient and genetically modified with a self-inactivating retroviral vector expressing the suicide gene herpes simplex virus thymidine kinase (HSV-TK), that can be used to activate synthetic acyclic guanosine analogues when co-administered. Upon intravenous administration of autologous mesenchymal stem cells apceth_101, the cells are actively recruited to the tumor stroma, differentiate into more mature mesenchymal cells, and become part of the tumor microenvironment. When a synthetic acyclic guanosine analogue, such as ganciclovir, is co-administered, the HSV-TK within the HSV-TK-transduced MSCs will monophosphorylate this prodrug. Subsequently the monophosphate form is further converted to the diphosphate form and then to its active triphosphate form by cellular kinases. The active form of ganciclovir kills the HSV-TK-transduced MSCs and leads to a bystander effect, which eliminates neighboring cancer cells. Therefore, synthetic acyclic guanosine analogues are activated only at the tumor site, which increases their local efficacy and reduces systemic toxicity.","Autologous Mesenchymal Stem Cells Apceth_101 | Agenmestencel-T | Autologous MSC_Apceth_101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810523","DCN wt Allele","C112874","Human DCN wild-type allele is located in the vicinity of 12q21.33 and is approximately 38 kb in length. This allele, which encodes decorin protein, is involved in extracellular matrix collagen fibril formation. A genetic deletion in this gene is associated with congenital stromal corneal dystrophy.","DCN wt Allele | CSCD | DSPG2 | Decorin wt Allele | PG40 | PGII | PGS2 | SLRR1B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0057252","decorin","C112875","Decorin (359 aa, ~40 kDa) is encoded by the human DCN gene. This protein plays a role in both the metabolism of proteoglycans and collagen fibril formation.","Decorin | Bone Proteoglycan II | Decorin Proteoglycan | Dermatan Sulphate Proteoglycans II | PG II | PG-S2 | PG40 | Proteoglycan Core Protein | Proteoglycan II | Small Leucine-Rich Protein 1B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415875","IDE Gene","C112876","This gene is involved in the catabolism of insulin and other bioactive peptides.","IDE Gene | IDE | Insulin-Degrading Enzyme Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814868","IDE wt Allele","C112877","Human IDE wild-type allele is located within 10q23-q25 and is approximately 122 kb in length. This allele, which encodes insulin-degrading enzyme protein, plays a role in the degradation of insulin and other bioactive peptides.","IDE wt Allele | INSULYSIN | Insulin-Degrading Enzyme wt Allele | RP11-366I13.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647980","Insulinase","C112878","Insulin-degrading enzyme (1019 aa, ~118 kDa) is encoded by the human IDE gene. This protein is involved in the metabolism of bioactive peptides.","Insulin-Degrading Enzyme | Abeta-Degrading Protease | EC 3.4.24.56 | IDE | Insulin Protease | Insulinase | Insulysin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415831","IAPP Gene","C112879","This gene plays a role in insulin-mediated glucose metabolism.","IAPP Gene | IAPP | Islet Amyloid Polypeptide Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL455247","Folate Receptor-Targeted Tubulysin Conjugate EC1456","C113176","An injectable targeted small molecule drug conjugate (SMDC) consisting of folate (vitamin B9) covalently linked to the potent mitotic poison and cytotoxic agent, tubulysin B hydrazide (Tub-B-H) with potential antineoplastic activity. Upon administration, the folate moiety of folate receptor-targeted tubulysin conjugate EC1456 preferentially binds to tumor cells expressing folate receptors (FR). After binding to FR, the agent is internalized by tumor cells and the Tub-B-H moiety inhibits the polymerization of tubulin into microtubules. This may lead to both cell cycle arrest and tumor cell apoptosis. FR, the membrane-bound, high-affinity receptor for folate, is overexpressed on a wide range of primary and metastatic human cancers.","Folate Receptor-Targeted Tubulysin Conjugate EC1456 | EC1456 | Folate Receptor-Targeting Folate-Tubulysin Conjugate EC1456",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2976397","recombinant human serum amyloid P/pentraxin 2","C113177","A fully recombinant form of the human pentraxin 2 (PTX2) protein with potential antifibrotic activity. Upon intravenous administration, zinpentraxin alfa may inhibit myofibroblast generation by preventing the differentiation of circulating monocytes into fibrocytes and profibrotic macrophages. PTX2 is a circulating plasma protein that belongs to the class of pattern recognition receptors (PRR) of the innate immune system.","Zinpentraxin Alfa | PRM 151 | PRM-151 | PRM-151/PTX2 | PRM151 | Pentraxin 2 | Recombinant Human PTX2 | Recombinant Human Pentraxin 2 | Recombinant Human Serum Amyloid P | ZINPENTRAXIN ALFA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1570187","BH3 Mimetic ABT-737","C114384","An orally bioavailable, selective small molecule B-cell lymphoma 2 (Bcl-2) Homology 3 (BH3) mimetic, with potential pro-apoptotic and antineoplastic activities. ABT-737 binds to the hydrophobic groove of multiple members of the anti-apoptotic Bcl-2 protein family, including Bcl-2, Bcl-xl and Bcl-w. This inhibits the activity of these pro-survival proteins and restores apoptotic processes in tumor cells, via activation of Bak/Bax-mediated apoptosis. The pro-survival Bcl-2 proteins are overexpressed in many cancers and play important roles in the regulation of apoptosis. Their expression is associated with increased drug resistance and tumor cell survival. ABT-737 does not inhibit the pro-survival proteins Mcl-1, Bcl-B, Bfl-1 (A1); therefore, tumors that overexpress these Bcl-2 family proteins are resistant to ABT-737.","BH3 Mimetic ABT-737 | ABT-737 | Benzamide, 4-(4-((4'-Chloro(1,1'-biphenyl)-2-yl)methyl)-1-piperazinyl)-n-((4-(((1r)-3-(dimethylamino)-1-((phenylthio)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811235","CACNA1D wt Allele","C113770","Human CACNA1D wild-type allele is located in the vicinity of 3p14.3 and is approximately 318 kb in length. This allele, which encodes voltage-dependent L-type calcium channel subunit alpha-1D protein, plays a role in voltage-dependent membrane polarization. Mutation of the gene is associated with sinoatrial node dysfunction and deafness.","CACNA1D wt Allele | CACH3 | CACN4 | CACNL1A2 | CCHL1A2 | Calcium Channel, Voltage-Dependent, L Type, Alpha 1D Subunit Gene | Calcium Channel, Voltage-Dependent, L Type, Alpha-1D Subunit Gene | Calcium Voltage-Gated Channel Subunit Alpha1 D wt Allele | Cav1.3 | PASNA | SANDD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1174900","Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1D, Human","C113771","Voltage-dependent L-type calcium channel subunit alpha-1D (2161 aa, ~245 kDa) is encoded by the human CACNA1D gene. This protein is involved in calcium transport.","Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1D | CACNA1D | Calcium Channel, L Type, Alpha-1 Polypeptide | Calcium Channel, L Type, Alpha-1 Polypeptide, Isoform 2 | Calcium Channel, Neuroendocrine/Brain-Type, Alpha 1 Subunit | Voltage-Gated Calcium Channel Alpha 1 Subunit | Voltage-Gated Calcium Channel Alpha Subunit Cav1.3 | Voltage-Gated Calcium Channel Subunit Alpha Cav1.3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1301055","Transthoracic Needle Biopsy","C113773","A diagnostic procedure in which a needle is inserted in the thoracic cavity to detect lesions of the pleura, lung parenchyma, or mediastinum.","Transthoracic Needle Biopsy | TTNA | TTNB | Transthoracic Needle Aspiration Biopsy",,,,,,,,,,,,,,,"4246261","Transthoracic needle biopsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3827528","Waiver","C113777","A formal statement that says a right, claim, law, or rule can be ignored.","Waiver | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827828","Timely","C113779","Happening at the appropriate time; not happening too late.","Timely | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829929","GRP Gene Product","C113249","A protein encoded by the GRP gene.","GRP Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0068602","neuromedin C, porcine","C113251","Neuromedin-C (10 aa, ~1 kDa) is encoded by the human GRP gene. This protein plays a role in hormone signaling.","Neuromedin-C | GRP-10 | Neuromedin C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811195","KLRC2 wt Allele","C113253","Human KLRC2 wild-type allele is located in the vicinity of 12p13 and is approximately 15 kb in length. This allele, which encodes NKG2-C type II integral membrane protein, is involved in the regulation of cell-mediated immunity.","KLRC2 wt Allele | CD159c | Killer Cell Lectin-Like Receptor Subfamily C, Member 2 wt Allele | Killer Cell Lectin-Like Receptor, Subfamily C, Member 2 Gene | NKG2-C | NKG2C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827643","VFQ25-Interviewer Administered Format - Difficulty Driving at Night","C112747","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Difficulty With Activities: How much difficulty do you have driving at night? Would you say you have:","VFQ25-Interviewer Administered Format - Difficulty Driving at Night | VFQ1-Difficulty Driving at Night | VFQ116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3813126","IAPP wt Allele","C112880","Human IAPP wild-type allele is located in the vicinity of 12p12.1 and is approximately 25 kb in length. This allele, which encodes islet amyloid polypeptide protein, is involved in the modulation of insulin-stimulated glycogen formation.","IAPP wt Allele | AMYLIN | DAP | IAP | IAPDAP | Islet Amyloid Polypeptide (Diabetes-Associated Peptide; Amylin) Gene | Islet Amyloid Polypeptide wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0063684","Islet Amyloid Polypeptide","C112881","Islet amyloid polypeptide (89 aa, ~10 kDa) is encoded by the human IAPP gene. This protein plays a role in the regulation of glucose metabolism.","Islet Amyloid Polypeptide | Amylin | DAP | Diabetes-Associated Peptide | Insulinoma Amyloid Peptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412728","BACE2 Gene","C112890","This gene is involved in proteolytic processing.","BACE2 Gene | BACE2 | Beta-Site APP-Cleaving Enzyme 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815637","ABCG1 wt Allele","C113600","Human ABCG1 wild-type allele is located in the vicinity of 21q22.3 and is approximately 98 kb in length. This allele, which encodes ATP-binding cassette sub-family G member 1 protein, plays a role in lipid homeostasis. Aberrant expression of the gene in macrophages is associated with Tangier disease.","ABCG1 wt Allele | ABC8 | ATP-Binding Cassette, Sub-Family G (WHITE), Member 1 wt Allele | ATP-Binding Cassette, Subfamily G, Member 1 Gene | Homolog of Drosophila White Gene | WHITE1 | WHT1 | White Protein Homolog (ATP-Binding Cassette Transporter 8) Gene | White, Drosophila, Homolog of Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0963751","ATP-Binding Cassette Sub-Family G Member 1, Human","C113601","ATP-binding cassette sub-family G member 1 (678 aa, ~76 kDa) is encoded by the human ABCG1 gene. This protein is involved in the transport of cholesterol and phospholipids.","ATP-Binding Cassette Sub-Family G Member 1 | ABC Transporter 8 | ABCG1 | ATP-Binding Cassette Transporter 8 | ATP-Binding Cassette Transporter Member 1 of Subfamily G | White Protein Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811152","HFE2A","C113603","Human HJV wild-type allele is located in the vicinity of 1q21.1 and is approximately 19 kb in length. This allele, which encodes hemojuvelin protein, is involved in both bone morphogenetic protein signaling and iron metabolism. Mutation of the gene is associated with hemochromatosis type 2A.","HJV wt Allele | HFE2 | HFE2 wt Allele | HFE2A | Hemochromatosis Type 2 (Juvenile) Gene | Hemojuvelin BMP Co-Receptor wt Allele | JH | RGMC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828081","SGRQ Past 4 Weeks Version - Coughing Disturbs My Sleep","C112700","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are more questions about your cough and shortness of breath these days: My coughing or breathing disturbs my sleep.","SGRQ Past 4 Weeks Version - Coughing Disturbs My Sleep | SGRQ02-Coughing Disturbs My Sleep | SGRQ0223",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828066","SGRQ Past 4 Weeks Version - I Get Exhausted Easily","C112701","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are more questions about your cough and shortness of breath these days: I get exhausted easily.","SGRQ Past 4 Weeks Version - I Get Exhausted Easily | SGRQ02-I Get Exhausted Easily | SGRQ0224",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828060","SGRQ Past 4 Weeks Version - My Cough is Embarrassing in Public","C112702","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about other effects that your respiratory problems may have on you these days: My cough or breathing is embarrassing in public.","SGRQ Past 4 Weeks Version - My Cough is Embarrassing in Public | SGRQ02-Cough Is Embarrassing in Public | SGRQ0225",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828056","SGRQ Past 4 Weeks Version - Respiratory Problems a Nuisance to Family","C112703","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about other effects that your respiratory problems may have on you these days: My respiratory problems are a nuisance to my family, friends or neighbors.","SGRQ Past 4 Weeks Version - Respiratory Problems a Nuisance to Family | SGRQ02-Respiratory Problems a Nuisance | SGRQ0226",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828073","SGRQ Past 4 Weeks Version - Get Afraid When Cannot Catch My Breath","C112704","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about other effects that your respiratory problems may have on you these days: I get afraid or panic when I cannot catch my breath.","SGRQ Past 4 Weeks Version - Get Afraid When Cannot Catch My Breath | SGRQ02-Afraid When Cannot Catch Breath | SGRQ0227",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828058","SGRQ Past 4 Weeks Version - Not in Control of My Respiratory Problems","C112705","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about other effects that your respiratory problems may have on you these days: I feel that I am not in control of my respiratory problems.","SGRQ Past 4 Weeks Version - Not in Control of My Respiratory Problems | SGRQ02-Not in Control of Resp Problems | SGRQ0228",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828059","SGRQ Past 4 Weeks Version - Not Expect Respiratory Problems Get Better","C112706","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about other effects that your respiratory problems may have on you these days: I do not expect my respiratory problems to get any better.","SGRQ Past 4 Weeks Version - Not Expect Respiratory Problems Get Better | SGRQ02-Not Expect Probs to Get Better | SGRQ0229",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828091","SGRQ Past 4 Weeks Version - Become Frail or Invalid Because of My Respiratory Problems","C112707","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about other effects that your respiratory problems may have on you these days: I have become frail or an invalid because of my respiratory problems.","SGRQ Past 4 Weeks Version - Become Frail or Invalid Because of My Respiratory Problems | SGRQ02-I Have Become Frail | SGRQ0230",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3828074","SGRQ Past 4 Weeks Version - Exercise Is Not Safe for Me","C112708","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about other effects that your respiratory problems may have on you these days: Exercise is not safe for me.","SGRQ Past 4 Weeks Version - Exercise Is Not Safe for Me | SGRQ02-Exercise Is Not Safe for Me | SGRQ0231",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0425205","Live in a Nursing Home","C113782","An indication that an individual is living in a nursing home.","Live in a Nursing Home | Live in a nursing home | Living in a Nursing Home",,,,,,,,,,,,,,,"4052486","Lives in nursing home",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3829265","Live with Child or Children","C113783","An indication that an individual is living in the home of their child.","Live with Child or Children | Live with child/children | Living with Child or Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268306","Indirect Hyperbilirubinemia","C113785","Abnormally high level of unconjugated bilirubin in the blood.","Indirect Hyperbilirubinemia | Unconjugated Hyperbilirubinemia",,,,,,,,,,,,,,,"4298325","Unconjugated hyperbilirubinemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828922","MSQOL-54 - Felt Calm and Peaceful","C114013","Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Have you felt calm and peaceful?","MSQOL-54 - Felt Calm and Peaceful | MSQL1-Have You Felt Calm and Peaceful | MSQL126",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831238","BWCS - Almost Lost Control of Your Bowels","C113959","Bowel Control Scale (BWCS) During the past 4 weeks, how often have you almost lost control of your bowels or almost had an accident?","BWCS - Almost Lost Control of Your Bowels | BWCS01-Almost Lost Control of Bowels | BWCS0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831237","BWCS - Altered Activities Because Bowel Control Problems","C113960","Bowel Control Scale (BWCS) During the past 4 weeks, how often have you altered your activities because of bowel control problems?","BWCS - Altered Activities Because Bowel Control Problems | BWCS01-Altered Activity Because Bowels | BWCS0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831235","BWCS - Bowel Problems Restrict Overall Lifestyle","C113961","Bowel Control Scale (BWCS) During the past 4 weeks, how much have bowel problems restricted your overall lifestyle?","BWCS - Bowel Problems Restrict Overall Lifestyle | BWCS01-Bowels Restricted Lifestyle | BWCS0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829484","IVIS - Read or Access Personal Letters","C113962","Impact of Visual Impairment Scale (IVIS) During the past 4 weeks, how difficult did you find it to read or access personal letters or notes?","IVIS - Read or Access Personal Letters | IVIS01-Read or Access Personal Letters | IVIS0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829483","IVIS - Read or Access Printed Materials","C113963","Impact of Visual Impairment Scale (IVIS) During the past 4 weeks, how difficult did you find it to read or access printed materials, such as books, magazines, newspaper, etc.?","IVIS - Read or Access Printed Materials | IVIS01-Read or Access Printed Materials | IVIS0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829485","IVIS - Read or Access Dials","C113964","Impact of Visual Impairment Scale (IVIS) During the past 4 weeks, how difficult did you find it to read or access dials, such as on stoves, thermostats, etc.,?","IVIS - Read or Access Dials | IVIS01-Read or Access Dials | IVIS0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829482","IVIS - Watch TV or Identify Faces From Distance","C113965","Impact of Visual Impairment Scale (IVIS) During the past 4 weeks, how difficult did you find it to watch television or identify faces from a distance?","IVIS - Watch TV or Identify Faces From Distance | IVIS01-Watch TV/ID Faces From Distance | IVIS0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829486","IVIS - Identify House Numbers or Street Signs","C113966","Impact of Visual Impairment Scale (IVIS) During the past 4 weeks, how difficult did you find it to identify house numbers, street signs, etc.?","IVIS - Identify House Numbers or Street Signs | IVIS01-Identify House Number/Street Sign | IVIS0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827623","VFQ25-Interviewer Administered Format - Driving in Difficult Condition","C112748","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Difficulty With Activities: How much difficulty do you have driving in difficult conditions, such as in bad weather, during rush hour, on the freeway, or in city traffic? Would you say you have:","VFQ25-Interviewer Administered Format - Driving in Difficult Condition | VFQ1-Driving in Difficult Conditions | VFQ116A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827646","VFQ25-Interviewer Administered Format - Accomplish Less Because of Vision","C112749","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Responses to Vision Problems: Do you accomplish less than you would like because of your vision?","VFQ25-Interviewer Administered Format - Accomplish Less Because of Vision | VFQ1-Accomplish Less Than You Would Like | VFQ117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827618","VFQ25-Interviewer Administered Format - Limited in How Long You Can Work Because of Vision","C112750","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Responses to Vision Problems: Are you limited in how long you can work or do other activities because of your vision?","VFQ25-Interviewer Administered Format - Limited in How Long You Can Work Because of Vision | VFQ1-Limited in How Long You Can Work | VFQ118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827611","VFQ25-Interviewer Administered Format - Pain in Eyes Keep You From Doing What You Like","C112751","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Responses to Vision Problems: How much does pain or discomfort in or around your eyes, for example, burning, itching, or aching, keep you from doing what you'd like to be doing? Would you say:","VFQ25-Interviewer Administered Format - Pain in Eyes Keep You From Doing What You Like | VFQ1-Eye Pain Keep From Doing What Like | VFQ119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827606","VFQ25-Interviewer Administered Format - Stay Home Because of Eyesight","C112752","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Responses to Vision Problems: I stay home most of the time because of my eyesight.","VFQ25-Interviewer Administered Format - Stay Home Because of Eyesight | VFQ1-I Stay Home Most of the Time | VFQ120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827621","VFQ25-Interviewer Administered Format - Feel Frustrated Because of Eyesight","C112753","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Responses to Vision Problems: I feel frustrated a lot of the time because of my eyesight.","VFQ25-Interviewer Administered Format - Feel Frustrated Because of Eyesight | VFQ1-I Feel Frustrated a Lot of the Time | VFQ121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827620","VFQ25-Interviewer Administered Format - Have Less Control Because of Eyesight","C112754","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Responses to Vision Problems: I have much less control over what I do, because of my eyesight.","VFQ25-Interviewer Administered Format - Have Less Control Because of Eyesight | VFQ1-Much Less Control Over What I Do | VFQ122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827619","VFQ25-Interviewer Administered Format - Have to Rely On Other People Because of Eyesight","C112755","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Responses to Vision Problems: Because of my eyesight, I have to rely too much on what other people tell me.","VFQ25-Interviewer Administered Format - Have to Rely On Other People Because of Eyesight | VFQ1-Rely Too Much on What Others Tell | VFQ123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827615","VFQ25-Interviewer Administered Format - Need Help From Others Because of Eyesight","C112756","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Responses to Vision Problems: I need a lot of help from others because of my eyesight.","VFQ25-Interviewer Administered Format - Need Help From Others Because of Eyesight | VFQ1-I Need a Lot of Help From Others | VFQ124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827604","VFQ25-Interviewer Administered Format - Worry About Embarrass Myself or Others Because of Eyesight","C112757","Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Responses to Vision Problems: I worry about doing things that will embarrass myself or others, because of my eyesight.","VFQ25-Interviewer Administered Format - Worry About Embarrass Myself or Others Because of Eyesight | VFQ1-Worry I'll Do Embarrassing Things | VFQ125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810562","Hemojuvelin, Human","C113604","Hemojuvelin (426 aa, ~45 kDa) is encoded by the human HJV gene. This protein plays a role in both iron metabolism and bone morphogenetic protein signaling pathways.","Hemojuvelin | HFE2 | HJV | Hemochromatosis Type 2 Protein | Hemojuvelin BMP Coreceptor | RGM Domain Family Member C | Repulsive Guidance Molecule C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810557","HDAC8 wt Allele","C113606","Human HDAC8 wild-type allele is located in the vicinity of Xq13 and is approximately 244 kb in length. This allele, which encodes histone deacetylase 8 protein, plays a role in post-translational modification of histones. Mutation of the gene is associated with both Wilson-Turner X-linked mental retardation syndrome and Cornelia de Lange syndrome 5.","HDAC8 wt Allele | CDA07 | CDLS5 | HD8 | HDACL1 | Histone Deacetylase 8 wt Allele | Histone Deacetylase-Like 1 Gene | MRXS6 | RPD3 | WTS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810556","HDAC8 protein, human","C113607","Histone deacetylase 8 (377 aa, ~24 kDa) is encoded by the human HDAC8 gene. This protein is involved in the deacetylation of core histones.","Histone Deacetylase 8 | EC 3.5.1.98 | HD8 | HDAC8 | Histone Deacetylase-Like 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3814039","NRARP wt Allele","C113610","Human NRARP wild-type allele is located in the vicinity of 9q34.3 and is approximately 3 kb in length. This allele, which encodes Notch-regulated ankyrin repeat-containing protein, is involved in both endothelial cell proliferation and Notch signaling pathways.","NRARP wt Allele | MGC61598 | NOTCH-Regulated Ankyrin Repeat Protein wt Allele | RP13-122B23.6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3849844","NRARP protein, human","C113611","Notch-regulated ankyrin repeat-containing protein (114 aa, ~12 kDa) is encoded by the human NRARP gene. This protein plays a role in the modulation of Notch signaling pathways.","Notch-Regulated Ankyrin Repeat-Containing Protein | NRARP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812220","ERN1 wt Allele","C113613","Human ERN1 wild-type allele is located in the vicinity of 17q24.2 and is approximately 88 kb in length. This allele, which encodes serine/threonine-protein kinase/endoribonuclease IRE1, plays a role in the unfolded protein response.","ERN1 wt Allele | ER To Nucleus Signalling 1 Gene | Endoplasmic Reticulum To Nucleus Signaling 1 wt Allele | IRE1 | IRE1P | IRE1a | Inositol-Requiring 1 Gene | Inositol-Requiring Enzyme 1, S. cerevisiae, Homolog of Gene | hIRE1p",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3550540","Primary Hypothyroidism","C113143","Abnormally low levels of thyroid hormones due to a disorder originating within the thyroid gland.","Primary Hypothyroidism | ",,,,,,,,,,,,,,,"40609121","Primary hypothyroidism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0271801","Central Hypothyroidism","C113144","Abnormally low levels of thyroid hormones due to a disorder originating within the hypothalamic-pituitary axis.","Central Hypothyroidism | Hypothalamic-Pituitary Hypothyroidism | Secondary Hypothyroidism | TSH Deficiency | Thyroid Stimulating Hormone Deficiency | Thyrotropin Deficiency",,,,,,,,,,,,,,,"4132435","Central hypothyroidism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3714618","Primary Hyperthyroidism","C113145","Overproduction of thyroid hormone due to a disorder originating within the thyroid gland.","Primary Hyperthyroidism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1095928","Central Hyperthyroidism","C113146","Overproduction of thyroid hormones due to a disorder originating within the hypothalamic-pituitary axis.","Central Hyperthyroidism | ",,,,,,,,,,,,,,,"36716766","Secondary hyperthyroidism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0342124","Hashitoxicosis","C113147","Severe, transient hyperthyroidism associated with Hashimoto thyroiditis.","Hashitoxicosis | Hashimoto Toxicosis",,,,,,,,,,,,,,,"4100629","Hyperthyroidism with Hashimoto disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828075","SGRQ Past 4 Weeks Version - Everything Too Much Effort","C112709","St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about other effects that your respiratory problems may have on you these days: Everything seems too much of an effort.","SGRQ Past 4 Weeks Version - Everything Too Much Effort | SGRQ02-Everything Too Much Effort | SGRQ0232",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL458232","EFS-ADA Lentiviral Vector-transduced CD34-positive Autologous Lymphocytes","C113438","A preparation of autologous, CD34-positive stem/progenitor cells transduced with a lentrivral vector encoding the human adenosine deaminase (ADA) gene under the control of the human elongation factor alpha short promoter (EFS), with potential to restore ADA expression and function. Autologous hematopoietic CD34+ cells are isolated from the patient's own bone marrow, peripheral blood or cord blood, and transduced with the EFS-ADA lentiviral vector ex vivo. Upon re-infusion of the EFS-ADA vector-transduced lymphocytes back into the patient, these cells may both restore ADA activity and prevent severe combined immunodeficiency (SCID) due to ADA deficiency. ADA, an enzyme that catalyzes the deamination of adenosine to inosine, plays a key role in the development and functioning of the immune system.","EFS-ADA Lentiviral Vector-transduced CD34-positive Autologous Lymphocytes | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL458233","Anti-PSMA Monoclonal Antibody MDX1201-A488","C113439","A recombinant, human monoclonal antibody targeting an extracellular epitope of human prostate specific membrane antigen (PSMA) that is conjugated with A488, a photostable fluorescent dye with a high quantum yield, with potential imaging activity. Upon intravenous administration of PSMA-targeting fluorescent imaging agent MDX1201-A488, the MDX1201 moiety targets PSMA expressed on cancer cells. Subsequently, the A488 moiety can then be visualized by fluorescence-based imaging and the amount of PSMA-expressing tumor cells can be assessed. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.","PSMA-targeting Fluorescent Imaging Agent MDX1201-A488 | Anti-PSMA Monoclonal Antibody MDX1201-A488 | MDX1201-A488",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1827357","Copper Cu 62-PTSM","C113440","A radioconjugate consisting of a lipophilic, bioreductive copper(II)bis(thiosemicarbazone) complex, copper-pyruvaldehyde-bis(N4-methylthiosemicarbazone) (Cu-PTSM), linked to the beta-emitting, radioisotope copper Cu 62, with potential perfusion and positron emitting tomography (PET) tumor imaging activities. Upon injection, the distribution of copper Cu 62-PTSM correlates with blood flow. This agent's high membrane permeability allows for rapid diffusion into cells. Once it enters the cell, 62Cu-PTSM is then reduced by the mitochondria, which prevents diffusion of the agent out of the cell. Upon PET imaging, tumor blood flow can be visualized and tumor perfusion can be assessed. Compared with other copper radionuclides, the short half-life of copper Cu 62 (9.7 minutes) reduces the amount of radiation a patient is subjected to and allows for several imaging studies to be performed. PTSM lacks selectivity for hypoxic cells.","Copper Cu 62-PTSM | 62Cu-PTSM",,,,,,,,,,,,,,,"4309706","Copper (62-Cu) pyruvaldehyde-bis N-(4)-methyl-thiosemicarbazone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL458235","Copper Cu 62-ATSM","C113441","A radioconjugate consisting of a lipophilic, neutral, bioreductive copper-bis(thiosemicarbazone) complex, copper-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM), labeled with the beta-emitting radioisotope copper Cu 62, with hypoxia-selective and positron emitting tomography (PET) radioimaging activities. With a high membrane permeability and low reduction potential, copper Cu 62-ATSM easily enters cells. This agent can only be reduced by mitochondria found in hypoxic cells with abnormally high electron concentrations. This chemical reaction traps Cu 62-ATSM in the cell, which allows for the selective accumulation of this agent in hypoxic cells compared to normoxic cells. The extent of copper Cu 62-ATSM retention in tissue is inversely related to the state of tissue oxygenation allowing the quantitation of tissue hypoxia with PET. This provides information about diagnosis, prognosis, treatment options and outcomes for certain cancers. The short half-life of copper Cu 62 (9.7 minutes) reduces the amount of radiation a patient is subjected to and allows for several imaging studies to be performed.  Hypoxic tumors are associated with increased malignancy and resistance to radiation and chemotherapy.","Copper Cu 62-ATSM | 62Cu-ATSM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829104","MFIS - Have Been Less Alert","C113967","Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have been less alert.","MFIS - Have Been Less Alert | MFIS01-I Have Been Less Alert | MFIS0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829102","MFIS - Have Difficulty Paying Attention for Long Time","C113968","Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have had difficulty paying attention for long periods of time.","MFIS - Have Difficulty Paying Attention for Long Time | MFIS01-Have Difficulty Paying Attention | MFIS0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829088","MFIS - Unable to Think Clearly","C113969","Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have been unable to think clearly.","MFIS - Unable to Think Clearly | MFIS01-Have Been Unable to Think Clearly | MFIS0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829105","MFIS - Have Been Forgetful","C113971","Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have been forgetful.","MFIS - Have Been Forgetful | MFIS01-I Have Been Forgetful | MFIS0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829090","MFIS - Pace Myself in Physical Activities","C113972","Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have had to pace myself in my physical activities.","MFIS - Pace Myself in Physical Activities | MFIS01-Pace Myself in Physical Activity | MFIS0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829097","MFIS - Less Motivated to Do Anything That Requires Physical Effort","C113973","Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have been less motivated to do anything that requires physical effort.","MFIS - Less Motivated to Do Anything That Requires Physical Effort | MFIS01-Less Motivated, Physical Effort | MFIS0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0474461","Spontaneous Onset of Labor","C113490","Labor without the use of pharmacological and/or mechanical interventions to initiate labor. Does not apply if artificial rupture of membranes is performed before the onset of labor. (reVITALize)","Spontaneous Onset of Labor | ",,,,,,,,,,,,,,,"4309364","Spontaneous onset of labor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3828493","Precipitous Birth","C113491","Unexpectedly sudden vaginal delivery.","Precipitous Birth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013418","Dysfunctional Labor","C113492","Uterine contractions (less than 3 in 10 minutes or inadequate strength) that do not result in progressive cervical dilation.","Dysfunctional Labor | Arrest of Dilatation | Failure to Progress | Labor Dystocia",,,,,,,,,,,,,,,"4164128","Labor problem",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0269841","Tetanic Contraction","C113493","A single uterine contraction lasting greater than 2 minutes.","Tetanic Contraction | ",,,,,,,,,,,,,,,"4222307","Tetanic contractions of uterus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0546980","Funic Presentation","C113494","The positioning of the umbilical cord before the main presenting part of the fetus.","Funic Presentation | Cord Presentation | Funis Presentation",,,,,,,,,,,,,,,"4262384","Funic presentation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0233276","Brow Presentation","C113495","A fetal presentation during delivery in which the brow of the fetus is first to descend into the birth canal.","Brow Presentation | ",,,,,,,,,,,,,,,"4213449","Brow presentation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0475718","Neonatal Hyperglycemia","C113496","Blood glucose concentration above the upper limit of established reference ranges in a newborn.","Neonatal Hyperglycemia | ",,,,,,,,,,,,,,,"4173184","Neonatal hyperglycemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3827843","Terminology Value Set","C113497","Terms drawn from one or more terminologies and defined as a separate set, generally for specific coding purposes and given a formal designation.","Terminology Value Set | Value Set",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0063465","Indicine-N-Oxide","C1134","A natural pyrrolizidine alkaloid with antineoplastic properties.  Indicine-N-oxide alkylates and crosslinks DNA. (NCI04)","Indicine-N-Oxide | 2,3-Dihydroxy-2-(1-methylethyl)butanoic Acid (2,3,5,7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl)methyl Ester N-Oxide | Butanoic Acid, 2,3-Dihydroxy-2-(1-methylethyl)- (2,3,5, 7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl) Methyl Ester, N-Oxide,(1R-(1alpha,7(2R*,3S*),7a-beta))-(9CI) | Butanoic acid, 2,3-dihydroxy-2-(1-methylethyl)- (2,3,5, 7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl) methyl ester, N-oxide, (1R-(1alpha,7(2R*,3S*),7a-beta))-(9CI) | INDICINE N-OXIDE | Indicine N-Oxide | Indicine N-oxide | Indicine, N-oxide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0158951","Fetal Blood Loss","C113148","Loss of blood from the fetal circulation.","Fetal Blood Loss | ",,,,,,,,,,,,,,,"79146","Fetal blood loss",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015959","Fetal-Maternal Hemorrhage","C113149","Loss of fetal blood into the maternal circulation.","Fetal-Maternal Hemorrhage | Fetal-Maternal Bleed | Fetomaternal Hemorrhage",,,,,,,,,,,,,,,"201366","Fetal-maternal hemorrhage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035404","Rhesus Isoimmunization","C113150","The mother develops antibodies against red blood cell Rhesus antigens. This may lead to potential fetal adverse outcomes such as anemia.","Rhesus Isoimmunization | Rh Isoimmunization",,,,,,,,,,,,,,,"199891","Rhesus isoimmunization affecting pregnancy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0410959","Fetal Acidosis","C113151","An abnormally high hydrogen ion concentration (umbilical arterial blood pH less than 7.00) in fetal blood or tissue.","Fetal Acidosis | Fetal Acidemia",,,,,,,,,,,,,,,"4344632","Fetal acidosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4228547","Short Umbilical Cord","C113152","An umbilical cord at term that is less than 35 cm in length.","Short Umbilical Cord | ",,,,,,,,,,,,,,,"40319195","Short umbilical cord",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0405124","Nuchal Cord","C113153","An umbilical cord that has become looped around the fetus's neck from movement in utero.","Nuchal Cord | ",,,,,,,,,,,,,,,"441646","Umbilical cord around neck",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3827733","Umbilical Cord Occlusion","C113154","Blockage of blood flow in the umbilical vessels.","Umbilical Cord Occlusion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0426209","Meconium Stained Amniotic Fluid","C113155","Presence of meconium into amniotic fluid.","Meconium Stained Amniotic Fluid | Meconium in Amniotic Fluid",,,,,,,,,,,,,,,"441959","Amniotic fluid -meconium stain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897348","Transient Myocardial Dysfunction of Newborn","C113156","A condition in a newborn characterized by a temporary decrease in right ventricular and/or left ventricular output.","Transient Myocardial Dysfunction of Newborn | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412849","BTNL2 Gene","C113157","This gene plays a role in the regulation of T-cell proliferation.","BTNL2 Gene | BTNL2 | Butyrophilin Like 2 Gene | Butyrophilin-Like 2 (MHC Class II Associated) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812665","BTNL2 wt Allele","C113158","Human BTNL2 wild-type allele is located in the vicinity of 6p21.3 and is approximately 13 kb in length. This allele, which encodes butyrophilin-like protein 2, is involved in the negative regulation of T-cell proliferation. Variation in the gene is associated with susceptibility to sarcoidosis 2.","BTNL2 wt Allele | BTL-II | BTN7 | Butyrophilin Like 2 wt Allele | Butyrophilin-Like 2 (MHC Class II Associated) Gene | Butyrophilin-Like 2 (MHC Class II Associated) wt Allele | Butyrophilin-Like 2 Gene | DAAP-282D22.2 | HSBLMHC1 | SS2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812664","BTNL2 protein, human","C113160","Butyrophilin-like protein 2 (455 aa, ~50 kDa) is encoded by the human BTNL2 gene. This protein plays a role in the inhibition of T-cell proliferation.","Butyrophilin-Like Protein 2 | BTL II | BTL-II | BTNL2 | Butyrophilin-Like Protein, Major Histocompatibility Complex Class II-Associated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811683","SOX4 wt Allele","C112920","Human SOX4 wild-type allele is located in the vicinity of 6p22.3 and is approximately 5 kb in length. This allele, which encodes transcription factor SOX-4 protein, is involved in both transcriptional regulation and T-cell differentiation.","SOX4 wt Allele | EVI16 | Ecotropic Viral Integration Site 16 | SRY (Sex Determining Region Y)-Box 4 wt Allele | SRY-Box 4 Gene | SRY-Related HMG-Box Gene 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2350540","Transcription Factor SOX-4","C112921","Transcription factor SOX-4 (474 aa, ~47 kDa) is encoded by the human SOX4 gene. This protein plays a role in both T-cell differentiation and transcriptional activation.","Transcription Factor SOX-4 | SOX-4 | SOX4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831159","Cell Culture-Based Biosynthesis","C112922","A process that synthesizes a material of interest using cell culture techniques.","Cell Culture-Based Biosynthesis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830390","Drying Method","C112923","A process that removes water or volatile solvents from a bed of solids.","Drying Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830127","Filling Method","C112924","A process that fills a dosage unit.","Filling Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0518864","Granulation","C112925","The act of forming something into grains.","Granulation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL455341","Particle Sizing","C112926","Separation of particles into size-differentiated fractions.","Particle Sizing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033268","production","C112927","The creation of goods and services by a manufacturing process.","Production | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831535","Animal Blood Product-Derived Intermediate Paste Production","C112929","The production of concentrated proteins from animal plasma during a protein purification process.","Animal Blood Product-Derived Intermediate Paste Production | Production/Fractionation, Intermediate Paste/Animal Blood, Blood Products",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831514","Antigen Reagent Production","C112930","A procedure to manufacture blood group antigens or cellular reagents for donor and recipient typing of blood or organs.","Antigen Reagent Production | Production, Antigen/Reagent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831513","Anti-Human Globulin Preparation","C112931","A procedure to isolate one or more anti-globulin antibodies from either serum derived from animals immunized with human serum globulins or from fluids harvested from stable immunoglobulin-secreting cell lines.","Anti-Human Globulin Preparation | Preparation, Anti-Human Globulin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815594","Subject is Randomized","C114209","A status indication that a subject is already assigned to an arm of a clinical trial by chance.","Subject is Randomized | RANDOMIZED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471821","IL-12-expressing Mesenchymal Stem Cell Vaccine GX-051","C114385","Human mesenchymal stem cells (MSCs) transduced with a retroviral vector encoding a modified form of the cytokine interleukin-12 (IL-12), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration, IL-12-expressing MSC vaccine GX-051 secretes IL-12. IL-12 activates the immune system by both promoting the secretion of interferon-gamma, which activates natural killer cells (NKs), and inducing cytotoxic T-cell responses, which may result in both decreased cell proliferation and increased cell death in tumor cells.","IL-12-expressing Mesenchymal Stem Cell Vaccine GX-051 | GX-051 | MSCs/IL-12M",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472263","Artichoke Whole Phytocomplex Concentrate","C114386","A whole phytocomplex concentrate (W.P.C.) composed of a standardized extract of the Cynara scolymus (artichoke) leaf with potential antioxidant, protective and chemopreventive activities. The artichoke W.P.C. is high in flavonoids and polyphenols, such as caffeoylquinic acids, which are mainly responsible for the pharmacological effects of the extract. Artichoke W.P.C. also contains protein, fiber, vitamins, minerals, numerous enzymes, volatile oils, phytosterols and polyunsaturated fatty acids.","Artichoke Whole Phytocomplex Concentrate | Artichoke Extract | Artichoke W.P.C.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472264","PAD Regimen","C114387","A regimen containing bortezomib, doxorubicin and dexamethasone regimen used in the treatment of plasma cell myeloma.","PAD Regimen | Bortezomib/ Dexamethasone/Doxorubicin | Bortezomib/Dexamethasone/Doxorubicin | Bortezomib/Doxorubicin/Dexamethasone Regimen | PAD | PS-341/Adriamycin/Dexamethasone Regimen | Velcade/Adriamycin/Dexamethasone Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0157461","Postpartum Acute Renal Failure","C114388","Renal failure that occurs postpartum due to any partum problem (hemorrhage, sepsis, preeclampsia).","Postpartum Acute Renal Failure | ",,,,,,,,,,,,,,,"37116834","Postpartum acute renal failure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0271815","Postpartum Thyroiditis","C114389","Inflammatory disorder of thyroid gland that occurs postpartum due to any partum problem.","Postpartum Thyroiditis | Postpartum thyroiditis",,,,,,,,,,,,,,,"4199437","Postpartum thyroiditis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898619","Late Preterm Infant","C114938","An age group comprised of infants greater than or equal to 34 weeks, 0 days and less than 37 weeks, 0 days gestational age.","Late Preterm Infant | Near Term Infant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3494262","Infant, Extremely Premature","C114939","An age group comprised of infants less than 28 weeks, 0 days gestational age.","Extremely Preterm Infant | Extreme Immaturity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897526","Stage IIIC Primary Peritoneal Cancer AJCC v7","C115097","Stage IIIC includes: (T3c, N0, M0); (Any T, N1, M0). T3c: Peritoneal tumor beyond pelvis more than 2cm in greatest dimension and/or regional lymph node metastasis. N0: No regional lymph node metastasis.  N1: Regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th Ed.)","Stage IIIC Primary Peritoneal Cancer AJCC v7 | Stage IIIC Primary Peritoneal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897083","Stage IV Primary Peritoneal Cancer AJCC v7","C115098","Stage IV includes: Any T, Any N, M1.  M1: Distant metastasis (excludes peritoneal metastasis). (AJCC 7th Ed.)","Stage IV Primary Peritoneal Cancer AJCC v7 | Stage IV Primary Peritoneal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472631","Acoustic Coupling Fluid","C115100","A brain mimicking fluid with an attenuation coefficient similar to that found in the adult human brain, which can potentially improve the quality of an image acquired during intraoperative ultrasonography. Upon administration into the resection cavity during surgical removal of a brain tumor, the acoustic coupling fluid may both increase the quality of the ultrasound image and improve the visualization of the tumor. This may facilitate the surgical removal of residual tumor while sparing normal, healthy brain tissue.","Acoustic Coupling Fluid | Acoustic Fluid | BMF | Brain Mimicking Fluid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472632","Anti-CD19/CD3 Tetravalent Antibody AFM11","C115101","An anti-CD19/anti-CD3 bispecific tetravalent antibody with potential immunostimulatory and antineoplastic activities. Anti-CD19/CD3 tetravalent antibody AFM11 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B-cells. Upon bolus infusion of AFM11, this bispecific antibody binds to CD3-expressing T-cells and CD19-expressing cancer cells, thereby crosslinking CD19-expressing tumor B-cells and cytotoxic T-lymphocytes (CTLs). This may result in a potent CTL-mediated cell lysis of CD19-expressing B-lymphocytes. CD19, a B-cell specific membrane antigen, is expressed during both B-cell development and B-cell malignant growth.","Anti-CD19/CD3 Tetravalent Antibody AFM11 | AFM-11 | AFM11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899790","CHART-SF Interview Version - Number of Relatives You Live With","C118013","Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) Of the people you live with how many are relatives?","CHART-SF Interview Version - Number of Relatives You Live With | CHSF1-Number of Relatives You Live With | CHSF114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899806","CHART-SF Interview Version - Associates Contacted per Month","C118014","Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) How many business or organizational associates do you visit, phone, or write to at least once a month?","CHART-SF Interview Version - Associates Contacted per Month | CHSF1-Associates Contacted per Month | CHSF115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896963","CHART-SF Interview Version - Friends Contacted per Month","C118015","Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) How many friends (non-relatives contacted outside business or organizational settings) do you visit, phone, or write to at least once a month?","CHART-SF Interview Version - Friends Contacted per Month | CHSF1-Friends Contacted per Month | CHSF116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899795","CHART-SF Interview Version - Initiated Conversation With Strangers Last Month","C118016","Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) With how many strangers have you initiated a conversation in the last month (for example, to ask information or place an order)?","CHART-SF Interview Version - Initiated Conversation With Strangers Last Month | CHSF1-Strangers Spoke with Last Month | CHSF117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899803","CHART-SF Interview Version - Combined Annual Household Income Last Year","C118017","Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) Approximately what was the combined annual income, in the last year, of all family members in your household? (consider all sources including wages and earnings, disability benefits, pensions and retirement income, income from court settlements, investments and trust funds, child support and alimony, contributions from relatives, and any other source).","CHART-SF Interview Version - Combined Annual Household Income Last Year | CHSF1-Combined Household Income Last Yr | CHSF118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899793","CHART-SF Interview Version - Medical Care Expense Last Year","C118018","Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) Approximately how much did you pay last year for medical care expenses? (Consider any amounts paid by yourself or the family members in your household and not reimbursed by insurance or benefits).","CHART-SF Interview Version - Medical Care Expense Last Year | CHSF1-Medical Care Expenses Last Year | CHSF119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899847","C-SSRS Lifetime/Recent Version - Wish to be Dead (Lifetime)","C118019","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Have you wished you were dead or wished you could go to sleep and not wake up? (Lifetime).","C-SSRS Lifetime/Recent Version - Wish to be Dead (Lifetime) | CSS11-Wish to be Dead-Life | CSS1101A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899846","C-SSRS Lifetime/Recent Version - Wish to be Dead (Past 1 Month)","C118020","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Have you wished you were dead or wished you could go to sleep and not wake up? (Past 1 Month).","C-SSRS Lifetime/Recent Version - Wish to be Dead (Past 1 Month) | CSS11-Wish to be Dead-P1M | CSS1101B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899883","C-SSRS Lifetime/Recent Version - Description of Wish to be Dead","C118021","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Description of wishing to be dead.","C-SSRS Lifetime/Recent Version - Description of Wish to be Dead | CSS11-Wish to be Dead, Describe | CSS1101C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899864","C-SSRS Lifetime/Recent Version - Non-Specific Active Suicidal Thoughts (Lifetime)","C118022","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Have you actually had any thoughts of killing yourself? (Lifetime).","C-SSRS Lifetime/Recent Version - Non-Specific Active Suicidal Thoughts (Lifetime) | CSS11-Non-Spec Suicid Thought-Life | CSS1102A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433751","Stage IIC Rectal Cancer AJCC v7","C115046","Stage IIC includes: T4b, N0, M0. T4b: Tumor directly invades or is adherent to other organs or structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)","Stage IIC Rectal Cancer AJCC v7 | Stage IIC Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433744","Stage IIIA Colon Cancer AJCC v7","C115047","Stage IIIA includes: (T1-T2, N1/N1c, M0); (T1, N2a, M0). T1: Tumor invades submucosa. T2: Tumor invades muscularis propria. N1: Metastasis in 1-3 regional lymph nodes. N1c: Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional lymph node metastasis. N2a: Metastasis in 4-6 regional lymph nodes. M0: No distant metastasis. (AJCC 7th ed.)","Stage IIIA Colon Cancer AJCC v7 | Stage IIIA Colon Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433745","Stage IIIB Colon Cancer AJCC v7","C115048","Stage IIIB includes: (T3-T4a, N1/N1c, M0); (T2-T3, N2a, M0); (T1-T2, N2b, M0). T1: Tumor invades submucosa. T2: Tumor invades muscularis propria. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor penetrates to the surface of the visceral peritoneum. N1: Metastasis in 1-3 regional lymph nodes. N1c: Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional lymph node metastasis. N2a: Metastasis in 4-6 regional lymph nodes. N2b: Metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 7th ed.)","Stage IIIB Colon Cancer AJCC v7 | Stage IIIB Colon Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889638","PKD1L1 wt Allele","C114554","Human PKD1L1 wild-type allele is located in the vicinity of 7p12.3 and is approximately 174 kb in length. This allele, which encodes polycystic kidney disease protein 1-like 1 protein, plays a role in the modulation of ciliary calcium concentration.","PKD1L1 wt Allele | PRO19563 | Polycystic Kidney Disease 1 Like 1 wt Allele | Polycystin 1-Like 1 Gene | UNQ5785/PRO19563",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473397","Polycystic Kidney Disease Protein 1-Like 1","C114555","Polycystic kidney disease protein 1-like 1 (2849 aa, ~315 kDa) is encoded by the human PKD1L1 gene. This protein is involved in ciliary calcium concentration modulation.","Polycystic Kidney Disease Protein 1-Like 1 | PC1-Like 1 Protein | PKD1L1 | Polycystin-1L1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418434","PDE8B Gene","C114556","This gene plays a role in the metabolism of cyclic AMP.","PDE8B Gene | PDE8B | Phosphodiesterase 8B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889378","PDE8B wt Allele","C114557","Human PDE8B wild-type allele is located in the vicinity of 5q13.3 and is approximately 219 kb in length. This allele, which encodes high affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8B protein, is involved in second messenger metabolism. Mutation of the gene is associated with both autosomal dominant striatal degeneration and primary pigmented nodular adrenocortical disease 3.","PDE8B wt Allele | ADSD | PIG22 | PPNAD3 | Phosphodiesterase 8B wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1172460","High Affinity cAMP-Specific and IBMX-Insensitive 3',5'-Cyclic Phosphodiesterase 8B, Human","C114558","High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8B (885 aa, ~99 kDa) is encoded by the human PDE8B gene. This protein plays a role in cyclic AMP catabolism.","High Affinity cAMP-Specific and IBMX-Insensitive 3',5'-Cyclic Phosphodiesterase 8B | 3',5' Cyclic Nucleotide Phosphodiesterase 8B | Cell Proliferation-Inducing Gene 22 Protein | EC 3.1.4.17 | High Affinity cAMP-Specific and IBMX-Insensitive 3,5-Cyclic Phosphodiesterase 8B | HsPDE8B | PDE8B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3502107","Breastfeeding Jaundice","C114561","Yellow coloring of skin, mucous membranes and eyes in an otherwise healthy breast-fed newborn due to insufficient intake of maternally-expressed milk. It commonly appears four to seven days after birth.","Breastfeeding Jaundice | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897805","RHEB wt Allele","C115284","Human RHEB wild-type allele is located in the vicinity of 7q36 and is approximately 54 kb in length. This allele, which encodes GTP-binding protein Rheb, is involved in the positive regulation of signaling.","RHEB wt Allele | RHEB2 | Ras Homolog Enriched In Brain 2 Gene | Ras Homolog Enriched In Brain Gene | Ras Homolog, mTORC1 Binding wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473393","GTP-Binding Protein Rheb","C115291","GTP-binding protein Rheb (184 aa, ~20 kDa) is encoded by the human RHEB gene. This protein plays a role in the positive regulation of MTORC1-mediated signal transduction.","GTP-Binding Protein Rheb | Ras Homolog Enriched In Brain | Ras Homolog Enriched In Brain 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898127","Non-Metastatic Childhood Soft Tissue Sarcoma","C115292","A soft tissue sarcoma that occurs during childhood and is confined to a specific site without evidence of spread to other anatomic sites.","Localized Childhood Soft Tissue Sarcoma | Non-Metastatic Childhood Soft Tissue Sarcoma | Soft Tissue Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897875","Post-Natal Death at 16-20 Weeks Gestation","C114870","A fetus of 16-20 weeks gestational age that shows signs of life at birth but dies after delivery.","Post-Natal Death at 16-20 Weeks Gestation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152159","Prolonged Latent Phase of Labor","C114871","Greater than 20 hours of labor in nulliparous women and greater than 14 hours in parous women.","Prolonged Latent Phase of Labor | Arrest of Labor in the Latent Phase | Latent Phase Arrest",,,,,,,,,,,,,,,"4308660","Prolonged latent phase of labor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3900112","Acute Intrapartum Hypoxic Event","C114872","A sentinel hypoxic event occurring during labor, with evidence of fetal metabolic acidosis in the fetal umbilical arterial blood; a sudden and sustained fetal bradycardia or the absence of fetal heart rate variability in the presence of persistent, late, or variable decelerations (category III tracing); previously normal Apgar scores that are 0-3 beyond 5 minutes.","Acute Intrapartum Hypoxic Event | Acute Intrapartum Hypoxia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472633","Decitabine and Cedazuridine","C115102","An orally available fixed-dose combination agent containing cedazuridine, a cytidine deaminase (CDA) inhibitor, and the cytidine antimetabolite decitabine, with potential antineoplastic activity. Upon oral administration of tdecitabine and cedazuridine, cedazuridine binds to and inhibits CDA, an enzyme primarily found in the gastrointestinal (GI) tract and liver that catalyzes the deamination of cytidine and cytidine analogs. This prevents the breakdown of decitabine, increases its bioavailability and efficacy while decreasing GI toxicity due to the administration of lower doses of decitabine. Decitabine exerts its antineoplastic activity through the incorporation of its triphosphate form into DNA, which inhibits DNA methyltransferase and results in hypomethylation of DNA. This interferes with DNA replication and decreases tumor cell growth.","Decitabine and Cedazuridine | ASTX 727 | ASTX-727 | ASTX727 | C-DEC | CDA Inhibitor E7727/Decitabine Combination Agent ASTX727 | Cedazuridine/Decitabine Combination Agent ASTX727 | Cedazuridine/Decitabine Tablet | DEC-C | Decitabine and cedazuridine | Inaqovi | Inqovi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899897","C-SSRS Lifetime/Recent Version - Actual Suicide Attempt (Lifetime)","C118048","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Have you made a suicide attempt? Have you done anything to harm yourself? Have you done anything dangerous where you could have died? (Lifetime).","C-SSRS Lifetime/Recent Version - Actual Suicide Attempt (Lifetime) | CSS11-Actual Attempt-Life | CSS1112A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889697","ATP8B2 wt Allele","C114664","Human ATP8B2 wild-type allele is located in the vicinity of 1q21.3 and is approximately 26 kb in length. This allele, which encodes probable phospholipid-transporting ATPase ID protein, plays a role in aminophospholipid translocation.","ATP8B2 wt Allele | ATPID | ATPase, Aminophospholipid Transporter, Class I, Type 8B, Member 2 wt Allele | ATPase, Class I, Type 8B, Member 2 Gene | KIAA1137 | RP11-350G8.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897854","Probable Phospholipid-Transporting ATPase ID, human","C114665","Phospholipid-transporting ATPase ID (1209 aa, ~137 kDa) is encoded by the human ATP8B2 gene. This protein is involved in the translocation of aminophospholipids.","Phospholipid-Transporting ATPase ID | ATP8B2 | ATPase Class I Type 8B Member 2 | EC 3.6.3.1, Formerly | EC 7.6.2.1 | P4-ATPase Flippase Complex Alpha Subunit ATP8B2 | Probable Phospholipid-Transporting ATPase ID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3549608","Nephrolithiasis","C114667","The presence of a calculus in the pelvis of the kidney; this is most often composed of mineral salts and proteins.","Nephrolithiasis | Kidney Stone | Renal Calculi",,,,,,,,,,,,,,,"201620","Kidney stone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1825495","ATG4C Gene","C114672","This gene plays a role in autophagy.","ATG4C Gene | ATG4C | Autophagy Related 4C, Cysteine Peptidase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899863","C-SSRS Lifetime/Recent Version - Non-Specific Active Suicidal Thoughts (Past 1 Months)","C118023","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Have you actually had any thoughts of killing yourself? (Past 1 Month).","C-SSRS Lifetime/Recent Version - Non-Specific Active Suicidal Thoughts (Past 1 Months) | CSS11-Non-Spec Suicid Thought-P1M | CSS1102B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899885","C-SSRS Lifetime/Recent Version - Description of Non-Specific Active Suicidal Thoughts","C118024","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Description of non-specific active suicidal thoughts.","C-SSRS Lifetime/Recent Version - Description of Non-Specific Active Suicidal Thoughts | CSS11-Non-Spec Suicid Thought, Describe | CSS1102C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474100","CD28CAR/CD137CAR-expressing T-Lymphocytes","C117232","Third generation, chimeric antigen receptor (CAR) cells composed of T-lymphocytes transduced with a lentiviral vector expressing a CAR consisting of an a single chain variable fragment specific for a particular antigen, coupled to the two co-stimulatory signaling domains Cluster of Differentiation 28 (CD28) and Cluster of Differentiation 137 (CD137; 4-1BB), and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3-zeta), with potential immunomodulating and antineoplastic activities. Upon transfusion, CD28CAR/CD137CAR-expressing T-lymphocytes are directed to, and induce selective toxicity in tumor cells expressing the particular antigen. CD28, a T-cell surface-associated co-stimulatory molecule, is required for T-cell activation, proliferation, and survival. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of the antigen. Furthermore, inclusion of the 4-1BB signaling domain may increase the antitumor activity when compared to the inclusion of the CD28 co-stimulatory domain and CD3-zeta alone.","CD28CAR/CD137CAR-expressing T-Lymphocytes | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474101","IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes","C117233","A preparation of ex vivo expanded, genetically modified autologous central memory-enriched T-cells (Tcm) transduced with a replication incompetent, self-inactivating (SIN) lentiviral vector expressing a hinge-optimized, chimeric antigen receptor (CAR) specific for interleukin-13 receptor alpha 2 (IL13Ra2), and containing the cluster of differentiation 137 (CD137; 4-1BB) co-stimulatory signaling domain fused to the signaling domain of the T cell antigen receptor complex zeta chain (CD3-zeta), and a truncated form of human cluster of differentiation 19 (CD19t), with potential immunostimulating and antineoplastic activities. Upon intratumoral or intracavitary administration, IL13Ra2-specific, hinge-optimized, 41BB-co-stimulatory CAR/truncated CD19 expressing T-lymphocytes are directed to, and induce selective toxicity and cytolysis in IL13Ra2-expressing tumor cells. IL13Ra2, overexpressed by a variety of tumor cell types, is associated with increased tumor cell proliferation, migration and invasiveness. The costimulatory signaling domain enhances both proliferation of T-cells and antitumor activity. Hinge optimization prevents the recognition and clearance of the CAR by endogenous Fc receptors (FcRs). CD19t is used as a surface marker to both quantify and track the gene modified T-cells in vivo.","IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes | Autologous IL13(EQ)BBzeta/CD19t+ TCM-enriched T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1455006","Alpha-tocopheryloxyacetic Acid","C117234","An orally bioavailable vitamin E derivative with potential antineoplastic and immunostimulating activities. Upon administration, alpha-tocopheryloxyacetic acid (alpha-TEA) induces tumor autophagy; the autophagosomes formed, which carry tumor associated antigens (TAAs), allow for increased cross-presentation of TAAs by professional antigen-presenting cells (APCs). This activates a T cell-mediated T helper type 1 (TH1) response, generates a cytotoxic T-lymphocyte (CTL) response against cancer cells, and reduces the frequency of regulatory T-cell (Treg) differentiation. In addition, alpha-TEA modulates the release of various cytokines and chemokines and induces tumor cell apoptosis. Altogether, this results in decreased tumor cell proliferation.","Alpha-tocopheryloxyacetic Acid | .ALPHA.-TOCOPHERYLOXYACETIC ACID | 2,5,7,8-Tetramethyl-(2R-(4R,8R,12-trimethyltridecyl) chroman-6-yloxy) Acetic Acid | a-TEA | alpha-TEA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474105","IDH1R132H-Specific Peptide Vaccine PEPIDH1M","C117235","A peptide vaccine consisting of a peptide derived from isocitrate dehydrogenase 1 (IDH1) containing the point mutation R132H (IDH1R132H), with potential antineoplastic activity. Intradermal vaccination with the IDH1R132H-specific peptide vaccine PEPIDH1M may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the IDH1R132H protein. The IDH1 point mutation of amino acid residue 132 is highly expressed in gliomas and is associated with increased production of the oncometabolite R-2-hydroxyglutarate (2HG).","IDH1R132H-Specific Peptide Vaccine PEPIDH1M | PEPIDH1M | PEPIDH1M Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538563","PACS1 Gene","C114563","This gene is involved in protein trafficking.","PACS1 Gene | PACS1 | Phosphofurin Acidic Cluster Sorting Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889454","PACS1 wt Allele","C114564","Human PACS1 wild-type allele is located within 11q13.1-q13.2 and is approximately 174 kb in length. This allele, which encodes phosphofurin acidic cluster sorting protein 1, plays a role in targeting proteins to the Golgi. Mutation of the gene is associated with autosomal dominant mental retardation 17.","PACS1 wt Allele | FLJ10209 | KIAA1175 | MRD17 | Phosphofurin Acidic Cluster Sorting Protein 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1452329","Phosphofurin Acidic Cluster Sorting Protein 1, Human","C114566","Phosphofurin acidic cluster sorting protein 1 (963 aa, ~105 kDa) is encoded by the human PACS1 gene. This protein is involved in mediating the localization of proteins to the Golgi.","Phosphofurin Acidic Cluster Sorting Protein 1 | Cytosolic Sorting Protein PACS-1 | PACS-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0369108","Anti-ss DNA Antibody","C114567","A type of antinuclear antibody that specifically targets single stranded (denatured) DNA; these antibodies are often detectable in multiple different autoimmune and rheumatologic disorders, but their presence is neither sensitive nor specific to diagnosing any one of these diseases.","Anti-ss DNA Antibody | Anti-single stranded DNA Antibody | Anti-ssDNA Antibody",,,,,,,,,,,,,,,"4283507","Single stranded anti DNA antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1417075","MCPH1 Gene","C114568","This gene plays a role in both mitotic checkpoints and brain development.","MCPH1 Gene | MCPH1 | Microcephalin 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433972","hereditary neuroblastoma","C115225","Genetic inheritance of neuroblastoma caused by mutations in the ALK or PHOX2B genes.  Familial neuroblastomas have a higher incidence of multiple primary tumors and are diagnosed at an earlier age.","Hereditary Neuroblastoma | Familial Neuroblastoma | Familial Neuroblastoma | Hereditary Neuroblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896964","Long-Term Effects Secondary to Cancer Therapy","C115226","Side effects of cancer treatment occurring a long time after the treatment was completed.","Long-Term Effects Secondary to Cancer Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831740","Long-Term Effects Secondary to Cancer Therapy in Adults","C115227","Side effects of cancer treatment received during adulthood occurring a long time after the treatment was completed.","Long-Term Effects Secondary to Cancer Therapy in Adults | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456091","Fetus Large for Gestational Age","C114873","A fetus exceeding 90% of expected weight for gestational age.","Fetus Large for Gestational Age | Fetal LGA | Fetal Large for Gestational Age",,,,,,,,,,,,,,,"4064287","Large for gestation age fetus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0302511","Fetus Small for Gestational Age","C114875","A fetus that does not grow beyond the 10th percentile of conventionally accepted weight for gestational age.","Fetus Small for Gestational Age | Fetal Growth Restriction | Fetal Growth Retardation | Fetal SGA | Fetal Small for Gestational Age | Fetal growth retardation | IUGR | Intrauterine Growth Restriction | Intrauterine Growth Retardation",,,,,,,,,,,,,,,"4145947","Small for gestational age fetus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899119","Fetus Small for Gestational Age with Oligohydraminos","C114876","A fetus that does not grow beyond the 10th percentile of conventionally accepted weight for gestational age and shows evidence of oligohydramnios.","Fetus Small for Gestational Age with Oligohydraminos | Fetal SGA with Oligohydraminois | Fetal SGA with Oligohydramnios | Fetal Small for Gestational Age with Oligohydraminos | Fetal Small for Gestational Age with Oligohydramnios",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899120","Fetus Small for Gestational Age with Abnormal Doppler","C114877","A fetus that does not grow beyond the 10th percentile of conventionally accepted weight for gestational age and has abnormal Doppler studies.","Fetus Small for Gestational Age with Abnormal Doppler | Fetal SGA with Abnormal Doppler | Fetal SGA with Abnormal Dopplers | Fetal Small for Gestational Age with Abnormal Doppler | Fetal Small for Gestational Age with Abnormal Dopplers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899121","Fetus Small for Gestational Age with Abdominal Circumference Less than Tenth Percentile","C114878","A fetus that does not grow beyond the 10th percentile of conventionally accepted weight for gestational age and whose abdominal circumference falls below the tenth percentile.","Fetus Small for Gestational Age with Abdominal Circumference Less than Tenth Percentile | Fetal SGA with Abdominal Circumference Less than Tenth Percentile | Fetal Small for Gestational Age with Abdominal Circumference Less than Tenth Percentile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890750","ATG4C wt Allele","C114673","Human ATG4C wild-type allele is located in the vicinity of 1p31.3 and is approximately 81 kb in length. This allele, which encodes cysteine protease ATG4C protein, is involved in proteolysis during autophagy.","ATG4C wt Allele | APG4 Autophagy 4 Homolog C (S. cerevisiae) Gene | APG4, S. cerevisiae, Homolog of, C Gene | APG4-C | APG4C | ATG4 Autophagy Related 4 Homolog C (S. cerevisiae) Gene | AUT (S. cerevisiae)-Like 1, Cysteine Endopeptidase Gene | AUT-Like 1, Cysteine Endopeptidase (S. cerevisiae) Gene | AUTL1 | AUTL3 | Autophagy 4, S. cerevisiae, Homolog of, C Gene | Autophagy Related 4C, Cysteine Peptidase wt Allele | FLJ14867",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3489603","Cysteine Protease ATG4C, Human","C114675","Cysteine protease ATG4C (458 aa, ~52 kDa) is encoded by the human ATG4C gene. This protein plays a role in proteolysis of autophagy-regulatory proteins.","Cysteine Protease ATG4C | APG4 Autophagy 4 Homolog C | ATG4 Autophagy Related 4 Homolog C | ATG4C | AUT-Like 1, Cysteine Endopeptidase | AUT-Like 3 Cysteine Endopeptidase | Autophagin 3 | Autophagin-3 | Autophagy-Related Cysteine Endopeptidase 3 | Autophagy-Related Protein 4 Homolog C | EC 3.4.22.-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899234","Experimental Organism Benign Keratoacanthoma","C117977","A benign neoplasm in the superficial dermis with direct association to the epidermis, composed of well differentiated squamous epithelium and a central cavity filled with concentric layers of keratin; a pore (opening in the epidermis) may be present. (CDISC)","Experimental Organism Benign Keratoacanthoma | KERATOACANTHOMA, BENIGN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897863","Preputial Gland/Clitoral Gland Specimen","C117978","A laboratory specimen consisting of the preputial gland and the clitoral gland.","Preputial Gland/Clitoral Gland | GLAND, PREPUTIAL/GLAND, CLITORAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242693","Plantaris Muscle","C117979","A small muscle that courses along the posterior aspect of the leg as part of the posterosuperficial compartment of the calf. This muscle originates from the lateral supracondylar line of the femur superior and medial to the lateral head of the gastrocnemius muscle as well as from the oblique popliteal ligament in the posterior aspect of the knee.","Plantaris Muscle | MUSCLE, PLANTARIS",,,,,,,,,,,,,,,"4106168","Plantaris muscle structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL474108","VEGF/HGF-targeting DARPin MP0250","C117236","A designed ankyrin repeat proteins (DARPin)-based agent targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), with potential antiangiogenic and antineoplastic activities. Compared to antibodies, DARPins are small in size, have favorable pharmacokinetics and allow for both high affinity binding and efficacy. Upon administration, the VEGF/HGF-targeting DARPin MP0250 binds to and inhibits both HGF and VEGF. This prevents HGF- and VEGF-mediated signaling, and inhibits the growth of HGF/VEGF-overexpressing tumor cells. This agent also prevents osteolysis, due to the inhibitory effect on HGF signaling. HGF and VEGF are overexpressed in a variety of cancer cell types and are associated with increased cell proliferation, migration and adhesion.","VEGF/HGF-targeting DARPin MP0250 | Bispecific VEGF/HGF-targeting Darpin | MP-0250 | MP0250",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899865","C-SSRS Lifetime/Recent Version - Most Severe Ideation (Lifetime)","C118034","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Most severe ideation. (Lifetime).","C-SSRS Lifetime/Recent Version - Most Severe Ideation (Lifetime) | CSS11-Most Severe Idea-Life | CSS1106A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899199","Exposure as Collected Start Date and Time of Treatment","C117496","The date and time of the beginning of exposure collection period.","Exposure as Collected Start Date and Time of Treatment | ECSTDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899221","Exposure as Collected End Date and Time of Treatment","C117497","The date and time of the end of the exposure collection period.","Exposure as Collected End Date and Time of Treatment | ECENDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518431","Novembichin","C1174","A nitrogen mustard agent that crosslinks with DNA, causing inhibition of DNA synthesis. (NCI)","Novembichin | NOVEMBICHIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890015","IMP3 wt Allele","C114818","Human IMP3 wild-type allele is located in the vicinity of 15q24 and is approximately 10 kb in length. This allele, which encodes U3 small nucleolar ribonucleoprotein protein IMP3, is involved in the maturation of ribosomal RNA.","IMP3 wt Allele | BRMS2 | C15orf12 | Chromosome 15 Open Reading Frame 12 Gene | FLJ10968 | IMP3, S. cerevisiae, Homolog of Gene | IMP3, U3 Small Nucleolar Ribonucleoprotein wt Allele | IMP3, U3 Small Nucleolar Ribonucleoprotein, Homolog (Yeast) Gene | MRPS4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900106","Adult B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1","C114819","A B acute lymphoblastic leukemia that occurs during adulthood. It is characterized by the presence of lymphoblasts that carry a translocation between the BCR gene on chromosome 22 and the ABL1 gene on chromosome 9. It results in the production of the p190 kd or p210 kd fusion protein. It has an unfavorable clinical outcome.","Adult B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 | Adult B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR::ABL1 | Adult B Acute Lymphoblastic Leukemia with t(9;22)(q34;q11.2); BCR-ABL1 | B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889627","U3 Small Nucleolar Ribonucleoprotein Protein IMP3, human","C114820","U3 small nucleolar ribonucleoprotein protein IMP3 (184 aa, ~22 kDa) is encoded by the human IMP3 gene. This protein plays a role in ribosomal RNA processing.","U3 Small Nucleolar Ribonucleoprotein Protein IMP3 | BRMS2 | Mitochondrial Ribosomal Protein S4 | Mitochondrial Ribosomal Subunit Component 4 | Ribonucleoprotein Protein IMP3 | U3 SnoRNP Protein 3 Homolog | U3 SnoRNP Protein IMP3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0271858","Tertiary Hyperparathyroidism","C114821","An overproduction of parathyroid hormone that is autonomous and often associated with chronic secondary hyperparathyroidism.","Tertiary Hyperparathyroidism | ",,,,,,,,,,,,,,,"4300058","Tertiary hyperparathyroidism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0280415","Stage IV Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","C115073","Stage IV includes: IVA: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB: (T4b, Any N, M0); (Any T, N3, M0); IVC: (Any T, Any N, M1).  T4a: Maxillary sinus: Moderately advanced local disease. Tumor invades anterior orbital contents, skin of cheek, pterygoid plates, infratemporal fossa, cribriform plate, sphenoid or frontal sinuses.  Nasal cavity and ethmoid sinus: Moderately advanced local disease. Tumor invades any of the following: anterior orbital contents, skin of nose or cheek, minimal extension to anterior cranial fossa, pterygoid plates, sphenoid or frontal sinuses.  T4b: Very advanced local disease.  Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than maxillary division of trigeminal nerve, nasopharynx, or clivus.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension.  N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. N3: Metastasis in a lymph node, more than 6 cm in greatest dimension.  M0: No distant metastasis.  M1: Distant metastasis.  (AJCC 7th ed.)","Stage IV Sinonasal Squamous Cell Carcinoma AJCC v7 | Stage IV Nasal Cavity and Paranasal Sinus Squamous Cell Cancer | Stage IV Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma | Stage IV Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433801","Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","C115074","Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); T4a: Maxillary sinus: Moderately advanced local disease. Tumor invades anterior orbital contents, skin of cheek, pterygoid plates, infratemporal fossa, cribriform plate, sphenoid or frontal sinuses.  Nasal cavity and ethmoid sinus: Moderately advanced local disease. Tumor invades any of the following: anterior orbital contents, skin of nose or cheek, minimal extension to anterior cranial fossa, pterygoid plates, sphenoid or frontal sinuses.  T1: Maxillary sinus: Tumor limited to the maxillary sinus mucosa with no erosion or destruction of bone.  Nasal cavity and ethmoid sinus: Tumor restricted to any one subsite, with or without bony invasion.  T2: Maxillary sinus: Tumor causing bone erosion or destruction including extension into the hard palate and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and pterygoid plates.  Nasal cavity and ethmoid sinus: Tumor invading two subsites in a single region or extending to involve an adjacent region within the nasoethmoidal complex, with or without bony invasion.  T3: Maxillary sinus: Tumor invading any of the following: bone of the posterior wall of maxillary sinus, subcutaneous tissues, floor or medial wall of orbit, pterygoid fossa, or ethmoid sinuses. Nasal cavity and ethmoid sinus: Tumor invading the medial wall or floor of the orbit, maxillary sinus, palate, or cribriform plate.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension.  N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. M0: No distant metastasis. (AJCC 7th ed.)","Stage IVA Sinonasal Squamous Cell Carcinoma AJCC v7 | Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Cancer | Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma | Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433803","Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","C115075","Stage IVB includes: (T4b, Any N, M0); (Any T, N3, M0).  T4b: Very advanced local disease.  Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than maxillary division of trigeminal nerve, nasopharynx, or clivus.  N3: Metastasis in a lymph node, more than 6 cm in greatest dimension.  M0: No distant metastasis. (AJCC 7th ed.)","Stage IVB Sinonasal Squamous Cell Carcinoma AJCC v7 | Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Cancer | Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma | Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433802","Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","C115076","Stage IVC includes: Any T, Any N, M1.  M1: Distant metastasis.  (AJCC 7th ed.)","Stage IVC Sinonasal Squamous Cell Carcinoma AJCC v7 | Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Cancer | Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma | Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539855","SSH1 Gene","C115077","This gene plays a role in both protein dephosphorylation and cell projection formation.","SSH1 Gene | SSH1 | Slingshot Protein Phosphatase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890214","SSH1 wt Allele","C115078","Human SSH1 wild-type allele is located in the vicinity of 12q24.12 and is approximately 75 kb in length. This allele, which encodes protein phosphatase Slingshot homolog 1 protein, is involved in both the regulation of cellular projection formation and the modulation of protein phosphorylation.","SSH1 wt Allele | KIAA1298 | SSH1L | Slingshot Homolog 1 (Drosophila) Gene | Slingshot Protein Phosphatase 1 wt Allele | Slingshot, Drosophila, Homolog of Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879504","cisplatin/cyclophosphamide/dexamethasone/etoposide/thalidomide","C11797","A regimen consisting of cisplatin, cyclophosphamide, dexamethasone, etoposide and thalidomide that can be used for the treatment of plasma cell (multiple) myeloma.","Cisplatin/Cyclophosphamide/Dexamethasone/Etoposide/Thalidomide Regimen | Cisplatin-Cyclophosphamide-Dexamethasone-Etoposide-Thalidomide | Cisplatin/Cyclophosphamide/Dexamethasone/Etoposide/Thalidomide | DCEP-T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224152","Sternocephalicus Muscle","C117980","A long muscle of the neck that extends from the manubrium sterni to the mandible and branches at the middle of the neck, forming the ventral border of the jugular groove.","Sternocephalicus Muscle | MUSCLE, STERNOCEPHALICUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003063","Animals, Domestic","C117982","The name for a domesticated animal that does not have a pedigree nor belong to a specific breed.","Domestic Animal | DOMESTIC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899656","Pediatric Infectious Disorder","C117984","An infectious disorder that occurs during infancy, childhood, or adolescence.","Pediatric Infectious Disorder | Pediatric Infectious Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896626","CDISC Questionnaire CHART-SF Interview Version Test Name Terminology","C117986","Test names of questionnaire questions associated with the Craig Handicap Assessment and Reporting Technique - Short Form Interview Version (CHART-SF Interview Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire CHART-SF Interview Version Test Name Terminology | CHSF1TN | Craig Handicap Assessment and Reporting Technique - Short Form Interview Version Questionnaire Test Name | QS-CHART-SF TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896627","CDISC Questionnaire CHART-SF Interview Version Test Code Terminology","C117987","Test codes of questionnaire questions associated with the Craig Handicap Assessment and Reporting Technique - Short Form Interview Version (CHART-SF Interview Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire CHART-SF Interview Version Test Code Terminology | CHSF1TC | Craig Handicap Assessment and Reporting Technique - Short Form Interview Version Questionnaire Test Code | QS-CHART-SF TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0297498","Heparan Sulfate Glucosamine 3-O-Sulfotransferase 1","C118218","Heparan sulfate glucosamine 3-O-sulfotransferase 1 (307 aa, ~36 kDa) is encoded by the human HS3ST1 gene. This protein is involved in the synthesis of heparan sulfate and anticoagulant heparan.","Heparan Sulfate Glucosamine 3-O-Sulfotransferase 1 | EC 2.8.2.23 | HS3ST1 | Heparan Sulfate 3-O-Sulfotransferase 1 | Heparan Sulfate D-Glucosaminyl 3-O-Sulfotransferase 1 | Heparin-Glucosamine 3-O-Sulfotransferase | h3-OST-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1311116","Recombining Binding Protein Suppressor of Hairless, Human","C114510","Recombining binding protein suppressor of hairless (500 aa, ~56 kDa) is encoded by the human RBPJ gene. This protein plays a role in both transcriptional regulation and signaling.","Recombining Binding Protein Suppressor of Hairless | C Promoter-Binding Factor 1 | CBF-1 | Immunoglobulin Kappa J Region Recombination Signal Binding Protein 1 | Immunoglobulin Kappa J Region Recombination Signal-Binding Protein 1 | J Kappa-Recombination Signal-Binding Protein | RBP-J | RBP-J Kappa | RBP-JK | RBPJ | Recombination Signal-Binding Protein 1 for J-Kappa | Recombination Signal-Binding Protein for Immunoglobulin Kappa J Region | Renal Carcinoma Antigen NY-REN-30",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889700","ADAM19 wt Allele","C114512","Human ADAM19 wild-type allele is located in the vicinity of 5q33.3 and is approximately 180 kb in length. This allele, which encodes disintegrin and metalloproteinase domain-containing protein 19, plays a role in proteolysis.","ADAM19 wt Allele | A Disintegrin and Metalloproteinase Domain 19 (Meltrin Beta) Gene | ADAM Metallopeptidase Domain 19 wt Allele | FKSG34 | MADDAM | MLTNB | Meltrin-Beta, Mouse, Homolog of Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0382545","Disintegrin and Metalloproteinase Domain-Containing Protein 19, Human","C114513","Disintegrin and metalloproteinase domain-containing protein 19 (955 aa, ~105 kDa) is encoded by the human ADAM19 gene. This protein is involved in proteolysis.","Disintegrin and Metalloproteinase Domain-Containing Protein 19 | A Disintegrin and Metalloproteinase Domain 19 | ADAM 19 | ADAM19 | EC 3.4.24.- | MADDAM | Meltrin Beta | Meltrin-Beta | Metalloprotease and Disintegrin Dendritic Antigen Marker | Metalloprotease-Disintegrin Meltrin Beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889147","DVL1 wt Allele","C114515","Human DVL1 wild-type allele is located in the vicinity of 1p36 and is approximately 14 kb in length. This allele, which encodes segment polarity protein dishevelled homolog DVL-1 protein, is involved in Wnt signaling.","DVL1 wt Allele | DSH, Drosophila, Homolog of, 1 Gene | DVL | DVL1L1 | DVL1P1 | Dishevelled 1 (Homologous to Drosophila dsh) Gene | Dishevelled Segment Polarity Protein 1 wt Allele | Dishevelled, Dsh Homolog 1 (Drosophila) Gene | Dishevelled, Dsh Homolog 1 Gene | RP5-890O3.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1674669","DVL1 protein, human","C114516","Segment polarity protein dishevelled homolog DVL-1 (695 aa, ~75 kDa) is encoded by the human DVL1 gene. This protein plays a role in signal transduction.","Segment Polarity Protein Dishevelled Homolog DVL-1 | DSH Homolog 1 | DVL1 | Dishevelled 1 | Dishevelled Segment Polarity Protein 1 | Dishevelled-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890427","HES2 wt Allele","C114518","Human HES2 wild-type allele is located in the vicinity of 1p36.31 and is approximately 12 kb in length. This allele, which encodes transcription factor HES-2 protein, plays a role in transcriptional repression.","HES2 wt Allele | BHLHB40 | HES-2 | Hairy and Enhancer of Split 2 (Drosophila) Gene | Hairy/Enhancer of Split, Drosophila, Homolog of Gene | Hes Family bHLH Transcription Factor 2 wt Allele | bHLHb40",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1531377","Transcription Factor HES-2, Human","C114519","Transcription factor HES-2 (173 aa, ~18 kDa) is encoded by the human HES2 gene. This protein is involved in the repression of transcription.","Transcription Factor HES-2 | Class B Basic Helix-Loop-Helix Protein 40 | HES-2 | HES2 | Hairy and Enhancer of Split 2 | bHLHb40",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889408","TJP1 wt Allele","C114823","Human TJP1 wild-type allele is located in the vicinity of 15q13 and is approximately 269 kb in length. This allele, which encodes tight junction protein ZO-1, is involved in the signal transduction and the formation of cell-cell junctions.","TJP1 wt Allele | DKFZp686M05161 | MGC133289 | Tight Junction Protein 1 wt Allele | ZO-1 | ZO1 | Zona Occludens 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1451683","Tight Junction Protein ZO-1, Human","C114824","Tight junction protein ZO-1 (1748 aa, ~195 kDa) is encoded by the human TJP1 gene. This protein plays a role in tight junction formation and signal transduction.","Tight Junction Protein ZO-1 | TJP1 | Tight Junction Protein 1 | Zona Occludens Protein 1 | Zonula Occludens 1 Protein | Zonula Occludens Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890915","EVL wt Allele","C114826","Human EVL wild-type allele is located in the vicinity of 14q32.2 and is approximately 173 kb in length. This allele, which encodes Ena/VASP-like protein, plays a role in actin polymerization.","EVL wt Allele | Enah/Vasp-Like wt Allele | RNB6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035086","Renal Osteodystrophy","C114827","Abnormalities of bone mineral metabolism associated with chronic kidney disease.","Renal Osteodystrophy | ROD",,,,,,,,,,,,,,,"197921","Renal osteodystrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1433078","Ena/VASP-Like Protein, Human","C114829","Ena/VASP-like protein (416 aa, ~45 kDa) is encoded by the human EVL gene. This protein is involved in actin binding and cytoskeletal remodeling.","Ena/VASP-Like Protein | EVL | Ena/Vasodilator-Stimulated Phosphoprotein-Like | Enah/Vasp-Like Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042870","Vitamin D Deficiency","C114830","Abnormally low level of 25-hydroxyvitamin D in the blood.","Vitamin D Deficiency | ",,,,,,,,,,,,,,,"436070","Vitamin D deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL433746","Stage IIIC Colon Cancer AJCC v7","C115049","Stage IIIC includes: (T4a, N2a, M0); (T3-T4a, N2b, M0); (T4b, N1-N2, M0). T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor penetrates to the surface of the visceral peritoneum. T4b: Tumor directly invades or is adherent to other organs or structures. N1: Metastasis in 1-3 regional lymph nodes. N2: Metastasis in four or more regional lymph nodes. N2a: Metastasis in 4-6 regional lymph nodes. N2b: Metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 7th ed.)","Stage IIIC Colon Cancer AJCC v7 | Stage IIIC Colon Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433752","Stage IIIA Rectal Cancer AJCC v7","C115050","Stage IIIA includes: (T1-T2, N1/N1c, M0); (T1, N2a, M0). T1: Tumor invades submucosa. T2: Tumor invades muscularis propria. N1: Metastasis in 1-3 regional lymph nodes. N1c: Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional lymph node metastasis. N2a: Metastasis in 4-6 regional lymph nodes. M0: No distant metastasis. (AJCC 7th ed.)","Stage IIIA Rectal Cancer AJCC v7 | Stage IIIA Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433753","Stage IIIB Rectal Cancer AJCC v7","C115051","Stage IIIB includes: (T3-T4a, N1/N1c, M0); (T2-T3, N2a, M0); (T1-T2, N2b, M0). T1: Tumor invades submucosa. T2: Tumor invades muscularis propria. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor penetrates to the surface of the visceral peritoneum. N1: Metastasis in 1-3 regional lymph nodes. N1c: Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional lymph node metastasis. N2a: Metastasis in 4-6 regional lymph nodes. N2b: Metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 7th ed.)","Stage IIIB Rectal Cancer AJCC v7 | Stage IIIB Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1450798","Protein Phosphatase Slingshot Homolog 1, Human","C115079","Protein phosphatase Slingshot homolog 1 (1049 aa, ~116 kDa) is encoded by the human SSH1 gene. This protein plays a role in the modulation of both protein phosphorylation and cellular projection formation.","Protein Phosphatase Slingshot Homolog 1 | EC 3.1.3.16 | EC 3.1.3.48 | SSH-1L | SSH-Like Protein 1 | SSH1 | Slingshot Homolog 1 | hSSH-1L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1702052","Protein Unc-13 Homolog D, Human","C114617","Protein unc-13 homolog D (1090 aa, ~123 kDa) is encoded by the human UNC13D gene. This protein is involved in maturation and secretion of cytolytic granules.","Protein Unc-13 Homolog D | UNC13D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889141","F-Box/LRR-Repeat Protein 18, Human","C114619","F-box/LRR-repeat protein 18 (805 aa, ~88 kDa) is encoded by the human FBXL18 gene. This protein is involved in the modulation of protein ubiquitination.","F-Box/LRR-Repeat Protein 18 | F-Box and Leucine-Rich Repeat Protein 18 | FBL18 | FBXL18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2716822","Syntaxin-11, Human","C114621","Syntaxin-11 (287 aa, ~33 kDa) is encoded by the human STX11 gene. This protein plays a role in the regulation of both targeting and fusion of intracellular transport vesicles.","Syntaxin-11 | STX11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1453681","Syntaxin-Binding Protein 2, Human","C114624","Syntaxin-binding protein 2 (593 aa, ~66 kDa) is encoded by the human STXBP2 gene. This protein is involved in intracellular vesicle trafficking and membrane fusion.","Syntaxin-Binding Protein 2 | Protein Unc-18 Homolog 2 | Protein Unc-18 Homolog B | STXBP2 | Unc-18B | Unc18-2 | pp10122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421920","ERO1A Gene","C114625","This gene plays a role in both protein oxidation and disulfide bond formation.","ERO1A Gene | ERO1A | ERO1L | Endoplasmic Reticulum Oxidoreductase 1 Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889692","ERO1L","C114626","Human ERO1A wild-type allele is located in the vicinity of 14q22.1 and is approximately 56 kb in length. This allele, which encodes ERO1-like protein alpha, is involved in protein folding.","ERO1A wt Allele | ERO1 (S. cerevisiae)-Like Gene | ERO1, S. cerevisiae, Homolog of Gene | ERO1-Alpha | ERO1-Like (S. cerevisiae) Gene | ERO1-Like, Alpha Gene | ERO1L | ERO1LA | Endoplasmic Reticulum Oxidoreductase 1 Alpha wt Allele | Endoplasmic Reticulum Oxidoreductin 1-Like Gene | Ero1alpha | UNQ434/PRO865",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1438821","ERO1-Like Protein Alpha, Human","C114627","ERO1-like protein alpha (468 aa, ~54 kDa) is encoded by the human ERO1A gene. This protein plays a role in the modulation of both oxidation of and disulfide bond formation in proteins.","ERO1-Like Protein Alpha | EC 1.8.4.- | ERO1-L | ERO1-L-Alpha | ERO1A | ERO1L | Endoplasmic Oxidoreductin-1-Like Protein | Oxidoreductin-1-L-Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539345","EIF3K Gene","C114628","This gene is involved in translation initiation.","EIF3K Gene | EIF3K | Eukaryotic Translation Initiation Factor 3, Subunit K Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889379","PNOC wt Allele","C118220","Human PNOC wild-type allele is located in the vicinity of 8p21 and is approximately 26 kb in length. This allele, which encodes prepronociceptin protein, is involved in the regulation of the perception of pain.","PNOC wt Allele | N/OFQ | Nocistatin Gene | OFQ | PPNOC | Prepronociceptin wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898041","PNOC Gene Product","C118221","A protein encoded by the PNOC gene.","PNOC Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0909206","prepronociceptin","C118222","Prepronociceptin (176 aa, ~20 kDa) is encoded by the human PNOC gene. This protein is involved in both locomotion and pain perception.","Prepronociceptin | Propronociceptin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887701","Nociceptin, human","C118223","Nociceptin (17 aa, ~2 kDa) is encoded by the human PNOC gene. This protein plays a role in the perception of pain.","Nociceptin | PPNOC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889153","SH2D1B wt Allele","C118225","Human SH2D1B wild-type allele is located in the vicinity of 1q23.3 and is approximately 17 kb in length. This allele, which encodes SH2 domain-containing protein 1B, is involved in signal transduction.","SH2D1B wt Allele | EAT2 | SH2 Domain Containing 1B wt Allele | SH2 Domain-Containing 1B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447490","SH2 Domain-Containing Protein 1B, Human","C118226","SH2 domain-containing protein 1B (132 aa, ~15 kDa) is encoded by the human SH2D1B gene. This protein plays a role in the regulation of receptor signaling.","SH2 Domain-Containing Protein 1B | EAT-2 | EWS/FLI1-Activated Transcript 2 | SH2 Domain-Containing Molecule EAT2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889418","SLC8A1 wt Allele","C118228","Human SLC8A1 wild-type allele is located in the vicinity of 2p22.1 and is approximately 514 kb in length. This allele, which encodes sodium/calcium exchanger 1 protein, plays a role in calcium ion transport.","SLC8A1 wt Allele | CNC | NCX1 | Solute Carrier Family 8 (Sodium/Calcium Exchanger), Member 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1738239","Sodium/Calcium Exchanger 1, Human","C118229","Sodium/calcium exchanger 1 (973 aa, ~109 kDa) is encoded by the human SLC8A1 gene. This protein is involved in calcium ion transport that regulates cardiac muscle cell relaxation.","Sodium/Calcium Exchanger 1 | Na(+)/Ca(2+)-Exchange Protein 1 | Na+/Ca++ Exchanger | Na+/Ca2+ Exchanger | SLC8A1 | Solute Carrier Family 8 Member 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890426","HEYL wt Allele","C114521","Human HEYL wild-type allele is located in the vicinity of 1p34.3 and is approximately 17 kb in length. This allele, which encodes hairy/enhancer-of-split related with YRPW motif-like protein, is involved in the modulation of both cardiac development and transcriptional regulation.","HEYL wt Allele | BHLHB33 | HESR3 | HEY3 | HRT3 | Hairy/Enhancer-of-Split Related With YRPW Motif 3 Gene | Hairy/Enhancer-of-Split Related With YRPW Motif-Like Gene | Hes-Related Family bHLH Transcription Factor With YRPW Motif-Like wt Allele | bHLHb33",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890390","CELA1 wt Allele","C115177","Human CELA1 wild-type allele is located in the vicinity of 12q13 and is approximately 18 kb in length. This allele, which encodes chymotrypsin-like elastase family member 1 protein, plays a role in the mediation of proteolysis.","CELA1 wt Allele | Chymotrypsin-Like Elastase Family, Member 1 wt Allele | ELA1 | Elastase 1, Pancreatic Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890046","Chymotrypsin-Like Elastase Family Member 1, human","C115178","Chymotrypsin-like elastase family member 1 (258 aa, ~28 kDa) is encoded by the human CELA1 gene. This protein is involved in protein hydrolysis.","Chymotrypsin-Like Elastase Family Member 1 | CELA1 | EC 3.4.21.36 | Elastase 1 | Elastase-1 | Pancreatic Elastase 1 | Pancreatic Elastase-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890723","PPIB wt Allele","C115180","Human PPIB wild-type allele is located within 15q21-q22 and is approximately 7 kb in length. This allele, which encodes peptidyl-prolyl cis-trans isomerase B protein, is involved in protein folding. Mutation of the gene is associated with osteogenesis imperfecta type 9.","PPIB wt Allele | CYP-S1 | CYPB | HEL-S-39 | OI9 | Peptidylprolyl Isomerase B (Cyclophilin B) wt Allele | SCYLP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1567679","Peptidyl-Prolyl Cis-Trans Isomerase B, Human","C115181","Peptidyl-prolyl cis-trans isomerase B (216 aa, ~24 kDa) is encoded by the human PPIB gene. This protein plays a role in the mediation of protein folding.","Peptidyl-Prolyl Cis-Trans Isomerase B | CYP-S1 | Cyclophilin B | Cyclophilin-Like Protein | EC 5.2.1.8 | PPIB | PPIase B | Peptidyl-Prolyl Isomerase B | Peptidylprolyl Isomerase B | Rotamase B | S-Cyclophilin | SCYLP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889469","MMRN1 wt Allele","C115183","Human MMRN1 wild-type allele is located in the vicinity of 4q22 and is approximately 75 kb in length. This allele, which encodes multimerin-1 protein, plays a role in platelet factor V/Va homeostasis.","MMRN1 wt Allele | ECM | EMILIN4 | GPIa* | MMRN | Multimerin 1 wt Allele | Multimerin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0129320","multimerin","C115184","Multimerin-1 (1228 aa, ~138 kDa) is encoded by the human MMRN1 gene. This protein is involved in stabilization of platelet-bound factor V/Va.","Multimerin-1 | EMILIN-4 | Elastin Microfibril Interface Located Protein 4 | Elastin Microfibril Interfacer 4 | Endothelial Cell Multimerin | Glycoprotein Ia* | MMRN1 | Multimerin | Multimerin 1 | Platelet Glycoprotein Ia*",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890909","MUC2 wt Allele","C115186","Human MUC2 wild-type allele is located in the vicinity of 11p15.5 and is approximately 30 kb in length. This allele, which encodes mucin-2 protein, is involved in preventing irritation of mucosal surfaces.","MUC2 wt Allele | MLP | MUC-2 | Mucin 2, Intestinal Gene | Mucin 2, Intestinal/Tracheal Gene | Mucin 2, Oligomeric Mucus/Gel-Forming wt Allele | SMUC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433754","Stage IIIC Rectal Cancer AJCC v7","C115052","Stage IIIC includes: (T4a, N2a, M0); (T3-T4a, N2b, M0); (T4b, N1-N2, M0). T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor penetrates to the surface of the visceral peritoneum. T4b: Tumor directly invades or is adherent to other organs or structures. N1: Metastasis in 1-3 regional lymph nodes. N2: Metastasis in four or more regional lymph nodes. N2a: Metastasis in 4-6 regional lymph nodes. N2b: Metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 7th ed.)","Stage IIIC Rectal Cancer AJCC v7 | Stage IIIC Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433747","Stage IVA Colon Cancer AJCC v7","C115053","Stage IVA includes: Any T, Any N, M1a. M1a: Metastasis confined to one organ or site (e.g., liver, lung, ovary, nonregional node). (AJCC 7th ed.)","Stage IVA Colon Cancer AJCC v7 | Stage IVA Colon Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433748","Stage IVB Colon Cancer AJCC v7","C115054","Stage IVB includes: Any T, Any N, M1b. M1b: Metastases in more than one organ/site or the peritoneum. (AJCC 7th ed.)","Stage IVB Colon Cancer AJCC v7 | Stage IVB Colon Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433755","Stage IVA Rectal Cancer AJCC v7","C115055","Stage IVA includes: Any T, Any N, M1a. M1a: Metastasis confined to one organ or site (e.g., liver, lung, ovary, nonregional node). (AJCC 7th ed.)","Stage IVA Rectal Cancer AJCC v7 | Stage IVA Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433756","Stage IVB Rectal Cancer AJCC v7","C115056","Stage IVB includes: Any T, Any N, M1b. M1b: Metastases in more than one organ/site or the peritoneum. (AJCC 7th ed.)","Stage IVB Rectal Cancer AJCC v7 | Stage IVB Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280343","Stage I Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","C115057","Stage I includes: T1, N0, M0. T1: Tumor 2 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage I Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage I Lip and Oral Cavity Squamous Cell Cancer | Stage I Lip and Oral Cavity Squamous Cell Carcinoma | Stage I Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 | Stage I Lip and Oral Cavity Squamous Cell Carcinoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280348","Stage II Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","C115058","Stage II includes: T2, N0, M0. T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage II Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage II Lip and Oral Cavity Squamous Cell Cancer | Stage II Lip and Oral Cavity Squamous Cell Carcinoma | Stage II Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 | Stage II Lip and Oral Cavity Squamous Cell Carcinoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890389","MCPH1 wt Allele","C114569","Human MCPH1 wild-type allele is located in the vicinity of 8p23.1 and is approximately 237 kb in length. This allele, which encodes microcephalin protein, is involved in both brain development and DNA damage checkpoints. Mutation of the gene is associated with primary, autosomal-recessive microcephaly 1.","MCPH1 wt Allele | BRCT-Repeat Inhibitor of TERT Expression 1 Gene | BRIT1 | FLJ12847 | MCT | Microcephalin 1 wt Allele | Microcephaly, Primary Autosomal Recessive 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1138529","Microcephalin, Human","C114570","Microcephalin (835 aa, ~93 kDa) is encoded by the human MCPH1 gene. This protein plays a role in both cell cycle regulation and neuronal development.","Microcephalin | MCPH1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538505","MBOAT2 Gene","C114571","This gene is involved in lysophospholipid metabolism.","MBOAT2 Gene | MBOAT2 | Membrane Bound O-Acyltransferase Domain Containing 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889155","MBOAT2 wt Allele","C114572","Human MBOAT2 wild-type allele is located in the vicinity of 2p25.1 and is approximately 151 kb in length. This allele, which encodes lysophospholipid acyltransferase 2 protein, plays a role in glycophospholipid metabolism.","MBOAT2 wt Allele | FLJ14415 | FLJ90298 | LPCAT4 | Membrane Bound O-Acyltransferase Domain Containing 2 wt Allele | O-Acyltransferase (Membrane Bound) Domain Containing 2 Gene | OACT2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889279","EIF3K wt Allele","C114630","Human EIF3K wild-type allele is located in the vicinity of 19q13.2 and is approximately 18 kb in length. This allele, which encodes eukaryotic translation initiation factor 3 subunit K protein, plays a role in the initiation of protein synthesis.","EIF3K wt Allele | ARG134 | EIF3-p28 | EIF3S12 | Eukaryotic Translation Initiation Factor 3, Subunit 12 Gene | Eukaryotic Translation Initiation Factor 3, Subunit K wt Allele | HSPC029 | M9 | MSTP001 | PLAC-24 | PLAC24 | PRO1474 | PTD001 | eIF3k",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0949083","Nosocomial Pneumonia","C115297","Pneumonia acquired during a hospital stay.","Nosocomial Pneumonia | ",,,,,,,,,,,,,,,"4143092","Hospital acquired pneumonia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0065718","Marcellomycin","C1152","An antineoplastic oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Actinosporangium bohemicum.  Marcellomycin intercalates into DNA and induces DNA crosslinks, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also induces differentiation in HL-60 promyelocytic leukemia cells by interfering with glycoprotein synthesis. (NCI04)","Marcellomycin | 1-Naphthacenecarboxylic acid, 4-[[O-2,6-dideoxy-alpha-L-lyxo-hexopyranosyl-(1-4)-O-2, 6-dideoxy-alpha-L-lyxo-hexopyranosyl-(1-4)-2,3, 6-trideoxy-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl]oxy]-2-e thyl-1,2,3,4,6,11-hexahydro-2,5,7,10-tetrahydroxy-6,11-dioxo-, methyl ester, (1R-(1alpha,2beta,4beta))- (9CI) | MARCELLOMYCIN | Rhodirubin E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889434","TFF2 wt Allele","C115189","Human TFF2 wild-type allele is located in the vicinity of 21q22.3 and is approximately 5 kb in length. This allele, which encodes trefoil factor 2 protein, plays a role in both gastrointestinal motility and gastric acid secretion.","TFF2 wt Allele | SML1 | SP | Spasmolytic Protein 1 Gene | Trefoil Factor 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2752147","Xeroderma Pigmentosum, Complementation Group C","C114770","Xeroderma pigmentosum caused by bi-allelic mutations in XPC gene.","Xeroderma Pigmentosum, Complementation Group C | XP-C | Xeroderma Pigmentosum Group C",,,,,,,,,,,,,,,"4093617","Xeroderma pigmentosum, group C",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1848411","Xeroderma Pigmentosum, Complementation Group E","C114771","Xeroderma pigmentosum caused by bi-allelic mutations in DDB2 gene.","Xeroderma Pigmentosum, Complementation Group E | XP-E | Xeroderma Pigmentosum Group E",,,,,,,,,,,,,,,"4210300","Xeroderma pigmentosum, group E",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0949072","Extracorporeal Circuit Clot","C114772","Thrombus formation within an apparatus that carries blood outside of the body, such as pheresis, dialysis or extracorporeal membrane oxygenation (ECMO).","Extracorporeal Circuit Clot | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899674","Childhood Brain Oligodendroglioma","C114773","An oligodendroglioma that arises from the brain and occurs during childhood.","Childhood Brain Oligodendroglioma | Brain Oligodendroglioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL343570","Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified","C114774","A supratentorial embryonal tumor, not otherwise specified that occurs in childhood.","Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified | Childhood Supratentorial Embryonal Tumor, NOS | Childhood Supratentorial PNET | Childhood Supratentorial Primitive Neuroectodermal Tumor | Supratentorial Embryonal Tumor, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887519","Childhood Central Nervous System Neuroblastoma","C114775","A rare central nervous system neoplasm with neuroblastic and/or neuronal differentiation that arises from the supratentorial brain and occurs during childhood. It is characterized by the presence of structural rearrangements of FOXR2 gene that result in the activation of the transcription factor FOXR2.","Childhood Central Nervous System Neuroblastoma, FOXR2-Activated | Central Nervous System Neuroblastoma | Childhood Brain Neuroblastoma | Childhood Brain Neuroblastoma, FOXR2-Activated | Childhood Central Nervous System Neuroblastoma | Childhood Central Nervous System Neuroblastoma | Childhood Cerebral Neuroblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0948812","Dialyzer Blood Leakage","C114776","Leakage of blood into the dialysate during hemodialysis due to apparatus malfunction.","Dialyzer Blood Leakage | Dialyzer Blood Leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900101","Adult Germ Cell Tumor","C114777","A germ cell tumor that occurs during adulthood.","Adult Germ Cell Tumor | Germ Cell Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1370508","Adult Intracranial Germ Cell Tumor","C114778","A germ cell tumor that arises within the cranium and occurs during adulthood.","Adult Intracranial Germ Cell Tumor | Intracranial Germ Cell Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2213246","Central Nervous System Non-Hodgkin Lymphoma","C114779","A non-Hodgkin lymphoma that arises from the central nervous system.","Central Nervous System Non-Hodgkin Lymphoma | Primary Central Nervous System Non-Hodgkin Lymphoma",,,,,,,,,,,,,,,"40488942","Non-Hodgkin's lymphoma of central nervous system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2742256","Lysophospholipid Acyltransferase 2, Human","C114573","Lysophospholipid acyltransferase 2 (520 aa, ~60 kDa) is encoded by the human MBOAT2 gene. This protein is involved in lysophospholipid metabolism.","Lysophospholipid Acyltransferase 2 | 1-Acylglycerophosphate O-Acyltransferase | 1-Acylglycerophosphoethanolamine O-Acyltransferase | EC 2.3.1.- | EC 2.3.1.51 | EC 2.3.1.n7 | LPAAT | LPEAT | LPLAT 2 | Lyso-PA Acyltransferase | Lyso-PE Acyltransferase | Lysophosphatidic Acid Acyltransferase | Lysophosphatidylcholine Acyltransferase 4 | Lysophosphatidylethanolamine Acyltransferase | Membrane-Bound O-Acyltransferase 2 | Membrane-Bound O-Acyltransferase Domain-Containing 2 | Membrane-Bound O-Acyltransferase Domain-Containing Protein 2 | O-Acyltransferase Domain-Containing Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416518","ITPR2 Gene","C114575","This gene plays a role in second messenger signaling.","ITPR2 Gene | ITPR2 | Inositol 1,4,5-Trisphosphate Receptor, Type 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889706","ITPR2 wt Allele","C114577","Human ITPR2 wild-type allele is located in the vicinity of 12p11 and is approximately 498 kb in length. This allele, which encodes inositol 1,4,5-trisphosphate receptor type 2 protein, is involved in intracellular calcium release.","ITPR2 wt Allele | IP3R2 | Inositol 1,4,5-Triphosphate Receptor, Type 2 Gene | Inositol 1,4,5-Trisphosphate Receptor, Type 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0753041","Inositol 1,4,5-trisphosphate Receptor Type 2","C114578","Inositol 1,4,5-trisphosphate receptor type 2 (2701 aa, ~308 kDa) is encoded by the human ITPR2 gene. This protein plays a role in in second messenger signaling.","Inositol 1,4,5-Trisphosphate Receptor Type 2 | IP3 Receptor Isoform 2 | IP3R 2 | Inositol 1,4,5-Triphosphate Receptor 2 | Inositol 1,4,5-Triphosphate Receptor Type 2 | InsP3R2 | Type 2 Inositol 1,4,5-Trisphosphate Receptor | Type 2 InsP3 Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0595916","Drug-Induced Nephropathy","C114583","Kidney damage resulting from exposure to drugs.","Drug-Induced Nephropathy | Drug-Induced Kidney Injury | Drug-Induced Renal Failure | Toxic Nephropathy",,,,,,,,,,,,,,,"4126119","Toxic nephropathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0278749","metastatic gastrointestinal carcinoid tumor","C115245","Digestive system neuroendocrine tumor G1 that has spread to other anatomic sites.","Metastatic Digestive System Neuroendocrine Tumor G1 | Metastatic Gastrointestinal Carcinoid Tumor | Metastatic Gastrointestinal Neuroendocrine Tumor G1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896998","Manufactures Animal Prescription Drugs","C114889","A business that makes prescription veterinary products.","Manufactures Animal Prescription Drugs | Manufactures animal prescription drug products",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898467","Manufactures Veterinary Feed Directive Type A Drugs","C114890","A business that makes veterinary Type A drugs that require a feed directive.","Manufactures Veterinary Feed Directive Type A Drugs | Manufactures veterinary feed directive Type A medicated article drug products",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898469","Manufactures Animal Over-the-Counter Drugs","C114891","A business that makes non-prescription veterinary drugs.","Manufactures Animal Over-the-Counter Drugs | Manufactures animal over-the-counter drug products",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898468","Manufactures Animal Over-the-Counter Type A Drugs","C114892","A business that makes non-prescription veterinary Type A drugs which do not require a feed directive.","Manufactures Animal Over-the-Counter Type A Drugs | Manufactures animal over-the-counter Type A medicated article drug products",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420372","SPRR1A Gene","C114893","This gene is involved in keratinization.","SPRR1A Gene | SPRR1A | Small Proline-Rich Protein 1A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890922","SPRR1A wt Allele","C114894","Human SPRR1A wild-type allele is located within 1q21-q22 and is approximately 2 kb in length. This allele, which encodes cornifin-A protein, plays a role in keratinocyte differentiation.","SPRR1A wt Allele | SPRK | Small Proline-Rich Protein 1A wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447203","Cornifin-A, Human","C114895","Cornifin-A (89 aa, ~10 kDa) is encoded by the human SPRR1A gene. This protein is involved in cornified envelope development.","Cornifin-A | 19 kDa Pancornulin | Cornifin A | SPR-IA | SPRK | Small Proline-Rich Protein 1A | Small Proline-Rich Protein IA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897676","SPRR2A wt Allele","C114897","Human SPRR2A wild-type allele is located within 1q21-q22 and is approximately 1 kb in length. This allele, which encodes small proline-rich protein 2A, is involved in cornified envelope formation.","SPRR2A wt Allele | Small Proline-Rich Protein 2A wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1449035","Small Proline-Rich Protein 2A, Human","C114898","Small proline-rich protein 2A (72 aa, ~8 kDa) is encoded by the human SPRR2A gene. This protein plays a role in keratinocyte differentiation.","Small Proline-Rich Protein 2A | 2-1 | SPR-2A | SPRR2A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342273","Transient Neonatal Diabetes Mellitus","C114899","Hyperglycemia in the first month of life due to a genetically determined defect in the structure, secretion and/or function of insulin that resolves spontaneously within nine months of onset.","Transient Neonatal Diabetes Mellitus | ",,,,,,,,,,,,,,,"4129378","Transient neonatal diabetes mellitus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL474126","CAIX Inhibitor DTP348","C117731","An orally bioavailable, nitroimidazole-based sulfamide, carbonic anhydrase IX (CAIX) inhibitor with potential antineoplastic activity. Upon administration, CAIX inhibitor DTP348 inhibits tumor-associated CAIX, a hypoxia-inducible transmembrane glycoprotein that catalyzes the reversible reaction and rapid interconversion of carbon dioxide and water to carbonic acid, protons, and bicarbonate ions. This prevents the acidification of the tumor's extracellular microenvironment and decreases the intracellular pH. This results in increased cell death in CAIX-expressing, hypoxic tumors. In addition, DTP348, through its nitroimidazole moiety, is able to sensitize hypoxic tumor cells to irradiation. CAIX is overexpressed in various tumors and plays a key role in intra- and extracellular pH regulation, cancer cell progression, survival, migration and invasion.","CAIX Inhibitor DTP348 | 2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethylsulfamide | DTP-348 | DTP348",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474127","Anti-CD70 Antibody-drug Conjugate SGN-CD70A","C117732","An antibody-drug conjugate (ADC) containing an engineered cysteine monoclonal antibody (EC-mAb), directed against the extracellular domain of the human CD70 molecule, conjugated to the synthetic, cytotoxic, DNA minor-groove crosslinking agent, pyrrolobenzodiazepine (PBD) dimer, via a stable, protease-cleavable, peptide-based linker, with potential antineoplastic activity. The anti-CD70 antibody moiety of the anti-CD70 antibody-drug conjugate SGN-CD70A selectively binds to the extracellular domain of CD70 on tumor cell surfaces. Upon internalization, the PBD dimer moiety is released and covalently binds, through its imine moieties, to the N2 positions of guanines on opposite strands of DNA. This induces DNA double strand breaks and inhibits DNA replication, which lead to the inhibition of cell growth of tumor cells that overexpress CD70. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on the surfaces of various types of cancer cells. The cysteine moiety of the EC-mAb allows for the stable conjugation of the PBD to the antibody.","Anti-CD70 Antibody-drug Conjugate SGN-CD70A | SGN-CD70A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474128","Electrokinetically Modified Water","C117733","Orally available, nanobubble-based, electrokinetically modified water (EMW) composed of reverse osmosis water where the minerals calcium chloride, magnesium chloride, and potassium bicarbonate have been added and with an increased oxygen concentration compared to normal water. Upon consumption, the EMW may have a beneficial effect on fatigue. This water may protect muscle cells against damage and may improve skeletal muscle function. The water is pretreated with strong, controlled turbulence to create charge-stabilized nanostructures.","Electrokinetically Modified Water | EMW | Electro-kinetically Altered Beverage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474129","Sitravatinib","C117734","An orally bioavailable, receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Upon administration, sitravatinib binds to and inhibits the activity of several RTKs including hepatocyte growth factor receptor (HGFR; c-Met; MET), tyrosine-protein kinase receptor UFO (AXL receptor tyrosine kinase; AXL), mast/stem cell growth factor receptor (SCFR; c-kit; KIT), the receptor tyrosine kinase MER, discoidin domain receptor 2 (DDR2), vascular endothelial growth factor receptor (VEGFR) types 1 (VEGFR-1; FLT1), 2 (VEGFR-2; KDR; Flk-1) and 3 (VEGFR-3), members of the platelet-derived growth factor receptor (PDGFR) family, RET (rearranged during transfection), tropomyosin-related kinases (TRK) and members of the ephrin (Eph) family of receptor tyrosine kinases. This may result in both the inhibition of signal transduction pathways mediated by these RTKs and the reduction of tumor cell proliferation in cancer cell types that overexpress these RTKs.","Sitravatinib | 1,1-Cyclopropanedicarboxamide, N-(3-Fluoro-4-((2-(5-(((2-methoxyethyl)amino)methyl)-2-pyridinyl)thieno(3,2-b)pyridin-7-yl)oxy)phenyl)-N'-(4-fluorophenyl)- | MGCD516 | SITRAVATINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474131","Anti c-KIT Antibody-drug Conjugate LOP628","C117735","An antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody against the stem cell factor receptor c-Kit (SCFR) and conjugated, via a non-cleavable linker, to the cytotoxic agent maytansine, with potential antineoplastic activity. The monoclonal antibody moiety of anti c-KIT ADC LOP628 targets and binds to the cell surface antigen c-Kit. After antibody-antigen interaction followed by internalization, the maytansine moiety binds to tubulin, inhibits microtubule assembly, and induces microtubule disassembly. This leads to a disruption of mitosis and the inhibition of cell proliferation in cancer cells expressing c-Kit. c-Kit, a transmembrane protein and receptor tyrosine kinase, is overexpressed in solid tumors and hematological malignancies; it plays a key role in the regulation of cell differentiation and proliferation.","Anti c-KIT Antibody-drug Conjugate LOP628 | Anti c-KIT ADC LOP628 | LOP628",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896603","CDISC SDTM Graft Type Terminology","C117737","Terminology associated with the graft type codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Graft Type Terminology | GRAFTTYP | Graft Type | SDTM-GRAFTTYP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900137","AV Fistula Maturation Failure","C114780","Inadequate development of an arteriovenous fistula within three months of creation.","AV Fistula Maturation Failure | Arteriovenous Fistula Maturation Failure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0403559","Dialysis Dysequilibrium Syndrome","C114781","A complication occurring during hemodialysis that is thought to be due to a rapid decrease in blood urea nitrogen, and is characterized by an increase in intracranial pressure resulting in nausea, headache, vomiting, restlessness, and/or a decreased level of consciousness.","Dialysis Disequilibrium Syndrome | Disequilibrium Syndrome",,,,,,,,,,,,,,,"4314555","Dialysis disequilibrium syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL034308","Hodgkin Lymphoma During Pregnancy","C114783","Hodgkin lymphoma that occurs during pregnancy.","Hodgkin Lymphoma During Pregnancy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL034394","Non-Hodgkin Lymphoma During Pregnancy","C114784","Non-Hodgkin lymphoma that occurs during pregnancy.","Non-Hodgkin Lymphoma During Pregnancy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1832034","Childhood Subependymal Giant Cell Astrocytoma","C114785","Subependymal giant cell astrocytoma that occurs during childhood.","Childhood Subependymal Giant Cell Astrocytoma | Subependymal Giant Cell Astrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889448","VLDLR wt Allele","C115014","Human VLDLR wild-type allele is located in the vicinity of 9p24 and is approximately 33 kb in length. This allele, which encodes very low-density lipoprotein receptor protein, is involved in lipoprotein metabolism and the reelin signaling pathway. Mutation of the gene is associated with cerebellar hypoplasia and mental retardation with or without quadrupedal locomotion 1.","VLDLR wt Allele | CARMQ1 | CHRMQ1 | RP11-320E16.1 | VLDLRCH | Very Low Density Lipoprotein Receptor wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2604501","Very Low-Density Lipoprotein Receptor, Human","C115015","Very low-density lipoprotein receptor (873 aa, ~96 kDa) is encoded by the human VLDLR gene. This protein plays a role in the modulation of both reeling signaling and lipoprotein endocytosis.","Very Low-Density Lipoprotein Receptor | VLDL Receptor | VLDL-R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415811","HTR2C Gene","C115016","This gene is involved in neurotransmitter-dependent G protein-coupled receptor signaling.","HTR2C Gene | 5-Hydroxytryptamine (Serotonin) Receptor 2C, G Protein-Coupled Gene | HTR2C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889121","HTR2C wt Allele","C115017","Human HTR2C wild-type allele is located in the vicinity of Xq23 and is approximately 326 kb in length. This allele, which encodes 5-hydroxytryptamine receptor 2C protein, plays a role in serotonin binding and signaling. This gene undergoes RNA deamination at sites designated A, B, C-prime, E, C, and D; RNA editing at sites C, D and C-prime may be associated with depression.","HTR2C wt Allele | 5-HT2C | 5-HTR2C | 5-Hydroxytryptamine (Serotonin) Receptor 2C Gene | 5-Hydroxytryptamine (Serotonin) Receptor 2C, G Protein-Coupled wt Allele | 5HTR2C | HTR1C | RP11-810O3.1 | Serotonin 5-HT-1C Receptor, Formerly Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889122","5-Hydroxytryptamine Receptor 2C, human","C115018","5-hydroxytryptamine receptor 2C (458 aa, ~52 kDa) is encoded by the human HTR2C gene. This protein is involved in serotonin-mediated neurotransmission pathways.","5-Hydroxytryptamine Receptor 2C | 5-HT-1C | 5-HT-2C | 5-HT1C | 5-HT2C | 5-HTR2C | 5-Hydroxytryptamine Receptor 1C | Serotonin 5-HT-2C Receptor | Serotonin Receptor 2C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0343401","Methicillin-Resistant Staphylococcus aureus Infection","C115248","A bacterial infection that is caused by Staphylococcus aureus that is not susceptible to methicillin.","Methicillin-Resistant Staphylococcus aureus Infection | MRSA | Methicillin-Resistant Staphylococcus Aureus Infection | Methicillin-Resistant Staphylococcus aureus (MRSA)",,,,,,,,,,,,,,,"440940","Methicillin resistant Staphylococcus aureus infection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897028","Adult Primary Meningeal Melanocytic Neoplasm","C115253","A melanocytic neoplasm that arises from the leptomeninges and occurs during adulthood.","Adult Central Nervous System Melanocytic Neoplasm | Adult Central Nervous System Melanocytic Tumor | Adult Primary Central Nervous System Melanocytic Neoplasm | Adult Primary Melanocytic Lesion of Meninges | Adult Primary Meningeal Melanocytic Neoplasm | Adult Primary Meningeal Melanocytic Neoplasm | Primary Meningeal Melanocytic Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889248","IDUA wt Allele","C115254","Human IDUA wild-type allele is located in the vicinity of 4p16.3 and is approximately 18 kb in length. This allele, which encodes alpha-L-iduronidase protein, is involved in the metabolism of glycosaminoglycans. Mutation of the gene is associated with mucopolysaccharidosis type 1.","IDUA wt Allele | Alpha-L-Iduronidase wt Allele | IDA | Iduronidase Alpha-L- Gene | Iduronidase, Alpha-L Gene | Iduronidase, Alpha-L- Gene | MPS1 | MPSI | Mucopolysaccharidosis Type I Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL773730","IDUA protein, human","C115255","Alpha-L-iduronidase (653 aa, ~73 kDa) is encoded by the human IDUA gene. This protein plays a role in glycosaminoglycan metabolism.","Alpha-L-Iduronidase | EC 3.2.1.76 | IDUA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1390523","Musculoskeletal Complication","C115258","Any disorder of the muscles and bones occurring as a consequence of injury to the musculoskeletal system.","Musculoskeletal Complication | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889655","PDCD5 wt Allele","C115259","Human PDCD5 wild-type allele is located in the vicinity of 19q13.11 and is approximately 6 kb in length. This allele, which encodes programmed cell death protein 5, plays a role in the regulation of apoptosis.","PDCD5 wt Allele | MGC9294 | Programmed Cell Death 5 wt Allele | TF1 Cell Apoptosis-Related Gene 19 | TFAR19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899672","Childhood Central Nervous System Embryonal Neoplasm","C114833","A central nervous system embryonal tumor that occurs during childhood.","Childhood Central Nervous System Embryonal Tumor | Central Nervous System Embryonal Neoplasm | Childhood Central Nervous System Embryonal Neoplasm | Childhood Central Nervous System Embryonal Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0065349","Recombinant Lymphotactin","C1148","A recombinant chemokine of human lymphotactin which is produced by activated progenitor T cells and characterized by specific chemotactic activity for lymphocytes. (NCI)","Recombinant Lymphotactin | Lymphotactin",,,,,,,,,,,,,,,"4233491","Lymphocyte chemotactic factor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1639304","Permanent Neonatal Diabetes Mellitus","C114902","Hyperglycemia in the first month of life due to a genetically determined defect in the structure, secretion and/or function of insulin that does not resolve spontaneously.","Permanent Neonatal Diabetes Mellitus | ",,,,,,,,,,,,,,,"43531641","Permanent neonatal diabetes mellitus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1420753","TLE2 Gene","C115080","This gene is involved in the regulation of Notch and Wnt signaling pathways.","TLE2 Gene | TLE2 | Transducin-Like Enhancer of Split 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890217","TLE2 wt Allele","C115081","Human TLE2 wild-type allele is located in the vicinity of 19p13.3 and is approximately 50 kb in length. This allele, which encodes transducin-like enhancer protein 2, plays a role in transcriptional repression.","TLE2 wt Allele | ESG | ESG2 | FLJ41188 | GRG2 | Transducin-Like Enhancer of Split 2 (E(Sp1) Homolog, Drosophila) Gene | Transducin-Like Enhancer of Split 2 wt Allele | Transducin-Like Enhancer of Split 2, Homolog of Drosophila E(Sp1) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1431649","Transducin-Like Enhancer Protein 2, Human","C115082","Transducin-like enhancer protein 2 (743 aa, ~80 kDa) is encoded by the human TLE2 gene. This protein is involved in Notch and Wnt signaling pathways and transcriptional repression.","Transducin-Like Enhancer Protein 2 | ESG2 | Enhancer of Split Groucho 2 | Enhancer of Split Groucho-Like Protein 2 | TLE2 | Transducin-Like Enhancer of Split 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420755","TLE4 Gene","C115083","This gene plays a role in Notch and Wnt signaling pathways and transcriptional repression.","TLE4 Gene | TLE4 | Transducin-Like Enhancer of Split 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889151","TLE4 wt Allele","C115084","Human TLE4 wild-type allele is located in the vicinity of 9q21.31 and is approximately 155 kb in length. This allele, which encodes transducin-like enhancer protein 4, is involved in the regulation of Notch and Wnt signaling pathways.","TLE4 wt Allele | B Lymphocyte Gene 1 | BCE-1 | BCE1 | E(spI) | ESG | ESG4 | GRG4 | KIAA1261 | RP11-79D8.3 | Transducin-Like Enhancer of Split 4 (E(Sp1) Homolog, Drosophila) Gene | Transducin-Like Enhancer of Split 4 wt Allele | Transducin-Like Enhancer of Split 4, Homolog of Drosophila E(Sp1) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1143721","Transducin-Like Enhancer Protein 4, Human","C115085","Transducin-like enhancer protein 4 (773 aa, ~84 kDa) is encoded by the human TLE4 gene. This protein plays a role in the repression of both transcription and signal transduction.","Transducin-Like Enhancer Protein 4 | ESG4 | Enhancer of Split Groucho 4 | Enhancer of Split Groucho-Like Protein 4 | TLE4 | Transducin-Like Enhancer of Split 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280369","Stage I Oropharyngeal Undifferentiated Carcinoma AJCC v6 and v7","C115086","Stage I includes: T1, N0, M0.  T1: Tumor 2 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)","Stage I Oropharyngeal Undifferentiated Carcinoma AJCC v6 and v7 | Stage I Oropharyngeal Lymphoepithelioma | Stage I Oropharyngeal Lymphoepithelioma AJCC v6 | Stage I Oropharyngeal Lymphoepithelioma AJCC v7 | Stage I Oropharyngeal Undifferentiated Carcinoma | Stage I Oropharyngeal Undifferentiated Carcinoma AJCC v6 | Stage I Oropharyngeal Undifferentiated Carcinoma AJCC v7 | Stage I Undifferentiated Oropharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896601","CDISC SDTM Hepatic Findings About Test Name Terminology","C117738","Terminology associated with the hepatic findings about test names codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Hepatic Findings About Test Name Terminology | SDTM-HEFATS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896572","CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology","C117988","Test names of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology | CSS11TN | Columbia-Suicide Severity Rating Scale Lifetime/Recent Version Questionnaire Test Name | QS-C-SSRS Lifetime/Recent Version TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896634","CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology","C117989","Test codes of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology | CSS11TC | Columbia-Suicide Severity Rating Scale Lifetime/Recent Version Questionnaire Test Code | QS-C-SSRS Lifetime/Recent Version TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896620","CDISC Clinical Classification ESRS-A Test Name Terminology","C117990","Test names of questionnaire questions associated with the Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification ESRS-A Test Name Terminology | ESRSA1TN | Extrapyramidal Symptom Rating Scale-Abbreviated Clinical Classification Test Name | QS-ESRS-A TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896621","CDISC Clinical Classification ESRS-A Test Code Terminology","C117991","Test codes of clinical classification questions associated with the Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification ESRS-A Test Code Terminology | ESRSA1TC | Extrapyramidal Symptom Rating Scale-Abbreviated Clinical Classification Test Code | QS-ESRS-A TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899786","CHART-SF Interview Version Questionnaire Question","C117992","A question associated with the CHART-SF questionnaire.","CHART-SF Interview Version Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899845","C-SSRS Lifetime/Recent Version Questionnaire Question","C117993","A question associated with the C-SSRS Lifetime/Recent Version questionnaire.","C-SSRS Lifetime/Recent Version Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1506953","Solute Carrier Family 2, Facilitated Glucose Transporter Member 3, Human","C115022","Solute carrier family 2, facilitated glucose transporter member 3 (496 aa, ~54 kDa) is encoded by the human SLC2A3 gene. This protein plays a role in the transport of glucose.","Solute Carrier Family 2, Facilitated Glucose Transporter Member 3 | GLUT-3 | Glucose Transporter 3 | Glucose Transporter Type 3, Brain | Glucose Transporter, Fetal Skeletal Muscle | SLC2A3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427910","SLC16A11 Gene","C115023","This gene is involved in transport of carboxylates.","SLC16A11 Gene | SLC16A11 | Solute Carrier Family 16 Member 11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890778","SLC16A11 wt Allele","C115024","Human SLC16A11 wild-type allele is located in the vicinity of 17p13.1 and is approximately 2 kb in length. This allele, which encodes monocarboxylate transporter 11 protein, plays a role in monocarboxylate transport. Variation of the gene is associated with susceptiblility to non-insulin dependent diabetes mellitus.","SLC16A11 wt Allele | FLJ90193 | MCT11 | Solute Carrier Family 16 (Monocarboxylic Acid Transporters), Member 11 Gene | Solute Carrier Family 16 Member 11 wt Allele | Solute Carrier Family 16, Member 11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3851417","Monocarboxylate transporter 11, Human","C115025","Monocarboxylate transporter 11 (471 aa, ~48 kDa) is encoded by the human SLC16A11 gene. This protein is involved in the mediation of monocarboxylate transport.","Monocarboxylate Transporter 11 | MCT 11 | Monocarboxylic Acid Transporter 11 | SLC16A11 | Solute Carrier Family 16 Member 11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415886","IFI16 Gene","C115026","This gene plays a role in transcriptional regulation, cell differentiation and immune response-mediated programmed cell death.","IFI16 Gene | IFI16 | Interferon, Gamma-Inducible Protein 16 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889251","IFI16 wt Allele","C115027","Human IFI16 wild-type allele is located in the vicinity of 1q22 and is approximately 55 kb in length. This allele, which encodes gamma-interferon-inducible protein 16, is involved in both transcriptional regulation and immunity-mediated cell death.","IFI16 wt Allele | IFNGIP1 | Interferon, Gamma-Inducible Protein 16 wt Allele | PYHIN2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1566530","Hairy/Enhancer-of-Split Related With YRPW Motif-Like Protein, Human","C114522","Hairy/enhancer-of-split related with YRPW motif-like protein (328 aa, ~35 kDa) is encoded by the human HEYL gene. This protein plays a role in both cardiac development and the negative regulation of transcription.","Hairy/Enhancer-of-Split Related With YRPW Motif-Like Protein | Class B Basic Helix-Loop-Helix Protein 33 | HEY-Like Protein | HEYL | HRT-3 | Hairy-Related Transcription Factor 3 | bHLHb33 | hHRT3 | hHeyL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890000","TAGLN wt Allele","C114524","Human TAGLN wild-type allele is located in the vicinity of 11q23.2 and is approximately 5 kb in length. This allele, which encodes transgelin protein, plays a role in actin binding.","TAGLN wt Allele | DKFZp686P11128 | SM22 | SMCC | TAGLN1 | Transgelin wt Allele | WS3-10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1429758","Transgelin, human","C114525","Transgelin (201 aa, ~23 kDa) is encoded by the human TAGLN gene. This protein is involved in both actin binding and cell contractility.","Transgelin | 22 kDa Actin-Binding Protein | Protein WS3-10 | SM22-Alpha | Smooth Muscle Protein 22-Alpha | TAGLN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890744","GRM2 wt Allele","C114527","Human GRM2 wild-type allele is located in the vicinity of 3p21.2 and is approximately 12 kb in length. This allele, which encodes metabotropic glutamate receptor 2 protein, is involved in G protein-coupled receptor signaling.","GRM2 wt Allele | GLUR2 | GPRC1B | Glutamate Receptor, Metabotropic 2 wt Allele | Glutamate Receptor, Metabotropic, 2 Gene | MGLUR2 | mGlu2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0667282","metabotropic glutamate receptor 2","C114528","Metabotropic glutamate receptor 2 (872 aa, ~96 kDa) is encoded by the human GRM2 gene. This protein plays a role in neurotransmitter-dependent signaling.","Metabotropic Glutamate Receptor 2 | GRM2 | Glutamate Metabotropic Receptor 2 | Glutamate Receptor Homolog | mGluR2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890563","SOX17 wt Allele","C114834","Human SOX17 wild-type allele is located in the vicinity of 8q11.23 and is approximately 3 kb in length. This allele, which encodes transcription factor SOX-17 protein, is involved in the formation of both the embryonic heart tube and presumptive gut endoderm. Mutation of the gene is associated with vesicoureteral reflux type 3.","SOX17 wt Allele | SOX-17 | SRY (Sex Determining Region Y)-Box 17 wt Allele | SRY-Box 17 Gene | SRY-Related HMG-Box Gene 17 | VUR3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1434776","Transcription Factor, SOX17, Human","C114835","Transcription factor SOX-17 (414 aa, ~44 kDa) is encoded by the human SOX17 gene. This protein plays a role in organogenesis.","Transcription Factor SOX-17 | SOX17 | SRY-Related HMG-Box Transcription Factor SOX17",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897757","Recurrent Childhood Central Nervous System Embryonal Neoplasm","C114836","The reemergence of childhood central nervous system embryonal tumor after a period of remission.","Recurrent Childhood Central Nervous System Embryonal Tumor | Recurrent Central Nervous System Embryonal Neoplasm | Recurrent Childhood Central Nervous System Embryonal Neoplasm | Recurrent Childhood Central Nervous System Embryonal Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0265152","Uremic Pericarditis","C114837","Inflammation of the pericardium associated with chronic kidney failure.","Uremic Pericarditis | ",,,,,,,,,,,,,,,"4196638","Pericarditis secondary to uremia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0238217","Acute Allograft Nephropathy","C114838","A sudden immune response occurring after transplantation, directed against donor kidney alloantigens.","Acute Allograft Nephropathy | Acute Kidney Allograft Nephropathy | Kidney Transplant Rejection",,,,,,,,,,,,,,,"4128369","Renal transplant rejection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3900115","Acute Cellular Allograft Nephropathy","C114839","A sudden onset of T-cell mediated immune response occurring after transplantation, directed against donor kidney alloantigens.","Acute Cellular Allograft Nephropathy | Acute Cellular Kidney Allograft Nephropathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898561","Lymphomatous Involvement of Non-Cutaneous Extranodal Site","C114840","A pathologic and/or clinical finding indicating the spread of a lymphomatous process to an anatomic site other than lymph nodes and skin.","Lymphomatous Involvement of Non-Cutaneous Extranodal Site | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900114","Acute Humoral Allograft Nephropathy","C114841","A sudden onset of B-cell mediated immune response occurring after transplantation, directed against donor kidney alloantigens.","Acute Humoral Allograft Nephropathy | Acute Humoral Kidney Allograft Nephropathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388388","Osteolytic Lesions of Multiple Myeloma","C114843","A radiologic finding indicating the presence of multiple radiolucent osteolytic bone lesions observed in a patient with a diagnosis of multiple myeloma.","Osteolytic Lesions of Multiple Myeloma | Osteolytic Lesions of Multiple Myeloma/Plasma Cell Myeloma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897720","Renal Allograft Thrombosis","C114844","Thrombus formation within the arterial or venous system of a donor kidney post transplantation.","Renal Allograft Thrombosis | Kidney Allograft Thrombosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342648","Extraosseous Calcification","C114845","Deposition of calcium in tissues outside of bone.","Extraosseous Calcification | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898833","Hyperacute Allograft Rejection","C114848","An immediate rejection of transplanted tissue caused by the presence of preformed antibodies to donor human leukocyte antigens.","Hyperacute Allograft Rejection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0340754","Subclavian Vein Stenosis","C114850","Narrowing of the lumen of the subclavian vein.","Subclavian Vein Stenosis | ",,,,,,,,,,,,,,,"4121648","Subclavian vein stenosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0280371","Stage II Oropharyngeal Undifferentiated Carcinoma AJCC v6 and v7","C115087","Stage II includes: T2, N0, M0.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage II Oropharyngeal Undifferentiated Carcinoma AJCC v6 and v7 | Stage II Oropharyngeal Lymphoepithelioma | Stage II Oropharyngeal Lymphoepithelioma AJCC v6 | Stage II Oropharyngeal Lymphoepithelioma AJCC v7 | Stage II Oropharyngeal Undifferentiated Carcinoma | Stage II Oropharyngeal Undifferentiated Carcinoma AJCC v6 | Stage II Oropharyngeal Undifferentiated Carcinoma AJCC v7 | Stage II Undifferentiated Oropharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280373","Stage III Oropharyngeal Undifferentiated Carcinoma AJCC v7","C115088","Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0).  T1: Tumor 2 cm or less in greatest dimension.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension.  T3: Tumor measuring more than 4 centimeters in greatest dimension or extension to lingual surface of epiglottis.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. M0: No distant metastasis. (AJCC 7th ed.)","Stage III Oropharyngeal Undifferentiated Carcinoma AJCC v7 | Stage III Oropharyngeal Lymphoepithelioma | Stage III Oropharyngeal Lymphoepithelioma AJCC v7 | Stage III Oropharyngeal Undifferentiated Carcinoma | Stage III Undifferentiated Oropharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899905","C-SSRS Lifetime/Recent Version - Aborted Suicide Attempt (Lifetime)","C118060","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Has there been a time when you started to do something to try to end your life but you stopped yourself before you actually did anything? (Lifetime).","C-SSRS Lifetime/Recent Version - Aborted Suicide Attempt (Lifetime) | CSS11-Aborted Attempt-Life | CSS1117A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1172194","Eukaryotic Translation Initiation Factor 3 Subunit K, Human","C114631","Eukaryotic translation initiation factor 3 subunit K (218 aa, ~25 kDa) is encoded by the human EIF3K gene. This protein is involved in both ribosomal binding and preinitiation complex formation.","Eukaryotic Translation Initiation Factor 3 Subunit K | EIF3K | Eukaryotic Translation Initiation Factor 3 Subunit 12 | Muscle-Specific Gene M9 Protein | PLAC-24 | eIF-3 p25 | eIF-3 p28",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413914","DAZL Gene","C114632","This gene plays a role in gametogenesis","DAZL Gene | DAZL | Deleted In Azoospermia-Like Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891075","DAZL wt Allele","C114633","Human DAZL wild-type allele is located in the vicinity of 3p24 and is approximately 84 kb in length. This allele, which encodes deleted in azoospermia-like protein, is involved in male and female gametogenesis.","DAZL wt Allele | DAZH | DAZL1 | DAZLA | Deleted In Azoospermia-Like wt Allele | MGC26406 | SPGYLA | Spermatogenesis Gene On The Y-Like Autosomal; Deleted In Azoospermia Homolog Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473380","Deleted In Azoospermia-Like","C114634","Deleted in azoospermia-like (295 aa, ~33 kDa) is encoded by the human DAZL gene. This protein plays a role in gametogenesis.","Deleted In Azoospermia-Like | DAZ Homolog | DAZ-Like Autosomal | Deleted In Azoospermia-Like 1 | Germline Specific RNA Binding Protein | SPGY-Like-Autosomal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899788","CHART-SF Interview Version - Paid Personal Care per Day","C117998","Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) How many hours in a typical 24-hour day do you have someone with you to provide physical assistance for personal care activities such as eating, bathing, dressing, toileting and mobility? Hours paid assistance.","CHART-SF Interview Version - Paid Personal Care per Day | CHSF1-Paid Personal Care per Day | CHSF101A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899787","CHART-SF Interview Version - Unpaid Personal Care per Day","C117999","Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) How many hours in a typical 24-hour day do you have someone with you to provide physical assistance for personal care activities such as eating, bathing, dressing, toileting and mobility? Hours unpaid (family, others).","CHART-SF Interview Version - Unpaid Personal Care per Day | CHSF1-Unpaid Personal Care per Day | CHSF101B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1870106","Immunoglobulin Lambda-Like Polypeptide 1, human","C118232","Immunoglobulin lambda-like polypeptide 1 (213 aa, ~23 kDa) is encoded by the human IGLL1 gene. This protein plays a role in both B-cell development and pre-B-cell receptor complex formation.","Immunoglobulin Lambda-Like Polypeptide 1 | CD179 Antigen-Like Family Member B | CD179b | CD179b Antigen | IGLL1 | Ig Lambda-5 | Immunoglobulin Omega Polypeptide | Immunoglobulin Omega Polypeptide Chain | Immunoglobulin-Related 14.1 Protein | Immunoglobulin-Related Protein 14.1 | Pre-B Lymphocyte-Specific Protein-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0494827","Childhood Linear IgA Disease","C118233","A blistering disorder characterized by linear deposition of IgA at the dermoepidermal junction.","Childhood Linear IgA Disease | Chronic Bullous Disease of Childhood",,,,,,,,,,,,,,,"4031099","Chronic bullous dermatosis of childhood",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1418799","PPIF Gene","C118234","This gene is involved in both protein folding and mitochondrial permeability transition pore activity.","PPIF Gene | PPIF | Peptidylprolyl Isomerase F Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890897","PPIF wt Allele","C118235","Human PPIF wild-type allele is located within 10q22-q23 and is approximately 8 kb in length. This allele, which encodes peptidyl-prolyl cis-trans isomerase F, mitochondrial protein, plays a role in the modulation of both protein folding and mitochondrial permeability transition pore-induced cell death.","PPIF wt Allele | CYP3 | CyP-M | Cyp-D | CypD | Peptidylprolyl Isomerase F (Cyclophilin F) Gene | Peptidylprolyl Isomerase F wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890436","Peptidyl-Prolyl Cis-Trans Isomerase F, Mitochondrial","C118236","Peptidyl-prolyl cis-trans isomerase F, mitochondrial (207 aa, ~22 kDa) is encoded by the human PPIF gene. This protein is involved in the regulation of both cell death and protein folding.","Peptidyl-Prolyl Cis-Trans Isomerase F, Mitochondrial | CyP-D | CyP-M | Cyclophilin 3 | Cyclophilin D | Cyclophilin F | CypD | EC 5.2.1.8 | Mitochondrial Cyclophilin | PPIF | PPIase F | Peptidyl-Prolyl Cis-Trans Isomerase, Mitochondrial | Peptidyl-Prolyl Cis/Trans Isomerase, Mitochondrial | Peptidylprolyl Isomerase F | Rotamase F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421408","USP7 Gene","C118237","This gene is involved in protein deubiquitination.","USP7 Gene | USP7 | Ubiquitin Specific Peptidase 7 (Herpes Virus-Associated) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889652","USP7 wt Allele","C118238","Human USP7 wild-type allele is located in the vicinity of 16p13.3 and is approximately 72 kb in length. This allele, which encodes ubiquitin carboxyl-terminal hydrolase 7 protein, plays a role in the deubiquitination of other proteins.","USP7 wt Allele | HAUSP | TEF1 | Ubiquitin Specific Peptidase 7 (Herpes Virus-Associated) wt Allele | Ubiquitin Specific Protease 7 (Herpes Virus-Associated) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1142946","Ubiquitin Carboxyl-Terminal Hydrolase 7, Human","C118239","Ubiquitin carboxyl-terminal hydrolase 7 (1102 aa, ~128 kDa) is encoded by the human USP7 gene. This protein is involved in catalyzing protein deubiquitination.","Ubiquitin Carboxyl-Terminal Hydrolase 7 | Deubiquitinating Enzyme 7 | EC 3.4.19.12 | Herpes Virus-Associated Ubiquitin-Specific Protease | Herpesvirus-Associated Ubiquitin-Specific Protease | USP7 | Ubiquitin Thioesterase 7 | Ubiquitin-Specific Protease, Herpesvirus-Associated | Ubiquitin-Specific-Processing Protease 7 | VMW110-Associated Protein, 135-kD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889979","Periodic Fever Syndrome","C118240","Fevers of unknown etiology recurring over months or years.","Periodic Fever Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890215","GRM3 wt Allele","C114530","Human GRM3 wild-type allele is located within 7q21.1-q21.2 and is approximately 221 kb in length. This allele, which encodes metabotropic glutamate receptor 3 protein, plays a role in the negative regulation of adenylate cyclase-mediated signaling.","GRM3 wt Allele | GLUR3 | GPRC1C | Glutamate Receptor, Metabotropic 3 wt Allele | Glutamate Receptor, Metabotropic, 3 Gene | MGLUR3 | mGlu3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0532371","Glutamate Metabotropic Receptor 3","C114531","Metabotropic glutamate receptor 3 (879 aa, ~99 kDa) is encoded by the human GRM3 gene. This protein is involved in G protein-coupled receptor signaling.","Metabotropic Glutamate Receptor 3 | GRM3 | Glutamate Metabotropic Receptor 3 | mGluR3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891073","GRM4 wt Allele","C114533","Human GRM4 wild-type allele is located in the vicinity of 6p21.3 and is approximately 134 kb in length. This allele, which encodes metabotropic glutamate receptor 4 protein, is involved in ligand-dependent signal transduction.","GRM4 wt Allele | GPRC1D | Glutamate Receptor, Metabotropic 4 wt Allele | Glutamate Receptor, Metabotropic, 4 Gene | MGLUR4 | mGlu4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0667286","Metabotropic Glutamate Receptor 4, human","C114534","Metabotropic glutamate receptor 4 (912 aa, ~102 kDa) is encoded by the human GRM4 gene. This protein plays a role in the regulation of G protein-dependent signaling.","Metabotropic Glutamate Receptor 4 | GRM4 | mGluR4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889720","GRM7 wt Allele","C114536","Human GRM7 wild-type allele is located in the vicinity of 3p26.1-p25.1 and is approximately 972 kb in length. This allele, which encodes metabotropic glutamate receptor 7 protein, plays a role in the modulation of G protein-coupled receptor signaling.","GRM7 wt Allele | GLUR7 | GPRC1G | Glutamate Receptor, Metabotropic 7 wt Allele | Glutamate Receptor, Metabotropic, 7 Gene | MGLU7 | MGLUR7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0905072","Trefoil Factor 2, Human","C115190","Trefoil factor 2 (129 aa, ~14 kDa) is encoded by the human TFF2 gene. This protein is involved in the negative regulation of gastrointestinal motility and gastric acid secretion.","Trefoil Factor 2 | SP | Spasmolysin | Spasmolytic Polypeptide | Spasmolytic Protein 1 | TFF2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1865268","TUBA1B Gene","C115191","This gene plays a role in microtubule assembly and disassembly.","TUBA1B Gene | TUBA1B | Tubulin, Alpha 1b Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899667","Childhood Ependymal Tumor","C115192","An ependymal tumor that occurs during childhood.","Childhood Ependymal Tumor | Ependymal Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889713","TUBA1B wt Allele","C115193","Human TUBA1B wild-type allele is located in the vicinity of 12q13.12 and is approximately 4 kb in length. This allele, which encodes tubulin alpha-1B chain protein, is involved in microtubule dynamics.","TUBA1B wt Allele | K-ALPHA-1 | Tubulin, Alpha 1b wt Allele | Tubulin, Alpha, Ubiquitous Gene | Tubulin, Alpha-1B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472687","Tubulin Alpha-1B Chain","C115194","Tubulin alpha-1B chain (451 aa, ~50 kDa) is encoded by the human TUBA1B gene. This protein plays a role in microtubule structure.","Tubulin Alpha-1B Chain | Alpha-Tubulin Ubiquitous | K-Alpha-1 Tubulin | Tubulin Alpha-3C/D Chain | Tubulin Alpha-Ubiquitous Chain | Tubulin K-Alpha-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388429","Childhood Mixed Glioma","C115195","A mixed glioma that occurs during childhood.","Childhood Mixed Glioma | Mixed Glioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897068","Childhood Pineal Parenchymal Cell Neoplasm","C115196","A pineal parenchymal cell neoplasm that occurs during childhood.","Childhood Pineal Parenchymal Cell Neoplasm | Childhood Pineocytic Neoplasm | Childhood Pineocytic Tumor | Pineal Parenchymal Cell Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388366","BRCA1 Mutation Carrier","C115197","A carrier of a mutation in BRCA1 gene.","BRCA1 Mutation Carrier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1167866","Renal Lymphocele","C114851","Encapsulated collection of lymphatic fluid around a transplanted kidney.","Renal Lymphocele | Kidney Lymphocele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280353","Stage III Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","C115059","Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T3: Tumor more than 4 cm in greatest dimension. N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage III Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage III Lip and Oral Cavity Squamous Cell Cancer | Stage III Lip and Oral Cavity Squamous Cell Carcinoma | Stage III Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 | Stage III Lip and Oral Cavity Squamous Cell Carcinoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280358","Stage IV Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","C115060","Stage IV includes: IVA (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0);. IVB (Any T, N3, M0); (T4b, Any N, M0); IVC (Any T, Any N, M1). T4a (lip): Tumor invades through cortical bone, inferior alveolar nerve, floor of mouth, or skin of face, i.e., chin or nose. T4a (oral cavity): Tumor invades adjacent structures (e.g., through cortical bone, into deep [extrinsic] muscles of tongue, maxillary sinus, skin of face). T4b: Tumor invades masticator space, pterygoid plates, or skull base and/or encases internal carotid artery. N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension; or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension; or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. N2a: Metastasis in a single ipsilateral lymph node more than 3 cm but not more than 6 cm in dimension. N2b: Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension. N2c: Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. N3: Metastasis in a lymph node more than 6 cm in greatest dimension. M1: Distant metastasis. (AJCC 6th and 7th eds.)","Stage IV Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage IV Lip and Oral Cavity Squamous Cell Cancer | Stage IV Lip and Oral Cavity Squamous Cell Carcinoma | Stage IV Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 | Stage IV Lip and Oral Cavity Squamous Cell Carcinoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433873","Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","C115061","Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0). T4a: Lip and oral cavity cancer with moderately advanced local disease. Lip: Tumor invades through cortical bone, inferior alveolar nerve, floor of mouth, or skin of face, i.e., chin or nose. Oral cavity: Tumor invades adjacent structures only (e.g., through cortical bone [mandible or maxilla] into deep [extrinsic] muscle of tongue [genioglossus, hyoglossus, palatoglossus, and styloglossus], maxillary sinus, skin of face). T1: Tumor 2 cm or less in greatest dimension. T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension. T3: Tumor more than 4 cm in greatest dimension. N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension; or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension; or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. M0: No distant metastasis. (AJCC 7th ed.)","Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage IVA Lip and Oral Cavity Squamous Cell Cancer | Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma | Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433874","Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","C115062","Stage IVB includes: (Any T, N3, M0); (T4b, Any N, M0). T4b: Lip and oral cavity cancer with very advanced local disease. Tumor invades masticator space, pterygoid plates, or skull base and/or encases internal carotid artery. N3: Metastasis in a lymph node more than 6 cm in greatest dimension. M0: No distant metastasis. (AJCC 7th ed.)","Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage IVB Lip and Oral Cavity Squamous Cell Cancer | Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma | Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 | Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433875","Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","C115063","Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 7th ed.)","Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage IVC Lip and Oral Cavity Squamous Cell Cancer | Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 | Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424970","CYP39A1 Gene","C114642","This gene is involved in bile acid metabolism.","CYP39A1 Gene | CYP39A1 | Cytochrome P450, Family 39, Subfamily A, Polypeptide 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0447436","Gingival Sulcus","C114645","The space between a tooth and the surrounding gingival tissue and lined by the sulcular epithelium.","Gingival Sulcus | ",,,,,,,,,,,,,,,"4003999","Structure of gingival sulcus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1432901","24-Hydroxycholesterol 7-Alpha-Hydroxylase, Human","C114646","24-hydroxycholesterol 7-alpha-hydroxylase (469 aa, ~54 kDa) is encoded by the human CYP39A1 gene. This protein is involved in the conversion of cholesterol to bile acids.","24-Hydroxycholesterol 7-Alpha-Hydroxylase | CYP39A1 | Cytochrome P450 39A1 | Cytochrome P450, Subfamily XXXIX Polypeptide 1 | EC 1.14.13.99 | Oxysterol 7-Alpha-Hydroxylase | hCYP39A1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1310944","Msx2-Interacting Protein, Human","C115312","Msx2-interacting protein (3664 aa, ~402 kDa) is encoded by the human SPEN gene. This protein plays a role in the negative regulation of gene transcription.","Msx2-Interacting Protein | Msx2 Interacting Nuclear Target | Nuclear Receptor Transcription Cofactor | SMART/HDAC1 Associated Repressor Protein | SMART/HDAC1-Associated Repressor Protein | SPEN | SPEN Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889385","CDH4 wt Allele","C115314","Human CDH4 wild-type allele is located in the vicinity of 20q13.3 and is approximately 688 kb in length. This allele, which encodes cadherin-4 protein, plays a role in both cell adhesion and development of the retina.","CDH4 wt Allele | CAD4 | Cadherin 4, Type 1, R-Cadherin (Retinal) wt Allele | Cadherin, Retinal Gene | R-CAD | RCAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1609419","Cadherin-4, human","C115315","Cadherin-4 (916 aa, ~100 kDa) is encoded by the human CDH4 gene. This protein is involved in both cell adhesion and retinal development.","Cadherin-4 | Cadherin 4 | Cadherin 4, Type 1, Preproprotein | R-CAD | R-Cadherin | Retinal Cadherin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889704","MGA wt Allele","C115317","Human MGA wild-type allele is located in the vicinity of 15q14 and is approximately 149 kb in length. This allele, which encodes MAX gene-associated protein, is involved in the regulation of MYC and MAX-dependent gene expression.","MGA wt Allele | FLJ12634 | KIAA0518 | MAD5 | MAX Dimerization Protein MGA wt Allele | MAX Gene Associated Gene | MGA, MAX Dimerization Protein Gene | MXD5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3712788","MAX Gene-Associated Protein, Human","C115318","MAX gene-associated protein (3026 aa, ~332 kDa) is encoded by the human MGA gene. This protein plays a role in the in the modulation of MYC and MAX-dependent gene transcription.","MAX Gene-Associated Protein | MAX Dimerization Protein 5 | MGA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413806","CTRB1 Gene","C118241","This gene plays a role in gastrointestinal proteolysis.","CTRB1 Gene | CTRB1 | Chymotrypsinogen B1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890748","CTRB1 wt Allele","C118242","Human CTRB1 wild-type allele is located in the vicinity of 16q23.1 and is approximately 6 kb in length. This allele, which encodes chymotrypsinogen B protein, is involved in the process of digestion in the gastrointestinal tract.","CTRB1 wt Allele | CTRB | Chymotrypsinogen B1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2606397","Chymotrypsinogen B, Human","C118243","Chymotrypsinogen B (263 aa, ~28 kDa) is encoded by the human CTRB1 gene. This protein plays a role in proteolytic processes during digestion of nutrients.","Chymotrypsinogen B | CTRB1 | Chymotrypsinogen B1 | EC 3.4.21.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413807","CTRB2 Gene","C118244","This gene is involved in the digestive process.","CTRB2 Gene | CTRB2 | Chymotrypsinogen B2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899745","CTRB2 wt Allele","C118245","Human CTRB2 wild-type allele is located in the vicinity of 16q22.1 and is approximately 3 kb in length. This allele, which encodes chymotrypsinogen B2 protein, plays a role in nutrient digestion.","CTRB2 wt Allele | Chymotrypsin B2 Gene | Chymotrypsinogen B2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2606396","Chymotrypsinogen B2, Human","C118246","Chymotrypsinogen B2 (263 aa, ~28 kDa) is encoded by the human CTRB2 gene. This protein is involved in the digestion of nutrients by the gastrointestinal tract.","Chymotrypsinogen B2 | CTRB2 | EC 3.4.21.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879426","doxorubicin HCl liposome/trastuzumab","C11744","A regimen consisting of pegylated liposomal doxorubicin and trastuzumab that may be used in the treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.","Pegylated Liposomal Doxorubicin/Trastuzumab Regimen | Doxil/Herceptin | Doxorubicin HCl Liposome/Trastuzumab | Pegylated Liposomal Doxorubicin-Trastuzumab | Pegylated Liposomal Doxorubicin/Trastuzumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899435","Date and Time of Informed Consent","C117452","The date and time of informed consent collection.","Date and Time of Informed Consent | RFICDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899434","Date and Time of Last Study Treatment","C117454","The date and time of the subject's final study treatment.","Date and Time of Last Study Treatment | RFXENDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899436","Date and Time of First Study Treatment","C117455","The date and time of the subject's first study treatment.","Date and Time of First Study Treatment | RFXSTDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890722","Organism Substrain","C117456","A further sub-classification of the organism strain.","Organism Substrain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897333","Trial Sets Code","C117457","A character or string that represents the trial set.","Trial Sets Code | SETCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388368","BRCA2 Mutation Carrier","C115198","A carrier of a mutation in BRCA2 gene.","BRCA2 Mutation Carrier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899671","Childhood Cerebellar Anaplastic Astrocytoma","C115201","A cerebellar anaplastic astrocytoma that occurs during childhood.","Childhood Cerebellar Anaplastic Astrocytoma | Cerebellar Anaplastic Astrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899670","Childhood Cerebral Anaplastic Astrocytoma","C115202","A cerebral anaplastic astrocytoma that occurs during childhood.","Childhood Cerebral Anaplastic Astrocytoma | Anaplastic Hemispheric Astrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL383485","Childhood Embryonal Tumor with Multilayered Rosettes, C19MC-Altered","C115203","An embryonal tumor with multilayered rosettes, C19MC-altered that occurs during childhood.","Childhood Embryonal Tumor with Multilayered Rosettes, C19MC-Altered | Childhood Ependymoblastoma | Embryonal Tumor with Multilayered Rosettes, C19MC-Altered",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1541446","Childhood Grade III Lymphomatoid Granulomatosis","C115204","Grade III lymphomatoid granulomatosis that occurs during childhood.","Childhood Grade III Lymphomatoid Granulomatosis | Grade III Lymphomatoid Granulomatosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039621","Tetany","C114789","Sudden and involuntary contraction of a muscle of group of muscles due to hypocalcemia.","Tetany | ",,,,,,,,,,,,,,,"380534","Tetany",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3890212","HOXA1 wt Allele","C115065","Human HOXA1 wild-type allele is located in the vicinity of 7p15.3 and is approximately 3 kb in length. This allele, which encodes homeobox protein Hox-A1, is involved in the modulation of embryotic segment patterning. Mutation of the gene is associated with Athabaskan brainstem dysgenesis syndrome and Bosley-Salih-Alorainy syndrome.","HOXA1 wt Allele | BSAS | HOX1 | HOX1F | Homeo Box A1 Gene | Homeobox 1F Gene | Homeobox A1 wt Allele | Hox-1.6, Mouse, Homolog of Gene | Lab, Drosophila, Homolog of Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890716","INTS4 wt Allele","C114584","Human INTS4 wild-type allele is located in the vicinity of 11q14.1 and is approximately 116 kb in length. This allele, which encodes integrator complex subunit 4 protein, plays a role in small nuclear RNA transcription.","INTS4 wt Allele | INT4 | Integrator Complex Subunit 4 wt Allele | MGC16733 | MST093 | MSTP093",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899731","Calcineurin Nephrotoxicity","C114585","Kidney injury caused by calcineurin inhibitor immunosuppressive therapy which may lead to diminished kidney function.","Calcineurin Nephrotoxicity | Calcineurin Inhibitor Nephrotoxicity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3657385","Integrator Complex Subunit 4, Human","C114586","Integrator complex subunit 4 (963 aa, ~108 kDa) is encoded by the human INTS4 gene. This protein is involved in the transcription and processing of small nuclear RNAs.","Integrator Complex Subunit 4 | INTS4 | Int4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422763","JPT1 Gene","C114589","This gene plays a role in signaling, cell cycle and cell adhesion.","JPT1 Gene | HN1 | JPT1 | Jupiter Microtubule Associated Homolog 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889471","HN1A","C114590","Human JPT1 wild-type allele is located in the vicinity of 17q25.1 and is approximately 33 kb in length. This allele, which encodes Jupiter microtubule associated homolog 1 protein, is involved in the modulation of cell adhesion, cell cycle progression and signal transduction.","JPT1 wt Allele | ARM2 | HN1 | HN1A | Hematologic- and Neurologic-Expressed 1 Gene | Hematological and Neurological Expressed 1 Gene | Jupiter Microtubule Associated Homolog 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3492217","Hematological and Neurological Expressed 1 Protein, Human","C114591","Jupiter microtubule associated homolog 1 (154 aa, ~16 kDa) is encoded by the human JPT1 gene. This protein plays a role in signal transduction, cell adhesion and cell cycle regulation.","Jupiter Microtubule Associated Homolog 1 | Androgen-Regulated Protein 2 | Hematological and Neurological Expressed 1 Protein | JPT1 | OPMRX60 Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388482","Ophthalmologic Complication","C115319","Any eye disorder occurring as a consequence of injury to the eye.","Ophthalmologic Complication | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388325","Oral Complication","C115320","Any oral disorder occurring as a consequence of injury to the mouth and lips.","Oral Complication | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388403","Oral Complication of Chemotherapy","C115321","Any oral disorder occurring as a consequence of chemotherapy treatment.","Oral Complication of Chemotherapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388494","Oral Complication of Radiation Therapy","C115322","Any oral disorder occurring as a consequence of radiation therapy.","Oral Complication of Radiation Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427203","FOXQ1 Gene","C115323","This gene is involved in both transcriptional regulation and tissue morphogenesis.","FOXQ1 Gene | FOXQ1 | Forkhead Box Q1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889718","FOXQ1 wt Allele","C115324","Human FOXQ1 wild-type allele is located in the vicinity of 6p25 and is approximately 2 kb in length. This allele, which encodes forkhead box protein Q1, plays a role in both tissue development and transcriptional regulation.","FOXQ1 wt Allele | Forkhead Box Q1 wt Allele | HFH1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472771","Forkhead Box Protein Q1","C115325","Forkhead box protein Q1 (403 aa, ~42 kDa) is encoded by the human FOXQ1 gene. This protein is involved in embryonic development.","Forkhead Box Protein Q1 | FOXQ1 | HFH-1 | HNF-3/Forkhead-Like Protein 1 | Hepatocyte Nuclear Factor 3 Forkhead Homolog 1 | Winged Helix/Forkhead Transcription Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342784","Pearson Syndrome","C115326","The most severe syndrome in the spectrum of single, large-scale mitochondrial DNA (mtDNA) deletions (SLSMDs), usually presenting shortly after birth with sideroblastic anemia. The condition is often associated with exocrine pancreas insufficiency and multi-system dysfunction including diabetes mellitus, cortisol deficiency, hypothyroidism, hypoparathyroidism, and growth hormone deficiency. Commonly associated clinical findings include the following: failure to thrive, hypotonia, ptosis, ophthalmoparesis, and renal disease.","Pearson Syndrome | Pearson Marrow-Pancreas Syndrome",,,,,,,,,,,,,,,"4035282","Pearson's syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0158983","Neonatal Thyrotoxicosis","C114906","A hypermetabolic syndrome characterized by tachycardia, palpitations, tremor, weight loss, and moist skin that is caused by the elevation of thyroid hormone levels in the serum of the newborn infant or thyroid-axis receptor activation, most commonly due to transplacental passage of thyroid stimulating globulins.","Neonatal Thyrotoxicosis | Infantile Hyperthyroidism",,,,,,,,,,,,,,,"137099","Neonatal thyrotoxicosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897347","Transient Neonatal Hypoparathyroidism","C114907","A disorder of decreased production of parathyroid hormone by the parathyroid gland in a newborn. It is due to maternal hyperparathyroidism. It may be characterized by hypocalcemic seizures in the first weeks of life.","Transient Neonatal Hypoparathyroidism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417825","NR1H4 Gene","C114908","This gene is involved in bile acid binding and metabolism.","NR1H4 Gene | NR1H4 | Nuclear Receptor Subfamily 1, Group H, Member 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898154","Necrotizing Enterocolitis Totalis","C114909","A severe and often fatal form of necrotizing enterocolitis, in which diffuse ischemia, necrosis, and pneumatosis intestinalis are evident in the small and large intestine. Short bowel syndrome is common among survivors.","Necrotizing Enterocolitis Totalis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897004","Spontaneous Intestinal Perforation","C114910","A focal intestinal perforation without a definite cause, commonly located in the terminal ileum, lacking the transmural inflammation and/or pneumatosis typically seen in necrotizing enterocolitis.","Spontaneous Intestinal Perforation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897328","Trial Summary Parameter Value Code","C117458","A character or string that represents the trial summary parameter value.","Trial Summary Parameter Value Code | TSVALCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897327","Trial Summary Parameter Value Null Flavor","C117459","A description of the value that describes missing trial summary data values.","Trial Summary Parameter Value Null Flavor | TSVALNF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897129","Trial Summary Parameter Name of the Reference Terminology","C117460","The textual description of the terminology system that is being used for the trial summary parameter.","Trial Summary Parameter Name of the Reference Terminology | TSVCDREF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897326","Trial Summary Parameter Version of the Reference Terminology","C117461","The version information of the terminology system that is being used for the trial summary parameter.","Trial Summary Parameter Version of the Reference Terminology | TSVCDVER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897331","Trial Sets Parameter","C117463","A character or string that represents the long name of the trial set parameter.","Trial Sets Parameter | TXPARM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897332","Trial Sets Parameter Code","C117464","A character or string that represents the short code name of the trial set parameter.","Trial Sets Parameter Code | TXPARMCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897329","Trial Sets Value","C117465","A factor assigned to a trial set boundary.","Trial Sets Value | TXVAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896602","CDISC SDTM Hepatic Findings About Test Code Terminology","C117739","Terminology associated with the hepatic findings about test codes codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Hepatic Findings About Test Code Terminology | SDTM-HEFATSCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896599","CDISC SDTM Multiple Sclerosis Findings About Test Name Terminology","C117740","Terminology associated with the multiple sclerosis findings about test names codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Multiple Sclerosis Findings About Test Name Terminology | MSFATS | Multiple Sclerosis Findings About Test Name | SDTM-MSFATS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896699","ANLREAS","C117744","Terminology associated with the analysis reason codelist of the Clinical Data Interchange Standards Consortium (CDISC) Define-XML standard.","CDISC Define-XML Analysis Reason Terminology | ANLREAS | Analysis Reason | DEFINE-ANLREAS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896700","ANLPURP","C117745","Terminology associated with the analysis purpose codelist of the Clinical Data Interchange Standards Consortium (CDISC) Define-XML standard.","CDISC Define-XML Analysis Purpose Terminology | ANLPURP | Analysis Purpose | DEFINE-ANLPURP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889995","CDISC SDTM West Haven Hepatic Encephalopathy Grade Terminology","C117746","Terminology associated with the West Haven hepatic encephalopathy grade codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM West Haven Hepatic Encephalopathy Grade Terminology | HEPENCGR | SDTM-HEPENCGR | West Haven Hepatic Encephalopathy Grade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898040","POMC Gene Product","C114795","A protein encoded by the POMC gene.","POMC Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899268","Elevated Blood Pressure Measurement","C114798","An abnormally high blood pressure reading.","Elevated Blood Pressure Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522250","Recombinant Interleukin-16","C1147","A recombinant chemokine of human lymphotactin which is produced by activated progenitor T cells and characterized by specific chemotactic activity for lymphocytes. (NCI)","Recombinant Interleukin-16 | IL-16 | Interleukin-16 | Lymphocyte Chemoattractant Factor | Lymphotactin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447180","Gamma-Interferon-Inducible Protein 16, Human","C115028","Gamma-interferon-inducible protein 16 (785 aa, ~88 kDa) is encoded by the human IFI16 gene. This protein plays a role in both immune response-mediated programmed cell death and transcriptional regulation.","Gamma-Interferon-Inducible Protein 16 | IFI 16 | IFI16 | Ifi-16 | Interferon-Gamma Induced Protein | Interferon-Gamma-Inducible Protein 16 | Interferon-Inducible Myeloid Differentiation Transcriptional Activator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL376202","stage I childhood anaplastic large cell lymphoma","C115029","Ann Arbor Classification: Stage I: Involvement of a single lymph node region (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE).","Ann Arbor Stage I Noncutaneous Childhood Anaplastic Large Cell Lymphoma | Ann Arbor Stage I Childhood Anaplastic Large Cell Lymphoma | Stage I Anaplastic Large Cell Lymphoma | Stage I Childhood Anaplastic Large Cell Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415129","GMDS Gene","C114601","This gene is involved in the metabolism of nucleotide-sugar complexes.","GMDS Gene | GDP-Mannose 4,6-Dehydratase Gene | GMDS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1431691","Programmed Cell Death Protein 5, Human","C115261","Programmed cell death protein 5 (125 aa, ~14 kDa) is encoded by the human PDCD5 gene. This protein is involved in the promotion of apoptosis.","Programmed Cell Death Protein 5 | PDCD5 | Protein TFAR19 | TF-1 Cell Apoptosis-Related Protein 19 | TFAR19 Novel Apoptosis-Related",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887518","Adult Myxopapillary Ependymoma","C115263","A myxopapillary ependymoma that occurs during adulthood.","Adult Myxopapillary Ependymoma | Myxopapillary Ependymoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425726","TAMALIN Gene","C115266","This gene plays a role in receptor localization.","TAMALIN Gene | GRASP | TAMALIN | Trafficking Regulator and Scaffold Protein Tamalin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890745","TAMALIN wt Allele","C115267","Human TAMALIN wild-type allele is located in the vicinity of 12q13.13 and is approximately 9 kb in length. This allele, which encodes protein TAMALIN, is involved in synaptic receptor localization.","TAMALIN wt Allele | GRASP | GRP1 (General Receptor For Phosphoinositides 1)-Associated Scaffold Protein Gene | General Receptor For Phosphoinositides 1 Associated Scaffold Protein Gene | Trafficking Regulator and Scaffold Protein Tamalin wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1433105","GRP1 (general receptor for phosphoinositides 1)-associated scaffold protein, human","C115268","Protein TAMALIN (395 aa, ~43 kDa) is encoded by the human TAMALIN gene. This protein plays a role in the localization of cell surface receptors.","Protein TAMALIN | GRASP | GRP1-Associated Scaffold Protein | General Receptor For Phosphoinositides 1 Associated Scaffold Protein | General Receptor For Phosphoinositides 1-Associated Scaffold Protein | TAMALIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898137","Newly Diagnosed Carcinoma of Unknown Primary Origin","C115269","A recently diagnosed metastatic carcinoma of unknown primary origin.","Newly Diagnosed Carcinoma of Unknown Primary Origin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796611","Newly Diagnosed Childhood Ependymoma","C115270","A recently diagnosed ependymoma during childhood.","Newly Diagnosed Childhood Ependymoma | Ependymoma",,,,,,,,,,,,,,,"37152449","Ependymoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3889135","NR1H4 wt Allele","C114911","Human NR1H4 wild-type allele is located in the vicinity of 12q23.1 and is approximately 91 kb in length. This allele, which encodes bile acid receptor protein, plays a role in both the metabolism of bile acids and ligand-dependent transcriptional regulation.","NR1H4 wt Allele | BAR | FXR | HRR-1 | HRR1 | Nuclear Receptor Subfamily 1, Group H, Member 4 wt Allele | RIP14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1173940","NR1H4 protein, human","C114912","Bile acid receptor (486 aa, ~56 kDa) is encoded by the human NR1H4 gene. This protein is involved in both ligand-mediated gene expression and the metabolism of bile acids.","Bile Acid Receptor | Farnesoid X Nuclear Receptor | Farnesoid X-Activated Receptor | Farnesol Receptor HRR-1 | NR1H4 | Nuclear Receptor Subfamily 1 Group H Member 4 | RXR-Interacting Protein 14 | Retinoid X Receptor-Interacting Protein 14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472550","Jaw Region","C114916","The body region composed of the jaw bones and supporting structures.","Jaw Region | ",,,,,,,,,,,,,,,"4281237","Jaw region structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3890603","RINT1 wt Allele","C114920","Human RINT1 wild-type allele is located in the vicinity of 7q22.3 and is approximately 36 kb in length. This allele, which encodes RAD50-interacting protein 1, is involved in both the regulation of vesicle transport and the maintenance of telomeres.","RINT1 wt Allele | FLJ11785 | RAD50 Interactor 1 wt Allele | RINT-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412302","Adult Epithelioid Hemangioendothelioma","C114923","An epithelioid hemangioendothelioma that occurs during adulthood.","Adult Epithelioid Hemangioendothelioma | Epithelioid Hemangioendothelioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280375","Stage IV Oropharyngeal Undifferentiated Carcinoma AJCC v7","C115089","Stage IV includes: IVA (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB (T4b, Any N, M0); (Any T, N3, M0); IVC (Any T, Any N, M1). T4a: Tumor with moderately advanced local disease.  Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible.  Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of larynx. T1: Tumor 2 cm or less in greatest dimension.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension.  T3: Tumor measuring more than 4 centimeters in greatest dimension or extension to lingual surface of epiglottis.  T4b: Tumor with very advanced local disease.  Tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base or encases carotid artery. N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. N2: Tumor with metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. N3: Tumor with metastasis in a lymph node more than 6 cm in greatest dimension. M0: No distant metastasis.  M1: Distant metastasis. (AJCC 7th ed.)","Stage IV Oropharyngeal Undifferentiated Carcinoma AJCC v7 | Stage IV Oropharyngeal Lymphoepithelioma | Stage IV Oropharyngeal Lymphoepithelioma AJCC v7 | Stage IV Oropharyngeal Undifferentiated Carcinoma | Stage IV Undifferentiated Oropharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086961","West Haven Criteria - West Haven Hepatic Encephalopathy Grade","C117747","West Haven Hepatic Encephalopathy Grade (West Haven Criteria) Grade.","West Haven Criteria - West Haven Hepatic Encephalopathy Grade | WHEG01-WH Hepatic Encephalopathy Grade | WHEG0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899452","Data Driven Analysis","C117750","The analysis has been performed based on findings in the data.","Data Driven Analysis | DATA DRIVEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900045","Analysis Requested by Regulatory Agency","C117751","The analysis has been performed based on request from a regulatory agency.","Analysis Requested by Regulatory Agency | REQUESTED BY REGULATORY AGENCY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900044","Analysis Specified in Protocol","C117752","The analysis has been performed based on the protocol.","Analysis Specified in Protocol | SPECIFIED IN PROTOCOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900043","Analysis Specified in Statistical Analysis Plan","C117753","The analysis has been performed based on the statistical analysis plan.","Analysis Specified in Statistical Analysis Plan | SPECIFIED IN SAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899804","CHART-SF Interview Version - Cognitive Assistance at Home per Day","C118000","Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) How much time is someone with you in your home to assist you with activities that require remembering, decision making, or judgment?","CHART-SF Interview Version - Cognitive Assistance at Home per Day | CHSF1-Home Cognitive Assistance per Day | CHSF102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899801","CHART-SF Interview Version - Hours Out of Bed per Day","C118002","Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) On a typical day, how many hours are you out of bed?","CHART-SF Interview Version - Hours Out of Bed per Day | CHSF1-Hours Out of Bed per Day | CHSF104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899802","CHART-SF Interview Version - Days Out of the House per Week","C118003","Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) In a typical week, how many days do you get out of your house and go somewhere?","CHART-SF Interview Version - Days Out of the House per Week | CHSF1-Days Out of the House per Week | CHSF105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899792","CHART-SF Interview Version - Nights Away From Home Last Year","C118004","Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) In the last year, how many nights have you spent away from your home (excluding hospitalizations)?","CHART-SF Interview Version - Nights Away From Home Last Year | CHSF1-Nights Away From Home Last Year | CHSF106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL376203","stage II childhood anaplastic large cell lymphoma","C115030","Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE).","Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma | Ann Arbor Stage II Childhood Anaplastic Large Cell Lymphoma | Stage II Anaplastic Large Cell Lymphoma | Stage II Childhood Anaplastic Large Cell Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL376204","stage III childhood anaplastic large cell lymphoma","C115031","Ann Arbor Classification: Stage III: Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S).","Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma | Ann Arbor Stage III Childhood Anaplastic Large Cell Lymphoma | Stage III Anaplastic Large Cell Lymphoma | Stage III Childhood Anaplastic Large Cell Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL376205","stage IV childhood anaplastic large cell lymphoma","C115032","Ann Arbor Classification: Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s); or any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid.","Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma | Ann Arbor Stage IV Childhood Anaplastic Large Cell Lymphoma | Stage IV Anaplastic Large Cell Lymphoma | Stage IV Childhood Anaplastic Large Cell Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898463","Masaoka-Koga Stage II","C115033","The tumor shows invasion into the capsule.","Masaoka-Koga Stage II | Masaoka Stage II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898462","Masaoka-Koga Stage IV","C115034","The tumor shows metastasis throughout the pleural and/or pericardial spaces or metastasis to distant sites.","Masaoka-Koga Stage IV | Masaoka Stage IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897519","Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7","C115035","Stage IVA includes: (T4a, N0, M0); (T4a, N1a, M0); (T1, N1b, M0); (T2, N1b, M0); (T3, N1b, M0); (T4a, N1b, M0). T4a: Moderately advanced local disease. Tumor of any size extending beyond the thyroid gland capsule to invade subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve. T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland. T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland. T3: Tumor more than 4 cm in greatest dimension and limited to the thyroid gland, or tumor of any size with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues). N0: No regional lymph node metastasis. N1a: Metastasis to pretracheal, paratracheal or prelaryngeal/Delphian lymph nodes (Level VI lymph nodes). N1b: Metastasis to unilateral, bilateral or contralateral cervical (Levels I, II, III, IV, or V) or retropharyngeal or superior mediastinal lymph nodes (Level VII). M0: No distant metastasis. (AJCC 7th ed.)","Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IVA Thyroid Gland Follicular Cancer | Stage IVA Thyroid Gland Follicular Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897512","Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7","C115036","Stage IVB includes: T4b, Any N, M0. T4b: Very advanced disease. Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels. M0: No distant metastasis. (AJCC 7th ed.)","Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IVB Thyroid Gland Follicular Cancer | Stage IVB Thyroid Gland Follicular Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897507","Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7","C115037","Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 7th ed.)","Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IVC Thyroid Gland Follicular Cancer | Stage IVC Thyroid Gland Follicular Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890743","GRM8 wt Allele","C114539","Human GRM8 wild-type allele is located within 7q31.3-q32.1 and is approximately 815 kb in length. This allele, which encodes metabotropic glutamate receptor 8 protein, is involved in glutamate-dependent signal transduction.","GRM8 wt Allele | GLUR8 | GPRC1H | Glutamate Receptor, Metabotropic 8 wt Allele | Glutamate Receptor, Metabotropic, 8 Gene | MGLUR8 | mGlu8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL413621","Non-Cancer Diagnosis","C115274","A term that refers to a broad group of diagnoses that may include any disease except for cancer or cancer related disorders.","Non-Cancer Diagnosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421348","UHRF1 Gene","C115275","This gene is involved in transcriptional regulation, chromatin remodeling and protein ubiquitination.","UHRF1 Gene | UHRF1 | Ubiquitin-Like With PHD and Ring Finger Domains 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1504532","New Onset Diabetes After Transplant","C114852","Development of diabetes after transplant, usually associated with calcineurin inhibitor use.","New Onset Diabetes After Transplant | NODAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1566590","Delayed Graft Function","C114853","The need for dialysis within a week of kidney transplant.","Delayed Graft Function | DGF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897979","Patient Military Status ICSR Terminology","C114855","Terminology used in Individual Case Safety Reports to specify a the military status of a patient.","Patient Military Status ICSR Terminology | Patient Military Status Individual Case Safety Report Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897263","Type of Vaccination Facility ICSR Terminology","C114856","Terminology used in Individual Case Safety Reports to specify the type of vaccination facility.","Type of Vaccination Facility ICSR Terminology | Type of Vaccination Facility Individual Case Safety Report Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897379","TRICARE Beneficiary","C114859","An individual who receives healthcare coverage for medical and dental services from the Department of Defense health care system (TRICARE).","TRICARE Beneficiary | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897480","Student Health Clinic","C114862","An onsite healthcare facility that provides routine therapeutic and preventive services to students.","Student Health Clinic | School Student Health Clinic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897521","Stage IVA Oropharyngeal Undifferentiated Carcinoma AJCC v7","C115090","Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0). T4a: Tumor with moderately advanced local disease.  Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible.  Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of larynx. T1: Tumor 2 cm or less in greatest dimension.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension.  T3: Tumor measuring more than 4 centimeters in greatest dimension or extension to lingual surface of epiglottis.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. N2: Tumor with metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. M0: No distant metastasis.  (AJCC 7th ed.)","Stage IVA Oropharyngeal Undifferentiated Carcinoma AJCC v7 | Stage IVA Oropharyngeal Lymphoepithelioma | Stage IVA Oropharyngeal Lymphoepithelioma AJCC v7 | Stage IVA Oropharyngeal Undifferentiated Carcinoma | Stage IVA Undifferentiated Oropharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897514","Stage IVB Oropharyngeal Undifferentiated Carcinoma AJCC v7","C115091","Stage IVB includes: (T4b, Any N, M0); (Any T, N3, M0). T4b: Tumor with very advanced local disease.  Tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base or encases carotid artery. N3: Tumor with metastasis in a lymph node more than 6 cm in greatest dimension. M0: No distant metastasis. (AJCC 7th ed.)","Stage IVB Oropharyngeal Undifferentiated Carcinoma AJCC v7 | Stage IVB Oropharyngeal Lymphoepithelioma | Stage IVB Oropharyngeal Lymphoepithelioma AJCC v7 | Stage IVB Oropharyngeal Undifferentiated Carcinoma | Stage IVB Undifferentiated Oropharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897508","Stage IVC Oropharyngeal Undifferentiated Carcinoma AJCC v7","C115092","Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 7th ed.)","Stage IVC Oropharyngeal Undifferentiated Carcinoma AJCC v7 | Stage IVC Oropharyngeal Lymphoepithelioma | Stage IVC Oropharyngeal Lymphoepithelioma AJCC v7 | Stage IVC Oropharyngeal Undifferentiated Carcinoma | Stage IVC Undifferentiated Oropharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280377","Recurrent Oropharyngeal Undifferentiated Carcinoma","C115093","The reemergence of oropharyngeal undifferentiated carcinoma after a period of remission.","Recurrent Oropharyngeal Undifferentiated Carcinoma | Recurrent Oropharyngeal Lymphoepithelioma | Recurrent Oropharyngeal Throat Undifferentiated Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897533","Stage III Primary Peritoneal Cancer AJCC v7","C115094","Stage III includes: T3, N0, M0.  T3: Microscopically confirmed peritoneal tumor outside pelvis.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th Ed.)","Stage III Primary Peritoneal Cancer AJCC v7 | Stage III Primary Peritoneal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897532","Stage IIIA Primary Peritoneal Cancer AJCC v7","C115095","Stage IIIA includes: T3a, N0, M0.  T3a: Microscopic peritoneal tumor beyond pelvis (no macroscopic tumor). N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th Ed.)","Stage IIIA Primary Peritoneal Cancer AJCC v7 | Stage IIIA Primary Peritoneal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897529","Stage IIIB Primary Peritoneal Cancer AJCC v7","C115096","Stage IIIB includes: T3b, N0, M0.  T3b: Macroscopic peritoneal tumor beyond pelvis 2 cm or less in greatest dimension. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th Ed.)","Stage IIIB Primary Peritoneal Cancer AJCC v7 | Stage IIIB Primary Peritoneal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897948","Periodontal Screening and Recording Code 0","C114648","Indicates that all probing depth in the sextant is less than 3.5mm, with no calculus or defective margins or bleeding on probing detected.","Periodontal Screening and Recording Code 0 | Code 0 | PSR Code 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899798","CHART-SF Interview Version - Hours of Paid Work per Week","C118005","Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) How many hours per week do you spend working in a job for which you get paid?","CHART-SF Interview Version - Hours of Paid Work per Week | CHSF1-Hours of Paid Work per Week | CHSF107A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899789","CHART-SF Interview Version - Occupation of Paid Work","C118006","Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) How many hours per week do you spend working in a job for which you get paid? (occupation).","CHART-SF Interview Version - Occupation of Paid Work | CHSF1-Occupation of Paid Work | CHSF107B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899796","CHART-SF Interview Version - Hours of Schoolwork per Week","C118007","Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) How many hours per week do you spend in school working toward a degree or in an accredited technical training program (including hours in class and studying)?","CHART-SF Interview Version - Hours of Schoolwork per Week | CHSF1-Hours of Schoolwork per Week | CHSF108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899800","CHART-SF Interview Version - Hours of Home Maintenance per Week","C118009","Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) How many hours per week do you spend in home maintenance activities such as gardening, house repairs or home improvement?","CHART-SF Interview Version - Hours of Home Maintenance per Week | CHSF1-Hours of Home Maintenance per Week | CHSF110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899797","CHART-SF Interview Version - Hours of Recreational Activities per Week","C118010","Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) How many hours per week do you spend in recreational activities such as sports, exercise, playing cards, or going to movies? Please do not include time spent watching TV or listening to the radio.","CHART-SF Interview Version - Hours of Recreational Activities per Week | CHSF1-Hours of Recreation per Week | CHSF111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899791","CHART-SF Interview Version - Number of People You Live With","C118011","Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) How many people do you live with?","CHART-SF Interview Version - Number of People You Live With | CHSF1-Number of People You Live With | CHSF112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897385","TK-10","C117217","An adenocarcinoma cell line established from a 43 year old male patient with renal cell carcinoma.","TK-10 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897259","UO-31","C117218","An adenocarcinoma cell line established from a female patient with renal cell carcinoma.","UO-31 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890720","PC-3 cell line","C117219","An adenocarcinoma cell line established in 1979 from a bone metastasis from a 62 year old Caucasian male patient with stage IV prostate carcinoma.","PC-3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899690","Character Result or Finding in Standard Format","C117222","The standardized result of the measurement, test, or examination in character format.","Character Result or Finding in Standard Format | STRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0673129","metabotropic glutamate receptor 8","C114540","Metabotropic glutamate receptor 8 (908 aa, ~102 kDa) is encoded by the human GRM8 gene. This protein plays a role in the negative regulation of adenylate cyclase activity.","Metabotropic Glutamate Receptor 8 | GRM8 | mGluR8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279546","Adult Undifferentiated Pleomorphic Sarcoma","C114541","An undifferentiated pleomorphic sarcoma that occurs during adulthood.","Adult Undifferentiated Pleomorphic Sarcoma | Adult Malignant Fibrous Histiocytoma | Adult Unclassified Pleomorphic Sarcoma | Undifferentiated Pleomorphic Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418910","PRKAR2A Gene","C114542","This gene is involved in the regulation of cyclic AMP-dependent signaling.","PRKAR2A Gene | PRKAR2A | Protein Kinase, cAMP-Dependent, Regulatory, Type II, Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889384","PRKAR2A wt Allele","C114543","Human PRKAR2A wild-type allele is located within 3p21.3-p21.2 and is approximately 103 kb in length. This allele, which encodes cAMP-dependent protein kinase type II-alpha regulatory subunit protein, plays a role in the modulation of cyclic AMP-dependent signaling.","PRKAR2A wt Allele | PKR2 | PRKAR2 | Protein Kinase, cAMP-Dependent, Regulatory, Type II, Alpha wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1870778","cAMP-dependent protein kinase type II-alpha regulatory subunit, human","C114544","cAMP-dependent protein kinase type II-alpha regulatory subunit (404 aa, ~46 kDa) is encoded by the human PRKAR2A gene. This protein is involved in the positive regulation of cyclic AMP-dependent signaling.","cAMP-Dependent Protein Kinase Type II-Alpha Regulatory Subunit | PRKAR2A | Protein Kinase A, RII-Alpha Subunit | cAMP-Dependent Protein Kinase Regulatory Subunit RII Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418626","PLA2R1 Gene","C114545","This gene plays a role in the localization of phospholipases.","PLA2R1 Gene | PLA2R1 | Phospholipase A2 Receptor 1, 180kDa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889278","PLA2R1 wt Allele","C114546","Human PLA2R1 wild-type allele is located within 2q23-q24 and is approximately 131 kb in length. This allele, which encodes secretory phospholipase A2 receptor protein, is involved in phospholipase activity and endocytosis.","PLA2R1 wt Allele | CLEC13C | PLA2-R | PLA2G1R | PLA2IR | PLA2R | Phospholipase A2 Receptor 1 Gene | Phospholipase A2 Receptor 1, 180kDa wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1670125","Secretory Phospholipase A2 Receptor, Human","C114547","Secretory phospholipase A2 receptor (1463 aa, ~169 kDa) is encoded by the human PLA2R1 gene. This protein plays a role in the modulation of phospholipase activity.","Secretory Phospholipase A2 Receptor | 180 kDa Secretory Phospholipase A2 Receptor | C-Type Lectin Domain Family 13 Member C | M-Type Phospholipase A2 Receptor | M-Type Receptor | PHOSPHOLIPASE A2 RECEPTOR | PLA2-R | PLA2R | Phospholipase A2 Receptor 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899705","CareLex eTMF Terminology","C114548","A controlled vocabulary developed to support content interoperability between electronic Trial Master File systems for clinical trials.","CareLex eTMF Terminology | CareLex electronic Trial Master File Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889427","Content Type Name","C114549","The text label assigned to a content type.","Content Type Name | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889737","Data Change Date","C114550","The date of data modification.","Data Change Date | Modification | Modified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898071","Organization Role","C114551","A title that describes the function of a designated group, governing body, or institution.","Organization Role | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899374","Digital Signature Status","C114552","An indication of the standing of a digital signature.","Digital Signature Status | eSign Status | eSignature Status | electronic Signature Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425267","PKD1L1 Gene","C114553","This gene is involved in the modulation of calcium transport.","PKD1L1 Gene | PKD1L1 | Polycystic Kidney Disease 1 Like 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891555","X-ray-Based Angiogram","C114864","An X-ray representation of blood vessels made after the injection of a radiopaque substance.","X-ray-Based Angiogram | Angiogram | Fluoroscopic Angiogram | Traditional Angiogram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897081","Military Healthcare Facility","C114865","A healthcare facility that provides routine therapeutic or preventive services on a military installation or one that is off base but is operated under the authority or direction of the Department of Defense or the Department of Homeland Security.","Military Healthcare Facility | Military Site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0157266","Arrest of Labor in Second Stage","C114869","At least 2 hours of pushing in multiparous women and at least 3 hours of pushing in nulliparous women. Longer durations may be appropriate on an individualized basis (e.g., with the use of epidural analgesia or with fetal malposition) as long as progress is being documented.","Arrest of Labor in Second Stage | Prolonged Second Stage of Labor | Second Stage Arrest",,,,,,,,,,,,,,,"434714","Prolonged second stage of labor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1741313","Homeobox Protein Hox-A1, Human","C115066","Homeobox protein Hox-A1 (335 aa, ~37 kDa) is encoded by the human HOXA1 gene. This protein plays a role in embryonic anterior-posterior pattern formation.","Homeobox Protein Hox-A1 | HOX A1 Homeodomain Protein | Homeobox Protein Hox-1F | Hox 1.6-Like Protein | Lab-Like Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424797","PLCE1 Gene","C115067","This gene is involved in both lipid metabolism and signal transduction.","PLCE1 Gene | PLCE1 | Phospholipase C, Epsilon 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889281","PLCE1 wt Allele","C115068","Human PLCE1 wild-type allele is located in the vicinity of 10q23 and is approximately 334 kb in length. This allele, which encodes 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase epsilon-1 protein, plays a role in signal transduction, cell growth, cell survival and lipid modification. Mutation of the gene is associated with nephrotic syndrome 3.","PLCE1 wt Allele | KIAA1516 | NPHS3 | Nephrosis Type 3 Gene | PLCE | PPLC | Phospholipase C, Epsilon 1 wt Allele | Phospholipase C, Epsilon-1 Gene | RP11-76P2.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1434268","1-Phosphatidylinositol 4,5-Bisphosphate Phosphodiesterase Epsilon-1, Human","C115069","1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase epsilon-1 (2302 aa, ~259 kDa) is encoded by the human PLCE1 gene. This protein is involved in phospholipid metabolism, signaling, cell growth and cell survival.","1-Phosphatidylinositol 4,5-Bisphosphate Phosphodiesterase Epsilon-1 | 1-Phosphatidylinositol-4,5-Bisphosphate Phosphodiesterase Epsilon-1 | EC 3.1.4.11 | PLC-Epsilon-1 | PLCE1 | Phosphoinositide Phospholipase C-Epsilon-1 | Phosphoinositide-Specific Phospholipase C Epsilon-1 | Phospholipase C-Epsilon-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280403","Stage I Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","C115070","Stage I includes: T1, N0, M0.  T1: Maxillary sinus: Tumor limited to the maxillary sinus mucosa with no erosion or destruction of bone.  Nasal cavity and ethmoid sinus: Tumor restricted to any one subsite, with or without bony invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage I Sinonasal Squamous Cell Carcinoma AJCC v6 and v7 | Stage I Nasal Cavity and Paranasal Sinus Squamous Cell Cancer | Stage I Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma | Stage I Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 | Stage I Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7 | Stage I Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824814","CUTA Gene","C114653","This gene may play a role in acetylcholine metabolism.","CUTA Gene | CUTA | CutA Divalent Cation Tolerance Homolog Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1568358","Protein CutA , Human","C114655","Protein CutA (179 aa, ~19 kDa) is encoded by the human CUTA gene. This protein may play a role in acetylcholinesterase activity.","Protein CutA | Acetylcholinesterase-Associated Protein | Brain Acetylcholinesterase Putative Membrane Anchor | Divalent Cation Tolerant Protein CUTA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896969","Endometrial Adenosquamous Carcinoma","C114656","A rare endometrial carcinoma characterized by the presence of both malignant glandular and malignant squamous cellular components.","Endometrial Adenosquamous Carcinoma | Endometrial Adenosquamous Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539148","CTAGE5 gene","C114657","This gene is involved in endoplasmic reticulum-to-Golgi protein transport and tumor induction of immune responses.","CTAGE5 Gene | CTAGE Family, Member 5 Gene | CTAGE5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890917","CTAGE5 wt Allele","C114658","Human CTAGE5 wild-type allele is located in the vicinity of 14q13.3 and is approximately 122 kb in length. This allele, which encodes endoplasmic reticulum export factor CTAGE5 protein, plays a role in the protein transport and induction of the immune response.","CTAGE5 wt Allele | CTAGE Family Member 5, ER Export Factor Gene | CTAGE Family, Member 5 wt Allele | Cutaneous T-Cell Lymphoma-Associated Antigen 5 Gene | MEA11 | MEA6 | MGEA | MGEA11 | MGEA6 | MIA2 | Meningioma Expressed Antigen 6 (Coiled-Coil Proline-Rich) Gene | cTAGE-5A | cTAGE-5B | cTAGE-5C | cTAGE-5D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1431063","CTAGE5 protein, human","C114659","Endoplasmic reticulum export factor CTAGE5 (804 aa, ~91 kDa) is encoded by the human CTAGE5 gene. This protein is involved in intracellular protein transport and tumor induced immune responses.","Endoplasmic Reticulum Export Factor CTAGE5 | CTAGE Family Member 5 ER Export Factor | CTAGE5 | Cutaneous T-Cell Lymphoma-Associated Antigen 5 | Meningioma-Expressed Antigen 6/11 | Protein cTAGE-5 | cTAGE Family Member 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1842747","BBS9 Gene","C114660","This gene plays a role in ciliogenesis.","BBS9 Gene | BBS9 | Bardet-Biedl Syndrome 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889128","BBS9 wt Allele","C114661","Human BBS9 wild-type allele is located in the vicinity of 7p14 and is approximately 477 kb in length. This allele, which encodes protein PTHB1, is involved in ciliogenesis. Mutation of both copies of this gene is associated with Bardet-Biedl syndrome 9.","BBS9 wt Allele | B1 | Bardet-Biedl Syndrome 9 wt Allele | C18 | D1 | PTH-Responsive B1 Gene | PTHB1 | Parathyroid Hormone Responsive B1 Gene | Parathyroid Hormone-Responsive B1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1175338","Protein PTHB1, Human","C114662","Protein PTHB1 (887 aa, ~99 kDa) is encoded by the human BBS9 gene. This protein plays a role in cilium formation.","Protein PTHB1 | BBS9 | Bardet-Biedl Syndrome 9 Protein | PTH-Responsive Osteosarcoma B1 Protein | Parathyroid Hormone-Responsive B1 Gene Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422044","ATP8B2 Gene","C114663","This gene is involved in phospholipid transport.","ATP8B2 Gene | ATP8B2 | ATPase, Aminophospholipid Transporter, Class I, Type 8B, Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898556","MDA-MB-231/ATCC","C117223","An adenocarcinoma cell line established at the M.D. Anderson Cancer Center in 1973 from the pleural effusion of a 51 year old Caucasian female patient with breast carcinoma previously treated with chemotherapy.","MDA-MB-231/ATCC | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898554","MDA-MB-468","C117224","An adenocarcinoma cell line established by R. Cailleau, et al. in 1977 from the pleural effusion of a 51 year old female patient with breast carcinoma.","MDA-MB-468 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898991","HS 578T","C117225","An adenocarcinoma cell line established by A.J. Hackett, et al. from a 74 year old Caucasian female patient with breast carcinoma.","HS 578T | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898553","MDA-N","C117226","A melanoma cell line derived from the MDA-MB-435 cell line.","MDA-N | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899963","BT-549","C117227","An adenocarcinoma cell line established from a 72 year old female patient with breast carcinoma.","BT-549 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897399","T-47D","C117228","An adenocarcinoma cell line established from the pleural effusion of a 54 year old female patient with ductal breast carcinoma.","T-47D | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474097","anti-CEACAM5 antibody-drug conjugate SAR408701","C117229","An immunoconjugate consisting of anti-carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) conjugated to a cytotoxic agent, with potential antineoplastic activity. Upon administration of tusamitamab ravtansine the antibody moiety targets CEACAM5 on tumor cells. Upon antibody/antigen binding and internalization, the immunoconjugate releases the cytotoxic agent, which results in tumor cell death. CEACAM5, a member of the CEA family of proteins that plays a key role in cell migration, cell invasion, and cell adhesion, is overexpressed by a variety of cancer cell types.","Tusamitamab Ravtansine | ADC SAR408701 | Anti-CEACAM5 Antibody-Drug Conjugate SAR408701 | SAR408701 | TUSAMITAMAB RAVTANSINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474098","pan-PI3K Inhibitor CLR457","C117230","An orally bioavailable pan inhibitor of phosphatidylinositol-3-kinase (PI3K), with potential antineoplastic activity. Upon oral administration, pan-PI3K inhibitor CLR457 inhibits all of the PI3K kinase isoforms, which may result in apoptosis and growth inhibition in tumor cells overexpressing PI3K. Activation of the PI3K pathway promotes cell growth, survival, and resistance to both chemotherapy and radiotherapy.","pan-PI3K Inhibitor CLR457 | CLR457",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474099","Allogeneic Natural Killer Cell Line NK-92","C117231","A proprietary, human cytotoxic cell line composed of allogeneic, activated, interleukin-2 (IL-2) dependent-natural killer cells derived from a 50-year old male patient with rapidly progressive non-Hodgkin's lymphoma, with potential antineoplastic activity. As NK-92 cells are devoid of killer inhibitory receptors (KIRs; also called killer cell immunoglobulin-like receptors), which are negative regulators of NK cell activity, cancer cells are unable to suppress the cancer cell killing ability of the NK-92 cells. Upon infusion of the allogeneic NK cell line NK-92, the NKs recognize and bind to tumor cells. This leads to the secretion and release of perforins, granzymes, cytokines and chemokines, which results in cancer cell lysis and apoptosis. In addition, NK-92 cells express high affinity Fc receptors, which bind to therapeutic antibodies; therefore, this agent can enhance antibody dependent cellular cytotoxicity (ADCC) of co-administered therapeutic antibodies.","Allogeneic Natural Killer Cell Line NK-92 | HUMAN NATURAL KILLER CELL LINE NK-92 | NK-92 | NK-92 Cells | haNK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL376168","Untreated Childhood Pineoblastoma","C115205","A finding of childhood pineoblastoma that has not been treated.","Untreated Childhood Pineoblastoma | Untreated Pineoblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899523","Cognitive Side Effects of Cancer Therapy","C115206","Cognitive impairment caused by cancer treatment.","Cognitive Side Effects of Cancer Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899332","Dysplasia in Crohn Disease","C115208","A morphologic finding indicating the presence of dysplastic epithelial changes in an intestinal tissue sample that is affected by Crohn disease.","Crohn Disease-Associated Dysplasia of the Colorectum | Dysplasia in Crohn Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831917","Dermatologic Complication","C115209","Any skin disorder occurring as a consequence of injury to the skin tissue.","Dermatologic Complication | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899345","Distal Urethral Carcinoma","C115210","A carcinoma that arises from the distal part of the urethra.","Distal Urethral Carcinoma | Distal Urethra Carcinoma | Distal Urethral Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2936755","Familial Waldenstrom Macroglobulinemia","C115212","Waldenstrom macroglobulinemia in a patient who has at least one first degree relative with either Waldenstrom macroglobulinemia or another B-cell lymphoproliferative disorder.","Familial Waldenstrom Macroglobulinemia | Familial Waldenström Macroglobulinemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279456","Fever, Sweat, and Hot Flashes","C115213","Temperature elevation, sweating, and red flushed face.","Fever, Sweat, and Hot Flashes | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL371841","Health Status Unknown","C115222","Indicates that a person's current status of health is not known.","Health Status Unknown | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280407","Stage II Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","C115071","Stage II includes: T2, N0, M0.  T2: Maxillary sinus: Tumor causing bone erosion or destruction including extension into the hard palate and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and pterygoid plates.  Nasal cavity and ethmoid sinus: Tumor invading two subsites in a single region or extending to involve an adjacent region within the nasoethmoidal complex, with or without bony invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th ed.)","Stage II Sinonasal Squamous Cell Carcinoma AJCC v6 and v7 | Stage II Nasal Cavity and Paranasal Sinus Squamous Cell Cancer | Stage II Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma | Stage II Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 | Stage II Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7 | Stage II Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280411","Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","C115072","Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0).  T3: Maxillary sinus: Tumor invading any of the following: bone of the posterior wall of maxillary sinus, subcutaneous tissues, floor or medial wall of orbit, pterygoid fossa, or ethmoid sinuses. Nasal cavity and ethmoid sinus: Tumor invading the medial wall or floor of the orbit, maxillary sinus, palate, or cribriform plate.  T1: Maxillary sinus: Tumor limited to the maxillary sinus mucosa with no erosion or destruction of bone.  Nasal cavity and ethmoid sinus: Tumor restricted to any one subsite, with or without bony invasion.  T2: Maxillary sinus: Tumor causing bone erosion or destruction including extension into the hard palate and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and pterygoid plates.  Nasal cavity and ethmoid sinus: Tumor invading two subsites in a single region or extending to involve an adjacent region within the nasoethmoidal complex, with or without bony invasion.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension.  M0: No distant metastasis. (AJCC 6th and 7th eds.)","Stage III Sinonasal Squamous Cell Carcinoma AJCC v6 and v7 | Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Cancer | Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma | Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 | Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7 | Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890725","GMDS wt Allele","C114602","Human GMDS wild-type allele is located in the vicinity of 6p25 and is approximately 622 kb in length. This allele, which encodes GDP-mannose 4,6 dehydratase protein, plays a role in nucleotide-sugar complex metabolism.","GMDS wt Allele | GDP-Mannose 4,6-Dehydratase wt Allele | GMD | RP1-118B18.1 | SDR3E1 | Short Chain Dehydrogenase/Reductase Family 3E, Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3888273","GDP-Mannose 4,6 Dehydratase","C114603","GDP-mannose 4,6 dehydratase (372 aa, ~42 kDa) is encoded by the human GMDS gene. This protein is involved in the metabolism of nucleotide-sugar complexes.","GDP-Mannose 4,6 Dehydratase | EC 4.2.1.47 | GDP-D-Mannose Dehydratase | GDP-Mannose 4,6-Dehydratase | Short Chain Dehydrogenase/Reductase Family 3E, Member 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2239452","FHDC1 Gene","C114604","This gene may play a role in cellular filament polymerization.","FHDC1 Gene | FH2 Domain Containing 1 Gene | FHDC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889707","FHDC1 wt Allele","C114605","Human FHDC1 wild-type allele is located in the vicinity of 4q31.3 and is approximately 43 kb in length. This allele, which encodes FH2 domain-containing protein 1, may be involved in cytoskeletal and microtubule dynamics.","FHDC1 wt Allele | FH2 Domain Containing 1 wt Allele | INF1 | KIAA1727",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889634","FH2 Domain-Containing Protein 1, human","C114606","FH2 domain-containing protein 1 (1143 aa, ~125 kDa) is encoded by the human FHDC1 gene. This protein may play a role in both cell shape and microtubule polymerization.","FH2 Domain-Containing Protein 1 | FHDC1 | Inverted Formin-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423716","FERMT2 Gene","C114607","This gene is involved in focal adhesion formation.","FERMT2 Gene | FERMT2 | Fermitin Family Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889283","FERMT2 wt Allele","C114608","Human FERMT2 wild-type allele is located in the vicinity of 14q22.1 and is approximately 95 kb in length. This allele, which encodes fermitin family homolog 2 protein, plays a role in both the assembly of focal adhesions and integrin signaling.","FERMT2 wt Allele | Fermitin Family (Drosophila) Homolog 2 Gene | Fermitin Family Homolog 2 (Drosophila) Gene | Fermitin Family Member 2 wt Allele | KIND2 | MIG2 | Mitogen-Inducible Gene 2 | PLEKHC1 | Pleckstrin Homology Domain Containing, Family C (With FERM Domain) Member 1 Gene | UNC112 | UNC112B | Unc112, C. Elegans, Homolog of Gene | mig-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890942","GNA13 wt Allele","C115329","Human GNA13 wild-type allele is located in the vicinity of 17q24.3 and is approximately 48 kb in length. This allele, which encodes guanine nucleotide-binding protein subunit alpha-13 protein, is involved in signaling that is regulated by heterotrimeric G proteins.","GNA13 wt Allele | G13 | Guanine Nucleotide Binding Protein (G Protein), Alpha 13 wt Allele | Guanine Nucleotide-Binding Protein, Alpha-13 Gene | MGC46138",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890925","Guanine Nucleotide-Binding Protein Subunit Alpha-13, human","C115330","Guanine nucleotide-binding protein subunit alpha-13 (377 aa, ~44 kDa) is encoded by the human GNA13 gene. This protein plays a role in heterotrimeric G protein-mediated signal transduction.","Guanine Nucleotide-Binding Protein Subunit Alpha-13 | G Alpha-13 | G-Alpha-13 | G-Protein Subunit Alpha-13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473424","Poor Performance Status","C115331","Performance status defined as poor according to the ECOG performance score or Karnofsky performance score.","Poor Performance Status | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897220","Untreated Childhood Rhabdomyosarcoma","C115333","A finding of childhood rhabdomyosarcoma that has not been treated.","Untreated Childhood Rhabdomyosarcoma | Untreated Rhabdomyosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897815","Proximal Urethral Carcinoma","C115334","A carcinoma that arises from the proximal part of the urethra.","Proximal Urethral Carcinoma | Proximal Urethral Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1744561","Distal urethra","C115336","The part of the urethra that is closer to the external urethral orifice.","Distal Urethra | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0339483","Radiation Retinopathy","C115339","Injury of the retina following exposure to radiation.  The retinal injury results from occlusive microangiopathy caused by endothelial cell loss.","Radiation Retinopathy | ",,,,,,,,,,,,,,,"4317952","Radiation retinopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL471825","Healthy Stem Cell Donor","C115223","Indicates that a donor of stem cells is healthy.","Healthy Stem Cell Donor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1832055","Hepatic Complication","C115224","Any disorder of the liver occurring as a consequence of injury to the liver parenchyma.","Hepatic Complication | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4228804","Childhood Gonadal Germ Cell Tumor","C114801","A germ cell tumor that arises from the testis or ovary and occurs during childhood.","Childhood Gonadal Germ Cell Tumor | Gonadal Germ Cell Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2902961","Page Kidney","C114802","Hypertension resulting from activation of the renin-angiotensin system in response to prolonged compression of the renal parenchyma and blood vessels.","Page Kidney | ",,,,,,,,,,,,,,,"45757756","Page kidney",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3889710","ALOX15B wt Allele","C114804","Human ALOX15B wild-type allele is located in the vicinity of 17p13.1 and is approximately 10 kb in length. This allele, which encodes arachidonate 15-lipoxygenase B protein, is involved in the oxidation of fatty acids.","ALOX15B wt Allele | 15-LOX-2 | 15-Lipoxygenase, Reticulocyte, Arachidonate, Second Type Gene | Arachidonate 15-Lipoxygenase, Second Type Gene | Arachidonate 15-Lipoxygenase, Type B wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1448313","ALOX15B protein, human","C114805","Arachidonate 15-lipoxygenase B (676 aa, ~76 kDa) is encoded by the human ALOX15B gene. This protein plays a role in fatty acid metabolism.","Arachidonate 15-Lipoxygenase B | 15-LOX-2 | 15-LOX-B | 15-Lipoxygenase 2 | 15S-Lipoxygenase | ALOX15B | Arachidonate 15-Lipoxygenase 2 | Arachidonate 15-Lipoxygenase Type II | Arachidonate Omega(6) Lipoxygenase | EC 1.13.11.33 | Linoleate 13-Lipoxygenase 15-Lob",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL376151","Childhood Favorable Prognosis Hodgkin Lymphoma","C114806","A Hodgkin lymphoma with favorable prognosis that occurs during childhood.","Childhood Favorable Prognosis Hodgkin Lymphoma | Favorable Prognosis Hodgkin Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL376153","Adult Favorable Prognosis Hodgkin Lymphoma","C114807","A Hodgkin lymphoma with favorable prognosis that occurs during adulthood.","Adult Favorable Prognosis Hodgkin Lymphoma | Favorable Prognosis Hodgkin Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL376152","Childhood Unfavorable Prognosis Hodgkin Lymphoma","C114808","A Hodgkin lymphoma with unfavorable prognosis that occurs during childhood.","Childhood Unfavorable Prognosis Hodgkin Lymphoma | Unfavorable Prognosis Hodgkin Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL376154","Adult Unfavorable Prognosis Hodgkin Lymphoma","C114809","A Hodgkin lymphoma with unfavorable prognosis that occurs during adulthood.","Adult Unfavorable Prognosis Hodgkin Lymphoma | Unfavorable Prognosis Hodgkin Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889284","SCN9A wt Allele","C114811","Human SCN9A wild-type allele is located in the vicinity of 2q24 and is approximately 181 kb in length. This allele, which encodes sodium channel protein type 9 subunit alpha protein, plays a role in sodium transport. Mutation of the gene is associated with several pain and seizure disorders.","SCN9A wt Allele | ETHA | FEB3B | GEFSP7 | HSAN2D | NE-NA | NENA | Nav1.7 | PN1 | SFNP | Sodium Channel, Voltage Gated, Type IX, Alpha Subunit Gene | Sodium Channel, Voltage-Gated, Type IX, Alpha Polypeptide Gene | Sodium Channel, Voltage-Gated, Type IX, Alpha Subunit Gene | Sodium Voltage-Gated Channel Alpha Subunit 9 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887520","Childhood Pineoblastoma","C114812","A pineoblastoma that occurs during childhood.","Childhood Pineoblastoma | Pineoblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1452369","Sodium Channel Protein Type 9 Subunit Alpha, Human","C114813","Sodium channel protein type 9 subunit alpha (1988 aa, ~226 kDa) is encoded by the human SCN9A gene. This protein is involved in sodium ion transport.","Sodium Channel Protein Type 9 Subunit Alpha | Neuroendocrine Sodium Channel | PN1 | Peripheral Sodium Channel 1 | SCN9A | Sodium Channel Protein Type IX Subunit Alpha | Voltage-Gated Sodium Channel Alpha Subunit Nav1.7 | Voltage-Gated Sodium Channel Subunit Alpha Nav1.7 | hNE-Na",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889282","Fermitin Family Homolog 2, human","C114609","Fermitin family homolog 2 (680 aa, ~78 kDa) is encoded by the human FERMT2 gene. This protein is involved in both integrin signaling and focal adhesion assembly.","Fermitin Family Homolog 2 | FERMT2 | Kindlin 2 | Kindlin-2 | MIG-2 | Mitogen Inducible Gene 2 Protein | Mitogen-Inducible Gene 2 Protein | PH Domain-Containing Family C Member 1 | Pleckstrin Homology Domain Containing, Family C Member 1 | Pleckstrin Homology Domain-Containing Family C Member 1 | Pleckstrin Homology Domain-Containing Protein, Family C, Member 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539492","FBXO38 Gene","C114610","This gene may play a role in protein ubiquitination.","FBXO38 Gene | F-Box Protein 38 Gene | FBXO38",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889143","FBXO38 wt Allele","C114611","Human FBXO38 wild-type allele is located in the vicinity of 5q32 and is approximately 59 kb in length. This allele, which encodes F-box only protein 38, may be involved in protein ubiquitination.","FBXO38 wt Allele | F-Box Protein 38 wt Allele | FLJ13962 | Fbx38 | HMN2D | MOKA | Modulator of Klf7 Activity, Mouse, Homolog of Gene | SP329",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889632","F-Box Only Protein 38, human","C114612","F-box only protein 38 (1188 aa, ~134 kDa) is encoded by the human FBXO38 gene. This protein may play a role in ubiquitination.","F-Box Only Protein 38 | F-Box Protein 38 | FBXO38 | MoKA | Modulator of KLF7 Activity Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539485","FBXL18 Gene","C114615","This gene is involved in protein ubiquitination.","FBXL18 Gene | F-Box and Leucine-Rich Repeat Protein 18 Gene | FBXL18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889140","FBXL18 wt Allele","C114616","Human FBXL18 wild-type allele is located in the vicinity of 7p22.2 and is approximately 82 kb in length. This allele, which encodes F-box/LRR-repeat protein 18, plays a role in both substrate recognition and the regulation of ubiquitination.","FBXL18 wt Allele | F-Box and Leucine-Rich Repeat Protein 18 wt Allele | FBL18 | FLJ11467 | Fbl18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890775","UHRF1 wt Allele","C115278","Human UHRF1 wild-type allele is located in the vicinity of 19p13.3 and is approximately 59 kb in length. This allele, which encodes E3 ubiquitin-protein ligase UHRF1 protein, plays a role in both protein ubiquitination and epigenetic silencing of gene transcription. Aberrant expression of the gene is associated with many neoplastic diseases.","UHRF1 wt Allele | FLJ21925 | ICBP90 | Np95 | RNF106 | Ubiquitin-Like With PHD and Ring Finger Domains 1 wt Allele | Ubiquitin-Like, Containing PHD and RING Finger Domains, 1 Gene | hNP95 | hUHRF1 | huNp95",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1438723","E3 Ubiquitin-Protein Ligase UHRF1, Human","C115279","E3 ubiquitin-protein ligase UHRF1 (793 aa, ~90 kDa) is encoded by the human UHRF1 gene. This protein is involved in the modification of both DNA and proteins.","E3 Ubiquitin-Protein Ligase UHRF1 | EC 2.3.2.27 | EC 6.3.2.-, Formerly | HuNp95 | Inverted CCAAT Box-Binding Protein of 90 kDa | Inverted CCAAT Box-Binding Protein, 90-kD | Nuclear Phosphoprotein, 95-kD | Nuclear Zinc Finger Protein Np95 | RING Finger Protein 106 | Transcription Factor ICBP90 | Ubiquitin-Like PHD and RING Finger Domain-Containing Protein 1 | Ubiquitin-Like Protein Containing PHD and Ring Finger Domains 1 | Ubiquitin-Like-Containing PHD and RING Finger Domains Protein 1 | hNp95 | hUHRF1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889152","NT5E wt Allele","C114925","Human NT5E wild-type allele is located within 6q14-q21 and is approximately 46 kb in length. This allele, which encodes 5'-nucleotidase protein, plays a role in nucleoside formation. Mutation of the gene is associated with calcification of joints and arteries.","NT5E wt Allele | 5' Nucleotidase (CD73) Gene | 5'-Nucleotidase, Ecto (CD73) wt Allele | CALJA | CD73 | E5NT | NT | NT5 | NTE | RP11-321N4.1 | eN | eNT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412304","Childhood Epithelioid Hemangioendothelioma","C114926","An epithelioid hemangioendothelioma that occurs during childhood.","Childhood Epithelioid Hemangioendothelioma | Epithelioid Hemangioendothelioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2932861","5'-Nucleotidase, Human","C114927","5'-nucleotidase (574 aa, ~63 kDa) is encoded by the human NT5E gene. This protein is involved in the conversion of nucleotides to nucleosides.","5'-Nucleotidase | 5'-NT | 5-Nucleotidase | CD73 | CD73 Antigen | EC 3.1.3.5 | Ecto-5'-Nucleotidase | Ecto-5-Prime Nucleotidase | NT5E | Nucleotidase, Ecto-5-Prime | Purine 5-Prime-Nucleotidase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3267180","Infant Formula Intolerance","C114928","Inability to effectively digest or absorb the components of breast milk substitutes. Symptoms may include emesis, abdominal distension or diarrhea.","Infant Formula Intolerance | Breast Milk Substitute Intolerance",,,,,,,,,,,,,,,"45769870","Intolerance to infant formula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL412310","Adult Langerhans Cell Histiocytosis","C114929","Langerhans cell histiocytosis that occurs during adulthood.","Adult Langerhans Cell Histiocytosis | Langerhans Cell Histiocytosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898903","Healthy Preterm Newborn","C114931","An age group comprised of healthy newborns whose only diagnoses are those related to prematurity.","Healthy Preterm Newborn | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412374","Hormone-Resistant Breast Carcinoma","C114932","Breast adenocarcinoma that does not respond to hormone therapy.","Hormone-Resistant Breast Carcinoma | Hormone-Refractory Breast Cancer | Hormone-Resistant Breast Adenocarcinoma | Hormone-Resistant Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412375","hormone-resistant prostate cancer","C114933","Prostate carcinoma that does not respond to hormone therapy.","Hormone-Resistant Prostate Carcinoma | Hormone-Resistant Prostate Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021296","Small for Gestational Age","C114934","A newborn infant who has weight and/or length at birth more than two standard deviations below the mean for the reference population of the same sex and gestational age.","Small for Gestational Age | Small For Dates Baby",,,,,,,,,,,,,,,"4064286","Small-for-dates baby",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0282666","Very Low Birth Weight","C114935","Birth weight less than 1500 grams.","Very Low Birth Weight | VLBW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456065","Extremely Low Birth Weight","C114936","Birth weight less than 1000 grams.","Extremely Low Birth Weight | ELBW",,,,,,,,,,,,,,,"4173323","Extremely low birth weight infant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3896584","Ultra Low Birth Weight","C114937","Birth weight less than 750 grams.","Ultra Low Birth Weight | ULBW",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899392","Device Intended But Not Used","C117758","A status indicating that a device was introduced to the subject for use but did not meet its intended goal and was removed.","Device Intended But Not Used | INTENDED BUT NOT USED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899689","Checkerboard Square Size","C117759","A visual stimulus that uses a checkerboard pattern which reverses every half-second. The check size, field size and field location can be changed to allow for testing of specific segments of the visual pathway.","Checkerboard Square Size | CHCKSIZE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891072","NUF2 wt Allele","C114815","Human NUF2 wild-type allele is located in the vicinity of 1q23.3 and is approximately 89 kb in length. This allele, which encodes kinetochore protein Nuf2, plays a role in the progression of mitosis.","NUF2 wt Allele | CDCA1 | CT106 | Cell Division Cycle Associated 1 Gene | NUF2, NDC80 Kinetochore Complex Component wt Allele | NUF2, NDC80 Kinetochore Complex Component, Homolog (S. cerevisiae) Gene | NUF2, NDC80 Kinetochore Complex Component, Homolog Gene | NUF2, S. cerevisiae, Homolog of Gene | NUF2R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1506549","Kinetochore Protein Nuf2, Human","C114816","Kinetochore protein Nuf2 (464 aa, ~54 kDa) is encoded by the human NUF2 gene. This protein is involved in mitosis.","Kinetochore Protein Nuf2 | Cancer/Testis Antigen 106 | Cell Division Cycle-Associated Protein 1 | NUF2 | hNuf2 | hNuf2R | hsNuf2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897518","Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7","C115038","Stage IVA includes: (T4a, N0, M0); (T4a, N1a, M0); (T1, N1b, M0); (T2, N1b, M0); (T3, N1b, M0); (T4a, N1b, M0). T4a: Moderately advanced local disease. Tumor of any size extending beyond the thyroid gland capsule to invade subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve. T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland. T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland. T3: Tumor more than 4 cm in greatest dimension and limited to the thyroid gland, or tumor of any size with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues). N0: No regional lymph node metastasis. N1a: Metastasis to pretracheal, paratracheal or prelaryngeal/Delphian lymph nodes (Level VI lymph nodes). N1b: Metastasis to unilateral, bilateral or contralateral cervical (Levels I, II, III, IV, or V) or retropharyngeal or superior mediastinal lymph nodes (Level VII). M0: No distant metastasis. (AJCC 7th ed.)","Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Papillary Cancer | Stage IVA Thyroid Gland Papillary Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897511","Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7","C115039","Stage IVB includes: T4b, Any N, M0. T4b: Very advanced disease. Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels. M0: No distant metastasis. (AJCC 7th ed.)","Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVB Thyroid Gland Papillary Cancer | Stage IVB Thyroid Gland Papillary Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897506","Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7","C115040","Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 7th ed.)","Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVC Thyroid Gland Papillary Cancer | Stage IVC Thyroid Gland Papillary Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433741","Stage IIA Colon Cancer AJCC v7","C115041","Stage IIA includes: T3, N0, M0. T3: Tumor invades through the muscularis propria into pericolorectal tissues. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)","Stage IIA Colon Cancer AJCC v7 | Stage IIA Colon Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433742","Stage IIB Colon Cancer AJCC v7","C115042","Stage IIB includes: T4a, N0, M0. T4a: Tumor penetrates to the surface of the visceral peritoneum. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)","Stage IIB Colon Cancer AJCC v7 | Stage IIB Colon Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433743","Stage IIC Colon Cancer AJCC v7","C115043","Stage IIC includes: T4b, N0, M0. T4b: Tumor directly invades or is adherent to other organs or structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)","Stage IIC Colon Cancer AJCC v7 | Stage IIC Colon Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433749","Stage IIA Rectal Cancer AJCC v7","C115044","Stage IIA includes: T3, N0, M0. T3: Tumor invades through the muscularis propria into pericolorectal tissues. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)","Stage IIA Rectal Cancer AJCC v7 | Stage IIA Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433750","Stage IIB Rectal Cancer AJCC v7","C115045","Stage IIB includes: T4a, N0, M0. T4a: Tumor penetrates to the surface of the visceral peritoneum. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)","Stage IIB Rectal Cancer AJCC v7 | Stage IIB Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890749","BCLAF1 wt Allele","C115995","Human BCLAF1 wild-type allele is located within 6q22-q23 and is approximately 33 kb in length. This allele, which encodes Bcl-2-associated transcription factor 1 protein, plays a role in both apoptosis promotion and the repression of transcription.","BCLAF1 wt Allele | BCL2-Associated Transcription Factor 1 wt Allele | BTF | KIAA0164 | bK211L9.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473362","Bcl-2-Associated Transcription Factor 1","C115996","Bcl-2-associated transcription factor 1 (920 aa, ~106 kDa) is encoded by the human BCLAF1 gene. This protein is involved in the positive regulation of apoptosis and the negative regulation of gene transcription.","Bcl-2-Associated Transcription Factor 1 | BCL2-Associated Transcription Factor 1 | BCLAF1 | Btf",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054601","Localized Adult Undifferentiated High Grade Pleomorphic Sarcoma of Bone","C115997","An undifferentiated high grade pleomorphic sarcoma of bone that occurs in adulthood and has not spread to other anatomic sites.","Localized Adult Undifferentiated High Grade Pleomorphic Sarcoma of Bone | Localized Adult Undifferentiated High Grade Pleomorphic Sarcoma | Undifferentiated High Grade Pleomorphic Sarcoma of Bone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054600","Localized Childhood Undifferentiated High Grade Pleomorphic Sarcoma of Bone","C115998","An undifferentiated high grade pleomorphic sarcoma of bone that occurs in childhood and has not spread to other anatomic sites.","Localized Childhood Undifferentiated High Grade Pleomorphic Sarcoma of Bone | Localized Childhood Undifferentiated High Grade Pleomorphic Sarcoma | Undifferentiated High Grade Pleomorphic Sarcoma of Bone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889978","Content Model Content Type","C115999","The name of the type of content in a content model.","Content Model Content Type | Content Type Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3892046","Phototoxicity Study","C116216","A study of the effect of an agent on the skin or eyes, such that it induces a sensitivity to sunlight or other forms of light.","Phototoxicity Study | PHOTOTOXICITY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900036","Anesthetized Lethal Injection Euthanasia","C116217","A method of euthanasia whereby a subject is anesthetized and a lethal chemical is administered by injection to induce death.","Anesthetized Lethal Injection Euthanasia | ANESTHETIZED LETHAL INJECTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900037","Anesthetized Intravenous Lethal Injection Euthanasia","C116218","A method of euthanasia whereby a subject is anesthetized and a lethal chemical is administered by intravenous injection to induce death.","Anesthetized Intravenous Lethal Injection Euthanasia | ANESTHETIZED LETHAL INJECTION INTRAVENOUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900039","Anesthetized Intraperitoneal Lethal Injection Euthanasia","C116219","A method of euthanasia whereby a subject is anesthetized and a lethal chemical is administered by intraperitoneal injection to induce death.","Anesthetized Intraperitoneal Lethal Injection Euthanasia | ANESTHETIZED LETHAL INJECTION INTRAPERITONEAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900041","Anesthetized Intracardiac Lethal Injection Euthanasia","C116220","A method of euthanasia whereby a subject is anesthetized and a lethal chemical is administered by intracardiac injection to induce death.","Anesthetized Intracardiac Lethal Injection Euthanasia | ANESTHETIZED LETHAL INJECTION INTRACARDIAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900035","Anesthetized Lethal Injection Exsanguination Euthanasia","C116221","A method of euthanasia whereby a subject is anesthetized, a lethal chemical is administered by injection and the body is drained of blood.","Anesthetized Lethal Injection Exsanguination Euthanasia | ANESTHETIZED LETHAL INJECTION EXSANGUINATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900038","Anesthetized Intraperitoneal Lethal Injection and Exsanguination Euthanasia","C116223","A method of euthanasia whereby a subject is anesthetized, a lethal chemical is administered by intraperitoneal injection and the body is drained of blood.","Anesthetized Intraperitoneal Lethal Injection and Exsanguination Euthanasia | ANESTHETIZED LETHAL INJECTION INTRAPERITONEAL EXSANGUINATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899347","Displaced Peritoneal Dialysis Catheter","C115162","Malposition and dysfunction of a peritoneal dialysis catheter.","Displaced Peritoneal Dialysis Catheter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0694549","Community-Acquired Pneumonia","C115163","Pneumonia that is not acquired in a hospital or long-term care facility setting.","Community-Acquired Pneumonia | Community-acquired Pneumonia",,,,,,,,,,,,,,,"4293463","Community acquired pneumonia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL472675","Sialitis","C115165","Inflammation of the salivary glands.","Sialitis | Sialadenitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890191","AGRP wt Allele","C115167","Human AGRP wild-type allele is located in the vicinity of 16q22 and is approximately 1 kb in length. This allele, which encodes agouti-related protein, is involved in the regulation of feeding behavior. Mutation of the gene is associated with obesity.","AGRP wt Allele | AGRT | ART | ASIP2 | Agouti (Mouse) Related Protein Gene | Agouti Related Protein Homolog (Mouse) wt Allele | Agouti-Related Protein, Mouse, Homolog of Gene | Agouti-Related Transcript, Mouse, Homolog of Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0156275","Spontaneous Bladder Rupture","C115168","Rupture in the bladder wall due to a pathologic process, in the absence of trauma.","Spontaneous Bladder Rupture | Spontaneous Bladder Perforation",,,,,,,,,,,,,,,"197037","Nontraumatic rupture of bladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1741739","Agouti-Related Protein, Human","C115169","Agouti-related protein (132 aa, ~14 kDa) is encoded by the human AGRP gene. This protein plays a role in the modulation of feeding behavior.","Agouti-Related Protein | AGRP | Agouti Related Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1568716","Gap Junction Alpha-1 Protein, Human","C115172","Gap junction alpha-1 protein (382 aa, ~43 kDa) is encoded by the human GJA1 gene. This protein is involved in the regulation of the assembly of gap junctions.","Gap Junction Alpha-1 Protein | Connexin 43 | Connexin-43 | Cx43 | GJA | Gap Junction 43 kDa Heart Protein | Heart Connexin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889446","ANO1 wt Allele","C115174","Human ANO1 wild-type allele is located in the vicinity of 11q13.3 and is approximately 111 kb in length. This allele, which encodes anoctamin-1 protein, is involved in the modulation of chloride transport.","ANO1 wt Allele | Anoctamin 1, Calcium Activated Chloride Channel wt Allele | Anoctamin 1, Calcium-Activated Chloride Channel Gene | DOG1 | ORAOV2 | Oral Cancer Overexpressed 2 Gene | TAOS2 | TMEM16A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0341505","Chemical Peritonitis","C114752","A non-infectious inflammation of the peritoneum.","Chemical Peritonitis | ",,,,,,,,,,,,,,,"4309917","Chemical peritonitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0340911","AV Fistula Aneurysm","C114753","A bulge in a weakened vessel wall segment of an arteriovenous fistula.","AV Fistula Aneurysm | Arteriovenous Fistula Aneurysm",,,,,,,,,,,,,,,"35624450|4116326","Arteriovenous fistula with aneurysm|Arteriovenous fistula aneurysm",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0340908","AV Fistula Stenosis","C114754","Narrowing of the lumen of an arteriovenous fistula.","AV Fistula Stenosis | Arteriovenous Fistula Stenosis",,,,,,,,,,,,,,,"4120283","Arteriovenous fistula stenosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1418636","PLCD3 Gene","C116272","This gene is involved in second messenger synthesis.","PLCD3 Gene | PLCD3 | Phospholipase C, Delta 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889280","PLCD3 wt Allele","C116273","Human PLCD3 wild-type allele is located in the vicinity of 17q21.31 and is approximately 24 kb in length. This allele, which encodes 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-3 protein, plays a role in the synthesis of second messenger signaling molecules. Variation in the gene is associated with dichotomous hypertension.","PLCD3 wt Allele | KIAA1964 | PLC-Delta-3 | Phospholipase C, Delta 3 wt Allele | Phospholipase C, Delta-3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1870412","1-Phosphatidylinositol 4,5-Bisphosphate Phosphodiesterase Delta-3, Human","C116274","1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-3 (789 aa, ~89 kDa) is encoded by the human PLCD3 gene. This protein is involved in the generation of second messenger molecules from phosphoinositides.","1-Phosphatidylinositol 4,5-Bisphosphate Phosphodiesterase Delta-3 | 1-Phosphatidylinositol-4,5-Bisphosphate Phosphodiesterase Delta-3 | EC 3.1.4.11 | PLC Delta3 | PLC-Delta-3 | PLCD3 | Phosphoinositide Phospholipase C-Delta-3 | Phospholipase C Delta 3 | Phospholipase C-Delta-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889436","LAMC2 wt Allele","C116276","Human LAMC2 wild-type allele is located within 1q25-q31 and is approximately 59 kb in length. This allele, which encodes laminin subunit gamma-2 protein, is involved in both the development of the epidermis and extracellular matrix organization. Mutation of the gene is associated with Herlitz junctional epidermolysis bullosa.","LAMC2 wt Allele | B2T | BM600 | CSF | EBR2 | EBR2A | LAMB2T | LAMNB2 | Lam5, Gamma-2 Subunit Gene | Laminin 5, Gamma-2 Subunit Gene | Laminin, Gamma 2 (Nicein (100kD), Kalinin (105kD), BM600 (100kD), Herlitz Junctional Epidermolysis Bullosa)) Gene | Laminin, Gamma 2 wt Allele | Laminin, Gamma-2 Gene | Laminin, Nicein, Beta-2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424590","WTAP Gene","C116278","This gene is involved in the modulation of both transcription and mRNA splicing.","WTAP Gene | WTAP | Wilms Tumor 1 Associated Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890920","WTAP wt Allele","C116279","Human WTAP wild-type allele is located within 6q25-q27 and is approximately 31 kb in length. This allele, which encodes pre-mRNA-splicing regulator WTAP protein, plays a role in the regulation of RNA processing.","WTAP wt Allele | KIAA0105 | MGC3925 | RP1-56L9.4 | Wilms Tumor 1 Associated Protein wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1432048","Pre-mRNA-Splicing Regulator WTAP, Human","C116280","Pre-mRNA-splicing regulator WTAP (396 aa, ~44 kDa) is encoded by the human WTAP gene. This protein is involved in the modulation of RNA processing.","Pre-mRNA-Splicing Regulator WTAP | Female-Lethal(2)D Homolog | Putative Pre-mRNA Splicing Regulator Female-Lethal(2D) | WT1-Associated Protein | WT1-Associating Protein | Wilms Tumor 1 Associated Protein | Wilms Tumor 1-Associated Protein | Wilms Tumor 1-Associating Protein | Wilms' Tumour 1-Associating Protein | hFL(2)D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890582","Institutional Review Board Independent Ethics Committee Subject Questionnaire","C115560","A document, approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC), intended to capture specific subject-related information through a series of questions.","Institutional Review Board Independent Ethics Committee Subject Questionnaire | IRB-IEC Approved Subject Questionnaire | Institutional Review Board Independent Ethics Committee Approved Subject Questionnaire | Subj Quest | Subject Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1437227","Alpha-Crystallin B Chain, Human","C115115","Alpha-crystallin B chain (175 aa, ~20 kDa) is encoded by the human CRYAB gene. This protein is involved in the stabilization of lens proteins.","Alpha-Crystallin B Chain | Alpha(B)-Crystallin | Heat Shock Protein Beta-5 | Heat-Shock 20 kD Like-Protein | Heat-Shock Protein Beta-5 | HspB5 | Renal Carcinoma Antigen NY-REN-27 | Rosenthal Fiber Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433918","Recurrent Childhood Gliosarcoma","C115365","The reemergence of gliosarcoma in childhood after a period of remission.","Recurrent Childhood Gliosarcoma | Recurrent Gliosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433932","Recurrent Childhood Gliomatosis Cerebri","C115366","The reemergence of gliomatosis cerebri in childhood after a period of remission.","Recurrent Childhood Gliomatosis Cerebri | Recurrent Gliomatosis Cerebri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1541447","Recurrent Childhood Grade III Lymphomatoid Granulomatosis","C115367","The reemergence of grade III lymphomatoid granulomatosis in childhood after a period of remission.","Recurrent Childhood Grade III Lymphomatoid Granulomatosis | Recurrent Grade III Lymphomatoid Granulomatosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054112","Recurrent Childhood Undifferentiated High Grade Pleomorphic Sarcoma of Bone","C115368","The reemergence of undifferentiated high grade pleomorphic sarcoma of bone in childhood after a period of remission.","Recurrent Childhood Undifferentiated High Grade Pleomorphic Sarcoma of Bone | Recurrent Childhood Undifferentiated High Grade Pleomorphic Sarcoma | Recurrent Undifferentiated High Grade Pleomorphic Sarcoma of Bone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433952","Recurrent Childhood Oligoastrocytoma","C115370","The reemergence of oligoastrocytoma in childhood after a period of remission.","Recurrent Childhood Oligoastrocytoma | Recurrent Oligoastrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433935","Recurrent Childhood Oligodendroglioma","C115371","The reemergence of oligodendroglioma in childhood after a period of remission.","Recurrent Childhood Oligodendroglioma | Recurrent Oligodendroglioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433937","Recurrent Childhood Pilocytic Astrocytoma","C115372","The reemergence of pilocytic astrocytoma in childhood after a period of remission.","Recurrent Childhood Pilocytic Astrocytoma | Recurrent Pilocytic Astrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433940","Recurrent Childhood Pilomyxoid Astrocytoma","C115373","The reemergence of pilomyxoid astrocytoma in childhood after a period of remission.","Recurrent Childhood Pilomyxoid Astrocytoma | Recurrent Pilomyxoid Astrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL376167","Recurrent Childhood Pineoblastoma","C115374","The reemergence of pineoblastoma in childhood after a period of remission.","Recurrent Childhood Pineoblastoma | Recurrent Pineoblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433943","Recurrent Childhood Pleomorphic Xanthoastrocytoma","C115375","The reemergence of pleomorphic xanthoastrocytoma in childhood after a period of remission.","Recurrent Childhood Pleomorphic Xanthoastrocytoma | Recurrent Pleomorphic Xanthoastrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433946","Recurrent Childhood Protoplasmic Astrocytoma","C115376","The reemergence of protoplasmic astrocytoma in childhood after a period of remission.","Recurrent Childhood Protoplasmic Astrocytoma | Recurrent Protoplasmic Astrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417516","MXRA5 Gene","C115377","This gene may play a role in the structure of the extracellular matrix.","MXRA5 Gene | MXRA5 | Matrix-Remodelling Associated 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433939","Childhood Pilomyxoid Astrocytoma","C114970","A pilomyxoid astrocytoma that occurs during childhood.","Childhood Pilomyxoid Astrocytoma | Pilomyxoid Astrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433942","Childhood Pleomorphic Xanthoastrocytoma","C114971","A pleomorphic xanthoastrocytoma that occurs during childhood.","Childhood Pleomorphic Xanthoastrocytoma | Pleomorphic Xanthoastrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433945","Childhood Protoplasmic Astrocytoma","C114972","A protoplasmic astrocytoma that occurs during childhood.","Childhood Protoplasmic Astrocytoma | Protoplasmic Astrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433948","Childhood Anaplastic Oligoastrocytoma","C114973","An anaplastic oligoastrocytoma that occurs during childhood.","Childhood Anaplastic Oligoastrocytoma | Anaplastic Oligoastrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433951","Childhood Oligoastrocytoma","C114974","An oligoastrocytoma that occurs during childhood.","Childhood Oligoastrocytoma | Oligoastrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831182","Category Description Type","C114461","A functional description of a classification type.","Category Description Type | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831019","Content Requirement Indicator","C114462","An indication as to the necessity of a particular content type within a content model.","Content Requirement Indicator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3827283","Digital Archive","C114463","A storage location for historical digital data.","Digital Archive | Archive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3831181","Category Name","C114464","The designation for a collection of related, classified entities.","Category Name | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829119","Metadata Use Type","C114465","A description of the implementation of metadata.","Metadata Use Type | Metadata Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3829120","Metadata Content Type","C114466","A description of the kind of metadata.","Metadata Content Type | Content Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3830601","Data Property","C114468","A type of metadata category used to describe attributes of entities.","Data Property | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034530","Radiation Damage","C114472","Injury resulting from exposure to ionizing radiation.","Radiation Damage | ",,,,,,,,,,,,,,,"4085340|4215012","Injury caused by ionizing radiation|Radiation injury",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0340909","AV Fistula Thrombosis","C114756","Partial or complete occlusion of the lumen within an arteriovenous fistula by a thrombus.","AV Fistula Thrombosis | Arteriovenous Fistula Thrombosis",,,,,,,,,,,,,,,"4125011","Arteriovenous fistula thrombosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0349761","AV Graft Aneurysm","C114758","A bulge in a weakened wall segment of an arteriovenous graft.","AV Graft Aneurysm | Arteriovenous Graft Aneurysm",,,,,,,,,,,,,,,"4094024","Arteriovenous graft aneurysm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3887517","Childhood Brain Stem Gliosarcoma","C114759","A gliosarcoma that arises from the brain stem and occurs during childhood.","Childhood Brain Stem Gliosarcoma | Brain Stem Gliosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887516","Childhood Brain Stem Mixed Glioma","C114760","A mixed glioma that arises from the brain stem and occurs during childhood.","Childhood Brain Stem Mixed Glioma | Brain Stem Mixed Glioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0349756","AV Graft Stenosis","C114762","Narrowing of the lumen of an arteriovenous graft.","AV Graft Stenosis | Arteriovenous Graft Stenosis",,,,,,,,,,,,,,,"4089918","Arteriovenous graft stenosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0349757","AV Graft Thrombosis","C114763","Partial or complete occlusion of the lumen of an arteriovenous graft by a thrombus.","AV Graft Thrombosis | Arteriovenous Graft Thrombosis",,,,,,,,,,,,,,,"4094022","Arteriovenous graft thrombosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1395369","Dialysis Catheter Obstruction","C114764","Blockage of a dialysis catheter by a thrombus or other substance.","Dialysis Catheter Obstruction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1850734","Carnitine Palmitoyltransferase II Deficiency","C114766","A rare, autosomal recessive inherited disorder of long-chain fatty-acid oxidation caused by mutations in the CPT2 gene. The disease includes three main types: a lethal neonatal form, a severe infantile hepatocardiomuscular form, and a myopathic form.","Carnitine Palmitoyltransferase II Deficiency | CPT II Deficiency",,,,,,,,,,,,,,,"4031804","Carnitine palmitoyltransferase II deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268155","Galactokinase Deficiency","C114767","An autosomal recessive disorder caused by mutations in the GALK1 gene. The disorder is characterized by an accumulation of galactose and galactitol secondary to the decreased conversion of galactose to galactose-1-phosphate by galactokinase. Its major clinical symptom is the development of cataracts during the first weeks or months of life.","Galactokinase Deficiency | GALK Deficiency | Galactosemia Type 2",,,,,,,,,,,,,,,"4050299","Deficiency of galactokinase",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2931058","Marfan Syndrome Type 2","C114768","A rare autosomal dominant inherited disorder of connective tissue caused by mutations in either the TGFBR1 or TGFBR2 gene. Like Loeys-Dietz syndrome type I the disease is characterized by enlargement of the aorta and other arteries, and arterial tortuosity, but skeletal signs are typically less severe or absent in type 2. Skin abnormalities, such as velvety skin are often present in type 2.","Loeys-Dietz Syndrome Type 2 | Loeys-Dietz Syndrome Type II | Marfan Syndrome Type 2 | Marfan Syndrome Type II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4015560","Maturity-Onset Diabetes of the Young","C114769","A rare autosomal dominant form of diabetes mellitus affecting young people with a positive family history. MODY is a form of monogenic diabetes, resulting from mutations in a single gene. The most common forms are HNF1alpha-MODY (MODY3) and GCK-MODY (MODY2), due to mutations in the HNF1A and GCK genes, respectively.","Maturity-Onset Diabetes of the Young | MODY | Maturity Onset Diabetes of the Young",,,,,,,,,,,,,,,"43531640","Maturity-onset diabetes of the young",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2716213","Pogo Transposable Element With ZNF Domain, Human","C115000","Pogo transposable element with ZNF domain (1410 aa, ~155 kDa) is encoded by the human POGZ gene. This protein is involved in cell cycle progression.","Pogo Transposable Element With ZNF Domain | Suppressor of Hairy Wing Homolog 5 | Zinc Finger Protein 280E | Zinc Finger Protein 635",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420873","TPM2 Gene","C115001","This gene plays a role in both muscle contraction and actin binding.","TPM2 Gene | TPM2 | Tropomyosin 2 (Beta) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897455","Study Subject Radiograph","C115561","A radiographic image taken of a study participant for use in a clinical trial.","Study Subject Radiograph | Study Subj RAD | Study Subject Radiography",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086715","normal values","C115562","A generally agreed upon set of laboratory values that allow for comparative interpretation of laboratory results, and on which medical decisions are made.","Laboratory Normal Ranges | Lab Normals | Laboratory Test Result Reference Range | Local Laboratory Normal Ranges | Locl Lab Norm Range | Reference Ranges",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899565","Clinical Trial Non-Investigational Product Supplies Shipment Documentation","C115563","Documentation providing information regarding the shipment of the non-investigational product(s) and other supplies for the clinical trial.","Clinical Trial Non-Investigational Product Supplies Shipment Documentation | Non-IP Docn Shipmt | Non-IP Documentation of Shipment | Non-IP Shipment Documentation | Non-Investigational Product Documentation of Shipment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898690","Investigational Product Accountability Record","C115564","Documentation detailing the dispensing and return of the investigational product(s) for the clinical trial.","Clinical Trial Investigational Product Accountability Documentation | Accountability Documentation | IP Accountability Documentation | IP Accountability Record | IP Acct Record | Inventory Documentation | Investigational Product Accountability Record | Investigational Product Accountability Record",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889392","Investigational Product and Clinical Trial Supplies Communication Record","C115565","Documentation providing information regarding communications pertaining to the investigational product, and associated trial supplies.","Investigational Product and Clinical Trial Supplies Communication Record | Correspondence | General Investigational Product and Trial Supplies Communications | IP Trial Suppl Comm | IP and Trial Supplies Communications | Relevant Communications",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898676","Investigational Product Shipment Record","C115567","Documentation providing information regarding the shipment of the investigational product(s) for the clinical trial.","Clinical Trial Investigational Product Shipment Documentation | IP Documentation of Shipment | IP Shipment Documentation | IP Shipment Record | IP Shipmt Record | Investigational Product Shipment Record | Investigational Product Shipment Record",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898673","Investigational Product Transfer Record","C115568","Documentation detailing the transfer of the investigational product(s) for the clinical trial.","Clinical Trial Investigational Product Transfer Documentation | IP Documentation of Transfer | IP Trans Record | IP Transfer Documentation | IP Transfer Record | Investigational Product Transfer Record | Investigational Product Transfer Record",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897765","Record of Retained Body Fluids or Tissue Sample","C115570","Documentation pertaining to the identification and location of retained specimens for the clinical trial.","Clinical Trial Record of Retained Biological Samples Documentation | Record RBF | Record of Retained Body Fluids / Tissue Samples | Record of Retained Body Fluids or Tissue Sample | Record of Retained Body Fluids or Tissue Samples | Record of Retained Samples",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897498","Statistical Report Record","C115571","Records pertaining to the statistical data from a clinical trial.","Statistical Report Record | SR Record | Statistical Report Records Subcategory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899945","Bioanalytical Report","C115573","Documentation describing final or interim results of the bioanalytical aspects of the clinical trial.","Clinical Trial Bioanalytical Report Documentation | Bioanalytical Documentation | Bioanalytical Report | Bioanalytical Report | Bioanalytical Reports | Bioanyl Rept",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3502319","Matrix-Remodeling-Associated Protein 5, Human","C115379","Matrix-remodeling-associated protein 5 (2828 aa, ~312 kDa) is encoded by the human MXRA5 gene. This protein may play a role in remodeling of the extracellular matrix.","Matrix-Remodeling-Associated Protein 5 | Adhesion Protein With Leucine-Rich Repeats and Immunoglobulin Domains Related To Perlecan | Adlican | MXRA5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889382","HHEX wt Allele","C114958","Human HHEX wild-type allele is located in the vicinity of 10q23.33 and is approximately 7 kb in length. This allele, which encodes hematopoietically-expressed homeobox protein HHEX, plays a role in transcriptional regulation.","HHEX wt Allele | HEX | HMPH | HOX11L-PEN | Hematopoietically Expressed Homeobox wt Allele | PRH | PRHX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1684365","Hematopoietically-Expressed Homeobox Protein HHEX, Human","C114959","Hematopoietically-expressed homeobox protein HHEX (270 aa, ~30 kDa) is encoded by the human HHEX gene. This protein is involved in the negative regulation of transcription.","Hematopoietically-Expressed Homeobox Protein HHEX | Homeobox Protein HEX | Homeobox Protein PRH | Homeobox, Hematopoietically Expressed | Proline-Rich Homeodomain-Containing Transcription Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899505","Congenital Disruption","C114960","A morphologic defect of an organ, part of an organ, or a larger region of the body that results from the extrinsic breakdown of, or an interference with, an originally normal developmental process.","Congenital Disruption | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897227","Untreated Childhood Low Grade Astrocytic Tumor","C114961","A finding of childhood low grade astrocytic tumor that has not been treated.","Untreated Childhood Low Grade Astrocytic Tumor | Untreated Low Grade Astrocytic Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897228","Untreated Childhood High Grade Astrocytic Tumor","C114962","A finding of childhood high grade astrocytic tumor that has not been treated.","Untreated Childhood High Grade Astrocytic Tumor | Untreated High Grade Astrocytic Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433903","Childhood Fibrillary Astrocytoma","C114963","A fibrillary astrocytoma that occurs during childhood.","Childhood Fibrillary Astrocytoma | Fibrillary Astrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433906","Childhood Gemistocytic Astrocytoma","C114964","A gemistocytic astrocytoma that occurs during childhood.","Childhood Gemistocytic Astrocytoma | Gemistocytic Astrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433909","Childhood Giant Cell Glioblastoma","C114966","A giant cell glioblastoma that occurs during childhood.","Childhood Giant Cell Glioblastoma | Giant Cell Glioblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433914","Childhood Diffuse Astrocytoma","C114967","A diffuse astrocytoma that occurs during childhood.","Childhood Diffuse Astrocytoma | Diffuse Astrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433917","Childhood Gliosarcoma","C114968","A gliosarcoma that occurs during childhood.","Childhood Gliosarcoma | Gliosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433930","Childhood Gliomatosis Cerebri","C114969","Gliomatosis cerebri that occurs during childhood.","Childhood Gliomatosis Cerebri | Gliomatosis Cerebri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0220983","Metabolic Alkalosis","C114478","Abnormally increased pH levels in the blood due to excessive loss of acid and/or accumulation of base.","Metabolic Alkalosis | ",,,,,,,,,,,,,,,"4030381","Metabolic alkalosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4049213","Ureter Compression","C114479","Narrowing of the luminal diameter of one or both ureters due to extrinsic pressure.","Ureter Compression | Ureteral Compression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433920","Stage IA Esophageal Cancer AJCC v7","C115117","Stage IA includes: For squamous cell carcinoma: T1, N0, M0, G1, GX, Tumor location: Any. T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  G1: Well differentiated.  GX: Grade cannot be assessed-stage grouping as G1.  Tumor location: Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumor in the esophagus.  For adenocarcinoma: T1, N0, M0, G1-2, X. T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  G1: Well differentiated.  G2: Moderately differentiated. GX: Grade cannot be assessed-stage grouping as G1. (AJCC 7th ed.)","Stage IA Esophageal Cancer AJCC v7 | Stage IA Esophageal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433921","Stage IB Esophageal Cancer AJCC v7","C115118","Stage IB includes: For squamous cell carcinoma: (T1, N0, M0, G2-3, Tumor location: Any); (T2-3, N0, M0, G1, GX, Tumor location: Lower, X). T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  T2: Tumor invades muscularis propria. T3: Tumor invades adventitia. N0: No regional lymph node metastasis.  M0: No distant metastasis.  G1: Well differentiated.  GX: Grade cannot be assessed-stage grouping as G1.  G2: Moderately differentiated.  G3: Poorly differentiated.  Tumor location: Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumor in the esophagus. For adenocarcinoma: (T1, N0, M0, G3); (T2, N0, M0, G1-2, GX).  T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  T2: Tumor invades muscularis propria. N0: No regional lymph node metastasis.  M0: No distant metastasis.  G1: Well differentiated.  G2: Moderately differentiated.  G3: Poorly differentiated.  GX: Grade cannot be assessed-stage grouping as G1. (AJCC 7th ed.)","Stage IB Esophageal Cancer AJCC v7 | Stage IB Esophageal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433925","Stage IIIA Esophageal Cancer AJCC v7","C115119","Stage IIIA includes: For squamous cell carcinoma: (T1-2, N2, M0, Any G, Tumor location: Any); (T3, N1, M0, Any G, Tumor location: Any); (T4a, N0, M0, Any G, Tumor location: Any). T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  T2: Tumor invades muscularis propria. T3: Tumor invades adventitia. T4a: Resectable tumor invading pleura, pericardium, or diaphragm. N0: No regional lymph node metastasis.  N1: Metastasis in 1-2 regional lymph nodes.  N2: Metastasis in 3-6 regional lymph nodes.  M0: No distant metastasis.  Tumor location: Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumor in the esophagus. For adenocarcinoma: (T1-2, N2, M0, Any G); (T3, N1, M0, Any G); (T4a, N0, M0, Any G). T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  T2: Tumor invades muscularis propria. T3: Tumor invades adventitia. T4a: Resectable tumor invading pleura, pericardium, or diaphragm. N0: No regional lymph node metastasis.  N1: Metastasis in 1-2 regional lymph nodes.  N2: Metastasis in 3-6 regional lymph nodes.  M0: No distant metastasis.  (AJCC 7th ed.)","Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889998","TPM2 wt Allele","C115002","Human TPM2 wild-type allele is located in the vicinity of 9p13 and is approximately 9 kb in length. This allele, which encodes tropomyosin beta chain protein, is involved in muscle contraction. Mutation of the gene is associated with nemaline myopathy type 4, cap myopathy type 2 and distal arthrogryposis types 1A and 2B.","TPM2 wt Allele | AMCD1 | Arthrogryposis Multiplex Congenital, Distal, Type 1 Gene | DA1 | DA2B | HEL-S-273 | NEM4 | Nemaline Myopathy Type 4 Gene | TMSB | Tropomyosin 2 (Beta) wt Allele | Tropomyosin, Skeletal Muscle Beta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1872554","Tropomyosin Beta Chain, Human","C115003","Tropomyosin beta chain (284 aa, ~33 kDa) is encoded by the human TPM2 gene. This protein plays a role in muscle contraction.","Tropomyosin Beta Chain | Beta-Tropomyosin | TPM2 | Tropomyosin 2 | Tropomyosin-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421390","USP13 Gene","C115004","This gene is involved in promoting protein stability.","USP13 Gene | USP13 | Ubiquitin Specific Peptidase 13 (Isopeptidase T-3) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890906","USP13 wt Allele","C115005","Human USP13 wild-type allele is located within 3q26.2-q26.3 and is approximately 137 kb in length. This allele, which encodes ubiquitin carboxyl-terminal hydrolase 13 protein, plays a role in deubiquitination.","USP13 wt Allele | ISOT3 | IsoT-3 | Ubiquitin Specific Peptidase 13 (Isopeptidase T-3) wt Allele | Ubiquitin Specific Protease 13 (Isopeptidase T-3) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3252111","USP13 protein, human","C115006","Ubiquitin carboxyl-terminal hydrolase 13 (863 aa, ~97 kDa) is encoded by the human USP13 gene. This protein is involved in protein deubiquitination.","Ubiquitin Carboxyl-Terminal Hydrolase 13 | Deubiquitinating Enzyme 13 | EC 3.4.19.12 | ISOT-3 | Isopeptidase T-3 | Isopeptidase T3 | USP13 | Ubiquitin Specific Peptidase 13 | Ubiquitin Thioesterase 13 | Ubiquitin Thiolesterase 13 | Ubiquitin-Specific Protease 13 | Ubiquitin-Specific-Processing Protease 13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418917","CAVIN3 Gene","C115007","This gene plays a role in circadian rhythm pathways, caveolae formation and protein kinase C binding.","CAVIN3 Gene | CAVIN3 | Caveolae Associated Protein 3 Gene | PRKCDBP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891070","SRBC","C115008","Human CAVIN3 wild-type allele is located in the vicinity of 11p15.4 and is approximately 2 kb in length. This allele, which encodes caveolae-associated protein 3, is involved in caveolae functioning, circadian signaling and binding to protein kinase C.","CAVIN3 wt Allele | CAVIN 3 | Caveolae Associated Protein 3 wt Allele | HSRBC | MGC20400 | PRKCDBP | Protein Kinase C, Delta Binding Protein Gene | SRBC | Sdr-Related Gene Product That Binds To C-Kinase Gene | cavin-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1622797","Protein Kinase C Delta-Binding Protein, Human","C115009","Caveolae-associated protein 3 (261 aa, ~28 kDa) is encoded by the human CAVIN3 gene. This protein plays a role in both circadian clock signaling pathways and caveolae formation.","Caveolae-Associated Protein 3 | CAVIN3 | Cavin 3 | Cavin-3 | PRKCDBP | Protein Kinase C Delta-Binding Protein | Serum Deprivation Response Factor-Related Gene Product That Binds To C-Kinase | hSRBC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422161","RCE1 Gene","C115010","This gene is involved in the modulation of protein prenylation.","RCE1 Gene | RCE1 | Ras Converting CAAX Endopeptidase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889452","RCE1 wt Allele","C115011","Human RCE1 wild-type allele is located in the vicinity of 11q13 and is approximately 4 kb in length. This allele, which encodes CAAX prenyl protease 2 protein, plays a role in the regulation of protein prenylation.","RCE1 wt Allele | FACE2 | RCE1 (S. cerevisiae) Homolog, Prenyl Protein Protease Gene | RCE1 Homolog, Prenyl Protein Peptidase (S. cerevisiae) Gene | RCE1 Homolog, Prenyl Protein Protease (S. cerevisiae) Gene | RCE1 Homolog, Prenyl Protein Protease Gene | RCE1A | RCE1B | Ras Converting CAAX Endopeptidase 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0769557","CAAX Prenyl Protease 2, Human","C115012","CAAX prenyl protease 2 (329 aa, ~36 kDa) is encoded by the human RCE1 gene. This protein is involved in the removal of prenylated peptides from proteins.","CAAX Prenyl Protease 2 | EC 3.4.22.- | FACE-2 | Farnesylated Protein-Converting Enzyme 2 | Farnesylated Proteins-Converting Enzyme 2 | Prenyl Protein Protease RCE1 | Prenyl Protein-Specific Endoprotease 2 | RCE1 Homolog | Ras Converting CAAX Endopeptidase 1 | hRCE1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421455","VLDLR Gene","C115013","This gene plays a role in both lipoprotein endocytosis and reelin signaling.","VLDLR Gene | VLDLR | Very Low Density Lipoprotein Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898055","PASAT - Total Correct","C115809","Paced Auditory Serial Addition Test (PASAT) Total correct.","PASAT - Total Correct | PASAT1-Total Correct | PASAT101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898059","PASAT - Percent Correct","C115810","Paced Auditory Serial Addition Test (PASAT) Percent correct.","PASAT - Percent Correct | PASAT1-Percent Correct | PASAT102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898060","PASAT - More Than One Attempt","C115811","Paced Auditory Serial Addition Test (PASAT) Did it take more than one attempt to get one successful trial?","PASAT - More Than One Attempt | PASAT1-More Than One Attempt | PASAT103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898057","PASAT - Total Correct in First Half","C115812","Paced Auditory Serial Addition Test (PASAT) Total correct in first half.","PASAT - Total Correct in First Half | PASAT1-Total Correct in First Half | PASAT104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898058","PASAT - Total Commission Errors","C115814","Paced Auditory Serial Addition Test (PASAT) Total commission errors.","PASAT - Total Commission Errors | PASAT1-Total Commission Errors | PASAT106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898054","PASAT - Total Omission Errors","C115815","Paced Auditory Serial Addition Test (PASAT) Total omission errors.","PASAT - Total Omission Errors | PASAT1-Total Omission Errors | PASAT107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897690","SDMT - Total Score","C115816","Symbol Digit Modalities Test (SDMT) Total score.","SDMT - Total Score | SDMT01-Total Score | SDMT0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897050","T25FW - Time to Complete 25-Foot Walk","C115817","Timed 25-Foot Walk (T25FW) Time in seconds to complete 25-foot walk.","T25FW - Time to Complete 25-Foot Walk | T25FW1-Time to Complete 25-Foot Walk | T25FW101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897396","T25FW - More Than Two Attempts","C115818","Timed 25-Foot Walk (T25FW) Did it take more than two attempts to get two successful trials?","T25FW - More Than Two Attempts | T25FW1-More Than Two Attempts | T25FW102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897375","TUG - Time to Complete TUG Test","C115819","Timed Up and Go (TUG) Time in seconds to complete TUG test.","TUG - Time to Complete TUG Test | TUG01-Time to Complete TUG Test | TUG0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899461","DRS - Eye Opening","C115820","Disability Rating Scale (DRS) Eye opening.","DRS - Eye Opening | DRS01-Eye Opening | DRS0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899463","DRS - Communication Ability","C115821","Disability Rating Scale (DRS) Communication ability.","DRS - Communication Ability | DRS01-Communication Ability | DRS0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899458","DRS - Motor Response","C115822","Disability Rating Scale (DRS) Motor response.","DRS - Motor Response | DRS01-Motor Response | DRS0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899457","DRS - Toileting","C115824","Disability Rating Scale (DRS) Toileting (cognitive ability only).","DRS - Toileting | DRS01-Toileting | DRS0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899459","DRS - Grooming","C115825","Disability Rating Scale (DRS) Grooming (cognitive ability only).","DRS - Grooming | DRS01-Grooming | DRS0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897058","DRS - Level of Functioning","C115826","Disability Rating Scale (DRS) Level of functioning (physical, mental, emotional or social function).","DRS - Level of Functioning | DRS01-Level of Functioning | DRS0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433941","Untreated Childhood Pilomyxoid Astrocytoma","C115952","A finding of pilomyxoid astrocytoma in childhood that has not been treated.","Untreated Childhood Pilomyxoid Astrocytoma | Untreated Pilomyxoid Astrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433944","Untreated Childhood Pleomorphic Xanthoastrocytoma","C115953","A finding of pleomorphic xanthoastrocytoma in childhood that has not been treated.","Untreated Childhood Pleomorphic Xanthoastrocytoma | Untreated Pleomorphic Xanthoastrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433947","Untreated Childhood Protoplasmic Astrocytoma","C115954","A finding of protoplasmic astrocytoma in childhood that has not been treated.","Untreated Childhood Protoplasmic Astrocytoma | Untreated Protoplasmic Astrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388362","Untreated Childhood Subependymal Giant Cell Astrocytoma","C115955","A finding of subependymal giant cell astrocytoma in childhood that has not been treated.","Untreated Childhood Subependymal Giant Cell Astrocytoma | Untreated Subependymal Giant Cell Astrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL343483","Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor","C115956","A finding of supratentorial primitive neuroectodermal tumor in childhood that has not been treated.","Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor | Untreated Supratentorial Primitive Neuroectodermal Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0338335","Untreated Childhood Visual Pathway Glioma","C115957","A finding of visual pathway glioma in childhood that has not been treated.","Untreated Childhood Visual Pathway Glioma | Untreated Visual Pathway Glioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521618","Ureteral Stenosis","C115958","Narrowing of the luminal diameter of one or both ureters due to intrinsic factors.","Ureteral Stenosis | ",,,,,,,,,,,,,,,"4318546","Stenosis of ureter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL473297","Gallium Ga 68-labeled-NODAGA-MJ9","C115960","A radiopharmaceutical agent comprised of a peptide targeting the gastrin releasing peptide receptor (GRPR) chelated with 1,4,7-triazacyclononane,1-glutaric acid-4,7 acetic acid (NODAGA) and radiolabeled with gallium Ga 68, with potential tumor imaging activity upon positron emission tomography (PET). After administration of gallium Ga 68-labeled-NODAGA-MJ9, the MJ9 moiety binds to GRPR located on tumor cells. Upon PET imaging, GRPR-expressing tumor cells can be visualized and expression levels can be quantified. GRPR is overexpressed on certain tumor cells and plays a key role in tumor proliferation and survival.","Gallium Ga 68-labeled-NODAGA-MJ9 | Ga-68-NODAGA-MJ9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473298","Carrageenan-containing Gel","C115961","A water-based, vaginal moisturizing gel containing a mixture of lambda- and kappa- carrageenans, sulfated polysaccharides derived from red seaweed (Chondrus crispus), with potential microbicidal activity against various viruses, including human papillomavirus (HPV), human immunodeficiencyvirus (HIV) and human herpes simplex virus (HSV). Upon vaginal insertion via an applicator, carrageenan specifically binds to the viral capsids, which prevents the binding of virions to heparan sulfate proteoglycan (HSPG) receptors or other, as of yet not fully identified, cellular proteins. In addition, the viral binding of carrageenan may also interfere with conformational changes within the virions after cellular attachment. This inhibits viral infection. Certain HPV types cause cervical cancer; therefore, the prevention of HPV infection by this gel may subsequently prevent the development of cervical cancer.","Carrageenan-containing Gel | Divine 9 with Carragel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433926","Stage IIIB Esophageal Cancer AJCC v7","C115120","Stage IIIB includes: For squamous cell carcinoma: T3, N2, M0, Any G, Tumor location: Any. T3: Tumor invades adventitia. N2: Metastasis in 3-6 regional lymph nodes.  M0: No distant metastasis.  Tumor location: Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumor in the esophagus. For adenocarcinoma: T3, N2, M0, Any G. T3: Tumor invades adventitia. N2: Metastasis in 3-6 regional lymph nodes.  M0: No distant metastasis.  (AJCC 7th ed.)","Stage IIIB Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433927","Stage IIIC Esophageal Cancer AJCC v7","C115121","Stage IIIC includes: For squamous cell carcinoma: (T4a, N1-2, M0, Any G, Tumor location: Any); (T4b, Any N, M0, Any G, Tumor location: Any); (Any T, N3, M0, Any G, Tumor location: Any).  T4a: Resectable tumor invading pleura, pericardium, or diaphragm. T4b: Unresectable tumor invading other adjacent structures, such as aorta, vertebral body, trachea, etc. N1: Metastasis in 1-2 regional lymph nodes.  N2: Metastasis in 3-6 regional lymph nodes.  N3: Metastasis in seven or more regional lymph nodes.  M0: No distant metastasis.  Tumor location: Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumor in the esophagus. For adenocarcinoma: (T4a, N1-2, M0, Any G); (T4b, Any N, M0, Any G); (Any T, N3, M0, Any G).  T4a: Resectable tumor invading pleura, pericardium, or diaphragm. T4b: Unresectable tumor invading other adjacent structures, such as aorta, vertebral body, trachea, etc.  N1: Metastasis in 1-2 regional lymph nodes.  N2: Metastasis in 3-6 regional lymph nodes.  N3: Metastasis in seven or more regional lymph nodes.  M0: No distant metastasis.  (AJCC 7th ed.)","Stage IIIC Esophageal Cancer AJCC v7 | Stage IIIC Esophageal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899034","Generic Investigational New Animal Drug File","C115122","Data submitted to a generic investigational new animal drug file.","Generic Investigational New Animal Drug File | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900136","Abbreviated New Animal Drug Application","C115123","Data submitted to an abbreviated new animal drug application.","Abbreviated New Animal Drug Application | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003460","Anuria","C114699","Absence of urine output.","Anuria | ",,,,,,,,,,,,,,,"4090272","Anuria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1428044","ACBD6 Gene","C114700","This gene plays a role in lipid binding.","ACBD6 Gene | ACBD6 | Acyl-CoA Binding Domain Containing 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889701","ACBD6 wt Allele","C114701","Human ACBD6 wild-type allele is located in the vicinity of 1q25.1 and is approximately 228 kb in length. This allele, which encodes acyl-CoA-binding domain-containing protein 6, is involved in binding to acylated coenzyme A.","ACBD6 wt Allele | Acyl-CoA Binding Domain Containing 6 wt Allele | MGC2404",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472433","Acyl-CoA-Binding Domain-Containing Protein 6","C114703","Acyl-CoA-binding domain-containing protein 6 (282 aa, ~31 kDa) is encoded by the human ACBD6 gene. This protein plays a role in acyl-coenzyme A binding.","Acyl-CoA-Binding Domain-Containing Protein 6 | ACBD6 | Acyl-Coenzyme A Binding Domain Containing 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1856431","Myoglobinuria","C114705","The presence of myoglobin in the urine.","Myoglobinuria | ",,,,,,,,,,,,,,,"439142","Myoglobinuria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3900040","Anesthetized Intracardiac Lethal Injection and Exsanguination Euthanasia","C116224","A method of euthanasia whereby a subject is anesthetized, a lethal chemical is administered by intracardiac injection and the body is drained of blood.","Anesthetized Intracardiac Lethal Injection and Exsanguination Euthanasia | ANESTHETIZED LETHAL INJECTION INTRACARDIAC EXSANGUINATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898696","Intravenous Lethal Injection Euthanasia","C116225","A method of euthanasia whereby a subject is given a lethal intravenous injection to induce death.","Intravenous Lethal Injection Euthanasia | LETHAL INJECTION INTRAVENOUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898699","Intraperitoneal Lethal Injection Euthanasia","C116226","A method of euthanasia whereby a subject is given a lethal intraperitoneal injection to induce death.","Intraperitoneal Lethal Injection Euthanasia | LETHAL INJECTION INTRAPERITONEAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898708","Intracardiac Lethal Injection Euthanasia","C116227","A method of euthanasia whereby a subject is given a lethal intracardiac injection to induce death.","Intracardiac Lethal Injection Euthanasia | LETHAL INJECTION INTRACARDIAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898695","Intravenous Lethal Injection and Exsanguination Euthanasia","C116228","A method of euthanasia whereby a subject is given a lethal intravenous injection and the body is drained of blood.","Intravenous Lethal Injection and Exsanguination Euthanasia | LETHAL INJECTION INTRAVENOUS EXSANGUINATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898698","Intraperitoneal Lethal Injection and Exsanguination Euthanasia","C116229","A method of euthanasia whereby a subject is given a lethal intraperitoneal injection and the body is drained of blood.","Intraperitoneal Lethal Injection and Exsanguination Euthanasia | LETHAL INJECTION INTRAPERITONEAL EXSANGUINATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898707","Intracardiac Lethal Injection and Exsanguination Euthanasia","C116230","A method of euthanasia whereby a subject is given a lethal intracardiac injection and the body is drained of blood.","Intracardiac Lethal Injection and Exsanguination Euthanasia | LETHAL INJECTION INTRACARDIAC EXSANGUINATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890432","Data Management Filenote","C115505","A notation regarding the decisions, and/or clarification of any information pertaining to data management.","Data Management Filenote | DM Flnote | Filenote",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896980","Investigational Product and Clinical Trial Supplies Filenote","C115506","A notation pertaining to the investigational product, and associated trial supplies used in a clinical trial.","Investigational Product and Clinical Trial Supplies Filenote | General Investigational Product and Trial Supplies Filenote | IP Trial Suppl Flnote | IP and Trial Supplies Filenote",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890406","Safety Filenote","C115507","A notation regarding the decisions, and/or clarification of any information pertaining to the safety report of a clinical trial.","Safety Filenote | Filenote | Safe Flnote",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890405","Statistics Filenote","C115508","A notation regarding the decisions, and/or clarification of any information pertaining to the statistics used in a clinical trial.","Statistics Filenote | Filenote | Stats Flnote",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890890","Study Subject Computed Tomography Report","C115510","Records pertaining to the findings from a study subject's computed tomography images.","Study Subject Computed Tomography Report | Study Subj CT Rept | Study Subject CT Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899462","DRS - Employability","C115827","Disability Rating Scale (DRS) Employability (as a full time worker, homemaker, or student).","DRS - Employability | DRS01-Employability | DRS0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899069","GOSE - Consciousness: Obey Simple Commands","C115828","Extended Glasgow Outcome Scale (GOSE) Is the head injured person able to obey simple commands, or say any words?","GOSE - Consciousness: Obey Simple Commands | GOSE1-Obey Simple Commands or Say Words | GOSE101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889161","LTBR wt Allele","C116041","Human LTBR wild-type allele is located in the vicinity of 12p13 and is approximately 17 kb in length. This allele, which encodes tumor necrosis factor receptor superfamily member 3 protein, is involved in lymphotoxin-mediated signaling.","LTBR wt Allele | CD18 | D12S370 | LT-BETA-R | Lymphotoxin Beta Receptor (TNFR Superfamily, Member 3) wt Allele | TNF-R-III | TNFCR | TNFR-RP | TNFR2-RP | TNFR3 | TNFRSF3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473701","Tumor Necrosis Factor Receptor Superfamily Member 3","C116042","Tumor necrosis factor receptor superfamily member 3 (435 aa, ~47 kDa) is encoded by the human LTBR gene. This protein plays a role in both receptor signaling and the positive regulation of apoptosis.","Tumor Necrosis Factor Receptor Superfamily Member 3 | LTBR | Lymphotoxin B Receptor | Lymphotoxin Beta Receptor | Lymphotoxin-Beta Receptor | TNF-RIII | TNFR-III | TNFRSF3 | Tumor Necrosis Factor C Receptor | Tumor Necrosis Factor Receptor 2-Related Protein | Tumor Necrosis Factor Receptor Type III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890887","SRSF1 wt Allele","C116044","Human SRSF1 wild-type allele is located in the vicinity of 17q22 and is approximately 6 kb in length. This allele, which encodes serine/arginine-rich splicing factor 1 protein, plays a role in both transcriptional termination and mRNA splicing","SRSF1 wt Allele | ASF | MGC5228 | OK/SW-cl.3 | SF2 | SF2P33 | SF2p33 | SFRS1 | SRp30a | Serine/Arginine-Rich Splicing Factor 1 wt Allele | Splicing Factor, Arginine/Serine-Rich, 1 Gene | Splicing Factor, Arginine/Serine-Rich, 30kD, A Gene | Splicing Factor, Serine/Arginine-Rich, 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2976046","Serine/Arginine-Rich Splicing Factor 1, Human","C116045","Serine/arginine-rich splicing factor 1 (248 aa, ~28 kDa) is encoded by the human SRSF1 gene. This protein is involved in the regulation of RNA splicing.","Serine/Arginine-Rich Splicing Factor 1 | ASF-1 | Alternate Splicing Factor | Alternative-Splicing Factor 1 | Pre-mRNA-Splicing Factor SF2, P33 Subunit | SR Splicing Factor 1 | Splicing Factor 2 | Splicing Factor, Arginine/Serine-Rich 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0520680","Central Sleep Apnea","C116046","The periodic cessation of breathing while asleep that occurs secondary to the decreased responsiveness of the respiratory center of the brain to carbon dioxide, resulting in alternating cycles of apnea and hyperpnea.","Central Sleep Apnea | CSA",,,,,,,,,,,,,,,"439794","Central sleep apnea syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3890206","PON1 wt Allele","C116048","Human PON1 wild-type allele is located in the vicinity of 7q21.3 and is approximately 99 kb in length. This allele, which encodes serum paraoxonase/arylesterase 1 protein, is involved in detoxification of lactones, aromatic carboxylic acid esters and organophosphates. Genetic variation is associated with microvascular complications of diabetes 5, and increased susceptibility to coronary artery disease, coronary artery spasm 2, and organophosphate poisoning.","PON1 wt Allele | ESA | MVCD5 | PON | Paraoxonase 1 wt Allele | Paraoxonase, Plasma Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473691","Serum Paraoxonase/Arylesterase 1","C116049","Serum paraoxonase/arylesterase 1 (355 aa, ~40 kDa) is encoded by the human PON1 gene. This protein plays a role in the catabolism of aromatic carboxylic acid esters, organophosphates and lactones.","Serum Paraoxonase/Arylesterase 1 | A-Esterase 1 | Aromatic Esterase 1 | Arylesterase B-Type | EC 3.1.1.2 | EC 3.1.1.81 | EC 3.1.8.1 | Esterase A | K-45 | PON 1 | PON1 | Paraoxonase B-Type | Serum Aryldiakylphosphatase | Serum Aryldialkylphosphatase 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4013782","Hypercalciuria","C114707","Abnormally high level of calcium in the urine.","Hypercalciuria | Hypercalcuria",,,,,,,,,,,,,,,"4215809","Hypercalciuria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2673444","Hypocitraturia","C114708","Abnormally low level of citrate in the urine.","Hypocitraturia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899382","Dialysis Membrane Reaction","C114714","A severe hypersensitivity-like reaction occurring during dialysis due to exposure to the dialysis membrane.","Dialysis Membrane Reaction | Dialyzer Reaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899384","Dialysis Catheter Fracture","C114717","A crack or break in a dialysis catheter caused by material weakness or mechanical compression.","Dialysis Catheter Fracture | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472572","TLR7/8/9 antagonist IMO-8400","C114975","An oligonucleotide targeted to the mRNA of MYD88 L265P, a mutant form of the linker protein MYD88, with potential antitumor activity. Bazlitoran binds to and inhibits the translation of mutated MYD88 L265P mRNA. This prevents overactivation of signaling pathways mediated by toll-like receptors (TLRs) 7, 8, and 9, nuclear factor-kappa B (NF-kB) activity, Janus-associated kinases-signal transducer and activator of transcription (JAK-STAT) signaling and the production of various cytokines. Together, this leads to an induction of apoptosis and an inhibition of tumor cell proliferation in MYD88 L265P-expressing tumor cells. MYD88, a key adaptor protein in the TLR signaling pathway, is mutated in a variety of B-cell lymphomas, including Waldenstrom's macroglobulinemia (WM) and activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL).","Bazlitoran | BAZLITORAN | IMO-8400 | Oligonucleotide IMO-8400",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897457","Study Subject Nuclear Medicine Report","C115513","Records pertaining to the findings from a study subject's nuclear medicine images.","Study Subject Nuclear Medicine Report | Study Subj NM Rept",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897456","Study Subject Radiography Report","C115514","Records pertaining to the findings from a study subject's radiographic images.","Study Subject Radiography Report | Study Subj RAD Rept",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897453","Study Subject Ultrasound Report","C115515","Records pertaining to the findings from a study subject's ultrasound images.","Study Subject Ultrasound Report | Study Subj US Rept",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897446","Subject Digital Photograph Report","C115516","Records pertaining to the findings from a study subject's digital photograph images.","Subject Digital Photograph Report | Study Subj DigPic Rept | Study Subject Digital Photos Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889262","Clinical Trial Subject Miscellaneous Form","C115518","Documentation provided to the subject to further assist with understanding the clinical trial requirements or concepts.","Clinical Trial Subject Miscellaneous Form Documentation | Clinical Trial Subject Miscellaneous Form | Other Information Given to Subjects | Other Subject Forms | Other Written Information Given to Subjects | Subj Other Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889670","Clinical Trial Subject Participation Form","C115519","Documentation provided to the subject to carry to document clinical trial participation.","Clinical Trial Subject Participation Form Documentation | Clinical Trial Subject Participation Form | Subj Partic | Subject Participation Card | Subject Participation Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899518","Completed Case Report Form","C115520","Documentation completed by an investigator on each subject in a clinical trial; they contain information required by the clinical study protocol, and which is reported to a sponsor.","Completed Case Report Form | Completed CRFs | Completed Case Report Forms | Complt CRF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899454","Data Clarification Form","C115521","Documentation used to query database discrepancies and record approved corrections to the clinical trial database.","Clinical Trial Corrections to Entered Data Documentation | Data Clarification Form | Data Clarification Forms | Data Correction Forms | Data Query Forms | Date Clarif Form | Documentation of Corrections to Entered Data | data clarification form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898685","Investigational Product Quality Complaint Form","C115522","Documentation of the complaint directed against the investigational product(s) for the clinical trial.","Clinical Trial Investigational Product Quality Complaint Documentation | IP QA Complt Form | IP Quality Complaint Form | Investigational Product Quality Complaint Form | Investigational Product Quality Complaint Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897459","Study Subject Medical Imaging","C115523","Medical imaging of a study participant as part of a clinical trial.","Study Subject Medical Imaging | Study Subj Med Img Unsp | Study Subject Medical Imaging Unspecified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268064","Transfusion Hemochromatosis","C115763","Accumulation of iron in internal organs that results from repeated blood transfusions.","Transfusion Hemochromatosis | Transfusion Hemosiderosis",,,,,,,,,,,,,,,"4239692","Transfusion hemosiderosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899530","Clinical Trials Operational Procedure Manual","C115764","Documentation describing clinical trial-related work processes.","Clinical Trials Operational Procedure Manual Documentation | Clinical Trials Operational Procedure Manual | Operational Procedure Manual | Ops Manual | Study Reference Manual | Work Instruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897334","Trial Master File Plan","C115765","Documentation describing how clinical trial records are managed and stored during and after the clinical trial.","Clincial Trial Master File Plan Documentation | File plan | Filing instructions | Records Management Plan | TM File Plan TMF Plan | Trial Master File Plan | Trial Master File Plan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899574","Clinical Trial Management","C115766","The Trial Master File Reference Model zone that contains the collection of documents relating to the general design, management and oversight of the clinical trial.","TMF-RM Trial Management Zone | Clinical Trial Management | Trial Management | Trial Management Category | Trial Mgmt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889138","SLX4 wt Allele","C116051","Human SLX4 wild-type allele is located in the vicinity of 16p13.3 and is approximately 30 kb in length. This allele, which encodes structure-specific endonuclease subunit SLX4 protein, plays a role in both the regulation of endonuclease activity and the recognition of damaged DNA. Mutation of the gene is associated with Fanconi anemia complementation group P.","SLX4 wt Allele | BTB (POZ) Domain Containing 12 Gene | BTBD12 | FANCP | Fanconi Anemia, Complementation Group P Gene | KIAA1784 | KIAA1987 | MUS312 | MUS312, Drosophila, Homolog of Gene | SLX4 Structure-Specific Endonuclease Subunit Homolog (S. cerevisiae) Gene | SLX4 Structure-Specific Endonuclease Subunit wt Allele | SLX4, S. cerevisiae, Homolog of Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1969641","HOTAIR Gene","C116284","This gene plays a role in the repression of HOXD gene expression.","HOTAIR Gene | HOTAIR | HOX Transcript Antisense RNA Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890913","HOTAIR wt Allele","C116285","Human HOTAIR wild-type allele is located in the vicinity of 12q13.13 and is approximately 13 kb in length. This allele, which encodes HOX transcript antisense RNA, is involved in the negative regulation of HOXD gene transcription.","HOTAIR wt Allele | HOX Antisense Intergenic RNA Gene | HOX Transcript Antisense RNA (Non-Protein Coding) Gene | HOX Transcript Antisense RNA wt Allele | HOX Transcript Antisense RNA, Noncoding Gene | HOXAS | HOXC Cluster Antisense RNA 4 (Non-Protein Coding) Gene | HOXC Cluster Antisense RNA 4 (Non-Protein Coding), Non-Protein Coding RNA 72 Gene | HOXC-AS4 | HOXC11-AS1 | Long Intergenic Noncoding RNA HOTAIR Gene | NCRNA00072 | Non-Protein Coding RNA 72 Gene | lincRNA HOTAIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3253717","HOX Transcript Antisense RNA, Human","C116287","HOX transcript antisense RNA (~2 kb) is encoded by the human HOTAIR gene. This non-coding RNA plays a role in the repression of HOXD genes.","HOX Transcript Antisense RNA | HOX Antisense Intergenic RNA | HOX Transcript Antisense RNA, Noncoding | HOXC Cluster Antisense RNA 4 | Long Intergenic Noncoding RNA HOTAIR | NCRNA00072 | Non-Protein Coding RNA 72 | lincRNA HOTAIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418779","PPARGC1A Gene","C116293","This gene plays a role in the regulation of nuclear receptor-dependent transcription.","PPARGC1A Gene | PPARGC1A | Peroxisome Proliferator-Activated Receptor Gamma, Coactivator 1 Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0599918","Renal Toxicity","C115459","Toxicity that impairs or damages the kidney. This condition is often caused by the administration of a pharmaceutical agent that causes damage to the kidney.","Renal Toxicity | Kidney Toxicity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796607","isotretinoin/temozolomide","C11545","A regimen consisting of isotretinoin and temozolomide that may be used in the treatment of glioblastoma.","Isotretinoin/Temozolomide Regimen | 13-CRA/TMZ | Isotretinoin-Temozolomide | Isotretinoin/Temozolomide | Temozolomide + CRA | Temozolomide-Isotretinoin | Temozolomide/13-cis-retinoic Acid | Temozolomide/Isotretinoin | Temozolomide/cRA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897566","Slowly Progressive Clinical Course","C115461","Clinical course characterized by slow progression without signs of aggressive disease.","Slowly Progressive Clinical Course | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890587","Clinical Trial Subject Recruitment Advertisement","C115462","Template documentation used in the clinical trial recruitment campaigns.","Clinical Trial Subject Recruitment Advertisement Documentation | Advertisements for Subject Recruitment | Clinical Trial Subject Recruitment Advertisement | Template Advertisement for Subject Recruitment | Templt Subj Ad",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889976","Institutional Review Board Independent Ethics Committee Advertisement for Subject Recruitment","C115463","An announcement approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) that is used to locate subjects for participation in a clinical trial.","Institutional Review Board Independent Ethics Committee Advertisement for Subject Recruitment | Advertisements for Subject Recruitment | IRB-IEC Approved Advertisement for Subject Recruitment | Institutional Review Board Independent Ethics Committee Approved Advertisement for Subject Recruitment | Subj Ad",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897204","Vendor Confidentiality Agreement","C115465","Documentation detailing the agreement between the sponsor or representative of the sponsor and the vendor that contains the provisions governing the access and use of confidential information pertaining to the clinical trial.","Clinical Trial Vendor Confidentiality Agreement Documentation | Confidentiality Agreement | Vend Confd Agrmnt | Vendor Confidentiality Agreement | Vendor Confidentiality Agreement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899587","Clinical Trial Import-Export License Application","C115466","Documentation submitted to regulatory authorities requesting a license to import or export an investigational product, and/or clinical supplies.","Clinical Trial Import-Export License Application Documentation | Clinical Trial Import-Export License Application | ImEx Lic Appl | Import or Export License Application | Import-Export License Application",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889287","Digital Content Category","C115468","A collection of digital content.","Digital Content Category | Category",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890588","Audit Certificate","C115469","Documentation that confirms an audit has been conducted.","Audit Certificate Documentation | Audit Cert | Audit Certificate | Audit Certificate | audit certificate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896938","RNR Inhibitor COH29","C114976","An orally available, aromatically substituted thiazole and inhibitor of the human ribonucleotide reductase (RNR), with potential antineoplastic activity. Upon oral administration, the RNR inhibitor COH29 binds to the ligand-binding pocket of the RNR M2 subunit (hRRM2) near the C-terminal tail. This blocks the interaction between the hRRM1 and hRRM2 subunits and interferes with the assembly of the active hRRM1/hRRM2 complex of RNR. Inhibition of RNR activity decreases the pool of deoxyribonucleotide triphosphates available for DNA synthesis. The resulting decrease in DNA synthesis causes cell cycle arrest and growth inhibition. In addition, this agent may inhibit the nuclear enzyme poly (ADP-ribose) polymerase (PARP) 1, which prevents the repair of damaged DNA, and causes both the accumulation of single and double strand DNA breaks and the induction of apoptosis. RNR, an enzyme that catalyzes the conversion of ribonucleoside diphosphate to deoxyribonucleoside diphosphate, is essential for de novo DNA synthesis and plays an important role in cell growth; it is overexpressed in many cancer cell types and is associated with increased drug resistance, cancer cell growth and metastasis.","RNR Inhibitor COH29 | COH-29 | COH29 | N-(4-(3,4-dihydroxyphenyl)-5-phenylthiazol-2-yl)-3,4-dihydroxybenzamide | Ribonucleotide Reductase Holoenzyme Inhibitor COH29",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472574","etoposide prodrug CAP7.1","C114977","A prodrug of etoposide, a semisynthetic derivative of podophyllotoxin extracted from the mandrake root Podophyllum peltatum, with potential antineoplastic activity. Upon intravenous administration of etoposide toniribate, etoposide is released after enzymatic cleavage of CAP7.1 by specific carboxylesterases (CE) 1 and 2, which are upregulated in certain tumor cell types. Etoposide acts primarily in the G2 and S phases of the cell cycle. This drug binds to and inhibits topoisomerase II, an enzyme elevated in tumor cells. This results in the accumulation of double-strand DNA breaks, the inhibition of DNA replication and transcription and the induction of apoptotic cell death. The tumor-specific activation of etoposide increases its efficacy while lowering its systemic toxicity.","Etoposide Toniribate | CAP7.1 | EDO-S7.1 | ETOPOSIDE TONIRIBATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472575","MAGE-A4-specific TCR Gene-transduced Autologous T Lymphocytes TBI-1201","C114978","Autologous human T-lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the human melanoma antigen A4 (MAGE-A4), with potential immunostimulatory and antineoplastic activities. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, MAGE-A4-specific TCR gene-transduced T-lymphocytes TBI-1201 binds to tumor cells expressing MAGE-A4. This may result in both an inhibition of growth and increased cell death for MAGE-A4-expressing tumor cells. The tumor-associated antigen MAGE-A4 is overexpressed by a variety of cancer cell types.","MAGE-A4-specific TCR Gene-transduced Autologous T Lymphocytes TBI-1201 | TBI-1201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896901","chlorotoxin-indocyanine green imaging Agent BLZ-100","C114979","A tumor targeting imaging agent composed of the tumor-specific peptide chlorotoxin (CTX), a 36-amino acid neurotoxin found in the venom of the Leiurus quinquestriatus scorpion, linked to the fluorescent dye indocyanine green (ICG), with potential tumor imaging activity using a near-infrared (NIR) imaging system. Upon intravenous administration of BLZ-100, the CTX moiety of BLZ-100 specifically binds to and is internalized by cancer cells of neuroectodermal origin. Using a NIR imaging system, the ICG, which emits light in the NIR range, permits the intraoperative visualization of tumor cells. This leads to the clear distinction of healthy tissues from tumor cells, and facilitates the surgical removal of tumor tissue while sparing normal, healthy cells.","Tozuleristide | BLZ-100 | TOZULERISTIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472577","MDM2 Antagonist RO6839921","C114980","An MDM2 (human homolog of murine double minute-2; HDM2) antagonist with potential antineoplastic activity. Upon intravenous administration, RO6839921 binds to MDM2 and prevents the binding of the MDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing MDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This may result in the restoration of p53 signaling, followed by p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein, is a negative regulator of the p53 pathway and is often overexpressed in cancer cells; p53 inhibition has been implicated in cancer cell proliferation and survival.","MDM2 Antagonist RO6839921 | RO6839921",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890210","IL17F wt Allele","C114482","Human IL17F wild-type allele is located in the vicinity of 6p12 and is approximately 8 kb in length. This allele, which encodes interleukin-17F protein, is involved in cytokine production, cartilage turnover and the regulation of angiogenesis. Mutation of the gene is associated with familial Candidiasis type 6.","IL17F wt Allele | CANDF6 | IL-17F | Interleukin 17F wt Allele | ML-1 | ML1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899557","Clinical Trial Recruitment Plan","C115769","Documentation describing the subject enrollment and recruitment goals during the clinical trial.","Clinical Trial Recruitment Plan Documentation | Clinical Trial Recruitment Plan | Recruit Plan | Recruitment Plan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899114","Financial Disclosure Summary","C115775","A synopsis of financial disclosure information.","Financial Disclosure Summary | FD Summary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898683","Investigational Product Randomization Plan","C115776","A proposed method of allocation and randomization of each subject in an investigational product study.","Investigational Product Randomization Plan | IP Random Plan | IP Randomization Plan | Randomization envelopes | Treatment Allocation Documentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898651","Joint Vendor Quality Assurance Plan","C115777","Documentation describing the operational techniques and activities undertaken within the quality management system to verify that the requirements for quality of the clinical trial-related activities have been fulfilled.","Clinical Trial Quality Assurance Plan Documentation | Joint Vendor Oversight Plan | Joint Vendor Quality Assurance Plan | QA Plan | Quality Plan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897778","Randomization Plan","C115778","Documentation describing the details of the randomization scheme for the clinical trial.","Clinical Trial Randomization Plan Documentation | Randomiz Plan | Randomization Plan | Randomization Plan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0065973","methanol extraction residue (MER) tubercle bacillus fraction","C1159","A cell wall fraction of bacillus Calmette-Guerin (BCG) obtained by menthol extraction with immunomodulating properties and potential use in cancer immunotherapy. (NCI04)","Methanol Extraction Residue of BCG | MER BCG | MER of BCG | MER-BCG | Methanol Extraction Residue of Bacillus Calmette-Guerin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890372","PPARGC1A wt Allele","C116294","Human PPARGC1A wild-type allele is located in the vicinity of 4p15.1 and is approximately 149 kb in length. This allele, which encodes peroxisome proliferator-activated receptor gamma coactivator 1-alpha protein, is involved in transcriptional regulation mediated by steroid and nuclear receptors.","PPARGC1A wt Allele | LEM6 | PGC-1(alpha) | PGC-1a | PGC-1v | PGC1 | PGC1-Alpha | PGC1A | PPARGC1 | Peroxisome Proliferative Activated Receptor, Gamma, Coactivator 1 Gene | Peroxisome Proliferative Activated Receptor, Gamma, Coactivator 1, Alpha Gene | Peroxisome Proliferator-Activated Receptor Gamma, Coactivator 1 Alpha wt Allele | Peroxisome Proliferator-Activated Receptor-Gamma, Coactivator 1 Gene | Peroxisome Proliferator-Activated Receptor-Gamma, Coactivator 1, Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473646","Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-Alpha","C116295","Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (798 aa, ~91 kDa) is encoded by the human PPARGC1A gene. This protein plays a role in the regulation of gene transcription.","Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-Alpha | L-PGC-1alpha | Ligand Effect Modulator 6 | Ligand Effect Modulator-6 | PGC-1-Alpha | PPAR-Gamma Coactivator 1 | PPAR-Gamma Coactivator 1-Alpha | PPARGC-1-Alpha | PPARGC1A | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1 Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889645","Clinical Trial Final Report","C115575","Records containing any interim or final results, as well as clinical and statistical descriptions, presentations, analyses and interpretations of any therapeutic, prophylactic, or diagnostic agent used in human subjects in a clinical trial.","Clinical Trial Final Report | CTrial Fin Rept Subcat | Central Trial Final Reports Subcategory | Reports | final report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899585","Clinical Trial Initiation Monitoring Report","C115576","Documentation of monitoring activities conducted to ensure the clinical trial site meets requirements to begin participation in the clinical trial.","Clinical Trial Site Initiation Monitoring Report Documentation | Clinical Trial Initiation Monitoring Report | Site Initiation Visit Report | Trial Initiation Monitoring Report | Trial Initn Mon Rept",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899569","Clinical Trial Monitoring Visit Report","C115577","Documentation of ongoing monitoring activities conducted for the evaluation of clinical trial conduct, and regulatory compliance of the clinical trial site.","Clinical Trial Site Monitoring Visit Report Documentation | Clinical Trial Monitoring Visit Report | Mon Visit Rept | Monitoring Visit Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899562","Clinical Trial Pregnancy Report","C115578","Documentation pertaining to a pregnancy and its outcome as experienced by the female subject, or by the partner of the male subject during the clinical trial.","Clinical Trial Pregnancy Report Documentation | Clinical Trial Pregnancy Report | Preg Rept | Pregnancy Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889410","Clinical Trial Regulatory Status Report","C115579","Records informing the regulatory authorities of the progress of a clinical trial.","Clinical Trial Regulatory Status Report | Trial Reg Stas Rept Subcat | Trial Regulatory Status Reporting Subcategory | Trial Status Reporting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889428","Clinical Trial Status Report Documentation","C115580","Documentation that contains routine trial status progress.","Clinical Trial Status Report Documentation | Trial Stas Rept | Trial Status Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897063","Final Clinical Trial Close Out Monitoring Report","C115581","Documentation of the monitoring activities conducted to ensure that the clinical trial site meets requirements for closure.","Final Clinical Trial Site Close Out Monitoring Report Documentation | Close Out Monitoring Visit Report | Close Out Visit Report | Fin Trial Close Mon Rept | Final Clinical Trial Close Out Monitoring Report | Final Trial Close Out Monitoring Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890900","Final Statistical Report","C115582","Documentation detailing the statistical aspects of a final analysis for the clinical trial.","Clinical Trial Final Statistical Report Documentation | Final Statistical Report | SR | Statistical Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889672","Institutional Review Board Independent Ethics Committee Clinical Trial Status Report","C115583","Records sent to an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) of all findings that may adversely affect the safety of a subject, impact the conduct of a clinical trial, alter the IRB/IEC's willingness to continue the trial.","Institutional Review Board Independent Ethics Committee Clinical Trial Status Report | IRB-IEC Trial Stas Subcat | IRB-IEC Trial Status Reporting Subcategory | Institutional Review Board Independent Ethics Committee Clinical Trial Status Reporting | Trial Status Reporting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898739","Interactive Response Technology User Acceptance Testing Certificate","C115470","Documentation pertaining to the user acceptance testing performed on the interactive response technology.","Interactive Response Technology User Acceptance Testing Certification Documentation | IRT UAT Scripts and Sign Off | IRT User Acceptance Testing (UAT) Certification | IRT User Acceptance Testing Certification | IRT User Test Certn | Interactive Response Technology User Acceptance Testing Certificate | Interactive Response Technology User Acceptance Testing Certification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898735","Interactive Response Technology Validation Certificate","C115471","Documentation confirming the validation of the interactive response technology.","Interactive Response Technology Validation Certification Documentation | IRT Valid Certn | IRT Validation Certification | Interactive Response Technology Validation Certificate | Interactive Response Technology Validation Certification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898668","Investigator Brochure Acceptance Document","C115711","Documentation confirming the receipt of the investigator brochure at the clinical trial site.","Investigator Brochure Acceptance Documentation | Accept Invstgr Broch | Acceptance of Investigator Brochure | IB Receipt Confirmation | IB signature page | Investigator Brochure Acceptance | Investigator Brochure Acceptance Document",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889677","Laboratory Certification Document","C115712","Official records indicating the competence of a laboratory to participate in a given clinical trial.","Laboratory Certification Document | Certification or Accreditation | Lab Cert | Laboratory Certification | Qualifications",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898584","Local Laboratory Certification or Accreditation Document","C115713","Official records of certification by an accredited body that recognizes the competence of a local laboratory to participate in a clinical trial.","Local Laboratory Certification or Accreditation Document | Lab Qualifications | Local Laboratory Certification or Accreditation | Locl Lab Certn Accred",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891285","Medical Coding Process Document","C115714","Documentation describing the process and tools used in the medical coding for the clinical trial.","Clinical Trial Medical Dictionary Coding Documentation | Dictionary Coding | Medical Coding | Medical Coding Process Document",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898435","Medical Imaging and Imaging Technique Documentation","C115715","Records detailing the proper use of digital medical images, and digital imaging techniques for the capture and interpretation of data in a clinical trial.","Medical Imaging and Imaging Technique Documentation | Imaging Cat | Medical Imaging Category",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898128","Non-Institutional Review Board Independent Ethics Committee Approved Submission Document","C115716","Records that describe the changes and/or updates made to a clinical trial, and are submitted for approval to a committee other than the Institutional Review Board (IRB)/Independent Ethics Committee (IEC).","Non-Institutional Review Board Independent Ethics Committee Approved Submission Document | Subm Non-IRB-IEC | Submissions Non-IRB-IEC Committees",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898119","Notification of Regulatory Identification Number Document","C115717","Documentation of the unique identification number assigned by a regulatory authority used to identify the clinical trial.","Clinical Trial Notification of Regulatory Identification Number Documentation | Notf Reg ID Num | Notification of Regulatory Identification Number | Notification of Regulatory Identification Number Document",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889416","Protocol Signature Page","C115719","Documentation signed by investigators confirming the agreement of the clinical trial site to follow the clinical study protocol.","Clinical Study Protocol Signature Page Documentation | Investigator Protocol Acknowledgement | Prot Sig Pg | Protocol Signature Page | Protocol Signature Page | Signature Page",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897808","Qualified Person Investigational Product Certification Document","C115720","Documentation from a Qualified Person confirming that the investigational product(s) for the clinical trial have been manufactured according to Good Manufacturing Processes.","Clinical Trial Qualified Person Investigational Product Certification Documentation | QP (Qualified Person) Certification | QP Certification | Qual Person Cert | Qualified Person Certification | Qualified Person Investigational Product Certification Document",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891450","Radiography Study File","C115721","Records pertaining to radiographic files.","Radiography Study File | RAD | Radiography Subcategory | X-ray",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897779","Randomization Documentation","C115722","The Trial Master File Reference Model section that contains a collection of documents related to the randomization scheme for the clinical trial.","TMF-RM Randomization Section | Randomiz | Randomization | Randomization Documentation | Randomization Record | Randomization Subcategory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412477","Childhood Langerhans Cell Histiocytosis","C114483","Langerhans cell histiocytosis that occurs during childhood.","Childhood Langerhans Cell Histiocytosis | Langerhans Cell Histiocytosis",,,,,,,,,,,,,,,"40278448","Langerhans' cell histiocytosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1705097","Interleukin-17F","C114484","Interleukin-17F (163 aa, ~18 kDa) is encoded by the human IL17F gene. This protein plays a role in the inhibition of angiogenesis, the promotion of cartilage turnover and the positive regulation of cytokine production.","Interleukin-17F | Cytokine ML-1 | IL-17F | IL17F | Interleukin 17F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891066","MAML1 wt Allele","C114486","Human MAML1 wild-type allele is located in the vicinity of 5q35 and is approximately 64 kb in length. This allele, which encodes mastermind-like protein 1, plays a role in the modulation of notch signaling-dependent transcription.","MAML1 wt Allele | KIAA0200 | Mam-1 | Mam1 | Mastermind (Drosophila)-Like 1 Gene | Mastermind Like Transcriptional Coactivator 1 wt Allele | Mastermind, Drosophila, Homolog of, 1 Gene | Mastermind-Like 1 (Drosophila) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0971698","Mastermind-Like Protein 1, Human","C114487","Mastermind-like protein 1 (1016 aa, ~108 kDa) is encoded by the human MAML1 gene. This protein is involved in the regulation of notch-dependent gene transcription.","Mastermind-Like Protein 1 | MAML1 | Mam-1 | Mastermind Homolog | Mastermind-Like 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0668894","latency-associated nuclear antigen","C114489","Latent nuclear antigen (1036 aa, ~119 kDa) is encoded by the human herpesvirus 8 ORF73 gene. This protein plays a role in both viral latency and the transcriptional regulation of host genes that modulate apoptosis and cell proliferation.","Latent Nuclear Antigen | LANA | LANA-1 | LNA | LNA-1 | Latency-Associated Nuclear Antigen | ORF 73 | Protein ORF73",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889259","FLICE Inhibitory Protein","C114491","FLICE inhibitory protein (188 aa, ~21 kDa) is encoded by the human HHV8 ORF71 gene. This protein is involved in the modulation of host signaling pathways.","FLICE Inhibitory Protein | Flice Inhibitory Protein | ORF71 Protein | ORF71/K13 | Putative Apoptosis Inhibitor Protein | Viral FLICE Protein | vFLIP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0971262","Putative Transcription Activator ORF50","C114493","Putative transcription activator ORF50 (691 aa, ~74 kDa) is encoded by the human herpesvirus 8 ORF50 gene. This protein plays a role in the initiation of the lytic phase of the viral life cycle.","Putative Transcription Activator ORF50 | ORF50 Protein | Replication Transactivation Activator | Transcription Activator ORF50",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036689","Streptococcal Pharyngitis","C116003","Inflammation of the throat due to Streptococcus pyogenes.","Streptococcal Pharyngitis | Strep Throat",,,,,,,,,,,,,,,"28060","Streptococcal sore throat",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040425","Tonsillitis","C116006","Inflammation of the tonsillar tissue.","Tonsillitis | ",,,,,,,,,,,,,,,"4234533","Tonsillitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014541","Epiglottitis","C116007","Inflammation of the epiglottis.","Epiglottitis | Supraglottitis",,,,,,,,,,,,,,,"4214374","Epiglottitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028992","Omphalitis","C116008","Inflammation of the umbilical cord stump in newborns.","Omphalitis | ",,,,,,,,,,,,,,,"4034650","Omphalitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3890598","Crown-Like Structure","C116010","An ultrastructural finding in adipose tissue that indicates macrophage infiltration to sites of adipocyte necrosis.","Crown-Like Structure | CLS | Crown-Like Structures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898750","Institutional Review Board Independent Ethics Committee Report","C115584","Records sent to the Institutional Review Board (IRB) or Independent ethics committee (IEC) at regular intervals, which provides information and updates about a clinical trial.","Institutional Review Board Independent Ethics Committee Report | IRB-IEC Report | IRB-IEC Rept | IRB/IEC Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898731","Interim Statistical Report","C115585","Documentation detailing the statistical aspects of an interim analysis for the clinical trial.","Clinical Trial Interim Statistical Report Documentation | Interim SR | Interim Statistical Report | Interim Statistical Report(s) | Interim Statistical Reports",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889682","Institutional Review Board Independent Ethics Committee Subject Diary","C115588","An instrument approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) that is used to record subject data away from a clinical trial site.","Institutional Review Board Independent Ethics Committee Subject Diary | IRB-IEC Approved Subject Diary | Institutional Review Board Independent Ethics Committee Approved Subject Diary | Subj Diary | Subject Diary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899059","GOSE - Independence in the Home: Assistance Essential for Daily Living","C115829","Extended Glasgow Outcome Scale (GOSE) Is the assistance of another person at home essential every day for some activities of daily living?","GOSE - Independence in the Home: Assistance Essential for Daily Living | GOSE1-Daily Assistance at Home Essential | GOSE102A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899057","GOSE - Independence in the Home: Need Frequent Help at Home","C115830","Extended Glasgow Outcome Scale (GOSE) Do they need frequent help or someone to be around at home most of the time?","GOSE - Independence in the Home: Need Frequent Help at Home | GOSE1-Need Frequent Help at Home | GOSE102B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899058","GOSE - Independence in the Home: Assistance at Home Before Injury","C115831","Extended Glasgow Outcome Scale (GOSE) Was assistance at home essential before the injury?","GOSE - Independence in the Home: Assistance at Home Before Injury | GOSE1-Assistance at Home Before Injury | GOSE102C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899061","GOSE - Independence Outside the Home: Able to Shop Without Assistance","C115832","Extended Glasgow Outcome Scale (GOSE) Are they able to shop without assistance?","GOSE - Independence Outside the Home: Able to Shop Without Assistance | GOSE1-Shop Without Assistance | GOSE103A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899062","GOSE - Independence Outside the Home: Able to Shop Without Assistance Before Injury","C115833","Extended Glasgow Outcome Scale (GOSE) Were they able to shop without assistance before the injury?","GOSE - Independence Outside the Home: Able to Shop Without Assistance Before Injury | GOSE1-Shop Without Assist Before Injury | GOSE103B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897023","GOSE - Independence Outside the Home: Travel Locally Without Assistance","C115834","Extended Glasgow Outcome Scale (GOSE) Are they able to travel locally without assistance?","GOSE - Independence Outside the Home: Travel Locally Without Assistance | GOSE1-Travel Locally Without Assistance | GOSE104A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899060","GOSE - Independence Outside the Home: Travel Locally Without Assistance Before Injury","C115835","Extended Glasgow Outcome Scale (GOSE) Were they able to travel without assistance before the injury?","GOSE - Independence Outside the Home: Travel Locally Without Assistance Before Injury | GOSE1-Travel Without Assist Before Inj | GOSE104B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899051","GOSE - Work: Able to Work to Previous Capacity","C115836","Extended Glasgow Outcome Scale (GOSE) Are they currently able to work to their previous capacity?","GOSE - Work: Able to Work to Previous Capacity | GOSE1-Able to Work to Previous Capacity | GOSE105A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889387","Regulatory Affair Documentation","C115723","The Trial Master File Reference Model zone that contains the collection of documents relating to the interactions with regulatory authorities, including submissions, decisions, notifications, and registrations for the clinical trial.","TMF-RM Regulatory Zone | Reg Docn Cat | Regulatory | Regulatory Affair Documentation | Regulatory Affairs | Regulatory Documentation Category",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897728","Regulatory Documentation Not Other Wise Specified","C115724","Records of regulatory communications, tracking records, and documents not otherwise specified.","Regulatory Documentation Not Other Wise Specified | Reg Doc Comm Track Subcat | Regulatory Documentation Communications and Tracking Subcategory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897660","Safety and Clinical Database Reconciliation Document","C115725","Documentation verifying that the safety database is consistent with the clinical trial database.","Clinical Trial Safety and Clinical Database Reconciliation Documentation | SAE Data Reconciliation | SAE Reconciliation | Safety and Clinical Database Reconciliation Document | Serious Adverse Event Data Reconciliation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889393","Safety Communication Document","C115726","Records containing information related to a safety report of a clinical trial.","Safety Communication Document | Correspondence | Relevant Communications | Safe Comm | Safety Communications",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889649","KMT2B wt Allele","C115963","Human KMT2B wild-type allele is located in the vicinity of 19q13.1 and is approximately 21 kb in length. This allele, which encodes histone-lysine N-methyltransferase 2B protein, plays a role in both lysine methylation and the positive regulation of gene transcription.","KMT2B wt Allele | CXXC10 | HRX2 | KIAA0304 | Lysine (K)-Specific Methyltransferase 2B wt Allele | MLL1B | MLL2 | MLL4 | MLL4 Gene | Mixed Lineage Leukemia Gene Homolog 2 Gene | Myeloid/Lymphoid Or Mixed-Lineage Leukemia (Trithorax Homolog, Drosophila) 4 Gene | Myeloid/Lymphoid Or Mixed-Lineage Leukemia 4 Gene | TRX2 | Trithorax, Drosophila, Homolog of, 2 Gene | WBP7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3888275","Histone-Lysine N-Methyltransferase 2B, human","C115964","Histone-lysine N-methyltransferase 2B (2715 aa, ~294 kDa) is encoded by the human KMT2B gene. This protein is involved in epigenetic transcriptional activation through the mediation of histone methylation.","Histone-Lysine N-Methyltransferase 2B | EC 2.1.1.43 | Histone-Lysine N-Methyltransferase MLL4 | KMT2B | Lysine N-Methyltransferase 2B | Lysine-Specific Methyltransferase 2B | MLL4 | Myeloid/Lymphoid Or Mixed-Lineage Leukemia 4 | Myeloid/Lymphoid Or Mixed-Lineage Leukemia Protein 4 | Trithorax Homolog 2 | Trithorax Homologue 2 | WBP-7 | WW Domain Binding Protein 7 | WW Domain-Binding Protein 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898764","Infiltrating Bladder Urothelial Cancer Associated with Urethral Cancer","C115966","Invasive urothelial carcinoma of the bladder which is associated with the presence of in situ or infiltrating urethral carcinoma.","Invasive Bladder Urothelial Carcinoma Associated with Urethral Carcinoma | Infiltrating Bladder Urothelial Cancer Associated with Urethral Cancer | Infiltrating Bladder Urothelial Carcinoma Associated with Urethral Carcinoma | Infiltrating Bladder Urothelial Carcinoma Associated with Urethral Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0156119","Gangrenous Umbilical Hernia","C115967","A protrusion of necrotic tissue through the abdominal wall under the skin near the umbilicus.","Gangrenous Umbilical Hernia | ",,,,,,,,,,,,,,,"198797","Umbilical hernia with gangrene",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1824952","DNER Gene","C115968","This gene plays a role in Notch-mediated signaling.","DNER Gene | DNER | Delta/Notch-Like EGF Repeat Containing Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473303","Hsp70-peptide TKD/IL-2-activated Autologous Natural Killer Cells","C115969","A preparation of autologous natural killer (NK) cells that are stimulated ex vivo by a 14-mer heat shock protein 70 (Hsp70) TKD peptide and interleukin-2 (IL-2), with potential tumor-selective cytolytic activity. Upon re-infusion into the patient, the treated NK cells recognize and bind to Hsp70-expressing tumor cells, which induces NK-mediated tumor cell lysis. Hsp70, a membrane-bound, stress-inducible protein, is overexpressed on almost all tumor cells; however, it is absent or minimally present on normal, healthy cells. TKD is the C-terminal substrate-binding domain of Hsp70 and is the structure recognized by the activated NK cells.","Hsp70-peptide TKD/IL-2-activated Autologous Natural Killer Cells | Hsp70-peptide TKD/IL-2-activated Autologous NK Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446656","stage IIA uterine sarcoma","C115130","Tumor involves adnexa.  No regional lymph node or distant metastasis.","Stage IIA Uterine Sarcoma AJCC v7 | Stage IIA Uterine Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898888","Hepatocellular Carcinoma by BCLC Stage","C115132","A staging classification system for hepatocellular carcinoma that uses variables related to tumor stage, liver functional status, physical status, and cancer-related symptoms, and links the stages with a treatment algorithm. (HPB (Oxford) 2005; 7(1):35-41)","Hepatocellular Carcinoma by BCLC Stage | BCLC Staging for Hepatocellular Carcinoma | Barcelona Clinic Liver Cancer Staging for Hepatocellular Carcinoma | Hepatocellular Carcinoma BCLC Staging | Hepatocellular Carcinoma Barcelona Clinic Liver Cancer Staging | Hepatocellular Carcinoma by Barcelona Clinic Liver Cancer Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899982","BCLC Stage 0 Hepatocellular Carcinoma","C115133","Very early hepatocellular carcinoma. Patients are optimal candidates for resection. (HPB (Oxford) 2005; 7(1):35-41)","BCLC Stage 0 Hepatocellular Carcinoma | BCLC Stage 0 Hepatocellular Cancer | Barcelona Clinic Liver Cancer Stage 0 Hepatocellular Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899974","BCLC Stage","C115134","A stage for hepatocellular carcinoma defined according to the Barcelona Clinic Liver Cancer (BCLC) criteria.","BCLC Stage | Barcelona Clinic Liver Cancer Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897124","BCLC Stage A Hepatocellular Carcinoma","C115135","Early hepatocellular carcinoma.  Patients are candidates for radical therapies (resection, liver transplantation, or percutaneous treatments). (HPB (Oxford) 2005; 7(1):35-41)","BCLC Stage A Hepatocellular Carcinoma | BCLC Stage A Hepatocellular Cancer | Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899979","BCLC Stage B Hepatocellular Carcinoma","C115136","Intermediate hepatocellular carcinoma.  Patients may benefit from chemoembolization. (HPB (Oxford) 2005; 7(1):35-41)","BCLC Stage B Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Cancer | Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899977","BCLC Stage C Hepatocellular Carcinoma","C115137","Advanced hepatocellular carcinoma.  Patients may receive new agents in the setting of randomized controlled trials. (HPB (Oxford) 2005; 7(1):35-41)","BCLC Stage C Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Cancer | Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899975","BCLC Stage D Hepatocellular Carcinoma","C115138","End-stage hepatocellular carcinoma.  Patients will receive symptomatic treatment. (HPB (Oxford) 2005; 7(1):35-41)","BCLC Stage D Hepatocellular Carcinoma | BCLC Stage D Hepatocellular Cancer | Barcelona Clinic Liver Cancer Stage D Hepatocellular Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899983","BCLC Stage 0 Adult Hepatocellular Carcinoma","C115139","Very early hepatocellular carcinoma. Patients are optimal candidates for resection. (HPB (Oxford) 2005; 7(1):35-41)","BCLC Stage 0 Adult Hepatocellular Carcinoma | BCLC Stage 0 Hepatocellular Cancer | Barcelona Clinic Liver Cancer Stage 0 Adult Hepatocellular Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890398","Per Thousand Cells","C116240","A unit of measure equal to the instances of an entity per 1000 cells.","Per Thousand Cells | /10*3{cells} | /10^3 cells | /10^3{cells}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3892223","Per Nanoliter","C116243","A volume unit equal to one nanoliter used as a denominator to build a derived unit expressed as a ratio.","Per Nanoliter | /nL | /nl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898987","IC50 Reference Control Result","C116248","A reference control sample response based on a concentration of a specific drug expected to produce 50% inhibition of the standard growth of a viral organism, or of a biological/biochemical reaction.","Viral Half Maximal Inhibitory Concentration Reference Control Result Measurement | IC50 Reference Control Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899050","GOSE - Work: How Restricted Are They","C115837","Extended Glasgow Outcome Scale (GOSE) How restricted are they?","GOSE - Work: How Restricted Are They | GOSE1-How Restricted Are They | GOSE105B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899049","GOSE - Work: Working or Seeking Employment Before the Injury","C115838","Extended Glasgow Outcome Scale (GOSE) Were they either working or seeking employment before the injury (answer 'yes') or were they doing neither (answer 'no')?","GOSE - Work: Working or Seeking Employment Before the Injury | GOSE1-Working Before Injury | GOSE105C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899053","GOSE - Social and Leisure Activities: Extent of Restriction on Social and Leisure Activities","C115840","Extended Glasgow Outcome Scale (GOSE) What is the extent of restriction on their social and leisure activities?","GOSE - Social and Leisure Activities: Extent of Restriction on Social and Leisure Activities | GOSE1-Extent Social/Leisure Restriction | GOSE106B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899054","GOSE - Social and Leisure Activities: Engage Regular Social and Leisure Activities Before Injury","C115841","Extended Glasgow Outcome Scale (GOSE) Did they engage in regular social and leisure activities outside home before the injury?","GOSE - Social and Leisure Activities: Engage Regular Social and Leisure Activities Before Injury | GOSE1-Engage Social/Leisure Before Inj | GOSE106C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899065","GOSE - Family and Friendships: Extent of Disruption or Strain","C115843","Extended Glasgow Outcome Scale (GOSE) What has been the extent of disruption or strain?","GOSE - Family and Friendships: Extent of Disruption or Strain | GOSE1-Extent of Disruption | GOSE107B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890774","Structure-Specific Endonuclease Subunit SLX4","C116052","Structure-specific endonuclease subunit SLX4 (1834 aa, ~200 kDa) is encoded by the human SLX4 gene. This protein is involved in the both the recognition of DNA damage and the promotion of endonuclease activity.","Structure-Specific Endonuclease Subunit SLX4 | BTB/POZ Domain-Containing Protein 12 | Fanconi Anemia Group P Protein | SLX4 | SLX4 Structure-Specific Endonuclease Subunit Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889405","DOCK8 wt Allele","C116054","Human DOCK8 wild-type allele is located in the vicinity of 9p24.3 and is approximately 250 kb in length. This allele, which encodes dedicator of cytokinesis protein 8, may be involved in the activation of small GTPases. Variation in the gene is associated with autosomal recessive hyperimmunoglobulin E recurrent infection syndrome and disruption or deletion of the gene is associated with autosomal dominant mental retardation 2.","DOCK8 wt Allele | Dedicator of Cytokinesis 8 wt Allele | FLJ00026 | FLJ00152 | FLJ00346 | HEL-205 | MRD2 | ZIR8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1872244","Dedicator of Cytokinesis Protein 8","C116055","Dedicator of cytokinesis protein 8 (2099 aa, ~239 kDa) is encoded by the human DOCK8 gene. This protein may play a role in the regulation of small GTPase activity.","Dedicator of Cytokinesis Protein 8 | 1200017A24Rik | DOCK8 | Epididymis Luminal Protein 205",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890378","ALDH1A1 wt Allele","C116057","Human ALDH1A1 wild-type allele is located in the vicinity of 9q21.13 and is approximately 180 kb in length. This allele, which encodes retinal dehydrogenase 1 protein, plays a role in retinoic acid metabolism.","ALDH1A1 wt Allele | ALDC | ALDH, Liver Cytosolic Gene | ALDH-E1 | ALDH1 | ALDH11 | Aldehyde Dehydrogenase 1 Family, Member A1 wt Allele | Aldehyde Dehydrogenase 1, Soluble Gene | Aldehyde Dehydrogenase, Liver Cytosolic Gene | HEL-9 | HEL-S-53e | HEL12 | PUMB1 | RALDH1 | RP11-151D14.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1721673","Retinal Dehydrogenase 1, Human","C116058","Retinal dehydrogenase 1 (501 aa, ~55 kDa) is encoded by the human ALDH1A1 gene. This protein is involved in the oxidation of retinaldehyde.","Retinal Dehydrogenase 1 | ALDH Class 1 | ALDH-E1 | ALDH1A1 | ALHDII | Aldehyde Dehydrogenase Family 1 Member A1 | Aldehyde Dehydrogenase, Cytosolic | EC 1.2.1.36 | RALDH 1 | RalDH1 | Retinaldehyde Dehydrogenase 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473304","chiauranib","C115970","An orally available, small molecule inhibitor of select serine-threonine kinases, including aurora kinase B (aurora B), vascular endothelial growth factor receptors (VEGFRs), stem cell factor receptor (c-KIT), and platelet-derived growth factor receptors (PDGFRs), with potential antineoplastic activity. Upon oral administration, ibcasertib binds to and inhibits the activity of aurora B, VEGFRs, c-kit and PDGFRs, which may result in a decrease in the proliferation of tumor cells that overexpress these kinases. These kinases are overexpressed by a variety of cancer cell types.","Ibcasertib | CHIAURANIB | CS2164 | Chiauranib | Chiauranib | IBCASERTIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889458","DNER wt Allele","C115971","Human DNER wild-type allele is located in the vicinity of 2q36.3 and is approximately 357 kb in length. This allele, which encodes Delta and Notch-like epidermal growth factor-related receptor protein, is involved in the activation of Notch signaling pathways.","DNER wt Allele | Delta/Notch-Like EGF Repeat Containing wt Allele | UNQ26 | UNQ262/PRO299 | bet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1257727","Delta and Notch-Like Epidermal Growth Factor-Related Receptor, Human","C115972","Delta and Notch-like epidermal growth factor-related receptor (737 aa, ~78 kDa) is encoded by the human DNER gene. This protein plays a role in the positive regulation of Notch signaling.","Delta and Notch-Like Epidermal Growth Factor-Related Receptor | DENR | Delta and Notch-like Epidermal Growth Factor-related Receptor | Delta- and Notch-Like EGF-Related Receptor | Delta-Notch-Like EGF Repeat-Containing Transmembrane | PCA-Tr Antigen | PURKINJE CELL CYTOPLASMIC TYPE TR ANTIGEN | Purkinje Cell Cytoplasmic-Tr | Tr Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423951","MYOCD Gene","C115973","This gene plays a role in both heart development and smooth muscle cell differentiation.","MYOCD Gene | MYOCD | Myocardin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889467","MYOCD wt Allele","C115974","Human MYOCD wild-type allele is located in the vicinity of 17p11.2 and is approximately 103 kb in length. This allele, which encodes myocardin protein, is involved in transcriptional regulation, myogenesis and heart development.","MYOCD wt Allele | MYCD | Myocardin wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1612757","myocardin protein, human","C115975","Myocardin (938 aa, ~102 kDa) is encoded by the human MYOCD gene. This protein plays a role in myogenesis, heart development and transcriptional regulation.","Myocardin | MYOCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1395365","Dialysis Catheter Embolism","C114722","An obstruction of a vessel caused by a detached fragment of an indwelling dialysis catheter.","Dialysis Catheter Embolism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1400574","Dialysis Catheter Infection","C114723","A local or systemic infection associated with the use of a dialysis catheter.","Dialysis Catheter Infection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3266735","Hemodialysis Catheter Infection","C114724","A local or systemic infection associated with the use of a hemodialysis catheter.","Hemodialysis Catheter Infection | ",,,,,,,,,,,,,,,"764921","Infection of hemodialysis catheter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2315425","Peritoneal Dialysis Catheter Infection","C114725","A local or systemic infection associated with the use of a peritoneal dialysis catheter.","Peritoneal Dialysis Catheter Infection | ",,,,,,,,,,,,,,,"4330222","Infection of peritoneal dialysis catheter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899383","Dialysis Catheter Tunnel Infection","C114726","Local infection involving the subcutaneously tunneled portion of a dialysis catheter.","Dialysis Catheter Tunnel Infection | Tunnel Infection Associated with Dialysis Access",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899385","Dialysis Catheter Exit Site Infection","C114727","Local infection at the dialysis catheter exit site.","Dialysis Catheter Exit Site Infection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898896","Hemodialysis Catheter-Associated Bacteremia","C114728","The presence of bacteria in the blood caused by an infected hemodialysis catheter.","Hemodialysis Catheter-Associated Bacteremia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2610960","Pyroptosis","C114729","An inflammatory form of programmed cell death characterized by caspase-dependent formation of plasma-membrane pores, which leads to pathological changes in osmotic potential that ultimately result in cellular lysis and release of pro-inflammatory cytokines. It occurs most frequently following infection with intracellular pathogens, but also has a role in tumor suppression and the initiation of anti-tumor immune responses, as well as in autoimmune and cardiovascular diseases.","Pyroptosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0300252","Plasma Membrane Calcium-Transporting ATPases","C114730","A family of plasma membrane resident proteins that hydrolyze ATP to facilitate the transport of calcium ions out of the cytoplasm into the extracellular space.","Plasma Membrane Calcium-Transporting ATPase | ATP2B | EC 3.6.3.8 | PMCA | Plasma Membrane Ca2+ ATPase | Plasma Membrane Calcium ATPase | Plasma Membrane Calcium Pump",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2681837","MPRIP Gene","C114731","This gene plays a role in myosin function.","MPRIP Gene | MPRIP | Myosin Phosphatase Rho Interacting Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890354","MPRIP wt Allele","C114732","Human MPRIP wild-type allele is located in the vicinity of 17p11.2 and is approximately 175 kb in length. This allele, which encodes myosin phosphatase Rho-interacting protein, is involved in the modulation of myosin phosphorylation.","MPRIP wt Allele | KIAA0864 | M-RIP | MRIP | Myosin Phosphatase Rho Interacting Protein wt Allele | RHOIP3 | RIP3 | p116Rip",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1567292","Myosin Phosphatase Rho-Interacting Protein, human","C114733","Myosin phosphatase Rho-interacting protein (1025 aa, ~117 kDa) is encoded by the human MPRIP gene. This protein plays a role in the recruitment of myosin phosphatase to the cytoskeleton.","Myosin Phosphatase Rho-Interacting Protein | M-RIP | MPRIP | RIP3 | Rho Interacting Protein 3 | Rho-Interacting Protein 3 | p116 Rho-Interacting Protein | p116Rip",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823656","WAPL Gene","C114734","This gene is involved in both DNA replication and sister chromatid cohesion.","WAPL Gene | WAPL | WAPL Cohesin Release Factor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899547","Clinical Trial Site Personnel Supporting Information","C115524","Documentation of an investigator's qualifications for participating in a clinical trial.","Clinical Trial Site Personnel Supporting Information | Site Pers Supt Info | Site Personnel Supporting Information",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898686","Investigational Product Handling Instruction","C115525","Documentation describing the safe handling, storage, distribution, and return of the investigational product(s) for the clinical trial.","Clinical Trial Investigational Product Handling Instruction Documentation | IP Instr Handl | IP Instructions for Handling | Investigational Product Handling Instruction | Investigational Product Instructions for Handling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890035","Clinical Trial Investigator Brochure","C115526","Documentation providing relevant and current clinical and non-clinical data for the investigational product(s) that is related to the study of the product(s) in human subjects.","Clinical Trial Investigator Brochure Documentation | Clinical Trial Investigator Brochure | IB | Investigator Brochure | Investigator's Brochure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898677","Investigational Product Sample Label","C115527","A sample of each investigational product label used in the clinical trial.","Clinical Trial Investigational Product Sample Label | IP Sample Label | IP Sample Labl | Investigational Product Sample Label | Investigational Product Sample Label",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899560","Clinical Trial Principal Investigator License","C115529","A record of medical and/or other licenses of the principal investigators in a clinical trial.","Clinical Trial Principal Investigator License | Medical License | PI Lic | PI License | Principal Investigator License",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899590","Clinical Trial Filenotes Master List","C115531","Documentation providing a consolidated list or index of file notes generated during the clinical trial.","Clinical Trial Filenotes Master List Documentation | Clinical Trial Filenotes Master List | Filenote Master List | Flnote Mstr List | Note to File Master List",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889674","Clinical Trial Independent Data Monitoring Committee Member List","C115532","A directory of the current membership of the Independent Data Monitoring Committee.","Clinical Trial Independent Data Monitoring Committee Member List | Data Monitoring Committee | Data Safety Monitoring Board Member List | IDMC Mbr list | Independent Data Monitoring Committee Member List",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898461","Master Randomization List","C115533","A document describing the assignment of subjects to the clinical study protocol-specified treatment groups in the clinical trial.","Clinical Trial Master Randomization List | Master Randomization List | Master Randomization List | Mstr Randomiz List | Randomization Schedule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897931","Pharmacovigilance Data List","C115534","Documentation containing the clinical trial data used for safety evaluations of investigational product(s).","Clinical Trial Pharmacovigilance Data Line List Documentation | PV DB Line Listg | Periodic Line Listing | Pharmacovigilance Data List | Pharmacovigilance Database Line Listing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899939","Biological Sample Storage Condition Log","C115535","Documentation detailing the monitoring and tracking of the specimens storage conditions for the clinical trial.","Clinical Trial Biological Sample Storage Condition Log Documentation | Biological Sample Storage Condition Log | Sample Stor Log | Sample Storage Condition Log | Specimen Storage Condition Log | Temperature Log",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899570","Clinical Trial Monitoring Visit Log","C115536","Documentation listing all clinical trial site monitoring visit dates and attendees.","Clinical Trial Site Visit Log Documentation | Clinical Trial Monitoring Visit Log | Monitor visit log | Visit Log | Vlog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899539","Clinical Trial Subject Enrollment Log","C115537","Records identifying all subjects enrolled in a clinical trial.","Clinical Trial Subject Enrollment Log | Subj Enrol Log | Subject Enrollment Log | Subject Log",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899538","Clinical Trial Subject Screen Log","C115538","Records of all subjects considered for participation in a clinical trial.","Clinical Trial Subject Screen Log | Subj Screen Log | Subject Identification Log | Subject Screen Log",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889999","TNFSF8 wt Allele","C116060","Human TNFSF8 wild-type allele is located in the vicinity of 9q33 and is approximately 37 kb in length. This allele, which encodes tumor necrosis factor ligand superfamily member 8 protein, is involved in the positive regulation of T-lymphocyte proliferation.","TNFSF8 wt Allele | CD153 | CD30L | CD30LG | Tumor Necrosis Factor (Ligand) Superfamily, Member 8 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1671930","Tumor Necrosis Factor Ligand Superfamily Member 8, Human","C116061","Tumor necrosis factor ligand superfamily member 8 (234 aa, ~26 kDa) is encoded by the human TNFSF8 gene. This protein plays a role in the induction of T-cell proliferation.","Tumor Necrosis Factor Ligand Superfamily Member 8 | CD153 | CD153 Antigen | CD30 Antigen Ligand | CD30 Ligand | CD30-L | TNFSF8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473483","Liposomal Mitoxantrone Hydrochloride","C116064","A formulation composed of the hydrochloride salt form of the anthracenedione antibiotic mitoxantrone encapsulated within liposomes, with potential antineoplastic activity. Upon intravenous administration, mitoxantrone intercalates into and forms crosslinks with DNA, thereby disrupting DNA and RNA replication. This agent also binds to topoisomerase II, which both results in DNA strand breaks and prevents DNA synthesis. This leads to the induction of apoptosis in the rapidly dividing cancer cells. The liposomal delivery of mitoxantrone improves drug penetration into tumors and decreases drug clearance, thereby increasing drug circulation and therapeutic efficacy while lowering the toxic effects.","Liposomal Mitoxantrone Hydrochloride | Mitoxantrone Hydrochloride Liposome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473484","Anti-GITR Monoclonal Antibody MK-4166","C116065","An anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) agonistic monoclonal antibody (MoAb) with potential immunomodulating activity. Anti-GITR monoclonal antibody MK-4166 binds to and activates GITRs found on multiple types of T-cells. This stimulates the immune system and induces both the activation and proliferation of tumor-antigen-specific T effector cells, and suppresses the function of activated T regulatory cells. This leads to tumor cell eradication. Also, this agent is shown to act synergistically with chemotherapeutic drugs in multiple cancer models. GITR, a member of the TNF receptor superfamily, is expressed on the surface of multiple types of immune cells, including regulatory T-cells, effector T-cells, B-cells, and natural killer (NK) cells.","Anti-GITR Monoclonal Antibody MK-4166 | MK-4166",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889444","ASXL2 wt Allele","C116297","Human ASXL2 wild-type allele is located in the vicinity of 2p24.1 and is approximately 145 kb in length. This allele, which encodes putative Polycomb group protein ASXL2, is involved in both transcriptional regulation and chromatin modification.","ASXL2 wt Allele | ASXH2 | Additional Sex Combs Like 2 (Drosophila) wt Allele | Additional Sex Combs-Like 2 Gene | FLJ10898 | KIAA1685",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1450762","Putative Polycomb Group Protein ASXL2, Human","C116298","Putative Polycomb group protein ASXL2 (1435 aa, ~154 kDa) is encoded by the human ASXL2 gene. This protein plays a role in both the activation of transcription and chromatin remodeling.","Putative Polycomb Group Protein ASXL2 | Additional Sex Combs-Like Protein 2 | Polycomb Group Protein ASXH2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1969088","CISD2 Gene","C116299","This gene plays a role in the regulation of autophagy.","CISD2 Gene | CDGSH Iron Sulfur Domain 2 Gene | CISD2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0066350","Methylene Dimethane Sulfonate","C1162","A member of the homologous series of dimethane sulphonic acid esters with alkylating properties. Methylene dimethane sulfonate alkylates DNA, resulting in interstrand DNA crosslinking, inhibition of DNA replication, disruption of the cell cycle, and cell death.","Methylene Dimethane Sulfonate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898688","Investigational Product Certificate of Destruction","C115472","Documentation describing and certifying the destruction of the investigational product(s) for the clinical trial.","Clinical Trial Investigational Product Certificate of Destruction Documentation | Cert Destruction | Certificate of Destruction | Documentation of Destruction | IP Certificate of Destruction | Investigational Product Certificate of Destruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898689","Investigational Product Certificate of Analysis","C115473","Documentation confirming the investigational product(s) are the correct identity, purity and strength for use in the intended clinical trial.","Clinical Trial Investigational Product Certificate of Analysis Documentation | Certificate of Analysis | Investigational Product Certificate of Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899593","Clinical Trial Data Privacy Agreement","C115474","Documentation containing the provisions governing the use of, and access to, any and all data obtained from the clinical trial.","Clinical Trial Data Privacy Agreement Documentation | Clinical Trial Data Privacy Agreement | Data Priv Agrmnt | Data Privacy Agreement | Personal Data Consent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899589","Clinical Trial Financial Agreement","C115475","Documentation detailing the agreement of the clinical trial requirements between sponsor or representative of the sponsor and other parties (excluding the investigator and institution) involved in the conduct of the clinical trial.","Clinical Trial Financial Agreement Documentation | Clinical Trial Financial Agreement | Other Finan Agrmnt | Other Financial Agreement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899584","Clinical Trial Investigator Confidentiality Agreement","C115476","Documentation detailing the agreement between the sponsor or representative of the sponsor and the investigator or institution that contains the provisions governing the access and use of confidential information pertaining to the clinical trial site.","Clinical Trial Site Investigator Confidentiality Agreement Documentation | Clinical Trial Investigator Confidentiality Agreement | Confidentiality Agreement | Investigator Confidentiality Agreement | Invstgr Confd Agrmnt | Non-disclosure Agreement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889712","KIAA0261","C114735","Human WAPL wild-type allele is located in the vicinity of 10q23.2 and is approximately 87 kb in length. This allele, which encodes wings apart-like protein homolog, plays a role in mitosis, meiosis and DNA replication.","WAPL wt Allele | FOE | Friend of EBNA2 (Epstein-Barr Virus Nuclear Protein 2) Gene | Friend of EBNA2 Gene | KIAA0261 | RP11-396M20.1 | WAPAL | WAPL Cohesin Release Factor wt Allele | Wings Apart-Like Homolog (Drosophila) Gene | Wings Apart-Like Protein, Drosophila, Homolog of Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1454599","Wings Apart-Like Protein Homolog, Human","C114736","Wings apart-like protein homolog (1190 aa, ~133 kDa) is encoded by the human WAPL gene. This protein is involved in meiosis, mitosis and DNA replication.","Wings Apart-Like Protein Homolog | Friend of EBNA2 Protein | WAPL Cohesin Release Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2933824","Daclatasvir","C114981","An orally available inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex, with potential activity against HCV. Although the exact mechanism of action of daclatasvir has yet to be fully determined, this agent, upon oral administration and after intracellular uptake, appears to bind to domain I of the NS5A protein. This inhibits the activity of the NS5A protein and results in the disruption of the viral RNA replication complex, blockage of viral HCV RNA production, and inhibition of viral replication. NS5A, a zinc-binding and proline-rich hydrophilic phosphoprotein, plays a crucial role in HCV RNA replication. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family.","Daclatasvir | BMS-790052 | Carbamic Acid, N,N'-((1,1'-biphenyl)-4,4'-diylbis(1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl((1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl)))bis-, C,C'-dimethyl Ester | DACLATASVIR | DCV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3491974","Asunaprevir","C114982","An orally bioavailable inhibitor of the nonstructural protein 3 (NS3), with potential activity against hepatitis C virus (HCV). Upon administration, asunaprevir binds to the active center of the HCV NS3 and prevents NS3 protease-mediated polyprotein maturation. This disrupts the processing of viral proteins required for HCV replication. NS3, a serine protease, is essential for the proteolytic cleavages within the HCV polyprotein and plays a key role during HCV viral RNA replication. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family.","Asunaprevir | 1,1-Dimethylethyl ((1S)-1-(((2S,4R)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2- (((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-ethenylcyclopropyl)carbamoyl) pyrrolidin-1-yl)carbonyl)-2,2-dimethylpropyl)carbamate | ASUNAPREVIR | ASV | BMS-650032",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3852614","NS5B polymerase inhibitor BMS-791325","C114983","A non-nucleoside, polymerase inhibitor of the hepatitis C virus (HCV) nonstructural protein 5B (NS5B), a RNA-dependent RNA polymerase, with potential activity against HCV. Upon administration and after intracellular uptake, beclabuvir allosterically binds to the non-catalytic Thumb 1 site of viral HCV NS5B polymerase and causes a decrease in viral RNA synthesis and replication. The HCV NS5B protein is essential for the replication of the viral HCV RNA genome. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family.","Beclabuvir | (4bS,5aR)-12-Cyclohexyl-N-(dimethylsulfamoyl)-3-methoxy-5a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)-4b,5,5a,6-tetrahydrocyclopropa(d)indolo(2,1-a)(2)benzazepine-9-carboxamide | BECLABUVIR | BMS-791325",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472580","Ex Vivo-activated Autologous Lymph Node Lymphocytes","C114985","Autologous human lymph node T-lymphocytes, with potential immunostimulatory and antineoplastic activity. Upon collection of immune cells from the tumor-draining lymph node, the human lymph node lymphocytes are activated with anti-CD3/anti-CD28 microbeads, cultured with recombinant, human interleukin-2 (IL-2), expanded and isolated ex vivo. Upon reintroduction into the patient, the ex vivo-activated autologous lymph node lymphocytes recognize and lyse the tumor cells.","Ex Vivo-activated Autologous Lymph Node Lymphocytes | X-ACT | X-ACT Autologous Lymph Node Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899575","Clinical Trial Management Plan","C115780","Documentation describing the overall strategy for timelines, management and conduct of the clinical trial.","Clinical Trial Management Plan Documentation | Clinical Trial Management Plan | Project Management Plan | TM Plan | Trial Management Plan | Trial Mgmt Plan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899552","Clinical Trial Site Communications and Tracking Management Documentation","C115781","Records pertaining to the management of a clinical trial site.","Clinical Trial Site Communications and Tracking Management Documentation | Site Management Communications and Tracking Subcategory | Site Mgmt Comm Track",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899549","Clinical Trial Site Management Documentation","C115782","The Trial Master File Reference Model zone that contains the collection of documents relating to the selection, setup, initiation and management of the investigational sites as well as multi-site records and communications for the clinical trial.","TMF-RM Site Management Zone | Clinical Trial Site Management Documentation | Site Management | Site Management Category | Site Mgmt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899542","Clinical Trial Stakeholder Communication Plan","C115783","Documentation describing the communication strategy between stakeholders of the clinical trial.","Clinical Trial Stakeholder Communication Plan Documentation | Clinical Trial Stakeholder Communication Plan | Comms Plan | Communication Plan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890189","Trial Master File","C115784","A formalized system of organizing and storing paper documents, images and other physical assets in a filing system for clinical trials.","Trial Master File | TMF | tmf | trial master file",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896580","Electronic Trial Master File","C115785","A formalized system of organizing and storing digital content in an electronic record system.","Electronic Trial Master File | eTMF | electronic TMF | electronic Trial Master File | electronic trial master file",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0473124","Perinephric Hematoma","C115786","A collection of blood around the kidney.","Perinephric Hematoma | ",,,,,,,,,,,,,,,"4056607","Perinephric hematoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897450","Subcapsular Renal Hematoma","C115788","A collection of blood between the renal capsule and the renal parenchyma.","Subcapsular Renal Hematoma | Subcapsular Hematoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889433","CISD2 wt Allele","C116300","Human CISD2 wild-type allele is located in the vicinity of 4q24 and is approximately 24 kb in length. This allele, which encodes CDGSH iron-sulfur domain-containing protein 2, is involved in both iron-sulfur binding and autophagy. Mutation of the gene is associated with Wolfram syndrome 2.","CISD2 wt Allele | CDGSH Iron Sulfur Domain 2 wt Allele | ERIS | Miner1 | MitoNEET Related 1 Gene | NAF-1 | WFS2 | Wolfram Syndrome 2 Gene | ZCD2 | Zinc Finger, CDGSH-Type Domain 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889404","CDGSH Iron-Sulfur Domain-Containing Protein 2, human","C116301","CDGSH iron-sulfur domain-containing protein 2 (135 aa, ~15 kDa) is encoded by the human CISD2 gene. This protein plays a role in the regulation of autophagy.","CDGSH Iron-Sulfur Domain-Containing Protein 2 | CDGSH Iron-Sulfur Domain Protein 2 | CISD2 | Endoplasmic Reticulum Intermembrane Small Protein | Miner1 | MitoNEET-Related 1 Protein | NAF-1 | Nutrient Deprivation Autophagy Factor 1 | Nutrient-Deprivation Autophagy Factor-1 | Zinc Finger Protein ZCD2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415674","HOXC10 Gene","C116302","This gene is involved in embryonic pattern formation.","HOXC10 Gene | HOXC10 | Homeobox C10 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898992","HOXC10 wt Allele","C116303","Human HOXC10 wild-type allele is located in the vicinity of 12q13.3 and is approximately 5 kb in length. This allele, which encodes homeobox protein Hox-C10, plays a role in embryonic axis determination.","HOXC10 wt Allele | HOX3I | Homeo Box C10 Gene | Homeobox C10 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1439024","Homeobox Protein Hox-C10, Human","C116304","Homeobox protein Hox-C10 (342 aa, ~38 kDa) is encoded by the human HOXC10 gene. This protein is involved in embryonic pattern specification.","Homeobox Protein Hox-C10 | Homeobox Protein Hox-3I | Homeoprotein C10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417020","MAP4K3 Gene","C116305","This gene plays a role in both protein phosphorylation and Jun signaling pathways.","MAP4K3 Gene | MAP4K3 | Mitogen-Activated Protein Kinase Kinase Kinase Kinase 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2742126","Mitogen-Activated Protein Kinase Kinase Kinase Kinase 3, Human","C116307","Mitogen-activated protein kinase kinase kinase kinase 3 (894 aa, ~101 kDa) is encoded by the human MAP4K3 gene. This protein plays a role in the Jun signaling pathway.","Mitogen-Activated Protein Kinase Kinase Kinase Kinase 3 | EC 2.7.11.1 | GLK | Germinal Center Kinase-Like Kinase | Germinal Center Kinase-Related Protein Kinase | MAP4K3 | MAPK/ERK Kinase Kinase Kinase 3 | MEK Kinase Kinase 3 | MEKKK 3 | RAB8-Interacting Protein-Like 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890200","SOS1 wt Allele","C116309","Human SOS1 wild-type allele is located in the vicinity of 2p21 and is approximately 143 kb in length. This allele, which encodes son of sevenless homolog 1 protein, plays a role in both signaling and guanine nucleotide exchange. Mutation of the gene is associated with both gingival fibromatosis type 1 and Noonan syndrome type 4.","SOS1 wt Allele | GF1 | GGF1 | GINGF | Gingival Fibromatosis, Hereditary, 1 Gene | HGF | NS4 | SOS Ras/Rho Guanine Nucleotide Exchange Factor 1 wt Allele | Son of Sevenless Homolog 1 (Drosophila) Gene | Son of Sevenless Homolog 1 Gene | Son of Sevenless, Drosophila, Homolog 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897020","Database Specification","C115590","A detailed description of the framework, and process required to build a database for paper and electronic data capture (EDC).","Database Specification | DB Spec | Database Programming Requirements",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899188","External Data Transfer Specification","C115591","A detailed description that specifies the import, export, and transfer of data.","External Data Transfer Specification | External Data Transfer Specifications | Extnl DT Spec",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898736","Interactive Response Technology User Specification","C115592","Documentation describing the end user requirements of the interactive response technology.","Interactive Response Technology User Specification Documentation | IRT User Reqrt Spec | IRT User Requirement Specification | Interactive Response Technology Specification | Interactive Response Technology User Specification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890569","Debarment Statement","C115593","Documentation verifying that the applicant or any of its principals should be excluded from certain rights, privileges and practices due to debarment or other circumstances.","Debarment Statement Documentation | Debar Stmt | Debarment Certification | Debarment Statement | Debarment Statement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899581","Clinical Trial Investigator Regulatory Agreement","C115477","Documentation containing the agreement by any/all investigators of the clinical trial that all trial activities will conform fully to all regulations as set forth by the law, or any other supervisory authority.","Clinical Trial Investigator Regulatory Agreement Documentation | Clinical Trial Investigator Regulatory Agreement | Investigator Regulatory Agreement | Invstgr Reg Agrmnt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889673","Institutional Review Board - Independent Ethics Committee Sponsor Communication","C115480","Records detailing all trial related communication between the Institutional Review Board (IRB) and/or the independent ethics committee (IEC), and the trial sponsor.","Institutional Review Board - Independent Ethics Committee Sponsor Communication | IRB-IEC Spons Comm Track Subcat | IRB-IEC Sponsor Communications and Tracking Subcategory | IRB/IEC and other Approvals",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889671","Study Subject Computed Tomography Image","C115481","A computed tomography image of a study participant for use in the clinical trial.","Study Subject Computed Tomography Image | Study Subj CT Rept | Study Subject CT | Study Subject Computed Tomography",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889675","Edit Check Program","C115482","A computer application that satisfies the edit check specification details in the data validation process.","Edit Check Program | ECP | Edit Check Programming",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899115","Final Analysis Program","C115483","Program files used to generate a final analysis dataset and output as referenced by the statistical analysis plan of the clinical trial.","Clinical Trial Final Analysis Programs Documentation | FinAnaly Prog | Final Analysis Program | Final Analysis Programs | Program File for Analysis Dataset",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898732","Interim Analysis Program","C115484","Program files used to generate interim analysis dataset and output as referenced by the statistical analysis plan of the clinical trial.","Clinical Trial Interim Analysis Programs Documentation | IntAnaly Prog | Interim Analysis Program | Interim Analysis Programs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890408","Clinical Trial Independent Data Monitoring Committee Correspondence","C115485","Records that document the correspondence between a clinical trial, and the trial's Independent Data Monitoring Committee.","Clinical Trial Independent Data Monitoring Committee Correspondence | DMC Correspondence | DSMB Correspondence | Data Monitoring Committee | Data Safety Monitoring Board Correspondence | IDMC Coresp | IDMC Correspondence | IDMC Data Package | Independent Data Monitoring Committee Correspondence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889686","Content Item Creator","C115486","The name of the entity who created the content item.","Content Item Creator | Creator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899561","Clinical Trial Principal Investigator Curriculum Vitae","C115487","Documentation detailing the education, qualification and work experience of the principal investigator involved in the conduct of the clinical trial.","Clinical Trial Principal Investigator Curriculum Vitae Documentation | Clinical Trial Principal Investigator Curriculum Vitae | Investigator CVs | PI CV | Principal Investigator CV | Principal Investigator Curriculum Vitae",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899541","Clinical Trial Sub-Investigator Curriculum Vitae","C115488","Documentation detailing the education, qualification and work experience of the sub-investigator(s) involved in the conduct of the clinical trial.","Clinical Trial Sub-Investigator Curriculum Vitae Documentation | Clinical Trial Sub-Investigator Curriculum Vitae | Sub-I CV | Sub-Investigator Curriculum Vitae",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891294","Safety Reporting Documentation","C115727","Records pertaining to the timely report of safety information in a clinical trial.","Safety Reporting Documentation | General | Safe Rept Comm Track | Safety Reporting Communications and Tracking Subcategory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890385","Safety Tracking Document","C115728","Records used to track activities related to safety reporting during the course of a clinical trial.","Safety Tracking Document | Safe Track Doc | Tracking Document",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890382","Statistic Tracking Document","C115730","Records used to track statistics during the course of a clinical trial.","Statistic Tracking Document | Statistics Tracking Document | Stats Track Doc | Tracking Document",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896867","E-101 Solution","C114986","An oxidant-generating coupled-enzyme system-based, topical solution comprised of two enzymes, Aspergillus niger-derived glucose oxidase (GO) and porcine myeloperoxidase (p-MPO), as well as glucose, sodium chloride and stabilizing amino acids, with potential broad-spectrum microbicidal activity. Following direct administration of E-101 solution into the surgical incisional wound via microspray, the enzyme GO converts oxygen into hydrogen peroxide (H2O2). In turn, p-MPO catalyzes the reaction of H2O2 with hypochlorous acid (HOCl), which is formed through oxidation of the chloride ion, to generate singlet oxygen (O2*). As p-MPO binds to microorganisms, O2* is able to exert direct oxidative damage to microorganisms, resulting in potent antimicrobial activity. E-101 may act as an anti-bactericidal agent against a variety of microorganisms, including multidrug-resistant strains. This may prevent infection at the surgical site.","E-101 Solution | E-101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900105","Adult Combined Hepatocellular Carcinoma and Cholangiocarcinoma","C114987","A combined hepatocellular carcinoma and cholangiocarcinoma that occurs during adulthood.","Adult Combined Hepatocellular Carcinoma and Cholangiocarcinoma | Combined Hepatocellular Cancer and Cholangiocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472320","allosteric Bcr-Abl tyrosine kinase inhibitor ABL001","C114494","An orally bioavailable, allosteric Bcr-Abl1 tyrosine kinase inhibitor, with antineoplastic activity. Upon administration, asciminib targets and binds to the myristoyl pocket of the Bcr-Abl1 fusion protein at a location that is distinct from the ATP-binding domain, thereby inhibiting the activity of both wild-type Bcr-Abl and certain mutation forms, including the T315I mutation. This binding results in the inhibition of Bcr-Abl1-mediated proliferation and enhanced apoptosis of Philadelphia chromosome-positive (Ph+) hematological malignancies. The Bcr-Abl1 fusion protein tyrosine kinase is an abnormal enzyme produced by leukemia cells that contain the Philadelphia chromosome.","Asciminib | ABL 001 | ABL-001 | ABL001 | ASCIMINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472321","Yttrium Y 90 Colloid","C114495","An injectable, colloidal formulation of the radioisotope yttrium Y 90, with potential antineoplastic activity. When injected into the tumor, the yttrium Y 90 colloid selectively delivers a cytotoxic dose of beta-emitting yttrium Y 90 to the tumor site, which may result in both tumor cell death and tumor regression.","Yttrium Y 90 Colloid | 90Y Colloid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472322","Glioma-associated Peptide-loaded Dendritic Cell Vaccine SL-701","C114496","A cell-based cancer vaccine comprised of dendritic cells (DCs) pulsed with various, synthetic glioma-associated antigen (GAA) peptides, with potential antineoplastic activity. Upon subcutaneous administration, the glioma-associated peptide-loaded DC vaccine SL-701 exposes the immune system to various GAA peptides. This may stimulate both anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against the GAA-expressing glioma cells, which may result in tumor cell lysis.","Glioma-associated Peptide-loaded Dendritic Cell Vaccine SL-701 | SL-701",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3252109","Relugolix","C114498","An orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation.","Relugolix | N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea | Orgovyx | RELUGOLIX | Relumina | TAK 385 | TAK-385 | TAK385 | Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890213","LAMP2 wt Allele","C116023","Human LAMP2 wild-type allele is located in the vicinity of Xq24 and is approximately 43 kb in length. This allele, which encodes lysosome-associated membrane glycoprotein 2, is involved in the maintenance of the lysosome. Mutation of the gene is associated with Danon disease.","LAMP2 wt Allele | CD107b | LAMP-2 | LAMPB | LGP110 | Lysosomal-Associated Membrane Protein 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898753","Institutional Review Board Independent Ethics Committee Good Clinical Practices Compliance Statement","C115594","Documentation confirming the Institutional Review Board or Independent Ethics Committee is in compliance with written operating procedures, Good Clinical Practices, and applicable regulatory requirements.","Institutional Review Board Independent Ethics Committee Compliance Documentation | IRB or IEC Compliance Documentation | IRB-IEC Attestation Form | IRB-IEC GCP Compliance Statement | IRB-IEC GCP Stmt | Institutional Review Board Independent Ethics Committee Good Clinical Practices Compliance Statement | Institutional Review Board Independent Ethics Committee Good Clinical Practices Compliance Statement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889397","Central Trial Communication Material","C115596","A collection of central trial-related communication agreements, significant discussions, or relevant information.","Central Trial Communication Material | CTrial Comm | Central Trial Communications | Correspondence | Relevant Communications",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889993","Central Trial Meeting Material","C115597","A collection of agendas, presentation materials, and other documents generated for attendees during a central trial-related meeting.","Central Trial Meeting Material | CTrial Mtg Matl | Meeting Material",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890409","Centralized Testing Meeting Material","C115598","A collection of agendas, presentation materials, and other documents generated for attendees during a centralized test-related meeting.","Centralized Testing Meeting Material | Centralz Test Mtng Matl | Meeting Material",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899583","Clinical Trial Investigator Meeting Material","C115599","Documentation pertaining to the clinical trial investigator meeting.","Clinical Trial Investigator Meeting Material Documentation | Clinical Trial Investigator Meeting Material | Investigators Meeting Material | Invstgr Mtg Matl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899579","Clinical Trial Kick-off Meeting Material","C115600","Documentation pertaining to the clinical trial kick-off meeting.","Clinical Trial Kick-off Meeting Material Documentation | Boot-up Meeting Material | Clinical Trial Kick-off Meeting Material | KO Mtng Matl | Kick-off Meeting Material",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889975","Clinical Trial Management Meeting Material","C115601","A collection of agendas, presentation materials, and other documents generated for attendees during a clinical trial management meeting.","Clinical Trial Management Meeting Material | Meeting Background Materials | Other Meeting Material | Trial Management Meeting Material | Trial Mgmt Mtng",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889391","Clinical Trial Site Management Communication Material","C115602","A collection of communications, agreements, significant discussions, and/or relevant information related to clinical trial site management.","Clinical Trial Site Management Communication Material | Correspondence | Relevant Communications | Site Management Communications | Site Mgmt Comm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890905","Clinical Trial Site Management Meeting Material","C115603","A collection of agendas, presentation materials, and other documents generated for attendees during a clinical trial site management meeting.","Clinical Trial Site Management Meeting Material | Meeting Material | Site Management Meeting Material | Site Mgmt Mtng Matl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427585","ARFIP1 Gene","C114681","This gene may be involved in vesicle trafficking.","ARFIP1 Gene | ADP-Ribosylation Factor Interacting Protein 1 Gene | ARFIP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889460","ARFIP1 wt Allele","C114682","Human ARFIP1 wild-type allele is located in the vicinity of 4q31.3 and is approximately 139 kb in length. This allele, which encodes arfaptin-1 protein, may play a role in vesicular transport.","ARFIP1 wt Allele | ADP-Ribosylation Factor Interacting Protein 1 wt Allele | HSU52521",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889396","Statistics Communication Document","C115731","Records pertaining to communications about statistics used in a clinical trial.","Statistics Communication Document | Correspondence | Relevant Communications | Statistics Communications | Stats Comm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897499","Statistical Analysis Documentation","C115732","The Trial Master File Reference Model zone that contains the collection of documents relating to biostatistics and statistical programming activities for the clinical trial.","TMF-RM Statistics Zone | Statistical Analysis Documentation | Statistics | Statistics Category | Stats Cat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897496","Statistics Oversight Documentation","C115733","The Trial Master File Reference Model section that contains a collection of documents related to the statistics oversight for the clinical trial.","TMF-RM Statistics Oversight Section | Statistics Oversight | Statistics Oversight Documentation | Statistics Oversight Subcategory | Stats Ovrsgt Subcat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897463","Study Registry Document","C115734","Documentation pertaining to the registration of the clinical trial in public registries.","Clinical Trial Public Registration Documentation | Public Registration | Study Regis Docs | Study Registry Document | Study Registry Documents",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890888","Subject Evaluability Criteria and Classification Document","C115735","Documentation detailing the decisions that define the criteria used to evaluate and assign subjects to a population group, which are established by the statistical analysis plan of the clinical trial.","Clinical Trial Subject Evaluability Criteria and Subject Classification Documentation | Deviations and Exemptions | Population Definition Criteria | Protocol Deviation Listing | Protocol Violations | Subj Eval Crit | Subject Evaluability Criteria and Classification Document | Subject Evaluability Criteria and Subject Classification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897427","Submission Response Document","C115736","Documentation detailing the decisions made by other committee(s) related to the clinical trial.","Clinical Trial Other Committees Decisions Documentation | Other Approv | Other Approvals | Submission Response Document",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897425","Supplementary Monitoring Activity Document","C115737","Documentation of additional clinical trial site monitoring activities.","Clinical Trial Site Additional Monitoring Activity Documentation | Additional Monitoring Activity | Supplementary Monitoring Activity | Supplementary Monitoring Activity Document | Suppmt Mon Actv",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897424","Supplies and Non-Drug Investigational Product Import Document","C115738","Records of the import of laboratory supplies, or a non-drug investigational product (IP).","Supplies and Non-Drug Investigational Product Import Document | Lab Safe Impt Doc | Lab Supply Import Documentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890726","Unselected Clinical Trial Site Document","C115739","Documentation pertaining to potential clinical trial sites that were evaluated, but not selected, for the clinical trial.","Unselected Clinical Trial Site Documentation | Investigators not used | SENS | Sites Evaluated but not Selected | Unselected Clinical Trial Site Document",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889399","Vendor Communication Documentation","C115741","Records pertaining to vendor communications.","Vendor Communication Documentation | Correspondence | Relevant Communications | Vend Comm | Vendor Communications",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897203","Vendor Documentation","C115742","Records pertaining to a specific vendor.","Vendor Documentation | Vend Comm Track Subcat | Vendors Communications and Tracking Subcategory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891300","Vendor Information Documentation","C115743","The Trial Master File Reference Model zone that contains the collection of documents relating to the establishment, maintenance and oversight of relationships between sponsors and vendors for the clinical trial.","TMF-RM Vendors Zone | Third Parties | Third parties | Vend Cat | Vendor | Vendor Information Documentation | Vendors Category",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897202","Vendor Oversight Document","C115744","The Trial Master File Reference Model section that contains a collection of documents related to vendor oversight for the clinical trial.","TMF-RM Vendor Oversight Section | Third Party Oversight | Vend Ovrsgt Subcat | Vendor Oversight Document | Vendor Oversight Subcategory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472324","Lutetium Lu 177 PP-F11N","C114499","A radioconjugate composed of PP-F11N, a gastrin analog, conjugated to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and potential use as an imaging agent for scintigraphy. Following intravenous administration, the PP-F11N moiety binds to the cholecystokinin-2 (CCK-2) receptor. Subsequently, the CCK-2 receptor-expressing tumor cells can be visualized scintigraphically. In addition, the radioisotope moiety delivers a cytotoxic dose of beta radiation to CCK-2 receptor-expressing tumor cells. CCK-2 receptors are expressed on a variety of tumor cell types.","Lutetium Lu 177 PP-F11N | 177Lu-PP-F11N | PP-F11N LUTETIUM LU-177",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0733433","Nafarelin Acetate","C1144","The acetate salt form of nafarelin, a modified synthetic porcine luteinizing hormone (LH)-releasing hormone peptide analog, with gonadotropin-releasing hormone (GnRH) agonist activity. Upon nasal inhalation, nafarelin acetate binds to the GnRH receptor. This initially results in the release of the gonadotropins, follicle-stimulating hormone (FSH) and LH, from the pituitary gland; however, prolonged stimulation of the GnRH receptor desensitizes the receptor, which leads to decreased secretion of FSH and LH. In females, the inhibition of gonadotropin secretion causes hypogonadotropic hypogonadism leading to decreased production of estrogen and progesterone and anovulation. In males, the inhibition of LH secretion prevents the production and release of testosterone from Leydig cells in the testes and causes a significant decline in testosterone production that is near the levels seen following castration.","Nafarelin Acetate | (6-D-(2-Naphthyl)alanine)LHRH Acetate | NAFARELIN ACETATE | RS-94991298 | Synarel | Synarela | Synrelina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899980","BCLC Stage B Adult Hepatocellular Carcinoma","C115141","Intermediate hepatocellular carcinoma.  Patients may benefit from chemoembolization. (HPB (Oxford) 2005; 7(1):35-41)","BCLC Stage B Adult Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Cancer | Barcelona Clinic Liver Cancer Stage B Adult Hepatocellular Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899978","BCLC Stage C Adult Hepatocellular Carcinoma","C115143","Advanced hepatocellular carcinoma.  Patients may receive new agents in the setting of randomized controlled trials. (HPB (Oxford) 2005; 7(1):35-41)","BCLC Stage C Adult Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Cancer | Barcelona Clinic Liver Cancer Stage C Adult Hepatocellular Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899976","BCLC Stage D Adult Hepatocellular Carcinoma","C115144","End-stage hepatocellular carcinoma.  Patients will receive symptomatic treatment. (HPB (Oxford) 2005; 7(1):35-41)","BCLC Stage D Adult Hepatocellular Carcinoma | BCLC Stage D Hepatocellular Cancer | Barcelona Clinic Liver Cancer Stage D Adult Hepatocellular Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1563373","Lysosome-Associated Membrane Glycoprotein 2, Human","C116024","Lysosome-associated membrane glycoprotein 2 (410 aa, ~45 kDa) is encoded by the human LAMP2 gene. This protein plays a role in lysosome function.","Lysosome-Associated Membrane Glycoprotein 2 | CD107 Antigen-Like Family Member B | CD107b | CD107b Antigen | LAMP-2 | LAMP2 | Lysosomal Membrane Glycoprotein, 110kD | Lysosomal Membrane Glycoprotein, 110kDa | Lysosomal-Associated Membrane Protein B | Lysosome-Associated Membrane Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890424","SOCS2 wt Allele","C116026","Human SOCS2 wild-type allele is located within 12q and is approximately 14 kb in length. This allele, which encodes suppressor of cytokine signaling 2 protein, plays a role in the negative regulation of cytokine signaling pathways.","SOCS2 wt Allele | CIS2 | Cish2 | SOCS-2 | SSI-2 | SSI2 | STATI2 | Suppressor of Cytokine Signaling 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0540340","Suppressor of Cytokine Signaling 2, Human","C116027","Suppressor of cytokine signaling 2 (198 aa, ~22 kDa) is encoded by the human SOCS2 gene. This protein is involved in the modulation of cytokine signaling.","Suppressor of Cytokine Signaling 2 | CIS-2 | Cytokine-Inducible SH2 Protein 2 | SOCS-2 | SSI-2 | STAT Induced STAT Inhibitor-2 | STAT-Induced STAT Inhibitor 2 | STAT-Induced STAT Inhibitor-2 | Suppressor of Cytokine Signaling-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898989","IC50 Fold Change from Baseline","C116250","A fold change based on a concentration of a specific drug expected to produce 50% inhibition of the standard growth of a viral organism, or of a biological/biochemical reaction. It is a ratio calculated by the current IC50 Treatment Result divided by the IC50 Treatment Result from the baseline visit.","Viral Half Maximal Inhibitory Concentration Fold Change from Baseline Measurement | IC50 Fold Change from Baseline",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900182","IC95 Treatment Result","C116251","A measurement of titer of a viral organism or biological/biochemical reaction that has been exposed to a concentration of a specific drug expected to produce 95% inhibition of the standard growth of the viral organism, or of a reaction.","Viral 95 Percent Maximal Inhibitory Concentration Subject Result Measurement | IC95 Treatment Result",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900184","IC95 Fold Change from Reference","C116253","A fold change based on a concentration of a specific drug expected to produce 95% inhibition of the standard growth of a viral organism, or of a biological/biochemical reaction. It is a ratio calculated by the IC95 Treatment Result divided by the IC95 Reference Control Result.","Viral 95 Percent Maximal Inhibitory Concentration Fold Change from Reference Measurement | IC95 Fold Change from Reference",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900185","IC95 Fold Change from Baseline","C116254","A fold change based on a concentration of a specific drug expected to produce 95% inhibition of the standard growth of a viral organism, or of a biological/biochemical reaction. It is a ratio calculated by the current IC95 Treatment Result divided by the IC95 Treatment Result from the baseline visit.","Viral 95 Percent Maximal Inhibitory Concentration Fold Change from Baseline Measurement | IC95 Fold Change from Baseline",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1308021","Arfaptin-1, Human","C114683","Arfaptin-1 (373 aa, ~42 kDa) is encoded by the human ARFIP1 gene. This protein may be involved in intracellular vesicle trafficking.","Arfaptin-1 | ADP-Ribosylation Factor-Interacting Protein 1 | ARFIP1 | Arfaptin 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1540194","AGPAT5 Gene","C114687","This gene plays a role in phospholipid metabolism.","AGPAT5 Gene | 1-Acylglycerol-3-Phosphate O-Acyltransferase 5 Gene | AGPAT5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889154","AGPAT5 wt Allele","C114689","Human AGPAT5 wild-type allele is located in the vicinity of 8p23.1 and is approximately 53 kb in length. This allele, which encodes 1-acyl-sn-glycerol-3-phosphate acyltransferase epsilon protein, is involved in lysophosphatidic acid metabolism.","AGPAT5 wt Allele | 1-Acylglycerol-3-Phosphate O-Acyltransferase 5 (Lysophosphatidic Acid Acyltransferase, Epsilon) Gene | 1-Acylglycerol-3-Phosphate O-Acyltransferase 5 wt Allele | 1AGPAT5 | FLJ11210 | LPAAT-Epsilon | LPAAT-e | LPAATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3888276","1-Acyl-Sn-Glycerol-3-Phosphate Acyltransferase Epsilon, human","C114690","1-acyl-sn-glycerol-3-phosphate acyltransferase epsilon (364 aa, ~42 kDa) is encoded by the human AGPAT5 gene. This protein plays a role in the synthesis of phosphatidic acid from lysophosphatidic acid.","1-Acyl-Sn-Glycerol-3-Phosphate Acyltransferase Epsilon | 1-AGP Acyltransferase 5 | 1-AGPAT 5 | 1-Acyl-Sn-Glycerol-3-Phosphate O-Acyltransferase 5 | 1-Acylglycerol-3-Phosphate O-Acyltransferase 5 | EC 2.3.1.51 | LPAAT-Epsilon | Lysophosphatidic Acid Acyltransferase Epsilon | Lysophosphatidic Acid Acyltransferase, Epsilon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890221","ASIC2 wt Allele","C114693","Human ASIC2 wild-type allele is located in the vicinity of 17q12 and is approximately 1162 kb in length. This allele, which encodes acid-sensing ion channel 2 protein, plays a role in the modulation of membrane potential through proton-gated cation transport.","ASIC2 wt Allele | ACCN | ACCN1 | ASIC2a | Acid-Sensing (Proton-Gated) Ion Channel 2 wt Allele | BNC1 | BNaC1 | Cation Channel, Amiloride-Sensitive, Neuronal, 1 Gene | MDEG | Mammalian Degenerin Gene | Sodium Channel, Nonvoltage-Gated, Neuronal, 1 Gene | hBNaC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041952","Ureterolithiasis","C114696","The presence of a calculus in the ureter of the kidney; this is most often composed of mineral salts and proteins.","Ureterolithiasis | ",,,,,,,,,,,,,,,"201916","Ureteric stone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1743434","Acid-Sensing Ion Channel 2, Human","C114697","Acid-sensing ion channel 2 (512 aa, ~58 kDa) is encoded by the human ASIC2 gene. This protein is involved in both synaptic transmission and cation transport.","Acid-Sensing Ion Channel 2 | ASIC2 | Amiloride-Sensitive Brain Sodium Channel | Amiloride-Sensitive Cation Channel 1, Neuronal | Amiloride-Sensitive Cation Channel Neuronal 1 | BNC1 | BNaC1 | Brain Sodium Channel 1 | Degenerin | Mammalian Degenerin Homolog | Neuronal Amiloride-Sensitive Cation Channel 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028961","Oliguria","C114698","Abnormally low urine output.","Oliguria | Decreased Urine Output",,,,,,,,,,,,,,,"4306451","Oliguria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL473308","Dendritic Cell-targeting Lentiviral Vector ID-LV305","C115976","An engineered lentiviral vector targeting dendritic cells (DCs) and containing nucleic acids encoding for the human tumor-associated cancer-testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, the DC-targeting lentiviral vector ID-LV305 targets and binds to dermal DCs via the DC-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) receptor. Upon internalization of the vector, the NY-ESO-1 protein is expressed, stimulates DC maturation and activates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against NY-ESO-1-expressing cells, which may result in tumor cell lysis. NY-ESO-1 is expressed in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival.","Dendritic Cell-targeting Lentiviral Vector ID-LV305 | DCvex-NY-ESO-1 | ID-LV305",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4278057","Larotrectinib","C115977","An orally available, tropomyosin receptor kinase (Trk) inhibitor, with potential antineoplastic activity. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Trk, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.","Larotrectinib | 1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)- | 3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide | ARRY 470 | LAROTRECTINIB | LOXO 101 | LOXO-101 | LOXO101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473310","Fluorine 18 F Fludarabine","C115978","A radiopharmaceutical containing the purine analog fludarabine that is labeled with the radioisotope fluorine F18 with potential use as a tumor imaging agent upon positron emission tomography (PET). After intravenous administration, the fludarabine is selectively taken up by tumor cells. The radioisotope moiety is detected using PET, which allows imaging and quantification of both the biodistribution of fludarabine and the presence of tumor cells. This could identify tumors and select patients that will likely respond to fludarabine treatment.","Fluorine 18 F Fludarabine | 18F-Fludarabine | 2-[(18)F]fludarabine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473311","HLA-DP0401/0402-Restricted MAGE-A3-Reactive T Cell Receptor-transduced Autologous T Cells","C115979","Human autologous T-lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the human leukocyte antigen (HLA)-DP0401/0402-restricted, melanoma antigen A3 (MAGE-A3), with potential antineoplastic activity. CD4-positive cells are isolated from a patient, transduced with an anti-MAGE-A3-DP0401/0402 restricted TCR, expanded ex vivo, and reintroduced into the HLA-DP0401/0402 positive patient. Then, the HLA-DP0401/0402-restricted, MAGE-A3-reactive TCR-transduced autologous T cells bind to tumor cells expressing the MAGE-A3 antigen, which may result in both an inhibition of growth and increased cell death for MAGE-A3-expressing cancer cells. The tumor-associated antigen MAGE-A3 is overexpressed by a variety of cancer cell types.","HLA-DP0401/0402-Restricted MAGE-A3-Reactive T Cell Receptor-transduced Autologous T Cells | Anti-MAGE-A3-DP4 TCR PBL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473312","Gallium Ga 68-DOTA-exendin-4","C115980","A radiopharmaceutical composed of the glucagon-like peptide 1 receptor (GLP-1R) agonist exendin-4 linked by the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to the positron-emitting radionuclide gallium Ga 68, with potential use in diagnostic imaging upon positron emission tomography (PET). Upon administration of gallium Ga 68-DOTA-exendin-4, the exendin-4 moiety binds to GLP-1R and is subsequently internalized. The radionuclide moiety can be detected using PET and GLP-1R-expressing tumors can be localized. GLP-1R, located on beta cells, is overexpressed on insulinomas, which are insulin-secreting neuroendocrine tumors.","Gallium Ga 68-DOTA-exendin-4 | 68Ga-DOTA-exendin-4 | [Lys40(Ahx-DOTA-68Ga)NH2]-exendin-4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473313","Indium In 111-DOTA-exendin-4","C115981","A radiopharmaceutical composed of the glucagon-like peptide 1 receptor (GLP-1R) agonist exendin-4 linked by the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to the positron-emitting radionuclide indium In 111, with potential use in diagnostic imaging upon positron emission tomography (PET). Upon administration of indium In 111-DOTA-exendin-4, the exendin-4 moiety binds to GLP-1R and is subsequently internalized. The radionuclide moiety can be detected using PET and GLP-1R-expressing tumors can be localized. GLP-1R, located on beta cells, is overexpressed on insulinomas, which are insulin-secreting neuroendocrine tumors.","Indium In 111-DOTA-exendin-4 | 111In-DOTA-exendin-4 | [Lys40(Ahx-DOTA-111In)NH2]-exendin-4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538266","ALPK2 Gene","C115982","This gene is involved in protein phosphorylation.","ALPK2 Gene | ALPK2 | Alpha-Kinase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1541468","Adult Grade III Lymphomatoid Granulomatosis","C115150","Grade III lymphomatoid granulomatosis that occurs in adulthood.","Adult Grade III Lymphomatoid Granulomatosis | Grade III Lymphomatoid Granulomatosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446663","Adult Myelodysplastic Syndrome","C115153","Myelodysplastic syndrome that occurs in adulthood.","Adult Myelodysplastic Syndrome | Myelodysplastic Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1879279","adult nasal type extranodal NK/T-cell lymphoma","C115154","Nasal type extranodal NK/T-cell lymphoma that occurs in adulthood.","Adult Nasal Type Extranodal NK/T-Cell Lymphoma | Nasal Type Extranodal NK/T-Cell Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890714","SYNJ1 wt Allele","C114738","Human SYNJ1 wild-type allele is located in the vicinity of 21q22.2 and is approximately 99 kb in length. This allele, which encodes synaptojanin-1 protein, is involved in the modulation of clathrin-coated vesicle endocytosis. Mutation of the gene is associated with early onset Parkinson disease 20.","SYNJ1 wt Allele | INPP5G | Inositol 5'-Phosphatase (Synaptojanin 1) Gene | KIAA0910 | PARK20 | Synaptojanin 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2002111","Synaptojanin-1, Human","C114739","Synaptojanin-1 (1573 aa, ~173 kDa) is encoded by the human SYNJ1 gene. This protein plays a role in vesicle endocytosis.","Synaptojanin-1 | EC 3.1.3.36 | SYNJ1 | Synaptic Inositol 1,4,5-Trisphosphate 5-Phosphatase 1 | Synaptic Inositol-1,4,5-Trisphosphate 5-Phosphatase 1 | Synaptojanin 1 | Synaptojanin-1, Polyphosphoinositide Phosphatase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421767","ZNF281 Gene","C114740","This gene is involved in both transcriptional repression and cell differentiation.","ZNF281 Gene | ZNF281 | Zinc Finger Protein 281 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889447","ZNF281 wt Allele","C114741","Human ZNF281 wild-type allele is located in the vicinity of 1q32.1 and is approximately 4 kb in length. This allele, which encodes zinc finger protein 281, plays a role in the regulation of cell differentiation and the modulation of gene transcription.","ZNF281 wt Allele | GZP1 | ZBP-99 | ZBP99 | ZNP-99 | Zinc Finger Protein 281 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0770066","Zinc Finger Protein 281, Human","C114742","Zinc finger protein 281 (895 aa, ~97 kDa) is encoded by the human ZNF281 gene. This protein is involved in the modulation of both gene expression and cell differentiation.","Zinc Finger Protein 281 | GC-Box-Binding Zinc Finger Protein 1 | Transcription Factor ZBP-99 | ZNF281 | ZNP-99 Transcription Factor | Zinc Finger DNA-Binding Protein 99",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889696","BCL2L12 wt Allele","C114744","Human BCL2L12 wild-type allele is located in the vicinity of 19q13.3 and is approximately 9 kb in length. This allele, which encodes Bcl-2-like protein 12, plays a role in the negative regulation of apoptosis. Aberrant expression of the gene is associated with various cancers.","BCL2L12 wt Allele | BCL2-Like 12 (Proline Rich) wt Allele | BCL2-Like 12 Gene | BPR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473416","Bioanalytical Validation Method","C115542","A process that ensures the use of selective, sensitive, and validated analytical methods for the quantitative evaluation of drugs and their metabolites (analytes) and biomarkers, for the successful conduction of nonclinical and/or clinical trials.","Bioanalytical Validation Method | BVM | Bioanalytical Validation Methods | Method validation | precision testing | quality control testing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889982","Taxonomy Category Name","C115543","The preferred word(s) used to describe a taxonomic category.","Taxonomy Category Name | Category Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899582","Clinical Trial Investigator Newsletter","C115544","Documentation that informs investigative staff of common implementation issues and the progress of the clinical trial.","Clinical Trial Investigator Newsletter Documentation | Clinical Trial Investigator Newsletter | Inv Newsltr | Investigator Newsletter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890433","Central Clinical Trial Filenote","C115546","A notation that describes the decisions, and/or clarification of any information pertaining to the central trial.","Central Clinical Trial Filenote | CTrial Flnote | Central Trial Filenote | Filenote",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899576","Clinical Trial Management Filenote","C115547","A notation that describes the decisions, and/or clarification of any information pertaining to the clinical trial management.","Clinical Trial Management Filenote | General Trial Filenotes | Trial Filenote | Trial Flnote",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889411","Clinical Trial Regulatory Filenote","C115548","A notation that describes any regulatory decisions, and/or clarification of any information in a clinical trial.","Clinical Trial Regulatory Filenote | Filenote | Reg Flnote | Regulatory Filenote",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890434","Clinical Trial Site Management Filenote","C115549","A notation that describes any decisions or clarifications of information pertaining to the site management of a clinical trial.","Clinical Trial Site Management Filenote | Filenote | Site Management Filenote | Site Mgmt Flnote",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898756","Institutional Review Board - Independent Ethics Committee Filenote","C115550","A notation that describes any decisions or clarifications of information pertaining to the Institutional Review Board (IRB)-Independent Ethics Committee (IEC).","Institutional Review Board - Independent Ethics Committee Filenote | IRB-IEC Filenote | IRB-IEC Flnote",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1541469","Recurrent Adult Grade III Lymphomatoid Granulomatosis","C115349","The reemergence of grade III lymphomatoid granulomatosis in adulthood after a period of remission.","Recurrent Adult Grade III Lymphomatoid Granulomatosis | Recurrent Grade III Lymphomatoid Granulomatosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054114","Recurrent Adult Undifferentiated High Grade Pleomorphic Sarcoma of Bone","C115351","The reemergence of undifferentiated high grade pleomorphic sarcoma of bone in adulthood after a period of remission.","Recurrent Adult Undifferentiated High Grade Pleomorphic Sarcoma of Bone | Recurrent Adult Undifferentiated High Grade Pleomorphic Sarcoma | Recurrent Undifferentiated High Grade Pleomorphic Sarcoma of Bone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL376175","Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor","C115352","The reemergence of borderline ovarian epithelial tumor after a period of remission.","Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890742","H1.4","C115354","Human H1-4 wild-type allele is located in the vicinity of 6p21.3 and is approximately 1 kb in length. This allele, which encodes histone H1.4 protein, plays a role in chromatin structure.","H1-4 wt Allele | H1 Histone Family, Member 4 Gene | H1 Histone Family, Member 4, Formerly Gene | H1 Histone Family, Member E Gene | H1.4 | H1.4 Linker Histone, Cluster Member wt Allele | H1E | H1F4 | H1s-4 | HIST1 Cluster, H1E Gene | HIST1H1E | Histone 1, H1e Gene | Histone Cluster 1, H1e Gene | Histone Gene Cluster 1, H1 Gene | Histone Gene Cluster 1, H1E Gene | dJ221C16.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433902","Recurrent Childhood Anaplastic Astrocytoma","C115356","The reemergence of anaplastic astrocytoma in childhood after a period of remission.","Recurrent Childhood Anaplastic Astrocytoma | Recurrent Anaplastic Astrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL376206","Recurrent Childhood Anaplastic Large Cell Lymphoma","C115357","The reemergence of anaplastic large cell lymphoma in childhood after a period of remission.","Recurrent Childhood Anaplastic Large Cell Lymphoma | Recurrent Anaplastic Large Cell Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433949","Recurrent Childhood Anaplastic Oligoastrocytoma","C115358","The reemergence of anaplastic oligoastrocytoma in childhood after a period of remission.","Recurrent Childhood Anaplastic Oligoastrocytoma | Recurrent Anaplastic Oligoastrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433924","Recurrent Childhood Anaplastic Oligodendroglioma","C115359","The reemergence of anaplastic oligodendroglioma in childhood after a period of remission.","Recurrent Childhood Anaplastic Oligodendroglioma | Recurrent Anaplastic Oligodendroglioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433915","Recurrent Childhood Diffuse Astrocytoma","C115360","The reemergence of diffuse astrocytoma in childhood after a period of remission.","Recurrent Childhood Diffuse Astrocytoma | Recurrent Diffuse Astrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433904","Recurrent Childhood Fibrillary Astrocytoma","C115361","The reemergence of fibrillary astrocytoma in childhood after a period of remission.","Recurrent Childhood Fibrillary Astrocytoma | Recurrent Fibrillary Astrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433907","Recurrent Childhood Gemistocytic Astrocytoma","C115362","The reemergence of gemistocytic astrocytoma in childhood after a period of remission.","Recurrent Childhood Gemistocytic Astrocytoma | Recurrent Gemistocytic Astrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889698","ALPK2 wt Allele","C115983","Human ALPK2 wild-type allele is located in the vicinity of 18q21.31 and is approximately 148 kb in length. This allele, which encodes alpha-protein kinase 2 protein, plays a role in the phosphorylation of serines and threonines in alpha-helical proteins.","ALPK2 wt Allele | Alpha-Kinase 2 wt Allele | HAK | Heart Alpha-Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3493756","Alpha-Protein Kinase 2, Human","C115984","Alpha-protein kinase 2 (2170 aa, ~237 kDa) is encoded by the human ALPK2 gene. This protein is involved in serine/threonine phosphorylation.","Alpha-Protein Kinase 2 | ALPK2 | EC 2.7.11.- | Heart Alpha-Kinase | Heart Alpha-Protein Kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0066142","Metoprine","C1161","A diaminopyrimidine folate antagonist with potential antineoplastic activity.  Metoprine inhibits dihydrofolate reductase, resulting in decreased cellular folate metabolism and cell growth; it also inhibits histamine-N-methyltransferase, resulting in decreased histamine catabolism. Lipid-soluble metoprine is capable of crossing the blood-brain barrier. (NCI04)","Metoprine | BW 197U | DDMP | METOPRINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1309992","Bcl-2-Like Protein 12, Human","C114745","Bcl-2-like protein 12 (334 aa, ~37 kDa) is encoded by the human BCL2L12 gene. This protein is involved in the inhibition of apoptosis.","Bcl-2-Like Protein 12 | Bcl-2 Related Proline-Rich Protein | Bcl-2-Related Proline-Rich Protein | Bcl2-L-12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898045","PDK4 wt Allele","C114747","Human PDK4 wild-type allele is located in the vicinity of 7q21.3 and is approximately 13 kb in length. This allele, which encodes [pyruvate dehydrogenase [lipoamide]] kinase isozyme 4, mitochondrial protein, is involved in the modulation of pyruvate dehydrogenase activity.","PDK4 wt Allele | PDHK4 | Pyruvate Dehydrogenase Kinase, Isoenzyme 4 Gene | Pyruvate Dehydrogenase Kinase, Isozyme 4 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2000214","PDK4 protein, human","C114748","[Pyruvate dehydrogenase [lipoamide]] kinase isozyme 4, mitochondrial (411 aa, ~46 kDa) is encoded by the human PDK4 gene. This protein plays a role in the inhibition of pyruvate dehydrogenase activity.","[Pyruvate Dehydrogenase [Lipoamide]] Kinase Isozyme 4, Mitochondrial | EC 2.7.11.2 | PDK4 | Pyruvate Dehydrogenase Kinase Isoform 4 | Pyruvate Dehydrogenase, Lipoamide, Kinase Isozyme 4, Mitochondrial | [Pyruvate Dehydrogenase (Acetyl-Transferring)] Kinase Isozyme 4, Mitochondrial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899638","Childhood Undifferentiated Pleomorphic Sarcoma","C114749","An undifferentiated pleomorphic sarcoma that occurs during childhood.","Childhood Undifferentiated Pleomorphic Sarcoma | Childhood Malignant Fibrous Histiocytoma | Childhood Unclassified Pleomorphic Sarcoma | Undifferentiated Pleomorphic Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL336909","Childhood Undifferentiated High Grade Pleomorphic Sarcoma of Bone","C114750","An undifferentiated high grade pleomorphic sarcoma that arises from the bone and occurs during childhood.","Childhood Undifferentiated High Grade Pleomorphic Sarcoma of Bone | Childhood Malignant Fibrous Histiocytoma of Bone | Childhood Undifferentiated High Grade Pleomorphic Sarcoma | Undifferentiated High Grade Pleomorphic Sarcoma of Bone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472583","Anti-HCV E2 Monoclonal Antibody MBL-HCV1","C114989","A neutralizing, human monoclonal antibody against the hepatitis C virus (HCV) E2 envelope glycoprotein, with potential immunomodulatory and antiviral activities against HCV. Upon administration, anti-HCV E2 monoclonal antibody MBL-HCV1 recognizes and binds to the E2 glycoprotein of HCV. This suppresses HCV load and provides passive immunization against HCV. This may prevent both infection by HCV in immunocompromised patients and hepatitis C-related liver disease. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family.","Anti-HCV E2 Monoclonal Antibody MBL-HCV1 | MBL-HCV1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896672","Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine","C114990","A cell-based vaccine composed of autologous-monocyte-derived dendritic cells (DCs) loaded with five immunogenic peptide epitopes, derived from the tumor-associated antigen human folate receptor alpha (FR alpha or FOLR1), including FR30, FR56, FR76, FR113, and FR238, with potential immunomodulatory and antineoplastic activity. Ex vivo treatment of the DCs with a p38 inhibitor decreases p38-mediated signaling and enhances ERK activation. This may allow, upon intradermal administration of the multi-epitope FR alpha-loaded DC vaccine into the patient, for decreased activation and expansion of CD4+ regulatory T-cells (Tregs), increased differentiation and expansion of interleukin-17 secreting T helper cells (Th17) and activation of CD8+ CTLs, which induces a strong anti-tumor T-cell immune response against FR alpha-overexpressing tumor cells. FR alpha is a high-affinity folate-binding protein and a member of the folate receptor family; this receptor is overexpressed in the majority of ovarian cancers and in about approximately 50% of breast cancers.","Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine | FRaDC Vaccine | FRalphaDC Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889274","Clinical Trial Notification of Safety Information","C115551","Documentation submitted to the regulatory authorities pertaining to any events that may impact the safety of subjects or the conduct of the clinical trial.","Clinical Trial Notification of Safety or Other Trial Information Documentation | Clinical Trial Notification of Safety Information | Notf Safe Info | Notification of Safety Information | Notification of Safety or Trial Information | Notification to Regulatory Authority of Safety/Trial Information | Safety Report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898737","Interactive Response Technology User Notification","C115552","Records of communications between the interactive response technology and the user.","Interactive Response Technology User Notification | IRT User Notf | IRT User Notifications | Interactive Response Technology User Notifications",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897458","Study Subject Nuclear Medicine Image","C115553","A nuclear medicine image taken of a study participant for use in a clinical trial.","Study Subject Nuclear Medicine Image | Study Subj NM | Study Subject Nuclear Medicine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899116","Final Analysis Output","C115554","Tables, listings, and figures output files generated from a final analysis for the clinical trial.","Clinical Trial Final Analysis Output Documentation | FinAnaly Output | Final Analysis Output | Final Analysis Output | Statistical Output",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898733","Interim Analysis Output","C115555","Tables, listings, and figures output files generated from an interim analysis for the clinical trial.","Clinical Trial Interim Analysis Output Documentation | IntAnaly Output | Interim Analysis Output | Interim Analysis Output | interim clinical trial/study report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899558","Clinical Trial Publication Policy","C115557","Documentation describing the publication of clinical trial results.","Clinical Trial Publication Policy Documentation | Clinical Trial Publication Policy | Publication Policy | Pubs Policy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890411","Clinical Trial Subject Questionnaire","C115559","Documentation used to capture specific subject related information through a series of questions.","Clinical Trial Subject Questionnaire Documentation | Clinical Trial Subject Questionnaire | Subj Quest Form | Subject Questionnaire | Subject Questionnaire Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433910","Recurrent Childhood Giant Cell Glioblastoma","C115363","The reemergence of giant cell glioblastoma in childhood after a period of remission.","Recurrent Childhood Giant Cell Glioblastoma | Recurrent Giant Cell Glioblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1432900","25-hydroxycholesterol 7-alpha-hydroxylase, Human","C114943","25-hydroxycholesterol 7-alpha-hydroxylase (506 aa, ~58 kDa) is encoded by the human CYP7B1 gene. This protein plays a role in the conversion of cholesterol into bile acids.","25-Hydroxycholesterol 7-Alpha-Hydroxylase | CYP7B1 | Cytochrome P450 7B1 | Cytochrome P450 Family 7 Subfamily B Polypeptide 1 | EC 1.14.13.100 | Oxysterol 7-Alpha-Hydroxylase | Oxysterol 7-Alpha-Hydroxylase 1 | Oxysterol 7alpha-Hydroxylase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1611725","Leukemic Infiltration of Brain","C114944","A finding indicating the presence of leukemic cell infiltrates in the brain tissue.","Leukemic Infiltration of Brain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890604","ATAD5 wt Allele","C114946","Human ATAD5 wild-type allele is located in the vicinity of 17q11.2 and is approximately 64 kb in length. This allele, which encodes ATPase family AAA domain-containing protein 5, plays a role in the cellular response to DNA damage.","ATAD5 wt Allele | ATPase Family, AAA Domain Containing 5 wt Allele | ATPase Family, AAA Domain-Containing, Member 5 Gene | C17orf41 | Chromosome 17 Open Reading Frame 41 Gene | Chromosome Fragility Associated Gene 1 | ELG1 | Enhanced Level Of Genomic Instability 1 Homolog (S. Cerevisiae) Gene | FLJ12735 | FRAG1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897871","Postterm Infant","C114947","An age group comprised of infants greater than or equal to 42 weeks, 0 days gestational age.","Postterm Infant | Post Dates | Postmature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472561","ATPase Family AAA Domain-Containing Protein 5","C114948","ATPase family AAA domain-containing protein 5 (1844 aa, ~208 kDa) is encoded by the human ATAD5 gene. This protein is involved in the DNA damage checkpoint.","ATPase Family AAA Domain-Containing Protein 5 | ATAD5 | Chromosome Fragility-Associated Gene 1 Protein | Enhanced Level of Genomic Instability 1 Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL416259","Secondary Central Nervous System Hodgkin Lymphoma","C114949","A Hodgkin lymphoma that has spread to the central nervous system following the initial presentation in another nodal or extranodal site.","Secondary Central Nervous System Hodgkin Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL416260","Secondary Central Nervous System Non-Hodgkin Lymphoma","C114950","A non-Hodgkin lymphoma that has spread to the central nervous system following the initial presentation in another nodal or extranodal site.","Secondary Central Nervous System Non-Hodgkin Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2046622","Central Nervous System Hodgkin Lymphoma","C114951","A Hodgkin lymphoma that arises from the central nervous system.","Central Nervous System Hodgkin Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414395","EN1 Gene","C114952","This gene plays a role in the regulation of both gene expression and embryo morphogenesis.","EN1 Gene | EN1 | Engrailed Homeobox 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899313","EN1 wt Allele","C114953","Human EN1 wild-type allele is located in the vicinity of 2q14.2 and is approximately 6 kb in length. This allele, which encodes homeobox protein engrailed-1, is involved in both embryonic morphogenesis and transcriptional regulation.","EN1 wt Allele | En-1 | Engrailed Homeobox 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899231","Experimental Organism Malignant Neuromyoblastoma","C116214","A malignant tumor that arises in the brain stem or adjacent cranial nerves, consisting of variable populations of cells which demonstrate both neuronal and myoblast differentiation. (INHAND)","Experimental Organism Malignant Neuromyoblastoma | NEUROMYOBLASTOMA, MALIGNANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899235","Experimental Organism Benign Acinar-islet Cell Tumor","C116215","A benign tumor of the pancreas with morphologic characteristics of endocrine, acinar and ductal cells. (INHAND)","Experimental Organism Benign Acinar-islet Cell Tumor | ACINAR-ISLET CELL TUMOR, BENIGN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899533","Clinical Trial Team Member Curriculum Vitae","C115489","Records detailing the education and work experience of a specific team member, sponsor and or other individual participating in a clinical trial.","Clinical Trial Team Member Curriculum Vitae | Trial Team CV | Trial Team Curriculum Vitae | Trial Team Member CV | Trial Tm CV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898636","Laboratory Director Curriculum Vitae","C115490","Records detailing the education and work experience of the director of the laboratory facility participating in the clinical trial.","Laboratory Director Curriculum Vitae | Head of Facility Curriculum Vitae | Lab Dir CV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899271","Electronic Data Capture Final Output","C115491","The final data output from the electronic data capture (EDC) system for a clinical study protocol.","Electronic Data Capture Final Output | EDC Fin Data | Final EDC Data",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890581","Final Analysis Dataset","C115492","Dataset files generated from a final analysis for the clinical trial.","Clinical Trial Final Analysis Datasets Documentation | Analysis Datasets | FinAnaly Datsets | Final Analysis Dataset | Final Analysis Datasets",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898734","Interim Analysis Dataset","C115493","Dataset files generated from an interim analysis for the clinical trial.","Clinical Trial Interim Analysis Datasets Documentation | IntAnaly Datasets | Interim Analysis Dataset | Interim Analysis Datasets",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897773","Raw Dataset for Final Analysis","C115494","The collection of unprocessed data records used for a final analysis of results for a clinical trial.","Raw Dataset for Final Analysis | FinAnaly Raw | Final Analysis Raw Datasets | Raw Datasets Final Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897772","Raw Dataset for Interim Analysis","C115495","The collection of unprocessed data records used for an interim analysis of results during a clinical trial.","Raw Dataset for Interim Analysis | IntAnaly Raw | Interim Analysis Raw Datasets",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897056","Study Subject Digital Photograph","C115496","A digital photograph taken of a study participant for use in a clinical trial.","Study Subject Digital Photograph | Study Subj DigPic | Study Subject Digital Photos",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899563","Clinical Trial Operation Documentation","C115497","Records of plans, policies, and procedures used in a clinical trial.","Clinical Trial Operation Documentation | Ops Subcat | Trial Operations Subcategory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899531","Clinical Trial Unblinding Documentation","C115498","Records pertaining to the reversal of randomization code to reveal a specific subject's trial group allocation data.","Clinical Trial Unblinding Documentation | Decoding Request | Randomization Release Request | Trial Unblind | Trial Unblinding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3888140","Computed Tomography Study File","C115499","A collection of computed tomography files pertaining to a clinical study.","Computed Tomography Study File | CT | Computed Tomography Subcategory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900102","Adult Fibrolamellar Carcinoma","C114992","A fibrolamellar carcinoma that occurs during adulthood.","Adult Fibrolamellar Carcinoma | Fibrolamellar Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900095","Adult Pleomorphic Hepatocellular Carcinoma","C114993","A hepatocellular pleomorphic carcinoma that occurs during adulthood.","Adult Hepatocellular Pleomorphic Carcinoma | Adult Pleomorphic Hepatocellular Carcinoma | Adult Pleomorphic Hepatocellular Carcinoma | Pleomorphic Hepatocellular Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412403","ANK2 Gene","C114995","This gene plays a role in both cytoskeletal structure and muscle contraction.","ANK2 Gene | ANK2 | Ankyrin 2, Neuronal Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889159","ANK2 wt Allele","C114996","Human ANK2 wild-type allele is located within 4q25-q27 and is approximately 566 kb in length. This allele, which encodes ankyrin-2 protein, is involved in both neuromuscular junction formation and cytoskeletal remodeling. Mutation of the gene is associated with long QT syndrome 4 and ankyrin-B-related cardiac arrhythmia.","ANK2 wt Allele | ANK-2 | Ankyrin 2, Neuronal wt Allele | Ankyrin, Brain Gene | Ankyrin, Neuronal Gene | Ankyrin, Nonerythroid Gene | Ankyrin-2, Nonerythrocytic Gene | LQT4 | Long (Electrocardiographic) QT Syndrome 4 Gene | brank-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1452342","Ankyrin-2, Human","C114997","Ankyrin-2 (3957 aa, ~434 kDa) is encoded by the human ANK2 gene. This protein plays a role in cytoskeletal remodeling.","Ankyrin-2 | ANK-2 | ANK2 | Ankyrin 2 | Ankyrin B | Ankyrin-B | Brain Ankyrin | Non-Erythroid Ankyrin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425785","POGZ Gene","C114998","This gene is involved in mitosis.","POGZ Gene | POGZ | Pogo Transposable Element With ZNF Domain Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889406","POGZ wt Allele","C114999","Human POGZ wild-type allele is located in the vicinity of 1q21.3 and is approximately 57 kb in length. This allele, which encodes pogo transposable element with ZNF domain protein, plays a role in the progression of mitosis.","POGZ wt Allele | Nbla00003 | Pogo Transposable Element With ZNF Domain wt Allele | SUHW5 | ZNF280E | ZNF635 | ZNF635m",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472326","Iodine I 124-labeled Anti-PSCA A11 Minibody","C114501","A radioconjugate composed of an affinity-matured antibody fragment, the A11 minibody, directed against human prostate stem cell antigen (PSCA), and conjugated with the radioisotope iodine I 124, that can potentially be used as an imaging agent for positron emission tomography (PET)/computed tomography (CT). The minibody moiety of iodine I 124-labeled anti-PSCA A11 minibody selectively targets and binds to PSCA. The PSCA-expressing tumor cells can then be visualized using PET/CT. PSCA, a cell surface antigen expressed in normal human prostate and bladder, is overexpressed in a variety of cancers, including bladder, pancreatic, and prostate cancer. The A11 minibody is formed by the fusion of a single chain Fv fragment with the immunoglobulin G1 CH3 domain.","Iodine I 124-labeled Anti-PSCA A11 Minibody | 124I-A11 PSCA Minibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0065904","Recombinant GRO1 Protein","C1157","A recombinant peptide chemically identical or similar to the endogenous alpha chemokine GRO1 (MGSA) protein. GRO1 protein belongs to a superfamily of proteins that includes interleukin-8 and platelet factor-4, beta-thromboglobulin (b-TG), IP-10, and ENA-78. It is chemotactic for neutrophils and plays a role in endothelial angiogenesis.","Recombinant GRO1 Protein | GRO Protein, Alpha | GRO1 Protein | MGSA | Melanoma Growth Stimulatory Activity | Neutrophil Activating Protein 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900194","6MWT - Distance at 2 Minutes","C115801","6 Minute Walk Test (6MWT) Distance at 2 minutes.","6MWT - Distance at 2 Minutes | SIXMW1-Distance at 2 Minutes | SIXMW102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900193","6MWT - Distance at 3 Minutes","C115802","6 Minute Walk Test (6MWT) Distance at 3 minutes.","6MWT - Distance at 3 Minutes | SIXMW1-Distance at 3 Minutes | SIXMW103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900192","6MWT - Distance at 4 Minutes","C115803","6 Minute Walk Test (6MWT) Distance at 4 minutes.","6MWT - Distance at 4 Minutes | SIXMW1-Distance at 4 Minutes | SIXMW104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900191","6MWT - Distance at 5 Minutes","C115804","6 Minute Walk Test (6MWT) Distance at 5 minutes.","6MWT - Distance at 5 Minutes | SIXMW1-Distance at 5 Minutes | SIXMW105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900190","6MWT - Distance at 6 Minutes","C115805","6 Minute Walk Test (6MWT) Distance at 6 minutes.","6MWT - Distance at 6 Minutes | SIXMW1-Distance at 6 Minutes | SIXMW106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899003","HAI - Ambulation Index","C115806","Hauser Ambulation Index (HAI) Ambulation index.","HAI - Ambulation Index | HAI01-Ambulation Index | HAI0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898195","NHPT - Time to Complete 9-Hole Peg Test","C115807","Nine-Hole Peg Test (NHPT) Time in seconds to complete 9-Hole Peg Test.","NHPT - Time to Complete 9-Hole Peg Test | NHPT01-Time to Complete 9-Hole Peg Test | NHPT0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898196","NHPT - More Than Two Attempts","C115808","Nine-Hole Peg Test (NHPT) Did it take more than two attempts to get two successful trials?","NHPT - More Than Two Attempts | NHPT01-More Than Two Attempts | NHPT0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889693","CLEC2A wt Allele","C116029","Human CLEC2A wild-type allele is located in the vicinity of 12p13.31 and is approximately 34 kb in length. This allele, which encodes C-type lectin domain family 2 member A protein, is involved in cell-mediated immunity.","CLEC2A wt Allele | C-Type Lectin Domain Family 2, Member A wt Allele | INPE5792 | KACL | PILAR | UNQ5792 | UNQ5792/PRO19597",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889641","C-Type Lectin Domain Family 2 Member A, Human","C116030","C-type lectin domain family 2 member A (174 aa, ~20 kDa) is encoded by the human CLEC2A gene. This protein plays a role in both T-cell functionality and natural killer cell-mediated cytotoxicity.","C-Type Lectin Domain Family 2 Member A | KACL | Keratinocyte-Associated C-Type Lectin | PILAR | Proliferation-Induced Lymphocyte-Associated Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL421590","Malignant Biliary Obstruction","C114954","Blockage in the biliary tract caused by a malignant neoplasm.","Malignant Biliary Obstruction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897758","Recurrent Childhood Astrocytic Tumor","C114956","The reemergence of a childhood astrocytic tumor after a period of remission.","Recurrent Childhood Astrocytic Tumor | Recurrent Astrocytic Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415537","HHEX Gene","C114957","This gene is involved in transcriptional modulation.","HHEX Gene | HHEX | Hematopoietically Expressed Homeobox Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472634","Dioscorea nipponica Makino Extract DNE3","C115103","An extract of the plant Dioscorea nipponica Makino and inhibitor of both the serine/threonine protein kinase Akt (protein kinase B) and members of the phosphatidylinositol 3-kinase (PI3K) family of lipid kinases, with potential antineoplastic and anti-metastatic activities. Dioscorea nipponica Makino extracted with ethyl acetate (DNE3) binds to and inhibits PI3K and Akt. This inhibits PI3K/Akt-mediated signaling and prevents both growth and survival of PI3K/Akt-overexpressing tumor cells. In addition, DNE3 increases the expression of tissue inhibitor of metalloproteinase-2 (TIMP-2), inhibits the secretion of matrix metalloproteinases (MMPs), primarily MMP-2 and MMP-9, and inhibits the serine protease urokinase (urokinase-type plasminogen activator; u-PA). This inhibits tumor cell invasion, migration, motility, and adhesion. This agent also inhibits the activation of both cAMP response element-binding (CREB) and activating protein-1 (AP-1), and increases the expression of IkappaB (IkB), which inhibits the activation of nuclear factor-kappa B (NF-kB). These processes further contribute to this agent's anti-tumor potential in susceptible tumor cells.","Dioscorea nipponica Makino Extract DNE3 | DNE3 | Dioscorea nipponica Extract with Ethyl Acetate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472635","Fluorescent cRGDY PEG-Cy5.5 C Dots","C115104","An imaging agent composed of silica-based nanoparticles labeled with a near-infrared (NIR) fluorophore, Cyanine 5.5 (Cy5.5) and surrounded by polyethylene glycol (PEG) chains attached to cyclo-[Arg-Gly-Asp-Tyr] (cRGDY) peptides, with potential use as a tumor-selective fluorescent imaging agent. Upon intradermal administration of the fluorescent cRGDY PEG-Cy5.5 C dots, the cRGD moiety selectively binds to alphaVbeta3 integrin expressed on tumor cells. Upon intraoperative fluorescence imaging, alphaVbeta3-expressing tumor cells can be visualized and the degree of both tumor metastasis and sentinel lymph node (SLN) trafficking can be assessed. Integrins are transmembrane glycoproteins upregulated on proliferating tumor vessel endothelial cells and various cancer cells; their overexpression has been associated with neovascularization, differentiation, proliferation of tumor cells, metastasis and an overall poor prognosis.","Fluorescent cRGDY PEG-Cy5.5 C Dots | cRGDY-PEG-Cy5.5-C Dots",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472636","Ovarian Tumor Antigen-activated Autologous Dendritic Cell Vaccine","C115105","A dendritic cell (DC)-based cancer vaccine composed of autologous dendritic cells (DCs) activated with an ovarian tumor cell lysate containing tumor-associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, the ovarian tumor antigen-activated autologous DC vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against ovarian cancer cells expressing ovarian tumor cell-specific antigens, which may result in ovarian tumor cell lysis.","Ovarian Tumor Antigen-activated Autologous Dendritic Cell Vaccine | DCVAC/OvCa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472637","prostate tumor antigen-activated autologous dendritic cell vaccine","C115106","A dendritic cell (DC)-based cancer vaccine composed of autologous dendritic cells (DCs) activated with a prostate tumor cell lysate containing tumor-associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, stapuldencel-T  may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against prostate cancer cells expressing prostate tumor cell-specific antigens, which may result in prostate tumor cell lysis.","Stapuldencel-T | DCVAC/PCa | Prostate Tumor Antigen-activated Autologous Dendritic Cell Vaccine | STAPULDENCEL | Stapuldencel-T ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472638","Allogeneic Multivirus-specific Cytotoxic T Lymphocytes","C115107","A population of closely human leukocyte antigen (HLA)-matched, donor-derived cytotoxic T lymphocytes (CTLs) that are specifically reactive towards five viruses, Epstein-Barr virus (EBV), cytomegalovirus (CMV), adenovirus (AdV), human herpesvirus 6 (HHV6), and human polyomavirus type I (BKV), with potential antiviral activity. Infusion of the multivirus-specific CTLs into allogeneic hematopoietic stem cell transplant (HSCT) recipients provides virus-specific cellular immunity and causes specific anti-viral effects against active viral infections. The administered CTLs also prevent EBV, CMV, AdV, HHV6, and BKV reactivation and infection as well as inhibiting viral-associated diseases in immunocompromised patients. The allogeneic multivirus-specific CTLs may also provide cellular immunity towards the human polyomavirus type II (JC virus; JCV), which is highly homologous to BKV.","Allogeneic Multivirus-specific Cytotoxic T Lymphocytes | Allogeneic EBV/CMV/AdV/HHV6/BKV-specific CTLs | Allogeneic Multivirus-specific CTLs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899375","Digital Photography Study File","C115500","A collection of digital photographs pertaining to a clinical study.","Digital Photography Study File | DigPic | Digital Photographs Subcategory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890166","Magnetic Resonance Imaging Study File","C115501","A collection of magnetic resonance image files pertaining to a clinical study.","Magnetic Resonance Imaging Study File | MRI | Magnetic Resonance Imaging Subcategory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890923","Nuclear Medicine Study File","C115502","A collection of nuclear medicine files pertaining to a clinical study.","Nuclear Medicine Study File | NM | Nuclear Medicine Subcategory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889164","Ultrasound Study File","C115503","A collection of ultrasound image files pertaining to a clinical study.","Ultrasound Study File | US | Ultrasound Subcategory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889991","Centralized Testing Filenote","C115504","A notation regarding the decisions, and/or clarification of any information pertaining to a centralized test.","Centralized Testing Filenote | Centralz Test Flnote | Filenote",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897201","Vendor Record Documentation","C115745","Records detailing the relationship between a vendor and a clinical trial sponsor, or contract research organization (CRO).","Vendor Record Documentation | Third Party Set-up | Vend Records Subcat | Vendor Records Subcategory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890565","Vendor Role and Responsibility Document","C115746","Records describing the tasks and responsibilities of a vendor in a clinical trial.","Vendor Role and Responsibility Document | Task Ownership Matrix | Technical Agreement | Transfer of Obligations | Transfer of Regulatory Obligation | Vend RR | Vendor Roles and Responsibilities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897200","Vendor Selection Process Document","C115747","Documentation describing the identification and selection of a vendor for the clinical trial.","Clinical Trial Vendor Selection Documentation | Contractor Selection | Vend Selectn | Vendor Selection | Vendor Selection Documents | Vendor Selection Process Document",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890383","Vendor Tracking Document","C115748","Records used to track activities pertaining to a vendor during the course of a clinical trial.","Vendor Tracking Document | Tracking Document | Vend Track Doc",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889688","Case Report Form Annotation Guideline","C115749","Documentation describing the process to map and assign subject information collected on the case report form into the proper structure of a dataset for the clinical trial.","Case Report Form Annotation Guideline Documentation | Annot CRF | Annotated CRF | Annotated Case Report Form | CRF Completion Guidelines | Case Report Form Annotation Guideline",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897057","Data Entry Guideline","C115751","Documentation describing the proper entry of data from a paper case report form (CRF) to a database.","Data Entry Guideline | DE Guidelines | Data Entry Guidelines",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899573","Clinical Trial Medical Monitoring Plan","C115752","Documentation describing the medical surveillance of subjects during the clinical trial.","Clinical Trial Medical Monitoring Plan Documentation | Clinical Trial Medical Monitoring Plan | Med Mon Plan | Medical Monitoring Plan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899571","Clinical Trial Monitoring Plan","C115753","Documentation describing the strategy, methods, responsibilities, and requirements for monitoring the clinical trial.","Clinical Trial Monitoring Plan Documentation | Clinical Monitoring Plan | Clinical Trial Monitoring Plan | Mon Plan | Monitoring Data Plan | Monitoring Plan | monitoring plan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899566","Clinical Trial Non-Investigational Product Supplies Plan","C115754","Documentation describing the supply management of the non-investigational product(s) and other supplies for the clinical trial.","Clinical Trial Non-Investigational Product Supplies Plan Documentation | Clinical Trial Non-Investigational Product Supplies Plan | Non-IP Supl Plan | Non-IP Supply Plan | Non-Investigational Product Supply Plan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899554","Clinical Trial Safety Management Plan","C115755","Documentation describing the safety evaluation process for investigational product(s) during the clinical trial.","Clinical Trial Safety Management Plan Documentation | Clinical Trial Safety Management Plan | Safe Mgmt Plan | Safety Management Plan | Safety Reporting Plan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899449","Data Management Plan","C115756","Documentation describing the overall data management process for the clinical trial.","Clinical Trial Data Management Plan Documentation | DM Plan | Data Management Operational Plan | Data Management Plan | Data Management Plan | Technology Plan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889727","Viral Interleukin-6 Homolog","C114503","Viral interleukin-6 homolog (204 aa, ~23 kDa) is encoded by the human herpesvirus 8 K2 gene. This protein is involved in the negative regulation of apoptosis and the positive regulation of both cell proliferation and cell differentiation.","Viral Interleukin-6 Homolog | Interleukin-6 Homolog | K2 | ORF K2 | Putative Interleukin 6 | Viral Interleukin-6 | vIL-6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0537408","ORF74 protein, Human herpesvirus 8","C114505","Viral G-protein coupled receptor (342 aa, ~39 kDa) is encoded by the human herpesvirus 8 ORF74 gene. This protein plays a role in the positive regulation of angiogenesis, cell migration, cell proliferation and cell survival.","Viral G-Protein Coupled Receptor | G Protein-Coupled Receptor | HHV8 G Protein-Coupled Receptor | IL-8 Receptor-Like G Protein Coupled Receptor Homolog | IL-8 Receptor-Like Protein | Protein ORF74 | Putative G-Protein Coupled Receptor | vGPCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0670710","DNA Polymerase Processivity Factor","C114507","DNA polymerase processivity factor (396 aa, ~42 kDa) is encoded by the human herpesvirus 8 ORF59 gene. This protein is involved in the replication of viral DNA.","DNA Polymerase Processivity Factor | Core Gene UL42 Family Protein | ORF 59 | ORF59",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889252","RBPJ wt Allele","C114509","Human RBPJ wild-type allele is located in the vicinity of 4p15.2 and is approximately 271 kb in length. This allele, which encodes recombining binding protein suppressor of hairless protein, is involved in both transcriptional regulation and intercellular communication. Mutation of the gene is associated with Adams-Oliver syndrome 3.","RBPJ wt Allele | AOS3 | CBF1 | IGKJRB | IGKJRB1 | KBF2 | RBP-J | RBPJK | RBPSUH | Recombination Signal Binding Protein For Immunoglobulin Kappa J Region wt Allele | Recombination Signal-Binding Protein Suppressor of Hairless, Drosophila, Homolog of Gene | Recombining Binding Protein Suppressor of Hairless (Drosophila) Gene | SUH | Suppressor of Hairless Homolog (Drosophila) Gene | csl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3888044","Nephrogenic Systemic Fibrosis","C115158","Fibrosis of the skin, joints and other organs usually associated with gadolinium exposure in the setting of kidney failure.","Nephrogenic Systemic Fibrosis | NSF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899350","Dislodged Peritoneal Dialysis Catheter","C115161","Malposition of a peritoneal dialysis catheter.","Dislodged Peritoneal Dialysis Catheter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890397","PRKAA1 wt Allele","C116032","Human PRKAA1 wild-type allele is located in the vicinity of 5p12 and is approximately 39 kb in length. This allele, which encodes 5'-AMP-activated protein kinase catalytic subunit alpha-1 protein, plays a role in the modulation of many cellular processes through the phosphorylation of metabolic enzymes and transcription regulatory proteins.","PRKAA1 wt Allele | AMP-Activated Protein Kinase, Catalytic, Alpha-1 Gene | AMP-Activated, Catalytic, Alpha-1 Gene | AMPK | AMPK1 | AMPKa1 | Protein Kinase, AMP-Activated, Alpha 1 Catalytic Subunit wt Allele | Protein Kinase, AMP-Activated, Catalytic, Alpha-1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1739697","PRKAA1 protein, human","C116033","5'-AMP-activated protein kinase catalytic subunit alpha-1 (559 aa, ~64 kDa) is encoded by the human PRKAA1 gene. This protein is involved in the phosphorylation of metabolic enzymes, transcription regulatory proteins and microtubule-associated protein tau.","5'-AMP-Activated Protein Kinase Catalytic Subunit Alpha-1 | 5'-AMP-Activated Protein Kinase, Catalytic Alpha-1 Chain | 5-AMP-Activated Protein Kinase Catalytic Subunit Alpha-1 | ACACA Kinase | AMP-Activated Protein Kinase Catalytic Subunit Alpha-1 | AMPK Subunit Alpha-1 | AMPK-Alpha-1 | Acetyl-CoA Carboxylase Kinase | EC 2.7.11.1 | EC 2.7.11.26 | EC 2.7.11.27 | EC 2.7.11.31 | HMGCR Kinase | Hydroxymethylglutaryl-CoA Reductase Kinase | Tau-Protein Kinase PRKAA1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889388","CES1 wt Allele","C116035","Human CES1 wild-type allele is located in the vicinity of 16q22.2 and is approximately 31 kb in length. This allele, which encodes liver carboxylesterase 1 protein, is involved in the metabolism of xenobiotics and aromatic and aliphatic esters. Mutation of the gene is associated with Carboxylesterase 1 deficiency.","CES1 wt Allele | ACAT | CE-1 | CEH | CES2 | Carboxylesterase 1 (Monocyte/Macrophage Serine Esterase 1) Gene | Carboxylesterase 1 wt Allele | Carboxylesterase 2 (Liver) Gene | Carboxylesterase 2, Formerly Gene | Carboxylesterase, Liver Gene | HMSE | HMSE1 | PCE-1 | REH | SES1 | TGH | hCE-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0073124","retinyl esterase","C116036","Liver carboxylesterase 1 (567 aa, ~63 kDa) is encoded by the human CES1 gene. This protein plays a role in the catabolism of drugs and aromatic and aliphatic esters.","Liver Carboxylesterase 1 | ACAT | Acyl Coenzyme A:Cholesterol Acyltransferase | Acyl-Coenzyme A:Cholesterol Acyltransferase | Brain Carboxylesterase HBr1 | CE-1 | CES1 | Cocaine Carboxylesterase | EC 3.1.1.1 | EC 3.1.1.56 | Egasyn | HMSE | Human Monocyte/Macrophage Serine Esterase 1 | Methylumbelliferyl-Acetate Deacetylase 1 | Monocyte/Macrophage Serine Esterase | REH | Retinyl Ester Hydrolase | Serine Esterase 1 | TGH | Triacylglycerol Hydrolase | hCE-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889432","CES2 wt Allele","C116038","Human CES2 wild-type allele is located in the vicinity of 16q22.1 and is approximately 11 kb in length. This allele, which encodes cocaine esterase protein, plays a role in the catabolism of xenobiotics.","CES2 wt Allele | CE-2 | CES2A1 | Carboxylesterase 2 (Intestine, Liver) Gene | Carboxylesterase 2 wt Allele | ICE | PCE-2 | iCE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1869509","Cocaine Esterase, Human","C116039","Cocaine esterase (559 aa, ~62 kDa) is encoded by the human CES2 gene. This protein is involved in drug catabolism.","Cocaine Esterase | CE-2 | CES2 | Carboxylesterase 2 | EC 3.1.1.1 | EC 3.1.1.56 | Intestinal Carboxylesterase | Liver Carboxylesterase-2 | Methylumbelliferyl-Acetate Deacetylase 2 | hCE-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472639","MYC-targeting siRNA DCR-MYC","C115108","A lipid nanoparticle-based formulation consisting of small-interfering RNAs (siRNAs) directed against the oncogene c-Myc encapsulated in lipids with potential antineoplastic activity. Upon intravenous administration of MYC-targeting siRNA DCR-MYC, the lipid formulation promotes the uptake by tumor cells where the siRNAs moieties are subsequently released. The siRNAs bind to c-Myc mRNAs, which may result in the inhibition of translation and expression of the c-Myc protein and leads to growth inhibition for tumor cells that are overexpressing c-Myc. c-Myc, a proto-oncogene overexpressed in a variety of cancers, is involved in cellular proliferation, differentiation, and apoptosis.","MYC-targeting siRNA DCR-MYC | DCR-M1711 | DCR-MYC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL472642","galectin inhibitor GR-MD-02","C115111","A carbohydrate-based galectin inhibitor, with potential antineoplastic activity. Belapectin binds to the carbohydrate-binding domain of galectins, especially galectin-3, and may result in an induction of apoptosis mediated through activation of both mitochondria and caspases. This may reduce tumor growth in galectin-overexpressing tumor cells. Galectins, often overexpressed on tumor cells, play a key role in cancer cell proliferation, apoptosis, tumor angiogenesis and evasion of immune responses.","Belapectin | BELAPECTIN | GR-MD-02 | Galactoarabino-rhamnogalacturonate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890600","CRYAB wt Allele","C115114","Human CRYAB wild-type allele is located within 11q22.3-q23.1 and is approximately 15 kb in length. This allele, which encodes alpha-crystallin B chain protein, plays a role in maintaining the structure of the lens. Mutation of the gene is associated with myofibrillar myopathy type 2, dilated cardiomyopathy type 1II; cataract 16 and alpha-B crystallin-related, fatal infantile hypertrophy myofibrillar myopathy.","CRYAB wt Allele | CMD1II | CRYA2 | CTPP2 | CTRCT16 | Crystallin, Alpha B wt Allele | Crystallin, Alpha-2 Gene | Crystallin, Alpha-B Gene | HEL-S-101 | HSPB5 | MFM2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899441","Database Quality Plan","C115757","A proposed method to define procedures for the creation and implementation of a quality control (QC) plan.","Database Quality Plan | DB QA Plan | Database QC/QA Plan & Results | QC/QA Database Documentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898682","Investigational Product Recall Plan","C115758","Documentation detailing the recall of the investigational product(s) for the clinical trial.","Clinical Trial Investigational Product Recall Documentation | IP Recall Documentation | IP Recall Plan | Investigational Product Recall Plan | Investigational Product Recall Plan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898674","Investigational Product Supply Plan","C115760","Documentation describing the supply management of the investigational product(s) for the clinical trial.","Clinical Trial Investigational Product Supply Plan Documentation | Clinical Trial Material Distribution Plan | IP Suppl Plan | IP Supply Plan | Investigational Product Supply Plan | Investigational Product Supply Plan | Trial Medication Plan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889277","Statistical Analysis Plan","C115761","Documentation describing the statistical aspects of the clinical trial design; the process of data selection for analyses; the detailed analyses of data items; the procedures and methods employed for analyzing the data; the planned presentation of results in formats such as tables, listings, and figures.","Clinical Trial Statistical Analysis Plan Documentation | SA Plan | SAP | Statistical Analysis Plan | Statistical Analysis Plan | StatisticalAnalysisPlanVersion | statistical analysis plan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415450","H4C5 Gene","C115985","This gene is involved in the formation of high order chromatin structures.","H4C5 Gene | H4 Clustered Histone 5 Gene | H4C5 | HIST1H4E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473316","Carbon Nanoparticle-based Formulation","C115986","A nanoparticle-based formulation containing carbon, with both a mean size of 150 nm, and potential use as a stain for lymph node draining. Upon injection of the carbon nanoparticles at the tumor site, these nanoparticles travel to regional lymph nodes and stain the lymph nodes black due to the presence of the carbon. This may allow for a more precise surgical removal of tumor-draining lymph nodes.","Carbon Nanoparticle-based Formulation | CNP | Carbon Nanoparticles",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889690","H4/j","C115987","Human H4C5 wild-type allele is located in the vicinity of 6p22.1 and is approximately 2 kb in length. This allele, which encodes histone H4 protein, plays a role in the modulation of chromatin structure.","H4C5 wt Allele | H4 Clustered Histone 5 wt Allele | H4 Histone Family, Member J Gene | H4/j | H4FJ | HIST1 Cluster, H4E Gene | HIST1H4E | Histone 1, H4e Gene | Histone Cluster 1, H4e Gene | Histone Gene Cluster 1 H4 Family Member E Gene | Histone Gene Cluster 1, H4 Histone Family, Member E Gene | Histone Gene Cluster 1, H4E Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897007","Neonatal Herpes Simplex Infection","C115988","Infection in the first month of life caused by the Herpes simplex virus.","Neonatal Herpes Simplex Infection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824035","ZNF750 Gene","C115989","This gene plays a role in epidermal differentiation.","ZNF750 Gene | ZNF750 | Zinc Finger Protein 750 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889401","ZNF750 wt Allele","C115990","Human ZNF750 wild-type allele is located in the vicinity of 17q25.3 and is approximately 11 kb in length. This allele, which encodes zinc finger protein 750, is involved in both transcriptional regulation and differentiation of the epidermis. Mutation of the gene is associated with seborrhea-like dermatitis with psoriasiform elements.","ZNF750 wt Allele | FLJ13841 | SLDPE | ZFP750 | Zfp750 | Zinc Finger Protein 750 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3490890","Zinc Finger Protein 750, Human","C115991","Zinc finger protein 750 (723 aa, ~77 kDa) is encoded by the human ZNF750 gene. This protein plays a role in transcriptional regulation that drives the development of the epidermis.","Zinc Finger Protein 750 | Protein ZNF750",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4011654","Periorbital Cellulitis","C115992","An acute infection of the anterior portion of the eyelid and surrounding tissues.","Periorbital Cellulitis | Preseptal Cellulitis",,,,,,,,,,,,,,,"4030977","Cellulitis of periorbital region",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4014513","Retinitis","C115993","Inflammation of the retina.","Retinitis | ",,,,,,,,,,,,,,,"4161546","Retinitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3890016","IGKV1D-13 wt Allele","C117124","Human IGKV1D-13 wild-type allele is located in the vicinity of 2p11.2 and is approximately 1 kb in length. This allele, which encodes immunoglobulin kappa variable 1D-13 protein, plays a role in immunoglobulin epitope specificity.","IGKV1D-13 wt Allele | IGKV1D13 | Immunoglobulin Kappa Variable 1D-13 wt Allele | L18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889453","PASD1 wt Allele","C116705","Human PASD1 wild-type allele is located in the vicinity of Xq28 and is approximately 113 kb in length. This allele, which encodes circadian clock protein PASD1, may play a role in the modulation of gene expression. Aberrant expression is detected in histologically normal tissues from patients with uterine, pulmonary and small intestinal neoplasms.","PASD1 wt Allele | CT63 | OXTES1 | PAS Domain Containing 1 Gene | PAS Domain Containing Repressor 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1869249","PAS Domain-Containing Protein 1, Human","C116706","Circadian clock protein PASD1 (773 aa, ~87 kDa) is encoded by the human PASD1 gene. This protein may be involved in the regulation of transcription.","Circadian Clock Protein PASD1 | CT63 | Cancer/Testis Antigen 63 | OX-TES-1 | PAS Domain-Containing Protein 1 | PASD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0270971","Floppy Infant","C116708","A syndrome of generalized poor muscle tone and muscle weakness presenting in a newborn infant.","Floppy Infant | Congenital Floppy Infant | Floppy Infant Syndrome | Infantile Hypotonia",,,,,,,,,,,,,,,"4006277","Neonatal hypotonia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL473906","DNA plasmid encoding interleukin-12 INO-9012","C116709","A plasmid DNA vaccine encoding the human pro-inflammatory cytokine interleukin-12 (IL-12) with potential immunoactivating activity. Upon intramuscular delivery by electroporation of rocakinogene sifuplasmid, IL-12 is translated in cells and activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma and promoting cytotoxic T-cell responses against tumor cells. This may result in both immune-mediated tumor cell death and the inhibition of tumor cell proliferation.","Rocakinogene Sifuplasmid | DNA Plasmid Encoding Interleukin-12 INO-9012 | INO-9012 | ROCAKINOGENE SIFUPLASMID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473908","Autologous MAGE-A3-specific HLA-A*01-Restricted T Cell Receptor Gene Engineered Lymphocytes","C116711","Human autologous T-lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the human leukocyte antigen (HLA)-A*01-restricted, human melanoma-associated antigen A3 (MAGE-A3), with potential antineoplastic activity. Peripheral blood mononuclear cells (PBMCs) are isolated from a patient, transduced with an anti-MAGE-A3-HLA-A*01 restricted TCR, expanded ex vivo, and reintroduced into the HLA-A*01-positive patient. Then, the autologous MAGE-A3-specific, HLA-A*01-restricted TCR gene engineered lymphocytes bind to tumor cells expressing the MAGE-A3 antigen, which may increase cell death and halt the growth of MAGE-A3-expressing cancer cells. The tumor-associated antigen MAGE-A3 is overexpressed by a variety of cancer cell types.","Autologous MAGE-A3-specific HLA-A*01-Restricted T Cell Receptor Gene Engineered Lymphocytes | Anti-MAGE-A3 HLA-A*01 Restricted TCR-Gene Engineered Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL413609","Pulsed-Dose Rate Brachytherapy","C116542","A method of delivering internal beam radiotherapy that involves delivering short bursts of radiation over a specified period of time.","Pulsed-Dose Rate Brachytherapy | PDR | Pulsed dose rate brachytherapy (procedure)",,,,,,,,,,,,,,,"607945","Pulsed dose rate brachytherapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL446614","Subcutaneous Hormonal Therapy","C116543","The administration of exogenous hormones via bolus injection into the tissue layer immediately deep to the dermis.","Subcutaneous Hormonal Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388416","Synthetic Tumor-Associated Peptide Vaccine Therapy","C116544","A type of immunotherapy that uses a synthetic peptide to deliver tumor-specific antigens into the body in an effort to induce a targeted immune system response directed at the tumor.","Synthetic Tumor-Associated Peptide Vaccine Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279020","Tumor Cell Lysate Vaccine Therapy","C116546","A method by which dendritic cells are pulsed in vitro with tumor cell lysate to induce maturation with the purpose of inducing a targeted immune system response against the tumor.","Tumor Cell Lysate Vaccine Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1768253","Psychogenic Seizure","C116548","Movements, behaviors and sensations similar to a seizure, but due to psychological distress instead of a neurological disorder.","Psychogenic Seizure | Psychogenic Non-Epileptic Seizure",,,,,,,,,,,,,,,"4098316","Dissociative convulsions",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL446613","Bioconductance Measurement","C116550","A test that uses electrical current conductance as measured through skin to help diagnose disease, most commonly lung tumors.","Bioconductance Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085971","Case Management","C116551","A collaborative process for the coordination of services for an individual undergoing some manner of treatment. This process includes assessment, planning, facilitation, care coordination, evaluation, and advocacy for options and services to meet the comprehensive health needs for the individual and their family.","Case Management | ",,,,,,,,,,,,,,,"4298179","Case management",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3896979","Laboratory Tests Reason For Exclusion From Statistics","C119851","A rationale for excluding a particular data point or subject from the laboratory test results statistical analysis.","Laboratory Tests Reason For Exclusion From Statistics | LBREASEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898633","Laboratory Test Results Biospecimen Usability","C119852","A qualitative or quantitative measure that describes a biospecimen's suitability for laboratory testing purposes.","Laboratory Test Results Biospecimen Usability | LBSPCUFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898498","Macroscopic Findings Anatomical Region of Specimen","C119853","The specific anatomical or biological region within the tissue or organ specimen used in the macroscopic findings assessment.","Macroscopic Findings Anatomical Region of Specimen | MAANTREG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887503","Neonatal Listeriosis","C116806","A bacterial infection by Listeria monocytogenes in a newborn infant up to 28 days old.","Neonatal Listeriosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0275686","Congenital Listeriosis","C116807","A bacterial infection by Listeria monocytogenes that is present at birth.","Congenital Listeriosis | ",,,,,,,,,,,,,,,"4195112","Congenital listeriosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3873513","Invasive Listeriosis","C116808","A bacterial infection by Listeria monocytogenes in a sterile body compartment.","Invasive Listeriosis | ",,,,,,,,,,,,,,,"45772913","Invasive listeriosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899346","Disseminated Listeriosis","C116809","A bacterial infection by Listeria monocytogenes in two or more non-contiguous sterile body compartments.","Disseminated Listeriosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0276682","Neonatal Candidiasis","C116810","A fungal infection by any of the Candida species in a newborn infant up to 28 days old.","Neonatal Candidiasis | ",,,,,,,,,,,,,,,"440840","Neonatal candidiasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0343875","Congenital Candidiasis","C116811","A fungal infection by any of the Candida species that is present at birth.","Congenital Candidiasis | ",,,,,,,,,,,,,,,"4174301","Congenital candidiasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1609535","Invasive Candidiasis","C116813","A fungal infection by any of the Candida species in a sterile body compartment.","Invasive Candidiasis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0343312","Tetanus Neonatorum","C116814","A syndrome of generalized rigidity with muscle spasms and seizures in the neonatal period resulting from Clostridium tetani toxin production.","Tetanus Neonatorum | Neonatal Tetanus",,,,,,,,,,,,,,,"133024","Tetanus neonatorum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029076","Ophthalmia Neonatorum","C116815","Inflammation of the conjunctiva in a newborn due to chemical or infectious causes. Aseptic conjunctivitis is often related to the use of prophylactic medications for infectious conjunctivitis. Septic conjunctivitis is related to perinatal exposure to microorganisms.","Ophthalmia Neonatorum | Neonatal Conjunctivitis",,,,,,,,,,,,,,,"4143745","Neonatal conjunctivitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL473759","Gonococcal Ophthalmia Neonatorum","C116816","Inflammation of the conjunctiva in a newborn due to Neisseria gonorrhoeae which was acquired during labor and delivery.","Gonococcal Ophthalmia Neonatorum | Conjunctivitis Gonococcal | Gonococcal Conjunctivitis",,,,,,,,,,,,,,,"372842","Gonococcal conjunctivitis neonatorum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0343723","Neonatal Chlamydia Conjunctivitis","C116817","Inflammation of the conjunctiva in a newborn due to Chlamydia trachomatis which was acquired during labor and delivery.","Neonatal Chlamydia Conjunctivitis | Chlamydial Conjunctivitis | Inclusion Conjunctivitis | Trachoma",,,,,,,,,,,,,,,"4084947","Neonatal chlamydial conjunctivitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0149866","Neonatal Chemical Conjunctivitis","C116818","Inflammation of the conjunctiva in a newborn due to chemical irritation which was acquired postnatally from iatrogenic causes.","Neonatal Chemical Conjunctivitis | Chemical Conjunctivitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0270178","Neonatal Dacryocystitis","C116819","Inflammation of the lacrimal sac in a newborn due to blocked drainage of tears or infection.","Neonatal Dacryocystitis | ",,,,,,,,,,,,,,,"4129185","Neonatal dacryocystitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0270091","Vacuum Extraction Chignon","C116821","A cone-shaped swelling on the head produced by applying suction during vacuum-assisted delivery. It is temporary and usually resolves without treatment.","Vacuum Extraction Chignon | ",,,,,,,,,,,,,,,"4071591","Vacuum extraction chignon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899090","Fracture Related to Birth","C116822","A broken bone sustained during the birthing process.","Fracture Related to Birth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL413549","Image-Guided Adaptive Radiation Therapy","C116432","A type of radiation therapy that uses information gathered during the treatment cycle to inform, guide, and alter future radiation treatments with respect to location and dose.","Image-Guided Adaptive Radiation Therapy | IGART",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412333","Breast Irradiation","C116438","Localized radiation therapy to the breast.","Breast Irradiation | Breast Radiation Therapy | Breast Radiotherapy",,,,,,,,,,,,,,,"4177684","Radiotherapy to breast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL412338","Partial Breast Irradiation","C116439","External beam radiation that is focused on a specific part of the breast.","Partial Breast Irradiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412339","Whole Breast Irradiation","C116440","External beam radiation that treats the entire breast.","Whole Breast Irradiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898548","MIR135B Pre-miRNA","C117065","MIR135B pre-miRNA (97 nucleotides) is encoded by the human MIR135B gene. This oligoribonucleotide is involved in the regulation of gene expression.","MIR135B Pre-miRNA | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420814","TNFSF12 Gene","C117066","This gene plays a role in angiogenesis.","TNFSF12 Gene | TNFSF12 | Tumor Necrosis Factor (Ligand) Superfamily, Member 12 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889965","TNFSF12 wt Allele","C117067","Human TNFSF12 wild-type allele is located in the vicinity of 17p13 and is approximately 13 kb in length. This allele, which encodes tumor necrosis factor ligand superfamily member 12 protein, is involved in the promotion of angiogenesis. A readthrough that fuses this gene and the neighboring TNFSF13 gene may be expressed in activated T-cells and T- or B-cell lymphoma.","TNFSF12 wt Allele | APO3L | DR3LG | TWEAK | Tumor Necrosis Factor (Ligand) Superfamily, Member 12 wt Allele | Tumor Necrosis Factor Ligand Superfamily, Member 12 Gene | UNQ181/PRO207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0669351","Tumor Necrosis Factor Ligand Superfamily Member 12, Human","C117068","Tumor necrosis factor ligand superfamily member 12 (249 aa, ~27 kDa) is encoded by the human TNFSF12 gene. This protein plays a role in the positive regulation of angiogenesis.","Tumor Necrosis Factor Ligand Superfamily Member 12 | APO3 Ligand | APO3/DR3 Ligand | TNF Superfamily Member 12 | TNF-Related Weak Inducer of Apoptosis | TNFSF12 | TWEAK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349436","Migraine-Triggered Seizure","C117069","A seizure triggered by a migraine.","Migraine-Triggered Seizure | Migraine-triggered Seizure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473909","Hyaluronic Acid-containing Topical Cream","C116712","A topical cream formulation containing hyaluronic acid (HA) with wound repair promoting, skin moisturizing and potential radioprotective activities. Upon application of the topical cream, HA adheres to injured tissues, provides hydration to the skin, and protects against dehydration and chemical or mechanical irritation. Hyaluronate, a non-sulfated glucosaminoglycan, is a major component of the extracellular matrix in connective, epithelial, and neural tissues and contributes significantly to cell proliferation and migration.","Hyaluronic Acid-containing Topical Cream | HylaCare Cream",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1312515","Ethaselen","C116713","An orally bioavailable organoselenium inhibitor of thioredoxin reductase 1 (TrxR1), with potential antineoplastic activity. Upon oral administration, ethaselen specifically binds to the selenocysteine-cysteine redox pair in the C-terminal active site of TrxR1 and inhibits its activity, which may result in growth inhibition and the induction of apoptosis in TrxR1 overexpressing tumor cells. TrxR1, upregulated in many cancer cell types, plays a key role in various redox-dependent cellular pathways, regulates transcription factor activity, inhibits apoptosis, and promotes cell growth and survival.","Ethaselen | 1, 2-[Bis (1, 2-Benzisoselenazolone-3 (2H) -Ketone)] Ethane | BBSKE | ETHASELEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1739075","Polyethylene Glycol Polymer Surgical Sealant","C116878","A resorbable hydrogel-based formulation containing synthetic, derivatized polyethylene glycol (PEG) polymers, with anti-adhesion activity upon wound application during surgery. Upon application of the PEG polymer surgical sealant to the wound during surgery using a spray, the PEG polymers polymerize and adhere to the wound tissue, thereby forming a protective barrier. This prevents post-operative adhesion formation.","Polyethylene Glycol Polymer Surgical Sealant | Adhibit | PEG Polymer Surgical Sealant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446610","Recombinant Adenovirus 5 Encoding Tumor Necrosis Factor-related Apoptosis-Inducing Ligand","C116879","An adenovirus type 5 (Ad5) encoding human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), with potential apoptosis-inducing and antineoplastic activities. Upon administration of recombinant Ad5 encoding TRAIL, the adenovirus selectively infects tumor cells and expresses TRAIL. The virally expressed TRAIL binds to and activates its receptors TRAIL receptor-1 (TRAIL-R1, death receptor 4, DR4) and TRAIL receptor-2 (TRAIL-R2, death receptor 5, DR5), which subsequently activate caspases and induce apoptosis in TRAIL-R1/R2-expressing tumor cells. The pro-apoptotic cell surface receptors TRAIL-R1 and -R2, members of the TNF receptor family, are overexpressed by a variety of cancer cell types.","Recombinant Adenovirus 5 Encoding Tumor Necrosis Factor-related Apoptosis-Inducing Ligand | Ad5-TNFSF10 | Ad5-TRAIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433728","Recombinant Anti-WT1 Immunotherapeutic GSK2302024A","C116880","An immunotherapeutic composed of the Wilms tumor 1 (WT1) and an as of yet undisclosed adjuvant, with potential antineoplastic activity. Upon administration, the immune system may be stimulated to exert a cytotoxic T-lymphocyte (CTL) response against WT1-expressing tumor cells. The adjuvant stimulates the immune system's response to WT1. WT1, a tumor-associated antigen (TAA) and transcription factor, is overexpressed in a variety of tumor cell types.","Recombinant Anti-WT1 Immunotherapeutic GSK2302024A | ASCI GSK2302024A | GSK2302024A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433841","Anti-CD44 Monoclonal Antibody RO5429083","C116881","A recombinant, humanized monoclonal antibody targeting the cancer stem cell (CSC) antigen CD44, with potential immunomodulating and antineoplastic activities. Upon administration, RO5429083 binds to the constant region of the extracellular domain of CD44, thereby preventing the activation of various CD44-mediated signal transduction pathways. This may lead to a reduction in the proliferation of CD44-expressing tumor stem cells. CD44, a transmembrane glycoprotein and hyaluronic acid receptor, is expressed in healthy tissue and overexpressed in numerous cancer cell types; it plays a key role in tumor cell proliferation, migration and survival.","Anti-CD44 Monoclonal Antibody RO5429083 | RG 7356 | RO-5429083 | RO5429083",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898495","Macroscopic Findings Body System","C119854","The body system or organ class associated with a macroscopic finding.","Macroscopic Findings Body System | MABODSYS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898491","Macroscopic Findings Directionality","C119855","A qualifier for the direction on the body the macroscopic findings test is performed.","Macroscopic Findings Directionality | MADIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898494","Macroscopic Findings Collection Date Time","C119856","The date and time of macroscopic findings data collection.","Macroscopic Findings Collection Date Time | MADTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898492","Macroscopic Findings Death Relationship","C119857","An indication or description of a correlation between death and a macroscopic finding.","Macroscopic Findings Death Relationship | MADTHREL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897473","Study Day of Macroscopic Findings","C119858","The study day that a macroscopic findings assessment is performed.","Study Day of Macroscopic Findings | MADY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897036","Macroscopic Findings Group Identifier","C119860","A character or string that represents a macroscopic findings group.","Macroscopic Findings Group Identifier | MAGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898489","Macroscopic Findings Laterality","C119861","A qualifier for the side of the body the macroscopic findings assessment is performed.","Macroscopic Findings Laterality | MALAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898479","Macroscopic Findings Vendor Name","C119862","The literal identifier of the vendor or laboratory that performs a macroscopic findings assessment.","Macroscopic Findings Vendor Name | MANAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898488","Macroscopic Findings Original Result","C119863","The outcome of the macroscopic findings assessment as originally received or collected.","Macroscopic Findings Original Result | MAORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898487","Macroscopic Findings Portion or Totality","C119864","A qualifier for the arrangement or apportioning of an entity within a body part, region or organ for the macroscopic findings assessment.","Macroscopic Findings Portion or Totality | MAPORTOT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898486","Macroscopic Findings Reason Not Done","C119865","The explanation given as to why a macroscopic findings assessment was not performed.","Macroscopic Findings Reason Not Done | MAREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898485","Macroscopic Findings Reference Identifier","C119866","A sequence of characters used to identify, name, or characterize the macroscopic findings reference.","Macroscopic Findings Reference Identifier | MAREFID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898483","Macroscopic Findings Severity","C119868","The degree of something undesirable as determined by macroscopic findings.","Macroscopic Findings Severity | MASEV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898482","Macroscopic Findings Specimen Condition","C119869","A characteristic that refers to the physical and organoleptic state of a biospecimen used for a macroscopic findings assessment.","Macroscopic Findings Specimen Condition | MASPCCND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898496","Macroscopic Findings Biospecimen Usability","C119870","A qualitative or quantitative measure that describes a biospecimen's suitability for macroscopic testing purposes.","Macroscopic Findings Biospecimen Usability | MASPCUFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898481","Macroscopic Findings Specimen Type","C119871","The type of material sample taken from a biological entity for macroscopic findings assessment testing.","Macroscopic Findings Specimen Type | MASPEC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033893","Tension Headache","C117070","A headache associated with muscle tightness which may radiate to other parts of the body.","Tension Headache | Stress Headache | Tension-type Headache",,,,,,,,,,,,,,,"376382","Tension-type headache",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1425348","TNFRSF12A Gene","C117071","This gene is involved in signal transduction and the promotion of angiogenesis.","TNFRSF12A Gene | TNFRSF12A | Tumor Necrosis Factor Receptor Superfamily, Member 12A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889966","TNFRSF12A wt Allele","C117072","Human TNFRSF12A wild-type allele is located in the vicinity of 16p13.3 and is approximately 4 kb in length. This allele, which encodes tumor necrosis factor receptor superfamily member 12A protein, plays a role in the modulation of both angiogenesis and apoptosis.","TNFRSF12A wt Allele | CD266 | FN14 | TWEAKR | Tumor Necrosis Factor Receptor Superfamily, Member 12A wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1438619","Tumor Necrosis Factor Receptor Superfamily Member 12A, Human","C117073","Tumor necrosis factor receptor superfamily member 12A (129 aa, ~14 kDa) is encoded by the human TNFRSF12A gene. This protein is involved in both apoptosis and angiogenesis.","Tumor Necrosis Factor Receptor Superfamily Member 12A | CD266 | CD266 Antigen | FGF-Inducible 14 | Fibroblast Growth Factor-Inducible Immediate-Early Response Protein 14 | Tweak Receptor | Tweak-Receptor | TweakR | Type I Transmembrane Protein Fn14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1565172","Trigeminal Autonomic Cephalalgia","C117074","A headache disorder characterized by episodes of unilateral, short lasting pain and associated ipsilateral cranial autonomic symptoms.","Trigeminal Autonomic Cephalalgia | ",,,,,,,,,,,,,,,"42709942","Trigeminal autonomic cephalalgia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1842840","FERMT3 Gene","C117075","This gene plays a role in cell adhesion in hematopoietic cells.","FERMT3 Gene | FERMT3 | Fermitin Family Member 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890182","FERMT3 wt Allele","C117076","Human FERMT3 wild-type allele is located in the vicinity of 11q13.1 and is approximately 17 kb in length. This allele, which encodes fermitin family homolog 3 protein, is involved in the modulation of cell adhesion. Mutation of the gene is associated with leukocyte adhesion deficiency-3.","FERMT3 wt Allele | Fermitin Family (Drosophila) Homolog 3 Gene | Fermitin Family Homolog 3 (Drosophila) Gene | Fermitin Family Member 3 wt Allele | KIND3 | MIG-2 | MIG2B | UNC112C | URP2 | URP2SF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009088","Cluster Headache","C117077","A headache disorder that is characterized by periodic severe, unilateral orbital, supraorbital, and/or temporal pain, and is associated with ipsilateral cranial autonomic symptoms.","Cluster Headache | ",,,,,,,,,,,,,,,"381278","Cluster headache",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0751185","Primary Cough Headache","C117078","Headache triggered by coughing or straining in the absence of an intracranial disorder.","Primary Cough Headache | Valsalva-maneuver Headache",,,,,,,,,,,,,,,"373463","Cough headache syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0522253","Primary Exertional Headache","C117079","Headache triggered by exercise.","Primary Exertional Headache | ",,,,,,,,,,,,,,,"372313","Benign exertional headache",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3889456","MAP1LC3C wt Allele","C116662","Human MAP1LC3C wild-type allele is located in the vicinity of 1q43 and is approximately 4 kb in length. This allele, which encodes microtubule-associated proteins 1A/1B light chain 3C protein, is involved in both autophagy and the regulation of mitochondrial quantity and quality.","MAP1LC3C wt Allele | ATG8J | LC3C | Microtubule-Associated Protein 1 Light Chain 3 Gamma wt Allele | Microtubule-Associated Protein 1, Light Chain 3, Gamma Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1311385","MAP1LC3C protein, human","C116663","Microtubule-associated proteins 1A/1B light chain 3C (147 aa, ~17 kDa) is encoded by the human MAP1LC3C gene. This protein plays a role in the both mitophagy and autophagy.","Microtubule-Associated Proteins 1A/1B Light Chain 3C | Autophagy-Related Protein LC3 C | Autophagy-Related Ubiquitin-Like Modifier LC3 C | LC3-Like Protein 3 | MAP1 Light Chain 3-Like Protein 3 | MAP1A/MAP1B LC3 C | MAP1A/MAP1B Light Chain 3 C | Microtubule-Associated Protein 1 Light Chain 3 Gamma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0430797","Electrocorticography","C116664","The use of electrodes placed directly on the exposed brain surface to record the electrical activity of the cerebral cortex.","Electrocorticography | ECoG",,,,,,,,,,,,,,,"4217613","Electrocorticogram",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3852556","PI3K-beta Inhibitor SAR260301","C116882","An orally bioavailable inhibitor of the class I phosphatidylinositol 3-kinase (PI3K) beta isoform with potential antineoplastic activity. PI3K beta inhibitor SAR260301 selectively inhibits PI3K beta kinase activity in the PI3K/Akt/mTOR pathway, which may result in apoptosis and growth inhibition in PI3K beta-expressing and/or phosphatase and tensin homolog (PTEN)-deficient tumor cells. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and contributes to increased tumor cell growth, tumor cell survival, and resistance to both chemotherapy and radiotherapy. PI3K beta is the p110-beta catalytic subunit of the class I PI3K. PTEN, a tumor suppressor protein and negative regulator of PI3K activity, is often mutated in a variety of cancer cells. By specifically targeting class I PI3K beta, this agent may be more efficacious and less toxic than pan-PI3K inhibitors.","PI3K-beta Inhibitor SAR260301 | (S)-2-(2-(2-Methylindolin-1-yl)-2-oxoethyl)-6-morpholinopyrimidin-4(3H)-one | SAR 260301 | SAR-260301 | SAR260301",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471720","Serum-derived Bovine Immunoglobulin Protein Isolate","C116883","A nutritional supplement composed of serum-derived bovine protein concentrate containing high levels of immunoglobulins (Ig), particularly IgG, with the potential to improve nutritional status. Upon oral administration of SBI, the Ig promotes gastrointestinal (GI) health by improving the composition of the GI microflora, enhancing digestive processes, and increasing gut barrier integrity and function. SBI may also improve immune function, maintain immune homeostasis, bind to and neutralize bacterial toxins and antigens, and decrease intestinal inflammation. Altogether, this may enhance the functioning of the GI tract, improve both the digestion and absorption of nutrients, and increase weight gain.","Serum-derived Bovine Immunoglobulin Protein Isolate | EnteraGam | SBI | Serum Bovine Immunoglobulin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1955931","Acoustic Radiation Force Impulse Imaging","C116484","A type of elastography that uses acoustic radiation force to generate images of the mechanical properties of soft tissue.","Acoustic Radiation Force Impulse Imaging | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388396","Bioelectric Field Imaging","C116485","Noninvasive measurement of the bioelectric fields across the epidermis.","Bioelectric Field Imaging | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473789","Diffuse Optical Imaging","C116486","A method of rendering images using near-infrared spectroscopic or fluorescence techniques. It is most commonly used to measure changes in oxygenated and deoxygenated hemoglobin concentrations as an indicator of wound or injury healing.","Diffuse Optical Imaging | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433731","Diffusion Kurtosis Imaging","C116487","An extension of conventional diffusion tension imaging, which estimates the kurtosis of the water diffusion probability distribution function. This technique is most commonly used to study the brain.","Diffusion Kurtosis Imaging | DKI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388454","Dynamic Contrast-Enhanced Ultrasound Imaging","C116488","A functional imaging technique that uses the combination of sonography and microbubble contrast agents to render the desired image.","Dynamic Contrast-Enhanced Ultrasound Imaging | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL421566","Intraoperative Imaging","C116490","Any images taken during an operation; this may be done for a variety of reasons, including providing the surgeon with immediate feedback to improve operative outcome or to documentation of the procedure.","Intraoperative Imaging | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471752","Laser Doppler Imaging","C116491","An imaging technique that is used to measure superficial blood flow in the skin.","Laser Doppler Imaging | Scanning Laser Doppler",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3854375","Laser Speckle Imaging","C116492","A noninvasive, non-scanning optical imaging technique that provides full-field visualization of blood flow to the tissue being imaged, which provides information about tissue perfusion and the efficiency of disease treatment.","Laser Speckle Imaging | LSCI | Laser Speckle Contrast Imaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL413573","Kv/Mv Imaging","C116493","Any imaging method that makes use of high-energy radiation in the Kv or Mv range.","Kv/Mv Imaging | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897369","Tegafur-Gimeracil-Oteracil Potassium-Leucovorin Calcium Oral Formulation","C120099","An orally bioavailable granular formulation composed of the fluoropyrimidine antagonist tegafur combined with two modulators of 5-fluorouracil (5-FU) activity, gimeracil and oteracil potassium, and the folic acid derivative leucovorin calcium, with potential antineoplastic activity. Tegafur is a prodrug of 5-fluorouracil (5-FU), an antimetabolite that is further metabolized to 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP inhibits thymidylate synthase, DNA synthesis and cell division; FUTP competes with uridine triphosphate (UTP), thus inhibiting RNA and protein synthesis. Gimeracil is a reversible inhibitor of dihydropyrimidine dehydrogenase (DPD), the liver enzyme responsible for rapid catabolism of 5-FU into inactive metabolites. Oteracil potassium preferentially localizes in the gut and inhibits the enzyme orotate phosphoribosyl-transferase (OPRT), which converts tegafur to 5-FU. This decreases the amount of 5-FU in the gut and prevents activated 5-FU-related gastrointestinal (GI) toxicity. Leucovorin calcium, an active metabolite of folic acid, counteracts the toxic effects of 5-FU, thereby 'rescuing' the patient while permitting the antitumor activity of 5-FU.","Tegafur-Gimeracil-Oteracil Potassium-Leucovorin Calcium Oral Formulation | TAS-118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3540384","APOBEC3A_B Fusion Hybrid Gene","C117006","A fusion gene (~10 kb) that results from the deletion of approximately 29.5 kb of sequence between the APOBEC3A gene and the adjacent APOBEC3B gene. The deletion hybrid is predicted to have the promoter and coding region of APOBEC3A, but the 3' UTR of APOBEC3B. This mutation results in an APOBEC3B null phenotype, which would impact antiretroviral defense processes, and may be associated with an increased risk of breast carcinoma and other neoplastic diseases.","APOBEC3A_B Fusion Hybrid Gene | APOBEC3A and APOBEC3B Deletion Hybrid Gene | APOBEC3A_B | CTA-150C2.14-001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898144","Neurovascular Disorder","C117007","A disorder of the nervous system related to a vascular etiology.","Neurovascular Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0338484","Familial Hemiplegic Migraine","C117009","A migraine disorder characterized by individual and family history of aura that includes motor weakness.","Familial Hemiplegic Migraine | ",,,,,,,,,,,,,,,"4318867","Familial hemiplegic migraine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0270860","Basilar-Type Migraine","C117013","A migraine disorder characterized by episodes that are preceded by focal neurological symptoms originating in the brainstem.","Basilar-Type Migraine | Basilar-type Migraine",,,,,,,,,,,,,,,"4307373","Basilar migraine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152164","Cyclical Vomiting","C117014","A condition characterized by recurrent, self-limiting episodes of vomiting associated with intense nausea, pallor, and lethargy. It is commonly a migraine precursor.","Cyclical Vomiting | ",,,,,,,,,,,,,,,"4077584","Cyclical vomiting syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1960870","Chronic Migraine","C117015","Episodes of migraine occurring on 15 or more days per month, for more than three months.","Chronic Migraine | ",,,,,,,,,,,,,,,"4141827","Transformed migraine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL412408","Ex-Vivo Umbilical Cord Blood Expansion","C116665","The laboratory process of extracting progenitor cells from a given sample of umbilical cord blood and growing them in culture to increase their total quantity prior to transfusion.","Ex-Vivo Umbilical Cord Blood Expansion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889663","DEXI wt Allele","C116667","Human DEXI wild-type allele is located in the vicinity of 16p13.13 and is approximately 14 kb in length. This allele, which encodes dexamethasone-induced protein, may play a role in the inflammatory response. Gene expression is increased in emphysematous lung.","DEXI wt Allele | Dexamethasone-Induced Gene | Dexamethasone-Induced Transcript Gene | Dexi Homolog (Mouse) Gene | Dexi Homolog wt Allele | MYLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0968916","Dexamethasone-Induced Protein, Human","C116668","Dexamethasone-induced protein (95 aa, ~10 kDa) is encoded by the human DEXI gene. This protein may be involved in inflammatory processes.","Dexamethasone-Induced Protein | DEXI | Protein MYLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891076","CAMK1 wt Allele","C116670","Human CAMK1 wild-type allele is located in the vicinity of 3p25.3 and is approximately 13 kb in length. This allele, which encodes calcium/calmodulin-dependent protein kinase type 1 protein, is involved in both serine/threonine protein phosphorylation and calcium/calmodulin-dependent signal transduction.","CAMK1 wt Allele | CAMKI | CaMKI | Calcium/Calmodulin-Dependent Protein Kinase I wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1871221","Calcium/Calmodulin-Dependent Protein Kinase Type 1, Human","C116671","Calcium/calmodulin-dependent protein kinase type 1 (370 aa, ~41 kDa) is encoded by the human CAMK1 gene. This protein plays a role in both calcium/calmodulin-dependent signaling pathways and protein phosphorylation.","Calcium/Calmodulin-Dependent Protein Kinase Type 1 | CaM Kinase I | CaM Kinase I Alpha | CaM-KI | CaMKI-Alpha | EC 2.7.11.17",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889443","ATRN wt Allele","C116673","Human ATRN wild-type allele is located in the vicinity of 20p13 and is approximately 180 kb in length. This allele, which encodes attractin protein, plays a role in both ligand binding and inflammation.","ATRN wt Allele | Attractin wt Allele | DPPT-L | KIAA0548 | MGCA | Mahogany, Mouse, Homolog of Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1144195","Attractin, Human","C116674","Attractin (1429 aa, ~159 kDa) is encoded by the human ATRN gene. This protein is involved in ligand binding. Secreted forms of the protein are involved in immune cell clustering during inflammation.","Attractin | DPPT-L | Mahogany Homolog | Mahogany Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831922","FLT3/ABL/Aurora Kinase Inhibitor KW-2449","C116858","An orally available inhibitor of FMS-related tyrosine kinase 3 (FLT3, STK1, or FLK2), the tyrosine kinase ABL, and aurora kinases, with potential antineoplastic activity. Upon administration, FLT3/ABL/Aurora kinase inhibitor KW-2449 specifically binds to and inhibits both wild-type and mutated forms of FLT3, ABL and aurora kinases, which both interferes with the activation of signal transduction pathways mediated by these kinases and reduces the proliferation of susceptible cancer cells. FLT3 and ABL kinases are upregulated in certain tumor cells and play important roles in tumor cell proliferation and metastasis. Aurora kinases, serine-threonine kinases overexpressed by a wide variety of cancer cell types, play essential roles in mitotic checkpoint control.","FLT3/ABL/Aurora Kinase Inhibitor KW-2449 | KW-2449",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898618","Lawsonia inermis-based Supplement","C116859","No value exists.","Lawsonia inermis-based Supplement | Henna-based Supplement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388340","Magnetic Resonance Thermal Imaging","C116494","A type of magnetic resonance imaging that provides a temperature map of the tissue being imaged.","Magnetic Resonance Thermal Imaging | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471826","Multispectral Imaging","C116495","An imaging technique that captures data at multiple frequencies across the electromagnetic spectrum, including those from visible and non-visible wavelengths.","Multispectral Imaging | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446647","Robotic-Assisted Imaging","C116498","An imaging technique that uses a specially designed robotic system to aid with the imaging of the desired object.","Robotic-Assisted Imaging | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388342","Ultrasound Elasticity Imaging","C116499","The use of ultrasonography to measure the elastic properties of soft tissue.","Ultrasound Elasticity Imaging | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0066608","Mitomycin A","C1164","A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus.  Bioreduced mitomycin A generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.  Mitomycin A is more toxic than mitomycin C due to increased and nonselective DNA cross-linking in both aerobic and hypoxic cells. (NCI04)","Mitomycin A | Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-6,8a-dimethoxy-5-methyl-, carbamate (ester) | MITOMYCIN A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898812","Ig Kappa Chain V-I Region D-13","C117125","Ig kappa chain V-I region D-13 is encoded by the human IGKV1D-13 gene. This protein is involved in the mediation of antibody-antigen specificity.","Immunoglobulin Kappa Variable 1D-13 | IGKV1D-13 | Ig Kappa Chain V-I Region D-13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891546","SR Tumor Cell Line","C117126","A lymphoma cell line established by Walter J. Urba and Dan L. Longo from the pleural effusion of an 11 year old male patient with childhood immunoblastic lymphoma.","SR | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900170","A549/ATCC","C117127","An adenocarcinoma cell line established by D.J. Giard in 1972 from lung carcinoma tissue removed from a 58 year old Caucasian male.","A549/ATCC | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889250","FCRL1 wt Allele","C117129","Human FCRL1 wild-type allele is located within 1q21-q22 and is approximately 26 kb in length. This allele, which encodes Fc receptor-like protein 1, may play a role in cellular immunity.","FCRL1 wt Allele | CD307a | FCRH1 | Fc Receptor-Like 1 wt Allele | IFGP1 | IRTA5 | Immunoglobulin Superfamily Fc Receptor, Gp42 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2975217","Fc Receptor-Like Protein 1, Human","C117130","Fc receptor-like protein 1 (429 aa, ~47 kDa) is encoded by the human FCRL1 gene. This protein may be involved in B-cell immune functions.","Fc Receptor-Like Protein 1 | CD307a | CD307a Antigen | Fc Receptor Homolog 1 | FcR-Like Protein 1 | FcRH1 | FcRL1 | IFGP Family Protein 1 | Immune Receptor Translocation-Associated Protein 5 | hIFGP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897001","EKVX","C117131","An adenocarcinoma cell line established by the passage of cells from lung carcinoma tissue through nude mice.","EKVX | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1271991","Early Neonatal Death","C116772","Death of a live newborn during the first 7 days of life.","Early Neonatal Death | Early Neonatal Mortality",,,,,,,,,,,,,,,"4307303","Early neonatal death",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0455987","Late Neonatal Death","C116773","Death of live newborn between 7 and 27 days after birth.","Late Neonatal Death | Late Neonatal Mortality",,,,,,,,,,,,,,,"4173168","Late neonatal death",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3900027","Anti-D Hemolytic Disease of the Newborn","C116774","A condition of the newborn characterized by the destruction of red blood cells initiated by the transmission of antibodies from a mother to the child via the placenta against the D antigen, the most common Rhesus factor.","Anti-D Hemolytic Disease of the Newborn | Isoimmunization of Newborn with Rhesus Anti-D Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0137073","Pinaverium Bromide","C116775","An orally available bromide salt form of pinaverium, a calcium channel blocker (CCB) with antispasmodic activity. Upon oral administration, pinaverium blocks the voltage-dependent calcium channels and inhibits calcium ion influx into the smooth muscle cells located in the gastrointestinal (GI) tract. This prevents smooth muscle contraction and relaxes the GI tract. In addition, pinaverium may both reduce bowel uptake of and facilitate the function of locally active, co-administered drugs.","Pinaverium Bromide | 4-(6-Bromoveratryl)-4-(2-(2-(6,6-dimethyl-2-norpinyl)ethoxy)ethyl)morpholinium Bromide | Morpholinium, 4-[(2-Bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethylbicyclo[3.1.1]hept-2-yl)ethoxy]ethyl]-, Bromide | PINAVERIUM BROMIDE | Pinverin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0409999","Undifferentiated Connective Tissue Disease","C116776","An autoimmune disorder which does not meet classification criteria used to establish the presence of other well-defined connective tissue diseases.","Undifferentiated Connective Tissue Disease | UCTD",,,,,,,,,,,,,,,"4344165","Undifferentiated connective tissue disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0949690","Spondyloarthritis","C116778","A group of inflammatory rheumatic diseases associated with arthritis and enthesitis, and often involving the axial skeleton. The most common form of spondyloarthritis is ankylosing spondylitis. Other forms include axial spondyloarthritis, peripheral spondyloarthritis, reactive arthritis, psoriatic arthritis/spondylitis and enteropathic arthritis/spondylitis.","Spondyloarthritis | Seronegative Spondyloarthropathy | Spondylitis | Spondyloarthropathy",,,,,,,,,,,,,,,"4153359","Arthritis of spine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018378","Guillain-Barre Syndrome","C116345","A rapidly progressive autoimmune disorder of the peripheral nervous system characterized by limb paresthesias, areflexia, and generalized muscle weakness or paralysis that often begins in the legs and spreads to the arms, torso, and face.","Guillain-Barre Syndrome | GBS | Guillain Barre Syndrome | Guillain Barré Syndrome | Guillain-Barré Syndrome | Guillain-Barré syndrome",,,,,,,,,,,,,,,"4164770","Guillain-Barré syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0549423","Non-Communicating Hydrocephalus","C116347","An abnormal accumulation of cerebrospinal fluid within the ventricles of the brain that occurs as a consequence of an obstruction at any location within the ventricular system that prevents cerebrospinal fluid flowing into the subarachnoid space.","Non-Communicating Hydrocephalus | Obstructive Hydrocephalus | Obstructive hydrocephalus",,,,,,,,,,,,,,,"4220220","Acquired obstructive hydrocephalus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897777","Randomization Protocol Document","C116348","Documentation describing how subjects are randomized in the clinical trial.","Clinical Trial Randomization Procedure Documentation | Randomiz Proced | Randomization Procedure | Randomization Protocol Document",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897430","Subject Unblinding Plan","C116349","Documentation describing the processes and procedures for breaking the blind for the clinical trial.","Clinical Trial Investigational Product Unblinding Plan Documentation | IP Unblinding Plan | Subj Unblind Plan | Subject Unblinding Plan | Subject Unblinding Plan | Unblinding Plan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473670","PI3K/mTORC1/mTORC2 Inhibitor DCBCI0901","C116351","An inhibitor of phosphatidylinositide 3-kinase (PI3K), raptor-mTOR (mTOR complex 1 or mTORC1) and rictor-mTOR (mTOR complex 2 or mTORC2) with potential antineoplastic activity. Upon intravenous infusion, PI3K/mTORC1/mTORC2 inhibitor DCBCI0901 binds to and inhibits PI3K as well as both mTORC1 and mTORC2, which may result in both apoptosis and a decrease in cell proliferation in tumor cells overexpressing PI3K, mTORC1, and mTORC2. Activation of the PI3K/mTOR signaling pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K.","PI3K/mTORC1/mTORC2 Inhibitor DCBCI0901 | DCBCI0901",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0338489","Status Migranosus","C117022","An episode of migraine that persists for more than 72 hours.","Status Migranosus | Status Migrainosus",,,,,,,,,,,,,,,"377844","Status migrainosus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1112466","Migrainous Infarction","C117024","Migraine associated with an ischemic brain lesion.","Migrainous Infarction | ",,,,,,,,,,,,,,,"37167039","Infarction of brain due to migraine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL433732","Angiopoietin-2-specific Fusion Protein PF-04856884","C116625","A humanized monoclonal antibody fused to two peptides that bind to angiopoietin 2 (Ang2; ANGPT2), with potential anti-angiogenic and antineoplastic activities. Upon intravenous administration, Ang2-targeting PF-04856884 CovX body specifically binds to Ang2 and prevents the binding of Ang2 to its receptor Tie2 expressed on endothelial cells. This inhibits Tie2-mediated signaling, prevents angiogenesis and inhibits tumor cell proliferation.  Ang2, a proangiogenic cytokine and ligand for the Tie2 receptor, plays a key role in the regulation of tumor angiogenesis and tumor cell proliferation; its expression is upregulated by tumor endothelial cells.","Angiopoietin-2-specific Fusion Protein PF-04856884 | CVX-060 | PF-04856884",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL421575","Anti-ENPP3/MMAF Antibody-Drug Conjugate AGS-16M8F","C116626","An antibody-drug conjugate (ADC) containing a human immunoglobulin (Ig) G2k monoclonal antibody (AGS-16C) directed against the ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3, NPP3, B10, PDNP3 CD203c, or PD-IBETA ), conjugated, via the non-cleavable maleimidocaproyl (mc) linker, to monomethyl auristatin F (MMAF), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity. Upon intravenous administration of anti-ENPP3/MMAF ADC AGS-16M8F, the monoclonal antibody moiety selectively binds to ENPP3 expressed on tumor cells; upon internalization, the ADC is degraded by lysosomal proteases and MMAF is released. In turn, MMAF binds to and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. While normally expressed at low levels in the proximal tubules of the kidney, the type II transmembrane glycoprotein ENPP3 is overexpressed in most renal neoplasms and some liver cancers.","Anti-ENPP3/MMAF Antibody-Drug Conjugate AGS-16M8F | ADC AGS-16M8F | AGS 16M8F | AGS-16M8F | Anti-ENPP3 ADC AGS-16M8F | Anti-ENPP3/MMAF ADC AGS-16M8F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL421599","Anti-angiopoietin Monoclonal Antibody AMG 780","C116627","An immunoglobulin (Ig) G2 monoclonal antibody targeting the proangiogenic cytokines angiopoietin 1 (Ang1) and 2 (Ang2), with potential anti-angiogenic and antineoplastic activities. Upon administration, anti-angiopoietin monoclonal antibody AMG 780 binds to Ang1 and Ang2. This prevents the binding of the angiopoietin ligands to their receptor Tie2 (TEK), an endothelial cell-specific receptor tyrosine kinase. This prevents Tie2-mediated signaling and results in an inhibition of Tie2-expressing, tumor-stimulated endothelial cell proliferation, which prevents angiogenesis and inhibits tumor cell proliferation.","Anti-angiopoietin Monoclonal Antibody AMG 780 | AMG 780 | AMG-780",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3490133","Duligotuzumab","C116628","An immunoglobulin (Ig) G1 monoclonal antibody directed against both human epidermal growth factor receptor 3 (HER3 or ERBB3) and human epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Duligotuzumab binds to both EGFR and HER3 and inhibits their activation. This may prevent EGFR/HER3-mediated signaling and inhibit EGFR/HER3-dependent tumor cell proliferation. In addition, MEHD7945A induces antibody-dependent cell-mediated cytotoxicity (ADCC) against EGR/HER3-expressing tumor cells. EGFR and HER3, members of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, are frequently overexpressed in tumors; their expression is associated with both poor prognosis and drug resistance.","Duligotuzumab | DULIGOTUZUMAB | Duligotumab | MEHD 7945A | MEHD-7945A | MEHD7945A | RG 7597",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3851400","Porcupine Inhibitor WNT974","C116860","An orally available inhibitor of porcupine (PORCN), with potential antineoplastic activity. Upon oral administration, WNT974 binds to and inhibits PORCN in the endoplasmic reticulum (ER), which blocks post-translational acylation of Wnt ligands and inhibits their secretion. This prevents the activation of Wnt ligands, interferes with Wnt-mediated signaling, and inhibits cell growth in Wnt-driven tumors. Porcupine, a membrane-bound O-acyltransferase (MBOAT), is required for the palmitoylation of Wnt ligands, and plays a key role in Wnt ligand secretion and activity. Wnt signaling is dysregulated in a variety of cancers.","Porcupine Inhibitor WNT974 | 2-(2,3-Dimethyl-[2,4-bipyridin]-5-yl)-N-(5-(pyrazin-2-yl)pyridin-2-yl)acetamide | LGK 974 | LGK-974 | LGK974 | PORCN inhibitor LGK974 | WNT 974 | WNT-974 | WNT974",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896821","Pan-RAF Inhibitor LY3009120","C116861","An orally available inhibitor of all members of the serine/threonine protein kinase Raf family, including A-Raf, B-Raf and C-Raf protein kinases, with potential antineoplastic activity. Upon administration, pan-RAF kinase inhibitor LY3009120 inhibits Raf-mediated signal transduction pathways, which may inhibit tumor cell growth. Raf protein kinases play a key role in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway, which is often dysregulated in human cancers and plays a key role in tumor cell proliferation and survival.","Pan-RAF Inhibitor LY3009120 | DP-4978 | LY-3009120 | LY3009120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433769","MAGE-A3/12-specific TCR Gene-transduced Autologous PBLs","C116862","Human autologous peripheral blood lymphocytes (PBLs) transduced with a retroviral vector encoding a T-cell receptor (TCR) that recognizes the human melanoma antigens A3 and A12 (MAGE-A3/12), with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the MAGE-A3/12-specific TCR gene-transduced autologous PBLs bind to and lyse tumor cells expressing MAGE-A3/12, which may halt the growth of MAGE-A3/12-expressing cancer cells. MAGE-A3 and MAGE-A12, tumor associated antigens and members of the melanoma-associated antigen gene family, are overexpressed by a variety of cancer cell types.","MAGE-A3/12-specific TCR Gene-transduced Autologous PBLs | Anti-MAGE A3/12 TCR PBLs | MAGE-A3/12-specific T Cell Receptor Gene-transduced Autologous Peripheral Blood Lymphocytes | MAGE-A3/12-specific T-Cell Receptor Gene-transduced Autologous Peripheral Blood Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL421586","Vofatamab","C116863","A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the fibroblast growth factor receptor type 3 (FGFR3), with potential antineoplastic activity. Upon intravenous administration, vofatamab specifically binds to and inhibits both wild-type and mutated forms of FGFR3. This may result in the inhibition of FGFR3 phosphorylation, and thereby preventing its activation and FGFR3-mediated signal transduction pathways. This results in the inhibition of cell proliferation and the induction of cell death in FGFR3-expressing tumor cells. FGFR3, a receptor tyrosine kinase upregulated or mutated in many tumor cell types, plays a key role in tumor cell proliferation.","Vofatamab | B-701 | MFGR-1877S | MFGR1877A | MFGR1877S | RG-7444 | VOFATAMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433737","Recombinant Human Apolipoprotein(a) Kringle V MG1102","C116864","An 86 amino-acid long polypeptide fragment of a recombinant form of human apolipoprotein (a) (apo(a)) kringle V, with potential anti-angiogenic and antineoplastic activities. Although the exact mechanism of action has yet to be fully elucidated, upon administration, recombinant human apo(a) kringle V MG1102 inhibits the fibronectin-mediated migration of endothelial cells, binds to and blocks the activity of alpha 3 beta 1 integrin (a3b1 integrin), inhibits the activation of focal adhesion kinase (FAK) and FAK-mediated signaling, and leads to the inhibition of the p130 Crk-associated substrate (p130CAS)-c-Jun NH2-terminal kinase (JNK) pathway. This inhibits tumor angiogenesis, induces mitochondrial-mediated apoptosis of tumor cells and tumor-associated endothelial cells, and suppresses tumor growth and metastasis. Apo(a), a glycoprotein component of human lipoprotein(a), contains repeated kringle domains; certain kringle domains of apo(a), including the plasminogen kringle V homolog (KV), have anti-angiogenic effects.","Recombinant Human Apolipoprotein(a) Kringle V MG1102 | MG1102 | Recombinant Human Apo (a) Kringle V MG1102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2717955","4-Dimensional Computed Tomography","C116441","Computed tomography scans designed to minimize motion artifacts. 4DCT can be accomplished by collecting data for the duration of the patient's respiratory cycle and by oversampling CT data acquisition at each slice.","4-Dimensional Computed Tomography | 4D CT | 4D Computed Tomography | 4DCT | Time-Resolved CT Data Acquisition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890202","FCRL2 wt Allele","C117133","Human FCRL2 wild-type allele is located in the vicinity of 1q23 and is approximately 31 kb in length. This allele, which encodes Fc receptor-like protein 2, may be involved in the development of B-cells.","FCRL2 wt Allele | CD307b | FCRH2 | Fc Receptor-Like 2 wt Allele | IFGP4 | IRTA4 | Immunoglobulin Superfamily Fc Receptor, Gp42 Gene | SPAP1 | SPAP1A | SPAP1B | SPAP1C | UNQ9236/PRO31998",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898994","HOP-62","C117134","An adenocarcinoma cell line established from lung carcinoma tissue removed from a 60 year old female.","HOP-62 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0971458","Fc Receptor-Like Protein 2, Human","C117135","Fc receptor-like protein 2 (508 aa, ~56 kDa) is encoded by the human FCRL2 gene. This protein may play a role in the development of B-cells.","Fc Receptor-Like Protein 2 | CD307b | CD307b Antigen | Fc Receptor Homolog 2 | FcR-Like Protein 2 | FcRH2 | FcRL2 | IFGP Family Protein 4 | Immune Receptor Translocation-Associated Protein 4 | Immunoglobulin Receptor Translocation-Associated Protein 4 | SH2 Domain Containing Phosphatase Anchor Protein 1 | SH2 Domain-Containing Phosphatase Anchor Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898993","HOP-92","C117136","A large cell carcinoma cell line established from lung carcinoma tissue removed from a 62 year old male.","HOP-92 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890229","BCL2L10 wt Allele","C117139","Human BCL2L10 wild-type allele is located in the vicinity of 15q21 and is approximately 4 kb in length. This allele, which encodes Bcl-2-like protein 10, is involved in the inhibition of apoptosis.","BCL2L10 wt Allele | BCL-B | BCL2-Like 10 (Apoptosis Facilitator) wt Allele | BCL2-Like 10 Gene | BCLB | Boo | Diva",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1098337","Bcl-2-Like Protein 10, Human","C117140","Bcl-2-like protein 10 (194 aa, ~22 kDa) is encoded by the human BCL2L10 gene. This protein plays a role in the promotion of cell survival and the negative regulation of apoptosis.","Bcl-2-Like Protein 10 | Anti-Apoptotic Protein NrH | Apoptosis Regulator Bcl-B | Bcl2-L-10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898211","NCI-H23","C117141","An adenocarcinoma cell line established from a 51 year old male patient with lung carcinoma.  The cell sample was removed prior to any treatment for the carcinoma.  NCI-H23 cells have mutations at the amino acid position 12 of GTPase KRas (K-ras) and in codon 246 of the p53 (TP53) gene.","NCI-H23 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473910","Carbon C 13 Acetate","C116714","The non-radioactive naturally occurring isotope of acetate, carbon C 13 acetate, with potential use for metabolic tumor imaging upon nuclear magnetic resonance (NMR) spectroscopy. Upon infusion, carbon C 13 acetate is taken up by cancer cells and is utilized by metabolic pathways in the tumor cell. Specifically, the tumor cells oxidize acetate, in the form of acetyl coenzyme A (acetyl-CoA), in the citric acid cycle. Upon 13C-NMR, the metabolic phenotype of a tumor can be assessed. Certain alternative metabolic pathways are activated in tumor cells and use substrates other than glucose, such as acetate, for acetyl-CoA production.","Carbon C 13 Acetate | 1,2-13C Acetate | 2-13C Acetate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897199","Venous Stroke","C116715","Ischemic or hemorrhagic stroke resulting from cerebral venous thrombosis.","Venous Stroke | Cerebral Thrombotic Stroke | Cerebral Venous Stroke | Cerebral venous sinus thrombosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3492634","fluorine F 18 DCFPyL","C116352","A urea-based radiotracer composed of the prostate specific membrane antigen (PSMA) targeting agent DCFPyL and labeled with the positron-emitting isotope, fluorine F 18, that can potentially be used for positron emitting tomography (PET) imaging. Upon administration of fluorine F piflufolastat, piflufolastat binds to PSMA expressed on tumor cells. The fluorine F 18 moiety facilitates PET imaging of PSMA-expressing tumor cells. PSMA, a cell-surface antigen, is abundantly present on the surface of prostate cancer cells and on the neovasculature of most solid tumors.","Fluorine F 18 Piflufolastat | 18F-DCFPYL | 18F-DCFPyL | 2-(3-(1-Carboxy-5-((6-(18f)fluoro-pyridine-3-carbonyl)-amino)-pentyl)-ureido)-pentanedioic Acid | 2-(3-{1-Carboxy-5-[(6-[(18)F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic Acid | Fluorine F 18 DCFPyL | PIFLUFOLASTAT F-18 | Piflufolastat F 18 | Piflufolastat F-18 | Piflufolastat F18 | Pylarify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473671","siRNA-transfected Peripheral Blood Mononuclear Cells APN401","C116353","Autologous peripheral blood mononuclear cells (PBMCs) transfected ex vivo with small-interfering ribonucleic acid (siRNA) directed against the E3 ubiquitin ligase casitas B-lineage lymphoma-b gene (Cbl-b), with potential immunoactivating and antineoplastic activities. The Cbl-b gene is silenced ex vivo through the binding of Cbl-b siRNA to Cbl-b mRNA, which prevents the translation of the Cbl-b protein in T-lymphocytes. Upon infusion, the activated, Cbl-b-silenced T-lymphocytes are able to increase the production of cytokines, proliferate and activate the immune system, which leads to cancer cell eradication. Cbl-b, a negative regulator of the immune system, is mutated in a variety of cancer cell types. Its expression is inversely correlated with activation of T-lymphocytes and tumor cell eradication.","siRNA-transfected Peripheral Blood Mononuclear Cells APN401 | APN401 | siRNA-transfected PBMC APN401",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473672","5-FITC-labeled Colon-Heptapeptide","C116354","A radioconjugate consisting of a 7 amino acid peptide sequence, KCCFPAQ, that specifically targets human colon cancer and labeled, via the linker, GGGSK, with the fluorescent dye, fluorescein isothiocyanate (5-FITC), with potential imaging activity. Following spray application to the colon wall during colonoscopy in areas that look abnormal, the colon heptapeptide moiety of 5-FITC-labeled colon-heptapeptide specifically targets and binds to a cell surface target overexpressed on pre-cancerous or cancerous colon cells. Upon internalization, the FITC moiety allows for fluorescent imaging and the area of interest for biopsies can then be visualized.","5-FITC-labeled Colon-Heptapeptide | KCCFPAQ-GGGSK-(5-FITC)-NH2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433718","anti-EphA3 monoclonal antibody KB004","C116629","A non-fucosylated monoclonal antibody directed against the ephrin receptor A3 (EphA3), with potential antineoplastic activity. Upon administration, ifabotuzumab selectively binds to tumor cells expressing EphA3. This blocks both EphA3 activation and EphA3-mediated signaling, and induces apoptosis in EphA3-expressing tumor cells. In addition, ifabotuzumab can stimulate antibody dependent cell-mediated cytotoxicity (ADCC) against EphA3-expressing tumor cells. This agent also prevents tumor cell proliferation by inhibiting both EphA3 signaling and proliferation of endothelial cells in the tumor vasculature. The cell-surface receptor EphA3, a member of the ephrin family of receptor tyrosine kinases (RTKs) that are involved in mammalian development, is overexpressed by a variety of tumor types but is not expressed in normal healthy adult tissues. It plays an important role in tumor cell proliferation. Non-fucosylation of the antibody enhances its ADCC activity.","Ifabotuzumab | Fibatuzumab | IFABOTUZUMAB | KB 004 | KB-004 | KB004",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433725","Anti-hepcidin Monoclonal Antibody LY2787106","C116630","A humanized monoclonal antibody (MoAb) targeting the peptide hormone hepcidin, with potential anti-anemic activity. Upon intravenous administration, anti-hepcidin MoAb LY2787106 binds to hepcidin and prevents it from binding to the iron exporting protein ferroportin, which is expressed on both the basolateral surface of gastrointestinal (GI) enterocytes and the plasma membrane of macrophages. This prevents hepcidin-induced internalization and degradation of ferroportin and increases ferroportin-mediated iron export, thus increasing iron export from macrophages and iron absorption by enterocytes. This normalizes plasma iron levels, increases erythropoiesis and may inhibit anemia. Hepcidin, produced in hepatocytes, plays a key role in the homeostasis of systemic iron; it is upregulated during acute and chronic inflammation in response to cytokines and, in certain cancers, may contribute to cancer-associated anemia.","Anti-hepcidin Monoclonal Antibody LY2787106 | LY-2787106 | LY2787106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898111","Occipital Diastasis","C116823","Birth trauma caused by excessive pressure to the suboccipital region of the skull resulting in separation of the occipital squama from the lateral or condylar parts of the occipital bone. It is a serious injury that may lead to subdural hemorrhage in the posterior fossa.","Occipital Diastasis | Occipital Osteodiastasis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899085","Fracture of Nose Related to Birth","C116824","A broken nasal bone sustained during the birthing process.","Fracture of Nose Related to Birth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899083","Fracture of Spine Related to Birth","C116825","A broken vertebra sustained during the birthing process.","Fracture of Spine Related to Birth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899087","Fracture of Humerus Related to Birth","C116826","A broken humerus sustained during the birthing process.","Fracture of Humerus Related to Birth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899084","Fracture of Radius Related to Birth","C116827","A broken radius sustained during the birthing process.","Fracture of Radius Related to Birth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899082","Fracture of Ulna Related to Birth","C116828","A broken ulna sustained during the birthing process.","Fracture of Ulna Related to Birth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899088","Fracture of Femur Related to Birth","C116829","A broken femur sustained during the birthing process.","Fracture of Femur Related to Birth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1535994","Omphalorrhexis","C116830","Rupture of the umbilical cord during labor and delivery.","Omphalorrhexis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0270088","Tentorial Tear Related to Birth","C116831","Disruption of the tentorium cerebelli incurred during delivery.","Tentorial Tear Related to Birth | ",,,,,,,,,,,,,,,"4071588","Tentorial tear due to birth trauma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL471827","Thermoacoustic Computed Tomography","C116443","A type of computer tomography that uses radiation to create thermoacustic waves, which are then recorded and translated into a three dimensional image of the tissue.","Thermoacoustic Computed Tomography | OAT | Opto-Acoustic Tomography | Optoacoustic Tomography | PAT | Photoacoustic Computer Tomography | Photoacoustic Tomography | TAT | Thermoacoustic Tomography",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL421668","Computed Tomography-Guided Optical Sensor-Guided Percutaneous Needle Biopsy","C116444","The use of CT imaging to guide the placement of a needle being used to obtain a tissue sample.","Computed Tomography-Guided Optical Sensor-Guided Percutaneous Needle Biopsy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL421669","Computed Tomography-Guided Optical Sensor-Guided Radiofrequency Ablation","C116445","The use of CT imaging to guide the placement of the electrode for radiofrequency ablation.","Computed Tomography-Guided Optical Sensor-Guided Radiofrequency Ablation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1328868","Diffuse Optical Tomography","C116446","A type of computer tomography that creates 3D, digital models of objects by constructing images created by interpreting light that has been transmitted and scattered through an object. Because the object being imaged must be at least partially translucent, this technique works best on soft tissues.","Diffuse Optical Tomography | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471725","Optical Doppler Tomography","C116447","An imaging modality that combines laser Doppler flowmetry with optical coherence tomography to produce high-resolution tissue images that demonstrate direction and velocity of blood flow.","Optical Doppler Tomography | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433887","Ultrasound Tomography","C116448","The quantitative computation of data obtained via ultrasonography to create a three dimensional map of the imaged tissue.","Ultrasound Tomography | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446643","Positron Emission Tomography with Radiolabeled Targeting Agent","C116449","A functional nuclear medicine test that utilizes a radioactive tracer, most commonly the radiolabeled sugar fluorodeoxyglucose, to identify tumors and metastasis.","Positron Emission Tomography with Radiolabeled Targeting Agent | Positron Emission Tomography with Radiolabeled Targeting Agents",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446667","Chemical Exchange Saturation Transfer Magnetic Resonance Imaging","C116451","An acquisition technique of MRI that uses differences in the tissue microenvironment, like protein concentration or intracellular pH, to generate contrast differences.","Chemical Exchange Saturation Transfer Magnetic Resonance Imaging | Chemical Exchange Saturation Transfer MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471734","Functional Connectivity Magnetic Resonance Imaging","C116454","A technique that monitors blood oxygen level dependent (BOLD) signals to map distant brain regions that work together while performing a task.","Functional Connectivity Magnetic Resonance Imaging | Functional Connectivity MRI | fcMRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446619","High Field Strength Magnetic Resonance Imaging","C116455","A type of magnetic resonance imaging that uses larger, stronger magnets to generate faster scans and higher resolution images.","High Field Strength Magnetic Resonance Imaging | High Field Strength MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473913","Topical Keratin","C116717","A topical formulation containing the naturally-derived biomaterial keratin that has wound repair promoting, hemostatic, moisturizing and potential radioprotective activities. Upon topical application to an injured site, keratin adheres to the injured tissue, and forms an extracellular matrix that mimics the structure and function of the native tissue. This exogenous extracellular matrix is able to absorb fluid, accelerate thrombus formation through beta1 integrin-mediated platelet adhesion and forms a physical seal on the wound. This facilitates tissue regeneration by promoting cellular proliferation and migration, reducing pro-inflammatory cytokine and chemokine expression and altering the expression of extracellular matrix components and adhesion molecules. Altogether, this promotes wound healing and provides protection from damage due to thermal or radiation exposure. Keratin is an essential component in nails, hair and skin.","Topical Keratin | KeraStat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL480952","Early Onset Primary Dystonia","C116718","A genetic disorder that usually presents in early childhood and is characterized by muscle contractions in a foot, leg, or arm that gradually spreads to other body regions.","Early Onset Primary Dystonia | Early Onset Torsion Dystonia | Oppenheim's Dystonia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1851920","Dopa-Responsive Dystonia","C116719","A genetic disorder in females that presents in early childhood and is responsive to dopamine. It is characterized by clubfeet and Parkinsonian symptoms that may progress from lower to upper extremities witha diurnal pattern, and involuntary muscle contractions and other uncontrolled movements in the lower limbs that worsen with excercise and improve with rest.","Dopa-Responsive Dystonia | Autosomal Dominant Dopa-Responsive Dystonia | Autosomal Dominant Segawa Syndrome | DYT5 Dystonia | Dopa-Responsive Dystonia, Autosomal Dominant | Segawa's Disease",,,,,,,,,,,,,,,"37396085|4044060","Autosomal dominant dopa responsive dystonia|Diurnal dystonia",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL473914","Thymidylate Synthase Inhibitor DFP-11207","C116720","An orally available thymidylate synthase (TS) inhibitor with potential antineoplastic activity. Upon oral administration, DFP-11207 binds to and inhibits TS. This reduces thymine nucleotide synthesis, inhibits DNA synthesis and cell division, causes DNA damage and leads to tumor cell apoptosis. TS catalyzes the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP).","Thymidylate Synthase Inhibitor DFP-11207 | DFP-11207 | TS Inhibitor DFP-11207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0270897","Erb's Palsy","C116723","Weakness or paralysis of muscles in the arm due to damage in the upper brachial plexus.","Erb's Palsy | Erb-Duchenne Palsy",,,,,,,,,,,,,,,"4300531","Erb-Duchenne paralysis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0270898","Klumpke Palsy","C116724","Weakness or paralysis of muscles in the forearm or hand due to damage of the lower brachial plexus.","Klumpke Palsy | Dejerine-Klumpke Palsy | Klumpke's Palsy",,,,,,,,,,,,,,,"4221837","Klumpke-Déjerine paralysis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2733359","Psychogenic Tremor","C116725","An involuntary, compulsive, repetitive stereotyped movement.","Psychogenic Tremor | Tics/Tremor",,,,,,,,,,,,,,,"40483671","Psychogenic tremor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1541510","Sustained-release Lipid Inhaled Cisplatin","C116884","A sustained-release formulation for inhalation in which the inorganic platinum (Pt) agent cisplatin is encapsulated in lipids, with potential antineoplastic activity. Upon inhalation of the sustained-release lipid inhalation targeting (SLIT) cisplatin into the lungs, this agent forms highly reactive, positively charged, Pt complexes, which covalently bind to nucleophilic groups in DNA, preferably at the N7 position of guanine bases. Pt complex binding introduces intrastrand and interstrand DNA cross-links, and DNA-Pt-protein cross-links. These cross-links result in apoptosis and cell growth inhibition of lung cancer cells. Encasement in liposomes prolongs cisplatin's efficacy when compared to intravenously administered cisplatin; inhalation of cisplatin improves its concentration at tumor sites in the lungs while minimizing its systemic toxicity.","Sustained-release Lipid Inhaled Cisplatin | SLIT Cisplatin | SR Inhaled Lipid Cisplatin | Sustained-release Lipid Inhalation Targeting Cisplatin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890391","CYP2A7 wt Allele","C116971","Human CYP2A7 wild-type allele is located in the vicinity of 19q13.2 and is approximately 7 kb in length. This allele, which encodes cytochrome P450 2A7 protein, may be involved in both the oxidation of steroids, fatty acids and xenobiotics and the NADPH-dependent electron transport pathway.","CYP2A7 wt Allele | CPA7 | CPAD | CYP2A | CYPIIA7 | Cytochrome P450, Family 2, Subfamily A, Polypeptide 7 wt Allele | Cytochrome P450, Subfamily 2A, Polypeptide 7 Gene | Cytochrome P450, Subfamily IIA (Phenobarbital-Inducible), Polypeptide 7 Gene | Cytochrome P450, Subfamily IIA, Polypeptide 7 Gene | P450-IIA4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474552","Cytochrome P450 2A7","C116972","Cytochrome P450 2A7 (494 aa, ~56 kDa) is encoded by the human CYP2A7 gene. This protein may play a role in both the NADPH-dependent electron transport pathway and the oxidation of steroids, fatty acids and xenobiotics.","Cytochrome P450 2A7 | CYP2A7 | CYPIIA7 | Cytochrome P450 IIA4 | Cytochrome P450 IIA7 | Cytochrome P450IIA4 | Cytochrome P450IIA7 | EC 1.14.14.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424667","HSPH1 Gene","C116974","This gene plays a role in the unfolded protein response.","HSPH1 Gene | HSPH1 | Heat Shock 105kDa/110kDa Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890017","HSPH1 wt Allele","C116975","Human HSPH1 wild-type allele is located in the vicinity of 13q12.3 and is approximately 26 kb in length. This allele, which encodes heat shock protein 105 kDa protein, is involved in the negative regulation of the aggregation of unfolded proteins.","HSPH1 wt Allele | HSP105 | HSP105A | HSP105B | HSP110 | Heat Shock 105kDa/110kDa Protein 1 wt Allele | KIAA0201 | NY-CO-25 | RP11-173P16.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL475597","Heat Shock Protein 105 kDa","C116976","Heat shock protein 105 kDa (858 aa, ~97 kDa) is encoded by the human HSPH1 gene. This protein plays a role in the cellular stress response to unfolded proteins.","Heat Shock Protein 105 kDa | Antigen NY-CO-25 | HSPH1 | Heat Shock 110 kDa Protein | Heat-Shock Protein, 105-kD | Heat-Shock Protein, 110-kD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889716","LIG3 wt Allele","C116586","Human LIG3 wild-type allele is located within 17q11.2-q12 and is approximately 25 kb in length. This allele, which encodes DNA ligase 3 protein, plays a role in DNA repair.","LIG3 wt Allele | DNA Ligase 3 wt Allele | DNA Ligase III Gene | LIG2 | LIG3alpha | Ligase II, DNA, ATP-Dependent Gene | Ligase III, DNA, ATP-Dependent Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1689854","LIG3 protein, human","C116587","DNA ligase 3 (1009 aa, ~113 kDa) is encoded by the human LIG3 gene. This protein is involved in the repair of double-strand breaks in DNA.","DNA Ligase 3 | DNA Ligase III | EC 6.5.1.1 | LIG3 | Polydeoxyribonucleotide Synthase [ATP] 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473865","Epidural Hematoma","C116588","A collection of blood into the space between the dura mater and the skull.","Epidural Hematoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897545","Splenic Rupture Related to Birth","C116839","Disruption of the spleen incurred during delivery.","Splenic Rupture Related to Birth | Spleen Rupture Related to Birth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2349425","Hemicrania Continua","C117081","A unilateral headache of moderate intensity with exacerbations of severe pain, not attributed to another disorder, that continuously persists for more than three months, and presents with ipsilateral autonomic symptoms during exacerbations.","Hemicrania Continua | ",,,,,,,,,,,,,,,"40480082","Hemicrania continua",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2349426","New Daily Persistent Headache","C117082","A bilateral, unremitting headache of mild to moderate intensity that occurs daily and may be associated with photophobia, phonophobia, or mild nausea.","New Daily Persistent Headache | ",,,,,,,,,,,,,,,"43530648","New daily persistent headache",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0393750","External Compression Headache","C117083","Headache resulting from pressure applied to the cutaneous nerves of the head.","External Compression Headache | ",,,,,,,,,,,,,,,"4012239","Headache due to external compression of head",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032768","Post-Herpetic Neuralgia","C117084","Pain that occurs after the disappearance of herpes zoster infection lesions.","Post-Herpetic Neuralgia | PHN | Post-herpetic Neuralgia",,,,,,,,,,,,,,,"4071164","Postherpetic neuralgia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1426048","IL27 Gene","C117085","This gene is involved in the modulation of cytokine expression and B- and T-cell activities.","IL27 Gene | IL27 | Interleukin 27 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889437","IL27 wt Allele","C117086","Human IL27 wild-type allele is located in the vicinity of 16p11 and is approximately 13 kb in length. This allele, which encodes interleukin-27 subunit alpha protein, plays a role in the stimulation of innate immunity.","IL27 wt Allele | IL-27 | IL-27A | IL27A | IL27p28 | IL30 | Interleukin 27 wt Allele | Interleukin 30 Gene | p28",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890355","Interleukin-27 Subunit Alpha","C117087","Interleukin-27 subunit alpha (243 aa, ~27 kDa) is encoded by the human IL27 gene. This protein is involved in the modulation of angiogenesis, inflammation and tumorigenesis.","Interleukin-27 Subunit Alpha | IL-27 Subunit Alpha | IL-27 p28 Subunit | IL-27-A | IL27 | IL27-A | IL27A | Interleukin 27, 28-kD Subunit | Interleukin-30 | p28",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414234","EBI3 Gene","C117088","This gene plays a role in innate immunity.","EBI3 Gene | EBI3 | Epstein-Barr Virus Induced 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890349","EBI3 wt Allele","C117089","Human EBI3 wild-type allele is located in the vicinity of 19p13.3 and is approximately 8 kb in length. This allele, which encodes interleukin-27 subunit beta protein, is involved in the regulation of inflammation, tumorigenesis and angiogenesis.","EBI3 wt Allele | Epstein-Barr Virus Induced 3 wt Allele | Epstein-Barr Virus Induced Gene 3 | Epstein-Barr Virus-Induced Gene | IL-27B | IL27 Subunit | IL27 Subunit B Gene | IL27, EBI3 Subunit | IL27B | IL35 Subunit | IL35 Subunit B Gene | IL35, EBI3 Subunit | Interleukin 27, EBI3 Subunit | Interleukin 35, EBI3 Subunit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0385988","EBI3 protein, human","C117090","Interleukin-27 subunit beta (229 aa, ~25 kDa) is encoded by the human EBI3 gene. This protein plays a role in the regulation of cytokine expression, the modulation of inflammation and the stimulation of innate immunity.","Interleukin-27 Subunit Beta | EBI3 | EBV-Induced Gene 3 Protein | Epstein-Barr Virus-Induced Gene 3 Protein | IL-27 Subunit Beta | IL-27B | IL27B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414091","DNA2 Gene","C117091","This gene is involved in the replication and repair of DNA.","DNA2 Gene | DNA Replication Helicase/Nuclease 2 Gene | DNA2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890746","DNA2 wt Allele","C117092","Human DNA2 wild-type allele is located within 10q21.3-q22.1 and is approximately 58 kb in length. This allele, which encodes DNA replication ATP-dependent helicase/nuclease DNA2 protein, plays a role in DNA replication and repair. Mutation of the gene is associated with autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions type 6 and may be associated with Seckel Syndrome 8.","DNA2 wt Allele | DNA Replication Helicase 2 Homolog (Yeast) Gene | DNA Replication Helicase 2, Yeast, Homolog of Gene | DNA Replication Helicase/Nuclease 2 wt Allele | DNA2 DNA Replication Helicase 2-Like (Yeast) Gene | DNA2-Like Gene | DNA2L | PEOA6 | RP11-9E13.1 | SCKL8 | hDNA2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1701412","DNA Replication ATP-Dependent Helicase/Nuclease DNA2, Human","C117093","DNA replication ATP-dependent helicase/nuclease DNA2 (1060 aa, ~120 kDa) is encoded by the human DNA2 gene. This protein is involved in Okazaki fragment processing and DNA double-strand break repair.","DNA Replication ATP-Dependent Helicase/Nuclease DNA2 | DNA Replication ATP-Dependent Helicase DNA2 | DNA Replication ATP-Dependent Helicase-Like Homolog | DNA Replication Helicase 2 Homolog | DNA Replication Nuclease DNA2 | DNA2 | DNA2-Like Helicase | hDNA2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446618","dUTPase/DPD Inhibitor TAS-114","C116885","An orally bioavailable inhibitor of both deoxyuridine triphosphatase (dUTPase) and dihydropyrimidine dehydrogenase (DPD), with potential antineoplastic adjuvant activity. Upon oral administration in combination with a prodrug of the pyrimidine antagonist 5-fluorouracil (5-FU), TAS-114 inhibits (DPD), the liver enzyme responsible for rapid catabolism of 5-FU into inactive metabolites. This prevents first-pass metabolism of 5-FU, allowing oral administration of the 5-FU prodrug and increasing the efficacy of 5-FU. In addition, as a dUTPase inhibitor, TAS-114 enhances the antitumor activity of 5-FU by preventing the hydrolysis and breakdown of 5-fluoro-deoxyuridine triphosphate (FdUTP) and deoxyuridine triphosphate (dUTP), which are active metabolites of 5-FU. This promotes DNA polymerase-dependent incorporation of these antimetabolites into DNA and leads to DNA damage and tumor cell death. Co-administration with TAS-114 allows lower dosing of 5-FU prodrugs, which decreases 5-FU-related toxicity, while maintaining therapeutic levels of 5-FU at the tumor site.","dUTPase/DPD Inhibitor TAS-114 | TAS-114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433974","DR5-targeting Tetrameric Nanobody Agonist TAS266","C116886","An agonistic tetravalent nanobody, in which the four single, high affinity heavy chain variable domain (VHH) antibodies are separated by a peptide linker, targeting death receptor type 5 (DR5), with potential antineoplastic activity. Upon administration, DR5-targeting tetrameric nanobody agonist TAS266, with its four DR5-specific single-chain antibodies, specifically binds to and activates DR5 receptors. This results in the activation of caspase cascades and induction of apoptosis in DR5-expressing tumor cells. DR5, a cell surface receptor and member of the tumor necrosis factor (TNF)-receptor superfamily, triggers apoptosis. Compared to certain anti-DR5 antibody agonists, TAS266 shows increased receptor activation.","DR5-targeting Tetrameric Nanobody Agonist TAS266 | TAS-266 | TAS266 | Tetrameric Nanobody Agonist-targeting death receptor 5 TAS266",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4045172","Technetium Tc 99m Trofolastat","C116887","A radioconjugate composed of an urea-based human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the gamma-emitting radioisotope technetium Tc 99m, with potential use as a tracer for PSMA-expressing tumors using single photon emission computed tomography/computed tomography (SPECT/CT). Upon intravenous administration of the technetium Tc 99m trofolastat, the trofolastat moiety targets and binds to PSMA-expressing tumor cells. Upon internalization, PSMA-expressing tumor cells can be detected during SPECT/CT imaging. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.","Technetium Tc 99m Trofolastat | 99mTc-MIP 1404 | 99mTc-MIP-1404",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL376181","hTERT-LAMP mRNA-loaded Autologous Dendritic Cell Vaccine GRNVAC1","C116888","A cancer vaccine containing autologous dendritic cells (DCs) that are pulsed with mRNA encoding the tumor-associated antigens (TAAs) human telomerase reverse transcriptase (hTERT) and lysosome-associated membrane protein 1 (LAMP1), with potential immunostimulatory and antineoplastic activities. Upon administration, hTERT-LAMP mRNA-loaded autologous DC Vaccine GRNVAC1 may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing hTERT and LAMP1. hTERT, the catalytic subunit of human telomerase, is upregulated in certain tumor cell types and plays an important role in tumor cell growth and survival. LAMP1, overexpressed on a variety of tumor cells, plays a key role in cell-cell adhesion and migration.","hTERT-LAMP mRNA-loaded Autologous Dendritic Cell Vaccine GRNVAC1 | GRNVAC1 | hTERT-LAMP mRNA-loaded Autologous DC Vaccine GRNVAC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471722","X-Ray Phase-Contrast Imaging","C116500","An imaging modality that transforms an x-ray beam's phase shift, caused by the passage of the beam through the object, into variations in intensity which are then used to create images.","X-Ray Phase-Contrast Imaging | Phase-Contrast X-Ray Imaging | Phase-Sensitive X-Ray Imaging | X-Ray PCI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL413574","Video-Based 3-Dimensional Surface Imaging","C116501","The use of recorded video images during stereotactic procedures to detect motion-induced misalignment, and allow for precise repositioning of the patient.","Video-Based 3-Dimensional Surface Imaging | Surface imaging | Video-Based 3D Surface Imaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433813","Contrast-Enhanced Harmonic Endoscopic Ultrasound","C116502","A type of doppler ultrasound that uses microbubble contrast to image perfusion and microvasculature within tissues.","Contrast-Enhanced Harmonic Endoscopic Ultrasound | CH-EUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889648","MAD2L2 wt Allele","C116590","Human MAD2L2 wild-type allele is located in the vicinity of 1p36 and is approximately 17 kb in length. This allele, which encodes mitotic spindle assembly checkpoint protein MAD2B, is involved in the mitotic spindle assembly checkpoint and the modulation of translesional DNA synthesis.","MAD2L2 wt Allele | FANCV | MAD2 (Mitotic Arrest Deficient, Yeast, Homolog)-Like 2 Gene | MAD2 Mitotic Arrest Deficient-Like 2 (Yeast) Gene | MAD2B | Mitotic Arrest Deficient 2 Like 2 wt Allele | Mitotic Arrest-Deficient 2, S. cerevisiae, Homolog of Gene | POLZ2 | Polymerase (DNA-Directed), Zeta 2, Accessory Subunit Gene | REV7 | REV7, S. cerevisiae, Homolog of Gene | RP3-330O12.4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2721649","Subgaleal Hematoma","C116591","A collection of blood between the scalp and the skull periosteum.","Subgaleal Hematoma | ",,,,,,,,,,,,,,,"37205099","Epicranial subaponeurotic hematoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL473867","Mitotic Spindle Assembly Checkpoint Protein MAD2B","C116592","Mitotic spindle assembly checkpoint protein MAD2B (211 aa, ~24 kDa) is encoded by the human MAD2L2 gene. This protein plays a role in DNA repair and the mitotic spindle assembly checkpoint.","Mitotic Spindle Assembly Checkpoint Protein MAD2B | MAD2-Like Protein 2 | Mitotic Arrest Deficient 2-Like Protein 2 | Mitotic Arrest Deficient Homolog-Like 2 | REV7 Homolog | hREV7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0270855","Early Myoclonic Encephalopathy","C116593","A neurologic disorder characterized by frequently recurring myoclonic seizures and other seizure types presenting within the first months of life.","Early Myoclonic Encephalopathy | EME",,,,,,,,,,,,,,,"4186206","Early myoclonic encephalopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1539105","CLEC11A Gene","C116594","This gene plays a role in the proliferation and differentiation of hematopoietic precursor cells","CLEC11A Gene | C-Type Lectin Domain Family 11, Member A Gene | CLEC11A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889160","CLEC11A wt Allele","C116595","Human CLEC11A wild-type allele is located in the vicinity of 19q13.3 and is approximately 2 kb in length. This allele, which encodes C-type lectin domain family 11 member A protein, is involved in the positive regulation of both proliferation and differentiation of hematopoietic cells.","CLEC11A wt Allele | C-Type (Calcium Dependent, Carbohydrate-Recognition Domain) Lectin, Superfamily Member 3 Gene | C-Type Lectin Domain Family 11, Member A wt Allele | CLECSF3 | LSLCL | Lectin, C-Type, Lymphocyte-Secreted Long Form Gene | P47 | SCGF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899760","CLEC11A Gene Product","C116596","A protein encoded by the CLEC11A gene.","CLEC11A Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0671154","C-Type Lectin Domain Family 11 Member A, Human","C116597","C-type lectin domain family 11 member A (323 aa, ~36 kDa) is encoded by the human CLEC11A gene. This protein plays a role in carbohydrate binding and hematopoietic cell growth factor activity.","C-Type Lectin Domain Family 11 Member A | C-Type Lectin Superfamily Member 3 | Lymphocyte Secreted C-Type Lectin | Lymphocyte Secreted Long Form of C-Type Lectin | Lymphocytic Secreted Long Form of C-Type Lectin | SCGF-Alpha | Stem Cell Growth Factor | p47",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221165","Diplegia","C116599","Paralysis affecting corresponding parts on both sides of the body.","Diplegia | ",,,,,,,,,,,,,,,"4277456","Diplegia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3889658","ABCA1 wt Allele","C116409","Human ABCA1 wild-type allele is located in the vicinity of 9q31 and is approximately 147 kb in length. This allele, which encodes ATP-binding cassette sub-family A member 1 protein, is involved in intracellular cholesterol transport. Mutation of the gene is associated with high density lipoprotein deficiency type 2 (autosomal dominant) and Tangier disease.","ABCA1 wt Allele | ABC-1 | ABC1 | ATP-Binding Cassette, Sub-Family A (ABC1), Member 1 wt Allele | ATP-Binding Cassette, Subfamily A, Member 1 Gene | CERP | HDLDT1 | TGD | Tangier Disease Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879268","cisplatin/fluorouracil/gemcitabine","C11640","A regimen consisting of gemcitabine, 5-fluorouracil and cisplatin that can be used in the treatment of bladder, hepatobiliary and pancreatic cancers.","GFP Regimen | Cisplatin-Fluorouracil-Gemcitabine | Cisplatin/Fluorouracil/Gemcitabine | Cisplatin/Fluorouracil/Gemcitabine Regimen | GemFLP | GemFLP Regimen | Gemcitabine/Fluorouracil/Leucovorin/Cisplatin | Gemcitabine/Fluorouracil/Platinol | Gemcitabine/Fluorouracil/Platinol Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3711161","ATP-Binding Cassette Sub-Family A Member 1, Human","C116410","ATP-binding cassette sub-family A member 1 (2261 aa, ~254 kDa) is encoded by the human ABCA1 gene. This protein plays a role in intracellular cholesterol transport.","Phospholipid-Transporting ATPase ABCA1 | ABC Transporter 1 | ABC-1 | ABCA1 | ATP Binding Cassette Subfamily A Member 1 | ATP-Binding Cassette 1 | ATP-Binding Cassette Sub-Family A Member 1 | ATP-Binding Cassette Transporter 1 | ATP-Binding Cassette Transporter A1 | Cholesterol Efflux Regulatory Protein | EC 7.6.2.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890209","MAML3 wt Allele","C117095","Human MAML3 wild-type allele is located in the vicinity of 4q31.1 and is approximately 438 kb in length. This allele, which encodes mastermind-like protein 3, is involved in both Notch signaling and transcriptional regulation.","MAML3 wt Allele | CAG Repeat Containing (Glia-Derived Nexin I Alpha) Gene | CAG Repeat Domain Gene | CAGH3 | ERDA3 | GDN | KIAA1816 | MAM-2 | MAM2 | Mastermind (Drosophila)-Like 3 Gene | Mastermind Like Transcriptional Coactivator 3 wt Allele | Mastermind-Like 3 (Drosophila) Gene | Mastermind-Like 3 (Drosophila) wt Allele | TNRC3 | Trinucleotide Repeat Containing 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890197","PSMB5 wt Allele","C116676","Human PSMB5 wild-type allele is located in the vicinity of 14q11.2 and is approximately 19 kb in length. This allele, which encodes proteasome subunit beta type-5 protein, is involved in protein catabolism.","PSMB5 wt Allele | LMPX | MB1 | Proteasome (Prosome, Macropain) Subunit, Beta Type, 5 wt Allele | Proteasome Subunit, Beta Type, 5 Gene | Proteasome Subunit, Beta-Type, 5 Gene | X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1313038","Proteasome Subunit Beta Type-5, Human","C116677","Proteasome subunit beta type-5 (263 aa, ~28 kDa) is encoded by the human PSMB5 gene. This protein plays a role in proteasomal protein degradation.","Proteasome Subunit Beta Type-5 | B5 Proteasome Subunit | EC 3.4.25.1 | Macropain Epsilon Chain | Multicatalytic Endopeptidase Complex Epsilon Chain | PSMB5 | PSX Large Multifunctional Protease X | Proteasome Beta 5 Subunit | Proteasome Catalytic Subunit 3 | Proteasome Chain 6 | Proteasome Epsilon Chain | Proteasome Subunit Beta-5 | Proteasome Subunit MB1 | Proteasome Subunit X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889123","SMG1 wt Allele","C116679","Human SMG1 wild-type allele is located in the vicinity of 16p12.3 and is approximately 122 kb in length. This allele, which encodes serine/threonine-protein kinase SMG1 protein, plays a role in the mediation of both mRNA nonsense-mediated decay and serine/threonine protein phosphorylation.","SMG1 wt Allele | 61E3.4 | ATX | KIAA0421 | LIP | SMG1 Phosphatidylinositol 3-Kinase-Related Kinase wt Allele | SMG1, C. elegans, Homolog of Gene | Smg-1 Homolog, Phosphatidylinositol 3-Kinase-Related Kinase (C. elegans) Gene | Smg-1 Homolog, Phosphatidylinositol 3-Kinase-Related Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1739091","Serine/Threonine-Protein Kinase SMG1, Human","C116680","Serine/threonine-protein kinase SMG1 (3661 aa, ~411 kDa) is encoded by the human SMG1 gene. This protein is involved in the phosphorylation of proteins that are involved in nonsense-mediated decay of mRNA.","Serine/Threonine-Protein Kinase SMG1 | 61E3.4 | EC 2.7.11.1 | Lambda-Interacting Protein | Lambda/Iota Protein Kinase C-Interacting Protein | PI-3-Kinase-Related Kinase SMG-1 | Phosphatidylinositol 3-Kinase-Related Kinase | SMG-1 | hSMG-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433832","Immune Function Testing","C116682","The use of a variety of different tests, including blood count and chemistry, urinalysis, and imaging to establish the status of an individual's immune system function.","Immune Function Testing | Immune Function Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0199242","Thromboembolism Prophylaxis","C116684","The use of medication to prevent the formation of clots and emboli.","Thromboembolism Prophylaxis | Anticoagulation for VTE prophylaxis",,,,,,,,,,,,,,,"4223006","Administration of prophylactic anticoagulant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3891079","H2B.1B","C116686","Human H2BC5 wild-type allele is located in the vicinity of 6p21.3 and is approximately 13 kb in length. This allele, which encodes histone H2B type 1-D protein, is involved in nucleosome formation.","H2BC5 wt Allele | H2B Clustered Histone 5 wt Allele | H2B Histone Family, Member B Gene | H2B.1B | H2B/b | H2BFB | HIRIP2 | HIST1H2BD | HIST1H2BD wt Allele | Hist 1 Cluster, H2BD Gene | Histone 1, H2bd Gene | Histone Cluster 1 H2B Family Member D Gene | Histone Cluster 1, H2bd Gene | Histone Gene Cluster 1, H2B Histone Family, Member D Gene | Histone Gene Cluster 1, H2bd Gene | dJ221C16.6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4228071","Febrile Seizure","C116503","A seizure occurring in infants and young children that occurs in the setting of fever.","Febrile Seizure | ",,,,,,,,,,,,,,,"444413","Febrile convulsion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL473327","Multiphoton Microscopy","C116504","An imaging technique that uses multiple photons to absorb infrared light, thereby minimizing phototoxicty and photobleaching, making it an ideal method for imaging living specimens, especially those involving deep tissue.","Multiphoton Microscopy | Multi-Photon Microscopy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471726","Diagnostic Microscopy","C116505","A diagnostic tool used to view tissues at high magnification, which allows for identification of cellular structures.","Diagnostic Microscopy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0969690","Image-Guided Surgery","C116506","An operative technique that uses real time correlation of the operative field with preoperative images in order to establish the precise location of surgical instruments in relation to surrounding anatomical structures.","Image-Guided Surgery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433931","Percutaneous Cryosurgery","C116507","An image-guided, minimally invasive surgical technique that uses a probe inserted through the skin to freeze the targeted tissue, causing cell death secondary to cryogenic injury.","Percutaneous Cryosurgery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433814","Robot-Assisted Endoscopic Surgery","C116508","A surgical technique that uses a specially designed robotic system to aid with an endoscopic procedure.","Robot-Assisted Endoscopic Surgery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412351","Ultrasound-Guided Prostate Biopsy","C116510","A diagnostic procedure that uses an ultrasound image to guide the placement of a biopsy needle into the prostate to obtain a tissue sample.","Ultrasound-Guided Prostate Biopsy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412352","Contrast-Enhanced Ultrasound-Guided Prostate Biopsy","C116511","A radiologic technique that employs contrast agents to enable a more precise needle placement during a biopsy of the prostate.","Contrast-Enhanced Ultrasound-Guided Prostate Biopsy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL416265","Endoscopic Ultrasound-Guided Fine-Needle Aspiration of the Pancreas","C116512","The use of endoscopic ultrasound to direct the placement of a needle being used to obtain a sample of cells from the pancreas. The use of the ultrasound allows for more precise needle placement and makes the procedure safer.","Endoscopic Ultrasound-Guided Fine-Needle Aspiration of the Pancreas | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412457","Endoscopic Ultrasound-Guided Celiac Plexus Neurolysis","C116514","The use of endoscopic ultrasound to guide the injection of local anesthetic and alcohol to the celiac plexus, which causes temporary degeneration to the nerve fibers. The procedure is performed in an effort to alleviate intractable plain, generally caused by cancer or chronic pancreatitis.","Endoscopic Ultrasound-Guided Celiac Plexus Neurolysis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006153","Breath Test","C116515","A technique to assess the presence and/or amount of analyte(s) in breath exhaled into a device.","Breath Test | BREATH TEST",,,,,,,,,,,,,,,"4064334","Breath test",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL412306","Nitric Oxide Breath Test","C116516","A diagnostic test that measures the amount of nitric oxide in an exhaled breath.","Nitric Oxide Breath Test | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0263409","Linear Scleroderma","C116780","A type of localized scleroderma characterized by a long strip of indurated skin, which is typically found unilaterally on an arm or leg, and sometimes on the forehead or trunk. This disorder often affects the tissues beneath the skin, causing damage to bones, muscle or other organs. It can limit movement, alter growth, and disfigure the affected area.","Linear Scleroderma | Linear scleroderma",,,,,,,,,,,,,,,"4331739","Linear scleroderma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0392441","Scleroderma en Coup de Sabre","C116781","A type of linear scleroderma characterized by a linear, colorless, atrophied band across the forehead or scalp. This disorder can affect the tissues under or near the lesion including brain, bone and eyes.","Scleroderma en Coup de Sabre | Frontal Linear Scleroderma",,,,,,,,,,,,,,,"4196974","Coup de sabre scleroderma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0263664","Generalized Morphea","C116782","A type of morphea characterized by four or more plaques found in two or more anatomic locations. The plaques are indurated, generally well-delineated, and may include muscle atrophy in affected areas; there is no visceral involvement.","Generalized Morphea | ",,,,,,,,,,,,,,,"4326583","Generalized morphea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0263324","Erythema Toxicum Neonatorum","C116783","A benign, self-limited eruption of vesicles, pustules, papules and macules seen in newborns. An eosinophilic infiltrate can be isolated suggesting an immune-mediated reaction in the skin.","Erythema Toxicum Neonatorum | Neonatal Erythema Toxicum | Neonatal Toxic Erythema",,,,,,,,,,,,,,,"37155404","Neonatal toxic erythema",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899621","Circumscribed Morphea","C116784","A type of morphea in which the lesions are circular or ovoid, and may be superficial or deep. The superficial lesions can have an indurated, waxy, ivory colored center with surrounding erythema or violaceous color during the active stage. Deep lesions can be sclerotic and depressed from underlying atrophy, and may show minimal skin color changes. When there are several (greater than or equal to 4), larger (greater than 3cm) lesions on two or more body areas this is classified as 'generalized morphea'.","Circumscribed Morphea | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897992","Pansclerotic Morphea","C116785","A rare, aggressive form of morphea characterized by sclerosis of the dermis, fascia, and muscle over large parts of the body, resulting in contractures and immobility.","Pansclerotic Morphea | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898280","Mixed Morphea","C116786","The presence of more than one variant of morphea in a single patient.","Mixed Morphea | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898649","Juvenile Localized Scleroderma","C116787","Localized scleroderma presenting before the age of eighteen.","Juvenile Localized Scleroderma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473936","HuCAL-based Antibody VAY736","C116788","A fully human combinatorial antibody library (HuCAL)-derived monoclonal antibody targeting the B-cell-activating factor receptor (BAFF-R), with potential anti-inflammatory and antineoplastic activities. Upon administration, ianalumab targets and binds to BAFF-R, which inhibits both BAFF/BAFF-R interaction and BAFF-R-mediated signaling. This may decrease cell growth in tumor cells expressing BAFF-R. BAFF-R, also known as tumor necrosis factor receptor superfamily member 13C, is overexpressed in certain tumor cell types and autoimmune diseases. In cancer cells, BAFF-R plays a key role in B-cell proliferation and survival. VAY736 was developed using HuCAL technology.","Ianalumab | HuCAL-based Antibody VAY736 | Human Combinatorial Antibody Library-based Monoclonal Antibody VAY736 | IANALUMAB | VAY 736 | VAY736",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1290138","Systemic Sclerosis without Skin Involvement","C116789","A condition in which there are visceral manifestations of systemic sclerosis without any cutaneous findings.","Systemic Sclerosis without Skin Involvement | SSC without Skin Involvement | Systemic Sclerosis sine Scleroderma",,,,,,,,,,,,,,,"4027230","Systemic sclerosis sine scleroderma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL473937","Carbon C 11 Sepantronium Bromide","C116790","A radiotracer composed of the bromide salt form of sepantronium, a small-molecule survivin antagonist and proapoptotic agent, labeled with the radionuclide carbon C 11, with potential positron emission tomography (PET) imaging activity. Upon administration, sepantronium is selectively taken up by tumor cells, binds to the survivin promoter and inhibits the transcription of survivin, which results in decreased survivin expression. Upon PET imaging, the tissue distribution of sepantronium and its tumor uptake can be assessed. Survivin, a member of the inhibitor of apoptosis (IAP) gene family, is overexpressed in a variety of human cancers; its expression in tumors is associated with a more aggressive phenotype, increased cancer cell proliferation, shorter survival times, and a decreased response to chemotherapy.","Carbon C 11 Sepantronium Bromide | 11C-YM155",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419810","SALL2 Gene","C117033","This gene is involved in the modulation of gene expression.","SALL2 Gene | SALL2 | Spalt-Like Transcription Factor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL475614","Sal-Like Protein 2","C117035","Sal-like protein 2 (1007 aa, ~105 kDa) is encoded by the human SALL2 gene. This protein is involved in the regulation of gene expression.","Sal-Like Protein 2 | Sal-2 | Zinc Finger Protein 795 | Zinc Finger Protein SALL2 | Zinc Finger Protein Spalt-2 | hSal2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898412","MicroRNA 105","C117036","A 23 ribonucleotide sequence that is a final product of the processing of either MIR105-1 pre-miRNA or MIR105-2 pre-miRNA. This oligonucleotide may be involved in the negative regulation of gene expression, and its expression is associated with metastatic breast cancer.","MicroRNA 105 | MIR105 | MIRN105 | has-mir-105 | hsa-miR-105-5p | hsa-mir-105 | miR-105 | miR105 | miRNA 105 | miRNA-105 | miRNA105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898445","MedDRA Body System or Organ Class Code","C117040","A coded value specifying the type of body system or organ class from the Medical Dictionary for Regulatory Activities (MedDRA).","MedDRA Body System or Organ Class Code | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891454","Dosing Days to Detection","C117041","The number of days from the start of dosing to the earliest detection of a condition or pathogen.","Dosing Days to Detection | DETECT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897888","Planned End of Assessment Interval","C117042","The period of time that the assessment, done over an interval of time, is intended to finish.","Planned End of Assessment Interval | ENINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889647","MHF2","C116632","Human CENPX wild-type allele is located in the vicinity of 17q25.3 and is approximately 5 kb in length. This allele, which encodes centromere protein X, is involved in DNA binding, DNA repair and the resolution of DNA replication forks.","CENPX wt Allele | CENP-X | CENPX | Centromere Protein X wt Allele | D9 | FAAP10 | Fanconi Anemia-Associated Polypeptide, 10-kD Gene | MHF2 | Retinoic Acid-Inducible Gene D9 | STRA13 | Stimulated By Retinoic Acid 13 Gene | Stimulated By Retinoic Acid 13 Homolog (Mouse) Gene | Stimulated By Retinoic Acid 13 Homolog Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388469","Intraoperative Complication Management and Prevention","C116687","Any action taken during surgery whose purpose is to mitigate and/or prevent the occurrence of an undesirable outcome.","Intraoperative Complication Management and Prevention | Intraoperative Complication Management/Prevention",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890928","Histone H2B Type 1-D, human","C116688","Histone H2B type 1-D (126 aa, ~14 kDa) is encoded by the human H2BC5 gene. This protein plays a role in the structure of nucleosomes.","Histone H2B Type 1-D | H2B/b | H2BC5 | HIRA-Interacting Protein 2 | HIST1H2BD | Histone H2B.1 B | Histone H2B.b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053617","Anti-alpha5beta1 Integrin Antibody MINT1526A","C116865","An antibody directed against the human alpha5beta1 integrin (a5b1) with potential antiangiogenic and antineoplastic activities. Anti-a5b1 antibody MINT1526A selectively binds to a5b1, thereby preventing the binding of integrin ligands. This may result in the inhibition of endothelial cell-cell interactions, endothelial cell-matrix interactions, and integrin-mediated tumor angiogenesis and metastasis in a5b1-expressing tumor cells. a5b1, a cell adhesion and signaling receptor, is often overexpressed on the surface of tumor vessel endothelial cells and plays a crucial role in both endothelial cell adhesion and migration.","Anti-alpha5beta1 Integrin Antibody MINT1526A | Anti-a5b1 Antibody MINT1526A | MINT-1526A | MINT1526A | RG-7594",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3659325","c-Met Inhibitor MK8033","C116866","An orally bioavailable inhibitor of c-Met, with potential antineoplastic activity. Upon administration, c-Met inhibitor MK8033 binds to and inhibits the autophosphorylation of the c-Met protein, which disrupts c-Met signal transduction pathways and may induce cell death in tumor cells overexpressing or expressing constitutively activated c-Met protein. In addition, MK8033 inhibits Ron (receptor originated from nantes, MST1R). c-Met protein, which is encoded by the proto-oncogene MET, is a receptor tyrosine kinase also known as hepatocyte growth factor receptor (HGFR); this protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis. Ron, a member of the Met family of cell surface receptor tyrosine kinases, is also overexpressed on certain tumor cell types.","c-Met Inhibitor MK8033 | 1-(3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl)-N-(pyridin-2-ylmethyl)methanesulfonamide | MK 8033 | MK-8033 | MK8033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433891","HDM2 Inhibitor MK-8242","C116867","An orally bioavailable inhibitor of human homolog of double minute 2 (HDM2), with potential antineoplastic activity. Upon oral administration, HDM2 inhibitor MK-8242 inhibits the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the degradation of p53 is inhibited, which may result in the restoration of p53 signaling. This induces p53-mediated tumor cell apoptosis. HDM2 is a member of the RING finger-type family of E3 ubiquitin protein ligases and targets p53 for degradation; it is often overexpressed in cancer cells and has been implicated in cancer cell proliferation and survival.","HDM2 Inhibitor MK-8242 | MK-8242 | SCH 900242",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1958831","Modified Vaccinia Virus Ankara Vaccine Expressing p53","C116868","A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the wild-type form of the tumor protein p53 (wt p53), with potential immunostimulating and antineoplastic activities. Upon subcutaneous vaccination with MVA vaccine expressing p53, the expressed p53 may stimulate the host immune system to mount a p53-specific cytotoxic T-lymphocyte (CTL) response against tumor cells expressing p53, resulting in tumor cell lysis. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attentuated, replication-defective vaccinia strain and is incapable of virion assembly. The p53 gene, a tumor suppressor gene, is mutated in many cancer cell types.","Modified Vaccinia Virus Ankara Vaccine Expressing p53 | MVA-p53 | MVA-p53 Vaccine | MVAp53 Vaccine | p53-MVA Vaccine | p53MVA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899761","CLDN6 wt Allele","C117144","Human CLDN6 wild-type allele is located in the vicinity of 16p13.3 and is approximately 5 kb in length. This allele, which encodes claudin-6 protein, plays a role in cell-cell adhesion.","CLDN6 wt Allele | Claudin 6 wt Allele | UNQ757/PRO1488",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1570897","Claudin-6, Human","C117145","Claudin-6 (220 aa, ~23 kDa) is encoded by the human CLDN6 gene. This protein is involved in the formation of tight junctions.","Claudin-6 | CLDN-6 | CLDN6 | Claudin 6 | Skullin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890907","TFAP2E wt Allele","C117147","Human TFAP2E wild-type allele is located in the vicinity of 1p34.3 and is approximately 22 kb in length. This allele, which encodes transcription factor AP-2-epsilon protein, is involved in transcriptional regulation.","TFAP2E wt Allele | AP2E | Transcription Factor AP-2 Epsilon (Activating Enhancer Binding Protein 2 Epsilon) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1529559","Transcription Factor AP-2-Epsilon, Human","C117148","Transcription factor AP-2-epsilon (442 aa, ~46 kDa) is encoded by the human TFAP2E gene. This protein plays a role in the regulation of gene transcription.","Transcription Factor AP-2-Epsilon | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890187","ARRDC3 wt Allele","C117151","Human ARRDC3 wild-type allele is located in the vicinity of 5q14.3 and is approximately 15 kb in length. This allele, which encodes arrestin domain-containing protein 3, is involved in the modulation of adrenergic receptor signaling.","ARRDC3 wt Allele | Alpha-Arrestin 3 Gene | Arrestin Domain Containing 3 wt Allele | KIAA1376 | TLIMP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1701014","ARRDC3 protein, human","C117152","Arrestin domain-containing protein 3 (414 aa, ~46 kDa) is encoded by the human ARRDC3 gene. This protein plays a role in the regulation of adrenergic receptor signaling pathways.","Arrestin Domain-Containing Protein 3 | Arrestin Domain-Containing 3 | TBP-2-Like Inducible Membrane Protein | Thioredoxin-Binding Protein-2-Like Inducible Membrane",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898210","NCI-H322M","C117155","A bronchioloalveolar carcinoma cell line established from a 52 year old male patient with lung carcinoma.","NCI-H322M | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0961212","Cytochrome P450 2A13, Human","C117156","Cytochrome P450 2A13 (494 aa, ~57 kDa) is encoded by the human CYP2A13 gene. This protein is involved in the oxidation of both flavoproteins and xenobiotics.","Cytochrome P450 2A13 | CYP2A13 | CYPIIA13 | EC 1.14.14.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898209","NCI-H460","C117157","A large cell carcinoma cell line established by A.F. Gazdar and associates in 1982 from the pleural fluid of a male patient with lung carcinoma.","NCI-H460 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898208","NCI-H522","C117158","An adenocarcinoma cell line established by A.F. Gazdar and associates from a 60 year old male patient with lung carcinoma.","NCI-H522 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899747","COLO 205","C117159","An adenocarcinoma cell line established from the ascites fluid of a 70 year old Caucasian male with colon carcinoma.","COLO 205 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1258104","Diffuse Cutaneous Systemic Sclerosis","C116791","A variant of systemic scleroderma characterized by sclerosis of the skin, Raynaud phenomenon, and organ involvement, including pulmonary fibrosis, renal disease, and gastrointestinal tract involvement.","Diffuse Cutaneous Systemic Sclerosis | dSSc | dcSSc",,,,,,,,,,,,,,,"4027727","Systemic sclerosis, diffuse",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL473674","EW-7197","C116357","An orally bioavailable inhibitor of the serine/threonine kinase, transforming growth factor (TGF)-beta receptor type 1 (TGFBR1), also known as activin receptor-like kinase 5 (ALK5), with potential antineoplastic activity. Upon oral administration, vactosertib inhibits the activity of TGFBR1 and prevents TGF-beta/TGFBR1-mediated signaling. This suppresses tumor growth in TGFBR1-overexpressing tumor cells. TGFBR1, which is overexpressed in a variety of tumor cell types, plays a key role in tumor cell proliferation. Expression of TGF-beta promotes tumor cell proliferation, enhances the migration of tumor cells and suppresses the response of the host immune system to tumor cells.","Vactosertib | TEW-7197 | TEW7197 | TGFBR1 Inhibitor TEW-7197 | VACTOSERTIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034734","Secondary Raynaud Phenomenon","C116359","Raynaud phenomenon associated with an underlying autoimmune disorder.","Secondary Raynaud Phenomenon | Raynaud Syndrome | Raynaud's Syndrome | Secondary Raynaud Disease | Secondary Raynaud's Disease | Secondary Raynaud's Phenomenon",,,,,,,,,,,,,,,"4229162","Secondary Raynaud's phenomenon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0151445","Primary Raynaud Phenomenon","C116360","Raynaud phenomenon without a known underlying autoimmune disorder.","Primary Raynaud Phenomenon | Primary Raynaud Disease | Primary Raynaud's Disease | Primary Raynaud's Phenomenon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1561701","Behavioral Insomnia of Childhood","C116361","A childhood disorder characterized by difficulty initiating and maintaining sleep due to negative sleep associations, refusal to go to bed, and/or repeated attempts to delay bedtime.","Behavioral Insomnia of Childhood | ",,,,,,,,,,,,,,,"43021812","Behavioral insomnia of childhood",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0854348","Alice in Wonderland Syndrome","C116362","A neurological syndrome characterized by distorted perceptions of shape, loss of sense of time, and visual, auditory, and tactile hallucinations.","Alice in Wonderland Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2717757","Susac Syndrome","C116363","An autoimmune microvascular disease that is characterized by the clinical triad of encephalopathy, branch retinal artery occlusions, and hearing loss.","Susac Syndrome | ",,,,,,,,,,,,,,,"45765600","Retinocochleocerebral vasculopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1852271","Auditory Neuropathy Spectrum Disorder","C116364","A hearing disorder characterized by impaired transmission of signals through the auditory nerve, resulting in mild to severe hearing loss and poor speech perception.","Auditory Neuropathy Spectrum Disorder | ANSD | Auditory Dys-synchrony | Auditory Neuropathy",,,,,,,,,,,,,,,"40483271","Auditory neuropathy spectrum disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018779","Functional Hearing Loss","C116365","Hearing loss in the absence of auditory system pathology.","Functional Hearing Loss | ",,,,,,,,,,,,,,,"4107706","Psychogenic deafness",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034880","Hyperacusis","C116366","A disorder in which an individual has an abnormally low noise tolerance, and increased sensitivity to sounds.","Hyperacusis | ",,,,,,,,,,,,,,,"378163","Hyperacusis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0033074","Presbycusis","C116367","Bilateral hearing loss caused by progressive degeneration of cochlear structures and central auditory pathways, typically associated with the aging process.","Presbycusis | ",,,,,,,,,,,,,,,"377574","Presbycusis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2364082","Hyposmia","C116368","Decreased ability to smell.","Hyposmia | ",,,,,,,,,,,,,,,"4307095","Sense of smell impaired",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0235287","Dysosmia","C116370","Abnormal sense of smell.","Dysosmia | Smell Disorder",,,,,,,,,,,,,,,"444223","Sense of smell altered",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3888024","Cacosmia","C116371","A hallucination of an unpleasant odor.","Cacosmia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2974597","Centromere Protein X, human","C116633","Centromere protein X (81 aa, ~9 kDa) is encoded by the human CENPX gene. This protein is involved in the processing of DNA replication forks, DNA binding and DNA repair.","Centromere Protein X | CENP-X | CENPX | Centromeric Protein X | FANCM Associated Histone Fold Protein 2 | FANCM-Associated Histone Fold Protein 2 | FANCM-Interacting Histone Fold Protein 2 | FANCM-Interacting Histone-Fold Protein 2 | Fanconi Anemia-Associated Polypeptide of 10 kDa | Fanconi Anemia-Associated Polypeptide, 10-kD | Retinoic Acid-Inducible Gene D9 Protein Homolog | Stimulated By Retinoic Acid Gene 13 Protein Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889265","RPA2 wt Allele","C116635","Human RPA2 wild-type allele is located in the vicinity of 1p35 and is approximately 23 kb in length. This allele, which encodes replication protein A 32 kDa protein, plays a role in DNA replication, repair and recombination.","RPA2 wt Allele | REPA2 | RP4-547C9.3 | RPA32 | RPA34 | Replication Protein A2 (32kD) Gene | Replication Protein A2 wt Allele | Replication Protein A2, 32-kD Gene | Replication Protein A2, 32kDa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1869222","RPA2 protein, human","C116636","Replication protein A 32 kDa (270 aa, ~29 kDa) is encoded by the human RPA2 gene. This protein is involved in DNA recombination, replication and repair.","Replication Protein A 32 kDa Subunit | RF-A Protein 2 | RP-A p32 | RP-A p34 | RPA2 | Replication Factor A Protein 2 | Replication Protein A 34 kDa Subunit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889264","RPA3 wt Allele","C116638","Human RPA3 wild-type allele is located in the vicinity of 7p21.3 and is approximately 82 kb in length. This allele, which encodes replication protein A 14 kDa protein, is involved in DNA repair, replication and recombination.","RPA3 wt Allele | REPA3 | RP-A p14 | RPA14 | Replication Protein A3 (14kD) Gene | Replication Protein A3 wt Allele | Replication Protein A3, 14-kD Gene | Replication Protein A3, 14kDa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897719","RPA3 protein, human","C116639","Replication protein A 14 kDa (121 aa, ~14 kDa) is encoded by the human RPA3 gene. This protein plays a role in replication, recombination and repair of DNA.","Replication Protein A 14 kDa | RF-A Protein 3 | RP-A P14 | RPA3 | Replication Factor A Protein 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0599662","magnetic cell separation system","C116641","A method of cell sorting that uses paramagnetic beads that are coated with antibodies, antigens, receptors, receptor substrates, binding proteins, etc to separate target cells from solution.","Magnetic Affinity Cell Sorting | MACS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206056","Microdialysis","C116642","A blood sampling technique that allows for the collecting of low-molecular-weight substances from the interstitial space. It is used to quantify hormones, neurotransmitters, and peptides in the study subject.","Microdialysis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3854551","Microwave Ablation","C116643","A treatment modality that uses directed electromagnetic waves within the microwave spectrum to heat the targeted tissue for the purpose of causing tissue necrosis within solid tissue tumors.","Microwave Ablation | Ablation, Microwave",,,,,,,,,,,,,,,"36684841","Microwave ablation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3889438","GSTA4 wt Allele","C116646","Human GSTA4 wild-type allele is located in the vicinity of 6p12.1 and is approximately 17 kb in length. This allele, which encodes glutathione S-transferase A4 protein, plays a role in the metabolism of endogenous and exogenous small hydrophobic molecules.","GSTA4 wt Allele | GSTA4-4 | GTA4 | Glutathione S-Transferase Alpha 4 wt Allele | Glutathione S-Transferase, Alpha-4 Gene | RP1-214M20.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471764","Pegylated Liposomal Nanoparticle-based Docetaxel Prodrug MNK-010","C116869","A formulation containing pegylated liposomal nanoparticles encapsulating a prodrug of the poorly water-soluble, second-generation taxane analog docetaxel, with potential antineoplastic activity. Upon intravenous administration of the liposomal docetaxel prodrug MNK-010, docetaxel is slowly released into the systemic circulation and accumulates at the tumor site due to the unique characteristics of the tumor's vasculature. In turn, docetaxel is taken up by tumor cells, and subsequently binds to and stabilizes the beta-subunit of tubulin, thereby stabilizing microtubules and inhibiting microtubule disassembly. This results in cell cycle arrest and induces cell death. Compared to the administration of docetaxel alone, this formulation is able to increase the delivery of docetaxel into tumors, thereby increasing docetaxel's efficacy while minimizing its toxicity. In addition, this formulation solubilizes docetaxel without the use of toxic solvents, thereby permitting the administration of larger doses of docetaxel while avoiding solvent-associated toxicity.","Pegylated Liposomal Nanoparticle-based Docetaxel Prodrug MNK-010 | MNK-010 | MP-3549-1 | Pegylated Liposomal Docetaxel Prodrug MNK-010",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898480","Macroscopic Findings Sponsor Defined Identifier","C119872","One or more sponsor defined characters used to identify, name, or characterize the macroscopic findings assessment.","Macroscopic Findings Sponsor Defined Identifier | MASPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897310","Tumor Findings Method","C119932","The technique used to administer the tumor findings assessment.","Tumor Findings Method | TFMETHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471761","Low Field Strength Magnetic Resonance Imaging","C116456","A type of magnetic resonance imaging that uses a weaker magnet (less than or equal to 0.3 Tesla) than is used in conventional magnetic resonance imaging. This is typical of open MRI machines and office-based MRI units.","Low Field Strength Magnetic Resonance Imaging | Low Field Strength MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471729","Magnetization Transfer Magnetic Resonance Imaging","C116457","A type of magnetic resonance imaging that involves the transfer of longitudinal magnetization of hydrogen nuclei between restricted motion water and free motion water, allowing for the calculation of the magnetization transfer ratio (MTR), an indicator of the structural integrity of the imaged tissue.","Magnetization Transfer Magnetic Resonance Imaging | Magnetization Transfer MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412385","Specimen Ultra-High-Field Magnetic Resonance Imaging","C116460","A type of magnetic resonance imaging that uses very high field stength to provide a very detailed image of the targeted tissue.","Specimen Ultra-High-Field Magnetic Resonance Imaging | Specimen Ultra-High-Field MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412368","Superparamagnetic Iron Oxide Magnetic Resonance Imaging","C116461","A magnetic resonance imaging technique that uses superparamagnetic iron oxide particles as a contrast agent to aid in the identification of multiple disorders, including atherosclerosis, blood-brain barrier dysfunction, and cancer.","Superparamagnetic Iron Oxide Magnetic Resonance Imaging | SPIO-MRI | Superparamagnetic Iron Oxide MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471727","Autologous Ovarian Tissue Transplantation","C116463","Ovarian transplantation using autologous tissue. The goal of this procedure is to restore both endocrine function and reproductive function.","Autologous Ovarian Tissue Transplantation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3712375","Androgen Receptor Downregulator AZD3514","C116726","An orally available selective androgen receptor (AR) downregulator (SARD), with potential antineoplastic activity. Upon oral administration, AZD3514 binds to the AR ligand binding domain and inhibits the binding of androgen, thereby preventing androgen-dependent AR signaling. AZD3514 also causes downregulation of AR expression, which further prevents AR-mediated signaling. This results in an inhibition of proliferation in AR-overexpressing tumor cells. AR plays a key role in the proliferation of castration-resistant prostate cancer cells.","Androgen Receptor Downregulator AZD3514 | AZD3514 | SARD AZD3514",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896911","ALK Inhibitor ASP3026","C116727","An orally available, small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon oral administration, ASP3026 binds to and inhibits ALK tyrosine kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors. Additionally, ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors.","ALK Inhibitor ASP3026 | ASP-3026 | ASP3026 | N2-[2-Methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-1,3,5-triazine-2,4-diamine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900153","iNOS Dimerization Inhibitor ASP9853","C116728","An orally bioavailable small molecule inhibitor of inducible nitric oxide synthase (iNOS) with potential antineoplastic activity. Upon administration, iNOS Dimerization Inhibitor FK-330 inhibits iNOS dimerization, which results in decreased nitric oxide (NO) production. iNOS expression is upregulated in certain cancers and may invoke a chronic inflammatory state in tumor cells that promotes metastatic growth.","iNOS Dimerization Inhibitor FK-330 | FK-330 | FR-260330 | iNOS Dimerization Inhibitor ASP9853",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3660880","Ilorasertib","C116729","An orally bioavailable, adenosine triphospate mimetic, and inhibitor of Aurora kinases, vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptor (PDGFRs), with potential antineoplastic activity. Upon administration, ilorasertib selectively binds to and inhibits Aurora kinases A, B and C, which may disrupt both the assembly of the mitotic spindle apparatus and chromosome segregation, and inhibit both cellular division and proliferation in Aurora kinase-overexpressing tumor cells. In addition, ilorasertib selectively binds to and inhibits VEGFRs and PDGFRs, which may result in the inhibition of both angiogenesis and tumor cell proliferation in VEGFR/PDGFR-overexpressing tumor cells. This agent also inhibits the Src family of cytoplasmic tyrosine kinases. Aurora kinases A, B and C, are serine/threonine kinases that play essential roles in mitotic checkpoint control and are overexpressed by a wide variety of tumor cell types. Both VEGFRs and PDGFRs are receptor tyrosine kinase families whose members may be upregulated in various tumor cell types.","Ilorasertib | 1-(4-(4-Amino-7-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)thieno[3,2-c]pyridin-3-yl)phenyl)-3-(3-fluorophenyl)urea | A-968660.0 | ABT-348 | ILORASERTIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3809594","Choreoathetosis","C116730","Abnormal movement characterized by involuntary jerking and writhing affecting the limbs, trunk, and facial muscles.","Choreoathetosis | Choreathetosis",,,,,,,,,,,,,,,"4181630","Choreoathetosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL433715","Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes","C116732","A population of autologous cytotoxic-T lymphocytes (CTLs) specifically reactive to the herpes virus cytomegalovirus (CMV) with potential immunomodulating and antiviral activities. Upon administration with the autologous CMV-specific CTLs, these CTLs lyse CMV-infected cells, thereby preventing or decreasing the occurrence of CMV viral disease, or reducing the amount of antiviral drug therapy needed to eradicate CMV.","Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes | Autologous CMV-specific CTLs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2242552","Phantosmia","C116372","Detection of odors that are not present.","Phantosmia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0151934","Hypogeusia","C116373","Decreased ability to taste.","Hypogeusia | ",,,,,,,,,,,,,,,"44783805","Hypogeusia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897936","Phantogeusia","C116375","A lingering, usually unpleasant, taste without the associated stimulus.","Phantogeusia | Phantom Taste Perception",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020453","Hyperesthesia","C116376","Increased sensitivity to tactile stimulation.","Hyperesthesia | ",,,,,,,,,,,,,,,"4031840","Hyperesthesia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899741","CTRP Terminology","C116977","Terminology that is used to support NCI's Clinical Trials Reporting Program (CTRP), a database that captures the required reporting data for all NCI-sponsored clinical trials.","CTRP Terminology | Clinical Trials Reporting Program Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899744","CTRP Agent Terminology","C116978","A subset of terminology about pharmacologic substances and formulations that are currently being used or tested in clinical trials for the treatment of cancer, cancer-related conditions and chemo/radiotherapy-related side effects.","CTRP Agent Terminology | Clinical Trials Reporting Program Agent Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890018","HSP90B2P wt Allele","C116983","Human HSP90B2P wild-type allele is located in the vicinity of 15q26.3 and is approximately 3 kb in length. This allele, which may encode putative endoplasmin-like protein, may be involved in protein folding.","HSP90B2P wt Allele | GRP94B | GRP94P1 | GRP94b | HSP | HSPCP2 | Heat Shock Protein 90kDa Beta (Grp94), Member 2, Pseudogene wt Allele | TRA1P1 | TRAP1 | Tumor Rejection Antigen (Gp96) 1 Pseudogene 1 | Tumor Rejection Antigen (Gp96) Pseudogene 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890929","Putative Endoplasmin-Like Protein, human","C116984","Putative endoplasmin-like protein (399 aa, ~46 kDa) is encoded by the human HSP90B2P gene. This protein may play a role in protein chaperone activity.","Putative Endoplasmin-Like Protein | HSP90B2P | Putative Heat Shock Protein 90 kDa Beta Member 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0151449","Primary Sjogren Syndrome","C116985","Sjogren syndrome without a concomitant systemic autoimmune disorder.","Primary Sjogren Syndrome | Primary Sjogren's syndrome | Primary Sjögren Syndrome",,,,,,,,,,,,,,,"4347058","Primary Sjögren's syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0151450","Secondary Sjogren Syndrome","C116986","Sjogren syndrome that occurs with another systemic autoimmune disorder, such as systemic lupus erythematosus or rheumatoid arthritis.","Secondary Sjogren Syndrome | Secondary Sjogren's syndrome | Secondary Sjögren Syndrome",,,,,,,,,,,,,,,"4344163","Secondary Sjögren's syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897492","Sternocleidomastoid Injury Related to Birth","C116842","Disruption of the sternocleidomastoid muscle incurred during delivery.","Sternocleidomastoid Injury Related to Birth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL774945","BTK inhibitor GDC-0853","C116844","An orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, fenebrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival.","Fenebrutinib | Bruton Tyrosine Kinase Inhibitor GDC-0853 | FENEBRUTINIB | GDC-0853",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446611","Chk1 Inhibitor GDC-0575","C116845","A small molecule inhibitor of cell cycle checkpoint kinase 1 (Chk1), with potential chemosensitization activity. Chk1 inhibitor GDC-0575 specifically binds to and inhibits Chk1; this may result in tumor cells bypassing Chk1-dependent cell cycle arrest in the S and G2/M phases, which permits the cells to undergo DNA repair prior to entry into mitosis. Therefore, Chk1 inhibition may sensitize tumor cells to the DNA-damaging effects of certain chemotherapeutic agents. Chk1 is an ATP-dependent serine-threonine kinase that phosphorylates cdc25 phosphatases in response to DNA damage. This results in both inhibitory tyrosine phosphorylation of cyclin-dependent kinase (CDK)-cyclin complexes and cell cycle arrest, which facilitates DNA damage repair.","Chk1 Inhibitor GDC-0575 | Checkpoint Kinase 1 Inhibitor GDC-0575 | GDC-0575",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433833","Genetically Engineered NY-ESO-1-specific T Lymphocytes","C116846","A preparation of human T-lymphocytes recognizing the tumor-associated antigen (TAA), cancer/testis antigen 1 (NY-ESO-1), with potential immunostimulating and antineoplastic activities. Genetically engineered NY-ESO-1-specific T-lymphocytes target tumor cells expressing the NY-ESO-1 antigen, resulting in tumor cell lysis. NY-ESO-1, an antigen found in normal testis, is overexpressed on the surface of various tumor cell types.","Genetically Engineered NY-ESO-1-specific T Lymphocytes | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433722","Anti-NY-ESO-1 Immunotherapeutic GSK-2241658A","C116847","An immunotherapeutic agent targeting the tumor-associated antigen (TAA), cancer/testis antigen NY-ESO-1, with potential antineoplastic activity.","Anti-NY-ESO-1 Immunotherapeutic GSK-2241658A | CTAG1A ASCI | GSK-2241658A | GSK2241658A | GSK2241658A Antigen-Specific Cancer Immunotherapeutic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL421661","Anti-PRAME Immunotherapeutic GSK2302032A","C116848","An immunotherapeutic agent targeting the tumor-associated antigen (TAA), preferentially expressed antigen of melanoma (PRAME), with potential antineoplastic activity.","Anti-PRAME Immunotherapeutic GSK2302032A | GSK-2302032A | GSK2302032A | PRAME ASCI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3713994","GSK-3 Inhibitor LY2090314","C116849","An inhibitor of glycogen synthase kinase-3 (GSK-3), with potential antineoplastic activity. Upon administration, LY2090314 binds to and inhibits GSK-3 in an ATP-competitive manner. This prevents GSK-3-mediated phosphorylation of beta-catenin, which inhibits the subsequent ubiquitination and proteasomal degradation of beta-catenin. This leads to the activation of the Wnt/beta-catenin pathway and the induction of apoptosis in susceptible tumor cells. GSK-3, a serine/threonine kinase, plays a key role in numerous pathways involved in protein synthesis, cellular proliferation, differentiation, and apoptosis. The Wnt/beta-catenin signaling pathway plays key roles in both cellular proliferation and differentiation. The increased expression of beta-catenin, a transcriptional activator, correlates with decreased cellular proliferation and improved prognosis in select cancers.","GSK-3 Inhibitor LY2090314 | 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione | LY 2090314 | LY-2090314 | LY2090314",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005976","Bone Graft","C116464","A surgical procedure to replace missing or severely damaged bone with healthy, viable bone tissue.","Bone Graft | Bone Graft Procedure | Bone Graft Surgery",,,,,,,,,,,,,,,"4214028","Bone graft",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL388422","Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation","C116465","Therapy that combines cytoreductive-therapy from high-dose therapy and autologous hematopoietic cell transplantation with adoptive immunotherapy (from allogeneic hematopoietic cell transplantation) as a treatment strategy for multiple myeloma.","Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation | auto-allo HCT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388423","Autologous-Autologous Tandem Hematopoietic Stem Cell Transplantation","C116466","Therapy that combines cytoreductive-therapy from high-dose therapy and autologous hematopoietic cell transplantation with adoptive immunotherapy (from autologous hematopoietic cell transplantation) as a treatment strategy for multiple myeloma.","Autologous-Autologous Tandem Hematopoietic Stem Cell Transplantation | Stem Cell Transplantation, Double Autologous | auto-auto HCT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1257990","Mesenchymal Stem Cell Transplantation","C116467","The transfer of multipotent stromal cells from donor to recipient for the treatment of a variety of different systemic and localized diseases.","Mesenchymal Stem Cell Transplantation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL421553","T Cell-Depleted Hematopoietic Stem Cell Transplantation","C116468","The removal of T-cells from the donor's hematopoietic stem cell specimen prior to its transfusion into the recipient.","T Cell-Depleted Hematopoietic Stem Cell Transplantation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1174310","Mastermind-Like Protein 3, Human","C117096","Mastermind-like protein 3 (1134 aa, ~122 kDa) is encoded by the human MAML3 gene. This protein plays a role in both the positive regulation of transcription and signal transduction.","Mastermind-Like Protein 3 | MAML3 | Mam-3 | Mastermind-Like 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412478","APOC3 Gene","C117097","This gene is involved in the regulation of lipoprotein metabolism and transport.","APOC3 Gene | APOC3 | Apolipoprotein C3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890739","APOC3 wt Allele","C117098","Human APOC3 wild-type allele is located in the vicinity of 11q23.3 and is approximately 3 kb in length. This allele, which encodes apolipoprotein C-III protein, plays a role in the transport and half-life of very low density lipoproteins and chylomicrons. Mutation of the gene is associated with hyperalphalipoproteinemia 2. Fusion of this gene with the 3' end of the neighboring APOA1 gene is associated with combined apoA-I and apoC-III deficiency.","APOC3 wt Allele | APOCIII | Apolipoprotein C-III Genes | Apolipoprotein C3 wt Allele | HALP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0052191","APOC3 protein, human","C117099","Apolipoprotein C-III (99 aa, ~11 kDa) is encoded by the human APOC3 gene. This protein is involved in the modulation of cellular uptake and metabolism of very low density lipoproteins and chylomicrons.","Apolipoprotein C-III | APOC3 | Apo-CII | ApoC-III | Apolipoprotein C3 | Apolipoprotein CIII",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0068006","Miltefosine","C1170","An orally- and topically-active alkyl-phosphocholine compound with potential antineoplastic activity.  Miltefosine targets cellular membranes, modulating cell membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth.  This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis.  As an immunomodulator, miltefosine stimulates T-cells, macrophages and the expression of interleukin 3 (IL-3), granulocyte-macrophage colony stimulating factor (GM-CSF), and interferon gamma (INF-gamma). (NCI04)","Miltefosine | 2-[[(Hexadecycloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethylethanaminium Inner Salt | Choline Phosphate Hexadecyl Ester, Hydroxide, Inner Salt | D-18506 | Hexadecyl 2-(N,N,N-trimethylamino)ethyl Phosphate | Hexadecylphosphocholine | MILTEFOSINE | Miltefosin | Miltefosina | Miltefosinum | Miltex | n-Hexadecylphosphorylcholine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433717","Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine","C116733","A plasmid DNA vaccine encoding an autologous lymphoma-derived idiotype-targeting immunoglobulin (Ig)-derived single chain variable fragment (scFv) fused to the chemokine macrophage inflammatory protein 3 alpha (MIP3a), with potential immunostimulating and antineoplastic activities. Upon intramuscular vaccination, the autologous lymphoma immunoglobulin-derived scFv-chemokine DNA vaccine is taken up by antigen-presenting cells (APCs) and stimulates the immune system to exert a cytotoxic T-lymphocyte (CTL) response against the idiotype expressed on the surface of B lymphoma cells. MIP3a, also called chemokine (C-C motif) ligand 20 (CCL20), is a chemotactic cytokine able to enhance the immune response through binding to chemokine receptors expressed on APCs.","Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine | Autologous Lymphoma Immunoglobulin-derived scFV-chemokine DNA Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL421664","Nanoparticle Albumin-bound Thiocolchicine Dimer nab-5404","C116890","A nanoparticle albumin-bound formulation of a thiocolchicine dimer, an inhibitor of both microtubule and topoisomerase I (TOP1), with antineoplastic and vascular disrupting activities. Upon administration of nanoparticle albumin-bound thiocolchicine dimer nab-5404, this agent binds to tubulin and inhibits its polymerization, which blocks mitotic spindle formation and leads to cell cycle arrest and tumor endothelial cell apoptosis. This disrupts the tumor vasculature and leads to tumor necrosis. In addition, nab-5404 binds to topoisomerase I (TOPI) and inhibits its activity. This results in the inhibition of the repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations. The nanoparticle albumin-based formulation permits the albumin-mediated endocytosis of the thiocolchicine dimer by tumor cells and endothelial cells.","Nanoparticle Albumin-bound Thiocolchicine Dimer nab-5404 | ABI-011 | IDN 5404 | IDN-5404 | NTB-011 | nab-5404 | nab-Thiocolchicine Dimer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3180910","Galunisertib","C116891","An orally available, small molecule antagonist of the tyrosine kinase transforming growth factor-beta (TGF-b) receptor type 1 (TGFBR1), with potential antineoplastic activity. Upon administration, galunisertib specifically targets and binds to the kinase domain of TGFBR1, thereby preventing the activation of TGF-b-mediated signaling pathways. This may inhibit the proliferation of TGF-b-overexpressing tumor cells. Dysregulation of the TGF-b signaling pathway is seen in a number of cancers and is associated with increased cancer cell proliferation, migration, invasion and tumor progression.","Galunisertib | 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide | GALUNISERTIB | LY-2157299 | LY2157299",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1541529","FGFR/VEGFR/PDGFR/FLT3/SRC Inhibitor XL999","C116894","A small molecule inhibitor of numerous tyrosine kinases (TKs) including fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), FMS-related tyrosine kinase 3 (FLT3), and SRC, with potential antineoplastic activity. Upon administration, XL999 binds to and inhibits the activity of these TKs, thereby preventing both the activation of downstream signaling pathways and the proliferation of tumor cells overexpressing these TKs. FGFR, VEGFR, PDGFR, FLT-3, and SRC are upregulated in a variety of cancer cell types and play key roles in tumor cell proliferation, angiogenesis, and metastasis.","FGFR/VEGFR/PDGFR/FLT3/SRC Inhibitor XL999 | SSKI XL999 | Spectrum Selective Kinase Inhibitor XL999 | XL-999 | XL999",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0392452","Craniotabes","C116895","Softening of the skull seen in newborns due to incomplete mineralization.","Craniotabes | ",,,,,,,,,,,,,,,"4219613","Craniotabes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1142052","Cranial Suture Separation","C116896","A finding of increased space between the intersections of a newborn's cranial bones.","Cranial Suture Separation | Cranial Suture Widening | Cranial Sutures Widening",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0235014","Fontanelle Bulging","C116897","Membranous areas between cranial bones in a newborn that appear elevated or full.","Fontanelle Bulging | Bulging Fontanel | Fontanel Bulging",,,,,,,,,,,,,,,"4011769","Bulging fontanelle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1095924","Fontanelle Depressed","C116898","Membranous areas between cranial bones in a newborn that appear depressed or sunken.","Fontanelle Depressed | Depressed Fontanel | Fontanel Depressed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
,,,,,,,,,,,,,,,,,,,"619218","Congenital malformation of lymphatic system of cervicofacial region",,,,,,,,,,,,,,,,,,,,,,"--"
"C0066615","2-Ethylhydrazide","C1165","A podophyllic acid derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, 2-ethylhydrazide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.","2-Ethylhydrazide | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4229495","Gross Motor Delay","C116601","Abnormally late development of the coordination of the muscles, bones, and/or nerves that produces whole body and large muscle group movements.","Gross Motor Delay | ",,,,,,,,,,,,,,,"4328436","Gross motor development delay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1735324","Fine Motor Delay","C116602","Delayed acquisition of age appropriate motor milestones that produce small and precise movements.","Fine Motor Delay | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900165","APOA4 wt Allele","C116604","Human APOA4 wild-type allele is located in the vicinity of 11q23 and is approximately 3 kb in length. This allele, which encodes apolipoprotein A-IV protein, plays a role in the modulation of chylomicron and very low density lipoprotein transport.","APOA4 wt Allele | Apolipoprotein A-IV Gene | Apolipoprotein A4 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0052181","Apolipoprotein A-IV","C116605","Apolipoprotein A-IV (396 aa, ~45 kDa) is encoded by the human APOA4 gene. This protein is involved in both the transport and catabolism of chylomicrons and very low density lipoproteins.","Apolipoprotein A-IV | APOA4 | Apo-A4 | Apo-AIV | ApoA-IV | Apolipoprotein A4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890185","HAVCR1 wt Allele","C116607","Human HAVCR1 wild-type allele is located in the vicinity of 5q33.2 and is approximately 30 kb in length. This allele, which encodes hepatitis A virus cellular receptor 1 protein, plays a role in asthma, allergic reactions, hepatitis A binding and T-helper cell development. Polymorphism of the gene can modulate susceptibility to both hepatitis A infection and atopy.","HAVCR1 wt Allele | CD365 | HAVCR | HAVCR-1 | Hepatitis A Virus Cellular Receptor 1 wt Allele | KIM-1 | KIM1 | T Cell Immunoglobin Domain and Mucin Domain Protein 1 | T-Cell Immunoglobulin Mucin Family Member 1 Gene | TIM | TIM-1 | TIM1 | TIMD-1 | TIMD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1313407","Hepatitis A Virus Cellular Receptor 1, Human","C116608","Hepatitis A virus cellular receptor 1 (359 aa, ~39 kDa) is encoded by the human HAVCR1 gene. This protein is involved in the modulation of asthma and allergic reactions.","Hepatitis A Virus Cellular Receptor 1 | CD365 | CD365 Antigen | HAVcr-1 | KIM-1 | KIM1 | Kidney Injury Molecule 1 | Kidney Injury Molecule-1 | T Cell Immunoglobin Domain and Mucin Domain Protein 1 | T-Cell Immunoglobulin Mucin Receptor 1 | T-Cell Immunoglobulin and Mucin Domain-Containing Protein 1 | T-Cell Immunoglobulin and Mucin Domains-Containing Protein 1 | T-Cell Membrane Protein 1 | TIM | TIM-1 | TIMD-1 | TIMD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2001522","HDAC inhibitor AR-42","C116850","An orally available phenylbutyrate-derived histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon oral administration, REC-2282 inhibits the catalytic activity of HDAC, which results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. This leads to the inhibition of tumor oncogene transcription, and the selective transcription of tumor suppressor genes, which inhibits tumor cell division and induces tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins.","HDAC Inhibitor REC-2282 | (S)-N-hydroxy-4-(3-methyl-2-phenylbutanamido)benzamide | AR-42 | HDAC-42 | OSU-HDAC42 | REC-2282",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890562","ISX wt Allele","C116412","Human ISX wild-type allele is located in the vicinity of 22q12.3 and is approximately 21 kb in length. This allele, which encodes intestine-specific homeobox protein, plays a role in the regulation of transcription in intestinal tissue.","ISX wt Allele | Intestine-Specific Homeobox wt Allele | Pix-1 | RAXLX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3657794","Intestine-Specific Homeobox, Human","C116413","Intestine-specific homeobox (245 aa, ~27 kDa) is encoded by the human ISX gene. This protein is involved in intestine tissue-specific regulation of gene transcription.","Intestine-Specific Homeobox | Pancreas-Intestine Homeodomain Transcription Factor | RAX-Like Homeobox",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890208","MTTP wt Allele","C116415","Human MTTP wild-type allele is located in the vicinity of 4q24 and is approximately 60 kb in length. This allele, which encodes microsomal triglyceride transfer protein large subunit protein, is involved in triglyceride, cholesteryl ester, and phospholipid transport. Mutation of the gene is associated with abetalipoproteinemia.","MTTP wt Allele | ABL | MTP | MTP, Large Subunit Gene | Microsomal Triglyceride Transfer Protein (Large Polypeptide, 88kD) Gene | Microsomal Triglyceride Transfer Protein (Large Polypeptide, 88kDa) Gene | Microsomal Triglyceride Transfer Protein wt Allele | Microsomal Triglyceride Transfer Protein, 88-kD Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473851","Microsomal Triglyceride Transfer Protein Large Subunit","C116416","Microsomal triglyceride transfer protein large subunit (894 aa, ~99 kDa) is encoded by the human MTTP gene. This protein plays a role in the targeting of triglycerides, cholesteryl esters, and phospholipids to membranes or vesicles.","Microsomal Triglyceride Transfer Protein Large Subunit | MTTP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900166","APOA1 wt Allele","C116418","Human APOA1 wild-type allele is located within 11q23-q24 and is approximately 2 kb in length. This allele, which encodes apolipoprotein A-I protein, plays a role in cholesterol metabolism and transport. Mutation of the gene is associated with several types of amyloidosis, APOA1 deficiency, hypoalphalipoproteinemia, autosomal recessive corneal clouding, and high density lipoprotein deficiency types 1 (recessive) and 2 (autosomal dominant). Fusion of this gene with the neighboring APOC3 gene is associated with combined apoA-I and apoC-III deficiency.","APOA1 wt Allele | Apolipoprotein A-I Gene | Apolipoprotein A1 wt Allele | Apolipoprotein of High Denisity Lipoprotein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1677784","Apolipoprotein A-I, Human","C116419","Apolipoprotein A-I (267 aa, ~31 kDa) is encoded by the human APOA1 gene. This protein is involved in the transport and metabolism of cholesterol.","Apolipoprotein A-I | APOA1 | Apo-AI | ApoA-I | Apolipoprotein A1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890601","SAR1B wt Allele","C116421","Human SAR1B wild-type allele is located in the vicinity of 5q31.1 and is approximately 48 kb in length. This allele, which encodes GTP-binding protein SAR1b, is involved in both GTPase activity and vesicle transport. Mutation and variation of the gene is associated with chylomicron retention disease.","SAR1B wt Allele | ANDD | CMRD | GTBPB | SAR1 Homolog B (S. cerevisiae) Gene | SAR1, S. cerevisiae, Homolog B Gene | SAR1A, S. cerevisiae, Homolog 2 Gene | SAR1a Gene Homolog (S. cerevisiae) 2 Gene | SAR1a Gene Homolog 2 | SAR1a Gene Homolog 2 (S. cerevisiae) Gene | SARA2 | SARB | Secretion Associated, Ras Related GTPase 1B wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414544","FBP1 Gene","C117100","This gene plays a role in gluconeogenesis.","FBP1 Gene | FBP1 | Fructose-1,6-Bisphosphatase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889142","FBP1 wt Allele","C117101","Human FBP1 wild-type allele is located in the vicinity of 9q22.3 and is approximately 37 kb in length. This allele, which encodes fructose-1,6-bisphosphatase 1 protein, is involved in gluconeogenesis. Mutation of the gene is associated with fructose-1,6-bisphosphatase deficiency, which can cause life-threatening episodes of hypoglycemia and metabolic acidosis.","FBP1 wt Allele | FBP | Fructose-1,6-Bisphosphatase 1 wt Allele | RP11-342C23.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016755","Fructose-1,6-Bisphosphatase 1","C117102","Fructose-1,6-bisphosphatase 1 (338 aa, ~37 kDa) is encoded by the human FBP1 gene. This protein plays a role in gluconeogenesis.","Fructose-1,6-Bisphosphatase 1 | D-Fructose-1,6-Bisphosphate 1-Phosphohydrolase 1 | EC 3.1.3.11 | FBP1 | FBPase 1 | Fructose-1,6-Bisphosphatase, Liver | Fructose-1,6-Diphosphatase | Fructose-Bisphosphatase 1 | Growth-Inhibiting Protein 17 | Liver FBPase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2931591","Juvenile Systemic Sclerosis","C117103","Systemic sclerosis that is diagnosed in children. Juvenile systemic sclerosis is more likely to be of the overlap variant and presents with musculoskeletal involvement.","Juvenile Systemic Sclerosis | JSSc | Juvenile Systemic Scleroderma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0409977","Bullous Systemic Lupus Erythematosus","C117104","A manifestation of systemic lupus erythematosus with a widespread vesiculobullous eruption.","Bullous Systemic Lupus Erythematosus | BSLE",,,,,,,,,,,,,,,"4346976","Bullous systemic lupus erythematosus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3805721","Discoid Rash","C117105","A disc-shaped patch(es) of skin inflammation that is red, raised, and scaly; it typically develops on the face, scalp, and neck, and often leaves scars and dyspigmentation as a result of postinflammatory hyperpigmentation.","Discoid Rash | Discoid Eruption",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0277942","Malar Rash","C117106","An erythematous eruption on the central face, which can be caused by a variety of different conditions.","Malar Rash | Malar Eruption",,,,,,,,,,,,,,,"4148792","Butterfly rash",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221201","Macular Rash","C117107","An outbreak of small, flat, red spots on the skin.","Macular Rash | Macular Eruption",,,,,,,,,,,,,,,"4154924|4233116","Macular eruption|Macular rash",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3899759","CLSPN wt Allele","C116690","Human CLSPN wild-type allele is located in the vicinity of 1p34.3 and is approximately 5 kb in length. This allele, which encodes claspin protein, plays a role in the G2 cell cycle checkpoint.","CLSPN wt Allele | Claspin Homolog (Xenopus laevis) Gene | Claspin Homolog Gene | Claspin wt Allele | Claspin, Xenopus, Homolog of Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447801","Claspin, Human","C116691","Claspin (1339 aa, ~151 kDa) is encoded by the human CLSPN gene. This protein is involved in cell cycle arrest in response to errors in DNA replication.","Claspin | hClaspin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889144","FBXO5 wt Allele","C116693","Human FBXO5 wild-type allele is located within 6q25-q26 and is approximately 13 kb in length. This allele, which encodes F-box only protein 5, is involved in both protein ubiquitination and cell cycle progression.","FBXO5 wt Allele | EMI1 | EMI1, Xenopus, Homolog of Gene | F-Box Protein 5 wt Allele | FBX5 | Fbxo31 | RP1-101K10.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1452363","FBXO5 protein, human","C116694","F-box only protein 5 (447 aa, ~50 kDa) is encoded by the human FBXO5 gene. This protein plays a role in modulating both protein catabolism and the activity of the anaphase promoting complex.","F-Box Only Protein 5 | Early Mitotic Inhibitor 1 | F-Box Protein Fbx5 | FBXO5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412305","Communication Analysis","C116695","The examination of the different ways that information is exchanged between parties.","Communication Analysis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0067116","Diethylnorspermine","C1168","A synthetic bis-ethyl analogue of spermine with potential antineoplastic activity. N(1),N(11)-bis(ethyl)norspermine (DENSPM), a N-terminally alkylated tetraamine and polyamine mimetics, disrupts polyamine pool homeostasis by modulating the activities of the biosynthetic enzymes, ornithine decarboxylase (ODC), and S-adenosylmethionine decarboxylase (AdoMetDC). This agent also reduces polyamine concentrations through the induction of the catabolic enzyme spermidine/spermine N1-acetyltransferase 1 (SSAT). Polyamines, an integral part of the DNA helix structure, play a critical role in cell division, differentiation and membrane function. Disruption of normal polyamine concentrations by DENSPM may lead to cell growth inhibition.","Diethylnorspermine | CI-1006 | DENSPM | DIETHYLNORSPERMINE | N(1),N(11)-diethylnorspermine | N1,N11-bis(ethyl)norspermine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897928","Phrenic Nerve Palsy Related to Birth","C116900","A condition characterized by reduced or absent movement of the ipsilateral diaphragm as a consequence of an injury to the phrenic nerve or its origin in cervical roots 3 through 5 sustained during the birthing process.","Phrenic Nerve Palsy Related to Birth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899160","Facial Nerve Palsy Related to Birth","C116901","A condition characterized by reduced or absent movement of the ipsilateral face as a consequence of an injury to the seventh cranial nerve sustained during the birthing process.","Facial Nerve Palsy Related to Birth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898067","Other Intervention or Procedure","C116518","Interventions or procedures not otherwise categorized.","Other Intervention or Procedure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433959","Cognitive Intervention","C116519","A set of therapy techniques derived from the school of cognitive psychology, which the practitioner uses to conduct therapy.","Cognitive Intervention | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1274143","Communication Intervention","C116520","An act of intercession by an outside party for the purpose of clarifying or improving the exchange of information between individuals, such as between physician and patient or by an individual with a communication disorder.","Communication Intervention | ",,,,,,,,,,,,,,,"4024583","Communication interventions",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL412297","Computer-Assisted Intervention","C116521","The use of a computer to facilitate the processing of complex information, and then aiding in the creation and execution of a plan of action based on that information.","Computer-Assisted Intervention | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412286","Caregiver-Related Intervention or Procedure","C116523","Any intervention or procedure performed by a caregiver during the course of their duties.","Caregiver-Related Intervention or Procedure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412296","Computer-Assisted Smoking Cessation Intervention","C116524","The use of a computer for the creation and execution of a plan to help an individual stop smoking.","Computer-Assisted Smoking Cessation Intervention | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412287","Intervention by Caregiver","C116525","An act of intercession or assistance for an individual that is performed by their caregiver.","Intervention by Caregiver | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433958","Memory Intervention","C116526","Any action taken for the purpose of improving an individual's memory.","Memory Intervention | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388339","Sham Intervention","C116527","A procedure that functions as the control arm of a clinical trial, mimicking the procedure under investigation in every way, including the preprocedure routine, anaesthesia and incisions (if necessary), and post-procedure follow-up, without actually providing or performing the procedure being studied.","Sham Intervention | Sham Comparator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388492","Telephone-Based Intervention","C116528","Any program that uses interactions over the telephone to alter, modify, or eliminate an undesired behavior.","Telephone-Based Intervention | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890430","GCKR wt Allele","C116610","Human GCKR wild-type allele is located in the vicinity of 2p23 and is approximately 27 kb in length. This allele, which encodes glucokinase regulatory protein, is involved in the negative regulation of carbohydrate modification. Variation of the gene is associated with fasting plasma glucose levels quantitative trait locus 5.","GCKR wt Allele | FGQTL5 | GKRP | Glucokinase (Hexokinase 4) Regulator wt Allele | Glucokinase (Hexokinase 4) Regulatory Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1451323","Glucokinase Regulatory Protein, Human","C116611","Glucokinase regulatory protein (625 aa, ~69 kDa) is encoded by the human GCKR gene. This protein plays a role in the inhibition of carbohydrate phosphorylation.","Glucokinase Regulatory Protein | GCKR | GKRP | Glucokinase Regulator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890183","ULK1 wt Allele","C116613","Human ULK1 wild-type allele is located in the vicinity of 12q24.3 and is approximately 29 kb in length. This allele, which encodes serine/threonine-protein kinase ULK1 protein, plays a role in both serine/threonine protein phosphorylation and the modulation of autophagy.","ULK1 wt Allele | ATG1 | ATG1 Autophagy Related 1 Homolog (S. cerevisiae) Gene | ATG1A | KIAA0722 | UNC51 | UNC51, C. elegans, Homolog of Gene | Unc-51 (C. elegans)-Like Kinase 1 Gene | Unc-51 Like Autophagy Activating Kinase 1 wt Allele | Unc-51-Like Kinase 1 (C. elegans) Gene | Unc51.1 | hATG1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896714","Patisiran","C116792","A lipid nanoparticle (LNP)-based formulation consisting of small-interfering RNAs (siRNAs) directed against transthyretin (TTR) encapsulated in lipids, which has potential use in the treatment of TTR-mediated amyloidosis (ATTR). Upon intravenous administration of patisiran, the lipid formulation promotes the uptake by cells. The siRNAs bind to TTR mRNAs, which may result in the inhibition of both the translation and expression of the TTR protein. ATTR is caused by mutations in the TTR gene and results in the formation of abnormal amyloid proteins that accumulate in and cause damage to various body organs and tissues.","Patisiran | ALN-18328 | ALN-TTR02 | PATISIRAN | RNAi Therapeutic-targeting Transthyretin ALN-TTR02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899007","Group B Streptococcal Infection, Early-Onset","C116793","Infection of an infant from birth to less than seven days of life caused by Group B Streptococcus (Streptococcus agalactiae) from a colonized mother.","Group B Streptococcal Infection, Early-Onset | GBS Infection, Early-Onset",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1861303","Blau Syndrome","C116794","An autoinflammatory disease caused by a NOD2 gene mutation, usually presenting in children younger than age four, and characterized by granulomatous dermatitis, arthritis with synovitis, and uveitis.","Blau Syndrome | Pediatric Granulomatous Arthritis",,,,,,,,,,,,,,,"37311774","Blau syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897032","Group B Streptococcal Infection, Late-Onset","C116795","Infection of an infant from seven days to three months of life caused by Group B Streptococcus (Streptococcus agalactiae).","Group B Streptococcal Infection, Late-Onset | GBS Infection, Late-Onset",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0751356","Idiopathic Inflammatory Myopathy","C116796","An umbrella term for diseases which have chronic muscle inflammation and weakness of unknown etiology. The types of idiopathic inflammatory myopathy are further defined by either clinicopathologic criteria or by the presence of certain autoantibodies.","Idiopathic Inflammatory Myopathy | IIM | Idiopathic Inflammatory Myopathies",,,,,,,,,,,,,,,"45765443","Idiopathic inflammatory myopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898650","Juvenile Dermatomyositis Sine Myositis","C116797","A rare form of juvenile dermatomyositis that manifests with characteristic cutaneous findings for at least six months in the absence of any detectable muscle involvement.","Juvenile Dermatomyositis Sine Myositis | Juvenile Amyopathic Dermatomyositis | Juvenile Dermatomyositis sine Myositis | Juvenile dermatomyositis without myopathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3280743","Childhood-Onset Systemic Lupus Erythematosus","C116798","Systemic lupus erythematosus (SLE) diagnosed in individuals under the age of eighteen. Children frequently have multi-organ involvement and acute disease onset. Symptoms include fever, arthritis, skin lesions, anemia, and fatigue.","Childhood-Onset Systemic Lupus Erythematosus | CSLE | JSLE | Juvenile SLE | PSLE | Pediatric SLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473854","GTP-Binding Protein SAR1b","C116422","GTP-binding protein SAR1b (198 aa, ~22 kDa) is encoded by the human SAR1B gene. This protein plays a role in the regulation of vesicle transport from the endoplasmic reticulum to the Golgi.","GTP-Binding Protein SAR1b | GTBPB | GTP-Binding Protein B | GTP-Binding Protein Sara | SAR1 Homolog B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889442","BCDO","C116424","Human BCO1 wild-type allele is located in the vicinity of 16q23.2 and is approximately 53 kb in length. This allele, which encodes beta,beta-carotene 15,15'-dioxygenase protein, plays a role in vitamin A biosynthesis.","BCO1 wt Allele | BCDO | BCDO1 | BCMO | BCMO1 | BCO | BCO1 | Beta-Carotene 15, 15'-Dioxygenase 1 Gene | Beta-Carotene 15,15'-Monooxygenase 1 Gene | Beta-Carotene Oxygenase 1 wt Allele | FLJ10730",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899241","Exclude from Statistics Indicator","C117045","Specifies whether result values should be excluded from the calculations or statistical analysis.","Exclude from Statistics Indicator | EXCLFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897766","Record Link Identifier","C117050","A sequence of characters used as a linkage between related records.","Record Link Identifier | LNKID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891158","Record Mood","C117051","The modes that may be applied to a record as it passes through various phases of a life cycle or business process.","Record Mood | MOOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897445","Subject Pool Identifier","C117053","A sequence of characters used to identify, name, or characterize the subject pool.","Subject Pool Identifier | POOLID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900125","Accountable Party Identifier","C117054","A sequence of characters used to identify, name, or characterize the accountable party.","Accountable Party Identifier | PRTYID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897935","Pharmaceutical Strength Unit","C117055","The unit of measure for the content of an active ingredient, expressed quantitatively per dosage unit.","Pharmaceutical Strength Unit | PSTRGU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897115","Run Identifier","C117058","A sequence of characters used to uniquely identify a particular run of a test on a particular batch of samples.","Run Identifier | RUNID | runIdentifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL383588","Electromagnetic Tracking Device Procedure","C116696","Any procedure that utilizes electromagnetic technology to create detailed, 3D, digital images of a target location, and then uses those images to help the clinician reach the target location via an endoscopic instrument.","Electromagnetic Tracking Device Procedure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388468","Lymphedema Management","C116697","Any therapeutic technique that is aimed at reducing and/or preventing obstruction of the lymphatic system.","Lymphedema Management | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412288","Psychosocial Support for Caregiver","C116698","Any act that provides mental and emotional succor for a caregiver.","Psychosocial Support for Caregiver | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1276367","Support for Caregiver","C116699","Any type of assistance, including emotional, financial, and spiritual, given to a caregiver.","Support for Caregiver | ",,,,,,,,,,,,,,,"4303295","Caregiver support",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0066618","Mitozolomide","C1166","A prodrug of imidazotetrazine alkylating agent with antineoplastic property. Mitozolomide undergoes ring opening upon the nucleophilic attack at C-4 by an activated molecule of water within the major groove of DNA. The resulting bioactive mono-alkyltriazene species are capable of alkylating nucleophilic residues in the immediate vicinity such as N-7 and/or O-6 sites of guanine, thereby causes intra- or inter-stranded DNA cross-links and trigger apoptosis.","Mitozolomide | Azolastone | Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3-(2-chloroethyl)-3,4-dihydro-4-oxo- | MITOZOLOMIDE | imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3-(2-chloroethyl)-3,4-dihydro-4-oxo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1140617","Intraoral radiation shield","C116700","Materials and practices designed to protect people and the environment from the damaging effects of ionizing radiation.","Radiation Shielding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446608","Tumor Cell-Encapsulating Diffusion Chamber Implantation","C116702","A method by which tumor cells are modified ex vivo to express specific tumor-associated antigens, enveloped in an immunoisolating substance, embedded in a matrix, and implanted at the tumor site where they allow for the diffusion of the desired recombinant proteins.","Tumor Cell-Encapsulating Diffusion Chamber Implantation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL413552","Tumor Interstitial Fluid Pressure Measurement","C116703","The act of quantifying the fluid pressure inside a tumor.","Tumor Interstitial Fluid Pressure Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538592","PASD1 Gene","C116704","This gene may be involved in transcriptional regulation.","PASD1 Gene | PAS Domain Containing Repressor 1 Gene | PASD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887898","Infantile Spasm","C116529","Seizures in the first years of life characterized by flexion and extension jerks of the neck, trunk, and extremities.","Infantile Spasm | Infantile Spasms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0588407","Communication Skills Training","C116531","The attempt to improve the techniques and tactics an individual uses to communicate.","Communication Skills Training | ",,,,,,,,,,,,,,,"4149623","Communication skills training",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL412294","Partner-Assisted Coping Skills Training","C116533","Any program that aims to teach the partner or caregiver of a patient a specific set of skills intended to help relieve the physical, emotional, and/or mental stress experienced by the patient.","Partner-Assisted Coping Skills Training | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412418","Electrical Stimulation Pain Therapy","C116535","The use of external electrical current to stimulate nerves for the purpose of reducing pain.","Electrical Stimulation Pain Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898999","HCC-2998","C117160","An adenocarcinoma cell line established from a patient with colon carcinoma.","HCC-2998 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898998","HCT-116","C117161","A carcinoma cell line established from an adult male patient with colon carcinoma. HCT-116 cells have a mutation in codon 13 of the ras proto-oncogene.","HCT-116 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700361","Emotional Distress","C117162","Disturbed mental state characterized by moodiness, irritability, agitation, anxiety, and/or depression resulting from physical or mental stress.","Emotional Distress | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898997","HCT-15","C117163","An adenocarcinoma cell line established from a male patient with colon carcinoma.","HCT-15 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887612","Psychomotor Agitation","C117164","Physical restlessness, often associated with increased motor activity.","Psychomotor Agitation | Severe Motor Restlessness",,,,,,,,,,,,,,,"4187507","Psychomotor agitation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898645","KM12","C117165","An adenocarcinoma cell line established from a patient with colon carcinoma.","KM12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897095","SW-620","C117166","An adenocarcinoma cell line established from a lymph node metastasis from a 51 year old Caucasian male with colon cancer.","SW-620 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898758","Inner Restlessness","C117167","A feeling of unrest and/or an inability to feel calm or relaxed.","Inner Restlessness | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0700075","Motor Restlessness","C117168","An inability to be still and/or the need to move.","Motor Restlessness | ",,,,,,,,,,,,,,,"4012381","Restlessness",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897689","SF-268","C117169","An astrocytoma cell line established from a 24 year old female patient with right parietal anaplastic astrocytoma.","SF-268 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897688","SF-295","C117170","A glioblastoma cell line established from a 67 year old female patient with glioblastoma.","SF-295 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899502","Congenital Varicella Zoster Infection","C116799","An infection, characterized by the rash of chickenpox or shingles, that is caused by the varicella-zoster virus transmitted directly from the mother to the fetus or neonate during late pregnancy or childbirth.","Congenital Varicella Zoster Infection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0067099","Cystemustine","C1167","A chloroethylating nitrosourea that causes DNA cross-linking, inhibiting DNA replication. (NCI)","Cystemustine | C6H12CLN3O4S | CMSO2EN2 | CYSTEMUSTINE | N'-(2-chloroethyl)-N-(2-(methylsulfonyl)ethyl)-N'-nitrosourea | N-(2-chloroethyl)-N'-[2-(methylsulfonyl)ethyl]-N-nitroso-urea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4275251","Congenital Varicella Syndrome","C116800","A condition, whose clinical manifestations include intrauterine growth restriction, scarring cicatricial lesion of the limbs, abnormalities of the limbs, microcephaly, chorioretinitis, microphthalmia, cataracts, cortical atrophy, seizures, and evidence of damage to the autonomic nervous system, that is caused by fetal exposure to the varicella zoster virus during the first trimester of pregnancy.","Congenital Varicella Syndrome | ",,,,,,,,,,,,,,,"4173980","Congenital varicella syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1096452","Neonatal Sepsis, Early-Onset","C116803","An infectious disorder of newborn infants that is characterized by a systemic inflammatory response within 72 hours of life and is most commonly caused by bacteria.","Neonatal Sepsis, Early-Onset | Early-Onset Neonatal Sepsis",,,,,,,,,,,,,,,"35622880","Early-onset neonatal sepsis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2721675","Posterior Fossa Syndrome","C116378","A postoperative syndrome, usually presenting after midline posterior fossa tumor resection, that involves a variety of signs and symptoms including aphasia, mutism or speech disturbances, dysphagia, mobility problems, cranial nerve palsies and emotional instability.","Posterior Fossa Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2938917","Cerebellar Mutism","C116379","A syndrome, usually presenting after midline posterior fossa tumor resection, which is characterized by abnormalities of speech, behavioral or affective disturbances, and diffuse cerebellar dysfunction.","Cerebellar Mutism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0409818","Chronic Infantile Neurological Cutaneous and Articular Syndrome","C116380","A congenital autoinflammatory disorder that presents within a few days of birth and is characterized by a clinical triad of skin rash, chronic meningitis, and joint pain with recurrent fever and inflammation.","Chronic Infantile Neurological Cutaneous and Articular Syndrome | CINCA | CINCA Syndrome | CINCA/NOMID | NOMID | Neonatal-Onset Multisystem Inflammatory Disease",,,,,,,,,,,,,,,"4079739","Chronic infantile neurological, cutaneous and articular syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027813","Neuritis","C116381","Inflammation of a nerve.","Neuritis | ",,,,,,,,,,,,,,,"4049810","Inflammatory neuropathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0431357","External Hydrocephalus","C116382","Abnormal increase of cerebrospinal fluid in the subdural space of the brain.","External Hydrocephalus | ",,,,,,,,,,,,,,,"4099834","External hydrocephalus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897887","Planned Start of Assessment Interval","C117061","The period of time that the assessment, done over an interval of time, is intended to begin.","Planned Start of Assessment Interval | STINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537788","MIR135B Gene","C117063","This gene is involved in the regulation of gene expression that modulates cell motility.","MIR135B Gene | MIR135B | MicroRNA 135b Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890012","MIR135B wt Allele","C117064","The human MIR135B wild-type allele is located in the vicinity of 1q32.1 and is approximately 97 bases in length. This allele, which encodes MIR135B pre-miRNA, plays a role in the regulation of gene expression. Alteration in the expression of this gene is associated with highly invasive non-small-cell lung cancer.","MIR135B wt Allele | MIRN135B | MicroRNA 135b wt Allele | hsa-mir-135b | mir-135b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388338","Standard Follow-Up Care","C116647","The commonly accepted clinical attention that occurs following a diagnosis or treatment, with the express purpose of monitoring that specific diagnosis or treatment.","Standard Follow-Up Care | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473887","Transarterial Radioembolization","C116649","A treatment for hepatocellular carcinoma that uses radioactive microspheres to both cause hepatic artery embolization and to deliver regional radiotherapy.","Transarterial Radioembolization | Hepatic Radioembolization | TARE | Transarterial Hepatic Radioembolization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0752939","Glutathione S-Transferase A4, Human","C116650","Glutathione S-transferase A4 (222 aa, ~26 kDa) is encoded by the human GSTA4 gene. This protein is involved in the conjugation of reduced glutathione to endogenous and exogenous small hydrophobic molecules.","Glutathione S-Transferase A4 | EC 2.5.1.18 | GST Class-Alpha Member 4 | Glutathione S-Alkyltransferase A4 | Glutathione S-Aralkyltransferase A4 | Glutathione S-Aryltransferase A4 | Glutathione S-Transferase A4-4 | Glutathione Transferase A4-4 | S-(Hydroxyalkyl)Glutathione Lyase A4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412369","Transversus Abdominis Plane Block","C116652","The administration of local anesthetic drugs into the transversus abdominal plane as an adjunct treatment for post operative pain following abdominal surgery.","Transversus Abdominis Plane Block | TAP Block",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412275","Pancreatic Surgical Procedure","C116653","A surgical procedure that involves the removal of the head, middle, distal pancreas or the entire pancreas. It is usually performed for the excision of pancreatic tumors.","Pancreatic Surgical Procedure | Pancreatic Surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1541465","TL-909","C116871","A semi-synthetic, orally bioavailable, third-generation taxane derivative and microtubule-stabilizing agent, with potential antineoplastic activity. Upon administration, simotaxel binds to tubulin, promotes microtubule assembly and stabilization, and prevents microtubule depolymerization. This results in G2/M arrest, apoptosis and the inhibition of cell proliferation in susceptible tumor cells. This agent is a poor substrate for P-glycoprotein-related drug resistance mechanisms; therefore, it may be useful for treating multi-drug resistant tumors. MST-997 is more potent than paclitaxel and docetaxel and overcomes paclitaxel and docetaxel resistance in certain tumor cell types.","Simotaxel | 5Beta,20-epoxy-1,2alpa,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one-4-acetate 2-benzoate Ester with (2R,3S)-N-Isopropoxycarbonyl-3-(2-thienyl) Isoserine | MST-997 | SIMOTAXEL | TL-909 | Taxane-997",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896900","GS/pan-Notch inhibitor BMS-906024","C116872","A small-molecule gamma secretase (GS) and pan-Notch inhibitor, with potential antineoplastic activity. Upon intravenous administration, osugacestat binds to GS and blocks activation of Notch receptors, which may inhibit the proliferation of tumor cells with an overly-active Notch pathway. The integral membrane protein GS is a multi-subunit protease complex that cleaves single-pass transmembrane proteins, such as Notch receptors, at residues within their transmembrane domains that lead to their activation. Overactivation of the Notch signaling pathway, often triggered by activating mutations, has been correlated with increased cellular proliferation and poor prognosis in certain tumor types.","Osugacestat | AL 101 | AL-101 | AL101 | BM-0018 | BM0018 | BMS-906024 | GS/pan-Notch Inhibitor AL101 | OSUGACESTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446660","STAT Inhibitor OPB-111077","C116873","An orally bioavailable inhibitor of one or more signal transducer and activator of transcription (STAT) protein(s), with potential antineoplastic activity. Upon oral administration, OPB-111077 binds to and inhibits the phosphorylation of STATs. This prevents binding of STATs to DNA sequences on a variety of STAT-responsive gene promoters, which may result in the inhibition of both STAT-mediated transcription and tumor cell proliferation. STATs are constitutively activated in a variety of cancers and play a key role in tumor cell proliferation.","STAT Inhibitor OPB-111077 | OPB-111077",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3660685","Smoothened Antagonist TAK-441","C116874","An orally bioavailable pyrrolopyridine derivative and Smoothened (Smo) antagonist with potential antineoplastic activity. Smo antagonist TAK-441 selectively binds to and inhibits the activity Smo, which is a cell surface co-receptor for ligands in the Hedgehog (Hh) family. This may result in a suppression of Hh-mediated signaling pathways, thereby inhibiting the growth of tumor cells in which this pathway is aberrantly activated.  Smo is a G-protein coupled receptor that lies just downstream of the Hh cell surface receptor Patched-1 in the Hh pathway; in the absence of ligand, Patched-1 (Ptch1) inhibits Smo, and ligand binding to Ptch1 results in increased levels of Smo. The Hh-mediated signaling pathways play an important role in cellular growth and differentiation, and tissue repair; constitutive activation of this pathway is associated with uncontrolled cellular proliferation in a variety of cancers.","Smoothened Antagonist TAK-441 | 6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide | TAK-441",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412403","Double-Unit Umbilical Cord Blood Transplantation","C116470","The transfusion of two units of umbilical cord blood, one unit from each of two patients. This is mostly commonly done as a form of stem cell transplant for patients with leukemia, lymphoma, or other serious blood disease who require a bone marrow transplant, but for whom no suitable donor can be found.","Double-Unit Umbilical Cord Blood Transplantation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0455769","Increased Energy","C117171","Feeling of excessive energy, which may be associated with increased activity.","Increased Energy | ",,,,,,,,,,,,,,,"4078452","Increased energy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897687","SF-539","C117174","A gliosarcoma cell line established from a 34 year old female patient with gliosarcoma previously treated with radiation and chemotherapy.","SF-539 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1563374","Thyroid Hormone-Inducible Hepatic Protein, Human","C117175","Thyroid hormone-inducible hepatic protein (146 aa, ~17 kDa) is encoded by the human THRSP gene. This protein plays a role in lipogenesis.","Thyroid Hormone-Inducible Hepatic Protein | Lipogenic Protein 1 | S14 | SPOT14 | SPOT14 Homolog | Spot 14 Protein | Thyroid Hormone Responsive SPOT14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897679","SNB-19","C117176","A glioblastoma cell line established from a 47 year old male with left parieto-occipital glioblastoma.","SNB-19 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897678","SNB-75","C117178","A glioblastoma cell line established from a 78 year old female with glioblastoma.","SNB-75 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897262","U251","C117179","A glioblastoma cell line established from a 75 year old male with glioblastoma.","U251 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446651","Autologous TNS9.3.55-transduced CD34-positive Cells","C116734","A preparation of autologous, CD34-positive hematopoietic progenitor cells (HPCs) ex vivo transduced with TNS9.3.55, a lentiviral vector encoding the human beta-globin (hemoglobin-beta, HBB) gene, with potential to restore beta-globin expression and function. Autologous CD34-positive stem cells are isolated from the patient's own bone marrow, the deficient HBB gene is removed, and the cells are transduced with the lentiviral vector. Upon re-infusion of the TNS9.3.55-transduced CD34-positive cells back into the patient, these cells express beta-globin, thereby allowing the body to make normal hemoglobin and thus normal, healthy red blood cells. Beta-globin, the beta-chain of the most common form of hemoglobin, is encoded by the HBB gene; mutations in this gene prevent normal beta-globin production.","Autologous TNS9.3.55-transduced CD34-positive Cells | Autologous CD34-positive Cells Transduced with TNS9.3.55",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899960","Bacteriophage phi X 174 Vaccine","C116736","A vaccine composed of the bacteriophage phi X 174, a virus that infects the bacterium Escherichia coli (E. coli), that can be used as a diagnostic agent to measure immune function of immunocompromised patients. Upon administration of the bacteriophage phi X 174 vaccine, the bacteriophage may activate the immune system to induce bacteriophage phi X174 specific antibody responses. The clearance of phage from the blood and the measurement of phage neutralization by antibodies can be used to assess the immune status of patients with suspected antibody-mediated immunodeficiency and to measure the response to certain therapies.","Bacteriophage phi X 174 Vaccine | BACTERIOPHAGE PHI X174 | phi X 174",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446627","Anti-CD33 Monoclonal Antibody BI 836858","C116737","An engineered, fully human, immunoglobulin (Ig) G1 anti-CD33 monoclonal antibody, with potential antineoplastic activity. Upon administration, anti-CD33 monoclonal antibody BI 836858 induces an antibody-dependent cellular cytotoxicity (ADCC) against CD33-expressing tumor cells, leading to cell death. CD33, a cell surface antigen expressed on normal non-pluripotent hematopoietic stem cells, is overexpressed on myeloid leukemia cells.","Anti-CD33 Monoclonal Antibody BI 836858 | BI 836858 | BI-836858",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897877","Post-Hemorrhagic Hydrocephalus","C116383","An abnormal accumulation of cerebrospinal fluid within the ventricles of the brain that occurs as a later sequela of an intraventricular or subarachnoid hemorrhage.","Post-Hemorrhagic Hydrocephalus | Post Hemorrhagic Hydrocephalus",,,,,,,,,,,,,,,"4159151","Posthemorrhagic hydrocephalus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897876","Post-Inflammatory Hydrocephalus","C116384","An abnormal accumulation of cerebrospinal fluid within the ventricles of the brain that occurs as a consequence of a central nervous system inflammation.","Post-Inflammatory Hydrocephalus | Post Inflammatory Hydrocephalus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810305","Lupus Anticoagulant Disorder","C116994","A hypercoaguable state that results from the presence of the immunoglobulin known as Lupus Anticoagulant. The antibody interacts with cell membrane phospholipids, causing increased aggregation and adhesion of platelets, which causes increased clot formation. Though the majority of patients who test positive for lupus anticoagulant do not have lupus, those individuals afflicted with lupus have a higher probability of developing the antibody.","Lupus Anticoagulant Disorder | ",,,,,,,,,,,,,,,"4078700","Lupus anticoagulant disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1414119","DNM1L Gene","C116995","This gene plays a role in the replication of mitochondria and peroxisomes.","DNM1L Gene | DNM1L | Dynamin 1-Like Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889148","DNM1L wt Allele","C116996","Human DNM1L wild-type allele is located in the vicinity of 12p11.21 and is approximately 66 kb in length. This allele, which encodes dynamin-1-like protein, is involved in the division process of both mitochondria and peroxisomes. Mutation of the gene is associated with lethal encephalopathy due to defective mitochondrial peroxisomal fission.","DNM1L wt Allele | DLP1 | DRP1 | DVLP | DYMPLE | Dynamin 1-Like wt Allele | Dynamin Family Member, Proline-Rich C-Terminal Domain Less Gene | EMPF | HDYNIV | S. cerevisiae DNM1/VPS1-Like Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0669938","Dynamin-1-Like Protein, Human","C116997","Dynamin-1-like protein (736 aa, ~82 kDa) is encoded by the human DNM1L gene. This protein plays a role in mitochondrial and peroxisomal division.","Dynamin-1-Like Protein | DNM1L | DVLP | Dnm1p/Vps1p-Like Protein | Dymple | Dynamin Family Member Proline-Rich Carboxyl-Terminal Domain Less | Dynamin-Like Protein | Dynamin-Like Protein 1 | Dynamin-Like Protein 4 | Dynamin-Like Protein IV | Dynamin-Related Protein 1 | EC 3.6.5.5 | HdynIV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424917","APOBEC3A Gene","C116998","This gene is involved in cytosine deamination of viral DNA.","APOBEC3A Gene | APOBEC3A | Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891071","PRDX4 wt Allele","C116656","Human PRDX4 wild-type allele is located in the vicinity of Xp22.11 and is approximately 22 kb in length. This allele, which encodes peroxiredoxin-4 protein, is involved in the regulation of both nuclear factor NF-kappa-B transcription factor activity and cellular redox.","PRDX4 wt Allele | AOE37-2 | HEL-S-97n | PRX-4 | Peroxiredoxin 4 wt Allele | Thioredoxin Peroxidase (Antioxidant Enzyme) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0914290","peroxiredoxin IV","C116657","Peroxiredoxin-4 (271 aa, ~31 kDa) is encoded by the human PRDX4 gene. This protein plays a role in both redox regulation and nuclear factor NF-kappa-B activation in cells.","Peroxiredoxin-4 | AOE37-2 | Antioxidant Enzyme 372 | Antioxidant Enzyme AOE372 | EC 1.11.1.15 | Epididymis Secretory Sperm Binding Protein Li 97n | PRDX4 | Peroxiredoxin IV | Prx-IV | Thioredoxin Peroxidase AO372 | Thioredoxin-Dependent Peroxide Reductase A0372",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889425","MAP1LC3B wt Allele","C116659","Human MAP1LC3B wild-type allele is located in the vicinity of 16q24.2 and is approximately 21 kb in length. This allele, which encodes microtubule-associated proteins 1A/1B light chain 3B protein, plays a role in autophagocytosis and mitochondrial catabolism.","MAP1LC3B wt Allele | ATG8F | LC3B | MAP1A/1BLC3 | MAP1ALC3 | MAP1LC3B-a | Microtubule-Associated Protein 1 Light Chain 3 Beta wt Allele | Microtubule-Associated Protein 1, Light Chain 3, Beta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1311384","MAP1LC3B protein, human","C116660","Microtubule-associated proteins 1A/1B light chain 3B (125 aa, ~15 kDa) is encoded by the human MAP1LC3B gene. This protein is involved in the both catabolism of mitochondria and autophagy.","Microtubule-Associated Proteins 1A/1B Light Chain 3B | Autophagy-Related Protein LC3 B | Autophagy-Related Ubiquitin-Like Modifier LC3 B | LC3-Like Protein 2 | MAP1 Light Chain 3-Like Protein 2 | MAP1A/MAP1B LC3 B | MAP1A/MAP1B Light Chain 3 B | Microtubule-Associated Protein 1 Light Chain 3 Beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433776","Hsp90 Inhibitor DS-2248","C116851","An orally active and small molecule inhibitor of heat shock protein 90 (Hsp90), with potential antineoplastic activity. Upon oral administration, Hsp90 inhibitor DS-2248 specifically blocks Hsp90, which inhibits its chaperone function and promotes the proteasomal degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. This may lead to an inhibition of tumor cell proliferation. Hsp90, a chaperone complex protein upregulated in a variety of tumor cell types, regulates the folding and degradation of many oncogenic signaling proteins.","Hsp90 Inhibitor DS-2248 | DS-2248 | Heat Shock Protein 90 Inhibitor DS-2248",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899948","Bimagrumab","C116852","A human monoclonal antibody directed against type II activin receptors (ActRII; ActR2), with potential muscle-sparing and anti-cachectic activities. Upon administration, bimagrumab binds to ActRII, which prevents the binding of the natural ligands, myostatin and activin, to activin receptors and blocks ActRII-mediated signaling. This increases protein synthesis, decreases protein degradation, stimulates skeletal muscle cell growth, and increases muscle function and strength. Overstimulation of the ActRII-mediated signaling pathway is associated with muscle loss and weakness.","Bimagrumab | BIMAGRUMAB | BYM338 | HuCAL-based Antibody BYM338 | Human Combinatorial Antibody Library-based Monoclonal Antibody BYM338",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433740","Hyperpolarized Carbon C 13 Pyruvate","C116853","A hyperpolarized pyruvate labeled with carbon C 13, with potential usage in the diagnostic imaging of cancer cells. Upon administration, carbon C 13 hyperpolarized pyruvate (13C-pyruvate) is taken up by cancer cells and is further metabolized to lactate and alanine for use in glycolysis, lipogenesis and protein synthesis, to support the enhanced metabolic needs of tumor cells. As tumor cells are rapidly proliferating, their uptake of pyruvate and its subsequent conversion to alanine and lactate are higher than non-proliferating cells. Upon nuclear magnetic resonance (NMR)-based imaging (MRI), both hyperpolarized 13C-pyruvate as well as its metabolites can be detected and visualized in cancer cells; this may aid in the diagnosis of cancer. Hyperpolarization of 13C-pyruvate, using dynamic nuclear polarization (DNP), enhances NMR signals.","Hyperpolarized Carbon C 13 Pyruvate | Hyperpolarized 13C-Pyruvate | Hyperpolarized Pyruvate (13C)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388448","Reduced-Intensity Transplant Conditioning Procedure","C116471","A method of preparation for stem cell transplant that uses less than standard doses of chemotherapy and radiation prior to the transfer of stem cells, with the goal of providing protection against graft vs. host disease, while simultaneously minimizing the toxic effects of the conditioning treatment.","Reduced-Intensity Transplant Conditioning Procedure | Non-Myeloablative Conditioning | Reduced Intensity Conditioning | Reduced Intensity Conditioning/Reduced Toxicity Conditioning",,,,,,,,,,,,,,,"601855","Nonmyeloablative conditioning regimen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL413596","Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion","C116472","A procedure to infuse progenitor cells that have been extracted from umbilical cord blood and expanded in culture.","Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446625","T Cell-Depleted Donor Lymphocyte Infusion","C116473","A lymphocyte transfusion where the donor's T-cells are removed prior infusion into the recipient.","T Cell-Depleted Donor Lymphocyte Infusion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1293883","Fresh Frozen Plasma Transfusion","C116475","The infusion of fresh frozen plasma into a recipient.","Fresh Frozen Plasma Transfusion | ",,,,,,,,,,,,,,,"4022171","Transfusion of fresh frozen plasma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL421642","Chromoendoscopy","C116476","Endoscopy that employs the use of tissue stains to increase tissue contrast, and enhance the ability to identify various tissue dysplasia and other abnormalities.","Chromoendoscopy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL413953","Confocal Laser Endomicroscopy","C116477","An investigative technique that permits high-resolution assessment of the histology of an endoluminal surface at a cellular and sub-cellular level. The technique is based upon the principle of illuminating a tissue with a low-power laser and then detecting fluorescent light reflected from the tissue. The laser is focused at a specific depth and only light reflected back from that plane is refocused and able to pass through the pinhole confocal aperture, increasing spacial resolution.","Confocal Laser Endomicroscopy | CLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1449565","Dermoscopy","C116478","A noninvasive diagnostic procedure that allows for in vivo microscopic examination of the epidermis, the dermoepidermal junction, and the papillary dermis. This aids in the identification of specific diagnostic patterns related to color and cell structure to aid in differentiating malignant and benign lesions.","Dermoscopy | DMS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412377","Electromagnetic Navigation Bronchoscopy","C116479","A two-stage bronchoscopic technique that uses electromagnetic technology to first prepare 3D, digital reconstructions of the patient's airways, and then helps the clinician use those images to guide instruments through the bronchi to the previously identified target. This is most often performed to biopsy lesions or lymph nodes, or place a brachytherapy catheter.","Electromagnetic Navigation Bronchoscopy | Virtual Navigation Bronchoscopy",,,,,,,,,,,,,,,"37208338","Electromagnetic navigation bronchoscopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL433768","High-Resolution Microendoscopy","C116480","A low-cost, high-resolution imaging tool consisting of a 1-mm diameter fiber-optic bundle that produces subcellular imaging at 1,000x magnification and 4 micrometer resolution, allowing for minimally invasive bioimaging.","High-Resolution Microendoscopy | HRME",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL413608","Image-Guided Needle Confocal Laser Endomicroscopy","C116481","A procedural technique that uses endoscopic ultrasound and confocal laser to obtain real time images, assess blood flow, and gain histopathology samples of the gastrointestinal tract.","Image-Guided Needle Confocal Laser Endomicroscopy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446670","Polarized Reflectance Spectroscopy","C116483","An endoscopic technique that uses polarized light to provide qualitative morphological information of tissue in situ, with reduced background signals, to evaluate epithelial tissue for dysplasia and ischemia.","Polarized Reflectance Spectroscopy | Light Scattering Spectroscopy with Polarized Light | Polarized Light Scattering Spectroscopy | Reflectance Spectroscopy with Polarized Light",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433810","CD30 CAR-expressing Autologous T Lymphocytes","C116738","A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the CD30 antigen, with potential immunostimulating and antineoplastic activities. Upon administration, the CD30 CAR-expressing autologous T-lymphocytes specifically recognize and bind to CD30-expressing tumor cells, resulting in tumor cell lysis. CD30, a cell surface receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is transiently expressed on activated lymphocytes and is constitutively expressed in hematologic malignancies.","CD30 CAR-expressing Autologous T Lymphocytes | Anti-CD30 CAR-expressing Autologous T Lymphocytes | CAR.CD30-expressing Autologous T Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3531069","Carrot Juice","C116739","The juice from carrots, with potential antioxidant and protective activities. Carrot juice, depending on the carrot varieties, may contain nutrients that include the provitamin A carotenoids alpha-carotene and beta-carotene, the non-provitamin A carotenoid lycopene, and the flavonoids anthocyanins, luteolin, quercetin and kaempferol. The antioxidants in carrot juice scavenge free radicals, thereby protecting cells from damage.","Carrot Juice | CARROT JUICE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL421597","CMV pp65 Peptide-pulsed Autologous Dendritic Cell Vaccine","C116740","A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with the human cytomegalovirus (CMV) phosphoprotein pp65, with potential immunostimulatory and antineoplastic activities. Upon administration, the CMV pp65 peptide-pulsed autologous DC vaccine exposes the immune system to the CMV pp65 peptide, which may result in a cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells leading to cell lysis. The CMV pp65 protein, also called the 65 kDa lower matrix phosphoprotein, is the primary component of the enveloped subviral particle of CMV and is expressed in certain tumor types, such as glioblastoma.","CMV pp65 Peptide-pulsed Autologous Dendritic Cell Vaccine | CMV pp65 Peptide-pulsed Autologous DC Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0911853","Dalbavancin","C116741","A second-generation, semi-synthetic lipoglycopeptide antibiotic, with bactericidal activity against a variety of gram-positive bacteria. Upon administration, dalbavancin binds, at a site different from that of penicillins and cephalosporins, tightly to the D-alanyl-D-alanine portion of peptidoglycan chains, thereby preventing peptidoglycan elongation and interfering with bacterial cell wall synthesis. This leads to activation of bacterial autolysins and induces cell wall lysis.","Dalbavancin | DALBAVANCIN | Dalvance | MDL 63,397 | Ristomycin A Aglycone, 5,31-Dichloro-38-de(methoxycarbonyl)-7-demethyl-19-deoxy-56-O-(2-deoxy-2-((10-methyl-1-oxoundecyl)amino)-beta-D-glucopyranuronosyl)-38-(((3-(dimethylamino)propyl)amino)carbonyl)-42-O-alpha-D-mannopyranosyl-N15-methyl- | VER001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0338596","Spastic Cerebral Palsy","C116903","A type of cerebral palsy characterized by increased muscle tone.","Spastic Cerebral Palsy | ",,,,,,,,,,,,,,,"4043747","Spastic cerebral palsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4227526","Spastic Quadriplegia","C116904","A type of spastic cerebral palsy characterized by increased muscle tone of all four extremities.","Spastic Quadriplegia | Spastic quadriplegic cerebral palsy",,,,,,,,,,,,,,,"4102341","Spastic tetraplegia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0154694","Spastic Hemiplegia","C116905","A type of spastic cerebral palsy characterized by increased muscle tone of the arm and leg on the same side of the body.","Spastic Hemiplegia | Spastic hemiplegia affecting unspecified side | Spastic hemiplegic cerebral palsy",,,,,,,,,,,,,,,"375528","Spastic hemiplegia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0394007","Hypotonic Cerebral Palsy","C116906","A type of cerebral palsy characterized by decreased muscle tone.","Hypotonic Cerebral Palsy | ",,,,,,,,,,,,,,,"4101736","Hypotonic cerebral palsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897447","Subgaleal Hemorrhage Related to Birth","C116907","Bleeding in the potential space between the skull periosteum and the scalp galea aponeurosis of a newborn infant due to shearing forces on the tentorium and deep venous system during labor and delivery.","Subgaleal Hemorrhage Related to Birth | Epicranial Subaponeurotic Hemorrhage Related to Birth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898705","Intracranial Laceration Related to Birth","C116908","Tearing of the cerebral or cerebellar parenchyma or vessels of a newborn infant due to forces occurring during labor and delivery.","Intracranial Laceration Related to Birth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899692","Cerebral Hemorrhage Related to Birth","C116909","Intracranial bleeding in the tissue of the cerebrum of a newborn infant occurring during labor and/or delivery.","Cerebral Hemorrhage Related to Birth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898706","Intracranial Hemorrhage Related to Birth","C116910","Bleeding within the skull of a newborn infant occurring during labor and/or delivery.","Intracranial Hemorrhage Related to Birth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890223","APOBEC3A wt Allele","C116999","Human APOBEC3A wild-type allele is located within 22q13.1-q13.2 and is approximately 10 kb in length. This allele, which encodes DNA dC->dU-editing enzyme APOBEC-3A protein, plays a role in the modulation of viral DNA modification. A deletion that fuses this gene and the 3' end of the APOBEC3B gene may be associated with increased susceptibility to neoplastic disease.","APOBEC3A wt Allele | A3A | ARP3 | Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3A wt Allele | PHRBN | bK150C2.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1611017","DNA dC to dU-Editing Enzyme APOBEC-3A, Human","C117000","DNA dC->dU-editing enzyme APOBEC-3A (199 aa, ~23 kDa) is encoded by the human APOBEC3A gene. This protein is involved in the modification of viral DNA.","DNA dC to dU-Editing Enzyme APOBEC-3A | A3A | APOBEC3A | DNA dC->dU-Editing Enzyme APOBEC-3A | EC 3.5.4.- | Phorbolin 1 | Phorbolin I | Phorbolin-1 | Probable DNA dC->dU-Editing Enzyme APOBEC-3A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890224","APOBEC3B wt Allele","C117002","Human APOBEC3B wild-type allele is located within 22q13.1-q13.2 and is approximately 10 kb in length. This allele, which encodes DNA dC->dU-editing enzyme APOBEC-3B protein, is involved in the modulation of DNA cytosine deamination. A deletion that fuses the 3' UTR of this gene to the 3' end of the APOBEC3A gene, essentially deletes the APOBEC3B coding sequence, and may be associated with increased susceptibility to neoplastic disease.","APOBEC3B wt Allele | A3B | APOBEC1L | ARCD3 | ARP4 | Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3B wt Allele | DJ742C19.2 | FLJ21201 | PHRBNL | bK150C2.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1565215","DNA dC to dU-Editing Enzyme APOBEC-3B, Human","C117003","DNA dC->dU-editing enzyme APOBEC-3B (382 aa, ~46 kDa) is encoded by the human APOBEC3B gene. This protein plays a role in the inhibition of replication of viral genomes.","DNA dC to dU-Editing Enzyme APOBEC-3B | A3B | APOBEC3B | Apolipoprotein B mRNA Editing Enzyme Catalytic Polypeptide-Like 3B | DNA dC->dU-Editing Enzyme APOBEC-3B | EC 3.5.4.- | Phorbolin 1-Related Protein | Phorbolin 2 | Phorbolin 3 | Phorbolin-1-Related Protein | Phorbolin-2/3 | Phorbolin-3 | Probable DNA dC->dU-Editing Enzyme APOBEC-3B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0338480","Migraine Without Aura","C117004","A migraine disorder characterized by episodes that occur in the absence of preceding focal neurological symptoms.","Migraine Without Aura | Common Migraine",,,,,,,,,,,,,,,"378735","Migraine without aura",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0154723","Migraine With Aura","C117005","A migraine disorder characterized by episodes that are preceded by focal neurological symptoms.","Migraine With Aura | ",,,,,,,,,,,,,,,"381549","Migraine with aura",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1313678","ULK1 protein, human","C116614","Serine/threonine-protein kinase ULK1 (1050 aa, ~113 kDa) is encoded by the human ULK1 gene. This protein is involved in protein phosphorylation that mediates the autophagocytotic process.","Serine/Threonine-Protein Kinase ULK1 | ATG1 | ATG1 Autophagy Related 1 Homolog | Autophagy-Related Protein 1 Homolog | EC 2.7.11.1 | ULK1 | Unc-51-Like Kinase 1 | Unc51-Like Kinase 1 | hATG1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890777","MUS81 wt Allele","C116616","Human MUS81 wild-type allele is located in the vicinity of 11q13 and is approximately 11 kb in length. This allele, which encodes crossover junction endonuclease MUS81 protein, is involved in DNA endonuclease activity.","MUS81 wt Allele | FLJ44872 | MUS81 Endonuclease Homolog (S. cerevisiae) Gene | MUS81 Endonuclease Homolog (Yeast) Gene | MUS81 Structure-Specific Endonuclease Subunit wt Allele | MUS81, S. cerevisiae, Homolog of Gene | SLX3 | SLX3 Structure-Specific Endonuclease Subunit Homolog (S. cerevisiae) Gene | SLX3, Yeast, Homolog of Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898807","Immediate-release Oxymorphone Hydrochloride Liquid Formulation","C116854","An orally bioavailable, immediate-release (IR), liquid formulation containing the hydrochloride salt form of oxymorphone, a semisynthetic opioid with potent analgesic activity. Upon oral administration, oxymorphone binds to and activates opioid receptors, specifically mu-receptors, in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids and providing analgesia.","Immediate-release Oxymorphone Hydrochloride Liquid Formulation | Opana IR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433702","Indium In 111-labeled Macroaggregated Albumin","C116856","A radiopharmaceutical formulation containing human, serum albumin (HSA) labeled with indium In 111 (In-111) in macroaggregates (MAA) with potential usage as a diagnostic imaging agent. Upon injection of indium In 111-labeled macroaggregated albumin and subsequent imaging, biodistribution patterns can be assessed and the expected distribution of agents with similar particle sizes may be predicted.","Indium In 111-labeled Macroaggregated Albumin | In-111-labeled Macroaggregated Albumin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3659426","Gandotinib","C116857","An orally bioavailable imidazopyridazine and inhibitor of Janus kinase 2 mutant V617F (JAK2V617F), with potential antineoplastic activity. Upon oral administration, gandotinib selectively and competitively inhibits the activation of JAK2V617F, which may result in the inhibition of the JAK-STAT signaling pathway and the induction of apoptosis in JAK2V617F-expressing tumor cells. JAK2V617F has a substitution of phenylalanine for valine at amino acid position 617 and plays a key role in tumor cell proliferation and survival.","Gandotinib | 3-(4-Chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(Morpholinomethyl)imidazo(1,2-b)pyridazin-6-amine | GANDOTINIB | LY 2784544 | LY2784544",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0053397","Beta,Beta-Carotene 15,15'-Dioxygenase","C116425","Beta,beta-carotene 15,15'-dioxygenase (547 aa, ~63 kDa) is encoded by the human BCO1 gene. This protein is involved in the oxidative cleavage of beta-carotene to form retinal.","Beta,Beta-Carotene 15,15'-Dioxygenase | BCO1 | Beta,Beta-Carotene 15, 15'-Dioxygenase 1 | Beta,Beta-Carotene 15,15'-Dioxygenase 1 | Beta,Beta-Carotene 15,15'-Monooxygenase | Beta,Beta-Carotene 15,15-Dioxygenase | Beta,Beta-Carotene 15,15-Prime-Monooxygenase | Beta,Beta-Carotene 15,15-Prime-Monooxygenase 1 | Beta-Carotene 15, 15'-Dioxygenase 1 | Beta-Carotene 15,15'-Dioxygenase 1 | Beta-Carotene 15,15'-Oxygenase 1 | Beta-Carotene 15,15-Prime-Dioxygenase | Beta-Carotene 15,15-Prime-Dioxygenase 1 | Beta-Carotene 15,15-Prime-Oxygenase 1 | Beta-Carotene Dioxygenase 1 | Beta-Carotene Oxygenase 1 | EC 1.14.99.36",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889465","PLIN2 wt Allele","C116427","Human PLIN2 wild-type allele is located in the vicinity of 9p22.1 and is approximately 41 kb in length. This allele, which encodes perilipin-2 protein, is involved in adipose tissue development and maintenance.","PLIN2 wt Allele | ADFP | ADRP | Perilipin 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0760488","perilipin 2","C116428","Perilipin-2 (437 aa, ~48 kDa) is encoded by the human PLIN2 gene. This protein plays a role in cellular lipid storage","Perilipin-2 | ADRP | Adipophilin | Adipose Differentiation-Related Protein | PLIN2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412359","3-Dimensional Ultrasound-Guided Radiation Therapy","C116429","No value exists.","3-Dimensional Ultrasound-Guided Radiation Therapy | 3D Ultrasound-Guided Radiation Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446648","4-Dimensional Conformal Radiation Therapy","C116430","3-Dimensional conformal radiation therapy that is designed to compensate for motion of the tumor and surrounding normal tissue during each treatment session.","4-Dimensional Conformal Radiation Therapy | 4D Conformal Radiation Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897484","SPL Business Entity Qualifier Terminology","C117110","Terminology used in the framework of identifying types of business entities.","SPL Business Entity Qualifier Terminology | Business Entity Qualifier | Structured Product Labeling Business Entity Qualifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024140","Subacute Cutaneous Lupus Erythematosus","C117111","A dermatologic manifestation of lupus involving erythematous, scaly patches or plaques, generally appearing on the upper back, chest, and arms, and often following sun exposure. It most often resolves without scarring.","Subacute Cutaneous Lupus Erythematosus | ",,,,,,,,,,,,,,,"4343923","Subacute cutaneous lupus erythematosus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0406636","Lupus Erythematosus Tumidus","C117112","A dermatologic manifestation of lupus involving edematous papules and plaques that are typically found on sun-exposed areas of the body. It most often resolves without scarring or pigmentation changes.","Lupus Erythematosus Tumidus | LET | Tumid Lupus Erythematosus",,,,,,,,,,,,,,,"4066481","Lupus erythematosus tumidus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899344","Doing Business As","C117113","A legal term meaning that the trade name, or fictitious business name, under which the business or operation is conducted and presented to the world is not the legal name of the legal person(s) who actually owns the business and is responsible for it.","Doing Business As | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899818","CCRF-CEM","C117114","A T-lymphoblastic cell line established by G.E. Foley, et al. from the peripheral blood buffy coat from a four year old female child with acute leukemia.","CCRF-CEM | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268634","Fatty Acid Metabolism Disorder","C117115","A group of genetic disorders that result from the inability to produce or use an enzyme required to oxidize fatty acids, resulting in an inability to generate energy from fatty acid sources.","Fatty Acid Metabolism Disorder | ",,,,,,,,,,,,,,,"435233","Disorder of fatty acid metabolism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0751434","Classical Phenylketonuria","C117117","A genetic disorder caused by a mutation in the gene that encodes the enzyme phenylalanine hydroxylase, resulting in a severe form of phenylketonuria.","Classical Phenylketonuria | CPKU | Phenylalanine Hydroxylase Deficiency",,,,,,,,,,,,,,,"432872","Classical phenylketonuria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898546","MOLT-4","C117119","A T-lymphoblastic cell line established from the peripheral blood of a 19 year old male patient with acute lymphoblastic leukemia in relapse.","MOLT-4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889129","IGKV4-1 wt Allele","C117120","Human IGKV4-1 wild-type allele is located in the vicinity of 2p11.2 and is approximately 1 kb in length. This allele, which encodes immunoglobulin kappa variable 4-1 protein, is involved in antibody structure and antigen specificity.","IGKV4-1 wt Allele | B3 | IGKV41 | Immunoglobulin Kappa Variable 4-1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898811","Ig Kappa Chain V-IV Region","C117121","Immunoglobulin kappa variable 4-1 (121 aa, ~13 kDa) is encoded by the human IGKV4-1 gene. This protein plays a role in antibody specificity.","Immunoglobulin Kappa Variable 4-1 | IGKV4-1 | Ig Kappa Chain V-IV Region | Ig Kappa Chain V-IV Region B171 | Ig Kappa Chain V-IV Region JI1 | Ig Kappa Chain V-IV Region Len1 | Ig Kappa Chain V-IV Region STH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897803","RPMI-8226","C117122","A lymphoblast-like cell line established from the peripheral blood of a 61 year old male patient with multiple myeloma (IgG lambda-type).","RPMI-8226 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898694","Intraventricular Hemorrhage Related to Birth","C116911","Bleeding into the cerebral ventricles that occurs during labor and/or delivery.","Intraventricular Hemorrhage Related to Birth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897351","Total Tumor RNA-loaded Dendritic Cell Vaccine","C116913","A cancer vaccine containing autologous dendritic cells (DCs) that are loaded with total tumor RNA (TTRNA) from a specific tumor, with potential immunostimulatory and antineoplastic activities. Upon administration, TTRNA-loaded DC vaccine may elicit a highly specific cytotoxic T-cell (CTL) response against the tumor-associated antigens (TAAs) encoded by the TTRNA.","Total Tumor RNA-loaded Dendritic Cell Vaccine | TTRNA-loaded DC Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473980","Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes","C116914","A preparation of genetically modified CD8+ central memory (Tcm) and CD4+ autologous T-lymphocytes (1:1) transduced with a replication incompetent, self-inactivating (SIN) lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-CD19 single chain variable fragment (scFv) derived from the murine IgG1 monoclonal antibody (mAb) FMC63, fused to the signaling domain of 4-1BB (CD137), the zeta chain of the TCR/CD3 complex (CD3-zeta), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T lymphocytes are directed to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a cetuximab-induced antibody dependent cellular cytotoxicity response. The 4-1BB costimulatory signaling domain enhances both proliferation of T-cells and antitumor activity.","Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015458","Progressive Hemifacial Atrophy","C116916","A rare disorder of unknown etiology, which is characterized by slowly progressive, unilateral facial atrophy of the skin, soft tissue, muscles, and underlying bony structures. Neurological, ocular, and oral symptoms are also often seen, including migraines, trigeminal neuralgia, enophthalmos, and dental and gingival abnormalities.","Progressive Hemifacial Atrophy | Parry-Romberg Syndrome",,,,,,,,,,,,,,,"37397558","Progressive hemifacial atrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4082167","Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis Syndrome","C116917","An autoinflammatory syndrome of childhood which often resolves in adolescence, and is characterized by periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis. The fever cycle generally occurs every three to five weeks, and during the interim periods the child appears healthy; diagnosis is exclusionary.","Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis Syndrome | Marshall Syndrome | PFAPA Syndrome",,,,,,,,,,,,,,,"37397178","PFAPA syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL421603","Electroporation-Mediated Plasmid DNA Vaccine Therapy","C116536","The use of an external electrical field to facilitate the transfer of a plasmid into a cell for the purpose of introducing genetically modified DNA and stimulating a immunological response.","Electroporation-Mediated Plasmid DNA Vaccine Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016286","Fluid Therapy","C116537","The administration of fluids, most commonly via an intravenous route, to restore intravascular volume.","Fluid Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2363129","Benign Rolandic Epilepsy","C116538","A neurological disorder of childhood characterized by partial seizures consisting of twitching, numbness, or tingling of the face or tongue that often progress to secondary generalized seizures.","Benign Rolandic Epilepsy | BECTS | BRE | Benign Childhood Epilepsy With Centrotemporal Spikes | Benign Childhood Epilepsy with Centrotemporal Spikes",,,,,,,,,,,,,,,"4185733","Benign Rolandic epilepsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL388426","Gene-Modified Tumor Cell Vaccine Therapy","C116539","A type of immunotherapy in which tumor cells have been modified to make them more immunogenic, thereby activating the immune system to attack and destroy the tumor.","Gene-Modified Tumor Cell Vaccine Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1505591","Crossover Junction Endonuclease MUS81, Human","C116617","Crossover junction endonuclease MUS81 (551 aa, ~61 kDa) is encoded by the human MUS81 gene. This protein plays a role in the catabolism of branched DNA structures.","Crossover Junction Endonuclease MUS81 | EC 3.1.22.- | EC 3.1.22.4 | MUS81 Endonuclease Homolog | SLX3 Structure-Specific Endonuclease Subunit Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890751","CENP-S","C116621","Human CENPS wild-type allele is located in the vicinity of 1p36.22 and is approximately 13 kb in length. This allele, which encodes centromere protein S, plays a role in binding to and repair of DNA.","CENPS wt Allele | APITD1 | Apoptosis-Inducing, TAF9-Like Domain 1 Gene | CENP-S | Centromere Protein S wt Allele | FAAP16 | MHF1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1528983","Centromere Protein S","C116622","Centromere protein S (138 aa, ~16 kDa) is encoded by the human CENPS gene. This protein is involved in both DNA binding and DNA damage repair.","Centromere Protein S | Apoptosis-Inducing TAF9-Like Domain-Containing Protein 1 | CENP-S | CENPS | Centromeric Protein S | FANCM-Associated Histone Fold Protein 1 | FANCM-Interacting Histone Fold Protein 1 | FANCM-Interacting Histone-Fold Protein 1 | Fanconi Anemia-Associated Polypeptide of 16 kDa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL421604","Alkaline Water","C116623","Water that has a pH above 7, that can be used to alter the conditions in the gastrointestinal (GI) tract and modify absorption of certain therapeutic agents. Upon oral administration, alkaline water provides alkaline conditions within the GI tract. This may decrease absorption of certain therapeutic agents, reduce epithelial damage and may alter bowel movements.","Alkaline Water | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473943","Perflenapent Emulsion","C116804","An oil-in-water nano-emulsion composed of the perfluorocarbon perflenapent, that has oxygen-carrying capacity, can be used as a contrast agent and has potential antihypoxic and radiosensitizing activities. Upon intravenous administration of the perflenapent emulsion, this agent increases the oxygen-carrying capacity of blood, enhances the transport of oxygen to hypoxic and ischemic tissues and increases the oxygen concentration in these tissues. Hypoxic tumors are correlated with increased resistance to radiation treatment; therefore, since perflenapent may increase tumor oxygenation, it may improve the tumor's sensitivity to radiation therapy.","Perflenapent Emulsion | DDFP LIquid Emulsion | Dodecafluoropentane Emulsion | NVX-108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1096721","Neonatal Sepsis, Late-Onset","C116805","An infectious disorder of newborn infants that is characterized by a systemic inflammatory response beyond 72 hours of life and is most commonly caused by bacteria.","Neonatal Sepsis, Late-Onset | Late-Onset Neonatal Sepsis",,,,,,,,,,,,,,,"35622881","Late-onset neonatal sepsis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0729538","Saphenous Vein Graft","C117822","A vessel graft comprised of the saphenous vein.","Saphenous Vein Graft | SAPHENOUS VEIN GRAFT | SVG",,,,,,,,,,,,,,,"4193170","Saphenous vein graft",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897409","Synthetic Vessel Graft","C117823","A vessel graft comprised of manufactured material.","Synthetic Vessel Graft | SYNTHETIC GRAFT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890401","West Haven Hepatic Encephalopathy Grade 0","C117824","Minimal - symptoms or pathological characteristics include minimal hepatic encephalopathy, lack of detectable changes in personality or behavior, minimal changes in memory, concentration and intellectual function, and absence of coordination asterixis. (Adapted from: Hepatic Encephalopathy. David C Wolf. http://emedicine.medscape.com/article/186101-overview)","West Haven Hepatic Encephalopathy Grade 0 | GRADE 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889292","West Haven Hepatic Encephalopathy Grade 1","C117825","Mild - symptoms or pathological characteristics include trivial lack of awareness, shortened attention span, impaired ability to perform addition or subtraction, hypersomnia, insomnia, or inversion of sleep pattern, euphoria, depression or irritability, mild confusion, slowing of ability to perform mental tasks. (Adapted from: Hepatic Encephalopathy. David C Wolf. http://emedicine.medscape.com/article/186101-overview.)","West Haven Hepatic Encephalopathy Grade 1 | GRADE 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889824","West Haven Hepatic Encephalopathy Grade 2","C117826","Moderate - symptoms or pathological characteristics include lethargy or apathy, disorientation, inappropriate behavior, slurred speech, obvious asterixis, drowsiness, lethargy, gross deficits in ability to perform mental tasks, obvious personality changes, inappropriate behavior, and intermittent disorientation, unsurely regarding time. (Adapted from: Hepatic Encephalopathy. David C Wolf. http://emedicine.medscape.com/article/186101-overview.)","West Haven Hepatic Encephalopathy Grade 2 | GRADE 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889290","West Haven Hepatic Encephalopathy Grade 3","C117827","Severe - symptoms or pathological characteristics include somnolence with some arousability, inability to perform mental tasks, disorientation about time and place, marked confusion, amnesia, occasional fits of rage, present but incomprehensible speech. (Adapted from: Hepatic Encephalopathy. David C Wolf. http://emedicine.medscape.com/article/186101-overview.)","West Haven Hepatic Encephalopathy Grade 3 | GRADE 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0585937","Albumin Urine Excretion Rate","C117829","A determination of the amount of albumin being excreted in urine over a defined period of time.","Albumin Urine Excretion Rate | ",,,,,,,,,,,,,,,"4143288","Albumin excretion rate measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899891","C-SSRS Lifetime/Recent Version - Description of Aborted Suicide Attempt","C118064","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Description of aborted or self-interrupted attempt.","C-SSRS Lifetime/Recent Version - Description of Aborted Suicide Attempt | CSS11-Aborted Attempt, Describe | CSS1118C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899854","C-SSRS Lifetime/Recent Version - Preparatory Acts or Behaviors Toward Suicide Attempt (Lifetime)","C118065","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Have you taken any steps towards making a suicide attempt or preparing to kill yourself (such as collecting pills, getting a gun, giving valuables away or writing a suicide note)? (Lifetime).","C-SSRS Lifetime/Recent Version - Preparatory Acts or Behaviors Toward Suicide Attempt (Lifetime) | CSS11-Preparatory Acts/Behavior-Life | CSS1119A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899853","C-SSRS Lifetime/Recent Version - Preparatory Acts or Behaviors Toward Suicide Attempt (Past 3 Months)","C118066","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Have you taken any steps towards making a suicide attempt or preparing to kill yourself (such as collecting pills, getting a gun, giving valuables away or writing a suicide note)? (Past 3 Months).","C-SSRS Lifetime/Recent Version - Preparatory Acts or Behaviors Toward Suicide Attempt (Past 3 Months) | CSS11-Preparatory Acts/Behavior-P3M | CSS1119B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899884","C-SSRS Lifetime/Recent Version - Description of Preparatory Acts or Behaviors Toward Suicide Attempt","C118067","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Description of preparatory acts or behavior.","C-SSRS Lifetime/Recent Version - Description of Preparatory Acts or Behaviors Toward Suicide Attempt | CSS11-Preparatory Acts/Behavior, Descr | CSS1119C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521007","Hypophonia","C116339","The inability to produce speech sounds at normal volume.","Hypophonia | ",,,,,,,,,,,,,,,"4142495","Hypophonia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898569","Low-Grade Astrocytic Tumor","C116342","A grade I or grade II astrocytoma. This category includes pilocytic astrocytoma (grade I), subependymal giant cell astrocytoma (grade I), and diffuse astrocytoma (grade II).","Low Grade Astrocytoma | Low Grade Astrocytic Neoplasm | Low Grade Astrocytic Tumor | Low-Grade Astrocytic Neoplasm | Low-Grade Astrocytic Tumor | Low-Grade Astrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033138","Idiopathic Hypersomnia","C116343","A disorder of central nervous system etiology characterized by excessive sleepiness during the daytime.","Idiopathic Hypersomnia | Primary Hypersomnia",,,,,,,,,,,,,,,"4262584","Primary hypersomnia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3890188","FMO3 wt Allele","C116953","Human FMO3 wild-type allele is located in the vicinity of 1q24.3 and is approximately 27 kb in length. This allele, which encodes flavin-containing monooxygenase 3 protein, plays a role in the oxygenation of drugs, dietary supplements and pesticides. Mutation of the gene is associated with trimethylaminuria.","FMO3 wt Allele | FMOII | Flavin Containing Dimethylaniline Monoxygenase 3 wt Allele | Flavin Containing Monooxygenase 3 Gene | Flavin Containing Monooxygenase 3 wt Allele | TMAU | dJ127D3.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0243600","flavin-containing monooxygenase 3","C116954","Flavin-containing monooxygenase 3 (532 aa, ~60 kDa) is encoded by the human FMO3 gene. This protein is involved in the oxygenation primary aliphatic alkylamines and both secondary and tertiary amines.","Flavin-Containing Monooxygenase 3 | Dimethylaniline Monooxygenase [N-Oxide-Forming] 3 | Dimethylaniline Monooxygenase [N-Oxide-Forming] 3 | Dimethylaniline Oxidase 3 | EC 1.14.13.148 | EC 1.14.13.32 | EC 1.14.13.8 | FMO 3 | FMO Form 2 | FMO II | FMO3 | Flavin Containing Dimethylaniline Monoxygenase 3 | Flavin Containing Monooxygenase 3 | Flavin-Containing Dimethylaniline Monooxygenase 3 | Flavin-Containing Monooxygenase 3 | Flavin-Containing Monooxygenase-3 | Hepatic Flavin-Containing Monooxygenase 3 | Hepatic Flavin-Containing Monooxygenase-3 | Trimethylamine Monooxygenase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0271889","Diencephalic Syndrome of Infancy","C116955","Emaciation in the setting of normal linear growth and intellectual development, which is usually associated with neoplasms involving the anterior hypothalamus in infancy or early childhood.","Diencephalic Syndrome of Infancy | Diencephalic Syndrome",,,,,,,,,,,,,,,"4164122","Diencephalic syndrome of infancy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3890776","SLFN11 wt Allele","C116957","Human SLFN11 wild-type allele is located in the vicinity of 17q12 and is approximately 23 kb in length. This allele, which encodes Schlafen family member 11 protein, is involved in the response to viral infection.","SLFN11 wt Allele | FLJ34922 | SLFN8/9 | Schlafen Family Member 11 wt Allele | Schlafen Family, Member 11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0393799","Miller Fisher Syndrome","C116958","An autoimmune process characterized by the clinical triad of ophthalmoplegia, ataxia, and areflexia.","Miller Fisher Syndrome | Fisher Syndrome | Fisher Syndrome | Miller Fisher Syndrome | Miller-Fisher syndrome",,,,,,,,,,,,,,,"4070552","Fisher's syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3889732","Schlafen Family Member 11","C116959","Schlafen family member 11 (901 aa, ~103 kDa) is encoded by the human SLFN11 gene. This protein plays a role in the inhibition of viral protein synthesis.","Schlafen Family Member 11 | SLFN11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815766","ABALON Gene","C118115","This gene plays a role in the modulation apoptosis.","ABALON Gene | ABALON | Apoptotic BCL2L1-Antisense Long Non-Coding RNA Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890884","ABALON wt Allele","C118116","Human ABALON wild-type allele is located in the vicinity of 20q11.21. This allele, which encodes apoptotic BCL2L1-antisense long non-coding RNA, is involved in the modulation of BCL2L1 protein expression.","ABALON wt Allele | Apoptotic BCL2L1-Antisense Long Non-Coding RNA wt Allele | INXS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889725","Apoptotic BCL2L1-Antisense Long Non-Coding RNA, human","C118117","Apoptotic BCL2L1-antisense long non-coding RNA (~2 kb) is encoded by the human ABALON gene. This non-coding RNA plays a role in the regulation of BCL2L1-mediated apoptosis.","Apoptotic BCL2L1-Antisense Long Non-Coding RNA | ABALON | Apoptotic BCL-X-Associated Long ncRNA | INXS | Intronic BCL-XS-Inducing lncRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891020","LUNAR1 Gene","C118118","This gene may play a role in both Notch signaling pathways and leukemogenesis.","LUNAR1 Gene | LUNAR1 | Leukemia-Associated Non-Coding IGF1R Activator RNA 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898638","LUNAR1 wt Allele","C118119","Human LUNAR1 wild-type allele is located in the vicinity of 15q26.3. This allele, which encodes leukemia-associated non-coding IGF1R activator RNA 1, may be involved in both acute lymphoblastic leukemia and Notch-mediated signaling.","LUNAR1 wt Allele | Leukemia-Associated Non-Coding IGF1R Activator RNA 1 wt Allele | Leukemia-Induced Noncoding Activator RNA 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890044","Leukemia-Associated Non-Coding IGF1R Activator RNA 1, human","C118120","Leukemia-associated non-coding IGF1R activator RNA 1 is encoded by the human LUNAR1 gene. This non-coding RNA plays a role in both leukemogenesis and Notch signaling.","Leukemia-Associated Non-Coding IGF1R Activator RNA 1 | LUNAR1 | Leukemia-Induced Noncoding Activator RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3148052","MIR4457 Gene","C118121","This gene may plays role in gene silencing.","MIR4457 Gene | MIR4457 | MicroRNA 4457 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890910","MIR4457 wt Allele","C118122","Human MIR4457 wild-type allele is located within chromosome 5 and is approximately 70 bases in length. This allele, which encodes MIR4457 pre-miRNA, may be involved in transcriptional regulation.","MIR4457 wt Allele | MicroRNA 4457 wt Allele | hsa-mir-4457 | mir-4457",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891811","MIR4457 Pre-miRNA","C118123","MIR4457 pre-miRNA (68 bases) is encoded by the human MIR4457 gene. This oligoribonucleotide may play a role in the negative regulation of gene transcription.","MIR4457 Pre-miRNA | hsa-mir-4457 | mir-4457",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3811619","LINC-PINT Gene","C118124","This gene is involved in signaling pathway regulation.","LINC-PINT Gene | LINC-PINT | Long Intergenic Non-Protein Coding RNA, p53 Induced Transcript Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890014","LINC-PINT wt Allele","C118125","Human LINC-PINT wild-type allele is located in the vicinity of 7q32.3 and is approximately 168 kb in length. This allele, which encodes long intergenic non-protein coding RNA, p53 induced transcript, plays a role in the transcriptional regulation of signaling protein genes.","LINC-PINT wt Allele | FLJ43663 | LincRNA-Pint Gene | Long Intergenic Non-Protein Coding RNA, p53 Induced Transcript wt Allele | Long Intergenic Noncoding RNA, p53-Induced Transcript Gene | MKLN1 Antisense RNA 1 (Head To Head) Gene | MKLN1-AS1 | PINT | hCG_2038586",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897055","Subarachnoid Hemorrhage Related to Birth","C117305","Bleeding within the subarachnoid space occurring during labor and/or delivery.","Subarachnoid Hemorrhage Related to Birth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897448","Subdural Hemorrhage Related to Birth","C117306","Bleeding within the subdural space occurring during labor and/or delivery.","Subdural Hemorrhage Related to Birth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899142","Female Reproductive System Finding","C117720","Symptoms, physical examination results, and/or laboratory test results related to the female reproductive system.","Female Reproductive System Finding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206539","Respirovirus","C117721","A genus of negative-stranded RNA viruses in the paramyxovirinae subfamily.","Respirovirus | ",,,,,,,,,,,,,,,"4236146","Genus Respirovirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206540","Avulavirus","C117722","A genus of negative-sense viruses in the subfamily paramyxovirinae that infect birds.","Avulavirus | Avian Rubulavirus",,,,,,,,,,,,,,,"4236147","Genus Avulavirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2973571","Flumatinib Mesylate","C117723","The orally bioavailable, mesylate salt form of the tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity. Upon administration, flumatinib inhibits the wild-type forms of Bcr-Abl, platelet-derived growth factor receptor (PDGFR) and mast/stem cell growth factor receptor (SCFR; c-Kit) and forms of these proteins with certain point mutations. This results in the inhibition of both Bcr-Abl-, PDGFR- and c-Kit-mediated signal transduction pathways, and the proliferation of tumor cells in which these kinases are overexpressed. Bcr-Abl fusion protein is an abnormal, constitutively active enzyme expressed in Philadelphia chromosome positive chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML). PDGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to cell migration and the development of the microvasculature. c-kit, a receptor tyrosine kinase mutated and constitutively activated in certain tumors, plays a key role in tumor cell survival, proliferation, and differentiation.","Flumatinib Mesylate | 4-(4-Methyl-piperazin-1-ylmethyl)-N-[6-methyl-5-(4-pyridin-3-yl-pyrimidin-2-ylamino)-pyridin-3-yl]-3-trifluoromethyl-benzamide Mesylate | FLUMATINIB MESYLATE | HH-GV-678 Mesylate | HH-GV678 Mesylate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474119","NY-ESO-1-specific CD4-positive T Lymphocytes","C117724","A preparation of autologous CD4+ T-lymphocytes sensitized to cancer-testis antigen NY-ESO-1, with potential immunostimulating and antineoplastic activities. CD4-positive T-lymphocytes are exposed to a NY-ESO-1 peptide ex vivo, expanded, and introduced into the patient. The NY-ESO-1-specific CD4-positive T-lymphocytes may stimulate the host immune system to produce a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the NY-ESO-1 antigen, which results in tumor cell lysis. NY-ESO-1, an antigen found in normal testis, may be upregulated in various cancers.","NY-ESO-1-specific CD4-positive T Lymphocytes | CD4+ NY-ESO-1-specific T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889643","CFP wt Allele","C118198","Human CFP wild-type allele is located in the vicinity of Xp11.4 and is approximately 6 kb in length. This allele, which encodes properdin protein, is involved in the positive regulation of the alternative complement pathway. Point mutations in the gene are associated with properdin deficiency.","CFP wt Allele | BFD | Complement Factor Properdin wt Allele | PFC | PFD | PROPERDIN | Properdin P Factor, Complement Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4227794","Developmental Regression","C118200","Reversion to an earlier stage of development.","Developmental Regression | Regression",,,,,,,,,,,,,,,"43531507","Developmental regression",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2242537","Cutting Behavior","C118201","Self-injury caused by making cuts into the skin.","Cutting Behavior | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889256","OPCML wt Allele","C116961","Human OPCML wild-type allele is located in the vicinity of 11q25 and is approximately 1117 kb in length. This allele, which encodes opioid-binding protein/cell adhesion molecule protein, plays a role in opioid receptor activity. Variation of the gene is associated with increased susceptibility to ovarian cancer.","OPCML wt Allele | IGLON1 | OBCAM | OPCM | Opioid Binding Protein/Cell Adhesion Molecule-Like wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1505098","Opioid-Binding Protein/Cell Adhesion Molecule, Human","C116962","Opioid-binding protein/cell adhesion molecule (345 aa, ~38 kDa) is encoded by the human OPCML gene. This protein may be involved in opioid signaling.","Opioid-Binding Protein/Cell Adhesion Molecule | IgLON Family Member 1 | OBCAM | OPCML | Opioid Binding Protein/Cell Adhesion Molecule-Like Preprotein | Opioid-Binding Cell Adhesion Molecule | Opioid-Binding Protein/Cell Adhesion Molecule-Like",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388398","Fourier Transform Ion Cyclotron Resonance Mass Spectrometry","C116571","A type of mass spectrometry that uses the cyclotron frequency of ions in a fixed magnetic field to determine their ionic mass-to-charge ratio.","Fourier Transform Ion Cyclotron Resonance Mass Spectrometry | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL371839","Gastrointestinal Stenting","C116572","The placement of a mesh tube anywhere within the gastrointestinal tract. It is used to keep the lumen open and free of obstruction.","Gastrointestinal Stenting | Enteral Stenting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0751122","Dravet Syndrome","C116573","A severe form of epilepsy that presents in early childhood and is characterized by frequent, prolonged febrile or myoclonic seizures that may progress to status epilepticus and poor development of language, motor, and socialization skills.","Dravet Syndrome | SMEI | Severe Myoclonic Epilepsy of Infancy",,,,,,,,,,,,,,,"4043550","Severe myoclonic epilepsy in infancy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1845265","Athetosis","C116574","Slow, involuntary, and nonpurposeful writhing movements that usually affect the upper limbs.","Athetosis | ",,,,,,,,,,,,,,,"4259277","Athetosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3887506","Hyperkinesia","C116575","Excessive movement.","Hyperkinesia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086439","Hypokinesia","C116576","Diminished movement.","Hypokinesia | ",,,,,,,,,,,,,,,"4195475","Behavior showing reduced motor activity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1852581","EPILEPSY, BENIGN NEONATAL, 2","C117307","A group of genetically-determined conditions characterized by a wide spectrum of seizure types occurring in otherwise healthy newborn infants that start during the first week of life and spontaneously disappear between the first and twelfth months of life.","Benign Familial Convulsion | Benign Familal Neonatal Seizures | Benign Familial Convulsions | Benign Familial Neonatal Seizures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0393943","Transient Neonatal Myasthenia Gravis","C117308","A condition characterized as a temporary autoimmune neuromuscular disease leading to fluctuating muscle weakness and fatigue in a newborn infant.","Transient Neonatal Myasthenia Gravis | ",,,,,,,,,,,,,,,"4045730","Transient neonatal myasthenia gravis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1142053","Poor Sucking Reflex","C117310","Uncoordinated or ineffective drawing of saliva or breast milk by a newborn infant.","Poor Sucking Reflex | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919872","Drug Exposure via Breast Milk","C117311","Ingestion of drugs contained in breast milk.","Drug Exposure via Breast Milk | Drug Exposure Via Breast Milk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1449721","Breast Engorgement in Newborn","C117312","Transient bilateral swelling of breast tissue in a neonate that results from the waning influence of maternal estrogen.","Breast Engorgement in Newborn | Neonatal Breast Enlargement",,,,,,,,,,,,,,,"73019","Breast engorgement in newborn",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1405546","Pseudomenstruation","C117313","Blood-tinged vaginal secretion in a neonate that results from the residual influence of maternal estrogen.","Pseudomenstruation | Pseudomenses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898145","Neonatal Vaginal Discharge","C117314","Secretions which may be thin or tenacious, mucoid or glairy, grayish or milky, occasionally blood tinged, that originate in the vagina and are a consequence of the residual influence of maternal estrogen.","Neonatal Vaginal Discharge | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1833431","Subependymal Pseudocyst","C117315","Cerebral periventricular cyst located on the floor of the lateral cerebral ventricle, most commonly in the caudothalamic groove, and results from regression of the germinal matrix or as a sequela of a prior subependymal hemorrhage or germinal matrix infarct.","Subependymal Pseudocyst | Germinolytic Cyst | Subependymal Cyst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897872","Postpartum Hysterectomy","C117316","The removal of the uterus after vaginal delivery of the fetus or in the postpartum period.","Postpartum Hysterectomy | ",,,,,,,,,,,,,,,"3655186","Postpartum hysterectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898110","Occult Umbilical Cord Prolapse","C117319","A situation in which the umbilical cord is prolapsed through the cervical canal but not through external os.","Occult Umbilical Cord Prolapse | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900107","Acute Placental Infarction","C117320","A focus of necrotic placental parenchyma with clearly visible outlines of necrotic villous structures and absence of any hyalinization and fibrosis, which is frequently 1-2 days of duration.","Acute Placental Infarction | Acute Placental Infact | Acute Placental Infarct",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897451","Subacute Placental Infarction","C117321","A focus of necrotic placental parenchyma with moderate hyalinization and fibrosis with partial absence of the necrotic chorionic villi, which is frequently 3-5 days of duration.","Subacute Placental Infarction | Subacute Placental Infarct",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897721","Remote Placental Infarction","C117322","A focus of necrotic placental parenchyma with marked hyalinization and fibrosis with complete absence of the necrotic chorionic villi, which is frequently more than 7 days of duration.","Remote Placental Infarction | Remote Placental Infarct",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898153","Necrotizing Funisitis","C117323","A ring of karyorrhectic debris that may exhibit dystrophic mineralization and/or identifiable fetal neutrophil infiltrate in Wharton's jelly that is oriented towards the amniotic surface. The cord has a denser ring externally and a fainter ring centrally.","Necrotizing Funisitis | Sclerosing Funisitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1611159","Acoria","C118186","Absence of satiety after eating.","Acoria | Akoria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899910","Bradyphagia","C118187","Abnormally slow eating.","Bradyphagia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963717","Sleep Related Eating Disorder","C118188","Eating during sleep.","Sleep Related Eating Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898830","Hypersexualism","C118189","Excessive sexual behavior.","Hypersexualism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034748","Reactive Attachment Disorder of Infancy or Early Childhood","C118190","A condition in which the failure to establish healthy bonds with caregivers in early childhood leads to lifelong impairment of social interactions.","Reactive Attachment Disorder of Infancy or Early Childhood | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474120","Autologous HNSCC DNA-transfected Semi-allogeneic Fibroblasts MRC-5 Vaccine","C117725","A vaccine consisting of lethally irradiated human fetal lung fibroblasts (Medical Research Council 5 or MRC-5) transfected with autologous tumor DNA derived from a head and neck squamous cell carcinoma (HNSCC), with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, the autologous HNSCC DNA-transfected semi-allogeneic fibroblasts MRC-5 vaccine expresses HNSCC tumor-associated antigens (TAAs), which may activate the immune system to induce a cytotoxic T-lymphocyte (CTL) response against HNSCC cells. The MRC-5 cell line, established in 1966, is a human diploid lung fibroblast cell line derived from the human lung tissue of a 14-week-old male fetus.","Autologous HNSCC DNA-transfected Semi-allogeneic Fibroblasts MRC-5 Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890007","SERPINA3 wt Allele","C116578","Human SERPINA3 wild-type allele is located in the vicinity of 14q32.1 and is approximately 33 kb in length. This allele, which encodes alpha-1-antichymotrypsin protein, plays a role in the negative regulation of the activity of both neutrophil cathepsin G and mast cell chymase. Mutation of the gene is associated with alpha-1-antichymotrypsin deficiency and occlusive cerebrovascular disease. Genetic polymorphisms may be associated with increased susceptibility to either Alzheimer disease or Parkinson disease.","SERPINA3 wt Allele | AACT | ACT | Antichymotrypsin, Alpha-1 Gene | Cell Growth-Inhibiting Gene 24/25 | GIG24 | GIG25 | Serine (Or Cysteine) Proteinase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 3 Gene | Serine (Or Cysteine) Proteinase Inhibitor, Clade A, Member 3 Gene | Serine Proteinase Inhibitor, Clade A, Member 3 Gene | Serpin Peptidase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 3 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1869853","Alpha-1-Antichymotrypsin, Human","C116579","Alpha-1-antichymotrypsin (423 aa, ~48 kDa) is encoded by the human SERPINA3 gene. This protein is involved in the inhibition of neutrophil cathepsin G and mast cell chymase proteolytic activity.","Alpha-1-Antichymotrypsin | ACT | Cell Growth-Inhibiting Gene 24/25 Protein | Growth-Inhibiting Protein 24 | Growth-Inhibiting Protein 25 | Serpin A3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889691","GLRX wt Allele","C116581","Human GLRX wild-type allele is located in the vicinity of 5q14 and is approximately 72 kb in length. This allele, which encodes glutaredoxin-1 protein, is involved in cellular redox","GLRX wt Allele | GRX | GRX1 | Glutaredoxin (Thioltransferase) wt Allele | Glutaredoxin1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1399315","Subarachnoid Hematoma","C116583","A collection of blood into the space between the pia membrane and arachnoid membrane.","Subarachnoid Hematoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018946","Subdural Hematoma","C116585","A collection of blood between the dura mater and the brain.","Subdural Hematoma | ",,,,,,,,,,,,,,,"4318408","Subdural hematoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0538963","interleukin 16 precursor","C116765","Pro-interleukin-16 (1332 aa, ~142 kDa) is encoded by the human IL16 gene. This protein is involved in both transcriptional repression and cytokine signaling.","Pro-Interleukin-16 | Pro-IL-16 | Prointerleukin 16 | Prointerleukin-16 | nPro-IL-16",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049211","Tourettism","C116766","Tics that are secondary to an identifiable cause.","Tourettism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040702","Transient Tic Disorder","C116767","A neurological disorder presenting in childhood that is characterized by motor and/or phonic tics that occur daily or nearly daily for one to twelve months and are not attributed to an identifiable cause.","Transient Tic Disorder | Benign Tic Disorder of Childhood",,,,,,,,,,,,,,,"4210636","Transient tic disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008701","Chronic Tic Disorder","C116768","A neurological disorder presenting in childhood that is characterized by either motor or phonic tics, but not both, that occur daily or nearly daily for at least a year and are not attributed to an identifiable cause.","Chronic Tic Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332865","Congenital Dysplasia","C116769","Abnormal tissue formation due to abnormal cellular organization, which may result in a morphologic defect.","Congenital Dysplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3812410","Retinopathy of Prematurity Stage 0","C116770","Prior to the development of ROP in the premature infant, vascularization of the retina is incomplete or immature. In Stage 0, there is no clear demarcation line between vascularized and non-vascularized retina.","Retinopathy of Prematurity Stage 0 | ",,,,,,,,,,,,,,,"45772079","Retinopathy of prematurity stage 0",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0406782","Transient Neonatal Pustular Melanosis","C116771","A benign, self-limited eruption of vesicles, pustules and macules seen in newborns. The fluid-filled lesions typically rupture and resolve within 48 hours while the macular lesions may persist for months.","Transient Neonatal Pustular Melanosis | ",,,,,,,,,,,,,,,"4033200","Transient neonatal pustulosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897712","Reproductive System Findings Data Collection Date Time","C117653","The date and time reproductive system findings data was collected.","Reproductive System Findings Data Collection Date Time | RPDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899230","Exposure as Collected Date Time of Reference Timepoint","C117505","The date and time of a specific reference point for the collected exposure data.","Exposure as Collected Date Time of Reference Timepoint | ECRFTDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474121","Anti-EGFR Monoclonal Antibody SCT200","C117726","A recombinant monoclonal antibody against human epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Upon administration, anti-EGFR monoclonal antibody SCT200 targets EGFR, prevents the activation and subsequent dimerization of this receptor and inhibits both EGFR-mediated signal transduction and cellular proliferation of EGFR-expressing tumor cells. In addition, SCT200 may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against EGFR-expressing tumor cells. EGFR, a member of the epidermal growth factor receptor family, is overexpressed on the cell surfaces of various solid tumors.","Anti-EGFR Monoclonal Antibody SCT200 | SCT200",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474122","EGFRvIII-specific CAR-transduced Autologous T Lymphocytes","C117727","Autologous human T-lymphocytes transduced with a retroviral vector encoding an anti-epidermal growth factor receptor variant III (EGFRvIII) mutant chimeric T-cell receptor (chimeric antigen receptor or CAR) gene, with potential immunostimulatory and antineoplastic activities. Upon administration, the EGFRvIII-specific CAR-transduced autologous T-lymphocytes bind to the EGFRvIII antigen on tumor cell surfaces; subsequently, EGFRvIII-expressing tumor cells may be lysed. EGFRvIII, an in-frame deletion of exons 2-7 in the EGFR gene, is overexpressed by a variety of cancer cell types but absent in normal, healthy cells. It plays a key role in tumor cell proliferation, tumor angiogenesis and resistance to both radio- and chemotherapy.","EGFRvIII-specific CAR-transduced Autologous T Lymphocytes | CART-EGFRvIII Autologous T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474123","CAIX Inhibitor SLC-0111","C117728","A sulfonamide carbonic anhydrase inhibitor with potential antineoplastic activity. Upon administration, CAIX inhibitor SLC-0111 inhibits tumor-associated carbonic anhydrase IX (CAIX), an hypoxia-inducible transmembrane glycoprotein that catalyzes the reversible reaction and rapid interconversion of carbon dioxide and water to carbonic acid, protons, and bicarbonate ions. This prevents both the acidification of the tumor's extracellular microenvironment and cytoplasmic alkalization. This increases cell death in CAIX-expressing, hypoxic tumors. CAIX is overexpressed in various tumors and plays a key role in intra- and extracellular pH regulation, cancer cell progression, survival, migration and invasion; it is also involved in resistance to both chemo- and radiotherapy.","CAIX Inhibitor SLC-0111 | SLC-0111 | U-104 | U104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899849","C-SSRS Lifetime/Recent Version - Suicidal Behavior (Lifetime)","C118068","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Suicidal behavior was present during the assessment period? (Lifetime).","C-SSRS Lifetime/Recent Version - Suicidal Behavior (Lifetime) | CSS11-Suicidal Behavior-Life | CSS1120A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899848","C-SSRS Lifetime/Recent Version - Suicidal Behavior (Past 3 Months)","C118069","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Suicidal behavior was present during the assessment period? (Past 3 Months).","C-SSRS Lifetime/Recent Version - Suicidal Behavior (Past 3 Months) | CSS11-Suicidal Behavior-P3M | CSS1120B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899868","C-SSRS Lifetime/Recent Version - Most Recent Suicide Attempt Actual Lethality/Medical Damage","C118071","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Most recent attempt actual lethality/medical damage.","C-SSRS Lifetime/Recent Version - Most Recent Suicide Attempt Actual Lethality/Medical Damage | CSS11-Most Recent Attempt Damage | CSS1121B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899866","C-SSRS Lifetime/Recent Version - Most Recent Suicide Attempt Potential Lethality","C118072","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Most recent attempt potential lethality.","C-SSRS Lifetime/Recent Version - Most Recent Suicide Attempt Potential Lethality | CSS11-Most Recent Attempt Potential | CSS1121C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899870","C-SSRS Lifetime/Recent Version - Most Lethal Suicide Attempt Date","C118073","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Most lethal attempt date.","C-SSRS Lifetime/Recent Version - Most Lethal Suicide Attempt Date | CSS11-Most Lethal Attempt Date | CSS1122A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899869","C-SSRS Lifetime/Recent Version - Most Lethal Suicide Attempt Potential Lethality","C118075","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Most lethal attempt potential lethality.","C-SSRS Lifetime/Recent Version - Most Lethal Suicide Attempt Potential Lethality | CSS11-Most Lethal Attempt Potential | CSS1122C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899877","C-SSRS Lifetime/Recent Version - First Suicide Attempt Date","C118076","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Initial/first attempt date.","C-SSRS Lifetime/Recent Version - First Suicide Attempt Date | CSS11-First Attempt Date | CSS1123A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899878","C-SSRS Lifetime/Recent Version - First Suicide Attempt Actual Lethality/Medical Damage","C118077","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Initial/first attempt actual lethality/medical damage.","C-SSRS Lifetime/Recent Version - First Suicide Attempt Actual Lethality/Medical Damage | CSS11-First Attempt Damage | CSS1123B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011304","Demyelination","C117277","Breakdown, or abnormal development, of a nerve fiber myelin sheath.","Demyelination | DEMYELINATION | Dysmyelination",,,,,,,,,,,,,,,"4139599","Demyelination",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898825","IDH1 Protein Variant","C117278","A variation in the amino acid sequence for the isocitrate dehydrogenase [NADP] cytoplasmic protein.","IDH1 Protein Variant | Cytosolic NADP-Isocitrate Dehydrogenase Protein Variant | Isocitrate Dehydrogenase [NADP] Cytoplasmic Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0069477","omega-N-Methylarginine","C1178","A pan-nitric oxide synthase (NOS) inhibitor, with potential immunomodulating and antineoplastic activities. Upon administration, tilarginine binds to and inhibits NOS, a free radical signaling molecule that promotes angiogenesis, metastasis, and immunosuppression in the tumor microenvironment (TME). Reduction in NOS activity may abrogate the immunosuppressive TME, enhance tumor antigen-specific immune response and inhibit tumor cell proliferation.","Tilarginine | L-NMMA | MMA | Monomethylarginine | N-Methylarginine | N5-(Methylamidino)-L-ornithine | NG-Monomethyl-L-Arginine | NG-monomethyl-L-arginine | NMA | TILARGININE | Targinine | omega-N-Monomethylarginine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899903","C-SSRS Lifetime/Recent Version - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act (Lifetime)","C118025","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Have you been thinking about how you might do this? (Lifetime).","C-SSRS Lifetime/Recent Version - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act (Lifetime) | CSS11-Idea, No Intent, No Plan-Life | CSS1103A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899902","C-SSRS Lifetime/Recent Version - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act (Past 1 Month)","C118026","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Have you been thinking about how you might do this? (Past 1 Month).","C-SSRS Lifetime/Recent Version - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act (Past 1 Month) | CSS11-Idea, No Intent, No Plan-P1M | CSS1103B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899890","C-SSRS Lifetime/Recent Version - Description of Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act","C118027","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Description of active suicidal ideation with any methods (not plan) without intent to act.","C-SSRS Lifetime/Recent Version - Description of Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act | CSS11-Idea, No Intent, No Plan, Describe | CSS1103C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899901","C-SSRS Lifetime/Recent Version - Active Suicidal Ideation with Some Intent to Act, without Specific Plan (Lifetime)","C118028","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Have you had these thoughts and had some intention of acting on them? (Lifetime).","C-SSRS Lifetime/Recent Version - Active Suicidal Ideation with Some Intent to Act, without Specific Plan (Lifetime) | CSS11-Idea, Intent, No Plan-Life | CSS1104A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897966","Per Picoliter","C117964","A volume unit equal to one picoliter used as a denominator to build a derived unit expressed as a ratio.","Per Picoliter | /pL | /pl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898821","IDH2 Protein Variant","C117279","A variation in the amino acid sequence for the isocitrate dehydrogenase [NADP], mitochondrial protein.","IDH2 Protein Variant | Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial Protein Variant | Isocitrate Dehydrogenase [NADP], Mitochondrial Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0679048","Obsessive Thinking","C117285","A series of thoughts that are difficult to suppress and may be a consequence or cause of anxiety.","Obsessive Thinking | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0456814","Amotivation","C117286","Lack of drive to participate in social activities or goal oriented behavior.","Amotivation | ",,,,,,,,,,,,,,,"4079571","Loss of motivation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2681720","MIR1208 Gene","C118127","This gene may play a role in the modulation of transcription.","MIR1208 Gene | MIR1208 | MicroRNA 1208 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889455","MIR1208 wt Allele","C118128","Human MIR1208 wild-type allele is located in the vicinity of 8q24.21 and is approximately 70 bases in length. This allele, which encodes MIR1208 pre-miRNA, may be involved in gene silencing.","MIR1208 wt Allele | MIRN1208 | MicroRNA 1208 wt Allele | hsa-mir-1208 | mir-1208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891810","MIR1208 Pre-miRNA, human","C118129","MIR1208 Pre-miRNA (73 bases) is encoded by the human MIR1208 gene. This oligoribonucleotide may play a role in transcriptional silencing.","MIR1208 Pre-miRNA | hsa-mir-1208 | mir-1208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890393","PPID wt Allele","C118131","Human PPID wild-type allele is located in the vicinity of 4q31.3 and is approximately 14 kb in length. This allele, which encodes peptidyl-prolyl cis-trans isomerase D protein, is involved in protein folding.","PPID wt Allele | CYP-40 | CYP40 | CYPD | Peptidylprolyl Isomerase D (Cyclophilin D) Gene | Peptidylprolyl Isomerase D wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899628","Chronic Choriodeciduitis","C118132","Increased parietal decidual lymphocytes invading the fetal chorion and/or amnion.","Chronic Choriodeciduitis | Chronic Chorionitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0390425","Peptidyl-Prolyl Cis-Trans Isomerase D","C118133","Peptidyl-prolyl cis-trans isomerase D (370 aa, ~41 kDa) is encoded by the human PPID gene. This protein plays a role in the isomerization of imidic peptide bonds.","Peptidyl-Prolyl Cis-Trans Isomerase D | 40 kDa Peptidyl-Prolyl Cis-Trans Isomerase | 40 kDa Peptidyl-Prolyl Cis-Trans Isomerase D | CYP-40 | Cyclophilin 40 | Cyclophilin D | Cyclophilin-40 | Cyclophilin-Related Protein | EC 5.2.1.8 | PPID | PPIase D | Peptidyl-Prolyl Isomerase D | Peptidylprolyl Isomerase D | Rotamase D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899627","Chronic Plasma Cell Deciduitis","C118134","The presence of decidual plasma cells, scattered or in aggregate.","Chronic Plasma Cell Deciduitis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900052","Amnion Epithelium Necrosis","C118135","Loss of the amnionic epithelial surface.","Amnion Epithelium Necrosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897770","Reactive Amniocyte","C118138","Proliferation and aggregation of amniocytes due to a meconium exposure.","Reactive Amniocyte | Reactive Amniocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0269802","Amnion Nodosum","C118139","An amnion with nodular deposits of squamous and cellular debris with varying staging of re-epithelialization.","Amnion Nodosum | ",,,,,,,,,,,,,,,"4324135","Amnion nodosum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899900","C-SSRS Lifetime/Recent Version - Active Suicidal Ideation with Some Intent to Act, without Specific Plan (Past 1 Month)","C118029","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Have you had these thoughts and had some intention of acting on them? (Past 1 Month).","C-SSRS Lifetime/Recent Version - Active Suicidal Ideation with Some Intent to Act, without Specific Plan (Past 1 Month) | CSS11-Idea, Intent, No Plan-P1M | CSS1104B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899899","C-SSRS Lifetime/Recent Version - Active Suicidal Ideation with Specific Plan and Intent (Lifetime)","C118031","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan? (Lifetime).","C-SSRS Lifetime/Recent Version - Active Suicidal Ideation with Specific Plan and Intent (Lifetime) | CSS11-Idea, Plan, Intent-Life | CSS1105A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899898","C-SSRS Lifetime/Recent Version - Active Suicidal Ideation with Specific Plan and Intent (Past 1 Month)","C118032","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan? (Past 1 Month).","C-SSRS Lifetime/Recent Version - Active Suicidal Ideation with Specific Plan and Intent (Past 1 Month) | CSS11-Idea, Plan, Intent-P1M | CSS1105B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899888","C-SSRS Lifetime/Recent Version - Description of Active Suicidal Ideation with Specific Plan and Intent","C118033","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Description of active suicidal ideation with specific plan and intent.","C-SSRS Lifetime/Recent Version - Description of Active Suicidal Ideation with Specific Plan and Intent | CSS11-Idea, Plan, Intent, Describe | CSS1105C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899893","C-SSRS Lifetime/Recent Version - Describe Most Severe Ideation (Lifetime)","C118035","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Description of most severe ideation. (Lifetime).","C-SSRS Lifetime/Recent Version - Describe Most Severe Ideation (Lifetime) | CSS11-Most Severe Idea, Desc-Life | CSS1106B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899850","C-SSRS Lifetime/Recent Version - Recent Most Severe Ideation (Past 1 Month)","C118036","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Most severe ideation. (Recent - Past 1 Month).","C-SSRS Lifetime/Recent Version - Recent Most Severe Ideation (Past 1 Month) | CSS11-Most Severe Idea-Recent-P1M | CSS1106C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899892","C-SSRS Lifetime/Recent Version - Describe Recent Most Severe Ideation (Past 1 Month)","C118037","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Description of most severe ideation. (Recent - Past 1 Month).","C-SSRS Lifetime/Recent Version - Describe Recent Most Severe Ideation (Past 1 Month) | CSS11-Most Severe Idea, Desc-Recent-P1M | CSS1106D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474110","ROR1 CAR-specific Autologous T-Lymphocytes","C117237","A mixture of two T-lymphocyte preparations expressing a chimeric antigen receptor (CAR) consisting of an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain variable fragment (scFv) fused to either the co-stimulatory signaling domain cluster of differentiation 28 (CD28), and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3-zeta) (ROR1CD28zeta), or the co-stimulatory signaling domain cluster of differentiation 137 (CD137; 4-1BB), and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3-zeta) (ROR1CD137zeta), with potential immunomodulating and antineoplastic activities. Upon simultaneous administration of the two T-lymphocyte populations ROR1CD28zeta and ROR1CD137zeta , the ROR1 CAR-specific autologous T-lymphocytes are directed to tumor cells expressing ROR1, which may result in a selective toxicity against, and lysis of ROR1-expressing tumor cells. CD28, a T-cell surface-associated co-stimulatory molecule, is required for full T-cell activation, proliferation, and survival. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of ROR1. ROR1, also known as neurotrophic tyrosine kinase, receptor-related 1, is expressed during embryogenesis and by certain leukemias.","ROR1 CAR-specific Autologous T-Lymphocytes | Autologous ROR1-CAR-T Cells | Chimeric Anti-ROR1 T-cell Receptor-expressing Autologous T-lymphocytes | ROR1-CAR-T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889464","SCHLAP1 wt Allele","C118203","Human SCHLAP1 wild-type allele is located in the vicinity of 2q31.3 and is approximately 225 kb in length. This allele, which encodes SWI/SNF complex antagonist associated with prostate cancer 1 long non-coding RNA, may play a role in metastatic prostate cancer.","SCHLAP1 wt Allele | LINC00913 | Long Intergenic Non-Protein Coding RNA 913 Gene | PCAT11 | PCAT114 | Prostate Cancer Associated Transcript 11 Gene | Prostate Cancer-Associated Transcript 114 Gene | SWI/SNF Complex Antagonist Associated With Prostate Cancer 1 (Non-Protein Coding) wt Allele | SWI/SNF Complex Antagonist Associated With Prostate Cancer 1, Noncoding Gene | Second Chromosome Locus Associated With Prostate 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889644","SWI/SNF Complex Antagonist Associated With Prostate Cancer 1, human","C118204","SWI/SNF complex antagonist associated with prostate cancer 1 (~1.4 kb) is encoded by the human SCHLAP1 gene. This non-coding RNA may be involved in prostate cancer metastasis.","SWI/SNF Complex Antagonist Associated With Prostate Cancer 1 | LINC00913 | LincRNA 913 | Long Intergenic Non-Protein Coding RNA 913 | Long Intergenic Noncoding RNA 913 | Prostate Cancer Associated Transcript 11 | Prostate Cancer-Associated Transcript 114 | SCHLAP1 | SChLAP1 | Schalp1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0455204","Homicidal Ideation","C118205","Thinking about ending or making plans to end another's life.","Homicidal Ideation | ",,,,,,,,,,,,,,,"4024763","Homicidal thoughts",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3890381","TOMM20 wt Allele","C118208","Human TOMM20 wild-type allele is located in the vicinity of 1q42 and is approximately 20 kb in length. This allele, which encodes mitochondrial import receptor subunit TOM20 homolog protein, is involved in transporting proteins from the cytosol into the mitochondrion.","TOMM20 wt Allele | MAS20 | MAS20, S. cerevisiae, Homolog of Gene | MOM19 | RP4-597N16.2 | TOM20 | Translocase of Outer Mitochondrial Membrane 20 Homolog (Yeast) wt Allele | Translocase of Outer Mitochondrial Membrane 20, S. Cerevisiae, Homolog of Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL475513","Mitochondrial Import Receptor Subunit TOM20 Homolog","C118209","Mitochondrial import receptor subunit TOM20 homolog (145 aa, ~16 kDa) is encoded by the human TOMM20 gene. This protein plays a role in mitochondrial protein localization.","Mitochondrial Import Receptor Subunit TOM20 Homolog | Mitochondrial 20 kDa Outer Membrane Protein | Outer Mitochondrial Membrane Receptor Tom20 | TOM-20 | TOMM20 | Translocase of Outer Mitochondrial Membrane 20 Homolog Type II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890901","FDPS wt Allele","C118211","Human FDPS wild-type allele is located in the vicinity of 1q22 and is approximately 12 kb in length. This allele, which encodes farnesyl pyrophosphate synthase protein, is involved in isoprenoid biosynthesis.","FDPS wt Allele | FPPS | FPS | Farnesyl Diphosphate Synthase wt Allele | Farnesyl Pyrophosphate Synthetase, Dimethylallyltranstransferase, Geranyltranstransferase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012408","Farnesyl Pyrophosphate Synthetase","C118212","Farnesyl pyrophosphate synthase (419 aa, ~48 kDa) is encoded by the human FDPS gene. This protein plays a role in the synthesis of geranyl pyrophosphate and farnesyl pyrophosphate.","Farnesyl Pyrophosphate Synthetase | (2E,6E)-Farnesyl Diphosphate Synthase | Dimethylallyltranstransferase | EC 2.5.1.1 | EC 2.5.1.10 | FPP Synthase | FPP Synthetase | Farnesyl Diphosphate Synthase | Farnesylpyrophosphate Synthetase | Geranyltranstransferase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898376","Microscopic Findings Data Collection Date Time","C117599","The date and time microscopic findings data was collected.","Microscopic Findings Data Collection Date Time | MIDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900017","Appropriate Placental Villous Maturation","C118140","Placental villous microscopic features that are typical for the gestational age at birth.","Appropriate Placental Villous Maturation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899124","Fetal Circulation with Increased Nucleated Erythrocytes","C118141","Increased nucleated red blood cells within the fetal circulation.","Fetal Circulation with Increased Nucleated Erythrocytes | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897893","Placental Villous Dysmaturity","C118142","Placental villous histology not typical of gestational age, with developmentally abnormal features.","Placental Villous Dysmaturity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900127","Accelerated Placental Villous Maturation","C118143","Placental villous histology not typical of gestational age, with features of more mature villi.","Accelerated Placental Villous Maturation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898771","Increased Placental Syncytial Knots","C118144","Increased number of syncytiotrophoblasts with clusters of apoptotic bodies compared to what would be expected for gestational age.","Increased Placental Syncytial Knots | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897892","Placental Villous Fibrosis","C118145","Increased density of placental villous stroma, often with decreased capillarization compared to what would be expected for gestational age.","Placental Villous Fibrosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899125","Fetal Chorionic Vasculitis","C117324","A neutrophilic infiltrate arising from fetal vessels in the chorionic plate and oriented towards the amniotic cavity.","Fetal Chorionic Vasculitis | Acute Chorionic Vasculitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897248","Umbilical Vasculitis","C117325","A neutrophilic infiltrate arising from fetal vessels of the umbilical cord into the umbilical vessel wall and oriented towards the amniotic cavity.","Umbilical Vasculitis | Acute Umbilical Vasculitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898711","Intervillous Thrombus","C117326","A focus of maternal thrombus within the intervillous space, often with peripheral villous compression. The clot may be wholly or minimally laminated reflecting age.","Intervillous Thrombus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900113","Acute Intervillous Thrombus","C117327","A focus of maternal thrombus within the placental intervillous space, often with peripheral villous compression, which is less than 1-2 days in age.","Acute Intervillous Thrombus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897452","Subacute Intervillous Thrombus","C117328","A focus of maternal thrombus within the placental intervillous space, often with peripheral villous compression, which is 3-5 days in age.","Subacute Intervillous Thrombus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897722","Remote Intervillous Thrombus","C117329","A focus of maternal thrombus within the placental intervillous space, often with peripheral villous compression, which is at least 5-7 days in age.","Remote Intervillous Thrombus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0473391","Retroplacental Thrombus","C117331","A focus of retroplacental thrombus variably extending into the intervillous space, often with peripheral villous compression. The clot may be wholly or minimally laminated reflecting age.","Retroplacental Thrombus | Parabasal Hematoma | Parabasal Thrombus | Retroplacental Hematoma",,,,,,,,,,,,,,,"4129037","Retroplacental hematoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899122","Fetal Stem Vessel Thrombus","C117332","A focus of thrombus adhered to the wall of a fetal stem vessel. It can be completely or partially obstructive and may lead to avascular villi.","Fetal Stem Vessel Thrombus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899123","Fetal Stem Vessel Thrombus with or without Dystrophic Calcification","C117333","A focus of thrombus adhered to the wall of a fetal stem vessel. It can be completely or partially obstructive and may lead to downstream villous injury and calcification.","Fetal Stem Vessel Thrombus with or without Dystrophic Calcification | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899631","Chorionic Plate Vessel Thrombus","C117334","A focus of thrombus adhered to the wall of a fetal blood vessel in the chorionic plate.","Chorionic Plate Vessel Thrombus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474112","anti-CD123/CD3 monoclonal antibody MGD006","C117238","An anti-CD123/anti-CD3 bispecific humanized monoclonal antibody with potential immunostimulatory and antineoplastic activities. Flotetuzumab possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD123, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of flotetuzumab, this bispecific antibody simultaneously binds to both CD3-expressing T-cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated cell lysis of CD123-expressing tumor cells. CD123, the interleukin-3 receptor alpha chain, is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells.","Flotetuzumab | CD123 x CD3 DART Bi-Specific Antibody MGD006 | CD123 x CD3 Dual Affinity Re-Targeting Bi-Specific Antibody MGD006 | FLOTETUZUMAB | MGD006 | RES234 | S80880",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474113","Anthocyanin-rich Corn Extract","C117239","A corn-based, water-soluble extract rich in the polyphenol anthocyanin, with potential antioxidant, anti-inflammatory and chemoprotective activities. Upon administration of the anthocyanin-rich corn extract, the anthocyanins scavenge reactive oxygen species (ROS), which protects healthy cells from radiation-induced oxidative stress and DNA damage. In addition, anthocyanins modulate the expression of various genes and proteins involved in inflammation, tumor cell proliferation, angiogenesis, tumor cell invasion and differentiation. This agent also chelates metals and induces the expression of enzymes involved in Phase II antioxidant and detoxification pathways, which may further protect cells against oxidative stress induced by toxins and carcinogens.","Anthocyanin-rich Corn Extract | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474114","HPV 16 E7 Antigen-expressing Lactobacillis casei Vaccine BLS-ILB-E710c","C117240","An orally available Lactobacillis casei (L. casei)-based vaccine expressing the human papillomavirus (HPV) type 16 isoform E7 protein linked to the poly-gamma-glutamate synthetase complex gene pgsA, with potential immunostimulating activity. Upon oral administration, the expressed HPV 16 E7 may stimulate the immune system to mount a mucosal cytotoxic T-lymphocyte (CTL) response against HPV 16 E7-expressing tumor cells. The poly-glutamic acid synthetase PgsA from Bacillus subtilis acts as an anchoring motif that facilitates the expression of the HPV antigen protein on the surface of the bacteria. HPV 16 E7, a cell surface glycoprotein and tumor associated antigen, is overexpressed in various viral-related cancers.","HPV 16 E7 Antigen-expressing Lactobacillis casei Vaccine BLS-ILB-E710c | Attenuated Live Listeria Encoding HPV 16 E7 Vaccine | BLS-ILB-E710c | BLS-ILS-E710c | L. casei-E7 BLS_ILB_E710c | L.casei-PgsA-E7 | LacE7 Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1452990","PCLO protein, human","C118215","Protein piccolo (5065 aa, ~553 kDa) is encoded by the human PCLO gene. This protein is involved in the structure and function of neuronal synapses.","Protein Piccolo | Aczonin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899730","Calcium Urine Excretion Rate","C117831","A determination of the amount of calcium being excreted in urine over a defined period of time.","Calcium Urine Excretion Rate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899635","Chloride Urine Excretion Rate","C117832","A determination of the amount of chloride being excreted in urine over a defined period of time.","Chloride Urine Excretion Rate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899024","Glucose Urine Excretion Rate","C117834","A determination of the amount of glucose being excreted in urine over a defined period of time.","Glucose Urine Excretion Rate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898665","Iron Urine Excretion Rate","C117838","A determination of the amount of iron being excreted in urine over a defined period of time.","Iron Urine Excretion Rate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897870","Potassium Urine Excretion Rate","C117839","A determination of the amount of potassium being excreted in urine over a defined period of time.","Potassium Urine Excretion Rate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897930","Phosphorus Urine Excretion Rate","C117845","A determination of the amount of phosphorus being excreted in urine over a defined period of time.","Phosphorus Urine Excretion Rate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899632","Chorionic Plate Vessel Thrombus with or without Dystrophic Calcification","C117335","A focus of thrombus adhered to the wall of a fetal blood vessel in the chorionic plate. It can be completely or partially obstructive and may lead to downstream villous injury and calcification.","Chorionic Plate Vessel Thrombus with or without Dystrophic Calcification | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897210","Uteroplacental Vessel Thrombus","C117336","A focus of thrombus adhered to the wall of an uteroplacental vessel.","Uteroplacental Vessel Thrombus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0426226","Placental Finding","C117337","Clinical and laboratory findings about the placenta.","Placental Finding | Placental Findings",,,,,,,,,,,,,,,"4014716","Placental finding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897325","Trimmed Placental Weight","C117338","The weight of the trimmed placenta to the nearest gram, with membranes severed at the disc edge and the umbilical cord cut to within 1 cm of insertion, after draining the blood from the specimen.","Trimmed Placental Weight | Disc Weight | Trimmed Placental Mass",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897216","Untrimmed Placental Weight","C117339","The weight of the placenta after delivery, with membranes intact and some length of the umbilical cord attached, to the nearest gram, before draining the blood from the specimen.","Untrimmed Placental Weight | Placental Weight NOS | Untrimmed Placental Mass",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898625","Larger Axis of Placenta","C117340","The length, in cm, of the longest axis of the chorionic disc.","Larger Axis of Placenta | Larger Diameter of Placenta | Longer Diameter of Placenta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897897","Placental Disc Thickness","C117342","The measured or estimated height of the placental disc perpendicular to the chorionic and basal plates.","Placental Disc Thickness | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897500","Start Date and Time of Procedure","C117529","The date and time of the beginning of the procedure.","Start Date and Time of Procedure | PRSTDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899266","End Date and Time of Procedure","C117530","The date and time of the end of the procedure.","End Date and Time of Procedure | PRENDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0393706","Early Infantile Epileptic Encephalopathy with Burst-Suppression","C116552","A neurological disorder characterized by recurring seizures presenting within the first three months of life, progressive cerebral dysfunction, and an EEG pattern of periods of low electrical brain activity interspersed with bursts of high spiky activity.","Early Infantile Epileptic Encephalopathy with Burst-Suppression | EIEE with Burst-Suppression | OS | Ohtahara Syndrome",,,,,,,,,,,,,,,"4043414","Early infantile epileptic encephalopathy with suppression bursts",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL433767","Circulating Tumor Cell Analysis","C116554","Methods to detect and examine metastatic cancer cells found in the peripheral blood.","Circulating Tumor Cell Analysis | Molecular Analysis of Circulating Tumor Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032042","Placebos","C116558","The use of a medically inactive substance or intervention in substitution for a drug or other medically active treatment.","Placebo Administration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412797","Positron Emission Mammography","C116559","An imaging technique that utilizes a radiolabeled sugar given intravenously to help define the size, shape, and location of a breast tumor.","Positron Emission Mammography | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412263","Radiomammography","C116560","A type of nuclear medicine study that utilizes a radioactive tracer to identify possible tumors.","Radiomammography | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412472","Cranial Electrical Stimulation","C116561","The use of skin electrodes to pass a low intensity, pulsed electrical current through the scalp and into the brain.  This procedure is used to treat a variety of illnesses including anxiety, depression, and chronic pain.","Cranial Electrical Stimulation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1955929","Sonoelastography","C116564","An ultrasound imaging technique that uses low amplitude, low frequency shear waves to find solid tumors within tissue.","Sonoelastography | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899876","C-SSRS Lifetime/Recent Version - First Suicide Attempt Potential Lethality","C118078","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Initial/first attempt potential lethality.","C-SSRS Lifetime/Recent Version - First Suicide Attempt Potential Lethality | CSS11-First Attempt Potential | CSS1123C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899287","ESRS-A - Rigidity: Upper Limbs","C118079","Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Parkinsonism, Rigidity: Upper limbs.","ESRS-A - Rigidity: Upper Limbs | ESRSA1-Rigidity: Upper Limbs | ESRSA101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899289","ESRS-A - Rigidity: Lower Limbs","C118080","Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Parkinsonism, Rigidity: Lower limbs.","ESRS-A - Rigidity: Lower Limbs | ESRSA1-Rigidity: Lower Limbs | ESRSA102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899288","ESRS-A - Rigidity: Neck","C118081","Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Parkinsonism, Rigidity: Neck.","ESRS-A - Rigidity: Neck | ESRSA1-Rigidity: Neck | ESRSA103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899286","ESRS-A - Tremor: Face/Jaw/Chin/Lips/Head","C118082","Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Parkinsonism, Tremor: Face, jaw or chin, lips, head.","ESRS-A - Tremor: Face/Jaw/Chin/Lips/Head | ESRSA1-Tremor: Face/Jaw/Chin/Lips/Head | ESRSA104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899285","ESRS-A - Tremor: Lower Limbs/Feet","C118084","Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Parkinsonism, Tremor: Lower limbs or feet.","ESRS-A - Tremor: Lower Limbs/Feet | ESRSA1-Tremor: Lower Limbs/Feet | ESRSA106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899290","ESRS-A - Reduced Facial Expression/Speech","C118085","Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Parkinsonism: Reduced facial expression or speech.","ESRS-A - Reduced Facial Expression/Speech | ESRSA1-Reduced Facial Expression/Speech | ESRSA107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899292","ESRS-A - Impaired Gait/Posture","C118086","Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Parkinsonism: Impaired gait/posture.","ESRS-A - Impaired Gait/Posture | ESRSA1-Impaired Gait/Posture | ESRSA108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899291","ESRS-A - Postural Instability","C118087","Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Parkinsonism: Postural instability.","ESRS-A - Postural Instability | ESRSA1-Postural Instability | ESRSA109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899307","ESRS-A - Bradykinesia/Hypokinesia","C118088","Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Parkinsonism: Bradykinesia or hypokinesia.","ESRS-A - Bradykinesia/Hypokinesia | ESRSA1-Bradykinesia/Hypokinesia | ESRSA110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896999","ESRS-A - Dystonia: Tongue","C118089","Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Dystonia: Tongue.","ESRS-A - Dystonia: Tongue | ESRSA1-Dystonia: Tongue | ESRSA111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897000","ESRS-A - Dystonia: Jaw","C118090","Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Dystonia: Jaw.","ESRS-A - Dystonia: Jaw | ESRSA1-Dystonia: Jaw | ESRSA112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899296","ESRS-A - Dystonia: Eyes/Upper and Lower Face/Larynx","C118091","Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Dystonia: Eyes, upper face, lower face, larynx.","ESRS-A - Dystonia: Eyes/Upper and Lower Face/Larynx | ESRSA1-Dystonia: Eyes/Face/Larynx | ESRSA113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899294","ESRS-A - Dystonia: Shoulder/Upper Limbs/Hands","C118092","Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Dystonia: Shoulders, upper limbs, hands.","ESRS-A - Dystonia: Shoulder/Upper Limbs/Hands | ESRSA1-Dystonia: Shoulder/Up Limb/Hand | ESRSA114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0069456","Oltipraz","C1177","A synthetic dithiolethione with potential chemopreventive and anti-angiogenic properties. Oltipraz induces phase II detoxification enzymes, such as glutathione S transferase (GST) and NAD(P)H:quinone oxidoreductase 1 (NQO1). The induction of detoxification enzymes enhances the detoxification of certain cancer-causing agents, thereby enhancing their elimination and preventing carcinogen-induced DNA damages. Although the exact mechanism through which the anti-angiogenesis effect remains to be fully elucidated, oltipraz maybe able to modulate the expression of a number of angiogenic factors, thereby blocking the sustained and focal neovascularization in multiple tumor cell types.","Oltipraz | 3H-1,2-Dithiole-3-thione, 4-methyl-5-pyrazinyl- | 3H-1,2-Dithiole-3-thione,4-methyl-5-pyrazinyl | 4-Methyl-5-(pyrazinyl)-3H-1,2-dithiole-3-thione | 4-Methyl-5-pyrazinyl-3H-1,2-dithiole-3-thione | 5-(2-Pyrazinyl)-4-methyl-1,2-dithiol-3-thione | 5-[2-Pyrazinyl]-4-methyl-1,2-3-thione | OLTIPRAZ | RP-35,972 | oltipraz",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899875","C-SSRS Lifetime/Recent Version - Frequency of Most Severe Ideation (Lifetime)","C118038","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) How many times have you had these thoughts? (Lifetime).","C-SSRS Lifetime/Recent Version - Frequency of Most Severe Ideation (Lifetime) | CSS11-Most Severe Idea, Frequency-Life | CSS1107A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017463","Comprehensive Geriatric Assessment","C116565","The complete examination of an elderly individual, which includes a full valuation of the physical and cognitive conditions, as well as a check of the patient's emotional state.","Comprehensive Geriatric Assessment | ",,,,,,,,,,,,,,,"4064499","Geriatric screening",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL413630","Convection-Enhanced Delivery","C116566","The delivery of pharmacological agents to a brain tumor or resection cavity via specially placed catheters that bypass the blood brain barrier.","Convection-Enhanced Delivery | CED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL413625","Electrodessication and Curettage","C116567","A procedure that uses both a curette and hyfrecator for treatment of various skin conditions, including basal cell carcinoma, squamous cell skin carcinoma, viral warts, and pyogenic granulomas.","Electrodessication and Curettage | ",,,,,,,,,,,,,,,"4247648","Electrodesiccation with curettage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL433764","Erythema Measurement","C116568","The use of instruments to quantify the redness of the skin. This is done to measure differences in erythema over time in a single patient and to gauge the stability or progression of a skin disease.","Erythema Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898639","LOX IMVI","C117181","A melanoma cell line established from a lymph node metastasis from a 58 year old male patient with cutaneous melanoma.","LOX IMVI | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898557","MALME-3M","C117182","A melanoma cell line with fibroblast-like morphology.  It was established in 1975 from a metastasis to the lung from a 43 year old Caucasian male with metastatic melanoma.","MALME-3M | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897041","M14","C117183","A melanoma cell line established from a patient with cutaneous melanoma.","M14 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898555","MDA-MB-435","C117184","A cell line established at M.D. Anderson Cancer Center in 1976 from the pleural effusion of a 31 year old female patient with history of breast cancer.  Gene expression analysis of the MDA-MB-435 cell line has revealed that the pattern of gene expression resembles that of melanoma cell lines.  Further investigation has revealed that breast-specific genes were not expressed and melanocytic-specific genes were expressed in this cell line.","MDA-MB-435 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897685","SK-MEL-2","C117188","A melanoma cell line established from a metastatic site on the skin of the thigh of a 60 year old Caucasian male with melanoma.  It expresses wild-type B-Raf and mutant N-Ras.","SK-MEL-2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897686","SK-MEL-28","C117189","A hypotetraploid melanoma cell line established from a 51 year old male patient with cutaneous melanoma.","SK-MEL-28 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899293","ESRS-A - Dystonia: Trunk/Neck","C118094","Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Dystonia: Trunk, neck.","ESRS-A - Dystonia: Trunk/Neck | ESRSA1-Dystonia: Trunk/Neck | ESRSA116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899298","ESRS-A - Dyskinesia: Tongue","C118095","Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Dyskinesia: Tongue.","ESRS-A - Dyskinesia: Tongue | ESRSA1-Dyskinesia: Tongue | ESRSA117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037320","Night Terrors","C117287","Episodes of abrupt awakening associated with screaming, agitation and hyperarousal.","Night Terrors | Sleep Terrors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474738","Isoquercetin","C117288","An orally bioavailable, glucoside derivative of the flavonoid quercetin and protein disulfide isomerase (PDI) inhibitor, with antioxidant and potential antithrombotic activity. As an antioxidant, isoquercetin scavenges free radicals and inhibits oxidative damage to cells. As a PDI inhibitor, this agent blocks PDI-mediated platelet activation, and fibrin generation, which prevents thrombus formation after vascular injury. In addition, isoquercetin is an alpha-glucosidase inhibitor. PDI, an oxidoreductase secreted by activated endothelial cells and platelets, plays a key role in the initiation of the coagulation cascade. Cancer, in addition to other thrombotic disorders, increases the risk of thrombus formation.","Isoquercetin | 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-chromen-4-one | IQC-950AN | ISOQUERCETIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474115","Realgar-Indigo naturalis Formulation","C117289","An orally bioavailable, traditional Chinese medicine (TCM)-based formulation composed of Realgar-Indigo naturalis formula (RIF) with potential antineoplastic activity. The main constituents in RIF are realgar, Indigo naturalis, and Salvia miltiorrhiza, with tetraarsenic tetrasulfide (As4S4), indirubin and tanshinone IIA as the main active ingredients, respectively, which appear to exert synergistic effects on cancer cells. Tetraarsenic tetrasulfide specifically induces the ubiquitination and degradation of promyelocytic leukemia retinoic acid receptor alpha (PML-RARalpha) oncoprotein. In addition, the active ingredients in the Realgar-Indigo naturalis formulation enhance the expression of myeloid differentiation genes, and induce G(1)/G(0) cell cycle arrest. PML-RARalpha, an acute promyelocytic leukemia (APL)-specific fusion gene, inhibits differentiation and promotes survival of myeloid precursor cells","Realgar-Indigo naturalis Formulation | Compound Huangdai | RIF | RIF Formula | Realgar-Indigo naturalis formulation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474116","mTORC1/mTORC2/DHFR Inhibitor ABTL0812","C117290","An orally bioavailable, lipid analogue and inhibitor of raptor-mammalian target of rapamycin (mTOR) (mTOR complex 1; mTORC1), rictor-mTOR (mTOR complex 2; mTORC2) and dihydrofolate reductase (DHFR) with potential antineoplastic activity. Upon oral administration, ibrilatazar binds to and inhibits both mTORC1 and mTORC2, which may result in apoptosis and a decrease in proliferation in mTORC1/2-expressing tumor cells. mTOR is a serine/threonine kinase that is upregulated in some tumors; it plays an important role in the PI3K/Akt/mTOR signaling pathway which is often deregulated in cancer cells. In addition, ibrilatazar inhibits DHFR, an enzyme that reduces dihydrofolic acid to tetrahydrofolic acid, thereby blocking tetrahydrofolate synthesis, and resulting in both the depletion of nucleotide precursors and the inhibition of DNA, RNA and protein synthesis. This induces autophagy-induced cell death and further inhibition of cell proliferation.","Ibrilatazar | 2-Hydroxylinoleic Acid | 9,12-Octadecadienoic Acid, 2-Hydroxy-, (9Z,12Z)- | ABTL-0812 | ABTL0812 | IBRILATAZAR | LP-10218 | LP10218 | SCLN-0812 | SCLN0812 | mTORC1/mTORC2/DHFR Inhibitor ABTL0812 | mTORC1/mTORC2/DHFR Inhibitor ABTL0812",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474117","PSMA-targeted Tubulysin B-containing Conjugate EC1169","C117291","An injectable, water soluble, small molecule drug conjugate (SMDC) containing a ligand specific for prostate-specific membrane antigen (PSMA), conjugated via a stable, enzyme-cleavable linker to the cytotoxic agent tubulysin B hydrazide (TubBH), with potential antineoplastic activity. Upon administration of PSMA-targeted tubulysin B-containing conjugate EC1169, the PSMA ligand specifically targets and binds to PSMA, a protein which is abundantly expressed on the surface of metastatic and hormone-refractory prostate cancer cells as well as on the neovasculature of many solid tumors. This allows for the specific delivery of TubBH to PSMA-expressing cancer cells. Upon internalization and cleavage, tubulysin B binds to tubulin and inhibits microtubule polymerization, which blocks cell division and results in G2/M phase arrest, tumor cell apoptosis and a decrease in PSMA-expressing tumor cells.","PSMA-targeted Tubulysin B-containing Conjugate EC1169 | EC1169 | EC1719",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0546474","Chorangiosis","C118146","An increased number of local terminal placental villous capillary cross-sections, generally with decreased capillary caliber, that shows variable distribution of villi.","Chorangiosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897896","Placental Fibrinoid Deposition","C118147","The presence of a small clot attached to the epithelial surface of a placental villus.","Placental Fibrinoid Deposition | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898893","Hemosiderin in Decidua Parietalis","C118149","The deposition of hemosiderin along the gravid uterine wall.","Hemosiderin in Decidua Parietalis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898894","Hemosiderin in Decidua Basalis","C118150","The deposition of hemosiderin along the gravid uterine fundus beneath the placenta.","Hemosiderin in Decidua Basalis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898892","Hemosiderin in Intervillous Thrombus","C118151","The deposition of hemosiderin in a focus of thrombus within the placental intervillous space.","Hemosiderin in Intervillous Thrombus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899874","C-SSRS Lifetime/Recent Version - Frequency of Most Severe Ideation (Past 1 Month)","C118039","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) How many times have you had these thoughts? (Past 1 Month).","C-SSRS Lifetime/Recent Version - Frequency of Most Severe Ideation (Past 1 Month) | CSS11-Most Severe Idea, Frequency-P1M | CSS1107B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899880","C-SSRS Lifetime/Recent Version - Duration of Most Severe Ideation (Lifetime)","C118040","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) When you have the thoughts how long do they last? (Lifetime).","C-SSRS Lifetime/Recent Version - Duration of Most Severe Ideation (Lifetime) | CSS11-Most Severe Idea, Duration-Life | CSS1108A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899879","C-SSRS Lifetime/Recent Version - Duration of Most Severe Ideation (Past 1 Month)","C118041","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) When you have the thoughts how long do they last? (Past 1 Month).","C-SSRS Lifetime/Recent Version - Duration of Most Severe Ideation (Past 1 Month) | CSS11-Most Severe Idea, Duration-P1M | CSS1108B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899895","C-SSRS Lifetime/Recent Version - Controllability of Most Severe Ideation (Lifetime)","C118042","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Could/can you stop thinking about killing yourself or wanting to die if you want to? (Lifetime).","C-SSRS Lifetime/Recent Version - Controllability of Most Severe Ideation (Lifetime) | CSS11-Most Severe Idea, Control-Life | CSS1109A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899894","C-SSRS Lifetime/Recent Version - Controllability of Most Severe Ideation (Past 1 Month)","C118043","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Could/can you stop thinking about killing yourself or wanting to die if you want to? (Past 1 Month).","C-SSRS Lifetime/Recent Version - Controllability of Most Severe Ideation (Past 1 Month) | CSS11-Most Severe Idea, Control-P1M | CSS1109B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899882","C-SSRS Lifetime/Recent Version - Deterrents to Most Severe Ideation (Lifetime)","C118044","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Are there things - anyone or anything (e.g., family, religion, pain of death) - that stopped you from wanting to die or acting on thoughts of committing suicide? (Lifetime).","C-SSRS Lifetime/Recent Version - Deterrents to Most Severe Ideation (Lifetime) | CSS11-Most Severe Idea, Deterrents-Life | CSS1110A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899881","C-SSRS Lifetime/Recent Version - Deterrents to Most Severe Ideation (Past 1 Month)","C118045","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Are there things - anyone or anything (e.g., family, religion, pain of death) - that stopped you from wanting to die or acting on thoughts of committing suicide? (Past 1 Month).","C-SSRS Lifetime/Recent Version - Deterrents to Most Severe Ideation (Past 1 Month) | CSS11-Most Severe Idea, Deterrents-P1M | CSS1110B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899852","C-SSRS Lifetime/Recent Version - Reasons for Most Severe Ideation (Lifetime)","C118046","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) What sort of reasons did you have for thinking about wanting to die or killing yourself? Was it to end the pain or stop the way you were feeling (in other words you couldn't go on living with this pain or how you were feeling) or was it to get attention, revenge or a reaction from others? Or both? (Lifetime).","C-SSRS Lifetime/Recent Version - Reasons for Most Severe Ideation (Lifetime) | CSS11-Most Severe Idea, Reasons-Life | CSS1111A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899896","C-SSRS Lifetime/Recent Version - Actual Suicide Attempt (Past 3 Months)","C118049","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Have you made a suicide attempt? Have you done anything to harm yourself? Have you done anything dangerous where you could have died? (Past 3 Months).","C-SSRS Lifetime/Recent Version - Actual Suicide Attempt (Past 3 Months) | CSS11-Actual Attempt-P3M | CSS1112B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897684","SK-MEL-5","C117190","A melanoma cell line established from an axillary lymph node metastasis from a 24 year old Caucasian female with cutaneous melanoma.","SK-MEL-5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897261","UACC-257","C117191","A melanoma cell line established from a patient with cutaneous melanoma.","UACC-257 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897260","UACC-62","C117192","A melanoma cell line established from a patient with cutaneous melanoma.","UACC-62 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0233469","Blunted Affect","C117195","Restricted range of emotional expressiveness.","Blunted Affect | Restricted Range of Emotion",,,,,,,,,,,,,,,"4264021","Blunted affect",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0424109","Tearfulness","C117198","Excessive crying.","Tearfulness | ",,,,,,,,,,,,,,,"4158475","Crying associated with mood",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL433966","Anti-ETBR/MMAE Antibody-Drug Conjugate DEDN6526A","C116742","An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin (Ig) G1 monoclonal antibody against anti-endothelin B receptor (ETBR) and covalently linked to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of DEDN6526A binds to ETBR-expressing tumor cells and is internalized, thereby delivering MMAE intracellularly. Proteolytic cleavage releases MMAE, which then binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. ETBR, a G-protein coupled receptor that can activate RAF/MEK signaling, is overexpressed in a variety of tumor cell types and plays a key role in tumor cell proliferation, invasion, epithelial-mesenchymal transition (EMT) and angiogenesis.","Anti-ETBR/MMAE Antibody-Drug Conjugate DEDN6526A | ADC DEDN6526A | DEDN6526A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0218003","Delta-Tocotrienol","C116743","The delta form of the vitamin E family member tocotrienol, with potential antineoplastic activity. Upon administration, delta-tocotrienol accumulates in cancer cells and may exert their anti-cancer activity in part through 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase downregulation and/or degradation, cell cycle arrest, and induction of caspase-mediated apoptosis. In addition, this agent may inhibit angiogenesis partially through the blockage of vascular endothelial growth factor receptor (VEGFR) and the inhibition of tumor cell-induced vessel formation. Altogether, this may result in the inhibition of tumor cell growth. Tocotrienols contain 3 double bonds, absent in tocopherols, on its farnesyl isoprenoid side chain that likely contribute to its anti-cancer activities.","Delta-Tocotrienol | .DELTA.-TOCOTRIENOL | Delta Tocotrienol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0091023","Nucleoside Analog DFP-10917","C116744","A deoxycytosine analog with potential antineoplastic activity. Upon administration, DFP-10917 is phosphorylated to generate its nucleotide form that functions as a deoxycytosine mimic and is incorporated into DNA in tumor cells. This causes DNA strand breaks during polymerization due to beta-elimination during the fidelity checkpoint, which results in G2/M phase-arrest and tumor cell apoptosis.","Nucleoside Analog DFP-10917 | 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine | CNDAC | DFP-10917",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473919","anti-Ly6E antibody-drug conjugate DLYE5953A","C116745","An antibody-drug conjugate (ADC) composed of an antibody against the tumor-associated antigen (TAA) lymphocyte antigen 6 complex locus E (Ly6E) and linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the antibody moiety of RG 7841 targets and binds to Ly6E expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills, through an as of yet unknown mechanism of action, the Ly6E-expressing cancer cells. Ly6E, an interferon (IFN)-inducible glycosylphosphatidylinositol (GPI)-linked cell membrane protein, is expressed on a variety of tumor cell types.","Anti-Ly6E Antibody-Drug Conjugate RG 7841 | ADC DLYE5953A | Anti-LY6E-VCMMAE | Anti-Ly6E Antibody-Drug Conjugate DLYE5953A | DLYE5953A | RG 7841 | RG-7841 | RG7841",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1738934","Boceprevir","C117292","An orally bioavailable, synthetic tripeptide inhibitor of the nonstructural protein 3 and 4A complex (NS3/NS4A), with potential activity against hepatitis C virus (HCV) genotype 1. Upon administration, boceprevir reversibly binds to the active center of the HCV NS3/NS4A and prevents NS3/NS4A protease-mediated polyprotein maturation. This disrupts the processing of viral proteins and the formation of a viral replication complex, which inhibits viral replication in HCV genotrype 1-infected host cells. NS3, a serine protease, is essential for the proteolytic cleavages within the HCV polyprotein and plays a key role during HCV viral RNA replication. NS4A is an activating factor for NS3. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family.","Boceprevir | 3-Azabicyclo(3.1.0)hexane-2-carboxamide, N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-((2S)-2-((((1,1- dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6- dimethyl-, (1R,2S,5S)- | BOCEPREVIR | EBP 520 | SCH 503034 | Victrelis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0069449","Olive Oil","C1175","Produced by pressing olives, Olive Oil has a high content of monounsaturated fats, thought beneficial for health. Major components of the phenolic fraction of olive oil, lignans and pinoresinols are potent antioxidants present in extra virgin (first pressed) oils. Containing vitamins E and F, other antioxidant compounds, foods containing high amounts of lignan precursors may be protective against breast, colon, and prostate cancer, as well as heart diseases. Used mainly in cooking today, olive oil has been used for medicines and in cosmetics. (NCI04)","Olive Oil | OLIVE OIL | Oil, Olive | Olea Europaea Oil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899987","Avascular Placental Villi","C118152","Focus of two or more placental terminal villi showing a total loss of villous capillaries and bland hyaline fibrosis of the villous stroma. Stromal karyorrhexis may or may not be evident.","Avascular Placental Villi | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897891","Placental Villous Stromal Hemorrhage","C118153","Extravascular blood in the chorionic villi.","Placental Villous Stromal Hemorrhage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897890","Placental Villous Stromal-Vascular Karyorrhexis","C118154","Three or more foci of two or more placental terminal villi showing karyorrhexis of fetal cells with preservation of the surrounding trophoblast. The villi may also show stromal hypercellularity and mineralization, and can either be hypovascular or only exhibit capillary degenerative changes. Entrapped red blood cells and red blood cell fragments are often seen.","Placental Villous Stromal-Vascular Karyorrhexis | Hemorrhagic Placental Endovasculitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900128","Absent Physiologic Conversion of Uteroplacental Vessel","C118156","Failure of the maternal spiral arteries to be transformed by extravillous cytotrophoblast to increase blood flow into the placental intervillous spaces, which may lead to an increased risk of early-onset pre-eclampsia and fetal growth restriction.","Absent Physiologic Conversion of Uteroplacental Vessel | Placental Membrane Arteriole Mural Hypertrophy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899626","Chronic Uteroplacental Vasculitis","C118157","A lymphocytic inflammation of the uteroplacental vessels.","Chronic Uteroplacental Vasculitis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897211","Uteroplacental Vessel Fibrinoid Necrosis with or without Atherosis","C118158","The degeneration of an uteroplacental vessel with or without medial foamy macrophages.","Uteroplacental Vessel Fibrinoid Necrosis with or without Atherosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899957","Basal Decidual Necrosis","C118159","Acellular areas of the basal plate.","Basal Decidual Necrosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899958","Basal Decidual Karyorrhexis","C118160","Collections of degenerated nuclear fragments that are associated with tissue injury during placental abruption.","Basal Decidual Karyorrhexis | Necrotizing Deciduitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1096298","Placental Mesenchymal Dysplasia","C118161","Aberrant mesenchymal cell growth within the placenta. It may be associated with Beckwith-Wiedemann Syndrome.","Placental Mesenchymal Dysplasia | Placental Dysplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2363734","Placental Hypertrophy","C118162","Aberrant growth of the placenta.","Placental Hypertrophy | Placentomegaly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899073","Fused Placenta","C117343","In pregnancies with more than one fetus, the composite structure that results from the growth of two (or more) placental chorionic discs such that the placental masses abut one another and are delivered as a single unit but can manually separated into individual units.","Fused Placenta | Multifetal Placenta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0266752","Bilobate Placenta","C117344","A variant placenta in which the chorionic tissue is partitioned into two distinct discs, without consistent relationship to umbilical cord insertion.","Bilobate Placenta | Bilobate Chorionic Surface Shape | Bipartite Placenta | Placenta Bipartita | Placenta Duplex",,,,,,,,,,,,,,,"4189020","Twin placenta",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3890893","SLC6A2 wt Allele","C117243","Human SLC6A2 wild-type allele is located in the vicinity of 16q12.2 and is approximately 51 kb in length. This allele, which encodes sodium-dependent noradrenaline transporter protein, is involved in the transport of norepinephrine into presynaptic cells. Variation of the gene is associated with orthostatic intolerance.","SLC6A2 wt Allele | NAT1 | NET | NET1 | Neurotransmitter Transporter, Noradrenalin Gene | SLC6A5 | Solute Carrier Family 6 (Neurotransmitter Transporter), Member 2 wt Allele | Solute Carrier Family 6 (Neurotransmitter Transporter, Noradrenalin), Member 2 Gene | Solute Carrier Family 6 Member 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1456447","Sodium-Dependent Noradrenaline Transporter, Human","C117244","Sodium-dependent noradrenaline transporter (617 aa, ~69 kDa) is encoded by the human SLC6A2 gene. This protein plays a role in the reuptake of norepinephrine by presynaptic cells.","Sodium-Dependent Noradrenaline Transporter | NET | Neurotransmitter Transporter | Norepinephrine Transporter | Norepinephrine Transporter Protein 1 | SLC6A2 | Solute Carrier Family 6 Member 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899403","Decreased Concentration","C117246","Reduced ability to sustain attention.","Decreased Concentration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415512","HERC2 Gene","C117247","This gene is involved in both protein ubiquitination and DNA damage repair.","HERC2 Gene | HECT and RLD Domain Containing E3 Ubiquitin Protein Ligase 2 Gene | HERC2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0564408","Manic Mood","C117248","An emotional state characterized by marked to extreme elevation of mood with noticeable effect of functioning.","Manic Mood | ",,,,,,,,,,,,,,,"4226696","Manic mood",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3890555","HERC2 wt Allele","C117249","Human HERC2 wild-type allele is located in the vicinity of 15q13 and is approximately 211 kb in length. This allele, which encodes E3 ubiquitin-protein ligase HERC2 protein, plays a role in the modulation of both DNA repair and protein ubiquitination. Variation in the gene defines the skin/hair/eye pigmentation variation locus 1, and mutation of the gene is associated with autosomal recessive mental retardation 38.","HERC2 wt Allele | D15F37S1 | HECT Domain and RCC1-Like Domain 2 Gene | HECT and RLD Domain Containing E3 Ubiquitin Protein Ligase 2 wt Allele | Hect Domain and RLD 2 Gene | MRT38 | SHEP1 | jdf2 | p528",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1439265","E3 Ubiquitin-Protein Ligase HERC2, Human","C117251","E3 ubiquitin-protein ligase HERC2 (4834 aa, ~527 kDa) is encoded by the human HERC2 gene. This protein is involved in ubiquitin-dependent retention of DNA repair proteins.","E3 Ubiquitin-Protein Ligase HERC2 | EC 2.3.2.26 | EC 6.3.2.-, Formerly | HECT Domain and RCC1-Like Domain-Containing Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3552907","Mood Lability","C117252","A condition of frequent mood changes associated with excessive emotional reactions.","Mood Lability | Emotional Lability | Mood Swing",,,,,,,,,,,,,,,"4078201","Mood swings",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0424296","Disinhibition","C117253","Unrestrained behavior, often at odds with social norms.","Disinhibition | Disinhibited",,,,,,,,,,,,,,,"4085840","Social disinhibition",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037899","Sphingolipidosis","C117254","An inherited metabolic disorder that affects the metabolism of the spinhgolipids. Representative examples include Gaucher disease, Tay-Sachs disease, and Niemann-Pick disease.","Sphingolipidosis | ",,,,,,,,,,,,,,,"4079874","Sphingolipidosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1428199","DIXDC1 Gene","C117255","This gene plays a role in the positive regulation of the Wnt signaling pathway.","DIXDC1 Gene | DIX Domain Containing 1 Gene | DIXDC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890395","DIXDC1 wt Allele","C117256","Human DIXDC1 wild-type allele is located in the vicinity of 11q23.1 and is approximately 95 kb in length. This allele, which encodes dixin protein, is involved in the Wnt signaling pathway.","DIXDC1 wt Allele | CCD1 | DIX Domain Containing 1 wt Allele | KIAA1735",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474722","Dixin","C117257","Dixin (683 aa, ~77 kDa) is encoded by the human DIXDC1 gene. This protein plays a role in Wnt signaling.","Dixin | Coiled-Coil DIX1 | Coiled-Coil Protein DIX1 | Coiled-Coil-DIX1 | DIX Domain-Containing Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433928","Anti-mesothelin/MMAE Antibody-Drug Conjugate DMOT4039A","C116746","An antibody-drug conjugate (ADC) composed of MMOT0530A, a humanized immunoglobulin (Ig) G1 monoclonal antibody directed against the cell surface glycoprotein mesothelin (MSLN), and covalently linked, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of DMOT4039A binds to MSLN-expressing tumor cells and is internalized, thereby delivering MMAE intracellularly. Proteolytic cleavage releases MMAE, which then binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. MSLN, a tumor-associated antigen (TAA), is overexpressed by all mesotheliomas and a variety of other cancers, while it is minimally expressed in normal tissue.","Anti-mesothelin/MMAE Antibody-Drug Conjugate DMOT4039A | DMOT-4039A | DMOT4039A | RG 7600 | RG7600",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433844","anti-NaPi2b/MMAE antibody-drug conjugate DNIB0600A","C116747","An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the sodium-dependent phosphate transport protein 2B (NaPi2b), and covalently linked to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of DNIB0600A binds to NaPi2b-expressing tumor cells and is internalized, thereby delivering MMAE intracellularly. Proteolytic cleavage releases MMAE, which then binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. NaPi2b, a tumor-associated antigen (TAA), overexpressed in a variety of cancer cell types, plays a key role in transport of inorganic phosphate and the maintenance of phosphate homeostasis.","Lifastuzumab Vedotin | ADC DNIB0600A | DNIB0600A | LIFASTUZUMAB VEDOTIN | RG-7599",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433770","Vandortuzumab Vedotin","C116748","An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the six transmembrane epithelial antigen of the prostate 1 (STEAP1), and conjugated, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration of vandortuzumab vedotin, the monoclonal antibody moiety of vandortuzumab vedotin binds to STEAP1-expressing tumor cells and is internalized, thereby delivering MMAE intracellularly. Proteolytic cleavage releases MMAE, which then binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. STEAP1, a tumor-associated antigen (TAA), is overexpressed in a variety of cancer cell types.","Vandortuzumab Vedotin | DSTP3086S | MSTP2109A | RG7450 | Thio-anti-STEAP1-MC-vc-PAB-MMAE | VANDORTUZUMAB VEDOTIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433992","Photoacoustic Imaging","C116749","An imaging technique during which non-ionizing pulses are delivered into tissue and the resulting ultrasonic waves are detected and converted into images.","Photoacoustic Imaging | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL475602","Central Nervous System Lupus","C116919","Inflammation that includes the brain, spinal cord and surrounding tissues secondary to systemic lupus erythematosus (SLE); it is associated with neurological and/or psychiatric features.","Central Nervous System Lupus | CNS Lupus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831615","Montanide ISA-51/Survivin Peptide Vaccine","C116920","No value exists.","Montanide ISA-51/Survivin Peptide Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085623","Akinesia","C116923","Lack of movement.","Akinesia | ",,,,,,,,,,,,,,,"4143471","Akinesia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897560","Sodium Urine Excretion Rate","C117856","A determination of the amount of sodium being excreted in urine over a defined period of time.","Sodium Urine Excretion Rate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0266769","Multilobate Placenta","C117345","A variant placenta in which the chorionic tissue is partitioned into more than two distinct discs, without consistent relationship to umbilical cord insertion.","Multilobate Placenta | Multilobate Chorionic Surface Shape | Placenta Multipartita | Placenta Multiplex",,,,,,,,,,,,,,,"4321153","Placenta multipartita",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0266771","Circummarginate Placenta","C117346","A placenta characterized by fetal membranes which extend smoothly off the disc edge, and a subamnionic fibrin ring on all or part of the disc perimeter that delimits the greatest extent of the chorionic surface vessels.","Circummarginate Placenta | Marginal Placenta | Placenta Marginalis",,,,,,,,,,,,,,,"3654844","Placenta circummarginate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0266770","Circumvallate Placenta","C117347","A placenta characterized by fetal membranes that are folded along all or part of the disc perimeter. The amnion may or may not be included in the folded tissue.","Circumvallate Placenta | Placenta Circumvallata",,,,,,,,,,,,,,,"4085900","Placenta circumvallata",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0266788","Marginal Cord Insertion","C117348","The location of the umbilical cord insertion at the disc edge.","Marginal Cord Insertion | Marginal Umbilical Cord Insertion",,,,,,,,,,,,,,,"4198832","Marginal insertion of umbilical cord",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0266789","Velamentous Cord Insertion","C117349","The location of the umbilical cord insertion on the extraplacental membranes.","Velamentous Cord Insertion | Membranous Insertion | Velamentous Umbilical Cord Insertion",,,,,,,,,,,,,,,"4300078","Velamentous insertion of umbilical cord",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897693","Ruptured Velamentous Vessel","C117350","A fetal blood vessel in the placental membranes that appears torn upon gross inspection of the placenta.","Ruptured Velamentous Vessel | Disrupted Membranous Vessel | Disrupted Velamentous Vessel | Ruptured Membranous Vessel | Torn Membranous Vessel | Torn Velamentous Vessel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897205","Velamentous Vessel","C117351","A fetal blood vessel in the placental membranes that extends from the cord insertion to the chorionic plate.","Velamentous Vessel | Membranous Vessel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0266791","Umbilical Cord True Knot","C117353","A folding of the umbilical cord in the form of a knot.","Umbilical Cord True Knot | ",,,,,,,,,,,,,,,"4101082","True knot of umbilical cord",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898829","Hypocoiled Umbilical Cord","C117355","Umbilical cord with apparent reduced helical coiling of the arteries around the vein.","Hypocoiled Umbilical Cord | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898832","Hypercoiled Umbilical Cord","C117356","Umbilical cord with apparent increased helical coiling of the arteries around the vein.","Hypercoiled Umbilical Cord | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897251","Umbilical Cord Diameter","C117357","The longest measured width of the umbilical cord.","Umbilical Cord Diameter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4012457","Single Umbilical Artery","C117359","The absence of one of the two umbilical arteries.","Single Umbilical Artery | ",,,,,,,,,,,,,,,"4005289","Single umbilical artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0566730","Umbilical Cord Finding","C117360","Clinical and laboratory findings about the umbilical cord.","Umbilical Cord Finding | ",,,,,,,,,,,,,,,"4128977","Umbilical cord finding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3889381","ZNF395 wt Allele","C117259","Human ZNF395 wild-type allele is located in the vicinity of 8p21 and is approximately 57 kb in length. This allele, which encodes zinc finger protein 395, plays a role in DNA binding, and may play a role in transcriptional regulation.","ZNF395 wt Allele | HDBP-2 | HDBP2 | HDRF-2 | PBF | PRF-1 | PRF1 | Si-1-8-14 | Zinc Finger Protein 395 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897850","Procedure Date Time of Reference Timepoint","C117538","The date and time of a specific reference point for the procedure.","Procedure Date Time of Reference Timepoint | PRRFTDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899410","Death Diagnosis Data Collection Date Time","C117549","The date and time of death diagnosis data collection.","Death Diagnosis Data Collection Date Time | DDDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038271","Motor Stereotypy","C116925","Persistent volitional repetition of non-purposeful movement.","Motor Stereotypy | Motor Stereotypies",,,,,,,,,,,,,,,"434890","Stereotyped routines",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3900111","Acute Motor and Sensory Axonal Neuropathy","C116927","A subtype of Guillain-Barre syndrome that targets sensory motor axons, and is characterized by acute onset of quadriparesis, distal sensory loss, areflexia, and respiratory insufficiency.","Acute Motor and Sensory Axonal Neuropathy | Acute Motor And Sensory Axonal Neuropathy | Acute Motor-Sensory Axonal Neuropathy",,,,,,,,,,,,,,,"37396785","Acute motor sensory axonal neuropathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899112","Fluocinonide Cream","C116928","A topical cream containing the synthetic glucocorticoid fluocinonide, with anti-inflammatory and antipruritic activities. Upon administration of the fluocinonide cream to the affected area(s), fluocinonide binds to the cytosolic glucocorticoid receptor, followed by translocation of the ligand-receptor complex to the nucleus and transcription activation of genes containing glucocorticoid-responsive elements (GREs), which increases the expression of specific target genes, such as lipocortin-1 (annexin A1). The induction of lipocortin-1 expression by fluocinonide leads to an increased interaction and inhibition of cytosolic phospholipase 2 alpha, thereby preventing phospholipase translocation to the perinuclear membrane and subsequent release and conversion of arachidonic acid to inflammatory prostaglandins and leukotrienes. This may relieve symptoms associated with skin inflammation.","Fluocinonide Cream | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890941","Acute Motor Axonal Neuropathy","C116929","A subtype of Guillain-Barre syndrome that targets motor axons, and is characterized by symmetric limb weakness, diffuse areflexia, facial and oropharyngeal muscle weakness, and respiratory insufficiency.","Acute Motor Axonal Neuropathy | AMAN",,,,,,,,,,,,,,,"37396086","Acute motor axonal neuropathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3890204","RAD51D wt Allele","C116931","Human RAD51D wild-type allele is located in the vicinity of 17q11 and is approximately 22 kb in length. This allele, which encodes DNA repair protein RAD51 homolog 4 protein, is involved in DNA repair. Mutation of the gene is associated with susceptibility to familial breast-ovarian cancer type 4.","RAD51D wt Allele | BROVCA4 | HsTRAD | R51H3 | RAD51 (S. cerevisiae)-Like 3 Gene | RAD51 Paralog D wt Allele | RAD51, S. cerevisiae, Homolog of, D Gene | RAD51-Like 3 (S. cerevisiae) Gene | RAD51L3 | S. cerevisiae RAD51-Like 3 Gene | TRAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890375","DNA Repair Protein RAD51 Homolog 4, human","C116932","DNA repair protein RAD51 homolog 4 (328 aa, ~35 kDa) is encoded by the human RAD51D gene. This protein plays a role in homologous recombination repair.","DNA Repair Protein RAD51 Homolog 4 | R51H3 | RAD51 Homolog D | RAD51-Like Protein 3 | RAD51D | TRAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1848201","Double Cortex Syndrome","C116933","A developmental brain abnormality characterized by atypical migration of neurons during cortical development.","Double Cortex Syndrome | Subcortical Band Heterotopia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890918","CHST3 wt Allele","C116935","Human CHST3 wild-type allele is located in the vicinity of 10q22.1 and is approximately 49 kb in length. This allele, which encodes carbohydrate sulfotransferase 3 protein, plays a role in the metabolism of proteoglycans. Mutation of the gene is associated with spondyloepiphyseal dysplasia with congenital joint dislocations.","CHST3 wt Allele | C6ST | C6ST1 | Carbohydrate (Chondroitin 6) Sulfotransferase 3 wt Allele | HSD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2678070","Polymicrogyria","C116936","A developmental brain abnormality characterized by an excessive amount of small convolutions on the surface of the brain and cognitive dysfunction.","Polymicrogyria | ",,,,,,,,,,,,,,,"4176896","Microgyria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0668363","CHST3 protein, human","C116937","Carbohydrate sulfotransferase 3 (479 aa, ~55 kDa) is encoded by the human CHST3 gene. This protein is involved in chondroitin sulfate biosynthesis.","Carbohydrate Sulfotransferase 3 | C6ST-1 | CHST3 | Chondroitin 6-O-Sulfotransferase 1 | Chondroitin 6-Sulfotransferase | EC 2.8.2.17 | GST-0 | Galactose/N-Acetylglucosamine/N-Acetylglucosamine 6-O-Sulfotransferase 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899807","CDK4/6 Inhibition","C116938","Inhibition of cyclin-dependent kinases 4 and 6 pathway activity to prevent proliferation of cancer cells and tumor growth.","CDK4/6 Inhibition | Cyclin-Dependent Kinases 4 and 6 Inhibition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899172","FGFR Inhibition","C116939","Inhibition of fibroblastic growth factor receptor signaling pathway activity to prevent tumor growth.","FGFR Inhibition | Fibroblastic Growth Factor Receptor Inhibition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899300","ESRS-A - Dyskinesia: Jaw","C118096","Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Dyskinesia: Jaw.","ESRS-A - Dyskinesia: Jaw | ESRSA1-Dyskinesia: Jaw | ESRSA118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899302","ESRS-A - Dyskinesia: Eyes/Upper Face/Lower Face","C118097","Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Dyskinesia: Eyes, upper face, lower face.","ESRS-A - Dyskinesia: Eyes/Upper Face/Lower Face | ESRSA1-Dyskinesia: Eyes/Up Face/Low Face | ESRSA119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899299","ESRS-A - Dyskinesia: Shoulder/Upper Limbs/Hands","C118098","Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Dyskinesia: Shoulders, upper limbs, hands.","ESRS-A - Dyskinesia: Shoulder/Upper Limbs/Hands | ESRSA1-Dyskinesia: Shoulder/Up Limb/Hand | ESRSA120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899301","ESRS-A - Dyskinesia: Hips/Lower Limbs/Feet","C118099","Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Dyskinesia: Hips, lower limbs, feet.","ESRS-A - Dyskinesia: Hips/Lower Limbs/Feet | ESRSA1-Dyskinesia: Hips/Lower Limbs/Feet | ESRSA121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887694","Recombinant Oncostatin M","C1180","A recombinant 26.0 kDa protein, containing 227 amino acid residues, a member of the cytokine family and growth and differentiation factor that participates in the regulation of neurogenesis, osteogenesis and hematopoiesis. Produced by activated T cells, monocytes and Kaposi's sarcoma cells, oncostatin M (OSM) can exert both stimulatory and inhibitory effects on cell proliferation. It stimulates the proliferation of fibroblasts, smooth muscle cells and Kaposi's sarcoma cells, but inhibits the growth of some normal and tumor cell lines. It also promotes cytokine release (e.g. IL-6, GM-CSF and G-CSF) from endothelial cells, and enhances the expression of low-density lipoprotein receptor in hepatoma cells.","Recombinant Oncostatin M | OSM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899297","ESRS-A - Dyskinesia: Trunk/Neck","C118100","Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Dyskinesia: Trunk, neck.","ESRS-A - Dyskinesia: Trunk/Neck | ESRSA1-Dyskinesia: Trunk/Neck | ESRSA122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899308","ESRS-A - Akathisia: Subjective","C118101","Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Akathisia: Subjective.","ESRS-A - Akathisia: Subjective | ESRSA1-Akathisia: Subjective | ESRSA123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899309","ESRS-A - Akathisia: Objective","C118102","Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Akathisia: Objective.","ESRS-A - Akathisia: Objective | ESRSA1-Akathisia: Objective | ESRSA124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897595","Skin Response Data Collection Date Time","C117692","The date and time skin response data was collected.","Skin Response Data Collection Date Time | SRDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897594","Skin Response Date Time of Reference Timepoint","C117698","The date and time of a specific reference point for the skin reponse assessment.","Skin Response Date Time of Reference Timepoint | SRRFTDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889651","Trial Disease Assessments Domain","C117699","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to trial disease assessments.","Trial Disease Assessments Domain | TD | Trial Disease Assessments",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0069454","Olsalazine","C1176","A prodrug of mesalamine (5-Aminosalicylic acid; 5-ASA) with anti-inflammatory activity. Unabsorbed olsalazine passes through gastrointestinal tract and is cleaved by azoreductases, produced by microflora in colon, into 2 active molecules of 5-ASA. 5-ASA exerts its anti-inflammatory action locally by inhibiting cyclooxygenase and lipoxygenase activities, thereby reducing the production of prostaglandins and leukotrienes. In addition, mesalamine may act as a scavenger of reactive oxygen free radicals.","Olsalazine | 3,3'-Azobis[6-hydroxybenzoic Acid] | 3,3'-Dicarboxy-4,4'-dihydroxyazobenzene | Azodisalicylate | C.I. Mordant Yellow 5 | OLSALAZINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897335","Trial Disease Sequence of Planned Assessment Schedule","C117700","A number that identifies the ordering relations in time of the schedules for planned trial disease assessments in a trial.","Trial Disease Sequence of Planned Assessment Schedule | TDORDER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897341","Trial Disease Anchor Variable Name","C117701","A reference to the CDISC date variable name that provides the start point from which the planned trial disease assessment schedule is measured.","Trial Disease Anchor Variable Name | TDANCVAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897337","Trial Disease Offset From Reference","C117702","The difference between a point and a fixed reference point of a trial disease assessment.","Trial Disease Offset From Reference | TDSTOFF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897338","Trial Disease Minimum Time Allowed in Planned Assessment","C117704","The lower limit in time of a planned period of time between planned trial disease assessments.","Trial Disease Minimum Time Allowed in Planned Assessment | TDMINPAI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897339","Trial Disease Maximum Time Allowed in Planned Assessment Interval","C117705","The upper limit in time of a planned period of time between planned trial disease assessments.","Trial Disease Maximum Time Allowed in Planned Assessment Interval | TDMAXPAI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897340","Trial Disease Maximum Number of Actual Assessments","C117706","The upper limit in number of actual trial disease assessments during a planned period of time.","Trial Disease Maximum Number of Actual Assessments | TDNUMRPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900011","Associated Persons Identifier","C117707","A character or string that identifies and represents a single associated person, a group of associated persons, or a pool of associated persons.","Associated Persons Identifier | APID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890921","SULT1C2 wt Allele","C116941","Human SULT1C2 wild-type allele is located in the vicinity of 2q12.3 and is approximately 21 kb in length. This allele, which encodes sulfotransferase 1C2 protein, is involved in the metabolism of hormones, xenobiotics and ribonucleotides.","SULT1C2 wt Allele | ST1C1 | ST1C2 | SULT1C1 | Sulfotransferase Family 1C, Member 1 Gene | Sulfotransferase Family 1C, Member 2 Gene | Sulfotransferase Family, Cytosolic, 1C, Member 1 Gene | Sulfotransferase Family, Cytosolic, 1C, Member 2 wt Allele | humSULTC2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3279121","Motor Developmental Delay","C116943","Failure to meet, or late achievement of motor development milestones.","Motor Developmental Delay | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1739907","Sulfotransferase 1C2, Human","C116944","Sulfotransferase 1C2 (296 aa, ~35 kDa) is encoded by the human SULT1C2 gene. This protein plays a role in the sulfation of xenobiotics, hormones and purine ribonucleotides.","Sulfotransferase 1C2 | EC 2.8.2.- | ST1C2 | SULT1C#1 | SULT1C2 | Sulfotransferase 1C1 | humSULTC2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900129","Absence of MYCN Gene Amplification","C116945","A molecular finding indicating the absence of multiple copies of the MYCN gene in a tissue sample.","Absence of MYCN Gene Amplification | MYCN Gene Amplification Negative | N-myc Gene Amplification Negative | NMYC Gene Amplification Negative | Neuroblastoma-Derived V-Myc Avian Myelocytomatosis Viral Related Oncogene Amplification Negative | V-Myc Avian Myelocytomatosis Viral Oncogene Neuroblastoma Derived Homolog Gene Amplification Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890184","ABCC6 wt Allele","C116947","Human ABCC6 wild-type allele is located in the vicinity of 16p13.1 and is approximately 75 kb in length. This allele, which encodes multidrug resistance-associated protein 6, plays a role in the active transport of drugs across the plasma membrane. Mutation of the gene is associated with pseudoxanthoma elasticum and generalized arterial calcification of infancy type 2.","ABCC6 wt Allele | ABC34 | ARA | ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 6 wt Allele | ATP-Binding Cassette, Subfamily C, Member 6 Gene | EST349056 | GACI2 | MLP1 | MOAT-E | MOATE | MRP6 | PXE | PXE1 | Pseudoxanthoma Elasticum Gene | URG7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0531026","ABCC6 protein, human","C116948","Multidrug resistance-associated protein 6 (1503 aa, ~165 kDa) is encoded by the human ABCC6 gene. This protein is involved in the active transport of xenobiotics and glutathione conjugates across the plasma membrane.","Multidrug Resistance-Associated Protein 6 | ABCC6 | ATP-Binding Cassette Sub-Family C Member 6 | Anthracycline Resistance-Associated Protein | MOAT-E | Multi-Specific Organic Anion Transporter E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889163","LTA4H wt Allele","C116950","Human LTA4H wild-type allele is located in the vicinity of 12q22 and is approximately 43 kb in length. This allele, which encodes leukotriene A-4 hydrolase, is involved in the biosynthesis of leukotriene B4.","LTA4H wt Allele | LTA4 | Leukotriene A4 Hydrolase wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0064844","Leukotriene A-4 Hydrolase","C116951","Leukotriene A-4 hydrolase (611 aa, ~69 kDa) is encoded by the human LTA4H gene. This protein plays a role in the conversion of leukotriene A4 to leukotriene B4.","Leukotriene A-4 Hydrolase | EC 3.3.2.6 | LTA-4 Hydrolase | LTA4H | Leukotriene A(4) Hydrolase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899303","ESRS-A - CGI-S Parkinsonism","C118103","Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Clinical Global Impression (CGI-S): Parkinsonism.","ESRS-A - CGI-S Parkinsonism | ESRSA1-CGI-S Parkinsonism | ESRSA125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899304","ESRS-A - CGI-S Dystonia","C118104","Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Clinical Global Impression (CGI-S): Dystonia.","ESRS-A - CGI-S Dystonia | ESRSA1-CGI-S Dystonia | ESRSA126",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899305","ESRS-A - CGI-S Dyskinesia","C118105","Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Clinical Global Impression (CGI-S): Dyskinesia.","ESRS-A - CGI-S Dyskinesia | ESRSA1-CGI-S Dyskinesia | ESRSA127",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899306","ESRS-A - CGI-S Akathisia","C118106","Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Clinical Global Impression (CGI-S): Akathisia.","ESRS-A - CGI-S Akathisia | ESRSA1-CGI-S Akathisia | ESRSA128",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899170","FIQR - Activities Sub-Total","C118107","Revised Fibromyalgia Impact Questionnaire (FIQR) Activities sub-total.","FIQR - Activities Sub-Total | FIQR01-Activities Sub-Total | FIQR0122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899167","FIQR - Symptoms Sub-Total","C118109","Revised Fibromyalgia Impact Questionnaire (FIQR) Symptoms sub-total.","FIQR - Symptoms Sub-Total | FIQR01-Symptoms Sub-Total | FIQR0124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899169","FIQR - FIQR Total","C118110","Revised Fibromyalgia Impact Questionnaire (FIQR) FIQR total.","FIQR - FIQR Total | FIQR01-FIQR Total | FIQR0125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899004","HADS - Total Score Anxiety","C118111","Hospital Anxiety and Depression Scale (HADS) Total score anxiety.","HADS - Total Score Anxiety | HADS01-Total Score Anxiety | HADS0115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474118","Agonistic Anti-OX40 Monoclonal Antibody MEDI6469","C117293","An agonistic monoclonal antibody against the co-stimulatory receptor OX40 (CD134), with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, anti-OX40 monoclonal antibody MEDI6469 selectively binds to and activates OX40. OX40 activation induces proliferation of effector T-lymphocytes. In the presence of tumor-associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T-cells.","Agonistic Anti-OX40 Monoclonal Antibody MEDI6469 | Agonistic Anti-CD134 Monoclonal Antibody MEDI6469 | MEDI-6469 | MEDI6469",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1743496","Fluorine F 18 Fluorobenzyl Triphenyl Phosphonium","C117294","A radioconjugate and cationic lipophilic agent consisting of fluorobenzyl triphenyl phosphonium (FBnTP), labeled with the radioisotope fluorine F 18, with potential use as a tracer for both mitochondrial membrane potential (MMP) and apoptosis, and as a tumor imaging agent using positron emission tomography (PET). Upon administration, fluorine F 18 FBnTP is taken up by cells and its uptake and accumulation within mitochondria is directly correlated with MMP. Apoptosis causes a loss of membrane potential across the inner mitochondrial membrane which decreases FBnTP mitochondrial uptake. As apoptosis is suppressed in tumor cells, the FBnTP uptake is increased as compared to normal cells. This allows, upon PET, for the imaging of cancer cells. As apoptotic-inducing chemotherapeutic agents cause a collapse of MMP, this agent can also be used to assess the response of tumor cells to those chemotherapeutic agents.","Fluorine F 18 Fluorobenzyl Triphenyl Phosphonium | 18F-FBnTP | 18F-fluorobenzyl Triphenyl Phosphonium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0343190","Cutaneous Polyarteritis Nodosa","C117295","A form of vasculitis that involves small to medium size arteries of the dermis and subcutaneous tissue. The disorder manifests with tender subcutaneous nodules, livedo reticularis, cutaneous ulcers and necrosis; while internal organ involvement is typically spared, extra-cutaneous symptoms may be present.","Cutaneous Polyarteritis Nodosa | Cutaneous PAN",,,,,,,,,,,,,,,"4347062","Cutaneous polyarteritis nodosa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2350476","Orbital Myositis","C117296","A rare form of myositis that affects only the orbital muscles.","Orbital Myositis | ",,,,,,,,,,,,,,,"433774","Orbital myositis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897725","Related Subject Identifier","C117708","A character or string that identifies and represents a related subject or pool of subjects.","Related Subject Identifier | RSUBJID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899858","C-SSRS Lifetime/Recent Version - Number of Actual Suicide Attempts (Lifetime)","C118050","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Total number of actual attempts. (Lifetime).","C-SSRS Lifetime/Recent Version - Number of Actual Suicide Attempts (Lifetime) | CSS11-Number of Actual Attempts-Life | CSS1113A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899857","C-SSRS Lifetime/Recent Version - Number of Actual Suicide Attempts (Past 3 Months)","C118051","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Total number of actual attempts. (Past 3 Months).","C-SSRS Lifetime/Recent Version - Number of Actual Suicide Attempts (Past 3 Months) | CSS11-Number of Actual Attempts-P3M | CSS1113B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899887","C-SSRS Lifetime/Recent Version - Description of Actual Suicide Attempt","C118052","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Description of actual attempt.","C-SSRS Lifetime/Recent Version - Description of Actual Suicide Attempt | CSS11-Actual Attempt, Describe | CSS1113C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899862","C-SSRS Lifetime/Recent Version - Non-suicidal Self-injurious Behavior (Lifetime)","C118053","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Has subject engaged in non-suicidal self-injurious behavior? (Lifetime).","C-SSRS Lifetime/Recent Version - Non-suicidal Self-injurious Behavior (Lifetime) | CSS11-Non-suicid Self-injur Behav-Life | CSS1114A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899861","C-SSRS Lifetime/Recent Version - Non-suicidal Self-injurious Behavior (Past 3 Months)","C118054","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Has subject engaged in non-suicidal self-injurious behavior? (Past 3 Months).","C-SSRS Lifetime/Recent Version - Non-suicidal Self-injurious Behavior (Past 3 Months) | CSS11-Non-suicid Self-injur Behav-P3M | CSS1114B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899873","C-SSRS Lifetime/Recent Version - Interrupted Suicide Attempt (Lifetime)","C118055","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Has there been a time when you started to do something to end your life but someone or something stopped you before you actually did anything? (Lifetime).","C-SSRS Lifetime/Recent Version - Interrupted Suicide Attempt (Lifetime) | CSS11-Interrupted Attempt-Life | CSS1115A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899872","C-SSRS Lifetime/Recent Version - Interrupted Suicide Attempt (Past 3 Months)","C118056","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Has there been a time when you started to do something to end your life but someone or something stopped you before you actually did anything? (Past 3 Months).","C-SSRS Lifetime/Recent Version - Interrupted Suicide Attempt (Past 3 Months) | CSS11-Interrupted Attempt-P3M | CSS1115B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899855","C-SSRS Lifetime/Recent Version - Number of Interrupted Suicide Attempts (Past 3 Months)","C118058","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Total number of interrupted attempts. (Past 3 Months).","C-SSRS Lifetime/Recent Version - Number of Interrupted Suicide Attempts (Past 3 Months) | CSS11-Num of Interrupted Attempts-P3M | CSS1116B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0068333","Nabilone","C1171","A synthetic cannabinoid and dibenzopyrane derivative with anti-emetic activity. Although the mechanism of action has not been fully elucidated yet, it has been suggested that nabilone is a highly selective and strong agonist for the cannabinoid receptors CB1 and CB2, both of which are coupled to Gi/o proteins. The CB1 receptors are expressed predominantly in central and peripheral neurons and receptor stimulation has been implicated in the reduction of chemotherapy-induced nausea.","Nabilone | Cesamet | Cpd 109514 | NABILONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475737","Perinatal Subependymal Hemorrhage","C117201","Bleeding into the thick layer of immature cells under the ependymal lining at the ventrolateral aspect of the lateral cerebral ventricles occurring around the time of birth.","Perinatal Subependymal Hemorrhage | ",,,,,,,,,,,,,,,"4079973","Perinatal subependymal hemorrhage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2910046","Intraventricular Hemorrhage with Parenchymal Hemorrhage of the Newborn","C117202","Bleeding into the lateral cerebral ventricles and the adjacent brain tissue of a newborn infant.","Intraventricular Hemorrhage with Parenchymal Hemorrhage of the Newborn | Grade 4 Intraventricular Hemorrhage of the Newborn | Intraventricular Hemorrhage of Newborn Grade 4 | Intraventricular Hemorrhage with Parenchymal Hemorrhage of Newborn",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898702","Intraparenchymal Hemorrhage of the Newborn","C117203","Bleeding into the brain tissue of a newborn infant.","Intraparenchymal Hemorrhage of the Newborn | Parenchymal Hemorrhage of Newborn | Parenchymal Hemorrhage of the Newborn",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898819","IGR-OV1","C117204","An adenocarcinoma cell line established from a 47 year old female patient with ovarian carcinoma. The sample was removed after the patient had received radiation and cobalt treatment. The carcinoma cells have highly tumorigenic properties, a paracentric inversion of chromosome 3, and a 2;5 translocation.","IGR-OV1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898115","OVCAR-3","C117205","An adenocarcinoma cell line established from a 60 year old Caucasian female patient with ovarian carcinoma previously treated with chemotherapy.","OVCAR-3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898114","OVCAR-4","C117206","An adenocarcinoma cell line established from a 42 year old female patient with ovarian carcinoma previously treated with chemotherapy.","OVCAR-4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898113","OVCAR-5","C117207","An adenocarcinoma cell line established from the ascetic fluid of a 67 year old female patient with ovarian carcinoma.","OVCAR-5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898112","OVCAR-8","C117208","An adenocarcinoma cell line established from a 64 year old female patient with ovarian carcinoma previously treated with chemotherapy.","OVCAR-8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898207","NCI/ADR-RES","C117209","An adriamycin-resistant cell line established by Batist, et al., in 1986, intended to be derived from the breast cancer cell line MCF-7. Recent single nucleotide polymorphism array analysis confirmed that the NCI/ADR-RES cell line is not derived from the MCF-7 cell line, but from the ovarian cancer cell line OVCAR-8.","NCI/ADR-RES | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897683","SK-OV-3","C117210","An adenocarcinoma cell line established from the ascetic fluid of a 64 year old Caucasian female patient with ovarian carcinoma previously treated with chemotherapy. These carcinoma cells are resistant to tumor necrosis factor and to several cytotoxic drugs.","SK-OV-3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900171","A498","C117212","An adenocarcinoma cell line established from a 52 year old female patient with renal cell carcinoma.","A498 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890222","ACHN - Tumor Cell Line","C117213","An adenocarcinoma cell line established in 1979 from the pleural effusion of a 22 year old Caucasian male patient with metastatic renal cell carcinoma.","ACHN | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899841","CAKI-1","C117214","A clear cell adenocarcinoma cell line established from a skin metastasis from a 49 year old Caucasian male patient with renal cell carcinoma previously treated with chemotherapy.","CAKI-1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896653","Juvenile Primary Fibromyalgia Syndrome","C117297","Chronic, diffuse, non-inflammatory musculoskeletal pain disorder associated with fatigue and sleep disturbance that can occur in childhood and adolescence. Tender points are not necessary to make the diagnosis, but if present may be less numerous than found in adults.","Juvenile Primary Fibromyalgia Syndrome | JPFS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900042","Anchor Variable Name","C117299","A reference to the CDISC date variable name that provides the start point from which the planned assessment schedule is measured.","Anchor Variable Name | ANCVAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897889","Planned Assessment Interval","C117300","A planned period of time between planned assessments.","Planned Assessment Interval | TGTPAI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898307","Minimum Time Allowed in Planned Assessment Interval","C117301","The lower limit in time of a planned period of time between planned assessments.","Minimum Time Allowed in Planned Assessment Interval | MINPAI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898455","Maximum Time Allowed in Planned Assessment Interval","C117302","The upper limit in time of a planned period of time between planned assessments.","Maximum Time Allowed in Planned Assessment Interval | MAXPAI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899743","CTRP Disease Terminology","C118168","A set of terminology that includes the diseases and neoplastic processes used in NCI-sponsored clinical trials.","CTRP Disease Terminology | Clinical Trials Reporting Program Disease Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899742","CTRP Intervention Terminology","C118169","A set of terminology that includes the interventions and therapies used in NCI-sponsored clinical trials.","CTRP Intervention Terminology | Clinical Trials Reporting Program Intervention Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0752295","Confusional Arousal","C118170","Disorganized thinking, disorientation, or inappropriate responsiveness to external stimuli that occurs during and after awakening.","Confusional Arousal | Excessive Sleep Inertia | Sleep Drunkeness",,,,,,,,,,,,,,,"40480875","Confusional arousal disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0456511","Sleep Paralysis","C118171","Temporary inability to speak or move while waking up or falling asleep.","Sleep Paralysis | ",,,,,,,,,,,,,,,"435238","Sleep paralysis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0270327","Nocturnal Enuresis","C118172","Urination during sleep.","Nocturnal Enuresis | Bedwetting | Sleep Enuresis",,,,,,,,,,,,,,,"193874","Nocturnal enuresis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0233718","Pressured Speech","C118173","Abnormal increased rate and amount of speech, delivered with urgency.","Pressured Speech | ",,,,,,,,,,,,,,,"4207219","Pressure of speech",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0233765","Olfactory Hallucination","C118175","Perception of a smell in the absence of a corresponding stimulus.","Olfactory Hallucination | ",,,,,,,,,,,,,,,"4218541","Olfactory hallucinations",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0233767","Tactile Hallucination","C118176","Perception of pressure or touch in the absence of a corresponding stimulus.","Tactile Hallucination | ",,,,,,,,,,,,,,,"4280834","Tactile hallucinations",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0233766","Gustatory Hallucination","C118177","Perception of a taste in the absence of a corresponding stimulus.","Gustatory Hallucination | ",,,,,,,,,,,,,,,"4104518","Gustatory hallucinations",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3277093","Hyperphagia","C118180","Excessive appetite.","Hyperphagia | ",,,,,,,,,,,,,,,"438872","Excessive eating",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899886","C-SSRS Lifetime/Recent Version - Description of Interrupted Suicide Attempt","C118059","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Description of interrupted attempt.","C-SSRS Lifetime/Recent Version - Description of Interrupted Suicide Attempt | CSS11-Interrupted Attempt, Describe | CSS1116C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899904","C-SSRS Lifetime/Recent Version - Aborted Suicide Attempt (Past 3 Months)","C118061","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Has there been a time when you started to do something to try to end your life but you stopped yourself before you actually did anything? (Past 3 Months).","C-SSRS Lifetime/Recent Version - Aborted Suicide Attempt (Past 3 Months) | CSS11-Aborted Attempt-P3M | CSS1117B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899860","C-SSRS Lifetime/Recent Version - Number of Aborted Suicide Attempts (Lifetime)","C118062","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Total number of aborted or self-interrupted attempts. (Lifetime).","C-SSRS Lifetime/Recent Version - Number of Aborted Suicide Attempts (Lifetime) | CSS11-Number of Aborted Attempts-Life | CSS1118A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899859","C-SSRS Lifetime/Recent Version - Number of Aborted Suicide Attempts (Past 3 Months)","C118063","Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Total number of aborted or self-interrupted attempts. (Past 3 Months).","C-SSRS Lifetime/Recent Version - Number of Aborted Suicide Attempts (Past 3 Months) | CSS11-Number of Aborted Attempts-P3M | CSS1118B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1450802","Zinc Finger Protein 395, Human","C117260","Zinc finger protein 395 (513 aa, ~55 kDa) is encoded by the human ZNF395 gene. This protein is involved in DNA binding.","Zinc Finger Protein 395 | HD Gene Regulatory Region-Binding Protein 2 | HD-Regulating Factor 2 | Huntington Disease Gene Regulatory Region-Binding Protein 2 | Huntington's Disease Gene Regulatory Region-Binding Protein 2 | Papillomavirus Regulatory Factor 1 | Papillomavirus Regulatory Factor PRF-1 | Papillomavirus-Binding Factor | Si-1-8-14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0860661","Oppositional Behavior","C117261","Negative, defiant, or hostile behavior directed towards authority.","Oppositional Behavior | Oppositionality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028084","Nightmare","C117263","A disturbing dream that occurs during rapid eye movement sleep and results in feelings of strong terror, fear, distress, or anxiety.","Nightmare | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0233632","Disordered Thinking","C117264","Incoherent, disorganized or illogical thought processes.","Disordered Thinking | Disordered Thoughts | Thought Disorganization",,,,,,,,,,,,,,,"4131797","Disturbance in thinking",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0554978","Racing Thoughts","C117265","Abnormally rapid thoughts with or without abrupt changes from one topic to another.","Racing Thoughts | ",,,,,,,,,,,,,,,"4115026","Racing thoughts",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0233657","Flight of Ideas","C117266","Rapid succession of thoughts pertaining to different subjects that are still connected.","Flight of Ideas | ",,,,,,,,,,,,,,,"4103071","Flight of ideas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1698479","Infant Irritability","C117267","Crying easily, difficult to console.","Infant Irritability | Irritability, Infant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825546","HSP90B1 Gene","C117268","This gene plays a role in both ATP metabolism and protein folding.","HSP90B1 Gene | HSP90B1 | Heat Shock Protein 90 Beta Family Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889457","HSP90B1 wt Allele","C117269","Human HSP90B1 wild-type allele is located within 12q24.2-q24.3 and is approximately 24 kb in length. This allele, which encodes endoplasmin protein, is involved in ATP-hydrolysis dependent post-translational protein processing.","HSP90B1 wt Allele | ECGP | GP96 | GRP94 | Glucose-Regulated Protein, 94-kD Gene | HEL-S-125m | HEL35 | Heat Shock Protein 90 Beta Family Member 1 wt Allele | Heat Shock Protein 90kDa Beta (Grp94), Member 1 Gene | Heat-Shock Protein, 90-kD, Beta, 1 Gene | TRA1 | Tumor Rejection Antigen (Gp96) 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897781","RXF 393","C117215","A clear cell adenocarcinoma cell line established from a 54 year old male patient with renal cell carcinoma.","RXF 393 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897680","SN12C","C117216","An adenocarcinoma cell line established from a 43 year old male patient with renal cell carcinoma extensively involving the perinephric fat.","SN12C | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471747","dual variable domain immunoglobulin ABT-165","C116750","A bispecific, tetravalent immunoglobulin (Ig) G-like molecule containing the target-binding variable domains of two monoclonal antibodies, one targeting the Notch ligand delta-like 4 (DLL4) and the other one targeting the human tyrosine kinase vascular endothelial growth factor (VEGF), combined via linkers, with potential anti-angiogenic and antineoplastic activities. Upon administration, dilpacimab targets and binds to both DLL4 and VEGF. This prevents the activation of DLL-4/Notch- and VEGF/VEGF receptor (VEGFR)-mediated signaling pathways, which play key roles in angiogenesis and tumor vascularization. This prevents angiogenesis and may halt tumor cell proliferation. Activation of Notch receptors by DLL4 stimulates proteolytic cleavage of the Notch intracellular domain (NICD); after cleavage, NICD is translocated to the nucleus and mediates the transcriptional regulation of a variety of genes involved in vascular development. The expression of DLL4 is highly restricted to the vascular endothelium; DLL4/Notch signaling is required for the development of functional tumor blood vessels. The expression of the pro-angiogenic growth factor VEGF is associated with tumor angiogenesis and tumor cell proliferation and invasion.","Dilpacimab | ABT-165 | DILPACIMAB | DVD-Ig ABT-165 | Immunoglobulin, Anti-(Notch Ligand DLL4/Vascular Endothelial Growth Factor) (Synthetic Human PR-1283233 Heavy Chain), Disulfide with Synthetic Human PR-1283233 Light Chain, Dimer | PR-1283233 | WHO 10863",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1564840","Fluorometholone Acetate Ophthalmic Suspension","C116751","An ophthalmic suspension containing the acetate form of fluorometholone, with potential anti-infective and immunosuppressive activities. Upon ocular administration, fluorometholone binds to glucocorticoid receptors in the cytoplasm and forms a receptor-ligand complex, which translocates to the nucleus where it binds to glucocorticoid response elements (GRE) in the promoter region of target genes. This leads to the expression of specific target genes that control inflammation. Specifically, by inducing the expression of lipocortins that inhibit the enzymatic activity of phospholipase A2, the release of arachidonic acid is blocked, which prevents the production of inflammatory mediators, and inflammatory-induced ocular swelling, redness and itching.","Fluorometholone Acetate Ophthalmic Suspension | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899378","Diffusion Coefficient","C116752","The weight of a material, in grams, diffusing across an area of 1 square centimeter in 1 second in a unit concentration gradient.","Diffusion Coefficient | Coefficient of Molecular Diffusion of Mass | Diffusivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433842","Chk1 Inhibitor GDC-0425","C116756","An orally bioavailable inhibitor of checkpoint kinase 1 (chk1), with potential antineoplastic and chemosensitization activities. Upon oral administration, chk1 inhibitor GDC-0425 selectively binds to chk1, thereby preventing activity of chk1 and abrogating the repair of damaged DNA. This may lead to an accumulation of damaged DNA, inhibition of cell cycle arrest, and induction of apoptosis. GDC-0425 may potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapeutic agents. Chk1, an ATP-dependent serine/threonine kinase, mediates cell cycle checkpoint control, is essential for DNA repair, and plays a key role in resistance to chemotherapeutic agents.","Chk1 Inhibitor GDC-0425 | GDC-0425 | RG7602",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040188","Tic","C116758","Involuntary sudden, rapid, recurrent, nonrhythmic, stereotyped motor movement or vocalization.","Tic | ",,,,,,,,,,,,,,,"4297396","Tic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0751900","Motor Tic","C116759","A tic affecting muscle movement.","Motor Tic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897250","Umbilical Cord Discoloration","C117363","Change in umbilical cord color resulting from postmortem changes. It indicates fetal death occurred at least 6 hours prior to delivery.","Umbilical Cord Discoloration | Brown Umbilical Cord | Dusky Umbilical Cord | Red Umbilical Cord",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897049","Green Fetal Membrane","C117364","Meconium staining of the fetal membrane.","Green Fetal Membrane | Green Fetal Membranes | Meconium Staining of the Membrane | Meconium Staining of the Membranes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898465","Marginal Insertion of Fetal Membrane","C117365","An observation that the fetal membranes are inserted at the edge of the placental disc.","Marginal Insertion of Fetal Membrane | Marginal Insertion of Fetal Membranes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897600","Site of Fetal Membrane Rupture","C117366","The space that occupies the distance between the shortest free edge of the fetal membranes and the disc edge.","Site of Fetal Membrane Rupture | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899519","Complete Maternal Surface of Placenta","C117367","A maternal placental surface that is smooth and without appreciable parenchymal loss.","Complete Maternal Surface of Placenta | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897244","Uniform Color of Placental Parenchyma","C117369","The typical uniform coloring of the placental parenchyma irrespective of gestational age.","Uniform Color of Placental Parenchyma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898225","Mottled Color of Placental Parenchyma","C117370","The variable or non-uniform coloring of the placental parenchyma indicating variable contribution of the blood contained within the fetal vessels to the color of the parenchyma.","Mottled Color of Placental Parenchyma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899010","Gross Placental Abruption","C117371","A separation of the placenta from the uterine wall that is manifested by a retroplacental hematoma with villous compression and change in villous coloration that is reflective of lesion age.","Gross Placental Abruption | Gross Abruption | Macroscopic Abruption",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1609942","Endoplasmin, Human","C117270","Endoplasmin (803 aa, ~92 kDa) is encoded by the human HSP90B1 gene. This protein plays a role in both post-translational protein folding and ATP hydrolysis.","Endoplasmin | 94 kDa Glucose-Regulated Protein | Endothelial Cell (HBMEC) Glycoprotein | Epididymis Luminal Protein 35 | Epididymis Secretory Sperm Binding Protein Li 125m | GRP-94 | Gp96 Homolog | HSP90B1 | Heat Shock Protein 90 kDa Beta Member 1 | Stress-Inducible Tumor Rejection Antigen Gp96 | Tumor Rejection Antigen 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0233818","Impaired Judgment","C117271","Reduced ability to plan, poor decision making.","Impaired Judgment | Impaired Judgement",,,,,,,,,,,,,,,"4244685","Impaired judgement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4049212","Periventricular Hemorrhage of the Newborn","C117272","Bleeding into the brain tissue adjacent to the lateral cerebral ventricles of newborn infant.","Periventricular Hemorrhage of the Newborn | PVH | Periventricular Hemorrhage of Newborn",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3178805","Heterotaxy Syndrome","C117273","A rare, genetic disorder in which symptoms are generally secondary to the abnormal location of the organs within the thoracic, abdominal, or peritoneal cavities. Anatomic and functional problems can include cardiac defects, intestinal malrotation leading to volvulus, biliary atresia, and various defects of the central nervous system, urinary tract, and skeleton.","Heterotaxy Syndrome | Heterotaxia Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0751901","Phonic Tic","C116760","A vocal tic.","Phonic Tic | Vocal Tic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278076","Simple Tic","C116761","A tic that involves one muscle or muscle group, or non-word sounds.","Simple Tic | ",,,,,,,,,,,,,,,"4297396","Tic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899516","Complex Tic","C116762","A tic that involves multiple muscles or muscle groups, or words or sentences.","Complex Tic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0233729","Corprolalia","C116763","Involuntary and repetitive utterances of obscene or socially inappropriate words or statements.","Corprolalia | Coprolalia",,,,,,,,,,,,,,,"4028516","Coprolalia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL473664","Anti-CD3 OKT3/Humanized Anti-GD2 3F8 Bispecific Antibody-activated T Lymphocytes","C116330","Autologous activated T cells that have been coated with bispecific antibodies (BiAb) comprised of anti-CD3 murine monoclonal antibody OKT3 heteroconjugated to anti-GD2 humanized monoclonal antibody 3F8 (hu3F8), with potential antineoplastic and immunomodulating activities. In vitro, T cells are exposed to OKT3, which binds to the T cell receptor-CD3 complex on the T cell surface, crosslinks the CD3 receptors and leads to T cell activation. In turn, the hu3F8 monoclonal antibody is heteroconjugated to OKT3. Upon administration, anti-CD3 x anti-GD2 bispecific antibody-armed activated T cells attach to GD2-expressing tumor cells, thereby selectively cross-linking T cells and tumor cells. This results in selective cytotoxicity towards the GD2-expressing tumor cells. In addition, cytokine and chemokine secretion by the T cells further activates the immune system, which leads to the recruitment and activation of cytotoxic T lymphocytes (CTLs), and additional CTL-mediated tumor-specific cell lysis. GD2, a disialoganglioside and tumor-associated antigen, is overexpressed in a variety of tumor cell types. CD3 is part of the functional T cell receptor (TCR) complex, which is necessary for antigen recognition by T cells, and is required for signal transduction.","Anti-CD3 OKT3/Humanized Anti-GD2 3F8 Bispecific Antibody-activated T Lymphocytes | Anti-CD3 x hu3F8 Bispecific Antibody Armed ATC | GD2Bi-aATC | Hu3F8Bi Armed ATC | OKT3/Humanized 3F8 Bispecific Antibody-activated T Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473665","Synthetic Glioblastoma Tumor-associated Peptides Vaccine Therapy APVAC1","C116331","A personalized peptide-based cancer vaccine comprised of five to ten peptides associated with glioblastoma (GB), with potential immunomodulating and antineoplastic activities. Vaccination with synthetic GB tumor-associated peptides vaccine therapy APVAC1 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the tumor associated peptides, and results in decreased GB growth. The peptides are derived from a glioma actively personalized vaccine consortium (GAPVAC) warehouse and are specifically selected based on the patient's expression of tumor-associated antigens.","Synthetic Glioblastoma Tumor-associated Peptides Vaccine Therapy APVAC1 | APVAC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL473666","Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine Therapy APVAC2","C116332","A personalized peptide-based cancer vaccine comprised of one or two de novo synthesized patient-specific tumor-mutated peptides associated with glioblastoma (GB), with potential immunomodulating and antineoplastic activities. Vaccination with synthetic GB mutated tumor-specific peptides vaccine therapy APVAC2 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the selected mutated tumor-associated peptides, which results in decreased GB growth. These peptides are specifically selected and synthesized based on the expression of the patient's own mutated tumor-associated antigens, which were detected during individual tumor genome sequencing.","Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine Therapy APVAC2 | APVAC2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963718","Oculo-Respiratory Syndrome","C116333","A transient condition that can occur following influenza vaccination that is characterized by bilateral conjunctivitis, facial edema, and upper respiratory symptoms.","Oculo-Respiratory Syndrome | ORS | Oculo-respiratory-syndrome | Oculorespiratory Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3808552","Central Apnea","C116335","Cessation of air flow due to abnormal central nervous system control.","Central Apnea | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020312","Hydrothorax","C116338","The accumulation of serous fluid within the pleural cavity.","Hydrothorax | ",,,,,,,,,,,,,,,"4195440","Hydrothorax",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899986","Average Thickness","C117882","The average number in a group of values that represent the thickness of an object at varying points along an axis.","Average Thickness | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897171","Which Diagnostic Criteria Met","C117883","A description of the diagnostic criterion that the subject fulfilled in order to establish a medical diagnosis.","Which Diagnostic Criteria Met | DXCRITMT | Diagnostic Criteria Met",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896966","Location of Disease Onset","C117884","The anatomical location of the beginning or early stages of a disease.","Location of Disease Onset | LOCONSET | Localization of Onset",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897018","HADS - Total Score Depression","C118112","Hospital Anxiety and Depression Scale (HADS) Total score depression.","HADS - Total Score Depression | HADS01-Total Score Depression | HADS0116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539033","MIR17HG Gene","C118113","This polycistronic gene locus is located in the vicinity of 13q31.3 and is approximately 7 kb in length. This locus encodes at least six microRNA genes. Microdeletions within this locus are associated with Feingold syndrome 2. Amplification of this locus may be associated with various cancers.","MIR17HG Gene | C13orf25 | Chromosome 13 Open Reading Frame 25 Gene | FGLDS2 | FLJ14178 | LINC00048 | Long Intergenic Non-Protein Coding RNA 48 Gene | MIHG1 | MIR17 Host Gene (Non-Protein Coding) Gene | MIR17HG | MIRH1 | MIRHG1 | MiR-17-92 Cluster Host Gene (Non-Protein Coding) Gene | Micro RNA 17 Host Gene | Micro RNA Host Gene 1 | MicroRNA Host Gene 1 (Non-Protein Coding) Gene | Mir17 Host Gene | Mir17-92 Cluster Host Gene | NCRNA00048 | Non-Protein Coding RNA 48 Gene | ONCOMIR1 Host Gene | RP11-121J7.2 | miR-17-92",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899445","Data Value Code","C117373","A character or string that represents the information contained in a data field.","Data Value Code | VALCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897207","Value Null Flavor","C117374","A description of the value that describes missing data, eg. unknown, not applicable.","Value Null Flavor | VALNF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898187","Name of the Reference Terminology","C117375","The textual description of the terminology system that is being used.","Name of the Reference Terminology | VCDREF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897197","Version of the Reference Terminology","C117376","The version information of the terminology system that is being used.","Version of the Reference Terminology | VCDVER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897726","Related Device Identifier","C117710","A character or string that identifies and represents a related device.","Related Device Identifier | RDEVID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079031","Bovine Immunodeficiency Virus","C117711","A lentivirus that is similar to human immunodeficiency virus and that infects cattle.","Bovine Immunodeficiency Virus | BIV",,,,,,,,,,,,,,,"4011704","Bovine immunodeficiency virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206439","Bovine Lentivirus Group","C117712","A non-taxonomic grouping of lentivuruses that infect cattle.","Bovine Lentivirus Group | Bovine Lentivirus Serogroup",,,,,,,,,,,,,,,"4251441","Bovine lentivirus group",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206440","Equine Lentivirus Group","C117713","A non-taxonomic grouping of lentivuruses that infect horses, asses, and zebras.","Equine Lentivirus Group | Equine Lentivirus Serogroup",,,,,,,,,,,,,,,"4248383","Equine lentivirus group",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206444","Feline Lentivirus Group","C117714","A non-taxonomic grouping of lentivuruses that infect lions, tigers, jaguars, and other wild and domestic cats.","Feline Lentivirus Group | Feline Lentivirus Serogroup",,,,,,,,,,,,,,,"4251442","Feline lentivirus group",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206447","Ovine/Caprine Lentivirus Group","C117715","A non-taxonomic grouping of lentivuruses that infect wild and domestic sheep and goats.","Ovine/Caprine Lentivirus Group | Ovine/Caprine Lentivirus Serogroup",,,,,,,,,,,,,,,"4231258","Ovine/caprine lentivirus group",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206438","Primate Lentivirus Group","C117716","A non-taxonomic grouping of lentivuruses that infect humans, apes, monkeys, lemurs, lorises, and tarsiers.","Primate Lentivirus Group | Primate Lentivirus Serogroup",,,,,,,,,,,,,,,"4231260","Primate lentivirus group",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL479732","FDA Master File","C117717","A submission to the Food and Drug Administration (FDA) that contains information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs or biologics.","FDA Master File | Food and Drug Administration Master File | Master File",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898474","Male Reproductive System Finding","C117719","Symptoms, physical examination results, and/or laboratory test results related to the male reproductive system.","Male Reproductive System Finding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899080","Free Arterial Graft","C117816","A vessel graft comprised of an artery that has been completely detached from its original location.","Free Arterial Graft | ARTERIAL GRAFT, FREE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898776","In Situ Arterial Graft","C117817","A vessel graft comprised of an artery whose origin remains in place.","In Situ Arterial Graft | ARTERIAL GRAFT, IN-SITU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0440766","Autologous Vein Graft","C117818","A vessel graft comprised of a vein harvested from a different anatomical location on the patient.","Autologous Vein Graft | AUTOLOGOUS VEIN GRAFT",,,,,,,,,,,,,,,"4127479","Autologous vein graft",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899733","Cadaveric Arterial Graft","C117819","An arterial graft harvested from a cadaver.","Cadaveric Arterial Graft | CADAVERIC GRAFT, ARTERIAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899732","Cadaveric Venous Graft","C117820","A venous graft harvested from a cadaver.","Cadaveric Venous Graft | CADAVERIC GRAFT, VENOUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899515","Composite Vessel Graft","C117821","A vessel graft comprised of two or more conduit materials.","Composite Vessel Graft | COMPOSITE GRAFT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896589","CDISC SDTM ARC Coronary Stent Thrombosis Timing Terminology","C119019","Terminology associated with the ARC coronary stent thrombosis timing responses codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM ARC Coronary Stent Thrombosis Timing Terminology | SDTM-STCTIMRS | STCTIMRS | Stent Thrombosis, Coronary, ARC Timing Responses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896590","CDISC SDTM ARC Coronary Stent Thrombosis Grade Responses Terminology","C119020","Terminology associated with the ARC coronary stent thrombosis grade responses codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM ARC Coronary Stent Thrombosis Grade Responses Terminology | SDTM-STCARCRS | STCARCRS | Stent Thrombosis, Coronary ARC Grade Responses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3808448","Oligoarticular Arthritis","C119021","An arthritis affecting fewer than five separate joints.","Oligoarticular Arthritis | Oligoarthritis | Pauciarthritis",,,,,,,,,,,,,,,"4083684","Undifferentiated inflammatory oligoarthritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899281","Early Inflammatory Arthritis","C119022","Early stages of inflammatory arthritis, when the underlying diagnosis is uncertain, usually little or no joint damage has occurred. Treatment may alter the disease course (e.g., potentially avert progression to full RA or other diagnosis).","Early Inflammatory Arthritis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898123","Nonerosive Arthritis","C119023","An inflammation of one or more joints, without loss of articular cartilage or destruction of subchondral bone.","Nonerosive Arthritis | Non-Erosive Arthritis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3495919","Enthesitis-Related Arthritis","C119024","A category of juvenile idiopathic arthritis associated with arthritis and enthesitis, which may involve the axial skeleton. It is a form of juvenile spondyloarthritis.","Enthesitis-Related Arthritis | ERA | Enthesitis-Related JIA | Enthesitis-Related Juvenile Idiopathic Arthritis",,,,,,,,,,,,,,,"4253902","Juvenile idiopathic arthritis, enthesitis related arthritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1290140","Post-Streptococcal Arthritis","C119025","The occurrence of arthritis after infection with group A streptococcus. It is non-migratory, protracted in course, and poorly responsive to anti-inflammatory agents. (from Textbook of Pediatric Rheumatology, 6th ed. Cassidy, Petty, Laxer, and Lindsley)","Post-Streptococcal Arthritis | PSRA | Post-Streptococcal Reactive Arthritis",,,,,,,,,,,,,,,"4047780","Post-streptococcal reactive arthritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242381","Lyme Arthritis","C119026","Joint inflammation, most often affecting large joints, associated with Lyme disease, presenting months after infection.","Lyme Arthritis | ",,,,,,,,,,,,,,,"4141757","Lyme arthritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898566","Lupus Headache","C119029","A severe, persistent headache that occurs in patients with systemic lupus erythematosus, and is nonresponsive to narcotic analgesia.","Lupus Headache | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035450","Rheumatoid Nodule","C119030","A well circumscribed lump of tissue, firm to touch, typically non-tender, predominantly occurring as a cutaneous manifestation of rheumatoid arthritis localized to extensor surfaces near joints, but may be internal.","Rheumatoid Nodule | Rheumatoid nodule, unspecified site",,,,,,,,,,,,,,,"40400211|4179799","Rheumatoid nodule|Rheumatoid nodule",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL388451","Central Lymph Node Dissection","C118544","Dissection of the lymph nodes that surround the thyroid gland.","Central Lymph Node Dissection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890226","ABHD12 wt Allele","C118546","Human ABHD12 wild-type allele is located in the vicinity of 20p11.21 and is approximately 96 kb in length. This allele, which encodes monoacylglycerol lipase ABHD12 protein, is involved in endocannabinoid catabolism. Mutation of the gene is associated with the neurological disorder, polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract.","ABHD12 wt Allele | ABHD12A | Abhydrolase Domain Containing 12 wt Allele | BEM46L2 | C20orf22 | Chromosome 20 Open Reading Frame 22 Gene | DKFZP434P106 | PHARC | RP5-965G21.2 | dJ965G21.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1531582","Anterior Segment Ischemia","C118861","Compromise of blood supply to the anterior segment of the eye.","Anterior Segment Ischemia | ",,,,,,,,,,,,,,,"4186102","Anterior segment ischemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0344258","Corneal Delle","C118862","Corneal thinning just anterior to the limbus secondary to abnormal and/or irregular bulbar conjunctival contour.","Corneal Delle | Corneal Dellen | Delle",,,,,,,,,,,,,,,"4087961","Corneal dellen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034938","Oculocardiac Reflex","C118863","Slowing or cessation of the heart rate secondary to traction on the extraocular muscle.","Oculocardiac Reflex | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0948292","Intraocular Lens Dislocation","C118865","Displacement of the intraocular lens from the visual axis.","Intraocular Lens Dislocation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3888283","Proheparin-Binding EGF-Like Growth Factor, human","C118380","Proheparin-binding EGF-like growth factor (208 aa, ~23 kDa) is encoded by the human HBEGF gene. This protein plays a role in both heart valve formation and mitogenesis for fibroblasts and smooth muscle cells.","Proheparin-Binding EGF-Like Growth Factor | Pro-HB-EGF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0264104","Apophysitis","C118381","Inflammation of a bony outgrowth located near the attachment site for muscles.","Apophysitis | ",,,,,,,,,,,,,,,"4164088","Apophysitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0149887","Slipped Capital Femoral Epiphysis","C118384","Separation of the femoral head and neck through the epiphyseal plate.","Slipped Capital Femoral Epiphysis | SCFE",,,,,,,,,,,,,,,"133848","Slipped upper femoral epiphysis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899498","Copper Cu 64 Anti-CEA Monoclonal Antibody M5A","C118454","A radioimmunoconjugate consisting of a humanized monoclonal antibody directed against the human carcinoembryonic antigen, carcinoembryonic antigen-related cell adhesion molecule 5 (CEA or CEACAM5), which is conjugated with the radioisotope copper Cu 64 via the chelator tetra-azacyclododecanetetra-acetic acid (DOTA), with potential use as an imaging agent during positron emission tomography (PET). Upon administration, the antibody moiety of copper Cu 64 anti-CEA monoclonal antibody M5A specifically binds to cells expressing CEA. Upon binding, the radioisotope moiety can be detected using PET, thereby allowing the imaging and quantification of CEA-expressing tumor cells. CEA, a tumor associated antigen and a member of the CEA family of proteins, plays a key role in cell migration, cell invasion, and cell adhesion and is overexpressed by a variety of cancer types.","Copper Cu 64 Anti-CEA Monoclonal Antibody M5A | 64Cu-DOTA-M5A | Cu 64-M5A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037205","Sirenomelia","C118455","A disorder characterized by the malformation of the legs into a single lower limb.","Sirenomelia | SIRENOMELIA | Symmelia",,,,,,,,,,,,,,,"37109977","Sirenomelus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1535897","Hair Tourniquet","C118456","A condition in which a hair or thread becomes wrapped around a digit obstructing blood flow.","Hair Tourniquet | Hair-Thread Tourniquet Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1392435","Cheiromegaly","C118458","Abnormal enlargement of one or both hands, along with hyperhydrosis.","Cheiromegaly | Chiromegaly",,,,,,,,,,,,,,,"607441","Cheiromegaly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0432357","Amastia","C118459","Absence of one or both mammary glands.","Amastia | ",,,,,,,,,,,,,,,"4152999","Congenital absence of breast with absent nipple",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL371922","MUC1-KLH Vaccine/QS21","C11845","A peptide vaccine containing the human tumor-associated antigen epithelial mucin (MUC1 antigen) conjugated with keyhole limpet hemocyanin (KLH) and combined with the nonspecific immunoadjuvant QS21, with potential antineoplastic activity.  MUC1 antigen is linked with KLH, an immunostimulant and a hapten carrier, in order to enhance immune recognition; the co-administration of saponin-derived QS21 potentially amplifies the total immune response to the MUC1 antigen.  Administration of MUC1-KLH vaccine/QS21 may result in both the production of antitumor antibodies and the stimulation of a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the MUC1 antigen. MUC1 antigen, a membrane-bound glycoprotein expressed by most glandular and ductal epithelial cells, is overexpressed as an aberrant or deglycosylated form in various cancers such as breast, prostate and ovarian cancers.","MUC1-KLH Vaccine/QS21 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0220757","Blount's Disease","C118460","A growth disorder of the tibia in children and adolescents that presents as progressive bowing of one or both legs.","Blount's Disease | Blount Disease",,,,,,,,,,,,,,,"619009","Blount disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3896920","MDM2/MDMX Inhibitor ALRN-6924","C118669","An orally available peptide inhibitor of both murine double minute 2 (MDM2) and murine double minute X (MDMX), with potential antineoplastic activity. Upon oral administration, sulanemadlin binds to both MDM2 and MDMX and interferes with their interaction with the transcriptional activation domain of the tumor suppressor protein p53. By preventing MDM2-p53 and MDMX-p53 interactions, p53 activity is restored, which leads to p53-mediated induction of tumor cell apoptosis. MDM2 and MDMX, negative regulators of p53 function, are often overexpressed in cancer cells.","Sulanemadlin | ALRN-6924 | MDM2/MDMX Inhibitor ALRN-6924 | MDM2/MDMX Inhibitor ALRN-6924 | SULANEMADLIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898007","Palm Extract Phytonutrient Supplement","C118296","A nutritional supplement composed of a palm oil extract containing high concentrations of mixed tocotrienols, tocopherols, carotenoids, phytosterols, and squalene, with antioxidant and potential hepato-, neuro-, and radio-protective activities. Upon oral administration, the palm extract phytonutrient supplement exerts an antioxidant effect by scavenging free radicals and inhibiting lipid peroxidation. This extract also prevents inflammation by inhibiting the expression of pro-inflammatory cytokines. Altogether, this prevents oxidative stress in cells and may improve symptoms of radiation-induced fibrosis. In addition, this supplement may modulate enzymes that play key roles in neuronal cell degeneration and fatty acid accumulation.","Palm Extract Phytonutrient Supplement | PALM OIL TOCOTRIENOL-RICH EXTRACT | PPALM-Palm Oil | Tocovid SupraBio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085437","Bacterial Meningitis","C118297","Inflammation of the membranes surrounding the brain and spinal cord due to a bacterial infection.","Bacterial Meningitis | ",,,,,,,,,,,,,,,"436091","Bacterial meningitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025297","Viral Meningitis","C118298","Inflammation of the membranes surrounding the brain and spinal cord due to a viral infection.","Viral Meningitis | ",,,,,,,,,,,,,,,"433403","Viral meningitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025290","Aseptic Meningitis","C118299","Inflammation of the membranes surrounding the brain and spinal cord without a bacterial pathogen.","Aseptic Meningitis | ",,,,,,,,,,,,,,,"4201096","Aseptic meningitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0069736","Piroxantrone","C1182","An anthrapyrazole antineoplastic antibiotic.  Piroxantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  Although less cardiotoxic than doxorubicin, this agent exhibits a narrow spectrum of antineoplastic activity. (NCI04)","Piroxantrone | Anthra(1,9-cd)pyrazol-6(2H)-one, 5-((3-aminopropyl)amino)-7,10-dihydroxy-2-(2-((2-hydroxyethyl)amino)ethyl) | CI-942 | Oxanthrazole | Oxantrazole | PD-111815 | PIROXANTRONE | Piroxantrone HCl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897697","Retinopathy of Prematurity Finding","C118300","An ophthalmoscopic finding that refers to retinopathy of prematurity.","Retinopathy of Prematurity Finding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037036","Sialorrhea","C118301","An increase in saliva secretion.","Sialorrhea | Hypersalivation",,,,,,,,,,,,,,,"4207204","Excessive salivation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0235195","Sedated","C118302","A state of a lowered level of consciousness.","Sedated | Sedation",,,,,,,,,,,,,,,"4077017","Sedated",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4013780","Polyuria","C118303","Excessive or frequent urination.","Polyuria | ",,,,,,,,,,,,,,,"79936","Polyuria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0233769","Micropsia","C118304","An alteration in visual perception that causes objects to appear smaller than their actual size.","Micropsia | ",,,,,,,,,,,,,,,"4223575","Micropsia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3550637","Tooth Malformation","C118306","Any abnormality in the growth or formation of one or more teeth.","Tooth Malformation | ",,,,,,,,,,,,,,,"4306814","Malformation of tooth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897170","White Matter Injury","C118307","Focal areas of necrosis, with or without cysts, and diffuse areas of white matter dysmaturation with maturation arrest of the pre-oligodendroglia cells, located in the cerebral white matter.","White Matter Injury | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897661","Sacral Fistula","C118308","A pathologic communication between the skin and the dural space that is located 5-25 mm from the anal verge.","Sacral Fistula | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890773","Coccygeal Sinus","C118309","A blind-ending, epithelial-lined tract that is located less than 5 mm from the anal verge.","Coccygeal Sinus | Coccygeal Pit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898748","Insufficient Breast Milk Syndrome","C118310","Failure to thrive due to poor intake by the infant, inadequate feeding schedule or insufficient maternal production of breast milk.","Insufficient Breast Milk Syndrome | Insufficient Milk Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2976455","Monoacylglycerol Lipase ABHD12, Human","C118547","Monoacylglycerol lipase ABHD12 (398 aa, ~45 kDa) is encoded by the human ABHD12 gene. This protein plays a role in endocannabinoid hydrolysis.","Monoacylglycerol Lipase ABHD12 | 2-Arachidonoylglycerol Hydrolase | ABHD12 | Abhydrolase Domain-Containing Protein 12 | EC 3.1.1.23",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889421","PDLIM3 wt Allele","C118549","Human PDLIM3 wild-type allele is located in the vicinity of 4q35 and is approximately 35 kb in length. This allele, which encodes PDZ and LIM domain protein 3, may play a role in the modulation of actin filament formation. Alternative splicing of the gene may be associated with myotonic dystrophy.","PDLIM3 wt Allele | ALP | PDZ and LIM Domain 3 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1431008","PDZ and LIM Domain Protein 3, Human","C118550","PDZ and LIM domain protein 3 (364 aa, ~39 kDa) is encoded by the human PDLIM3 gene. This protein may be involved in the arrangement of the actin cytoskeleton.","PDZ and LIM Domain Protein 3 | Actinin-Associated LIM Protein | Alpha-Actinin-2-Associated LIM Protein | Enigma Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889722","SHROOM2 wt Allele","C118552","Human SHROOM2 wild-type allele is located in the vicinity of Xp22.3 and is approximately 163 kb in length. This allele, which encodes protein Shroom2, may be involved in the modulation of cell shape. Deletion of the gene may be associated with ocular albinism type 1.","SHROOM2 wt Allele | APXL | Apical Protein, Xenopus laevis-Like Gene | Apical Protein-Like (Xenopus laevis) Gene | HSAPXL | Shroom Family Member 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1307782","Protein Shroom2, Human","C118553","Protein Shroom2 (1616 aa, ~176 kDa) is encoded by the human SHROOM2 gene. This protein may play a role in the regulation of cell spreading.","Protein Shroom2 | APX Homolog of Xenopus | Apical Protein of Xenopus-Like | Apical-Like Protein | Protein APXL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890010","PVR wt Allele","C118555","Human PVR wild-type allele is located in the vicinity of 19q13.2 and is approximately 22 kb in length. This allele, which encodes poliovirus receptor protein, plays a role in poliovirus adhesion to host cells and the adhesion and activation of natural killer cells.","PVR wt Allele | CD155 | HVED | NECL5 | Necl-5 | Nectin-Like 5 Gene | PVR Cell Adhesion Molecule wt Allele | PVS | Poliovirus Receptor Gene | Poliovirus Receptor wt Allele | TAGE4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890597","CTRC wt Allele","C118558","Human CTRC wild-type allele is located in the vicinity of 1p36.21 and is approximately 11 kb in length. This allele, which encodes chymotrypsin-C protein, is involved in the proteolytic activation of other serine proteinases. Mutation of the gene is associated with hereditary pancreatitis.","CTRC wt Allele | CLCR | Chymotrypsin C (Caldecrin) wt Allele | ELA4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2001156","Chymotrypsin-C, Human","C118559","Chymotrypsin-C (268 aa, ~29 kDa) is encoded by the human CTRC gene. This protein plays a role in site-specific proteolysis.","Chymotrypsin-C | CTRC | Caldecrin | Chymotrypsin C | EC 3.4.21.2 | Elastase 4 | Elastase IV | Serum Calcium Decreasing Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016665","Nonunion of Bone","C118392","The permanent failure of bone to heal, commonly due to a fracture or an osteotomy.","Nonunion of Bone | Nonunion",,,,,,,,,,,,,,,"4140519|73574","Fracture, ununited|Nonunion of fracture",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0158454","Malunion of Bone","C118393","Faulty healing of bone, resulting in improper anatomical alignment.","Malunion of Bone | Malunion",,,,,,,,,,,,,,,"4181408|75634","Malunion of fracture|Fracture malunion",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3896684","CDISC Clinical Classification TIMI Thrombus Grade Test Name Terminology","C119073","Test names of clinical classification questions associated with the Coronary Thrombus TIMI Grade (TIMI Thrombus Grade) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification TIMI Thrombus Grade Test Name Terminology | CC-TIMI Thrombus Grade TEST | Coronary Thrombus TIMI Grade Clinical Classification Test Name | TIMG01TN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896685","CDISC Clinical Classification TIMI Thrombus Grade Test Code Terminology","C119074","Test codes of clinical classification questions associated with the Coronary Thrombus TIMI Grade (TIMI Thrombus Grade) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification TIMI Thrombus Grade Test Code Terminology | CC-TIMI Thrombus Grade TESTCD | Coronary Thrombus TIMI Grade Clinical Classification Test Code | TIMG01TC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896686","CDISC Clinical Classification NHLBI CAD Grade Test Name Terminology","C119075","Test names of clinical classification questions associated with the Coronary Artery Dissection NHLBI Grade (NHLBI CAD Grade) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification NHLBI CAD Grade Test Name Terminology | CADG01TN | CC-NHLBI CAD Grade TEST | Coronary Artery Dissection NHLBI Grade Clinical Classification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896687","CDISC Clinical Classification NHLBI CAD Grade Test Code Terminology","C119076","Test codes of clinical classification questions associated with the Coronary Artery Dissection NHLBI Grade (NHLBI CAD Grade) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification NHLBI CAD Grade Test Code Terminology | CADG01TC | CC-NHLBI CAD Grade TESTCD | Coronary Artery Dissection NHLBI Grade Clinical Classification Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896688","CDISC Clinical Classification ARC STC Timing Test Name Terminology","C119077","Test names of clinical classification questions associated with the Stent Thrombosis Coronary ARC Timing (ARC STC Timing) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification ARC STC Timing Test Name Terminology | CC-ARC STC Timing TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896690","CDISC Clinical Classification ARC STC Grade Test Name Terminology","C119079","Test names of clinical classification questions associated with the Stent Thrombosis Coronary ARC Grade (ARC STC Grade) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification ARC STC Grade Test Name Terminology | CC-ARC STC Grade TEST | STCG01TN | Stent Thrombosis Coronary ARC Grade Clinical Classification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896691","CDISC Clinical Classification ARC STC Grade Test Code Terminology","C119080","Test codes of clinical classification questions associated with the Stent Thrombosis Coronary ARC Grade (ARC STC Grade) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Clinical Classification ARC STC Grade Test Code Terminology | CC-ARC STC Grade TESTCD | STCG01TC | Stent Thrombosis Coronary ARC Grade Clinical Classification Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897117","Rhenium Re 188 BMEDA-labeled Liposomes","C118670","A liposome-based preparation consisting of the beta- and gamma-emitting radionuclide rhenium Re 188 (Re 188) linked to the chelator N,N-bis (2-mercaptoethyl)-N',N'-diethylethylenediamine (BMEDA) and encapsulated in liposomes, with potential tumor imaging and antineoplastic activities. Upon intravenous infusion of rhenium Re 188 BMEDA-labeled liposomes, the liposomes selectively target tumor cells, facilitate the retention of the radioisotope by those cells, and cause localized antitumor radiocytotoxicity while sparing surrounding normal, healthy cells. In addition, Re 188 BMEDA-labeled liposomes can be used for imaging purposes. Re 188 has a short half-life and a short path length, which further contribute to limiting the radiotoxicity to the tumor cells.","Rhenium Re 188 BMEDA-labeled Liposomes | (188) Re-BMEDA-liposomes | 188Re-BMEDA-liposomes | 188Re-N,N-bis (2-Mercaptoethyl)-N',N'-diethylethylenediamine-labeled Liposomes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053687","Avitinib Maleate","C118671","The maleate salt form of abivertinib, an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. Upon oral administration, abivertinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the drug-resistant T790M EGFR mutant, which prevents signaling mediated by mutant forms of EGFR. This may both induce cell death and inhibit tumor growth in EGFR-mutated tumor cells. EGFR, a receptor tyrosine kinase that is mutated in a variety of cancers, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors, which also inhibit wild-type EGFR.","Abivertinib Maleate Anhydrous | ABIVERTINIB MALEATE ANHYDROUS | AC0010 Maleate | AC0010 Maleate Dihydrate | AC0010MA | Avitinib Maleate | Avitinib Maleate | STI-5656",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896866","FGF/FGFR pathway inhibitor E7090","C118672","An inhibitor of the fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR) pathway, with potential antineoplastic activity. Upon administration, tasurgratinib selectively interferes with the binding of FGF to FGFR through an as of yet not fully elucidated mechanism. This inhibits FGFR-mediated signaling and leads to both cell proliferation inhibition and cell death in FGFR-overexpressing tumor cells. FGFR is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation, and survival; its expression is upregulated in many tumor cell types.","Tasurgratinib | E-7090 | E7090 | FGF/FGFR Pathway Inhibitor E7090 | TASURGRATINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896850","Opioid Agonist GIC-1002","C118673","An orally available, peripherally-acting opioid agonist, with potential visceral analgesic activity. Upon oral administration of GIC-1002, this agent binds to colonic mu and kappa opioid receptors causing analgesic effects.","Opioid Agonist GIC-1002 | GIC-1002",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896762","Trastuzumab vc-seco-DUBA","C118674","An antibody-drug conjugate (ADC) composed of the recombinant humanized anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab linked, via a cleavable linker, to the duocarmycin prodrug, seco-duocarmycin-hydroxybenzamide-azaindole (seco-DUBA), with potential antineoplastic activity. Upon administration of trastuzumab duocarmazine, the trastuzumab moiety binds to HER2 on the tumor cell surface, which triggers the endocytosis of this agent. The linker is then cleaved inside the tumor cell by proteases at the dipeptide valine-citrulline (vc), and releases the active moiety, duocarmycin. Duocarmycin binds to the minor groove of DNA, alkylates adenine at the N3 position, and induces cell death. In addition, trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER2. HER2 is overexpressed by many carcinomas and is associated with a poor prognosis.","Trastuzumab Duocarmazine | ADC SYD985 | Antibody-drug Conjugate SYD985 | SYD985 | TRASTUZUMAB DUOCARMAZINE | Trastuzumab VC-seco-DUBA | Trastuzumab-drug Conjugate SYD985 | vic-Trastuzumab Duocarmazine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963826","Mitochondrial Enzyme Deficiency","C118675","A constellation of disorders whose common thread is the insufficient quantity of one or more mitochondrial enzymes.","Mitochondrial Enzyme Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0701826","Perinatal Mortality","C118676","Fetal or infant death during the period of time that includes the antepartum, intrapartum, and neonatal stages.","Perinatal Mortality | Perinatal Death",,,,,,,,,,,,,,,"4024541","Perinatal death",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897192","Very Preterm Infant","C118677","An age group comprised of infants greater than 28 weeks, 0 days and less than 34 weeks, 0 days.","Very Preterm Infant | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900119","Acquired Growth Hormone Deficiency","C118678","Growth hormone deficiency that is not present at birth; this condition may result from a variety of causes such as intracranial tumors or their treatment, infection, trauma or other cause.","Acquired Growth Hormone Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897061","Congenital Growth Hormone Deficiency","C118679","Growth hormone deficiency the cause of which is present at birth.","Congenital Growth Hormone Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898879","Hormone Receptor/HER2 Positive","C118311","A finding indicating that the neoplastic cells in a breast cancer tissue sample test positive for estrogen, progesterone, and HER2 receptors.","Hormone Receptor/HER2 Positive | ER+PR+HER2/neu+ | ER/PR/HER2 Postive | Hormone Receptor/Epidermal Growth Factor Receptor 2 Positive | Triple Positive | Triple-Positive | Triple-Positive Breast Cancer Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019326","Ventral Hernia","C118313","The protrusion of abdominal cavity contents through the anterior abdominal wall.","Ventral Hernia | ",,,,,,,,,,,,,,,"4188155","Hernia of anterior abdominal wall",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3890717","TIPARP wt Allele","C118975","Human TIPARP wild-type allele is located in the vicinity of 3q25.31 and is approximately 34 kb in length. This allele, which encodes TCDD-inducible poly [ADP-ribose] polymerase protein, plays a role in modifying guanine residues with ADP-ribose.","TIPARP wt Allele | ARTD14 | DDF1 | DKFZP434J214 | DKFZp686N0351 | PARP-7 | PARP7 | RM1 | TCDD-Inducible Poly(ADP-Ribose) Polymerase wt Allele | pART14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3657668","TCDD-Inducible Poly [ADP-Ribose] Polymerase, Human","C118976","TCDD-inducible poly [ADP-ribose] polymerase (657 aa, ~76 kDa) is encoded by the human TIPARP gene. This protein is involved in protein modification.","TCDD-Inducible Poly [ADP-Ribose] Polymerase | ADP-Ribosyltransferase Diphtheria Toxin-Like 14 | ARTD14 | EC 2.4.2.30 | PARP-7 | Poly [ADP-Ribose] Polymerase 7 | TIPARP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890013","LZTS1 wt Allele","C118978","Human LZTS1 wild-type allele is located in the vicinity of 8p22 and is approximately 58 kb in length. This allele, which encodes leucine zipper putative tumor suppressor 1 protein, is involved in cell cycle regulation, cell growth modulation, transcriptional regulation, and tumor suppression. Mutation of the gene is associated with esophageal squamous cell carcinoma and several other neoplastic diseases.","LZTS1 wt Allele | F37 | FEZ1 | Leucine Zipper, Putative Tumor Suppressor 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1309037","Leucine Zipper Putative Tumor Suppressor 1, Human","C118979","Leucine zipper putative tumor suppressor 1 (596 aa, ~67 kDa) is encoded by the human LZTS1 gene. This protein plays a role in tumor suppression, cell cycle modulation, cell growth control and transcriptional regulation.","Leucine Zipper Putative Tumor Suppressor 1 | F37/Esophageal Cancer-Related Gene-Coding Leucine-Zipper Motif | Fez1 | LZTS1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889439","EIF1B wt Allele","C118981","Human EIF1B wild-type allele is located in the vicinity of 3p22.1 and is approximately 3 kb in length. This allele, which encodes eukaryotic translation initiation factor 1b protein, plays a role in the translation of proteins.","EIF1B wt Allele | Eukaryotic Translation Initiation Factor 1B wt Allele | GC20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890607","Eukaryotic Translation Initiation Factor 1b, human","C118982","Eukaryotic translation initiation factor 1b (113 aa, ~13 kDa) is encoded by the human EIF1B gene. This protein is involved in both RNA binding and the initiation of protein synthesis.","Eukaryotic Translation Initiation Factor 1b | EIF1B | Protein Translation Factor SUI1 Homolog GC20 | Translation Factor Sui1 Homolog | eIF1b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889257","OPRM1 wt Allele","C118984","Human OPRM1 wild-type allele is located within 6q24-q25 and is approximately 236 kb in length. This allele, which encodes Mu-type opioid receptor protein, is involved in opioid binding and signaling. A point mutation in the gene may be associated with addiction to opioids and alcohol, and variations in pain sensitivity","OPRM1 wt Allele | LMOR | M-OR-1 | MOP | MOR | MOR1 | OPRM | Opioid Receptor, Mu 1 wt Allele | Opioid Receptor, Mu-1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1436808","Human Mu-Type Opioid Receptor","C118985","Mu-type opioid receptor (400 aa, ~45 kDa) is encoded by the human OPRM1 gene. This protein plays a role in G protein-coupled receptor signaling.","Mu-Type Opioid Receptor | M-OR-1 | MOP | MOR-1 | Mu Opiate Receptor | Mu Opioid Receptor | Mu Opioid Receptor hMOR-1a | hMOP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0070218","Penberol","C1187","A derivative of bromoacrylic acid with cytostatic activity. Although the mechanism of action is unclear, penberol might inhibit tumor growth mediated through inhibition of the cell energetic metabolism.","Penberol | PENBEROL | cis-beta-4-pentoxy-benzoyl-beta-bromoacrylic acid | cis-beta-4-pentoxybenzoyl-beta-bromoacrylic acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898138","Newborn or Infant Finding","C118807","Clinical, laboratory or molecular evidence, or absence of evidence of disease in a neonate or infant.","Newborn or Infant Finding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899669","Childhood Colorectal Carcinoma","C118808","A rare colorectal carcinoma that occurs during childhood.","Childhood Colorectal Carcinoma | Colorectal (Colon or Rectal) Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897071","Childhood Breast Carcinoma","C118809","A rare breast carcinoma that occurs during childhood.","Childhood Breast Carcinoma | Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899673","Childhood Carcinoid Tumor","C118810","A neuroendocrine tumor grade 1 that occurs during childhood.","Childhood Neuroendocrine Tumor G1 | Childhood Carcinoid Tumor | Childhood Carcinoid Tumor | Pediatric Neuroendocrine Tumor G1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899654","Childhood Laryngeal Carcinoma","C118811","A rare carcinoma of the larynx that occurs during childhood.","Childhood Laryngeal Carcinoma | Laryngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899664","Childhood Esophageal Carcinoma","C118812","A rare carcinoma of the esophagus that occurs during childhood.","Childhood Esophageal Carcinoma | Esophageal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899661","Childhood Gastric Carcinoma","C118813","A rare carcinoma of the stomach that occurs during childhood.","Childhood Gastric Carcinoma | Childhood Carcinoma of the Stomach | Gastric (Stomach) Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900142","AUDIT Questionnaire Question","C119081","A question associated with the AUDIT questionnaire.","AUDIT Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900138","AUDIT-C Questionnaire Question","C119082","A question associated with the AUDIT-C questionnaire.","AUDIT-C Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899819","CCQ 24 Hour Version Questionnaire Question","C119083","A question associated with the CCQ 24 Hour Version questionnaire.","CCQ 24 Hour Version Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899829","CCQ 1 Week Version Questionnaire Question","C119084","A question associated with the CCQ 1 Week Version questionnaire.","CCQ 1 Week Version Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899765","CHART-SF Paper Version Questionnaire Question","C119085","A question associated with the CHART-SF Paper Version questionnaire.","CHART-SF Paper Version Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899466","DLQI Questionnaire Question","C119086","A question associated with the DLQI questionnaire.","DLQI Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897783","RPQ Questionnaire Question","C119087","A question associated with the RPQ questionnaire.","RPQ Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897386","TIMI Thrombus Grade Clinical Classification Question","C119088","A question associated with the TIMI Thrombus Grade clinical classification.","TIMI Thrombus Grade Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1505164","ASAP1 protein, human","C118599","Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 (1129 aa, ~125 kDa) is encoded by the human ASAP1 gene. This protein plays a role in the activation of GTPases.","Arf-GAP with SH3 Domain, Ankyrin Repeat and PH Domain-Containing 1 | 130 kDa Phosphatidylinositol 4,5-Biphosphate-Dependent ARF1 GTPase-Activating Protein | 130 kDa Phosphatidylinositol 4,5-Bisphosphate-Dependent ARF1 GTPase-Activating Protein | ADP-Ribosylation Factor-Directed GTPase-Activating Protein 1 | ARF GTPase-Activating Protein 1 | ASAP1 | Arf-GAP with SH3 Domain, Ankyrin Repeat and PH Domain 1 | DEF-1 | Development and Differentiation-Enhancing Factor 1 | Development- and Differentiation-Enhancing Factor 1 | Differentiation-Enhancing Factor 1 | PIP2-Dependent ARF1 GAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887570","Recombinant Parathyroid Hormone-Related Protein","C1185","A recombinantly produced form of the hormone parathyroid hormone-related protein. Endogenous parathyroid hormone-related protein regulates calcium usage in bone and mammary glands.","Recombinant Parathyroid Hormone-Related Protein | PTH-like protein | PTHrP | Parathyroid Hormone Like Tumor Factor | Parathyroid Hormone-Related Peptide | Parathyroid Hormone-Related Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879557","fluorouracil/leucovorin calcium/oxaliplatin/trastuzumab","C11826","A regimen consisting of leucovorin, 5-fluorouracil and oxaliplatin (FOLFOX), plus trastuzumab that can be used for the treatment of esophageal and esophagogastric junction, gastric and colon cancers.","FOLFOX/Trastuzumab Regimen | FOLFOX Plus Herceptin | FOLFOX Plus Trastuzumab | FOLFOX/Herceptin | FOLFOX/Trastuzumab | Fluorouracil/Leucovorin Calcium/Oxaliplatin/Trastuzumab | Folinic Acid/Fluorouracil/Oxaliplatin/Trastuzumab | Folinic Acid/Fluorouracil/Oxaliplatin/Trastuzumab Regimen | Oxaliplatin/Leucovorin/Fluorouracil  Plus Trastuzumab | Oxaliplatin/Leucovorin/Fluorouracil Plus Trastuzumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474133","Anti-Met/EGFR Monoclonal Antibody LY3164530","C118281","A monoclonal antibody (MoAb) against human epidermal growth factor receptor (EGFR) and human hepatocyte growth factor receptor (HGFR or c-Met), with potential antineoplastic activity. Upon administration, anti-Met/EGFR MoAb LY3164530 targets and prevents the activation of EGFR and c-Met. This leads to a downstream inhibition of EGFR/c-Met-mediated signal transduction pathways, and prevents cellular proliferation in tumor cells overexpressing EGFR and c-Met. EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surface of various solid tumor cell types. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.","Anti-Met/EGFR Monoclonal Antibody LY3164530 | LY-3164530 | LY3164530",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891078","LUM wt Allele","C118987","Human LUM wild-type allele is located in the vicinity of 12q21.33 and is approximately 9 kb in length. This allele, which encodes lumican protein, plays a role in the structure of the extracellular matrix.","LUM wt Allele | LDC | Lumican wt Allele | SLRR2D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900015","Artemether Sublingual Spray","C118504","A sublingual spray containing artemether, a semisynthetic derivative of artemisinin, an endoperoxide extracted from the Chinese herb qinghaosu (Artemisia annua or annual wormwood), with antiparasitic and potential antineoplastic activity. Upon sublingual application of the spray, artemether exerts its antineoplastic activity through as of yet not fully elucidated mechanism(s) of action. This agent binds to heme molecules inside cells, thereby inducing reactive oxygen species (ROS)-mediated damage which selectively kills cancer cells. In addition, artemether appears to target and modulate the expression of various proteins involved in cancer cell proliferation, angiogenesis, invasion and metastasis. Also, this agent depletes T regulatory cells, and modulates the production of inflammatory cytokines, such as interleukin-4 and interferon-gamma. Altogether, this inhibits tumor cell proliferation. The sublingual spray allows faster absorption of a higher percentage of the artemether dose, when compared to the oral form, as it avoids first pass metabolism; this results in an increased efficacy.","Artemether Sublingual Spray | LON002 | Sublingual Artemether Spray",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3885071","RSV fusion inhibitor GS-5806","C118505","An orally available inhibitor of human respiratory syncytial virus (RSV) fusion protein (F protein), with potential antiviral activity. Upon oral administration of GS-5806, this agent specifically binds to F protein on the viral surface, which inhibits RSV F protein-mediated fusion with the host cell membrane and prevents viral entry. This blocks RSV replication, reduces viral load, and decreases the severity of the disease. RSV F protein, a viral surface glycoprotein, plays a key role in RSV fusion with and entry into target cells.","Presatovir | GS 5806 | GS-5806 | Methanesulfonamide, N-(2-(((2S)-2-(5-((3S)-3-amino-1-pyrrolidinyl)-6-methylpyrazolo(1,5-a)pyrimidin-2-yl)-1-piperidinyl)carbonyl)-4-chlorophenyl)- | PRESATOVIR | Respiratory Syncytial Virus Fusion Inhibitor GS-5806",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0159020","Neonatal Seizure","C118507","Abnormal hypersynchronous electrical activity in the brain of a newborn which may be associated with stereotyped movements or autonomic changes.","Neonatal Seizure | ",,,,,,,,,,,,,,,"380533","Convulsions in the newborn",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2609173","Gasping Syndrome","C118508","A syndrome in preterm neonates exposed to benzyl alcohol preservative in intravascular solutions that is characterized by unremitting gasping respirations and may include anion gap metabolic acidosis, neurologic deterioration, renal failure, convulsions, intraventricular hemorrhage, and cardiovascular collapse.","Gasping Syndrome | Neonatal Gasping Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898146","Neonatal Spell","C118509","Cardiorespiratory events that are characterized by variable combinations of cessation of breathing, decrease in blood oxygen saturation, and decreased heart rate.","Neonatal Spell | Neonatal Spells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897048","Satellite Tumor","C118511","No value exists.","Satellite Tumor | satellite tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428662","SKA2 Gene","C118352","This gene plays a role in microtubule binding and chromosome segregation.","SKA2 Gene | SKA2 | Spindle and Kinetochore Associated Complex Subunit 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889463","SKA2 wt Allele","C118353","Human SKA2 wild-type allele is located in the vicinity of 17q23.2 and is approximately 45 kb in length. This allele, which encodes spindle and kinetochore-associated protein 2, is involved in chromosome segregation.","SKA2 wt Allele | FAM33A | FLJ12758 | Family With Sequence Similarity 33, Member A Gene | Spindle and Kinetochore Associated Complex Subunit 2 wt Allele | Spindle- and Kinetochore-Associated Complex, Subunit 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1872419","Spindle and Kinetochore-Associated Protein 2","C118354","Spindle and kinetochore-associated protein 2 (121 aa, ~14 kDa) is encoded by the human SKA2 gene. This protein plays a role in both chromosome segregation and microtubule binding.","Spindle and Kinetochore-Associated Protein 2 | Protein FAM33A | Spindle and KT (Kinetochore) Associated 2 | Spindle- and Kinetochore-Associated Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413960","DDX20 Gene","C118355","This gene is involved in catalyzing the assembly of small nuclear ribonucleoproteins.","DDX20 Gene | DDX20 | DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 20 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891074","DDX20 wt Allele","C118356","Human DDX20 wild-type allele is located within 1p21.1-p13.2 and is approximately 13 kb in length. This allele, which encodes probable ATP-dependent RNA helicase DDX20 protein, plays a role in the formation of the spliceosome.","DDX20 wt Allele | DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 20 wt Allele | DEAD/H (Asp-Glu-Ala-Asp/His) Box Polypeptide 20, 103kD Gene | DEAD/H Box 20 Gene | DP103 | GEMIN3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1438415","Probable ATP-Dependent RNA Helicase DDX20, Human","C118357","Probable ATP-dependent RNA helicase DDX20 (824 aa, ~92 kDa) is encoded by the human DDX20 gene. This protein is involved in spliceosome formation and ATP hydrolysis.","Probable ATP-Dependent RNA Helicase DDX20 | Component of Gems 3 | DDX20 | DEAD Box Protein 20 | DEAD Box Protein DP 103 | DEAD-Box Protein DP103 | EC 3.6.4.13 | Gemin-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3852822","Carbon C 11 Methylaminoisobutyrate","C118360","A synthetic neutral amino acid analog radiolabeled with carbon C 11 with potential use for metabolic tumor imaging during positron emission tomography (PET). Upon administration, carbon C 11 methylaminoisobutyrate ([(11)C]MeAIB) is taken up by and accumulates in cancer cells through the A-type (alanine-preferring) amino acid transport system. Upon imaging of the radioisotope, the distribution patterns of MeAIB and its uptake by cancer cells can be further elucidated. This may establish its usefulness as a tumor tracer in the diagnosis of certain cancers. Amino acid transport system A is highly upregulated in malignant cells and facilitates the uptake of amino acids needed for tumor cell proliferation.","Carbon C 11 Methylaminoisobutyrate | 11C-MeAIB | N-methyl-11C-methylaminoisobutyric Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3501105","HCV Antigen Therapeutic Bivalent Vaccine V5","C118361","An orally bioavailable, therapeutic bivalent vaccine composed of heat- and chemical-inactivated hepatitis C virus (HCV) antigens derived from the blood of HCV-infected carriers, with potential immunomodulating activity. Upon oral administration of the HCV antigen therapeutic bivalent vaccine V5, the HCV antigens may stimulate the host immune system to mount an immune response against HCV-infected cells, thereby preventing further HCV-infection and HCV-induced liver injury.","HCV Antigen Therapeutic Bivalent Vaccine V5 | V-5 Immunitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896895","Anti-MUC1 Monoclonal Antibody BTH1704","C118362","A monoclonal antibody against the tumor associated antigen (TAA) mucin-1 (MUC1), with potential antineoplastic activity. Upon administration, anti-MUC1 monoclonal antibody BTH1704 targets and binds to MUC1 expressed on the surface of tumor cells, which can potentially activate the immune system to induce an antibody-dependent cellular cytotoxicity (ADCC) against MUC1-expressing tumor cells. MUC1, a glycoprotein overexpressed on the surface of a variety of cancer cells, plays a key role in tumor cell survival and proliferation.","Anti-MUC1 Monoclonal Antibody BTH1704 | BTH1704",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898631","Laboratory Test Results End Day","C119846","The final day of the laboratory test.","Laboratory Test Results End Day | LBENDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899244","Exclude Laboratory Test Data From Statistics Indicator","C119847","Specifies whether the laboratory test result values should be excluded from the statistical analysis.","Exclude Laboratory Test Data From Statistics Indicator | LBEXCLFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898628","Laboratory Test Results Portion or Totality","C119850","A qualifier for the arrangement or apportioning of an entity within a body part, region or organ for a laboratory test.","Laboratory Test Results Portion or Totality | LBPORTOT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896948","Fluorine F 18-labeled 2-FACPC","C120070","A radioconjugate composed of an analog of the synthetic, alicyclic amino acid aminocyclopentane carboxylic acid (ACPC) radiolabeled with the positron-emitting isotope fluorine F 18 (2-[18F]FACPC), with potential cancer cell imaging activity during positron emission tomography (PET). As tumor cells have a higher rate of protein synthesis than normal, healthy cells, upon administration, fluorine F 18 labeled 2-FACPC is selectively taken up by rapidly proliferating tumor cells through the sodium-independent subtype L amino acid transport system (AAT) which leads to the accumulation of this tracer in tumor cells. Upon PET, tumor cells can then be visualized.","Fluorine F 18-labeled 2-FACPC | 1-Amino-2-[18F]fluorocyclopentane-1-carboxylic Acid | 2-[(18)F]FACPC | 2-[18F]FACPC | Anti-1-amino-2-[18F]fluorocyclopentyl-1-carboxylic Acid | Anti-2-[(18)F]FACPC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474134","agonistic anti-OX40 monoclonal antibody MEDI6383","C118282","An agonistic monoclonal antibody against receptor OX40 (CD134), with potential immunostimulatory activity. Upon administration, efizonerimod selectively binds to and activates the OX40 receptor, by mimicking the action of endogenous OX40 ligand (OX40L). OX40 receptor activation induces proliferation of memory and effector T lymphocytes. In the presence of tumor-associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor family, is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T cells.","Efizonerimod | EFIZONERIMOD | Efizonerimod Alfa | Immunoglobulin G4 (10-proline) (Human Heavy Chain Fc Fragment) Fusion Protein with Tumor Necrosis Factor Receptor-associated Factor TRAF2 (Human C-C  Domain Fragment) Fusion Protein with CD252 Antigen (Human Extracellular Domain Fragment), Hexamer | Immunoglobulin G4 (10-proline) (Human Heavy Chain Fc Fragment) Fusion Protein with Tumor Necrosis Factor Receptor-associated Factor TRAF2 (Human C-C Domain Fragment) Fusion Protein with CD252 Antigen (Human Extracellular Domain Fragment), Hexamer | MEDI6383",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0961804","ICOS Ligand, Human","C118943","ICOS ligand (302 aa, ~33 kDa) is encoded by the human ICOSLG gene. This protein is involved in lymphocyte proliferation, costimulation of T-cells and the modulation of B-cell proliferation and differentiation.","ICOS Ligand | B7 Homologue 2 | B7-H2 | B7-Like Protein Gl50 | B7-Related Protein 1 | B7RP-1 | CD275 | CD275 Antigen | Transmembrane Protein B7-H2 | Transmembrane Protein B7-H2 ICOS Ligand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889705","LAMTOR5 wt Allele","C118945","Human LAMTOR5 wild-type allele is located in the vicinity of 1p13.3 and is approximately 7 kb in length. This allele, which encodes ragulator complex protein LAMTOR5, is involved in both the inhibition of hepatitis B replication and the regulation of mitogenic signaling pathways.","LAMTOR5 wt Allele | HBXIP | Late Endosomal/Lysosomal Adaptor, MAPK and MTOR Activator 5 wt Allele | MGC71071 | XIP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1431182","Ragulator complex protein LAMTOR5, Human","C118946","Ragulator complex protein LAMTOR5 (91 aa, ~10 kDa) is encoded by the human LAMTOR5 gene. This protein plays a role in both the modulation of mitogenic signaling and the down-regulation of hepatitis B virus replication.","Ragulator Complex Protein LAMTOR5 | HBV X-Interacting Protein | HBX-Interacting Protein | Hepatitis B Virus X Interacting Protein | Hepatitis B Virus X Protein-Interacting Protein | Hepatitis B Virus X-Interacting Protein | Hepatitis B Virus X-Interacting Protein (9.6kD) | Late Endosomal/Lysosomal Adaptor and MAPK and MTOR Activator 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897804","RNA Electroporated CD19CAR-CD3zeta-4-1BB-expressing Autologous T-lymphocytes","C118947","Autologous, genetically engineered T-lymphocytes that have been electroporated with an mRNA encoding for an anti-CD19 chimeric antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv) coupled to the co-stimulatory signaling domain of 4-1BB (CD137) and the zeta chain of the T-cell receptor CD3 complex (CD3-zeta), with potential immunomodulating and antineoplastic activities.  Upon transfusion, the RNA electroporated CD19CAR-CD3zeta-4-1BB-expressing autologous T-lymphocytes attach to cancer cells expressing CD19. This induces selective toxicity against CD19-expressing tumor cells and causes tumor cell lysis. The 4-1BB co-stimulatory molecule signaling domain enhances T-cell activation and signaling after recognition of CD19. CD19 antigen is a B-cell specific cell surface antigen, which is expressed in all B-cell lineage malignancies.","RNA Electroporated CD19CAR-CD3zeta-4-1BB-expressing Autologous T-lymphocytes | RNA Anti-CD19 CAR T Cells | RNA CART19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896871","NTRK/ROS1 inhibitor DS-6051b","C118948","An orally available inhibitor of the receptor tyrosine kinases C-ros oncogene 1 (ROS1) and the neurotrophic tyrosine receptor kinase (NTRK) types 1, 2 and 3, with potential antineoplastic activity. Upon oral administration, taletrectinib binds to and inhibits ROS1 and the NTRK family members. This inhibition leads to a disruption of ROS1- and NTRK-mediated signaling and eventually inhibits the growth of tumor cells that are overexpressing ROS1 and/or NTRKs. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells. NTRK mutations or rearrangements play a key role in cancer progression.","Taletrectinib | AB 106 | AB-106 | AB106 | DS-6051A | DS-6051b | TALETRECTINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897252","Umbilical Cord Blood-derived Natural Killer Cells","C118949","A population of allogeneic, cytokine-differentiated, highly lytic natural killer (NK) cells derived from CD34+ cells isolated from human umbilical cord blood (UCB) with potential cytotoxic activity. CD34+ hematopoietic stem cells (HSC) are isolated from human UCB mononuclear cells, differentiated into mature, highly lytic, CD3- CD56+ NK cells, by a specific combination of cytokines that includes stem cell factor (SCF), fms-related tyrosine kinase 3 ligand (Flt3-L), interleukin-15 (IL-15) and insulin-like growth factor-1 (IGF-1), and expanded ex vivo. Upon administration, the UCB-derived NK cells may lyse cancer cells.","Umbilical Cord Blood-derived Natural Killer Cells | Cord Blood NK Cells | Umbilical Cord Blood-derived NK Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890231","FGF13 wt Allele","C118514","Human FGF13 wild-type allele is located in the vicinity of Xq26.3 and is approximately 591 kb in length. This allele, which encodes fibroblast growth factor 13 protein, is involved in microtubule polymerization, neural development and neuronal migration. Deletion of the region of the X chromosome where the gene is located is associated with Borjeson-Forssman-Lehmann syndrome.","FGF13 wt Allele | FGF-13 | FGF2 | FHF-2 | FHF2 | Fibroblast Growth Factor 13 wt Allele | Fibroblast Growth Factor Homologous Factor 2 Gene | RP6-27P15.3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1313752","Fibroblast Growth Factor 13, Human","C118515","Fibroblast growth factor 13 (245 aa, ~28 kDa) is encoded by the human FGF13 gene. This protein plays a role in the regulation of both the development of the nervous system and microtubule polymerization.","Fibroblast Growth Factor 13 | FGF-13 | FGF13 | FHF-2 | Fibroblast Growth Factor Homologous Factor 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029184","Orbital Fracture","C118744","A break in the orbital bone.","Orbital Fracture | ",,,,,,,,,,,,,,,"4320022","Fracture of orbit",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0302497","Retrobulbar Hemorrhage","C118745","Bleeding in the orbital cavity that results in compression of orbital structures, resulting in ischemia of the optic nerve, and possible loss of vision.","Retrobulbar Hemorrhage | ",,,,,,,,,,,,,,,"4110661","Retrobulbar hemorrhage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898098","Open Globe Injury","C118748","A full thickness wound of the eyewall (sclera and cornea). (Birmingham Eye Trauma Terminology System (BETTS))","Open Globe Injury | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049208","Infectious Keratitis","C118749","Inflammation of the cornea secondary to an infectious process.","Infectious Keratitis | Infective Keratitis",,,,,,,,,,,,,,,"37116563","Keratitis caused by infection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0155078","Photokeratitis","C118750","Injury to the cornea secondary to ultraviolet light.","Photokeratitis | Ultraviolet Keratitis",,,,,,,,,,,,,,,"375258","Photokeratitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1608436","Orbital Muscle Entrapment","C118752","The binding of one or more ocular muscles by orbital bone pieces, resulting in decreased eye mobility.","Orbital Muscle Entrapment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1405500","Uveal Prolapse","C118754","The protrusion of uveal tissue through an opening in the sclera.","Uveal Prolapse | ",,,,,,,,,,,,,,,"4216450","Uveal prolapse",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0271055","Rhegmatogenous Retinal Detachment","C118755","Retinal detachment secondary to retinal tear or break.","Rhegmatogenous Retinal Detachment | ",,,,,,,,,,,,,,,"4055484","Rhegmatogenous retinal detachment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0154822","Serous Retinal Detachment","C118756","Retinal detachment secondary to fluid accumulation under the neurosensory retina without a retinal tear or break.","Serous Retinal Detachment | ",,,,,,,,,,,,,,,"374640","Serous retinal detachment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1384600","Systemic Juvenile Idiopathic Arthritis","C119031","A category of juvenile idiopathic arthritis defined by the presence of arthritis and high fevers, and accompanied by at least 2 of the following systemic features: lymphadenopathy, organomegaly, rash, or serositis. Macrophage activation syndrome is a well known complication.","Systemic Juvenile Idiopathic Arthritis | Systemic Onset Juvenile Idiopathic Arthritis | sJIA",,,,,,,,,,,,,,,"4116447","Systemic onset juvenile chronic arthritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898105","Oligoarticular Juvenile Idiopathic Arthritis","C119032","A category of juvenile idiopathic arthritis defined by the presence of arthritis affecting between one and four separate joints during the first six months of disease.","Oligoarticular Juvenile Idiopathic Arthritis | Oligoarticular JIA | Pauciarticular JIA | Pauciarticular Juvenile Idiopathic Arthritis",,,,,,,,,,,,,,,"4132811","Juvenile idiopathic arthritis, oligoarthritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3890733","Polyarticular Juvenile Idiopathic Arthritis, Rheumatoid Factor Positive","C119034","A category of juvenile idiopathic arthritis defined by the presence of arthritis affecting five or more separate joints during the first six months of disease, with positive serologic testing for rheumatoid factor.","Polyarticular Juvenile Idiopathic Arthritis, Rheumatoid Factor Positive | Polyarticular JIA, RF+ | Polyarticular Juvenile Idiopathic Arthritis, RF+",,,,,,,,,,,,,,,"4132809","Juvenile seropositive polyarthritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1444845","Undifferentiated Juvenile Idiopathic Arthritis","C119035","A category of juvenile idiopathic arthritis that does not fulfill any single category or has criteria for more than one category.","Undifferentiated Juvenile Idiopathic Arthritis | Undifferentiated JIA",,,,,,,,,,,,,,,"4257972","Juvenile idiopathic arthritis, undifferentiated arthritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899280","Early Localized Lyme Disease","C119036","An early stage of Lyme disease that may present within 3-30 days after a tick bite with a red, concentrically-expanding rash (erythema migrans), fatigue, chills, fever, headache, muscle and joint aches, and swollen lymph nodes.","Early Localized Lyme Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899282","Early Disseminated Lyme Disease","C119037","An early stage of Lyme disease that may present days to weeks after a tick bite with relapsing signs of a red, concentrically-expanding rash (erythema migrans), facial palsy, meningismus, neuralgia, heart palpitations, and dizziness.","Early Disseminated Lyme Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898623","Late Disseminated Lyme Disease","C119038","A late stage of Lyme disease that may present in untreated patients months to years after a tick bite manifested with intermittent bouts of arthralgia, arthritis and neurologic complaints.","Late Disseminated Lyme Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890422","Post-Treatment Lyme Disease Syndrome","C119039","A constellation of symptoms lasting months to years reported by some Lyme disease patients who had undergone previous antibiotic therapy.","Post-Treatment Lyme Disease Syndrome | Chronic Lyme Disease | PTLDS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1444842","Persistent Oligoarticular Juvenile Idiopathic Arthritis","C119040","Oligoarticular juvenile idiopathic arthritis that never involves more than four separate joints after six months.","Persistent Oligoarticular Juvenile Idiopathic Arthritis | Persistent Oligoarticular JIA",,,,,,,,,,,,,,,"4132812","Juvenile idiopathic arthritis, persistent oligoarthritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1444843","Extended Oligoarticular Juvenile Idiopathic Arthritis","C119041","Oligoarticular juvenile idiopathic arthritis that eventually involves more than four separate joints.","Extended Oligoarticular Juvenile Idiopathic Arthritis | Extended Oligoarticular JIA",,,,,,,,,,,,,,,"4261027","Juvenile idiopathic arthritis, extended oligoarthritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0410422","Chronic Recurrent Multifocal Osteomyelitis","C119042","An autoinflammatory disease characterized by sterile bone lesions which are multifocal and/or recurrent.","Chronic Recurrent Multifocal Osteomyelitis | CRMO | NBO | Non-bacterial Osteomyelitis",,,,,,,,,,,,,,,"36713754","Chronic symmetric plasma cell osteomyelitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897034","NALP12-Associated Hereditary Periodic Fever Syndrome","C119043","An autoinflammatory disease caused by mutations in the NLRP12 gene. It is characterized by periodic fevers beginning in the first year of life that are triggered by cold exposure. Episodes occur more than once per month.","NALP12-Associated Hereditary Periodic Fever Syndrome | NLRP12-Associated Hereditary Periodic Fever Syndrome",,,,,,,,,,,,,,,"37204482","NLRP12-associated hereditary periodic fever syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3890176","Psoriatic Juvenile Idiopathic Arthritis","C119044","A category of juvenile idiopathic arthritis defined by the presence of arthritis with a personal or family history of psoriasis, and features such as dactylitis and nail dystrophy.","Psoriatic Juvenile Idiopathic Arthritis | Psoriatic JIA | psJIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009405","Hereditary Nonpolyposis Colorectal Cancer Syndrome","C120083","An inherited syndrome characterized by the development of several cancers, particularly colon and rectal cancers.  It includes Lynch syndrome which is associated with germline mutations in DNA mismatch-repair genes and familial colorectal cancer type X which is characterized by the absence of germline mutations in DNA mismatch-repair genes.","Hereditary Nonpolyposis Colorectal Cancer Syndrome | Familial Nonpolyposis Colorectal Cancer Syndrome | HNPCC | Hereditary Non-polyposis Colon Cancer | Hereditary Nonpolyposis Colorectal Cancer | Hereditary Nonpolyposis Colorectal Cancer (HNPCC) | hereditary nonpolyposis colon cancer",,,,,,,,,,,,,,,"4198567","HNPCC - hereditary nonpolyposis colon cancer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3896578","Hereditary Colorectal Cancer Type X","C120084","Hereditary nonpolyposis colorectal cancer syndrome characterized by the absence of germline mutations in DNA mismatch-repair genes.","Hereditary Colorectal Cancer Type X | FCCTX | Familial Colorectal Cancer Type X | Familial Colorectal Cancer Type X",,,,,,,,,,,,,,,"37162740","Familial colorectal cancer type X",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3890724","SDC3 wt Allele","C118951","Human SDC3 wild-type allele is located in the vicinity of 1p35.2 and is approximately 39 kb in length. This allele, which encodes syndecan-3 protein, plays a role in both the biosynthesis and catabolism of glycosaminoglycans. Single-nucleotide polymorphisms in the gene are associated with obesity in some ethnic groups.","SDC3 wt Allele | KIAA0468 | SDCN | SYND3 | Syndecan 3 (N-Syndecan) Gene | Syndecan 3 wt Allele | Syndecan, Neural Type Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1608836","Human Syndecan-3","C118952","Syndecan-3 (442 aa, ~45 kDa) is encoded by the human SDC3 gene. This protein is involved in glycosaminoglycan metabolism.","Syndecan-3 | N-Syndecan | SDC3 | SYND3 | Syndecan Neural Type | Syndecan Proteoglycan 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897974","Pediatric Adverse Events Terminology","C118464","Terminology developed by a collaborative effort of the National Cancer Institute's Enterprise Vocabulary Services, the National Institute of Child Health and Human Development, and an international group of clinicians and informaticists to support the reporting of adverse events in the pediatric population.","Pediatric Adverse Events Terminology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897949","Perinatal Terminology","C118466","Terminology developed by a collaborative effort of the National Cancer Institute's Enterprise Vocabulary Services, the National Institute of Child Health and Human Development, and an international group of clinicians and informaticists to support the reporting of events in the perinatal population.","Perinatal Terminology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897973","Pediatric Endocrinology Terminology","C118467","Terminology developed by a collaborative effort of the National Cancer Institute's Enterprise Vocabulary Services, the National Institute of Child Health and Human Development, and an international group of clinicians and informaticists to support the reporting of events in the pediatric population that are related to endocrine disorders.","Pediatric Endocrinology Terminology | Pediatric Endocrine Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897971","Pediatric Rheumatology Terminology","C118468","Terminology developed by a collaborative effort of the National Cancer Institute's Enterprise Vocabulary Services, the National Institute of Child Health and Human Development, and an international group of clinicians and informaticists to support the reporting of events observed in clinical care and research in children and adolescents seen by experts in diseases of joints, muscles, and bones.","Pediatric Rheumatology Terminology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899159","Failure of Catch-Up Growth","C118470","Failure to achieve a linear growth rate sufficient to restore height to within the normative range for the reference population.","Failure of Catch-Up Growth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3809742","Abnormal vision","C118760","Disturbance of eyesight.","Abnormal Vision | Vision abnormalities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015300","Exophthalmos","C118763","The anterior displacement of the eye within the orbit, giving a bulging appearance.","Exophthalmos | ",,,,,,,,,,,,,,,"436700","Exophthalmos",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3280425","Amblyopia","C118764","Decreased vision that results from abnormal visual development.","Amblyopia | Lazy Eye",,,,,,,,,,,,,,,"376981","Amblyopia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4231606","Band Keratopathy","C118765","The deposition of calcium on the cornea, resulting in pain and decreased visual acuity.","Band Keratopathy | ",,,,,,,,,,,,,,,"436695","Band-shaped keratopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3896652","L-4-chlorokynurenine","C118314","An orally bioavailable, blood brain barrier (BBB) penetrating, chlorinated analog of the endogenous neuromodulator kynurenic acid and prodrug of 7-chlorokynurenic acid (7-Cl-KYNA), a N-methyl-D-aspartate receptor (NMDA-R) antagonist at the glycine-coagonist (GlyB) site, with potential anti-hyperalgesic, neuroprotective and anti-epileptic activities. Unlike 7-Cl-KYNA, L-4-chlorokynurenine, upon oral administration, crosses the BBB and is enzymatically converted, through transamination, within activated astrocytes located at sites of injury in the central nervous system (CNS) to its active metabolite, 7-Cl-KYNA, which allows for high levels of this active metabolite at these specific sites. In turn, 7-Cl-KYNA selectively binds to and blocks the GlyB site within the NMDA receptors. This inhibits both NMDA-R overstimulation by the excitatory neurotransmitter glutamate and NMDA-R-mediated excitotoxicity, which prevents neuronal damage and induces analgesia. In addition, another metabolite, 4-chloro-3-hydroxyanthranilic acid, inhibits the synthesis of quinolinic acid, an endogenous NMDA receptor agonist, thereby further preventing excitotoxic damage. Compared to conventional NMDA-R antagonists, NMDA-R GlyB-specific antagonists appear to have fewer side effects.","L-4-chlorokynurenine | 4-Cl-KYN | AV-101 | L-4-C1-KYN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3852853","T-type Calcium Channel Blocker ABT-639","C118315","An orally bioavailable, CaV3.2 T-type calcium channel blocker with potential anti-hyperalgesic activity. Upon oral administration, ABT-639 selectively binds to and blocks the CaV3.2 isoform of the low voltage-gated T-type calcium channels located in peripheral sensory neurons. This prevents the influx of calcium ions into the cell upon membrane depolarization. The inhibition of both neuronal hyperexcitability and firing of nociceptive, peripheral sensory neurons induces an anti-nociceptive effect. The expression of the CaV3.2 T-type channels plays a key role in nociceptive and neuropathic pain.","T-type Calcium Channel Blocker ABT-639 | ABT-639 | Benzenesulfonamide, 4-Chloro-2-fluoro-N-(2-fluorophenyl)-5-(((8AR)-hexahydropyrrolo(1,2-A)pyrazin-2(1H)-yl)carbonyl)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3806378","Mucosal Ulcer","C118316","A circumscribed loss of integrity of the mucous membrane.","Mucosal Ulcer | ",,,,,,,,,,,,,,,"442121","Mucosal ulcer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898126","Non-Neoplastic Muscle Disorder","C118317","A non-neoplastic disorder that affects the smooth, skeletal, or cardiac muscles.","Non-Neoplastic Muscle Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899278","Early Rheumatoid Arthritis","C119045","Recent diagnosis of rheumatoid arthritis (usually within one to two years of onset) during which treatment may be more effective and possibly improve the disease course.","Early Rheumatoid Arthritis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036416","Scleritis","C119046","Inflammation of the sclera.","Scleritis | ",,,,,,,,,,,,,,,"434944","Scleritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3890729","PRSS2 wt Allele","C118561","Human PRSS2 wild-type allele is located in the vicinity of 7q34 and is approximately 4 kb in length. This allele, which encodes trypsin-2 protein, plays a role in protein metabolism. This gene may be associated with pancreatitis.","PRSS2 wt Allele | Protease, Serine, 2 (Trypsin 2) wt Allele | Protease, Serine, 2, Preproprotein Gene | TRY2 | TRY8 | TRYP2 | Trypsinogen, Anionic Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0103396","Trypsin-2, Human","C118562","Trypsin-2 (247 aa, ~26 kDa) is encoded by the human PRSS2 gene. This protein is involved in the catabolism of proteins in the small intestine.","Trypsin-2 | Anionic Trypsinogen | EC 3.4.21.4 | PRSS2 | Protease Serine 2 Preproprotein | Serine Protease 2 | Trypsin 2 | Trypsin II | Trypsinogen 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889664","CBR1 wt Allele","C118564","Human CBR1 wild-type allele is located in the vicinity of 21q22.1 and is approximately 3 kb in length. This allele, which encodes carbonyl reductase [NADPH] 1 protein, is involved in the reduction of a wide variety of carbonyl compounds.","CBR1 wt Allele | CBPR1 | CBR | CRN | Carbonyl Reductase 1 wt Allele | SDR21C1 | Short Chain Dehydrogenase/Reductase Family 21C, Member 1 Gene | hCBR1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2604870","Carbonyl Reductase [NADPH] 1, Human","C118565","Carbonyl reductase [NADPH] 1 (277 aa, ~30 kDa) is encoded by the human CBR1 gene. This protein plays a role in the reduction of carbonyl compounds.","Carbonyl Reductase [NADPH] 1 | 15-Hydroxyprostaglandin Dehydrogenase | 15-Hydroxyprostaglandin Dehydrogenase [NADP(+)] | CBR1 | Carbonyl Reductase | Carbonyl Reductase (NADPH) 1 | Carbonyl Reductase 1 | NADPH-Dependent Carbonyl Reductase 1 | Prostaglandin 9-Ketoreductase | Prostaglandin-E(2) 9-Reductase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474095","Biodynamic Imaging","C118566","A technique that uses low-coherence laser light scattering (digital holography) to measure cellular motions inside living tissue. This information can be used to map the effects of a drug or xenobiotic within different zones of a tissue or tumor, allowing for near immediate feedback regarding the efficacy of treatment.","Biodynamic Imaging | BDI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446642","Health Telemonitoring","C118567","The use of video, audio, and other methods of telecommunicating to monitor a patient's health status from a site distant to the patient.","Health Telemonitoring | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474089","Notch Signaling Inhibitor PF-06650808","C118569","No value exists.","Notch Signaling Inhibitor PF-06650808 | PF-06650808",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474086","Antibody-drug Conjugate PF-06664178","C118570","An antibody-drug conjugate (ADC) composed of PF-06478924 (RN926), a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1), site-specifically conjugated via a valine-citrulline cleavable linker with the auristatin-based cytotoxic agent Aur0101 (PF-06380101), with potential antineoplastic activity. Upon administration of anti-TROP-2 ADC PF-06664178, the anti-TROP-2 monoclonal antibody moiety PF-06478924 targets and binds to TROP-2 expressed on tumor cells. Upon binding, internalization and linker cleavage, Aur0101 binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and apoptosis of TROP-2-expressing tumor cells. TROP-2 is a transmembrane protein overexpressed in various tumors. Its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival.","Anti-TROP-2 Antibody-drug Conjugate PF-06664178 | Anti-TROP-2 ADC PF-06664178 | Anti-TROP-2/Aur0101 ADC PF-06664178 | Antibody-drug Conjugate PF-06664178 | PF 06664178 | PF-06664178 | PF06664178 | RN 927C | RN-927C | RN927C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0935781","carboplatin/irinotecan","C11934","A regimen consisting of irinotecan and carboplatin that may be used in the treatment of small cell lung cancer (SCLC) and occult primary adenocarcinomas.","IC Regimen | Carboplatin and Irinotecan | Carboplatin/Irinotecan | IC | Irinotecan-Carboplatin | Irinotecan/Carboplatin | Irinotecan/Carboplatin Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0149256","Mycobacterium tuberculosis Arabinomannan Z-100","C118445","An extract from Mycobacterium tuberculosis (M. tuberculosis) containing the polysaccharide arabinomannan, with potential immunostimulating activity. Upon administration of M. tuberculosis arabinomannan Z-100, this agent may activate the immune system by increasing the expression of various cytokines, such as interferon-gamma (IFNg) and interleukin-12. This inhibits the activity of suppressor T-cells, increases T helper 1 cell (Th1) activity and may restore the balance between Th1/Th2 cells. Additionally, Z-100 may inhibit metastasis and tumor cell proliferation.","Mycobacterium tuberculosis Arabinomannan Z-100 | MYCOBACTERIUM TUBERCULOSIS (OAYAMA STRAIN) LIPOPOLYSACCHARIDE | Z-100",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2607564","Gemigliptin","C118446","An orally bioavailable inhibitor of the serine protease dipeptidyl peptidase 4 (DPP-4), with hypoglycemic and potential renoprotective activities. Upon administration, gemigliptin binds to DPP-4 and inhibits the breakdown of the incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This prolongs incretin activity, increases postprandial insulin secretion from pancreatic beta cells, decreases glucagon secretion, delays gastric emptying and lowers blood glucose levels. In addition, gemigliptin exerts a renoprotective effect, probably through enhanced GLP-1 signaling, may prevent apoptosis and acute kidney injury induced by nephrotoxic agents, and may protect against diabetic nephropathy.","Gemigliptin | 1-((2S)-2-Amino-4-(2,4-bis(trifluoromethyl)-5,8-dihydropyrido(3,4-d)pyrimidin-7(6H)-yl)-4-oxobutyl-5,5-difluoropiperidin-2-one | GEMIGLIPTIN | LC15-0444",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471759","Anti-EphA2 Monoclonal Antibody DS-8895a","C118447","A monoclonal antibody directed against the ephrin receptor A2 (EphA2), with potential antineoplastic activity. Upon administration, anti-EphA2 monoclonal antibody DS-8895a selectively binds to cells expressing the EphA2 receptor. This blocks EphA2 activation and EphA2-mediated signaling. In addition, DS-8895a may activate an immune response against EphA2-expressing tumor cells. The cell-surface receptor EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) that are involved in mammalian development, is overexpressed by a variety of cancer cell types and plays an important role in tumor growth.","Anti-EphA2 Monoclonal Antibody DS-8895a | DS-8895a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897700","Resolved License","C118471","The disciplinary action taken against an active license has been settled and/or removed thus re-instating the permissions previously accorded.","Resolved License | Resolved",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889261","Other License Status","C118472","A disciplinary action has been taken against a license but its status is different from active, suspended, revoked, or resolved.","Other License Status | Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891815","Suppurative Arthritis","C118475","Acute inflammation of one or more joints caused by the presence of pus within the joint cavity.","Suppurative Arthritis | Pyogenic Arthritis",,,,,,,,,,,,,,,"80482","Suppurative arthritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0342382","Growth Hormone Neurosecretory Dysfunction","C118680","Reduced spontaneous secretion of growth hormone with normal range response to growth hormone provocative stimuli.","Growth Hormone Neurosecretory Dysfunction | ",,,,,,,,,,,,,,,"4034982","Growth hormone neurosecretory dysfunction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898814","Idiopathic Isolated Growth Hormone Deficiency","C118682","Insufficient secretion of growth hormone for which no underlying cause can be found.","Idiopathic Isolated Growth Hormone Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898816","Iatrogenic Growth Failure","C118683","Growth failure due to medical intervention.","Iatrogenic Growth Failure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899157","Familial Idiopathic Short Stature","C118688","Idiopathic short stature in a child when either one or both parents is short in stature.","Familial Idiopathic Short Stature | Constitutional Short Stature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1740819","Idiopathic Short Stature","C118689","Height greater than two standard deviations below the mean for the age and sex of the reference population.","Idiopathic Short Stature | ISS",,,,,,,,,,,,,,,"36712855","Idiopathic short stature",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898124","Non-familial Idiopathic Short Stature","C118690","Idiopathic short stature in a child when neither parent is short in stature.","Non-familial Idiopathic Short Stature | Non-Familial Idiopathic Short Stature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889723","ZNRF3 wt Allele","C118320","Human ZNRF3 wild-type allele is located in the vicinity of 22q12.1 and is approximately 174 kb in length. This allele, which encodes E3 ubiquitin-protein ligase ZNRF3 protein, plays a role in the both Wnt pathway modulation and protein modification.","ZNRF3 wt Allele | BK747E2.3 | FLJ22057 | KIAA1133 | Novel C3HC4 Type Zinc Finger (Ring Finger) Gene | RNF203 | Zinc and Ring Finger 3 wt Allele | hCG_40978",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL479813","E3 Ubiquitin-Protein Ligase ZNRF3","C118321","E3 ubiquitin-protein ligase ZNRF3 (936 aa, ~101 kDa) is encoded by the human ZNRF3 gene. This protein is involved in the ubiquitination of Wnt pathway proteins.","E3 Ubiquitin-Protein Ligase ZNRF3 | EC 2.3.2.27 | EC 6.3.2.-, Formerly | RING Finger Protein 203 | Zinc Finger and Ring Finger Protein 3 | Zinc/RING Finger Protein 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412099","ABO Gene","C118322","This gene is involved in blood group determination.","ABO Gene | ABO | ABO Blood Group (Transferase A, Alpha 1-3-N-Acetylgalactosaminyltransferase; Transferase B, Alpha 1-3-Galactosyltransferase) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890216","ABO wt Allele","C118323","Human ABO wild-type allele is located in the vicinity of 9q34.2 and is approximately 2 kb in length. This allele, which encodes histo-blood group ABO system transferase protein, plays a role in blood group determination. Variation of the gene determines whether the protein can catalyze the transfer of carbohydrates to the H antigen to form carbohydrate antigen A or B on the surface of red blood cells.","ABO wt Allele | A3GALNT | A3GALT1 | ABO Blood Group (Transferase A, Alpha 1-3-N-Acetylgalactosaminyltransferase; Transferase B, Alpha 1-3-Galactosyltransferase) wt Allele | GTB | NAGAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0389533","Histo-Blood Group ABO System Transferase","C118324","Histo-blood group ABO system transferase (354 aa, ~41 kDa) is encoded by the human ABO gene. This protein is involved in blood group antigen expression.","Histo-Blood Group ABO System Transferase | A Transferase | ABO A3 Transferase | ABO Glycosyltransferase | ABO Histo-Blood Group Glycosyltransferases | ABO Weak Transfer | B Transferase | B(A) Alpha-1,3-Galactosyltransferase | EC 2.4.1.37 | EC 2.4.1.40 | Fucosylglycoprotein 3-Alpha-Galactosyltransferase | Fucosylglycoprotein Alpha-N-Acetylgalactosaminyltransferase | Glycoprotein-Fucosylgalactoside Alpha-Galactosyltransferase | Glycoprotein-Fucosylgalactoside Alpha-N-Acetylgalactosaminyltransferase | Histo-Blood Group A Transferase | Histo-Blood Group A2 Transferase | Histo-Blood Group B Transferase | NAGAT | Transferase A, Alpha 1-3-N-Acetylgalactosaminyltransferase | Transferase B, Alpha 1-3-Galactosyltransferase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890396","ASPM wt Allele","C118990","Human ASPM wild-type allele is located in the vicinity of 1q31 and is approximately 63 kb in length. This allele, which encodes abnormal spindle-like microcephaly-associated protein, is involved in the regulation of the mitotic spindle. Mutation of the gene is associated with primary microcephaly type 5.","ASPM wt Allele | ASP | ASP, Drosophila, Homolog of Gene | Abnormal Spindle-Like, Microcephaly-Associated Gene | Asp (Abnormal Spindle) Homolog, Microcephaly Associated (Drosophila)wt Allele | Asp (Abnormal Spindle)-Like, Microcephaly Associated (Drosophila) Gene | Calmbp1 | FLJ10517 | FLJ10549 | MCPH5 | Microcephaly, Primary Autosomal Recessive 5 Gene | RP11-32D17.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1171771","Abnormal Spindle-Like Microcephaly-Associated Protein, Human","C118991","Abnormal spindle-like microcephaly-associated protein (3477 aa, ~410 kDa) is encoded by the human ASPM gene. This protein plays a role in the activity of the mitotic spindle.","Abnormal Spindle-Like Microcephaly-Associated Protein | ASPM | Abnormal Spindle Protein Homolog | Asp Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889419","SLC7A6 wt Allele","C118993","Human SLC7A6 wild-type allele is located in the vicinity of 16q22.1 and is approximately 37 kb in length. This allele, which encodes y+L amino acid transporter 2 protein, plays a role in the internalization of dibasic amino acids.","SLC7A6 wt Allele | KIAA0245 | LAT-2 | LAT3 | Solute Carrier Family 7 (Amino Acid Transporter Light Chain, y+L System), Member 6 wt Allele | Solute Carrier Family 7 (Cationic Amino Acid Transporter, y+ System), Member 6 Gene | y(+)LAT2 | y+LAT-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1173147","Y+L Amino Acid Transporter 2, Human","C118994","Y+L amino acid transporter 2 (515 aa, ~57 kDa) is encoded by the human SLC7A6 gene. This protein is involved in dibasic amino acid transport.","Y+L Amino Acid Transporter 2 | Cationic Amino Acid Transporter, y+ System | Solute Carrier Family 7 Member 6 | Y(+)L-Type Amino Acid Transporter 2 | Y+LAT2 | y+LAT-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474084","antibody-drug conjugate ABBV-399","C118571","An antibody-drug conjugate (ADC) composed of telisotuzumab, a monoclonal antibody against the tumor-associated antigen (TAA) and proto-oncogene, c-Met receptor tyrosine kinase (c-Met; MET; hepatocyte growth factor receptor; HGFR) conjugated to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline (vc) peptide linker (vc-MMAE; vedotin), with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of telisotuzumab vedotin targets and binds to c-Met expressed on tumor cells. Upon binding, internalization and enzymatic cleavage, the cytotoxic agent MMAE is released into the cytosol. MMAE binds to tubulin and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. This kills the c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis.","Telisotuzumab Vedotin | ABBV 399 | ABBV-399 | ABT 399 | ABT-399 | ABT-700-VCMMAE | TELISOTUZUMAB VEDOTIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896742","Antibody-drug Conjugate PF-06647263","C118572","No value exists.","Antibody-drug Conjugate PF-06647263 | PF-06647263",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899641","Childhood Small Cell Lung Cancer","C118815","A rare small cell carcinoma of the lung that occurs during childhood.","Childhood Lung Small Cell Carcinoma | Childhood Small Cell Lung Cancer | Childhood Small Cell Lung Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899675","Childhood Bladder Carcinoma","C118816","A rare carcinoma of the bladder that occurs during childhood.","Childhood Bladder Carcinoma | Bladder Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899648","Childhood Paranasal Sinus Carcinoma","C118818","A rare carcinoma of the paranasal sinus that occurs during childhood.","Childhood Paranasal Sinus Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899647","Childhood Parathyroid Gland Carcinoma","C118819","A rare carcinoma of the parathyroid gland that occurs during childhood.","Childhood Parathyroid Gland Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900097","Adult Penile Carcinoma","C118820","A carcinoma of the penis that occurs during adulthood.","Adult Penile Carcinoma | Penile Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899653","Childhood Malignant Penile Neoplasm","C118821","A rare malignant neoplasm of the penis that occurs during childhood.","Childhood Malignant Penile Neoplasm | Malignant Childhood Penile Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL495771","Childhood Adrenal Gland Pheochromocytoma","C118822","A rare pheochromocytoma of the adrenal gland that occurs during childhood.","Childhood Adrenal Gland Pheochromocytoma | Childhood Pheochromocytoma | Pediatric Adrenal Gland Pheochromocytoma | Pediatric Pheochromocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899643","Childhood Rectal Carcinoma","C118823","A rare carcinoma of the rectum that occurs during childhood.","Childhood Rectal Carcinoma | Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899642","Childhood Salivary Gland Carcinoma","C118824","A rare carcinoma of the salivary gland that occurs during childhood.","Childhood Salivary Gland Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897069","Childhood Malignant Small Intestinal Neoplasm","C118826","A rare malignant small intestinal neoplasm that occurs during childhood.","Childhood Malignant Small Intestinal Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899640","Childhood Thyroid Gland Carcinoma","C118827","A rare carcinoma of the thyroid gland that occurs during childhood.","Childhood Thyroid Gland Carcinoma | Childhood Thyroid Carcinoma | Thyroid Gland Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896673","FNMTC","C118829","A papillary or follicular thyroid gland carcinoma with a genetic component that develops within the same family. Current studies suggest that it is inherited in an autosomal dominant pattern. It is often multifocal and bilateral and usually affects younger patients.","Hereditary Nonmedullary Thyroid Gland Carcinoma | FNMTC | Familial Non-medullary Thyroid Gland Carcinoma | Familial Nonmedullary Thyroid Gland Carcinoma | Familial Nonmedullary Thyroid Gland Carcinoma | NSFNMTC | Non-Syndromic Familial Thyroid Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898460","Matricaria recutita Gel","C118448","A gel-based formulation containing an extract of the herb Matricaria chamomilla (M. recutita or German chamomile), which is native to eastern and southern Europe, belongs to the Asteraceae family and is high in flavonoids, with potential anti-inflammatory, skin protective, moisturizing, anti-bacterial, anti-oxidant and calming activities. M. recutita extract contains flavonoids, including apigenin, luteolin and quercetin, as well as coumarins, herniarin, umbelliferone, anthemic acid, anthemidine, tannin and matricarin. Upon topical application of the Matricaria recutita gel, the active ingredients in the chamomile may exert anti-inflammatory, calming and anti-oxidant effects on the skin and may protect the skin against radiotherapy-induced dermatitis.","Matricaria recutita Gel | Chamomilla recutita Gel | German Chamomile Gel | Matricaria chamomilla L. Gel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898459","Matricaria recutita Topical Infusion","C118449","A gel-based formulation containing an extract of the herb Matricaria chamomilla (M. recutita or German chamomile), which is native to eastern and southern Europe, belongs to the Asteraceae family and is high in flavonoids, with potential anti-inflammatory, skin protective, moisturizing, anti-bacterial, anti-oxidant and calming activities. M. recutita extract contains flavonoids, including apigenin, luteolin and quercetin, as well as coumarins, herniarin, umbelliferone, anthemic acid, anthemidine, tannin and matricarin. Upon topical application of the Matricaria recutita infusion, the active ingredients in the chamomile may exert anti-inflammatory, calming and anti-oxidant effects on the skin and may protect the skin against radiotherapy-induced dermatitis.","Matricaria recutita Topical Infusion | Chamomilla recutita Infuse | German Chamomile Infuse | Matricaria chamomilla L. Topical Infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896752","epothilone analog UTD1","C118450","A genetically engineered epothilone analog with potential antineoplastic activity. Upon administration, utidelone binds to tubulin, induces microtubule polymerization and stabilizes microtubules against depolymerization, which may result in the inhibition of cell division, the induction of G2/M arrest, and apoptosis. Compared to first-generation epothilones, this agent exhibits greater safety and enhanced activity against certain multidrug-resistant (MDR) tumors.","Utidelone | Epothilone Analog UTD1 | Epothilone Analog UTD1 | UTD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900146","AUDIT - How Often Last Year You Feel Guilt or Remorse After Drinking","C119114","Alcohol Use Disorder Identification Test Self-Report Version (AUDIT) How often during the last year have you had a feeling of guilt or remorse after drinking?","AUDIT - How Often Last Year You Feel Guilt or Remorse After Drinking | ADT01-Feeling of Guilt or Remorse | ADT0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900144","AUDIT - How Often Last Year You Unable to Remember What Happened the Night Before","C119115","Alcohol Use Disorder Identification Test Self-Report Version (AUDIT) How often during the last year have you been unable to remember what happened the night before because of your drinking?","AUDIT - How Often Last Year You Unable to Remember What Happened the Night Before | ADT01-Unable to Remember What Happened | ADT0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900143","AUDIT - Injured Because of Drinking","C119116","Alcohol Use Disorder Identification Test Self-Report Version (AUDIT) Have you or someone else been injured because of your drinking?","AUDIT - Injured Because of Drinking | ADT01-Injured Because of Your Drinking | ADT0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900152","AUDIT - Concerned About Your Drinking","C119117","Alcohol Use Disorder Identification Test Self-Report Version (AUDIT) Has a relative, friend, doctor, or other health care worker been concerned about your drinking or suggested you cut down?","AUDIT - Concerned About Your Drinking | ADT01-Suggested to Cut Down | ADT0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897031","AUDIT - Total","C119118","Alcohol Use Disorder Identification Test Self-Report Version (AUDIT) Total.","AUDIT - Total | ADT01-Total | ADT0111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3279055","Tall Stature","C118691","Height greater than two standard deviations above the mean of the appropriate reference population for the age and sex of the individual.","Tall Stature | ",,,,,,,,,,,,,,,"4086989","Tall stature",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898813","Idiopathic Tall Stature","C118692","Tall stature for which no underlying cause can be found.","Idiopathic Tall Stature | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899156","Familial Idiopathic Tall Stature","C118693","Idiopathic tall stature in a child when either one or both parents is tall in stature.","Familial Idiopathic Tall Stature | Constitutional Tall Stature | Familial Tall Stature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897108","Non-familial Idiopathic Tall Stature","C118695","Idiopathic tall stature in a child when neither parent is tall in stature.","Non-familial Idiopathic Tall Stature | Non-Familial Idiopathic Tall Stature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899171","FGFR3 Chondrodysplasia","C118696","A constellation of disorders involving mutations of the FGFR3 gene, which result in abnormal growth of bone and cartilage; this includes achondroplasia and hypochondroplasia.","FGFR3 Chondrodysplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897563","Small for Gestational Age for Weight","C118698","Birth weight greater than two standard deviations below the mean for the reference population of the same sex and gestational age.","Small for Gestational Age for Weight | SGA for Weight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474135","OxPhos Inhibitor VLX600","C118283","A lipophilic cation-based triazinoindolyl-hydrazone compound and mitochondrial oxidative phosphorylation (OxPhos) inhibitor, with potential antineoplastic activity. Upon infusion, in normal cells and proliferating tumor cells where glucose is readily available, inhibition of OxPhos by VLX600 induces a hypoxia-inducible factor 1-alpha (HIF-1alpha)-dependent shift to, and an increase in glycolysis. Glycolysis alone does not produce enough energy to support the growth of tumor cells in this environment, and the induction of autophagy occurs. In the metabolically compromised tumor microenvironment, the availability of oxygen and glucose is limited due to poor vascularization and perfusion of tumor micro-areas. Tumor cells growing in this environment are thus unable to compensate for decreased mitochondrial function by increasing glycolysis. This leads to nutrient depletion, decreased energy production, induction of autophagy, tumor cell death and an inhibition of cell proliferation in quiescent tumor cells. Mitochondrial OxPhos, which is hyperactivated in cancer cells, plays a key role in the promotion of cancer cell proliferation.","OxPhos Inhibitor VLX600 | 1-(2-Pyridinyl)ethanone(6-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)hydrazone | VLX-600",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474136","cirmtuzumab","C118284","A humanized monoclonal antibody against the extracellular domain of the human receptor tyrosine kinase-like orphan receptor 1 (ROR1), with potential antineoplastic activity. Upon administration, zilovertamab binds to ROR1 and blocks ROR1-mediated signaling. This prevents tumor cell proliferation in cancer cells overexpressing ROR1. ROR1, also known as neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), is normally expressed during embryogenesis.  It is overexpressed in certain leukemias and solid tumors, but minimally expressed in healthy cells.","Zilovertamab | Cirmtuzumab | UC-961 | ZILOVERTAMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474138","FASN inhibitor TVB-2640","C118285","An orally bioavailable fatty acid synthase (FASN) inhibitor, with potential antineoplastic activity. Upon administration, denifanstat binds to and blocks FASN, which prevents the synthesis of palmitate needed for tumor cell growth and survival. This leads to a reduction in cell signaling, an induction of tumor cell apoptosis and the inhibition of cell proliferation in susceptible tumor cells. FASN, an enzyme responsible for the de novo synthesis of palmitic acid, is overexpressed in tumor cells and plays a key role in tumor metabolism, lipid signaling, tumor cell survival and drug resistance; tumor cells are dependent on increased fatty acid production for their enhanced metabolic needs and rapid growth.","Denifanstat | ASC 40 | ASC-40 | ASC40 | DENIFANSTAT | FASN Inhibitor TVB-2640 | TVB 2640 | TVB-2640 | TVB2640",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889157","SLC7A7 wt Allele","C118996","Human SLC7A7 wild-type allele is located in the vicinity of 14q11.2 and is approximately 57 kb in length. This allele, which encodes y+L amino acid transporter 1 protein, is involved in cationic amino acid transport. Mutation of the gene is associated with lysinuric protein intolerance.","SLC7A7 wt Allele | LAT3 | LPI | MOP-2 | Solute Carrier Family 7 (Amino Acid Transporter Light Chain, y+L System), Member 7 wt Allele | Solute Carrier Family 7 (Cationic Amino Acid Transporter, y+ System), Member 7 Gene | Y+LAT1 | y(+)LAT1 | y+LAT-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL480871","Y+L Amino Acid Transporter 1","C118997","Y+L amino acid transporter 1 (511 aa, ~56 kDa) is encoded by the human SLC7A7 gene. This protein plays a role in the localization of cationic amino acids.","Y+L Amino Acid Transporter 1 | MOP-2 | Monocyte Amino Acid Permease 2 | Solute Carrier Family 7 Member 7 | Y(+)L-Type Amino Acid Transporter 1 | Y+LAT1 | y+LAT-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891077","SLC43A2 wt Allele","C118999","Human SLC43A2 wild-type allele is located in the vicinity of 17p13.3 and is approximately 60 kb in length. This allele, which encodes large neutral amino acids transporter small subunit 4 protein, plays a role in neutral amino acid transport.","SLC43A2 wt Allele | LAT4 | MGC34680 | PP7664 | Solute Carrier Family 43 (Amino Acid System L Transporter), Member 2 wt Allele | Solute Carrier Family 43 (L-Type Amino Acid Transporter), Member 2 Gene | Solute Carrier Family 43, Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0935719","capecitabine/irinotecan/oxaliplatin","C11899","A regimen consisting of capecitabine, oxaliplatin, and irinotecan that may be used for the treatment of colorectal cancer.","COI Regimen | COI | Capecitabine-Oxaliplatin-Irinotecan | Capecitabine/Irinotecan/Oxaliplatin | Capecitabine/Oxaliplatin/Irinotecan | Capecitabine/Oxaliplatin/Irinotecan Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0070302","Pentamethylmelamine","C1189","A principal metabolite of hexamethylmelamine with antineoplastic activity.  Pentamethylmelamine alkylates DNA and other macromolecules and forms DNA intrastrand and DNA-protein crosslinks, thereby preventing DNA replication. (NCI04)","Pentamethylmelamine | 1,3,5-Triazine-2,4,6-triamine, N,N,N',N', N''-pentamethyl-, monohydrochloride (9CI) | Melamine | Melamine, N2,N2,N4,N4,N6-pentamethyl-, monohydrochloride | N,N,N',N',N'-pentamethyl-1,3,5-triazine | PENTAMETHYLMELAMINE | PMM | Pentamethylmelamine MonoHCl | Pentamethylmelamine Monohydrochloride | Pentamethylmelamine monoHCl | Pentamethylmelamine monohydrochloride | melamine, N2,N2,N4,N4,N6-pentamethyl-, monohydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889133","BPIFA1 wt Allele","C118517","Human BPIFA1 wild-type allele is located in the vicinity of 20q11.21 and is approximately 7 kb in length. This allele, which encodes BPI fold-containing family A member 1 protein, may play a role in anti-bacterial defense in the upper airway. This gene may be associated with micrometastasis in non-small-cell lung carcinoma.","BPIFA1 wt Allele | BPI Fold Containing Family A, Member 1 wt Allele | BPI Fold-Containing, Family A, Member 1 Gene | LUNX | NASG | PLUNC | Palate, Lung and Nasal Epithelium Associated Gene | Palate, Lung and Nasal Epithelium Carcinoma Associated Gene | SPLUNC1 | SPURT | UNQ787/PRO1606 | bA49G10.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL479937","BPI Fold-Containing Family A Member 1","C118518","BPI fold-containing family A member 1 (256 aa, ~27 kDa) is encoded by the human BPIFA1 gene. This protein may be involved in innate immunity in the upper respiratory tract.","BPI Fold-Containing Family A Member 1 | Ligand-Binding Protein RYA3 | Lung-Specific Protein X | Nasopharyngeal Carcinoma-Related Protein | Palate Lung and Nasal Epithelium Clone Protein | Palate, Lung and Nasal Epithelium Carcinoma-Associated Protein | Protein Plunc | SPLUNC1 | Secretory Protein in Upper Respiratory Tracts | Short PLUNC1 | Tracheal Epithelium Enriched Protein | Tracheal Epithelium-Enriched Protein | Von Ebner Protein Hl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890606","EGR3 wt Allele","C118520","Human EGR3 wild-type allele is located within 8p23-p21 and is approximately 6 kb in length. This allele, which encodes early growth response protein 3, is involved in biological rhythms, muscle development, and the growth and migration of endothelial cells.","EGR3 wt Allele | EGR-3 | Early Growth Response 3 wt Allele | PILOT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896651","Leuprolide Mesylate Injectable Suspension","C118363","A depot suspension for injection composed of the mesylate salt of leuprolide, a synthetic, long-acting nonapeptide analog of the endogenous hormone gonadotropin-releasing hormone (GnRH), with potential antineoplastic activity. Upon subcutaneous injection of the depot suspension, leuprolide binds to and activates the gonadotropin-releasing hormone receptor (GnRHR). The continuous stimulation of GnRHR by leuprolide results in both the desensitization of pituitary GnRHR and the inhibition of pituitary secretion of the gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH). In males, this results in a significant decline in testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.","Leuprolide Mesylate Injectable Suspension | LMIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897146","hVEGF26-104/RFASE Peptide Vaccine","C118364","A therapeutic cancer vaccine containing a truncated, synthetic peptide mimic of the human angiogenic activator vascular endothelial growth factor (VEGF), consisting of 79 amino acids (amino acids 26-104 of VEGF), and emulsified in the immunoadjuvant RFASE, with potential immunostimulatory and antitumor activities. Upon intramuscular vaccination, the hVEGF26-104 moiety of hVEGF26-104/RFASE acts as an antigen and induces an immune response against VEGF, which results in anti-VEGF antibody binding to and neutralization of endogenous VEGF. This prevents the binding of endogenous VEGF to the VEGF receptor (VEGFR) and blocks VEGFR-mediated endothelial cell signaling, resulting in an inhibition of both angiogenesis and tumor cell proliferation. VEGF plays a key role in angiogenesis, tumor cell proliferation and invasion. RFASE, which belongs to the group of sulpholipopolysaccharides (SLPs), is a synthetic polysaccharide covalently coupled to lipid groups and sulphate groups, and is able to induce a strong humoral immune response upon antigen administration.","hVEGF26-104/RFASE Peptide Vaccine | hVEGF26-104/RFASE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899040","Ganoderma lucidum Spores Powder Capsule","C118365","An orally available powder-based nutritional supplement containing the spores of the mushroom Ganoderma lucidum (Ganoderma l.), a traditional Chinese medicine, with potential protective, sedative, anti-oxidant, immunomodulating, and antineoplastic activities. The spores contain various bioactive components including polysaccharides, triterpenoids, peptidoglycans, amino acids, fatty acids, vitamins, and minerals. Upon oral administration of the Ganoderma lucidum spores powder capsule, the active ingredients may modulate the immune system, may activate dendritic cells, natural killer cells, and macrophages and may modulate the production of certain cytokines, such as tumor necrosis factor-alpha (TNFa), interleukin (IL) 1-beta (IL-1b), IL-2, IL-6 and IL-8. This supplement may improve cancer-related fatigue and may be used as a sleep aid; it may also have a beneficial effect on the heart, lung, liver, pancreas, kidney, and the central nervous system.","Ganoderma lucidum Spores Powder Capsule | Ganoderma l. Spores Powder Capsule | Lingzhi Spores Powder Capsule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900140","AUDIT-C - How Often Have Alcohol Drink","C119119","Alcohol Use Disorder Identification Test Alcohol Consumption Questions (AUDIT-C) How often do you have a drink containing alcohol?","AUDIT-C - How Often Have Alcohol Drink | ADTC01-How Often Drink Alcohol | ADTC0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900141","AUDIT-C - How Many Alcohol Drinks on a Typical Day","C119120","Alcohol Use Disorder Identification Test Alcohol Consumption Questions (AUDIT-C) How many standard drinks containing alcohol do you have on a typical day?","AUDIT-C - How Many Alcohol Drinks on a Typical Day | ADTC01-Alcohol Drinks on a Typical Day | ADTC0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900139","AUDIT-C - How Often Have Six or More Drinks","C119121","Alcohol Use Disorder Identification Test Alcohol Consumption Questions (AUDIT-C) How often do you have six or more drinks on one occasion?","AUDIT-C - How Often Have Six or More Drinks | ADTC01-Six or More Drinks One Occasion | ADTC0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899821","CCQ 24 Hour Version - Short of Breath Doing Physical Activity","C119123","Clinical COPD Questionnaire 24 Hour Version (CCQ 24 Hour Version) On average, during the past 24 hours, how often did you feel: Short of breath while doing physical activities?","CCQ 24 Hour Version - Short of Breath Doing Physical Activity | CCQ01-Short of Breath Physical Activity | CCQ0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899825","CCQ 24 Hour Version - Concern About Breathing Get Worse","C119124","Clinical COPD Questionnaire 24 Hour Version (CCQ 24 Hour Version) On average, during the past 24 hours, how often did you feel: Concerned about getting a cold or your breathing getting worse?","CCQ 24 Hour Version - Concern About Breathing Get Worse | CCQ01-Concern About Breathing Get Worse | CCQ0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899824","CCQ 24 Hour Version - Depressed Because of Breathing Problem","C119125","Clinical COPD Questionnaire 24 Hour Version (CCQ 24 Hour Version) On average, during the past 24 hours, how often did you feel: Depressed because of your breathing problems?","CCQ 24 Hour Version - Depressed Because of Breathing Problem | CCQ01-Depressed for Breathing Problem | CCQ0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899823","CCQ 24 Hour Version - Did You Cough","C119126","Clinical COPD Questionnaire 24 Hour Version (CCQ 24 Hour Version) In general, during the past 24 hours, how much of the time: Did you cough?","CCQ 24 Hour Version - Did You Cough | CCQ01-Cough | CCQ0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899822","CCQ 24 Hour Version - Produce Sputum or Phlegm","C119127","Clinical COPD Questionnaire 24 Hour Version (CCQ 24 Hour Version) In general, during the past 24 hours, how much of the time: Did you produce sputum or phlegm?","CCQ 24 Hour Version - Produce Sputum or Phlegm | CCQ01-Produce Sputum or Phlegm | CCQ0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899826","CCQ 24 Hour Version - Breathing Problems Limit Strenuous Activity","C119128","Clinical COPD Questionnaire 24 Hour Version (CCQ 24 Hour Version) On average, during the past 24 hours, how limited were you in these activities because of your breathing problems: Strenuous physical activities?","CCQ 24 Hour Version - Breathing Problems Limit Strenuous Activity | CCQ01-Breathing Limit Strenuous Activity | CCQ0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0266526","Norrie Syndrome","C118634","A rare, X-linked recessive inherited syndrome caused by mutations in the NDP gene. It is characterized by developmental retinal abnormalities that result in blindness in male infants at birth or soon after birth. Additional manifestations include progressive hearing loss and developmental motor skills delays.","Norrie Syndrome | ",,,,,,,,,,,,,,,"4035184","Atrophia bulborum hereditaria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0410538","Pseudoachondroplasia","C118635","A rare, autosomal dominant inherited disorder caused by mutations in the COMP gene. It is characterized by short stature, short arms and legs, waddling walk, osteoarthritis, and limited range of motion at the elbows and hips.","Pseudoachondroplasia | ",,,,,,,,,,,,,,,"4331587","Pseudoachondroplastic spondyloepiphyseal dysplasia syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1861456","Stiff Skin Syndrome","C118636","A rare, autosomal dominant inherited syndrome caused by mutations in the FBN1 gene. It is characterized by hard and thickened skin, usually over the entire body, and limited joint motility.","Stiff Skin Syndrome | ",,,,,,,,,,,,,,,"35622942","Stiff skin syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3896891","p97 Inhibitor CB-5083","C118287","An orally bioavailable inhibitor of valosin-containing protein (VCP) p97, with potential antineoplastic activity. Upon oral administration, CB-5083 specifically binds to and inhibits the activity of p97. This prevents ubiquitin-dependent protein degradation and causes cellular accumulation of poly-ubiquitinated proteins. The inhibition of endoplasmic reticulum (ER)-associated protein degradation activates the ER-dependent stress response pathway, and leads to both an induction of apoptosis and inhibition of cell proliferation in susceptible tumor cells. p97, a type II AAA ATPase, plays a key role in cellular protein homeostasis. Its overexpression in many tumor cell types is associated with increased tumor cell proliferation and survival.","p97 Inhibitor CB-5083 | CB-5083",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474140","Oral Azacitidine","C118288","An orally bioavailable formulation of azacitidine, a pyrimidine nucleoside analogue of cytidine, with antineoplastic activity. Upon oral administration, azacitidine is taken up by cells and metabolized to 5-azadeoxycitidine triphosphate. The incorporation of 5-azadeoxycitidine triphosphate into DNA reversibly inhibits DNA methyltransferase, and blocks DNA methylation. Hypomethylation of DNA by azacitidine may re-activate tumor suppressor genes previously silenced by hypermethylation, resulting in an antitumor effect. In addition, the incorporation of 5-azacitidine triphosphate into RNA disrupts normal RNA function and impairs tRNA (cytosine-5)-methyltransferase activity, resulting in an inhibition of RNA and protein synthesis.","Oral Azacitidine | Azacitidine Oral | Azacitidine oral | CC 486 | CC-486 | CC486 | Onureg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896908","EGFR inhibitor AZD3759","C118289","An orally available inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration,  zorifertinib binds to and inhibits the activity of EGFR as well as certain mutant forms of EGFR. This prevents EGFR-mediated signaling, and may lead to both induction of cell death and inhibition of tumor growth in EGFR-overexpressing cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","Zorifertinib | AZD3759 | ZORIFERTINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896857","HER2-targeting Antibody Fc Fragment FS102","C118953","A proprietary, antibody fragment composed of a constant (Fc) region that is engineered to bind to the tumor-associated antigen human epidermal growth factor receptor-2 (HER2), with potential antineoplastic activity. HER2-targeted antibody Fc fragment FS102 specifically binds to its HER2 epitope, and causes downregulation of HER2-mediated signaling. This leads to tumor cell apoptosis. HER2, a member of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (EGFR) superfamily, is overexpressed on the cell surface of various solid tumors.","HER2-targeting Antibody Fc Fragment FS102 | Anti-HER2 FCAB FS102 | BMS-986186 | FS-102 | FS102 | Fcab FS102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896577","LMP1/BARF1/EBNA1-specific Cytotoxic T-lymphocytes","C118956","A preparation of allogeneic cytotoxic T-lymphocytes (CTL) made specifically reactive to three Epstein-Barr virus (EBV) proteins, latent membrane protein (LMP) 1, BamH1-A rightward frame-1 (BARF1) and EBV nuclear antigen 1 (EBNA1), with potential antineoplastic activity. Administration of LMP1/BARF1/ EBNA1-specific CTLs to patients with LMP1/BARF1/EBNA1-positive tumors may result in a specific CTL response against the tumor cells expressing these antigens, which can result in both cell lysis and the inhibition of tumor cell proliferation. LMP1, BARF1 and EBNA1 are expressed in various, EBV-associated malignancies, including nasopharyngeal cancer and EBV-positive Hodgkin lymphoma.","LMP1/BARF1/EBNA1-specific Cytotoxic T-lymphocytes | LMP1/BARF1/ EBNA1-specific CTLs | LMP1/BARF1/EBNA-1 MABEL CTLs | LMP1/BARF1/EBNA-1 Minimum Anticipated Biological Effect Level Cytotoxic T-lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1571614","Early Growth Response Protein 3","C118521","Early growth response protein 3 (387 aa, ~43 kDa) is encoded by the human EGR3 gene. This protein plays a role in the regulation of muscle development, endothelial tube formation and transcription.","Early Growth Response Protein 3 | EGR-3 | Zinc Finger Protein Pilot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889127","CHST15 wt Allele","C118523","Human CHST15 wild-type allele is located in the vicinity of 10q26 and is approximately 86 kb in length. This allele, which encodes carbohydrate sulfotransferase 15 protein, plays a role in the metabolism of chondroitin sulfate.","CHST15 wt Allele | B-Cell RAG-Associated Gene | BRAG | Carbohydrate (N-Acetylgalactosamine 4-Sulfate 6-O) Sulfotransferase 15 wt Allele | GALNAC4S-6ST | GALNAC4S6ST | KIAA0598",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0962401","N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase","C118524","Carbohydrate sulfotransferase 15 (561 aa, ~65 kDa) is encoded by the human CHST15 gene. This protein is involved in chondroitin sulfate metabolism.","Carbohydrate Sulfotransferase 15 | B Cell RAG Associated Protein | B-Cell RAG-Associated Gene Protein | CHST15 | EC 2.8.2.33 | GalNAc4S-6ST | N-Acetylgalactosamine 4-Sulfate 6-O-Sulfotransferase | hBRAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889702","ATPMB","C118526","Human ATP5F1B wild-type allele is located in the vicinity of 12p13.3 and is approximately 8 kb in length. This allele, which encodes ATP synthase subunit beta, mitochondrial protein, is involved in both ATP synthesis and proton transport.","ATP5F1B wt Allele | ATP Synthase F1 Subunit Beta wt Allele | ATP Synthase, H+ Transporting, Mitochondrial F1 Complex, Beta Polypeptide Gene | ATP Synthase, H+ Transporting, Mitochondrial F1 Complex, Beta Subunit Gene | ATP5B | ATP5B wt Allele | ATPMB | ATPSB | HEL-S-271 | Mitochondrial ATP Synthase, Beta Subunit Gene | Mitochondrial ATP Synthetase, Beta Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1669085","ATP Synthase Subunit Beta, Mitochondrial, Human","C118527","ATP synthase subunit beta, mitochondrial (529 aa, ~57 kDa) is encoded by the human ATP5F1B gene. This protein plays a role in ATP synthesis, hydrogen ion exchange and oxidative phosphorylation.","ATP Synthase Subunit Beta, Mitochondrial | ATP Synthase F1 Subunit Beta | ATP5B | ATP5F1B | EC 3.6.3.14, Formerly | EC 7.1.2.2 | Epididymis Secretory Protein Li 271 | Mitochondrial ATP Synthase Beta Subunit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889131","NCR3LG1 wt Allele","C118529","Human NCR3LG1 wild-type allele is located in the vicinity of 11p15.1 and is approximately 26 kb in length. This allele, which encodes natural cytotoxicity triggering receptor 3 ligand 1 protein, plays a role in both the activation of and cytotoxicity mediated by natural killer cells.","NCR3LG1 wt Allele | B7-H6 | B7H6 | DKFZp686O24166 | Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898103","Olive Oil/Soybean Oil/Multi-amino Acid/Glucose Parenteral Nutrition Emulsion","C118366","An electrolyte-based parenteral emulsion for infusion consisting of a three chamber bag system containing a glucose solution, an amino acid solution and a lipid emulsion that can be used to provide parenteral nutritional supplementation. The lipid emulsion portion contains 20% refined soybean oil and 80% refined olive oil; the amino acid solution contains alanine, arginine, aspartic acid, glutamic acid, leucine, isoleucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine. The parenteral nutrition emulsion also contains the electrolytes phosphate and acetate. The three separate bags are mixed together before infusion. Upon infusion, the emulsion provides calories for energy. The lipid portion supplies essential fatty acids that can be incorporated into cell membranes. The amino acids facilitate protein synthesis.","Olive Oil/Soybean Oil/Multi-amino Acid/Glucose Parenteral Nutrition Emulsion | ZentroOLIMEL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898189","NY-ESO-1/MAGE-A4/PRAME/Survivin/SSX2-specific Autologous Cytotoxic T Lymphocytes","C118367","A preparation of autologous cytotoxic T-lymphocytes (CTL) that are specifically reactive to five tumor-associated antigens (TAAs), cancer-testis antigen NY-ESO-1, melanoma-associated antigen 4 (MAGE-A4), preferentially expressed antigen in melanoma (PRAME), survivin and synovial sarcoma X breakpoint 2 (SSX2; cancer/testis antigen 5.2; CT5.2), with potential antineoplastic activity. Autologous peripheral blood mononuclear cells (PBMCs) are collected and exposed ex vivo to autologous dendritic cells (DCs) that are pulsed with pepmixes, which contain overlapping peptide libraries (15 mers overlapping by 11 amino acids) spanning the entire sequence of each of the five target antigens, and simultaneously treated with the Th1-polarizing and pro-proliferative cytokines interleukin (IL) 6 (IL-6), IL-7, IL-12 and IL-15. The treated cells are expanded in culture with IL-2 and IL-15. Upon administration of the NY-ESO-1/MAGE-A4/PRAME/survivin/SSX2-specific autologous CTLs, these cells target tumor cells expressing these TAAs, which leads to cell lysis and inhibition of cell proliferation. These five TAAs are upregulated in a variety of tumor cells and play key roles in tumor cell proliferation and survival, but are absent or minimally expressed on normal, healthy human cells.","NY-ESO-1/MAGE-A4/PRAME/Survivin/SSX2-specific Autologous Cytotoxic T Lymphocytes | Autologous NY-ESO-1/MAGE-A4/PRAME/Survivin/SSX2-specific Cytotoxic T Lymphocytes | NY-ESO-1/MAGE-A4/PRAME/Survivin/SSX2-specific Autologous CTLs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014740","Erythema Migrans","C119047","A red, concentrically-expanding rash sometimes with central clearing, that is part of the first stage of Lyme disease caused by infection with Borrelia species.","Erythema Migrans | Bulls-Eye Rash | Erythema Chronicum Migrans",,,,,,,,,,,,,,,"4289612","Erythema chronica migrans",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL480775","Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis Syndrome","C119049","A syndrome characterized by synovitis, acne, pustulosis, hyperostosis, and non-infectious osteomyelitis. Includes a spectrum of aseptic neutrophilic dermatoses associated with aseptic osteoarticular lesions.","Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis Syndrome | PPHS | Pustulo-Psoriatic Hyperostotic Spondyloarthritis | SAPHO Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1275126","Tumor Necrosis Factor Receptor 1-Associated Periodic Syndrome","C119051","An autoinflammatory disease caused by mutations in the TNFRSF1A gene coding for tumor necrosis factor receptor 1 (TNFR1). This results in attacks of fever, rash, peritoneal, pleural, or pericardial serositis and/or synovial inflammation along with increased acute phase reactants. Complications may include amyloidosis.","Tumor Necrosis Factor Receptor 1-Associated Periodic Syndrome | Familial Hibernian Fever | TNF Receptor 1-Associated Periodic Syndrome | TRAPS",,,,,,,,,,,,,,,"4300462","TNF receptor-associated periodic fever syndrome (TRAPS)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0343068","Familial Cold Autoinflammatory Syndrome","C119053","An autoinflammatory disease caused by mutations in the NLRP3 gene which encodes cryopyrin. It is characterized by short episodes of fever, rash, and arthralgia after exposure to cold or rapid decrease in temperature.","Familial Cold Autoinflammatory Syndrome | FCAS",,,,,,,,,,,,,,,"4033845","Familial cold urticaria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL446640","1,2-Carbon C 13-labeled Glucose","C118637","A radioconjugate composed of glucose that is labeled at carbon position 1 and 2 with carbon C13, with potential metabolic imaging and isotope tracing purposes. Upon administration of 1,2-carbon C 13-labeled glucose, the glucose is taken up and metabolized by tumors and the 13C-containing metabolites can be imaged by 13C nuclear magnetic resonance (NMR) spectroscopy. Since tumor cells take up and metabolize glucose in higher amounts and through different pathways than normal cells, this agent may help assess metabolic tumor pathways.","1,2-Carbon C 13-labeled Glucose | D-Glucose-1,2-13C2 | Dextrose-1,2-13C2 | [1,2-13C]glucose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899391","Device Remains Implanted","C118639","An appliance or mechanism that continues to be implanted.","Device Remains Implanted | Active (Implanted)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899390","Device or Fragments Remain in Patient","C118640","A device or pieces of the device remain in a patient.","Device or Fragments Remain in Patient | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898437","Tip Breakage","C118641","The end of a device is fractured or damaged.","Tip Breakage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3885553","Cadazolid","C118642","An oxazolidinone-type antibiotic, with activity against gram-positive bacteria, including Clostridium difficile. Although the exact mode of action through which cadazolid exerts its effect has yet to be fully elucidated, upon administration, this agent inhibits bacterial protein synthesis and leads to bacterial cell death.","Cadazolid | 1-Cyclopropyl-6-fluoro-7-(4-((2-fluoro-4-((R)-5-hydroxymethyl-2-oxooxazolidin-3-yl)phenoxy)methyl)-4-hydroxypiperidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid | ACT-179811 | CADAZOLID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900000","Autologous Fecal Microbiota Transplantation","C118644","Fecal transplantation that uses a fecal sample provided by the patient before medical treatment began.","Autologous Fecal Microbiota Transplantation | auto-FMT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898806","Immediate/Early Loading","C118645","The attachment of a prosthetic to an implant prior to the traditional four-six month wait period.","Immediate/Early Loading | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897349","Traditional Use","C118647","Employing something to be used in an established convention.","Traditional Use | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898158","Nanoparticle-based Paclitaxel Suspension","C118648","A nanoparticle-based suspension containing the water-insoluble taxane paclitaxel, with potential antineoplastic activity. Upon intraperitoneal administration, paclitaxel binds to tubulin and inhibits the disassembly of microtubules, which leads to the inhibition of cell division. The nanoparticle-based formulation is devoid of toxic solvents, such as cremophor; therefore, this agent has fewer side effects than the standard, solvent-based paclitaxel formulation.","Nanoparticle-based Paclitaxel Suspension | Nanotax",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898744","Intended Use of Immediate/Early Load","C118649","Planned use during the intermediate/early load time.","Intended Use of Immediate/Early Load | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898745","Intended Use for Traditional Use","C118650","Planned to be used in the customary way.","Intended Use for Traditional Use | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889994","Censor","C118959","To ban access to or remove portions of a publication, film, letter, etc., usually for moral, religious, or political reasons.","Censor | Censored | Censoring",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898149","Neoantigen-based Glioblastoma Vaccine","C118960","A peptide-based, personalized glioblastoma cancer vaccine consisting of patient-specific glioblastoma derived immunogenic mutated epitopes (neoantigens), with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-based glioblastoma vaccine stimulates the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. Neoantigens are tumor-specific antigens derived from mutated proteins that are present only in a specific tumor.","Neoantigen-based Glioblastoma Vaccine | NeoVax (TM) Glioblastoma Vaccine | Personalized Neoantigen Glioblastoma Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899840","CCND1 Gene Product","C118476","A protein encoded by the CCND1 gene.","CCND1 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3257744","Ingenol Mebutate Gel","C118776","A topical, aqueous gel formulation containing the mebutate salt form of ingenol, a selective small-molecule activator of protein kinase C (PKC) that is isolated from the sap of Euphorbia species, with potential antineoplastic activity. Upon topical application of the ingenol mebutate gel, ingenol activates various PKC isoforms, which induces apoptosis in certain tumor cells, including myeloid leukemia cells, melanoma cells, and basal cell carcinoma cells. The PKC family consists of signaling isoenzymes that regulate many cell processes, including proliferation, differentiation, and apoptosis.","Ingenol Mebutate Gel | Ingenol-3-angelate Gel | PEP-005 Topical Gel | PEP005 Gel | Picato",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889833","Structured Product Labeling Licensing Terminology","C118777","Terminology used to indicate the authorization of a business to perform specific duties or functions.","SPL Licensing Terminology | Licensing | Structured Product Labeling Licensing Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897481","SPL Marketing Status Terminology","C118778","Terminology used to indicate whether a product is being marketed.","SPL Marketing Status Terminology | Marketing Status | Structured Product Labeling Marketing Status Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889832","Licensed as Wholesale Drug Distributor or Third Party Logistics Provider","C118779","An indication that an entity has been an issued a license to function as a wholesale drug distributor or as a third party logistics provider within a state's territory.","Licensed as Wholesale Drug Distributor or Third Party Logistics Provider | Licensed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0410203","X-Linked Centronuclear Myopathy","C118781","An X-linked recessive inherited disorder caused by mutations in the MTM1 gene. Primarily it affects males. Female carriers are usually asymptomatic.  It is characterized by skeletal muscle weakness and hypotonia. The muscle weakness ranges from mild to severe. Newborns with severe X-linked centronuclear myopathy develop respiratory distress which may lead to respiratory failure requiring constant ventilator assistance. Patients with mild X-linked centronuclear myopathy usually require ventilator support during the newborn period only.","X-Linked Centronuclear Myopathy | CNMX | MTM | MTM1 | Myotubular Myopathy 1 | X-Linked Myotubular Myopathy | XLCNM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0270912","Charcot-Marie-Tooth Disease Type 1B","C118782","Charcot-Marie-Tooth disease caused by mutations in the MPZ gene (mapped to chromosome 1q23.3). It results in sensorineural peripheral neuropathy.","Charcot-Marie-Tooth Disease Type 1B | ",,,,,,,,,,,,,,,"4179972","Charcot-Marie-Tooth disease, type IB",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1413036","ADAMTS13 Gene","C118325","This gene plays a role in von Willebrand factor function.","ADAMTS13 Gene | ADAM Metallopeptidase With Thrombospondin Type 1 Motif, 13 Gene | ADAMTS13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268390","Muckle-Wells Syndrome","C119054","An autoinflammatory disease caused by mutations in the NLRP3 gene which encodes cryopyrin. It is characterized by recurrent episodes of urticaria and fever which develop in infancy. It may lead to sensorineural hearing loss and/or amyloidosis.","Muckle-Wells Syndrome | MWS",,,,,,,,,,,,,,,"4034712","Familial amyloid nephropathy with urticaria AND deafness",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1858361","Pyogenic Arthritis, Pyoderma Gangrenosum and Acne","C119055","An autoinflammatory disease caused by mutations in the PSTPIP1 gene. It is characterized by episodes of destructive arthritis, ulcerative skin lesions and cystic acne.","Pyogenic Arthritis, Pyoderma Gangrenosum and Acne | PAPA",,,,,,,,,,,,,,,"37110004","Pyogenic arthritis, pyoderma gangrenosum, acne syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2748507","Deficiency of the Interleukin-1 Receptor Antagonist","C119056","An autoinflammatory disease caused by mutations in the IL1RN gene, which encodes the IL1 receptor antagonist. It presents in infancy, and is characterized by systemic inflammation, pustular rash, bone pain, sterile osteitis, and periostitis.","Deficiency of the Interleukin-1 Receptor Antagonist | Autoinflammatory Disease due to Interleukin-1 Receptor Antagonist Deficiency | DIRA",,,,,,,,,,,,,,,"36676721","Sterile multifocal osteomyelitis with periostitis and pustulosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0343056","Deficiency of the Interleukin-36 Receptor Antagonist","C119057","An autoinflammatory disease caused by mutations in the IL36RN gene, which encodes the IL36 receptor antagonist. It is characterized by periodic fevers and psoriasiform rash.","Deficiency of the Interleukin-36 Receptor Antagonist | DITRA | Familial Generalized Pustular Psoriasis | PSORP",,,,,,,,,,,,,,,"37205061|4031142","Deficiency of interleukin 36 receptor antagonist|Generalized pustular psoriasis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1864997","Majeed Syndrome","C119058","An autoinflammatory disease caused by mutations in the LPIN2 gene. It is characterized by early-onset chronic recurrent multifocal osteomyelitis, congenital dyserythropoietic anemia and inflammatory dermatosis.","Majeed Syndrome | ",,,,,,,,,,,,,,,"45766392","Majeed syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3896636","CDISC Questionnaire AUDIT-SR Test Code Terminology","C119060","Test codes of questionnaire questions associated with the Alcohol Use Disorder Identification Test: Self-Report Version (AUDIT-SR) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire AUDIT-SR Test Code Terminology | ADT01TC | Alcohol Use Disorder Identification Test: Self-Report Version Questionnaire Test Code | QS-AUDIT-SR TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471756","GS-pan Notch inhibitor BMS-986115","C118573","An orally bioavailable, gamma secretase (GS) and pan-Notch inhibitor, with potential antineoplastic activity. Upon administration, varegacestat binds to GS and blocks the proteolytic cleavage and release of the Notch intracellular domain (NICD), which would normally follow ligand binding to the extracellular domain of the Notch receptor. This prevents both the subsequent translocation of NICD to the nucleus to form a transcription factor complex and the expression of Notch-regulated genes. This results in the induction of apoptosis and the inhibition of growth of tumor cells that overexpress Notch. Overexpression of the Notch signaling pathway plays an important role in tumor cell proliferation and survival. The integral membrane protein GS is a multi-subunit protease complex that cleaves single-pass transmembrane proteins, such as Notch receptors, at residues within their transmembrane domains and leads to their activation.","Varegacestat | AL 102 | AL-102 | AL102 | BMS-986115 | GS/pan-Notch Inhibitor AL102 | GS/pan-Notch Inhibitor AL102 | VAREGACESTAT | WHG 626 | WHG-626 | WHG626",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471753","Plectin-1 Targeting Agent PTP-01","C118575","An imaging agent containing a plectin-1 (Plec1; plectin) targeting peptide (PTP), with potential use for the detection of Plec1-expressing tumor cells using single-photon emission computed tomography (SPECT). Upon administration, the Plec1 targeting agent PTP-01 specifically targets and binds to Plec1 on Plec1-expressing cancer cells. Upon SPECT imaging, the Plec1-expressing cancer cells can be visualized. Plec1, a pro-tumorigenic protein, is normally found inside the cytoplasm of healthy cells but is only selectively expressed on the cell surface of various cancer cells and plays an important role in cancer cell proliferation, migration and invasion.","Plectin-1 Targeting Agent PTP-01 | PTP-01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471750","NGFR-transduced Autologous T Lymphocytes","C118576","A preparation of autologous, genetically modified T-lymphocytes that are expressing the tumor-associated antigen (TAA) nerve growth factor receptor (NGFR; p75 neurotrophin receptor; p75(NTR); CD271), with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the NGFR-transduced autologous T-lymphocytes may induce an immune response and may kill NGF-expressing tumor cells. Dysregulated NGF signaling may promote proliferation and invasion in certain tumor cell types.","NGFR-transduced Autologous T Lymphocytes | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471717","Trifarotene","C118577","A selective retinoic acid receptor gamma (RAR gamma) agonist that can be used in the treatment of acne vulgaris.  Upon topical application, trifarotene selectively binds to the RAR gamma receptor, thereby altering the expression of certain genes that are involved in inflammation and cellular differentiation. ","Trifarotene | 3''-Tert-butyl-4'-(2-hydroxyethoxy)-4''-(pyrrolidin-1-yl)(1,1':3',1'')terphenyl-4-carboxylic Acid | Aklief | CD5789 | TRIFAROTENE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0070220","penclomedine","C1188","A synthetic derivative of pyrimidine with antineoplastic activity. Penclomedine alkylates and crosslinks DNA, resulting in DNA strand breaks and inhibition of DNA and RNA synthesis. This agent is more active against tumor cells that are defective in p53 function. (NCI04)","Penclomedine | 3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl) pyridine | CRC 88-04 | PEN | PENCLOMEDINE | Pyridine, 3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl)- | penclomedine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890350","IL18BP wt Allele","C118905","Human IL18BP wild-type allele is located in the vicinity of 11q13 and is approximately 7 kb in length. This allele, which encodes interleukin-18-binding protein, is involved in the inhibition of interleukin-18-mediated signaling.","IL18BP wt Allele | IL18BPa | Interleukin 18 Binding Protein wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1743775","interleukin 18 binding protein, human","C118906","Interleukin-18-binding protein (194 aa, ~21 kDa) is encoded by the human IL18BP gene. This protein plays a role in binding to and sequestration of interleukin-18.","Interleukin-18-Binding Protein | IL-18BP | Interleukin 18-Binding Protein | MC51L-53L-54L Homolog Gene Product",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890230","CD1C wt Allele","C118908","Human CD1C wild-type allele is located in the vicinity of 1q23.1 and is approximately 5 kb in length. This allele, which encodes T-cell surface glycoprotein CD1c, plays a role in the presentation of lipid and glycolipid antigens to T-cells.","CD1C wt Allele | BDCA1 | CD1 | CD1A | CD1C Antigen, C Polypeptide Gene | CD1c Molecule wt Allele | R7 | RP11-101J8.3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1611863","T-Cell Surface Glycoprotein CD1c, Human","C118909","T-cell surface glycoprotein CD1c (333 aa, ~38 kDa) is encoded by the human CD1C gene. This protein is involved in lipid and glycolipid antigen presentation to T-cells.","T-Cell Surface Glycoprotein CD1c | BDCA-1 | CD1c | CD1c Antigen | Cortical Thymocyte Antigen CD1C | Differentiation Antigen CD1-Alpha-3 | Thymocyte Antigen CD1C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889430","CARD14 wt Allele","C118911","Human CARD14 wild-type allele is located in the vicinity of 17q25 and is approximately 39 kb in length. This allele, which encodes caspase recruitment domain-containing protein 14, is involved in the inhibition of apoptosis. Mutation of the gene is associated with both psoriasis type 2 and autosomal dominant pityriasis rubra pilaris.","CARD14 wt Allele | BIMP2 | CARMA2 | Caspase Recruitment Domain Family, Member 14 wt Allele | PRP | PSORS2 | PSS1 | Psoriasis Susceptibility 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1309905","Caspase Recruitment Domain-Containing Protein 14, Human","C118912","Caspase recruitment domain-containing protein 14 (1004 aa, ~113 kDa) is encoded by the human CARD14 gene. This protein plays a role in the promotion of cell survival.","Caspase Recruitment Domain-Containing Protein 14 | Bcl10-Interacting Maguk Protein 2 | CARD-Containing MAGUK Protein 2 | CARD-MAGUK Protein 2 | CARD14 | Carma 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897675","SSTR2 Gene Product","C118483","A protein encoded by the SSTR2 gene.","SSTR2 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897565","Small for Gestational Age for Length","C118699","Birth length greater than two standard deviations below the mean for the reference population of the same sex and gestational age.","Small for Gestational Age for Length | SGA for Length",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0070165","PCNU","C1186","A chloroethylnitrosourea compound and an alkylating agent with antineoplastic property. PCNU inhibits DNA synthesis by alkylating DNA and causing DNA cross links, thereby inducing apoptosis. In addition, this agent may be associated with pulmonary, hepatic, and hematologic toxicities. Unlike other nitrosoureas, PCNU has strong alkylating while weak carbamoylating activity.","PCNU | 1-(2-CHLOROETHYL)-3-(2,6-DIOXO-3-PIPERIDYL)-1-NITROSOUREA | 1-(2-Chloroethyl)-3-(2,6-Dioxo-3-Piperidyl)-1-Nitrourea | Urea, N-(2-chloroethyl)-N'-(2,6-dioxo-3-piperidinyl)-N-nitroso-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897564","Small for Gestational Age for Weight and Length","C118700","Birth weight and length greater than two standard deviations below the mean for the reference population of the same sex and gestational age.","Small for Gestational Age for Weight and Length | SGA for Weight and Length",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890421","ADAMTS13 wt Allele","C118326","Human ADAMTS13 wild-type allele is located in the vicinity of 9q34 and is approximately 45 kb in length. This allele, which encodes a disintegrin and metalloproteinase with thrombospondin motifs 13 protein, is involved in the processing of von Willebrand factor multimers. Mutation of the gene is associated with congenital thrombotic thrombocytopenic purpura.","ADAMTS13 wt Allele | A Disintegrin-Like and Metalloprotease (Reprolysin Type) With Thrombospondin Type 1 Motif, 13 Gene | A Disintegrin-Like and Metalloprotease With Thrombospondin Type 1 Motif, 13 Gene | ADAM Metallopeptidase With Thrombospondin Type 1 Motif, 13 wt Allele | ADAM-TS13 | ADAMTS-13 | C9orf8 | DKFZp434C2322 | MGC118899 | MGC118900 | UNQ6102/PRO20085 | VWFCP | vWF-CP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0389918","A Disintegrin and Metalloproteinase With Thrombospondin Motifs 13, Human","C118327","A disintegrin and metalloproteinase with thrombospondin motifs 13 (1427 aa, ~154 kDa) is encoded by the human ADAMTS13 gene. This protein plays a role in the proteolysis of von Willebrand factor multimers.","A Disintegrin and Metalloproteinase with Thrombospondin Motifs 13 | A Disintegrin and Metalloprotease with Thrombospondin Motifs-13 | A Disintegrin and Metalloproteinase With Thrombospondin Motifs 13 | A Disintegrin and Metalloproteinase with Thrombospondin Type 1 Motif 13 | ADAM Metallopeptidase With Thrombospondin Type 1 Motif 13 | ADAM-TS 13 | ADAM-TS13 | ADAMTS-13 | ADAMTS13 | EC 3.4.24.87 | Von Willebrand Coagulation Factor Cleaving Protease | vWF-CP | vWF-Cleaving Protease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421148","TRIP13 Gene","C118328","This gene is involved in meiotic recombination.","TRIP13 Gene | TRIP13 | Thyroid Hormone Receptor Interactor 13 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3502613","Pachytene Checkpoint Protein 2 Homolog, Human","C118330","Pachytene checkpoint protein 2 homolog (432 aa, ~49 kDa) is encoded by the human TRIP13 gene. This protein plays a role in meiotic chromosome recombination.","Pachytene Checkpoint Protein 2 Homolog | 16E1-BP | HPV16 E1 Protein Binding Protein | HPV16 E1 Protein-Binding Protein | Human Papillomavirus Type 16 E1 Protein-Binding Protein | TR-Interacting Protein 13 | TRIP-13 | TRIP13 | Thyroid Receptor Interacting Protein 13 | Thyroid Receptor-Interacting Protein 13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420806","TNFRSF25 Gene","C118331","This gene plays a role in cytokine-mediated apoptosis.","TNFRSF25 Gene | TNFRSF25 | Tumor Necrosis Factor Receptor Superfamily, Member 25 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890192","TNFRSF25 wt Allele","C118332","Human TNFRSF25 wild-type allele is located in the vicinity of 1p36.2 and is approximately 5 kb in length. This allele, which encodes tumor necrosis factor receptor superfamily member 25 protein, is involved in the positive regulation of apoptosis.","TNFRSF25 wt Allele | APO-3 | APO3 | DDR3 | DR3 | LARD | RP4-650H14.2 | TNFR25 | TNFRSF12 | TR3 | TRAMP | Tumor Necrosis Factor Receptor Superfamily, Member 12 (Translocating Chain-Association Membrane Protein) Gene | Tumor Necrosis Factor Receptor Superfamily, Member 12 Gene | Tumor Necrosis Factor Receptor Superfamily, Member 25 wt Allele | UNQ455/PRO779 | WSL | WSL-1 | WSL-LR | WSL1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1665342","TNFRSF25 protein, human","C118333","Tumor necrosis factor receptor superfamily member 25 (417 aa, ~45 kDa) is encoded by the human TNFRSF25 gene. This protein plays a role in the promotion of cytokine-mediated apoptosis.","Tumor Necrosis Factor Receptor Superfamily Member 25 | Apo-3 | Apoptosis Inducing Receptor | Apoptosis-Inducing Receptor AIR | Apoptosis-Mediating Receptor DR3 | Apoptosis-Mediating Receptor TRAMP | Death Receptor 3 | LARD | Lymphocyte-Associated Receptor of Death | Protein WSL | Protein WSL-1 | Translocating Chain-Association Membrane Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412426","ANXA6 Gene","C118334","This gene is involved in calcium transport and exocytosis.","ANXA6 Gene | ANXA6 | Annexin A6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889445","ANXA6 wt Allele","C118335","Human ANXA6 wild-type allele is located in the vicinity of 5q33.1 and is approximately 57 kb in length. This allele, which encodes annexin A6 protein, plays a role in calcium binding and transport.","ANXA6 wt Allele | ANX6 | Annexin A6 wt Allele | CBP68",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0081594","Annexin A6","C118336","Annexin A6 (673 aa, ~76 kDa) is encoded by the human ANXA6 gene. This protein is involved in both exocytosis and calcium localization.","Annexin A6 | 67 kDa Calelectrin | Annexin VI | Annexin-6 | CPB-II | Calcium-Binding Protein p68 | Calphobindin II | Calphobindin-II | Chromobindin-20 | Lipocortin VI | Protein III | p68 | p70",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446653","Vanucizumab","C118578","A humanized bispecific immunoglobulin G (IgG1) monoclonal antibody targeting both the vascular endothelial growth factor receptor (VEGFR) ligand VEGF-A and the Tie2 receptor ligand angiopoietin-2 (Ang-2), with potential antineoplastic and anti-angiogenic activities. Upon administration of vanucizumab, the anti-VEGF-A arm, which is based on bevacizumab, targets and binds to VEGF-A and the anti-Ang2 arm, which is based on the anti-Ang-2 antibody LC06, targets and binds to Ang2, thereby simultaneously binding and neutralizing both VEGF-A and Ang2. This prevents the activation of both VEGF-A/VEGFR- and Ang2/Tie2-mediated signaling pathways. Altogether, this results in the inhibition of proliferation of VEGF-A- and/or Ang2-overexpressing tumor cells. VEGF-A and Ang2, both upregulated in a variety of tumor cell types, play key roles in tumor cell proliferation, angiogenesis and metastasis.","Vanucizumab | Ang2-VEGF-A CrossMab RO5520985 | Immunoglobulin Recombined G1-kappa/lambda, Anti-(Homo sapiens Angpt2 (Angiopoietin 2, Ang2))/Anti-Homo sapiens VEGFa (Vascular Endothelial Growth Factor A, VEGF-a, VEGF)), Humanized Monoclonal Antibody | RG-7221 | RG7221 | RO-5520985 | RO5520985 | VANUCIZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889997","UBQLN4 wt Allele","C118580","Human UBQLN4 wild-type allele is located in the vicinity of 1q21 and is approximately 18 kb in length. This allele, which encodes ubiquilin-4 protein, may play a role in the regulation of the proteasome.","UBQLN4 wt Allele | A1U | C1orf6 | CIP75 | Chromosome 1 Open Reading Frame 6 Gene | RP11-336K24.8 | UBIN | Ubiquilin 4 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1312691","Ubiquilin-4, Human","C118581","Ubiquilin-4 (601 aa, ~64 kDa) is encoded by the human UBQLN4 gene. This protein may be involved in the modulation of proteasome-mediated protein degradation.","Ubiquilin-4 | A1Up | Ataxin-1 Interacting Ubiquitin-Like Protein | Ataxin-1 Ubiquitin-Like Interacting Protein | Ataxin-1 Ubiquitin-Like-Interacting Protein A1U | CIP75 | Connexin 43-Interacting Protein, 75 kD | Connexin43-Interacting Protein of 75 kDa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889715","PROCR wt Allele","C118583","Human PROCR wild-type allele is located in the vicinity of 20q11.2 and is approximately 5 kb in length. This allele, which encodes endothelial protein C receptor protein, is involved in the modulation of protein C localization.","PROCR wt Allele | CCCA | CCD41 | EPCR | Protein C Receptor, Endothelial wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1312737","Endothelial Protein C Receptor, Human","C118584","Endothelial protein C receptor (238 aa, ~27 kDa) is encoded by the human PROCR gene. This protein plays a role in the regulation of protein C-mediated blood coagulation.","Endothelial Protein C Receptor | APC Receptor | Activated Protein C Receptor | CD201 | CD201 Antigen | Cell Cycle, Centrosome-Associated Protein | Centrocyclin | Endothelial Cell Protein C Receptor | PROCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889380","SLC9A1 wt Allele","C118914","Human SLC9A1 wild-type allele is located within 1p36.1-p35 and is approximately 68 kb in length. This allele, which encodes sodium/hydrogen exchanger 1 protein, plays a role in the regulation of cellular pH.","SLC9A1 wt Allele | APNH | APNH1 | Antiporter, Sodium-Hydrogen Ion, Amiloride Sensitive Gene | NHE-1 | NHE1 | PPP1R143 | RP4-633N17.1 | Solute Carrier Family 9 (Sodium/Hydrogen Exchanger), Isoform 1 (Antiporter, Na+/H+, Amiloride Sensitive) Gene | Solute Carrier Family 9 (Sodium/Hydrogen Exchanger), Member 1 (Antiporter, Na+/H+, Amiloride Sensitive) Gene | Solute Carrier Family 9 (Sodium/Hydrogen Exchanger), Member 1 Gene | Solute Carrier Family 9, Member 1 Gene | Solute Carrier Family 9, Subfamily A (NHE1, Cation Proton Antiporter 1), Member 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1453959","Sodium/Hydrogen Exchanger 1, Human","C118915","Sodium/hydrogen exchanger 1 (815 aa, ~91 kDa) is encoded by the human SLC9A1 gene. This protein is involved in the antiport of sodium ions and hydrogen ions.","Sodium/Hydrogen Exchanger 1 | NHE-1 | Na(+)/H(+) Antiporter | Na(+)/H(+) Antiporter, Amiloride-Sensitive | Na(+)/H(+) Exchanger 1 | SLC9A1 | Solute Carrier Family 9 Member 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890912","KIR2DS4 wt Allele","C118917","Human KIR2DS4 wild-type allele is located in the vicinity of 19q13.4 and is approximately 16 kb in length. This allele, which encodes killer cell immunoglobulin-like receptor 2DS4 protein, is involved in natural killer cell-mediated immunity.","KIR2DS4 wt Allele | CD158I | KIR-2DS4 | KIR1D | KIR2DS1 | KIR412 | KKA3 | Killer Cell Immunoglobulin-Like Receptor, Two Domains, Short Cytoplasmic Tail, 4 wt Allele | NK-Associated Transcript 8 Gene | NKAT-8 | NKAT8 | XXbac-BPG230H20.3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1258253","Killer Cell Immunoglobulin-Like Receptor 2DS4","C118918","Killer cell immunoglobulin-like receptor 2DS4 (304 aa, ~34 kDa) is encoded by the human KIR2DS4 gene. This protein plays a role in the modulation of natural killer cell activity.","Killer Cell Immunoglobulin-Like Receptor 2DS4 | CD158 Antigen-Like Family Member I | CD158i | CD158i Antigen | KIR Antigen 2DS4 | Killer Cell Immunoglobulin-Like Receptor Two Domains Short Cytoplasmic Tail 1 | Killer Inhibitory Receptor 4-1-2 | MHC Class I NK Cell Receptor Eb6 ActI | NKAT-8 | p58 NK Receptor CL-39/CL-17 | p58 Natural Killer Cell Receptor Clones CL-39/CL-17",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889166","SLC36A1 wt Allele","C118920","Human SLC36A1 wild-type allele is located in the vicinity of 5q33.1 and is approximately 55 kb in length. This allele, which encodes proton-coupled amino acid transporter 1 protein, plays a role in the mediation of pH-dependent transport of small amino acids.","SLC36A1 wt Allele | Dct1 | LYAAT1 | PAT1 | Solute Carrier Family 36 (Proton/Amino Acid Symporter), Member 1 wt Allele | TRAMD3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1259895","Proton-Coupled Amino Acid Transporter 1, Human","C118921","Proton-coupled amino acid transporter 1 (476 aa, ~53 kDa) is encoded by the human SLC36A1 gene. This protein is involved in the transport of small amino acids and hydrogen ions.","Proton-Coupled Amino Acid Transporter 1 | Lysosomal Amino Acid Transporter 1 | Proton/Amino Acid Transporter 1 | SLC36A1 | Solute Carrier Family 36 Member 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890180","DDX39B wt Allele","C118923","Human DDX39B wild-type allele is located in the vicinity of 6p21.3 and is approximately 12 kb in length. This allele, which encodes spliceosome RNA helicase DDX39B protein, is involved in both mRNA nuclear export and pre-mRNA splicing.","DDX39B wt Allele | BAT1 | D6S81E | DAAP-97M17.4 | DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 39B wt Allele | HLA-B Associated Transcript 1 Gene | HLA-B-Associated Transcript 1 Gene | Nuclear RNA Helicase (DEAD Family) Gene | UAP56",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897562","Small for Gestational Age with Failure of Catch-Up Growth","C118702","A condition in which a child who was born small for gestational age, fails to achieve a linear growth rate sufficient to restore height to within the normal range for the reference population.","Small for Gestational Age with Failure of Catch-Up Growth | Small for Gestational Age with Failure of Catch-up Growth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1262270","Orbital Contusion","C118708","Bruising of the skin and soft tissue surrounding the eye.","Orbital Contusion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0740445","Chemical Burn of Eye","C118709","Injury to the eye secondary to a chemical substance.","Chemical Burn of Eye | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4227774","Cerebral Visual Impairment","C118710","Visual impairment due to central nervous system dysfunction.","Cerebral Visual Impairment | Central Visual Impairment",,,,,,,,,,,,,,,"762803","Central visual impairment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3810249","Optic Neuropathy","C118711","Disorder of the optic nerve.","Optic Neuropathy | ",,,,,,,,,,,,,,,"374360","Disorder of optic nerve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0155018","Acquired Color Blindness","C118712","Non-heritable difficulty in distinguishing colors.","Acquired Color Blindness | ",,,,,,,,,,,,,,,"377865","Acquired color vision deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0751042","Inherited Color Blindness","C118713","Genetic based difficulty in distinguishing colors.","Inherited Color Blindness | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0234632","Decreased Visual Acuity","C118714","Diminished clarity of vision.","Decreased Visual Acuity | Visual Acuity Decreased",,,,,,,,,,,,,,,"4027502","Reduced visual acuity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4231171","Decreased Best Corrected Visual Acuity","C118715","Diminished clarity of vision despite optimal optical correction (glasses and/or contacts).","Decreased Best Corrected Visual Acuity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896881","Altiratinib","C118290","An orally bioavailable inhibitor of c-Met/hepatocyte growth factor receptor (HGFR), vascular endothelial growth factor receptor type 2 (VEGFR2), Tie2 receptor tyrosine kinase (TIE2), and tropomyosin receptor kinase (Trk), with potential antiangiogenic and antineoplastic activities. Upon administration, altiratinib selectively binds to c-Met, VEGFR2, Tie2 and Trk tyrosine kinases, which may lead to the inhibition of endothelial cell migration, proliferation and survival. This also results in both an inhibition of tumor cell proliferation and increased tumor cell death in c-Met/VEGFR2/Tie2/Trk-expressing cells. These receptor tyrosine kinases (RTKs), frequently overexpressed or mutated by a variety of tumor cell types, play crucial roles in the regulation of angiogenesis, tumor cell growth and survival.","Altiratinib | 1,1-Cyclopropanedicarboxamide, N-(4-((2-((cyclopropylcarbonyl)amino)-4-pyridinyl)oxy)-2,5-difluorophenyl)-N'-(4-fluorophenyl)- | ALTIRATINIB | DCC-2701",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3469805","CCDC170 Gene","C118337","This gene may play a role in bone development.","CCDC170 Gene | CCDC170 | Coiled-Coil Domain Containing 170 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889628","Solute Carrier Family 43 Member 2","C119000","Large neutral amino acids transporter small subunit 4 (569 aa, ~63 kDa) is encoded by the human SLC43A2 gene. This protein is involved in the transport of large neutral amino acids.","Large Neutral Amino Acids Transporter Small Subunit 4 | L-Type Amino Acid Transporter 4 | SLC43A2 | Solute Carrier Family 43 Member 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889158","SLC7A8 wt Allele","C119002","Human SLC7A8 wild-type allele is located in the vicinity of 14q11.2 and is approximately 58 kb in length. This allele, which encodes large neutral amino acids transporter small subunit 2 protein, is involved in the transport of amino acids.","SLC7A8 wt Allele | LAT2 | LPI-PC1 | Solute Carrier Family 7 (Amino Acid Transporter Light Chain, L System), Member 8 wt Allele | Solute Carrier Family 7 (Amino Acid Transporter, L-Type), Member 8 Gene | Solute Carrier Family 7 (Cationic Amino Acid Transporter, y+ System), Member 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0893104","SLC7A8 protein, human","C119003","Large neutral amino acids transporter small subunit 2 (535 aa, ~58 kDa) is encoded by the human SLC7A8 gene. This protein plays a role in amino acid transport.","Large Neutral Amino Acids Transporter Small Subunit 2 | Integral Membrane Protein E16H | L-Type Amino Acid Transporter 2 | SLC7A8 | Solute Carrier Family 7 Member 8 | hLAT2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890005","SLC5A2 wt Allele","C119005","Human SLC5A2 wild-type allele is located in the vicinity of 16p11.2 and is approximately 8 kb in length. This allele, which encodes sodium/glucose cotransporter 2 protein, plays a role in sodium-dependent glucose transport. Mutation of the gene is associated with renal glucosuria.","SLC5A2 wt Allele | SGLT2 | Sodium-Glucose Cotransporter, Kidney Low Affinity Gene | Sodium-Glucose Cotransporter, Renal Gene | Solute Carrier Family 5 (Sodium/Glucose Cotransporter), Member 2 wt Allele | Solute Carrier Family 5 (Sodium/Glucose Transporter), Member 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1505133","Sodium/Glucose Cotransporter 2, Human","C119006","Sodium/glucose cotransporter 2 (672 aa, ~73 kDa) is encoded by the human SLC5A2 gene. This protein is involved in sodium/glucose symport.","Sodium/Glucose Cotransporter 2 | Low Affinity Sodium-Glucose Cotransporter | Na(+)/Glucose Cotransporter 2 | SGLT2 | SLC5A2 | Solute Carrier Family 5 Member 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889451","SLC2A2 wt Allele","C119008","Human SLC2A2 wild-type allele is located within 3q26.2-q27 and is approximately 31 kb in length. This allele, which encodes solute carrier family 2, facilitated glucose transporter member 2 protein, is involved in glucose transport.","SLC2A2 wt Allele | GLUT2 | Glucose Transporter, Liver/Islet Gene | Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0795889","Allan-Herndon-Dudley Syndrome","C118843","A rare, X-linked recessive inherited syndrome caused by mutations in the SLC16A2 (MCT8) gene. It affects exclusively males and is characterized by mental retardation, limited mobility, muscle hypoplasia, hypotonia, contractures, and spasticity.","Allan-Herndon-Dudley Syndrome | MCT8-Specific Thyroid Hormone Cell Membrane Transporter Deficiency | Monocarboxylate Transporter 8 Deficiency",,,,,,,,,,,,,,,"45773358","Allan-Herndon-Dudley syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1846006","Ectodermal Dysplasia and Immunodeficiency","C118844","A rare disorder caused by mutations either in the IKBKG gene resulting in an X-linked recessive inheritance pattern or in the NFKBIA gene resulting in an autosomal dominant inheritance pattern. It is characterized by abnormal development of ectodermal tissues including the skin, hair, teeth, and sweat glands and immune system deficiency. It results in dry and wrinkled skin, sparse scalp and body hair, missing teeth, and reduced ability to sweat. Patients have abnormally low levels of antibodies causing inability to fight infections.","Ectodermal Dysplasia and Immunodeficiency | Anhidrotic Ectodermal Dysplasia with Immune Deficiency | EDA-ID | Hypohidrotic Ectodermal Dysplasia with Immune Deficiency",,,,,,,,,,,,,,,"45766381","Anhidrotic ectodermal dysplasia with immune deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265251","Otopalatodigital Syndrome Type 1","C118845","A rare, X-linked dominant inherited syndrome caused by mutations in the FLNA gene. It is characterized by hearing loss caused by malformations in the ossicles, cleft palate, wide-set eyes, prominent brow ridges, small and flat nose, and skeletal abnormalities in the fingers and toes. Males usually experience more severe symptoms than females.","Otopalatodigital Syndrome Type 1 | ",,,,,,,,,,,,,,,"4207361","Oto-palato-digital syndrome, type I",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152109","Spinal Muscular Atrophy Type 3","C118847","A rare, autosomal recessive inherited disorder caused by mutations in the SMN1 gene. It is characterized by progressive degeneration and loss of the anterior horn cells in the spinal cord and brain stem. It is manifested with hypotonia and muscle weakness, usually in late childhood or adolescence.  Affected individuals can stand and walk but walking and climbing stairs becomes progressively difficult.","Spinal Muscular Atrophy Type 3 | Juvenile Spinal Muscular Atrophy | Kugelberg-Welander Disease | Kugelberg-Welander Syndrome | Spinal Muscular Atrophy III",,,,,,,,,,,,,,,"374634","Kugelberg-Welander disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3896736","Anti-OFA Immunotherapeutic BB-MPI-03","C118368","A cancer vaccine composed of 3 different cytotoxic T-cell epitopes derived from the tumor-associated antigen oncofetal antigen (OFA), with potential immunostimulating and antineoplastic activities. Upon intradermal administration, anti-OFA immunotherapeutic vaccine BB-MPI-03 activates the immune system to elicit a specific cytotoxic T-lymphocyte (CTL) response against tumor cells expressing OFA. OFA, also called immature laminin receptor protein (iLRP), is expressed in fetal tissues and is overexpressed in various cancers; its expression is correlated with cancer cell survival.","Anti-OFA Immunotherapeutic BB-MPI-03 | BB-MPI-03 | BBMPI03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1454215","Spliceosome RNA Helicase DDX39B, Human","C118924","Spliceosome RNA helicase DDX39B (428 aa, ~49 kDa) is encoded by the human DDX39B gene. This protein plays a role in spliceosome assembly and the nuclear export of spliced and unspliced mRNA.","Spliceosome RNA Helicase DDX39B | 56 kDa U2AF65-Associated Protein | ATP-Dependent RNA Helicase p47 | DEAD Box Polypeptide 39B | DEAD Box Protein UAP56 | EC 3.6.4.13 | HLA-B-Associated Transcript 1 Protein | Spliceosome RNA Helicase BAT1 | U2AF65-Associated Protein 56 | U2AF65-Associated Protein, 56-kD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896981","CCQ 24 Hour Version - Breathing Problems Limit Moderate Activity","C119129","Clinical COPD Questionnaire 24 Hour Version (CCQ 24 Hour Version) On average, during the past 24 hours, how limited were you in these activities because of your breathing problems: Moderate physical activities?","CCQ 24 Hour Version - Breathing Problems Limit Moderate Activity | CCQ01-Breathing Limit Moderate Activity | CCQ0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899828","CCQ 24 Hour Version - Breathing Problems Limit Daily Activity","C119130","Clinical COPD Questionnaire 24 Hour Version (CCQ 24 Hour Version) On average, during the past 24 hours, how limited were you in these activities because of your breathing problems: Daily activities at home?","CCQ 24 Hour Version - Breathing Problems Limit Daily Activity | CCQ01-Breathing Limit Daily Activity | CCQ0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899827","CCQ 24 Hour Version - Breathing Problems Limit Social Activity","C119131","Clinical COPD Questionnaire 24 Hour Version (CCQ 24 Hour Version) On average, during the past 24 hours, how limited were you in these activities because of your breathing problems: Social activities?","CCQ 24 Hour Version - Breathing Problems Limit Social Activity | CCQ01-Breathing Limit Social Activity | CCQ0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899830","CCQ 1 Week Version - Short of Breath at Rest","C119132","Clinical COPD Questionnaire 1 Week Version (CCQ 1 Week Version) On average, during the past 7 days, how often did you feel: Short of breath while at rest?","CCQ 1 Week Version - Short of Breath at Rest | CCQ02-Short of Breath at Rest | CCQ0201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899831","CCQ 1 Week Version - Short of Breath Doing Physical Activity","C119133","Clinical COPD Questionnaire 1 Week Version (CCQ 1 Week Version) On average, during the past 7 days, how often did you feel: Short of breath while doing physical activities?","CCQ 1 Week Version - Short of Breath Doing Physical Activity | CCQ02-Short of Breath Physical Activity | CCQ0202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899835","CCQ 1 Week Version - Concern About Breathing Get Worse","C119134","Clinical COPD Questionnaire 1 Week Version (CCQ 1 Week Version) On average, during the past 7 days, how often did you feel: Concerned about getting a cold or your breathing getting worse?","CCQ 1 Week Version - Concern About Breathing Get Worse | CCQ02-Concern About Breathing Get Worse | CCQ0203",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899834","CCQ 1 Week Version - Depressed Because of Breathing Problem","C119135","Clinical COPD Questionnaire 1 Week Version (CCQ 1 Week Version) On average, during the past 7 days, how often did you feel: Depressed because of your breathing problems?","CCQ 1 Week Version - Depressed Because of Breathing Problem | CCQ02-Depressed for Breathing Problem | CCQ0204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899833","CCQ 1 Week Version - Did You Cough","C119136","Clinical COPD Questionnaire 1 Week Version (CCQ 1 Week Version) In general, during the past 7 days, how much of the time: Did you cough?","CCQ 1 Week Version - Did You Cough | CCQ02-Cough | CCQ0205",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899832","CCQ 1 Week Version - Produce Sputum or Phlegm","C119137","Clinical COPD Questionnaire 1 Week Version (CCQ 1 Week Version) In general, during the past 7 days, how much of the time: Did you produce sputum or phlegm?","CCQ 1 Week Version - Produce Sputum or Phlegm | CCQ02-Produce Sputum or Phlegm | CCQ0206",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899836","CCQ 1 Week Version - Breathing Problems Limit Strenuous Activity","C119138","Clinical COPD Questionnaire 1 Week Version (CCQ 1 Week Version) On average, during the past 7 days, how limited were you in these activities because of your breathing problems: Strenuous physical activities?","CCQ 1 Week Version - Breathing Problems Limit Strenuous Activity | CCQ02-Breathing Limit Strenuous Activity | CCQ0207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899371","Diphenhydramine/Lidocaine/Antacid Mouthwash","C118291","An oral rinse containing the antihistamine diphenhydramine hydrochloride, the topical anesthetic agent lidocaine, and the antacids aluminum hydroxide and magnesium hydroxide (DLA), with potential analgesic and anti-mucositic activities. Upon swishing and gargling with the DLA rinse, the diphenhydramine may provide analgesia; the lidocaine exerts an anesthetic activity which may further relieve mucositis-associated pain; the antacids, aluminum and magnesium hydroxide, are able to provide a coating of the rinse over the lesions in the oral mucosa and neutralize acids. Altogether, this rinse may reduce the symptoms of chemo- and radiotherapy-induced mucositis.","Diphenhydramine/Lidocaine/Antacid Mouthwash | DLA Mouthwash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0391752","CAP18 lipopolysaccharide-binding protein","C118292","A synthetic form of a human antimicrobial peptide (37 amino acids), belonging to the cathelicidin family, with antimicrobial, anti-inflammatory, immunostimulating and potential antineoplastic activities. Upon intratumoral injection of the ropocamptide, this peptide increases p53 expression, and induces phosphatidylserine externalization, DNA fragmentation, cell cycle arrest and caspase-independent apoptosis-inducing factor (AIF)/ endonuclease G (EndoG)-mediated apoptotic cell death in susceptible cancer cells. This suppresses tumor cell proliferation.  LL-37, a protein secreted by bone marrow cells, circulating leukocytes, and various epithelial tissues, plays a crucial role in the innate host immune defense via the regulation of leukocyte chemotaxis and cytokine production; it also promotes wound healing.","Ropocamptide | Antimicrobial Peptide, Human LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | Cathelicidin LL-37 | LL-37 | ROPOCAMPTIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896647","Miracle Mouthwash Plus Hydrocortisone","C118293","An oral rinse containing miracle mouthwash and the corticosteroid hydrocortisone, with potential anti-mucositic activity. Upon rinsing with this mouthwash, the ingredients in the miracle mouthwash may provide analgesia; the hydrocortisone modulates the production of pro-inflammatory cytokines which may prevent inflammation of the oral mucosa, and reduce chemotherapy- and/or radiation-induced oral mucositis.","Miracle Mouthwash Plus Hydrocortisone | MMW Plus HC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899341","Donafenib","C118294","An orally available multikinase inhibitor that targets Raf kinase and various receptor tyrosine kinases (RTKs), with potential antineoplastic activity. Upon oral administration, donafenib binds to and blocks the activity of Raf kinase, and inhibits Raf-mediated signal transduction pathways. This inhibits cell proliferation in Raf-expressing tumor cells. In addition, this agent may inhibit unidentified RTKs, and thus may further block tumor cell proliferation in susceptible tumor cells. Raf, a serine/threonine protein kinase, plays a key role in the Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway. Deregulation of this pathway often results in tumor cell proliferation and survival.","Donafenib | 2-Pyridinecarboxamide, 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-(methyl-d3)- | 4-(4-((4-Chloro-3-(trifluoromethyl)phenyl)carbamoylamino)phenoxy)-N-(trideuteriomethyl)pyridine-2-carboxamide | CM 4307 | CM-4307 | CM4307 | DONAFENIB | Zepsun",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897147","Zirconium Zr 89 Girentuximab","C118295","A radioimmunoconjugate comprised of the recombinant chimeric monoclonal antibody girentuximab, that binds an extracellular epitope of carbonic anhydrase IX (CAIX), and labeled with the radioisotope zirconium 89 (Zr 89) with potential use as an imaging agent upon positron emission tomography (PET). The antibody moiety of zirconium Zr 89 girentuximab binds to CAIX expressed on tumor cells. Upon binding, the radioisotope moiety may be detected using PET, which enables the imaging and quantification of CAIX-expressing tumor cells. CAIX, a hypoxia-inducible transmembrane glycoprotein, is overexpressed on renal cell carcinoma (RCC) and various other tumors; it plays a key role in intra- and extracellular pH regulation, cancer cell progression, survival, migration and invasion.","Zirconium Zr 89 Girentuximab | 89Zr-DFO-TFP-girentuximab | 89Zr-TLX250 | 89Zr-girentuximab | Zirconium Zr 89 cG250 | Zirconium Zr 89-TLX250",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890198","LGR6 wt Allele","C118964","Human LGR6 wild-type allele is located in the vicinity of 1q32.1 and is approximately 126 kb in length. This allele, which encodes leucine-rich repeat-containing G-protein coupled receptor 6 protein, plays a role in the mediation of R-spondin-dependent signaling.","LGR6 wt Allele | FLJ14471 | GPCR | Leucine-Rich Repeat Containing G Protein-Coupled Receptor 6 wt Allele | RP11-572A16.3 | UNQ6427/PRO21331 | VTS20631",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0962886","Leucine-Rich Repeat-Containing G-Protein Coupled Receptor 6, Human","C118965","Leucine-rich repeat-containing G-protein coupled receptor 6 (967 aa, ~104 kDa) is encoded by the human LGR6 gene. This protein is involved in both binding to R-spondin proteins and potentiating ligand-dependent signaling pathways.","Leucine-Rich Repeat-Containing G-Protein Coupled Receptor 6 | Leucine-Rich Repeat-Containing G Protein-Coupled Receptor 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896604","CDISC SDTM Cardiovascular Findings About Test Name Terminology","C119014","Terminology associated with the cardiovascular findings about test names codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Cardiovascular Findings About Test Name Terminology | CVFATS | Cardiovascular Findings About Test Name | SDTM-CVFATS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2717358","Natural Cytotoxicity Triggering Receptor 3 Ligand 1, Human","C118530","Natural cytotoxicity triggering receptor 3 ligand 1 (454 aa, ~51 kDa) is encoded by the human NCR3LG1 gene. This protein is involved in the activation of natural killer cell-mediated cytotoxicity.","Natural Cytotoxicity Triggering Receptor 3 Ligand 1 | B7-H6 | NCR3LG1 | Putative Ig-Like Domain-Containing Protein DKFZp686O24166/DKFZp686I21167",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890356","EP400 wt Allele","C118532","Human EP400 wild-type allele is located in the vicinity of 12q24.33 and is approximately 131 kb in length. This allele, which encodes E1A-binding protein p400, is involved in the regulation of both gene expression and histone acetylation.","EP400 wt Allele | CAGH32 | DKFZP434I225 | Domino, Drosophila, Homolog of Gene | E1A Binding Protein P400 wt Allele | P400 | TNRC12 | Trinucleotide Repeat-Containing Gene 12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1567299","E1A-Binding Protein P400, Human","C118533","E1A-binding protein p400 (3159 aa, ~343 kDa) is encoded by the human EP400 gene. This protein plays a role in the modulation of transcription through the regulation of histone acetylation.","E1A-Binding Protein P400 | CAG Repeat Protein 32 | Domino Homolog | E1A-Binding Protein, 400-kD | EC 3.6.4.- | EP400 | Trinucleotide Repeat Containing 12 | Trinucleotide Repeat-Containing Gene 12 Protein | hDomino | p400 | p400 SWI2/SNF2-Related Protein | p400 kDa SWI2/SNF2-Related Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890004","SPATA20 wt Allele","C118535","Human SPATA20 wild-type allele is located in the vicinity of 17q21.33 and is approximately 13 kb in length. This allele, which encodes spermatogenesis-associated protein 20, may play a role in germ cell maturation.","SPATA20 wt Allele | FLJ21347 | SSP411 | Spermatogenesis Associated 20 wt Allele | Tisp78 | Transcript Increased in Spermiogenesis 78 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889633","Spermatogenesis-Associated Protein 20, human","C118536","Spermatogenesis-associated protein 20 (786 aa, ~88 kDa) is encoded by the human SPATA20 gene. This protein may be involved in fertility.","Spermatogenesis-Associated Protein 20 | Hypothetical Protein FLJ21347 | Sperm Protein SSP411 | Sperm-Specific Protein 411 | Ssp411",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890374","PEX5L wt Allele","C118538","Human PEX5L wild-type allele is located in the vicinity of 3q27.33 and is approximately 242 kb in length. This allele, which encodes PEX5-related protein, is involved in the regulation of both hyperpolarization-activated cyclic nucleotide-gated channels and downstream signaling pathways.","PEX5L wt Allele | PEX5R | PEX5RP | PXR2 | PXR2B | Peroxisomal Biogenesis Factor 5-Like wt Allele | TRIP8b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2354707","PEX5-Related Protein, Human","C118539","PEX5-related protein (626 aa, ~70 kDa) is encoded by the human PEX5L gene. This protein plays a role in the localization of hyperpolarization-activated cyclic nucleotide-gated channels.","PEX5-Related Protein | PEX2-Related Protein | PEX5-Like Protein | Peroxin-5-Related | Peroxisome Biogenesis Factor 5-Like | Pex5Rp | Pex5p-Related Protein | TRIP8b | Tetratricopeptide Repeat-Containing Rab8b-Interacting Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899335","Doxycycline Hyclate Foam","C118369","A foam-based formulation composed of the hyclate salt form of doxycycline, a synthetic, broad-spectrum tetracycline antibiotic, with antimicrobial activity. Upon topical application of the foam, doxycycline reversibly binds to the bacterial 30S ribosomal subunit, and blocks the binding of aminoacyl-tRNA to the mRNA-ribosome complex. This leads to an inhibition of bacterial protein synthesis. This may prevent both the bacterial infections and the subsequent infections and pain associated with epidermal growth factor receptor inhibitor (EGFRI)-induced acne-like rash.","Doxycycline Hyclate Foam | FDX104 | FDX104 Antibiotic Foam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0286382","Polaprezinc","C118371","An orally bioavailable chelate composed of zinc and L-carnosine, with potential gastroprotective, anti-oxidant, anti-ulcer and anti-inflammatory activities. Upon administration, polaprezinc increases the expression of various anti-oxidant enzymes, such as superoxide dismutase 1 (SOD-1), SOD-2, heme oxygenase-1 (HO-1), glutathione S-transferase (GST), glutathione peroxidase (GSH-px), peroxidredoxin-1 (PRDX1; PRXI) and PRXD5 (PRXV) in the gastric mucosa, which protect cells against reactive oxygen species (ROS). In addition, this agent inhibits the activity of the transcription factor nuclear factor-kappaB (NF-kappaB) and reduces the expression of several pro-inflammatory cytokines, such as interleukin (IL) 1beta, IL-6, IL-8, and tumor necrosis factor alpha (TNF-a). Polaprezinc also increases the expression of various growth factors, such as platelet-derived growth factor-B (PDGF-B), vascular endothelial growth factor (VEGF), and nerve growth factor (NGF), and various heat shock proteins (HSPs), including HSP90, HSP70, HSP60, HSP47, HSP27, and HSP10. This protects against damages to, and accelerates healing of the gastric mucosa.","Polaprezinc | Aprozinate | Carnosine Zinc Complex | POLAPREZINC | Z 103 | Zinc L-carnosine | Zinc, (beta-alanyl-kappaN-L-histidinato(2-)-kappaN,kappaO)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899962","BTC Gene Product","C118372","A protein encoded by the BTC gene.","BTC Gene Product | BTC Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897853","Probetacellulin","C118373","Probetacellulin (178 aa, ~20 kDa) is encoded by the human BTC gene. This protein plays a role in cellular proliferation.","Probetacellulin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019287","Epigastric Hernia","C118374","Protrusion of abdominal cavity contents or pre-peritoneal fat through the abdominal wall between the umbilicus and the xiphoid process.","Epigastric Hernia | ",,,,,,,,,,,,,,,"4128844","Epigastric hernia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3276775","Umbilical Hernia","C118375","Protrusion of the abdominal cavity contents through the abdominal wall at the umbilicus.","Umbilical Hernia | ",,,,,,,,,,,,,,,"4245842","Umbilical hernia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899001","HBEGF Gene Product","C118379","A protein encoded by the HBEGF gene.","HBEGF Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899838","CCQ 1 Week Version - Breathing Problems Limit Moderate Activity","C119139","Clinical COPD Questionnaire 1 Week Version (CCQ 1 Week Version) On average, during the past 7 days, how limited were you in these activities because of your breathing problems: Moderate physical activities?","CCQ 1 Week Version - Breathing Problems Limit Moderate Activity | CCQ02-Breathing Limit Moderate Activity | CCQ0208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899837","CCQ 1 Week Version - Breathing Problems Limit Social Activity","C119141","Clinical COPD Questionnaire 1 Week Version (CCQ 1 Week Version) On average, during the past 7 days, how limited were you in these activities because of your breathing problems: Social activities?","CCQ 1 Week Version - Breathing Problems Limit Social Activity | CCQ02-Breathing Limit Social Activity | CCQ0210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897247","Unable to Confirm Conditions of Use","C118651","Cannot verify the situation surrounding the condition in which something is used.","Unable to Confirm Conditions of Use | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898743","Intended for Transitional Use","C118652","Planned to be used transitionally.","Intended for Transitional Use | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890553","FABP6 wt Allele","C118967","Human FABP6 wild-type allele is located within 5q33.3-q34 and is approximately 51 kb in length. This allele, which encodes gastrotropin protein, is involved in bile acid and bile salt transport.","FABP6 wt Allele | Fatty Acid Binding Protein 6, Ileal wt Allele | I-15P | I-BABP | I-BALB | I-BAP | IBABP | ILBP | ILBP3 | ILLBP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1435727","Gastrotropin, Human","C118968","Gastrotropin (128 aa, ~14 kDa) is encoded by the human FABP6 gene. This protein plays a role in bile salt and bile acid transport.","Gastrotropin | FABP6 | Fatty Acid-Binding Protein 6 | GT | I-15P | I-BABP | ILBP | Ileal Bile Acid Binding Protein | Ileal Lipid-Binding Protein | Illeal Lipid-Binding Protein | Intestinal 15 kDa Protein | Intestinal Bile Acid-Binding Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899617","Clinical Classification","C118969","A named instrument whose output is an ordinal or categorical score that serves as a surrogate for, or ranking of, disease status or other physiological or biological status.","Clinical Classification | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899810","CDISC Clinical Classification Terminology","C118970","The terminology subset that includes terms pertaining to the CDISC clinical classification terminology.","CDISC Clinical Classification Terminology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1955902","Annonaceous Acetogenins","C118972","A family of naturally occurring polyketides that consist of C32 or C34 long chain fatty acids and combined with a propan-2-ol unit at C-2 to form a gamma-lactone, which are isolated from various species of the plant family Annonaceae, with potential antineoplastic and antimicrobial activity. Annonaceous acetogenins bind to the ubiquinone catalytic site(s) within the mitochondrial NADH:ubiquinone oxidoreductase (complex I), and block the electron transport chain in mitochondria. In addition, the acetogenins bind to and block the activity of ubiquinone-linked NADH oxidase, an enzyme overexpressed in the plasma membranes of cancer cells. This inhibits adenosine triphosphate (ATP) production, decreases intracellular ATP levels, and induces tumor cell apoptosis. Compared to normal cells, cancer cells have higher ATP demands. The Annonaceous acetogenins also inhibit microbial glucose dehydrogenase 6.","Annonaceous Acetogenins | Acetogenins",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897113","PTPRC Gene Product","C118491","A protein encoded by the human PTPRC gene.","PTPRC Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889972","ASS1 wt Allele","C118541","Human ASS1 wild-type allele is located in the vicinity of 9q34.1 and is approximately 57 kb in length. This allele, which encodes argininosuccinate synthase protein, plays a role in amino acid metabolism and blood pressure. Mutation of the gene is associated with citrullinemia type 1.","ASS1 wt Allele | ASS | Argininosuccinate Synthase 1 wt Allele | CTLN1 | RP11-618A20.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003776","Argininosuccinate Synthase","C118542","Argininosuccinate synthase (412 aa, ~47 kDa) is encoded by the human ASS1 gene. This protein is involved in the biosynthesis of arginine.","Argininosuccinate Synthase | ASS1 | Argininosuccinate Synthase 1 | Argininosuccinate Synthetase | Argininosuccinate Synthetase 1 | Citrulline--Aspartate Ligase | Citrulline-Aspartate Ligase | Citrulline—Aspartate Ligase | EC 6.3.4.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471795","Paravertebral Block","C118543","A technique where a bolus of local anesthetic is injected in the paravertebral space, in the vicinity of the thoracic spinal nerves, resulting in ipsilateral somatic and sympathetic nerve blockade within the chest or abdomen.","Paravertebral Block | PVB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1263858","Merosin-Deficient Congenital Muscular Dystrophy Type 1A","C118783","An autosomal recessive inherited congenital muscular dystrophy caused by mutations in the LAMA2 gene. It is characterized by severe hypotonia, muscle weakness, elevated levels of serum creatinine kinase, and white matter abnormalities.","Merosin-Deficient Congenital Muscular Dystrophy Type 1A | MDC1A",,,,,,,,,,,,,,,"37204001|4006462","Congenital muscular dystrophy type 1A|Merosin deficient congenital muscular dystrophy",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1850569","Nemaline Myopathy 2","C118784","An autosomal recessive inherited myopathy caused by mutations in the NEB gene. It is characterized by generalized hypotonia and skeletal muscle weakness.","Nemaline Myopathy 2 | NEM2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342684","Ocular Albinism Type 1","C118785","An X-linked inherited disorder caused by mutations in the GPR143 gene. It is characterized by reduced visual acuity and reduced stereoscopic vision. Other abnormalities include nystagmus, strabismus, and photophobia.","Ocular Albinism Type 1 | Nettleship-Falls Syndrome | OA1",,,,,,,,,,,,,,,"4301895","Ocular albinism, type I",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265259","Autosomal Dominant Popliteal Pterygium Syndrome","C118786","A rare, autosomal dominant inherited syndrome caused by mutations in the IRF6 gene. It is characterized by the presence of cleft palate, cleft lip, pits in the lower lip, web behind the knee (popliteal pterygium), syndactyly, cryptorchidism, scrotal malformation, and hypoplasia of the labia majora.","Autosomal Dominant Popliteal Pterygium Syndrome | ",,,,,,,,,,,,,,,"37397557","Autosomal dominant popliteal pterygium syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0796154","Simpson Golabi Behmel Syndrome Type 1","C118787","A rare, X-linked inherited syndrome caused by mutations in the GPC3 and GPC4 genes. It is characterized by pre-and postnatal overgrowth, coarse facial features, macrocephaly, macroglossia, congenital heart defects, and intellectual disability.","Simpson Golabi Behmel Syndrome Type 1 | SGBS1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0339510","Vitelliform Macular Dystrophy","C118788","A rare genetic disorder characterized by macular degeneration in the retina resulting in progressive loss of central vision with retention of the peripheral vision. It may be of early onset, autosomal dominant inherited and caused by mutations in the BEST1 gene (BEST disease) or late onset, caused by mutations in the PRPH2 gene.","Vitelliform Macular Dystrophy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896884","Modified-release Calcifediol Capsule","C118789","An orally available, modified-release formulation containing the calcitriol prohormone, calcifediol (25-hydroxyvitamin D), which can potentially be used for vitamin D supplementation. Upon oral administration of the modified-release calcifediol capsule, calcifediol is slowly and gradually released in the gastrointestinal tract. Then it is taken up by the body and converted, in the kidneys, to the active form calcitriol (1,25-dihydroxyvitamin D or 1,25 D). This form increases and normalizes vitamin D plasma levels, which, in turn, regulates calcium plasma levels, and normalizes elevated parathyroid hormone (PTH) levels by suppressing both PTH synthesis, and secretion. This formulation appears to have fewer side effects than supplementation with formulations containing active 1,25 D and does not stimulate the upregulation of vitamin D 24-hydroxylase (CYP24), a cytochrome P-450 family enzyme that inactivates vitamin D.","Modified-release Calcifediol Capsule | CTAP101 | Rayaldee",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896573","CDISC Questionnaire AUDIT-C Test Name Terminology","C119061","Test names of questionnaire questions associated with the Alcohol Use Disorder Identification Test-Consumption Questions (AUDIT-C) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire AUDIT-C Test Name Terminology | ADTC01TN | Alcohol Use Disorder Identification Test-Consumption Questions Questionnaire Test Name | QS-AUDIT-C TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896637","CDISC Questionnaire AUDIT-C Test Code Terminology","C119062","Test codes of questionnaire questions associated with the Alcohol Use Disorder Identification Test-Consumption Questions (AUDIT-C) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire AUDIT-C Test Code Terminology | ADTC01TC | Alcohol Use Disorder Identification Test-Consumption Questions Questionnaire Test Code | QS-AUDIT-C TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896630","CDISC Questionnaire CCQ 24 Hour Version Test Name Terminology","C119063","Test names of questionnaire questions associated with the Clinical COPD Questionnaire 24 Hour Version (CCQ 24 Hour Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire CCQ 24 Hour Version Test Name Terminology | CCQ01TN | Clinical COPD Questionnaire 24 Hour Version Questionnaire Test Name | QS-CCQ 24 Hour Version TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896631","CDISC Questionnaire CCQ 24 Hour Version Test Code Terminology","C119064","Test codes of questionnaire questions associated with the Clinical COPD Questionnaire 24 Hour Version (CCQ 24 Hour Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire CCQ 24 Hour Version Test Code Terminology | CCQ01TC | Clinical COPD Questionnaire 24 Hour Version Questionnaire Test Code | QS-CCQ 24 Hour Version TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896632","CDISC Questionnaire CCQ 1 Week Version Test Name Terminology","C119065","Test names of questionnaire questions associated with the Clinical COPD Questionnaire 1 Week Version (CCQ 1 Week Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire CCQ 1 Week Version Test Name Terminology | CCQ02TN | Clinical COPD Questionnaire 1 Week Version Questionnaire Test Name | QS-CCQ 1 Week Version TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896628","CDISC Questionnaire CHART-SF Paper Version Test Name Terminology","C119067","Test names of questionnaire questions associated with the Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire CHART-SF Paper Version Test Name Terminology | CHSF2TN | Craig Handicap Assessment and Reporting Technique - Short Form Paper Version Questionnaire Test Name | QS-CHART-SF Paper Version TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896629","CDISC Questionnaire CHART-SF Paper Version Test Code Terminology","C119068","Test codes of questionnaire questions associated with the Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire CHART-SF Paper Version Test Code Terminology | CHSF2TC | Craig Handicap Assessment and Reporting Technique - Short Form Paper Version Questionnaire Test Code | QS-CHART-SF Paper Version TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896624","CDISC Questionnaire DLQI Test Name Terminology","C119069","Test names of questionnaire questions associated with the Dermatology Life Quality Index (DLQI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire DLQI Test Name Terminology | DLQI1TN | Dermatology Life Quality Index Questionnaire Test Name | QS-DLQI TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896625","CDISC Questionnaire DLQI Test Code Terminology","C119070","Test codes of questionnaire questions associated with the Dermatology Life Quality Index (DLQI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire DLQI Test Code Terminology | DLQI1TC | Dermatology Life Quality Index Questionnaire Test Code | QS-DLQI TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897884","Polyethylene Glycol Hydrogel","C118668","A 2- or 3-dimensional hydrophilic, cross-linked polymer of polyethylene glycol (PEG). These hydrogels can be used as scaffolds for tissue engineering or as drug delivery carriers.","Polyethylene Glycol Hydrogel | PEG Hydrogel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826562","PDX1 Gene","C118247","This gene plays a role in the regulation of insulin and insulin-responsive genes.","PDX1 Gene | PDX1 | Pancreatic and Duodenal Homeobox 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889249","PDX1 wt Allele","C118248","Human PDX1 wild-type allele is located in the vicinity of 13q12.1 and is approximately 6 kb in length. This allele, which encodes pancreas/duodenum homeobox protein 1, is involved in transcriptional regulation of insulin and other pancreatic genes. Mutation of the gene is associated with pancreatic agenesis, susceptibility to early-onset insulin-dependent diabetes mellitus, and maturity onset diabetes of the young type 4.","PDX1 wt Allele | GSF | IDX-1 | IPF1 | IUF1 | Insulin Promoter Factor 1, Homeodomain Transcription Factor Gene | MODY4 | PAGEN1 | PDX-1 | Pancreatic and Duodenal Homeobox 1 wt Allele | STF-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1528563","Pancreas/Duodenum Homeobox Protein 1, Human","C118249","Pancreas/duodenum homeobox protein 1 (283 aa, ~31 kDa) is encoded by the human PDX1 gene. This protein plays a role in the modulation of insulin expression.","Pancreas/Duodenum Homeobox Protein 1 | GSF | Glucose-Sensitive Factor | Homeodomain Transcription Factor IPF1 | IDX-1 | IUF-1 | Insulin Promoter Factor 1 | Insulin Upstream Factor 1 | Islet/Duodenum Homeobox-1 | PDX-1 | Pancreatic-Duodenal Homeobox Factor 1 | STF-1 | Somatostatin Transcription Factor 1 | Somatostatin-Transactivating Factor 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899814","CD45RC","C118494","CD45RC (1193 aa, ~136 kDa) is encoded by the human PTPRC gene. This protein plays a role in both lymphocyte activity and protein dephosphorylation. It is an isoform of receptor-type tyrosine-protein phosphatase C that is missing the amino acids encoded by exons 4 and 5 of the PTPRC gene.","CD45RC | CD45RC Antigen | Receptor-Type Tyrosine-Protein Phosphatase C Isoform 8 | Receptor-Type Tyrosine-Protein Phosphatase C Isoform CD45RC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0070005","Pancratistatin","C1184","A isoquinoline alkaloid from amaryllis with antineoplastic activity.","Pancratistatin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0422985","Binocular Diplopia","C118718","Perception of two images secondary to misalignment of the eyes.","Binocular Diplopia | ",,,,,,,,,,,,,,,"4080689","Binocular diplopia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0271190","Monocular Diplopia","C118719","Perception of more than one image when viewing with one eye.","Monocular Diplopia | ",,,,,,,,,,,,,,,"4175300","Monocular diplopia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899995","Autologous NY-ESO-1-specific CD8-positive T Lymphocytes","C118790","A preparation of autologous CD8+ T-lymphocytes specifically reactive to the cancer-testis antigen NY-ESO-1, with potential immunostimulating and antineoplastic activities. Autologous NY-ESO-1-specific CD8+ T-lymphocytes were generated from T-cells isolated from a particular cancer patient, which were made specifically reactive to the NY-ESO-1 antigen, expanded ex vivo, and reintroduced into the patient. These tumor-reactive T-cells may stimulate a host immune response against tumor cells expressing the NY-ESO-1 antigen, resulting in tumor cell lysis. NY-ESO-1, an antigen found in normal testis, may be upregulated in various cancers.","Autologous NY-ESO-1-specific CD8-positive T Lymphocytes | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2610844","Shelterin","C118795","A protein complex that is physically bound to chromosomal telomeres and plays a role in both the elongation and maintenance of telomeric repeats.","Shelterin | Shelterin Complex | Telosome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889132","CCDC170 wt Allele","C118338","Human CCDC170 wild-type allele is located in the vicinity of 6q25.1 and is approximately 127 kb in length. This allele, which encodes coiled-coil domain-containing protein 170, may be involved in bone development.","CCDC170 wt Allele | C6orf97 | Chromosome 6 Open Reading Frame 97 Gene | Coiled-Coil Domain Containing 170 wt Allele | FLJ23305 | bA282P11.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889631","Coiled-Coil Domain-Containing Protein 170, Human","C118339","Coiled-coil domain-containing protein 170 (715 aa, ~82 kDa) is encoded by the human CCDC170 gene. This protein may play a role in bone development.","Coiled-Coil Domain-Containing Protein 170 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824811","CTR9 Gene","C118340","This gene is involved in embryonic stem cell pluripotency, transcriptional elongation and histone modification.","CTR9 Gene | CTR9 | CTR9, Paf1/RNA Polymerase II Complex Component Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890203","CTR9 wt Allele","C118341","Human CTR9 wild-type allele is located in the vicinity of 11p15.3 and is approximately 29 kb in length. This allele, which encodes RNA polymerase-associated protein CTR9 homolog protein, plays a role in histone modification, embryonic stem cell pluripotency and transcriptional elongation.","CTR9 wt Allele | CTR9, Paf1/RNA Polymerase II Complex Component wt Allele | CTR9, S. cerevisiae, Homolog of Gene | Ctr9, Paf1/RNA Polymerase II Complex Component, Homolog (S. cerevisiae) Gene | Ctr9, Paf1/RNA Polymerase II Complex Component, Homolog Gene | KIAA0155 | SH2 Domain Binding Protein 1 (Tetratricopeptide Repeat Containing) Gene | SH2BP1 | TSBP | p150 | p150TSP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1434625","RNA Polymerase-Associated Protein CTR9 Homolog, Human","C118342","RNA polymerase-associated protein CTR9 homolog (1173 aa, ~134 kDa) is encoded by the human CTR9 gene. This protein is involved in transcriptional elongation, histone modification and embryonic stem cell pluripotency.","RNA Polymerase-Associated Protein CTR9 Homolog | SH2 Domain-Binding Protein 1 | TPR-Containing, SH2-Binding Phosphoprotein | Tetratricopeptide-Containing SH2-Binding Phosphoprotein, 150-kD | p150(TSP)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428996","TENT4B Gene","C118343","This gene is involved in mRNA polyadenylation.","TENT4B Gene | PAPD5 | TENT4B | Terminal Nucleotidyltransferase 4B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896615","CDISC Questionnaire RPQ Test Name Terminology","C119071","Test names of questionnaire questions associated with the Rivermead Post-Concussion Symptoms Questionnaire (RPQ) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).","CDISC Questionnaire RPQ Test Name Terminology | QS-RPQ TEST | RPQ01TN | Rivermead Post Concussion Symptoms Questionnaire Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889149","SMAD5 wt Allele","C118586","Human SMAD5 wild-type allele is located in the vicinity of 5q31 and is approximately 56 kb in length. This allele, which encodes mothers against decapentaplegic homolog 5 protein, plays a role in the regulation of gene expression.","SMAD5 wt Allele | DWFC | JV5-1 | MAD, Mothers Against Decapentaplegic Homolog 5 (Drosophila) Gene | MAD, Mothers Against Decapentaplegic Homolog 5 Gene | MADH5 | Mothers Against Decapentaplegic, Drosophila, Homolog of, 5 Gene | SMAD Family Member 5 wt Allele | SMAD, Mothers Against DPP Homolog 5 (Drosophila) Gene | SMAD, Mothers Against DPP Homolog 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1566807","Mothers Against Decapentaplegic Homolog 5, Human","C118587","Mothers against decapentaplegic homolog 5 (465 aa, ~52 kDa) is encoded by the human SMAD5 gene. This protein is involved in transcriptional regulation mediated by receptor signaling.","Mothers Against Decapentaplegic Homolog 5 | JV5-1 | MAD Homolog 5 | Mothers Against DPP Homolog 5 | SMA- and MAD-Related Protein 5 | SMAD 5 | Smad5 | hSmad5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889694","CEACAM8 wt Allele","C118589","Human CEACAM8 wild-type allele is located in the vicinity of 19q13.2 and is approximately 15 kb in length. This allele, which encodes carcinoembryonic antigen-related cell adhesion molecule 8 protein, may be involved in immune cell activation.","CEACAM8 wt Allele | CD66b | CD67 | CGM6 | Carcinoembryonic Antigen-Related Cell Adhesion Molecule 8 wt Allele | NCA-95",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1619633","Carcinoembryonic Antigen-Related Cell Adhesion Molecule 8","C118590","Carcinoembryonic antigen-related cell adhesion molecule 8 (349 aa, ~38 kDa) is encoded by the human CEACAM8 gene. This protein may play a role in the activation of immune cells.","Carcinoembryonic Antigen-Related Cell Adhesion Molecule 8 | CD66b | CD66b Antigen | CD67 Antigen | CEACAM8 | Carcinoembryonic Antigen CGM6 | Carcinoembryonic Antigen Gene Family Member 6 | Non-Specific Cross-Reacting Antigen NCA-95",,,,,,,,,,,,,,,"4216980","Lymphocyte antigen CD67",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3890557","F11R wt Allele","C118592","Human F11R wild-type allele is located within 1q21.2-q21.3 and is approximately 26 kb in length. This allele, which encodes junctional adhesion molecule A protein, plays a role in the modulation of cell-cell junction formation.","F11R wt Allele | CD321 | F11 Receptor wt Allele | JAM | JAM1 | JAMA | JCAM | Junctional Adhesion Molecule, Mouse, Homolog of Gene | KAT | PAM-1 | RP11-544M22.2 | UNQ264/PRO301",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0913854","Junctional Adhesion Molecule A, Human","C118593","Junctional adhesion molecule A (299 aa, ~33 kDa) is encoded by the human F11R gene. This protein is involved in the regulation of cell-cell junction formation.","Junctional Adhesion Molecule A | CD321 | CD321 Antigen | JAM-1 | JAM-A | Junctional Adhesion Molecule 1 | PAM-1 | Platelet Adhesion Molecule 1 | Platelet F11 Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897359","Thymic Damage","C118258","Anatomic injury or physiologic dysfunction of the thymus gland.","Thymic Damage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889386","SLC1A5 wt Allele","C118926","Human SLC1A5 wild-type allele is located in the vicinity of 19q13.32 and is approximately 14 kb in length. This allele, which encodes neutral amino acid transporter B(0) protein, plays a role in both the transport of neutral amino acids and binding to select retroviruses.","SLC1A5 wt Allele | AAAT | ASCT2 | ATBO | M7V1 | M7VS1 | R16 | RD144 Sensitivity Gene | RDR | RDRC | Solute Carrier Family 1 (Neutral Amino Acid Transporter), Member 5 Gene | Solute Carrier Family 1 (Neutral Amino Acid Transporter), Member 5 wt Allele | Solute Carrier Family 1 Member 5 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0765165","SLC1A5 protein, human","C118927","Neutral amino acid transporter B(0) (541 aa, ~57 kDa) is encoded by the human SLC1A5 gene. This protein is involved in neutral amino acid transport and as a receptor for select retroviruses.","Neutral Amino Acid Transporter B(0) | ASC Amino Acid Transporter-2 | ASCT2 | ATB(0) | Alanine/Serine/Cysteine Transporter 2 | Baboon M7 Virus Receptor | Neutral Amino Acid Transporter B | Neutral Amino Acid Transporter-Like Protein | RD114 Virus Receptor | RD114/Simian Type D Retrovirus Receptor | SLC1A5 | Sodium-Dependent Neutral Amino Acid Transporter Type 2 | Solute Carrier Family 1 Member 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889435","KRT16 wt Allele","C118929","Human KRT16 wild-type allele is located in the vicinity of 17q21.2 and is approximately 6 kb in length. This allele, which encodes keratin, type I cytoskeletal 16 protein, is involved in epidermal and hair follicle maturation. Mutation of the gene is associated with type 1 pachyonychia congenita, non-epidermolytic palmoplantar keratoderma and unilateral palmoplantar verrucous nevus.","KRT16 wt Allele | CK16 | FNEPPK | Focal Non-Epidermolytic Palmoplantar Keratoderma Gene | K16 | K1CP | KRT16A | Keratin 16 wt Allele | NEPPK | PC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1672521","Keratin, Type I Cytoskeletal 16, Human","C118930","Keratin, type I cytoskeletal 16 (473 aa, ~51 kDa) is encoded by the human KRT16 gene. This protein plays a role in the maturation of the epidermis, hair follicles, and some mucosal surfaces.","Keratin, Type I Cytoskeletal 16 | CK-16 | Cytokeratin 16 | Cytokeratin-16 | K16 | KRT16 | Keratin-16",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1003859","Rhodobacteraceae","C118931","A taxonomic family of Gram negative bacterium in the phylum Proteobacteria that includes the genera Actibacterium, Agaricicola and Rhodobacter, among others.","Rhodobacteraceae | ",,,,,,,,,,,,,,,"4190245","Rhodobacteraceae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2651106","Amoebozoa","C118932","An unranked group of ameoboid protozoa that include Mycetozoa (slime-molds) and Archamoebae.","Amoebozoa | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019917","Stye","C118722","An infection of one or more of the glands surrounding the eye.","Stye | Hordeolum",,,,,,,,,,,,,,,"380403","External hordeolum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3808655","Blepharospasm","C118723","Involuntary twitching of the eyelid.","Blepharospasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0235267","Eye Redness","C118724","The prominence of the superficial vessels of the sclera or conjunctiva resulting in a red or pink appearance.","Eye Redness | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152246","Iridodialysis","C118725","A separation of the iris from the ciliary body.","Iridodialysis | Coredialysis",,,,,,,,,,,,,,,"437268","Iridodialysis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0730504","Pseudostrabismus","C118726","The false appearance of misalignment of the eyes.","Pseudostrabismus | ",,,,,,,,,,,,,,,"4193563","Pseudostrabismus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899501","Congruent Visual Field Defect","C118729","Identically shaped visual field defect in the same location in both eyes.","Congruent Visual Field Defect | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896988","Heteronymous Visual Field Defect","C118732","A bilateral visual field defect on opposite sides of the visual space of each eye (right or left).","Heteronymous Visual Field Defect | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0271202","Homonymous Visual Field Defect","C118733","A bilateral visual field defect on the same side of visual space of each eye (right or left).","Homonymous Visual Field Defect | ",,,,,,,,,,,,,,,"372897","Homonymous hemianopia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898773","Incongruent Visual Field Defect","C118734","Non-identically shaped visual field defect in the same location in both eyes.","Incongruent Visual Field Defect | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0271193","Peripheral Visual Field Defect","C118736","Reduced or abnormal sight in the peripheral visual field.","Peripheral Visual Field Defect | ",,,,,,,,,,,,,,,"4140833","Peripheral visual field defect",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036454","Scotoma","C118737","An area of impaired sight within the normal visual field.","Scotoma | ",,,,,,,,,,,,,,,"4050743","Visual field scotoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015401","Ocular Foreign Body","C118739","External material that enters the eye.","Ocular Foreign Body | ",,,,,,,,,,,,,,,"378747|765578","Retained foreign body in eye|Foreign body in eye",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0161003","Conjunctival Foreign Body","C118740","External material in or on the conjunctiva.","Conjunctival Foreign Body | ",,,,,,,,,,,,,,,"4334738","Conjunctival foreign body",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0161002","Corneal Foreign Body","C118741","External material in or on the cornea.","Corneal Foreign Body | ",,,,,,,,,,,,,,,"432768","Corneal foreign body",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL497251","Intraocular Foreign Body","C118742","External material inside the eyeball.","Intraocular Foreign Body | ",,,,,,,,,,,,,,,"378747","Retained foreign body in eye",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3889466","TRF4-2","C118344","Human TENT4B wild-type allele is located in the vicinity of 16q12.1 and is approximately 82 kb in length. This allele, which encodes non-canonical terminal nucleotidyltransferase 4B protein, plays a role in mRNA modification and stability.","TENT4B wt Allele | GLD4 | PAP Associated Domain Containing 5 Gene | PAPD5 | Poly(A) RNA Polymerase D5, Non-Canonical Gene | TRF4-2 | TUT3 | Terminal Nucleotidyltransferase 4B wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3252008","Non-Canonical PolyA RNA Polymerase PAPD5, Human","C118345","Terminal nucleotidyltransferase 4B (572 aa, ~63 kDa) is encoded by the human TENT4B gene. This protein is involved in mRNA quality control processes.","Terminal Nucleotidyltransferase 4B | EC 2.7.7.19 | Non-Canonical Poly(A) RNA Polymerase PAPD5 | Non-Canonical PolyA RNA Polymerase PAPD5 | PAP-Associated Domain-Containing Protein 5 | Poly(A) Polymerase-Associated Domain-Containing Protein 5 | TENT4B | TRF4-2 | TUTase 3 | TUTase3 | Terminal Guanylyltransferase | Terminal Uridylyltransferase 3 | Topoisomerase-Related Function Protein 4-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823922","ZC3H11A Gene","C118346","This gene plays a role in nuclear mRNA export.","ZC3H11A Gene | ZC3H11A | Zinc Finger CCCH-Type Containing 11A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889711","ZC3H11A wt Allele","C118347","Human ZC3H11A wild-type allele is located in the vicinity of 1q32.1 and is approximately 59 kb in length. This allele, which encodes zinc finger CCCH domain-containing protein 11A, is involved in RNA export.","ZC3H11A wt Allele | KIAA0663 | ZC3HDC11A | Zinc Finger CCCH-Type Containing 11A wt Allele | Zinc Finger CCCH-Type Domain Containing 11A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889403","Zinc Finger CCCH Domain-Containing Protein 11A, human","C118348","Zinc finger CCCH domain-containing protein 11A (810 aa, ~89 kDa) is encoded by the human ZC3H11A gene. This protein plays a role in mRNA export.","Zinc Finger CCCH Domain-Containing Protein 11A | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418870","PRC1 Gene","C118349","This gene is involved in cytokinesis.","PRC1 Gene | PRC1 | Protein Regulator of Cytokinesis 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889989","PRC1 wt Allele","C118350","Human PRC1 wild-type allele is located in the vicinity of 15q26.1 and is approximately 30 kb in length. This allele, which encodes protein regulator of cytokinesis 1, plays a role in both mitotic spindle integrity and cytokinesis.","PRC1 wt Allele | ASE1 | Anaphase Spindle Elongation 1 Homolog (S. cerevisiae) Gene | Protein Regulator of Cytokinesis 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1308877","Protein Regulator of Cytokinesis 1, Human","C118351","Protein regulator of cytokinesis 1 (620 aa, ~72 kDa) is encoded by the human PRC1 gene. This protein is involved in both mitotic spindle crosslinks and cytokinesis.","Protein Regulator of Cytokinesis 1 | Anaphase Spindle Elongation 1 Homolog | Protein Regulating Cytokinesis 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896605","CDISC SDTM Cardiovascular Findings About Test Code Terminology","C119015","Terminology associated with the cardiovascular findings about test codes codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Cardiovascular Findings About Test Code Terminology | CVFATSCD | Cardiovascular Findings About Test Code | SDTM-CVFATSCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896606","CDISC SDTM Cardiovascular Findings About Results Terminology","C119016","Terminology associated with the cardiovascular findings about results codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Cardiovascular Findings About Results Terminology | CVFARS | Cardiovascular Findings About Results | SDTM-CVFARS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896607","CDISC SDTM Coronary Thrombus TIMI Grade Responses Terminology","C119017","Terminology associated with the coronary thrombus TIMI grade responses codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Coronary Thrombus TIMI Grade Responses Terminology | CTTIMIRS | Coronary Thrombus TIMI Grade Responses | SDTM-CTTIMIRS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896608","CDISC SDTM NHLBI Coronary Artery Dissection Grade Responses Terminology","C119018","Terminology associated with the NHLBI coronary artery dissection grade responses codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM NHLBI Coronary Artery Dissection Grade Responses Terminology | CADGRS | Coronary Artery Dissection NHLBI Grade Responses | SDTM-CADGRS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889402","ASAP1 wt Allele","C118598","Human ASAP1 wild-type allele is located within 8q24.1-q24.2 and is approximately 392 kb in length. This allele, which encodes Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1, is involved in the regulation of phosphoinositol-mediated signaling.","ASAP1 wt Allele | AMAP1 | ArfGAP with SH3 Domain, Ankyrin Repeat and PH Domain 1 wt Allele | CENTB4 | Centaurin, Beta 4 Gene | DDEF1 | Development and Differentiation Enhancing Factor 1 Gene | KIAA1249 | PAG2 | PAP | ZG14P",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900005","Autologous Anti-HPV-16 E6 T-cell Receptor Gene-engineered Peripheral Blood Lymphocytes","C118850","Human autologous peripheral blood lymphocytes (PBLs) transduced with a retroviral vector encoding a T cell receptor (TCR) that is specifically directed against the viral oncoprotein human papillomavirus type 16 (HPV-16) E6, with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the autologous anti-HPV-16 E6 TCR gene-engineered PBLs bind to HPV-16 E6-expressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of HPV-16 E6-positive cancer cells. HPV-16 E6, a cell surface glycoprotein, is overexpressed by a variety of HPV-associated cancers and is absent from healthy human tissues.","Autologous Anti-HPV-16 E6 T-cell Receptor Gene-engineered Peripheral Blood Lymphocytes | Autologous Anti-HPV-16 E6 TCR Gene-engineered PBLs | Autologous Anti-HPV-16 E6 TCR Gene-engineered Peripheral Blood Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899998","Autologous IL-2-expressing B-CLL Vaccine","C118851","A cancer vaccine consisting of autologous, B-chronic lymphocytic leukemia (B-CLL) cells harvested from a patient and transduced ex vivo with an adenoviral vector encoding the gene for the human cytokine interleukin-2 (IL-2), with potential immunostimulating and antineoplastic activities.  Upon reintroduction into the patient, the autologous IL-2-expressing B-CLL vaccine expresses IL-2, stimulates natural killer (NK) cells, and may enhance the cytotoxic T-lymphocyte (CTL) immune response against the patient's B-CLL cells.","Autologous IL-2-expressing B-CLL Vaccine | Autologous IL2-transduced CLL B Cell Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900003","Autologous CD40L-expressing B-CLL Vaccine","C118852","A cancer vaccine consisting of autologous, B-chronic lymphocytic leukemia (B-CLL) cells harvested from a patient and transduced with an adenoviral vector encoding the gene for the human CD40 ligand (CD40L; TRAP; CD154), with potential immunostimulating and antineoplastic activities. Upon reintroduction into the patient, the autologous CD40L-expressing B-CLL vaccine expresses the co-stimulatory molecule CD40L, which binds to its cognate receptor, CD40, on antigen presenting cells (APC). This induces apoptosis, stimulates maturation and proliferation of APCs, and facilitates a cytotoxic T-lymphocyte (CTL) response against tumor cells. CD40L is a type II membrane protein that binds to CD40, which is a cell surface receptor that belongs to the tumor necrosis factor (TNF) receptor superfamily.","Autologous CD40L-expressing B-CLL Vaccine | Autologous hCD40L-transduced CLL B Cell Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898626","Lamellar Laceration of the Globe","C118857","Traumatic injury to the globe, resulting in a partial thickness wound of the eyewall (cornea and/or sclera). (adapted from the Birmingham Eye Trauma Terminology System (BETTS))","Lamellar Laceration of the Globe | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0438624","Ocular Contusion","C118858","A closed globe injury without violation of the eyewall (cornea and/or sclera), resulting in injury to one or more intraocular structures. (adapted from the Birmingham Eye Trauma Terminology System (BETTS))","Ocular Contusion | ",,,,,,,,,,,,,,,"381444","Contusion of eye",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0154841","Central Retinal Vein Occlusion","C118859","Blockage of the central retinal vein.","Central Retinal Vein Occlusion | Central Retinal Venous Occlusion",,,,,,,,,,,,,,,"313761","Central retinal vein occlusion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899153","Fat Adherence Syndrome","C118860","Violation of Tenon's capsule with prolapse of orbital fat into the sub-Tenon's space.","Fat Adherence Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0000879","Acanthamoeba","C118934","A genus of motile, unicellular eukaryotic amoebae within the family of Acanthamoebidae that are characterized with the presence of acanthopodia (spiny surface projections) and are commonly found in air, soil, and water environments. Members of the Acanthamoeba genus are opportunistic and nonopportunistic human pathogens, and may cause granulomatous amoebic encephalitis, cutaneous acanthamebiasis and amoebic keratitis.","Acanthamoeba | ACANTHAMOEBA",,,,,,,,,,,,,,,"4179939","Acanthamoeba",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001180","Acremonium","C118935","A genus of slow growing, filamentous and cosmopolitan fungi within the phylum Ascomycota. Members of this genus produce hyaline, septate hyphae, whereas vegetative hyphae form hyphal ropes. Phialides are unbranched, solitary and erect, and form directly on the hyphal tips, the hyphal ropes, or both. Some species within the Acremonium genus are opportunistic pathogens and may cause mycetoma, onychomycosis, and hyalohyphomycosis in humans.","Acremonium | ACREMONIUM",,,,,,,,,,,,,,,"4274504","Acremonium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3900109","Acute Myocardial Infarction Type","C118936","A classification or description of the acute myocardial infarction.","Acute Myocardial Infarction Type | ACMITYPE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889130","ICOSLG wt Allele","C118937","Human ICOSLG wild-type allele is located in the vicinity of 21q22.3 and is approximately 18 kb in length. This allele, which encodes ICOS ligand protein, plays a role in the modulation of T-cell activity, B-cell differentiation, and lymphocyte proliferation.","ICOSLG wt Allele | B7-H2 | B7H2 | B7RP-1 | B7RP1 | CD275 | GL50 | ICOS-L | ICOSL | Inducible T-Cell Co-Stimulator Ligand wt Allele | KIAA0653 | LICOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1234552","Pannonibacter","C118938","No value exists.","Pannonibacter | ",,,,,,,,,,,,,,,"4330228","Pannonibacter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1032172","Actinobaculum","C118939","No value exists.","Actinobaculum | ",,,,,,,,,,,,,,,"4015403","Actinobaculum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024756","Mansonella","C118942","No value exists.","Mansonella | ",,,,,,,,,,,,,,,"4071436","Mansonella",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2927728","Sodium Sulfate/Potassium Sulfate/Magnesium Sulfate-based Laxative","C118453","An oral preparation containing sodium sulfate, potassium sulfate and magnesium sulfate, with osmotic laxative activity. Upon oral administration of the sodium sulfate/potassium sulfate/magnesium sulfate-based laxative, this osmotic laxative promotes the retention of water in the bowel. This increases the water content of stool, which results in increased gastrointestinal motility and facilitates the evacuation of colonic contents. This results in a complete cleansing of the colon.","Sodium Sulfate/Potassium Sulfate/Magnesium Sulfate-based Laxative | Suprep | Trisulfate Bowel Cleansing Solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890730","PTX3 wt Allele","C119681","Human PTX3 wild-type allele is located in the vicinity of 3q25 and is approximately 7 kb in length. This allele, which encodes pentraxin-related protein PTX3, plays a role in both complement activation and inflammation.","PTX3 wt Allele | Pentaxin-Related Gene, Rapidly Induced by IL-1 Beta Gene | Pentraxin 3, Long wt Allele | Pentraxin-Related Gene, Rapidly Induced by IL-1 Beta Gene | TNFAIP5 | TSG-14 | TSG14 | Tumor Necrosis Factor, Alpha-Induced Protein 5 Gene | Tumor Necrosis Factor-Inducible Gene 14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1571040","Human PTX3 Protein","C119682","Pentraxin-related protein PTX3 (381 aa, ~42 kDa) is encoded by the human PTX3 gene. This protein is involved in both inflammation and complement recognition of pathogens.","Pentraxin-Related Protein PTX3 | Pentaxin-Related Protein PTX3 | Pentraxin 3 | Pentraxin-3 | TNF Alpha-Induced Protein 5 | TSG-14 | Tumor Necrosis Factor Alpha-Induced Protein 5 | Tumor Necrosis Factor-Inducible Gene 14 Protein | Tumor Necrosis Factor-Inducible Protein TSG-14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823185","AMIGO2 Gene","C119683","This gene plays a role in cell-cell adhesion.","AMIGO2 Gene | AMIGO2 | Adhesion Molecule With Ig-Like Domain 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890772","AMIGO2 wt Allele","C119684","Human AMIGO2 wild-type allele is located in the vicinity of 12q13.11 and is approximately 4 kb in length. This allele, which encodes amphoterin-induced protein 2, is involved in both cell-cell adhesion and the inhibition of apoptosis.","AMIGO2 wt Allele | ALI1 | AMIGO-2 | Adhesion Molecule With Ig-Like Domain 2 wt Allele | Amphoterin Induced Gene 2 | Amphoterin-Induced Gene and Open Reading Frame 2 | DEGA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL480854","Amphoterin-Induced Protein 2","C119685","Amphoterin-induced protein 2 (522 aa, ~58 kDa) is encoded by the human AMIGO2 gene. This protein plays a role in both the negative regulation of apoptosis and the mediation of cell-cell adhesion.","Amphoterin-Induced Protein 2 | AMIGO-2 | Alivin 1 | Alivin-1 | DEGA | Differentially Expressed In Gastric Adenocarcinoma | Differentially Expressed In Gastric Adenocarcinomas | Transmembrane Protein AMIGO2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1442752","SLC7A2 Gene","C119686","This gene is involved in the transport of the cationic amino acids.","SLC7A2 Gene | SLC7A2 | Solute Carrier Family 7 (Cationic Amino Acid Transporter, Y+ System), Member Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897681","SLC7A2 wt Allele","C119687","Human SLC7A2 wild-type allele is located in the vicinity of 8p22 and is approximately 73 kb in length. This allele, which encodes cationic amino acid transporter 2, plays a role in amino acid transport.","SLC7A2 wt Allele | ATRC2 | Amino Acid Transporter, Cationic 2 Gene | CAT2 | HCAT2 | Solute Carrier Family 7 (Cationic Amino Acid Transporter, Y+ System), Member 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1609650","Cationic Amino Acid Transporter 2, Human","C119688","Cationic amino acid transporter 2 (658 aa, ~72 kDa) is encoded by the human SLC7A2 gene. This protein is involved in the transmembrane transport of cationic amino acids.","Cationic Amino Acid Transporter 2 | CAT-2 | Low Affinity Cationic Amino Acid Transporter 2 | SLC7A2 | Solute Carrier Family 7 Member 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413503","CLOCK Gene","C119689","This gene plays a role in the expression of genes involved in circadian rhythm.","CLOCK Gene | CLOCK | Clock Circadian Regulator Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002343","Alternaria","C119320","A genus of dematiaceous fungi within the phylum Ascomycota that are ubiquitous in nature and are common allergens in humans. Members of the Alternaria genus produce septate, brown and filamentous hyphae, and may cause opportunistic infections in immunocompromised individuals, such as phaeohyphomycosis, onychomycosis, sinusitis, ulcerated cutaneous infections, keratitis, visceral infections and osteomyelitis.","Alternaria | ALTERNARIA",,,,,,,,,,,,,,,"4326249","Alternaria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004613","Anaerobic Bacteria","C119321","Any bacteria that does not require oxygen to grow or respirate.","Anaerobic Bacteria | ANAEROBIC BACTERIA | Anaerobe",,,,,,,,,,,,,,,"4241214","Anaerobic bacteria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3900050","Anaerobic Coccus","C119322","Any spherical shaped bacteria that does not require oxygen to grow or respirate.","Anaerobic Coccus | ANAEROBIC COCCUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018149","Anaerobic Gram-negative Bacteria","C119323","Any bacteria that does not require oxygen to grow or respirate, has a cell wall that contains low levels of peptidoglycan, and stains pink with the Gram staining technique.","Anaerobic Gram-negative Bacteria | ANAEROBIC GRAM-NEGATIVE BACTERIA | Anaerobic Gram Negative Bacteria | Gram-negative Anaerobe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1651518","Bacteroides intestinalis","C119324","A species of indole-positive, gram negative, anaerobic rod shaped bacteria belonging to the genus Bacteroides that hydrolyses esculin and has been isolated from human feces.","Bacteroides intestinalis | BACTEROIDES INTESTINALIS",,,,,,,,,,,,,,,"37016792","Bacteroides intestinalis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0315102","Clostridium sartagoforme","C119325","A species of gram-positive, anaerobic rod shaped bacteria belonging to the genus Clostridium that hydrolyses esculin and ferments carbohydrates, and has been isolated from human feces.","Clostridium sartagoforme | CLOSTRIDIUM SARTAGOFORME",,,,,,,,,,,,,,,"4331512","Clostridium sartagoforme",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1042008","Pandoraea sputorum","C119327","A species of gram-negative, non-fermenting rod-shaped bacteria belonging to the genus Pandoraea that has been isolated in human sputum.","Pandoraea sputorum | PANDORAEA SPUTORUM",,,,,,,,,,,,,,,"4216112","Pandoraea sputorum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1057314","Pannonibacter phragmitetus","C119328","A species of gram-negative, catalase and oxidase positive, rod-shaped bacteria belonging to the genus Pannonibacter that has been isolated from human blood cultures.","Pannonibacter phragmitetus | Achromobacter group B | Achromobacter group E | PANNONIBACTER PHRAGMITETUS",,,,,,,,,,,,,,,"4200179","Pannonibacter phragmitetus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1627003","Peptostreptococcus stomatis","C119329","A species of anaerobic, gram-positive coccoid bacteria belonging to the genus Peptostreptococcus that is weakly saccharolytic and has been isolated from the human oral cavity.","Peptostreptococcus stomatis | PEPTOSTREPTOCOCCUS STOMATIS",,,,,,,,,,,,,,,"42537994","Peptostreptococcus stomatis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1690620","Prevotella bergensis","C119330","A species of gram-negative rod-shaped bacteria belonging to the genus Prevotella that is saccharolytic and ferments carbohydrates; it is a human pathogen in skin and soft tissue infections.","Prevotella bergensis | PREVOTELLA BERGENSIS",,,,,,,,,,,,,,,"46270939","Prevotella bergensis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1831583","Elasticity (tissue integrity)","C119332","A quantitative measurement of an organ's ability to deform in response to physiological force and return to its normal shape by passive elastic recoil.","Organ Elasticity | ELASTIC | Elasticity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1310463","Interferon-Induced Helicase C Domain-Containing Protein 1, Human","C119721","Interferon-induced helicase C domain-containing protein 1 (1025 aa, ~117 kDa) is encoded by the human IFIH1 gene. This protein is involved in the positive regulation of antiviral responses.","Interferon-Induced Helicase C Domain-Containing Protein 1 | CADM-140 Autoantigen | Clinically Amyopathic Dermatomyositis Autoantigen 140 kDa | EC 3.6.4.13 | Helicard | Helicase with 2 CARD Domains | IFIH1 | Interferon-Induced With Helicase C Domain Protein 1 | MDA-5 | Melanoma Differentiation Associated Protein-5 | Melanoma Differentiation-Associated Protein 5 | Murabutide Down-Regulated Protein | RLR-2 | RNA Helicase-DEAD Box Protein 116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899377","Digestive System Hemorrhage","C119722","Bleeding originating from any part of the digestive system.","Digestive System Hemorrhage | ",,,,,,,,,,,,,,,"37311947","Hemorrhage of digestive system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3890435","ATG16L1 wt Allele","C119724","Human ATG16L1 wild-type allele is located in the vicinity of 2q37.1 and is approximately 86 kb in length. This allele, which encodes autophagy-related protein 16-1, is involved in the formation of autophagosomes. Mutation of the gene is associated with Crohn disease (inflammatory bowel disease 10).","ATG16L1 wt Allele | APG16 Autophagy 16-Like (S. cerevisiae) Gene | APG16L | APG16L Beta | ATG16 Autophagy Related 16-Like (S. cerevisiae) Gene | ATG16 Autophagy Related 16-Like 1 (S. cerevisiae) Gene | ATG16A | ATG16L | Autophagy Related 16-Like 1 (S. cerevisiae) wt Allele | FLJ10035 | IBD10 | UNQ9393/PRO34307 | WDR30 | hCG_1817841",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1870238","ATG16L1 protein, human","C119725","Autophagy-related protein 16-1 (607 aa, ~68 kDa) is encoded by the human ATG16L1 gene. This protein plays a role in the mediation of autophagy.","Autophagy-Related Protein 16-1 | APG16-Like | APG16-Like 1 | ATG16 Autophagy Related 16-Like 1 | Autophagy 16-Like 1 | WD Repeat Domain 30",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539329","EEF2K Gene","C119726","This gene is involved in both protein phosphorylation and the inhibition of translation.","EEF2K Gene | EEF2K | Eukaryotic Elongation Factor-2 Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890605","EEF2K wt Allele","C119727","Human EEF2K wild-type allele is located in the vicinity of 16p12.2 and is approximately 82 kb in length. This allele, which encodes eukaryotic elongation factor 2 kinase protein, plays a role in the inhibition of protein translation.","EEF2K wt Allele | Eukaryotic Elongation Factor-2 Kinase wt Allele | HSU93850 | eEF-2K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1870461","Eukaryotic Elongation Factor 2 Kinase, Human","C119728","Eukaryotic elongation factor 2 kinase (725 aa, ~82 kDa) is encoded by the human EEF2K gene. This protein is involved in both the negative regulation of protein synthesis and serine/threonine protein phosphorylation.","Eukaryotic Elongation Factor 2 Kinase | Calcium/Calmodulin-Dependent Eukaryotic Elongation Factor 2 Kinase | Calcium/Calmodulin-Dependent Eukaryotic Elongation Factor-2 Kinase | Calmodulin-Dependent Protein Kinase III | EC 2.7.11.20 | EEF-2 Kinase | Elongation Factor-2 Kinase | eEF-2K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412466","APLP1 Gene","C119729","This gene plays a role in synaptic signaling.","APLP1 Gene | APLP1 | Amyloid Beta (A4) Precursor-Like Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0701807","Acute Anterior Uveitis","C119989","Sudden onset of anterior uveitis, usually unilateral, and associated with pain, erythema, photophobia, and blurred vision. Often associated with HLA-B27, with or without co-existing spondyloarthritis.","Acute Anterior Uveitis | ",,,,,,,,,,,,,,,"4176864","Acute anterior uveitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3150902","C1q Deficiency","C119990","Lack of production of functional C1q proteins, due to a genetic defect. Virtually 100% of patients with a C1q deficiency will develop a severe systemic lupus erythematosus at an early age. Patients also present with frequent sinopulmonary infections often with Streptococcus pneumoniae.","C1q Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3150274","C1r/C1s Deficiency","C119991","Lack of production of either functional C1r or C1s protein, due to a genetic defect. Approximately 60% of patients with a C1r/C1s deficiency will develop a severe systemic lupus erythematosus at an early age. Patients also present with frequent sinopulmonary infections often with Streptococcus pneumoniae.","C1r/C1s Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897390","TIMI Coronary Thrombus Grade 3","C119585","Moderate size definite thrombus, with greatest linear dimension greater than 1/2 but less than 2 vessel diameters. (Gibson, C. M., de Lemos, J. A., Murphy, S. A., Marble, S. J., McCabe, C. H., Cannon, C. P., Antman, E. M., Braunwald, E. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy Circulation. 2001;103(21):2550-4.)","TIMI Coronary Thrombus Grade 3 | CORONARY THROMBUS TIMI GRADE 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897389","TIMI Coronary Thrombus Grade 4","C119586","Large size definite thrombus, with the largest dimension greater than or equal to 2 vessel diameters. (Gibson, C. M., de Lemos, J. A., Murphy, S. A., Marble, S. J., McCabe, C. H., Cannon, C. P., Antman, E. M., Braunwald, E. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy Circulation. 2001;103(21):2550-4.)","TIMI Coronary Thrombus Grade 4 | CORONARY THROMBUS TIMI GRADE 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897388","TIMI Coronary Thrombus Grade 5","C119587","Total vessel occlusion. (Gibson, C. M., de Lemos, J. A., Murphy, S. A., Marble, S. J., McCabe, C. H., Cannon, C. P., Antman, E. M., Braunwald, E. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy Circulation. 2001;103(21):2550-4.)","TIMI Coronary Thrombus Grade 5 | CORONARY THROMBUS TIMI GRADE 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898202","NHLBI Coronary Artery Dissection Type A","C119588","Minor radiolucencies within the lumen during contrast injection with no persistence after dye clearance. (Adapted from: Coronary artery angiographic changes after PTCA: Manual of Operations NHLBI PTCA Registry 1985-6:9)","NHLBI Coronary Artery Dissection Type A | CORONARY DISSECTION NHLBI GRADE A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898352","Mild Bronchopulmonary Dysplasia","C119756","A chronic lung disorder associated with pulmonary maldevelopment, scarring, and/or inflammation that develops in preterm neonates exposed to supplemental oxygen for at least 28 days. For infants born before 32 weeks gestation with mild BPD, there is no supplemental oxygen requirement at 36 weeks postmenstrual age or earlier discharge. For infants born after 32 weeks with mild BPD, there is no supplemental oxygen requirement at 56 days post-natal age or at earlier discharge.","Mild Bronchopulmonary Dysplasia | Mild BPD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898279","Moderate Bronchopulmonary Dysplasia","C119757","A chronic lung disorder associated with pulmonary maldevelopment, scarring, and/or inflammation that develops in preterm neonates exposed to supplemental oxygen for at least 28 days. For infants born before 32 weeks gestation with moderate BPD, there is a supplemental oxygen requirement of less than 30% at 36 weeks postmenstrual age or earlier discharge. For infants born after 32 weeks with moderate BPD, there is a supplemental oxygen requirement of less than 30% at 56 days post-natal age or at earlier discharge.","Moderate Bronchopulmonary Dysplasia | Moderate BPD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896934","Allogeneic Cellular Vaccine 1650-G","C119759","A pluripotent, allogeneic, tumor cell vaccine composed of irradiated tumor cells from the non-small cell lung cancer (NSCLC) cell line 1650 and the immunoadjuvant recombinant granulocyte-macrophage colony stimulating factor (GM-CSF) (1650-G), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic cellular vaccine 1650-G may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against tumor-associated antigens (TAAs) expressed on NSCLC cells. GM-CSF potentiates the antitumor immune response. The 1650 cell line is used as a source for TAAs.","Allogeneic Cellular Vaccine 1650-G | 1650-G | 1650-G Vaccine | 1650G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899808","CDISC SEND Variable Terminology","C119760","The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) variables used by the Standard for the Exchange of Non-clinical Data (SEND) group.","CDISC SEND Variable Terminology | CDISC-SEND VARIABLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889478","Body Weight Gain Data Collection Date Time","C119761","The date and time of body weight gain assessment data collection.","Body Weight Gain Data Collection Date Time | BGDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899929","Body Weight Gain Elapsed Time","C119763","The interval between two body weight gain measurement reference time points.","Body Weight Gain Elapsed Time | BGELTM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897133","Body Weight Gain End Date Time","C119764","The date and time a body weight gain assessment has concluded.","Body Weight Gain End Date Time | BGENDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899928","Body Weight Gain End Day","C119765","The final day of the body weight gain assessment.","Body Weight Gain End Day | BGENDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899022","Gluten-free/Fiber-enriched Compact Nutritional Supplement Drink","C120034","A gluten-free, calorie-dense, fiber-enriched milkshake-like nutritional supplement drink containing all essential vitamins, minerals, and trace elements, as well as protein, fat and carbohydrates. Upon oral intake, gluten-free, fiber-enriched compact nutritional supplement drink may aid in the prevention of malnutrition and weight loss. The drink is provided in a reduced volume (125 ml) but with the same complete nutrition as the standard drink (200 ml); the reduced volume may increase patient compliance. The fiber, acting as a prebiotic, promotes beneficial bacterial growth in the gastrointestinal (GI) tract, increases digestive health and may reduce the incidence of constipation and/or diarrhea.","Gluten-free/Fiber-enriched Compact Nutritional Supplement Drink | Fortimel Compact Fibre",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1540053","TRIB1 Gene","C119628","This gene plays a role in modulation of MAP kinase-dependent signaling.","TRIB1 Gene | TRIB1 | Tribbles Pseudokinase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889462","TRIB1 wt Allele","C119629","Human TRIB1 wild-type allele is located in the vicinity of 8q24.13 and is approximately 8 kb in length. This allele, which encodes tribbles homolog 1 protein, is involved in the regulation of MAP kinase-dependent signaling.","TRIB1 wt Allele | C8FW | GIG-2 | GIG2 | SKIP1 | TRB-1 | TRB1 | Tribbles Homolog 1 (Drosophila) Gene | Tribbles Pseudokinase 1 wt Allele | Tribbles, Drosophila, Homolog of, 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1528889","Tribbles Homolog 1, Human","C119630","Tribbles homolog 1 (372 aa, ~41 kDa) is encoded by the human TRIB1 gene. This protein plays a role in the regulation of MAP kinase activity.","Tribbles Homolog 1 | G-Protein-Coupled Receptor-Induced Gene 2 Protein | G-Protein-Coupled Receptor-Induced Protein 2 | GIG-2 | Phosphoprotein Regulated By Mitogenic Pathways | SKIP1 | TRB-1 | Tribbles-Like Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826758","RAB7A Gene","C119631","This gene is involved in the trafficking of endosomes and lysosomes.","RAB7A Gene | RAB7A | RAB7A, Member RAS Oncogene Family Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890376","RAB7A wt Allele","C119632","Human RAB7A wild-type allele is located in the vicinity of 3q21 and is approximately 89 kb in length. This allele, which encodes ras-related protein Rab-7a, plays a role in the localization and function of both endosomes and lysosomes. Mutation of the gene is associated with Charcot-Marie-Tooth disease 2B.","RAB7A wt Allele | CMT2B | PRO2706 | RAB7 | RAB7, Member RAS Oncogene Family Gene | RAB7A, Member RAS Oncogene Family wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890561","Ras-Related Protein Rab-7a , human","C119633","Ras-related protein Rab-7a (207 aa, ~23 kDa) is encoded by the human RAB7A gene. This protein is involved in many cellular processes that involve endosomes or lysosomes.","Ras-Related Protein Rab-7a | Ras-Associated Protein RAB7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890009","RAB27A wt Allele","C119635","Human RAB27A wild-type allele is located within 15q15-q21.1 and is approximately 116 kb in length. This allele, which encodes ras-related protein Rab-27A, is involved in the maturation and release of lymphocytic granules. Mutation of the gene is associated with Griscelli syndrome 2.","RAB27A wt Allele | GS2 | HsT18676 | RAB27 | RAB27A, Member RAS Oncogene Family wt Allele | RAM | RAS-Related Gene From Megakaryocyte Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL480859","Ras-Related Protein Rab-27A","C119636","Ras-related protein Rab-27A (221 aa, ~25 kDa) is encoded by the human RAB27A gene. This protein plays a role in the exocytosis of cytotoxic granules from lymphocytes.","Ras-Related Protein Rab-27A | GTP-Binding Protein Ram | Rab-27 | Ras-Associated Protein RAB27A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427259","HACE1 Gene","C119637","This gene is involved in both protein ubiquitination and Golgi membrane dynamics.","HACE1 Gene | HACE1 | HECT Domain and Ankyrin Repeat Containing E3 Ubiquitin Protein Ligase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889717","HACE1 wt Allele","C119638","Human HACE1 wild-type allele is located in the vicinity of 6q16.3 and is approximately 132 kb in length. This allele, which encodes E3 ubiquitin-protein ligase HACE1 protein, plays a role in the modulation of both Golgi membrane dynamics and ubiquitination. Mutations of the gene, including translocations that either reduce expression of the gene (t(6;15)(q21;q21)) or truncate the gene (t(5;6)(q21;q21)), are associated with Wilms tumor.","HACE1 wt Allele | HECT Domain and Ankyrin Repeat Containing E3 Ubiquitin Protein Ligase 1 wt Allele | KIAA1320",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1566616","E3 Ubiquitin-Protein Ligase HACE1, Human","C119639","E3 ubiquitin-protein ligase HACE1 (909 aa, ~102 kDa) is encoded by the human HACE1 gene. This protein is involved in the regulation of both the ubiquitination and subsequent degradation of small GTPases, which modulates Golgi membrane dynamics.","E3 Ubiquitin-Protein Ligase HACE1 | EC 2.3.2.26 | EC 6.3.2.-, Formerly | HECT Domain and Ankyrin Repeat-Containing E3 Ubiquitin-Protein Ligase 1 | HECT Domain- and Ankyrin Repeat-Containing E3 Ubiquitin Protein Ligase 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3150275","C2 Deficiency","C119992","Lack of production of functional C2 protein, due to a genetic defect. It is the most common genetic complement deficiency. Ten percent of C2 deficient patient will develop systemic lupus erythematosus at an early age. Patients also present with frequent sinopulmonary infections often with Streptococcus pneumoniae.","C2 Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899844","C4 Deficiency","C119993","Lack of production of functional C4 protein, due to a genetic defect requiring homozygous loss of both the C4A and C4B genetic paralogs. Approximately 75% of patients with a C4 deficiency will develop a severe systemic lupus erythematosus at an early age. Patients also present with frequent sinopulmonary infections often with Streptococcus pneumoniae.","C4 Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521144","Seronegative","C119994","A laboratory result which shows no presence of antibodies for which sera are being tested. In rheumatology this typically refers to absence of rheumatoid factor.","Seronegative | ",,,,,,,,,,,,,,,"4218556","Seronegative",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897137","Low Complement","C119995","A decreased amount of complement (e.g. C3, C4, CH50) as determined through quantitative measurement. May be due to a genetic deficiency or from overconsumption due to an infection or a co-morbid autoimmune disorder.","Low Complement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0264080","Pediatric Osteoporosis","C119996","The finding of one or more vertebral compression (crush) fractures in the absence of local disease or high-energy trauma or the presence of both a clinically significant fracture history and BMD Z-score less than or equal to -2.0. A clinically significant fracture history is one or more of the following: 1) two or more long bone fractures by age ten years; 2) three or more long bone fractures at any age up to age nineteen years. (from 2013 International Society for Clinical Densitometry definition of Osteoporosis-Pediatric)","Pediatric Osteoporosis | Idiopathic Juvenile Osteoporosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3888532","Vasculitic Ulcer","C119997","A circumscribed inflammatory lesion associated with underlying ischemic disease.","Vasculitic Ulcer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898568","Low Natural Killer Cell Activity","C119998","A decrease in the ability of peripheral mononuclear blood cells to lyse MHC I deficient target cells either due to low numbers of natural killer cells, or a reduction of their lytic activity.","Low Natural Killer Cell Activity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1262147","Scleroderma Renal Crisis","C119999","The onset of acute renal failure, normally coupled with marked hypertension in a patient with scleroderma.","Scleroderma Renal Crisis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL557928","Polyestradiol Phosphate","C1199","A synthetic long-acting polymer derivative of the female sex hormone estradiol.  As the primary, most potent estrogen hormone produced by the ovaries, estradiol binds to and activates specific nuclear receptors.  Estradiol exhibits mild anabolic and metabolic properties, and increases blood coagulability.  Administration of polyestradiol phosphate leads to the marked decrease of testosterone levels and may exhibit a bone mass-preserving effect in patients with prostatic cancer. (NCI04)","Polyestradiol Phosphate | Estradiol Phosphate Polymer | Estradurin | Leo 114 | PEP | POLYESTRADIOL PHOSPHATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898658","Joint Task Force Type 1 Myocardial Infarction","C119220","Spontaneous myocardial infarction related to ischaemia due to a primary coronary event such as plaque erosion and/or rupture, fissuring, or dissection. (Universal definition of myocardial infarction, Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Eur Heart J (2007) 28 (20): 2525-2538.)","Joint Task Force Type 1 Myocardial Infarction | Joint ESC/ACCF/AHA/WHF Task Force Type 1 Myocardial Infarction | TYPE 1 MYOCARDIAL INFARCTION",,,,,,,,,,,,,,,"604179","Myocardial infarction due to atherothrombotic coronary artery disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898201","NHLBI Coronary Artery Dissection Type B","C119589","Parallel tracts or double lumen separated by a radiolucent area during contrast injection with no persistence after dye clearance. (Adapted from: Coronary artery angiographic changes after PTCA: Manual of Operations NHLBI PTCA Registry 1985-6:9)","NHLBI Coronary Artery Dissection Type B | CORONARY DISSECTION NHLBI GRADE B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898200","NHLBI Coronary Artery Dissection Type C","C119590","Extraluminal cap with persistence of contrast after dye clearance from the lumen. (Adapted from: Coronary artery angiographic changes after PTCA: Manual of Operations NHLBI PTCA Registry 1985-6:9)","NHLBI Coronary Artery Dissection Type C | CORONARY DISSECTION NHLBI GRADE C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898199","NHLBI Coronary Artery Dissection Type D","C119591","Spiral luminal filling defect with delayed but complete distal flow. (Adapted from: Coronary artery angiographic changes after PTCA: Manual of Operations NHLBI PTCA Registry 1985-6:9)","NHLBI Coronary Artery Dissection Type D | CORONARY DISSECTION NHLBI GRADE D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898198","NHLBI Coronary Artery Dissection Type E","C119592","New persistent filling defect with delayed antegrade flow. May represent thrombus. (Adapted from: Coronary artery angiographic changes after PTCA: Manual of Operations NHLBI PTCA Registry 1985-6:9)","NHLBI Coronary Artery Dissection Type E | CORONARY DISSECTION NHLBI GRADE E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898197","NHLBI Coronary Artery Dissection Type F","C119593","Non-A-E types with total coronary occlusion and no distal antegrade flow. May represent thrombus. (Adapted from: Coronary artery angiographic changes after PTCA: Manual of Operations NHLBI PTCA Registry 1985-6:9)","NHLBI Coronary Artery Dissection Type F | CORONARY DISSECTION NHLBI GRADE F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900157","ARC Stent Thrombosis Timing Acute","C119594","0 to 24 hours after stent implantation. (Cutlip DE, Windecker S, Mehran R, et al. Clinical Endpoints in Coronary Stent Trials : A Case for Standardized Definitions. Circulation. 2007;115:2344-2351)","ARC Stent Thrombosis Timing Acute | STENT THROMBOSIS ARC ACUTE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900155","ARC Stent Thrombosis Timing Subacute","C119595","Greater than 24 hours to 30 days after stent implantation. (Cutlip DE, Windecker S, Mehran R, et al. Clinical Endpoints in Coronary Stent Trials : A Case for Standardized Definitions. Circulation. 2007;115:2344-2351)","ARC Stent Thrombosis Timing Subacute | STENT THROMBOSIS ARC SUBACUTE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900156","ARC Stent Thrombosis Timing Late","C119596","Greater than 30 days to 1 year after stent implantation. (Cutlip DE, Windecker S, Mehran R, et al. Clinical Endpoints in Coronary Stent Trials : A Case for Standardized Definitions. Circulation. 2007;115:2344-2351)","ARC Stent Thrombosis Timing Late | STENT THROMBOSIS ARC LATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900154","ARC Stent Thrombosis Timing Very Late","C119597","Greater than 1 year after stent implantation. (Cutlip DE, Windecker S, Mehran R, et al. Clinical Endpoints in Coronary Stent Trials : A Case for Standardized Definitions. Circulation. 2007;115:2344-2351)","ARC Stent Thrombosis Timing Very Late | STENT THROMBOSIS ARC VERY LATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031982","Piritramide","C119750","A diphenylpropylamine and opioid receptor agonist, with analgesic activity. Upon administration, piritramide binds to and activates mu-opioid receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids and producing analgesic relief.","Piritramide | (1,4'-Bipiperidine)-4'-carboxamide, 1'-(3-Cyano-3,3-diphenylpropyl) | 1'-(3-Cyano-3,3-diphenylpropyl)-(1,4'-bipiperidine)-4'-carboxamide | Dipidolor | PIRITRAMIDE | R 3365",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0149878","Neonatal Hypoxic Ischemic Encephalopathy","C119751","Injury to the central nervous system in the newborn period that occurs when there is insufficient delivery of oxygen to all or part of the brain.","Neonatal Hypoxic Ischemic Encephalopathy | Neonatal HIE",,,,,,,,,,,,,,,"602824","Hypoxic ischemic encephalopathy of newborn",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4015048","Developmental Dysplasia of Hip","C119752","A spectrum of hip abnormalities commonly presenting in infancy involving the relationship between the femoral head and the acetabulum and that includes subluxation or dislocation at rest or upon provocation.","Developmental Dysplasia of Hip | Congenital Dislocation of Hip | DDH | Developmental Dislocation of Hip",,,,,,,,,,,,,,,"4167532|4199440","Congenital dislocation of hip|Congenital hip dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3900029","Anti-CD22-CAR m971-BBz Lentiviral Vector-transduced Autologous T Lymphocytes","C120035","Autologous human T-lymphocytes transduced with a recombinant lentiviral vector encoding a chimeric T-cell receptor (chimeric antigen receptor or CAR) consisting of an anti-CD22 single chain variable fragment (scFv) derived from the monoclonal antibody (moAb) 971 (m971), and the co-stimulatory domain 4-1BB (CD137) coupled to the zeta chain of the TCR/CD3 complex (CD3-zeta), with potential immunostimulating and antineoplastic activities. Autologous peripheral blood lymphocytes (PBLs) from a patient with CD22-positive cancer are transduced with this lentiviral vector that encodes the CAR gene specific for CD22. After expansion in culture and reintroduction into the patient, the anti-CD22-CAR m971-BBz lentiviral vector-transduced autologous T-lymphocytes express anti-CD22-CAR on their cell surfaces and bind to the CD22 antigen on tumor cell surfaces. Subsequently, CD22-expressing tumor cells are lysed. CD22, a B-lineage-restricted, transmembrane phosphoglycoprotein, is expressed on malignant B-cells. m971 binds to a membrane proximal epitope on CD22 and has a higher binding affinity compared to other anti-CD22 moAb.","Anti-CD22-CAR m971-BBz Lentiviral Vector-transduced Autologous T Lymphocytes | Anti-CD22-CAR m971-BBz Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896805","DNA-PK inhibitor MSC2490484A","C120036","An orally bioavailable inhibitor of DNA-dependent protein kinase (DNA-PK) with potential antineoplastic activity, and potential sensitizing and enhancing activities for both chemo- and radiotherapies. Upon administration, peposertib binds to and inhibits the activity of DNA-PK, thereby interfering with the non-homologous end joining (NHEJ) process and preventing repair of DNA double strand breaks (DSBs) caused by ionizing radiation or chemotherapeutic treatment. This increases chemo- and radiotherapy cytotoxicity and leads to enhanced tumor cell death. The enhanced ability of tumor cells to repair DSBs plays a major role in the resistance of tumor cells to chemo- and radiotherapy; DNA-PK plays a key role in the NHEJ pathway and DSB repair.","Peposertib | (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol | 3-Pyridazinemethanol, alpha-(2-Chloro-4-fluoro-5-(7-(4-morpholinyl)-4-quinazolinyl)phenyl)-6-methoxy-, (alphaS)- | M 3814 | M-3814 | M3814 | MSC 2490484A | MSC-2490484A | MSC2490484A | Nedisertib | PEPOSERTIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896765","Selective Estrogen Receptor Degrader SRN-927","C120037","An orally available, nonsteroidal selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, SERD GDC-0927 specifically binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This prevents ER-mediated signaling and inhibits the growth and survival of ER-expressing cancer cells.","Selective Estrogen Receptor Degrader GDC-0927 | GDC 0927 | GDC-0927 | GDC0927 | RG 6047 | RG-6047 | RG6047 | SERD GDC-0927 | SERD RG6047 | SERD SRN-927 | SRN 927 | SRN-927 | SRN927 | Selective Estrogen Receptor Degrader SRN-927",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900022","Antigen-targeted Personalized Breast Cancer Vaccine","C120039","An individualized, therapeutic cancer vaccine (IVAC) composed of liposomes containing RNA encoding two or three tumor associated antigens (TAAs) that are specifically expressed in the patient's individual cancer selected from a warehouse ('off the shelf') and p53 RNA, with potential immunostimulatory and antineoplastic activities. Upon administration, the antigen-targeted personalized breast cancer vaccines are translated by antigen presenting cells (APCs) and the expressed protein is presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL) and memory T-cell immune responses against the TAAs. The RNAs in the vaccine are specifically selected for an individual patient after RNA profiling of the patient's tumor.","Antigen-targeted Personalized Breast Cancer Vaccine | IVAC_W_bre1_uID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424774","OPTN Gene","C119640","This gene plays a role in both neuroprotection and Golgi maintenance","OPTN Gene | OPTN | Optineurin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889422","OPTN wt Allele","C119641","Human OPTN wild-type allele is located in the vicinity of 10p13 and is approximately 39 kb in length. This allele, which encodes optineurin protein, is involved in both Golgi maintenance and neuronal survival. Mutation of the gene is associated with both amyotrophic lateral sclerosis 12 and open angle glaucoma 1E.","OPTN wt Allele | ALS12 | FIP2 | GLC1E | Glaucoma 1, Open Angle, E (Adult-Onset) Gene | HIP7 | HYPL | NRP | Optineurin wt Allele | RP11-730A19.1 | TFIIIA-INTP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899102","Food and Water Consumption End Day","C119830","The final day of the food and water consumption assessment.","Food and Water Consumption End Day | FWENDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899245","Exclude Food and Water Consumption Data From Statistics Indicator","C119831","Specifies whether the food and water consumption result values should be excluded from the statistical analysis.","Exclude Food and Water Consumption Data From Statistics Indicator | FWEXCLFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899098","Food and Water Consumption Original Result","C119833","The outcome of the food and water consumption assessment as originally received or collected.","Food and Water Consumption Original Result | FWORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899099","Food and Water Consumption Original Result Unit","C119834","The unit of measure for the result of the food and water consumption assessment as originally received or collected.","Food and Water Consumption Original Result Unit | FWORRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899097","Food and Water Consumption Reason For Exclusion From Statistics","C119835","A rationale for excluding a particular data point or subject from the food and water consumption statistical analysis.","Food and Water Consumption Reason For Exclusion From Statistics | FWREASEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899096","Food and Water Consumption Reason Not Done","C119836","The explanation given as to why food and water consumption was not assessed.","Food and Water Consumption Reason Not Done | FWREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899094","Food and Water Consumption Sequence Number","C119837","An identifier that describes the relative position of food and water consumption data within a series.","Food and Water Consumption Sequence Number | FWSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899105","Food and Water Consumption Completion Status","C119838","A term used to describe the state or condition of the completeness of the food and water consumption data.","Food and Water Consumption Completion Status | FWSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899106","Food and Water Consumption Character Result in Standard Format","C119839","The standard character or string for representation and reporting of food and water consumption data.","Food and Water Consumption Character Result in Standard Format | FWSTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899100","Food and Water Consumption Numeric Result in Standard Unit","C119840","The numerical identifier of a food and water consumption assessment result in standard units.","Food and Water Consumption Numeric Result in Standard Unit | FWSTRESN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890741","Food and Water Consumption Test","C119842","A character or string that represents the long name of the food and water consumption assessment.","Food and Water Consumption Test | FWTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890740","Food and Water Consumption Test Code","C119843","A character or string that represents the short code name of the food and water consumption assessment.","Food and Water Consumption Test Code | FWTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898634","Laboratory Test Results Anatomical Region of Specimen","C119844","The specific anatomical or biological region within the tissue or organ specimen used in the laboratory assessment.","Laboratory Test Results Anatomical Region of Specimen | LBANTREG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898632","Laboratory Test Results Directionality","C119845","A qualifier for the direction on the body the laboratory test is performed.","Laboratory Test Results Directionality | LBDIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL778373","Joint Task Force Type 2 Myocardial Infarction","C119221","Myocardial infarction secondary to ischaemia due to either increased oxygen demand or decreased supply, e.g. coronary artery spasm, coronary embolism, anaemia, arrhythmias, hypertension, or hypotension. (Universal definition of myocardial infarction, Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Eur Heart J (2007) 28 (20): 2525-2538.)","Joint Task Force Type 2 Myocardial Infarction | Joint ESC/ACCF/AHA/WHF Task Force Type 2 Myocardial Infarction | TYPE 2 MYOCARDIAL INFARCTION",,,,,,,,,,,,,,,"37309626","Myocardial infarction due to demand ischemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898656","Joint Task Force Type 3 Myocardial Infarction","C119222","Sudden unexpected cardiac death, including cardiac arrest, often with symptoms suggestive of myocardial ischaemia, accompanied by presumably new ST elevation, or new LBBB, or evidence of fresh thrombus in a coronary artery by angiography and/or at autopsy, but death occurring before blood samples could be obtained, or at a time before the appearance of cardiac biomarkers in the blood. (Universal definition of myocardial infarction, Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Eur Heart J (2007) 28 (20): 2525-2538.)","Joint Task Force Type 3 Myocardial Infarction | Joint ESC/ACCF/AHA/WHF Task Force Type 3 Myocardial Infarction | TYPE 3 MYOCARDIAL INFARCTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898655","Joint Task Force Type 4A Myocardial Infarction","C119223","Myocardial infarction associated with PCI. (Universal definition of myocardial infarction, Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Eur Heart J (2007) 28 (20): 2525-2538.)","Joint Task Force Type 4A Myocardial Infarction | Joint ESC/ACCF/AHA/WHF Task Force Type 4A Myocardial Infarction | TYPE 4A MYOCARDIAL INFARCTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898654","Joint Task Force Type 4B Myocardial Infarction","C119224","Myocardial infarction associated with stent thrombosis as documented by angiography or at autopsy. (Universal definition of myocardial infarction, Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Eur Heart J (2007) 28 (20): 2525-2538.)","Joint Task Force Type 4B Myocardial Infarction | Joint ESC/ACCF/AHA/WHF Task Force Type 4B Myocardial Infarction | TYPE 4B MYOCARDIAL INFARCTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898653","Joint Task Force Type 4C Myocardial Infarction","C119225","Myocardial infarction associated with stent restenosis as detected by coronary angiography or at autopsy. (Universal definition of myocardial infarction, Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Eur Heart J (2007) 28 (20): 2525-2538.)","Joint Task Force Type 4C Myocardial Infarction | Joint ESC/ACCF/AHA/WHF Task Force Type 4C Myocardial Infarction | TYPE 4C MYOCARDIAL INFARCTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898652","Joint Task Force Type 5 Myocardial Infarction","C119226","Myocardial infarction associated with CABG. (Universal definition of myocardial infarction, Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Eur Heart J (2007) 28 (20): 2525-2538.)","Joint Task Force Type 5 Myocardial Infarction | Joint ESC/ACCF/AHA/WHF Task Force Type 5 Myocardial Infarction | TYPE 5 MYOCARDIAL INFARCTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899311","ER or Office Visit Due to Heart Failure","C119227","A finding of heart failure during a visit to the emergency room or a doctor's office.","ER or Office Visit Due to Heart Failure | URGENT HEART FAILURE VISIT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897158","Worsened End-Organ Perfusion","C119228","A finding of a worsening decrease in blood supply to the vital organs.","Worsened End-Organ Perfusion | WORSENED END-ORGAN PERFUSION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899262","Endpoint Event Indicator","C119230","An indication as to whether the event meets the criteria for a clinical endpoint.","Endpoint Event Indicator | ENDPTIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898904","Healthcare Encounter Type","C119231","A classification or description of the visit by a patient or study participant to a medical professional.","Healthcare Encounter Type | Encounter Type | HETYPE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898637","Lab Findings of New or Worsening Heart Failure","C119232","A description of the clinical, laboratory or molecular evidence of heart failure that can be classified as new or worsening.","Lab Findings of New or Worsening Heart Failure | HFLBFNW | Heart Failure New/Worsening Lab Findings",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0320460","Acanthamoeba astronyxis","C119297","A species of motile, unicellular eukaryotic amoebae within the family of Acanthamoebidae. A. astronyxis is placed in morphological group I with a 18s rRNA gene sequence type of T7. Members of this group are characterized by the presence of relatively large cysts in comparison to that of species in morphological groups II and III. This species is a human pathogen and may cause granulomatous amoebic encephalitis and amoebic keratitis.","Acanthamoeba astronyxis | ACANTHAMOEBA ASTRONYXIS",,,,,,,,,,,,,,,"4207083","Acanthamoeba astronyxis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320458","Acanthamoeba castellanii","C119298","A species of motile, unicellular eukaryotic amoebae within the family of Acanthamoebidae. A. castellanii is placed in morphological group II with a 18s rRNA gene sequence type of T4. Members of this group are characterized by the presence of wrinkled ectocysts and endocysts which could be stellate, polygonal, triangular, or oval. This species is a human pathogen and may cause granulomatous amoebic encephalitis and amoebic keratitis.","Acanthamoeba castellanii | ACANTHAMOEBA CASTELLANII",,,,,,,,,,,,,,,"4237226","Acanthamoeba castellanii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018608","Acanthamoeba culbertsoni","C119299","A species of motile, unicellular eukaryotic amoebae within the family of Acanthamoebidae. A. culbertsoni is placed in morphological group III with a 18s rRNA gene sequence type of T10. Members of this group are characterized by the presence of thin, smooth ectocysts and round endocysts. This species is a human pathogen and may cause granulomatous amoebic encephalitis and amoebic keratitis.","Acanthamoeba culbertsoni | ACANTHAMOEBA CULBERTSONI",,,,,,,,,,,,,,,"4043868","Acanthamoeba culbertsoni",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3889709","CLOCK wt Allele","C119690","Human CLOCK wild-type allele is located in the vicinity of 4q12 and is approximately 119 kb in length. This allele, which encodes circadian locomoter output cycles protein kaput, is involved in the regulation of circadian rhythms, histone acetylation and gene transcription.","CLOCK wt Allele | BHLHE8 | Circadian Locomoter Output Cycles Kaput Gene | Clock (Mouse) Homolog Gene | Clock Circadian Regulator wt Allele | Clock Homolog (Mouse) Gene | Clock, Mouse, Homolog of Gene | KAT13D | KIAA0334 | bHLHe8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1743089","Circadian Locomoter Output Cycles Protein Kaput, Human","C119691","Circadian locomoter output cycles protein kaput (846 aa, ~95 kDa) is encoded by the human CLOCK gene. This protein plays a role in the modulation of histone acetylation that regulates both gene expression and circadian rhythms.","Circadian Locomoter Output Cycles Protein Kaput | CLOCK | Circadian Locomoter Output Cycles Kaput Protein | Class E Basic Helix-Loop-Helix Protein 8 | Clock Homolog | EC 2.3.1.48 | bHLHe8 | hCLOCK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412544","BMAL1 Gene","C119692","This gene is involved in transcriptional activation of genes in the circadian clock pathway.","BMAL1 Gene | ARNTL | ARNTL Gene | Aryl Hydrocarbon Receptor Nuclear Translocator-Like Gene | BMAL1 | Basic Helix-Loop-Helix ARNT Like 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889970","ARNTL wt Allele","C119693","Human BMAL1 wild-type allele is located in the vicinity of 11p15.3 and is approximately 111 kb in length. This allele, which encodes basic helix-loop-helix ARNT-like protein 1, plays a role in the transcriptional activation of genes involved in circadian rhythms.","BMAL1 wt Allele | ARNT-Like Protein 1, Brain and Muscle Gene | ARNTL | ARNTL wt Allele | Aryl Hydrocarbon Receptor Nuclear Translocator-Like Gene | Aryl Hydrocarbon Receptor Nuclear Translocator-Like wt Allele | BHLHE5 | BMAL1 | BMAL1b | BMAL1c | Basic Helix-Loop-Helix ARNT Like 1 wt Allele | Basic Helix-Loop-Helix Family Member E5 Gene | Cycle, Drosophila, Homolog of Gene | JAP3 | MOP3 | PAS Domain Containing 3 Gene | PASD3 | TIC | TIC, Mouse, Homolog of Gene | bHLHe5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897307","Tumor Findings Reference Identifier","C119936","A sequence of characters used to identify, name, or characterize the tumor findings reference.","Tumor Findings Reference Identifier | TFREFID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897306","Tumor Findings Result Category","C119937","A classification of a tumor findings result.","Tumor Findings Result Category | TFRESCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897305","Tumor Findings Sequence Number","C119938","An identifier that describes the relative position of tumor findings data within a series.","Tumor Findings Sequence Number | TFSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897304","Tumor Findings Specimen Condition","C119939","A characteristic that refers to the physical and organoleptic state of a biospecimen used for a tumor findings assessment.","Tumor Findings Specimen Condition | TFSPCCND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897303","Tumor Findings Specimen Type","C119940","The type of material sample taken from a biological entity for tumor findings assessment testing.","Tumor Findings Specimen Type | TFSPEC | TUMOR_TISSUE_TYPE | Tumor Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897317","Tumor Findings Completion Status","C119942","A term used to describe the state or condition of the completeness of the tumor findings data.","Tumor Findings Completion Status | TFSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889657","Tumor Findings Test","C119944","A character or string that represents the long name of the tumor findings assessment.","Tumor Findings Test | TFTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889417","Tumor Findings Test Code","C119945","A character or string that represents the short code name of the tumor findings assessment.","Tumor Findings Test Code | TFTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897186","Vital Signs Consciousness State","C119946","The level of awareness of an organism during a vital signs assessment.","Vital Signs Consciousness State | VSCSTATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897185","Vital Signs End Date Time","C119947","The date and time a vital signs assessment has concluded","Vital Signs End Date Time | VSENDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897184","Vital Signs End Day","C119948","The final day of the vital signs assessment.","Vital Signs End Day | VSENDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0914894","Optineurin, Human","C119642","Optineurin (577 aa, ~66 kDa) is encoded by the human OPTN gene. This protein plays a role in the maintenance of both neurons and the Golgi apparatus.","Optineurin | E3-14.7K-Interacting Protein | FIP-2 | HIP-7 | Huntingtin Interacting Protein L | Huntingtin Yeast Partner L | Huntingtin-Interacting Protein 7 | Huntingtin-Interacting Protein L | NEMO-Related Protein | Optic Neuropathy-Inducing Protein | TFIIIA-IntP | Transcription Factor IIIA-Interacting Protein | Tumor Necrosis Factor Alpha-Inducible Cellular Protein Containing Leucine Zipper Domains",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825715","KLB Gene","C119643","This gene is involved in growth factor signaling.","KLB Gene | KLB | Klotho Beta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890428","KLB wt Allele","C119644","Human KLB wild-type allele is located in the vicinity of 4p14 and is approximately 45 kb in length. This allele, which encodes beta-klotho protein, plays a role in the modulation of growth factor signaling pathways.","KLB wt Allele | BKL | Klotho Beta Like Gene | Klotho Beta wt Allele | Klotho, Beta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2714298","Beta-Klotho, Human","C119645","Beta-klotho (1044 aa, ~120 kDa) is encoded by the human KLB gene. This protein is involved in the regulation of growth factor-dependent signaling.","Beta-Klotho | BKL | BetaKlotho | KLB | Klotho Beta-Like Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421290","UBE2N Gene","C119646","This gene plays a role in polyubiquitination.","UBE2N Gene | UBE2N | Ubiquitin-Conjugating Enzyme E2N Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890181","UBE2N wt Allele","C119647","Human UBE2N wild-type allele is located in the vicinity of 12q22 and is approximately 37 kb in length. This allele, which encodes ubiquitin-conjugating enzyme E2 N protein, is involved in polyubiquitination of target proteins and may play a role in transcriptional regulation.","UBE2N wt Allele | BLU | Bendless, Drosophila, Homolog of Gene | HEL-S-71 | MGC8489 | UBC13 | UBCHBEN | UbcH-ben | UbcH13 | Ubiquitin-Conjugating Enzyme 13, S. cerevisiae, Homolog of Gene | Ubiquitin-Conjugating Enzyme E2N (Homologous To Yeast UBC13) Gene | Ubiquitin-Conjugating Enzyme E2N (UBC13 Homolog, Yeast) Gene | Ubiquitin-Conjugating Enzyme E2N wt Allele | Yeast UBC13 Homolog Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1174531","Ubiquitin-Conjugating Enzyme E2 N, Human","C119648","Ubiquitin-conjugating enzyme E2 N (152 aa, ~17 kDa) is encoded by the human UBE2N gene. This protein plays a role in the polyubiquitination of protein substrates, which may regulate transcription.","Ubiquitin-Conjugating Enzyme E2 N | Bendless-Like Ubiquitin Conjugating Enzyme | Bendless-Like Ubiquitin-Conjugating Enzyme | E2 Ubiquitin-Conjugating Enzyme N | EC 2.3.2.23 | EC 6.3.2.19, Formerly | Epididymis Secretory Protein Li 71 | UBE2N | Ubc13 | UbcH13 | Ubiquitin Carrier Protein N | Ubiquitin-Protein Ligase N",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1822712","SH3PXD2B Gene","C119649","This gene is involved in the formation of invadopodia.","SH3PXD2B Gene | SH3 and PX Domains 2B Gene | SH3PXD2B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890186","SH3PXD2B wt Allele","C119650","Human SH3PXD2B wild-type allele is located in the vicinity of 5q35.1 and is approximately 129 kb in length. This allele, which encodes SH3 and PX domain-containing protein 2B, plays a role in podosome assembly. Mutation of the gene is associated with Frank-Ter Haar syndrome.","SH3PXD2B wt Allele | FAD49 | FLJ20831 | FTHS | HOFI | KIAA1295 | SH3 and PX Domains 2B wt Allele | TKS4 | TSK4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2932484","SH3 and PX Domain-Containing Protein 2B, Human","C119651","SH3 and PX domain-containing protein 2B (911 aa, ~102 kDa) is encoded by the human SH3PXD2B gene. This protein is involved in the assembly of invadopodia.","SH3 and PX Domain-Containing Protein 2B | Adapter Protein HOFI | Adaptor Protein HOFI | Factor For Adipocyte Differentiation 4 | SH3PXD2B | Tyrosine Kinase Substrate With Four SH3 Domains",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900164","ARC Definite Stent Thrombosis","C119598","Includes acute ischemic symptoms at rest, acute post ischemic ECG, positive biomarkers and pathological evidence. Definite stent thrombosis is considered to have occurred when there is either angiographic or pathological confirmation. Angiographic confirmation is the presence of a thrombus at coronary angiography that originates in the stent or in the segment 5 mm proximal or distal to the stent, with the presence of at least 1 of 3 clinical criteria within a 48-hour time window: 1) acute onset of ischemic symptoms at rest; 2) new ischemic ECG changes that suggest acute ischemia; or 3) typical rise and fall in cardiac biomarkers. Pathological confirmation is evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following thrombectomy. (Cutlip DE, Windecker S, Mehran R, et al. Clinical End Points in Coronary Stent Trials : A Case for Standardized Definitions. Circulation. 2007;115:2344-2351)","ARC Definite Stent Thrombosis | STENT THROMBOSIS ARC GRADE DEFINITE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900162","ARC Probable Stent Thrombosis","C119599","Includes death within 30 days and myocardial infarction of stent territory. Probable stent thrombosis is considered to have occurred after intracoronary stenting in the following situations: 1) any unexplained death within the first 30 days; or 2) irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause. (Cutlip DE, Windecker S, Mehran R, et al. Clinical End Points in Coronary Stent Trials : A Case for Standardized Definitions. Circulation. 2007;115:2344-2351)","ARC Probable Stent Thrombosis | STENT THROMBOSIS ARC GRADE PROBABLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1176007","Piceatannol","C1195","A polyhydroxylated stilbene extract from the seeds of Euphorbia lagascae, which inhibits protein tyrosine kinase Syk and induces apoptosis. (NCI)","Piceatannol | 3,4,3',5'-Tetrahydroxy-trans-stilbene | PICEATANNOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900163","ARC Possible Stent Thrombosis","C119600","Possible stent thrombosis is considered to have occurred with any unexplained death more than 30 days after intracoronary stenting. (Cutlip DE, Windecker S, Mehran R, et al. Clinical End Points in Coronary Stent Trials : A Case for Standardized Definitions. Circulation. 2007;115:2344-2351)","ARC Possible Stent Thrombosis | STENT THROMBOSIS ARC GRADE POSSIBLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420470","PLK4 Gene","C119601","This gene plays a role in the formation of centrioles or basal bodies.","PLK4 Gene | PLK4 | Polo-Like Kinase 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889275","PLK4 wt Allele","C119602","Human PLK4 wild-type allele is located in the vicinity of 4q28 and is approximately 18 kb in length. This allele, which encodes serine/threonine-protein kinase PLK4 protein, is involved in centriole duplication.","PLK4 wt Allele | Polo-Like Kinase 4 (Drosophila) Gene | Polo-Like Kinase 4 wt Allele | SAK | SAK, Mouse, Homolog of Gene | STK18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL480576","Serine/Threonine-Protein Kinase PLK4","C119603","Serine/threonine-protein kinase PLK4 (970 aa, ~109 kDa) is encoded by the human PLK4 gene. This protein plays a role in the duplication of centrioles during the cell cycle.","Serine/Threonine-Protein Kinase PLK4 | EC 2.7.11.21 | PLK-4 | Polo-Like Kinase 4 | Serine/Threonine Kinase 18 | Serine/Threonine Protein Kinase 18 | Serine/Threonine Protein Kinase SAK | Serine/Threonine-Protein Kinase 18 | Serine/Threonine-Protein Kinase Sak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890008","FLJ10416","C119605","Human COP1 wild-type allele is located within 1q25.1-q25.2 and is approximately 263 kb in length. This allele, which encodes E3 ubiquitin-protein ligase COP1 protein, plays a role in protein ubiquitination.","COP1 wt Allele | COP1, E3 Ubiquitin Ligase wt Allele | Constitutive Photomorphogenesis Protein 1, Arabadopsis, Homolog of Gene | Constitutive Photomorphogenic Protein 1 (Arabidopsis) Gene | FLJ10416 | RFWD2 | RNF200 | RP11-318C24.3 | Ring Finger and WD Repeat Domain 2, E3 Ubiquitin Protein Ligase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1174826","E3 Ubiquitin-Protein Ligase RFWD2, Human","C119606","E3 ubiquitin-protein ligase COP1 (731 aa, ~80 kDa) is encoded by the human COP1 gene. This protein is involved in post-translational ubiquitination of target proteins.","E3 Ubiquitin-Protein Ligase COP1 | COP1 | Constitutive Photomorphogenesis Protein 1 Homolog | E3 Ubiquitin-Protein Ligase RFWD2 | EC 2.3.2.27 | EC 6.3.2.-, Formerly | Putative Ubiquitin Ligase COP1 | RING Finger Protein 200 | RING Finger and WD Repeat Domain Protein 2 | RING Finger and WD Repeat Domains-Containing Protein 2 | RING-Type E3 Ubiquitin Transferase RFWD2 | Ring Finger and WD Repeat Domain 2 | hCOP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899242","Exclude Vital Signs Data From Statistics Indicator","C119949","Specifies whether the vital signs result values should be excluded from the statistical analysis.","Exclude Vital Signs Data From Statistics Indicator | VSEXCLFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897183","Vital Signs Reason For Exclusion From Statistics","C119950","A rationale for excluding a particular data point or subject from the vital signs results statistical analysis.","Vital Signs Reason For Exclusion From Statistics | VSREASEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897471","Study Day of Organ Measurements","C119951","The study day that an organ measurements assessment is performed.","Study Day of Organ Measurements | OMDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898815","Icodextrin Solution","C119953","An isosmotic solution containing icodextrin, a starch-derived, water-soluble glucose polymer, used in peritoneal dialysis and for the prevention of adhesion after surgery. Due to its iso-osmotic nature and inability to cross the peritoneal membrane, the icodextrin solution, upon administration into the peritoneal cavity, is able to exert osmotic pressure. This allows for the removal of excess fluids and waste products in dialysis patients. In addition, icodextrin can provide a barrier between tissue surfaces when administered during surgery. This physically separates tissues, prevents adhesion after surgery and promotes wound healing.","Icodextrin Solution | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899468","DLQI - Skin Prevent Work or Study","C119169","Dermatology Life Quality Index (DLQI) Over the last week, has your skin prevented you from working or studying?","DLQI - Skin Prevent Work or Study | DLQI1-Prevented Working or Studying | DLQI107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899472","DLQI - Skin Has Been a Problem at Work or Study","C119170","Dermatology Life Quality Index (DLQI) If 'No', over the last week how much has your skin been a problem at work or studying?","DLQI - Skin Has Been a Problem at Work or Study | DLQI1-Problem at Work or Studying | DLQI107A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899473","DLQI - Skin Create Problem With Partner, Friends or Relatives","C119171","Dermatology Life Quality Index (DLQI) Over the last week, how much has your skin created problems with your partner or any of your close friends or relatives?","DLQI - Skin Create Problem With Partner, Friends or Relatives | DLQI1-Problem Partner, Friends, Relative | DLQI108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899474","DLQI - Skin Cause Sexual Difficulties","C119172","Dermatology Life Quality Index (DLQI) Over the last week, how much has your skin caused any sexual difficulties?","DLQI - Skin Cause Sexual Difficulties | DLQI1-Caused Any Sexual Difficulties | DLQI109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899467","DLQI - Treatment for Skin Make Home Messy","C119173","Dermatology Life Quality Index (DLQI) Over the last week, how much of a problem has the treatment for your skin been, for example by making your home messy, or by taking up time?","DLQI - Treatment for Skin Make Home Messy | DLQI1-How Much a Problem is Treatment | DLQI110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897059","DLQI - Score","C119174","Dermatology Life Quality Index (DLQI) Score.","DLQI - Score | DLQI1-Score | DLQI111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897791","RPQ - Headaches","C119175","Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Headaches.","RPQ - Headaches | RPQ01-Headaches | RPQ0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897793","RPQ - Feelings of Dizziness","C119176","Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Feelings of dizziness.","RPQ - Feelings of Dizziness | RPQ01-Feelings of Dizziness | RPQ0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897789","RPQ - Nausea and/or Vomiting","C119177","Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Nausea and/or vomiting.","RPQ - Nausea and/or Vomiting | RPQ01-Nausea and/or Vomiting | RPQ0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890919","APLP1 wt Allele","C119730","Human APLP1 wild-type allele is located in the vicinity of 19q13.1 and is approximately 12 kb in length. This allele, which encodes amyloid-like protein 1, is involved in signal transduction.","APLP1 wt Allele | APLP | Amyloid Beta (A4) Precursor-Like Protein 1 wt Allele | Amyloid Beta A4 Precursor-Like Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0662273","Amyloid-Like Protein 1, Human","C119731","Amyloid-like protein 1 (650 aa, ~72 kDa) is encoded by the human APLP1 gene. This protein plays a role in the mediation of postsynaptic signaling.","Amyloid-Like Protein 1 | APLP | APLP-1 | Amyloid Precursor-Like Protein | Amyloid Precursor-Like Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899843","C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs","C119735","Autologous CD34-positive, hematopoietic stem progenitor cells (HSPCs) genetically modified with a lentiviral vector expressing short hairpin RNA that targets human chemokine receptor 5 (CCR5) mRNA (shCCR5), the HIV entry inhibitor C46, a membrane-anchored 46-amino acid sequence found in HIV-1 gp41, and the drug resistance gene P140K, a mutant form of the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT), used to potentially provide resistance against human immunodeficiency virus (HIV) infection. Human autologous CD34+ HSPCs are isolated and transduced ex vivo with the pRSC-H1.shCCR5.Ubic.C46.EF1alpha.P140K.wpre lentiviral vector. shCCR5 binds to CCR5 mRNA and inhibits the expression of CCR5, a HIV-1 co-receptor that mediates HIV attachment and cell entry. Additionally, the expression of C46 blocks HIV-1 fusion to the cellular membrane. Upon re-infusion into the HIV-infected lymphoma patient, the C46/shCCR5/P140K lentiviral vector-transduced autologous HSPCs are resistant to HIV entry, which protects these cells against HIV infection and replication, and increases the amount of HIV-resistant CD4+ T-cells. HIV-resistant HSPCs could provide long-term protection against latent HIV infection and against HIV-associated cancers. In addition, the formation of immune cells resistant to HIV may result in the destruction of HIV-infected cells. P140K expression facilitates the in vivo chemoselection of gene-modified HSPCs, using O6-benzylguanine (O6BG)/bis-chloroethylnitrosourea (BCNU/carmustine), which increases the proportion of these HIV resistant CD34+ cells. P140K also protects these stem cells from future destruction by certain chemotherapeutic agents; if cancer were to develop, P140K is not inactivated by the MGMT inhibitor O6BG.","C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3666714","Mechlorethamine Hydrochloride Gel","C119736","A gel formulation composed of the hydrochloride salt form of mechlorethamine, which is a nitrogen mustard alkylating agent and an analog of sulfur mustard, with antineoplastic and immunosuppressive activities. Upon topical application, mechlorethamine is metabolized to an unstable, highly reactive ethyleniminium intermediate that binds to and alkylates DNA, with a high affinity to the N7 nitrogen of guanine residues. This results in DNA base pair mismatching, DNA interstrand crosslinking, the inhibition of DNA repair and synthesis, cell-cycle arrest, and apoptosis.","Mechlorethamine Hydrochloride Gel | Mechlorethamine HCl Gel | Valchlor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890201","KNSTRN wt Allele","C119653","Human KNSTRN wild-type allele is located in the vicinity of 15q15.1 and is approximately 12 kb in length. This allele, which encodes small kinetochore-associated protein, is involved in the metaphase/anaphase transition of the mitotic cell cycle.","KNSTRN wt Allele | C15orf23 | Chromosome 15 Open Reading Frame 23 Gene | FLJ14502 | HSD11 | Kinetochore-Localized Astrin/SPAG5 Binding Protein wt Allele | SKAP | Small Kinetochore-Associated Protein, Kinetochore-Localized Astrin-Binding Protein, TRAF4 Associated Factor 1 Gene | TRAF4AF1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3179638","Small Kinetochore-Associated Protein, Human","C119654","Small kinetochore-associated protein (316 aa, ~35 kDa) is encoded by the human KNSTRN gene. This protein plays a role in the progression of mitosis.","Small Kinetochore-Associated Protein | Kinastrin | Kinetochore-Localized Astrin-Binding Protein | Kinetochore-Localized Astrin/SPAG5-Binding Protein | Putative TRAF4-Associated Factor 1 | SKAP | Small Kinetochore Associated Protein | TRAF4 Associated Factor 1 | TRAF4-Associated Factor 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3470867","FALEC Gene","C119655","This gene may be involved in carcinogenesis.","FALEC Gene | FALEC | Focally Amplified Long Non-Coding RNA in Epithelial Cancer Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898493","Macroscopic Findings Completion Status","C119873","A term used to describe the state or condition of the completeness of the macroscopic findings data.","Macroscopic Findings Completion Status | MASTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898497","Macroscopic Findings Assessment Character Result in Standard Format","C119874","The standard character or string for representation and reporting of macroscopic findings data.","Macroscopic Findings Assessment Character Result in Standard Format | MASTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890584","Macroscopic Findings Assessment Test","C119875","A character or string that represents the long name of the macroscopic findings assessment.","Macroscopic Findings Assessment Test | MATEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898383","Microscopic Findings Anatomical Region of Specimen","C119877","The specific anatomical or biological region within the tissue or organ specimen used in the microscopic findings assessment.","Microscopic Findings Anatomical Region of Specimen | MIANTREG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898380","Microscopic Findings Body System","C119878","The body system or organ class associated with a microscopic finding.","Microscopic Findings Body System | MIBODSYS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898375","Microscopic Findings Death Relationship","C119879","An indication or description of a correlation between death and a microscopic finding.","Microscopic Findings Death Relationship | MIDTHREL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898360","Microscopic Findings Severity","C119880","The degree of something undesirable as determined by microscopic findings.","Microscopic Findings Severity | MISEV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898381","Microscopic Findings Biospecimen Usability","C119881","A qualitative or quantitative measure that describes a biospecimen's suitability for microscopic testing purposes.","Microscopic Findings Biospecimen Usability | MISPCUFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898085","Organ Measurements Anatomical Region of Specimen","C119882","The specific anatomical or biological region within the tissue or organ specimen used in the organ measurement.","Organ Measurements Anatomical Region of Specimen | OMANTREG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898081","Organ Measurements Directionality","C119883","A qualifier for the direction on the body the organ measurement is performed.","Organ Measurements Directionality | OMDIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890931","Organ Measurements Collection Date Time","C119884","The date and time of organ measurements data collection.","Organ Measurements Collection Date Time | OMDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898080","Organ Measurements Laterality","C119886","A qualifier for the side of the body the organ measurements assessment is performed.","Organ Measurements Laterality | OMLAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898078","Organ Measurements Original Result","C119887","The outcome of the organ measurements as originally received or collected.","Organ Measurements Original Result | OMORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539273","DET1 Gene","C119607","This gene plays a role in the regulation of both protein ubiquitination and degradation.","DET1 Gene | DET1 | De-Etiolated Homolog 1 (Arabidopsis) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899248","Exclude Body Weight Gain Data From Statistics Indicator","C119766","Specifies whether the body weight gain result values should be excluded from the statistical analysis.","Exclude Body Weight Gain Data From Statistics Indicator | BGEXCLFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899925","Body Weight Gain Original Result","C119767","The outcome of the body weight gain assessment as originally received or collected.","Body Weight Gain Original Result | BGORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899926","Body Weight Gain Original Result Unit","C119768","The unit of measure for the result of the body weight gain assessment as originally received or collected.","Body Weight Gain Original Result Unit | BGORRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899924","Body Weight Gain Reason For Exclusion From Statistics","C119769","A rationale for excluding a particular data point or subject from the body weight gain statistical analysis.","Body Weight Gain Reason For Exclusion From Statistics | BGREASEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899923","Body Weight Gain Reason Not Done","C119770","The explanation given as to why body weight gain was not assessed.","Body Weight Gain Reason Not Done | BGREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899930","Body Weight Gain Date Time of Reference Timepoint","C119771","The date and time of a specific reference point for the body weight gain assessment.","Body Weight Gain Date Time of Reference Timepoint | BGRFTDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899921","Body Weight Gain Sequence Number","C119772","An identifier that describes the relative position of body weight gain data within a series.","Body Weight Gain Sequence Number | BGSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899931","Body Weight Gain Completion Status","C119773","A term used to describe the state or condition of the completeness of the body weight gain data.","Body Weight Gain Completion Status | BGSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899927","Body Weight Gain Numeric Result in Standard Unit","C119775","The numerical identifier of a body weight gain result in standard units.","Body Weight Gain Numeric Result in Standard Unit | BGSTRESN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899922","Body Weight Gain Result Standard Unit","C119776","The standard unit of measure for body weight gain results.","Body Weight Gain Result Standard Unit | BGSTRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890425","Body Weight Gain Test","C119777","A character or string that represents the long name of the body weight gain assessment.","Body Weight Gain Test | BGTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890403","Body Weight Gain Test Code","C119778","A character or string that represents the short code name of the body weight gain assessment.","Body Weight Gain Test Code | BGTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899920","Body Weight Gain Time Point Reference","C119779","The point in time that acts as a fixed reference point to a body weight gain assessment.","Body Weight Gain Time Point Reference | BGTPTREF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899937","Body Weight Baseline Flag","C119780","An indication or description that body weight data is a baseline value.","Body Weight Baseline Flag | BWBLFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899934","Body Weight Data Collection Date Time","C119781","The date and time of body weight assessment data collection.","Body Weight Data Collection Date Time | BWDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897788","RPQ - Noise Sensitivity","C119178","Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Noise sensitivity, easily upset by loud noise.","RPQ - Noise Sensitivity | RPQ01-Noise Sensitivity/Loud Noise | RPQ0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897785","RPQ - Sleep Disturbance","C119179","Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Sleep disturbance.","RPQ - Sleep Disturbance | RPQ01-Sleep Disturbance | RPQ0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896977","RPQ - Being Irritable, Easily Angered","C119181","Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Being irritable, easily angered.","RPQ - Being Irritable, Easily Angered | RPQ01-Being Irritable, Easily Angered | RPQ0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897795","RPQ - Feeling Depressed or Tearful","C119182","Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Feeling depressed or tearful.","RPQ - Feeling Depressed or Tearful | RPQ01-Feeling Depressed or Tearful | RPQ0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897794","RPQ - Feeling Frustrated or Impatient","C119183","Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Feeling frustrated or impatient.","RPQ - Feeling Frustrated or Impatient | RPQ01-Feeling Frustrated or Impatient | RPQ0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897792","RPQ - Forgetfulness, Poor Memory","C119184","Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Forgetfulness, poor memory.","RPQ - Forgetfulness, Poor Memory | RPQ01-Forgetfulness, Poor Memory | RPQ0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896833","hTERT-encoding DNA Vaccine INVAC-1","C119737","A DNA vaccine consisting of a plasmid encoding a modified, inactive form of the human telomerase reverse transcriptase (hTERT), the catalytic subunit of human telomerase which synthesizes telomeric DNA at the chromosome ends, fused to ubiquitin, with potential immunostimulating and antineoplastic activities. Upon intradermal vaccination of the hTERT encoding DNA vaccine INVAC-1 in combination with electroporation, hTERT protein is expressed and activates the immune system to mount a cytotoxic T-cell (CTL) response against telomerase-expressing tumor cells, which may result in tumor cell death. Telomerase prolongs the functional lifespan of cells via the restoration and maintenance of telomere length. Abnormally activated in tumorigenesis, telomerase is expressed in the majority of human cancer cells, but its expression is low or non-existent in normal cells. hTERT conjugation to ubiquitin, a 76 amino-acid peptide involved in the regulation of normal protein intracellular turnover in the cytoplasm, enhances proteasome-dependent degradation of the hTERT protein, increases hTERT presentation by major histocompatibility complex (MHC) class I molecules and results in an increased immune response against hTERT.","hTERT-encoding DNA Vaccine INVAC-1 | INVAC-1 | INVAC-1, A DOUBLE STRANDED DNA PLASMID VACCINE CONSTRUCT ENCODING UBIQUITIN-HUMAN TELOMERASE REVERSE TRANSCRIPTASE (HTERT) FUSION PROTEIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896702","Yttrium Y 90-DOTA-di-HSG Peptide IMP-288","C119738","A radiolabeled divalent histamine-succinyl-glycine (HSG) hapten-peptide linked with the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to the beta-emitting radionuclide yttrium 90 (Y-90), with radioimmunotherapeutic activity. After pre-treating and targeting tumor cells with a bi-specific monoclonal antibody (BiMoAB) directed against both a tumor-associated antigen (TAA) and the HSG hapten-peptide, the HSG portion of the administered yttrium Y 90-DOTA-di-HSG peptide IMP-288 binds to the anti-HSG sequence on the BiMoAB. In turn, Y-90 delivers a cytotoxic dose of beta radiation to tumor cells expressing the specific TAA.","Yttrium Y 90-DOTA-di-HSG Peptide IMP-288 | 90-Y-IMP-288 | 90Y-IMP288",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899738","CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes","C120001","A preparation of autologous tumor infiltrating lymphocytes (TILs) that are transduced, ex vivo, with a retroviral vector encoding a gene for CXC chemokine receptor 2 (CXCR2), with potential antineoplastic activity. Upon administration of the CXCR2-transduced autologous TILs, the CXCR2-expressing T-cells selectively migrate toward tumor cells expressing CXCR2 ligands, which leads to tumor cell killing. CXCR2 expression allows for optimal TIL migration towards tumor cells and enhances the TILs anti-tumor activity. This leads to a reduction in both tumor cell proliferation and survival. CXCR2, a transmembrane protein also known as IL-8 receptor B (IL-8RB), plays a key role in inflammation and cancer progression. Certain CXCR2 ligands, such as CXCL1 and CXCL8 (IL-8), are expressed by tumor cells.","CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes | CXCR2-transduced Autologous TILs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898079","Organ Measurements Original Result Unit","C119888","The unit of measure for the result of the organ measurement as originally received or collected.","Organ Measurements Original Result Unit | OMORRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898077","Organ Measurements Portion or Totality","C119889","A qualifier for the arrangement or apportioning of an entity within a body part, region or organ for the organ measurements.","Organ Measurements Portion or Totality | OMPORTOT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897087","Organ Measurements Reason For Exclusion From Statistics","C119890","A rationale for excluding a particular data point or subject from the organ measurement results statistical analysis.","Organ Measurements Reason For Exclusion From Statistics | OMREASEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898076","Organ Measurements Reason Not Done","C119891","The explanation given as to why an organ measurement was not performed.","Organ Measurements Reason Not Done | OMREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898075","Organ Measurements Sequence Number","C119892","An identifier that describes the relative position of organ measurement data within a series.","Organ Measurements Sequence Number | OMSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898074","Organ Measurements Specimen Condition","C119893","A characteristic that refers to the physical and organoleptic state of a biospecimen used for an organ measurement.","Organ Measurements Specimen Condition | OMSPCCND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896947","Fluorine F 18 Ara-G","C120100","A radioconjugate composed of the guanosine analog arabinosyl guanine (Ara-G), a high-affinity substrate for both cytoplasmic deoxycytidine kinase (DCK) and mitochondrial deoxyguanosine kinase (dGK), labeled with fluorine F 18, that can potentially be used as a tracer for imaging of activated T-lymphocytes during positron emission tomography (PET). Upon administration, fluorine F 18 ara-G is taken up by and accumulates in activated T-lymphocytes with high levels of DCK and dGK. After phosphorylation by DCK and dGK, the 18F moiety can be visualized by PET imaging. Fluorine F 18 ara-G can potentially be used as an imaging agent to detect anti-tumor immune responses and to predict the therapeutic efficacy of immunotherapies. DCK and dGK, both nucleoside salvage pathway enzymes, are overexpressed in activated T-cells.","Fluorine F 18 Ara-G | (18F)F-Arag | 18F-F-Ara-G | 2'-Deoxy-2'-[18F]Fluoro-9-beta-D-arabinofuranosylguanine | 2-Amino-9-((2R,3S,4R,5R)-3-fluoranyl-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-purin-6-one | F-ARAG F-18 | VisAcT | [18F]-AraG | [18F]F-AraG | [18F]F-ara-G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896828","src/tubulin inhibitor KX02","C120101","A lipophilic, orally available inhibitor of both Src kinase activity and tubulin polymerization, with potential antineoplastic activity. Upon oral administration,Src/tubulin Inhibitor KX2-361 binds to and inhibits the activity of Src kinase. This inhibits both downstream signaling and the proliferation of Src kinase-expressing tumor cells. KX02 also binds to tubulin heterodimers and inhibits microtubule polymerization, thereby disrupting microtubule formation, mitosis, and further proliferation. Src, a non-receptor tyrosine kinase, is overexpressed in a variety of tumor cell types and plays a key role in tumor cell proliferation, angiogenesis, migration, and metastasis.","Src/tubulin Inhibitor KX2-361 | KX02 | KX2-361 | Src/tubulin Inhibitor KX02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507817","FGF401","C120102","An inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon administration, roblitinib binds to and inhibits the activity of FGFR4, which leads to an inhibition of tumor cell proliferation in FGFR4-overexpressing cells. FGFR4 is a receptor tyrosine kinase upregulated in certain tumor cells and involved in tumor cell proliferation, differentiation, angiogenesis, and survival.","Roblitinib | FGF401 | FGFR4 Inhibitor FGF401 | ROBLITINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897479","Study Day of Body Weight","C119782","The study day that a body weight assessment is performed.","Study Day of Body Weight | BWDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899933","Body Weight Fasting Status","C119784","An indication or description of whether a body weight measurement was obtained from a subject that has abstained from food and possibly water for the prescribed amount of time.","Body Weight Fasting Status | BWFAST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899917","Body Weight Original Result","C119785","The outcome of the body weight assessment as originally received or collected.","Body Weight Original Result | BWORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899918","Body Weight Original Result Unit","C119786","The unit of measure for the result of the body weight assessment as originally received or collected.","Body Weight Original Result Unit | BWORRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896858","anti-FGFR2 monoclonal antibody FPA144","C120040","A glycoengineered, humanized monoclonal antibody directed against the fibroblast growth factor receptor type 2b (FGFR2b), with potential antineoplastic activity. Upon administration, bemarituzumab specifically binds to and inhibits FGFR2b on tumor cell surfaces, which prevents FGFR2 from binding to its ligands, FGFR2b activation and the activation of FGFR2b-mediated signal transduction pathways. The binding of FPA144 to FGFR2b protein also induces antibody-dependent cell-mediated cytotoxicity (ADCC) against FGFR2b-expressing tumor cells. This results in the inhibition of cell proliferation and the induction of cell death of FGFR2-expressing tumor cells. FGFR2b, a specific isoform of the receptor tyrosine kinase FGFR2 upregulated in many tumor cell types, is essential to tumor proliferation, differentiation and survival. Glycoengineering enhances the FPA144-mediated ADCC.","Bemarituzumab | BEMARITUZUMAB | FPA144",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896818","anti-OX40 monoclonal antibody MEDI0562","C120041","An agonistic, humanized monoclonal antibody against receptor OX40 (CD134), with potential immunostimulatory activity. Upon administration, tavolimab selectively binds to and activates the OX40 receptor. OX40 receptor activation induces proliferation of memory and effector T-lymphocytes. In the presence of tumor-associated antigens (TAAs), this agent may promote an immune response against TAAs-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor family, is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T-cells.","Tavolimab | Anti-OX40 Monoclonal Antibody MEDI0562 | MEDI-0562 | MEDI0562 | TAVOLIMAB | Tavolixizumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899275","Eicosapentaenoic Acid-enriched Nutritional Supplement","C120042","A nutritional supplement enriched with eicosapentaenoic acid (EPA), which is an essential, polyunsaturated, 20-carbon omega-3 fatty acid found in fish oil, with potential anti-inflammatory and anti-cachectic activities. Upon oral intake of the EPA-enriched nutritional supplement, EPA is incorporated in cell membrane phospholipids and replaces arachidonic acid. This affects the production of pro-inflammatory mediators, such as tumor necrosis factor-alpha (TNF-a), interleukin-1 (IL-1) and IL-6, through the inhibition of nuclear factor kappa B (NF-kB) activity. This inhibits inflammation and may abrogate the cachexia-mediated decrease of lean body mass (LBM), which may lead to increased body weight. Pro-inflammatory mediators, such as TNF-a, interferon-gamma, and certain interleukins, such as IL-6 and IL-1b, play a key role in cachexia.","Eicosapentaenoic Acid-enriched Nutritional Supplement | EPA-enriched Nutritional Supplement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898224","Mouse Colon Adenocarcinoma","C120044","An adenocarcinoma arising from the colon of a mouse. It can be used as a mouse model of the human disease.","Mouse Colon Adenocarcinoma | Adenocarcinoma of Mouse Colon | Mouse Model of Colon Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899716","Canine Osteosarcoma","C120045","An osteosarcoma of mesenchymal origin in a dog. It is the most common bone cancer in dogs, most often developing in the limbs of large or giant breed dogs. The morphologic and biologic behavior of canine osteosarcomas is similar to that of human osteosarcomas.","Canine Osteosarcoma | Dog Osteosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1431330","Aryl Hydrocarbon Receptor Nuclear Translocator-Like Protein 1, Human","C119694","Basic helix-loop-helix ARNT-like protein 1 (626 aa, ~69 kDa) is encoded by the human BMAL1 gene. This protein is involved in the activation of gene transcription that mediates circadian rhythm.","Basic Helix-Loop-Helix ARNT-Like Protein 1 | ARNTL | Aryl Hydrocarbon Receptor Nuclear Translocator-Like Protein | Aryl Hydrocarbon Receptor Nuclear Translocator-Like Protein 1 | Aryl Hydrocarbon Receptor Nuclear Translocator-Like Protein 1 | BHLH-PAS Protein JAP3 | BMAL1 | BMAL1B | Basic-Helix-Loop-Helix-PAS Protein MOP3 | Brain and Muscle ARNT-Like 1 | Brain and Muscle ARNT-Like Protein 1 | Class E Basic Helix-Loop-Helix Protein 5 | Member of PAS Protein 3 | Member of PAS Superfamily 3 | PAS Domain-Containing Protein 3 | bHLH-PAS protein JAP3 | bHLHe5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425931","BMAL2 Gene","C119695","This gene plays a role in the positive regulation of transcription for genes involved in circadian rhythms.","BMAL2 Gene | ARNTL2 | ARNTL2 Gene | Aryl Hydrocarbon Receptor Nuclear Translocator-Like 2 Gene | BMAL2 | Basic Helix-Loop-Helix ARNT Like 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889459","ARNTL2 wt Allele","C119696","Human BMAL2 wild-type allele is located in the vicinity of 12p11.23 and is approximately 92 kb in length. This allele, which encodes basic helix-loop-helix ARNT-like protein 2, is involved in both transcriptional activation and circadian rhythms.","BMAL2 wt Allele | ARNTL2 | ARNTL2 wt Allele | Aryl Hydrocarbon Receptor Nuclear Translocator Like 2 Gene | Aryl Hydrocarbon Receptor Nuclear Translocator-Like 2 wt Allele | BHLHE6 | BMAL2 | Basic Helix-Loop-Helix ARNT Like 2 wt Allele | CLIF | MOP9 | PASD9 | bHLHe6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1309562","Human ARNTL2 protein","C119697","Basic helix-loop-helix ARNT-like protein 2 (636 aa, ~71 kDa) is encoded by the human BMAL2 gene. This protein plays a role in the transcriptional activation of genes involved in circadian rhythms.","Basic Helix-Loop-Helix ARNT-Like Protein 2 | ARNTL2 | Aryl Hydrocarbon Receptor Nuclear Translocator-Like Protein 2 | Aryl Hydrocarbon Receptor Nuclear Translocator-Like Protein 2 | BMAL2 | Basic-Helix-Loop-Helix-PAS Protein MOP9 | Brain and Muscle ARNT-Like 2 | Brain and Muscle ARNT-Like Protein 2 | CLIF | CYCLE-Like Factor | Class E Basic Helix-Loop-Helix Protein 6 | Member of PAS Protein 9 | Member of PAS Superfamily  9 | PAS Domain-Containing Protein 9 | Transcription Factor BMAL2 | bHLHe6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897927","Physical Examination Findings of New or Worsening Heart Failure","C119233","A description of the physical examination evidence of heart failure that can be classified as new or worsening.","Physical Examination Findings of New or Worsening Heart Failure | HFPEFNW | Heart Failure New/Worsening PE Findings",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896989","Heart Failure Therapy Intensification Type","C119234","A classification or description of the therapeutic agent or procedure that is being escalated.","Heart Failure Therapy Intensification Type | HFTHERIN | Heart Failure Therapy, Intensification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898664","Ischemic Discomfort Indicator","C119235","An indication as to whether the subject has symptoms of ischemic discomfort.","Ischemic Discomfort Indicator | ISCDIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898663","Ischemic Evidence Type","C119236","A classification or description of the evidence of ischemia in the subject.","Ischemic Evidence Type | ISCETYP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899240","Exclusion of Type 1 and Type 2 Myocardial Infarction Diagnosis Indicator","C119237","An indication as to whether type 1 and type 2 myocardial infarction is excluded as a diagnosis.","Exclusion of Type 1 and Type 2 Myocardial Infarction Diagnosis Indicator | Exclusion of Type 1 and Type 2 MI | MI12EXC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900110","Acute Myocardial Infarction From PCI Complication Type","C119239","A description of the complications from a percutaneous coronary intervention procedure that lead to an acute myocardial ischemic event.","Acute Myocardial Infarction From PCI Complication Type | PCI Acute Angiographic Complication | PCIAAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896925","Listeria monocytogenes-LLO-PSA Vaccine ADXS31-142","C120103","A cancer vaccine containing a live-attenuated strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding a fusion protein composed of the tumor-associated antigen (TAA) human prostate-specific antigen (PSA) fused to a fragment of the immunostimulant listeriolysin O (LLO) protein, with potential immunostimulatory and antineoplastic activities. Upon administration of the Lm-LLO-PSA vaccine ADXS31-142, the expressed LLO-PSA is processed by antigen presenting cells (APCs), presented to the immune system by both major histocompatibility complex (MHC) I and II molecules, and activates the immune system to exert both an innate and adaptive immune response involving the recruitment and activation of T-lymphocytes against PSA-expressing tumor cells as well as the inhibition of tumor-infiltrating T regulatory cells (T regs) and myeloid-derived suppressor cells (MDSCs). This eventually results in tumor cell lysis.","Listeria monocytogenes-LLO-PSA Vaccine ADXS31-142 | ADXS-PSA | ADXS31-142 | Lm-LLO-PSA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899043","Gallium Ga 68-RGD","C120104","A radiopharmaceutical agent comprised of a cyclic arginine-glycine-aspartic acid (Arg-Gly-Asp/RGD) peptide labeled with gallium Ga 68, with potential alphaVbeta3 integrin (avb3) imaging activity during positron emission topography (PET). After intravenous administration, gallium Ga 68-RGD selectively binds to avb3 on the cell membrane via the cyclic RGD motif. Upon PET imaging, avb3-expressing tumor cells can be visualized and their expression levels can be quantified. avb3, a member of the integrin receptor family, is overexpressed on certain tumor cells and tumor endothelial cells while minimally or not expressed on healthy, normal cells; it plays a key role in angiogenesis, tumor proliferation and survival.","Gallium Ga 68-RGD | (68)Ga-RGD | RGD (68Ga)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0546264","Congenital Fiber-Type Disproportion","C120046","A rare genetic disorder caused by mutations in the TPM3, ACTA1, RYR1 and SEPN1 genes. It is inherited in an autosomal dominant or recessive pattern and rarely in an X-linked pattern. It manifests with myopathy throughout the body, particularly in the muscles of the shoulders, upper arms, hips, and thighs. Affected individuals may have contractures, lordosis, or scoliosis.  In a minority of cases mild to severe breathing problems may occur.","Congenital Fiber-Type Disproportion | Congenital Fiber-Type Disproportion Myopathy",,,,,,,,,,,,,,,"4347282","Congenital myopathy with fiber type disproportion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0070798","Phosphatidylinositol 4,5-Diphosphate","C1192","A phospholipid that is a component of the plasma membrane with signal transduction inducing activity. Phosphatidylinositol 4,5-bisphosphate (PIP2) is an intermediate that can be converted into either the second messenger signaling molecules, inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), or phosphatidylinositol (3,4,5)-trisphosphate (PtdIns(3,4,5)P3; PIP3). Both PIP2 and PIP3 can act as docking phospholipids, which recruit signaling proteins to the plasma membrane and promotes the activation of several signaling cascades.","Phosphatidylinositol 4,5-bisphosphate | 1,2-Diacyl-sn-Glycero-3-Phospho-(1'-myo-Inositol-4',5'-Bisphosphate) | 1-O-(3-sn-Phosphatidyl)-1D-myo-Inositol 4,5-Bis(Dihydrogen Phosphate) | 1-Phosphatidyl-1D-myo-Inositol 4,5-Bisphosphate | 1-Phosphatidyl-D-myo-Inositol 4,5-Bisphosphate | PIP2 | PIPP | Phosphatidyl-myo-Inositol 4,5-Bisphosphate | Phosphatidylinositol 4,5-Diphosphate | PtdIns(4,5)P2 | PtsIns-4,5-P2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1002519","Acanthamoeba griffini","C119300","A species of motile, unicellular eukaryotic amoebae within the family of Acanthamoebidae. A. griffini is placed in morphological group II with a 18s rRNA gene sequence type of T3. Members of this group are characterized by the presence of wrinkled ectocysts and endocysts which could be stellate, polygonal, triangular, or oval. This species is a human pathogen and may cause granulomatous amoebic encephalitis and amoebic keratitis.","Acanthamoeba griffini | ACANTHAMOEBA GRIFFINI",,,,,,,,,,,,,,,"4219537","Acanthamoeba griffini",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0585181","Acanthamoeba hatchetti","C119301","A species of motile, unicellular eukaryotic amoebae within the family of Acanthamoebidae. A. hatchetti is placed in morphological group II with a 18s rRNA gene sequence type of T11. Members of this group are characterized by the presence of wrinkled ectocysts and endocysts which could be stellate, polygonal, triangular, or oval. This species is a human pathogen and may cause granulomatous amoebic encephalitis and amoebic keratitis. It may also cause amoebic placentitis in horses.","Acanthamoeba hatchetti | ACANTHAMOEBA HATCHETTI",,,,,,,,,,,,,,,"4145891","Acanthamoeba hatchetti",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1022927","Acanthamoeba lugdunensis","C119302","A species of motile, unicellular eukaryotic amoebae within the family of Acanthamoebidae. A. lugdunensis is placed in morphological group II with a 18s rRNA gene sequence type of T4. Members of this group are characterized by the presence of wrinkled ectocysts and endocysts which could be stellate, polygonal, triangular, or oval. This species is a human pathogen and may cause granulomatous amoebic encephalitis and amoebic keratitis.","Acanthamoeba lugdunensis | ACANTHAMOEBA LUGDUNENSIS",,,,,,,,,,,,,,,"4219547","Acanthamoeba lugdunensis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0585180","Acanthamoeba palestinensis","C119303","A species of motile, unicellular eukaryotic amoebae within the family of Acanthamoebidae. A. palestinensis is placed in morphological group III with a 18s rRNA gene sequence type of T2. Members of this group are characterized by the presence of thin, smooth ectocysts and round endocysts. This species is a human pathogen and may cause granulomatous amoebic encephalitis and amoebic keratitis.","Acanthamoeba palestinensis | ACANTHAMOEBA PALESTINENSIS",,,,,,,,,,,,,,,"4143886","Acanthamoeba palestinensis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320459","Acanthamoeba polyphaga","C119304","A species of motile, unicellular eukaryotic amoebae within the family of Acanthamoebidae. A. polyphaga is placed in morphological group II with a 18s rRNA gene sequence type of T4. Members of this group are characterized by the presence of wrinkled ectocysts and endocysts which could be stellate, polygonal, triangular, or oval. This species is a human pathogen and may cause granulomatous amoebic encephalitis and amoebic keratitis. A. polyphaga also serves as a secondary decomposer to remineralize soil with carbon, nitrogen, and phosphorous by consuming bacterial primary decomposers.","Acanthamoeba polyphaga | ACANTHAMOEBA POLYPHAGA",,,,,,,,,,,,,,,"4096782","Acanthamoeba polyphaga",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0071072","Pimonidazole","C1196","A 2-nitroimidazole with hypoxic selectivity and potential radiosensitizing activities. Pimonidazole is reduced in hypoxic environments such as those found in tumors. In hypoxic cells, reduced pimonidazole binds to thiol-containing proteins. The resulting complexes accumulate in hypoxic tumors, thereby depleting radioprotective thiol compounds and sensitizing tumor cells to be more susceptible for radiation treatment.","Pimonidazole | 1-piperidineethanol, alpha-((2-nitro-1h-imidazol-1-yl)methyl)- | PD 126675 | PIMONIDAZOLE | Ro 03-8799",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896733","Anti-CD37 MMAE Antibody-drug Conjugate AGS67E","C119700","An antibody-drug conjugate (ADC) composed of AGS67C, a human anti-CD37 monoclonal antibody covalently linked, via reduced cysteines and a protease cleavable linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of AGS67E binds to CD37 antigens on tumor B-cells and is rapidly internalized, thereby delivering MMAE intracellularly. Upon proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M checkpoint arrest and apoptosis in CD37-expressing tumor cells. CD37, a transmembrane glycoprotein, is overexpressed in B-cell malignancies.","Anti-CD37 MMAE Antibody-drug Conjugate AGS67E | AGS67E | Anti-CD37 MMAE ADC AGS67E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL421596","Antroquinonol Capsule","C119701","An orally available capsule containing antroquinonol, a farnesylated quinone derivative isolated from the mycelium of Antrodia camphorata, with potential antineoplastic activity. Upon oral administration, antroquinonol binds to and inhibits protein prenylation mediated by the enzymes farnesyltransferase (FTase) and geranylgeranyltransferase 1 (GGTase-1). This prevents both post-translational prenylation and signaling activity of a number of Ras superfamily proteins, such as Ras and Rho. This results in the inhibition of downstream signaling, such as the PI3K/mTOR signaling pathway, and induces apoptosis in susceptible tumor cells. Ras superfamily proteins are overexpressed in numerous cancer cell types, and play a key role in tumor cell proliferation and survival.","Antroquinonol Capsule | ANTROQUINONOL | Hocena",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899706","Carbon C14-labeled Carboplatin","C119702","A radioconjugate composed of the platinum compound carboplatin conjugated to the isotope carbon C 14 (14C-carboplatin), which can potentially be used to predict chemoresistance to carboplatin using accelerator mass spectrometry (AMS). Upon administration of a microdose of 14C-carboplatin, the carboplatin moiety covalently binds to DNA and forms carboplatin-DNA monoadducts. Using AMS, the 14C-carboplatin-DNA monoadducts can be detected and measured. The levels of microdose-induced carboplatin-DNA monoadducts can be used to assess the degree of chemoresistance to carboplatin and can predict cancer response to carboplatin-based chemotherapy. The carboplatin microdose is defined as 1/100 of the pharmacologically effective concentration of carboplatin. Low levels of carboplatin monoadduct formation and increased DNA repair, measured by a decrease in the detection of carboplatin-DNA monoadducts over a given time period, are correlated with increased resistance to platinum-based chemotherapeutics.","Carbon C14-labeled Carboplatin | 14C Carboplatin | Carbon-14-labeled Carboplatin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3281115","Macrosomia","C119954","A newborn infant who has a weight at birth greater than 4500 grams.","Macrosomia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897822","Procedure Success Indicator","C119240","An indication as to whether the procedure is considered successful.","Procedure Success Indicator | PRSUCIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897422","Symptom Indicator","C119241","An indication as to whether the subject had symptoms related to the clinical event of interest.","Symptom Indicator | SYMPINDC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898757","Insignificant Disease by ECG Finding","C119244","An electrocardiographic recording that does not demonstrate any significant signs of ischemia or conduction abnormalities.","Insignificant Disease by ECG Finding | INSIGNIFICANT DISEASE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890914","FALEC wt Allele","C119656","Human FALEC wild-type allele is located in the vicinity of 1q21.3 and is approximately 2 kb in length. This allele, which encodes focally amplified long non-coding RNA in epithelial cancer, may play a role in tumorigenesis.","FALEC wt Allele | ENSG00000228126 | FAL1 | Focally Amplified LncRNA on Chromosome 1 Gene | Focally Amplified Long Non-Coding RNA in Epithelial Cancer wt Allele | LINC00568 | Long Intergenic Non-Protein Coding RNA 568 Gene | RP11-54A4.8 | ncRNA-a1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889726","Focally Amplified Long Non-Coding RNA in Epithelial Cancer, human","C119657","Focally amplified long non-coding RNA in epithelial cancer (566 bp) is encoded by the human FALEC gene. This non-coding RNA may be involved in oncogenesis.","Focally Amplified Long Non-Coding RNA in Epithelial Cancer | FAL1 | FALEC | Focally Amplified LncRNA on Chromosome 1 | LINC00568 | Long Intergenic Non-Protein Coding RNA 568 | ncRNA-a1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414034","DGKH Gene","C119658","This gene plays a role in both diacylglycerol phosphorylation and the promotion of cell growth.","DGKH Gene | DGKH | Diacylglycerol Kinase, Eta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890916","DGKH wt Allele","C119659","Human DGKH wild-type allele is located in the vicinity of 13q14.11 and is approximately 217 kb in length. This allele, which encodes diacylglycerol kinase eta protein, is involved in second messenger signaling to promote cell growth.","DGKH wt Allele | DGKeta | Diacylglycerol Kinase, Eta wt Allele | RP11-215B13.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3888278","Diacylglycerol Kinase Eta, human","C119660","Diacylglycerol kinase eta (1220 aa, ~135 kDa) is encoded by the human DGKH gene. This protein plays a role in the phosphorylation of diacylglycerol.","Diacylglycerol Kinase Eta | DAG Kinase Eta | DGK-Eta | DGKH | Diglyceride Kinase Eta | EC 2.7.1.107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890908","RCSD1 wt Allele","C119662","Human RCSD1 wild-type allele is located in the vicinity of 1q24.2 and is approximately 76 kb in length. This allele, which encodes CapZ-interacting protein, may play a role in the remodeling of F-actin.","RCSD1 wt Allele | CAPZIP | MGC21854 | MK2S4 | RCSD Domain Containing 1 wt Allele | RP3-503M14.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1461218","Acanthamoeba quina","C119305","A species of motile, unicellular eukaryotic amoebae within the family of Acanthamoebidae. A. quina is placed in morphological group II with a 18s rRNA gene sequence type of T4. Members of this group are characterized by the presence of wrinkled ectocysts and endocysts which could be stellate, polygonal, triangular, or oval. This species is a human pathogen and may cause granulomatous amoebic encephalitis and amoebic keratitis.","Acanthamoeba quina | ACANTHAMOEBA QUINA",,,,,,,,,,,,,,,"4218156","Acanthamoeba quina",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0585182","Acanthamoeba rhysodes","C119306","A species of motile, unicellular eukaryotic amoebae within the family of Acanthamoebidae. A. rhysodes is placed in morphological group II with a 18s rRNA gene sequence type of T4. Members of this group are characterized by the presence of wrinkled ectocysts and endocysts which could be stellate, polygonal, triangular, or oval. This species is a human pathogen and may cause granulomatous amoebic encephalitis and amoebic keratitis.","Acanthamoeba rhysodes | ACANTHAMOEBA RHYSODES",,,,,,,,,,,,,,,"4143887","Acanthamoeba rhysodes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0544166","Achromobacter ruhlandii","C119307","A species of Gram-negative, non-fermentative, non-hemolytic, and non-halophilic, non-spore forming rod-shaped bacteria, in the phylum Proteobacteria. This species is catalase- and oxidase-positive, urease-, phenylalanine-, deaminase-, and DNase-negative, reduces nitrate to nitrite, assimilates glucose, and does not hydrolyze esculin, gelatin and starch. A. ruhlandii is commonly found in soil.","Achromobacter ruhlandii | ACHROMOBACTER RUHLANDII | Alcaligenes ruhlandii | Hydrogenomonas ruhlandii | Pseudomonas ruhlandii",,,,,,,,,,,,,,,"4184844","Achromobacter ruhlandii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3896694","MAGE-A3-expressing Adenovirus Type 5 Vaccine","C119614","An oncolytic adenoviral vaccine composed of a replication-defective, E1- and E3-deleted adenovirus serotype 5 (Ad5) with a transgene encoding the human melanoma antigen A3 (MAGE-A3), with potential antineoplastic activity. Upon administration, MAGE-A3-expressing adenovirus type 5 vaccine selectively replicates in cancer cells and expresses MAGE-A3. This induces an immune response against tumor cells expressing the MAGE-A3 antigen, which leads to tumor cell death. The tumor-associated antigen MAGE-A3 is overexpressed by a variety of cancer cell types.","MAGE-A3-expressing Adenovirus Type 5 Vaccine | AdMA3 | Adenovirus/MAGE-A3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896743","anti-CD20/CD3 monoclonal antibody REGN1979","C119615","A bispecific, human monoclonal antibody with potential antineoplastic activity. Anti-CD20/CD3 monoclonal antibody REGN1979 contains two antigen-recognition sites: one for human CD3, a T cell surface antigen, and one for human CD20, a tumor-associated antigen that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, odronextamab binds to both T-cells and CD20-expressing tumor B-cells, which cross-links the T-cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B-cells.","Odronextamab | Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody REGN1979 | ODRONEXTAMAB | REGN1979 | WHO 11035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897787","RPQ - Poor Concentration","C119185","Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Poor concentration.","RPQ - Poor Concentration | RPQ01-Poor Concentration | RPQ0111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897784","RPQ - Taking Longer to Think","C119186","Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Taking longer to think.","RPQ - Taking Longer to Think | RPQ01-Taking Longer to Think | RPQ0112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897798","RPQ - Blurred Vision","C119187","Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Blurred vision.","RPQ - Blurred Vision | RPQ01-Blurred Vision | RPQ0113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1690139","CapZ-Interacting Protein, Human","C119663","CapZ-interacting protein (416 aa, ~45 kDa) is encoded by the human RCSD1 gene. This protein may be involved in the modulation of actin filament formation.","CapZ-Interacting Protein | Protein Kinase Substrate CapZIP | Protein Kinase Substrate MK2S4 | RCSD Domain-Containing Protein 1 | RCSD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896946","Gilteritinib Fumarate","C119665","The fumarate salt form of gilteritinib, an orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), with potential antineoplastic activity. Upon administration, gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL, ALK and LTK. This may result in an inhibition of FLT3-, AXL-, ALK-, and LTK-mediated signal transduction pathways and reduced proliferation in cancer cells that overexpress these RTKs. FLT3, AXL, ALK, and LTK, which are overexpressed or mutated in a variety of cancer cell types, play key roles in tumor cell growth and survival.","Gilteritinib Fumarate | 2-Pyrazinecarboxamide, 6-ethyl-3-((3-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)-, (2E)-2-Butenedioate (2:1) | ASP-2215 Hemifumarate | ASP2215 Hemifumarate | GILTERITINIB FUMARATE | Gilteritinib Hemifumarate | Xospata",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823956","ZMIZ1 Gene","C119666","This gene plays a role in androgen receptor-mediated gene expression.","ZMIZ1 Gene | ZMIZ1 | Zinc Finger, MIZ-Type Containing 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889263","ZMIZ1 wt Allele","C119667","Human ZMIZ1 wild-type allele is located in the vicinity of 10q22.3 and is approximately 247 kb in length. This allele, which encodes zinc finger MIZ domain-containing protein 1, is involved in the modulation of androgen receptor-dependent genes.","ZMIZ1 wt Allele | FLJ00092 | FLJ13541 | KIAA1224 | MIZ | RAI17 | RP11-519K18.1 | Retinoic Acid Induced 17 Gene | Retinoic Acid-Induced Gene 17 | TRAFIP10 | ZIMP10 | Zinc Finger, MIZ-Type Containing 1 wt Allele | Zinc Finger-Containing, Miz1, PIAS-Like Protein on Chromosome 10 Gene | hZIMP10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898083","Organ Measurements Biospecimen Usability","C119894","A qualitative or quantitative measure that describes a biospecimen's suitability for organ measurement purposes.","Organ Measurements Biospecimen Usability | OMSPCUFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898073","Organ Measurements Specimen Type","C119895","The type of material sample taken from a biological entity for organ measurements.","Organ Measurements Specimen Type | OMSPEC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898084","Organ Measurements Assessment Character Result in Standard Format","C119897","The standard character or string for representation and reporting of organ measurements data.","Organ Measurements Assessment Character Result in Standard Format | OMSTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898087","Organ Measurement Numeric Result in Standard Unit","C119898","The numerical identifier of an organ measurement result in standard units.","Organ Measurement Numeric Result in Standard Unit | OMSTRESN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898086","Organ Measurement Result Standard Unit","C119899","The standard unit of measure for the organ measurement results.","Organ Measurement Result Standard Unit | OMSTRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896843","hTERT Multipeptide/Montanide ISA-51 VG/Imiquimod Vaccine GX 301","C119616","A therapeutic cancer vaccine consisting of four epitopes derived from the human telomerase reverse transcriptase (hTERT), the catalytic subunit of human telomerase, including hTERT (540-548) acetate, hTERT (611-626) acetate, hTERT (672-686) acetate and hTERT (766-780) acetate, emulsified individually in the adjuvant montanide ISA-51 VG and administered with the immune response modifier (IRM) imiquimod, with potential immunostimulating and antineoplastic activities. Each hTERT peptide emulsion is administered individually by intradermal injection. Subsequently, imiquimod is applied topically to the injection site(s). Vaccination with GX 301 may elicit a cytotoxic T-cell (CTL) response against telomerase-expressing tumor cells. Telomerase is expressed in the majority of human cancer cells, infrequently expressed in normal cells, and is directly linked to tumorigenesis. Imiquimod stimulates cytokine production through the activation of toll-like receptor 7 (TLR-7), and also exhibits antiproliferative effects. Montanide ISA-51, also known as incomplete Freund's adjuvant (IFA), is a stabilized water-in-oil emulsion containing mineral oil with mannide oleate, which contains vegetable-grade (VG) oleic acid derived from olive oil. ISA-51 non-specifically stimulates cell-mediated immune responses to antigens.","hTERT Multipeptide/Montanide ISA-51 VG/Imiquimod Vaccine GX 301 | GX 301 | GX301",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896800","telomerase-specific type 5 adenovirus OBP-301","C119617","A replication-competent oncolytic, telomerase-specific adenovirus serotype 5 (Ad5), with potential antineoplastic activity. Suratadenoturev contains the human telomerase reverse transcriptase (hTERT) gene promoter sequence that drives the expression of the E1A and E1B genes, and is linked to an internal ribosomal entry site (IRES). Upon administration, OBP-301 selectively infects and replicates in cancer cells that are expressing telomerase, which causes cell lysis. This adenovirus does not infect or replicate in normal, healthy cells. OBP-301 may also potentially be used as a chemosensitizer. hTERT, which encodes for the catalytic protein subunit of telomerase, is overexpressed in a variety of cancer cell types but not in normal, healthy cells. The insertion of an IRES further improves selectivity towards telomerase-expressing cancer cells.","Suratadenoturev | OBP-301 | SURATADENOTUREV | Telomelycin | Telomelysin | Telomerase-specific Type 5 Adenovirus OBP-301",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896783","HIF-2alpha Inhibitor PT2385","C119618","An orally active, small molecule inhibitor of hypoxia inducible factor (HIF)-2alpha, with potential antineoplastic activity. Upon oral administration, HIF-2alpha inhibitor PT2385 allosterically binds to HIF-2alpha, thereby preventing HIF-2alpha heterodimerization and its subsequent binding to DNA. This results in decreased transcription and expression of HIF-2alpha downstream target genes, many of which regulate tumor cell growth and survival. Blocking HIF-2alpha reduces the proliferation of HIF-2alpha-expressing tumor cells. HIF-2alpha, a heterodimeric transcription factor overexpressed in many cancers, promotes tumorigenesis.","HIF-2alpha Inhibitor PT2385 | PT2385",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899915","Body Weight Reason Not Done","C119788","The explanation given as to why body weight was not assessed.","Body Weight Reason Not Done | BWREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897132","Body Weight Sequence Number","C119789","An identifier that describes the relative position of body weight data within a series.","Body Weight Sequence Number | BWSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899935","Body Weight Completion Status","C119790","A term used to describe the state or condition of the completeness of the body weight data.","Body Weight Completion Status | BWSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899936","Body Weight Character Result in Standard Format","C119791","The standard character or string for representation and reporting of body weight data.","Body Weight Character Result in Standard Format | BWSTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899919","Body Weight Numeric Result in Standard Unit","C119792","The numerical identifier of a body weight result in standard units.","Body Weight Numeric Result in Standard Unit | BWSTRESN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899914","Body Weight Result Standard Unit","C119793","The standard unit of measure for body weight results.","Body Weight Result Standard Unit | BWSTRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889974","Body Weight Test Code","C119795","A character or string that represents the short code name of the body weight assessment.","Body Weight Test Code | BWTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899614","Clinical Observations Body System or Organ Class","C119796","The body system or organ class associated with a clinical observation.","Clinical Observations Body System or Organ Class | CLBODSYS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897790","RPQ - Light Sensitivity","C119188","Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Light sensitivity, easily upset by bright light.","RPQ - Light Sensitivity | RPQ01-Light Sensitivity/Bright Light | RPQ0114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897797","RPQ - Double Vision","C119189","Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Double vision.","RPQ - Double Vision | RPQ01-Double Vision | RPQ0115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897786","RPQ - Restlessness","C119190","Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Restlessness.","RPQ - Restlessness | RPQ01-Restlessness | RPQ0116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897802","RPQ - Any Other Difficulties 1 (Text)","C119191","Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, are you experiencing any other difficulties 1? (Text).","RPQ - Any Other Difficulties 1 (Text) | RPQ01-Any Other Difficulties 1 (Text) | RPQ0117A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897799","RPQ - Any Other Difficulties 2 (Text)","C119193","Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, are you experiencing any other difficulties 2? (Text).","RPQ - Any Other Difficulties 2 (Text) | RPQ01-Any Other Difficulties 2 (Text) | RPQ0118A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897800","RPQ - Any Other Difficulties 2 (Number)","C119194","Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, are you experiencing any other difficulties 2? (Number).","RPQ - Any Other Difficulties 2 (Number) | RPQ01-Any Other Difficulties 2 | RPQ0118B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897387","TIMI Thrombus Grade - Coronary Thrombus TIMI Grade","C119195","Coronary Thrombus TIMI Grade (TIMI Thrombus Grade) A grade corresponding to thrombus development as defined in the grading system by the Thrombolysis in the Myocardial Infarction Group.","TIMI Thrombus Grade - Coronary Thrombus TIMI Grade | TIMG01-Coronary Thrombus TIMI Grade | TIMG0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898204","NHLBI CAD Grade - Coronary Artery Dissection NHLBI Grade","C119196","Coronary Artery Dissection NHLBI Grade (NHLBI CAD Grade) A grading system to describe coronary artery dissection per the NHLBI, American College of Cardiology, American Heart Association.","NHLBI CAD Grade - Coronary Artery Dissection NHLBI Grade | CADG01-Coronary Dissection NHLBI Grade | CADG0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900159","ARC STC Timing - Stent Thrombosis Coronary ARC Timing","C119197","Stent Thrombosis Coronary ARC Timing (ARC STC Timing) Categorization of the timing of coronary stent thrombosis occurrence per the classification schema described by the Academic Research Consortium.","ARC STC Timing - Stent Thrombosis Coronary ARC Timing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900161","ARC STC Grade - Stent Thrombosis Coronary ARC Grade","C119198","Stent Thrombosis Coronary ARC Grade (ARC STC Grade) A grading system to describe the coronary stent thrombosis per the classification schema described by the Academic Research Consortium.","ARC STC Grade - Stent Thrombosis Coronary ARC Grade | STCG01-STC ARC Grade | STCG0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898091","Oral Diuretic Therapy Augmentation for Heart Failure","C119199","Initiation or intensification of oral diuretics to treat heart failure.","Oral Diuretic Therapy Augmentation for Heart Failure | AUGMENTATION OF ORAL DIURETIC THERAPY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896775","CD40 agonist monoclonal antibody RO7009789","C119740","A human immunoglobulin G2 (IgG2) monoclonal antibody agonist of the cell surface receptor CD40, with potential immunostimulatory and antineoplastic activities. Upon administration, selicrelumab targets and binds to CD40 expressed on a variety of immune cell types. This induces CD40-dependent signaling pathways and triggers the cellular proliferation and activation of antigen-presenting cells (APCs), and activates B-cells and T-cells, resulting in an enhanced anti-tumor immune response. CD40, a cell surface receptor and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells and certain cancer cells; it plays a key role in the activation of the immune system.","Selicrelumab | CD40 Agonist Monoclonal Antibody CP-870,893 | CP-870,893 | RO7009789 | SELICRELUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899687","ChiNing Decoction","C119741","A decoction of Liang Ge San, a traditional Chinese herbal medicine, with potential anti-inflammatory and anti-stomatitis activities. Although the complete mechanism of action through which the ChiNing decoction works has yet to be fully elucidated, upon oral administration, the active ingredients may inhibit the inflammatory response, possibly by reducing the levels of pro-inflammatory cytokines, such as interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNFa), in the saliva. This may protect the oral mucosa against these inflammatory mediators, and may reduce and relieve radiation-induced stomatitis and the associated pain.","ChiNing Decoction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899707","Carbon C 13/Nitrogen N 15-labeled Valine","C119742","A radioconjugate composed of the essential amino acid valine radiolabeled to carbon C 13 and nitrogen N 15, that can potentially be used as a tracer for protein metabolism in vivo using mass spectrometry (MS). Upon administration of carbon C 13/nitrogen N 15-labeled valine, the exogenous valine is taken up by cells and incorporated into proteins. Upon imaging, protein biomarkers containing radiolabeled valine are secreted by tumor cells and can be identified by MS. This may aid in cancer diagnosis and prognosis. Compared to normal cells, tumor cells rapidly take up amino acids to use as protein building blocks.","Carbon C 13/Nitrogen N 15-labeled Valine | (+)-2-Amino-3-Methylbutyric Acid-13C5,15N | C13 N15 Valine | Carbonomic | L-2-Amino-3-methylbutanoic Acid-13C5,15N | L-Valine-13C5,15N",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896849","E-selectin antagonist GMI-1271","C119743","A synthetic, glycomimetic molecule and E-selectin (CD62E) antagonist, with potential anti-thrombotic, antineoplastic and chemopotentiating activities. Upon administration, uproleselan binds to E-selectin expressed on endothelial cells and prevents their interaction with selectin-E ligand-expressing cancer cells. This may prevent tumor cell activation, migration and metastasis. GMI-1271 also interferes with the binding of selectin E-expressing vascular endothelial cells to selectin-E ligand-expressing monocytes and neutrophils, thereby disrupting their activation. Consequently, this inhibits both the activation of the coagulation cascade and thrombus formation. This agent also prevents both leukocyte activation and inflammation. E-selectin is a cell adhesion molecule involved in cell rolling, signaling and chemotaxis; it also plays a crucial role in inflammatory processes and cancer.","Uproleselan | GMI-1271 | UPROLESELAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889254","Organ Measurements Assessment Test","C119900","A character or string that represents the long name of the organ measurements.","Organ Measurements Assessment Test | OMTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889255","Organ Measurements Assessment Test Code","C119901","A character or string that represents the short code name of the organ measurements.","Organ Measurements Assessment Test Code | OMTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897934","Pharmacokinetic Concentration Baseline Flag","C119902","An indication or description that pharmacokinetic concentration data is a baseline value.","Pharmacokinetic Concentration Baseline Flag | PCBLFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897933","Pharmacokinetic Concentration End Day","C119903","The final day of the pharmacokinetic concentration assessment.","Pharmacokinetic Concentration End Day | PCENDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897091","Pharmacokinetic Concentration Reason For Exclusion From Statistics","C119905","A rationale for excluding a particular data point or subject from the pharmacokinetic concentration results statistical analysis.","Pharmacokinetic Concentration Reason For Exclusion From Statistics | PCREASEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898003","Palpable Masses Collection Date Time","C119906","The date and time of palpable masses data collection.","Palpable Masses Collection Date Time | PMDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897470","Study Day of Palpable Masses","C119907","The study day that a palpable masses assessment is performed.","Study Day of Palpable Masses | PMDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898002","Palpable Masses Evaluator","C119908","A person who determines the significance of a palpable masses assessment.","Palpable Masses Evaluator | PMEVAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898001","Palpable Masses Group Identifier","C119909","A character or string that represents a palpable masses group.","Palpable Masses Group Identifier | PMGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898000","Palpable Masses Location","C119910","The site in or on the body at which the palpable masses assessment or result is performed or collected.","Palpable Masses Location | PMLOC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897998","Palpable Masses Original Result","C119911","The outcome of the palpable masses assessment as originally received or collected.","Palpable Masses Original Result | PMORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897999","Palpable Masses Original Result Unit","C119912","The unit of measure for the result of the palpable masses assessment as originally received or collected.","Palpable Masses Original Result Unit | PMORRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899767","CHART-SF Paper Version - Paid Personal Care per Day","C119142","Craig Handicap Assessment and Reporting Technique-Short Form Paper Version (CHART-SF Paper Version) How many hours in a typical 24-hour day do you have someone with you to provide physical assistance for personal care activities such as eating, bathing, dressing, toileting and mobility? Hours paid assistance.","CHART-SF Paper Version - Paid Personal Care per Day | CHSF2-Paid Personal Care per Day | CHSF201A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899766","CHART-SF Paper Version - Unpaid Personal Care per Day","C119143","Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) How many hours in a typical 24-hour day do you have someone with you to provide physical assistance for personal care activities such as eating, bathing, dressing, toileting and mobility? Hours unpaid (family, others).","CHART-SF Paper Version - Unpaid Personal Care per Day | CHSF2-Unpaid Personal Care per Day | CHSF201B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899783","CHART-SF Paper Version - Cognitive Assistance at Home per Day","C119144","Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) How much time is someone with you in your home to assist you with activities that require remembering, decision making, or judgment?","CHART-SF Paper Version - Cognitive Assistance at Home per Day | CHSF2-Home Cognitive Assistance per Day | CHSF202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889669","Clinical Observations Category","C119797","A classification of clinical observation data.","Clinical Observations Category | CLCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899611","Clinical Observations Data Collection Date Time","C119798","The date and time of clinical observation data collection.","Clinical Observations Data Collection Date Time | CLDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897478","Study Day of Clinical Observations","C119799","The study day that a clinical observation is made.","Study Day of Clinical Observations | CLDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899609","Clinical Observations Evaluator","C119801","A person who determines the significance of a clinical observation assessment.","Clinical Observations Evaluator | CLEVAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899247","Exclude Clinical Observation Data From Statistics Indicator","C119802","Specifies whether the clinical observation result values should be excluded from the statistical analysis.","Exclude Clinical Observation Data From Statistics Indicator | CLEXCLFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899608","Clinical Observations Group Identifier","C119803","A character or string that represents a clinical observation findings group.","Clinical Observations Group Identifier | CLGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899606","Clinical Observations Original Result","C119805","The outcome of the clinical observation as originally received or collected.","Clinical Observations Original Result | CLORRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899615","Clinical Observation Reason For Exclusion From Statistics","C119806","A rationale for excluding a particular data point or subject from the clinical observation statistical analysis.","Clinical Observation Reason For Exclusion From Statistics | CLREASEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890011","PIN1 wt Allele","C120049","Human PIN1 wild-type allele is located in the vicinity of 19p13 and is approximately 14 kb in length. This allele, which encodes peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 protein, is involved in protein conformation.","PIN1 wt Allele | DOD | DODO, Drosophila, Homolog of Gene | Peptidyl-Prolyl Cis/Trans Isomerase, NIMA-Interacting, 1 Gene | Peptidylprolyl Cis/Trans Isomerase, NIMA-Interacting 1 wt Allele | Protein (Peptidyl-Prolyl Cis/Trans Isomerase) NIMA-Interacting 1 Gene | UBL5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1453967","Peptidyl-Prolyl Cis-Trans Isomerase NIMA-Interacting 1, Human","C120050","Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (163 aa, ~18 kDa) is encoded by the human PIN1 gene. This protein plays a role in the modulation of phosphoprotein conformation.","Peptidyl-Prolyl Cis-Trans Isomerase NIMA-Interacting 1 | EC 5.2.1.8 | PIN1 | PPIase Pin1 | Peptidyl-Prolyl Cis-Trans Isomerase Pin1 | Rotamase Pin1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0935871","Dexa-BEAM protocol","C12001","A regimen consisting of dexamethasone, carmustine, etoposide, cytarabine, and melphalan that may be used followed by high-dose and stem-cell rescue for the treatment of relapsed or refractory lymphoma.","Dexa-BEAM Regimen | Carmustine/Cytarabine/Dexamethasone/Etoposide/Melphalan | Dexa-BEAM | DexaBEAM | Dexamethasone-BCNU-Etoposide-Cytarabine-Melphalan | Dexamethasone-Carmustine-Etoposide-Cytarabine-Melphalan | Dexamethasone/BCNU/Etoposide/Ara-C/Melphalan | Dexamethasone/Carmustine/Etoposide/Cytarabine/Melphalan | Dexamethasone/Carmustine/Etoposide/Cytarabine/Melphalan Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899779","CHART-SF Paper Version - Hours Out of Bed per Day","C119146","Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) On a typical day, how many hours are you out of bed?","CHART-SF Paper Version - Hours Out of Bed per Day | CHSF2-Hours Out of Bed per Day | CHSF204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899781","CHART-SF Paper Version - Days Out of the House per Week","C119147","Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) In a typical week, how many days do you get out of your house and go somewhere?","CHART-SF Paper Version - Days Out of the House per Week | CHSF2-Days Out of the House per Week | CHSF205",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899771","CHART-SF Paper Version - Nights Away From Home Last Year","C119148","Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) In the last year, how many nights have you spent away from your home (excluding hospitalizations)?","CHART-SF Paper Version - Nights Away From Home Last Year | CHSF2-Nights Away From Home Last Year | CHSF206",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899776","CHART-SF Paper Version - Hours of Paid Work per Week","C119149","Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) How many hours per week do you spend working in a job for which you get paid?","CHART-SF Paper Version - Hours of Paid Work per Week | CHSF2-Hours of Paid Work per Week | CHSF207A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899768","CHART-SF Paper Version - Occupation of Paid Work","C119150","Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) How many hours per week do you spend working in a job for which you get paid? (occupation).","CHART-SF Paper Version - Occupation of Paid Work | CHSF2-Occupation of Paid Work | CHSF207B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896962","CHART-SF Paper Version - Hours of Schoolwork per Week","C119151","Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) How many hours per week do you spend in school working toward a degree or in an accredited technical training program (including hours in class and studying)?","CHART-SF Paper Version - Hours of Schoolwork per Week | CHSF2-Hours of Schoolwork per Week | CHSF208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899777","CHART-SF Paper Version - Hours of Homemaking per Week","C119152","Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) How many hours per week do you spend in active homemaking including parenting, housekeeping, and food preparation?","CHART-SF Paper Version - Hours of Homemaking per Week | CHSF2-Hours of Homemaking per Week | CHSF209",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899778","CHART-SF Paper Version - Hours of Home Maintenance per Week","C119153","Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) How many hours per week do you spend in home maintenance activities such as gardening, house repairs or home improvement?","CHART-SF Paper Version - Hours of Home Maintenance per Week | CHSF2-Hours of Home Maintenance per Week | CHSF210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899775","CHART-SF Paper Version - Hours of Recreational Activities per Week","C119154","Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) How many hours per week do you spend in recreational activities such as sports, exercise, playing cards, or going to movies? Please do not include time spent watching TV or listening to the radio.","CHART-SF Paper Version - Hours of Recreational Activities per Week | CHSF2-Hours of Recreation per Week | CHSF211",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889440","CHIT1 wt Allele","C120052","Human CHIT1 wild-type allele is located in the vicinity of 1q32.1 and is approximately 61 kb in length. This allele, which encodes chitotriosidase-1 protein, plays a role in the metabolism of chitins. This gene is associated with Gaucher disease.","CHIT1 wt Allele | CHI3 | CHIT | CHITD | Chitinase 1 (Chitotriosidase) wt Allele | Chitinase, Macrophage Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0253005","Chitotriosidase-1","C120053","Chitotriosidase-1 (466 aa, ~52 kDa) is encoded by the human CHIT1 gene. This protein is involved in the degradation of chitins.","Chitotriosidase-1 | CHIT1 | Chitinase-1 | Chitotriosidase | EC 3.2.1.14 | Methylumbelliferyl-Tetra-N-Acetylchitotetraoside Hydrolase | Plasma Methylumbelliferyl Tetra-N-Acetylchitotetraoside Hydrolase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889146","USP17L2 wt Allele","C120055","Human USP17L2 wild-type allele is located in the vicinity of 8p23.1 and is approximately 2 kb in length. This allele, which encodes ubiquitin carboxyl-terminal hydrolase 17 protein, is involved in the modulation of protein ubiquitination.","USP17L2 wt Allele | DUB-3 | DUB3 | USP17 | USP17H | USP17I | USP17J | USP17K | USP17L | USP17M | Ubiquitin Specific Peptidase 17-Like Family Member 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1451084","Ubiquitin Carboxyl-Terminal Hydrolase 17, Human","C120056","Ubiquitin carboxyl-terminal hydrolase 17 (530 aa, ~60 kDa) is encoded by the human USP17L2 gene. This protein plays a role in the mediation of protein deubiquitination.","Ubiquitin Carboxyl-Terminal Hydrolase 17 | DUB-3 | Deubiquitinating Enzyme 17-Like Protein 2 | Deubiquitinating Enzyme 3 | Deubiquitinating Protein 3 | EC 3.4.19.12 | USP17 | Ubiquitin Carboxyl-Terminal Hydrolase 17-Like Protein 2 | Ubiquitin Specific Peptidase 17-Like 2 | Ubiquitin Thioesterase 17-Like Protein 2 | Ubiquitin Thiolesterase 17-Like Protein 2 | Ubiquitin-Specific Peptidase 17-Like Family Member 2 | Ubiquitin-Specific-Processing Protease 17-Like Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889139","KDM2B wt Allele","C120058","Human KDM2B wild-type allele is located in the vicinity of 12q24.31 and is approximately 152 kb in length. This allele, which encodes lysine-specific demethylase 2B protein, plays a role in histone demethylation.","KDM2B wt Allele | CXXC2 | F-Box and Leucine-Rich Repeat Protein 10 Gene | FBXL10 | Fbl10 | JEMMA (Jumonji Domain, EMSY-Interactor, Methyltransferase Motif) Protein Gene | JHDM1B | Lysine (K)-Specific Demethylase 2B wt Allele | Lysine Specific Demethylase 2B wt Allele | PCCX2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2000996","Lysine-Specific Demethylase 2B, Human","C120059","Lysine-specific demethylase 2B (1336 aa, ~153 kDa) is encoded by the human KDM2B gene. This protein is involved in the demethylation of lysine-4 and lysine-36 in histone H3.","Lysine-Specific Demethylase 2B | CXXC Finger Protein 2 | CXXC-Type Zinc Finger Protein 2 | EC 1.14.11.27 | F-Box Protein FBL10 | F-Box and Leucine-Rich Repeat Protein 10 | F-Box/LRR-Repeat Protein 10 | JmjC Domain-Containing Histone Demethylation Protein 1B | Jumonji C Domain-Containing Histone Demethylase 1B | Jumonji Domain-Containing EMSY-Interactor Methyltransferase Motif Protein | KDM2B | Protein JEMMA | Protein-Containing CXXC Domain 2 | [Histone-H3]-Lysine-36 Demethylase 1B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1064930","Acinetobacter parvus","C119308","A species of Gram-negative, strictly aerobic, oxidase-negative, non-fermentative, non-motile coccobacilli, in the phylum Proteobacteria. This species is glucose-non-acidifying, non-proteolytic, and is unable to oxidize D-glucose, to hydrolyze gelatin and to utilize DL-lactate, DL-4-aminobutyrate, citrate, azelate, beta-alanine and L-histidine. A. parvus is an opportunistic pathogen associated with nosocomial infections and may cause bacteremia or septicemia in humans.","Acinetobacter parvus | ACINETOBACTER PARVUS | Acinetobacter sp. phenon 4",,,,,,,,,,,,,,,"4313313","Acinetobacter parvus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1051095","Acinetobacter ursingii","C119309","A species of Gram-negative, strictly aerobic, oxidase-negative, non-fermentative, non-motile coccobacilli, in the phylum Proteobacteria. This species is glucose-non-acidifying, non-proteolytic, and is unable to hydrolyze gelatin. DL-lactate, citrate, azelate, D-malate, ethanol and acetate are utilized. A. ursingii is an opportunistic pathogen associated with nosocomial infections and may cause bacteremia or septicemia in humans.","Acinetobacter ursingii | ACINETOBACTER URSINGII | Acinetobacter sp. phenon 1",,,,,,,,,,,,,,,"4175185","Acinetobacter ursingii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3900007","Autologous 4-1BB Selected Tumor Infiltrating Lymphocytes","C119703","A preparation of autologous tumor infiltrating lymphocytes (TILs) expressing the co-stimulatory signaling domain 4-1BB (CD137), with potential antineoplastic activity. TILs are isolated from a patient's tumor and those expressing 4-1BB are selected for expansion in vitro. Upon re-infusion into the patient, the 4-1BB-expressing TILs re-infiltrate the tumor to initiate tumor cell lysis. 4-1BB, a member of the tumor necrosis factor (TNF) receptor superfamily, enhances TIL survival and antitumor cytolytic activity.","Autologous 4-1BB Selected Tumor Infiltrating Lymphocytes | Autologous 4-1BB selected TILs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824740","CKAP5 Gene","C119704","This gene is involved in the regulation of microtubule organization.","CKAP5 Gene | CKAP5 | Cytoskeleton Associated Protein 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890227","CKAP5 wt Allele","C119705","Human CKAP5 wild-type allele is located in the vicinity of 11p11.2 and is approximately 103 kb in length. This allele, which encodes cytoskeleton-associated protein 5, plays a role in the modulation of microtubule polymerization.","CKAP5 wt Allele | CHTOG | Colonic and Hepatic Tumor Over-Expressed Gene | Colonic and Hepatic Tumor Overexpressed Gene | Cytoskeleton Associated Protein 5 wt Allele | KIAA0097 | MSPS | Mini Spindles, Drosophila, Homolog of Gene | TOG | TOGp | ch-TOG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1122316","Cytoskeleton-Associated Protein 5, Human","C119706","Cytoskeleton-associated protein 5 (2032 aa, ~225 kDa) is encoded by the human CKAP5 gene. This protein is involved in mitotic spindle organization.","Cytoskeleton-Associated Protein 5 | Ch-TOG | Colonic and Hepatic Tumor Over-Expressed Gene Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538901","ACD Gene","C119707","This gene plays a role in telomere maintenance.","ACD Gene | ACD | ACD, Shelterin Complex Subunit and Telomerase Recruitment Factor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890178","ACD wt Allele","C119708","Human ACD wild-type allele is located in the vicinity of 16q22.1 and is approximately 3 kb in length. This allele, which encodes adrenocortical dysplasia protein homolog, is involved in telomere protection.","ACD wt Allele | ACD, Mouse, Homolog of Gene | ACD, Shelterin Complex Subunit and Telomerase Recruitment Factor wt Allele | Adrenocortical Dysplasia Homolog (Mouse) Gene | PIP1 | PTOP | TPP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1565285","Adrenocortical Dysplasia Protein Homolog, Human","C119709","Adrenocortical dysplasia protein homolog (544 aa, ~58 kDa) is encoded by the human ACD gene. This protein plays a role in both the elongation and maintenance of telomeres.","Adrenocortical Dysplasia Protein Homolog | ACD | POT1 and TIN2 Organizing Protein | POT1 and TIN2-Interacting Protein | POT1- and TIN2- Organizing Protein | POT1-Interacting Protein 1 | TIN2 Interacting Protein 1 | TIN2-Interacting Protein 1 | Telomere Protein TPP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896642","Oxygen 15-labeled Oxygen","C119710","A radiopharmaceutical comprised of oxygen-15 labeled oxygen (15O-O2) used as a tracer molecule during positron emission tomography (PET). Upon inhalation, 15O-O2 binds to hemoglobin in the blood and the labeled red blood cells distribute throughout the vasculature in the body. Upon PET imaging, 15O-O2 can be used to determine both the oxygen extraction fraction (OEF) and the metabolic rate of oxygen.","Oxygen 15-labeled Oxygen | 15O-O2 | 15O-labeled Molecular Oxygen | 15O2 | O2-15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1268558","Oxygen 15-labeled Carbon Monoxide","C119711","A radiopharmaceutical comprised of oxygen-15 (15O)-labeled carbon monoxide (15O-CO) for use as a tracer molecule during positron emission tomography (PET). Upon inhalation, 15O-CO binds to hemoglobin in the blood and the labeled red blood cells distribute evenly throughout the vasculature in the body. Upon PET imaging, tissue blood volume can be quantified.","Oxygen 15-labeled Carbon Monoxide | (15)O-labeled Carbon Monoxide | C(15)O | CO-15 | O15 Carbon Monoxide | Oxygen-15 Labeled Oxygen Gas | [(15)O]CO | [15O]Carbon Monoxide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897816","Proteogenomics","C119712","A method of study that relates annotated genomic information to global protein expression in order to determine the relationship between genomic sequences and both expressed proteins and predicted peptide sequences; these studies can identify novel coding regions.","Proteogenomics | Proteogenomic Analysis | Proteogenomic Characterization | Proteogenomic Research",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413231","CD5L Gene","C119713","This gene may be involved in the regulation of both apoptosis and immunity.","CD5L Gene | CD5 Molecule-Like Gene | CD5L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1433857","Zinc Finger MIZ Domain-Containing Protein 1, Human","C119668","Zinc finger MIZ domain-containing protein 1 (1067 aa, ~115 kDa) is encoded by the human ZMIZ1 gene. This protein plays a role in the regulation of transcription by mediating the sumoylation of androgen receptor.","Zinc Finger MIZ Domain-Containing Protein 1 | PIAS-Like Protein Zimp10 | Retinoic Acid-Induced Protein 17 | ZMIZ1 | Zinc Finger MIZ-Domain Containing 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3718934","Acremonium atrogriseum","C119310","A species of white colored acremonioid fungus in the phylum Ascomycota. A. atrogriseum forms fusoid conidia in long chains.","Acremonium atrogriseum | ACREMONIUM ATROGRISEUM | Gliomastix atrogriseum | Phaeoscopulariopsis atrogrisea | Phialemonium atrogriseum",,,,,,,,,,,,,,,"36683315","Acremonium atrogriseum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1021577","Actinobaculum schaalii","C119311","A species of facultatively anaerobic, Gram-positive, catalase-negative, nonmotile, non-spore forming, non-acid fast, nonhemolytic, straight to curved rod-shaped bacteria, in the phylum Actinobacteria. This species ferments glucose and produces acetate, succinate and acid; hydrolyzes hippurate, but does not reduce nitrate to nitrite; and does not hydrolyze esculin, gelatin or urea. A. schaalii is a part of the commensal flora of the human genitourinary tract and may cause urinary tract infections, urosepsis, bacteremia, cellulitis, spondylodiscitis, and endocarditis in humans.","Actinobaculum schaalii | ACTINOBACULUM SCHAALII | Actinotignum schaalii",,,,,,,,,,,,,,,"37396645","Actinotignum schaalii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1025751","Actinomyces europaeus","C119312","A species of facultative anaerobic, Gram-positive, fermentative, catalase-negative, nonmotile, non-spore forming, irregular rod-shaped bacteria arranged in clusters, in the phylum Actinobacteria. This species ferments glucose, maltose, galactose and D-fructose to produce succinic acid, does not hydrolyze urea, and nitrate is not reduced to nitrite. A. europaeus is a human pathogen and may cause infections of the urinary track, of skin and of soft tissue. It has been linked to the development of breast abscesses.","Actinomyces europaeus | ACTINOMYCES EUROPAEUS",,,,,,,,,,,,,,,"4014250","Gleimia europaea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1264789","Actinomyces neuii Subspecies neuii","C119313","A species of anaerobic rod-shaped or coccoid coryneform group 1 bacteria belonging to the genus Actinomyces that reduces nitrate, ferments carbohydrates, and is commonly found as a human pathogen in tissue, bone and blood stream infections.","Actinomyces neuii Subspecies neuii | ACTINOMYCES NEUII SUBSP. NEUII | Actinomyces neuii subsp. neuii | CDC coryneform group 1",,,,,,,,,,,,,,,"4013794","Actinomyces neuii subspecies neuii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1057150","Aerococcus sanguinicola","C119314","A species of gram-positive, catalase-negative, vancomycin-susceptible coccoid bacteria belonging to the genus Aerococcus that is commonly found as a human pathogen, particularly in urinary tract infections, sepsis, and endocarditis.","Aerococcus sanguinicola | AEROCOCCUS SANGUINICOLA",,,,,,,,,,,,,,,"4146127","Aerococcus sanguinicola",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3900064","Aggregatibacter aphrophilus, Beta-lactamase Negative","C119315","Any bacterial species identified as Aggregatibacter aphrophilus that does not produce the enzyme beta-lactamase.","Aggregatibacter aphrophilus, Beta-lactamase Negative | AGGREGATIBACTER APHROPHILUS, BETA-LACTAMASE NEGATIVE | Haemophilus aphrophilus, Beta-lactamase Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900063","Aggregatibacter aphrophilus, Beta-lactamase Positive","C119316","Any bacterial species identified as Aggregatibacter aphrophilus that produces the enzyme beta-lactamase.","Aggregatibacter aphrophilus, Beta-lactamase Positive | AGGREGATIBACTER APHROPHILUS, BETA-LACTAMASE POSITIVE | Haemophilus aphrophilus, Beta-lactamase Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897025","Aggregatibacter aphrophilus, Penicillinase Negative","C119317","Any bacterial species identified as Aggregatibacter aphrophilus that does not produce the enzyme penicillinase.","Aggregatibacter aphrophilus, Penicillinase Negative | AGGREGATIBACTER APHROPHILUS, PENICILLINASE NEGATIVE | Haemophilus aphrophilus, Penicillinase Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900062","Aggregatibacter aphrophilus, Penicillinase Positive","C119318","Any bacterial species identified as Aggregatibacter aphrophilus that produces the enzyme penicillinase.","Aggregatibacter aphrophilus, Penicillinase Positive | AGGREGATIBACTER APHROPHILUS, PENICILLINASE POSITIVE | Haemophilus aphrophilus, Penicillinase Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2806447","Alphacoronavirus","C119319","A genus of single-stranded, positive-sense RNA viruses in the family coronaviridae. The alphacoronavirus envelope contains glycoprotein trimers that project outward.","Alphacoronavirus | ALPHACORONAVIRUS | Coronavirus Group 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896772","Anti-C-met Monoclonal Antibody SAIT301","C119619","A humanized monoclonal antibody targeting the alpha chain of the extracellular domain of human hepatocyte growth factor receptor (HGFR or c-Met), with potential antineoplastic activity. Anti-c-Met monoclonal antibody SAIT301 binds to c-Met, thereby preventing both binding of its ligand, HGF, and the subsequent activation of the HGF/c-Met signaling pathway. In addition, SAIT301 induces c-MET internalization and subsequent degradation, which further inhibits c-Met-mediated signaling. This leads to a reduction in the proliferation of c-Met-expressing cancer cells. c-Met, a proto-oncogene receptor tyrosine kinase overexpressed in certain cancer cell types, is involved in various tumors.","Anti-C-met Monoclonal Antibody SAIT301 | SAIT301",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890193","CD5L wt Allele","C119714","Human CD5L wild-type allele is located within 1q21-q23 and is approximately 67 kb in length. This allele, which encodes CD5 antigen-like protein, may play a role in both immunity and apoptosis regulation.","CD5L wt Allele | AIM | API6 | CD5 Antigen-Like (Scavenger Receptor Cysteine Rich Family) Gene | CD5 Molecule-Like wt Allele | Lymphocyte Antigen CD5-Like Gene | PRO229 | SP-ALPHA | Scavenger Receptor Cysteine-Rich Family, Member SP-Alpha Gene | Spalpha | UNQ203/PRO229",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1528456","CD5 Antigen-Like, Human","C119715","CD5 antigen-like (347 aa, ~38 kDa) is encoded by the human CD5L gene. This protein may be involved in both immunity and the inhibition of apoptosis.","CD5 Antigen-Like | Apoptosis Inhibitor 6 | Apoptosis Inhibitor of Macrophages | CT-2 | IgM-Associated Peptide | SP-Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0935816","carboplatin/methotrexate/vinblastine","C11956","A regimen consisting of methotrexate, carboplatin and vinblastine that may be used in the treatment of certain urothelial cancers.","M-CAVI Regimen | Carboplatin-Methotrexate-Vinblastine | Carboplatin/Methotrexate/Vinblastine | Carboplatin/Methotrexate/Vinblastine Regimen | M-CAVI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899233","Experimental Organism Malignant Astrocytoma","C119574","A malignant neoplasm of the brain or spinal cord originating from astrocytes.","Experimental Organism Malignant Astrocytoma | ASTROCYTOMA, MALIGNANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899232","Experimental Organism Malignant Ependymoma","C119575","A malignant neoplasm of ependymal origin.","Experimental Organism Malignant Ependymoma | EPENDYMOMA, MALIGNANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL480887","Experimental Organism Benign Ganglioglioma","C119576","A benign neoplasm comprised of neoplastic ganglion and glial cells.","Experimental Organism Benign Ganglioglioma | GANGLIOGLIOMA, BENIGN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3892045","Experimental Organism Malignant Oligodendroglioma","C119577","A malignant neoplasm of the central nervous system arising from oligodendrocytes.","Experimental Organism Malignant Oligodendroglioma | OLIGODENDROGLIOMA, MALIGNANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227296","Duodenal Papilla","C119578","Either one of two openings from the pancreatic ducts into the duodenum. The major duodenal papilla opens from the pancreatic duct into the duodenum. The minor duodenal papilla opens from the accessory pancreatic duct into the descending second section of the duodenum.","Duodenal Papilla | PAPILLA, DUODENAL",,,,,,,,,,,,,,,"4303047","Duodenal papilla structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3890196","ATF7IP wt Allele","C119671","Human ATF7IP wild-type allele is located in the vicinity of 12p13.1 and is approximately 133 kb in length. This allele, which encodes activating transcription factor 7-interacting protein 1, plays a role in the modulation of both transcription and histone methylation.","ATF7IP wt Allele | AM | ATF-IP | ATFA Modulator, Mouse, Homolog of Gene | Activating Transcription Factor 7 Interacting Protein wt Allele | MCAF | MCAF1 | p621",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416472","IQGAP2 Gene","C119673","This gene plays a role in the regulation of Ras superfamily GTPase activity.","IQGAP2 Gene | IQ Motif Containing GTPase Activating Protein 2 Gene | IQGAP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898817","IQGAP2 wt Allele","C119674","Human IQGAP2 wild-type allele is located in the vicinity of 5q13.3 and is approximately 305 kb in length. This allele, which encodes Ras GTPase-activating-like protein IQGAP2, is involved in the modulation of the activity of small GTPases.","IQGAP2 wt Allele | IQ Motif Containing GTPase Activating Protein 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1438270","Ras GTPase-Activating-Like Protein IQGAP2, Human","C119675","Ras GTPase-activating-like protein IQGAP2 (1575 aa, ~181 kDa) is encoded by the human IQGAP2 gene. This protein plays a role in the modulation of Ras family-mediated signaling.","Ras GTPase-Activating-Like Protein IQGAP2 | IQ Motif Containing GTPase-Activating Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342870","D-Bifunctional Protein Deficiency","C119676","A rare, autosomal recessive inherited disorder caused by mutation in the HSD17B4 gene. It is characterized by neurodegeneration that begins in infancy, hypotonia, and seizures. The majority of the affected individuals lack developmental skills.","D-Bifunctional Protein Deficiency | D-Bifunctional Enzyme Deficiency | Multifunctional Enzyme Deficiency | Peroxisomal Multifunctional Enzyme (MFE2) Deficiency | Peroxisomal Multifunctional Enzyme Deficiency | Pseudo-Zellweger Syndrome",,,,,,,,,,,,,,,"4029126","Bifunctional peroxisomal enzyme deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0872218","Mitochondrial Neurogastrointestinal Encephalopathy","C119678","A rare, autosomal recessive inherited disorder caused by mutation in the TYMP gene. It affects several parts of the body, particularly the gastrointestinal tract and nervous system. Signs and symptoms can appear in infancy, but they often begin by age twenty. The gastrointestinal signs and symptoms result from gastrointestinal dysmotility and include fullness after eating small amounts of food, dysphagia, nausea and vomiting after eating, abdominal pain, diarrhea, and intestinal blockage. The nervous system abnormalities include leukoencephalopathy, tingling, numbness, peripheral neuropathy, ptosis, ophthalmoplegia, and hearing loss.","Mitochondrial Neurogastrointestinal Encephalopathy | MNGIE",,,,,,,,,,,,,,,"37397550","Mitochondrial neurogastrointestinal encephalomyopathy syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899334","Dual-Energy Contrast-Enhanced Digital Spectral Mammography","C119679","A technique that uses high-energy and low-energy digital mammography with administration of an iodinated contrast agent. The differences between X-ray attenuation of iodine and breast tissues at these two energy levels are used to suppress the background breast tissue. This technique is useful in identifying lesions in dense breasts that are not visible using standard mammography.","Dual-Energy Contrast-Enhanced Digital Spectral Mammography | Dual-Energy CEDM | Dual-Energy Contrast-Enhanced Digital Subtraction Mammography",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896797","anti-DLL4/VEGF bispecific monoclonal antibody OMP-305B83","C119620","A bispecific monoclonal antibody directed against both the Notch ligand delta-like 4 (DLL4) and the human tyrosine kinase vascular endothelial growth factor (VEGF), with potential anti-angiogenic and antineoplastic activities. The anti-DLL4 moiety of navicixizumab specifically binds to DLL4, prevents its interaction with Notch receptors, and inhibits Notch-mediated signaling and gene transcription, which may both block tumor angiogenesis and inhibit tumor cell growth. The anti-VEGF moiety binds to VEGF and prevents the binding of VEGF to its receptor, which blocks VEGF-mediated signaling and further inhibits the growth and maintenance of tumor blood vessels. The expression of DLL4 is highly restricted to the vascular endothelium; DLL4/Notch signaling is required for the development of functional tumor blood vessels. The expression of the pro-angiogenic growth factor VEGF is associated with tumor angiogenesis and tumor cell proliferation and invasion.","Navicixizumab | Immunoglobulin G2-kappa, Anti-(Homo sapiens DLL4(delta-like 4)) and Anti-(Homo sapiens VEGFA (Vascular Endothelial Growth Factor A,VEGF-a, VEGF)), Humanized and Chimeric Monoclonal Antibody, Bispecific | NAVICIXIZUMAB | OMP 305B83 | OMP-305B83 | OMP305B83",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889719","DET1 wt Allele","C119621","Human DET1 wild-type allele is located in the vicinity of 15q25.3 and is approximately 35 kb in length. This allele, which encodes DET1 homolog protein, is involved in the modulation of protein degradation following ubiquitination.","DET1 wt Allele | De-Etiolated 1, Arabadopsis, Homolog of Gene | De-Etiolated Homolog 1 (Arabidopsis) wt Allele | FLJ10103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1435863","DET1 Homolog, Human","C119622","DET1 homolog (550 aa, ~64 kDa) is encoded by the human DET1 gene. This protein plays a role in the regulation of protein ubiquitination.","DET1 Homolog | De-Etiolated 1 | De-Etiolated-1 Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3502472","(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol","C119623","An orally bioavailable inhibitor of the sodium-glucose co-transporter subtype 1 (SGLT1) and 2 (SGLT2), with potential antihyperglycemic activity. Upon oral administration, sotagliflozin binds to and blocks both SGLT1 in the gastrointestinal (GI) tract and SGLT2 in the kidneys, thereby suppressing the absorption of glucose from the GI tract and the reabsorption of glucose by the proximal tubule into the bloodstream, respectively. This decreases glucose uptake and enhances the urinary excretion of glucose, which lowers and/or normalizes blood glucose levels. SGLT1 is the primary transporter responsible for glucose absorption from the GI tract. SGLT2, a transport protein exclusively expressed in the proximal renal tubules, mediates approximately 90% of renal glucose reabsorption from tubular fluid.","Sotagliflozin | Beta-l-Xylopyranoside, methyl 5-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-1-thio-, (5S)- | LP 802034 | LX4211 | SOTAGLIFLOZIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896788","Mutant-selective EGFR Inhibitor PF-06459988","C119624","An orally available, small molecule, third-generation, irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant (EGFRm) forms with potential antineoplastic activity. EGFR inhibitor PF-06459988 specifically binds to and inhibits mutant forms of EGFR, including the secondary acquired resistance mutation T790M, which prevents EGFR-mediated signaling and leads to cell death in EGFRm-expressing tumor cells. Compared to some other EGFR inhibitors, PF-06459988 may have therapeutic benefits in tumors with T790M-mediated drug resistance. This agent shows minimal activity against wild-type EGFR (WT EGFR), and does not cause dose-limiting toxicities that are seen with the use of non-selective EGFR inhibitors, which also inhibit WT EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","Mutant-selective EGFR Inhibitor PF-06459988 | PF-06459988",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824499","DDA1 Gene","C119625","This gene may be involved in protein ubiquitination and turnover.","DDA1 Gene | DDA1 | DET1 and DDB1 Associated 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889708","DDA1 wt Allele","C119626","Human DDA1 wild-type allele is located in the vicinity of 19p13.11 and is approximately 14 kb in length. This allele, which encodes DET1- and DDB1-associated protein 1, may play a role in the regulation of protein ubiquitination.","DDA1 wt Allele | C19orf58 | Chromosome 19 Open Reading Frame 58 Gene | DET1 and DDB1 Associated 1 wt Allele | MGC2594 | PCIA1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2716335","DET1- and DDB1-Associated Protein 1, Human","C119627","DET1- and DDB1-associated protein 1 (102 aa, ~12 kDa) is encoded by the human DDA1 gene. This protein may be involved in the ubiquitination of target proteins.","DET1- and DDB1-Associated Protein 1 | Cross-Immune Reaction Antigen PCIA1 | PCIA-1 | Placenta Cross-Immune Reaction Antigen 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896995","Clinical Observations Reason Not Done","C119807","The explanation given as to why a clinical observation was not made.","Clinical Observations Reason Not Done | CLREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897172","Weight Gain Due to Fluid Retention","C119200","A finding of rapid weight gain due to fluid retention.","Weight Gain Due to Fluid Retention | CLINICALLY SIGNIFICANT OR RAPID WEIGHT GAIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4228443","Decreased Exercise Tolerance","C119203","A reduction in the ability to perform or withstand activities that induce physical or mental exertion.","Decreased Exercise Tolerance | DECREASED EXERCISE TOLERANCE | Decreased exercise tolerance",,,,,,,,,,,,,,,"4147189","Impaired exercise tolerance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898876","Hospitalization Due to Heart Failure","C119204","A finding of a hospitalization event due to a heart failure diagnosis.","Hospitalization Due to Heart Failure | HEART FAILURE HOSPITALIZATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898772","Increase in B-type Natriuretic Peptide or N-terminal pro-B-type Natriuretic Peptide","C119205","A finding of an increased amount of either B-type natriuretic peptide or N-terminal pro-B-type natriuretic peptide","Increase in B-type Natriuretic Peptide or N-terminal pro-B-type Natriuretic Peptide | INCREASE IN HEART FAILURE BIOMARKER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0520861","Increase in Jugular Venous Pressure","C119206","A finding of an increase in the jugular venous pressure, as measured by the height of the mean jugular venous waveform above the right atrium.","Increase in Jugular Venous Pressure | INCREASED JUGULAR VENOUS PRESSURE OR HEPATOJUGULAR REFLUX",,,,,,,,,,,,,,,"4329988","Raised jugular venous pressure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3898766","Inducible Myocardial Ischemia","C119207","A finding of abnormal heart wall motion contractility in response to stress, and which is not seen at rest.","Inducible Myocardial Ischemia | INDUCIBLE MYOCARDIAL ISCHEMIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898697","Intravenous Diuretic, Inotropic or Vasodilator Augmentation for Heart Failure","C119208","Initiation or intensification of intravenous diuretics, inotropics or vasodilators to treat heart failure.","Intravenous Diuretic, Inotropic or Vasodilator Augmentation for Heart Failure | INTRAVENOUS DIURETIC, INOTROPE, OR VASODILATOR THERAPY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898899","Heart Failure by Invasive Diagnostic Technique","C119209","A finding of heart failure through an invasive diagnostic technique.","Heart Failure by Invasive Diagnostic Technique | INVASIVE DIAGNOSTIC EVIDENCE OF HEART FAILURE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898573","Loss of Patency of Side Branch","C119210","A decrease in the openness of a side branch of a blood vessel.","Loss of Patency of Side Branch | LOSS OF A SIDE BRANCH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897206","Vasculature Mechanical or Surgical Intervention","C119212","That treatment of vessel disease or injury by dialysis, operative procedures, or device placement.","Vasculature Mechanical or Surgical Intervention | MECHANICAL OR SURGICAL INTERVENTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897486","Stroke Type","C119579","A classification or description of a stroke.","Stroke Type | STROKTYP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002642","Amoeba","C119581","A genus of motile, unicellular eukaryotic amoeboid protists within the family Amoebidae that are commonly found in fresh water environments. Members of the Amoeba genus are not generally considered to be human pathogens.","Amoeba | AMOEBA | Ameba",,,,,,,,,,,,,,,"4166089","Amoeba",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897392","TIMI Coronary Thrombus Grade 1","C119583","Possible thrombus present - angiography demonstrates characteristics such as reduced contrast density, haziness, irregular lesion contour or a smooth convex 'meniscus' at the site of total occlusion suggestive but not diagnostic of thrombus. (Gibson, C. M., de Lemos, J. A., Murphy, S. A., Marble, S. J., McCabe, C. H., Cannon, C. P., Antman, E. M., Braunwald, E. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy Circulation. 2001;103(21):2550-4.)","TIMI Coronary Thrombus Grade 1 | CORONARY THROMBUS TIMI GRADE 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897391","TIMI Coronary Thrombus Grade 2","C119584","Small size definite thrombus, with greatest dimensions less than or equal to 1/2 vessel diameter. (Gibson, C. M., de Lemos, J. A., Murphy, S. A., Marble, S. J., McCabe, C. H., Cannon, C. P., Antman, E. M., Braunwald, E. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy Circulation. 2001;103(21):2550-4.)","TIMI Coronary Thrombus Grade 2 | CORONARY THROMBUS TIMI GRADE 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896830","Burosumab","C119744","An orally bioavailable recombinant human immunoglobulin G1 monoclonal antibody directed against human fibroblast growth factor 23 (FGF23), that can be used to increase serum phosphate levels. Upon subcutaneous administration, burosumab binds to and inhibits FGF23, thereby interfering with FGF23 signaling. This increases tubular phosphate reabsorption, decreases excretion of phosphate, and increases serum phosphate levels, resulting in enhanced bone mineralization. FGF23, a member of the fibroblast growth factor (FGF) family produced by osteocytes, plays a key role in hypophosphatemic rickets/osteomalacia, such as X-linked hypophosphatemia (XLH) and tumor-induced rickets/osteomalacia. Increased FGF23 levels lead to decreased expression of the sodium-phosphate co-transporters in the proximal tubules, reduced renal phosphate reabsorption, increased excretion by the kidneys, and low serum phosphate concentration.","Burosumab | Anti-FGF23 IgG1 Monoclonal Antibody KRN23 | BUROSUMAB | Burosumab-TWZA | Crysvita | KRN23 | UX023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896801","Globo H-DT Vaccine OBI-833","C119745","A carbohydrate-based vaccine comprised of the Globo H hexasaccharide 1 (Globo H) antigen conjugated to DT-CRM197, a non-toxic, mutated form of diphtheria toxin (DT), with potential immunostimulating and antineoplastic activities. Upon administration of Globo H-DT vaccine OBI-833, the carbohydrate antigen Globo H may stimulate a cytotoxic T-lymphocyte (CTL) response against Globo H-expressing tumor cells, thereby decreasing tumor cell proliferation. The hexasaccharide Globo H is a tumor-associated antigen (TAA) commonly found on a variety of tumor cells. DT-CRM197, also called diphtheria toxin cross-reacting material 197, is used to increase the immunogenicity of the Globo H carbohydrate antigen.","Globo H-DT Vaccine OBI-833 | Globo H-CRM197 Vaccine | OBI-833",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900004","Autologous CD171-specific CAR-CD28 zeta-4-1-BB-EGFRt-expressing T Lymphocytes","C119746","A preparation of genetically modified autologous human T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) specific for the L1 cell adhesion molecule (L1-CAM/CD171) antigen, and the co-stimulatory signaling domains CD28, 4-1BB (CD137) and CD3 zeta, and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon re-infusion into the patient, the autologous L1-CAM-specific CAR-CD28 zeta-4-1-BB-EGFRt-expressing T-lymphocytes are directed to and induce selective toxicity in L1-CAM-expressing tumor cells. L1-CAM, a neuronal cell adhesion molecule and member of the L1 protein family, plays a key role in the development of the nervous system; it is overexpressed in various tumor cell types and is associated with increased chemoresistance, tumor progression, migration and metastasis. Devoid of both ligand-binding domains and tyrosine kinase activity, EGFRt facilitates both the detection of the administered T-cells in vivo and the elimination of the modified T-cells following a cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) response. The co-stimulatory signaling domains enhance both proliferation of T-cells and antitumor activity.","Autologous CD171-specific CAR-CD28 zeta-4-1-BB-EGFRt-expressing T Lymphocytes | CD171 CAR+ T Cells | CE7R CAR T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897997","Palpable Masses Reason Not Done","C119913","The explanation given as to why a palpable masses assessment was not performed.","Palpable Masses Reason Not Done | PMREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897995","Palpable Masses Sequence Number","C119914","An identifier that describes the relative position of palpable masses data within a series.","Palpable Masses Sequence Number | PMSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897994","Palpable Masses Sponsor Defined Identifier","C119915","One or more sponsor defined characters used to identify, name, or characterize the palpable masses assessment.","Palpable Masses Sponsor Defined Identifier | PMSPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898006","Palpable Masses Assessment Character Result in Standard Format","C119917","The standard character or string for representation and reporting of palpable masses data.","Palpable Masses Assessment Character Result in Standard Format | PMSTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897098","Palpable Masses Numeric Result in Standard Unit","C119918","The numerical identifier of a palpable masses assessment result in standard units.","Palpable Masses Numeric Result in Standard Unit | PMSTRESN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897996","Palpable Masses Result Standard Unit","C119919","The standard unit of measure for the palpable masses assessment results.","Palpable Masses Result Standard Unit | PMSTRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898004","Palpable Masses Assessment Test","C119920","A character or string that represents the long name of the palpable masses assessment.","Palpable Masses Assessment Test | PMTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898005","Palpable Masses Assessment Test Code","C119921","A character or string that represents the short code name of the palpable masses assessment.","Palpable Masses Assessment Test Code | PMTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897932","Pharmacokinetic Parameters Time Point Reference","C119922","The point in time that acts as a fixed reference point to a pharmacokinetic parameter assessment.","Pharmacokinetic Parameters Time Point Reference | PPTPTREF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897319","Tumor Findings Anatomical Region of Specimen","C119923","The specific anatomical or biological region within the tissue or organ specimen used in the tumor findings assessment.","Tumor Findings Anatomical Region of Specimen | TFANTREG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897314","Tumor Findings Dosing Days to Detection","C119924","The number of days from the start of dosing to the earliest detection of cancer.","Tumor Findings Dosing Days to Detection | TFDETECT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897128","Tumor Findings Collection Date Time","C119926","The date and time of tumor findings data collection.","Tumor Findings Collection Date Time | TFDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897316","Tumor Findings Death Relationship","C119927","An indication or description of a correlation between death and a tumor finding.","Tumor Findings Death Relationship | TFDTHREL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897313","Tumor Findings Evaluator","C119929","A person who determines the significance of a tumor findings assessment.","Tumor Findings Evaluator | TFEVAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897312","Tumor Findings Group Identifier","C119930","A character or string that represents a tumor identifier group.","Tumor Findings Group Identifier | TFGRPID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899610","Clinical Observations Date Time of Reference Timepoint","C119808","The date and time of a specific reference point for the clinical observation.","Clinical Observations Date Time of Reference Timepoint | CLRFTDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899603","Clinical Observations Sequence Number","C119809","An identifier that describes the relative position of clinical observation data within a series.","Clinical Observations Sequence Number | CLSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899602","Clinical Observations Severity","C119810","The degree of something undesirable as determined by clinical observations.","Clinical Observations Severity | CLSEV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899612","Clinical Observations Completion Status","C119812","A term used to describe the state or condition of the completeness of the clinical observation data.","Clinical Observations Completion Status | CLSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899613","Clinical Observations Character Result in Standard Format","C119813","The standard character or string for representation and reporting of clinical observations data.","Clinical Observations Character Result in Standard Format | CLSTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899599","Clinical Observations Test","C119814","A character or string that represents the long name of the clinical observation assessment.","Clinical Observations Test | CLTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899600","Clinical Observations Test Code","C119815","A character or string that represents the short code name of the clinical observation assessment.","Clinical Observations Test Code | CLTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899605","Clinical Observations Planned Time Point Name","C119816","The literal identifier of a planned point in time for a clinical observation.","Clinical Observations Planned Time Point Name | CLTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899604","Clinical Observations Planned Time Point Number","C119817","The numerical identifier of a clinical observation point in time.","Clinical Observations Planned Time Point Number | CLTPTNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899598","Clinical Observations Time Point Reference","C119818","The point in time that acts as a fixed reference point to a clinical observation.","Clinical Observations Time Point Reference | CLTPTREF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897477","Study Day of Comment","C119819","The study day that the comment pertains.","Study Day of Comment | CODY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897002","ECG Test Results End Date Time","C119821","The date and time an electrocardiogram assessment has concluded.","ECG Test Results End Date Time | EGENDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899321","ECG Test Results End Day","C119822","The final day of the electrocardiographic test.","ECG Test Results End Day | EGENDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899320","ECG Test Results Evaluation Interval","C119823","The period of time during which an electrocardiogram was performed.","ECG Test Results Evaluation Interval | EGEVLINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899246","Exclude ECG Data From Statistics Indicator","C119824","Specifies whether the ECG result values should be excluded from the statistical analysis.","Exclude ECG Data From Statistics Indicator | EGEXCLFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899327","ECG Reason For Exclusion From Statistics","C119825","A rationale for excluding a particular data point or subject from the ECG test results statistical analysis.","ECG Reason For Exclusion From Statistics | EGREASEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897475","Study Day of Food and Water Consumption","C119828","The study day that the food and water consumption data is captured.","Study Day of Food and Water Consumption | FWDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898142","New Loss of Viable Myocardium by Non-invasive Imaging Technique","C119213","A finding of loss of viable myocardium, which is new compared to prior non-invasive imaging techniques.","New Loss of Viable Myocardium by Non-invasive Imaging Technique | NEW LOSS OF VIABLE MYOCARDIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898140","New Regional Wall Motion Abnormality by Non-invasive Imaging Technique","C119214","A finding of decreased regional heart wall motion contractility, which is new compared to prior non-invasive imaging techniques.","New Regional Wall Motion Abnormality by Non-invasive Imaging Technique | NEW REGIONAL WALL MOTION ABNORMALITY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898898","Heart Failure by Non-invasive Diagnostic Technique","C119215","A finding of heart failure through a non-invasive diagnostic technique.","Heart Failure by Non-invasive Diagnostic Technique | NON-INVASIVE DIAGNOSTIC EVIDENCE OF HEART FAILURE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897810","Pulmonary Congestion by Radiological Technique","C119217","Imaging findings consistent with increased intravascular blood volume in the lungs.","Pulmonary Congestion by Radiological Technique | Pulmonary congestion | RADIOLOGICAL EVIDENCE OF PULMONARY CONGESTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899113","Flow Reduced in Coronary Microcirculation","C119219","A finding of decreased blood flow in the microcirculation of the heart.","Flow Reduced in Coronary Microcirculation | SLOW-FLOW/NO-FLOW/EMBOLIZATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896889","ERK Inhibitor CC-90003","C119747","An orally available inhibitor of extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon oral administration, CC-90003 inhibits ERK activity, and prevents the activation of ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.","ERK Inhibitor CC-90003 | CC-90003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1871272","Absorbable Fibrin Sealant Patch","C119748","A sterile, absorbable surgical sealing patch composed of an equine collagen sponge coated with the coagulation factors human fibrinogen and human thrombin, with potential hemostatic activity. Applied on the wound tissue, the absorbable fibrin sealant patch adheres to the tissue and the solid fibrinogen and thrombin dissolve upon contact with the physiological fluid. In turn, fibrinogen is converted to fibrin monomers by thrombin, and polymerize to form a fibrin clot at the wound surface. This causes the patch to adhere to the wound surface and promotes tissue sealing. This may reduce lymphatic drainage and prevent seroma formation.","Absorbable Fibrin Sealant Patch | HFTP | Human Fibrinogen/Thrombin Patch | TachoSil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896574","Iodine I 124 Monoclonal Antibody 3F8","C119749","A radioimmunoconjugate consisting of 3F8, a murine anti-GD2 ganglioside monoclonal antibody labeled with iodine I 124 (I-124), with radioimaging activity using positron emission tomography (PET). Upon intravenous administration of iodine I 124 monoclonal antibody 3F8, the 3F8 moiety binds to GD2 expressed on tumor cells. This binding enables both PET imaging via iodine I 124 and the visualization of GD2-expressing tumor cells. GD2 is a ganglioside overexpressed in a variety of cancer cells, including neuroblastoma cells.","Iodine I 124 Monoclonal Antibody 3F8 | 124 mAb 3F8 | 124I-Humanized 3F8 | 124I-hu3F8 | I 124 Monoclonal Antibody 3F8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2350307","Microparticle","C120025","A small, membrane-bound vesicle between 100 nm to 1000 nm in size found in the circulatory system. These vesicles are plasma membrane fragments shed from cells. The protein composition is similar to that of the cell that shed the particle.","Microparticle | Cell-Derived Microparticle | Circulating Microparticle | Circulating Microvesicle | Ectosome | Microvesicle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897127","Tumor Findings Vendor Name","C119933","The literal identifier of the vendor or laboratory that performs a tumor findings assessment.","Tumor Findings Vendor Name | TFNAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897308","Tumor Findings Reason Not Done","C119935","The explanation given as to why a tumor findings assessment was not performed.","Tumor Findings Reason Not Done | TFREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899770","CHART-SF Paper Version - Number of People You Live With","C119155","Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) How many people do you live with?","CHART-SF Paper Version - Number of People You Live With | CHSF2-Number of People You Live With | CHSF212",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899773","CHART-SF Paper Version - Live With Spouse or Significant Other","C119156","Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) Is one of them your spouse or significant other?","CHART-SF Paper Version - Live With Spouse or Significant Other | CHSF2-Live With Spouse or Signif Other | CHSF213",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899769","CHART-SF Paper Version - Number of Relatives You Live With","C119157","Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) Of the people you live with how many are relatives?","CHART-SF Paper Version - Number of Relatives You Live With | CHSF2-Number of Relatives You Live With | CHSF214",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899785","CHART-SF Paper Version - Associates Contacted per Month","C119158","Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) How many business or organizational associates do you visit, phone, or write to at least once a month?","CHART-SF Paper Version - Associates Contacted per Month | CHSF2-Associates Contacted per Month | CHSF215",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2346915","MUC1 Antigen/SB AS-2","C11915","No value exists.","MUC1 Antigen/SB AS-2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899774","CHART-SF Paper Version - Initiated Conversation With Strangers Last Month","C119160","Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) With how many strangers have you initiated a conversation in the last month (for example, to ask information or place an order)?","CHART-SF Paper Version - Initiated Conversation With Strangers Last Month | CHSF2-Strangers Spoke with Last Month | CHSF217",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899782","CHART-SF Paper Version - Combined Annual Household Income Last Year","C119161","Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) Approximately what was the combined annual income, in the last year, of all family members in your household? (consider all sources including wages and earnings, disability benefits, pensions and retirement income, income from court settlements, investments and trust funds, child support and alimony, contributions from relatives, and any other source).","CHART-SF Paper Version - Combined Annual Household Income Last Year | CHSF2-Combined Household Income Last Yr | CHSF218",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899772","CHART-SF Paper Version - Medical Care Expense Last Year","C119162","Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) Approximately how much did you pay last year for medical care expenses? (Consider any amounts paid by yourself or the family members in your household and not reimbursed by insurance or benefits).","CHART-SF Paper Version - Medical Care Expense Last Year | CHSF2-Medical Care Expenses Last Year | CHSF219",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899476","DLQI - Itchy, Sore, Painful or Stinging Skin","C119163","Dermatology Life Quality Index (DLQI) Over the last week, how itchy, sore, painful or stinging has your skin been?","DLQI - Itchy, Sore, Painful or Stinging Skin | DLQI1-How Itchy, Sore, Painful, Stinging | DLQI101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899477","DLQI - Embarrassed Because of Skin","C119164","Dermatology Life Quality Index (DLQI) Over the last week, how embarrassed or self conscious have you been because of your skin?","DLQI - Embarrassed Because of Skin | DLQI1-How Embarrassed, Self Conscious | DLQI102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899470","DLQI - Skin Interfere With Shopping, Looking After Home or Yard","C119165","Dermatology Life Quality Index (DLQI) Over the last week, how much has your skin interfered with you going shopping or looking after your home or yard?","DLQI - Skin Interfere With Shopping, Looking After Home or Yard | DLQI1-Interfered Shopping, Home, Yard | DLQI103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890001","SYNE2 wt Allele","C120061","Human SYNE2 wild-type allele is located in the vicinity of 14q23.2 and is approximately 373 kb in length. This allele, which encodes nesprin-2 protein, is involved in the structure, organization, and localization of the nucleus. Variation of the gene is associated with Emery-Dreifuss muscular dystrophy type 5.","SYNE2 wt Allele | DKFZP434H2235 | EDMD5 | KIAA1011 | NUA | NUANCE | Nesp2 | Nesprin-2 | SYNE-2 | Spectrin Repeat Containing, Nuclear Envelope 2 wt Allele | Synaptic Nuclei Expressed Gene 2 | TROPH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1431963","Nesprin-2, Human","C120062","Nesprin-2 (6885 aa, ~796 kDa) is encoded by the human SYNE2 gene. This protein plays a role in anchoring organelles to the cytoskeleton.","Nesprin-2 | Nesprin 2 | Nuclear Envelope Spectrin Repeat Protein 2 | Nuclear Envelope Spectrin Repeat-2 | Nucleus and Actin Connecting Element | Nucleus and Actin Connecting Element Protein | Polytrophin | Protein NUANCE | Spectrin Repeat-Containing Nuclear Envelope Protein 2 | Synaptic Nuclear Envelope Protein 2 | Syne-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889400","PSMA5 wt Allele","C120066","Human PSMA5 wild-type allele is located in the vicinity of 1p13 and is approximately 27 kb in length. This allele, which encodes proteasome subunit alpha type-5 protein, plays a role in protein metabolism.","PSMA5 wt Allele | PSC5 | Proteasome (Prosome, Macropain) Subunit, Alpha Type, 5 wt Allele | Proteasome Subunit, Alpha-Type, 5 Gene | ZETA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3529801","Proteasome Subunit Alpha Type-5, Human","C120067","Proteasome subunit alpha type-5 (241 aa, ~26 kDa) is encoded by the human PSMA5 gene. This protein is involved in ATP-dependent protein catabolism.","Proteasome Subunit Alpha Type-5 | EC 3.4.25.1 | Macropain Subunit Zeta | Macropain Zeta Chain | Multicatalytic Endopeptidase Complex Zeta Chain | PSMA5 | Proteasome Alpha 5 Subunit | Proteasome Component 5 | Proteasome Subunit Zeta | Proteasome Zeta Chain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896827","Anti-CEACAM6 AFAIKL2 Antibody Fragment/Jack Bean Urease Immunoconjugate L-DOS47","C120068","A lyophilized formulation of DOS47, an immunoconjugate composed of AFAIKL2, a recombinant camelid single-domain antibody which recognizes carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), and the enzyme urease derived from the plant Canavalia ensiformis (Jack bean), with potential antineoplastic activity. Upon intravenous administration, the AFAIKL2 antibody fragment moiety of L-DOS47 specifically targets and binds to CEACAM6 expressed on certain tumor cells. In turn, the urease moiety of L-DOS47 catalyzes the hydrolysis of urea into ammonia, which is further hydrolyzed to produce hydroxyl ions, and causes a locally increased concentration of the toxic waste product ammonia, which under normal conditions is converted into the nontoxic substance urea via the urea cycle. This increases the pH of the tumor microenvironment and alkalinizes the highly acidic environment that is needed for cancer cell survival and proliferation. In addition, the ammonia diffuses into cancer cells and exerts a cytotoxic effect. Altogether, this leads to cell death of CEACAM6-expressing cancer cells. The naturally-occurring enzyme urease catalyzes the hydrolysis of urea into ammonia and carbon dioxide. CEACAM6, a tumor-associated antigen and CEA family member, is overexpressed in a variety of tumor cells and plays a key role in tumor initiation, progression, metastasis and survival.","Anti-CEACAM6 AFAIKL2 Antibody Fragment/Jack Bean Urease Immunoconjugate L-DOS47 | L-DOS47",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899267","Encephalopathy of Prematurity","C120069","A condition affecting premature infants characterized by white matter injury, which is frequently accompanied by neuronal/axonal disease, that may affect all brain parenchymal structures and is due to a combination of destructive processes as well as maturational and trophic disturbances.","Encephalopathy of Prematurity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0071011","Phytoestrogen","C1194","Compounds from plant sources with estrogen-like activities","Phytoestrogen | Phytoestrogens | phytoestrogen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428445","SGO1 Gene","C119716","This gene plays a role in chromosome cohesion during mitosis.","SGO1 Gene | SGO1 | SGOL1 | Shugoshin 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890006","NY-BR-85","C119717","Human SGO1 wild-type allele is located in the vicinity of 3p24.3 and is approximately 29 kb in length. This allele, which encodes shugoshin 1 protein, is involved in the promotion of chromosome cohesion.","SGO1 wt Allele | CAID | NY-BR-85 | SGO | SGOL1 | Sgo1 | Shugoshin 1 wt Allele | Shugoshin-Like 1 (S. pombe) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1565925","Shugoshin-Like 1, Human","C119718","Shugoshin 1 (561 aa, ~64 kDa) is encoded by the human SGO1 gene. This protein plays a role in the positive regulation of chromosome adhesion during prophase.","Shugoshin 1 | SGO1 | Serologically Defined Breast Cancer Antigen NY-BR-85 | Shugoshin-Like 1 | hSgo1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537399","IFIH1 Gene","C119719","This gene is involved in binding to viral ribonucleic acids.","IFIH1 Gene | IFIH1 | Interferon Induced With Helicase C Domain 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3888243","IFIH1 wt Allele","C119720","Human IFIH1 wild-type allele is located in the vicinity of 2q24 and is approximately 52 kb in length. This allele, which encodes interferon-induced helicase C domain-containing protein 1, plays a role in the induction of antiviral responses. Mutation of the gene is associated with Aicardi-Goutieres syndrome 7. Variation in the gene is associated with type 1 diabetes, Graves disease, and systemic lupus erythematosus.","IFIH1 wt Allele | AGS7 | CADM-140 Autoantigen | Hlcd | IDDM19 | Interferon Induced With Helicase C Domain 1 | Interferon Induced With Helicase C Domain 1 wt Allele | MDA-5 | MDA5 | Melanoma Differentiation-Associated Gene 5 | Melanoma Differentiation-Associated Protein 5 | RH116 | RLR-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899023","Gluten-free Compact Nutritional Supplement Drink","C120033","A gluten-free, calorie-dense, milkshake-like nutritional supplement drink containing all essential vitamins, minerals, and trace elements, as well as protein, fat and carbohydrates. Upon oral intake, gluten-free compact nutritional supplement drink may aid in the prevention of malnutrition and weight loss. The drink is provided in a reduced volume (125 ml) but with the same complete nutrition as the standard drink (200 ml); the reduced volume may increase patient compliance.","Gluten-free Compact Nutritional Supplement Drink | Fortimel Compact",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899471","DLQI - Skin Influence Clothes You Wear","C119166","Dermatology Life Quality Index (DLQI) Over the last week, how much has your skin influenced the clothes you wear?","DLQI - Skin Influence Clothes You Wear | DLQI1-Influenced Clothes You Wear | DLQI104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899475","DLQI - Skin Affect Social or Leisure Activities","C119167","Dermatology Life Quality Index (DLQI) Over the last week, how much has your skin affected any social or leisure activities?","DLQI - Skin Affect Social or Leisure Activities | DLQI1-Affected Social, Leisure Activity | DLQI105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899469","DLQI - Skin Made Difficult to Do Sport","C119168","Dermatology Life Quality Index (DLQI) Over the last week, how much has your skin made it difficult for you to do any sport?","DLQI - Skin Made Difficult to Do Sport | DLQI1-Made It Difficult to Do Any Sports | DLQI106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899993","Autologous PBMCs in GM-CSF","C120182","Autologous peripheral blood mononuclear cells (PBMCs) that are suspended in a solution containing the immunostimulant granulocyte-macrophage colony stimulating factor (GM-CSF).","Autologous PBMCs in GM-CSF | Autologous Peripheral Blood Mononuclear Cells in Granulocyte-macrophage Colony-stimulating Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049611","CD48 wt Allele","C120950","Human CD48 wild-type allele is located within 1q21.3-q22 and is approximately 33 kb in length. This allele, which encodes CD48 antigen protein, is involved in CD2 signaling.","CD48 wt Allele | BCM1 | BLAST | BLAST1 | CD48 Antigen (B-Cell Membrane Protein) Gene | CD48 Molecule wt Allele | MEM-102 | SLAM Family, Member 2 Gene | SLAMF2 | hCD48 | mCD48",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1457877","CD48 Antigen","C120951","CD48 antigen (243 aa, ~28 kDa) is encoded by the human CD48 gene. This protein plays a role in both CD2 binding and activation of ligand-dependent signaling pathways.","CD48 Antigen | B-Cell Activation Marker | B-Cell Membrane Protein | B-Lymphocyte Activation Marker BLAST-1 | BCM1 Surface Antigen | Leukocyte Antigen MEM-102 | SLAM Family Member 2 | SLAMF2 | Signaling Lymphocytic Activation Molecule 2 | TCT.1",,,,,,,,,,,,,,,"4339287","Lymphocyte antigen CD48",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055024","FGF22 wt Allele","C120955","Human FGF22 wild-type allele is located in the vicinity of 19p13.3 and is approximately 4 kb in length. This allele, which encodes fibroblast growth factor 22 protein, plays a role in both glucose homeostasis and lipid metabolism.","FGF22 wt Allele | Fibroblast Growth Factor 22 wt Allele | UNQ2500/PRO5800",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049603","Fibroblast Growth Factor 22","C120958","Fibroblast growth factor 22 (170 aa, ~20 kDa) is encoded by the human FGF22 gene. This protein is involved in the regulation of both lipid metabolism and glucose homeostasis.","Fibroblast Growth Factor 22 | FGF-22",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0072580","Pteropterin","C1206","A crystalline conjugate of folic acid, having general properties of a polypeptide. Pteropterin differs from folic acid in that it consists of three molecules of glutamic acid instead of one. Pteropterin can potentially be used as an antimetabolite in the treatment of cancer.","Pteropterin | PTEROPTERIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055471","Anaerobic Gram Positive Bacteria","C120704","Any bacteria that does not require oxygen to grow or respirate and has a peptidoglycan rich cell wall that stains dark purple with the Gram staining technique","Anaerobic Gram Positive Bacteria | ANAEROBIC GRAM-POSITIVE BACTERIA | Gram-positive Anaerobe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002824","Ancylostoma","C120705","A genus of parasitic nematodes within the family Ancylostomatidae that are commonly found in dogs and cats. Infestation causes ancylostomiasis.","Ancylostoma | ANCYLOSTOMA",,,,,,,,,,,,,,,"4064358","Ancylostoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0446035","Candida intermedia","C120706","A species of pseudohyphae fungus belonging to the genus Candida that has been isolated from human skin, throat, and feces; it is a rare human pathogen in nosocomial infections.","Candida intermedia | Blastodendrion intermedium | Blastodendrion intermedius | CANDIDA INTERMEDIA | Cryptococcus intermedius | Kluyveromyces cellobiovorus | Mycotorula intermedia",,,,,,,,,,,,,,,"4348281","Candida intermedia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053633","Pemigatinib","C121553","An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), with potential antineoplastic activity. Pemigatinib binds to and inhibits FGFR1/2/3, which may result in the inhibition of FGFR1/2/3-related signal transduction pathways. This inhibits proliferation in FGFR1/2/3-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, plays a key role in cellular proliferation, migration, and survival.","Pemigatinib | 2H-Pyrrolo(3',2':5,6)pyrido(4,3-d)pyrimidin-2-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-8-(4-morpholinylmethyl)- | INCB 054828 | INCB-054828 | INCB054828 | PEMIGATINIB | Pemazyre",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3658638","gallium Ga 68-labeled GRPR antagonist BAY86-7548","C121773","A radioconjugate containing a synthetic bombesin receptor antagonist targeting the gastrin-releasing peptide receptor (GRPR), that is linked by the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to the radionuclide gallium (Ga) 68, with potential use in diagnostic imaging using positron emission tomography/computed tomography (PET/CT). Upon administration of gallium Ga 68 GRPR antagonist BAY86-7548, the peptide moiety targets and binds to GRPR. Upon PET/CT, GRPR-expressing tumor cells can then be visualized. GRPR, also called bombesin receptor 2 (BB2), is a G protein-coupled seven-transmembrane receptor belonging to the bombesin receptor family. It is overexpressed in certain types of cancers.","Gallium Ga 68-labeled RM2 | (68)Ga-DOTA-4-amino-1-carboxymethylpiperidine-d-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 | 68-Ga RM2 | 68Ga-Bombesin Antagonist BAY86-7548 | 68Ga-DOTA RM2 | 68Ga-DOTA-Bombesin Analog BAY86-7548 | 68Ga-RM2 | BAY 86-7548 | Ga-68-labeled Bombesin Antagonist BAY 86-7548 | Gallium Ga 68-labeled GRPR Antagonist BAY86-7548 | Gallium Ga68-labeled GRPR Antagonist RM2 | RM-2 GA-68 | [68Ga]-labeled Bombesin Analog BAY86-7548 | [68Ga]RM2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1436437","Transcription Factor MafA","C120573","Transcription factor MafA (353 aa, ~37 kDa) is encoded by the human MAFA gene. This protein plays a role in the activation of insulin gene expression in the pancreas.","Transcription Factor MafA | Pancreatic Beta-Cell-Specific Transcriptional Activator | Transcription Factor RIPE3b1 | v-Maf Musculoaponeurotic Fibrosarcoma Oncogene Homolog A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049866","B7-H5","C120578","Human VSIR wild-type allele is located in the vicinity of 10q22.1 and is approximately 26 kb in length. This allele, which encodes V-type immunoglobulin domain-containing suppressor of T-cell activation protein, is involved in the modulation of T-cell function.","VSIR wt Allele | B7-H5 | B7H5 | C10orf54 | Chromosome 10 Open Reading Frame 54 Gene | DD1alpha | GI24 | PD-1 Homolog Gene | PD-H1 | PP2135 | Programmed Death-1 Homolog Gene | SISP1 | UNQ730/PRO1412 | V-Domain Ig Suppressor of T Cell Activation Gene | V-Domain Immunoglobulin Suppressor of T Cell Activation Gene | V-Set Immunoregulatory Receptor wt Allele | VISTA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049985","V-Type Immunoglobulin Domain-Containing Suppressor of T-Cell Activation","C120581","V-type immunoglobulin domain-containing suppressor of T-cell activation (311 aa, ~34 kDa) is encoded by the human VSIR gene. This protein plays a role in the negative regulation of T-cell function.","V-Type Immunoglobulin Domain-Containing Suppressor of T-Cell Activation | DD1-Alpha | Death Domain 1-Alpha | Death Domain1alpha | PDCD1 Homolog | Platelet Receptor GI24 | Platelet Receptor Gi24 | Sisp-1 | Stress Induced Secreted Protein 1 | Stress-Induced Secreted Protein-1 | V-Domain Ig Suppressor of T Cell Activation | V-Set Domain-Containing Immunoregulatory Receptor | V-Set Immunoregulatory Receptor | VISTA | VSIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049737","ATG7 wt Allele","C120966","Human ATG7 wild-type allele is located in the vicinity of 3p25.3 and is approximately 285 kb in length. This allele, which encodes ubiquitin-like modifier-activating enzyme ATG7 protein, is involved in the regulation of autophagy.","ATG7 wt Allele | APG7 | APG7 Autophagy 7-Like (S. cerevisiae) Gene | APG7-LIKE | APG7L | ATG7 Autophagy Related 7 Homolog (S. cerevisiae) Gene | Autophagy 7, S. cerevisiae, Homolog of Gene | Autophagy Related 7 wt Allele | DKFZp434N0735 | GSA7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1857854","Pro-Opiomelanocortin Deficiency","C120393","Deficiency of the hormone precursor, pro-opiomelanocortin, associated with loss-of-function mutation(s) in the POMC gene.","Pro-Opiomelanocortin Deficiency | POMC Deficiency",,,,,,,,,,,,,,,"45771307","Proopiomelanocortin deficiency syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2061911","Mixed Flora","C120707","The presence of more than one fungal and/or bacterial organism in a culture.","Mixed Flora | MIXED FLORA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899762","CIC-DUX4L Fusion Protein Expression","C120221","Expression of a fusion protein that results from a t(10;19)(q26;q13) translocation, which involves the human genes CIC (capicua transcriptional suppressor) and DUX4L (double homeobox 4-like).","CIC-DUX4L Fusion Protein Expression | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897140","t(4;19)(q35;q13)","C120222","A cytogenetic abnormality that refers to the translocation involving the genes CIC (capicua transcriptional suppressor) on chromosome 19 and DUX4 (double homeobox 4) on chromosome 4 resulting in CIC-DUX4 fusion.","t(4;19)(q35;q13) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897143","t(10;19)(q26;q13)","C120223","A cytogenetic abnormality that refers to the translocation involving the genes CIC (capicua transcriptional suppressor) on chromosome 19 and DUX4L (double homeobox 4-like) on chromosome 10 resulting in CIC-DUX4L fusion.","t(10;19)(q26;q13) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899764","CIC-Rearranged Sarcoma","C120224","An undifferentiated, high grade small round cell sarcoma affecting predominantly young adults. It is characterized by a recurrent translocation involving the CIC gene on chromosome 19 and either DUX4 gene on chromosome 4 or DUX4L gene on chromosome 10. The translocation results in either CIC-DUX4, t(4;19)(q35;q13) or CIC-DUX4L, t(10;19)(q26;q13) fusions.","CIC-Rearranged Sarcoma | CIC-DUX Sarcoma",,,,,,,,,,,,,,,"37152438","CIC-rearranged sarcoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053664","anti-PD-1 monoclonal antibody BGB-A317","C121775","A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tislelizumab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.","Tislelizumab | BGB A317 | BGB-A317 | BGBA317 | TISLELIZUMAB | Tevimbra | Tirelizumab | Tislelizumab-jsgr",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055498","Acute Lymphoblastic Leukemia by Gene Expression Profile","C121973","Gene expression-based patient cluster groups in acute lymphoblastic leukemia.","Acute Lymphoblastic Leukemia by Gene Expression Profile | ALL Gene Expression Cluster Subtype | ALL Gene Expression Subtype | ALL by Gene Expression Profile | ALL by Gene Expression Signature | Acute Lymphoblastic Leukemia Gene Expression Subtype | Acute Lymphoblastic Leukemia by Gene Expression Signature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897130","Branched-chain Amino Acid Supplement","C120121","A nutritional supplement containing essential branched-chain amino acids (BCAAs), including leucine, isoleucine and valine, with potential anti-cachectic, antiangiogenic, hepatocellular carcinoma (HCC) inhibiting and hepatoprotective activities. Upon oral administration, BCAAs inhibit the expression of both hypoxia-inducible factor 1-alpha subunit (HIF-1a) and vascular endothelial growth factor (VEGF), which prevents VEGF-mediated angiogenesis in HCC cells. In addition, BCAAs inhibit proliferation and induce apoptosis of HCC cells by both suppressing the expression of insulin-like growth factor (IGF), and inhibiting the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway. BCAAs also correct the plasma amino acid imbalance and promote protein metabolism, including the synthesis of albumin and glycogen. They reduce oxidative stress by inducing the activation of genes involved in antioxidant defenses, which prevent the production of reactive oxygen species (ROS). BCAAs also strengthen the immune system by increasing hepatic lymphocytes and stimulating natural killer (NK) cell activity. This supplement is able to improve insulin resistance and promote ammonia detoxification through increased glutamine (Gln) production.","Branched-chain Amino Acid Supplement | BCAA Supplement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891716","Compound Sodium Lactate Solution","C120128","A multiple electrolyte, isotonic, crystalloid solution for intravenous infusion containing sodium chloride, potassium chloride, calcium chloride dihydrate, and sodium lactate, which can restore the electrolyte balance, normalize pH, and provide water for hydration. Upon intravenous administration, the compound sodium lactate solution will replace any lost body fluids and electrolytes thereby providing hydration as well as normalizing electrolyte concentrations. In addition, conversion of sodium lactate to bicarbonate increases plasma bicarbonate levels, which facilitates the removal of hydrogen ions from the blood stream, raises blood pH and normalizes the acid-base balance.","Compound Sodium Lactate Solution | CSL Solution | Hartmann's Solution | Sodium Chloride, Potassium Chloride, Calcium Chloride Dihydrate, Sodium Lactate 60% Solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898188","NY-ESO-1/MART-1 Peptide-pulsed Dendritic Cell Vaccine","C120129","A cell-based cancer vaccine composed of dendritic cells (DC) pulsed with peptides derived from the tumor-associated antigens human cancer/testis antigen NY-ESO-1 and melanoma antigen recognized by T-cells (MART-1/Melan-A), with potential immunostimulatory and antineoplastic activities. Upon administration, the NY-ESO-1/MART-1-peptide pulsed DC vaccine may stimulate the immune system to mount an anti-tumor cytotoxic T-lymphocyte (CTL) response against NY-ESO-1/MART-1-expressing tumor cells, which may result in tumor cell lysis. NY-ESO-1 is expressed both in normal testes and on the surfaces of various tumor cells. MART-1 is expressed by melanoma cells.","NY-ESO-1/MART-1 Peptide-pulsed Dendritic Cell Vaccine | NY-ESO-1/MART-1 Peptide-pulsed DC Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054546","Melanocortin 4 Receptor Deficiency","C120394","Deficiency or dysfunction of the melanocortin 4 receptor, associated with loss-of-function mutation(s) in the MCFR4 gene.","Melanocortin 4 Receptor Deficiency | MC4R Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055324","CRQ-SAS First Administration Version - Feeling Emotional","C121010","Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) Feeling emotional such as angry or upset.","CRQ-SAS First Administration Version - Feeling Emotional | CRQ01-Feeling Emotional | CRQ0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055313","CRQ-SAS First Administration Version - Take Care of Basic Needs","C121011","Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) Taking care of your basic needs (bathing, showering, eating or dressing).","CRQ-SAS First Administration Version - Take Care of Basic Needs | CRQ01-Take Care of Basic Needs | CRQ0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055314","CRQ-SAS First Administration Version - Performing Chores","C121013","Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) Performing chores (such as housework, shopping groceries).","CRQ-SAS First Administration Version - Performing Chores | CRQ01-Performing Chores | CRQ0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055315","CRQ-SAS First Administration Version - Participate in Social Activities","C121014","Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) Participating in social activities.","CRQ-SAS First Administration Version - Participate in Social Activities | CRQ01-Participate in Social Activities | CRQ0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055321","CRQ-SAS First Administration Version - Felt Frustrated or Impatient","C121015","Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) In general, how much of the time during the last 2 weeks have you felt frustrated or impatient?","CRQ-SAS First Administration Version - Felt Frustrated or Impatient | CRQ01-Felt Frustrated or Impatient | CRQ0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055323","CRQ-SAS First Administration Version - Feeling of Fear or Panic","C121016","Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) How often during the last 2 weeks did you have a feeling of fear or panic when you had difficulty getting your breath?","CRQ-SAS First Administration Version - Feeling of Fear or Panic | CRQ01-Feeling of Fear or Panic | CRQ0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054347","Non-Biologic Disease-Modifying Antirheumatic Drug","C121333","A drug used to alter the progression of autoimmune disease that is not a biologic.","Non-Biologic Disease-Modifying Antirheumatic Drug | Non-Biologic DMARD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055380","Biologic Disease-Modifying Antirheumatic Drug","C121334","A biologic used to alter the progression of autoimmune disease.","Biologic Disease-Modifying Antirheumatic Drug | Biologic DMARD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055473","American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus","C121336","The classification of systemic lupus erythematosus based on eleven criteria. Intended to be used as inclusion criteria for clinical studies, a person is defined as having systemic lupus erythematosus if any four or more of the eleven criteria are present, serially or simultaneously, during any interval of observation.","American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus | ACR Classification Criteria for SLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053951","Systemic Lupus International Collaborating Clinics Classification Criteria","C121337","A validated revision of American College of Rheumatology (ACR) criteria for systemic lupus erythematosus with extension to seventeen criteria. Intended to be used as inclusion criteria for clinical studies, if the patient has biopsy-proven lupus nephritis with antinuclear antibodies (ANA) or anti-dsDNA, or the patient satisfies four of the criteria, including at least one clinical and one immunologic criterion.","Systemic Lupus International Collaborating Clinics Classification Criteria | SLICC Criteria | Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054703","International League of Associations for Rheumatology Classification Criteria for Juvenile Idiopathic Arthritis","C121338","A set of criteria used to assign children with chronic arthritis to one of the seven mutually exclusive categories of juvenile idiopathic arthritis (JIA), intended to be used for research purposes.","International League of Associations for Rheumatology Classification Criteria for Juvenile Idiopathic Arthritis | ILAR Classification Criteria for JIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053756","European League Against Rheumatism Classification Criteria for Juvenile Chronic Arthritis","C121339","A set of antiquated criteria used to assign children with chronic arthritis to one of six mutually exclusive categories.","European League Against Rheumatism Classification Criteria for Juvenile Chronic Arthritis | EULAR Classification Criteria for Juvenile Chronic Arthritis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055474","American College of Rheumatology Classification Criteria for Juvenile Rheumatoid Arthritis","C121340","A set of antiquated criteria used to assign children with chronic arthritis to one of the three mutually exclusive categories.","American College of Rheumatology Classification Criteria for Juvenile Rheumatoid Arthritis | ACR Classification Criteria for JRA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054754","Hypertrophy and Hyperplasia","C120891","A finding of both hypertrophy and hyperplasia in the same lesion.","Hypertrophy and Hyperplasia | HYPERTROPHY/HYPERPLASIA | Hyperplasia/Hypertrophy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054753","Hypertrophy and Karyomegaly","C120892","A finding of both hypertrophy and karyomegaly in the same lesion.","Hypertrophy and Karyomegaly | HYPERTROPHY/KARYOMEGALY | Karyomegaly/Hypertrophy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL494549","Karyocytomegaly","C120894","An increase in nuclear size and amount of cytoplasm of a cell. The cells or nucleus may be slightly irregular and/or may be polyploid.","Karyocytomegaly | KARYOCYTOMEGALY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053740","Karyocytomegaly and Multinucleated Hepatocytes","C120895","A finding of both karyocytomegaly and multinucleated hepatocytes in the same lesion.","Karyocytomegaly and Multinucleated Hepatocytes | KARYOCYTOMEGALY/MULTINUCLEATED HEPATOCYTES | Multinucleated Hepatocytes/Karyocytomegaly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333902","Karyomegaly","C120896","An increase in the size of a cellular nucleus.","Karyomegaly | KARYOMEGALY | Nuclear Enlargement",,,,,,,,,,,,,,,"4286026","Macronucleus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054531","Mesangiolysis","C120897","A process characterized by the degeneration of mesangial cells and the dissolution of the mesangial matrix in the glomerulus of the kidney, in response to injury or disease.","Mesangiolysis | MESANGIOLYSIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3686874","Microgliosis","C120898","An accumulation of microglial cells in nervous tissue as a result of injury.","Microgliosis | MICROGLIOSIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006660","Mineralization","C120899","The process by which an organic substance is converted into organic minerals, such as in the formation of bone.","Mineralization | Calcification | MINERALIZATION | Mineral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0072661","pyrazofurin","C1208","A nucleoside analog.  Pyrazofurin potently inhibits orotidine 5'-monophosphate (OMP) decarboxylase, thereby interfering with de novo synthesis of uridine nucleotides and resulting in cytotoxicity.  This agent also causes a rapid depletion of the pyrimidine deoxynucleotide pool, thereby inhibiting DNA synthesis and cell replication. (NCI04)","Pyrazofurin | .beta.-Pyrazomycin | 1H-Pyrazole-5-carboxamide, 4-Hydroxy-3-beta-D-ribofuranosyl- (9CI) | 1H-Pyrazole-5-carboxamide, 4-hydroxy-3-.beta.-D-ribofuranosyl- (9CI) | 4-Hydroxy-3-.beta.-D-ribofuranosylpyrazole-5-carboxamide | 4-Hydroxy-3-beta-D-ribofuranosylpyrazole-5-carboxamide | 47599 | Beta-Pyrazomycin | Compound 47599 | PRZF | PYRAZOFURIN | Pirazofurin | Pyrazole, -3-Carboxamide, 4-Hydroxy-5-beta-L-ribofuranosyl | Pyrazole, -3-carboxamide, 4-hydroxy-5-.beta.-L-ribofuranosyl- | Pyrazomycin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054455","Multinucleated Hepatocyte","C120900","A giant hepatocyte with multiple nuclei.","Multinucleated Hepatocyte | MULTINUCLEATED HEPATOCYTES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333734","Neuronophagia","C120901","The phagocytic destruction of nerve cells.","Neuronophagia | NEURONOPHAGIA",,,,,,,,,,,,,,,"4215582","Neuronophagia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0149939","Obstructive Nephropathy","C120902","Renal damage and impaired renal function secondary to urinary tract obstruction.","Obstructive Nephropathy | OBSTRUCTIVE NEPHROPATHY",,,,,,,,,,,,,,,"4313582","Obstructive nephropathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4050301","Parasite Present","C120903","Confirmatory presence of parasitic microorganisms.","Parasite Present | PARASITE | Parasites",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054145","Proteinaceous Plug","C120904","A loosely organized mass found in the bladder and/or urethra of male rats, composed of eosinophilic material intermingled with exfoliated urothelial cells, and occasionally containing spermatozoa. Plug formation is assumed to be a result of abnormal ejaculation and secretions from the male accessory sex glands, and may occur during euthanasia.","Proteinaceous Plug | PROTEINACEOUS PLUG | Seminal Plug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0451718","Reflux Nephropathy","C120905","Chronic kidney damage due to vesicoureteral reflux.","Reflux Nephropathy | RETROGRADE NEPHROPATHY",,,,,,,,,,,,,,,"194685","Non-obstructive reflux-associated chronic pyelonephritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054001","Spermatic Stasis","C120907","Stoppage of flow of sperm due to obstruction.","Spermatic Stasis | SPERM STASIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896681","DC-TC","C120183","A therapeutic melanoma vaccine consisting of autologous dendritic cells (DCs) pulsed with antigens from lethally irradiated autologous tumor cells derived from a patient-specific, continuously proliferating and melanoma-initiating cell line and suspended in a solution containing the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration, eltrapuldencel-T may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against the patient's repertoire of melanoma-associated antigens, particularly tumor stem cell antigens, found in the irradiated autologous cancer cells. As an immunostimulant, GM-CSF enhances the activation of dendritic cells (DCs) and promotes antigen presentation to both B- and T-lymphocytes.","Eltrapuldencel-T | Autologous DCs Loaded with Irradiated Autologous Tumor Cells in GM-CSF | Autologous Dendritic Cells Loaded with Irradiated Autologous Tumor Cells in Granulocyte-macrophage Colony-stimulating Factor | DC-TC | ELTRAPULDENCEL-T | Melapuldencel-T | NBS-20 | NBS20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897009","Nasal Saline Irrigation Solution","C120184","A solution containing sodium chloride that can be used to cleanse the nasal passages. Upon nasal irrigation, the saline washes out thick or dry mucus, and irritants, such as pollen, dust particles, pollutants and bacteria, from the nasal cavities. This reduces nasal blockage, improves nasal airflow and helps keep nasal passages clean and clear, which decreases the risk of irritation and inflammation. The saline solution also moisturizes and soothes irritated mucus membranes.","Nasal Saline Irrigation Solution | Nasal Saline Rinse | Nasal Saline Wash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054588","Lymphocytic Neurohypophysitis","C121719","An autoimmune condition affecting the posterior pituitary gland, which is characterized by lymphocytic infiltration, and which often presents as diabetes insipidus.","Lymphocytic Neurohypophysitis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054917","Functional Pituitary Macroadenoma","C121720","A pituitary neuroendocrine tumor/macroadenoma associated with a hormonal syndrome.","Functioning Pituitary Neuroendocrine Tumor/Macroadenoma | Functional Pituitary Macroadenoma | Functioning PitNET/Macroadenoma | Functioning Pituitary Gland Macroadenoma | Functioning Pituitary Gland Macroadenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054344","Nonfunctional Pituitary Macroadenoma","C121721","A pituitary neuroendocrine tumor/macroadenoma not associated with a hormonal syndrome.","Non-Functioning Pituitary Neuroendocrine Tumor/Macroadenoma | Non-Functioning PitNET/Macroadenoma | Non-Functioning Pituitary Gland Macroadenoma | Non-Functioning Pituitary Gland Macroadenoma | Nonfunctional Pituitary Gland Macroadenoma | Nonfunctional Pituitary Macroadenoma | Nonfunctioning Pituitary Gland Macroadenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342163","Compensated Hypothyroidism","C121727","Hypothyroidism characterized by elevated thyroid-stimulating hormone (TSH) with normal circulating concentrations of thyroid hormones.","Compensated Hypothyroidism | ",,,,,,,,,,,,,,,"4183422","Subclinical hypothyroidism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055472","American College of Rheumatology Pediatric Core Set for Juvenile Arthritis","C121341","A set of criteria used to assess clinical response (improvement) or worsening (flare), in juvenile idiopathic arthritis clinical trials.","American College of Rheumatology Pediatric Core Set for Juvenile Arthritis | ACR Pediatric Core Set for Juvenile Arthritis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050205","Pediatric Vasculitis Activity Score","C121342","A set of criteria used to determine the activity of childhood vasculitis.","Pediatric Vasculitis Activity Score | PVAS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053544","Birmingham Vasculitis Activity Score","C121343","A set of criteria used to determine the activity of vasculitis.","Birmingham Vasculitis Activity Score | BVAS",,,,,,,,,,,,,,,"3654982","Birmingham Vasculitis Activity Score",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4050350","Childhood Myositis Assessment Scale","C121344","An observational performance-based instrument developed to evaluate muscle strength, physical function, and endurance in children with juvenile idiopathic inflammatory myopathy.","Childhood Myositis Assessment Scale | CMAS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890596","Compound Kushen Injection","C120314","A traditional Chinese medicine (TCM) formulation composed of compound Kushen injection (CKI) containing aqueous extracts from the roots of Kushen (Radix Sophorae Flavescentis) and Baituling (Rhizoma smilacis Glabrae), with potential antineoplastic and immunomodulating activities. CKI contains numerous chemicals including alkaloids, such as matrine and oxymatrine, flavonoids, alkylxanthones, quinones, triterpene glycosides, fatty acids, and essential oils. Although the exact mechanism(s) of action through which CKI exerts its effects has yet to be fully elucidated, CKI is able to interfere with the activation of various signal transduction pathways, such as the Wnt/beta-catenin signaling pathway, inhibit nuclear factor-kappa B (NF-KB) activation, and block the activity of multiple receptor tyrosine kinases, such as epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR). CKI induces apoptosis in and inhibits proliferation, migration, invasion and adhesion of tumor cells. CKI also modulates the production of inflammatory mediators.","Compound Kushen Injection | CKI | Yanshu Injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2702462","Ibuprofen Injection","C120315","A formulation for intravenous injection containing ibuprofen, a propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID), with anti-inflammatory, analgesic, and antipyretic activities. Upon intravenous injection, ibuprofen inhibits the activity of the enzymes cyclooxygenase I (COX-1) and II (COX-2), resulting in a decreased formation of precursors of prostaglandins and thromboxanes. Inhibition of COX-2 specifically blocks the conversion of arachidonic acid (AA) to prostaglandins, which mediate inflammation, fever and pain.","Ibuprofen Injection | Caldolor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896855","Anti-EGFR Monoclonal Antibody GC1118","C120316","A recombinant, human monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Upon intravenous administration, GC1118 binds to and blocks the ligand binding site of EGFR, which prevents receptor dimerization and activation. This may lead to an inhibition of both EGFR-dependent downstream pathways and EGFR-dependent tumor cell proliferation and metastasis. EGFR, a receptor tyrosine kinase, may be overexpressed on the surfaces of various tumor cell types.","Anti-EGFR Monoclonal Antibody GC1118 | GC1118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896815","Anti-CD157 Monoclonal Antibody MEN1112","C120317","A humanized, Fc engineered, de-fucosylated monoclonal immunoglobulin G1 (IgG1) antibody directed against the bone marrow stromal cell antigen 1 (BST1/CD157), with potential antineoplastic activity. Upon intravenous infusion, anti-CD157 monoclonal antibody MEN1112 specifically binds to and induces an antibody dependent cell cytotoxic (ADCC) response against CD157-expressing tumor cells. CD157, also known as ADP-ribosyl cyclase 2, is a glycosyl-phosphatidylinositol (GPI)-anchored transmembrane protein belonging to the ADP-ribosyl-cyclase family and is overexpressed on certain cancer cell types. Fc-optimization of MEN1112, which involves the removal of fucose residues from its Fc domain, allows for enhanced Fc-gamma receptor binding on effector cells, such as natural killer (NK) cells, and further enhances tumor cell lysis.","Anti-CD157 Monoclonal Antibody MEN1112 | MEN1112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054000","Spermatid Retention","C120908","Persistence of mature elongating spermatids in the seminiferous tubules after the normal stage of physiologic release.","Spermatid Retention | SPERMATID RETENTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL494558","Spermatocele","C120909","A benign cystic dilatation in the head of the epididymis that contains milky or watery fluid and spermatozoa.","Spermatocele | SPERMATOCELE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897182","WT1 Peptide-loaded Allogeneic Dendritic Cell Vaccine","C120185","A cell-based cancer vaccine composed of donor-derived dendritic cells (DCs) loaded with three, human leukocyte antigen A2 (HLA-A2)-binding peptides derived from the human tumor-associated antigen (TAA) Wilms tumor protein 1 (WT1), with potential immunomodulating and antineoplastic activities. Upon vaccination, WT1 peptide-loaded allogeneic DC vaccine exposes the immune system to WT1-derived peptides and may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against WT1-expressing cancer cells, which could result in tumor cell lysis. WT1, a transcription factor, is overexpressed in leukemic cells and in various solid tumors, and only minimally in normal tissues; its expression often correlates with disease progression and poor prognosis. HLA-A2 is an MHC class I molecule that presents antigenic peptides to CD8+ T-cells; restricting the peptides to those epitopes that bind most efficiently to HLA-A2 may improve antigenic peptide immunogenicity.","WT1 Peptide-loaded Allogeneic Dendritic Cell Vaccine | WT1 Peptide-loaded Allogeneic DC Vaccine | Wilms Tumor 1 Peptide-loaded Allogeneic Dendritic Cell Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897060","Contrasexual Sexual Development","C120187","The development of secondary sexual characteristics contrary to pre-pubertal phenotype (feminization in boys; virilization in girls).","Contrasexual Sexual Development | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1849930","Persistent Mullerian Duct Syndrome","C120188","The presence of Mullerian duct-derived structures in a phenotypically male individual.","Persistent Mullerian Duct Syndrome | Hernia Uteri Inguinale",,,,,,,,,,,,,,,"45765424","Persistent Müllerian duct syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897939","Persistent Mullerian Duct Syndrome Type I","C120189","Persistent Mullerian duct syndrome due to deficiency of anti-Mullerian hormone.","Persistent Mullerian Duct Syndrome Type I | Anti-Mullerian Hormone Deficiency | Persistent Mullerian Duct Syndrome Type 1 | Persistent Müllerian Duct Syndrome Type 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897940","Persistent Mullerian Duct Syndrome Type II","C120190","Persistent Mullerian duct syndrome due to resistance to anti-Mullerian hormone (AMH), resulting from mutations in the AMH receptor (AMHR) gene.","Persistent Mullerian Duct Syndrome Type II | Anti-Mullerian Hormone Resistance | Persistent Mullerian Duct Syndrome Type 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0936016","Complete Androgen Insensitivity Syndrome","C120191","A genetic disorder associate with a mutation in the AR gene, resulting in the complete resistance to androgenic hormones.","Complete Androgen Insensitivity Syndrome | CAIS | Complete androgen insensitivity syndrome",,,,,,,,,,,,,,,"45770921","Complete androgen insensitivity syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268301","Partial Androgen Insensitivity Syndrome","C120192","A genetic disorder associated with a mutation in the AR gene, resulting in partial resistance to androgenic hormones.","Partial Androgen Insensitivity Syndrome | PAIS",,,,,,,,,,,,,,,"45757367","Partial androgen insensitivity syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3900198","46,XY Disorder of Androgen Action","C120194","Conditions in 46,XY individuals in which androgens are produced in typical amounts, but tissue response to androgens is reduced.","46,XY Disorder of Androgen Action | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899349","Disorder of AMH Receptor","C120196","A defect in the Anti-Muellerian hormone receptor.","Disorder of AMH Receptor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054189","Personalized Synthetic Long Peptide Breast Cancer Vaccine","C121947","A cancer vaccine consisting of one or more long, synthetic peptides derived from patient-specific breast cancer tumor-associated antigens (TAAs), with potential immunomodulating and antineoplastic activities. Upon intramuscular administration of the personalized synthetic long peptide breast cancer vaccine, the peptides stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the TAAs, which results in tumor cell lysis.","Personalized Synthetic Long Peptide Breast Cancer Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053634","BET Inhibitor INCB054329","C121948","An inhibitor of the Bromodomain and Extra-Terminal (BET) family of bromodomain-containing proteins with potential antineoplastic activity. Upon administration, the BET inhibitor INCB054329 binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomain at the N-terminus, BET proteins, BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during cellular growth.","BET Inhibitor INCB054329 | INCB054329",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053683","anti-CD25-PBD antibody-drug conjugate ADCT-301","C121949","An immunoconjugate consisting of a human immunoglobulin (Ig) G1 monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha or CD25) and conjugated, via a cleavable linker, to a synthetic, cross-linking agent pyrrolobenzodiazepine (PBD) dimer that targets DNA minor grooves, with potential antineoplastic activity. The monoclonal antibody portion of the anti-CD25 antibody-drug conjugate (ADC) ADCT-301 specifically binds to the cell surface antigen CD25. This causes the internalization of ADCT-301 and the subsequent release of the cytotoxic PBD moiety. The imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces interstrand cross-links in the minor groove of DNA and inhibits DNA replication, which inhibits the proliferation of CD25-overexpressing tumor cells. CD25, a transmembrane receptor and tumor-associated antigen (TAA), is expressed on certain cancer cells.","Camidanlumab Tesirine | ADC ADCT-301 | ADCT-301 | CAMIDANLUMAB TESIRINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0536128","Xanthohumol","C121950","A prenylated flavonoid derived from the female flowers of the hops plant (Humulus lupulus L), with potential chemopreventive and antineoplastic activities. Upon administration, xanthohumol scavenges reactive oxygen species (ROS), thereby preventing DNA damage due to oxidative stress. In addition, xanthohumol is able to increase the expression of phase II cytoprotective enzymes, thereby inactivating carcinogens. This agent exerts anti-inflammatory activity, through the inhibition of inflammation-inducing enzymes, inhibits DNA synthesis, and induces apoptosis of susceptible cancer cells. Xanthohumol also decreases the expression of C-X-C chemokine receptor 4 (CXCR4), thereby preventing cancer cell invasion.","Xanthohumol | 3'-[3,3-Dimethyl allyl]-2',4',4-trihydroxy-6'-methoxychalcone | XANTHOHUMOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053651","Mutant p53 Activator COTI-2","C121951","An orally available third generation thiosemicarbazone and activator of mutant forms of the p53 protein, with potential antineoplastic activity. Upon oral administration, mutant p53 activator COTI-2 targets and binds to the misfolded mutant forms of the p53 protein, which induces a conformational change that normalizes p53 and restores its activity. This induces apoptosis in tumor cells in which the p53 protein is mutated. In addition, COTI-2 inhibits the activation of Akt2 and prevents the activation of the PI3K/AKT/mTOR pathway, thereby inducing apoptosis in cancer cells in which this pathway is overexpressed. p53, a tumor suppressor protein, plays a key role in controlling cellular proliferation and survival. High levels of mutant p53 are seen in many cancers and are associated with uncontrolled cellular growth.","Mutant p53 Activator COTI-2 | COTI-2 | COTI2 | Coti-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053656","pan-RAF Kinase Inhibitor CCT3833","C121952","An orally available inhibitor of the serine/threonine protein kinase family Raf, including A-Raf, B-Raf and C-Raf, with potential antineoplastic activity. Upon administration, pan-RAF kinase inhibitor CCT3833 inhibits Raf-mediated signal transduction pathways, which may inhibit the proliferation of Raf-overexpressing tumor cells. Raf protein kinases play a key role in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway, which is often dysregulated in human cancers and plays a key role in tumor cell proliferation and survival.","pan-RAF Kinase Inhibitor CCT3833 | BAL 3833 | BAL-3833 | BAL3833 | CCT 3833 | CCT-3833 | CCT3833",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054287","Ovarian Microcystic Stromal Tumor","C121953","A benign, unilateral tumor that arises from the ovary and is characterized by the presence of conspicuous microcystic changes, cellular areas, and a fibrous stroma.","Ovarian Microcystic Stromal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889731","Procaspase Activating Compound-1 VO-100","C120318","An orally bioavailable procaspase activating compound-1 (PAC-1), with potential proapoptotic and antineoplastic activities. Upon administration, VO-100 binds to and forms a chelating complex with zinc (Zn) ions inside cells, which prevents the binding of Zn ions to procaspase-3 (PC3) and abrogates the Zn-mediated inhibition of PC3. This allows for the proteolytic autoactivation of PC3 into the active form caspase-3. This results in the selective caspase-3-mediated induction of apoptosis and cell death in cancer cells. In addition, VO-100 is able to cross the blood-brain-barrier (BBB). PC3, a Zn-inhibited proenzyme, is upregulated in a variety of cancer cell types, while its expression is minimal in normal healthy cells.","Procaspase Activating Compound-1 VO-100 | PAC-1 | PAC-1 VO-100 | VO-100",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896922","GalNAc-Anti-C5 siRNA ALN-CC5","C120319","A proprietary formulation composed of small-interfering RNAs (siRNAs) directed against terminal complement component 5 (C5) of the complement pathway conjugated to a N-acetylgalactosamine (GalNAc) ligand, which has potential use in the treatment of complement-mediated diseases, such as paroxysmal nocturnal hemoglobinuria (PNH). Upon subcutaneous administration of cemdisiran, the GalNAc ligand moiety specifically binds to and is taken up by the asialoglycoprotein receptor (ASGPR) expressed on hepatocytes. Inside the cell, the siRNAs bind to C5 mRNAs, which results in the inhibition of both the translation and expression of the C5 protein. This lowers plasma C5 levels, prevents C5 cleavage into pro-inflammatory components and blocks complement-mediated hemolysis. C5, a complement pathway protein, is expressed at high levels by the liver.","Cemdisiran | AD-62643 Free Acid | ALN-62643 Free Acid | ALN-CC5 | CEMDISIRAN | GalNAc-siRNA Conjugate ALN-CC5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055612","APACHE II - Oxygenation, A-aDO2","C121100","Acute Physiology and Chronic Health Evaluation II (APACHE II) Oxygenation (mm Hg): FIO2 greater than or equal to 0.5 record A-aDO2.","APACHE II - Oxygenation, A-aDO2 | APCH1-Oxygenation: A-aDO2 | APCH105A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055611","APACHE II - Oxygenation, PaO2","C121101","Acute Physiology and Chronic Health Evaluation II (APACHE II) Oxygenation (mm Hg): FIO2 less than 0.5 record only PaO2.","APACHE II - Oxygenation, PaO2 | APCH1-Oxygenation: PaO2 | APCH105B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055617","APACHE II - Arterial pH","C121102","Acute Physiology and Chronic Health Evaluation II (APACHE II) Arterial pH (preferred).","APACHE II - Arterial pH | APCH1-Arterial pH | APCH106A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055608","APACHE II - Serum HCO3","C121103","Acute Physiology and Chronic Health Evaluation II (APACHE II) Serum HCO3 (venous mMol/L) (Not preferred, use if no ABGs).","APACHE II - Serum HCO3 | APCH1-Serum HCO3 | APCH106B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055606","APACHE II - Serum Sodium","C121104","Acute Physiology and Chronic Health Evaluation II (APACHE II) Serum sodium (mMol/L).","APACHE II - Serum Sodium | APCH1-Serum Sodium | APCH107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055607","APACHE II - Serum Potassium","C121105","Acute Physiology and Chronic Health Evaluation II (APACHE II) Serum potassium (mMol/L).","APACHE II - Serum Potassium | APCH1-Serum Potassium | APCH108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055085","Early Stillbirth","C120583","Delivery of a dead fetus greater than 22 weeks but less than 28 weeks gestational age, and/or whose birth weight is greater than 500 grams but less than 1,000 grams.","Early Stillbirth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054663","Late Stillbirth","C120585","Delivery of a dead fetus greater than 28 weeks gestational age and/or greater than 1,000 grams birth weight.","Late Stillbirth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050010","CD160 wt Allele","C120594","Human CD160 wild-type allele is located in the vicinity of 1q21.2 and is approximately 20 kb in length. This allele, which encodes CD160 antigen protein, is involved in the recognition of class I major histocompatibility complex proteins.","CD160 wt Allele | BY55 | CD160 Molecule wt Allele | NK1 | NK28",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1701777","Ubiquitin-Like Modifier-Activating Enzyme ATG7, Human","C120969","Ubiquitin-like modifier-activating enzyme ATG7 (703 aa, ~78 kDa) is encoded by the human ATG7 gene. This protein plays a role in both cytoplasm to vacuole transport and autophagy.","Ubiquitin-Like Modifier-Activating Enzyme ATG7 | APG7-Like | ATG12-Activating Enzyme E1 ATG7 | ATG7 Autophagy Related 7 Homolog | Autophagy-Related Protein 7 | Ubiquitin Activating Enzyme E1-Like Protein | Ubiquitin-Activating Enzyme E1-Like Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049719","TNFAIP2 wt Allele","C120976","Human TNFAIP2 wild-type allele is located in the vicinity of 14q32 and is approximately 14 kb in length. This allele, which encodes tumor necrosis factor alpha-induced protein 2, may play a role in angiogenesis and inflammation.","TNFAIP2 wt Allele | B94 | EXOC3L3 | Tumor Necrosis Factor, Alpha-Induced Protein 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0251858","Tumor Necrosis Factor Alpha-Induced Protein 2, Human","C120977","Tumor necrosis factor alpha-induced protein 2 (654 aa, ~73 kDa) is encoded by the human TNFAIP2 gene. This protein may be involved in the regulation of both inflammation and angiogenesis.","Tumor Necrosis Factor Alpha-Induced Protein 2 | Exocyst Complex Component 3-Like 3 | Primary Response Gene B94 Protein | TNF Alpha-Induced Protein 2 | TNFAIP2 | Tumor Necrosis Factor-Alpha-Induced Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053511","CDISC Questionnaire CRQ-SAS First Administration Version Test Name Terminology","C120978","Test names of questionnaire questions associated with the Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version (CRQ-SAS First Administration Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire CRQ-SAS First Administration Version Test Name Terminology | CRQ01TN | Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire Test Name | QS-CRQ-SAS First Administration Version TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053512","CDISC Questionnaire CRQ-SAS First Administration Version Test Code Terminology","C120979","Test codes of questionnaire questions associated with the Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version (CRQ-SAS First Administration Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire CRQ-SAS First Administration Version Test Code Terminology | CRQ01TC | Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire Test Code | QS-CRQ-SAS First Administration Version TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053509","CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Name Terminology","C120980","Test names of questionnaire questions associated with the Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version (CRQ-SAS Follow-Up Administration Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Name Terminology | CRQ02TN | Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire Test Name | QS-CRQ-SAS Follow-Up Administration Version TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055609","APACHE II - Serum Creatinine","C121106","Acute Physiology and Chronic Health Evaluation II (APACHE II) Serum creatinine (mg/100 mL) (double point score for acute renal failure).","APACHE II - Serum Creatinine | APCH1-Serum Creatinine | APCH109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055614","APACHE II - Hematocrit","C121107","Acute Physiology and Chronic Health Evaluation II (APACHE II) Hematocrit (%).","APACHE II - Hematocrit | APCH1-Hematocrit | APCH110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055603","APACHE II - White Blood Count","C121108","Acute Physiology and Chronic Health Evaluation II (APACHE II) White blood count (total/mm3) (in 1,000s).","APACHE II - White Blood Count | APCH1-White Blood Count | APCH111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055619","APACHE II - 15 Minus Glasgow Coma Score","C121109","Acute Physiology and Chronic Health Evaluation II (APACHE II) Glasgow coma score: Score equals 15 minus actual GCS.","APACHE II - 15 Minus Glasgow Coma Score | APCH1-15 Minus Glasgow Coma Score | APCH112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055618","APACHE II - A, Total Acute Physiology Score","C121110","Acute Physiology and Chronic Health Evaluation II (APACHE II) A: Total acute physiology score.","APACHE II - A, Total Acute Physiology Score | APCH1-A: Total Acute Physiology Score | APCH113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055616","APACHE II - B, Age Points","C121111","Acute Physiology and Chronic Health Evaluation II (APACHE II) B: Age points (years).","APACHE II - B, Age Points | APCH1-B: Age Points | APCH114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053790","APACHE II - C, Chronic Health Points","C121112","Acute Physiology and Chronic Health Evaluation II (APACHE II) C: Chronic health points.","APACHE II - C, Chronic Health Points | APCH1-C: Chronic Health Points | APCH115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055604","APACHE II - Total APACHE II Score","C121113","Acute Physiology and Chronic Health Evaluation II (APACHE II) Total APACHE II score.","APACHE II - Total APACHE II Score | APCH1-Total APACHE II Score | APCH116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049879","TP53AIP1 wt Allele","C121115","Human TP53AIP1 wild-type allele is located in the vicinity of 11q24.3 and is approximately 9 kb in length. This allele, which encodes p53-regulated apoptosis-inducing protein 1, is involved in the mediation of apopotosis.","TP53AIP1 wt Allele | P53AIP1 | Tumor Protein p53 Regulated Apoptosis Inducing Protein 1 wt Allele | p53AIP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1612758","alpha-folate receptor-targeting thymidylate synthase inhibitor ONX-0801","C120550","An alpha-folate receptor (aFR)-mediated inhibitor of thymidylate synthase (TS), with potential antineoplastic activity. Upon intravenous infusion, idetrexed selectively targets and binds to aFR-expressing tumor cells. Upon uptake by aFR, this agent binds to and inhibits TS. This reduces thymine nucleotide synthesis, inhibits both DNA synthesis and cell division, and leads to tumor cell apoptosis. TS catalyzes the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), an essential precursor for DNA synthesis, and plays a key role in cell growth and division. aFR, a cell-surface receptor glycoprotein, is overexpressed on various tumor cell types, but is minimally expressed by normal, healthy tissue.","Idetrexed | BGC 945 | IDETREXED | N-[4-[2-Propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-l-gamma-glutamyl-d-glutamic Acid | ONX 0801 | ONX-0801 | alpha-Folate Receptor-targeting Thymidylate Synthase Inhibitor ONX-0801",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055277","Cannabis Extract Oil SR Capsule","C120551","A sustained-release (SR), oil-based oral capsule composed of a cannabis extract, which contains a variety of cannabinoids but is comprised mainly of tetrahydrocannabinol (THC), with potential anti-cachexic and analgesic activities. Upon oral administration, the cannabinoids bind to the cannabinoid G-protein coupled receptor CB1, which is located in both central and peripheral neurons; CB1 receptor activation inhibits adenyl cyclase, increases various signal transduction pathways, and modulates the activity of various ion channels. This provides an analgesic effect, increases appetite, decreases chemotherapy-induced nausea and vomiting, and improves weight gain. The formulation allows for the immediate release of cannabinoids and quick onset of action, which is followed by a gradual release of cannabinoids. The SR form facilitates longer lasting therapeutic effects and causes fewer psychoactive side effects when compared to non-SR cannabinoid-containing oral formulations.","Cannabis Extract Oil SR Capsule | Cannabics SR | Cannabis SR Capsule | Cannabis SR Capsules",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0757560","CD160 protein, human","C120596","CD160 antigen (181 aa, ~20 kDa) is encoded by the human CD160 gene. This protein plays a role in binding to class I major histocompatibility complexes.","CD160 Antigen | Natural Killer Cell Receptor BY55",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050414","Rapid Virologic Response","C120597","A finding of aviremia at a specified timepoint, early during the treatment period.","Rapid Virologic Response | RAPID VIROLOGIC RESPONSE | RVR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0769356","Tectorigenin","C1205","An isoflavone from Pueraria thunbergiana, which induces differentiation and apoptosis in cancer cells. (NCI)","Tectorigenin | 4',5,7-Trihydroxy-6-methoxyisoflavone | 4H-1-benzopyran-4-one, 5,7-dihydroxy-3-(4-hydroxyphenyl)-8-methoxy- | Psi-Tectorigenin | TECTORIGENIN | psi-Tectorigenin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053867","Viral Relapse","C120600","A recurrence of the same virus after a finding of aviremia at the end of planned or actual treatment.","Viral Relapse | VIRAL RELAPSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054356","Neurotropic Tyrosine Kinase Receptor Type 2 Deficiency","C120406","Deficiency or dysfunction of the type 2 receptor for neurotropic tyrosine kinase associated with loss-of-function mutation(s) in the NTKR2 gene.","Neurotropic Tyrosine Kinase Receptor Type 2 Deficiency | NTKR2 Deficiency | Neurotrophic Tyrosine Kinase, Receptor Type 2 Deficiency | Receptor Tyrosine Kinase B | TKRB Deficiency | TRKB Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054147","Prohormone Convertase 1 Deficiency","C120407","Deficiency or dysfunction of the enzyme prohormone convertase 1 associated with loss-of-function mutation(s) in the PCSK1 gene.","Prohormone Convertase 1 Deficiency | PCSK1 Deficiency | Prohormone Convertase 1/3 Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3697355","Chromosome 16p11.2 Deletion Syndrome","C120408","A microdeletion at 16p11.2, characterized by a predisposition to obesity, developmental delay and autism spectrum disorders.","Chromosome 16p11.2 Deletion Syndrome | ",,,,,,,,,,,,,,,"44783246","Chromosome 16p11.2 deletion syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4015558","Maternal Uniparental Disomy Chromosome 14 Syndrome","C120409","A cause of obesity that results from inheritance of two copies of chromosome 14 from the mother, and no copy of chromosome 14 from the father.","Maternal Uniparental Disomy Chromosome 14 Syndrome | Temple Syndrome | mUPD14 Syndrome",,,,,,,,,,,,,,,"36674509|604611","Temple syndrome|Maternal uniparental disomy of chromosome 14",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1257772","Erythroid Colony Forming Unit","C121533","A unit of viable cell concentration defined as the minimum number of hematopoietic stem cells able to produce a detectable colony of erythroid lineage cells that are past the burst forming stage.","Erythroid Colony Forming Unit | CFU-E | Colony Forming Unit-Erythroid | Colony-Forming Units, Erythroid",,,,,,,,,,,,,,,"40483365","Colony-forming unit of erythroid lineage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055424","Autologous CM-CS1 T Cells","C121536","A preparation of autologous peripheral blood T-lymphocytes (PBTLs) that have been genetically modified and transduced with a retroviral vector to express a chimeric antigen receptor (CAR) encoding full-length human natural-killer group 2, member D receptor protein (NKG2D or KLRK1) fused to the CD3zeta cytoplasmic signaling domain and containing the naturally-expressed adaptor molecule DNAX-activating protein of 10 kDa (DAP10), with potential immunostimulating and antineoplastic activities. Upon infusion back into the patient, autologous NKG2D CAR-CD3zeta-DAP10-expressing T-lymphocytes CYAD-01 specifically recognize and bind to tumor cells expressing NKG2D ligands. This induces secretion of pro-inflammatory cytokines and results in the lysis of NKG2D ligand-expressing tumor cells. In addition, CYAD-01 targets, binds to and kills NKG2D ligand expressing tumor-associated endothelial cells in the neovasculature and immunosuppressive cells, such as regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TME) that express NKG2D ligands. It also activates macrophages within the TME. Ligands for NKG2D, such as MHC class I chain-related protein A (MICA), MICB, and members of the UL16-binding proteins (ULBP)/retinoic acid early transcript 1 (RAET1) family, are overexpressed on infected cells and most cancer cell types, but are not expressed on most normal, healthy cells. NKG2D, a dimeric, type II transmembrane protein expressed on human natural killer (NK) and certain T-cells, in association with the natural adaptive protein DAP10, promotes the elimination of NKG2D ligand-expressing cells. The CD3zeta signaling domain and DAP10 provide co-stimulatory signaling upon ligand binding, enhance the secretion of pro-inflammatory cytokines in response to binding to NKG2D ligand-expressing tumor cells and enhances T-cell cytotoxicity. DAP10 also associates with and stabilizes NKG2D, which facilitates expression of the NKG2D-CAR-CD3zeta construct at the cell surface.","Autologous NKG2D CAR-CD3zeta-DAP10-expressing T-Lymphocytes CYAD-01 | Autologous CAR NKG2D | Autologous CAR-T NKG2D | Autologous CAR-T NKR-2 | Autologous CM-CS1 T Cells | Autologous NKG2D CAR-CD3zeta-DAP10-expressing T-cells CYAD-01 | Autologous NKR 2 T-cells | Autologous NKR-2 CAR-T Cells | CM CS-1 | CM-CS-1 | CM-CS1 | CYAD-01 | CYAD-101 | NKR 2 | NKR-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053624","autologous tumor infiltrating lymphocytes LN-144","C120552","A preparation of autologous tumor infiltrating lymphocytes (TILs), with potential antineoplastic activity. TILs are isolated from a patient's tumor tissue, cultured in vitro with high-dose interleukin-2 (lL-2), further selected based on antigen specificity and tumor reactivity, and the selected TILs are subsequently expanded. Upon re-introduction of lifileucel into the patient, the TILs re-infiltrate the tumor, specifically recognize the tumor-associated antigens (TAAs), and initiate tumor cell lysis. IL-2 induces the proliferation and expansion of TILs in vitro.","Lifileucel | Amtagvi | Autologous TIL LN-144 | Autologous Tumor Infiltrating Lymphocytes LN-144 | Contego | LIFILEUCEL | LN 144 | LN-144 | LN144 | Lifileuecel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053665","PARP inhibitor BGB-290","C120553","An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP), with potential antineoplastic activity. Upon administration, pamiparib selectively binds to PARP and prevents PARP-mediated repair of single-strand DNA breaks via the base-excision repair (BER) pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability, and eventually leads to apoptosis. PARP is activated by single-strand DNA breaks and, subsequently, catalyzes post-translational ADP-ribosylation of nuclear proteins which then transduce signals to recruit other proteins to repair damaged DNA. Pamiparib may both potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell chemo- and radioresistance.","Pamiparib | 5,6,7a,11-Tetraazacyclohepta(def)cyclopenta(a)fluoren-4(7H)-one, 2-Fluoro-5,8,9,10,10a,11-hexahydro-10a-methyl-, (10aR)- | BGB-290 | PAMIPARIB | PARP Inhibitor BGB-290",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3712029","anti-TLR2 monoclonal antibody OPN-305","C120554","A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against toll-like receptor type 2 (TLR2), with potential anti-inflammatory and antineoplastic activities. Upon intravenous administration, tomaralimab binds to the ligand-binding site on the TLR2 receptor and blocks the activation of TLR2-mediated innate immunity signaling. This prevents the TLR2-mediated production of pro-inflammatory mediators and prevents inflammation. TLR2, a member of the TLR family primarily found on leukocytes, plays a key role in the activation of innate immunity; it is overexpressed in various inflammatory diseases and in certain types of cancer.","Tomaralimab | Anti-TLR2 Monoclonal Antibody OPN-305 | OPN-305 | TOMARALIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054587","MAG-Tn3/AS15 Vaccine","C120555","A vaccine containing synthetic multiple antigenic glycopeptide (MAG) composed of tri Tn glycotope (MAG-Tn3), which is comprised of a dendrimeric, nonimmunogenic lysine core linked to a tetravalent peptidic CD4+ T-cell epitope backbone and each attached to three Tn antigens (tri-Tn cluster), combined with the immunoadjuvant AS15, with potential antineoplastic activity. Upon administration of the MAG-Tn3/AS15 vaccine, MAG-Tn3 induces the production of tumor-specific anti-Tn glycosidic antibodies, which results in antibody-dependent cell cytotoxicity (ADCC) against Tn-expressing tumor cells. The Tn carbohydrate antigen, a tumor-associated antigen (TAA), is overexpressed in a number of tumor cell types. The tri-Tn clusters mimic carbohydrate structures found on tumor cells. The T-cell epitope stimulates effective T-cell responses. AS15, a potent adjuvant liposomal formulation that contains CpG 7909, monophosphoryl lipid (MPL), and QS-21, increases the immune response against the Tn antigens.","MAG-Tn3/AS15 Vaccine | MAG-Tn3 Plus AS15 Cancer Vaccine | MAG-Tn3/AS15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896896","anti-CD40L Fc-fusion protein BMS-986004","C120140","A dimeric fusion protein composed of the C-terminus of the domain antibody (dAb) BMS2h-572-633 targeting the CD40 ligand (CD40L or CD154) linked to a modified Fc fragment of immunoglobulin G1 (IgG1), with potential immunomodulatory activity. Upon intravenous administration, the peptide moiety of letolizumab specifically targets and binds to CD40L expressed on T-lymphocytes. This prevents the binding of CD40L to its cognate receptor CD40 expressed on B-lymphocytes, macrophages, and dendritic cells (DCs). This prevents T-cell mediated proliferation and differentiation of B-cells, and prevents the production of antibodies. By inhibiting both the production of anti-glycoprotein (GP) IIb/IIIa antibodies by B-cells and GPIIb/IIIa-dependent T-cell proliferation, letolizumab may prevent platelet destruction and may increase platelet counts in idiopathic thrombocytopenic purpura (ITP). The direct binding of letolizumab to CD40L on platelets further prevents CD40L/CD40-mediated destruction by macrophages and DCs in ITP. The modified Fc domain prevents the binding of letolizumab to the Fc receptor FcgammaRIIA on platelets, thereby preventing FcgammaRIIA-dependent platelet activation and anti-CD40L-induced thromboembolism. CD40L, a transmembrane protein of the tumor necrosis factor (TNF) superfamily, is primarily expressed on activated T-cells, but is also expressed on eosinophils, basophils, natural killer (NK) cells, mast cells, platelets and activated endothelial cells.","Letolizumab | BMS-986004 | BMS986004 | Fc-Fusion Protein BMS986004 | LETOLIZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342549","Familial Male Precocious Puberty","C120143","Early development of isosexual secondary characteristics in boys, due to autosomal dominant mutations in the LHCGR gene.","Familial Male Precocious Puberty | Familial Testotoxicosis | Gonadotropin-independent Familial Sexual Precocity | Male-limited Precocious Puberty | Testotoxicosis",,,,,,,,,,,,,,,"37110836","Familial male-limited precocious puberty",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3891159","Aromatase Deficiency","C120144","Deficiency of activity of the enzyme aromatase, which converts androgens to estrogens.","P450-Aromatase Deficiency | Aromatase Deficiency | Aromatase deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3489396","Isolated Hypogonadotropic Hypogonadism","C120145","Hypogonadotropic hypogonadism not associated with a deficiency of other pituitary hormones.","Isolated Hypogonadotropic Hypogonadism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897086","Ovarian Hyperandrogenism","C120146","Increased production of androgens by the ovaries.","Ovarian Hyperandrogenism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053945","Tension Lipidosis","C120910","A focus of hepatocytes containing well delineated circular clear spaces in the liver, often near mesenteric attachments such as the falciform ligament.","Tension Lipidosis | TENSION LIPIDOSIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055475","Alzheimer Type II Astrocyte","C120911","An abnormal and pathological astrocyte which appears enlarged and metabolically hyperactive. It is characterized by the presence of vesicular and basophilic nuclei. This cell type is not associated with Alzheimer's Disease.","Alzheimer Type II Astrocyte | TYPE II ASTROCYTES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL494561","Vesicle","C120912","An abnormal fluid-filled cleft (e.g. as in the epidermis) or membrane-bound space.","Vesicle | VESICLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049929","Yeast Present","C120913","Confirmatory presence of yeast microorganisms.","Yeast Present | YEAST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049938","Physical Activity Measurement","C120914","A measurement of a subject's physical activity or movement.","Physical Activity Measurement | ACTIVITY | Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053826","dP/dt Average","C120915","The average rate of pressure change over time within the left ventricle, which is used as a measurement of left ventricular contractility.","dP/dt Average | DPDTAVG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050617","Autologous HPV-16/18 E6/E7-specific TGF-beta-resistant T Lymphocytes","C121537","A preparation of autologous transforming growth factor-beta (TGF-beta)-resistant cytotoxic T-lymphocytes (CTL) reactive to human papilloma virus (HPV) types 16 and 18 E6/E7 antigens, with potential antineoplastic activity. Autologous T-lymphocytes from a HPV-positive cancer patient are exposed to and stimulated with dendritic cells (DCs) loaded with the HPV-16/18 proteins E6 and E7. In turn, the HPV-16/18 E6/E7-specific T-lymphocytes are transduced with a retroviral vector expressing a dominant-negative mutant of type II transforming growth factor (TGF)-beta receptor, which blocks signaling mediated by all three TGF-beta isoforms. Following re-administration to patients with HPV-positive tumors, the HPV-16/18 E6/E7-specific TGF-beta-resistant T lymphocytes target HPV16/18 E6/E7-positive cells, which may result in a specific cytotoxic T-lymphocyte (CTL) response, followed by cell lysis and the inhibition of tumor cell proliferation. Tumors expressing TGF-beta inhibit T-lymphocyte activation and expansion.","Autologous HPV-16/18 E6/E7-specific TGF-beta-resistant T Lymphocytes | Anti-VEGFR2-CAR Retroviral Vector-transduced Autologous T-lymphocytes | HPVST Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053684","agonistic anti-CD40 monoclonal antibody ADC-1013","C121538","A human immunoglobulin (Ig) G1 monoclonal antibody directed against the cell surface receptor CD40 with potential immunostimulatory and antineoplastic activities. Upon intratumoral administration, mitazalimab binds to CD40 on antigen-presenting dendritic cells, which leads to the activation and proliferation of effector and memory T-cells, and enhances the immune response against tumor cells. In addition, this agent binds to the CD40 antigen present on the surfaces of tumor cells, which induces antibody-dependent cytotoxicity (ADCC). This eventually inhibits the proliferation of CD40-expressing tumor cells. CD40, a stimulatory receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells, such as macrophages, dendritic cells and various tumor cell types; it plays a key role in the activation of the immune system.","Mitazalimab | ADC 1013 | ADC-1013 | ADC1013 | JNJ 7107 | JNJ-64457107 | MITAZALIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054705","Intermediate Soft Tissue Tumor of Uncertain Differentiation","C121738","A soft tissue neoplasm of uncertain differentiation which is locally aggressive but rarely metastasizes.","Intermediate Soft Tissue Neoplasm of Uncertain Differentiation | Intermediate Soft Tissue Neoplasm of Uncertain Differentiation | Intermediate Soft Tissue Tumor of Uncertain Differentiation | Intermediate Soft Tissue Tumor of Uncertain Differentiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055118","Dose Response Control","C120841","A type of control using different doses or regimens of the same treatment (fixed dose) among the study groups. [From ICH E10].","Dose Response Control | DOSE RESPONSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054739","Immunogenicity Study","C120842","A study that assesses an agent's ability to provoke an immune response (humoral and/or cell-mediated) in the subject.","Immunogenicity Study | IMMUNOGENICITY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332212","Chronic Active","C120853","Having characteristics of chronic disease superimposed with areas of acute (active) disease.","Chronic Active | CHRONIC ACTIVE",,,,,,,,,,,,,,,"4165522","Chronic active",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054658","Left Ventricular Minimum Positive dP/dt","C120917","The minimum rate of positive pressure (systolic) change within the left ventricle during a unit time.","Left Ventricular Minimum Positive dP/dt | -dP/dt | DPDTMIN | Left Ventricular Maximum Negative dP/dt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054568","Maximum QA Interval","C120921","The maximum time between the recording of a Q wave on ECG and the onset of the aortic blood pressure pulse.","Maximum QA Interval | QAMAX | Summary (Max) QA Interval",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054564","Mean QA Interval","C120922","The calculated average time period between the recording of a Q wave on ECG and the onset of the aortic blood pressure pulse as determined over a number of cardiac cycles during a given interval of time.","Mean QA Interval | QAMEAN | Summary (Mean) QA Interval",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054554","Median QA Interval","C120923","The median time period between the recording of a Q wave on ECG and the onset of the aortic blood pressure pulse as determined over a number of cardiac cycles during a given interval of time.","Median QA Interval | QAMEDIAN | Summary (Median) QA Interval",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054489","Minimum QA Interval","C120924","The minimum time between the recording of a Q wave on ECG and the onset of the aortic blood pressure pulse.","Minimum QA Interval | QAMIN | Summary (Min) QA Interval",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053990","Standard for the Exchange of Nonclinical Data Implementation Guide Version 3.1","C120925","The 3.1 version of the standard for exchange of nonclinical data (SEND) implementation guide.","Standard for the Exchange of Nonclinical Data Implementation Guide Version 3.1 | SEND IG Version 3.1 | SEND IMPLEMENTATION GUIDE VERSION 3.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001878","Air Sacs","C120926","A part of the respiratory system in multiple species (predominantly avian) which are variably connected with the lung.","Air Sac | AIR SAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050158","Depth of Respiration Test","C120928","A clinical judgment made based on the apparent volume of gas being inspired or expired.","Depth of Respiration | DEPTHRES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055066","End Expiratory Pause","C120929","The period of time between the end of exhalation and the active start of inspiration.","End Expiratory Pause | ENDEXPPR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0949595","Gonadal Dysgenesis, 46,XX","C120197","Gonadal dysgenesis in an individual with 46,XX karyotype and female phenotype.","46,XX Gonadal Dysgenesis | 46,XX Ovarian Dysgenesis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018054","46,XY Gonadal Dysgenesis","C120198","Gonadal dysgenesis in an individual with 46.XY karyotype.","46,XY Gonadal Dysgenesis | Swyer Syndrome",,,,,,,,,,,,,,,"4317951","Pure gonadal dysgenesis 46,XY",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018055","45,X/46,XY Mixed Gonadal Dysgenesis","C120199","A congenital condition characterized by asymmetrical gonadal development in an individual with mosaic karyotype 45,X/46,XY.  45,X/46,XY mosaic is the most common form of mixed gonadal dysgenesis.","45,X/46,XY Mixed Gonadal Dysgenesis | 45,X/46,XY Disorder of Sex Development | 45,X/46,XY Gonadal Dysgenesis | Mixed Gonadal Dysgenesis",,,,,,,,,,,,,,,"4308443","Mixed gonadal dysgenesis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0071677","Polysialic Acid","C1201","A highly negative-charged carbohydrate composed of a linear polymer of alpha 2,8-linked sialic acid residue with potential immunotherapeutic activity. Polysialic acid (PSA) is mainly attached to the neural cell adhesion molecule (NCAM), a membrane-bound glycoprotein overexpressed in certain types of cancers. In embryonic tissue PSA-NCAM is abundantly expressed and PSA plays an important role in formation and remodeling of the neural system through modulation of the adhesive properties of NCAM, thereby reducing cell-cell interactions and promoting cellular mobility. In adult tissue however, the expression of PSA-NCAM is associated with a variety of malignant tumors, signifying its potential role in tumor metastasis. When administered in a vaccine formulation, PSA may stimulate a cytotoxic T cell response against tumors expressing PSA, thereby resulting in a reduction in tumor size.","Polysialic Acid | PolySA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0266427","Testicular Regression","C120200","A condition characterized by typical male genital appearance in a 46,XY individual in whom testes are unable to be located.","Testicular Regression | Gonadal Regression | Vanishing Testes",,,,,,,,,,,,,,,"4201736","Testicular regression syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1960540","Placental Aromatase Deficiency","C120202","An autosomal recessive condition that results in aromatase deficiency in the placenta, causing temporary virilization of the pregnant woman and virilization of her 46,XX fetus.","Placental Aromatase Deficiency | ",,,,,,,,,,,,,,,"4138017","Placental aromatase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268296","17-Beta-Hydroxysteroid Dehydrogenase 3 Deficiency","C120203","Decreased activity of the steroidogenic enzyme, 17-beta-hydroxysteroid dehydrogenase, associated with mutation(s) in the HSD17B3 gene, leading to reduced testosterone production.","17-Beta-Hydroxysteroid Dehydrogenase 3 Deficiency | 17 Beta HSD3 Deficiency | 17 beta HSD3 Deficiency | Pseudohermaphroditism, Male, with Gynecomastia",,,,,,,,,,,,,,,"4174657","Testosterone 17-beta-dehydrogenase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3899399","Defect in the Gene for MIS Type II Receptor","C120204","A defect in the MISR II gene.","Defect in the Gene for MIS Type II Receptor | AMHR2 Gene Defect | Defect in the Gene for MIS Type 2 Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1861923","Acampomelic Campomelic Dysplasia","C120205","A variant of campomelic dysplasia characterized by the absence of skeletal dysplasia.","Acampomelic Campomelic Dysplasia | Acampomelic Campomelic Dysplasia (AQ)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1291316","Reductase Deficiency","C120206","A deficiency in an enzyme that promotes reduction of an organic compound.","Reductase Deficiency | ",,,,,,,,,,,,,,,"4049561","Deficiency of reductase",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3665349","Pituitary Hypothyroidism","C121743","Hypothyroidism due to dysfunction of the pituitary gland, which results in inadequate secretion of thyroid-stimulating hormone (thyrotropin).","Pituitary Hypothyroidism | ",,,,,,,,,,,,,,,"4220368","Secondary hypothyroidism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0271829","Pendred Syndrome","C121745","A condition associated with reduced export of iodide across the apical membrane of the follicular cells of the thyroid gland that may progress to hypothyroidism. Pendred syndrome is associated with an increased risk of goiter and sensorineural hearing loss due to malformations of the inner ear (vestibular system). Inactivating mutations in the SLC26A4 gene encoding the pendrin transport protein are responsible for the condition.","Pendred Syndrome | ",,,,,,,,,,,,,,,"4290064","Pendred's syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0271826","Iodide Transport Defect","C121747","A condition associated with reduced active import of iodide across the basolateral membrane of the follicular cells of the thyroid gland. Inactivating mutations in the SLC5A5 gene encoding the sodium-iodide symporter are responsible for the condition.","Iodide Transport Defect | ",,,,,,,,,,,,,,,"4331585","Iodide transport defect",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054906","Gallium Ga 68-NOTA-AE105","C121954","A radiotracer composed of AE105, an urokinase-type plasminogen activator receptor (uPAR) peptide antagonist, conjugated with the bifunctional, macrocyclic chelating agent 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA) and labeled with the radionuclide gallium Ga 68, with potential imaging activity using positron emission tomography (PET). Upon administration, the AE105 moiety of gallium Ga 68-NOTA-AE105 targets and binds, with high affinity, to uPAR expressed on tumor cells. Upon PET imaging, uPAR-expressing tumor cells can be visualized and the degree of tumor aggressiveness can be assessed. uPAR expression is correlated with increased tumor invasiveness and aggressiveness, as well as a poor prognosis.","Gallium Ga 68-NOTA-AE105 | 68Ga-NOTA-AE105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053671","MKNK1 Inhibitor BAY 1143269","C121956","An orally bioavailable inhibitor of mitogen-activated protein kinase interacting serine/threonine-protein kinase 1 (MKNK1), with potential antineoplastic activity. Upon oral administration, MKNK1 inhibitor BAY 1143269 binds to MKNK1, thereby preventing its activation and the downstream MKNK1-mediated phosphorylation and activation of eukaryotic translation initiation factor 4E (eIF4E). As eIF4E enhances the synthesis of oncogenic proteins, preventing eIF4E activity inhibits the synthesis of tumor angiogenic factors and leads to both the inhibition of cellular proliferation and apoptosis in susceptible tumor cells. eIF4E, overexpressed in a variety of cancer cells, plays a key role in tumor cell proliferation and survival.","MKNK1 Inhibitor BAY 1143269 | BAY 1143269",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3686989","Peracute","C120854","An excessively sharp or violent acute episode.","Peracute | PERACUTE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205365","Subacute","C120855","A disease characteristic falling between acute and chronic, but predominantly acute.","Subacute | SUBACUTE",,,,,,,,,,,,,,,"4060546","Subacute",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054942","Focal/Multifocal","C120857","A finding that generally has features of focal and multifocal distribution.","Focal/Multifocal | FOCAL/MULTIFOCAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3686771","Locally extensive","C120858","Being widespread throughout a specific area.","Locally Extensive | Focally Extensive | LOCALLY EXTENSIVE | Regionally Extensive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055508","Accessory Tissue","C120859","A supernumerary tissue in addition to normal tissues.","Accessory Tissue | ACCESSORY TISSUE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055506","Accumulation","C120860","A state characterized by the gradual increase in entities or substances.","Accumulation | ACCUMULATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055488","Adnexal Dysplasia","C120862","A finding of dysplasia in the adnexal appendages.","Adnexal Dysplasia | ADNEXAL DYSPLASIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4083296","Experimental Organism Astrocytosis","C120865","Reactive astrocytic proliferation often associated with degenerative, inflammatory or neoplastic changes in the central nervous system.","Experimental Organism Astrocytosis | ASTROCYTOSIS | Astrogliosis | Gemistocytosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055430","Atypical Residual Bodies","C120866","Abnormally large, misshapen and/or clumped vacuoles containing cell debris in the testis, or present in stages of spermatogenesis when not normally seen.","Atypical Residual Bodies | ATYPICAL RESIDUAL BODIES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4038931","Bacteria Present","C120867","Confirmatory presence of bacterial microorganisms.","Bacteria Present | BACTERIA | Bacterium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055390","Basophilic Phagolysosome","C120868","Intracytoplasmic phagolysosomes that are strongly basophilic. These structures are usually seen within the tubular epithelium and glomeruli of the kidney in response to antisense oligonucleotides.","Basophilic Phagolysosome | BASOPHILIC GRANULES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055264","Cellular Debris","C120869","An accumulation of cell fragments.","Cellular Debris | CELL DEBRIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1439242","p53-Regulated Apoptosis-Inducing Protein 1, Human","C121116","p53-regulated apoptosis-inducing protein 1 (124 aa, ~13 kDa) is encoded by the human TP53AIP1 gene. This protein plays a role in the mediation of p53-dependent apoptosis.","p53-Regulated Apoptosis-Inducing Protein 1 | Tumor Protein p53-Regulated Apoptosis-Inducing Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055502","Acquired Hypogonadotropic Hypogonadism","C120369","Hypogonadotropic hypogonadism, the cause of which is not present from birth.","Acquired Hypogonadotropic Hypogonadism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053866","Virologic End Of Treatment Response","C120601","A finding of aviremia at the end of the planned or actual end of treatment period.","Virologic End Of Treatment Response | VIROLOGIC END OF TREATMENT RESPONSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1699206","Virologic Failure","C120602","A finding of viremia at or after end of planned or actual treatment, excluding treatment discontinuations for non-virologic reasons.","Virologic Failure | VIROLOGIC FAILURE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053865","Virologic Non-Response","C120603","The subject remains viremic during the treatment period.","Virologic Non-Response | VIROLOGIC NON-RESPONSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053864","Virologic Null-Response","C120604","The subject remains viremic during the treatment period and the decrease in viral load from baseline at a specified timepoint is below or equal to a predetermined threshold.","Virologic Null-Response | VIROLOGIC NULL-RESPONSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053510","CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Code Terminology","C120981","Test codes of questionnaire questions associated with the Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version (CRQ-SAS Follow-Up Administration Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Code Terminology | CRQ02TC | Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire Test Code | QS-CRQ-SAS Follow-Up Administration Version TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053524","CDISC Functional Test BACS Test Name Terminology","C120982","Test names of functional test questions associated with the Brief Assessment of Cognition in Schizophrenia (BACS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Functional Test BACS Test Name Terminology | BACS1TN | Brief Assessment of Cognition in Schizophrenia Functional Test Test Name | FT- BACS TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053525","CDISC Functional Test BACS Test Code Terminology","C120983","Test codes of functional test questions associated with the Brief Assessment of Cognition in Schizophrenia (BACS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Functional Test BACS Test Code Terminology | BACS1TC | Brief Assessment of Cognition in Schizophrenia Functional Test Test Code | FT- BACS TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053542","CDISC Clinical Classification APACHE II Test Name Terminology","C120984","Test names of clinical classification questions associated with the Acute Physiology and Chronic Health Evaluation II (APACHE II) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification APACHE II Test Name Terminology | APCH1TN | Acute Physiology and Chronic Health Evaluation II Clinical Classification Test Name | CC-APACHE II TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053543","CDISC Clinical Classification APACHE II Test Code Terminology","C120985","Test codes of clinical classification questions associated with the Acute Physiology and Chronic Health Evaluation II (APACHE II) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification APACHE II Test Code Terminology | APCH1TC | Acute Physiology and Chronic Health Evaluation II Clinical Classification Test Code | CC-APACHE II TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053540","CDISC Clinical Classification BODE Index Test Name Terminology","C120986","Test names of clinical classification questions associated with the The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index (BODE Index) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification BODE Index Test Name Terminology | BODE01TN | CC-BODE Index TEST | The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index Clinical Classification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053538","CDISC Clinical Classification Child-Pugh Test Name Terminology","C120988","Test names of clinical classification questions associated with the Child-Pugh Classification (Child-Pugh) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification Child-Pugh Test Name Terminology | CC-Child-Pugh TEST | CPS01TN | Child-Pugh Classification Clinical Classification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053539","CDISC Clinical Classification Child-Pugh Test Code Terminology","C120989","Test codes of clinical classification questions associated with the Child-Pugh Classification (Child-Pugh) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification Child-Pugh Test Code Terminology | CC-Child-Pugh TESTCD | CPS01TC | Child-Pugh Classification Clinical Classification Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053649","WT1 Protein-derived Peptide Vaccine DSP-7888","C121957","A peptide cancer vaccine comprised of peptides derived from the Wilms tumor gene 1 (WT1) protein, with potential immunomodulating and antineoplastic activities. Upon administration, WT1 protein-derived peptide vaccine DSP-7888 may induce a specific cytotoxic T-lymphocyte (CTL) response against WT1-overexpressing tumor cells. In addition, DSP-7888 induces a helper T-lymphocyte-mediated immune response against WT1 expressing tumor cells. WT1 protein, a zinc finger DNA-binding protein and transcription factor, is overexpressed in leukemic cells and in many non-hematological solid tumors.","WT1 Protein-derived Peptide Vaccine DSP-7888 | DSP-7888",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055272","Carbon C 14 Vemurafenib","C121958","A radioconjugate composed of vemurafenib, an ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase, labeled with the radioisotope carbon C 14, with potential use for evaluating the pharmacokinetic profile of vemurafenib. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in both an inhibition of an over-activated MAPK signaling pathway in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Labeling of vemurafenib with the radioactive tracer carbon C 14 allows for the evaluation of vemurafenib's pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME). The BRAF(V600E) gene mutation in which valine is substituted for glutamic acid at residue 600 (V600E), is found in many cancer cell types and plays a key role in the over-activation of the MAPK signaling pathway.","Carbon C 14 Vemurafenib | 14 C-labeled Vemurafenib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3852643","Fluorine F 18 Alfatide II","C121959","A radiotracer composed of a pegylated, dimeric arginine-glycine-aspartic acid (RGD) peptide (PRGD2), radiolabeled, via the chelating agent 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA), to a fluorine F 18-aluminum complex (AlF), with potential alphaVbeta3 integrin (vitronectin receptor) imaging activity using positron emission topography (PET). Upon administration, the RGD moiety of fluorine F 18 alfatide II selectively binds to alphaVbeta3 integrin. During PET, alphaVbeta3-expressing tumor cells can be visualized and the degree of tumor angiogenesis can be determined. AlphaVbeta3 integrin, a cell adhesion and signaling receptor, is upregulated in tumor vessel endothelial cells and has been associated with neovascularization, differentiation, proliferation of tumor cells, and metastasis. Pegylation provides improved drug penetration into tumors and decreases drug clearance, thereby increasing efficacy while lowering systemic toxicity.","Fluorine F 18 Alfatide II | (18)F-AlF-NOTA-E[PEG4-c(RGDfk)]2 | 18F-Al-NOTA-PRGD2 | 18F-AlF-NOTA-PRGD2 | 18F-Alfatide II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054177","Pirotinib","C121960","An orally bioavailable inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with potential antineoplastic activity. Upon administration, pirotinib selectively and irreversibly binds to and inhibits the epidermal growth factor receptors 1 (ErbB1; EGFR), 2 (ErbB2; HER2), and 4 (ErbB4; HER4). This may result in the inhibition of cell growth and angiogenesis in tumors overexpressing these RTKs. EGFRs play major roles in both tumor cell proliferation and tumor vascularization, and are overexpressed in many cancer cell types.","Pirotinib | KBP-5209 | KBP5209",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054164","Post Neonatal Death","C121303","Death between 28 days and 1 year of life.","Post Neonatal Death | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054482","Moderate to Late Preterm Birth","C121305","Birth when a fetus is between 32 weeks and less than 37 weeks gestational age.","Moderate to Late Preterm Birth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053870","Very Preterm Birth","C121306","Birth when a fetus is between 28 weeks and less than 32 weeks gestational age.","Very Preterm Birth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4048236","Sigmodon hispidus","C121130","From the Sigmodon genus of rodents, Sigmodon hispidus was the first animal model to be used in polio research. It has a stout body, small ears and a dark coat that can be dark brown or mixed buff and black, with a tail length that is 35% of its total body length. As its name suggests, this breed has a proclivity for cotton in its nesting, and is a natural Hanta viral reservoir.","Sigmodon hispidus | Hispid Cotton Rat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054724","Infiltrating Intramuscular Lipoma","C121131","An infiltrating lipoma that affects skeletal muscle.  It has a higher rate of local recurrence.","Infiltrating Intramuscular Lipoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055343","C11orf95-MRTFB Fusion Protein Expression","C121132","Expression of a fusion protein that results from a t(11;16)(q13;p13) translocation, which involves the human genes ZFTA and MKL2.","ZFTA-MRTFB Fusion Protein Expression | C11orf95-MKL2 Fusion Protein Expression | C11orf95-MRTFB Fusion Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053819","t(11;16)(q13;p13)","C121133","A cytogenetic abnormality that refers to the translocation involving the genes C11orf95 on chromosome 11 and MKL2 on chromosome 16 resulting in C11orf95-MKL2 fusion.","t(11;16)(q13;p13) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053863","Virologic Partial Response","C120605","The subject remains viremic during the treatment period and the decrease in viral load from baseline at a specified timepoint is above a predetermined threshold.","Virologic Partial Response | VIROLOGIC PARTIAL RESPONSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054591","Luminescence Type","C120606","A description of the type of light emission, which does not involve the release of heat.","Luminescence Type | LUMNCTYP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1449720","Pubertal Gynecomastia","C120148","Gynecomastia that occurs during puberty and is not due to exogenous substances or disease processes.","Pubertal Gynecomastia | Transient Gynecomastia",,,,,,,,,,,,,,,"4129211","Pubertal gynecomastia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053536","CDISC Clinical Classification MELD Test Name Terminology","C120990","Test names of clinical classification questions associated with the Model for End Stage Liver Disease (MELD) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification MELD Test Name Terminology | CC-MELD TEST | MELD01TN | Model for End Stage Liver Disease Clinical Classification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053537","CDISC Clinical Classification MELD Test Code Terminology","C120991","Test codes of clinical classification questions associated with the Model for End Stage Liver Disease (MELD) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification MELD Test Code Terminology | CC-MELD TESTCD | MELD01TC | Model for End Stage Liver Disease Clinical Classification Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053534","CDISC Clinical Classification NSA-16 Test Name Terminology","C120992","Test names of clinical classification questions associated with the Negative Symptom Assessment-16 (NSA-16) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification NSA-16 Test Name Terminology | CC-NSA-16 TEST | NSA01TN | Negative Symptom Assessment-16 Clinical Classification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342388","Adrenocorticotropic Hormone Deficiency","C120433","Subnormal concentration of adrenocorticotropic hormone (ACTH) resulting in decreased secretion of cortisol by the adrenal gland.","Adrenocorticotropic Hormone Deficiency | ACTH Deficiency | Corticotropin Deficiency | Secondary Adrenal Insufficiency | Secondary Hypoadrenalism",,,,,,,,,,,,,,,"4029439","ACTH deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055505","Acquired Adrenocorticotropic Hormone Deficiency","C120434","Adrenocorticotropic hormone (ACTH) deficiency, the cause of which is not present at birth.","Acquired Adrenocorticotropic Hormone Deficiency | Acquired ACTH Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055046","Extreme Preterm Birth","C121307","Birth when a fetus is less than 28 weeks gestational age.","Extreme Preterm Birth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055421","Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes","C121308","Autologous, human CD8 T-lymphocytes, comprised of both central memory T-cells (Tcm) and naïve T-cells (Tn), that are transduced, ex vivo, with a self-inactivating (SIN) lentiviral vector encoding a high-affinity T-cell receptor (TCRc4) specific for the human tumor antigen Wilms tumor 1 (WT1) epitope 126-134 (RMFPNAPYL), with potential antineoplastic activity. Upon isolation of peripheral blood lymphocytes (PBLs), transduction, expansion ex vivo, priming of the Tn subset, but not the Tcm subset, with interleukin-21 (IL-21) and reintroduction of equal amounts of Tcm and Tn cells into the patient, WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes redirect T-lymphocytes to WT1-expressing tumor cells and specifically bind to and lyse those cells. This inhibits proliferation of WT1-expressing tumor cells. WT1 protein, a zinc finger DNA-binding transcriptional regulator, is overexpressed in most leukemias and various solid tumors, while expression in normal, healthy tissues is very limited; its expression is correlated with aggressiveness and poor prognosis.","Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053653","Docetaxel-loaded Nanopharmaceutical CRLX301","C121539","A nanoparticle-based formulation containing the poorly water-soluble, second-generation taxane analog docetaxel, with antineoplastic activity. Upon intravenous administration of the docetaxel-loaded nanopharmaceutical CRLX301, the nanoparticles are able to accumulate at the tumor site due to the unique characteristics of the tumor's vasculature, while avoiding normal, healthy tissue. In turn, CRLX301 is taken up by the tumor cell via macropinocytosis. Subsequently, docetaxel is slowly released into the cytoplasm where it binds to and stabilizes the beta-subunit of tubulin, thereby stabilizing microtubules and inhibiting microtubule disassembly. This prevents mitosis and results in cell death. Compared to the administration of docetaxel alone, this formulation is able to increase docetaxel's efficacy while avoiding systemic exposure, which minimizes its toxicity.","Docetaxel-loaded Nanopharmaceutical CRLX301 | CRLX301",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055621","ABBV-221","C120556","An antibody-drug conjugate (ADC) composed of an immunoglobulin G1 (IgG1) monoclonal antibody directed against the epidermal growth factor receptor (EGFR), conjugated, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity.  Upon administration, the monoclonal antibody moiety of losatuxizumab vedotin selectively targets and binds to EGFR. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","Losatuxizumab Vedotin | ABBV-221 | LOSATUXIZUMAB VEDOTIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053586","NY-ESO-1-specific TCR Gene-transduced T Lymphocytes TBI-1301","C120557","Human peripheral blood T-lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1, with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and introduction into the patient, the NY-ESO-1-specific TCR gene-transduced T lymphocytes TBI-1301 bind to NY-ESO-1 on tumor cells. This may result in cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1-positive cancer cells. NY-ESO-1, a tumor-associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types.","NY-ESO-1-specific TCR Gene-transduced T Lymphocytes TBI-1301 | NY-ESO-1-specific TCR Gene-transduced T Lymphocytes | TBI-1301",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049607","TCERG1L wt Allele","C120564","Human TCERG1L wild-type allele is located in the vicinity of 10q26.3 and is approximately 219 kb in length. This allele, which encodes transcription elongation regulator 1-like protein, may be involved in insulin resistance.","TCERG1L wt Allele | 5730476P14Rik | FLJ38950 | Transcription Elongation Regulator 1-Like wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053924","Transcription Elongation Regulator 1-Like Protein","C120565","Transcription elongation regulator 1-like protein (586 aa, ~67 kDa) is encoded by the human TCERG1L gene. This protein may plays a role in the modulation of insulin activity.","Transcription Elongation Regulator 1-Like Protein | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0865181","Female Virilization","C120160","The development of male secondary sexual characteristics (such as hirsutism, deepening of the voice, or clitoral enlargement) in girls or adult females.","Female Virilization | Virilization in Girls",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899503","Congenital Hypogonadotropic Hypogonadism","C120162","Insufficient production of estrogen or testosterone in the ovaries or testes due to decreased secretion of gonadotropins as a result of pituitary or hypothalamus gland dysfunction that is present at birth.","Congenital Hypogonadotropic Hypogonadism | ",,,,,,,,,,,,,,,"36716769","Congenital hypogonadotropic hypogonadism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897980","Pathological Gynecomastia","C120163","Gynecomastia that is due to exogenous substances or disease processes.","Pathological Gynecomastia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898662","Isolated Premature Menarche","C120164","Occurrence of the first menstrual period in a girl before the lower limit of the normal age range for the reference population, without other signs of puberty.","Isolated Premature Menarche | Premature Menarche",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2113596","Idiopathic Precocious Puberty","C120165","Precocious puberty for which no underlying cause can be identified.","Idiopathic Precocious Puberty | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055333","CDISC QRS Terminology","C120166","The terminology subset that includes terms pertaining to the CDISC questionnaires, ratings and scales terminology.","CDISC QRS Terminology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899070","GH1 Gene Product","C120168","A protein encoded by the GH1 gene.","GH1 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055196","Congenital Isolated Adrenocorticotropic Hormone Deficiency","C120437","Adrenocorticotropic hormone (ACTH) deficiency due to mutation(s) in the TBX19 gene.","Congenital Isolated Adrenocorticotropic Hormone Deficiency | Congenital Isolated ACTH Deficiency",,,,,,,,,,,,,,,"37164547","Congenital isolated adrenocorticotropic hormone deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055504","Acquired Central Hypothyroidism","C120442","Central hypothyroidism, the cause of which is not present at birth.","Acquired Central Hypothyroidism | ",,,,,,,,,,,,,,,"36717595","Acquired central hypothyroidism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053868","Viral Identification","C120680","A diagnostic procedure to identify and characterize a viral organism.","Viral Identification | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053682","LmddA-LLO-chHER2 fusion protein-secreting live-attenuated Listeria cancer vaccine ADXS31-164","C121541","A cancer vaccine containing a live, highly attenuated strain of the Gram-positive bacterium Listeria monocytogenes (LmddA) encoding a fusion protein composed of a chimeric peptide comprised of three highly immunogenic epitopes of the human tumor-associated antigen (TAA) HER2/neu (chHER2) fused to a non-hemolytic fragment of the immunostimulant listeriolysin O (LLO) protein, with potential immunostimulatory and antineoplastic activities. Upon administration of the LmddA-LLO-chHER2 vaccine OST31-164, the LmddA is taken up by phagocytic cells; then the listeriolysin portion of the expressed LLO-chHER2 can form pores in the phagolysosomes and the fusion protein can escape into the cytosol. In turn, the LLO-chHER2 is processed and presented to the immune system by major histocompatibility complex (MHC) I on the phagocytic cells. Antigen presentation activates the immune system to exert an immune response involving the recruitment and activation of T-lymphocytes against HER2-expressing tumor cells, and inhibits tumor-infiltrating T regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSCs). This eventually results in tumor cell lysis. HER2/neu, a tyrosine kinase receptor belonging to the epidermal growth factor receptor (EGFR) family, is overexpressed in various tumor cell types.","LmddA-LLO-chHER2 Fusion Protein-secreting Live-attenuated Listeria Cancer Vaccine OST31-164 | ADXS 31164 | ADXS-HER2 | ADXS31-164 | OST-HER2 | OST31 164 | OST31164",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053486","Recombinant Super-compound Interferon","C121542","A recombinant form of the naturally-occurring cytokine interferon-alpha (IFN-a) that has a modified spatial configuration, with immunomodulating, antiviral and antineoplastic activities. Upon administration of recombinant super-compound interferon (rSIFN-co), this agent binds to IFN-specific cell surface receptors, resulting in the transcription and translation of genes whose protein products have antiviral, antiproliferative, anticancer, and immune-modulating effects. The 3-dimensional conformational change improves efficacy and causes less side effects compared to IFN-a.","Recombinant Super-compound Interferon | Recombinant Super Compound Interferon | rSIFN-co",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055431","Attenuated Chimpanzee Adenovirus 5T4 Vaccine","C121544","A cancer vaccine comprised of a recombinant, attenuated, replication-defective simian adenovirus vector (ChAdOx1) encoding the human 5T4 fetal oncoprotein (ChAdOx1.5T4), with potential immuno-activating and antineoplastic activities. Upon administration of the recombinant attenuated chimpanzee adenovirus 5T4 vaccine, the viral vector expresses 5T4 and stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing 5T4, which results in tumor cell lysis. 5T4, a transmembrane glycoprotein, is overexpressed by a variety of cancer cell types; its expression is correlated with increased invasiveness.","Attenuated Chimpanzee Adenovirus 5T4 Vaccine | ChAdOx.5T4 Vaccine | ChAdOx1.5T4 Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055115","Dual Oxidase 2 Deficiency","C121748","Thyroid peroxidase system defect due to presumed mutation(s) in the DUOX2 gene, resulting in decreased activity of dual oxidase 2.","Dual Oxidase 2 Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053936","Thyroglobulin Deficiency","C121749","Subnormal production of thyroglobulin, the glycoprotein precursor of thyroid hormones, presumed to result from loss-of-function mutation(s) in the TG gene.","Thyroglobulin Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049873","FBN2 wt Allele","C120567","Human FBN2 wild-type allele is located within 5q23-q31 and is approximately 401 kb in length. This allele, which encodes fibrillin-2 protein, plays a role in the formation of extracellular microfibrils and elastic fibers. Mutation of the gene is associated with both congenital contractural arachnodactyly and early-onset macular degeneration.","FBN2 wt Allele | CCA | Congenital Contractural Arachnodactyly Gene | DA9 | EOMD | Fibrillin 2 wt Allele | Fibrillin 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0252313","fibrillin-2","C120568","Fibrillin-2 (2912 aa, ~315 kDa) is encoded by the human FBN2 gene. This protein is involved in the structure of extracellular calcium-binding microfibrils.","Fibrillin-2 | Fibrillin 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1837475","Insulin Growth Factor I Deficiency","C120106","Insufficient circulating insulin-like growth factor-I.","Insulin Growth Factor I Deficiency | IGF-I Deficiency | IGF1 Deficiency | Insulin-like Growth Factor I Deficiency",,,,,,,,,,,,,,,"37110207","Growth delay due to insulin-like growth factor type 1 deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1849157","Insulin Growth Factor I Resistance","C120107","Tissue unresponsiveness to insulin-like growth factor-I.","Insulin Growth Factor I Resistance | IGF-I Resistance | IGF1R | Somatomedin-C Resistance",,,,,,,,,,,,,,,"37395978","Growth delay due to insulin-like growth factor I resistance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3889695","BNIP3 wt Allele","C120109","Human BNIP3 wild-type allele is located in the vicinity of 10q26.3 and is approximately 14 kb in length. This allele, which encodes BCL2/adenovirus E1B 19 kDa protein-interacting protein 3, is involved in the positive regulation of both autophagy and apoptosis.","BNIP3 wt Allele | BCL2/Adenovirus E1B 19kD-Interacting Protein 3 Gene | BCL2/Adenovirus E1B 19kDa Interacting Protein 3 wt Allele | NIP3 | Nip3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0763459","BCL2/Adenovirus E1B 19 kDa Protein-Interacting Protein 3, Human","C120110","BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (194 aa, ~22 kDa) is encoded by the human BNIP3 gene. This protein plays a role in the promotion of both apoptosis and autophagy.","BCL2/Adenovirus E1B 19 kDa Protein-Interacting Protein 3 | BCL2/Adenovirus E1B 19-kD Protein-Interacting Protein 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897045","Short Stature Homeobox Deficiency","C120113","A rare genetic deficiency characterized by mutations in the SHOX gene and reduced expression or function of the SHOX protein. It results in the disruption of normal bone development and growth starting before birth. It manifests with skeletal abnormalities and short stature.","Short Stature Homeobox Deficiency | SHOX Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493270","Acid-Labile Subunit Deficiency","C120114","Reduced serum concentration of the acid-labile subunit (ALS, a protein encoded by the IGFALS gene) of the complex usually comprised of IGF-I, IGFBP-3 and ALS.","Acid-Labile Subunit Deficiency | ALS Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055065","End Inspiratory Pause","C120930","The period of time between the end of inhalation and the active start of expiration.","End Inspiratory Pause | ENDINSPR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL494703","Expiratory Time","C120932","The recorded time interval between the initiation of exhalation and the time at which no further lung volume reduction occurs.","Expiratory Time | EXPTIME | Expiration Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL494701","Inspiratory Time","C120934","The recorded time interval between the initiation of inhalation and the point at which no further lung volume expansion occurs.","Inspiratory Time | INSTIME | Inspiration Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3854605","Mean Pulmonary Arterial Pressure","C120935","The average blood pressure reading in the pulmonary artery as calculated through multiple cardiac cycles.","Mean Pulmonary Arterial Pressure | MPAP | PA mean pressure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL494622","Minute Volume","C120936","The volume of gas inhaled or exhaled from the lungs during sixty seconds.","Minute Volume | MV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055062","Enhanced Pause","C120937","A composite lung function endpoint that is composed of peak inspiratory and peak expiratory flows, expiration time, and relaxation time, is used to measure the occurrence and prolongation of apnea periods, and is scaled to inspiratory/expiratory strength to account for breathing variability.","Enhanced Pause | PENH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL494700","Peak Expiratory Pressure","C120938","The maximum amount of pressure applied to the lungs during expiration.","Peak Expiratory Pressure | PKEXPPR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL494702","Peak Inspiratory Pressure","C120940","The maximum amount of pressure applied to the lungs during inhalation.","Peak Inspiratory Pressure | PKINSPR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3714738","Pulmonary Compliance","C120942","A measure of the lung's ability to stretch and expand, either statically, the change in volume for a given applied pressure, or dynamically, the elasticity of the lung at any given time during the actual movement of air.","Pulmonary Compliance | PULMCOMP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054893","Good Laboratory Practice Indicator Flag","C120944","An indicator that can be set or unset in order to signal whether the study has been conducted using good laboratory practice standards.","Good Laboratory Practice Indicator Flag | GLP Flag | GLPFL | Good Laboratory Practice Flag",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007637","Inclusion Body","C120945","A detectable aggregation of substance in the cytoplasm or nucleus.","Inclusion Body | INCLUSION | Inclusion Bodies | Inclusions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049725","GNLY wt Allele","C120947","Human GNLY wild-type allele is located in the vicinity of 2p11.2 and is approximately 14 kb in length. This allele, which encodes granulysin protein, plays a role in defense responses to microbial infection.","GNLY wt Allele | 519 | D2S69E | Granulysin wt Allele | LAG-2 | LAG2 | Lymphocyte-Activation Gene 2 | NKG5 | T-Lymphocyte Activation Gene 519 | TLA519",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896859","FLT3/CDK4/6 Inhibitor FLX925","C120209","An orally available inhibitor of FMS-related tyrosine kinase 3 (FLT3, STK1, or FLK2) and the cyclin-dependent kinases 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon administration, FLT3/CDK4/6 inhibitor FLX925 specifically binds to and inhibits FLT3, which interferes with the activation of FLT3-mediated signal transduction pathways and reduces cell proliferation in cancer cells that overexpress FLT3. In addition FLX925 inhibits CDK4 and 6 and prevents the phosphorylation of retinoblastoma (Rb) protein in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, which causes G1 phase cell cycle arrest, suppresses DNA synthesis and inhibits cancer cell growth. FLT3, a class III tyrosine kinase receptor, is overexpressed in a variety of cancers. Overexpression of CDK4/6, which is seen in certain types of cancer, causes cell cycle deregulation.","FLT3/CDK4/6 Inhibitor FLX925 | FLX925",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897543","Src kinase inhibitor KX2-391 ointment","C120210","An ointment containing an inhibitor for both Src tyrosine kinase and tubulin polymerization, with potential antineoplastic activity. Unlike other Src kinase inhibitors which bind to the ATP-binding site, tirbanibulin binds to the peptide substrate binding site of Src kinase, upon topical application. This inhibits both downstream signaling and the proliferation of tumor cells overexpressing Src. Src tyrosine kinase, a non-receptor tyrosine kinase upregulated in many tumor cell types, plays an important role in tumor cell proliferation, motility, invasiveness and survival. Tirbanibulin also binds to tubulin heterodimers and inhibits microtubule polymerization, which disrupts microtubule formation and mitosis, leading to further inhibition of cell proliferation. In addition, Tirbanibulin inhibits T-cell migration.","Topical Tirbanibulin | KX2 391 Ointment | KX2-391 Ointment | Src Kinase Inhibitor KX2-391 Ointment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1291299","Thyroid Peroxidase Deficiency","C121750","Thyroid peroxidase system defect due to presumed mutation(s) in the TPO gene, resulting in decreased activity of thyroid peroxidase.","Thyroid Peroxidase Deficiency | ",,,,,,,,,,,,,,,"4049444","Deficiency of iodide peroxidase",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL496169","Thyroid Dyshormonogenesis","C121751","A defect in any step of the biochemical pathway leading to production of thyroid hormones.","Thyroid Dyshormonogenesis | Dyshormonogenesis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896835","Synthetic hTERT DNA Vaccine INO-1400","C120118","A DNA vaccine consisting of a plasmid encoding the full-length sequence of the tumor-associated antigen (TAA) human telomerase reverse transcriptase (hTERT), which is the catalytic subunit of human telomerase and synthesizes telomeric DNA at the chromosome ends, containing two immunogenic mutations, with potential immunostimulating and antineoplastic activities. Upon intradermal vaccination of the hTERT encoding DNA vaccine INO-1400 in combination with electroporation, hTERT protein is expressed and activates the immune system to mount a cytotoxic T-cell (CTL) response against telomerase-expressing tumor cells, which may result in tumor cell death. Telomerase prolongs the functional lifespan of cells via the restoration and maintenance of telomere length. Abnormally activated in tumorigenesis, telomerase is expressed in the majority of human cancer cells, but its expression is low or non-existent in normal cells.","Synthetic hTERT DNA Vaccine INO-1400 | INO-1400",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3686582","Cholesterol Cleft","C120870","A finding of an empty space in a histological section of paraffin-embedded tissue created by the dissolution of cholesterol crystals.","Cholesterol Cleft | Acicular Cleft | CHOLESTEROL CLEFT | Cholesterol Clefts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333712","Chromatolysis","C120871","The dissolution of chromatin in a cell.","Chromatolysis | CHROMATOLYSIS",,,,,,,,,,,,,,,"4178733","Chromatolysis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055237","Chronic Progressive Nephropathy","C120872","A spontaneous, age-related renal disease of rats, characterized by morphological changes such as degeneration of the epithelium lining of the tubules, thickening of glomerular, Bowman and proximal tubular basement membranes, and lesions in the glomeruli leading to mesangial overload and glomerulosclerosis.","Chronic Progressive Nephropathy | CHRONIC PROGRESSIVE NEPHROPATHY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205204","Cutaneous Crust","C120873","A hard covering or layer of solid matter formed by dried bodily exudate or secretion.","Cutaneous Crust | CRUST | Scab",,,,,,,,,,,,,,,"4256133|4320339","Scab of skin|Crust",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C4055158","Degeneration and Atrophy","C120874","A finding that generally has features of degeneration and atrophy.","Degeneration and Atrophy | Atrophy/Degeneration | DEGENERATION/ATROPHY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1547215","Degeneration and Necrosis","C120875","A finding that generally has features of degeneration and necrosis.","Degeneration and Necrosis | DEGENERATION/NECROSIS | Necrosis/Degeneration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055157","Degeneration and Regeneration","C120876","A finding that generally has features of degeneration and regeneration.","Degeneration and Regeneration | DEGENERATION/REGENERATION | Regeneration/Degeneration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL494537","Ectasia","C120877","A pathophysiological process characterized by the dilatation or expansion of a hollow, tubular tissue or organ.","Ectasia | ECTASIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333448","Elastosis","C120878","Degenerative changes in elastic tissues.","Elastosis | ELASTOSIS",,,,,,,,,,,,,,,"4329563","Elastoid degeneration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054065","Respiratory Tract Epithelial Alteration","C120879","A change or slight modification in the epithelial cells along the respiratory tract.","Respiratory Tract Epithelial Alteration | EPITHELIAL ALTERATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055054","Eroded and Ulcerated Lesion","C120880","A finding of both erosion and ulceration in the same lesion.","Eroded and Ulcerated Lesion | EROSION/ULCER | Erosion/Ulceration | Ulcer/Erosion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049604","Fibroplasia","C120881","The formation of fibrous tissue characterized by an increased number of active, plump fibroblasts and variable amounts of collagen.","Fibroplasia | FIBROPLASIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1437538","Granulysin, Human","C120948","Granulysin (145 aa, ~16 kDa) is encoded by the human GNLY gene. This protein is involved in the antimicrobial activity of cytotoxic granules of cytotoxic T-lymphocytes and natural killer cells.","Granulysin | Lymphokine LAG-2 | Protein NKG5 | T-Cell Activation Protein 519",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054941","Follicle Stimulating Hormone Receptor Deficiency","C120370","Reduced or absent function of the receptor for follicle stimulating hormone associated with a mutation in the FSHR gene.","Follicle Stimulating Hormone Receptor Deficiency | FSH Receptor Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055381","Bio-Inactive Somatotropin","C120371","Bio-inactive somatotropin is encoded by mutated forms of the human GH1 gene. This protein lacks biological activity and is associated with a phenotype of functional growth hormone deficiency.","Bio-Inactive Somatotropin | Bio-Inactive Growth Hormone | Bio-inactive Growth Hormone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342544","Idiopathic Central Precocious Puberty","C120372","Central precocious puberty for which no underlying cause can be identified.","Idiopathic Central Precocious Puberty | ",,,,,,,,,,,,,,,"4029586","Idiopathic central precocious puberty",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054031","Sex Hormone-Binding Globulin Deficiency","C120373","Subnormal concentration of the glycoprotein, sex hormone-binding globulin (SHBG), the primary transport protein for androgens and estrogens in serum, resulting in reduced concentrations of total sex steroids, but minimal change in concentrations of free sex steroids.","Sex Hormone-Binding Globulin Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055166","DAX1 Deficiency","C120374","Decreased activity of the nuclear receptor protein DAX1, caused by mutation(s) in the NR0B1 gene (on the X chromosome), resulting in adrenal hypoplasia congenita that may be associated with hypogonadotropic hypogonadism.","DAX1 Deficiency | Cytomegalic Form of AHC | DSS-AHC Critical Region on the X Chromosome 1 Deficiency | Dosage Sensitive Sex Reversal - Adrenal Hypoplasia Congenita Critical Region On The X Chromosome 1 Deficiency | Dosage Sensitive Sex Reversal - Adrenal Hypoplasia Congenita Critical Region on the X Chromosome 1 Deficiency | NR0B1 Deficiency | Nuclear Receptor DAX1 Deficiency | Nuclear Receptor Subfamily 0 Group B Member 1 Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055126","Disorder of Androgen Synthesis","C120375","An enzyme deficiency in the androgen biosynthesis pathway, resulting in the underproduction of one or more androgens by the adrenal glands and/or gonads.","Disorder of Androgen Synthesis | Androgen Biosynthesis Defect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2675014","Mullerian Aplasia and Hyperandrogenism","C120376","Deficiency of the glycoprotein WNT4, associated with loss of function mutation(s) in the WNT4 gene. The condition in 46,XX individuals is characterized by mild hyperandrogenism, absence of underdevelopment of the uterus, and sometimes absence of underdevelopment of the vagina.","Mullerian Aplasia and Hyperandrogenism | WNT4 Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3472250","Childhood Overweight","C120377","A condition in which a child's body mass index (BMI) falls at or above the 85th percentile, but below the 95th percentile based on the normative values for the age and sex of the reference population.","Childhood Overweight | ",,,,,,,,,,,,,,,"42872460","Overweight in childhood",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054748","Iatrogenic Obesity","C120378","Obesity resulting from medical treatment or intervention.","Iatrogenic Obesity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054170","Polygenic Obesity","C120379","Obesity associated with variations in multiple genes.","Polygenic Obesity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1281429","Exogenous Obesity","C120380","Obesity caused by caloric intake greater than caloric expenditures.","Exogenous Obesity | Common Obesity | Simple Obesity",,,,,,,,,,,,,,,"4217557","Simple obesity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4014296","Central Obesity","C120381","Obesity in which excess fat is accumulated primarily in the area of the abdomen.","Central Obesity | Central Adiposity | Truncal Obesity",,,,,,,,,,,,,,,"4087487","Central obesity",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054476","Monogenic Obesity","C120382","Obesity associated with an identifiable mutation in a single gene.","Monogenic Obesity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896781","selective estrogen receptor degrader/modulator RAD1901","C120211","An orally available, selective estrogen receptor degrader (SERD), with antineoplastic activity. Upon oral administration, elacestrant acts as a SERD, which binds to the estrogen receptor (ER) and induces a conformational change that results in the proteosomal degradation of the receptor. This prevents ER-mediated signaling and inhibits proliferation of ER-expressing cancer cells.","Elacestrant | (6R)-6-(2-(Ethyl((4-(2- (ethylamino)ethyl)phenyl)methyl)amino)-4-methoxyphenyl)- 5,6,7,8-tetrahydronaphthalen-2-ol | ELACESTRANT | ER-306323 | RAD 1901 | RAD-1901 | RAD1901 | SERD/SERM RAD1901",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899256","Evaux Spring Water-based Cream","C120212","A cream containing Evaux thermal spring water, with potential moisturizing and skin protecting activities. Upon application to the skin, Evaux spring water-based cream forms a protective barrier, which prevents water loss, provides moisture to the skin, protects the skin from damage, and soothes irritated skin. The Evaux thermal spring water contains the trace elements lithium and manganese which may help heal the skin.","Evaux Spring Water-based Cream | Evoskin Cream",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890943","DPT/BCG/Measles/Serratia/Pneumococcus Vaccine","C120213","A proprietary lipid emulsion containing five vaccines: diphtheria, pertussis, tetanus (DPT), Bacille Calmette-Guerin (BCG), measles, Serratia marcescens and pneumococcal, with potential immunostimulating activity. Subcutaneous administration of the DPT/BCG/measles/Serratia/pneumococcus vaccine activates the immune system and may both abrogate tumor-induced immune tolerance and induce an antitumor immune response, which may eradicate the tumor.","DPT/BCG/Measles/Serratia/Pneumococcus Vaccine | G250 Peptide Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899464","DPT/Typhoid/Staphylococcus aureus/Paratyphoid A/Paratyphoid B Vaccine","C120214","A proprietary lipid emulsion containing five vaccines: diphtheria, pertussis, tetanus (DPT), typhoid, Staphylococcus aureus, paratyphoid A and paratyphoid B, with potential immunostimulating activity. Subcutaneous administration of the DPT/typhoid/Staphylococcus aureus/paratyphoid A/paratyphoid B vaccine activates the immune system and may both abrogate tumor-induced immune tolerance and induce an antitumor immune response, which may eradicate the tumor.","DPT/Typhoid/Staphylococcus aureus/Paratyphoid A/Paratyphoid B Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897969","Pen Needle","C120216","A single use, hollow needle embedded in a plastic hub, which is then attached to a preloaded syringe (pen) to facilitate the delivery of medication.","Pen Needle | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053535","CDISC Clinical Classification NSA-16 Test Code Terminology","C120993","Test codes of clinical classification questions associated with the Model for Negative Symptom Assessment-16 (NSA-16) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification NSA-16 Test Code Terminology | CC-NSA-16 TESTCD | NSA01TC | Negative Symptom Assessment-16 Clinical Classification Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055602","APACHE II Clinical Classification Question","C120994","A question associated with the APACHE II clinical classification.","APACHE II Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053727","BODE Index Clinical Classification Question","C120995","A question associated with the BODE Index clinical classification.","BODE Index Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055252","Child-Pugh Clinical Classification Question","C120996","A question associated with the Child-Pugh clinical classification.","Child-Pugh Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053749","MELD Clinical Classification Question","C120997","A question associated with the MELD clinical classification.","MELD Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054421","nanoparticle-encapsulated docetaxel","C121961","A polymeric nanoparticle (PNP) formulation containing the poorly water-soluble taxane docetaxel, a semi-synthetic analogue of paclitaxel, with antineoplastic activity. Upon intravenous administration of the docetaxel nanoparticle CPC634, the nanoparticles are able to accumulate at the tumor site due to the unique characteristics of the tumor's vasculature, while avoiding normal, healthy tissue. In turn, docetaxel is released locally at the target tumor site, binds specifically to the beta-tubulin subunit of the microtubule, stabilizing tubulin and inhibiting microtubule disassembly, which results in cell-cycle arrest at the G2/M phase, thereby preventing cell proliferation. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response. Compared to docetaxel alone, this formulation may enhance stability and improve delivery, thereby increasing docetaxel's efficacy while avoiding systemic exposure, which minimizes its toxicity.","Docetaxel Nanoparticle CPC634 | CPC 634 | CPC-634 | CPC634 | CriPec (R) Docetaxel | Docetaxel containing CriPec (R) Nanoparticles | Docetaxel-containing CriPec (R) Nanoparticles CPC634 | Nanoparticle-encapsulated Docetaxel CPC634",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2351151","Carbon C 11 PBR-28","C121962","A radioconjugate composed of a ligand for the 18 kDa translocator protein (TSPO) conjugated to the radioisotope carbon C 11, that can be used as a diagnostic imaging agent to detect TSPO-expressing cells using positron emission tomography (PET). Upon administration of carbon C 11 PBR-28, the PBR-28 moiety targets and binds to TSPO-expressing cells. Upon PET, carbon C 11 can be detected and TSPO-expressing cells can be visualized. This can facilitate detection of inflammatory sites and cancer cells. TSPO, also called the peripheral benzodiazepine receptor (PBR), is found on the outer mitochondrial membrane and is overexpressed on a variety of cancer cells and during inflammation.","Carbon C 11 PBR-28 | (11C) N-ACETYL-N-(2-METHOXYBENZYL)-2-PHENOXY-5-PYRIDINAMINE | (11C)PBR-28 | Acetamide, N-((2-(methoxy-11C)-phenyl)methyl)-N-(6-phenoxy-3-pyridinyl)- | PBR-28 C-11 | [11C] PBR28",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053528","Cribriform Neuroepithelial Tumor","C121963","A very rare, nonrhabdoid, intraventricular tumor with relatively favorable prognosis.  It is characterized by the presence of neuroepithelial cells forming cribriform patterns, trabeculae, epithelial membrane antigen immunopositivity on epithelial surfaces, and loss of nuclear INI 1 expression.","Cribriform Neuroepithelial Tumor | CRINET",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054534","Meningioangiomatosis","C121967","A rare vascular malformation in the cerebral cortex and overlying leptomeninges.  It can occur sporadically or in association with neurofibromatosis type 2.","Meningioangiomatosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053530","Cutaneous Neurocristic Hamartoma","C121968","A rare dermal and subcutaneous lesion that results from the aberrant development of neural crest-derived melanocytes.  It affects the head and neck with a predilection for the scalp.  It presents as a slowly enlarging multinodular plaque.  Morphologically is characterized by the presence of melanocytes and structures with schwannian differentiation in the dermis and subcutaneous tissue.","Cutaneous Neurocristic Hamartoma | CNH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054900","Germ Cell Degeneration","C120884","Disturbance of cellular integrity and deterioration of germ cells.","Germ Cell Degeneration | GERM CELL DEGENERATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054898","Germ Cell Depletion","C120885","Reduction in the number of germ cells.","Germ Cell Depletion | GERM CELL DEPLETION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054899","Germ Cell Depletion and Germ Cell Degeneration","C120886","A finding of both germ cell depletion and germ cell degeneration.","Germ Cell Depletion and Germ Cell Degeneration | GERM CELL DEPLETION/GERM CELL DEGENERATION | Germ Cell Degeneration/Germ Cell Depletion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268731","Glomerulopathy","C120887","Chronic degenerative changes in the glomeruli characterized by loss of cellularity of glomerular capillary tufts and acellular deposition of immunoglobulins.","Glomerulopathy | GLOMERULOPATHY",,,,,,,,,,,,,,,"4059452","Glomerular disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0178664","Glomerulosclerosis","C120888","A hardening of the kidney glomerulus caused by scarring of the blood vessels.","Glomerulosclerosis | GLOMERULOSCLEROSIS | Glomerular Sclerosis",,,,,,,,,,,,,,,"261071|4221289","Glomerulosclerosis|Glomerulosclerosis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C4054755","Hyperplasia and Metaplasia","C120890","A finding of both hyperplastic and metaplastic changes in a pathologic process.","Hyperplasia and Metaplasia | HYPERPLASIA/METAPLASIA | Metaplasia/Hyperplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3554224","Leptin Deficiency","C120384","Deficiency of the adipose tissue-derived peptide hormone leptin, associated with loss-of-function mutation(s) in the LEP gene.","Leptin Deficiency | ",,,,,,,,,,,,,,,"45763687","Congenital leptin deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055350","Brain-Derived Neurotropic Factor Deficiency","C120385","Presumed deficiency of brain-derived neurotropic factor (BDNF), associated with loss-of-function mutation(s) in the BDNF gene.","Brain-Derived Neurotropic Factor Deficiency | BDNF Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3554225","Leptin Receptor Deficiency","C120386","Deficiency or dysfunction of the leptin receptor associated with loss-of-function mutation(s) in the LEPR gene.","Leptin Receptor Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054427","NSA-16 Clinical Classification Question","C120998","A question associated with the NSA-16 clinical classification.","NSA-16 Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055404","BACS Functional Test Question","C120999","A question associated with the BACS functional test.","BACS Functional Test Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0072667","pyrene","C1209","A parent class of polycyclic aromatic hydrocarbons containing four fused rings. (IUPAC 1998)","Pyrene | Benzo(def)phenanthrene | PYRENE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055311","CRQ-SAS First Administration Version Questionnaire Question","C121000","A question associated with the CRQ-SAS First Administration Version questionnaire.","CRQ-SAS First Administration Version Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055290","CRQ-SAS Follow-Up Administration Version Questionnaire Question","C121001","A question associated with the SAS Follow-Up Administration Version questionnaire.","CRQ-SAS Follow-Up Administration Version Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1859974","Isolated Glucocorticoid Deficiency","C120446","Abnormally low or absent production of glucocorticoids, characterized by unresponsiveness to adrenocorticotropic hormone. It is hereditary and potentially lethal.","Isolated Glucocorticoid Deficiency | Familial Glucocorticoid Deficiency",,,,,,,,,,,,,,,"35608125","Familial glucocorticoid deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054251","Pancreaticobiliary Malunion","C121970","An abnormality of the pancreatic and biliary ducts in which their junction occurs above the duodenal wall.","Pancreaticobiliary Malunion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055240","Chloroquine Compound","C121321","A pharmaceutical agent initially used to cure or prevent malaria. A principal rheumatologic indication is the treatment of autoimmune disease including dermatomyositis, lupus, rheumatoid arthritis, and Sjogren syndrome.","Chloroquine Compound | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1525410","Cyclic Citrullinated Peptide Antibody","C121326","An autoantibody directed against peptides or proteins whose arginine residues have been enzymatically converted to citrulline. It is often associated with rheumatoid arthritis.","Cyclic Citrullinated Peptide Antibody | ACPA | Anti-Keratin Antibody | Anti-Perinuclear Factor Antibody | CCP",,,,,,,,,,,,,,,"4228925","Cyclic citrullinated peptide antibody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2732494","Childhood Health Assessment Questionnaire","C121329","A pediatric modification of the Stanford Health Assessment Questionnaire (HAQ) used in the evaluation of functional disability and discomfort in children.","Childhood Health Assessment Questionnaire | C-HAQ | CHAQ",,,,,,,,,,,,,,,"40480169","Childhood health assessment questionnaire",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053531","Child Health Questionnaire","C121330","A collection of general quality of life surveys that measures physical and psychosocial concepts in children.","Child Health Questionnaire | CHQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3535910","pentetate calcium","C120569","The calcium salt form of diethylene triamine pentaacetate (Ca-DTPA or pentetate calcium), with chelating activity. Upon administration, Ca-DTPA loses the Ca ion to form stable chelates with metal ions because DTPA has a higher affinity for heavy metal ions than for Ca ions. Specifically, this agent is able to bind to and form strong complexes with radioactive plutonium, americium, and cerium after internal contamination. The formation of these heavy metal chelates enhances radionuclide excretion. enhances radionuclide excretion.","Pentetate Calcium | Ca-DTPA | Calcium DTPA | Calcium N,N-bis(2-(bis(carboxymethyl)amino)ethyl)glycinate (1:1) | Diethylenetriaminepentaacetic Acid, Calcium Salt | PENTETATE CALCIUM | Pentetic Acid Calcium | pentetic acid calcium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043501","Pentetate Zinc","C120570","The zinc salt form of diethylene triamine pentaacetate (Zn-DTPA or pentetate zinc) with chelating activity. Upon administration, Zn-DTPA loses the Zn ion to form stable chelates with metal ions because DTPA has a higher affinity for heavy metal ions than for Zn ions. Specifically, this agent is able to bind to and form strong complexes with the radioactive plutonium, americium, and cerium after internal contamination. The formation of these heavy metal chelates enhances radionuclide excretion.","Pentetate Zinc | Diethylenetriaminepentaacetic Acid, Zinc Salt | PENTETATE ZINC | Zinc DTPA | Zinc, (((Carboxymethylimino)bis(ethylenenitrilo))tetraacetato)- | Zincate(3-), (N,N-bis(2-(((carboxy-kappaO)methyl)(carboxymethyl)amino-kappaN)ethyl)glycinato(5-)-kappaN,kappaO)-, Trihydrogen | Zn-DTPA | ZnDTPA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049596","MAFA wt Allele","C120572","Human MAFA wild-type allele is located in the vicinity of 8q24.3 and is approximately 11 kb in length. This allele, which encodes transcription factor MafA protein, is involved in the modulation of insulin gene expression.","MAFA wt Allele | MAF bZIP Transcription Factor A wt Allele | RIPE3B1 | RIPE3b1 | hMafA | v-Maf Avian Musculoaponeurotic Fibrosarcoma Oncogene Homolog A Gene | v-Maf Musculoaponeurotic Fibrosarcoma Oncogene Homolog A (Avian) Gene | v-Maf Musculoaponeurotic Fibrosarcoma Oncogene Homolog A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3161105","Neuroendocrine Cell Hyperplasia of Infancy","C120169","A form of interstitial lung disease characterized by increased numbers of pulmonary neuroendocrine cells, typically presenting in the first year of life with persistent tachypnea, retractions, crackles and hypoxemia that has a highly specific chest CT pattern that includes ground-glass opacities and air-trapping.","Neuroendocrine Cell Hyperplasia of Infancy | NEHI",,,,,,,,,,,,,,,"45771019","Neuroendocrine cell hyperplasia of infancy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055195","Congenital Isolated Thyroid Stimulating Hormone Deficiency","C120449","Thyroid stimulating hormone (TSH) deficiency associated with mutations(s) in the TSHB gene that encodes thyrotropin subunit beta.","Congenital Isolated Thyroid Stimulating Hormone Deficiency | Congenital Isolated TSH Deficiency | Congenital TSH Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055224","Clinical Outcome Assessment Subsection Name","C120461","The textual header or description used to group a set of questions or tests in a clinical outcome assessment instrument.","Clinical Outcome Assessment Subsection Name | COA Subsection Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242708","Disease-Modifying Antirheumatic Drug","C121332","A pharmaceutical agent that is categorized by its ability to alter the progression of autoimmune disease.","Disease-Modifying Antirheumatic Drug | DMARD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0451208","Health Assessment Questionnaire","C121546","A comprehensive, self-report survey consisting of twenty questions intended as a functional measure of an individual's current ability to accomplish the activities of daily living.","Health Assessment Questionnaire | HAQ | Stanford Health Assessment Questionnaire",,,,,,,,,,,,,,,"4164977","Health assessment questionnaire",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4050142","Numeric Rating Scale","C121548","A psychometric response scale to assess subjective characteristics or symptoms, which relies upon a scale of numeric result values in between two fixed end-points.","Numeric Rating Scale | NRS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0458261","Verbal Rating Scale","C121549","A psychometric response scale to assess subjective characteristics or symptoms, which relies upon a scale of word values along a continuum in between two fixed end-points.","Verbal Rating Scale | VRS",,,,,,,,,,,,,,,"4133653","Verbal rating scale",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053588","Anti-EGFR Monoclonal Antibody SYN004","C121550","A glyco-engineered monoclonal antibody directed against the receptor tyrosine kinase epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, anti-EGFR monoclonal antibody SYN004 binds to the extracellular domain of EGFR, which prevents ligand binding and the subsequent activation and dimerization of the receptor. This inhibits the activation of EGFR-mediated signaling pathways and inhibits EGFR-dependent tumor cell proliferation. EGFR, a member of the EGFR receptor tyrosine kinase family, may be overexpressed on the cell surfaces of various tumor cell types.","Anti-EGFR Monoclonal Antibody SYN004 | SYN004",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055273","Carbon C 14 Roniciclib","C121551","An orally bioavailable radioconjugate composed of roniciclib, a cyclin dependent kinase (CDK) inhibitor, radiolabeled with carbon C 14, with potential use for evaluating the pharmacokinetic profile of roniciclib. Roniciclib selectively binds to and inhibits the activity of various CDK subtypes, which leads to cell cycle arrest and an inhibition of tumor cell proliferation. Labeling of roniciclib with the radioactive tracer carbon C 14 allows for the evaluation of roniciclib's pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME). CDKs, serine/threonine kinases overexpressed in various tumor cell types, play key roles in the regulation of both cell cycle progression and cellular proliferation.","Carbon C 14 Roniciclib | [14C]-BAY1000394 | [14C]-roniciclib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053742","Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes","C121552","Peripheral blood lymphocytes (PBLs) transduced with a gene encoding for a thyroglobulin (TG)-specific murine T-cell receptor (mTCR), with potential antineoplastic activity. PBLs are harvested from a thyroid cancer patient, and transfected with a retroviral vector that encodes the mTCR gene specific for the human TG antigen. The transduced PBLs are then expanded in culture. When reintroduced to the patient, these anti-TG mTCR-expressing PBLs target and bind to TG-overexpressing tumor cells, which results in both cytokine secretion and tumor cell lysis. TG is a thyroid-specific protein.","Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes | Anti-thyroglobulin mTCR-transduced Autologous PBL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054229","Patient Assessment of Overall Well-Being","C121350","A patient's estimation of the overall impact of a disease on him or herself at a given time. Typically scored on a numeric rating scale or visual analogue scale.","Patient Assessment of Overall Well-Being | Patient Global Assessment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049882","Systemic Lupus International Collaborating Clinics/American College of Rheumatology-Damage Index","C121353","A clinical index used to measure accumulated organ damage from either the disease process or its sequelae, in twelve organ systems. The index scores damage regardless of cause. The definition of damage is an irreversible change in an organ or system that has occurred since the onset of systemic lupus erythematosus and is present for at least six months.","Systemic Lupus International Collaborating Clinics/American College of Rheumatology-Damage Index | SDI | SLICC/ACR Damage Index for SLE | SLICC/ACR-DI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053518","Juvenile Arthritis Disease Activity Score","C121354","A continuous measure of disease activity in juvenile arthritis related to inflammation. This validated measure has established cut points of minimal disease activity, inactive disease and remission.","Juvenile Arthritis Disease Activity Score | JA-DAS | JADAS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053515","Myositis Disease Activity Assessment Tool","C121356","A tool that assesses disease activity of extramuscular organ systems and muscle to assess patients with adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis.","Myositis Disease Activity Assessment Tool | MDAAT",,,,,,,,,,,,,,,"36684886","Myositis disease activity assessment tool",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4049613","Myositis Damage Index","C121357","A scoring system used to measure damage from myositis, complications of therapy, or other events.","Myositis Damage Index | MDI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050322","Myositis Activities Profile","C121358","An assessment of disease-specific limitations of activities of daily living in patients with polymyositis and dermatomyositis.","Myositis Activities Profile | MAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053533","Cutaneous Dermatomyositis Disease Area and Severity Index","C121359","An instrument that measures activity and damage in the skin of dermatomyositis patients.","Cutaneous Dermatomyositis Disease Area and Severity Index | CDASI",,,,,,,,,,,,,,,"3655499","Cutaneous Dermatomyositis Disease Area and Severity Index",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0699782","Manual muscle testing","C121360","A graded muscle strength measurement performed as part of a physical examination without the need for specialized equipment.","Manual Muscle Testing | MMT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053513","Quantitative Muscle Testing","C121361","Measurement of maximum isometric force generation from a muscle group; performed with specialized equipment.","Quantitative Muscle Testing | QMT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053489","Fluorine F 18 Fluorthanatrace","C121942","A radiotracer consisting of an analogue of the poly(ADP-ribose) polymerase 1 (PARP1) inhibitor rucaparib radiolabeled with the positron emitting isotope fluorine F 18, which can potentially be used for the imaging of PARP1 expression using positron emission tomography (PET). Upon administration, fluorine F 18 fluorthanatrace targets and binds to PARP1. Upon PET, PARP1-expressing tumor cells can be visualized. PARP1, which is overexpressed in many cancer cell types, catalyzes post-translational ADP-ribosylation of nuclear proteins and plays a key role in the repair of DNA strand breaks.","Fluorine F 18 Fluorthanatrace | FLUORTHANATRACE F-18 | [18F]FTT | [18F]FluorThanatrace",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053640","ASK1 inhibitor GS-4997","C121943","An orally bioavailable inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with potential anti-inflammatory, antineoplastic and anti-fibrotic activities. Upon oral administration, selonsertib targets and binds to the catalytic kinase domain of ASK1 in an ATP-competitive manner, thereby preventing its phosphorylation and activation. This prevents the phosphorylation of downstream kinases, such as c-Jun N-terminal kinases (JNKs) and p38 mitogen-activated protein kinase (p38 MAPK). By preventing the activation of ASK1-dependent signal transduction pathways, GS-4997 prevents the production of inflammatory cytokines, down-regulates the expression of genes involved in fibrosis, suppresses excessive apoptosis and inhibits cellular proliferation. ASK1, also called mitogen-activated protein kinase kinase kinase 5 (MAP3K5), is activated in response to oxidative and endoplasmic reticulum (ER) stress, calcium influx and infection. It plays a key role in the development of certain cardiovascular and neurodegenerative diseases, diabetes, as well as certain types of cancer.","Selonsertib | GS-4997 | SELONSERTIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053506","Rapid-Onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation","C121944","A very rare disorder that appears after the first year and a half of life in previously healthy children. It is characterized by rapid-onset weight gain, hypothalamic dysfunction, breathing abnormalities, and autonomic system dysregulation. The hypothalamic dysfunction manifestations include inability to maintain normal water balance, high prolactin levels, low thyroid, low cortisol, and early or late puberty. The breathing abnormalities include sleep apnea and alveolar hypoventilation, requiring ventilation support. The autonomic system dysregulation includes eye abnormalities, intestinal abnormalities, temperature dysregulation, and low heart rhythm. This disorder requires early recognition because it may lead to cardiorespiratory arrest. Up to 40% of the patients develop tumors of neural crest origin.","Rapid-Onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation | ROHHAD | ROHHAD Syndrome | Rapid-Onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL476349","Heritable Pulmonary Arterial Hypertension","C121945","A rare, progressive, autosomal dominant inherited disorder. It is caused by mutation in the BMPR2 gene in most cases. It is characterized by abnormally high blood pressure in the pulmonary artery, caused by obstruction and obliteration of the small pulmonary arteries.","Heritable Pulmonary Arterial Hypertension | HPAH",,,,,,,,,,,,,,,"44783618","Heritable pulmonary arterial hypertension",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055116","Drug- and Toxin-Induced Pulmonary Arterial Hypertension","C121946","A rare, progressive disorder characterized by abnormally high blood pressure in the pulmonary artery caused by obstruction and obliteration of the small pulmonary arteries due to drugs or toxins. The stimulant appetite suppressant aminorex fumarate and other stimulant anorectics such as the serotonin reuptake inhibitor dexfenfluramine, as well as other agents, including illegal substances have been reported as causative agents.","Drug- and Toxin-Induced Pulmonary Arterial Hypertension | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0948817","Catheter-Related Inflammation","C121604","Inflammation associated with the use of a catheter.","Catheter-Related Inflammation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054043","Secondary Peripheral Chondrosarcoma","C121882","A chondrosarcoma arising within the cartilaginous cap of a pre-existing osteochondroma.","Secondary Peripheral Chondrosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053667","anti-FGFR2 antibody-drug conjugate BAY1187982","C121212","An antibody-drug conjugate (ADC) directed against the fibroblast growth factor receptor type 2 (FGFR2) and conjugated to an as of yet unidentified toxin, with potential antineoplastic activity. Upon intravenous administration, aprutumab ixadotin binds to FGFR2. Upon binding, the toxin selectively induces cell death, through an as of yet undisclosed mechanism of action, in FGFR2-expressing tumor cells. FGFR2, a receptor tyrosine kinase upregulated in many tumor cell types, plays an essential role in tumor cell proliferation, differentiation and survival.","Aprutumab Ixadotin | ADC BAY1187982 | APRUTUMAB IXADOTIN | BAY 1187982 | BAY1187982",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053666","BET Inhibitor BAY1238097","C121213","An inhibitor of the Bromodomain (BRD) and Extra-Terminal domain (BET) family of proteins, with potential antineoplastic activity. Upon administration, the BET inhibitor BAY1238097 binds to the acetylated lysine recognition motifs on the BRD of BET proteins, thereby preventing the interaction between BET proteins and histones. This disrupts chromatin remodeling and prevents the expression of certain growth-promoting genes. This leads to an inhibition of tumor cell growth. BET proteins (BRD2, BRD3, BRD4 and BRDT) are transcriptional regulators that bind to acetylated lysines on the tails of histones H3 and H4, and regulate chromatin structure and function; they play an important role in the modulation of gene expression during development and cellular growth.","BET Inhibitor BAY1238097 | BAY 1238097 | BAY-1238097 | BAY1238097",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054425","Nanocell-encapsulated miR-16-based microRNA Mimic","C121214","A nanoparticle-based formulation composed of a microRNA 16 (miR-16) mimic, a double-stranded, 23 base pair, synthetic RNA molecule, encapsulated in nonliving bacterial minicells and coated with anti-epidermal growth factor receptor (EGFR) antibodies, with potential antineoplastic activity. Upon intravenous administration and subsequent transfection, nanocell-encapsulated miR-16-based microRNA mimic targets EGFR-expressing tumor cells and facilitates the restoration of expression of the miR-16 family. This leads to the downregulation of the expression of tumor promoting genes and the inhibition of tumor cell growth. In addition, restoration of miR-16 expression sensitizes the tumor cell to certain chemotherapeutic agents. miR-16, a family of microRNAs, is critical to the regulation of gene expression and appears to have a tumor suppressor function; its expression is downregulated in various cancer cell types.","Nanocell-encapsulated miR-16-based microRNA Mimic | TargomiRs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055160","Deep Circumscribed Morphea","C121651","Circumscribed morphea in which the lesions are found in the deep dermis, panniculus, fascia, or superficial muscle.","Deep Circumscribed Morphea | Deep Morphea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4044528","Anti-mesothelin-Pseudomonas Exotoxin 24 Cytolytic Fusion Protein LMB-100","C121653","An anti-mesothelin (MSLN) recombinant cytolytic fusion protein (cFP) composed of a humanized Fab fragment of anti-MSLN monoclonal antibody SS1 linked to a truncated and de-immunized 24 kDa fragment of the Pseudomonas exotoxin (PE) (PE24), with potential antineoplastic activity. Upon intravenous administration of anti-MSLN-PE24 cFP LMB-100, the anti-MSLN moiety targets and binds to MSLN-expressing tumor cells. Upon binding and internalization through endocytosis, the toxin moiety ADP-ribosylates and inactivates eukaryotic elongation factor 2 (eEF2), preventing the elongation step of protein synthesis and leading to both an inhibition of protein synthesis and an induction of MSLN-expressing tumor cell apoptosis. MSLN, a tumor-associated antigen overexpressed in a variety of cancer cell types, plays a key role in tumor cell proliferation and migration. The engineered PE24 portion of LMB-100 does contain the targeting domain and furin cleavage site, which are needed for cytotoxicity, but most of the translocation domain II is deleted and the catalytic domain III contains point mutations, which result in the deletion and silencing of most T- and B-cell epitopes; therefore, the immunogenicity and toxicity is reduced compared to non-engineered PE toxin, which allows for the administration of larger doses of LMB-100.","Anti-mesothelin-Pseudomonas Exotoxin 24 Cytolytic Fusion Protein LMB-100 | Anti-MSLN-PE24 cFP LMB-100 | LMB-100 | RG 7787 | RG-7787 | RG7787 | RO 6927005 | RO6927005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3854394","TEMPI Syndrome","C121656","A rare syndrome characterized by telangiectasias, elevated erythropoietin level and erythrocytosis, monoclonal gammopathy, perinephric fluid collections, and intrapulmonary shunting.  It is best classified as a type of plasma cell dyscrasia with paraneoplastic manifestations.","TEMPI Syndrome | ",,,,,,,,,,,,,,,"36713680","TEMPI syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0318855","Porcine Epidemic Diarrhea Virus","C121657","An alphacoronavirus that infects the cells lining the small intestine of the pig. It is the causative agent of porcine epidemic diarrhea.","Porcine Epidemic Diarrhea Virus | PEDV",,,,,,,,,,,,,,,"4203635","Porcine epidemic diarrhea virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1300303","H5N2 Avian Influenza Virus","C121658","A highly pathogenic subtype of avian influenza A virus. This virus was responsible for a large outbreak of avian influenza in commercial flocks, starting in late 2014 and continuing into 2015.","H5N2 Avian Influenza Virus | H5N2 Influenza Virus | Highly Pathogenic Avian Influenza Virus | Highly Pathogenic H5N2 Avian Influenza Virus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0406834","Wound Discharge","C121616","The material exuded from a wound, either surgical or traumatic.","Wound Discharge | Wound Drainage",,,,,,,,,,,,,,,"35621982|4343235","Wound discharge observable|Wound discharge",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C4054897","Germinomatous Germ Cell Tumor","C121618","A term that refers to germinoma, seminoma, or dysgerminoma.","Germinomatous Germ Cell Tumor | Seminoma/Dysgerminoma/Germinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054923","Fucosylated Umbilical Cord Blood Regulatory T Cells","C121830","Fucosylated, human umbilical cord blood (UCB)-derived regulatory T-cells (Tregs), with potential immunomodulating activity. Ex vivo, Tregs are isolated from cord blood, expanded, and fucosylated. Upon infusion, the fucosylated UCB Tregs modulate immune responses and induce tolerance to allogeneic transplants, such as hematopoietic stem cell transplants (HSCTs). This suppresses graft-versus-host disease (GVHD). Fucosylation improves the activity of Tregs and reduces the amount of Tregs that need to be expanded and infused.","Fucosylated Umbilical Cord Blood Regulatory T Cells | Fucosylated UCB Tregs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055372","Bone Tumor of Undefined Neoplastic Nature","C121831","A group of lesions that affect the bone and have the appearance and cytogenetic or molecular characteristics of neoplasms but the clinical behavior is suggestive of a non-neoplastic process.","Bone Tumor of Undefined Neoplastic Nature | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053985","SPL Suspect Drug Classification of Notification Terminology","C121832","Terminology used to specify whether a suspect drug or product has been determined to have been fraudulently obtained, produced or altered intentionally to deceive, unfit for distribution, diverted for illicit use, or stolen.","SPL Suspect Drug Classification of Notification Terminology | Structured Product Labeling Suspect Drug Classification of Notification Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053984","SPL Suspect Drug Use Terminology","C121833","Terminology used to specify in whom a suspect drug or product was approved to be used.","SPL Suspect Drug Use Terminology | Structured Product Labeling Suspect Drug Use Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2609232","Counterfeit Product","C121834","A product has been determined to be counterfeit.","Counterfeit Product | Counterfeit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053575","USP14/UCHL5 Inhibitor VLX1570","C121215","An inhibitor of the 19S proteasome-specific deubiquitylating enzymes (DUBs) USP14 and UCHL5, with apoptosis-inducing and antineoplastic activities. Upon administration, VLX1570 specifically binds to both USP14 and UCHL5, thereby blocking their deubiquitylating activity. This blocks the ubiquitin proteasome degradation pathway, prevents the degradation of defective proteins, and leads to an accumulation of poly-ubiquitylated proteins. This induces the unfolded protein response (UPR) and results in both the induction of tumor cell apoptosis and the inhibition of tumor cell growth. USP14 and UCHL5, overexpressed in various tumor cell types, play a key role in the correct folding and deubiquitination of proteins.","USP14/UCHL5 Inhibitor VLX1570 | VLX-1570 | VLX1570",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053579","P-cadherin Inhibitor PCA062","C121216","An agent that inhibits p-cadherin, with potential antineoplastic activity. Upon intravenous infusion, PCA062 binds to and inhibits the activity of p-cadherin. Inhibition of the activity of p-cadherin may inhibit both invasion and proliferation of p-cadherin expressing tumor cells. P-cadherin, a cell-surface protein and member of the cadherin family, is overexpressed in a variety of tumors and plays a role in cell adhesion, motility, invasion, and proliferation.","P-cadherin Inhibitor PCA062 | P-CAD Inhibitor PCA062 | P-cadherin Antagonist PCA062 | PCA062",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0558066","Intrusive Thought","C121661","An unwelcome and persistent idea, image or thought that is upsetting to an individual.","Intrusive Thought | ",,,,,,,,,,,,,,,"4021190","Intrusive thoughts",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054484","Mixture of Embryonal and Alveolar Features Present","C121662","A morphologic finding indicating the presence of a mixture of embryonal and alveolar components in a rhabdomyosarcoma.","Mixture of Embryonal and Alveolar Features Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053608","adenosine A2A receptor antagonist PBF-509","C121664","An orally bioavailable adenosine A2A receptor (A2AR) antagonist, with potential antineoplastic activity. Upon administration, A2AR antagonist PBF-509 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This abrogates the adenosine/A2AR-mediated inhibition of T-lymphocytes and activates a T-cell-mediated immune response against tumor cells, thereby reducing proliferation of susceptible tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often produced in excess by cancer cells.","Taminadenant | 4-Pyrimidinamine, 5-Bromo-2,6-di-1H-pyrazol-1-yl- | A2AR Antagonist PBF-509 | PBF-509 | TAMINADENANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049974","Prostate Mechanical Imager","C121712","A transrectal probe equipped with a pressure sensor array and position tracking sensor that translates the prostate's elastic properties into a digital three-dimensional map of the tested organ. Similar in concept to digital rectal examination (DRE), PMI can minimize subjectivity by providing an easy-to-use and accurate tool for visualizing abnormalities of the prostate.","Prostate Mechanical Imager | PMI | Prostate Mechanical Imaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050475","Diverted Product","C121835","A product has been determined to have been diverted for illicit use or distribution.","Diverted Product | Diverted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053987","Stolen Product","C121836","A product has been determined to have been stolen.","Stolen Product | Stolen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054710","Intentionally Adulterated Product","C121837","A product has been determined to have been intentionally adulterated.","Intentionally Adulterated Product | Intentional adulteration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053894","Unfit for Distribution Product","C121838","A product has been determined to be unfit for distribution.","Unfit for Distribution Product | Product Unfir for Distribution | Unfit for distribution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054930","Fraudulently Obtained Product","C121839","A product has been determined to have been obtained fraudulently.","Fraudulently Obtained Product | Fraudulent transaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055444","Approved for Non-Human Use Product","C121841","A product has been approved for use in non-humans.","Approved for Non-Human Use Product | Other than Human Use | Product Approved for Non-Human Use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055162","De Novo Classification Request","C121843","A premarket submission made to the FDA for classification of a device for which general controls or general and special controls provide a reasonable assurance of safety and effectiveness, but for which there is no legally marketed predicate device.","De Novo Classification Request | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3890896","PROKR2 wt Allele","C118610","Human PROKR2 wild-type allele is located in the vicinity of 20p12.3 and is approximately 15 kb in length. This allele, which encodes prokineticin receptor 2 protein, plays a role in ligand-dependent G protein-coupled receptor signaling. Mutation of the gene is associated with hypogonadotropic hypogonadism 3 with or without anosmia.","PROKR2 wt Allele | GPR73L1 | GPR73b | GPRg2 | HH3 | KAL3 | Kallmann Syndrome 3 (Autosomal Dominant) Gene | PKR2 | Prokineticin Receptor 2 wt Allele | dJ680N4.3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1173927","Prokineticin Receptor 2, Human","C118611","Prokineticin receptor 2 (384 aa, ~44 kDa) is encoded by the human PROKR2 gene. This protein is involved in the modulation of ligand-dependent signaling pathways.","Prokineticin Receptor 2 | G Protein-Coupled Receptor 73-Like 1 | G-Protein Coupled Receptor 73-Like 1 | GPR73b | GPRg2 | PK-R2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889721","PRR","C118613","Human NECTIN1 wild-type allele is located in the vicinity of 11q23.3 and is approximately 106 kb in length. This allele, which encodes nectin-1 protein, is involved in both viral entry and the promotion of cell-cell adhesion. Mutation of the gene is associated with both cleft lip/palate-ectodermal dysplasia syndrome and orofacial cleft 7.","NECTIN1 wt Allele | CD111 | CLPED1 | ED4 | Ectodermal Dysplasia 4 (Margarita Island Type) Gene | HIgR | HV1S | HVEC | Herpes Simplex Virus Type 1 Sensitivity Gene | Nectin Cell Adhesion Molecule 1 wt Allele | OFC7 | PRR | PRR1 | PVRL1 | PVRR | PVRR1 | Poliovirus Receptor-Related 1 (Herpesvirus Entry Mediator C) Gene | SK-12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0234665","Lid Retraction","C118866","Abnormal superior displacement of resting upper lid margin or abnormal inferior displacement of resting lower lid margin.","Lid Retraction | ",,,,,,,,,,,,,,,"443794","Retraction of eyelid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897569","Slipped Extraocular Muscle","C118867","Weakness of extraocular muscle function as a result of inadequate securing of the muscle to the sclera during strabismus surgery.","Slipped Extraocular Muscle | Slipped Muscle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898627","Laceration of the Globe","C118868","Full-thickness wound of the eyewall (cornea and/or sclera) caused by a sharp object.","Laceration of the Globe | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897968","Penetrating Open Globe Injury","C118869","Full thickness wound of the eyewall (cornea and/or sclera) caused by the entry of a sharp object into the eye. (adapted from the Birmingham Eye Trauma Terminology System (BETTS))","Penetrating Open Globe Injury | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897952","Perforating Open Globe Injury","C118870","Open globe injury with both entrance and exit wounds in the eyewall (cornea and/or sclera) caused by the same object.","Perforating Open Globe Injury | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0339052","Ruptured Globe","C118871","Full thickness wound of the eyewall (cornea and/or sclera) due to blunt trauma. (adapted from the Birmingham Eye Trauma Terminology System (BETTS))","Ruptured Globe | ",,,,,,,,,,,,,,,"4334721","Rupture of globe",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2930835","Optic Disc Edema","C118872","Swelling of the optic disc in the absence of increased intracranial pressure.","Optic Disc Edema | ",,,,,,,,,,,,,,,"4308632","Optic disc edema",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0073184","Rhizoxin","C1218","A macrocyclic lactone. Rhizoxin binds to tubulin and inhibits microtubule assembly, thereby inducing cytotoxicity. This agent also may inhibit endothelial cell-induced angiogenic activity, which may result in decreased tumor cell proliferation. (NCI04)","Rhizoxin | RHIZOXIN | WF-1360 | rhizoxin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053590","anti-CD40 monoclonal antibody SEA-CD40","C121217","A proprietary, non-fucosylated monoclonal antibody directed against the cell surface receptor CD40 with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, cifurtilimab binds to CD40 on a variety of immune cell types, triggering both cellular proliferation and activation of antigen-presenting cells (APCs), which activates B-cells and T-cells, and enhances the immune response against tumor cells. In addition, this agent binds to the CD40 antigen present on the surfaces of tumor cells, which induces antibody-dependent cytotoxicity (ADCC), and eventually inhibits the proliferation of CD40-expressing tumor cells. CD40, a stimulatory receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells, such as macrophages, dendritic cells and various tumor cell types; it plays a key role in the activation of the immune system. The non-fucosylated antibody shows increased efficacy as compared to its fucosylated counterpart.","Cifurtilimab | Anti-CD40 Monoclonal Antibody SEA-CD40 | Anti-CD40 Monoclonal Antibody SEA-CD40 | CIFURTILIMAB | SEA CD40 | SEA-CD40",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3489514","Gallium Ga 68 Citrate","C121554","A radiopharmaceutical citrate salt form of the positron-emitting radioisotope gallium Ga 68, with potential imaging activity upon positron emission tomography (PET). Upon administration of Gallium Ga 68 citrate, the gallium Ga 3+ ion dissociates from the weak citrate chelator. As Ga3+ is very similar to iron (Fe3+) in chemical properties, this ion acts as an iron analogue. Ga3+ binds to the iron-binding protein transferrin, distributes in blood, and enters and accumulates in the extracellular fluid space of inflamed or tumor-bearing tissue. In turn, the Ga3+-transferrin complex binds to transferrin receptors and is taken up by tumor cells. Tumor cells can then be imaged upon PET. Compared to healthy cells, tumor cells have increased iron metabolism and transferrin receptor expression. Increased Ga3+ uptake is seen in inflamed and infected tissues as well.","Gallium Ga 68 Citrate | (68)Ga-citrate | 68Ga-Citrate | GALLIUM CITRATE GA-68 | Gallium-68 Citrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL494053","Back Arching","C121556","A convex curvature of the spine that occurs when an individual thrusts forward the shoulders and pulls back the abdomen.","Back Arching | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333271","Bloody Discharge","C121557","The leaking of serosanguinous fluids from an orifice or wound.","Bloody Discharge | Bloody Drainage",,,,,,,,,,,,,,,"4144054|4239375","Bloody discharge|Bloody discharge",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0235744","Breath Holding","C121558","Episodic apnea, which is more common in young children and usually resolves by age six.","Breath Holding | Breath Holding Spell | Breath-holding Spell | Breath-holding spell",,,,,,,,,,,,,,,"4233530","Interrupted breathing",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0417713","Cat Bite","C121560","A wound received from the teeth of a cat.","Cat Bite | ",,,,,,,,,,,,,,,"4316183","Cat bite",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1135342","Cystic Fibrosis Pulmonary Exacerbation","C121562","An acute episode of worsening pulmonary symptoms related to cystic fibrosis.","Cystic Fibrosis Pulmonary Exacerbation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268647","Lysinuric Protein Intolerance","C121563","A disorder caused by the inability to digest and use lysine, arginine, and ornithine. Lysinuric protein intolerance is caused by mutations in the SLC7A7 gene. y+L amino acid transporter 1, the product of the SLC7A7 gene, is involved in transporting lysine, arginine, and ornithine between cells in the body.","Lysinuric Protein Intolerance | ",,,,,,,,,,,,,,,"4124551","Lysinuric protein intolerance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268120","Adenine Phosphoribosyltransferase Deficiency","C121564","An inherited condition caused by mutations in the APRT gene that affects the kidneys and urinary tract. The most common feature of this condition is recurrent kidney stones.","Adenine Phosphoribosyltransferase Deficiency | ",,,,,,,,,,,,,,,"4050169","Deficiency of AMP pyrophorylase",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0406586","Neonatal Progeroid Syndrome","C121565","A rare autosomal recessive disorder associated with abnormalities in bone maturation, and lipids and hormone metabolism and characterized by intrauterine growth retardation, failure to thrive, short stature, a progeroid appearance, hypotonia, variable mental impairment, and death in childhood. Its cause is unknown.","Neonatal Progeroid Syndrome | Wiedemann-Rautenstrauch Syndrome",,,,,,,,,,,,,,,"4032912","Neonatal pseudo-hydrocephalic progeroid syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054121","Rat Insulinoma","C121566","An insulin-producing neuroendocrine tumor arising from beta cells of the rat pancreas.","Rat Insulinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054120","Rat Neuroblastoma","C121567","A tumor of the rat that arises from nerve tissue outside of the central nervous system.","Rat Neuroblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055461","Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein","C121167","An Escherichia coli periplasm-expressed tetrameric fusion protein composed of four single-chain variable regions (scFv) of the murine immunoglobulin (Ig) G2a anti-CD20 monoclonal antibody B9E9 fused to the streptavidin (SA) gene of Streptomyces avidinii (scFv-SA), with potential use in pretargeted radioimmunotherapy (PRIT). Upon intravenous administration of the anti-CD20 B9E9 scFv-SA fusion protein, this agent targets and binds to CD20-expressing tumor cells. Subsequently, a biotinylated N-acetylgalactosamine-containing clearing agent is administered, which binds to the streptavidin moiety of the unbound fusion protein and promotes its hepatic excretion. In turn, radiolabeled DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)-biotin is administered and, due to its small size, quickly distributes. The biotin moiety efficiently binds to the SA moiety of the bound fusion protein, which localizes the biotin-conjugated radionuclide to the tumor site. CD20, a tumor-associated antigen (TAA), is overexpressed on B-cell malignancies. PRIT increases both tumor uptake and renal elimination of the radionuclide conjugate as compared to conventional radioimmunotherapy (RIT), where the radioisotope is bound to the antibody before administration; this increases the dose of radionuclide delivered to the tumor while limiting radiation exposure for normal, healthy tissues.","Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein | Anti-CD20 B9E9 scFv-SA Fusion Protein | Anti-CD20 B9E9-SA Fusion Protein | B9E9 scFvSA Fusion Protein | Recombinant Anti-CD20 B9E9 scFvSA Fusion Protein | scFv B9E9-streptavidin Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0069919","Ranpirnase","C1183","A natural homologue of ribonuclease A isolated from the eggs of the frog Rana pipiens.  Ranpirnase primarily degrades cellular transfer RNA with a substrate specificity for uridine-guanidine base-pair sequences, resulting in inhibition of protein synthesis and cytotoxicity. This agent also activates caspase-9 in mitochondria, resulting in tumor cell apoptosis. (NCI04)","Ranpirnase | Onconase | P-30 | P-30 Protein | P-30 protein | P30 | P30 Protein | RANPIRNASE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899318","EGF Gene Product","C118402","A protein encoded by the EGF gene.","EGF Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054122","Rat Adrenal Gland Pheochromocytoma","C121568","A benign or malignant neuroendocrine neoplasm of the rat sympathetic nervous system that secretes catecholamines. It arises from the chromaffin cells of the rat adrenal medulla.","Rat Adrenal Gland Pheochromocytoma | Rat Pheochromocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055460","Anti-CEA-CAR Autologous T Lymphocytes","C121784","Autologous lymphocytes transduced with a retroviral vector encoding a chimeric antigen receptor (CAR) specific for the tumor-associated antigen human carcinoembryonic antigen (CEA), with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CEA-CAR autologous T-lymphocytes target and bind to tumor cells expressing CEA, which results in the cytotoxic T-lymphocyte (CTL)-mediated cell killing of CEA-expressing tumor cells. CEA is overexpressed in various tumor cell types.","Anti-CEA-CAR Autologous T Lymphocytes | Autologous Anti-CEA CAR-T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050504","Ectomesenchymal Chondromyxoid Tumor","C121785","A rare, well circumscribed, non-encapsulated tumor that arises in the oral cavity, most often the anterior tongue.  It is characterized by the presence of round to spindle cells in a chondromyxoid or hyalinized stroma.  Recurrences have been observed in a minority of patients.","Ectomesenchymal Chondromyxoid Tumor | EMCMT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054048","Sclerosing PEComa","C121790","A tumor with perivascular epithelioid cell differentiation characterized by the presence of cords of neoplastic cells in a densely collagenous stroma.","Sclerosing PEComa | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2188153","USTS","C121793","A term that refers to a heterogeneous group of uncommon soft tissue sarcomas that do not show an identifiable line of differentiation using currently available technologies.  This is a diagnosis of exclusion and includes undifferentiated pleomorphic sarcoma (also known as malignant fibrous histiocytoma), undifferentiated spindle cell sarcoma, undifferentiated round cell sarcoma, and undifferentiated epithelioid sarcoma.","Undifferentiated Soft Tissue Sarcoma | USTS | Unclassified Soft Tissue Sarcoma | Undifferentiated Sarcoma | Undifferentiated sarcoma | Undifferentiated/Unclassified Sarcoma | Undifferentiated/Unclassified Soft Tissue Sarcoma","8805/3","Undifferentiated sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C3897855","Pro-Epidermal Growth Factor","C118403","Pro-epidermal growth factor (1207 aa, ~134 kDa) is encoded by the human EGF gene. This protein plays a role in the modulation of cell proliferation and differentiation.","Pro-Epidermal Growth Factor | ProEGF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897482","SPL License Disciplinary Action Terminology","C118404","Terminology used for representation of the information regarding license disciplinary actions concerned with medical product development, manufacturing, and marketing in the framework of the Structured Product Labeling documents.","SPL License Disciplinary Action Terminology | License Disciplinary Action | Structured Product Labeling License Disciplinary Action Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898603","License Status","C118405","The standing or condition of the license of an individual or business.","License Status | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889823","Suspended License","C118406","The temporary halt to permissions accorded to an active license.","Suspended License | Suspended",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891658","Revoked License","C118407","The permanent cessation to permissions accorded to an active license.","Revoked License | Revoked",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899310","EREG Gene Product","C118409","A protein encoded by the EREG gene.","EREG Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3888282","Proepiregulin, human","C118410","Proepiregulin (169 aa, ~19 kDa) is encoded by the human EREG gene. This protein plays a role in the promotion of cell proliferation.","Proepiregulin | EREG | Epiregulin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897168","Wholesale Drug Distributor","C118411","An individual or business licensed to distribute drugs in the state where business is conducted.","Wholesale Drug Distributor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897361","Third-Party Logistics Provider","C118412","An entity that coordinates processes involved in the provision of a product or service.","Third-Party Logistics Provider | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898193","NRG1 Gene Product","C118413","A protein encoded by the NRG1 gene.","NRG1 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3888287","Pro-Neuregulin-1, Membrane-Bound Isoform, human","C118414","Pro-neuregulin-1, membrane-bound isoform (640 aa, ~70 kDa) is encoded by the human NRG1 gene. This protein plays a role in tyrosine kinase receptor-mediated signal transduction.","Pro-Neuregulin-1, Membrane-Bound Isoform | Pro-NRG1 | Pro-Neuregulin-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898192","NRG2 Gene Product","C118415","A protein encoded by the NRG2 gene.","NRG2 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900158","ARC STC Timing Clinical Classification Question","C119090","A question associated with the ARC STC Timing clinical classification.","ARC STC Timing Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900160","ARC STC Grade Clinical Classification Question","C119091","A question associated with the ARC STC Grade clinical classification.","ARC STC Grade Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3661318","HDAC Inhibitor OBP-801","C121665","An inhibitor of histone deacetylase (HDAC) enzymes, with potential antineoplastic activity. Upon administration, OBP-801 inhibits the activity of HDACs; this results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. This leads to selective transcription of tumor suppressor genes, tumor suppressor protein-mediated inhibition of tumor cell division and induction of tumor cell apoptosis. This may inhibit proliferation of susceptible tumor cells. HDAC, which is upregulated in many tumor cell types, deacetylates chromatin histone proteins.","HDAC Inhibitor OBP-801 | Histone Deacetylase Inhibitor OBP-801 | OBP-801 | YM753",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053628","Inotersen","C121667","An antisense oligonucleotide (ASO) targeting transthyretin (TTR), which has potential use in the treatment of TTR amyloidosis (ATTR). Upon subcutaneous administration, inotersen targets and binds to messenger RNA (mRNA) for both variant and wild-type forms of TTR inside liver cells, thereby inhibiting translation of both mutant and wild-type TTR. Inhibition of TTR protein synthesis lowers TTR blood levels and decreases the amount of and/or prevents TTR amyloid deposits, which accumulate in and cause damage to various body organs and tissues. ATTR is caused by mutations in the TTR gene, which lead to TTR protein misfolding; misfolded wild-type and mutant forms of TTR protein accumulate in tissues as amyloid deposits in most ATTR patients.","Inotersen | INOTERSEN | IONIS TTRRx | ISIS 420915 | ISIS-TTR Rx | ISIS-TTRRx | TTR ASO ISIS-TTR Rx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4048234","Undifferentiated Spindle Cell Sarcoma","C121797","An undifferentiated soft tissue sarcoma characterized by the presence of a malignant spindle cell infiltrate with amphophilic or palely eosinophilic cytoplasm.","Undifferentiated Spindle Cell Sarcoma | Undifferentiated spindle cell sarcoma",,,,,,,,,,,,,,,"4321133","Spindle cell sarcoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4049718","PCDH7 wt Allele","C122004","Human PCDH7 wild-type allele is located in the vicinity of 4p15 and is approximately 426 kb in length. This allele, which encodes protocadherin-7 protein, is involved in the modulation of cell-cell adhesion.","PCDH7 wt Allele | BH-Pcdh | BH-Protocadherin (Brain-Heart) Gene | BHPCDH | PPP1R120 | Protein Phosphatase 1, Regulatory Subunit 120 Gene | Protocadherin 7 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1431403","Protocadherin-7, Human","C122005","Protocadherin-7 (1069 aa, ~116 kDa) is encoded by the human PCDH7 gene. This protein plays a role in the mediation of calcium-dependent cell-cell adhesion.","Protocadherin-7 | BH-Pcdh | Brain-Heart Protocadherin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053502","CDISC SDTM COPD Findings About Test Name Terminology","C122006","Terminology associated with the COPD findings about test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM COPD Findings About Test Name Terminology | COPD Findings About Test Name | CPFATS | SDTM-CPFATS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053503","CDISC SDTM COPD Findings About Test Code Terminology","C122007","Terminology associated with the COPD findings about test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM COPD Findings About Test Code Terminology | COPD Findings About Test Code | CPFATSCD | SDTM-CPFATSCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3854344","Cardiovascular Examination","C122008","Tests and assessments pertaining to the cardiovascular system.","Cardiovascular Examination | Cardiac Examination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1008539","Dialister","C122009","A genus of Gram-negative rod-shaped bacteria in the phylum Firmicutes.","Dialister | ",,,,,,,,,,,,,,,"4015693","Dialister",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0012146","Dientamoeba","C122010","A genus of nonflagellate trichomonad parasite in the family Dientamoebidae. Unlike most other intestinal protozoa, its life cycle has no cyst stage and infection between humans occurs during the trophozoite stage.","Dientamoeba | ",,,,,,,,,,,,,,,"4162173","Dientameba",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013101","Dracunculus","C122011","A genus of spiruroid nematode parasites in the family Dracunculidae. Dracunculus worms can reach a meter in length.","Dracunculus | ",,,,,,,,,,,,,,,"4222314","Dracunculus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054910","GALC wt Allele","C121622","Human GALC wild-type allele is located in the vicinity of 14q31.3 and is approximately 156 kb in length. This allele, which encodes galactocerebrosidase protein, is involved in catabolism of galactosylceramide. Mutations in this gene are associated with Krabbe disease.","GALC wt Allele | Galactocerebrosidase (Krabbe Disease) Gene | Galactocerebrosidase wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0566306","Aphagia","C121623","The inability or refusal to swallow.","Aphagia | Unable to Eat",,,,,,,,,,,,,,,"4263845","Aphagia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0425449","Agonal Respiration","C121624","An abnormal breathing pattern originating from lower brainstem neurons and characterized by labored breaths, gasping, and, often, myoclonus and grunting.","Agonal Respiration | Agonal Breathing | Gasping",,,,,,,,,,,,,,,"4160405","Agonal respiration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL507832","anti-PD-1 monoclonal antibody PDR001","C121625","A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, spartalizumab binds to PD-1 expressed on activated T-cells and blocks the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation.","Spartalizumab | PDR-001 | PDR001 | SPARTALIZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055482","Airway Compromise","C121626","The inhibition of normal respiration by physical obstruction(s) to the airway.","Airway Compromise | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0854171","Disturbance of Temperature Regulation","C121629","Any condition characterized by an inability to regulate body temperature.","Disturbance of Temperature Regulation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1372558","Increased Respiratory Secretion","C121630","An increase in respiratory secretions.","Increased Respiratory Secretion | Increased Respiratory Secretions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0070556","Phenesterin","C1190","A steroidal nitrogen mustard with antineoplastic and mutagenic activities. After attachment to cell-surface steroid receptors and uptake, phenesterin enters the nucleus where it alkylates macromolecules, resulting in decreased cell proliferation. (NCI04)","Phenesterin | (3-beta)-cholest-5-en-3-ol 4-(bis(2-chloroethyl)amino)benzeneacetate | (4-(bis(2-chloroethyl)amino)phenyl)acetic acid cholesteryl ester | (p-(bis(2-chloroethyl)amino)phenyl) acetate cholesterol | (p-(bis(2-chloroethyl)amino)phenyl)acetic acid cholesteryl ester | 5-Cholesten-3-beta-ol 3-(p-(bis(2-chloroethyl)amino)phenyl)acetate | Cholest-5-en-3-ol, (3.beta.)-, 4-[bis(2-chloroethyl)amino]benzeneacetate | Cholest-5-en-3beta-ol 4-(bis(2-chloroethyl)amino)benzeneacetate | Cholesteryl p-bis(2-chloroethyl)aminophenylacetate | Fenesterin | Fenestrin | NCI-C01558 | PHENESTERINE | Phenesterine | p-bis(2-chloroethyl)amino phenylacetate cholesterol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1737926","Nectin-1, Human","C118614","Nectin-1 (517 aa, ~57 kDa) is encoded by the human NECTIN1 gene. This protein plays a role in both the formation of cell-cell contact points and host cell entry of herpes simplex virus and pseudorabies virus.","Nectin-1 | CD111 Antigen | HIgR | Herpes Virus Entry Mediator C | Herpesvirus Entry Mediator C | Herpesvirus Ig-Like Receptor | HveC | Nectin | Nectin 1 | Nectin Cell Adhesion Molecule 1 | PVRL1 | Poliovirus Receptor-Like 1 | Poliovirus Receptor-Related 1 | Poliovirus Receptor-Related Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL494123","Disordered Eating","C121669","Abnormal eating behaviors, including binge eating, compulsive eating, emotional eating, night eating, and self-induced vomiting, though not at a level that rises to the diagnosis of eating disorder.","Disordered Eating | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053855","WWTR1-CAMTA1 Fusion Protein Expression","C121670","A fusion protein that results from a t(1;3)(p36;q23-25).  This fusion protein expression is seen in virtually all cases of epithelioid hemangioendothelioma and is unique to this neoplasm.","WWTR1-CAMTA1 Fusion Protein Expression | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053853","WWTR1/CAMTA1 Fusion Protein","C121673","A fusion protein that is encoded by the WWTR1/CAMTA1 fusion gene. This protein contains the 14-3-3 protein binding domain and most or all of the WW domain from WW domain-containing transcription regulator protein 1 fused to the transcription factor immunoglobulin-like DNA-binding domain, ankyrin repeats and IQ calmodulin-binding motifs from calmodulin-binding transcription activator 1.","WWTR1/CAMTA1 Fusion Protein | WW Domain-Containing Transcription Regulator Protein 1-Calmodulin-Binding Transcription Activator 1 Fusion Protein | WW Domain-Containing Transcription Regulator Protein 1/Calmodulin-Binding Transcription Activator 1 Fusion Protein | WWTR1-CAMTA1 Fusion Protein | WWTR1::CAMTA1 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054192","Peritumoral Brain Edema","C121674","An intracranial edema that develops around a tumor in the meninges or brain.","Peritumoral Brain Edema | PTBE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053766","Rhizomelic Dysplasia","C121675","A form of skeletal dysplasia characterized by shortening of the bones of the proximal segments of the limbs (i.e. the humeri and femora).","Rhizomelic Dysplasia | ",,,,,,,,,,,,,,,"37166984","Rhizomelic dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054126","Radiofrequency-Guided Localization","C121676","A system consisting of an implantable radiofrequency identification (RFID) tag and a hand-held radiofrequency reader to preoperatively mark breast lesions and later surgically retrieve them.","Radiofrequency-Guided Localization | RFID | RFID Localization | RFID-Guided Localization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055182","Conventional Schwannoma","C121677","A common, usually encapsulated benign nerve sheath tumor composed of well-differentiated Schwann cells.","Conventional Schwannoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162364","Enterobius","C122012","A genus of parasitic nematode pinworms in the family Oxyuridae. Pinworms spread through animal-to-animal transmission, by ingestion of infectious pinworm eggs, and/or by anal insertion.","Enterobius | ",,,,,,,,,,,,,,,"4228969","Enterobius",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043271","Wuchereria","C122013","A genus of parasitic filarial nematodes in the family Onchocercidae that mainly affects humans in warm climates.  The adult forms live chiefly in lymphatic vessels, causing obstruction to lymph flow and producing microfilariae that disseminate via the bloodstream.","Wuchereria | WUCHERERIA",,,,,,,,,,,,,,,"4300523","Wuchereria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004693","Balantidium","C122015","A genus of ciliated intestinal protozoan parasites in the family Balantiididae. Balantidium is the only ciliated protozoan known to infect humans and is the causative agent of balantidiasis. Infection occurs through contact with feces from an infected pig.","Balantidium | ",,,,,,,,,,,,,,,"4030852","Balantidium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005707","Blastocystis","C122016","A genus of protozoan parasites in the family Blastocystidae. The taxonomic classification of Blastocystis is not well established. Human infection with Blastocystis is usually self-limiting.","Blastocystis | ",,,,,,,,,,,,,,,"4323985","Blastocystis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008108","Chilomastix","C122017","A genus of nonpathogenic flagellates in the family Retortamonadidae. Infection occurs by the ingestion of cysts in contaminated water, food, or by the fecal-oral route.","Chilomastix | ",,,,,,,,,,,,,,,"4217657","Chilomastix",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4050461","Cutaneous Assessment Tool","C121362","An assessment of a wide range of cutaneous manifestations reflecting activity and damage from idiopathic inflammatory myopathy in children and adults.","Cutaneous Assessment Tool | CAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053527","Dermatomyositis Skin Severity Index","C121363","An assessment of disease activity in the skin of patients with dermatomyositis.","Dermatomyositis Skin Severity Index | DSSI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053719","Valentini Scleroderma Disease Activity Index","C121364","A clinical index used to assess the activity of scleroderma that has been validated in adults.","Valentini Scleroderma Disease Activity Index | Valentini SDAI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053517","Juvenile Spondyloarthritis Disease Activity Index","C121365","A set of criteria used to determine the activity of juvenile spondyloarthritis related to inflammation.","Juvenile Spondyloarthritis Disease Activity Index | JSpADA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054701","Intraarticular Corticosteroid Therapy","C121366","Treatment with a corticosteroid formulation designed for and administered into a joint space.","Intraarticular Corticosteroid Therapy | Intra-articular Corticosteroid | Intra-articular Corticosteroid Therapy | Intraarticular Corticosteroid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054599","Localized Corticosteroid Therapy","C121367","Treatment with a corticosteroid formulation designed for delivery locally and specified by site of administration (intraarticular, topical, or inhaled).","Localized Corticosteroid Therapy | Localized Corticosteroid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053986","Stress Dose Steroid Therapy","C121368","The administration of corticosteroids to an individual with either a long term history of corticosteroid use, or a history of or increased risk for adrenal insufficiency during times of increased physiological stress, including surgery or serious illness.","Stress Dose Steroid Therapy | Stress Dose Steroid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054708","Intermediate Chondrogenic Neoplasm","C121846","A locally aggressive or rarely metastasizing cartilaginous matrix-producing neoplasm characterized by the presence of neoplastic chondrocytes.","Intermediate Chondrogenic Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054446","NCPDP Dose Unit of Measure Terminology","C121847","A set of terminology for NCPDP that contains concepts of the intended dose unit of measure (e.g.  tablet, drop, puff, mL, lozenge) as presented in the medication directions for use (sig).  The purpose of this subset is to state dosing quantities, therefore the concepts contained within may not be the same, or appropriate, units used for dispensing/billing.","NCPDP Dose Unit of Measure Terminology | NCPDP DoseUnitOfMeasure Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055423","Autologous NSCLC Peptide-specific Dendritic Cell Vaccine","C121848","A personalized cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with immunogenic peptides derived from autologous non-small cell lung cancer (NSCLC) cells, with potential immunostimulating and antineoplastic activities. During leukapheresis, mature DCs are loaded with autologous NSCLC-derived peptides. Upon re-administration of the NSCLC peptide-specific DC vaccine, the immune system is exposed to NSCLC-associated antigens. This results in the induction of a specific cytotoxic T-lymphocyte (CTL) response against NSCLC cells and tumor cell lysis.","Autologous NSCLC Peptide-specific Dendritic Cell Vaccine | Autologous NSCLC Peptide-specific DC Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053659","BET Inhibitor BMS-986158","C121849","An inhibitor of the Bromodomain (BRD) and Extra-Terminal domain (BET) family of proteins, with potential antineoplastic activity. Upon administration, ezobresib binds to the acetyl-lysine binding site in the BRD of BET proteins, thereby preventing the interaction between BET proteins and acetylated histones. This disrupts chromatin remodeling and prevents the expression of certain growth-promoting genes, resulting in an inhibition of tumor cell growth. BET proteins (BRD2, BRD3, BRD4 and BRDT) are transcriptional regulators that bind to acetylated lysines on the tails of histones H3 and H4, and regulate chromatin structure and function; they play an important role in the modulation of gene expression during development and cellular growth.","Ezobresib | BET Inhibitor BMS-986158 | BET Inhibitor BMS-986158 | BMS-986158 | EZOBRESIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053596","cetuximab-IR700 conjugate RM-1929","C121850","The sodium salt form of cetuximab sarotalocan, which consists of a chemical conjugate composed of the dye IR700 linked to cetuximab, a monoclonal antibody directed against the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon injection of cetuximab sarotalocan sodium, the cetuximab moiety targets and binds to EGFR-expressing tumor cells, resulting in the internalization of the conjugate. Upon localized application of near-infrared (NIR) light, the IR700 dye becomes activated, disrupts the cell membrane and selectively kills the EGFR-expressing tumor cells. EGFR, a tyrosine kinase receptor, is overexpressed in a variety of cancers.","Cetuximab Sarotalocan Sodium | ASP 1929 | ASP-1929 | ASP1929 | CETUXIMAB SAROTALOCAN | CETUXIMAB SAROTALOCAN SODIUM | Cet-IR700 | Cetuximab Sarotalocan | Cetuximab-IR700 Conjugate RM-1929 | RM-1929",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1138626","Cocoa Extract","C121851","A dietary supplement containing cocoa extract derived from the cacao bean, with potential vasodilating, anti-inflammatory, cardiovascular protective, neuroprotective, cognition enhancing and chemopreventive activities. Cocoa extract contains flavonoids, including high levels of epicatechin, catechin, procyanidins and xanthines, such as theobromine. Upon oral administration, the bioactive ingredients in the cocoa extract inhibit angiotensin-converting enzyme (ACE) and increase the production of nitric oxide (NO) through the activation of endothelial nitric oxide synthase (eNOS). This causes vasodilation, improves blood flow, and decreases blood pressure. The cocoa extract also improves insulin sensitivity, enhances cognition, and decreases the production of pro-inflammatory molecules. In addition, this extract exerts antioxidant effects and is able to scavenge reactive oxygen species (ROS). As a result, healthy cells are protected from oxidative stress and DNA damage.","Cocoa Extract | COCOA | Cocoa Extract Supplement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3891068","MAOA wt Allele","C118616","Human MAOA wild-type allele is located in the vicinity of Xp11.3 and is approximately 91 kb in length. This allele, which encodes amine oxidase [flavin-containing] A, plays a role in the metabolism of neuroactive and vasoactive amines. Mutation of the gene is associated with Brunner syndrome and a variety of other psychiatric disorders.","MAOA wt Allele | MAO-A | Monoamine Oxidase A wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3657721","Amine oxidase [flavin-containing] A, Human","C118617","Amine oxidase [flavin-containing] A (527 aa, ~60 kDa) is encoded by the human MAOA gene. This protein is involved in the deamination of neuroactive and vasoactive amines.","Amine Oxidase [Flavin-Containing] A | Amine Oxidase (Flavin-Containing) A | EC 1.4.3.4 | MAO-A | MAOA | Monoamine Oxidase Type A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898131","Non-Cytotoxic Chemotherapy","C118620","Chemotherapy using a pharmacologic agent that does not directly kill cells.","Non-Cytotoxic Chemotherapy | Chemotherapy non-cytotoxic | Non-Cytotoxic Drug Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897258","ubidecarenone injectable nanosuspension","C118621","A nanodispersion containing the benzoquinone ubidecarenone (coenzyme Q10), with potential protective, antioxidant and antineoplastic activities. Upon administration, ubidecarenone nanodispersion BPM31510 modulates tumor cell metabolism and causes an anti-Warburg effect by inducing a shift from lactate dependency towards mitochondrial oxidative phosphorylation, and induces tumor cell apoptosis. This inhibits tumor cell proliferation. BPM 31510 also induces the activation and maturation of T-lymphocytes, and changes the surface expression of certain immune checkpoint modulators. In addition, as an antioxidant, ubidecarenone protects against cell damage, by preventing both the peroxidation of lipid membranes and the oxidation of LDL-cholesterol. Ubidecarenone is an essential coenzyme for mitochondrial enzyme complexes involved in oxidative phosphorylation and the production of adenosine triphosphate (ATP).","Ubidecarenone Nanodispersion BPM31510n | BP31510 | Coenzyme Q10 Injectable Nanosuspension | Ubidecarenone Injectable Nanosuspension | Ubiquinone Injectable Nanosuspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831750","Dimethicone/Polymer Barrier Cream","C118622","A topical cream containing the silicon-based polymer dimethicone, with potential skin protective activity. Upon topical application of the dimethicone/polymer barrier cream to the skin, dimethicone protects the skin against damage, and moisturizes and soothes the skin.","Dimethicone/Polymer Barrier Cream | Cavilon Durable Barrier Cream",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896726","Lung-targeted Immunomodulator QBKPN","C118623","A proprietary, lung-targeted, site specific immunomodulator (SSI), with potential immunostimulating and antineoplastic activities. Although the exact type and composition of the lung-targeted immunomodulator QBKPN has yet to be fully disclosed, upon subcutaneous administration, this agent is able to activate a local innate immune response in the lung tissue. This results in an increased number of M1 macrophages, which induces a shift from M2 to M1 macrophage dominance in the tumor microenvironment, and stimulates the recruitment of other immune cells. The M1 macrophages exert antitumor activity and eradicate lung cancer cells through phagocytosis. QBKPN does not induce a systemic immune response or affect other organs or tissues. Altogether, this SSI may decrease tumor cell growth in the lungs. SSIs contain specific, inactivated components of pathogens, such as bacteria and/or viruses, which normally cause an acute infection in the specific organ or tissue of interest.","Lung-targeted Immunomodulator QBKPN | QBKPN | SSI QBKPN | Site Specific Immunomodulator QBKPN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896907","PI3Kalpha Inhibitor AZD8835","C118624","An orally bioavailable inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) catalytic subunit alpha (PIK3CA), with potential antineoplastic activity. PI3K alpha inhibitor AZD8835 selectively binds to and inhibits PIK3CA and its mutated forms, in the PI3K/Akt (protein kinase B) /mammalian target of rapamycin (mTOR) pathway. This results in both apoptosis and growth inhibition in PIK3CA-expressing tumor cells. By specifically targeting PIK3CA, this agent may be more efficacious and less toxic than pan-PI3K inhibitors. Dysregulation of the PI3K/Akt/mTOR pathway is often found in solid tumors and results in the promotion of tumor cell growth, survival, and resistance to chemo- and radio-therapy. PIK3CA, one of the most frequently mutated oncogenes, encodes the p110-alpha catalytic subunit of the class I PI3K.","PI3Kalpha Inhibitor AZD8835 | AZD-8835 | AZD8835",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054880","HEY1/NCOA2 Fusion Protein","C121918","A fusion protein that is encoded by the HEY1/NCOA2 fusion gene. This protein contains the N-terminal basic helix-loop-helix domain of hairy/enhancer-of-split related with YRPW motif protein 1 fused to the C-terminal region of the nuclear receptor coactivator 2 protein, which includes its CREB binding and histone acetyl transferase domains.","HEY1/NCOA2 Fusion Protein | HEY1-NCOA2 Fusion Protein | HEY1::NCOA2 Fusion Protein | Hairy/Enhancer-of-Split Related With YRPW Motif Protein 1-Nuclear Receptor Coactivator 2 Fusion Protein | Hairy/Enhancer-of-Split Related With YRPW Motif Protein 1/Nuclear Receptor Coactivator 2 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053639","PI3Kdelta Inhibitor GS-9901","C121374","An orally bioavailable, small molecule inhibitor of the delta isoform of phosphoinositide-3 kinase (PI3Kdelta) with potential immunomodulating and antineoplastic activities. Upon oral administration, PI3Kdelta inhibitor GS-9901 selectively binds to the delta isoform of PI3K and inhibits its activity. This inhibits the activation of the PI3Kdelta-mediated signaling pathway and prevents proliferation of PI3Kdelta-overexpressing tumor cells. Unlike other isoforms of PI3K, PI3Kdelta is expressed primarily in certain tumor cell types and plays a key role in tumor cell proliferation, motility and survival. The targeted inhibition of PI3Kdelta is designed to preserve PI3K signaling in normal, non-neoplastic cells and thus reduces toxicity to normal, healthy cells.","PI3Kdelta Inhibitor GS-9901 | GS-9901",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474103","PT-112","C121375","A platinum (Pt)-based agent belonging to the phosphaplatin family comprised of Pt complexed to a pyrophosphate ligand, with potential antineoplastic activity. Although the exact mechanisms through which imifoplatin exerts its effect have yet to be fully elucidated, this agent, upon intravenous administration, binds to certain transmembrane proteins and activates several genes involved in tumor suppression and apoptosis. This leads to the activation of various signal transduction pathways, induces S/G2 phase cell cycle, and causes tumor cell apoptosis. In addition, imifoplatin may inhibit angiogenesis. Unlike conventional Pt-based chemotherapeutics, imifoplatin does not bind to DNA and is able to overcome drug resistance, which occurs with conventional Pt-based chemotherapeutics; it also has a more favorable side effect profile and is more stable in plasma.","Imifoplatin | Cyclohexanediamine Pyrophosphatoplatinum(II), (1R,2R)- | IMIFOPLATIN | PT 112 | PT-112 | Phosphaplatin PT-112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053630","HCV DNA Vaccine INO-8000","C121570","A multi-antigen DNA vaccine consisting of plasmids encoding the hepatitis C virus (HCV) nonstructural proteins 3 (NS3), 4A (NS4A), 4B (NS4B) and 5A (NS5A), with potential immunomodulating and cancer preventive activities. Administered via intramuscular injection followed by electroporation, cells transfected with the HCV DNA vaccine INO-8000 express the encoded HCV proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against HCV-infected liver cells expressing the NS3, NS4A, NS4B or NS5A proteins. This results in the eradication of HCV-infected cells. HCV, a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family, is associated with the development of hepatocellular carcinoma (HCC).","HCV DNA Vaccine INO-8000 | INO-8000",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054654","Leiomyosarcoma of Deep Soft Tissue","C121571","A rare leiomyosarcoma that arises from the deep soft tissue in the retroperitoneum or abdominal cavity.","Leiomyosarcoma of Deep Soft Tissue | Leiomyosarcoma of the Deep Soft Tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007462","Complex Regional Pain Syndrome II","C121572","A neurologic condition characterized by burning pain, tenderness, swelling, and changes in the skin color and temperature of a body part or extremity associated with demonstrable nerve injury. This form is less frequent in pediatric patients.","Complex Regional Pain Syndrome II | CRPS II | Causalgia",,,,,,,,,,,,,,,"4256912","Complex regional pain syndrome, type II",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0277964","Crepitus","C121573","Air trapped in the subcutaneous space. It can be palpated or heard as a crackling or grating sensation under the skin.","Crepitus | ",,,,,,,,,,,,,,,"4271715","Subcutaneous crepitus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1504561","Hypophagia","C121574","Reduced ingestion of food.","Hypophagia | Decreased Oral Intake | Decreased PO Intake | Oral Intake Reduced | Poor Oral Intake",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016865","Fursultiamine","C121852","A nutritional supplement and vitamin B1 derivative, with potential antineoplastic activity. Upon oral administration, fursultiamine inhibits the expressions of octamer-binding transcription factor 4 (OCT-4), SRY (sex determining region Y)-box 2 (SOX-2), and Nanog homeobox (NANOG) in cancer stem cells (CSCs). This may inhibit the proliferation of CSCs thereby preventing tumor cell growth. In addition, fursultiamine inhibits the expression of ATP-binding cassette (ABC) transporters subfamily B member 1 (ABCB1) and subfamily G member 2 (ABCG2) in cancer CSCs, which may abrogate resistance to chemo- and radiotherapy in CSCs. CSCs promote tumor initiation, progression and metastasis; they play a key role in cancer recurrence and resistance to chemotherapy and radiation.","Fursultiamine | FURSULTIAMINE | Formamide, N-((4-amino-2-methyl-5-pyrimidinyl)methyl)-N-(4-hydroxy-1-methyl-2-(((tetrahydro-2-furanyl)methyl)dithio)-1-butenyl)- | TTFD | Thiamine Tetrahydrofurfuryl Disulfide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054044","Secondary Hemophagocytic Lymphohistiocytosis","C121184","Hemophagocytic lymphohistiocytosis due to infections, autoimmune disorders, or underlying malignancies. Signs and symptoms include fever, lymphadenopathy, hepatomegaly, splenomegaly, and pancytopenia.","Secondary Hemophagocytic Lymphohistiocytosis | ",,,,,,,,,,,,,,,"603020","Secondary hemophagocytic lymphohistiocytosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053771","Pressure at dP/dt Maximum","C121185","No value exists.","Pressure at dP/dt Maximum | Left Ventricular Pressure Maximum | PDPDTMAX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054157","Pressure at dP/dt Minimum","C121186","No value exists.","Pressure at dP/dt Minimum | Left Ventricular Pressure Minimum | PDPDTMIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055462","Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1","C121231","A humanized version of the immunoglobulin (Ig) G1 monoclonal antibody Mik-Beta-1 (Hu-Mik-Beta-1) directed against CD122, the beta-subunit shared by the interleukin-2 (IL-2) and IL-15 receptor (IL-2/IL-15Rbeta). Upon intravenous infusion, Hu-Mik-Beta-1 binds to CD122 expressed on certain tumor cells. This blocks the binding of the inflammatory cytokines IL-2 and IL-15 to IL-2R and IL-15R, respectively, and prevents IL-2/IL-2R- and IL-15/IL-15R-mediated signaling. This may inhibit the proliferation of CD122-expressing tumor cells. In addition, blocking CD122 on T-lymphocytes prevents the over-activation of T-lymphocytes in various T-cell mediated autoimmune diseases, which is predominantly mediated by IL-15/IL-15R signaling. CD122, involved in both IL-2 and IL-15 signaling, is overexpressed on certain cancer cells, such as those found in T-cell large granular lymphocyte (T-LGL) leukemia.","Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1 | Hu-Mik-Beta-1 | Hu-Mik-beta1 | Hu-Mikb1 | HuMikBeta1 | Humanized Mik-beta-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0438186","Pulmonary Function Test Normal","C121579","Results that are standard and expected for the reference population with any of the parameters used to measure the mechanical function of the lungs and associated structures.","Pulmonary Function Test Normal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3551991","Drooling","C121582","Saliva spilling out of the mouth.","Drooling | ",,,,,,,,,,,,,,,"4266842","Dribbling from mouth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054345","Non-Cutaneous Leiomyosarcoma","C121583","A leiomyosarcoma arising from an anatomic site other than skin.","Non-Cutaneous Leiomyosarcoma | Leiomyosarcoma (Excluding Skin)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0073115","Retinyl Palmitate","C1217","A naturally-occurring phenyl analogue of retinol (vitamin A) with potential antineoplastic and chemopreventive activities.  As the most common form of vitamin A taken for dietary supplementation, retinyl palmitate binds to and activates retinoid receptors, thereby inducing cell differentiation and decreasing cell proliferation.  This agent also inhibits carcinogen-induced neoplastic transformation, induces apoptosis in some cancer cell types, and exhibits immunomodulatory properties. (NCI04)","Retinyl Palmitate | Palmitate-1-14C | Retinol Hexadecanoate | Retinol Palmitate | Retinol-15-3H | Retinyl-10,11-14C2 | VITAMIN A PALMITATE | Vitamin A Palmitate | retinyl palmitate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053730","t(11;16)(p11;p11)","C121429","A cytogenetic abnormality that refers to the translocation of the short arm (p11) of chromosome 11 and the short arm (p11) of chromosome 16. It results in a FUS-CREB3L1 fusion.","t(11;16)(p11;p11) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3888284","Pro-Neuregulin-2, Membrane-Bound Isoform, human","C118416","Pro-neuregulin-2, membrane-bound isoform (850 aa, ~92 kDa) is encoded by the human NRG2 gene. This protein plays a role in receptor signaling.","Pro-Neuregulin-2, Membrane-Bound Isoform | Pro-NRG2 | Pro-Neuregulin-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898191","NRG3 Gene Product","C118417","A protein encoded by the NRG3 gene.","NRG3 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3888285","Pro-Neuregulin-3, Membrane-Bound Isoform, human","C118418","Pro-neuregulin-3, membrane-bound isoform (720 aa, ~78 kDa) is encoded by the human NRG3 gene. This protein plays a role in signaling.","Pro-Neuregulin-3, Membrane-Bound Isoform | Pro-NRG3 | Pro-Neuregulin-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022865","Labor Complication","C118419","Any unintended event during the labor process that makes delivery more difficult.","Labor Complication | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2931517","Anaplastic Plasmacytoma","C118421","A plasmacytoma characterized by the presence of malignant plasma cells with anaplastic features.","Anaplastic Plasmacytoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009492","Compartment Syndrome","C118422","Elevated pressure in a confined space enclosed by fascia or eschar, which may lead to vascular compromise and subsequent ischemic injury to the tissue within the space.","Compartment Syndrome | Compartment syndrome",,,,,,,,,,,,,,,"134734","Compartment syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3890228","Structural Modifier","C118425","A molecule that binds to a macromolecule and can change the structural properties of that macromolecule.","Structural Modifier | Chemical Modification | STRUCTURAL MODIFICATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899037","Gene Product Variation Site","C118426","The amino acid position that is substituted in a gene product variant.","Gene Product Variation Site | AMINO ACID SUBSTITUTION POINT | Protein Substitution Site | Substituted Amino Acid | aa change | aa_change",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897967","Peptide Bond Constituents","C118427","The amine group and carboxyl group found in adjacent amino acids that form a peptide bond.","Peptide Bond Constituents | AMINO ACID CONNECTION POINTS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898836","Human Glycan","C118428","An oligosaccharide protein modification that is synthesized by human cells.","Human Glycan | HUMAN TYPE GLYCAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899985","Avian Glycan","C118429","An oligosaccharide protein modification that is synthesized by avian cells.","Avian Glycan | AVIAN TYPE GLYCAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899961","Bacterial Glycan","C118430","An oligosaccharide protein modification that is synthesized by bacterial cells.","Bacterial Glycan | BACTERIAL TYPE GLYCAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898470","Mammalian Glycan","C118431","An oligosaccharide protein modification that is synthesized by mammalian cells.","Mammalian Glycan | MAMMALIAN TYPE GLYCAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899074","Fungal Glycan","C118432","An oligosaccharide protein modification that is synthesized by fungal cells.","Fungal Glycan | FUNGAL TYPE GLYCAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2931404","Albright's Hereditary Osteodystrophy","C118434","A rare, autosomal dominant syndrome caused by mutations in the GNAS gene. It is characterized by the presence of short stature, obesity, round face, brachydactyly, subcutaneous ossifications, and pseudohypoparathtyroidism.","Albright's Hereditary Osteodystrophy | Albright Hereditary Osteodystrophy | Albright's Hereditary Osteodystrophy with Multiple Hormone Resistance | PHP1A | Pseudohypoparathyroidism, Type IA",,,,,,,,,,,,,,,"4239626","Pseudohypoparathyroidism type I A",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4049731","GZMA wt Allele","C121489","Human GZMA wild-type allele is located within 5q11-q12 and is approximately 8 kb in length. This allele, which encodes granzyme A protein, is involved in cell-mediated cytolysis.","GZMA wt Allele | CTLA3 | Granzyme A (Cytotoxic T-Lymphocyte-Associated Serine Esterase-3; Hanukah Factor Serine Protease) Gene | Granzyme A (Granzyme 1, Cytotoxic T-Lymphocyte-Associated Serine Esterase 3) wt Allele | HFSP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1313497","Granzyme A","C121490","Granzyme A (262 aa, ~29 kDa) is encoded by the human GZMA gene. This protein plays a role in both proteolysis and apoptosis.","Granzyme A | CTL Tryptase | Cytolytic T Cell- and Natural Killer Cell-Specific Trypsin-Like Serine Protease | Cytotoxic T-Lymphocyte Proteinase 1 | Cytotoxic T-Lymphocyte-Associated Serine Esterase 3 | EC 3.4.21.78 | Fragmentin-1 | GZMA | Granzyme 1 | Granzyme-1 | H Factor | HF | Hanukah Factor Serine Protease | Hanukkah Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049717","B3GAT2 wt Allele","C121492","Human B3GAT2 wild-type allele is located in the vicinity of 6q12 and is approximately 100 kb in length. This allele, which encodes galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 2 protein, plays a role in carbohydrate modification of lipids and proteins.","B3GAT2 wt Allele | Beta-1,3-Glucuronyltransferase 2 wt Allele | GLCATS | KIAA1963",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1259497","B3GAT2 protein, human","C121493","Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 2 (323 aa, ~37 kDa) is encoded by the human B3GAT2 gene. This protein is involved in glycolipid and glycoprotein synthesis.","Galactosylgalactosylxylosylprotein 3-Beta-Glucuronosyltransferase 2 | B3GAT2 | Beta-1,3-Glucuronyltransferase 2 | EC 2.4.1.135 | GlcAT-D | GlcAT-S | Glucuronosyltransferase S | UDP-Glucuronosyltransferase S | UDP-Glucuronyltransferase S | Uridine Diphosphate Glucuronic Acid:Acceptor Glucuronosyltransferase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053829","ZNF793 wt Allele","C121495","Human ZNF793 wild-type allele is located in the vicinity of 19q13.12 and is approximately 42 kb in length. This allele, which encodes zinc finger protein 793, may be involved in the regulation of transcription.","ZNF793 wt Allele | Zinc Finger Protein 793 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050521","Zinc Finger Protein 793, human","C121496","Zinc finger protein 793 (406 aa, ~47 kDa) is encoded by the human ZNF793 gene. This protein may play a role in transcriptional regulation.","Zinc Finger Protein 793 | ZNF793",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049878","SLC5A8 wt Allele","C121498","Human SLC5A8 wild-type allele is located in the vicinity of 12q23.1 and is approximately 55 kb in length. This allele, which encodes sodium-coupled monocarboxylate transporter 1 protein, plays a role in iodide transport and the sodium ion-dependent transport of monocarboxylates.","SLC5A8 wt Allele | AIT | SMCT | SMCT1 | Solute Carrier Family 5 (Iodide Transporter), Member 8 Gene | Solute Carrier Family 5 (Sodium/Monocarboxylate Cotransporter), Member 8 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1311170","Sodium-Coupled Monocarboxylate Transporter 1, Human","C121499","Sodium-coupled monocarboxylate transporter 1 (610 aa, ~67 kDa) is encoded by the human SLC5A8 gene. This protein is involved in the transport of ions and monocarboxylates.","Sodium-Coupled Monocarboxylate Transporter 1 | Apical Iodide Transporter | Electrogenic Sodium Monocarboxylate Cotransporter | SLC5A8 | Sodium Iodide-Related Cotransporter | Sodium-Coupled Monocarboxylate Transporter | Solute Carrier Family 5 Member 8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054352","No Identifiable Line of Differentiation","C121813","A laboratory finding indicating that the line of differentiation in a cellular infiltrate cannot be identified.","No Identifiable Line of Differentiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382535","Pegcetacoplan","C121135","A pegylated peptide inhibitor of human complement components C3 and C3b, with potential use as a treatment for various diseases in which excessive complement activation plays a key role, including paroxysmal nocturnal hemoglobinuria (PNH), geographic atrophy (GA), cold agglutinin disease (CAD), and C3 glomerulopathy (C3G). Upon administration, pegcetacoplan selectively binds to C3 and C3b and inhibits their activities. This prevents complement pathway activation, and inhibits complement-mediated inflammation and cell lysis. Excessive complement activation plays a key role in various inflammatory and autoimmune diseases, and leads to tissue destruction. C3 is a key component of the complement system, and the complement system is an integral component of the innate immune response.","Pegcetacoplan | APL 2 | APL-2 | APL2 | C3-targeted Complement Inhibitor APL-2 | Empaveli | PEGCETACOPLAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053774","Polihexanide Solution","C121637","A solution containing the polymer polihexanide, with potential antimicrobial, disinfectant and wound healing activities. Upon application to a wound, polihexanide strongly binds to the wound surface and exerts an antiseptic effect through the binding of the positively charged guanidine groups of polihexanide with the negatively charged phospholipids of the bacterial cell membrane. This compromises the stability of the bacterial cell membrane, which results in the leakage of cytoplasmic components and leads to bacterial cell death. In addition, polihexanide accelerates wound healing by promoting epithelial cell migration and proliferation.","Polihexanide Solution | PHMB Solution | Polyhexamethylenebiguanide Solution | Polyhexanide Solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055459","Anti-GPC3-CAR Autologous T Lymphocytes","C121638","A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for glypican-3 (GPC3), with potential immunostimulating and antineoplastic activities. Upon administration, anti-GPC3-CAR autologous T-lymphocytes specifically target and bind to GPC3-expressing tumor cells, resulting in tumor cell lysis. GPC3, a heparan sulfate proteoglycan and a member of the glypican family, is overexpressed on certain tumor cell types while minimally expressed in normal, healthy cells; GPC3 plays an important role in cellular proliferation and differentiation.","Anti-GPC3-CAR Autologous T Lymphocytes | Anti-GPC3 CAR Autologous T Cells | CAR-GPC3 T Cells | GPC3-targeted CAR Autologous T Cells | Glypican-3-specific CAR T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0406775","Dyschromatosis Symmetrica Hereditaria","C118435","A rare, autosomal dominant inherited disorder caused by heterozygous mutation in the DSRAD gene. Most cases have been reported from countries in East Asia. It is characterized by the presence of hyperpigmented and hypopigmented macules on the dorsal aspect of the extremities and face.","Dyschromatosis Symmetrica Hereditaria | DSH1 | Dyschromatosis Symmetrica Hereditaria 1 | RAD | Reticulate Acropigmentation of Dohi | Symmetric Dyschromatosis of the Extremities",,,,,,,,,,,,,,,"4082497","Symmetrical dyschromatosis of extremities",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897494","Stent Thrombosis Coronary ARC Timing Clinical Classification","C119106","A standardized grading system developed by the Academic Research Consortium (ARC) to describe coronary stent thrombosis based on the timing of the event. This grading system includes 4 classifications: acute, subacute, late and very late stent thrombosis.","Stent Thrombosis Coronary ARC Timing Clinical Classification | ARC STC Timing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900150","AUDIT - How Often Have Alcohol Drink","C119108","Alcohol Use Disorder Identification Test Self-Report Version (AUDIT) How often do you have a drink containing alcohol?","AUDIT - How Often Have Alcohol Drink | ADT01-How Often Drink Alcohol | ADT0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900151","AUDIT - How Many Alcohol Drinks on a Typical Day","C119109","Alcohol Use Disorder Identification Test Self-Report Version (AUDIT) How many drinks containing alcohol do you have on a typical day when you are drinking?","AUDIT - How Many Alcohol Drinks on a Typical Day | ADT01-Alcohol Drinks on a Typical Day | ADT0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900149","AUDIT - How Often Have Six or More Drinks","C119110","Alcohol Use Disorder Identification Test Self-Report Version (AUDIT) How often do you have six or more drinks on one occasion?","AUDIT - How Often Have Six or More Drinks | ADT01-Six or More Drinks One Occasion | ADT0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900145","AUDIT - How Often Last Year You Found Not Able to Stop Drinking","C119111","Alcohol Use Disorder Identification Test Self-Report Version (AUDIT) How often during the last year have you found that you were not able to stop drinking once you had started?","AUDIT - How Often Last Year You Found Not Able to Stop Drinking | ADT01-Not Able Stop Drinking Once Start | ADT0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0073081","Resiniferatoxin","C1214","A naturally occurring capsaicin analog found in the latex of the cactus Euphorbia resinifera with analgesic activity. Resiniferatoxin (RTX) binds to and activates the transient receptor potential vanilloid 1 (TRPV1), a non-selective cation channel in the plasma membrane of primary afferent sensory neurons. This increases the permeability to cations, and leads to an influx of calcium and sodium ions. This results in membrane depolarization, causing an irritant effect, followed by desensitization of the sensory neurons thereby inhibiting signal conduction in afferent pain pathways and causing analgesia. TRPV1, a member of the transient receptor potential channel (TRP) superfamily, is a heat- and chemo-sensitive calcium/sodium ion channel that is selectively expressed in a subpopulation of pain-sensing primary afferent neurons.","Resiniferatoxin | RESINIFERATOXIN | RTX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053795","Nonfunctional Pituitary Microadenoma","C121678","A pituitary neuroendocrine tumor/microadenoma not associated with a hormonal syndrome.","Non-Functioning Pituitary Neuroendocrine Tumor/Microadenoma | Non-Functioning PitNET/Microadenoma | Non-Functioning Pituitary Gland Microadenoma | Non-Functioning Pituitary Gland Microadenoma | Nonfunctional Pituitary Gland Microadenoma | Nonfunctional Pituitary Microadenoma | Nonfunctioning Pituitary Gland Microadenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054916","Functional Pituitary Microadenoma","C121679","A pituitary neuroendocrine tumor/microadenoma associated with a hormonal syndrome.","Functioning Pituitary Neuroendocrine Tumor/Microadenoma | Functional Pituitary Microadenoma | Functioning PitNET/Microadenoma | Functioning Pituitary Gland Microadenoma | Functioning Pituitary Gland Microadenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054533","Meningothelial Hamartoma","C121682","A hamartoma characterized by the presence of collections of non-neoplastic arachnoidal cells.","Meningothelial Hamartoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004039","Aspergillus niger","C121138","A species of mesophilic fungi belonging to the genus Aspergillus that is a human pathogen, causing lung or ear infections in immunocompromised patients","Aspergillus niger | ASPERGILLUS NIGER",,,,,,,,,,,,,,,"4231112","Aspergillus niger",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0271586","Hypoprolactinemia","C121140","Subnormal concentration of prolactin.","Hypoprolactinemia | Lactogenic Hormone Deficiency | Prolactin Deficiency",,,,,,,,,,,,,,,"4284412","Isolated prolactin deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0342386","Follicle Stimulating Hormone Deficiency","C121141","Subnormal concentration of follicle stimulating hormone.","Follicle Stimulating Hormone Deficiency | FSH Deficiency",,,,,,,,,,,,,,,"4096059","Follicle stimulating hormone deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4049735","EIF4B wt Allele","C121144","Human EIF4B wild-type allele is located in the vicinity of 12q13.13 and is approximately 36 kb in length. This allele, which encodes eukaryotic translation initiation factor 4B protein, is involved in the regulation of translational initiation.","EIF4B wt Allele | EIF-4B | Eukaryotic Translation Initiation Factor 4B wt Allele | PRO1843",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0058985","eIF-4B","C121145","Eukaryotic translation initiation factor 4B (611 aa, ~69 kDa) is encoded by the human EIF4B gene. This protein plays a role in the initiation of translation through promoting the binding of mRNA to ribosomes.","Eukaryotic Translation Initiation Factor 4B | eIF-4B | eIF4B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054176","Pituitary Stalk Lesion","C121146","An anomaly in the pituitary stalk that can be developmental, inflammatory, infiltrative, iatrogenic or traumatic.","Pituitary Stalk Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342409","Hypophysitis","C121147","An inflammatory process in the pituitary gland.","Hypophysitis | ",,,,,,,,,,,,,,,"4129537","Hypophysitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL474130","anti-OX40 monoclonal antibody MOXR0916","C121376","An agonistic humanized monoclonal antibody against the receptor, OX40 (CD134), with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, vonlerolizumab selectively binds to and activates OX40, by mimicking the action of endogenous OX40 ligand (OX40L). OX40 activation induces proliferation of effector T-lymphocytes and inhibits the activity of regulatory T-cells. In the presence of tumor-associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T-cells.","Vonlerolizumab | Anti-OX40 Monoclonal Antibody MOXR0916 | MOXR0916 | Pogalizumab | RG 7888 | RG-7888 | RG7888 | RO7021608 | VONLEROLIZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053654","EZH2 inhibitor CPI-1205","C121639","An orally available selective inhibitor of the histone lysine methyltransferase EZH2, with potential antineoplastic activity. Upon oral administration, lirametostat selectively inhibits the activity of both wild-type and mutated forms of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 on lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased proliferation of EZH2-expressing cancer cells. EZH2, a histone lysine methyltransferase (HMT) class enzyme and the catalytic subunit of the polycomb repressive complex 2 (PRC2), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation; its expression is correlated with tumor initiation, progression, stem cell self-renewal, migration and angiogenesis.","Lirametostat | CPI-1205 | EZH2 Inhibitor CPI-1205 | LIRAMETOSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053747","Allogeneic Mesothelioma Tumor Lysate-pulsed Autologous Dendritic Cell Vaccine","C121640","A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with a mixture of lysates from five allogeneic mesothelioma tumor cell lines, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, DCs are loaded with allogeneic mesothelioma tumor cell lysates. Upon re-administration of the allogeneic mesothelioma tumor lysate-pulsed autologous DC vaccine, the immune system is exposed to an undefined amount of mesothelioma-associated antigens, which stimulates the induction of a specific cytotoxic T-lymphocyte (CTL) response against mesothelioma tumor cells and leads to tumor cell lysis.","Allogeneic Mesothelioma Tumor Lysate-pulsed Autologous Dendritic Cell Vaccine | Allogeneic Mesothelioma Tumor Lysate-pulsed Autologous DC Vaccine | MesoCancerVac",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053685","HDAC inhibitor ACY-241","C121641","An orally available histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon oral administration, citarinostat inhibits the activity of HDACs; this results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. This leads to the inhibition of tumor oncogene transcription, and the selective transcription of tumor suppressor genes, which inhibit tumor cell division and induce tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins.","Citarinostat | 2-((2-Chlorophenyl)phenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)-5-pyrimidinecarboxamide | 5-Pyrimidinecarboxamide, 2-((2-Chlorophenyl)phenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)- | ACY-241 | CC-96241 | CITARINOSTAT | HDAC-IN-2 | Histone Deacetylase Inhibitor ACY-241",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053490","Calculus bovis/Moschus/Olibanum/Myrrha Capsule","C121642","An orally available traditional Chinese medicine (TCM)-based capsule formulation containing Calculus bovis, the dried gallstones of cattle, Moschus, also referred to as deer musk, the resin Olibanum and the resin Myrrha, with potential antineoplastic and chemopreventive activities. Although the exact mechanisms of action through which the active ingredients in the Calculus bovis/Moschus/Olibanum/Myrrha capsule elicit their effects have yet to be fully elucidated, they may, upon intake, exert their antineoplastic activity through modulation of the immune system, inhibition of tumor cell proliferation and induction of apoptosis.","Calculus bovis/Moschus/Olibanum/Myrrha Capsule | Wangbang Pharmaceutical Xihuang Capsule | XHP | Xihuang Capsule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL777354","AXL inhibitor BGB324","C121854","An orally available and selective inhibitor of the AXL receptor tyrosine kinase (UFO), with potential antineoplastic activity. Upon administration, bemcentinib targets and binds to the intracellular catalytic kinase domain of AXL and prevents its activity. This blocks AXL-mediated signal transduction pathways and inhibits the epithelial-mesenchymal transition (EMT), which, in turn, inhibits tumor cell proliferation and migration. In addition, bemcentinib enhances chemo-sensitivity. AXL, a member of the TAM (TYRO3, AXL and MER) family of receptor tyrosine kinases overexpressed by many tumor cell types, plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance and poor prognosis.","Bemcentinib | 1H-1,2,4-Triazole-3,5-diamine, 1-(6,7-Dihydro-5H-benzo(6,7)cyclohepta(1,2-C)pyridazin-3-yl)-N3-((7S)-6,7,8,9-tetrahydro-7-(1-pyrrolidinyl)-5H-benzocyclohepten-2-yl)- | AXL Inhibitor BGB324 | BEMCENTINIB | BGB 324 | BGB-324 | BGB324 | R-428 | R428 | WHO 10631",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053686","Autologous Dendritic Cell Vaccine ACT2001","C121856","A cell-based cancer vaccine composed of autologous, immature dendritic cells (DCs), with potential immunostimulating and antineoplastic activities. Upon leukapheresis, immature DCs are isolated and re-administered intra-tumorally. The immature DCs internalize and process the tumor-associated antigens (TAAs), migrate to the lymphatic system, and then expose the immune system to the TAAs. This induces a specific cytotoxic T-lymphocyte (CTL) response against the cancer cells leading to tumor cell lysis.","Autologous Dendritic Cell Vaccine ACT2001 | ACT2001 | Autologous DC Vaccine ACT2001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900147","AUDIT - How Often Last Year You Failed to Do Normally Expected of You","C119112","Alcohol Use Disorder Identification Test Self-Report Version (AUDIT) How often during the last year have you failed to do what was normally expected of you because of drinking?","AUDIT - How Often Last Year You Failed to Do Normally Expected of You | ADT01-Failed to Do as Expected | ADT0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900148","AUDIT - How Often Last Year Need a Drink in the Morning to Get Going","C119113","Alcohol Use Disorder Identification Test Self-Report Version (AUDIT) How often during the last year have you needed a first drink in the morning to get yourself going after a heavy drinking session?","AUDIT - How Often Last Year Need a Drink in the Morning to Get Going | ADT01-Need Drink Morning After Drinking | ADT0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896763","Activin Type 2B Receptor Fc Fusion Protein STM 434","C118625","A soluble fusion protein containing the extracellular domain of the activin receptor type 2B (ACVR2B or ActRIIB) fused to a human Fc domain, with potential antineoplastic activity. Upon intravenous administration, STM 434 selectively binds to the growth factor activin A, thereby preventing its binding to and the activation of endogenous ActRIIB. This prevents activin A/ActRIIB-mediated signaling and inhibits the proliferation of activin A-overexpressing tumor cells. Activin A, a member of the transforming growth factor beta (TGF-beta) superfamily, is overexpressed in a variety of cancers and plays a key role in promoting cancer cell proliferation, migration, and survival.","Activin Type 2B Receptor Fc Fusion Protein STM 434 | Activin Inhibitor STM 434 | STM 434 | STM-434",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896808","Anti-PSMA/CD3 Monoclonal Antibody MOR209/ES414","C118626","An anti-prostate specific membrane antigen (PSMA)/anti-CD3 bispecific humanized monoclonal antibody, with potential immunostimulatory and antineoplastic activities. Anti-PSMA/CD3 monoclonal antibody MOR209/ES414 possesses two antigen-recognition sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for PSMA, a tumor-associated antigen (TAA) overexpressed on the surface of prostate tumor cells. Upon intravenous administration of MOR209/ES414, this bispecific antibody simultaneously binds to both CD3-expressing T-cells and PSMA-expressing cancer cells, thereby crosslinking PSMA-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This results in CTL-mediated cancer cell lysis of prostate cancer cells expressing PSMA.","Anti-PSMA/CD3 Monoclonal Antibody MOR209/ES414 | MOR209/ES414",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896971","Ellagic Acid/Annona muricata Supplement","C118627","A nutritional supplement containing the phytochemical polyphenol, ellagic acid, and an extract of Annona muricata, with potential chemopreventive activity. Although the exact mechanism of action for ellagic acid has yet to be fully elucidated, this agent acts as an anti-oxidant and reduces oxidative stress. This agent also appears to protect the body against certain carcinogens, either through preventing DNA binding or by increasing the rate of their metabolism and deactivation. Certain extracts of Annona muricata, a member of the custard apple plants and belonging to the Annonaceae family, may have antiviral activity, potential targets include human papilloma virus (HPV), and may be cytotoxic against various types of cancer cells.","Ellagic Acid/Annona muricata Supplement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896799","VEGFR/FGFR Inhibitor ODM-203","C118628","An orally available inhibitor of the human vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs), with potential antiangiogenic and antineoplastic activities. VEGFR/FGFR inhibitor ODM-203 inhibits both VEGFRs and FGFRs, which may result in the inhibition of VEGFR- and FGFR-mediated signaling. This leads to an inhibition of angiogenesis and cell proliferation in tumor cells overexpressing VEGFR and/or FGFR. Both VEGFRs and FGFRs belong to the superfamily of receptor tyrosine kinases and are upregulated in various tumor cell types.","VEGFR/FGFR Inhibitor ODM-203 | ODM 203 | ODM-203",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896740","JAK1 Inhibitor INCB052793","C118629","An orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1), with potential antineoplastic activity. Upon oral administration, INCB052793 specifically binds to and inhibits the phosphorylation of JAK1, which interferes with JAK-dependent signaling and may lead to an inhibition of cellular proliferation in JAK1-overexpressing tumor cells. The JAK-STAT (signal transducer and activator of transcription) signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types.","JAK1 Inhibitor INCB052793 | INCB052793",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898586","Liver Adenosquamous Carcinoma","C118630","A rare carcinoma that arises from the intrahepatic bile ducts and is composed of malignant glandular cells and malignant squamous cells.","Liver Adenosquamous Carcinoma | Liver Adenosquamous Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054881","HEY1/NCOA2 Fusion Gene","C121919","A fusion gene that results from a chromosomal rearrangement involving 8q21.1 and 8q13.3 which fuses the first 4 exons of the HEY1 gene in frame with exon 13 of the NCOA2 gene. This fusion is associated with mesenchymal chondrosarcoma.","HEY1/NCOA2 Fusion Gene | HEY1-NCOA2 Fusion Gene | HEY1::NCOA2 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054694","Ivory Exostosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054706","Intermediate Osteogenic Neoplasm","C121925","A non-metastasizing, locally aggressive, bone-forming neoplasm.","Intermediate Osteogenic Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054709","Intermediate Bone Neoplasm","C121926","A locally aggressive or rarely metastasizing neoplasm that arises from the bone.","Intermediate Bone Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053606","anti-OX40 antibody PF-04518600","C121927","An agonistic antibody that recognizes the co-stimulatory receptor OX40 (CD134; TNFRSF4), with potential immunostimulatory activity. Upon administration, ivuxolimab selectively binds to and activates OX40; which induces proliferation of memory and effector T-lymphocytes. In the presence of tumor-associated antigens (TAAs), this may promote a T-cell-mediated immune response against TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and plays an essential role in T-cell activation.","Ivuxolimab | Anti-OX40 Agonist Monoclonal Antibody PF-04518600 | IVUXOLIMAB | PF-04518600 | PF-8600 | PF04518600",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055180","Copper Cu 64-DOTA B-Fab","C121928","A radioimmunoconjugate containing a bivalent monospecific tandem immunoglobulin fragment (B-Fab) derived from the humanized monoclonal antibody DS6 targeting the tumor-associated mucin-1 (MUC1)-sialoglycotope CA6 conjugated with the bifunctional, macrocyclic chelating agent 1,4,7,10-tetra-azacyclododecane-1,4,7,10-tetra-acetic acid (DOTA) and labeled with the radioisotope copper Cu 64 with potential use as an imaging agent for CA6-expressing tumors using positron emission tomography (PET). The B-Fab moiety of Copper Cu 64-DOTA B-Fab binds, with high affinity, to the cell surface antigen CA6. Upon binding, the radioisotope moiety may be detected using PET, thereby allowing the imaging and quantification of CA6-expressing tumor cells. This tracer could be used to select patients who could benefit from and to monitor efficacy of CA6-targeted anti-cancer therapies. Compared to DS6, the antibody fragment allows for increased tumor penetration, faster blood clearance, and more rapid renal elimination. The CA6 epitope is found on a variety of solid tumors.","Copper Cu 64-DOTA B-Fab | 64 Cu-DOTA B-Fab | 64 Cu-DOTA DS6 B-Fab | Cu 64-labeled B-Fab DS6 Antibody-like Binding Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471811","Dual-Energy Computed Tomography","C121378","An application of computed tomography that uses different x-ray spectra to acquire two image sets at the same anatomic location. This technique allows for the analysis of energy-dependent changes in the attenuation of different materials and facilitates the differentiation, characterization, isolation, and distinction of the imaged tissue and material.","Dual-Energy Computed Tomography | DECT",,,,,,,,,,,,,,,"36715385","Dual energy computed tomography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053620","Multicarotenoid Supplement MCS-8","C121859","A supplement containing multiple, as of yet undisclosed, carotenoids, with potential chemopreventive activity. Upon oral administration of the multicarotenoid supplement MCS-8, the carotenoids may be able to exert their chemopreventive activity through multiple mechanisms of action.","Multicarotenoid Supplement MCS-8 | MCS-8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3553350","Congenital Nephrotic Syndrome - Diffuse Mesangial Sclerosis","C121198","Nephrotic syndrome within the first three motnhs of life, characterized initially by increased mesangial matrix, with or without hypertrophy and hyperplasia of podocytes, and eventual glomerular sclerosis.","Congenital Nephrotic Syndrome - Diffuse Mesangial Sclerosis | Diffuse Mesangial Sclerosis",,,,,,,,,,,,,,,"4008560","Diffuse mesangial sclerosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1845055","Alpha Thalassemia X-Linked Mental Retardation Syndrome","C118631","A rare, X-linked recessive inherited syndrome caused by mutations in the ATRX gene. It is characterized by intellectual disability, developmental delays, hypotonia, widely spaced eyes, small nose, low-set ears, tented upper lip, skeletal abnormalities, and a mild form of alpha thalassemia.","Alpha Thalassemia X-Linked Mental Retardation Syndrome | ATRX | Alpha Thalassemia/Mental Retardation Syndrome X-Linked",,,,,,,,,,,,,,,"37399441","Alpha thalassemia X-linked intellectual disability syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0752166","Bardet-Biedl Syndrome","C118632","An autosomal recessive inherited syndrome caused by mutations in at least fourteen different genes, called BBS genes. It is characterized by loss of vision, obesity, diabetes, hypertension, hypercholesterolemia, polydactyly, intellectual disability, genital organs abnormalities, and delayed development of motor skills.","Bardet-Biedl Syndrome | BBS | Laurence-Moon Syndrome | Laurence-Moon-Bardet-Biedl Syndrome | Laurence-Moon-Biedl Syndrome",,,,,,,,,,,,,,,"4209284","Bardet-Biedl syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0020074","Neuropathy, Hereditary Sensory and Autonomic, Type IV","C118633","A rare, autosomal recessive inherited disorder caused by mutations in the NTRK1 gene. It is characterized by inability to feel pain and temperature that leads to repeated unintentional self-injuries, and decreased or absent sweating that leads to hyperpyrexia and febrile seizures.","Neuropathy, Hereditary Sensory and Autonomic, Type IV | CIPA | Congenital Insensitivity to Pain with Anhidrosis | HSAN4 | Hereditary Sensory and Autonomic Neuropathy Type IV",,,,,,,,,,,,,,,"4271311","Hereditary insensitivity to pain with anhidrosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054154","Primary Non-Hodgkin Lymphoma of the Bone","C121930","A non-Hodgkin lymphoma that arises from the bone, without lymph node or other extranodal involvement.  The femur, spine, and pelvic bones are the most frequently affected areas.  The majority of cases are diffuse large B-cell lymphomas.  Most patients present with pain in the affected area.  Systemic symptoms are rare.","Primary Bone Non-Hodgkin Lymphoma | Primary Non-Hodgkin Lymphoma of Bone | Primary Non-Hodgkin Lymphoma of the Bone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054707","Intermediate Osteoclastic Giant Cell-Rich Tumor of Bone","C121931","A benign but locally aggressive giant cell tumor that arises from the bone.","Intermediate Osteoclastic Giant Cell-Rich Tumor of Bone | Intermediate Osteoclastic Giant Cell-Rich Tumor of the Bone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206638","Giant Cell Tumor of Bone","C121932","A benign but locally aggressive tumor that arises from the bone and is composed of mononuclear cells admixed with macrophages and osteoclast-like giant cells.  It usually arises from the ends of long bones or the vertebrae.  Clinical presentation includes pain, edema, and decreased range of motion in the affected joint.","Giant Cell Tumor of Bone | Benign Bone Giant Cell Tumor | GCTB | GIANT CELL TUMOR, BENIGN | Giant Cell Tumor of the Bone | Giant cell tumor of bone, NOS | Osteoclastoma | Osteoclastoma, Benign","9250/1","Giant cell tumor of bone, NOS",,,,,,,,,,,,,"4239133|44783785","Giant cell tumor of bone|Giant cell tumor of bone",,,,,,,,,,,,,"--","--",,,,,,,,"--|--"
"C4054576","Malignant Osteoclastic Giant Cell-Rich Tumor of Bone","C121933","A giant cell tumor that arises from the bone and is characterized by the presence of a malignant cellular component.","Malignant Osteoclastic Giant Cell-Rich Tumor of Bone | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054136","Questionnaire Subsection Name","C121934","The textual identifier used to group a set of questions or tests in a questionnaire.","Questionnaire Subsection Name | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054776","High Reference Range in Text Format","C121935","The upper limit of the test reference range, reported in text.","High Reference Range in Text Format | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0520753","Foreign Body Ingestion","C121588","The swallowing of an item not intended for consumption.","Foreign Body Ingestion | ",,,,,,,,,,,,,,,"4031190","Swallowed foreign body",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1522559","Recombinant RANTES","C1211","A member of the IL-8 superfamily of cytokines and released from platelets and activated T-cells, RANTES is a selective chemoattractant for eosinophils, monocytes, and T-lymphocytes.  RANTES is one of the ligands for chemokine receptor CCR5. RANTES expression in peripheral lymphocytes increases exponentially following mitogenic or antigenic stimulation.  RANTES is one of the major HIV-suppressive factors produced by CD8-positive T-cells.","Recombinant RANTES | CCL5 | RANTES | Regulated on Activation, Normal T Expressed and Secreted | SIS delta | T-Cell RANTES Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055193","Congenital Nephrotic Syndrome - Focal Segmental Glomerulosclerosis","C121200","Nephrotic syndrome within the first three months of life, characterized by scarring of the glomerulus, in which only part of the glomerulus is involved, and less than 50% of the glomeruli are affected.","Congenital Nephrotic Syndrome - Focal Segmental Glomerulosclerosis | Congenital FSGS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034215","Pyometra","C121207","An infectious process characterized by the accumulation of pus within the uterus.","Pyometra | PYOMETRA",,,,,,,,,,,,,,,"4230796","Pyometra",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055156","Denys-Drash Syndrome, Incomplete","C121209","Condition comprising congenital nephrotic syndrome with associated WT1 gene mutation with either intersex disorder or Wilms tumor.","Denys-Drash Syndrome, Incomplete | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0560258","IgA Nephropathy, Liver Disease-associated","C121210","IgA nephropathy secondary to hepatobiliary disease.","IgA Nephropathy, Liver Disease-associated | ",,,,,,,,,,,,,,,"4104770","IgA nephropathy associated with liver disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055479","Allogeneic CD3- CD19- Selected Natural Killer Cells","C121445","Human leukocyte antigen (HLA)-haploidentical donor-derived natural killer (NK) cells that are activated with the cytokine interleukin-15 (IL-15), with immunomodulating and antineoplastic activities. Upon leukapheresis, the HLA-haploidentical donor peripheral blood mononuclear cells (PBMCs) are treated to remove T-lymphocytes (CD3+) and B-lymphocytes (CD19+) cells. In turn, NK cells are expanded and activated with IL-15. Upon infusion of the allogeneic CD3- CD19- selected NK cells, these cells recognize and bind to tumor cells, and secrete perforins, granzymes, and cytokines, which results in cancer cell lysis.","Allogeneic CD3- CD19- Selected Natural Killer Cells | Allogeneic CD3-/CD19- NK Cell Product | Allogeneic CD3-/CD19- NK Cells | Allogeneic CD3-/CD19- Natural Killer Cells | CD3/CD19-depleted Donor NK Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899967","BRAF NM_004333.4:c.1797_1798insACA","C118895","A genetic variation where the trinucleotide, adenine-cytosine-adenine, has been inserted between the nucleotides at positions 1797 and 1798 of the coding sequence of the BRAF gene.","BRAF NM_004333.4:c.1797_1798insACA | B-RAF1 c.1797_1798insACA | BRAF c.1795_1797dup | BRAF c.1797_1798insACA | NM_004333.4:c.1795_1797dup | NM_004333.4:c.1795_1797dupACA | NM_004333.4:c.1797_1798insACA | v-raf Murine Sarcoma Viral Oncogene Homolog B1 c.1797_1798insACA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899968","BRAF NM_004333.4:c.1796_1797insTAC","C118896","A genetic variation where the trinucleotide, thymine-adenine-cytosine, has been inserted between the nucleotides at positions 1796 and 1797 of the coding sequence of the BRAF gene.","BRAF NM_004333.4:c.1796_1797insTAC | B-RAF c.1796_1797insTAC | BRAF c.1796_1797insTAC | BRAF c.1798insTAC | NM_004333.4:c.1796_1797insTAC | NM_004333.6:c.1794_1796dup | v-raf Murine Sarcoma Viral Oncogene Homolog B1 c.1796_1797insTAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL479890","Fraser Syndrome","C118436","A rare, autosomal recessive inherited disorder caused by mutations in the FRAS1, FREM2, or GRIP1 genes. It is characterized by the presence of cryptophthalmos, cutaneous syndactyly, and genitourinary abnormalities.","Fraser Syndrome | Cryptophthalmos-Syndactyly Syndrome",,,,,,,,,,,,,,,"442057","Cryptophthalmos syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017926","Glycogen Storage Disease Type VII","C118437","A rare, autosomal recessive inherited metabolic disorder caused by mutation in the PFKM gene. It results in the deficiency of the M subunit of the phosphofructokinase enzyme. It is characterized by the presence of muscle pain and weakness and sometimes rhabdomyolysis with myoglobinuria, following exercise. Affected infants develop muscle weakness. Patients with the hemolytic form of this disorder develop hemolytic anemia without signs or symptoms of muscle pain and weakness.","Glycogen Storage Disease Type VII | GSD7 | GSDVII | Glycogen Storage Disease VII | Muscle Phosphofructokinase Deficiency | PFKM Deficiency | Phosphofructokinase Deficiency | Tarui Disease",,,,,,,,,,,,,,,"4230040","Glycogen storage disease, type VII",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0345407","Osteopetrosis with Renal Tubular Acidosis","C118438","A rare, autosomal recessive inherited disorder caused by mutation in the CA2 gene. It is characterized by osteopetrosis, renal tubular acidosis, and cerebral calcifications. It results in growth failure, mental retardation, and fractures.","Osteopetrosis with Renal Tubular Acidosis | Autosomal Recessive Osteopetrosis 3 | Autosomal Recessive Osteopetrosis, Type 3 | Carbonic Anhydrase II Deficiency | Guibaud-Vainsel Syndrome | Marble Brain Disease | OPTB3",,,,,,,,,,,,,,,"4111326","Osteopetrosis with renal tubular acidosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3897393","TGFA Gene Product","C118439","A protein encoded by the TGFA gene.","TGFA Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0072502","Protransforming Growth Factor Alpha, human","C118440","Protransforming growth factor alpha (160 aa, ~17 kDa) is encoded by the human TGFA gene. This protein plays a role in cell proliferation.","Protransforming Growth Factor Alpha | Pro-Transforming Growth Factor Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3900167","anti-inflammatory antibody ALXN1007","C118441","A humanized monoclonal antibody directed against the complement protein C5a, with potential immunomodulating and anti-inflammatory activities. Upon administration, olendalizumab targets and binds to C5a. This prevents the binding of C5a to its receptor C5a receptor (C5aR) and prevents C5a/C5aR-mediated pro-inflammatory signaling, thereby reducing inflammation and tissue and organ damage. C5a, a factor in the complement cascade, plays important roles in inflammation and immunity.","Olendalizumab | ALXN 1007 | ALXN-1007 | ALXN1007 | Immunoglobulin, Anti-(human complement C5a) (human-mus musculus ALXN1007 heavy chain), Disulfide with Human-mus Musculus ALXN1007 Kappa-chain, Dimer | Lendalizumab | OLENDALIZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446628","PI3K/mTOR inhibitor LY3023414","C121817","An orally bioavailable, small molecule inhibitor of certain class I phosphoinositide 3-kinase (PI3K) isoforms and mammalian target of rapamycin kinase (mTOR) in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Samotolisib inhibits both certain PI3K isoforms and mTOR in an ATP-competitive manner which may inhibit both the PI3K/mTOR signaling pathway in and proliferation of tumor cells overexpressing PI3K and/or mTOR. The PI3K/mTOR pathway is upregulated in a variety of tumor cells and plays a key role in promoting cancer cell proliferation, and survival, motility and resistance to chemotherapy and radiotherapy. mTOR, a serine/threonine kinase downstream of PI3K, may also be activated in a PI3K-independent fashion; therefore, this agent may be more potent than an agent that inhibits either PI3K or mTOR alone. In addition, LY3023414 may inhibit DNA-dependent protein kinase (DNA-PK), thereby inhibiting the ability of tumor cells to repair damaged DNA. DNA-PK is activated upon DNA damage and plays a key role in repairing double-stranded DNA breaks.","Samotolisib | 2H-Imidazo(4,5-C)quinolin-2-one, 1,3-Dihydro-8-(5-(1-hydroxy-1-methylethyl)-3-pyridinyl)-1-((2S)-2-methoxypropyl)-3-methyl- | LY 3023414 | LY-3023414 | LY3023414 | PI3K/mTOR Inhibitor LY3023414 | SAMOTOLISIB | WHO 10889",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471744","P-TEFb inhibitor BAY1143572","C121456","An inhibitor of positive transcription elongation factor b (P-TEFb), which is composed of cyclin-dependent kinase 9 (CDK9) and cyclin-T (CycT), with potential antineoplastic activity. Upon administration, atuveciclib binds to and inhibits the activity of P-TEFb, thereby preventing the phosphorylation of its downstream target, the carboxyl terminal domain (CTD) of RNA polymerase II (RNA Pol II), and inhibiting the activation of transcriptional elongation by RNA Pol II. This prevents the transcription of tumor promoting genes, induces tumor cell apoptosis, and inhibits tumor cell proliferation. P-TEFb plays an important role in the regulation of gene transcription; over-activation in cancer cells leads to both the transcription of key tumor-promoting genes and cancer cell proliferation.","Atuveciclib | 1,3,5-Triazin-2-amine, 4-(4-Fluoro-2-methoxyphenyl)-N-(3-((S-methylsulfonimidoyl)methyl)phenyl)-, (+)- | ATUVECICLIB | BAY 1143572 | BAY1143572",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896811","Anti-gpA33/CD3 Monoclonal Antibody MGD007","C118442","An anti-glycoprotein A33 (gpA33)/anti-CD3 bispecific humanized monoclonal antibody with potential immunostimulatory and antineoplastic activities. Anti-gpA33/CD3 monoclonal antibody MGD007 possesses two antigen-recognition sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for gpA33, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of MGD007, this bispecific antibody simultaneously binds to both CD3-expressing T-cells and gpA33-expressing cancer cells, thereby crosslinking cytotoxic T-lymphocytes (CTLs) to gpA33-expressing tumor cells. This may result in CTL-mediated cell lysis of the crosslinked tumor cells. The gpA33 antigen, a member of the immunoglobulin superfamily, is expressed in certain malignancies, including colon and gastrointestinal cancers.","Anti-gpA33/CD3 Monoclonal Antibody MGD007 | Humanized gpA33 x CD3 DART (TM) Protein MGD007 | MGD-007 | MGD007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896899","Anti-fucosyl-GM1 Monoclonal Antibody BMS-986012","C118443","A monoclonal antibody directed against the ganglioside fucosyl-GM1, with potential antineoplastic and immunomodulating activities. Upon administration, atigotatug binds to fucosyl-GM1 on cancer cells and may activate both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity against the bound tumor cells. This may inhibit the proliferation of GM1-expressing tumor cells. Fucosyl-GM1, a sphingolipid monosialoganglioside and tumor associated antigen (TAA), is overexpressed on the surface of many cancer cells while its expression is minimal or non-existent in normal tissues.","Atigotatug | ATIGOTATUG | Anti-fucosyl-GM1 Monoclonal Antibody BMS-986012 | Anti-fucosyl-GM1 Monoclonal Antibody BMS-986012 | BMS-986012",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896755","Gamboge Resin Extract TSB-9-W1","C118444","An orally bioavailable extract from the yellow to brown gum-resin of the gamboge tree (genus Garcinia) belonging to the Clusiaceae (or Guttiferae) family, with potential anti-inflammatory and antineoplastic activities. Gamboge resin extract TSB-9-W1 contains various active ingredients, including gambogic acid, formoxanthone A, betulin, betulinic acid, morellic acid, isomorellic acid, isogambogic acid, isomorellinol and desoxymorellin. Upon oral administration, the various active components of the gamboge resin extract TSB-9-W1 may bind to and inhibit the activity of a variety of cancer-related proteins, may induce apoptosis, and may exert cytotoxic activity on tumor cells, thereby inhibiting tumor cell proliferation. TSB-9 is derived from TSB-14, which is the acetone-extract of gamboge resin, and pulverized into powder form; TSB-9 is 90% extract and 10% brown sugar. TSB-9-W1 is a milled form of TSB-9 with a particle size of 5 micrometers.","Gamboge Resin Extract TSB-9-W1 | GARCINIA HANBURYI ROOT RESIN | Garcinia Hanburyi Rhizome Resin | Garcinia Hanburyi Root Resin | TSB-9-W1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053593","Cancer Peptide Vaccine S-588410","C121776","A cancer peptide vaccine containing five human leukocyte antigen (HLA)-A*2402-restricted epitope peptides derived from as of yet not disclosed oncoantigens, with potential immunostimulating and antineoplastic activities. Upon administration of the cancer peptide vaccine S-588410, the peptides may stimulate a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing the antigens. This decreases proliferation of susceptible tumor cells.","Cancer Peptide Vaccine S-588410 | S-588410",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053487","Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118","C121777","A cancer vaccine containing pTVG4 plasmid DNA encoding the human androgen receptor (AR) ligand-binding domain (LBD) (pTVG-AR), with potential immunostimulating and antineoplastic activities. Upon intradermal administration of AR LBD-encoding plasmid DNA vaccine MVI-118, the plasmid DNA vaccine expresses AR LBD and may stimulate the host immune system to generate a cytotoxic T-lymphocyte (CTL) response against AR LBD-expressing prostate cancer cells. This reduces proliferation of AR-expressing tumor cells. AR, a tumor-associated antigen (TAA) overexpressed in prostate cancer cells, plays a key role in the development and progression of prostate cancer; its expression is correlated with poor prognosis.","Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118 | AR LBD-encoding Plasmid DNA Vaccine MVI-118 | MVI-118 | pTVG-AR | pTVG-AR Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053577","anti-sCLU monoclonal antibody AB-16B5","C121778","A humanized, immunoglobulin (Ig) G2 monoclonal antibody against the secreted form of human clusterin (sCLU) expressed by tumor cells, with potential antineoplastic and anti-metastatic activities. Upon administration, sotevtamab specifically binds to tumor-associated sCLU and inhibits its activity. This inhibits both the sCLU-mediated signal transduction pathways and epithelial-to-mesenchymal transition (EMT), which leads to the inhibition of tumor cell migration and invasion. In addition, sotevtamab enhances chemo-sensitivity. sCLU, a heterodimeric disulfide-linked glycoprotein overexpressed by various types of cancer cells, contributes to proliferation and survival of cancer cells, and stimulates tumor cell EMT.","Sotevtamab | AB-16B5 | Anti-sCLU Monoclonal Antibody AB-16B5 | SOTEVTAMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0073109","Retinyl Acetate","C1216","A naturally-occurring fatty acid ester form of retinol (vitamin A) with potential antineoplastic and chemopreventive activities.  Retinyl acetate binds to and activates retinoid receptors, inducing cell differentiation and decreasing cell proliferation.  This agent also inhibits carcinogen-induced neoplastic transformation in some cancer cell types and exhibits immunomodulatory properties. (NCI04)","Retinyl Acetate | Retinol Acetate | Retinyl acetate | VITAMIN A ACETATE | Vitamin A, acetate | vitamin A acetate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0647434","2'-deoxy-4'-thiocytidine","C121828","An orally bioavailable 4-thio modified 2-deoxycytidine analog, with potential antineoplastic activity. Upon administration of 4-thio-2-deoxycytidine (TdCyd), this cytidine analog gets incorporated into DNA during replication and inhibits the activity of DNA methyltransferase 1 (DNMT1), which blocks DNA hypermethylation. This results in DNMT1 depletion, hypomethylation of DNA, and the reactivation of tumor suppressor genes that were silenced by hypermethylation; this results in antitumor activity and an inhibition of tumor cell proliferation.","4-Thio-2-deoxycytidine | 4'-THIO-2'-DEOXYCYTIDINE | 4'-Thio-2'-deoxycytidine | T-dCyd | TdCyd",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053689","bromodomain inhibitor ABBV-075","C121829","An inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, mivebresib binds to the acetyl-lysine binding site of  BRD-containing protein(s), thereby preventing the interaction between those proteins and acetylated histones. This disrupts chromatin remodeling, prevents the expression of certain growth-promoting genes, and leads to an inhibition of cell growth in susceptible tumors.","Mivebresib | ABBV-075 | Ethanesulfonamide, N-(4-(2,4-difluorophenoxy)-3-(6,7-dihydro-6-methyl-7-oxo-1H-pyrrolo(2,3-C)pyridin-4-yl)phenyl)- | MIVEBRESIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054585","MYH9/USP6 Fusion Gene","C121149","A fusion gene that results from a chromosomal translocation t(17;22)(p13;q12.3-q13) which fuses the promoter region of the MYH9 gene upstream of the coding region of the USP6 gene. This fusion causes increased expression of the USP6 gene and is associated with nodular fasciitis.","MYH9/USP6 Fusion Gene | MYH9-USP6 Fusion Gene | MYH9::USP6 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053775","Pituitary Stalk Interruption Syndrome","C121150","A syndrome characterized by hypoplastic or aplastic anterior pituitary gland, a very thin or interrupted pituitary stalk, and ectopic or absent posterior pituitary gland, which may be associated with mutation(s) in the HESX1 or LHX4 genes.","Pituitary Stalk Interruption Syndrome | Hypoplastic Anterior Pituitary, Missing Stalk, and Ectopic Posterior Pituitary | PSIS",,,,,,,,,,,,,,,"37398939","Pituitary stalk interruption syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4230764","Ectopic Posterior Pituitary","C121151","Atypically located posterior pituitary gland that may be associated with anterior or posterior pituitary hormone deficiencies.","Ectopic Posterior Pituitary | Ectopic Neurohypophysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055021","FSH-producing Adenoma","C121152","A pituitary neuroendocrine tumor that produces follicle-stimulating hormone (FSH).","FSH-Producing Pituitary Neuroendocrine Tumor | FSH-Producing Gonadotroph Adenoma | FSH-Producing Pituitary Gland Adenoma | FSH-producing Adenoma | Follicle Stimulating Hormone-Producing Adenoma | Follicle Stimulating Hormone-Producing Gonadotroph Adenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054682","LH-producing Adenoma","C121153","A pituitary neuroendocrine tumor that produces luteinizing hormone (LH).","LH-Producing Pituitary Neuroendocrine Tumor | LH-Producing Gonadotroph Adenoma | LH-Producing Pituitary Gland Adenoma | LH-producing Adenoma | Luteinizing Hormone-Producing Adenoma | Luteinizing Hormone-Producing Gonadotroph Adenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054901","Genomically-Directed Monotherapy","C121155","The use of genomic sequencing to direct cancer therapy. A profile of the DNA and RNA expressed by a patient's tumor is obtained and used to select known therapies that will exploit the specific genetic defects found in that tumor.","Genomically-Directed Monotherapy | Genomically Directed Monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0410536","Mesomelic Dysplasia","C121156","A form of skeletal dysplasia characterized by shortening of the bones of the middle segments of the limbs (i.e., the radii, ulnae, tibiae and fibulae).","Mesomelic Dysplasia | Mesomelic Dysplasias",,,,,,,,,,,,,,,"4006936","Mesomelic dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053737","Casein/Whey Protein/Soy Protein/Pea Protein/Fat Mix/EPA/DHA-based Nutritional Supplement","C121643","A gluten-free, calorie-rich nutritional supplement containing all essential vitamins, minerals, and trace elements, as well as protein, fat and carbohydrates. The protein contained in this supplement is derived from a variety of sources, including casein, whey, soy and pea; it helps maintain digestive health throughout the gastrointestinal tract and reduces the risk of digestive complications. This supplement contains the essential omega-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexanaeoic acid (DHA). DHA and EPA are incorporated into cell membranes and affect the production of pro-inflammatory mediators, eliciting an anti-inflammatory effect. Medium chain triglycerides (MCT) in this supplement enhance fat absorption. Upon oral intake of this nutritional supplement, the ingredients may prevent both malnutrition and weight loss.","Casein/Whey Protein/Soy Protein/Pea Protein/Fat Mix/EPA/DHA-based Nutritional Supplement | Nutrison",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0359587","Peptamen","C121644","An orally available, gluten-free, enzymatically hydrolyzed cysteine-rich whey-protein based nutritional supplement containing essential vitamins, minerals, and trace elements, as well as fat and carbohydrates. Upon oral intake of the nutritional supplement, the whey protein may improve gastric functioning and gastrointestinal health, thereby reducing vomiting and diarrhea. The whey-based hydrolyzed protein helps to alleviate the digestive burden for the pancreas and may be beneficial for patients with a pancreas-associated disease, such as pancreatitis or pancreatic cancer. Due to the high levels of cysteine in the whey protein, this supplement increases levels of the antioxidant glutathione (GSH). The polyunsaturated fatty acids in this supplement are incorporated in cell membranes and affect the production of pro-inflammatory mediators, eliciting an anti-inflammatory effect. Medium chain triglycerides (MCT) in this supplement enhance fat absorption and may aid in the prevention of fat malabsorption. Altogether, this supplement may prevent both malnutrition and weight loss.","Enzymatically-hydrolyzed Whey Protein-based Nutritional Supplement | Peptamen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053603","BMI1 inhibitor PTC596","C121645","An orally active inhibitor of the polycomb ring finger oncogene BMI1 (B-cell-specific Moloney murine leukemia virus integration site 1), with potential antineoplastic activity. Upon oral administration, unesbulin targets BMI1 expressed by both tumor cells and cancer stem cells (CSCs), and induces hyper-phosphorylation of BMI1 leading to its degradation. This inhibits BMI1-mediated signal transduction pathways and results in a reduction of proliferation of BMI1-expressing tumor cells.  BMI1, a key protein in the polycomb repressive complex 1 (PRC1), is overexpressed in certain tumor cell types, and plays a key role in CSC survival, proliferation and resistance to chemotherapeutics; its expression is associated with increased tumor aggressiveness and a poor prognosis.","Unesbulin | PTC596 | Polycomb Ring Finger Oncogene Inhibitor PTC596 | UNESBULIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053637","Raf kinase inhibitor HM95573","C121646","An orally available inhibitor of members of the Raf family of serine/threonine protein kinases, with potential antineoplastic activity. Upon administration, belvarafenib binds to and inhibits the B-Raf mutant V600E and C-Raf. This inhibits B-Raf V600E- and C-Raf-mediated signal transduction pathways, thereby inhibiting tumor cell growth of susceptible tumor cells. In addition, belvarafenib may also inhibit mutated Ras proteins. Raf protein kinases play a key role in the Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway, which is often dysregulated in human cancers and plays a key role in tumor cell proliferation and survival. The Raf mutation B-Raf V600E, where the valine at residue 600 is substituted for glutamic acid, is frequently overexpressed in a variety of human tumors and results in the constitutive activation of the Raf/MEK/ERK signaling pathway.","Belvarafenib | BELVARAFENIB | HM95573",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053605","c-Kit inhibitor PLX9486","C121647","An orally bioavailable protein tyrosine kinase inhibitor of mutated forms of the tumor-associated antigen mast/stem cell factor receptor c-Kit (SCFR), with potential antineoplastic activity. Upon oral administration, bezuclastinib binds to and inhibits specific c-Kit mutants. This may result in an inhibition of tumor cell proliferation in cancer cell types that overexpress these c-Kit mutations. c-Kit, a transmembrane protein and receptor tyrosine kinase, is overexpressed in solid tumors and hematological malignancies; it plays a key role in the regulation of cell differentiation and proliferation.","Bezuclastinib | BEZUCLASTINIB | CGT 9486 | CGT-9486 | CGT9486 | PLX9486 | c-Kit Inhibitor PLX9486",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053587","HPV16 L2/E6/E7 Fusion Protein Vaccine TA-CIN","C121648","A recombinant human papillomavirus (HPV), genetically engineered fusion protein vaccine in which the three HPV16 viral proteins L2, E6 and E7 are fused together in a single tandem fusion protein (TA-CIN; HPV16 L2\E6\E7), with potential immunoprotective and antineoplastic properties. Upon administration, HPV16 L2\E6\E7 fusion protein vaccine TA-CIN may stimulate the immune system to generate HPV16 E6\E7-specific CD4+ and CD8+ T-cell responses as well as the induction of L2-specific antibodies. In addition, this vaccine may prevent infection and the development of other HPV16-associated diseases. L2, a minor viral capsid protein, is able to induce a strong antibody response against certain HPV types.","HPV16 L2/E6/E7 Fusion Protein Vaccine TA-CIN | TA-CIN | Tissue Antigen-Cervical Intraepithelial Neoplasia Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1368845","Estriol Vaginal Gel","C121779","A vaginal gel formulation containing a very low concentration of the estrogen estriol, that can be used for hormone replacement. Upon topical application to the vagina, estriol maintains adequate levels of estrogen in the vagina, and decreases vaginal atrophy and its associated symptoms, such as vaginal dryness and itching.","Estriol Vaginal Gel | Blissel | Gelistrol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055241","Chlorhexidine/Ethyl Alcohol Mouthwash","C121780","A mouthwash containing the biguanide chlorhexidine and ethyl alcohol, with topical antibacterial activity. Upon rinsing the oral cavity with the chlorhexidine/ethyl alcohol mouthwash, the positively charged chlorhexidine cation exerts its antibacterial activity through binding to the negatively charged microbial cell surface, which destroys the integrity of the cell membrane. This causes leakage of intracellular components leading to cell death. Ethyl alcohol denatures bacterial proteins, and dissolves and disrupts the bacterial lipid membrane, thereby killing the bacteria. This reduces oral colonization with harmful bacteria and may prevent oral mucositis.","Chlorhexidine/Ethyl Alcohol Mouthwash | ChloraPrep | Chlorhexidine/Ethyl Alcohol Mouth Rinse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055052","Ethyl Alcohol Mouthwash","C121781","A mouthwash containing ethyl alcohol, with topical antibacterial activity. Upon rinsing the oral cavity with the ethyl alcohol mouthwash, ethyl alcohol denatures bacterial proteins, and dissolves and disrupts the bacterial lipid membrane, thereby killing the bacteria. This reduces oral colonization with harmful bacteria and may prevent oral mucositis.","Ethyl Alcohol Mouthwash | Ethyl Alcohol Mouth Rinse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055455","Anti-mesothelin iCasp9M28z CAR-transduced Autologous T Lymphocytes","C121782","Genetically modified, autologous T-lymphocytes transduced with a retroviral vector encoding a chimeric antigen receptor (CAR) specific for mesothelin linked to the signaling domains for the co-stimulatory molecules CD28 and CD3 zeta, as well as the suicide gene inducible caspase 9 (iCasp9 or iC9), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, anti-mesothelin iCasp9M28z CAR-transduced autologous T lymphocytes specifically target and kill mesothelin-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, a dimerizing agent can be administered, which binds to the FKBP12-F36V drug-binding domain and activates caspase 9, resulting in the apoptosis of the administered T-cells. Mesothelin, a tumor-associated antigen, is overexpressed in a variety of cancer cell types.","Anti-mesothelin iCasp9M28z CAR-transduced Autologous T Lymphocytes | iCasp9M28z T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054250","Panitumumab-IRDye800","C121783","An imaging agent composed of panitumumab, a humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody, conjugated to the near-infrared (NIR) fluorescent dye IRDye800, that can potentially be used for the imaging of EGFR-expressing tumors. Upon administration of panitumumab-IRDye800, the panitumumab moiety targets and binds to EGFR expressed on tumor cells. Upon fluorescence imaging of IRDye800, the tumor cells can be detected.","Panitumumab-IRDye800 | Panitumumab IRDye 800 | RDye800-Panitumumab Conjugate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054415","Neihulizumab","C121711","A humanized, agonistic monoclonal antibody against P selectin glycoprotein ligand-1 (PSGL-1; SELPLG; CD162), with potential immunosuppressive activity. Upon administration, neihulizumab specifically targets and binds to CD162 expressed on activated T-lymphocytes. This induces apoptosis of activated T-cells and reduces T-cell-mediated immune responses. This may halt disease progression of T-cell-mediated autoimmune diseases and acute graft-versus-host disease (GvHD).","Neihulizumab | AbGn 168H | AbGn-168 | AbGn-168H | NEIHULIZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053750","Low Reference Range in Text Format","C121936","The lower limit of the test reference range, reported in text.","Low Reference Range in Text Format | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054777","High Reference Range in Numeric Format","C121937","The upper limit of the test reference range, reported in numerals.","High Reference Range in Numeric Format | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054592","Low Reference Range in Numeric Format","C121938","The lower limit of the test reference range, reported in numerals.","Low Reference Range in Numeric Format | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054135","Questionnaire Subsection","C121939","A specific section, grouping or division of questions or tests within a questionnaire.","Questionnaire Subsection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055374","Bone Epithelioid Hemangioendothelioma","C121941","A low-grade malignant blood vessel neoplasm arising from the bone.  It is characterized by the presence of epithelioid endothelial cells.  The neoplastic cells are arranged in cords and nests, which are embedded in a myxoid to hyalinized stroma.","Bone Epithelioid Hemangioendothelioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471819","Anti-DR5 Agonistic Antibody DS-8273a","C121158","An agonistic monoclonal antibody directed against human death receptor type 5 (DR5), also called tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2, with potential pro-apoptotic and antitumor activities. Upon administration, anti-DR5 agonistic antibody DS-8273a mimics the natural receptor ligand TRAIL and binds to DR5. This activates DR5 and leads to the activation of the death receptor signal pathway, which results in the activation of caspase cascades, the induction of tumor cell apoptosis and a reduction in proliferation of DR5-expressing tumor cells. DR5, a member of the TNF receptor superfamily, is expressed on the surfaces of a variety of tumor cells and plays a key role in the induction of tumor cell apoptosis.","Anti-DR5 Agonistic Antibody DS-8273a | DS 8273 | DS-8273A | DS-8273a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054698","Iodine I 124-labeled Albumin","C121159","A radioconjugate containing serum albumin labeled with the radioisotope iodine I 124, with potential use as an imaging agent using positron emission tomography (PET). Upon administration, iodine I 124 albumin distributes in a similar manner to endogenous albumin. Upon PET, albumin distribution patterns can be imaged. Specifically, the distribution to and residence time in a tumor can be assessed upon imaging. These findings may predict the distribution patterns of agents with similar particle sizes.","Iodine I 124-labeled Albumin | 124I-albumin | 124I-labeled Albumin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1290049","Superficial Circumscribed Morphea","C121650","Circumscribed morphea in which the lesions are restricted to the skin and the immediately underlying subcutaneous tissues.","Superficial Circumscribed Morphea | Plaque Morphea",,,,,,,,,,,,,,,"4134289","Plaque morphea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054046","Secondary Central Chondrosarcoma","C121881","A chondrosarcoma that arises in a pre-existing enchondroma.","Secondary Central Chondrosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050365","Recognition of Outliers by Sampling Ends","C121991","A hierarchical clustering method for the unsupervised, unbiased selection of gene expression patterns. The ROSE probe set clusters are based on the size of the outlier group they identify as well as the magnitude of the deviation from expected intensity.","Recognition of Outliers by Sampling Ends | ROSE | ROSE Clustering",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054248","Parent Global Assessment of Disease Activity","C121347","A parent-scored instrument that estimates the level of activity of a disease at a given time taking into account all disease manifestations. Typically scored on a numeric rating scale or visual analogue scale, or may be recorded using descriptors such as remission, or low, moderate, or high disease activity.","Parent Global Assessment of Disease Activity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054249","Parent Assessment of Overall Well-Being","C121348","A parent's estimation of the overall impact of a disease on their child at a given time. Typically scored on a numeric rating scale or visual analogue scale.","Parent Assessment of Overall Well-Being | Parent Global Assessment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054228","Patient Global Assessment of Disease Activity","C121349","A patient-scored instrument that estimates the level of activity of a disease at a given time taking into account all disease manifestations. Typically scored on a numeric rating scale or visual analogue scale, or may be recorded using descriptors such as remission, or low, moderate, or high disease activity.","Patient Global Assessment of Disease Activity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004572","Babesia","C122040","A genus of apicomplexan parasites in the family Babesiidae. Babesia are spread by ticks and are the causative agent of the hemolytic disease babesiosis.","Babesia | BABESIA | Nuttalia",,,,,,,,,,,,,,,"4146056","Babesia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1025956","Balamuthia","C122041","A genus of free-living amoeba in the family Balamuthiidae. Its life cycle includes a cystic stage and a trophozoite stage, both of which are infectious.","Balamuthia | BALAMUTHIA",,,,,,,,,,,,,,,"4218966","Balamuthia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1641848","Angiostrongylus","C122042","A genus of parasitic nematode in the family Angiostrongylidae. Memebers of the genus can cause severe gastrointestinal or central nervous system disease in humans, depending on the species.","Angiostrongylus | ANGIOSTRONGYLUS",,,,,,,,,,,,,,,"4324148","Angiostrongylus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006896","Capillaria","C122044","A genus of parasitic nematodes in the family Capillariidae. Members of this genus infect dogs and cats, livestock, poultry, and wild mammals, birds and fish.","Capillaria | CAPILLARIA | Hairworm",,,,,,,,,,,,,,,"4170070","Capillaria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1706526","Cestoda","C122045","A taxonomic grouping of parasitic tapeworms that can be assigned to the class Cestoda.","Cestoda | CESTODA | Tapeworm",,,,,,,,,,,,,,,"4196187","Cestoda",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0314760","Coliform Bacteria","C122046","Any rod-shaped, Gram-negative, non-spore forming, motile or non-motile bacteria which can ferment lactose with the production of acid and gas.","Coliform Bacteria | COLIFORM BACTERIA",,,,,,,,,,,,,,,"4299510","Coliform bacteria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0522435","Cyclospora","C122047","A genus of obligate intracellular parasites in the family Eimeriidae. Cyclospora are transmitted through contaminated food or water. Infection causes diarrhea, nausea, and vomiting.","Cyclospora | CYCLOSPORA",,,,,,,,,,,,,,,"4014344","Cyclospora",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014321","Entamoeba","C122048","A genus of commensal or parasitic Amoebozoans in the class Archamoebae. Almost all species form cysts; the number of nuclei in the cyst varies from 1 to 8 among species and is one of the characteristics used to tell species apart.","Entamoeba | ENTAMOEBA",,,,,,,,,,,,,,,"4242550","Entamoeba",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2742389","C-Type Lectin Domain Family 10 Member A, Human","C122766","C-type lectin domain family 10 member A (316 aa, ~35 kDa) is encoded by the human CLEC10A gene. This protein is involved in the regulation of adaptive and innate immune responses.","C-Type Lectin Domain Family 10 Member A | C-Type (Calcium Dependent, Carbohydrate-Recognition Domain) Lectin, Superfamily Member 13 (Macrophage-Derived) | C-Type (Calcium Dependent, Carbohydrate-Recognition Domain) Lectin, Superfamily Member 14 (Macrophage-Derived) | C-Type Lectin Superfamily Member 14 | CD301 Antigen | Macrophage Lectin 2 | Macrophage Lectin 2 (Calcium Dependent)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0276447","Rhinovirus Infection","C122572","An infectious process caused by rhinovirus. The virus usually causes upper respiratory infections, but can infect the lower tract as well.","Rhinovirus Infection | ",,,,,,,,,,,,,,,"435186","Disease due to Rhinovirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0521008","Screaming","C122573","A loud, vociferous cry or yell; it can be the result of many emotions, including pain, excitement, or fear.","Screaming | ",,,,,,,,,,,,,,,"4219235","Screaming",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1735608","Lupus Flare","C122574","An exacerbation of the chronic disease lupus.","Lupus Flare | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2748200","Positive Herpes Simplex Virus Culture","C122575","Laboratory test results demonstrating the presence of the Herpes Simplex virus in a specimen.","Positive Herpes Simplex Virus Culture | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1318973","Staphylococcus aureus Infection","C122576","An infectious process in which the bacteria Staphylococcus aureus is present.","Staphylococcus aureus Infection | Staphylococcus aureus",,,,,,,,,,,,,,,"433125","Infection due to Staphylococcus aureus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038218","Status Asthmaticus","C122577","An acute exacerbation of asthma, characterized by inadequate response to initial bronchodilators.","Status Asthmaticus | ",,,,,,,,,,,,,,,"45769438","Acute severe exacerbation of asthma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0236071","Throat Tightening","C122578","The sensation of constriction or contraction in the throat area.","Throat Tightening | ",,,,,,,,,,,,,,,"4083757|4090424","Constriction in throat|Tightness in throat",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0751466","Phonophobia","C122579","A fear of sounds, which can include fear of voices, including one's own voice, in addition to other sounds.","Phonophobia | ",,,,,,,,,,,,,,,"4209114","Phonophobia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1112565","Pneumatosis Intestinalis","C122580","The presence of gas within the wall of the large or small intestine.","Pneumatosis Intestinalis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0392618","Postoperative Infection","C122581","Any infection documented following a surgical procedure that was not evident or suspected prior to the procedure.","Postoperative Infection | ",,,,,,,,,,,,,,,"437474","Postoperative infection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2748111","Positive Pseudomonas Culture","C122582","A laboratory test result demonstrating the presence of bacteria from the genus Pseudomonas in a sample after culture.","Positive Pseudomonas Culture | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0075019","Spiromustine","C1233","A bifunctional nitrogen alkylating agent with antineoplastic activity and lipophilic properties. Containing a lipophilic hydantoin group that serves as a carrier to cross the blood brain barrier, spiromustine forms covalent linkages with nucleophilic centers in DNA, causing depurination, base-pair miscoding, strand scission, and DNA-DNA cross-linking, which may result in cytotoxicity. (NCI04)","Spiromustine | 1,3-diazaspiro(4,5)decane-2,4-dione,3-(2-(bis-chloroethyl)amino)ethyl | SHM | SPIROMUSTINE | Spirohydantoin Mustard | Spirohydantoin mustard",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055087","Early Relapse of Acute Lymphoblastic Leukemia","C123401","Clinical and/or laboratory evidence of reemergence of acute lymphoblastic leukemia less than 18 months (extramedullary) or 36 months (marrow) from diagnosis.","Early Relapse of Acute Lymphoblastic Leukemia | Early Recurrence of ALL | Early Recurrence of Acute Lymphoblastic Leukemia | Early Relapse of ALL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054666","Late Relapse of Acute Lymphoblastic Leukemia","C123402","Clinical and/or laboratory evidence of reemergence of acute lymphoblastic leukemia greater than or equal to 18 months (extramedullary) or 36 months (marrow) from diagnosis.","Late Relapse of Acute Lymphoblastic Leukemia | Late Recurrence of ALL | Late Recurrence of Acute Lymphoblastic Leukemia | Late Relapse of ALL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053782","Early Relapse of Acute Myeloid Leukemia","C123403","Clinical and/or laboratory evidence of reemergence of acute myeloid leukemia less than 12 months from diagnosis.","Early Relapse of Acute Myeloid Leukemia | Early Recurrence of AML | Early Recurrence of Acute Myeloid Leukemia | Early Relapse of AML",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054665","Late Relapse of Acute Myeloid Leukemia","C123404","Clinical and/or laboratory evidence of reemergence of acute myeloid leukemia greater than or equal to 12 months from diagnosis.","Late Relapse of Acute Myeloid Leukemia | Late Recurrence of AML | Late Recurrence of Acute Myeloid Leukemia | Late Relapse of AML",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0457577","Multi-Organ Involvement","C123405","A finding indicating the spread of a neoplastic process to multiple organs.","Multi-Organ Involvement | ",,,,,,,,,,,,,,,"4079989","Multi-organ involvement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4050250","Likely Residual Metabolic Tumor Activity","C123409","A finding of focal metabolic activity at the primary or nodal sites that is greater than liver uptake.","Likely Residual Metabolic Tumor Activity | Likely Residual Metabolic Disease | Likely residual metabolic disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050249","Likely Inflammatory Activity","C123410","A finding of metabolic activity at the primary or nodal sites that is greater than liver uptake, but can be attributed to inflammation activity.","Likely Inflammatory Activity | Likely inflammatory | Post-Radiation Inflammation Activity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050462","Definite Residual Metabolic Tumor Activity","C123411","A finding of strong focal metabolic activity at the primary or nodal sites that is greater than liver uptake.","Definite Residual Metabolic Tumor Activity | Definite Residual Metabolic Disease | Definite residual metabolic disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053804","Experimental Organism Luteinized Unruptured Follicle","C123640","A corpus luteum-like structure with a retained oocyte and variably luteinized granulosa cells.","Experimental Organism Luteinized Unruptured Follicle | LUTEINIZED FOLLICLE | Luteinized Unruptured Follicle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054169","Polyovular Follicle","C123641","An ovarian follicle that contains more than one oocyte.","Polyovular Follicle | POLYOVULAR FOLLICLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1548486","Staphage Lysate","C1236","A preparation of bacterial lysate with potential immunomodulatory activity. Staphage lysate, obtained by phage lysis of Staphylococcal aureus, may be used as an antigenic stimulus to elicit non-specific humoral and cellular immune responses.","Staphage Lysate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055576","AVLT-REY - List B Word 1","C123700","The Rey Auditory Verbal Learning TEST (AVLT-REY) List B, Word 1.","AVLT-REY - List B Word 1 | AVL02-List B Word 1 | AVL0218",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055575","AVLT-REY - List B Word 2","C123701","The Rey Auditory Verbal Learning TEST (AVLT-REY) List B, Word 2.","AVLT-REY - List B Word 2 | AVL02-List B Word 2 | AVL0219",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1099662","Trodusquemine","C123882","A naturally-occurring cholestane and non-competitive, allosteric inhibitor of protein tyrosine phosphatase 1B (PTP1B), with potential hypoglycemic, anti-diabetic, anti-obesity, and antineoplastic activities. Upon administration, trodusquemine selectively targets and inhibits PTP1B, thereby preventing PTP1B-mediated signaling. This prevents the dephosphorylation of the insulin receptor, which improves insulin signaling and insulin sensitivity, and decreases blood glucose levels. In susceptible cancer cells, inhibition of PTP1B causes a reduction of tumor cell proliferation. In addition, as trodusquemine can cross the blood-brain barrier (BBB), it centrally suppresses appetite and causes weight loss. PTP1B, a tyrosine phosphatase, is elevated in certain cancer cells; it is specifically upregulated in human epidermal growth factor receptor 2 (HER2)-driven cancers where it promotes cell growth, and is correlated with a poor prognosis and increased metastatic potential. In diabetes, PTP1B upregulation plays a major role in insulin resistance.","Trodusquemine | (24R)-3beta-((3-((4-((3-aminopropyl)amino)butyl)amino)propyl)amino)-7alpha-hydroxy-5alpha-cholestan-24-yl Hydrogen Sulfate | Cholestane-7,24-diol, 3-((3-((4-((3-aminopropyl)amino)butyl)amino)propyl)amino)-, 24-(Hydrogen Sulfate), (3beta,5alpha,7alpha,24R)- | MSI-1436 | MSI-1436C | TRODUSQUEMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053768","RARA Gene Product","C122775","A protein encoded by the RARA gene.","RARA Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521197","Indwelling Urinary Catheter","C122587","A hollow tube that is inserted and left in the bladder to promote the drainage of urine.","Indwelling Urinary Catheter | ",,,,,,,,,,,,,,,"4035421","Indwelling urinary catheter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0179783","Peritoneal Dialysis Catheter","C122588","A hollow tube that is inserted in the abdomen to carry fluid into and out of the abdominal cavity.","Peritoneal Dialysis Catheter | ",,,,,,,,,,,,,,,"4236069","Peritoneal dialysis catheter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0179760","Hemodialysis Catheter","C122589","A hollow tube that is inserted into a large vein to carry blood to and from a dialysis machine.","Hemodialysis Catheter | ",,,,,,,,,,,,,,,"42872871","Hemodialysis catheter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0772051","Samarium Sm-153 Lexidronam Pentasodium","C1220","The pentasodium salt of samarium Sm 153 lexidronam, a therapeutic agent consisting of a medium energy beta- and gamma-emitting radioisotope, samarium Sm 153, and a teraphosphonate chelator, ethylenediaminetetramethylene phosphonic acid (EDTMP). The chelator moiety of samarium Sm 153 lexidronam associates with hydroxyapatite crystals concentrated in areas of bone turnover, thereby selectively delivering samarium Sm 153-mediated cytotoxic radiation to osteoblastic bone metastases.","Samarium Sm-153 Lexidronam Pentasodium | Quadramet | SAMARIUM SM-153 LEXIDRONAM PENTASODIUM | Samarium Sm 153 Lexidronam Pentasodium | Samarium Sm-153 EDTMP Pentasodium | Samarium-153 EDTMP Pentasodium | Sm 153 Lexidronam Pentasodium | samarium Sm 153 lexidronam pentasodium",,,,,,,,,,,,,,,"37161054","Samarium (153-Sm) lexidronam pentasodium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054146","Prostatic Rudiment","C123642","An embryological structure composed of epithelial cells surrounded by mesenchyme, which gives rise to the prostate gland.","Prostatic Rudiment | PROSTATIC RUDIMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053961","Syringomyelia and Hydromyelia","C123643","Syringomyelia associated with accumulation of cerebrospinal fluid in the spinal cord.","Syringomyelia and Hydromyelia | SYRINGOMYELIA/HYDROMYELIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054931","Fox Chase SCID Beige Mouse","C123644","A CB17 SCID mouse with an additional mutation on the Lyst gene which results in defective natural killer cells.","Fox Chase SCID Beige Mouse | CB17 SCID BEIGE | CB17 SCID Beige Mouse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002830","Ancylostomatoidea","C123646","A superfamily of parasitic nematodes. Members of this superfamily have a characteristic bent head, giving their buccal cavity a hook shape and providing the superfamily the common name of hookworm.","Ancylostomatoidea | ANCYLOSTOMATOIDEA | Hookworms",,,,,,,,,,,,,,,"4023837","Superfamily Ancylostomatoidea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022254","Cystoisospora belli","C123647","A species of coccidian protozoan parasite in the family Sarcocystidae. C. belli is an opportunistic pathogen in immunocompromised individuals. Transmission occurs by ingestion of fecal-contaminated food or water. This species is the causative agent of cystoisosporiasis.","Cystoisospora belli | CYSTOISOSPORA BELLI | Isospora belli",,,,,,,,,,,,,,,"4129072","Cystoisospora belli",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0445685","Neisseria elongata subsp nitroreducens","C123648","A subspecies of Neisseria elongata with the ability to reduce nitrate.","Neisseria elongata subsp nitroreducens | CDC Group M-6 | NEISSERIA ELONGATA SUBSP. NITROREDUCENS | Neisseria elongata subsp. nitroreducens",,,,,,,,,,,,,,,"4035093","Neisseria elongata ss nitroreducens",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053638","MAGE-A3-specific Immunotherapeutic GSK 2132231A","C123649","An immunotherapeutic agent composed of a fusion protein containing the human melanoma-associated antigen MAGE-A3 fused to a lipidated protein D derived from Haemophilus influenzae and combined with the immunoadjuvant AS15, with potential immunostimulating and antineoplastic activities. Upon intramuscular (IM) administration, GSK 2132231A may stimulate a specific cytotoxic T-lymphocyte (CTL) response against MAGE-A3-expressing tumor cells, resulting in tumor cell death. MAGE-A3, a tumor-associated antigen, is upregulated in a variety of cancer cell types. This fusion protein may boost antitumoral immune responses. AS15, a liposomal formulation containing the immunostimulating compounds CpG 7909, 3-O-desacyl-4'-monophosphoryl lipid A (MPL), and QS-21, increases the immune response against MAGE-A3-expressing tumors.","MAGE-A3-specific Immunotherapeutic GSK 2132231A | ASCI GSK 2132231A | Antigen Specific Cancer Immunotherapeutic GSK 2132231A | GSK 2132231A | GSK2132231A | MAGE-A3 ASCI GSK 2132231A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053507","CDISC Questionnaire EXACT Test Name Terminology","C123652","Test names of questionnaire questions associated with Exacerbations of Chronic Pulmonary Disease Tool (EXACT) Patient-Reported Outcome for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire EXACT Test Name Terminology | EXACT1TN | Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome Questionnaire Test Name | QS-EXACT TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053508","CDISC Questionnaire EXACT Test Code Terminology","C123653","Test codes of questionnaire questions associated with the Exacerbations of Chronic Pulmonary Disease Tool (EXACT) Patient-Reported Outcome for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire EXACT Test Code Terminology | EXACT1TC | Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome Questionnaire Test Code | QS-EXACT TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053522","CDISC Functional Test AVLT-REY Test Name Terminology","C123654","Test names of functional test questions associated with the Rey Auditory Verbal Learning Test (AVLT-REY) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Functional Test AVLT-REY Test Name Terminology | AVL02TN | FT-AVLT-REY TEST | Rey Auditory Verbal Learning Test Functional Test Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054163","Posterior Urethral Valves Type 1","C123210","A posterior urethral valve extending from the vera montanum towards the distal meatus.","Posterior Urethral Valves Type 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054162","Posterior Urethral Valves Type 3","C123211","A posterior urethral valve, presumed to result from incomplete canalization of the urethra, that is located immediately distal to the vera montanum.","Posterior Urethral Valves Type 3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268164","Primary Hyperoxaluria Type I","C123212","Recessively inherited primary hyperoxaluria due to alanine-glyoxylate aminotransferase (AGXT) deficiency.","Primary Hyperoxaluria Type I | ",,,,,,,,,,,,,,,"4276513","Primary hyperoxaluria, type I",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268165","Primary Hyperoxaluria Type II","C123213","Recessively inherited primary hyperoxaluria due to glyoxylate reductase/hydroxypyruvate reductase (GRHPR) deficiency.","Primary Hyperoxaluria Type II | ",,,,,,,,,,,,,,,"4164956","Primary hyperoxaluria, type II",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0520575","Acute Pyelonephritis","C123215","Sudden onset pyelonephritis.","Acute Pyelonephritis | ",,,,,,,,,,,,,,,"4280571","Acute pyelonephritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085697","Chronic Pyelonephritis","C123216","Persistent pyelonephritis.","Chronic Pyelonephritis | ",,,,,,,,,,,,,,,"4269363","Chronic pyelonephritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704380","Distal Renal Tubular Acidosis","C123217","Failure of the renal tubules of the kidney to excrete urine of sufficient acidity, resulting in metabolic acidosis.","Distal Renal Tubular Acidosis | ",,,,,,,,,,,,,,,"4030525","Distal renal tubular acidosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268435","Proximal Renal Tubular Acidosis","C123218","Impairment in renal proximal tubule bicarbonate reabsorption that results in a hypokalemic hyperchloremic metabolic acidosis, which is most commonly associated with renal Fanconi syndrome.","Proximal Renal Tubular Acidosis | Type II Renal Tubular Acidosis",,,,,,,,,,,,,,,"4085194","Proximal renal tubular acidosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054066","Renal Tubular Acidosis Associated With Deafness","C123219","Renal tubular acidosis associated with sensorineural hearing loss, and which is typically associated with recessive mutations.","Renal Tubular Acidosis Associated With Deafness | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0259810","Type I Renal Tubular Acidosis","C123220","Impairment in renal collecting tubule acid secretion that results in a hypokalemic hyperchloremic metabolic acidosis.","Type I Renal Tubular Acidosis | ",,,,,,,,,,,,,,,"4030525","Distal renal tubular acidosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0340608","Renal Artery Thrombosis","C123222","The formation of a thrombus in the renal artery.","Renal Artery Thrombosis | ",,,,,,,,,,,,,,,"4316367","Thrombosis of renal artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1321596","Miglustat","C1222","A synthetic, N-alkylated imino analogue of D-glucose. Miglustat competitively and reversibly binds to and inhibits the activity of UDP-glucose ceramide glucosyltransferase, which catalyzes the initial step in the synthesis of glycosphingolipids (GSL). This leads to a decrease in the production of glycosphingolipid, which has important roles in various cellular processes. Miglustat can be used in substrate reduction therapy in diseases in which the enzyme glucocerebrosidase, that is responsible for the breakdown of GSL, is deficient.","Miglustat | 1,5-(butylimino)-1,5-dideoxy-D-glucitol | 3,4,5-Piperidinetriol, 1-butyl-2-(hydroxymethyl)-,(2R-(2alpha,3beta,4alpha,5beta))- | MIGLUSTAT | N-Butyl Deoxynojirimycin | N-Butylmoranoline | SC 48334 | SC-48334 | Zavesca",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600211","Enterobius vermicularis","C122300","A species of parasitic pinworms in the family Oxyuridae. Infestation with E. vermicularis causes enterobiasis in humans. Its entire lifecycle takes place in the gastrointestinal tract of a single human host.","Enterobius vermicularis | ENTEROBIUS VERMICULARIS",,,,,,,,,,,,,,,"4208259","Enterobius vermicularis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0445646","Enterococcus saccharolyticus","C122301","A species of Gram-positive, catalase-negative, facultatively anaerobic, fermentative, non-motile, coccus-shaped bacteria in the family Enterococcaceae.","Enterococcus saccharolyticus | ENTEROCOCCUS SACCHAROLYTICUS | Streptococcus saccharolyticus",,,,,,,,,,,,,,,"4013411","Enterococcus saccharolyticus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320973","Enterocytozoon","C122302","A genus of microsporidian fungi in the family Enterocytozoonidae. Members of the genus are obligate intracellular parasites, infectibg intestinal epithelial cells. Cases of intestinal microsporidiosis due to Enterocytozoon are sometimes seen in immunocompromised individuals.","Enterocytozoon | ENTEROCYTOZOON",,,,,,,,,,,,,,,"4071355","Enterocytozoon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320302","Enteromonas hominis","C122303","A species of nonpathogenic flagellate protozoa in the family Enteromonadidae. Trophozoites reside in the large intestine of humans, primates, and rodents, and infection occurs after the ingestion of cysts in fecal-contaminated food or water.","Enteromonas hominis | ENTEROMONAS HOMINIS",,,,,,,,,,,,,,,"4302043","Enteromonas hominis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320181","Epicoccum","C122304","A genus of dematiaceous mitosporic fungi in the family Pleosporaceae. Members of the genus are normally found in soil, plant litter, decaying plants, or damaged plant tissue, but may also occur on building materials. Epicoccum infection in humans or animals has not been documented.","Epicoccum | EPICOCCUM",,,,,,,,,,,,,,,"4297015","Epicoccum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1444097","Escherichia coli, Extended-spectrum Beta-lactamase Positive","C122305","Any strain of Escherichia coli that is resistant to penicillins, cephalosporins, and aztreonam. These strains are often cross-resistant to trimethoprim/sulfamethoxazole and quinolones.","Escherichia coli, Extended-spectrum Beta-lactamase Positive | ESCHERICHIA COLI, ESBL | Escherichia coli, Extended-spectrum Beta-lactamases",,,,,,,,,,,,,,,"4249829","ESBL Escherichia coli",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320090","Exserohilum","C122306","A genus of asexual dematiaceous fungi in the family Pleosporaceae which produces conidia with an exserted hilum. Members of the genus live on plant material like grasses, rotten wood, and in the soil, but three species have been identified as human pathogens.","Exserohilum | EXSEROHILUM",,,,,,,,,,,,,,,"4303235","Exserohilum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1203770","Facklamia hominis","C122307","A species of gram-positive, catalase-negative, facultatively anaerobic, coccus-shaped bacteria in the family Firmicutes. F. hominis is a normal part of the female genital tract flora but may act as an opportunistic pathogen.","Facklamia hominis | FACKLAMIA HOMINIS",,,,,,,,,,,,,,,"4190119","Facklamia hominis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015648","Fasciola hepatica","C122308","A species of flatworms in the family Fasciolidae. The life cycle of F. hepatica involves snails as the intermediate host and humans and herbivores as the definitive host. Infection usually occurs through consumption of contaminated water plants.","Fasciola hepatica | FASCIOLA HEPATICA | Sheep liver fluke",,,,,,,,,,,,,,,"4010739","Fasciola hepatica",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0321945","Fasciolopsis buski","C122309","A species of parasitic tremadoda flatworms in the family Fasciolidae. The life cycle of F. buski involes snails as the intermediate host and pigs and humans as the definitive host. It is the largest intestinal fluke of humans.","Fasciolopsis buski | FASCIOLOPSIS BUSKI",,,,,,,,,,,,,,,"4154434","Fasciolopsis buski",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2959924","Flavonifractor","C122310","A genus of strictly anaerobic, Gram-variable, bacillus-shaped bacteria with variable motility in the family Firmicutes. Bacteria in the genus are asaccharolytic and weakly fermentative on glucose, fructose, and ribose.","Flavonifractor | FLAVONIFRACTOR",,,,,,,,,,,,,,,"40490847","Flavonifractor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4049720","ETNK1 wt Allele","C122824","Human ETNK1 wild-type allele is located in the vicinity of 12p12.1 and is approximately 66 kb in length. This allele, which encodes ethanolamine kinase 1 protein, is involved in phosphatidylethanolamine synthesis. Mutations may be associated with hematological and myeloproliferative diseases.","ETNK1 wt Allele | EKI | EKI 1 | EKI1 | Ethanolamine Kinase 1 wt Allele | Nbla10396",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1565603","Ethanolamine Kinase 1, Human","C122825","Ethanolamine kinase 1 (452 aa, ~51 kDa) is encoded by the human ETNK1 gene. This protein plays a role in lipid phosphorylation.","Ethanolamine Kinase 1 | EC 2.7.1.82 | EKI 1 | ETNK1 | Putative Protein Product of Nbla10396",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413292","CDKN2D Gene","C122826","This gene is involved in the regulation of both cyclin-dependent kinase activity and cell cycle progression.","CDKN2D Gene | CDKN2D | Cyclin-Dependent Kinase Inhibitor 2D (p19, Inhibits CDK4) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049865","CDKN2D wt Allele","C122827","Human CDKN2D wild-type allele is located in the vicinity of 19p13 and is approximately 3 kb in length. This allele, which encodes cyclin-dependent kinase 4 inhibitor D protein, plays a role in the negative regulation of cyclin-dependent kinase activity.","CDKN2D wt Allele | Cell Cycle Inhibitor, Nur77 Associating Protein Gene | Cyclin-Dependent Kinase Inhibitor 2D (p19, Inhibits CDK4) wt Allele | INK4D | p19 | p19-INK4D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085550","GPC2 wt Allele","C123851","Human GPC2 wild-type allele is located in the vicinity of 7q22.1 and is approximately 8 kb in length. This allele, which encodes glypican-2 protein, plays a role in the localization of heparin sulfate on cell membranes.","GPC2 wt Allele | DKFZp547M109 | FLJ38962 | Glypican 2 (Cerebroglycan) Gene | Glypican 2 wt Allele | Glypican Proteoglycan 2, Cerebroglycan Proteoglycan Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1609965","Glypican-2, Human","C123852","Glypican-2 (579 aa, ~63 kDa) is encoded by the human GPC2 gene. This protein is involved in heparin sulfate binding.","Glypican-2 | Cerebroglycan | Cerebroglycan Proteoglycan | GPC2 | Glypican Proteoglycan 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084710","KLRG1 wt Allele","C123854","Human KLRG1 wild-type allele is located in the vicinity of 12p13.31 and is approximately 108 kb in length. This allele, which encodes killer cell lectin-like receptor subfamily G member 1 protein, is involved in the modulation of T-lymphocyte and natural killer cell-mediated immunity.","KLRG1 wt Allele | 2F1 | C-Type Lectin Domain Family 15, Member A Gene | CLEC15A | Killer Cell Lectin-Like Receptor Subfamily G, Member 1 wt Allele | Killer Cell Lectin-Like Receptor, Subfamily G, Member 1 Gene | MAFA | MAFA-2F1 | MAFA-L | MAFA-LIKE | Mast Cell Function-Associated Antigen (ITIM-Containing) Gene | Mast Cell Function-Associated Antigen, Rat, Homolog of Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1431404","Killer Cell Lectin-Like Receptor Subfamily G Member 1, Human","C123855","Killer cell lectin-like receptor subfamily G member 1 (195 aa, ~22 kDa) is encoded by the human KLRG1 gene. This protein plays a role in immunomodulation.","Killer Cell Lectin-Like Receptor Subfamily G Member 1 | C-Type Lectin Domain Family 15 Member A | ITIM-Containing Receptor MAFA-L | KLRG1 | MAFA-Like Receptor | Mast Cell Function-Associated Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084730","CALB2 wt Allele","C123857","Human CALB2 wild-type allele is located in the vicinity of 16q22.2 and is approximately 32 kb in length. This allele, which encodes calretinin protein, plays a role in calcium binding.","CALB2 wt Allele | CAB29 | CAL2 | CR | Calbindin 2 wt Allele | Calbindin 2, (29kD, Calretinin) Gene | Calbindin 2, 29kDa (Calretinin) Gene | Calbindin, 29-kD Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084714","ABCB11 wt Allele","C123860","Human ABCB11 wild-type allele is located in the vicinity of 2q24 and is approximately 108 kb in length. This allele, which encodes bile salt export pump protein, is involved in bile salt transport. Mutation of the gene is associated with hereditary intrahepatic cholestasis.","ABCB11 wt Allele | ABC Member 16, MDR/TAP Subfamily Gene | ABC16 | ATP Binding Cassette Subfamily B Member 11 wt Allele | ATP-Binding Cassette, Sub-Family B (MDR/TAP), Member 11 Gene | ATP-Binding Cassette, Subfamily B, Member 11 Gene | BRIC2 | BSEP | PFIC-2 | PFIC2 | PGY4 | Progressive Familial Intrahepatic Cholestasis 2 Gene | SPGP | Sister of P-Glycoprotein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1313221","Bile Salt Export Pump, Human","C123861","Bile salt export pump (1321 aa, ~146 kDa) is encoded by the human ABCB11 gene. This protein plays a role in bile salt secretion.","Bile Salt Export Pump | ABCB11 | ATP-Binding Cassette Sub-Family B Member 11 | ATP-Binding Cassette Subfamily B Member 11 | Sister P-Glycoprotein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2931788","Atypical Hemolytic Uremic Syndrome","C123223","Hemolytic uremic syndrome not associated with shiga toxin-producing enterobacteria.","Atypical Hemolytic Uremic Syndrome | Non-diarrhea-associated Hemolytic Uremic Syndrome",,,,,,,,,,,,,,,"37312165","Atypical hemolytic uremic syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2242703","Cardiorenal Syndrome","C123225","A disorder of the heart and kidneys in which dysfunction of one of the organs induces dysfunction of the other organ.","Cardiorenal Syndrome | ",,,,,,,,,,,,,,,"40482857","Cardiorenal syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1268936","Diarrhea-associated Hemolytic Uremic Syndrome","C123226","Hemolytic uremic syndrome caused by gastrointestinal infection, usually with shiga toxin-producing enterobacteria.","Diarrhea-associated Hemolytic Uremic Syndrome | ",,,,,,,,,,,,,,,"4190190","Diarrhea-associated hemolytic uremic syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055108","Dysfunctional Elimination Syndrome","C123227","Fecal constipation or impaction resulting in bowel and bladder dysfunction.","Dysfunctional Elimination Syndrome | Pelvic Elimination Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055018","Familial Atypical Hemolytic Uremic Syndrome","C123228","Hemolytic uremic syndrome associated with an inherited defect, but which is not associated with shiga toxin-producing enterobacteria.","Familial Atypical Hemolytic Uremic Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1852759","Renal Coloboma Syndrome","C123230","A genetic disorder caused by PAX2 gene mutations that is characterized by renal hypoplasia and a spectrum of congenital anomalies of the eye and urinary tract.","Renal Coloboma Syndrome | Papillorenal Syndrome",,,,,,,,,,,,,,,"40487865","Renal coloboma syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2936861","Syndrome of Apparent Mineralocorticoid Excess","C123231","An autosomal recessive disorder caused by a deficiency of 11-beta-hydroxysteroid dehydrogenase, which is characterized by hypertension, hypokalemia, low renin, and hypoaldosteronism.","Syndrome of Apparent Mineralocorticoid Excess | ",,,,,,,,,,,,,,,"4035123","Syndrome of apparent mineralocorticoid excess",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0266328","Ectopic Ureter","C123232","A congenital anomaly in which the ureteral orifice drains into an abnormal location.","Ectopic Ureter | ",,,,,,,,,,,,,,,"4259147","Ectopic ureter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0315174","Corynebacterium diphtheriae bv. mitis","C122272","A biovar of Corynebacterium diphtheriae. Biovar mitis is nitrate positive and positive for fermentation of glucose and maltose.","Corynebacterium diphtheriae bv. mitis | CORYNEBACTERIUM DIPHTHERIAE TYPE MITIS",,,,,,,,,,,,,,,"4028997","Corynebacterium diphtheriae type mitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0445693","Corynebacterium diphtheriae bv. belfanti","C122273","A biovar of Corynebacterium diphtheriae distinguished by its morphogenic and biochemical properties. Biovar belfanti is positive for fermentation of glucose and maltose. This biovar is one of the two main disease-causing biovars.","Corynebacterium diphtheriae bv. belfanti | CORYNEBACTERIUM DIPHTHERIAE VAR. BELFANTI",,,,,,,,,,,,,,,"4352617","Corynebacterium diphtheriae var belfanti",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1019967","Corynebacterium mucifaciens","C122274","A species of aerobic, non-motile, non-spore forming, non-partially acid-fast, gram-positive, coryneform bacteria in the family Corynebacteriaceae. C. mucifaciens is catalase positive, nonfermenting, nitrate reduction negative, and urea and esculin hydrolysis negative; acid was produced from glucose but not from maltose, mannitol, and xylose. The species is nonlipophilic and negative for the CAMP reaction.","Corynebacterium mucifaciens | CORYNEBACTERIUM MUCIFACIENS",,,,,,,,,,,,,,,"4188994","Corynebacterium mucifaciens",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1070698","Corynebacterium simulans","C122275","A species of nonlipophilic, non-motile, fermentative, catalase-positive bacteria in the family Corynebacteriaceae. C. simulans is positive for nitrate and the nitrite reductase test, does not ferment maltose, and is unable to acidify ethylene glycol.","Corynebacterium simulans | CORYNEBACTERIUM SIMULANS",,,,,,,,,,,,,,,"4217867","Corynebacterium simulans",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085319","Cryptosporidium parvum","C122276","A species of parasitic protozoa in the family Cryptosporidiidae. C. parvum is one of the main agents of cryptosporidiosis. Transmission occurs mainly through contact with contaminated water and infection is generally self-limiting in immunocompetent individuals.","Cryptosporidium parvum | CRYPTOSPORIDIUM PARVUM",,,,,,,,,,,,,,,"4197797","Cryptosporidium parvum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320077","Curvularia","C122277","A genus of hyphomycete fungi in the family Pleosporaceae. Members of the genus are normally found in the soil, but are facultative pathogen of many plant species. Three species have been recovered from human infections, principally from cases of mycotic keratitis.","Curvularia | CURVULARIA",,,,,,,,,,,,,,,"4181422","Curvularia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0446189","Cyclospora cayetanensis","C122278","A species of apicomplexan, cyst-forming coccidian protozoa in the family Eimeriidae. C. cayetanensis appears to be the causative agent of all cases of human cyclosporiasis and humans are its only known host.","Cyclospora cayetanensis | CYCLOSPORA CAYETANENSIS | Cyclospora cayetanesis",,,,,,,,,,,,,,,"4012991","Cyclospora cayetanensis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320095","Fonsecaea","C122311","A genus of soil fungi in the family Herpotrichiellaceae characterized by indistinct melanised conidiophores with blunt, scattered denticles bearing conidia singly or in short chains that eventually become branched. Both species in this genus can cause chromoblastomycosis following skin damage.","Fonsecaea | FONSECAEA",,,,,,,,,,,,,,,"4053294","Fonsecaea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0317554","Fusobacterium periodonticum","C122312","A species of non-motile bacteria in the family Fusobacteriaceae. F. periodonticum is characterized by its ability to ferment only on glucose, fructose, and galactose and an ability to hydrolyze hippurate.","Fusobacterium periodonticum | FUSOBACTERIUM PERIODONTICUM",,,,,,,,,,,,,,,"4288146","Fusobacterium periodonticum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1142536","Methicillin-Resistant Staphylococcus aureus Pneumonia","C122523","Pneumonia that is caused by Staphylococcus aureus that is resistant to methicillin treatment.","Methicillin-Resistant Staphylococcus aureus Pneumonia | MRSA Pneumonia",,,,,,,,,,,,,,,"46270027","Pneumonia due to methicillin resistant Staphylococcus aureus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0856166","Disrupted Suture","C122527","The loss of tension or continuity of sutures.","Disrupted Suture | Stitches Coming Loose",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0424323","Violent Behavior","C122528","Any action that results in intimidation, harm, damage, or destruction of someone or something.","Violent Behavior | ",,,,,,,,,,,,,,,"4085332","Physical aggression",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4084872","ABCB4 wt Allele","C123863","Human ABCB4 wild-type allele is located in the vicinity of 7q21.1 and is approximately 79 kb in length. This allele, which encodes multidrug resistance protein 3, plays a role in the intramembrane transport of phosphatidylcholine and the export of organic anions and drugs across the plasma membrane. Mutation of the gene is associated with progressive familial intrahepatic cholestasis 2, intrahepatic cholestasis of pregnancy 3 and gall bladder disease 3.","ABCB4 wt Allele | ABC21 | ATP-Binding Cassette, Sub-Family B (MDR/TAP), Member 4 wt Allele | ATP-Binding Cassette, Subfamily B, Member 4 Gene | GBD1 | ICP3 | MDR2 | MDR2/3 | MDR3 | Multidrug Resistance 3 Gene | P Glycoprotein 3/Multiple Drug Resistance 3 Gene | P-Glycoprotein-3/Multiple Drug Resistance-3 Gene | PFIC-3 | PGY3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049615","Megaureter","C123161","Enlargement of the diameter of the ureter, which can be partial or complete.","Megaureter | ",,,,,,,,,,,,,,,"4318840","Dilatation of ureter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053857","Voiding Disorders","C123162","A group of conditions comprising dysfunction of the storage and elimination of urine.","Voiding Disorders | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0403452","Acute Cortical Necrosis","C123163","Acute kidney injury caused by ischemic necrosis of the renal cortex.","Acute Cortical Necrosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055623","A1 Hydronephrosis","C123164","Antenatal hydronephrosis with the following clinical findings: 1) an anterior-posterior renal pelvis diameter (APRPD) of 4 to less than 7 mm at less than 28 weeks, 2) to less than10 mm at greater than or equal to 28 weeks, and 3) may have central calyceal dilation. (Adapted from: Hiep T. Nguyen, Carol B. Benson, Bryann Bromley, Jeffrey B. Campbell, Jeanne Chow, Beverly Coleman, Christopher Cooper, Jude Crino, Kassa Darge, C.D. Anthony Herndon, Anthony O. Odibo, Michael J.G. Somers, Deborah R. Stein; Multidisciplinary consensus on the classification of prenatal and postnatal urinary tract dilation (UTD classification system); Pediatric Urology; December 2014 Volume 10, Issue 6, Pages 982-998)","A1 Hydronephrosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055622","A2/3 Hydronephrosis","C123165","Antenatal hydronephrosis with the following clinical findings: 1) an anterior-posterior renal pelvis diameter (APRPD) of greater than or equal to 7mm at less than 28 weeks, 2) greater than or equal to10 mm at greater than or equal to 28 weeks, or 3) any one of the following findings: a)dilation of peripheral calyces, b) abnormal parenchymal thickness or appearance, c) visibly dilated ureter, d) an abnormal bladder, or e) the presence of oligohydramnios suspected to be related to the urinary tract. (Adapted from: Hiep T. Nguyen, Carol B. Benson, Bryann Bromley, Jeffrey B. Campbell, Jeanne Chow, Beverly Coleman, Christopher Cooper, Jude Crino, Kassa Darge, C.D. Anthony Herndon, Anthony O. Odibo, Michael J.G. Somers, Deborah R. Stein; Multidisciplinary consensus on the classification of prenatal and postnatal urinary tract dilation (UTD classification system); Pediatric Urology; December 2014 Volume 10, Issue 6, Pages 982-998)","A2/3 Hydronephrosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2751306","Autosomal Dominant Polycystic Kidney Disease Type 2","C123166","Autosomal dominant polycystic kidney disease caused by a mutation in PKD2.","Autosomal Dominant Polycystic Kidney Disease Type 2 | ",,,,,,,,,,,,,,,"4109809","Adult type polycystic kidney disease type 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3149841","Autosomal Dominant Polycystic Kidney Disease Type I","C123167","Autosomal dominant polycystic kidney disease caused by a mutation in PKD1.","Autosomal Dominant Polycystic Kidney Disease Type I | ",,,,,,,,,,,,,,,"4109637","Adult type polycystic kidney disease type 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0375530","Congenital Ureteropelvic Junction Obstruction","C123168","Complete or partial blockage of the ureter at the point where it enters the kidney that is present at birth.","Congenital Ureteropelvic Junction Obstruction | ",,,,,,,,,,,,,,,"441961","Congenital obstruction of ureteropelvic junction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4048274","Congenital Ureterovesical Junction Obstruction","C123169","Complete or partial blockage of the ureter at the point where it enters the bladder that is present at birth.","Congenital Ureterovesical Junction Obstruction | Congenital Vesicoureteral Obstruction",,,,,,,,,,,,,,,"4051785|4162438|440516","Congenital stricture of ureterovesical orifice|Congenital obstructive megaureter|Congenital obstruction of ureteral orifice",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"C0748283","Complex Cyst of Kidney","C123170","A heterogeneous and/or septated cyst located in the kidney.","Complex Cyst of Kidney | ",,,,,,,,,,,,,,,"42536545","Complex renal cyst",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3441987","Deltacoronavirus","C122279","A genus of enveloped and spherical positive sense ssRNA viruses in the subfamily Coronavirinae of the family Coronaviridae with a diameter of about 120 nm. Deltacoronaviruses have a nonopartite, linear genome of 26-26.5 kb. Birds are the most common reservoir for deltacoronaviruses.","Deltacoronavirus | Coronavirus Group 3 | DELTACORONAVIRUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1677945","Dialister micraerophilus","C122280","A species of Gram-negative, non-motile, non-sporulating, rod-shaped bacteria in the family Veillonellaceae. D. micraerophilus is generally anaerobic but will also grow under microaerophilic conditions. It can be differentiated from other Dialister species by phenylalanine arylamidase activity and tyrosine arylamidase activity.","Dialister micraerophilus | DIALISTER MICRAEROPHILUS",,,,,,,,,,,,,,,"40489797","Dialister micraerophilus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0314935","Dialister pneumosintes","C122281","A species of Gram-negative, non-fermenting, anaerobic, rod-shaped bacterium in the family Veillonellaceae. The species was first isolated from nasopharyngeal secretions of patients during the flu epidemic of 1918 to 1921.","Dialister pneumosintes | Bacillus pneumosintes | Bacteroides pneumosintes | DIALISTER PNEUMOSINTES",,,,,,,,,,,,,,,"4015533","Dialister pneumosintes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320317","Dientamoeba fragilis","C122282","A species of nonflagellate trichomonad parasites in the family Dientamoebidae. Infections occurs through direct fecal-oral spread. Nonhuman primates are its only natural hosts.","Dientamoeba fragilis | DIENTAMOEBA FRAGILIS",,,,,,,,,,,,,,,"4187489","Dientamoeba fragilis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0012516","Dipetalonema","C122283","A genus of hematophagous parasitic nematodes in the superfamily Filarioidea. Species in this genus are transmitted by gnats to humans and other vertebrates, producing microfilariae in the blood or tissue fluids. They live as adults in deep connective tissue or on membranes or visceral surfaces.","Dipetalonema | DIPETALONEMA",,,,,,,,,,,,,,,"4284996","Dipetalonema",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0012564","Diphyllobothrium latum","C122284","A species of tapeworms in the family Diphyllobothriidae. The lifecycle of D. latum involves crustaceans, freshwater fish, and humans. Humans become infested by eating infested fish. The resulting tapeworm is the largest human tapeworm.","Diphyllobothrium latum | Broad Fish Tapeworm | DIPHYLLOBOTHRIUM LATUM",,,,,,,,,,,,,,,"4223628","Diphyllobothrium latum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0322217","Dipylidium caninum","C122285","A species of tapeworms in the family Dipylidiidae. The definitive host for D. caninum is the dog, with intermediate hosts of fleas and chewing lice. Humans can become infected by ingesting an infected flea.","Dipylidium caninum | Cucumber Tapeworm | DIPYLIDIUM CANINUM | Double-pore Tapeworm | Flea Tapeworm",,,,,,,,,,,,,,,"4248843","Dipylidium caninum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4049617","GOLPH3 wt Allele","C122051","Human GOLPH3 wild-type allele is located in the vicinity of 5p13.3 and is approximately 50 kb in length. This allele, which encodes Golgi phosphoprotein 3, plays a role in both Golgi morphology and membrane trafficking.","GOLPH3 wt Allele | GOPP1 | GPP34 | Golgi Peripheral Membrane Protein 1, 34 kDa Gene | Golgi Phosphoprotein 3 (Coat-Protein) wt Allele | Golgi-Associated Protein, 34-kD Gene | MIDAS | Vps74",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1309950","Golgi Phosphoprotein 3, Human","C122052","Golgi phosphoprotein 3 (298 aa, ~34 kDa) is encoded by the human GOLPH3 gene. This protein is involved in cellular membrane trafficking.","Golgi Phosphoprotein 3 | Coat Protein GPP34 | Golgi-Associated Protein | MIDAS | Mitochondrial DNA Absence Factor | Mitochondrial DNA Absence-Sensitive Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049608","RPRM wt Allele","C122054","Human RPRM wild-type allele is located in the vicinity of 2q24.3 and is approximately 2 kb in length. This allele, which encodes protein reprimo, is involved in the mediation of p53-dependent cell cycle arrest.","RPRM wt Allele | FLJ90327 | REPRIMO | Reprimo, TP53 Dependent G2 Arrest Mediator Candidate wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1439144","Protein Reprimo, Human","C122055","Protein reprimo (109 aa, ~12 kDa) is encoded by the human RPRM gene. This protein plays a role in p53-mediated G2 phase arrest.","Protein Reprimo | Candidate Mediator of the p53 Dependent G2 Arrest | Candidate Mediator of the p53-Dependent G2 Arrest",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049605","CEP72 wt Allele","C122057","Human CEP72 wild-type allele is located in the vicinity of 5p15.33 and is approximately 55 kb in length. This allele, which encodes centrosomal protein of 72 kDa, plays a role in the recruitment of proteins to the centrosome.","CEP72 wt Allele | Centrosomal Protein 72 wt Allele | Centrosomal Protein 72kDa Gene | Centrosomal Protein 72kDa wt Allele | Centrosomal Protein, 72-kD Gene | FLJ10565 | KIAA1519",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2717442","Centrosomal Protein of 72 kDa, Human","C122058","Centrosomal protein of 72 kDa (647 aa, ~72 kDa) is encoded by the human CEP72 gene. This protein is involved in the formation of the mitotic spindle.","Centrosomal Protein of 72 kDa | Cep72",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049733","ITGA6 wt Allele","C122060","Human ITGA6 wild-type allele is located in the vicinity of 2q31.1 and is approximately 79 kb in length. This allele, which encodes integrin alpha-6 protein, is involved in cell-matrix adhesion. Mutation of the gene is associated with epidermolysis bullosa with pyloric atresia.","ITGA6 wt Allele | CD49f | ITGA6A | ITGA6B | Integrin Subunit Alpha 6 wt Allele | Integrin, Alpha 6 Gene | Integrin, Alpha 6 wt Allele | Integrin, Alpha-6 Gene | JEB6 | VLA-6 | Very Late Activation Protein 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054288","Outsourcing Animal Drug Compounding","C122061","Compounding drug dosage forms for animal consumption under a contract by other sources than the facilities that use the pharmaceutics.","Outsourcing Animal Drug Compounding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498216","Autologous CEA-specific Cytotoxic T-lymphocytes","C123822","Autologous cytotoxic T-lymphocytes (CTLs) specifically reactive to the tumor-associated antigen (TAA) human carcinoembryonic antigen (CEA), with potential antineoplastic activity. Dendritic cells (DCs) isolated from the patient's blood are infected with recombinant adeno-associated virus (AAV) expressing the CEA gene. Exposure of T-lymphocytes to DCs creates CEA-specific CTLs which are expanded. Upon reintroduction of these CTLs into the patient, these cells recognize and kill CEA-expressing tumor cells. CEA, a tumor-associated antigen and a member of the CEA family of proteins, plays a key role in cell migration, cell invasion, and cell adhesion and is overexpressed by a variety of cancer types.","Autologous CEA-specific Cytotoxic T-lymphocytes | CEA-specific AAV-DC-CTLs | CEA-specific CTLs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054550","Medullary Cystic Kidney Disease Type II","C123172","An inherited form of cystic kidney disease leading to fibrosis and impaired renal function that is caused by mutations in the UMOD gene, which encodes uromodulin/Tamm-Horsfall mucoprotein.","Medullary Cystic Kidney Disease Type II | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268800","Simple Cyst of Kidney","C123173","A homogenous cyst located in the kidney.","Simple Cyst of Kidney | ",,,,,,,,,,,,,,,"196813","Simple renal cyst",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0156270","Radiation Cystitis","C123174","Inflammation of the bladder due to irradiation.","Radiation Cystitis | ",,,,,,,,,,,,,,,"201353","Irradiation cystitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1261278","Trigonitis","C123175","Inflammation of the trigone of the urinary bladder.","Trigonitis | ",,,,,,,,,,,,,,,"441615","Trigonitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268830","Urethrotrigonitis","C123176","Inflammation of both the urethra and the trigone of the urinary bladder.","Urethrotrigonitis | ",,,,,,,,,,,,,,,"4284706","Urethrotrigonitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1843013","Alzheimer disease, familial, type 3","C123412","Alzheimer's disease with an early onset (starts before the age of 65). It is caused by mutations in the PSEN1 gene.","Alzheimer's Disease 3 | AD3 | Familial Alzheimer Disease, Type 3 | Familial Alzheimer's Disease, Type 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1847200","ALZHEIMER DISEASE 4","C123413","Alzheimer's disease with an early onset (starts before the age of 65). It is caused by mutations in the PSEN2 gene.","Alzheimer's Disease 4 | AD4 | Familial Alzheimer Disease, Type 4 | Familial Alzheimer's Disease, Type 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053736","Catecholaminergic Polymorphic Ventricular Tachycardia Type 1","C123414","Polymorphic ventricular tachycardia induced by adrenergic stress. It is inherited in an autosomal dominant pattern and is caused by mutations in the ryanodine receptor 2 (RYR2) gene.","Catecholaminergic Polymorphic Ventricular Tachycardia Type 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1857093","Autosomal Recessive Torsion Dystonia 2","C123415","An autosomal recessive inherited disorder caused by mutation in the HPCA gene. It begins in childhood or adolescence and is characterized by involuntary, sustained muscle contractions and torsions affecting initially distal limbs and later the neck, orofacial, and craniocervical regions.","Autosomal Recessive Torsion Dystonia 2 | DYT2 | Dystonia Musculorum Deformans 2",,,,,,,,,,,,,,,"37396093","Primary dystonia type 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2931909","Familial Hypercholesterolemia","C123416","An autosomal dominant inherited disorder characterized by very high levels of low-density lipoprotein cholesterol (LDL-C) and total cholesterol in the blood. It is usually caused by mutations in the LDLR gene which is located on the short arm of chromosome 19.","Hyperlipoproteinemia, Type IIa | FH | Familial Hypercholesterolemia | Hyperlipidemia Type IIa | Type IIa Hyperlipidemia",,,,,,,,,,,,,,,"4134862","Familial hypercholesterolemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0432291","Mandibuloacral Dysplasia with Type A Lipodystrophy","C123417","A rare, autosomal recessive inherited disorder caused by mutations in the LMNA gene. It is characterized by growth retardation, craniofacial abnormalities with mandibular hypoplasia, skeletal abnormalities with progressive osteolysis of the distal phalanges and clavicles, and mottled or patchy skin pigmentation. The affected individuals have a marked acral loss of adipose tissue with normal or increased adipose tissue in the neck and trunk.","Mandibuloacral Dysplasia with Type A Lipodystrophy | MADA",,,,,,,,,,,,,,,"604637","Mandibuloacral dysplasia with type A lipodystrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053880","Vasoprotective Agent","C123418","Any agent that is used to prevent or inhibit damage to blood vessels.","Vasoprotective Agent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0320732","Cystoisospora","C123419","No value exists.","Cystoisospora | ",,,,,,,,,,,,,,,"4261979","Cystoisospora",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320450","Iodamoeba","C123420","A genus of nonpathogenic parasitic amoeba whose cysts show a characteristic brown color when stained with iodine due to large glycogen inclusions.","Iodamoeba | ",,,,,,,,,,,,,,,"4232771","Iodamoeba",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023270","Leishmania","C123421","A genus of parasitic trypanosomatid protozoa in the family Trypanosomatidae. These parasites are transmitted by the bite of a sand fly and they are causative for leishmaniasis.","Leishmania | ",,,,,,,,,,,,,,,"4193901","Leishmania",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027320","Naegleria","C123422","A genus of parasitic amoeba in the family Vahlkampfiidae.","Naegleria | NAEGLERIA",,,,,,,,,,,,,,,"4087104","Naegleria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3850450","Integrin Alpha-6, Human","C122062","Integrin alpha-6 (1130 aa, ~127 kDa) is encoded by the human ITGA6 gene. This protein plays a role in both cell adhesion and laminin binding.","Integrin Alpha-6 | CD49 Antigen-Like Family Member F | CD49f | CD49f Antigen | ITGA6 | Integrin Alpha 6 | VLA-6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050220","PLA2G7 wt Allele","C122065","Human PLA2G7 wild-type allele is located within 6p21.2-p12 and is approximately 31 kb in length. This allele, which encodes platelet-activating factor acetylhydrolase protein, plays a role in the modulation of the inflammatory activity of platelet-activating factor. Mutation of the gene is associated with platelet-activating factor acetylhydrolase deficiency and increased susceptibility to asthma or atopy.","PLA2G7 wt Allele | LDL-PLA2 | LP-PLA2 | PAFAD | PAFAH | Phospholipase A2, Group VII (Platelet-Activating Factor Acetylhydrolase, Plasma) wt Allele | Platelet-Activating Factor Acetylhydrolase, Plasma Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2351517","Platelet-Activating Factor Acetylhydrolase, Human","C122066","Platelet-activating factor acetylhydrolase (441 aa, ~50 kDa) is encoded by the human PLA2G7 gene. This protein is involved in platelet-activating factor metabolism.","Platelet-Activating Factor Acetylhydrolase | 1-Alkyl-2-Acetylglycerophosphocholine Esterase | 2-Acetyl-1-Alkylglycerophosphocholine Esterase | EC 3.1.1.47 | Group-VIIA Phospholipase A2 | LDL-Associated Phospholipase A2 | LDL-PLA(2) | Lipoprotein-Associated Phospholipase A2 | PAF 2-Acylhydrolase | PAF Acetylhydrolase | PLA2G7 | gVIIA-PLA2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054269","PPARGC1A Gene Product","C122779","A protein encoded by the PPARGC1A gene.","PPARGC1A Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086431","Hurler-Scheie Syndrome","C122782","An autosomal recessive disorder representing the intermediate form of mucopolysaccharidosis type I. It is characterized by deficiency of the enzyme alpha-L-iduronidase. Signs and symptoms include short stature, cloudy cornea, umbilical hernia, joint stiffening, hepatosplenomegaly, and mental retardation.","Hurler-Scheie Syndrome | MPS I H-S",,,,,,,,,,,,,,,"4097554","Mucopolysaccharidosis, MPS-I-H/S",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055278","Canine Hemangiosarcoma","C122783","Hemangiosarcoma occurring in a dog. It is an incurable tumor of vascular endothelial cells and occurs more commonly in dogs beyond middle age, and is especially common in certain breeds. Most hemangiosarcomas do not have a known cause.","Canine Hemangiosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040586","Tracheobronchitis","C122784","Inflammation of the tracheobronchial tree.","Tracheobronchitis | ",,,,,,,,,,,,,,,"4028970","Tracheobronchitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0333139","Pneumatosis","C122785","The presence of gas in an anatomical location where it is not normally found.","Pneumatosis | ",,,,,,,,,,,,,,,"4314558","Gas retention",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4084782","4H11-28z/fIL-12/EGFRt-expressing Autologous T-lymphocytes","C123823","A preparation of genetically modified autologous T-lymphocytes transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) targeting the human tumor-associated antigen (TAA) MUC16ecto and encoding the human pro-inflammatory cytokine interleukin-12 (IL-12), fused to the signaling domain of the zeta chain of the TCR/CD3 complex (28z), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, 4H11-28z/fIL-12/EGFRt-expressing autologous T-lymphocytes are directed to and induce selective toxicity in MUC16-expressing tumor cells. In addition, the T-cells secrete IL-12 which induces secretion of interferon-gamma, promotes the activation of natural killer cells (NKs), and induces cytotoxic T-cell responses against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) response. MUC16, a transmembrane protein and glycosylated mucin, is overexpressed on the cell surface of the majority of ovarian cancer cells but not on healthy cells. MUC16ecto is the extracellular portion of MUC-16 and is the part that is retained by cells after cleavage of CA-125.","4H11-28z/fIL-12/EGFRt-expressing Autologous T-lymphocytes | 4H11-28z/fIL-12/EGFRt+ Genetically-modified T Cells | 4H11-28z/fIL-12/EGFRt+ T Cells | Autologous 4H11-28z/fIL-12/EGFRt+ Genetically-modified T Cells | Autologous MUC16ecto-targeting EGFR-secreting T Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498218","antineoplastic agent TRX-818","C123824","An orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry activities. Upon oral administration, foslinanib targets and inhibits the formation of vasculogenic mimicry (VM; vascular mimicry). By destroying the VM channels and network, cancer cells are devoid of perfusion leading to an induction of cancer cell apoptosis and inhibition of cancer cell proliferation. VM is associated with tumor metastasis.","Foslinanib | 4(1H)-Quinolinone, 2-(3-Fluorophenyl)-6-methoxy-5-(phosphonooxy)- | CVM 1118 | CVM-1118 | CVM1118 | FOSLINANIB | TRX 818 | TRX-818 | TRX818 | WHO 10721",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498219","ncmtRNA oligonucleotide Andes-1537","C123825","A proprietary antisense oligonucleotide targeting a novel non-coding mitochondrial RNA (ncmtRNA), with potential antineoplastic activity. Upon administration, mulnitorsen binds to ncmtRNA, which is overexpressed in rapidly proliferating cells, such as cancer cells, and not expressed in resting cells. This may decrease the expression of the ncmtRNA, which may inhibit cell proliferation and eventually induce apoptosis in susceptible cancer cells. The proprietary mitochondrial RNA (mtRNA) belongs to the family of non-coding RNAs (ncRNA); it contains an inverted repeat (IR) of 815 nucleotides (nt), which can form a covalent link to the 5' end of the mitochondrial 16S ribosomal RNA (16S mtrRNA).","Mulnitorsen | Andes-1537 | MULNITORSEN | ncmtRNA Oligonucleotide Andes-1537 | ncmtRNA Oligonucleotide Andes-1537",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498220","FGFR4 inhibitor BLU-554","C123826","An orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon oral administration, fisogatinib specifically binds to and blocks the binding of the ligand FGF19 to FGFR4. This prevents the activation of FGFR4, inhibits FGFR4-mediated signaling and leads to an inhibition of tumor cell proliferation in FGFR4-overexpressing cells. FGFR4 is a receptor tyrosine kinase and is involved in tumor cell proliferation, differentiation, angiogenesis, and survival. FGF19 is overexpressed by certain tumor cell types.","Fisogatinib | 2-Propenamide, N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl)amino)tetrahydro-2H-pyran-4-yl)- | BLU 554 | BLU-554 | BLU554 | CS 3008 | CS-3008 | CS3008 | FISOGATINIB | Fibroblast Growth Factor Receptor 4 Inhibitor BLU-554 | N-((3S,4S)-3-((6-(2,6-Dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)oxan-4-yl)prop-2-enamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050407","Pauci-immune Glomerulonephritis associated with Granulomatosis with Polyangiitis","C123111","Glomerulonephritis in the context of granulomatosis with polyangiitis in which anti-neutrophil cytoplasm antibody (ANCA) is almost always present.","Pauci-Immune Glomerulonephritis associated with Granulomatosis with Polyangiitis | Pauci-immune Glomerulonephritis associated with Granulomatosis with Polyangiitis | Wegener Granulomatosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055509","Academic Research Council Coronary Stent Thrombosis Timing","C123424","Categorization of the timing of coronary stent thrombosis occurrence per the classification schema described by the Academic Research Consortium (ARC).","Academic Research Council Coronary Stent Thrombosis Timing | STCTIMNG | Stent Thrombosis, Coronary, ARC Timing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023923","Loa","C123425","No value exists.","Loa | ",,,,,,,,,,,,,,,"4163845","Loa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027526","Necator","C123426","No value exists.","Necator | ",,,,,,,,,,,,,,,"4187799","Necator",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054056","Rolapitant Hydrochloride Anhydrous","C123427","No value exists.","Rolapitant Hydrochloride Anhydrous | ROLAPITANT HYDROCHLORIDE ANHYDROUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054758","Naxitamab","C123428","A humanized monoclonal antibody directed against the human tumor-associated antigen GD2, with potential antineoplastic activity. Upon vaccination, naxitamab stimulates antibody-dependent cell-mediated cytotoxicity (ADCC) against GD2-expressing tumor cells. GD2, a disialoganglioside with expression in normal tissues restricted primarily to the cerebellum and peripheral nerves, is commonly expressed at high levels on tumors of neuroectodermal origins such as melanomas and neuroblastomas. Compared to the murine monoclonal antibody 3F8 (m3F8), the humanized form does not cause a human anti-mouse antibody (HAMA) response and shows enhanced ADCC activity.","Naxitamab | Anti-Gd2 IGG3 Monoclonal Antibody 3f8 Humanized | Danyelza | Hu3F8 | Humanized Anti-GD2 Antibody 3F8 | Humanized Monoclonal Antibody Hu3f8-IGG1 | NAXITAMAB | Naxitamab-gqgk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053523","CDISC Functional Test AVLT-REY Test Code Terminology","C123655","Test codes of functional test questions associated with the Rey Auditory Verbal Learning Test (AVLT-REY) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Functional Test AVLT-REY Test Code Terminology | AVL02TC | FT-AVLT-REY TESTCD | Rey Auditory Verbal Learning Test Functional Test Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055088","EXACT Questionnaire Question","C123656","A question associated with the EXACT questionnaire.","EXACT Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055566","AVLT-REY Functional Test Question","C123657","A question associated with the AVLT-REY functional test.","AVLT-REY Functional Test Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002630","Amnion","C12365","The innermost layer of membrane that surrounds an embryo and amniotic fluid in mammals, birds, and reptiles.","Amnion | Amniotic",,,,,,,,,,,,,,,"4321867","Structure of amnion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055249","Childhood Acute Myeloid Leukemia with Abnormalities of Chromosome 7","C122726","A rare acute myeloid leukemia that occurs in childhood and is characterized by deletion of chromosome 7.","Childhood Acute Myeloid Leukemia with Abnormalities of Chromosome 7 | Acute Myeloid Leukemia (AML) with Abnormalities of Chromosome 7 | Childhood AML with Abnormalities of Chromosome 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049614","TSPO wt Allele","C122728","Human TSPO wild-type allele is located in the vicinity of 22q13.3 and is approximately 12 kb in length. This allele, which encodes both translocator protein and putative peripheral benzodiazepine receptor-related protein, plays a role in the transport of cholesterol across mitochondrial membranes.","TSPO wt Allele | BPBS | BZRP | Benzodiazepine Receptor (Peripheral) Gene | Benzodiazepine Receptor, Peripheral Gene | DBI | IBP | MBR | MDRC | PBR | PBRS | PBS | PKBS | PTBR | Pk18 | Translocator Protein (18kDa) wt Allele | Translocator Protein, 18-kD Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1828221","Non-Dystrophic Myotonia","C122787","A group of rare skeletal muscle ion-channel disorders caused by genetic mutations in the sodium and chloride channel genes. It is characterized by altered membrane excitability resulting in skeletal muscle stiffness. This group of myotonias is distinct from myotonic dystrophy because of the absence of systemic features or progressive weakness.","Non-Dystrophic Myotonia | Non Dystrophic Myotonia",,,,,,,,,,,,,,,"4313610","Non dystrophic myotonia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2931826","Potassium Aggravated Myotonia","C122788","A group of autosomal dominant inherited non-dystrophic myotonias caused by mutations of the SCN4A gene, resulting in sodium muscle channelopathy. They are characterized by muscle stiffness, which worsens by ingestion of potassium-rich food.  This group includes myotonia fluctuans, myotonia permanens, and acetazolamide-responsive myotonia.","Potassium Aggravated Myotonia | PAM",,,,,,,,,,,,,,,"45765421","Potassium aggravated myotonia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0752355","Myotonia Fluctuans","C122789","An autosomal dominant inherited potassium aggravated myotonia caused by mutations of the SCN4A gene. It is characterized by mild muscle stiffness that develops during rest approximately an hour after exercise and lasts for about an hour.  It worsens by ingestion of potassium-rich food.","Myotonia Fluctuans | Exercise-Induced Delayed-Onset Myotonia | MF",,,,,,,,,,,,,,,"37396103","Myotonia fluctuans",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221055","Paramyotonia Congenita","C122790","An autosomal dominant inherited non-dystrophic myotonia caused by mutations of the SCN4A gene, resulting in sodium muscle channelopathy. It is characterized by muscle stiffness, which is increased by exposure to cold or activity, and usually eases when the patient warms up through physical activity.","Paramyotonia Congenita | PMC | Paramyotonia Congenita of von Eulenburg",,,,,,,,,,,,,,,"4188585","Paramyotonia congenita",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268445","Normokalemic Periodic Paralysis","C122791","An autosomal dominant inherited non-dystrophic myotonia caused by mutations of the SCN4A gene, resulting in sodium muscle channelopathy. Currently, it is considered a variant of hyperkalemic periodic paralysis.  Patients with normokalemic periodic paralysis do not have any change in their potassium levels during weakness, but become weak when they ingest potassium.","Normokalemic Periodic Paralysis | NormoKPP",,,,,,,,,,,,,,,"4222754","Familial normokalemic periodic paralysis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2806460","Gammacoronavirus","C122313","A genus of enveloped and spherical positive sense ssRNA viruses in the subfamily Coronavirinae of the family Coronaviridae with a diameter of about 120 nm. Gammacoronaviruses have a nonopartite, linear genome of 27-32 kb. Birds are the most common reservoir for gammacoronaviruses.","Gammacoronavirus | Coronavirus group 3 | GAMMACORONAVIRUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1033207","Geomyces","C122314","Either of two genera of filamentous fungi in the phylum Ascomycota that are characterized by conidiophores bearing branched clusters of small oval- or pear-shaped arthroconidia. Geomyces destructans is the causative agent of white-nose syndrome in hibernating bats.","Geomyces | GEOMYCES",,,,,,,,,,,,,,,"4189948","Geomyces",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017456","Geotrichum","C122315","A genus of fungi in the family Endomycetaceae, found in soil and water and characterized by chains of hyaline, smooth, one-celled, subglobose to cylindrical, slimy arthroconidia. Species within Geotrichum are the causative agents of geotrichosis.","Geotrichum | GEOTRICHUM",,,,,,,,,,,,,,,"4145438","Geotrichum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017535","Giardia lamblia","C122316","A species of flagellated protozoan parasite in the family Hexamitidae. It is the causative agent of giardiasis.","Giardia lamblia | GIARDIA LAMBLIA | Giardia duodenalis | Giardia intestinalis | Lamblia intestinalis",,,,,,,,,,,,,,,"4301615","Giardia lamblia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017637","Gliocladium","C122317","A genus of asexual fungi in the family Hypocreaceae characterized by hyphae, conidiophores, and conidia borne from hyaline phialides. Gliocladium is not known to be pathogenic in humans or animals.","Gliocladium | GLIOCLADIUM",,,,,,,,,,,,,,,"4104019","Gliocladium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0321612","Gnathostoma spinigerum","C122318","A species of parasitic nematodes in the family Gnathostomatidae. The life cycle of G. spinigerum involves copepods of the genus Cyclops as the first intermediate host, freshwater fish as the second intermediate host, and canine and feline species, and possibly pigs, as the the definitive hosts.","Gnathostoma spinigerum | GNATHOSTOMA SPINIGERUM",,,,,,,,,,,,,,,"4147674","Gnathostoma spinigerum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0314756","Gram-Negative Coccobacillus","C122319","Any bacteria with a shape between that of a sphere and a rod that contains low levels of peptidoglycan in its cell wall and stains pink with the Gram staining technique.","Gram-Negative Coccobacillus | GRAM-NEGATIVE COCCOBACILLUS",,,,,,,,,,,,,,,"4205000","Gram-negative coccobacillus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054224","Pauci-Immune Glomerulonephritis associated with Microscopic Polyangiitis","C123112","Glomerulonephritis in the context of systemic, small vessel vasculitis in which anti neutrophil cytoplasm antibody (ANCA) is almost always present.","Pauci-Immune Glomerulonephritis associated with Microscopic Polyangiitis | Pauci-immune Glomerulonephritis associated with Microscopic Polyangiitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054155","Primary Collapsing Glomerulopathy","C123113","Collapsing glomerulopathy for which no underlying cause has been identified.","Primary Collapsing Glomerulopathy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054045","Secondary Collapsing Glomerulopathy","C123114","Collapsing glomerulopathy for which an underlying cause has been identified.","Secondary Collapsing Glomerulopathy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053954","Systemic Lupus Erythematosus Nephritis Class I","C123115","Systemic lupus erythematosus nephritis that appears normal under light microscopy, but with evidence of immune deposits by immunofluorescence. (Weening, Jan J. et al. (2004). The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited. Journal of the American Society of Nephrology 15(2), 241-50.)","Systemic Lupus Erythematosus Nephritis Class I | Minimal Mesangial Lupus Nephritis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053958","Systemic Lupus Erythematosus Nephritis Class II","C123116","Systemic lupus erythematosus nephritis exhibiting mesangial hypercellularity or mesangial expansion by light microscopy, with mesangial immune deposits. Isolated subepithelial or subendothelial deposits may be visible by immunofluorescence or electron microscopy, but not by light microscopy. (Weening, Jan J. et al. (2004). The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited. Journal of the American Society of Nephrology 15(2), 241-50.)","Systemic Lupus Erythematosus Nephritis Class II | Mesangial Proliferative Lupus Nephritis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053959","Systemic Lupus Erythematosus Nephritis Class III","C123117","Systemic lupus erythematosus nephritis with active of inactive focal, segmental or global endo- or extracapillary glomerulonephritis involving less than 50% of all glomeruli, typically with focal subendothelial immune deposits with or without mesangial alterations. (Weening, Jan J. et al. (2004). The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited. Journal of the American Society of Nephrology 15(2), 241-50.)","Systemic Lupus Erythematosus Nephritis Class III | Focal Lupus Nephritis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053955","Systemic Lupus Erythematosus Nephritis Class IV","C123118","Systemic lupus erythematosus nephritis, with active or inactive diffuse, segmental or global endo- or extracapillary glomerulonephritis involving greater than or equal to 50% of all glomeruli, typically with diffuse subendothelial immune deposits, with or without mesangial alterations. (Weening, Jan J. et al. (2004). The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited. Journal of the American Society of Nephrology 15(2), 241-50.)","Systemic Lupus Erythematosus Nephritis Class IV | Diffuse Lupus Nephritis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053957","Systemic Lupus Erythematosus Nephritis Class IV G","C123119","Systemic lupus erythematosus nephritis, characterized by active or inactive diffuse, global endo- or extracapillary glomerulonephritis that involves 50% or more of all glomeruli. (Weening, Jan J. et al. (2004). The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited. Journal of the American Society of Nephrology 15(2), 241-50.)","Systemic Lupus Erythematosus Nephritis Class IV G | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053952","Systemic Lupus Erythematosus Nephritis Class V","C123121","Systemic lupus erythematosus nephritis, with global or segmental subepithelial immune deposits or their morphologic sequelae by light microscopy and by immunofluorescence or electron microscopy, with or without mesangial alterations. (Weening, Jan J. et al. (2004). The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited. Journal of the American Society of Nephrology 15(2), 241-50.)","Systemic Lupus Erythematosus Nephritis Class V | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053953","Systemic Lupus Erythematosus Nephritis Class VI","C123122","Systemic lupus erythematosus nephritis, with 90% or more of glomeruli globally sclerosed without residual activity. (Weening, Jan J. et al. (2004). The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited. Journal of the American Society of Nephrology 15(2), 241-50.)","Systemic Lupus Erythematosus Nephritis Class VI | Advanced Sclerotic Lupus Nephritis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968836","ABCB4 protein, human","C123864","Phosphatidylcholine translocator ABCB4 (1286 aa, ~142 kDa) is encoded by the human ABCB4 gene. This protein is involved in the transport of phosphatidylcholine, organic anions and drugs.","Phosphatidylcholine Translocator ABCB4 | ABCB4 | ATP-Binding Cassette Sub-Family B Member 4 | EC 3.6.3.44, Formerly | EC 7.6.2.2 | Multidrug Resistance Protein 3 | Multiple Drug Resistance 3 | P-Glycoprotein 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086360","Malignant Germinomatous Cells Present","C123865","A morphologic finding indicating the presence of germinoma, dysgerminoma, or seminoma germ cells.","Malignant Germinomatous Cells Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085197","IFI44 wt Allele","C123867","Human IFI44 wild-type allele is located in the vicinity of 1p31.1 and is approximately 14 kb in length. This allele, which encodes interferon-induced protein 44, may be involved in interferon-mediated viral responses.","IFI44 wt Allele | Interferon-Induced Protein 44 wt Allele | Interferon-Induced, Hepatitis C-Associated Microtubular Aggregate Protein (44kD) Gene | Interferon-Induced, Hepatitis C-Associated Microtubular Aggregate Protein, 44kD Gene | MTAP44 | TLDC5 | p44",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1433278","Interferon-Induced Protein 44, Human","C123868","Interferon-induced protein 44 (444 aa, ~50 kDa) is encoded by the human IFI44 gene. This protein may play a role in interferon-dependent processes.","Interferon-Induced Protein 44 | IFI44 | Microtubule-Associated Protein 44 | TBC/LysM-Associated Domain Containing 5 | p44",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084765","SIGLEC9 wt Allele","C123870","Human SIGLEC9 wild-type allele is located in the vicinity of 19q13.41 and is approximately 14 kb in length. This allele, which encodes sialic acid-binding Ig-like lectin 9 protein, plays a role in both cell adhesion and sialic acid binding.","SIGLEC9 wt Allele | CD329 | CDw329 | FOAP-9 | OBBP-LIKE | Sialic Acid Binding Ig-Like Lectin 9 wt Allele | Sialic Acid-Binding Immunoglobulin-Like Lectin 9 Gene | siglec-9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049851","TSPO protein, human","C122729","Translocator protein (169 aa, ~19 kDa) is encoded by the human TSPO gene. This protein is involved in cholesterol transport.","Translocator Protein | Benzodiazepine Peripheral Binding Site | Isoquinoline Carboxamide-Binding Protein | Mitochondrial Benzodiazepine Receptor | Peripheral-Type Benzodiazepine Receptor | Peripheral-Type Benzodiazepine Receptor/Recognition Site | Putative Peripheral Benzodiazepine Receptor-related Protein | TSPO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049739","SLC35B2 wt Allele","C122736","Human SLC35B2 wild-type allele is located in the vicinity of 6p21.1 and is approximately 4 kb in length. This allele, which encodes adenosine 3'-phospho 5'-phosphosulfate transporter 1 protein, is involved in the transport of adenosine 3'-phospho 5'-phosphosulfate (PAPS) from the cytosol into the Golgi lumen.","SLC35B2 wt Allele | PAPST1 | SLL | Slalom. Drosophila, Homolog of Gene | Solute Carrier Family 35 (Adenosine 3'-Phospho 5'-Phosphosulfate Transporter), Member B2 wt Allele | Solute Carrier Family 35 (Adenosine 3-Prime-Phospho 5-Prime-Phosphosulfate Transporter), Member B2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1310692","Adenosine 3'-phospho 5'-phosphosulfate Transporter 1, Human","C122737","Adenosine 3-phospho 5-phosphosulfate transporter 1 (432 aa, ~48 kDa) is encoded by the human SLC35B2 gene. This protein plays a role in adenosine 3'-phospho 5'-phosphosulfate (PAPS) transport.","Adenosine 3'-phospho 5'-phosphosulfate Transporter 1 | 3'-Phosphoadenosine 5'-Phosphosulfate Transporter | Adenosine 3-phospho 5-phosphosulfate Transporter 1 | PAPS Transporter 1 | Putative MAPK-Activating Protein PM15 | Putative NF-Kappa-B-Activating Protein 48 | Solute Carrier Family 35 Member B2 | Solute Carrier Family 35 Member B2 Variant 2 | Solute Carrier Family 35, Member B2 | UGTrel4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0314755","Gram-Negative Diplococcus","C122320","Any bacteria appearing as paired spheres that contains low levels of peptidoglycan in its cell wall and stains pink with the Gram staining technique.","Gram-Negative Diplococcus | GRAM-NEGATIVE DIPLOCOCCUS",,,,,,,,,,,,,,,"4308411","Gram-negative diplococcus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054890","Gram-Negative Microaerophilic Bacillus","C122321","Any rod-shaped bacteria that contains low levels of peptidoglycan in its cell wall and stains pink with the Gram staining technique and that require oxygen to grow but are poisoned by high concentrations of oxygen.","Gram-Negative Microaerophilic Bacillus | GRAM-NEGATIVE MICROAEROPHILIC BACILLUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054889","Gram-Negative Microaerophilic Coccus","C122322","Any sphere-shaped bacteria that contains low levels of peptidoglycan in its cell wall and stains pink with the Gram staining technique and that require oxygen to grow but are poisoned by high concentrations of oxygen.","Gram-Negative Microaerophilic Coccus | GRAM-NEGATIVE MICROAEROPHILIC COCCUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1498327","Intestinibacter bartlettii","C122324","A species of obligately anaerobic, Gram-positive, rod-shaped, non-motile, spore-forming bacteria in the family Clostridiaceae. I. bartlettii is negative for lecithinase, lipase, catalase and urease, and is unable to hydrolyze esculin or gelatin, or reduce nitrate to nitrite, but positive for acid phosphatase, galactosidase and beta-glucuronidase. The species was originally isolated from fecal samples.","Intestinibacter bartlettii | Clostridium bartlettii | INTESTINIBACTER BARTLETTII",,,,,,,,,,,,,,,"4331500","Intestinibacter bartlettii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022253","Isospora","C122325","A genus of coccidian parasites in the family Eimeriidae. They are the causative agents of isosporiasis. Most members of the genus infect a single host species.","Isospora | ISOSPORA",,,,,,,,,,,,,,,"4097251","Isospora",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024757","Mansonella ozzardi","C122326","A species of parasitic nematodes in the family Onchocercidae. The lifecycle of M. ozzardi involves biting midges or blackflies and humans. Infestation causes serous cavity filariasis.","Mansonella ozzardi | Filaria ozzardi | MANSONELLA OZZARDI | Tetrapetalonema ozzardi",,,,,,,,,,,,,,,"4289605","Mansonella ozzardi",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0446315","Mansonella streptocerca","C122327","A species of parasitic nematodes in the family Onchocercidae. The lifecycle of M. streptocerca involves biting midges and humans. Infestation causes streptocerciasis.","Mansonella streptocerca | Dipetalonema streptocerca | MANSONELLA STREPTOCERCA",,,,,,,,,,,,,,,"4087868","Mansonella streptocerca",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043272","Wuchereria bancrofti","C122328","A species of parasitic nematodes in the family Onchocercidae. Infestation with W. bancrofti causes lymphatic filariasis. It is spread by a mosquito vector, its intermediate host.","Wuchereria bancrofti | Filaria bancrofti | WUCHERERIA BANCROFTI",,,,,,,,,,,,,,,"4225740","Wuchereria bancrofti",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053632","HPV-6-targeting Immunotherapeutic Vaccine INO-3106","C123378","A DNA vaccine consisting of plasmids encoding the E6 and E7 genes of human papilloma virus subtype 6 (HPV-6), with potential immunostimulating and antineoplastic activities. Administered via intramuscular electroporation, HPV-6-targeting immunotherapeutic vaccine INO-3106 expresses the HPV-6 E6 and E7 proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells that are expressing those proteins, resulting in tumor cell lysis. HPV-6 infections are associated with aerodigestive malignancies.","HPV-6-targeting Immunotherapeutic Vaccine INO-3106 | HPV-6 E6/E7 DNA Vaccine INO-3106 | HPV-6-targeting Immunotherapeutic INO-3106 | INO-3106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471731","ingenol derivative LEO 43204 gel","C123379","A topical, aqueous gel formulation containing a derivative of ingenol, a selective small-molecule activator of protein kinase C (PKC) that is isolated from the sap of Euphorbia species, with the potential to treat preneoplastic skin lesions. Upon topical application of the ingenol disoxate gel, the agent presumably activates various PKC isoforms, which may induce apoptosis in abnormal cells found in severely sun-damaged skin with multiple actinic keratoses. This may decrease the number of actinic keratoses and prevent the development of skin neoplasms. The PKC family consists of signaling isoenzymes that regulate many cell processes, including proliferation, differentiation, and apoptosis.","Ingenol Disoxate | 4-Isoxazolecarboxylic acid, 3,5-Diethyl-, (1aR,2S,5R,5aS,6S,8aS,9R,10aR)-1a,2,5,5a,6,9,10,10a-octahydro-5,5a-dihydroxy-4-(hydroxymethyl)-1,1,7,9-tetramethyl-11-oxo-1H-2,8a-methanocyclopenta(a)cyclopropa(E)cyclodecen-6-yl Ester | INGENOL DISOXATE | LEO 43204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474096","Anti-CD123 Monoclonal Antibody KHK2823","C123380","A fully human monoclonal antibody against CD123 (interleukin-3 receptor alpha chain) with potential antineoplastic activity. Anti-CD123 monoclonal antibody KHK2823 binds to and neutralizes CD123, which is upregulated on leukemic stem cells (LSC) found in myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). This agent may inhibit IL-3-dependent signaling and proliferation and may prevent the uncontrolled growth and differentiation of mutated LSC.","Anti-CD123 Monoclonal Antibody KHK2823 | KHK2823",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433866","Mimotope-P10s-PADRE Peptide Vaccine","C123381","A peptide-based vaccine containing a carbohydrate mimetic peptide (CMP) P10s fused to the pan HLA DR-binding epitope (PADRE) peptide, with immunomoadjuvant activity and potential antineoplastic activity. Upon injection of the mimotope-P10s-PADRE peptide vaccine, the P10s peptide, which mimics gangliosides and other tumor-associated carbohydrate antigens (TACA), both stimulates a cytotoxic T-lymphocyte (CTL) response towards cells expressing TACAs and induces the production of antibodies that are reactive with a broad set of TACAs. Additionally, the anti-TACA antibodies may interfere with cellular pathways involved in tumor cell survival and may induce antibody-dependent cellular cytotoxicity (ADCC) toward cells expressing TACAs. PADRE is a helper T-cell epitope that is able to increase the magnitude and duration of the CTL response.","Mimotope-P10s-PADRE Peptide Vaccine | P10s-PADRE | P10s-PADRE Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474106","MVX-1-loaded Macrocapsule/autologous Tumor Cell Vaccine MVX-ONCO-1","C123382","A two-component, anti-cancer vaccine containing irradiated tumor cells from a patient, and a capsule implanted with a genetically modified allogeneic cell line that continuously releases granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immune-protective and -boosting activities. Upon subcutaneous injection of MVX-1-loaded macrocapsule/autologous tumor cell vaccine MVX-ONCO-1, the GM-CSF-secreting allogeneic cell capsules and the autologous irradiated cells isolated from the patient's tumor are co-localized in the patient's tissue. This permits the production of GM-CSF and exposes the immune system to the tumor-associated antigens (TAA) expressed by the autologous tumor cells at the injection site. Local expression of GM-CSF recruits and activates antigen-presenting cells (APC), which induces both antibody-dependent cell-mediated cytotoxicity (ADCC) and cytotoxic T-lymphocyte responses at the site of the injection and systemically. This may lead to tumor regression. By using the patient's own irradiated cancer cells as vaccine antigens, the patient's immune system is exposed to the entire repertoire of this individual's TAAs. The encapsulated cell technology (ECT) of GM-CSF-secreting allogeneic cell capsules ensures the continuous release of GM-CSF. GM-CSF, a monomeric glycoprotein that functions as a cytokine, is a strong immune booster and plays an important role in the activation of immune system.","MVX-1-loaded Macrocapsule/autologous Tumor Cell Vaccine MVX-ONCO-1 | MVX-ONCO-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0916595","Sialic Acid-Binding Ig-Like Lectin 9, Human","C123871","Sialic acid-binding Ig-like lectin 9 (463 aa, ~50 kDa) is encoded by the human SIGLEC9 gene. This protein is involved in sialic acid binding.","Sialic Acid-Binding Ig-Like Lectin 9 | CD329 Antigen | CDw329 | Protein FOAP-9 | Siglec-9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084862","FCRL5 wt Allele","C123873","Human FCRL5 wild-type allele is located in the vicinity of 1q21 and is approximately 39 kb in length. This allele, which encodes Fc receptor-like protein 5, may be involved in the modulation of B-cell development and functionality.","FCRL5 wt Allele | BXMAS1 | CD307 | CD307e | FCRH5 | Fc Receptor-Like 5 wt Allele | IRTA2 | Immunoglobulin Superfamily Receptor Translocation Associated 2 (IRTA2) Gene | Immunoglobulin Superfamily Receptor Translocation-Associated Gene 2 | PRO820 | UNQ503/PRO820",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0968435","Fc Receptor-Like Protein 5, Human","C123874","Fc receptor-like protein 5 (977 aa, ~106 kDa) is encoded by the human FCRL5 gene. This protein may play a role in the regulation of B-cell-mediated immunity.","Fc Receptor-Like Protein 5 | BXMAS1 | CD307e | CD307e Antigen | Fc Receptor Homolog 5 | FcR-Like Protein 5 | FcRH5 | FcRL5 | Immune Receptor Translocation-Associated Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084890","GUCY2C wt Allele","C123876","Human GUCY2C wild-type allele is located in the vicinity of 12p12 and is approximately 84 kb in length. This allele, which encodes heat-stable enterotoxin receptor protein, plays a role in the mediation of ligand-mediated nucleotide cyclase activity. Mutation of the gene is associated with congenital diarrhea type 6 and meconium ileus.","GUCY2C wt Allele | DIAR6 | GCC | GUC2C | Guanylate Cyclase 2C (Heat Stable Enterotoxin Receptor) Gene | Guanylate Cyclase 2C wt Allele | Guanylate Cyclase C Gene | MECIL | MUCIL | STAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055185","Continent Epispadias","C123177","Epispadias with urinary continence.","Continent Epispadias | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054734","Incontinent Epispadias","C123178","Epispadias with urinary incontinence.","Incontinent Epispadias | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055178","Cryoglobulinemic Glomerulonephritis Secondary to Systemic Disease","C123179","Cryoglobulinemia glomerulonephritis associated with chronic disease, often inflammatory conditions.","Cryoglobulinemic Glomerulonephritis Secondary to Systemic Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268744","Focal and Segmental Proliferative Glomerulonephritis","C123180","Glomerulonephritis characterized by proliferation of endothelial or mesangial cells, affecting the glomeruli in a focal and segmental pattern.","Focal and Segmental Proliferative Glomerulonephritis | ",,,,,,,,,,,,,,,"4222610","Focal AND segmental proliferative glomerulonephritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2721603","Henoch-Schönlein Purpura Nephritis","C123181","Glomerulonephritis in the context of Henoch-Schönlein purpura.","Henoch-Schönlein Purpura Nephritis | Henoch-Sch??nlein Purpura Nephritis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053944","Terminal Hematuria","C123182","Gross hematuria that occurs at the end of, or immediately after voiding.","Terminal Hematuria | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054281","P1 Hydronephrosis","C123183","Postnatal Hydronephrosis with the following clinical findings: 1) APRPD is 10 to less than 15 mm, 2) central calyceal dilation may be present, but peripheral calyceal dilation is considered to increase risk, 3) renal parenchyma should have normal thickness and appearance, 4) the ureter is not seen, and 5) the bladder is normal. If there is central calyceal dilation but the APRPD is less than 10 mm, it is still considered UTD P1. (Adapted from: Hiep T. Nguyen, Carol B. Benson, Bryann Bromley, Jeffrey B. Campbell, Jeanne Chow, Beverly Coleman, Christopher Cooper, Jude Crino, Kassa Darge, C.D. Anthony Herndon, Anthony O. Odibo, Michael J.G. Somers, Deborah R. Stein; Multidisciplinary consensus on the classification of prenatal and postnatal urinary tract dilation (UTD classification system); Pediatric Urology; December 2014 Volume 10, Issue 6, Pages 982-998)","P1 Hydronephrosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1173517","Serine/Threonine-Protein Kinase 35","C122740","Serine/threonine-protein kinase 35 (534 aa, ~58 kDa) is encoded by the human STK35 gene. This protein may be a regulator of actin stress fibers in nonmuscle cells.","Serine/Threonine-Protein Kinase 35 | CLIK-1 | CLP-36 Interacting Kinase | CLP-36-Interacting Kinase 1 | CLP36-Interacting Kinase 1 | EC 2.7.11.1 | Intestinal Cell Kinase | PDLIM1-Interacting Kinase 1 | STK35 | Serine Threonine Kinase 35 Long Form | Serine/Threonine-Protein Kinase 35 L1 | hICK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050150","PLEC wt Allele","C122742","Human PLEC wild-type allele is located in the vicinity of 8q24 and is approximately 62 kb in length. This allele, which encodes plectin protein, is involved in anchoring intermediate filaments to desmosomes or hemidesmosomes. Mutations in this gene are associated with epidermolysis bullosa simplex, ogna type and epidermolysis bullosa simplex with pyloric atresia.","PLEC wt Allele | EBS1 | EBSO | HD1 | LGMD2Q | PCN | PLEC1 | PLEC1b | PLTN | Plectin wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0071277","Plectin","C122743","Plectin (4684 aa, ~53 kDa) is encoded by the human PLEC gene. This protein plays a role in linking intermediate filaments to desmosomes or hemidesmosomes.","Plectin | Epidermolysis Bullosa Simplex 1 (Ogna) | Hemidesmosomal Protein 1 | Plectin 1, Intermediate Filament Binding Protein 500kDa | Plectin-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049727","REST wt Allele","C122745","Human REST wild-type allele is located in the vicinity of 4q12 and is approximately 28 kb in length. This allele, which encodes RE1-silencing transcription factor protein, plays a role in repressing neuronal gene expression in non-neuronal tissues.","REST wt Allele | NRSF | RE1-Silencing Transcription Factor wt Allele | XBR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1742913","REST protein, human","C122746","RE1-silencing transcription factor (1097 aa, ~12 kDa) is encoded by the human REST gene. This protein is involved in repressing neuronal gene expression.","RE1-Silencing Transcription Factor | Neural-Restrictive Silencer Factor | Neuron Restrictive Silencer Factor | Neuron-Restrictive Silencer Factor | REST | Repressor Binding To The X2 Box | X2 Box Repressor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055023","FLOT1 wt Allele","C122748","Human FLOT1 wild-type allele is located in the vicinity of 6p21.3 and is approximately 15 kb in length. This allele, which encodes flotillin-1 protein, may play a role in caveolae structure.","FLOT1 wt Allele | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1311167","Flotillin-1, Human","C122749","Flotillin-1 (427 aa, ~47 kDa) is encoded by the human FLOT1 gene. This protein may be involved in caveolae formation.","Flotillin-1 | FLOT1 | Integral Membrane Component Of Caveolae",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049859","PSMD4 wt Allele","C122751","Human PSMD4 wild-type allele is located in the vicinity of 1q21.3 and is approximately 13 kb in length. This allele, which encodes 26S proteasome non-ATPase regulatory subunit 4 protein, plays a role in ATP/ubiquitin-dependent proteolysis.","PSMD4 wt Allele | AF | AF-1 | ASF | MCB1 | PUB-R5 | Protease 26S, Subunit 5A Gene | Proteasome (Prosome, Macropain) 26S Subunit, Non-ATPase, 4 wt Allele | Proteasome 26S Subunit, Non-ATPase, 4 Gene | RPN10 | S5A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3807366","DNAJB1/PRKACA Fusion Gene","C122558","A fusion gene that results from a heterozygous deletion in chromosome 19 that fuses the first 1 or 2 exons of the DNAJB1 gene in frame with exon 2 of the PRKACA gene. This fusion is associated with fibrolamellar carcinoma.","DNAJB1/PRKACA Fusion Gene | DNAJB1-PRKACA Fusion Gene | DNAJB1::PRKACA Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049732","IL34 wt Allele","C122068","Human IL34 wild-type allele is located in the vicinity of 16q22.1 and is approximately 81 kb in length. This allele, which encodes interleukin-34 protein, is involved in cytokine receptor signaling.","IL34 wt Allele | C16orf77 | Chromosome 16 Open Reading Frame 77 Gene | IL-34 | Interleukin 34 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2353974","interleukin-34, human","C122069","Interleukin-34 (242 aa, ~27 kDa) is encoded by the human IL34 gene. This protein plays a role in binding to macrophage colony-stimulating factor 1 receptor and the induction of receptor signaling.","Interleukin-34 | IL-34 | IL34 | Interleukin 34",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0075143","ST 638","C1235","A tyrosine kinase inhibitor that inhibits phospholipase D activity in human neutrophils at a site between the receptor and phospholipase. (NCI)","ST 638 | 2-Cyano-3-(3-ethoxy-4-hydroxy-5-((phenylthio)methyl)phenyl)-2-propenamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054279","P2 Hydronephrosis","C123184","Postnatal Hydronephrosis with the following clinical findings: 1) APRPD is greater than or equal to 15 mm, 2) the calyces may be dilated centrally and peripherally, 3) or a dilated ureter is visible, 4) the parenchymal thickness and appearance is normal, and 5) the bladder is normal. Cases in which there is peripheral calyceal dilation but the APRPD is less than 15 mm are classified as UTD P2. (Adapted from: Hiep T. Nguyen, Carol B. Benson, Bryann Bromley, Jeffrey B. Campbell, Jeanne Chow, Beverly Coleman, Christopher Cooper, Jude Crino, Kassa Darge, C.D. Anthony Herndon, Anthony O. Odibo, Michael J.G. Somers, Deborah R. Stein; Multidisciplinary consensus on the classification of prenatal and postnatal urinary tract dilation (UTD classification system); Pediatric Urology; December 2014 Volume 10, Issue 6, Pages 982-998)","P2 Hydronephrosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054278","P3 Hydronephrosis","C123185","Postnatal Hydronephrosis with the following clinical findings: 1) calyceal dilation and the ureter are the same as those in UTD P2, 2) the renal parenchymal is thinned, has increased echogenicity and/or has decreased corticomedullary differentiation, or 3) the bladder is abnormal (wall thickening, ureterocele, posterior urethral dilation). Cases in which there are parenchymal abnormalities but the APRPD is less than 15 mm, are classified as UTD P3. (Adapted from: Hiep T. Nguyen, Carol B. Benson, Bryann Bromley, Jeffrey B. Campbell, Jeanne Chow, Beverly Coleman, Christopher Cooper, Jude Crino, Kassa Darge, C.D. Anthony Herndon, Anthony O. Odibo, Michael J.G. Somers, Deborah R. Stein; Multidisciplinary consensus on the classification of prenatal and postnatal urinary tract dilation (UTD classification system); Pediatric Urology; December 2014 Volume 10, Issue 6, Pages 982-998)","P3 Hydronephrosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342642","Autosomal Dominant Hypophosphatemia Rickets","C123186","An autosomal dominant renal phosphate wasting disorder that results in rickets.","Autosomal Dominant Hypophosphatemia Rickets | Autosomal Dominant Hypophosphatemic Rickets | Autosomal Dominant Vitamin D-resistant Rickets",,,,,,,,,,,,,,,"4030363","Autosomal dominant hypophosphatemic rickets",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0342643","Autosomal Recessive Hypophosphatemia Rickets","C123187","An autosomal recessive renal phosphate wasting disorder that results in rickets.","Autosomal Recessive Hypophosphatemia Rickets | Autosomal Recessive Hypophosphatemic Rickets",,,,,,,,,,,,,,,"4234996","Autosomal recessive hypophosphatemic vitamin D refractory rickets",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054547","Megacystis - Megaureter","C123188","A condition characterized by a large capacity, thin-walled bladder and megaureter(s).","Megacystis - Megaureter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054339","Non-Obstructed Non-Refluxing Megaureter","C123190","A megaureter in which there is no obstruction at the ureterovesical junction and no vesicoureteral reflux.","Non-Obstructed Non-Refluxing Megaureter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054324","Obstructed Megaureter","C123191","A megaureter in which there is obstruction to the flow of urine at the ureterovesical junction.","Obstructed Megaureter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0238357","Hyperkalemic Periodic Paralysis","C123429","A rare, autosomal dominant inherited disorder caused by mutations in the SCN4A gene. It is characterized by occasional episodes of muscle weakness or paralysis which are usually accompanied by increased levels of potassium in the blood. In some cases, the episodes of paralysis are associated with normal blood potassium levels.  Ingestion of potassium can trigger attacks in affected individuals.","Hyperkalemic Periodic Paralysis | ",,,,,,,,,,,,,,,"4121515","Familial hyperkalemic periodic paralysis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0350998","Glibornuride","C123430","An orally bioavailable sulfonamide urea derivative with antihyperglycemic activity. Upon administration, glibornuride binds to and blocks the sulfonylurea receptor type 1 (SUR1) subunit of the ATP-sensitive inwardly-rectifying potassium (K(ATP)) channels on the membranes of pancreatic beta cells. This prevents the inward flow of positively charged potassium (K+) ions into the cell, and induces a calcium ion (Ca2+) influx through voltage-sensitive calcium channels, which triggers exocytosis of insulin-containing granules. Insulin stimulates glycogen synthesis and inhibits gluconeogenesis, which together lower blood glucose levels.","Glibornuride | 1-((1R)-2-endo-hydroxy-3-endo-bornyl)-3-(p-tolylsulfonyl)urea | GLIBORNURIDE | Glutril | Ro 6-4563 | Ro 6-4563/8 | Urea, 1-(2-Hydroxy-3-bornyl)-3-(p-tolylsulfonyl)-, (1R,2R,3S,4S)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049874","SPAG11B wt Allele","C122071","Human SPAG11B wild-type allele is located in the vicinity of 8p23.1 and is approximately 21 kb in length. This allele, which encodes sperm-associated antigen 11B protein, may play a role in sperm development.","SPAG11B wt Allele | BIN1B, Rat, Homolog of Gene | EDDM2B | EP2 | EP2C | EP2D | HE2 | HE2C | SPAG11 | Sperm Associated Antigen 11B wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1958501","Sperm-Associated Antigen 11B, Human","C122072","Sperm-associated antigen 11B (103 aa, ~11 kDa) is encoded by the human SPAG11B gene. This protein may be involved in the regulation of sperm motility and maturation.","Sperm-Associated Antigen 11B | Epididymal Protein 2B | He2 | Human Epididymis-Specific Protein 2 | Protein EP2 | Sperm Antigen HE2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049703","MMP16 wt Allele","C122074","Human MMP16 wild-type allele is located in the vicinity of 8q21.3 and is approximately 296 kb in length. This allele, which encodes matrix metalloproteinase-16 protein, is involved in endoproteolysis.","MMP16 wt Allele | C8orf57 | Chromosome 8 Open Reading Frame 57 Gene | DKFZp761D112 | MMP-X2 | MMPX2 | MT-MMP2 | MT-MMP3 | MT3-MMP | Matrix Metallopeptidase 16 (Membrane-Inserted) wt Allele | Matrix Metalloproteinase 16 (Membrane-Inserted) Gene | Matrix Metalloproteinase 16, Membrane-Type Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1568288","Matrix Metalloproteinase-16, Human","C122075","Matrix metalloproteinase-16 (607 aa, ~70 kDa) is encoded by the human MMP16 gene. This protein plays a role in endoproteolysis that mediates 72 kDa type IV collagenase activation and extracellular matrix remodeling.","Matrix Metalloproteinase-16 | EC 3.4.24.- | MMP-16 | MMP-X2 | MMP16 | MT-MMP 3 | MT3-MMP | MT3MMP | MTMMP3 | Matrix Metalloprotease 16 | Matrix Metalloprotease-16 | Matrix Metalloproteinase 16 | Membrane-Type Matrix Metalloproteinase 3 | Membrane-Type-3 Matrix Metalloproteinase | Putative Transmembrane Protein C8orf57",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049860","FAM3C wt Allele","C122077","Human FAM3C wild-type allele is located in the vicinity of 7q31 and is approximately 48 kb in length. This allele, which encodes protein FAM3C, plays a role in cell differentiation.","FAM3C wt Allele | Family With Sequence Similarity 3, Member C wt Allele | GS3786 | ILEI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1743459","Protein FAM3C , Human","C122079","Protein FAM3C (227 aa, ~25 kDa) is encoded by the human FAM3C gene. This protein is involved in the regulation of epithelial-to-mesenchymal transition.","Protein FAM3C | Interleukin-Like EMT Inducer | Interleukin-Like Epithelial-Mesenchymal Transition Inducer | Predicted Osteoblast Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3149517","Severe Neonatal Episodic Laryngospasm","C122792","Myotonia caused by mutations of the SCN4A gene, resulting in sodium muscle channelopathy. It is characterized by severe episodes of laryngospasm in the neonatal period, which can be alleviated by channel blockers.","Severe Neonatal Episodic Laryngospasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1135188","Critical Illness Myopathy","C122793","Acute muscle weakness and paralysis that develops in critically ill patients who have been treated with multiple drugs during their intensive care unit stay. It is associated with delayed weaning from mechanical ventilation and prolonged rehabilitation.","Critical Illness Myopathy | Critical illness myopathy",,,,,,,,,,,,,,,"40483286","Critical illness myopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL498222","Anti-FGFR3 Antibody-drug Conjugate LY3076226","C123829","An antibody-drug conjugate (ADC) composed of a human monoclonal antibody against the fibroblast growth factor receptor type 3 (FGFR3) that is conjugated to an undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration, the antibody moiety of anti-FGFR3 ADC LY3076226 binds to FGFR3. Upon internalization, the cytotoxic moiety causes cell death in FGFR3-expressing tumor cells. FGFR3, a receptor tyrosine kinase upregulated or mutated in many tumor cell types, plays a key role in tumor cell proliferation.","Anti-FGFR3 Antibody-drug Conjugate LY3076226 | ADC LY3076226 | Anti-FGFR3 ADC LY3076226 | Anti-fibroblast Growth Factor Receptor 3 Antibody-Drug Conjugate LY3076226 | LY-3076226 | LY3076226",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498223","Porcupine Inhibitor ETC-1922159","C123830","An orally bioavailable inhibitor of the membrane-bound O-acyltransferase (MBOAT) porcupine (PORCN), with potential antineoplastic activity. Upon oral administration, ETC-1922159 binds to and inhibits PORCN in the endoplasmic reticulum (ER), which blocks post-translational palmitoylation of Wnt ligands and inhibits their secretion. This prevents the activation of Wnt ligands, interferes with Wnt-mediated signaling, and inhibits cell growth in Wnt-driven tumors. Porcupine catalyzes the palmitoylation of Wnt ligands, and plays a key role in Wnt ligand secretion. Wnt signaling is dysregulated in a variety of cancers.","Porcupine Inhibitor ETC-1922159 | ETC-159 | ETC-1922159 | PORCN Inhibitor ETC-1922159",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084783","CAPN1 wt Allele","C123833","Human CAPN1 wild-type allele is located in the vicinity of 11q13 and is approximately 31 kb in length. This allele, which encodes calpain-1 catalytic subunit protein, plays a role in limited proteolysis of substrates, which modulates cytoskeletal remodeling and signal transduction.","CAPN1 wt Allele | CANP | CANP1 | CANPL1 | Calcium-Activated Neutral Proteinase 1, Catalytic Subunit Gene | Calpain 1, (Mu/I) Large Subunit wt Allele | Calpain I, Large Subunit Gene | Calpain, Large Polypeptide L1 Gene | muCANP | muCL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0078049","varicella-zoster immune globulin","C123431","A human plasma-derived immunoglobulin G (IgG) formulation containing high levels of antibodies against varicella zoster virus (VZV), a double-stranded DNA virus that causes chickenpox and herpes zoster (shingles), with potential immunomodulating and antiviral activities. VZV IgG (VARIZIG) is isolated from donors expressing high amounts of VZV antibodies. Upon intramuscular (IM) administration, the anti-VZV antibodies provide passive immunization against VZV. This may prevent infection by VZV in immunocompromised patients.","Human Varicella Zoster Immune Globulin | HUMAN VARICELLA-ZOSTER IMMUNE GLOBULIN | Human Varicella-Zoster Immune Globulin | VARIZIG | Varicella Zoster Immune Globulin Human",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3840920","Hyperlysinemia","C123433","An autosomal recessive inherited condition caused by mutations in the AASS gene. It is characterized by elevated levels of the amino acid lysine in the blood. It usually does not cause health problems.","Hyperlysinemia | ",,,,,,,,,,,,,,,"4241701","Hyperlysinemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2931161","Immunoglobulin a deficiency 1","C123434","Decreased or absent levels of serum immunoglobulin A, with normal serum levels of immunoglobulin G and immunoglobulin M in a patient who is older than 4 years of age and in whom all other causes of hypogammaglobulinemia have been excluded. Affected individuals may be asymptomatic or have frequent infections, allergic reactions, or autoimmune disorders.","Immunoglobulin A Deficiency 1 | IGAD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268621","Methionine Adenosyltransferase Deficiency","C123435","A metabolic disorder usually inherited in an autosomal recessive pattern and caused by mutations in the MAT1A gene. Affected individuals usually do not have clinical abnormalities.","Methionine Adenosyltransferase Deficiency | Hypermethioninemia, Isolated Persistent | Isolated Persistent Hypermethioninemia | MAT Deficiency | MAT I/III Deficiency",,,,,,,,,,,,,,,"4212620","Hepatic methionine adenosyltransferase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0796012","Peters-Plus Syndrome","C123436","A rare, autosomal recessive inherited syndrome caused by mutations in the B3GALTL gene. It is characterized by abnormalities in the anterior chamber of the eye, short stature, cleft lip with or without cleft palate, distinctive facial features, and intellectual disability.","Peters-Plus Syndrome | ",,,,,,,,,,,,,,,"42709945","Peters plus syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1850155","Multicentric Osteolysis, Nodulosis, and Arthropathy","C123437","A rare, autosomal recessive inherited syndrome caused by mutations in the MMP2 gene. It is characterized by the presence of multiple, painless subcutaneous nodules, osteolysis particularly in the hands and feet, osteoporosis, and arthropathy.","Multicentric Osteolysis, Nodulosis, and Arthropathy | Hereditary Multicentric Osteolysis | MONA",,,,,,,,,,,,,,,"37396889","Multicentric osteolysis nodulosis arthropathy spectrum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0410179","Ullrich Congenital Muscular Dystrophy","C123438","A rare, autosomal recessive inherited disorder caused by mutations in the COL6A1, COL6A2, and COL6A3 genes. Signs and symptoms usually appear at birth or early infancy. Affected individuals have severe muscle weakness, multiple contractures, and hypermobility in their distal joints.","Ullrich Congenital Muscular Dystrophy | Scleroatonic Ullrich Disease | UCMD",,,,,,,,,,,,,,,"4344608","Ullrich congenital muscular dystrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4050549","Academic Research Council Acute Stent Thrombosis","C123439","The formation of a clot within a stent less than 24 hours after the stent is placed. (Cutlip DE, Windecker S, Mehran R, et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions. Circulation. 2007;115:2344-2351)","Academic Research Council Acute Stent Thrombosis | STENT THROMBOSIS ARC ACUTE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055100","EXACT - Chest Feel Congested","C123669","Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT) Did your chest feel congested today?","EXACT - Chest Feel Congested | EXACT1-Chest Feel Congested | EXACT101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055095","EXACT - How Often Cough Today","C123670","Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT) How often did you cough today?","EXACT - How Often Cough Today | EXACT1-How Often Cough | EXACT102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0074442","Atamestane","C1224","A synthetic steroidal substance with antineoplastic activity.  Atamestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. (NCI04)","Atamestane | ATAMESTANE | atamestane",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1868619","Paramyotonia Congenita without Cold Paralysis","C122794","An autosomal dominant inherited non-dystrophic myotonia caused by mutations of the SCN4A gene. It is characterized by muscle stiffness, which is increased by exposure to cold but does not change to flaccid paralysis with intense cooling.","Paramyotonia Congenita without Cold Paralysis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0403399","Nephrotic Syndrome - NPHS1 Associated","C122795","Nephrotic syndrome attributed to mutation(s) in the NPHS1 gene, which encodes the protein nephrin, and most commonly presents during the first three months of life.","Nephrotic Syndrome - NPHS1 Associated | Congenital Nephrotic Syndrome - Finnish Type",,,,,,,,,,,,,,,"4058844","Finnish congenital nephrotic syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3496337","Idiopathic Nephrotic Syndrome","C122796","Nephrotic syndrome for which no cause has been identified.","Idiopathic Nephrotic Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3266102","Nephrotic Syndrome of Childhood - Steroid Resistant","C122798","Nephrotic syndrome, occurring in the pediatric population, in which proteinuria does not normalize with administration of steroids; this condition is unresponsive to a minimum of four weeks administration of oral corticosteroids.","Nephrotic Syndrome of Childhood - Steroid Resistant | Nephrotic Syndrome-Steroid-Resistant | Steroid-Resistant Nephrotic Syndrome",,,,,,,,,,,,,,,"42709948","Steroid resistant nephrotic syndrome of childhood",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0403398","Nephrotic Syndrome- Steroid Dependent","C122799","Nephrotic syndrome characterized by two or more consecutive relapses during steroid tapering or within fourteen days of discontinuing steroids.","Nephrotic Syndrome- Steroid Dependent | ",,,,,,,,,,,,,,,"4125954","Steroid-dependent nephrotic syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0074548","Simalikalactone D","C1227","A quassinoid phytochemical isolated from Simaba multiflora, Quassia africana and other plant species with potential antineoplastic activity.  This agent also has antimalarial and antiviral properties. (NCI04)","Simalikalactone D | (+)-Simalikalactone D | Picras-3-ene-2,16-dione, 13,20-epoxy-1,11,12-trihydroxy-15-(2-methyl-1-oxobutoxy)-, (11beta)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054736","Incident Nephrotic Syndrome","C122800","New onset nephrotic syndrome.","Incident Nephrotic Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054156","Prevalent Nephrotic Syndrome","C122801","Pre-existing nephrotic syndrome.","Prevalent Nephrotic Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054368","Nephrotic Syndrome - Relapse","C122802","Nephrotic syndrome characterized by recurrent proteinuria by dipstick of first morning urine: 2+ or greater for three days or longer, or the presence of edema with proteinuria of any duration following a remission.","Nephrotic Syndrome - Relapse | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049701","Nephrotic Syndrome - Frequently Relapsing","C122803","Nephrotic syndrome in which there is relapse occurring two or more times in the first six months, or four or more times in a year.","Nephrotic Syndrome - Frequently Relapsing | FRNS | Frequently Relapsing Nephrotic Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2675904","Wilms Tumor-Aniridia-Genitourinary Anomalies-Mental Retardation-Obesity Syndrome","C122804","A condition resembling WAGR (Wilms tumor, aniridia, genitourinary anomalies and developmental delay) syndrome that also includes obesity. This is a contiguous gene syndrome due to deletion in the vicinity of chromosome 11p13-p12 in a region containing the WT1, PAX6 and BDNF genes.","WAGRO Syndrome | WAGRO | WAGRO Syndrome | Wilms Tumor, Aniridia, Genitourinary Anomalies, Mental Retardation, and Obesity Syndrome | Wilms Tumor-Aniridia-Genitourinary Anomalies-Mental Retardation-Obesity Syndrome | Wilms Tumor-Aniridia-Genitourinary Anomalies-Mental Retardation-Obesity Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0950122","Frasier Syndrome","C122805","A condition, which typically presents during adolescence, that is caused by WT-1 mutation, and is characterized by a developmental sex disorder, FSGS, and may be associated with gonadoblastoma.","Frasier Syndrome | ",,,,,,,,,,,,,,,"40483743","Frasier syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055141","Diffuse Endocapillary Glomerulonephritis","C122806","Glomerulonephritis characterized by endocapillary proliferation and the presence of inflammatory cells affecting 50% or more of all glomeruli.","Diffuse Endocapillary Glomerulonephritis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086161","Childhood Immature Teratoma","C123834","An immature teratoma occurring in children.","Childhood Immature Teratoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086173","Childhood Testicular Immature Teratoma","C123835","An immature teratoma that arises from the testis and occurs in children.","Childhood Testicular Immature Teratoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086163","Childhood Mature Teratoma","C123836","A mature teratoma occurring in children.","Childhood Mature Teratoma | Childhood Mature Cystic Teratoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053934","Tip Lesion Glomerulopathy","C123123","Segmental glomerulopathy of localized intracapillary foam cells with adjacent, often vacuolated glomerular epithelial cells confluent to the origin of the proximal tubule.","Tip Lesion Glomerulopathy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054360","Nephrotic Syndrome-Remission, Partial Remission","C123124","Nephrotic syndrome in which proteinuria has decreased by at least 50% and below the nephrotic range cutoff from disease onset, but does not normalize following a defined course of treatment.","Nephrotic Syndrome-Remission, Partial Remission | Partial Remission Nephrotic Syndrome Remission",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055452","Antimicrobial - Induced Nephropathy","C123125","Kidney damage resulting from exposure to antimicrobials.","Antimicrobial - Induced Nephropathy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055379","Bisphosphonate - Induced Nephropathy","C123126","Kidney damage resulting from exposure to bisphosphonates.","Bisphosphonate - Induced Nephropathy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053745","Calcineurin Inhibitor - Induced Nephropathy","C123127","Kidney damage resulting from exposure to calcineurin inhibitors.","Calcineurin Inhibitor - Induced Nephropathy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055261","Chemotherapeutic Drug - Induced Nephropathy","C123128","Kidney damage resulting from exposure to chemotherapeutic drugs.","Chemotherapeutic Drug - Induced Nephropathy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054602","Lithium - Induced Nephropathy","C123130","Kidney damage resulting from lithium which may include distal or collecting tubular cysts, proteinuria, interstitial nephritis and nephrogenic diabetes insipidus.","Lithium - Induced Nephropathy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053823","mTOR Inhibitor - Induced Nephropathy","C123131","Kidney damage resulting from exposure to mechanistic target of rapamycin (mTOR) kinase inhibitors.","mTOR Inhibitor - Induced Nephropathy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054407","Nephropathy due to Aminoglycosides","C123132","Kidney damage resulting from aminoglycosides.","Nephropathy due to Aminoglycosides | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3875310","Nephropathy due to Amphotericin","C123133","Kidney damage resulting from amphotericin.","Nephropathy due to Amphotericin | ",,,,,,,,,,,,,,,"45766812","Nephropathy induced by amphotericin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054405","Nephropathy due to Analgesic Drugs","C123134","Kidney damage resulting from analgesic drugs.","Nephropathy due to Analgesic Drugs | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054403","Nephropathy due to Cisplatin","C123136","Kidney damage resulting from cisplatin.","Nephropathy due to Cisplatin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3875433","Nephropathy due to Tacrolimus","C123137","Kidney damage resulting from tacrolimus.","Nephropathy due to Tacrolimus | ",,,,,,,,,,,,,,,"45766936","Nephropathy induced by tacrolimus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053796","NSAID-Induced Nephropathy","C123138","Kidney damage resulting from exposure to non-steroidal anti-inflammatory drugs (NSAIDs).","NSAID-Induced Nephropathy | Non-steroidal Anti-inflammatory Drug-Induced Nephropathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055101","EXACT - Bring Up Mucus When Coughing","C123671","Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT) How much mucus (phlegm) did you bring up when coughing today?","EXACT - Bring Up Mucus When Coughing | EXACT1-Bring Up Mucus When Coughing | EXACT103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055097","EXACT - Difficult to Bring Up Mucus","C123672","Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT) How difficult was it to bring up mucus (phlegm) today?","EXACT - Difficult to Bring Up Mucus | EXACT1-Difficult to Bring Up Mucus | EXACT104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055099","EXACT - Chest Feel Tight","C123674","Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT) Did your chest feel tight today?","EXACT - Chest Feel Tight | EXACT1-Chest Feel Tight | EXACT106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055090","EXACT - Were You Breathless","C123675","Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT) Were you breathless today?","EXACT - Were You Breathless | EXACT1-Breathless | EXACT107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055098","EXACT - Describe How Breathless","C123676","Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT) Describe how breathless you were today.","EXACT - Describe How Breathless | EXACT1-Describe How Breathless | EXACT108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055093","EXACT - Short of Breath When Performing Usual Indoor Activities","C123678","Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT) Were you short of breath today when performing your usual indoor activities like cleaning or household work?","EXACT - Short of Breath When Performing Usual Indoor Activities | EXACT1-Short Breath Indoor Activities | EXACT110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053783","EXACT - Short of Breath When Performing Usual Activities Outside","C123679","Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT) Were you short of breath today when performing your usual activities outside the home such as yard work or errands?","EXACT - Short of Breath When Performing Usual Activities Outside | EXACT1-Short Breath Outside Activities | EXACT111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055091","EXACT - Tired or Weak","C123680","Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT) Were you tired or weak today?","EXACT - Tired or Weak | EXACT1-Tired or Weak | EXACT112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055094","EXACT - Night Sleep Disturbed","C123681","Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT) Last night, was your sleep disturbed?","EXACT - Night Sleep Disturbed | EXACT1-Night Sleep Disturbed | EXACT113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055089","EXACT - Worried About Lung Problems","C123682","Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT) How scared or worried were you about your lung problems today?","EXACT - Worried About Lung Problems | EXACT1-Worried About Lung Problems | EXACT114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1451001","Heat-Stable Enterotoxin Receptor, Human","C123877","Heat-stable enterotoxin receptor (1073 aa, ~123 kDa) is encoded by the human GUCY2C gene. This protein is involved in ligand-stimulated guanylate cyclase activity.","Heat-Stable Enterotoxin Receptor | EC 4.6.1.2 | GC-C | GCC | GUCY2C | Guanylate Cyclase 2C | Guanylyl Cyclase 2C | Guanylyl Cyclase C | Heat Stable Enterotoxin Receptor | Intestinal Guanylate Cyclase | STA Receptor | StAR | hSTAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014165","Endolimax","C122018","A genus of amoebozoa parasites in the phylum Archamoebae. Cysts and trophozoites of these species are passed in stool and excystation occurs in the small intestine.","Endolimax | ",,,,,,,,,,,,,,,"4294244","Endolimax",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320301","Enteromonas","C122019","A genus of flagellate protozoa in the family Enteromonadidae. Both cysts and trophozoites are shed in feces.","Enteromonas | ",,,,,,,,,,,,,,,"4243221","Enteromonas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1002615","Dolosigranulum","C122020","A genus of Gram-positive, rod-shaped bacteria in the family Firmicutes.","Dolosigranulum | ",,,,,,,,,,,,,,,"4179837","Dolosigranulum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015646","Fasciola","C122021","A genus of flatworms in the family Fasciolidae. Fasciola are the causative agents of fasciolosis.","Fasciola | ",,,,,,,,,,,,,,,"4152314","Genus Fasciola",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015657","Fasciolopsis","C122022","A genus of parasitic tremadoda flatworms in the family Fasciolidae. It is the causative agent of faciolopsiasis.","Fasciolopsis | ",,,,,,,,,,,,,,,"4009233","Fasciolopsis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018010","Gnathostoma","C122023","A genus of parasitic nematodes in the family Gnathostomatidae. The Gnathostoma lifecycle involves copepods as the first intermediate host; fish, frogs, or snakes as the second intermediate host; and pigs, cats, dogs, or wild animals as its natural definitive host. Humans may become infested by eating infested fish or fowl. Infestation causes gnathostomiasis.","Gnathostoma | GNATHOSTOMA",,,,,,,,,,,,,,,"4141896","Gnathostoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032211","Platyhelminthes","C122024","The taxanomic phylum of flatworms. Flatworms have simple bilateral symmetry, are unsegmented, soft-bodied, and have no body cavity and no specialized circulatory or respiratory organs.","Platyhelminthes | Platyhelminth",,,,,,,,,,,,,,,"4026267","Phylum Platyhelminthes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013506","Echinococcus","C122025","A genus of cyclophyllid tapeworms in the family Taeniidae. The definitive hosts for echinococcus are carnivorous predators; humans become by zoonotic transfer. Infection with Echinococcus results in hydatid disease, also known as echinococcosis.","Echinococcus | ",,,,,,,,,,,,,,,"4171046","Genus Echinococcus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4049702","Focal Segmental Glomerulosclerosis, Not Otherwise Specified","C123139","Segmental scarring of the glomerulus, which may result in isolated proteinuria or nephrotic syndrome, which affects only part of the glomerulus and only some of the glomeruli. Additionally, the Not Otherwise Specified classification excludes FSGS tip, perihilar, collapsing, and cellular variants. (D'Agati VD, et al. 'Pathologic Classification of Focal Segmental Glomerulosclerosis: A Working Proposal.' Am J Kidney Dis 43.2 (2004): 368-82.)","Focal Segmental Glomerulosclerosis, Not Otherwise Specified | FSGS | FSGS (NOS) | Focal Segmental Glomerulosclerosis (NOS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054746","IgA Nephropathy, Familal","C123140","IgA nephropathy secondary to a genetic mutation that is transmitted from parents to offspring.","IgA Nephropathy, Familal | IgA Nephropathy, Familial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268167","Enteric Hyperoxaluria","C123142","Excessive urinary oxalate excretion resulting from increased absorption of oxalate.","Enteric Hyperoxaluria | ",,,,,,,,,,,,,,,"4291473","Enteric hyperoxaluria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4045791","CXC Chemokine Receptor 2 Antagonist AZD5069","C123383","An orally bioavailable, selective and reversible antagonist of CXC chemokine receptor 2 (CXCR2), with potential anti-inflammatory and antineoplastic activities. Upon administration, CXC chemokine receptor 2 antagonist AZD5069 directly binds to CXCR2 and inhibits its activation. This inhibits CXCR2-mediated signaling and may inhibit tumor cell proliferation in CXCR2-overexpressing tumor cells. In addition, AZD5069 reduces both neutrophil recruitment and migration from the systemic circulation into sites of inflammation, including the lung mucosa; it may also prevent neutrophil migration from the bone marrow. This results in the reduction of inflammation, mucus production, and neutrophil proteinase-mediated tissue destruction in the lung. CXCR2, a G protein-coupled receptor protein also known as IL-8 receptor B (IL-8RB), is upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation and progression; it is known to be elevated in several inflammatory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and fibrotic pulmonary disorders.","CXC Chemokine Receptor 2 Antagonist AZD5069 | AZD-5069 | AZD5069 | CXCR2 Antagonist AZD5069 | N-(2-(((2,3-difluorophenyl)methyl)thio)-6-(((1R,2S)-2,3-dihydroxy-1-methylpropyl)oxy)-4-pyrimidinyl)-1-azetidinesulfonamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1301707","Patient-Controlled Epidural Analgesia","C123385","A method of analgesia that uses an epidural catheter and a pump to allow the patient to administer predetermined doses of analgesic into the epidural space as needed to maintain adequate pain control.","Patient-Controlled Epidural Analgesia | Epidural Patient-Controlled Analgesia | PCEA",,,,,,,,,,,,,,,"4287923","Patient controlled epidural analgesia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3888064","4-Hydroxy-3-methoxybenzenesulfonic Acid","C123387","No value exists.","4-Hydroxy-3-methoxybenzenesulfonic Acid | 4-Guaiacolsulfonic Acid | Benzenesulfonic Acid, 4-Hydroxy-3-methoxy- | SULFOGAIACOL | Sulfogaiacol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0145631","Potassium Guaiacolsulfonate Anhydrous","C123388","No value exists.","Potassium Guaiacolsulfonate Anhydrous | Benzenesulfonic Acid, Hydroxymethoxy-, Potassium Salt (1:1) | Guaiacolsulfonate Potassium Anhydrous | POTASSIUM GUAIACOLSULFONATE ANHYDROUS | Thiocol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054647","Light Dosimetry","C123389","Methods to measure the administered light dose during photodynamic therapy (PDT).","Light Dosimetry | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3713322","Ombitasvir","C123878","An orally available inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex, with potential activity against HCV. Upon oral administration and after intracellular uptake, ombitasvir binds to and blocks the activity of the NS5A protein. This results in the disruption of the viral RNA replication complex, blockage of HCV RNA production, and inhibition of viral replication. NS5A, a zinc-binding and proline-rich hydrophilic phosphoprotein, plays a crucial role in HCV RNA replication. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family; HCV infection is associated with the development of hepatocellular carcinoma (HCC).","Ombitasvir | ABT 267 | ABT-267 | ABT267 | Carbamic Acid, N,N'-(((2S,5S)-1-(4-(1,1-dimethylethyl)phenyl)-2,5-pyrrolidinediyl)bis(4,1-phenyleneiminocarbonyl-(2S)-2,1-pyrrolidinediyl((1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl)))bis-, C,C'-Dimethyl Ester | L-Prolinamide,2,2'-(((2S,5S)-1-(4-(1,1-dimethylethyl)phenyl)-2,5-pyrrolidinediyl)di-4,1-phenylene)bis(N-(methoxycarbonyl)-L-valy | OMBITASVIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3712108","Paritaprevir","C123879","An orally bioavailable, synthetic acylsulfonamide inhibitor of the hepatitis C virus (HCV) protease complex comprised of non-structural protein 3 and 4A (NS3/NS4A), with potential activity against HCV genotype 1. Upon administration, paritaprevir reversibly binds to the active center and binding site of the HCV NS3/NS4A protease and prevents NS3/NS4A protease-mediated polyprotein maturation. This disrupts both the processing of viral proteins and the formation of the viral replication complex, which inhibits viral replication in HCV genotype 1-infected host cells. NS3, a serine protease, is essential for the proteolytic cleavage of multiple sites within the HCV polyprotein and plays a key role during HCV ribonucleic acid (RNA) replication. NS4A is an activating factor for NS3. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family, and infection is associated with the development of hepatocellular carcinoma (HCC).","Paritaprevir | (2R,6S,12Z,13aS,14aR,16aS)-N-(Cyclopropylsulfonyl)-6-{[(5-methyl-2-pyrazinyl)carbonyl]amino}-5,16-dioxo-2-(6-phenanthridinyloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo [1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide | ABT 450 | ABT-450 | ABT450 | PARITAPREVIR | Veruprevir",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3850285","Dasabuvir","C123880","A non-nucleoside inhibitor of the hepatitis C virus (HCV) non-structural protein 5B (NS5B), an RNA-dependent RNA polymerase, with potential activity against HCV. Upon administration and after intracellular uptake, dasabuvir binds HCV NS5B polymerase and blocks viral RNA synthesis and replication. The HCV NS5B protein is essential for the replication of the HCV RNA genome. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family; HCV infection is associated with the development of hepatocellular carcinoma (HCC).","Dasabuvir | ABT 333 | ABT-333 | ABT333 | DASABUVIR | Exviera | Methanesulfonamide, N-(6-(5-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-3-(1,1-dimethylethyl)-2-methoxyphenyl)-2-naphthalenyl)- | N-(6-(3-tert-Butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498250","autologous beta-A(T87Q)-globin gene-transduced CD34-positive cells","C123881","A preparation of autologous, CD34-positive hematopoietic stem cells (HSCs) transduced ex vivo with the BB305 recombinant replication-defective, self-inactivating lentiviral vector encoding for an engineered form of human beta-globin (hemoglobin-beta, HBB) gene, beta-A-T87Q (b-A-T87Q) where the threonine at position 87 has been substituted with glutamine, with potential to restore beta-globin expression and function. Autologous CD34-positive stem cells are isolated from the patient's own bone marrow and the cells are transduced with the lentiviral vector. Upon re-infusion of betibeglogene autotemcel back into the patient, these cells express b-A-T87Q-globin, thereby allowing the body to make normal hemoglobin and thus normal, healthy red blood cells. Beta-globin, the beta-chain of the most common form of hemoglobin, is encoded by the HBB gene; mutations in this gene prevent normal beta-globin production and are associated with beta-thalassemia and sickle cell anemia. The b-A-T87Q form of beta-globin has increased antisickling activity compared to the wild type protein.","Betibeglogene Autotemcel | Autologous CD34+ Cells Encoding beta-A-T87Q-globin Gene | Autologous CD34+ HSCs Transduced with LentiGlobin BB305 | Autologous CD34+ Hematopoietic Stem Cells Transduced Ex Vivo with Betibeglogene Darolentivec | BETIBEGLOGENE AUTOTEMCEL | LentiGlobin BB305 Drug Product for TDT | LentiGlobin BB305 Lentiviral Vector-transduced Autologous CD34+ HSCs | LentiGlobin BB305-transduced CD34-positive Cells | LentiGlobin Drug Product for Transfusion Dependent beta-Thalassemia | Lentiviral b-A(T87Q)-Globin-transduced CD34-positive Cells | Zynteglo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054087","Refluxing Megaureter","C123192","A megaureter that demonstrates retrograde urine flow without ureteral obstruction.","Refluxing Megaureter | Refluxing Non-Obstructed Megaureter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054086","Refluxing Obstructed Megaureter","C123193","A megaureter in which there is retrograde flow of urine and a concomitant, episodic obstruction resulting from ureteral folding.","Refluxing Obstructed Megaureter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049728","MARCKS wt Allele","C122754","Human MARCKS wild-type allele is located in the vicinity of 6q21 and is approximately 6 kb in length. This allele, which encodes myristoylated alanine-rich C-kinase substrate protein, is involved in the crosslinking of actin filaments and may be involved in cell motility, phagocytosis, membrane trafficking, and mitogenesis.","MARCKS wt Allele | MAC | MACS | MRACKS | Myristoylated Alanine-Rich Protein Kinase C Substrate (MARCKS, 80K-L) Gene | Myristoylated Alanine-rich Protein Kinase C Substrate wt Allele | PKCSL | PRKCSL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0378964","Myristoylated Alanine-Rich C-Kinase Substrate, Human","C122755","Myristoylated alanine-rich C-kinase substrate (332 aa, ~32 kDa) is encoded by the human MARCKS gene. This protein plays a role in the crosslinking of actin filaments.","Myristoylated Alanine-Rich C-Kinase Substrate | 80K-L | 80K-L Protein | MARCKS | Phosphomyristin | Protein Kinase C Substrate, 80 kDa Protein, Light Chain | Protein Kinase C Substrate, 80-kD, Light Chain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054335","Normal Range Comparison Result","C122756","A value that specifies the relationship of a value to a normal range or reference range of values.","Normal Range Comparison Result | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054090","Reference Range Comparison","C122757","The activity of determining whether a test result value is within acceptable reference limits.","Reference Range Comparison | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049869","TRIM63 wt Allele","C122759","Human TRIM63 wild-type allele is located within 1p34-p33 and is approximately 17 kb in length. This allele, which encodes E3 ubiquitin-protein ligase TRIM63 protein, plays a role in the degradation of myosin proteins during amino acid starvation.","TRIM63 wt Allele | IRF | MURF1 | MURF2 | RNF28 | SMRZ | Tripartite Motif Containing 63, E3 Ubiquitin Protein Ligase wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055165","DNAJB1/PRKACA Fusion Protein","C122559","A fusion protein that is encoded by the DNAJB1/PRKACA fusion gene. This protein contains the N-terminus of DnaJ homolog subfamily B member 1 protein fused to almost the entire cAMP-dependent protein kinase catalytic subunit alpha (PKA C-alpha) protein. The chimeric protein lacks the PKA C-alpha domains that interact with PKA regulatory subunits.","DNAJB1/PRKACA Fusion Protein | DNAJB1-PRKACA Fusion Protein | DNAJB1::PRKACA Fusion Protein | DnaJ Homolog Subfamily B Member 1-cAMP-Dependent Protein Kinase Catalytic Subunit Alpha Fusion Protein | DnaJ Homolog Subfamily B Member 1/cAMP-Dependent Protein Kinase Catalytic Subunit Alpha Fusion Protein | HSP40-PKA C-alpha Fusion Protein | HSP40/PKA C-alpha Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049600","DNAJB1 wt Allele","C122561","Human DNAJB1 wild-type allele is located in the vicinity of 19p13.2 and is approximately 15 kb in length. This allele, which encodes DnaJ homolog subfamily B member 1 protein, is involved in the modulation of heat shock protein 70 activity. A chromosomal deletion that fuses this gene and the PRKACA gene is associated with fibrolamellar carcinoma.","DNAJB1 wt Allele | DNAJ1 | DnaJ (Hsp40) Homolog, Subfamily B, Member 1 wt Allele | DnaJ Homolog, Subfamily B, Member 1 Gene | HDJ1 | HSPF1 | Hdj1 | Hsp40 | RSPH16B | Radial Spoke 16 Homolog B (Chlamydomonas) Gene | Radial Spoke 16 Homolog B Gene | Sis1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL496644","DnaJ Homolog Subfamily B Member 1","C122562","DnaJ homolog subfamily B member 1 (340 aa, ~38 kDa) is encoded by the human DNAJB1 gene. This protein plays a role in the regulation of both heat shock protein 70 activity and protein folding.","DnaJ Homolog Subfamily B Member 1 | DNAJB1 | DnaJ Protein Homolog 1 | HSP40 | Heat Shock 40 kDa Protein 1 | Heat Shock 40kD Protein 1 | Heat Shock Protein 40 | Heat-Shock 40-kD Protein 1 | Human DnaJ Protein 1 | Radial Spoke 16 Homolog B | hDj-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055244","Childhood Lymphomatoid Granulomatosis","C123392","Lymphomatoid granulomatosis that occurs during childhood.","Childhood Lymphomatoid Granulomatosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054113","Recurrent Childhood Lymphomatoid Granulomatosis","C123393","The reemergence of lymphomatoid granulomatosis in childhood after a period of remission.","Recurrent Childhood Lymphomatoid Granulomatosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055247","Childhood Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","C123394","An extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue that occurs during childhood.","Childhood Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Childhood Extranodal Marginal Zone Lymphoma of MALT | Childhood MALT Lymphoma | Childhood MALToma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055246","Childhood Langerhans Cell Histiocytosis with Risk Organ Involvement","C123395","Langerhans cell histiocytosis that occurs during childhood and involves the bone marrow, spleen, liver, or lung.","Childhood Langerhans Cell Histiocytosis with Risk Organ Involvement | High Risk Childhood Langerhans Cell Histiocytosis | High-Risk Childhood Langerhans Cell Histiocytosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055245","Childhood Langerhans Cell Histiocytosis without Risk Organ Involvement","C123396","Langerhans cell histiocytosis that occurs during childhood and does not involve the bone marrow, spleen, liver, or lung.","Childhood Langerhans Cell Histiocytosis without Risk Organ Involvement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2315541","Calyceal Diverticulum","C123194","An out-pouching of the calyx into the renal parenchyma.","Calyceal Diverticulum | ",,,,,,,,,,,,,,,"4333223","Diverticulum of renal calyx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054747","Idiopathic Renal Papillary Necrosis","C123195","Necrosis of the renal papillae, for which no underlying cause has been identified.","Idiopathic Renal Papillary Necrosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2721575","Ischemic Nephropathy","C123196","Nephropathy due to hypoperfusion of the kidney.","Ischemic Nephropathy | ",,,,,,,,,,,,,,,"46272236","Ischemic nephropathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054578","Malignant Hypertensive Nephropathy","C123197","Hypertensive nephropathy secondary to malignant hypertension.","Malignant Hypertensive Nephropathy | Accelerated Hypertensive Nephropathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0266317","Megacalycosis","C123198","Isolated enlargement of renal calyces without obstruction.","Megacalycosis | ",,,,,,,,,,,,,,,"4312212","Megacalycosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268732","Nephritic Syndrome","C123199","A syndrome characterized by hematuria with dysmorphic red blood cells, red blood cell casts, and proteinuria; systemic manifestations may be present, including hypertension, edema, oliguria.","Nephritic Syndrome | ",,,,,,,,,,,,,,,"4298809","Nephritic syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1524076","Amilomer","C1231","A synthetic microsphere formulation with arterial occlusive properties. Amilomer, a product produced by partially hydrolyzing starch and epichlorohydrin, contains degradable starch microspheres (DSM) with a diameter size of 45 micrometers that are readily degraded by amylase. When used in transcatheter arterial chemoembolization (TACE) procedures, infusion leads to lodging of the microspheres in the precapillary vessels and, consequently, to the occlusion of the hepatic artery. Local occlusion of selected blood vessels in conjunction with intrahepatic chemotherapy administration, results in elevated intracellular hepatocyte drug concentrations and enhances localized cytotoxicity against hepatic tumor lesions.","Amilomer | Starch Microspheres",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054408","Nephropathy Associated with Rhabdomyolysis","C123201","Nephropathy associated with rhabdomyolysis.","Nephropathy Associated with Rhabdomyolysis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0431694","Oligomeganephronia","C123202","Congenital renal hypoplasia characterized by small kidneys; reduced nephron number; tubular and glomerular hypertrophy.","Oligomeganephronia | ",,,,,,,,,,,,,,,"4086459","Oligomeganephronic hypoplasia of kidney",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0238305","Sickle Cell Nephropathy","C123203","Nephropathy secondary to sickle cell disease, characterized by the presence of sickled erythrocytes in the renal medullary vessels, renal ischemia and microinfarctions, renal papillary necrosis, and renal tubular abnormalities.","Sickle Cell Nephropathy | ",,,,,,,,,,,,,,,"4029479","Sickle cell nephropathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055501","Acquired Neurogenic Bladder","C123204","Neurogenic bladder, the cause of which is not present at birth.","Acquired Neurogenic Bladder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055188","Congenital Neurogenic Bladder","C123205","Neurogenic bladder, the cause of which is present at birth.","Congenital Neurogenic Bladder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1997362","Non-Neurogenic Neurogenic Bladder","C123206","Bladder sphincter dysfunction in an individual with normal bladder innervation, which may lead to renal impairment.","Non-Neurogenic Neurogenic Bladder | Hinman Syndrome",,,,,,,,,,,,,,,"4179391","Nonneurogenic neurogenic bladder dysfunction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2751046","Bladder Exstrophy","C123207","A congenital anomaly that involves the protrusion of the exstrophied bladder through the abdominal wall. It is an anomaly that exists along the exstrophy-epispadias complex, which frequently includes urethra exstrophy, separation of the pubic symphysis, external rotation of the pelvic bones, and opening of the puborectal sling and sphincters.","Bladder Exstrophy | Ectopia Vesicae",,,,,,,,,,,,,,,"197667","Exstrophy of bladder sequence",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055377","Bladder Sphincter Dysfunction","C123208","Non-coordinated, reflexive contraction of the bladder and sphincter relaxation.","Bladder Sphincter Dysfunction | Detrusor Sphincter Dysynergia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0968461","E3 Ubiquitin-Protein Ligase TRIM63, Human","C122760","E3 ubiquitin-protein ligase TRIM63 (353 aa, ~40 kDa) is encoded by the human TRIM63 gene. This protein is involved in the degradation of myosin proteins.","E3 Ubiquitin-Protein Ligase TRIM63 | E3 Ubiquitin Protein Ligase TRIM63 | EC 2.3.2.27 | EC 6.3.2.-, Formerly | Iris Ring Finger Protein | MuRF-1 | Muscle Specific Ring Finger Protein 2 | Muscle-Specific RING Finger Protein 1 | Ring Finger Protein 28 | Striated Muscle RING Zinc Finger Protein | Tripartite Motif Containing 63 | Tripartite Motif-Containing 63 | Tripartite Motif-Containing Protein 63",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049730","CLEC7A wt Allele","C122762","Human CLEC7A wild-type allele is located in the vicinity of 12p13.2 and is approximately 13 kb in length. This allele, which encodes C-type lectin domain family 7 member A protein, is involved in phagocytosis and in the inflammatory response. Mutations in this gene are associated with autosomal recessive familial candidiasis 4.","CLEC7A wt Allele | BGR | C-type Lectin Domain Family 7, Member A wt Allele | CANDF4 | CD369 | CLECSF12 | DECTIN1 | Lectin, C-Type, Superfamily Member 12 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0053443","C-Type Lectin Domain Family 7 Member A, Human","C122763","C-type lectin domain family 7 member A (247 aa, ~28 kDa) is encoded by the human CLEC7A gene. This protein plays a role in the innate immune response against pathogenic bacteria and fungi.","C-Type Lectin Domain Family 7 Member A | Beta-Glucan Receptor | C-Type (Calcium Dependent, Carbohydrate-Recognition Domain) Lectin, Superfamily Member 12 | C-Type Lectin Superfamily Member 12 | DC-Associated C-Type Lectin 1 | Dectin 1 | Dectin-1 | Dendritic Cell-Associated C-Type Lectin 1 | Lectin-Like Receptor 1 | hDectin-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049597","CLEC10A wt Allele","C122765","Human CLEC10A wild-type allele is located in the vicinity of 17p13.1 and is approximately 6 kb in length. This allele, which encodes C-type lectin domain family 10 member A protein, plays a role in regulating innate and adaptive immune responses.","CLEC10A wt Allele | C-type Lectin Domain Family 10, Member A wt Allele | CD301 | CLECSF13 | CLECSF14 | HML | HML2 | Lectin, C-Type, Superfamily Member 14 Gene | MGL | Macrophage Galactose-Type C-Type Lectin Gene | Macrophage Lectin 2 (Macrophage-Derived) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1002616","Dolosigranulum pigrum","C122286","A species of gram-positive, catalase-negative, non-pigmented, nonmotile, coccus-shaped bacteria in the family Carnobacteriaceae. D. pigrum is positive for pyrrolidonylarylamidase, leucine aminopeptidase, and arginine dehydrogenase.","Dolosigranulum pigrum | DOLOSIGRANULUM PIGRUM",,,,,,,,,,,,,,,"4181033","Dolosigranulum pigrum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1212549","Dorea","C122287","A genus of Gram-positive, obligately anaerobic, non-spore-forming, rod-shaped bacterium in the phylum Firmicutes.","Dorea | DOREA",,,,,,,,,,,,,,,"4335245","Dorea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013102","Dracunculus medinensis","C122288","A species of parasitic nematode in the family Dracunculidae. The lifecycle of D. medinensis involves copepods and humans. Humans become infected by drinking water containing infected copepods.","Dracunculus medinensis | DRACUNCULUS MEDINENSIS | Guinea worm",,,,,,,,,,,,,,,"4242535","Dracunculus medinensis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0322177","Echinococcus granulosus","C122289","A species of cyclophyllid tapeworms in the family Taeniidae. The lifecycle for E. granulosus involves ungulates as the intermediate host and canids as the definitive host. Infestation causes cystic echinococcosis. Humans are not a natural host of the parasite, but in very rare cases can be infected by ingesting eggs from canid feces.","Echinococcus granulosus | ECHINOCOCCUS GRANULOSUS | Hydatid Worm | Hyper Tapeworm",,,,,,,,,,,,,,,"4085733","Echinococcus granulosus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0322178","Echinococcus multilocularis","C122290","A species of cyclophyllid tapeworms in the family Taeniidae. The lifecycle for E. multilocularis involves rodents as the intermediate host and canids as the definitive host. This species causes alveolar echinococcosis.","Echinococcus multilocularis | ECHINOCOCCUS MULTILOCULARIS",,,,,,,,,,,,,,,"4315045","Echinococcus multilocularis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4040043","Collagenous Gastritis","C122082","A rare type of gastritis characterized by gastric subepithelial collagen deposition and inflammatory infiltrates in the lamina propria.  The pathogenesis of this disorder is unclear although an association with autoimmune disorders has been reported.  It affects both children and adults.  Children present with iron deficiency anemia and have a nodular stomach on gastroscopy.  Adults present with chronic watery diarrhea and may have an associated collagenous colitis.","Collagenous Gastritis | ",,,,,,,,,,,,,,,"46273027","Collagenous gastritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054341","Non-Moribund Sacrifice","C123635","An indication that a subject was euthanized due to factors not associated with the general health of the subject.","Non-Moribund Sacrifice | NON-MORIBUND SACRIFICE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049629","Experimental Organism Decidual Reaction","C123636","A primarily uterine reaction with generally indistinct borders and two recognizable regions. These regions are an antimesometrial region containing closely packed mesenchymal cells and a mesometrial region containing mesometrial cells with long cytoplasmic processes and abundant glycogen. (INHAND)","Experimental Organism Decidual Reaction | DECIDUAL REACTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050319","Experimental Organism Decidualization","C123637","A focal lesion within the uterus consisting of markedly hypertrophied stromal cells with cytoplasmic glycogen and prominent nuclei.","Experimental Organism Decidualization | DECIDUALIZATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152444","Hydromyelia","C123638","Abnormal widening of the central spinal canal.","Hydromyelia | HYDROMYELIA",,,,,,,,,,,,,,,"378533","Hydromyelia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0266414","Imperforate Vagina","C123639","A congenital birth defect characterized by the absence of a normal vaginal opening.","Imperforate Vagina | IMPERFORATE VAGINA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086174","Childhood Testicular Mature Teratoma","C123837","A mature teratoma that arises from the testis and occurs in children.","Childhood Testicular Mature Teratoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086160","Childhood Germinomatous Germ Cell Tumor","C123838","A germinomatous germ cell tumor occurring in children.","Childhood Germinomatous Germ Cell Tumor | Germinomatous Germ Cell Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1436406","Calpain-1 Catalytic Subunit, Human","C123839","Calpain-1 catalytic subunit (714 aa, ~82 kDa) is encoded by the human CAPN1 gene. This protein is involved in proteolysis and the regulation of signal transduction and cytoskeletal modeling.","Calpain-1 Catalytic Subunit | CANP 1 | CAPN1 | Calcium-Activated Neutral Proteinase 1 | Calpain Mu-Type | Calpain-1 Large Subunit | Cell Proliferation-Inducing Gene 30 Protein | Cell Proliferation-Inducing Protein 30 | EC 3.4.22.52 | Micromolar-Calpain | Mu-Calpain | MuCANP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086170","Childhood Seminoma","C123840","A seminoma occurring in children.","Childhood Seminoma | Childhood Testicular Germinomatous Germ Cell Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086166","Childhood Nongerminomatous Germ Cell Tumor","C123841","A nongerminomatous germ cell tumor occurring in children.","Childhood Nongerminomatous Germ Cell Tumor | Childhood Non-Germinomatous Germ Cell Tumor | Nongerminomatous Germ Cell Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086168","Childhood Ovarian Nongerminomatous Germ Cell Tumor","C123842","A nongerminomatous germ cell tumor that arises in the ovary and occurs in children.","Childhood Ovarian Nongerminomatous Germ Cell Tumor | Childhood Ovarian Non-Germinomatous Germ Cell Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050550","Academic Research Council Late Stent Thrombosis","C123440","The formation of a clot within a stent greater than thirty days but less than one year after the stent is placed. (Cutlip DE, Windecker S, Mehran R, et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions. Circulation. 2007;115:2344-2351)","Academic Research Council Late Stent Thrombosis | STENT THROMBOSIS ARC LATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049712","Academic Research Council Subacute Stent Thrombosis","C123441","The formation of a clot within a stent greater than 24 hours but less than thirty days after the stent is placed. (Cutlip DE, Windecker S, Mehran R, et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions. Circulation. 2007;115:2344-2351)","Academic Research Council Subacute Stent Thrombosis | STENT THROMBOSIS ARC SUBACUTE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049653","Academic Research Council Very Late Stent Thrombosis","C123442","The formation of a clot within a stent more than one year after the stent is placed. (Cutlip DE, Windecker S, Mehran R, et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions. Circulation. 2007;115:2344-2351)","Academic Research Council Very Late Stent Thrombosis | STENT THROMBOSIS ARC VERY LATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055225","Clinical Change by Non-Invasive Imaging Procedure","C123443","Any clinical change to a subject as determined by a non-invasive imaging procedure.","Clinical Change by Non-Invasive Imaging Procedure | NINVIMGC | Non-Invasive Imaging Change",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0322179","Echinococcus vogeli","C122291","A species of cyclophyllid tapeworms in the family Taeniidae. Common in the neotropics, E. vogeli has a lifecycle that involves the paca as the intermediate host and the bush dog as the definitive host. This species causes polycystic echinococcosis in humans.","Echinococcus vogeli | ECHINOCOCCUS VOGELI",,,,,,,,,,,,,,,"4259276","Echinococcus vogeli",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013722","Ehrlichia","C122292","A genus of tick-borne bacteria in the family Anaplasmataceae. Ehrlichia are obligately intracellular pathogens and are the causative agent of ehrlichiosis.","Ehrlichia | Cowdria | EHRLICHIA | Kurlovia | Nicollea",,,,,,,,,,,,,,,"4099777","Ehrlichia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085350","Encephalitozoon","C122293","A genus of single-celled microsporidian fungi in the family Unikaryonidae. Members of the genus are obligate intracellular parasites and were once thought to be protozoans or protists. Encephalitozoonosis is rare in healthy people, but it is a common cause of severe infections in immunocompromised individuals.","Encephalitozoon | ENCEPHALITOZOON | Septata",,,,,,,,,,,,,,,"4328906","Encephalitozoon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320452","Endolimax nana","C122294","A species of amoebozoa in the phylum Archamoebae. Although E. nana is generally considered nonpathogenic it may be a cause of intermittent or chronic diarrhea.","Endolimax nana | ENDOLIMAX NANA",,,,,,,,,,,,,,,"4180863","Endolimax nana",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320420","Entamoeba coli","C122295","A species of commensal parasite in the class Archamoebae. E. coli is considered nonpathogenic.","Entamoeba coli | ENTAMOEBA COLI",,,,,,,,,,,,,,,"4195441","Entamoeba coli",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320423","Entamoeba hartmanni","C122296","A species of commensal parasite in the class Archamoebae. E. hartmanni is considered nonpathogenic. Cysts are transmitted through contaminated food or water.","Entamoeba hartmanni | ENTAMOEBA HARTMANNI",,,,,,,,,,,,,,,"4323293","Entamoeba hartmanni",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014323","Entamoeba histolytica","C122297","A species of anaerobic parasitic protozoa in the class Archamoebae. E. histolytica is the causative agent of invasive amoebiasis. Cysts are transmitted through contaminated food or water.","Entamoeba histolytica | ENTAMOEBA HISTOLYTICA",,,,,,,,,,,,,,,"4186305","Entamoeba histolytica",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320422","Entamoeba polecki","C122298","A species of commensal parasite in the class Archamoebae. E. polecki is considered nonpathogenic. This species is primarily a parasite of pigs and monkeys, and human infection is more prevalent in areas where the people have animal contact.","Entamoeba polecki | ENTAMOEBA POLECKI",,,,,,,,,,,,,,,"4282174","Entamoeba polecki",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1532308","Enterobacter cloacae Complex","C122299","A non-taxonomic grouping of at least six bacterial species that are morphologically similar to the Enterobacter cloacae species.","Enterobacter cloacae Complex | ENTEROBACTER CLOACAE COMPLEX",,,,,,,,,,,,,,,"4189174","Enterobacter cloacae complex",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0239940","Hemoglobin A1c Increased","C122507","A laboratory test result demonstrating an increase in the glycosylated hemoglobin in a blood sample.","Hemoglobin A1c Increased | HbA1c Increased | HgbA1c Increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054274","PD-L1 Status Unknown","C122810","Indicates that the immunohistochemical test result for PD-L1 is unknown or the test has not been performed.","PD-L1 Status Unknown | CD274 Status Unknown | Unknown: Could not be determined or unsure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
,,"C122811","A rare, genetically heterogeneous disorder caused by mutations in the SCN1A, GABRG2, GABRD, SCN9A, or STX1B genes. It is characterized by early childhood onset febrile seizures, generalized tonic-clonic seizures, absence seizures, myoclonic seizures, and atonic seizures","Generalized Epilepsy with Febrile Seizures Plus | GEFS+",,,,,,,,,,,,,,,"44783583","Generalized epilepsy with febrile seizures plus",,,,,,,,,,,,,,,,,,,,,,"--"
"C0014547","Partial Epilepsy","C122812","A seizure caused by a localized disorder.","Partial Epilepsy | ",,,,,,,,,,,,,,,"374915|4106574","Focal epilepsy|Focal onset epileptic seizure",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3264002","Juvenile Myoclonic Epilepsy, Intractable, without Status Epilepticus","C122813","Intractable juvenile myoclonic epilepsy which is not associated with an acute, prolonged epileptic crisis.","Juvenile Myoclonic Epilepsy, Intractable, without Status Epilepticus | Juvenile myoclonic epilepsy, intractable, without status epilepticus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2931919","Developmental and Epileptic Encephalopathy","C122814","A neurological disorder characterized by recurring seizures presenting within the first three months of life and progressive cerebral dysfunction.","Developmental and Epileptic Encephalopathy | EIEE | Early Infantile Epileptic Encephalopathy",,,,,,,,,,,,,,,"37168142","Developmental and epileptic encephalopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1412765","BCL5 gene","C122817","Human BCL5 gene is located in the vicinity of 17q22 and is approximately 2 kb in length. This phenotype-only gene has not been linked to a known protein product. This locus may play a role in hematopoiesis. Chromosomal rearrangements involving this gene locus may be associated with both aberrant expression of the MYC gene and leukemia.","BCL5 Gene | B-Cell CLL/Lymphoma 5 Gene | B-Cell Leukemia/Lymphoma 5 Gene | BCL3, Formerly Gene | BCL5 | Leukemia/Lymphoma, Chronic B-Cell, 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL497253","Closure Patent Ductus Arteriosus","C122818","The closing of the ductus arteriosus; this can occur naturally or as a result of a therapeutic procedure.","Closure Patent Ductus Arteriosus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL496812","NAB2/STAT6 Fusion Gene","C122819","A fusion gene that results from a chromosomal rearrangement involving 12q13.3 and 12q13 which fuses the first 6 exons of the NAB2 gene in frame with exon 3, 17, or 18 of the STAT6 gene. This fusion is associated with solitary fibrous tumors.","NAB2/STAT6 Fusion Gene | NAB2-STAT6 Fusion Gene | NAB2::STAT6 Fusion Gene | STAT6/NAB2 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086175","Childhood Testicular Non-Seminomatous Germ Cell Tumor","C123843","A non-seminomatous germ cell tumor that arises in the testis and occurs in children.","Childhood Testicular Non-Seminomatous Germ Cell Tumor | Childhood Testicular Non-Germinomatous Germ Cell Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086155","Childhood Choriocarcinoma","C123844","A choriocarcinoma occurring in children.","Childhood Choriocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086156","Childhood Embryonal Carcinoma","C123847","An embryonal carcinoma occurring in children.","Childhood Embryonal Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086164","Childhood Mixed Germ Cell Tumor","C123848","A mixed germ cell tumor occurring in children.","Childhood Mixed Germ Cell Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086167","Childhood Ovarian Mixed Germ Cell Tumor","C123849","A mixed germ cell tumor that arises from the ovary and occurs in children.","Childhood Ovarian Mixed Germ Cell Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049601","HSPA4L wt Allele","C123145","Human HSPA4L wild-type allele is located in the vicinity of 4q28 and is approximately 59 kb in length. This allele, which encodes heat shock 70 kDa protein 4L, plays a role in protein chaperone activity.","HSPA4L wt Allele | APG-1 | APG1 | HSPH3 | Heat Shock 70kDa Protein 4-Like wt Allele | OSP94 | Osp94",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1452345","Heat Shock 70 kDa Protein 4L, Human","C123146","Heat shock 70 kDa protein 4L (839 aa, ~95 kDa) is encoded by the human HSPA4L gene. This protein is involved in the inhibition of protein aggregation.","Heat Shock 70 kDa Protein 4L | HSPA4L | Heat Shock 70-Related Protein APG-1 | Osmotic Stress Protein 94",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053779","CDISC Occurrence Data Structure","C123454","The CDISC ADaM data structure for occurrence analysis. Occurrence analysis is the counting of subjects with a record or term, and often includes a structured hierarchy of dictionary coding categories.","CDISC Occurrence Data Structure | OCCDS | OCCURRENCE DATA STRUCTURE | Occurrence Data Structure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055592","AVLT-REY - List A Word 1","C123683","The Rey Auditory Verbal Learning TEST (AVLT-REY) List A, Word 1.","AVLT-REY - List A Word 1 | AVL02-List A Word 1 | AVL0201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055591","AVLT-REY - List A Word 2","C123684","The Rey Auditory Verbal Learning TEST (AVLT-REY) List A, Word 2.","AVLT-REY - List A Word 2 | AVL02-List A Word 2 | AVL0202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055590","AVLT-REY - List A Word 3","C123685","The Rey Auditory Verbal Learning TEST (AVLT-REY) List A, Word 3.","AVLT-REY - List A Word 3 | AVL02-List A Word 3 | AVL0203",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055589","AVLT-REY - List A Word 4","C123686","The Rey Auditory Verbal Learning TEST (AVLT-REY) List A, Word 4.","AVLT-REY - List A Word 4 | AVL02-List A Word 4 | AVL0204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055588","AVLT-REY - List A Word 5","C123687","The Rey Auditory Verbal Learning TEST (AVLT-REY) List A, Word 5.","AVLT-REY - List A Word 5 | AVL02-List A Word 5 | AVL0205",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055587","AVLT-REY - List A Word 6","C123688","The Rey Auditory Verbal Learning TEST (AVLT-REY) List A, Word 6.","AVLT-REY - List A Word 6 | AVL02-List A Word 6 | AVL0206",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055586","AVLT-REY - List A Word 7","C123689","The Rey Auditory Verbal Learning TEST (AVLT-REY) List A, Word 7.","AVLT-REY - List A Word 7 | AVL02-List A Word 7 | AVL0207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053789","AVLT-REY - List A Word 8","C123690","The Rey Auditory Verbal Learning TEST (AVLT-REY) List A, Word 8.","AVLT-REY - List A Word 8 | AVL02-List A Word 8 | AVL0208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055585","AVLT-REY - List A Word 9","C123691","The Rey Auditory Verbal Learning TEST (AVLT-REY) List A, Word 9.","AVLT-REY - List A Word 9 | AVL02-List A Word 9 | AVL0209",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055598","AVLT-REY - List A Word 10","C123692","The Rey Auditory Verbal Learning TEST (AVLT-REY) List A, Word 10.","AVLT-REY - List A Word 10 | AVL02-List A Word 10 | AVL0210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055597","AVLT-REY - List A Word 11","C123693","The Rey Auditory Verbal Learning TEST (AVLT-REY) List A, Word 11.","AVLT-REY - List A Word 11 | AVL02-List A Word 11 | AVL0211",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055596","AVLT-REY - List A Word 12","C123694","The Rey Auditory Verbal Learning TEST (AVLT-REY) List A, Word 12.","AVLT-REY - List A Word 12 | AVL02-List A Word 12 | AVL0212",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055595","AVLT-REY - List A Word 13","C123695","The Rey Auditory Verbal Learning TEST (AVLT-REY) List A, Word 13.","AVLT-REY - List A Word 13 | AVL02-List A Word 13 | AVL0213",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055593","AVLT-REY - List A Word 15","C123697","The Rey Auditory Verbal Learning TEST (AVLT-REY) List A, Word 15.","AVLT-REY - List A Word 15 | AVL02-List A Word 15 | AVL0215",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055599","AVLT-REY - List A Total","C123698","The Rey Auditory Verbal Learning TEST (AVLT-REY) The number of List A words recalled from a trial.","AVLT-REY - List A Total | AVL02-List A Total | AVL0216",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055600","AVLT-REY - List A Intrusions","C123699","The Rey Auditory Verbal Learning TEST (AVLT-REY) The number of List A intrusions while recalling from a trial.","AVLT-REY - List A Intrusions | AVL02-List A Intrusions | AVL0217",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3281117","Ketonuria","C122512","The presence of ketone bodies in the urine.","Ketonuria | ",,,,,,,,,,,,,,,"4171926","Ketonuria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0795692","Hyperlactemia","C122513","Abnormally high level of lactate in the blood.","Hyperlactemia | Elevated Lactate | Elevated Lactate Level",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4042682","Gallium Ga 68-HA-DOTA-TATE","C122036","A radioconjugate consisting of consisting of the high affinity somatostatin analogue iodo-tyrosine-3-octreotate (HA-TATE), labeled with the positron emission tomography (PET) tracer gallium Ga 68 via the macrocyclic chelating agent 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra-acetic acid (DOTA), which may be used as a human somatostatin receptor (SSTR) imaging agent in conjunction with PET to image neuroendocrine tumors (NETs). Gallium Ga 68-HA-DOTATATE binds to SSTRs, with high affinity for SSTR2, present on the cell membranes of many types of NETs. This allows for visualization of SSTR-positive cells upon imaging. SSTRs have been shown to be present in large numbers on NETs and their metastases, while most other normal tissues express low levels of SSTRs. HA-TATE is an octreotide derivative in which phenylalanine at position 3 is substituted with iodo-tyrosine and threoninol at position 8 is replaced by threonine. The iodo addition in Gallium Ga 68-HA-DOTA-TATE may allow for higher affinity for the SSTRs when compared to gallium Ga 68-DOTA-TATE.","Gallium Ga 68-HA-DOTA-TATE | 68Ga-DOTA-3-iodo-Tyr3-octreotate | 68Ga-DOTA-iodoTyr3-octreotate | 68Ga-HA-DOTATATE | [68Ga]DOTA-3-iodo-Tyr3-octreotate | [68Ga]high-affinity DOTATATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054447","NAB2/STAT6 Fusion Protein","C122820","A fusion protein that is encoded by the NAB2/STAT6 fusion gene. This protein contains the N-terminal early growth response (EGR)-binding domain of NGFI-A-binding protein 2 fused to part of signal transducer and activator of transcription 6 protein that includes its DNA-binding transcriptional activation domain.","NAB2/STAT6 Fusion Protein | NAB2-STAT6 Fusion Protein | NAB2::STAT6 Fusion Protein | NGFI-A-Binding Protein 2/Signal Transducer and Activator of Transcription 6 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049722","SOD3 wt Allele","C123148","Human SOD3 wild-type allele is located in the vicinity of 4p15.2 and is approximately 11 kb in length. This allele, which encodes extracellular superoxide dismutase [Cu-Zn] protein, is involved in the detoxification of superoxides.","SOD3 wt Allele | EC-SOD | Superoxide Dismutase 3, Extracellular wt Allele | Superoxide Dismutase, Extracellular Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1099812","Extracellular Superoxide Dismutase [Cu-Zn], Human","C123150","Extracellular superoxide dismutase [Cu-Zn] (240 aa, ~26 kDa) is encoded by the human SOD3 gene. This protein plays a role in the conversion of extracellular superoxides into hydrogen peroxide and oxygen.","Extracellular Superoxide Dismutase [Cu-Zn] | EC 1.15.1.1 | EC-SOD | SOD3 | Superoxide Dismutase 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055463","Antenatal Hydronephrosis","C123155","Hydronephrosis that occurs in a fetus.","Antenatal Hydronephrosis | Prenatal Hydronephrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0854260","Congenital Urinary Tract Obstruction","C123157","An impediment to the flow of urine along the urinary tract, which is present at birth.","Congenital Urinary Tract Obstruction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020501","Primary Hyperoxaluria","C123158","A hereditary disorder characterized by excessive oxalate production, leading to hyperoxaluria.","Primary Hyperoxaluria | ",,,,,,,,,,,,,,,"4074393","Primary hyperoxaluria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041960","Ureterocele","C123159","A cystic and dysplastic dilation of the distal ureter within the bladder that may extend into the bladder neck and urethra.","Ureterocele | ",,,,,,,,,,,,,,,"192440","Ureterocele",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055242","Childhood Spindle Cell Rhabdomyosarcoma","C123397","A spindle cell rhabdomyosarcoma occurring in children.","Childhood Spindle Cell Rhabdomyosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055243","Childhood Periosteal Osteosarcoma","C123398","A periosteal osteosarcoma occurring in childhood.","Childhood Periosteal Osteosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498210","anti-PD-1 monoclonal antibody SHR-1210","C123816","A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody SHR-1210 binds to and blocks the binding of PD-1, expressed on activated T-lymphocytes, B-cells and natural killer (NK) cells, to its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen presenting cells (APCs). This prevents the activation of PD-1 and its downstream signaling pathways. This restores immune function through the activation of cytotoxic T-lymphocytes (CTLs) and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","Camrelizumab | AiRuiKa | AiRuiKa (TM) | CAMRELIZUMAB | Carrelizumab | Carrizumab | Erica | HR 301210 | HR-301210 | HR301210 | SHR 1210 | SHR-1210 | SHR1210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498211","Donor-derived WT1/PRAME/NY-ESO-1/Survivin-specific T-lymphocytes","C123817","Allogeneic T-lymphocytes specifically reactive to the tumor-associated antigens (TAAs) human Wilms tumor protein-1 (WT1), Preferentially Expressed Antigen in Melanoma (PRAME), the cancer-testis antigen NY-ESO-1, and survivin, with potential antineoplastic activity. Donor derived T-cells are mixed, ex vivo, with protein fragments derived from the TAAs WT1, PRAME, NY-ESO-1, and survivin. Upon intravenous administration, the donor-derived WT1/PRAME/NY-ESO-1/Survivin-specific T-lymphocytes recognize and kill cancer cells expressing these TAAs. WT1, NY-ESO-1, PRAME, and survivin, are expressed on certain tumor cell types and play key role in tumor cell proliferation and survival.","Donor-derived WT1/PRAME/NY-ESO-1/Survivin-specific T-lymphocytes | Donor-derived Multi-Tumor Associated Antigen (multiTAA)-Specific T Cells | Multi-TAA Specific T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498212","Cromolyn Sodium Inhalant PA101","C123818","A solution containing a high concentration of cromolyn sodium, with potential mast cell stabilizing, anti-tussive and anti-inflammatory activities. Upon inhalation of PA101 via a nebulizer, cromolyn blocks calcium ion influx into mast cells, thereby preventing the degranulation of mast cells in the lungs. This blocks the release of pro-inflammatory mediators from mast cells, such as histamine and slow-reacting substance of anaphylaxis (SRS-A), and prevents both bronchoconstriction and an inflammatory response. In indolent systemic mastocytosis (ISM), PA101 may be able to reduce the symptoms associated with this disease","Cromolyn Sodium Inhalant PA101 | PA 101 | PA101 | Sodium Cromoglicate Inhalant PA10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498213","Therapeutic Dendritic Cells/Cytokine-induced Killer Cells","C123819","A preparation of autologous dendritic cells (DC) mixed with cytokine-induced killer (CIK) cells (DC-CIK), with potential immunopotentiating and antineoplastic activities. DCs were obtained ex vivo by incubation of peripheral blood lymphocytes (PBLs) with granulocyte-macrophage colony-stimulating factor stimulating factor (GM-CSF or CSF2), tumor necrosis factor (TNF), and interleukin (IL)-24 and were sensitized with tumor-associated antigens (TAAs). Cytokine-induced killer (CIK) cells are immune effector cells with both T-cell and natural killer (NK) cell like phenotype. CIKs are non-major histocompatibility complex (MHC)-restricted, NK-like T-lymphocytes, which express both CD3, a T-cell surface marker, and CD56, a natural killer cell surface marker, and have been generated ex vivo by incubation of peripheral blood lymphocytes (PBLs) with anti-CD3 monoclonal antibody, IL-2, IL-1 alpha, and interferon gamma (IFN-gamma) and then expanded. Upon co-culture of DCs and CIKs, and administration of DC-CIK cells into the patient, the DCs are able to stimulate the immune response to exert a specific anti-tumor immune response, while the CIK cells exert direct oncolytic activity.","Therapeutic Dendritic Cells/Cytokine-induced Killer Cells | DC-CIK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3874987","Intravesical Ureterocele","C123237","A ureterocele that is located entirely within the bladder, and which may be associated with a single system, with the upper pole ureter of a completely duplicated system, or rarely associated with a lower pole ureter. (Adapted from Glassberg KI, Braren V, Duckett JW, Jacobs EC, King LR, Lebowitz RL et al. Suggested terminology for duplex systems, ectopic ureters and ureteroceles. J Urol 1984; 132(6):1153-1154.)","Intravesical Ureterocele | Orthotopic Ureterocele",,,,,,,,,,,,,,,"45757597","Orthotopic ureterocele",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4049883","Obstructive Ureterocele","C123238","A ureterocele with a small, obstructive orifice.","Obstructive Ureterocele | Stenotic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0457838","Sphincteric Ureterocele","C123239","A ureterocele in which the orifice is distal to the external urinary sphincter.","Sphincteric Ureterocele | Transsphincteric",,,,,,,,,,,,,,,"4149665","Transsphincteric approach - anal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3872634","Acquired Urinary Tract Obstruction","C123241","A urinary tract obstruction, the cause of which is not present at birth.","Acquired Urinary Tract Obstruction | ",,,,,,,,,,,,,,,"45769789","Acquired obstruction of urinary tract",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1833683","Calcium Oxalate Urolithiasis","C123242","Urolithiasis in which the composition of the stones is predominantly calcium oxalate.","Calcium Oxalate Urolithiasis | ",,,,,,,,,,,,,,,"40480656","Calcium oxalate urolithiasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3671880","Calcium Phosphate Urolithiasis","C123243","Urolithiasis in which the composition of the stones is predominantly calcium phosphate.","Calcium Phosphate Urolithiasis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3671878","Cystine Urolithiasis","C123244","Urolithiasis in which the composition of the stones is predominantly cystine.","Cystine Urolithiasis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0403719","Uric Acid Urolithiasis","C123245","Urolithiasis in which the composition of the stones is predominantly urate.","Uric Acid Urolithiasis | ",,,,,,,,,,,,,,,"80070","Uric acid urolithiasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152032","Urinary Hesitancy","C123246","Difficulty in initiating urination.","Urinary Hesitancy | ",,,,,,,,,,,,,,,"201688","Delay when starting to pass urine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0749948","Urinary Straining","C123247","The need to increase intra-abdominal pressure in order to initiate and maintain voiding.","Urinary Straining | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4048297","Idiopathic Retroperitoneal Fibrosis","C123249","A condition characterized by abnormal proliferation of fibrous tissue in the compartment posterior to the peritoneum, for which no underlying cause has been identified.","Idiopathic Retroperitoneal Fibrosis | Ormond's Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054716","Infundibular Stenosis","C123250","Narrowing of the infundibulum to the calyx, which produces an impediment to urine flow.","Infundibular Stenosis | Infundibular Stenosis of the Calyces of the Kidney",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268436","Pseudohypoaldosteronism Type 1","C123251","A hereditary, heterogeneous disorder of electrolyte metabolism that is characterized by renal resistance to aldosterone action, resulting in salt wasting, hypotension, hyperkalemia, and metabolic acidosis.","Pseudohypoaldosteronism Type 1 | PHA1B | Pseudohypoaldosteronism Type I Autosomal Recessive",,,,,,,,,,,,,,,"4194851","Pseudohypoaldosteronism, type 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1449844","Pseudohypoaldosteronism Type 2","C123252","A hereditary renal tubular defect characterized by hypertension and hyperkalemic metabolic acidosis in the presence of suppressed plasma renin levels and relatively low aldosterone levels.","Pseudohypoaldosteronism Type 2 | Gordon Syndrome",,,,,,,,,,,,,,,"4049157","Pseudohypoaldosteronism, type 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054780","Hepatitis C mRNA Measurement","C123456","The determination of the amount of Hepatitis C mRNA present in a sample.","Hepatitis C mRNA Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054779","Hepatitis E mRNA Measurement","C123457","The determination of the amount of Hepatitis E mRNA present in a sample.","Hepatitis E mRNA Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1455477","monoacetyldiglyceride EC-18","C123775","A synthetic version of a monoacetyldiacylglyceride naturally occurring in various seed oils, bovine udder and milk fat, antlers of sika deer, with potential antineoplastic activity. Although the exact mechanism of action through which EC-18 exerts its pharmacological effect has yet to be fully identified, upon administration, mosedipimod stimulates calcium influx into T-lymphocytes and increases the production of various cytokines, including interleukin (IL) -2, IL-4, IL-12, interferon-gamma (IFN-g), and granulocyte-macrophage colony-stimulating factor (GM-CSF). This stimulates the proliferation of hematopoietic stem cells, bone marrow stromal cells and immune cells, including T- and B-lymphocytes, dendritic cells (DCs) and macrophages. Therefore, EC18 may stimulate the immune system to target cancer cells. In addition, EC-18 enhances the cytolytic activity of natural killer (NK) cells and suppresses the expression of the transmembrane protein tumor cell toll-like receptor 4 (TLR-4) on cancer cells. As activation of TLR-4 enhances immunosuppression and stimulates cancer cell growth, blocking TLR-4 expression suppresses tumor cell proliferation.","Mosedipimod | 1-Palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol | 9,12-Octadecadienoic acid (9Z,12Z)-, 1-((Acetyloxy)methyl)-2-((1-oxohexadecyl)oxy)ethyl Ester | EC-18 | MOSEDIPIMOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4020705","Glomerulocystic Disease","C123015","A condition characterized by dilatation of the Bowman space and affecting more than 5% of the glomeruli.","Glomerulocystic Disease | Glomerulocystic Kidney Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0238212","Perinephric Abscess","C123016","An abscess that is located outside the renal capsule, but which is within Gerota's space.","Perinephric Abscess | ",,,,,,,,,,,,,,,"4216208","Perirenal abscess",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0151465","Renal Abscess","C123017","An abscess that is located within the renal parenchyma.","Renal Abscess | Kidney Abscess",,,,,,,,,,,,,,,"4142194","Renal abscess",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0431693","Renal Cysts and Diabetes Syndrome","C123018","Monogenic diabetes caused by inactivating mutation(s) in the gene HNF1B, encoding hepatocyte nuclear factor 1-beta. In addition to diabetes, this condition may be associated with renal cysts and urogenital anomalies. Homozygous HNF1B mutations result in permanent neonatal diabetes.","Renal Cysts and Diabetes Syndrome | HNF1B-Related Autosomal Dominant Tubulointerstitial Kidney Disease | Hepatocyte Nuclear Factor 1-Beta-Associated Monogenic Diabetes | MODY5 | Maturity Onset Diabetes of the Young, Type 5 | RCAD | RCAD Syndrome",,,,,,,,,,,,,,,"43531014","Maturity-onset diabetes of the young, type 5",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041328","Renal Tuberculosis","C123020","Infection of the kidney due to mycobacteria.","Renal Tuberculosis | ",,,,,,,,,,,,,,,"193955","Tuberculosis of kidney",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0410226","Congenital Myotonic Dystrophy","C123308","Myotonic dystrophy that is present at birth.","Congenital Myotonic Dystrophy | ",,,,,,,,,,,,,,,"75804","Congenital myotonic dystrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054472","Moraxella catarrhalis, Penicillinase Positive","C123520","Any bacterial species identified as Moraxella catarrhalis that produces the enzyme penicillinase.","Moraxella catarrhalis, Penicillinase Positive | MORAXELLA CATARRHALIS, PENICILLINASE POSITIVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054470","Morganella morganii, Lysine-Positive","C123521","Any bacterial species identified as Morganella morganii that can metabolize lysine.","Morganella morganii, Lysine-Positive | MORGANELLA MORGANII, LYSINE-POSITIVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498214","GD2-CAR-expressing Autologous T-lymphocytes","C123820","Genetically modified, autologous T-lymphocytes transduced with a retroviral vector encoding a 14g2a.zeta chimeric antigen receptor (CAR) directed against the disialoganglioside GD2, with potential immunomodulating and antineoplastic activities. Upon intravenous administration, the activated T-lymphocytes target the GD2 antigen on tumor cells and selectively kill those cells. The tumor-associated antigen GD2 is overexpressed on the surface of almost all tumors of neuroectodermal origin.","GD2-CAR-expressing Autologous T-lymphocytes | GD2-CAR-expressing autologous T-lymphocytes | tvs-CTL Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498215","Gallium Ga 68-NEB","C123821","A radiotracer composed of a truncated form of the azo dye Evans blue (EB) conjugated, via a 1,4,7-triazacyclononane-N,N',N'-triacetic acid (NOTA) linker (NEB), to the radioisotope gallium Ga 68, with potential blood pool imaging activity for use in positron emission tomography (PET). Upon administration of gallium Ga 68-NEB, the NEB moiety, which has high affinity for serum albumin, targets and forms a complex with albumin. Upon PET, the lymph nodes (LN) and lymphatic vessels as well as other desired tissues can be visualized.","Gallium Ga 68-NEB | 68Ga-NEB | 68Ga-NOTA Conjugated Truncated Form of Evans Blue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054374","Nephrotic Syndrome - NEIL1 Associated","C123094","Nephrotic syndrome attributed to mutation(s) in the NEIL1 gene.","Nephrotic Syndrome - NEIL1 Associated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054373","Nephrotic Syndrome - NPHS2 Associated","C123095","Nephrotic syndrome attributed to mutation(s) in the NPHS2 gene.","Nephrotic Syndrome - NPHS2 Associated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054369","Nephrotic Syndrome - Parvovirus B19 Associated","C123096","Nephrotic syndrome associated with a parvovirus B19 infection.","Nephrotic Syndrome - Parvovirus B19 Associated | Parvovirus B19 Associated Nephrotic Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054372","Nephrotic Syndrome - PDSS2 Associated","C123097","Nephrotic syndrome attributed to mutation(s) in the PDSS2 gene.","Nephrotic Syndrome - PDSS2 Associated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054371","Nephrotic Syndrome - PLCE1 Associated","C123098","Nephrotic syndrome attributed to mutation(s) in the PLCE1 gene.","Nephrotic Syndrome - PLCE1 Associated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054370","Nephrotic Syndrome - PTPRO Associated","C123099","Nephrotic syndrome attributed to mutation(s) in the PTPRO gene.","Nephrotic Syndrome - PTPRO Associated | Nephrotic Syndrome - GLEPP1 Associated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054367","Nephrotic Syndrome - SCARB2 Associated","C123100","Nephrotic syndrome attributed to mutation(s) in the SCARB2 gene.","Nephrotic Syndrome - SCARB2 Associated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054366","Nephrotic Syndrome - SMARCAL1 Associated","C123102","Nephrotic syndrome attributed to mutation(s) in the SMARCAL1 gene.","Nephrotic Syndrome - SMARCAL1 Associated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054364","Nephrotic Syndrome - Syphilis Associated","C123103","Nephrotic syndrome associated with a syphilis infection.","Nephrotic Syndrome - Syphilis Associated | Syphilis Associated Nephrotic Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0314753","Gram-Negative Pleomorphic Bacillus","C123469","Any rod-shaped bacteria with variable length or shape that contains low levels of peptidoglycan in its cell wall and stains pink with the Gram staining technique.","Gram-Negative Pleomorphic Bacillus | GRAM-NEGATIVE PLEOMORPHIC BACILLUS",,,,,,,,,,,,,,,"4250624","Gram-negative pleomorphic bacillus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0314751","Gram-Positive Diplococcus","C123470","Any paired spherical bacteria that has a peptidoglycan rich cell wall that stains dark purple with the Gram staining technique.","Gram-Positive Diplococcus | GRAM-POSITIVE DIPLOCOCCUS",,,,,,,,,,,,,,,"4015777","Gram-positive diplococcus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054888","Gram-Positive Microaerophilic Bacillus","C123471","Any rod shaped bacteria that requires oxygen, but is poisoned by high concentrations, and has a peptidoglycan rich cell wall that stains dark purple with the Gram staining technique.","Gram-Positive Microaerophilic Bacillus | GRAM-POSITIVE MICROAEROPHILIC BACILLUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054887","Gram-Positive Microaerophilic Coccus","C123472","Any spherical shaped bacteria that requires oxygen, but is poisoned by high concentrations, and has a peptidoglycan rich cell wall that stains dark purple with the Gram staining technique.","Gram-Positive Microaerophilic Coccus | GRAM-POSITIVE MICROAEROPHILIC COCCUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1843273","Tubulointerstitial Nephritis and Uveitis","C123021","An autoimmune disorder comprising tubulointerstitial nephritis and uveitis.","Tubulointerstitial Nephritis and Uveitis | TINU",,,,,,,,,,,,,,,"4303512","Tubulointerstitial nephritis with uveitis syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0403433","IgM - Associated Nephropathy","C123022","A condition characterized by deposition of IgM antibody in the glomerulus.","IgM - Associated Nephropathy | ",,,,,,,,,,,,,,,"4128063","IgM nephropathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054543","Membranous Lupus Nephritis","C123023","Membranous nephritis associated with systemic lupus erythematosus.","Membranous Lupus Nephritis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004698","Aristolochic Acid Nephropathy","C123025","Chronic tubulointerstitial disease resulting from aristolochic acid.","Aristolochic Acid Nephropathy | Balkan Endemic Nephropathy | Balkan Nephropathy | Chinese Herb Endemic Nephropathy | Endemic Nephropathy",,,,,,,,,,,,,,,"36713444","Aristolochic acid nephropathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053762","Congenital Renal Hypoplasia","C123026","The underdevelopment of otherwise normal renal parenchyma, characterized by decreased nephron size and possibly a decreased number of nephrons at birth.","Congenital Renal Hypoplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1262280","Hantavirus Nephropathy","C123027","Tubulointerstitial hemorrhage resulting from hantavirus infection.","Hantavirus Nephropathy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268774","Heavy-Metal-Induced Nephropathy","C123028","Damage to the kidney and renal tubules resulting from heavy metal exposure.","Heavy-Metal-Induced Nephropathy | ",,,,,,,,,,,,,,,"4056595","Nephropathy induced by heavy metals",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054651","Leptospirosis Nephropathy","C123029","Interstitial nephritis due to Leptospira, which may be associated with non-oliguric acute kidney injury.","Leptospirosis Nephropathy | Leptospiral Nephropathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2919886","Magnesium Ammonium Phosphate Urolithiasis","C123030","Urolithiasis in which the composition of the stone(s) is predominantly magnesium ammonium phosphate.","Magnesium Ammonium Phosphate Urolithiasis | Struvite Urolithiasis",,,,,,,,,,,,,,,"40480625","Magnesium ammonium phosphate urolithiasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034216","Pyonephrosis","C123032","Pus within the collecting system of the kidney.","Pyonephrosis | ",,,,,,,,,,,,,,,"4174994","Pyonephrosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054127","Radiation Nephropathy","C123033","Tissue damage to the glomerulus and renal tubules resulting from irradiation, which is characterized by vascular endothelial damage, mesangial damage, platelet aggregation in the capillary loops, thickening of the glomerular arteriolar intimal layer, and atrophic tubules.","Radiation Nephropathy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054067","Renal Dysplasia Due to Fetal Exposure to ACE Inhibitor or ARB","C123034","Tubular dysgenesis resulting from maternal exposure to a class of drugs known as angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB).","Renal Dysplasia Due to Fetal Exposure to ACE Inhibitor or ARB | Tubular Dysgenesis related to Fetal Exposure to ACE Inhibitor or ARB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054469","Morganella morganii, Ornithine-Negative","C123522","Any bacterial species identified as Morganella morganii that is unable to metabolize ornithine.","Morganella morganii, Ornithine-Negative | MORGANELLA MORGANII, ORNITHINE-NEGATIVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027321","Naegleria fowleri","C123523","A species of parasitic amoeba in the family Vahlkampfiidae. N. fowleri is the only species of Naegleria that infects humans. Infection occurs through the nose and causes a very rare, but severe, infection of the brain called primary amoebic meningoencephalitis.","Naegleria fowleri | NAEGLERIA FOWLERI",,,,,,,,,,,,,,,"4049775","Naegleria fowleri",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002826","Necator americanus","C123524","A species of parasitic nematodes in the family Ancylostomatidae. N. americanus can be passed person-to-person through contact with infested feces.","Necator americanus | NECATOR AMERICANUS",,,,,,,,,,,,,,,"4184647","Necator americanus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1532160","Neisseria gonorrhoeae, Beta-lactamase Negative","C123525","Any bacterial species identified as Neisseria gonorrhoeae that does not produce the enzyme beta-lactamase.","Neisseria gonorrhoeae, Beta-lactamase Negative | NEISSERIA GONORRHOEAE, BETA-LACTAMASE NEGATIVE",,,,,,,,,,,,,,,"4214667","Neisseria gonorrhoeae, beta lactamase negative",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054413","Neisseria gonorrhoeae, Penicillinase Negative","C123527","Any bacterial species identified as Neisseria gonorrhoeae that does not produce the enzyme penicillinase.","Neisseria gonorrhoeae, Penicillinase Negative | NEISSERIA GONORRHOEAE, PENICILLINASE NEGATIVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054412","Neisseria gonorrhoeae, Penicillinase Positive","C123528","Any bacterial species identified as Neisseria gonorrhoeae that produces the enzyme penicillinase.","Neisseria gonorrhoeae, Penicillinase Positive | NEISSERIA GONORRHOEAE, PENICILLINASE POSITIVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0320123","Nigrospora","C123529","A genus of mold fungi in the family Trichosphaeriaceae. Species within this genus are typically found growing on live or dead grasses in tropical, subtropical, and temperate regions, are rarely found growing indoors, and rarely pose a health hazard to humans.","Nigrospora | NIGROSPORA",,,,,,,,,,,,,,,"4185458","Nigrospora",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085349","Nosema","C123530","A genus of unicellular obligate parasitic fungi in the family Nosematidae. Most species within this genus are limited to a specific insect or other arthropod host. Nosema apis is a cause of colony collapse in honeybees.","Nosema | NOSEMA",,,,,,,,,,,,,,,"4103007","Genus Nosema",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1621288","Oidiodendron","C123531","A genus of soil fungi in the family Myxotrichaceae with dark, erect conidiophores that terminate in an irregular system of tree-like branches . Species within the genus are commonly isolated from wood, wood pulp, and soil. They are not known to pose a health hazard to humans.","Oidiodendron | OIDIODENDRON",,,,,,,,,,,,,,,"42537423","Oidiodendron",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030182","Paecilomyces","C123532","A genus of fungi in the subphylum Pezizomycotina with species grouped within orders Sordariales, Hypocreales, and Eurotiales. Some species within these genera cause opportunistic infections and allergic disorders in humans.","Paecilomyces | PAECILOMYCES",,,,,,,,,,,,,,,"4093927","Paecilomyces",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1042004","Pandoraea apista","C123534","A species of aerobic, Gram negative, rod shaped bacterium in the family Burkholderiaceae. This species is positive for catalase, growth on Drigalsky agar, growth in 0.5 and 1.5% NaCl, assimilation of d-gluconate, l-malate and phenylacetate, acid and alkaline phosphatase, and leucine arylamidase activity. P. apista is found in the soil and also in the sputum of cystic fibrosis patients.","Pandoraea apista | PANDORAEA APISTA",,,,,,,,,,,,,,,"4216110","Pandoraea apista",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3855809","Magnesium L-threonate","C123781","A nutritional supplement containing the L-threonate form of magnesium (Mg) that can be used to normalize Mg levels in the body. Upon administration, Mg is utilized by the body for many biochemical functions and reactions including: bone and muscle function, protein and fatty acid formation, activation of B vitamins, blood clotting, insulin secretion, and ATP formation. Mg also serves as a catalyst for many enzymes throughout the body. In addition, magnesium improves the functioning of the immune system by enhancing the expression of natural killer activating receptor NKG2D in cytotoxic T-lymphocytes and natural killer (NK) cells. This increases their anti-viral and anti-tumor cytotoxic effects.","Magnesium L-threonate | MAGNESIUM L-THREONATE | Magnesium, Bis((2R,3S)-2,3,4-trihydroxybutanoato-kappaO,kappaO')-, (T-4)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054362","Nephrotic Syndrome - Toxoplasmosis Associated","C123104","Nephrotic syndrome associated with a toxoplasmosis infection.","Nephrotic Syndrome - Toxoplasmosis Associated | Toxoplasmosis Associated Nephrotic Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054363","Nephrotic Syndrome - TRPC6 Associated","C123105","Nephrotic syndrome attributed to mutation(s) in the TRPC6 gene.","Nephrotic Syndrome - TRPC6 Associated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054361","Nephrotic Syndrome - WT1 Associated","C123106","Nephrotic syndrome attributed to mutation(s) in the WT1 gene.","Nephrotic Syndrome - WT1 Associated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054226","Pauci-Immune Glomerulonephritis - ANCA Negative","C123108","Glomerulonephritis with paucity of glomerular staining for immunoglobulins that may be accompanied by systemic, small vessel vasculitis containing no anti neutrophil cytoplasm antibody (ANCA).","Pauci-Immune Glomerulonephritis - ANCA Negative | Pauci-immune Glomerulonephritis - ANCA Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053792","Pauci-Immune Glomerulonephritis - Renal Limited","C123109","Glomerulonephritis in which anti-neutrophil cytoplasm antibody (ANCA) is almost always present and vasculitis is limited to the kidney.","Pauci-Immune Glomerulonephritis - Renal Limited | Pauci-immune Glomerulonephritis - Renal Limited",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054225","Pauci-Immune Glomerulonephritis associated with Eosinophilic Granulomatosis with Polyangiitis","C123110","Glomerulonephritis in the context of eosinophilic-rich granulomatosis with polyangiitis, eosinophilia, asthma and commonly anti-neutrophil cytoplasmic antibody.","Pauci-Immune Glomerulonephritis associated with Eosinophilic Granulomatosis with Polyangiitis | Churg-Strauss Syndrome Associated Glomerulonephritis | Pauci-immune Glomerulonephritis associated with Eosinophilic Granulomatosis with Polyangiitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3850293","FLT3 Tyrosine Kinase Inhibitor TTT-3002","C123362","An orally bioavailable indolocarbazole derivative and inhibitor of constitutively active mutant forms of FMS-like tyrosine kinase 3 (FLT3) with potential antineoplastic activity. Following administration, FLT3 tyrosine kinase inhibitor TTT-3002 binds to and inhibits ligand-dependent dimerization and autophosphorylation of mutant forms of FLT3 with constitutively activating mutations, including FLT3 internal tandem duplication (FLT3/ITD) and the activating point mutation D835Y. Prevention of autophosphorylation inhibits uncontrolled FLT3 signaling and may result in the inhibition of proliferation in tumor cells expressing constitutively active mutant forms of FLT3. The ability of TTT-3002 to inhibit FLT3 proteins with activating point mutations may result in increased efficacy because the activity of these mutants are resistant to other FLT3 kinase inhibitors. FLT3, a tyrosine kinase receptor, plays a role in the regulation of hematopoietic progenitor cell proliferation, and in leukemic cell proliferation and survival. Constitutively activating mutations of FLT3 are the most frequent genetic alterations in acute myeloid leukemia.","FLT3 Tyrosine Kinase Inhibitor TTT-3002 | TTT-3002",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055481","Akt-1/2 Inhibitor-treated Tumor Infiltrating Lymphocytes","C123720","Autologous tumor infiltrating lymphocytes (TILs) harvested directly from the infiltrate of a patient's tumor and treated with an inhibitor of the serine/threonine kinases Akt-1 and -2 (Akti-1/2) during ex vivo expansion, with potential antineoplastic activity. Upon reintroduction into the patient, the Akti-1/2-treated TILs recognize and kill cancer cells. Akt inhibition promotes the immunologic memory of the TILs and enhances their expansion, in vivo long-term persistence and antitumor activity.","Akt-1/2 Inhibitor-treated Tumor Infiltrating Lymphocytes | AKTi-treated TIL | AKTi-treated TILs | Akti-1/2-treated Tumor Infiltrating Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055163","DWJ1319","C123721","An orally available agent that may prevent the formation of gallstones.","DWJ1319 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053636","EGFR Antagonist Hemay022","C123722","An orally available, irreversible inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration, Hemay022 covalently binds to and inhibits the activity of EGFR, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","EGFR Antagonist Hemay022 | EGFR Inhibitor Hemay022 | Hemay022",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049872","Package Type Not Applicable","C123723","There is no associated package type.","Package Type Not Applicable | NA | Not Applicable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053520","Interferon Beta-secreting Mesenchymal Stem Cells","C123724","Human autologous mesenchymal stem cells (MSCs) harvested from the bone marrow of healthy individuals and transduced with a retroviral vector encoding the human cytokine interferon beta (IFNb), with potential immunomodulating and antineoplastic activities. Upon administration of IFNb-secreting MSCs, the cells are attracted and specifically migrate to tumor sites and become part of the tumor microenvironment. Since the MSCs express IFNb, these cells selectively deliver high levels of IFNb to the tumor site. In turn, IFNb binds to IFN-specific cell surface receptors and modulates the transcription and translation of certain genes whose protein products are involved in tumor cell proliferation. This decreases tumor cell growth.","Interferon Beta-secreting Mesenchymal Stem Cells | IFNb-MSC | IFNb-secreting MSCs | IFNbeta-MSC | MSC-IFN beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342482","X-Linked Adrenal Hypoplasia Congenita","C123725","A X-linked condition characterized by underdevelopment of the adrenal gland and adrenal insufficiency caused by mutation(s) in the NR0B1 gene, resulting in decreased activity of the nuclear receptor protein DAX1, which may be associated with hypogonadotropic hypogonadism.","X-Linked Adrenal Hypoplasia Congenita | Adrenal Hypoplasia Congenita",,,,,,,,,,,,,,,"4030211","Congenital adrenal hypoplasia, X-linked",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2678492","SERKAL Syndrome","C123726","An autosomal recessive condition characterized by female to male sex reversal and kidney, adrenal, and lung dysgenesis, due to mutation(s) in the WNT4 gene.","SERKAL Syndrome | 46,XX Sex Reversal with Dysgenesis of Kidneys Adrenals and Lungs | 46,XX Sex Reversal with Dysgenesis of Kidneys, Adrenals, and Lungs",,,,,,,,,,,,,,,"37109842","SERKAL syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4049650","Familial Glucocorticoid Deficiency Type 1","C123727","Familial glucocorticoid deficiency caused by mutation(s) in the MC2R gene encoding the adrenocorticotropin (ACTH) receptor, also known as the melanocortin-2 receptor.","Familial Glucocorticoid Deficiency Type 1 | ACTH Receptor Defect | GCCD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1846284","GLUCOCORTICOID DEFICIENCY 2","C123728","Familial glucocorticoid deficiency caused by mutation(s) in the MRAP gene encoding the melanocortin-2 receptor accessory protein.","Familial Glucocorticoid Deficiency Type 2 | Familial Glucocorticoid Deficiency Type 1 | GCCD2 | Melanocortin-2 Receptor Accessory Protein Defect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1864947","Natural Killer Cell Deficiency, Familial Isolated","C123729","A congenital condition characterized by growth retardation, a decreased number of NK cells, glucocorticoid deficiency, and increased chromosome breakage, associated with mutation(s) in the MCM4 gene.","Natural Killer Cell and Glucocorticoid Deficiency with DNA Repair Defect | IMD54 | Immunodeficiency 54 | Mini-chromosome Maintenance 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054668","Lampalizumab","C123730","No value exists.","Lampalizumab | FCFD4514S | LAMPALIZUMAB | RG 7417",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055329","CRQ-SAS First Administration Version - Fatigue","C121017","Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) How about fatigue? How tired have you felt over the last 2 weeks?","CRQ-SAS First Administration Version - Fatigue | CRQ01-Fatigue | CRQ0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055331","CRQ-SAS First Administration Version - Embarrassed by Coughing","C121018","Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) How often during the last 2 weeks have you felt embarrassed by your coughing or heavy breathing?","CRQ-SAS First Administration Version - Embarrassed by Coughing | CRQ01-Embarrassed by Coughing | CRQ0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055328","CRQ-SAS First Administration Version - Feel Confident to Deal With Illness","C121019","Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) In the last 2 weeks, how much of the time did you feel very confident and sure that you could deal with your illness?","CRQ-SAS First Administration Version - Feel Confident to Deal With Illness | CRQ01-Confident to Deal With Illness | CRQ0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3658612","Selective Androgen Receptor Modulator LY2452473","C123792","An orally bioavailable selective androgen receptor modulator (SARM), with potential tissue-selective androgenic/anti-androgenic activity. Upon oral administration, LY2452473 acts as an agonist in select tissues and organs, including skeletal muscle, bone and the penis, thereby binding to and activating androgen receptor (AR) while acting as an antagonist in the prostate, thereby blocking AR activation and AR-mediated cellular proliferation. This may improve muscle mass and strength, bone formation, and erectile dysfunction while not stimulating growth of the prostate.","Selective Androgen Receptor Modulator LY2452473 | Isopropyl N-[(2S)-7-cyano-4-(2-pyridylmethyl)-2,3-dihydro-1H-cyclopenta[b]indol-2-yl]carbamate | LY SARM | LY2452473 | OPK-88004 | SARM LY2452473",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054912","Fusion-Positive Alveolar Rhabdomyosarcoma","C123731","An alveolar rhabdomyosarcoma characterized by the presence of chromosomal translocation t(1;13)(p36;q14) that results in PAX7-FOXO1 gene fusion; or translocation t(2;13)(q35;q14) that results in PAX3-FOXO1 gene fusion.  Approximately 80% of alveolar rhabdomyosarcomas are fusion-positive.","Fusion-Positive Alveolar Rhabdomyosarcoma | Fusion Gene Positive Alveolar Rhabdomyosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054914","Fusion-Negative Alveolar Rhabdomyosarcoma","C123732","An alveolar rhabdomyosarcoma characterized by the absence of chromosomal translocation t(1;13)(p36;q14) or t(2;13)(q35;q14) and therefore the absence of PAX7-FOXO1 or PAX3-FOXO1 gene fusion.","Fusion-Negative Alveolar Rhabdomyosarcoma | Fusion Gene Negative Alveolar Rhabdomyosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498274","GlyT2/5HT2A Antagonist VVZ-149","C123910","An antagonist of both glycine transporter type 2 (GlyT2) and serotonin receptor 2A (5HT2A), with potential anti-nociceptive activity. Upon administration, GlyT2/5HT2A antagonist VVZ-149 binds to and blocks both GlyT2 and 5HT2A. Blockage of GlyT2 prevents the re-uptake of the inhibitory neurotransmitter glycine in the synaptic cleft, thereby potentiating glycine-mediated inhibitory signaling, and inhibiting the firing of neurons, which suppresses the transmission of pain signals to the brain and induces analgesia. Blockage of 5HT2A prevents both the binding of its ligand serotonin and 5HT/5HT2A-mediated signaling. This also suppresses pain signaling and induces analgesia. GlyT2 and 5HT2A play key roles in the induction and transmission of pain signals. GlyT2, a glycine plasma membrane transporter, modulates glycine-mediated inhibition of synaptic transmission in the spinal cord and mediates pain signal transmission to the brain; inhibition of GlyT2 potentiates glycinergic mediated pain signaling. Serotonin and its 5HT2A receptor are involved in both serotonin receptor-mediated signaling and the perception of pain.","GlyT2/5HT2A Antagonist VVZ-149 | VVZ-149",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498275","Allodepleted T Cell Immunotherapeutic ATIR101","C123911","A cell-based immunotherapeutic product containing T-lymphocyte-enriched leukocytes that are devoid of alloreactive T-lymphocytes, that can potentially be used to restore lymphocyte levels after stem cell transplantations and are derived from partially matched (haploidentical) family donors for blood cancer patients who do not have a matching stem cell donor available. Host alloreactive T-cells, which can cause graft-versus-host disease (GVHD), are eliminated from the donor lymphocytes ex vivo using photodynamic therapy. After allogeneic hematopoietic stem cell transplantation (HSCT), allodepleted T cell immunotherapeutic ATIR101 is administered. This maintains a T-cell-mediated immune response against tumor cells and the donor T-cells can prevent opportunistic infections. ATIR101 does not cause severe, acute GVHD. In addition, administration of ATIR101 eliminates the need for immunosuppressants.","Allodepleted T Cell Immunotherapeutic ATIR101 | ATIR101 | Allodepleted T-cell ImmunotheRapeutics | Theralux-ATIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498276","Syk inhibitor HMPL-523","C123912","An orally available inhibitor of spleen tyrosine kinase (Syk), with potential immunomodulating and antineoplastic activities. Upon oral administration of sovleplenib, this agent binds to and inhibits the activity of Syk. This inhibits B-cell receptor (BCR) signaling, which leads to the inhibition of B-cell activation, and prevents tumor cell activation, migration, adhesion and proliferation. Syk, a non-receptor cytoplasmic, BCR-associated tyrosine kinase, is expressed in hematopoietic tissues and is often overexpressed in hematopoietic malignancies; it plays a key role in B-cell receptor signaling.","Sovleplenib | (S)-7-(4-(1-(Methylsulfonyl)piperidin-4-yl)phenyl)-N-(morpholin-2-ylmethyl)pyrido(4,3-b)pyrazin-5-amine | HMPL 523 | HMPL-523 | HMPL523 | SOVLEPLENIB | Spleen Tyrosine Kinase Inhibitor HMPL-523 | Syk Inhibitor HMPL-523 | Syk Inhibitor HMPL-523",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498277","XIAP/cIAP1 antagonist ASTX660","C123913","An orally bioavailable, non-peptidomimetic antagonist of both X chromosome-linked inhibitor of apoptosis protein (XIAP) and cellular IAP 1 (cIAP1), with potential antineoplastic and pro-apoptotic activities. Upon administration, tolinapant selectively binds to and inhibits the activity of XIAP and cIAP1. This restores and promotes the induction of apoptotic signaling pathways in cancer cells, and inactivates the nuclear factor-kappa B (NF-kB)-mediated survival pathway. XIAP and cIAP1 are overexpressed by many cancer cell types and suppress apoptosis by inhibiting the activity of certain caspases; they promote both cancer cell survival and chemotherapy resistance.","Tolinapant | ASTX 660 | ASTX660 | TOLINAPANT | XIAP/cIAP1 Antagonist ASTX660",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026716","Mucor","C120708","A genus of fungi within the phylum Zygomycota that are ubiquitous in nature and generally not considered pathogenic. Members of the Mucor genus produce apical, globular sporangia supported by columella, and do not produce rhizoids. Though generally thermointolerant, at least one species, Mucor indicus, may cause opportunistic infections in immunocompromised individuals to include zygomycosis.","Mucor | MUCOR",,,,,,,,,,,,,,,"4172434","Genus Mucor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319529","Rhizomucor pusillus","C120709","A species of grey mycelium fungi belonging to the genus Rhizomucor that is most commonly found in compost heaps; it is a rare human pathogen, causing pulmonary, disseminated or cutaneous infection.","Rhizomucor pusillus | Mucor pusillus | RHIZOMUCOR PUSILLUS",,,,,,,,,,,,,,,"4323131","Rhizomucor pusillus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053765","Schistosomiasis Nephropathy","C123035","Kidney disease associated with Schistosoma infection. Injury to the kidney may be a result of immunologically mediated glomerular or interstitial injury and/or a result of reflux nephropathy.","Schistosomiasis Nephropathy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0558595","Uric Acid Nephrolithiasis","C123037","Nephrolithiasis in which the composition of the stone(s) is predominantly uric acid.","Uric Acid Nephrolithiasis | ",,,,,,,,,,,,,,,"4170813","Uric acid renal calculus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0034188","Xanthogranulomatous Pyelonephritis","C123038","Chronic, destructive infection of the kidney characterized by lipid-laden macrophages in the setting of obstruction secondary to infected renal stones, most commonly caused by Proteus or Escherichia coli.","Xanthogranulomatous Pyelonephritis | ",,,,,,,,,,,,,,,"4306541","Xanthogranulomatous pyelonephritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268743","Dense Deposit Disease","C123039","Proliferative glomerulonephritis characterized by activation of the alternative complement pathway, resulting in mesangial hypercellularity, endocapillary proliferation, and glomerular basement membrane intramembranous highly electron dense deposits.","Dense Deposit Disease | Membranoproliferative Glomerulonephritis Type 2 | Mesangiocapillary Glomerulonephritis Type 2",,,,,,,,,,,,,,,"36717583","Dense deposit disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054325","Obesity Related Glomerulopathy","C123042","Diffuse glomerular (greater than 50% of glomeruli) hypertrophy (greater than 250 micron diameter) that occurs in the context of obesity.","Obesity Related Glomerulopathy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055342","C3 Glomerulonephritis","C123043","Glomerulonephritis characterized by C3 accumulation with little or absent deposition of immunoglobulin, in the absence of ultrastructural electron-dense transformation seen in dense deposit disease.","C3 Glomerulonephritis | Complement-Mediated Membranoproliferative Glomerulonephritis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2749515","Collapsing Glomerulopathy","C123044","Segmental or global glomerulopathy with tuft wrinkling, collapse and contraction without increased matrix or cells, but with adjacent podocyte hypertrophy and hyperplasia.","Collapsing Glomerulopathy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055194","Congenital Nephrotic Syndrome - Cytomegalovirus Associated","C123045","Nephrotic syndrome associated with a cytomegalovirus infection, most commonly presenting in the first three months of life.","Congenital Nephrotic Syndrome - Cytomegalovirus Associated | Cytomegalovirus Associated Congenital Nephrotic Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055192","Congenital Nephrotic Syndrome - Infection Associated","C123046","Nephrotic syndrome presenting within the first three months of life, and which is associated with an infectious process.","Congenital Nephrotic Syndrome - Infection Associated | Infection Associated Congenital Nephrotic Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055191","Congenital Nephrotic Syndrome - Rubivirus Associated","C123047","Nephrotic syndrome associated with rubella, most commonly presenting in the first three months of life.","Congenital Nephrotic Syndrome - Rubivirus Associated | Rubivirus Associated Congenital Nephrotic Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055189","Congenital Nephrotic Syndrome - Treponema Pallidum Associated","C123049","Nephrotic syndrome associated with syphilis, most commonly presenting in the first three months of life.","Congenital Nephrotic Syndrome - Treponema Pallidum Associated | Treponema Pallidum Associated Congenital Nephrotic Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0473221","Cryoglobulinemic Glomerulonephritis","C123050","Glomerulonephritis in the context of cryoglobulinemia.","Cryoglobulinemic Glomerulonephritis | ",,,,,,,,,,,,,,,"4030665","Cryoglobulinemic glomerulonephritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054946","Focal Segmental Glomerulosclerosis Cellular Variant","C123051","A variant of FSGS characterized by hypercellularity of the glomerulus; this excludes the tip and collapsing FSGS. (D'Agati VD, et al. 'Pathologic Classification of Focal Segmental Glomerulosclerosis: A Working Proposal.' Am J Kidney Dis 43.2 (2004): 368-82.)","Focal Segmental Glomerulosclerosis Cellular Variant | FSGS Cellular Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899717","Canine Melanoma","C120298","Melanoma occurring in a dog. It is the most common malignant tumor found in the mouths of dogs and also occurs frequently on the digits. All canine melanomas are locally invasive and malignant canine melanomas show a high rate of metastasis. Melanoma in dogs has been established as a relevant model for human melanoma.","Canine Melanoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0071839","Prednisolone Acetate","C1202","The acetate salt form of prednisolone, a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. As a glucocorticoid receptor agonist, prednisolone acetate binds to specific intracellular glucocorticoid receptors, and causes the ligand-receptor complex to be translocated to the nucleus where it initiates the transcription of glucocorticoid-responsive genes such as various cytokines and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both potent mediators of inflammation. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","Prednisolone Acetate | Ak-Tate | Articulose-50 | Balpred | Deltacortilen | Deltastab | Di-Adreson-F | Diopred | Econopred | Flo-Pred | Hexacortone | Hydrocortancyl | Inf-Oph | Inflanefran | Key-Pred | Locaseptil-Neo | Ophtho-Tate | PREDNISOLONE ACETATE | Pred Fort | Pred Forte | Pred Mild | Predaject | Predalone | Predate | Predcor | Prednefrin SF | Predni-H | Predni-POS | Prednihexal | Predniocil | Prednisolone acetate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055405","BACS - Verbal Fluency Total","C121060","Brief Assessment of Cognition in Schizophrenia (BACS) Verbal Fluency: Total number of Verbal Fluency items.","BACS - Verbal Fluency Total | BACS1-Verbal Fluency Total | BACS104D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055408","BACS - Symbol Coding Raw Score","C121061","Brief Assessment of Cognition in Schizophrenia (BACS) Symbol Coding: Raw score.","BACS - Symbol Coding Raw Score | BACS1-Symbol Coding Raw Score | BACS105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055406","BACS - Tower of London Correct Responses","C121062","Brief Assessment of Cognition in Schizophrenia (BACS) Tower of London: Number of correct responses.","BACS - Tower of London Correct Responses | BACS1-Tower of London Correct Responses | BACS106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055400","BODE Index - Body-mass Index","C121063","The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index (BODE Index) Body-mass index.","BODE Index - Body-mass Index | BODE01-Body-mass Index | BODE0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055398","BODE Index - FEV1 Percent Predicted","C121064","The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index (BODE Index) FEV1 (% of predicted).","BODE Index - FEV1 Percent Predicted | BODE01-FEV1 % Predicted | BODE0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498278","anti-CD73 monoclonal antibody MEDI9447","C123914","A monoclonal antibody against the ectoenzyme CD73 (cluster of differentiation 73), also known as 5'-nucleotidase (5'-NT; ecto-5'-nucleotidase) with potential antineoplastic activity. Upon administration, oleclumab targets and binds to CD73, leading to clustering of and internalization of CD73. This prevents CD73-mediated conversion of adenosine monophosphate (AMP) to adenosine and decreases the amount of free adenosine. This prevents adenosine-mediated lymphocyte suppression and increases the activity of CD8-positive effector cells. This also activates macrophages, and reduces both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes. By abrogating the inhibitory effect on the immune system and enhancing the cytotoxic T-cell-mediated immune response against cancer cells, tumor cell growth decreases. In addition, clustering and internalization of CD73 decreases the migration of cancer cells and prevents metastasis. CD73, a plasma membrane protein upregulated on a number of cancer cell types, catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment.","Oleclumab | Anti-CD73 Monoclonal Antibody MEDI9447 | MEDI9447 | OLECLUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054144","Pseudotumor of Kidney","C123253","A parenchymal lesion, which may appear neoplastic in origin, that results from abnormal architecture of the renal calyx.","Pseudotumor of Kidney | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0431743","Urachal Diverticulum","C123254","A condition in which the urachus fails to close proximal to the bladder, resulting in a non-detrusor, blind-ending pouch at the dome of the bladder.","Urachal Diverticulum | ",,,,,,,,,,,,,,,"4113454","Urachal diverticulum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1739389","Urachal Remnant","C123255","Remaining collapsed and obliterated urachal tissue between the bladder dome and umbilicus.","Urachal Remnant | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3551840","Urethral Prolapse","C123256","Prolapse of the urethral mucosa from the exterior urethral opening.","Urethral Prolapse | ",,,,,,,,,,,,,,,"36674348|441906","Prolapse of urethral mucosa|Prolapse of urethra",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C4055438","Ascending Testicle","C123257","A condition in which a previously descended testicle permanently moves out of the scrotum.","Ascending Testicle | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0266424","Retractile Testicle","C123258","A normal variant in which the testicle may move freely between the scrotum and the groin.","Retractile Testicle | ",,,,,,,,,,,,,,,"435648","Retractile testis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1834858","Testicular Atrophy","C123259","Loss of testicular volume.","Testicular Atrophy | ",,,,,,,,,,,,,,,"438477","Atrophy of testis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1845168","X-Linked Recessive Hypophosphatemic Rickets","C123260","An X-linked, recessive disorder of the proximal renal tubules that presents during childhood, and is characterized by low-molecular weight proteinuria, hypercalciuria, hypophosphatemia rickets, nephrocalcinosis, nephrolithiasis, and progressive kidney failure.","Dent Disease | X-Linked Recessive Hypophosphatemic Rickets | X-linked Recessive Hypophosphatemic Rickets",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342345","Familial Hypercalciuric Hypocalcemia","C123261","A hereditary condition caused by calcium sensing receptor gene mutations, resulting in calcium-hypersensitivity, and compensatory hypocalcemia and hypercalciuria.","Familial Hypercalciuric Hypocalcemia | ",,,,,,,,,,,,,,,"46272736","Autosomal dominant hypocalcemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1809471","Familial Hypocalciuric Hypercalcemia","C123262","A hereditary condition caused by calcium sensing receptor gene mutations, resulting in calcium-hyposensitivity, and compensatory hypercalcemia and hypocalciuria.","Familial Hypocalciuric Hypercalcemia | Familial Benign Hypercalcemia",,,,,,,,,,,,,,,"4029603","Familial hypocalciuric hypercalcemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268448","Familial Primary Hypomagnesemia","C123263","A hereditary disorder that leads to a selective defect in renal or intestinal magnesium absorption, resulting in a low serum magnesium concentration.","Familial Primary Hypomagnesemia | ",,,,,,,,,,,,,,,"4215733","Primary hypomagnesemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053943","Testicular Hypotrophy","C123264","Less than expected testicular size.","Testicular Hypotrophy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054945","Focal Segmental Glomerulosclerosis Collapsing Variant","C123052","A variant of FSGS characterized by glomerular tuft collapse, which may result in scarring. (D'Agati VD, et al. 'Pathologic Classification of Focal Segmental Glomerulosclerosis: A Working Proposal.' Am J Kidney Dis 43.2 (2004): 368-82.)","Focal Segmental Glomerulosclerosis Collapsing Variant | FSGS Collapsing Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055397","BODE Index - MMRC Dyspnea Scale","C121065","The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index (BODE Index) MMRC dyspnea scale.","BODE Index - MMRC Dyspnea Scale | BODE01-MMRC Dyspnea Scale | BODE0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055399","BODE Index - Distance Walked in 6 Minutes","C121066","The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index (BODE Index) Distance walked in 6 min (in meter).","BODE Index - Distance Walked in 6 Minutes | BODE01-Distance Walked in 6 Minutes | BODE0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055259","Child-Pugh - Encephalopathy Grade","C121068","Child-Pugh Classification (Child-Pugh) Encephalopathy grade.","Child-Pugh - Encephalopathy Grade | CPS01-Encephalopathy Grade | CPS0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053735","Child-Pugh - Ascites","C121069","Child-Pugh Classification (Child-Pugh) Ascites.","Child-Pugh - Ascites | CPS01-Ascites | CPS0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055254","Child-Pugh - Serum Bilirubin","C121070","Child-Pugh Classification (Child-Pugh) Serum bilirubin, mg/dL.","Child-Pugh - Serum Bilirubin | CPS01-Serum Bilirubin | CPS0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055255","Child-Pugh - Serum Albumin","C121071","Child-Pugh Classification (Child-Pugh) Serum albumin, g/dL.","Child-Pugh - Serum Albumin | CPS01-Serum Albumin | CPS0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055256","Child-Pugh - PT, Sec Prolonged","C121072","Child-Pugh Classification (Child-Pugh) Prothrombin time, sec prolonged.","Child-Pugh - PT, Sec Prolonged | CPS01-PT, Sec Prolonged | CPS0105A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055257","Child-Pugh - PT, INR","C121073","Child-Pugh Classification (Child-Pugh) Prothrombin time, international normalized ratio (INR).","Child-Pugh - PT, INR | CPS01-PT, INR | CPS0105B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055253","Child-Pugh - Total Score","C121074","Child-Pugh Classification (Child-Pugh) Child-Pugh total score.","Child-Pugh - Total Score | CPS01-Total Score | CPS0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055258","Child-Pugh - Grade","C121075","Child-Pugh Classification (Child-Pugh) Child-Pugh grade.","Child-Pugh - Grade | CPS01-Grade | CPS0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054435","NSA-16 - Prolonged Time to Respond","C121077","Negative Symptom Assessment-16 (NSA-16) Prolonged time to respond.","NSA-16 - Prolonged Time to Respond | NSA01-Prolonged Time to Respond | NSA0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054429","NSA-16 - Restricted Speech Quantity","C121078","Negative Symptom Assessment-16 (NSA-16) Restricted speech quantity.","NSA-16 - Restricted Speech Quantity | NSA01-Restricted Speech Quantity | NSA0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054440","NSA-16 - Impoverished Speech Content","C121079","Negative Symptom Assessment-16 (NSA-16) Impoverished speech content.","NSA-16 - Impoverished Speech Content | NSA01-Impoverished Speech Content | NSA0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053504","CDISC SDTM Anti-Viral Outcome of Treatment Terminology","C120521","Terminology associated with the anti-viral outcome of treatment codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Anti-Viral Outcome of Treatment Terminology | AVOUTTRT | Anti-Viral Outcome of Treatment | SDTM-AVOUTTRT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055152","Diclofenac Epolamine Patch","C123266","A topical patch containing the epolamine salt form of the nonsteroid anti-inflammatory drug (NSAID) diclofenac, with anti-inflammatory, anti-pyretic and analgesic activities.  Upon topical application of the diclofenac epolamine patch to a specific area, the patch releases diclofenac epolamine into the skin. Diclofenac locally binds to cyclooxygenase isoforms 1 and 2 (COX-1 and -2). The inhibition of COX-2 by diclofenac prevents the COX-2-mediated synthesis of proprostaglandins (PGs) and thereby locally relieves PG-mediated pain, fever and inflammation.","Diclofenac Epolamine Patch | Flector Patch",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049939","FDA Establishment Activity Terminology","C123268","Terminology used in the framework of identifying types of establishment activities.","FDA Establishment Activity Terminology | ACTIVITY | ESTABLISHMENT ACTIVITY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054877","Haemophilus haemolyticus, Beta-Lactamase Negative","C123473","Any bacterial species identified as Haemophilus haemolyticus that does not produce the enzyme beta-lactamase.","Haemophilus haemolyticus, Beta-Lactamase Negative | HAEMOPHILUS HAEMOLYTICUS, BETA-LACTAMASE NEGATIVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054875","Haemophilus haemolyticus, Penicillinase Negative","C123475","Any bacterial species identified as Haemophilus haemolyticus that does not produce the enzyme penicillinase.","Haemophilus haemolyticus, Penicillinase Negative | HAEMOPHILUS HAEMOLYTICUS, PENICILLINASE NEGATIVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054874","Haemophilus haemolyticus, Penicillinase Positive","C123476","Any bacterial species identified as Haemophilus haemolyticus that produces the enzyme penicillinase.","Haemophilus haemolyticus, Penicillinase Positive | HAEMOPHILUS HAEMOLYTICUS, PENICILLINASE POSITIVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054873","Haemophilus influenzae, Beta-Lactamase Negative","C123477","Any bacterial species identified as Haemophilus influenzae that does not produce the enzyme beta-lactamase.","Haemophilus influenzae, Beta-Lactamase Negative | HAEMOPHILUS INFLUENZAE, BETA-LACTAMASE NEGATIVE",,,,,,,,,,,,,,,"36716367","Haemophilus influenzae, beta lactamase negative",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054872","Haemophilus influenzae, Beta-Lactamase Positive","C123478","Any bacterial species identified as Haemophilus influenzae that produces the enzyme beta-lactamase.","Haemophilus influenzae, Beta-Lactamase Positive | HAEMOPHILUS INFLUENZAE, BETA-LACTAMASE POSITIVE",,,,,,,,,,,,,,,"36716369","Haemophilus influenzae, beta lactamase positive",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054871","Haemophilus influenzae, Penicillinase Negative","C123479","Any bacterial species identified as Haemophilus influenzae that does not produce the enzyme penicillinase.","Haemophilus influenzae, Penicillinase Negative | HAEMOPHILUS INFLUENZAE, PENICILLINASE NEGATIVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054870","Haemophilus influenzae, Penicillinase Positive","C123480","Any bacterial species identified as Haemophilus influenzae that produces the enzyme penicillinase.","Haemophilus influenzae, Penicillinase Positive | HAEMOPHILUS INFLUENZAE, PENICILLINASE POSITIVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053809","Haemophilus parahaemolyticus, Beta-Lactamase Negative","C123481","Any bacterial species identified as Haemophilus parahaemolyticus that does not produce the enzyme beta-lactamase.","Haemophilus parahaemolyticus, Beta-Lactamase Negative | HAEMOPHILUS PARAHAEMOLYTICUS, BETA-LACTAMASE NEGATIVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054869","Haemophilus parahaemolyticus, Beta-Lactamase Positive","C123482","Any bacterial species identified as Haemophilus parahaemolyticus that produces the enzyme beta-lactamase.","Haemophilus parahaemolyticus, Beta-Lactamase Positive | HAEMOPHILUS PARAHAEMOLYTICUS, BETA-LACTAMASE POSITIVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054867","Haemophilus parahaemolyticus, Penicillinase Positive","C123484","Any bacterial species identified as Haemophilus parahaemolyticus that produces the enzyme penicillinase.","Haemophilus parahaemolyticus, Penicillinase Positive | HAEMOPHILUS PARAHAEMOLYTICUS, PENICILLINASE POSITIVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054866","Haemophilus parainfluenzae, Beta-Lactamase Negative","C123485","Any bacterial species identified as Haemophilus parainfluenzae that does not produce the enzyme beta-lactamase.","Haemophilus parainfluenzae, Beta-Lactamase Negative | HAEMOPHILUS PARAINFLUENZAE, BETA-LACTAMASE NEGATIVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055325","CRQ-SAS First Administration Version - Feel Upset, Worried or Depressed","C121021","Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) In general, how much of the time did you feel upset, worried, or depressed during the last 2 weeks?","CRQ-SAS First Administration Version - Feel Upset, Worried or Depressed | CRQ01-Feel Upset, Worried or Depressed | CRQ0112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055317","CRQ-SAS First Administration Version - Had Control of Breathing Problems","C121022","Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) How often during the last 2 weeks did you feel you had complete control of your breathing problems?","CRQ-SAS First Administration Version - Had Control of Breathing Problems | CRQ01-Control of Breathing Problems | CRQ0113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055327","CRQ-SAS First Administration Version - Feel Relaxed and Free of Tension","C121023","Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) How much of the time during the last 2 weeks did you feel relaxed and free of tension?","CRQ-SAS First Administration Version - Feel Relaxed and Free of Tension | CRQ01-Feel Relaxed and Free of Tension | CRQ0114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055320","CRQ-SAS First Administration Version - Felt Low in Energy","C121024","Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) How often during the last 2 weeks have you felt low in energy?","CRQ-SAS First Administration Version - Felt Low in Energy | CRQ01-Felt Low in Energy | CRQ0115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1631325","Parabacteroides goldsteinii","C123535","A species of obligately anaerobic, non-spore-forming, non-motile, Gram negative, rod-shaped bacterium in the family Porphyromonadaceae. This species is negative for urease and nitrate reduction. Acid is produced from cellobiose, glucose, rhamnose, sucrose, trehalose and xylose, but not from arabinose or xylan. P. goldsteinii was isolated from human clinical specimens of intestinal origin.","Parabacteroides goldsteinii | Bacteroides goldsteinii | PARABACTEROIDES GOLDSTEINII",,,,,,,,,,,,,,,"37018966","Parabacteroides goldsteinii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1937786","Parabacteroides johnsonii","C123536","A species of obligately anaerobic, non-spore-forming, non-motile, Gram negative, rod-shaped bacterium in the family Porphyromonadaceae. This species is negative for urease, indole, catalase, and digestion of gelatin; mannose and raffinose are fermented. P. johnsonii was isolated from human feces.","Parabacteroides johnsonii | PARABACTEROIDES JOHNSONII",,,,,,,,,,,,,,,"37016533","Parabacteroides johnsonii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1071043","Paracoccus yeei","C123537","A species of aerobic Gram-negative coccobacillus in the family Rhodobacteraceae. This species is catalase and oxidase positive and can reduce nitrate. P. yeei is found naturally in soil and brines and has be identified as an unusual etiologic opportunistic agent of peritonitis.","Paracoccus yeei | CDC Group EO-2 | PARACOCCUS YEEI",,,,,,,,,,,,,,,"4187186","Paracoccus yeei",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030426","Paragonimus westermani","C123538","A species of parasitic flatworms in the family Troglotrematidae. The lifecycle of P. westermani involves freshwater snails as the first intermediate host, freshwater crustaceans as the second intermediate host, and humans or cats as the definitive host. Infestation causes paragonimiasis.","Paragonimus westermani | Japanese Lung Fluke | Oriental Lung Fluke | PARAGONIMUS WESTERMANI",,,,,,,,,,,,,,,"4242262","Paragonimus westermani - oriental liver fluke",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0445656","Pediococcus pentosaceus","C123539","A species of Gram positive, facultatively anaerobic, non-motile, non-spore forming, cocci shaped bacterium in the family Lactobacillaceae. This species possesses a strictly fermentative metabolism with lactic acid as the major metabolic end product. P. pentosaceus can be found in plant materials, ripened cheese, and a variety of processed meats.","Pediococcus pentosaceus | PEDIOCOCCUS PENTOSACEUS | Pediococcus hennebergii",,,,,,,,,,,,,,,"4348013","Pediococcus pentosaceus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030843","Penicillium","C123540","A genus of fungi in the family Trichocomaceae characterized by broom-shaped conidia. Several species within this genus are economically important for the production of penicillin and the making of cheese.","Penicillium | PENICILLIUM",,,,,,,,,,,,,,,"4180730","Penicillium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040920","Pentatrichomonas hominis","C123541","An obligate symbiont, flagellate protozoan in the family Trichomonadidae. P. hominis is found in the intestinal tract of infected individuals, but is considered nonpathogenic.","Pentatrichomonas hominis | PENTATRICHOMONAS HOMINIS",,,,,,,,,,,,,,,"4228223","Pentatrichomonas hominis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1007107","Pestalotiopsis","C123542","A genus of fungi in the family Amphisphaeriaceae with 4-6 celled conidia and 2 or 3 apical appendages. Species within the genus are known as plant pathogens.","Pestalotiopsis | PESTALOTIOPSIS",,,,,,,,,,,,,,,"4313347","Pestalotiopsis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031519","Phialophora","C123543","A genus of fungi in the family Herpotrichiellaceae with short conidiophores and unicellular conidia. Most species within the genus are saprophytes commonly found in soil or on decaying wood. P. richardsiae is a rare causative agent for subcutaneous phaeohyphomycosis and P. verrucosa can cause chromoblastomycosis.","Phialophora | PHIALOPHORA",,,,,,,,,,,,,,,"4189156","Phialophora",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031874","Pichia","C123544","A genus of yeasts in the family Saccharomycetaceae with spherical, elliptical or oblong acuminate cells.","Pichia | Hansenula | PICHIA",,,,,,,,,,,,,,,"4219535","Pichia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4050258","CDISC SEND Chronicity Terminology","C120529","Terminology associated with the chronicity codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).","CDISC SEND Chronicity Terminology | CHRNCTY | Chronicity | SEND-CHRNCTY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0520511","CDISC SEND Distribution Terminology","C120530","Terminology associated with the distribution codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).","CDISC SEND Distribution Terminology | DSTRBN | Distribution | SEND-DSTRBN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053497","CDISC SEND Non-Neoplastic Finding Type Terminology","C120531","Terminology associated with the non-neoplastic finding type codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).","CDISC SEND Non-Neoplastic Finding Type Terminology | NONNEO | Non-Neoplastic Finding Type | SEND-NONNEO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053496","CDISC SEND Cardiovascular Test Code Terminology","C120532","Terminology associated with the cardiovascular test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).","CDISC SEND Cardiovascular Test Code Terminology | SCVTSTCD | SEND Cardiovascular Test Code | SEND-SCVTSTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053495","CDISC SEND Cardiovascular Test Name Terminology","C120533","Terminology associated with the cardiovascular test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).","CDISC SEND Cardiovascular Test Name Terminology | SCVTST | SEND Cardiovascular Test Name | SEND-SCVTST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053494","CDISC SEND Respiratory Test Code Terminology","C120534","Terminology associated with the respiratory test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).","CDISC SEND Respiratory Test Code Terminology | SEND Respiratory Test Code | SEND-SRETSTCD | SRETSTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054865","Haemophilus parainfluenzae, Beta-Lactamase Positive","C123486","Any bacterial species identified as Haemophilus parainfluenzae that produces the enzyme beta-lactamase.","Haemophilus parainfluenzae, Beta-Lactamase Positive | HAEMOPHILUS PARAINFLUENZAE, BETA-LACTAMASE POSITIVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054864","Haemophilus parainfluenzae, Penicillinase Negative","C123487","Any bacterial species identified as Haemophilus parainfluenzae that does not produce the enzyme penicillinase.","Haemophilus parainfluenzae, Penicillinase Negative | HAEMOPHILUS PARAINFLUENZAE, PENICILLINASE NEGATIVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054863","Haemophilus parainfluenzae, Penicillinase Positive","C123488","Any bacterial species identified as Haemophilus parainfluenzae that produces the enzyme penicillinase.","Haemophilus parainfluenzae, Penicillinase Positive | HAEMOPHILUS PARAINFLUENZAE, PENICILLINASE POSITIVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0322058","Heterophyes heterophyes","C123489","A species of parasitic flatworms in the family Heterophyidae. The lifecycle of H. heterophyes involves snails as the first intermediate host, freshwater fish as the second intermediate host, and humans, fish-eating carnivores, or birds as the definitive host. Infestation causes heterophyiasis.","Heterophyes heterophyes | HETEROPHYES HETEROPHYES",,,,,,,,,,,,,,,"4034995","Heterophyes heterophyes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053643","BET Inhibitor FT-1101","C123733","An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, the BET inhibitor FT-1101 binds to the acetylated lysine recognition motifs in the bromodomain sites of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to the inhibition of tumor cell growth. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.","BET Inhibitor FT-1101 | CC 95775 | CC-95775 | CC95775 | FT-1101 | FT1101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053581","CD40 agonistic monoclonal antibody APX005M","C123734","A humanized monoclonal antibody agonist of the cell surface receptor CD40, with potential immunostimulatory and antineoplastic activities. Similar to the endogenous CD40 ligand (CD40L or CD154), sotigalimab binds to CD40 on a variety of immune cell types. This triggers the cellular proliferation and activation of antigen-presenting cells (APCs), and activates B-cells, and effector and memory T-cells. This results in an enhanced immune response against tumor cells. Sotigalimab also binds to and activates CD40 present on the surfaces of some solid tumor cells, leading to apoptosis and decreased tumor growth. CD40, a cell surface receptor and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells and certain cancer cells; it mediates both indirect tumor cell killing through the activation of the immune system and direct tumor cell apoptosis.","Sotigalimab | APX 005 | APX 005M | APX-005M | APX005M | CD40 Agonistic Monoclonal Antibody APX005M | EPI-0050 | SOTIGALIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054911","Fusion-Positive Rhabdomyosarcoma","C123735","A rhabdomyosarcoma characterized by the presence of chromosomal translocation t(1;13)(p36;q14) that results in PAX7-FOXO1 gene fusion; or translocation t(2;13)(q35;q14) that results in PAX3-FOXO1 gene fusion.","Fusion-Positive Rhabdomyosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054913","Fusion-Negative Rhabdomyosarcoma","C123736","A rhabdomyosarcoma characterized by the absence of chromosomal translocation t(1;13)(p36;q14) or t(2;13)(q35;q14) and therefore the absence of PAX7-FOXO1 or PAX3-FOXO1 gene fusion.","Fusion-Negative Rhabdomyosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054084","Refractory Childhood Malignant Germ Cell Tumor","C123737","A malignant germ cell tumor that occurs during childhood and is resistant to treatment.","Refractory Childhood Malignant Germ Cell Tumor | Refractory Childhood Malignant Germ Cell Neoplasm | Refractory Malignant Germ Cell Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049868","Gitter Cell","C123738","A microglial cell that is unable to phagocytose any further materials. Named for its grainy appearance, gitter cells can indicate post-infection areas that have healed.","Gitter Cell | Granular Corpuscle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054083","Refractory Malignant Germ Cell Tumor","C123739","Malignant germ cell tumor resistant to treatment.","Refractory Malignant Germ Cell Tumor | Refractory Malignant Germ Cell Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055322","CRQ-SAS First Administration Version - Felt Discouraged or Down","C121025","Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) In general, how often during the last 2 weeks have you felt discouraged or down in the dumps?","CRQ-SAS First Administration Version - Felt Discouraged or Down | CRQ01-Felt Discouraged or Down | CRQ0116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055318","CRQ-SAS First Administration Version - Felt Worn Out or Sluggish","C121026","Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) How often during the last 2 weeks have you felt worn out or sluggish?","CRQ-SAS First Administration Version - Felt Worn Out or Sluggish | CRQ01-Felt Worn Out or Sluggish | CRQ0117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055316","CRQ-SAS First Administration Version - Happy, Satisfied or Pleased With Life","C121027","Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) How happy, satisfied, or pleased have you been with your personal life during the last 2 weeks?","CRQ-SAS First Administration Version - Happy, Satisfied or Pleased With Life | CRQ01-Happy, Satisfied or Pleased | CRQ0118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055326","CRQ-SAS First Administration Version - Feel Upset When Had Difficulty Getting Breath","C121028","Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) How often during the last 2 weeks did you feel upset or scared when you had difficulty getting your breath?","CRQ-SAS First Administration Version - Feel Upset When Had Difficulty Getting Breath | CRQ01-Feel Upset Diff Getting Breath | CRQ0119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055319","CRQ-SAS First Administration Version - Felt Restless, Tense or Uptight","C121029","Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) In general, how often during the last 2 weeks have you felt restless, tense, or uptight?","CRQ-SAS First Administration Version - Felt Restless, Tense or Uptight | CRQ01-Felt Restless, Tense or Uptight | CRQ0120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055292","CRQ-SAS Follow-Up Administration Version - Take Care of Basic Needs","C121031","Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) Taking care of your basic needs (bathing, showering, eating or dressing).","CRQ-SAS Follow-Up Administration Version - Take Care of Basic Needs | CRQ02-Take Care of Basic Needs | CRQ0202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0319612","Piedraia","C123545","A genus of fungi in the family Piedraiaceae. Species in this genus are generally nonpathogenic but may cause opportunistic infection of hair shafts in humans.","Piedraia | PIEDRAIA",,,,,,,,,,,,,,,"4198527","Piedraia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320161","Pithomyces","C123546","A genus of fungi in the family Pleosporaceae. Species within this genus are commonly found on dead leaves and stems.","Pithomyces | PITHOMYCES",,,,,,,,,,,,,,,"4133833","Pithomyces",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032150","Plasmodium falciparum","C123547","A protozoan parasite in the family Plasmodiidae. P. falciparum is transmitted by the female Anopheles mosquito and is a causative agent of malaria in humans. The malaria caused by this species is the most dangerous form of malaria.","Plasmodium falciparum | PLASMODIUM FALCIPARUM",,,,,,,,,,,,,,,"4107212","Plasmodium falciparum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032153","Plasmodium malariae","C123548","A protozoan parasite in the family Plasmodiidae. P. malariae causes quartan malaria, a milder form of malaria than that caused by P. falciparum or P. vivax.","Plasmodium malariae | PLASMODIUM MALARIAE",,,,,,,,,,,,,,,"4207072","Plasmodium malariae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0072657","Pyrazine Diazohydroxide","C1207","A congener of pyridine 2-diazohydroxide.  Pyrazine diazohydroxide forms DNA adducts via the reactive pyrazine diazonium ion, thereby inhibiting DNA synthesis. (NCI04)","Pyrazine Diazohydroxide | PZDH | Pyrazinamine, N-nitroso-, sodium salt | Pyrazine diazohydroxide | Pyrazineamine, N-nitroso-, sodium salt | pyrazinamine, N-nitroso-, sodium salt | pyrazine diazohydroxide | pyrazine-2-diazohydroxide | pyrazineamine, N-nitroso-, sodium salt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206003","Kosovo","C123740","A southeastern European country between Servia and Macedonia.","Kosovo | 901 | KOSOVO | XK | XKS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050199","Ashmore and Cartier Islands","C123741","Islands in the Indian Ocean, located midway between northwestern Australia and Timor island.","Ashmore and Cartier Islands | 902 | ASHMORE AND CARTIER ISLANDS | XA | XAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050140","Baker Island","C123742","An atoll in the North Pacific Ocean, about halfway between Hawaii and Australia.","Baker Island | 903 | BAKER ISLAND | XB | XBK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050239","Bassas da India","C123743","An atoll in the southern Mozambique Channel that is part of the French Southern and Antartic Lands.","Bassas da India | 904 | BASSAS DA INDIA | QS | XBI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050020","Clipperton Island","C123744","An atoll in the North Pacific Ocean, southwest of Mexico.","Clipperton Island | 905 | CLIPPERTON ISLAND | CP | CPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053564","Coral Sea Islands","C123745","Numerous islands scattered over more than three-quarters of a million square kilometers of ocean that are a territory of Australia and located in Oceania, northeast of Austrualia.","Coral Sea Islands | 906 | CORAL SEA ISLANDS | XC | XCS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049652","Diego Garcia","C123746","An atoll and the largest of 60 small islands comprising the Chagos Archipelago.","Diego Garcia | 908 | DG | DGA | DIEGO GARCIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053567","GENC Entity 1","C123747","A geopolitical entity designated by the Geopolitical Entities, Names, anc Codes Standard (GENC).","GENC Entity 1 | 909 | ENTITY 1 | XAZ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053514","Nasal Chondromesenchymal Hamartoma","C122985","A very rare benign lesion that arises from the sinonasal tract. It usually affects infants and children. It presents as a polypoid mass and is composed of cartilage, myxoid stroma, and other mesenchymal elements.","Nasal Chondromesenchymal Hamartoma | NCMH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053602","Anti-IL-4/IL-13 Combination Agent QBX258","C122986","A combination agent composed of the two human monoclonal antibodies VAK694 (VAK296), targeting interleukin-4 (IL-4), and QAX576, targeting IL-13, that can potentially be used to block signaling mediated by IL-4 and IL-13. Upon intravenous administration of the anti-IL-4/IL-13 co,mbination agent QBX258, the two antibodies VAK694 and QAX576 target and block the activity of the two cytokines IL-4 and IL-13, respectively, which prevents IL-4/IL-13-mediated signaling.  In patients with breast cancer related lymphedema (BCRL), this agent may prevent lymphedema-associated effects, such as fibrosis, hyperkeratosis, the deposition of fibroadipose tissue, fluid accumulation, limb swelling, reduction of skin elasticity, and pain. By reducing the excess volume, QBX258 may improve lymphatic and arm functions. The development of lymphedema after lymphatic injury is associated with tissue inflammation, the infiltration of CD4-positive cells and their differentiation to the type 2 helper T-cell (Th2) phenotype. Th2 cells produce IL-4 and IL-13 that play a key role in the development of lymphedema-associated symptoms as well as other Th2-mediated diseases.","Anti-IL-4/IL-13 Combination Agent QBX258 | QBX-258 | QBX258 | VAK296 Plus QAX576 | VAK296/QAX576 | VAK694 Plus QAX576 | VAK694/QAX576",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0075193","Staurosporine","C1237","A cell permeable alkaloid isolated from Streptomyces staurosporeus exhibiting anti-cancer activity.  Staurosporine is a potent, non-selective inhibitor of protein kinases, including protein kinase C.  This agent induces apoptosis by an undetermined mechanism. (NCI)","Staurosporine | (9alpha,10beta,11beta,13alpha)-(+)-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H-9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one | 8,12-Epoxy-1H,8H-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)trinden-1-one, 2,3,9,10,11,12-hexahydro-9-methoxy-8-methyl-10-(methylamino)-, (8alpha,9beta,10beta,12alpha)-(+)- | AM-2282 | Antibiotic 230 | Antibiotic AM 2282 | CGP-39360 | STAUROSPORINE | staurosporine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054944","Focal Segmental Glomerulosclerosis Perihilar Variant","C123053","A variant of FSGS characterized by scarring of the glomerulus where at least 50% of the scars are adjacent to the hilum and must have hyalinosis; this excludes cellular, tip and collapsing FSGS. (D'Agati VD, et al. 'Pathologic Classification of Focal Segmental Glomerulosclerosis: A Working Proposal.' Am J Kidney Dis 43.2 (2004): 368-82.)","Focal Segmental Glomerulosclerosis Perihilar Variant | FSGS Perihilar Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054943","Focal Segmental Glomerulosclerosis Tip Lesion Variant","C123054","A variant of FSGS characterized by scarring of the glomerulus adjacent to the origin of the proximal convoluted tubule; this occurs in the absence of collapsing and perihilar FSGS. (D'Agati VD, et al. 'Pathologic Classification of Focal Segmental Glomerulosclerosis: A Working Proposal.' Am J Kidney Dis 43.2 (2004): 368-82.)","Focal Segmental Glomerulosclerosis Tip Lesion Variant | FSGS Tip Lesion Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268742","Immune Complex Mediated Membranoproliferative Glomerulonephritis","C123055","Glomerulonephritis characterized by mesangial proliferation, endocapillary proliferation, and glomerular capillary wall remodeling with immune complex deposits from classical complement pathway activation.","Immune Complex Mediated Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis Type I | Mesangiocapillary Glomerulonephritis Type 1",,,,,,,,,,,,,,,"4294813","Mesangiocapillary glomerulonephritis, type I",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054544","Membranoproliferative Glomerulonephritis Type 3 (AQ)","C123056","Glomerulonephritis similar in appearance under light microscopy to membranoproliferative glomerulonephritis (MPGN) I, but with subepithelial or transmembranous and subendothelial deposits on electron microscopy.","Membranoproliferative Glomerulonephritis Type 3 (AQ) | Mesangiocapillary Glomerulonephritis Type 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054541","Membranous Nephropathy - Drug Associated","C123059","Membranous nephropathy associated with exposure to a drug.","Membranous Nephropathy - Drug Associated | Drug Associated Membranous Nephropathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086445","Membranous Nephropathy - Idiopathic","C123060","Membranous nephropathy for which no cause has been identified.","Membranous Nephropathy - Idiopathic | Idiopathic Membranous Glomerulopathy | Idiopathic Membranous Nephropathy",,,,,,,,,,,,,,,"36716199","Idiopathic membranous glomerulonephritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3896897","Anti-mesothelin Antibody-drug Conjugate BMS-986148","C120303","An antibody-drug conjugate (ADC) composed of a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface glycoprotein and tumor-associated antigen (TAA) mesothelin and conjugated, via a valine-citrulline linker, to the cytotoxic agent tubulysin, with potential antineoplastic activity. Upon administration of anti-mesothelin ADC BMS-986148, the monoclonal antibody moiety targets and binds to mesothelin. Upon internalization, the tubulysin moiety inhibits the polymerization of tubulin into microtubules. This leads to cell cycle arrest, induces tumor cell apoptosis, and may inhibit cellular proliferation of mesothelin-expressing tumor cells. Mesothelin is overexpressed by all mesotheliomas and a variety of other cancers, while it is minimally expressed in normal tissue.","Anti-mesothelin Antibody-drug Conjugate BMS-986148 | BMS-986148",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896798","CYP17/Androgen Receptor Inhibitor ODM 204","C120304","An orally available inhibitor of both the steroid 17-alpha-hydroxylase/C17,20 lyase (CYP17A1 or CYP17) and androgen receptor (AR), with potential anti-androgen and antineoplastic activities. Upon oral administration, CYP17/AR inhibitor ODM 204 selectively inhibits the enzymatic activity of CYP17A1 in both the testes and adrenal glands, thereby inhibiting androgen production. This may both decrease androgen-dependent growth signaling and inhibit the proliferation of androgen-dependent tumor cells. In addition, ODM 204 binds to ARs in target tissues and inhibits androgen-induced receptor activation and AR nuclear translocation, which prevents the binding to and transcription of AR-responsive genes. This leads to an inhibition of growth in AR-expressing prostate cancer cells. The cytochrome P450 enzyme CYP17A1, which is localized to the endoplasmic reticulum, exhibits both 17alpha-hydroxylase and 17,20-lyase activities.","CYP17/Androgen Receptor Inhibitor ODM 204 | ODM 204 | ODM-204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896886","Anti-CEACAM1 Monoclonal Antibody CM-24","C120305","A humanized monoclonal immunoglobulin G4 (IgG4) antibody targeting the anti-carcinoembryonic antigen (CEA)-related cell adhesion molecule 1 (CEACAM1; CD66a), with potential immunomodulating and antineoplastic activities. Upon administration of anti-CEACAM1 monoclonal antibody CM-24, this agent binds to CEACAM1 on cancer cells and certain immune cells. This blocks the binding of CEACAM1-expressing cancer cells to CEACAM1-expressing immune cells and abrogates CEACAM1-mediated immunosuppression. This enhances the activation of cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells and increases CTL- and NK-mediated killing of CEACAM1-overexpressing cancer cells. CEACAM1, a member of the CEA family of proteins that plays a key role in cell migration, cell invasion, and cell adhesion, is overexpressed by a variety of cancer cell types. Its overexpression is correlated with both immunosuppression and poor prognosis.","Anti-CEACAM1 Monoclonal Antibody CM-24 | CM-24",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3897937","Personalized Polyepitope Plasmid DNA Breast Cancer Vaccine","C120306","A polyepitope DNA vaccine composed of a DNA plasmid encoding multiple, highly immunogenic tumor associated antigens (TAAs) that are specifically selected after genome profiling of the patient's breast cancer cells, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration and electroporation of the personalized polyepitope plasmid DNA breast cancer vaccine, the expressed TAAs induce cytotoxic T-lymphocyte (CTL) immune responses against tumor cells expressing the TAAs.","Personalized Polyepitope Plasmid DNA Breast Cancer Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896903","Transdermal 17beta-Estradiol Gel BHR-200","C120308","A proprietary, transdermal, hydroalcoholic gel formulation containing 17beta-estradiol, with potential antineoplastic activity. Upon topical administration, 17beta-estradiol exerts its antineoplastic effect(s) through as of yet not fully elucidated mechanism(s) of action(s). This formulation may induce feedback inhibition via the hypothalamic-pituitary-gonadal axis feedback loop, block the secretion of luteinizing hormone (LH) and prevent the release of testosterone from Leydig cells in the testes, thus suppressing testosterone secretion. In addition, 17beta-estradiol inhibits enzymes involved in steroidogenesis, thereby further inhibiting androgen production. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation. In addition, 17beta-estradiol prevents bone loss, and suppresses andropause symptoms, such as hot flashes, which appear during androgen-deprivation therapy (ADT) where the standard of care is the use of gonadotrophin releasing hormone (GnRH) analogs. Compared to oral estrogens, the topical gel formulation lowers the risk of cardiovascular side effects.","Transdermal 17beta-Estradiol Gel BHR-200 | BHR-200",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054210","Penile Chordee","C122990","Congenital curvature of the penis.","Penile Chordee | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0156259","Renal Hypertrophy","C122991","Global enlargement of the renal parenchyma in one or both kidneys.","Renal Hypertrophy | Hypertrophy of the Kidney",,,,,,,,,,,,,,,"192686","Hypertrophy of kidney",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4022836","Solitary Cyst of Kidney","C122992","A single cyst located in the kidney.","Solitary Cyst of Kidney | Solitary Renal Cyst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050255","Other Establishment Activity","C123269","The establishment activity is other than that which already appears in the establishment activity value set.","Other Establishment Activity | OTHER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050606","FDA Application Type Terminology","C123270","Terminology used in the framework of identifying types of pharmaceutical application types.","FDA Application Type Terminology | APPLICATION TYPE | APPLTYPE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1546968","No Application Type","C123271","There is no associated application type (e.g., as with an over-the-counter monograph drug), and therefore this field is not applicable.","No Application Type | NA | Not Applicable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054540","Membranous Nephropathy - Infection Associated","C123061","Membranous nephropathy associated with infectious disease.","Membranous Nephropathy - Infection Associated | ",,,,,,,,,,,,,,,"36716231","Infection-associated membranous nephropathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054539","Membranous Nephropathy - Malignancy Associated","C123062","Membranous nephropathy in the context of malignancy.","Membranous Nephropathy - Malignancy Associated | Malignancy Associate Membranous Nephropathy",,,,,,,,,,,,,,,"36716176","Malignancy-associated membranous nephropathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054538","Membranous Nephropathy - NEP Induced","C123063","Membranous nephropathy due to neural endopeptidase (NEP) antibodies.","Membranous Nephropathy - NEP Induced | NEP Induced Membranous Nephropathy | Neural Endopeptidase Induced Membranous Nephropathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054537","Membranous Nephropathy - PLA2R Induced","C123064","Membranous nephropathy due to phospholipase 2 receptor (PLA2R) antibodies.","Membranous Nephropathy - PLA2R Induced | PLA2R Induced Membranous Nephropathy | Phospholipase 2 Receptor Membranous Nephropathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054536","Membranous Nephropathy - THSD7A Induced","C123065","Membranous nephropathy due to thrombospondin type-1 domain-containing protein 7A (THSD7A) antibodies.","Membranous Nephropathy - THSD7A Induced | THSD7A Induced Membranous Nephropathy | Thrombospondin Type-1 domain-containing Protein Membranous Nephropathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054401","Nephrotic Syndrome - ACTN4 Associated","C123067","Nephrotic syndrome attributed to mutation(s) in the ACTN4 gene.","Nephrotic Syndrome - ACTN4 Associated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054400","Nephrotic Syndrome - ADCK4 Associated","C123068","Nephrotic syndrome attributed to mutation(s) in the ADCK4 gene.","Nephrotic Syndrome - ADCK4 Associated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054399","Nephrotic Syndrome - ANLN Associated","C123069","Nephrotic syndrome attributed to mutation(s) in the ANLN gene.","Nephrotic Syndrome - ANLN Associated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054398","Nephrotic Syndrome - ARHGAP24 Associated","C123070","Nephrotic syndrome attributed to mutation(s) in the ARHGAP24 gene.","Nephrotic Syndrome - ARHGAP24 Associated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054699","Invasive Focus of Carcinoma Cells Measuring More Than 5 mm Present","C123331","A morphologic finding indicating the presence of an invasive component of carcinoma cells that measures more than 5 mm in greatest dimension.","Invasive Focus of Carcinoma Cells Measuring More Than 5 mm Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054439","NSA-16 - Inarticulate Speech","C121080","Negative Symptom Assessment-16 (NSA-16) Inarticulate speech.","NSA-16 - Inarticulate Speech | NSA01-Inarticulate Speech | NSA0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054444","NSA-16 - Emotion: Reduced Range","C121081","Negative Symptom Assessment-16 (NSA-16) Emotion: Reduced range.","NSA-16 - Emotion: Reduced Range | NSA01-Emotion: Reduced Range | NSA0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054445","NSA-16 - Affect: Reduced Display on Demand","C121083","Negative Symptom Assessment-16 (NSA-16) Affect: Reduced display on demand.","NSA-16 - Affect: Reduced Display on Demand | NSA01-Affect: Reduced Display on Demand | NSA0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054430","NSA-16 - Reduced Social Drive","C121084","Negative Symptom Assessment-16 (NSA-16) Reduced social drive.","NSA-16 - Reduced Social Drive | NSA01-Reduced Social Drive | NSA0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054436","NSA-16 - Poor Rapport With Interviewer","C121085","Negative Symptom Assessment-16 (NSA-16) Poor rapport with interviewer.","NSA-16 - Poor Rapport With Interviewer | NSA01-Poor Rapport With Interviewer | NSA0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054438","NSA-16 - Interest in Emotional and Physical Intimacy","C121086","Negative Symptom Assessment-16 (NSA-16) Interest in emotional and physical intimacy.","NSA-16 - Interest in Emotional and Physical Intimacy | NSA01-Interest Emotional/Phys Intimacy | NSA0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054437","NSA-16 - Poor Grooming and Hygiene","C121087","Negative Symptom Assessment-16 (NSA-16) Poor grooming and hygiene.","NSA-16 - Poor Grooming and Hygiene | NSA01-Poor Grooming and Hygiene | NSA0111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054431","NSA-16 - Reduced Sense of Purpose","C121088","Negative Symptom Assessment-16 (NSA-16) Reduced sense of purpose.","NSA-16 - Reduced Sense of Purpose | NSA01-Reduced Sense of Purpose | NSA0112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054432","NSA-16 - Reduced Interests","C121089","Negative Symptom Assessment-16 (NSA-16) Reduced interests.","NSA-16 - Reduced Interests | NSA01-Reduced Interests | NSA0113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054434","NSA-16 - Reduced Daily Activity","C121090","Negative Symptom Assessment-16 (NSA-16) Reduced daily activity.","NSA-16 - Reduced Daily Activity | NSA01-Reduced Daily Activity | NSA0114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054433","NSA-16 - Reduced Expressive Gestures","C121091","Negative Symptom Assessment-16 (NSA-16) Reduced expressive gestures.","NSA-16 - Reduced Expressive Gestures | NSA01-Reduced Expressive Gestures | NSA0115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054441","NSA-16 - Global Negative Symptoms Rating","C121093","Negative Symptom Assessment-16 (NSA-16) Global negative symptoms rating.","NSA-16 - Global Negative Symptoms Rating | NSA01-Global Negative Symptoms Rating | NSA0117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054442","NSA-16 - Global Negative Symptoms Rating-Severity","C121094","Negative Symptom Assessment-16 (NSA-16) Global negative symptoms rating - severity.","NSA-16 - Global Negative Symptoms Rating-Severity | NSA01-Global Neg Symptom Rating-Severity | NSA0118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054443","NSA-16 - Global Level of Functioning","C121095","Negative Symptom Assessment-16 (NSA-16) Global level of functioning.","NSA-16 - Global Level of Functioning | NSA01-Global Level of Functioning | NSA0119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055605","APACHE II - Temperature, Rectal","C121096","Acute Physiology and Chronic Health Evaluation II (APACHE II) Temperature - rectal (degree C).","APACHE II - Temperature, Rectal | APCH1-Temperature - Rectal | APCH101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055613","APACHE II - Mean Arterial Pressure","C121097","Acute Physiology and Chronic Health Evaluation II (APACHE II) Mean arterial pressure - mm Hg.","APACHE II - Mean Arterial Pressure | APCH1-Mean Arterial Pressure | APCH102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054221","Pediatric Nephrology Terminology","C123272","Terminology developed by a collaborative effort of the National Cancer Institute's Enterprise Vocabulary Services, the National Institute of Child Health and Human Development, and an international group of clinicians and informaticists to support the reporting of events in the pediatric population with issues pertaining to nephrology.","Pediatric Nephrology Terminology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055027","FDA Quality Metrics Terminology","C123273","Terminology developed to support activities regarding quality metrics within the FDA operations.","FDA Quality Metrics Terminology | Quality Metrics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053851","Warehouse Human Prescription Drug Products","C123274","Activities that include storing human prescription drug products prior to distribution to the points of dispensing.","Warehouse Human Prescription Drug Products | Warehouses human prescription drug products",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053529","COPDAC Regimen","C123278","A regimen consisting of cyclophosphamide, vincristine sulfate, prednisone and dacarbazine used for the treatment of male children with classical Hodgkin's lymphoma (HL).","COPDAC Regimen | COPDAC | Cyclophosphamide/Oncovin/Prednisone/Dacarbazine Regimen | Cyclophosphamide/Vincristine/Prednisone/Dacarbazine Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053642","Trilaciclib","C123281","A small molecule, competitive inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6), with potential antineoplastic and chemoprotective activities. Upon intravenous administration, trilaciclib binds to and inhibits the activity of CDK4/6, thereby blocking the phosphorylation of the retinoblastoma protein (Rb) in early G1. This prevents G1/S phase transition, causes cell cycle arrest in the G1 phase, induces apoptosis, and inhibits the proliferation of CDK4/6-overexpressing tumor cells. In patients with CDK4/6-independent tumor cells, G1T28 may protect against multi-lineage chemotherapy-induced myelosuppression (CIM) by transiently and reversibly inducing G1 cell cycle arrest in hematopoietic stem and progenitor cells (HSPCs) and preventing transition to the S phase. This protects all hematopoietic lineages, including red blood cells, platelets, neutrophils and lymphocytes, from the DNA-damaging effects of certain chemotherapeutics and preserves the function of the bone marrow and the immune system. CDKs are serine/threonine kinases involved in the regulation of the cell cycle and may be overexpressed in certain cancer cell types. HSPCs are dependent upon CDK4/6 for proliferation.","Trilaciclib | 2'-((5-(4-Methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one | G1T28 | Spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)- | TRILACICLIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1613950","Influenza A (H5N1) Virus","C123490","A strain of avian influenza A virus. This strain has caused major outbreaks in domestic poultry in parts of Asia and the Middle East and can cause infections in humans.","Influenza A (H5N1) Virus | H5N1 Influenza Virus | HPAI H5N1 Virus | Highly Pathogenic Asian Avian Influenza A (H5N1) Virus | INFLUENZA A VIRUS SUBTYPE H5N1 | Influenza A Virus H5N1 Subtype | Influenza A/H5N1",,,,,,,,,,,,,,,"36676232","Influenza A virus subtype H5N1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320451","Iodamoeba butschlii","C123491","A species of nonpathogenic parasitic amoeba. Transmission of I. butschlii is by a fecal-oral route and infection is usually asymptomatic.","Iodamoeba butschlii | IODAMOEBA BUTSCHLII | Iodamoeba buetschlii",,,,,,,,,,,,,,,"4203603","Iodamoeba bütschlii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3896941","Palbociclib Isethionate","C120259","The isethionate salt form of palbociclib, an orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.","Palbociclib Isethionate | 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino(pyrido(2,3-d)pyrimidin-7(8h)-one mono(2-hydroxyethanesulfonate) | PALBOCICLIB ISETHIONATE | PD 0332991-0054 | PF-00080665-73",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898620","Late Pregnancy Loss","C120260","The loss of a pregnancy between 13 and 22 weeks.","Late Pregnancy Loss | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3898122","Normal Virilization","C120261","The normal development of male secondary sexual characteristics (such as hirsutism, deepening of the voice) in pubertal boys due to testosterone effects.","Normal Virilization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0777169","Lancet","C120263","A small, sharp, needle-like instrument that is used to puncture the skin.","Lancet | Blood Lancet",,,,,,,,,,,,,,,"4232069","Lancet",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3851031","anti-CD33/CD3 BiTE antibody AMG 330","C123332","A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) CD33 fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of eluvixtamab, this bispecific antibody binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD33 antigen found on CD33-expressing tumor cells. This activates and redirects CTLs to CD33-expressing tumor cells, which results in the CTL-mediated cell death of CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem cells and overexpressed on neoplastic cells in patients with acute myeloid leukemia.","Eluvixtamab | AMG 330 | AMG-330 | AMG330 | Anti-CD33/CD3 BiTE Antibody AMG 330 | BiTE Antibody AMG 330 | Bispecific T-cell Engager Antibody AMG 330 | CD33/CD3-directed Bispecific T-cell Engager Antibody AMG 330 | ELUVIXTAMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0917724","Microsporida","C123335","A taxonomic grouping of spore-forming, unicellular, and parasitic fungi that can be assigned to the Microsporidia phylum.","Microsporidia | MICROSPORIDIA | Microspora | Microsporea | Microsporida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1011299","Paenibacillus","C123336","A taxonomic grouping of facultative anaerobic, endospore-forming bacteria that can be assigned to the genus Paenibacillus.","Paenibacillus | ",,,,,,,,,,,,,,,"4015673","Paenibacillus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030410","Paracoccus","C123337","A taxonomic grouping of chemoorganoheterotrophic, facultative chemolitoautotrophic, methylotrophic and anaerobic bacteria that can be assigned to the genus of Paracoccus.","Paracoccus | ",,,,,,,,,,,,,,,"4189799","Paracoccus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040818","Trematoda","C123338","A taxonomic grouping of parasitic flatworms that can be assigned to the class Trematoda.","Trematoda | TREMATODA",,,,,,,,,,,,,,,"4086238","Trematode",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1059410","Solobacterium","C123339","A taxonomic grouping of none spore-forming, strict anaerobic Gram positive bacillus that can be assigned to the genus Solobacterium.","Solobacterium | ",,,,,,,,,,,,,,,"4188435","Solobacterium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032154","Plasmodium vivax","C123550","A protozoan parasite in the family Plasmodiidae. P. vivax is the most frequent and widely distributed causative agent of tertian malaria.","Plasmodium vivax | PLASMODIUM VIVAX",,,,,,,,,,,,,,,"4254260","Plasmodium vivax",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2615814","Shewanella algae","C123551","A species of Gram negative, facultatively anaerobic, rod-shaped bacterium in the family Shewanellaceae. This species is motile with a single polar flagellum. S. algae is found in warm marine environments throughout the world and is known to cause peritonitis, obstructive pneumonia, ear infections, bacteremia, and infections of skin, soft tissue, bone, and joints.","Shewanella algae | SHEWANELLA ALGAE",,,,,,,,,,,,,,,"4034347","Shewanella algae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1047161","Solobacterium moorei","C123552","A species of non-spore-forming, obligately anaerobic, Gram-positive bacillus in the family Erysipelotrichaceae. This species is positive for arginine dihydrolase, alpha- and beta-galactosidase, alpha-glucosidase, arginine arylamidase, proline arylamidase, and leucine arylamidase. S. moorei was initially isolated from human feces, is involved in human infection, and has been implicated as a causative agent of halitosis.","Solobacterium moorei | SOLOBACTERIUM MOOREI",,,,,,,,,,,,,,,"4189813","Solobacterium moorei",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055615","APACHE II - Heart Rate","C121098","Acute Physiology and Chronic Health Evaluation II (APACHE II) Heart rate (ventricular response).","APACHE II - Heart Rate | APCH1-Heart Rate | APCH103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055610","APACHE II - Respiratory Rate","C121099","Acute Physiology and Chronic Health Evaluation II (APACHE II) Respiratory rate (non-ventilated or ventilated).","APACHE II - Respiratory Rate | APCH1-Respiratory Rate | APCH104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053492","CDISC SEND Vital Signs Test Code Terminology","C120536","Terminology associated with the vital signs test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).","CDISC SEND Vital Signs Test Code Terminology | SEND Vital Signs Test Code | SEND-SVSTSTCD | SVSTSTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053491","CDISC SEND Vital Signs Test Name Terminology","C120537","Terminology associated with the vital signs test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).","CDISC SEND Vital Signs Test Name Terminology | SEND Vital Signs Test Name | SEND-SVSTST | SVSTST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2283745","Mucoromycotina","C120539","A taxonomic grouping of saprotrophic fungi in the Mucoromycotina subphylum.","Mucoromycotina | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0260180","Pupillometry","C120540","A technique used to measure the diameter of the pupil in response to stimuli.","Pupillometry | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0319527","Rhizomucor","C120541","A genus of fungi within the phylum Zygomycota that are ubiquitous in nature and generally not considered pathogenic. Most members of the Rhizomucor genus are thermophillic, produce sporangiophores, sporangiospores, and sporangia, and produce rudimentary rhizoids. Though rarely shown to be agents of infection, Rhizomucor species may cause zygomycosis.","Rhizomucor | RHIZOMUCOR",,,,,,,,,,,,,,,"4312459","Rhizomucor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053862","Virologic Response","C120544","A description of the change in viral disease status in response to treatment.","Virologic Response | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054449","Myocardial Contractility Measurement","C120545","An assessment of the intrinsic ability of the myocardium to contract, which subsequently determines the force (pressure) with which blood is ejected from both ventricles, and contributes to measured values like blood pressure and cardiac output.","Myocardial Contractility Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0317620","Lactobacillus gasseri","C123492","A species of Gram-positive, rod shaped, anaerobic bacteria in the phylum Firmicutes. This species is nonmotile and non spore forming. L. gasseri is found in the gastrointestinal tract and the vaginal tract where it produces lactic acid by fermentation; it also produces hydrogen peroxide. It is a causative agent of Fournier's gangrene.","Lactobacillus gasseri | LACTOBACILLUS GASSERI",,,,,,,,,,,,,,,"4324548","Lactobacillus gasseri",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0317650","Lactobacillus oris","C123493","A species of Gram-positive, rod shaped, facultatively anaerobic bacteria in the phylum Firmicutes. This species is nonmotile and non spore forming, catalase negative, and obligately heterofermentative, producing both D- and L-lactic acid. L. oris is a normal flora component of the human oral cavity and gastrointestinal tract.","Lactobacillus oris | LACTOBACILLUS ORIS",,,,,,,,,,,,,,,"4337815","Limosilactobacillus oris",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1080735","Lactobacillus paracasei","C123494","A species of Gram-positive, rod shaped, facultatively heterofermentative bacteria in the phylum Firmicutes. This species is nonmotile and non spore forming. L. paracasei is a normal flora component of the the human oral cavity and gastrointestinal tract. It may be considered a subspecies of Lactobacillus casei.","Lactobacillus paracasei | LACTOBACILLUS PARACASEI",,,,,,,,,,,,,,,"4034194","Lacticaseibacillus paracasei",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0317597","Lactobacillus rhamnosus","C123495","A species of Gram-positive, rod shaped, facultatively heterofermentative bacteria in the phylum Firmicutes. This species is nonmotile and non spore forming. L. paracasei is a normal flora component of the the human gastrointestinal tract and female reproductive tract. It is closely related to L. casei and L. paracasei.","Lactobacillus rhamnosus | LACTOBACILLUS RHAMNOSUS | Lactobacillus casei rhamnosus",,,,,,,,,,,,,,,"40277034","Lacticaseibacillus rhamnosus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0445725","Lactobacillus vaginalis","C123496","A species of Gram-positive, rod shaped, facultatively anaerobic, heterofermentative bacteria in the phylum Firmicutes that occur singly or in pairs or short chains. This species is nonmotile and non spore forming. L. vaginalis was isolated from the vaginas of patients suffering from trichomoniasis.","Lactobacillus vaginalis | LACTOBACILLUS VAGINALIS",,,,,,,,,,,,,,,"4034197","Limosilactobacillus vaginalis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1449851","Lactococcus lactis subsp lactis","C123497","A species of Gram positive, cocci shaped, lactic acid bacteria assigned to the phylum Firmicutes. It is used in the manufacturing of cultured milk products and differs from Lactococcus lactis subsp. cremoris by being more hardy to salt, pH, and high temperatures.","Lactococcus lactis subsp lactis | LACTOCOCCUS LACTIS SUBSP. LACTIS | Lactobacillus xylosus | Lactococcus lactis subsp. lactis | Streptococcus diacetilactis",,,,,,,,,,,,,,,"4243313","Lactococcus lactis subsp. lactis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0522384","Legionella pneumophila Serogroup 1","C123498","A subgroup of Legionella pneumophila differentiated by its antigenicity. Serogroup 1 is the serogroup most commonly associated with disease, responsible for 70-90% of cases of legionellosis.","Legionella pneumophila Serogroup 1 | LEGIONELLA PNEUMOPHILA SEROGROUP 1",,,,,,,,,,,,,,,"4013414","Legionella pneumophila serogroup 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0522385","Legionella pneumophila Serogroup 2","C123499","Subgroup 2 of Legionella pneumophila, differentiated by its antigenicity. Although this serogroup is rarely identified in infected individuals it causes clinical features similar to the pneumonia caused by other serogroups.","Legionella pneumophila Serogroup 2 | LEGIONELLA PNEUMOPHILA SEROGROUP 2",,,,,,,,,,,,,,,"4014195","Legionella pneumophila serogroup 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0522386","Legionella pneumophila Serogroup 3","C123500","Subgroup 3 of Legionella pneumophila, differentiated by its antigenicity.","Legionella pneumophila Serogroup 3 | LEGIONELLA PNEUMOPHILA SEROGROUP 3",,,,,,,,,,,,,,,"4013856","Legionella pneumophila serogroup 3",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0522387","Legionella pneumophila Serogroup 4","C123501","Subgroup 4 of Legionella pneumophila, differentiated by its antigenicity.","Legionella pneumophila Serogroup 4 | LEGIONELLA PNEUMOPHILA SEROGROUP 4",,,,,,,,,,,,,,,"4014196","Legionella pneumophila serogroup 4",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0522388","Legionella pneumophila Serogroup 5","C123502","Subgroup 5 of Legionella pneumophila, differentiated by its antigenicity.","Legionella pneumophila Serogroup 5 | LEGIONELLA PNEUMOPHILA SEROGROUP 5",,,,,,,,,,,,,,,"4013857","Legionella pneumophila serogroup 5",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0522389","Legionella pneumophila Serogroup 6","C123503","A subgroup of Legionella pneumophila differentiated by its antigenicity. Serogroup 6 is the second most common serogroup causing legionellosis, according to the frequency of isolation from clinical samples.","Legionella pneumophila Serogroup 6 | LEGIONELLA PNEUMOPHILA SEROGROUP 6",,,,,,,,,,,,,,,"4014197","Legionella pneumophila serogroup 6",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053571","GENC Entity 2","C123748","A geopolitical entity designated by the Geopolitical Entities, Names, anc Codes Standard (GENC).","GENC Entity 2 | 910 | ENTITY 2 | XCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055293","CRQ-SAS Follow-Up Administration Version - Performing Chores","C121033","Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) Performing chores (such as housework, shopping groceries).","CRQ-SAS Follow-Up Administration Version - Performing Chores | CRQ02-Performing Chores | CRQ0204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055294","CRQ-SAS Follow-Up Administration Version - Participate in Social Activities","C121034","Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) Participating in social activities.","CRQ-SAS Follow-Up Administration Version - Participate in Social Activities | CRQ02-Participate in Social Activities | CRQ0205",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055300","CRQ-SAS Follow-Up Administration Version - Felt Frustrated or Impatient","C121035","Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) In general, how much of the time during the last 2 weeks have you felt frustrated or impatient?","CRQ-SAS Follow-Up Administration Version - Felt Frustrated or Impatient | CRQ02-Felt Frustrated or Impatient | CRQ0206",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055302","CRQ-SAS Follow-Up Administration Version - Feeling of Fear or Panic","C121036","Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) How often during the last 2 weeks did you have a feeling of fear or panic when you had difficulty getting your breath?","CRQ-SAS Follow-Up Administration Version - Feeling of Fear or Panic | CRQ02-Feeling of Fear or Panic | CRQ0207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055308","CRQ-SAS Follow-Up Administration Version - Fatigue","C121037","Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) How about fatigue? How tired have you felt over the last 2 weeks?","CRQ-SAS Follow-Up Administration Version - Fatigue | CRQ02-Fatigue | CRQ0208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055310","CRQ-SAS Follow-Up Administration Version - Embarrassed by Coughing","C121038","Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) How often during the last 2 weeks have you felt embarrassed by your coughing or heavy breathing?","CRQ-SAS Follow-Up Administration Version - Embarrassed by Coughing | CRQ02-Embarrassed by Coughing | CRQ0209",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055307","CRQ-SAS Follow-Up Administration Version - Feel Confident to Deal With Illness","C121039","Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) In the last 2 weeks, how much of the time did you feel very confident and sure that you could deal with your illness?","CRQ-SAS Follow-Up Administration Version - Feel Confident to Deal With Illness | CRQ02-Confident to Deal With Illness | CRQ0210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055309","CRQ-SAS Follow-Up Administration Version - Energy","C121040","Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) How much energy have you had in the last 2 weeks?","CRQ-SAS Follow-Up Administration Version - Energy | CRQ02-Energy | CRQ0211",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055304","CRQ-SAS Follow-Up Administration Version - Feel Upset, Worried or Depressed","C121041","Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) In general, how much of the time did you feel upset, worried, or depressed during the last 2 weeks?","CRQ-SAS Follow-Up Administration Version - Feel Upset, Worried or Depressed | CRQ02-Feel Upset, Worried or Depressed | CRQ0212",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055306","CRQ-SAS Follow-Up Administration Version - Feel Relaxed and Free of Tension","C121043","Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) How much of the time during the last 2 weeks did you feel relaxed and free of tension?","CRQ-SAS Follow-Up Administration Version - Feel Relaxed and Free of Tension | CRQ02-Feel Relaxed and Free of Tension | CRQ0214",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0445672","Nutritionally Variant Streptococcus","C123554","A bacterium that is assigned to the genus Streptococcus that is incapable of supporting its own growth on standard culture plates but can sustain growth using substances released into the medium by the dominant colonies. These Streptococci require L-cysteine for growth. They have been identified as an etiologic agent of endocarditis and other infections.","Nutritionally Variant Streptococcus | NVS | Nutritionally Variant Streptococci | STREPTOCOCCUS NUTRITIONALLY VARIANT",,,,,,,,,,,,,,,"44784186","Nutritionally variant streptococci",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054669","Lactobacillus-based Probiotic Capsule","C120549","A capsule containing a strain of the probiotic bacterium Lactobacillus with potential antimicrobial and immunomodulatory activities. As a dietary supplement, Lactobacillus, a naturally-occurring bacteria, may improve digestion and help maintain adequate colonization of the gastrointestinal (GI) tract by modulating the composition of the normal microflora. Because it produces lactic acid and hydrogen peroxide and other substances during fermentation, this bacterium creates an acidic environment that is unfavorable for pathogens. In addition, during colonization of the GI tract, this bacterium adheres to human epithelial cells and forms a protective barrier, thereby preventing the attachment of pathogens. Dietary supplementation with this bacterium has been shown to enhance innate and acquired immunity.","Lactobacillus-based Probiotic Capsule | Lactobacillus-based Capsule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053570","GENC Entity 3","C123749","A geopolitical entity designated by the Geopolitical Entities, Names, anc Codes Standard (GENC).","GENC Entity 3 | 911 | ENTITY 3 | XCY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053569","GENC Entity 4","C123750","A geopolitical entity designated by the Geopolitical Entities, Names, anc Codes Standard (GENC).","GENC Entity 4 | 912 | ENTITY 4 | XKM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053568","GENC Entity 5","C123751","A geopolitical entity designated by the Geopolitical Entities, Names, anc Codes Standard (GENC).","GENC Entity 5 | 913 | ENTITY 5 | XKN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049920","GENC Entity 6","C123752","A geopolitical entity designated by the Geopolitical Entities, Names, anc Codes Standard (GENC).","GENC Entity 6 | 914 | A3 | AX3 | ENTITY 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050518","Europa Island","C123753","An atoll in the Mozambique channel between southern Madagascar and southern Mozambique.","Europa Island | 915 | EUROPA ISLAND | XE | XEU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017209","Gaza Strip","C123754","360 square kilometers in the Middle East, bordering the Mediterranean Sea, between Egypt and Israel.","Gaza Strip | 916 | GAZA STRIP | XG | XGZ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053565","Glorioso Islands","C123755","A group of French islands and rocks in the northern Mozambique channel, northwest of Madagascar.","Glorioso Islands | 917 | GLORIOSO ISLANDS | QX | XGL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049889","Guantanamo Bay Naval Base","C123756","A US Navy military base located on Guantanamo Bay in Cuba.","Guantanamo Bay Naval Base | 918 | A2 | AX2 | GUANTANAMO BAY NAVAL BASE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053563","Jan Mayen [Island]","C123760","An island in Northern Europe, between the Greenland Sea and the Norwegian Sea.","Jan Mayen | 920 | JAN MAYEN | XJ | XJM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050520","Jarvis Island","C123761","An island in the South Pacific Ocean between Hawaii and the Marshall Islands.","Jarvis Island | 921 | JARVIS ISLAND | XJV | XQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3846574","Johnston Atoll","C123762","An island in the North Pacific Ocean, between Hawaii and the Marshall Islands.","Johnston Atoll | 922 | JOHNSTON ATOLL | XJA | XU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053566","Juan de Nova Island","C123763","An island in the Mozambique Channel, between Madagascar and Mozambique.","Juan de Nova Island | 923 | JUAN DE NOVA ISLAND | QU | XJN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049853","Kingman Reef","C123764","A reef in the North Pacific Ocean, between Hawaii and American Samoa.","Kingman Reef | 924 | KINGMAN REEF | XKR | XM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055299","CRQ-SAS Follow-Up Administration Version - Felt Low in Energy","C121044","Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) How often during the last 2 weeks have you felt low in energy?","CRQ-SAS Follow-Up Administration Version - Felt Low in Energy | CRQ02-Felt Low in Energy | CRQ0215",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054749","IGF1R Gene Product","C120491","A protein encoded by the IGF1R gene.","IGF1R Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086584","Minibody","C123812","An engineered antibody comprised of a dimeric complex consisting of two immunoglobulin fragments. Each fragment consists of a single chain variable fragment (scFv) joined to a heavy CH3 domain by a linker peptide. The dimer is formed by interactions between the two CH3 domains; additionally, the linker peptide may stabilize the dimer.","Minibody | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1852406","Beare-Stevenson Cutis Gyrata Syndrome","C123813","A rare, autosomal dominant inherited disorder caused by mutations in the FGFR2 gene. It is characterized by the premature fusion of the bones of the skull (craniosynostosis) and a skin abnormality called cutis gyrata. The craniosynostosis results in a cloverleaf-shaped skull, wide-set eyes, ear abnormalities, underdeveloped upper jaw, and developmental delays. Cutis gyrata is characterized by a wrinkled skin appearance, especially on the face, near the ears, and on the palms and soles.","Beare-Stevenson Cutis Gyrata Syndrome | ",,,,,,,,,,,,,,,"45773093","Cutis gyrata syndrome of Beare and Stevenson",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0795998","Jackson-Weiss Syndrome","C123814","A rare, autosomal dominant inherited disorder caused by mutations in the FGFR2 gene. It is characterized by the premature fusion of the bones of the skull (craniosynostosis) and foot abnormalities. The craniosynostosis results in a malformed skull, widely spaced eyes, and a bulging forehead. The foot abnormalities consist of short and wide first toes, which bend away from the other toes. In addition, syndactyly in some toes may be present. The hands are almost always normal.","Jackson-Weiss Syndrome | ",,,,,,,,,,,,,,,"46271070","Jackson-Weiss syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0796081","Myhre Syndrome","C123815","A rare, autosomal dominant inherited disorder caused by mutations in the SMAD4 gene.  It is characterized by developmental abnormalities, mild to moderate intellectual disability, hearing loss, skin stiffness, skeletal abnormalities, and typical facial features (short palpebral fissures, shortened distance between the nose and upper lip, midface hypoplasia, prognathism, cleft palate, and/or cleft lip).","Myhre Syndrome | ",,,,,,,,,,,,,,,"44783252","Myhre syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054397","Nephrotic Syndrome - ARHGDIA Associated","C123071","Nephrotic syndrome attributed to mutation(s) in the ARHGDIA gene.","Nephrotic Syndrome - ARHGDIA Associated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896913","CYP17 Lyase Inhibitor ASN001","C120310","An orally available non-steroidal, lyase-selective inhibitor of the steroid 17-alpha-hydroxylase/C17,20 lyase (CYP17A1 or CYP17), with potential anti-androgenic and antineoplastic activities. Upon oral administration, CYP17 lyase inhibitor ASN001 selectively binds to and inhibits the lyase activity of CYP17A1 in both the testes and adrenal glands, resulting in a significant reduction in androgen production to castrate-range levels. This may both decrease androgen-dependent growth signaling and inhibit the proliferation of androgen-dependent tumor cells. The cytochrome P450 enzyme CYP17A1, which is localized to the endoplasmic reticulum, exhibits both 17alpha-hydroxylase and 17,20-lyase activities; it plays a key role in the steroidogenic pathway. The selective inhibition of CYP17A1 lyase activity by ASN001 prevents the increased synthesis of mineralocorticoids that is normally seen with non-selective CYP17 inhibitors, which also inhibit the 17-alpha-hydroxylase activity of CYP17A1.","CYP17 Lyase Inhibitor ASN001 | ASN001 | EN-3356",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0665292","meta-Fluorine F 18 Fluorobenzylguanidine","C120311","A radioconjugate composed of the positron-emitting radioisotope fluorine F 18 labeled benzylguanidine, a synthetic analogue of the adrenergic neurotransmitter norepinephrine (NE), with potential use in the diagnostic imaging of human norepinephrine transporter (hNET)-expressing cells by either positron emitting tomography (PET) or computed tomography (CT). Upon administration, florbenguane F18 is taken up by and accumulates in both the granules of adrenal medullary chromaffin cells and the pre-synaptic granules of adrenergic neurons in a manner almost identical to that of NE. In turn, hNET-expressing tumor cells can be imaged by PET or CT. hNET, a transmembrane protein and regulator of catecholamine uptake normally restricted to the central and peripheral sympathetic nervous system, is overexpressed in certain tumor cell types.","Florbenguane F18 | 18F meta-Fluoro Benzylguanidine | 18F-MFBG | FLORBENGUANE F-18 | Florbenguane (18F) | IRP 101 | IRP-101 | M-(18F)-FLUOROBENZYLGUANIDINE | Meta-fluoro Benzylguanidine F-18 | [(18)F]-MFBG | meta-Fluorine F 18 Fluorobenzylguanidine | meta-Fluorine F 18 Fluorobenzylguanidine | meta-[(18)F]-Fluorobenzylguanidine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0074765","Sodium Selenate","C1229","The sodium salt of selenium.  As a trace mineral that is toxic in high doses, selenium is a cofactor for glutathione peroxidase, an anti-oxidant enzyme that neutralizes hydrogen peroxide.  Selenium may be chemoprotective for certain cancers, particularly prostate cancer.  High dietary supplementation with sodium selenate may inhibit the progression of hormone-refractory prostate cancer due, in part, to an antiangiogenesis effect. (NCI04)","Sodium Selenate | SODIUM SELENATE | Selenate, Sodium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0072522","polysaccharide-K","C1204","A protein-bound polysaccharide derived from the mushroom Trametes versicolor (Turkey Tail) with immunoadjuvant and potential antitumor activities. Although its mechanism of action has yet to be fully elucidated, in vitro and in vivo studies indicate that polysaccharide-K induces peripheral blood monocyte secretion of IL-8 and TNF-alpha, induces T cell proliferation, and prevents cyclophosphamide-induced immunosuppression. This agent has also been reported to stimulate macrophages to produce reactive nitrogen intermediates and superoxide anions and to promote apoptosis in the promyelocytic leukemia cell line HL-60.","Polysaccharide-K | Glycoproteins | KS-2 | Krestin | PSK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054396","Nephrotic Syndrome - CD2AP Associated","C123072","Nephrotic syndrome attributed to mutation(s) in the CD2AP gene.","Nephrotic Syndrome - CD2AP Associated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054395","Nephrotic Syndrome - CFH Associated","C123073","Nephrotic syndrome attributed to mutation(s) in the CFH gene.","Nephrotic Syndrome - CFH Associated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054394","Nephrotic Syndrome - COQ2 Associated","C123074","Nephrotic syndrome attributed to mutation(s) in the COQ2 gene.","Nephrotic Syndrome - COQ2 Associated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054393","Nephrotic Syndrome - COQ6 Associated","C123075","Nephrotic syndrome attributed to mutation(s) in the COQ6 gene.","Nephrotic Syndrome - COQ6 Associated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054392","Nephrotic Syndrome - CRB2 Associated","C123076","Nephrotic syndrome attributed to mutation(s) in the CRB2 gene.","Nephrotic Syndrome - CRB2 Associated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054390","Nephrotic Syndrome - Cytomegalovirus Associated","C123078","Nephrotic syndrome associated with a cytomegalovirus infection.","Nephrotic Syndrome - Cytomegalovirus Associated | Cytomegalovirus Associated Nephrotic Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054389","Nephrotic Syndrome - DGKE Associated","C123079","Nephrotic syndrome attributed to mutation(s) in the DGKE gene.","Nephrotic Syndrome - DGKE Associated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054388","Nephrotic Syndrome - EMP2 Associated","C123080","Nephrotic syndrome attributed to mutation(s) in the EMP2 gene.","Nephrotic Syndrome - EMP2 Associated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054387","Nephrotic Syndrome - Epstein-Barr Virus Associated","C123081","Nephrotic syndrome associated with Epstein-Barr infection.","Nephrotic Syndrome - Epstein-Barr Virus Associated | Epstein-Barr Virus Associated Nephrotic Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054386","Nephrotic Syndrome - Hepatitis B Virus Associated","C123082","Nephrotic syndrome associated with hepatitis B.","Nephrotic Syndrome - Hepatitis B Virus Associated | Hepatitis B Virus Associated Nephrotic Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054385","Nephrotic Syndrome - Hepatitis C Virus Associated","C123083","Nephrotic syndrome associated with a hepatitis C infection.","Nephrotic Syndrome - Hepatitis C Virus Associated | Hepatitis C Virus Associated Nephrotic Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054383","Nephrotic Syndrome - INF2 Associated","C123085","Nephrotic syndrome attributed to mutation(s) in the INF2 gene.","Nephrotic Syndrome - INF2 Associated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054380","Nephrotic Syndrome - Infection Associated","C123086","Nephrotic syndrome associated with an infectious process.","Nephrotic Syndrome - Infection Associated | Infection Associated Nephrotic Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054382","Nephrotic Syndrome - ITGA3 Associated","C123087","Nephrotic syndrome attributed to mutation(s) in the ITGA3 gene.","Nephrotic Syndrome - ITGA3 Associated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054381","Nephrotic Syndrome - ITGB4 Associated","C123088","Nephrotic syndrome attributed to mutation(s) in the ITGB4 gene.","Nephrotic Syndrome - ITGB4 Associated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054379","Nephrotic Syndrome - LAMB2 Associated","C123089","Nephrotic syndrome attributed to mutation(s) in the LAMB2 gene.","Nephrotic Syndrome - LAMB2 Associated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054378","Nephrotic Syndrome - LMX1B Associated","C123090","Nephrotic syndrome attributed to mutation(s) in the LMX1B gene.","Nephrotic Syndrome - LMX1B Associated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3661262","HDAC Inhibitor MPT0E028","C120312","An orally bioavailable N-hydroxyacrylamide-derived inhibitor of both human pan-histone deacetylase (HDAC) enzymes and the serine/threonine protein kinase Akt (protein kinase B), with potential antineoplastic activity. Upon administration, HDAC inhibitor MPT0E028 selectively binds to and inhibits HDACs, which inhibits deacetylation of histone proteins and leads to the accumulation of highly acetylated histones. This may result in both an induction of chromatin remodeling, and the selective transcription of tumor suppressor genes. This prevents cell division and induces both cell cycle arrest and apoptosis, which may inhibit the proliferation of susceptible tumor cells. In addition, MPT0E028 inhibits the phosphorylation and activation of Akt, which prevents the activation of downstream signaling pathways, independent of its HDAC inhibitory activity. HDACs, upregulated in many tumor cell types, are a family of enzymes that deacetylate histone proteins. Akt, overexpressed in many tumor cell types, plays a key role in tumor cell proliferation and survival.","HDAC Inhibitor MPT0E028 | (E)-N-hydroxy-3-(1-(phenylsulfonyl)indolin-5-yl)acrylamide | 3-(1-Benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxy-acrylamide | MPT 0E028 | MPT-0E028 | MPT0E028",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896945","S-equol","C120313","An orally bioavailable, non-steroidal estrogen naturally produced by the metabolism of the isoflavonoid daidzein by human intestinal microflora, with potential chemoprotective and estrogen receptor (ER) modulating activities. S-equol preferentially binds to and activates the beta isoform of ER in certain target tissues, while having an antagonistic effect in other tissues. This modulates the expression of ER-responsive genes in a tissue-specific manner. This agent may increase bone mineral density, affect vasomotor symptoms, and may decrease the proliferation rate of susceptible cancer cells. In addition, this agent interferes with the activity of enzymes involved in steroid biosynthesis. S-equol inhibits dihydrotestosterone (DHT) production and may inhibit the proliferation of androgen-driven prostate cancer. S-equol is the biologically active enantiomer while R-equol is essentially inactive and has a weak affinity for alpha-ER.","S-equol | (-)-Equol | (3S)-3,4-dihydro-3-(4-hydroxyphenyl)-2H-1-benzopyran-7-ol | 2H-1-benzopyran-7-ol, 3,4-Dihydro-3-(4-hydroxyphenyl)-, (3S)- | EQUOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055573","AVLT-REY - List B Word 4","C123703","The Rey Auditory Verbal Learning TEST (AVLT-REY) List B, Word 4.","AVLT-REY - List B Word 4 | AVL02-List B Word 4 | AVL0221",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055572","AVLT-REY - List B Word 5","C123704","The Rey Auditory Verbal Learning TEST (AVLT-REY) List B, Word 5.","AVLT-REY - List B Word 5 | AVL02-List B Word 5 | AVL0222",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055571","AVLT-REY - List B Word 6","C123705","The Rey Auditory Verbal Learning TEST (AVLT-REY) List B, Word 6.","AVLT-REY - List B Word 6 | AVL02-List B Word 6 | AVL0223",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055570","AVLT-REY - List B Word 7","C123706","The Rey Auditory Verbal Learning TEST (AVLT-REY) List B, Word 7.","AVLT-REY - List B Word 7 | AVL02-List B Word 7 | AVL0224",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053788","AVLT-REY - List B Word 9","C123708","The Rey Auditory Verbal Learning TEST (AVLT-REY) List B, Word 9.","AVLT-REY - List B Word 9 | AVL02-List B Word 9 | AVL0226",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055582","AVLT-REY - List B Word 10","C123709","The Rey Auditory Verbal Learning TEST (AVLT-REY) List B, Word 10.","AVLT-REY - List B Word 10 | AVL02-List B Word 10 | AVL0227",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055581","AVLT-REY - List B Word 11","C123710","The Rey Auditory Verbal Learning TEST (AVLT-REY) List B, Word 11.","AVLT-REY - List B Word 11 | AVL02-List B Word 11 | AVL0228",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055580","AVLT-REY - List B Word 12","C123711","The Rey Auditory Verbal Learning TEST (AVLT-REY) List B, Word 12.","AVLT-REY - List B Word 12 | AVL02-List B Word 12 | AVL0229",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055579","AVLT-REY - List B Word 13","C123712","The Rey Auditory Verbal Learning TEST (AVLT-REY) List B, Word 13.","AVLT-REY - List B Word 13 | AVL02-List B Word 13 | AVL0230",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268769","Chronic Urate Nephropathy","C123013","Chronic kidney disease resulting from deposition of urate crystals or microtophi in the medullary interstitium.","Chronic Urate Nephropathy | ",,,,,,,,,,,,,,,"192276","Chronic gouty nephropathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2584556","Drug-Induced Tubulointerstitial Nephritis","C123014","Tubulointerstitial nephritis resulting from a drug exposure.","Drug-Induced Tubulointerstitial Nephritis | ",,,,,,,,,,,,,,,"4208918","Drug-induced tubulointerstitial nephritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053631","PSA/PSMA DNA Plasmid INO-5150","C123283","A plasmid DNA vaccine encoding the tumor-associated antigens (TAAs) prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA), with potential immunoactivating and antineoplastic activities. Upon intramuscular delivery and electroporation of the PSA/PSMA DNA plasmid INO-5150, both PSA and PSMA are translated in cells which then activate the immune system. This induces cytotoxic T-lymphocyte (CTL) responses against tumor cells expressing PSA and PSMA. This may result in both immune-mediated tumor cell death and the inhibition of tumor cell proliferation. PSA and PSMA are overexpressed on a variety of cancer cell types. The DNA encoding the TAAs in INO-5150 is based on both human and other primate antigen gene sequences. As the plasmid genes differ from the human gene sequences encoding these antigens, INO-5150 may overcome immune tolerance to human TAAs.","PSA/PSMA DNA Plasmid INO-5150 | INO 5150 | INO-5150 | PSA/PSMA Synthetic DNA Vaccine INO-5150 | PSA/PSMA-encoding DNA Plasmid INO-5150",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0967624","Antibody-drug Conjugate SC-002","C123284","An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3), site-specifically conjugated to the cytotoxic pyrrolobenzodiazepine (PBD) dimer SC-DR002 via a plasma-stable valine-alanine dipeptide linker, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of anti-DLL3 ADC SC-002 targets and binds to DLL3 expressed on tumor cells. Upon binding and internalization, the dipeptide linker is cleaved upon cathepsin-mediated proteolysis and SC-DR002 is released. Then the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of DLL3-overexpressing tumor cells. DLL3, a membrane protein that binds to Notch receptors and regulates Notch-mediated signaling and gene transcription, is overexpressed by certain cancers but is rarely expressed by normal, healthy cells.","Anti-DLL3 Antibody-drug Conjugate SC-002 | ADC SC-002 | Anti-DLL3 ADC SC-002 | Antibody-drug Conjugate SC-002 | SC 002 | SC-002 | SC002",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1134443","anastrozole/trastuzumab","C12027","A regimen consisting of anastrozole and trastuzumab that may be used in the treatment of hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2)-positive breast cancer.","Anastrozole/Trastuzumab Regimen | Anastrozole and Trastuzumab | Anastrozole and Trastuzumab-anns | Anastrozole and Trastuzumab-dkst | Anastrozole and Trastuzumab-dttb | Anastrozole and Trastuzumab-herw | Anastrozole and Trastuzumab-pkrb | Anastrozole and Trastuzumab-qyyp | Anastrozole and Trastuzumab-strf | Anastrozole and Trastuzumab-zerc | Anastrozole-Trastuzumab | Anastrozole-Trastuzumab Regimen | Anastrozole/Trastuzumab | Arimidex-Herceptin | Arimidex/Herceptin | Herceptin-Arimidex | Trastuzumab-Anastrozole | Trastuzumab/Anastrozole | Trastuzumab/Anastrozole Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054375","Nephrotic Syndrome - Malaria Associated","C123091","Nephrotic syndrome associated with malaria.","Nephrotic Syndrome - Malaria Associated | Malaria Associated Nephrotic Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054377","Nephrotic Syndrome - MEFV Associated","C123092","Nephrotic syndrome attributed to mutation(s) in the MEFV gene.","Nephrotic Syndrome - MEFV Associated | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055578","AVLT-REY - List B Word 14","C123713","The Rey Auditory Verbal Learning TEST (AVLT-REY) List B, Word 14.","AVLT-REY - List B Word 14 | AVL02-List B Word 14 | AVL0231",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055577","AVLT-REY - List B Word 15","C123714","The Rey Auditory Verbal Learning TEST (AVLT-REY) List B, Word 15.","AVLT-REY - List B Word 15 | AVL02-List B Word 15 | AVL0232",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055583","AVLT-REY - List B Total","C123715","The Rey Auditory Verbal Learning TEST (AVLT-REY) The number of words recalled from List B trial.","AVLT-REY - List B Total | AVL02- List B Total | AVL0233",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055584","AVLT-REY - List B Intrusions","C123716","The Rey Auditory Verbal Learning TEST (AVLT-REY) The number of intrusions while recalling from List B trial.","AVLT-REY - List B Intrusions | AVL02-List B Intrusions | AVL0234",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055567","AVLT-REY - Recognition Total","C123717","The Rey Auditory Verbal Learning TEST (AVLT-REY) The number of words correct on recognition test.","AVLT-REY - Recognition Total | AVL02-Recognition Total | AVL0235",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055568","AVLT-REY - Recognition Intrusions","C123718","The Rey Auditory Verbal Learning TEST (AVLT-REY) The number of intrusions on recognition test.","AVLT-REY - Recognition Intrusions | AVL02-Recognition Intrusions | AVL0236",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053611","Polyethylene Glycol 3350-containing Enema NER1008","C123719","An enema containing the osmotic agent polyethylene glycol (PEG) 3350, also called macrogol 3350, with laxative activity. Upon rectal administration of the PEG3350-containing enema NER1008, PEG creates an osmotic gradient, which promotes the retention of water in the bowel. This increases the water content of stool, which results in increased gastrointestinal (GI) motility, decreased stool transit time and evacuation of colonic contents.","Polyethylene Glycol 3350-containing Enema NER1008 | Movidra | NER1008 | NER1008 Enema | PEG3350-containing Enema NER1008",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086444","Hepatic Thrombosis","C123898","Formation of a blood clot (thrombus) in the lumen of the veins in the liver or hepatic artery.","Hepatic Thrombosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3805052","Splenic Thrombosis","C123899","Formation of a blood clot (thrombus) in the lumen of the splenic vein or splenic artery.","Splenic Thrombosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4082928","Mesenteric Thrombosis","C123900","Formation of a blood clot (thrombus) in the lumen of a mesenteric vein or mesenteric artery.","Mesenteric Thrombosis | ",,,,,,,,,,,,,,,"4317289","Thrombosis of mesenteric vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086365","Gonadal Thrombosis","C123901","Formation of a blood clot (thrombus) in the lumen of the vein that carries blood away from the testis or ovary.","Gonadal Thrombosis | Gonadal Vein Thrombosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0522390","Legionella pneumophila Serogroup 7","C123504","Subgroup 7 of Legionella pneumophila, differentiated by its antigenicity.","Legionella pneumophila Serogroup 7 | LEGIONELLA PNEUMOPHILA SEROGROUP 7",,,,,,,,,,,,,,,"4014198","Legionella pneumophila serogroup 7",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0522391","Legionella pneumophila Serogroup 8","C123505","Subgroup 8 of Legionella pneumophila, differentiated by its antigenicity.","Legionella pneumophila Serogroup 8 | LEGIONELLA PNEUMOPHILA SEROGROUP 8",,,,,,,,,,,,,,,"4013415","Legionella pneumophila serogroup 8",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0522392","Legionella pneumophila Serogroup 9","C123506","Subgroup 9 of Legionella pneumophila, differentiated by its antigenicity.","Legionella pneumophila Serogroup 9 | LEGIONELLA PNEUMOPHILA SEROGROUP 9",,,,,,,,,,,,,,,"4011493","Legionella pneumophila serogroup 9",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023271","Leishmania braziliensis","C123507","A species of parasitic trypanosomatid protozoa in the family Trypanosomatidae. L. braziliensis is a New World pathogen. As well as causing localized cutaneous lesions in affected people, this species can also result in a destructive, progressive infection of mucosal tissue.","Leishmania braziliensis | LEISHMANIA BRAZILIENSIS | Leishmania brasiliensis | Leishmania viannia",,,,,,,,,,,,,,,"4307954","Leishmania braziliensis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023273","Leishmania donovani","C123508","A species of parasitic trypanosomatid protozoa in the family Trypanosomatidae. L. donovani causes both visceral and dermal leishmaniasis. This species is the primary cause of visceral leishmaniasis in the Indian subcontinent and East Africa.","Leishmania donovani | LEISHMANIA DONOVANI",,,,,,,,,,,,,,,"4196345","Leishmania donovani complex",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023272","Leishmania infantum","C123509","A species of parasitic trypanosomatid protozoa in the family Trypanosomatidae. L. infantum is the causative agent of infantile visceral leishmaniasis in the Mediterranean region and in Latin America.","Leishmania infantum | LEISHMANIA INFANTUM | Leishmania chagasi | Leishmania donovani infantum",,,,,,,,,,,,,,,"4087866","Leishmania infantum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023277","Leishmania mexicana","C123510","A species of parasitic trypanosomatid protozoa in the family Trypanosomatidae. L. mexicana is endemic in South and Central America and causes the mildest form of leishmaniasis.","Leishmania mexicana | LEISHMANIA MEXICANA",,,,,,,,,,,,,,,"4085766","Leishmania mexicana",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023280","Leishmania tropica","C123511","A species of parasitic trypanosomatid protozoa in the family Trypanosomatidae. L. tropica infection results in a non-ulcerating disease.","Leishmania tropica | LEISHMANIA TROPICA | Leishmania tropica minor",,,,,,,,,,,,,,,"4085612","Leishmania tropica",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023924","Loa loa","C123512","A species of parasitic nematodes in the family Onchocercidae. The lifecycle of L. loa involves deer flies as the intermediate host and humans as the definitive host. Infestation causes loa loa filariasis (loiasis).","Loa loa | Eye Worm | LOA LOA",,,,,,,,,,,,,,,"4165717","Loa loa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1416492","ITGAD Gene","C120290","This gene plays a role in cell-cell and cell-extracellular matrix interactions.","ITGAD Gene | ITGAD | Integrin, Alpha D Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3889470","ITGAD wt Allele","C120291","Human ITGAD wild-type allele is located in the vicinity of 16p11.2 and is approximately 33 kb in length. This allele, which encodes integrin alpha-D protein, is involved in both cell-cell and cell-extracellular matrix interactions and cell communication.","ITGAD wt Allele | ADB2 | CD11D | Integrin, Alpha D wt Allele | Integrin, Alpha-D Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055301","CRQ-SAS Follow-Up Administration Version - Felt Discouraged or Down","C121045","Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) In general, how often during the last 2 weeks have you felt discouraged or down in the dumps?","CRQ-SAS Follow-Up Administration Version - Felt Discouraged or Down | CRQ02-Felt Discouraged or Down | CRQ0216",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055297","CRQ-SAS Follow-Up Administration Version - Felt Worn Out or Sluggish","C121046","Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) How often during the last 2 weeks have you felt worn out or sluggish?","CRQ-SAS Follow-Up Administration Version - Felt Worn Out or Sluggish | CRQ02-Felt Worn Out or Sluggish | CRQ0217",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055295","CRQ-SAS Follow-Up Administration Version - Happy, Satisfied or Pleased With Life","C121047","Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) How happy, satisfied, or pleased have you been with your personal life during the last 2 weeks?","CRQ-SAS Follow-Up Administration Version - Happy, Satisfied or Pleased With Life | CRQ02-Happy, Satisfied or Pleased | CRQ0218",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055305","CRQ-SAS Follow-Up Administration Version - Feel Upset When Had Difficulty Getting Breath","C121048","Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) How often during the last 2 weeks did you feel upset or scared when you had difficulty getting your breath?","CRQ-SAS Follow-Up Administration Version - Feel Upset When Had Difficulty Getting Breath | CRQ02-Feel Upset Diff Getting Breath | CRQ0219",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055298","CRQ-SAS Follow-Up Administration Version - Felt Restless, Tense or Uptight","C121049","Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) In general, how often during the last 2 weeks have you felt restless, tense, or uptight?","CRQ-SAS Follow-Up Administration Version - Felt Restless, Tense or Uptight | CRQ02-Felt Restless, Tense or Uptight | CRQ0220",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055411","BACS - Number of Items Recalled Total","C121051","Brief Assessment of Cognition in Schizophrenia (BACS) Verbal Memory: Total number of items recalled.","BACS - Number of Items Recalled Total | BACS1-Number of Items Recalled Total | BACS101A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055412","BACS - Number of Correct Sequences","C121052","Brief Assessment of Cognition in Schizophrenia (BACS) Digit Sequencing: Number of correct sequences.","BACS - Number of Correct Sequences | BACS1-Number of Correct Sequences | BACS102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498266","CDK2/5/9 inhibitor CYC065","C123902","An orally bioavailable inhibitor of cyclin dependent kinases 2, 5 and 9 (CDK2/5/9), with potential antineoplastic and chemoprotective activities. Upon oral administration, fadraciclib selectively binds to and inhibits the activity of CDK2, 5 and 9, which leads to inhibition of CDK2, 5 and 9-dependent cellular pathways, downregulation of genes involved in the pro-survival pathway, prevention of the activation of DNA double-strand break repair pathways, and induction of both cell cycle arrest and apoptosis. This inhibits the proliferation of CDK2/5/9-overexpressing tumor cells. In addition, CYC065 protects hematopoietic stem and progenitor cells (HSPCs), prevents myelosuppression, and preserves the function of the bone marrow. CDKs are serine/threonine kinases involved in the regulation of the cell cycle and may be overexpressed in certain cancer cell types; they play key roles in tumor cell proliferation, the regulation of transcription, and DNA damage repair.","Fadraciclib | CYC065 | Cyclin Dependent Kinase Inhibitor 2/5/9 CYC065 | FADRACICLIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086178","Childhood Thyroid Gland Papillary Carcinoma","C123903","A papillary thyroid gland carcinoma occurring during childhood.","Childhood Thyroid Gland Papillary Carcinoma | Childhood Papillary Thyroid Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086176","Childhood Thyroid Gland Follicular Carcinoma","C123904","A follicular thyroid gland carcinoma occurring in childhood.","Childhood Thyroid Gland Follicular Carcinoma | Childhood Follicular Thyroid Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086177","Childhood Thyroid Gland Medullary Carcinoma","C123905","A medullary thyroid gland carcinoma occurring in childhood.","Childhood Thyroid Gland Medullary Carcinoma | Childhood Medullary Thyroid Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086159","Childhood Gastrointestinal Stromal Tumor","C123906","A gastrointestinal stromal tumor (GIST) occurring in childhood. Pediatric GISTs differ biologically from adult GISTs in that only 11% of pediatric GISTs have activating mutations of KIT and PDGFRA.","Childhood Gastrointestinal Stromal Tumor | Childhood GIST | Gastrointestinal Stromal Tumor (GIST)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086162","Childhood Malignant Kidney Neoplasm","C123907","A malignant neoplasm that affects the kidney and occurs in childhood.","Childhood Malignant Kidney Neoplasm | Childhood Malignant Kidney Tumor | Childhood Malignant Renal Neoplasm | Childhood Malignant Renal Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4021079","Ureter Fissus","C123233","A condition in which two ipsilateral ureters unite and drain into the bladder at a single ureteric orifice.","Ureter Fissus | Partial Ureteral Duplication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053892","Ureteral Kinking","C123234","The folding of a ureter, which results in the impediment of urine flow.","Ureteral Kinking | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2910230","Cecoureterocele","C123235","A ureterocele in which the orifice is located in the bladder, with the ureterocele pouch extending submucosally into the urethra.","Cecoureterocele | ",,,,,,,,,,,,,,,"43020941","Cecoureterocele",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0474874","Ectopic Ureterocele","C123236","A ureterocele in which some portion of the ureterocele is situated permanently at the bladder neck or in the urethra. The orifice may be situated in the bladder, at the bladder neck, or in the urethra. (Adapted from Glassberg KI, Braren V, Duckett JW, Jacobs EC, King LR, Lebowitz RL et al. Suggested terminology for duplex systems, ectopic ureters and ureteroceles. J Urol 1984; 132(6):1153-1154.)","Ectopic Ureterocele | ",,,,,,,,,,,,,,,"4109813","Ectopic ureterocele",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0317722","Megamonas hypermegale","C123513","A species of Gram-negative, rod-shaped, non-spore-forming anaerobic bacterium assigned to the phylum Firmicutes. M. hypermegale can ferment glycerol and inositol and possesses key enzymes of the pentose phosphate pathway. It is native to the intestines of poultry.","Megamonas hypermegale | Bacteroides hypermegas | MEGAMONAS HYPERMEGALE | Megamonas hypermegas | Sphaerophorus hypermegas",,,,,,,,,,,,,,,"4239732","Megamonas hypermegale",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043423","Metagonimus yokogawai","C123514","A species of parasitic flatworms in the family Heterophyidae. The lifecycle of M. yokogawai involves snails as the first intermediate host, freshwater fish as the second intermediate host, and humans, fish-eating carnivores, or birds as the definitive host. Infestation causes metagonimiasis.","Metagonimus yokogawai | Japanese Fluke | METAGONIMUS YOKOGAWAI",,,,,,,,,,,,,,,"4297759","Metagonimus yokogawai",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054474","Moraxella catarrhalis, Beta-Lactamase Negative","C123517","Any bacterial species identified as Moraxella catarrhalis that does not produce the enzyme beta-lactamase.","Moraxella catarrhalis, Beta-Lactamase Negative | MORAXELLA CATARRHALIS, BETA-LACTAMASE NEGATIVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1533055","Moraxella catarrhalis, Beta-Lactamase Positive","C123518","Any bacterial species identified as Moraxella catarrhalis that produces the enzyme beta-lactamase.","Moraxella catarrhalis, Beta-Lactamase Positive | MORAXELLA CATARRHALIS, BETA-LACTAMASE POSITIVE",,,,,,,,,,,,,,,"4186391","Moraxella catarrhalis, beta lactamase positive",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054473","Moraxella catarrhalis, Penicillinase Negative","C123519","Any bacterial species identified as Moraxella catarrhalis that does not produce the enzyme penicillinase.","Moraxella catarrhalis, Penicillinase Negative | MORAXELLA CATARRHALIS, PENICILLINASE NEGATIVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053560","Navassa Island","C123766","An island in the Caribbean Sea that is west of Haiti.","Navassa Island | 926 | NAVASSA ISLAND | XNV | XV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053562","Palmyra Atoll","C123767","An atoll in the North Pacific Ocean halfway between Hawaii and American Samoa.","Palmyra Atoll | 927 | PALMYRA ATOLL | XL | XPL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050519","Paracel Islands","C123768","A group of small islands and reefs in the South China Sea, between Vietnam and the Philippines.","Paracel Islands | 928 | PARACEL ISLANDS | XP | XPR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049921","Spratly Islands","C123769","More than 100 small islands in the South China Sea, between southern Vietnam and the southern Philippines.","Spratly Islands | 929 | SPRATLY ISLANDS | XS | XSP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038976","Svalbard","C123770","Islands in the Artic Ocean, between Norway and the North Pole.","Svalbard | 930 | SVALBARD | XR | XSV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053561","Tromelin Island","C123771","An island in the Indian Ocean east of Madagascar.","Tromelin Island | 931 | TROMELIN ISLAND | XT | XTR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050014","Unknown by GENC Standard","C123772","Values reserved for a geopolitical name of Unknown by the Geopolitical entities, names and codes (GENC) standard.","Unknown GENC | 932 | A1 | AX1 | UNKNOWN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043011","Wake Island","C123773","An atoll in the North Pacific Ocean, between Hawaii and the Northern Mariana Islands.","Wake Island | 933 | QW | WAKE ISLAND | XWK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282246","West Bank","C123774","5860 square kilometers in the Middle east that is west of Jordan and east of Israel.","West Bank | 934 | WEST BANK | XW | XWB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055409","BACS - Number of Tokens Left on the Table","C121053","Brief Assessment of Cognition in Schizophrenia (BACS) Token Motor Task: Total number of tokens left on the table.","BACS - Number of Tokens Left on the Table | BACS1-Number of Tokens Left on the Table | BACS103A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055407","BACS - Total Number Tokens in Container","C121054","Brief Assessment of Cognition in Schizophrenia (BACS) Token Motor Task: Total number of tokens placed in the container.","BACS - Total Number Tokens in Container | BACS1-Total Number Tokens in Container | BACS103B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055413","BACS - Number Tokens Incorrectly Placed","C121055","Brief Assessment of Cognition in Schizophrenia (BACS) Token Motor Task: Total number of tokens incorrectly placed in container.","BACS - Number Tokens Incorrectly Placed | BACS1-Number Tokens Incorrectly Placed | BACS103C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053728","BACS - Number of Tokens Correctly Placed","C121056","Brief Assessment of Cognition in Schizophrenia (BACS) Token Motor Task: Number of tokens correctly placed.","BACS - Number of Tokens Correctly Placed | BACS1-Number of Tokens Correctly Placed | BACS103D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055416","BACS - Category Instances","C121057","Brief Assessment of Cognition in Schizophrenia (BACS) Verbal Fluency: Category instances.","BACS - Category Instances | BACS1-Category Instances | BACS104A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055415","BACS - Letter Fluency 1","C121058","Brief Assessment of Cognition in Schizophrenia (BACS) Verbal Fluency: Letter fluency 1.","BACS - Letter Fluency 1 | BACS1-Letter Fluency 1 | BACS104B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055414","BACS - Letter Fluency 2","C121059","Brief Assessment of Cognition in Schizophrenia (BACS) Verbal Fluency: Letter fluency 2.","BACS - Letter Fluency 2 | BACS1-Letter Fluency 2 | BACS104C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419029","PSMD11 Gene","C125533","This gene plays a role in the assembly and activity of the proteasome.","PSMD11 Gene | PSMD11 | Proteasome 26S Subunit, Non-ATPase 11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039748","theca cell","C12572","An endocrine cell located in the ovary that functions to produce androgens for estrogen biosynthesis and provide structural support during oocyte maturation.","Theca Cell | Ovarian Interstitial Cell | Ovarian Interstitial Cells | Theca Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502886","androgen receptor inhibitor EPI-506","C124654","An orally bioavailable, small molecule inhibitor of the acetate form of ralaniten, a N-terminal domain (NTD) of the androgen receptor (AR), with potential antineoplastic activity. Upon oral administration of ralaniten acetate, ralaniten specifically binds to the NTD of AR, thereby inhibiting both AR activation and the AR-mediated signaling pathway. This inhibits cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in proliferation, survival and chemoresistance of tumor cells.","Ralaniten Acetate | 1,2-Propanediol, 3-(4-(1-(4-((2S)-2-(acetyloxy)-3-chloropropoxy)phenyl)-1-methylethyl)phenoxy)-, 1,2-Diacetate, (2S)- | AR Inhibitor EPI-506 | EPI-506 | RALANITEN ACETATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502887","Autologous T-lymphocytes-expressing NY-ESO-1-C259-specific Enhanced T-cell Receptors","C124655","Human autologous lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the cancer/testis antigen NY-ESO-1, with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the autologous T-lymphocytes expressing NY-ESO-1-C259-specific enhanced T-cell receptors bind to NY-ESO-1-overexpressing tumor cells. This may result in the specific cytotoxic T-lymphocyte (CTL) killing of NY-ESO-1-positive cancer cells. NY-ESO-1, a tumor-associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types; the TCR is specific for SLLMWITQC, an NY-ESO-1-derived peptide, in a complex with human leukocyte antigen (HLA) A2 peptide.","Autologous T-lymphocytes-expressing NY-ESO-1-C259-specific Enhanced T-cell Receptors | NY-ESO-1/C259T | NY-ESO-1C259T | NY-ESOc259T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502888","Anti-CD22 scFv TCRz:41BB-CAR Lentiviral Vector-transduced Autologous T-lymphocytes","C124656","Autologous human T-lymphocytes transduced with a recombinant lentiviral vector encoding a chimeric T-cell receptor consisting of an anti-CD22 single chain variable fragment (scFv) and the co-stimulatory domain 4-1BB (CD137) coupled to the zeta chain of the TCR/CD3 complex (CD3-zeta), with potential immunostimulating and antineoplastic activities. Autologous peripheral blood lymphocytes (PBLs) from a patient with CD22-positive cancer are transduced with this lentiviral vector that encodes the CAR gene specific for CD22. After isolation, transduction, expansion in culture and reintroduction into the patient, the anti-CD22 scFv TCRz:41BB-CAR lentiviral vector-transduced autologous T-lymphocytes express anti-CD22-CAR on their cell surfaces and bind to the CD22 antigen on tumor cell surfaces. Subsequently, CD22-expressing tumor cells are lysed. CD22, a B-lineage-restricted, transmembrane phosphoglycoprotein, is expressed on malignant B-cells.","Anti-CD22 scFv TCRz:41BB-CAR Lentiviral Vector-transduced Autologous T-lymphocytes | Autologous T-lymphocytes-expressing CD22 CARs-expressing Tandem TCR-zeta/4-1BB | TCRzeta/4-1BB CART22 Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502889","Ravulizumab","C124657","A longer-acting antibody directed against terminal complement protein C5, with potential anti-inflammatory activity. Upon administration, ravulizumab binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and preventing the complement-mediated destruction of red blood cells (RBCs) as seen in paroxysmal nocturnal hemoglobinuria (PNH). Compared to other anti-C5 antibodies, ALXN1210 is longer-acting and allows for monthly dosing. C5, a complement pathway protein, is expressed at high levels by the liver.","Ravulizumab | ALXN 1210 | ALXN-1210 | ALXN1210 | RAVULIZUMAB | Ravulizumab-cwvz | Ultomiris",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502890","Concentrated Fortified Collagen Protein Hydrolysate Liquid Supplement","C124658","A liquid-based nutritional supplement containing enzyme-hydrolyzed concentrated protein derived from collagen, and fortified with L-tryptophan, with potential anti-cachexic and wound-healing activities. The concentrated, fortified, collagen protein hydrolysate liquid supplement contains all essential and non-essential amino acids. Upon oral administration, this supplement may improve both gastric functioning and gastrointestinal (GI) health, thereby reducing vomiting and diarrhea. The hydrolyzed protein helps to alleviate the digestive burden and allows for fast and efficient absorption and utilization of the protein. This may prevent both malnutrition and weight loss.","Concentrated Fortified Collagen Protein Hydrolysate Liquid Supplement | Pro-Stat 101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4279768","EP4 receptor antagonist AAT-007","C124131","An orally bioavailable antagonist of the prostaglandin E receptor subtype 4 (EP4), with potential analgesic, immunomodulating and antineoplastic activities. Upon administration of grapiprant, this agent selectively binds to and inhibits the binding of prostaglandin E2 (PGE2) and prevents the activation of the EP4 receptor. This inhibits PGE2-EP4 receptor-mediated signaling and prevents proliferation in tumor cells in which the PGE2-EP4 signaling pathway is over-activated. In addition, EP4 receptor inhibition modulates the immune system by preventing both interleukin-23 (IL-23) production and the IL-23-mediated expansion of Th17 cells. As EP4 is expressed by peripheral sensory neurons, blockade of EP4-mediated signaling may induce an analgesic effect. EP4, a prostanoid receptor subtype, is a G protein-coupled receptor that is expressed in certain types of cancers; it promotes tumor cell proliferation and invasion.","Grapiprant | AAT-007 | AT-001 | CJ 023,423 | CJ-023,423 | CJ023,423 | GRAPIPRANT | N-[[2,4-(2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenylethylamino]carbonyl]-4-methyl-benzenesulfonamide | RQ-00000007 | RQ-07",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084855","FIG4 wt Allele","C124944","Human FIG4 wild-type allele is located in the vicinity of 6q21 and is approximately 134 kb in length. This allele, which encodes polyphosphoinositide phosphatase protein, is involved in polyphosphoinositide metabolism. Mutation of the gene is associated with amyotrophic lateral sclerosis 11, Yunis-Varon syndrome, Yunis-Varon syndrome, bilateral temporooccipital polymicrogyria, and Charcot-Marie-Tooth disease, type 4J.","FIG4 wt Allele | ALS11 | BTOP | CMT4J | FIG4 Homolog (S. cerevisiae) Gene | FIG4 Homolog, SAC Domain Containing Lipid Phosphatase Gene | FIG4 Homolog, SAC1 Domain Containing Lipid Phosphatase 3 Gene | FIG4 Homolog, SAC1 Lipid Phosphatase Domain Containing (S. cerevisiae) Gene | FIG4 Homolog, SAC1 Lipid Phosphatase Domain Containing 3 Gene | FIG4 Phosphoinositide 5-Phosphatase wt Allele | FIG4, S. cerevisiae, Homolog of Gene | KIAA0274 | SAC3 | YVS | dJ249I4.1 | hSac3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0259479","polyphosphoinositide phosphatase","C124945","Polyphosphoinositide phosphatase (907 aa, ~104 kDa) is encoded by the human FIG4 gene. This protein plays a role in the mediation of polyphosphoinositide metabolism.","Polyphosphoinositide Phosphatase | EC 3.1.3.- | FIG4 | Phosphatidylinositol 3,5-Bisphosphate 5-Phosphatase | SAC Domain-Containing Protein 3 | Sac Domain-Containing Inositol Phosphatase 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1822695","SETX Gene","C124949","This gene is involved in DNA and RNA metabolism","SETX Gene | SETX | Senataxin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084756","SETX wt Allele","C124950","Human SETX wild-type allele is located in the vicinity of 9q34.13 and is approximately 95 kb in length. This allele, which encodes probable helicase senataxin protein, plays a role in the metabolism of both DNA and RNA. Mutation of the gene is associated with juvenile amyotrophic lateral sclerosis 4 and autosomal recessive spinocerebellar ataxia 1.","SETX wt Allele | ALS4 | AOA2 | Amyotrophic Lateral Sclerosis 4 Gene | KIAA0625 | SCAR1 | Senataxin wt Allele | Spinocerebellar Ataxia, Recessive, Non-Friedreich Type 1 Gene | bA479K20.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1450815","Probable Helicase Senataxin, Human","C124951","Probable helicase senataxin (2677 aa, ~303 kDa) is encoded by the human SETX gene. This protein is involved in nucleic acid processing.","Probable Helicase Senataxin | Amyotrophic Lateral Sclerosis 4 Protein | EC 3.6.4.- | SEN1 Homolog | SETX | Senataxin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826521","OTUD5 Gene","C124952","This gene plays a role in both protein deubiquitination and immune system regulation.","OTUD5 Gene | OTU Deubiquitinase 5 Gene | OTUD5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085338","OTUD5 wt Allele","C124953","Human OTUD5 wild-type allele is located in the vicinity of Xp11.23 and is approximately 37 kb in length. This allele, which encodes OTU domain-containing protein 5, is involved in protein deubiquitination, modulation of interferon expression and immune system regulation.","OTUD5 wt Allele | DKFZp761A052 | DUBA | OTU Deubiquitinase 5 wt Allele | OTU Domain Containing 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2000427","OTU Domain-Containing Protein 5, Human","C124954","OTU domain-containing protein 5 (571 aa, ~61 kDa) is encoded by the human OTUD5 gene. This protein plays a role in protein deubiquitination that modulates inate immunity.","OTU Domain-Containing Protein 5 | DUBA | Deubiquinating Enzyme A | Deubiquitinating Enzyme A | EC 3.4.19.12 | OTUD5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538296","ANXA8L1 Gene","C124955","This gene is involved in binding to calcium and phospholipids.","ANXA8L1 Gene | ANXA8L1 | Annexin A8-Like 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085237","ANXA8L1 wt Allele","C124956","Human ANXA8L1 wild-type allele is located in the vicinity of 10q11.22 and is approximately 162 kb in length. This allele, which encodes annexin A8-like protein 1, plays a role in calcium-mediated phospholipid binding.","ANXA8L1 wt Allele | ANXA8 | ANXA8L2 | Annexin A8-Like 1 wt Allele | Annexin A8-Like 2 Gene | VAC-beta | bA145E20.2 | bA301J7.3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014793","Abnormal Red Blood Cell","C12522","No value exists.","Abnormal Red Blood Cell | Abnormal Erythrocyte",,,,,,,,,,,,,,,"4264114","Abnormal red blood cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0450454","FIGO Stage","C125738","A set of staging terms for gynecologic cancers developed by the International Federation of Gynecology and Obstetrics (FIGO).","FIGO Stage | Histologic Grade: International Federation of Gynecology and Obstetrics (FIGO) Grading System (endometrioid and mucinous adenocarcinomas only) | figo stage | figo_stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502528","Anti-CD133-CAR Vector-transduced Allogeneic T Lymphocytes","C124132","A preparation of allogeneic peripheral blood T-lymphocytes (PBTL) that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the chimeric CD (cluster of differentiation) 133 antigen receptor, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD133-CAR vector-transduced allogeneic T-lymphocytes specifically recognize and kill CD133-expressing tumor cells. CD133, a tumor associated antigen (TAA), is overexpressed on a variety of tumor cell types.","Anti-CD133-CAR Vector-transduced Allogeneic T Lymphocytes | Allogeneic Anti-CD133 CAR T Cells | Allogeneic CART133",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502529","antibody-drug conjugate SC-003","C124133","An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody against dipeptidase 3 (DPEP3) conjugated, via a plasma-stable valine-alanine dipeptide linker, to a cytotoxic pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of tamrintamab pamozirine targets DPEP3 expressed on tumor cells. Upon binding and internalization, the cytotoxic, DNA cross-linking PBD moiety is released. This inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of DPEP3-expressing tumor cells. DPEP3, a membrane-bound glycoprotein, is overexpressed in some ovarian cancers.","Tamrintamab Pamozirine | ADC SC-003 | Immunoglobulin G1(226-serine), Anti-(Human Dipeptidase 3)(Human-mus musculus Monoclonal sc34.28SS1 Gamma1-chain), Compd. with Human-mus musculus Monoclonal sc34.28SS1 Kappa-chain, Dimer, Bis(thioether) with N-(6-(3-mercapto-2, 5-dioxo-1-pyrrolidinyl)-1 | SC 003 | SC-003 | SC003 | TAMRINTAMAB PAMOZIRINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086674","Outer Diameter","C124136","The longest possible length of a straight line passing through the center of a circular or spheroid object that connects two points on the outer circumference.","Outer Diameter | Outer/Greatest Diameter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086169","Childhood Pineal Parenchymal Tumor of Intermediate Differentiation","C124137","A pineal parenchymal tumor of intermediate differentiation that occurs during childhood.","Childhood Pineal Parenchymal Tumor of Intermediate Differentiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036113","Salmonella enterica subsp. enterica Serovar enteritidis","C124375","A gram negative, rod shaped non-motile serotype of the bacteria genus Salmonella, species Salmonella enterica, subspecies enterica. Salmonella Enteritidis is one of the most commonly reported pathogens of salmonellosis in humans, with eggs as the primary vehicle for infection.","Salmonella enterica subsp. enterica Serovar enteritidis | Bacillus enteritidis | SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR ENTERITIDIS | Salmonella enteritidis",,,,,,,,,,,,,,,"4249155","Salmonella Enteritidis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4084469","Annexin A8-Like Protein 1","C124957","Annexin A8-like protein 1 (327 aa, ~37 kDa) is encoded by the human ANXA8L1 gene. This protein is involved in calcium-dependent binding to phospholipids.","Annexin A8-Like Protein 1 | ANXA8L1 | Annexin A8-Like Protein 2 | Annexin A8L2 | Vascular Anticoagulant-Beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084875","TAOK1 wt Allele","C125174","Human TAOK1 wild-type allele is located in the vicinity of 17q11.2 and is approximately 161 kb in length. This allele, which encodes serine/threonine-protein kinase TAO1 protein, is involved in the mediation of protein kinase activity and the modulation of signaling.","TAOK1 wt Allele | FLJ14314 | KFC-B | KIAA1361 | MAP3K16 | MARKK | PSK-2 | PSK2 | TAO Kinase 1 wt Allele | TAO1 | hKFC-B | hTAOK1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084926","Financial Disclosure Form","C125177","An official legal document to disclose any financial arrangement between the parties involved in a business arrangement.","Financial Disclosure Form | FDF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426009","RBPMS Gene","C125180","This gene is involved in both RNA binding and transcriptional activation.","RBPMS Gene | RBPMS | RNA Binding Protein With Multiple Splicing Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085200","RBPMS wt Allele","C125181","Human RBPMS wild-type allele is located in the vicinity of 8p12 and is approximately 188 kb in length. This allele, which encodes RNA-binding protein with multiple splicing, plays a role in transcription coactivator activity.","RBPMS wt Allele | HERMES | RNA Binding Protein With Multiple Splicing wt Allele | RNA-Binding Protein Gene With Multiple Splicing Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0530601","RNA-Binding Protein With Multiple Splicing, Human","C125182","RNA-binding protein with multiple splicing (196 aa, ~22 kDa) is encoded by the human RBPMS gene. This protein is involved in poly(A) RNA binding and transcriptional coactivation.","RNA-Binding Protein With Multiple Splicing | Heart and RRM Expressed Sequence | Hermes | RBP-MS | RBPMS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504004","Anti-CD3/Anti-EGFR-bispecific Monoclonal Antibody-armed Activated Autologous T-lymphocytes","C125185","Autologous activated T-cells that have been coated with bispecific antibodies (BiAb) comprised of an anti-CD3 monoclonal antibody heteroconjugated to an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, with potential antineoplastic and immunomodulating activities. Upon administration, anti-CD3 x anti-EGFR bispecific antibody-armed activated T-cells (AATC) attach to and selectively cross-link CD3-expressing T-cells and EGFR-expressing tumor cells. This results in the activation of cytotoxic T-lymphocytes (CTLs) and selective cytotoxicity towards the EGFR-expressing tumor cells. In addition, cytokine and chemokine secretion by the T-cells further activates the immune system, which leads to the recruitment and activation of CTLs, and additional CTL-mediated tumor-specific cell lysis. CD3 is part of the functional T-cell receptor (TCR) complex, which is necessary for antigen recognition by T-cells, and is required for signal transduction. EGFR, a receptor tyrosine kinase, is overexpressed on the surfaces of various tumor cell types.","Anti-CD3/Anti-EGFR-bispecific Monoclonal Antibody-armed Activated Autologous T-lymphocytes | Anti-CD3 x Anti-EGFR AATCs | Anti-CD3 x Anti-EGFR BATs | Anti-CD3 x Anti-EGFR-bispecific Antibody Armed Activated Autologous T-cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086228","Curcuminoid","C125480","No value exists.","Curcuminoid | CURCUMINOIDS | Curcuminoids",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086336","GAIA Terminology","C125481","A subset of terms developed in collaboration with NICHD that focuses on developing common standards, guidance, and tools to strengthen programs of immunization in pregnancy.","GAIA Terminology | Global Alignment of Immunization safety Assessment in pregnancy Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419426","RNF5 Gene","C125482","This gene is involved in both mono- and polyubiqutination of protein substrates.","RNF5 Gene | RNF5 | Ring Finger Protein 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084740","RNF5 wt Allele","C125483","Human RNF5 wild-type allele is located in the vicinity of 6p21.3 and is approximately 2 kb in length. This allele, which encodes E3 ubiquitin-protein ligase RNF5 protein, plays a role in protein ubiquitination and protein catabolism.","RNF5 wt Allele | G16 | NG2 | RING5 | RMA1 | Ring Finger Protein 5, E3 Ubiquitin Protein Ligase wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504230","Ectopia Lentis","C125484","Partial or complete displacement of the crystalline lens from its normal position in the eye.","Ectopia Lentis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1308468","E3 Ubiquitin-Protein Ligase RNF5, Human","C125486","E3 ubiquitin-protein ligase RNF5 (180 aa, ~20 kDa) is encoded by the human RNF5 gene. This protein is involved in the regulation of protein catabolism.","E3 Ubiquitin-Protein Ligase RNF5 | EC 2.3.2.27 | EC 6.3.2.-, Formerly | HsRma1 | Protein G16 | RING Finger Protein 5 | Ram1 Homolog | Ring Finger Protein 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2936904","Opitz G/BBB Syndrome","C125487","An X-linked syndrome caused by mutations in the MID1 gene or autosomal dominant syndrome caused by changes in chromosome 22. It is characterized by ocular hypertelorism, and defects of the larynx, trachea, or esophagus. Most males have hypospadias, cryptorchidism, underdeveloped scrotum, or a scrotum divided into two lobes. Mild intellectual disability and developmental delays occur in approximately half of the affected individuals.","Opitz G/BBB Syndrome | Opitz G Syndrome | Opitz GBBB Syndrome | Opitz-G Syndrome",,,,,,,,,,,,,,,"4305010","Opitz-Frias syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265202","Seckel Syndrome","C125488","A rare autosomal recessive inherited syndrome caused by mutations in the ATR gene, RBBP8 gene, CENPJ gene, CEP152 gene, CEP63 gene, NIN gene, DNA2 gene, or TRAIP gene. It is characterized by intrauterine growth retardation, dwarfism, microcephaly, mental retardation, and a 'bird-headed' facial appearance.","Seckel Syndrome | Bird-Headed Dwarfism | Microcephalic Primordial Dwarfism | Nanocephalic Dwarfism | SCKL | Seckel-Type Dwarfism",,,,,,,,,,,,,,,"4240091","Seckel syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1418435","PDE9A Gene","C125489","This gene plays a role in the metabolism of cyclic nucleotide monophosphates.","PDE9A Gene | PDE9A | Phosphodiesterase 9A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079852","Monocyte, Activated Killer","C12548","A monocyte that has been activated for cytotoxicity by gamma interferon.","Monocyte, Activated Killer | Monocytes, Activated Killer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085330","PDE9A wt Allele","C125490","Human PDE9A wild-type allele is located in the vicinity of 21q22.3 and is approximately 122 kb in length. This allele, which encodes high affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A protein, is involved in the metabolism of both cyclic GMP and cyclic AMP.","PDE9A wt Allele | HSPDE9A2 | Phosphodiesterase 9A wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2745881","PhenX","C125689","A project supported by the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH) with the goal to provide the scientific community with recommended, standard high-priority measures of phenotypes and exposures for use in Genome-wide Association Studies (GWAS) and more generally, epidemiological and biomedical research.","PhenX | Consensus Measures for Phenotypes and Exposures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084857","BRCC4","C124105","Human BABAM2 wild-type allele is located in the vicinity of 2p23.2 and is approximately 449 kb in length. This allele, which encodes BRISC and BRCA1-A complex member 2 protein, plays a role in the recognition of damaged DNA.","BABAM2 wt Allele | BRCC4 | BRCC45 | BRE | BRISC and BRCA1 A Complex Member 2 wt Allele | Brain and Reproductive Organ-Expressed (TNFRSF1A Modulator) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1430133","BRCA1-A Complex Subunit BRE, Human","C124107","BRISC and BRCA1-A complex member 2 (383 aa, ~43 kDa) is encoded by the human BABAM2 gene. This protein is involved in binding to ubiquitinated histones.","BRISC and BRCA1-A Complex Member 2 | BABAM2 | BRCA1-A Complex Subunit BRE | BRCA1/BRCA2-Containing Complex Subunit 45 | BRCA1/BRCA2-Containing Complex, Subunit 4 | Brain and Reproductive Organ-Expressed Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084856","BRCC3 wt Allele","C124110","Human BRCC3 wild-type allele is located in the vicinity of Xq28 and is approximately 52 kb in length. This allele, which encodes Lys-63-specific deubiquitinase BRCC36 protein, is involved in histone deubiquitination and DNA repair.","BRCC3 wt Allele | BRCA1/BRCA2-Containing Complex, Subunit 3 wt Allele | BRCC36 | C6.1A | CXorf53 | Chromosome X Open Reading Frame 53 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1872069","Lys-63-Specific Deubiquitinase BRCC36, Human","C124111","Lys-63-specific deubiquitinase BRCC36 (316 aa, ~36 kDa) is encoded by the human BRCC3 gene. This protein plays a role in DNA repair and the removal of ubiquitin from histones.","Lys-63-Specific Deubiquitinase BRCC36 | BRCA1-A Complex Subunit BRCC36 | BRCA1/BRCA2-Containing Complex Subunit 3 | BRCA1/BRCA2-Containing Complex Subunit 36 | BRCC3 | BRISC Complex Subunit BRCC36 | EC 3.4.19.-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1264905","Salmonella enterica subsp. enterica Serovar gallinarum","C124376","A gram negative, rod shaped, non-motile serotype of the bacteria genus Salmonella, species Salmonella enterica, subspecies enterica. Salmonella Gallinarum, one of two poultry-adapted strains of Salmonella bacteria, causes fowl typhoid.","Salmonella enterica subsp. enterica Serovar gallinarum | SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR GALLINARUM | Salmonella gallinarum",,,,,,,,,,,,,,,"4153671","Salmonella Gallinarum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1299786","Salmonella enterica subsp. enterica Serovar Pullorum","C124377","A gram negative, rod shaped, non-motile serotype of the bacteria genus Salmonella, species Salmonella enterica, subspecies enterica. Salmonella Pullorum, one of two poultry-adapted strains of Salmonella bacteria, causes Pullorum disease almost exclusively in young chickens.","Salmonella enterica subsp. enterica Serovar Pullorum | SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR PULLORUM | Salmonella pullorum",,,,,,,,,,,,,,,"4049779","Salmonella Pullorum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0315445","Salmonella enterica subsp. enterica Serovar typhisuis","C124378","A gram negative, rod shaped serotype of the bacteria genus Salmonella, species Salmonella enterica, subspecies enterica that causes swine fever in pigs.","Salmonella enterica subsp. enterica Serovar typhisuis | SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHISUIS | Salmonella typhisuis",,,,,,,,,,,,,,,"4202820","Salmonella Typhisuis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086838","Salmonella Serotype Group A","C124379","Characterization of salmonella bacteria subspecies as serotype group A based on the specific immunologic reactivity of cell surface lipopolysaccharide-protein chains called O antigens.","Salmonella Serotype Group A | SALMONELLA SEROTYPE GROUP A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086839","Salmonella Serotype Group B","C124380","Characterization of salmonella bacteria subspecies as serotype group B based on the specific immunologic reactivity of cell surface lipopolysaccharide-protein chains called O antigens.","Salmonella Serotype Group B | SALMONELLA SEROTYPE GROUP B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086842","Salmonella Serotype Group C","C124381","Characterization of salmonella bacteria subspecies as serotype group C based on the specific immunologic reactivity of cell surface lipopolysaccharide-protein chains called O antigens.","Salmonella Serotype Group C | SALMONELLA SEROTYPE GROUP C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086840","Salmonella Serotype Group C1","C124382","Characterization of salmonella bacteria subspecies as serotype group C1 based on the specific immunologic reactivity of cell surface lipopolysaccharide-protein chains called O antigens.","Salmonella Serotype Group C1 | SALMONELLA SEROTYPE GROUP C1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086841","Salmonella Serotype Group C2","C124383","Characterization of salmonella bacteria subspecies as serotype group C2 based on the specific immunologic reactivity of cell surface lipopolysaccharide-protein chains called O antigens.","Salmonella Serotype Group C2 | SALMONELLA SEROTYPE GROUP C2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0318084","Sarcina ventriculi","C124384","A species of Gram-positive cocci bacteria in the family Clostridiaceae with an obligate anaerobic fermentative metabolism. S. ventriculi found in soil and may be a normal part of the human gut flora.","Sarcina ventriculi | SARCINA VENTRICULI | Zymosarcina ventriculi",,,,,,,,,,,,,,,"4318951","Sarcina ventriculi",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320717","Sarcocystis hominis","C124385","A species of Sarcocystis protozoa that uses cows as the intermediate host and humans as the definitive host. Infections with S. hominis are rare, are often asymptomatic, and generally clear spontaneously.","Sarcocystis hominis | SARCOCYSTIS HOMINIS",,,,,,,,,,,,,,,"4070558","Sarcocystis hominis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320721","Sarcocystis suihominis","C124386","A species of Sarcocystis protozoa that uses pigs as the intermediate host and humans as the definitive host. Infections with S. hominis are rare, are often asymptomatic, and generally clear spontaneously.","Sarcocystis suihominis | SARCOCYSTIS SUIHOMINIS",,,,,,,,,,,,,,,"4148069","Sarcocystis suihominis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL502717","Schistosoma Cercariae","C124387","The free-swimming, freshwater, aquatic form of Schistosoma flatworms. The cercariae is responsible for host finding and invasion, able to penetrate through intact skin rapidly.","Schistosoma Cercariae | SCHISTOSOMA CERCARIAE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504005","Doxycycline Hyclate Injection","C125186","An injectable formulation composed of the hyclate salt form of doxycycline, a synthetic, broad-spectrum tetracycline antibiotic, with antimicrobial activity. Upon injection, doxycycline reversibly binds to the bacterial 30S ribosomal subunit, and blocks the binding of aminoacyl-tRNA to the mRNA-ribosome complex. This leads to an inhibition of bacterial protein synthesis and abrogates bacterial infections.","Doxycycline Hyclate Injection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005712","Blastomere","C12518","A cell formed by cleavage division during embryogenesis.","Blastomere | Blastomeres",,,,,,,,,,,,,,,"4273790","Structure of blastomere",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086193","Clinical Trial Device Review Committee","C125430","Committee established by the sponsor to assess, at intervals, the functioning of device; or review of specified features in relationship to study objectives or safety and efficacy of device.","Clinical Trial Device Review Committee | Device Review Committee",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086567","Medical Device Report of Prior Investigations","C125431","Documentation reporting all prior clinical, animal, and laboratory testing of a medical device.","Medical Device Report of Prior Investigations Documentation | Medical Device Report of Prior Investigations | Report of Prior Investigations",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086194","Clinical Trial Medical Device Investigators Agreement","C125432","Documentation pertaining to the non-financial agreement for medical devices between the sponsor and the clinical trial investigator(s) documenting various responsibilities.","Clinical Trial Medical Device Investigators Agreement Documentation | Clinical Trial Medical Device Investigators Agreement | Device Investigators Agreement | Investigators Agreement (Device) | Investigators Agreement - Device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084925","Clinical Trial Subject Identification Log","C125434","Documentation identifying all the subjects screened, screen failed and enrolled for the clinical trial.","Clinical Trial Subject Identification Log Documentation | Clinical Trial Subject Identification Log | Subject Identification Log",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086526","Investigational Product Retest and Expiry Document","C125435","Documentation describing the batch retesting of the investigational product(s) for the clinical trial.","Clinical Trial Investigational Product Retest and Expiry Documentation | IP Retest and Expiry Document | IP Retest and Expiry Documentation | Investigational Product Retest and Expiry Document",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086525","Investigational Product Device Maintenance Log","C125436","A record or log of activities documenting the quality and condition of medical devices used in clinical trials.","Investigational Product Device Maintenance Log | IP Device Maintenance Log",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086262","Electronic Case Report Form Technical Design Document","C125437","Document containing the design elements of the electronic case report form (eCRF) system used in a clinical trial.","Electronic Case Report Form Technical Design Document | Technical Design Document",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086197","Clinical Trial Patient Database Change Control","C125438","Documentation detailing the changes made to the clinical trial database.","Clinical Trial Database Change Control Documentation | Clinical Trial Patient Database Change Control | Database Change Control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086521","Independent Review Committee Member Curriculum Vitae","C125439","A summary of the qualifications of independent review committee members, including educational and work experience.","Independent Review Committee Member Curriculum Vitae | Committee Member Curriculum Vitae",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504366","Antimetabolite FF-10502","C125690","An antimetabolite with potential antineoplastic activity. Upon administration, FF-10502 is able to enter the nucleus where it inhibits DNA polymerases, thereby preventing DNA synthesis and halting tumor cell proliferation.","Antimetabolite FF-10502 | FF-10502 | FF-10502-01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504367","Autologous Anti-CD19 CAR-expressing T Lymphocytes","C125691","A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) that targets the human tumor associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR-expressing T lymphocytes bind to and induce selective toxicity against CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.","Autologous Anti-CD19 CAR-expressing T Lymphocytes | Autologous Anti-CD19-CAR T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504368","Multipeptide Vaccine S-588210","C125692","A cancer vaccine composed of a combination of the injectable formulations S-488210, which contains the three HLA-A*02:01-restricted peptides up-regulated lung cancer 10 (lymphocyte antigen 6K; LY6K; URLC10), cell division cycle-associated protein 1 (kinetochore protein Nuf2; NUF2; CDCA1) and insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3; KOC1) and S-488211, which contains the two HLA-A*02:01-restricted peptides DEP domain-containing protein 1A (DEPDC1) and M-phase phosphoprotein 1 (kinesin-like protein KIF20B; MPHOSPH1), with potential immunostimulatory and antitumor activities. Upon administration, multipeptide vaccine S-588210 may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing KOC1, CDCA1, URLC10, DEPDC1 or MPHOSPH1 peptides, resulting in tumor cell lysis and decreased tumor growth.","Multipeptide Vaccine S-588210 | S-488210/S-488211 | S-588210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521802","Atransferrinemia","C125693","An extremely rare iron overload disorder caused by mutation in the structural gene for transferrin (TF gene). It is characterized by hypochromic microcytic anemia and hemosiderosis.","Atransferrinemia | Congenital Atransferrinemia | Familial Hypotransferrinemia | Hereditary Atransferrinemia",,,,,,,,,,,,,,,"4009784","Congenital atransferrinemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0342907","Sitosterolemia","C125694","An extremely rare autosomal recessive inherited disorder caused by mutations in the ABCG5 or ABCG8 genes. It is characterized by a defective sterolin transporter that impairs the elimination of plant sterols and, to a lesser degree, cholesterol from the body. These fatty substances build up in the tissues including arteries and skin, resulting in atherosclerosis and xanthomas.","Sitosterolemia | ",,,,,,,,,,,,,,,"4031951","Sitosterolemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0270733","Striatonigral Degeneration","C125695","A progressive neurodegenerative disorder caused by a disruption in the connection between the striatum and the substantia nigra. It is a type of multiple system atrophy (MSA). Signs and symptoms include rigidity, instability, impaired speech, and slow movements.","Striatonigral Degeneration | Striatonigral degeneration",,,,,,,,,,,,,,,"4106410","Striatonigral degeneration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4225429","Ehlers-Danlos Syndrome, Type I","C125696","A classic type of Ehlers-Danlos syndrome resulting from autosomal dominant mutation(s) in the COL5A1 gene, encoding collagen alpha-1(V) chain.","Ehlers-Danlos Syndrome, Type I | ",,,,,,,,,,,,,,,"37395762","Ehlers-Danlos syndrome classic type",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268336","Ehlers-Danlos Syndrome, Type II","C125697","A classic type of Ehlers-Danlos syndrome resulting from autosomal dominant mutation(s) in the COL5A2 gene, encoding collagen alpha-2(V) chain.","Ehlers-Danlos Syndrome, Type II | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268337","Ehlers-Danlos Syndrome, Type III","C125698","Ehlers-Danlos syndrome, type III is the hypermobility type Ehlers-Danlos syndrome. In most cases, the cause is unknown. Mutations in the TNXB gene have been found in a very small percentage of cases.","Ehlers-Danlos Syndrome, Type III | ",,,,,,,,,,,,,,,"4148925","Hypermobile Ehlers-Danlos syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL503842","Iodine I 131 Tenatumomab","C124996","A radioimmunoconjugate of tenatumomab, a murine monoclonal antibody targeting the tumor-associated antigen (TAA) tenascin-C (TNC), labeled with iodine I 131, with potential antineoplastic activity. The antibody moiety of iodine I 131 tenatumomab binds to TNC, thereby delivering a cytotoxic dose of iodine I 131 specifically to tumors expressing TNC. TNC, an extracellular matrix protein, is upregulated in a variety of tumor cell types; it plays a key role in invasion, tumor cell proliferation and immune evasion.","Iodine I 131 Tenatumomab | 131I-Tenatumomab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084863","BABAM1 wt Allele","C124113","Human BABAM1 wild-type allele is located in the vicinity of 19p13.11 and is approximately 14 kb in length. This allele, which encodes BRISC and BRCA1-A complex member 1 protein, plays a role in DNA repair.","BABAM1 wt Allele | BRISC and BRCA1 A Complex Member 1 wt Allele | C19orf62 | Chromosome 19 Open Reading Frame 62 Gene | FLJ20571 | HSPC142 | MERIT40 | Mediator of Rap80 Interactions and Targeting, 40-KD Gene | NBA1 | New Component of BRCAA1 A Complex Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2715587","BRISC and BRCA1-A Complex Member 1, Human","C124114","BRISC and BRCA1-A complex member 1 (329 aa, ~37 kDa) is encoded by the human BABAM1 gene. This protein is involved in the modulation of BRCA1-mediated double-strand break repair.","BRISC and BRCA1-A Complex Member 1 | BABAM1 | BRCA1-A Complex Subunit MERIT40 | Mediator of RAP80 Interactions and Targeting Subunit of 40 kDa | Mediator of Rap80 Interactions and Targeting 40 KD | Mediator of Rap80 Interactions and Targeting 40 kDa | New Component of the BRCA1 A Complex | New Component of the BRCA1-A Complex | New Component of the BRCAA1 A Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084711","SLC3A2 wt Allele","C124116","Human SLC3A2 wild-type allele is located in the vicinity of 11q12.3 and is approximately 33 kb in length. This allele, which encodes amino acid transporter heavy chain SLC3A2 protein, is involved in amino acid transport.","SLC3A2 wt Allele | 4F2 | 4F2HC | 4T2HC | Antigen Defined By Monoclonal Antibody 4F2, Heavy Chain Gene | Antigen Identified by Monoclonal Antibodies 4F2, TRA1.10, TROP4, and T43 Gene | CD98 | CD98HC | MDU1 | NACAE | Solute Carrier Family 3 (Activator of Dibasic and Neutral Amino Acid Transport), Member 2 Gene | Solute Carrier Family 3 (Activators of Dibasic And Neutral Amino Acid Transport), Member 2 Gene | Solute Carrier Family 3 (Activators of Dibasic and Neutral Amino Acid Transport), Member 2 Gene | Solute Carrier Family 3 (Amino Acid Transporter Heavy Chain), Member 2 Gene | Solute Carrier Family 3 (Amino Acid Transporter Heavy Chain), Member 2 wt Allele | Solute Carrier Family 3 Member 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2744118","4F2 Cell-Surface Antigen Heavy Chain, Human","C124117","Amino acid transporter heavy chain SLC3A2 (630 aa, ~68 kDa) is encoded by the human SLC3A2 gene. This protein plays a role in the positive regulation of amino acid transport.","Amino Acid Transporter Heavy Chain SLC3A2 | 4F2 Cell-Surface Antigen Heavy Chain | 4F2 Cell-Surface Antigen Heavy Chain | 4F2 Heavy Chain | 4F2 Heavy Chain Antigen | 4F2hc | Antigen Defined By Monoclonal Antibody 4F2 | CD98 Antigen | CD98 Heavy Chain | Lymphocyte Activation Antigen 4F2 Large Subunit | Monoclonal Antibody 44D7 Antigen | SLC3A2 | Solute Carrier Family 3 Member 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086619","NRXN2 wt Allele","C124913","Human NRXN2 wild-type allele is located in the vicinity of 11q13 and is approximately 117 kb in length. This allele, which encodes neurexin-2 protein and neurixin-2-beta protein, may be involved in neuronal cell adhesion.","NRXN2 wt Allele | KIAA0921 | Neurexin 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086618","NRXN2 Gene Product","C124914","A protein encoded by the NRXN2 gene.","NRXN2 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085685","Neurexin-2-Beta","C124916","Neurexin-2-beta (666 aa, ~71 kDa) is encoded by the human NRXN2 gene. This protein is involved in cell-cell adhesion in neurons.","Neurexin-2-Beta | Neurexin II-Beta | Neurexin-2 Isoform 1b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427739","COPS6 Gene","C124917","This gene is involved in signalosome function.","COPS6 Gene | COP9 Signalosome Subunit 6 Gene | COPS6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084732","COPS6 wt Allele","C124918","Human COPS6 wild-type allele is located in the vicinity of 7q22.1 and is approximately 3 kb in length. This allele, which encodes COP9 signalosome complex subunit 6 protein, plays a role in the modulation of signalosome function.","COPS6 wt Allele | COP9 Constitutive Photomorphogenic Homolog Subunit 6 (Arabidopsis) Gene | COP9 Signalosome Subunit 6 wt Allele | COP9 Signalosome, Subunit 6 Gene | COP9 Subunit 6 (MOV34 Homolog, 34 kD) Gene | CSN6 | HVIP | MOV34 Family, 34-kD Member Gene | MOV34 Homolog, 34 kD Gene | MOV34-34KD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1173741","COP9 Signalosome Complex Subunit 6, Human","C124919","COP9 signalosome complex subunit 6 (327 aa, ~36 kDa) is encoded by the human COPS6 gene. This protein is involved in the mediation of signalosome-dependent cellular processes.","COP9 Signalosome Complex Subunit 6 | COP9 Constitutive Photomorphogenic Homolog Subunit 6 | COPS6 | JAB1-Containing Signalosome Subunit 6 | MOV34 Homolog | SGN6 | Signalosome Subunit 6 | Vpr-Interacting Protein | hVIP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412165","ACTN1 Gene","C124920","This gene plays a role in actin crosslink formation.","ACTN1 Gene | ACTN1 | Actinin, Alpha 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086203","Clinical Trials Third Party Curriculum Vitae","C125440","Documentation detailing the education, qualification and work experience of the vendor team members participating in the clinical trial.","Clinical Trials Vendor Curriculum Vitae Documentation | Clinical Trials Third Party Curriculum Vitae | Third Party Curriculum Vitae",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086199","Clinical Trial Source Data","C125442","Documentation pertaining to the original records or certified copies of data collected from the clinical trial.","Clinical Trial Source Data Documentation | Clinical Trial Source Data | Source Data | source data",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086195","Clinical Trial Monitoring Visit Follow-up Letter","C125443","Documentation pertaining to the follow-up of a monitoring visit of the clinical trial site.","Clinical Trial Site Monitoring Visit Follow-up Documentation | Clinical Trial Monitoring Visit Follow-up Letter | MVR FU | MVR Follow-up | Monitoring Visit Follow-up Documentation | Monitoring Visit Follow-up Letter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1456390","PFN1 Gene","C125444","This gene plays a role in the regulation of actin polymerization.","PFN1 Gene | PFN1 | Profilin 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3247214","Liposomal Bupivacaine","C125652","A liposome-encapsulated formulation of bupivacaine, which is an amide-type, long-acting local anesthetic. Upon administration, bupivacaine reversibly binds to specific sodium ion channels in the neuronal membrane, resulting in both a decrease in the voltage-dependent membrane permeability to sodium ions and membrane stabilization. This leads to inhibition of both depolarization and nerve impulse conduction, and a reversible loss of sensation. Compared to bupivacaine alone, liposomal delivery increases the duration of local anesthetic action and delays the peak plasma concentration of bupivacaine due to its slow release from the liposome.","Liposomal Bupivacaine | Bupivacaine Liposome Injectable Suspension | Exparel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3667599","Vortioxetine Hydrobromide","C125653","A hydrobromide salt form of vortioxetine, a serotonin (5-HT) modulator and stimulator (SMS), with antidepressant activity. Vortioxetine inhibits the reuptake of serotonin and norepinephrine from the synaptic cleft and acts variably as a serotonin receptor agonist (5-HT1A), partial agonist (5-HT1B) or antagonist (5-HT3, 5-HT1D and 5-HT7). It is not clear how this agent's purported multimodal mechanism of action contributes to its antidepressant effect; however, it is presumed to increase the synaptic availability of serotonin and norepinephrine.","Vortioxetine Hydrobromide | 1-(2-((2,4-Dimethylphenyl)sulfanyl)phenyl)piperazine Monohydrobromide | Brintellix | Piperazine, 1-(2-((2,4-dimethylphenyl)thio)phenyl)-, Hydrobromide (1:1) | Trintellix | VORTIOXETINE HYDROBROMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504340","Anti-Programmed Cell Death Protein 1 Antibody Expressing Pluripotent Killer T-Lymphocytes","C125654","A specific population of pluripotent killer (PIK) T-cells that have been induced to express high levels of antibodies against the negative immunoregulatory human cell surface receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential antitumor activity. Although the exact mechanism(s) of action through which PIK-PD-1 cells exert their effects has yet to be elucidated, upon infusion, these cells secrete antibodies that target PD-1 expressed on the surface of activated T-cells and tumor cells. This may block the interaction of PD-1 with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1; CD274) and PD-1 ligand 2 (PD-L2, PD-1L2; CD273). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation; PD-L1 is overexpressed on certain cancer cells, and PD-L2 is primarily expressed on antigen presenting cells (APCs).","Anti-Programmed Cell Death Protein 1 Antibody Expressing Pluripotent Killer T-Lymphocytes | Anti-PD-1 Antibody Expressing Pluripotent Killer T-Cells | Anti-PD-1 Antibody Expressing Pluripotent Killer T-Lymphocytes | Anti-PDCD1 Antibody Expressing Pluripotent Killer T-Cells | Anti-PDCD1 Antibody Expressing Pluripotent Killer T-Lymphocytes | Anti-Programmed Cell Death Protein 1 Antibody Expressing Pluripotent Killer T-Cells | PIK-PD-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504341","Smoked Plum","C125655","The fruit of the Prunus mume tree that is used as a traditional Chinese medicine (TCM) called Wu Mei, which may be used to promote hydration and improve bowel function. Although the exact mechanism(s) of action through which this TCM exerts its effect has yet to be fully elucidated, upon oral administration, this TCM may reduce dehydration and improve peristalsis in the bowel.","Smoked Plum | Black Plum | Chinese Plum | Japanese Apricot | Mume Fruit | PRUNUS MUME FRUIT | Wu Mei",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503843","Autologous Cytotoxic T-lymphocytes Induced with MUC1 Gene-transfected Dendritic Cells","C124997","A preparation of autologous cytotoxic T-lymphocytes (CTL), specifically reactive to the tumor-associated antigen (TAA) mucin-1 (MUC1), with potential antineoplastic activity. Peripheral blood mononuclear cells (PBMCs) are collected from the patient with MUC1-positive tumors and are exposed ex vivo to dendritic cells (DCs) transfected with a replication-deficient adenovirus encoding MUC1 to generate MUC1-specific CTLs, which are subsequently expanded in vitro. Upon re-infusion of autologous CTLs induced with MUC1 gene-transfected DCs to the patient, the CTLs target and lyse the MUC1-expressing tumor cells. This inhibits tumor cell proliferation. MUC1 is expressed by a variety of tumor cell types.","Autologous Cytotoxic T-lymphocytes Induced with MUC1 Gene-transfected Dendritic Cells | MUC1-DC-CTL | MUC1-Gene-DC-CTL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503844","Autologous Cytotoxic T-lymphocytes Induced with MUC1 Peptide-pulsed Dendritic Cells","C124998","A preparation of autologous cytotoxic T-lymphocytes (CTL), specifically reactive to the tumor-associated antigen (TAA) mucin-1 (MUC1), with potential antineoplastic activity. Peripheral blood mononuclear cells (PBMCs) are collected from the patient with MUC1-positive tumors and are exposed ex vivo to dendritic cells (DCs) that are pulsed with a MUC1 peptide to generate MUC1-specific CTLs, which are subsequently expanded in vitro. Upon re-infusion of autologous CTLs induced with MUC1 peptide-pulsed DCs to the patient, the CTLs target and lyse the MUC1-expressing tumor cells. This inhibits tumor cell proliferation. MUC1 is expressed by a variety of tumor cell types.","Autologous Cytotoxic T-lymphocytes Induced with MUC1 Peptide-pulsed Dendritic Cells | MUC1-Peptide-DC-CTL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503845","anti-KIR3DL2 monoclonal antibody IPH4102","C124999","A humanized monoclonal antibody against the immune receptor human killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2 (KIR3DL2), with potential immunomodulating and antineoplastic activities. Upon administration, lacutamab binds to KIR3DL2 expressed on certain tumor cells. This recruits natural killer (NK) cells and leads to lysis of KIR3DL2-expressing tumor cells. In addition, IPH4102 induces antibody-dependent cellular cytotoxicity (ADCC), thereby further eliminating tumor cells. KIR3DL2, a tumor-associated antigen (TAA) and inhibitory receptor of the KIR family, is specifically expressed in most subtypes of cutaneous T-cell lymphomas (CTCL) and expressed only on a fraction of normal NK cells.","Lacutamab | Anti-KIR3DL2 Monoclonal Antibody IPH4102 | Anti-KIR3DL2 mAb IPH4102 | IPH-4102 | IPH4102 | LACUTAMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0076195","Testosterone Undecanoate","C1249","The undecanoate ester form of the androgen testosterone, with gonadotropin-secretory inhibiting and hormone replacement activity. As testosterone inhibits the secretion of gonadotropins from the pituitary gland, administration of testosterone decreases the secretion of luteinizing hormone (LH). By inhibiting LH secretion, the growth of Leydig cells, which are normally stimulated by LH to produce testosterone, may be suppressed. In addition, this agent promotes the maintenance of male sex characteristics and can be used for testosterone replacement in hypogonadal males.","Testosterone Undecanoate | Andriol | Nebido | Pantestone | Restandol | TESTOSTERONE UNDECANOATE | Testosterone 17Beta-Undecylate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503846","Ginseng Compound","C125000","A compound containing the traditional Chinese medicine (TCM) ginseng, a herb belonging to the Araliaceae family, with potential antioxidant, chemopreventive, anti-inflammatory and antineoplastic activities. Upon administration of the ginseng compound, the active ingredients, mainly ginsenosides, inhibit various signal transduction pathways that play key roles in carcinogenesis and inflammation. This leads to the induction of apoptosis in and inhibits proliferation of tumor cells. In addition, ginsenosides enhance the activity of various antioxidant enzymes, induce nitric oxide (NO) formation, inhibit the formation of reactive oxygen species (ROS) and protect against free radical-induced DNA damage. Ginseng also modulates various components of the immune system, including the activation of dendritic cells (DCs).","Ginseng Compound | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503847","Huaier Extract Granule","C125001","An orally bioavailable traditional Chinese medicine (TCM) composed of a granule containing an aqueous extract of Trametes robiniophila murr (Huaier), a mushroom found on hardwood tree trunks, with potential antineoplastic and anti-angiogenic activities. Although the exact mechanism of action through which Huaier exerts its effects is largely unknown, upon administration, this agent induces cell cycle arrest and apoptosis, and inhibits proliferation and migration of susceptible cancer cells through the modulation of various signal transduction pathways involved in carcinogenesis and angiogenesis.","Huaier Extract Granule | Huaier Granule | Trametes robiniophila murr Extract Granule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796004","Kabuki Syndrome","C124837","A rare, autosomal dominant or X-linked dominant inherited syndrome caused by mutations in the KMT2D gene (also known as MLL2) or the KDM6A gene. It is characterized by distinctive facial features including arched eyebrows, long eyelashes, long palpebral fissures with the lower lids turned out at the outside edges, a flat nose, and large protruding earlobes, developmental delay and intellectual disability.","Kabuki Syndrome | KMS | Kabuki Make-Up Syndrome | Kabuki Make-up Syndrome | Niikawa-Kuroki Syndrome",,,,,,,,,,,,,,,"4197599","Kabuki make-up syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1861537","OROFACIAL CLEFT 1","C124838","Cleft lip with or without cleft palate mapped to chromosome 6p24.","Orofacial Cleft 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796254","Pettigrew Syndrome","C124839","A rare, X-linked inherited syndrome characterized by mental retardation and additional features, which include choreoathetosis, hydrocephalus, Dandy-Walker malformation, seizures, and iron or calcium deposition in the brain.","Pettigrew Syndrome | PGS",,,,,,,,,,,,,,,"36714054","Pettigrew syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1321551","Shprintzen-Goldberg Craniosynostosis Syndrome","C124840","A rare, autosomal dominant inherited syndrome often caused by mutations in the SKI gene. It is characterized by premature fusion of skull bones and distinctive facial features, including a long, narrow head, hypertelorism, exophthalmos, downslanting palpebral fissures, a high, narrow palate, micrognathia, and low-set ears. The bodies of affected individuals resemble those of people with Marfan syndrome.","Shprintzen-Goldberg Craniosynostosis Syndrome | ",,,,,,,,,,,,,,,"36717691","Shprintzen Goldberg craniosynostosis syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0447120","Sagittal Sinus","C12513","A space between the endosteal and meningeal layer of the dura mater, which traverses through the midline along the superior and inferior borders of the falx cerebri, ultimately dividing into two parts: the superior and inferior sagittal sinus.","Sagittal Sinus | ",,,,,,,,,,,,,,,"4087391","Sagittal sinus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014805","Primary Erythromelalgia","C125383","An autosomal dominant condition caused by mutation(s) in the SCN9A gene, encoding sodium channel protein type 9 subunit alpha. It is characterized by episodes of recurrent warmth, redness, and burning sensations in the extremities.","Primary Erythromelalgia | PERYTHM | Primary Erythermalgia",,,,,,,,,,,,,,,"4301022","Primary erythromelalgia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2930868","Rasmussen Subacute Encephalitis","C125384","A rare, progressive chronic inflammation of a single cerebral hemisphere that usually affects children. It is characterized by severe seizures, loss of motor skills and speech, hemiparesis, and dementia.","Rasmussen Subacute Encephalitis | CFE | Chronic Focal Encephalitis | Rasmussen Encephalitis",,,,,,,,,,,,,,,"4041672","Rasmussen syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1833661","Paroxysmal Extreme Pain Disorder","C125385","A very rare, autosomal dominant inherited disorder caused by mutations in the SCN9A gene. It is characterized by skin redness and flushing and attacks of severe pain. The pain attacks usually last seconds to minutes.","Paroxysmal Extreme Pain Disorder | ",,,,,,,,,,,,,,,"44783143","Paroxysmal extreme pain disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002768","Indifference to Pain, Congenital, Autosomal Recessive","C125386","A very rare, autosomal recessive inherited condition caused by mutations in the SCN9A gene. It is characterized by a lack of the ability to perceive physical pain.","Indifference to Pain, Congenital, Autosomal Recessive | CIP | Congenital Insensitivity to Pain | Congenital Pain Insensitivity",,,,,,,,,,,,,,,"4295331","Congenital indifference to pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504342","Methotrexate-Encapsulating Autologous Tumor-Derived Microparticles","C125656","A suspension of autologous tumor-derived microparticles (ATMP), that are harvested from a patient with malignant pleural effusion, encapsulating the antimetabolic drug methotrexate (MTX), with potential anticancer activity. Although the exact mechanism(s) of action through which this agent exerts its effect has yet to be fully elucidated, upon administration of MTX-ATMP, the MTX moiety is released and internalized by tumor cells. It then binds to and inhibits the enzyme dihydrofolate reductase. This results in the inhibition of purine nucleotide synthesis and leads to decreased synthesis of both DNA and RNA, which induces cell death. Presumably, the encapsulation of MTX by the ATMP improves its bioavailability and decreases its toxicity.","Methotrexate-Encapsulating Autologous Tumor-Derived Microparticles | MTX-ATMP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504343","Ets-family Transcription Factor Inhibitor TK216","C125657","A proprietary biologic that inhibits the transcriptional-promoting activity of E26 transformation-specific (Ets, E-twenty-six) family transcription factors, with potential antineoplastic activity. Although the exact mechanism(s) of action through which this agent exerts its effect has yet to be fully elucidated, upon administration, Ets-family transcription factor inhibitor TK216 inhibits transcriptional activation mediated by Ets family proteins, including the oncogenic Ewing sarcoma breakpoint region 1/Friend leukemia virus integration 1 (EWSR1/FLI1; EWS/FLI1) fusion protein. This agent may both inhibit the malignant downstream effects mediated by genomic rearrangements that result in the overexpression of Ets family transcription factors and decrease tumor cell growth and proliferation. A chromosomal translocation t(11;22)(q24;q12) fuses the EWSR1 gene and the FLI1 gene and encodes the EWSR1/FLI1 fusion protein, which is an oncoprotein expressed by peripheral primitive neuroectodermal (pPNET) tumors.","Ets-family Transcription Factor Inhibitor TK216 | TK-216 | TK216",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826280","MRGPRX2 Gene","C124958","This gene plays a role in both G protein-coupled receptor signaling and mast cell activation.","MRGPRX2 Gene | MAS-Related GPR, Member X2 Gene | MRGPRX2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085333","MRGPRX2 wt Allele","C124963","Human MRGPRX2 wild-type allele is located in the vicinity of 11p15.1 and is approximately 6 kb in length. This allele, which encodes Mas-related G-protein coupled receptor member X2 protein, is involved in both mast cell activation and receptor signaling.","MRGPRX2 wt Allele | MAS-Related G Protein-Coupled Receptor, Member X2 Gene | MAS-Related GPR, Member X2 wt Allele | MGRG3 | MRGX2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1433192","Mas-Related G-Protein Coupled Receptor Member X2, Human","C124965","Mas-related G-protein coupled receptor member X2 (330 aa, ~37 kDa) is encoded by the human MRGPRX2 gene. This protein plays a role in G protein-coupled receptor signaling and mast cell activation.","Mas-Related G-Protein Coupled Receptor Member X2 | G Protein-Coupled Receptor MRGX2 | G-Protein Coupled Receptor MRGX2 | Mas-Related G Protein-Coupled Receptor G3 | Mas-Related G Protein-Coupled Receptor Member X2 | Mas-Related G-Protein Coupled Receptor G3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0000886","Acanthocyte","C12523","An abnormal red blood cell, characterized by an irregularly spiculated cell membrane, that is typically associated with abetalipoproteinemia or liver disease.","Acanthocyte | Acanthocytes | Crenated Red Blood Cell | Spur Cell",,,,,,,,,,,,,,,"4270069","Acanthocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504040","Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin DFP-13318","C125243","A long-acting formulation composed of 7-ethyl-10-hydroxycamptothecin (SN38), a camptothecin derivative and active metabolite of irinotecan conjugated to polyethylene glycol (PEG), via a proprietary, cleavable linker, with potential antineoplastic activity. Upon administration, the proprietary linkage system allows for very slow release of SN38 from the formulation. Upon release, SN38 selectively stabilizes covalent topoisomerase I-DNA complexes, and results in single-stranded and double-stranded DNA breaks, the inhibition of DNA replication, and the induction of apoptosis. This agent is designed to deliver the active metabolite to tumor cells without the need for conversion as is the case with irinotecan. Compared to other PEG-SN38-based formulations, the linker system in DFP-13318 increases its half-life and the exposure time for tumor cells, while decreasing both blood plasma concentrations and exposure to off-target organs; this results in increased efficacy.","Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin DFP-13318 | DFP-13318 | PEG SN38 DFP-13318 | PL 0264 | PL-0264 | PLX-0264 | Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin | Ultra-Long-Acting-PEG-SN-38 | Ultra-long Acting PEG-SN38",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086625","Non-Clinical Premating Trial Phase","C124606","The period of time in a non-clinical study prior to cohabitation.","Non-Clinical Premating Trial Phase | PREMATING | Pre-pairing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086277","Experimental Organism Malignant Neuroepithelial Carcinoma","C124608","A carcinoma that arises from neuroepithelial tissues of the olfactory epithelium.","Experimental Organism Malignant Neuroepithelial Carcinoma | CARCINOMA, NEUROEPITHELIAL, MALIGNANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086272","Experimental Organism Benign Epithelial Stromal Tumor","C124609","A benign neoplasm containing two or more cell types arising from the mesenchymal and epithelial components.","Experimental Organism Benign Epithelial Stromal Tumor | EPITHELIAL-STROMAL TUMOR, BENIGN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086275","Experimental Organism Malignant Mesovarial Leiomyoma","C124610","A smooth muscle neoplasm with malignant charcateristics that arises from the mesovarium.","Experimental Organism Malignant Mesovarial Leiomyoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3494976","Migrating Partial Seizures in Infancy","C125387","A very rare severe form of epilepsy with poor prognosis that usually begins within a few weeks of birth. The seizure activity can appear in multiple locations in the brain or migrate from one region to another during an episode. It results in severe developmental delay.","Migrating Partial Seizures in Infancy | MMPSI | MPSI | Malignant Migrating Partial Seizures in Infancy",,,,,,,,,,,,,,,"37205067","Malignant migrating partial seizures of infancy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3809882","Neuropathy, Hereditary Sensory and Autonomic, Type VII","C125388","A very rare disorder caused by mutation in the SCN11A gene.  Affected individuals are unable to experience pain since birth resulting in self-inflicted injuries.","Neuropathy, Hereditary Sensory and Autonomic, Type VII | HSAN7 | Hereditary Sensory and Autonomic Neuropathy Type VII",,,,,,,,,,,,,,,"37204686","Hereditary sensory and autonomic neuropathy type 7",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3276706","Small Fiber Neuropathy","C125389","Neuropathy caused by damage to the small myelinated (A-delta) fibers or unmyelinated C fibers in the peripheral nerves. It manifests with burning pain, shooting pain, allodynia, and hyperesthesia.","Small Fiber Neuropathy | Painful Peripheral Neuropathy Small Nerve Fiber Neuropathy",,,,,,,,,,,,,,,"46271378","Small fiber neuropathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504160","BET Inhibitor GSK2820151","C125391","An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, the BET inhibitor GSK2820151 binds to the acetylated lysine recognition motifs in the bromodomains of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.","BET Inhibitor GSK2820151 | GSK 2820151 | GSK2820151",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0222712","Jugular Foramen","C12496","An orifice in the base of the skull between the temporal and occipital bone through which cranial nerves IX, X, and XI, the inferior petrosal sinus, and the internal jugular vein pass.","Jugular Foramen | Posterior Lacerate Foramen",,,,,,,,,,,,,,,"4172179","Jugular foramen structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504007","XPO1 inhibitor KPT-8602","C125193","An orally bioavailable inhibitor of exportin-1 (XPO1; chromosome region maintenance 1 protein homolog; CRM1), with potential antineoplastic activity. Upon administration, eltanexor binds to the XPO1 cargo binding site, which prevents the XPO1-mediated nuclear export of cargo proteins such as tumor suppressor proteins (TSPs), including p53, p73, BRCA1/2, pRB, FOXO, and other growth regulatory proteins and leads to their selective accumulation in the nuclei of tumor cells. As a selective inhibitor of nuclear export (SINE), KPT-8602 restores the nuclear localization and function of tumor suppressing proteins which leads to the induction of apoptosis in tumor cells. XPO1, the major export factor that transports proteins from the nucleus to the cytoplasm, is overexpressed in a variety of cancer cell types while minimally expressed in normal, healthy cells. The export of tumor suppressor proteins into the cytoplasm prevents them from initiating apoptosis and leads to uncontrolled tumor cell proliferation.","Eltanexor | (2E)-3-(3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)prop-2-enamide | ATG 016 | ATG-016 | ATG016 | ELTANEXOR | Exportin 1 Inhibitor KPT-8602 | KPT-8602 | Selective Inhibitor of Nuclear Export KPT-8602 | XPO1-inhibiting SINE Compound KPT-8602",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504232","High Affinity cGMP-Specific 3',5'-Cyclic Phosphodiesterase 9A","C125491","High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A (593 aa, ~68 kDa) is encoded by the human PDE9A gene. This protein plays a role in the conversion of cyclic nucleotide monophosphates to non-cyclic monophosphates.","High Affinity cGMP-Specific 3',5'-Cyclic Phosphodiesterase 9A | EC 3.1.4.35 | High Affinity cGMP-Specific 3,5-Cyclic Phosphodiesterase 9A | Homo sapiens Phosphodiesterase PDE9A2 | PDE9A | Phosphodiesterase PDE9A21 | cGMP-Specific 3',5'-Cyclic Phosphodiesterase Type 9 | cGMP-Specific 3,5-Cyclic Phosphodiesterase Type 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086315","First Trimester Antepartum Hemorrhage","C125492","Excessive blood loss within the first trimester but prior to onset of labor.","First Trimester Antepartum Hemorrhage | Antepartum Hemorrhage, First Trimester",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504234","Second Trimester Antepartum Hemorrhage","C125493","Excessive blood loss within the second trimester but prior to onset of labor.","Second Trimester Antepartum Hemorrhage | Antepartum Hemorrhage, Second Trimester",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086902","Third Trimester Antepartum Hemorrhage","C125494","Excessive blood loss within the third trimester but prior to onset of labor.","Third Trimester Antepartum Hemorrhage | Antepartum Hemorrhage, Third Trimester",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418929","PRKG1 Gene","C125495","This gene is involved in the modulation of the nitric oxide/cyclic GMP signaling pathway.","PRKG1 Gene | PRKG1 | Protein Kinase, cGMP-Dependent, Type I Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084713","PRKG1 wt Allele","C125496","Human PRKG1 wild-type allele is located in the vicinity of 10q11.2 and is approximately 1307 kb in length. This allele, which encodes cGMP-dependent protein kinase 1 protein, plays a role in both protein phosphorylation and nitric oxide signaling. Mutation of the gene is associated with familial thoracic aortic aneurysm type 8.","PRKG1 wt Allele | AAT8 | PGK | PKG | PRKG1B | PRKGR1B | Protein Kinase, cGMP-Dependent, Regulatory, Type I Gene | Protein Kinase, cGMP-Dependent, Regulatory, Type I, Alpha Gene | Protein Kinase, cGMP-Dependent, Regulatory, Type I, Beta Gene | Protein Kinase, cGMP-Dependent, Type I wt Allele | cGK | cGK 1 | cGK1 | cGKI | cGKI-Alpha | cGKI-BETA | cGMP-Dependent Protein Kinase, Type I, Alpha Gene | cGMP-Dependent Protein Kinase, Type I, Beta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3489929","cGMP-Dependent Protein Kinase 1, Human","C125497","cGMP-dependent protein kinase 1 (671 aa, ~76 kDa) is encoded by the human PRKG1 gene. This protein is involved in nitric oxide/cyclic GMP-dependent signal transduction.","cGMP-Dependent Protein Kinase 1 | EC 2.7.11.12 | cGK 1 | cGK1 | cGKI | cGKI-Alpha | cGKI-BETA | cGMP-Dependent Protein Kinase I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084719","ID4 wt Allele","C125499","Human ID4 wild-type allele is located in the vicinity of 6p22.3 and is approximately 5 kb in length. This allele, which encodes DNA-binding protein inhibitor ID-4 protein, is involved in the inhibition of basic helix-loop-helix transcription factors.","ID4 wt Allele | IDB4 | Inhibitor of DNA Binding 4, Dominant Negative Helix-Loop-Helix Protein wt Allele | bHLHb27",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505099","DNA-Binding Protein Inhibitor ID-4","C125500","DNA-binding protein inhibitor ID-4 (161 aa, ~17 kDa) is encoded by the human ID4 gene. This protein plays a role in transcriptional repression.","DNA-Binding Protein Inhibitor ID-4 | Class B Basic Helix-Loop-Helix Protein 27 | ID4 | Inhibitor of DNA Binding 4 | Inhibitor of Differentiation 4 | bHLHb27",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086274","Experimental Organism Glandular Polyp","C124612","A benign polyp with prominent, hyperplastic glandular structures.","Experimental Organism Glandular Polyp | POLYP, GLANDULAR, BENIGN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086278","Experimental Organism Malignant Sarcoma Arising From Fibroadenoma","C124613","A malignant mesenchymal neoplasm that arises from a pre-existing benign fibroadenoma.","Experimental Organism Malignant Sarcoma Arising From Fibroadenoma | SARCOMA ARISING IN FIBROADENOMA, MALIGNANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086273","Experimental Organism Benign Mixed Sex Cord Stromal Tumor","C124614","A sex cord-stromal tumor that arises from the testis or ovary and does not metastasize.","Experimental Organism Benign Mixed Sex Cord Stromal Tumor | SEX CORD STROMAL TUMOR, MIXED, BENIGN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086276","Experimental Organism Malignant Mixed Sex Cord Stromal Tumor","C124615","A malignant sex cord-stromal neoplasm that arises from the testis or ovary and is composed of a mix of cell types.","Experimental Organism Malignant Mixed Sex Cord Stromal Tumor | SEX CORD STROMAL TUMOR, MIXED, MALIGNANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL497470","Experimental Organism Aborted","C124616","Loss of all or part of the products of conception prior to the scheduled c-section date or expected delivery date.","Experimental Organism Aborted | ABORTED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086799","Resorbed or Dead Litter","C124618","A pregnancy result for a female that had all intrauterine deaths.","Resorbed or Dead Litter | RESORBED OR DEAD LITTER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086223","Corpora Lutea Number","C124619","The number of corpora lutea present in the ovary or ovaries.","Corpora Lutea Number | CORPLUT | Corpora Lutea Count",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010087","Corpora Quadrigemina","C12461","The two pairs of colliculi located on the dorsal surface of the midbrain known as the inferior and superior colliculus.","Corpora Quadrigemina | Quadrigeminal Body",,,,,,,,,,,,,,,"4259132","Corpora quadrigemina structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086636","Number of Dead Fetuses","C124620","A measurement of the number of dead fetuses in the uterus.","Number of Dead Fetuses | FETDENUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086311","Fetal Female Sex Ratio","C124621","The determination of the ratio of live female fetuses compared to the total number of live fetuses present in the uterus. The measurement may be expressed as a fraction or percentage.","Fetal Female Sex Ratio | FETFSEXR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086643","Number of Live Female Fetuses","C124622","A measurement of the number of live female fetuses present in the uterus.","Number of Live Female Fetuses | FETLFNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086645","Number of Live Male Fetuses","C124623","A measurement of the number of live male fetuses present in the uterus.","Number of Live Male Fetuses | FETLMNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086644","Number of Live Fetuses","C124624","A measurement of the number of live fetuses in the uterus.","Number of Live Fetuses | FETLVNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0422809","Number of Fetuses","C124626","A measurement of the total number of fetuses, which includes alive and dead fetuses, present in the uterus.","Number of Fetuses | FETNUM",,,,,,,,,,,,,,,"4077859","Number of fetuses",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086012","Average Live Fetal Weight","C124627","A measurement of the average weight of all live fetuses.","Average Live Fetal Weight | FWAVGL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086011","Average Female Live Fetal Weight","C124628","A measurement of the average weight of all live female fetuses.","Average Female Live Fetal Weight | FWAVGLF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086996","Average Male Live Fetal Weight","C124629","A measurement of the average weight of all live male fetuses.","Average Male Live Fetal Weight | FWAVGLM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086909","Total Live Fetal Weight","C124630","A measurement of the total weight of all live fetuses.","Total Live Fetal Weight | FWTOTL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017527","Foreign Body Giant Cell","C12561","An assemblage of macrophages that become fused in an inflammatory response to the presence of exogenous material.","Foreign Body Giant Cell | Giant Cell, Foreign Body",,,,,,,,,,,,,,,"4058659","Foreign body giant cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504322","anti-c-KIT monoclonal antibody KTN0158","C125620","A humanized immunoglobulin (Ig) G1 monoclonal antibody against the stem cell factor receptor c-Kit (SCFR; KIT; CD117), with potential antineoplastic and anti-allergic activities. Upon administration, the anti-c-KIT monoclonal antibody CDX 0158 binds to and inhibits the activation of the cell surface antigen c-Kit. This leads to an inhibition of the activation of c-KIT-mediated signal transduction pathways and inhibits cell proliferation in cancer cells expressing c-Kit. In mast cells, inhibition of c-KIT and c-KIT-mediated signaling prevents mast cell activation, degranulation and subsequent cytokine release. c-Kit, a transmembrane protein and receptor tyrosine kinase, is overexpressed in various cell types, including certain cancer cells and mast cells; it plays a key role in the regulation of cell differentiation and proliferation.","Anti-c-KIT Monoclonal Antibody CDX 0158 | Anti-c-KIT Monoclonal Antibody KTN0158 | CDX 0158 | CDX-0158 | CDX0158 | KTN 0158 | KTN-0158 | KTN0158",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504326","Carbon C 14 Anlotinib Hydrochloride","C125624","A radioconjugate composed of the orally bioavailable hydrochloride salt form of anlotinib, a receptor tyrosine kinase (RTK) inhibitor, labeled with the radioisotope carbon C 14, with potential use for evaluating the pharmacokinetic profile of anlotinib. Upon administration of carbon C 14 anlotinib hydrochloride, anlotinib targets multiple RTKs, including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt cell growth in tumor cells that overexpress these RTKs. Labeling of anlotinib with the radioactive tracer carbon C 14 permits the evaluation of this agent's pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME).","Carbon C 14 Anlotinib Hydrochloride | 14C-labeled Anlotinib Hydrochloride | [14C] Anlotinib Hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085341","ACTN1 wt Allele","C124921","Human ACTN1 wild-type allele is located in the vicinity of 14q24 or within 14q22-q24 and is approximately 105 kb in length. This allele, which encodes alpha-actinin-1 protein, is involved in the formation of F-actin crosslinks. Mutation of the gene is associated with autosomal dominant platelet-type bleeding disorder-15.","ACTN1 wt Allele | Actinin, Alpha 1 wt Allele | Actinin, Alpha-1 Gene | BDPLT15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0720488","Flurox","C125194","A topical formulation containing the antimetabolite 5-fluorouracil (5-FU), with antineoplastic activity. Upon topical administration, 5-FU is converted into the active metabolite 5-fluoroxyuridine monophosphate (F-UMP), which competes with uracil during RNA synthesis and inhibits RNA processing. Conversion of 5-FU into another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase; this results in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in DNA synthesis, and thus inhibits DNA synthesis. Altogether, this prevents the proliferation of tumor cells locally.","Topical Fluorouracil | Actino-Hermal | Arumel | Carac | Cytosafe | Efudex | Efurix | Fiverocil | Fluoroplex | Flurox | Timazin | Tolak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087092","Previous Device Identifier","C125195","The identifier previously used to specify a medical device, prior to a change of the identifier.","Previous Device Identifier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086757","Previous Labeling Company","C125196","The company that was formerly responsible for labeling a medical device.","Previous Labeling Company | Previous Company Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538659","PKN1 Gene","C125197","This gene is involved in the phosphorylation of cytoskeletal intermediate filaments, cell migration and histone modification.","PKN1 Gene | PKN1 | Protein Kinase N1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084905","PKN1 wt Allele","C125198","Human PKN1 wild-type allele is located in the vicinity of 19p13.12 and is approximately 39 kb in length. This allele, which encodes serine/threonine-protein kinase N1 protein, plays a role in the phosphorylation of intermediate filaments and histone H3.","PKN1 wt Allele | DBK | MGC46204 | PAK-1 | PAK1 | PAK1, Rat, Homolog of Gene | PKN | PKN-ALPHA | PRK1 | PRKCL1 | Protein Kinase N1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0252902","Serine/Threonine-Protein Kinase N1, Human","C125199","Serine/threonine-protein kinase N1 (942 aa, ~104 kDa) is encoded by the human PKN1 gene. This protein is involved in post-translational protein phosphorylation.","Serine/Threonine-Protein Kinase N1 | EC 2.7.11.13 | PAK-1 | PKN1 | Protease-Activated Kinase 1 | Protein Kinase C-Like 1 | Protein Kinase C-Like PKN | Protein Kinase C-Related Kinase 1 | Protein Kinase PKN-Alpha | Protein-Kinase C-Related Kinase 1 | Serine-Threonine Kinase N | Serine-Threonine Protein Kinase N | Serine/Threonine Protein Kinase N",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0076415","Thiamiprine","C1251","A cytotoxic purine antagonist that has both immunosuppressive and antiarthritic activity. (NCI)","Thiamiprine | THIAMIPRINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086748","Post-Allogeneic Bone Marrow Transplant","C125200","The time subsequent to an allogeneic bone marrow transplant.","Post-Allogeneic Bone Marrow Transplant | Post-Allogeneic BMT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085182","PFN1 wt Allele","C125445","Human PFN1 wild-type allele is located in the vicinity of 17p13.3 and is approximately 3 kb in length. This allele, which encodes profilin-1 protein, is involved in cytoskeleton regulation. Deletion of the gene may be associated with Miller-Dieker syndrome and mutation of the gene is associated with amyotrophic lateral sclerosis 18.","PFN1 wt Allele | ALS18 | Profilin 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0525216","profilin 1","C125446","Profilin-1 (140 aa, ~15 kDa) is encoded by the human PFN1 gene. This protein plays a role in the modulation of actin polymerization.","Profilin-1 | Epididymis Tissue Protein Li 184a | Profilin I | Profilin-I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419097","PTPN14 Gene","C125447","This gene is involved in protein dephosphorylation, cell migration, cell adhesion and lymphangiogenesis.","PTPN14 Gene | PTPN14 | Protein Tyrosine Phosphatase, Non-Receptor Type 14 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085332","PTPN14 wt Allele","C125448","Human PTPN14 wild-type allele is located in the vicinity of 1q32.2 and is approximately 204 kb in length. This allele, which encodes tyrosine-protein phosphatase non-receptor type 14 protein, plays a role in the regulation of cellular processes that are mediated by tyrosine dephosphorylation. Deletion of the gene may be associated with choanal atresia and lymphedema (CHATLY).","PTPN14 wt Allele | PEZ | PTP36 | PTPD2 | Protein Tyrosine Phosphatase, Non-Receptor Type 14 wt Allele | Protein Tyrosine Phosphatase, Nonreceptor-Type, 14 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417002","MAOB Gene","C125502","This gene is involved in the oxidation of amines.","MAOB Gene | MAOB | Monoamine Oxidase B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268338","Ehlers-Danlos Syndrome, Type IV","C125699","Ehlers-Danlos syndrome, type IV is the vascular type Ehlers-Danlos syndrome. It results from mutations in the COL3A1 gene.","Ehlers-Danlos Syndrome, Type IV | ",,,,,,,,,,,,,,,"4062070","Vascular Ehlers-Danlos syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029432","Osteocyte","C12569","A cell that is formed when an osteoblast becomes embedded within the bone matrix that it has secreted. Osteoclasts reside in chambers called lacunae that are found in mature bone.","Osteocyte | Osteocytes",,,,,,,,,,,,,,,"4031294","Osteocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268342","Ehlers-Danlos Syndrome, Type VI","C125700","Ehlers-Danlos syndrome, type VI is the kyphoscoliosis type Ehlers-Danlos syndrome. It results from mutations in the PLOD1 gene.","Ehlers-Danlos Syndrome, Type VI | Ehlers-Danlos Syndrome, Kyphoscoliotic Type, 1",,,,,,,,,,,,,,,"37397547|4106173","Ehlers-Danlos syndrome kyphoscoliotic type|Ehlers-Danlos syndrome, hydroxylysine-deficient",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL504369","Ehlers-Danlos Syndrome, Type VII","C125701","Ehlers-Danlos syndrome, type VII includes the arthrochalasia type (types VIIA and VIIB) Ehlers-Danlos syndrome, and the dermatosparaxis type (type VIIC) Ehlers-Danlos syndrome. The arthrochalasia type Ehlers-Danlos syndrome is caused by mutations in the COL1A1 gene or the COL1A2 gene. The dermatosparaxis type Ehlers-Danlos syndrome is caused by mutations in the ADAMTS2 gene.","Ehlers-Danlos Syndrome, Type VII | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3469521","FANCONI ANEMIA, COMPLEMENTATION GROUP A (disorder)","C125702","Fanconi anemia caused by mutations of the FANCA gene. FANCA gene mutations are the most common cause of Fanconi anemia. This gene provides instructions for making a protein that is involved in the Fanconi anemia (FA) pathway.","Fanconi Anemia, Complementation Group A | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1845292","FANCONI ANEMIA, COMPLEMENTATION GROUP B","C125703","Fanconi anemia caused by mutations of the FANCB gene. This gene encodes the protein for complementation group B.","Fanconi Anemia, Complementation Group B | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3468041","Fanconi Anemia, Complementation Group C","C125704","Fanconi anemia caused by mutations of the FANCC gene. This gene provides instructions for making a protein that delays the onset of apoptosis and promotes homologous recombination repair of damaged DNA.","Fanconi Anemia, Complementation Group C | ",,,,,,,,,,,,,,,"37168560","Fanconi anemia of complementation group C",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1838457","FANCONI ANEMIA, COMPLEMENTATION GROUP D1","C125705","Fanconi anemia caused by mutations of the BRCA2 gene.","Fanconi Anemia, Complementation Group D1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3160738","FANCONI ANEMIA, COMPLEMENTATION GROUP D2","C125706","Fanconi anemia caused by mutations of the FANCD2 gene. This gene is involved in the repair of DNA double-strand breaks, both by homologous recombination and single-strand annealing.","Fanconi Anemia, Complementation Group D2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3469526","FANCONI ANEMIA, COMPLEMENTATION GROUP F","C125707","Fanconi anemia caused by mutations of the FANCF gene. This gene encodes a polypeptide with homology to the prokaryotic RNA-binding protein ROM.","Fanconi Anemia, Complementation Group F | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3469527","fanconi anemia complementation group g","C125708","Fanconi anemia caused by mutations of the FANCG gene.","Fanconi Anemia, Complementation Group G | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086640","Number of Implantations","C124631","A measurement of the number of implantations in the uterus.","Number of Implantations | IMLNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086641","Number of Intrauterine Deaths","C124632","A measurement of the total number of deaths (dead fetuses plus resorptions) in the uterus/uterine horn(s).","Number of Intrauterine Deaths | IUDNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086750","Pre-implantation Loss Percent","C124633","The percentage of released ova that failed to implant.","Pre-implantation Loss Percent | PREIMLSP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086749","Post-implantation Loss Percent","C124634","The percentage of released ova that implanted and died.","Post-implantation Loss Percent | PSTIMLSP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086637","Number of Early Resorptions","C124635","A measurement of the number of early resorptions in the uterus.","Number of Early Resorptions | RSRPENUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086642","Number of Late Resorptions","C124636","A measurement of the number of late resorptions in the uterus.","Number of Late Resorptions | RSRPLNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086649","Number of Resorptions","C124637","A measurement of the total number of resorptions in the uterus.","Number of Resorptions | RSRPNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086834","SEND Developmental and Reproductive Toxicology Implementation Guide Version 1.0","C124638","The 1.0 version of the standard for exchange of nonclinical data (SEND) developmental and reproductive toxicology (DART) implementation guide.","SEND Developmental and Reproductive Toxicology Implementation Guide Version 1.0 | SEND DART IG v1.0 | SEND DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY IMPLEMENTATION GUIDE VERSION 1.0 | SEND IG DART Version 1.0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503140","Depression (sunken area)","C124639","An area that is sunken; lower than the surrounding surface.","Depression | DEPRESSION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0544726","Hole","C124640","An aperture or hollow space within a solid mass","Hole | HOLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086874","Supernumerary Cranial Sutures","C124642","Sutures commonly found within the parietal and occipital bones of the skull due to their multiple ossification centers. These sutures exhibit a zigzag pattern with interdigitations and sclerotic borders similar to, and join and merge with the major sutures.","Supernumerary Cranial Sutures | Supernumerary Suture | UNOSSIFIED LINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087047","Late Intrauterine Death","C124643","A death of the fetus occurring inside the uterus.","Late Intrauterine Death | LATE INTRAUTERINE DEATH | Late IUD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502876","Therapeutic gamma delta T-lymphocytes","C124644","A subset of therapeutic autologous T-lymphocytes that express a T-cell receptor (TCR) composed of one gamma chain and one delta chain, with potential immunomodulating and antineoplastic activities. Upon administration of the therapeutic gamma delta T-lymphocytes, these cells secrete interferon-gamma (IFN-g), and exert direct killing of tumor cells. In addition, these cells activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against tumor cells. Gamma delta T-lymphocytes play a key role in the activation of the immune system and do not require major histocompatibility complex (MHC)-mediated antigen presentation to exert their cytotoxic effect.","Therapeutic gamma delta T-lymphocytes | gammadelta T Cells | gd T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1848519","Waardenburg Syndrome Type 4","C124842","A rare, autosomal dominant or autosomal recessive syndrome caused by mutations in the SOX10, EDN3, or EDNRB genes. It is characterized by pigmentary abnormalities of the hair, skin, and eyes, congenital sensorineural hearing loss, and Hirschsprung disease.","Waardenburg Syndrome Type 4 | Waardenburg Syndrome Type IV | Waardenburg-Shah Syndrome",,,,,,,,,,,,,,,"37396221","Waardenburg Shah syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2351743","Alpha-Actinin-1, Human","C124922","Alpha-actinin-1 (892 aa, ~103 kDa) is encoded by the human ACTN1 gene. This protein plays a role in F-actin crosslinking.","Alpha-Actinin-1 | ACTN1 | Actinin 1 Smooth Muscle | Alpha-Actinin Cytoskeletal Isoform | F-Actin Cross-Linking Protein | Non-Muscle Alpha-Actinin-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085566","PTPRS wt Allele","C124924","Human PTPRS wild-type allele is located in the vicinity of 19p13.3 and is approximately 182 kb in length. This allele, which encodes receptor-type tyrosine-protein phosphatase S protein, plays a role in tyrosine dephosphorylation.","PTPRS wt Allele | PTPSIGMA | Protein Tyrosine Phosphatase, Receptor Type, S wt Allele | Protein-Tyrosine Phosphatase, Receptor-Type, Sigma Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1873003","Receptor-Type Tyrosine-Protein Phosphatase S, Human","C124925","Receptor-type tyrosine-protein phosphatase S (1948 aa, ~217 kDa) is encoded by the human PTPRS gene. This protein is involved in the dephosphorylation of tyrosine residues.","Receptor-Type Tyrosine-Protein Phosphatase S | EC 3.1.3.48 | PTPRS | Protein Tyrosine Phosphatase PTPsigma | R-PTP-S | R-PTP-Sigma | RPTP-Sigma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538299","ATXN2 Gene","C124926","This gene plays a role in receptor trafficking.","ATXN2 Gene | ATXN2 | Ataxin 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084798","ATXN2 wt Allele","C124927","Human ATXN2 wild-type allele is located in the vicinity of 12q24.1 and is approximately 147 kb in length. This allele, which encodes ataxin-2 protein, is involved in the regulation of endocytosis of the epidermal growth factor receptor. Mutation of the gene is associated with spinocerebellar ataxia type 2, susceptibility to amyotrophic lateral sclerosis 13 and increased susceptibility for late-onset Parkinson disease.","ATXN2 wt Allele | ASL13 | ATX2 | Ataxin 2 wt Allele | SCA2 | Spinocerebellar Ataxia 2 (Olivopontocerebellar Ataxia 2, Autosomal Dominant, Ataxin 2) Gene | TNRC13 | Trinucleotide Repeat-Containing Gene 13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1569985","Ataxin-2, Human","C124928","Ataxin-2 (1313 aa, ~140 kDa) is encoded by the human ATXN2 gene. This protein plays a role in the modulation of epidermal growth factor receptor internalization.","Ataxin-2 | ATXN2 | Spinocerebellar Ataxia Type 2 Protein | Trinucleotide Repeat Containing 13 | Trinucleotide Repeat-Containing Gene 13 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503798","177Lu-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-Cpa-cyclo(d-Cys-amino-Phe-hydroorotic acid-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)-D-Tyr-NH2","C124929","A radioconjugate consisting of the somatostatin antagonistic peptide satoreotide tetraxetan (JR11) that is linked, via the chelating agent dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and imaging activity during positron emission tomography/computed tomography (PET/CT). Upon administration, lutetium Lu 177-DOTA-JR11 binds to somatostatin receptors (SSTRs), with high affinity for SSTR2, present on the cell membranes of many types of neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. SSTRs have been shown to be present in large numbers on NETs and their metastases, while most normal tissues express low levels of SSTRs.","Lutetium Lu 177 Satoreotide Tetraxetan | 177Lu-DOTA-Cpa-c[d-Cys-Aph(Hor)-d-Aph(Cbm)-Lys-Thr-Cys]-d-Tyr-NH2 | 177Lu-DOTA-JR11 | 177Lu-DOTA-[Cpa-c(DCys-Aph(Hor)-DAph(Cbm)-Lys-Thr-Cys)-DTyr-NH2] | Lu-177 OPS-201 | SATOREOTIDE TETRAXETAN LUTETIUM LU-177 | SATOREOTIDE TETRAXETAN LUTETIUM-177 | SOMther | Satoreotide Tetraxetan Lutetium Lu-177 | Satoreotide Tetraxetan Lutetium-177",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503799","gallium Ga 68 DOTA-JR11","C124930","A radioconjugate consisting of the somatostatin antagonistic peptide satoreotide that is linked via the chelating agent tetraxetan (dodecanetetraacetic acid; DOTA), to the beta-emitting radioisotope gallium Ga 68, with potential imaging activity during positron emission topography/computed tomography (PET/CT). Upon administration, gallium Ga 68 satoreotide tetraxetan binds to somatostatin receptors (SSTRs), with high affinity for SSTR2, present on the cell membranes of many types of neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate can be used to quantify tumor uptake of satoreotide using PET/CT. SSTRs have been shown to be present in large numbers on NETs and their metastases, while most normal tissues express low levels of SSTRs.","Gallium Ga 68 Satoreotide Tetraxetan | 68Ga-DOTA-Cpa-c[d-Cys-Aph(Hor)-d-Aph(Cbm)-Lys-Thr-Cys]-d-Tyr-NH2 | 68Ga-DOTA-JR11 | 68Ga-DOTA-[Cpa-c(DCys-Aph(Hor)-DAph(Cbm)-Lys-Thr-Cys)-DTyr-NH2] | Gallium Ga 68 DOTA-JR11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1430253","Tyrosine-Protein Phosphatase Non-Receptor Type 14, Human","C125449","Tyrosine-protein phosphatase non-receptor type 14 (1187 aa, ~135 kDa) is encoded by the human PTPN14 gene. This protein is involved in lymphangiogenesis, cell migration, cell adhesion and protein dephosphorylation.","Tyrosine-Protein Phosphatase Non-Receptor Type 14 | Cytoskeletal-Associated Protein Tyrosine Phosphatase | EC 3.1.3.48 | PTPN14 | Phosphatase with Ezrin Domain | Protein-Tyrosine Phosphatase Pez",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504344","Fructooligosaccharide/Lactobacillus paracasei/Lactobacillus rhamnosus/Lactobacillus acidophilus/Bifidobacterium lactis Probiotic Supplement","C125658","A synbiotic nutritional supplement containing fructooligosaccharides (FOS), which are linear chains of fructose units that are linked by beta (2-1) bonds, and probiotic cultures of Lactobacillus paracasei (L. paracasei), L. rhamnosus, L. acidophilus and Bifidobacterium lactis (B. lactis), with gastrointestinal (GI) protective and immunomodulating activities. Upon oral administration, the bacteria in this probiotic supplement help maintain adequate colonization of the GI tract and modulate the composition of the normal microflora. Upon colonization of the GI tract, the probiotic bacteria form a protective barrier that helps maintain the integrity of the epithelial barrier. This will interfere with the attachment of pathogenic bacteria and other harmful substances, prevent inflammation and improve GI function. Additionally, the reconstituted microflora may metabolize FOS, which may promote calcium mobilization into the bloodstream by maintaining a neutral pH in the lower gut.","Fructooligosaccharide/Lactobacillus paracasei/Lactobacillus rhamnosus/Lactobacillus acidophilus/Bifidobacterium lactis Probiotic Supplement | Fructooligosaccharide/L. paracasei/L. rhamnosus/L. acidophilus/B. lactis Probiotic Supplement | LactoFos",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3160739","FANCONI ANEMIA, COMPLEMENTATION GROUP E","C125709","Fanconi anemia caused by mutations of the FANCE gene. This is a protein coding gene. It is required for the nuclear accumulation of FANCC and provides a critical bridge between the FA complex and FANCD2.","Fanconi Anemia, Complementation Group E | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086913","Transfill","C125710","The transfer of gas, either in a liquid or gaseous state, from a larger container, or from permanently mounted tanks, into smaller high-pressure cylinders or cryogenic vessels, in a process known as 'cascading'.  During the transfer, different gases may be mixed together.","Transfill | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503848","Topical Trichloroacetic Acid","C125002","A topical solution containing the caustic agent trichloroacetic acid (TCA), with potential keratolytic, anti-viral and antineoplastic activities. Upon topical application to the affected area, TCA causes tissue necrosis through coagulation of proteins, leads to the destruction of human papilloma virus (HPV)-associated warts and inhibits HPV-driven proliferation of cancer cells.","Topical Trichloroacetic Acid | Topical TCA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503849","pan-Raf inhibitor LXH254","C125003","An orally available inhibitor of all members of the serine/threonine protein kinase Raf family, with potential antineoplastic activity. Upon administration, naporafenib binds to Raf proteins and inhibits Raf-mediated signal transduction pathways. This inhibits proliferation of Raf-overexpressing tumor cells. Raf protein kinases are critical enzymes in the Ras/Raf/MEK/ERK signaling pathway and are upregulated in a variety of cancer cell types. They play key roles in tumor cell proliferation and survival.","Naporafenib | LXH 254 | LXH-254 | LXH254 | NAPORAFENIB | Raf Family Kinase Inhibitor LXH254 | pan-RAF Inhibitor LXH254 | pan-RAF Kinase Inhibitor LXH254",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086187","Clinical Interpretation","C125009","The determination of the meaning of a clinical result.","Clinical Interpretation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015183","Eustachian Tube","C12500","A tubular structure that runs from the middle ear to the nasopharynx and is approximately 3-4 cm length. Its lumen is roughly triangular and has average diameter of 2-3 mm. The lumen is lined by ciliated pseudostratified, columnar epithelium, which sweeps material from the middle ear to the nasopharynx. It is functionally collapsed at rest, with slight negative pressure present in the middle ear, and opens during swallowing, sneezing, and yawning.  It serves to ventilate pressure differences between the middle ear and nasopharynx. This tube also allows middle ear secretions to drain into the nasopharynx.","Eustachian Tube | Auditory Tube | EUSTACHIAN TUBE | Pharyngotympanic Tube | Tuba Auditoria",,,,,,,,,,,,,,,"4238728","Structure of pharyngotympanic tube",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086761","Quantitation Range","C125010","A set of values that demarcate the detection limits for a specific assay.","Quantitation Range | ROQ | Range of Quantitation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503062","live-attenuated Listeria monocytogenes encoding EGFRvIII-mesothelin vaccine JNJ-64041757","C124843","A proprietary, live-attenuated, double-deleted (LADD) strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding the tumor-associated antigens (TAAs) epidermal growth factor receptor mutant form EGFRvIII and human mesothelin, with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, the live-attenuated Listeria monocytogenes encoding EGFRvIII-mesothelin vaccine Pemlimogene merolisbac is taken up by antigen-presenting cells (APCs), including dendritic cells (DCs). EGFRvIII and mesothelin are subsequently expressed by the APCs and then processed and presented to the immune system by both major histocompatibility complex (MHC) class I and II molecules. This activates the immune system and leads to the recruitment and activation of cytotoxic T-lymphocytes (CTLs) against EGFRvIII- and mesothelin-expressing tumor cells, eventually resulting in tumor cell lysis. EGFRvIII and mesothelin are overexpressed in many types of cancer. Two genes contributing to the virulence of Lm have been removed to minimize the risk of infection.","Pemlimogene Merolisbac | ADU-214 | JNJ-64041757 | LADD Listeria monocytogenes JNJ-64041757 | PEMLIMOGENE MEROLISBAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0265286","Dyggve-Melchior-Clausen Syndrome","C124844","A rare, autosomal recessive inherited syndrome caused by mutations in the DYM gene. It is characterized by abnormal skeletal development, microcephaly, and intellectual disability.","Dyggve-Melchior-Clausen Syndrome | DMC | Dyggve-Melchior-Clausen Disease",,,,,,,,,,,,,,,"4220978","Dyggve-Melchior-Clausen syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268418","Hyperglycerolemia","C124845","A rare, X-linked recessive genetic disorder of glycerol metabolism caused by mutations or deletion in the GK gene. It results in deficiency of the enzyme glycerol kinase.  It is characterized by elevated plasma and urine glycerol levels and neurometabolic manifestations which can cause life-threatening metabolic crisis in children.","Hyperglycerolemia | GKD | Glycerol Kinase Deficiency",,,,,,,,,,,,,,,"4050304","Deficiency of glycerol kinase",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1970482","Potocki-Lupski Syndrome","C124846","A rare genetic disorder characterized by hypotonia, failure to thrive, mental retardation, developmental disorders, congenital anomalies, and autism spectrum disorders. The majority of patients harbor a microduplication of chromosome 17p11.","Potocki-Lupski Syndrome | 17p11.2 Duplication Syndrome | PTLS",,,,,,,,,,,,,,,"37116955","17p11.2 microduplication syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1539219","DAZ1 Gene","C124847","This gene is involved in spermatogenesis.","DAZ1 Gene | DAZ1 | Deleted in Azoospermia 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084899","DAZ1 wt Allele","C124848","Human DAZ1 wild-type allele is located in the vicinity of Yq11.223 and is approximately 70 kb in length. This allele, which encodes deleted in azoospermia protein 1, is a candidate for the human Y-chromosomal azoospermia factor (AZF) and plays a role in germ-cell progression to meiosis and the formation of haploid germ cells.","DAZ1 wt Allele | DAZ | Deleted in Azoospermia 1 wt Allele | Deleted in Azoospermia Gene | SPGY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0381573","Deleted in Azoospermia Protein 1, Human","C124849","Deleted in azoospermia protein 1 (744 aa, ~83 kDa) is encoded by the human DAZ1 gene. This protein is involved in spermatogenesis.","Deleted in Azoospermia Protein 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503128","Analbuminemia","C124851","A rare, autosomal recessive inherited disorder characterized by the absence or severe reduction of circulating human serum albumin.","Analbuminemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0265219","Miller-Dieker Syndrome","C124852","A rare syndrome caused by deletion of genetic material in the short arm of chromosome 17. It is characterized by an abnormally smooth brain with fewer folds and grooves. It results in intellectual disability, developmental delay, seizures, spasticity, hypotonia, and feeding difficulties. Affected individuals have distinctive facial features that include a prominent forehead, midface hypoplasia, small, upturned nose, low-set ears, small jaw, and thick upper lip.","Miller-Dieker Syndrome | Miller-Dieker Lissencephaly Syndrome",,,,,,,,,,,,,,,"4102525","Miller Dieker syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL503972","Co-ArgI-PEG","C125143","A recombinant modified form of the human enzyme arginase 1 (ARG1), in which cobalt is substituted for manganese as a cofactor, covalently attached to polyethylene glycol (PEG), with potential arginine degrading and antineoplastic activities. Upon intravenous administration of pegzilarginase, ARG1 metabolizes the amino acid arginine to ornithine and urea, thereby lowering blood arginine levels. This normalizes blood arginine levels in patients with ARG1 deficiency and prevents hyperargininemia. This also inhibits the proliferation of cancer cells that are dependent on extracellular arginine uptake for their proliferation. In normal, healthy cells, arginine is synthesized intracellularly by the enzymes ornithine transcarbamylase (OTC), argininosuccinate synthase (ASS), and argininosuccinate lyase (ASL); thus they are not dependent on extracellular arginine for survival. In cancer cells these enzymes are disabled; therefore, this agent may inhibit proliferation and survival of these cells by depleting extracellular arginine. Pegylation improves blood circulation times and cobalt substitution increases the catalytic activity of ARG1.","Pegzilarginase | AEB-1102 | AEB1102 | Co-ArgI-PEG | PEGZILARGINASE | Pegylated Recombinant Arginase AEB1102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226861","Inferior Sagittal Sinus","C12514","An intracranial venous sinus that lies in a midline location along the lower free border of the falx cerebri of the brain. The sinus receives blood from the great cerebral vein and joins the superior sagittal sinus posteriorly.","Inferior Sagittal Sinus | Lesser Sagittal Sinus | Sagittal Sinus, Inferior | Sagittal Sinus, Lesser",,,,,,,,,,,,,,,"4144951","Structure of inferior sagittal sinus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504345","adenosine-A2A receptor antagonist CPI-444","C125659","A small molecule immune checkpoint inhibitor of the adenosine A2A receptor (ADORA2A) with potential antineoplastic activity. Upon oral administration, ciforadenant binds to adenosine A2A receptors expressed on the surface of immune cells, including T-lymphocytes, natural killer (NK) cells, macrophages and dendritic cells (DCs). This prevents tumor-released adenosine from interacting with the A2A receptors on these key immune surveillance cells, thereby abrogating adenosine-induced immunosuppression in the tumor microenvironment. This may stimulate anti-tumor immune responses, resulting in tumor regression.","Ciforadenant | 3H-1,2,3-Triazolo(4,5-d)pyrimidin-5-amine, 7-(5-Methyl-2-furanyl)-3-((6-((((3S)-tetrahydro-3-furanyl)oxy)methyl)-2-pyridinyl)methyl)- | Adenosine-A2A Receptor-Targeting Agent CPI-444 | CIFORADENANT | CPI-444 | V81444",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085236","Alveolar Macrophage","C12565","Phagocytic macrophages on the surface of the pulmonary alveoli.  They ingest foreign substances inhaled into the alveoli.","Alveolar Macrophage | Pulmonary Macrophage | Pulmonary Macrophages",,,,,,,,,,,,,,,"4141879","Alveolar macrophage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086609","Mouse Trisomy 16","C125660","A mouse chromosomal abnormality consisting of the presence of a third copy of chromosome 16 in somatic cells. Mice that are trisomic for chromosome 16 offer a genetic model for studies relevant to Down syndrome.","Mouse Trisomy 16 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3495555","Carnosinemia","C125661","A rare autosomal recessive metabolic disorder caused by mutation in CNDP1 gene. It is characterized by deficiency of carnosinase and manifests with severe mental defects and myoclonic seizures.","Carnosinemia | Carnosinase Deficiency",,,,,,,,,,,,,,,"4254777","Carnosinemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0338585","Carotid Artery Dissection","C125662","Spontaneous or traumatic separation of the layers of the carotid artery wall. It manifests with headache, neck pain, temporary vision loss, and/or ischemic stroke.","Carotid Artery Dissection | Dissection of carotid artery",,,,,,,,,,,,,,,"37109512","Dissection of carotid artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1836797","Combined Oxidative Phosphorylation Deficiency 1","C125663","A progressive, fatal autosomal recessive disorder. It results from a defect in the mitochondrial oxidative phosphorylation system. It manifests with growth retardation, microcephaly, hypertonicity, axial hypotonia, encephalopathy, cardiomyopathy, and liver dysfunction.","Combined Oxidative Phosphorylation Deficiency 1 | COXPD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0563625","Pain Agnosia","C125664","Loss of the ability to perceive and process pain.","Pain Agnosia | Analgesia",,,,,,,,,,,,,,,"4116732","Agnosia for pain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1845862","Cerebral Creatine Deficiency Syndrome 1","C125665","A rare X-linked inherited disorder. It is caused by mutations in the SLC6A8 gene resulting in the absence of a compound needed to transport creatine into cells. It manifests with intellectual disability, seizures, short stature, and midface hypoplasia.","Cerebral Creatine Deficiency Syndrome 1 | CCDS1 | X-Linked Creatine Transporter Deficiency",,,,,,,,,,,,,,,"44782653","X-linked creatine deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3501867","MnSOD Mimetic BMX-001","C125666","A third generation, cationic, lipophilic, manganese (Mn) and porphyrin-based mimetic of the human mitochondrial manganese superoxide dismutase (MnSOD), with antioxidant and potential chemoprotective activities. Upon administration, MnSOD mimetic BMX-001 is internalized by cells and mimics the activity of MnSOD by scavenging reactive oxygen species (ROS), such as superoxide anion, hydrogen peroxide, and hydroxyl radical. This prevents oxidative damage to macromolecules such as DNA and minimizes oxygen free radical-related chemotoxicity in normal tissues. This agent was designed to be more lipophilic and less toxic than first and second generation Mn-porphyrin mimetics.","MnSOD Mimetic BMX-001 | BMX-001 | Manganese (III) ortho N-Butoxyethylpyridylporphyrin | Manganese Butoxyethyl Pyridyl Porphyrin | Manganese(5+), ((2,2',2'',2'''-(21H,23H-porphine-5,10,15,20-tetrayl-kappaN21,kappaN22,kappaN23,kappaN24)tetrakis(1-(2-butoxyethyl)pyridiniumato))(2-))-, Chloride (1:5), (sp-4-1)- | Mitochondrial Manganese Superoxide Dismutatse Mimetic BMX-001 | Mn(III) meso-tetrakis(N-n-butoxyethylpyridinium-2-yl)porphyrin | MnTnBuOE-3-PyP 5+",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025171","Megaloblast","C12524","No value exists.","Megaloblast | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2681613","INO80D Gene","C125258","This gene plays a role in ATP-dependent chromatin remodeling.","INO80D Gene | INO80 Complex Subunit D Gene | INO80D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085575","INO80D wt Allele","C125259","Human INO80D wild-type allele is located in the vicinity of 2q33.3 and is approximately 93 kb in length. This allele, which encodes INO80 complex subunit D protein, is involved in chromatin remodeling.","INO80D wt Allele | FLJ20309 | INO80 Complex Subunit D wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037888","Spherocyte","C12525","An abnormally small appearing red blood cell that is sphere-shaped and lacks the characteristic central pallor due to cell membrane loss with preservation of cellular contents.","Spherocyte | Spherocytes",,,,,,,,,,,,,,,"4123834","Spherocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1698581","Mayer-Rokitansky-Kuster-Hauser Syndrome","C124853","A rare syndrome of unknown cause that occurs in females. It is characterized by underdeveloped or absent vagina and uterus in an otherwise phenotypically normal female with a normal 46,XX karyotype. Other abnormalities include unilateral renal agenesis, skeletal abnormalities, hearing loss, and heart defects.","Mayer-Rokitansky-Kuster-Hauser Syndrome | MRKH | MRKH Syndrome | Mullerian Aplasia/Dysgenesis",,,,,,,,,,,,,,,"4338806","Rokitansky sequence",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0322197","Hymenolepis diminuta","C124354","A species of tapeworm in the family Hymenolepididae with a long cylindrical body, 4 suckers, and an apical organ at its scolex with no rostellar hooks. The lifecycle of H. diminuta involves beetles as the intermediate host and rodents as the definitive host. This tapeworm is prevalent in tropical zones worldwide but only rarely infects humans.","Hymenolepis diminuta | HYMENOLEPIS DIMINUTA | Rat Tapeworm",,,,,,,,,,,,,,,"4033502","Hymenolepis diminuta",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029000","Onchocerca volvulus","C124355","A species of nematode in the family Onchocercidae with a smooth cuticle, blunt anterior and posterior ends, and lacking lips or a buccal capsule. The lifecycle of O. volvulus involves the black fly as the intermediate host and humans as the definitive host. This nematode is the causative agent of onchocerciasis (river blindness).","Onchocerca volvulus | ONCHOCERCA VOLVULUS",,,,,,,,,,,,,,,"4182077","Onchocerca volvulus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029109","Opisthorchis felineus","C124356","A species of trematode parasite in the family Opisthorchiidae characterized by a light brownish-to pink color, a cuticle lacking spines, and 2 prominent suckers, an oral sucker and a ventral one. The life cycle of O. felineus involves freshwater snails as the first intermediate host, freshwater fish as the second intermediate host, and fish-eating mammals as the definitive host. Humans may become infested by eating undercooked fish.","Opisthorchis felineus | Cat Liver Fluke | OPISTHORCHIS FELINEUS",,,,,,,,,,,,,,,"4086610","Opisthorchis felineus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0522439","Pleistophora","C124357","A genus of unicellular obligate parasitic fungi in the family Pleistophoridae. Members of the species infect the muscle of fish and aquatic arthropods.","Pleistophora | PLEISTOPHORA",,,,,,,,,,,,,,,"4249592","Pleistophora",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0597258","Pneumocystis","C124358","A genus of yeast-like fungi in the family Pneumocystidaceae. Members of the genus are found in the lungs of terrestrial mammals from almost all geographic regions. Communication between hosts likely happens by an airborne route to uninfected individuals. Latent infections can develop into pneumonia in immunologically impaired individuals.","Pneumocystis | PNEUMOCYSTIS",,,,,,,,,,,,,,,"4019006","Pneumocystis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0076612","Thymalfasin","C1253","A synthetic analogue of thymosin-alpha-1, a 28-amino acid protein derived from the precursor protein prothymosin-alpha.  Exhibiting a variety of immunoregulating properties, thymosin-alpha-1 induces differentiation of murine T-cell precursors and human thymocytes and the terminal differentiation of functionally immature cord blood lymphocytes and induces production of IL-2, high affinity IL-2 receptors, and B-cell growth factors by peripheral blood mononuclear cells. T-helper and cytotoxic/suppressor T-cell populations are targets of thymosin activity. Thymosin-alpha-1 has been shown to increase the efficiency of antigen presentation by macrophages and to be an endogenous modulator of alpha-thrombin activity. (NCI04)","Thymalfasin | THYMALFASIN | Thymosin Alpha 1 | Zadaxin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036609","Sella Turcica","C12497","A bony prominence situated on the upper surface of the body of the sphenoid bone housing the pituitary gland.","Sella Turcica | sella turcica",,,,,,,,,,,,,,,"4174391","Structure of pituitary fossa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1414142","DPP9 Gene","C124980","This gene is involved in dipeptidyl aminopeptidase activity.","DPP9 Gene | DPP9 | Dipeptidyl-Peptidase 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085342","DPP9 wt Allele","C124981","Human DPP9 wild-type allele is located in the vicinity of 19p13.3 and is approximately 50 kb in length. This allele, which encodes dipeptidyl peptidase 9 protein, plays a role in post-translational protein cleavage.","DPP9 wt Allele | DP9 | DPLP9 | DPRP-2 | DPRP2 | Dipeptidyl-Peptidase 9 wt Allele | Dipeptidylpeptidase 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1174250","Dipeptidyl Peptidase 9, Human","C124982","Dipeptidyl peptidase 9 (863 aa, ~98 kDa) is encoded by the human DPP9 gene. This protein is involved in the removal of dipeptides from the amino-termini of substrates.","Dipeptidyl Peptidase 9 | DP9 | DPLP9 | DPP IX | DPP9 | DPRP-2 | Dipeptidyl Peptidase IV-Related Protein | Dipeptidyl Peptidase IV-Related Protein 2 | Dipeptidyl Peptidase IV-Related Protein-2 | Dipeptidyl Peptidase IX | Dipeptidyl Peptidase-Like Protein 9 | EC 3.4.14.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417088","MDH2 Gene","C124983","This gene plays a role in the metabolism of both carbohydrates and oxoacids.","MDH2 Gene | MDH2 | Malate Dehydrogenase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085195","MDH2 wt Allele","C124984","Human MDH2 wild-type allele is located within 7cen-q22 and is approximately 19 kb in length. This allele, which encodes malate dehydrogenase, mitochondrial protein, is involved in the metabolism of malate and the synthesis of oxaloacetate.","MDH2 wt Allele | M-MDH | MDH | MGC:3559 | MOR1 | Malate Dehydrogenase 2 wt Allele | Malate Dehydrogenase 2, NAD (Mitochondrial) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4083833","Malate Dehydrogenase, Mitochondrial","C124985","Malate dehydrogenase, mitochondrial (338 aa, ~36 kDa) is encoded by the human MDH2 gene. This protein plays a role in the conversion of malate to oxaloacetate.","Malate Dehydrogenase, Mitochondrial | EC 1.1.1.37 | MDH2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416473","IRF5 Gene","C124986","This gene is involved in the transcriptional regulation of genes encoding interferons and inflammatory cytokines.","IRF5 Gene | IRF5 | Interferon Regulatory Factor 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085323","INO80 Complex Subunit D","C125260","INO80 complex subunit D (878 aa, ~98 kDa) is encoded by the human INO80D gene. This protein plays a role in chromatin remodeling.","INO80 Complex Subunit D | INO80D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424865","TRIM29 Gene","C125261","This gene may be involved in cellular stress signaling.","TRIM29 Gene | TRIM29 | Tripartite Motif Containing 29 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085636","TRIM29 wt Allele","C125262","Human TRIM29 wild-type allele is located in the vicinity of 11q23.3 and is approximately 74 kb in length. This allele, which encodes tripartite motif-containing protein 29, may play a role in the modulation of cellular stress responses. Mutation of the gene may be associated with ataxia-telangiectasia.","TRIM29 wt Allele | ATDC | FLJ36085 | Tripartite Motif Containing 29 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414227","E2F4 Gene","C125264","This gene plays a role in tumor suppressor-dependent transcriptional regulation.","E2F4 Gene | E2F Transcription Factor 4 Gene | E2F4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085335","E2F4 wt Allele","C125265","Human E2F4 wild-type allele is located in the vicinity of 16q22.1 and is approximately 7 kb in length. This allele, which encodes transcription factor E2F4 protein, is involved in the regulation of gene expression.","E2F4 wt Allele | E2F Transcription Factor 4 wt Allele | E2F Transcription Factor 4, p107/p130-Binding Gene | E2F-4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0291135","Transcription Factor E2F4","C125266","Transcription factor E2F4 (413 aa, ~44 kDa) is encoded by the human E2F4 gene. This protein plays a role in the modulation of tumor suppressor-dependent gene expression.","Transcription Factor E2F4 | E2F Transcription Factor 4 | E2F-4 | p107/p130-Binding Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427060","SLC9A9 Gene","C125267","This gene is involved in intracellular organelle ion homeostasis.","SLC9A9 Gene | SLC9A9 | Solute Carrier Family 9, Subfamily A (NHE9, Cation Proton Antiporter 9), Member 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084873","MAOB wt Allele","C125504","Human MAOB wild-type allele is located in the vicinity of Xp11.23 and is approximately 116 kb in length. This allele, which encodes amine oxidase [flavin-containing] B protein, plays a role in the metabolism of amines.","MAOB wt Allele | MAO, Brain Gene | MAO, Platelet Gene | MAO-B | Monoamine Oxidase B wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026456","Monoamine Oxidase B","C125505","Amine oxidase [flavin-containing] B (520 aa, ~59 kDa) is encoded by the human MAOB gene. This protein is involved in the deamination of amines.","Amine Oxidase [Flavin-Containing] B | Adrenalin Oxidase | Amine Oxidase (Flavin-Containing) B | EC 1.4.3.4 | MAO-B | MAOB | Monoamine Oxidase Type B | Tyramine Oxidase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2274359","Prevotella amnii","C124359","A species of anaerobic, non-motile, Gram-negative, rod-shaped bacteria in the family Prevotellaceae first isolated from human amniotic fluid. P. amnii is positive for phosphor-6-beta-galactosidase and negative for alpha-fucosidase and glutamyl-glutamic acid arylamidase.","Prevotella amnii | PREVOTELLA AMNII",,,,,,,,,,,,,,,"37016557","Prevotella amnii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1623544","Prevotella baroniae","C124360","A species of obligately anaerobic, non-motile, Gram-negative coccoid and short bacilli bacteria in the family Prevotellaceae first isolated from the human oral cavity. P. baroniae is able to ferment cellobiose, fructose, glucose, lactose, maltose, mannose, melibiose, raffinose, salicin, and sucrose.","Prevotella baroniae | PREVOTELLA BARONIAE | Prevotella Genomospecies E4",,,,,,,,,,,,,,,"37016558","Prevotella baroniae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL498279","anti-CD20 monoclonal antibody-interferon alpha fusion protein IGN002","C123915","A humanized monoclonal antibody directed against the human B-cell-specific cell surface antigen CD20 and fused to the recombinant cytokine, interferon-alpha (IFN-a), with potential antineoplastic and immunomodulating activities. Upon administration of eramkafusp alfa, the antibody moiety specifically targets and binds to CD20. In turn, the IFN-a moiety binds to the IFN receptor, and activates IFN-mediated signal transduction, which induces the transcription and translation of genes whose protein products mediate anticancer effects. This results in the induction of both G2 cell cycle arrest and apoptosis in CD20-expressing tumor cells. In addition, IGN002 causes the induction of complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B-cells, which leads to B-cell apoptosis and the inhibition of tumor cell proliferation. CD20, a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B-cells during most stages of B-cell development, is often overexpressed in B-cell malignancies.","Eramkafusp Alfa | Anti-CD20 Monoclonal Antibody-IFN-a Fusion Protein IGN002 | Anti-CD20 Monoclonal Antibody-Interferon-alpha Fusion Protein IGN002 | ERAMKAFUSP ALFA | IGN002",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498280","Cholecalciferol/Whey Protein Isolate/EPA/DHA-based Nutritional Supplement","C123916","A gluten-free, energy-rich, non-complete nutritional supplement drink composed of juice from the concentrates of apple pear, pomegranate, purple chokeberry and passion fruit, plus fish oil derived from salmon and cod, the minerals potassium, phosphorus and iodine, whey protein isolate derived from cow's milk, tocopherols (vitamin E), and cholecalciferol (vitamin D3) with potential anti-cachexic activity. Upon oral intake of the cholecalciferol/whey protein isolate/EPA/DHA-based nutritional supplement, the protein components maintain digestive health throughout the gastrointestinal (GI) tract and reduce the risk of digestive complications. The essential omega-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) from the fish oil are incorporated into cell membranes and affect the production of pro-inflammatory mediators, which elicits an anti-inflammatory effect. Cholecalciferol plays an important role in maintaining bone mineralization and regulating blood calcium and phosphorus levels. Tocopherols neutralize free radicals, thereby protecting tissues and organs from oxidative damage. In particular, alpha-tocopherol gets incorporated into biological membranes, maintains cell membrane integrity and protects the cell against damage. This nutritional supplement may prevent both malnutrition and weight loss.","Cholecalciferol/Whey Protein Isolate/EPA/DHA-based Nutritional Supplement | NutriFriend 1100 | Nutrifriend Cachexia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498281","anti-HER2 antibody-drug conjugate ARX788","C123917","An antibody-drug conjugate (ADC) composed of anvatabart, a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2) site-specifically conjugated at two engineered residues of para-acetyl-phenylalanine (pAcF) via a stable oxime linker to the monomethyl auristatin F (MMAF) analog and potent microtubule inhibitor opadotin, with potential antineoplastic activity. Upon administration of anvatabart opadotin, the antibody moiety targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, opadotin binds to and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. The site-specific conjugation of the cytotoxic agent to the antibody improves the biophysical properties of anvatabart opadotin, increases payload stability and optimizes its efficacy.","Anvatabart Opadotin | ADC ARX788 | ANVATABART OPADOTIN | ARX-788 | ARX788 | Anti-HER2 ADC ARX788 | Anti-HER2 Antibody-drug Conjugate ARX788 | Anti-HER2 Antibody-drug Conjugate ARX788 | Anti-Her2 Mab PAF- MMAF Toxin Oxime Conjugate ARX-788",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086766","Rat Malignant Peripheral Nerve Sheath Tumor","C125415","A malignant peripheral nerve sheath tumor occurring in a rat.","Rat Malignant Peripheral Nerve Sheath Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017528","Langhans Cell","C12562","No value exists.","Langhans Cell | Langhans' - Type Giant Cell",,,,,,,,,,,,,,,"4149870","Langhans giant cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504330","live-attenuated double-deleted Listeria monocytogenes bacteria JNJ-64041809","C125631","A proprietary, live-attenuated, double-deleted (LADD) strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding multiple, as of yet undisclosed, tumor-associated antigens (TAAs), with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, opolimogene capmilisbac is taken up by antigen-presenting cells (APCs), including dendritic cells (DCs). The TAAs are subsequently expressed by the APCs and then processed and presented to the immune system by both major histocompatibility complex (MHC) class I and II molecules. This activates the immune system and leads to the recruitment and activation of cytotoxic T-lymphocytes (CTLs) against the TAA-expressing tumor cells, eventually resulting in tumor cell lysis. Two genes contributing to the virulence of Lm have been removed to minimize the risk of infection.","Opolimogene Capmilisbac | ADU-741 | JNJ-64041809 | JNJ-809 | OPOLIMOGENE CAPMILISBAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504331","Shi Pi Yin Herbal Decoction","C125632","A traditional Chinese medicine (TCM) decoction containing a mixture of Aconiti lateral root, Zingiberis (ginger) root, Fu Ling (Poria), Atractylodis macrocephalae, Chaenomelis fruit (flowering quince fruit), magnolia bark, Aucklandia costus root, Arecae pericarpium, Tsao-Ko (cardamon) fruit, and licorice root, and may also contain Arecae seeds and Ziziphus jujuba fruit (red date), which may be used to treat edema. Although the exact mechanism(s) of action through which Shi Pi Yin decoction exerts its effect has yet to be fully elucidated, upon oral administration, this TCM may reduce edema.","Shi Pi Yin Herbal Decoction | Shi Pi Decoction | Shi Pi TCM Herbal Decoction | Shi Pi Traditional Chinese Medicine Herbal Decoction | Shi Pi Yin | Shi-pi-yin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504332","Anti-Epidermal Growth Factor Receptor 2 Antibody Expressing Pluripotent Killer T-Lymphocytes","C125633","A specific population of pluripotent killer (PIK) T-cells that have been induced to express high levels of antibodies against human epidermal growth factor receptor 2 (ERBB2; HER2), with potential antitumor activity. Although the exact mechanism(s) of action through which PIK-HER2 cells exert their effects has yet to be elucidated, upon infusion, these cells secrete antibodies targeting HER2 expressed on the surface of tumor cells. This may inhibit HER2-dependent signaling, which may lead to inhibition of cellular proliferation and differentiation. Additionally, these cells may stimulate the host immune system to mount both a highly-specific cytotoxic T-lymphocyte (CTL) response and antibody-dependent cell cytotoxicity (ADCC) directed against HER2-overexpressing tumors, which leads to tumor cell lysis. HER2 is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases and is frequently overexpressed in solid tumors.","Anti-Epidermal Growth Factor Receptor 2 Antibody Expressing Pluripotent Killer T-Lymphocytes | Anti-ERBB2 Antibody Expressing Pluripotent Killer T-Cells | Anti-ERBB2 Antibody Expressing Pluripotent Killer T-Lymphocytes | Anti-Epidermal Growth Factor Receptor 2 Antibody Expressing Pluripotent Killer T-Cells | Anti-HER2 Antibody Expressing Pluripotent Killer T-Cells | Anti-HER2 Antibody Expressing Pluripotent Killer T-Lymphocytes | PIK-HER2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086798","Relapse of Prior Malignancy","C125202","Clinical and/or laboratory evidence of reemergence of a malignancy after a period of remission.","Relapse of Prior Malignancy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086914","Transplant-Related Mortality","C125203","Death due to complications following an organ transplant.","Transplant-Related Mortality | TRM | Transplant Related Death | Transplant Related Mortality | Transplant-Related Death",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086829","Reversal of Disease Phenotype","C125205","Lack of the prior infectious complications or malignancy that preceded a transplant","Reversal of Disease Phenotype | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085573","TMEM37 wt Allele","C125212","Human TMEM37 wild-type allele is located in the vicinity of 2q14.2 and is approximately 8 kb in length. This allele, which encodes voltage-dependent calcium channel gamma-like subunit protein, may play a role in the modulation of calcium channel activity.","TMEM37 wt Allele | PR | PR1 | Transmembrane Protein 37 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085567","Voltage-Dependent Calcium Channel Gamma-Like Subunit","C125213","Voltage-dependent calcium channel gamma-like subunit (190 aa, ~21 kDa) is encoded by the human TMEM37 gene. This protein may be involved in the regulation of voltage-gated calcium ion channel activity.","Voltage-Dependent Calcium Channel Gamma-Like Subunit | Neuronal Voltage-Gated Calcium Channel Gamma-Like Subunit | Transmembrane Protein 37 | Voltage-Dependent Calcium Channel Gamma Subunit-Like Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3495846","Immune Reconstitution Inflammatory Syndrome Associated with Kaposi Sarcoma","C125712","A syndrome that occurs in a proportion of patients with HIV infection and Kaposi sarcoma after initiation of highly active antiretroviral therapy. It is characterized by a deterioration in their clinical status, despite control of virologic and immunologic parameters.","Immune Reconstitution Inflammatory Syndrome Associated with Kaposi Sarcoma | IRIS-Associated KS | IRIS-KS | KS-Associated IRIS | KS-IRIS | Kaposi Sarcoma Immune Reconstitution Syndrome | Kaposi Sarcoma-Associated Immune Reconstitution Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3489797","Alvelestat","C125714","An orally bioavailable, selective and reversible inhibitor of human neutrophil elastase (NE), with potential anti-inflammatory activity. Upon administration, alvelestat binds to and inhibits the activity of human NE. This inhibits NE-mediated inflammatory responses, which may prevent lung inflammation and injury, and may improve lung function associated with NE-induced respiratory diseases. NE, a serine protease released by neutrophils during inflammation, is upregulated in a number of respiratory diseases.","Alvelestat | 6-Methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-((5-(methylsulfonyl)pyridin-2-yl)methyl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide | ALVELESTAT | AZD 9668 | AZD-9668 | AZD9668",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086782","Relapsed or Refractory HRMDS","C125715","The reemergence of acute myeloid leukemia, myelodysplasia-related after a period of remission.","Recurrent Acute Myeloid Leukemia, Myelodysplasia-Related | Recurrent Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes | Recurrent Acute Myeloid Leukemia with Myelodysplasia-Related Changes | Recurrent Acute Myeloid Leukemia with Myelodysplasia-Related Changes | Recurrent HRMDS | Recurrent Myelodysplastic Syndrome | Relapsed or Refractory HRMDS | Relapsed or Refractory High-Risk Myelodysplastic Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498282","Autologous Colorectal Tumor Antigen-pulsed Dendritic Cell Vaccine","C123918","A dendritic cell (DC)-based cancer vaccine composed of autologous DCs pulsed with tumor cell lysates from a colorectal cancer patient containing tumor-associated antigens (TAAs), with potential immunostimulatory and antineoplastic activities. Upon administration, autologous colorectal tumor antigen-pulsed DC vaccine exposes the immune system to colorectal tumor cell antigens, which may result in cytotoxic T-lymphocyte (CTL)-mediated immune responses against the colorectal cancer cells. This leads to cancer cell lysis. The tumor cell lysate contains a range of antigens that are essential for the neoplastic growth and survival of the cancer cells.","Autologous Colorectal Tumor Antigen-pulsed Dendritic Cell Vaccine | APDC Vaccine | Autologous Colorectal Tumor Antigen-pulsed DC Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498283","DNA plasmid-encoding interleukin-12/HPV DNA plasmids therapeutic vaccine INO-3112","C123919","A DNA-based combination immunotherapeutic, MEDI0457, composed of VGX-3100, a preparation of DNA plasmids encoding the E6 and E7 genes of human papillomavirus (HPV) subtypes 16 and 18, combined with INO-9012, a DNA plasmid encoding the immune activator and pro-inflammatory cytokine human interleukin-12 (IL-12) with potential immunoactivating and antineoplastic activities. Upon intramuscular delivery by electroporation of VGX-3100, the HPV E6 and E7 proteins are translated in cells and elicit a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing the E6 and E7 antigens, resulting in tumor cell lysis. HPV type 16 and HPV type 18 are associated with the development of certain types of cancer. Upon intramuscular delivery by electroporation of INO-9012, IL-12 is expressed and activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma (IFN-g) and promoting CTL responses against tumor cells. This boosts the immune response and results in increased CTL-mediated tumor cell death as compared with the administration of VGX-3100 alone.","DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457 | INO 3112 | INO-3112 | INO-3112 Vaccine | MEDI 0457 | MEDI-0457 | MEDI0457 | VGX-3100 Plus INO-9012",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502877","Ranitidine Hydrochloride/Bismuth Potassium Citrate/Sucralfate Hydrate Formulation","C124645","A formulation containing the hydrochloride salt form of the non-imidazole histamine H2 receptor antagonist ranitidine, bismuth potassium citrate, and the hydrate form of sucralfate, a basic aluminum complex of sulfated sucrose, with potential antacid, radio- and cytoprotective activities. Upon oral administration of the ranitidine hydrochloride/bismuth potassium citrate/sucralfate hydrate formulation, ranitidine binds to and blocks the activity of the histamine H2 receptors in the parietal cells in the stomach and in the gastrointestinal (GI) tract, thereby decreasing acid secretion. Sucralfate physically binds to the surface of damaged mucosa, thereby forming a protective barrier that shields the GI tract from stomach acid. It also neutralizes stomach acid. Bismuth inhibits peptic activity, increases mucosal secretions and acts as a barrier to prevent damage by acid. Altogether, this protects against ulcer formation and may help to heal existing ulcers.","Ranitidine Hydrochloride/Bismuth Potassium Citrate/Sucralfate Hydrate Formulation | Albis | Ranitidine Hydrochloride/Bismuth Potassium Citrate/Sucralfate Hydrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502878","Anti-MUC1 CAR-transduced Autologous T-lymphocytes","C124646","Autologous T-lymphocytes transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) against the human tumor-associated epithelial antigen mucin 1 (MUC1), with potential immunomodulating and antineoplastic activities. Autologous PBLs from a patient with MUC1-positive cancer are transduced with a retroviral vector that encodes the CAR gene specific for MUC1. After expansion in culture and reintroduction into the patient, anti-MUC1 CAR-transduced autologous T-lymphocytes target and induce selective toxicity in MUC1-expressing tumor cells. MUC-1 is a human, hypoglycosylated tumor-associated antigen (TAA) overexpressed by epithelial cancer cells.","Anti-MUC1 CAR-transduced Autologous T-lymphocytes | Anti-MUC1 Autologous CAR T Cells | Anti-MUC1 CAR-transduced Autologous T Cells | Anti-Mucin1 Autologous CAR T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502879","Anti-nf-P2X7 Antibody Ointment BIL-010t","C124647","An ointment formulation composed of a purified sheep immunoglobulin G (IgG) antibody against the non-functional form of the purinergic P2X7 receptor (nf-P2X7), with potential antineoplastic activity. Upon topical application of the anti-nf-P2X7 antibody ointment BIL-010t, the antibody binds to nf-P2X7 and inhibits its antiapoptotic activity. This may induce apoptosis and inhibit the growth of nf-P2X7-overexpressing cancer cells. P2X7, an ATP-gated cation-selective channel, plays a role in the induction of apoptosis; nf-P2X7, is upregulated in a variety of cancer cell types while not expressed on normal, healthy cells and is unable to form a large transmembrane, apoptotic pore upon exposure to ATP and prevents apoptosis.","Anti-nf-P2X7 Antibody Ointment BIL-010t | BIL-010t | BSCT 10 % Ointment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504333","Dendritic Cell-Precision Multiple Antigen T-Lymphocytes","C125634","A preparation of dendritic cell-precision multiple antigen T-cells (DC-PMAT) that have been induced to specifically target multiple undisclosed tumor-associated antigens (TAAs), with potential antitumor activity. Although the exact mechanism(s) of action through which DC-PMAT cells exert their effects has yet to be elucidated, upon infusion, these cells may stimulate the host immune system to mount a highly-specific cytotoxic T-lymphocyte (CTL) response against tumors expressing common TAAs, which leads to tumor cell lysis.","Dendritic Cell-Precision Multiple Antigen T-Lymphocytes | DC-PMAT | Dendritic Cell-Precision Multiple Antigen T-Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503800","pan FGFR Inhibitor PRN1371","C124931","A highly specific covalent inhibitor of human fibroblast growth factor receptor types 1, 2, 3 and 4 (FGFR1-4) with potential antiangiogenic and antineoplastic activities. FGFR1-4 tyrosine kinase inhibitor PRN1371 specifically binds to a conserved cysteine residue in the glycine-rich loop in FGFRs and inhibits their tyrosine kinase activity, which may result in the inhibition of both tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. FGFRs are a family of receptor tyrosine kinases, which may be upregulated in various tumor cell types and may be involved in tumor cell differentiation, proliferation and survival, and in tumor angiogenesis. This agent potently inhibits FGFR1-4 but does not inhibit other tyrosine kinases, even those that share the conserved cysteine, which may improve therapeutic responses and decrease toxicity when compared with less selective inhibitors.","pan FGFR Inhibitor PRN1371 | FGFR 1-4 Inhibitor PRN1371 | PRN 1371 | PRN-1371 | PRN-1371 FREE BASE | PRN1371 | Pan-FGFR Tyrosine Kinase Inhibitor PRN1371",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421437","VCP Gene","C124932","This gene is involved in the formation of the transitional endoplasmic reticulum and Golgi apparatus maintenance during mitosis.","VCP Gene | VCP | Valosin Containing Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085181","VCP wt Allele","C124933","Human VCP wild-type allele is located in the vicinity of 9p13.3 and is approximately 17 kb in length. This allele, which encodes transitional endoplasmic reticulum ATPase protein, plays a role in maintenance of both the transitional endoplasmic reticulum and the Golgi apparatus. Mutation of the gene is associated with amyotrophic lateral sclerosis 14 and inclusion body myopathy with early-onset Paget disease and frontotemporal dementia 1 (IBMPFD1).","VCP wt Allele | ALS14 | CDC48, Yeast, Homolog of Gene | IBMPFD | TERA | Valosin Containing Protein wt Allele | Yeast Cdc48p Homolog Gene | p97",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1613884","p97 ATPase","C124934","Transitional endoplasmic reticulum ATPase (806 aa, ~89 kDa) is encoded by the human VCP gene. This protein is involved in maintaining the Golgi during and after mitosis and the the formation of the transitional endoplasmic reticulum.","Transitional Endoplasmic Reticulum ATPase | 15S Mg(2+)-ATPase P97 Subunit | ATPase p97 | EC 3.6.4.6 | Epididymis Luminal Protein 220 | Epididymis Secretory Protein Li 70 | TER ATPase | VCP | Valosin Containing Protein | Valosin-Containing Protein | p97 ATPase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421425","VAPB Gene","C124935","This gene plays a role in the endoplasmic reticulum unfolded protein response.","VAPB Gene | VAMP (Vesicle-Associated Membrane Protein)-Associated Protein B and C Gene | VAPB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084874","MAP2 wt Allele","C125215","Human MAP2 wild-type allele is located within 2q34-q35 and is approximately 310 kb in length. This allele, which encodes microtubule-associated protein 2, may be involved in the stabilization of microtubules.","MAP2 wt Allele | MAP, Dendrite-Specific Gene | MAP2A | MAP2B | MAP2C | Microtubule Associated Protein 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024773","Microtubule-Associated Protein 2","C125216","Microtubule-associated protein 2 (1827 aa, ~200 kDa) is encoded by the human MAP2 gene. This protein may play a role in microtubule stability.","Microtubule-Associated Protein 2 | MAP-2 | MAP2 | Microtubule Associated Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428194","GPR158 Gene","C125462","This gene plays a role in the mediation of G protein-coupled receptor signaling.","GPR158 Gene | G Protein-Coupled Receptor 158 Gene | GPR158",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085336","GPR158 wt Allele","C125463","Human GPR158 wild-type allele is located in the vicinity of 10p12.31 and is approximately 427 kb in length. This allele, which encodes probable G-protein coupled receptor 158 protein, is involved in G protein-coupled receptor signal transduction.","GPR158 wt Allele | G Protein-Coupled Receptor 158 wt Allele | KIAA1136",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084888","Probable G-Protein Coupled Receptor 158","C125464","Probable G-protein coupled receptor 158 (1215 aa, ~135 kDa) is encoded by the human GPR158 gene. This protein plays a role in G protein-coupled receptor activity.","Probable G-Protein Coupled Receptor 158 | G Protein-Coupled Receptor 158 | G-Protein Coupled Receptor 158 | GPR158 | Probable G Protein-Coupled Receptor 158",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538923","ARHGAP11B Gene","C125465","This gene is involved in corticogenesis.","ARHGAP11B Gene | ARHGAP11B | Rho GTPase-Activating Protein 11B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085577","ARHGAP11B wt Allele","C125466","Human ARHGAP11B wild-type allele is located in the vicinity of 15q13.2 and is approximately 149 kb in length. This allele, which encodes Rho GTPase-activating protein 11B, plays a role in both signal transduction and brain cortex development.","ARHGAP11B wt Allele | B'-T | FAM7B1 | Family With Sequence Similarity 7, Member B1 Gene | GAP (1-8) Gene | Rho GTPase-Activating Protein 11B wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4042334","Rho GTPase-Activating Protein 11B, Human","C125467","Rho GTPase-activating protein 11B (267 aa, ~30 kDa) is encoded by the human ARHGAP11B gene. This protein is involved in corticogenesis.","Rho GTPase-Activating Protein 11B | ARHGAP11B | Protein FAM7B1 | Rho-Type GTPase-Activating Protein 11B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425067","TREM2 Gene","C125468","This gene plays a role in the activation of immune responses.","TREM2 Gene | TREM2 | Triggering Receptor Expressed On Myeloid Cells 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085570","TREM2 wt Allele","C125469","Human TREM2 wild-type allele is located in the vicinity of 6p21.1 and is approximately 5 kb in length. This allele, which encodes triggering receptor expressed on myeloid cells 2 protein, is involved in inflammation. Expression of the gene may be associated with chronic inflammation and mutation of the gene is associated with polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (Nasu-Hakola disease).","TREM2 wt Allele | TREM-2 | Trem2a | Trem2b | Trem2c | Triggering Receptor Expressed On Myeloid Cells 2 wt Allele | Triggering Receptor Expressed On Myeloid Cells 2a Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1143976","Triggering Receptor Expressed On Myeloid Cells 2, Human","C125470","Triggering receptor expressed on myeloid cells 2 (230 aa, ~25 kDa) is encoded by the human TREM2 gene. This protein plays a role in macrophage and dendritic cell immune responses.","Triggering Receptor Expressed On Myeloid Cells 2 | TREM-2 | TREM2 | Triggering Receptor Expressed On Monocytes 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086280","Expiratory Muscle Strength Training","C125716","High-intensity, low-repetition expiratory exercises designed to promote strength in the expiratory muscles. Expiratory muscle strength training typically uses a pressure threshold device with a regimented treatment protocol. This treatment may benefit individuals with spinal cord injury, chronic obstructive pulmonary disease, multiple sclerosis, Parkinson's disease, voice disorders, and the sedentary elderly.","Expiratory Muscle Strength Training | EMST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504373","Anti-CD33 Antibody-drug Conjugate IMGN779","C125717","An antibody-drug conjugate (ADC) consisting of the humanized monoclonal antibody Z4681A conjugated, via a cleavable disulfide linker, to the cytotoxic DNA alkylating agent DGN462, which is an indolino-benzodiazepine dimer containing a mono-imine moiety, with potential antineoplastic activity. The monoclonal antibody portion of anti-CD33 monoclonal antibody-DGN462 conjugate IMGN779 specifically binds to the cell surface antigen CD33 expressed on myeloid leukemia cells; upon internalization, the DGN462 moiety is released, and covalently binds to and alkylates DNA, thereby causing cell cycle arrest, apoptosis and inhibition of cell growth in myeloid leukemia cells that express CD33. CD33 is expressed on normal non-pluripotent hematopoietic stem cells and myeloid leukemia cells.","Anti-CD33 Antibody-drug Conjugate IMGN779 | ADC IMGN779 | Anti-CD33 ADC IMGN779 | IMGN-779 | IMGN779",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504374","SIRPa-Fc fusion protein TTI-621","C125718","A soluble recombinant antibody-like fusion protein composed of the N-terminal CD47 binding domain of human signal-regulatory protein alpha (SIRPa) linked to the Fc domain of human immunoglobulin G1 (IgG1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, ontorpacept selectively targets and binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with endogenous SIRPa, a cell surface protein expressed on macrophages. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, thereby allowing cancer cells to proliferate.","Ontorpacept | ONTORPACEPT | SIRPa-Fc Fusion Protein TTI-621 | SIRPaFc | TTI 621 | TTI-621",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502880","ATM Kinase Inhibitor AZD0156","C124648","An orally bioavailable ataxia telangiectasia mutated (ATM) kinase inhibitor, with potential chemo-/radio-sensitizing and antineoplastic activities. Upon oral administration, AZD0156 targets and binds to ATM, thereby inhibiting the kinase activity of ATM and ATM-mediated signaling. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, induces tumor cell apoptosis, and leads to cell death of ATM-overexpressing tumor cells. In addition, AZD0156 sensitizes tumor cells to chemo- and radiotherapy. ATM, a serine/threonine protein kinase, is upregulated in a variety of cancer cell types; it is activated in response to DNA damage and plays a key role in DNA-strand repair.","ATM Kinase Inhibitor AZD0156 | AZD-0156 | AZD0156",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502881","Sheng-Yu-Tang","C124649","A Traditional Chinese Medicine (TCM) containing Radix Rehmanniae Praeparata, Radix Paeoniae Alba, Radix Astragali, Radix Ginseng, Radix Angelicae Sinensis, and Rhizoma Chuanxiong, with potential immunomodulating activity. Although the exact mechanism of action through which Sheng-Yu-Tang exerts its effect has yet to be fully elucidated, upon oral administration, this TCM may have a beneficial effect on the immune system.","Sheng-Yu-Tang | Chinese Medicine Sheng-Yu-Tang | Sagacious Cure Decoction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502882","Anti-mesothelin CAR Vector-transduced Autologous T-lymphocytes","C124650","Genetically modified, autologous T-lymphocytes transduced with a retroviral vector encoding a chimeric antigen receptor (CAR) consisting of an anti-human tumor-associated antigen (TAA) mesothelin single chain variable fragment (scFv), the intracellular CD3 zeta T-cell receptor domain and the 4-1BB (cd137) costimulatory domain, with potential immunomodulating and antineoplastic activities. After isolation, transduction, expansion in culture, and reintroduction into the patient, the anti-mesothelin CAR vector-transduced autologous T-lymphocytes specifically target and kill mesothelin-expressing tumor cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types.","Anti-mesothelin CAR Vector-transduced Autologous T-lymphocytes | Anti-meso-CAR Vector-transduced Autologous T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085329","HOXC9 wt Allele","C124119","Human HOXC9 wild-type allele is located in the vicinity of 12q13.3 and is approximately 8 kb in length. This allele, which encodes homeobox protein Hox-C9, plays a role in the modulation of anterior-posterior axis formation.","HOXC9 wt Allele | HOX3 | HOX3B | Homeo Box C9 Gene | Homeobox 3B Gene | Homeobox C9 wt Allele | Hox-3.2, Mouse, Homolog of Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502522","Homeobox Protein Hox-C9","C124120","Homeobox protein Hox-C9 (260 aa, ~29 kDa) is encoded by the human HOXC9 gene. This protein is involved in anterior-posterior axis specification.","Homeobox Protein Hox-C9 | Homeobox Protein Hox-3B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084728","HOXC5 wt Allele","C124122","Human HOXC5 wild-type allele is located in the vicinity of 12q13.3 and is approximately 19 kb in length. This allele, which encodes homeobox protein Hox-C5, is involved in the regulation of gene transcription and anterior-posterior patterning.","HOXC5 wt Allele | CP11 | HOX3 | HOX3D | Homeo Box C5 Gene | Homeobox 3D Gene | Homeobox C5 wt Allele | Hox-6.2, Mouse, Homolog of Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502524","Homeobox Protein Hox-C5","C124123","Homeobox protein Hox-C5 (222 aa, ~25 kDa) is encoded by the human HOXC5 gene. This protein plays a role in the modulation of anterior-posterior axis formation.","Homeobox Protein Hox-C5 | Homeobox Protein CP11 | Homeobox Protein Hox-3D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085193","SLC16A3 wt Allele","C124125","Human SLC16A3 wild-type allele is located in the vicinity of 17q25 and is approximately 33 kb in length. This allele, which encodes monocarboxylate transporter 4 protein, plays a role in monocarboxylate transport.","SLC16A3 wt Allele | MCT 3 | MCT 4 | MCT-3 | MCT-4 | MCT3 | MCT4 | Solute Carrier Family 16 (Monocarboxylate Transporter), Member 3 wt Allele | Solute Carrier Family 16 (Monocarboxylic Acid Transporters), Member 3 Gene | Solute Carrier Family 16, Member 3 (Monocarboxylic Acid Transporter 4) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085183","VAPB wt Allele","C124936","Human VAPB wild-type allele is located in the vicinity of 20q13.33 and is approximately 62 kb in length. This allele, which encodes vesicle-associated membrane protein-associated protein B and vesicle-associated membrane protein-associated protein C, is involved in the mediation of the response to unfolded proteins. Mutation of the gene is associated with amyotrophic lateral sclerosis 8 and autosomal dominant adult proximal spinal muscular atrophy (SMAPAD).","VAPB wt Allele | ALS8 | DVAP33A, Drosophila, Homolog of Gene | UNQ484/PRO983 | VAMP (Vesicle-Associated Membrane Protein)-Associated Protein B and C wt Allele | VAMP-B | VAMP-B/VAMP-C | VAMP-C | VAP-B | VAP-B/VAP-C | VAP-C | VAPC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086941","VAPB Gene Product","C124937","A protein encoded by the VAPB gene.","VAPB Gene Product | VAMP-Associated Protein B/C | VAMP-B/C | VAP-B/C | Vesicle-Associated Membrane Protein-Associated Protein B/C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503804","Vesicle-Associated Membrane Protein-Associated Protein B","C124938","Vesicle-associated membrane protein-associated protein B (243 aa, ~27 kDa) is encoded by the human VAPB gene. This protein plays a role in the regulation of the unfolded protein response.","Vesicle-Associated Membrane Protein-Associated Protein B | VAMP-Associated 33 kDa Protein | VAMP-Associated Protein B | VAMP-B | VAP-B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4083142","Vesicle-Associated Membrane Protein-Associated Protein C","C124939","Vesicle-associated membrane protein-associated protein C (99 aa, ~11 kDa) is encoded by the human VAPB gene. This protein plays a role in the unfolded protein response.","Vesicle-Associated Membrane Protein-Associated Protein C | VAMP-Associated Protein C | VAMP-C | VAP-C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413903","DAO Gene","C124940","This gene is involved in the modification of amino acids.","DAO Gene | D-Amino-Acid Oxidase Gene | DAO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084885","DAO wt Allele","C124941","Human DAO wild-type allele is located in the vicinity of 12q24 and is approximately 42 kb in length. This allele, which encodes D-amino-acid oxidase protein, plays a role in amino acid modification. Mutation of the gene is associated with schizophrenia and may be associated with familial amyotrophic lateral sclerosis.","DAO wt Allele | D-Amino-Acid Oxidase wt Allele | DAAO | DAMOX | OXDA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010895","D-Amino-Acid Oxidase","C124942","D-amino-acid oxidase (347 aa, ~39 kDa) is encoded by the human DAO gene. This protein is involved in amino acid metabolism.","D-Amino-Acid Oxidase | D-Amino Acid Oxidase | DAAO | DAMOX | DAO | EC 1.4.3.3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504347","Autologous Interferon-producing Killer Dendritic Cells","C125667","A preparation of autologous dendritic cells (DC) with a molecular expression profile similar to both natural killer (NK) cells and DCs, with potential antineoplastic activity. Autologous interferon-producing killer dendritic cells (IKDCs) are characterized by double-negative expression of CD3 and CD19; these cells also express low levels of CD11 and are positive for B220. They are distinguished from plasmacytoid DCs (pDCs) by the absence of lymphocyte antigen 6C (Ly6C, Gr-1) expression. IKDCs produce interferon gamma (IFN-gamma) and interleukin (IL) -12, and are able to kill typical NK target cells using NK receptors while retaining DC-like antigen-presenting activity. Upon administration of the autologous IKDCs, these cells secrete high levels of IFN-gamma and, when in contact with tumor cells, mediate TNF-related apoptosis-inducing ligand (TRAIL)-dependent direct lysis of tumor cells. The resulting apoptotic tumor antigens may be presented by the IKDCs, thus activating the immune system to exert a cytotoxic T-lymphocyte (CTL) response to further eliminate tumor cells.","Autologous Interferon-producing Killer Dendritic Cells | Autologous IKDC | Autologous IKDC-like Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086013","BCL2L1 Gene Product","C125668","A protein encoded by the human BCL2L1 gene.","BCL2L1 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206190","Peritoneal Macrophage","C12566","A differentiated macrophage that resides in the serosal peritoneal membrane and plays an important role in the defense against peritoneal cavity infections.","Peritoneal Macrophage | Peritoneal Macrophages",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0539599","Monocarboxylate Transporter 4, Human","C124126","Monocarboxylate transporter 4 (465 aa, ~49 kDa) is encoded by the human SLC16A3 gene. This protein is involved in the transport of monocarboxylates.","Monocarboxylate Transporter 4 | MCT 4 | Monocarboxylate Transporter 3 | SLC16A3 | Solute Carrier Family 16 Member 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2614782","Prevotella timonensis","C124361","A species of obligately anaerobic, non-pigmented, non-spore-forming, non-motile, Gram-negative straight rod-shaped bacteria in the family Prevotellaceae first isolated from a human breast abscess. P. timonensis is able to ferment glucose, lactose and maltose.","Prevotella timonensis | PREVOTELLA TIMONENSIS",,,,,,,,,,,,,,,"42873121","Prevotella timonensis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0331712","Prototheca stagnora","C124362","A species of achlorophyllic alga in the family Chlorellaceae. P. stagnora is mucoid and grows only at 30 degrees C.","Prototheca stagnora | PROTOTHECA STAGNORUM",,,,,,,,,,,,,,,"4310098","Prototheca stagnora",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0331709","Prototheca zopfii","C124363","A species of achlorophyllic alga in the family Chlorellaceae. P. zopfii is a rare opportunistic pathogen, mostly infecting dogs and cattle.","Prototheca zopfii | PROTOTHECA ZOPFII",,,,,,,,,,,,,,,"4138977","Prototheca zopfii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086924","Urea-Positive Providencia stuartii","C124364","A subtype of Providencia stuartii that are positive for urease enzyme activity and are capable of hydrolyzing urea to ammonia and carbon dioxide. The determinant for urease likely resides on a transmissible plasmid.","Urea-Positive Providencia stuartii | PROVIDENCIA STUARTII, UREA-POSITIVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0318041","Pseudomonas nitroreducens","C124365","A species of gram-negative, motile, non-spore-forming, rod-shaped, aerobic soil bacteria in the family Pseudomonadaceae first isolated from oil brine in Japan. P. nitroreducens is negative for beta-galactosidase and hydrolysis of gelatin.","Pseudomonas nitroreducens | PSEUDOMONAS NITROREDUCENS | Pseudomonas azelaica | Pseudomonas multiresinivorans",,,,,,,,,,,,,,,"4023766","Pseudomonas nitroreducens",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0321459","Pseudoterranova decipiens","C124366","A species of parasitic nematodes in the family Anisakidae. The lifecycle of P. decipiens involves crustaceans as the first intermediate host, fish or squids as the second intermediate host, and marine mammals as the definitive host. Humans may become infested by eating undercooked fish and may also develop anaphylaxis upon contact with the worm in properly prepared fish.","Pseudoterranova decipiens | Codworm | PSEUDOTERRANOVA DECIPIENS | Phocanema decipiens | Sealworm",,,,,,,,,,,,,,,"4154590","Pseudoterranova decipiens",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1456386","MAP2K3 Gene","C125164","This gene is involved in stress-mediated signaling.","MAP2K3 Gene | MAP2K3 | Mitogen-Activated Protein Kinase Kinase 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084906","MAP2K3 wt Allele","C125165","Human MAP2K3 wild-type allele is located in the vicinity of 17q11.2 and is approximately 31 kb in length. This allele, which encodes dual specificity mitogen-activated protein kinase kinase 3 protein, plays a role in signal transduction.","MAP2K3 wt Allele | MAPKK3 | MEK3 | MKK3 | Mitogen-Activated Protein Kinase Kinase 3 wt Allele | PRKMK3 | Protein Kinase, Mitogen-Activated, Kinase 3 Gene | SAPKK-2 | SAPKK2 | SKK2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1434650","Dual Specificity Mitogen-Activated Protein Kinase Kinase 3, Human","C125166","Dual specificity mitogen-activated protein kinase kinase 3 (347 aa, ~39 kDa) is encoded by the human MAP2K3 gene. This protein is involved in signaling induced by environmental stress.","Dual Specificity Mitogen-Activated Protein Kinase Kinase 3 | Dual Specificity Mitogen Activated Protein Kinase Kinase 3 | MAP Kinase Kinase 3 | MAP2K3 | MAPK/ERK Kinase 3 | MAPKK 3 | MEK 3 | SAPK Kinase 2 | SAPKK-2 | SAPKK2 | Stress-Activated Protein Kinase Kinase 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823863","WWC1 Gene","C125167","This gene plays a role in both transcriptional regulation and signal transduction.","WWC1 Gene | WW and C2 Domain Containing 1 Gene | WWC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085340","WWC1 wt Allele","C125168","Human WWC1 wild-type allele is located in the vicinity of 5q34 and is approximately 181 kb in length. This allele, which encodes protein KIBRA, is involved in the hippo signaling pathway and as a transcriptional coactivator for estrogen receptor.","WWC1 wt Allele | HBEBP3 | HBEBP36 | KIAA0869 | KIBRA | MEMRYQTL | PPP1R168 | Protein Phosphatase 1, Regulatory Subunit 168 Gene | WW and C2 Domain Containing 1 wt Allele | WW, C2 and Coiled-Coil Domain Containing 1 Gene | WW, C2, and Coiled-Coil Domain-Containing 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1743032","KIBRA Protein, Human","C125169","Protein KIBRA (1113 aa, ~125 kDa) is encoded by the human WWC1 gene. This protein plays a role in transcription coactivation and signaling.","Protein KIBRA | HBeAg-Binding Protein 3 | KIBRA | Kidney and Brain Expressed Protein | Kidney and Brain Protein | Protein WWC1 | WW Domain-Containing Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539224","DCHS2 Gene","C125170","This gene is involved in calcium-dependent cell adhesion.","DCHS2 Gene | DCHS2 | Dachsous Cadherin-Related 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085214","DCHS2 wt Allele","C125171","Human DCHS2 wild-type allele is located in the vicinity of 4q31.3 and is approximately 260 kb in length. This allele, which encodes protocadherin-23 protein, plays a role in cell-cell adhesion.","DCHS2 wt Allele | CDH27 | CDHJ | CDHR7 | Dachsous 2 (Drosophila) Gene | Dachsous Cadherin-Related 2 wt Allele | Dachsous, Drosophila, Homolog of, 2 Gene | FLJ20047 | PCDH23 | PCDHJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539922","TAOK1 Gene","C125173","This gene plays a role in both serine/threonine phosphorylation and mitogen-activated kinase pathways.","TAOK1 Gene | TAO Kinase 1 Gene | TAOK1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086767","Rat Multiple Myeloma","C125416","Plasma cell myeloma occurring in a rat.","Rat Multiple Myeloma | Rat Plasma Cell Myeloma | Rat Plasma Cell Myeloma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086608","Mouse Multiple Myeloma","C125417","Plasma cell myeloma occurring in a mouse.","Mouse Multiple Myeloma | Mouse Plasma Cell Myeloma | Mouse Plasma Cell Myeloma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1849649","Pseudotrisomy 13 Syndrome","C125418","A rare syndrome likely inherited in an autosomal recessive pattern. It is characterized by holoprosencephaly, polydactyly, phenotypic features reminiscent of trisomy 13, and normal karyotype.","Pseudotrisomy 13 Syndrome | Holoprosencephaly-Polydactyly Syndrome",,,,,,,,,,,,,,,"37399496","Holoprosencephaly and postaxial polydactyly syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0028875","Odontoblast","C12567","A cell derived from a preodontoblast that secretes predentin. Each odontoblast has a cytoplasmic extension, an odontoblastic process that traverses the thickness of the dentin and helps to maintain the dentin.","Odontoblast | Odontoblasts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084870","IRF5 wt Allele","C124987","Human IRF5 wild-type allele is located in the vicinity of 7q32 and is approximately 12 kb in length. This allele, which encodes interferon regulatory factor 5 protein, plays a role in the regulation of interferon and inflammatory cytokine expression. Mutation of the gene is associated with inflammatory bowel disease 14 and susceptibility to systemic lupus erythematosus 10.","IRF5 wt Allele | IBD14 | Interferon Regulatory Factor 5 wt Allele | SLEB10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505086","Interferon Regulatory Factor 5","C124988","Interferon regulatory factor 5 (498 aa, ~56 kDa) is encoded by the human IRF5 gene. This protein is involved in the modulation of pro-inflammatory gene expression.","Interferon Regulatory Factor 5 | IRF-5 | IRF5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420095","SLC12A7 Gene","C124989","This gene plays a role in the transport of calcium and potassium ions across cell membranes.","SLC12A7 Gene | SLC12A7 | Solute Carrier Family 12 (Potassium/Chloride Transporter), Member 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013444","External Acoustic Meatus","C12498","A part of the ear canal that is external to the ear drum.","External Acoustic Meatus | Auditory Canal | Auditory Canal, External | EAR CANAL | EXTERNAL ACOUSTIC MEATUS | Ear Canal | External Auditory Canal | External Auditory Meatus | auditory canal | ear canal | external acoustic meatus | external acoustic tube | external auditory canal | external auditory tube",,,,,,,,,,,,,"UBERON:0001352","external acoustic meatus","4223398","External auditory canal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4085334","SLC12A7 wt Allele","C124990","Human SLC12A7 wild-type allele is located in the vicinity of 5p15 and is approximately 62 kb in length. This allele, which encodes solute carrier family 12 member 7 protein, is involved in cellular homeostasis.","SLC12A7 wt Allele | DKFZP434F076 | KCC4 | Solute Carrier Family 12 (Potassium/Chloride Transporter), Member 7 wt Allele | Solute Carrier Family 12 (Potassium/Chloride Transporters), Member 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503838","SLC12A7 protein, human","C124991","Solute carrier family 12 member 7 (1083 aa, ~119 kDa) is encoded by the human SLC12A7 gene. This protein plays a role in transmembrane transport of both potassium and calcium ions.","Solute Carrier Family 12 Member 7 | Electroneutral Potassium-Chloride Cotransporter 4 | K-Cl Cotransporter 4 | Potassium-Chloride Coransporter 4 | Potassium/Chloride Transporter KCC4 | SLC12A7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084741","SLC9A9 wt Allele","C125269","Human SLC9A9 wild-type allele is located in the vicinity of 3q24 and is approximately 583 kb in length. This allele, which encodes sodium/hydrogen exchanger 9 protein, plays a role in the regulation of ion exchange in the Golgi. Mutations in the gene are associated with autism susceptibility 16 and a pericentric inversion of inv(3)(p14;q21), which disrupts the gene, is associated with attention-deficit/hyperactivity disorder.","SLC9A9 wt Allele | AUTS16 | FLJ35613 | NHE9 | Nbla00118 | Solute Carrier Family 9 (Sodium/Hydrogen Exchanger), Isoform 9 Gene | Solute Carrier Family 9 (Sodium/Hydrogen Exchanger), Member 9 Gene | Solute Carrier Family 9, Subfamily A (NHE9, Cation Proton Antiporter 9), Member 9 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1312870","Sodium/Hydrogen Exchanger 9, Human","C125271","Sodium/hydrogen exchanger 9 (645 aa, ~73 kDa) is encoded by the human SLC9A9 gene. This protein is involved in both cation exchange and pH homeostasis.","Sodium/Hydrogen Exchanger 9 | NHE-9 | Na(+)/H(+) Exchanger 9 | Putative Protein Product Of Nbla00118 | SLC9A9 | Sodium/Proton Exchanger NHE9 | Solute Carrier Family 9 Member 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0320183","Pyrenochaeta","C124367","A genus of fungi in the family Cucurbitariaceae that is found in soil and plant debris. Some species in the genus can cause mycetoma in humans.","Pyrenochaeta | PYRENOCHAETA",,,,,,,,,,,,,,,"4143760","Pyrenochaeta",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4075562","Ralstonia pickettii Biovariant 1","C124368","A subspecies of R. pickettii positive for tartrate and maleate, fermentation of lactose and maltose, and nitrate reduction.","Ralstonia pickettii Biovariant 1 | Pseudomonas Group CDC Va-1 | RALSTONIA PICKETTII BIOVARIANT 1 | Ralstonia pickettii biovar 1 | Ralstonia pickettii biovar Va-1",,,,,,,,,,,,,,,"37018747","Ralstonia pickettii biovar Va-1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320288","Retortamonas intestinalis","C124369","A species of Retortamonas protozoa that form cysts and trophozoites in the large intestines of humans. Infestation with R. intestinalis occurs through ingestion of cysts in fecal-contaminated food or water. The species is considered non-pathogenic.","Retortamonas intestinalis | RETORTAMONAS INTESTINALIS",,,,,,,,,,,,,,,"4226860","Retortamonas intestinalis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2587210","Rhodotorula","C124370","A genus of unicellular pigmented yeast in the order Sporidiales that are positive for urease and negative for fermentation of carbohydrates. Rhodotorula species are widespread in the environment with only three species isolated from human clinical samples, usually in hosts with central venous catheters and/or immunosuppression.","Rhodotorula | RHODOTORULA",,,,,,,,,,,,,,,"4198407","Rhodotorula",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1223037","Roseomonas gilardii","C124371","A species of Gram-negative, non-fermentative bacteria in the family Acetobacteraceae characterized as coccoid rods, appearing in pairs or short chains. R. gilardii does not hydrolyze esculin or oxidize salicin; citrate is utilized, and fructose and glycerol are oxidized.","Roseomonas gilardii | ROSEOMONAS GILARDII",,,,,,,,,,,,,,,"4034349","Roseomonas gilardii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1224283","Roseomonas mucosa","C124372","A species of Gram-negative cocco bacillus in the family Acetobacteraceae. R. mucosa is characterized by the formation of mucoid, runny colonies. The species has urease activity and assimilates arabinose, maltose, citrate, and glucose.","Roseomonas mucosa | ROSEOMONAS MUCOSA",,,,,,,,,,,,,,,"4190953","Roseomonas mucosa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0318078","Ruminococcus gnavus","C124373","A species of anaerobic, Gram-positive gut microbes in the class Clostridia. R. gnavus is described as a normal part of the human gut flora, but can form opportunistic infections. The species is catalase negative, and growth is inhibited by metronidazole, bile, and vancomycin but not by kanamycin or colistin.","Ruminococcus gnavus | RUMINOCOCCUS GNAVUS",,,,,,,,,,,,,,,"4227569","Ruminococcus gnavus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0315444","Salmonella enterica Serotype choleraesuis var. decatur","C124374","A gram-negative, rod-shaped serotype of the bacteria genus Salmonella, species Salmonella enterica, subspecies enterica. Salmonella Decatur, a rare human pathogen, was formerly classified as serotype Choleraesuis variant Decatur.","Salmonella enterica Serotype choleraesuis var. decatur | SALMONELLA CHOLERAESUIS VAR. DECATUR | Salmonella decatur",,,,,,,,,,,,,,,"4167697|4197395","Salmonella Choleraesuis var. Decatur|Salmonella Choleraesuis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3864967","Ombitasvir/Paritaprevir/Ritonavir","C123920","An orally bioavailable combination agent containing ombitasvir, an inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex, paritaprevir, a synthetic acylsulfonamide inhibitor of the HCV protease complex comprised of non-structural protein 3 and 4A (NS3/NS4A), and the cytochrome P450 (CYP) 3A4 inhibitor ritonavir, with potential activity against HCV. Upon oral administration of ombitasvir/paritaprevir/ritonavir, ombitasvir, enters the cell and binds to and blocks the activity of the NS5A protein. This results in the disruption of the viral RNA replication complex, blockage of HCV RNA production, and inhibition of viral replication. After intracellular uptake, paritaprevir reversibly binds to the active center and binding site of the HCV NS3/NS4A protease and prevents NS3/NS4A protease-mediated polyprotein maturation. This disrupts both the processing of viral proteins and the formation of the viral replication complex, which inhibits viral replication in HCV genotype 1-infected host cells. Although ritonavir is not active against HCV, it strongly inhibits the activity of CYP3A4, thereby blocking the degradation of paritaprevir, which is a CYP3A4 substrate. This leads to an increased concentration and half-life of paritaprevir as compared to the administration of paritaprevir without ritonavir. NS5A, a zinc-binding and proline-rich hydrophilic phosphoprotein, plays a crucial role in HCV RNA replication. NS3, a serine protease essential for the proteolytic cleavage of multiple sites within the HCV polyprotein, plays a key role during HCV ribonucleic acid (RNA) replication. NS4A is an activating factor for NS3. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family, and infection is associated with the development of hepatocellular carcinoma (HCC).","Ombitasvir/Paritaprevir/Ritonavir | OBV/PTV/r | VIEKIRAX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085945","Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes","C125420","A preparation of genetically modified allogeneic T-cells transduced with a replication-incompetent, self-inactivating lentiviral vector expressing a hinge-optimized, chimeric antigen receptor (CAR), comprised of a CD28 co-stimulatory signaling domain fused to CD3 zeta, the single-chain variable fragment of CD123 antigen (interleukin-3 receptor alpha chain or IL3RA), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes are directed to and induce selective toxicity in CD123-expressing tumor cells. CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with increased leukemic cell proliferation and aggressiveness. Devoid of both ligand binding domains and tyrosine kinase activity, EGFRt both facilitates detection of the administered T-cells in vivo and can promote elimination of those cells following a cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) response. The costimulatory signaling domain enhances both proliferation of T-cells and antitumor activity. Hinge optimization prevents recognition of the CAR by Fc receptors (FcRs).","Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes | Allogeneic CD123R(EQ)28zeta/EGFRt+ T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087009","Clinical Trial Operational Oversight","C125421","Documentation describing clinical trial operations oversight by a sponsor.","Clinical Trial Operational Oversight Documentation | Clinical Trial Operational Oversight | Clinical Trial Operational Oversight | Operational Oversight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504180","Clinical Study Committee Financial Disclosure Form","C125422","A document pertaining to the financial interests and arrangements of the committee members for the clinical trial.","Clinical Trial Committee Member Financial Disclosure Form Documentation | Clinical Study Committee Financial Disclosure Form | Committee Member Financial Disclosure Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086190","Clinical Trial Committe Member Contract","C125423","Documentation describing the contractual responsibilities between a sponsor or vendor and a member from a committee established for the clinical trial.","Clinical Trial Committee Member Contract Documentation | Clinical Trial Committe Member Contract | Committee Member Contract",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086191","Clinical Trial Committee Member Confidentiality Disclosure Agreement","C125424","Documentation describing the provisions governing the nondisclosure requirements between a sponsor or vendor and a member from a committee established for the clinical trial.","Clinical Trial Committee Member Confidentiality Disclosure Agreement Documentation | Clinical Trial Committee Member Confidentiality Disclosure Agreement | Committee Member Confidentiality Disclosure Agreement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086202","Clinical Trial Team Training Document","C125425","Documentation verifying clinical trial team training completion.","Clinical Trial Team Evidence of Training Documentation | Clinical Trial Team Training Document | Clinical Trial Team Training Documents | Trial Team Evidence of Training",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086192","Clinical Trial Coordinating Investigator Documentation","C125426","Documentation pertaining to a coordinating investigator in the clinical trial.","Clinical Trial Coordinating Investigator Documentation | Coordinating Investigator Documentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086200","Clinical Trial Subject Eligibility Verification Form and Worksheet","C125427","Documentation verifying a subject is an appropriate candidate to participate in the clinical trial, as outlined by the clinical study protocol.","Clinical Trial Subject Eligibility Verification Form and Worksheet Documentation | Clinical Trial Eligibility Forms | Clinical Trial Subject Eligibility Verification Form and Worksheet | Subject Eligibility Verification Forms and Worksheets",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086196","Clinical Trial Ongoing Third Party Oversight Document","C125428","Documentation confirming that a vendor continues to meet all relevant criteria to fulfill a contractual obligation for the clinical trial.","Clinical Trial Ongoing Vendor Oversight Documentation | Clinical Trial Ongoing Third Party Oversight Document | Clinical Trial Third Party Compliance | Ongoing Third Party Oversight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504187","Clinical Trial Roles and Responsibilities Matrix","C125429","Documentation describing the range and distribution of tasks and responsibilities.","Clinical Trial Roles and Responsibilities Matrix Documentation | Clinical Trial Roles and Responsibilities Matrix | Roles and Responsibilities Matrix | Roles and Responsibility Matrix | Task Ownership Matrix | Technical Agreement | Third Party Roles and Responsibilities | Transfer of Obligations | Transfer of Regulatory Obligation | table of roles and responsibilities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503839","Adipose-derived Stromal Vascular Fraction Cells","C124992","A population of stromal vascular fraction (SVF) cells derived from autologous adipose tissue, with potential tissue regenerative activity. SVF cells are obtained through liposuction and contain multiple cell types, including adipose-derived stem cells (ADSCs), mesenchymal and endothelial progenitor cells, leukocyte subtypes, lymphatic cells, pericytes, and vascular smooth muscle cells. The SVF cells are processed in such a way as to contain a reproducible and consistent composition of heterogeneous cells. Upon processing and administration, the adipose-derived SVF cells can differentiate into different tissue types, support neovascularization, replace cells and repair injured issue.","Adipose-derived Stromal Vascular Fraction Cells | Adipose-derived SVF Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503840","Amivantamab","C124993","A human bispecific antibody targeting both epidermal growth factor receptor EGFR and hepatocyte growth factor receptor (HGFR; cMet), with potential antineoplastic activity. Upon administration, amivantamab simultaneously targets and binds to wild-type or certain mutant forms of both EGFR and cMet expressed on cancer cells, thereby preventing receptor phosphorylation. This prevents the activation of both EGFR- and cMet-mediated signaling pathways. In addition, binding results in receptor degradation, which further inhibits EGFR- and cMet-mediated signaling. JNJ-61186372 also causes antibody-dependent cellular cytotoxicity (ADCC). Altogether, this results in the inhibition of tumor cell proliferation. EGFR and cMet, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation.","Amivantamab | AMIVANTAMAB | Amivantamab-vmjw | Anti-EGFR/c-Met Bispecific Antibody JNJ-61186372 | CNTO-4424 | JNJ 61186372 | JNJ-611 | JNJ-61186372 | JNJ61186372 | Rybrevant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505142","Salvia hispanica Seed","C124994","The edible seed of the flowering plant Salvia hispanica (chia) used as a nutritional supplement, with potential immunomodulating activity. Upon ingestion, chia seed supplies essential fatty acids, including alpha linolenic acid (an omega-3) and linoleic acid (an omega-6), B vitamins, especially niacin (B3) and thiamine (B1), and several minerals, including calcium, zinc, manganese, magnesium, phosphorus and iron; it also contains high levels of antioxidants and dietary soluble fiber. When used as a dietary supplement, this agent may improve a patient's nutrient intake and may balance their intestinal microbiome.","Salvia hispanica Seed | CHIA SEED | Chia | Chia Seed | SH Seed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503841","BRAF/EGFR inhibitor BGB-283","C124995","An inhibitor of the serine/threonine protein kinase B-raf (BRAF) and epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Lifirafenib selectively binds to and inhibits the activity of BRAF and certain BRAF mutant forms, and EGFR. This prevents BRAF- and EGFR-mediated signaling and inhibits the proliferation of tumor cells that either contain a mutated BRAF gene or express over-activated EGFR. In addition, BGB-283 inhibits mutant forms of the Ras proteins K-RAS and N-RAS. BRAF and EGFR are mutated or upregulated in many tumor cell types.","Lifirafenib | BGB 283 | BGB-283 | Begeine-283 | LIFIRAFENIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425643","SLC39A6 Gene","C125523","This gene plays a role in zinc transport.","SLC39A6 Gene | SLC39A6 | Solute Carrier Family 39 (Zinc Transporter), Member 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084736","SLC39A6 wt Allele","C125524","Human SLC39A6 wild-type allele is located in the vicinity of 18q12.2 and is approximately 21 kb in length. This allele, which encodes zinc transporter ZIP6 protein, is involved in the transport of zinc ions. Aberrant expression of the gene is associated with luminal A breast cancer.","SLC39A6 wt Allele | LIV-1 | LIV-1 Protein, Estrogen Regulated Gene | LIV1 | Solute Carrier Family 39 (Metal Ion Transporter), Member 6 Gene | Solute Carrier Family 39 (Zinc Transporter), Member 6 wt Allele | ZIP6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505095","Zinc Transporter ZIP6","C125525","Zinc transporter ZIP6 (755 aa, ~85 kDa) is encoded by the human SLC39A6 gene. This protein plays a role in zinc ion transport.","Zinc Transporter ZIP6 | Estrogen-Regulated Protein LIV-1 | SLC39A6 | Solute Carrier Family 39 Member 6 | ZIP-6 | Zrt- And Irt-Like Protein 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423939","PARD3 Gene","C125526","This gene is involved in asymmetric cell division, signal transduction, and tight junction formation.","PARD3 Gene | PARD3 | Par-3 Family Cell Polarity Regulator Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085213","PARD3 wt Allele","C125527","Human PARD3 wild-type allele is located in the vicinity of 10p11.21 and is approximately 706 kb in length. This allele, which encodes partitioning defective 3 homolog protein, plays a role in signaling processes involved in both cell division and cell-cell adhesion.","PARD3 wt Allele | ASIP | Baz | Bazooka Gene | PAR3 | PAR3A | PAR3alpha | PARD-3 | PARD3A | PPP1R118 | Par-3 (Partitioning Defective 3, C.elegans) Homolog Gene | Par-3 Family Cell Polarity Regulator Alpha Gene | Par-3 Family Cell Polarity Regulator wt Allele | Par-3 Partitioning Defective 3 Homolog (C. elegans) Gene | Partitioning-Defective Protein 3, C. elegans, Homolog of Gene | Protein Phosphatase 1, Regulatory Subunit 118 Gene | SE2-5L16 | SE2-5LT1 | SE2-5T2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084947","Attitudes and Preferences Questionnaire","C125528","A questionnaire designed to assess a patient's attitudes toward the goals and benefits of personalized treatment and conventional treatment.","Attitudes and Preferences Questionnaire | APQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498285","MiHA-loaded PD-L1/L2-silenced Dendritic Cell Vaccine","C123921","A dendritic cell (DC)-based vaccine composed of program death ligands 1 and 2 (PDL1/L2)-silenced DCs and loaded with the recipient's minor histocompatibility antigens (MiHA), with potential use for graft-versus-tumor (GVT) induction following allogeneic stem cell transplantation (allo-SCT). Donor DCs are electroporated ex vivo with MiHA mRNA and small interfering RNAs (siRNAs) designed to silence the expression of PD L1/L2. After allo-SCT and upon intravenous administration of the MiHA-loaded PD-L1/L2-silenced DC vaccine, the DCs induce the expansion and activation of MiHA-specific CD8-positive T-cells. These tumor antigen-reactive T-cells exert their GVT effect by killing miHA-positive tumor cells. PD-L1/L2, co-inhibitory ligands expressed on DCs, play key roles in preventing MiHA-specific CD8-positive T-cell expansion; silencing enhances MiHA-specific CD8-positive T-cell expansion and activity and improves the GVT effect. The MiHA are human leukocyte antigen (HLA)-bound peptides and are exclusively expressed by the recipient's hematopoietic tumor cells.","MiHA-loaded PD-L1/L2-silenced Dendritic Cell Vaccine | MiHA-loaded PD-L-silenced DC Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498286","iAPA-based Dendritic Cells/Cytotoxic T Lymphocytes","C123922","A cell-based product composed of dendritic cells (DCs) pulsed with tumor-associated antigens (TAAs) and devoid of the inhibitory effect of antigen presentation attenuators (iAPA) combined with cytotoxic T-lymphocytes (CTLs) (iAPA-DC/CTL), with potential immunostimulating and antineoplastic activities.  DCs are transduced with a viral vector containing small interfering RNAs (siRNAs) against APAs, which prevents the expression of APA genes and inhibits attenuation of antigen presentation. Upon administration of iAPA-DC/CTL, the DCs are able to efficiently present antigens to the immune system, stimulate the immune system against tumor-associated antigens (TAAs) and hyperactivate TAA-specific CTLs and T-helper cells. Also, the iAPA-based DCs inhibit the activity of the T-regulatory cells (Tregs), thereby abrogating their negative effect on CTL activation and preventing their immunosuppressive activity against TAAs. Altogether, this inhibits tumor cell proliferation. Additionally, the administered CTLs induce direct cancer cell lysis. APAs negatively regulate antigen presentation, activate Tregs and their immunosuppressive activity, affect inflammatory cytokine production by DCs, and negatively regulate the immunostimulatory activity of DCs; they have an overall inhibitory effect on the stimulation of the immune system.","iAPA-based Dendritic Cells/Cytotoxic T Lymphocytes | Inhibition of Antigen Presentation Attenuators-based Dendritic Cells/Cytotoxic T Lymphocytes | iAPA-DC/CTL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498287","DNA Vaccine VB10.16","C123923","A therapeutic DNA vaccine composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), the second is a dimerization entity and the third part encodes a protein that specifically binds to antigen presenting cells (APCs), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration, abipapogene suvaplasmid expresses HPV16 E6/7 and a protein that targets receptors on APCs. Upon binding to APCs and subsequent internalization, the APCs mature and the HPV16 E6/7 antigenic protein is presented by the APCs. This attracts and stimulates B-lymphocytes, CD4-positive T-lymphocytes and elicits a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing HPV16-associated E6 and E7 oncoproteins, which result in tumor cell lysis. HPV16 E6/7, a viral antigen, plays a key role in the development of certain types of cancer.","Abipapogene Suvaplasmid | ABIPAPOGENE SUVAPLASMID | DNA Vaccine VB10.16 | DNA Vaccine VB10.16 | VB-10.16 | VB10.16 | VB10.16 Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086505","ICT-121 Dendritic Cell Vaccine","C124652","A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with purified peptides derived from the tumor-associated antigen (TAA) CD133, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, monocytes are differentiated into DCs and are mixed with the CD133 peptides. Upon intradermal re-administration of the ICT-121 DC vaccine, the DCs present the CD133 peptides to the immune system, which stimulates the immune system to induce a specific cytotoxic T-lymphocyte (CTL) response against CD133-expressing tumor cells and leads to tumor cell lysis. CD133 is overexpressed on various types of cancer cells; its overexpression is correlated with increased resistance to chemotherapy.","ICT-121 Dendritic Cell Vaccine | CD133 Peptides-pulsed Autologous DC Vaccine | CD133 Peptides-pulsed Autologous Dendritic Cell Vaccine | ICT-121 | ICT-121 DC Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502885","MEDI 9197","C124653","A toll-like receptor type 7 and 8 (TLR7/8) agonist with potential immunostimulating and antitumor activities. Upon intratumoral administration, telratolimod binds to and activates TLR7 and 8, thereby stimulating antigen-presenting cells (APCs), including dendritic cells (DCs). Activation of DCs results in the production of proinflammatory cytokines, and the activation of cytotoxic T-lymphocyte (CTL) and B-lymphocyte immune responses. This may cause tumor cell lysis. TLR7 and 8, members of the TLR family, play fundamental roles in the activation of the immune system.","Telratolimod | 3M 052 | 3M-052 | MEDI 9197 | MEDI-9197 | MEDI9197 | TELRATOLIMOD | TLR7/TLR8 Dual Agonist MEDI9197 | Toll-like Receptor 7/8 Agonist MEDI9197",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022801","Kupffer Cell","C12564","Large star-shaped or pyramidal cells with a large oval nucleus and a small prominent nucleolus. These intensely phagocytic cells line the walls of the sinusoids of the liver and form a part of the reticuloendothelial system.","Kupffer Cell | Kupffer Cells | Kupffer's Cell | Stellate Sinusoidal Macrophage",,,,,,,,,,,,,,,"4103442","Kupffer cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1424608","FIG4 Gene","C124943","This gene plays a role in the metabolism of polyphosphoinositides.","FIG4 Gene | FIG4 | FIG4 Phosphoinositide 5-Phosphatase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055378","Black Raspberry Nectar","C122398","A concentrated fruit juice containing black raspberries, with potential antioxidant, pro-apoptotic, anti-angiogenic and chemopreventive activities. In addition to vitamins, minerals and phytosterols, black raspberries are rich in phenolic acids, such as gallic acid, ellagic acid, anthocyanidins, and flavonoids. Upon oral administration, the phytochemicals in the black raspberry nectar inhibit the activation of several signal transduction pathways involved in carcinogenesis and the expression of downstream target genes that are upregulated in a variety of cancer cell types. In addition, the phytochemicals in black raspberry may protect the oral microbiome and may enhance the bacterial defense against pathogens.","Black Raspberry Nectar | BRB Nectar",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2716396","Diphtheria-Tetanus-Acellular Pertussis-Inactivated Poliomyelitis-Haemophilus influenzae Type B Vaccine","C122399","A vaccine consisting of detoxified diphtheria toxoid (D), detoxified tetanus toxoid (T), acellular pertussis (aP) antigens, inactivated poliovirus (IPV) types 1, 2 and 3, and Haemophilus influenzae type b (Hib) capsular polysaccharide (polyribosylribitol phosphate; PRP) covalently bound to tetanus protein, suspended in water for injection and with active immunizing activity against diphtheria, tetanus, pertussis, poliomyelitis and H. influenzae type b. The five purified pertussis antigens in this vaccine are pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (PRN) and fimbriae types 2 and 3 (FIM). Upon intramuscular injection of the diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis-Haemophilus influenzae type b vaccine (DTaP-IPV-Hib), this vaccine activates the immune system to develop antibodies against diphtheria toxin, tetanus toxin, B. pertussis antigens, polioviruses and Hib, thereby providing active immunization against these diseases. The diphtheria and tetanus toxoids and pertussis antigens (inactivated PT, FHA, PRN and FIM) are adsorbed separately onto aluminum phosphate and then combined with IPV and PRP.","Diphtheria-Tetanus-Acellular Pertussis-Inactivated Poliomyelitis-Haemophilus influenzae Type B Vaccine | DTaP(5)-IPV-Hib | DTaP-IPV-Hib | Pediacel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053962","Synthetic Hypericin","C122400","A topical ointment formulation containing a synthetic form of hypericin, an anthraquinone derivative that is naturally found in the yellow flower of Hypericum perforatum (St. John's wort), with potential antineoplastic and photosensitizing activities. Upon topical administration of the ointment to the tumor site, hypericin becomes activated through the application of visible fluorescent light. During photoactivation, hypericin generates singlet oxygen, which induces DNA damage, necrosis and apoptosis, thereby inhibiting tumor cell growth. The use of visible light for activation avoids the risk of developing secondary malignancies, which are frequently associated with other photodynamic therapies that are dependent on ultraviolet A exposure.","Synthetic Hypericin | Topical SGX301",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0239113","Coombs Test Positive","C122443","A laboratory test result demonstrating the presence of antibodies that act against red blood cells.","Coombs Test Positive | Positive Coombs Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1112251","Feeding Tube Complication","C122445","Any problem with a feeding tube or its site of insertion.","Feeding Tube Complication | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055275","Carbon C 11 Sarcosine","C122684","A radiotracer consisting of sarcosine, the N-methyl derivative of the amino acid glycine, labeled with the positron-emitting isotope carbon C 11, that can be used for tumor imaging upon positron emission tomography/computed tomography (PET/CT). Upon administration, C-11 sarcosine is taken up by and accumulates in tumor cells, thereby allowing tumor imaging with PET/CT. Sarcosine, a non-proteinogenic amino acid and oncometabolite, is elevated in certain tumor cell types. Its expression seems to correlate with increased tumor invasiveness.","Carbon C 11 Sarcosine | 11C-labeled Sarcosine | 11C-sarcosine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0362046","Prediabetes","C122685","A condition in which blood glucose levels are high, but not high enough to be classified as type 2 diabetes.","Prediabetes | Borderline Diabetes",,,,,,,,,,,,,,,"37018196","Prediabetes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054752","Hypoplastic Myelodysplastic Syndrome","C122686","Myelodysplastic syndrome characterized by decreased cellularity in the bone marrow.","Hypoplastic Myelodysplastic Syndrome | Hypocellular Myelodysplastic Syndrome | Hypocellular Myelodysplastic Syndrome | MDS-h | Myelodysplastic Neoplasm, Hypoplastic",,,,,,,,,,,,,,,"37154182|37166870","Hypoplastic myelodysplastic syndrome|Hypoplastic myelodysplastic syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C3839868","Cytogenetically Normal Acute Myeloid Leukemia","C122687","Acute myeloid leukemia that is not associated with cytogenetic abnormalities.","Cytogenetically Normal Acute Myeloid Leukemia | CN-AML | Normal Karyotype Acute Myeloid Leukemia",,,,,,,,,,,,,,,"45766268","Cytogenetically normal acute myeloid leukemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053813","t(7;12)(q36;p13)","C122689","A chromosomal translocation involving the ETV6 gene on chromosome 12p13 and HLXB9 gene on chromosome 7q36.","t(7;12)(q36;p13) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0076451","Thiocolchicine","C1252","An antimitotic alkaloid that binds to microtubules and inhibits tubulin polymerization and induces apoptosis. (NCI)","Thiocolchicine | THIOCOLCHICINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504277","Loncastuximab Tesirine","C125549","An antibody-drug conjugate (ADC) consisting of an anti-CD19 humanized monoclonal antibody conjugated, via a cleavable linker comprised of valine-alanine and maleimide, to a cytotoxic, cross-linking agent pyrrolobenzodiazepine (PBD) dimer, which targets DNA minor grooves, with potential antineoplastic activity. Upon administration, the monoclonal antibody portion of loncastuximab tesirine targets the cell surface antigen CD19 on various cancer cells. Upon antibody/antigen binding and internalization, the cytotoxic PBD moiety is released. The imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces interstrand cross-links in the minor groove of DNA and inhibits DNA replication, which inhibits the proliferation of CD19-overexpressing tumor cells. CD19, a transmembrane receptor and tumor-associated antigen (TAA), is expressed on a number of B-cell-derived cancers.","Loncastuximab Tesirine | ADC ADCT-402 | ADCT 402 | ADCT-402 | ADCT402 | Anti-CD19 PBD-conjugate ADCT-402 | LONCASTUXIMAB TESIRINE | Loncastuximab Tesirine-lpyl | Loncastuximab tesirine | MT 2111 | MT-2111 | MT2111 | Zynlonta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376604","Chromaffin Cell","C12554","Neuroendocrine cells, found in the medulla of the adrenal gland and other sympathetic nervous system ganglia, that release catecholamines into circulation.","Chromaffin Cell | Chromaffin Cells | chromaffin cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414152","DRG2 Gene","C125551","This gene is involved in the modulation of cell proliferation and differentiation.","DRG2 Gene | DRG2 | Developmentally Regulated GTP Binding Protein 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0915111","Developmentally-Regulated GTP-Binding Protein 2, Human","C125553","Developmentally-regulated GTP-binding protein 2 (364 aa, ~41 kDa) is encoded by the human DRG2 gene. This protein is involved in cell proliferation and cell differentiation.","Developmentally-Regulated GTP-Binding Protein 2 | DRG-2 | DRG2 | Developmentally Regulated GTP-Binding Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL449028","Enterochromaffin Cell","C12575","The most abundant and widely distributed type of enteroendocrine cell found in the gastrointestinal tract. It is characterized by serotonin production and an affinity to binding silver and chromium salts.","Enterochromaffin Cell | EC Cell | Enterochromaffin | Enterochromaffin Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504414","ODI v2.1a - Oswestry Disability Index","C125762","The Oswestry Disability Index Version 2.1a (ODI v2.1a) Your ODI.","ODI v2.1a - Oswestry Disability Index | ODI01-Oswestry Disability Index | ODI0111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504415","ASEX-Female Version - Sex Drive","C125763","Arizona Sexual Experiences Scale-Female Version (ASEX-Female Version) How strong is your sex drive?","ASEX-Female Version - Sex Drive | ASEX01-Sex Drive | ASEX0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504308","Bcl-2 Inhibitor BCL201","C125603","A selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon administration, Bcl-2 inhibitor BCL201 binds to and inhibits the activity of Bcl-2. This restores apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in many cancers and plays an important role in the negative regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival.","Bcl-2 Inhibitor BCL201 | BCL-201 | BCL201 | S-55746 | S55746 | Servier 1 | Servier-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3668765","Conjugated Estrogens/Bazedoxifene","C125604","A combination preparation of conjugated estrogens and the selective estrogen receptor modulator (SERM) bazedoxifene that can be used for hormone replacement purposes. The conjugated estrogens increase the diminishing levels of estrogen in menopausal and postmenopausal women by binding to and activating estrogen receptors (ERs), which, in turn, bind to estrogen response elements (EREs) in target genes; this results in the transcription of estrogen-regulated genes. Maintaining adequate estrogen levels decreases symptoms such as hot flashes, night sweats, irregular menstruation, fat redistribution, mood swings, sleep disorders, vaginal dryness and osteoporosis. Bazedoxifene specifically binds to and activates ERs in certain tissues, including liver, bone, breast, and endometrium, and also promotes the transcription of estrogen-regulated genes in these tissues. However, bazedoxifene acts as an estrogen antagonist in uterine and breast tissue, thereby blocking the proliferative effects of estrogen-binding to ER-positive cells in these tissues.","Conjugated Estrogens/Bazedoxifene | CE/BZA | CE/BZA Formulation | Duavee",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504311","P-cadherin-targeting Agent PF-06671008","C125607","An agent that targets p-cadherin (CDH3), with potential antineoplastic activity. Upon administration, PF-06671008 binds to and inhibits the activity of p-cadherin; this may inhibit both invasion and proliferation of p-cadherin expressing tumor cells. P-cadherin, a cell-surface protein and member of the cadherin family, is overexpressed in a variety of tumors and plays a role in cell adhesion, motility, invasion, and proliferation.","P-cadherin-targeting Agent PF-06671008 | PF-06671008",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504312","Begelomab","C125608","A monoclonal antibody against the human dipeptidyl peptidase 4 (dipeptidylpeptidase IV, DPPIV, DPP4; CD26), with potential activity against graft-versus-host disease (GvHD). Upon administration, begelomab binds to CD26 expressed on T-cells. This inhibits the stimulation of T-cells and may prevent GvHD. CD26, a membrane-bound glycoprotein with dipeptidyl peptidase activity, plays a key role in T-cell activation and immune regulation.","Begelomab | BEGELOMAB | BT 5/9 | Begedina | SAND-26",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016390","Foam Cell","C12560","A type of macrophage that ingests low-density lipoproteins found in fatty deposits on blood vessel walls, resulting in a foamy appearance.","Foam Cell | Foam Cells | Foamy Macrophage",,,,,,,,,,,,,,,"4060363","Foam cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055493","Acute Myeloid Leukemia with t(7;12)(q36;p13); HLXB9-ETV6","C122690","An acute myeloid leukemia in infancy characterized by t(7;12)(q36;p13) and fusion of the homeobox gene HLXB9 (MNX1) with the ETV6 gene.","Acute Myeloid Leukemia with t(7;12)(q36;p13); HLXB9-ETV6 | AML with t(7;12)(q36;p13); HLXB9-ETV6 | AML with t(7;12)(q36;p13); MNX1-ETV6 | Acute Myeloid Leukemia with t(7;12)(q36;p13); MNX1-ETV6 | Acute Myeloid Leukemia with t(7;12)(q36;p13); MNX1::ETV6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054426","NUP98 Gene Rearrangement","C122692","A molecular abnormality indicating rearrangement of the NUP98 gene.","NUP98 Gene Rearrangement | ADAR2 Gene Rearrangement | ADIR2 Gene Rearrangement | NUP196 Gene Rearrangement | NUP96 Gene Rearrangement | Nucleoporin 98 Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474102","Wnt Signaling Inhibitor SM04755","C122693","An orally bioavailable small molecule inhibitor of the Wnt signaling pathway, with potential antineoplastic activity. Upon oral administration, Wnt signaling inhibitor SM04755 targets and binds to an as of yet undisclosed target in the Wnt signaling pathway, thereby preventing Wnt-mediated signaling. This may inhibit growth of tumor cells in which the Wnt signaling pathway is overactivated. The Wnt signaling pathway is upregulated in many cancers and plays a key role in tumor cell proliferation.","Wnt Signaling Inhibitor SM04755 | SM04755",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009781","Connective and Soft Tissue Cell","C12555","A non-epithelial cell of mesodermal origin that is found in mesenchymal tissue and functions to support, surround, or protect other structures or organs in the body.","Connective and Soft Tissue Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504404","CDISC Questionnaire PHQ Screener Version Test Code Terminology","C125749","Test codes of questionnaire questions associated with the Patient Health Questionnaire Screener Version (PHQ Screener Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PHQ Screener Version Test Code Terminology | PHQ03TC | Patient Health Questionnaire Screener Version Questionnaire Test Code | QS-PHQ Screener Version TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504405","ASEX-Female Version Questionnaire Question","C125750","A question associated with the ASEX-Female Version questionnaire.","ASEX-Female Version Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504406","ASEX-Male Version Questionnaire Question","C125751","A question associated with the ASEX-Male Version questionnaire.","ASEX-Male Version Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504407","Expanded DRS-PI Caregiver Version Questionnaire Question","C125752","A question associated with the Expanded DRS-PI Caregiver Version questionnaire.","Expanded DRS-PI Caregiver Version Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504408","Expanded DRS-PI Survivor Version Questionnaire Question","C125753","A question associated with the Expanded DRS-PI Survivor Version questionnaire.","Expanded DRS-PI Survivor Version Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503920","Toll-like receptor 9 agonist IMO-2125","C125080","The sodium salt form of tilsotolimod, a proprietary synthetic oligonucleotide-based agonist of toll-like receptor 9 (TLR9), with potential immunostimulating activity. Upon administration, tilsotolimod binds to and activates TLR9 expressed by plasmacytoid dendritic cells (pDCs) and B-cells. This initiates immune signaling pathways, activates B-cells and pDCs, and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.","Tilsotolimod Sodium | IMO 2125 | IMO-2125 | TILSOTOLIMOD SODIUM | TLR9 Agonist IMO-2125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503921","Lenzilumab","C125081","A recombinant monoclonal antibody against the cytokine granulocyte macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating activity. Upon administration, lenzilumab binds to and neutralizes GM-CSF. This prevents GM-CSF binding to the GM-CSF receptor, which is a heterodimeric protein expressed on myeloid progenitor cells, and prevents GM-CSF-mediated signaling. This may induce apoptosis in and inhibit proliferation of cancer cells that overproduce GM-CSF. GM-CSF plays a key role in the differentiation and proliferation of monocytes, macrophages and granulocytes; elevated levels of GM-CSF are associated with certain autoimmune diseases, inflammatory diseases, and cancers.","Lenzilumab | Immunoglobulin G1-kappa, Anti-(Homo sapiens CSF2 (Colony Stimulating Factor 2 (Granulocyte-Macrophage), Granulocyte Macrophage Colony Stimulating Factor, GM-CSF)), Homo sapiens Monoclonal Antibody | KB 003 | KB003 | LENZILUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085337","HLA-DOB wt Allele","C124903","Human HLA-DOB wild-type allele is located in the vicinity of 6p21.3 and is approximately 4 kb in length. This allele, which encodes HLA class II histocompatibility antigen, DO beta chain protein, is involved in the regulation of presentation of exogenous peptides.","HLA-DOB wt Allele | DOB | Major Histocompatibility Complex, Class II, DO Beta wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0122001","HLA Class II Histocompatibility Antigen, DO Beta Chain","C124907","HLA class II histocompatibility antigen, DO beta chain (273 aa, ~31 kDa) is encoded by the human HLA-DOB gene. This protein plays a role in the modulation of exogenous antigen presentation.","HLA Class II Histocompatibility Antigen, DO Beta Chain | HLA-DO Histocompatibility Type, Beta Chain | MHC Class II Antigen DOB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425222","TRPM3 Gene","C124909","This gene is involved in calcium homeostasis.","TRPM3 Gene | TRPM3 | Transient Receptor Potential Cation Channel, Subfamily M, Member 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084753","TRPM3 wt Allele","C124910","Human TRPM3 wild-type allele is located in the vicinity of 9q21.12 and is approximately 918 kb in length. This allele, which encodes transient receptor potential cation channel subfamily M member 3 protein, plays a role in calcium transport.","TRPM3 wt Allele | GON-2 | KIAA1616 | LTRPC3 | MLSN2 | Transient Receptor Potential Cation Channel, Subfamily M, Member 3 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1259684","Transient Receptor Potential Cation Channel Subfamily M Member 3, Human","C124911","Transient receptor potential cation channel subfamily M member 3 (1732 aa, ~198 kDa) is encoded by the human TRPM3 gene. This protein is involved in calcium internalization.","Transient Receptor Potential Cation Channel Subfamily M Member 3 | LTrpC-3 | LTrpC3 | Long Transient Receptor Potential Channel 3 | MLSN2 | Melastatin 2 | Melastatin-2 | TRPM3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417852","NRXN2 Gene","C124912","This gene may play a role in cell adhesion.","NRXN2 Gene | NRXN2 | Neurexin 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050219","Laryngeal Pouch","C122233","An accessory mucosal membranous diverticulum of the laryngeal region, found in certain nonhuman primates.","Laryngeal Pouch | LARYNGEAL POUCH",,,,,,,,,,,,,,,"4308746","Structure of laryngeal pouch",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4049076","Black Swiss Mouse","C122234","Developed by Dr. Carl Hansen at the NIH, this strain was derived from a cross between NIH Swiss and C57BL/6N mice. The Black Swiss mouse has genotype  Tyrp1B, (a) and is homozygous for the rd1 mutation of the Pde6b gene.","Black Swiss Mouse | BS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053825","db/db Mouse","C122235","The diabetic mutant mouse was derived from a spontaneous mutation in a C57BL/K progenitor mouse at the Jackson Laboratory in 1966. The db/db mouse is characterized by abnormal fat deposition at 3-4 weeks of age followed by hyperglycemia, glucosuria, polyuria and the development of lesions in the islets of Langerhans.","db/db Mouse | db/db",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053822","ob/ob Mouse","C122236","The obese mutant mouse was derived from a spontaneous mutation in a V/Le progenitor mouse at the Jackson Laboratory in 1949.","ob/ob Mouse | ob/ob",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0321189","Ancylostoma braziliense","C122239","A species of nematodes in the family Ancylostomatidae. A. braziliense infects domestic dogs and cats, wild canids, and occasionally humans. It is endemic in the southern United States.","Ancylostoma braziliense | ANCYLOSTOMA BRAZILIENSE | Ancylostoma ceylanicum | Ancylostoma ceylonicum",,,,,,,,,,,,,,,"4242407","Ancylostoma braziliense",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162313","Ancylostoma caninum","C122240","A species of nematodes in the family Ancylostomatidae. A. caninum infects domestic dogs and wild canids. It occasionally infects cats and humans. It is largely restricted to temperate, tropical, and sub-tropical regions.","Ancylostoma caninum | ANCYLOSTOMA CANINUM | Dog Hookworm",,,,,,,,,,,,,,,"4290429","Ancylostoma caninum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162314","Ancylostoma duodenale","C122241","A species of nematodes in the family Ancylostomatidae. A. duodenale infects humans, cats, and dogs. The species is most commonly found in the Mediterranean region, Southeast Asia, and scattered in the Southern Americas.","Ancylostoma duodenale | ANCYLOSTOMA DUODENALE | European Hookworm | Old World Hookworm",,,,,,,,,,,,,,,"4304389","Ancylostoma duodenale",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162620","Angiostrongylus cantonensis","C122242","A species of parasitic nematode in the family Angiostrongylidae. A. cantonensis causes eosinophilic meningitis and is prevalent in Southeast Asia and tropical Pacific islands.","Angiostrongylus cantonensis | ANGIOSTRONGYLUS CANTONENSIS | Rat Lungworm",,,,,,,,,,,,,,,"4169409","Angiostrongylus cantonensis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0321453","Anisakis simplex","C122243","A species of parasitic nematode in the family Anisakidae. A. simplex is the causative agent of anisakiasis.","Anisakis simplex | ANISAKIS SIMPLEX | Herring Worm",,,,,,,,,,,,,,,"4286283","Anisakis simplex",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053609","anti-RSPO3 monoclonal antibody OMP-131R10","C122921","An immunoglobulin (Ig) G1 humanized monoclonal antibody targeting human R-spondin 3 (RSPO3), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, rosmantuzumab targets and binds to RSPO3 expressed on tumor cells. This prevents the activation of RSPO3, and inhibits both the binding of RSPO3 to leucine-rich repeat-containing G-coupled receptors (LGRs) and the activation of the RSPO-LGR pathway. This may result in an inhibition of both cancer stem cell (CSC) survival and the proliferation of cancer cells in which this pathway is overactivated. The RSPO-LGR pathway is a CSC pathway activated in a variety of cancer cell types.","Rosmantuzumab | OMP-131R10 | ROSMANTUZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0386669","Cyclin-Dependent Kinase 4 Inhibitor D, Human","C122828","Cyclin-dependent kinase 4 inhibitor D (166 aa, ~18 kDa) is encoded by the human CDKN2D gene. This protein is involved in both cell cycle regulation and the inhibition of cyclin-dependent kinases.","Cyclin-Dependent Kinase 4 Inhibitor D | CDK Inhibitor P19INK4d | CDKN2D | Cyclin-Dependent Kinase 4 Inhibitor D p19 | Inhibitor of Cyclin-Dependent Kinase 4d | p19-INK4d",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426966","WDFY2 Gene","C122829","This gene may play a role in ligand binding.","WDFY2 Gene | WD Repeat and FYVE Domain Containing Gene | WDFY2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049875","WDFY2 wt Allele","C122830","Human WDFY2 wild-type allele is located in the vicinity of 13q14.3 and is approximately 178 kb in length. This allele, which encodes WD repeat and FYVE domain-containing protein 2, may be involved in protein or phospholipid binding.","WDFY2 wt Allele | PROF | WD Repeat and FYVE Domain Containing wt Allele | WDF2 | ZFYVE22",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1741293","WD Repeat and FYVE Domain-Containing Protein 2, Human","C122831","WD repeat and FYVE domain-containing protein 2 (400 aa, ~45 kDa) is encoded by the human WDFY2 gene. This protein may play a role in phospholipid or protein ligand binding.","WD Repeat and FYVE Domain-Containing Protein 2 | Propeller-FYVE Protein | WD Repeat- and FYVE Domain-Containing Protein 2 | WD40 and FYVE Domain Containing 2 | WD40- and FYVE Domain-Containing Protein 2 | Zinc Finger FYVE Domain-Containing Protein 22",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053876","Vepoloxamer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433789","Anti-CD37 Monoclonal Antibody BI 836826","C122833","An Fc-engineered, chimeric immunoglobulin (Ig) G1 monoclonal antibody against the tumor-associated antigen (TAA) CD37, with potential antineoplastic activity. Upon administration, the anti-CD37 monoclonal antibody BI 836826 both activates the immune system to induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against CD37-overexpressing tumor cells and induces apoptosis in these tumor cells. BI 836826 is Fc-engineered to improve ADCC activity and enhance affinity for the receptor Fc-gamma-RIIIa, which is expressed on human natural killer (NK) cells. CD37, a member of the tetraspanin superfamily of cell surface antigens, is overexpressed on a variety of cancer cell types and plays a key role in tumor cell proliferation.","Anti-CD37 Monoclonal Antibody BI 836826 | BI 836826 | BI-836826 | MAb 37.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053488","Heterodimeric Interleukin-15","C122401","A fusion protein complex composed of heterodimeric IL-15 (hetIL-15), which consists of a synthetic form of the endogenous cytokine interleukin-15 chain (IL-15) complexed to the soluble IL-15 binding protein IL-15 receptor alpha chain (IL-15Ra) (IL15:sIL-15Ra), with potential immunomodulatory, anti-infective and antineoplastic activities. Upon administration, hetIL-15 binds to the IL-2/IL-15 receptor beta-common gamma chain (IL-2Rbeta-gamma) receptor on natural killer (NK) and T-lymphocytes, which activates and increases the levels of NK cells and CD8+ and CD4+ T-cells. The T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. Altogether, this enhances tumor cell killing and decreases tumor cell proliferation. By coupling IL-15 to IL15Ra, this agent has an improved pharmacokinetic profile, shows an increased ability to bind IL-2Rbeta-gamma, and shows increased immunostimulatory activity as compared to IL-15 alone.","Heterodimeric Interleukin-15 | IL-15/sIL-15Ra | hetIL-15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0546258","Nephrostomy Site","C122648","A surgically created external opening into the renal pelvis.","Nephrostomy Site | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054151","Progesterone Receptor Staining Method","C122649","An immunohistochemical technique used to detect the presence of progesterone receptor (PR) in a tissue sample.","Progesterone Receptor Staining Method | PR Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055053","Estrogen Receptor Staining Method","C122650","An immunohistochemical technique used to detect the presence of estrogen receptor (ER) in a tissue sample.","Estrogen Receptor Staining Method | ER Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055454","Antibody Ki67 Staining Method","C122651","An immunohistochemical technique used to quantify the percent of cells in a tissue sample that can react with monoclonal antibody Ki67. Antibody Ki67 recognizes antigen KI-67 protein, which is a nuclear protein that is exclusively expressed by proliferating cells.","Antibody Ki67 Staining Method | Antibody Ki-67 Staining Method | Ki-67 Antibody Staining Method | Ki-67 Staining Method | Ki67 Antibody Staining Method | Ki67 Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0751781","Dentatorubral-Pallidoluysian Atrophy","C122653","A rare, autosomal dominant inherited progressive neurodegenerative disorder. It is caused by a mutation in the ATN1 gene, resulting in a combined degeneration of the dentatorubral and pallidoluysian systems. It can appear at any age, but it usually affects individuals between 20 and 30 years and leads to death within 10-15 years. The clinical presentation depends on the age of the affected individual; juvenile patients develop severe progressive myoclonus epilepsy and cognitive decline, whereas adult patients develop ataxia, choreoathetosis and dementia.","Dentatorubral-Pallidoluysian Atrophy | DRPLA | Dentatorubropallidoluysian Atrophy",,,,,,,,,,,,,,,"4239176","Dentatorubropallidoluysian degeneration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024507","Short-Rib Thoracic Dysplasia 6 with or without Polydactyly","C122654","A group of rare, autosomal recessive inherited disorders characterized by a constricted thoracic cage, short ribs, and a 'trident' appearance of the acetabular roof. Polydactyly may or may not be present. Other abnormalities include cleft lip and palate and abnormalities of the brain, eye, heart, liver, pancreas, intestine, kidney, and genitalia.","Short-Rib Thoracic Dysplasia 6 with or without Polydactyly | Majewski Syndrome | Polydactyly with Neonatal Chondrodystrophy Type II | Short Rib-Polydactyly Syndrome Type II",,,,,,,,,,,,,,,"4249461","Short rib-polydactyly syndrome, Majewski type",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1863843","Neuronal Intranuclear Inclusion Disease","C122655","A rare, slowly progressive, multisystem neurodegenerative disorder that usually affects children.  It is characterized by the presence of eosinophilic neuronal intranuclear inclusions and neuronal loss.  It results in abnormalities of the central, peripheral, and autonomic nervous systems.  Patients present with ataxia, extra-pyramidal signs, absent deep tendon reflexes, weakness, muscle wasting, foot deformities, and behavioral or cognitive abnormalities.","Neuronal Intranuclear Inclusion Disease | NIID",,,,,,,,,,,,,,,"37395853","Neuronal intranuclear inclusion disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2931488","Cleft Lip/Palate-Ectodermal Dysplasia Syndrome","C122656","A very rare genetic disorder characterized by cleft lip and palate, sparse scalp hair, and partial syndactyly of the fingers and toes.","Cleft Lip/Palate-Ectodermal Dysplasia Syndrome | CLPED1",,,,,,,,,,,,,,,"37396437","Zlotogora Ogur syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053576","Immunotherapeutic Combination Product CMB305","C122922","An immunotherapeutic combination product composed of LV305, an engineered lentiviral vector that both targets dendritic cells (DCs) and contains nucleic acids encoding the human tumor-associated cancer-testis antigen NY-ESO-1 (CTAG1), and G305, a cancer vaccine comprised of an NY-ESO-1 recombinant protein and glucopyranosyl lipid adjuvant (GLA)-stable emulsion (GLA-SE), with potential synergistic immunostimulatory and antineoplastic activities. Upon intradermal administration of LV305, the DC-targeting lentiviral vector targets and binds to dermal DCs via the DC-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) receptor. Upon internalization of the vector, the NY-ESO-1 protein is expressed, which stimulates DC maturation, and activates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against NY-ESO-1-expressing cells; this may result in tumor cell lysis. Upon the sequential intramuscular injection of G305, the adjuvant portion of G305 binds to toll-like receptor 4 (TLR-4) expressed on various immune cells, including DCs, monocytes, macrophages and B-cells. The activated DCs present the NY-ESO-1 antigen to CD4-positive Th1 T-lymphocytes. The induction of antigen-specific CD4-positive T-lymphocytes further induces a CTL response against NY-ESO-1-expressing tumor cells. In addition, G305 induces an NY-ESO-1-specific antibody response. NY-ESO-1, expressed in normal testes and on the surfaces of various tumor cells, plays a key role in tumor cell proliferation and survival.","Immunotherapeutic Combination Product CMB305 | CMB 305 | CMB305 | ID-CMB305 | ID-LV305 Plus ID G305 | LV 305 Plus G 305 | LV305 Plus G305",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3888018","Persistent Hyperinsulinemic Hypoglycemia of Infancy","C122923","A genetic condition caused by mutation(s) in the ABCC8 gene, encoding ATP-binding cassette sub-family C member 8.","Persistent Hyperinsulinemic Hypoglycemia of Infancy | Familial Hyperinsulinemic Hypoglycemia-1 | HHF1 | PHHI",,,,,,,,,,,,,,,"4236230","Congenital hyperinsulinism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL474104","Anti-B7-H3 Antibody DS-5573a","C122924","An antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, anti-B7-H3 antibody DS-5573a binds to the cell surface antigen B7-H3, thereby blocking B7-H3-mediated signaling. This abrogates the inhibitory effect on T-cell activation and may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It is a negative regulator of the T-cell activation and its overexpression plays a key role in tumor cell invasion and metastasis.","Anti-B7-H3 Antibody DS-5573a | DS-5573a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053908","Type A Tylosis","C122925","An inherited form of tylosis that presents between 5-14 years of age and is characterized by focal areas of nonepidermolytic palmoplantar keratoderma. Individuals have an increased incidence of esophageal carcinoma.","Type A Tylosis | Late Onset Tylosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053907","Type B Tylosis","C122926","An inherited form of tylosis that presents by one year and is characterized by benign palmoplantar keratoderma.","Type B Tylosis | Early Onset Tylosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4048704","Unna-Thost Disease","C122927","An autosomally dominant inherited form of palmoplantar keratoderma that is characterized by a non-gradient diffuse pattern and often, hyperhidrosis of the palms of the hands and soles of the feet. It does not extend beyond the palms, knucklels pads, nails, and the soles.","Unna-Thost Disease | ",,,,,,,,,,,,,,,"4269888","Diffuse palmoplantar keratoderma of Thost-Unna",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0581447","Arterial Catheter","C122592","A hollow tube that is inserted into an artery.","Arterial Catheter | Arterial catheter",,,,,,,,,,,,,,,"4118298","Arterial catheter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013302","Duodenostomy","C122593","Surgical creation of an external opening into the duodenum.","Duodenostomy | ",,,,,,,,,,,,,,,"4148472","Duodenostomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054317","Oral Endotracheal Tube","C122594","A hollow tube that is directed into the trachea from the mouth.","Oral Endotracheal Tube | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054420","Nasal Endotracheal Tube","C122595","A hollow tube that is directed into the trachea from the nose.","Nasal Endotracheal Tube | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4028821","Laryngeal Tube","C122596","A supraglottic airway device.","Laryngeal Tube | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417557","MYO15A Gene","C125572","This gene plays a role in the structure of stereocilia.","MYO15A Gene | MYO15A | Myosin XVA Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085316","MYO15A wt Allele","C125573","Human MYO15A wild-type allele is located in the vicinity of 17p11.2 and is approximately 71 kb in length. This allele, which encodes unconventional myosin-XV protein, is involved in the formation of stereocilia. Mutation of the gene is associated with autosomal recessive deafness 3.","MYO15A wt Allele | DFNB3 | MYO15 | Myosin XV Gene | Myosin XVA wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4016019","DNA Ligase I Deficiency","C122658","A very rare genetic syndrome characterized by reduced replicative DNA ligase I.  It results in immunodeficiency and cellular hypersensitivity to DNA-damaging agents.","DNA Ligase I Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1832274","Charcot-Marie-Tooth Disease Type 2D","C122659","Charcot-Marie-Tooth disease inherited in an autosomal dominant pattern.  It is caused by mutations in the GARS gene. It results in axonal peripheral neuropathy.","Charcot-Marie-Tooth Disease Type 2D | ",,,,,,,,,,,,,,,"37397002","Autosomal dominant Charcot-Marie-Tooth disease type 2D",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1862177","Hardcastle's Syndrome","C122660","A rare, autosomal dominant inherited dysplasia of the long bones, characterized by symmetrical diaphyseal medullary stenosis, bone infarctions, pathologic fractures, and a high risk of development of malignant fibrous histiocytoma.","Hardcastle's Syndrome | DMS-MFH | Diaphyseal Medullary Stenosis with Malignant Fibrous Histiocytoma",,,,,,,,,,,,,,,"4191491","Diaphyseal medullary stenosis with bone malignancy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003955","Ascaris lumbricoides","C122177","A genus of parasitic nematode in the family Ascarididae. A. lumbricoides is the largest intestinal roundworm infecting humans and is the causative agent of ascariasis.","Ascaris lumbricoides | ASCARIS LUMBRICOIDES | Giant Roundworm",,,,,,,,,,,,,,,"4077731","Ascaris lumbricoides",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1035233","Atopobium vaginae","C122178","A species of facultative anaerobic, Gram-positive, rod-shaped or elliptical coccobacillus in the family Coriobacteriaceae. It is commonly isolated from women with bacterial vaginosis and it is implicated in treatment failures.","Atopobium vaginae | ATOPOBIUM VAGINAE",,,,,,,,,,,,,,,"4213520","Fannyhessea vaginae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320813","Babesia divergens","C122179","A species of intraerythrocytic protozoan parasites in the family Babesiidae. B. divergens is transmitted by the tick Ixodes ricinus and it is the main causative agent of bovine babesiosis.","Babesia divergens | BABESIA DIVERGENS",,,,,,,,,,,,,,,"4314137","Babesia divergens",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004574","Babesia microti","C122180","A species of intraerythrocytic protozoan parasites in the family Babesiidae. B. microti is transmitted by the tick Ixodes scapularis and is the primary causative agent of human babesiosis.","Babesia microti | BABESIA MICROTI",,,,,,,,,,,,,,,"4297978","Babesia microti",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1630527","Bacteroides salyersiae","C122182","A species of anaerobic, Gram-negative, non-motile bacterium in the family Bacteroidaceae. B. salyersiae is a normal part of the gut flora and an opportunistic pathogen.","Bacteroides salyersiae | BACTEROIDES SALYERSIAE",,,,,,,,,,,,,,,"37016312","Bacteroides salyersiae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2614420","Bacteroides xylanisolvens","C122183","A species of a Gram-negative, anaerobic, rod-shaped bacterium in the family Bacteroidaceae. B. xylanisolvens is positive for degradation of xylan but negative for degradation of starch. It was isolated from human fecal samples.","Bacteroides xylanisolvens | BACTEROIDES XYLANISOLVENS",,,,,,,,,,,,,,,"37159391","Bacteroides xylanisolvens",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1084834","Balamuthia mandrillaris","C122184","A species of free-living amoeba in the family Balamuthiidae. B. mandrillaris is the causative agent of granulomatous amoebic encephalitis. It was isolated from the brain of a captive baboon and has not been definitively isolated in nature.","Balamuthia mandrillaris | BALAMUTHIA MANDRILLARIS",,,,,,,,,,,,,,,"4021690","Balamuthia mandrillaris",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054491","Minimal Residual Disease-Based Risk Stratification in Acute Leukemia","C122456","Risk stratification of acute lymphoblastic leukemia, and less often acute myeloid leukemia, based on minimal residual disease levels.","Minimal Residual Disease-Based Risk Stratification in Acute Leukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054193","Pericardial Tube","C122598","A hollow tube that is inserted into the pericardium through a surgical incision in the chest wall.","Pericardial Tube | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0074447","Shiga Toxin","C1225","A bacterial toxin produced by Shigella dysenteriae and by some strains of E. coli that inhibits protein synthesis by blocking the interaction of ribosomal RNA with peptide elongation factors.  The non-catalytic beta subunit of Shiga toxin may be useful as a fusion vector for induction of antigen-specific cytotoxic T lymphocyte responses.","Shiga Toxin | ",,,,,,,,,,,,,,,"4113774","Shiga toxin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0150740","Rectal Tube","C122600","A hollow tube that is directed into the colon from the rectum.","Rectal Tube | ",,,,,,,,,,,,,,,"4147550","Flatus tube",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055373","Bone Marrow and Extramedullary Involvement","C122602","A finding indicating the involvement of the bone marrow and other anatomic sites, which may include the peripheral blood, lymph nodes, and/or extranodal sites, by a hematopoietic neoplasm.","Bone Marrow and Extramedullary Involvement | Marrow and Extramedullary Involvement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054726","Infant Leukemia","C122603","An acute lymphoblastic or acute myeloid leukemia that occurs in infancy.","Infant Leukemia | Leukemia in Infancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054725","Infantile Lesion","C122604","A benign or malignant lesion that occurs in infancy.","Infantile Lesion | Lesion in Infancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054409","Neonatal Lesion","C122605","A benign or malignant lesion that occurs in the neonatal period.","Neonatal Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055086","Early Relapse","C122606","Clinical and/or laboratory evidence of early reemergence of a disorder after a period of remission.","Early Relapse | Early Recurrence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0850121","Tympanostomy Tube","C122608","A hollow tube that is inserted into the eardrum through a surgical incision.","Tympanostomy Tube | ",,,,,,,,,,,,,,,"4218005","Tympanic ventilation tube",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053966","Surgical Wound Drain","C122609","A hollow tube inserted into a surgical incision to promote drainage during wound healing.","Surgical Wound Drain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0175731","T-Tube","C122611","A hollow tube in the shape of a T that is inserted into a body cavity through the skin to promote drainage.","T-Tube | ",,,,,,,,,,,,,,,"4264728","T-tube",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054178","Pigtail Drain","C122612","A hollow tube that has holes in the wall of the tube and a coiled tip and is inserted into a body cavity or organ to promote drainage.","Pigtail Drain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505094","Unconventional Myosin-XV","C125574","Unconventional myosin-XV (3530 aa, ~395 kDa) is encoded by the human MYO15A gene. This protein plays a role in stereocilia organization.","Unconventional Myosin-XV | MYO15A | Myosin XV | Myosin-15 | Myosin-XV | Unconventional Myosin-15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826266","MORC2 Gene","C125575","This gene may be involved in the regulation of fatty acid metabolism.","MORC2 Gene | MORC Family CW-Type Zinc Finger 2 Gene | MORC2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086100","COL18A1 Gene Product","C124854","A protein encoded by the COL18A1 gene.","COL18A1 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086880","TAC1 Gene Product","C124855","A protein encoded by the TAC1 gene.","TAC1 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0071942","preprotachykinin","C124856","Protachykinin-1 (129 aa, ~15 kDa) is encoded by the human TAC1 gene. This protein is involved in neuronal excitation, behavioral responses, and smooth muscle contraction.","Protachykinin-1 | PPT | Preprotachykinin | Protachykinin | Protachykinin 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049881","DCTN1 wt Allele","C122876","Human DCTN1 wild-type allele is located in the vicinity of 2p13 and is approximately 31 kb in length. This allele, which encodes dynactin subunit 1 protein, plays a role in the regulation of dynein-dependent transport. Mutation of the gene is associated with Perry syndrome, amyotrophic lateral sclerosis, and distal hereditary motor neuronopathy type VIIB (HMN7B).","DCTN1 wt Allele | DAP-150 | DP-150 | Dynactin 1 (p150, Glued (Drosophila) Homolog) Gene | Dynactin 1 wt Allele | P135 | p150 Glued Homolog (Drosophila) Gene | p150(Glued), Drosophila, Homolog of Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0287134","dynactin subunit 1","C122877","Dynactin subunit 1 (1278 aa, ~142 kDa) is encoded by the human DCTN1 gene. This protein is involved in the dynein-mediated retrograde transport of vesicles and organelles along microtubules.","Dynactin Subunit 1 | 150 kDa Dynein-Associated Polypeptide | DAP-150 | DP-150 | p135 | p150-glued",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049724","ZCCHC8 wt Allele","C122879","Human ZCCHC8 wild-type allele is located in the vicinity of 12q24.31 and is approximately 29 kb in length. This allele, which encodes zinc finger CCHC domain-containing protein 8, may be involved in RNA binding and splicing.","ZCCHC8 wt Allele | DKFZp434E2220 | Zinc Finger CCHC-Type Containing 8 wt Allele | Zinc Finger, CCHC Domain Containing 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1685094","Zinc Finger CCHC Domain-Containing Protein 8, Human","C122880","Zinc finger CCHC domain-containing protein 8 (707 aa, ~79 kDa) is encoded by the human ZCCHC8 gene. This protein plays a role in RNA binding.","Zinc Finger CCHC Domain-Containing Protein 8 | TRAMP-Like Complex RNA-Binding Factor ZCCHC8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053670","Mps1 Inhibitor BAY 1217389","C122707","An orally bioavailable, selective inhibitor of the serine/threonine kinase monopolar spindle 1 (Mps1, TTK), with potential antineoplastic activity. Upon administration, the Mps1 inhibitor BAY 1217389 selectively binds to and inhibits the activity of Mps1. This inactivates the spindle assembly checkpoint (SAC), accelerates mitosis, causes chromosomal misalignment and missegregation, and mitotic checkpoint complex destabilization. This induces cell death in Mps1-overexpressing cancer cells. Mps1, a kinase expressed in proliferating normal tissues and aberrantly overexpressed in a wide range of human tumors, is activated during mitosis and is essential for proper SAC functioning and chromosome alignment.","Mps1 Inhibitor BAY 1217389 | BAY 1217389 | TTK Inhibitor BAY 1217389",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049734","MYO5A wt Allele","C122882","Human MYO5A wild-type allele is located in the vicinity of 15q21 and is approximately 222 kb in length. This allele, which encodes unconventional myosin-Va protein, plays a role in melanosome transport along actin filaments. Mutation of the gene is associated with Elejalde disease and Griscelli syndrome types-1 and -3.","MYO5A wt Allele | Dilute, Mouse, Homolog of Gene | GS1 | MYH12 | MYO5 | MYR12 | Myosin VA (Heavy Chain 12, Myoxin) wt Allele | Myosin VA (Heavy Polypeptide 12, Myoxin) Gene | Myosin, Heavy Chain 12 Gene | Myosin, Heavy Polypeptide Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0654795","Unconventional Myosin-Va, Human","C122883","Unconventional myosin-Va (1855 aa, ~215 kDa) is encoded by the human MYO5A gene. This protein is involved in the transport of cytoplasmic cargo along actin filaments.","Unconventional Myosin-Va | Dilute Myosin Heavy Chain, Non-Muscle | MYO5A | Myosin Heavy Chain 12 | Myosin V | Myosin-12 | Myoxin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049721","LSM14A wt Allele","C122885","Human LSM14A wild-type allele is located in the vicinity of 19q13.11 and is approximately 57 kb in length. This allele, which encodes protein LSM14 homolog A protein, is involved in the maintenance of mRNAs.","LSM14A wt Allele | C19orf13 | Chromosome 19 Open Reading Frame 13 Gene | DKFZP434D1335 | FAM61A | Family with Sequence Similarity 61, Member A Gene | LSM14 Homolog A (SCD6, S. cerevisiae) Gene | LSM14A, SCD6 Homolog A (S. cerevisiae) wt Allele | RAP55 | RAP55A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1722111","Protein LSM14 Homolog A, Human","C122886","Protein LSM14 homolog A (463 aa, ~51 kDa) is encoded by the human LSM14A gene. This protein plays a role in RNA maintenance.","Protein LSM14 Homolog A | AlphaSNBP | LSM14 Homolog A | LSM14A Protein | Protein FAM61A | Protein SCD6 Homolog | Putative Alpha-Synuclein-Binding Protein | RNA Associated Protein 55 | RNA Associated Protein 55A | RNA-Associated Protein 55 | RNA-Associated Protein 55A | hRAP55 | hRAP55A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049606","CEP89 wt Allele","C122888","Human CEP89 wild-type allele is located in the vicinity of 19q13.11 and is approximately 93 kb in length. This allele, which encodes centrosomal protein of 89 kDa, plays a role in the modulation of ciliogenesis.","CEP89 wt Allele | CCDC123 | CEP123 | Centrosomal Protein 89kDa wt Allele | Centrosomal Protein, 89-kD Gene | Coiled-Coil Domain-Containing Protein 123, Mitochondrial Gene | FLJ14640",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055422","Autologous Oxidized Ovarian Tumor Cell Lysate Vaccine","C122402","An autologous cancer vaccine composed of oxidized ovarian tumor cell lysate, with potential immunostimulatory and antineoplastic activities. Upon administration, the autologous oxidized ovarian tumor cell lysate vaccine exposes the immune system to an undefined amount of tumor-associated antigens (TAAs), which may result in the induction of both anti-tumor cytotoxic T-lymphocytes (CTLs) and antibody-dependent responses against TAA-expressing cells, leading to tumor cell lysis. Compared to non-oxidized tumor cell lysate vaccines, oxidized tumor cell lysate vaccines induce necrotic cell death, increase the immunogenicity of the TAAs and may enhance the anti-tumor immune response.","Autologous Oxidized Ovarian Tumor Cell Lysate Vaccine | Autologous OC-L Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054033","sevacizumab","C122403","A monoclonal antibody directed against the human vascular endothelial growth factor (VEGF), with potential antiangiogenic activity. Upon administration, suvemcitug specifically binds to and inhibits VEGF, thereby preventing its binding to VEGF receptors (VEGFRs). This prevents VEGF/VEGFR-mediated signaling and inhibits the proliferation of vascular endothelial cells and tumor cells. VEGF, overexpressed in a variety of cancer cells, is associated with increased invasiveness and decreased survival.","Suvemcitug | APX 003 | BD 0801 | BD-0801 | BD0801 | SUVEMCITUG | Sevacizumab | Sevacizumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053827","zirconium Zr 89-labeled anti-PD-L1 monoclonal antibody MPDL3280A","C122404","A radioimmunoconjugate composed of atezolizumab, a humanized, Fc-optimized, monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1) and labeled with the radioisotope zirconium Zr 89, with potential use for assessing PD-L1-expressing tumor cells using positron emission tomography (PET). Upon administration of zirconium Zr 89-labeled atezolizumab, the antibody moiety targets and binds to PD-L1. Following tumor cell uptake, the radioisotope moiety can be visualized using PET. This may result in the quantification of PD-L1-expressing tumor cells, an assessment of the expected response to treatment with atezolizumab as well as selection of patients that would respond to atezolizumab.  PD-L1 is overexpressed on many human cancer cell types; PD-L1 binding to programmed cell death 1 (PD-1) on T-cells suppresses the immune system and results in increased immune evasion.","Zirconium Zr 89-labeled Atezolizumab | 89Zr-DFO-Atezolizumab | 89Zr-Desferrioxamine-Atezolizumab | 89Zr-MPDL-3280A | 89Zr-MPDL3280A | Zirconium Zr 89 Atezolizumab | Zirconium Zr 89-DFO-Atezolizumab | Zirconium Zr 89-labeled MPDL3280A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055175","Curcumin-based Gel","C122708","A proprietary topical gel formulation containing an extract of curcumin, the polyphenol derived from the plant Curcuma longa, with potential anti-inflammatory, antioxidant, and wound healing activities. Upon topical administration to the affected areas, curcumin inhibits a variety of pro-inflammatory enzymes and reduces the production of certain pro-inflammatory mediators. Curcumin also blocks the formation of reactive oxygen species (ROS), neutralizes free radicals and prevents oxidative stress and DNA damage. In addition, curcumin inhibits phosphorylase kinase (PhK) in the skin, which prevents multiple PhK-mediated signal transduction pathways that are induced upon skin injury. This further prevents inflammation, promotes healing and reduces scar tissue formation. The proprietary curcumin-based gel also provides moisture to the skin and contains tetrahydropiperine (THP), which is derived from black pepper fruit and increases skin uptake of curcumin.","Curcumin-based Gel | Curcumin Gel | Psoria-Gold | Topical Curcumin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054919","Functional Photoacoustic Microscopy","C122709","A hybrid imaging technique that combines the high-resolution advantage of ultrasonic detection of absorbed photons with the high-contrast advantage of optical imaging. It can provide better spatial resolution than pure optical imaging when the imaging depth is beyond 1 mm.","Functional Photoacoustic Microscopy | fPAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025078","Medical Device Failure","C122710","A medical device that is no longer functioning.","Medical Device Failure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1504465","Medical Device Malfunction","C122711","A medical device that is functioning incorrectly.","Medical Device Malfunction | Malfunctioning",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055436","Aspergillus Fumigatus Complex","C122245","A non-taxanomic grouping of bacteria that have been assigned to the Aspergillus genus and are morphologically and physiologically similar to Aspergillus fumigatus.","Aspergillus Fumigatus Complex | ASPERGILLUS FUMIGATUS COMPLEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004694","Balantidium coli","C122246","A species of ciliated intestinal protozoan parasites in the family Balantiididae. Infection occurs by ingestion of a cyst, with the motile trophozoite residing in the large intestine. B. coli is the largest protozoan that infects humans.","Balantidium coli | BALANTIDIUM COLI | Paramecium coli",,,,,,,,,,,,,,,"4287534","Balantidium coli",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1264802","Bifidobacterium animalis","C122247","A species of a Gram-positive, anaerobic, rod-shaped bacterium in the family Bifidobacteriaceae. B. animalis does not ferment alpha-l-fucose, D-glucuronate, amylose, arabinogalactan, porcine gastric mucin, arabic gum, ghatti gum, or tragacanth gum. This bacteria is a normal part of the gut flora and is frequently used as a probiotic.","Bifidobacterium animalis | BIFIDOBACTERIUM ANIMALIS",,,,,,,,,,,,,,,"4290358","Bifidobacterium animalis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0314975","Bifidobacterium breve","C122248","A bacterial species in the family Bifidobacteriaceae. B. breve ferments alpha-l-fucose but does not ferment D-blucuronate, arabinogalactan, xylan, porcine gastric mucin, or gums. This bacteria is a normal part of the gut flora and is frequently used as a probiotic.","Bifidobacterium breve | BIFIDOBACTERIUM BREVE | Bifidobacterium parvulorum",,,,,,,,,,,,,,,"4147282","Bifidobacterium breve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0314992","Bifidobacterium pseudocatenulatum","C122249","A bacterial species in the family Bifidobacteriaceae. B. pseudocatenulatum hydrolyzes phytate and ferments amylopectin and amylose and does not ferment D-galactosamine, D-glucuronate, arabinogalactan, pectin, or gums. This bacteria is a normal part of the gut flora and is frequently used as a probiotic.","Bifidobacterium pseudocatenulatum | BIFIDOBACTERIUM PSEUDOCATENULATUM",,,,,,,,,,,,,,,"4078715","Bifidobacterium pseudocatenulatum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320086","Bipolaris","C122250","A genus of moderately fast growing dematiaceous fungi in the family Pleosporaceae with straight, fusiform to ellipsoidal pseudoseptate conidia. The genus contains about 45 species which are mostly subtropical and tropical plant parasites; however several species, notably B. australiensis, B. hawaiiensis, and B. spicifera are well documented human pathogens.","Bipolaris | BIPOLARIS",,,,,,,,,,,,,,,"4083107","Bipolaris",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085373","Blastocystis hominis","C122251","A species of protozoan parasites in the family Blastocystidae. External transmission of B. hominis is believed to occur by infection with a cyst. The cysts infect epithelial cells of the digestive tract and multiply asexually.","Blastocystis hominis | BLASTOCYSTIS HOMINIS",,,,,,,,,,,,,,,"4103712","Blastocystis hominis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053676","Selective Estrogen Receptor Degrader AZD9496","C122834","An orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon administration, SERD AZD9496 binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This prevents ER-mediated signaling and inhibits the growth and survival of ER-expressing cancer cells.","Selective Estrogen Receptor Degrader AZD9496 | (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid | AZD 9496 | AZD-9496 | AZD9496 | SERD AZD9496",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471745","mTORC1/2 Kinase Inhibitor BI 860585","C122836","An orally bioavailable inhibitor of raptor-mammalian target of rapamycin (mTOR) complex 1 (mTOR complex 1; mTORC1) and rictor-mTOR complex 2 (mTOR complex 2; mTORC2), with potential antineoplastic activity. Upon oral administration, mTORC1/2 kinase inhibitor BI 860585 binds to the kinase domain of mTOR and inhibits both mTORC1 and mTORC2, in an ATP-competitive manner. This inhibits mTOR-mediated signaling and leads to both an induction of apoptosis and a decrease in the proliferation of mTORC1/2-expressing tumor cells. mTOR is a serine/threonine kinase that is upregulated in certain tumor cell types. It plays an important role in the PI3K/Akt/mTOR signaling pathway, which is often deregulated in cancer cells and promotes cell growth, survival, and resistance to chemotherapy and radiotherapy.","mTORC1/2 Kinase Inhibitor BI 860585 | BI 860585",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474094","Clostridium butyricum-containing Probiotic","C122837","A probiotic containing the anaerobic, butyric acid-forming Gram-positive bacterium Clostridium butyricum (C. butyricum), with potential immunomodulatory activity. Upon oral administration of C. butyricum-containing probiotic, C. butyricum modulates the composition of the normal gastrointestinal (GI) microflora and help maintain adequate colonization of the GI tract, thereby improving digestion and preventing GI disturbances. This bacterium creates an environment unfavorable to pathogens by adhering to human epithelial cells, thereby forming a protective mucosal barrier. This prevents attachment of pathogens and reduces the risk of infection. Dietary supplementation with this bacterium may restore or enhance intestinal immunity.","Clostridium butyricum-containing Probiotic | C. butyricum-containing Probiotic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053903","Type IV Collagen Staining Method","C122838","An immunohistochemical technique used to detect the presence of type IV collagen in a tissue sample.","Type IV Collagen Staining Method | Collagen 4 Staining Method | Collagen IV Staining Method | Type 4 Collagen Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053906","Type I Collagen Staining Method","C122839","An immunohistochemical technique used to detect the presence of type I collagen in a tissue sample.","Type I Collagen Staining Method | Collagen 1 Staining Method | Collagen I Staining Method | Type 1 Collagen Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054650","Leucine-Rich Repeat-Containing G-Protein Coupled Receptor 5 Staining Method","C122840","An immunohistochemical technique used to detect the presence of leucine-rich repeat-containing G-protein coupled receptor 5 in a tissue sample.","Leucine-Rich Repeat-Containing G-Protein Coupled Receptor 5 Staining Method | LGR5 Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054270","POU Domain, Class 5, Transcription Factor 1 Staining Method","C122841","An immunohistochemical technique used to detect the presence of POU domain, class 5, transcription factor 1 in a tissue sample.","POU Domain, Class 5, Transcription Factor 1 Staining Method | OCT4 Staining Method | Oct-4 Staining Method | Octomer-Binding Protein 4 Staining Method | POU5F1 Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425471","IP6K1 Gene","C125099","This gene is involved in the synthesis of inositol pyrophosphates.","IP6K1 Gene | IP6K1 | Inositol Hexakisphosphate Kinase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0076329","Ormaplatin","C1250","A platinum(IV) analogue with antineoplastic activity. Ormaplatin alkylates DNA, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity.","Ormaplatin | ORMAPLATIN | Platinum, tetrachloro(1,2-cyclohexanediamine-N,N')-, (OC-6-22-(trans))- | Tetraplatin | tetrachloro(1,2-cyclohexanediamine-N,N')-, (OC-6-22-(trans))Platinum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085189","IP6K1 wt Allele","C125100","Human IP6K1 wild-type allele is located in the vicinity of 3p21.31 and is approximately 62 kb in length. This allele, which encodes inositol hexakisphosphate kinase 1 protein, plays a role in inositol phosphate metabolism.","IP6K1 wt Allele | IHPK1 | Inositol Hexakisphosphate Kinase 1 wt Allele | KIAA0263 | PiUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053526","Yttrium Y 90 Anti-CDH3 Monoclonal Antibody FF-21101","C122405","A radioimmunoconjugate consisting of a chimeric monoclonal antibody targeting human cadherin-3 (CDH3) and labeled, via the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), with the beta-emitting radioisotope yttrium Y 90, with potential antineoplastic activities. Upon administration, the antibody moiety of yttrium Y 90 anti-CDH3 monoclonal antibody FF-21101 binds to CDH3 expressed on tumor cells, thereby specifically delivering cytotoxic beta radiation to CDH3-expressing tumor cells. CDH3, also known as P-cadherin, is a tumor-associated antigen (TAA) and member of the cadherin family; it is overexpressed in a variety of tumors and plays a role in cell adhesion, motility, invasion, and proliferation.","Yttrium Y 90 Anti-CDH3 Monoclonal Antibody FF-21101 | FF-21101(90Y)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053583","CD19/CD3 dual-affinity retargeting protein JNJ-64052781","C122406","An anti-CD19/anti-CD3 bispecific, humanized antibody-like protein, with potential immunostimulatory and antineoplastic activities. Duvortuxizumab possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B-cells. Upon administration, duvortuxizumab binds to CD3-expressing T-cells and CD19-expressing cancer cells, thereby crosslinking CD19-expressing tumor B-cells and cytotoxic T-lymphocytes (CTLs). This may result in a potent CTL-mediated cell lysis of CD19-expressing B-lymphocytes. CD19, a B-cell specific membrane antigen, is expressed during normal B-cell development and on B-cell malignancies.","Duvortuxizumab | CD19 x CD3 DART Protein JNJ-64052781 | DUVORTUXIZUMAB | JNJ-64052781 | MGD011 | RES192M1.2 | hBU12(2.4)-hXR32-MP3 M1.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0748164","Multiple Pulmonary Nodules","C122408","Multiple, small, round or oval, benign or malignant growths in the lung(s), which can be due to infectious, inflammatory, or neoplastic processes.","Multiple Pulmonary Nodules | Pulmonary Nodules",,,,,,,,,,,,,,,"40482871","Multiple nodules of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1142209","Ostomy Site Pain","C122409","Pain at the site of an ostomy.","Ostomy Site Pain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055511","Absence of Bowel Movement","C122410","The lack of any bowel movements.","Absence of Bowel Movement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3806113","Scleral Icterus","C122411","Yellowing of the white part of the eyes, often due to a rise in bilirubin levels.","Scleral Icterus | ",,,,,,,,,,,,,,,"4081004","Scleral icterus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268146","Glycogen Storage Disease Type Ib","C122661","Glycogen storage disease type I that is caused by mutations in the SLC37A4 gene.  It is characterized by a deficiency of glucose-6-phosphate translocase.  It may be associated with neutropenia resulting in recurrent bacterial infections, inflammatory bowel disease, gingivitis, periodontal disease, and mouth ulcers.","Glycogen Storage Disease Type Ib | Glycogen Storage Disease Type I non-a",,,,,,,,,,,,,,,"4107542","Glucose-6-phosphate transport defect",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268147","Glycogen Storage Disease Type IX","C122662","Glycogen storage disease usually inherited in an X-linked recessive pattern.  It is characterized by a deficiency of hepatic phosphorylase kinase.","Glycogen Storage Disease Type IX | Phosphorylase Kinase Deficiency",,,,,,,,,,,,,,,"4342778","Glycogen phosphorylase kinase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1833662","Inclusion Body Myopathy with Early-Onset Paget Disease with or without Frontotemporal Dementia 1","C122663","A rare autosomal dominant inherited disorder caused by mutations in the VCP gene. It can affect the muscles, bones, and brain.  Patients may develop myopathy that initially involves the muscles of the hips and shoulders and as the disorder progresses it may affect the cardiac and respiratory muscles, leading to life-threatening cardiac and pulmonary failure.  Approximately half of the adults develop Paget disease of bone, and approximately one-third develop frontotemporal dementia.","Inclusion Body Myopathy with Early-Onset Paget Disease with or without Frontotemporal Dementia 1 | IBMPFD1",,,,,,,,,,,,,,,"45766396","Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1013303","Borrelia miyamotoi","C122252","A species of Gram-negative, anaerobic, spiral-shaped bacteria in the family Spirochaetaceae. B. miyamotoi can be transferred to humans through the bite of an infected tick and is the causative agent of Borrelia miyamotoi disease, a relapsing fever.","Borrelia miyamotoi | BORRELIA MIYAMOTOI",,,,,,,,,,,,,,,"4013812","Borrelia miyamotoi",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1035773","Buttiauxella ferragutiae","C122253","A species of facultatively anaerobic, Gram-negative, rod-shaped bacteria in the family Enterobacteriaceae. B. ferragutiae is positive for lysine decarboxylase and D-sorbitol metabolism and negative for ketogluconate and malonate activity. It was originally isolated from soil.","Buttiauxella ferragutiae | BUTTIAUXELLA FERRAGUTIAE | CDC Enteric Group 63",,,,,,,,,,,,,,,"4214813","Buttiauxella ferragutiae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1035774","Buttiauxella gaviniae","C122254","A species of facultatively anaerobic, Gram-negative, rod-shaped bacteria in the family Enterobacteriaceae. B. gaviniae is positive for arginine dihydrolase, 5-ketogluconate, and palatinose reactions and negative for ornithine decarboxylase and raffinose reactions.","Buttiauxella gaviniae | BUTTIAUXELLA GAVINIAE | CDC Enteric Group 64",,,,,,,,,,,,,,,"4220283","Buttiauxella gaviniae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1035776","Buttiauxella noackiae","C122255","A species of facultatively anaerobic, Gram-negative, rod-shaped bacteria in the family Enterobacteriaceae. B. noackiae is positive for N-acetyl-L-glutamine, L-arginine dihydrolase, melibiose, and L-ornithine decarboxylase.","Buttiauxella noackiae | BUTTIAUXELLA NOACKIAE | CDC Enteric Group 59",,,,,,,,,,,,,,,"4016447","Buttiauxella noackiae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0019157","Calodium hepaticum","C122256","A species of parasitic nematodes in the family Capillariidae. C. hepaticum causes hepatic capillariasis in rodents and other mammals. Its life cycle is completed in a single host species but the eggs must mature outside of the host body prior to infecting a new host.","Calodium hepaticum | CALODIUM HEPATICUM | Capillaria hepatica",,,,,,,,,,,,,,,"4212248","Capillaria hepatica",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007929","Chaetomium","C122258","A genus of rapidly growing moniliaceous fungi in the family Chaetomiaceae characterized by the production of solitary, hyaline, smooth walled aleurioconidia. Species in this genus are normally found in soil, air, cellulose and plant debris. Some species within the genus are causative agents of infections in immunocompromised individuals.","Chaetomium | CHAETOMIUM",,,,,,,,,,,,,,,"4009137","Chaetomium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4050503","Ectopic Graft","C122932","A graft transferred from one organ site to another, within the same individual or between individuals.","Ectopic Graft | Ectopic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054334","Normal Tissue Graft","C122933","A graft of normal tissue from one location to another, within the same individual or between individuals.","Normal Tissue Graft | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524930","Organ Graft","C122934","An organ that is transplanted from a donor to a recipient.","Organ Graft | Organ Transplant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0686909","Orthotopic Graft","C122935","A graft transferred to the same anatomic site in another individual.","Orthotopic Graft | Orthotopic",,,,,,,,,,,,,,,"4011477","Orthotopic graft",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4050317","Patient Derived Xenograft","C122936","A mouse model for human cancer studies in which a human-derived tumor sample is transplanted into an immunodeficient mouse.","Patient Derived Xenograft | PDTX | PDX | PDX Model | Patient-Derived Xenograft | Patient-Derived Xenograft Model",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054034","Serial Transplantation","C122938","The transfer of a graft from a primary recipient into a secondary recipient.","Serial Transplantation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0392763","Syngeneic Graft","C122939","A graft transferred from a donor to a recipient with an identical, or immunologically compatible, genetic profile.","Syngeneic Graft | Isograft | Syngenic Graft",,,,,,,,,,,,,,,"4281977","Syngraft",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0348047","Tissue Graft","C122940","The transfer of tissue from one anatomic site to another, within the same individual or between individuals, without transfer of the tissue's blood supply.","Tissue Graft | ",,,,,,,,,,,,,,,"4130396","Tissue graft - material",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054909","GATA-Binding Factor 3 Staining Method","C122842","An immunohistochemical technique used to detect the presence of GATA-binding factor 3 in a tissue sample.","GATA-Binding Factor 3 Staining Method | GATA Binding Factor 3 Staining Method | GATA Binding Protein 3 Staining Method | GATA-3 Staining Method | GATA-Binding Protein 3 Staining Method | GATA3 Staining Method | Trans-Acting T-Cell-Specific Transcription Factor GATA-3 Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054150","Programmed Cell Death Protein 1 Staining Method","C122843","An immunohistochemical technique used to detect the presence of programmed cell death protein 1 in a tissue sample.","Programmed Cell Death Protein 1 Staining Method | CD279 Staining Method | PD-1 Staining Method | PD1 Staining Method | PDCD1 Staining Method | Programmed Cell Death 1 Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054581","Major Histocompatibility Complex Class II Staining Method","C122844","An immunohistochemical technique used to detect the presence of class II major histocompatibility complex antigens in a tissue sample.","Major Histocompatibility Complex Class II Staining Method | Class II MHC Staining Method | MHC Class II Staining Method | MHC II Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084716","MORC2 wt Allele","C125576","Human MORC2 wild-type allele is located in the vicinity of 22q12.2 and is approximately 43 kb in length. This allele, which encodes MORC family CW-type zinc finger protein 2, may play a role in lipid metabolism. Variation of the gene is associated with autosomal dominant axonal Charcot-Marie-Tooth disease type 2Z.","MORC2 wt Allele | AC004542.C22.1 | KIAA0852 | MORC Family CW-Type Zinc Finger 2 wt Allele | Microrchidia, Mouse, Homolog of, 2 Gene | ZCW3 | ZCWCC1 | Zinc Finger, CW Type With Coiled-Coil Domain 1 Gene | Zinc Finger, CW-Type With Coiled-Coil Domain 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504298","MORC Family CW-Type Zinc Finger Protein 2","C125577","MORC family CW-type zinc finger protein 2 (1032 aa, ~118 kDa) is encoded by the human MORC2 gene. This protein may be involved in fatty acid metabolism.","MORC Family CW-Type Zinc Finger Protein 2 | MORC2 | Zinc Finger CW Domain Protein 3 | Zinc Finger CW Domain- And Coiled-Coil Domain-Containing Protein 1 | Zinc Finger CW-Type Coiled-Coil Domain Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418189","OSBP2 Gene","C125578","This gene plays a role in binding to oxysterols.","OSBP2 Gene | OSBP2 | Oxysterol Binding Protein 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084881","OSBP2 wt Allele","C125579","Human OSBP2 wild-type allele is located in the vicinity of 22q12.2 and is approximately 214 kb in length. This allele, which encodes oxysterol-binding protein 2, is involved in 7-ketocholesterol binding.","OSBP2 wt Allele | HLM | KIAA1664 | ORP-4 | ORP4 | OSBPL1 | OSBPL4 | Oxysterol Binding Protein 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225369","Chondrocyte","C12557","A cell arising from mesenchymal stem cells that produces and is surrounded by the extracellular matrix of cartilage.","Chondrocyte | Chondrocytes | chondrocyte",,,,,,,,,,,,,,,"4198777|4217446","Chondrocyte|Chondrocyte",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1309976","OSBP2 protein, human","C125580","Oxysterol-binding protein 2 (916 aa, ~101 kDa) is encoded by the human OSBP2 gene. This protein plays a role in binding to oxidized forms of cholesterol.","Oxysterol-Binding Protein 2 | ORP-4 | OSBP-Related Protein 4 | OSPB2 | Oxysterol Binding Protein-Like 1 | Oxysterol-Binding Protein-Related Protein 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539732","SCRIB Gene","C125582","This gene is involved in the establishment of cell polarity.","SCRIB Gene | SCRIB | Scribbled Planar Cell Polarity Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1858991","Leukoencephalopathy with Vanishing White Matter","C122664","A rare, progressive neurological disorder inherited in an autosomal recessive pattern.  It is caused by mutations in the EIF2B1, EIF2B2, EIF2B3, EIF2B4, and EIF2B5 genes, resulting in deterioration of central nervous system's white matter.  Usually, there are no signs and symptoms of the disorder at birth.  During early childhood, affected individuals develop spasticity and ataxia which may be associated with deterioration of the metal function.  Examination of the brain at autopsy reveals normal gray matter while the white matter is soft and gelatinous with numerous small cavities.","Leukoencephalopathy with Vanishing White Matter | ",,,,,,,,,,,,,,,"40492344","Vanishing white matter disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055121","Dixon MRI","C122667","An imaging method that combines in-phase and out-of-phase echoes to create water-only and fat-only images. This technique is particularly useful in abdominal imaging at 3T.","Dixon MRI | Dixon Fat-Suppression MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049704","Lipid R1 MRI","C122668","An imaging method for the mapping of oxygen in tissues. It is based on higher solubility of oxygen in lipids than in water. By monitoring changes in the R1 relaxation rate of the lipid peak rather than those of water, estimates of variations in tissue oxygenation are obtained.","Lipid R1 MRI | MOBILE | Mapping of Oxygen by Imaging Lipids Relaxation Enhancement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053909","Tumor Graft","C122941","The transfer of a tumor fragment into an ectopic or orthotopic site, within the same individual or between individuals.","Tumor Graft | Tumor Explant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055364","Borg Category-Ratio 10 Scale Score 11 Point Scale","C122944","A scale for the subjective scoring of perceived exertion that ranges from 0: Nothing at all to 10: Maximal.","Borg Category-Ratio 10 Scale Score 11 Point Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1868822","Fistula Discharge","C122470","The leakage of a substance from a fistula.","Fistula Discharge | Fistula Drainage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0179790","Swan Ganz Catheter","C122613","A hollow tube with a balloon or sail tip that is advanced into the pulmonary artery to measure right heart pressure and cardiac output, and enable mixed venous blood sampling.","Swan Ganz Catheter | ",,,,,,,,,,,,,,,"4166563|4262295","Pulmonary artery flotation catheter|Pulmonary artery catheter",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C4054727","Infant Acute Lymphoblastic Leukemia","C122614","An acute lymphoblastic leukemia that occurs in infancy.","Infant Acute Lymphoblastic Leukemia | Infant ALL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053717","Biliary Duct Stent","C122615","A hollow tube that is advanced into an obstructed bile duct to allow the flow of bile into the bowel.","Biliary Duct Stent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0687568","Coronary Artery Stent","C122616","An expandable hollow tube that is advanced into an obstructed or narrow coronary artery to restore blood flow to the heart.","Coronary Artery Stent | ",,,,,,,,,,,,,,,"45767945","Coronary artery stent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054729","Infant ALL with MLL Rearrangement","C122617","An acute lymphoblastic leukemia with rearrangement of the KMT2A gene that occurs in infancy.","Infant Acute Lymphoblastic Leukemia with KMT2A Rearrangement | Infant ALL with MLL Rearrangement | Infant Acute Lymphoblastic Leukemia with MLL Gene Rearrangement | Infant Acute Lymphoblastic Leukemia with MLL Rearrangement | Infant Acute Lymphoblastic Leukemia with MLL Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055177","Cuffed Hemodialysis Catheter","C122618","A hollow tube that is inserted into a large vein to carry blood to and from a dialysis machine where the exit site is secured just under the skin with a band-like structure to prevent slippage and infection.","Cuffed Hemodialysis Catheter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055176","Cuffed Peritoneal Dialysis Catheter","C122619","A hollow tube that is inserted in the abdomen to carry fluid into and out of the abdominal cavity where the exit site is secured just under the skin with a band-like structure to prevent slippage and infection.","Cuffed Peritoneal Dialysis Catheter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053900","Uncuffed Dialysis Catheter","C122620","A hemodialysis or peritoneal dialysis catheter that does not utilize a band-like structure at the exit site just under the skin to prevent slippage and infection.","Uncuffed Dialysis Catheter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054728","Infant Acute Lymphoblastic Leukemia without MLL Gene Rearrangement","C122621","An acute lymphoblastic leukemia without rearrangement of the KMT2A gene that occurs in infancy.","Infant Acute Lymphoblastic Leukemia without KMT2A Rearrangement | Infant ALL without MLL Rearrangement | Infant Acute Lymphoblastic Leukemia without KMT2A Gene Rearrangement | Infant Acute Lymphoblastic Leukemia without MLL Gene Rearrangement | Infant Acute Lymphoblastic Leukemia without MLL Gene Rearrangement | Infant Acute Lymphoblastic Leukemia without MLL Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084759","SCRIB wt Allele","C125583","Human SCRIB wild-type allele is located in the vicinity of 8q24.3 and is approximately 24 kb in length. This allele, which encodes protein scribble homolog, plays a role in the differentiation of polarized cells.","SCRIB wt Allele | CRIB1 | Circletail, Mouse, Homolog of Gene | KIAA0147 | LAP4 | SCRB1 | SCRIB1 | Scribble 1 Gene | Scribble, Drosophila, Homolog of Gene | Scribbled Homolog (Drosophila) Gene | Scribbled Homolog Gene | Scribbled Planar Cell Polarity Protein wt Allele | VARTUL | Vartul",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504302","Protein Scribble Homolog","C125584","Protein scribble homolog (1630 aa, ~175 kDa) is encoded by the human SCRIB gene. This protein is involved in cell polarization.","Protein Scribble Homolog | Protein LAP4 | Scribble | hScrib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421894","ANP32A Gene","C125585","This gene plays a role in tumor suppression, cell proliferation, transcriptional repression and many other cellular processes.","ANP32A Gene | ANP32A | Acidic Nuclear Phosphoprotein 32 Family Member A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084869","ANP32A wt Allele","C125586","Human ANP32A wild-type allele is located in the vicinity of 15q23 and is approximately 42 kb in length. This allele, which encodes acidic leucine-rich nuclear phosphoprotein 32 family member A protein, is involved in number of cellular processes, including cellular proliferation and differentiation, apoptosis, tumor suppression, inhibition of protein phosphatase 2A and acetyltransferases, regulation of mRNA trafficking and stability, and transcriptional repression.","ANP32A wt Allele | Acidic (Leucine-Rich) Nuclear Phosphoprotein 32 Family, Member A Gene | Acidic Leucine-Rich Nuclear Phosphoprotein 32 Family, Member A Gene | Acidic Nuclear Phosphoprotein 32 Family Member A wt Allele | C15orf1 | HPPCn | I1PP2A | LANP | MAPM | PHAP1 | PHAPI | PP32",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447285","Acidic Leucine-Rich Nuclear Phosphoprotein 32 Family Member A, Human","C125587","Acidic leucine-rich nuclear phosphoprotein 32 family member A (249 aa, ~29 kDa) is encoded by the human ANP32A gene. This protein plays a role in enzyme inhibition, transcriptional regulation, apoptosis, mRNA localization and stability, cell proliferation and differentiation, and tumor suppression.","Acidic Leucine-Rich Nuclear Phosphoprotein 32 Family Member A | ANP32A | Acidic Nuclear Phosphoprotein Pp32 | Cerebellar Leucine Rich Acidic Nuclear Protein | Hepatopoietin Cn | Inhibitor-1 of Protein Phosphatase-2A | LANP | Leucine-Rich Acidic Nuclear Protein | Mapmodulin | PHAP I | PHAPI | Potent Heat-Stable Protein Phosphatase 2A Inhibitor I1PP2A | Putative HLA-DR-Associated Protein I | Putative Human HLA Class II Associated Protein I | Putative Human HLA Class II-Associated Protein I | pp32",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413755","CSNK1D Gene","C125588","This gene is involved in cellular growth and survival processes.","CSNK1D Gene | CSNK1D | Casein Kinase 1, Delta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1384665","HFE Gene","C124875","This gene plays a role in the modulation of iron transport.","HFE Gene | HFE | Hemochromatosis Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085201","HFE wt Allele","C124876","Human HFE wild-type allele is located in the vicinity of 6p21.3 and is approximately 11 kb in length. This allele, which encodes hereditary hemochromatosis protein, is involved in iron homeostasis. Mutation of the gene is associated with hemochromatosis and microvascular complications of diabetes 7.","HFE wt Allele | HFE1 | HH | HLA-H | HLAH | Hemochromatosis wt Allele | High Fe Gene | MVCD7 | TFQTL2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0074037","Saperconazole","C1221","A synthetic broad-spectrum fluorinated triazole with potential antifungal activity. Saperconazole preferentially inhibits fungal cytochrome P450 sterol 14 alpha-demethylase (CYP51), an enzyme responsible for the conversion of lanosterol to ergosterol, an important component of the fungal cell membrane. Enzyme inhibition by this agent leads to a decrease in ergosterol pool that distresses synthesis of fungal cell membrane, thereby increases cell membrane permeability, and promotes loss of essential intracellular elements. This ultimately causes fungal cell lysis and death.","Saperconazole | (+-)-1-sec-Butyl-4-(p-(4-(p-(((2R*,4S*)-2-(2,4-difluorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-delta(sup 2)-1,2,4-triazolin-5-one | R 66905 | R66905 | SAPERCONAZOLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0231686","Gait Unsteady","C122478","A shaky or wobbly manner of walking.","Gait Unsteady | ",,,,,,,,,,,,,,,"4331737","Unsteady when walking",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054553","Medical Device Dislodged","C122712","A medical device that was placed properly, but which has moved from the intended location.","Medical Device Dislodged | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1608950","Medical Device Misplaced","C122713","A medical device that was placed in an unintended location.","Medical Device Misplaced | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053754","Acute Myeloid Leukemia with inv(3) (q21.3;q26.2); GATA2, MECOM","C122716","An acute myeloid leukemia associated with inv(3)(q21.3q26.2) resulting in the reposition of a distal GATA2 enhancer to activate MECOM expression. It may present de novo or follow a myelodysplastic syndrome. The clinical course is aggressive.","Acute Myeloid Leukemia with inv(3) (q21.3;q26.2); GATA2, MECOM | Acute Myeloid Leukemia with inv(3) (q21.3;q26.2); GATA2, EVI1 | Acute Myeloid Leukemia with inv(3) (q21.3;q26.2); GATA2, MECOM(EVI1) | Acute Myeloid Leukemia with inv(3)(q21.3;q26.2); GATA2::MECOM | Acute Myeloid Leukemia with inv(3)(q21q26.2); RPN1-EVI1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054085","Refractory Childhood Acute Lymphoblastic Leukemia","C122624","Acute lymphoblastic leukemia that occurs in childhood and does not respond to treatment.","Refractory Childhood Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia (ALL)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055251","Childhood Acute Myeloid Leukemia Not Otherwise Specified","C122625","Acute myeloid leukemias that occur in children and do not fulfill the criteria for inclusion in the group of acute myeloid leukemias with recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related. This category includes entities classified according to the French-American-British classification scheme.","Childhood Acute Myeloid Leukemia Not Otherwise Specified | Childhood AML, NOS | Childhood Acute Myeloid Leukemia Defined by Differentiation | Childhood Acute Myeloid Leukemia, NOC | Childhood Acute Myeloid Leukemia, NOS | Childhood Acute Myeloid Leukemia, Not Otherwise Characterized | Childhood Acute Myeloid Leukemia, Not Otherwise Specified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054571","Maternal Proteinuria","C122628","The presence of excessive protein, chiefly albumin but also globulin, in the urine of a pregnant woman.","Maternal Proteinuria | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055499","Actuation Dosing Unit","C122629","A dosing unit equal to the amount of active ingredient(s) contained in an actuation.","Actuation Dosing Unit | ACTUATION | Act Dosing Unit | Actuation | actuation | {ACTUATION} | {Actuation} | {actuation}",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0534369","Hereditary Hemochromatosis Protein, Human","C124877","Hereditary hemochromatosis protein (348 aa, ~40 kDa) is encoded by the human HFE gene. This protein plays a role in the regulation of transport of iron.","Hereditary Hemochromatosis Protein | HFE | HLA-H | Hereditary Hemochromatosis Protein HLA-H | MHC Class I-Like Protein HFE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428985","PDGFD Gene","C124878","This gene is involved in growth factor signaling.","PDGFD Gene | PDGFD | Platelet Derived Growth Factor D Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084758","PDGFD wt Allele","C124879","Human PDGFD wild-type allele is located in the vicinity of 11q22.3 and is approximately 257 kb in length. This allele, which encodes platelet-derived growth factor D protein, plays a role in growth factor signaling, embryonic development, cell proliferation, wound healing and angiogenesis.","PDGFD wt Allele | IEGF | MSTP036 | Platelet Derived Growth Factor D wt Allele | SCDGF-B | SCDGFB | UNQ1899/PRO4345",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447990","Platelet-Derived Growth Factor D, Human","C124880","Platelet-derived growth factor D (370 aa, ~43 kDa) is encoded by the human PDGFD gene. This protein is involved in growth factor signaling that modulates many developmental and cellular processes.","Platelet-Derived Growth Factor D | Iris-Expressed Growth Factor | PDGF-D | SCDGF-B | Spinal Cord Derived Growth Factor B | Spinal Cord-Derived Growth Factor B | Spinal Cord-Derived Growth Factor-B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538441","CFHR1 Gene","C124881","This gene plays a role in complement regulation.","CFHR1 Gene | CFHR1 | Complement Factor H-Related 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084892","CFHR1 wt Allele","C124882","Human CFHR1 wild-type allele is located in the vicinity of 1q32 and is approximately 12 kb in length. This allele, which encodes complement factor H-related protein 1, is involved in the modulation of complement activity. Mutation of the gene is associated with atypical hemolytic-uremic syndrome and age-related macular degeneration.","CFHR1 wt Allele | CFHL | CFHL1 | CFHL1P | CFHR1P | Complement Factor H-Related 1 Pseudogene | Complement Factor H-Related 1 wt Allele | FHR1 | Factor H-Related Gene 1 | H Factor (Complement)-Like 1 Gene | H Factor (Complement)-Like 2 Gene | H36-1 | H36-2 | HFL1 | HFL2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503939","Autologous Anti-CD123 CAR TCR/4-1BB-expressing T-lymphocytes","C125101","Autologous, genetically engineered T-lymphocytes that have been electroporated with a messenger RNA (mRNA) encoding a chimeric antigen receptor (CAR) consisting of an anti-human interleukin-3 receptor alpha chain (IL3RA; CD123) single chain variable fragment (scFv) coupled to the co-stimulatory signaling domains of 4-1BB (CD137) and the zeta chain of the T-cell receptor (TCR) CD3 complex (CD3-zeta), with potential immunomodulating and antineoplastic activities.  Upon transfusion, the mRNA-electroporated autologous anti-CD123 CAR TCR/4-1BB expressing T-lymphocytes attach to cancer cells expressing CD123. This induces selective toxicity in and causes lysis of CD123-expressing tumor cells. The 4-1BB co-stimulatory molecule signaling domain enhances T-cell activation and signaling after recognition of CD123. CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with both increased leukemic cell proliferation and aggressiveness.","Autologous Anti-CD123 CAR TCR/4-1BB-expressing T-lymphocytes | Anti-CD123 CAR mRNA-electroporated Autologous T-lymphocytes | Autologous Anti-CD123 CAR TCR/4-1BB-expressing T Lymphocytes | Autologous RNA CART123 Cells | RNA Anti-CD123 CAR T Cells | RNA CART123 Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1431526","Inositol Hexakisphosphate Kinase 1, Human","C125102","Inositol hexakisphosphate kinase 1 (441 aa, ~50 kDa) is encoded by the human IP6K1 gene. This protein is involved in the metabolism of second messenger molecules.","Inositol Hexakisphosphate Kinase 1 | ATP:1D-Myo-Inositol-Hexakisphosphate Phosphotransferase | EC 2.7.4.21 | IP6K1 | Inositol Hexaphosphate Kinase 1 | InsP6 Kinase 1 | Pi Uptake Stimulator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049736","PWWP2A wt Allele","C122891","Human PWWP2A wild-type allele is located in the vicinity of 5q33.3 and is approximately 58 kb in length. This allele, which encodes PWWP domain-containing protein 2A, may be involved in binding to other proteins or to DNA.","PWWP2A wt Allele | KIAA1935 | MST101 | MSTP101 | PWWP Domain Containing 2A wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054263","PWWP Domain-Containing Protein 2A","C122892","PWWP domain-containing protein 2A (755 aa, ~82 kDa) is encoded by the human PWWP2A gene. This protein may play a role in protein-DNA or protein-protein interactions.","PWWP Domain-Containing Protein 2A | PWWP2A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3147069","ZSCAN30 Gene","C122893","This gene may be involved in both transcriptional regulation and DNA binding.","ZSCAN30 Gene | ZSCAN30 | Zinc Finger and SCAN Domain Containing 30 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049740","ZSCAN30 wt Allele","C122894","Human ZSCAN30 wild-type allele is located in the vicinity of 18q12.2 and is approximately 39 kb in length. This allele, which encodes zinc finger and SCAN domain-containing protein 30, may play a role in DNA binding and transcriptional regulation.","ZSCAN30 wt Allele | ZNF-WYM | ZNF397 Opposite Strand Gene | ZNF397OS | ZNF917 | Zinc Finger and SCAN Domain Containing 30 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050522","Zinc Finger and SCAN Domain-Containing Protein 30, human","C122895","Zinc finger and SCAN domain-containing protein 30 (494 aa, ~56 kDa) is encoded by the human ZSCAN30 gene. This protein may be involved in the modulation of transcription and in DNA binding.","Zinc Finger and SCAN Domain-Containing Protein 30 | ZNF-WYM | ZSCAN30 | Zinc Finger Protein 397 Opposite Strand | Zinc Finger Protein 397OS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414997","GATM Gene","C122896","This gene plays a role in creatine biosynthesis.","GATM Gene | GATM | Glycine Amidinotransferase (L-Arginine:Glycine Amidinotransferase) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049625","GATM wt Allele","C122897","Human GATM wild-type allele is located in the vicinity of 15q21.1 and is approximately 41 kb in length. This allele, which encodes glycine amidinotransferase, mitochondrial protein, is involved in the synthesis of creatine from L-arginine and glycine.","GATM wt Allele | AGAT | AT | CCDS3 | Glycine Amidinotransferase (L-Arginine:Glycine Amidinotransferase) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1530825","Glycine Amidinotransferase, Mitochondrial, Human","C122898","Glycine amidinotransferase, mitochondrial (423 aa, ~48 kDa) is encoded by the human GATM gene. This protein plays a role in the conversion of L-arginine and glycine to creatine.","Glycine Amidinotransferase, Mitochondrial | EC 2.1.4.1 | L-Arginine:Glycine Amidinotransferase | Transamidinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0074747","Sodium Molybdate","C1228","A crystalline powder essential for the metabolism and development of plants and animals as a cofactor for enzymes. (NCI)","Sodium Molybdate | Disodium Molybdate | SODIUM MOLYBDATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049598","HACL1 wt Allele","C122901","Human HACL1 wild-type allele is located in the vicinity of 3p25.1 and is approximately 41 kb in length. This allele, which encodes 2-hydroxyacyl-CoA lyase 1 protein, plays a role in lipid metabolism.","HACL1 wt Allele | 1600020H07Rik | 2-HPCL | 2-Hydroxyacyl-CoA Lyase 1 wt Allele | HPCL | HPCL2 | HPCl2 | HSPC279 | PHYH2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3253651","2-Hydroxyacyl-CoA Lyase 1, Human","C122902","2-hydroxyacyl-CoA lyase 1 (578 aa, ~64 kDa) is encoded by the human HACL1 gene. This protein is involved in the metabolism of fatty acids.","2-Hydroxyacyl-CoA Lyase 1 | 2-HPCL | 2-Hydroxyphytanol-CoA Lyase | 2-Hydroxyphytanoyl-CoA Lyase | EC 4.1.-.- | Phytanoyl-CoA 2-Hydroxylase 2 | Phytanoyl-CoA Hydroxylase 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049738","NAB2 wt Allele","C122904","Human NAB2 wild-type allele is located in the vicinity of 12q13.3 and is approximately 7 kb in length. This allele, which encodes NGFI-A-binding protein 2, is involved in the modulation of early growth response protein-dependent gene transcription.","NAB2 wt Allele | MADER | NGFI-A Binding Protein 2 (EGR1 Binding Protein 2) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055495","Acute Myeloid Leukemia with t(3;3) (q21.3;q26.2); GATA2, MECOM","C122717","An acute myeloid leukemia associated with t(3;3)(q21.3;q26.2) resulting in the reposition of a distal GATA2 enhancer to activate MECOM expression. It may present de novo or follow a myelodysplastic syndrome. The clinical course is aggressive.","Acute Myeloid Leukemia with t(3;3) (q21.3;q26.2); GATA2, MECOM | AML with inv(3)(q21;q26.2) or t(3;3) (q21;q26.2);RPNI-EVI1 | Acute Myeloid Leukemia with t(3;3) (q21.3;q26.2); GATA2, EVI1 | Acute Myeloid Leukemia with t(3;3) (q21.3;q26.2); GATA2, MECOM(EVI1) | Acute Myeloid Leukemia with t(3;3)(q21.3;q26.2); GATA2::MECOM | Acute Myeloid Leukemia with t(3;3)(q21;q26.2); RPN1-EVI1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053652","Anti-human Cytomegalovirus Monoclonal Antibody Combination CSJ-148","C122718","A combination agent composed of two human monoclonal antibodies against the human cytomegalovirus (HCMV), LJP538 and LJP539, with potential immunomodulating activity. Upon administration of CSJ-148, both LJP538 and LJP539 bind to and inhibit the function of viral HCMV glycoproteins that are essential for HCMV infection; LJP538 targets and binds to glycoprotein B (gB) and LJP539 targets and inhibits the pentameric complex, consisting of glycoproteins gH, gL, UL128, UL130, and UL131. Human cytomegalovirus (HCMV) can cause significant disease in immunocompromised patients.","Anti-human Cytomegalovirus Monoclonal Antibody Combination CSJ-148 | Antiviral Agent CSJ148 | CSJ 148 | CSJ-148 | CSJ148 | HCMV Neutralizing Human mAb Combination CSJ-148 | LJP538 Plus LJP539 | LJP538 and LJP539 | LJP538/LJP539",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL471763","FGFR Inhibitor ASP5878","C122719","An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR), with potential antineoplastic activity. Upon oral administration, FGFR inhibitor ASP5878 binds to and inhibits FGFR, which results in the inhibition of FGFR-mediated signal transduction pathways. This inhibits proliferation in FGFR-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, plays a key role in cellular proliferation and survival.","FGFR Inhibitor ASP5878 | ASP-5878 | ASP5878",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055601","ASP4132","C122720","A molecule with potential antineoplastic activity. Upon oral administration, ASP4132 affects oxidative phosphorylation in mitochondria of metabolically-active tumor cells, which reduces both energy production and tumor cell proliferation. Mitochondrial oxidative phosphorylation is hyperactivated in tumor cells and plays a key role in the promotion of tumor cell proliferation.","ASP4132 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020440","Hypercarbia","C122721","Excessive concentration of carbon dioxide in the blood.","Hypercarbia | Hypercapnia",,,,,,,,,,,,,,,"4105765","Hypercapnia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055250","Childhood Acute Myeloid Leukemia with Abnormalities of Chromosome 5q","C122725","A rare acute myeloid leukemia that occurs in children and is characterized primarily by deletions of 5q.","Childhood Acute Myeloid Leukemia with Abnormalities of Chromosome 5q | Acute Myeloid Leukemia (AML) with Abnormalities of Chromosome 5q | Childhood AML with Abnormalities of Chromosome 5q",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0320280","Chilomastix mesnili","C122259","A species of nonpathogenic flagellates in the family Retortamonadidae. C. mesnili trophozoites reside in the human cecum and/or colon and transmission occurs by ingestion of cysts.","Chilomastix mesnili | CHILOMASTIX MESNILI",,,,,,,,,,,,,,,"4189821","Chilomastix mesnili",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054582","Major Histocompatibility Complex Class I Staining Method","C122845","An immunohistochemical technique used to detect the presence of class I major histocompatibility complex antigens in a tissue sample.","Major Histocompatibility Complex Class I Staining Method | Class I MHC Staining Method | MHC Class I Staining Method | MHC I Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055490","Adhesion G Protein-Coupled Receptor E1 Staining Method","C122846","An immunohistochemical technique used to detect the presence of adhesion G protein-coupled receptor E1 in a tissue sample.","Adhesion G Protein-Coupled Receptor E1 Staining Method | ADGRE1 Staining Method | Antibody F4/80 Staining Method | EMR1 Staining Method | F4/80 Antibody Staining Method | F4/80 Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054932","Forkhead Box Protein P3 Staining Method","C122847","An immunohistochemical technique used to detect the presence of forkhead box protein P3 in a tissue sample.","Forkhead Box Protein P3 Staining Method | Fox3P Staining Method | FoxP3 Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053729","B220 Staining Method","C122848","An immunohistochemical technique used to detect the presence of the B220 isoform of the receptor-type tyrosine-protein phosphatase C in a tissue sample.","B220 Staining Method | CD45R Staining Method | PTPRC B220 Staining Method | Receptor-Type Tyrosine-Protein Phosphatase C Isoform B220 Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054584","Macrosialin Staining Method","C122849","An immunohistochemical technique used to detect the presence of macrosialin (CD68) in a tissue sample.","Macrosialin Staining Method | CD68 Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055334","CD8 Co-Receptor Staining Method","C122850","An immunohistochemical technique used to detect the presence of the heterodimeric T-cell surface glycoprotein CD8 co-receptor protein complex in a tissue sample.","CD8 Co-Receptor Staining Method | CD8 Complex Staining Method | CD8 Staining Method | T-Cell Surface Glycoprotein CD8 Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2608049","TRAIP Gene","C125106","This gene plays a role in protein ubiquitination and signal pathway regulation.","TRAIP Gene | TRAF Interacting Protein Gene | TRAIP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085339","TRAIP wt Allele","C125107","Human TRAIP wild-type allele is located in the vicinity of 3p21.31 and is approximately 28 kb in length. This allele, which encodes E3 ubiquitin-protein ligase TRAIP protein, is involved in the ubiquitination of protein substrates.","TRAIP wt Allele | RNF206 | TRAF Interacting Protein wt Allele | TRIP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084847","E3 Ubiquitin-Protein Ligase TRAIP","C125108","E3 ubiquitin-protein ligase TRAIP (469 aa, ~53 kDa) is encoded by the human TRAIP gene. This protein plays a role in ubiquitination.","E3 Ubiquitin-Protein Ligase TRAIP | EC 2.3.2.27 | EC 6.3.2.-, Formerly | Ring Finger Protein 206 | TRAF-Interacting Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421480","WASF2 Gene","C125109","This gene is involved in both the mediation of signal transduction and the regulation of cytoskeletal reorganization.","WASF2 Gene | WAS Protein Family, Member 2 Gene | WASF2 | WASP Family Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084757","WASF2 wt Allele","C125110","Human WASF2 wild-type allele is located in the vicinity of 1p36.11 and is approximately 86 kb in length. This allele, which encodes actin-binding protein WASF2 protein, plays a role in signal transduction that regulates actin filament organization.","WASF2 wt Allele | IMD2 | Putative Wiskott-Aldrich Syndrome Protein Family Member 4 Gene | SCAR, Dictyostelium, Homolog of, 2 Gene | SCAR2 | Suppressor of Cyclic-AMP Receptor (WASP-Family) Gene | WAS Protein Family Member 2 Gene | WAS Protein Family, Member 2 Gene | WAS Protein Family, Member 2 wt Allele | WASF4 | WASP Family Member 2 wt Allele | WASP Family Protein Member 4 Gene | WASP Family Verprolin-Homologous Protein 2 Gene | WASP Family, Member 2 Gene | WASP Family, Verprolin Homology Domain-Containing Protein 2 Gene | WASP Protein Family, Member 2 Gene | WAVE2 | dJ393P12.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1442513","MAP3K3 Gene","C125112","This gene plays a role in mitogen-activated kinase signaling pathways.","MAP3K3 Gene | MAP3K3 | Mitogen-Activated Protein Kinase Kinase Kinase 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0390081","NGFI-A-Binding Protein 2, Human","C122905","NGFI-A-binding protein 2 (525 aa, ~57 kDa) is encoded by the human NAB2 gene. This protein plays a role in the inhibition of early growth response protein-dependent gene expression.","NGFI-A-Binding Protein 2 | EGR-1-Binding Protein 2 | EGR1 Binding Protein 2 | Melanoma-Associated Delayed Early Response Protein | NAB2 | NAG2 | NGFI-A Binding Protein 2 | Protein MADER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1142417","Ulcerative Colitis Flare","C122413","An exacerbation of ulcerative colitis.","Ulcerative Colitis Flare | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0393639","Autoimmune Encephalitis","C122414","Inflammation of the brain secondary to an immune response triggered by the body itself.","Autoimmune Encephalitis | ",,,,,,,,,,,,,,,"4318558","Autoimmune encephalitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054417","Near-Infrared Fluorescence Endoscopy","C122415","The use of near-infrared light (700-1000 nm) for biomedical imaging with an endoscope.","Near-Infrared Fluorescence Endoscopy | NIR Fluorescence Endoscopy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0563560","Refusal to Bear Weight","C122416","A reluctance to place any body weight on a limb, which is most commonly secondary to pain or discomfort.","Refusal to Bear Weight | ",,,,,,,,,,,,,,,"4112788","Difficulty weight-bearing",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0259797","Dog Bite","C122419","A wound received from the teeth of a dog.","Dog Bite | ",,,,,,,,,,,,,,,"433116","Dog bite",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4053824","integrated Cancer Repository for Cancer Research","C122420","A system for the standardized collection, mining and sharing of comprehensive cancer-related data. It consists of registry databases and human biological material. Currently, there are seven registries/tissue banks developed under the umbrella of iCaRe2: the Pancreatic Cancer Collaborative Registry, Thyroid Cancer and Tumor Collaborative Registry, GenitoUrinary Cancer Collaborative Registry, Thoracic Oncology Collaborative Registry, Gastrointestinal and Abdominal Cancer Collaborative Registry, Head and Neck Cancer Collaborative Registry, and the Central Nervous System Tumor Collaborative Registry for collaborative multi-center research.","integrated Cancer Repository for Cancer Research | iCaRe2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1112210","Port Site Infection","C122425","An infection at an anatomic location used for vascular access.","Port Site Infection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055503","Acquired Cytomegaloviral Infection","C122426","An infection with the Cytomegalovirus that is not present from birth.","Acquired Cytomegaloviral Infection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008724","Chrysosporium","C122260","A genus of of hyaline hyphomycetes fungi in the family Onygenaceae characterized by the production of solitary, hyaline, smooth walled aleurioconidia. Although they are rarely encountered in human skin infections, Chrysosporium species have been identified as an emerging infectious agent in North American snakes.","Chrysosporium | CHRYSOSPORIUM",,,,,,,,,,,,,,,"4207545","Chrysosporium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008886","Cladosporium","C122261","A genus of fungi in the family Davidiellaceae with olive-green to brown or black colonies and dark-pigmented conidia that are formed in simple or branching chains. Cladosporium species occur as a plant pathogens and contaminants for other foods and their airborne spores are significant allergens.","Cladosporium | CLADOSPORIUM",,,,,,,,,,,,,,,"4135700","Cladosporium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009022","Clonorchis sinensis","C122262","A species of liver fluke in the class Trematoda. The life cycle of C. sinensis involves freshwater snails, fish, and humans. In humans they are found mainly in the common bile duct and gall bladder where they feed on bile.","Clonorchis sinensis | CLONORCHIS SINENSIS | Chinese Liver Fluke | Oriental liver fluke",,,,,,,,,,,,,,,"4267507","Clonorchis sinensis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1638074","Clostridium aldenense","C122263","A species of gram-positive, obligate anaerobic bacteria in the family Clostridiaceae. C. aldenense is differentiated from others in the clostridioforme group by exhibiting a positive indole reaction.","Clostridium aldenense | CLOSTRIDIUM ALDENENSE",,,,,,,,,,,,,,,"40491996","Enterocloster aldenensis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1638075","Clostridium citroniae","C122264","A species of gram-positive, obligate anaerobic bacteria in the family Clostridiaceae. C. aldenense is indole positive and produces acid from glucose, maltose, mannose, rhamnose, sucrose, trehalose, and xylose but not from cellobiose, esculin, lactose, mannitol, melezitose, raffinose, salicin, sorbitol, or starch. This species does not hydrolyze urea, esculin, starch, or gelatin or reduce nitrate.","Clostridium citroniae | CLOSTRIDIUM CITRONIAE",,,,,,,,,,,,,,,"37016386","Enterocloster citroniae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0315065","Clostridium oroticum","C122265","A species of mesophilic and nonmotile bacteria in the family Clostridiaceae. C. oroticum is distinguished by its occurrence as oval Gram-positive cells in chains of 100 or more units and its ability to metabolize orotic acid.","Clostridium oroticum | CLOSTRIDIUM OROTICUM | Zymobacterium oroticum",,,,,,,,,,,,,,,"4164711","Faecalicatena orotica",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0315126","Clostridium spiroforme","C122266","A species of helically coiled, obligately anaerobic, non-motile, gram-positive, spore-forming, rod-shaped bacteria in the family Clostridiaceae. Unlike most clostridia, C. spiroforme does not produce butyric acid as an end product of glucose fermentation. The species produces a toxin that is associated with severe diarrhea and enterocolitis in rabbits.","Clostridium spiroforme | CLOSTRIDIUM SPIROFORME",,,,,,,,,,,,,,,"4178643","Clostridium spiroforme",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055218","Coliform Bacteria, Lactose Fermenting","C122267","Any rod-shaped, gram-negative, non-spore forming bacteria that is capable of fermenting lactose to produce acid and gas.","Coliform Bacteria, Lactose Fermenting | COLIFORM BACTERIA, LACTOSE FERMENTING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055217","Coliform Bacteria, Non-Lactose Fermenting","C122268","Any rod-shaped, gram-negative, non-spore forming bacteria that is incapable of fermenting lactose to produce acid and gas.","Coliform Bacteria, Non-Lactose Fermenting | COLIFORM BACTERIA, NON-LACTOSE FERMENTING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1017347","Corynebacterium coyleae","C122269","A species of non-motile, catalase-positive, non-lipophilic, pleomorphic coryneform bacteria in the family Corynebacteriaceae. C. coyleae is characterized by slow fermentative acid production from glucose but no acid production from maltose and sucrose and a strongly positive CAMP reaction. The species produces acid from fructose, glucose, maltose, and sucrose and is urease-positive.","Corynebacterium coyleae | CORYNEBACTERIUM COYLEAE",,,,,,,,,,,,,,,"4023089","Corynebacterium coyleae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0315172","Corynebacterium diphtheriae bv. gravis","C122270","A biovar of Corynebacterium diphtheriae distinguished by its morphogenic and biochemical properties. Biovar gravis is nitrate positive and positive for fermentation of glucose, maltose, and starch. This biovar is one of the two main disease-causing biovars.","Corynebacterium diphtheriae bv. gravis | CORYNEBACTERIUM DIPHTHERIAE TYPE GRAVIS",,,,,,,,,,,,,,,"4306916","Corynebacterium diphtheriae type gravis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0315173","Corynebacterium diphtheriae bv. intermedius","C122271","A biovar of Corynebacterium diphtheriae. Biovar intermedius is nitrate positive and positive for fermentation of glucose and maltose.","Corynebacterium diphtheriae bv. intermedius | CORYNEBACTERIUM DIPHTHERIAE TYPE INTERMEDIUS",,,,,,,,,,,,,,,"4321988","Corynebacterium diphtheriae type intermedius",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055337","CD3 Complex Staining Method","C122852","An immunohistochemical technique used to detect the presence of the CD3 protein complex in a tissue sample.","CD3 Complex Staining Method | CD3 Staining Method | T-Cell Surface Glycoprotein CD3 Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053935","Tight Junction Protein ZO-1 Staining Method","C122853","An immunohistochemical technique used to detect the presence of tight junction protein ZO-1 in a tissue sample.","Tight Junction Protein ZO-1 Staining Method | TJP1 Staining Method | Tight Junction Protein 1 Staining Method | ZO-1 Staining Method | Zona Occludens Protein 1 Staining Method | Zonula Occludens Protein 1 Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053746","Cadherin-2 Staining Method","C122854","An immunohistochemical technique used to detect the presence of cadherin-2 (N-cadherin) in a tissue sample.","Cadherin-2 Staining Method | CDH2 Staining Method | N-cadherin Staining Method | NCAD Staining Method | Neural-Cadherin Staining Method | nCadherin Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055288","Cadherin-3 Staining Method","C122855","An immunohistochemical technique used to detect the presence of cadherin-3 (P-cadherin) in a tissue sample.","Cadherin-3 Staining Method | CDH3 Staining Method | P-cadherin Staining Method | PCAD Staining Method | Placental Cadherin Staining Method | pCadherin Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055232","Claudin-7 Staining Method","C122856","An immunohistochemical technique used to detect the presence of claudin-7 in a tissue sample.","Claudin-7 Staining Method | CLDN-7 Staining Method | CLDN7 Staining Method | Claudin 7 Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054252","Pan Cytokeratin Staining Method","C122857","An immunohistochemical technique used to detect the presence of a broad spectrum of acidic and basic cytokeratin proteins in a tissue sample.","Pan Cytokeratin Staining Method | PCK Staining | PCK Staining Method | Pan-CK Staining Method | Pan-Cytokeratin Staining Method | Pancytokeratin Staining | Pancytokeratin Staining Method | Poly-CK Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055167","Cytokeratin-6 Staining Method","C122858","An immunohistochemical technique used to detect the presence of cytokeratin-6 in a tissue sample.","Cytokeratin-6 Staining Method | CK6 Staining Method | Cytokeratin 6 | Cytokeratin 6 Staining Method | KRT6 Staining Method | Keratin, Type II Cytoskeletal 6 Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053759","Cytokeratin-5 Staining Method","C122859","An immunohistochemical technique used to detect the presence of cytokeratin-5 in a tissue sample.","Cytokeratin-5 Staining Method | CK5 Staining Method | Cytokeratin 5 | Cytokeratin 5 Staining Method | KRT5 Staining Method | Keratin, Type II Cytoskeletal 5 Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084895","CSNK1D wt Allele","C125589","Human CSNK1D wild-type allele is located in the vicinity of 17q25 and is approximately 35 kb in length. This allele, which encodes casein kinase I isoform delta protein, plays a role in protein phosphorylation, cellular growth and cellular survival. Mutation of the gene is associated with familial advanced sleep phase syndrome-2.","CSNK1D wt Allele | ASPS | CKIdelta | Casein Kinase 1, Delta wt Allele | FASPS2 | HCKID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084846","Casein Kinase I Isoform Delta","C125590","Casein kinase I isoform delta (415 aa, ~47 kDa) is encoded by the human CSNK1D gene. This protein is involved in protein phosphorylation, cell survival and cellular growth.","Casein Kinase I Isoform Delta | CKI-Delta | CKId | EC 2.7.11.1 | EC 2.7.11.26 | Tau-Protein Kinase CSNK1D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4230871","Abnormal Behavior","C122430","Conduct that is unusual for the individual.","Abnormal Behavior | Behavioral Disturbance | Behavioral change | Not Acting Normal | Not Acting Self",,,,,,,,,,,,,,,"4093424","Abnormal behavior",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4055274","Carbon C 14 Gilteritinib","C122677","A radioconjugate composed of gilteritinib, an inhibitor of the receptor tyrosine kinases (RTKs) FMS-related tyrosine kinase 3 (FLT3, STK1, or FLK2), AXL (UFO or JTK11) and anaplastic lymphoma kinase (ALK or CD246), labeled with the radioisotope carbon C 14, with potential use for evaluating the pharmacokinetic profile of gilteritinib. Gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL and ALK. This may result in an inhibition of FLT3, AXL, and ALK-mediated signal transduction pathways and the reduction of tumor cell proliferation in cancers that overexpress these RTKs. Labeling of gilteritinib with the radioactive tracer carbon C 14 allows for the evaluation of gilteritinib's pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME).","Carbon C 14 Gilteritinib | 14C-labeled Gilteritinib | [14C] ASP2215",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054750","IDH1R132H Mutation-targeting IDH1 Peptide Vaccine","C122678","A peptide vaccine consisting of a 20-mer peptide derived from isocitrate dehydrogenase type 1 (IDH1) containing the point mutation R132H (IDH1R132H), with potential antineoplastic activity. Upon subcutaneous vaccination with the IDH1R132H mutation-targeting IDH1 peptide vaccine, the vaccine stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells that express the IDH1R132H protein. R132H is a point mutation, which contains an amino acid substitution where arginine is replaced by histidine at position 132 of IDH1, and is highly expressed in gliomas as well as other tumor types; this mutation is associated with increased production of the oncometabolite R-2-hydroxyglutarate (2HG).","IDH1R132H Mutation-targeting IDH1 Peptide Vaccine | IDH1R132H-specific Peptide Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055458","Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes","C122679","Autologous human peripheral blood T-lymphocytes transduced with a lentiviral or retroviral vector encoding a human leukocyte antigen A2 (HLA-A2) restricted anti-cancer-testis antigen 1 (NY-ESO-1) T-cell receptor (TCR) gene, with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and re-introduction into the patient, the anti-HLA-A2/NY-ESO-1 TCR-transduced autologous T lymphocytes recognize and bind to NY-ESO-1/HLA-A2-positive tumor cells. This results in cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1-positive cancer cells. NY-ESO-1, a tumor-associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types.","Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes | Anti-HLA-A2/NY-ESO1 TCR-transduced Autologous T cells | Autologous Anti-HLA-A2/NY-ESO1 TCR-transduced T Lymphocytes | Autologous HLA-A2/NY-ESO-1-specific TCR Gene-transduced T-lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053591","anti-CD20 monoclonal antibody SCT400","C122680","A chimeric monoclonal antibody directed against human CD20, with potential antineoplastic activity. Ripertamab binds to the B-cell-specific cell surface antigen CD20, which triggers an immune response against CD20-positive B-cells, leading to apoptosis. CD20, a non-glycosylated cell surface phosphoprotein, is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies.","Ripertamab | Anti-CD20 Monoclonal Antibody SCT400 | RIPERTAMAB | SCT400",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053828","Zhongyao Fufang","C122681","A combination formula consisting of two or more unknown Traditional Chinese Medicine (TCM) ingredients, with potential anti-osteoporotic activity. Upon oral administration, this particular formula of zhongyao fufang may promote increased bone strength and density.","Zhongyao Fufang | Zhongyaofufang",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085198","PSMD11 wt Allele","C125535","Human PSMD11 wild-type allele is located in the vicinity of 17q11.2 and is approximately 39 kb in length. This allele, which encodes 26S proteasome non-ATPase regulatory subunit 11 protein, is involved in proteasome assembly and activity.","PSMD11 wt Allele | MGC3844 | Proteasome (Prosome, Macropain) 26S Subunit, Non-ATPase, 11 Gene | Proteasome 26S Subunit, Non-ATPase 11 wt Allele | Proteasome 26S Subunit, Non-ATPase, 11 Gene | Rpn6 | S9 | p44.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2934474","PSMD11 protein, human","C125536","26S proteasome non-ATPase regulatory subunit 11 (422 aa, ~47 kDa) is encoded by the human PSMD11 gene. This protein plays a role in the assembly of the proteasome.","26S Proteasome Non-ATPase Regulatory Subunit 11 | 26S Proteasome Regulatory Subunit 9 | 26S Proteasome Regulatory Subunit P44.5 | 26S Proteasome Regulatory Subunit RPN6 | 26S Proteasome Regulatory Subunit S9 | PSMD11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055198","Confocal Laser Microlaryngoscopy","C122390","An endoscopic modality using confocal laser endomicroscopy to produce high magnification and resolution images during the study of the laryngeal tissues.","Confocal Laser Microlaryngoscopy | Confocal Endoscopy of the Larynx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507845","Red Blood Cell Exchange and Depletion Procedure","C122391","Procedures for the removal of defective, infected, or contaminated red blood cells (RBCs) and their replacement with normal donor RBCs.","Red Blood Cell Exchange and Depletion Procedure | RBCx | Red Blood Cell Exchange Transfusion | Red Blood Cell Exchange and Depletion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050515","Simo Decoction","C122395","A traditional Chinese medicine (TCM) containing simo decoction which contains Fructus aurantii, Radix aucklandiae, Semen arecae and Radix linderae, that can potentially be used to improve gastrointestinal (GI) function following surgery. Upon oral intake of simo decoction, this TCM may stimulate mainly muscarinic M3 receptors, but also muscarinic M2 receptors, calcium channels and nicotinic receptors triggering a release of nitric oxide (NO), while inhibiting adrenergic receptors Altogether, this stimulates the contraction of antral circular smooth muscle, thereby abrogating GI hypomotility and enhances the return of GI function after surgery.","Simo Decoction | SMD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053753","tetravalent RNA-lipoplex cancer vaccine","C122396","A RNA-lipoplex (RNA-LIP)-based cancer vaccine containing four naked ribonucleic acid (RNA)-drug products (DPs) RBL001.1, RBL002.2, RBL003.1, and RBL004.1 encoding the four melanoma-associated antigens (MAAs), the cancer-testis antigen NY-ESO-1, the human melanoma-associated antigen A3 (MAGE-A3), tyrosinase, and putative tyrosine-protein phosphatase (TPTE), encapsulated in liposomes, with potential antineoplastic activity. Upon intravenous administration of the tetravalent RNA-lipoplex cancer vaccine BNT111, the liposomes protect the RNA from degradation in the bloodstream, travel to the spleen and are taken up by antigen-presenting cells (APCs). The RNA is translocated to the cytoplasm and translated into the four tumor-associated proteins. The expressed proteins are processed and the human leukocyte antigen (HLA)-peptide complexes are presented to the immune system. This results in the production of various pro-inflammatory cytokines and induces antigen-specific CD8+ and CD4+ T-cell responses against the four selected MAAs NY-ESO-1, MAGE-A3, tyrosinase, and TPTE.","Tetravalent RNA-lipoplex Cancer Vaccine BNT111 | BNT 111 | BNT-111 | BNT111 | Cancer Vaccine BNT111 | Lipo-MERIT Vaccine | RNA(LIP) BNT111 | RNA-LPX BNT111 | RNA-lipoplex Vaccine BNT111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049992","Auto-Injector Dosing Unit","C122630","A dosing unit equal to the amount of active ingredient(s) contained in an auto-injector.","Auto-Injector Dosing Unit | Auto-Injector",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1719829","Dropperful Dosing Unit","C122631","A dosing unit equal to the amount of active ingredient(s) contained in a dropperful.","Dropperful Dosing Unit | Dropperful",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049935","Injection Dosing Unit","C122632","A dosing unit equal to the amount of active ingredient(s) contained in an injection.","Injection Dosing Unit | Injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049764","Lollipop Dosing Unit","C122633","A dosing unit equal to the amount of active ingredient(s) contained in a lollipop.","Lollipop Dosing Unit | Lollipop",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050254","Pre-Filled Pen Syringe Dosing Unit","C122635","A dosing unit equal to the amount of active ingredient(s) contained in an pre-filled pen syringe.","Pre-Filled Pen Syringe Dosing Unit | Pre-Filled Pen Syringe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0175691","Dubowitz Syndrome","C125591","A rare, autosomal recessive inherited syndrome characterized by microcephaly, growth retardation, and a small, round, triangular shaped face with a pointed, receding chin, a broad, wide-tipped nose, and wide-set eyes with drooping eyelids.","Dubowitz Syndrome | ",,,,,,,,,,,,,,,"4093756","Dubowitz's syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265264","Holt-Oram Syndrome","C125592","A rare, autosomal dominant inherited syndrome caused by mutations in the TBX5 gene. It is characterized by skeletal abnormalities in the upper limbs and heart abnormalities.","Holt-Oram Syndrome | ",,,,,,,,,,,,,,,"4078058","Holt-Oram syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0282526","Hyperpipecolatemia","C125593","A rare, autosomal recessive inherited metabolic disorder characterized by high levels of pipecolic acid in the blood, leading to neuropathy and hepatomegaly.","Hyperpipecolatemia | Pipecolic Acidemia",,,,,,,,,,,,,,,"4028040","Pipecolic acidemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265279","Kniest Dysplasia","C125594","A rare, autosomal dominant inherited bone growth disorder caused by mutations in the COL2A1gene. It is characterized by short stature (dwarfism) and other skeletal abnormalities, round, flat face with bulging and wide-set eyes, myopia and retinal detachment that can lead to blindness.","Kniest Dysplasia | ",,,,,,,,,,,,,,,"4207347","Kniest dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086611","Mucolipidosis Type IIIA","C125595","A lysosomal storage disease characterized by multiple bone formation abnormalities, progressive joint stiffness, developmental abnormalities, hearing loss, hepatosplenomegaly, increased acne, enlarged tongue, and cornea clouding due to accumulation of lipid substances.","Mucolipidosis Type IIIA | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268226","Neuraminidase Deficiency","C125596","An autosomal recessive inherited lysosomal storage disease characterized by excessive intracellular accumulation and urinary excretion of sialic acid associated with neuraminidase deficiency.","Neuraminidase Deficiency | Mucolipidosis I | Sialidosis Type II",,,,,,,,,,,,,,,"4307744","Sialidosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3808274","Polysyndactyly","C125597","A rare anatomical malformation characterized by polydactyly (extra fingers or toes) and syndactyly (webbed fingers or toes).","Polysyndactyly | ",,,,,,,,,,,,,,,"79126","Polysyndactyly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265343","Spondylocostal Dysostosis","C125598","A rare disorder caused by mutations in the DLL3 gene, MESP2 gene, LFNG gene, or HES7 gene. It is characterized by abnormal development of bones in the spine and ribs.","Spondylocostal Dysostosis | ",,,,,,,,,,,,,,,"4247644","Jarcho-Levin syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265210","Weaver Syndrome","C125599","A rare syndrome caused by mutations in the EZH2 gene, and rarely mutations in the NSD1 gene. It is characterized by advanced bone age, foot deformities, permanently bent joints, macrocephaly, flattened back of the head, a broad forehead, hypertelorism, large, low-set ears, micrognathia, delayed development of motor skills, and mild intellectual disability.","Weaver Syndrome | WVS | Weaver-Smith Syndrome",,,,,,,,,,,,,,,"4268475","Weaver syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0076691","Tin Ethyl Etiopurpurin","C1255","A synthetic purpurin with photosensitizing activity.  Tin ethyl etiopurpurin preferentially accumulates in tumor cells due to an increased rate of metabolism. Upon exposure to a light source, this agent absorbs light, forming an extended high energy conformational state that produces high quantum yields of singlet oxygen with local cytotoxic effects. (NCI04)","Tin Ethyl Etiopurpurin | DRG-0268 | SnET2 | Tin, (ethyl tetramethyl-20-phorbinecarboxylato(2-)-N23,N24,N25,N26)-, (SP-4-2)- | tin ethyl etiopurpurin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504306","Carboplatin/Etoposide/Melphalan Regimen","C125601","A regimen containing carboplatin, etoposide and melphalan used for the treatment of childhood neuroblastoma.","Carboplatin/Etoposide/Melphalan Regimen | CEM | CEM Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3492499","Xianling Gubao","C122682","An orally bioavailable phytoestrogen-rich Traditional Chinese Medicine (TCM) containing extracts from the six herbs Herba epimedii, Radix dipsaci (Dipsacus root), Radix salvia miltiorrhiza (Salvia root, Danshen, red sage root), Rhizoma anemarrhenae (zhi Mu), Fructus Psoraleae (fruit of Psoralea corylifolia L), and Radix Rehmanniae (Rehmannia root, Rehmannia glutinosa, Sheng Di Huang, Rehmannia glutinosa Libosch), with potential anti-osteoporotic and bone-strengthening activities. Xianling gubao (XLGB) contains various phytochemicals, including flavonoids, coumarins, saponins, alkaloids and terpenes. Upon oral administration of XLGB, the active ingredients may strengthen bones and may treat or prevent osteoporosis, osteoarthritis, bone loss and bone fractures.","Xianling Gubao | XLGB | Xian Ling Gu Bao | Xian-ling-gu-bao | Xianlinggubao",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053626","anti-LAG-3 monoclonal antibody LAG525","C122683","A humanized monoclonal antibody directed against the inhibitory receptor lymphocyte activation gene-3 (LAG-3), with potential immunomodulating and antineoplastic activities. Upon administration, Ieramilimab binds to LAG-3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF) and expressed on various immune cells, negatively regulates cellular proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.","Ieramilimab | IERAMILIMAB | IMP-701 | LAG 525 | LAG525",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433956","emactuzumab","C125548","A humanized monoclonal antibody directed against the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R; CSF-1R; CD115), also known as macrophage colony-stimulating factor receptor (M-CSFR), with potential antineoplastic and immunomodulating activities. Upon administration, emactuzumab binds to CSF1R expressed on macrophages and inhibits the binding of colony-stimulating factor-1 (CSF-1) to CSF1R. This prevents CSF1R activation and CSF1R-mediated signaling in these cells, which blocks the production of inflammatory mediators by macrophages and reduces inflammation. By blocking both the activity of CSF1R-dependent tumor-associated macrophages (TAMs) and the recruitment of TAMs to the tumor microenvironment, emactuzumab enhances T-cell infiltration and antitumor T-cell immune responses, which inhibits the proliferation of tumor cells. TAMs play key roles in immune suppression and promoting inflammation, tumor cell proliferation and survival.","Emactuzumab | EMACTUZUMAB | RG-7155 | RG7155 | RO-5509554 | RO5509554",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504394","BRD4 Inhibitor PLX51107","C125739","An inhibitor of the bromodomain-containing protein 4 (BRD4), with potential antineoplastic activity. Upon administration, the BRD4 inhibitor PLX51107 binds to the acetylated lysine recognition motifs in the bromodomains of the BRD4 protein, thereby preventing the binding of BRD4 to acetylated lysines on histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an induction of apoptosis and an inhibition of proliferation in BRD4-overexpressing tumor cells. BRD4, a member of the human bromodomain and extra-terminal (BET) family of proteins, is a transcriptional regulator that is overexpressed in certain tumor cells and plays an important role in cellular proliferation.","BRD4 Inhibitor PLX51107 | PLX 51107 | PLX-51107 | PLX51107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3899265","Endocrine Cell of the Digestive System","C12573","No value exists.","Endocrine Cell of the Digestive System | Endocrine Cell of Gut | Endocrine Cells of Gut | Gastrointestinal Endocrine Cell | Gastrointestinal Endocrine Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504395","CDISC Questionnaire ASEX-Female Version Test Name Terminology","C125740","Test names of questionnaire questions associated with the Arizona Sexual Experiences Scale-Female Version (ASEX-Female Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire ASEX-Female Version Test Name Terminology | ASEX01TN | Arizona Sexual Experiences Scale - Female Questionnaire Test Name | QS-ASEX-Female Version TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504396","CDISC Questionnaire ASEX-Female Version Test Code Terminology","C125741","Test codes of questionnaire questions associated with the Arizona Sexual Experiences Scale-Female Version (ASEX-Female Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire ASEX-Female Version Test Code Terminology | ASEX01TC | Arizona Sexual Experiences Scale - Female Questionnaire Test Code | QS-ASEX-Female Version TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504397","CDISC Questionnaire ASEX-Male Version Test Name Terminology","C125742","Test names of questionnaire questions associated with the Arizona Sexual Experiences Scale-Male Version (ASEX-Male Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire ASEX-Male Version Test Name Terminology | ASEX02TN | Arizona Sexual Experiences Scale - Male Questionnaire Test Name | QS-ASEX-Male Version TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504398","CDISC Questionnaire ASEX-Male Version Test Code Terminology","C125743","Test codes of questionnaire questions associated with the Arizona Sexual Experiences Scale-Male Version (ASEX-Male Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire ASEX-Male Version Test Code Terminology | ASEX02TC | Arizona Sexual Experiences Scale - Male Questionnaire Test Code | QS-ASEX-Male Version TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504399","CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology","C125744","Test names of questionnaire questions associated with the Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology | ED1TN | Expanded Disability Rating Scale - Postacute Interview Caregiver Version Questionnaire Test Name | QS-Expanded DRS-PI Caregiver Version TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504400","CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology","C125745","Test codes of questionnaire questions associated with the Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology | ED1TC | Expanded Disability Rating Scale - Postacute Interview Caregiver Version Questionnaire Test Code | QS-Expanded DRS-PI Caregiver Version TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054222","Pediatric Medical Device Terminology","C122636","Terminology developed by a collaborative effort of the National Cancer Institute's Enterprise Vocabulary Services, the National Institute of Child Health and Human Development, and an international group of clinicians and informaticists to support the use of medical devices in the pediatric population.","Pediatric Medical Device Terminology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054313","Ostomy Site","C122638","The anatomic location of a surgically created ostomy.","Ostomy Site | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0546255","Colostomy site","C122640","A surgically created external opening into the colon.","Colostomy Site | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055173","Cystostomy Site","C122641","A surgically created external opening into the anterior wall of the bladder.","Cystostomy Site | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054742","Ileostomy Site","C122642","A surgically created external opening into the ileum.","Ileostomy Site | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0546259","Tracheostomy Site","C122643","A surgically created external opening into the trachea.","Tracheostomy Site | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053891","Urostomy Site","C122644","A surgically created external opening into the urinary tract.","Urostomy Site | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0546256","Gastrostomy Site","C122646","A surgically created external opening into the stomach.","Gastrostomy Site | ",,,,,,,,,,,,,,,"4155548","Gastrostomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4054691","Jejunostomy Site","C122647","A surgically created external opening into the jejunum.","Jejunostomy Site | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415586","HLA-F Gene","C124890","This gene is involved in the presentation of cytoplasmic protein fragments to cytotoxic lymphocytes.","HLA-F Gene | HLA-F | Major Histocompatibility Complex, Class I, F Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085202","HLA-F wt Allele","C124891","Human HLA-F wild-type allele is located in the vicinity of 6p21.3 and is approximately 16 kb in length. This allele, which encodes HLA class I histocompatibility antigen, alpha chain F protein, plays a role in antigen presentation.","HLA-F wt Allele | CDA12 | HLA-5.4 | HLA-CDA12 | HLA-F Histocompatibility Type Gene | HLAF | Major Histocompatibility Complex, Class I, F wt Allele | cda12 Class I Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1429503","HLA Class I Histocompatibility Antigen, Alpha Chain F, Human","C124892","HLA class I histocompatibility antigen, alpha chain F (346 aa, ~39 kDa) is encoded by the human HLA-F gene. This protein is involved in antigen presentation.","HLA Class I Histocompatibility Antigen, Alpha Chain F | HLA F Antigen | HLA-F | Leukocyte Antigen F | MHC Class I Antigen F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0076192","Testosterone Isobutyrate","C1248","An four-carbon ester form of Testosterone. The number of ester carbon atoms correlate with the half-life of the prodrug.  Testosterone inhibits gonadotropin secretion from the pituitary gland and ablates estrogen production in the ovaries, thereby decreasing endogenous estrogen levels.  In addition, this agent promotes the maintenance of male sex characteristics and is indicated for testosterone replacement in hypogonadal males. (NCI04)","Testosterone Isobutyrate | Agovirin-Depot | Perandren M | TESTOSTERONE ISOBUTYRATE | Testocryst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415566","HLA-DOB Gene","C124902","This gene plays a role in the presentation of exogenous peptide antigens.","HLA-DOB Gene | HLA-DOB | Major Histocompatibility Complex, Class II, DO Beta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4050467","Shootin-1, human","C122908","Shootin-1 (631 aa, ~72 kDa) is encoded by the human SHTN1 gene. This protein is involved in establishing neuronal polarity.","Shootin-1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1869579","Receptor-Type Tyrosine-Protein Phosphatase Beta, Human","C122911","Receptor-type tyrosine-protein phosphatase beta (1997 aa, ~224 kDa) is encoded by the human PTPRB gene. This protein is involved in both blood vessel maintenance and protein dephosphorylation.","Receptor-Type Tyrosine-Protein Phosphatase Beta | EC 3.1.3.48 | PTPRB | Protein-Tyrosine Phosphatase Beta | R-PTP-beta | VE-PTP | Vascular Endothelial Protein Tyrosine Phosphatase | Vascular Endothelial Protein-Tyrosine Phosphatase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416961","MADCAM1 Gene","C122912","This gene plays a role in leukocyte migration.","MADCAM1 Gene | MADCAM1 | Mucosal Vascular Addressin Cell Adhesion Molecule 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504401","CDISC Questionnaire Expanded DRS-PI Survivor Version Test Name Terminology","C125746","Test names of questionnaire questions associated with the Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire Expanded DRS-PI Survivor Version Test Name Terminology | ED2TN | Expanded Disability Rating Scale - Postacute Interview Survivor Version Questionnaire Test Name | QS-Expanded DRS-PI Survivor Version TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504402","CDISC Questionnaire Expanded DRS-PI Survivor Version Test Code Terminology","C125747","Test codes of questionnaire questions associated with the Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire Expanded DRS-PI Survivor Version Test Code Terminology | ED2TC | Expanded Disability Rating Scale - Postacute Interview Survivor Version Questionnaire Test Code | QS-Expanded DRS-PI Survivor Version TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504403","CDISC Questionnaire PHQ Screener Version Test Name Terminology","C125748","Test names of questionnaire questions associated with the Patient Health Questionnaire Screener Version (PHQ Screener Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PHQ Screener Version Test Name Terminology | PHQ03TN | Patient Health Questionnaire Screener Version Questionnaire Test Name | QS-PHQ Screener Version TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503903","MNK1/2 inhibitor eFT508","C125062","An orally bioavailable inhibitor of mitogen-activated protein kinase (MAPK)-interacting serine/threonine-protein kinase 1 (MNK1) and 2 (MNK2), with potential antineoplastic activity. Upon oral administration, tomivosertib binds to and inhibits the activity of MNK1 and 2. This prevents MNK1/2-mediated signaling, and inhibits the phosphorylation of certain regulatory proteins, including eukaryotic translation initiation factor 4E (eIF4E), that regulate the translation of messenger RNAs (mRNAs) involved in tumor cell proliferation, angiogenesis, survival and immune signaling. This inhibits tumor cell proliferation in MNK1/2-overexpressing tumor cells. MNK1/2 are overexpressed in a variety of tumor cell types and promote phosphorylation of eIF4E; eIF4E is overexpressed in many tumor cell types and contributes to tumor development, maintenance and resistance.","Tomivosertib | EFT-508 | Spiro(cyclohexane-1,3'(2'H)-imidazo(1,5-a)pyridine)-1',5'-dione, 6'-((6-Amino-4-pyrimidinyl)amino)-8'-methyl- | TOMIVOSERTIB | eFT508",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503904","Botanical Lotion CG428","C125063","A proprietary lotion containing a blend of the four botanicals Allium cepa L. (Onion), Citrus limon L. (Citrus), Theobroma cacao L. (Cocoa), Paullinia cupana (Guarana), with potential activity against chemotherapy-induced alopecia (CIA). Upon administration to the scalp, botanical lotion CG428 may normalize the apoptotic process of hair follicular cells and reduce inflammation in the scalp. This may reverse chemotherapy-induced alopecia (CIA), restore the natural hair cycle, improve hair regrowth, and improve the psychosocial well-being of the affected patient.","Botanical Lotion CG428 | CG428",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053859","Vitamin D3 Receptor Staining Method","C122860","An immunohistochemical technique used to detect the presence of vitamin D3 receptor in a tissue sample.","Vitamin D3 Receptor Staining Method | NR1I1 Staining Method | VDR Staining Method | Vitamin D Receptor Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055469","Androgen Receptor Staining Method","C122861","An immunohistochemical technique used to detect the presence of androgen receptor in a tissue sample.","Androgen Receptor Staining Method | AR Staining Method | NR3C4 Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085192","MAP3K3 wt Allele","C125113","Human MAP3K3 wild-type allele is located in the vicinity of 17q23.3 and is approximately 74 kb in length. This allele, which encodes mitogen-activated protein kinase kinase kinase 3 protein, is involved in protein phosphorylation and signal transduction.","MAP3K3 wt Allele | MAPKKK3 | MEKK3 | Mitogen-Activated Protein Kinase Kinase Kinase 3 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0528266","MAP Kinase Kinase Kinase 3","C125114","Mitogen-activated protein kinase kinase kinase 3 (626 aa, ~71 kDa) is encoded by the human MAP3K3 gene. This protein plays a role in the propagation of signaling pathways.","Mitogen-Activated Protein Kinase Kinase Kinase 3 | EC 2.7.11.25 | MAP/ERK Kinase Kinase 3 | MAP3K3 | MAPK/ERK Kinase Kinase 3 | MEK Kinase 3 | MEKK 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049716","MADCAM1 wt Allele","C122913","Human MADCAM1 wild-type allele is located in the vicinity of 19p13.3 and is approximately 16 kb in length. This allele, which encodes mucosal addressin cell adhesion molecule 1 protein, is involved in lymphocyte trafficking.","MADCAM1 wt Allele | Addressin, Mucosal Gene | MACAM1 | Mucosal Vascular Addressin Cell Adhesion Molecule 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1138490","Mucosal Addressin Cell Adhesion Molecule 1, Human","C122914","Mucosal addressin cell adhesion molecule 1 (382 aa, ~40 kDa) is encoded by the human MADCAM1 gene. This protein plays a role in both lymphocyte migration and integrin-mediated cell adhesion.","Mucosal Addressin Cell Adhesion Molecule 1 | MADCAM1 | MAdCAM-1 | Mucosal Addressin Cell Adhesion Molecule-1 | hMAdCAM-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426592","PCSK9 Gene","C122915","This gene is involved in both cholesterol metabolism and protein degradation.","PCSK9 Gene | PCSK9 | Proprotein Convertase Subtilisin/Kexin Type 9 Gene",,,,,,,,,,,,,,,"40479181","Proprotein convertase subtilisin/kexin type 9 gene",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4049729","PCSK9 wt Allele","C122916","Human PCSK9 wild-type allele is located in the vicinity of 1p32.3 and is approximately 25 kb in length. This allele, which encodes proprotein convertase subtilisin/kexin type 9 protein, plays a role in both receptor protein degradation and lipid metabolism. Mutation of the gene is associated with autosomal dominant familial hypercholesterolemia type 3.","PCSK9 wt Allele | FH3 | HCHOLA3 | Hypercholesterolemia, Autosomal Dominant 3 Gene | LDLCQ1 | NARC-1 | NARC1 | PC9 | PSEC0052 | Proprotein Convertase Subtilisin/Kexin Type 9 wt Allele | Proprotein Convertase, Subtilisin/Kexin-Type, 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049638","Cutaneous Small Vessel Vasculitis","C122919","A skin hypersensitivity reaction characterized by raised purpuric lesions, red macules, hemorrhagic blisters and ulcerations.","Cutaneous Small Vessel Vasculitis | Cutaneous Leukocytoclastic Vasculitis | Cutaneous Small-Vessel Vasculitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0151539","Blood Urea Nitrogen Increased","C122438","Laboratory results demonstrating an increase in the concentration of urea nitrogen in a blood sample.","Blood Urea Nitrogen Increased | Elevated Blood Urea Nitrogen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086733","Pegol-sihematide Injection","C125064","A synthetic peptide derived from erythropoietin (EPO) linked to polyethylene glycol (PEG), with erythropoietic stimulating activity. Upon administration, pegol sihematide binds to and activates EPO receptors on the surface of erythroid progenitor cells in the bone marrow resulting in their differentiation and proliferation. This increases the production of red blood cells and prevents anemia. Pegylation increases this agent's blood circulation time.","Pegol-sihematide Injection | EPO 018B | EPO-018B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054187","Phosphatase and Tensin Homolog Staining Method","C122863","An immunohistochemical technique used to detect the presence of phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN in a tissue sample.","Phosphatase and Tensin Homolog Staining Method | PTEN Staining Method | Phosphatidylinositol-3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055348","Breast Cancer Type 2 Susceptibility Protein Staining Method","C122864","An immunohistochemical technique used to detect the presence of breast cancer type 2 susceptibility protein in a tissue sample.","Breast Cancer Type 2 Susceptibility Protein Staining Method | BRCA2 Staining Method | BROVCA2 Staining Method | Breast Cancer 2, Early Onset Protein Staining Method | FANCD1 Staining Method | Fanconi Anemia Group D1 Protein Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055349","Breast Cancer Type 1 Susceptibility Protein Staining Method","C122865","An immunohistochemical technique used to detect the presence of breast cancer type 1 susceptibility protein in a tissue sample.","Breast Cancer Type 1 Susceptibility Protein Staining Method | BRCA1 Staining Method | BROVCA1 Staining Method | Breast Cancer 1, Early Onset Protein Staining Method | Breast-Ovarian Cancer Protein Staining Method | FANCS Staining Method | Fanconi Anemia Group S Protein Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054063","Retinoblastoma-Associated Protein Staining Method","C122867","An immunohistochemical technique used to detect the presence of retinoblastoma-associated protein in a tissue sample.","Retinoblastoma-Associated Protein Staining Method | RB Staining Method | RB1 Staining Method | Retinoblastoma Protein Staining Method | p105-Rb Staining Method | pRB Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4055263","Cellular Tumor Antigen p53 Staining Method","C122868","An immunohistochemical technique used to detect the presence of cellular tumor antigen p53 in a tissue sample.","Cellular Tumor Antigen p53 Staining Method | NY-CO-13 Staining Method | TP53 Staining Method | Tumor Protein p53 Staining Method | p53 Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054357","Neurogenic Locus Notch Homolog Protein 3 Staining Method","C122869","An immunohistochemical technique used to detect the presence of neurogenic locus notch homolog protein 3 in a tissue sample.","Neurogenic Locus Notch Homolog Protein 3 Staining Method | NOTCH-3 Staining Method | NOTCH3 Staining Method | Notch 3 Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054358","Neurogenic Locus Notch Homolog Protein 1 Staining Method","C122870","An immunohistochemical technique used to detect the presence of neurogenic locus notch homolog protein 1 in a tissue sample.","Neurogenic Locus Notch Homolog Protein 1 Staining Method | NOTCH-1 Staining Method | NOTCH1 Staining Method | Notch 1 Staining Method | TAN-1 Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054024","Signal Transducer and Activator of Transcription 3 Staining Method","C122872","An immunohistochemical technique used to detect the presence of signal transducer and activator of transcription 3 in a tissue sample.","Signal Transducer and Activator of Transcription 3 Staining Method | APRF Staining Method | Acute-Phase Response Factor Staining Method | STAT-3 Staining Method | STAT3 Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4054025","Signal Transducer and Activator of Transcription 1 Staining Method","C122873","An immunohistochemical technique used to detect the presence of one or both isoforms of signal transducer and activator of transcription 1 in a tissue sample.","Signal Transducer and Activator of Transcription 1 Staining Method | STAT-1 Staining Method | STAT1 Staining Method | STAT1-alpha/beta Staining Method | Signal Transducer and Activator of Transcription 1-alpha/beta Staining Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509336","CDISC SDTM Observational Study Biospecimen Retention Terminology","C127258","Terminology associated with the observational study biospecimen retention codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Observational Study Biospecimen Retention Terminology | OBSSBSR | Observational Study Biospecimen Retention | SDTM-OBSSBSR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509337","CDISC SDTM Observational Study Model Terminology","C127259","Terminology associated with the observation study model codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Observational Study Model Terminology | OBSSMO | Observational Study Model | SDTM-OBSSMO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509338","CDISC SDTM Observational Study Sampling Method Terminology","C127260","Terminology associated with the observation study sampling method codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Observational Study Sampling Method Terminology | OBSSSM | Observational Study Sampling Method | SDTM-OBSSSM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509339","CDISC SDTM Observational Study Time Perspective Terminology","C127261","Terminology associated with the observation study time perspective codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Observational Study Time Perspective Terminology | OBSSTP | Observational Study Time Perspective | SDTM-OBSSTP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509803","CDISC SDTM Environmental Setting Terminology","C127262","Terminology associated with the environmental setting codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Environmental Setting Terminology | Environmental Setting | SDTM-SETTING | SETTING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509824","CDISC SDTM Case Finding Terminology","C127263","Terminology associated with the case finding codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Case Finding Terminology | CASEFIND | Case Finding | SDTM-CASEFIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509815","CDISC SDTM Mode of Disease Transmission Terminology","C127265","Terminology associated with the mode of disease transmission codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Mode of Disease Transmission Terminology | MODTRN | Mode of Disease Transmission | SDTM-MODTRN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508797","FACT-P Version 4 - I Am Able to Feel Like a Man","C127498","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Additional Concerns: I am able to feel like a man.","FACT-P Version 4 - I Am Able to Feel Like a Man | FAC023-I Am Able to Feel Like a Man | FAC02334",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508813","FACT-P Version 4 - I Have Trouble Moving My Bowels","C127499","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Additional Concerns: I have trouble moving my bowels.","FACT-P Version 4 - I Have Trouble Moving My Bowels | FAC023-I Have Trouble Moving My Bowels | FAC02335",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0078255","Vinepidine","C1274","A vinca alkaloid compound and semi-synthetic vincristine derivative with antineoplastic activity. Vinepidine binds to and stabilizes tubulin, thereby preventing tubulin polymerization and depolymerization, which result in microtubule assembly and disassembly, respectively. Treated cells are unable to complete mitosis process and are arrested in the metaphase, thereby leading to an inhibition of cell growth.","Vinepidine | 4'-Deoxyepivincristine | VINEPIDINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508810","FACT-P Version 4 - I Have Difficulty Urinating","C127500","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Additional Concerns: I have difficulty urinating.","FACT-P Version 4 - I Have Difficulty Urinating | FAC023-I Have Difficulty Urinating | FAC02336",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508816","FACT-P Version 4 - I Urinate More Frequently","C127501","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Additional Concerns: I urinate more frequently than usual.","FACT-P Version 4 - I Urinate More Frequently | FAC023-I Urinate More Frequently | FAC02337",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040551","Toxocara canis","C125963","A species of parasitic nematodes in the genus Toxocara where canids are the definitive host.  Human infection occurs through the accidental ingestion of infective larvae in the tissues of other terrestrial mammals, which serve as paratenic hosts. Toxocara canis is the most common cause of toxocariasis in humans.","Toxocara canis | Dog Roundworm | TOXOCARA CANIS",,,,,,,,,,,,,,,"4228195","Toxocara canis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040552","Toxocara cati","C125964","A species of parasitic nematodes in the genus Toxocara where felids are the definitive host.  Paratenic hosts include invertebrates, birds, and rodents. Human infection most commonly occurs in children through accidental ingestion of larvated eggs from a contaminated environment.","Toxocara cati | Cat Roundworm | Feline Roundworm | TOXOCARA CATI",,,,,,,,,,,,,,,"4263790","Toxocara cati",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040892","Trichinella spiralis","C125965","A species of parasitic nematodes in the genus Trichinella that is found worldwide. There are four region-specific subspecies that have different carnivorous animal hosts. Trichinosis infection may occur through the ingestion of raw or undercooked animal tissue that contains encysted larvae. The larvae invade intestinal mucosa, where sexual maturation occurs. Female nematodes penetrate the mucosa and larvae travel through the bloodstream to penetrate and encyst in muscle tissue.","Trichinella spiralis | TRICHINELLA SPIRALIS",,,,,,,,,,,,,,,"4040124","Trichinella spiralis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040914","Trichoderma","C125966","A genus of green-spored ascomycetes fungi in the family Hypocreaceae where nonseptate conidia are produced on two- or three-branched conidiophores. Trichoderma is present in all soil.  Some species are pathogenic to other fungi and others have reportedly caused opportunistic infection in immune-compromised humans, particularly children.","Trichoderma | TRICHODERMA",,,,,,,,,,,,,,,"4308448","Trichoderma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040922","Trichomonas vaginalis","C125967","A species of flagellated protozoan parasite in the genus Trichomonas that resides in the genitourinary tract of both male and female humans, which are the only natural hosts. Transmission occurs through sexual intercourse, and results in trichomonal vaginitis in females or urethral infection in males.","Trichomonas vaginalis | TRICHOMONAS VAGINALIS",,,,,,,,,,,,,,,"4330317","Trichomonas vaginalis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0321217","Trichostrongylus axei","C125968","A species of parasitic roundworms in the family Trichostrongylidae that infest horses and ruminants, causing anorexia, persistent diarrhea, and weight loss. Adult T. axei are slender, measuring up to 8 mm long, and are usually found in the stomach of infected animals. Humans are rarely infected.","Trichostrongylus axei | TRICHOSTRONGYLUS AXEI",,,,,,,,,,,,,,,"4230792","Trichostrongylus axei",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040950","Trichostrongylus colubriformis","C125969","A species of parasitic roundworms in the family Trichostrongylidae that causes black scour disease in sheep, cattle, and goats.","Trichostrongylus colubriformis | Bankrupt Worm | Black Scour Worm | TRICHOSTRONGYLUS COLUBRIFORMIS",,,,,,,,,,,,,,,"4240326","Trichostrongylus colubriformis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015161","Eukaryotic Cells","C12596","A cell with a membrane-bound nucleus.","Eukaryotic Cell | Eukaryotic Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0321214","Trichostrongylus orientalis","C125970","A species of parasitic roundworms in the family Trichostrongylidae that is most prevalent in Asian countries.","Trichostrongylus orientalis | TRICHOSTRONGYLUS ORIENTALIS",,,,,,,,,,,,,,,"4178894","Trichostrongylus orientalis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0321215","Trichostrongylus probolurus","C125971","A species of parasitic roundworms in the family Trichostrongylidae that most often infests sheep, goats, and camels.","Trichostrongylus probolurus | TRICHOSTRONGYLUS PROBOLURUS",,,,,,,,,,,,,,,"4186716","Trichostrongylus probolurus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0078250","Vindoline","C1273","An indole alkaloid that exhibits antimitotic activity by inhibiting microtubule assembly. (NCI)","Vindoline | (2beta,3beta,4beta,5alpha,12beta,19alpha)-4-(Acetyloxy)-6,7-didehydro-3-hydroxy-16-methoxy-1-methylaspidospermidine-3-carboxylic acid | VINDOLINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508722","EPIC-CP - Problem Urinary Dripping/Leakage","C127402","Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) How big a problem, if any, has urinary dripping or leakage been for you?","EPIC-CP - Problem Urinary Dripping/Leakage | EPIC2-Problem Urinary Dripping/Leakage | EPIC204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508720","EPIC-CP - Pain or Burning With Urination","C127403","Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) How big a problem, if any, has each of the following been for you? Pain or burning with urination.","EPIC-CP - Pain or Burning With Urination | EPIC2-Problem Pain/Burning w/Urination | EPIC205A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508730","EPIC-CP - Weak Urine Stream or Incomplete Bladder Emptying","C127404","Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) How big a problem, if any, has each of the following been for you? Weak urine stream/incomplete bladder emptying.","EPIC-CP - Weak Urine Stream or Incomplete Bladder Emptying | EPIC2-Problem Weak Stream/Incompl Empty | EPIC205B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508716","EPIC-CP - Need to Urinate Frequently","C127405","Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) How big a problem, if any, has each of the following been for you? Need to urinate frequently. How big a problem, if any, has each of the following been for you? Need to urinate frequently.","EPIC-CP - Need to Urinate Frequently | EPIC2-Problem Need to Urinate Frequently | EPIC205C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508714","EPIC-CP - Increased Frequency of Bowel Movements","C127407","Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) How big a problem, if any, has each of the following been for you? Increased frequency of your bowel movements.","EPIC-CP - Increased Frequency of Bowel Movements | EPIC2-Problem Increased Freq Bowel Move | EPIC206B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507992","Peristomal Skin","C126756","The skin surrounding a stoma and on which the pouching system is placed.","Peristomal Skin | Healthy Peristomal Skin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508154","Double-Walled Airbag Breast Immobilization Device","C126757","A device that utilizes an inflatable double-walled airbag to establish and maintain the breast in a fixed and well-defined position during radiotherapy.","Double-Walled Airbag Breast Immobilization Device | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508044","PRICKLE1 wt Allele","C126759","Human PRICKLE1 wild-type allele is located in the vicinity of 12q12 and is approximately 134 kb in length. This allele, which encodes prickle-like protein 1, plays a role in the negative regulation of Wnt signaling and in embryonic development. Mutation of the gene is associated with progressive myoclonic epilepsy 1B.","PRICKLE1 wt Allele | EPM1B | FLJ31937 | Prickle Homolog 1 (Drosophila) Gene | Prickle Planar Cell Polarity Protein 1 wt Allele | Prickle, Drosophila, Homolog of, 1 Gene | Prickle-Like 1 (Drosophila) Gene | RILP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1571680","Germinal Center-Associated Signaling and Motility Protein, Human","C126994","Germinal center-associated signaling and motility protein (178 aa, ~21 kDa) is encoded by the human GCSAM gene. This protein plays a role in both the negative regulation of lymphocyte motility and the modulation of signaling.","Germinal Center-Associated Signaling and Motility Protein | Germinal Center B-Cell-Expressed Transcript 2 Protein | Germinal Center-Associated Lymphoma Protein | hGAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507968","GDF2 wt Allele","C126996","Human GDF2 wild-type allele is located in the vicinity of 10q11.22 and is approximately 5 kb in length. This allele, which encodes growth/differentiation factor 2 protein, plays a role in angiogenesis regulation. Mutation of the gene is associated with hereditary hemorrhagic telangiectasia type 5.","GDF2 wt Allele | BMP-9 | BMP9 | Growth Differentiation Factor 2 wt Allele | HHT5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2003591","Growth/Differentiation Factor 2, Human","C126997","Growth/differentiation factor 2 (429 aa, ~47 kDa) is encoded by the human GDF2 gene. This protein is involved in the negative regulation of angiogenesis.","Growth/Differentiation Factor 2 | BMP-9 | Bone Morphogenetic Protein 9 | GDF-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508195","Uterine Corpus High Grade Endometrial Stromal Sarcoma","C126998","A rare, high grade sarcoma that arises from the endometrial stroma. It is characterized by round cell morphology. It was previously also known as undifferentiated uterine sarcoma. In 2014, high grade endometrial stromal sarcoma was reclassified and is currently considered a distinct and rare neoplasm. It appears to have a prognosis that falls between low grade endometrial stromal sarcoma and undifferentiated sarcoma.","Uterine Corpus High Grade Endometrial Stromal Sarcoma | Endometrial Stromal Sarcoma, High Grade | High Grade ESS | Uterine Corpus High Grade ESS | YWHAE-FAM22 ESS | YWHAE-FAM22 Endometrial Stromal Sarcoma | YWHAE::FAM22 Endometrial Stromal Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507987","GJB2 wt Allele","C127000","Human GJB2 wild-type allele is located within 13q11-q12 and is approximately 6 kb in length. This allele, which encodes gap junction beta-2 protein, is involved in the assembly and function of gap junctions. Mutation in the gene is associated with syndromic deafness.","GJB2 wt Allele | CX26 | DFNA3 | DFNA3A | DFNB1 | DFNB1A | Gap Junction Protein Beta 2 wt Allele | Gap Junction Protein, 26kD Gene | Gap Junction Protein, Beta 2, 26kD (Connexin 26) Gene | Gap Junction Protein, Beta 2, 26kDa (Connexin 26) Gene | Gap Junction Protein, Beta 2, 26kDa Gene | Gap Junction Protein, Beta-2 Gene | HID | KID | NSRD1 | PPK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0163742","connexin 26","C127001","Gap junction beta-2 protein (226 aa, ~26 kDa) is encoded by the human GJB2 gene. This protein plays a role in gap junction-mediated facilitated diffusion.","Gap Junction Beta-2 Protein | Connexin 26 | Connexin-26 | Cx26 | GJB | Gap Junction Protein Beta 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508150","GPX3 wt Allele","C127003","Human GPX3 wild-type allele is located 5q33.1 and is approximately 9 kb in length. This allele, which encodes glutathione peroxidase 3 protein, plays a role in hydrogen peroxide and lipid peroxide metabolism.","GPX3 wt Allele | GPXP | GPx-P | GSHPx-3 | GSHPx-P | Glutathione Peroxidase 3 (Plasma) Gene | Glutathione Peroxidase 3 wt Allele | Glutathione Peroxidase 3, Plasma Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508822","FACT-P Version 4 - Problem Urinating Limits Activity","C127502","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Additional Concerns: My problems with urinating limit my activities.","FACT-P Version 4 - Problem Urinating Limits Activity | FAC023-Problem Urinating Limits Activity | FAC02338",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508789","FACT-P Version 4 - Able to Have and Maintain an Erection","C127503","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Additional Concerns: I am able to have and maintain an erection.","FACT-P Version 4 - Able to Have and Maintain an Erection | FAC023-Able to Have/Maintain Erection | FAC02339",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508937","PROSQOLI - Pain","C127504","Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) Pain.","PROSQOLI - Pain | PROS01-Pain | PROS0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508938","PROSQOLI - Physical Activity","C127505","Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) Physical activity.","PROSQOLI - Physical Activity | PROS01-Physical Activity | PROS0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508934","PROSQOLI - Fatigue","C127506","Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) Fatigue.","PROSQOLI - Fatigue | PROS01-Fatigue | PROS0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508931","PROSQOLI - Appetite","C127507","Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) Appetite.","PROSQOLI - Appetite | PROS01-Appetite | PROS0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508932","PROSQOLI - Constipation","C127508","Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) Constipation.","PROSQOLI - Constipation | PROS01-Constipation | PROS0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508940","PROSQOLI - Urinary Problems","C127509","Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) Urinary problems.","PROSQOLI - Urinary Problems | PROS01-Urinary Problems | PROS0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025485","Mesoderm","C12750","The middle of the three germ layers found in the trilaminar embryo (endo-, meso-, ecto-).","Mesoderm | ",,,,,,,,,,,,,,,"4277592","Mesoderm structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508933","PROSQOLI - Enjoying Time with Friends and Family","C127510","Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) Enjoying time with friends and family.","PROSQOLI - Enjoying Time with Friends and Family | PROS01-Enjoying Time Friends/Family | PROS0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508936","PROSQOLI - Overall Well-Being","C127512","Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) Overall well-being (how do you feel?).","PROSQOLI - Overall Well-Being | PROS01-Overall Well-Being | PROS0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508241","GAIA Obstetric Case Definitions","C126834","A set of terms and defintions created by the Global Alignment of Immunization safety Assessment in pregnancy that are related to the maternal effects of immunizations.","GAIA Obstetric Case Definitions | Global Alignment of Immunization safety Assessment in pregnancy Obstetric Case Definitions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508125","DRD2 Gene Mutation","C126835","A change in the nucleotide sequence of the DRD2 gene.","DRD2 Gene Mutation | Dopamine Receptor D2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0321216","Trichostrongylus vitrinus","C125972","A species of parasitic roundworms in the family Trichostrongylidae that most often infests sheep, goats, camel, deer, and rabbits and are mostly found in the proximal third of the small intestine.","Trichostrongylus vitrinus | TRICHOSTRONGYLUS VITRINUS",,,,,,,,,,,,,,,"4054255","Trichostrongylus vitrinus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320052","Tritirachium","C125974","A genus of anamorphic molds in the phylum Basidiomycota characterized by the zig-zag shape of the fertile portions of the conidiogenous cells and the absence of distinct denticles. Tritirachium species are hyphal in culture and the colonies are colored in shades ranging from pale pinkish or lilac to brown.","Tritirachium | TRITIRACHIUM",,,,,,,,,,,,,,,"4132727","Tritirachium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041218","Trypanosoma brucei gambiense","C125975","A species of parasitic flagellate protozoa in the order Kinetoplastida. T. b. gambiense is transmitted by the tsetse fly and causes West African trypanosomiasis. Humans are the main reservoir for T. b. gambiense, but this species can also be found in animals.","Trypanosoma brucei gambiense | TRYPANOSOMA BRUCEI GAMBIENSE",,,,,,,,,,,,,,,"4062272","Trypanosoma brucei gambiense",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041219","Trypanosoma brucei rhodesiense","C125976","A species of parasitic flagellate protozoa in the order Kinetoplastida. T. b. rhodesiense is transmitted by the tsetse fly and causes East African trypanosomiasis. Wild game animals are the main reservoir of T. b. rhodesiense.","Trypanosoma brucei rhodesiense | TRYPANOSOMA BRUCEI RHODESIENSE",,,,,,,,,,,,,,,"4196908","Trypanosoma brucei rhodesiense",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508111","Autologous MAGE-A10-specific HLA-A2-restricted TCR c796 Gene-engineered Lymphocytes","C126686","Human autologous T-lymphocytes transduced with a retroviral vector encoding a high-affinity T-cell receptor (TCR) specific for human leukocyte antigen (HLA)-A2-restricted, human melanoma-associated antigen A10 (MAGE-A10), clone 796 (c796), with potential antineoplastic activity. Peripheral blood mononuclear cells (PBMCs) are isolated from a patient, transduced with an anti-MAGE-A10(c796)-HLA-A2 restricted TCR, expanded ex vivo, and reintroduced into the HLA-A2-positive patient. Upon reintroduction, the autologous MAGE-A10-specific, HLA-A2-restricted TCR c796 gene-engineered lymphocytes bind to tumor cells expressing the MAGE-A10 antigen, which may induce cell death in and halt the growth of MAGE-A10-expressing cancer cells. The tumor-associated antigen MAGE-A10, a member of the MAGE-A family of cancer/testis tumor-associated antigens (CT-TAAs), is overexpressed by a variety of cancer cell types.","Autologous MAGE-A10-specific HLA-A2-restricted TCR c796 Gene-engineered Lymphocytes | Autologous Genetically-modified T-cells MAGEA10c796 | Autologous MAGE A10c796 T-Cells | MAGEA10c796 T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507900","ERK inhibitor LTT462","C126687","An orally available inhibitor of extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon oral administration, rineterkib binds to and inhibits ERK, thereby preventing the activation of ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is upregulated in numerous tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.","Rineterkib | ERK Inhibitor LTT462 | LTT 462 | LTT462 | RINETERKIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1834674","Bethlem Myopathy 1","C126688","A usually autosomal dominant inherited movement disorder caused by mutations in the COL6A1, COL6A2, and COL6A3 genes. It is characterized by progressive muscle weakness and joint stiffness in the fingers, wrists, elbows, and ankles.","Bethlem Myopathy 1 | BTHLM1",,,,,,,,,,,,,,,"36713650","Bethlem myopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1872988","Prickle-Like Protein 1, Human","C126760","Prickle-like protein 1 (831 aa, ~94 kDa) is encoded by the human PRICKLE1 gene. This protein is involved in embryonic morphology.","Prickle-Like Protein 1 | Prickle-Like 1 | REST (RE-1 Silencing Transcription Factor)/NRSF (Neuron-Restrictive Silencer Factor)-Interacting LIM Domain Protein | REST-Interacting LIM Domain Protein | REST/NRSF Interacting LIM Domain Protein | REST/NRSF-Interacting LIM Domain Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508115","CDX4 wt Allele","C126762","Human CDX4 wild-type allele is located in the vicinity of Xq13.2 and is approximately 8 kb in length. This allele, which encodes homeobox protein CDX-4, is involved in the regulation of gene expression.","CDX4 wt Allele | Caudal Type Homeobox 4 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508114","Homeobox Protein CDX-4","C126763","Homeobox protein CDX-4 (284 aa, ~30 kDa) is encoded by the human CDX4 gene. This protein plays a role in the regulation of embryonic development.","Homeobox Protein CDX-4 | Caudal Type Homeo Box Transcription Factor 4 | Caudal-Type Homeo Box Transcription Factor 4 | Caudal-Type Homeobox Protein 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507980","H2AZ","C126765","Human H2AZ1 wild-type allele is located in the vicinity of 4q24 and is approximately 2 kb in length. This allele, which encodes histone H2A.Z protein, plays a role in chromatin packaging.","H2AZ1 wt Allele | H2A Histone Family Member Z Gene | H2A Histone Family, Member Z Gene | H2A.Z Variant Histone wt Allele | H2A.Z-1 | H2A.z | H2A/z | H2AFZ | H2AFZ wt Allele | H2AZ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507981","Histone H2A.Z","C126766","Histone H2A.Z (128 aa, ~14 kDa) is encoded by the human H2AZ1 gene. This protein is involved in nucleosome and heterochromatin formation.","Histone H2A.Z | H2A.Z-1 | H2A.Z.1 | H2A/z | H2AZ Histone | H2AZ1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508242","GTF2A1 Gene Product","C126767","A protein encoded by the GTF2A1 gene.","GTF2A1 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004811","Basilar Artery","C12676","An artery formed by the union of the two vertebral arteries at the posterior border of the pons then diverges at the anterior border forming the two superior and two posterior cerebral arteries.","Basilar Artery | BA | BASILAR ARTERY",,,,,,,,,,,,,,,"4239789","Structure of basilar artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508151","Dedifferentiated Malignant Infiltrate","C126770","A morphologic finding indicating the presence of a high grade undifferentiated malignant cellular infiltrate and a second component of a low grade malignant cellular infiltrate in a tissue sample.","Dedifferentiated Malignant Infiltrate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508107","SELENOF wt Allele","C126954","Human SELENOF wild-type allele is located in the vicinity of 1p22.3 and is approximately 52 kb in length. This allele, which encodes selenoprotein F, may be involved in protein folding.","SELENOF wt Allele | 15 kDa Selenoprotein Gene | SEP15 | Selenoprotein F (15kDa) Gene | Selenoprotein F wt Allele | Selenoprotein, 15-kD Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1138240","15 kDa selenoprotein, human","C126955","Selenoprotein F (162 aa, ~18 kDa) is encoded by the human SELENOF gene. This protein binds selenium and may play a role in protein folding.","Selenoprotein F | 15 kDa Selenoprotein | SELENOF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1436542","Glutathione Peroxidase 3, Human","C127004","Glutathione peroxidase 3 (226 aa, ~26 kDa) is encoded by the human GPX3 gene. This protein is involved in hydrogen peroxide and lipid peroxide detoxification.","Glutathione Peroxidase 3 | EC 1.11.1.9 | Extracellular Glutathione Peroxidase | GPX3 | GPx-3 | GPx-P | GSHPx-3 | GSHPx-P | Plasma Glutathione Peroxidase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509478","Mouse Urological Syndrome","C127195","A constellation of findings in male mice characterized by ulceration and/or inflammation of the penis and prepuce, proteinaceous material with inflammatory cells, spermatozoa or desquamated urothelial cells forming a plug in the urethra and generally dilatation of the bladder, hydroureter and hydronephrosis.","Mouse Urological Syndrome | MURINE OBSTRUCTIVE UROPATHY | Mouse Urological Syndrome (MUS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509739","Growth Hormone and Prolactin-Producing Neoplastic Cells Present","C127196","An immunohistochemical finding indicating the presence of growth hormone and prolactin producing cells in a tumor.","Growth Hormone and Prolactin-Producing Neoplastic Cells Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507902","IL-10 Immunomodulator MK-1966","C126840","An agent that downregulates the activity of the anti-inflammatory cytokine human interleukin-10 (IL-10), with potential immunomodulating and antineoplastic activities. Upon administration, IL-10 immunomodulator MK-1966 blocks the activity of IL-10 and may abrogate the IL-10-induced immunosuppressive tumor microenvironment. This activates cell-mediated immunity against cancer cells, increases cytokine production, including interferon-gamma (IFN-g), decreases T regulatory cell (Treg) activity, and induces a tumor-specific cytotoxic CD8+ T-cell-mediated immune response, which enhances tumor cell death.","IL-10 Immunomodulator MK-1966 | MK 1966 | MK-1966",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508129","GAIA Major Congenital Anomalies Level of Diagnostic Certainty","C126842","A classification of maternal and fetal outcomes relating to major congenital anomalies, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.","GAIA Major Congenital Anomalies Level of Diagnostic Certainty | Global Alignment of Immunization safety Assessment in pregnancy Major Congenital Anomalies Level of Diagnostic Certainty | Major Congenital Anomalies Level of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508132","GAIA Neonatal Death Level of Diagnostic Certainty","C126843","A classification of maternal and fetal outcomes relating to neonatal death, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.","GAIA Neonatal Death Level of Diagnostic Certainty | Global Alignment of Immunization safety Assessment in pregnancy Neonatal Death Level of Diagnostic Certainty | Neonatal Death Level of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1834558","Centronuclear Myopathy 1","C126689","A myopathy inherited in an autosomal dominant or recessive pattern, caused by mutations in the DNM2, BIN1, and TTN genes. Microscopically there is central displacement of the nucleus in muscle cells. It is characterized by muscle weakness and atrophy in the skeletal muscles.","Centronuclear Myopathy 1 | CNM1",,,,,,,,,,,,,,,"37399011","Autosomal dominant centronuclear myopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3150416","Congenital Muscular Dystrophy-Dystroglycanopathy with Mental Retardation Type B2","C126690","An autosomal recessive inherited congenital muscular dystrophy caused by mutations in the POMT2 gene. It is characterized by mental retardation and mild structural brain abnormalities resulting from defective glycosylation of alpha-dystroglycan.","Congenital Muscular Dystrophy-Dystroglycanopathy with Mental Retardation Type B2 | MDDGB2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0410180","Rigid Spine Muscular Dystrophy 1","C126691","An inherited muscular dystrophy caused by mutations in the SEPN1 gene. It is characterized by severe limitation in flexion of the dorsolumbar and cervical spine, due to contracture of the spinal extensors. It leads to loss of movement of the spine and the thoracic cage.","Rigid Spine Muscular Dystrophy 1 | RSMD1 | RSS | Rigid Spine Syndrome",,,,,,,,,,,,,,,"37395994|4347186","Desmin related myopathy with Mallory body-like inclusions|Eichsfeld type congenital muscular dystrophy",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C2675336","Chromosome 15q11-q13 Duplication Syndrome","C126692","A syndrome caused by duplication of chromosome 15q11-q13. It is characterized by autism, mental retardation, ataxia, seizures, developmental delays, and behavioral problems.","Chromosome 15q11-q13 Duplication Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508223","BCG Tokyo-172 Strain Vaccine","C126693","A vaccine containing bacillus Calmette-Guerin (BCG), a live, attenuated strain of Mycobacterium bovis obtained from the Pasteur Institute in 1924, with non-specific immunoadjuvant and immunotherapeutic activities. Upon intradermal administration, BCG Tokyo-172 strain vaccine activates the immune system and enhances a specific, systemic BCG antigen immune response. This results in active immunization against tuberculosis and primes the immune system against future administered BCG antigens.","BCG Tokyo-172 Strain Vaccine | Bacillus Calmette-Guerin Tokyo-172 Strain Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242245","Follicular Dendritic Cell","C12622","Antigen Presenting Cells (APCs) located in the follicles of secondary lymphoid organs.  These dendritic cells are unique because of their location, primarily in lymphoid follicles, and because of their function in retaining antigen molecules for extended periods of time and serving as APCs for B cells.","Follicular Dendritic Cell | Follicular Dendritic Cells",,,,,,,,,,,,,,,"4209719","Follicular dendritic cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504814","Very Low Nicotine Content Cigarette","C126234","A tobacco cigarette with a nicotine yield of less than 0.1 mg.","Very Low Nicotine Content Cigarette | VLNCC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508109","C2 wt Allele","C126957","Human C2 wild-type allele is located in the vicinity of 6p21.3 and is approximately 48 kb in length. This allele, which encodes complement C2 protein, plays a role in proteolysis and complement activation. Mutation of the gene is associated with C2 deficiency and increased susceptibility for age-related macular degeneration.","C2 wt Allele | ARMD14 | CO2 | Complement Component 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1647978","Complement Component 2","C126958","Complement C2 (752 aa, ~83 kDa) is encoded by the human C2 gene. This protein is involved in post-translational protein processing and complement activity.","Complement C2 | C2 | C3/C5 Convertase | Complement Component 2 | EC 3.4.21.43",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508039","MICA wt Allele","C126960","Human MICA wild-type allele is located in the vicinity of 6p21.3 and is approximately 16 kb in length. This allele, which encodes MHC class I polypeptide-related sequence A protein, is involved in natural killer cell inhibition. Variation of the gene may be associated with increased susceptibility to psoriasis 1 and psoriatic arthritis.","MICA wt Allele | MHC Class I Polypeptide-Related Sequence A wt Allele | MIC-A | Major Histocompatibility Class I Chain-Related Gene A | PERB11.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1448848","MHC Class I Polypeptide-Related Sequence A, Human","C126961","MHC class I polypeptide-related sequence A (383 aa, ~43 kDa) is encoded by the human MICA gene. This protein plays a role in the negative regulation of natural killer cells.","MHC Class I Polypeptide-Related Sequence A | MIC-A | MICA | Stress Inducible Class I Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508025","KRT8 wt Allele","C126963","Human KRT8 wild-type allele is located in the vicinity of 12q13 and is approximately 53 kb in length. This allele, which encodes keratin, type II cytoskeletal 8 protein, plays a role in the structure of striated muscle and simple epithelia. Mutation of the gene is associated with cryptogenic cirrhosis.","KRT8 wt Allele | CARD2 | CK-8 | CK8 | CYK8 | K2C8 | K8 | KO | Keratin 8 wt Allele | Keratin 8, Type II Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1432126","Keratin, Type II Cytoskeletal 8, Human","C126964","Keratin, type II cytoskeletal 8 (483 aa, ~54 kDa) is encoded by the human KRT8 gene. This protein is involved in maintaining the structure of striated muscles and simple epithelia.","Keratin, Type II Cytoskeletal 8 | CK-8 | Cytokeratin 8 | Cytokeratin-8 | K8 | KRT8 | Keratin 8 | Keratin-8 | Type-II Keratin Kb8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507983","ORM1 wt Allele","C126966","Human ORM1 wild-type allele is located in the vicinity of 9q32 and is approximately 3 kb in length. This allele, which encodes alpha-1-acid glycoprotein 1, is involved in immunity and small molecule binding.","ORM1 wt Allele | AGP | AGP-A | AGP1 | ALPHA-1-AGP | Glycoprotein, Alpha-1-Acid, of Serum Gene | HEL-S-153w | ORM | Orosomucoid 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509497","NCCN-FACT-FPSI 17 Version 2 - Pain Keeps Me From Doing Things","C127455","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) My pain keeps me from doing things I want to do.","NCCN-FACT-FPSI 17 Version 2 - Pain Keeps Me From Doing Things | FAC052-Pain Keeps Me From Doing Things | FAC05208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509495","NCCN-FACT-FPSI 17 Version 2 - I Have a Good Appetite","C127456","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I have a good appetite.","NCCN-FACT-FPSI 17 Version 2 - I Have a Good Appetite | FAC052-I Have a Good Appetite | FAC05209",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509487","NCCN-FACT-FPSI 17 Version 2 - I Am Sleeping Well","C127457","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I am sleeping well.","NCCN-FACT-FPSI 17 Version 2 - I Am Sleeping Well | FAC052-I Am Sleeping Well | FAC05210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509498","NCCN-FACT-FPSI 17 Version 2 - Worry My Condition Will Get Worse","C127458","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I worry that my condition will get worse.","NCCN-FACT-FPSI 17 Version 2 - Worry My Condition Will Get Worse | FAC052-Worry My Condition Will Get Worse | FAC05211",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509491","NCCN-FACT-FPSI 17 Version 2 - I Have Nausea","C127459","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I have nausea.","NCCN-FACT-FPSI 17 Version 2 - I Have Nausea | FAC052-I Have Nausea | FAC05212",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509493","NCCN-FACT-FPSI 17 Version 2 - I Have Trouble Moving My Bowels","C127460","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I have trouble moving my bowels.","NCCN-FACT-FPSI 17 Version 2 - I Have Trouble Moving My Bowels | FAC052-I Have Trouble Moving My Bowels | FAC05213",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509482","NCCN-FACT-FPSI 17 Version 2 - Bothered by Treatment Side Effect","C127462","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I am bothered by side effects of treatment.","NCCN-FACT-FPSI 17 Version 2 - Bothered by Treatment Side Effect | FAC052-Bothered by Treatment Side Effect | FAC05215",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509484","NCCN-FACT-FPSI 17 Version 2 - I Am Able to Enjoy Life","C127463","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I am able to enjoy life.","NCCN-FACT-FPSI 17 Version 2 - I Am Able to Enjoy Life | FAC052-I Am Able to Enjoy Life | FAC05216",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509483","NCCN-FACT-FPSI 17 Version 2 - Content With Quality of My Life","C127464","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I am content with the quality of my life right now.","NCCN-FACT-FPSI 17 Version 2 - Content With Quality of My Life | FAC052-Content With Quality of My Life | FAC05217",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508103","YWHAE/FAM22 Fusion Gene","C127057","A fusion gene that results from a chromosomal translocation t(10;17)(q22;p13) which fuses the exon 5 the YWHAE gene with exon 2 of the FAM22A (NUTM2A), FAM22B (NUTM2B), or FAM22E (NUTM2E) gene. These fusions are associated with high grade endometrial stromal sarcomas and clear cell sarcomas of the kidney.","YWHAE/FAM22 Fusion Gene | YWHAE-FAM22 Fusion Gene | YWHAE-FAM22A-B-E Fusion Gene | YWHAE-NUTM2 Fusion Gene | YWHAE-NUTM2A-B-E Fusion Gene | YWHAE/FAM22A-B-E Fusion Gene | YWHAE/NUTM2 Fusion Gene | YWHAE/NUTM2A-B-E Fusion Gene | YWHAE::FAM22 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014144","Endoderm","C12706","The deepest of the three primary germ layers (ectoderm, mesoderm and endoderm) found in the early trilaminar embryo, which forms the epithelial linings of the respiratory and digestive tracts.","Endoderm | ",,,,,,,,,,,,,,,"4207810","Endoderm structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508941","PROSQOLI Questionnaire Question","C127366","A question associated with the PROSQOLI questionnaire.","PROSQOLI Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508196","NRXN3 Gene Product","C126710","A protein encoded by the NRXN3 gene.","NRXN3 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508180","Neurexin-3-Beta","C126711","Neurexin-3-beta (637 aa, ~69 kDa) is encoded by the human NRXN3 gene. This protein plays a role in cell adhesion.","Neurexin-3-Beta | Neurexin III-Beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0949665","Fluoroquinolone Antibiotic","C126712","Any quinolone antibiotic with a fluorine (F) atom attached to the quinolone structure, with broad-spectrum antibacterial activity. Fluoroquinolones diffuse through the bacterial cell wall and act by inhibiting bacterial topoisomerase II, DNA gyrase and/or bacterial topoisomerase IV, which are enzymes involved in bacterial DNA replication. This prevents DNA replication and leads to a blockage of bacterial cell proliferation.","Fluoroquinolone Antibiotic | Fluoroquinolone | Fluoroquinolones",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508046","Partial Response in GvHD","C126713","No value exists.","Partial Response in GvHD | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509665","RAMP2 wt Allele","C127151","Human RAMP2 wild-type allele is located within 17q12-q21.1 and is approximately 5 kb in length. This allele, which encodes receptor activity-modifying protein 2, plays a role in the regulation of calcitonin gene-related peptide type 1 receptor activity.","RAMP2 wt Allele | Receptor (Calcitonin) Activity Modifying Protein 2 Gene | Receptor (G Protein-Coupled) Activity Modifying Protein 2 Gene | Receptor Activity Modifying Protein 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1570781","Receptor Activity-Modifying Protein 2, Human","C127152","Receptor activity-modifying protein 2 (175 aa, ~20 kDa) is encoded by the human RAMP2 gene. This protein is involved in the membrane localization of calcitonin gene-related peptide type 1 receptor.","Receptor Activity-Modifying Protein 2 | CRLR Activity-Modifying Protein 2 | Calcitonin-Receptor-Like Receptor Activity-Modifying Protein 2 | RAMP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509522","Recurrent Malignant Solid Neoplasm","C127153","A malignant solid neoplasm that has recurred after a period of remission.","Recurrent Malignant Solid Neoplasm | Recurrent Malignant Solid Tumor | Recurrent Solid Neoplasm | Recurrent Solid Tumor | Relapsed Malignant Solid Neoplasm | Relapsed Solid Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507920","Ad-ISF35","C127154","A replication-defective adenovirus vector (Ad-ISF35), which encodes a membrane-stabilized, chimeric human-mouse CD40 binding protein (CD40 ligand; CD40L; CD154), with potential immunomodulatory and antineoplastic activities. Upon intratumoral administration, Ad-ISF135 preferentially transduces tumor cells and immunoregulatory cells in the tumor microenvironment. This increases the expression of CD154 in tumor cells, activates CD40 and stimulates signaling and immunoactivation, which are both mediated by CD40. This increases the expression of co-stimulatory molecules on these cells, which enhances their ability to function as antigen presenting cells (APCs) and increases their apoptotic potential. This leads to an increase in the infiltration of macrophages and neutrophils, which promote direct cytotoxicity, enhances the production of pro-inflammatory cytokines in the tumor microenvironment, and induces a specific cytotoxic T-lymphocyte (CTL) response against the tumor cells. In addition, transduction with Ad-ISF35 induces direct tumor cell death, probably through an anti-viral immune response. Ad-ISF35 also exerts a strong bystander effect in non-transduced cells thereby further inducing tumor cell death. Altogether, this will eradicate tumor cells. CD154, the main ligand for CD40, plays a key role in the activation of APCs, promotes immunoactivation, and increases apoptotic potential. The protein encoded by Ad-ISF35 does not contain the mouse antibody binding domains and does not induce human neutralizing antibodies. The metalloprotease cleavage site is deleted in this chimeric CD154 and thus it resists cleavage; the encoded protein also contains amino acid substitutions within the carboxy-terminal. Both sets of engineered mutations promote cell surface expression.","Ad-ISF35 | Ad-CD154 ISF35 | Ad-CD40L ISF35",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509790","Unresectable Solid Neoplasm","C127156","A solid neoplasm that is not amenable to surgical resection.","Unresectable Solid Neoplasm | Unresectable Solid Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4021127","Corticotropin-Releasing Hormone Deficiency","C127157","Diminished production of adrenocortical hormones due to presumed insufficient secretion of corticotropin-releasing hormone from the hypothalamus.","Corticotropin-Releasing Hormone Deficiency | CRH Deficiency | Tertiary Adrenal Insufficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509768","Primary Adrenal Glucocorticoid Excess","C127158","Supranormal glucocorticoid concentrations resulting from a condition originating within the adrenal gland.","Primary Adrenal Glucocorticoid Excess | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508815","FACT-P Version 4 - I Have a Lack of Energy","C127465","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Physical Well-Being: I have a lack of energy.","FACT-P Version 4 - I Have a Lack of Energy | FAC023-I Have a Lack of Energy | FAC02301",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508811","FACT-P Version 4 - I Have Nausea","C127466","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Physical Well-Being: I have nausea.","FACT-P Version 4 - I Have Nausea | FAC023-I Have Nausea | FAC02302",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508826","FACT-P Version 4 - Trouble Meeting Needs of Family","C127467","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Physical Well-Being: Because of my physical condition, I have trouble meeting the needs of my family.","FACT-P Version 4 - Trouble Meeting Needs of Family | FAC023-Trouble Meeting Needs of Family | FAC02303",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508812","FACT-P Version 4 - I Have Pain","C127468","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Physical Well-Being: I have pain.","FACT-P Version 4 - I Have Pain | FAC023-I Have Pain | FAC02304",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507896","EpCAM-specific CAR-expressing Autologous T-lymphocytes","C126801","A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the antigen epithelial cell adhesion molecule (EpCAM), with potential immunostimulating and antineoplastic activities. Upon administration, the EpCAM-specific CAR-expressing autologous T-lymphocytes specifically recognize and bind to EpCAM-expressing tumor cells, resulting in tumor cell lysis. EpCAM, a cell surface protein, is expressed by a variety of tumor cells.","EpCAM-specific CAR-expressing Autologous T-lymphocytes | EpCAM-specific CAR Autologous T-cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2351765","Phytochlorin Sodium-Polyvinylpyrrolidone Complex","C126802","A photosensitizer composed of the sodium salt form of chlorin e6 and its derivatives complexed with a low-molecular weight polyvinylpyrrolidone (PVP) polymer component, with diagnostic and antineoplastic activities upon photodynamic therapy (PDT). Upon intravenous administration, the photosensitizer phytochlorin-PVP sodium complex preferentially accumulates in hyperproliferative tissues, such as tumors. Local application of light with a certain wavelength to the tumor site results in the absorption of light by this agent leading to its photoactivation. This results in a photodynamic reaction between phytochlorin and oxygen, which causes the production of reactive oxygen species (ROS), including singlet oxygen molecules, the superoxide ion, and other cytotoxic free radicals. The formation of ROS induces free radical-mediated oxidative DNA damage followed by apoptosis of tumor cells. Chlorin e6-PVP is able to penetrate deeply into tissues and is therefore able to treat hard-to-reach tumors.","Phytochlorin Sodium-Polyvinylpyrrolidone Complex | BLC-1013 | Chlorin E6-PVP | Chlorin E6-polyvinylpyrrolidone | Chlorin E6/PVP | Fotolon | Photolon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1566001","Tris-acryl Gelatin Microspheres","C126803","An embolic particle composed of water-soluble, compressible, nonabsorbable microspheres composed of tris-acryl gelatin, with potential use for embolization. Upon administration, the tris-acryl gelatin microspheres (TAGM) serve as an embolic agent before surgery for highly vascularized areas, such as those seen in certain tumors, by penetrating into the blood vessel system and blocking blood flow. These microspheres may be used to encapsulate various therapeutic agents; drug-loaded microspheres can then be used as drug delivery vehicles during embolization of tumor vasculature.","Tris-acryl Gelatin Microspheres | Embospheres | TAGM | Trisacryl Gelatin Microspheres",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507897","anti-ICOS agonist antibody GSK3359609","C126804","An agonistic antibody for the inducible T-cell co-stimulator (ICOS; CD278), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, feladilimab targets and binds to ICOS expressed on tumor infiltrating CD4-positive T-cells. This stimulates ICOS-positive T-cell proliferation, enhances cytotoxic T-lymphocyte (CTL) survival and increases CTL-mediated immune responses against tumor cells. ICOS, a T-cell specific, CD28-superfamily costimulatory molecule and immune checkpoint protein, is normally expressed on certain activated T-cells and plays a key role in the proliferation and activation of T-cells.","Feladilimab | Anti-ICOS Agonist Antibody GSK3359609 | FELADILIMAB | GSK3359609",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509345","CDISC SDTM Tuberculosis Findings About Test Code Terminology","C127266","Terminology associated with the tuberculosis findings about test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Tuberculosis Findings About Test Code Terminology | SDTM-TBFATSCD | TBFATSCD | Tuberculosis Findings About Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509346","CDISC SDTM Tuberculosis Findings About Test Name Terminology","C127267","Terminology associated with the tuberculosis findings about test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Tuberculosis Findings About Test Name Terminology | SDTM-TBFATS | TBFATS | Tuberculosis Findings About Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509331","CDISC SDTM Disease Presentation Type Terminology","C127268","Terminology associated with the disease presentation type codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Disease Presentation Type Terminology | DSPRTYP | Disease Presentation Type | SDTM-DSPRTYP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0319531","Apophysomyces","C127271","A genus of filamentous fungi that are found in soil and on decaying vegetation in tropical and subtropical regions. The genus can be identified by its sporangiophores, having a distinctive funnel or bell-shaped apophyses and hemispherical-shaped columellae. Species in this genus are resistant to cycloheximide.","Apophysomyces | ",,,,,,,,,,,,,,,"4238547","Apophysomyces",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1053048","Arthrinium","C127272","A genus of fungi in the phylum Ascomycota that are found as saprobes on plant materials. Several species in the genus synthesize compounds of pharmacologic interest.","Arthrinium | Apiospora",,,,,,,,,,,,,,,"4215340","Arthrinium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0027371","Arthroderma","C127273","A genus of fungi in the phylum Ascomycota that are causative agents of dermatophytosis.","Arthroderma | ",,,,,,,,,,,,,,,"4038836","Arthroderma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320068","Aureobasidium","C127275","A genus of yeast-like fungi in the phylum Ascomycota with colonies that start cream to pink, becoming dark brown with age.","Aureobasidium | ",,,,,,,,,,,,,,,"4142026","Aureobasidium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1080701","Byssochlamys","C127276","A genus of heat resistant fungi in the phylum Ascomycota and the family Trichocomaceae.","Byssochlamys | Paecilomyces",,,,,,,,,,,,,,,"37206128","Byssochlamys",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508676","Case Search","C127277","The activity of looking for individuals with a shared characteristic such as a disease.","Case Search | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1208815","Coprinellus","C127278","A genus of mushroom-forming fungi in the phylum Basidiomycota and the family Psathyrellaceae.","Coprinellus | ",,,,,,,,,,,,,,,"45765403","Coprinellus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1222486","Cystobasidium","C127279","A genus of yeast in the phylum Basidiomycota and the family Cystobasidiaceae.","Cystobasidium | ",,,,,,,,,,,,,,,"606753","Cystobasidium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014529","Epidermophyton","C127281","A genus of filamentous fungi in the phylum Ascomycota. Species in this genus are causative agents of superficial and cutaneous mycoses in humans.","Epidermophyton | ",,,,,,,,,,,,,,,"4011240","Epidermophyton",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508244","Progression in GvHD","C126724","No value exists.","Progression in GvHD | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508712","EPIC-CP - Feeling Depressed","C127413","Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) How big a problem, if any, has each of the following been for you? Feeling depressed.","EPIC-CP - Feeling Depressed | EPIC2-Problem Feeling Depressed | EPIC210B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508715","EPIC-CP - Lack of Energy","C127414","Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) How big a problem, if any, has each of the following been for you? Lack of energy.","EPIC-CP - Lack of Energy | EPIC2-Problem Lack of Energy | EPIC210C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508726","EPIC-CP - Sexual Symptom Score","C127418","Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) Sexual symptom score.","EPIC-CP - Sexual Symptom Score | EPIC2-Sexual Symptom Score | EPIC214",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508778","FACT-G Version 4 - I Have a Lack of Energy","C127421","Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Physical Well-Being: I have a lack of energy.","FACT-G Version 4 - I Have a Lack of Energy | FAC001-I Have a Lack of Energy | FAC00101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508777","FACT-G Version 4 - I Have Nausea","C127422","Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Physical Well-Being: I have nausea.","FACT-G Version 4 - I Have Nausea | FAC001-I Have Nausea | FAC00102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507898","BET Bromodomain Inhibitor ZEN-3694","C126805","An orally bioavailable inhibitor of the bromodomain and extra-terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, the BET inhibitor ZEN-3694 binds to the acetylated lysine recognition motifs in the bromodomains of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of proliferation in BET-overexpressing tumor cells. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.","BET Bromodomain Inhibitor ZEN-3694 | BETi ZEN-3694 | ZEN 3694 | ZEN-3694 | ZEN003694",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1841972","Glucocorticoid Receptor Deficiency","C126809","An autosomal dominant condition due to mutation(s) in the NR3C1 gene, encoding the glucocorticoid receptor, resulting in decreased receptor affinity to glucocorticoids. Compensatory activation of the hypothalamic- pituitary-adrenal (HPA) axis results in increased mineralocorticoid and androgen production; clinical manifestations of glucocorticoid deficiency are rare.","Glucocorticoid Resistance | Chrousos Syndrome | Generalized Glucocorticoid Resistance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508217","Uterine Corpus Tumor Resembling Ovarian Sex Cord Tumor","C127005","A usually benign neoplasm that arises from the uterine corpus. It resembles ovarian sex cord tumors. It lacks a component of recognizable endometrial stroma and the JAZF1-SUZ12 fusion which is characteristic of the endometrial stromal neoplasms.","Uterine Corpus Tumor Resembling Ovarian Sex Cord Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507985","HGFAC wt Allele","C127007","Human HGFAC wild-type allele is located in the vicinity of 4p16 and is approximately 8 kb in length. This allele, which encodes hepatocyte growth factor activator protein, plays a role in the activation of hepatocyte growth factor.","HGFAC wt Allele | HGF Activator wt Allele | HGFA | HGFAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0215993","hepatocyte growth factor activator","C127008","Hepatocyte growth factor activator (655 aa, ~71 kDa) is encoded by the human HGFAC gene. This protein is involved in the proteolysis of single-chain hepatocyte growth factor.","Hepatocyte Growth Factor Activator | EC 3.4.21.- | HGF Activator | HGFA | HGFAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507988","HHIP wt Allele","C127010","Human HHIP wild-type allele is located within 4q28-q32 and is approximately 99 kb in length. This allele, which encodes hedgehog-interacting protein, is involved in the modulation of hedgehog-mediated signaling.","HHIP wt Allele | FLJ20992 | HIP | Hedgehog Interacting Protein wt Allele | UNQ5825/PRO19644",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1505163","Hedgehog-Interacting Protein, Human","C127011","Hedgehog-interacting protein (700 aa, ~79 kDa) is encoded by the human HHIP gene. This protein plays a role in the regulation of hedgehog signaling pathways.","Hedgehog-Interacting Protein | HHIP | HIP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1002105","Eurotium","C127282","A genus of filamentous fungi in the phylum Ascomycota that are the sexual states of Aspergillus species.","Eurotium | ",,,,,,,,,,,,,,,"37397369","Eurotium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015298","Exophiala","C127283","A genus of anamorphic fungi in the phylum Ascomycota.","Exophiala | ",,,,,,,,,,,,,,,"4047035","Exophiala",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2790329","Hannaella","C127284","A genus of fungi in the phylum Basidiomycota.","Hannaella | ",,,,,,,,,,,,,,,"37018870","Hannaella",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508939","PROSQOLI - Present Pain Intensity","C127513","Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) Present pain intensity: please circle the appropriate number according to how much pain you felt on average during the past 24 hours.","PROSQOLI - Present Pain Intensity | PROS01-Present Pain Intensity | PROS0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508661","Active Case Search","C127515","Purposefully looking for subjects with a particular characteristic or disease.","Active Case Search | ACTIVE CASE SEARCH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508948","Passive Case Search","C127516","Finding subjects with a particular characteristic or disease without actively searching.","Passive Case Search | PASSIVE CASE SEARCH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3266603","Blood Agar Growth Medium","C127517","A solid and selective growth medium containing agar and blood; it allows for the cultivation and differentiation of microorganisms based on hemolytic activity.","Blood Agar Growth Medium | BLOOD AGAR | Blood Agar",,,,,,,,,,,,,,,"764648","Blood agar",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL505200","Middlebrook 7H10S Growth Medium","C127518","A solid and selective growth medium modified from the Middlebrook 7H10 agar by the addition of four antimicrobial agents: polymyxin B, carbenicillin, amphotericin B, and trimethoprim lactate.","Middlebrook 7H10S Growth Medium | MIDDLEBROOK 7H10S AGAR | Middlebrook 7H10 Selective Agar",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505199","Middlebrook 7H11S Growth Medium","C127519","A solid and selective growth medium modified from the Middlebrook 7H11 agar by the addition of four antimicrobial agents: polymyxin B, carbenicillin, amphotericin B, and trimethoprim lactate.","Middlebrook 7H11S Growth Medium | MIDDLEBROOK 7H11S AGAR | Middlebrook 7H11 Selective Agar",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509272","Middlebrook 7H12 Growth Medium","C127520","A liquid growth medium modified from the Middlebrook 7H9 broth by the addition of the following: bovine serum albumin, casein hydrolysate, catalase, and 14C-labelled palmitic acid.","Middlebrook 7H12 Growth Medium | MIDDLEBROOK 7H12 BROTH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3266619","Middlebrook 7H9 Growth Medium","C127521","A liquid growth medium developed specifically for the primary and secondary cultivation of mycobacterium, which comprises albumin, glycerol, dextrose, and inorganic compounds.","Middlebrook 7H9 Growth Medium | MIDDLEBROOK 7H9 BROTH",,,,,,,,,,,,,,,"764668","Middlebrook 7H9 broth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509027","Competent Authority Applicant","C127522","The person responsible for the competent authority application.","Competent Authority Applicant | CA APPLICANT | CA Applicant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509696","Central Contact for Recruitment","C127523","The main or principle contact person responsible for coordinating recruitment information for a study.","Central Contact for Recruitment | CENTRAL CONTACT FOR RECRUITMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509695","Central Contact for Recruitment Backup","C127524","The secondary contact person responsible for coordinating recruitment information for a study.","Central Contact for Recruitment Backup | CENTRAL CONTACT FOR RECRUITMENT BACKUP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509712","Clinical Investigator Network Contact","C127525","The main or principle contact person for a clinical investigator network.","Clinical Investigator Network Contact | CLINICAL NETWORK CONTACT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509773","Public Queries Study Contact","C127526","The study contact person who is responsible for questions from the public.","Public Queries Study Contact | CONTACT FOR PUBLIC QUERIES | Contact for Public Queries",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509550","Scientific Queries Study Contact","C127527","The study contact person who is responsible for questions from the scientific community.","Scientific Queries Study Contact | CONTACT FOR SCIENTIFIC QUERIES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3555502","Tocopherylquinone","C126913","An oxidized form of alpha-tocopherol with potent anticoagulant activity. Although the mechanism of action has not been fully elucidated, dietary supplementation with tocopherylquinone may lead to the inhibition of the vitamin K-dependent gamma-carboxylase (gamma-glutamyl carboxylase). This prevents the carboxylation of glutamyl residues in coagulation factor proteins and inhibits platelet aggregation and clotting.","Tocopherylquinone | 2,5-Cyclohexadiene-1,4-Dione, 2-(3-Hydroxy-3,7,11,15-Tetramethylhexadecyl)-3,5,6-Trimethyl-, (3R-(3R*,7R*,11R*))- | 2-(3-Hydroxy-3,7,11,15-Tetramethylhexadecyl)-3,5,6-Trimethyl-p-Benzoquinone | Alpha-TQ | Alpha-Tocopherol Quinone | Alpha-Tocopherolquinone | Alpha-Tocopheroquinone | Alpha-Tocoquinone | TOCOQUINONE | TQ | Tocoquinone | VEQ | Vitamin E Quinone | p-Benzoquinone, 2-(3-Hydroxy-3,7,11,15-Tetramethylhexadecyl)-3,5,6-Trimethyl-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507909","umbilical cord blood-derived hematopoietic CD34-positive progenitor cells","C127119","A population of cryopreserved, ex vivo expanded and nicotinamide (NAM)-treated, CD34-positive hematopoietic progenitor cells (HPCs) derived from allogeneic, CD34+ cells isolated from human umbilical cord blood (UCB) that can be used during transplantation. CD34+ HPCs were isolated from human UCB mononuclear cells, and expanded ex vivo. Upon transplantation with omidubicel, these cells can differentiate into a variety of cell types including fibroblasts, osteoblasts, chondrocytes, myocytes, adipocytes, and endothelial cells. Compared to bone marrow transplants, these HPCs have decreased risk of causing graft-versus host disease (GvHD), increased survival, and enhanced transplant and engraftment potential for any given patient as there is no need for a matched donor. Compared to untreated HPCs, treating the cells ex vivo with NAM increases the number of HPCs from UCB, enhances migration, bone marrow (BM) homing, engraftment and increases neutrophil and platelet recovery.","Omidubicel | Ex Vivo-expanded Umbilical Cord Blood-derived Hematopoietic CD34-positive Progenitor Cells | NiCord | OMIDUBICEL | Omidubicel-onlv | Omisirge | UCB-derived CD34+ HPCs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507910","XmAb14045","C127120","An anti-CD123/anti-CD3 bispecific monoclonal antibody, in which most of the naturally-occurring Fc domain is maintained, with potential immunostimulatory and antineoplastic activities. Vibecotamab possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD123, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of vibecotamab, this bispecific antibody simultaneously binds to both CD3-expressing T-cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated cell lysis of CD123-expressing tumor cells. CD123, the interleukin-3 receptor alpha chain, is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells. The Fc domain on the antibody prolongs the half-life of the bispecific antibody and enhances T-cell mediated tumor cell killing through its binding to the Fc receptors.","Vibecotamab | Anti-CD123/Anti-CD3 Bispecific Antibody XmAb14045 | VIBECOTAMAB | XmAb14045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508786","FACT-G Version 4 - Trouble Meeting Needs of Family","C127423","Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Physical Well-Being: Because of my physical condition, I have trouble meeting the needs of my family.","FACT-G Version 4 - Trouble Meeting Needs of Family | FAC001-Trouble Meeting Needs of Family | FAC00103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508780","FACT-G Version 4 - I have pain","C127424","Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Physical Well-Being: I have pain.","FACT-G Version 4 - I have pain | FAC001-I Have Pain | FAC00104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508215","Uterine Corpus Neuroendocrine Neoplasm","C126771","An epithelial neoplasm with neuroendocrine differentiation that arises from the uterine corpus. It includes neuroendocrine tumor G1 (carcinoid tumor), small cell carcinoma pulmonary type, and large cell neuroendocrine carcinoma.","Uterine Corpus Neuroendocrine Neoplasm | Uterine Corpus Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507997","Endometrial Large Cell Neuroendocrine Carcinoma","C126772","A high grade neuroendocrine carcinoma that arises from the endometrium. It is composed of large polygonal cells arranged in well-demarcated nests, trabeculae or cords with peripheral palisading.","Endometrial Large Cell Neuroendocrine Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508212","Uterine Corpus Well Differentiated Neuroendocrine Tumor, Grade 1","C126773","A very rare, well-differentiated, low-grade neuroendocrine neoplasm that arises from the uterine corpus.","Uterine Corpus Neuroendocrine Tumor G1 | Uterine Corpus Carcinoid Tumor | Uterine Corpus Carcinoid Tumor | Uterine Corpus Neuroendocrine Tumor Grade 1 | Uterine Corpus Well Differentiated Neuroendocrine Tumor, Grade 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508056","ROBO2 wt Allele","C126775","Human ROBO2 wild-type allele is located in the vicinity of 3p12.3 and is approximately 1743 kb in length. This allele, which encodes roundabout homolog 2 protein, is involved in axon guidance, cell migration and ligand binding. Chromosomal anomalies, including t(Y;3)(p11;p12), that cause dominant-negative mutations in this gene are associated with vesicoureteral reflux.","ROBO2 wt Allele | KIAA1568 | Roundabout (Axon Guidance Receptor, Drosophila) Homolog 2 Gene | Roundabout Guidance Receptor 2 wt Allele | Roundabout, Axon Guidance Receptor, Homolog 2 (Drosophila) Gene | Roundabout, Axon Guidance Receptor, Homolog 2 Gene | Roundabout, Drosophila, Homolog of, 2 Gene | SAX3 | SAX3, C. elegans, Homolog of, 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508201","Roundabout Homolog 2","C126776","Roundabout homolog 2 (1378 aa, ~151 kDa) is encoded by the human ROBO2 gene. This protein plays a role in cell migration, axon guidance and ligand binding.","Roundabout Homolog 2 | ROBO2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1567879","ROBO3 protein, human","C126779","Roundabout homolog 3 (1386 aa, ~148 kDa) is encoded by the human ROBO3 gene. This protein is involved in the modulation of neurite outgrowth and axon guidance.","Roundabout Homolog 3 | ROBO3 | Roundabout-Like Protein 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1396635","Endometrial Metaplasia","C126780","A morphologic finding indicating the alteration of the mature endometrial glandular epithelium to another that differs from that of normal endometrioid glands.","Endometrial Metaplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4044947","Baricitinib","C127012","An orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon administration, baricitinib binds to JAK1/2, which inhibits JAK1/2 activation and leads to the inhibition of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This decreases the production of inflammatory cytokines and may prevent an inflammatory response. In addition, baricitinib may induce apoptosis and reduce proliferation of JAK1/2-expressing tumor cells. JAK kinases are intracellular enzymes involved in cytokine signaling, inflammation, immune function and hematopoiesis; they are also upregulated and/or mutated in various tumor cell types.","Baricitinib | 3-Azetidineacetonitrile, 1-(Ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)- | BARICITINIB | INCB 028050 | INCB028050 | JAK inhibitors: baricitinib | LY 3009104 | LY-3009104 | LY3009104 | Olumiant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508159","IGHV3-21 wt Allele","C127014","Human IGHV3-21 wild-type allele is located in the vicinity of 14q32.33 and is approximately 1 kb in length. This allele, which encodes the immunoglobulin heavy variable 3-21 protein, plays a role in the structure of immunoglobulin heavy chains. Expression of mutated IGHV3-21 in chronic lymphocytic leukemia may be associated with a poor prognosis.","IGHV3-21 wt Allele | Homo sapiens Immunoglobulin Heavy Variable 3-21 Gene | IGHV321 | Immunogloblin Heavy Chain Variable Region 3-21 Gene | Immunoglobulin Heavy Variable 3-21 wt Allele | VH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508160","Protein IGHV3-21, Human","C127015","Immunoglobulin heavy variable 3-21 (117 aa, ~13 kDa) is encoded by the human IGHV3-21 gene. This protein is involved in immunoglobulin heavy chain variability.","Immunoglobulin Heavy Variable 3-21 | Homo sapiens Immunoglobulin Heavy Variable 3-21 | IGHV3-21 | Immunogloblin Heavy Chain Variable Region 3-21 | Protein IGHV3-21",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508157","ITPKC wt Allele","C127017","Human ITPKC wild-type allele is located in the vicinity of 19q13.1 and is approximately 24 kb in length. This allele, which encodes inositol-trisphosphate 3-kinase C protein, is involved in calcium homeostasis and inositol phosphate metabolism.","ITPKC wt Allele | IP3-3KC | IP3KC | Inositol-Trisphosphate 3-Kinase C wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508853","Facility Contact","C127528","The main or principle contact person at a facility.","Facility Contact | FACILITY CONTACT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508981","Study Further Information Contact","C127530","The contact person responsible for disseminating additional information about a study.","Study Further Information Contact | FURTHER INFORMATION CONTACT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509247","Independent Ethics Committee Applicant","C127531","The person responsible for the independent ethics committee application.","Independent Ethics Committee Applicant | IEC APPLICANT | IEC Applicant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508134","GAIA Neonatal Infections Level of Diagnostic Certainty","C126844","A classification of maternal and fetal outcomes relating to neonatal infections, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.","GAIA Neonatal Infections Level of Diagnostic Certainty | Global Alignment of Immunization safety Assessment in pregnancy Neonatal Infections Level of Diagnostic Certainty | Neonatal Infections Level of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508144","GAIA Preterm Birth Level of Diagnostic Certainty","C126845","A classification of maternal and fetal outcomes relating to preterm birth, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.","GAIA Preterm Birth Level of Diagnostic Certainty | Global Alignment of Immunization safety Assessment in pregnancy Preterm Birth Level of Diagnostic Certainty | Preterm Birth Level of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508146","GAIA Stillbirth Level of Diagnostic Certainty","C126846","A classification of maternal and fetal outcomes relating to stillbirth, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.","GAIA Stillbirth Level of Diagnostic Certainty | Global Alignment of Immunization safety Assessment in pregnancy Stillbirth Level of Diagnostic Certainty | Stillbirth Level of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508136","GAIA Non-Reassuring Fetal Status Level of Diagnostic Certainty","C126847","A classification of maternal and fetal outcomes relating to non-reassuring fetal status, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.","GAIA Non-Reassuring Fetal Status Level of Diagnostic Certainty | Global Alignment of Immunization safety Assessment in pregnancy Non-Reassuring Fetal Status Level of Diagnostic Certainty | Non-Reassuring Fetal Status Level of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508058","GAIA Maternal Death Level of Diagnostic Certainty","C126848","A classification of maternal and fetal outcomes relating to maternal death, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.","GAIA Maternal Death Level of Diagnostic Certainty | Global Alignment of Immunization safety Assessment in pregnancy Maternal Death Level of Diagnostic Certainty | Maternal Death Level of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508140","GAIA Postpartum Hemorrhage Level of Diagnostic Certainty","C126849","A classification of maternal and fetal outcomes relating to postpartum hemorrhage, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.","GAIA Postpartum Hemorrhage Level of Diagnostic Certainty | Global Alignment of Immunization safety Assessment in pregnancy Postpartum Hemorrhage Level of Diagnostic Certainty | Postpartum Hemorrhage Level of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508142","GAIA Preeclampsia Level of Diagnostic Certainty","C126850","A classification of maternal and fetal outcomes relating to preeclampsia, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.","GAIA Preeclampsia Level of Diagnostic Certainty | Global Alignment of Immunization safety Assessment in pregnancy Preeclampsia Level of Diagnostic Certainty | Preeclampsia Level of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507911","Bifunctional Expression Vector Plasmid DNA-bi-shRNA EWS/FLI1 Type 1 Lipoplex","C127121","A proprietary plasmid DNA expression vector encoding bi-functional short hairpin RNAs (bi-shRNAs) targeting the identical type 1 translocation junction region of the human fusion oncogene Ewing sarcoma (EWS)/Ets family transcription factor Friend leukemia virus integration 1 (FLI1) and are encapsulated in liposomal delivery vehicle (lipoplex; LPX), with potential antineoplastic activity. pbi-shRNA EWS/FLI1 type 1 contains 2 stem-loop structures encoded by a plasmid vector: one cleavage-dependent unit with perfectly matched passenger- and guide-strand, which is the small interfering RNA (siRNA)-like component, and one cleavage-independent unit composed of a strategically mismatched double strand, which is the microRNA (miRNA)-like component. Upon intratumoral administration and transcription into tumor cells, one shRNA unit with an imperfectly matched sequence causes inhibition of EWS/FLI1 messenger RNA (mRNA) translation (through mRNA sequestration and cleavage-independent degradation) while the other unit with a perfectly matched sequence promotes EWS/FLI1 mRNA degradation (through cleavage-dependent mRNA silencing). This prevents EWS/FLI1 expression in tumor cells, which results in a reduction of tumor cell proliferation. The EWS/FLI1 type 1 fusion gene product is overexpressed in type 1 Ewing's sarcoma and correlates with increased tumor proliferation and poor prognosis.","Bifunctional Expression Vector Plasmid DNA-bi-shRNA EWS/FLI1 Type 1 Lipoplex | Pbi-functional Short Hairpin RNA EWS/FLI1 Type 1 Lipoplex | Pbi-functional shRNA EWS-FLI1 Type 1 Lipoplex | Pbi-shRNA EWS/FLI1 Type 1 Lipoplex | pbi-shRNA EWS/FLI1 Type 1 LP | pbi-shRNA EWS/FLI1 Type 1 LPX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507912","Absorbable Modified Polymer Hemostatic Powder","C127122","A hemostatic powder composed of hydrophilic, absorbable modified polymers (AMPs) derived from plant starch, with potential anti-hemorrhagic activity. Upon local administration of the AMP hemostatic powder directly sprayed over the bleeding surface, this powder adheres to the bleeding area, and the AMPs are able to absorb fluid and therefore soak up blood at the bleeding site. This leads to the formation of a gelled matrix that seals the affected site, and allows platelets, red blood cells and clotting factors in the blood to concentrate at the wound. In turn, this promotes the coagulation cascade, helps to stop or control bleeding, and prevents further blood loss. The AMP particles are naturally degraded by human enzymes over time.","Absorbable Modified Polymer Hemostatic Powder | AMP | AMP Hemostatic Powder | Endo-Clot | Endoclot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507913","Emapalumab","C127123","A human monoclonal antibody against the cytokine interferon-gamma (IFN-gamma; IFNg), with potential immunomodulating activity. Upon administration, emapalumab binds to and neutralizes IFNg. This inhibits IFNg-mediated signaling pathways and suppresses the activation of the immune system. IFNg, a cell-signaling protein, plays a key role in the regulation and activation of the immune system; its upregulation is associated with certain auto-immune and auto-inflammatory diseases in which the immune system is abnormally activated.","Emapalumab | Anti-IFN gamma Monoclonal Antibody NI-0501 | Anti-IFNg mAb NI-0501 | Anti-interferon gamma Monoclonal Antibody NI-0501 | EMAPALUMAB | Emapalumab-lzsg | Gamifant | NI 0501 | NI-0501 | NI0501",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507998","Endometrial Lymphoma-Like Lesion","C126781","Dense diffuse and superficial infiltration of the endometrium by lymphoid cells. It is typically seen in association with chronic endometritis.","Endometrial Lymphoma-Like Lesion | Endometrial Pseudolymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508054","SLIT1 wt Allele","C126783","Human SLIT1 wild-type allele is located within 10q23.3-q24 and is approximately 188 kb in length. This allele, which encodes slit homolog 1 protein, is involved in both angiogenesis and axon guidance.","SLIT1 wt Allele | KIAA0813 | MEGF4 | SLIL1 | SLIT-1 | SLIT3 | Slit (Drosophila) Homolog 1 Gene | Slit Guidance Ligand 1 wt Allele | Slit Homolog 1 (Drosophila) Gene | Slit, Drosophila, Homolog of, 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1454834","Slit Homolog 1 Protein, Human","C126784","Slit homolog 1 protein (1534 aa, ~168 kDa) is encoded by the human SLIT1 gene. This protein plays a role in the development of blood vessels and the differentiation of neurons.","Slit Homolog 1 Protein | Multiple EGF-Like Domains Protein 4 | Multiple Epidermal Growth Factor-Like Domains Protein 4 | Slit Homolog 1 | Slit-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508113","IL15RA wt Allele","C126969","Human IL15RA wild-type allele is located in the vicinity of 10p15.1 and is approximately 41 kb in length. This allele, which encodes interleukin-15 receptor subunit alpha protein, plays a role in interleukin-mediated signaling.","IL15RA wt Allele | CD215 | Interleukin 15 Receptor Subunit Alpha wt Allele | Interleukin 15 Receptor, Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1700975","Interleukin-15 Receptor Subunit Alpha, Human","C126970","Interleukin-15 receptor subunit alpha (267 aa, ~28 kDa) is encoded by the human IL15RA gene. This protein is involved in interleukin-dependent signaling.","Interleukin-15 Receptor Subunit Alpha | CD215 Antigen | IL-15 Receptor Subunit Alpha | IL-15R-Alpha | IL-15RA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507964","ADRB3 wt Allele","C126972","Human ADRB3 wild-type allele is located in the vicinity of 8p11.23 and is approximately 4 kb in length. This allele, which encodes beta-3 adrenergic receptor protein, is involved in catecholamine-dependent G protein-coupled receptor signaling. Mutation and variation in the gene is associated with increased susceptibility to obesity.","ADRB3 wt Allele | ADRB3R | Adrenergic, Beta-3-, Receptor Gene | Adrenoceptor Beta 3 wt Allele | B3AR | BETA3AR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3252518","Beta-3 Adrenergic Receptor, Human","C126973","Beta-3 adrenergic receptor (408 aa, ~44 kDa) is encoded by the human ADRB3 gene. This protein plays a role in G protein-coupled receptor signaling, lipolysis, and thermogenesis.","Beta-3 Adrenergic Receptor | Beta 3 Adrenergic Receptor | Beta 3 Adrenoceptor | Beta-3 Adrenoceptor | Beta-3 Adrenoreceptor | Beta-3-Adrenergic Receptor | Beta-3-Adrenoceptor | Beta-3-Adrenoreceptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508214","Uterine Corpus Hydropic Leiomyoma","C126975","A variant of leiomyoma arising from the uterine corpus. It is characterized by conspicuous zonal edema. Hyalinization may also be present.","Uterine Corpus Hydropic Leiomyoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508051","Piezoelectric Elastic Modulus Scanner","C126976","A device that maps the elasticity modulus of a material surface using a piezoresonance probe during scanning microscopy.","Piezoelectric Elastic Modulus Scanner | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017406","Geniculate Ganglion","C12721","A cluster of cranial nerve VII cell bodies located within the petrous temporal bone at the facial genu; it contains sensory nerve cell bodies for taste (from chorda tympani) and external ear sensation (from sensory auricular branch).","Geniculate Ganglion | Facial Nerve Ganglion | Genicular Ganglia | Genicular Ganglion",,,,,,,,,,,,,,,"4034282","Structure of geniculate ganglion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508790","FACT-P Version 4 - Bothered by Treatment Side Effect","C127469","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Physical Well-Being: I am bothered by side effects of treatment.","FACT-P Version 4 - Bothered by Treatment Side Effect | FAC023-Bothered by Treatment Side Effect | FAC02305",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508805","FACT-P Version 4 - I Feel Ill","C127470","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Physical Well-Being: I feel ill.","FACT-P Version 4 - I Feel Ill | FAC023-I Feel Ill | FAC02306",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508799","FACT-P Version 4 - I Am Forced to Spend Time in Bed","C127471","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Physical Well-Being: I am forced to spend time in bed.","FACT-P Version 4 - I Am Forced to Spend Time in Bed | FAC023-I Am Forced to Spend Time in Bed | FAC02307",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508138","GAIA Pathways to Preterm Birth Level of Diagnostic Certainty","C126851","A classification of maternal and fetal outcomes relating to pathways to preterm birth, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.","GAIA Pathways to Preterm Birth Level of Diagnostic Certainty | Global Alignment of Immunization safety Assessment in pregnancy Pathways to Preterm Birth Level of Diagnostic Certainty | Pathways to Preterm Birth Level of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508128","GAIA Major Congenital Anomalies Level of Diagnostic Certainty Terminology","C126852","A subset of terminology related to major congenital anomalies, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.","GAIA Major Congenital Anomalies Level of Diagnostic Certainty Terminology | Global Alignment of Immunization safety Assessment in pregnancy Major Congenital Anomalies Level of Diagnostic Certainty Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508131","GAIA Neonatal Death Level of Diagnostic Certainty Terminology","C126853","A subset of terminology related to neonatal death, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.","GAIA Neonatal Death Level of Diagnostic Certainty Terminology | Global Alignment of Immunization safety Assessment in pregnancy Neonatal Death Level of Diagnostic Certainty Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508224","Benign Uterine Corpus PEComa","C127071","A benign neoplasm with perivascular epithelioid cell differentiation arising from the uterine corpus. It is characterized by the absence of pleomorphism and scarcity or absence of mitotic figures. It usually affects perimenopausal women. Patients present with a pelvic mass or abnormal bleeding.","Benign Uterine Corpus PEComa | Benign Uterine Corpus Perivascular Epithelioid Cell Tumor | Uterine Corpus Benign PEComa | Uterine Corpus Benign Perivascular Epithelioid Cell Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508057","Malignant Uterine Corpus Perivascular Epithelioid Cell Tumor","C127072","A malignant neoplasm with perivascular epithelioid cell differentiation arising from the uterine corpus. The neoplasm is usually a large size, and charcaterized by the presence of marked nuclear atypia, pleomorphism, increased mitotic activity, necrosis, and infiltrative margins.  The most common metastatic sites are lungs, lymph nodes, and bone. Patients present with a pelvic mass or abnormal bleeding.","Uterine Corpus Malignant PEComa | Malignant Uterine Corpus PEComa | Malignant Uterine Corpus Perivascular Epithelioid Cell Tumor | Uterine Corpus Malignant Perivascular Epithelioid Cell Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003847","Arteriole","C12672","A small, terminal branch in the arterial system. Arterioles often connect to capillaries.","Arteriole | ",,,,,,,,,,,,,,,"4151381","Structure of arteriole",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508060","CD46 wt Allele","C126978","Human CD46 wild-type allele is located in the vicinity of 1q32 and is approximately 43 kb in length. This allele, which encodes membrane cofactor protein, plays a role in the stimulation of T-regulatory cell differentiation, oocyte fertilization, the classical complement pathway and pathogen binding. Mutation of the gene is associated with increased susceptibility to hemolytic uremic syndrome.","CD46 wt Allele | AHUS2 | CD46 Antigen, Complement Regulatory Protein Gene | CD46 Molecule wt Allele | CD46 Molecule, Complement Regulatory Protein Gene | MCP | MGC26544 | MIC10 | Membrane Cofactor Protein (CD46, Trophoblast-Lymphocyte Cross-Reactive Antigen) Gene | TLX | TRA2.10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1505678","Membrane Cofactor Protein, Human","C126979","Membrane cofactor protein (392 aa, ~44 kDa) is encoded by the human CD46 gene. This protein is involved in the classical complementation pathway, pathogen binding, fertilization and T-cell differentiation.","Membrane Cofactor Protein | Antigen Defined By Monoclonal Antibody TRA-2-10 | Antigen Identified By Monoclonal Antibody TRA-2-10 | CD46 Antigen | Complement Membrane Cofactor Protein | Measles Virus Receptor | TLX | Trophoblast Leucocyte Common Antigen | Trophoblast Leukocyte Common Antigen | Trophoblast-Lymphocyte Cross-Reactive Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3713420","Familial Hyperaldosteronism","C127160","A heritable form of hyperaldosteronism.","Familial Hyperaldosteronism | ",,,,,,,,,,,,,,,"45773172","Familial hyperaldosteronism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508854","Familial Hyperaldosteronism Type 1","C127161","Familial hyperaldosteronism caused by a chimeric gene containing regions of CYP11B1 and CYP11B2. This condition is responsive to exogenous glucocorticoids.","Familial Hyperaldosteronism Type 1 | CYP11B1/CYP11B2 Chimerism | Glucocorticoid Remediable Aldosteronism | Glucocorticoid Suppressible Hypertension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1854107","Familial Hyperaldosteronism Type 2","C127162","Familial hyperaldosteronism unresponsive to glucocorticoid therapy. The molecular basis for this condition has not been fully elucidated.","Familial Hyperaldosteronism Type 2 | ",,,,,,,,,,,,,,,"45766133","Familial hyperaldosteronism type 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3838758","Familial Hyperaldosteronism Type 3","C127163","Familial hyperaldosteronism caused by a mutation in the KCNJ5 gene, which encodes the inwardly rectifying potassium channel. This condition, characterized by hypokalemia and severe hypertension, presents during early childhood, and is unresponsive to glucocorticoid therapy.","Familial Hyperaldosteronism Type 3 | ",,,,,,,,,,,,,,,"45766134","Familial hyperaldosteronism type 3",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509480","Multinodular Adrenal Hyperplasia","C127164","A subtype of adrenal hyperplasia, based on histopathologic features, in which there are multiple nodules.","Multinodular Adrenal Hyperplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342496","Micronodular Adrenal Hyperplasia","C127165","Adrenal hyperfunction associated with multiple bilateral adrenal nodules, usually less than one centimeter in diameter.","Micronodular Adrenal Hyperplasia | Micronodular Adrenal Disease",,,,,,,,,,,,,,,"4030217","Micronodular adrenal hyperplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2748895","Ovotesticular Differences of Sex Development","C127167","Difference of sex development characterized by the presence of ovarian and testicular tissue in the same individual. The clinical manifestations of the condition, which can be associated with 46,XX, 46,XY or 46,XX/46,XY mosaic karyotype, are variable.","Ovotesticular Differences of Sex Development | Ovotesticular DSD | Ovotesticular Disorders of Sex Development | True Hermaphroditism",,,,,,,,,,,,,,,"37164816|619050","Ovotesticular disorder of sex development|46,XX testicular disorder of sex development",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL509553","Sex Chromosome Differences of Sex Development","C127168","A condition affecting gonadal and/or internal and/or external reproductive/genital development in which there is an atypical number of sex chromosomes (i.e. fewer or greater than the typical 2 X chromosomes or 1 X and 1 Y chromosome).","Sex Chromosome Differences of Sex Development | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2936403","46,XX Differences of Sex Development","C127169","Conditions affecting individuals with 46,XX karyotype characterized by atypical development of one or more of the following: the gonads, the internal reproductive structures, the external reproductive/genital structures.","46,XX Differences of Sex Development | 46,XX DSD | 46,XX Disorders of Sex Development",,,,,,,,,,,,,,,"604391","46,XX disorder of sex development",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508803","FACT-P Version 4 - I Feel Close to My Friends","C127472","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Social/Family Well-Being: I feel close to my friends.","FACT-P Version 4 - I Feel Close to My Friends | FAC023-I Feel Close to My Friends | FAC02308",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508794","FACT-P Version 4 - Get Emotional Support From Family","C127473","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Social/Family Well-Being: I get emotional support from my family.","FACT-P Version 4 - Get Emotional Support From Family | FAC023-Get Emotional Support From Family | FAC02309",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508808","FACT-P Version 4 - I Get Support From My Friends","C127474","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Social/Family Well-Being: I get support from my friends.","FACT-P Version 4 - I Get Support From My Friends | FAC023-I Get Support From My Friends | FAC02310",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508819","FACT-P Version 4 - My Family Has Accepted My Illness","C127475","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Social/Family Well-Being: My family has accepted my illness.","FACT-P Version 4 - My Family Has Accepted My Illness | FAC023-My Family Has Accepted My Illness | FAC02311",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508824","FACT-P Version 4 - Satisfied With Family Communication","C127476","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Social/Family Well-Being: I am satisfied with family communication about my illness.","FACT-P Version 4 - Satisfied With Family Communication | FAC023-Satisfied Communication Illness | FAC02312",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508804","FACT-P Version 4 - I Feel Close to My Partner","C127477","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Social/Family Well-Being: I feel close to my partner (or the person who is my main support).","FACT-P Version 4 - I Feel Close to My Partner | FAC023-I Feel Close to My Partner | FAC02313",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508801","FACT-P Version 4 - I Am Satisfied With My Sex Life","C127478","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Social/Family Well-Being: I am satisfied with my sex life.","FACT-P Version 4 - I Am Satisfied With My Sex Life | FAC023-I Am Satisfied With My Sex Life | FAC02314",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508825","FACT-P Version 4 - Satisfied With How I Am Coping","C127480","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Emotional Well-Being: I am satisfied with how I am coping with my illness.","FACT-P Version 4 - Satisfied With How I Am Coping | FAC023-Satisfied With How I Am Coping | FAC02316",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508818","FACT-P Version 4 - Losing Hope Against Illness","C127481","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Emotional Well-Being: I am losing hope in the fight against my illness.","FACT-P Version 4 - Losing Hope Against Illness | FAC023-Losing Hope Against Illness | FAC02317",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508806","FACT-P Version 4 - I Feel Nervous","C127482","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Emotional Well-Being: I feel nervous.","FACT-P Version 4 - I Feel Nervous | FAC023-I Feel Nervous | FAC02318",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1449842","Pseudohypoaldosteronism, Type I, Autosomal Dominant","C126810","An autosomal dominant condition presenting with hyponatremia and hyperkalemia, mimicking low concentrations of aldosterone, associated with loss-of-function mutation(s) in the NR3C2 gene, encoding the mineralocorticoid receptor.","Hyponatremic Mineralocorticoid Resistance due to Mineralocorticoid Receptor Defect | PHA1AD | Pseudohypoaldosteronism Type I Autosomal Dominant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508175","Hyponatremic Mineralocorticoid Resistance due to Urinary Tract Infection","C126811","A transient condition associated with urinary tract infections in infants presenting with hyponatremia and hyperkalemia, mimicking low concentrations of aldosterone.","Hyponatremic Mineralocorticoid Resistance due to Urinary Tract Infection | Mineralocorticoid Resistance due to UTI | Secondary PHA due to UTI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1002874","Hanseniaspora","C127285","A genus of apiculate yeast in the phylum Ascomycota that are frequently present in fruit juices and fermenting musts.","Hanseniaspora | Kloeckera",,,,,,,,,,,,,,,"4225183","Hanseniaspora",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0995448","Herbaspirillum","C127286","A genus of Gram-negative, motile, spirillum-shaped bacteria in the Proteobacteria phylum and Betaproteobacteria class that colonize diverse plants. Many species within Herbaspirillum are able to fix nitrogen. Sugars are oxidized, but not fermented.","Herbaspirillum | ",,,,,,,,,,,,,,,"4022590","Herbaspirillum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1041330","Hortaea","C127287","A genus of dematiaceous melanized fungi in the phylum Ascomycota comprising plant-infecting pathogens and free-living saprobes.","Hortaea | ",,,,,,,,,,,,,,,"37399374","Hortaea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1496383","Kerstersia","C127288","A genus of Gram-negative, catalase-positive, oxidase-negative bacteria in the in phylum Proteobacteria that occur as single cells, in pairs, or in short chains.","Kerstersia | ",,,,,,,,,,,,,,,"4218491","Kerstersia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1094113","Kodamaea","C127289","A genus of yeast-like fungi in the phylum Ascomycota that are part of the normal or transient flora of the human throat and alimentary tract.","Kodamaea | ",,,,,,,,,,,,,,,"40490855","Kodamaea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3973393","Lomentospora","C127290","A genus of filamentous fungi in the phylum Ascomycota which is isolated from soils, polluted water, composts, and manure of cattle and fowl.","Lomentospora | ",,,,,,,,,,,,,,,"37206132","Lomentospora",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024448","Madurella","C127291","A genus of fungi in the phylum Ascomycota Species in this genus are causative agents of mycetoma.","Madurella | ",,,,,,,,,,,,,,,"4044916","Madurella",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024541","Malassezia","C127292","A genus of obligatory lipophilic yeast in the phylum Basidiomycota naturally found on the skin of many warm-blooded animals. Species in this genus are associated with superficial infections of the skin and associated structures.","Malassezia | MALASSEZIA",,,,,,,,,,,,,,,"4106429","Malassezia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1001418","Metschnikowia","C127293","A genus of yeast in the phylum Ascomycota characterized by the formation of needle-shaped ascospores.","Metschnikowia | ",,,,,,,,,,,,,,,"37018597","Metschnikowia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508179","Iodine I 123 RISAD-P","C126731","A radioconjugate containing an androgen receptor (AR) targeting agent, 5-radioiodo-3'-O-(17beta-succinyl-5alpha-androstan-3-one)-2'-deoxyuridin-5'-yl phosphate (RISAD-P), labeled with the radioisotope iodine I 123 ([123]I-RISAD-P), with potential use as an imaging agent for single photon emission computed tomography (SPECT) imaging. Upon administration, iodine I 123 RISAD-P selectively binds to and is taken up by AR. Upon SPECT imaging, AR-expressing tumor cells can be imaged and AR expression levels can be assessed. AR, which is overexpressed on certain tumor cells, plays key roles in tumor cell growth and survival.","Iodine I 123 RISAD-P | (123) IRISAD-P | 123IRISAD-P | 5-[123I]iodo-3'-O-(17b-succinyl-5a-androstan-3-one)-2'-deoxyuridin-5'-yl Monophosphate | I 123 RISAD-P | [123]I-5-Radioiodo-3'-O-(17beta-succinyl-5alpha-androstan-3-one)-2'-deoxyuridin-5'-yl Phosphate | [123]I-RISAD-P",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1970848","Phosphoglycerate Kinase 1 Deficiency","C126738","An X-linked recessive inherited disorder caused by mutations in the PGK1 gene. Clinical manifestations include hemolytic anemia, myopathy, and neurologic involvement.","Phosphoglycerate Kinase 1 Deficiency | ",,,,,,,,,,,,,,,"37162328|4050307","Glycogen storage disease due to phosphoglycerate kinase 1 deficiency|Deficiency of phosphoglycerate kinase",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1846672","Muscular Dystrophy-Dystroglycanopathy (Limb-Girdle) Type C, 5","C126739","An autosomal recessive inherited limb-girdle muscular dystrophy caused by mutations in the gene encoding fukutin-related protein (FKRP). It is characterized by variable age at onset, normal cognition, and no structural brain changes.","Muscular Dystrophy-Dystroglycanopathy (Limb-Girdle) Type C, 5 | LGMD2I | Limb-Girdle Muscular Dystrophy Type 2I | MDDGC5",,,,,,,,,,,,,,,"37204689|37397524","Autosomal recessive limb girdle muscular dystrophy type 2U|Autosomal recessive limb girdle muscular dystrophy type 2I",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0410174","Muscular Dystrophy-Dystroglycanopathy (Congenital with Brain and Eye Anomalies) Type A, 4","C126741","An autosomal recessive muscular dystrophy caused by mutations in the gene encoding fukutin (FKTN).  It is associated with characteristic brain and eye malformations, seizures, and mental retardation.","Muscular Dystrophy-Dystroglycanopathy (Congenital with Brain and Eye Anomalies) Type A, 4 | MDDGA4",,,,,,,,,,,,,,,"4008570","Fukuyama congenital muscular dystrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3150411","MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 2","C126742","An autosomal recessive muscular dystrophy caused by mutations in the POMT2 gene. It is associated with characteristic brain and eye malformations and profound mental retardation.","Muscular Dystrophy-Dystroglycanopathy (Congenital with Brain and Eye Anomalies) Type A, 2 | MDDGA2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2936419","46,XX Testicular Differences of Sex Development","C127170","Presence of testes in an individual with a 46,XX karyotype, typically associated with translocation of the SRY gene, encoding the transcription factor sex-determining region Y protein, from the paternal Y chromosome to the paternal X chromosome during gametogenesis (SRY-positive). Approximately 15-20% of individuals with 46,XX testicular DSD are SRY-negative. These individuals may have other genetic variations affecting testis determination, such as duplication of the SOX9 gene, which encodes the transcription factor SOX-9.","46,XX Testicular Differences of Sex Development | 46,XX Testicular DSD | 46,XX Testicular Disorders of Sex Development",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2751824","46,XY Differences of Sex Development","C127171","Differences of sex development in individuals with 46,XY karyotype.","46,XY Differences of Sex Development | 46,XY DSD | 46,XY Disorders of Sex Development",,,,,,,,,,,,,,,"619027","46,XY disorder of sex development",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508653","46,XX Ovotesticular Difference of Sex Development","C127172","The presence of ovarian and testicular tissue in the an individual with 46,XX karyotype. The anatomical expression of this condition is variable.","46,XX Ovotesticular Difference of Sex Development | 46,XX True Hermaphroditism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2697358","46,XY Ovotesticular Differences of Sex Development","C127173","The presence of ovarian and testicular tissue in the an individual with 46,XY karyotype. The anatomical expression of this condition is variable.","46,XY Ovotesticular Differences of Sex Development | 46,XY True Hermaphroditism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508761","FACT-G Version 4 - Bothered by Treatment Side Effect","C127425","Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Physical Well-Being: I am bothered by side effects of treatment.","FACT-G Version 4 - Bothered by Treatment Side Effect | FAC001-Bothered by Treatment Side Effect | FAC00105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508771","FACT-G Version 4 - I Feel Ill","C127426","Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Physical Well-Being: I feel ill.","FACT-G Version 4 - I Feel Ill | FAC001-I Feel Ill | FAC00106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508769","FACT-G Version 4 - I Feel Close to My Friends","C127428","Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Social/Family Well-Being: I feel close to my friends.","FACT-G Version 4 - I Feel Close to My Friends | FAC001-I Feel Close to My Friends | FAC00108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508774","FACT-G Version 4 - I Get Emotional Support From My Family","C127429","Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Social/Family Well-Being: I get emotional support from my family.","FACT-G Version 4 - I Get Emotional Support From My Family | FAC001-Get Emotional Support From Family | FAC00109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508775","FACT-G Version 4 - I Get Support From My Friends","C127430","Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Social/Family Well-Being: I get support from my friends.","FACT-G Version 4 - I Get Support From My Friends | FAC001-I Get Support From My Friends | FAC00110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508782","FACT-G Version 4 - My Family Has Accepted My Illness","C127431","Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Social/Family Well-Being: My family has accepted my illness.","FACT-G Version 4 - My Family Has Accepted My Illness | FAC001-My Family Has Accepted My Illness | FAC00111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508784","FACT-G Version 4 - Satisfied With Family Communication","C127432","Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Social/Family Well-Being: I am satisfied with family communication about my illness.","FACT-G Version 4 - Satisfied With Family Communication | FAC001-Satisfied Communication Illness | FAC00112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508173","Hyperkalemic Mineralocorticoid Resistance","C126812","A genetically heterogenous condition characterized by hyperkalemia, hyperchloremic acidosis, low or suppressed renin activity, and normal to high concentrations of aldosterone. Mutations in genes (for example WNK1 or WNK4), regulating Na-Cl cotransporters (NCC), Na-K-Cl cotransporters (NKCC2), or the renal outer medullary potassium (ROMK) channel have been identified as causative in this condition. The primary abnormality is thought to be a specific defect of the renal secretory mechanism for potassium, which limits the kaliuretic response to, but not the sodium and chloride reabsorptive effect of, mineralocorticoid.","Hyperkalemic Mineralocorticoid Resistance | Chloride Shunt Syndrome | Familial Hyperkalemic Hypertension | Gordon Hyperkalemia | Mineralocorticoid Resistant Hyperkalemia | PHA Type 2 | Pseudohypoaldosteronism, Type II | Spitzer-Weinstein Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268293","Aldosterone Synthase Deficiency","C126813","An autosomal recessive condition due to mutation(s) in the CYP11B2 gene that results in decreased activity of mitochondrial cytochrome P450 11B2 with reduced aldosterone synthesis and salt wasting.","Aldosterone Synthase Deficiency | Corticosterone Methyl Oxidase Deficiency",,,,,,,,,,,,,,,"4166355","Corticosterone 18-monooxygenase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL507966","Aldosterone Synthase Deficiency Type 1","C126814","Aldosterone synthase deficiency characterized by decreased conversion of corticosterone to 18-hydroxycorticosterone.","Aldosterone Synthase Deficiency Type 1 | CMO Type 1 | Corticosterone Methyl Oxidase Deficiency Type 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507967","Aldosterone Synthase Deficiency Type 2","C126815","Aldosterone synthase deficiency characterized by decreased conversion of 18-hydroxycorticosterone to aldosterone.","Aldosterone Synthase Deficiency Type 2 | CMO Type 2 | Corticosterone Methyl Oxidase Deficiency Type 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376185","Hyporeninenmic Hypoaldosteronism","C126816","Hypoaldosteronism characterized by hyperkalemia and inappropriately low renin activity. This condition may be caused by a primary renal disorder, drugs or autoimmune processes.","Hyporeninenmic Hypoaldosteronism | Hyporeninemic Hypoaldosteronism",,,,,,,,,,,,,,,"4030526|4126432","Hyporeninemic hypoaldosteronism|Hyperkalemic renal tubular acidosis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0342483","Hyperreninemic Hypoaldosteronism","C126817","Hypoaldosteronism characterized by impaired secretion of aldosterone, despite increased renin activity. This condition may be caused by chronic or critical illness, aldosterone synthase deficiency or other genetic conditions.","Hyperreninemic Hypoaldosteronism | ",,,,,,,,,,,,,,,"4028929","Hyperreninemic hypoaldosteronism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508024","KIT Protein Variant","C126819","A variation in the amino acid sequence for the mast/stem cell growth factor receptor Kit protein.","KIT Protein Variant | CD117 Antigen Protein Variant | Mast/Stem Cell Growth Factor Receptor Kit Protein Variant | Proto-Oncogene Tyrosine-Protein Kinase Kit Protein Variant | Proto-Oncogene c-Kit Protein Variant | Stem Cell Factor Receptor Protein Variant | Tyrosine-Protein Kinase Kit Protein Variant | c-KIT Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026033","Microsporum","C127294","A genus of fungi in the phylum Ascomycota that forms both macroconidia and microconidia on short conidiophores. Species in this genus are causative agents of tinea capitis, tinea corpus, ringworm, and other types of dermatophytoses.","Microsporum | ",,,,,,,,,,,,,,,"4002052","Microsporum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0997448","Monascus","C127295","A genus of saprobic mold in the phylum Ascomycota. Species in this genus are used in the production of various fermented food products, pigments, and food supplements.","Monascus | ",,,,,,,,,,,,,,,"4215355","Monascus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3364586","Purpureocillium","C127296","A genus of fungi in the phylum Ascomycota characterized by purple conidia.","Purpureocillium | ",,,,,,,,,,,,,,,"37399378","Purpureocillium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320117","Scedosporium","C127297","A genus of filamentous fungi in the phylum Ascomycota which is isolated from soils, polluted water, composts, and manure of cattle and fowl.","Scedosporium | ",,,,,,,,,,,,,,,"4136685","Scedosporium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320146","Scolecobasidium","C127298","A genus of mitosporic fungi in the phylum Ascomycota characterized by short conidiospores with thread-like sterigmata bearing a terminal conidium.","Scolecobasidium | ",,,,,,,,,,,,,,,"4031194","Scolecobasidium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1008541","Setosphaeria","C127299","A genus of fungi in the phylum Ascomycota.","Setosphaeria | ",,,,,,,,,,,,,,,"4265911","Setosphaeria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508902","Legal Representative for the Study","C127532","An individual with expertise in the law who provides legal counsel and representation for a study.","Legal Representative for the Study | LEGAL REPRESENTATIVE FOR THE STUDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509292","Primary Study Contact","C127533","The main or principle contact person for a study.","Primary Study Contact | PRIMARY CONTACT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508985","Subcontractor Contact","C127534","The main or principle contact person for a subcontractor or subcontracting organization.","Subcontractor Contact | SUBCONTRACTOR CONTACT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508770","FACT-G Version 4 - I Feel Close to My Partner","C127433","Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Social/Family Well-Being: I feel close to my partner (or the person who is my main support).","FACT-G Version 4 - I Feel Close to My Partner | FAC001-I Feel Close to My Partner | FAC00113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508767","FACT-G Version 4 - I Am Satisfied With My Sex Life","C127434","Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Social/Family Well-Being: I am satisfied with my sex life.","FACT-G Version 4 - I Am Satisfied With My Sex Life | FAC001-I Am Satisfied With My Sex Life | FAC00114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508773","FACT-G Version 4 - I Feel Sad","C127435","Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Emotional Well-Being: I feel sad.","FACT-G Version 4 - I Feel Sad | FAC001-I Feel Sad | FAC00115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508785","FACT-G Version 4 - Satisfied With How I Am Coping With Illness","C127436","Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Emotional Well-Being: I am satisfied with how I am coping with my illness.","FACT-G Version 4 - Satisfied With How I Am Coping With Illness | FAC001-Satisfied With How I Am Coping | FAC00116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508781","FACT-G Version 4 - Losing Hope Against Illness","C127437","Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Emotional Well-Being: I am losing hope in the fight against my illness.","FACT-G Version 4 - Losing Hope Against Illness | FAC001-Losing Hope Against Illness | FAC00117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508772","FACT-G Version 4 - I Feel Nervous","C127438","Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Emotional Well-Being: I feel nervous.","FACT-G Version 4 - I Feel Nervous | FAC001-I Feel Nervous | FAC00118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508078","SLIT2 wt Allele","C126786","Human SLIT2 wild-type allele is located in the vicinity of 4p15.2 and is approximately 369 kb in length. This allele, which encodes slit homolog 2 protein, plays a role in both nervous system development and cell migration.","SLIT2 wt Allele | SLIL3 | Slit (Drosophila) Homolog 2 Gene | Slit Guidance Ligand 2 wt Allele | Slit Homolog 2 (Drosophila) Gene | Slit, Drosophila, Homolog of, 2 Gene | Slit-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1741674","Slit Homolog 2 Protein, Human","C126787","Slit homolog 2 protein (1529 aa, ~170 kDa) is encoded by the human SLIT2 gene. This protein is involved in the modulation of cell migration and the development of the nervous system.","Slit Homolog 2 Protein | Slit Homolog 2 | Slit-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508055","SLIT3 wt Allele","C126789","Human SLIT3 wild-type allele is located in the vicinity of 5q35 and is approximately 640 kb in length. This allele, which encodes slit homolog 3 protein, is involved in cell migration.","SLIT3 wt Allele | KIAA0814 | MEGF5 | SLIL2 | SLIT1 | Slit (Drosophila) Homolog 3 Gene | Slit Guidance Ligand 3 wt Allele | Slit Homolog 3 (Drosophila) Gene | Slit, Drosophila, Homolog of, 3 Gene | Slit-3 | UNQ691/PRO1336 | slit2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1452501","Slit Homolog 3 Protein, Human","C126790","Slit homolog 3 protein (1523 aa, ~168 kDa) is encoded by the human SLIT3 gene. This protein plays a role in the modulation of cell migration.","Slit Homolog 3 Protein | Multiple EGF-Like Domains Protein 5 | Multiple Epidermal Growth Factor-Like Domains Protein 5 | Slit Homolog 3 | Slit-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508023","Maba1","C127020","Human ELAPOR1 wild-type allele is located in the vicinity of 1p13.3 and is approximately 93 kb in length. This allele, which encodes endosome/lysosome-associated apoptosis and autophagy regulator 1 protein, plays a role in poly(A) RNA binding and autophagosome assembly.","ELAPOR1 wt Allele | EIG121 | Endosome-Lysosome Associated Apoptosis and Autophagy Regulator 1 wt Allele | Endosome-Lysosome-Associated Apoptosis and Autophagy Regulator 1 Gene | Estrogen Induced Gene 121 | Estrogen-Induced Gene 121 | KIAA1324 | KIAA1324 wt Allele | Maba1 | UNQ2426/PRO4985",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508127","maba1protein, human","C127021","Endosome/lysosome-associated apoptosis and autophagy regulator 1 (1013 aa, ~111 kDa) is encoded by the human ELAPOR1 gene. This protein is involved in promoting autophagy and binding to RNA.","Endosome/Lysosome-Associated Apoptosis and Autophagy Regulator 1 | ELAPOR1 | Estrogen-Induced Gene 121 Protein | UPF0577 Protein KIAA1324",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508038","MBP wt Allele","C127023","Human MBP wild-type allele is located in the vicinity of 18q23 and is approximately 155 kb in length. This allele, which encodes myelin basic protein, is involved in neuronal development and myelination.","MBP wt Allele | Myelin A1 Protein, Basic Gene | Myelin Basic Protein wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1567500","Myelin Basic Protein, Human","C127025","Myelin basic protein (304 aa, ~33 kDa) is encoded by the human MBP gene. This protein plays a role in myelination and neuronal development.","Myelin Basic Protein | MBP | Myelin A1 Protein | Myelin Membrane Encephalitogenic Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508143","GAIA Preterm Birth Level of Diagnostic Certainty Terminology","C126855","A subset of terminology related to preterm birth, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.","GAIA Preterm Birth Level of Diagnostic Certainty Terminology | Global Alignment of Immunization safety Assessment in pregnancy Preterm Birth Level of Diagnostic Certainty Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508145","GAIA Stillbirth Level of Diagnostic Certainty Terminology","C126856","A subset of terminology related to stillbirth, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.","GAIA Stillbirth Level of Diagnostic Certainty Terminology | Global Alignment of Immunization safety Assessment in pregnancy Stillbirth Level of Diagnostic Certainty Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508135","GAIA Non-Reassuring Fetal Status Level of Diagnostic Certainty Terminology","C126857","A subset of terminology related to non-reassuring fetal status, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.","GAIA Non-Reassuring Fetal Status Level of Diagnostic Certainty Terminology | Global Alignment of Immunization safety Assessment in pregnancy Non-Reassuring Fetal Status Level of Diagnostic Certainty Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508130","GAIA Maternal Death Level of Diagnostic Certainty Terminology","C126858","A subset of terminology related to maternal death, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.","GAIA Maternal Death Level of Diagnostic Certainty Terminology | Global Alignment of Immunization safety Assessment in pregnancy Maternal Death Level of Diagnostic Certainty Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507914","anti-VISTA monoclonal antibody JNJ 61610588","C127124","A human monoclonal antibody against the protein V-domain immunoglobulin (Ig) suppressor of T-cell activation (VISTA; programmed death 1 homolog; PD1H; PD-1H), with potential negative checkpoint regulatory and antineoplastic activities. Upon administration, onvatilimab targets and binds to VISTA. This inhibits VISTA signaling, abrogates the VISTA-induced suppression of T-lymphocyte-mediated immune responses, enhances cytotoxic T-cell responses against tumor cells and inhibits tumor cell growth. VISTA, mainly expressed on hematopoietic cells, plays a key role in immunosuppression.","Onvatilimab | CI 8993 | CI-8993 | CI8993 | Immunoglobulin G1, Anti-(Human Protein Vista (v-domain Immunoglobulin Suppressor of T Cell Activation)) (Human Clone JNJ 61610588 gamma1-chain), Disulfide with Human Clone JNJ | JNJ 61610588 | JNJ-61610588 | ONVATILIMAB | WHO 10758",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507915","NY-ESO-1/PRAME/MAGE-A3/WT-1 Peptide Vaccine","C127125","A peptide-based cancer vaccine comprised of synthetic peptides derived from the cancer-testis antigen NY-ESO-1, preferentially expressed antigen in melanoma (PRAME), human melanoma antigen A3 (MAGE-A3) and the human Wilms tumor protein-1 (WT-1), with potential immunostimulating and antineoplastic activities. Upon administration, NY-ESO-1/PRAME/MAGE-A3/WT-1 peptide vaccine may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing NY-ESO-1, PRAME, MAGE-A3 and WT-1, resulting in tumor cell lysis. The NY-ESO-1, PRAME, MAGE-A3 and WT-1 peptides, tumor-associated antigens (TAAs) overexpressed in a variety of cancer cell types, play a key role in tumor cell proliferation.","NY-ESO-1/PRAME/MAGE-A3/WT-1 Peptide Vaccine | NPMW-peptide Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508914","Ostomy Skin Barrier","C127126","A device designed to adhere to the peristomal skin to protect it from the output of the stoma. It may be incorporated into a system for attaching an ostomy pouch.","Ostomy Skin Barrier | Skin Barrier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826153","MIR574 Gene","C127130","This gene may play a role in the modulation of target gene expression.","MIR574 Gene | MIR574 | MicroRNA 574 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509274","MIR574 wt Allele","C127131","Human MIR574 wild-type allele is located within chromosome 4 and is approximately 1 kb in length. This allele, which encodes MIR574 pre-miRNA, may be involved in the regulation of gene expression.","MIR574 wt Allele | MIRN574 | Micro RNA 574 Gene | MicroRNA 574 wt Allele | hsa-mir-574 | mir-574",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509741","MIR574 Pre-miRNA","C127132","MIR574 pre-miRNA (96 bp) is encoded by the human MIR574 gene. This oligoribonucleotide may play a role in the regulation of protein synthesis.","MIR574 Pre-miRNA | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508203","Ruxolitinib Phosphate Cream","C126791","A topical cream formulation containing the phosphate salt form of ruxolitinib, a bioavailable Janus-associated kinase (JAK) inhibitor, with potential immunomodulating activity. Upon topical administration of the ruxolitinib phosphate cream, ruxolitinib specifically binds to and inhibits the protein tyrosine kinases JAK 1 and 2; this inhibits signal transduction pathways of various cytokines and reduces inflammation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling pathways initiated by many cytokines and growth factors; JAK kinases are upregulated in various inflammatory and autoimmune diseases, including alopecia areata.","Ruxolitinib Phosphate Cream | INCB018424 Phosphate Cream",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507901","Kava-based Supplement","C126793","A Kava supplement derived from Piper methysticum and containing high amounts of kavalactones, with potential cancer preventative and anxiolytic activities and that may be used to facilitate tobacco cessation. Upon oral administration, the kava-based supplement may affect the metabolism of certain carcinogens, presumably because of the kavalactones present in this product. This increases detoxification of the carcinogens and may suppress carcinogen-induced DNA damage and may lower the risk of carcinogenesis. Intake of the kava-based supplement may also suppress stress-mediated protein kinase A (PKA) activation, and reduces plasma cortisol levels. This may induce relaxation, may relief stress and anxiety, improve sleep, and may help reduce tobacco use and tobacco dependence, and may ultimately decrease the risk of tobacco-associated lung carcinogenesis. The Kava-based supplement is free of flavokavains A and B, which are potential hepatotoxic ingredients in kava.","Kava-based Supplement | AB-free Kava | Flavokavain A/Flavokavain B-free Kava Supplement | Flavokavains A and B-free Kava Supplement | Flavokavains A/B-free Kava Supplement | Kava Supplement | Kavalactones-based Supplement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507886","Anti-LGR5 Monoclonal Antibody BNC101","C126794","A humanized monoclonal antibody targeting leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), with potential antineoplastic activity. Upon administration, the anti-LGR5 humanized monoclonal antibody BNC101 targets and binds to LGR5, thereby inhibiting LRG5-mediated signal transduction pathways. This prevents proliferation of LRG5-expressing tumor cells. LGR5, a member of the Wnt signaling pathway, is a cancer stem cell (CSC) receptor overexpressed on certain cancer cells; it plays a key role in CSC proliferation and survival.","Anti-LGR5 Monoclonal Antibody BNC101 | BNC-101 | BNC101 | ET-101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507887","Wu-ling-San","C126795","A traditional Chinese medicine (TCM) composed of Polyporus sclerotium (Sclerotium polypori Umbrellati; Zhu Ling), Sclerotium Poriae Cocos (Poria; Fu Ling), Alismatis rhizome (Alisma; Rhizoma Alismatis Orientalis; Ze Xie), Cinnamomi cortex (Ramulus Cinnamomi Cassiae; Gui Zhi) and Atractylodis macrocephalae rhizome (Rhizoma Atractylodis Macrocephalae; Bai Zhu) with potential diuresis-inducing and kidney protective activities. Upon oral administration, wu-ling san may increase the removal of excess fluid, prevent the retention of water, maintain healthy water metabolism by promoting diuresis, and protect kidney function.","Wu-ling-San | Hoelen Five Herb Formula | Poria Five Powder | Powder of Five Drugs with Poria | WLS | WLS Formula | Wu Ling Pian | Wu Ling San | Wu Ling Wan | Wuling San",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507889","Balanced Crystalloid Solution","C126796","A multiple electrolyte, isotonic, crystalloid solution for intravenous infusion containing sodium chloride, sodium gluconate, sodium acetate, potassium chloride and magnesium chloride, which can restore electrolyte balance, normalize pH, and provide hydration. Upon intravenous administration, the balanced crystalloid solution will replace lost body fluids and electrolytes thereby providing hydration, normalizing electrolyte concentrations and regulating acid-base balance.","Balanced Crystalloid Solution | PLASMALYTE A | Plasma-Lyte A | PlasmaLyte-A | Sodium Chloride/Sodium Gluconate/Sodium Acetate/Potassium Chloride/Magnesium Chloride Solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1172090","CDK9 protein, human","C126982","Cyclin-dependent kinase 9 (372 aa, ~43 kDa) is encoded by the human CDK9 gene. This protein plays a role in the positive regulation of transcriptional elongation.","Cyclin-Dependent Kinase 9 | C-2K | CDK9 | Cell Division Cycle 2-Like Protein Kinase 4 | Cell Division Protein Kinase 9 | EC 2.7.11.22 | EC 2.7.11.23 | Serine/Threonine Protein Kinase PITALRE | Serine/Threonine-Protein Kinase PITALRE | Tat-Associated Kinase Complex Catalytic Subunit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507994","CYP26A1 wt Allele","C126984","Human CYP26A1 wild-type allele is located within 10q23-q24 and is approximately 4 kb in length. This allele, which encodes cytochrome P450 26A1 protein, plays a role in the metabolism of retinoids.","CYP26A1 wt Allele | CP26 | CYP26 | Cytochrome P450 Family 26 Subfamily A Member 1 wt Allele | Cytochrome P450, Family 26, Subfamily A, Polypeptide 1 Gene | Cytochrome P450, Subfamily XXVIA, Polypeptide 1 Gene | P450, Retinoic Acid-Inactivating, 1 Gene | P450RAI | P450RAI1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1744261","Cytochrome P450 26A1, Human","C126985","Cytochrome P450 26A1 (497 aa, ~56 kDa) is encoded by the human CYP26A1 gene. This protein is involved in the hydroxylation of retinoic acid.","Cytochrome P450 26A1 | CYP26A1 | Cytochrome P450 Retinoic Acid-Inactivating 1 | Cytochrome P450RAI | EC 1.14.-.- | Retinoic Acid 4-Hydroxylase | Retinoic Acid-Metabolizing Cytochrome | hP450RAI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508139","GAIA Postpartum Hemorrhage Level of Diagnostic Certainty Terminology","C126859","A subset of terminology related to postpartum hemorrhage, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.","GAIA Postpartum Hemorrhage Level of Diagnostic Certainty Terminology | Global Alignment of Immunization safety Assessment in pregnancy Postpartum Hemorrhage Level of Diagnostic Certainty Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508141","GAIA Preeclampsia Level of Diagnostic Certainty Terminology","C126860","A subset of terminology related to preeclampsia, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.","GAIA Preeclampsia Level of Diagnostic Certainty Terminology | Global Alignment of Immunization safety Assessment in pregnancy Preeclampsia Level of Diagnostic Certainty Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3179455","Niemann-Pick Disease, Type C1","C126864","Type C Niemann-Pick disease associated with a mutation in the gene NPC1, encoding Niemann-Pick C1 protein.","Niemann-Pick Disease, Type C1 | Type C1 Niemann-Pick Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1843366","NIEMANN-PICK DISEASE, TYPE C2","C126865","Type C Niemann-Pick disease associated with a mutation in the gene NPC2, encoding Niemann-Pick C2 protein.","Niemann-Pick Disease, Type C2 | Type C2 Niemann-Pick Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268243","Niemann-Pick Disease, Type B","C126866","An autosomal recessive lysosomal storage disease caused by mutations in the SMPD1 gene, encoding sphingomyelin phosphodiesterase. The condition is characterized by hepatosplenomegaly and interstitial lung disease, but with little neurological involvement. It is part of a continuum of disease resulting from decrease activity of sphingomyelin phosphodiesterase, with Type B being the milder form.","Niemann-Pick Disease, Type B | Type B Niemann-Pick Disease",,,,,,,,,,,,,,,"4214475","Niemann-Pick disease, type B",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508059","GAIA Maternal Immunization Level of Diagnostic Certainty","C126867","A classification of maternal and fetal outcomes relating to maternal immunization, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.","GAIA Maternal Immunization Level of Diagnostic Certainty | Global Alignment of Immunization safety Assessment in pregnancy Maternal Immunization Level of Diagnostic Certainty | Maternal Immunisation Level of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0349653","Congenital Disorder of Glycosylation Type Ia","C126868","A congenital disorder of glycosylation subtype caused by mutation(s) in the PMM2 gene, encoding phosphomannomutase 2.","Congenital Disorder of Glycosylation Type Ia | CDGIa",,,,,,,,,,,,,,,"43020878","Congenital disorder of glycosylation type Ia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL507982","DNAJA1 wt Allele","C126987","Human DNAJA1 wild-type allele is located in the vicinity of 9p13.3 and is approximately 15 kb in length. This allele, which encodes DnaJ homolog subfamily A member 1 protein, is involved in both protein folding and protein trafficking.","DNAJA1 wt Allele | DJ-2 | DNAJ2 | DjA1 | DnaJ (Hsp40) Homolog, Subfamily A, Member 1 Gene | DnaJ Heat Shock Protein Family (Hsp40) Member A1 wt Allele | DnaJ/Hsp40 Homolog, Subfamily A, Member 1 Gene | HDJ2 | HSDJ | HSJ-2 | HSJ2 | HSPF4 | Heat Shock Protein, DNAJ-Like 2 Gene | NEDD7 | Neural Precursor Cell Expressed, Developmentally Down-Regulated 7 Gene | hDJ-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0664319","DnaJ Homolog Subfamily A Member 1, Human","C126988","DnaJ homolog subfamily A member 1 (397 aa, ~45 kDa) is encoded by the human DNAJA1 gene. This protein plays a role in both protein trafficking and protein folding.","DnaJ Homolog Subfamily A Member 1 | DNAJA1 | DnaJ Protein Homolog 2 | HSDJ | HSJ-2 | Heat Shock 40 kDa Protein 4 | Heat Shock Protein J2 | Human DnaJ Protein 2 | hDj-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508121","DRG1 wt Allele","C126990","Human DRG1 wild-type allele is located in the vicinity of 22q12.2 and is approximately 129 kb in length. This allele, which encodes developmentally-regulated GTP-binding protein 1, plays a role in both cell growth regulation and GTP binding.","DRG1 wt Allele | DRG | Developmentally Regulated GTP Binding Protein 1 wt Allele | NEDD3 | Neural Precursor Cell Expressed, Developmentally Down-Regulated 3 Gene | Neural Precursor Cell Expressed, Developmentally Downregulated 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0905573","Developmentally-Regulated GTP-Binding Protein 1, Human","C126991","Developmentally-regulated GTP-binding protein 1 (367 aa, ~41 kDa) is encoded by the human DRG1 gene. This protein is involved in both GTP binding and the regulation of cell growth.","Developmentally-Regulated GTP-Binding Protein 1 | DRG-1 | DRG1 | Developmentally Regulated GTP-Binding Protein | Developmentally Regulated GTP-Binding Protein 1 | NEDD-3 | Neural Precursor Cell Expressed Developmentally Down-Regulated Protein 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507984","GCSAM wt Allele","C126993","Human GCSAM wild-type allele is located in the vicinity of 3q13.2 and is approximately 16 kb in length. This allele, which encodes germinal center-associated signaling and motility protein, is involved in signaling pathways and the negative regulation of lymphocyte migration.","GCSAM wt Allele | GCAT2 | GCET2 | Germinal Center Associated Signaling and Motility wt Allele | Germinal Center B-Cell-Expressed Transcript 2 Gene | Germinal Center Expressed Transcript 2 Gene | Germinal Center-Associated, Signaling and Motility Gene | Germinal Center-Expressed Transcript 2 Gene | HGAL | Human Germinal Center-Associated Lymphoma Gene | MGC40441",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508817","FACT-P Version 4 - I Worry About Dying","C127483","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Emotional Well-Being: I worry about dying.","FACT-P Version 4 - I Worry About Dying | FAC023-I Worry About Dying | FAC02319",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508827","FACT-P Version 4 - Worry My Condition Will Get Worse","C127484","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Emotional Well-Being: I worry that my condition will get worse.","FACT-P Version 4 - Worry My Condition Will Get Worse | FAC023-Worry My Condition Will Get Worse | FAC02320",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508798","FACT-P Version 4 - I Am Able to Work","C127485","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Functional Well-Being: I am able to work (include work at home).","FACT-P Version 4 - I Am Able to Work | FAC023-I Am Able to Work | FAC02321",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508820","FACT-P Version 4 - My Work Is Fulfilling","C127486","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Functional Well-Being: My work (include work at home) is fulfilling.","FACT-P Version 4 - My Work Is Fulfilling | FAC023-My Work Is Fulfilling | FAC02322",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508796","FACT-P Version 4 - I Am Able to Enjoy Life","C127487","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Functional Well-Being: I am able to enjoy life.","FACT-P Version 4 - I Am Able to Enjoy Life | FAC023-I Am Able to Enjoy Life | FAC02323",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508809","FACT-P Version 4 - I Have Accepted My Illness","C127488","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Functional Well-Being: I have accepted my illness.","FACT-P Version 4 - I Have Accepted My Illness | FAC023-I Have Accepted My Illness | FAC02324",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508802","FACT-P Version 4 - I Am Sleeping Well","C127489","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Functional Well-Being: I am sleeping well.","FACT-P Version 4 - I Am Sleeping Well | FAC023-I Am Sleeping Well | FAC02325",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508793","FACT-P Version 4 - Enjoy Things I Usually Do for Fun","C127490","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Functional Well-Being: I am enjoying the things I usually do for fun.","FACT-P Version 4 - Enjoy Things I Usually Do for Fun | FAC023-Enjoy Things I Usually Do for Fun | FAC02326",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508792","FACT-P Version 4 - Content With Quality of My Life","C127491","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Functional Well-Being: I am content with the quality of my life right now.","FACT-P Version 4 - Content With Quality of My Life | FAC023-Content With Quality of My Life | FAC02327",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508800","FACT-P Version 4 - I Am Losing Weight","C127492","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Additional Concerns: I am losing weight.","FACT-P Version 4 - I Am Losing Weight | FAC023-I Am Losing Weight | FAC02328",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038035","Sporothrix","C127301","A genus of thermally dimorphic fungi in the phylum Ascomycota that is found growing as filamentous hyphae at lower temperatures and as a yeast at 37C. Species in this genus are characterized by brown, thick-walled conidia attached along the hyphae.","Sporothrix | ",,,,,,,,,,,,,,,"4268468","Sporothrix",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1895632","Tausonia","C127302","A genus of yeast-like fungi in the phylum Basidiomycota with arthroconidia developing from disarticulate hyphae. Species in this genus are positive for urease and diazonium blue B. Sexual reproduction is not observed.","Tausonia | Guehomyces",,,,,,,,,,,,,,,"35624659","Tausonia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3150414","Muscular Dystrophy-Dystroglycanopathy (Congenital with Brain and Eye Anomalies) Type A, 6","C126743","An autosomal recessive muscular dystrophy caused by mutations in the LARGE gene. It is associated with characteristic brain and eye malformations, profound mental retardation, and death usually in the first years of life.","Muscular Dystrophy-Dystroglycanopathy (Congenital with Brain and Eye Anomalies) Type A, 6 | MDDGA6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1838180","Codas Syndrome","C126744","A rare syndrome caused by mutations in the LONP1 gene. It is characterized by developmental delay, cerebral, ocular, dental, auricular, and skeletal abnormalities.","Codas Syndrome | ",,,,,,,,,,,,,,,"36713445","CODAS syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0410190","Emery-Dreifuss Muscular Dystrophy 2, Autosomal Dominant","C126745","Emery-Dreifuss muscular dystrophy inherited in an autosomal dominant pattern and caused by mutations in the LMNA gene.","Emery-Dreifuss Muscular Dystrophy 2, Autosomal Dominant | EDMD2",,,,,,,,,,,,,,,"605270","Autosomal dominant Emery-Dreifuss muscular dystrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3808991","Congenital Disorder of Deglycosylation","C126746","A rare autosomal recessive inherited disorder caused by mutations in the NGLY1 gene. It is characterized by developmental delay, hypotonia, abnormal involuntary movements, poor tear production, microcephaly, intractable seizures, abnormal eye movements, and liver abnormalities.","Congenital Disorder of Deglycosylation | CDDG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1846058","Lubs X-Linked Mental Retardation Syndrome","C126747","An X-linked inherited syndrome caused by duplication or triplication of the gene encoding methyl-CpG-binding protein-2 (MECP2). It is characterized by mental retardation, infantile hypotonia, mild dysmorphic features, poor speech development, autistic features, seizures, progressive spasticity, and recurrent infections.","Lubs X-Linked Mental Retardation Syndrome | MECP2 Duplication Syndrome | MRXSL",,,,,,,,,,,,,,,"45765797","MECP2 duplication syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL507965","Acute Myeloid Leukemia with FLT3/ITD Mutation","C126748","Acute myeloid leukemia characterized by the presence of a FLT3-internal tandem duplication (ITD) mutation. Patients with this mutation usually present with more aggressive disease and have higher rates of relapse after remission.","Acute Myeloid Leukemia with FLT3/ITD Mutation | Acute Myeloid Leukemia (AML) with FLT3/ITD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508198","Oropharyngeal Poorly Differentiated Carcinoma","C126750","A high-grade carcinoma that arises from the oropharynx. It is characterized by the presence of malignant cells which bear minimal resemblance to the cells from which they arose.","Oropharyngeal Poorly Differentiated Carcinoma | Poorly Differentiated Oropharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508197","Oropharyngeal Basaloid Carcinoma","C126751","A high-grade variant of squamous cell carcinoma that arises from the oropharynx. It is characterized by the presence of small malignant cells with hyperchromatic nuclei and scant amount of cytoplasm forming lobules with peripheral palisading.","Oropharyngeal Basaloid Squamous Cell Carcinoma | Oropharyngeal Basaloid Carcinoma | Oropharyngeal Basaloid Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509740","Growth Hormone and Prolactin-Producing Adenoma","C127194","A pituitary neuroendocrine tumor that produces both growth hormone and prolactin.","Somatotroph-Lactotroph Pituitary Neuroendocrine Tumor | Growth Hormone and Prolactin-Producing Adenoma | Somatotroph-Lactotroph PitNET/Adenoma | Somatotroph-Lactotroph Pituitary Neuroendocrine Tumor/Adenoma | Somatotroph/Lactotroph Adenoma | Somatotroph/Lactotroph Adenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508787","FACT-G Version 4 - Worry My Condition Will Get Worse","C127440","Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Emotional Well-Being: I worry that my condition will get worse.","FACT-G Version 4 - Worry My Condition Will Get Worse | FAC001-Worry My Condition Will Get Worse | FAC00120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508765","FACT-G Version 4 - I Am Able to Work","C127441","Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Functional Well-Being: I am able to work (include work at home).","FACT-G Version 4 - I Am Able to Work | FAC001-I Am Able to Work | FAC00121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508795","FACT-P Version 4 - Have Aches and Pains That Bother Me","C127494","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Additional Concerns: I have aches and pains that bother me.","FACT-P Version 4 - Have Aches and Pains That Bother Me | FAC023-Have Aches/Pains That Bother Me | FAC02330",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508791","FACT-P Version 4 - Certain Parts of Body Experience Pain","C127495","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Additional Concerns: I have certain parts of my body where I experience pain.","FACT-P Version 4 - Certain Parts of Body Experience Pain | FAC023-Certain Parts of Body Have Pain | FAC02331",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508821","FACT-P Version 4 - Pain Keeps Me From Doing Things","C127496","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Additional Concerns: My pain keeps me from doing things I want to do.","FACT-P Version 4 - Pain Keeps Me From Doing Things | FAC023-Pain Keeps Me From Doing Things | FAC02332",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508823","FACT-P Version 4 - Satisfied With Comfort Level","C127497","Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Additional Concerns: I am satisfied with my present comfort level.","FACT-P Version 4 - Satisfied With Comfort Level | FAC023-Satisfied With Comfort Level | FAC02333",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL409909","MPL NM_005373.2:c.1544G>T","C126822","A nucleotide substitution at position 1544 of the coding sequence of the MPL gene where guanine has been mutated to thymine.","MPL NM_005373.2:c.1544G>T | CD110 c.1544G>T | MPL Proto-Oncogene, Thrombopoietin Receptor c.1544G>T | MPL c.1544G>T | Myeloproliferative Leukemia Virus Oncogene c.1544G>T | NM_005373.2:c.1544G>T | TPOR c.1544G>T | c-MPL c.1544G>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508043","MPL Protein Variant","C126823","A variation in the amino acid sequence for the thrombopoietin receptor protein.","MPL Protein Variant | CD110 Antigen Protein Variant | Myeloproliferative Leukemia Protein Protein Variant | Proto-Oncogene c-Mpl Protein Variant | TPO-R Protein Variant | Thrombopoietin Receptor Protein Variant | c-MPL Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508041","CD110 c.1543_1544TG>AA","C126826","A complex substitution where the nucleotide sequence at positions 1543 and 1544 of the coding sequence of the MPL gene has changed from thymine-guanine to adenine-adenine.","MPL NM_005373.2:c.1543_1544delinsAA | CD110 c.1543_1544TG>AA | MPL NM_005373.2:c.1543_1544TG>AA | MPL NM_005373.2:c.1543_1544delTGinsAA | MPL NM_005373.2:c.1543_1544delTGinsAA | MPL Proto-Oncogene, Thrombopoietin Receptor c.1543_1544TG>AA | MPL c.1543_1544TG>AA | Myeloproliferative Leukemia Virus Oncogene c.1543_1544TG>AA | NM_005373.2:c.1543_1544TG>AA | NM_005373.2:c.1543_1544delTGinsAA | NM_005373.2:c.1543_1544delinsAA | TPOR c.1543_1544TG>AA | c-MPL c.1543_1544TG>AA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508042","NM_005373.2: c.1543_1544TGG>AAA","C126827","A complex substitution where the nucleotide sequence at positions 1543 and 1545 of the coding sequence of the MPL gene has changed from thymine-guanine-guanine to adenine-adenine-adenine.","MPL NM_005373.2:c.1543_1545delinsAAA | CD110 c.1543_1544TGG>AAA | MPL NM_005373.2:c.1543_1545TGG>AAA | MPL NM_005373.2:c.1543_1545delTGG>insAAA | MPL NM_005373.2:c.1543_1545delTGGinsAAA | MPL NM_005373.2:c.1543_1545delTGGinsAAA | MPL Proto-Oncogene, Thrombopoietin Receptor c.1543_1544TGG>AAA | MPL c.1543_1545TGG>AAA | Myeloproliferative Leukemia Virus Oncogene c.1543_1544TGG>AAA | NM_005373.2: c.1543_1544TGG>AAA | NM_005373.2:c.1543_1545delTGG>insAAA | NM_005373.2:c.1543_1545delinsAAA | TPOR c.1543_1544TGG>AAA | c-MPL c.1543_1544TGG>AAA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1087880","Trematosphaeria","C127303","A genus of mostly saprobic or hemibiotrophic fungi in the phylum Ascomycota with additional species inhabiting marine and freshwater environments. Species in this genus are characterized by medium to large sized ascomata with peridia composed of small compressed cells, clavate to cylindrical bitunicate asci, a trabeculate hamathecium in a gelatinous matrix and reddish-brown ellipsoid to fusoid transversely septate ascospores sometimes with paler end cells.","Trematosphaeria | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1463540","Trichomonascus","C127304","A genus of endomycete-like fungi in the phylum Ascomycota. Species in this genus may or may not be mycoparasitic.","Trichomonascus | ",,,,,,,,,,,,,,,"35624641","Trichomonascus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040933","Trichophyton Preparation","C127305","A genus of fungi in the phylum Ascomycota that includes those that cause tinea, athlete's foot, ringworm, and jock itch. Species in this genus are molds, characterized by the development of smooth-walled macro- and microconidia.","Trichophyton | ",,,,,,,,,,,,,,,"4228685","Trichophyton",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1029075","Kocuria rhizophila","C127307","No value exists.","Kocuria rhizophila | KOCURIA RHIZOPHILA",,,,,,,,,,,,,,,"4161534","Kocuria rhizophila",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509650","Quantitative Ultrasound Spectroscopy","C127309","An application of conventional frequency spectroscopic ultrasound data that uses ultrasound backscattered radiofrequency (RF) signals to determine the bioacoustic properties of the underlying tissue for characterizing its microstructure.","Quantitative Ultrasound Spectroscopy | QUS | Quantitative Ultrasound Imaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507888","EGFR/HER2 inhibitor AP32788","C126752","An orally available inhibitor of human epidermal growth factor receptor (EGFR) exon 20 insertion mutations, with antineoplastic activity. Upon oral administration, mobocertinib, and its active metabolites, specifically and irreversibly binds to and inhibits exon 20 insertion mutations of EGFR. This prevents EGFR-mediated signaling and leads to cell death in tumor cells expressing exon 20 insertion mutations. In addition, mobocertinib may inhibit the activity of other EGFR family members, such as human epidermal growth factor receptor 2 (HER2; ERBB2) and HER4. EGFR, HER-2 and -4 are receptor tyrosine kinases often mutated in numerous tumor cell types. They play key roles in tumor cell proliferation and tumor vascularization.","Mobocertinib | AP 32788 | AP-32788 | AP32788 | EGFR/HER2 Inhibitor TAK-788 | MOBOCERTINIB | TAK 788 | TAK-788 | TAK788",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508783","FACT-G Version 4 - My Work Is Fulfilling","C127442","Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Functional Well-Being: My work (include work at home) is fulfilling.","FACT-G Version 4 - My Work Is Fulfilling | FAC001-My Work Is Fulfilling | FAC00122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508764","FACT-G Version 4 - I Am Able to Enjoy Life","C127443","Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Functional Well-Being: I am able to enjoy life.","FACT-G Version 4 - I Am Able to Enjoy Life | FAC001-I Am Able to Enjoy Life | FAC00123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508776","FACT-G Version 4 - I Have Accepted My Illness","C127444","Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Functional Well-Being: I have accepted my illness.","FACT-G Version 4 - I Have Accepted My Illness | FAC001-I Have Accepted My Illness | FAC00124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508768","FACT-G Version 4 - I Am Sleeping Well","C127445","Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Functional Well-Being: I am sleeping well.","FACT-G Version 4 - I Am Sleeping Well | FAC001-I Am Sleeping Well | FAC00125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508763","FACT-G Version 4 - Enjoy Things I Usually Do for Fun","C127446","Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Functional Well-Being: I am enjoying the things I usually do for fun.","FACT-G Version 4 - Enjoy Things I Usually Do for Fun | FAC001-Enjoy Things I Usually Do for Fun | FAC00126",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508762","FACT-G Version 4 - Content With Quality of My Life","C127447","Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Functional Well-Being: I am content with the quality of my life right now.","FACT-G Version 4 - Content With Quality of My Life | FAC001-Content With Quality of My Life | FAC00127",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509496","NCCN-FACT-FPSI 17 Version 2 - I Have a Lack of Energy","C127448","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I have a lack of energy.","NCCN-FACT-FPSI 17 Version 2 - I Have a Lack of Energy | FAC052-I Have a Lack of Energy | FAC05201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509492","NCCN-FACT-FPSI 17 Version 2 - I Have Pain","C127449","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I have pain.","NCCN-FACT-FPSI 17 Version 2 - I Have Pain | FAC052-I Have Pain | FAC05202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509490","NCCN-FACT-FPSI 17 Version 2 - I Have Difficulty Urinating","C127450","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I have difficulty urinating.","NCCN-FACT-FPSI 17 Version 2 - I Have Difficulty Urinating | FAC052-I Have Difficulty Urinating | FAC05203",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509485","NCCN-FACT-FPSI 17 Version 2 - I Am Losing Weight","C127451","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I am losing weight.","NCCN-FACT-FPSI 17 Version 2 - I Am Losing Weight | FAC052-I Am Losing Weight | FAC05204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509489","NCCN-FACT-FPSI 17 Version 2 - I Have Bone Pain","C127452","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I have bone pain.","NCCN-FACT-FPSI 17 Version 2 - I Have Bone Pain | FAC052-I Have Bone Pain | FAC05205",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509488","NCCN-FACT-FPSI 17 Version 2 - I Feel Fatigued","C127453","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I feel fatigued.","NCCN-FACT-FPSI 17 Version 2 - I Feel Fatigued | FAC052-I Feel Fatigued | FAC05206",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509494","NCCN-FACT-FPSI 17 Version 2 - I Have Weakness in My Legs","C127454","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I have weakness in my legs.","NCCN-FACT-FPSI 17 Version 2 - I Have Weakness in My Legs | FAC052-I Have Weakness in My Legs | FAC05207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508239","GAIA Level of Diagnostic Certainty","C126828","A classification of maternal and fetal outcomes developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.","GAIA Level of Diagnostic Certainty | Global Alignment of Immunization safety Assessment in pregnancy Level of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508240","GAIA Neonatal Case Definitions","C126830","A set of terms and defintions created by the Global Alignment of Immunization safety Assessment in pregnancy that are related to the neonatal effects of immunizations.","GAIA Neonatal Case Definitions | Global Alignment of Immunization safety Assessment in pregnancy Neonatal Case Definitions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013574","Ectoderm","C12703","The outer of the three germ layers of the embryo; it gives rise to epidermis and neural tissue.","Ectoderm | Ectodermal",,,,,,,,,,,,,,,"4269339","Ectoderm structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL507962","ADGRE1 Gene","C126950","This gene is involved in immunity, cell adhesion and G protein-coupled receptor signaling.","ADGRE1 Gene | ADGRE1 | Adhesion G Protein-Coupled Receptor E1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419254","RAMP1 Gene","C127136","This gene is involved in the localization of calcitonin gene-related peptide type 1 receptor.","RAMP1 Gene | RAMP1 | Receptor Activity Modifying Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509664","RAMP1 wt Allele","C127137","Human RAMP1 wild-type allele is located within 2q36-q37.1 and is approximately 53 kb in length. This allele, which encodes receptor activity-modifying protein 1, plays a role in the modulation of ligand-dependent signaling.","RAMP1 wt Allele | Receptor (Calcitonin) Activity Modifying Protein 1 Gene | Receptor (G Protein-Coupled) Activity Modifying Protein 1 Gene | Receptor Activity Modifying Protein 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1570780","Receptor Activity-Modifying Protein 1, Human","C127138","Receptor activity-modifying protein 1 (148 aa, ~17 kDa) is encoded by the human RAMP1 gene. This protein is involved in the transport of calcitonin gene-related peptide type 1 receptor to the plasma membrane.","Receptor Activity-Modifying Protein 1 | CRLR Activity-Modifying Protein 1 | Calcitonin-Receptor-Like Receptor Activity-Modifying Protein 1 | RAMP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507890","Autologous Tumor-associated Peptide Antigen-pulsed Dendritic Cell Vaccine","C126797","A dendritic cell (DC)-based cancer vaccine composed of autologous DCs pulsed with specific tumor-associated peptide antigens (TAPA), with potential immunostimulatory and antineoplastic activities. Upon administration, autologous TAPA-pulsed DC vaccine exposes the immune system to the specific TAPAs, which may result in cytotoxic T-lymphocyte (CTL)-mediated immune responses against the TAPA-expressing cancer cells. This leads to cancer cell lysis. This vaccine is specific towards peptides derived from the following proteins: sperm autoantigenic protein 17 (SP17), ropporin, A-kinase anchor protein 4 (AKAP4), pituitary tumor-transforming 1 (PTTG1) and SPANX family member B (SPANX-B).","Autologous Tumor-associated Peptide Antigen-pulsed Dendritic Cell Vaccine | Autologous TAPA loaded DC Vaccine | Autologous TAPA-pulsed DC Vaccine KiroVAX | Autologous Tumor Associated Peptide Antigen-pulsed DC Vaccine KiroVAX | KiroVAX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3180849","Pol I inhibitor CX5461","C126798","An orally bioavailable inhibitor of RNA polymerase I (Pol I), with potential antineoplastic activity. Upon oral administration, pidnarulex selectively binds to and inhibits Pol I, prevents Pol I-mediated ribosomal RNA (rRNA) synthesis, induces apoptosis, and inhibits tumor cell growth. Pol I, the multiprotein complex that synthesizes rRNA, is upregulated in cancer cells and plays a key role in cell proliferation and survival. Hyperactivated rRNA transcription is associated with uncontrolled cancer cell proliferation.","Pidnarulex | 2-(4-Methyl-1,4-diazepan-1-yl)-N-((5-methylpyrazin-2-yl)methyl)-5-oxo-5H-benzo[4,5]thiazolo[3,2-a][1,8]naphthyridine-6-carboxamide | 2-(4-Methyl-1,4-diazepan-1-yl)-N-[(5-methylpyrazin-2-yl)methyl]-5-oxo-[1,3]benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide | 5H-Benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide, 2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-N-[(5-methyl-2-pyrazinyl)methyl]-5-oxo- | CX-5461 | CX5461 | PIDNARULEX | Pol I Inhibitor CX5461 | RNA Pol I Inhibitor CX5461",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1676862","Dostarlimab","C126799","A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, dostarlimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells. PD-1, a transmembrane protein in the Ig superfamily expressed on T-cells, functions as an immune checkpoint protein that negatively regulates T-cell activation and T-cell-mediated immune responses when activated by its ligands programmed cell death receptor ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","Dostarlimab | ANB011 | DOSTARLIMAB | Dostarlimab-gxly | Immunoglobulin G4, Anti-programmed Cell Death Protein 1 (PDCD1) (Humanized Clone ABT1 Gamma4-chain), Disulfide with Humanized Clone ABT1 Kappa-chain, Dimer | Jemperli | TSR 042 | TSR-042 | TSR042",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507895","CEBPA-targeting saRNA MTL-CEBPA Liposome","C126800","A lipid-based nanoparticle formulation composed of liposomes encapsulating a small oligonucleotide encoding a small activating RNA (saRNA) targeting the CCAAT enhancer binding protein alpha (CEBPA; C/EBP-a) gene, with potential antineoplastic activity. Although the exact mechanism of action through which saRNAs exert their effect(s) is still largely being investigated, it appears that, upon administration, the CEBPA-targeting saRNA MTL-CEBPA liposome targets and binds to a specific DNA regulatory target region, most likely the promoter region, for the CEBPA gene. This restores CEBPA gene transcription, and increases both CEBPA mRNA levels and protein expression. This in turn activates the expression of tumor suppressor genes and may halt proliferation of susceptible tumor cells. Specifically, upregulation of CEBPA in liver cells abrogates liver cancer cell proliferation, thereby prevents liver failure and normalizes liver function. CEBPA, a transcription factor that plays a key role in the regulation of the expression of genes with many functions, including those involved in cellular proliferation, metastasis and normal hepatocyte function, is found in many tissues, including liver cells, adipose tissue and myeloid cells. CEBPA is downregulated in certain types of cancer cells, such as liver cancer cells. saRNA is a short, double-stranded RNA that is structurally related to siRNAs; saRNA is most likely to bind to a target site on the promoter of the CEBPA gene and upregulates its gene expression.","CEBPA-targeting saRNA MTL-CEBPA Liposome | MTL-501 | MTL-CEBPA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508238","Atypical Endometriosis","C127048","A precancerous lesion characterized by the presence of atypical glandular epithelial features in foci of endometriosis. Atypical endometriosis has been observed in contiguity with carcinomas.","Atypical Endometriosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508106","t(10;17)(q22;p13)","C127049","A cytogenetic abnormality that refers to the translocation of the long arm (q22) of chromosome 10 and the short arm (p13) of chromosome 17. It results in an YWHAE-FAM22 fusion. It has been described in high grade endometrial stromal sarcomas and a subset of clear cell sarcomas of the kidney.","t(10;17)(q22;p13) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508102","YWHAE-FAM22 Fusion Protein Expression","C127050","Expression of fusion protein YWHAE-FAM22 transcripts resulting from a t(10;17)(q22;p13). The translocation results in rearrangement of the YWHAE gene on chromosome 17 and FAM22 gene on chromosome 10. It has been described in high grade endometrial stromal sarcomas and a subset of clear cell sarcomas of the kidney.","YWHAE-FAM22 Fusion Protein Expression | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509330","CDISC SDTM Contact Role for Clinical Study Terminology","C127257","Terminology associated with the contact role for clinical study codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Contact Role for Clinical Study Terminology | CONROL | Contact Role for Clinical Study | SDTM-CONROL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2930997","Congenital Disorder of Glycosylation Type Ic","C126869","A congenital disorder of glycosylation sub-type caused by mutation(s) in the ALG6 gene, encoding dolichyl pyrophosphate Man9GlcNAc2 alpha-1,3-glucosyltransferase.","Congenital Disorder of Glycosylation Type Ic | CDGIc",,,,,,,,,,,,,,,"46271312","Congenital disorder of glycosylation type 1c",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1832736","Congenital Disorder of Glycosylation Type Id","C126870","A congenital disorder of glycosylation subtype caused by mutation(s) in the ALG3 gene, encoding dol-P-Man:Man(5)GlcNAc(2)-PP-Dol alpha-1,3-mannosyltransferase.","Congenital Disorder of Glycosylation Type Id | CDGId",,,,,,,,,,,,,,,"36715346","ALG3 congenital disorder of glycosylation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1837396","Congenital Disorder of Glycosylation Type Ie","C126871","A congenital disorder of glycosylation sub-type caused by mutation(s) in the DPM1 gene, encoding dolichol-phosphate mannosyltransferase subunit 1.","Congenital Disorder of Glycosylation Type Ie | CDGIe",,,,,,,,,,,,,,,"37110735","Congenital disorder of glycosylation type 1e",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1836669","Congenital Disorder of Glycosylation Type If","C126872","A congenital disorder of glycosylation sub-type caused by mutation(s) in the MPDU1 gene, encoding mannose-P-dolichol utilization defect 1 protein.","Congenital Disorder of Glycosylation Type If | CDGIf",,,,,,,,,,,,,,,"37119231","Congenital disorder of glycosylation type 1f",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2931001","Congenital Disorder of Glycosylation Type Ig","C126873","A congenital disorder of glycosylation sub-type caused by mutation(s) in the ALG12 gene, dol-P-Man:Man(7)GlcNAc(2)-PP-Dol alpha-1,6-mannosyltransferase.","Congenital Disorder of Glycosylation Type Ig | CDGIg",,,,,,,,,,,,,,,"46272739","ALG12-congenital disorder of glycosylation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2931004","Congenital Disorder of Glycosylation Type Ij","C126874","A congenital disorder of glycosylation sub-type caused by mutation(s) in the DPAGT1 gene, encoding UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferase.","Congenital Disorder of Glycosylation Type Ij | CDGIj",,,,,,,,,,,,,,,"37110736","Congenital disorder of glycosylation type 1j",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017925","Glycogen Storage Disease Type VI","C126875","An autosomal recessive sub-type of glycogen storage disease caused by mutation(s) in the PYGL gene, encoding glycogen phosphorylase, liver form. The condition is characterized by mild-moderate hypoglycemia, growth retardation and hepatomegaly.","Glycogen Storage Disease Type VI | ",,,,,,,,,,,,,,,"4163346","Glycogen storage disease, type VI",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0432230","Langer Mesomelic Dysplasia","C126876","An autosomal recessive condition caused by mutation (s) in the SHOX gene, encoding short stature homeobox protein. The condition is characterized by shortening of the bones of the middle segments of the limbs.","Langer Mesomelic Dysplasia | Langer Syndrome | Langer Type Mesomelic Dysplasia",,,,,,,,,,,,,,,"4242871","Langer mesomelic dysplasia syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014522","Epidermodysplasia Verruciformis","C126877","An extremely rare skin disorder usually inherited in an autosomal recessive pattern and caused by mutation(s) in the TMC6 or TMC8 gene, encoding transmembrane channel-like protein 6 and transmembrane channel-like protein 8, respectively. It is characterized by chronic human papillomavirus infection. Patients develop papillomatous wart-like lesions and pigmented plaques on the skin. It predisposes to cutaneous carcinomas, especially in situ and invasive squamous cell carcinomas.","Epidermodysplasia Verruciformis | EV | Lewandowsky-Lutz Dysplasia",,,,,,,,,,,,,,,"4078931","Epidermodysplasia verruciformis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508908","ME1 wt Allele","C127140","Human ME1 wild-type allele is located in the vicinity of 6q12 and is approximately 221 kb in length. This allele, which encodes NADP-dependent malic enzyme protein, is involved in glycolysis, the citric acid cycle and fatty acid biogenesis.","ME1 wt Allele | HUMNDME | MES | Malate Dehydrogenase (Oxaloacetate-Decarboxylating) (NADP(+)) Gene | Malate Dehydrogenase, NADP(+)-Dependent, Soluble Gene | Malic Enzyme 1 wt Allele | Malic Enzyme 1, NADP(+)-Dependent, Cytosolic Gene | Malic Enzyme 1, Soluble Gene | Malic Enzyme, Cytoplasmic Gene | Malic Enzyme, NADP(+)-Dependent, Cytosolic Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509805","NADP-Dependent Malic Enzyme, Human","C127141","NADP-dependent malic enzyme (572 aa, ~64 kDa) is encoded by the human ME1 gene. This protein plays a role in the oxidative decarboxylation of malate.","NADP-Dependent Malic Enzyme | EC 1.1.1.40 | ME1 | Malate Dehydrogenase | Malic Enzyme 1 | NADP-ME | Pyruvic-Malic Carboxylase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086816","Respiratory System Findings Planned End of Assessment Interval","C123964","The period of time that the respiratory system assessment, done over an interval of time, is intended to finish.","Respiratory System Findings Planned End of Assessment Interval | REENINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086269","Exclude Cardiovascular System Findings Data From Statistics Indicator","C123967","Specifies whether the cardiovascular system result values should be excluded from the statistical analysis.","Exclude Cardiovascular System Findings Data From Statistics Indicator | CVEXCLFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087091","Tanner Scale-Girl Clinical Classification Question","C124690","A question associated with the Tanner Scale-Girl clinical classification.","Tanner Scale-Girl Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085921","ASCVD 10-Year Risk Estimator Clinical Classification Question","C124691","A question associated with the ASCVD 10-Year Risk Estimator clinical classification.","ASCVD 10-Year Risk Estimator Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0045396","2,3-Dinor-6-Ketoprostaglandin F1alpha","C126898","A beta-oxidation product of 6-keto prostaglandin F1 alpha (PGF1a) and the major urinary metabolite of prostaglandin I2 (prostacyclin, PGI2). 2,3-dinor-6-ketoprostaglandin F1alpha in urine is often used as a correlative marker to indirectly measure prostacyclin production.","2,3-Dinor-6-Ketoprostaglandin F1alpha | 2,3-Dinor-6-Keto-Pgf1alpha | 2,3-Dinor-6-Oxo-Pgf1alpha | 2,3-Dinor-6-Oxoprostaglandin F1alpha | 2,3-Dkpgf1alpha | 2,3d-6K-PGF1alpha | Cyclopentanepentanoic Acid, 3,5-Dihydroxy-2-((1E,3S)-3-Hydroxy-1-Octenyl)-Gamma-Oxo-, (1R,2R,3R,5S)- | Cyclopentanepentanoic Acid, 3,5-Dihydroxy-2-(3-Hydroxy-1-Octenyl)-Gamma-Oxo-, (1R-(1alpha,2beta(1E,3S*),3alpha,5alpha))- | PGI2-M | Pgi2-M",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0077375","Trofosfamide","C1268","An orally bioavailable oxazaphosphorine prodrug with antineoplastic activity. Trofosfamide (TFF) is metabolized predominantly to the cyclophosphamide analogue ifosfamide (IFO), which is then metabolized by liver cytochrome P450s to the active isophosphoramide mustard (IPM). IPM alkylates DNA to form DNA-DNA cross-links, which may result in inhibition of DNA, RNA and protein synthesis, and ultimately lead to tumor cell apoptosis.","Trofosfamide | 2-[bis(2-chloroethyl)amino]-3-(2-chloroethyl)tetrahydro-2H-1,3,2-oxaphosphorine 2-oxide | 2H-1,3,2-Oxazaphosphorin-2-amine, N,N, 3-tris(2-chloroethyl)tetrahydro-, 2-oxide, (+)- | 2H-1,3,2-Oxazaphosphorin-2-amine, N,N, 3-tris(2-chloroethyl)tetrahydro-, 2-oxide, (-)- | A-4828 | Genoxal Trofosfamida | Ixoten | N,N,3-tris(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide | N,N,N'-tris(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide | TROFOSFAMIDE | Trilophosphamide | Trofosfamid | Trophosphamide | Z 4828 | Z-4828",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086137","Cardiovascular System Findings Planned Time Point Number","C124031","The numerical identifier of a cardiovascular system finding point in time.","Cardiovascular System Findings Planned Time Point Number | CVTPTNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086819","Respiratory System Findings Planned Time Point Number","C124032","The numerical identifier of a respiratory system finding point in time.","Respiratory System Findings Planned Time Point Number | RETPTNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086342","GCS01-Confounder: Hypoxia/Hypotension","C124732","Glasgow Coma Scale-NINDS Version 1.0 (GCS NINDS Version 1.0) GCS Confounder Type: hypoxia or hypotension.","Glasgow Coma Scale-NINDS Version 1.0 - Confounder: Hypoxia or Hypotension | GCS NINDS Version - Confounder: Hypoxia or Hypotension | GCS01-Confounder: Hypoxia/Hypotension | GCS0105E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086341","GCS0105F","C124733","Glasgow Coma Scale-NINDS Version 1.0 (GCS NINDS Version 1.0) GCS Confounder Type: hypothermia.","Glasgow Coma Scale-NINDS Version 1.0 - Confounder: Hypothermia | GCS NINDS Version - Confounder: Hypothermia | GCS01-Confounder: Hypothermia | GCS0105F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086344","GCS01-Confounder: Sedation","C124734","Glasgow Coma Scale-NINDS Version 1.0 (GCS NINDS Version 1.0) GCS Confounder Type: sedation.","Glasgow Coma Scale-NINDS Version 1.0 - Confounder: Sedation | GCS NINDS Version - Confounder: Sedation | GCS01-Confounder: Sedation | GCS0105G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086345","GCS01-Confounder: Unknown","C124735","Glasgow Coma Scale-NINDS Version 1.0 (GCS NINDS Version 1.0) GCS Confounder Type: unknown.","Glasgow Coma Scale-NINDS Version 1.0 - Confounder: Unknown | GCS NINDS Version - Confounder: Unknown | GCS01-Confounder: Unknown | GCS0105H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086106","CRS-R - Diagnosis","C124736","JFK Coma Recovery Scale-Revised (CRS-R) Diagnosis.","CRS-R - Diagnosis | CRSR01-Diagnosis | CRSR0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086107","CRS-R - Etiology","C124737","JFK Coma Recovery Scale-Revised (CRS-R) Etiology.","CRS-R - Etiology | CRSR01-Etiology | CRSR0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086105","CRS-R - Date of Onset","C124738","JFK Coma Recovery Scale-Revised (CRS-R) Date of onset.","CRS-R - Date of Onset | CRSR01-Date of Onset | CRSR0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086104","CRS-R - Date of Admission","C124739","JFK Coma Recovery Scale-Revised (CRS-R) Date of admission.","CRS-R - Date of Admission | CRSR01-Date of Admission | CRSR0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086102","CRS-R - Auditory Function Scale","C124740","JFK Coma Recovery Scale-Revised (CRS-R) Auditory function scale.","CRS-R - Auditory Function Scale | CRSR01-Auditory Function Scale | CRSR0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087002","CRS-R - Visual Function Scale","C124741","JFK Coma Recovery Scale-Revised (CRS-R) Visual function scale.","CRS-R - Visual Function Scale | CRSR01-Visual Function Scale | CRSR0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086108","CRS-R - Motor Function Scale","C124742","JFK Coma Recovery Scale-Revised (CRS-R) Motor function scale.","CRS-R - Motor Function Scale | CRSR01-Motor Function Scale | CRSR0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086109","CRS-R - Oromotor/Verbal Function","C124743","JFK Coma Recovery Scale-Revised (CRS-R) Oromotor/verbal function scale.","CRS-R - Oromotor/Verbal Function | CRSR01-Oromotor/Verbal Function | CRSR0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086103","CRS-R - Communication Scale","C124744","JFK Coma Recovery Scale-Revised (CRS-R) Communication scale.","CRS-R - Communication Scale | CRSR01-Communication Scale | CRSR0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086101","CRS-R - Arousal Scale","C124745","JFK Coma Recovery Scale-Revised (CRS-R) Arousal scale.","CRS-R - Arousal Scale | CRSR01-Arousal Scale | CRSR0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086110","CRS-R - Total Score","C124746","JFK Coma Recovery Scale-Revised (CRS-R) Total score.","CRS-R - Total Score | CRSR01-Total Score | CRSR0111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087066","PANSS - Delusions","C124747","Positive and Negative Syndrome Scale (PANSS) Temperature - Delusions.","PANSS - Delusions | PANSS1-Delusions | PANSS101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0685706","Membranous Ventricular Septal Defect","C124556","A congenital heart defect resulting from deficient growth or failure of fusion of the membranous component of the ventricular septum.","Membranous Ventricular Septal Defect | ",,,,,,,,,,,,,,,"4312035","Membranous ventricular septum defect",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0266456","Encephalomeningocele","C124557","A congenital neural tube closure defect resulting in the protrusion of the brain and meninges through a skull opening.","Encephalomeningocele | MENINGOENCEPHALOCELE | Meningoencephalocele",,,,,,,,,,,,,,,"4182061","Meningoencephalocele",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4087051","Meningohydroencephalocele","C124558","A congenital neural tube closure defect resulting in protrusion of the brain, the meninges, and the ventricular system through an opening in the skull, usually involving the squamous part of the occipital bone..","Meningohydroencephalocele | MENINGOHYDROENCEPHALOCELE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1275957","Misalignment","C124559","Abnormallly positioned or aligned in relation to another structure.","Misalignment | MISALIGNED | Malaligned | Misaligned",,,,,,,,,,,,,,,"4290827","Misalignment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086614","Multiple Malformations","C124561","The presence of more than one malformed entities or structures.","Multiple Malformations | MULTIPLE MALFORMATIONS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503122","Multiple Abnormalities","C124562","The presence of more than one anomaly.","Multiple Abnormalities | MULTIPLE VARIATIONS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0685707","Muscular Ventricular Septal Defect","C124563","A congenital heart defect resulting from deficient growth or failure of fusion of the muscular component of the ventricular septum.","Muscular Ventricular Septal Defect | ",,,,,,,,,,,,,,,"4315819","Muscular ventricular septum defect",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0333164","Narrow","C124564","Having a width, or side to side dimension, that is less than is normally expected.","Narrow | Coarctation | Constricted | NARROW",,,,,,,,,,,,,,,"4047534","Narrow",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086908","Tooth Not Erupted","C124565","A finding that a tooth has not emerged.","Tooth Not Erupted | NOT ERUPTED TOOTH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL497338","Open Eye","C124567","A finding in which the eye appears open at birth, either due to the congenital absence of eyelids or incomplete fusion of the eyelid.","Open Eye | Lid Gap",,,,,,,,,,,,,,,"4028337","Ablepharon",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265242","Otocephaly","C124568","A fatal, congenital, anatomic defect of the head characterised by a total or near total absence of the lower jaw, resulting in the union or close approach of the ears on the ventral side of the neck.","Otocephaly | OTOCEPHALY",,,,,,,,,,,,,,,"4167843","Otocephalic syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265886","Overriding Aorta","C124569","A congenital anatomic anomaly in which the aorta is positioned directly above a ventricular septal defect, thus receiving blood from both the right and left ventricles, resulting in an overall decrease In oxygenated haemoglobin and tissue cyanosis.","Overriding Aorta | ",,,,,,,,,,,,,,,"4273708","Overriding aorta",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512085","Ductal Epithelial Cell","C12479","A stratified columnar epithelial cell that surrounds a lumen in a gland such as the breast, pancreas or prostate. These cells are uniform in appearance and have uniformly sized and shaped nuclei.","Ductal Epithelial Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0076189","Testosterone Enanthate","C1247","A long-acting intramuscular form of the androgen testosterone. Testosterone inhibits gonadotropin secretion from the pituitary gland and ablates estrogen production in the ovaries, thereby decreasing endogenous estrogen levels. In addition, this agent promotes the maintenance of male sex characteristics and is indicated for testosterone replacement in hypogonadal males, delayed puberty, and metastatic mammary cancer. (NCI04)","Testosterone Enanthate | Andro LA | Androtardyl | Delatestryl | Everone | Primosteston | TESTOSTERONE ENANTHATE | Testate | Testinon | Testo-Enant | Testosterone enanthate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086607","Mouse Kidney Carcinoma","C124802","A carcinoma arising from the epithelium of the renal parenchyma or the renal pelvis of a mouse.","Mouse Kidney Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086081","CDISC SDTM Schizophrenia Findings About Test Code Terminology","C124302","Terminology associated with the schizophrenia findings about test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Schizophrenia Findings About Test Code Terminology | SDTM-SZFATSCD | SZFATSCD | Schizophrenia Findings About Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507903","EZH1/2 inhibitor DS-3201","C127114","An orally available selective inhibitor of the histone lysine methyltransferases enhancer of zeste homolog 1 (EZH1) and 2 (EZH2), with potential antineoplastic activity. Upon oral administration, valemetostat selectively inhibits the activity of both wild-type and mutated forms of EZH1 and EZH2. Inhibition of EZH1/2 specifically prevents the methylation of lysine 27 on histone H3 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways, enhances transcription of certain target genes, and results in decreased proliferation of EZH1/2-expressing cancer cells. EZH1/2, histone lysine methyltransferase (HMT) class enzymes and catalytic subunits of the polycomb repressive complex 2 (PRC2), are overexpressed or mutated in a variety of cancer cells and play key roles in tumor cell proliferation, progression, stem cell self-renewal and migration.","Valemetostat | DS 3201 | DS-3201 | DS3201 | VALEMETOSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507905","Autologous Neuroblastoma Lysate/KLH-pulsed Dendritic Cell Vaccine","C127115","A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with a cell lysate from an autologous neuroblastoma containing tumor-associated antigens (TAAs) and the immunostimulant keyhole limpet hemocyanin (KLH), with potential immunostimulatory and antineoplastic activities. Upon administration, autologous neuroblastoma lysate/KLH-pulsed DC vaccine may stimulate the immune system to mount an anti-tumoral cytotoxic T-lymphocyte (CTL) response against neuroblastoma cells, which may result in tumor cell lysis. KLH is an immunogenic carrier and serves as an immunostimulant to improve antigenic immune recognition and T-cell responses.","Autologous Neuroblastoma Lysate/KLH-pulsed Dendritic Cell Vaccine | Autologous Neuroblastoma Lysate/KLH-pulsed DC Vaccine | Keyhole Limpet Hemocyanin-pulsed Dendritic Cell Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507907","Mucoadhesive Hydrogel Gargle","C127117","An oral rinse composed of a viscous, mucoadhesive hydrogel, with potential protective and antimucositis activities. Upon gargling with the oral viscous mucoadhesive hydrogel formulation in the oral cavity, the hydrogel forms a protective barrier over the oral mucosa, which prevents inflammation of the mucosal membranes and may decrease chemotherapy- and/or radiation-induced oral mucositis.","Mucoadhesive Hydrogel Gargle | FORRAD | Oral Ulcer Gargle | Oral Viscous Mucoadhesive Hydrogel Gargle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086687","PANSS - Conceptual Disorganization","C124748","Positive and Negative Syndrome Scale (PANSS) Temperature - Conceptual disorganization.","PANSS - Conceptual Disorganization | PANSS1-Conceptual Disorganization | PANSS102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086693","PANSS - Excitement","C124750","Positive and Negative Syndrome Scale (PANSS) Temperature - Excitement.","PANSS - Excitement | PANSS1-Excitement | PANSS104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084735","LILRB1 wt Allele","C124241","Human LILRB1 wild-type allele is located in the vicinity of 19q13.4 and is approximately 127 kb in length. This allele, which encodes leukocyte immunoglobulin-like receptor subfamily B member 1 protein, plays a role in the inhibition of immune responses.","LILRB1 wt Allele | CD85J | ILT-2 | ILT2 | LIR-1 | LIR1 | Leukocyte Immunoglobulin-Like Receptor, Subfamily B (With TM and ITIM Domains), Member 1 wt Allele | Leukocyte Immunoglobulin-Like Receptor, Subfamily B, Member 1 Gene | MIR-7 | MIR7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1741325","Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 1, Human","C124242","Leukocyte immunoglobulin-like receptor subfamily B member 1 (650 aa, ~71 kDa) is encoded by the human LILRB1 gene. This protein is involved in the modulation of class I MHC-dependent immune responses.","Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 1 | CD85 Antigen-Like Family Member J | CD85j | CD85j Antigen | ILT-2 | Ig-Like Transcript 2 | Immunoglobulin-Like Transcript 2 | LILRB1 | LIR-1 | Leukocyte Immunoglobulin-Like Receptor 1 | MIR-7 | Monocyte/Macrophage Immunoglobulin-Like Receptor 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085186","CMA1 wt Allele","C124244","Human CMA1 wild-type allele is located in the vicinity of 14q11.2 and is approximately 3 kb in length. This allele, which encodes chymase protein, is involved in the metabolism of both vasoactive peptides and the extracellular matrix.","CMA1 wt Allele | CYH | CYM | Chymase 1, Mast Cell wt Allele | Chymase Gene | Chymase, Heart Gene | Chymase, Mast Cell Gene | MCT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1699434","Chymase, Human","C124245","Chymase (247 aa, ~27 kDa) is encoded by the human CMA1 gene. This protein plays a role in vasoactive peptide synthesis and extracellular matrix degradation.","Chymase | Alpha-Chymase | CMA1 | EC 3.4.21.39 | Mast Cell Protease I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086885","TPSB2 wt Allele","C124247","Human TPSB2 wild-type allele is located in the vicinity of 16p13.3 and is approximately 3 kb in length. This allele, which encodes tryptase beta-2 protein, plays a role in the proteolytic activity of mast cell granules.","TPSB2 wt Allele | TPS2 | Tryptase Beta 2 (Gene/Pseudogene) wt Allele | Tryptase, Beta Gene | Tryptase, Beta-2 Gene | Tryptase, Beta-II Gene | Tryptase, Beta-III Gene | TryptaseB Gene | TryptaseC Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503118","Tryptase Beta-2, Human","C124248","Tryptase beta-2 (275 aa, ~31 kDa) is encoded by the human TPSB2 gene. This protein is involved in protein degradation.","Tryptase Beta-2 | Chymase | EC 3.4.21.59 | Mast Cell Tryptase Beta II | Mast Cell Tryptase Beta III | TPSB2 | Tryptase Beta 2 | Tryptase Beta III | Tryptase II | Tryptase-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086114","Canine Mammary Carcinoma","C124249","Mammary carcinoma occurring in a dog.","Canine Mammary Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514389","Pregnant Uterus","C12406","A uterus containing one or more viable embryos or fetuses.","Pregnant Uterus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086293","FGFR2 Gene Product","C124074","A protein encoded by the FGFR2 gene.","FGFR2 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503027","Carbon C 14 Lenvatinib Mesylate","C124797","A radioconjugate composed of the orally bioavailable mesylate salt form of lenvatinib, a receptor tyrosine kinase (RTK) inhibitor, labeled with the radioisotope carbon C 14, with potential use for evaluating the pharmacokinetic profile of lenvatinib. Upon administration of carbon C14 lenvatinib mesylate, lenvatinib targets and binds strongly to multiple RTKs, including vascular endothelial growth factor receptor 1 (VEGFR1;FLT1), VEGFR2 (KDR), VEGFR3 (FLT4), fibroblast growth factor receptor 1 (FGFR1), FGFR2, FGFR3, and FGFR4, platelet derived growth factor receptor alpha (PDGFRa), KIT, and RET. This inhibits growth of tumor cells that overexpress these RTKs. Labeling of lenvatinib with the radioactive tracer carbon C 14 permits the evaluation of lenvatinib's pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME).","Carbon C 14 Lenvatinib Mesylate | 14C Lenvatinib Mesylate | 14C-lenvatinib Mesylate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1741339","Technetium Tc 99m-labeled Rhenium Sulfide Nanocolloid","C124799","A colloid formulation of rhenium sulfide that is labeled with the gamma-emitting epitope technetium Tc 99m (Tc-99m) with diagnostic imaging activity. Upon administration, the 99mTc-colloidal rhenium sulfide is taken up by the lymph nodes. This allows imaging of the lymphatic drainage pattern during lymphoscintigraphic or sentinel lymph node mapping procedures.","Technetium Tc 99m-labeled Rhenium Sulfide Nanocolloid | 99mTc-labeled Rhenium Sulfide Nanocolloid | Nanocis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086082","CDISC SDTM Schizophrenia Findings About Test Name Terminology","C124303","Terminology associated with the schizophrenia findings about test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Schizophrenia Findings About Test Name Terminology | SDTM-SZFATS | SZFATS | Schizophrenia Findings About Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085568","CDISC SDTM Treatment Intent Terminology","C124307","Terminology associated with the treatment intent codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Treatment Intent Terminology | SDTM-TRTINTNT | TRTINTNT | Treatment Intent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503141","CDISC SDTM Treatment Setting Terminology","C124308","Terminology associated with the treatment setting codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Treatment Setting Terminology | SDTM-TRTSET | TRTSET | Treatment Setting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086088","CDISC SEND Fetal Pathology Findings Result Terminology","C124310","Terminology associated with the fetal pathology findings result codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical data (SEND).","CDISC SEND Fetal Pathology Findings Result Terminology | FXFINDRS | Fetal Pathology Findings Result | SEND-FXFINDRS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086085","CDISC SEND Fetal Measurement Test Code Terminology","C124311","Terminology associated with the fetal measurement test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical data (SEND).","CDISC SEND Fetal Measurement Test Code Terminology | FMTESTCD | Fetal Measurement Test Code | SEND-FMTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086086","CDISC SEND Fetal Measurement Test Name Terminology","C124312","Terminology associated with the fetal measurement test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical data (SEND).","CDISC SEND Fetal Measurement Test Name Terminology | FMTEST | Fetal Measurement Test Name | SEND-FMTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086089","CDISC SEND Fetal Pathology Findings Test Code Terminology","C124314","Terminology associated with the fetal pathology findings test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical data (SEND).","CDISC SEND Fetal Pathology Findings Test Code Terminology | FXTESTCD | Fetal Pathology Findings Test Code | SEND-FXTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086090","CDISC SEND Fetal Pathology Findings Test Name Terminology","C124315","Terminology associated with the fetal pathology findings test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical data (SEND).","CDISC SEND Fetal Pathology Findings Test Name Terminology | FXTEST | Fetal Pathology Findings Test Name | SEND-FXTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507908","Cyanocobalamin/Dexamethasone/Gentamicin/Procaine Formulation","C127118","A quadruple mixture composed of the corticosteroid dexamethasone, the aminoglycoside antibiotic gentamicin, the vitamin cyanocobalamin (vitamin B12), and the local anesthetic agent procaine, with antimucositic activity. Upon oral administration of the cyanocobalamin/dexamethasone/gentamicin/procaine formulation, the active ingredients prevent or inhibit inflammation and infection of the oral mucosa and reduce the associated pain. This may prevent or treat radiation-induced oral mucositis (OM).","Cyanocobalamin/Dexamethasone/Gentamicin/Procaine Formulation | Cyanocobalamin/Dexamethasone/Gentamicin/Procaine Oral Formulation | Quadruple Mixture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509377","CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Name Terminology","C127355","Test names of questionnaire questions associated with the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Name Terminology | FAC052TN | QS-NCCN-FACT-FPSI 17 Version 2 TEST | The National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509376","CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Code Terminology","C127356","Test codes of questionnaire questions associated with the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Code Terminology | FAC052TC | QS-NCCN-FACT-FPSI 17 Version 2 TESTCD | The National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509375","CDISC Questionnaire FACT-P Version 4 Test Name Terminology","C127357","Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACT-P Version 4 Test Name Terminology | FAC023TN | QS-FACT-P Version 4 TEST | The Functional Assessment of Cancer Therapy-Prostate Version 4 Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509374","CDISC Questionnaire FACT-P Version 4 Test Code Terminology","C127358","Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACT-P Version 4 Test Code Terminology | FAC023TC | QS-FACT-P Version 4 TESTCD | The Functional Assessment of Cancer Therapy-Prostate Version 4 Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509294","CDISC Questionnaire PROSQOLI Test Name Terminology","C127359","Test names of questionnaire questions associated with the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PROSQOLI Test Name Terminology | PROS01TN | QS-PROSQOLI TEST | The Prostate Cancer Specific Quality of Life Instrument Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509293","CDISC Questionnaire PROSQOLI Test Code Terminology","C127360","Test codes of questionnaire questions associated with the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PROSQOLI Test Code Terminology | PROS01TC | QS-PROSQOLI TESTCD | The Prostate Cancer Specific Quality of Life Instrument Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508708","EPIC-26 Questionnaire Question","C127361","A question associated with the EPIC-26 questionnaire.","EPIC-26 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508731","EPIC-CP Questionnaire Question","C127362","A question associated with the EPIC-CP questionnaire.","EPIC-CP Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508788","FACT-G Version 4 Questionnaire Question","C127363","A question associated with the FACT-G Version 4 questionnaire.","FACT-G Version 4 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509499","NCCN-FACT-FPSI 17 Version 2 Questionnaire Question","C127364","A question associated with the NCCN-FACT-FPSI 17 Version 2 questionnaire.","NCCN-FACT-FPSI 17 Version 2 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086965","Woodchuck Hepatocellular Carcinoma","C124251","Hepatocellular carcinoma (HCC) occurring in a woodchuck, usually as a result of chronic infection by the woodchuck hepatitis virus. The woodchuck model of viral-induced HCC provides an animal model that resembles the complex human liver environment of HCC in the context of chronic hepatitis B viral infection.","Woodchuck Hepatocellular Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024838","Eastern Woodchuck","C124252","A burrowing rodent of the family Sciuridae, belonging to the group of large ground squirrels known as marmots. The woodchuck model of viral-induced hepatocellular carcinoma (HCC) provides an animal model that resembles the complex human liver environment of HCC in the context of chronic hepatitis B viral infection.","Eastern Woodchuck | Ground Hog | Groundhog | Marmota monax | Woodchuck",,,,,,,,,,,,,,,"4213578","Genus Marmota",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206407","Woodchuck Hepatitis Virus","C124253","A species of double-stranded, retro-transcribing viruses in the genus Orthohepadnavirus that is naturally capable of infecting the woodchuck Marmota monax.","Woodchuck Hepatitis Virus | WHV",,,,,,,,,,,,,,,"4170708","Woodchuck hepatitis B virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4085932","Abnormal Suture Line","C124490","Any line of sutures that deviates from its normal anatomical location.","Abnormal Suture Line | ABNORMAL SUTURE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085949","Altered Texture","C124491","A change resulting in a texture that is different from the original.","Altered Texture | ABNORMAL TEXTURE | Altered Surface Texture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085933","Absent Fissure","C124492","The lack of a long, narrow slit or groove that divides a tissue into distinct areas.","Absent Fissure | ABSENT FISSURE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0685897","Acephalostomia","C124493","A congenital defect characterized by the absence of most or all of the head, with the presence of a mouth-like opening on the upper thorax.","Acephalostomia | ACEPHALOSTOMIA",,,,,,,,,,,,,,,"4237529","Acephalostomia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2586048","Amniotic Band","C124494","One or more strands of fibrous amniotic tissue that can wrap around the fetus, causting constriction resulting in anatomic malformation.","Amniotic Band | AMNIOTIC BAND",,,,,,,,,,,,,,,"45772918","Amniotic adhesion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4085634","Aorticopulmonary Septal Defect","C124495","A congenital heart malformation characterised by incomplete separation of the truncus arteriosus and the aorticopulmonary trunk, resulting in communication between the aorta and pulmonary trunk.","Aorticopulmonary Septal Defect | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085997","Asymmetric Ossification","C124496","A finding of a lack of symmetry between two or more bilateral aligned primary ossific nuclei (ossification centers), typically indicated by greater stain uptake in one or more primary ossification centers as compared to others.","Asymmetric Ossification | ASYMMETRIC OSSIFICATION | Misaligned Ossification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0243066","Atresia","C124497","A congenital anatomic defect characterised by the absence of a normally present opening in an organ or tissue.","Atresia | ATRESIA | Atretic",,,,,,,,,,,,,,,"4208825","Congenital atresia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205133","Bent","C124498","A physical quality in which the entity or structure is bowed or curved.","Bent | BENT | Bending | Bowed | Curved",,,,,,,,,,,,,,,"4212937","Bent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086023","Bilobular","C124499","Of or pertaining to two lobes of an anatomic structure; divided into two lobes.","Bilobular | BILOBED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036316","Schistosoma haematobium","C124388","A species of flatworms in the family Schistosomatidae with a strong oral sucker and a smaller posterior ventral sucker. Adult males are around 10 mm and females are 15 mm in length. The life cycle of S. haematobium involves snails as the intermediate host and humans as the definitive host. Within the body infestation is usual seen in the venous plexus of bladder, but it can also be found in the rectal venules.","Schistosoma haematobium | SCHISTOSOMA HAEMATOBIUM",,,,,,,,,,,,,,,"4140213","Schistosoma haematobium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL498288","Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4","C123924","A T-cell receptor (TCR)-like monoclonal antibody against PR1, a 9 amino-acid (VLQELNVTV) human leukocyte antigen (HLA)-A2-restricted leukemia-associated antigen (LAA) derived from the myeloid leukemia-associated antigens proteinase 3 (P3) and neutrophil elastase (NE), with potential immunostimulating and antineoplastic activities. Upon administration, anti-PR1/HLA-A2 monoclonal antibody Hu8F4 selectively binds to a combined epitope of the PR1/HLA-A2 complex expressed on acute myeloid leukemia (AML) blasts and leukemic stem cells (LSC), and prevents PR1/HLA-A2-mediated signaling. This induces complement-dependent cytotoxicity (CDC), to a lesser extent, antibody-dependent cell-mediated cytotoxicity (ADCC), and CDC/ADCC-independent cytolysis of myeloid leukemia cells. This results in a reduction of cellular proliferation in PR1/HLA-A2-overexpressing leukemic cells. PR1 in combination with the HLA-A2 molecule is highly expressed on AML blasts and LSCs.","Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4 | HU8F4 | Hu8F4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498289","PI3K delta inhibitor PWT143","C123925","An orally bioavailable inhibitor of the delta isoform of phosphatidylinositide 3-kinase (PI3K), with potential antineoplastic activity. Upon oral administration, zandelisib selectively inhibits the delta isoform of PI3K and prevents the activation of the PI3K/AKT signaling pathway. This both decreases proliferation and induces cell death in PI3K-delta-overexpressing tumor cells. PI3K-delta plays a key role in the proliferation and survival of hematologic cancer cells. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.","Zandelisib | ME 401 | ME-401 | PI3K-delta Inhibitor PWT143 | PWT-143 | PWT143 | ZANDELISIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527845","Ezetimibe/Simvastatin","C123926","An orally bioavailable combination agent containing the cholesterol absorption inhibitor ezetimibe and the hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitor simvastatin, with lipid-lowering activity. Upon oral administration, ezetimibe binds to the sterol transporter Niemann-Pick C1-Like 1 (NPC1L1) at the brush border of the small intestine and inhibits the intestinal absorption of biliary and dietary cholesterol and related phytosterols. This decreases blood cholesterol levels, decreases the delivery of intestinal cholesterol to the liver, reduces hepatic cholesterol stores and enhances the clearance of cholesterol from the bloodstream. Upon administration of simvastatin and subsequent hydrolyzation to its active beta-hydroxyacid form, this statin competitively inhibits HMG-CoA reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, which is an essential step in cholesterol synthesis. Ezetimibe and simvastatin together reduce blood levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides (TGs), very-low-density lipoproteins (VLDL), and apolipoprotein B (Apo B), and increase the plasma concentration of high-density lipoprotein cholesterol (HDL-C). Higher cholesterol blood levels appear to be associated with an increased risk in the proliferation of certain cancer cells, such as prostate cancer cells.","Ezetimibe/Simvastatin | Butanoic Acid, 2,2-Dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl Ester, Mixture with (3R,4S)-1-(4-Fluorophenyl)-3-((3S)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)-2-azetidinone | Vytorin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498290","Pegfilgrastim Anti-neutropenic Factor","C123927","A long-acting, engineered and pegylated version of human granulocyte-colony stimulating factor (G-CSF), with potential hematopoietic activity. Similar to G-CSF, pegfilgrastim anti-neutropenic factor (ANF) binds to and activates specific cell surface receptors, and stimulates neutrophil progenitor proliferation and differentiation. Therefore, this agent may prevent the duration and incidence of chemotherapy-induced neutropenia. Compared to filgrastim, the conjugation with a branched polyethylene glycol molecule reduces renal clearance and increases its plasma half-life.","Pegfilgrastim Anti-neutropenic Factor | ANF-Rho | PEG G-CSF ANF | Pegfilgrastim ANF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332996","Persistent Embryonic Structure","C124570","An embryological structure that is retained past the usual embryonic stage.","Persistent Embryonic Structure | ",,,,,,,,,,,,,,,"4136522","Persistent embryonic structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL502820","Premature Closure","C124571","Fusion, stoppage, or loss of patency occurring before the usual or proper time.","Premature Closure | PREMATURE CLOSURE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3463932","Proboscis","C124572","An elongated appendage originating from the head of an animal; in invertebrates, the term most often references tubular mouthparts used for feeding and sucking, whilst in vertebrates, the term references an elongated nose or snout.","Proboscis | PROBOSCIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0685787","Prosoposchisis","C124573","A congenital anatomic defect characterised by a facial cleft that extends from the mouth to the orbit of the eye.","Prosoposchisis | PROSOPOSCHISIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085565","Protruding","C124574","Extending beyond a surface or boundary.","Protruding | PROTRUDING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033804","Pseudohermaphroditism","C124575","A condition consisting of possessing the internal reproductive organs of one sex while exhibiting some of the secondary sex characteristics of the opposite sex.","Pseudohermaphroditism | PSEUDOHERMAPHRODITISM",,,,,,,,,,,,,,,"4326589","Pseudohermaphroditism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086783","Red Material","C124576","Matter that is red in color.","Red Material | RED MATERIAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229197","Retinal Fold","C124578","A crease in the retina.","Retinal Fold | RETINAL FOLD | Retinal Folds",,,,,,,,,,,,,,,"4292421","Retinal fold",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086828","Retroesophageal","C124579","Denoting the area behind the esophagus.","Retroesophageal | RETROESOPHAGEAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152361","Epithalamus","C12457","A dorsal posterior section of the diencephalon that comprises the trigonum habenula, habenular commissure, stria medullaris, and pineal gland. The epithalamus is the connection between the limbic system and basal ganglia, and is involved in the secretion of melatonin and the regulation of motor pathways and emotions.","Epithalamus | ",,,,,,,,,,,,,,,"4209288","Epithalamic structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0685895","Rhinocephaly","C124580","A congenital anatomic defect characterised by the presence of a proboscis-like nose located above the eyes, which are partially or completely fused.","Rhinocephaly | RHINOCEPHALY",,,,,,,,,,,,,,,"4316069","Rhinocephaly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0444532","Right-Sided","C124581","Pertaining to the physical area of an object that is located to the right of its center.","Right-Sided | RIGHT-SIDED",,,,,,,,,,,,,,,"4141311","Right sided",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086851","Shared Placenta","C124582","A condition found in some polyzygotic pregnancies where two or more fetuses share a single placenta.","Shared Placenta | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086921","Unilobular","C124583","Having or posessing a single lobe.","Unilobular | SINGLE LOBE | Single Lobe | Single Lobed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086866","Splayed","C124584","Spread outward and apart.","Splayed | SPLAYED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086875","Supernumerary Fissure","C124585","An extraneous, additional long narrow slit or groove that divides an organ into lobes, or tissues and bone into parts.","Supernumerary Fissure | Additional Fissure | SUPERNUMERARY FISSURE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0685638","Thoracogastroschisis","C124586","A congenital fissure of both the thoracic and abdominal walls.","Thoracogastroschisis | THORACOGASTROSCHISIS | Thoracoceloschisis",,,,,,,,,,,,,,,"4244334","Thoracoceloschisis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0685639","Thoracoschisis","C124587","A congenital fissure of the thoracic wall.","Thoracoschisis | THORACOSCHISIS",,,,,,,,,,,,,,,"4319185","Thoracoschisis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1979891","Thread-Like","C124588","Resembling a thread.","Thread-Like | Filamentous | THREAD-LIKE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0344583","Cor Triloculare","C124589","A congenital anatomic anomaly in which the heart has only three chambers.","Cor Triloculare | ",,,,,,,,,,,,,,,"4068742","Cor triloculare",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4085924","ASSIGN Score Clinical Classification Question","C124692","A question associated with the ASSIGN Score clinical classification.","ASSIGN Score Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086296","FHS CVD 10-Year Risk Score Clinical Classification Question","C124693","A question associated with the FHS CVD 10-Year Risk Score clinical classification.","FHS CVD 10-Year Risk Score Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086831","Reynolds CVD 10-Year Risk Score Clinical Classification Question","C124694","A question associated with the Reynolds CVD 10-Year Risk Score clinical classification.","Reynolds CVD 10-Year Risk Score Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086962","West Haven Criteria Clinical Classification Question","C124695","A question associated with the West Haven Criteria clinical classification.","West Haven Criteria Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086349","GCS NINDS Version 1.0 Clinical Classification Question","C124696","A question associated with the GCS NINDS Version 1.0 clinical classification.","GCS NINDS Version 1.0 Clinical Classification Question | GCS NINDS Version Clinical Classification Question",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086111","CRS-R Clinical Classification Question","C124697","A question associated with the CRS-R clinical classification.","CRS-R Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086712","PANSS Clinical Classification Question","C124698","A question associated with the PANSS clinical classification.","PANSS Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086957","WHO Clinical Staging of HIV/AIDS for Adults and Adolescents Clinical Classification Question","C124699","A question associated with the WHO Clinical Staging of HIV/AIDS for Adults and Adolescents clinical classification.","WHO Clinical Staging of HIV/AIDS for Adults and Adolescents Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0076181","Testosterone Cypionate","C1246","An eight-carbon ester form of Testosterone. The number of ester carbon atoms correlate with the half-life of the prodrug.  Testosterone inhibits gonadotropin secretion from the pituitary gland and ablates estrogen production in the ovaries, thereby decreasing endogenous estrogen levels.  In addition, this agent promotes the maintenance of male sex characteristics and is indicated for testosterone replacement in hypogonadal males. (NCI04)","Testosterone Cypionate | 17Beta-Cyclopentanepropionate | Depo-Testosterone | Depo-testosterone | Depotest | Depovirin | Pertestis | TESTOSTERONE CYPIONATE | Testosterone cypionate | Virilon | depAndro",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086046","CDC Classification System for HIV-Infected Adults and Adolescents Clinical Classification Question","C124701","A question associated with the CDC Classification System for HIV-Infected Adults and Adolescents clinical classification.","CDC Classification System for HIV-Infected Adults and Adolescents Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087090","TMT Functional Test Question","C124702","A question associated with the TMT functional test.","TMT Functional Test Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0686763","Bipartite Ossification","C124500","A finding of two unfused primary ossification centers, as indicated by staining, usually resulting in two separate and distinct bones.","Bipartite Ossification | BIPARTITE OSSIFICATION",,,,,,,,,,,,,,,"36683257|4008490","Bipartite ossification|Bipartite ossification",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C4086026","Blood-Filled","C124501","A finding indicating that that an anatomic space or cavity is filled with blood.","Blood-Filled | BLOOD FILLED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086027","Blunt-Tipped Tail","C124502","A finding that the apex of the tail is rounded or dulled.","Blunt-Tipped Tail | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086143","Cartilage Not Fused","C124503","A finding referring to incomplete or absent chondrogenesis.","Cartilage Not Fused | CARTILAGE NOT FUSED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086144","Cartilaginous Fusion","C124504","Joined together by cartilage.","Cartilaginous Fusion | CARTILAGINOUS FUSION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086146","Caudal Dysplasia","C124505","A congenital abnormality characterized by the abnormal development of the lower portion of the body. Findings include hypoplastic lower extremities, defects of the caudal vertebrae, sacrum and neural tube, or maldeveloped gastrointestinal or genital organs.","Caudal Dysplasia | CAUDAL DYSPLASIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086579","Microscopic Findings Distribution","C124035","The placement, arrangement or instance of microscopic findings within an anatomical space.","Microscopic Findings Distribution | MIDISTR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086125","Cardiovascular System Findings Derived Flag","C124036","An indication or description that cardiovascular system data is a derived value.","Cardiovascular System Findings Derived Flag | CVDRVFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086807","Respiratory System Findings Derived Flag","C124037","An indication or description that respiratory system data is a derived value.","Respiratory System Findings Derived Flag | REDRVFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1137703","Adenylate Cyclase Type 9, Human","C124038","Adenylate cyclase type 9 (1353 aa, ~151 kDa) is encoded by the human ADCY9 gene. This protein is involved in the synthesis of cyclic AMP in response to activation of beta-adrenergic receptors.","Adenylate Cyclase Type 9 | AC9 | ACIX | ADCY9 | ATP Pyrophosphate-Lyase 9 | Adenyl Cyclase 9 | Adenylate Cyclase Type IX | Adenylyl Cyclase 9 | Adenylylcyclase 9 | EC 4.6.1.1 | Type IX ATP Pyrophosphate-Lyase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498291","autologous dendritic cell-based immunotherapeutic AV0113","C123928","A therapeutic interleukin-12 (IL-12)-expressing dendritic cell (DC)-based vaccine composed of autologous monocyte-derived DCs loaded with autologous tumor cell lysate and exposed to the microbial cell wall component lipopolysaccharide (LPS), with potential immunomodulating and antineoplastic activities. The monocyte-derived immature DCs are loaded with autologous tumor cell lysates and are subsequently exposed to LPS and interferon-gamma (IFN-gamma). Upon administration of audencel, the mature DCs migrate into the lymph nodes, express the immune stimulatory cytokine interleukin-12 (IL-12) and activate the immune system by promoting the activation of natural killer (NK) cells and induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation. Exposure to LPS and IFN-gamma allows the maturation of DCs and optimizes the presentation of tumor-associated antigens (TAAs) by DCs to T-lymphocytes.","Audencel | AUDENCEL | AV0113 | AV0113 DC-CIT | AV0113 Dendritic Cell Cancer Immunotherapeutic | Autologous DC-based Immunotherapeutic AV0113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502891","Nitroglycerin/Sodium Citrate/Ethanol Solution","C124659","An antimicrobial lock solution (ALS) containing the nitrate nitroglycerin, sodium citrate and ethanol, with potential antimicrobial and anticoagulant activities. Upon application to the catheter as an ALS, the nitroglycerin is converted into nitric oxide (NO), which exerts antimicrobial activity. The citrate exerts anticoagulant activity, thereby preventing blood clotting and occlusion and maintaining the fluidity of the administered solution. In addition, both citrate and ethanol exert antimicrobial activity. This may prevent bacterial colonization on the surface of the catheter, biofilm formation and prevents catheter-associated infections.","Nitroglycerin/Sodium Citrate/Ethanol Solution | GTN-Citrate-Ethanol | Glyceryl Trinitrate-Citrate-Ethanol | NiCE | Nitroglycerin - Citrate - Ethanol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086205","Cobiprostone Spray","C124660","A topical spray formulation containing the prostone cobiprostone, a type 2 chloride channel (ClC-2) agonist, with potential mucosal protective and anti-mucositis activities. Upon administration of cobiprostine via a spray into the oral cavity, cobiprostone specifically binds to and activates the ClC2 channel located on the mucosal membrane. This activates the epithelial ClC2 channel, enhances secretion of chloride, and promotes epithelial barrier repair.  This prevents or reduces mucosal injury and reduces mucositis. ClC2 plays a key role in the protection of mucosal barrier function.","Cobiprostone Spray | Cobiprostone Oral Spray | SPI-8811 | SPI-8811 Spray",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086065","CDISC Clinical Classification Tanner Scale-Boy Test Name Terminology","C124661","Test names of clinical classification questions associated with the Tanner Scale Boy Version (Tanner Scale-Boy) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification Tanner Scale-Boy Test Name Terminology | CC-Tanner Scale-Boy TEST | TANN02TN | Tanner Scale Boy Clinical Classification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086064","CDISC Clinical Classification Tanner Scale-Boy Test Code Terminology","C124662","Test codes of clinical classification questions associated with the Tanner Scale Boy Version (Tanner Scale-Boy) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification Tanner Scale-Boy Test Code Terminology | CC-Tanner Scale-Boy TESTCD | TANN02TC | Tanner Scale Boy Clinical Classification Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086067","CDISC Clinical Classification Tanner Scale-Girl Test Name Terminology","C124663","Test names of clinical classification questions associated with the Tanner Scale Girl Version (Tanner Scale-Girl) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification Tanner Scale-Girl Test Name Terminology | CC-Tanner Scale-Girl TEST | TANN01TN | Tanner Scale Girl Clinical Classification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086066","CDISC Clinical Classification Tanner Scale-Girl Test Code Terminology","C124664","Test codes of clinical classification questions associated with the Tanner Scale Girl Version (Tanner Scale-Girl) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification Tanner Scale-Girl Test Code Terminology | CC-Tanner Scale-Girl TESTCD | TANN01TC | Tanner Scale Girl Clinical Classification Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086051","CDISC Clinical Classification Atherosclerotic Cardiovascular Disease 10-Year Risk Estimator Test Name Terminology","C124665","Test names of clinical classification questions associated with the Atherosclerotic Cardiovascular Disease 10-Year Risk Estimator (ASCVD 10-Year Risk Estimator) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification Atherosclerotic Cardiovascular Disease 10-Year Risk Estimator Test Name Terminology | ASCVD1TN | Atherosclerotic Cardiovascular Disease 10-Year Risk Estimator Clinical Classification Test Name | CC-ASCVD 10-Year Risk Estimator TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084734","ITLN1 wt Allele","C124077","Human ITLN1 wild-type allele is located in the vicinity of 1q21.3 and is approximately 9 kb in length. This allele, which encodes intelectin-1 protein, plays a role in the regulation of insulin-mediated glucose uptake.","ITLN1 wt Allele | HL-1 | HL1 | INTL | ITLN | Intelectin 1 (Galactofuranose Binding) wt Allele | LFR | UNQ640/PRO1270 | hIntL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0968453","Intelectin-1, Human","C124078","Intelectin-1 (313 aa, ~35 kDa) is encoded by the human ITLN1 gene. This protein is involved in the enhancement of insulin-dependent signaling.","Intelectin-1 | Endothelial Lectin HL-1 | Galactofuranose-Binding Lectin | ITLN1 | Intelectin | Intelectin 1 | Intestinal Lactoferrin Receptor | Lactoferrin Receptor | Omentin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085188","IFNL4 wt Allele","C124080","Human IFNL4 wild-type allele is located in the vicinity of 19q13.2 and is approximately 3 kb in length. This allele, which encodes interferon lambda-4 protein, is involved in JAK-STAT pathway activation and the antiviral response. Mutation of the gene is associated with susceptibility to hepatitis C virus (HCV) infection.","IFNL4 wt Allele | IFNAN | Interferon, Lambda 4 (Gene/Pseudogene) wt Allele | Interferon, Lambda-4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3657783","Interferon Lambda-4, Human","C124081","Interferon lambda-4 (179 aa, ~20 kDa) is encoded by the human IFNL4 gene. This protein plays a role in JAK-STAT pathway-mediated antiviral responses.","Interferon Lambda-4 | IFN-Lambda-4 | IFNL4 | INFL4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085190","IL18R1 wt Allele","C124083","Human IL18R1 wild-type allele is located in the vicinity of 2q12 and is approximately 87 kb in length. This allele, which encodes interleukin-18 receptor 1 protein, plays a role in interleukin-18 binding and signal transduction.","IL18R1 wt Allele | CD218a | CDw218a | IL-18 Receptor Alpha Gene | IL-1Rrp | IL18RA | IL1RRP | Interleukin 18 Receptor 1 wt Allele | Interleukin 18 Receptor, Alpha Chain Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447429","Interleukin-18 Receptor 1, Human","C124084","Interleukin-18 receptor 1 (541 aa, ~62 kDa) is encoded by the human IL18R1 gene. This protein is involved in both interleukin-18 binding and the regulation of NF-kB signaling.","Interleukin-18 Receptor 1 | CD218 Antigen-Like Family Member A | CD218a | CD218a Antigen | IL-18R-1 | IL-18R1 | IL-1Rrp | IL1 Receptor-Related Protein | IL1R-rp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086359","GENC Terminology","C124085","Codes for the representation of names of countries and their subdivisions that have been approved by the US Board on Geographic Names.","Geopolitical Entities, Names, and Codes Terminology | GENC Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086881","TIMP4 wt Allele","C124087","Human TIMP4 wild-type allele is located in the vicinity of 3p25 and is approximately 6 kb in length. This allele, which encodes metalloproteinase inhibitor 4 protein, is involved in the regulation of extracellular matrix degradation.","TIMP4 wt Allele | TIMP Metallopeptidase Inhibitor 4 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0075639","Sunflower Oil","C1241","Pressed from sunflower seeds (Helianthus annus), Sunflower Oil has a high content of beneficial monounsaturated fats, and antioxidant vitamins E and F, as well as triglycerides and linoleic acids. Used mainly in cooking today, sunflower oil has been used for medicines and in cosmetics. (NCI04)","Sunflower Oil | Oil, Sunflower | SUNFLOWER OIL | Sunflower Seed Oil",,,,,,,,,,,,,,,"4024178","Sunflowerseed oil",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0169868","8-Chloroadenosine","C124047","An antimetabolite and a chlorine derivative of the purine nucleoside adenosine, with potential antineoplastic activity. Upon administration, 8-chloro-adenosine is phosphorylated to form 8-chloro-adenosine triphosphate (8-chloro-ATP), which functions as a ribonucleoside analogue and competes with ATP during transcription. Therefore, this agent causes RNA synthesis inhibition, inhibits cellular proliferation, and induces apoptosis.","8-Chloroadenosine | 8-CHLOROADENOSINE | 8-Chloro-adenosine | 8-Cl-Ado | 8-Cl-adenosine | Adenosine, 8-Chloro-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086694","PANSS - Grandiosity","C124751","Positive and Negative Syndrome Scale (PANSS) Temperature - Grandiosity.","PANSS - Grandiosity | PANSS1-Grandiosity | PANSS105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087067","PANSS - Suspiciousness or Persecution","C124752","Positive and Negative Syndrome Scale (PANSS) Temperature - Suspiciousness or persecution.","PANSS - Suspiciousness or Persecution | PANSS1-Suspiciousness/Persecution | PANSS106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086697","PANSS - Hostility","C124753","Positive and Negative Syndrome Scale (PANSS) Temperature - Hostility.","PANSS - Hostility | PANSS1-Hostility | PANSS107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086686","PANSS - Blunted Affect","C124754","Positive and Negative Syndrome Scale (PANSS) Temperature - Blunted affect.","PANSS - Blunted Affect | PANSS1-Blunted Affect | PANSS108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086692","PANSS - Emotional Withdrawal","C124755","Positive and Negative Syndrome Scale (PANSS) Temperature - Emotional withdrawal.","PANSS - Emotional Withdrawal | PANSS1-Emotional Withdrawal | PANSS109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086705","PANSS - Poor Rapport","C124756","Positive and Negative Syndrome Scale (PANSS) Temperature - Poor rapport.","PANSS - Poor Rapport | PANSS1-Poor Rapport | PANSS110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086702","PANSS - Passive or Apathetic Social Withdrawal","C124757","Positive and Negative Syndrome Scale (PANSS) Temperature - Passive or apathetic social withdrawal.","PANSS - Passive or Apathetic Social Withdrawal | PANSS1-Passive/Apathetic Social Withdraw | PANSS111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086689","PANSS - Difficulty in Abstract Thinking","C124758","Positive and Negative Syndrome Scale (PANSS) Temperature - Difficulty in abstract thinking.","PANSS - Difficulty in Abstract Thinking | PANSS1-Difficulty in Abstract Thinking | PANSS112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086699","PANSS - Lack of Spontaneity","C124759","Positive and Negative Syndrome Scale (PANSS) Temperature - Lack of spontaneity and flow of conversation.","PANSS - Lack of Spontaneity | PANSS1-Lack of Spontaneity | PANSS113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086050","CDISC Clinical Classification Atherosclerotic Cardiovascular Disease 10-Year Risk Estimator Test Code Terminology","C124666","Test codes of clinical classification questions associated with the Atherosclerotic Cardiovascular Disease 10-Year Risk Estimator (ASCVD 10-Year Risk Estimator) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification Atherosclerotic Cardiovascular Disease 10-Year Risk Estimator Test Code Terminology | ASCVD1TC | Atherosclerotic Cardiovascular Disease 10-Year Risk Estimator Clinical Classification Test Code | CC-ASCVD 10-Year Risk Estimator TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086049","CDISC Clinical Classification ASSIGN Score Test Name Terminology","C124667","Test names of clinical classification questions associated with the ASSIGN Cardiovascular Disease 10-Year Risk Score (ASSIGN Score) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification ASSIGN Score Test Name Terminology | ASSG01TN | ASSIGN Cardiovascular Disease 10-Year Risk Score Clinical Classification Test Name | CC-ASSIGN Score TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086048","CDISC Clinical Classification ASSIGN Score Test Code Terminology","C124668","Test codes of clinical classification questions associated with the ASSIGN Cardiovascular Disease 10-Year Risk Score (ASSIGN Score) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification ASSIGN Score Test Code Terminology | ASSG01TC | ASSIGN Cardiovascular Disease 10-Year Risk Score Clinical Classification Test Code | CC-ASSIGN Score TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085579","USP28 wt Allele","C124090","Human USP28 wild-type allele is located in the vicinity of 11q23 and is approximately 78 kb in length. This allele, which encodes ubiquitin carboxyl-terminal hydrolase 28 protein, is involved in the DNA damage checkpoint and protein deubiquitination.","USP28 wt Allele | KIAA1515 | Ubiquitin Specific Peptidase 28 wt Allele | Ubiquitin Specific Protease 28 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086605","Most Severe Acute Stressor","C124437","The agent, stimulus, activity, or event that causes stress with an acute frequency, which has the highest level of severity.","Most Severe Acute Stressor | ACUTSTRS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085940","Age at First Episode","C124438","The age at which the first episode occurred.","Age at First Episode | AGEEPSD1 | Age At First Episode",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085941","Age at First Hospitalization","C124439","The age at which the first hospitalization event occurred.","Age at First Hospitalization | AGEHOSP1 | Age At First Hospitalization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085942","Age at First Treatment","C124440","The age at which the first treatment event occurred.","Age at First Treatment | AGETRT1 | Age At First Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086606","Most Severe Chronic Stressor","C124441","The agent, stimulus, activity, or event that causes stress with a chronic frequency, which has the highest level of severity.","Most Severe Chronic Stressor | CHRNSTRS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086186","Clinic Stay Indicator","C124442","An indication as to whether the subject was admitted to a healthcare clinic.","Clinic Stay Indicator | CLININD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086639","Number of Hospitalizations","C124443","A measurement of the total number of hospitalization events that have occurred.","Number of Hospitalizations | HOSPNUM | Number Of Hospitalizations",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086708","PANSS - Stereotyped Thinking","C124760","Positive and Negative Syndrome Scale (PANSS) Temperature - Stereotyped thinking.","PANSS - Stereotyped Thinking | PANSS1-Stereotyped Thinking | PANSS114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086707","PANSS - Somatic Concern","C124761","Positive and Negative Syndrome Scale (PANSS) Temperature - Somatic concern.","PANSS - Somatic Concern | PANSS1-Somatic Concern | PANSS115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086695","PANSS - Guilt Feelings","C124763","Positive and Negative Syndrome Scale (PANSS) Temperature - Guilt feelings.","PANSS - Guilt Feelings | PANSS1-Guilt Feelings | PANSS117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086709","PANSS - Tension","C124764","Positive and Negative Syndrome Scale (PANSS) Temperature - Tension.","PANSS - Tension | PANSS1-Tension | PANSS118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086700","PANSS - Mannerisms and Posturing","C124765","Positive and Negative Syndrome Scale (PANSS) Temperature - Mannerisms and posturing.","PANSS - Mannerisms and Posturing | PANSS1-Mannerisms and Posturing | PANSS119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086688","PANSS - Depression","C124766","Positive and Negative Syndrome Scale (PANSS) Temperature - Depression.","PANSS - Depression | PANSS1-Depression | PANSS120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086701","PANSS - Motor Retardation","C124767","Positive and Negative Syndrome Scale (PANSS) Temperature - Motor retardation.","PANSS - Motor Retardation | PANSS1-Motor Retardation | PANSS121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086710","PANSS - Uncooperativeness","C124768","Positive and Negative Syndrome Scale (PANSS) Temperature - Uncooperativeness.","PANSS - Uncooperativeness | PANSS1-Uncooperativeness | PANSS122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086711","PANSS - Unusual Thought Content","C124769","Positive and Negative Syndrome Scale (PANSS) Temperature - Unusual thought content.","PANSS - Unusual Thought Content | PANSS1-Unusual Thought Content | PANSS123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084887","PIK3R5 wt Allele","C124255","Human PIK3R5 wild-type allele is located in the vicinity of 17p13.1 and is approximately 87 kb in length. This allele, which encodes phosphoinositide 3-kinase regulatory subunit 5 protein, is involved in the modulation of phosphoinositide-3-kinase gamma activity. Mutation of the gene is associated with ataxia-oculomotor apraxia 3.","PIK3R5 wt Allele | F730038I15Rik | FOAP-2 | P101-PI3K | Phosphatidylinositol 3-Kinase, Regulatory Subunit 5 Gene | Phosphoinositide-3-Kinase Regulatory Subunit 5 wt Allele | Phosphoinositide-3-Kinase, Regulatory Subunit 5 Gene | p101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2936439","Phosphoinositide 3-Kinase Regulatory Subunit 5","C124256","Phosphoinositide 3-kinase regulatory subunit 5 (880 aa, ~97 kDa) is encoded by the human PIK3R5 gene. This protein plays a role in the regulation of phospholipid metabolism.","Phosphoinositide 3-Kinase Regulatory Subunit 5 | PI3-Kinase P101 Subunit | PI3-Kinase Regulatory Subunit 5 | PIK3R5 | Phosphatidylinositol 4,5-Bisphosphate 3-Kinase Regulatory Subunit 5 | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Regulatory Subunit 5 | Phosphoinositol 3-Kinase Regulatory Subunit 5 | Protein FOAP-2 | PtdIns-3-Kinase P101 | PtdIns-3-Kinase Regulatory Subunit 5 | p101-PI3K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0321799","Schistosoma intercalatum","C124389","A species of flatworms in the family Schistosomatidae. S intercalatum is characterized by eggs that have a terminal spine and are intermediate in size between the smaller S. haematobium and larger S. bovis. These eggs are unique because they will stain red when exposed to the Ziehl-Neelsen staining technique. S. intercalatum has two major strains, each with its own preferred snail host: the Zaire strain uses Bulinus africanus as its intermediate host, while the Lower Guinea strain uses B. forskalii. Within the human body infestation is most often seen in the inferior mesenteric vein.","Schistosoma intercalatum | SCHISTOSOMA INTERCALATUM",,,,,,,,,,,,,,,"4048882","Schistosoma intercalatum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036317","Schistosoma japonicum","C124390","A species of flatworms in the family Schistosomatidae. These flatworms are yellow or yellow-brown and the males are slightly larger than the other Schistosomes. This species' geographic range is restricted to China, Indonesia, and the Philippines. S. japonicum uses snails of the Oncomelania genus as its intermediate host. Within the body infestation is most frequently found in the superior mesenteric veins draining the small intestine.","Schistosoma japonicum | SCHISTOSOMA JAPONICUM",,,,,,,,,,,,,,,"4198674","Schistosoma japonicum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036319","Schistosoma mansoni","C124391","A species of flatworms in the family Schistosomatidae. The lifecycle of S. mansoni involves Biomphalaria snails as the intermediate host and humans as the definitive host. Infestation is most often found in the superior mesenteric veins draining the large intestine. This schistosome is a causative agent of intestinal schistosomiasis.","Schistosoma mansoni | SCHISTOSOMA MANSONI",,,,,,,,,,,,,,,"4006474","Schistosoma mansoni",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0321809","Schistosoma mekongi","C124392","A species of flatworms in the family Schistosomatidae. S. mekongi is found exclusively in the Mekong river basin of Laos and Cambodia in South-east Asia. The snail Neotricula aperta acts as the intermediate host for this schistosome. Dogs serve as a reservoir for S. mekongi.","Schistosoma mekongi | SCHISTOSOMA MEKONGI",,,,,,,,,,,,,,,"4327051","Schistosoma mekongi",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036360","Schizophyllum","C124393","A genus of basidiomycete fungi in the family Schizophyllaceae with worldwide distribution. Species in the genus are isolated on rotting wood and only rarely infect humans.","Schizophyllum | SCHIZOPHYLLUM",,,,,,,,,,,,,,,"4348185","Schizophyllum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319944","Scopulariopsis","C124394","A genus of anamorphic fungi in the family Microascaceae. Species in the genus are commonly found in soil and decaying wood, but some cause opportunistic infections in immunocompromised individuals.","Scopulariopsis | SCOPULARIOPSIS",,,,,,,,,,,,,,,"4221076","Scopulariopsis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086092","CDISC SEND Implantation Findings Result Terminology","C124317","Terminology associated with the implantation findings result codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical data (SEND).","CDISC SEND Implantation Findings Result Terminology | ICFINDRS | Implantation Findings Result | SEND-ICFINDRS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086093","CDISC SEND Implantation Findings Test Code Terminology","C124318","Terminology associated with the implantation findings test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical data (SEND).","CDISC SEND Implantation Findings Test Code Terminology | ICTESTCD | Implantation Findings Test Code | SEND-ICTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086094","CDISC SEND Implantation Findings Test Name Terminology","C124319","Terminology associated with the implantation findings test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical data (SEND).","CDISC SEND Implantation Findings Test Name Terminology | ICTEST | Implantation Findings Test Name | SEND-ICTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086095","CDISC SEND Nonclinical DART Sex Terminology","C124320","Terminology associated with the nonclinical DART sex codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical data (SEND).","CDISC SEND Nonclinical DART Sex Terminology | NCDSEX | Nonclinical DART Sex | SEND-NCDSEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087055","CDISC SEND Nonclinical DART Trial Phases Terminology","C124321","Terminology associated with the nonclinical DART trial phases codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical data (SEND).","CDISC SEND Nonclinical DART Trial Phases Terminology | NCDPHASE | Nonclinical DART Trial Phases | SEND-NCDPHASE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086096","CDISC SEND Pregnancy Findings Result Category Terminology","C124322","Terminology associated with the pregnancy findings result category codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical data (SEND).","CDISC SEND Pregnancy Findings Result Category Terminology | PYRESCAT | Pregnancy Findings Result Category | SEND-PYRESCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086097","CDISC SEND Pregnancy Findings Result Terminology","C124323","Terminology associated with the pregnancy findings result codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical data (SEND).","CDISC SEND Pregnancy Findings Result Terminology | PYFINDRS | Pregnancy Findings Result | SEND-PYFINDRS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086098","CDISC SEND Pregnancy Findings Test Code Terminology","C124324","Terminology associated with the pregnancy findings test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical data (SEND).","CDISC SEND Pregnancy Findings Test Code Terminology | PYTESTCD | Pregnancy Findings Test Code | SEND-PYTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084929","CDISC SEND Pregnancy Findings Test Name Terminology","C124325","Terminology associated with the pregnancy findings test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical data (SEND).","CDISC SEND Pregnancy Findings Test Name Terminology | PYTEST | Pregnancy Findings Test Name | SEND-PYTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084850","Adjuvant Therapy Clinical Trial Setting","C124450","A clinical trial or treatment setting in which the therapy of interest is considered adjuvant.","Adjuvant Therapy Clinical Trial Setting | ADJUVANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086812","Respiratory System Findings Method","C123980","The technique used to administer the respiratory system assessment.","Respiratory System Findings Method | REMETHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498417","Trial Sets Name","C123981","A character or string that represents the long name of the trial set.","Trial Sets Name | SET",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086801","Respiratory System Findings Body Position","C123988","The physical bearing of the body during a respiratory system assessment.","Respiratory System Findings Body Position | REPOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086138","Cardiovascular System Findings Reason For Exclusion From Statistics","C123990","A rationale for excluding a particular data point or subject from the cardiovascular system statistical analysis.","Cardiovascular System Findings Reason For Exclusion From Statistics | CVREASEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086820","Respiratory System Findings Reason For Exclusion From Statistics","C123991","A rationale for excluding a particular data point or subject from the respiratory system statistical analysis.","Respiratory System Findings Reason For Exclusion From Statistics | REREASEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086821","Respiratory System Findings Reason Not Done","C123994","The explanation given as to why respiratory system test was not performed.","Respiratory System Findings Reason Not Done | REREASND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1849655","Cebocephaly","C124506","A congenital abnormality characterized by a malformation of the head. The eyes are hypoteleric and the nose may be absent or misshapen (small, flattened, single nostril) and defective.","Cebocephaly | CEBOCEPHALY",,,,,,,,,,,,,,,"4069786","Cebocephaly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086147","Celosomy","C124507","A developmental abnormality characterized by the complex protrusion of viscera outside the abdominal wall.","Celosomy | CELOSOMY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0266090","Cheilognathopalatoschisis","C124508","A congenital abnormality consisting of a fissure in the midline of the lip, hard and/or soft palate and upper jaw.","Cheilognathopalatoschisis | CHEILOGNATHOPALATOSCHISIS | Cheilognathouranoschisis",,,,,,,,,,,,,,,"4221171","Cleft upper lip, upper jaw AND palate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0266089","Cheilognathoschisis","C124509","A congenital abnormality consisting of a fissure in the midline of the lip and upper jaw.","Cheilognathoschisis | CHEILOGNATHOSCHISIS",,,,,,,,,,,,,,,"4299636","Cheilognathoschisis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL502798","Facial Cleft","C124510","A congenital abnormality consisting of an opening or gap in the face, which results from incomplete fusion of one or more of the embryonic facial prominences.","Facial Cleft | ",,,,,,,,,,,,,,,"35608018","Craniofacial cleft",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2609072","Cleft Jaw","C124511","A congenital abnormality consisting of clefting in the jaw, which results from incomplete fusion of the embryonic mandibular prominence.","Cleft Jaw | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0685786","Mandibular Cleft","C124512","A congenital abnormality consisting of clefting in the lower face through the midline of the lip and/or mandible, which results from incomplete fusion of the embryonic mandibular prominence.","Mandibular Cleft | ",,,,,,,,,,,,,,,"4242038","Cleft mandible",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086185","Cleft Maxilla","C124513","A congenital abnormality consisting of a fissure in the midline of the upper jawbone.","Cleft Maxilla | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086848","Serratia liquefaciens Group","C124395","A non-hierarchical grouping of similar bacteria assigned to the Serratia liquifaciens species.","Serratia liquefaciens Group | SERRATIA LIQUEFACIENS GROUP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1301187","Serratia odorifera Biogroup 1","C124396","A subspecies of Serratia odorifera that is ornithine decarboxylase positive and ferments raffinose and sucrose.","Serratia odorifera Biogroup 1 | SERRATIA ODORIFERA BIOGROUP 1",,,,,,,,,,,,,,,"4287331","Serratia odorifera biogroup 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1301188","Serratia odorifera Biogroup 2","C124397","A subspecies of Serratia odorifera that is ornithine decarboxylase negative and negative for fermentation of raffinose and sucrose.","Serratia odorifera Biogroup 2 | SERRATIA ODORIFERA BIOGROUP 2",,,,,,,,,,,,,,,"4264130","Serratia odorifera biogroup 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4085184","Shewanella putrefaciens Group","C124398","A non-hierarchical grouping of similar bacteria assigned to the Shewamella putrefaciens species.","Shewanella putrefaciens Group | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0318099","Spirillum minus","C124399","A species of Spirillum bacteria that is the causative agent of sodoku, a form of rat-bite fever.","Spirillum minus | SPIRILLUM MINUS",,,,,,,,,,,,,,,"4149331","Spirillum minus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL502720","Beta-Lactamase Negative Staphylococcus Aureus","C124400","A subgroup of S. aureus bacteria that lack the enzymatic function of beta-lactamase and are therefore sensitive to beta-lactam (penicillin) antibiotics.","Beta-Lactamase Negative Staphylococcus Aureus | STAPHYLOCOCCUS AUREUS, BETA-LACTAMASE NEGATIVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502722","Penicillinase Negative Staphylococcus Aureus","C124402","A subgroup of S. aureus bacteria that lack the enzymatic function of beta-lactamase (penicillinase) and are therefore sensitive to beta-lactam (penicillin) antibiotics.","Penicillinase Negative Staphylococcus Aureus | STAPHYLOCOCCUS AUREUS, PENICILLINASE NEGATIVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498292","Gallium Ga 68-NOTA-Aca-BBN(7-14)","C123929","A radioconjugate containing the bombesin (BBN) fragment BBN(7-14) comprised of the amino acid sequence of Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2, which targets the gastrin-releasing peptide receptor (GRPR), bound to aminocaproic acid (Aca), and linked by the macrocyclic chelating agent, 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA), to the radionuclide gallium (Ga) 68, with potential use in diagnostic imaging using positron emission tomography/computed tomography (PET/CT). Upon administration of gallium Ga 68-NOTA-Aca-BBN(7-14), the peptide moiety targets and binds to GRPR. Upon PET/CT, GRPR-expressing tumor cells can then be visualized. GRPR, also called bombesin receptor 2 (BB2), is a seven-transmembrane G protein-coupled receptor belonging to the bombesin receptor family. It is overexpressed in certain types of cancers.","Gallium Ga 68-NOTA-Aca-BBN(7-14) | 68Ga-NOTA-Aca-BBN(7-14) | 68Gallium-labeled NOTA-Aca-BBN(7-14) | Gallium Ga 68-NOTA-Aca-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 | Gallium Ga 68-NOTA-aminocaproic Acid-bombesin(7-14)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084854","Aliquotting","C124326","The act of dividing a liquid item into multiple items of smaller volume.","Aliquotting | ALIQUOTING | Aliquot",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087019","Number of Mild Episodes","C124328","The number of times an event, which is classified as mild, occurred.","Number of Mild Episodes | EPMLDNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086647","Number of Moderate Episodes","C124329","The number of times an event, which is classified as moderate, occurred.","Number of Moderate Episodes | EPMODNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086650","Number of Severe Episodes","C124330","The number of times an event, which is classified as severe, occurred.","Number of Severe Episodes | EPSEVNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086906","Thymic Cord","C124590","A fibrous band that connects the cervical thymus to the pharynx or mediastinum.","Thymic Cord | Extra Thymic Tissue | THYMIC CORD | Thymic Remnant in the Neck | Thymus Long Cranially",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152238","Cor Biloculare","C124591","A congenital anatomic anomaly in which the heart has only two chambers.","Cor Biloculare | ",,,,,,,,,,,,,,,"441409","Cor biloculare",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1969185","Wavy Rib","C124592","A physical quality in which the rib is undulating.","Wavy Rib | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502831","Wide","C124593","Having a width, or side to side dimension, that is greater than is normally expected.","Wide | WIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084883","Ossification Abnormality","C124594","The abnormal formation of bone or bony substance.","Ossification Abnormality | OSSIFICATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086289","External Examination","C124596","An assessment of the outside of the body.","External Examination | EXTREXAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086565","Maternal-Fetal Examination","C124597","An assessment of the shared maternal-fetal structures.","Maternal-Fetal Examination | MTFTEXAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086854","Skeletal Examination","C124598","An assessment of the bone and cartilage structures.","Skeletal Examination | SKELEXAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086954","Visceral Examination","C124599","An assessment of the internal soft tissue structures.","Visceral Examination | VISCEXAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087003","Cardiovascular System Findings Date Time of Reference Timepoint","C123996","The date and time of a specific reference point for the cardiovascular system assessment.","Cardiovascular System Findings Date Time of Reference Timepoint | CVRFTDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086281","Exposure Date Time of Reference Timepoint","C123997","The date and time of a specific reference point for the exposure assessment.","Exposure Date Time of Reference Timepoint | EXRFTDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086206","Collapsed Lumen","C124514","A finding in which the walls of a tube or tubular organ have contorted or buckled into its cavity or channel.","Collapsed Lumen | COLLAPSED LUMEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086784","Red-Brown Material","C124515","Matter that is red and brown in color.","Red-Brown Material | COLORED MATERIAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086951","Vessel Common Origin","C124516","A finding that the blood vessels are arising from the same location.","Vessel Common Origin | COMMON ORIGIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0266459","Cranial Meningocele","C124517","A congenital abnormality in which the meninges protrude through a defect in the cranium.","Cranial Meningocele | CRANIAL MENINGOCELE",,,,,,,,,,,,,,,"4262717","Congenital cerebral meningocele",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265537","Craniofenestria","C124518","A congenital abnormality characterized by round or oval shaped defects in the membranous skull vault resulting in non-ossified, honey comb-like areas in the calvaria.","Craniofenestria | CRANIOFENESTRIA",,,,,,,,,,,,,,,"4162042","Craniolacunia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0311249","Cryptophthalmia","C124520","A congenital abnormality characterized by the presence of a continuous layer of skin extending over the eyeballs and the absence of eyelids and the palpebral fissure.","Cryptophthalmia | CRYPTOPHTHALMIA | Cryptophthalmos",,,,,,,,,,,,,,,"4268276","Cryptophthalmos",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086229","Curled Tail","C124521","A finding that the tail is curved or coiled into a circular shape.","Curled Tail | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1849656","Cyclopia","C124522","A rare congenital abnormality characterized by the failure of the embryonic prosencephalon to separate the eye orbit into two distinct cavities. Facial features tend to be absent although a proboscis has been seen to develop in conjunction.","Cyclopia | CYCLOPIA | Monophthalmia | Single Eyeball | Synophthalmia",,,,,,,,,,,,,,,"4007742","Cyclops",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0404533","Anogenital Distance Decreased","C124523","An indication that the anogenital distance is less than the norm.","Anogenital Distance Decreased | DECREASED ANOGENITAL DISTANCE",,,,,,,,,,,,,,,"4247070","Decreased anogenital distance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0687118","Detached","C124524","Physically separated or not connected.","Detached | DETACHED | Floating | Non-articulated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0332572","Discoloration","C124525","A change in color that deviates from the norm or outwith the bounds of what is considered normal.","Discoloration | DISCOLORED | Discolored",,,,,,,,,,,,,,,"4165350","Abnormal color",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0685206","Dome-Shaped Head","C124527","A head having the shape of a dome.","Dome-Shaped Head | ",,,,,,,,,,,,,,,"4247585","Domed head",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL498403","Dimethicone-containing Botanicals-based Lotion","C124049","A skin lotion containing various proprietary botanical ingredients and the skin protectant dimethicone, a silicon-based polymer, with potential to prevent radiation dermatitis (RD). Upon topical application to the affected area before and after radiation therapy, the phytochemicals in the dimethicone-containing botanicals-based lotion may act as free radical scavengers and exert an antioxidant effect. The dimethicone component of the skin lotion protects against damage, and moisturizes and soothes the skin.","Dimethicone-containing Botanicals-based Lotion | Difinsa53",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498404","Nutrient-rich Whole Wheat Flour Supplement","C124050","A nutritional supplement composed of nutrient-rich whole wheat flour-based bread mix, with potential anti-cachexia activity. Following the production of an unleavened bread from the mix and upon oral intake of the nutrient-rich whole wheat flour supplement, the various nutrients in the bread may improve cachexia symptoms. The bread is made from the flour of pulverized whole wheat from an Indian crop.","Nutrient-rich Whole Wheat Flour Supplement | IAtta | Nutrient-rich Bread Mix IAtta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498293","Ad5-yCD/mutTKSR39rep-hIL12","C123930","A replication-competent oncolytic adenovirus encoding the murine pro-inflammatory cytokine interleukin-12 (IL-12) gene and two suicide fusion genes, a yeast cytosine deaminase (yCD) and a mutant form of herpes simplex virus type 1 thymidine kinase (HSV-1 TKSR39), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration of Ad5-yCD/mutTKSR39rep-hIL12, the adenovirus selectively infects and replicates in tumor cells, which results in direct tumor cell lysis. Synergistically, IL-12 expressed by the adenovirus may activate the immune system by promoting the activation of natural killer cells (NKs), inducing secretion of interferon-gamma (IFN-g) and inducing cytotoxic T-lymphocyte (CTL) responses against tumor cells, which may result in immune-mediated tumor cell death, inhibition of tumor cell proliferation and inhibition of tumor angiogenesis. In addition, Ad5-yCD/mutTKSR39rep-hIL12-infected cancer cells express yCD and TKSR39; upon administration of the prodrugs 5-fluorocytosine (5-FC) and valganciclovir (vGCV), the yCD and HSV-1 TKSR39 activate these prodrugs to form 5-fluorouracil (5-FU) and ganciclovir, respectively. 5-FU gets converted to 5-fluoro-uridine monophosphate (5-FUMP) and subsequently to 5-fluoro-deoxyuridine monophosphate (5-FdUMP); 5-FdUMP irreversible inhibits thymidylate synthase, inhibits deoxythymidine triphosphate (dTTP) formation and halts DNA synthesis. Once phosphorylated intracellularly, ganciclovir triphosphate competitively inhibits deoxyguanosine triphosphate (dGTP) incorporation into DNA and inhibits DNA synthesis.","Ad5-yCD/mutTKSR39rep-hIL12 | Oncolytic Adenovirus Ad5-yCD/mutTKSR39rep-hIL12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498294","Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells","C123931","Autologous, CD34-positive hematopoietic progenitor cells (HPCs) transduced with a lentiviral vector encoding three anti-human immunodeficiency virus (HIV) genes: a short hairpin RNA (shRNA) that targets human chemokine receptor 5 (CCR5), a human/rhesus macaque chimeric tripartite motif-containing protein 5 alpha isoform (TRIM5alpha), and a TAT activation response (TAR) decoy, as well as a pre-selective cell-surface marker, which is a truncated and mutated form of human CD25, used to potentially provide resistance against human immunodeficiency virus (HIV) infection. Human autologous CD34-positive HPCs are isolated and transduced ex vivo with the lentiviral vector. Upon pre-selection, purification using CD25 immunomagnetic separation, and subsequent administration of effectively transduced HPCs, the HPCs display 3 separate mechanisms of action against HIV infection: CCR5 shRNA binds to CCR5 mRNA and inhibits the expression of CCR5, a HIV-1 co-receptor that mediates HIV attachment and host cell entry; TRIM5alpha prevents HIV genome integration upon cell entry; and the TAR decoy binds to the HIV TAT protein and prevents TAT-dependent viral gene transcription, thereby preventing HIV replication. Upon transfer of the lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive HPCs into the patient, the HPCs are resistant to HIV entry and replication and could provide long-term protection against both HIV infection and HIV-associated cancers.","Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells | Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive HPCs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086172","Childhood Small Intestinal Leiomyosarcoma","C123932","A small intestinal leiomyosarcoma occurring in childhood.","Childhood Small Intestinal Leiomyosarcoma | Childhood Small Intestine Leiomyosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086171","Childhood Small Intestinal Carcinoma","C123933","A small intestinal carcinoma occurring in childhood.","Childhood Small Intestinal Carcinoma | Small Intestinal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086236","Definitive Host","C123934","The host in which a parasite spends the sexual stage of its life cycle.","Definitive Host | Primary Host",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086523","Intermediate Host","C123935","A host in which a parasite goes through its larval or developmental stages but does not reach sexual maturity.","Intermediate Host | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0547045","Chronicity","C123936","A description or characterization of the duration of a biological process.","Chronicity | CHRON",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086057","CDISC Clinical Classification FHS CVD 10-Year Risk Score Test Name Terminology","C124669","Test names of clinical classification questions associated with the Framingham Heart Study Cardiovascular Disease 10-Year Risk Score (FHS CVD 10-Year Risk Score) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification FHS CVD 10-Year Risk Score Test Name Terminology | CC-FHS CVD 10-Year Risk Score TEST | FCVD1TN | Framingham Heart Study Cardiovascular Disease 10-Year Risk Score Clinical Classification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0076116","Terephthalamidine","C1245","A derivative of the phthalanilide compounds. Terephthalamidine belongs to a family of compounds which appear to reversibly bind to the minor groove of the DNA double helix but not intercalate DNA. This agent also has been suggested to form ionic complexes with many biological components in vitro, including nucleic acids, proteins and lipids.","Terephthalamidine | 1,4-Benzenedicarboximidamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086259","Early Intrauterine Death","C124600","A death of the embryo occurring inside the uterus.","Early Intrauterine Death | EARLY INTRAUTERINE DEATH | Early IUD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086263","Empty Implantation Site","C124601","An implantation site that contains no discernible embryonic or placental tissue but may contain remnants of the implantation.","Empty Implantation Site | EMPTY IMPLANTATION SITE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085228","Non-Clinical Pairing Trial Phase","C124603","The period of time in a non-clinical study from the start of cohabitation until evidence of mating is observed and/or the subjects are separated.","Non-Clinical Pairing Trial Phase | PAIRING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085572","Non-Clinical Postnatal Trial Phase","C124604","The protocol defined period of time in a study that begins immediately after the birth of the subject.","Non-Clinical Postnatal Trial Phase | POSTNATAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086624","Non-Clinical Postpairing Trial Phase","C124605","The period of time in a non-clinical study that occurs after the paired subjects are separated. This includes males and non-confirmed mated females.","Non-Clinical Postpairing Trial Phase | POSTPAIRING | Post-cohabitation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1100344","Ubiquitin Carboxyl-Terminal Hydrolase 28, Human","C124091","Ubiquitin carboxyl-terminal hydrolase 28 (1077 aa, ~122 kDa) is encoded by the human USP28 gene. This protein plays a role in both protein deubiquitination and cellular responses to DNA damage.","Ubiquitin Carboxyl-Terminal Hydrolase 28 | Deubiquitinating Enzyme 28 | EC 3.4.19.12 | USP28 | Ubiquitin Thioesterase 28 | Ubiquitin-Specific-Processing Protease 28",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085576","RIF1 wt Allele","C124093","Human RIF1 wild-type allele is located in the vicinity of 2q23.3 and is approximately 98 kb in length. This allele, which encodes Telomere-associated protein RIF1, plays a role in the DNA damage checkpoint.","RIF1 wt Allele | FLJ10599 | FLJ12870 | RAP1 Interacting Factor Homolog (Yeast) Gene | RAP1-Interacting Factor, 1, Yeast, Homolog of Gene | Replication Timing Regulatory Factor 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502512","Telomere-Associated Protein RIF1","C124094","Telomere-associated protein RIF1 (2472 aa, ~274 kDa) is encoded by the human RIF1 gene. This protein is involved in DNA damage-induced cell cycle arrest.","Telomere-Associated Protein RIF1 | Rap1-Interacting Factor 1 Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084738","NEIL1 wt Allele","C124096","Human NEIL1 wild-type allele is located in the vicinity of 15q24.2 and is approximately 10 kb in length. This allele, which encodes endonuclease 8-like 1 protein, is involved in the repair of damaged or mismatched DNA.","NEIL1 wt Allele | DNA Endonuclease Eight-Like Glycosylase 1 Gene | FLJ22402 | FPG1 | NEI1 | Nei Endonuclease VIII-Like 1 (E. coli) Gene | Nei-Like DNA Glycosylase 1 wt Allele | hFPG1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1122828","Endonuclease 8-Like 1, Human","C124097","Endonuclease 8-like 1 (390 aa, ~44 kDa) is encoded by the human NEIL1 gene. This protein plays a role in base excision-based repair of DNA.","Endonuclease 8-Like 1 | DNA Glycosylase/AP Lyase Neil1 | DNA-(Apurinic Or Apyrimidinic Site) Lyase Neil1 | EC 3.2.2.- | EC 4.2.99.18 | Endonuclease VIII | Endonuclease VIII-Like 1 | FPG1 | NEH1 | NEIL1 | Nei Homolog 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1260926","Pigmentary Change in Skin","C124224","Abnormal skin pigmentation.","Pigmentary Change in Skin | Pigment Changes | Pigmentary Change of Skin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498405","antineoplastic agent combination SM-88","C124051","A combination agent containing racemetyrosine, methoxsalen, phenytoin and sirolimus, with potential antineoplastic activity. Upon administration of racemetyrosine/methoxsalen/phenytoin/sirolimus SM-88, racemetyrosine, being a dysfunctional and modified form of the non-essential amino acid tyrosine, is specifically taken up by cancer cells through the transporter L-amino acid transferase-1 (LAT1; CD98). As a tyrosine derivative and faulty amino acid protein building block, racemetyrosine prevents protein synthesis in cancer cells. Specifically, this prevents mucin-1 (MUC1) protein synthesis. MUC1 is highly overexpressed by most cancer cells and regulates the increased reactive oxygen species (ROS) in cancer cells created from the altered metabolism that cancer cells utilize, by upregulating key antioxidant defenses and preventing ROS-mediated apoptosis. In the absence of MUC1, ROS levels are increased, leading to an increase in oxidative stress, and induction of apoptosis. Also, being a protective transmembrane protein, MUC1 is part of the protective layer on the outside of cancer cells and plays a key role in shielding the cancer cell from the immune system. The loss of MUC1 compromises the cell membrane, thereby making the cancer cell more vulnerable to be recognized and attacked by the immune system. Rapamycin, a mammalian target of rapamycin (mTOR) inhibitor, increases the cancer cells' need for tyrosine uptake and increases the uptake of racemetyrosine by LAT1. Phenytoin stimulates the release of reactive lipid species by the liver which accumulate in the tumor microenvironment (TME) and are taken up by cancer cells, thereby further increasing ROS within the cancer cell and increasing oxidative-related apoptosis. Mehoxsalen promotes toxic electron transfer and increases melanin, increases oxidative reactions and production of ROS. This further stimulates oxidative stress-mediated apoptosis. Normal cells do not regularly take up certain non-essential amino acids, such as tyrosine, but readily convert phenylalanine to tyrosine, so normal healthy cells are not expected to consume racemetyrosine.","Racemetyrosine/Methoxsalen/Phenytoin/Sirolimus | Racemetyrosine/Methoxsalen/Phenytoin/Sirolimus Combination | SM-88 Used with MPS | SM-88 Used with Methoxsalen/Phenytoin/Sirolimus | SM-88/Methoxsalen/Phenytoin/Sirolimus | Tyrosine Isomers/Phenytoin/Methoxsalen/Sirolimus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498406","Granisetron Hydrochloride Nasal Spray","C124052","An intranasal formulation containing the hydrochloride salt form of the indazole derivative granisetron, a selective serotonin (5-hydroxytryptamine; 5-HT) receptor antagonist, with antinauseant and antiemetic activities. Upon administration to the nostril, granisetron selectively binds to and inhibits 5-HT subtype 3 receptors (5-HT3R) located peripherally on vagus nerve terminals and centrally in the chemoreceptor trigger zone (CTZ) of the area postrema, which may result in suppression of chemotherapy-induced nausea and vomiting (CINV).","Granisetron Hydrochloride Nasal Spray | GNS | Granisetron HCl Nasal Spray | Intranasal Granisetron Hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498407","Bendamustine-containing Nanoparticle-based Formulation RXDX-107","C124053","A nanoparticle-based formulation containing the alkyl ester of bendamustine, a bifunctional mechlorethamine derivative, encapsulated in human serum albumin (HSA), with potential alkylating and antineoplastic activities. Upon administration of the alkyl ester bendamustine-containing nanoparticle formulation RXDX-107, the nanoparticle formulation permits high concentrations of the alkyl ester of bendamustine be localized at the tumor site. The modified bendamustine alkylates and crosslinks macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and, subsequently, apoptosis.","Bendamustine-containing Nanoparticle-based Formulation RXDX-107 | BENDAMUSTINE DODECYL ESTER | CEP-40125 | RXDX 107 | RXDX-107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086703","PANSS - Poor Attention","C124771","Positive and Negative Syndrome Scale (PANSS) Temperature - Poor attention.","PANSS - Poor Attention | PANSS1-Poor Attention | PANSS125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086698","PANSS - Lack of Judgement","C124772","Positive and Negative Syndrome Scale (PANSS) Temperature - Lack of judgement and insight.","PANSS - Lack of Judgement | PANSS1-Lack of Judgment and Insight | PANSS126",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086691","PANSS - Disturbance of Volition","C124773","Positive and Negative Syndrome Scale (PANSS) Temperature - Disturbance of volition.","PANSS - Disturbance of Volition | PANSS1-Disturbance of Volition | PANSS127",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086056","CDISC Clinical Classification FHS CVD 10-Year Risk Score Test Code Terminology","C124670","Test codes of clinical classification questions associated with the Framingham Heart Study Cardiovascular Disease 10-Year Risk Score (FHS CVD 10-Year Risk Score) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification FHS CVD 10-Year Risk Score Test Code Terminology | CC-FHS CVD 10-Year Risk Score TESTCD | FCVD1TC | Framingham Heart Study Cardiovascular Disease 10-Year Risk Score Clinical Classification Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086063","CDISC Clinical Classification Reynolds CVD 10-Year Risk Score Test Name Terminology","C124671","Test names of clinical classification questions associated with the Reynolds Cardiovascular Disease 10-Year Risk Score (Reynolds CVD 10-Year Risk Score) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification Reynolds CVD 10-Year Risk Score Test Name Terminology | CC-Reynolds CVD 10-Year Risk Score TEST | RCVD01TN | Reynolds Cardiovascular Disease 10-Year Risk Score Clinical Classification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086062","CDISC Clinical Classification Reynolds CVD 10-Year Risk Score Test Code Terminology","C124672","Test codes of clinical classification questions associated with the Reynolds Cardiovascular Disease 10-Year Risk Score (Reynolds CVD 10-Year Risk Score) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification Reynolds CVD 10-Year Risk Score Test Code Terminology | CC-Reynolds CVD 10-Year Risk Score TESTCD | RCVD01TC | Reynolds Cardiovascular Disease 10-Year Risk Score Clinical Classification Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086069","CDISC Clinical Classification WHO Clinical Staging of HIV/AIDS for Adults and Adolescents Test Name Terminology","C124673","Test names of clinical classification questions associated with the World Health Organization Clinical Staging of HIV/AIDS for Adults and Adolescents (WHO Clinical Staging of HIV/AIDS for Adults and Adolescents) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification WHO Clinical Staging of HIV/AIDS for Adults and Adolescents Test Name Terminology | CC-WHO Clinical Staging of HIV/AIDS for Adults and Adolescents TEST | WHIVS1TN | WHO Clinical Staging of HIV/AIDS for Adults and Adolescents Clinical Classification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086068","CDISC Clinical Classification WHO Clinical Staging of HIV/AIDS for Adults and Adolescents Test Code Terminology","C124674","Test codes of clinical classification questions associated with the World Health Organization Clinical Staging of HIV/AIDS for Adults and Adolescents (WHO Clinical Staging of HIV/AIDS for Adults and Adolescents) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification WHO Clinical Staging of HIV/AIDS for Adults and Adolescents Test Code Terminology | CC-WHO Clinical Staging of HIV/AIDS for Adults and Adolescents TESTCD | WHIVS1TC | WHO Clinical Staging of HIV/AIDS for Adults and Adolescents Clinical Classification Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086071","CDISC Clinical Classification WHO Clinical Staging of HIV/AIDS for Children Test Name Terminology","C124675","Test names of clinical classification questions associated with the World Health Organization Clinical Staging of HIV/AIDS for Children (WHO Clinical Staging of HIV/AIDS for Children) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification WHO Clinical Staging of HIV/AIDS for Children Test Name Terminology | CC-WHO Clinical Staging of HIV/AIDS for Children TEST | WHIVS2TN | WHO Clinical Staging of HIV/AIDS for Children Clinical Classification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086070","CDISC Clinical Classification WHO Clinical Staging of HIV/AIDS for Children Test Code Terminology","C124676","Test codes of clinical classification questions associated with the World Health Organization Clinical Staging of HIV/AIDS for Children (WHO Clinical Staging of HIV/AIDS for Children) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification WHO Clinical Staging of HIV/AIDS for Children Test Code Terminology | CC-WHO Clinical Staging of HIV/AIDS for Children TESTCD | WHIVS2TC | WHO Clinical Staging of HIV/AIDS for Children Clinical Classification Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086053","CDISC Clinical Classification CDC Classification System for HIV-Infected Adults and Adolescents Test Name Terminology","C124677","Test names of clinical classification questions associated with the Center for Disease Control and Prevention Classification System for HIV-Infected Adults and Adolescents (CDC Classification System for HIV-Infected Adults and Adolescents) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification CDC Classification System for HIV-Infected Adults and Adolescents Test Name Terminology | CC-CDC Classification System for HIV-Infected Adults and Adolescents TEST | CDC Classification System for HIV-Infected Adults and Adolescents Clinical Classification Test Name | CHIVC1TN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085578","UIMC1 wt Allele","C124099","Human UIMC1 wild-type allele is located in the vicinity of 5q35.2 and is approximately 118 kb in length. This allele, which encodes BRCA1-A complex subunit RAP80 protein, plays a role in DNA damage responses and binding to ubiquitinated histones.","UIMC1 wt Allele | RAP80 | RXRIP110 | Receptor-Associated Protein, 80-kD Gene | Ubiquitin Interaction Motif Containing 1 wt Allele | X2HRIP110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1143925","BRCA1-A Complex Subunit RAP80, Human","C124100","BRCA1-A complex subunit RAP80 (719 aa, ~80 kDa) is encoded by the human UIMC1 gene. This protein is involved in the recognition of damaged DNA.","BRCA1-A Complex Subunit RAP80 | Receptor Associated Protein 80 | Receptor-Associated Protein 80 | Retinoid X Receptor Interacting Protein | Retinoid X Receptor-Interacting Protein 110 | UIMC1 | Ubiquitin Interaction Motif-Containing Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2606719","Flap endonuclease GEN homolog 1, Human","C124103","Flap endonuclease GEN homolog 1 (908 aa, ~103 kDa) is encoded by the human GEN1 gene. This protein plays a role in homologous recombination and DNA repair.","Flap Endonuclease GEN Homolog 1 | EC 3.1.-.- | GEN1 | GEN1 Holliday Junction 5 Flap Endonuclease | Gen Endonuclease Homolog 1 | Holliday Junction Resolvase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502605","LNA-based antimiR-155 MRG-106","C124225","A locked nucleic acid (LNA)-based oligonucleotide inhibitor of microRNA (miRNA) 155 (miR-155), with potential antineoplastic activity. Upon administration, cobomarsen targets, binds to and inhibits miR-155. This silences miR-155 and prevents the translation of certain tumor promoting genes, which leads to the induction of cancer cell apoptosis and the inhibition of tumor cell growth. miR-155, an oncogenic single-stranded, non-coding RNA that is critical to the regulation of gene expression, is overexpressed in certain tumor cell types. Up-regulation of miR-155 plays a key role in increased tumor cell proliferation and survival. The LNA is an RNA analog in which the ribose ring is locked in a particular confirmation that increases stability. Compared to the unmodified oligonucleotide, the LNA-modified oligonucleotide shows increased affinity for its target miR-155.","Cobomarsen | COBOMARSEN | MRG-106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502606","pan-PIM inhibitor INCB053914","C124226","An orally available, small molecule and selective ATP-competitive pan-inhibitor of proviral integration sites for Moloney murine leukemia virus (PIM) kinases, with potential antineoplastic activity. Upon oral administration, uzansertib binds to and inhibits the activities of the three PIM isoforms, PIM1, PIM2 and PIM3. This prevents phosphorylation of their downstream targets and inhibits proliferation in cells that overexpress PIMs. PIMs, constitutively active proto-oncogenic serine/threonine kinases upregulated in various types of cancers, play key roles in tumor cell proliferation and survival.","Uzansertib | INCB 053914 | INCB053914 | INCB53914 | Pan-PIM Inhibitor INCB053914 | Pan-PIM Kinase Inhibitor INCB053914 | UZANSERTIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086552","Locally Advanced Disease Clinical Trial Setting","C124451","A clinical trial or treatment setting in which the therapy of interest is used to treat locally advanced disease.","Locally Advanced Disease Clinical Trial Setting | LOCALLY ADVANCED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085632","Metastatic Disease Clinical Trial Setting","C124452","A clinical trial or treatment setting in which the therapy of interest is used to treat metastatic disease.","Metastatic Disease Clinical Trial Setting | METASTATIC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086621","Neoadjuvant Therapy Clinical Trial Setting","C124453","A clinical trial or treatment setting in which the therapy of interest is considered neo-adjuvant.","Neoadjuvant Therapy Clinical Trial Setting | NEO-ADJUVANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085574","Preventative Therapy Clinical Trial Setting","C124454","A clinical trial or treatment setting in which the therapy of interest is considered preventative.","Preventative Therapy Clinical Trial Setting | PREVENTATIVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086704","PANSS - Poor Impulse Control","C124774","Positive and Negative Syndrome Scale (PANSS) Temperature - Poor impulse control.","PANSS - Poor Impulse Control | PANSS1-Poor Impulse Control | PANSS128",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086706","PANSS - Preoccupation","C124775","Positive and Negative Syndrome Scale (PANSS) Temperature - Preoccupation.","PANSS - Preoccupation | PANSS1-Preoccupation | PANSS129",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086684","PANSS - Active Social Avoidance","C124776","Positive and Negative Syndrome Scale (PANSS) Temperature - Active social avoidance.","PANSS - Active Social Avoidance | PANSS1-Active Social Avoidance | PANSS130",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086956","WHO Clinical Staging of HIV/AIDS for Adults and Adolescents - WHO Clinical Stage of HIV/AIDS","C124777","World Health Organization Clinical Staging of HIV/AIDS for Adults and Adolescents (WHO Clinical Staging of HIV/AIDS for Adults and Adolescents) WHO clinical stage of HIV/AIDS.","WHO Clinical Staging of HIV/AIDS for Adults and Adolescents - WHO Clinical Stage of HIV/AIDS | WHIVS1-WHO Clinical Stage of HIV/AIDS | WHIVS101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087087","WHO Clinical Staging of HIV/AIDS for Children - WHO Clinical Stage of HIV/AIDS","C124778","World Health Organization Clinical Staging of HIV/AIDS for Children (WHO Clinical Staging of HIV/AIDS for Children) WHO clinical stage of HIV/AIDS.","WHO Clinical Staging of HIV/AIDS for Children - WHO Clinical Stage of HIV/AIDS | WHIVS2-WHO Clinical Stage of HIV/AIDS | WHIVS201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086883","TMT - Time to Complete Trails A","C124780","Trail Making Test (TMT) Time (in seconds) to complete Trails A.","TMT - Time to Complete Trails A | TMT01-Time to Complete Trails A | TMT0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086884","TMT - Time to Complete Trails B","C124781","Trail Making Test (TMT) Time (in seconds) to complete Trails B.","TMT - Time to Complete Trails B | TMT01-Time to Complete Trails B | TMT0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086715","PHQ-15 - Total Score","C124782","Patient Health Questionnaire - 15 (PHQ-15) Total score.","PHQ-15 - Total Score | PHQ02-Total Score | PHQ0216",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503015","Anti-OX40 Monoclonal Antibody GSK3174998","C124783","An agonistic humanized immunoglobulin G1 (IgG1) monoclonal antibody against the cell surface receptor OX40 (CD134; TNFRSF4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-OX40 monoclonal antibody GSK3174998 selectively binds to and activates OX40. Receptor activation induces proliferation of memory and effector T-lymphocytes and results in a T-cell-mediated immune response against tumor cells, which leads to tumor cell lysis. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and provides a co-stimulatory signal that promotes both the proliferation and survival of activated T-cells.","Anti-OX40 Monoclonal Antibody GSK3174998 | GSK-3174998 | GSK3174998",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416502","ITGB6 Gene","C124265","This gene plays a role in cell-matrix adhesion.","ITGB6 Gene | ITGB6 | Integrin Beta 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0075616","Exisulind","C1239","An inactive metabolite of the nonsteroidal, anti-inflammatory agent sulindac.  After oral administration, sulindac undergoes extensive biotransformation including irreversible oxidation to sulindac sulfone.  Approximately, one half of an administered dose of sulindac is eliminated through the urine, mostly as the conjugated sulfone metabolite. (NCI04)","Exisulind | (Z)-5-Fluoro-2-methyl-1-[[4-(methylsulfonyl)phenyl]methylene]-1H-indene-3-acetic Acid | 1H-Indene-3-acetic Acid, 5-Fluoro-2-methyl-1-((4-(methylsulfonyl)phenyl)methylene), (Z) | Aptosyn | EXISULIND | FGN-1 | Sulindac Sulfone | Sulindac sulfone | exisulind",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086141","Cardiovascular System Findings Sequence Number","C124000","An identifier that describes the relative position of cardiovascular system findings data within a series.","Cardiovascular System Findings Sequence Number | CVSEQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084852","ITGB6 wt Allele","C124266","Human ITGB6 wild-type allele is located in the vicinity of 2q24.2 and is approximately 172 kb in length. This allele, which encodes integrin beta-6, is involved in cell matrix adhesion. Mutation of the gene is associated with amelogenesis imperfecta, type IH.","ITGB6 wt Allele | AI1H | Integrin Beta 6 wt Allele | Integrin, Beta 6 Gene | Integrin, Beta-6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0123744|C5771838","Integrin Beta-6|ITGB6 protein, human","C124267","Integrin beta-6 (788 aa, ~86 kDa) is encoded by the human ITGB6 gene. This protein plays a role in cell-matrix adhesion.","Integrin Beta-6 | ITGB6 | Integrin Beta 6 | Integrin Beta6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--|--"
"C4087096","Childhood Myxopapillary Ependymoma","C124269","A myxopapillary ependymoma that occurs during childhood.","Childhood Myxopapillary Ependymoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086165","Childhood Neuroblastoma","C124270","A neuroblastoma that occurs during childhood.","Childhood Neuroblastoma | Neuroblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086158","Childhood Ganglioneuroblastoma","C124271","A ganglioneuroblastoma that occurs during childhood.","Childhood Ganglioneuroblastoma | Ganglioneuroblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502654","Childhood Central Nervous System Ganglioneuroblastoma","C124272","A central nervous system ganglioneuroblastoma that occurs during childhood.","Childhood Central Nervous System Ganglioneuroblastoma | Central Nervous System Ganglioneuroblastoma | Childhood Cerebral Ganglioneuroblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086157","Childhood Ganglioneuroblastoma, Nodular","C124274","A nodular ganglioneuroblastoma that occurs during childhood.","Childhood Ganglioneuroblastoma, Nodular | Childhood Nodular Ganglioneuroblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL413560","Childhood Astrocytoma","C124275","An astrocytoma that occurs during childhood.","Childhood Astrocytoma | Astrocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503135","Anogenital Distance","C124276","A measurement of the length of the span between the anus and the base of the genitalia.","Anogenital Distance | ANGDIST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086198","Clinical Trial Setting","C124277","No value exists.","Clinical Trial Setting | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020414","Hymenolepis","C124278","No value exists.","Hymenolepis | ",,,,,,,,,,,,,,,"4297030","Hymenolepis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086512","Implantation Site Characterization","C124279","No value exists.","Implantation Site Characterization | IMPSCHCT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086627","Nonclinical Trial Phase","C124280","A distinguishable part or stage in a nonclinical study.","Nonclinical Trial Phase | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0686762","Dumbbell Ossification","C124528","A finding of a fusion of two approximately spherical primary ossification centers at or near the mid-line through an ossified bony bridge, as indicated by staining.","Dumbbell Ossification | DUMBBELL OSSIFICATION",,,,,,,,,,,,,,,"4008489","Dumbbell ossification",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0266680","Ethmocephaly","C124529","A congenital abnormality characterized by the presence of holoprosencephaly, a proboscis, the absence of a nose and microphthalmic, close-set eyes.","Ethmocephaly | ETHMOCEPHALY",,,,,,,,,,,,,,,"4206486","Ethmocephalus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL502723","Penicillinase Positive Staphylococcus Aureus","C124403","A subgroup of S. aureus bacteria that produce beta-lactamase (penicillinase) and are therefore resistant to beta-lactam (penicillin) antibiotics.","Penicillinase Positive Staphylococcus Aureus | STAPHYLOCOCCUS AUREUS, PENICILLINASE POSITIVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0445627","Staphylococcus cohnii subsp. urealyticus","C124404","A subspecies of Staphylococcus cohnii that is positive for urease, beta-glucuronidase, and beta-galactosidase activities, with delayed alkaline phosphatase activity and the ability to produce acid aerobically from alpha-lactose. This subspecies is most frequently isolated in homes and is only rarely encountered in the hospital setting.","Staphylococcus cohnii subsp. urealyticus | STAPHYLOCOCCUS COHNII SUBSP. UREALYTICUS",,,,,,,,,,,,,,,"4014323","Staphylococcus ureilyticus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1265289","Staphylococcus schleiferi subsp. coagulans","C124405","A subspecies of Staphylococcus schleiferi that is coagulase tube test positive, produces betahemolysin and a heat-stable nuclease but not a clumping factor. This subspecies has not been isolated from humans.","Staphylococcus schleiferi subsp. coagulans | STAPHYLOCOCCUS SCHLEIFERI SUBSP. COAGULANS",,,,,,,,,,,,,,,"4015542","Staphylococcus schleiferi subsp. coagulans",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1022538","Staphylococcus succinus","C124406","A species of coagulase-negative, Gram-positive coccoid bacterium in the order Bacillales.","Staphylococcus succinus | STAPHYLOCOCCUS SUCCINUS",,,,,,,,,,,,,,,"4236267","Staphylococcus succinus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320124","Stemphylium","C124407","A genus of brown-pigmented fungi in the family Pleosporaceae with terminal, multicellular conidia. Species in the genus are commonly found in soil and on decaying plant matter, but several species are plant pathogens.","Stemphylium | STEMPHYLIUM",,,,,,,,,,,,,,,"4236760","Stemphylium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242709","Streptococcus equi subsp. zooepidemicus","C124408","A subspecies of Streptococcus equi that is positive for beta hemolysis, produces hyaluronic acid but not streptolysin O, and occurs in pairs or long chains. This subspecies is also lactose positive and capable of fermenting sorbitol but not trehalose.","Streptococcus equi subsp. zooepidemicus | STREPTOCOCCUS EQUI SUBSP. ZOOEPIDEMICUS",,,,,,,,,,,,,,,"4142898","Streptococcus equi subsp. zooepidemicus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1192147","Streptococcus lutetiensis","C124409","A species of Gram-positive, non-sporulating, non-motile coccus-shaped bacteria in the order Lactobacillales. S.lutetiensis is positive for alpha-galactosidase and beta-glucosidase and negative for catalase, urease, alkaline phosphatase, beta-glactosidase, and beta-glucuronidase. The species has been isolated from human cerebrospinal fluid, urine, and stool.","Streptococcus lutetiensis | STREPTOCOCCUS LUTETIENSIS",,,,,,,,,,,,,,,"4214083","Streptococcus lutetiensis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1679657","Streptococcus massiliensis","C124410","A species of Gram-positive, non-motile, non-spore-forming coccus-shaped bacteria in the order Lactobacillales. S. massiliensis is negative for beta-glucosidase, beta-galactosidase, beta-glucuronidase, alpha-galactosidase, urease, beta-glucosaminidase and beta-mannosidase. The species ferments maltose but is negative for fermentation of other sugars. It was originally isolated form a human clinical blood sample.","Streptococcus massiliensis | STREPTOCOCCUS MASSILIENSIS",,,,,,,,,,,,,,,"40480270","Streptococcus massiliensis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038409","Streptococcus mutans","C124411","A species of Gram-positive coccus-shaped bacteria in the order Lactobacillales. S. mutants is commonly found in the human oral cavity, where is a primary causative agent of tooth decay.","Streptococcus mutans | STREPTOCOCCUS MUTANS",,,,,,,,,,,,,,,"4064691","Streptococcus mutans",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1035386","Streptococcus pluranimalium","C124412","A species of Gram-positive coccus-shaped, non-motile bacteria in the order Lactobacillales. S. pluranimalium is positive for acid production from glucose, fructose, and trehalose. This species is primarily responsible for infection in bovine and avian species with only limited identification of infection in human clinical isolates.","Streptococcus pluranimalium | STREPTOCOCCUS PLURANIMALIUM",,,,,,,,,,,,,,,"4229355","Streptococcus pluranimalium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1140704","Streptococcus viridans","C124413","A non-taxonomic grouping of Streptococcal bacteria that are either alpha-hemolytic, producing a green coloration on blood agar plates, or nonhemolytic. Within this heterogeneous group, some species are commensal flora while others are human pathogens.","Streptococcus viridans | STREPTOCOCCUS VIRIDANS | VGS | Viridans Group Streptococci | Viridans Streptococcal Species | Viridans Streptococci",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086824","Respiratory System Findings Sponsor Defined Identifier","C124005","One or more sponsor defined characters used to identify, name, or characterize the respiratory system findings.","Respiratory System Findings Sponsor Defined Identifier | RESPID | Respiratory System Findings Sponsor-Defined Identifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086436","Healthcare Encounters Start Date Time","C124009","The date and time a healthcare encounter began.","Healthcare Encounters Start Date Time | HOSTDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086135","Cardiovascular System Findings Planned Start of Assessment Interval","C124011","The period of time that the cardiovascular system findings assessment, done over an interval of time, is intended to begin.","Cardiovascular System Findings Planned Start of Assessment Interval | CVSTINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086261","Electrocardiogram Planned Start of Assessment Interval","C124012","The period of time that the electrocardiogram assessment, done over an interval of time, is intended to begin.","Electrocardiogram Planned Start of Assessment Interval | EGSTINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086817","Respiratory System Findings Planned Start of Assessment Interval","C124014","The period of time that the respiratory system findings assessment, done over an interval of time, is intended to begin.","Respiratory System Findings Planned Start of Assessment Interval | RESTINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333056","Evagination","C124530","A finding that indicates an anatomic structure is partially or completely turned inside out.","Evagination | EVAGINATION",,,,,,,,,,,,,,,"4012790","Protrusion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0266453","Exencephaly","C124531","A congenital abnormality characterized by the extrusion of the brain outside of the skull.","Exencephaly | EXENCEPHALY",,,,,,,,,,,,,,,"4309376","Exencephaly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086288","External Auditory Canal Fistula","C124532","An abnormal communication between the external auditory canal and the adjacent tissues.","External Auditory Canal Fistula | EXTERNAL AURAL FISTULA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085199","Externalized Heart","C124533","A type of exocardia in which the heart develops outside of the body.","Externalized Heart | EXTERNALIZED HEART | Ectopia Cordis | Exocardia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086316","Fleshy Tab","C124534","A tag or fold of skin or mucous tissue that extends from an anatomical structure without bony support.","Fleshy Tab | FLESHY TAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0699952","Fused","C124537","A physical quality in which the entity or structure is physically attached or combined with another entity or structure to become a whole.","Fused | FUSED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152415","Ankyloglossia","C124538","A developmental abnormality in which the bottom of the tongue is attached to the floor of the mouth.","Ankyloglossia | FUSED TO FLOOR OF MOUTH",,,,,,,,,,,,,,,"436812","Tongue tie",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086442","Hemicentric","C124539","Of or pertaining to the lateral aspects of the vertebral centrum.","Hemicentric | HEMICENTRIC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3553522","Hemivertebra","C124541","A congenital abnormality characterized by incomplete development of one side of the vertebrae (arch and hemicentrum), resulting in spinal malformation.","Hemivertebra | HEMIVERTEBRA",,,,,,,,,,,,,,,"79930","Congenital hemivertebra",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3553704","High Arch","C124542","Abnormally raised arch.","High Arch | HIGH-ARCHED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0685866","Holorachischisis","C124543","A form of the neural tube defect spina bifida in which the entire spinal column is open.","Holorachischisis | HOLORACHISCHISIS",,,,,,,,,,,,,,,"4247601","Holorachischisis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086449","Hooked Tail","C124544","A finding that the tail has an approximate 180 degree bend or curve.","Hooked Tail | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0231454","Hyperflexion","C124545","Flexion of a limb or part beyond its normal range.","Hyperflexion | HYPERFLEXION",,,,,,,,,,,,,,,"4169451","Increased flexion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086519","Incomplete Chondrogenesis","C124546","Incomplete formation of cartilage.","Incomplete Chondrogenesis | INCOMPLETE CHONDROGENESIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086119","Cardiovascular System Findings Baseline Flag","C123938","An indication or description that cardiovascular data is a baseline value.","Cardiovascular System Findings Baseline Flag | CVBLFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086800","Respiratory System Findings Baseline Flag","C123939","An indication or description that respiratory data is a baseline value.","Respiratory System Findings Baseline Flag | REBLFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086578","Microscopic Findings Chronicity","C123941","A description or characterization of the duration of a microscopic finding.","Microscopic Findings Chronicity | MICHRON",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086123","Cardiovascular System Findings Consciousness State","C123942","The level of awareness of an organism during a cardiovascular system assessment.","Cardiovascular System Findings Consciousness State | CVCSTATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086804","Respiratory System Findings Consciousness State","C123943","The level of awareness of an organism during a respiratory system assessment.","Respiratory System Findings Consciousness State | RECSTATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086124","Cardiovascular System Findings Data Collection Date Time","C123946","The date and time of cardiovasulcar system data collection.","Cardiovascular System Findings Data Collection Date Time | CVDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086422","Healthcare Encounters Data Collection Date Time","C123947","The date and time of healthcare encounters data collection.","Healthcare Encounters Data Collection Date Time | HODTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086805","Respiratory System Findings Data Collection Date Time","C123948","The date and time of respiratory system data collection.","Respiratory System Findings Data Collection Date Time | REDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086871","Study Day of Cardiovascular System Findings","C123950","The study day that a cardiovascular system assessment is performed.","Study Day of Cardiovascular System Findings | CVDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0077640","Adozelesin","C1270","An alkylating agent that bind to the DNA minor groove in a sequence-specific manner and form covalent adducts with adenines, resulting in the inhibition of DNA replication and induction of apoptosis. (NCI04)","Adozelesin | (7bR,8aS)-N-(2-((4,5,8,8a-Tetrahydro-7-methyl-4-oxocyclopropa(c)pyrrolo(3,2-e)indol-2(1H)-yl)carbonyl)indol-5-yl)-2-benzofurancarboxamide | ADOZELESIN | U-73,975 | U-73975",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085920","ASCVD 10-Year Risk Estimator - Risk Score","C124720","Atherosclerotic Cardiovascular Disease 10-Year Risk Estimator (ASCVD 10-Year Risk Estimator) Risk score.","ASCVD 10-Year Risk Estimator - Risk Score | ASCVD1-ASCVD 10-Year Risk Score | ASCVD101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085923","ASSIGN Score - Risk Score","C124721","ASSIGN Cardiovascular Disease 10-Year Risk Score (ASSIGN Score) Risk score.","ASSIGN Score - Risk Score | ASSG01-ASSIGN Score | ASSG0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086295","FHS CVD 10-Year Risk Score - Risk Score","C124722","Framingham Heart Study Cardiovascular Disease 10-Year Risk Score (FCVD1-Framingham CVD 10-Year Risk Score) Risk score.","FHS CVD 10-Year Risk Score - Risk Score | FCVD1-Framingham CVD 10-Year Risk Score | FCVD101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086830","Reynolds CVD 10-Year Risk Score - Risk Score","C124723","Reynolds Cardiovascular Disease 10-Year Risk Score (Reynolds CVD 10-Year Risk Score) Risk score.","Reynolds CVD 10-Year Risk Score - Risk Score | RCVD01-Reynolds CVD 10-Year Risk Score | RCVD0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086337","GCS01-Best Eye Response","C124724","Glasgow Coma Scale-NINDS Version 1.0 (GCS NINDS Version 1.0) Best eye response.","Glasgow Coma Scale-NINDS Version 1.0 - Best Eye Response | GCS NINDS Version - Best Eye Response | GCS01-Best Eye Response | GCS0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086346","GCS0102","C124725","Glasgow Coma Scale-NINDS Version 1.0 (GCS NINDS Version 1.0) Motor response.","Glasgow Coma Scale-NINDS Version 1.0 - Motor Response | GCS NINDS Version - Motor Response | GCS01-Motor Response | GCS0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086348","GCS0103","C124726","Glasgow Coma Scale-NINDS Version 1.0 (GCS NINDS Version 1.0) Verbal response.","Glasgow Coma Scale-NINDS Version 1.0 - Verbal Response | GCS NINDS Version - Verbal Response | GCS01-Verbal Response | GCS0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086347","GCS0104","C124727","Glasgow Coma Scale-NINDS Version 1.0 (GCS NINDS Version 1.0) Total score.","Glasgow Coma Scale-NINDS Version 1.0 - Total Score | GCS NINDS Version - Total Score | GCS01-Total Score | GCS0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086343","GCS01-Confounder: Paralytic","C124729","Glasgow Coma Scale-NINDS Version 1.0 (GCS NINDS Version 1.0) GCS Confounder Type: paralytic.","Glasgow Coma Scale-NINDS Version 1.0 - Confounder: Paralytic | GCS NINDS Version - Confounder: Paralytic | GCS01-Confounder: Paralytic | GCS0105B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086338","GCS01-Confounder: Alcohol/Drug of Abuse","C124730","Glasgow Coma Scale-NINDS Version 1.0 (GCS NINDS Version 1.0) GCS Confounder Type: alcohol or drugs of abuse.","Glasgow Coma Scale-NINDS Version 1.0 - Confounder: Alcohol or Drug of Abuse | GCS NINDS Version - Confounder: Alcohol or Drug of Abuse | GCS01-Confounder: Alcohol/Drug of Abuse | GCS0105C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086339","GCS01-Confounder: C-Spine Injury","C124731","Glasgow Coma Scale-NINDS Version 1.0 (GCS NINDS Version 1.0) GCS Confounder Type: C-spine injury.","Glasgow Coma Scale-NINDS Version 1.0 - Confounder: C-Spine Injury | GCS NINDS Version - Confounder: C-Spine Injury | GCS01-Confounder: C-Spine Injury | GCS0105D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086445","High Occupancy Target Region","C124228","A regulatory element that is a target for a large number of transcription regulatory proteins. These DNA sequences, which play a role in the regulation of gene expression, bind to transcription factors or coregulatory proteins at a higher density than would be expected by chance.","High Occupancy Target Region | HOT Region | High Occupancy of TRF Region | High Occupancy of Target Region | High Occupancy of Transcription-Related Factors Region | High-Occupancy Target Region",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL498409","Tumor Peptide-loaded Myeloid Dendritic Cells","C124055","A cell-based cancer vaccine composed of myeloid dendritic cells (myDCs) pulsed with tumor peptides with potential immunostimulatory and antineoplastic activities. Upon administration, the tumor peptide-loaded myDCs stimulate a specific cytotoxic T-lymphocyte (CTL) response against the tumor cells, resulting in tumor cell lysis.","Tumor Peptide-loaded Myeloid Dendritic Cells | Tumor Peptide-loaded myDC Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0432242","Desbuquois Dysplasia","C124056","A rare osteochondrodysplasia characterized by short stature, joint laxity, multiple dislocations, vertebral and metaphyseal abnormalities, and advanced carpotarsal ossification. Two forms have been identified: type 1 caused by mutation in the gene CANT1 and type 2 caused by mutations in the gene XYLT1.","Desbuquois Dysplasia | DBQD",,,,,,,,,,,,,,,"4113729","Desbuquois syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2932714","Pontocerebellar Hypoplasia Type 2","C124057","A rare brain developmental disorder caused by mutations in the TSEN54, TSEN2, TSEN34, or SEPSECS gene. The pons and cerebellum are the brain structures that are more severely affected. It is characterized by microcephaly, lack of voluntary motor skills, dysphagia, inability to communicate, abnormal patterns of movement, and spasticity.","Pontocerebellar Hypoplasia Type 2 | PCH2",,,,,,,,,,,,,,,"37395869","Congenital pontocerebellar hypoplasia type 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL502495","anti-PD-1 checkpoint inhibitor PF-06801591","C124058","An inhibitor of the human inhibitory receptor programmed cell death 1 (PD-1; PDCD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sasanlimab targets and binds to PD-1 and blocks the interaction between PD-1 and its ligands, PD-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs) against tumor cells. PD-1, an inhibitory receptor belonging to the B7-receptor family, is expressed on activated T-lymphocytes, B-cells and NK cells; it functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, and plays an important role in tumor evasion from host immunity.","Sasanlimab | Anti-PD-1 PF-06801591 | PF-06801591 | SASANLIMAB | WHO 11161",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086873","Study Day of Respiratory System Findings","C123952","The study day that a respiratory system assessment is performed.","Study Day of Respiratory System Findings | REDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086127","Cardiovascular System Findings End Date Time","C123955","The date and time a cardiovascular system assessment has concluded.","Cardiovascular System Findings End Date Time | CVENDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086425","Healthcare Encounters End Date Time","C123956","The date and time a healthcare encounter assessment has concluded.","Healthcare Encounters End Date Time | HOENDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086052","CDISC Clinical Classification CDC Classification System for HIV-Infected Adults and Adolescents Test Code Terminology","C124678","Test codes of clinical classification questions associated with the Center for Disease Control and Prevention Classification System for HIV-Infected Adults and Adolescents (CDC Classification System for HIV-Infected Adults and Adolescents) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification CDC Classification System for HIV-Infected Adults and Adolescents Test Code Terminology | CC-CDC Classification System for HIV-Infected Adults and Adolescents TESTCD | CDC Classification System for HIV-Infected Adults and Adolescents Clinical Classification Test Code | CHIVC1TC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086073","CDISC Clinical Classification West Haven Criteria Test Name Terminology","C124679","Test names of clinical classification questions associated with the West Haven Hepatic Encephalopathy Grade (West Haven Criteria) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification West Haven Criteria Test Name Terminology | CC-West Haven Criteria TEST | WHEG01TN | West Haven Hepatic Encephalopathy Grade Clinical Classification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086072","CDISC Clinical Classification West Haven Criteria Test Code Terminology","C124680","Test codes of clinical classification questions associated with the West Haven Hepatic Encephalopathy Grade (West Haven Criteria) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification West Haven Criteria Test Code Terminology | CC-West Haven Criteria TESTCD | WHEG01TC | West Haven Hepatic Encephalopathy Grade Clinical Classification Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086059","CC-GCS NINDS Version TEST","C124681","Test names of clinical classification questions associated with the Glasgow Coma Scale-NINDS Version 1.0 (GCS NINDS Version 1.0) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification Glasgow Coma Scale-NINDS Version 1.0 Test Name Terminology | CC-GCS NINDS Version TEST | CDISC Clinical Classification GCS NINDS Version Test Name Terminology | GCS01TN | Glasgow Coma Scale NINDS Version 1.0 Clinical Classification Test Name | Glasgow Coma Scale NINDS Version Clinical Classification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086055","CDISC Clinical Classification CRS-R Test Name Terminology","C124683","Test names of clinical classification questions associated with the JFK Coma Recovery Scale-Revised (CRS-R) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification CRS-R Test Name Terminology | CC-CRS-R TEST | CRSR01TN | JFK Coma Recovery Scale-Revised Clinical Classification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086054","CDISC Clinical Classification CRS-R Test Code Terminology","C124684","Test codes of clinical classification questions associated with the JFK Coma Recovery Scale-Revised (CRS-R) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification CRS-R Test Code Terminology | CC-CRS-R TESTCD | CRSR01TC | JFK Coma Recovery Scale-Revised Clinical Classification Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502610","Fluorine F 18 FP-R01-MG-F2","C124230","A radiotracer composed of the integrin alphaVbeta6 (aVb6) ligand and cystine knot peptide R01 variant R01-MG-F2 radiolabeled with [18F]-fluoropropionate (F 18 FP), with potential integrin aVb6 imaging activity using positron emission tomography (PET). Upon administration, the R01-MG-F2 moiety of fluorine F 18 FP-R01-MG-F2 selectively binds to integrin aVb6-positive cancer cells. During PET, aVb6-expressing tumor cells can be visualized. Integrin aVb6, a cell adhesion and signaling receptor, is upregulated in certain cancer cell types and has been associated with increased proliferation of tumor cells. The cystine knot peptide shows high stability and allows for rapid and high uptake into aVb6-expressing tumor cells.","Fluorine F 18 FP-R01-MG-F2 | [18F] FP-R01-MG-F2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086518","Inch Strip Dosing Unit","C124231","A dosing unit equal to the amount of active ingredient(s) contained in an inch ribbon of a topical substance.","Inch Strip Dosing Unit | Inch Strip",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL502612","Anti-CD3 OKT3/Anti-EGFR Bispecific Antibody Armed Activated T Lymphocytes","C124232","No value exists.","Anti-CD3 OKT3/Anti-EGFR Bispecific Antibody Armed Activated T Lymphocytes | EGFR BATs | EGFRBi-armed Autologous ATCs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084746","SLC45A2 wt Allele","C124235","Human SLC45A2 wild-type allele is located in the vicinity of 5p13.2 and is approximately 40 kb in length. This allele, which encodes membrane-associated transporter protein, plays a role in both melanocyte differentiation and melanin synthesis. Mutation of the gene is associated with oculocutaneous albinism type 4, and polymorphisms in this gene are associated with variations in skin and hair color.","SLC45A2 wt Allele | 1A1 | AIM-1 | AIM1 | MATP | OCA4 | SHEP5 | Solute Carrier Family 45, Member 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1721526","Membrane-Associated Transporter Protein, Human","C124236","Membrane-associated transporter protein (530 aa, ~58 kDa) is encoded by the human SLC45A2 gene. This protein is involved in the modulation of both melanin synthesis and melanocyte differentiation.","Membrane-Associated Transporter Protein | Melanoma Antigen AIM1 | Membrane Associated Transporter | Protein AIM-1 | SLC45A2 | Solute Carrier Family 45 Member 2 | Underwhite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447562","Src Kinase-Associated Phosphoprotein 1, Human","C124239","Src kinase-associated phosphoprotein 1 (359 aa, ~41 kDa) is encoded by the human SKAP1 gene. This protein plays a role in integrin clustering following T-cell receptor signaling.","Src Kinase-Associated Phosphoprotein 1 | Epididymis Secretory Sperm Binding Protein Li 81p | SCAP1 | SKAP-55 | Src Family-Associated Phosphoprotein 1 | Src Kinase-Associated Phosphoprotein of 55 kDa | Src Kinase-Associated Phosphoprotein, 55-kD | pp55",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086287","Extended Release Chewable Tablet","C124794","A tablet that must be chewed in order to release active and/or inert ingredient(s) at a controlled, prolonged rate so as to reduce dosing frequency.","Extended Release Chewable Tablet Dosage Form | CHEWABLE EXTENDED RELEASE TABLET | Extended Release Chewable Tablet | Extended Release Chewable Tablet | Extended Release Chewable Tablet Dosage Form | Extended Release Chewable Tablet Dose Form | Prolonged-release chewable tablet | TABLET, CHEWABLE, EXTENDED RELEASE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086061","CDISC Clinical Classification PANSS Test Name Terminology","C124685","Test names of clinical classification questions associated with the Positive and Negative Syndrome Scale (PANSS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification PANSS Test Name Terminology | CC-PANSS TEST | PANSS1TN | Positive and Negative Syndrome Scale Clinical Classification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086060","CDISC Clinical Classification PANSS Test Code Terminology","C124686","Test codes of clinical classification questions associated with the Positive and Negative Syndrome Scale (PANSS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification PANSS Test Code Terminology | CC-PANSS TESTCD | PANSS1TC | Positive and Negative Syndrome Scale Clinical Classification Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086075","CDISC Functional Test TMT Test Name Terminology","C124687","Test names of functional test questions associated with the Trail Making Test (TMT) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Functional Test TMT Test Name Terminology | FT-TMT TEST | TMT01TN | Trail Making Test Functional Test Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086074","CDISC Functional Test TMT Test Code Terminology","C124688","Test codes of functional test questions associated with the Trail Making Test (TMT) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Functional Test TMT Test Code Terminology | FT-TMT TESTCD | TMT01TC | Trail Making Test Functional Test Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086892","Tanner Scale-Boy Clinical Classification Question","C124689","A question associated with the Tanner Scale-Boy clinical classification.","Tanner Scale-Boy Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509055","CDISC Questionnaire EPIC-26 Test Name Terminology","C127349","Test names of questionnaire questions associated with the Expanded Prostate Cancer Index Composite Short Form (EPIC-26) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire EPIC-26 Test Name Terminology | EPIC1TN | QS-EPIC-26 TEST | The Expanded Prostate Cancer Index Composite Short Form Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509057","CDISC Questionnaire EPIC-CP Test Name Terminology","C127351","Test names of questionnaire questions associated with the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire EPIC-CP Test Name Terminology | EPIC2TN | QS-EPIC-CP TEST | The Expanded Prostate Cancer Index Composite for Clinical Practice Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509056","CDISC Questionnaire EPIC-CP Test Code Terminology","C127352","Test codes of questionnaire questions associated with the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire EPIC-CP Test Code Terminology | EPIC2TC | QS-EPIC-CP TESTCD | The Expanded Prostate Cancer Index Composite for Clinical Practice Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509373","CDISC Questionnaire FACT-G Version 4 Test Name Terminology","C127353","Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACT-G Version 4 Test Name Terminology | FAC001TN | QS-FACT-G Version 4 TEST | The Functional Assessment of Cancer Therapy-General Version 4 Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086367","Gravid Uterus Adjusted Maternal Body Weight Gain","C124476","The amount of maternal body weight gained over a period of time where the weight at the end of the interval is adjusted for the gravid uterus weight. This is derived by subtracting the maternal body weight adjusted for the gravid uterus from the total maternal body weight.","Gravid Uterus Adjusted Maternal Body Weight Gain | BWGAINGU | Gravid Uterus Adjusted Body Weight Gain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086368","Gravid Uterus Adjusted Maternal Body Weight","C124477","The maternal body weight adjusted for the weight of the gravid uterus. This is derived by subtracting the gravid uterus weight from the total maternal body weight.","Gravid Uterus Adjusted Maternal Body Weight | BWADJGU | Gravid Uterus Adjusted Body Weight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086024","Biparietal Distance","C124478","A measurement of the length of the span between the protuberances of the parietal bones of the skull.","Biparietal Distance | BIPADIST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0751992","Fetal Body Weight","C124479","An estimate or direct measurement of the heaviness of a fetus.","Fetal Body Weight | BWFETAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2145651","Occipitofrontal Diameter","C124481","A measurement of the skull diameter, measured from the external occipital protuberance to the most prominent point of the frontal bone in the midline.","Occipitofrontal Diameter | OCCFDIAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086648","Number of Ossified Skeletal Elements","C124482","A measurement of the number of skeletal elements with ossification centers present.","Number of Ossified Skeletal Elements | OSSKELCT | Ossified Skeletal Element Count",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086313","Fetal Organ Weight","C124483","An estimate or direct measurement of the heaviness of a fetal organ.","Fetal Organ Weight | OWFETAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086850","Sex of Fetus","C124484","The determination of the sex of the fetus.","Sex of Fetus | Fetal Sex | SEXFETAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085928","Abnormal Fissure","C124486","An aberrant or malpositioned long, narrow slit or groove that divides a tissue into distinct areas.","Abnormal Fissure | ABNORMAL FISSURE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085929","Abnormal Flexure","C124487","A flexure that is deviating from the norm or outwith the bounds of what is considered normal.","Abnormal Flexure | ABNORMAL FLEXURE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085930","Abnormal Lobation","C124488","The formation of a lobe of tissue that is aberrant in comparison to normal anatomy.","Abnormal Lobation | ABNORMAL LOBATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086002","Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes","C124795","A preparation of genetically modified autologous lymphocytes comprised of CD62L-positive naïve and memory T-cells (Tn/mem), that are transduced ex vivo with a self-inactivating (SIN) lentiviral vector expressing a hinge-optimized chimeric antigen receptor (CAR) specific for the CD19 antigen and containing CD28 and CD3 zeta signaling domains, and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon isolation of peripheral blood lymphocytes (PBLs), transduction of the CD62L-positive T-lymphocytes, expansion ex vivo and reintroduction of the cells into the patient, the autologous CD19R(EQ)-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-cells target CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.  Devoid of both ligand binding domains and tyrosine kinase activity, EGFRt both facilitates in vivo detection of the administered T-cells and can promote elimination of those cells upon a cetuximab-induced antibody dependent cellular cytotoxicity response. Tn/mem T-cells include naïve T-cells, central memory T-cells (Tcm) and stem cell memory T-cells (Tscm). CD19R(EQ) contains two point mutations in the immunoglobulin (Ig) G4 spacer region, thereby preventing recognition of the CAR by Fc receptors (FcRs).","Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes | CD19R(EQ)28zetaEGFRt+ Tn/Tmem | CD19R(EQ)28zetaEGFRt+ Tn/mem Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503026","protein kinase C inhibitor LXS196","C124796","An orally available protein kinase C (PKC) inhibitor with potential immunosuppressive and antineoplastic activities. Upon oral administration, darovasertib inds to and inhibits PKC, which prevents the activation of PKC-mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells. PKC, a serine/threonine protein kinase overexpressed in certain types of cancer cells, is involved in tumor cell differentiation, proliferation, invasion and survival.","Darovasertib | DAROVASERTIB | IDE 196 | IDE-196 | IDE196 | LXS196 | PKC Inhibitor IDE196 | Protein Kinase C Inhibitor IDE196 | Protein Kinase C Inhibitor LXS196",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028999","Onchocerca","C124282","No value exists.","Onchocerca | ",,,,,,,,,,,,,,,"4192129","Onchocerca",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0321472","Pseudoterranova","C124283","No value exists.","Pseudoterranova | ",,,,,,,,,,,,,,,"4187107","Pseudoterranova",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029108","Opisthorchis","C124284","No value exists.","Opisthorchis | ",,,,,,,,,,,,,,,"4173292","Opisthorchis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036315","Schistosoma","C124285","A genus of trematoda flatworms that are the causative agents of schistosomiasis diseases. The lifecycle of Schistosoma flatworms involves freshwater snails as the intermediate host and humans as the definitive host. They are unique among trematodes, and other flatworms, in that they are dioecious with distinct sexual dimorphism between male and female.","Schistosoma | Blood Fluke",,,,,,,,,,,,,,,"4202359","Schistosoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036230","Sarcocystis","C124286","A genus of intracellular protozoan parasites in the class Conoidasida. The life cycle of Sarcocystis species involve a prey animal as the intermediate host and its predator as the definitive host. Infection with this parasite is known as sarcosporidiosis.","Sarcocystis | SARCOCYSTIS",,,,,,,,,,,,,,,"4146811","Sarcocystis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037964","Spirillaceae","C124287","No value exists.","Spirillaceae | ",,,,,,,,,,,,,,,"4168830","Family Spirillaceae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320287","Retortamonas","C124289","A genus of flagellate protozoa in the phylum Metamonada that reside in the intestines of both vertebrate and invertebrate animals.","Retortamonas | ",,,,,,,,,,,,,,,"4267275","Retortamonas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036197","Sarcina","C124290","No value exists.","Sarcina | ",,,,,,,,,,,,,,,"4240213","Sarcina",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086153","Childhood Atypical Choroid Plexus Papilloma","C124291","An atypical choroid plexus papilloma that occurs during childhood.","Childhood Atypical Choroid Plexus Papilloma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280623","Childhood Choroid Plexus Carcinoma","C124292","A choroid plexus carcinoma that occurs during childhood.","Childhood Choroid Plexus Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086151","Childhood Anaplastic Ependymoma","C124293","An anaplastic ependymoma that occurs during childhood.","Childhood Anaplastic Ependymoma | Anaplastic Ependymoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509564","Volume at End Ventricular Diastole","C127604","The volume of blood remaining in a receptacle chamber at end ventricular diastole.","Volume at End Ventricular Diastole | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509565","Volume at End Ventricular Systole","C127605","The volume of blood remaining in a receptacle chamber at end ventricular systole.","Volume at End Ventricular Systole | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085931","Abnormal Origin","C124489","An origin that is deviating from the norm or outwith the bounds of what is considered normal.","Abnormal Origin | ABNORMAL ORIGIN | Malpositioned Origin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086121","Cardiovascular System Findings Character Result in Standard Format","C124015","The standard character or string for representation and reporting of cardiovascular system findings data.","Cardiovascular System Findings Character Result in Standard Format | CVSTRESC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086131","Cardiovascular System Findings Numeric Result in Standard Unit","C124017","The numerical identifier of a cardiovascular system finding result in standard units.","Cardiovascular System Findings Numeric Result in Standard Unit | CVSTRESN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086813","Respiratory System Findings Numeric Result in Standard Unit","C124018","The numerical identifier of a respiratory system finding result in standard units.","Respiratory System Findings Numeric Result in Standard Unit | RESTRESN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086140","Cardiovascular System Findings Result Standard Unit","C124019","The standard unit of measure for cardiovascular system findings results.","Cardiovascular System Findings Result Standard Unit | CVSTRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086822","Respiratory System Findings Result Standard Unit","C124020","The standard unit of measure for respiratory system findings results.","Respiratory System Findings Result Standard Unit | RESTRESU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084733","Cardiovascular System Findings Test","C124024","A character or string that represents the long name of the cardiovascular system findings assessment.","Cardiovascular System Findings Test | CVTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084864","Cardiovascular System Findings Test Code","C124026","A character or string that represents the short code name of the cardiovascular system findings assessment.","Cardiovascular System Findings Test Code | CVTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4084809","Respiratory System Findings Test Code","C124027","A character or string that represents the short code name of the respiratory system findings assessment.","Respiratory System Findings Test Code | RETESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086136","Cardiovascular System Findings Planned Time Point Name","C124028","The literal identifier of a planned point in time for a cardiovascular system findings assessment.","Cardiovascular System Findings Planned Time Point Name | CVTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086818","Respiratory System Findings Planned Time Point Name","C124029","The literal identifier of a planned point in time for a respiratory system findings assessment.","Respiratory System Findings Planned Time Point Name | RETPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086078","CDISC SDTM Biospecimen Events Dictionary Derived Term Terminology","C124297","Terminology associated with the biospecimen events dictionary derived term codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Biospecimen Events Dictionary Derived Term Terminology | BEDECOD | Biospecimen Events Dictionary Derived Term | SDTM-BEDECOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086077","CDISC SDTM Biospecimen Characteristics Test Name Terminology","C124299","Terminology associated with the biospecimen characteristics test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Biospecimen Characteristics Test Name Terminology | BSTEST | Biospecimen Characteristics Test Name | SDTM-BSTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3713846","Tazobactam Sodium","C1242","The sodium salt form of tazobactam, a penicillanic acid sulfone derivative and beta-lactamase inhibitor with antibacterial activity. Tazobactam contains a beta-lactam ring and irreversibly binds to beta-lactamase at or near its active site. This protects other beta-lactam antibiotics from beta-lactamase catalysis. This drug is used in conjunction with beta-lactamase susceptible penicillins to treat infections caused by beta-lactamase producing organisms.","Tazobactam Sodium | TAZOBACTAM SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086076","CDISC SDTM Biospecimen Characteristics Test Code Terminology","C124300","Terminology associated with the biospecimen characteristics test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Biospecimen Characteristics Test Code Terminology | BSTESTCD | Biospecimen Characteristics Test Code | SDTM-BSTESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0685835","Anogenital Distance Increased","C124548","An indication that the anogenital distance is greater than the norm.","Anogenital Distance Increased | INCREASED ANOGENITAL DISTANCE",,,,,,,,,,,,,,,"4247704","Increased anogenital distance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152234","Iniencephaly","C124549","A rare neural tube defect characterized by extreme retroflexion of the head and severe defects of the spine. It is usually associated with other congenital anomalies.","Iniencephaly | INIENCEPHALY",,,,,,,,,,,,,,,"378848","Iniencephaly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152355","Subthalamic Nucleus","C12454","The paired, biconvex cluster of neurons located under the thalamus that plays a major role in the motor cortico-basal ganglia-thalamo-cortical circuit. The subthalamic nucleus is primary involved in the control of voluntary movement.","Subthalamic Nucleus | Luy's nucleus | body of Forel | body of Luys | nucleus of Luys | nucleus of corpus luysii | nucleus subthalamicus | subthalamic nucleus | subthalamic nucleus (of Luys)",,,,,,,,,,,,,"UBERON:0001906","subthalamic nucleus",,,,,,,,,,,,,,,"--"
"CL503126","Discontinuous Anatomic Feature","C124550","An anatomic structure that is disjointed or contains gaps.","Discontinuous Anatomic Feature | Discontinuous | INTERRUPTED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086529","Isolated Ossification Site","C124551","An ossification site not localized to the main ossification area, as indicated by staining, but is still considered to be within the margins of a normal bone precursor.","Isolated Ossification Site | ISOLATED OSSIFICATION SITE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086534","Kinked Tail","C124552","A finding that the tail has a localized undulation.","Kinked Tail | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443246","Left-Sided","C124553","An abnormal transposition to the left side.","Left-Sided | LEFT-SIDED",,,,,,,,,,,,,,,"4137157","Left sided",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4086563","Malrotated","C124555","Abnormally or pathologically rotated.","Malrotated | MALROTATED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086809","Respiratory System Findings End Date Time","C123957","The date and time a respiratory system assessment has concluded.","Respiratory System Findings End Date Time | REENDTC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086128","Cardiovascular System Findings End Day","C123958","The final day of the cardiovascular system assessment.","Cardiovascular System Findings End Day | CVENDY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086134","Cardiovascular System Findings Planned End of Assessment Interval","C123961","The period of time that the cardiovascular system assessment, done over an interval of time, is intended to finish.","Cardiovascular System Findings Planned End of Assessment Interval | CVENINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086260","Electrocardiogram Planned End of Assessment Interval","C123962","The period of time that the electrocardiogram assessment, done over an interval of time, is intended to finish.","Electrocardiogram Planned End of Assessment Interval | EGENINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512280","4SCAR-GD2-modified T-lymphocytes","C128896","Genetically modified autologous T-lymphocytes transduced with a lentiviral vector encoding a fourth generation specific chimeric antigen receptor (4SCAR) specific for the disialoganglioside GD2 and which includes the CD3zeta chain and the signaling domains of the co-stimulatory molecules CD28, CD137, and CD27 fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunomodulating and antineoplastic activities. Upon intravenous administration of 4SCAR-GD2 T-cells, these cells target the GD2 antigen on tumor cells to induce selective toxicity against GD2-expressing tumor cells. The tumor-associated antigen (TAA) GD2 is overexpressed on the surface of neuroblastoma cells and by other neuroectoderm-derived neoplasms, while it is minimally expressed on normal cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered; this binds to the drug binding FKBP12-F36V domain and activates caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation.","4SCAR-GD2-modified T-lymphocytes | 4S-GD2-CAR-T-cells | 4SCAR-GD2 | 4SCAR-GD2 T Cells | 4SCAR-GD2-modified T Cells | GD2-specific 4th Generation Chimeric Antigen Receptor-modified T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512145","Doxorubicin-loaded EGFR-targeting Nanocells","C128897","A nanocell formulation targeting the epidermal growth factor receptor (EGFR) using bispecific antibodies (bsAb) against EGFR and containing the antineoplastic anthracycline antibiotic doxorubicin, with potential antineoplastic activity. Upon administration of doxorubicin-loaded EGFR-targeting nanocells, the nanocells are stable in the bloodstream and the anti-EGFR bsAb moiety targets and binds to EGFR-expressing tumor cells. Upon binding, the nanocell allows for specific delivery of doxorubicin to tumor cells overexpressing EGFR. Upon endocytosis by the tumor cells, the nanocell is broken down and releases doxorubicin, which intercalates into DNA and interferes with topoisomerase II activity, thereby inhibiting DNA replication and RNA synthesis. Compared to doxorubicin alone or liposomal doxorubicin, targeted delivery of doxorubicin improves efficacy while lowering the toxicity profile. EGFR, a tyrosine kinase receptor, is overexpressed in many cancer cell types. The nanocell is a bacterially derived nanosphere; the bacterial components are unlikely to induce an immune response in the immunosuppressed tumor microenvironment.","Doxorubicin-loaded EGFR-targeting Nanocells | Doxorubicin-loaded EGFR-targeting Nanocell | EGFR (Vectibix Sequence)-Targeted EnGeneIC Dream Vectors Containing Doxorubicin | EGFR(V)-EDV-Dox | EGFR-targeted EnGeneIC Dream Vectors Containing Doxorubicin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512118","CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Name Terminology","C129091","Test names of questionnaire questions associated with the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Name Terminology | FAC028TN | National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 Questionnaire Test Name | QS-NCCN-FACT FBLSI-18 Version 2 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512117","CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Code Terminology","C129092","Test codes of questionnaire questions associated with the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Code Terminology | FAC028TC | National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 Questionnaire Test Code | QS-NCCN-FACT FBLSI-18 Version 2 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512114","CDISC Questionnaire FACT-B Version 4 Test Name Terminology","C129093","Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACT-B Version 4 Test Name Terminology | FAC005TN | Functional Assessment of Cancer Therapy-Breast Version 4 Questionnaire Test Name | QS-FACT-B Version 4 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512113","CDISC Questionnaire FACT-B Version 4 Test Code Terminology","C129094","Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACT-B Version 4 Test Code Terminology | FAC005TC | Functional Assessment of Cancer Therapy-Breast Version 4 Questionnaire Test Code | QS-FACT-B Version 4 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512116","CDISC Questionnaire FOSI Test Name Terminology","C129095","Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FOSI Test Name Terminology | FAC049TN | Functional Assessment of Cancer Therapy-Ovarian Symptom Index Questionnaire Test Name | QS-FOSI TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509108","GAIA Level 1 Neonatal Respiratory Distress","C128768","GAIA Level 1 Neonatal Respiratory Distress is defined by four criteria: first, the newborn must be between 0 and 28 days of life; second, the presence of any one of the following three symptoms that indicate an abnormal respiratory rate: a) Tachypnea (respiratory rate of 60 or more breaths per minute); b) Bradypnea (respiratory rate of less than 30 breaths per minute); c) Apnea [cessation of respiratory effort (no breaths) for at least 20 seconds]; third, one of the following five clinical symptoms that indicate labored breathing: a) Nasal flaring (dilatation of alae nasi); b) Noisy respirations in the form of expiratory grunting, stridor, or wheeze; c) Retractions or increased chest indrawings on inspiration (subcostal, intercostal, sternal, suprasternal notch); d) Central cyanosis (whole body, including lips and tongue) on room air; e) Low Apgar score (less than 7 points) at 10 minutes, with respiration score less than 2; fourth, examination and documentation by qualified, trained health care providers who are appropriate for the clinical setting.","GAIA Level 1 Neonatal Respiratory Distress | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Neonatal Respiratory Distress | Level 1 Neonatal Respiratory Distress",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509115","GAIA Level 2 Neonatal Respiratory Distress","C128769","GAIA Level 2 Neonatal Respiratory Distress is defined by four criteria: first, the newborn must be between 0 and 28 days of life; second, an abnormal respiratory rate (not measured, but reported as 'rapid breathing', 'slow breathing', having periods of 'no breathing', or 'abnormal breathing'); third, the presence of any one of the following five clinical symptoms that indicate labored breathing: a) Nasal flaring (dilatation of alae nasi); b) Noisy respirations in the form of expiratory grunting, stridor, or wheeze; c) Retractions or increased chest indrawings on inspiration (subcostal, intercostal, sternal, suprasternal notch) or seesaw respirations; d) Central cyanosis (whole body, including lips and tongue) on room air; e) Low Apgar score (less than 7 points) at 10 minutes with a respiration score less than 2; fourth, one of the following two requirements: a) No medical record documentation, but reporting through either a non-medical observer (e.g., mother, father, community worker) or via standard census mechanisms (e.g., Demographic and Health Surveillance System), or b) Collection of information from medical review or billing codes.","GAIA Level 2 Neonatal Respiratory Distress | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Neonatal Respiratory Distress | Level 2 Neonatal Respiratory Distress",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226233","Posterior Spinal Artery","C12876","An artery arising from the vertebral artery at the level of the medulla oblongata that descends along the posterior roots of the spinal nerves on each side of the spinal cord with branches supplying the spinal cord, pia mater and medulla.","Posterior Spinal Artery | ",,,,,,,,,,,,,,,"4184739","Structure of posterior spinal artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509105","GAIA Level 1 Failure to Thrive","C128770","GAIA Level 1 Failure to Thrive is defined by four criteria: first, the infant's age is determined by a documented birth date; second, weights are obtained using an electronic scale; third, a minimum of two documented weights measured at least four weeks apart; fourth, the weight for age deceleration must pass through at least two centile spaces on a growth chart. Additionally, the following information applies to this term: a. Age: This case definition is limited to infants up to 12 months of age. b. Weight and Length: Weight should be documented on the appropriate growth chart at the time of assessment. A fall through 2 centile spaces may be demonstrated at any point in the first 12 months of life, using any two weights as long as they are taken at least 4 weeks apart. Details of use of the weight balances allowable under this case definition and use of the Infantometer for length assessment are in Appendix A. c. Growth charts: For infants born at 37 weeks gestation or above, the WHO growth charts should be applied. When using weight for age use the growth chart most accurate for the infants age. The birth to 6 months age range should be used where data is available for this range only, the birth to 2 years chart should be used where data is available beyond 6 months of life. When using weight for length, use the chart for birth to 2 years. For infants born less than 37 completed weeks gestation, the Intergrowth charts for postnatal growth standards in preterm infant should be used. All infants should be plotted on their respective growth chart using their corrected age. Links to relevant growth charts can be found in Appendix A (www.gaia-consortium.net).","GAIA Level 1 Failure to Thrive | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Failure to Thrive | Level 1 Failure to Thrive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509117","GAIA Level 2a Failure to Thrive","C128771","GAIA Level 2a Failure to Thrive is defined by either of two criteria: first, the following four requirements must be present: a) Infant age determined by a documented birth date; b) Weights are obtained using a beam balance scale; c) A minimum of two documented weights measured at least four weeks apart; d) Weight for age deceleration must pass through at least two centile spaces on a growth chart; OR second, the following four requirements must be present: a) Infants have an undocumented birth date, where age is determined based on mother's recall to the nearest month; b) Weights are obtained using an electronic scale; c) A minimum of two weights measured at least four weeks apart; d) Weight for age deceleration must pass through at least two centile spaces on a growth chart.","GAIA Level 2a Failure to Thrive | Global Alignment of Immunization safety Assessment in pregnancy Level 2a Failure to Thrive | Level 2a Failure to Thrive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229094","Posterior Chamber of the Eye","C12900","A space within the eye located between the iris and the lens. It is filled with aqueous humor.","Posterior Chamber of the Eye | EYE, POSTERIOR CHAMBER | Eye, Posterior Compartment | Posterior Chamber (Eye) | Posterior Chamber of Eye",,,,,,,,,,,,,,,"4277279","Structure of posterior chamber of eye",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043867","1,24,25-Trihydroxyergocalciferol","C129013","A biologically inactive vitamin D derivative that is produced by the hydroxylation of 1,25-dihydroxyvitamin D2 presumably by 1,25-dihydroxyvitamin D3 24-hydroxylase (CYP24A1). 1,24,25-trihydroxyergocalciferol may be a marker for the metabolism of dietary ergocalciferol.","1,24,25-Trihydroxyergocalciferol | (1alpha,3beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-Tetraene-1,3,24,25-Tetrol | 1,24,25(OH)3 D2 | 1,24,25-Trihydroxyvitamin D2 | 9,10-Secoergosta-5,7,10(19),22-Tetraene-1,3,24,25-Tetrol, (1alpha,3beta,5Z,7E,22E)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509718","Complete Healthcare Knowledge Assessment","C128500","The healthcare provider or setting must complete a knowledge assessment. This applies to knowledge assessments that are standalone questionnaires as well as those that are incorporated into training/educational materials.","Complete Healthcare Knowledge Assessment | Complete Knowledge Assessment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512088","Train Staff about Medication Use Process","C128501","The healthcare setting must train staff who are involved in the medication use process (e.g. prescribing, dispensing, or administering the drug).","Train Staff about Medication Use Process | Train Staff",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509076","GAIA Level 1 Dysfunctional First Stage of Labor","C128717","GAIA Level 1 Dysfunctional First Stage of Labor is defined by progress of less than 0.5 cm of cervical dilation per hour, for at least 4 hours, in women with established labor (i.e. have regular contractions and cervical dilation of at least 4 cm) and with confirmed ruptured membranes.","GAIA Level 1 Dysfunctional First Stage of Labor | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Dysfunctional First Stage of Labor | Level 1 Dysfunctional First Stage of Labor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509077","GAIA Level 1 Dysfunctional Second Stage of Labor","C128719","GAIA Level 1 Dysfunctional Second Stage of Labor is defined by three criteria. For nulliparous women: first, full dilation of the cervix (10 cm dilated, or no palpable cervix around the presenting part of the fetus); second, the onset of the active stage of labor (active maternal effort (i.e. pushing) or visible baby); third, at least one of the following requirements must be met: a) Greater than 2 hours of pushing; OR b) The use of an instrument (forceps or vacuum/ventouse) for the indication of dystocia; OR c) Cesarean delivery for the indication of dystocia. For multiparous women: first, full dilation of the cervix (10 cm dilated, or no palpable cervix around the presenting part of the fetus); second, the onset of the active stage of labor (active maternal effort (i.e. pushing) or visible baby); third, at least one of the following requirements must be met: a) Greater than 1 hour of pushing; OR b) The use of an instrument (forceps or vacuum/ventouse) for the indication of dystocia; OR c) Cesarean delivery for the indication of dystocia.","GAIA Level 1 Dysfunctional Second Stage of Labor | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Dysfunctional Second Stage of Labor | Level 1 Dysfunctional Second Stage of Labor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509089","GAIA Level 2 Dysfunctional Second Stage of Labor","C128720","GAIA Level 2 Dysfunctional Second Stage of Labor is defined by two criteria. For nulliparous and multiparous women: first, full dilation of the cervix (10 cm dilated, or no palpable cervix around the presenting part of the fetus) during any phase of the second stage of labor; second, at least one of the following requirements must be met: a) No delivery within 3 hours of full dilation; OR b) The use of an instrument (forceps or vacuum/ventouse) for the indication of dystocia; OR d) Cesarean delivery for the indication of dystocia.","GAIA Level 2 Dysfunctional Second Stage of Labor | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Dysfunctional Second Stage of Labor | Level 2 Dysfunctional Second Stage of Labor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509086","GAIA Level 1a Fetal Growth Restriction","C128721","GAIA Level 1a Fetal Growth Restriction is defined by two criteria: first, Level 1 evidence of pregnancy dating; second, at least one of the following requirements must be met: a) Estimated fetal weight below the third percentile using locally-accepted growth curve; OR b) Estimated fetal weight below the tenth percentile using locally-accepted growth curve AND either findings of absent or reversed end-diastolic flow of the umbilical artery Doppler OR a finding of oligohydramnios.","GAIA Level 1a Fetal Growth Restriction | Global Alignment of Immunization safety Assessment in pregnancy Level 1a Fetal Growth Restriction | Level 1a Fetal Growth Restriction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512115","CDISC Questionnaire FOSI Test Code Terminology","C129096","Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FOSI Test Code Terminology | FAC049TC | Functional Assessment of Cancer Therapy-Ovarian Symptom Index Questionnaire Test Code | QS-FOSI TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512122","CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Name Terminology","C129097","Test names of questionnaire questions associated with the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Name Terminology | FAC050TN | National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 Questionnaire Test Name | QS-NCCN-FACT FOSI-18 Version 2 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512121","CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Code Terminology","C129098","Test codes of questionnaire questions associated with the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Code Terminology | FAC050TC | National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 Questionnaire Test Code | QS-NCCN-FACT FOSI-18 Version 2 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512441","FACIT-F Version 4 Questionnaire Question","C129099","A question associated with the FACIT-F Version 4 questionnaire.","FACIT-F Version 4 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079784","Recombinant Macrophage Colony-Stimulating Factor","C1290","A recombinant therapeutic agent which is chemically identical to or similar to the endogenous protein cytokine macrophage colony-stimulating factor (M-CSF). Synthesized endogenously by mesenchymal cells, M-CSF stimulates the survival, proliferation, and differentiation of hematopoietic cells of the monocyte-macrophage series and can reverse treatment-related neutropenias. Recombinant M-CSF may also enhance antigen presentation and activate antitumoral cytotoxic T-cells.","Recombinant Macrophage Colony-Stimulating Factor | Macrophage Colony Stimulating Factor | Recombinant Colony Stimulating Factor 1 | rM-CSF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512204","NCCN-FACT FKSI-19 Version 2 Questionnaire Question","C129100","A question associated with the NCCN-FACT FKSI-19 Version 2 questionnaire.","NCCN-FACT FKSI-19 Version 2 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0318793","Zika Virus","C128553","A species of positive sense ssRNA viruses in the family Flaviviridae that is carried and spread by Aedes mosquitoes. This virus causes zika fever and infection in pregnant women can pass to the fetus and is associated with microcephaly and other birth defects. Zika virus infection can also trigger Guillain-Barre paralysis.","Zika Virus | ZIKA VIRUS | ZIKV",,,,,,,,,,,,,,,"4198530","Zika virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512086","Frameless Fractionated Stereotactic Radiation Therapy","C128555","A type of fractionated stereotactic radiotherapy that does not involve the use of a frame to hold the patient's head still or provide external reference points.","Frameless Fractionated Stereotactic Radiation Therapy | FFSRT | FSRS | Frameless SRT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507942","Anti-CD22 CAR-expressing T Lymphocytes","C128556","A preparation of human T-lymphocytes transduced with a recombinant viral vector encoding a chimeric T-cell receptor (chimeric antigen receptor or CAR) consisting of one or more binding domains targeting the tumor-associated antigen (TAA) CD22 and fused to one or more co-stimulatory, TCR-signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD22 CAR-expressing T-lymphocytes, express anti-CD22-CAR on their cell surfaces and bind to the CD22 antigen on tumor cell surfaces. Subsequently, CD22-expressing B-cells are lysed. CD22, a B-lineage-restricted, transmembrane phosphoglycoprotein, is expressed on malignant B-cells.","Anti-CD22 CAR-expressing T Lymphocytes | Anti-CD22 CAR-expressing T-cells | CD22 CAR-T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512370","MIR551A wt Allele","C128930","Human MIR551A wild-type allele is located in the vicinity of 1p36.32 and is 96 bases in length. This allele, which encodes MIR551A pre-miRNA, is involved in the negative regulation of gene expression.","MIR551A wt Allele | MIRN551A | Micro RNA 551A Gene | MicroRNA 551a wt Allele | hsa-miR-551a | miR-551a | miRNA155A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512369","MIR551A Pre-miRNA","C128931","MIR551A pre-miRNA (96 bases) is encoded by the human MIR551A gene. This oligoribonucleotide may play a role in transcriptional silencing.","MIR551A Pre-miRNA | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512225","NELL1 wt Allele","C128935","Human NELL1 wild-type allele is located in the vicinity of 11p15.1 and is approximately 906 kb in length. This allele, which encodes protein kinase C-binding protein NELL1, plays a role in bone mineralization.","NELL1 wt Allele | IDH3GL | NEL-Like 1 (Chicken) Gene | NEL-Like 1 Gene | NRP1 | Nel (Chicken)-Like Gene | Neural EGFL Like 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512304","Protein Kinase C-Binding Protein NELL1","C128936","Protein kinase C-binding protein NELL1 (810 aa, ~90 kDa) is encoded by the human NELL1 gene. This protein is involved in the modulation of osteoblast cell growth and differentiation.","Protein Kinase C-Binding Protein NELL1 | NEL-Like Protein 1 | Nel-Related Protein 1 | Neural Epidermal Growth Factor-Like 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0581631","Cervical Spinal Nerve Root","C12893","The initial segment of a nerve leaving the cervical spine. There are eight pairs of cervical roots, each consisting of two parts: the ventral (efferent motor) and the dorsal (afferent sensory) root which unite to form a single spinal nerve. All cervical nerves exit superiorly to their corresponding vertebrae with the exception of C8, which exits inferiorly to the C7 vertebra.","Cervical Spinal Nerve Root | Cervical Spinal Nerve Roots",,,,,,,,,,,,,,,"4195119","Cervical spinal nerve root structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512371","MT-CO1 wt Allele","C128942","Human MT-CO1 wild-type allele is located within the circular mitochondrial (MT) chromosome and is approximately 1 kb in length. This allele, which encodes cytochrome c oxidase subunit 1, is involved in positive regulation of the mitochondrial electron transport chain. Allelic variation of the gene is associated with Leber hereditary optic neuropathy (LHON). Mutation of the gene is associated with mitochondrial complex IV deficiency (MT-C4D), recurrent mitochondrial myoglobinuria, and mitochondrially inherited nonsyndromic sensorineural deafness. Mutations may also be associated with colorectal cancer.","MT-CO1 wt Allele | COI | COX1 | COXI | Complex IV, Cytochrome c Oxidase Subunit I Gene | MTCO1 | Mitochondrially Encoded Cytochrome C Oxidase I wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3657243","Cytochrome C Oxidase Subunit 1, Human","C128943","Cytochrome c oxidase subunit 1 (513 aa, ~57 kDa) is encoded by the human MT-CO1 gene. This protein plays a role in the final step of oxidative phosphorylation in the mitochondrion.","Cytochrome C Oxidase Subunit 1 | COX Complex IV Subunit I | COX1 | Cytochrome C Oxidase I | Cytochrome C Oxidase Polypeptide I | Cytochrome C Oxidase Subunit I | EC 1.9.3.1 | EC 1.9.3.1, Formerly | EC 7.1.1.9 | MT-CO1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3279058","Lisch Nodule","C128454","A clear, yellow, or brown, well-defined, dome-shaped elevation projecting from the surface of the iris. It is composed of hamartomatous melanocytic aggregates and is the most common ocular manifestation of neurofibromatosis type 1.","Lisch Nodule | Iris Hamartoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509613","Quadrivalent Inactivated Influenza Vaccine","C128455","A synthetic vaccine consisting of hemagglutinin (HA) antigens derived from four inactivated influenza viruses, two different influenza type A strains and two different influenza type B strains, with protective immunizing activity. Quadrivalent influenza vaccine (QIV) is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season. Upon administration, the QIV provides active immunization against the four influenza virus strains, thereby protecting against influenza infection.","Quadrivalent Inactivated Influenza Vaccine | Flucelvax Quadrivalent | Flucelvax Quadrivalent Influenza Vaccine | Fluzone Quadrivalent | Fluzone Quadrivalent Influenza Vaccine | QIV | Quadrivalent Influenza Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509688","Australian/New Zealand Ethnicity","C128458","A collection of ethnic geographical categories including Australian and New Zealander.","Australian/New Zealand Ethnicity | Australian/New Zealand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205826","Lumbar Plexus","C12845","A network of nerves lying within the substance of the psoas muscle that is formed by the ventral rami of L1-L4, and which provides motor and sensory contributions to the anterior and medial compartments of the leg, abdominal wall, and pelvic areas.","Lumbar Plexus | ",,,,,,,,,,,,,,,"4042045","Lumbar plexus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509774","Recurrent Gastrointestinal Stromal Tumor","C128460","The reemergence of a gastrointestinal stromal tumor after a period of remission.","Recurrent Gastrointestinal Stromal Tumor | Recurrent Gastrointestinal Stromal Tumor (GIST)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509259","Inch of Mercury","C128461","A measurement of the pressure exerted by a column of mercury of 1 inch in height at the standard acceleration of gravity. This measurement is used for barometric pressure in aviation, refrigeration, and weather reports. The conversion to metric units is dependent upon the temperature of the mercury.","Inch of Mercury | Inches of Mercury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509689","BET Inhibitor","C128462","No value exists.","BET Inhibitor | BET Bromodomain Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509519","OXT Gene Product","C128463","A protein encoded by the OXT gene.","OXT Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508918","Oxytocin-Neurophysin 1, Human","C128464","Oxytocin-neurophysin 1 (125 aa, ~13kDa) is encoded by the human OXT gene. This protein plays a role in hormonal signaling involved in smooth muscle contraction in both the mammary gland and uterus, and many other psychological and physiological processes.","Oxytocin-Neurophysin 1 | OT-NPI | OXT | Oxytocin, Prepropeptide | Oxytocin--Neurophysin I | Oxytocin-Neurophysin I | Oxytocin-Neurophysin I, Preproprotein | Preprooxytocin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509087","GAIA Level 1b Fetal Growth Restriction","C128722","GAIA Level 1b Fetal Growth Restriction is defined by two criteria: first, Level 1 evidence of pregnancy dating; second, an estimated fetal weight below the tenth percentile using locally-accepted growth curve AND either no findings of absent or reversed end-diastolic flow of the umbilical artery Doppler OR absence of oligohydramnios.","GAIA Level 1b Fetal Growth Restriction | Global Alignment of Immunization safety Assessment in pregnancy Level 1b Fetal Growth Restriction | Level 1b Fetal Growth Restriction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509097","GAIA Level 2a Fetal Growth Restriction","C128723","GAIA Level 2a Fetal Growth Restriction is defined by two criteria: first, Level 2 evidence of pregnancy dating; second, at least one of the following requirements must be met: a) Estimated fetal weight below the third percentile using locally-accepted growth curve; OR b) Estimated fetal weight below the tenth percentile using locally-accepted growth curve AND either findings of absent or reversed end-diastolic flow of the umbilical artery Doppler OR a finding of oligohydramnios.","GAIA Level 2a Fetal Growth Restriction | Global Alignment of Immunization safety Assessment in pregnancy Level 2a Fetal Growth Restriction | Level 2a Fetal Growth Restriction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512384","FGFR4 Inhibitor H3B-6527","C128862","An orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon administration, H3B-6527 specifically binds to and blocks FGFR4. This prevents the activation of FGFR4, inhibits FGFR4-mediated signaling and leads to an inhibition of cell proliferation in FGFR4-overexpressing tumor cells. FGFR4, a receptor tyrosine kinase overexpressed by certain tumor cell types, is involved in tumor cell proliferation, differentiation, angiogenesis, and survival; FGFR4 expression is associated with poor prognosis.","FGFR4 Inhibitor H3B-6527 | Fibroblast Growth Factor Receptor 4 Inhibitor H3B-6527 | H3B 6527 | H3B-6527 | H3B6527",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542831","C4B_2 Gene","C128863","This gene is involved in complement-mediated immunity.","C4B_2 Gene | C4B_2 | Complement Component 4B (Chido Blood Group), Copy 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512103","C4B_2 wt Allele","C128864","Human C4B_2 wild-type allele is located in the vicinity of the 6p21.3 alternate reference locus and is approximately 21 kb in length. This allele, which encodes complement C4-B protein, plays a role in complement-dependent immune processes. The expression of this gene is associated with the expression of Chido blood group antigens. Mutation of the gene is associated with complement component C4B deficiency. Copy number variation and polymorphisms are associated with increased risk for systemic lupus erythematosus.","C4B_2 wt Allele | Complement Component 4B (Chido Blood Group), Copy 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009517","Complement C4-A","C128865","Complement C4-A (1744 aa, ~193 kDa) is encoded by the human C4A gene. This protein plays a role in both host defense and inflammation.","Complement C4-A | Acidic C4 | Acidic Complement C4 | C3 and PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 2 | C4A | Complement Component 4A | Complement Component 4S | Rodgers Form of C4",,,,,,,,,,,,,,,"4223080","Complement component C4a",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009518","Complement Component 4B","C128866","Complement C4-B (1744 aa, ~193 kDa) is encoded by the human C4B and C4B_2 genes. This protein is involved in the propagation of the classical complement pathway.","Complement C4-B | Basic C4 | Basic Complement C4 | C3 and PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 2 | C4B | Chido Form of C4 | Complement Component 4B | Complement Component 4F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512127","CSTA wt Allele","C128868","Human CSTA wild-type allele is located in the vicinity of 3q21 and is approximately 17 kb in length. This allele, which encodes cystatin-A protein, is involved in the inhibition of thiol proteinases and desmosome-mediated cell-cell adhesion. Mutation of the gene is associated with peeling skin syndrome 4.","CSTA wt Allele | AREI | Cystatin A (Stefin A) Gene | Cystatin A wt Allele | PSS4 | STF1 | STFA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0074365","Cystatin-A, Human","C128869","Cystatin-A (98 aa, ~11 kDa) is encoded by the human CSTA gene. This protein plays a role in both cell-cell adhesion in the epidermis and the regulation of thiol proteinase activity.","Cystatin-A | Cystatin A | Cystatin AS | Cystatin-AS | Stefin A | Stefin-A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227629","Renal Pyramid","C12886","A cone-shaped structure of the kidney. It is located in the medullary portion of the kidney (pyramid of Malpighi) or the cortical portion of the kidney (pyramid of Ferrein).","Renal Pyramid | ",,,,,,,,,,,,,,,"4052637","Renal pyramid structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL507943","Topoisomerase I/II Inhibitor NEV-801","C128557","A multi-targeted agent with potential antineoplastic activity. Upon administration, NEV-801 appears to selectively inhibit topoisomerase (Topo) I and II, and activates hypoxia-inducible factor 1 (HIF-1) transcription and the expression of vascular endothelial growth factor (VEGF) mRNA. NEV-801 is also able to overcome multidrug resistance (MDR) 1-mediated resistance.","Topoisomerase I/II Inhibitor NEV-801 | NEV-801 | NEV801 | TopI/II NEV-801",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507944","TLR4 Agonist GSK1795091","C128558","A toll-like receptor 4 (TLR4) agonist, with potential immunoadjuvant activity. Upon administration, GSK1795091 binds to and activates TLR4, thereby stimulating dendritic cells (DCs), monocytes and macrophages. This activation results in the production of pro-inflammatory cytokines, including interferon gamma (IFN-g), tumor necrosis factor-alpha (TNF-a) and the interleukins (IL), IL-1 beta, -6 and -12. This may induce a T helper cell-1 (Th1) immune response and, upon co-administration of a vaccine containing tumor-associated antigens (TAAs), activates a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing those TAAs. TLR4, a member of the TLR family, plays a key role in the activation of innate immunity.","TLR4 Agonist GSK1795091 | GSK-1795091 | GSK1795091 | TLR 4 Agonist GSK1795091 | Toll-like Receptor 4 Agonist GSK1795091",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507946","Sumac/Black Cumin Powder","C128559","An Iranian traditional herbal medicine composed of powder derived from sumac and Bunium persicum (black cumin, black zira), with potential anti-emetic activity. Upon oral administration, sumac/black cumin powder may inhibit chemotherapy-induced nausea and vomiting (CINV). The powder may also have some anti-oxidant activities.","Sumac/Black Cumin Powder | Persumac | Rhus coriaria L./Bunium persicum Boiss Powder | Sumac/Black Zira Powder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509621","Cord Blood-derived Expanded Natural Killer Cells PNK-007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507950","Fructooligosaccharide Supplement","C128561","A supplement containing oligosaccharide fructans, with gastrointestinal (GI) protective and immumopotentiating activities. Upon oral administration of the supplement, the oligosaccharides stimulate the growth of certain GI bacteria and activate the immune system. This improves the intestinal microflora, strengthens the immune system and increases the protective function of the GI barrier.","Fructooligosaccharide Supplement | FOS Supplement | Fructo-oligosaccharide Supplement | Fructo-oligosaccharides Supplement | Oligofructan Supplement | Oligofructose Supplement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509075","GAIA Level 1 Cesarean Scar Pregnancy","C128750","GAIA Level 1 Cesarean Scar Pregnancy is defined by a transvaginal ultrasound that demonstrates the following five findings: first, an empty uterine cavity; second, an empty cervical canal, without contact with the gestational sac; third, the presence of a gestational sac, with or without a fetal pole, with or without cardiac activity, in the anterior uterine segment adjacent to the cesarean scar; fourth, an absence of or a defect in the myometrium between the bladder and the gestational sac; fifth, a well-perfused gestational sac as demonstrated by Doppler ultrasound (to differentiate from an expulsing, avascular gestational sac). Alternatively, Level 1 may be defined as a hysterectomy specimen with evidence of a pregnancy implanted into the cesarean scar.","GAIA Level 1 Cesarean Scar Pregnancy | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Cesarean Scar Pregnancy | Level 1 Cesarean Scar Pregnancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509080","GAIA Level 1 Intra-abdominal Pregnancy","C128751","GAIA Level 1 Intra-abdominal Pregnancy is defined by the discovery of a fetus within the abdominal cavity during laparotomy, without evidence of uterine rupture, and with placentation not within the uterine cavity.","GAIA Level 1 Intra-abdominal Pregnancy | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Intra-abdominal Pregnancy | Level 1 Intra-abdominal Pregnancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509084","GAIA Level 1 Uterine Rupture","C128752","GAIA Level 1 Uterine Rupture is the complete disruption of the uterus, at the time of laparotomy, in the context of vaginal or intra-abdominal bleeding.","GAIA Level 1 Uterine Rupture | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Uterine Rupture | Level 1 Uterine Rupture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512424","FACIT-F Version 4 - I Have Energy","C129144","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Additional Concerns: I have energy.","FACIT-F Version 4 - I Have Energy | FAC071-I Have Energy | FAC07134",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512401","FACIT-F Version 4 - Able to Do My Usual Activities","C129145","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Additional Concerns: I am able to do my usual activities.","FACIT-F Version 4 - Able to Do My Usual Activities | FAC071-Able to Do My Usual Activities | FAC07135",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512428","FACIT-F Version 4 - I Need to Sleep During the Day","C129146","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Additional Concerns: I need to sleep during the day.","FACIT-F Version 4 - I Need to Sleep During the Day | FAC071-I Need to Sleep During the Day | FAC07136",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512412","FACIT-F Version 4 - I Am Too Tired to Eat","C129147","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Additional Concerns: I am too tired to eat.","FACIT-F Version 4 - I Am Too Tired to Eat | FAC071-I Am Too Tired to Eat | FAC07137",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512434","FACIT-F Version 4 - Need Help Doing Usual Activities","C129148","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Additional Concerns: I need help doing my usual activities.","FACIT-F Version 4 - Need Help Doing Usual Activities | FAC071-Need Help Doing Usual Activities | FAC07138",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512405","FACIT-F Version 4 - Frustrated by Being Too Tired","C129149","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Additional Concerns: I am frustrated by being too tired to do the things I want to do.","FACIT-F Version 4 - Frustrated by Being Too Tired | FAC071-Frustrated by Being Too Tired | FAC07139",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333826","Neoplastic Lymphoblast","C12914","No value exists.","Neoplastic Lymphoblast | Atypical Lymphoblast",,,,,,,,,,,,,,,"4225088","Atypical lymphoblast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512430","FACIT-F Version 4 - Limit Social Activity, I am Tired","C129150","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Additional Concerns: I have to limit my social activity because I am tired.","FACIT-F Version 4 - Limit Social Activity, I am Tired | FAC071-Limit Social Activity, I am Tired | FAC07140",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512202","NCCN-FACT FKSI-19 Version 2 - I Have a Lack of Energy","C129151","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I have a lack of energy.","NCCN-FACT FKSI-19 Version 2 - I Have a Lack of Energy | FAC042-I Have a Lack of Energy | FAC04201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512200","NCCN-FACT FKSI-19 Version 2 - I Have Pain","C129152","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I have pain.","NCCN-FACT FKSI-19 Version 2 - I Have Pain | FAC042-I Have Pain | FAC04202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512192","NCCN-FACT FKSI-19 Version 2 - I Feel Fatigued","C129154","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I feel fatigued.","NCCN-FACT FKSI-19 Version 2 - I Feel Fatigued | FAC042-I Feel Fatigued | FAC04204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512195","NCCN-FACT FKSI-19 Version 2 - I Have Been Short of Breath","C129155","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I have been short of breath.","NCCN-FACT FKSI-19 Version 2 - I Have Been Short of Breath | FAC042-I Have Been Short of Breath | FAC04205",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512189","NCCN-FACT FKSI-19 Version 2 - I Am Bothered by Fevers","C129156","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I am bothered by fevers (episodes of high body temperature).","NCCN-FACT FKSI-19 Version 2 - I Am Bothered by Fevers | FAC042-I Am Bothered by Fevers | FAC04206",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508760","F2 Gene Mutation","C128466","A change in the nucleotide sequence of the F2 gene.","F2 Gene Mutation | Coagulation Factor II (Thrombin) Gene Mutation | Coagulation Factor II, Thrombin Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509068","CDISC SDTM Gastrointestinal Test Code Terminology","C128682","Terminology associated with the gastrointentestinal test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Gastrointestinal Test Code Terminology | GASTROCD | Gastrointestinal Test Code | SDTM-GASTROCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512701","GAIA Neonatal Encephalopathy Level of Diagnostic Certainty","C128692","A classification of maternal and fetal outcomes relating to neonatal encephalopathy, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.","GAIA Neonatal Encephalopathy Level of Diagnostic Certainty | Global Alignment of Immunization safety Assessment in pregnancy Neonatal Encephalopathy Level of Diagnostic Certainty | Neonatal Encephalopathy Level of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512128","CSTB wt Allele","C128871","Human CSTB wild-type allele is located in the vicinity of 21q22.3 and is approximately 4 kb in length. This allele, which encodes cystatin-B protein, plays a role in thiol protease inhibition. Mutation of the gene is associated with progressive myoclonic epilepsy 1A (myoclonic epilepsy of Unverricht and Lundborg).","CSTB wt Allele | CPI-B | CST6 | Cystatin B (Stefin B) Gene | Cystatin B wt Allele | EPM1 | EPM1A | PME | STFB | ULD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1609848","Cystatin-B, Human","C128872","Cystatin-B (98 aa, ~11 kDa) is encoded by the human CSTB gene. This protein is involved in the regulation of cathepsins.","Cystatin-B | CPI-B | Cystatin B | Liver Thiol Proteinase Inhibitor | Stefin B | Stefin-B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512129","DDC wt Allele","C128875","Human DDC wild-type allele is located in the vicinity of 7p12.2 and is approximately 107 kb in length. This allele, which encodes aromatic-L-amino-acid decarboxylase protein, is involved in monoamine neurotransmitter synthesis. Mutation of the gene is associated with aromatic L-amino-acid decarboxylase deficiency (AADCD).","DDC wt Allele | AADC | Dopa Decarboxylase (Aromatic L-Amino Acid Decarboxylase) Gene | Dopa Decarboxylase wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010641","Cystathionine Beta-Synthase","C129051","Cystathionine beta-synthase (551 aa, ~61 kDa) is encoded by the human CBS gene. This protein plays a role in homocysteine metabolism.","Cystathionine Beta-Synthase | Beta-Thionase | Cystathionine-Beta-Synthase | EC 4.2.1.22 | Methylcysteine Synthase | Serine Sulfhydrase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512261","AKR1C3 wt Allele","C129053","Human AKR1C3 wild-type allele is located within 10p15-p14 and is approximately 72 kb in length. This allele, which encodes aldo-keto reductase family 1 member C3 protein, plays a role in the metabolism of prostaglandins and steroids.","AKR1C3 wt Allele | Aldo-Keto Reductase Family 1 Member C3 wt Allele | Aldo-Keto Reductase Family 1, Member C3 (3-Alpha Hydroxysteroid Dehydrogenase, Type II) Gene | Aldo-Keto Reductase Family 1, Member C3 Gene | DD3 | DDH2 | DDX | HA1753 | HAKRB | HAKRD | HAKRe | HSD17B5 | KIAA0119 | PGFS | hluPGFS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1453067","Aldo-Keto Reductase Family 1 Member C3, Human","C129054","Aldo-keto reductase family 1 member C3 (323 aa, ~37 kDa) is encoded by the human AKR1C3 gene. This protein is involved in steroid and prostaglandin metabolism.","Aldo-Keto Reductase Family 1 Member C3 | 17-Beta-HSD 5 | 17-Beta-Hydroxysteroid Dehydrogenase Type 5 | 17-Beta-Hydroxysteroid Dehydrogenase V | 3-Alpha Hydroxysteroid Dehydrogenase, Type II | 3-Alpha-HSD Type 2 | 3-Alpha-HSD Type II, Brain | 3-Alpha-Hydroxysteroid Dehydrogenase Type 2 | AKR1C3 | Aldo-Keto Reductase 1C3 | Aldo-Keto Reductase B | Chlordecone Reductase Homolog HAKRb | DD-3 | DD3 | Dihydrodiol Dehydrogenase 3 | Dihydrodiol Dehydrogenase Type I | Dihydrodiol Dehydrogenase X | EC 1.-.-.- | HA1753 | Hydroxysteroid (17-Beta) Dehydrogenase 5 | Indanol Dehydrogenase | PGFS | Testosterone 17-Beta-Dehydrogenase 5 | Trans-1,2-Dihydrobenzene-1,2-Diol Dehydrogenase | Type IIb 3-Alpha Hydroxysteroid Dehydrogenase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512133","DUSP10 wt Allele","C129056","Human DUSP10 wild-type allele is located in the vicinity of 1q41 and is approximately 41 kb in length. This allele, which encodes dual specificity protein phosphatase 10 protein, is involved in the downregulation of mitogen-activated kinases.","DUSP10 wt Allele | Dual Specificity Phosphatase 10 wt Allele | MKP-5 | MKP5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1744133","Dual Specificity Protein Phosphatase 10, Human","C129057","Dual specificity protein phosphatase 10 (482 aa, ~53 kDa) is encoded by the human DUSP10 gene. This protein plays a role in both the dephosphorylation and inactivation of MAP kinases.","Dual Specificity Protein Phosphatase 10 | DUSP10 | Dual Specificity Phosphatase MKP-5 | Dual-Specificity Phosphatase 10 | EC 3.1.3.16 | EC 3.1.3.48 | MAP Kinase Phosphatase 5 | MKP-5 | Map Kinase Phosphatase 5 | Mitogen-Activated Protein Kinase Phosphatase 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509106","GAIA Level 1 Gestational Diabetes Mellitus","C128753","GAIA Level 1 Gestational Diabetes Mellitus is defined by three criteria: first, at least one of the following requirements must be met: a) absence of pre-gestational diabetes [pre-gestational diabetes is defined as a) previous diagnosis of diabetes while not pregnant OR b) first trimester hemoglobin A1c level of greater than or equal to 6.5% (47.5 mmol/mol) OR c) first trimester fasting blood glucose greater than or equal to 126 mg/dL (7 mmol/L)]; second, gestational age with level 1 or level 2 certainty, using the GAIA definition for gestational age; third, a diagnosis of gestational diabetes as determined by a positive result from an international standard oral glucose tolerance test using venous blood samples.","GAIA Level 1 Gestational Diabetes Mellitus | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Gestational Diabetes Mellitus | Level 1 Gestational Diabetes Mellitus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509113","GAIA Level 2 Gestational Diabetes Mellitus","C128754","GAIA Level 2 Gestational Diabetes Mellitus is defined by three criteria: first, absence of pre-gestational diabetes [pre-gestational diabetes is defined as a) previous diagnosis of diabetes while not pregnant OR b) first trimester hemoglobin A1c level of greater than or equal to 6.5% (47.5 mmol/mol) OR c) first trimester fasting blood glucose greater than or equal to 126 mg/dL (7 mmol/L)]; second, gestational age with at least level 1-2 certainty, using the GAIA definition for gestational age; third the diagnosis of gestational diabetes as determined by a positive result from an international standard oral glucose tolerance test using capillary blood samples.","GAIA Level 2 Gestational Diabetes Mellitus | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Gestational Diabetes Mellitus | Level 2 Gestational Diabetes Mellitus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509122","GAIA Level 3 Gestational Diabetes Mellitus","C128755","GAIA Level 3 Gestational Diabetes Mellitus is defined by three criteria: first, absence of pre-gestational diabetes [pre-gestational diabetes is defined as a) previous diagnosis of diabetes while not pregnant OR b) first trimester hemoglobin A1c level of greater than or equal to 6.5% (47.5 mmol/mol) OR c) first trimester fasting blood glucose greater than or equal to 126 mg/dL (7 mmol/L)]; second, gestational age with at least level 3 certainty, using the GAIA definition for gestational age; third, the diagnosis of gestational diabetes as determined by fasting plasma glucose of 5.1-6.9 mmol/L (92-125 mg/dL) using either venous or capillary blood samples.","GAIA Level 3 Gestational Diabetes Mellitus | Global Alignment of Immunization safety Assessment in pregnancy Level 3 Gestational Diabetes Mellitus | Level 3 Gestational Diabetes Mellitus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509104","GAIA Insufficient Evidence for Diagnosis of Gestational Diabetes Mellitus","C128756","GAIA Insufficient Evidence for Diagnosis of Gestational Diabetes Mellitus (GDM) is a category of individuals for whom a diagnosis of GDM cannot be made due to one of the following: a) the blood glucose cannot be measured; b) elevated postprandial blood glucose level without confirmatory fasting venous blood or capillary glucose level; c) use of Hemoglobin A1c alone, without a diagnostic oral glucose tolerance test or elevated fasting plasma glucose level; d) clinical and laboratory findings, including glucosuria, fundal height greater than dates, obesity, prior history of GDM, or family history for the diagnosis of gestational diabetes mellitus, without a diagnostic test.","GAIA Insufficient Evidence for Diagnosis of Gestational Diabetes Mellitus | Global Alignment of Immunization safety Assessment in pregnancy Insufficient Evidence for Diagnosis of Gestational Diabetes Mellitus | Insufficient Evidence for Gestational Diabetes Mellitus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512164","Multi-epitope Anti-folate Receptor Peptide Vaccine TPIV 200","C128898","A peptide vaccine containing five immunogenic peptide epitopes of the human folate receptor 1 (FOLR1; FR-alpha), with potential immunomodulating and antineoplastic activities. Upon intradermal administration, multi-epitope anti-folate receptor peptide vaccine TPIV 200 may induce a cytotoxic T-lymphocyte (CTL) response against FR-alpha-overexpressing tumor cells. FR-alpha is a high-affinity folate-binding protein and a member of the folate receptor family; this receptor is overexpressed in various cancer cell types.","Multi-epitope Anti-folate Receptor Peptide Vaccine TPIV 200 | TPIV 200 | TPIV 200 Vaccine | TPIV-200 | TPIV200 | TPIV200/huFR-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512329","REMS Approval","C128899","The approval of a Risk Evaluation and Mitigation Strategy (REMS) Program.","REMS Approval | Risk Evaluation and Mitigation Strategies Approval",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0587901","Auditory System","C12889","The organs involved with detecting and processing auditory information, including the pinna, external auditory canal, ear drum, middle ear, and inner ear (including the cochlear organ).","Auditory System | ",,,,,,,,,,,,,,,"4235458","Structure of auditory system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0771825","Triptorelin Acetate","C128693","No value exists.","Triptorelin Acetate | TRIPTORELIN ACETATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509213","GAIA Postnatally Diagnosed Congenital Microcephaly Level of Diagnostic Certainty","C128694","A classification of maternal and fetal outcomes relating to diagnosing congenital microcephaly postnatally, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.","GAIA Postnatally Diagnosed Congenital Microcephaly Level of Diagnostic Certainty | Global Alignment of Immunization safety Assessment in pregnancy Postnatally Diagnosed Congenital Microcephaly Level of Diagnostic Certainty | Postnatally Diagnosed Congenital Microcephaly Level of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512270","CTRC Gene Mutation","C128818","A change in the nucleotide sequence of the CTRC gene.","CTRC Gene Mutation | CTRC Mutation | Chymotrypsin C Gene Mutation | ELA4 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226661","Small Cardiac Vein","C12881","A vein running parallel to the right coronary artery in the coronary sulcus that drains into the right extremity of the coronary sinus.","Small Cardiac Vein | ",,,,,,,,,,,,,,,"4170388","Structure of small cardiac vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512312","PRSS1 Gene Mutation","C128823","A change in the nucleotide sequence of the PRSS1 gene.","PRSS1 Gene Mutation | PRSS1 Mutation | Protease, Serine, 1 Gene Mutation | TRY1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512313","PRSS2 Gene Mutation","C128824","A change in the nucleotide sequence of the PRSS2 gene.","PRSS2 Gene Mutation | PRSS2 Mutation | Protease, Serine, 2 Gene Mutation | TRY2 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0854530","HHV6 Infection","C128829","An infection that is caused by human herpesvirus-6.","HHV6 Infection | HHV-6 Infection | Human Herpes Virus-6 Infection | Human Herpesvirus-6 (HHV-6) | Human Herpesvirus-6 Infection",,,,,,,,,,,,,,,"40482261","Infection by human herpesvirus 6",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512224","NCR1 wt Allele","C129059","Human NCR1 wild-type allele is located in the vicinity of 19q13.42 and is approximately 32 kb in length. This allele, which encodes natural cytotoxicity triggering receptor 1 protein, plays a role in the modulation of natural killer cell-mediated cytotoxicity.","NCR1 wt Allele | CD335 | LY94 | Lymphocyte Antigen 94 (Mouse) Homolog (Activating NK-Receptor; NK-P46) Gene | Lymphocyte Antigen 94 Homolog (Activating NK-Receptor; NK-P46) Gene | Lymphocyte Antigen 94, Mouse, Homolog of Gene | NK-p46 | NKP46 | Natural Cytotoxicity Triggering Receptor 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0674917","Natural Cytotoxicity Triggering Receptor 1, Human","C129060","Natural cytotoxicity triggering receptor 1 (304 aa, ~34 kDa) is encoded by the human NCR1 gene. This protein is involved in the positive regulation of natural killer cell-mediated cytotoxicity.","Natural Cytotoxicity Triggering Receptor 1 | Activating Natural Killer Receptor p46 | CD335 Antigen | HNKp46 | Lymphocyte Antigen 94 Homolog | NK Cell-Activating Receptor | NK-p46 | NKp46 | Natural Killer Cell p46-Related Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512131","DNA-dependent Protein Kinase Inhibitor VX-984","C129061","An ATP-competitive inhibitor of the catalytic subunit of DNA-dependent protein kinase (DNA-PK), with potential sensitizing and enhancing activities for both chemo- and radiotherapies. Upon administration, DNA-PK inhibitor VX-984 binds to and inhibits the catalytic subunit of DNA-PK, thereby interfering with the non-homologous end joining (NHEJ) process and preventing repair of DNA double strand breaks (DSBs) caused by ionizing radiation or chemotherapeutic treatment. This increases chemo- and radiotherapy cytotoxicity and leads to enhanced tumor cell death. The enhanced ability of tumor cells to repair DSBs plays a major role in the resistance of tumor cells to chemo- and radiotherapy; DNA-PK plays a key role in the NHEJ pathway and DSB repair.","DNA-dependent Protein Kinase Inhibitor VX-984 | DNA-PK Inhibitor VX-984 | VX-984 | VX984",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509306","REMS Participate in Training Session","C128502","In the context of REMS, the healthcare provider or setting must participate in a training session administered by a specified trainer, such as a REMS program or continuing education provider.","REMS Participate in Training Session | Participate in Training Session | Risk Evaluation and Mitigation Strategies Participate in Training Session",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508754","Establish Processes and Procedures to Verify REMS Safe Use Conditions","C128503","In the context of REMS, the healthcare provider or setting must establish a system to verify that safe use conditions required by the REMS are in place. For purposes of this definition, 'safe use condition' refers to any activity that must be completed before the drug is dispensed (e.g., enrollment or completion of a lab test).","Establish Processes and Procedures to Verify REMS Safe Use Conditions | Establish Processes and Procedures to Verify Risk Evaluation and Mitigation Strategies Safe Use Conditions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512398","Enroll in the REMS","C128504","The healthcare provider or patient must enroll in the REMS Program. Enrollment is the process by which REMS participants provide basic identifying and demographic information to the REMS Program (e.g. through a paper form or a website), allowing the application holder to track participants and communicate with them.","Enroll in the REMS | Enroll in The Risk Evaluation and Mitigation Strategies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512089","REMS Counsel Patient","C128505","In the context of REMS, the healthcare provider or setting must counsel the patient. The REMS may require that the counseling cover a specific topic, that the counseling use a specific REMS material (such as a Patient-Prescriber Agreement Form or Medication Guide), or both.","REMS Counsel Patient | Counsel Patient | Risk Evaluation and Mitigation Strategies Counsel Patient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509772","Provide Patient with Materials","C128506","The healthcare provider or setting must provide certain materials to a patient, such as patient education materials, or a Medication Guide.","Provide Patient with Materials | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509721","Complete Patient Form","C128508","The healthcare provider, healthcare setting, and/or patient must complete a form such as a patient agreement or patient-prescriber agreement form.","Complete Patient Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512269","FGFR3 Protein Variant","C128903","A variation in the amino acid sequence for the fibroblast growth factor receptor 3 protein.","FGFR3 Protein Variant | CD333 Antigen Protein Variant | FGFR-3 Protein Variant | Fibroblast Growth Factor Receptor 3 Protein Variant | Tyrosine Kinase JKT4 Protein Variant | Tyrosine Kinase JTK4 Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512184","NCCN-FACT FBLSI-18 Version 2 Questionnaire Question","C129101","A question associated with the NCCN-FACT FBLSI-18 Version 2 questionnaire.","NCCN-FACT FBLSI-18 Version 2 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512479","FACT-B Version 4 Questionnaire Question","C129102","A question associated with the FACT-B Version 4 questionnaire.","FACT-B Version 4 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512488","FOSI Questionnaire Question","C129103","A question associated with the FOSI questionnaire.","FOSI Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512223","NCCN-FACT FOSI-18 Version 2 Questionnaire Question","C129104","A question associated with the NCCN-FACT FOSI-18 Version 2 questionnaire.","NCCN-FACT FOSI-18 Version 2 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036387","Schwann Cell","C12620","A supporting cell of the peripheral nervous system that aids the growth, development, function, maintenance and repair of peripheral nerves. Myelinating Schwann cells form the myelin sheath around large diameter axons while non-myelinating Schwann cells bundle together portions of several unmyelinated smaller diameter axons and may also play a role in the formation and maintenance of synaptic connections in the neuromuscular junction.","Schwann Cell | Neurilemma Cell | Neurilemmal Cell | Schwann Cells | Schwann cell",,,,,,,,,,,,,,,"4195459","Neurilemma cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512271","Epstein-Barr Virus Early RNA Positive","C128833","Indicates that Epstein-Barr virus early RNA has been detected in a sample.","Epstein-Barr Virus Early RNA Positive | EBER Positive | Epstein-Barr Encoded RNA Positive | Epstein-Barr Virus-Associated Early RNA Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2605855","Simeprevir","C129015","An orally bioavailable inhibitor of the hepatitis C virus (HCV) protease complex comprised of non-structural protein 3 and 4A (NS3/NS4A), with activity against HCV genotype 1. Upon administration, simeprevir reversibly binds to the active center and binding site of the HCV NS3/NS4A protease and prevents NS3/NS4A protease-mediated polyprotein maturation. This disrupts both the processing of viral proteins and the formation of the viral replication complex, which inhibits viral replication in HCV genotype 1-infected host cells. NS3, a serine protease, is essential for the proteolytic cleavage of multiple sites within the HCV polyprotein and plays a key role during HCV ribonucleic acid (RNA) replication. NS4A is an activating factor for NS3. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family; HCV infection is associated with the development of hepatocellular carcinoma (HCC).","Simeprevir | HSDB 8227 | N-(17-(2-(4-isopropylthiazole-2-yl)-7-methoxy-8-methylquinolin-4-yloxy)-13-methyl-2,14-dioxo-3,13-diazatricyclo(13.3.0.04,6)octadec-7-ene-4-carbonyl)(cyclopropyl)sulfonamide | Olysio | SIMEPREVIR | TMC 435 | TMC-435 | TMC435",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512265","KIR2DL1 wt Allele","C129018","Human KIR2DL1 wild-type allele is located in the vicinity of 19q13.4 and is approximately 15 kb in length. This allele, which encodes killer cell immunoglobulin-like receptor 2DL1 protein, plays a role in the regulation of the immune response.","KIR2DL1 wt Allele | 47.11 | CD158A | KIR-K64 | KIR221 | KIR2DL1/3DL2 | KIR2DL3 | KIR2DS5 | Killer Cell Immunoglobulin Like Receptor, Two Ig Domains and Long Cytoplasmic Tail 1 wt Allele | Killer Cell Immunoglobulin-Like Receptor, Two Domains, Long Cytoplasmic Tail, 1 Gene | NKAT | NKAT-1 | NKAT1 | cl-42 | p58.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3851350","Ledipasvir","C129019","An orally available inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex, with potential activity against HCV. Upon oral administration and after intracellular uptake, ledipasvir binds to and blocks the activity of the NS5A protein. This results in the disruption of the viral RNA replication complex, blockage of HCV RNA production, and inhibition of viral replication. NS5A, a zinc-binding and proline-rich hydrophilic phosphoprotein, plays a crucial role in HCV RNA replication. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family; HCV infection is associated with the development of hepatocellular carcinoma (HCC).","Ledipasvir | Carbamic Acid, N-((1S)-1-(((6S)-6-(5-(9,9-difluoro-7-(2-((1R,3S,4S)-2-((2S)-2-((methoxycarbonyl)amino)-3-methyl-1-oxobutyl)-2-azabicyclo(2.2.1)hept-3-yl)-1H-benzimidazol-6-yl)-9H-fluoren-2-yl)-1H-imidazol-2-yl)-5-azaspiro(2.4)hept-5-yl)carbonyl)-2-methylpropyl)-, Methyl Ester | GS 5885 | GS-5885 | GS5885 | LEDIPASVIR | WHO 9796",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1430233","Killer Cell Immunoglobulin-Like Receptor 2DL1, Human","C129020","Killer cell immunoglobulin-like receptor 2DL1 (348 aa, ~39 kDa) is encoded by the human KIR2DL1 gene. This protein is involved in the negative regulation of natural killer cell activity.","Killer Cell Immunoglobulin-Like Receptor 2DL1 | CD158 Antigen-Like Family Member A | CD158a | CD158a Antigen | KIR2DL1 | Killer Inhibitory Receptor 2-2-1 | MHC Class I NK Cell Receptor | NK-Associated Transcript 1 | NKAT-1 | Natural Killer-Associated Transcript 1 | p58 Killer Cell Inhibitory Receptor KIR-K64 | p58 NK Cell Inhibitory Receptor NKR-K6 | p58 NK Receptor CL-42/47.11 | p58 Natural Killer Cell Receptor Clones CL-42/47.11 | p58.1 MHC Class-I-Specific NK Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508740","Enroll Patient in the REMS","C128509","The healthcare provider or setting must enroll the patient in the REMS Program. Enrollment is the process by which REMS participants provide basic identifying and demographic information to the REMS Program (e.g. through a paper form or a website), allowing the application holder to track participants and communicate with them.","Enroll Patient in the REMS | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221924","Stratum Spinosum","C12850","The part of the epidermis layer of the skin containing Langerhans cells, which are dendritic, MHC class II-expressing antigen presenting cells.","Stratum Spinosum | Spiny Layer",,,,,,,,,,,,,,,"4183592","Stratum spinosum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509445","Do Not Prescribe Refills","C128510","The prescriber must not prescribe refills of the drug.","Do Not Prescribe Refills | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509443","Do Not Dispense Refills","C128511","The dispenser must not dispense refills of the drug.","Do Not Dispense Refills | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509766","Prescribe Limited Days Supply","C128512","The prescriber must prescribe only a limited days supply of the drug.","Prescribe Limited Days Supply | Prescribe limited days' supply",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509442","Dispense Limited Days Supply","C128513","The dispenser must dispense only a limited days supply of the drug.","Dispense Limited Days Supply | Dispense limited days' supply",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509680","Use REMS Prescription Ordering Form","C128514","The prescriber must order the prescription using a special prescription ordering form provided by the REMS program. These forms are used to order product from a pharmacy and, may also remind prescribers of counseling, screening, and dosing requirements.","Use REMS Prescription Ordering Form | Use Risk Evaluation and Mitigation Strategies Prescription Ordering Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509362","Verify Safe Use Conditions","C128515","The healthcare provider or setting must verify that required safe use conditions are in place before the drug is dispensed using established processes and procedures. For purposes of this definition, 'safe use conditions' refers to any activity that must be completed before the drug is dispensed (e.g., enrollment or completion of a lab test).","Verify Safe Use Conditions | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509316","Return Unused Product","C128517","The healthcare provider or setting must return unused product to the manufacturer.","Return Unused Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509444","Do Not Distribute, Transfer, Loan, or Sell Product","C128518","The healthcare provider or setting must not distribute, transfer, loan, or sell the product.","Do Not Distribute, Transfer, Loan, or Sell Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509098","GAIA Level 2b Fetal Growth Restriction","C128724","GAIA Level 2b Fetal Growth Restriction is defined by two criteria: first, Level 2 evidence of pregnancy dating; second, at least one of the following requirements must be met: a) Estimated fetal weight below the tenth percentile using locally-accepted growth curve AND either no findings of absent or reversed end-diastolic flow of the umbilical artery Doppler OR absence of oligohydramnios. Alternatively, Level 2b may be defined by the following two criteria: first, Level 1 evidence of pregnancy dating; second, an estimated fetal weight below the tenth percentile using locally-accepted growth curve, and absence of oligohydramnios with the inability to assess umbilical artery Doppler.","GAIA Level 2b Fetal Growth Restriction | Global Alignment of Immunization safety Assessment in pregnancy Level 2b Fetal Growth Restriction | Level 2b Fetal Growth Restriction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509107","GAIA Level 1 Low Birth Weight","C128725","GAIA Level 1 Low Birth Weight is defined by one of the two following criteria: first, a newborn infant is weighed within 24 hours of birth; an electronic scale that is graduated to 10 grams is used; the scale is calibrated at least once a year; the scale is placed on level, hard surface; the scale is tared to zero grams; AND the birth weight recorded is less than 2500 grams; OR second, a birth weight is recorded as less than 2500 grams as assessed per the health care facility's standard operating procedure, which fulfills criteria 1 to 5 of diagnostic level of certainty one.","GAIA Level 1 Low Birth Weight | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Low Birth Weight | Level 1 Low Birth Weight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512427","FACIT-F Version 4 - I Have a Lack of Energy","C129111","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Physical Well-Being: I have a lack of energy.","FACIT-F Version 4 - I Have a Lack of Energy | FAC071-I Have a Lack of Energy | FAC07101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512425","FACIT-F Version 4 - I Have Nausea","C129112","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Physical Well-Being: I have nausea.","FACIT-F Version 4 - I Have Nausea | FAC071-I Have Nausea | FAC07102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027884","Neurons, Efferent","C12643","A neuron that sends impulses from the central nervous system to skeletal muscles, glands, and visceral organs.","Efferent Neuron | Efferent Nerve | Efferent Neurons",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2931817","Chromosome 2q37 Deletion Syndrome","C129021","A syndrome of high phenotypic variability caused by contiguous gene deletions in 2q37.  The inheritance is autosomal dominant. The condition may be characterized by brachydactly type E; mental retardation; short stature; and other skeletal, cardiovascular, and neurologic manifestations.","Chromosome 2q37 Deletion Syndrome | BDMR | Brachydactyly Mental Retardation Syndrome",,,,,,,,,,,,,,,"45765423","Chromosome 2q37 deletion syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2673759","DEAFNESS, AUTOSOMAL RECESSIVE 1A (disorder)","C129022","An autosomal recessive disorder caused by mutations in the GJB2 gene, encoding gap junction beta-2 protein. The condition is characterized by profound sensorineural hearing loss and may be associated with vestibular dysfunction.","Deafness, Autosomal Recessive 1A | DFNB1A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1853276","Deafness, Autosomal Recessive 28","C129023","An autosomal recessive disorder caused by mutations in the TRIOBP gene, encoding TRIO and F-actin-binding protein. The condition is characterized by severe to profound sensorineural hearing loss.","Deafness, Autosomal Recessive 28 | DFNB28",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4017220","DEAFNESS, AUTOSOMAL RECESSIVE 49","C129024","An autosomal recessive disorder caused by mutations in the MARVELD2 gene, encoding MARVEL domain-containing protein 2. The condition is characterized  by profound prelingual deafness.","Deafness, Autosomal Recessive 49 | DFNB49",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206368","Exfoliation Syndrome","C129025","An autosomal dominant disorder caused by mutations in the LOXL1 gene, encoding lysyl oxidase homolog 1. The condition is characterized by abnormal fibrillar extracellular material in anterior segment tissues, and may lead to glaucoma.","Exfoliation Syndrome | Exfoliation Glaucoma | XFG | XFS",,,,,,,,,,,,,,,"437273","Pseudoexfoliation glaucoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0205827","Sacral Plexus","C12846","A network of nerve fibers that are derived from the anterior rami of spinal nerves L4-L5 and S1-S4, and which are part of the larger lumbosacral plexus, providing motor and sensory innervation for the posterior thigh, most of the lower leg, the entire foot, and part of the pelvis.","Sacral Plexus | Sacral plexus structure (body structure)",,,,,,,,,,,,,,,"4266531","Sacral plexus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509547","SPHK2 wt Allele","C128471","Human SPHK2 wild-type allele is located in the vicinity of 19q13.33 and is approximately 11 kb in length. This allele, which encodes sphingosine kinase 2 protein, plays a role in lipid phosphorylation.","SPHK2 wt Allele | SK 2 | SK-2 | SK2 | SPK 2 | SPK-2 | Sphingosine Kinase 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3884157","Sphingosine Kinase 2, Human","C128472","Sphingosine kinase 2 (654 aa, ~69 kDa) is encoded by the human SPHK2 gene. This protein is involved in phosphosphingolipid synthesis.","Sphingosine Kinase 2 | EC 2.7.1.91 | SK 2 | SPHK2 | SPK 2 | Sphingosine Kinase Type 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508928","PGRMC1 wt Allele","C128474","Human PGRMC1 wild-type allele is located within Xq22-q24 and is approximately 8 kb in length. This allele, which encodes membrane-associated progesterone receptor component 1 protein, is involved in steroid binding.","PGRMC1 wt Allele | HPR6.6 | MPR | PGRMC | Progesterone Receptor Membrane Component 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1431543","Membrane-Associated Progesterone Receptor Component 1, Human","C128475","Membrane-associated progesterone receptor component 1 (195 aa, ~22 kDa) is encoded by the human PGRMC1 gene. This protein may play a role in progesterone uptake.","Membrane-Associated Progesterone Receptor Component 1 | PGRMC1 | Progesterone Binding Protein | mPR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509114","GAIA Level 2 Low Birth Weight","C128726","GAIA Level 2 Low Birth Weight is defined by either one of the following two criteria: first, a newborn infant is weighed within 24 hours of birth; either an electronic or a spring scale that is graduated to 50 grams is used; the scale is calibrated at least once a year, or more often if moved; the scale is tared to zero grams or 0.00 kg; AND the birth weight recorded is less than 2500 grams; OR second, a birth weight is recorded as less than 2500 grams as assessed per the health care facility's standard operating procedure, which fulfills criteria 1 to 4 of diagnostic level of certainty two.","GAIA Level 2 Low Birth Weight | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Low Birth Weight | Level 2 Low Birth Weight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509123","GAIA Level 3 Low Birth Weight","C128727","GAIA Level 3 Low Birth Weight is defined by three criteria: first, a newborn infant must be weighed within the  first 48 hours of life; second, weight is measured using a dial/ spring/ color-coded scale; third, weight is assessed as less than 2500 grams.","GAIA Level 3 Low Birth Weight | Global Alignment of Immunization safety Assessment in pregnancy Level 3 Low Birth Weight | Level 3 Low Birth Weight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509126","GAIA Level 4 Low Birth Weight","C128728","GAIA Level 4 Low Birth Weight is defined by either one of the following two criteria: first, the newborn's weight is assessed between 1 and 2 days of age (first 48 hrs of life); AND second, a proxy measure of birth weight is used, AND the weight category is assessed as less than 2500 grams.","GAIA Level 4 Low Birth Weight | Global Alignment of Immunization safety Assessment in pregnancy Level 4 Low Birth Weight | Level 4 Low Birth Weight",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512636","GAIA Level 1 Neonatal Encephalopathy","C128729","GAIA Level 1 Neonatal Encephalopathy is defined by three criteria: first, a newborn infant (1-28 days of life) born at or beyond 35 weeks of gestation; second, an abnormal level of alertness or seizures; third, difficulty with initiating and maintaining respiration; fourth, depression of muscle tone.","GAIA Level 1 Neonatal Encephalopathy | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Neonatal Encephalopathy | Level 1 Neonatal Encephalopathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512637","GAIA Level 2 Neonatal Encephalopathy","C128730","GAIA Level 2 Neonatal Encephalopathy is defined by three criteria: first, a newborn infant (1 to 28 days of life) born at or beyond 35 weeks of gestation; second, an abnormal level of alertness or seizures; third, either difficulty with initiating and maintaining respiration OR depression of muscle tone.","GAIA Level 2 Neonatal Encephalopathy | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Neonatal Encephalopathy | Level 2 Neonatal Encephalopathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512638","GAIA Level 3 Neonatal Encephalopathy","C128731","GAIA Level 3 Neonatal Encephalopathy is defined by three criteria: first, a newborn infant (1-28 days of life) born at or beyond 35 weeks of gestation; second, an abnormal level of alertness or seizures; third, none of the following: a) difficulty with initiating or maintaining respiration; b) depression of muscle tone.","GAIA Level 3 Neonatal Encephalopathy | Global Alignment of Immunization safety Assessment in pregnancy Level 3 Neonatal Encephalopathy | Level 3 Neonatal Encephalopathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2677180","Congenital Microcephaly","C128732","A congenital developmental disorder in which the circumference of the head is smaller than normal for the person's age and sex.","Congenital Microcephaly | ",,,,,,,,,,,,,,,"606879","Congenital microcephaly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4042618","Aromatic-L-Amino-Acid Decarboxylase, Human","C128876","Aromatic-L-amino-acid decarboxylase (480 aa, ~54 kDa) is encoded by the human DDC gene. This protein plays a role in the conversion of amino acids to monoamine neurotransmitters.","Aromatic-L-Amino-Acid Decarboxylase | AADC | Aromatic L-Amino Acid Decarboxylase | DDC | DOPA Decarboxylase | EC 4.1.1.28",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512276","EPHA5 wt Allele","C128878","Human EPHA5 wild-type allele is located in the vicinity of 4q13.1 and is approximately 351 kb in length. This allele, which encodes ephrin type-A receptor 5 protein, plays a role in cell-cell signaling, hippocampus development, and neuron development.","EPHA5 wt Allele | BSK | BSK, Mouse, Homolog of Gene | CEK7 | EHK-1 | EHK1 | EHK1, Rat, Homolog of Gene | EK7 | EPH Homology Kinase 1, Rat, Homolog of Gene | EPH Receptor A5 wt Allele | HEK7 | Hek7 | TYRO4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509616","HLA-A2-restricted IL-13Ra2/EphA2/Survivin/Tetanus Toxoid T-helper Epitopes-Montanide 51 Vaccine","C128562","A peptide vaccine comprised of synthetic human leukocyte antigen (HLA)-A2-restricted peptides derived from the tumor-associated antigens (TAAs) interleukin-13 receptor alpha-2 (IL-13Ra2), the tyrosine kinase receptor Ephrin receptor A2 (EphA2), and the apoptosis inhibitor protein survivin, combined with the adjuvant tetanus toxoid (TT)-derived helper T-cell peptide, and emulsified in the immunoadjuvant Montanide ISA-51, with potential immunostimulating and antineoplastic activities. Specifically, this vaccine contains the epitopes: IL-13Ralpha2 345-353:1A9V, which is an engineered peptide based on amino acids 345-353 of IL-13Ra2 where the amino acids at the first and ninth positions of the peptide have been replaced with alanine and valine, respectively, EphA2 883-891, and survivin 96-104. Upon administration, the HLA-A2-restricted IL-13Ra2/EphA2/survivin/TT T-helper epitopes-Montanide 51 vaccine may stimulate a HLA-A2-restricted cytotoxic T-lymphocyte (CTL) response against tumor cells that overexpress IL-13Ra2, EphA2, or survivin, and results in tumor cell lysis. TT T-helper peptide binds to class II major histocompatibility molecules (MHC) molecules as a nonspecific vaccine helper epitope, resulting in long-term immunopotentiation by increasing the helper T-cell response. Montanide ISA-51, a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide monooleate added as a surfactant, non-specifically stimulates cell-mediated immune responses to antigens. IL-13Ra2, EphA2 and survivin, TAAs that are overexpressed in certain tumor cell types, play key roles in tumor cell proliferation. HLA-A2 presents antigenic peptides to CD8+ T-cells; epitope design restricted to epitopes that bind most efficiently to HLA-A2 may improve peptide immunogenicity.","HLA-A2-restricted IL-13Ra2/EphA2/Survivin/Tetanus Toxoid T-helper Epitopes-Montanide 51 Vaccine | HLA-A2-restricted IL-13Ra2/EphA2/Survivin/Tetanus Toxoid T-helper Peptides-Montanide 51 Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509679","Unresectable Esophageal Carcinoma","C128563","A carcinoma that arises from the esophagus and is not amenable to surgical resection.","Unresectable Esophageal Carcinoma | Esophageal Cancer Unresectable | Esophageal Carcinoma Unresectable | Unresectable Cancer of Esophagus | Unresectable Cancer of the Esophagus | Unresectable Esophageal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509647","Plant Glycan","C128564","An oligosaccharide modifying a protein in plant cells.","Plant Glycan | PLANT TYPE GLYCAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509681","Anatomic Imaging Concept","C128567","Concepts created to assist in identifying anatomic areas on radiographic images.","Anatomic Imaging Concept | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509771","Prostate Imaging Area","C128568","The region(s) of the prostate being visualized through one or more radiologic techniques, including ultrasound (U/S), computed tomography (CT), and magnetic resonance imaging (MRI).","Prostate Imaging Area | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508855","Fibromuscular Stroma of Prostate","C128569","The portion of the prostate comprising both fibrous and muscle tissue that fills the spaces between the glandular tissue.","Fibromuscular Stroma of Prostate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504986","CABIN1 wt Allele","C126454","Human CABIN1 wild-type allele is located in the vicinity of 22q11.23 and is approximately 167 kb in length. This allele, which encodes calcineurin-binding protein cabin-1, may play a role in the negative regulation of calcineurin-mediated signaling.","CABIN1 wt Allele | CAIN | Calcineurin Binding Protein 1 wt Allele | KB-318B8.7 | KIAA0330 | PPP3IN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1453118","Calcineurin-Binding Protein 1, Human","C126455","Calcineurin-binding protein cabin-1 (2220 aa, ~246 kDa) is encoded by the human CABIN1 gene. This protein may be involved in both calcineurin binding and chromatin assembly.","Calcineurin-Binding Protein Cabin-1 | CAIN | Calcineurin Binding Protein Cabin 1 | Calcineurin Inhibitor | Calcineurin-Binding Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030559","Parietal Cell","C12594","A large epithelial cell located in the mucous membrane of the stomach that secretes gastric intrinsic factor and hydrochloric acid.","Parietal Cell | Gastric Parietal Cells | Oxyntic Cells | Parietal Cells",,,,,,,,,,,,,,,"4210897","Gastric parietal cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504583","Aerobic Gram-Negative Coccobacillus","C125954","Any bacteria with a shape between that of a sphere and a rod that requires oxygen to grow or respirate and has a cell wall that contains low levels of peptidoglycan and stains pink with the Gram staining technique.","Aerobic Gram-Negative Coccobacillus | AEROBIC GRAM-NEGATIVE COCCOBACILLUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2919914","Anaerobic Gram-Negative Coccobacillus","C125955","Any bacteria with a shape between that of a sphere and a rod that does not require oxygen to grow or respirate and has a cell wall that contains low levels of peptidoglycan and stains pink with the Gram staining technique.","Anaerobic Gram-Negative Coccobacillus | ANAEROBIC GRAM-NEGATIVE COCCOBACILLUS",,,,,,,,,,,,,,,"40483344","Anaerobic Gram negative coccobacillus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0949907","Metapneumovirus","C125956","A genus of nonsegmented, negative-strand ssRNA viruses in the Pneumovirinae subfamily that uniquely accomplishes cell fusion without the help of an attachment protein. This virus has a genome of about 13 kb, encoding eight proteins. The virion is enveloped and spherical with a diameter of about 150 nm","Metapneumovirus | METAPNEUMOVIRUS",,,,,,,,,,,,,,,"4253155","Genus Metapneumovirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0314761","Normal Flora","C125957","Harmless or beneficial population of microorganisms or plant life that normally occur in specific areas of the body or the environment.","Normal Flora | NORMAL FLORA",,,,,,,,,,,,,,,"4052707","Normal flora",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0318196","Streptomyces paraguayensis","C125958","A species of gram-positive, aerobic actinomycetes bacteria in the genus Streptomyces that has a branching, filamentous growth pattern and is associated with black grained mycetoma disease in humans.","Streptomyces paraguayensis | STREPTOMYCES PARAGUAYENSIS",,,,,,,,,,,,,,,"4278541","Streptomyces paraguayensis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509030","SELPLG wt Allele","C128477","Human SELPLG wild-type allele is located in the vicinity of 12q24 and is approximately 12 kb in length. This allele, which encodes P-selectin glycoprotein ligand 1 protein, plays a role in the regulation of migration and cell adhesion for leukocytes.","SELPLG wt Allele | CD162 | CLA | PSGL-1 | PSGL1 | Selectin P Ligand wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1667075","P-Selectin Glycoprotein Ligand 1, Human","C128478","P-selectin glycoprotein ligand 1 (412 aa, ~43 kDa) is encoded by the human SELPLG gene. This protein is involved in the modulation of rolling and cell adhesion in circulating leukocytes.","P-Selectin Glycoprotein Ligand 1 | CD162 | CD162 Antigen | CLA | Cutaneous Lymphocyte Antigen | Cutaneous Lymphocyte-Associated Associated Antigen | P-Selectin Glycoprotein Ligand | PSGL-1 | Selectin P Ligand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508925","PDIA6 wt Allele","C128480","Human PDIA6 wild-type allele is located in the vicinity of 2p25.1 and is approximately 55 kb in length. This allele, which encodes protein disulfide-isomerase A6 protein, is involved in both platelet aggregation and protein folding.","PDIA6 wt Allele | ERP5 | P5 | Protein Disulfide Isomerase Family A Member 6 wt Allele | Protein Disulfide Isomerase Family A, Member 6 Gene | TXNDC7 | Thioredoxin Domain Containing 7 (Protein Disulfide Isomerase) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1566163","Protein Disulfide-Isomerase A6, Human","C128481","Protein disulfide-isomerase A6 (440 aa, ~48 kDa) is encoded by the human PDIA6 gene. This protein plays a role in the inhibition of aggregation of misfolded proteins and the positive regulation of platelet activation.","Protein Disulfide-Isomerase A6 | EC 5.3.4.1 | ER Protein 5 | ERp5 | Endoplasmic Reticulum Protein 5 | PDIA6 | Protein Disulfide Isomerase P5 | Protein Disulfide Isomerase-Associated 6 | Thioredoxin Domain-Containing Protein 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509501","NK-Cell Lymphoma, Unclassifiable","C128697","A very rare NK-cell lymphoma with pathologic and clinical features posing difficulty in its exact diagnosis and classification.","NK-Cell Lymphoma, Unclassifiable | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509210","GAIA Neonatal Encephalopathy Level of Diagnostic Certainty Terminology","C128699","A subset of terminology related to neonatal encephalopathy, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.","GAIA Neonatal Encephalopathy Level of Diagnostic Certainty Terminology | Global Alignment of Immunization safety Assessment in pregnancy Neonatal Encephalopathy Level of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522073","Recombinant Transforming Growth Factor-Beta 2","C1286","A recombinant polypeptide chemically identical to or similar to the endogenous cytokine transforming growth factor-beta-2 (TGF-beta-2). TGF-beta-2 modulates cell growth and immune function and may promote or inhibit tumor growth, depending on the tumor cell type. TGF-beta-2 may also suppress host immune system recognition of and/or response to tumor cells.","Recombinant Transforming Growth Factor-Beta-2 | CETERMIN | Cartilage-Inducing Factor-B | Glioblastoma-Derived T-Cell Suppressor Factor | TGF-Beta 2 | Transforming Growth Factor-Beta 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1435808","Ephrin Type-A Receptor 5, Human","C128879","Ephrin type-A receptor 5 (1037 aa, ~115 kDa) is encoded by the human EPHA5 gene. This protein is involved in tyrosine phosphorylation, cell-cell signaling and central nervous system development.","Ephrin Type-A Receptor 5 | Brain-Specific Kinase | EC 2.7.10.1 | EHK-1 | EK7 | EPH Homology Kinase 1 | EPH-Like Kinase 7 | EPHA5 | Ephrin Receptor EphA5 | Receptor Protein-Tyrosine Kinase HEK7 | Tyrosine-Protein Kinase Receptor EHK-1 | hEK7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512305","Ultrasound-Guided Near-Infrared Optical Tomography","C128880","An imaging modality that combines ultrasound imaging with diffused light imaging by near-infrared (NIR) optical tomography to obtain coregistered ultrasound and NIR diffusive light images in order to improve optical imaging reconstruction and location certainty. The use of NIR in this combination can also be used to assess functional parameters of a tissue.","Ultrasound-Guided Near-Infrared Optical Tomography | NIR/US | Ultrasound-Guided Near-Infrared Tomography",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512157","IRF7 wt Allele","C128882","Human IRF7 wild-type allele is located in the vicinity of 11p15.5 and is approximately 3 kb in length. This allele, which encodes interferon regulatory factor 7 protein, is involved in the regulation of antiviral gene expression.","IRF7 wt Allele | IMD39 | IRF-7H | IRF7A | IRF7B | IRF7C | IRF7H | Interferon Regulatory Factor 7 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1530281","Interferon Regulatory Factor 7, Human","C128883","Interferon regulatory factor 7 (503 aa, ~54 kDa) is encoded by the human IRF7 gene. This protein plays a role in the cellular response to viral infection.","Interferon Regulatory Factor 7 | IRF-7 | IRF7 | Interferon Regulatory Factor-7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512284","GSK3B wt Allele","C128885","Human GSK3B wild-type allele is located in the vicinity of 3q13.3 and is approximately 273 kb in length. This allele, which encodes glycogen synthase kinase-3 beta protein, is involved in the negative regulation of glycogen synthesis.","GSK3B wt Allele | Glycogen Synthase Kinase 3 Beta wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3253756","Glycogen Synthase Kinase-3 Beta, Human","C128886","Glycogen synthase kinase-3 beta (420 aa, ~47 kDa) is encoded by the human GSK3B gene. This protein plays a role in both protein phosphorylation and the inhibition of glycogen synthesis.","Glycogen Synthase Kinase-3 Beta | EC 2.7.11.1 | EC 2.7.11.26 | GSK-3 Beta | GSK3-beta | GSK3B | Glycogen Synthase Kinase 3-Beta | Serine/Threonine-Protein Kinase GSK3B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019025","Hereditary Persistence of Fetal Hemoglobin","C129072","The persistence of substantial fetal hemoglobin production into adulthood, usually associated with hemoglobinopathies due to mutations in the alpha and/or beta chain of hemoglobin.","Hereditary Persistence of Fetal Hemoglobin | ",,,,,,,,,,,,,,,"4098015","Hereditary persistence of fetal hemoglobin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512108","CCR3 wt Allele","C129063","Human CCR3 wild-type allele is located in the vicinity of 3p21.3 and is approximately 103 kb in length. This allele, which encodes C-C chemokine receptor type 3 protein, is involved in eosinophil migration.","CCR3 wt Allele | C-C Motif Chemokine Receptor 3 wt Allele | CC-CKR-3 | CD193 | CKR3 | CMKBR3 | Chemokine (C-C Motif) Receptor 3 Gene | Chemokine (C-C) Receptor 3 Gene | Chemokine, CC Motif, Receptor 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1871518","C-C Chemokine Receptor Type 3, Human","C129064","C-C chemokine receptor type 3 (355 aa, ~41 kDa) is encoded by the human CCR3 gene. This protein plays a role in eosinophil chemotaxis.","C-C Chemokine Receptor Type 3 | B-Chemokine Receptor | C-C CKR-3 | CC Chemokine Receptor 3 | CC-CKR-3 | CCR-3 | CCR3 | CD193 Antigen | CKR3 | Eosinophil CC Chemokine Receptor 3 | Eosinophil Eotaxin Receptor | Eotaxin Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4274178","Left Apical Anterior Fibromuscular Stroma of Prostate","C128574","The portion of the fibromuscular stroma of the prostate that is located on the anatomical left side of the apical division of the anterior lobe.","Left Apical Anterior Fibromuscular Stroma of Prostate | Apex L AS",,,,,,,,,,,,,,,"37396934","Left apical anterior fibromuscular stroma of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4274170","Left Anterior Apical Peripheral Zone of Prostate","C128575","The region of the prostate that is located on the anatomical left side of the anterior portion of the apical division of the peripheral zone.","Left Anterior Apical Peripheral Zone of Prostate | Apex L PZa",,,,,,,,,,,,,,,"37399019","Left anterior apical peripheral zone of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509109","GAIA Level 1 Postnatally Diagnosed Congenital Microcephaly","C128757","GAIA Level 1 Postnatally Diagnosed Congenital Microcephaly is defined by three criteria: first, a live birth, stillbirth, or spontaneous or therapeutic abortion of at least 24 weeks Gestational Age (GA), with GA assessed by either a certain last menstrual period (LMP) date with confirmatory 1st trimester (less than 14 weeks) or 2nd trimester ultrasound (US) scan OR intrauterine insemination (IUI) OR embryo transfer date; second, a head circumference (HC) measurement either 2 standard deviations (SD) below the mean or less than the third percentile as assessed by GA and gender, using appropriate, standardized reference charts for the population (e.g. WHO growth reference charts if GA greater than or equal to 37 weeks and Intergrowth-21st reference charts for GA 24 to 36 weeks); third, the measurement is taken either between 24 and 36 hours after birth or at the end of the pregnancy.","GAIA Level 1 Postnatally Diagnosed Congenital Microcephaly | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Postnatally Diagnosed Congenital Microcephaly | Level 1 Postnatally Diagnosed Congenital Microcephaly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509118","GAIA Level 2a Postnatally Diagnosed Congenital Microcephaly","C128758","GAIA Level 2a Postnatally Diagnosed Congenital Microcephaly is defined by three criteria: first, a live birth, stillbirth, or spontaneous or therapeutic abortion of at least 24 weeks gestational age (GA), with GA assessed by either a certain last menstrual period (LMP) date with confirmatory 1st trimester (less than 14 weeks) or 2nd trimester ultrasound (US) scan OR intrauterine insemination (IUI) OR embryo transfer date; second, a head circumference (HC) measurement either 2 standard deviations (SD) below the mean or less than the third percentile as assessed by GA and gender, using appropriate, standardized reference charts for the population (e.g. WHO growth reference charts if GA greater than or equal to 37 weeks and Intergrowth-21st reference charts for GA 24 to 36 weeks); third, one of the following requirements is met: a) the measurement is taken within the first 24 hours after birth or at the end of the pregnancy taking into consideration the molding of the head; OR b) the measurement is taken greater than 36 hours and up to 6 weeks after birth or the end of the pregnancy with no apparent post-natal insult resulting in microcephaly.","GAIA Level 2a Postnatally Diagnosed Congenital Microcephaly | Global Alignment of Immunization safety Assessment in pregnancy Level 2a Postnatally Diagnosed Congenital Microcephaly | Level 2a Postnatally Diagnosed Congenital Microcephaly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509120","GAIA Level 2b Postnatally Diagnosed Congenital Microcephaly","C128759","GAIA Level 2b Postnatally Diagnosed Congenital Microcephaly is defined by three criteria: first, a live birth, stillbirth, or spontaneous or therapeutic abortion of at least 24 weeks gestational age (GA), with GA assessed based on uncertain LMP with 2nd trimester ultrasound (US) scan; second, a head circumference (HC) measurement either 2 standard deviations (SD) below the mean or less than the third percentile as assessed by GA and gender, using appropriate, standardized reference charts for the population (e.g. WHO growth reference charts if GA greater than or equal to 37 weeks and Intergrowth-21st reference charts for GA 24 to 36 weeks); third, one of the following requirements is met: a) the measurement is taken within the first 24 hours after birth or at the end of the pregnancy taking into consideration the molding of the head; OR b) the measurement is taken greater than 36 hours and up to 6 weeks after birth or the end of the pregnancy with no apparent post-natal insult resulting in microcephaly.","GAIA Level 2b Postnatally Diagnosed Congenital Microcephaly | Global Alignment of Immunization safety Assessment in pregnancy Level 2b Postnatally Diagnosed Congenital Microcephaly | Level 2b Postnatally Diagnosed Congenital Microcephaly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512641","GAIA Level 3b Postnatally Diagnosed Congenital Microcephaly","C128760","GAIA Level 3b Postnatally Diagnosed Congenital Microcephaly is defined by two criteria: first, a live birth, stillbirth, or spontaneous or therapeutic abortion, and second, the case meets criteria for microcephaly using a validated algorithm: 1 inpatient diagnosis OR 2 outpatient diagnoses OR 1 outpatient diagnosis AND death in first year using the following diagnostic codes ICD-9-CM code 742.1 or ICD-10-CM code Q02.","GAIA Level 3b Postnatally Diagnosed Congenital Microcephaly | Global Alignment of Immunization safety Assessment in pregnancy Level 3b Postnatally Diagnosed Congenital Microcephaly | Level 3b Postnatally Diagnosed Congenital Microcephaly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0319533","Syncephalastrum","C125959","The only fungal genus in the Syncephalastraceae family within the Mucorales order. Sporangiospores are produced asexually through the development of cylindrical merosporangia; however, syncephalastrum also undergoes a sexual cycle that produces zygospores. It is primarily isolated from animal excrement, plant material, and soil in tropical or subtropical regions.","Syncephalastrum | SYNCEPHALASTRUM",,,,,,,,,,,,,,,"4269076","Syncephalastrum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036770","Sertoli Cell","C12595","Elongated cells in the seminiferous tubules to which spermatids are attached during spermiogenesis; they secrete androgen-binding protein and establish the blood-testis barrier by forming tight junctions with adjacent Sertoli's cells.","Sertoli Cell | Sertoli Cells | Sustentacular Cell of Testis",,,,,,,,,,,,,,,"4225873","Structure of sertoli cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221085","Taenia saginata","C125960","A species of parasitic cestodes in the genus Taenia that is acquired through the ingestion of infected bovine tissue. Humans are the definitive host of the adult cestodes, resulting in taeniasis.","Taenia saginata | Beef Tapeworm | TAENIA SAGINATA",,,,,,,,,,,,,,,"4265322","Taenia saginata",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039251","Taenia solium","C125961","A species of parasitic cestodes in the genus Taenia that is acquired through the ingestion of infected porcine tissue. Humans are the definitive host of the adult cestodes, resulting in taeniasis. Taenia solium also causes cysticercosis, a tissue infection caused by larval cysts, which results when humans serve as an intermediate host.","Taenia solium | Cysticercus cellulosae | Pork Tapeworm | TAENIA SOLIUM",,,,,,,,,,,,,,,"4075757","Taenia solium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0997372","Torulaspora delbrueckii","C125962","A species of ascomycetous yeast in the Torulaspora genus that has the ability to ferment and assimilate carbon compounds.","Torulaspora delbrueckii | TORULASPORA DELBRUECKII",,,,,,,,,,,,,,,"37018611","Torulaspora delbrueckii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0228686","Oculomotor Nucleus","C12897","A collection of neurons of cranial nerve III located in the rostral half of the midbrain at the level of the superior colliculus, which contain somatic efferent motor neurons that innervate all the extraocular muscles except the superior oblique and lateral rectus.","Oculomotor Nucleus | ",,,,,,,,,,,,,,,"4245132","Oculomotor nucleus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509132","GAIA Congenital Microcephaly Level of Diagnostic Certainty Terminology","C128700","A subset of terminology related to congenital microcephaly, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.","GAIA Congenital Microcephaly Level of Diagnostic Certainty Terminology | Global Alignment of Immunization safety Assessment in pregnancy Congenital Microcephaly Level of Diagnostic Certainty Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509208","GAIA Low Birth Weight Level of Diagnostic Certainty Terminology","C128701","A subset of terminology related to low birth weight, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.","GAIA Low Birth Weight Level of Diagnostic Certainty Terminology | Global Alignment of Immunization safety Assessment in pregnancy Low Birth Weight Level of Diagnostic Certainty Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509211","GAIA Neonatal Respiratory Distress Level of Diagnostic Certainty Terminology","C128702","A subset of terminology related to neonatal respiratory distress, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.","GAIA Neonatal Respiratory Distress Level of Diagnostic Certainty Terminology | Global Alignment of Immunization safety Assessment in pregnancy Neonatal Respiratory Distress Level of Diagnostic Certainty Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509219","GAIA Small for Gestational Age Level of Diagnostic Certainty Terminology","C128703","A subset of terminology related to small for gestational age, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.","GAIA Small for Gestational Age Level of Diagnostic Certainty Terminology | Global Alignment of Immunization safety Assessment in pregnancy Small for Gestational Age Level of Diagnostic Certainty Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509137","GAIA Failure to Thrive Level of Diagnostic Certainty Terminology","C128704","A subset of terminology related to failure to thrive, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.","GAIA Failure to Thrive Level of Diagnostic Certainty Terminology | Global Alignment of Immunization safety Assessment in pregnancy Failure to Thrive Level of Diagnostic Certainty Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509130","GAIA Antenatal Bleeding Level of Diagnostic Certainty Terminology","C128706","A subset of terminology related to antenatal bleeding, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.","GAIA Antenatal Bleeding Level of Diagnostic Certainty Terminology | Global Alignment of Immunization safety Assessment in pregnancy Antenatal Bleeding Level of Diagnostic Certainty Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512275","Latent Membrane Protein 1 Positive","C128835","Indicates that Epstein-Barr virus latent membrane protein 1 expression has been detected in a sample.","Latent Membrane Protein 1 Positive | EBV Latent Membrane Protein 1 Positive | Epstein-Barr Virus Latent Membrane Protein 1 Positive | LMP Positive | LMP1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512324","RUNX1/RUNX1T1 Fusion Positive","C128837","Indicates that expression of the RUNX1/RUNXT1 fusion has been detected in a sample.","RUNX1/RUNX1T1 Fusion Positive | AML-ETO Fusion Positive | AML-ETO Positive | AML/ETO Fusion Positive | AML/ETO Positive | RUNX1-RUNX1T1 Fusion Positive | RUNX1-RUNX1T1 Positive | RUNX1/RUNX1T1 Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512109","CCR4 wt Allele","C129066","Human CCR4 wild-type allele is located in the vicinity of 3p24 and is approximately 5 kb in length. This allele, which encodes C-C chemokine receptor type 4 protein, plays a role in leukocyte migration.","CCR4 wt Allele | C-C Motif Chemokine Receptor 4 wt Allele | CC-CKR-4 | CD194 | CKR4 | CMKBR4 | ChemR13 | Chemokine (C-C Motif) Receptor 4 Gene | Chemokine (C-C) Receptor 4 Gene | Chemokine, CC Motif, Receptor 4 Gene | HGCN:14099 | K5-5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0393808","Charcot-Marie-Tooth Neuropathy X Type 1","C129068","Charcot-Marie-Tooth neuropathy that is inherited in an X-linked manner, and is associated with mutation(s) in the GJB1 gene, encoding gap junction beta-1 protein. The condition is characterized by moderate to severe motor and sensory neuropathy in males, and mild to no symptoms in females.","Charcot-Marie-Tooth Neuropathy X Type 1 | CMTX1",,,,,,,,,,,,,,,"4046239","X-linked hereditary motor and sensory neuropathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4013869","Corticobasal Degeneration","C129069","A progressive neurodegenerative condition affecting the cerebral cortex and basal ganglia. The disorder is characterized by varying degrees of cognitive and motor impairment.","Corticobasal Degeneration | Cortical Basal Ganglionic Degeneration | Corticobasal degeneration",,,,,,,,,,,,,,,"4077904","Corticobasal degeneration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0278450","Posterior Eye Segment","C12906","The larger portion of the eye behind the lens containing the retina, vitreous humor, choroid, and optic nerve.","Posterior Eye Segment | ",,,,,,,,,,,,,,,"4093707","Entire posterior segment of eyeball",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0220993","Cystathioninuria","C129070","An autosomal recessive disorder caused by mutations in the CTH gene, encoding cystathionine gamma-lyase. The condition is characterized by increased concentrations of cystathionine in the plasma and urine.","Cystathioninuria | ",,,,,,,,,,,,,,,"4045236","Cystathioninuria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3810388","Fetal Akinesia Deformation Sequence","C129071","A condition characterized by fetal akinesia and intrauterine growth restriction, that may be associated with mutation(s) in the RAPSN or DOK7 genes, encoding 43 kDa receptor-associated protein of the synapse and protein Dok-7, respectively.","Fetal Akinesia Deformation Sequence | FADS | Pena-Shokeir syndrome, Type 1",,,,,,,,,,,,,,,"4269041","Pena-Shokeir syndrome type I",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4017061","Mucopolysaccharidosis Type IX","C129073","An autosomal recessive lysosomal storage disease caused by mutation(s) in the HYAL1 gene, encoding hyaluronidase-1. It is characterized by short stature and hyaluronidase deficiency.","Mucopolysaccharidosis Type IX | Hyaluronidase Deficiency | MPS9",,,,,,,,,,,,,,,"4053073","Deficiency of hyaluronoglucosaminidase",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1720956","Hyper-IgM Immunodeficiency Syndrome, Type 2","C129074","An autosomal recessive immunodeficiency that is caused by mutation(s) in the AICDA gene, single-stranded DNA cytosine deaminase. It is characterized by normal or elevated concentrations of IgM and decreased or absent concentrations of IgG, IgA, and IgE.","Immunodeficiency with Hyper-IgM Type 2 | HIGM2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3553847","Leber Congenital Amaurosis","C129075","A congenital retinopathy that is associated with mutation(s) in at least eighteen genes, typically characterized by severe visual impairment.","Leber Congenital Amaurosis | ",,,,,,,,,,,,,,,"4108958","Leber's amaurosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512396","Canine Mastocytoma","C129077","A tumor composed of mast cells that occurs in dogs.","Canine Mastocytoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509744","Maintain Healthcare Records","C128519","The healthcare provider or setting must maintain records of certain activities which may be provided to the sponsor or requested in audits. This may include records of dispensing or distribution of a drug.","Maintain Healthcare Records | Maintain Records",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509127","GAIA Level 4 Postnatally Diagnosed Congenital Microcephaly","C128761","GAIA Level 4 Postnatally Diagnosed Congenital Microcephaly is defined by two criteria: first, a live birth, stillbirth, or spontaneous or therapeutic abortion; second, a diagnosis of congenital microcephaly based on either a physical inspection without head circumference (HC) measurement, OR  an ICD-9-CM or ICD-10-CM code that does not meet the validated algorithm criteria used in the case definition for GAIA Level 3 Postnatally Diagnosed Congenital Microcephaly.","GAIA Level 4 Postnatally Diagnosed Congenital Microcephaly | Global Alignment of Immunization safety Assessment in pregnancy Level 4 Postnatally Diagnosed Congenital Microcephaly | Level 4 Postnatally Diagnosed Congenital Microcephaly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512278","GAIA Insufficient Evidence for Diagnosis of Fetal Growth Restriction","C128915","GAIA Insufficient Evidence for Diagnosis of Fetal Growth Restriction is defined as the absence of an ultrasound for use in the assessment of estimated fetal weight.","GAIA Insufficient Evidence for Diagnosis of Fetal Growth Restriction | Global Alignment of Immunization safety Assessment in pregnancy Insufficient Evidence for Diagnosis of Fetal Growth Restriction | Insufficient Evidence for Fetal Growth Restriction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0228740","Facial Nerve Nucleus","C12898","A collection of cell bodies of cranial nerve VII found in the brainstem. There are three nuclei with distinct functions: the facial motor nucleus, which sends muscular efferent nerves to the muscles of facial expression and the stapedius; the superior salivary nucleus, which sends visceral parasympathetic efferent nerves mostly to the lacrimal and salivary glands; and the geniculate ganglion, which receives mostly afferent nerves for taste sensation.","Facial Nerve Nucleus | Facial Nucleus",,,,,,,,,,,,,,,"4090143","Facial nucleus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512168","NCCN-FACT FBLSI-18 Version 2 - Content With Quality of My Life","C129187","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I am content with the quality of my life right now.","NCCN-FACT FBLSI-18 Version 2 - Content With Quality of My Life | FAC028-Content With Quality of My Life | FAC02818",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512466","FACT-B Version 4 - I Have a Lack of Energy","C129188","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Physical Well-Being: I have a lack of energy.","FACT-B Version 4 - I Have a Lack of Energy | FAC005-I Have a Lack of Energy | FAC00501",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512464","FACT-B Version 4 - I Have Nausea","C129189","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Physical Well-Being: I have nausea.","FACT-B Version 4 - I Have Nausea | FAC005-I Have Nausea | FAC00502",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512475","FACT-B Version 4 - Trouble Meeting Needs of Family","C129190","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Physical Well-Being: Because of my physical condition, I have trouble meeting the needs of my family.","FACT-B Version 4 - Trouble Meeting Needs of Family | FAC005-Trouble Meeting Needs of Family | FAC00503",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512465","FACT-B Version 4 - I Have Pain","C129191","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Physical Well-Being: I have pain.","FACT-B Version 4 - I Have Pain | FAC005-I Have Pain | FAC00504",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512442","FACT-B Version 4 - Bothered by Treatment Side Effect","C129192","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Physical Well-Being: I am bothered by side effects of treatment.","FACT-B Version 4 - Bothered by Treatment Side Effect | FAC005-Bothered by Treatment Side Effect | FAC00505",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512279","GART wt Allele","C128849","Human GART wild-type allele is located in the vicinity of 21q22.11 and is approximately 40 kb in length. This allele, which encodes trifunctional purine biosynthetic protein adenosine-3, plays a role in the synthesis of purines.","GART wt Allele | AIRS | GARFT | GARS | GARTF | PAIS | PGFT | PRGS | Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase wt Allele | Phosphoribosylglycinamide Formyltransferase/Phosphoribosylglycinamide Synthetase/Phosphoribosylaminoimidazole Synthetase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1836861","FANCONI ANEMIA, COMPLEMENTATION GROUP I","C129026","Fanconi anemia caused by mutations in the FANCI gene, encoding Fanconi anemia group I protein.","Fanconi Anemia, Complementation Group I | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1836860","FANCONI ANEMIA, COMPLEMENTATION GROUP J","C129027","Fanconi anemia caused by mutations in the BRIP1 gene, encoding Fanconi anemia group J protein.","Fanconi Anemia, Complementation Group J | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1876203","Frontonasal Dysplasia","C129028","Frontonasal dysplasia caused by mutations in the ALX3 gene, encoding homeobox protein aristaless-like 3. It is inherited in an autosomal recessive fashion.","Frontonasal Dysplasia | FND1 | Frontonasal Dysplasia 1",,,,,,,,,,,,,,,"37164301","Frontorhiny",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268540","Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome","C129029","An autosomal recessive disorder caused by mutation(s) in the SLC25A15 gene, encoding mitochondrial ornithine transporter 1. The condition is characterized by failure to thrive, liver dysfunction, psychomotor retardation, encephalopathy and seizures.","Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome | HHH",,,,,,,,,,,,,,,"4146759","Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509312","Report Adverse Events","C128520","The healthcare provider or setting must report adverse events of interest to the Manufacturer, MedWatch, and/or a REMS Program.","Report Adverse Events | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509731","Cooperate with REMS Audits","C128521","The healthcare provider or setting must cooperate with audits of their activities conducted by the REMS program.","Cooperate with REMS Audits | Cooperate with Risk Evaluation and Mitigation Strategies Audits",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509074","Get Lab Test or Monitoring","C128523","The patient must be monitored or have a lab test completed.","Get Lab Test or Monitoring | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509663","Receive Counseling","C128524","The patient must receive counseling from a healthcare provider. The counseling may cover a specific topic, use a specific material, or both.","Receive Counseling | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508663","Adhere to REMS Patient Safe Use Conditions","C128526","The patient must adhere to certain safe use conditions, such as using contraception or following the safe use conditions described in REMS materials.","Adhere to REMS Patient Safe Use Conditions | Adhere to Risk Evaluation and Mitigation Strategies Patient Safe Use Conditions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3715209","REMS Protocol","C128528","The 'Protocol' data element is used to specify when REMS requirements must be carried out: either at a specific point in the medication use process (e.g. prescribing, dispensing, administering), or based on the receipt of REMS certification.","REMS Protocol | Protocol | Risk Evaluation and Mitigation Strategies Protocol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509320","REMS Certification","C128529","The receipt of certification by a healthcare provider or setting, allowing them to prescribe, dispense, and/or administer a drug under a REMS program.","REMS Certification | Risk Evaluation and Mitigation Strategies Certification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508964","Pharmacotherapy Initiation","C128530","The start of treatment with a drug; the first prescription or order for a drug associated with a given course of treatment.","Pharmacotherapy Initiation | Medication Initiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508963","Pharmacotherapy Continuation","C128531","The continuation of an existing prescription or order for a given course of treatment.","Pharmacotherapy Continuation | Medication Continuation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508665","All Pharmacotherapy Prescriptions","C128532","Any prescription or order associated with a given course of treatment; a new prescription or order or the continuation of an existing prescription or order.","All Pharmacotherapy Prescriptions | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0947323","Medication Dispensing","C128533","The dispensing of a drug to be self-administered by a patient or to be administered by a healthcare provider.","Medication Dispensing | ",,,,,,,,,,,,,,,"4162585","Dispensing medication",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509624","Pharmacotherapy Discontinuation","C128535","The discontinuation of treatment with a drug.","Pharmacotherapy Discontinuation | Medication Discontinuation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509625","Medication Distribution","C128536","The distribution, sale, or transfer of a drug not pursuant to a specific prescription.","Medication Distribution | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509321","REMS Stakeholder","C128537","The 'Stakeholder' data element represents stakeholders who participate in the REMS based on the role they play in the medication use and distribution process (e.g., whether they prescribe, dispense, or distribute the drug).","REMS Stakeholder | Risk Evaluation and Mitigation Strategies Stakeholder | Stakeholder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509626","Medication Prescriber","C128538","Healthcare providers who prescribe the drug.","Medication Prescriber | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512378","Radio Frequency Energy Therapy","C128918","A procedure that uses low-level, non-thermal, non-ionizing radio frequency energy (RFE) to create an oscillating magnetic field that blocks the division of cancer cells by inhibiting cancer cell dynamics.","Radio Frequency Energy Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512438","FACIT-F Version 4 - Trouble Meeting Needs of Family","C129113","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Physical Well-Being: Because of my physical condition, I have trouble meeting the needs of my family.","FACIT-F Version 4 - Trouble Meeting Needs of Family | FAC071-Trouble Meeting Needs of Family | FAC07103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512426","FACIT-F Version 4 - I Have Pain","C129114","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Physical Well-Being: I have pain.","FACIT-F Version 4 - I Have Pain | FAC071-I Have Pain | FAC07104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512402","FACIT-F Version 4 - Bothered by Treatment Side Effect","C129115","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Physical Well-Being: I am bothered by side effects of treatment.","FACIT-F Version 4 - Bothered by Treatment Side Effect | FAC071-Bothered by Treatment Side Effect | FAC07105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512416","FACIT-F Version 4 - I Feel Ill","C129116","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Physical Well-Being: I feel ill.","FACIT-F Version 4 - I Feel Ill | FAC071-I Feel Ill | FAC07106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512409","FACIT-F Version 4 - I Am Forced to Spend Time in Bed","C129117","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Physical Well-Being: I am forced to spend time in bed.","FACIT-F Version 4 - I Am Forced to Spend Time in Bed | FAC071-I Am Forced to Spend Time in Bed | FAC07107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512413","FACIT-F Version 4 - I Feel Close to My Friends","C129118","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Social/Family Well-Being: I feel close to my friends.","FACIT-F Version 4 - I Feel Close to My Friends | FAC071-I Feel Close to My Friends | FAC07108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512406","FACIT-F Version 4 - Get Emotional Support From Family","C129119","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Social/Family Well-Being: I get emotional support from my family.","FACIT-F Version 4 - Get Emotional Support From Family | FAC071-Get Emotional Support From Family | FAC07109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512432","FACIT-F Version 4 - My Family Has Accepted My Illness","C129121","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Social/Family Well-Being: My family has accepted my illness.","FACIT-F Version 4 - My Family Has Accepted My Illness | FAC071-My Family Has Accepted My Illness | FAC07111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512435","FACIT-F Version 4 - Satisfied Family Communication of Illness","C129122","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Social/Family Well-Being: I am satisfied with family communication about my illness.","FACIT-F Version 4 - Satisfied Family Communication of Illness | FAC071-Satisfied Communication Illness | FAC07112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512457","FACT-B Version 4 - I Feel Ill","C129193","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Physical Well-Being: I feel ill.","FACT-B Version 4 - I Feel Ill | FAC005-I Feel Ill | FAC00506",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512452","FACT-B Version 4 - I Am Forced to Spend Time in Bed","C129194","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Physical Well-Being: I am forced to spend time in bed.","FACT-B Version 4 - I Am Forced to Spend Time in Bed | FAC005-I Am Forced to Spend Time in Bed | FAC00507",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512455","FACT-B Version 4 - I Feel Close to My Friends","C129195","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Social/Family Well-Being: I feel close to my friends.","FACT-B Version 4 - I Feel Close to My Friends | FAC005-I Feel Close to My Friends | FAC00508",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512446","FACT-B Version 4 - Get Emotional Support From Family","C129196","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Social/Family Well-Being: I get emotional support from my family.","FACT-B Version 4 - Get Emotional Support From Family | FAC005-Get Emotional Support From Family | FAC00509",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512469","FACT-B Version 4 - My Family Has Accepted My Illness","C129198","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Social/Family Well-Being: My family has accepted my illness.","FACT-B Version 4 - My Family Has Accepted My Illness | FAC005-My Family Has Accepted My Illness | FAC00511",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512472","FACT-B Version 4 - Satisfied Family Communication of Illness","C129199","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Social/Family Well-Being: I am satisfied with family communication about my illness.","FACT-B Version 4 - Satisfied Family Communication of Illness | FAC005-Satisfied Communication Illness | FAC00512",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4018803","Antisense Oligonucleotides","C1291","Antisense Oligonucleotides, short synthetic segments of DNA or RNA, designed with a sequence complimentary to a specific mRNA that target and bind with mRNA, causing inhibition of translation or overexpression of the protein encoded by the mRNA.","Antisense Oligonucleotides | AS ODNs | Antisense Agents | Gene Expression Inhibitor | antisense agent | antisense oligonucleotide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3280527","Pancreatic Lipase Deficiency","C129030","An autosomal recessive disorder caused by mutation(s) in the PNLIP gene, encoding pancreatic triacylglycerol lipase. The condition is characterized by absent or reduced pancreatic lipase.","Pancreatic Lipase Deficiency | PNLIPD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1300260","Spondyloepimetaphyseal Dysplasia, Sponastrime Type","C129031","A rare disorder characterized by severe short stature, lumbar lordosis, midface hypoplasia, micromelia, frontal bossing, epiphyseal and metaphyseal abnormalities. The inheritance is autosomal recessive.","Spondyloepimetaphyseal Dysplasia, Sponastrime Type | Short Limb Dwarfism-Saddle Nose-Spinal Alterations-Metaphyseal Striation Syndrome | Short-Limb Dwarfism with Saddle Nose, Spinal Alterations, and Metaphyseal Striation | Sponastrime Dysplasia",,,,,,,,,,,,,,,"4191481","Sponastrime dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3844597","Tyrosinemia Type II","C129032","Tyrosinemia caused by mutation(s) in the TAT gene, encoding tyrosine aminotransferase. The inheritance is autosomal recessive.","Tyrosinemia Type II | ",,,,,,,,,,,,,,,"4172136","Tyrosinemia type 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512392","Canine GM1-Gangliosidosis","C129034","GM1-gangliosidosis that occurs in dogs, caused by mutation(s) in the GLB1 gene, encoding beta-galactosidase.","Canine GM1-Gangliosidosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1861185","Thrombocytopenia, Autosomal Dominant, 2","C129035","An autosomal dominant disorder caused by mutation(s) in the ANKRD26 gene, encoding ANKRD26 protein. Additionally, in one family, a mutation(s) has been identified in the MASTL gene, encoding serine/threonine-protein kinase greatwall. The condition is characterized by mild to moderate bruisability.","Thrombocytopenia 2 | THC2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512266","KIR2DL2 wt Allele","C129037","Human KIR2DL2 wild-type allele is located in the vicinity of 19q13.4 and is approximately 15 kb in length. This allele, which encodes killer cell immunoglobulin-like receptor 2DL2 protein, is involved in the modulation of natural killer cell activity.","KIR2DL2 wt Allele | CD158B1 | CD158b | CD158k | Killer Cell Immunoglobulin Like Receptor, Two Ig Domains and Long Cytoplasmic Tail 2 wt Allele | Killer Cell Immunoglobulin-Like Receptor, Two Domains, Long Cytoplasmic Tail, 2 Gene | NKAT-6 | NKAT6 | cl-43 | p58.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1741807","Killer Cell Immunoglobulin-Like Receptor 2DL2, Human","C129038","Killer cell immunoglobulin-like receptor 2DL2 (348 aa, ~38 kDa) is encoded by the human KIR2DL2 gene. This protein plays a role in the inhibition of natural killer cell activity.","Killer Cell Immunoglobulin-Like Receptor 2DL2 | CD158 Antigen-Like Family Member B1 | CD158b1 | CD158b1 Antigen | KIR2DL2 | MHC Class I NK Cell Receptor | NK-Associated Transcript 6 | NKAT-6 | Natural Killer-Associated Transcript 6 | p58 NK Receptor CL-43 | p58 Natural Killer Cell Receptor Clone CL-43",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509067","B4GALNT1 wt Allele","C128483","Human B4GALNT1 wild-type allele is located in the vicinity of 12q13.3 and is approximately 10 kb in length. This allele, which encodes beta-1,4 N-acetylgalactosaminyltransferase 1 protein, plays a role in the synthesis of glycosphingolipids. Mutation of the gene is associated with autosomal recessive spastic paraplegia 26.","B4GALNT1 wt Allele | Beta-1,4-N-Acetyl-Galactosaminyltransferase 1 wt Allele | GALGT | GALNACT | GalNAc-T | SIAT2 | SPG26 | Spastic Paraplegia 26 Gene | UDP-Gal:BetaGlcNAc Beta-1,4-N-Acetylgalactosaminyltransferase Transferase 1 Gene | UDP-N-Acetyl-Alpha-D-Galactosamine:(N-Acetylneuraminyl)-Galactosylglucosylceramide N-Acetylgalactosaminyltransferase (GalNAc-T) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4041978","Beta-1,4 N-Acetylgalactosaminyltransferase 1, Human","C128484","Beta-1,4 N-acetylgalactosaminyltransferase 1 (533 aa, ~59 kDa) is encoded by the human B4GALNT1 gene. This protein is involved in ganglioside synthesis.","Beta-1,4 N-Acetylgalactosaminyltransferase 1 | (N-Acetylneuraminyl)-Galactosylglucosylceramide | B4GALNT1 | Beta-1,4-N-Acetyl-Galactosaminyl Transferase 1 | Beta-1,4-N-Acetyl-Galactosaminyltransferase 1 | Beta-1,4-N-Acetylgalactosaminyltransferase | Beta1,4GalNAc-T | EC 2.4.1.92 | G(M2)/G(D2) Synthase | GD2 Synthase | GD2 Synthase, GM2 Synthase | GM2 Synthase | GM2/GD2 Synthase | GalNAc-T | GalNAcT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509110","GAIA Level 1 Small for Gestational Age","C128733","GAIA Level 1 Small for Gestational Age is defined by three criteria: first, weight below the 10th percentile for gestational age; second, assessment of weight by both of the following: a) Newborn weighed within 24 hours of birth; AND b) Weight assessed using a calibrated electronic scale with 10 g resolution; third, the gestational age is assessed by confirmatory ultrasound during the first trimester, with or without certain LMP, or IUI or embryo transfer date OR by first trimester ultrasound.","GAIA Level 1 Small for Gestational Age | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Small for Gestational Age | Level 1 Small for Gestational Age",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509119","GAIA Level 2a Small for Gestational Age","C128734","GAIA Level 2a Small for Gestational Age is defined by three criteria: first, weight below the 10th percentile for gestational age; second, newborn weighed within 24 hours of birth on any scale with a less than or equal to 50 g resolution, calibrated and tared to zero; third, the gestational age is assessed by either a) Certain LMP with first or second trimester ultrasound; or b) Certain LMP with first trimester physical exam.","GAIA Level 2a Small for Gestational Age | Global Alignment of Immunization safety Assessment in pregnancy Level 2a Small for Gestational Age | Level 2a Small for Gestational Age",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509121","GAIA Level 2b Small for Gestational Age","C128735","GAIA Level 2b Small for Gestational Age is defined by three criteria: first, weight below the 10th percentile for gestational age; second, the newborn weighed within 24 hours on any scale with a less than or equal to 50 g resolution, calibrated and tared to zero; third, gestational age determined by uncertain LMP with second trimester ultrasound.","GAIA Level 2b Small for Gestational Age | Global Alignment of Immunization safety Assessment in pregnancy Level 2b Small for Gestational Age | Level 2b Small for Gestational Age",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509124","GAIA Level 3a Small for Gestational Age","C128736","GAIA Level 3a Small for Gestational Age is defined by three criteria: first, weight is below the 10th percentile for gestational age; second, the newborn is weighed within the first 48 hours of life on any scale with a less than or equal to 50 g resolution, calibrated and tared to zero; third, gestational age assessed by one of the following four methods: a) Certain LMP with third trimester ultrasound; b) Certain LMP with confirmatory 2nd trimester fundal height; c) Certain LMP with birthweight; or d) Uncertain LMP with first trimester physical exam.","GAIA Level 3a Small for Gestational Age | Global Alignment of Immunization safety Assessment in pregnancy Level 3a Small for Gestational Age | Level 3a Small for Gestational Age",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509125","GAIA Level 3b Small for Gestational Age","C128737","GAIA Level 3b Small for Gestational Age is defined by three criteria: first, the weight is below the 10th percentile for gestational age; second, the infant is weighed within the first 48 hours of life, and the weight is assessed on any scale by measuring the difference between an adult holding the infant and the adult being weighed alone; third, gestational age is assessed by one of following three methods: a) Uncertain LMP with fundal height; b) Uncertain LMP with newborn physical assessment; or c) Uncertain LMP with birthweight.","GAIA Level 3b Small for Gestational Age | Global Alignment of Immunization safety Assessment in pregnancy Level 3b Small for Gestational Age | Level 3b Small for Gestational Age",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509129","GAIA Level 4 Small for Gestational Age","C128738","GAIA Level 4 Small for Gestational Age is defined by one of the following three criteria: first, the infant is noted to be small, but has no documented weight; second, the gestational age is assessed by infant examination only; third, the diagnosis is extracted from either billing codes or a chart with no documentation of the actual birth weight or the gestational age.","GAIA Level 4 Small for Gestational Age | Global Alignment of Immunization safety Assessment in pregnancy Level 4 Small for Gestational Age | Level 4 Small for Gestational Age",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1997142","Organic Failure to Thrive","C128739","Failure to thrive (FTT), that occurs in less than five percent of FTT cases; it is caused by acute or chronic disorders that interfere with nutritional uptake, including cleft palate, malabsorption due to cystic fibrosis, and short gut syndrome.","Organic Failure to Thrive | Organic FTT",,,,,,,,,,,,,,,"4324055","Organic failure to thrive",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509515","Non-Organic Failure to Thrive","C128740","Failure to thrive caused by inadequate intake due to environmental influences, stimulus deprivation- poverty, feeding techniques, or psychological reason, and without any apparent growth-inhibiting organic disorder.","Non-Organic Failure to Thrive | Non-Organic FTT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509642","Mixed Failure to Thrive","C128741","Failure to thrive due to both organic and non-organic causes.","Mixed Failure to Thrive | Mixed FTT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509081","GAIA Level 1 Placenta Previa","C128742","GAIA Level 1 Placenta Previa is defined by a second or third trimester ultrasound (and/or MRI) that demonstrates evidence of placental tissue overlying or abutting the internal cervical os.","GAIA Level 1 Placenta Previa | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Placenta Previa | Level 1 Placenta Previa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512414","FACIT-F Version 4 - I Feel Close to My Partner","C129123","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Social/Family Well-Being: I feel close to my partner (or the person who is my main support).","FACIT-F Version 4 - I Feel Close to My Partner | FAC071-I Feel Close to My Partner | FAC07113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512410","FACIT-F Version 4 - I Am Satisfied With My Sex Life","C129124","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Social/Family Well-Being: I am satisfied with my sex life.","FACIT-F Version 4 - I Am Satisfied With My Sex Life | FAC071-I Am Satisfied With My Sex Life | FAC07114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512419","FACIT-F Version 4 - I Feel Sad","C129125","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Emotional Well-Being: I feel sad.","FACIT-F Version 4 - I Feel Sad | FAC071-I Feel Sad | FAC07115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512436","FACIT-F Version 4 - Satisfied With How I Am Coping","C129126","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Emotional Well-Being: I am satisfied with how I am coping with my illness.","FACIT-F Version 4 - Satisfied With How I Am Coping | FAC071-Satisfied With How I Am Coping | FAC07116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512431","FACIT-F Version 4 - Losing Hope Against Illness","C129127","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Emotional Well-Being: I am losing hope in the fight against my illness.","FACIT-F Version 4 - Losing Hope Against Illness | FAC071-Losing Hope Against Illness | FAC07117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512418","FACIT-F Version 4 - I Feel Nervous","C129128","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Emotional Well-Being: I feel nervous.","FACIT-F Version 4 - I Feel Nervous | FAC071-I Feel Nervous | FAC07118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4274168","Left Posterolateral Apical Peripheral Zone of Prostate","C128576","The region of the prostate that is located on the anatomical left side of the posterolateral portion of the apical division of the peripheral zone.","Left Posterolateral Apical Peripheral Zone of Prostate | Apex L PZpl",,,,,,,,,,,,,,,"37396944","Left posterolateral apical peripheral zone of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4274166","Left Posteromedial Apical Peripheral Zone of Prostate","C128577","The region of the prostate that is located on the anatomical left side of the posteromedial portion of the apical division of the peripheral zone.","Left Posteromedial Apical Peripheral Zone of Prostate | Apex L PZpm",,,,,,,,,,,,,,,"37396945","Left posteromedial apical peripheral zone of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508866","Left Anterior Apical Transition Zone of Prostate","C128578","The region of the prostate that is located on the anatomical left side of the anterior portion of the apical division of the transition zone.","Left Anterior Apical Transition Zone of Prostate | Apex L TZa",,,,,,,,,,,,,,,"37396938","Left anterior apical part of transition zone of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4273870","Right Apical Anterior Fibromuscular Stroma of Prostate","C128580","The portion of the fibromuscular stroma of the prostate that is located on the anatomical right side of the apical division of the anterior lobe.","Right Apical Anterior Fibromuscular Stroma of Prostate | Apex R AS",,,,,,,,,,,,,,,"37396933","Right apical anterior fibromuscular stroma of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4274125","Right Anterior Apical Peripheral Zone of Prostate","C128581","The region of the prostate that is located on the anatomical right side of the anterior portion of the apical division of the peripheral zone.","Right Anterior Apical Peripheral Zone of Prostate | Apex R PZa",,,,,,,,,,,,,,,"37399567","Right anterior apical peripheral zone of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4273861","Right Posterolateral Apical Peripheral Zone of Prostate","C128582","The region of the prostate that is located on the anatomical right side of the posterolateral portion of the apical division of the peripheral zone.","Right Posterolateral Apical Peripheral Zone of Prostate | Apex R PZpl",,,,,,,,,,,,,,,"37396943","Right posterolateral apical peripheral zone of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4274167","Right Posteromedial Apical Peripheral Zone of Prostate","C128583","The region of the prostate that is located on the anatomical right side of the posteromedial portion of the apical division of the peripheral zone.","Right Posteromedial Apical Peripheral Zone of Prostate | Apex R PZpm",,,,,,,,,,,,,,,"37399568","Right posteromedial apical peripheral zone of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509675","Tru-Cut Biopsy Needle","C128664","A proprietary biopsy needle designed for manual capture of high-quality tissue samples with minimal trauma to the patient.","Tru-Cut Biopsy Needle | Tru-Cut",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509136","GAIA Dysfunctional Labor Level of Diagnostic Certainty","C128669","A classification of maternal and fetal outcomes relating to dysfunctional labor, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.","GAIA Dysfunctional Labor Level of Diagnostic Certainty | Dysfunctional Labor Level of Diagnostic Certainty | Global Alignment of Immunization safety Assessment in pregnancy Dysfunctional Labor Level of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509131","GAIA Antenatal Bleeding Level of Diagnostic Certainty","C128670","A classification of maternal and fetal outcomes relating to antenatal bleeding, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.","GAIA Antenatal Bleeding Level of Diagnostic Certainty | Antenatal Bleeding Level of Diagnostic Certainty | Global Alignment of Immunization safety Assessment in pregnancy Antenatal Bleeding Level of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226654","Cardiac Vein","C12878","Any of the three cardiac veins including the small, middle and great cardiac veins.","Cardiac Vein | ",,,,,,,,,,,,,,,"4311543","Structure of cardiac vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL507949","Anti-CD123/CD3 Bispecific Antibody JNJ-63709178","C128486","A humanized anti-CD123/anti-CD3 bispecific monoclonal antibody, with potential immunostimulating and antineoplastic activities. Anti-CD123/CD3 bispecific antibody JNJ-63709178 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD123, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of JNJ-63709178, this bispecific antibody simultaneously binds to both CD3-expressing T-cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated cell lysis of CD123-expressing tumor cells. CD123, the interleukin-3 receptor alpha chain, is overexpressed in a variety of cancers; its expression is low or absent in normal, healthy cells.","Anti-CD123/CD3 Bispecific Antibody JNJ-63709178 | Humanized CD123 x CD3 DuoBody JNJ-63709178 | JNJ-63709178",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507947","iodine I 124 PU-AD","C128487","A radioconjugate composed of icapamespib, a synthetic purine-scaffold inhibitor of the molecular chaperone heat shock protein 90 (Hsp90), conjugated to the radioisotope iodine I 124, with potential imaging activity upon positron emission tomography (PET). Upon administration of iodine I 124 icapamespib, the icapamespib moiety selectively binds to cancer cells expressing stress-induced Hsp90 (stress Hsp90). Upon PET, Hsp90-overexpressing cancer cells can be visualized and patients who may benefit from icapamespib therapy can be identified. This radioconjugate may also be used to determine the pharmacokinetics of icapamespib. Icapamespib is able to cross the blood-brain-barrier (BBB) and specifically targets stress Hsp90, as seen in certain conditions, such as cancer and neurodegenerative diseases, while normal housekeeping Hsp90 complexes are not targeted by icapamespib at dose levels administered for imaging.  Additionally, housekeeping Hsp90 complexes are only targeted at doses that are much larger than that are needed to exert an anticancer effect.","Iodine I 124 Icapamespib | 124I-PU-AD | ICAPAMESPIB I-124 | Iodine I 124 PU-AD | [124I]-PU-AD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3252337","Perflubutane Microbubble","C128488","A phospholipid-stabilized suspension composed of microbubbles containing the gas perfluorobutane (perflubutane, PFB) with an outer layer of hydrogenated egg phosphatidylserine (HEPS), which can be used as an ultrasound imaging contrast agent. Upon administration, the PFB microbubbles enhance echo differences between various tissues, which enhances the visualization of images during ultrasound. In particular, the PFB microbubbles seem to preferentially target the reticuloendothelial system (RES); they are taken up by macrophages in the spleen and liver (Kupffer cells), and are taken up in lymph nodes. This may aid in the detection and diagnosis of cancer and liver disease, and may improve imaging of the lymphatic and vascular systems. The microbubbles provide increased stability during ultrasound imaging.","Perflubutane Microbubble | Microbubble Ultrasound Contrast Agent PFB | PFB Microbubble | Perflubutane Microsphere | Sonazoid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509135","GAIA Dysfunctional Labor Level of Diagnostic Certainty Terminology","C128707","A subset of terminology related to dysfunctional labor, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.","GAIA Dysfunctional Labor Level of Diagnostic Certainty Terminology | Global Alignment of Immunization safety Assessment in pregnancy Dysfunctional Labor Level of Diagnostic Certainty Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509139","GAIA Fetal Growth Restriction Level of Diagnostic Certainty Terminology","C128708","A subset of terminology related to fetal growth restriction, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.","GAIA Fetal Growth Restriction Level of Diagnostic Certainty Terminology | Global Alignment of Immunization safety Assessment in pregnancy Fetal Growth Restriction Level of Diagnostic Certainty Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509093","GAIA Level 2 Placenta Previa","C128743","GAIA Level 2 Placenta Previa is defined by three criteria: first, painless vaginal bleeding during the second or third trimester; second, a high presenting part or abnormal fetal lie; third, pelvic exam with fullness palpable in the fornices (avoiding digital cervical exam) OR a speculum exam with placental tissue visible through an open cervical os.","GAIA Level 2 Placenta Previa | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Placenta Previa | Level 2 Placenta Previa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512226","NY-ESO-1 Protein/Microparticle MDP/Bacterial DNA-containing MIS416 Vaccine","C128887","A combination preparation composed of a protein derived from the human tumor-associated antigen (TAA) cancer-testis antigen 1 (NY-ESO-1) and a microparticle combining two immune-modifying components derived from the bacterium Propionibacterium acnes, a bacterial cell wall component that is rich in muramyl dipeptide (MDP) and bacteria-derived single-stranded DNA fragments, with potential immunomodulating, immunoadjuvant and antineoplastic activities. Upon administration of NY-ESO-1 protein/microparticle MDP/bacterial DNA-containing MIS416 vaccine, MIS416 localizes in and is taken up mainly by the liver, thereby forming a liver depot. MIS416 is then taken up by immune cells, such as monocytes and dendritic cells (DCs), where MDP and the bacterial DNA target and bind to the cytosolic innate pattern recognition receptors (PRRs) nucleotide-binding oligomerization domain-containing protein 2 (NOD2), and toll-like receptor 9 (TLR9), respectively. The simultaneous binding and activation of both NOD2 and TLR9, leads to activation of both NOD2 and TLR9 signaling pathways. This stimulates the innate immune system, induces secretion of cytokines, particularly interferon (IFN), and modulates the activation of various immune cells. In the presence of the NY-ESO-1 peptide, MIS416 enhances the cytotoxic T-lymphocyte (CTL)-mediated immune response against NY-ESO-1, resulting in an increased anti-tumor immune response. NY-ESO-1 is expressed in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival.","NY-ESO-1 Protein/Microparticle MDP/Bacterial DNA-containing MIS416 Vaccine | NY-ESO-1 Protein with MIS416 | NY-ESO-1 Protein/MIS416",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1328712","Cytarabine Monophosphate Prodrug MB07133","C128888","A prodrug of the monophosphate (MP) form of the antimetabolite cytarabine (araCMP), an analogue of cytidine with a modified sugar moiety (arabinose instead of ribose), with potential antineoplastic activity. Upon administration of the cytarabine MP prodrug MB07133, the targeting moiety of this agent specifically delivers the cytarabine moiety to the liver. In turn, araCMP is selectively converted to araC triphosphate (araCTP) by a liver kinase, where it binds to and competes with cytidine for incorporation into DNA, thereby inhibiting DNA polymerase, and DNA synthesis. This leads to the inhibition of tumor cell proliferation and destruction of liver cancer cells. The liver is not able to convert araC into araCMP; araCMP is not converted into araCTP in tissues other than the liver. This enhances efficacy and minimizes systemic toxicity.","Cytarabine Monophosphate Prodrug MB07133 | (2R,4S)-4-amino-1-[5-O-[2-oxo-4-(4-pyridyl)-1,3,2-dioxaphosphorinan-2-yl]-beta-d-arabinofuranosyl]-2(1H)-pyrimidinone | Cytarabine Prodrug MB07133 | MB07133",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0072642","Pycnogenol","C128889","A nutritional supplement containing an extract obtained from the French maritime pine bark Pinus pinaster, with potential immunomodulating and antioxidant activities. The French maritime pine bark extract contains high amounts of the phytochemicals proanthocyanidins. Proanthocyanidins are able to scavenge free radicals, and therefore may inhibit cellular damage. This extract may also ameliorate the symptoms of lymphedema and improve blood flow. It might also stimulate the immune system and have antioxidant effects.","French Maritime Pine Bark Extract | MARITIME PINE | PYC | Pycnogenol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3536733","Visual System","C12888","The part of the central nervous system that contains the organs and connections that allow for the processing of visual images as well as some non-image forming visual functions, including circadian photoentrainment. Structures comprising the visual system include the eye, the optic nerve, the optic chiasma, the optic tract, the lateral geniculate nucleus, the optic radiations, the visual cortex, and the visual association cortex.","Visual System | Visual Pathway",,,,,,,,,,,,,,,"4177661","Structure of visual system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL507952","Fluorescent Antibody SGM-101","C128890","A near infrared-emitting fluorochrome-labeled anti-carcinoembryonic antigen (ACE; anti-CEA) monoclonal antibody, with potential diagnostic imaging activity. Upon administration, the fluorescent antibody SGM-101 binds CEA-overexpressing cancer cells. Upon fluorescence imaging, the fluorochrome can be visualized and CEA-overexpressing cancer cell can be imaged and detected. CEA, a tumor-associated antigen (TAA), is overexpressed on the surface of tumor cells.","Fluorescent Antibody SGM-101 | Anti-CEA Fluorescent Antibody SGM-101 | SGM-101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512491","Pegteograstim","C128891","An analogue of pegfilgrastim, a recombinant, pegylated form of endogenous human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Similar to endogenous G-CSF, this agent binds to and activates specific cell surface receptors, and stimulates neutrophil progenitor proliferation, differentiation and selected neutrophil functions. Pegteograstim may prevent and shorten the duration of chemotherapy-induced neutropenia (CIN). Pegylation of teograstim increases the half-life of this agent.","Pegteograstim | Neurapeg | PEGTEOGRASTIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509529","Right Anterior Apical Transition Zone of Prostate","C128584","The region of the prostate that is located on the anatomical right side of the anterior portion of the apical division of the transition zone.","Right Anterior Apical Transition Zone of Prostate | Apex R TZa",,,,,,,,,,,,,,,"37396937","Right anterior apical part of transition zone of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509537","Right Posterior Apical Transition Zone of Prostate","C128585","The region of the prostate that is located on the anatomical right side of the posterior portion of the apical division of the transition zone.","Right Posterior Apical Transition Zone of Prostate | Apex R TZp",,,,,,,,,,,,,,,"37396939","Right posterior apical part of transition zone of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4274482","Left Basal Anterior Fibromuscular Stroma of Prostate","C128586","The portion of the fibromuscular stroma of the prostate that is located on the anatomical left side of the basal division of the anterior lobe.","Left Basal Anterior Fibromuscular Stroma of Prostate | Base L AS",,,,,,,,,,,,,,,"37396905","Left basal anterior fibromuscular stroma of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4273857","Left Anterior Basal Peripheral Zone of Prostate","C128588","The region of the prostate that is located on the anatomical left side of the anterior portion of the basal division of the peripheral zone.","Left Anterior Basal Peripheral Zone of Prostate | Base L PZa",,,,,,,,,,,,,,,"37396915","Left anterior basal peripheral zone of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4274204","Left Posterior Basal Transition Zone of Prostate","C128590","The region of the prostate that is located on the anatomical left side of the posterior portion of the basal division of the transition zone.","Left Posterior Basal Transition Zone of Prostate | Base L TZp",,,,,,,,,,,,,,,"37396910","Left posterior basal transition zone of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4274197","Left Posterolateral Basal Peripheral Zone of Prostate","C128591","The region of the prostate that is located on the anatomical left side of the posterolateral portion of the basal division of the peripheral zone.","Left Posterolateral Basal Peripheral Zone of Prostate | Base L PZpl",,,,,,,,,,,,,,,"37396917","Left posterolateral basal peripheral zone of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4273849","Right Basal Anterior Fibromuscular Stroma of Prostate","C128592","The portion of the fibromuscular stroma of the prostate that is located on the anatomical right side of the basal division of the anterior lobe.","Right Basal Anterior Fibromuscular Stroma of Prostate | Base R AS",,,,,,,,,,,,,,,"37396904","Right basal anterior fibromuscular stroma of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509111","GAIA Level 1a Prenatally Diagnosed Congenital Microcephaly","C128762","GAIA Level 1a Prenatally Diagnosed Congenital Microcephaly is defined by three criteria: first, the fetus is at least 24 weeks gestational age (GA) based on certain last menstrual period (LMP) date with confirmatory 1st trimester or 2nd trimester ultrasound (US) scan OR intrauterine insemination (IUI) or embryo transfer date; second, a head circumference (HC) measurement either 2 standard deviations (SD) below the mean or less than the third percentile according to fetal US examination, using appropriate, standardized reference charts according to GA and gender for the population (e.g. WHO growth reference charts if GA greater than or equal to 37 weeks and Intergrowth-21st reference charts for GA 24-36 weeks); third, confirmation of microcephaly (i.e., HC 2 SD below the mean or less than 3%) in the fetus by either at least one additional US after 24 weeks that occurs at least one week after the first US, OR confirmation of microcephaly by HC measurement with a standard tape measure at either birth or autopsy.","GAIA Level 1a Prenatally Diagnosed Congenital Microcephaly | Global Alignment of Immunization safety Assessment in pregnancy Level 1a Prenatally Diagnosed Congenital Microcephaly | Level 1a Prenatally Diagnosed Congenital Microcephaly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509112","GAIA Level 1b Prenatally Diagnosed Congenital Microcephaly","C128763","GAIA Level 1b Prenatally Diagnosed Congenital Microcephaly is defined by three criteria: first, the fetus is at least 24 weeks gestational age (GA) based on uncertain last menstrual period (LMP) date with a 2nd trimester ultrasound (US) scan; second, a head circumference (HC) measurement either 2 standard deviations (SD) below the mean or less than the third percentile according to fetal US examination, using appropriate, standardized reference charts according to GA and gender for the population (e.g. WHO growth reference charts if GA greater than or equal to 37 weeks and Intergrowth-21st reference charts for GA 24-36 weeks); third, confirmation of microcephaly (i.e., HC 2 SD below the mean or less than 3%) in the fetus by either at least one additional US after 24 weeks that occurs at least one week after the first US, OR confirmation of microcephaly by HC measurement with a standard tape measure at either birth or autopsy.","GAIA Level 1b Prenatally Diagnosed Congenital Microcephaly | Global Alignment of Immunization safety Assessment in pregnancy Level 1b Prenatally Diagnosed Congenital Microcephaly | Level 1b Prenatally Diagnosed Congenital Microcephaly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509770","Proliferating Cell Count","C128794","The number of proliferating cells found during a review of a slide(s) derived from a tissue sample.","Proliferating Cell Count | Number Proliferating Cells | Proliferating Cell | Proliferating Cell Number | number proliferating cells | number_proliferating_cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509451","Hemoblast Bellows","C128796","A proprietary investigational device that is in trials for cardiothoracic, abdominal, and orthopedic lower extremity surgeries as an adjunct to hemostasis when control of bleeding by conventional procedures is ineffective or impractical.","Hemoblast Bellows | Hemoblast Bellows Hemostatic Device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509666","Recurrent Non-Squamous Non-Small Cell Lung Cancer","C128797","The reemergence of non-squamous non-small cell lung carcinoma after a period of remission.","Recurrent Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Non-Squamous Non-Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509628","Metastatic Non-Squamous Non-Small Cell Lung Cancer","C128798","A non-squamous non-small cell carcinoma that arises from the lung and has metastasized to another anatomic site.","Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Non-Squamous Non-Small Cell Lung Cancer | Metastatic Non-Squamous Non-Small Cell Lung Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509598","Trastuzumab Deruxtecan","C128799","An antibody-drug conjugate (ADC) composed of trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2) conjugated to deruxtecan, a derivative of the camptothecin analog exatecan (DXd; DX-8951 derivative), a DNA topoisomerase 1 (topoisomerase I; Top1) inhibitor, with antineoplastic activity. Upon administration of trastuzumab deruxtecan, trastuzumab targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, deruxtecan binds to and inhibits Top1-DNA complexes, which results in an inhibition of DNA replication, cell cycle arrest and tumor cell apoptosis. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. In addition, trastuzumab deruxtecan induces antibody-dependent cell-mediated cytotoxicity (ADCC) and causes a bystander killing effect.","Trastuzumab Deruxtecan | DS-8201 | DS-8201a | Enhertu | Fam-trastuzumab Deruxtecan-nxki | T-DXd | TRASTUZUMAB DERUXTECAN | Trastuzumab deruxtecan | WHO 10516",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226659","Great Cardiac Vein","C12879","A vein originating at the apex of the heart that receives numerous tributaries as it ascends before draining into the left extremity of the coronary sinus.","Great Cardiac Vein | ",,,,,,,,,,,,,,,"4245007","Great cardiac vein structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508986","Submucosal Lesion","C128800","A pathologic process that affects the loose connective tissue beneath the mucosa.","Submucosal Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509134","GAIA Gestational Diabetes Mellitus Level of Diagnostic Certainty Terminology","C128709","A subset of terminology related to gestational diabetes mellitus, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.","GAIA Gestational Diabetes Mellitus Level of Diagnostic Certainty Terminology | Global Alignment of Immunization safety Assessment in pregnancy Gestational Diabetes Mellitus Level of Diagnostic Certainty Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509078","GAIA Level 1 Ectopic Pregnancy","C128710","GAIA Level 1 Ectopic Pregnancy is defined by either of the following two criteria: first, the following three requirements must be met: a) Gestational age is within the pre-defined range for the selected ectopic pregnancy definition as assessed by maternal and/or fetal parameters (Level 1-2) (Brighton Preterm Birth Gestational Age algorithm; b) B-HCG serum blood test greater than 2000 mIU/ml; c) Transvaginal ultrasound showing no intrauterine pregnancy; OR second, the following two criteria must be met: a) Gestational age is within the pre-defined range for the selected ectopic pregnancy definition as assessed by maternal and/or fetal parameters (Level 1-2) (Brighton Preterm Birth Gestational Age algorithm; b) Transvaginal ultrasound showing extrauterine pregnancy OR no products of conception found on endometrial curettage after dilation and curettage procedure.","GAIA Level 1 Ectopic Pregnancy | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Ectopic Pregnancy | Level 1 Ectopic Pregnancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509090","GAIA Level 2 Ectopic Pregnancy","C128711","GAIA Level 2 Ectopic Pregnancy is defined by three criteria: first, it does not qualify as a Level 1 Ectopic Pregnancy; second, gestational age is within the pre-defined range for the selected ectopic pregnancy definition as assessed by maternal and/or fetal parameters (Level 1-2) (Brighton Preterm Birth Gestational Age algorithm); third, at least one of the following two requirements must be met: a) Transvaginal ultrasound showing no intrauterine pregnancy; OR b) No products of conception found on endometrial curettage after dilation and curettage procedure.","GAIA Level 2 Ectopic Pregnancy | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Ectopic Pregnancy | Level 2 Ectopic Pregnancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509099","GAIA Level 3 Ectopic Pregnancy","C128712","GAIA Level 3 Ectopic Pregnancy is defined by four criteria: first, it does not qualify as either a Level 1 or a Level 2 Ectopic Pregnancy; second, gestational age is within the pre-defined range for the selected ectopic pregnancy definition as assessed by maternal and/or fetal parameters (Level 2-3) (Brighton Preterm Birth Gestational Age algorithm); third, a positive urine pregnancy test; fourth, no products of conception are found on endometrial curettage after a dilation and curettage procedure.","GAIA Level 3 Ectopic Pregnancy | Global Alignment of Immunization safety Assessment in pregnancy Level 3 Ectopic Pregnancy | Level 3 Ectopic Pregnancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509101","GAIA Level 4 Ectopic Pregnancy","C128713","GAIA Level 4 Ectopic Pregnancy is defined by two criteria: first, it does not qualify as a Level 1, a Level 2, or a Level 3 Ectopic Pregnancy; second, a maternal self-report or documentation in the medical record of a pregnancy loss without sufficient ultrasound or laboratory evidence to confirm.","GAIA Level 4 Ectopic Pregnancy | Global Alignment of Immunization safety Assessment in pregnancy Level 4 Ectopic Pregnancy | Level 4 Ectopic Pregnancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0405107","Morbidly Adherent Placenta","C128714","A condition in which the placenta implants abnormally into the uterine myometrium, rather than implanting into the uterine decidua basalis as is normal.","Morbidly Adherent Placenta | Morbidly Adherent Placentation",,,,,,,,,,,,,,,"4129831","Placenta accreta spectrum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509037","Cesarean Scar Pregnancy","C128715","An ectopic pregnancy implanted in a previous cesarean (hysterotomy) scar, surrounded by myometrium and connective tissue.","Cesarean Scar Pregnancy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042143","Uterine Rupture","C128716","The complete, nonsurgical disruption of all layers of the uterus.","Uterine Rupture | ",,,,,,,,,,,,,,,"444066","Rupture of uterus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1530787","Trifunctional Purine Biosynthetic Protein Adenosine-3, Human","C128850","Trifunctional purine biosynthetic protein adenosine-3 (1010 aa, ~108 kDa) is encoded by the human GART gene. This protein is involved in the de novo biosynthesis of purine nucleotides.","Trifunctional Purine Biosynthetic Protein Adenosine-3 | 5'-Phosphoribosylglycinamide Transformylase | AIR Synthase | AIRS | EC 2.1.2.2 | EC 6.3.3.1 | EC 6.3.4.13 | GAR Transformylase | GARS | GARS-AIRS-GART | GART | Glycinamide Ribonucleotide Formyltransferase | Glycinamide Ribonucleotide Synthetase | Phosphoribosyl-Aminoimidazole Synthetase | Phosphoribosylamine--Glycine Ligase | Phosphoribosylamine-Glycine Ligase | Phosphoribosylformylglycinamidine Cyclo-Ligase | Phosphoribosylglycinamide Formyltransferase | Phosphoribosylglycinamide Synthetase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520812","Maxillary Sinus Cancer pT1 TNM Finding v8","C133035","Maxillary sinus cancer with tumor limited to the maxillary sinus mucosa with no erosion or destruction of bone. (from AJCC 8th Ed.)","Maxillary Sinus Cancer pT1 TNM Finding v8 | Maxillary Sinus Carcinoma pT1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512326","RHO wt Allele","C129079","Human RHO wild-type allele is located in the vicinity of 3q22.1 and is approximately 7 kb in length. This allele, which encodes rhodopsin protein, is involved in photoreceptor cell activity and maintenance. Mutation of the gene is associated with congenital stationary night blindness, retinitis pigmentosa 4, and retinitis punctata albescens.","RHO wt Allele | CSNBAD1 | OPN2 | Opsin 2, Rod Pigment Gene | RP4 | Retinitis Pigmentosa 4, Autosomal Dominant Gene | Rhodopsin wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035499","Rhodopsin","C129080","Rhodopsin (348 aa, ~39 kDa) is encoded by the human RHO gene. This protein plays a role in rod-dependent visual processes.","Rhodopsin | Opsin 2 | Opsin-2 | Rod Pigment 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512233","SART1 wt Allele","C129082","Human SART1 wild-type allele is located in the vicinity of 11q13.1 and is approximately 18 kb in length. This allele, which encodes U4/U6.U5 tri-snRNP-associated protein 1, plays a role in mRNA splicing.","SART1 wt Allele | Ara1 | HOMS1 | SART1(259) Protein Gene | SART1259 | SNRNP110 | Small Nuclear Ribonucleoprotein 110kDa (U4/U6.U5) Gene | Snu66 | Squamous Cell Carcinoma Antigen Recognised By T Cells Gene | Squamous Cell Carcinoma Antigen Recognized By T Cells 1 Gene | Squamous Cell Carcinoma Antigen Recognized By T-Cells 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0671655","U4/U6.U5 Tri-SnRNP-Associated Protein 1, Human","C129083","U4/U6.U5 tri-snRNP-associated protein 1 (800 aa, ~90 kDa) is encoded by the human SART1 gene. This protein is involved in RNA splicing.","U4/U6.U5 Tri-SnRNP-Associated Protein 1 | Allergen Hom S 1 | Hom s 1 | SART-1 | SNU66 Homolog | Squamous Cell Carcinoma Antigen Recognized By T-Cells 1 | U4/U6.U5 Tri-SnRNP-Associated 110 kDa Protein | hSART-1 | hSnu66",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512125","CERK wt Allele","C129085","Human CERK wild-type allele is located in the vicinity of 22q13.31 and is approximately 54 kb in length. This allele, which encodes ceramide kinase protein, is involved in lipid phosphorylation.","CERK wt Allele | Ceramide Kinase wt Allele | DKFZp434E0211 | FLJ21430 | FLJ23239 | KIAA1646 | LK4 | dA59H18.2 | dA59H18.3 | hCERK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1432649","Ceramide Kinase, Human","C129086","Ceramide kinase (537 aa, ~60 kDa) is encoded by the human CERK gene. This protein plays a role in the phosphorylation of ceramides.","Ceramide Kinase | Acylsphingosine Kinase | EC 2.7.1.138 | LK4 | Lipid Kinase 4 | Lipid Kinase LK4 | hCERK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512112","CDISC Questionnaire FACIT-F Version 4 Test Name Terminology","C129087","Test names of questionnaire questions associated with the Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACIT-F Version 4 Test Name Terminology | FAC071TN | Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 Questionnaire Test Name | QS-FACIT-F Version 4 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509116","GAIA Level 2 Prenatally Diagnosed Congenital Microcephaly","C128764","GAIA Level 2 Prenatally Diagnosed Congenital Microcephaly is defined by three criteria: first, the fetus is at least 24 weeks gestational age (GA) based on last menstrual period (LMP) date with fundal height and no confirmatory first or second trimester ultrasound (US) scan; second, a head circumference (HC) measurement either 2 standard deviations (SD) below the mean or less than the third percentile according to fetal US examination, using appropriate, standardized reference charts according to GA and gender for the population (e.g. WHO growth reference charts if GA greater than or equal to 37 weeks and Intergrowth-21st reference charts for GA 24 to 36 weeks) with femur length and abdominal circumference concordant with GA assessment; third, confirmation of microcephaly (i.e., HC 2 SD below the mean or less than 3%) in the fetus by either at least one additional US after 24 weeks that occurs at least one week after the first US, OR confirmation of microcephaly by HC measurement with a standard tape measure at either birth or autopsy.","GAIA Level 2 Prenatally Diagnosed Congenital Microcephaly | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Prenatally Diagnosed Congenital Microcephaly | Level 2 Prenatally Diagnosed Congenital Microcephaly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512642","GAIA Level 3b Prenatally Diagnosed Congenital Microcephaly","C128765","GAIA Level 3B Prenatally Diagnosed Congenital Microcephaly is defined by three criteria: first, the fetus is at least 24 weeks gestational age (GA), with GA based on certain or uncertain last menstrual period (LMP) date, with fundal height and no confirmatory first or second trimester ultrasound (US) scan, OR uncertain LMP with second trimester ultrasound, intrauterine insemination (IUI) OR embryo transfer date; second, a head circumference (HC) measurement either 2 standard deviations (SD) below the mean or less than the third percentile according to fetal US examination, using appropriate, standardized reference charts according to GA and gender for the population (e.g. WHO growth reference charts if GA greater than or equal to 37 weeks and Intergrowth-21st reference charts for GA 24 to 36 weeks); third, no confirmation of microcephaly with any additional US or by HC measurement at either birth or autopsy.","GAIA Level 3b Prenatally Diagnosed Congenital Microcephaly | Global Alignment of Immunization safety Assessment in pregnancy Level 3b Prenatally Diagnosed Congenital Microcephaly | Level 3b Prenatally Diagnosed Congenital Microcephaly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509128","GAIA Level 4 Prenatally Diagnosed Congenital Microcephaly","C128766","GAIA Level 4 Prenatally Diagnosed Congenital Microcephaly is defined by three criteria: first, the fetus is at least 24 weeks gestational age (GA), with GA based on certain last menstrual period (LMP) date with confirmatory first or second trimester ultrasound (US) scan, OR uncertain LMP with second trimester ultrasound, intrauterine insemination (IUI), OR embryo transfer, OR certain or uncertain LMP with fundal height and no confirmatory first or second trimester scan; second, HC 2 SD below mean or less than 3 percentile according to fetal US scan using appropriate standardized reference charts according to GA and gender for the population (e.g., WHO growth reference charts if GA greater than or equal to 37 weeks and Intergrowth-21st reference charts for GA 24-36 weeks); third, HC at birth or autopsy is in the normal range using appropriate standardized reference charts according to GA and gender for the population, which means that this is NOT a case of prenatally diagnosed congenital microcephaly.","GAIA Level 4 Prenatally Diagnosed Congenital Microcephaly | Global Alignment of Immunization safety Assessment in pregnancy Level 4 Prenatally Diagnosed Congenital Microcephaly | Level 4 Prenatally Diagnosed Congenital Microcephaly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0459414","Central Canal of Spinal Cord","C12891","The hollow tube filled with cerebrospinal fluid that begins in the inferior portion of the fourth ventricle and runs the entire length of the spinal.","Central Canal of Spinal Cord | Central Canal | Central Canal of the Spinal Cord | central canal of spinal cord",,,,,,,,,,,,,,,"4220932","Central cord canal structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512263","FLT3 Protein Variant","C128920","A variation in the amino acid sequence for the receptor-type tyrosine-protein kinase FLT3 protein.","FLT3 Protein Variant | CD135 Antigen Protein Variant | Fetal Liver Kinase-2 Protein Variant | Flt-3 Receptor Protein Variant | Fms-Related Tyrosine Kinase 3 Protein Variant | Receptor-Type Tyrosine-Protein Kinase FLT3 Protein Variant | Stem Cell Tyrosine Kinase 1 Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0228802","Nucleus of the Hypoglossal Nerve","C12899","A motor nucleus within the medulla oblongata with axons projecting to the tongue muscles.","Nucleus of the Hypoglossal Nerve | Hypoglossal Nucleus",,,,,,,,,,,,,,,"4188626","Hypoglossal nerve nucleus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1527432","Recombinant Interleukin-8","C1289","A member of the CXC chemokine family. This chemokine is one of the major mediators of the inflammatory response. This chemokine is secreted by several cell types including monocytes, macrophages, T-lymphocytes, fibroblasts, endothelial cells, and keratinocytes. It functions as a chemoattractant, and is also a potent angiogenic factor. (from LocusLink)","Recombinant Interleukin-8 | Anionic Neutrophil Activating Peptide | Anionic Neutrophil-Activating Peptide | CXCL8 | GCP-IL-8 | Granulocyte Chemotactic Peptide Interleukin 8 | IL-8 | Interleukin-8 | Leukocyte Adhesion Inhibitor | MDNCF | Macrophage-Derived Chemotactic Factor | Monocyte-Derived Neutrophil Chemotactic Factor | Monocyte-Derived Neutrophil-Activating Peptide | NAP-1 | Neutrophil Activation Factor | Neutrophil Activation Peptide | Neutrophil Chemotactic Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0920631","Patient Registry Study","C129000","Observational studies which include an organized system that uses observational methods to collect uniform data (clinical and other) prospectively for a population defined by a particular disorder/disease, condition (including susceptibility to a disorder), or exposure (including products, health care services, and/or procedures) and that serves a predetermined scientific, clinical, or policy purpose. Patient registries may be single purpose or on-going data collection programs that address one or more questions. (AHRQ)","Patient Registry Study | PATIENT REGISTRY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512390","Pharmacogenetic Study","C129001","A study that assesses variation in DNA sequence, usually within a single gene, and its effect on drug response.","Pharmacogenetic Study | PHARMACOGENETIC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512376","Qualitative Food Consumption","C129003","An evaluation of food consumption that is primarily descriptive and interpretative, and may or may not lend itself to quantification","Qualitative Food Consumption | QUALITATIVE FOOD CONSUMPTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512161","Increased Mucification Present","C129004","A finding indicating an increase in the numbers of epithelial cells that have been transformed into mucus-secreting cells. This does not include the normal increase in mucification seen in the estrous cycle.","Increased Mucification Present | MUCIFICATION, INCREASED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512386","Lung/Bronchus/Trachea/Larynx","C129005","A laboratory specimen consisting of the lungs, bronchus, trachea, and larynx.","Lung/Bronchus/Trachea/Larynx | LUNG/BRONCHUS/TRACHEA/LARYNX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512456","FACT-B Version 4 - I Feel Close to My Partner","C129200","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Social/Family Well-Being: I feel close to my partner (or the person who is my main support).","FACT-B Version 4 - I Feel Close to My Partner | FAC005-I Feel Close to My Partner | FAC00513",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512106","CCK wt Allele","C128852","Human CCK wild-type allele is located in the vicinity of 3p22.1 and is approximately 8 kb in length. This allele, which encodes cholecystokinin protein, plays a role in the stimulation of both gallbladder contraction and pancreatic enzyme release.","CCK wt Allele | Cholecystokinin Triacontatriapeptide Gene | Cholecystokinin wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008328","Cholecystokinin","C128853","Cholecystokinin (115 aa, ~13 kDa) is encoded by the human CCK gene. This protein is involved in both pancreatic enzyme release and gallbladder contraction.","Cholecystokinin | CCK | CCK-PZ | Pancreozymin | Prepro-CCK | Prepro-Cholecystokinin | Preprocholecystokinin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512258","MUC4 wt Allele","C128855","Human MUC4 wild-type allele is located in the vicinity of 3q29 and is approximately 66 kb in length. This allele, which encodes mucin-4 protein, plays a role in both cell adhesion and tumor progression.","MUC4 wt Allele | ASGP | HSA276359 | MUC-4 | Mucin 4, Cell Surface Associated wt Allele | Mucin 4, Tracheobronchial Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512101","C4A wt Allele","C128858","Human C4A wild-type allele is located in the vicinity of 6p21.3 and is approximately 21 kb in length. This allele, which encodes complement C4-A protein, is involved in the innate immune response. The expression of this gene is associated with the expression of Rodgers blood group antigens. Mutation of the gene is associated with complement component C4A deficiency. Copy number variation and polymorphisms are associated with increased risk for systemic lupus erythematosus.","C4A wt Allele | C4 | C4, Rodgers Form Gene | C4A2 | C4A3 | C4A4 | C4A6 | C4AD | C4S | CO4 | CPAMD2 | Complement Component 4A (Rodgers Blood Group) wt Allele | RG | SLP | SLP, Mouse, Homolog of Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413000","C4B Gene","C128859","This gene is involved in innate immunity.","C4B Gene | C4B | Complement Component 4B (Chido Blood Group) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512260","Ad5-survivin-transduced Autologous Dendritic Cell Vaccine","C128860","A cell-based cancer vaccine containing autologous dendritic cells (DCs) that are transduced with a replication-deficient adenovirus type 5 vector (Ad5) encoding a mutated form of the tumor-associated antigen (TAA) survivin, with potential immunostimulatory and antineoplastic activities. Upon administration, Ad5-survivin-transduced autologous DC vaccine may elicit an immune response against cancer cells expressing survivin by activating cytotoxic T-cells (CTLs). This leads to an induction of cell death in survivin-positive tumor cells. Survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types and plays a key role in tumor cell growth and survival.","Ad5-survivin-transduced Autologous Dendritic Cell Vaccine | Ad5-survivin-transduced Autologous DC Vaccine | Autologous DC:AdmS | Autologous Dendritic Cell Adenovirus Type 5-Survivin Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512102","C4B wt Allele","C128861","Human C4B wild-type allele is located in the vicinity of 6p21.3 and is approximately 21 kb in length. This allele, which encodes complement C4-B protein, plays a role in both host defense and inflammation. The expression of this gene is associated with the expression of Chido blood group antigens. Mutation of the gene is associated with complement component C4B deficiency. Copy number variation and polymorphisms are associated with increased risk for systemic lupus erythematosus.","C4B wt Allele | C4, Chido Form Gene | C4B1 | C4B12 | C4B2 | C4B3 | C4B5 | C4BD | C4F | CH | CO4 | CPAMD3 | Complement Component 4B (Chido Blood Group) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512111","CDISC Questionnaire FACIT-F Version 4 Test Code Terminology","C129088","Test codes of questionnaire questions associated with the Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACIT-F Version 4 Test Code Terminology | FAC071TC | Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 Questionnaire Test Code | QS-FACIT-F Version 4 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512120","CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Name Terminology","C129089","Test names of questionnaire questions associated with the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Name Terminology | FAC042TN | National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 Questionnaire Test Name | QS-NCCN-FACT FKSI-19 Version 2 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509825","Medication Dispenser","C128539","Healthcare providers who dispense or administer the drug, settings in which the drug is dispensed or administered, or authorized representatives of the setting in which the drug is dispensed or administered. This encompasses a wide range of settings, including outpatient pharmacies, chain pharmacies, independent pharmacies, mail-order pharmacies, clinics, infusion centers, hospitals, health systems, and closed health systems.","Medication Dispenser | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509516","Non-Prescribing Non-Dispensing Healthcare Provider","C128540","Healthcare providers or healthcare settings that treat patients who take the drug but neither prescribe or dispense the drug.","Non-Prescribing Non-Dispensing Healthcare Provider | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509627","Medication-Taking Patient","C128541","Patients who use the drug.","Medication-Taking Patient | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509514","Non-Manufacturing Medication Distributor","C128542","Parties other than the drug's manufacturer who distribute, sell, or transfer the drug for reasons other than filling a specific prescription.","Non-Manufacturing Medication Distributor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1065384","Nocardia cyriacigeorgica","C128543","A species of Gram-positive, catalase-positive, rod-shaped bacteria in the phylum Actinobacteria. This species is positive for use of acetate, gluconate, and sucrose as sole carbon sources and acetamide as a sole source of carbon and nitrogen. It was isolated from the bronchial secretion of a patient with chronic bronchitis and is seen as an emerging human pathogen.","Nocardia cyriacigeorgica | NOCARDIA CYRIACIGEORGICA",,,,,,,,,,,,,,,"4186418","Nocardia cyriacigeorgica",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3716043","Paenibacillus phoenicis","C128544","A species of Gram-positive, aerobic, bacillus-shaped, endospore-forming bacteria in the phylum Firmicutes. This species is negative for urease, tryptophan deaminase, and hydrolysis of gelatin. It is positive for sole carbon use with glucose, mannitol, sucrose, glycogen, and several others. The type strain was isolated from surfaces of the Payload Hazardous Servicing Facility located at the Kennedy Space Center where the Phoenix lander was assembled.","Paenibacillus phoenicis | PAENIBACILLUS PHOENICIS",,,,,,,,,,,,,,,"37157248","Paenibacillus phoenicis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2620631","Prevotella histicola","C128545","A species of obligately anaerobic, non-motile, Gram-negative bacillus-shaped bacteria in the phylum Bacteroidetes. This species is considered a normal part of the human oral microbiota. P. histicola is considered to be commensal.","Prevotella histicola | PREVOTELLA HISTICOLA",,,,,,,,,,,,,,,"42873120","Prevotella histicola",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2761184","Porphyromonas bennonis","C128546","A species of obligately-anaerobic, non-spore-forming, Gram-negative bacillus-shaped bacteria in the phylum Bacteroidetes. This species is part of the indigenous bacterial flora in the oral cavity of humans and animals.","Porphyromonas bennonis | PORPHYROMONAS BENNONIS",,,,,,,,,,,,,,,"36712908","Porphyromonas bennonis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1630633","Pseudomonas otitidis","C128547","A species of Gram-negative, motile, bacillus-shaped bacteria in the phylum Proteobacteria. The species was isolated from patients with otic infections.","Pseudomonas otitidis | PSEUDOMONAS OTITIDIS",,,,,,,,,,,,,,,"42872422","Pseudomonas otitidis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1482252","Staphylococcus pettenkoferi","C128548","A species of facultative anaerobic, Gram-positive, nonmotile, nonspore-forming, coccus-shaped bacteria in the phylum Firmicutes. This species is coagulase-negative and is a commensal organism on the skin of healthy humans but may cause infections in immunocompromised individuals.","Staphylococcus pettenkoferi | STAPHYLOCOCCUS PETTENKOFERI",,,,,,,,,,,,,,,"4181305","Staphylococcus pettenkoferi",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512147","High Resolution Anoscopy with Biopsy","C128922","A procedure that uses a rigid, tubular anoscope along with a high resolution colposcope to examine the anal canal for abnormalities and to recover tissue samples.","High Resolution Anoscopy with Biopsy | High Resolution Anoscopy-Monitored Biopsy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0059816","Ethylene-vinyl Alcohol Copolymer-based Embolic Agent","C128925","A non-adhesive, non-absorbable, permanent liquid embolic agent comprised of ethylene vinyl alcohol (EVOH) copolymer dissolved in dimethyl sulfoxide (DMSO), and of micronized tantalum powder that can be used to occlude blood vessels. Upon administration of the EVOH-based embolic agent, contact with fluids, such as blood, induces the solidification of EVOH into a sponge-like material. This causes occlusion of blood vessels and prevents blood flow to the treated area.","Ethylene-vinyl Alcohol Copolymer-based Embolic Agent | EVOH-based Embolic Agent | Onyx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512130","DLX5 wt Allele","C128927","Human DLX5 wild-type allele is located in the vicinity of 7q21.3 and is approximately 5 kb in length. This allele, which encodes homeobox protein DLX-5, plays a role in transcriptional activation that is essential for osteoblast differentiation. Mutation of the gene is associated with split-hand/foot malformation 1 with sensorineural hearing loss.","DLX5 wt Allele | Distal-Less Homeo Box 5 Gene | Distal-Less Homeobox 5 wt Allele | SHFM1D | Split Hand/Foot Malformation Type 1 With Sensorineural Hearing Loss Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1571636","Homeobox Protein DLX-5, Human","C128928","Homeobox protein DLX-5 (289 aa, ~32 kDa) is encoded by the human DLX5 gene. This protein is involved in the positive regulation of osteoblast differentiation.","Homeobox Protein DLX-5 | DLX5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512429","FACIT-F Version 4 - I Worry About Dying","C129129","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Emotional Well-Being: I worry about dying.","FACIT-F Version 4 - I Worry About Dying | FAC071-I Worry About Dying | FAC07119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282560","Caco-2 Cell","C12912","Human colonic adenocarcinoma cells that express features characteristic of mature intestinal cells, including enterocytes or mucus cells, which are used as in vitro models for studies investigating intestinal cell function and differentiation.","Caco-2 Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512440","FACIT-F Version 4 - Worry My Condition Will Get Worse","C129130","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Emotional Well-Being: I worry that my condition will get worse.","FACIT-F Version 4 - Worry My Condition Will Get Worse | FAC071-Worry My Condition Will Get Worse | FAC07120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512408","FACIT-F Version 4 - I Am Able to Work","C129131","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Functional Well-Being: I am able to work (include work at home).","FACIT-F Version 4 - I Am Able to Work | FAC071-I Am Able to Work | FAC07121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512453","FACT-B Version 4 - I Am Satisfied With My Sex Life","C129201","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Social/Family Well-Being: I am satisfied with my sex life.","FACT-B Version 4 - I Am Satisfied With My Sex Life | FAC005-I Am Satisfied With My Sex Life | FAC00514",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512473","FACT-B Version 4 - Satisfied With How I Am Coping","C129203","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Emotional Well-Being: I am satisfied with how I am coping with my illness.","FACT-B Version 4 - Satisfied With How I Am Coping | FAC005-Satisfied With How I Am Coping | FAC00516",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512468","FACT-B Version 4 - Losing Hope Against Illness","C129204","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Emotional Well-Being: I am losing hope in the fight against my illness.","FACT-B Version 4 - Losing Hope Against Illness | FAC005-Losing Hope Against Illness | FAC00517",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512458","FACT-B Version 4 - I Feel Nervous","C129205","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Emotional Well-Being: I feel nervous.","FACT-B Version 4 - I Feel Nervous | FAC005-I Feel Nervous | FAC00518",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512467","FACT-B Version 4 - I Worry About Dying","C129206","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Emotional Well-Being: I worry about dying.","FACT-B Version 4 - I Worry About Dying | FAC005-I Worry About Dying | FAC00519",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512478","FACT-B Version 4 - Worry My Condition Will Get Worse","C129207","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Emotional Well-Being: I worry that my condition will get worse.","FACT-B Version 4 - Worry My Condition Will Get Worse | FAC005-Worry My Condition Will Get Worse | FAC00520",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512449","FACT-B Version 4 - I Am Able to Work","C129208","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Functional Well-Being: I am able to work (include work at home).","FACT-B Version 4 - I Am Able to Work | FAC005-I Am Able to Work | FAC00521",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512470","FACT-B Version 4 - My Work Is Fulfilling","C129209","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Functional Well-Being: My work (include work at home) is fulfilling.","FACT-B Version 4 - My Work Is Fulfilling | FAC005-My Work Is Fulfilling | FAC00522",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0393073","autologous Epstein-Barr virus-specific cytotoxic T lymphocytes (cell)","C12920","A white blood cell that is derived from a lymphocyte stem cell matured in the thymus and characterized by a CD8 marker on the surface and an antigen-specific Epstein Barr virus T cell receptor.","EBV-Specific Cytotoxic T-Lymphocyte | EBV-specific CTL | EBV-specific Cytotoxic T-lymphocytes | Epstein-Barr virus-specific cytotoxic T-lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512462","FACT-B Version 4 - I Have Accepted My Illness","C129211","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Functional Well-Being: I have accepted my illness.","FACT-B Version 4 - I Have Accepted My Illness | FAC005-I Have Accepted My Illness | FAC00524",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512454","FACT-B Version 4 - I Am Sleeping Well","C129212","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Functional Well-Being: I am sleeping well.","FACT-B Version 4 - I Am Sleeping Well | FAC005-I Am Sleeping Well | FAC00525",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512445","FACT-B Version 4 - Enjoy Things I Usually Do for Fun","C129213","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Functional Well-Being: I am enjoying the things I usually do for fun.","FACT-B Version 4 - Enjoy Things I Usually Do for Fun | FAC005-Enjoy Things I Usually Do for Fun | FAC00526",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512444","FACT-B Version 4 - Content With Quality of My Life","C129214","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Functional Well-Being: I am content with the quality of my life right now.","FACT-B Version 4 - Content With Quality of My Life | FAC005-Content With Quality of My Life | FAC00527",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512463","FACT-B Version 4 - I Have Been Short of Breath","C129215","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Additional Concerns: I have been short of breath.","FACT-B Version 4 - I Have Been Short of Breath | FAC005-I Have Been Short of Breath | FAC00528",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512267","KIR2DL3 wt Allele","C129040","Human KIR2DL3 wild-type allele is located in the vicinity of 19q13.4 and is approximately 15 kb in length. This allele, which encodes killer cell immunoglobulin-like receptor 2DL3 protein, plays a role in the regulation of the immune response.","KIR2DL3 wt Allele | CD158B2 | CD158b | GL183 | KIR-023GB | KIR-K7b | KIR-K7c | KIR2DL | KIR2DS3 | KIR2DS5 | KIRCL23 | Killer Cell Immunoglobulin Like Receptor, Two Ig Domains and Long Cytoplasmic Tail 3 wt Allele | Killer Cell Immunoglobulin-Like Receptor, Two Domains, Long Cytoplasmic Tail, 3 Gene | Killer Cell Immunoglobulin-Like Receptor, Two Domains, Short Cytoplasmic Tail, 5 Gene | NKAT | NKAT2 | NKAT2A | NKAT2B | cl-6 | p58",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0296537","Killer Cell Immunoglobulin-Like Receptor 2DL3, Human","C129041","Killer cell immunoglobulin-like receptor 2DL3 (341 aa, ~38 kDa) is encoded by the human KIR2DL3 gene. This protein is involved in the modulation of natural killer cell-mediated immunity.","Killer Cell Immunoglobulin-Like Receptor 2DL3 | CD158 Antigen-Like Family Member B2 | CD158b2 | CD158b2 Antigen | KIR-023GB | Killer Inhibitory Receptor Cl 2-3 | MHC Class I NK Cell Receptor | NK-Associated Transcript 2 | NKAT-2 | NKAT2a | Natural Killer Associated Transcript 2 | Natural Killer Cell Inhibitory Receptor KIR2DL3 | Natural Killer-Associated Transcript 2 | p58 NK Receptor CL-6 | p58 Natural Killer Cell Receptor Clone CL-6 | p58.2 MHC Class-I Specific NK Receptor | p58.2 MHC Class-I-Specific NK Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512236","STMN1 wt Allele","C129043","Human STMN1 wild-type allele is located in the vicinity of 1p36.11 and is approximately 23 kb in length. This allele, which encodes stathmin protein, is involved in the disassembly of microtubules.","STMN1 wt Allele | C1orf215 | Chromosome 1 Open Reading Frame 215 Gene | FLJ32206 | LAP18 | Lag | OP18 | PP17 | PP19 | PR22 | SMN | Stathmin 1 wt Allele | Stathmin 1/Oncoprotein 18 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1529976","Stathmin, Human","C129044","Stathmin (149 aa, ~17 kDa) is encoded by the human STMN1 gene. This protein plays a role in the inhibition of assembly of microtubules.","Stathmin | Leukemia-Associated Phosphoprotein p18 | Metablastin | Oncoprotein 18 | Op18 | Phosphoprotein 19 | Phosphoprotein p19 | Prosolin | Protein Pr22 | STMN1 | Testicular Tissue Protein Li 189 | Transmembrane Protein C1orf215 | pp17 | pp19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512255","ARRB2 wt Allele","C129046","Human ARRB2 wild-type allele is located in the vicinity of 17p13 and is approximately 11 kb in length. This allele, which encodes beta-arrestin-2 protein, plays a role in the downregulation of G protein-coupled receptor signaling.","ARRB2 wt Allele | ARB2 | ARR2 | Arrestin 3 Gene | Arrestin Beta 2 wt Allele | Arrestin, Beta 2 Gene | Arrestin, Beta, 2 Gene | BARR2 | DKFZp686L0365",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1620195","Beta-Arrestin-2, Human","C129047","Beta-arrestin-2 (409 aa, ~46 kDa) is encoded by the human ARRB2 gene. This protein is involved in the modulation of G protein-receptor signaling.","Beta-Arrestin-2 | Arrestin Beta-2 | Beta-Arrestin 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1482098","Streptococcus urinalis","C128549","A species of facultatively anaerobic, non-motile, non-spore forming, Gram-positive, catalase-negative, chain-forming, coccus-shaped bacteria in the phylum Firmicutes first isolated from human urine.","Streptococcus urinalis | STREPTOCOCCUS URINALIS",,,,,,,,,,,,,,,"4235054","Streptococcus urinalis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0446055","Trichosporon mucoides","C128550","A species of yeast-like fungi in the phylum Basidiomycota characterized by growth with galactitol and at 37C. This species was first isolated from human clinical samples. It is known to cause deep invasive infections.","Trichosporon mucoides | TRICHOSPORON MUCOIDES",,,,,,,,,,,,,,,"4348457","Cutaneotrichosporon mucoides",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1947956","Fusarium solani","C128551","A species of non-dermatophytic hyaline mold in the phylum Ascomycota. The species is a ubiquitous soil borne pathogen causing several diseases on a broad range of plants.","Fusarium solani | FUSARIUM SOLANI | Neocosmospora solani",,,,,,,,,,,,,,,"4262515","Fusarium solani",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0579230","Streptococcus suis serotype 2","C128552","A serotype of Streptococcus suis that is considered the most virulent serotype and the serotype most frequently isolated from diseased animals.","Streptococcus suis serotype 2 | S. suis 2 | STREPTOCOCCUS SUIS SEROTYPE 2 | Streptococcus Group R",,,,,,,,,,,,,,,"4121160","Streptococcus suis serotype 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509622","GAIA Level 1 Morbidly Adherent Placentation","C128744","GAIA Level 1 Morbidly Adherent Placentation is defined by three criteria: first, evidence of placenta previa by either a second- or third-trimester ultrasound or an MRI; second, one of the following ultrasound features must be present: for Greyscale: a) Loss of the retroplacental sonolucent zone; OR b) Irregular retroplacental sonolucent zone; OR c) Thinning or disruption of the hyperechoic serosa-bladder interface; OR d) Presence of focal exophytic masses invading the urinary bladder; OR e) Abnormal placental lacunae; for Color Doppler: a) Diffuse or focal lacunar flow; OR b) Vascular lakes with turbulent flow (peak systolic velocity over 15 cm/s); OR c) Hypervascularity of serosa-bladder interface; OR d) Markedly dilated vessels over peripheral subplacental zone; for 3D Power Doppler: a) Numerous coherent vessels involving the entire uterine serosa-bladder junction (basal view); OR b) Hypervascularity (lateral view); OR c) Inseparable cotyledonal and intervillous circulations, chaotic branching, and detour vessels (lateral view); third, one of the following risk factors must be present: a) Prior cesarean delivery; OR b) Prior uterine surgery (including endometrial ablation); OR c) Cesarean scar pregnancy. Alternatively, Level 1 may be defined as morbidly adherent placentation found on histology in a hysterectomy or partial wedge resection specimen.","GAIA Level 1 Morbidly Adherent Placentation | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Morbidly Adherent Placentation | Level 1 Morbidly Adherent Placentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509092","GAIA Level 2 Morbidly Adherent Placentation","C128745","GAIA Level 2 Morbidly Adherent Placentation is defined by two criteria: first, ultrasound evidence of placenta previa; second, hypervascularity of the lower uterine segment, diagnosed during a laparotomy. Alternatively, Level 2 may be defined as difficulty with placental separation after delivery of the infant, during either a vaginal or a cesarean delivery, with resultant hemorrhage due to partial separation.","GAIA Level 2 Morbidly Adherent Placentation | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Morbidly Adherent Placentation | Level 2 Morbidly Adherent Placentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509085","GAIA Level 1 Vasa Previa","C128746","GAIA Level 1 Vasa Previa is defined by two criteria: first, second trimester ultrasound evidence of fetal vessels (vessel with fetal heart rate identified by color flow Doppler) traversing the membranes and overlying the internal cervical os; second, post-delivery examination of the placental specimen that demonstrates unsupported fetal vessels within the membranes.","GAIA Level 1 Vasa Previa | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Vasa Previa | Level 1 Vasa Previa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509096","GAIA Level 2 Vasa Previa","C128747","GAIA Level 2 Vasa Previa is defined by four criteria: first, vaginal bleeding during the second or third trimester at the time of ruptured amniotic membranes; second, fetal heart rate changes ultimately resulting in sinusoidal rhythm/terminal bradycardia; third, delivery of one of the following: a) a pale, anemic infant; OR b) a recent stillbirth; OR c) a neonatal death; fourth, post-delivery examination of the placental specimen that demonstrates unsupported fetal vessels within the membranes.","GAIA Level 2 Vasa Previa | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Vasa Previa | Level 2 Vasa Previa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512433","FACIT-F Version 4 - My Work Is Fulfilling","C129132","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Functional Well-Being: My work (include work at home) is fulfilling.","FACIT-F Version 4 - My Work Is Fulfilling | FAC071-My Work Is Fulfilling | FAC07122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512423","FACIT-F Version 4 - I Have Accepted My Illness","C129134","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Functional Well-Being: I have accepted my illness.","FACIT-F Version 4 - I Have Accepted My Illness | FAC071-I Have Accepted My Illness | FAC07124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512411","FACIT-F Version 4 - I Am Sleeping Well","C129135","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Functional Well-Being: I am sleeping well.","FACIT-F Version 4 - I Am Sleeping Well | FAC071-I Am Sleeping Well | FAC07125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512404","FACIT-F Version 4 - Enjoy Things I Usually Do for Fun","C129136","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Functional Well-Being: I am enjoying the things I usually do for fun.","FACIT-F Version 4 - Enjoy Things I Usually Do for Fun | FAC071-Enjoy Things I Usually Do for Fun | FAC07126",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512415","FACIT-F Version 4 - I Feel Fatigued","C129138","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Additional Concerns: I feel fatigued.","FACIT-F Version 4 - I Feel Fatigued | FAC071-I Feel Fatigued | FAC07128",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512421","FACIT-F Version 4 - I Feel Weak All Over","C129139","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Additional Concerns: I feel weak all over.","FACIT-F Version 4 - I Feel Weak All Over | FAC071-I Feel Weak All Over | FAC07129",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512417","FACIT-F Version 4 - I Feel Listless","C129140","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Additional Concerns: I feel listless ('washed out').","FACIT-F Version 4 - I Feel Listless | FAC071-I Feel Listless | FAC07130",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512420","FACIT-F Version 4 - I Feel Tired","C129141","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Additional Concerns: I feel tired.","FACIT-F Version 4 - I Feel Tired | FAC071-I Feel Tired | FAC07131",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512439","FACIT-F Version 4 - Trouble Starting Things","C129142","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Additional Concerns: I have trouble starting things because I am tired.","FACIT-F Version 4 - Trouble Starting Things | FAC071-Trouble Starting Things | FAC07132",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512437","FACIT-F Version 4 - Trouble Finishing Things","C129143","Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Additional Concerns: I have trouble finishing things because I am tired.","FACIT-F Version 4 - Trouble Finishing Things | FAC071-Trouble Finishing Things | FAC07133",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4274157","Central Zone of Right Half Prostate","C128593","The portion of the central zone of the prostate that is located to the anatomical right of center.","Central Zone of Right Half Prostate | Base R CZ",,,,,,,,,,,,,,,"37396911","Central zone of right half prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4274200","Right Anterior Basal Peripheral Zone of Prostate","C128594","The region of the prostate that is located on the anatomical right side of the anterior portion of the basal division of the peripheral zone.","Right Anterior Basal Peripheral Zone of Prostate | Base R PZa",,,,,,,,,,,,,,,"37399563","Right anterior basal peripheral zone of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4274198","Right Posterolateral Basal Peripheral Zone of Prostate","C128595","The region of the prostate that is located on the anatomical right side of the posterolateral portion of the basal division of the peripheral zone.","Right Posterolateral Basal Peripheral Zone of Prostate | Base R PZpl",,,,,,,,,,,,,,,"37396916","Right posterolateral basal peripheral zone of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509072","GAIA Gestational Diabetes Mellitus Level of Diagnostic Certainty","C128671","A classification of maternal and fetal outcomes relating to gestational diabetes mellitus, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.","GAIA Gestational Diabetes Mellitus Level of Diagnostic Certainty | Gestational Diabetes Mellitus Level of Diagnostic Certainty | Global Alignment of Immunization safety Assessment in pregnancy Gestational Diabetes Mellitus Level of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509140","GAIA Fetal Growth Restriction Level of Diagnostic Certainty","C128672","A classification of maternal and fetal outcomes relating to fetal growth restriction, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.","GAIA Fetal Growth Restriction Level of Diagnostic Certainty | Fetal Growth Restriction Level of Diagnostic Certainty | Global Alignment of Immunization safety Assessment in pregnancy Fetal Growth Restriction Level of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509138","GAIA Failure to Thrive Level of Diagnostic Certainty","C128673","A classification of maternal and fetal outcomes relating to failure to thrive, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.","GAIA Failure to Thrive Level of Diagnostic Certainty | Failure to Thrive Level of Diagnostic Certainty | Global Alignment of Immunization safety Assessment in pregnancy Failure to Thrive Level of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509220","GAIA Small for Gestational Age Level of Diagnostic Certainty","C128674","A classification of maternal and fetal outcomes relating to small for gestational age, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.","GAIA Small for Gestational Age Level of Diagnostic Certainty | Global Alignment of Immunization safety Assessment in pregnancy Small for Gestational Age Level of Diagnostic Certainty | Small for Gestational Age Level of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509209","GAIA Low Birth Weight Level of Diagnostic Certainty","C128675","A classification of maternal and fetal outcomes relating to low birth weight, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.","GAIA Low Birth Weight Level of Diagnostic Certainty | Global Alignment of Immunization safety Assessment in pregnancy Low Birth Weight Level of Diagnostic Certainty | Low Birth Weight Level of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509212","GAIA Neonatal Respiratory Distress Level of Diagnostic Certainty","C128676","A classification of maternal and fetal outcomes relating to neonatal respiratory distress, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.","GAIA Neonatal Respiratory Distress Level of Diagnostic Certainty | Global Alignment of Immunization safety Assessment in pregnancy Neonatal Respiratory Distress Level of Diagnostic Certainty | Neonatal Respiratory Distress Level of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509223","GAIA Spontaneous Abortion and Ectopic Pregnancy Level of Diagnostic Certainty","C128677","A classification of maternal and fetal outcomes relating to spontaneous abortion and ectopic pregnancy, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.","GAIA Spontaneous Abortion and Ectopic Pregnancy Level of Diagnostic Certainty | Global Alignment of Immunization safety Assessment in pregnancy Spontaneous Abortion and Ectopic Pregnancy Level of Diagnostic Certainty | Spontaneous Abortion and Ectopic Pregnancy Level of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509133","GAIA Congenital Microcephaly Level of Diagnostic Certainty","C128678","A classification of maternal and fetal outcomes relating to congenital microcephaly, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.","GAIA Congenital Microcephaly Level of Diagnostic Certainty | Congenital Microcephaly Level of Diagnostic Certainty | Global Alignment of Immunization safety Assessment in pregnancy Congenital Microcephaly Level of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225694","Alveolar Epithelium","C12867","Epithelia of lung alveoli. The layer of cells covering the lining of the tiny air sacs at the end of the bronchioles.","Alveolar Epithelium | Lung Alveolar Epithelia",,,,,,,,,,,,,,,"4102144","Structure of alveolar epithelium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509061","GAIA Ectopic Pregnancy Level of Diagnostic Certainty","C128680","A classification of maternal and fetal outcomes relating to ectopic pregnancies, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.","GAIA Ectopic Pregnancy Level of Diagnostic Certainty | Global Alignment of Immunization safety Assessment in pregnancy Ectopic Pregnancy Level of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512105","CBS wt Allele","C129050","Human CBS wild-type allele is located in the vicinity of 21q22.3 and is approximately 24 kb in length. This allele, which encodes cystathionine beta-synthase protein, is involved in the detoxification of homocysteine and the synthesis of cysteine. Mutation of the gene is associated with cystathionine beta-synthase deficiency (CBSD), which can lead to homocystinuria and an increase risk of thrombosis.","CBS wt Allele | Cystathionine-Beta-Synthase wt Allele | HIP4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509065","HLA-A2-restricted Melanoma-specific Peptides Vaccine GRN-1201","C128489","A cancer peptide vaccine composed of four human leukocyte antigen (HLA)-A2 (HLA-A*02)-restricted peptides derived from four specific and separate tumor-associated antigens (TAAs) expressed by melanoma cells, with potential antineoplastic activity. Upon administration of the HLA-A2-restricted melanoma-specific peptides vaccine, the melanoma specific antigens in the vaccine activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against the HLA-A2-positive melanoma cells.","HLA-A2-restricted Melanoma-specific Peptides Vaccine GRN-1201 | Cancer Vaccine GRN-1201 | GRN-1201 | Peptide Cancer Vaccine GRN-1201 | Peptide Vaccine GRN-1201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221909","Squamous Epithelium","C12848","A simple or stratified flat epithelium.","Squamous Epithelium | ",,,,,,,,,,,,,,,"4222736","Squamous epithelium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509545","REMS Terminology","C128490","Risk Evaluation and Mitigation Strategies (REMS) are programs required by FDA and put in place by drug manufacturers to help ensure that the benefits of certain drugs outweigh their risks.","Risk Evaluation and Mitigation Strategies Terminology | REMS Terminology | Risk Evaluation and Mitigation Strategies Terminology | SPL REMS Terminology | SPL Risk Evaluation and Mitigation Strategies Terminology | Structured Product Labeling Risk Evaluation and Mitigation Strategies Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508979","SPL REMS Requirement Terminology","C128491","Terminology used in the framework of REMS SPL data to represent the clinical or administrative activities that a REMS program may require participants to perform.","SPL REMS Requirement Terminology | Structured Product Labeling REMS Requirement Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508978","SPL REMS Protocol Terminology","C128492","Terminology used in the framework of REMS SPL data used to specify when REMS requirements must be carried out.","SPL REMS Protocol Terminology | Structured Product Labeling REMS Protocol Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508980","SPL REMS Stakeholder Terminology","C128493","Terminology used in the framework of REMS SPL data to represent stakeholders who participate in the REMS based on the role they play in the medication use and distribution process.","SPL REMS Stakeholder Terminology | Structured Product Labeling REMS Stakeholder Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509313","Risk Evaluation and Mitigation Strategies Requirement","C128494","Data elements that represent the clinical or administrative activities that a REMS program participant may be required to perform.","Risk Evaluation and Mitigation Strategies Requirement | REMS Requirement | Requirement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509437","Designate a Healthcare Setting Representative","C128495","The healthcare setting must designate an authorized representative to act on that setting's behalf.","Designate a Healthcare Setting Representative | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509611","Be Able To Perform a Clinical Activity","C128496","The healthcare provider or setting must have the ability to carry out a particular clinical activity, such as administer a particular treatment, diagnose a particular disease, or recognize a particular adverse event.","Be Able To Perform a Clinical Activity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509620","Have Necessary Healthcare Personnel or Equipment","C128497","The healthcare provider or setting must have particular medical equipment or personnel with particular training on-site.","Have Necessary Healthcare Personnel or Equipment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509317","Review Prescribing Information","C128498","The healthcare provider or setting must review the drug's Prescribing Information.","Review Prescribing Information | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509082","GAIA Level 1 Placental Abruption","C128748","GAIA Level 1 Placental Abruption is defined by two criteria: first, vaginal bleeding during the second or third trimester in the absence of placenta previa on ultrasound; second, one of the following two requirements must be met: a) Uterine irritability (irregular, frequent uterine activity, not coalesced into clear contractions in a regular pattern) or labor; OR b) Clinical signs of hypovolemic shock or coagulopathy. Alternatively, Level 1 may be defined as placental pathology with histologic findings of a chronic abruption.","GAIA Level 1 Placental Abruption | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Placental Abruption | Level 1 Placental Abruption",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509094","GAIA Level 2 Placental Abruption","C128749","GAIA Level 2 Placental Abruption is defined by two criteria: first, vaginal bleeding during the second or third trimester; second, uterine irritability (irregular, frequent uterine activity, not coalesced into clear contractions in a regular pattern) or labor without clinical signs of hypovolemic shock or coagulopathy. Alternatively, Level 2 may be defined as vaginal bleeding during the second or third trimester with clinical evidence of retroplacental clot or visually evident placental infarcts at the time of delivery.","GAIA Level 2 Placental Abruption | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Placental Abruption | Level 2 Placental Abruption",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512380","Type-1 Polarized Dendritic Cell-induced Antigen-specific Autologous Cytotoxic T Lymphocytes","C128892","A preparation of autologous cytotoxic T-lymphocytes (CTL), specifically reactive to melanoma-associated antigen 3 (MAGE-3), MAGE-4, survivin, human epidermal growth factor receptor 2 (HER2; ERBB2) and cyclooxygenase-2 (COX-2), with potential immunomodulating activity. Peripheral blood mononuclear cells (PBMCs) are collected from the patient. Subsequently, autologous dendritic cells (DCs) are separated, treated with a certain combination of cytokines to produce polarized type-1 DCs (DC1), and then are loaded with MAGE-3/MAGE-4/survivin/HER2/COX-2 CTL epitope peptides. In turn, autologous CTLs are collected, exposed ex vivo to the antigen-loaded DC1s and subsequently expanded in vitro. Upon re-infusion of the DC1-induced MAGE-3/MAGE-4/survivin/HER2/COX-2-specific autologous CTLs, the CTLs target and lyse tumor cells expressing the tumor-associated antigens (TAAs). Exposure to DC1s generates more potent CTLs and thus induces a more potent CTL response against TAA-expressing tumor cells. The targeted TAAs play key roles in cellular proliferation and are overexpressed by a variety of cancer cell types.","Type-1 Polarized Dendritic Cell-induced Antigen-specific Autologous Cytotoxic T Lymphocytes | Autologous DC1-CTL | DC1-induced Antigen-specific Autologous CTLs | Type-1 Polarized DC-induced Antigen-specific Autologous CTLs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512346","Chinese Herbal Formulation LC09","C128893","A traditional Chinese medicine (TCM) decoction containing Herba Epimedii that can be used for chemotherapy-induced hand-foot syndrome (HFS; Palmar-Plantar Erythrodysesthesia; PPE). Soaking of the affected hands and feet with TCM Formula LC09 may reduce the severity of HFS and may decrease HFS-associated pain.","Chinese Herbal Formulation LC09 | Herba Epimedii Compound Extraction LC09 | LC09 | TCM Formula LC09 | TCM LC09 | Traditional Chinese Medicine Formula LC09",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1174887","Thrombomodulin Alfa","C128894","A recombinant, soluble form of the human protein thrombomodulin, with potential anticoagulant activity. Upon administration, thrombomodulin binds to thrombin, which stimulates the activation of protein C. Activated protein C (APC) degrades factor Va and Factor VIIa in the presence of the cofactor protein S, inhibits thrombin formation, and prevents both thrombin-mediated coagulation and further clot formation.","Thrombomodulin Alfa | 1-498-Thrombomodulin (Human Clone TMP26/TMJ1 Protein Moiety Reduced) | ART 123 | ART-123 | Recomodulin | THROMBOMODULIN ALFA | Thrombomodulin (Human 498-Amino Acid Fragment)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512254","c-Met Inhibitor HS-10241","C128895","An orally bioavailable small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration, HS-10241 targets and binds to the c-Met protein, prevents c-Met phosphorylation and disrupts c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","c-Met Inhibitor HS-10241 | HS-10241",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4273547","Right Anterior Basal Transition Zone of Prostate","C128596","The region of the prostate that is located on the anatomical right side of the anterior portion of the basal division of the transition zone.","Right Anterior Basal Transition Zone of Prostate | Base R TZa",,,,,,,,,,,,,,,"37396908","Right anterior basal transition zone of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4274205","Right Posterior Basal Transition Zone of Prostate","C128597","The region of the prostate that is located on the anatomical right side of the posterior portion of the basal division of the transition zone.","Right Posterior Basal Transition Zone of Prostate | Base R TZp",,,,,,,,,,,,,,,"37399562","Right posterior basal transition zone of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4274479","Left Middle Anterior Fibromuscular Stroma of Prostate","C128599","The portion of the fibromuscular stroma of the prostate that is located on the anatomical left side of the middle division of the anterior lobe.","Left Middle Anterior Fibromuscular Stroma of Prostate | Mid L AS",,,,,,,,,,,,,,,"37396920","Left middle anterior fibromuscular stroma of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0079281","Endothelin-1","C1285","Endothelin-1 (212 aa, ~24 kDa) is encoded by the human EDN1 gene. This protein is involved in vasoconstriction.","Endothelin-1 | EDN1 | ET-1 | Endothelin 1 | PPET1 | Preproendothelin 1 | Preproendothelin-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4274185","Left Anterior Middle Peripheral Zone of Prostate","C128600","The region of the prostate that is located on the anatomical left side of the anterior portion of the middle division of the peripheral zone.","Left Anterior Middle Peripheral Zone of Prostate | Mid L PZa",,,,,,,,,,,,,,,"37396928","Left anterior middle peripheral zone of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4274180","Left Posterolateral Middle Peripheral Zone of Prostate","C128601","The region of the prostate that is located on the anatomical left side of the posterolateral portion of the middle division of the peripheral zone.","Left Posterolateral Middle Peripheral Zone of Prostate | Mid L PZpl",,,,,,,,,,,,,,,"37396930","Left posterolateral middle peripheral zone of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4274183","Left Posteromedial Middle Peripheral Zone of Prostate","C128602","The region of the prostate that is located on the anatomical left side of the posteromedial portion of the middle division of the peripheral zone.","Left Posteromedial Middle Peripheral Zone of Prostate | Mid L PZpm",,,,,,,,,,,,,,,"37396932","Left posteromedial middle peripheral zone of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4274190","Left Anterior Middle Transition Zone of Prostate","C128603","The region of the prostate that is located on the anatomical left side of the anterior portion of the middle division of the transition zone.","Left Anterior Middle Transition Zone of Prostate | Mid L TZa",,,,,,,,,,,,,,,"37396923","Left anterior middle transition zone of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4273544","Right Middle Anterior Fibromuscular Stroma of Prostate","C128605","The portion of the fibromuscular stroma of the prostate that is located on the anatomical right side of the middle division of the anterior lobe.","Right Middle Anterior Fibromuscular Stroma of Prostate | Mid R AS",,,,,,,,,,,,,,,"37396919","Right middle anterior fibromuscular stroma of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4274141","Right Anterior Middle Peripheral Zone of Prostate","C128606","The region of the prostate that is located on the anatomical right side of the anterior portion of the middle division of the peripheral zone.","Right Anterior Middle Peripheral Zone of Prostate | Mid R PZa",,,,,,,,,,,,,,,"37396927","Right anterior middle peripheral zone of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4274184","Right Posterolateral Middle Peripheral Zone of Prostate","C128607","The region of the prostate that is located on the anatomical right side of the posterolateral portion of the middle division of the peripheral zone.","Right Posterolateral Middle Peripheral Zone of Prostate | Mid R PZpl",,,,,,,,,,,,,,,"37396929","Right posterolateral middle peripheral zone of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4274181","Right Posteromedial Middle Peripheral Zone of Prostate","C128608","The region of the prostate that is located on the anatomical right side of the posteromedial portion of the middle division of the peripheral zone.","Right Posteromedial Middle Peripheral Zone of Prostate | Mid R PZpm",,,,,,,,,,,,,,,"37396931","Right posteromedial middle peripheral zone of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4274147","Right Anterior Middle Transition Zone of Prostate","C128609","The region of the prostate that is located on the anatomical right side of the anterior portion of the middle division of the transition zone.","Right Anterior Middle Transition Zone of Prostate | Mid R TZa",,,,,,,,,,,,,,,"37396922","Right anterior middle transition zone of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509069","CDISC SDTM Gastrointestinal Test Name Terminology","C128681","Terminology associated with the gastrointentestinal test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Gastrointestinal Test Name Terminology | GASTRO | Gastrointestinal Test Name | SDTM-GASTRO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1835044","Cutaneous Malignant Melanoma 2","C128801","A hereditary cutaneous melanoma caused by germline mutation(s) in the CDKN2A gene.","Hereditary Melanoma with CDKN2A Mutation | CMM2 | Cutaneous Malignant Melanoma 2 | Cutaneous Malignant Melanoma 2 | Familial Cutaneous Melanoma with CDKN2A Gene Mutation | Familial Cutaneous Melanoma with CDKN2A Mutation | Familial Melanoma with CDKN2A Gene Mutation | Familial Melanoma with CDKN2A Mutation | Hereditary Cutaneous Melanoma with CDKN2A Gene Mutation | Hereditary Cutaneous Melanoma with CDKN2A Mutation | Hereditary Melanoma with CDKN2A Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221036","Acrodermatitis Enteropathica","C128802","An autosomal recessive genetic disorder caused by mutations in the SLC39A4 gene, encoding zinc transporter ZIP4. The condition is characterized by zinc deficiency, periorificial and acral dermatitis, and diarrhea.","Acrodermatitis Enteropathica | ",,,,,,,,,,,,,,,"4292404","Hereditary acrodermatitis enteropathica",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3808338","Bicuspid Aortic Valve","C128803","A genetically heterogenous congenital anomaly in which the aortic valve has two leaflets. It affects 1-2 percent of the population.  It is a clinically heterogeneous condition, with a high incidence of aortic valve and ascending aortic complications requiring surgery.","Bicuspid Aortic Valve | Bicommissural Aortic Valve",,,,,,,,,,,,,,,"4218450","Bicuspid aortic valve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0342765","D-Glyceric Aciduria","C128804","An autosomal recessive genetic disorder caused by mutations in the GLYCTK gene, encoding glycerate kinase. The condition is characterized by excretion of D-glyceric acid in the urine. The phenotype varies from mild to severe, and may result in encephalopathy, mental retardation, microcephaly and early death.","D-Glyceric Aciduria | ",,,,,,,,,,,,,,,"4029103","D-Glyceric aciduria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1859727","Arterial calcification of infancy","C128805","An autosomal recessive genetic disorder caused by mutations in the ENPP1 gene, encoding ectonucleotide pyrophosphatase/phosphodiesterase family member 1. The condition is characterized by calcification and narrowing of medium- and large-sized arteries, resulting in cardiovascular complications.","Generalized Arterial Calcification of Infancy 1 | GACI1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342883","Hyperalphalipoproteinemia","C128806","An autosomal dominant genetic condition caused by mutation(s) in the CETP gene, encoding cholesteryl ester transfer protein. Affected individuals may have increased longevity due to decreased risk of coronary heart disease.","Hyperalphalipoproteinemia | HALP1",,,,,,,,,,,,,,,"4079886","Hyperalphalipoproteinemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3544265","Recurrent Intrahepatic Cholangiocarcinoma","C128807","The reemergence of intrahepatic cholangiocarcinoma after a period of remission.","Recurrent Intrahepatic Cholangiocarcinoma | Recurrent Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226660","Middle Cardiac Vein","C12880","A vein originating at the apex of the heart that ascends along the posterior interventricular sulcus and drains into the coronary sinus.","Middle Cardiac Vein | ",,,,,,,,,,,,,,,"4249169","Structure of middle cardiac vein",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512159","IgG Monoclonal Gammopathy","C128810","An abnormal laboratory test result indicating the presence of IgG monoclonal immunoglobulin in the blood or urine.","IgG Monoclonal Gammopathy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512158","IgA Monoclonal Gammopathy","C128811","An abnormal laboratory test result indicating the presence of IgA monoclonal immunoglobulin in the blood or urine.","IgA Monoclonal Gammopathy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512160","IgM Monoclonal Gammopathy","C128812","An abnormal laboratory test result indicating the presence of IgM monoclonal immunoglobulin in the blood or urine.","IgM Monoclonal Gammopathy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504443","Expanded DRS-PI Caregiver Version - Require Assistance Thinking Tasks","C125791","Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [s/he] require assistance from another person in tasks that require thinking abilities?","Expanded DRS-PI Caregiver Version - Require Assistance Thinking Tasks | ED1-Require Assistance Thinking Tasks | ED107_4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504444","Expanded DRS-PI Caregiver Version - Require Assistance Managing Emotions","C125792","Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [s/he] require assistance from another person to manage emotions and behavior?","Expanded DRS-PI Caregiver Version - Require Assistance Managing Emotions | ED1-Require Assistance Managing Emotions | ED107_5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504445","Expanded DRS-PI Caregiver Version - Need a Helper Always Close By","C125793","Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [s/he] take care of some of their needs but also need a helper who is always close by?","Expanded DRS-PI Caregiver Version - Need a Helper Always Close By | ED1-Need a Helper Always Close By | ED107_6A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504447","Expanded DRS-PI Caregiver Version - Need 24-Hour Care","C125795","Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [s/he] need 24-hour care and is not able to help with their own care at all?","Expanded DRS-PI Caregiver Version - Need 24-Hour Care | ED1-Need 24-Hour Care | ED107_6C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504448","Expanded DRS-PI Caregiver Version - Function With Independent Work or Social Situations","C125796","Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Can [name] function with complete independence in work or social situations?","Expanded DRS-PI Caregiver Version - Function With Independent Work or Social Situations | ED1-Independent Work/Social Situations | ED108_1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504449","Expanded DRS-PI Caregiver Version - Understand and Follow Directions","C125797","Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Can [name] understand, remember, and follow directions?","Expanded DRS-PI Caregiver Version - Understand and Follow Directions | ED1-Understand/Follow Directions | ED108_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504450","Expanded DRS-PI Caregiver Version - Keep Track of Time","C125798","Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Can [name] keep track of time, schedules and appointments?","Expanded DRS-PI Caregiver Version - Keep Track of Time | ED1-Keep Track of Time/Schedules | ED108_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504451","Expanded DRS-PI Caregiver Version - Perform Jobs or Manage a Home Independently","C125799","Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) How certain are you that [name] can perform in a wide variety of jobs of [his/her] choosing or manage a home independently or participate in school full-time?","Expanded DRS-PI Caregiver Version - Perform Jobs or Manage a Home Independently | ED1-Perform Jobs, Manage Home/School | ED108_4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002449","Ameloblast","C12579","A columnar epithelial cell located in the inner layer of the enamel organ of a developing tooth that plays a role in calcium transport and the synthesis and resorption of enamel matrix proteins.","Ameloblast | Ameloblasts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504452","Expanded DRS-PI Caregiver Version - Successful With Accommodations","C125800","Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) How certain are you that [name] can be successful at work, school or in home management with some reduction in the work load or with other accommodations due to disabilities?","Expanded DRS-PI Caregiver Version - Successful With Accommodations | ED1-Successful With Accommodations | ED108_5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0077063","Trichostatin A","C1261","A natural derivative of dienohydroxamic acid isolated from species of the bacterial genus Streptomyces.  Trichostatin A (TSA) reversibly and specifically inhibits histone deacetylases, resulting in hyperacetylation of core histones which modulate chromatin structure.  The increase in histone acetylation promotes selective gene transcription and the inhibition of tumor growth.  This agent is a potent inducer of tumor cell growth arrest, differentiation and apoptosis in a variety of transformed cells in culture and in tumor-bearing animals. (NCI04)","Trichostatin A | (2E,4E,6R)-7-[4-(Dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide | TRICHOSTATIN A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504962","H1.1","C126424","Human H1-1 wild-type allele is located in the vicinity of 6p21.3 and is approximately 1 kb in length. This allele, which encodes histone H1.1 protein, plays a role in the formation of nucleosomes and higher-order chromatin structures.","H1-1 wt Allele | H1 Histone Family, Member 1 Gene | H1 Histone Family, Member A Gene | H1.1 | H1.1 Linker Histone, Cluster Member wt Allele | H1A | H1F1 | HIST1 | HIST1 Cluster, H1A Gene | HIST1H1A | HIST1H1A wt Allele | Histone 1, H1A Gene | Histone Cluster 1, H1a Gene | Histone Gene Cluster 1, H1 Gene | Histone Gene Cluster 1, H1 Histone Family, Member A Gene | Histone Gene Cluster 1, H1A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3252388","Histone H1.1, Human","C126425","Histone H1.1 (215 aa, ~22 kDa) is encoded by the human H1-1 gene. This protein is involved in both DNA binding and chromatin compaction into higher order structures.","Histone H1.1 | H1-1 | HIST1H1A | Histone H1a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504487","PHQ Screener Version - Chest Pain","C125835","Patient Health Questionnaire Screener Version (PHQ Screener Version) During the last 4 weeks, how much have you been bothered by chest pain?","PHQ Screener Version - Chest Pain | PHQ03-Chest Pain | PHQ0301G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504489","PHQ Screener Version - Fainting Spells","C125837","Patient Health Questionnaire Screener Version (PHQ Screener Version) During the last 4 weeks, how much have you been bothered by fainting spells?","PHQ Screener Version - Fainting Spells | PHQ03-Fainting Spells | PHQ0301I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504490","PHQ Screener Version - Feeling Your Heart Pound or Race","C125838","Patient Health Questionnaire Screener Version (PHQ Screener Version) During the last 4 weeks, how much have you been bothered by feeling your heart pound/race?","PHQ Screener Version - Feeling Your Heart Pound or Race | PHQ03-Feeling Your Heart Pound/Race | PHQ0301J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504491","PHQ Screener Version - Shortness of Breath","C125839","Patient Health Questionnaire Screener Version (PHQ Screener Version) During the last 4 weeks, how much have you been bothered by shortness of breath?","PHQ Screener Version - Shortness of Breath | PHQ03-Shortness of Breath | PHQ0301K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504492","PHQ Screener Version - Constipation or Diarrhea","C125840","Patient Health Questionnaire Screener Version (PHQ Screener Version) During the last 4 weeks, how much have you been bothered by constipation, loose bowels, or diarrhea?","PHQ Screener Version - Constipation or Diarrhea | PHQ03-Constipation/Diarrhea | PHQ0301L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504493","PHQ Screener Version - Nausea, Gas or Indigestion","C125841","Patient Health Questionnaire Screener Version (PHQ Screener Version) During the last 4 weeks, how much have you been bothered by nausea, gas, indigestion?","PHQ Screener Version - Nausea, Gas or Indigestion | PHQ03-Nausea/Gas/Indigestion | PHQ0301M",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0752125","Spinocerebellar Ataxia Type 7","C126562","An autosomal dominant inherited neurodegenerative disorder caused by mutations in the ATXN7 gene. It is characterized by progressive cerebellar ataxia, including dysarthria and dysphagia, cone-rod and retinal dystrophy, and progressive central visual loss resulting in blindness.","Spinocerebellar Ataxia Type 7 | ",,,,,,,,,,,,,,,"37399713","Spinocerebellar ataxia type 7",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1421713","ZNF224 Gene","C126563","This gene plays a role in the negative regulation of gene transcription.","ZNF224 Gene | ZNF224 | Zinc Finger Protein 224 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505034","ZNF224 wt Allele","C126564","Human ZNF224 wild-type allele is located in the vicinity of 19q13.2 and is approximately 16 kb in length. This allele, which encodes zinc finger protein 224, is involved in transcriptional repression.","ZNF224 wt Allele | BMZF-2 | BMZF2 | KOX22 | ZNF255 | ZNF27 | Zinc Finger 2, Bone Marrow Gene | Zinc Finger Protein 224 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1173181","Zinc Finger Protein 224, Human","C126565","Zinc finger protein 224 (707 aa, ~82 kDa) is encoded by the human ZNF224 gene. This protein plays a role in the regulation of gene transcription.","Zinc Finger Protein 224 | Bone Marrow Zinc Finger 2 | Bone Marrow Zinc Finger Protein 2 | ZNF224 | Zinc Finger Protein 233 | Zinc Finger Protein 255 | Zinc Finger Protein 27 | Zinc Finger Protein KOX22 | Zinc Finger Protein ZNF255",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1839780","Fragile X Tremor/Ataxia Syndrome","C126566","An X-linked dominant inherited syndrome caused by mutations in the FMR1 gene. It is a late onset disorder, usually occurring after age 50. It affects males more frequently than females. It is characterized by abnormalities in the cerebellum and white matter. It manifests with intention tremor, ataxia, and cognitive disabilities. The symptoms worsen with age.","Fragile X Tremor/Ataxia Syndrome | FXTAS",,,,,,,,,,,,,,,"40487948","Fragile X associated tremor ataxia syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1415023","GCNT3 Gene","C126568","This gene is involved in the glycosylation of mucins.","GCNT3 Gene | GCNT3 | Glucosaminyl (N-Acetyl) Transferase 3, Mucin Type Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504717","LY6K wt Allele","C126133","Human LY6K wild-type allele is located in the vicinity of 8q24.3 and is approximately 5 kb in length. This allele, which encodes lymphocyte antigen 6K protein, may play a role in the regulation of cell growth.","LY6K wt Allele | CO16 | CT97 | FLJ35226 | HSJ001348 | Lymphocyte Antigen 6 Complex, Locus K wt Allele | URLC10 | ly-6K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2003478","Lymphocyte Antigen 6K, Human","C126134","Lymphocyte antigen 6K (165 aa, ~19 kDa) is encoded by the human LY6K gene. This protein may be involved in cell growth.","Lymphocyte Antigen 6K | Cancer/Testis Antigen 97 | LY6K | Ly-6K | Up-Regulated In Lung Cancer 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227525","Hepatocyte","C12588","A parenchymal liver cell.","Hepatocyte | Hepatic Cells | Hepatic Parenchymal Cell | Hepatocytes | hepatocyte",,,,,,,,,,,,,,,"4147203","Hepatic parenchymal cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1272516","Small Cell Glioblastoma","C125890","A morphologic variant of glioblastoma characterized by the presence of a highly proliferative and monotonous population of malignant small glial cells.","Small Cell Glioblastoma | ",,,,,,,,,,,,,,,"4298749","Small cell glioblastoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1561610","signed - ParticipationSignature","C125891","Indicates the person who has signed a document, physically or electronically (digital signature).","Signed By | Signatory | Signer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504545","Experimental Organism Anal Sac Gland","C125895","Apocrine gland of the anal sac.","Experimental Organism Anal Sac Gland | GLAND, ANAL SAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002759","Anal Sacs","C125896","One of two pouches located on either side of the anus that contain the secretions of the anal glands.","Anal Sac | SAC, ANAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504546","Thoracic Fluid","C125897","Fluid that is present in the thoracic cavity.","Thoracic Fluid | FLUID, THORAX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037890","Spheroplast","C12661","A cell that has lost it's typical shape and becomes spherical due to partial loss of the cell wall.","Spheroplast | Spheroplasts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505061","MYO1F wt Allele","C126621","Human MYO1F wild-type allele is located within 19p13.3-p13.2 and is approximately 57 kb in length. This allele, which encodes unconventional myosin-If, is involved in intracellular movement.","MYO1F wt Allele | MYO1F | Myosin IF wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3252286","MYO1F protein, human","C126622","Unconventional myosin-If (1098 aa, ~125 kDa) is encoded by the human MYO1F gene. This protein plays a role in the transport of intracellular components.","Unconventional Myosin-If | MYO1F | Myosin ID | Myosin-ID | Myosin-Ie",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825320","FRYL Gene","C126623","This gene is involved in the regulation of cell shape and polarity.","FRYL Gene | FRY-Like Gene | FRYL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505062","FRYL wt Allele","C126624","Human FRYL wild-type allele is located in the vicinity of 4p11 and is approximately 283 kb in length. This allele, which encodes protein furry homolog-like, plays a role in the modulation of both cell polarity and cell shape.","FRYL wt Allele | AF4p12 | DKFZp686E205 | FRY-Like wt Allele | Furry Homolog-Like (Drosophila) Gene | Furry-Like Gene | KIAA0826 | MOR2 | Mor2 Cell Polarity Protein Homolog (S. pombe) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505063","Protein Furry Homolog-Like","C126625","Protein furry homolog-like (3013 aa, ~340 kDa) is encoded by the human FRYL gene. This protein is involved in the regulation of cell shape in polarized cells.","Protein Furry Homolog-Like | ALL1-Fused Gene From Chromosome 4p12 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539330","EEFSEC Gene","C126626","This gene plays a role in protein translation.","EEFSEC Gene | EEFSEC | Eukaryotic Elongation Factor, Selenocysteine-tRNA-Specific Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035316","Retinal Ganglion Cell","C12642","An output neuron in the retina that receives visual signals from photoreceptors via interneurons, and transmits the information to the thalamus, hypothalamus, and superior colliculus of the brain through the optic nerve.","Retinal Ganglion Cell | Retinal Ganglion Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504969","CITED2 wt Allele","C126434","Human CITED2 wild-type allele is located in the vicinity of 6q23.3 and is approximately 3 kb in length. This allele, which encodes Cbp/p300-interacting transactivator 2 protein, is involved in transcriptional coactivation. Mutation of the gene is associated with cardiac septal defects.","CITED2 wt Allele | ASD8 | Cbp/p300 Interacting Transactivator, With Glu/Asp-Rich Carboxy-Terminal Domain 2 wt Allele | Cbp/p300-Interacting Transactivator, With Glu/Asp Rich Carboxy-Terminal Domain, 2 Gene | Cbp/p300-Interacting Transactivator, With Glu/Asp-Rich C-Terminal Domain, 2 Gene | Cbp/p300-Interacting Transactivator, With Glu/Asp-Rich Carboxy-Terminal Domain, 2 Gene | MRG-1 | MRG1 | MSG1-Related Gene 1 Gene | Melanocyte-Specific Gene 1-Related Gene 1 | P35SRJ | VSD2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1436100","Cbp/p300-Interacting Transactivator 2, Human","C126435","Cbp/p300-interacting transactivator 2 (270 aa, ~28 kDa) is encoded by the human CITED2 gene. This protein plays a role in the positive regulation of gene expression.","Cbp/p300-Interacting Transactivator 2 | CITED2 | MRG-1 | MSG-Related Protein 1 | p35SRJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040949","Trichostrongylus","C125930","A genus of parasitic nematodes in the family Strongylidae that affect domestic and wild ruminants, pigs, horses, and poultry. All Trichostrongylus species have a direct life cycle with no intermediate host. The typical route of infection is through oral ingestion of larvae-contaminated water or vegetation.","Trichostrongylus | TRICHOSTRONGYLUS",,,,,,,,,,,,,,,"4066368","Trichostrongylus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0041215","Trypanosoma","C125931","A genus of kinetoplastid, unicellular, parasitic flagellate protozoa in the phylum Euglenozoa. Most trypanosomes are heteroxenous, requiring more than one obligatory host to complete its life cycle.","Trypanosoma | Trypanosome",,,,,,,,,,,,,,,"4234370","Genus Trypanosoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL505035","GCNT3 wt Allele","C126569","Human GCNT3 wild-type allele is located in the vicinity of 15q21.3 and is approximately 45 kb in length. This allele, which encodes beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 3 protein, plays a role in mucin glycosylation.","GCNT3 wt Allele | C2/4GnT | C24GNT | C2GNT2 | C2GNTM | GNTM | Glucosaminyl (N-Acetyl) Transferase 3, Mucin Type wt Allele | Glucosaminyl (N-Acetyl) Transferase 3, Mucin-Type Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2350736","glucosaminyl (N-acetyl) transferase 3, mucin type protein, human","C126570","Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 3 (438 aa, ~51 kDa) is encoded by the human GCNT3 gene. This protein is involved in O-linked glycosylation of mucin proteins.","Beta-1,3-Galactosyl-O-Glycosyl-Glycoprotein Beta-1,6-N-Acetylglucosaminyltransferase 3 | Beta-1,6-N-Acetylglucosaminyltransferase-3 | Beta1,6-N-Acetylglucosaminyltransferase-M | Beta1,6GlcNAc-Transferase | C2/4GnT | C2GnT-M | C2GnT-Mucin Type | Core 2/Core 4 Beta-1,6-N-Acetylglucosaminyltransferase | EC 2.4.1.102 | EC 2.4.1.150 | GCNT3 | Mucus-Type Core 2 Beta-1,6-N-Acetylglucosaminyltransferase | hC2GnT-M",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826483","NUAK1 Gene","C126571","This gene plays a role in DNA damage response, apoptosis inhibition, cell adhesion, cellular senescence, and cell proliferation.","NUAK1 Gene | NUAK Family Kinase 1 Gene | NUAK1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505036","NUAK1 wt Allele","C126572","Human NUAK1 wild-type allele is located in the vicinity of 12q23.3 and is approximately 77 kb in length. This allele, which encodes NUAK family SNF1-like kinase 1 protein, is involved in serine/threonine phosphorylation.","NUAK1 wt Allele | ARK5 | KIAA0537 | NUAK Family Kinase 1 wt Allele | NUAK Family, SNF1-Like Kinase, 1 Gene | OMPHK1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1173934","NUAK1 protein, human","C126573","NUAK family SNF1-like kinase 1 (661 aa, ~74 kDa) is encoded by the human NUAK1 gene. This protein plays a role in protein phosphorylation, which regulates DNA damage response, apoptosis, cell adhesion, cellular senescence, and cell proliferation.","NUAK Family SNF1-Like Kinase 1 | AMP-Activated Protein Kinase Family Member 5 | AMPK-Related Protein Kinase 5 | ARK5 | EC 2.7.11.1 | Omphalocele Kinase 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1970022","NELFB Gene","C126574","This gene is involved in pausing transcriptional elongation.","NELFB Gene | NELFB | Negative Elongation Factor Complex Member B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505038","NELFB wt Allele","C126575","Human NELFB wild-type allele is located in the vicinity of 9q34 and is approximately 18 kb in length. This allele, which encodes negative elongation factor B protein, plays a role in the modulation of transcriptional elongation.","NELFB wt Allele | COBRA1 | KIAA1182 | NELF-B | Negative Elongation Factor Complex Member B wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504685","Experimental Organism Malignant Renal Mesenchymal Tumor","C126088","A malignant neoplasm arising from foci of atypical fibroblast-like cells in the interstitium of the outer stripe of the outer medulla of the kidney. (INHAND)","Experimental Organism Malignant Renal Mesenchymal Tumor | RENAL MESENCHYMAL TUMOR, MALIGNANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504686","Needle Tract Lesion","C126089","A localized pathological or traumatic structural change due to insertion and/or withdrawal of a needle.","Needle Tract Lesion | NEEDLE TRACT LESION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504688","Transfills Medical Gas","C126091","The process of transfilling in order to produce a medical gas product.","Transfills Medical Gas | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504928","Anti-CD19 Antibody-drug Conjugate SGN-CD19B","C126377","An antibody-drug conjugate (ADC) consisting of an anti-CD19 humanized monoclonal antibody (hBU12ec) with engineered cysteines (EC-mAb) conjugated, via a maleimidocaproyl-valine-alanine dipeptide protease-cleavable linker, to the cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer (SGD-1882), with potential antineoplastic activity. Upon administration of anti-CD19 ADC SGN-CD19B, the antibody moiety targets the cell surface antigen CD19, which is found on B-cell-derived cancers. Upon antibody/antigen binding, internalization and lysosome uptake, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of CD19-overexpressing tumor cells. CD19, a transmembrane receptor belonging to the immunoglobulin superfamily and a B-cell specific antigen, is expressed on B-cell-derived cancers. The cysteine engineering of the EC-mAb allows for a site-specific and stable conjugation of PBD to the antibody.","Anti-CD19 Antibody-drug Conjugate SGN-CD19B | ADC SGN-CD19B | SGN CD19B | SGN-CD19B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504929","Drinking Status","C126378","The current status of a person with regard to the amount of alcoholic beverages they consume.","Drinking Status | alcohol intensity | alcohol_intensity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206428","Retinal Cone","C12637","A photoreceptor cell located in the retina of the eye that allows high spatial acuity and color sensitivity.","Retinal Cone | Cone | Cone Cell | Cones",,,,,,,,,,,,,,,"4283383","Cone of retina",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504535","PHQ Screener Version - Drank Alcohol at Work or School","C125883","Patient Health Questionnaire Screener Version (PHQ Screener Version) Have any of the following happened to you more than once in the last 6 months: You drank alcohol, were high from alcohol, or hung over while you were working, or going to school, or taking care of children or other responsibilities?","PHQ Screener Version - Drank Alcohol at Work or School | PHQ03-Alcohol at Work/School | PHQ0310B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504536","PHQ Screener Version - Missed Work Because of Drinking","C125884","Patient Health Questionnaire Screener Version (PHQ Screener Version) Have any of the following happened to you more than once in the last 6 months: You missed or were late for work, school, or other activities because you were drinking or hung over?","PHQ Screener Version - Missed Work Because of Drinking | PHQ03-Missed Work Because of Drinking | PHQ0310C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504537","PHQ Screener Version - Problem Getting Along With People While Drinking","C125885","Patient Health Questionnaire Screener Version (PHQ Screener Version) Have any of the following happened to you more than once in the last 6 months: You had a problem getting along with other people while you were drinking?","PHQ Screener Version - Problem Getting Along With People While Drinking | PHQ03-Problem With People While Drinking | PHQ0310D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504538","PHQ Screener Version - Drove Car After Several Drinks","C125886","Patient Health Questionnaire Screener Version (PHQ Screener Version) Have any of the following happened to you more than once in the last 6 months: You drove a car after having several drinks or after drinking too much?","PHQ Screener Version - Drove Car After Several Drinks | PHQ03-Drove After Several Drinks | PHQ0310E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504539","PHQ Screener Version - Problems Made It Difficult to Work","C125887","Patient Health Questionnaire Screener Version (PHQ Screener Version) If you checked off any problems on this questionnaire, how difficult have these problems made it for you to do your work, take care of things at home, or get along with other people?","PHQ Screener Version - Problems Made It Difficult to Work | PHQ03-Problems Made It Difficult to Work | PHQ0311",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505064","EEFSEC wt Allele","C126627","Human EEFSEC wild-type allele is located in the vicinity of 3q21.3 and is approximately 273 kb in length. This allele, which encodes selenocysteine-specific elongation factor protein, is involved in the translation of selenocysteine-containing proteins.","EEFSEC wt Allele | EFSEC | Eukaryotic Elongation Factor, Selenocysteine-tRNA-Specific wt Allele | SELB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505065","EEFSEC protein, human","C126628","Selenocysteine-specific elongation factor (596 aa, ~65 kDa) is encoded by the human EEFSEC gene. This protein plays a role in the synthesis of selenocysteine-containing proteins.","Selenocysteine-Specific Elongation Factor | EEFSEC | Elongation Factor Sec | Elongation Factor for Selenoprotein Translation | Selenoprotein Translation Factor SELB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828831","BTBD18 Gene","C126629","This gene may be involved in protein ubiquitination.","BTBD18 Gene | BTB Domain Containing 18 Gene | BTBD18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505066","BTBD18 wt Allele","C126630","Human BTBD18 wild-type allele is located in the vicinity of 11q12.1 and is approximately 9 kb in length. This allele, which encodes BTB/POZ domain-containing protein 18, may play a role in the ubiquitination of proteins.","BTBD18 wt Allele | BTB (POZ) Domain Containing 18 Gene | BTB Domain Containing 18 wt Allele | HCG1730474",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505067","BTB/POZ Domain-Containing Protein 18","C126631","BTB/POZ domain-containing protein 18 (712 aa, ~78 kDa) is encoded by the human BTBD18 gene. This protein may be involved in the regulation of ubiquitination.","BTB/POZ Domain-Containing Protein 18 | BTB Domain-Containing 18 | BTBD18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412168","ACTN4 Gene","C126632","This gene plays a role in the binding of actin to other cellular structures.","ACTN4 Gene | ACTN4 | Actinin Alpha 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505068","ACTN4 wt Allele","C126633","Human ACTN4 wild-type allele is located in the vicinity of 19q13 and is approximately 84 kb in length. This allele, which encodes alpha-actinin-4 protein, is involved in crosslinking actin to other cellular proteins. Mutations in this gene are associated with focal segmental glomerulosclerosis.","ACTN4 wt Allele | ACTININ-4 | Actinin Alpha 4 wt Allele | Actinin, Alpha 4 Gene | Actinin, Alpha-4 Gene | FSGS | FSGS1 | Focal Segmental Glomerulosclerosis 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1308458","Alpha-Actinin-4, Human","C126634","Alpha-actinin-4 (911 aa, ~105 kDa) is encoded by the human ACTN4 gene. This protein plays a role in actin crosslinking.","Alpha-Actinin-4 | ACTN4 | Actinin Alpha4 Isoform | F-Actin Cross-Linking Protein | Non-Muscle Alpha-Actinin 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826722","PRRC1 Gene","C126635","This gene has no known function.","PRRC1 Gene | PRRC1 | Proline Rich Coiled-Coil 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504719","ATG13 wt Allele","C126136","Human ATG13 wild-type allele is located in the vicinity of 11p11.2 and is approximately 59 kb in length. This allele, which encodes autophagy-related protein 13, is involved in both mitophagy and autophagy.","ATG13 wt Allele | ATG13 Autophagy Related 13 Homolog (S. cerevisiae) Gene | ATG13 Autophagy Related 13 Homolog Gene | Autophagy 13, S. cerevisiae, Homolog of Gene | Autophagy Related 13 wt Allele | KIAA0652 | PARATARG8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504720","Autophagy-Related Protein 13","C126137","Autophagy-related protein 13 (517 aa, ~57 kDa) is encoded by the human ATG13 gene. This protein plays a role in the modulation of autophagy.","Autophagy-Related Protein 13 | ATG13 | PARATARG 8 | Paraprotein Target 8 | Paratarg-8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504573","Tumor Response System","C125932","A standard from which a judgment concerning tumor response to therapy can be established.","Tumor Response System | RESPONSE_SYSTEM | Tumor Response Criteria | Tumor Response Criterion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504576","Protein Interaction Domain Inhibitor Therapy","C125935","A form of treatment that uses substances which inhibit protein-protein interactions.","Protein Interaction Domain Inhibitor Therapy | Protein-Protein Interaction Inhibitor Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504689","Institutional Review Board Independent Ethics Committee Progress Report","C126092","Documentation containing regular reports of the clinical trial conduct, other than safety reports, submitted to the Institutional Review Board or Independent Ethics Committee.","Institutional Review Board Independent Ethics Committee Progress Report Documentation | IRB or IEC Progress Report | IRB-IEC Progress Report | IRB/IEC Progress Report | Institutional Review Board Independent Ethics Committee Progress Report | Spon IRB Prog Rpt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504690","Other Clinical Trial Submission Document","C126093","Documentation submitted to other committee(s) for approval of the clinical trial, and those related to any changes or updates made to that trial.","Clinical Trial Submission to Other Committees Documentation | Other Clinical Trial Submission Document | Other Submissions | Spon Othr IRB Subm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504691","Vendor Management Plan","C126094","Documentation describing the overall management strategy for vendors used to conduct clinical trial-related activities.","Clinical Trial Vendor Management Plan Documentation | Vendor Management Plan | Vendor Management Plan | Vendor Mgmt Pln",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023602","Leydig Cell","C12609","Testosterone-secreting interstitial cells located between the seminiferous tubules of the testes.","Leydig Cell | Interstitial Cell of Testis | Interstitial Cell of the Testis | Interstitial cell of Leydig | Leydig Cells",,,,,,,,,,,,,,,"4196095","Structure of interstitial cell of Leydig",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0077025","tributyrin","C1260","A triglyceride prodrug of butyric acid with potential antineoplastic activity. Butyrate, the active metabolite of tributyrin, inhibits histone deacetylase, resulting in increased differentiation, decreased proliferation, cell cycle arrest, and apoptosis in some tumor cell lines. (NCI04)","Tributyrin | 1,2,3-Propanetriyl Butanoate | 1,2,3-Tributyrylglycerol | Butanoic Acid 1,2,3-Propanetriyl Ester | Butanoic Acid, 1,2,3-Propanetriyl Ester | Butyryl Triglyceride | Glyceryl Tributyrate | Glyceryl tributyrate | TB | TRIBUTYRIN | tributyrin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1568247","Usher Syndrome Type 1","C126327","A syndrome characterized by congenital, bilateral, severe sensorineural hearing loss, abnormalities in the vestibular system, and adolescent-onset retinitis pigmentosa.","Usher Syndrome Type 1 | ",,,,,,,,,,,,,,,"4339018","Usher syndrome type 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0339534","Usher Syndrome Type 2","C126328","A syndrome characterized by congenital, bilateral sensorineural hearing loss that is mild to moderate in the low frequencies and severe to profound in the higher frequencies, no abnormalities in the vestibular system, and retinitis pigmentosa.","Usher Syndrome Type 2 | ",,,,,,,,,,,,,,,"4334251","Usher syndrome type 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1568248","Usher Syndrome Type 3","C126329","A syndrome characterized by postlingual progressive hearing loss, abnormalities in the vestibular system, and onset of retinitis pigmentosa symptoms usually by the second decade of life.","Usher Syndrome Type 3 | ",,,,,,,,,,,,,,,"605187","Retinitis pigmentosa-deafness syndrome type 3",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504987","High Grade Fallopian Tube Serous Adenocarcinoma","C126456","A rapidly growing serous adenocarcinoma that arises from the fallopian tube. It is characterized by the presence of high grade cytologic features and frequent mitotic figures.","Fallopian Tube High Grade Serous Adenocarcinoma | Fallopian Tube High-Grade Serous Adenocarcinoma | High Grade Fallopian Tube Serous Adenocarcinoma | High Grade Fallopian Tube Serous Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504988","Low Grade Fallopian Tube Serous Adenocarcinoma","C126457","A slow-growing serous adenocarcinoma that arises from the fallopian tube. It is characterized by the presence of low grade cytologic features and infrequent mitotic figures.","Low Grade Fallopian Tube Serous Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504989","PTPN21 wt Allele","C126459","Human PTPN21 wild-type allele is located in the vicinity of 14q31.3 and is approximately 89 kb in length. This allele, which encodes tyrosine-protein phosphatase non-receptor type 21 protein, is involved in protein dephosphorylation.","PTPN21 wt Allele | DJ1175B15.2 (Protein Tyrosine Phosphatase, Non-Receptor Type 21) Gene | PTPD1 | PTPRL10 | Protein Tyrosine Phosphatase, Non-Receptor Type 21 wt Allele | Protein-Tyrosine Phosphatase, Nonreceptor-Type, 21 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003154","Anterior Horn Cells","C12645","A motor neuron that is located in one of the ventral horns of the spinal cord and innervates skeletal muscles of the trunk or head.","Anterior Horn Cell | Anterior Horn Cells | Anterior Horn Neuron | Anterior Horn Neurons | Ventral Horn Cell | Ventral Horn Cells | Ventral Horn Neuron | Ventral Horn Neurons",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242873","Fast-Twitch Muscle Fiber","C12613","A large-diameter skeletal muscle fiber that uses glycogen reserves rather than oxygen-rich blood for quick energy and a more rapid production of force. Fast twitch muscle fibers have a low oxidative capacity and can produce ATP without the need for oxygen, resulting in a higher activation threshold and a higher velocity signal conduction.","Fast-Twitch Muscle Fiber | Muscle Fibers, Fast-Twitch | Type II Muscle Fiber | Type II Skeletal Muscle Fiber",,,,,,,,,,,,,,,"4338667","Skeletal muscle fiber, type II",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0242874","Slow-Twitch Muscle Fiber","C12614","A skeletal muscle fiber that utilizes aerobic respiration to fuel muscle contraction.  Slow twitch muscle fibers, which have a high concentration of myoglobin and mitochondrial oxidative enzymes, are resistant to fatigue.","Slow-Twitch Muscle Fiber | Muscle Fiber, Slow-Twitch | Type I Muscle Fiber | Type I Skeletal Muscle Fiber",,,,,,,,,,,,,,,"4270995","Skeletal muscle fiber, type I",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0337679","Ex-Drinker","C126381","An individual who used to drink regularly, but does not drink at the present time.","Ex-Drinker | ",,,,,,,,,,,,,,,"4220362","Ex-drinker",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0556298","Occasional Drinker","C126382","An individual who drinks from time to time, but generally less than once per week.","Occasional Drinker | ",,,,,,,,,,,,,,,"4027342","Occasional drinker",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504931","Drinker","C126383","An individual who drinks at least once per week with regularity.","Drinker | Regular Drinker",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337678","Heavy Drinker","C126384","A man who drinks more than 14 standard drinks per week or a woman who drinks more than 7 standard drinks per week.","Heavy Drinker | ",,,,,,,,,,,,,,,"4336673","Heavy drinker",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504453","Expanded DRS-PI Caregiver Version - Successful With Limited Choices","C125801","Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) How certain are you that [name] can be successful at work, school or in home management but with limited choices in jobs or school courses due to disabilities?","Expanded DRS-PI Caregiver Version - Successful With Limited Choices | ED1-Successful With Limited Choices | ED108_6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505021","GUCA2A wt Allele","C126516","Human GUCA2A wild-type allele is located within 1p35-p34 and is approximately 2 kb in length. This allele, which encodes guanylin protein, is involved in the regulation of intestinal guanylate cyclase activity.","GUCA2A wt Allele | GCAP-I | GUCA2 | Guanylate Cyclase Activator 2A (Guanylin 2, Intestinal, Heat-Stable) Gene | Guanylate Cyclase Activator 2A (Guanylin) Gene | Guanylate Cyclase Activator 2A wt Allele | Guanylin 2, Intestinal Gene | STARA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0120489","Guanylin","C126517","Guanylin (115 aa, ~12 kDa) is encoded by the human GUCA2A gene. This protein plays a role in the activation of intestinal guanylate cyclase.","Guanylin | GCAP-I | GUCA2A | Guanylate Cyclase Activator 2A | Guanylate Cyclase-Activating Protein 1 | Guanylate Cyclase-Activating Protein I | Prepro-Guanylin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505022","GNAS Gene Product","C126518","A protein encoded by the GNAS gene.","GNAS Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505023","Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short","C126519","Guanine nucleotide-binding protein G(s) subunit alpha isoforms short (394 aa, ~46 kDa) is encoded by the human GNAS gene. This protein plays a role in the activation of adenylate cyclase activity.","Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short | Adenylate Cyclase-Stimulating G Alpha Protein | G(s) Alpha | GNAS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034143","Purkinje Cell","C12651","A large neuron that transmits signals from the cerebellar cortex and play a major role in controlling motor movement.","Purkinje Cell | Cerebellar Purkinje Cell | Purkinje Cells | Purkinje's Cell | Purkinje's Corpuscle | Purkinje's Corpuscles",,,,,,,,,,,,,,,"4308907","Purkinje cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1122812","Neuroendocrine Secretory Protein 55, Human","C126520","Neuroendocrine secretory protein 55 (245 aa, ~28 kDa) is encoded by the human GNAS gene. This protein is involved in the response to parathyroid hormone.","Neuroendocrine Secretory Protein 55 | NESP55 | Secretogranin VI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505024","Protein ALEX","C126521","Protein ALEX (626 aa, ~68 kDa) is encoded by the human GNAS gene. This protein plays a role in the inhibition of adenylate cyclase-stimulating G alpha proteins.","Protein ALEX | Alternative Gene Product Encoded by XL-Exon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419216","KIF20A Gene","C126522","This gene is involved in both protein trafficking and cytokinesis.","KIF20A Gene | KIF20A | Kinesin Family Member 20A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505025","KIF20A wt Allele","C126523","Human KIF20A wild-type allele is located in the vicinity of 5q31 and is approximately 9 kb in length. This allele, which encodes kinesin-like protein KIF20A, plays a role in both cytokinesis and intracellular protein transport.","KIF20A wt Allele | Kinesin Family Member 20A wt Allele | MKLP2 | RAB6 Interacting, Kinesin-Like (Rabkinesin6) Gene | RAB6-Interacting Protein, Kinesin-Like Gene | RAB6KIFL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1439005","KIF20A protein, human","C126524","Kinesin-like protein KIF20A (890 aa, ~100 kDa) is encoded by the human KIF20A gene. This protein is involved in both intracellular protein transport and cell division.","Kinesin-Like Protein KIF20A | GG10_2 | KIF20A | MKlp2 | Mitotic Kinesin-Like Protein | Mitotic Kinesin-Like Protein 2 | Rab6-Interacting Kinesin-Like Protein | Rabkinesin 6 | Rabkinesin-6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413983","DFFB Gene","C126525","This gene is involved in apoptosis.","DFFB Gene | DFFB | DNA Fragmentation Factor Subunit Beta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505026","DFFB wt Allele","C126526","Human DFFB wild-type allele is located in the vicinity of 1p36.3 and is approximately 28 kb in length. This allele, which encodes DNA fragmentation factor subunit beta protein, plays a role in the regulation of DNA fragmentation and chromosome condensation during apoptosis.","DFFB wt Allele | CAD | CPAN | DFF-40 | DFF2 | DFF40 | DNA Fragmentation Factor Subunit Beta wt Allele | DNA Fragmentation Factor, 40-kD, Beta Subunit Gene | DNA Fragmentation Factor, 40kDa, Beta Polypeptide (Caspase-Activated DNase) Gene | Deoxyribonuclease III, Caspase-Activated Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206511","Vestibular Hair Cell","C12632","A sensory receptor cell, located within the vestibular system, that detects and transduces head movements into neural impulses that are transmitted by vestibular afferent nerves to the brain.","Vestibular Hair Cell | Vestibular Hair Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1839130","X-Linked Dystonia Parkinsonism","C126330","An X-linked recessive inherited movement disorder caused by mutations in and near the TAF1 gene. It is found only in people of Filipino descent. It is characterized by parkinsonism and later in life the development of involuntary, sustained muscle contractions.","X-Linked Dystonia Parkinsonism | DYT3 | Dystonia 3 | X-Linked Dystonia-Parkinsonism | XDP",,,,,,,,,,,,,,,"44784241","X-linked dystonia parkinsonism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504897","Ovarian Adenomatoid Tumor","C126331","A rare benign mesothelial tumor that arises from the ovary. It is characterized by the presence of gland-like structures.","Ovarian Adenomatoid Tumor | Benign Ovarian Mesothelioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504898","Zirconium Zr 89-labeled Anti-CA19-9 Monoclonal Antibody 5B1","C126332","A radioimmunoconjugate comprised of the recombinant human monoclonal antibody against the carbohydrate antigen sialyl-Lewis a (carbohydrate antigen 19-9; CA19-9) conjugated to the chelator desferrioxamine (DFO) and labeled with the radioisotope zirconium Zr 89 (Zr 89), with radioisotopic activity and potential use as an imaging agent in positron emission tomography (PET). The antibody moiety of zirconium Zr 89 anti-CA19-9 monoclonal antibody 5B1 targets and binds to CA19-9 expressing-tumor cells. Upon binding, internalization and proteolysis, the radioisotope moiety may be detected using PET, thus allowing imaging and quantification of CA19-9-expressing tumor cells. CA19-9, overexpressed on a number of different tumor cell types, plays a key role in tumor cell survival and metastasis.","Zirconium Zr 89-labeled Anti-CA19-9 Monoclonal Antibody 5B1 | 89Zr-DFO-HuMab-5B1 | MVT-2163",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504899","Lamellar Body Mimetic Mouth Spray LMS-611","C126333","A suspension-based oral spray containing multilamellar lipid vesicles in which the lipids mimic the lipidic composition of endogenous extra-alveolar lamellar bodies, with muco-restorative and protective activity against radiotherapy (RT)-induced xerostomia (RIX). Upon sublingual administration of the lamellar body mimetic LMS-611 using a spray, the lipids in this agent mimic the natural secretions of endogenous lamellar bodies. This makes mucus more fluid and may prevent dryness of the mouth. This restores saliva functions and makes it easier to chew, swallow and talk, and also prevents xerostomia-induced infections, tooth decay and tooth enamel decay. RT decreases saliva secretion by causing the destruction of the parotid and submandibular serous salivary glands and lamellar bodies. This results in thicker and more visco-adhesive saliva, which causes various xerostomia-induced symptoms; intact lamellar bodies maintain the fluidity of mucus and lubricate the mouth.","Lamellar Body Mimetic Mouth Spray LMS-611 | LMS-611 | OXB/1-20 | RIX-LMS-611x-20 | Visco-ease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504900","Anti-FGFR4 Monoclonal Antibody U3-1784","C126334","A human monoclonal antibody against human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon administration, U3-1784 specifically binds to and blocks FGFR4. This prevents the activation of FGFR4, inhibits FGFR4-mediated signaling and leads to an inhibition of cell proliferation in FGFR4-overexpressing tumor cells. FGFR4, a receptor tyrosine kinase overexpressed by certain tumor cell types, is involved in tumor cell proliferation, differentiation, angiogenesis, and survival.","Anti-FGFR4 Monoclonal Antibody U3-1784 | U3 1784 | U3-1784",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504494","PHQ Screener Version - Little Interest in Doing Things","C125842","Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 2 weeks, how often have you been bothered by little interest or pleasure in doing things?","PHQ Screener Version - Little Interest in Doing Things | PHQ03-Little Interest in Doing Things | PHQ0302A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1871858","Tyrosine-Protein Phosphatase Non-Receptor Type 21, Human","C126460","Tyrosine-protein phosphatase non-receptor type 21 (1174 aa, ~133 kDa) is encoded by the human PTPN21 gene. This protein plays a role in dephosphorylation of phosphotyrosines.","Tyrosine-Protein Phosphatase Non-Receptor Type 21 | EC 3.1.3.48 | PTPN21 | Protein Tyrosine Phosphatase D1 | Protein-Tyrosine Phosphatase D1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504991","Tubal Hyperplasia","C126461","Benign proliferation of the fallopian tube epithelium.","Tubal Hyperplasia | Tubal Epithelial Hyperplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041343","Tubo-Ovarian Abscess","C126462","An abscess involving the distal fallopian tube and ovary. It is caused by pelvic inflammatory disease or other infections.","Tubo-Ovarian Abscess | ",,,,,,,,,,,,,,,"4239651","Tubo-ovarian abscess",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504992","Fallopian Tube Mucinous Metaplasia","C126463","Metaplastic mucinous changes in the fallopian tube epithelium. It may be seen in association with gynecological, appendiceal, or colonic mucinous tumors, or chronic inflammation.","Fallopian Tube Mucinous Metaplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504993","Fallopian Tube Lymphoma","C126464","An exceedingly rare lymphoma that arises from the fallopian tube.","Fallopian Tube Lymphoma | Primary Fallopian Tube Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504994","Metastatic Head and Neck Carcinoma","C126465","A carcinoma that arises from the head and neck and has spread from the original site of growth to another anatomic site.","Metastatic Head and Neck Carcinoma | Metastatic Head and Neck Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504995","NAPA wt Allele","C126467","Human NAPA wild-type allele is located in the vicinity of 19q13.33 and is approximately 28 kb in length. This allele, which encodes alpha-soluble NSF attachment protein, plays a role in intracellular vesicle transport.","NAPA wt Allele | N-Ethylmaleimide-Sensitive Factor Attachment Protein, Alpha Gene | NSF Attachment Protein Alpha wt Allele | SNAP, Alpha Gene | SNAPA | Soluble NSF-Attachment Protein, Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0169268","alpha-SNAP","C126468","Alpha-soluble NSF attachment protein (295 aa, ~33 kDa) is encoded by the human NAPA gene. This protein is involved in the transport of vesicles between the endoplasmic reticulum and Golgi.","Alpha-Soluble NSF Attachment Protein | Alpha SNAP | Alpha-SNAP | N-Ethylmaleimide-Sensitive Factor Attachment Protein Alpha | NAPA | SNAP-Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504996","Borderline Broad Ligament Serous Tumor","C126469","A rare non-invasive tumor that arises from the broad ligament. It is characterized by the presence of serous epithelial cell proliferation and cytological atypia.","Borderline Broad Ligament Serous Tumor | Serous Borderline Broad Ligament Tumor/Atypical Proliferative Serous Broad Ligament Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504997","MARK2 wt Allele","C126471","Human MARK2 wild-type allele is located in the vicinity of 11q13.1 and is approximately 72 kb in length. This allele, which encodes serine/threonine-protein kinase MARK2 protein, is involved in both protein phosphorylation and microtubule dynamics.","MARK2 wt Allele | EMK-1 | EMK1 | MAP/Microtubule Affinity-Regulating Kinase 2 wt Allele | PAR-1 | PAR1. C. elegans, Homolog of, B Gene | Par-1b | Par1b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0299851","MARK2 protein, human","C126472","Serine/threonine-protein kinase MARK2 (788 aa, ~88 kDa) is encoded by the human MARK2 gene. This protein plays a role in both microtubule dynamics and serine/threonine phosphorylation.","Serine/Threonine-Protein Kinase MARK2 | EC 2.7.11.1 | EC 2.7.11.26 | ELKL Motif Kinase | ELKL Motif Kinase 1 | EMK-1 | MAP/Microtubule Affinity-Regulating Kinase 2 | MARK2 | PAR1 Homolog | PAR1 Homolog B | Par-1b | Par1b | Ser/Thr Protein Kinase PAR-1B | Serine/Threonine Protein Kinase EMK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206427","Retinal Rod","C12638","A photoreceptor cell located in the retina of the eye that allows low light vision.","Retinal Rod | Rod | Rod Cell | Rods",,,,,,,,,,,,,,,"4065056","Rod of retina",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035798","Rod Outer Segment","C12639","A portion of the retinal rod cell largely consisting of a stack of discs (membrane infoldings that are incompletely separated in cones) that are continually replenished near the inner segment and that are shed from the distal end and phagocytosed by the pigmented epithelium.","Rod Outer Segment | Rod Outer Segment of the Retina | Rod Outer Segments",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0077144","Trilostane","C1263","A synthetic derivative of androstane with adrenocortical suppressive properties.  Trilostane reversibly inhibits 3 beta-hydroxysteroid dehydrogenase delta 5-4 isomerase in the adrenal cortex, resulting in the decreased synthesis of mineralocorticoids and glucocorticoids and the decreased conversion of pregnenolone to progesterone. (NCI04)","Trilostane | (4Alpha,5alpha,17beta)-4,5-epoxy-3,17-dihydroxyandrost-2-ene-2-carbonitrile | 2Alpha-cyano-4alpha,5alpha-epoxyandrostan-17beta-ol-3-one | 4,5-Epoxy-17-hydroxy-3-oxoandrostane-2-carbonitrile | Desopan | Modrastane | Modrenal | TRILOSTANE | WIN 24,540 | WIN 24540",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504547","Evaux Thermal Spring Water-based Solution","C125898","A topical solution containing Evaux thermal spring water, with potential moisturizing and skin protecting activities. Upon application to the nails and surrounding skin, Evaux spring water-based solution forms a film on the nails that serves as a protective barrier. This prevents water loss from, provides moisture to, and strengthens the nails, and protects them from damage. The solution also relieves pain caused by cracked, peeled, thinning or soft nails. Evaux thermal spring water contains the elements lithium, manganese and strontium which may help heal the nails and prevent onycholysis. It also contains chlorphenesin and piroctone olamine, both of which have antifungal activity. Some chemotherapy and/or radiation therapy can induce damage to the nails.","Evaux Thermal Spring Water-based Solution | EvoNail",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1504769","DNA Fragmentation Factor Subunit Beta, Human","C126527","DNA fragmentation factor subunit beta (338 aa, ~39 kDa) is encoded by the human DFFB gene. This protein is involved in the modulation of DNA fragmentation and chromosome condensation during apoptosis.","DNA Fragmentation Factor Subunit Beta | CAD | CPAN | Caspase-Activated DNase | Caspase-Activated Deoxyribonuclease | Caspase-Activated Nuclease | DFF-40 | DFFB | DNA Fragmentation Factor 40 kDa Subunit | EC 3.-.-.-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206441","Pyramidal Cell","C12652","A neuron located in the cerebral cortex, hippocampus, and amygdala that is characterized by a pyramidal-shaped cell body and apical and basal dendritic trees. Pyramidal cells are involved in complex cortical functions.","Pyramidal Cell | Pyramidal Cells",,,,,,,,,,,,,,,"4068408","Pyramidal cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504495","PHQ Screener Version - Feeling Down or Depressed","C125843","Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 2 weeks, how often have you been bothered by feeling down, depressed, or hopeless?","PHQ Screener Version - Feeling Down or Depressed | PHQ03-Feeling Down/Depressed | PHQ0302B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504497","PHQ Screener Version - Feeling Tired or Little Energy","C125845","Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 2 weeks, how often have you been bothered by feeling tired or having little energy?","PHQ Screener Version - Feeling Tired or Little Energy | PHQ03-Feeling Tired/Little Energy | PHQ0302D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504498","PHQ Screener Version - Poor Appetite or Overeating","C125846","Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 2 weeks, how often have you been bothered by poor appetite or overeating?","PHQ Screener Version - Poor Appetite or Overeating | PHQ03-Poor Appetite or Overeating | PHQ0302E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504499","PHQ Screener Version - Feeling Bad About Yourself","C125847","Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 2 weeks, how often have you been bothered by feeling bad about yourself - or that you are a failure or have let yourself or your family down?","PHQ Screener Version - Feeling Bad About Yourself | PHQ03-Feeling Bad About Yourself | PHQ0302F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504500","PHQ Screener Version - Last 2 Weeks, Trouble Concentrating","C125848","Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 2 weeks, how often have you been bothered by trouble concentrating on things, such as reading the newspaper or watching television?","PHQ Screener Version - Last 2 Weeks, Trouble Concentrating | PHQ03-Last 2 Week Trouble Concentrating | PHQ0302G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504501","PHQ Screener Version - Moving Slowly or Moving More","C125849","Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 2 weeks, how often have you been bothered by moving or speaking so slowly that other people could have noticed? Or the opposite - being so fidgety or restless that you have been moving around a lot more than usual?","PHQ Screener Version - Moving Slowly or Moving More | PHQ03-Moving Slowly/Fidgety/Restless | PHQ0302H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504502","PHQ Screener Version - Thoughts Be Better Off Dead","C125850","Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 2 weeks, how often have you been bothered by thoughts that you would be better off dead or of hurting yourself in some way?","PHQ Screener Version - Thoughts Be Better Off Dead | PHQ03-Thoughts Be Better Off Dead | PHQ0302I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504503","PHQ Screener Version - Anxiety Attack","C125851","Patient Health Questionnaire Screener Version (PHQ Screener Version) In the last 4 weeks, have you had an anxiety attack - suddenly feeling fear or panic?","PHQ Screener Version - Anxiety Attack | PHQ03-Anxiety Attack | PHQ0303A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504505","PHQ Screener Version - Anxiety Attacks Come Suddenly","C125853","Patient Health Questionnaire Screener Version (PHQ Screener Version) Do some of these attacks come suddenly out of the blue - that is, in situations where you don't expect to be nervous or uncomfortable?","PHQ Screener Version - Anxiety Attacks Come Suddenly | PHQ03-Anxiety Attacks Come Suddenly | PHQ0303C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504506","PHQ Screener Version - Anxiety Attacks Bother a Lot","C125854","Patient Health Questionnaire Screener Version (PHQ Screener Version) Do these attacks bother you a lot or are you worried about having another attack?","PHQ Screener Version - Anxiety Attacks Bother a Lot | PHQ03-Anxiety Attacks Bother a Lot | PHQ0303D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504999","EHD1 wt Allele","C126474","Human EHD1 wild-type allele is located in the vicinity of 11q13 and is approximately 37 kb in length. This allele, which encodes EH domain-containing protein 1, plays a role in endocytic recycling.","EHD1 wt Allele | CDABP0131 | EH Domain Containing 1 wt Allele | EH Domain-Containing 1 Gene | EH-Domain Containing 1 Gene | FLJ42622 | FLJ44618 | H-PAST | HPAST1 | PAST | PAST1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0389585","testilin","C126475","EH domain-containing protein 1 (534 aa, ~61 kDa) is encoded by the human EHD1 gene. This protein is involved in plasma membrane endocytosis and recycling.","EH Domain-Containing Protein 1 | PAST Homolog 1 | Testilin | hPAST1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505000","Broad Ligament Serous Cystadenoma","C126476","A rare serous cystadenoma arising from the broad ligament.","Broad Ligament Serous Cystadenoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505001","Broad Ligament Serous Cystadenofibroma","C126477","A rare serous cystadenofibroma arising from the broad ligament.","Broad Ligament Serous Cystadenofibroma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505002","Broad Ligament Serous Adenofibroma","C126478","A rare serous adenofibroma arising from the broad ligament.","Broad Ligament Serous Adenofibroma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0949753","Nitrergic Neuron","C12647","A nerve cell that uses nitric oxide as its neurotransmitter.","Nitrergic Neuron | Nitrergic Neurons | Nitroxidergic Neurons",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505004","Low Grade Broad Ligament Serous Adenocarcinoma","C126480","A slow-growing serous adenocarcinoma that arises from the broad ligament. It is characterized by the presence of low grade cytologic features and infrequent mitotic figures.","Low Grade Broad Ligament Serous Adenocarcinoma | Low-Grade Broad Ligament Serous Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417869","NTS Gene","C126484","This gene may play a role in both fat digestion and antimicrobial activity.","NTS Gene | NTS | Neurotensin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505008","NTS wt Allele","C126486","Human NTS wild-type allele is located in the vicinity of 12q21 and is approximately 9 kb in length. This allele, which encodes neurotensin/neuromedin N protein, may be involved in both antimicrobial activity and fat digestion.","NTS wt Allele | NMN-125 | NN | NT | NT/N | NTS1 | Neurotensin wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505009","NTS Gene Product","C126487","A protein encoded by the NTS gene.","NTS Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508158","BCG Tokyo-172 Strain Solution","C126694","A solution containing an attenuated, live culture preparation of the bacillus Calmette-Guerin (BCG) strain of Mycobacterium bovis obtained from the Pasteur Institute in 1924, with potential immunostimulating and antineoplastic activities. Although the precise mechanism of action is unknown, upon intravesical instillation through a catheter, the attenuated, live BCG bacteria in the BCG Tokyo-172 strain solution come into direct contact with the bladder wall and elicits a local, multifaceted immune response against the BCG antigens, which kills the bladder cancer cells. Previous vaccination with a systemic BCG vaccine may enhance the immune system's response against the BCG antigens.","BCG Tokyo-172 Strain Solution | BACILLUS CALMETTE-GUERIN SUBSTRAIN TOKYO 172-1 LIVE ANTIGEN | BCG Tokyo-172 Strain Vaccine | Bacillus Calmette-Guerin Tokyo-172 Strain Solution | Immunobladder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0077008","Triazinate","C1258","A synthetic dihydrotriazine derivative with antineoplastic properties.  As an antifolate agent related to methotrexate (MTX), triazinate inhibits the enzyme dihydrofolate reductase (DHFR), resulting in decreased tetrahydrofolate production and interference with thymidylate synthesis.  Unlike MTX, this agent is not converted to polyglutamate forms. Triazinate also inhibits the transport of folates and may be selectively toxic to MTX-resistant tumor cells. (NCI04)","Triazinate | BAF | Baker's Antifol | Baker's Antifol soluble | Baker's Antifolate | Bakers Antifol | Bakers Antifolate | Benzenesulfonyl fluoride, 3-chloro-4-[4-[2-chloro-4-(4, 6-diamino-2,2-dimethyl-1,3,5-triazin-1(2H)-yl)phenyl]butyl]-, monoethanesulfonate (9CI) | Ethanesulfonic Acid Compound | Ethanesulfonic acid, compd. with 3-chloro-4-[4-[2-chloro-4-(4, 6-diamino-2, 2-dimethyl-s-triazin-1(2H)-yl)phenyl]butyl]benzenesulfonyl fluoride (1:1) (8CI) | Ethanesulfonic acid, compd. with 3-chloro-4-[4-[2-chloro-4-(4,6-diamino-2, 2-dimethyl-s-triazin-1(2H)-yl)phenyl]butyl]benzenesulfonyl fluoride | Ethanesulfonic acid, compd. with 3-chloro-4-[4-[2-chloro-4-(4,6-diamino-2,2-dimethyl-1,3, 5-triazin-1(2H)-yl)phenyl]butyl]benzenesulfonyl fluoride (1:1) (9CI) | Soluble Baker's Antifol | TRIAZINATE | TZT | alpha-(2-chloro-4-(4,6-diamino-2,2-dimethyl-s-trizin-1(2H)-yl)phenoxy)-N,N-dimethyl-m-toluamide ethanesulfonic acid | benzenesulfonyl fluoride, 3-chloro-4-[4-[2-chloro-4-(4, 6-diamino-2,2-dimethyl-1,3,5-triazin-1(2H)-yl)phenyl]butyl]-, monoethanesulfonate (9CI) | ethanesulfonic acid compound with 3-((2-chloro-4-(4,6-diamino-2,2-dimethyl-1,3,5-triazin-1(2H)-yl)phenoxy)methyl)-N,N-dimethylben zamide (1:1) | ethanesulfonic acid, compd. with 3-chloro-4-[4-[2-chloro-4-(4, 6-diamino-2, 2-dimethyl-s-triazin-1(2H)-yl)phenyl]butyl]benzenesulfonyl fluoride (1:1)(8CI) | ethanesulfonic acid, compd. with 3-chloro-4-[4-[2-chloro-4-(4,6-diamino-2, 2-dimethyl-s-triazin-1(2H)-yl)phenyl]butyl]benzenesulfonyl fluoride | ethanesulfonic acid, compd. with 3-chloro-4-[4-[2-chloro-4-(4,6-diamino-2,2-dimethyl-1,3, 5-triazin-1(2H)-yl)phenyl]butyl]benzenesulfonyl fluoride (1:1)(9CI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504549","Anti-CA19-9 Monoclonal Antibody 5B1","C125900","A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the carbohydrate antigen sialyl Lewis A (carbohydrate antigen 19-9; CA19-9), with potential antineoplastic activity. Upon administration, anti-CA19-9 monoclonal antibody BNT321 targets and binds to CA19-9, and kills CA19-9-expressing tumor cells through the induction of both complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). CA19-9 is overexpressed on a number of different tumor cell types, and plays a key role in tumor cell survival and metastasis.","Anti-CA19-9 Monoclonal Antibody BNT321 | 5B1 | Anti-CA19-9 Monoclonal Antibody 5B1 | Anti-CA19-9 Monoclonal Antibody 5B1 | BNT 321 | BNT-321 | BNT321 | HuMab 5B1 | HuMab-5B1 | MVT-5873",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504550","Etidronate-Cytarabine Conjugate MBC-11","C125901","A synthetic conjugate composed of the bisphosphonate etidronate linked to the cytostatic agent and antimetabolite cytarabine, with potential antineoplastic and antiresorptive activities. Upon intravenous administration of the etidronate-cytarabine conjugate MBC-11, the etidronate moiety targets bone and the two moieties are released upon hydrolysis. Etidronate binds to hydroxyapatite crystals in bone tissues and prevents its resorption. This prevents bone destruction and induces bone cell mineralization. In addition, the bone-targeting nature of this agent allows for the accumulation of cytarabine in bone tissue, where it is able to exert its antitumor effect locally by competing with cytidine for incorporation into DNA, thereby inhibiting DNA synthesis, while reducing systemic exposure. This leads to a destruction of bone-associated tumor cells, an inhibition of tumor cell proliferation and bone metastasis, and prevents tumor-mediated bone destruction.","Etidronate-Cytarabine Conjugate MBC-11 | Etidronate-ara-C Conjugate MBC-11 | MBC-11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505069","PRRC1 wt Allele","C126636","Human PRRC1 wild-type allele is located in the vicinity of 5q23.2 and is approximately 37 kb in length. This allele, which encodes protein PRRC1, has no known function. Mutation or deletion of the gene may be associated with leukemogenesis.","PRRC1 wt Allele | FLJ32875 | Proline Rich Coiled-Coil 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505070","Protein PRRC1","C126637","Protein PRRC1 (445 aa, ~47 kDa) is encoded by the human PRRC1 gene. The function of this protein is unknown.","Protein PRRC1 | Proline-Rich Coiled-Coil 1 | Proline-Rich and Coiled-Coil-Containing Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037844","Head of the Spermatozoon","C12603","The anterior, often oval-shaped, part of a mature spermatozoon, which contains haploid male nuclear material.","Head of the Spermatozoon | Sperm Head",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027883","Afferent neuron","C12628","An afferent neuron that converts environmental stimuli into electrical impulses that are transmitted to the central nervous system.","Sensory Neuron | Afferent Neuron | Afferent Neurons | Sensory Cell Afferent Neuron | Sensory Neurons",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1100589","cofactor of BRCA1 protein, human","C126576","Negative elongation factor B (580 aa, ~66 kDa) is encoded by the human NELFB gene. This protein is involved in the negative regulation of transcript elongation.","Negative Elongation Factor B | Cofactor of BRCA1 | NELF-B | NELFB | Negative Elongation Factor Polypeptide B | Negative Elongation Factor Protein B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412813","BOK Gene","C126577","This gene plays a role in the activation of apoptosis.","BOK Gene | BCL2-Related Ovarian Killer Gene | BOK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505039","BOK wt Allele","C126578","Human BOK wild-type allele is located in the vicinity of 2q37.3 and is approximately 16 kb in length. This allele, which encodes Bcl-2-related ovarian killer protein, is involved in the induction of apoptosis.","BOK wt Allele | BCL2-Like 9 Gene | BCL2-Related Ovarian Killer wt Allele | BCL2L9 | BOKL | MGC4631",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1611390","Bcl-2-Related Ovarian Killer Protein, Human","C126579","Bcl-2-related ovarian killer protein (212 aa, ~23 kDa) is encoded by the human BOK gene. This protein plays a role in the positive regulation of apoptosis.","Bcl-2-Related Ovarian Killer Protein | Bcl-2-Like Protein 9 | Bcl2-L-9 | hBOK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3280816","GMNC Gene","C126580","This gene is involved in the modulation of DNA replication.","GMNC Gene | GMNC | Geminin Coiled-Coil Domain Containing Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505041","GMNC wt Allele","C126581","Human GMNC wild-type allele is located in the vicinity of 3q28 and is approximately 49 kb in length. This allele, which encodes geminin coiled-coil domain-containing protein 1, plays a role in the positive regulation of DNA replication.","GMNC wt Allele | GEMC1 | Geminin Coiled-Coil Domain Containing wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505144","Geminin Coiled-Coil Domain-Containing Protein 1","C126582","Geminin coiled-coil domain-containing protein 1 (334 aa, ~38 kDa) is encoded by the human GMNC gene. This protein is involved in the promotion of DNA replication.","Geminin Coiled-Coil Domain-Containing Protein 1 | GMNC | Geminin Coiled-Coil Domain-Containing Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417732","NIT1 Gene","C126583","This gene plays a role in apoptosis and the catabolism of nitrogen compounds.","NIT1 Gene | NIT1 | Nitrilase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505042","NIT1 wt Allele","C126584","Human NIT1 wild-type allele is located within 1q21-q22 and is approximately 7 kb in length. This allele, which encodes deaminated glutathione amidase protein, is involved in both the catabolism of nitrogen compounds and the regulation of apoptosis.","NIT1 wt Allele | Nitrilase 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505043","Deaminated Glutathione Amidase","C126585","Deaminated glutathione amidase (327 aa, ~38 kDa) is encoded by the human NIT1 gene. This protein plays a role in both nitrogen compound metabolism and the positive regulation of apoptosis.","Deaminated Glutathione Amidase | EC 3.5.1.128 | NIT1 | Nitrilase Homolog 1 | dGSH amidase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505044","ROBO1 wt Allele","C126589","Human ROBO1 wild-type allele is located in the vicinity of 3p12 and is approximately 1170 kb in length. This allele, which encodes roundabout homolog 1 protein, plays a role in both axon guidance and neuroblast migration.","ROBO1 wt Allele | CPHD8 | DUTT1 | Deleted in U Twenty Twenty Gene | FLJ21882 | NORS | NYS8 | Roundabout (Axon Guidance Receptor, Drosophila) Homolog 1 Gene | Roundabout Guidance Receptor 1 wt Allele | Roundabout, Axon Guidance Receptor, Homolog 1 (Drosophila) Gene | Roundabout, Axon Guidance Receptor, Homolog 1 Gene | Roundabout, Drosophila, Homolog of, 1 Gene | SAX3 | SAX3, C. elegans, Homolog of, 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0755410","roundabout, axon guidance receptor, homolog 1 (Drosophila) protein, human","C126590","Roundabout homolog 1 (1651 aa, ~181 kDa) is encoded by the human ROBO1 gene. This protein is involved in neuronal development.","Roundabout Homolog 1 | Deleted in U Twenty Twenty | H-Robo-1 | ROBO1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474518","Digital Tomosynthesis","C126695","An imaging technique in which multiple X-rays of an object are take from a discrete number of angles. These cross-sectional images are used to reconstruct 3-D images of the object being scanned. Tomosynthesis differs from computed tomography because the range of angles used is less than 360 degrees, as used in computed tomography.","Digital Tomosynthesis | DT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508093","Stationary Digital Tomosynthesis","C126696","Digital tomosynthesis that uses an array of x-ray sources to obtain cross-sectional images of an object for 3-D image construction. Stationary digital tomosynthesis eliminates the blur associated with a moving x-ray source and also decreases the time needed to obtain the images.","Stationary Digital Tomosynthesis | s-DT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412434","Digital Chest Tomosynthesis","C126697","Digital tomosynthesis used to image structures in the thoracic cavity.","Digital Chest Tomosynthesis | Digital Tomosynthesis of Chest | Digital Tomosynthesis of Thorax",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508092","Stationary Digital Chest Tomosynthesis","C126698","Stationary digital tomography used to image structures in the thoracic cavity.","Stationary Digital Chest Tomosynthesis | s-DCT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508243","Complete Response in GvHD","C126699","No value exists.","Complete Response in GvHD | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0077238","Trioxifene","C1266","A nonsteroidal selective estrogen receptor modulator (SERM) with potential antineoplastic activity.  Trioxifene competes with estradiol in binding to estrogen receptor alpha (ER alpha), thereby inhibiting ER alpha-mediated signal transduction and gene expression. In addition, trioxifene exerts intrinsic estrogenic activity depending on the tissue. Clinical development of trioxifene has not been preceded due to its side effect profile and lack of increased efficacy over tamoxifen.","Trioxifene | (3,4-Dihydro-2-(4-methoxyphenyl)-1-naphthalenyl)(4-(2-(1-pyrrolidinyl)ethoxy)phenyl) Methanone | TRIOXIFENE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505071","Imipramine Blue","C126638","A triphenylmethane-based dye and an inhibitor of nicotinamide adenine dinucleotide phosphate (NADP+) oxidase 4 (NOX4), with potential anti-invasive and anti-oxidative activities. Upon administration, imipramine blue (IB) inhibits the activity of NOX4 and prevents NOX4-mediated cell signaling. This prevents the formation of NOX4-mediated reactive oxygen species (ROS), abrogates the ROS-induced inhibition of protein tyrosine phosphatase (PTP) activation, and induces both G2/M cell cycle arrest and apoptosis. NOX4, an enzyme belonging to the NOX family of proteins, promotes the production of ROS and plays a key role in the suppression of PTP activation; it is upregulated in a variety of cancers.","Imipramine Blue | IB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505072","Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014","C126639","A defined preparation of CD4+ and CD8+ central memory (CM) autologous T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-CD19 single chain variable fragment (scFv) fused to the signaling domains of CD28, 4-1BB (CD137), the zeta chain of the TCR/CD3 complex (CD3-zeta), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+CM T-lymphocytes JCAR014 are directed to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a cetuximab-induced antibody dependent cellular cytotoxicity (ADCC) response. The 4-1BB costimulatory signaling domain enhances both proliferation of T-cells and antitumor activity.","Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014 | Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ CM T-lymphocytes JCAR014 | JCAR014",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505073","GS 5829","C126640","An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, alobresib binds to the acetylated lysine recognition motifs in the bromodomains of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of proliferation in BET-overexpressing tumor cells. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.","Alobresib | (2-Cyclopropyl-6-(3,5-dimethyl-1,2-oxazol-4-yl)-1hbenzimidazol-4-yl)(dipyridin-2-yl)methanol | ALOBRESIB | GS 5829 | GS-5829 | GS5829",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505074","CDC7 inhibitor TAK-931","C126641","An orally bioavailable inhibitor of cell division cycle 7 (cell division cycle 7-related protein kinase; CDC7), with potential antineoplastic activity. Upon administration, simurosertib binds to and inhibits CDC7; this prevents the initiation of DNA replication during mitosis, which causes cell cycle arrest and induces apoptosis. This inhibits cell growth in CDC7-overexpressing tumor cells. CDC7, a serine/threonine kinase and cell division cycle protein, is overexpressed in a variety of cancers and plays a key role in the activation of DNA replication and the regulation of cell cycle progression.","Simurosertib | Cell Division Cycle 7 Inhibitor TAK-931 | SIMUROSERTIB | TAK 931 | TAK-931 | Thieno(3,2-d)pyrimidin-4(3H)-one, 2-(2S)-1-Azabicyclo(2.2.2)oct-2-yl-6-(3-methyl-1H-pyrazol-4-yl)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503759","sustained-release mitomycin C hydrogel formulation","C126642","A sustained-release (SR) hydrogel polymer-based formulation containing the antineoplastic antibiotic mitomycin C (MMC), with potential antineoplastic activity. Upon local administration of the SR MMC hydrogel formulation to the upper urinary tract via a ureteral catheter, the gel solidifies and deposits MMC locally to prevent the excretion of this chemotherapeutic agent via urinary flow. In turn, MMC alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis. Due to its reverse thermal-gelation properties, this gel is able to stay in a liquid state at cold temperatures and solidifies at body temperature. This allows for increased accumulation of MMC locally in the upper urinary tract which leads to increased efficacy compared to standard intravesical delivery of MMC for upper tract urothelial carcinoma (UTUC).","Sustained-release Mitomycin C Hydrogel Formulation UGN-101 | MP77-08 | Mitogel | RTGel with MMC | RTGel with Mitomycin C | SR Mitomycin C | Sustained-release Mitomycin C Gel Formulation | Sustained-release Mitomycin C Hydrogel Formulation | UGN-101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504868","Immunodeficiency of Unknown Origin","C126296","A condition of compromised immune function resulting from an uncharacterized defect.","Immunodeficiency of Unknown Origin | Unidentified Immunodeficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504869","Vector of Transplantation Incompatibility","C126297","Refers to the direction of allorecognition between donor and recipient.","Vector of Transplantation Incompatibility | Vector of HLA Allele Mismatch | Vector of Incompatibility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504871","Unidirectional HLA Mismatch","C126299","The state when a recipient of a hematopoietic stem cell transplantation is not fully matched with their unrelated adult volunteer donor for HLA-A, HLA-B, HLA-C, and HLA-DRB1 and either the recipient or donor is heterozygous at one locus. Occurs when only the donor or recipient is homozygous.","Unidirectional HLA Mismatch | Unidirectional HLA Allele Mismatch | Unidirectional HLA Locus Mismatch",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504454","Expanded DRS-PI Caregiver Version - Work With Frequent Supervision and Support","C125802","Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) How certain are you that [name] can be able to work at home or in a special setting like a sheltered workshop in which the work is very routine and there is very frequent supervision and support?","Expanded DRS-PI Caregiver Version - Work With Frequent Supervision and Support | ED1-Work With Frequent Support | ED108_7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504455","Expanded DRS-PI Survivor Version - Give Correct Date and Time When Asked","C125803","Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Are you able to give the correct date and time within a few seconds of being asked?","Expanded DRS-PI Survivor Version - Give Correct Date and Time When Asked | ED2-Correct Date and Time | ED202_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504456","Expanded DRS-PI Survivor Version - Feed Yourself Independently Without Help","C125804","Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Can you feed yourself independently or manage tube feedings appropriately without help or reminders?","Expanded DRS-PI Survivor Version - Feed Yourself Independently Without Help | ED2-Feed Independently Without Help | ED204_1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504457","Expanded DRS-PI Survivor Version - Understand Feeding Utensils","C125805","Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Do you understand what eating or feeding utensils or equipment are for and how they should be used?","Expanded DRS-PI Survivor Version - Understand Feeding Utensils | ED2-Understand Feeding Utensils | ED204_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504458","Expanded DRS-PI Survivor Version - Know Meal Times","C125806","Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Do you know when meal or feeding times are?","Expanded DRS-PI Survivor Version - Know Meal Times | ED2-Know Meal Times | ED204_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504459","Expanded DRS-PI Survivor Version - Use Toilet Independently","C125807","Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Can you use the toilet or manage your bowel and bladder routine independently and appropriately without help or reminders?","Expanded DRS-PI Survivor Version - Use Toilet Independently | ED2-Use Toilet Independently | ED205_1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504460","Expanded DRS-PI Survivor Version - Manage Clothing When Toileting","C125808","Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Do you understand how to manage your clothing or special equipment when toileting or in bowel and bladder management?","Expanded DRS-PI Survivor Version - Manage Clothing When Toileting | ED2-Manage Clothing When Toileting | ED205_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826442","NLRX1 Gene","C126591","This gene plays a role in the response to virus.","NLRX1 Gene | NLR Family Member X1 Gene | NLRX1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505045","NLRX1 wt Allele","C126592","Human NLRX1 wild-type allele is located in the vicinity of 11q23.3 and is approximately 17 kb in length. This allele, which encodes NLR family member X1 protein, is involved in antiviral signaling.","NLRX1 wt Allele | CLR11.3 | DLNB26 | NLR Family Member X1 wt Allele | NLR Family, X1 Gene | NOD-Like Receptor X1 Gene | NOD26 | NOD5 | NOD9 | Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat Containing X1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504700","bendamustine-vorinostat fusion molecule EDO-S101","C126105","An alkylating histone-deacetylase inhibitor (HDACi) fusion molecule composed of the alkylating agent bendamustine fused to the pan-HDACi vorinostat, with potential bi-functional antineoplastic activity. Upon administration of tinostamustine the vorinostat moiety targets and binds to HDACs. This leads to an accumulation of highly acetylated histones, which results in an induction of chromatin remodeling, a modulation of gene expression, an inhibition of tumor cell division and the induction of tumor cell apoptosis. The bendamustine moiety binds to, alkylates and crosslinks macromolecules, inhibiting DNA, RNA and protein synthesis, which also results in tumor cell apoptosis. Thus, tinostamustine shows superior efficacy compared to the activity of either agent alone. In addition, the inhibition of HDAC6 activity by tinostamustine induces the activation of inositol-requiring enzyme 1 (IRE-1), the key regulatory protein for the unfolded protein response (UPR). Induction of the UPR increases the sensitivity of certain cancer cell types to certain chemotherapeutic agents, such as proteasome inhibitors. Therefore, tinostamustine may work synergistically with proteasome inhibitors. HDACs, enzymes that deacetylate chromatin histone proteins, are overexpressed in various cancers and play a key role in proliferation and resistance of tumor cells.","Tinostamustine | 1H-Benzimidazole-2-heptanamide, 5-(Bis(2-chloroethyl)amino)-N-hydroxy-1-methyl- | 7-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)-N-hydroxyheptanamide | EDO-S 101 | EDO-S-101 | EDO-S101 | TINOSTAMUSTINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004385","Preganglionic Autonomic Fiber","C12624","An axon that projects from a nerve cell body within the central nervous system and innervates a cell within an autonomic ganglia. Preganglionic sympathetic fibers use acetylcholine as transmitters, sometimes with peptide cotransmitters.","Preganglionic Autonomic Fiber | Autonomic Fibers, Preganglionic | Preganglionic Fiber",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021792","Interneuron","C12625","A type of neuron in the central nervous system that conducts impulses between other neurons.","Interneuron | Connector Neuron | Intercalary Neuron | Intercalated Neuron | Intercalated Neurons | Interneurons | Internuncial Cell | Internuncial Neuron",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027836","Glial Cell","C12615","A non-neuronal cell of the nervous system. Glial cells have diverse roles, including in regulation of neuronal survival and differentiation, maintenance of ion and neurotransmitter concentrations in the neuronal environment, synapse formation, and support of synaptic interactions and electrical signal propagation.","Glial Cell | Glia | Glial Cells | Kolliker Reticulum | Neuroglia | Neuroglial Cell | Neuroglial Cells | glial cell | neuroglia",,,,,,,,,,,,,,,"4063403","Glial cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504461","Expanded DRS-PI Survivor Version - Know When to Use Toilet","C125809","Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Do you know when to use the toilet or to conduct bowel and bladder management?","Expanded DRS-PI Survivor Version - Know When to Use Toilet | ED2-Know When to Use Toilet | ED205_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516470","Chief Cell","C12580","One of three cell types that are found in the gastric or parathyroid glands, or in the carotid body. Gastric chief cells secrete pepsinogen and chymosin. Parathyroid chief cells secrete parathyroid hormone. Type 1 (chief) cells in the carotid body contain neurosecretory vesicles that may play a role in chemoreception.","Chief Cell | Chief Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504462","Expanded DRS-PI Survivor Version - Can Dress and Groom Self Independently","C125810","Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Can you dress and groom yourself independently and appropriately or direct someone else in these activities without help or reminders?","Expanded DRS-PI Survivor Version - Can Dress and Groom Self Independently | ED2-Can Dress/Groom Independently | ED206_1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504463","Expanded DRS-PI Survivor Version - Know How to Bathe and Wash","C125811","Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Do you know how to bathe and wash?","Expanded DRS-PI Survivor Version - Know How to Bathe and Wash | ED2-Know How to Bathe/Wash | ED206_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504464","Expanded DRS-PI Survivor Version - Understand How to Get Dressed","C125812","Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Do you understand how to get dressed?","Expanded DRS-PI Survivor Version - Understand How to Get Dressed | ED2-Understand How to Get Dressed | ED206_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504465","Expanded DRS-PI Survivor Version - Start and Finish Grooming Activities","C125813","Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Can you start and finish these grooming activities without prompting?","Expanded DRS-PI Survivor Version - Start and Finish Grooming Activities | ED2-Start/Finish Grooming Activities | ED206_4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414073","DLST Gene","C126540","This gene plays a role in both the citric acid cycle and lysine degradation.","DLST Gene | DLST | Dihydrolipoamide S-Succinyltransferase (E2 Component of 2-Oxo-Glutarate Complex) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504701","Fluorine F 18 Clofarabine","C126106","A radioconjugate composed of the nucleoside analog and deoxycytidine kinase (DCK)-dependent pro-drug clofarabine (Cl-F-ara-A) linked to the radioisotope fluorine F 18, with potential imaging activity using positron emission tomography/computed tomography (PET/CT). Upon administration of fluorine F 18 clofarabine, the clofarabine moiety is preferentially taken up by and accumulates in cells with dysregulated nucleoside metabolism, including tumor cells expressing high levels of DCK. The clofarabine moiety is phosphorylated by DCK into its active triphosphate form, Cl-F-ara-ATP. The 18F moiety can be visualized by PET imaging.  As many nucleoside analog prodrugs are chemotherapeutic agents that require DCK for their phosphorylation and activation, fluorine F 18 clofarabine can potentially be used as a marker to measure DCK activity and to predict the chemotherapeutic efficacy of DCK-dependent prodrugs. DCK, a rate-limiting enzyme in the deoxyribonucleoside salvage pathway for DNA synthesis, is overexpressed in certain solid tumors, lymphoid and myeloid malignancies and certain immune cells, such as proliferating T-lymphocytes. Compared to other nucleoside analogs, clofarabine is not susceptible to deamination by cytidine deaminase (CDA).","Fluorine F 18 Clofarabine | 18F-CA | 18F-Clofarabine | 2-Chloro-9-(2'-deoxy-2'-18F-fluoro-beta-D-arabinofuranosyl)adenine | Cl-18F-ara-A | [18F]-Clofarabine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL414327","Olfactory Receptor Neuron","C12633","A bipolar neuron located in the sensory epithelium within the nasal cavity that detects odor signal molecules and transmits olfactory information to the central nervous system.","Olfactory Receptor Neuron | Olfactory Receptor Cell | Olfactory Receptor Cells | Olfactory Receptor Neurons",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504416","ASEX-Female Version - Sexually Aroused","C125764","Arizona Sexual Experiences Scale-Female Version (ASEX-Female Version) How easily are you sexually aroused (turned on)?","ASEX-Female Version - Sexually Aroused | ASEX01-Sexually Aroused | ASEX0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504417","ASEX-Female Version - Vagina Become Moist","C125765","Arizona Sexual Experiences Scale-Female Version (ASEX-Female Version) How easily does your vagina become moist or wet during sex?","ASEX-Female Version - Vagina Become Moist | ASEX01-Vagina Become Moist | ASEX0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504418","ASEX-Female Version - Reach Orgasm","C125766","Arizona Sexual Experiences Scale-Female Version (ASEX-Female Version) How easily can you reach an orgasm?","ASEX-Female Version - Reach Orgasm | ASEX01-Reach Orgasm | ASEX0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504419","ASEX-Female Version - Orgasms Satisfying","C125767","Arizona Sexual Experiences Scale-Female Version (ASEX-Female Version) Are your orgasms satisfying?","ASEX-Female Version - Orgasms Satisfying | ASEX01-Orgasms Satisfying | ASEX0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504420","ASEX-Male Version - Sex Drive","C125768","Arizona Sexual Experiences Scale-Male Version (ASEX-Male Version) How strong is your sex drive?","ASEX-Male Version - Sex Drive | ASEX02-Sex Drive | ASEX0201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504421","ASEX-Male Version - Sexually Aroused","C125769","Arizona Sexual Experiences Scale-Male Version (ASEX-Male Version) How easily are you sexually aroused (turned on)?","ASEX-Male Version - Sexually Aroused | ASEX02-Sexually Aroused | ASEX0202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524980","Enterochromaffin-Like Cell","C12576","A type of enteroendocrine cell located in the oxyntic glands of the stomach that releases histamine in regulation of acid secretion. It is morphologically similar to enterochromaffin cells, but lacks an affinity to binding silver salts.","Enterochromaffin-Like Cell | ECL Cell | ECL Cells | Enterochromaffin-like Cells",,,,,,,,,,,,,,,"4030873","Enterochromaffin-like cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504422","ASEX-Male Version - Keep Erection","C125770","Arizona Sexual Experiences Scale-Male Version (ASEX-Male Version) Can you easily get and keep an erection?","ASEX-Male Version - Keep Erection | ASEX02-Keep Erection | ASEX0203",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504423","ASEX-Male Version - Reach Orgasm","C125771","Arizona Sexual Experiences Scale-Male Version (ASEX-Male Version) How easily can you reach an orgasm?","ASEX-Male Version - Reach Orgasm | ASEX02-Reach Orgasm | ASEX0204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504424","ASEX-Male Version - Orgasms Satisfying","C125772","Arizona Sexual Experiences Scale-Male Version (ASEX-Male Version) Are your orgasms satisfying?","ASEX-Male Version - Orgasms Satisfying | ASEX02-Orgasms Satisfying | ASEX0205",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504426","Expanded DRS-PI Caregiver Version - How They Communicate Primarily","C125774","Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) How do they communicate primarily?","Expanded DRS-PI Caregiver Version - How They Communicate Primarily | ED1-How They Communicate Primarily | ED102_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504427","Expanded DRS-PI Caregiver Version - Give Correct Date and Time When Asked","C125775","Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Is [name] able to give the correct date and time within a few seconds of being asked?","Expanded DRS-PI Caregiver Version - Give Correct Date and Time When Asked | ED1-Correct Date and Time | ED102_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504428","Expanded DRS-PI Caregiver Version - Use Few Words or Random Shouting","C125776","Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [name] have only a few words that [s/he] uses over and over or does [s/he] express him/herself only through random answers, shouting or swearing?","Expanded DRS-PI Caregiver Version - Use Few Words or Random Shouting | ED1-Few Words or Random Answers/Shouting | ED102_4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504942","Bronchial Epithelial Dysplasia","C126401","A non-invasive, precancerous lesion in the bronchial epithelium. Depending on the morphologic features it is classified as columnar cell dysplasia, basal cell dysplasia, squamous dysplasia, or bronchial epithelial dysplasia with transitional differentiation.","Bronchial Epithelial Dysplasia | Endobronchial Dysplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504943","Near-Infrared Fluorescence Imaging","C126402","Fluorescence imaging using dyes that fluoresce in the near-infrared range. NIR optical imaging permits relatively deep photon penetration into tissue, minimal tissue auto-fluorescence, less scatter, and high optical contrast.","Near-Infrared Fluorescence Imaging | NIR Fluorescence Imaging | NIR Optical Imaging | NIRF | Near Infrared Fluoroscopy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504949","Cribriform-Morular Variant Thyroid Gland Papillary Cancer","C126408","A thyroid gland carcinoma characterized by the presence of cribriform, trabecular, follicular, papillary, and solid growth patterns and squamoid morulae formation. It may occur with familial adenomatous polyposis or sporadically.","Thyroid Gland Cribriform Morular Carcinoma | CMTC | Cribriform Morular Thyroid Gland Carcinoma | Cribriform-Morular Variant Thyroid Gland Papillary Cancer | Cribriform-Morular Variant Thyroid Gland Papillary Carcinoma | Cribriform-Morular Variant Thyroid Gland Papillary Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504950","Warthin Tumor-Like Variant Thyroid Gland Papillary Cancer","C126409","A rare variant of papillary thyroid gland carcinoma characterized by the presence of eosinophilic large cells lining the papillae and a brisk lymphoplasmacytic infiltrate in the papillary stalks.","Warthin-Like Variant Thyroid Gland Papillary Carcinoma | Warthin Tumor-Like Variant Thyroid Gland Papillary Cancer | Warthin Tumor-Like Variant Thyroid Gland Papillary Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0752062","Posterior Horn Cell","C12640","Neurons in the posterior (dorsal) horn of the spinal cord whose cell bodies and processes are confined entirely to the central nervous system. They receive collateral or direct terminations of dorsal root fibers. They send their axons either directly to anterior horn cells or to the white matter ascending and descending longitudinal fibers.","Posterior Horn Cell | Dorsal Horn Cells | Neurons, Dorsal Horn | Neurons, Posterior Horn | Posterior Horn Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504951","Nodular Fasciitis-like Stroma Variant Thyroid Gland Papillary Cancer","C126410","A rare morphologic variant of papillary thyroid gland carcinoma characterized by the presence of abundant and cellular stroma resembling nodular fasciitis, fibromatosis, or other proliferative myofibroblastic processes. (WHO)","Thyroid Gland Papillary Carcinoma with Fibromatosis/Fasciitis-Like/Desmoid-Type Stroma | Nodular Fasciitis-Like Stroma Variant Thyroid Gland Papillary Carcinoma | Nodular Fasciitis-like Stroma Variant Thyroid Gland Papillary Cancer | Thyroid Gland Papillary Carcinoma with Fibromatosis/Fasciitis-Like Stroma | Thyroid Gland Papillary Carcinoma with Fibromatosis/Fasciitis-Like Stroma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505028","DLST wt Allele","C126541","Human DLST wild-type allele is located in the vicinity of 14q24.3 and is approximately 22 kb in length. This allele, which encodes dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial protein, is involved in both lysine degradation and the tricarboxylic acid cycle.","DLST wt Allele | Alpha-Ketoglutarate Dehydrogenase Complex, E2 Component of Gene | DLTS | Dihydrolipoamide S-Succinyltransferase (E2 Component of 2-Oxo-Glutarate Complex) wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505083","Dihydrolipoyllysine-Residue Succinyltransferase Component of 2-Oxoglutarate Dehydrogenase Complex, Mitochondrial","C126542","Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial (453 aa, ~49 kDa) is encoded by the human DLST gene. This protein plays a role in both the Krebs cycle and lysine catabolism.","Dihydrolipoyllysine-Residue Succinyltransferase Component of 2-Oxoglutarate Dehydrogenase Complex, Mitochondrial | 2-Oxoglutarate Dehydrogenase Complex Component E2 | Dihydrolipoamide S-Succinyltransferase | Dihydrolipoamide Succinyltransferase Component of 2-Oxoglutarate Dehydrogenase Complex | E2K | EC 2.3.1.61 | OGDC-E2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414910","GABRA3 Gene","C126543","This gene is involved in neurotransmission and ligand-gated ion transport.","GABRA3 Gene | GABRA3 | Gamma-Aminobutyric Acid Type A Receptor Alpha3 Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505029","GABRA3 wt Allele","C126544","Human GABRA3 wild-type allele is located in the vicinity of Xq28 and is approximately 285 kb in length. This allele, which encodes gamma-aminobutyric acid receptor subunit alpha-3 protein, plays a role in both the inhibition of neurotransmission and chloride transport.","GABRA3 wt Allele | GABA(A) Receptor, Alpha 3 Gene | Gaba-A Receptor, Alpha-3 Polypeptide Gene | Gamma-Aminobutyric Acid (GABA) A Receptor, Alpha 3 Gene | Gamma-Aminobutyric Acid Receptor, Alpha-3 Gene | Gamma-Aminobutyric Acid Type A Receptor Alpha3 Subunit wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505030","GP1BA wt Allele","C126547","Human GP1BA wild-type allele is located in the vicinity of 17p13.2 and is approximately 3 kb in length. This allele, which encodes platelet glycoprotein Ib alpha chain protein, is involved in the regulation of blood coagulation. Mutation of the gene is associated with Bernard-Soulier syndrome type A1 and platelet-type von Willebrand disease and with increased susceptibility to nonarteritic anterior ischemic optic neuropathy.","GP1BA wt Allele | BDPLT1 | BDPLT3 | BSS | CD42B | CD42b-alpha | DBPLT3 | GP Ib, Alpha Subunit Gene | GP1B | GPIbA | GPIbalpha | Glycoprotein Ib (Platelet), Alpha Polypeptide Gene | Glycoprotein Ib Platelet Alpha Subunit wt Allele | Glycoprotein Ib, Platelet, Alpha Polypeptide Gene | Platelet Glycoprotein Ib, Alpha Polypeptide Gene | VWDP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504507","PHQ Screener Version - Anxiety Attack Short of Breath","C125855","Patient Health Questionnaire Screener Version (PHQ Screener Version) Think about your last bad anxiety attack. Were you short of breath?","PHQ Screener Version - Anxiety Attack Short of Breath | PHQ03-Anxiety Attack Short of Breath | PHQ0304A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504508","PHQ Screener Version - Anxiety Attack Heart Race or Pound","C125856","Patient Health Questionnaire Screener Version (PHQ Screener Version) Think about your last bad anxiety attack. Did your heart race, pound, or skip?","PHQ Screener Version - Anxiety Attack Heart Race or Pound | PHQ03-Anxiety Attack Heart Race/Pound | PHQ0304B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504509","PHQ Screener Version - Anxiety Attack Chest Pain","C125857","Patient Health Questionnaire Screener Version (PHQ Screener Version) Think about your last bad anxiety attack. Did you have chest pain or pressure?","PHQ Screener Version - Anxiety Attack Chest Pain | PHQ03-Anxiety Attack Chest Pain | PHQ0304C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504511","PHQ Screener Version - Anxiety Attack Choking","C125859","Patient Health Questionnaire Screener Version (PHQ Screener Version) Think about your last bad anxiety attack. Did you feel as if you were choking?","PHQ Screener Version - Anxiety Attack Choking | PHQ03-Anxiety Attack Choking | PHQ0304E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0682610","Enterocyte","C12585","A type of epithelial cell that lines the intestines and colon. It participates in the absorption of water and nutrients from the intestinal lumen, and in the secretion of digestive enzymes.","Enterocyte | Enterocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504512","PHQ Screener Version - Anxiety Attack Hot Flash or Chill","C125860","Patient Health Questionnaire Screener Version (PHQ Screener Version) Think about your last bad anxiety attack. Did you have hot flashes or chills?","PHQ Screener Version - Anxiety Attack Hot Flash or Chill | PHQ03-Anxiety Attack Hot Flash/Chill | PHQ0304F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504429","Expanded DRS-PI Caregiver Version - Make Sounds Not Understandable","C125777","Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [name] only moan, groan or make other sounds that are not understandable?","Expanded DRS-PI Caregiver Version - Make Sounds Not Understandable | ED1-Moan/Groan/Sounds Not Understandable | ED102_5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504430","Expanded DRS-PI Caregiver Version - Feed Independently Without Help","C125778","Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Can [name] feed him/herself independently or manage tube feedings appropriately without help or reminders?","Expanded DRS-PI Caregiver Version - Feed Independently Without Help | ED1-Feed Independently Without Help | ED104_1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004384","Postganglionic Autonomic Fiber","C12648","An axon that projects from a nerve cell body within an autonomic ganglion and innervates an effector cell within a target organ.","Postganglionic Autonomic Fiber | Autonomic Fibers, Postganglionic | Postganglionic Fiber",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0068604","neuromedin N","C126491","Neuromedin N (5 aa, ~1 kDa) is encoded by the human NTS gene. This protein may play a role in antimicrobial activity.","Neuromedin N | IPYIL | Ile-Pro-Tyr-Ile-Leu | NN | NmN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0865093","Benign Uterine Ligament Neoplasm","C126493","A neoplasm that arises from the broad or other uterine ligaments and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Uterine Ligament Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505011","PENK wt Allele","C126494","Human PENK wild-type allele is located in the vicinity of 8q12.1 and is approximately 10 kb in length. This allele, which encodes proenkephalin-A protein, plays a role in opioid receptor signaling.","PENK wt Allele | Enkephalin A Gene | PE | PENK-A | Proenkephalin wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505012","PENK Gene Product","C126495","A protein encoded by the PENK gene.","PENK Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0138352","Proenkephalin-A","C126496","Proenkephalin-A (267 aa, ~31 kDa) is encoded by the human PENK gene. This protein is involved in opioid receptor signaling.","Proenkephalin-A | Preproenkephalin | Preproenkephalin A | Preproenkephalin-A | Proenkephalin | Proenkephalin A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014295","Met-Enkephalin","C126497","Met-enkephalin (5 aa, ~1 kDa) is encoded by the human PENK and POMC genes. This protein plays a role in the activation of delta opioid receptors.","Met-Enkephalin | OGF | Opioid Growth Factor | Tyr-Gly-Gly-Phe-Met | YGGPM | [Met(5)]-Enkephalin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014294","Leu-Enkephalin","C126499","Leu-enkephalin (5 aa, ~1 kDa) is encoded by the human PENK gene. This protein is involved in the activation of mu and delta opioid receptors.","Leu-Enkephalin | Tyr-Gly-Gly-Phe-Leu | YGGPL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206252","Postganglionic Parasympathetic Fiber","C12649","An axon that projects from a nerve cell body within a parasympathetic ganglion and innervates an effector cell within a target organ. Postganglionic parasympathetic fibers use acetylcholine as transmitters, sometimes with peptide cotransmitters.","Postganglionic Parasympathetic Fiber | Parasympathetic Fibers, Postganglionic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504952","Prominent Stromal Reaction","C126411","A morphologic finding indicating the presence of an exuberant proliferation of fibroblasts and myofibroblasts in the stroma of a tumor sample.","Prominent Stromal Reaction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504953","VEGFA Gene Product","C126412","A protein encoded by the VEGFA gene.","VEGFA Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504551","STING-activating Cyclic Dinucleotide Agonist MIW815","C125902","A synthetic, cyclic dinucleotide (CDN) and agonist of stimulator of interferon genes protein (STING; transmembrane protein 173; TMEM173), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration, the STING agonist MIW815 binds to STING and stimulates STING-mediated pathways. This activates the immune response through the activation of certain immune cells, including dendritic cells (DCs), which induces the expression of cytokines and chemokines, and leads to an antigen-specific T-cell mediated immune response against cancer cells. STING, a transmembrane protein that activates immune cells in the tumor microenvironment, plays a key role in the activation of the innate immune system.","STING-activating Cyclic Dinucleotide Agonist MIW815 | ADU-S100 | CDN Agonist ADU-S100 | MIW815",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504552","CD24 extracellular domain-IgG1 Fc domain recombinant fusion protein CD24Fc","C125903","A recombinant fusion protein composed of the extracellular domain of the mature human glycoprotein CD24 linked to a human immunoglobulin G1 (IgG1) Fc domain, with potential immune checkpoint inhibitory, anti-inflammatory and antineoplastic activities. Upon administration, efprezimod alfa binds to injured cell components, also called DAMPs (Danger-Associated Molecular Patterns), thereby preventing the interaction of DAMPs with toll-like receptors (TLRs) and inhibiting both nuclear factor-kappa B (NFkB) activation and secretion of inflammatory cytokines. In addition, efprezimod alfa binds to and activates Siglec G/10, a sialic acid-binding immunoglobulin-type lectin, and stimulates SHP-1-mediated inhibitory signaling, while also preventing NFkB activation and secretion of inflammatory mediators, which further prevents inflammatory responses. DAMPs activate the innate immune system. CD24 binds to both DAMPs and Siglec G/10 to regulate immune responses.CD24/Siglec G/10 interaction plays a key role in a number of immune-mediated diseases including graft-versus-host disease (GvHD), multiple sclerosis and rheumatoid arthritis.","Efprezimod Alfa | CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc | CD24Fc | CD24Fc CD24IgG | EFPREZIMOD ALFA | MK-7110 | SACCOVID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504655","Percent Change From Nadir in Sum of Area","C126057","The most recently recorded sum of areas minus the lowest sum of diameters previously recorded divided by the lowest sum of areas previously recorded, multiplied by 100.","Percent Change From Nadir in Sum of Area | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504660","Protocol Keyword","C126062","A word or small set of words designed to convey the subject of a clinical study.","Protocol Keyword | KEYWORD | Keyword",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0077070","Triciribine Phosphate","C1262","The phosphate salt of the synthetic, cell-permeable tricyclic nucleoside triciribine with potential antineoplastic activity. Triciribine inhibits the phosphorylation, activation, and signalling of Akt-1, -2, and -3, which may result in the inhibition of Akt-expressing tumor cell proliferation. Akts are anti-apoptotic serine/threonine-specific protein kinases that phosphorylate and inactivate components of the apoptotic machinery, including Bcl-xL/Bcl-2-associated death promoter (BAD) and caspase 9.","Triciribine Phosphate | 1, 5-Dihydro-5-methyl-1-(5-O-phosphono-.beta.-D-ribofuranosyl)-1,4,5, 6,8-pentaazaacenaphthylen-3-amine | 1, 5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-1,4,5, 6,8-pentaazaacenaphthylen-3-amine | 1,4, 5,6,8-Pentaazaacenaphthylen-3-amine, 1, 5-dihydro-5-methyl-1-(5-O-phosphono-.beta.-D-ribofuranosyl)- (9CI) | 1,4, 5,6,8-pentaazaacenaphthylen-3-amine, 1, 5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)- (9CI) | 1,4,5,6, 8-Pentaazaacenaphthalen-3-amine, 1, 5-dihydro-5-methyl-1-(5-O-phosphono-.beta.-D-ribofuranosyl)- | 1,4,5,6, 8-pentaazaacenaphthalen-3-amine, 1, 5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl) | 3-Amino-1, 5-dihydro-5-methyl-1-.beta.-D-ribofuranosyl-1,4,5,6, 8-pentaazaacenaphthylene 5'-(dihydrogen phosphate) | 3-amino-1, 5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6, 8-pentaazaacenaphthylene 5'-(dihydrogen phosphate) | TCN | TRICIRIBINE PHOSPHATE | Triciribine | Tricyclic Nucleoside 5'-Phosphate | Tricycloside Phosphate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504513","PHQ Screener Version - Anxiety Attack Nausea or Diarrhea","C125861","Patient Health Questionnaire Screener Version (PHQ Screener Version) Think about your last bad anxiety attack. Did you have nausea or an upset stomach, or the feeling that you were going to have diarrhea?","PHQ Screener Version - Anxiety Attack Nausea or Diarrhea | PHQ03-Anxiety Attack Nausea/Diarrhea | PHQ0304G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504514","PHQ Screener Version - Anxiety Attack Dizzy or Faint","C125862","Patient Health Questionnaire Screener Version (PHQ Screener Version) Think about your last bad anxiety attack. Did you feel dizzy, unsteady, or faint?","PHQ Screener Version - Anxiety Attack Dizzy or Faint | PHQ03-Anxiety Attack Dizzy/Faint | PHQ0304H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504515","PHQ Screener Version - Anxiety Attack Tingling or Numbness","C125863","Patient Health Questionnaire Screener Version (PHQ Screener Version) Think about your last bad anxiety attack. Did you have tingling or numbness in parts of your body?","PHQ Screener Version - Anxiety Attack Tingling or Numbness | PHQ03-Anxiety Attack Tingling/Numbness | PHQ0304I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504516","PHQ Screener Version - Anxiety Attack Tremble or Shake","C125864","Patient Health Questionnaire Screener Version (PHQ Screener Version) Think about your last bad anxiety attack. Did you tremble or shake?","PHQ Screener Version - Anxiety Attack Tremble or Shake | PHQ03-Anxiety Attack Tremble/Shake | PHQ0304J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504517","PHQ Screener Version - Anxiety Attack Afraid You Were Dying","C125865","Patient Health Questionnaire Screener Version (PHQ Screener Version) Think about your last bad anxiety attack. Were you afraid you were dying?","PHQ Screener Version - Anxiety Attack Afraid You Were Dying | PHQ03-Anxiety Attack Afraid You Dying | PHQ0304K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504518","PHQ Screener Version - Feeling Nervous or Anxious","C125866","Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 4 weeks, how often have you been bothered by feeling nervous, anxious, on edge, or worrying a lot about different things?","PHQ Screener Version - Feeling Nervous or Anxious | PHQ03-Feeling Nervous/Anxious | PHQ0305A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504519","PHQ Screener Version - Feeling Restless","C125867","Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 4 weeks, how often have you been bothered by feeling restless so that it is hard to sit still?","PHQ Screener Version - Feeling Restless | PHQ03-Feeling Restless | PHQ0305B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504521","PHQ Screener Version - Muscle Tension","C125869","Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 4 weeks, how often have you been bothered by muscle tension, aches, or soreness?","PHQ Screener Version - Muscle Tension | PHQ03-Muscle Tension/Aches/Soreness | PHQ0305D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505090","NLR Family Member X1","C126593","NLR family member X1 (975 aa, ~108 kDa) is encoded by the human NLRX1 gene. This protein plays a role in the modulation of antiviral signaling pathways.","NLR Family Member X1 | CLR11.3 | Caterpiller Protein 11.3 | Nucleotide-Binding Oligomerization Domain Protein 26 | Nucleotide-Binding Oligomerization Domain Protein 5 | Nucleotide-Binding Oligomerization Domain Protein 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826729","PSMC3IP Gene","C126595","This gene is involved in meiotic recombination and nuclear receptor-dependent gene regulation.","PSMC3IP Gene | PSMC3 Interacting Protein Gene | PSMC3IP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505047","PSMC3IP wt Allele","C126596","Human PSMC3IP wild-type allele is located in the vicinity of 17q21.2 and is approximately 6 kb in length. This allele, which encodes homologous-pairing protein 2 homolog protein, plays a role in both meiosis and transcriptional activation.","PSMC3IP wt Allele | 26S Proteasome Regulatory Subunit, ATPase 3, Interacting Protein Gene | GT198 | HOP2 | HOP2, S. cerevisiae, Homolog of Gene | HUMGT198A | ODG3 | PSMC3 Interacting Protein wt Allele | TBPIP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0077183","Trimethylcolchicinic Acid","C1264","A colchicine analog with potential antineoplastic activity.  Trimethylcolchicinic acid binds to tubulin, inhibiting its polymerization into microtubules and preventing cell division. (NCI04)","Trimethylcolchicinic Acid | Colchicinic Acid, Trimethyl- | Desacetyl Colchicine D-tartrate | Desacetylcholchiceine | N-Deacetylcolchiceine | SKF 284 | TMCA | TRIMETHYLCOLCHICINIC ACID | Trimethylcolchicinic Acid Methyl Ether d-tartrate | Trimethylcolchicinic acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505013","CD2BP2 wt Allele","C126501","Human CD2BP2 wild-type allele is located in the vicinity of 16p11.2 and is approximately 5 kb in length. This allele, which encodes CD2 antigen cytoplasmic tail-binding protein 2, is involved in T-cell activation and RNA splicing.","CD2BP2 wt Allele | CD2 (Cytoplasmic Tail) Binding Protein 2 wt Allele | CD2 Antigen (Cytoplasmic Tail) Binding Protein 2 Gene | CD2 Antigen (Cytoplasmic Tail)-Binding Protein 2 Gene | FWP010 | KIAA1178 | LIN1 | PPP1R59 | Protein Phosphatase 1, Regulatory Subunit 59 Gene | Snu40 | U5-52K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0320125","Ulocladium","C125978","A genus of saprophytic fungi in the family Pleosporaceae with numerous, usually solitary, multicelled conidia that are typically obovoid, dark brown, and often rough-walled. Ulocladium species are commonly found in the soil and on decaying herbaceous plants but they also grown indoors on cellulose containing materials.","Ulocladium | ULOCLADIUM",,,,,,,,,,,,,,,"4278529","Ulocladium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042122","Ustilago","C125979","A genus of smut fungi in the phylum Basidiomycota with a branched, septate, hyaline, intercellular mycellium, with or without haustoria. Species in this genus infect the floral parts of wheat, barley, oat, maize, sugarcane, rye and wild grasses.","Ustilago | USTILAGO",,,,,,,,,,,,,,,"4173888","Ustilago",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1319192","Vancomycin Resistant Staphylococcus Aureus","C125980","Strains of Staphylococcus aureus that are not readily killed by vancomycin antibiotics. Vancomycin resistance is acquired by mutation and thickening of the cell wall due to accumulation of excess amounts of peptidoglycan.","Vancomycin Resistant Staphylococcus Aureus | STAPHYLOCOCCUS AUREUS, VANCOMYCIN RESISTANT | VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS | VRSA | Vancomycin-Resistant Staphylococcus Aureus | Vancomycin-resistant Staphylococcus aureus",,,,,,,,,,,,,,,"4225532","Vancomycin resistant Staphylococcus aureus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504584","Vancomycin Susceptible Enterococcus","C125981","A non-taxonomic grouping of enterococcus species that are sensitive to vancomycin antibiotics.","Vancomycin Susceptible Enterococcus | VANCOMYCIN SUSCEPTIBLE ENTEROCOCCUS | VSE | Vancomycin-Susceptible Enterococcus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1504662","Verticillium","C125983","A genus of fungi in the phylum Ascomycota. Species in this genus cause verticillium wilt in eudicot plants.","Verticillium | VERTICILLIUM",,,,,,,,,,,,,,,"4174679","Verticillium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1022442","Vorticella","C125984","A genus of stalked, inverted bell-shaped, ciliated protozoa in the phylum Ciliophora.","Vorticella | VORTICELLA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022891","Supporting Cell of Organ of Corti","C12590","One of the non-sensory cells that compose the supporting structures of the Organ of Corti.","Supporting Cell of Organ of Corti | Labyrinth Supporting Cell | Labyrinth Supporting Cells",,,,,,,,,,,,,,,"4150929","Structure of supporting cell of organ of Corti",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL503760","anti-GITR agonistic monoclonal antibody INCAGN01876","C126643","An anti-human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor superfamily, member 18; TNFRSF18; GITR; CD357) agonistic humanized monoclonal antibody, with potential immune checkpoint modulating activity. Ragifilimab binds to and activates GITRs found on multiple types of T-cells. This stimulates the immune system, induces both the activation and proliferation of tumor-antigen-specific T effector cells (Teff), and suppresses the function of activated T regulatory cells (Tregs). This leads to tumor cell eradication. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B-cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress Teffs and suppress T-cell receptor (TCR) signaling.","Ragifilimab | Anti-GITR Agonistic Monoclonal Antibody INCAGN01876 | INCAGN 01876 | INCAGN 1876 | INCAGN-1876 | INCAGN01876 | RAGIFILIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503761","Anti-VEGF/ANG2 Nanobody BI 836880","C126644","A nanobody directed against angiopoietin-2 (Ang2; ANGPT2)- and vascular endothelial growth factor (VEGF)-derived peptides, with potential antiangiogenic and antineoplastic activities. Anti-VEGF/ANG2 nanobody BI 836880 binds to Ang2 and VEGF and inhibits receptor binding; this prevents Ang2- and VEGF-mediated signaling and inhibits both tumor angiogenesis and tumor cell proliferation. Both VEGF and Ang2 are upregulated in a variety of cancer cell types and play a crucial role in angiogenesis. The nanobody is based on functional fragments of single-chain antibodies.","Anti-VEGF/ANG2 Nanobody BI 836880 | Anti-VEGF/ANG2 BI 836880 | BI 836880 | BI-836880 | Bi-specific Anti-VEGF/Ang2 Nanobody BI 836880",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503762","Dehydrated Human Amnion/Chorion Membrane","C126645","Tissue derived from portions of the placenta donated by the patient during a C-section, with potential regenerative activity. Upon placement of the tissue around or on the affected area, dehydrated human amnion/chorion membrane (dHCAM), which contains regenerative cytokines, promotes wound angiogenesis and may help heal the wound, restore tissue function and reduce risk of inflammation.","Dehydrated Human Amnion/Chorion Membrane | AmnioFix | dHACM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503763","PAK4/NAMPT inhibitor KPT-9274","C126646","An orally bioavailable inhibitor of both the serine/threonine kinase P21-activated kinase 4 (PAK4) and the nicotinamide adenine dinucleotide (NAD)-synthesizing enzyme nicotinamide phosphoribosyltransferase (NAMPT; NAMPRTase), with potential antineoplastic activity. Upon administration, padnarsertib allosterically binds to, destabilizes and causes degradation of PAK4. This inhibits PAK4-mediated signaling, induces cell death in, and inhibits the proliferation of PAK4-overexpressing tumor cells. In addition, padnarsertib binds to and inhibits the activity of NAMPT. This depletes cellular NAD and inhibits NAD-dependent enzymes, both of which are needed for rapid cell proliferation; this results in tumor cell death in NAMPT-overexpressing cancer cells. PAK4, a serine/threonine kinase and member of the PAK family of proteins upregulated in various cancer cell types, regulates cell motility, proliferation and survival. NAMPT, an enzyme that is responsible for maintaining the intracellular NAD pool, plays a key role in the regulation of cellular metabolism and has cytokine-like activities. NAMPT is often overexpressed in a variety of cancers and metabolic disorders and tumor cells rely on NAMPT activity for their NAD supply.","Padnarsertib | ATG 019 | ATG-019 | ATG019 | KCP-9274 | KPT-9274 | PADNARSERTIB | PAK4/NAMPT Inhibitor ATG-019 | PAK4/NAMPT Inhibitor ATG-019 | PAK4/NAMPT Inhibitor KPT-9274",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504872","Bidirectional HLA Mismatch","C126300","The state when a recipient of a hematopoietic stem cell transplantation is not fully matched with their unrelated adult volunteer donor for HLA-A, HLA-B, HLA-C, and HLA-DRB1 and both are heterozygous for different alleles at one locus.","Bidirectional HLA Mismatch | Bidirectional HLA Allele Mismatch | Bidirectional HLA Locus Mismatch",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504876","Dilated Cystic Spaces Present","C126305","A morphologic finding indicating the presence of dilated cystic spaces in the stroma of a neoplasm.","Dilated Cystic Spaces Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1739113","Recurrent Bladder Urothelial Carcinoma","C126307","The reemergence of bladder urothelial carcinoma after a period of remission.","Recurrent Bladder Urothelial Carcinoma | Recurrent Bladder Transitional Cell Carcinoma | Recurrent Bladder Urothelial Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504879","Refractory Adult Acute Lymphoblastic Leukemia","C126309","Acute lymphoblastic leukemia that occurs in adulthood and does not respond to treatment.","Refractory Adult Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia (ALL)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018497","Type I Hair Cell","C12630","A flask-shaped mechanoreceptor cell that detects and transduces head movements into neural impulses and is located within the vestibular systems of mammals, birds, and reptiles.","Type I Hair Cell | Inner Hair Cell | Inner Hair Cells",,,,,,,,,,,,,,,"4330695","Type I hair cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504467","Expanded DRS-PI Survivor Version - Require Special Aids or Equipment","C125815","Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Do you REQUIRE special aids or equipment, such as, a brace, walker, wheelchair, memory notebook, day planner, verbal reminders, prompts, cues, or alarm watch because of a disability?","Expanded DRS-PI Survivor Version - Require Special Aids or Equipment | ED2-Require Specific Aids/Equipment | ED207_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1310336","Homologous-Pairing Protein 2 Homolog, Human","C126597","Homologous-pairing protein 2 homolog (217 aa, ~25 kDa) is encoded by the human PSMC3IP gene. This protein is involved in the pairing of homologous chromosomes during meiosis and coactivation of hormone-dependent transcription.","Homologous-Pairing Protein 2 Homolog | DBD-Interacting | Nuclear Receptor Coactivator GT198 | PSMC3-Interacting Protein | Proteasome 26S ATPase Subunit 3-Interacting Protein | TBP-1 Interacting Protein | TBP-1-Interacting Protein | TBP1-Interacting Protein | Tat-Binding Protein 1-Interacting Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505049","Thyroid Gland Noninvasive Follicular Neoplasm with Papillary-Like Nuclear Features","C126598","A non-invasive neoplasm of thyroid follicular cells with a follicular growth pattern and nuclear features of papillary thyroid carcinoma that has an extremely low malignant potential. These tumors were formerly classified as non-invasive encapsulated follicular variant of papillary thyroid carcinoma or well-differentiated tumor of uncertain malignant potential. (WHO)","Thyroid Gland Noninvasive Follicular Neoplasm with Papillary-Like Nuclear Features | Follicular Thyroid Tumor | NIEFVPTC | NIFTP | Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) | Noninvasive Encapsulated Follicular Variant Papillary Thyroid Gland Carcinoma | Noninvasive Encapsulated Follicular Variant Thyroid Gland Papillary Carcinoma | Noninvasive Follicular Thyroid Gland Neoplasm with Papillary-Like Nuclear Features | Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features | Thyroid Gland Noninvasive Follicular Tumor with Papillary-Like Nuclear Features",,,,,,,,,,,,,,,"37312117","Non-invasive follicular thyroid neoplasm with papillary like nuclear features",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2681372","CT45A2 Gene","C126599","This gene may be involved in testis development and tumorigenesis.","CT45A2 Gene | CT45A2 | Cancer/Testis Antigen Family 45, Member A2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033731","Protoplast","C12659","A bacterial cell deprived of its cell wall, for example by growth in an isotonic medium in the presence of antibiotics that block synthesis of the wall peptidoglycan. Alternatively, a plant cell similarly deprived by enzymic treatment.","Protoplast | Protoplasts",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505050","CT45A2 wt Allele","C126600","Human CT45A2 wild-type allele is located in the vicinity of Xq26.3 and is approximately 18 kb in length. This allele, which encodes cancer/testis antigen family 45 member A2 protein, may play a role in tumorigenesis.","CT45A2 wt Allele | CT45-2 | CT45.2 | Cancer/Testis Antigen Family 45, Member 2 Gene | Cancer/Testis Antigen Family 45, Member A2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505051","Cancer/Testis Antigen Family 45 Member A2","C126601","Cancer/testis antigen family 45 member A2 (189 aa, ~21 kDa) is encoded by the human CT45A2 gene. This protein may be involved in tumorigenesis and testis development.","Cancer/Testis Antigen Family 45 Member A2 | Cancer/Testis Antigen 45-2 | Cancer/Testis Antigen 45A2 | Cancer/Testis Antigen CT45-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823080","SORBS2 Gene","C126602","This gene plays a role in the formation of signaling protein complexes.","SORBS2 Gene | SORBS2 | Sorbin and SH3 Domain Containing 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505052","SORBS2 wt Allele","C126603","Human SORBS2 wild-type allele is located in the vicinity of 4q35.1 and is approximately 371 kb in length. This allele, which encodes sorbin and SH3 domain-containing protein 2, is involved in the positive regulation of signaling.","SORBS2 wt Allele | ARGBP2 | KIAA0777 | PRO0618 | Sorbin and SH3 Domain Containing 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024156","Luteal Cells","C12610","A cell located in the corpus luteum of the ovary that is derived from theca or granulosa cells and secretes progesterone and estrogen or androgens.","Lutein Cell | Luteal Cell | Lutein Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504703","Infant Acute Undifferentiated Leukemia","C126110","An acute undifferentiated leukemia that occurs in infancy.","Infant Acute Undifferentiated Leukemia | Acute Undifferentiated Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504846","iodine I 131 SGMIB-anti-HER2 VHH1","C126269","A radioconjugate composed of a camelid single domain antibody (sdAb) CAM-H2 (VHH1; sdAb 2Rs 15d) directed against human epidermal growth factor receptor 2 (HER2, EGFR2, ERBB2) that is covalently linked via N-succinimidyl 4-guanidinomethyl-3-iodobenzoate (SGMIB) to the radionuclide iodine I 131, with radioimaging and antineoplastic activities. Upon administration of iodine I 131 SGMIB-anti-HER2 CAM-H2, the anti-HER2 antibody moiety targets and binds to HER2-expressing cells. This facilitates both the detection of HER2-expressing tumor cells and the targeted destruction of HER2-positive tumors. HER2, a tyrosine kinase is overexpressed on the cell surfaces of various tumor cell types. CAM-H2 is composed of small (15 kDa), heavy chain-only anti-HER2 antibody fragments that are able to cross the blood-brain barrier (BBB) and are thus potentially useful in the treatment of central nervous system (CNS) metastases.","Iodine I 131 SGMIB-Anti-HER2 CAM-H2 | I-131-CAM H2 | I-131-CAM-H2 | I-131-CAMH2 | I-131-VHH1 | Iodine I 131 N-succinimidyl 4-guanidinomethyl-3-iodobenzoate-Anti-HER2 VHH1 | Iodine I 131 SGMIB-Anti-HER2 VHH1 | Iodine I 131 SGMIB-Anti-HER2 VHH1 | Iodine I 131 SGMIB-Anti-HER2 sdAb 2Rs 15d | [131I]-SGMIB Anti-HER2 VHH1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229216","Amacrine Cell","C12626","A retinal neuron that lacks large axons, having only processes that resemble dendrites.","Amacrine Cell | Amacrine Cell of Retina | Amacrine Cells | Amacrine Cells of Retina",,,,,,,,,,,,,,,"4314626","Amacrine cell of retina",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504847","Autologous HBV-specific TCR-redirected T-Lymphocytes","C126270","A preparation of human autologous T-lymphocytes transduced with a viral vector encoding for a T-cell receptor (TCR) specific for a human hepatitis B virus (HBV) surface antigen (HBsAg), with potential antineoplastic activity. Following administration, the autologous HBV antigen specific TCR-redirected autologous T-lymphocytes recognize and bind to the HBV antigen-positive cells, which induces cytotoxic T-lymphocyte (CTL)-mediated elimination of HBV antigen-positive cancer cells. HBV antigens are found on HBV-positive cells and HPV-induced hepatocellular carcinoma (HCC).","Autologous HBV-specific TCR-redirected T-Lymphocytes | Autologous HBV Antigen-specific TCR-redirected T-Cells | Autologous HBV/TCR-T-Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504848","PI3K p110beta/delta Inhibitor KA2237","C126271","A dual selective inhibitor of the beta and delta isoforms of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K-beta/delta), with potential antineoplastic activity. PI3K-beta/delta inhibitor CVL237 selectively inhibits the PI3K-beta and -delta isoforms and prevents their activation, which inhibits PI3K-beta/delta-mediated signal transduction pathways. This decreases proliferation and induces cell death in susceptible tumor cells. Unlike other isoforms of PI3K, PI3K-beta and -delta are overexpressed primarily in solid and hematological tumor cells and play crucial roles in tumor cell survival, and immunoregulation. The targeted inhibition of these PI3Ks allows this agent to potentially be more efficacious and less toxic than pan PI3K inhibitors, which also affect normal, healthy cells.","PI3K p110beta/delta Inhibitor CVL237 | CVL 237 | CVL-237 | CVL237 | KA 2237 | KA2237 | PI3 Kinase b/d Inhibitor KA2237 | PI3K p110beta/delta Inhibitor KA2237 | PI3K p110beta/delta Inhibitor KA2237",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504849","Fluorescence Imaging Agent EMI-137","C126272","A water-soluble compound composed of a 26-amino acid cyclic peptide targeting the human hepatocyte growth factor receptor (c-MET) conjugated to a cyanine-based fluorescent dye, with potential fluorescent imaging activity. Upon administration of EMI-137, the peptide moiety specifically targets and binds to the human tyrosine kinase receptor c-Met, which is often overexpressed on cancer cells. Upon imaging, the cancer cells can be visualized.","Fluorescence Imaging Agent EMI-137 | EMI-137",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3660913","Imidazolyl Ethanamide Pentandioic Acid","C126647","An orally bioavailable small molecule, with potential hematopoiesis inducing and antiviral activities. Upon oral administration, myelo001 stimulates the differentiation of bone marrow cells of the leukocytic, lymphocytic, and erythrocytic lineages, and prevents apoptosis of hematopoietic cells. This prevents chemotherapy-induced neutropenia (CIN), inhibits the risk of infections, increases tolerance and allows for the continuation of the neutropenia-inducing chemotherapeutic agent. In addition, myelo 001 has antiviral properties.","Imidazolyl Ethanamide Pentandioic Acid | 6-(2-(1H-Imidazol-4-yl)ethylamino)-5-oxohexanoic Acid | Dicarbamin | IEPA | INGAVIRIN | Ingavirin | Myelo 001 | Myelo001 | Pentanedioic Acid Imidazolyl Ethanamide | Vitaglutam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503764","ALK/FAK/Pyk2 Inhibitor CT-707","C126648","An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2), with potential antineoplastic activity. Upon administration, ALK/FAK/Pyk2 inhibitor CT-707 selectively binds to and inhibits ALK , FAK and Pyk2. The inhibition leads to disruption of ALK- , FAK- and Pyk2-mediated signal transduction pathways and eventually inhibits tumor cell growth in ALK-, FAK- and Pyk2-overexpressing tumor cells. Expression of these tyrosine kinases is dysregulated in various tumor types; they play a key role in tumor cell migration, proliferation, survival, and tumor angiogenesis.","ALK/FAK/Pyk2 Inhibitor CT-707 | CT 707 | CT-707",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503765","White Carrot","C126649","A vegetable, also known as Arracacha, with potential chemoprevenitve, anti-oxidant and protective activities. White carrot contains a variety of nutrients, including minerals and vitamins. Polyacetylenes, including falcarinol, falcarindiol and falcarindiol-3-acetate are mainly responsible for its potential anti-cancer activity.","White Carrot | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504468","Expanded DRS-PI Survivor Version - Require Physical Assistance","C125816","Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Do you require physical assistance from another person to meet daily needs?","Expanded DRS-PI Survivor Version - Require Physical Assistance | ED2-Require Physical Assistance | ED207_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504470","Expanded DRS-PI Survivor Version - Require Assistance Managing Emotions","C125818","Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Do you require assistance from another person to manage emotions and behavior?","Expanded DRS-PI Survivor Version - Require Assistance Managing Emotions | ED2-Require Assistance Managing Emotions | ED207_5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504471","Expanded DRS-PI Survivor Version - Need a Helper Always Close By","C125819","Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Do you take care of some of your needs but also need a helper who is always close by?","Expanded DRS-PI Survivor Version - Need a Helper Always Close By | ED2-Need a Helper Always Close By | ED207_6A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008572","Chromatophore","C12581","A pigment-producing cell located in the deeper layers of the skin.","Chromatophore | Chromatophores",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504472","Expanded DRS-PI Survivor Version - Need Help With All Major Activities","C125820","Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Do you need help with all major activities and the assistance of another person all the time?","Expanded DRS-PI Survivor Version - Need Help With All Major Activities | ED2-Need Help With All Major Activities | ED207_6B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504473","Expanded DRS-PI Survivor Version - Need 24-Hour Care","C125821","Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Do you need 24-hour care and are not able to help with your own care at all?","Expanded DRS-PI Survivor Version - Need 24-Hour Care | ED2-Need 24-Hour Care | ED207_6C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504474","Expanded DRS-PI Survivor Version - Function With Independent Work or Social Situations","C125822","Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Can you function with complete independence in work or social situations?","Expanded DRS-PI Survivor Version - Function With Independent Work or Social Situations | ED2-Independent Work/Social Situations | ED208_1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504475","Expanded DRS-PI Survivor Version - Understand and Follow Directions","C125823","Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Can you understand, remember, and follow directions?","Expanded DRS-PI Survivor Version - Understand and Follow Directions | ED2-Understand/Follow Directions | ED208_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504476","Expanded DRS-PI Survivor Version - Keep Track of Time","C125824","Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Can you keep track of time, schedules and appointments?","Expanded DRS-PI Survivor Version - Keep Track of Time | ED2-Keep Track of Time/Schedules | ED208_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504477","Expanded DRS-PI Survivor Version - Perform Jobs or Manage a Home Independently","C125825","Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) How certain are you that you can perform in a wide variety of jobs of your choosing or manage a home independently or participate in school full-time?","Expanded DRS-PI Survivor Version - Perform Jobs or Manage a Home Independently | ED2-Perform Jobs, Manage Home/School | ED208_4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504478","Expanded DRS-PI Survivor Version - Successful With Accommodations","C125826","Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) How certain are you that you can be successful at work, school or in home management with some reduction in the work load or with other accommodations due to disabilities?","Expanded DRS-PI Survivor Version - Successful With Accommodations | ED2-Successful With Accommodations | ED208_5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504479","Expanded DRS-PI Survivor Version - Successful With Limited Choices","C125827","Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) How certain are you that you can be successful at work, school or in home management but with limited choices in jobs or school courses due to disabilities?","Expanded DRS-PI Survivor Version - Successful With Limited Choices | ED2-Successful With Limited Choices | ED208_6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504704","Infant Acute Biphenotypic Leukemia","C126111","An acute biphenotypic leukemia that occurs in infancy.","Infant Acute Biphenotypic Leukemia | Acute Biphenotypic Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504705","Infant T Acute Lymphoblastic Leukemia","C126112","A T acute lymphoblastic leukemia that occurs in infancy.","Infant T Acute Lymphoblastic Leukemia | Infant Precursor T Lymphoblastic Leukemia | Infant Precursor T-Lymphoblastic Leukemia | Infant T-ALL | Infant T-Acute Lymphoblastic Leukemia | T Acute Lymphoblastic Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504706","anti-CTLA-4 monoclonal antibody AGEN1884","C126113","A recombinant human monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, zalifrelimab binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.","Zalifrelimab | AGEN-1884 | AGEN1884 | Anti-CTLA-4 Monoclonal Antibody AGEN1884 | UGN 301 | UGN-301 | UGN301 | ZALIFRELIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504708","PGF Gene Product","C126116","A protein encoded by the PGF gene.","PGF Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003273","Antibody-Producing Cell","C12611","A type of B lymphocyte that reacts with antigens to produce immune proteins called antibodies.","Antibody-Producing Cell | Antibody Producing Cell | Antibody-Producing Cells | Immunoglobulin-Producing Cell | Immunoglobulin-Producing Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504851","fluzoparib","C126274","An orally available inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2, with potential antineoplastic activity. Upon oral administration, fuzuloparib inhibits PARP 1 and 2 activity, which inhibits PARP-mediated repair of damaged DNA via the base excision repair (BER) pathway, enhances the accumulation of DNA strand breaks, promotes genomic instability, and leads to an induction of apoptosis. The PARP family of proteins catalyze post-translational ADP-ribosylation of nuclear proteins, which then transduce signals to recruit other proteins to repair damaged DNA. PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance.","Fuzuloparib | 4-((3-((5,6-Dihydro-2-(trifluoromethyl)(1,2,4)triazolo(1,5-a)pyrazin-7(8H)-yl)carbonyl)-4-fluorophenyl)methyl)-1(2H)-phthalazinone | AiRuiYi | FUZULOPARIB | Fluzoparib | SHR-3162 | SHR3162",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504431","Expanded DRS-PI Caregiver Version - Understand Feeding Utensils","C125779","Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [name] understand what eating or feeding utensils or equipment are for and how they should be used?","Expanded DRS-PI Caregiver Version - Understand Feeding Utensils | ED1-Understand Feeding Utensils | ED104_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524983","G-Cell","C12577","A gastrin-producing enteroendocrine cell that is located in the gastric antrum.","G-Cell | G Cell | G Cells | Gastrin Cell | Gastrin Cells | Gastrin Secreting Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504432","Expanded DRS-PI Caregiver Version - Know Meal Times","C125780","Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [name] know when meal or feeding times are?","Expanded DRS-PI Caregiver Version - Know Meal Times | ED1-Know Meal Times | ED104_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504433","Expanded DRS-PI Caregiver Version - Use Toilet Independently","C125781","Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Can [name] use the toilet or manage their bowel and bladder routine independently and appropriately without help or reminders?","Expanded DRS-PI Caregiver Version - Use Toilet Independently | ED1-Use Toilet Independently | ED105_1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504434","Expanded DRS-PI Caregiver Version - Manage Clothing When Toileting","C125782","Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [name] understand how to manage their clothing or special equipment when toileting or in bowel and bladder management?","Expanded DRS-PI Caregiver Version - Manage Clothing When Toileting | ED1-Manage Clothing When Toileting | ED105_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504435","Expanded DRS-PI Caregiver Version - Know When to Use Toilet","C125783","Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [name] know when to use the toilet or to conduct bowel and bladder management?","Expanded DRS-PI Caregiver Version - Know When to Use Toilet | ED1-Know When to Use Toilet | ED105_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504436","Expanded DRS-PI Caregiver Version - Can Dress and Groom Self Independently","C125784","Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Can [name] dress and groom him/herself independently and appropriately or direct someone else in these activities without help or reminders?","Expanded DRS-PI Caregiver Version - Can Dress and Groom Self Independently | ED1-Can Dress/Groom Independently | ED106_1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504437","Expanded DRS-PI Caregiver Version - Know How to Bathe and Wash","C125785","Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [s/he] know how to bathe and wash?","Expanded DRS-PI Caregiver Version - Know How to Bathe and Wash | ED1-Know How to Bathe/Wash | ED106_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415187","GP1BB Gene","C126549","This gene is involved in the regulation of blood coagulation.","GP1BB Gene | GP1BB | Glycoprotein Ib Platelet Beta Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0949666","Oxyphil Cells","C12654","A glandular cell with acidophilic cytoplasm that contains tightly packed mitochondria. Oxyphil cells are found in the thyroid gland (Hurthle cells) and parathyroid gland.","Oxyphil Cell | Askenazy Cells | Oncocyte | Oncocytes | Oxyphil Cells | Oxyphilic Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505031","GP1BB wt Allele","C126550","Human GP1BB wild-type allele is located in the vicinity of 22q11.21 and is approximately 2 kb in length. This allele, which encodes platelet glycoprotein Ib beta chain protein, plays a role in platelet aggregation. Mutation of the gene is associated with Bernard-Soulier syndrome type B.","GP1BB wt Allele | BDPLT1 | CD42C | GP Ib, Beta Subunit Gene | GPIBB | GPIbbeta | Glycoprotein Ib (Platelet), Beta Polypeptide Gene | Glycoprotein Ib Platelet Beta Subunit wt Allele | Glycoprotein Ib, Platelet, Beta Polypeptide Gene | Nuclear Localization Signal Deleted In Velocardiofacial Syndrome Gene | Platelet Glycoprotein Ib, Beta Polypeptide Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3852783","Platelet Membrane Glycoprotein 1b Beta Chain, Human","C126551","Platelet glycoprotein Ib beta chain (206 aa, ~22 kDa) is encoded by the human GP1BB gene. This protein is involved in the modulation of platelet aggregation.","Platelet Membrane Glycoprotein 1b Beta Chain | Antigen CD42b-Beta | CD42c Antigen | GP-Ib Beta | GPIb-Beta | GPIbB | Glycoprotein Ibbeta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1439350","GP9 Gene","C126552","This gene plays a role in von Willebrand factor binding.","GP9 Gene | GP9 | Glycoprotein IX Platelet Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505032","GP9 wt Allele","C126553","Human GP9 wild-type allele is located in the vicinity of 3q21.3 and is approximately 7 kb in length. This allele, which encodes platelet glycoprotein IX protein, is involved in the regulation of platelet aggregation. Mutation of the gene is associated with Bernard-Soulier syndrome type C.","GP9 wt Allele | CD42a | GPIX | Glycoprotein IX (Platelet) Gene | Glycoprotein IX Platelet wt Allele | Glycoprotein IX, Platelet Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032193","Platelet Glycoprotein IX","C126554","Platelet glycoprotein IX (177 aa, ~19 kDa) is encoded by the human GP9 gene. This protein plays a role in blood coagulation.","Platelet Glycoprotein IX | CD42a | CD42a Antigen | GP IX | GP-IX | GPIX | Glycoprotein 9 | Platelet Glycoprotein 9",,,,,,,,,,,,,,,"4012715","Lymphocyte antigen CD42a",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1415189","GP5 Gene","C126555","This gene is involved in blood coagulation.","GP5 Gene | GP5 | Glycoprotein V Platelet Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505033","GP5 wt Allele","C126556","Human GP5 wild-type allele is located in the vicinity of 3q29 and is approximately 4 kb in length. This allele, which encodes platelet glycoprotein V protein, plays a role in von Willebrand factor-dependent platelet aggregation.","GP5 wt Allele | CD42d | GPV | Glycoprotein V (Platelet) Gene | Glycoprotein V Platelet wt Allele | Glycoprotein V, Platelet Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0543479","Platelet Glycoprotein V","C126557","Platelet glycoprotein V (560 aa, ~61 kDa) is encoded by the human GP5 gene. This protein is involved in von Willebrand factor binding.","Platelet Glycoprotein V | CD42d | CD42d Antigen | GP V | GP-V | GPV | Glycoprotein 5 | Platelet Glycoprotein 5",,,,,,,,,,,,,,,"4012271","Lymphocyte antigen CD42d",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1855498","Combined Lipase Deficiency","C126558","A rare disorder caused by mutation in the LMF1 gene resulting in combined lipase deficiency with concomitant hypertriglyceridemia and associated disorders.","Combined Lipase Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1850079","Hard Skin Syndrome Parana Type","C126559","A rare disorder characterized by rigid, thick skin that covers the entire body and affects movements. The movement of the chest and abdomen is severely restricted. Affected individuals develop respiratory insufficiency which may lead to death.","Hard Skin Syndrome Parana Type | Parana Hard-Skin Syndrome",,,,,,,,,,,,,,,"37204372","Parana hard skin syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003649","APUD Cell","C12655","An endocrine cell that has the capabilities of amine precursor uptake and decarboxylation, and low molecular weight polypeptide hormone secretion.","APUD Cell | APUD Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031760","Photoreceptors","C12634","A sensory neuron, located in the retina of the eye, that converts light signals into nerve impulses.","Photoreceptor Cell | Photosensitive Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504912","Chronic Eosinophilic Leukemia with FIP1L1-PDGFRA","C126351","Chronic eosinophilic leukemia characterized by the rearrangement of the PDGFRA gene, most often resulting in the formation of FIP1L1-PDGFRA fusion transcripts.","Chronic Eosinophilic Leukemia with FIP1L1-PDGFRA | Chronic Eosinophilic Leukemia with FIP1L1::PDGFRA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504914","Primary Peritoneal Low Grade Serous Adenocarcinoma","C126354","A serous adenocarcinoma that arises from the lining of the peritoneum. It is characterized by low grade histopathologic features.","Primary Peritoneal Low Grade Serous Adenocarcinoma | Invasive Micropapillary Serous Carcinoma of the Peritoneum | Primary Peritoneal Low-Grade Serous Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504915","Anti-HER2 Antibody-drug Conjugate MEDI4276","C126355","An antibody-drug conjugate (ADC) composed of a bispecific antibody against the extracellular domain of human epidermal growth factor receptor 2 (HER2; ERBB2) comprised of the single-chain variable fragment (scFv) of the anti- HER2 monoclonal antibody trastuzumab, which binds to domain IV of HER2, fused to the heavy chains of the anti-HER2 monoclonal antibody 39S, which binds to domain II of HER2, and conjugated, via a cleavable linker, to the cytotoxic anti-microtubule agent tubulysin, with potential antineoplastic activity. Upon administration of ADC MEDI4276, the anti-HER2 bispecific antibody specifically targets and binds to HER2 on the surface of certain cancer cells. Upon binding, crosslinking and internalization of antibody-HER2 complexes occurs and MEDI4276 is transported to the lysosome where the linker is cleaved, thereby delivering tubulysin inside HER2-expressing cancer cells. Tubulysin binds to tubulin and inhibits microtubule polymerization, which blocks cell division. This results in G2/M phase arrest, tumor cell apoptosis, and decreased proliferation of HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","Anti-HER2 Antibody-drug Conjugate MEDI4276 | ADC MEDI4276 | MEDI-4276 | MEDI4276",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504916","Peritoneal Desmoplastic Small Round Cell Tumor","C126356","A desmoplastic small round cell tumor that occurs in the abdominal and/or pelvic peritoneum.","Peritoneal Desmoplastic Small Round Cell Tumor | Peritoneal DSRCT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504917","Peritoneal Solitary Fibrous Tumor","C126357","A rare, usually benign fibroblastic neoplasm that arises from the peritoneum. It is characterized by the presence of prominent hemangiopericytoma-like vessels.","Peritoneal Solitary Fibrous Tumor | Peritoneal SFT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504919","Abdominal Inflammatory Myofibroblastic Tumor","C126359","Inflammatory myofibroblastic tumor that arises from the abdominal cavity.","Abdominal Inflammatory Myofibroblastic Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206436","Photoreceptors, Invertebrate","C12635","Specialized cells in invertebrate animals that convert light signals into nerve impulses.","Photoreceptors, Invertebrate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2938915","Peritoneal Gliomatosis","C126360","A benign condition characterized by the presence of peritoneal implants composed of mature glial tissue. It is usually accompanied by an ovarian teratoma.","Peritoneal Gliomatosis | Gliomatosis Peritonei",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504438","Expanded DRS-PI Caregiver Version - Understand How to Get Dressed","C125786","Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [s/he] understand how to get dressed?","Expanded DRS-PI Caregiver Version - Understand How to Get Dressed | ED1-Understand How to Get Dressed | ED106_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504440","Expanded DRS-PI Caregiver Version - Function Completely Independently","C125788","Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [name] function completely independently? That is, [s/he] does not require any physical assistance, supervision, equipment, devices or reminders for cognitive, social, behavioral, emotional, and physical function?","Expanded DRS-PI Caregiver Version - Function Completely Independently | ED1-Function Completely Independently | ED107_1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504441","Expanded DRS-PI Caregiver Version - Require Special Aids or Equipment","C125789","Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [name] REQUIRE special aids or equipment such as a brace, walker, wheelchair, memory notebook, day planner, verbal reminders, prompts, cues, or alarm watch because of a disability?","Expanded DRS-PI Caregiver Version - Require Special Aids or Equipment | ED1-Require Specific Aids/Equipment | ED107_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504442","Expanded DRS-PI Caregiver Version - Require Physical Assistance","C125790","Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [name] require physical assistance from another person to meet daily needs?","Expanded DRS-PI Caregiver Version - Require Physical Assistance | ED1-Require Physical Assistance | ED107_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1438413","CD2 Antigen Cytoplasmic Tail-Binding Protein 2, Human","C126502","CD2 antigen cytoplasmic tail-binding protein 2 (341 aa, ~38 kDa) is encoded by the human CD2BP2 gene. This protein plays a role in mRNA splicing and T-cell activation.","CD2 Antigen Cytoplasmic Tail-Binding Protein 2 | CD2 Antigen-Binding Protein 2 | CD2 Cytoplasmic Domain-Binding Protein 2 | CD2 Tail-Binding Protein 2 | CD2BP2 | U5 SnRNP 52K Protein | U5-52K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505015","NUSAP1 wt Allele","C126504","Human NUSAP1 wild-type allele is located in the vicinity of 15q15.1 and is approximately 48 kb in length. This allele, which encodes nucleolar and spindle-associated protein 1, plays a role in cell division.","NUSAP1 wt Allele | ANKT | BM-037 | BM037 | FLJ13421 | LNP | NUSAP | Nucleolar and Spindle Associated Protein 1 wt Allele | PRO0310 | PRO0310p1 | Q0310 | SAPL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505016","Nucleolar and Spindle-Associated Protein 1","C126505","Nucleolar and spindle-associated protein 1 (441 aa, ~49 kDa) is encoded by the human NUSAP1 gene. This protein is involved in mitotic spindle stabilization.","Nucleolar and Spindle-Associated Protein 1 | NuSAP | Nucleolar Protein ANKT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505017","CDCA8 wt Allele","C126507","Human CDCA8 wild-type allele is located in the vicinity of 1p34.3 and is approximately 17 kb in length. This allele, which encodes borealin protein, is involved in the modulation of cell division.","CDCA8 wt Allele | BOR | BOREALIN | Cell Division Cycle Associated 8 wt Allele | DasraB | FLJ12042 | MESRGP | PESCRG3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505141","CDCA8 protein, human","C126508","Borealin (280 aa, ~31 kDa) is encoded by the human CDCA8 gene. This protein plays a role in mitosis.","Borealin | CDCA8 | Cell Division Cycle-Associated Protein 8 | Dasra B | Dasra-B | Pluripotent Embryonic Stem Cell-Related Gene 3 Protein | hDasra-B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420312","SORL1 Gene","C126509","This gene is involved in both endocytosis and protein sorting.","SORL1 Gene | SORL1 | Sortilin-Related Receptor, L(DLR Class) A Repeats Containing Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038588","Substantia Gelatinosa","C12641","A collection of gelatinous-appearing grey matter cells in the dorsal horn of the spinal cord that receives direct input from the dorsal nerve roots and plays a role in regulating pain impulses at the spinal cord level.","Substantia Gelatinosa | ",,,,,,,,,,,,,,,"4140534","Structure of substantia gelatinosa of posterior horn of spinal cord",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504960","Lysine-specific Demethylase 1 Inhibitor INCB059872","C126421","An orally available inhibitor of lysine-specific demethylase 1 (LSD1), with potential antineoplastic activity. Upon administration, INCB059872 binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4, respectively, through amine oxidation. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor-suppressor genes. In addition, LSD1 demethylates mono- or di-methylated H3K9 which increases gene expression of tumor promoting genes; inhibition of LSD1 promotes H3K9 methylation and decreases transcription of these genes. Altogether, this may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. LSD1, an enzyme belonging to the flavin adenine dinucleotide (FAD)-dependent amine oxidase family, is overexpressed in certain tumor cells and plays a key role in the regulation of gene expression and in tumor cell growth and survival.","Lysine-specific Demethylase 1 Inhibitor INCB059872 | INCB-059872 | INCB059872 | LSD1 Inhibitor INCB059872",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0265309","Leri-Weill Dyschondrosteosis","C126560","A bone growth disorder inherited in a pseudoautosomal dominant pattern caused by mutations in the SHOX gene. It is characterized by short long bones in the arms and legs, short stature, and abnormalities of the wrist and forearm bones which may cause pain and limit wrist movement.","Leri-Weill Dyschondrosteosis | Dyschondrosteosis | Leri-Weill Syndrome",,,,,,,,,,,,,,,"4075151","Leri-Weill dyschondrosteosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268242","Niemann-Pick Disease, Type A","C126561","An autosomal recessive inherited lysosomal storage disease caused by mutations in the SMPD1 gene. It manifests with hepatosplenomegaly, failure to thrive, psychomotor regression, and interstitial lung disease.","Niemann-Pick Disease, Type A | ",,,,,,,,,,,,,,,"4181427","Niemann-Pick disease, type A",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037866","Spermatogonium","C12606","An undeveloped male germ cell. Spermatogonia develop into primary spermatocytes.","Spermatogonium | Spermatogonia",,,,,,,,,,,,,,,"4195699","Spermatogonia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504522","PHQ Screener Version - Last 4 Weeks, Trouble Falling or Staying Asleep","C125870","Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 4 weeks, how often have you been bothered by trouble falling asleep or staying asleep?","PHQ Screener Version - Last 4 Weeks, Trouble Falling or Staying Asleep | PHQ03-Last 4 Week Trouble Falling Asleep | PHQ0305E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504523","PHQ Screener Version - Last 4 Weeks, Trouble Concentrating","C125871","Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 4 weeks, how often have you been bothered by trouble concentrating on things, such as reading a book or watching TV?","PHQ Screener Version - Last 4 Weeks, Trouble Concentrating | PHQ03-Last 4 Week Trouble Concentrating | PHQ0305F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504524","PHQ Screener Version - Becoming Easily Annoyed","C125872","Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 4 weeks, how often have you been bothered by becoming easily annoyed or irritable?","PHQ Screener Version - Becoming Easily Annoyed | PHQ03-Becoming Easily Annoyed | PHQ0305G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504525","PHQ Screener Version - No Control What or How Much Eat","C125873","Patient Health Questionnaire Screener Version (PHQ Screener Version) Do you often feel that you can't control what or how much you eat?","PHQ Screener Version - No Control What or How Much Eat | PHQ03-No Control What/How Much Eat | PHQ0306A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504526","PHQ Screener Version - Often Eat Large Amount Food","C125874","Patient Health Questionnaire Screener Version (PHQ Screener Version) Do you often eat, within any 2 - hour period, what most people would regard as an unusually large amount of food?","PHQ Screener Version - Often Eat Large Amount Food | PHQ03-Eat 2-Hours Large Amount Food | PHQ0306B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504527","PHQ Screener Version - Eat a Lot Twice Week","C125875","Patient Health Questionnaire Screener Version (PHQ Screener Version) Has this been as often, on average, as twice a week for the last 3 months?","PHQ Screener Version - Eat a Lot Twice Week | PHQ03-Eat a Lot Twice Week | PHQ0306C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504528","PHQ Screener Version - Avoid Gaining Weight, Made Yourself Vomit","C125876","Patient Health Questionnaire Screener Version (PHQ Screener Version) In the last 3 months have you often done any of the following in order to avoid gaining weight: Made yourself vomit?","PHQ Screener Version - Avoid Gaining Weight, Made Yourself Vomit | PHQ03-Made Yourself Vomit | PHQ0307A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504529","PHQ Screener Version - Avoid Gaining Weight, Took Twice Dose of Laxatives","C125877","Patient Health Questionnaire Screener Version (PHQ Screener Version) In the last 3 months have you often done any of the following in order to avoid gaining weight: Took more than twice the recommended dose of laxatives to avoid gaining weight?","PHQ Screener Version - Avoid Gaining Weight, Took Twice Dose of Laxatives | PHQ03-Took Twice Dose of Laxatives | PHQ0307B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504531","PHQ Screener Version - Avoid Gaining Weight, Exercise","C125879","Patient Health Questionnaire Screener Version (PHQ Screener Version) In the last 3 months have you often done any of the following in order to avoid gaining weight: Exercised for more than an hour specifically to avoid gaining weight after binge eating?","PHQ Screener Version - Avoid Gaining Weight, Exercise | PHQ03-Exercised Avoid Gaining Weight | PHQ0307D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018207","granulosa cell","C12587","No value exists.","Granulosa Cell | Granulosa Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504532","PHQ Screener Version - Avoid Gaining Weight Twice Week","C125880","Patient Health Questionnaire Screener Version (PHQ Screener Version) If you checked 'YES' to any of these ways of avoiding gaining weight, were any as often, on average, as twice a week?","PHQ Screener Version - Avoid Gaining Weight Twice Week | PHQ03-Avoid Gaining Weight Twice Week | PHQ0308",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504533","PHQ Screener Version - Drink Alcohol","C125881","Patient Health Questionnaire Screener Version (PHQ Screener Version) Do you ever drink alcohol (including beer or wine)?","PHQ Screener Version - Drink Alcohol | PHQ03-Drink Alcohol | PHQ0309",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504534","PHQ Screener Version - Drank Alcohol With Health Problem","C125882","Patient Health Questionnaire Screener Version (PHQ Screener Version) Have any of the following happened to you more than once in the last 6 months: You drank alcohol even though a doctor suggested that you stop drinking because of a problem with your health?","PHQ Screener Version - Drank Alcohol With Health Problem | PHQ03-Drank Alcohol With Health Problem | PHQ0310A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206254","Postganglionic Sympathetic Fiber","C12650","An axon that projects from a nerve cell body within a sympathetic ganglion and innervates an effector cell within a target organ. Postganglionic sympathetic fibers use norepinephrine and acetylcholine as transmitters, sometimes with peptide cotransmitters.","Postganglionic Sympathetic Fiber | Sympathetic Fibers, Postganglionic",,,,,,,,,,,,,,,"4259155","Structure of postganglionic sympathetic fiber",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL505018","SORL1 wt Allele","C126510","Human SORL1 wild-type allele is located within 11q23.2-q24.2 and is approximately 182 kb in length. This allele, which encodes sortilin-related receptor protein, plays a role in both intracellular protein sorting and endocytosis of lipoproteins and enzymes. Mutation of the gene may be associated with Alzheimer disease.","SORL1 wt Allele | C11orf32 | Chromosome 11 Open Reading Frame 32 Gene | LR11 | LRP9 | SORLA | SorLA-1 | Sortilin-Related Receptor, L(DLR Class) A Repeats Containing wt Allele | Sortilin-Related Receptor, L(DLR Class) A Repeats-Containing Gene | gp250",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1307867","SORL1 protein, human","C126511","Sortilin-related receptor (2214 aa, ~248 kDa) is encoded by the human SORL1 gene. This protein is involved in both endocytosis and protein trafficking.","Sortilin-Related Receptor | LDLR Relative With 11 Ligand-Binding Repeats | LR11 | Low-Density Lipoprotein Receptor Relative With 11 Ligand-Binding Repeats | Mosaic Protein LR11 | SorLA | SorLA-1 | Sorting Protein-Related Receptor Containing LDLR Class A Repeats",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828858","ZFTA Gene","C126512","This gene may be involved in the repression of transcription.","ZFTA Gene | C11orf95 | ZFTA | Zinc Finger Translocation Associated Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505019","MGC3032","C126513","Human ZFTA wild-type allele is located in the vicinity of 11q13.1 and is approximately 9 kb in length. This allele, which encodes zinc finger translocation-associated protein, may play a role in transcriptional regulation. A chromosomal aberration, t(11;16)(q13;p13), involving this gene and the MRTFB (MKL2) gene may be associated with chondroid lipomas. A chromosomal aberration involving chromothripsis of the long arm of chromosome 11 causes fusions of this gene and the RELA gene and is associated with more than two-thirds of supratentorial ependymomas.","ZFTA wt Allele | C11orf95 | Chromosome 11 Open Reading Frame 95 Gene | MGC3032 | Zinc Finger Translocation Associated wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505020","C11orf95 protein, human","C126514","Zinc finger translocation-associated protein (678 aa, ~73 kDa) is encoded by the human ZFTA gene. This protein may be involved in the downregulation of gene transcription.","Zinc Finger Translocation-Associated Protein | Uncharacterized Protein C11orf95 | ZFTA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0077021","Tri-N-butyl Phosphate","C1259","Tri-n-butyl phosphate, Bu3-P, TBP.  Industrial chemical; used as a plasticizer, in hydraulic fluid, as a solvent and extractant for metal ions, and as a heat exchange agent.","Tri-N-butyl Phosphate | TRI-N-BUTYL PHOSPHATE | Tributyl Phosphate | Tributyl phosphate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039249","Taenia","C125925","A genus of parasitic cestodes in the family Taeniidae that infect mammals and are characterized by ribbon-like bodies.","Taenia | TAENIA",,,,,,,,,,,,,,,"4102628","Taenia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0997371","Torulaspora","C125926","A genus of ascomycetous yeasts in the family Saccharomycetaceae. Species in this genus reproduce vegetatively by multilateral budding. Cells are globose or ellipsoid and pseudohyphae may be formed. Members of this genus are vigorous fermenters but will not grow on nitrate as a sole source of nitrogen.","Torulaspora | ",,,,,,,,,,,,,,,"37016460","Torulaspora",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040550","Toxocara","C125927","A genus of parasitic nematodes in the family Toxocaridae that is commonly found in the digestive tracts of carnivorous animals, with the final host being domestic animals. The typical route of infection is through ingestion of larvae contaminated soil. Human infections more frequently occur in children.","Toxocara | TOXOCARA",,,,,,,,,,,,,,,"4307025","Toxocara",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040891","Trichinella","C125928","A genus of parasitic nematodes in the family Trichinellidae that is found in the digestive tract of a broad spectrum of both wild and domestic mammals. The typical route of infection is through oral ingestion of larvae contaminated tissue.","Trichinella | TRICHINELLA",,,,,,,,,,,,,,,"4242211","Trichinella",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040955","Trichuris","C125929","A genus of parasitic nematodes in the family Trichuridae that is found in the mucosa of the lower intestines of humans and domestic animals. The typical route of infection is through oral ingestion of egg contaminated food, water, or soil.","Trichuris | TRICHURIS",,,,,,,,,,,,,,,"4093446","Trichuris",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1865926","Infantile Convulsions and Paroxysmal Choreoathetosis, Familial","C126650","An autosomal dominant inherited disorder caused by mutation(s) in the PRRT2 gene, encoding proline-rich transmembrane protein 2. It is characterized by epileptic seizures and paroxysmal kinesigenic choreoathetosis. It shares features with episodic kinesigenic dyskinesia-1, which is an allelic disorder.","Infantile Convulsions and Paroxysmal Choreoathetosis, Familial | ICCA | ICCA Syndrome | PKD/IC | Paroxysmal Kinesigenic Dyskinesia with Infantile Convulsions",,,,,,,,,,,,,,,"37395921","ICCA syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1879286","Progressive Familial Heart Block, Type Ia","C126651","An autosomal dominant inherited cardiac bundle branch disorder which can progress to complete heart block.","Progressive Familial Heart Block, Type Ia | Lenegre's Disease | Lenegre-Lev Disease | PFHB1A | Progressive Familial Heart Block 1A",,,,,,,,,,,,,,,"4153404","Lev's syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL503766","Oat Biscuit","C126652","A biscuit containing oats.","Oat Biscuit | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503767","Fluorine F 18 Dabrafenib","C126653","A radioconjugate containing dabrafenib, a tyrosine kinase inhibitor of the V600 mutated version of the B-raf (BRAF) protein and labeled with the positron-emitting isotope fluorine F 18 with potential prostate tumor imaging upon positron emission tomography (PET). Upon administration, the dabrafenib moiety of fluorine F 18 dabrafenib specifically targets and binds to the BRAF V600-mutated form, expressed on tumor cells, thereby allowing the visualization of tumor cells expressing BRAF V600 upon PET. BRAF is constitutively activated in a variety of cancers due to BRAF gene mutations.","Fluorine F 18 Dabrafenib | DABRAFENIB F-18 | [F18]dabrafenib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504682","Experimental Organism Benign Mixed Mullerian Tumor","C126085","A benign neoplasm arising from pluripotent mesodermal cells of the Mullerian ducts. (INHAND)","Experimental Organism Benign Mixed Mullerian Tumor | MULLERIAN TUMOR, MIXED, BENIGN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504683","Experimental Organism Benign Neuroendocrine Cell Tumor","C126086","A benign neoplasm arising from neuroendocrine cells.","Experimental Organism Benign Neuroendocrine Cell Tumor | NEUROENDOCRINE CELL TUMOR, BENIGN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504684","Experimental Organism Malignant Neuroendocrine Cell Tumor","C126087","A malignant neoplasm arising from neuroendocrine cells with evidence of invasion.","Experimental Organism Malignant Neuroendocrine Cell Tumor | NEUROENDOCRINE CELL TUMOR, MALIGNANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504880","Ovarian Seromucinous Cystadenoma","C126310","A non-metastasizing cystic mixed epithelial neoplasm that arises from the ovary. It is characterized by the presence of more than one epithelial cell type, most often serous and endocervical-type mucinous.","Ovarian Seromucinous Cystadenoma | ","8474/0","Seromucinous cystadenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"CL504881","Ovarian Seromucinous Adenofibroma","C126311","A non-metastasizing mixed epithelial neoplasm that arises from the ovary. It is characterized by the presence of more than one epithelial cell type, most often serous and endocervical-type mucinous and prominent fibrous stroma..","Ovarian Seromucinous Adenofibroma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206513","Type II Hair Cell","C12631","A cylinder-shaped mechanoreceptor cell that detects and transduces head movements into neural impulses and is located within the vestibular systems of all vertebrates.","Type II Hair Cell | Outer Hair Cell | Outer Hair Cells | Type II Hair Cells",,,,,,,,,,,,,,,"4061280","Type II hair cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504891","Ovarian Luteinized Thecoma Associated with Sclerosing Peritonitis","C126321","A rare usually bilateral luteinized thecoma that arises from the ovary and is associated with sclerosing peritonitis. It occurs mostly in premenopausal women. The ovarian tumor is benign but patients may develop intestinal obstruction due to the sclerosing peritonitis.","Ovarian Luteinized Thecoma Associated with Sclerosing Peritonitis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447389","Sorbin and SH3 Domain-Containing Protein 2, Human","C126604","Sorbin and SH3 domain-containing protein 2 (1100 aa, ~124 kDa) is encoded by the human SORBS2 gene. This protein plays a role in linking signaling proteins to the cytoskeleton.","Sorbin and SH3 Domain-Containing Protein 2 | Arg Binding Protein 2 | Arg-Binding Protein 2 | Arg/Abl Interacting Protein 2 | Arg/Abl-Interacting Protein 2 | ArgBP2 | Sorbin | Sorbin and SH3 Domains-Containing Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537472","CIP2A Gene","C126605","This gene is involved in phosphatase inhibition and anchorage-independent cell growth.","CIP2A Gene | CIP2A | Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A Gene | KIAA1524",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505053","p90","C126606","Human CIP2A wild-type allele is located in the vicinity of 3q13.13 and is approximately 44 kb in length. This allele, which encodes protein CIP2A, plays a role in both tumorigenesis and the inhibition of protein phosphatase 2A.","CIP2A wt Allele | Autoantigen, 90-kD Gene | Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A wt Allele | KIAA1524 | p90",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505098","Protein CIP2A","C126607","Protein CIP2A (905 aa, ~102 kDa) is encoded by the human CIP2A gene. This protein is involved in the positive regulation of cell growth.","Protein CIP2A | Cancerous Inhibitor of PP2A | Cancerous Inhibitor of Protein Phosphatase 2A | p90 Autoantigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2239805","PDS5A Gene","C126608","This gene plays a role in the regulation of both mitosis and cell proliferation.","PDS5A Gene | PDS5 Cohesin Associated Factor A Gene | PDS5A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505054","PDS5A wt Allele","C126609","Human PDS5A wild-type allele is located in the vicinity of 4p14 and is approximately 155 kb in length. This allele, which encodes sister chromatid cohesion protein PDS5 homolog A protein, is involved in cell division.","PDS5A wt Allele | KIAA0648 | PDS5 Cohesin Associated Factor A wt Allele | PDS5, Regulator of Cohesion Maintenance, Homolog A (S. cerevisiae) Gene | PDS5, Regulator of Cohesion Maintenance, Homolog A Gene | PDS5, Regulator of Cohesion Maintenance, S. cerevisiae, Homolog of, A Gene | PIG54 | SCC-112 | SCC112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085133","Reed-Sternberg Cell","C12660","No value exists.","Reed-Sternberg Cell | R-S Cell | Reed-Sternberg cell",,,,,,,,,,,,,,,"4140206","Reed-Sternberg cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1452012","Sister Chromatid Cohesion Protein PDS5 Homolog A, Human","C126610","Sister chromatid cohesion protein PDS5 homolog A (1337 aa, ~151 kDa) is encoded by the human PDS5A gene. This protein plays a role in sister chromatid cohesion in mitosis.","Sister Chromatid Cohesion Protein PDS5 Homolog A | Cell Proliferation-Inducing Gene 54 Protein | PDS5A | SCC-112 | Sister Chromatid Cohesion Protein 112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426896","CEP170B Gene","C126611","This gene may be involved in microtubule organization.","CEP170B Gene | CEP170B | Centrosomal Protein 170B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505055","CEP170B wt Allele","C126612","Human CEP170B wild-type allele is located in the vicinity of 14q32.33 and is approximately 31 kb in length. This allele, which encodes centrosomal protein of 170 kDa protein B, may play a role in microtubule organization.","CEP170B wt Allele | CEP170R | Centrosomal Protein 170B wt Allele | FAM68C | KIAA0284",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505056","Centrosomal Protein of 170 kDa Protein B","C126613","Centrosomal protein of 170 kDa protein B (1589 aa, ~172 kDa) is encoded by the human CEP170B gene. This protein may be involved in microtubule dynamics.","Centrosomal Protein of 170 kDa Protein B | Centrosomal Protein 170B | Cep170-Related | Cep170B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412866","NRIP3 Gene","C126614","This gene may play a role in proteolysis or nuclear receptor activity.","NRIP3 Gene | NRIP3 | Nuclear Receptor Interacting Protein 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505057","NRIP3 wt Allele","C126615","Human NRIP3 wild-type allele is located in the vicinity of 11p15.3 and is approximately 23 kb in length. This allele, which encodes nuclear receptor-interacting protein 3, may be involved in the modulation of nuclear receptor activity.","NRIP3 wt Allele | C11orf14 | Chromosome 11 Open Reading Frame 14 Gene | NY-SAR-105 | Nuclear Receptor Interacting Protein 3 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413133","CASP8AP2 Gene","C126617","This gene is involved in apoptotic signaling.","CASP8AP2 Gene | CASP8AP2 | Caspase 8 Associated Protein 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL505059","CASP8AP2 wt Allele","C126618","Human CASP8AP2 wild-type allele is located in the vicinity of 6q15 and is approximately 45 kb in length. This allele, which encodes CASP8-associated protein 2, plays a role in the regulation of apoptosis.","CASP8AP2 wt Allele | CED-4 | Caspase 8 Associated Protein 2 wt Allele | FLASH | FLJ11208 | KIAA1315 | RIP25",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029048","Primary Oocyte","C12600","An oocyte that is arrested in the diplotene stage of meiosis prophase 1.","Primary Oocyte | Oogonia | Oogonium | Primordial Ovum",,,,,,,,,,,,,,,"4302921","Primordial ovum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043544","Zygote","C12601","The cell formed by the union of two gametes, especially a fertilized ovum before cleavage. (Online Medical Dictionary)","Zygote | Egg, Fertilized | Fertilized Egg | Fertilized Ovums | Ovum, Fertilized",,,,,,,,,,,,,,,"4238975","Structure of zygote",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504852","Anti-LAMP1 Antibody-drug Conjugate SAR428926","C126275","An antibody-drug conjugate (ADC) consisting of a monoclonal antibody against lysosome-associated membrane protein 1 (LAMP1) conjugated, via the disulfide-containing cleavable linker N-succinimidyl-4-(2-pyridyldithio)butyrate (SPDB), to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. Upon administration of anti-LAMP1 ADC SAR428926, the anti-LAMP1 monoclonal antibody moiety targets and binds to the cell surface antigen LAMP1. After antibody-antigen interaction and internalization, the SPDB linker is selectively cleaved by proteases in the cytosol and the DM4 moiety is released. DM4 binds to tubulin and disrupts microtubule assembly/disassembly dynamics, thereby inhibiting both cell division and cell growth of LAMP1-expressing tumor cells. LAMP1, overexpressed on a variety of cancer cells, plays a key role in cell-cell adhesion and migration. The SPDB linker is resistant to cleavage in the bloodstream, which may increase stability and reduce toxicity.","Anti-LAMP1 Antibody-drug Conjugate SAR428926 | ADC SAR428926 | Anti-LAMP1 ADC SAR428926 | SAR428926",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503771","NCIt Neoplasm Core Terminology","C126659","A core reference set of NCIt neoplasm classification concepts to facilitate consistent coding, analysis, and data sharing across a broad range of NCI and related resources.","NCIt Neoplasm Core Terminology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL503772","Apilimod Dimesylate Capsule","C126661","A capsule containing the dimesylate salt form of apilimod, an inhibitor of the class III PI kinase phosphatidylinositol-3-phosphate 5-kinase (PIKfyve), with potential antineoplastic and immunomodulatory activities. Upon oral administration of apilimod dimesylate capsule, apilimod selectively binds to and inhibits PIKfyve. The inhibition leads to disruption of PIKfyve-mediated signal transduction pathways and eventually inhibits tumor cell growth in PIKfyve-overexpressing tumor cells. Also, PIKfyve inhibition by apilimod inhibits the toll-like receptor (TLR)-induced production of various cytokines, including interleukin-12 (IL-12) and IL-23, thereby preventing IL-12/IL-23-mediated immune responses. PIKfyve, a lipid kinase dysregulated in various tumor types, plays a key role in TLR signaling and tumor cell migration, proliferation and survival.","Apilimod Dimesylate Capsule | LAM 002A | LAM-002A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504892","Ovarian Retiform Sertoli-Leydig Cell Tumor, Variant with Heterologous Elements","C126322","A retiform Sertoli-Leydig cell tumor that arises from the ovary. It is characterized by the presence of an epithelial and/or mesenchymal heterologous component.","Ovarian Retiform Sertoli-Leydig Cell Tumor, Variant with Heterologous Elements | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504893","Gastroesophageal Junction Large Cell Neuroendocrine Carcinoma","C126323","An aggressive high-grade carcinoma with neuroendocrine differentiation that arises from the gastroesophageal junction and is composed of malignant large cells. The mitotic count is more than 20 per 2 mm2 and/or the Ki-67 index is more than 20%.","Gastroesophageal Junction Large Cell Neuroendocrine Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504894","Gastroesophageal Junction Neuroendocrine Carcinoma","C126324","An aggressive high-grade carcinoma with neuroendocrine differentiation that arises from the gastroesophageal junction. It is composed of malignant small or large cells. The mitotic count is more than 20 per 2 mm2 and/or the Ki-67 index is more than 20%.","Gastroesophageal Junction Neuroendocrine Carcinoma | Gastroesophageal Junction NEC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504895","Gastroesophageal Junction Small Cell Neuroendocrine Carcinoma","C126325","An aggressive high-grade carcinoma with neuroendocrine differentiation that arises from the gastroesophageal junction and is composed of malignant small cells. The mitotic count is more than 20 per 2 mm2 and/or the Ki-67 index is more than 20%.","Gastroesophageal Junction Small Cell Neuroendocrine Carcinoma | Gastroesophageal Junction Small Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504896","Roberts Syndrome","C126326","A rare, autosomal recessive inherited syndrome caused by mutations in the ESCO2 gene. It is characterized by limb and facial abnormalities and slow growth. Intellectual impairment occurs in approximately half of the affected individuals.","Roberts Syndrome | ",,,,,,,,,,,,,,,"4169061","Roberts-SC phocomelia syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL504481","PHQ Screener Version - Stomach Pain","C125829","Patient Health Questionnaire Screener Version (PHQ Screener Version) During the last 4 weeks, how much have you been bothered by stomach pain?","PHQ Screener Version - Stomach Pain | PHQ03-Stomach Pain | PHQ0301A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025207","Melanophore","C12582","A specialized cell, derived from the neural crest, that contains melanin and regulates changes in pigment.","Melanophore | Melanophores",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504482","PHQ Screener Version - Back Pain","C125830","Patient Health Questionnaire Screener Version (PHQ Screener Version) During the last 4 weeks, how much have you been bothered by back pain?","PHQ Screener Version - Back Pain | PHQ03-Back Pain | PHQ0301B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504483","PHQ Screener Version - Pain in Arms, Legs, Joints","C125831","Patient Health Questionnaire Screener Version (PHQ Screener Version) During the last 4 weeks, how much have you been bothered by pain in your arms, legs, or joints (knees, hips, etc.)?","PHQ Screener Version - Pain in Arms, Legs, Joints | PHQ03-Pain in Your Arms/Legs/Joints | PHQ0301C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504484","PHQ Screener Version - Menstrual Cramp or Other Problem","C125832","Patient Health Questionnaire Screener Version (PHQ Screener Version) During the last 4 weeks, how much have you been bothered by menstrual cramps or other problems with your periods?","PHQ Screener Version - Menstrual Cramp or Other Problem | PHQ03-Menstrual Cramp/Problem | PHQ0301D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504485","PHQ Screener Version - Pain During Intercourse","C125833","Patient Health Questionnaire Screener Version (PHQ Screener Version) During the last 4 weeks, how much have you been bothered by pain or problems during sexual intercourse?","PHQ Screener Version - Pain During Intercourse | PHQ03-Pain/Problems During Intercourse | PHQ0301E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504486","PHQ Screener Version - Headaches","C125834","Patient Health Questionnaire Screener Version (PHQ Screener Version) During the last 4 weeks, how much have you been bothered by headaches?","PHQ Screener Version - Headaches | PHQ03-Headaches | PHQ0301F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1436635","CASP8-Associated Protein 2, Human","C126619","CASP8-associated protein 2 (1982 aa, ~223 kDa) is encoded by the human CASP8AP2 gene. This protein is involved in the positive regulation of caspase-dependent apoptosis.","CASP8-Associated Protein 2 | CASP8 Associated Protein 2 | Caspase 8-Associated Protein 2 | FLASH Homolog RIP25 | FLICE-Associated Huge Protein | Human FLASH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504712","TIGIT wt Allele","C126124","Human TIGIT wild-type allele is located in the vicinity of 3q13.31 and is approximately 33 kb in length. This allele, which encodes T-cell immunoreceptor with Ig and ITIM domains protein, plays a role in dendritic cell maturation, the inhibition of T-cell activation and cell adhesion.","TIGIT wt Allele | DKFZp667A205 | FLJ39873 | T Cell Immunoreceptor with Ig and ITIM Domains Gene | T-Cell Immunoreceptor with Ig and ITIM Domains wt Allele | V-Set and Immunoglobulin Domain Containing 9 Gene | V-Set and Transmembrane Domain Containing 3 Gene | VSIG9 | VSTM3 | WUCAM | Washington University Cell Adhesion Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2607657","TIGIT protein, human","C126125","T-cell immunoreceptor with Ig and ITIM domains (244 aa, ~26 kDa) is encoded by the human TIGIT gene. This protein is involved in immunomodulation and cell-cell adhesion.","T-Cell Immunoreceptor with Ig and ITIM Domains | T-Cell Immunoreceptor with Immunoglobulin and ITIM Domains | TIGIT | V-Set and Immunoglobulin Domain-Containing Protein 9 | V-Set and Transmembrane Domain-Containing Protein 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504714","KIF20B wt Allele","C126127","Human KIF20B wild-type allele is located in the vicinity of 10q23.31 and is approximately 73 kb in length. This allele, which encodes kinesin-like protein KIF20B, is involved in cytokinesis, cell polarity and microtubule-based transport.","KIF20B wt Allele | CT90 | KRMP1 | Kinesin Family Member 20B wt Allele | MPHOSPH1 | MPP-1 | MPP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1310246","Kinesin-Like Protein, Human","C126128","Kinesin-like protein KIF20B (1820 aa, ~211 kDa) is encoded by the human KIF20B gene. This protein plays a role in cell polarity, microtubule-based transport and cytokinesis.","Kinesin-Like Protein KIF20B | CT90 | Cancer/Testis Antigen 90 | Kinesin-Related Motor Interacting with PIN1 | M-Phase Phosphoprotein 1 | MPP1 | Mitotic Kinesin-Like Protein | Mitotic Kinesin-Related Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596981","Muscle Cell","C12612","A connective tissue cell with the ability to convert chemical energy into mechanical energy via a contractile apparatus. As part of the contractile apparatus, the proteins actin and myosin form parallel myofilaments. The interaction of actin and myosin mediates muscle cell contraction in response to stimulation of the excitable cell membrane.","Muscle Cell | Muscle Cells | Myocyte",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504715","DEPDC1 wt Allele","C126130","Human DEPDC1 wild-type allele is located in the vicinity of 1p31.2 and is approximately 23 kb in length. This allele, which encodes DEP domain-containing protein 1A, plays a role in transcriptional regulation. Aberrant expression of this gene is associated with bladder cancer.","DEPDC1 wt Allele | DEP Domain Containing 1 wt Allele | DEP.8 | DEPDC1-V2 | DEPDC1A | FLJ20354 | SDP35",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504716","DEPDC1 protein, human","C126131","DEP domain-containing protein 1A (811 aa, ~93 kDa) is encoded by the human DEPDC1 gene. This protein is involved in the negative regulation of transcription.","DEP Domain-Containing Protein 1A | Cell Cycle Control Protein SDP35 | DEPDC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504853","PE/HPV16 E7/KDEL fusion protein TVGV-1","C126276","A fusion protein consisting of a peptide sequence of human papillomavirus (HPV) type 16 E7 nuclear protein and fused to the Pseudomonas aeruginosa exotoxin A (PE) and a endoplasmic reticulum (ER) retention signal (KDEL), with potential antineoplastic activity. Upon administration of PE/HPV16 E7/KDEL fusion protein TVGV-1, the PE moiety binds to CD91 (LRP1) expressed on a variety of cells, including antigen-presenting cells such as dendritic cells (DCs), which facilitates the internalization, through endocytosis, of TVGV-1. Following endocytosis, this agent is proteolytically cleaved by the proteasome and the epitopes from the HPV E7 protein become bound to MHC-I molecules and are presented on the DC-cell surface. This facilitates a cytotoxic T-cell- mediated immune response against HPV16 E7 expressing-tumor cells. KDEL targets the fusion protein to the ER, which increases this agent's potential to be bound by MHC-I molecules; this increases the immune response against HPV16 E7-expressing cancer cells.","PE/HPV16 E7/KDEL Fusion Protein/GPI-0100 TVGV-1 | PE-E7-KDEL/GPI-0100 TVGV-1 | PEK Fusion Protein/GPI-0100 Vaccine | TVGV-1 | TVGV-1 Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL504854","Neutrophil Activation Probe Imaging Agent","C126277","A fluorescence imaging agent composed of a fluorescent agent linked, via a human neutrophil elastase (HNE) cleavable peptide, to a dequencher molecule, with imaging activity for diagnostic purposes. Upon local administration, the neutrophil activation probe (NAP) imaging agent, initially quenched, is quickly taken up by activated neutrophils. In turn, the HNE expressed by these cells, specifically cleaves the linker and dequenches the fluorescent agent. The activated fluorescent moiety allows for visualization of activated neutrophils and HNE activity upon using a fluorescence imaging device. Activated neutrophils are upregulated at sites of inflammation and in inflammation-induced cancers, and express high levels of HNE.","Neutrophil Activation Probe Imaging Agent | NAP | NAP Imaging Agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027750","Myelinated Nerve Fiber","C12627","A nerve axon that is surrounded by a layer of myelin.","Myelinated Nerve Fiber | Myelinated Nerve Fibers",,,,,,,,,,,,,,,"4203924","Myelinated nerve fiber structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513142","HAMD 24 - Depressed Mood","C130335","Hamilton Depression Rating Scale-24 Item (HAMD 24) Depressed mood.","HAMD 24 - Depressed Mood | HAMD3-Depressed Mood | HAMD301",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513152","HAMD 24 - Low Self-esteem, Guilt","C130336","Hamilton Depression Rating Scale-24 Item (HAMD 24) Low self-esteem, guilt.","HAMD 24 - Low Self-esteem, Guilt | HAMD3-Low Self-Esteem, Guilt | HAMD302",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513159","HAMD 24 - Suicidal Thoughts","C130337","Hamilton Depression Rating Scale-24 Item (HAMD 24) Suicidal thoughts.","HAMD 24 - Suicidal Thoughts | HAMD3-Suicidal Thoughts | HAMD303",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513151","HAMD 24 - Insomnia - Middle","C130339","Hamilton Depression Rating Scale-24 Item (HAMD 24) Insomnia: middle.","HAMD 24 - Insomnia - Middle | HAMD3-Insomnia - Middle | HAMD305",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512650","Immune System Part","C13033","Any component of the complex group of organs including the thymus, spleen, tonsils, lymphatic system, hematopoietic system and cells like lymphocytes, granulocytes, monocytes and macrophages that defends the body against infection or disease.","Immune System Part | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513150","HAMD 24 - Insomnia - Late","C130340","Hamilton Depression Rating Scale-24 Item (HAMD 24) Insomnia: late.","HAMD 24 - Insomnia - Late | HAMD3-Insomnia - Late | HAMD306",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513162","HAMD 24 - Work and Interests","C130341","Hamilton Depression Rating Scale-24 Item (HAMD 24) Work and interests.","HAMD 24 - Work and Interests | HAMD3-Work and Interests | HAMD307",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513156","HAMD 24 - Psychomotor Retardation","C130342","Hamilton Depression Rating Scale-24 Item (HAMD 24) Psychomotor retardation.","HAMD 24 - Psychomotor Retardation | HAMD3-Psychomotor Retardation | HAMD308",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513155","HAMD 24 - Psychomotor Agitation","C130343","Hamilton Depression Rating Scale-24 Item (HAMD 24) Psychomotor agitation.","HAMD 24 - Psychomotor Agitation | HAMD3-Psychomotor Agitation | HAMD309",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513139","HAMD 24 - Anxiety, Psychic","C130344","Hamilton Depression Rating Scale-24 Item (HAMD 24) Anxiety, psychic.","HAMD 24 - Anxiety, Psychic | HAMD3-Anxiety - Psychic | HAMD310",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513140","HAMD 24 - Anxiety, Somatic","C130345","Hamilton Depression Rating Scale-24 Item (HAMD 24) Anxiety, somatic.","HAMD 24 - Anxiety, Somatic | HAMD3-Anxiety - Somatic | HAMD311",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513158","HAMD 24 - Somatic Symptoms, General","C130347","Hamilton Depression Rating Scale-24 Item (HAMD 24) Somatic symptoms, general.","HAMD 24 - Somatic Symptoms, General | HAMD3-Somatic Symptoms - General | HAMD313",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513157","HAMD 24 - Sexual Disturbances","C130348","Hamilton Depression Rating Scale-24 Item (HAMD 24) Sexual disturbances.","HAMD 24 - Sexual Disturbances | HAMD3-Sexual Disturbances | HAMD314",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513147","HAMD 24 - Hypochondriasis (Somatisation)","C130349","Hamilton Depression Rating Scale-24 Item (HAMD 24) Hypochondriasis (somatisation).","HAMD 24 - Hypochondriasis (Somatisation) | HAMD3-Hypochondriasis (Somatisation) | HAMD315",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513148","HAMD 24 - Insight","C130350","Hamilton Depression Rating Scale-24 Item (HAMD 24) Insight.","HAMD 24 - Insight | HAMD3-Insight | HAMD316",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513161","HAMD 24 - Weight Loss","C130351","Hamilton Depression Rating Scale-24 Item (HAMD 24) Weight loss.","HAMD 24 - Weight Loss | HAMD3-Weight Loss | HAMD317",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514147","IDS-SR - Mood Worse in Morning, Afternoon, or Night","C130560","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Is your mood typically worse in the morning, afternoon or night?","IDS-SR - Mood Worse in Morning, Afternoon, or Night | IDSR1-Mood Worse Morn/Afternoon/Night | IDSR109A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513741","WHODAS 2.0 36-item Version Self-administered - Understanding What People Say","C130814","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Generally understanding what people say?","WHODAS 2.0 36-item Version Self-administered - Understanding What People Say | WD7-Understanding What People Say | WD7D1_5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513738","WHODAS 2.0 36-item Version Self-administered - Starting or Maintaining Conversation","C130815","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Starting and maintaining a conversation?","WHODAS 2.0 36-item Version Self-administered - Starting or Maintaining Conversation | WD7-Starting/Maintaining Conversation | WD7D1_6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513736","WHODAS 2.0 36-item Version Self-administered - Standing Up From Sitting Down","C130817","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Standing up from sitting down?","WHODAS 2.0 36-item Version Self-administered - Standing Up From Sitting Down | WD7-Standing Up From Sitting Down | WD7D2_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513802","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.756G>T Mutation","C130206","A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where guanine has been substituted with thymine at nucleotide position 756 of the ABL1 gene.","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.756G>T Mutation | BCR/ABL Fusion Gene with NM_005157.4:c.756G>T | BCR/ABL Fusion Gene with NM_005157.5:c.756G>T | BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.756G>T | BCR/ABL1 Fusion Gene with NM_005157.4:c.756G>T | BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.756G>T Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513801","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.756G>C Mutation","C130207","A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where guanine has been substituted with cytosine at nucleotide position 756 of the ABL1 gene.","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.756G>C Mutation | BCR/ABL Fusion Gene with NM_005157.4:c.756G>C | BCR/ABL Fusion Gene with NM_005157.5:c.756G>C | BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.756G>C | BCR/ABL1 Fusion Gene with NM_005157.4:c.756G>C | BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.756G>C Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513803","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.758A>T Mutation","C130209","A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where adenine has been substituted with thymine at nucleotide position 758 of the ABL1 gene.","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.758A>T Mutation | BCR/ABL Fusion Gene with NM_005157.4:c.758A>T | BCR/ABL Fusion Gene with NM_005157.5:c.758A>T | BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.758A>T | BCR/ABL1 Fusion Gene with NM_005157.4:c.758A>T | BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.758A>T Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1268091","Breast Part","C13020","Any anatomic component of one or both breasts.","Breast Part | Breast-Related Entity",,,,,,,,,,,,,,,"4000495","Breast part",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509003","Three-Dimensional Echo-Planar Spectroscopic Imaging","C127837","A three-dimensional application of magnetic resonance spectroscopic imaging that uses an alternating gradient applied along one of the spatial readout directions to simultaneously encode the space and chemical shift, thereby reducing the phase-encoding dimension by one and increasing speed.","Three-Dimensional Echo-Planar Spectroscopic Imaging | 3D-EPSI | Volumetric Echo-Planar Spectroscopic Imaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040954","Trichuriasis","C128399","An infection that is caused by the nematode Trichuris trichiura, a soil-transmitted helminth, which is transmitted via food and/or water contaminated with the eggs of the worm. Symptoms are usually mild and include abdominal pain, diarrhea, fatigue, and possibly anemia secondary to blood loss in diarrhea.","Trichuriasis | Whipworm Infection",,,,,,,,,,,,,,,"196907","Trichuriasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1524094","Recombinant Cytokines","C1283","No value exists.","Recombinant Cytokine | Cytokines",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027030","Myiasis","C128400","The infection of a fly larva (maggot) in human tissue, which most commonly occurs in tropical climates. Affected tissues most commonly include skin, especially if open wounds are present, nasal passages, ears, and eyes.","Myiasis | ",,,,,,,,,,,,,,,"441799","Infestation by fly larvae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030756","Infestation by Anoplura","C128401","A contagious infestation of parasitic insects found on the head (Pediculus humanus capitis), body (Pediculus humanus corporis), or pubic area (Pthirus pubis) that typically cause itching and rash.","Pediculosis | Lice Infestation",,,,,,,,,,,,,,,"4327199","Infestation by Anoplura",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153042","Herpetic Whitlow","C128402","A painful blister of the periungual skin that is caused by herpes simplex virus type 1 or 2.","Herpetic Whitlow | ",,,,,,,,,,,,,,,"76034","Herpetic whitlow",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0685928","Suppurative Parotitis","C128403","Parotitis that is caused by a bacterial agent.","Suppurative Parotitis | ",,,,,,,,,,,,,,,"4317256","Suppurative parotitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0340445","Bacterial Pericarditis","C128404","Pericarditis that is caused by an infection with a bacterial agent.","Bacterial Pericarditis | ",,,,,,,,,,,,,,,"4124694","Bacterial pericarditis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0276139","Viral Pericarditis","C128405","Pericarditis that is caused by an infection with a viral agent.","Viral Pericarditis | ",,,,,,,,,,,,,,,"4289908","Viral pericarditis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0276647","Fungal Pericarditis","C128406","Pericarditis that is caused by an infection with a fungal agent.","Fungal Pericarditis | ",,,,,,,,,,,,,,,"4196524","Mycotic pericarditis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0341503","Bacterial Peritonitis","C128407","Peritonitis that is caused by a bacterial infection.","Bacterial Peritonitis | ",,,,,,,,,,,,,,,"4026017","Bacterial peritonitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0343398","Cyclosporiasis","C128409","A protozoan infection that is caused by Cyclospora cayetanensis, which is most commonly acquired from contaminated food or water, and which is characterized by watery diarrhea and abdominal pain.","Cyclosporiasis | ",,,,,,,,,,,,,,,"200017","Cyclosporiasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513657","WHODAS 2.0 36-item Version Interviewer-administered - Staying by Yourself for a Few Days","C130741","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Staying by yourself for a few days?","WHODAS 2.0 36-item Version Interviewer-administered - Staying by Yourself for a Few Days | WD5-Staying by Yourself for a Few Days | WD5D3_4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0082338","Dolastatin 10","C1300","A pentapeptide originally isolated from the marine mollusk Dolabella auricularia with potential antineoplastic activity.  Binding to tubulin, Dolastatin 10 inhibits microtubule assembly, resulting in the formation of tubulin aggregates and inhibition of mitosis.  This agent also induces tumor cell apoptosis through a mechanism involving bcl-2, an oncoprotein that is overexpressed in some cancers. (NCI04)","Dolastatin 10 | B720389K560 | DOLASTATIN 10 | Dolastatin-10 | L-Valinamide, N,N-dimethyl-L-valyl-N-[2-methoxy-4-[2-[1- methoxy-2-methyl-3-oxo-3-[[2-phenyl-1-(2-thiazolyl)ethyl]amino]propyl]-1-pyrrolidinyl]-1-(1-methylpropyl)-4-oxobutyl]-N-methyl-, [2S-[1[1R*(R*),2S*],2R*[1S*,2S*,3(R*)]]] | dolastatin 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006323","Brunner's Gland","C13010","Compound, tubular, submucosal glands located in the duodenum proximal to the sphincter of Oddi; these glands produce alkaline-rich secretions that function to both protect the duodenum from the acidic content of the stomach and to enable intestinal enzymes to activate, thus enabling absorption to start.","Brunner's Gland | Brunner's Glands | GLAND, BRUNNER'S",,,,,,,,,,,,,,,"37017948","Structure of duodenal gland",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514146","IDS-SR - Mood Variation Attributed to Environment","C130561","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Is your mood variation attributed to the environment?","IDS-SR - Mood Variation Attributed to Environment | IDSR1-Mood Attributed to Environment | IDSR109B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514152","IDS-SR - The Quality of Your Mood","C130562","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: The quality of your mood.","IDS-SR - The Quality of Your Mood | IDSR1-Quality of Your Mood | IDSR110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514133","IDS-SR - Decreased Appetite","C130563","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Decreased appetite.","IDS-SR - Decreased Appetite | IDSR1-Decreased Appetite | IDSR111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514142","IDS-SR - Increased Appetite","C130564","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Increased appetite.","IDS-SR - Increased Appetite | IDSR1-Increased Appetite | IDSR112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514160","IDS-SR - Weight (Decrease)","C130565","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: within the last two weeks: Weight (decrease).","IDS-SR - Weight (Decrease) | IDSR1-Weight (Decrease) | IDSR113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514161","IDS-SR - Weight (Increase)","C130566","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: within the last two weeks: Weight (increase).","IDS-SR - Weight (Increase) | IDSR1-Weight (Increase) | IDSR114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514131","IDS-SR - Concentration or Decision Making","C130567","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Concentration/decision making.","IDS-SR - Concentration or Decision Making | IDSR1-Concentration/Decision Making | IDSR115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514158","IDS-SR - View of Myself","C130568","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: View of myself.","IDS-SR - View of Myself | IDSR1-View of Myself | IDSR116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514157","IDS-SR - View of My Future","C130569","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: View of my future.","IDS-SR - View of My Future | IDSR1-View of My Future | IDSR117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514156","IDS-SR - Thoughts of Death or Suicide","C130570","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Thoughts of death or suicide.","IDS-SR - Thoughts of Death or Suicide | IDSR1-Thoughts of Death or Suicide | IDSR118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514141","IDS-SR - General Interest","C130571","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: General interest.","IDS-SR - General Interest | IDSR1-General Interest | IDSR119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514134","IDS-SR - Energy Level","C130572","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Energy level.","IDS-SR - Energy Level | IDSR1-Energy Level | IDSR120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514151","IDS-SR - Capacity for Pleasure or Enjoyment","C130573","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Capacity for pleasure or enjoyment (excluding sex).","IDS-SR - Capacity for Pleasure or Enjoyment | IDSR1-Pleasure/Enjoyment (Exclude Sex) | IDSR121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513804","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.763G>A Mutation","C130211","A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where guanine has been substituted with adenine at nucleotide position 763 of the ABL1 gene. This mutation is associated with imatinib- and nilotinib-resistant leukemias.","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.763G>A Mutation | BCR/ABL Fusion Gene with NM_005157.4:c.763G>A | BCR/ABL Fusion Gene with NM_005157.5:c.763G>A | BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.763G>A | BCR/ABL1 Fusion Gene with NM_005157.4:c.763G>A | BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.763G>A Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513309","QIDS-C - Appetite (Decreased)","C130399","Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Appetite (decreased).","QIDS-C - Appetite (Decreased) | QIDSC1-Appetite (Decreased) | QIDSC106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513310","QIDS-C - Appetite (Increased)","C130400","Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Appetite (increased).","QIDS-C - Appetite (Increased) | QIDSC1-Appetite (Increased) | QIDSC107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513327","QIDS-C - Weight (Decrease)","C130401","Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Weight (decrease) within the last two weeks.","QIDS-C - Weight (Decrease) | QIDSC1-Weight (Decrease) | QIDSC108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513328","QIDS-C - Weight (Increase)","C130402","Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Weight (increase) within the last two weeks.","QIDS-C - Weight (Increase) | QIDSC1-Weight (Increase) | QIDSC109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513311","QIDS-C - Concentration or Decision Making","C130403","Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Concentration/decision making.","QIDS-C - Concentration or Decision Making | QIDSC1-Concentration/Decision Making | QIDSC110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513321","QIDS-C - Outlook (Self)","C130404","Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Outlook (self).","QIDS-C - Outlook (Self) | QIDSC1-Outlook (Self) | QIDSC111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035793","Rocky Mountain Spotted Fever","C128410","An infection that is caused by Rickettsia rickettsii, which is transmitted to humans from infected ticks; it is characterized by the sudden onset of fever, headache, and myalgia, followed by rash that usually begins peripherally.","Rocky Mountain Spotted Fever | ",,,,,,,,,,,,,,,"4089968","Rocky Mountain spotted fever",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0149512","Acute Sinusitis","C128411","Sinusitis lasting less than or equal to thirty days.","Acute Sinusitis | ",,,,,,,,,,,,,,,"260123","Acute sinusitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2931317","Primary Syphilis","C128412","The subclinical or symptomatic stage of syphilis, occurring at an average of three weeks after contact with an infected individual. It manifests with one or more painless, indurated ulcers (chancres) of the skin or mucous membranes at the site of inoculation. These lesions heal spontaneously within a few weeks.","Primary Syphilis | ",,,,,,,,,,,,,,,"433410","Primary syphilis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0149985","Secondary Syphilis","C128413","The secondary stage of syphilis typically that is characterized by generalized rash (including palms and soles), mucocutaneous lesions, and lymphadenopathy. It usually begins one to two months after the primary stage.","Secondary Syphilis | ",,,,,,,,,,,,,,,"437787","Secondary syphilis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0153188","Tertiary Syphilis","C128414","A stage of syphilis that occurs fifteen to thirty years after the initial infection; it can include gumma formation and cardiovascular or central nervous system involvement (neurosyphilis).","Tertiary Syphilis | Late Syphilis",,,,,,,,,,,,,,,"435739","Late syphilis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0206526","Multidrug-Resistant Tuberculosis","C128415","Tuberculosis disease that is caused by a multidrug-resistant strain of Mycobacterium tuberculosis.","Multidrug-Resistant Tuberculosis | MDR-TB | Multidrug-Resistant TB",,,,,,,,,,,,,,,"4307131","Multidrug resistant tuberculosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509765","Pre-Extensively Drug-Resistant Tuberculosis","C128416","Tuberculosis disease that is caused by a pre-extensively drug-resistant strain of Mycobacterium tuberculosis.","Pre-Extensively Drug-Resistant Tuberculosis | Pre-Extensively Drug-Resistant TB | Pre-XDR-TB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509195","GAIA Level 3 Maternal Immunization","C127983","GAIA Level 3 Maternal immunization is defined by two criteria: first, the woman/medical attendant reports the pregnancy; second, the woman reports receipt of vaccination during pregnancy, but no formal recording of the immunization is available.","GAIA Level 3 Maternal Immunization | Global Alignment of Immunization safety Assessment in pregnancy Level 3 Maternal Immunization | Level 3 Maternal Immunisation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509228","GAIA Level 1 Neonatal Invasive Bloodstream Infection","C127984","GAIA Level 1 Neonatal Invasive Bloodstream Infection is defined by two criteria: first, identification of a recognized pathogen from a normally sterile site using a validated method; second, if a normally non-pathogenic organism is isolated from blood cultures the following two requirements must be met: a) The cultures must be obtained from two different sites OR taken at two different times; b) One or more of the level 2 criteria must be present.","GAIA Level 1 Neonatal Invasive Bloodstream Infection | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Neonatal Invasive Blood Stream Infection | Level 1 Neonatal Blood Stream Infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509232","GAIA Level 2 Neonatal Invasive Bloodstream Infection","C127985","GAIA Level 2 Neonatal Invasive Bloodstream Infection is defined by two criteria: first, the criteria does not meet the requirements for level 1 diagnostic certainty; second, three or more of the following requirements must be met: a) Temperature greater than or equal to 37.5 degrees C or less than 35.5 degrees C; b) Tachycardia or new or more frequent episodes of bradycardia; c) New or more frequent episodes of apnea or increased oxygen requirement or increased requirement for ventilatory support; d) Lethargy or moving only when stimulated or hypotonia or irritability; e) Difficulty in feeding or abdominal distention; f) Pallor or poor perfusion or hypotension; g) Abnormal white cell count or I/T (immature/total neutrophil) ratio greater than 0.2; h) Abnormal platelet count; i) Increased number of inflammatory markers (CRP, procalcitonin); j) Metabolic acidosis as defined by a base excess.","GAIA Level 2 Neonatal Invasive Bloodstream Infection | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Neonatal Invasive Blood Stream Infection | Level 2 Neonatal Blood Stream Infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509235","GAIA Level 3 Neonatal Invasive Bloodstream Infection","C127986","GAIA Level 3 Neonatal Invasive Bloodstream Infection is defined by two criteria: first, the criteria does not meet the requirements for level 1 or 2 diagnostic certainty; second, two or more of the following requirements must be met: a) Temperature greater than or equal to 37.5 degrees C or less than 35.5 degrees C; b) Tachypnea or severe chest indrawing or grunting or cyanosis; c) Change in level of activity; d) History of feeding difficulty; e) History of convulsions.","GAIA Level 3 Neonatal Invasive Bloodstream Infection | Global Alignment of Immunization safety Assessment in pregnancy Level 3 Neonatal Invasive Blood Stream Infection | Level 3 Neonatal Blood Stream Infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514189","WHODAS 2.0 12-item Version Self-administered Questionnaire Question","C130302","A question associated with the WHODAS 2.0 12-item Version Self-administered questionnaire.","WHODAS 2.0 12-item Version Self-administered Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514186","WHODAS 2.0 12 24-item Version Interviewer-administered Questionnaire Question","C130303","A question associated with the WHODAS 2.0 12+24-item Version Interviewer-administered questionnaire.","WHODAS 2.0 12 24-item Version Interviewer-administered Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513698","WHODAS 2.0 36-item Version Proxy-administered - Starting or Maintaining Conversation","C130776","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Starting and maintaining a conversation?","WHODAS 2.0 36-item Version Proxy-administered - Starting or Maintaining Conversation | WD6-Starting/Maintaining Conversation | WD6D1_6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513697","WHODAS 2.0 36-item Version Proxy-administered - Standing for Long Periods","C130777","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Standing for long periods such as 30 minutes?","WHODAS 2.0 36-item Version Proxy-administered - Standing for Long Periods | WD6-Standing for Long Periods | WD6D2_1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513696","WHODAS 2.0 36-item Version Proxy-administered - Standing Up From Sitting Down","C130778","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Standing up from sitting down?","WHODAS 2.0 36-item Version Proxy-administered - Standing Up From Sitting Down | WD6-Standing Up From Sitting Down | WD6D2_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513688","WHODAS 2.0 36-item Version Proxy-administered - Moving Around Inside Their Home","C130779","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Moving around inside their home?","WHODAS 2.0 36-item Version Proxy-administered - Moving Around Inside Their Home | WD6-Moving Around Inside Their Home | WD6D2_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513680","WHODAS 2.0 36-item Version Proxy-administered - Getting Out of Their Home","C130780","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Getting out of their home?","WHODAS 2.0 36-item Version Proxy-administered - Getting Out of Their Home | WD6-Getting Out of Their Home | WD6SD2_4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513703","WHODAS 2.0 36-item Version Proxy-administered - Walking a Long Distance","C130781","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Walking a long distance such as a kilometre [or equivalent]?","WHODAS 2.0 36-item Version Proxy-administered - Walking a Long Distance | WD6-Walking a Long Distance | WD6SD2_5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513704","WHODAS 2.0 36-item Version Proxy-administered - Washing His or Her Whole Body","C130782","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Because of their health condition, in the past 30 days, how much difficulty did your relative have in: Washing his or her whole body?","WHODAS 2.0 36-item Version Proxy-administered - Washing His or Her Whole Body | WD6-Washing His/Her Whole Body | WD6D3_1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513677","WHODAS 2.0 36-item Version Proxy-administered - Getting Dressed","C130783","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Because of their health condition, in the past 30 days, how much difficulty did your relative have in: Getting dressed?","WHODAS 2.0 36-item Version Proxy-administered - Getting Dressed | WD6-Getting Dressed | WD6D3_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513672","WHODAS 2.0 36-item Version Proxy-administered - Eating","C130784","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Because of their health condition, in the past 30 days, how much difficulty did your relative have in: Eating?","WHODAS 2.0 36-item Version Proxy-administered - Eating | WD6-Eating | WD6D3_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513318","QIDS-C - Involvement","C130406","Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Involvement.","QIDS-C - Involvement | QIDSC1-Involvement | QIDSC113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513313","QIDS-C - Energy or Fatiguability","C130407","Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Energy/fatiguability.","QIDS-C - Energy or Fatiguability | QIDSC1-Energy/Fatiguability | QIDSC114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513323","QIDS-C - Psychomotor Slowing","C130408","Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Psychomotor slowing.","QIDS-C - Psychomotor Slowing | QIDSC1-Psychomotor Slowing | QIDSC115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513322","QIDS-C - Psychomotor Agitation","C130409","Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Psychomotor agitation.","QIDS-C - Psychomotor Agitation | QIDSC1-Psychomotor Agitation | QIDSC116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518256","Nervous System Part","C13040","Any component of the entire nerve apparatus, including the brain, spinal cord, spinal nerves, autonomic ganglia, and plexuses.","Nervous System Part | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513220","Q-LES-Q - Felt Clearheaded","C130617","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: felt clearheaded?","Q-LES-Q - Felt Clearheaded | QLES1-Felt Clearheaded | QLES114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513233","Q-LES-Q - Felt Satisfied With Your Life","C130618","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: felt satisfied with your life?","Q-LES-Q - Felt Satisfied With Your Life | QLES1-Felt Satisfied With Your Life | QLES115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513224","Q-LES-Q - Felt Good About Your Appearance","C130619","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: felt good about your appearance?","Q-LES-Q - Felt Good About Your Appearance | QLES1-Felt Good About Your Appearance | QLES116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513228","Q-LES-Q - Felt Happy or Cheerful","C130620","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: felt happy or cheerful?","Q-LES-Q - Felt Happy or Cheerful | QLES1-Felt Happy or Cheerful | QLES117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513229","Q-LES-Q - Felt Independent","C130621","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: felt independent?","Q-LES-Q - Felt Independent | QLES1-Felt Independent | QLES118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513221","Q-LES-Q - Felt Content","C130622","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: felt content?","Q-LES-Q - Felt Content | QLES1-Felt Content | QLES119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513192","Q-LES-Q - Able to Communicate With Others","C130623","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: felt able to communicate with others?","Q-LES-Q - Able to Communicate With Others | QLES1-Able to Communicate With Others | QLES120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513281","Q-LES-Q - Taking Care of Your Appearance","C130624","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: felt interested in taking care of your appearance (hair, clothing) and personal hygiene (bathing, dressing)?","Q-LES-Q - Taking Care of Your Appearance | QLES1-Taking Care of Your Appearance | QLES121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509227","GAIA Level 1 Neonatal Infectious Meningitis","C127987","GAIA Level 1 Neonatal Infectious Meningitis is defined by two criteria: first, the recognized pathogen must be identified, using a validated method, from cerebrospinal fluid (CSF); second, if an organism normally considered to be non-pathogenic is identified from the CSF, level 1 of diagnostic certainty additionally requires all level 2 criteria: i.e. CSF pleocytosis AND temperature criteria AND one or more clinical criteria.","GAIA Level 1 Neonatal Infectious Meningitis | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Neonatal Infectious Meningitis | Level 1 Neonatal Meningitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509231","GAIA Level 2 Neonatal Infectious Meningitis","C127988","GAIA Level 2 Neonatal Infectious Meningitis is defined by four criteria: first, CSF pleocytosis OR positive IgM antibodies to a specific pathogen in the CSF; second, a recognized pathogen is identified, using a validated method from a normally sterile site other than the CSF; third, a temperature greater than or equal to 37.5 degrees C or less than 35.5 degrees C; fourth, one or more of the following requirements must be met: a) History of convulsions; b) Lethargy or irritability; c) Coma; d) Apnea; e) Bulging fontanel; f) Neck stiffness.","GAIA Level 2 Neonatal Infectious Meningitis | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Neonatal Infectious Meningitis | Level 2 Neonatal Meningitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509238","GAIA Level 3a Neonatal Infectious Meningitis","C127989","GAIA Level 3a Neonatal Infectious Meningitis is defined by four criteria: first, CSF pleocytosis; second, NO recognized pathogen is identified, using a validated method, from a normally sterile site; third, temperature greater than or equal to 37.5 degrees C or less than 35.5 degrees C; fourth, three or more of the following requirements must be met: a) History of convulsions; b) Lethargy or irritability; c) Coma; d) Apnea; e) Bulging fontanel; f) Neck stiffness.","GAIA Level 3a Neonatal Infectious Meningitis | Global Alignment of Immunization safety Assessment in pregnancy Level 3a Neonatal Infectious Meningitis | Level 3a Neonatal Bacterial/Fungal/Viral Meningitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509239","GAIA Level 3b Neonatal Infectious Meningitis","C127990","GAIA Level 3b Neonatal Infectious Meningitis is defined by three criteria: first, no lumbar puncture is done or no sample is available; second, temperature greater than or equal to 37.5 degrees C or less than 35.5 degrees C; third, four or more of the following requirements must be met: a) History of convulsions; b) Lethargy or irritability; c) Coma; d) Apnea; e) Bulging fontanel; f) Neck stiffness.","GAIA Level 3b Neonatal Infectious Meningitis | Global Alignment of Immunization safety Assessment in pregnancy Level 3b Neonatal Infectious Meningitis | Level 3b Neonatal Meningitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513927","FACT-LYM Version 4 - I Am Satisfied With My Sex Life","C130516","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Social/Family Well-Being: I am satisfied with my sex life.","FACT-LYM Version 4 - I Am Satisfied With My Sex Life | FAC018-I Am Satisfied With My Sex Life | FAC01814",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513933","FACT-LYM Version 4 - I Feel Sad","C130517","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Emotional Well-Being: I feel sad.","FACT-LYM Version 4 - I Feel Sad | FAC018-I Feel Sad | FAC01815",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513951","FACT-LYM Version 4 - Satisfied With How I Am Coping","C130518","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Emotional Well-Being: I am satisfied with how I am coping with my illness.","FACT-LYM Version 4 - Satisfied With How I Am Coping | FAC018-Satisfied With How I Am Coping | FAC01816",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513947","FACT-LYM Version 4 - Losing Hope Against Illness","C130519","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Emotional Well-Being: I am losing hope in the fight against my illness.","FACT-LYM Version 4 - Losing Hope Against Illness | FAC018-Losing Hope Against Illness | FAC01817",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229619","Hematopoietic Tissue","C13051","No value exists.","Hematopoietic Tissue | hematopoietic tissue",,,,,,,,,,,,,,,"4029619","Bone marrow structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513932","FACT-LYM Version 4 - I Feel Nervous","C130520","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Emotional Well-Being: I feel nervous.","FACT-LYM Version 4 - I Feel Nervous | FAC018-I Feel Nervous | FAC01818",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513945","FACT-LYM Version 4 - I Worry About Dying","C130521","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Emotional Well-Being: I worry about dying.","FACT-LYM Version 4 - I Worry About Dying | FAC018-I Worry About Dying | FAC01819",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513954","FACT-LYM Version 4 - Worry My Condition Will Get Worse","C130522","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Emotional Well-Being: I worry that my condition will get worse.","FACT-LYM Version 4 - Worry My Condition Will Get Worse | FAC018-Worry My Condition Will Get Worse | FAC01820",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513699","WHODAS 2.0 36-item Version Proxy-administered - Staying by Him or Herself a Few Days","C130785","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Because of their health condition, in the past 30 days, how much difficulty did your relative have in: Staying by himself or herself for a few days?","WHODAS 2.0 36-item Version Proxy-administered - Staying by Him or Herself a Few Days | WD6-Staying by Him/Herself a Few Days | WD6D3_4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513668","WHODAS 2.0 36-item Version Proxy-administered - Dealing With People Does Not Know","C130786","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Because of their health condition, in the past 30 days, how much difficulty did your relative have in: Dealing with people he or she does not know?","WHODAS 2.0 36-item Version Proxy-administered - Dealing With People Does Not Know | WD6-Dealing With People Does Not Know | WD6D4_1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162534","Transmissible Spongiform Encephalopathy","C128346","A transmissible, infectious disease that is caused by a protein that is able to induce abnormal folding of normal cellular proteins, leading to characteristic spongiform brain changes, which are associated with neuronal loss without an inflammatory response. Such disorders have typically long incubation periods, but are then generally rapidly progressive and are uniformly fatal.","Transmissible Spongiform Encephalopathy | Prion Disease | Spongiform Encephalopathy | Transmissible Spongiform Encephalopathy(TSE)",,,,,,,,,,,,,,,"444407","Prion disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085819","Antibiotic-Associated Colitis","C128347","Inflammation of the colon that is caused by an alteration in intestinal flora by antibiotic use.","Antibiotic-Associated Colitis | ",,,,,,,,,,,,,,,"4262170","Antibiotic enterocolitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1562344","Fecal-Oral Transmission","C128348","The transmission of an infectious agent to a host's oral cavity via the fecal particles of another living organism.","Fecal-Oral Transmission | ",,,,,,,,,,,,,,,"4219299","Fecal-oral transmission",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509032","Cercarial Dermatitis","C128349","A pruritic rash that occurs as consequence of cercariae penetration of the skin after aquatic exposure to animal (usually avian) schistosomes, often in countries non-endemic to human schistosomiasis. The condition is non-invasive and responsive to symptomatic treatment.","Cercarial Dermatitis | Duck Itch | Lake Itch | Swimmer's Itch",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0578159","Antibiotic-Associated Diarrhea","C128350","Diarrhea that is associated with current or recent antibiotic use.","Antibiotic-Associated Diarrhea | ",,,,,,,,,,,,,,,"4115563","Antibiotic-associated diarrhea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0016479","Foodborne Illness","C128351","Any disorder that results from the consumption of food contaminated with an infectious agent or toxin.","Foodborne Illness | Food Poisoning",,,,,,,,,,,,,,,"434854","Food poisoning",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509447","Droplet Transmission","C128352","The direct transmission of an infectious agent to a host by a spray of a relatively large (greater than five microns), short range respiratory aerosol.","Droplet Transmission | Droplet Pathogen Transmission | Droplet Spread",,,,,,,,,,,,,,,"37208192","Droplet transmission",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1562835","Airborne Transmission","C128353","The direct transmission of an infectious agent to a host via droplet nuclei (less than or equal to five microns) or dust suspended in the air.","Airborne Transmission | Airborne Pathogen Transmission",,,,,,,,,,,,,,,"4216586","Airborne transmission",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0003898","Arthropod Vector","C128354","An animal within the phylum Arthropoda that transmits an infectious agent to a vertebrate animal.","Arthropod Vector | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1142550","Native Valve Endocarditis","C128355","Endocarditis affecting a native valve of the heart.","Native Valve Endocarditis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0340359","Prosthetic Valve Endocarditis","C128356","Endocarditis occurring on parts of a valve prosthesis or a reconstructed heart valve; it can be classified into early and late prosthetic valve endocarditis.","Prosthetic Valve Endocarditis | ",,,,,,,,,,,,,,,"4121469","Prosthetic valve endocarditis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508733","Early Prosthetic Valve Endocarditis","C128357","Prosthetic valve endocarditis that occurs days to weeks after surgery.","Early Prosthetic Valve Endocarditis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014121","Bacterial Endocarditis","C128359","Endocarditis that is caused by an infection with a bacterial agent.","Bacterial Endocarditis | ",,,,,,,,,,,,,,,"4116649","Bacterial endocarditis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509013","Vulvar Adenocarcinoma of Mammary Gland Type","C128162","A rare adenocarcinoma that arises from the vulva and is characterized by the presence of morphological features identical to those seen in breast adenocarcinomas.","Vulvar Adenocarcinoma of Mammary Gland Type | AGMLGs | Adenocarcinoma of Anogenital Mammary-Like Glands | Adenocarcinoma of Anogenital Mammary-Type Glands | Adenocarcinoma of Mammary Gland Type | Adenocarcinoma of Mammary Gland-Type | Adenocarcinoma of the Vulva with Breast Carcinoma Features | Vulvar Adenocarcinoma of Mammary Gland-Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509752","Mammary Gland Type Features Present","C128163","A microscopic finding indicating the presence of mammary gland type morphological features in a tumor sample.","Mammary Gland Type Features Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509751","Malignant Vulvar Phyllodes Tumor","C128165","A rare malignant phyllodes tumor arising from the vulva.","Malignant Vulvar Phyllodes Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509363","Vulvar Cloacogenic Carcinoma","C128166","A rare vulvar mucinous adenocarcinoma that resembles a large intestinal adenocarcinoma.","Vulvar Mucinous Adenocarcinoma, Intestinal-Type | Primary Villoglandular Mucinous Adenocarcinoma Arising in the Surface Epithelium of the Vulva | Vulvar Adenocarcinoma of Intestinal Type | Vulvar Adenocarcinoma, Intestinal-Type | Vulvar Adenocarcinoma, Intestinal-Type | Vulvar Cloacogenic Adenocarcinoma | Vulvar Cloacogenic Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509571","Vulvar Keratoacanthoma","C128167","A keratoacanthoma that arises from the vulva. It grows rapidly and may regress spontaneously. It is considered a variant of well-differentiated squamous cell carcinoma with distinct clinical behavior.","Vulvar Keratoacanthoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509727","Contact Transmission","C128168","The transmission of an infectious agent via touch.","Contact Transmission | Contact Pathogen Transmission",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509440","Direct Transmission","C128169","The transmission of an infectious agent from a source (e.g., person, animal, or surface) to a host without an intermediary.","Direct Transmission | Direct Contact Transmission",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507918","glucocorticoid receptor antagonist CORT125134","C127838","An orally available antagonist of the glucocorticoid receptor (GR), with potential antineoplastic activity. Upon administration,  relacorilant competitively binds to and blocks GRs. This inhibits the activity of GRs, and prevents both the translocation of the ligand-GR complexes to the nucleus and gene expression of GR-associated genes. This decreases the negative effects that result from excess levels of endogenous glucocorticoids, like those seen when tumors overproduce glucocorticoids. In addition, by binding to GRs and preventing their activity, inhibition with CORT125134 also inhibits the proliferation of GR-overexpressing cancer cells. GRs are overexpressed in certain tumor cell types and promote tumor cell proliferation.","Relacorilant | ((4aR)-1-(4-Fluorophenyl)-6-(1-methyl-1H-pyrazole-4-sulfonyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone | CORT-125134 | CORT125134 | Methanone, ((4aR)-1-(4-Fluorophenyl)-1,4,5,6,7,8-hexahydro-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4aH-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)-2-pyridinyl)- | RELACORILANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513922","FACT-LYM Version 4 - I Am Able to Work","C130523","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Functional Well-Being: I am able to work (include work at home).","FACT-LYM Version 4 - I Am Able to Work | FAC018-I Am Able to Work | FAC01821",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513949","FACT-LYM Version 4 - My Work Is Fulfilling","C130524","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Functional Well-Being: My work (include work at home) is fulfilling.","FACT-LYM Version 4 - My Work Is Fulfilling | FAC018-My Work Is Fulfilling | FAC01822",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513936","FACT-LYM Version 4 - I Have Accepted My Illness","C130526","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Functional Well-Being: I have accepted my illness.","FACT-LYM Version 4 - I Have Accepted My Illness | FAC018-I Have Accepted My Illness | FAC01824",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513928","FACT-LYM Version 4 - I Am Sleeping Well","C130527","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Functional Well-Being: I am sleeping well.","FACT-LYM Version 4 - I Am Sleeping Well | FAC018-I Am Sleeping Well | FAC01825",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513918","FACT-LYM Version 4 - Enjoy Things I Usually Do for Fun","C130528","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Functional Well-Being: I am enjoying the things I usually do for fun.","FACT-LYM Version 4 - Enjoy Things I Usually Do for Fun | FAC018-Enjoy Things I Usually Do for Fun | FAC01826",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513916","FACT-LYM Version 4 - Content With Quality of My Life","C130529","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Functional Well-Being: I am content with the quality of my life right now.","FACT-LYM Version 4 - Content With Quality of My Life | FAC018-Content With Quality of My Life | FAC01827",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513915","FACT-LYM Version 4 - Certain Parts of Body Have Pain","C130530","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Additional Concerns: I have certain parts of my body where I experience pain.","FACT-LYM Version 4 - Certain Parts of Body Have Pain | FAC018-Certain Parts of Body Have Pain | FAC01828",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513643","WHODAS 2.0 36-item Version Interviewer-administered - Maintaining a Friendship","C130743","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Maintaining a friendship?","WHODAS 2.0 36-item Version Interviewer-administered - Maintaining a Friendship | WD5-Maintaining a Friendship | WD5D4_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513629","WHODAS 2.0 36-item Version Interviewer-administered - Get Along With People Close to You","C130744","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Getting along with people who are close to you?","WHODAS 2.0 36-item Version Interviewer-administered - Get Along With People Close to You | WD5-Get Along With People Close to You | WD5D4_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513644","WHODAS 2.0 36-item Version Interviewer-administered - Making New Friends","C130745","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Making new friends?","WHODAS 2.0 36-item Version Interviewer-administered - Making New Friends | WD5-Making New Friends | WD5D4_4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513615","WHODAS 2.0 36-item Version Interviewer-administered - Care of Household Responsibilities","C130747","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) Because of your health condition, in the past 30 days, how much difficulty did you have in: Taking care of your household responsibilities?","WHODAS 2.0 36-item Version Interviewer-administered - Care of Household Responsibilities | WD5-Care of Household Responsibilities | WD5D5_1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513143","HAMD 24 - Diurnal Variation","C130352","Hamilton Depression Rating Scale-24 Item (HAMD 24) Diurnal variation.","HAMD 24 - Diurnal Variation | HAMD3-Diurnal Variation | HAMD318",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513141","HAMD 24 - Depersonalization and Derealisation","C130353","Hamilton Depression Rating Scale-24 Item (HAMD 24) Depersonalization and derealisation.","HAMD 24 - Depersonalization and Derealisation | HAMD3-Depersonalization/Derealization | HAMD319",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513154","HAMD 24 - Paranoid Symptoms","C130354","Hamilton Depression Rating Scale-24 Item (HAMD 24) Paranoid symptoms.","HAMD 24 - Paranoid Symptoms | HAMD3-Paranoid Symptoms | HAMD320",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513153","HAMD 24 - Obsessional and Compulsive Symptoms","C130355","Hamilton Depression Rating Scale-24 Item (HAMD 24) Obsessional and compulsive symptoms.","HAMD 24 - Obsessional and Compulsive Symptoms | HAMD3-Observational/Compulsive Symptoms | HAMD321",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513145","HAMD 24 - Helplessness","C130356","Hamilton Depression Rating Scale-24 Item (HAMD 24) Helplessness.","HAMD 24 - Helplessness | HAMD3-Helplessness | HAMD322",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513146","HAMD 24 - Hopelessness","C130357","Hamilton Depression Rating Scale-24 Item (HAMD 24) Hopelessness.","HAMD 24 - Hopelessness | HAMD3-Hopelessness | HAMD323",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513163","HAMD 24 - Worthlessness","C130358","Hamilton Depression Rating Scale-24 Item (HAMD 24) Worthlessness.","HAMD 24 - Worthlessness | HAMD3-Worthlessness | HAMD324",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513160","HAMD 24 - Total Score","C130359","Hamilton Depression Rating Scale-24 Item (HAMD 24) Total score.","HAMD 24 - Total Score | HAMD3-Total Score | HAMD325",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519832","Urinary System Part","C13035","Any component of the organs involved in the creation and excretion of urine.","Urinary System Part | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514124","IDS-C - Sleep Onset Insomnia","C130360","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Sleep onset insomnia.","IDS-C - Sleep Onset Insomnia | IDSC1-Sleep Onset Insomnia | IDSC101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514107","IDS-C - Mid-Nocturnal Insomnia","C130361","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Mid-nocturnal insomnia.","IDS-C - Mid-Nocturnal Insomnia | IDSC1-Mid-Nocturnal Insomnia | IDSC102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514100","IDS-C - Early Morning Insomnia","C130362","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Early morning insomnia.","IDS-C - Early Morning Insomnia | IDSC1-Early Morning Insomnia | IDSC103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0152400","Nucleus Ambiguus","C12835","A very slender, longitudinal column of motor neurons in the ventrolateral medulla oblongata; its efferent fibres leave with the vagus and glossopharyngeal nerve and innervate the striated muscle fibres of the pharynx (including the musculus levator veli palatini) and the vocal cord muscles of the larynx.","Nucleus Ambiguus | ",,,,,,,,,,,,,,,"4049630","Structure of nucleus ambiguus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0013884","Lymphatic Filariasis","C128360","A clinical disorder that is caused by obstruction of the lymphatic system years after filarial infection. It is characterized by painful and profound lymphedema, resulting in significant swelling (elephantiasis) of extremities and genitals.","Lymphatic Filariasis | Elephantiasis",,,,,,,,,,,,,,,"4346040","Lymphatic filariasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1562222","Dimorphic Fungus","C128362","A fungus that grows as either a yeast or a mold.","Dimorphic Fungus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509193","GAIA Level 3 Major Internal Structural Defect","C127963","GAIA Level 3 Major Internal Structural Defect is defined by three criteria: first, the defects are prenatal in origin; second, the defect(s) affect (or have the propensity to affect) the health, survival, or physical or cognitive functioning of the individual; third, for a live birth, alterations in the internal anatomy must be present at the time of live birth, must persist beyond the immediate peripartum period unless surgically repaired, and must either a) Require documented confirmation of a diagnosis made by a clinician with some experience diagnosing congenital anomalies; OR b) Confirmation of a diagnosis using either individual (ICD-9/ICD-10) codes or as part of an ICD-9/ICD-10 code based algorithm, for which the outcome (individual code or algorithm) has been validated.","GAIA Level 3 Major Internal Structural Defect | Global Alignment of Immunization safety Assessment in pregnancy Level 3 Major Internal Structural Defect | Level 3 Major Internal Structural Defect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509207","GAIA Level 4 Major Internal Structural Defect","C127964","GAIA Level 4 Major Internal Structural Defect is defined by three criteria: first, the defects are prenatal in origin; second, the defect(s) affect (or have the propensity to affect) the health, survival, or physical or cognitive functioning of the individual; third, at least one of the following requirements must be met: a) Alterations in the internal anatomy that are present at the time of live birth, and that persist beyond the immediate peripartum period unless surgically repaired; OR b) Alterations in the internal anatomy that are present at the time of the stillbirth or of the spontaneous or therapeutic abortion; fourth, at least one of the following requirements must be met: a) Documented confirmation in the medical record that the anomaly was present at the time of live birth or at the time of fetal demise, and that the anomaly was diagnosed by a trained maternal or a child health care provider who has minimal experience diagnosing congenital anomalies; OR b) Confirmed by claims data (ICD-9/ICD-10 diagnoses).","GAIA Level 4 Major Internal Structural Defect | Global Alignment of Immunization safety Assessment in pregnancy Level 4 Major Internal Structural Defect | Level 4 Major Internal Structural Defect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509153","GAIA Level 1 Major Functional Defect","C127965","GAIA Level 1 Major Functional Defect is defined by two criteria. first, at least one of the following requirements must be met: a) For live births, there must be alterations in functioning of one or more organs or body parts that are not due to a structural defect, that are present at the time of birth (or propensity to develop alteration present at live birth), and that persist beyond the immediate peripartum period unless treated through gene therapy or stem cell transplantation; OR b) For stillbirths or for spontaneous or therapeutic abortions, there must be alterations in the function of one or more organs or body parts that are not due to a structural defect; second, there must be confirmation of the defect(s) by definitive diagnostic study.","GAIA Level 1 Major Functional Defect | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Major Functional Defect | Level 1 Major Functional Defect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509172","GAIA Level 2 Major Functional Defect","C127966","GAIA Level 2 Major Functional Defect is defined by two criteria: first, at least one of the following requirements must be met: a) For live births, there must be alterations in the functioning of one or more organs or body parts that are not due to a structural defect, that are present at live birth (or propensity to develop alteration present at live birth), and that persist beyond the immediate peripartum period, unless treated through gene therapy or stem cell transplantation; OR b) For stillbirths or for spontaneous or therapeutic abortions, there must be alterations in the function of one or more organs or body parts that are not due to a structural defect; second, there must be documented confirmation of a diagnosis made by a clinician who is experienced in diagnosing congenital anomalies, and who has the highest level of training in the diagnosis of functional defects for the specific setting.","GAIA Level 2 Major Functional Defect | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Major Functional Defect | Level 2 Major Functional Defect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507917","highly purified Staphylococcal protein A PRTX-100","C127839","A proprietary formulation containing a highly purified form of Staphylococcal protein A (SpA; protein A), with potential immunomodulating activity. Upon administration of bevifimod, this protein is able to specifically bind to both the subset of B-lymphocytes that express the heavy chain variable region 3 (VH3)-encoded immunoglobulin (Ig) (VH3-B-cells) and macrophages. This prevents B-cell activation, induces apoptosis, prevents VH3-derived antibody formation, antibody-mediated immune responses, and destruction by macrophages. This may modulate specific immune signaling pathways and restore normal immune system functions caused by certain immune-mediated inflammatory diseases.  In patients with the autoimmune-mediated disease immune thrombocytopenia (ITP), PRTX-100 prevents destruction of platelets, increases platelet production and platelet blood levels, and decreases the risk of bleeding. SpA, a 42 kDa bacterial membrane protein produced by Staphylococcus aureus bacteria, consists of five nearly identical Ig binding domains; each SpA domain binds with high affinity to the Igs containing regions encoded by the VH3 gene family. B-lymphocytes that express VH3-encoded Igs are specifically involved in various auto-immune diseases.","Bevifimod | BEVIFIMOD | Highly Purified Staphylococcal Protein A PRTX-100 | PRTX-100 | SpA PRTX-100",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0853709","Recurrent Waldenstrom Macroglobulinemia","C127840","The reemergence of Waldenstrom macroglobulinemia after a period of remission.","Recurrent Waldenstrom Macroglobulinemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0476427","Abnormal PAP Smear","C127841","A finding indicating the presence of abnormal cervical cells in a Pap smear.","Abnormal PAP Smear | Abnormal PAP Test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509296","NR1I2 wt Allele","C127843","Human NR1I2 wild-type allele is located within 3q12-q13.3 and is approximately 38 kb in length. This allele, which encodes nuclear receptor subfamily 1 group I member 2 protein, plays a role in the regulation of both gene expression and steroid metabolism.","NR1I2 wt Allele | BXR | Nuclear Receptor Subfamily 1 Group I Member 2 wt Allele | Nuclear Receptor Subfamily 1, Group I, Member 2 Gene | ONR1 | PAR | PAR1 | PAR2 | PARq | PRR | PXR | SAR | SXR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1744349","Nuclear Receptor Subfamily 1 Group I Member 2, Human","C127844","Nuclear receptor subfamily 1 group I member 2 (434 aa, ~50 kDa) is encoded by the human NR1I2 gene. This protein is involved in the metabolism of xenobiotics and steroids.","Nuclear Receptor Subfamily 1 Group I Member 2 | NR1I2 | Orphan Nuclear Receptor PAR1 | Orphan Nuclear Receptor PXR | Pregnane X Nuclear Receptor | Pregnane X Receptor | Steroid and Xenobiotic Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509518","OPHN1 wt Allele","C127846","Human OPHN1 wild-type allele is located in the vicinity of Xq12 and is approximately 392 kb in length. This allele, which encodes oligophrenin-1 protein, is involved in the regulation of small GTPase mediated signal transduction. Mutation of the gene is associated with X-linked mental retardation with cerebellar hypoplasia and distinctive facial dysmorhphism.","OPHN1 wt Allele | ARHGAP41 | MRX60 | Mental Retardation, X-Linked 60 Gene | OPN1 | Oligophrenin 1 wt Allele | Oligophrenin-1, Rho-GTPase Activating Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0674249","Oligophrenin-1, Human","C127848","Oligophrenin-1 (802 aa, ~92 kDa) is encoded by the human OPHN1 gene. This protein plays a role in GTP hydrolysis.","Oligophrenin-1 | ARHGAP41 | Oligophrenin 1 | Rho GTPase-Activating Protein 41",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513302","Q-LES-Q-SF - Physical Health","C130705","Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Taking everything into consideration, during the past week how satisfied have you been with your: physical health?","Q-LES-Q-SF - Physical Health | QLES2-Physical Health | QLES201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513622","WHODAS 2.0 36-item Version Interviewer-administered - Doing Important Household Tasks","C130748","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) Because of your health condition, in the past 30 days, how much difficulty did you have in: Doing your most important household tasks well?","WHODAS 2.0 36-item Version Interviewer-administered - Doing Important Household Tasks | WD5-Doing Important Household Tasks | WD5D5_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513632","WHODAS 2.0 36-item Version Interviewer-administered - Getting Household Work Done Needed","C130749","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) Because of your health condition, in the past 30 days, how much difficulty did you have in: Getting all the household work done that you needed to do?","WHODAS 2.0 36-item Version Interviewer-administered - Getting Household Work Done Needed | WD5-Getting Household Work Done Needed | WD5D5_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513633","WHODAS 2.0 36-item Version Interviewer-administered - Getting Household Work Done Quickly","C130750","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) Because of your health condition, in the past 30 days, how much difficulty did you have in: Getting your household work done as quickly as needed?","WHODAS 2.0 36-item Version Interviewer-administered - Getting Household Work Done Quickly | WD5-Getting Household Work Done Quickly | WD5D5_4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513618","WHODAS 2.0 36-item Version Interviewer-administered - Days Reduce or Miss Household Work","C130751","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, on how many days did you reduce or completely miss household work because of your health condition?","WHODAS 2.0 36-item Version Interviewer-administered - Days Reduce or Miss Household Work | WD5-Days Reduce or Miss Household Work | WD5D5_01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513663","WHODAS 2.0 36-item Version Interviewer-administered - Your Day-to-Day Work or School","C130752","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) Because of your health condition, in the past 30 days how much difficulty did you have in: Your day-to-day work/school?","WHODAS 2.0 36-item Version Interviewer-administered - Your Day-to-Day Work or School | WD5-Your Day-to-Day Work/School | WD5D5_5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513623","WHODAS 2.0 36-item Version Interviewer-administered - Doing Important Work or School Tasks","C130753","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) Because of your health condition, in the past 30 days how much difficulty did you have in: Doing your most important work/school tasks well?","WHODAS 2.0 36-item Version Interviewer-administered - Doing Important Work or School Tasks | WD5-Doing Important Work/School Tasks | WD5D5_6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514103","IDS-C - Hypersomnia","C130363","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Hypersomnia.","IDS-C - Hypersomnia | IDSC1-Hypersomnia | IDSC104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514110","IDS-C - Mood (Sad)","C130364","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Mood (sad).","IDS-C - Mood (Sad) | IDSC1-Mood (Sad) | IDSC105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514109","IDS-C - Mood (Irritable)","C130365","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Mood (irritable).","IDS-C - Mood (Irritable) | IDSC1-Mood (Irritable) | IDSC106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514108","IDS-C - Mood (Anxious)","C130366","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Mood (anxious).","IDS-C - Mood (Anxious) | IDSC1-Mood (Anxious) | IDSC107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514121","IDS-C - Reactivity of Mood","C130367","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Reactivity of mood.","IDS-C - Reactivity of Mood | IDSC1-Reactivity of Mood | IDSC108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514140","IDS-SR - Feeling Slowed Down","C130575","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Feeling slowed down.","IDS-SR - Feeling Slowed Down | IDSR1-Feeling Slowed Down | IDSR123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514138","IDS-SR - Feeling Restless","C130576","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Feeling restless.","IDS-SR - Feeling Restless | IDSR1-Feeling Restless | IDSR124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514149","IDS-SR - Other Bodily Symptoms","C130578","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Other bodily symptoms.","IDS-SR - Other Bodily Symptoms | IDSR1-Other Bodily Symptoms | IDSR126",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514150","IDS-SR - Panic or Phobic Symptoms","C130579","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Panic/phobic symptoms.","IDS-SR - Panic or Phobic Symptoms | IDSR1-Panic/Phobic Symptoms | IDSR127",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229606","Fibroblastic Reticular Cell","C13057","A cell with processes making contact with those of other similar cells to form a cellular sheath for a network of reticular fibers, which constitutes the stroma of all secondary lymphoid organs.","Fibroblastic Reticular Cell | FRC | Fibroblastic Reticular Cells",,,,,,,,,,,,,,,"4292430","Reticulum cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514132","IDS-SR - Constipation or Diarrhea","C130580","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Constipation/diarrhea.","IDS-SR - Constipation or Diarrhea | IDSR1-Constipation/Diarrhea | IDSR128",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514144","IDS-SR - Interpersonal Sensitivity","C130581","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Interpersonal sensitivity.","IDS-SR - Interpersonal Sensitivity | IDSR1-Interpersonal Sensitivity | IDSR129",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514145","IDS-SR - Leaden Paralysis or Physical Energy","C130582","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Leaden paralysis/physical energy.","IDS-SR - Leaden Paralysis or Physical Energy | IDSR1-Leaden Paralysis/Physical Energy | IDSR130",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509192","GAIA Level 3 Major Functional Defect","C127967","GAIA Level 3 Major Functional Defect is defined by two criteria: first, at least one of the following requirements must be met: a) For live births, there must be alterations in the functioning of one or more organs or body parts that are not due to a structural defect, that are present at live birth (or propensity to develop alteration present at live birth), and that persist beyond the immediate peripartum period, unless treated through gene therapy or stem cell transplantation; OR b) For stillbirths or spontaneous or therapeutic abortions, there must be alterations in the functioning of one or more organs or body parts that are not due to a structural defect; second, at least one of the following requirements must be met: a) Documented confirmation of a diagnosis made by a clinician who has some experience diagnosing functional defects; OR b) Confirmation of a diagnosis using either individual (ICD-9/ICD-10) codes or as part of an ICD-9/ICD-10 code based algorithm, for which the outcome (individual code or algorithm) has been validated.","GAIA Level 3 Major Functional Defect | Global Alignment of Immunization safety Assessment in pregnancy Level 3 Major Functional Defect | Level 3 Major Functional Defect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509502","Nephrotic Syndrome - Infrequently Relapsing","C128110","Nephrotic syndrome in which there is a relapse occurring less than twice in the first six months, or less than four times in a year.","Nephrotic Syndrome - Infrequently Relapsing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509763","Postoperative Spindle Cell Nodule of the Vagina","C128111","A rare, benign, non-neoplastic reactive lesion that develops in the vagina at the site of a prior operative procedure. It is composed of spindle cells, small blood vessels, and chronic inflammation.","Postoperative Spindle Cell Nodule of the Vagina | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509794","Vaginal Germ Cell Tumor","C128112","A germ tumor that arises from the vagina.","Vaginal Germ Cell Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509355","Vaginal Mature Cystic Teratoma","C128113","A rare benign cystic teratoma that arises from the vagina. It presents as a slow growing cyst in the vaginal wall that contains sebaceous material and hair. The cyst is lined by squamous epithelium. Skin adnexal structures and sometimes smooth and skeletal muscle are present.","Vaginal Dermoid Cyst | Vaginal Mature Cystic Teratoma | Vaginal Teratoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1863512","Hypercholesterolemia, Familial, 4","C128114","An autosomal recessive condition caused by mutation(s) in the LDLRAP1 gene, encoding low density lipoprotein receptor adaptor protein 1. The phenotype is similar to that of familial hypercholesterolemia, but generally considered to be a milder form of hypercholesterolemia.","Hypercholesterolemia, Familial, 4 | Autosomal Recessive Hypercholesterolemia | FCHL4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0265235","Marshall Syndrome","C128115","An autosomal dominant condition caused by mutation(s) in the COL11A1 gene, encoding collagen alpha-1(XI) chain. The syndrome may be characterized by facial dysmorphism, cataracts, myopia, hearing loss, and short stature. Mutation(s) in the COL11A1 gene are causative in Stickler syndrome, but the phenotype of Marshall syndrome is more mild.","Marshall Syndrome | ",,,,,,,,,,,,,,,"4142775","Marshall syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1834207","Neuronal Ceroid Lipofuscinosis Type 4B","C128116","A condition associated with mutation(s) in the DNAJC5 gene, encoding dnaJ homolog subfamily C member 5. The condition is one of a group of genetically heterogeneous neurodegenerative disorders, characterized by accumulation of intracellular lipopigments.","Neuronal Ceroid Lipofuscinosis Type 4B | Autosomal Dominant Kufs Disease | CLN4B | Neuronal Ceroid Lipofuscinosis, Parry Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509769","Primary Ciliary Dyskinesia 1","C128117","An autosomal recessive primary ciliary motility defect caused by mutation(s) in the DNAI1 gene, encoding dynein intermediate chain 1, axonemal.","Primary Ciliary Dyskinesia 1 | CILD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509267","Muscular Dystrophy-Dystroglycanopathy (Congenital with Brain and Eye Anomalies) Type A, 1","C128118","An autosomal recessive muscular dystrophy caused by mutations in the POMT1 gene, encoding protein O-mannosyl-transferase 1. It is associated with characteristic brain and eye malformations, profound mental retardation, and early death.","Muscular Dystrophy-Dystroglycanopathy (Congenital with Brain and Eye Anomalies) Type A, 1 | MDDGA1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016756","Fructose-1,6-Bisphosphatase Deficiency","C128119","No value exists.","Fructose-1,6-Bisphosphatase Deficiency | ",,,,,,,,,,,,,,,"4102294","Fructose-biphosphatase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513300","Q-LES-Q-SF - Mood","C130706","Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Taking everything into consideration, during the past week how satisfied have you been with your: mood?","Q-LES-Q-SF - Mood | QLES2-Mood | QLES202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513307","Q-LES-Q-SF - Work","C130707","Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Taking everything into consideration, during the past week how satisfied have you been with your: work?","Q-LES-Q-SF - Work | QLES2-Work | QLES203",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513296","Q-LES-Q-SF - Household Activities","C130708","Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Taking everything into consideration, during the past week how satisfied have you been with your: household activities?","Q-LES-Q-SF - Household Activities | QLES2-Household Activities | QLES204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513305","Q-LES-Q-SF - Social Relationships","C130709","Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Taking everything into consideration, during the past week how satisfied have you been with your: social relationships?","Q-LES-Q-SF - Social Relationships | QLES2-Social Relationships | QLES205",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513295","Q-LES-Q-SF - Family Relationships","C130710","Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Taking everything into consideration, during the past week how satisfied have you been with your: family relationships?","Q-LES-Q-SF - Family Relationships | QLES2-Family Relationships | QLES206",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513297","Q-LES-Q-SF - Leisure Time Activities","C130711","Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Taking everything into consideration, during the past week how satisfied have you been with your: leisure time activities?","Q-LES-Q-SF - Leisure Time Activities | QLES2-Leisure Time Activities | QLES207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513292","Q-LES-Q-SF - Ability to Function in Daily Life","C130712","Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Taking everything into consideration, during the past week how satisfied have you been with your: ability to function in daily life?","Q-LES-Q-SF - Ability to Function in Daily Life | QLES2-Ability to Function in Daily Life | QLES208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513304","Q-LES-Q-SF - Sex Drive, Interest, Performance","C130713","Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Taking everything into consideration, during the past week how satisfied have you been with your: sexual drive, interest and/or performance?","Q-LES-Q-SF - Sex Drive, Interest, Performance | QLES2-Sex Drive, Interest, Performance | QLES209",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513294","Q-LES-Q-SF - Economic Status","C130714","Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Taking everything into consideration, during the past week how satisfied have you been with your: economic status?","Q-LES-Q-SF - Economic Status | QLES2-Economic Status | QLES210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513298","Q-LES-Q-SF - Living or Housing Situation","C130715","Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Taking everything into consideration, during the past week how satisfied have you been with your: living/housing situation?","Q-LES-Q-SF - Living or Housing Situation | QLES2-Living/Housing Situation | QLES211",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513293","Q-LES-Q-SF - Ability to Get Around Physically","C130716","Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Taking everything into consideration, during the past week how satisfied have you been with your: ability to get around physically without feeling dizzy or unsteady or falling?","Q-LES-Q-SF - Ability to Get Around Physically | QLES2-Ability to Get Around Physically | QLES212",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513306","Q-LES-Q-SF - Vision Ability to Do Work or Hobbies","C130717","Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Taking everything into consideration, during the past week how satisfied have you been with your: your vision in terms of ability to do work or hobbies?","Q-LES-Q-SF - Vision Ability to Do Work or Hobbies | QLES2-Vision Ability to Do Work/Hobbies | QLES213",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514153","IDS-SR - Score","C130583","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Score.","IDS-SR - Score | IDSR1-Score | IDSR131",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513334","QIDS-SR - Falling Asleep","C130584","Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: Falling asleep.","QIDS-SR - Falling Asleep | QIDSR1-Falling Asleep | QIDSR101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513344","QIDS-SR - Sleep During the Night","C130585","Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: Sleep during the night.","QIDS-SR - Sleep During the Night | QIDSR1-Sleep During the Night | QIDSR102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513349","QIDS-SR - Waking Up Too Early","C130586","Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: Waking up too early.","QIDS-SR - Waking Up Too Early | QIDSR1-Waking Up Too Early | QIDSR103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513345","QIDS-SR - Sleeping Too Much","C130587","Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: Sleeping too much.","QIDS-SR - Sleeping Too Much | QIDSR1-Sleeping Too Much | QIDSR104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513331","QIDS-SR - Decreased Appetite","C130589","Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: Decreased appetite.","QIDS-SR - Decreased Appetite | QIDSR1-Decreased Appetite | QIDSR106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513686","WHODAS 2.0 36-item Version Proxy-administered - Maintaining a Friendship","C130787","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Because of their health condition, in the past 30 days, how much difficulty did your relative have in: Maintaining a friendship?","WHODAS 2.0 36-item Version Proxy-administered - Maintaining a Friendship | WD6-Maintaining a Friendship | WD6D4_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513675","WHODAS 2.0 36-item Version Proxy-administered - Get Along With People Close to Him","C130788","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Because of their health condition, in the past 30 days, how much difficulty did your relative have in: Getting along with people who are close to him or her?","WHODAS 2.0 36-item Version Proxy-administered - Get Along With People Close to Him | WD6-Get Along With People Close to Him | WD6D4_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513687","WHODAS 2.0 36-item Version Proxy-administered - Making New Friends","C130789","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Because of their health condition, in the past 30 days, how much difficulty did your relative have in: Making new friends?","WHODAS 2.0 36-item Version Proxy-administered - Making New Friends | WD6-Making New Friends | WD6D4_4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513695","WHODAS 2.0 36-item Version Proxy-administered - Sexual Activities","C130790","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Because of their health condition, in the past 30 days, how much difficulty did your relative have in: Sexual activities?","WHODAS 2.0 36-item Version Proxy-administered - Sexual Activities | WD6-Sexual Activities | WD6D4_5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513665","WHODAS 2.0 36-item Version Proxy-administered - Care of Household Responsibilities","C130791","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Because of their health condition, in the past 30 days, how much difficulty did your relative have in: Taking care of his or her household responsibilities?","WHODAS 2.0 36-item Version Proxy-administered - Care of Household Responsibilities | WD6-Care of Household Responsibilities | WD6D5_1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508668","Canine Leukemia","C128120","An acute or chronic malignant (clonal) hematologic disorder, arising from hematopoietic stem cells in dogs. It is characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.","Canine Leukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508670","Canine Prostate Carcinoma","C128122","A malignant epithelial neoplasm arising from the prostate gland of a dog.","Canine Prostate Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509477","Mouse Testicular Teratoma","C128123","A non-seminomatous germ cell tumor arising from the testis of a mouse, characterized by the presence of various tissues corresponding to the different germinal layers (endoderm, mesoderm, and ectoderm).","Mouse Testicular Teratoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509812","Diffusion Spectrum Imaging","C128124","A high angular resolution diffusion MRI technique that maps complex tissue structures at the scale of single MRI voxels.","Diffusion Spectrum Imaging | DSI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508667","Canine Histiocytic Sarcoma","C128125","A malignant neoplasm that affects dogs, characterized by the presence of malignant cells with morphologic and immunophenotypic characteristics similar to those seen in mature histiocytes.","Canine Histiocytic Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508672","Canine Transitional Cell Carcinoma","C128126","A malignant neoplasm that affects dogs, arising from transitional epithelium.","Canine Transitional Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513593","WHODAS 2.0 12+24-item Version Interviewer-administered - Miss Work Half Day or More","C130888","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, on how many days did you miss work for half a day or more because of your health condition?","WHODAS 2.0 12+24-item Version Interviewer-administered - Miss Work Half Day or More | WD4-Miss Work Half Day or More | WD4D5_02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513595","WHODAS 2.0 12+24-item Version Interviewer-administered - Problem Because of Barriers in World","C130889","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days: How much of a problem did you have because of barriers or hindrances in the world around you?","WHODAS 2.0 12+24-item Version Interviewer-administered - Problem Because of Barriers in World | WD4-Problem Because of Barriers in World | WD4D6_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513599","WHODAS 2.0 12+24-item Version Interviewer-administered - Problem Living With Dignity","C130890","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days: How much of a problem did you have living with dignity because of the attitudes and actions of others?","WHODAS 2.0 12+24-item Version Interviewer-administered - Problem Living With Dignity | WD4-Problem Living With Dignity | WD4D6_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513608","WHODAS 2.0 12+24-item Version Interviewer-administered - Time Spend on Your Health Condition","C130891","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days: How much time did you spend on your health condition, or its consequences?","WHODAS 2.0 12+24-item Version Interviewer-administered - Time Spend on Your Health Condition | WD4-Time Spend on Your Health Condition | WD4D6_4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513573","WHODAS 2.0 12+24-item Version Interviewer-administered - Drain on Financial Resources","C130892","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days: How much has your health been a drain on the financial resources of you or your family?","WHODAS 2.0 12+24-item Version Interviewer-administered - Drain on Financial Resources | WD4-Drain on Financial Resources | WD4D6_6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513596","WHODAS 2.0 12+24-item Version Interviewer-administered - Problem Did Your Family Have","C130893","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days: How much of a problem did your family have because of your health problems?","WHODAS 2.0 12+24-item Version Interviewer-administered - Problem Did Your Family Have | WD4-Problem Did Your Family Have | WD4D6_7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513597","WHODAS 2.0 12+24-item Version Interviewer-administered - Problem Doing Things for Relaxation","C130894","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days: How much of a problem did you have in doing things by yourself for relaxation or pleasure?","WHODAS 2.0 12+24-item Version Interviewer-administered - Problem Doing Things for Relaxation | WD4-Problem Doing Things for Relaxation | WD4D6_8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513586","WHODAS 2.0 12+24-item Version Interviewer-administered - How Many Days Difficulties Present","C130895","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) Overall, in the past 30 days, how many days were these difficulties present?","WHODAS 2.0 12+24-item Version Interviewer-administered - How Many Days Difficulties Present | WD4-How Many Days Difficulties Present | WD4H1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513568","WHODAS 2.0 12+24-item Version Interviewer-administered - Days Unable to Carry Out Activities","C130896","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, for how many days were you totally unable to carry out your usual activities or work because of any health condition?","WHODAS 2.0 12+24-item Version Interviewer-administered - Days Unable to Carry Out Activities | WD4-Days Unable to Carry Out Activities | WD4H2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0445620","Brain Part","C13031","Any component of the central nervous system that is contained within the cranium.","Brain Part | ",,,,,,,,,,,,,,,"4001213","Brain part",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513678","WHODAS 2.0 36-item Version Proxy-administered - Getting Household Work Done Needed","C130793","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Because of their health condition, in the past 30 days, how much difficulty did your relative have in: Getting all the household work done that is needed?","WHODAS 2.0 36-item Version Proxy-administered - Getting Household Work Done Needed | WD6-Getting Household Work Done Needed | WD6D5_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513679","WHODAS 2.0 36-item Version Proxy-administered - Getting Household Work Done Quickly","C130794","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Because of their health condition, in the past 30 days, how much difficulty did your relative have in: Getting the household work done as quickly as needed?","WHODAS 2.0 36-item Version Proxy-administered - Getting Household Work Done Quickly | WD6-Getting Household Work Done Quickly | WD6D5_4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513700","WHODAS 2.0 36-item Version Proxy-administered - Their Day-to-Day Work or School","C130795","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: His or her day-to-day work/school?","WHODAS 2.0 36-item Version Proxy-administered - Their Day-to-Day Work or School | WD6-Their Day-to-Day Work/School | WD6D5_5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513670","WHODAS 2.0 36-item Version Proxy-administered - Doing Important Work or School Tasks","C130796","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Doing his or her most important work/school tasks well?","WHODAS 2.0 36-item Version Proxy-administered - Doing Important Work or School Tasks | WD6-Doing Important Work/School Tasks | WD6D5_6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513676","WHODAS 2.0 36-item Version Proxy-administered - Getting All Work Done You Need","C130797","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Getting all the work done that is needed?","WHODAS 2.0 36-item Version Proxy-administered - Getting All Work Done You Need | WD6-Getting All Work Done You Need | WD6D5_7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3178802","Interferon-Gamma Release Assay","C128363","A blood test that exposes a person's T-lymphocytes ex vivo to specific microbial antigen(s) to stimulate the production and release of interferon gamma, which provides an indication that the person has been exposed to a specific microbe.","Interferon-Gamma Release Assay | IGRA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509361","Vehicle Transmission","C128364","The indirect transmission of an infectious agent to a host via inanimate objects such as food, water, biologic products, or fomites.","Vehicle Transmission | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509360","Vector Transmission","C128365","The indirect transmission of an infectious agent to a host via another living organism, either through purely mechanical means (e.g., insect bite) or by that organism supporting the growth or changes in the agent that make it infectious to the host.","Vector Transmission | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0275521","Clinical Infection","C128366","No value exists.","Clinical Infection | ",,,,,,,,,,,,,,,"4269943","Clinical infection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508739","Endogenous Infection","C128367","An infection caused by an infectious agent that is present on or in the host prior to the start of the infection.","Endogenous Infection | Auto-Infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024904","Mastoiditis","C128368","Inflammation of the mucosal lining of the mastoid antrum and mastoid air cell system of the mastoid process.","Mastoiditis | ",,,,,,,,,,,,,,,"374655","Mastoiditis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1168225","Labyrinthitis","C128369","Inflammation of the anatomical structures of the inner ear secondary to an infectious process. Symptoms include severe vertigo, nausea, vomiting, anxiety, and pain. Viral etiology is most common, and recent history of an upper respiratory infection is common.","Labyrinthitis | Infectious Otitis Interna | Inner Ear Infection | Internal Ear Infection | Labrynthitis",,,,,,,,,,,,,,,"74052","Labyrinthitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152407","Abducens Nucleus","C12836","The cranial nerve nucleus from which the abducens nerve originates from. It is located in the middle portion of the brain stem.","Abducens Nucleus | Sixth Cranial Nerve Nucleus",,,,,,,,,,,,,,,"4151002","Structure of abducens nucleus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1262117","Fungal Keratitis","C128370","Keratitis caused by fungi.","Fungal Keratitis | ",,,,,,,,,,,,,,,"4152070","Fungal keratitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1260915","Late Latent Syphilis","C128371","Latent syphilis when infection was acquired more than twelve months previously.","Late Latent Syphilis | ",,,,,,,,,,,,,,,"4087756","Late latent syphilis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513587","WHODAS 2.0 12+24-item Version Interviewer-administered - How Many Days Reduce Activities","C130897","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, not counting the days that you were totally unable, for how many days did you cut back or reduce your usual activities or work because of any health condition?","WHODAS 2.0 12+24-item Version Interviewer-administered - How Many Days Reduce Activities | WD4-How Many Days Reduce Activities | WD4H3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513446","CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology","C130272","Test names of questionnaire questions associated with the World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology | QS-WHODAS 2.0 36-item Version Self-administered TEST | WD7TN | World Health Organization Disability Assessment Schedule 2.0 - 36-Item Self Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513445","CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology","C130273","Test codes of questionnaire questions associated with the World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology | QS-WHODAS 2.0 36-item Version Self-administered TESTCD | WD7TC | World Health Organization Disability Assessment Schedule 2.0 - 36-Item Self Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513436","CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Name Terminology","C130274","Test names of questionnaire questions associated with the World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Name Terminology | QS-WHODAS 2.0 12-item Version Interviewer-administered TEST | WD1TN | World Health Organization Disability Assessment Schedule 2.0 - 12-Item Interviewer Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513435","CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Code Terminology","C130275","Test codes of questionnaire questions associated with the World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Code Terminology | QS-WHODAS 2.0 12-item Version Interviewer-administered TESTCD | WD1TC | World Health Organization Disability Assessment Schedule 2.0 - 12-Item Interviewer Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513438","CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Name Terminology","C130276","Test names of questionnaire questions associated with the World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Name Terminology | QS-WHODAS 2.0 12-item Version Proxy-administered TEST | WD2TN | World Health Organization Disability Assessment Schedule 2.0 - 12-Item Proxy Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513437","CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Code Terminology","C130277","Test codes of questionnaire questions associated with the World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Code Terminology | QS-WHODAS 2.0 12-item Version Proxy-administered TESTCD | WD2TC | World Health Organization Disability Assessment Schedule 2.0 - 12-Item Proxy Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513440","CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Name Terminology","C130278","Test names of questionnaire questions associated with the World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Name Terminology | QS-WHODAS 2.0 12-item Version Self-administered TEST | WD3TN | World Health Organization Disability Assessment Schedule 2.0 - 12-Item Self Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513913","FACT-LYM Version 4 - Bothered by Lumps or Swelling","C130531","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Additional Concerns: I am bothered by lumps or swelling in certain parts of my body (e.g., neck, armpits, or groin).","FACT-LYM Version 4 - Bothered by Lumps or Swelling | FAC018-Bothered by Lumps or Swelling | FAC01829",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513923","FACT-LYM Version 4 - I Am Bothered by Fevers","C130532","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Additional Concerns: I am bothered by fevers (episodes of high body temperature).","FACT-LYM Version 4 - I Am Bothered by Fevers | FAC018-I Am Bothered by Fevers | FAC01830",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513939","FACT-LYM Version 4 - I Have Night Sweats","C130533","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Additional Concerns: I have night sweats.","FACT-LYM Version 4 - I Have Night Sweats | FAC018-I Have Night Sweats | FAC01831",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513924","FACT-LYM Version 4 - I Am Bothered by Itching","C130534","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Additional Concerns: I am bothered by itching.","FACT-LYM Version 4 - I Am Bothered by Itching | FAC018-I Am Bothered by Itching | FAC01832",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513942","FACT-LYM Version 4 - I Have Trouble Sleeping at Night","C130535","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Additional Concerns: I have trouble sleeping at night.","FACT-LYM Version 4 - I Have Trouble Sleeping at Night | FAC018-I Have Trouble Sleeping at Night | FAC01833",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513935","FACT-LYM Version 4 - I Get Tired Easily","C130536","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Additional Concerns: I get tired easily.","FACT-LYM Version 4 - I Get Tired Easily | FAC018-I Get Tired Easily | FAC01834",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513926","FACT-LYM Version 4 - I Am Losing Weight","C130537","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Additional Concerns: I am losing weight.","FACT-LYM Version 4 - I Am Losing Weight | FAC018-I Am Losing Weight | FAC01835",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513944","FACT-LYM Version 4 - I Have a Loss of Appetite","C130538","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Additional Concerns: I have a loss of appetite.","FACT-LYM Version 4 - I Have a Loss of Appetite | FAC018-I Have a Loss of Appetite | FAC01836",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513941","FACT-LYM Version 4 - I Have Trouble Concentrating","C130539","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Additional Concerns: I have trouble concentrating.","FACT-LYM Version 4 - I Have Trouble Concentrating | FAC018-I Have Trouble Concentrating | FAC01837",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014261","Vascular Endothelium","C13053","The layer of simple squamous epithelial tissue that lines the luminal surface of the entire circulatory system.","Vascular Endothelium | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513953","FACT-LYM Version 4 - Worry I Might Get New Symptoms","C130541","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Additional Concerns: I worry that I might get new symptoms of my illness.","FACT-LYM Version 4 - Worry I Might Get New Symptoms | FAC018-Worry I Might Get New Symptoms | FAC01839",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513919","FACT-LYM Version 4 - Feel Isolated Because of Illness","C130542","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Additional Concerns: I feel isolated from others because of my illness or treatment.","FACT-LYM Version 4 - Feel Isolated Because of Illness | FAC018-Feel Isolated Because of Illness | FAC01840",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513937","FACT-LYM Version 4 - I Have Emotional Ups and Downs","C130543","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Additional Concerns: I have emotional ups and downs.","FACT-LYM Version 4 - I Have Emotional Ups and Downs | FAC018-I Have Emotional Ups and Downs | FAC01841",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513917","FACT-LYM Version 4 - Difficulty Planning for Future","C130544","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Additional Concerns: Because of my illness, I have difficulty planning for the future.","FACT-LYM Version 4 - Difficulty Planning for Future | FAC018-Difficulty Planning for Future | FAC01842",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514113","IDS-C - Mood Worse in Morning, Afternoon, or Night","C130369","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Is mood typically worse in morning, afternoon, or night.","IDS-C - Mood Worse in Morning, Afternoon, or Night | IDSC1-Mood Worse Morn/Afternoon/Night | IDSC109A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514111","IDS-C - Mood Variation Attributed to Environment","C130370","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Is mood variation attributed to environment by the patient?","IDS-C - Mood Variation Attributed to Environment | IDSC1-Mood Attributed to Environment | IDSC109B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514120","IDS-C - Quality of Mood","C130371","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Quality of mood.","IDS-C - Quality of Mood | IDSC1-Quality of Mood | IDSC110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514097","IDS-C - Appetite (Decreased)","C130372","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Appetite (decreased).","IDS-C - Appetite (Decreased) | IDSC1-Appetite (Decreased) | IDSC111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514098","IDS-C - Appetite (Increased)","C130373","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Appetite (increased).","IDS-C - Appetite (Increased) | IDSC1-Appetite (Increased) | IDSC112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514128","IDS-C - Weight (Decrease)","C130374","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Weight (decrease) within the last two weeks.","IDS-C - Weight (Decrease) | IDSC1-Weight (Decrease) | IDSC113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024534","Cerebral Malaria","C128373","A sequestration of Plasmodium falciparum in the brain, which can cause coma and/or seizures.","Cerebral Malaria | ",,,,,,,,,,,,,,,"4202367","Cerebral malaria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0154652","Eosinophilic Meningitis","C128374","Meningitis in which eosinophils predominate in the cerebrospinal fluid.","Eosinophilic Meningitis | ",,,,,,,,,,,,,,,"443746","Eosinophilic meningitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1443844","Mode of Transmission","C128376","The process by which an infection is transmitted to a person.","Mode of Transmission | ",,,,,,,,,,,,,,,"4256113","Mode of transmission",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1609538","Tuberculosis Infection","C128377","The asymptomatic presence of Mycobacterium tuberculosis in the body, which is determined by a positive result to a tuberculin skin test or interferon-gamma release assay.","Tuberculosis Infection | LTBI | Latent Tuberculosis Infection | Mycobacterium tuberculosis",,,,,,,,,,,,,,,"4003404","Inactive tuberculosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0270627","Acute Transverse Myelitis","C128378","A neurologic disorder that is caused by inflammation across both sides of one level, or segment, of the spinal cord. (from NINDS)","Acute Transverse Myelitis | ",,,,,,,,,,,,,,,"139803","Acute transverse myelitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508662","Acute Flaccid Myelitis","C128379","An acute onset of focal limb weakness that is associated mainly with gray matter abnormalities or CSF pleocytosis, but which is without an apparent cause.","Acute Flaccid Myelitis | ",,,,,,,,,,,,,,,"604439","Acute flaccid myelitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152411","Cochlear Nucleus","C12837","Located at the brainstem, this sensory organ receives auditory signals from the cochlear auditory nerve fibers. It is composed of the dorsal cochlear nucleus located on the dorsolateral surface of the inferior peduncle and the ventral (or accessory) cochlear nucleus located on the ventral aspect of the inferior peduncle.","Cochlear Nucleus | BRAIN, COCHLEAR NUCLEI | Cochlear Nuclei",,,,,,,,,,,,,,,"4070462","Cochlear nucleus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1384588","Bacterial Myocarditis","C128380","Myocarditis that is caused by an infection with a bacterial agent.","Bacterial Myocarditis | ",,,,,,,,,,,,,,,"320127","Bacterial myocarditis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1704275","Pyomyositis","C128382","A suppurative infection of muscle.","Pyomyositis | Tropical Pyomyositis",,,,,,,,,,,,,,,"4147680","Purulent myositis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509206","GAIA Level 4 Major Functional Defect","C127968","GAIA Level 4 Major Functional Defect is defined by two criteria: first, at least one of the following requirements must be met: a) For live births, there must be alterations in the functioning of one or more organs or body parts that are not due to a structural defect, that are present at the time of live birth (or propensity to develop alteration present at live birth), and that persist beyond the immediate peripartum period, unless treated through gene therapy or stem cell transplantation; OR b) For stillbirths or spontaneous or therapeutic abortions, there must be alterations in the function of one or more organs or body parts that are not due to a structural defect; second, at least one of the following requirements must be met: a) Documented confirmation in the medical record that the anomaly was present at the time of live birth or at the time of fetal demise, and that the anomaly was diagnosed by a trained maternal or child health care provider who is not a qualified geneticist, neonatologist, pathologist, subspecialist, pediatrician, obstetrician, or family medicine practitioner; OR b) Confirmation by claims data (ICD-9/ICD-10 diagnoses).","GAIA Level 4 Major Functional Defect | Global Alignment of Immunization safety Assessment in pregnancy Level 4 Major Functional Defect | Level 4 Major Functional Defect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509157","GAIA Level 1 Neonatal Death in a Non-viable Live Birth","C127969","GAIA Level 1 Neonatal Death in a Non-viable Live Birth is defined by three criteria: first, the infant must be live born; second, at least one of the following requirements must be met: a) Gestational age less than 22 weeks (a GA level of certainty of one); OR b) Birth weight less than 500g; third, the death of the infant within the first 28 days of life must be documented.","GAIA Level 1 Neonatal Death in a Non-viable Live Birth | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Neonatal Death in a Non-viable Live Birth | Level 1 Neonatal Death in a Non-viable Live Birth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513439","CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Code Terminology","C130279","Test codes of questionnaire questions associated with the World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Code Terminology | QS-WHODAS 2.0 12-item Version Self-administered TESTCD | WD3TC | World Health Organization Disability Assessment Schedule 2.0 - 12-Item Self Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513434","CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology","C130280","Test names of questionnaire questions associated with the World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology | QS-WHODAS 2.0 12+24-item Version Interviewer-administered TEST | WD4TN | World Health Organization Disability Assessment Schedule 2.0 - 12 + 24-Item Interviewer Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513839","FACT-HEP Version 4 - I Can Digest My Food Well","C130488","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I can digest my food well.","FACT-HEP Version 4 - I Can Digest My Food Well | FAC015-I Can Digest My Food Well | FAC01531",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513849","FACT-HEP Version 4 - I Have Diarrhea","C130489","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I have diarrhea (diarrhoea).","FACT-HEP Version 4 - I Have Diarrhea | FAC015-I Have Diarrhea | FAC01532",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027713","Nephron","C13048","The basic structural and functioning unit of the kidney. It is composed of the glomerulus, where waste products are filtered from the blood, the proximal and distal tubules, the loop of Henle, and the collecting ducts, where urine is produced for excretion from the body.","Nephron | Uriniferous Tube",,,,,,,,,,,,,,,"4203906","Nephron structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513856","FACT-HEP Version 4 - I Have a Good Appetite","C130490","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I have a good appetite.","FACT-HEP Version 4 - I Have a Good Appetite | FAC015-I Have a Good Appetite | FAC01533",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513867","FACT-HEP Version 4 - Unhappy About Change in My Appearance","C130491","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I am unhappy about a change in my appearance.","FACT-HEP Version 4 - Unhappy About Change in My Appearance | FAC015-Unhappy About Change in My Appear | FAC01534",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513854","FACT-HEP Version 4 - I Have Pain in My Back","C130492","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I have pain in my back.","FACT-HEP Version 4 - I Have Pain in My Back | FAC015-I Have Pain in My Back | FAC01535",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513834","FACT-HEP Version 4 - I Am Bothered by Constipation","C130493","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I am bothered by constipation.","FACT-HEP Version 4 - I Am Bothered by Constipation | FAC015-I Am Bothered by Constipation | FAC01536",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513824","FACT-HEP Version 4 - Able to Do My Usual Activities","C130495","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I am able to do my usual activities.","FACT-HEP Version 4 - Able to Do My Usual Activities | FAC015-Able to Do My Usual Activities | FAC01538",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513825","FACT-HEP Version 4 - Bothered by Jaundice or Yellow Skin","C130496","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I am bothered by jaundice or yellow color to my skin.","FACT-HEP Version 4 - Bothered by Jaundice or Yellow Skin | FAC015-Bothered by Jaundice/Yellow Skin | FAC01539",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513851","FACT-HEP Version 4 - I Have Had Fevers","C130497","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I have had fevers (episodes of high body temperature).","FACT-HEP Version 4 - I Have Had Fevers | FAC015-I Have Had Fevers | FAC01540",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513132","HAM-D6 Self-Report Version - Depressed Mood","C130545","Hamilton Depression Rating Scale 6 Self-Report Version (HAM-D6 Self-Report Version) (1)=Depressed mood per clinician version: How you have been feeling over the past three days, including today.","HAM-D6 Self-Report Version - Depressed Mood | HAMDS1-Depressed Mood | HAMDS101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513630","WHODAS 2.0 36-item Version Interviewer-administered - Getting All Work Done You Need to Do","C130754","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) Because of your health condition, in the past 30 days how much difficulty did you have in: Getting all the work done that you need to do?","WHODAS 2.0 36-item Version Interviewer-administered - Getting All Work Done You Need to Do | WD5-Getting All Work Done You Need | WD5D5_7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513635","WHODAS 2.0 36-item Version Interviewer-administered - Getting Work Done Quickly as Needed","C130755","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) Because of your health condition, in the past 30 days how much difficulty did you have in: Getting your work done as quickly as needed?","WHODAS 2.0 36-item Version Interviewer-administered - Getting Work Done Quickly as Needed | WD5-Getting Work Done Quickly as Needed | WD5D5_8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513636","WHODAS 2.0 36-item Version Interviewer-administered - Had to Work at a Lower Level","C130756","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) Because of your health condition, in the past 30 days how much difficulty did you have in: Have you had to work at a lower level because of a health condition?","WHODAS 2.0 36-item Version Interviewer-administered - Had to Work at a Lower Level | WD5-Had to Work at a Lower Level | WD5D5_9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513625","WHODAS 2.0 36-item Version Interviewer-administered - Earn Less Money","C130757","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) Because of your health condition, in the past 30 days how much difficulty did you have in: Did you earn less money as the result of a health condition?","WHODAS 2.0 36-item Version Interviewer-administered - Earn Less Money | WD5-Earn Less Money | WD5D5_10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513637","WHODAS 2.0 36-item Version Interviewer-administered - How Many Days Did You Miss Work","C130758","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, on how many days did you miss work for half a day or more because of your health condition?","WHODAS 2.0 36-item Version Interviewer-administered - How Many Days Did You Miss Work | WD5-How Many Days Did You Miss Work | WD5D5_02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513649","WHODAS 2.0 36-item Version Interviewer-administered - Problem Joining Community Activities","C130759","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days: How much of a problem did you have joining in community activities (for example, festivities, religious or other activities) in the same way as anyone else can?","WHODAS 2.0 36-item Version Interviewer-administered - Problem Joining Community Activities | WD5-Problem Joining Community Activities | WD5D6_1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031346","Pharyngeal Muscles","C13075","The muscles that form the walls of the pharynx, including the inferior, middle, and superior constrictors, salpingopharyngeus, and stylopharyngeus.","Pharyngeal Muscles | ",,,,,,,,,,,,,,,"4247414","Muscle structure of pharynx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513646","WHODAS 2.0 36-item Version Interviewer-administered - Problem Because of Barriers in World","C130760","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days: How much of a problem did you have because of barriers or hindrances in the world around you?","WHODAS 2.0 36-item Version Interviewer-administered - Problem Because of Barriers in World | WD5-Problem Because of Barriers in World | WD5D6_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513650","WHODAS 2.0 36-item Version Interviewer-administered - Problem Living with Dignity","C130761","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days: How much of a problem did you have living with dignity because of the attitudes and actions of others?","WHODAS 2.0 36-item Version Interviewer-administered - Problem Living with Dignity | WD5-Problem Living with Dignity | WD5D6_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514129","IDS-C - Weight (Increase)","C130375","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Weight (increase) within the last two weeks.","IDS-C - Weight (Increase) | IDSC1-Weight (Increase) | IDSC114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514099","IDS-C - Concentration or Decision Making","C130376","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Concentration/decision making.","IDS-C - Concentration or Decision Making | IDSC1-Concentration/Decision Making | IDSC115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514115","IDS-C - Outlook (Self)","C130377","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Outlook (self).","IDS-C - Outlook (Self) | IDSC1-Outlook (Self) | IDSC116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514114","IDS-C - Outlook (Future)","C130378","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Outlook (future).","IDS-C - Outlook (Future) | IDSC1-Outlook (Future) | IDSC117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514126","IDS-C - Suicidal Ideation","C130379","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Suicidal ideation.","IDS-C - Suicidal Ideation | IDSC1-Suicidal Ideation | IDSC118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514105","IDS-C - Involvement","C130380","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Involvement.","IDS-C - Involvement | IDSC1-Involvement | IDSC119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514117","IDS-C - Pleasure or Enjoyment","C130382","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Pleasure/enjoyment (exclude sexual activities).","IDS-C - Pleasure or Enjoyment | IDSC1-Pleasure/Enjoyment (Exclude Sex) | IDSC121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514123","IDS-C - Sexual Interest","C130383","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Sexual interest.","IDS-C - Sexual Interest | IDSC1-Sexual Interest | IDSC122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0228069","Special Sense Organ System","C13058","Any one of the specialized organ systems, including the auditory, gustatory, olfactory, vestibular, and visual systems, which transmit signals from their respective organs to the brain via specialized somatic and visceral afferent fibers.","Special Sense Organ System | ",,,,,,,,,,,,,,,"4212481","Structure of special senses organ system",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513342","QIDS-SR - Increased Appetite","C130590","Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: Increased appetite.","QIDS-SR - Increased Appetite | QIDSR1-Increased Appetite | QIDSR107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513332","QIDS-SR - Decreased Weight","C130591","Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: within the last two weeks: Decreased weight.","QIDS-SR - Decreased Weight | QIDSR1-Decreased Weight | QIDSR108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513343","QIDS-SR - Increased Weight","C130592","Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: within the last two weeks: Increased weight.","QIDS-SR - Increased Weight | QIDSR1-Increased Weight | QIDSR109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513330","QIDS-SR - Concentration or Decision Making","C130593","Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: Concentration/decision making.","QIDS-SR - Concentration or Decision Making | QIDSR1-Concentration/Decision Making | QIDSR110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509176","GAIA Level 2 Neonatal Death in a Non-viable Live Birth","C127970","GAIA Level 2 Neonatal Death in a Non-viable Live Birth is defined by three criteria: first, the infant must be live born; second, at least one of the following requirements must be met: a) Gestational age less than 22 weeks (where the GA level of certainty is either level one or level two) OR b) Birth weight less than 500g; third, the death of the infant within the first 28 days of life must be documented.","GAIA Level 2 Neonatal Death in a Non-viable Live Birth | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Neonatal Death in a Non-viable Live Birth | Level 2 Neonatal Death in a Non-viable Live Birth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509196","GAIA Level 3 Neonatal Death in a Non-viable Live Birth","C127971","GAIA Level 3 Neonatal Death in a Non-viable Live Birth is defined by three criteria: first, the infant must be live born; second, the gestational age must be less than 5 months according to parent/family member/delivery attendant (a GA level of certainty of either level two or three); third, the death of the infant within the first 28 days of life must be documented.","GAIA Level 3 Neonatal Death in a Non-viable Live Birth | Global Alignment of Immunization safety Assessment in pregnancy Level 3 Neonatal Death in a Non-viable Live Birth | Level 3 Neonatal Death in a Non-viable Live Birth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509160","GAIA Level 1 Neonatal Death in an Extremely Preterm Live Birth","C127972","GAIA Level 1 Neonatal Death in an Extremely Preterm Live Birth is defined by three criteria: first, the infant must be live born; second, at least one of the following requirements must be met: a) Gestational age greater than or equal to 22 weeks and less than 28 weeks (where the GA level of certainty is one); OR b) Birth weight greater than or equal to 500g but less than 1000g. Third, the death of the infant within the first 28 days of life must be documented.","GAIA Level 1 Neonatal Death in an Extremely Preterm Live Birth | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Neonatal Death in an Extremely Preterm Live Birth | Level 1 Neonatal Death in an Extremely Preterm Live Birth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509179","GAIA Level 2 Neonatal Death in an Extremely Preterm Live Birth","C127973","GAIA Level 2 Neonatal Death in an Extremely Preterm Live Birth is defined by three criteria: first, the infant must be live born; second, at least one of the following requirements must be met: a) Gestational age greater than or equal to 22 and less than 28 weeks (where the GA level of certainty is either level one or level two) OR b) Birth weight greater than or equal to 500g but less than 1000g; third, the death of the infant within the first 28 days of life must be documented.","GAIA Level 2 Neonatal Death in an Extremely Preterm Live Birth | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Neonatal Death in an Extremely Preterm Live Birth | Level 2 Neonatal Death in an Extremely Preterm Live Birth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509199","GAIA Level 3 Neonatal Death in an Extremely Preterm Live Birth","C127974","GAIA Level 3 Neonatal Death in an Extremely Preterm Live Birth is defined by three criteria: first, the infant must be live born; second, the gestational age must be greater than or equal to 5 months but less than 7 months according to parent/family member/delivery attendant (a GA level of certainty of either level two or three); third, the death of the infant within the first 28 days of life must be documented.","GAIA Level 3 Neonatal Death in an Extremely Preterm Live Birth | Global Alignment of Immunization safety Assessment in pregnancy Level 3 Neonatal Death in an Extremely Preterm Live Birth | Level 3 Neonatal Death in an Extremely Preterm Live Birth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513852","FACT-HEP Version 4 - I Have Had Itching","C130498","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I have had itching.","FACT-HEP Version 4 - I Have Had Itching | FAC015-I Have Had Itching | FAC01541",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513831","FACT-HEP Version 4 - Had Change in the Way Food Tastes","C130499","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I have had a change in the way food tastes.","FACT-HEP Version 4 - Had Change in the Way Food Tastes | FAC015-Had Change in the Way Food Tastes | FAC01542",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024296","Lymphoid Tissue","C13049","Tissue characterized by the presence of large numbers of lymphocytes in different stages of transformation. Connective tissue cells including fibroblasts and macrophages may be present. Lymphoid tissue is framed by a network of reticular fibers and may be diffuse, or densely aggregated.","Lymphoid Tissue | Lymphoid Normal",,,,,,,,,,,,,,,"4320466","Lymphocytic tissue structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0083036","PEG-interleukin-2","C1304","A complex of polyethylene glycol conjugated with human recombinant cytokine interleukin-2 (IL-2) with antineoplastic activity. PEG-interleukin-2 induces natural killer (NK) cell activity and the production of interferon-gamma (IFN-gamma), and enhances T cell-mediated cytotoxicity. Pegylation of IL-2 protects the cytokine from degradation. (NCI04)","PEG-interleukin-2 | PEG-IL-2 | Polyethylene Glycol-Modified Recombinant Interleukin-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513850","FACT-HEP Version 4 - I Have Had Chills","C130500","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I have had chills.","FACT-HEP Version 4 - I Have Had Chills | FAC015-I Have Had Chills | FAC01543",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513299","Q-LES-Q-SF - Medication","C130719","Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Taking everything into consideration, during the past week how satisfied have you been with your: medication?","Q-LES-Q-SF - Medication | QLES2-Medication | QLES215",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513303","Q-LES-Q-SF - Rate Overall Life Satisfaction","C130720","Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) How would you rate your overall life satisfaction and contentment during the past week?","Q-LES-Q-SF - Rate Overall Life Satisfaction | QLES2-Rate Overall Life Satisfaction | QLES216",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513642","WHODAS 2.0 36-item Version Interviewer-administered - Living Situation at Interview","C130721","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) Living situation at time of interview.","WHODAS 2.0 36-item Version Interviewer-administered - Living Situation at Interview | WD5-Living Situation at Interview | WD5F5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513652","WHODAS 2.0 36-item Version Interviewer-administered - Sex as Observed","C130722","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) Record sex as observed.","WHODAS 2.0 36-item Version Interviewer-administered - Sex as Observed | WD5-Sex as Observed | WD5A1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513662","WHODAS 2.0 36-item Version Interviewer-administered - Years Studying in School or College","C130724","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) How many years in all did you spend studying in school, college or university?","WHODAS 2.0 36-item Version Interviewer-administered - Years Studying in School or College | WD5-Years Studying in School/College | WD5A3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513617","WHODAS 2.0 36-item Version Interviewer-administered - Current Marital Status","C130725","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) What is your current marital status?","WHODAS 2.0 36-item Version Interviewer-administered - Current Marital Status | WD5-Current Marital Status | WD5A4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513658","WHODAS 2.0 36-item Version Interviewer-administered - Time Spend on Your Health Condition","C130762","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days: How much time did you spend on your health condition or its consequences?","WHODAS 2.0 36-item Version Interviewer-administered - Time Spend on Your Health Condition | WD5-Time Spend on Your Health Condition | WD5D6_4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513627","WHODAS 2.0 36-item Version Interviewer-administered - Emotionally Affected by Health","C130763","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days: How much have you been emotionally affected by your health condition?","WHODAS 2.0 36-item Version Interviewer-administered - Emotionally Affected by Health | WD5-Emotionally Affected by Health | WD5D6_5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513348","QIDS-SR - View of Myself","C130594","Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: View of myself.","QIDS-SR - View of Myself | QIDSR1-View of Myself | QIDSR111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513346","QIDS-SR - Thoughts of Death or Suicide","C130595","Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: Thoughts of death or suicide.","QIDS-SR - Thoughts of Death or Suicide | QIDSR1-Thoughts of Death or Suicide | QIDSR112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513338","QIDS-SR - General Interest","C130596","Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: General interest.","QIDS-SR - General Interest | QIDSR1-General Interest | QIDSR113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513333","QIDS-SR - Energy Level","C130597","Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: Energy level.","QIDS-SR - Energy Level | QIDSR1-Energy Level | QIDSR114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513337","QIDS-SR - Feeling Slowed Down","C130598","Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: Feeling slowed down.","QIDS-SR - Feeling Slowed Down | QIDSR1-Feeling Slowed Down | QIDSR115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513335","QIDS-SR - Feeling Restless","C130599","Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: Feeling restless.","QIDS-SR - Feeling Restless | QIDSR1-Feeling Restless | QIDSR116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0224522","Synovial Cell","C13059","A fibroblast that lies between the cartilaginous fibers in the synovial membrane of joints.","Synovial Cell | Synovial Cells",,,,,,,,,,,,,,,"4296315","Synoviocytes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0083406","Methyl 2,5-dihydroxycinnamate","C1305","A cell-permeable analog of erbstatin, a compound isolated from Streptomyces that inhibits the autophosphorylation of epidermal growth factor receptor.  Erbstatin analogue competitively inhibits epidermal growth factor receptor-associated tyrosine kinase, inhibiting the activation of v-abl tyrosine kinase.  In addition, this agent has induced apoptosis in mouse thymocytes and inhibits the G2/M phase of the cell cycle. (NCI)","Methyl 2,5-dihydroxycinnamate | 2,4-Dihydroxymethylcinnamate | 2,5-Dihydroxycinnamic Acid Methyl Ester | 3-(2,5-Dihydroxyphenyl)-2-propenoic Acid Methyl Ester | ALX-270-098 | BML-EI146 | Methyl 3-(2,5-dihydroxyphenyl)-2-propenoate | Methyl-2,5-dihydroxycinnamate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513341","QIDS-SR - Highest Score Sleep Items","C130600","Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Enter the highest score on any 1 of the 4 sleep items.","QIDS-SR - Highest Score Sleep Items | QIDSR1-Highest Score Sleep Items | QIDSR117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513339","QIDS-SR - High Score Appetite or Weight Items","C130601","Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Enter the highest score on any 1 of the 4 appetite/weight change items.","QIDS-SR - High Score Appetite or Weight Items | QIDSR1-High Score Appetite/Weight Items | QIDSR118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513681","WHODAS 2.0 36-item Version Proxy-administered - Getting Work Done Quickly as Needed","C130798","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Getting the work done as quickly as needed?","WHODAS 2.0 36-item Version Proxy-administered - Getting Work Done Quickly as Needed | WD6-Getting Work Done Quickly as Needed | WD6D5_8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513692","WHODAS 2.0 36-item Version Proxy-administered - Problem Joining Community Activities","C130799","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Participation in society in the past 30 days: How much of a problem did your relative have in joining in community activities (for example, festivities, religious or other activities) in the same way as anyone else can?","WHODAS 2.0 36-item Version Proxy-administered - Problem Joining Community Activities | WD6-Problem Joining Community Activities | WD6D6_1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433766","Iodine I 124-cRGDY-PEG-C Dots","C128132","An imaging agent composed of silica-based nanoparticles labeled with a near-infrared (NIR) fluorophore, Cyanine 5.5 (Cy5.5) and surrounded by polyethylene glycol (PEG) chains attached to cyclo-[Arg-Gly-Asp-Tyr] (cRGDY) peptides labeled with the positron-emitting radioisotope iodine I 124 via a tyrosine linker, with potential use in positron emission tomography (PET)/spiral computed tomography (CT) imaging. Upon intravenous administration of the radiolabeled iodine I 124-cRGDY-PEG-C dots, the cRGD moiety selectively binds to alphaVbeta3 integrin expressed on tumor cells. Upon PET/CT imaging, alphaVbeta3 integrin-expressing tumor cells can be visualized and the degree of both tumor metastasis and sentinel lymph node (SLN) trafficking can be assessed. Integrins are transmembrane glycoproteins upregulated on proliferating tumor vessel endothelial cells and various cancer cells; their overexpression has been associated with neovascularization, differentiation, proliferation of tumor cells, metastasis and an overall poor prognosis.","Iodine I 124-cRGDY-PEG-C Dots | 124I-cRGDY-PEG-C Dots | 124I-cRGDY-PEG-dots | 124I-cRGDY-PEG-ylated Dots | 124I-cRGDY-PEG-ylated-C Dots | I-124 cRGDY-PEG-C Dots | I-124 cRGDY-PEG-dots | Iodine I 124-cRGDY-PEG-dots",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509446","Dose Response Study","C127803","A study of the effect of dose changes on the efficacy of a drug in order to determine the dose-response relationship and optimal dose of a therapy.","Dose Response Study | DOSE RESPONSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513621","WHODAS 2.0 36-item Version Interviewer-administered - Describes Main Work Status Best","C130726","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) Which describes your main work status best?","WHODAS 2.0 36-item Version Interviewer-administered - Describes Main Work Status Best | WD5-Describes Main Work Status Best | WD5A5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513616","WHODAS 2.0 36-item Version Interviewer-administered - Concentrating for Ten Minutes","C130727","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Concentrating on doing something for ten minutes?","WHODAS 2.0 36-item Version Interviewer-administered - Concentrating for Ten Minutes | WD5-Concentrating for Ten Minutes | WD5D1_1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513651","WHODAS 2.0 36-item Version Interviewer-administered - Remembering to Do Important Things","C130728","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Remembering to do important things?","WHODAS 2.0 36-item Version Interviewer-administered - Remembering to Do Important Things | WD5-Remembering to Do Important Things | WD5D1_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513628","WHODAS 2.0 36-item Version Interviewer-administered - Finding Solutions to Problems","C130729","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Analysing and finding solutions to problems in day-to-day life?","WHODAS 2.0 36-item Version Interviewer-administered - Finding Solutions to Problems | WD5-Finding Solutions to Problems | WD5D1_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513641","WHODAS 2.0 36-item Version Interviewer-administered - Learning a New Task","C130730","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Learning a new task, for example, learning how to get to a new place?","WHODAS 2.0 36-item Version Interviewer-administered - Learning a New Task | WD5-Learning a New Task | WD5D1_4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513522","WHODAS 2.0 12-item Version Interviewer-administered - Living Situation at Interview","C130898","World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) Living situation at time of interview.","WHODAS 2.0 12-item Version Interviewer-administered - Living Situation at Interview | WD1-Living Situation at Interview | WD1F5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513525","WHODAS 2.0 12-item Version Interviewer-administered - Observed Sex","C130899","World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) Record sex as observed.","WHODAS 2.0 12-item Version Interviewer-administered - Observed Sex | WD1-Sex as Observed | WD1A1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0084089","Poly (RGD)","C1308","A synthetic polypeptide based on the arg-gly-asp (RGD) sequence present in some cell adhesion molecules.  Displays antimetastatic activity in model systems.","Poly (RGD) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513520","WHODAS 2.0 12-item Version Interviewer-administered - How Old Are You Now","C130900","World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) How old are you now?","WHODAS 2.0 12-item Version Interviewer-administered - How Old Are You Now | WD1-How Old Are You Now | WD1A2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513529","WHODAS 2.0 12-item Version Interviewer-administered - Years Studying in School or College","C130901","World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) How many years in all did you spend studying in school, college or university?","WHODAS 2.0 12-item Version Interviewer-administered - Years Studying in School or College | WD1-Years Studying in School/College | WD1A3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513814","BUERS - Brooke Upper Extremity Rating Scale","C130326","Brooke Upper Extremity Rating Scale (BUERS) Brooke upper extremity rating scale.","BUERS - Brooke Upper Extremity Rating Scale | BUERS1-Brooke Upper Extremity Rating | BUERS101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027792","Neural Pathway","C13079","The route in which a nerve impulse travels through a series of linked axons to connect different regions within the central nervous system or to convey information from the peripheral nervous system to the brain.","Neural Pathway | Neural Pathways",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1524097","Recombinant Pleiotrophin","C1307","A recombinant form of the heparin-binding cytokine pleiotrophin.  Developmentally regulated, pleiotrophin functions as a growth factor during embryogenesis and the neonatal period, contributing to trophoblast formation, organ development, bone formation, and early brain development by inducing the differentiation and proliferation of neuronal tissue.  Expressed in certain tumor cell types, this agent may stimulate tumor cell growth, angiogenesis, and metastasis. (NCI04)","Recombinant Pleiotrophin | HARP | HBGF-8 | HBNF | Heparin Affin Regulatory Peptide | Heparin-Binding Growth Factor-8 | Heparin-Binding Neurotrophic Factor | OSF-1 | Osteoblast Specific Factor 1 | Pleiotrophin | Recombinant Heparin-Binding Neurotrophic Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513689","WHODAS 2.0 36-item Version Proxy-administered - Problem Because of Barriers in World","C130800","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Participation in society in the past 30 days: How much of a problem did your relative have because of barriers or hindrances in the world around him or her?","WHODAS 2.0 36-item Version Proxy-administered - Problem Because of Barriers in World | WD6-Problem Because of Barriers in World | WD6D6_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513701","WHODAS 2.0 36-item Version Proxy-administered - Time Spend on Your Health Condition","C130802","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Participation in society in the past 30 days: How much time did your relative spend on his or her health condition, or its consequences?","WHODAS 2.0 36-item Version Proxy-administered - Time Spend on Your Health Condition | WD6-Time Spend on Your Health Condition | WD6D6_4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513673","WHODAS 2.0 36-item Version Proxy-administered - Emotionally Affected by Health","C130803","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Participation in society in the past 30 days: How much has your relative been emotionally affected by his or her health condition?","WHODAS 2.0 36-item Version Proxy-administered - Emotionally Affected by Health | WD6-Emotionally Affected by Health | WD6D6_5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513671","WHODAS 2.0 36-item Version Proxy-administered - Drain on Financial Resources","C130804","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Participation in society in the past 30 days: How much has his or her health been a drain on his or her financial resources or on the financial resources of other relatives?","WHODAS 2.0 36-item Version Proxy-administered - Drain on Financial Resources | WD6-Drain on Financial Resources | WD6D6_6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513690","WHODAS 2.0 36-item Version Proxy-administered - Problem Did Your Family Have","C130805","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Participation in society in the past 30 days: How much of a problem did you or the rest of his or her family have because of his or her health problems?","WHODAS 2.0 36-item Version Proxy-administered - Problem Did Your Family Have | WD6-Problem Did Your Family Have | WD6D6_7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513691","WHODAS 2.0 36-item Version Proxy-administered - Problem Doing Things for Relaxation","C130806","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Participation in society in the past 30 days: How much of a problem did your relative have in doing things by himself or herself for relaxation or pleasure?","WHODAS 2.0 36-item Version Proxy-administered - Problem Doing Things for Relaxation | WD6-Problem Doing Things for Relaxation | WD6D6_8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508758","Experimental Organism Benign Endometrial Adenoma","C127811","A benign epithelial neoplasm arising from the endometrium.","Experimental Organism Benign Endometrial Adenoma | ADENOMA, ENDOMETRIAL, BENIGN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508856","Iodine I 125 RISAD-P","C127815","A radioconjugate containing an androgen receptor (AR) targeting agent, 5-radioiodo-3'-O-(17beta-succinyl-5alpha-androstan-3-one)-2'-deoxyuridin-5'-yl phosphate (RISAD-P), labeled with the radioisotope iodine I 125 ([125]I-RISAD-P), with potential use as an imaging agent for single photon emission computed tomography (SPECT) imaging. Upon administration, iodine I 125 RISAD-P selectively binds to and is taken up by AR. Upon SPECT imaging, AR-expressing tumor cells can be imaged and AR expression levels can be assessed. AR, which is overexpressed on certain tumor cells, plays key roles in tumor cell growth and survival.","Iodine I 125 RISAD-P | (125) IRISAD-P | 125IRISAD-P | 5-[125I]iodo-3'-O-(17b-succinyl-5a-androstan-3-one)-2'-deoxyuridin-5'-yl Monophosphate | I 125 RISAD-P | [125]I-5-Radioiodo-3'-O-(17beta-succinyl-5alpha-androstan-3-one)-2'-deoxyuridin-5'-yl Phosphate | [125]I-RISAD-P",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507931","MCL-1 Inhibitor AMG 176","C127817","An inhibitor of induced myeloid leukemia cell differentiation protein MCL-1 (myeloid cell leukemia-1), with potential pro-apoptotic and antineoplastic activities. Upon administration, tapotoclax binds to and inhibits the activity of MCL-1. This disrupts the formation of MCL-1/Bcl-2-like protein 11 (BCL2L11; BIM) complexes and induces apoptosis in tumor cells. MCL-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival.","Tapotoclax | AMG 176 | TAPOTOCLAX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509045","Collapsed Lung","C128384","Atelectasis of an entire lung.","Collapsed Lung | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042174","Uvulitis","C128385","Inflammation of the uvula.","Uvulitis | ",,,,,,,,,,,,,,,"4115233","Uvulitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0271454","Chronic Suppurative Otitis Media","C128386","Otitis media that persists for at least six weeks, and that is associated with otorrhea through a perforated tympanic membrane.","Chronic Suppurative Otitis Media | CSOM",,,,,,,,,,,,,,,"377886","Chronic purulent otitis media",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513512","WHODAS 2.0 12-item Version Interviewer-administered - Current Marital Status","C130902","World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) What is your current marital status?","WHODAS 2.0 12-item Version Interviewer-administered - Current Marital Status | WD1-Current Marital Status | WD1A4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513526","WHODAS 2.0 12-item Version Interviewer-administered - Standing for Long Periods","C130904","World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Standing for long periods such as 30 minutes?","WHODAS 2.0 12-item Version Interviewer-administered - Standing for Long Periods | WD1-Standing for Long Periods | WD1S1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513510","WHODAS 2.0 12-item Version Interviewer-administered - Care of Household Responsibilities","C130905","World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Taking care of your household responsibilities?","WHODAS 2.0 12-item Version Interviewer-administered - Care of Household Responsibilities | WD1-Care of Household Responsibilities | WD1S2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513521","WHODAS 2.0 12-item Version Interviewer-administered - Learning a New Task","C130906","World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Learning a new task, for example, learning how to get to a new place?","WHODAS 2.0 12-item Version Interviewer-administered - Learning a New Task | WD1-Learning a New Task | WD1S3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513524","WHODAS 2.0 12-item Version Interviewer-administered - Problem Joining Community Activities","C130907","World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: How much of a problem did you have joining in community activities (for example, festivities, religious or other activities) in the same way as anyone else can?","WHODAS 2.0 12-item Version Interviewer-administered - Problem Joining Community Activities | WD1-Problem Joining Community Activities | WD1S4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513516","WHODAS 2.0 12-item Version Interviewer-administered - Emotionally Affected by Health","C130908","World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: How much have you been emotionally affected by your health problems?","WHODAS 2.0 12-item Version Interviewer-administered - Emotionally Affected by Health | WD1-Emotionally Affected by Health | WD1S5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513433","CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology","C130281","Test codes of questionnaire questions associated with the World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology | QS-WHODAS 2.0 12+24-item Version Interviewer-administered TESTCD | WD4TC | World Health Organization Disability Assessment Schedule 2.0 - 12 + 24-Item Interviewer Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514023","BUERS Clinical Classification Question","C130282","A question associated with the BUERS clinical classification.","BUERS Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514184","VLERS Clinical Classification Question","C130283","A question associated with the VLERS clinical classification.","VLERS Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513131","HAM-D6 Clinician Version Clinical Classification Question","C130284","A question associated with the HAM-D6 Clinician Version clinical classification.","HAM-D6 Clinician Version Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513164","HAMD 24 Clinical Classification Question","C130285","A question associated with the HAMD 24 clinical classification.","HAMD 24 Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514169","IDS-C Clinical Classification Question","C130286","A question associated with the IDS-C clinical classification.","IDS-C Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513506","VLERS - Vignos Lower Extremity Rating","C130327","Vignos Lower Extremity Rating Scale (VLERS) Vignos rating scale.","VLERS - Vignos Lower Extremity Rating | VLERS1-Vignos Lower Extremity Rating | VLERS101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513124","HAM-D6 - Clinician Version - Depressed Mood","C130328","Hamilton Depression Rating Scale 6 Clinician Version (HAM-D6 Clinician Version) Depressed mood.","HAM-D6 - Clinician Version - Depressed Mood | HAMD4-Depressed Mood | HAMD401",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513125","HAM-D6 - Clinician Version - Low Self-esteem and Guilt","C130329","Hamilton Depression Rating Scale 6 Clinician Version (HAM-D6 Clinician Version) Low self-esteem and guilt.","HAM-D6 - Clinician Version - Low Self-esteem and Guilt | HAMD4-Low Self-esteem and Guilt | HAMD402",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513128","HAM-D6 - Clinician Version - Social Life Activities or Interests","C130330","Hamilton Depression Rating Scale 6 Clinician Version (HAM-D6 Clinician Version) Social life activities and interests.","HAM-D6 - Clinician Version - Social Life Activities or Interests | HAMD4-Social Life Activities/Interests | HAMD403",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513127","HAM-D6 - Clinician Version - Psychomotor Retardation, General","C130331","Hamilton Depression Rating Scale 6 Clinician Version (HAM-D6 Clinician Version) Psychomotor retardation, general.","HAM-D6 - Clinician Version - Psychomotor Retardation, General | HAMD4-Psychomotor Retardation, General | HAMD404",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513133","HAM-D6 Self-Report Version - Low Self-esteem and Guilt","C130546","Hamilton Depression Rating Scale 6 Self-Report Version (HAM-D6 Self-Report Version) (2)=Low self-esteem and guilt per clinician version: How you have been feeling over the past three days, including today.","HAM-D6 Self-Report Version - Low Self-esteem and Guilt | HAMDS1-Low Self-esteem and Guilt | HAMDS102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513136","HAM-D6 Self-Report Version - Social Life Activities or Interests","C130547","Hamilton Depression Rating Scale 6 Self-Report Version (HAM-D6 Self-Report Version) (3)=Social life activities and interests per clinician version: How you have been feeling over the past three days, including today.","HAM-D6 Self-Report Version - Social Life Activities or Interests | HAMDS1-Social Life Activities/Interests | HAMDS103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513135","HAM-D6 Self-Report Version - Psychomotor Retardation","C130548","Hamilton Depression Rating Scale 6 Self-Report Version (HAM-D6 Self-Report Version) (4)=Psychomotor retardation, general per clinician version: How you have been feeling over the past three days, including today.","HAM-D6 Self-Report Version - Psychomotor Retardation | HAMDS1-Psychomotor Retardation, General | HAMDS104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513134","HAM-D6 Self-Report Version - Psychic Anxiety","C130549","Hamilton Depression Rating Scale 6 Self-Report Version (HAM-D6 Self-Report Version) (5)=Psychic anxiety per clinician version: How you have been feeling over the past three days, including today.","HAM-D6 Self-Report Version - Psychic Anxiety | HAMDS1-Psychic Anxiety | HAMDS105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1947950","Embryonic Cell","C13054","A cell formed in the initial stages of embryonic development, after zygote formation.","Embryonic Cell | Blastomere | Embryonic Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513137","HAM-D6 Self-Report Version - Tiredness and Pains","C130550","Hamilton Depression Rating Scale 6 Self-Report Version (HAM-D6 Self-Report Version) (6)=Tiredness and pains per clinician version: How you have been feeling over the past three days, including today.","HAM-D6 Self-Report Version - Tiredness and Pains | HAMDS1-Tiredness and Pains | HAMDS106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514135","IDS-SR - Falling Asleep","C130551","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Falling asleep.","IDS-SR - Falling Asleep | IDSR1-Falling Asleep | IDSR101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514159","IDS-SR - Waking Up Too Early","C130553","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Waking up too early.","IDS-SR - Waking Up Too Early | IDSR1-Waking Up Too Early | IDSR103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514717","Experimental Organism Benign Plasma Cell Tumor","C130197","A benign neoplasm of the epithelium originating from plasma cells.","Experimental Organism Benign Plasma Cell Tumor | PLASMA CELL TUMOR, BENIGN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513375","Total Number of Study Animals Purchased","C130198","The absolute count of all animals bought for an intended purpose within a study.","Total Number of Study Animals Purchased | TOTANPCH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
,,"C13019","Any component associated with the organ for sight or vision.","Eye Part | ",,,,,,,,,,,,,,,"4001052","Eye part",,,,,,,,,,,,,,,,,,,,,,"--"
"C0082481","Esperamicin A1","C1301","An enediyne antineoplastic antibiotic hybrid containing an anthranilate moiety.  Esperamicin A1 is isolated from the bacterium Actinomadura verrucosospora.  The anthranilate component of esperamicin A1 intercalates DNA and the benzene diradical intermediate of the enediyne core binds to the minor groove of DNA, resulting in single- and double-stranded breaks in DNA and apoptosis. (NCI04)","Esperamicin A1 | ESPERAMICIN A1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513799","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.742C>G Mutation","C130201","A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where cytosine has been substituted with guanine at nucleotide position 742 of the ABL1 gene.","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.742C>G Mutation | BCR/ABL Fusion Gene with NM_005157.4:c.742C>G | BCR/ABL Fusion Gene with NM_005157.5:c.742C>G | BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.742C>G | BCR/ABL1 Fusion Gene with NM_005157.4:c.742C>G | BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.742C>G Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513800","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.749G>A Mutation","C130204","A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where guanine has been substituted with adenine at nucleotide position 749 of the ABL1 gene.","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.749G>A Mutation | BCR/ABL Fusion Gene with NM_005157.4:c.749G>A | BCR/ABL Fusion Gene with NM_005157.5:c.749G>A | BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.749G>A | BCR/ABL1 Fusion Gene with NM_005157.4:c.749G>A | BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.749G>A Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514119","IDS-C - Psychomotor Slowing","C130384","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Psychomotor slowing.","IDS-C - Psychomotor Slowing | IDSC1-Psychomotor Slowing | IDSC123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015652","Fasciolosis","C128387","A parasitic infection that is caused by liver flukes, usually Fasciola hepatica, of sheep, goats, and cattle. Humans become infected by eating uncooked, infested aquatic vegetation (classically watercress). Adult flukes inhabit the bile ducts, gallbladder, and occasionally ectopic sites. Symptoms arise secondary to inflammatory response or obstruction.","Fasciolosis | Fascioliasis",,,,,,,,,,,,,,,"436342","Infection by Fasciola",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015656","Fasciolopsiasis","C128388","A small bowel infection that is caused by Fasciolopsis buski, which is endemic in the Far East and Southeast Asia, and which is transmitted via the consumption of raw or undercooked aquatic plants. The spectrum of manifestations range from  asymptomatic to intestinal symptoms from local invasion or allergic response.","Fasciolopsiasis | ",,,,,,,,,,,,,,,"442273","Infection by Fasciolopsis buski",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152071","Heterophyiasis","C128389","An infection that is caused by the intestinal fluke Heterophyes heterophyes, which is most commonly found in Asia, the Middle East, and Africa, and which is transmitted via consumption of contaminated raw or undercooked fish. Symptoms typically range from asymptomatic to intermittent abdominal pain and diarrhea, with occasional ectopic infection.","Heterophyiasis | ",,,,,,,,,,,,,,,"4119258","Infection by Heterophyes heterophyes",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025530","Metagonimiasis","C128390","An infection that is most commonly caused by the intestinal fluke Metagonimus yokogawai, which is most commonly found in the Far East, and which is transmitted via consumption of contaminated raw or undercooked fish. Symptoms typically range from asymptomatic to intermittent abdominal pain and diarrhea, with occasional ectopic infection.","Metagonimiasis | ",,,,,,,,,,,,,,,"444075","Infection by Metagonimus yokogawai",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0012561","Diphyllobothriasis","C128391","An infection that is caused by the tapeworm Diphyllobothrium latum and related species; it is transmitted via consumption of raw or undercooked fish, and symptoms include abdominal discomfort, diarrhea, vomiting, fatigue, weight loss, and vitamin B12 deficiency.","Diphyllobothriasis | ",,,,,,,,,,,,,,,"4089500","Diphyllobothriasis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2711266","Anisakiasis","C128393","An infection that is caused by nematodes of the genus Anisakis, which is most commonly transmitted via ingestion of infective larvae from consumption of raw or undercooked fish or squid; it is characterized by invasion of the stomach wall or intestines, resulting in the death of the worm, and triggering an inflammatory response that surrounds the worm and that can result in intestinal obstruction.","Anisakiasis | ",,,,,,,,,,,,,,,"40484496","Infection by Anisakis larva",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0392662","Angiostrongyliasis","C128394","An infection that is caused by nematodes of the genus Angiostrongylus; signs and symptoms are dependent on the invading species, but generally include gastrointestinal symptoms and fever, and can have extraintestinal manifestations (e.g., central nervous system, anterior and posterior eye).","Angiostrongyliasis | ",,,,,,,,,,,,,,,"4264169","Infection by Angiostrongylus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018013","Gnathostomiasis","C128395","An infection that is caused by nematodes of the genus Gnathostoma, which is commonly found in Southeast Asia, and which is transmitted via the consumption of contaminated raw/undercooked birds, eels, fish, frogs, or reptiles. The pattern of symptoms is species-dependent, and extraintestinal manifestations are due to larval migration (e.g., pulmonary infiltrates, eosinophilic meningitis, or painful, pruritic subcutaneous swellings, and peripheral blood eosinophilia).","Gnathostomiasis | ",,,,,,,,,,,,,,,"442343","Infection by Gnathostoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509610","Baylisascariasis","C128397","An infection that is caused by the raccoon nematode Baylisascaris procyonis, which is transmitted by the ingestion of embryonated eggs in contaminated soil; symptoms depend on larval migration sites (visceral organs, eye, or brain) provoking severe inflammatory responses.","Baylisascariasis | Raccoon Roundworm Infection",,,,,,,,,,,,,,,"4238591","Infection by Baylisascaris",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038463","Strongyloidiasis","C128398","An infection that is caused by nematodes of the genus Strongyloides, most commonly Strongyloides stercoralis, which is a soil-transmitted helminth, and which is characterized by a variety of gastrointestinal, dermatologic, and, occasionally, pulmonary manifestations. The worm's autoinfective life cycle can lead to hyper-infection and life-threatening dissemination in immunocompromised hosts decades after initial infection.","Strongyloidiasis | ",,,,,,,,,,,,,,,"436040","Infection by Strongyloides",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513962","KDPI Clinical Classification Question","C130288","A question associated with the KDPI clinical classification.","KDPI Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514051","FACT-LEU Version 4 Questionnaire Question","C130289","A question associated with the FACT-LEU Version 4 questionnaire.","FACT-LEU Version 4 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514050","FACT-HEP Version 4 Questionnaire Question","C130290","A question associated with the FACT-HEP Version 4 questionnaire.","FACT-HEP Version 4 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514052","FACT-LYM Version 4 Questionnaire Question","C130291","A question associated with the FACT-LYM Version 4 questionnaire.","FACT-LYM Version 4 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513138","HAM-D6 Self-Report Version Questionnaire Question","C130292","A question associated with the HAM-D6 Self-Report Version questionnaire.","HAM-D6 Self-Report Version Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514170","IDS-SR Questionnaire Question","C130293","A question associated with the IDS-SR questionnaire.","IDS-SR Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513350","QIDS-SR Questionnaire Question","C130294","A question associated with the QIDS-SR questionnaire.","QIDS-SR Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513308","Q-LES-Q-SF Questionnaire Question","C130296","A question associated with the Q-LES-Q-SF questionnaire.","Q-LES-Q-SF Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514190","WHODAS 2.0 36-item Version Interviewer-administered Questionnaire Question","C130297","A question associated with the WHODAS 2.0 36-item Version Interviewer-administered questionnaire.","WHODAS 2.0 36-item Version Interviewer-administered Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514191","WHODAS 2.0 36-item Version Proxy-administered Questionnaire Question","C130298","A question associated with the WHODAS 2.0 36-item Version Proxy-administered questionnaire.","WHODAS 2.0 36-item Version Proxy-administered Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514192","WHODAS 2.0 36-item Version Self-administered Questionnaire Question","C130299","A question associated with the WHODAS 2.0 36-item Version Self-administered questionnaire.","WHODAS 2.0 36-item Version Self-administered Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516847","Endocrine System Part","C13029","Any component of the tissues capable of secreting hormones.","Endocrine System Part | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522221","Recombinant I-309","C1302","A recombinant form of human I-309, an inflammatory CXC cytokine secreted by activated T lymphocytes that appears to be an inducer of angiogenesis.","Recombinant I309 | CCL1 | I309",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513861","FACT-HEP Version 4 - My Mouth Is Dry","C130501","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: My mouth is dry.","FACT-HEP Version 4 - My Mouth Is Dry | FAC015-My Mouth Is Dry | FAC01544",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513828","FACT-HEP Version 4 - Discomfort or Pain in Stomach Area","C130502","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I have discomfort or pain in my stomach area.","FACT-HEP Version 4 - Discomfort or Pain in Stomach Area | FAC015-Discomfort/Pain in Stomach Area | FAC01545",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513943","FACT-LYM Version 4 - I Have a Lack of Energy","C130503","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Physical Well-Being: I have a lack of energy.","FACT-LYM Version 4 - I Have a Lack of Energy | FAC018-I Have a Lack of Energy | FAC01801",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513938","FACT-LYM Version 4 - I Have Nausea","C130504","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Physical Well-Being: I have nausea.","FACT-LYM Version 4 - I Have Nausea | FAC018-I Have Nausea | FAC01802",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514155","IDS-SR - Sleeping Too Much","C130554","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Sleeping too much.","IDS-SR - Sleeping Too Much | IDSR1-Sleeping Too Much | IDSR104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514139","IDS-SR - Feeling Sad","C130555","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Feeling sad.","IDS-SR - Feeling Sad | IDSR1-Feeling Sad | IDSR105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514137","IDS-SR - Feeling Irritable","C130556","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Feeling irritable.","IDS-SR - Feeling Irritable | IDSR1-Feeling Irritable | IDSR106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514136","IDS-SR - Feeling Anxious or Tense","C130557","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Feeling anxious or tense.","IDS-SR - Feeling Anxious or Tense | IDSR1-Feeling Anxious or Tense | IDSR107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514162","IDS-SR - Response of Your Mood to Good or Desired Events","C130558","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Response of your mood to good or desired events.","IDS-SR - Response of Your Mood to Good or Desired Events | IDSR1-Your Mood to Good/Desired Events | IDSR108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514148","IDS-SR - Mood in Relation to the Time of Day","C130559","Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Mood in relation to the time of day.","IDS-SR - Mood in Relation to the Time of Day | IDSR1-Mood in Relation to Time of Day | IDSR109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513647","WHODAS 2.0 36-item Version Interviewer-administered - How Much Problem Did Your Family Have","C130765","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days: How much of a problem did your family have because of your health problems?","WHODAS 2.0 36-item Version Interviewer-administered - How Much Problem Did Your Family Have | WD5-Problem Did Your Family Have | WD5D6_7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513648","WHODAS 2.0 36-item Version Interviewer-administered - Problem Doing Things for Relaxation","C130766","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days: How much of a problem did you have in doing things by yourself for relaxation or pleasure?","WHODAS 2.0 36-item Version Interviewer-administered - Problem Doing Things for Relaxation | WD5-Problem Doing Things for Relaxation | WD5D6_8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513638","WHODAS 2.0 36-item Version Interviewer-administered - How Many Days Difficulties Present","C130767","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) Overall, in the past 30 days, how many days were these difficulties present?","WHODAS 2.0 36-item Version Interviewer-administered - How Many Days Difficulties Present | WD5-How Many Days Difficulties Present | WD5H1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513619","WHODAS 2.0 36-item Version Interviewer-administered - Days Unable to Carry Out Activities","C130768","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, for how many days were you totally unable to carry out your usual activities or work because of any health condition?","WHODAS 2.0 36-item Version Interviewer-administered - Days Unable to Carry Out Activities | WD5-Days Unable to Carry Out Activities | WD5H2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514118","IDS-C - Psychomotor Agitation","C130385","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Psychomotor agitation.","IDS-C - Psychomotor Agitation | IDSC1-Psychomotor Agitation | IDSC124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514125","IDS-C - Somatic Complaints","C130386","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Somatic complaints.","IDS-C - Somatic Complaints | IDSC1-Somatic Complaints | IDSC125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514127","IDS-C - Sympathetic Arousal","C130387","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Sympathetic arousal.","IDS-C - Sympathetic Arousal | IDSC1-Sympathetic Arousal | IDSC126",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514116","IDS-C - Panic or Phobic Symptoms","C130388","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Panic/phobic symptoms.","IDS-C - Panic or Phobic Symptoms | IDSC1-Panic/Phobic Symptoms | IDSC127",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514102","IDS-C - Gastrointestinal","C130389","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Gastrointestinal.","IDS-C - Gastrointestinal | IDSC1-Gastrointestinal | IDSC128",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518163","Male Reproductive System Part","C13038","Any component of the male organs and tissues involved in the production and maturation of gametes and in their union and subsequent development as offspring.","Male Reproductive System Part | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514104","IDS-C - Interpersonal Sensitivity","C130390","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Interpersonal sensitivity.","IDS-C - Interpersonal Sensitivity | IDSC1-Interpersonal Sensitivity | IDSC129",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514106","IDS-C - Leaden Paralysis or Physical Energy","C130391","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Leaden paralysis/physical energy.","IDS-C - Leaden Paralysis or Physical Energy | IDSC1-Leaden Paralysis/Physical Energy | IDSC130",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514122","IDS-C - Score","C130392","Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Score.","IDS-C - Score | IDSC1-Score | IDSC131",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513961","KDPI - KDPI Score","C130393","Kidney Donor Profile Index (KDPI) KDPI score.","KDPI - KDPI Score | KDPI01-KDPI Score | KDPI0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513324","QIDS-C - Sleep Onset Insomnia","C130394","Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Sleep onset insomnia.","QIDS-C - Sleep Onset Insomnia | QIDSC1-Sleep Onset Insomnia | QIDSC101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513319","QIDS-C - Mid-Nocturnal Insomnia","C130395","Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Mid-nocturnal insomnia.","QIDS-C - Mid-Nocturnal Insomnia | QIDSC1-Mid-Nocturnal Insomnia | QIDSC102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513312","QIDS-C - Early Morning Insomnia","C130396","Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Early morning insomnia.","QIDS-C - Early Morning Insomnia | QIDSC1-Early Morning Insomnia | QIDSC103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513317","QIDS-C - Hypersomnia","C130397","Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Hypersomnia.","QIDS-C - Hypersomnia | QIDSC1-Hypersomnia | QIDSC104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509158","GAIA Level 1 Neonatal Death in a Preterm Live Birth","C127975","GAIA Level 1 Neonatal Death in a Preterm Live Birth is defined by three criteria: first, the infant must be live born; second, at least one of the following requirements must be met: a) Gestational age greater than or equal to 28 weeks and less than 37 weeks (where the GA level of certainty is one); OR b) Birth weight greater than or equal to 1000g but less than 2500g; third, the death of the infant within the first 28 days of life must be documented.","GAIA Level 1 Neonatal Death in a Preterm Live Birth | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Neonatal Death in a Preterm Live Birth | Level 1 Neonatal Death in a Preterm Live Birth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509177","GAIA Level 2 Neonatal Death in a Preterm Live Birth","C127976","GAIA Level 2 Neonatal Death in a Preterm Live Birth is defined by three criteria: first, the infant must be live born; second, at least one of the following requirements must be met: a) Gestational age greater than or equal to 28 and less than 37 weeks (where the GA level of certainty is either level one or level two); OR b) Birth weight greater than or equal to 1000g but less than 2500g; third, the death of the infant within the first 28 days of life must be documented.","GAIA Level 2 Neonatal Death in a Preterm Live Birth | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Neonatal Death in a Preterm Live Birth | Level 2 Neonatal Death in a Preterm Live Birth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509197","GAIA Level 3 Neonatal Death in a Preterm Live Birth","C127977","GAIA Level 3 Neonatal Death in a Preterm Live Birth is defined by three criteria: first, the infant must be live born; second, the gestational age must be greater than or equal to 7 months but less than 9 months according to parent/family member/delivery attendant (a GA level of certainty of either level two or three); third, the death of the infant within the first 28 days of life must be documented.","GAIA Level 3 Neonatal Death in a Preterm Live Birth | Global Alignment of Immunization safety Assessment in pregnancy Level 3 Neonatal Death in a Preterm Live Birth | Level 3 Neonatal Death in a Preterm Live Birth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509159","GAIA Level 1 Neonatal Death in a Term Live Birth","C127978","GAIA Level 1 Neonatal Death in a Term Live Birth is defined by four criteria: first, the infant must be live born; second, the gestational age must be greater than or equal to 37 weeks (a GA level of certainty of one); third, at least one of the following requirements must be met: a) Birth weight greater than 2500g; OR b) Documented intra-uterine growth retardation if weight is less than or equal to 2500g; fourth, the death of the infant within the first 28 days of life must be documented.","GAIA Level 1 Neonatal Death in a Term Live Birth | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Neonatal Death in a Term Live Birth | Level 1 Neonatal Death in a Term Live Birth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509178","GAIA Level 2 Neonatal Death in a Term Live Birth","C127979","GAIA Level 2 Neonatal Death in a Term Live Birth is defined by three criteria: first, the infant must be live born; second, at least one of the following requirements must be met: a) Gestational age greater than or equal to 37 weeks (where the GA level of certainty is either level one or level two) OR b) Birth weight greater than or equal to 2500g; third, the death of the infant within the first 28 days of life must be documented.","GAIA Level 2 Neonatal Death in a Term Live Birth | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Neonatal Death in a Term Live Birth | Level 2 Neonatal Death in a Term Live Birth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509198","GAIA Level 3 Neonatal Death in a Term Live Birth","C127980","GAIA Level 3 Neonatal Death in a Term Live Birth is defined by three criteria: first, the infant must be live born; second, the gestational age must be greater than or equal to 9 months according to parent/ family member/delivery attendant (a GA level of certainty of either level two or three); third, the death of the infant within the first 28 days of life must be documented.","GAIA Level 3 Neonatal Death in a Term Live Birth | Global Alignment of Immunization safety Assessment in pregnancy Level 3 Neonatal Death in a Term Live Birth | Level 3 Neonatal Death in a Term Live Birth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509156","GAIA Level 1 Maternal Immunization","C127981","GAIA Level 1 Maternal immunization is defined by three criteria: first, the pregnancy must be confirmed by either a positive pregnancy test or by ultrasound confirmation; second, the date/time of the immunization of the pregnant woman must be recorded in the medical records by the health care worker who administered/witnessed administration of vaccine; third, the details of vaccine must include the lot number and the date of immunization.","GAIA Level 1 Maternal Immunization | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Maternal Immunization | Level 1 Maternal Immunisation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513952","FACT-LYM Version 4 - Trouble Meeting Needs of Family","C130505","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Physical Well-Being: Because of my physical condition, I have trouble meeting the needs of my family.","FACT-LYM Version 4 - Trouble Meeting Needs of Family | FAC018-Trouble Meeting Needs of Family | FAC01803",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513940","FACT-LYM Version 4 - I Have Pain","C130506","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Physical Well-Being: I have pain.","FACT-LYM Version 4 - I Have Pain | FAC018-I Have Pain | FAC01804",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513914","FACT-LYM Version 4 - Bothered by Treatment Side Effect","C130507","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Physical Well-Being: I am bothered by side effects of treatment.","FACT-LYM Version 4 - Bothered by Treatment Side Effect | FAC018-Bothered by Treatment Side Effect | FAC01805",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513931","FACT-LYM Version 4 - I Feel Ill","C130508","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Physical Well-Being: I feel ill.","FACT-LYM Version 4 - I Feel Ill | FAC018-I Feel Ill | FAC01806",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513925","FACT-LYM Version 4 - I Am Forced to Spend Time in Bed","C130509","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Physical Well-Being: I am forced to spend time in bed.","FACT-LYM Version 4 - I Am Forced to Spend Time in Bed | FAC018-I Am Forced to Spend Time in Bed | FAC01807",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513934","FACT-LYM Version 4 - I Get Support From My Friends","C130512","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Social/Family Well-Being: I get support from my friends.","FACT-LYM Version 4 - I Get Support From My Friends | FAC018-I Get Support From My Friends | FAC01810",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513948","FACT-LYM Version 4 - My Family Has Accepted My Illness","C130513","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Social/Family Well-Being: My family has accepted my illness.","FACT-LYM Version 4 - My Family Has Accepted My Illness | FAC018-My Family Has Accepted My Illness | FAC01811",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513950","FACT-LYM Version 4 - Satisfied With Communication About Illness","C130514","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Social/Family Well-Being: I am satisfied with family communication about my illness.","FACT-LYM Version 4 - Satisfied With Communication About Illness | FAC018-Satisfied Communication Illness | FAC01812",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513930","FACT-LYM Version 4 - I Feel Close to My Partner","C130515","Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Social/Family Well-Being: I feel close to my partner (or the person who is my main support).","FACT-LYM Version 4 - I Feel Close to My Partner | FAC018-I Feel Close to My Partner | FAC01813",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513659","WHODAS 2.0 36-item Version Interviewer-administered - Understanding What People Say","C130731","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Generally understanding what people say?","WHODAS 2.0 36-item Version Interviewer-administered - Understanding What People Say | WD5-Understanding What People Say | WD5D1_5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513639","WHODAS 2.0 36-item Version Interviewer-administered - How Many Days Reduce Activities","C130769","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, not counting the days that you were totally unable, for how many days did you cut back or reduce your usual activities or work because of any health condition?","WHODAS 2.0 36-item Version Interviewer-administered - How Many Days Reduce Activities | WD5-How Many Days Reduce Activities | WD5H3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513684","WHODAS 2.0 36-item Version Proxy-administered - I Am (Fill in the Blank) of this Person","C130770","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) I am the (Fill in the Blank) of this person.","WHODAS 2.0 36-item Version Proxy-administered - I Am (Fill in the Blank) of this Person | WD6-I Am (Fill in Blank) of This Person | WD6H4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513666","WHODAS 2.0 36-item Version Proxy-administered - Concentrating for Ten Minutes","C130771","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Concentrating on doing something for ten minutes?","WHODAS 2.0 36-item Version Proxy-administered - Concentrating for Ten Minutes | WD6-Concentrating for Ten Minutes | WD6D1_1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513694","WHODAS 2.0 36-item Version Proxy-administered - Remembering to Do Important Things","C130772","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Remembering to do important things?","WHODAS 2.0 36-item Version Proxy-administered - Remembering to Do Important Things | WD6-Remembering to Do Important Things | WD6D1_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513674","WHODAS 2.0 36-item Version Proxy-administered - Finding Solutions to Problems","C130773","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Analysing and finding solutions to problems in day-to-day life?","WHODAS 2.0 36-item Version Proxy-administered - Finding Solutions to Problems | WD6-Finding Solutions to Problems | WD6D1_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513685","WHODAS 2.0 36-item Version Proxy-administered - Learning a New Task","C130774","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Learning a new task, for example, learning how to get to a new place?","WHODAS 2.0 36-item Version Proxy-administered - Learning a New Task | WD6-Learning a New Task | WD6D1_4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513702","WHODAS 2.0 36-item Version Proxy-administered - Understanding What People Say","C130775","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Generally understanding what people say?","WHODAS 2.0 36-item Version Proxy-administered - Understanding What People Say | WD6-Understanding What People Say | WD6D1_5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513320","QIDS-C - Mood (Sad)","C130398","Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Mood (sad).","QIDS-C - Mood (Sad) | QIDSC1-Mood (Sad) | QIDSC105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513340","QIDS-SR - Highest Score Psychomotor Items","C130602","Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Enter the highest score on either of the 2 psychomotor items.","QIDS-SR - Highest Score Psychomotor Items | QIDSR1-Highest Score Psychomotor Items | QIDSR119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513347","QIDS-SR - Total Score","C130603","Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Total score.","QIDS-SR - Total Score | QIDSR1-Total Score | QIDSR120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513237","Q-LES-Q - Free of Aches, Pains, Discomfort","C130604","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) With regard to your physical health, during the past week how much of the time have you: been completely free of aches, pains, or discomfort?","Q-LES-Q - Free of Aches, Pains, Discomfort | QLES1-Free of Aches, Pains, Discomfort | QLES101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513232","Q-LES-Q - Felt Rested","C130605","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) With regard to your physical health, during the past week how much of the time have you: felt rested?","Q-LES-Q - Felt Rested | QLES1-Felt Rested | QLES102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513222","Q-LES-Q - Felt Energetic","C130606","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) With regard to your physical health, during the past week how much of the time have you: felt energetic?","Q-LES-Q - Felt Energetic | QLES1-Felt Energetic | QLES103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513236","Q-LES-Q - Felt in Excellent Physical Health","C130607","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) With regard to your physical health, during the past week how much of the time have you: felt in excellent physical health?","Q-LES-Q - Felt in Excellent Physical Health | QLES1-Felt in Excellent Physical Health | QLES104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513239","Q-LES-Q - Free of Worry of Physical Health","C130609","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) With regard to your physical health, during the past week how much of the time have you: been free of worry about your physical health?","Q-LES-Q - Free of Worry of Physical Health | QLES1-Free of Worry of Physical Health | QLES106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206429","Sensory Ganglion","C13060","A cluster of nerve cell bodies that transmit sensory impulses and are located on either the dorsal root of a spinal nerve or on certain cranial nerves.","Sensory Ganglion | Sensory Ganglia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513235","Q-LES-Q - Felt You Got Enough Sleep","C130610","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) With regard to your physical health, during the past week how much of the time have you: felt you got enough sleep?","Q-LES-Q - Felt You Got Enough Sleep | QLES1-Felt You Got Enough Sleep | QLES107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513199","Q-LES-Q - Be as Physically Active as Needed","C130611","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) With regard to your physical health, during the past week how much of the time have you: felt able to be as physically active as needed?","Q-LES-Q - Be as Physically Active as Needed | QLES1-Be as Physically Active as Needed | QLES108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513234","Q-LES-Q - Felt Well Coordinated","C130612","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) With regard to your physical health, during the past week how much of the time have you: felt well coordinated?","Q-LES-Q - Felt Well Coordinated | QLES1-Felt Well Coordinated | QLES109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513230","Q-LES-Q - Felt Memory Was Functioning Well","C130613","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) With regard to your physical health, during the past week how much of the time have you: felt your memory was functioning well?","Q-LES-Q - Felt Memory Was Functioning Well | QLES1-Felt Memory Was Functioning Well | QLES110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509175","GAIA Level 2 Maternal Immunization","C127982","GAIA Level 2 Maternal immunization is defined by three criteria: first, pregnancy must be confirmed by both the patient's report of cessation of menstrual period and by physical exam revealing a gravid uterus; second, the date (at least month and year) of the immunization of the pregnant woman must be recorded in the medical records by the health care worker who administered/witnessed administration of vaccine; third, the medical record must contain details of the disease against which the individual was vaccinated.","GAIA Level 2 Maternal Immunization | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Maternal Immunization | Level 2 Maternal Immunisation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507936","LY3300054","C128138","A monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1) with immune checkpoint inhibitory and potential antineoplastic activities. Upon administration, lodapolimab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T-cells.","Lodapolimab | Anti-PD-L1 Checkpoint Antibody LY3300054 | Anti-PD-L1 Monoclonal Antibody LY3300054 | Anti-Programmed Cell Death Ligand 1 Checkpoint Antibody LY3300054 | LODAPOLIMAB | LY3300054 | WHO 11185",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508988","Swallowable Sponge Cell Sampling Device","C128141","A minimally invasive cell sampling device comprising a sponge-like material that is compressed into a swallowable and dissolvable capsule, and a cord for retrieval.","Swallowable Sponge Cell Sampling Device | Cytosponge | Swallowable Sponge | Swallowable Sponge Device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509577","Vulvar Squamous Intraepithelial Lesion, HPV-Associated","C128142","An intraepithelial lesion of the vulvar squamous epithelium associated with HPV infection. It is characterized by maturation abnormalities and nuclear hyperchromasia that are confined to the basement membrane.","Vulvar Squamous Intraepithelial Lesion, HPV-Associated | Vulvar Intraepithelial Neoplasia, HPV-Associated | Vulvar SIL | Vulvar Squamous Intraepithelial Lesion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509460","Idiopathic Crescentic Glomerulonephritis","C128143","Crescentic glomerulonephritis, the cause of which is unknown.","Idiopathic Crescentic Glomerulonephritis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509756","Membranous Nephropathy - Secondary","C128144","Membranous nephropathy due to another medical condition.","Membranous Nephropathy - Secondary | Secondary Membranous Glomerulopathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1836876","Pierson Syndrome","C128145","An autosomal recessive disorder caused by mutation(s) in the LAMB2 gene, encoding laminin subunit beta-2. It is characterized by congenital nephrotic syndrome with diffuse mesangial sclerosis and distinct ocular abnormalities.","Pierson Syndrome | ",,,,,,,,,,,,,,,"37109670","Pierson syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035085","Renal Infarct","C128146","Ischemic necrosis of the kidney caused by interruption of the blood supply to the area.","Renal Infarct | Kidney Infarct",,,,,,,,,,,,,,,"194994","Renal infarction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508659","Acquired Solitary Kidney","C128147","A finding of one kidney after the loss of the second, whether due to injury, disease or surgery.","Acquired Solitary Kidney | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513656","WHODAS 2.0 36-item Version Interviewer-administered - Starting or Maintaining Conversation","C130732","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Starting and maintaining a conversation?","WHODAS 2.0 36-item Version Interviewer-administered - Starting or Maintaining Conversation | WD5-Starting/Maintaining Conversation | WD5D1_6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513655","WHODAS 2.0 36-item Version Interviewer-administered - Standing for Long Periods","C130733","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Standing for long periods such as 30 minutes?","WHODAS 2.0 36-item Version Interviewer-administered - Standing for Long Periods | WD5-Standing for Long Periods | WD5D2_1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513654","WHODAS 2.0 36-item Version Interviewer-administered - Standing Up From Sitting Down","C130734","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Standing up from sitting down?","WHODAS 2.0 36-item Version Interviewer-administered - Standing Up From Sitting Down | WD5-Standing Up From Sitting Down | WD5D2_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513645","WHODAS 2.0 36-item Version Interviewer-administered - Moving Around Inside Your Home","C130735","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Moving around inside your home?","WHODAS 2.0 36-item Version Interviewer-administered - Moving Around Inside Your Home | WD5-Moving Around Inside Your Home | WD5D2_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513634","WHODAS 2.0 36-item Version Interviewer-administered - Getting Out of Your Home","C130736","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Getting out of your home?","WHODAS 2.0 36-item Version Interviewer-administered - Getting Out of Your Home | WD5-Getting Out of Your Home | WD5SD2_4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513660","WHODAS 2.0 36-item Version Interviewer-administered - Walking a Long Distance","C130737","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Walking a long distance such as a kilometre [or equivalent]?","WHODAS 2.0 36-item Version Interviewer-administered - Walking a Long Distance | WD5-Walking a Long Distance | WD5SD2_5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513661","WHODAS 2.0 36-item Version Interviewer-administered - Washing Your Whole Body","C130738","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Washing your whole body?","WHODAS 2.0 36-item Version Interviewer-administered - Washing Your Whole Body | WD5-Washing Your Whole Body | WD5D3_1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513631","WHODAS 2.0 36-item Version Interviewer-administered - Getting Dressed","C130739","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Getting dressed?","WHODAS 2.0 36-item Version Interviewer-administered - Getting Dressed | WD5-Getting Dressed | WD5D3_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513626","WHODAS 2.0 36-item Version Interviewer-administered - Eating","C130740","World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Eating?","WHODAS 2.0 36-item Version Interviewer-administered - Eating | WD5-Eating | WD5D3_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513126","HAM-D6 - Clinician Version - Psychic Anxiety","C130332","Hamilton Depression Rating Scale 6 Clinician Version (HAM-D6 Clinician Version) Psychic anxiety.","HAM-D6 - Clinician Version - Psychic Anxiety | HAMD4-Psychic Anxiety | HAMD405",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513129","HAM-D6 - Clinician Version - Tiredness and Pains","C130333","Hamilton Depression Rating Scale 6 Clinician Version (HAM-D6 Clinician Version) Tiredness and pains.","HAM-D6 - Clinician Version - Tiredness and Pains | HAMD4-Tiredness and Pains | HAMD406",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513130","HAM-D6 - Clinician Version - Total Score","C130334","Hamilton Depression Rating Scale 6 Clinician Version (HAM-D6 Clinician Version) Total score.","HAM-D6 - Clinician Version - Total Score | HAMD4-Total Score | HAMD407",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513227","Q-LES-Q - Felt Good Physically","C130614","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) With regard to your physical health, during the past week how much of the time have you: felt good physically?","Q-LES-Q - Felt Good Physically | QLES1-Felt Good Physically | QLES111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513223","Q-LES-Q - Felt Full of Pep and Vitality","C130615","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) With regard to your physical health, during the past week how much of the time have you: felt full of pep and vitality?","Q-LES-Q - Felt Full of Pep and Vitality | QLES1-Felt Full of Pep and Vitality | QLES112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513238","Q-LES-Q - Free of Visual Problems","C130616","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) With regard to your physical health, during the past week how much of the time have you: been free of visual problems?","Q-LES-Q - Free of Visual Problems | QLES1-Free of Visual Problems | QLES113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513682","WHODAS 2.0 36-item Version Proxy-administered - How Many Days Difficulties Present","C130807","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Overall, in the past 30 days, how many days were these difficulties present?","WHODAS 2.0 36-item Version Proxy-administered - How Many Days Difficulties Present | WD6-How Many Days Difficulties Present | WD6H1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513667","WHODAS 2.0 36-item Version Proxy-administered - Days Unable to Carry Out Activities","C130808","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, for how many days was your relative totally unable to carry out his or her usual activities or work because of any health condition?","WHODAS 2.0 36-item Version Proxy-administered - Days Unable to Carry Out Activities | WD6-Days Unable to Carry Out Activities | WD6H2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513683","WHODAS 2.0 36-item Version Proxy-administered - How Many Days Reduce Activities","C130809","World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, not counting the days that your relative was totally unable, for how many days did your relative cut back or reduce his or her usual activities or work because of any health condition?","WHODAS 2.0 36-item Version Proxy-administered - How Many Days Reduce Activities | WD6-How Many Days Reduce Activities | WD6H3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001728","Afferent Pathway","C13080","A sensory pathway that conducts impulses toward the central nervous system.","Afferent Pathway | Afferent Pathways",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513707","WHODAS 2.0 36-item Version Self-administered - Concentrating for Ten Minutes","C130810","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Concentrating on doing something for ten minutes?","WHODAS 2.0 36-item Version Self-administered - Concentrating for Ten Minutes | WD7-Concentrating for Ten Minutes | WD7D1_1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513734","WHODAS 2.0 36-item Version Self-administered - Remembering to Do Important Things","C130811","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Remembering to do important things?","WHODAS 2.0 36-item Version Self-administered - Remembering to Do Important Things | WD7-Remembering to Do Important Things | WD7D1_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513715","WHODAS 2.0 36-item Version Self-administered - Finding Solutions to Problems","C130812","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Analysing and finding solutions to problems in day-to-day life?","WHODAS 2.0 36-item Version Self-administered - Finding Solutions to Problems | WD7-Finding Solutions to Problems | WD7D1_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513725","WHODAS 2.0 36-item Version Self-administered - Learning a New Task","C130813","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Learning a new task, for example, learning how to get to a new place?","WHODAS 2.0 36-item Version Self-administered - Learning a New Task | WD7-Learning a New Task | WD7D1_4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509736","Cryoballoon Ablation Therapy","C127818","An image-guided, minimally invasive surgical technique that uses a balloon-tipped catheter to deliver cryogenic energy to targeted tissue, resulting in cell death secondary to cryogenic injury.","Cryoballoon Ablation Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509713","Colon Adenoma with Severe Dysplasia","C128171","An adenoma that arises from the colon.  It is characterized by the presence of severe epithelial dysplasia.","Colon Adenoma with Severe Dysplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508924","PDGFRB Protein Variant","C128173","A variation in the amino acid sequence of the platelet-derived growth factor receptor beta protein.","PDGFRB Protein Variant | Beta Platelet-Derived Growth Factor Receptor Protein Variant | Beta-Type Platelet-Derived Growth Factor Receptor Protein Variant | CD140 Antigen-Like Family Member B Protein Variant | CD140b Protein Variant | PDGF-R-Beta Protein Variant | PDGFR-1 Protein Variant | PDGFR-Beta Protein Variant | Platelet-Derived Growth Factor Receptor 1 Protein Variant | Platelet-Derived Growth Factor Receptor Beta Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509283","MYD88 Protein Variant","C128177","A variation in the amino acid sequence of the myeloid differentiation primary response protein MyD88.","MYD88 Protein Variant | Myeloid Differentiation Primary Response Protein MyD88 Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509191","GAIA Level 3 Major External Structural Defect","C127959","GAIA Level 3 Major External Structural Defect is defined by four criteria: first, the defects are of a prenatal origin; second, at least one of the following requirements must be met: a) Alterations in the external anatomy that are present and visible at the time of live birth, and that persist beyond the immediate peripartum period unless surgically repaired OR b) Alterations in the external anatomy that are present and visible in a stillbirth or in the products of conception of a spontaneous or therapeutic abortion; third, the defect(s) affect (or have the propensity to affect) the health, survival, or physical or cognitive functioning of the individual; fourth, at least one of the following requirements must be met: a) Documented confirmation of a diagnosis made by a trained maternal or child health care provider with at least minimal experience diagnosing congenital anomalies; OR b) For live births, the diagnosis is confirmed using individual (ICD-9/ICD-10) codes or as part of an ICD-9/ICD-10 code based algorithm, for which the outcome (individual code or algorithm) has been validated.","GAIA Level 3 Major External Structural Defect | Global Alignment of Immunization safety Assessment in pregnancy Level 3 Major External Structural Defect | Level 3 Major External Structural Defect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039044","Sympathetic Nervous System","C12795","The part of the autonomic nervous system comprising paired, paraspinal sympathetic trunks together with their branches, plexi, and subsidiary ganglia; it functions to mobilize the body for activity and opposes the physiological effects of the parasympathetic nervous system.","Sympathetic Nervous System | SNS | sympathetic nervous system",,,,,,,,,,,,,,,"4285288","Sympathetic nervous system structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509205","GAIA Level 4 Major External Structural Defect","C127960","GAIA Level 4 Major External Structural Defect is defined by four criteria: first, the defects are of a prenatal origin; second, at least one of the following requirements must be met: a) Alterations in the external anatomy that are present and visible at the time of live birth, and that persist beyond the immediate peripartum period unless surgically repaired OR b) Alterations in the external anatomy that are present and visible in a stillbirth or in the products of conception of a spontaneous or therapeutic abortion; third, the defect(s) affect (or have the propensity to affect) the health, survival, or physical or cognitive functioning of the individual; fourth, at least one of the following requirements must be met: a) Confirmation by medical record review; OR b) Confirmed in claims data (ICD-9/ICD-10 diagnoses).","GAIA Level 4 Major External Structural Defect | Global Alignment of Immunization safety Assessment in pregnancy Level 4 Major External Structural Defect | Level 4 Major External Structural Defect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509154","GAIA Level 1 Major Internal Structural Defect","C127961","GAIA Level 1 Major Internal Structural Defect is defined by three criteria: first, the defects are prenatal in origin; second, the defect(s) affect (or have the propensity to affect) the health, survival, or physical or cognitive functioning of the individual; third, one of the following requirements must be met: a) For a live birth, alterations in the internal anatomy must be present at the time of live birth, must persist beyond the immediate peripartum period unless surgically repaired, and require confirmation of the diagnosis by definitive imaging study or intraoperative diagnosis; OR b) For a stillbirth, or for a spontaneous or therapeutic abortion, alterations in the internal anatomy must be detected during an autopsy, which are subsequently confirmed by documentation by a pathologist or other relevant subspecialist.","GAIA Level 1 Major Internal Structural Defect | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Major Internal Structural Defect | Level 1 Major Internal Structural Defect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509173","GAIA Level 2 Major Internal Structural Defect","C127962","GAIA Level 2 Major Internal Structural Defect is defined by three criteria: first, the defects are prenatal in origin; second, the defect(s) affect (or have the propensity to affect) the health, survival, or physical or cognitive functioning of the individual; third, one of the following requirements must be met: a) For a live birth, alterations in the internal anatomy must be present at the time of live birth, must persist beyond the immediate peripartum period unless surgically repaired, and require documented confirmation of a diagnosis made by a clinician who is experienced in diagnosing congenital anomalies, and who has the highest level of morphology training for the specific setting without using definitive imaging or intraoperative evaluation; OR b) For a stillbirth, or for a spontaneous or therapeutic abortion, an internal structural defect is visible prenatally either by ultrasound or by other imaging modality.","GAIA Level 2 Major Internal Structural Defect | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Major Internal Structural Defect | Level 2 Major Internal Structural Defect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509366","Vulvar Neuroendocrine Carcinoma","C128243","A neuroendocrine carcinoma that arises from the vulva. This category includes small cell and large cell neuroendocrine carcinoma. Most small cell neuroendocrine carcinomas of the vulva are Merkel cell carcinomas.","Vulvar Neuroendocrine Carcinoma | Vulvar High Grade Neuroendocrine Carcinoma | Vulvar High Grade Neuroendocrine Neoplasm | Vulvar Neuroendocrine Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509576","Vulvar Small Cell Neuroendocrine Carcinoma","C128244","A rare small cell neuroendocrine carcinoma that arises from the vulva.","Vulvar Small Cell Neuroendocrine Carcinoma | Vulvar Small Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509572","Vulvar Large Cell Neuroendocrine Carcinoma","C128245","A high-grade carcinoma with neuroendocrine differentiation that arises from the vulva and is characterized by the presence of malignant large cells.","Vulvar Large Cell Neuroendocrine Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509575","Vulvar Merkel Cell Carcinoma","C128247","A Merkel cell carcinoma that arises from the vulva. It usually presents as a cutaneous nodular lesion. Most small cell neuroendocrine carcinomas of the vulva are Merkel cell carcinomas.","Vulvar Merkel Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508926","PEB Regimen","C128248","A regimen consisting of bleomycin, etoposide and cisplatin used for the treatment of pediatric germ cell tumors (GCT). In the PEB regimen, the pediatric patients receive bleomycin once per cycle and do not receive weekly bleomycin during the weeks between cycles (every 21 days); in the adult BEP regimen, patients receive weekly bleomycin.","PEB Regimen | Cisplatin-Etoposide-Bleomycin Regimen | Cisplatin/Etoposide/Bleomycin | PEB | Pediatric BEP Regimen | Pediatric PEB | Pediatric PEB Regimen | Platinol-Etoposide-Bleomycin Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507930","Autologous CD34-positive Hematopoietic Progenitor Cells","C128249","A population of autologous CD34-positive hematopoietic progenitor cells (HPCs) that can be used for autotransplantation. CD34+ HPCs are isolated from human blood stem cells upon apheresis. Upon transplantation with the CD34+ HPCs, these cells can differentiate into a variety of cell types including fibroblasts, osteoblasts, chondrocytes, myocytes, adipocytes, and endothelial cells.","Autologous CD34-positive Hematopoietic Progenitor Cells | Autologous CD34-positive HPCs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509275","Microparticle MDP/Bacterial DNA-containing MIS416","C127934","A microparticle combining two immune-modifying components derived from the bacterium Propionibacterium acnes, a bacterial cell wall component that is rich in muramyl dipeptide (MDP) and single-stranded bacteria-derived DNA fragments, with potential immunomodulating and immunoadjuvant activities. Upon administration of MIS416, this agent localizes in and is taken up mainly by the liver, thereby forming a liver depot. MIS416 is then taken up by immune cells, such as monocytes and dendritic cells (DCs), where MDP and the bacterial DNA target and bind to the cytosolic innate pattern recognition receptors (PRRs) nucleotide-binding oligomerization domain-containing protein 2 (NOD2), and toll-like receptor 9 (TLR9), respectively. The simultaneous binding and activation of both NOD2 and TLR9, leads to activation of both NOD2 and TLR9 signaling. This stimulates the innate immune system, induces secretion of cytokines, particularly interferon (IFN), and modulates the activation of various immune cells.  In the presence of tumor-associated antigens (TAAs), through simultaneous administration of a TAA-based vaccine, MIS416 modulates T-cell subsets and enhances the cytotoxic T lymphocyte (CTL)-mediated immune response against TAAs, resulting in an increased anti-tumor immune response. The combination of NOD2 and TLR9 agonists in MIS416 appears to activate different signaling pathways as compared to the administration of NOD2 and TLR9 agonists alone.","Microparticle MDP/Bacterial DNA-containing MIS416 | MIS 416 | MIS-416 | MIS416 | Microparticle MIS416",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509703","Cervical Mesonephric Remnants and Hyperplasia","C127935","The presence of embryonic remnants of mesonephric ducts in the cervix and their benign hyperplastic proliferations.","Cervical Mesonephric Remnants and Hyperplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509699","Cervical Endocervicosis","C127936","A benign lesion characterized by the presence of endocervical-type glands in the outer half of the cervical wall.","Cervical Endocervicosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507928","Gallium Ga 68-NOTA-BBN(7-14)-RGD","C128035","A radioconjugate containing the bombesin (BBN) fragment BBN(7-14) comprised of the amino acid sequence Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2, which targets the gastrin-releasing peptide receptor (GRPR), and linked, via a glutamate linker, to the cyclic arginine-glycine-aspartic acid (RGD) sequence-based peptide cyclo[Arg-Gly-Asp-D-Tyr-Lys] (c(RGDyK)), which targets integrin alphaVbeta3 (aVb3), and labeled with the radionuclide gallium (Ga) 68 through the macrocyclic chelating agent, 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA), with potential use in diagnostic imaging using positron emission tomography/computed tomography (PET/CT). Upon administration of gallium Ga 68-NOTA-BBN(7-14)-RGD, the BBN peptide moiety of the RGD-BBN heterodimer specifically targets and binds to GRPR while the RGD moiety specifically binds to the aVb3. Upon PET/CT, GRPR- and/or aVb3-expressing tumor cells can be visualized and expression levels can be quantified. GRPR, also called bombesin receptor 2 (BB2), is a seven-transmembrane G protein-coupled receptor belonging to the bombesin receptor family. aVb3, an integrin receptor, plays a key role in angiogenesis, tumor proliferation and survival. Both are overexpressed in certain types of cancers.","Gallium Ga 68-NOTA-BBN(7-14)-RGD | 68Ga-NOTA-BBN(7-14)-RGD | 68Ga-NOTA-BBN-RGD | Gallium Ga 68-NOTA-BBN-RGD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509682","Anti-CTLA-4 Monoclonal Antibody","C128036","Any monoclonal antibody against the antigen cytotoxic T-lymphocyte associated protein 4 (CTLA-4; CTLA4; CD152).","Anti-CTLA-4 Monoclonal Antibody | Anti-CTLA4 Monoclonal Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3859650","Naloxegol Oxalate","C128038","No value exists.","Naloxegol Oxalate | 4,5Alpha-epoxy-6alpha-((3,6,7,12,15,18,21-Heptaoxadocosyl)oxy)-17-(prop-2-enyl)morphinan-3,14-diol Hydrogen Ethanedioate | Morphinan-3,14-diol, 4,5-Epoxy-6-(3,6,9,12,15,18,21-heptaoxadocos-1-yloxy)-17-(2-propen-1-yl)-, (5alpha,6alpha)-, Ethanedioate (1:1) | NALOXEGOL OXALATE | NKTR-118 Oxalate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512846","Defactinib Hydrochloride","C128039","The hydrochloride salt form of defactinib, an orally bioavailable, small-molecule focal adhesion kinase (FAK) inhibitor with potential antiangiogenic and antineoplastic activities. Defactinib inhibits FAK, which may prevent the integrin-mediated activation of several downstream signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, thus inhibiting tumor cell migration, proliferation, survival, and tumor angiogenesis. The tyrosine kinase FAK, a signal transducer for integrins, is normally activated by binding to integrins in the extracellular matrix (ECM) but may be upregulated and constitutively activated in various tumor cell types.","Defactinib Hydrochloride | Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, Hydrochloride (1:1) | DEFACTINIB HYDROCHLORIDE | PF-04554878 | VS-6063",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0522428","Fusarium incarnatum","C127712","A fungal plant pathogen in the phylum Ascomycota.","Fusarium incarnatum | FUSARIUM INCARNATUM | Fusarium pallidoroseum | Fusarium semitectum",,,,,,,,,,,,,,,"37016438","Fusarium incarnatum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319893","Geotrichum klebahnii","C127713","A species of filamentous yeast-like fungi in the family Endomycetaceae normally found in plant tissues, silage and soil. It is also a component of the natural flora of the human mouth, skin and gastrointestinal tract.","Geotrichum klebahnii | GEOTRICHUM KLEBAHNII | Geotrichum penicillatum | Trichosporon penicillatum",,,,,,,,,,,,,,,"40487914","Geotrichum klebahnii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319901","Guehomyces pullulans","C127714","A species of yeast-like fungi in the phylum Basidiomycota having cell walls containing xylose and lacking septal pores. It is characterized by an optimum growth temperature of 17 C, assimilation of nitrate, and an absence of growth with lactate.","Guehomyces pullulans | Basidiotrichosporon pullulans | GUEHOMYCES PULLULANS | Monilia pullulans | Oidium pullulans | Oospora pullulans | Tausonia pullulans | Trichosporon pullulans",,,,,,,,,,,,,,,"4093268","Tausonia pullulans",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0317573","Haemophilus paraphrohaemolyticus","C127715","A species of Gram-negative, pleomorphic, coccobacilli bacteria in the phylum Proteobacteria that is positive for nitrate reduction and for growth with glucose, fructose, maltose, and sucrose.","Haemophilus paraphrohaemolyticus | HAEMOPHILUS PARAPHROHAEMOLYTICUS",,,,,,,,,,,,,,,"4222025","Haemophilus paraphrohaemolyticus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319889","Hannaella luteola","C127716","A species of fungi in the phylum Basidiomycota. This species is positive for assimilation of arabinose, sucrose, maltose, galactose, and others. It is generally non-fermenting.","Hannaella luteola | Chromotorula luteola | Cryptococcus luteolus | HANNAELLA LUTEOLA | Hannaella luteolus | Rhodotorula luteola | Torula luteola | Torulopsis luteola",,,,,,,,,,,,,,,"37018603","Hannaella luteola",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1019436","Hanseniaspora guilliermondii","C127717","A species of apiculate yeast in the phylum Ascomycota that are found on dates, grapes, tomatoes, figs, and in soil. This species is only able to ferment glucose.","Hanseniaspora guilliermondii | Acaromyces laviae | HANSENIASPORA GUILLIERMONDII | Hanseniaspora apuliensis | Hanseniaspora melligeri | Kloeckera apiculata | Kloeckera apis | Willia guilliermondii",,,,,,,,,,,,,,,"45770826","Hanseniaspora guilliermondii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1017564","Hanseniaspora valbyensis","C127719","A species of apiculate yeast in the phylum Ascomycota with hat or bell-shaped spores.","Hanseniaspora valbyensis | HANSENIASPORA VALBYENSIS",,,,,,,,,,,,,,,"45757554","Hanseniaspora valbyensis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL507940","Broccoli Sprout/Broccoli Seed Extract Supplement","C128293","A tablet-based nutritional supplement composed of a mixture of sprout and seed extracts of the cruciferous vegetable broccoli, with potential chemopreventive and antioxidant activities. Broccoli sprout/broccoli seed extract contains a high amount of both the glycosinolate glucoraphanin and the enzyme myrosinase, which catalyzes the production of glucoraphanin to sulforaphane. Upon administration of the broccoli sprout/broccoli seed extract, sulforaphane activates the transcription factor NF-E2-related factor 2 (Nrf2), a member of the basic leucine zipper family, which binds to and activates antioxidant-response elements (AREs). Subsequently, activated AREs promote the transcription of antioxidant and detoxifying enzymes, particularly glutathione-S-transferase and NAD(P)H dehydrogenase [quinone] 1 (NAD(P)H:quinone oxidoreductase; NQO1), resulting in the detoxification of highly reactive carcinogens. This accelerates the elimination of carcinogens, may protect against cellular damage, and prevents cancer formation. AREs are cis-acting regulatory enhancer elements found in the 5' flanking region of many phase II detoxification enzymes.","Broccoli Sprout/Broccoli Seed Extract Supplement | Avmacol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508831","FIGO Stage IC1","C128099","A FIGO stage term that applies to ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It refers to cancer with surgical spill.","FIGO Stage IC1 | Stage IC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508833","FIGO Stage IC2","C128100","A FIGO stage term that applies to ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It refers to cancer with capsule rupture before surgery or tumor on ovarian surface.","FIGO Stage IC2 | Stage IC2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508835","FIGO Stage IC3","C128101","A FIGO stage term that applies to ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It refers to cancer with malignant cells in the ascites or peritoneal washings.","FIGO Stage IC3 | Stage IC3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508844","FIGO Stage IIIA1","C128102","A FIGO stage term that applies to ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It refers to cancer with positive retroperitoneal lymph nodes only.","FIGO Stage IIIA1 | Stage IIIA1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508841","FIGO Stage IIIA1(i)","C128103","A FIGO stage term that applies to ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It refers to cancer with positive retroperitoneal lymph nodes only. Metastasis equal or less than 10 mm.","FIGO Stage IIIA1i | FIGO Stage IIIA1(i) | FIGO Stage IIIA1(i) | Stage IIIA1(i)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508843","FIGO Stage IIIA1(ii)","C128104","A FIGO stage term that applies to ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It refers to cancer with positive retroperitoneal lymph nodes only. Metastasis greater than 10 mm.","FIGO Stage IIIA1ii | FIGO Stage IIIA1(ii) | FIGO Stage IIIA1(ii) | Stage IIIA1(ii)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508915","Ovarian Cancer by AJCC v6 and v7 Stage","C128106","A category of staging terms for ovarian cancer according to the American Joint Committee on cancer (AJCC) 6th and 7th editions. International Federation of Gynecology and Obstetrics (FIGO) ovarian cancer staging terms prior to 2014 are included in this category if synonymous with the AJCC terms.","Ovarian Cancer by AJCC v6 and v7 Stage | Ovarian Carcinoma by AJCC v6 and v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507938","intermediate-affinity interleukin-2 receptor agonist ALKS 4230","C128107","A selective effector cell activator protein and agonist of the intermediate-affinity interleukin-2 (IL-2) receptor with potential immunostimulating and antineoplastic activity. Upon administration, nemvaleukin alfa binds to and signals through the intermediate-affinity IL-2 receptor complex; this may selectively stimulate and activate natural killer (NK) cells and memory CD8 T-cells, leading to tumor cell elimination, while circumventing the activation of immunosuppressive cells that may prevent the anti-tumor response. IL-2 is a cytokine signaling molecule that plays a critical role in the immune response.","Nemvaleukin Alfa | ALKS 4230 | Intermediate-affinity IL-2R Agonist ALKS 4230 | Intermediate-affinity Interleukin-2 Receptor Agonist ALKS 4230 | NEMVALEUKIN ALFA | RDB 1450 | RDB-1450",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509461","Idiopathic Membranous Glomerulopathy","C128108","Chronic degenerative changes in the kidney characterized by thickened and inflamed glomeruli and proteinurea, the cause of which is unknown.","Idiopathic Membranous Glomerulopathy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507932","Pan-AKT Inhibitor ARQ751","C128250","An orally bioavailable pan inhibitor of the serine/threonine protein kinase AKT (protein kinase B) enzyme family with potential antineoplastic activity. Upon oral administration, AKT inhibitor ARQ 751 selectively binds to and inhibits the activity of the AKT isoforms 1, 2 and 3, which may result in the inhibition of the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway. This may lead to a reduction in tumor cell proliferation and the induction of tumor cell apoptosis. The AKT signaling pathway is often deregulated in cancer and is associated with tumor cell proliferation, survival and migration.","Pan-AKT Inhibitor ARQ751 | AKT Inhibitor ARQ751 | ARQ 751 | ARQ751",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509040","CHD4 wt Allele","C128252","Human CHD4 wild-type allele is located in the vicinity of 12p13 and is approximately 37 kb in length. This allele, which encodes chromodomain-helicase-DNA-binding protein 4, plays a role in DNA unwinding.","CHD4 wt Allele | CHD-4 | Chromodomain Helicase DNA Binding Protein 4 wt Allele | Mi-2b | Mi2-BETA | SIHIWES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1431547","Chromodomain-Helicase-DNA-Binding Protein 4, Human","C128253","Chromodomain-helicase-DNA-binding protein 4 (1912 aa, ~218 kDa) is encoded by the human CHD4 gene. This protein is involved in chromatin remodeling.","Chromodomain-Helicase-DNA-Binding Protein 4 | ATP-Dependent Helicase CHD4 | CHD-4 | CHD4 | Chromodomain Helicase DNA-Binding Protein 4 | Dermatomyositis Autoantigen Mi-2 Beta | EC 3.6.4.12 | MI-2 BETA ANTIGEN | MI-2 Beta | MI-2b | Mi-2 Autoantigen 218 kDa Protein | Mi-2 Beta | Mi2-Beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2605043","Protocadherin Fat 4, Human","C128256","Protocadherin Fat 4 (4981 aa, ~543 kDa) is encoded by the human FAT4 gene. This protein plays a role in cell polarity.","Protocadherin Fat 4 | Cadherin Family Member 14 | Cadherin-Related Family Member 11 | FAT Tumor Suppressor Homolog 4 | Fat-Like Cadherin Protein FAT-J | hFat4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1453940","Serine Palmitoyltransferase 1, Human","C127890","Serine palmitoyltransferase 1 (473 aa, ~53 kDa) is encoded by the human SPTLC1 gene. This protein plays a role in the biosynthesis of sphingolipids.","Serine Palmitoyltransferase 1 | EC 2.3.1.50 | LCB 1 | Long Chain Base Biosynthesis Protein 1 | SPT 1 | SPT1 | Serine C-Palmitoyltransferase | Serine-Palmitoyl-CoA Transferase 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509297","SUMF1 wt Allele","C127892","Human SUMF1 wild-type allele is located in the vicinity of 3p26.1 and is approximately 766 kb in length. This allele, which encodes sulfatase-modifying factor 1 protein, plays a role in the positive regulation of sulfatase activity. Mutation of the gene is associated with multiple sulfatase deficiency.","SUMF1 wt Allele | AAPA3037 | FGE | PSEC0152 | Sulfatase Modifying Factor 1 wt Allele | UNQ3037 | UNQ3037/PRO9852",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1433596","Sulfatase-Modifying Factor 1, Human","C127893","Sulfatase-modifying factor 1 (374 aa, ~41 kDa) is encoded by the human SUMF1 gene. This protein is involved in sulfatase oxidation.","Sulfatase-Modifying Factor 1 | C-Alpha-Formylglycine-Generating Enzyme 1 | EC 1.8.99.- | FGly-Generating Enzyme | Sulfatase Modifying Factor 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508992","TH wt Allele","C127895","Human TH wild-type allele is located in the vicinity of 11p15.5 and is approximately 8 kb in length. This allele, which encodes tyrosine 3-monooxygenase protein, is involved in tyrosine metabolism. Mutation of the gene is associated with autosomal recessive Segawa syndrome.","TH wt Allele | DYT14 | DYT5b | Dystonia 14 Gene | TYH | Tyrosine Hydroxylase wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040573","Trabecular Meshwork","C12803","Mesh-like tissue responsible for draining the aqueous humor from the eye that is located at the iridocorneal angle of the eye, between the anterior chamber and the venous sinus of the sclera.","Trabecular Meshwork | ",,,,,,,,,,,,,,,"4280962","Trabecular meshwork structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509004","Brostacillin Hydrochloride","C128040","The hydrochloride salt form of brostacillin, a synthetic, alpha-bromoacrylic, second-generation minor groove binder (MGB), related to distamycin A, with potential antineoplastic activity. Brostallicin binds to DNA minor groove DNA, after having formed a highly reactive glutathione (GSH)-brostallicin complex in the presence of the enzyme glutathione S-transferase (GST), which is overexpressed in cancer cells; DNA replication and cell division are inhibited, resulting in tumor cell death. Compared to typical MGBs, this agent appears to bind covalently to DNA in a different manner and its activity does not depend on a functional DNA mismatch repair (MMR) mechanism. Accordingly, brostallicin may be effective against MMR-defective tumors that are refractory to various anticancer agents.","Brostacillin Hydrochloride | 4-(2-Bromoacrylamido)-N'''-(2-guanidinoethyl)-1,1',1',1'''-tetramethyl-N,4':N',4':N',4'''-quater(pyrrole-2-carboxamide) Hydrochloride | BROSTALLICIN HYDROCHLORIDE | PNU-166196 Hydrochloride | brostallicin hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509706","Cervical Neuroendocrine Neoplasm","C128041","A neuroendocrine neoplasm that arises from the cervix. This category includes neuroendocrine tumor grade 1, neuroendocrine tumor grade 2, and neuroendocrine carcinoma (small cell and large cell neuroendocrine carcinoma).","Cervical Neuroendocrine Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509643","Moderate to Late Preterm Infant","C128042","An age group comprised of infants born alive with a gestational age between 32 to less than 37 weeks.","Moderate to Late Preterm Infant | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509034","Cervical Carcinoid Tumor","C128043","A well-differentiated, low-grade neuroendocrine neoplasm that arises from the cervix.","Cervical Neuroendocrine Tumor G1 | Cervical Carcinoid Tumor | Cervical Low Grade Neuroendocrine Tumor, Grade 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1222823","Dickeya dadantii","C127705","A species of gram-negative, motile, nonsporulating bacillus bacteria in the family Enterobacteriaceae. D. dadantii causes necrosis, blight and soft rot on a wide range of ornamental and horticultural host plants.","Dickeya dadantii | DICKEYA DADANTII | Erwinia chrysanthemi",,,,,,,,,,,,,,,"37016424","Dickeya dadantii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508741","Enteric Bacteria","C127706","Any of the bacteria that normally or pathogenically reside in the intestinal tracts of animals.","Enteric Bacteria | ENTERIC BACTERIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014530","Epidermophyton floccosum","C127707","A species of dermatophylic and anthropophilic fungi in the phylum Ascomycota. E. floccosum is the causative agent of various cutaneous mycoses, but is restricted to the cornified layers of the epidermis.","Epidermophyton floccosum | Acrothecium floccosum | EPIDERMOPHYTON FLOCCOSUM | Epidermophyton floccosum var. nigricans",,,,,,,,,,,,,,,"4096942","Epidermophyton floccosum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319920","Eurotium herbariorum","C127708","A species of filamentous fungi in the phylum Ascomycota with conidial heads and characterized by smooth ascospores. E. herbariorum is the source for aspergiolide A, an anthraquinone derivative.","Eurotium herbariorum | Aspergillus glaucus | Aspergillus herbariorum | EUROTIUM HERBARIORUM",,,,,,,,,,,,,,,"4023969","Aspergillus glaucus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031521","Exophiala dermatitidis","C127709","A species of anamorphic, thermophilic black yeast in the phylum Ascomycota that is commonly isolated from saunas, steam baths, and dish washers. E. dermatitidis is considered a human opportunistic pathogen.","Exophiala dermatitidis | EXOPHIALA DERMATITIDIS | Wangiella dermatitidis",,,,,,,,,,,,,,,"4070309","Exophiala dermatitidis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2718299","Exophiala jeanselmei","C127710","A species of saprobic fungi in the phylum Ascomycota. E. jeanselmei is the causative agent of maduromycosis, an asymptomatic disease which presents with black or brown macular lesions.","Exophiala jeanselmei | EXOPHIALA JEANSELMEI | Phialophora jeanselmei | Pullularia jeanselmei | Torula jeanselmei",,,,,,,,,,,,,,,"42536939","Sporotrichum gougerotii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320169","Fusarium chlamydosporum","C127711","A species of filamentous fungi in the phylum Ascomycota. Infection with F. chlamydosporum is associated with superficial mycoses and keratitis in immunocompetent individuals and with invasive and disseminated infection in immunocompromised individuals.","Fusarium chlamydosporum | FUSARIUM CHLAMYDOSPORUM",,,,,,,,,,,,,,,"4194685","Fusarium chlamydosporum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509570","Vulvar Germ Cell Tumor","C128294","A rare germ cell tumor that arises from the vulva.","Vulvar Germ Cell Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509364","Vulvar Yolk Sac Tumor","C128295","A rare yolk sac tumor that arises from the vulva.","Vulvar Yolk Sac Tumor | Vulvar Endodermal Sinus Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508996","TP63 Gene Product","C128297","A protein encoded by the TP63 gene.","TP63 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0149561","Anterior Cerebral Artery","C12829","One of the two arteries arising from the internal carotid artery and being part of the Circle of Willis. Both left and right anterior cerebral arteries are connected by the anterior communicating artery.","Anterior Cerebral Artery | ACA | ANTERIOR CEREBRAL ARTERY | Anterior Cerebral Arteries",,,,,,,,,,,,,,,"4244586","Structure of anterior cerebral artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526014","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hands Are Weak","C138522","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: My child's hands are weak.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hands Are Weak | PQL15-Hands Are Weak | PQL1508",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509786","Tuboendometrioid Metaplasia","C127937","Replacement of the endocervical-type epithelium of the cervix by benign tubal or endometrioid epithelium.","Tuboendometrioid Metaplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508735","Ectopic Prostate Tissue in the Cervix","C127938","Replacement of the endocervical epithelium with benign-appearing prostatic glands.","Ectopic Prostate Tissue in the Cervix | Ectopic Prostatic Tissue in the Cervix",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509285","NK Cell-enriched Donor Lymphocytes","C127939","A preparation of donor-derived lymphocytes that are enriched for donor-derived natural killer (NK) cells, with direct tumor cytotoxic activity. Following allogeneic stem cell transplantation and subsequent infusion of the NK cell-enriched donor lymphocytes, these cells recognize and bind to tumor cells, upon which they secrete and release perforins, granzymes, and cytokines, which results in cancer cell lysis. Infusion of donor lymphocytes is limited by the risk of graft-versus-host disease (GVHD) and NK cells normally constitute only a small portion of circulating lymphocytes. Therefore, NK cell-enrichment may result in higher amounts of NK cells per infusion and improved anti-tumor immunity without increasing the risk of GVHD.","NK Cell-enriched Donor Lymphocytes | NK Cell-enriched Allogeneic Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509215","GAIA Premature Preterm Rupture of Membranes Levels of Diagnostic Certainty","C127940","A classification of maternal and fetal outcomes relating to the assessment of premature preterm rupture of membranes, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.","GAIA Premature Preterm Rupture of Membranes Levels of Diagnostic Certainty | Global Alignment of Immunization safety Assessment in pregnancy Premature Preterm Rupture of Membranes Levels of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509452","Horizontal Transmission","C127773","The transmission of a disease from one individual to another.","Horizontal Transmission | HORIZONTAL TRANSMISSION | Horizontal Disease Transmission",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509323","Retained Specimens Contain DNA","C127777","An indication as to whether retained biospecimens contain DNA.","Retained Biospecimen Contains DNA Indicator | BRDNAIND | Biospecimen Retention Contains DNA Ind | Retained Specimens Contain DNA | SAMPLES WITH DNA RETAINED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509324","Retained Specimens Do Not Contain DNA","C127778","An indication that the retained biospecimens do not contain DNA.","Retained Specimens Do Not Contain DNA | SAMPLES WITHOUT DNA RETAINED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509028","Observational Case-Crossover Study","C127779","A study in which the subject with the condition under study (the case) at the timepoint of disease onset is compared against an earlier, pre-disease timepoint in that subject's life (the control).","Observational Case-Crossover Study | CASE CROSSOVER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508734","Ecologic or Community Based Study","C127780","A study in which participants within a certain population or community are observed to determine whether there might be a correlation between a disease and an exposure or suspected cause.","Ecologic or Community Based Study | ECOLOGIC OR COMMUNITY | Ecological Study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509286","Non-Probability Sampling Method","C127781","A non-random process used to select a study population in which the participants have been selected based on convenience or with a particular purpose in mind.","Non-Probability Sampling Method | NON-PROBABILITY SAMPLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041491","Tyrosine 3-Monooxygenase","C127896","Tyrosine 3-monooxygenase (528 aa, ~59 kDa) is encoded by the human TH gene. This protein plays a role in the synthesis of dopamine from L-tyrosine.","Tyrosine 3-Monooxygenase | EC 1.14.16.2 | TH | Tyrosine 3-Hydroxylase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508993","TIA1 wt Allele","C127898","Human TIA1 wild-type allele is located in the vicinity of 2p13 and is approximately 39 kb in length. This allele, which encodes nucleolysin TIA-1 isoform p40, plays a role in both RNA binding and splicing. Mutation of the gene is associated with Welander distal myopathy.","TIA1 wt Allele | P40-TIA-1 (Containing P15-TIA-1) Gene | TIA-1 | TIA1 Cytotoxic Granule-Associated RNA Binding Protein wt Allele | TIA1 Cytotoxic Granule-Associated RNA-Binding Protein Gene | WDM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509262","Topoisomerase-1 Inhibitor LMP744","C127900","An indenoisoquinoline derivative and topoisomerase 1 (Top1) inhibitor, with potential antineoplastic activity. Upon administration, LMP744 binds to and stabilizes cleaved DNA-Top1 complexes, which prevents DNA re-ligation, induces stable, irreversible DNA strand breaks, prevents DNA repair, and leads to cell cycle arrest and apoptosis. As tumor cells proliferate at a much higher rate than normal cells, LMP744 specifically targets cancer cells. Top1, a DNA modifying enzyme essential for transcription, replication, and repair of double-strand DNA breaks, is overexpressed in tumor cells.","Topoisomerase-1 Inhibitor LMP744 | 5H-(1,3)Dioxolo(5,6)indeno(1,2-C)isoquinoline-5,12(6H)-dione, 6-(3-((2-Hydroxyethyl)amino)propyl)-2,3-dimethoxy- | Indenoisoquinoline LMP744 | LMP-744 | LMP744",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509185","GAIA Level 3 Antepartum Stillbirth","C128020","GAIA Level 3 Antepartum Stillbirth is defined by three criteria: first, delivery of an infant with no signs of life at birth, including the following: no spontaneous movements, no umbilical cord pulse, no heartbeat, no crying, no spontaneous respirations or chest movement, and full body cyanosis; second, one or more of the following three requirements must be met: a) Maternal report of the absence of fetal movement for 24 hours or more prior to delivery; b) Report of auscultation for fetal heart tones using electronic devices (e.g. handheld Doppler or fetal heart rate monitor) or non-electronic devices (e.g. stethoscope, fetoscope or Pinard horn) that documents the absence of a fetal heartbeat; c) Non-attended delivery followed by a post-delivery physical examination of the fetus that is performed by a health care professional who meets the standard of care in the immediate health care setting, and that is consistent with antepartum death; d) a verbal history provided by a trained health care provider, non-medical witness, or the mother of the fetus documenting that the fetus was born with no signs of life, was unresponsive to resuscitation efforts immediately after delivery, and had physical features consistent with antepartum death; third, gestational age within the pre-defined range for selected stillbirth definition as assessed by maternal and/or fetal parameters.","GAIA Level 3 Antepartum Stillbirth | Global Alignment of Immunization safety Assessment in pregnancy Level 3 Antepartum Stillbirth | Level 3 Antepartum Stillbirth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512196","NCCN-FACT FKSI-19 Version 2 - I Have Bone Pain","C129157","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I have bone pain.","NCCN-FACT FKSI-19 Version 2 - I Have Bone Pain | FAC042-I Have Bone Pain | FAC04207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512194","NCCN-FACT FKSI-19 Version 2 - I Have Been Coughing","C129158","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I have been coughing.","NCCN-FACT FKSI-19 Version 2 - I Have Been Coughing | FAC042-I Have Been Coughing | FAC04208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4273542","Right Posterior Middle Transition Zone of Prostate","C128610","The region of the prostate that is located on the anatomical right side of the posterior portion of the middle division of the transition zone.","Right Posterior Middle Transition Zone of Prostate | Mid R TZp",,,,,,,,,,,,,,,"37396924","Right posterior middle transition zone of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0227979","Right Seminal Vesicle","C128611","The seminal gland that is located to the anatomical right of the bladder.","Right Seminal Vesicle | R SV",,,,,,,,,,,,,,,"4253795","Structure of right seminal vesicle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0815353","Male External Urethral Sphincter","C128612","The muscle that surrounds the membranous urethra, functioning to control the voluntary flow of urine.","Male External Urethral Sphincter | US",,,,,,,,,,,,,,,"37397016","Structure of male external urethral sphincter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508649","PI-RADS Terminology","C128613","Terminology created to support the work of the Prostate Imaging Reporting and Data System.","PI-RADS Terminology | Prostate Imaging Reporting and Data System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509022","Manuka Honey Breast Pads","C128614","Breast pads containing Manuka honey, with potential healing, wound repair, antibacterial, anti-inflammatory and protective activities. Compared to other honey products, Manuka honey contains a high concentration of the 1,2-dicarbonyl compound methylglyoxal (MG), which may account for its antibacterial activity. Upon application of the Manuka honey breast pads to the nipples, the honey may decrease nipple sensitivity, such as radiation-induced nipple sensitivity. It may also decrease itching and pain, prevent inflammation and infection, and promote wound healing. The Manuka honey is produced by bees fed on the flowers of the New Zealand bush Leptospermum scoparium (Manuka, Manuka myrtle, New Zealand teatree).","Manuka Honey Breast Pads | Breast Pads with Manuka Honey | Manuka Honey-containing Breast Pads",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509289","pan-PIM Kinase Inhibitor NVP-LGB-321","C128615","An orally available, small molecule and selective ATP-competitive pan-inhibitor of proviral integration sites for Moloney murine leukemia virus (PIM) kinases, with potential antineoplastic activity. Upon oral administration, pan-PIM kinase inhibitor NVP-LGB-321 binds to and prevents the activation of the three PIM family kinases, PIM1, PIM2 and PIM3. This prevents the activation of PIM-mediated signaling pathways and inhibits proliferation in cells that overexpress PIMs. PIMs, constitutively active proto-oncogenic serine/threonine kinases upregulated in various types of cancers, play key roles in tumor cell proliferation and survival.","pan-PIM Kinase Inhibitor NVP-LGB-321 | LGB321 | NVP-LGB-321 | PIM Inhibitor NVP-LGB-321 | PIM Kinase Inhibitor NVP-LGB-321",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509217","GAIA Preterm Labor Levels of Diagnostic Certainty","C127941","A classification of maternal and fetal outcomes relating to the assessment of preterm labor, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.","GAIA Preterm Labor Levels of Diagnostic Certainty | Global Alignment of Immunization safety Assessment in pregnancy Preterm Labor Levels of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509142","GAIA Insufficient Cervix Levels of Diagnostic Certainty","C127942","A classification of maternal and fetal outcomes relating to the assessment of an insufficient cervix, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.","GAIA Insufficient Cervix Levels of Diagnostic Certainty | Global Alignment of Immunization safety Assessment in pregnancy Insufficient Cervix Levels of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509218","GAIA Provider Initiated Preterm Delivery Levels of Diagnostic Certainty","C127943","A classification of maternal and fetal outcomes relating to the assessment of provider initiated preterm delivery, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.","GAIA Provider Initiated Preterm Delivery Levels of Diagnostic Certainty | Global Alignment of Immunization safety Assessment in pregnancy Provider Initiated Preterm Delivery Levels of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509147","GAIA Level 1 Assessment of Premature Preterm Rupture of Membranes","C127944","GAIA Level 1 Assessment of Premature Preterm Rupture of Membranes is defined by five criteria: first, presentation between 24 0/7 and 36 6/7 weeks gestation with a clinical history of rupture of membranes, the fluid from which may be any color, including clear, blood-tinged, meconium-tinged (fetal stool), or purulent-tinged (yellowish, suggesting infection); second, the patient is determined to not be in preterm labor (having less than or equal to 4 contractions per hour documented clinically or on tocodynometer, with less than 2cm cervical dilation); third, visible leakage of fluid on vaginal speculum exam; fourth, one of the two following requirements must be met: a) Visible arborization (ferning) on microscopy of amniotic fluid; OR b) Ultrasound with oligohydramnios (amniotic fluid index (AFI) less than 5, or maximum vertical pocket (MVP) less than 2); fifth, documentation of the membrane rupture by one of the following diagnostic tests: a) Positive intra-amniotic dye-injection method; b) Positive result on amniotic fluid alpha-fetoprotein test kit; c) Amniotic fluid pH measurement (nitrazine paper test); d) Amniotic fluid placental alpha macroglobulin-1 protein assay (PAMG-1) test (AmniSure test); e) Amniotic fluid insulin-like growth factor binding protein (IGFBP-1) test (Actim PROM test).","GAIA Level 1 Assessment of Premature Preterm Rupture of Membranes | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Assessment of Premature Preterm Rupture of Membranes | Level 1 Assessment of Premature Preterm Rupture of Membranes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509033","Cervical Low Grade Neuroendocrine Tumor, Grade 2","C128044","A well-differentiated, intermediate-grade neuroendocrine neoplasm arising from the cervix.","Cervical Neuroendocrine Tumor G2 | Cervical Low Grade Neuroendocrine Tumor, Grade 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4013425","Cervical Neuroendocrine Carcinoma","C128045","An aggressive high-grade carcinoma with neuroendocrine differentiation that arises from the cervix. This category includes small cell and large cell neuroendocrine carcinoma.","Cervical Neuroendocrine Carcinoma | Cervical High Grade Neuroendocrine Neoplasm | Cervical Neuroendocrine Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509700","Cervical Leiomyoma","C128046","An uncommon benign smooth muscle neoplasm that arises from the cervix.","Cervical Leiomyoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509701","Cervical Leiomyosarcoma","C128047","A malignant neoplasm with smooth muscle differentiation arising from the cervix.","Cervical Leiomyosarcoma | ",,,,,,,,,,,,,,,"35622339","Leiomyosarcoma of cervix uteri",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509707","Cervical Rhabdomyosarcoma","C128048","A rare malignant neoplasm with skeletal muscle differentiation arising from the cervix.","Cervical Rhabdomyosarcoma | ",,,,,,,,,,,,,,,"35622091","Rhabdomyosarcoma of cervix uteri",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509698","Cervical Angiosarcoma","C128049","A highly aggressive malignant vascular neoplasm that arises from the cervix and shows endothelial cell differentiation.","Cervical Angiosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509702","Cervical Malignant Peripheral Nerve Sheath Tumor","C128050","A rare malignant neoplasm with nerve sheath differentiation arising from the cervix.","Cervical Malignant Peripheral Nerve Sheath Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1309711","Protein GREB1, Human","C128184","Protein GREB1 (1949 aa, ~216 kDa) is encoded by the human GREB1 gene. This protein may be involved in estrogen-stimulated cell proliferation.","Protein GREB1 | Gene Regulated In Breast Cancer 1 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508942","PTGER4 wt Allele","C128186","Human PTGER4 wild-type allele is located in the vicinity of 5p13.1 and is approximately 62 kb in length. This allele, which encodes prostaglandin E2 receptor EP4 subtype protein, is involved in prostaglandin-mediated G protein-coupled receptor signaling.","PTGER4 wt Allele | EP4 | EP4R | PGE Receptor, EP4 Subtype Gene | Prostaglandin E Receptor 4 (Subtype EP4) Gene | Prostaglandin E Receptor 4 wt Allele | Prostaglandin E Receptor 4, EP4 Subtype Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2746066","2-Hydroxyglutaric Aciduria","C128187","A group of genetic disorders characterized by elevated urinary concentrations of 2-hydroxyglutaric acid. Three different types have been identified based on the steroisomeric composition of the elevated alpha-hydroxyglutaric acid metabolites. Additionally, the disease may be categorized by the genetic mutation that is causative. Genes associated with 2-hydroxyglutaric aciduria are L2HGDH, D2HGDH, IDH2, and/or SLC25A1. Generally, there is nervous system involvement, but the clinical manifestations are variable and are dependent on the specific type of defect present.","2-Hydroxyglutaric Aciduria | ",,,,,,,,,,,,,,,"44782868","2-hydroxyglutaric aciduria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2748896","46,XY Sex Reversal 1","C128188","Sex reversal in an individual with 46,XY karyotype caused by point mutations or deletions in the SRY gene, encoding sex-determining region Y protein.","46,XY Sex Reversal 1 | SRXY1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509709","Childhood Absence Epilepsy","C128189","A common generalized epilepsy syndrome occurring in children, characterized by absence seizures of short duration. The cause of the syndrome is presumed to be genetic. Genes which are associated with the condition include GABRB3, GABRG2, GABRA1, CACNA1H, and ECA1.","Childhood Absence Epilepsy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042520","Venule","C12818","The part of the microvasculature that receives blood from the capillaries, and which then converges to form veins.","Venule | ",,,,,,,,,,,,,,,"4239964","Structure of venule",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1283620","Congenital Sucrase-Isomaltase Deficiency","C128190","An autosomal recessive genetic disorder caused by mutations in the SI gene, encoding sucrase-isomaltase, intestinal. The condition is characterized by malabsorption and osmotic diarrhea.","Congenital Sucrase-Isomaltase Deficiency | Disaccharide Intolerance 1",,,,,,,,,,,,,,,"4237269|4301746","Deficiency of isomaltase|Sucrase-isomaltase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0265345","Lymphedema-Distichiasis Syndrome","C128191","An autosomal dominant genetic disorder caused by mutation(s) in the FOXC2 gene, encoding forkhead box protein C2. The condition is characterized by lymphedema and distichiasis.","Lymphedema-Distichiasis Syndrome | ",,,,,,,,,,,,,,,"4311419","Distichiasis-lymphedema syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1850343","Mosaic Variegated Aneuploidy Syndrome 1","C128192","An autosomal recessive genetic disorder caused by mutation(s) in the BUB1B gene, encoding mitotic checkpoint serine/threonine-protein kinase B. The condition is characterized by a predisposition to mitotic non-disjunction, resulting in a high percentage of aneuploid cells. The phenotype is variable and there is a predisposition to cancer.","Mosaic Variegated Aneuploidy Syndrome 1 | MVA1",,,,,,,,,,,,,,,"44784139","Mosaic variegated aneuploidy syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3844620","Glutathione Synthetase Deficiency","C128193","An autosomal recessive genetic disorder caused by mutation(s) in the GSS gene, encoding glutathione synthetase. Mutation(s) in the same gene is causative in hemolytic anemia due to glutathione synthetase deficiency, with the more severe condition causing elevated urinary concentrations of 5-oxoproline and central nervous system damage in addition to hemolytic anemia.","Glutathione Synthetase Deficiency | 5-Oxoprolinuria | GSSD | Pyroglutamic Aciduria",,,,,,,,,,,,,,,"4121287","Glutathione synthetase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509203","GAIA Level 4 Antepartum Stillbirth","C128021","GAIA Level 4 Antepartum Stillbirth is defined by two criteria: first, a report of a stillbirth, but the fetus is unavailable for physical examination after birth so no objective assessment can be made; second, maternal information is insufficient to assess gestational age.","GAIA Level 4 Antepartum Stillbirth | Global Alignment of Immunization safety Assessment in pregnancy Level 4 Antepartum Stillbirth | Level 4 Antepartum Stillbirth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509151","GAIA Level 1 Intrapartum Stillbirth","C128022","GAIA Level 1 Intrapartum Stillbirth is defined by four criteria: first, delivery of an infant with no of signs of life at birth, including the following: no spontaneous movements, no umbilical cord pulse, no heartbeat, no respirations, and an Apgar score of 0 at both 1 and 5 minutes. Determination of the absence of signs of life is made by physical examination after delivery, with or without electronic monitoring of heart rate, respiratory rate, and pulse oximetry; second, evidence of a live fetus prior to the onset of labor (confirmed by documentation of fetal movement and of fetal heart tones by ultrasound prior to onset of labor). NOTE: In the absence of evidence of a live fetus prior to the onset of labor, the fetal death should be reported as a stillbirth or an antepartum stillbirth; third, attended delivery followed by post-delivery physical examination by an obstetrician, a neonatologist, a pediatrician, a maternal-fetal medicine specialist, or a pathologist that is consistent with intrapartum death. In a setting where access to a specialist is not feasible, diagnosis by a health care provider trained or experienced to make the diagnosis is acceptable (e.g. general practice physician, mid-wife, or other qualified trained practitioner); fourth, gestational age within the pre-defined range for selected stillbirth definition as assessed by maternal and/or fetal-neonatal parameters (level 1 in GA assessment algorithm).","GAIA Level 1 Intrapartum Stillbirth | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Intrapartum Stillbirth | Level 1 Intrapartum Stillbirth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509170","GAIA Level 2 Intrapartum Stillbirth","C128023","GAIA Level 2 Intrapartum Stillbirth is defined by four criteria: first, the delivery of an infant with no signs of life at birth, including the following: no spontaneous movements, no umbilical cord pulse, no heartbeat, no respirations, and an Apgar score of 0 at both 1 and 5 minutes. Determination of the absence of signs of life is made by physical examination after delivery, with or without electronic monitoring of heart rate, respiratory rate, and pulse oximetry OR documentation of lack of response to resuscitation efforts; second, evidence of a live fetus prior to the onset of labor (maternal report of fetal movement prior to the onset of labor and documentation of fetal heart tones by auscultation or hand held Doppler). NOTE: In the absence of evidence of a live fetus prior to the onset of labor, the fetal death should be reported as a stillbirth or an antepartum stillbirth; third, attended delivery followed by post-delivery physical examination that is performed by a health care professional who meets the standard of care in the immediate health care setting, and which is consistent with intrapartum death; fourth, gestational age within the pre-defined range for selected stillbirth definition as assessed by maternal and/or fetal parameters (level 1-2 in GA assessment algorithm).","GAIA Level 2 Intrapartum Stillbirth | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Intrapartum Stillbirth | Level 2 Intrapartum Stillbirth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507893","BET Inhibitor INCB057643","C128622","An inhibitor of the Bromodomain (BRD) and Extra-Terminal (BET) family of BRD-containing proteins, with potential antineoplastic activity. Upon administration, the BET inhibitor INCB057643 binds to the acetylated lysine recognition motifs found in the BRD of BET proteins, thereby preventing the interaction between the BET proteins and acetylated lysines on histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes, such as c-Myc-dependent target genes, may lead to an inhibition of tumor cell growth. BET proteins are transcriptional regulators that are overexpressed in certain tumor cells and play an important role in cellular growth.","BET Inhibitor INCB057643 | INCB 057643 | INCB-057643 | INCB057643",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509755","Megavoltage Topographic Imaging","C128624","The generation of a topographic image using megavolt x-ray beams.","Megavoltage Topographic Imaging | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509224","GAIA Level 2b Failure to Thrive","C128772","GAIA Level 2b Failure to Thrive is defined by either of two criteria: first, the following four requirements must be present: a) Infant age determined by a documented birth date; b) Weights are obtained using a spring balance scale; c) A minimum of two weights measured at least four weeks apart; d) Weight for age deceleration must pass through at least two centile spaces on a growth chart; OR second, the following three requirements must be present: a) Weight is measured using an electronic scale or beam balance scale; b) Length is documented using infantometer; c) Weight for length ratio less than or equal to the third centile on an appropriate growth chart.","GAIA Level 2b Failure to Thrive | Global Alignment of Immunization safety Assessment in pregnancy Level 2b Failure to Thrive | Level 2b Failure to Thrive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509225","GAIA Level 3a Failure to Thrive","C128773","GAIA Level 3a Failure to Thrive is defined by four criteria: first, infants with an undocumented birth date, where age is determined based on mother's recall to the nearest month; second, weight obtained using either beam balance or spring balance scale; third, a minimum of two weights measured at least four weeks apart; fourth, weight for age deceleration must pass through at least two centile spaces on a growth chart.","GAIA Level 3a Failure to Thrive | Global Alignment of Immunization safety Assessment in pregnancy Level 3a Failure to Thrive | Level 3a Failure to Thrive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509226","GAIA Level 3b Failure to Thrive","C128774","GAIA Level 3b Failure to Thrive is defined by three criteria: first, infants have no weight available; second, physical examination is consistent with failure to thrive, which is defined as having at least two findings, one of which must be a major finding: reduced subcutaneous fat stores, poor muscle mass, loose skin folds, prominent ribs, and thin limbs. Less specific findings include sparse hair, rashes, pallor, irritable temperament, and lethargy/fatigue; third, a mid-upper arm circumference (MUAC) measurement, which is indicative of severe wasting, that is less than or equal to 110 mm in infants up to six months of age, and that is less than or equal to 115 mm in infants six to twelve months of age.","GAIA Level 3b Failure to Thrive | Global Alignment of Immunization safety Assessment in pregnancy Level 3b Failure to Thrive | Level 3b Failure to Thrive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0269388","First Trimester Spontaneous Abortion","C128775","Pregnancy loss at less than 14 weeks 0 days gestation.","First Trimester Spontaneous Abortion | 1st Trimester Spontaneous Abortion",,,,,,,,,,,,,,,"4078393","Miscarriage in first trimester",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509036","Postoperative Spindle Cell Nodule of the Cervix","C128051","A rare, benign, non-neoplastic reactive lesion that develops in the cervix at the site of a prior operative procedure. It is composed of spindle cells, small blood vessels, and chronic inflammation.","Postoperative Spindle Cell Nodule of the Cervix | Cervical Postoperative Spindle Cell Nodule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509000","Gusperimus","C128052","No value exists.","Gusperimus | 15-Deoxyspergualin | Deoxyspergualin | GUSPERIMUS | Heptanamide, 7-((Aminoiminomethyl)amino)-N-(2-((4-((3-aminopropyl)amino)butyl)amino)-1-hydroxy-2-oxoethyl)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509694","Benign Cervical Soft Tissue Neoplasm","C128053","A rare benign mesenchymal neoplasm that arises from the cervix.","Benign Cervical Soft Tissue Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509750","Malignant Cervical Soft Tissue Neoplasm","C128054","A rare malignant mesenchymal neoplasm that arises from the cervix.","Malignant Cervical Soft Tissue Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509035","Cervical Yolk Sac Tumor","C128055","A yolk sac tumor that arises from the cervix. Patients present with abnormal vaginal bleeding and a polypoid, friable mass, protruding into the vagina.","Cervical Yolk Sac Tumor | Cervical Endodermal Sinus Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879554","Perfusion-Weighted Magnetic Resonance Imaging","C128056","A magnetic resonance imaging modality used to quantify the blood supply to an organ or tissue using signal measurement as detected from a parenterally administered contrast agent.","Perfusion-Weighted Magnetic Resonance Imaging | PWI | Perfusion-Weighted MR | Perfusion-Weighted MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3644554","Dabrafenib Mesylate","C128059","The mesylate salt form of dabrafenib, an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.","Dabrafenib Mesylate | DABRAFENIB MESYLATE | Dabrafenib Methanesulfonate | GSK2118436 Methane Sulfonate Salt | GSK2118436B | Tafinlar",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509357","Vaginal Papillary Carcinoma","C128060","A rare squamous cell carcinoma that arises from the vagina resembling transitional cell carcinoma of the urinary tract.","Vaginal Papillary Carcinoma | Vaginal Squamotransitional Carcinoma | Vaginal Squamotransitional Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0318021","Herbaspirillum huttiense","C127720","A species of Gram-negative, motile, spirillum-shaped bacteria in the phylum Proteobacteria that is unable to grow in N2-free medium and lacks the nitrogen-fixing genes nifH and nifD. H. huttiense is oxidase- and catalase-positive, nitrate reduction negative, and able to hydrolyse urea.","Herbaspirillum huttiense | HERBASPIRILLUM HUTTIENSE | Pseudomonas huttiensis",,,,,,,,,,,,,,,"4142986","Herbaspirillum huttiense",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008889","Hortaea werneckii","C127721","A species of saprophytic fungi in the phylum Ascomycota with two-celled yeast-like cells producing annelloconidia. H. werneckii is the causative agent of tinea nigra in humans.","Hortaea werneckii | Exophiala werneckii | HORTAEA WERNECKII",,,,,,,,,,,,,,,"4309052","Hortaea werneckii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1224179","Kerstersia gyiorum","C127722","A species of Gram-negative, catalase-positive, oxidase-negative bacteria in the in phylum Proteobacteria that is positive for assimilation of caprylate and the absence of assimilation of isobutyrate, isovalerate, or glutarate.","Kerstersia gyiorum | KERSTERSIA GYIORUM",,,,,,,,,,,,,,,"4214948","Kerstersia gyiorum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1676302","Kloeckera japonica","C127723","A species of apiculate yeast in the phylum Ascomycota with polar budding and evanescent asci containing 1 to 4 hat-shaped ascospores.","Kloeckera japonica | KLOECKERA JAPONICA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1739015","Prostaglandin E2 Receptor EP4 Subtype, Human","C128194","Prostaglandin E2 receptor EP4 subtype (488 aa, ~53 kDa) is encoded by the human PTGER4 gene. This protein plays a role in the regulation of prostaglandin E2-dependent signaling.","Prostaglandin E2 Receptor EP4 Subtype | E-Type Prostanoid Receptor 4 | EP4 Receptor | PGE Receptor EP4 Subtype | PGE2 Receptor EP(4) | PGE2 Receptor EP4 Subtype | Prostanoid EP4 Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508671","Canine Sarcoma","C128195","A malignant mesenchymal neoplasm that affects dogs. It arises from muscle, fat, fibrous tissue, bone, cartilage, and blood vessels.","Canine Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0948780","Rhinosinusitis","C128434","Inflammation of the mucous membranes lining the nose and paranasal sinuses.","Rhinosinusitis | ",,,,,,,,,,,,,,,"619759","Rhinosinusitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509777","Tonsillopharyngitis","C128436","Inflammation of the palatine tonsils and the posterior pharynx (throat).","Tonsillopharyngitis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018572","Hand Foot and Mouth Disease","C128439","A clinical syndrome that is usually caused by enterovirus infection, and that is characterized by fever, anorexia, and painful sores in the mouth, distal extremities, and/or other sites, including the buttocks.","Hand Foot and Mouth Disease | HFMD | Hand, Foot, and Mouth Disease",,,,,,,,,,,,,,,"4141481","Enteroviral vesicular stomatitis with exanthem",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0029307","Carrión Disease","C128441","An infection that is caused by Bartonella bacilliformis, which is transmitted to humans from infected sandflies. The acute phase (Oroya Fever) is characterized by fever, headache, myalgia, enlargement of the lymph nodes, and anemia. The chronic phase (verruga peruana/Peruvian wart) is characterized by benign, eruptive lesions that are bleeding and pruritic, arthralgia, and malaise.","Carrión Disease | Carri??n Disease | Carrion Disease",,,,,,,,,,,,,,,"4096184|4347537","Infection by Bartonella bacilliformis|Oroya fever",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL508861","LZTR1 wt Allele","C128258","Human LZTR1 wild-type allele is located in the vicinity of 22q11.21 or within 22q11.1-q11.2 and is approximately 20 kb in length. This allele, which encodes leucine-zipper-like transcriptional regulator 1 protein, may play a role in transcriptional regulation or Golgi functions. Mutation of the gene is associated with Noonan syndrome 10 and increased susceptibility to schwannomatosis 2. Deletion of the gene may be associated with DiGeorge syndrome.","LZTR1 wt Allele | BTBD29 | LZTR-1 | Leucine Zipper Like Transcription Regulator 1 wt Allele | Leucine-Zipper-Like Transcription Regulator 1 Gene | NS10 | SWNTS2 | TCFL2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1701463","Leucine-Zipper-Like Transcriptional Regulator 1, Human","C128259","Leucine-zipper-like transcriptional regulator 1 (840 aa, ~95 kDa) is encoded by the human LZTR1 gene. This protein may be involved in embryogenesis.","Leucine-Zipper-Like Transcriptional Regulator 1 | LZTR-1 | Leucine Zipper-Like Transcriptional Regulator 1 | Leucine-Zipper-Like Transcription Regulator 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509079","GAIA Level 1 First Trimester Spontaneous Abortion","C128776","GAIA Level 1 First Trimester Spontaneous Abortion is defined by two criteria: first, at least one of the following three requirements must be met: a) Crown-rump length greater than or equal to 7 mm and no visible heartbeat on transvaginal ultrasound; OR b) Crown-rump length greater than or equal to 15 mm and no visible heartbeat on abdominal ultrasound; OR c) Ultrasound examination demonstrating mean gestational sac diameter greater than or equal to 25 mm and no visible embryo or yolk sac; second, at least one of the following three requirements must be met: a) A second transvaginal ultrasound performed greater than or equal to 7 days later (or 14 days later if transabdominal) confirming the diagnosis of a non-viable pregnancy; OR b) The absence of an embryo with heartbeat 2 weeks or more after a transabdominal scan that initially showed a gestational sac without a yolk sac; OR c) The absence of an embryo with a heartbeat 11 days or more after a transvaginal scan that initially showed a gestational sac with a yolk sac. Alternatively, GAIA Level 1 First Trimester Spontaneous Abortion can be defined by the following two criteria: first, the gestational age is within the pre-defined range for the selected abortion definition as assessed by maternal and/or fetal parameters ( Level 1-2) (using the Brighton Preterm Birth Gestational Age algorithm); second, at least one of the following four requirements must be met: a) Positive urine or blood pregnancy test that becomes negative after 7 days; OR b) Products of conception found on histopathological evaluation of pregnancy tissue; OR c) Ultrasound examination demonstrating an empty uterine cavity in a woman who had clear evidence of intrauterine pregnancy on previous ultrasound examination; OR d) Vaginal bleeding, external cervical os open or closed, with visible expulsion of pregnancy tissues/products of conception.","GAIA Level 1 First Trimester Spontaneous Abortion | Global Alignment of Immunization safety Assessment in pregnancy Level 1 First Trimester Spontaneous Abortion | Level 1 First Trimester Spontaneous Abortion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509091","GAIA Level 2 First Trimester Spontaneous Abortion","C128777","GAIA Level 2 First Trimester Spontaneous Abortion is defined by three criteria: first, it does not qualify as a Level 1 First Trimester Spontaneous Abortion; second, at least one of the following three requirements must be met: a) Crown-rump length greater than 7 mm and no visible heartbeat, confirmed by transvaginal ultrasound; OR b) Crown-rump length greater than 15 mm and no visible heartbeat, confirmed by abdominal ultrasound; OR c) Mean gestational sac diameter is 25 mm or more and no visible embryo; third, gestational age is within the pre-defined range for the selected abortion definition as assessed by maternal and/or fetal parameters (Level 1-2) (using Brighton Preterm Birth Gestational Age algorithm).","GAIA Level 2 First Trimester Spontaneous Abortion | Global Alignment of Immunization safety Assessment in pregnancy Level 2 First Trimester Spontaneous Abortion | Level 2 First Trimester Spontaneous Abortion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509100","GAIA Level 3 First Trimester Spontaneous Abortion","C128778","GAIA Level 3 First Trimester Spontaneous Abortion is defined by three criteria: first, it does not qualify as either a Level 1 or Level 2 First Trimester Spontaneous Abortion; second, gestational age is within the pre-defined range for the selected abortion definition as assessed by maternal and/or fetal parameters (Level 3) (using Brighton Preterm Birth Gestational Age algorithm); third, a positive urine or blood pregnancy test that becomes negative after 7 days.","GAIA Level 3 First Trimester Spontaneous Abortion | Global Alignment of Immunization safety Assessment in pregnancy Level 3 First Trimester Spontaneous Abortion | Level 3 First Trimester Spontaneous Abortion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512155","IFT88 wt Allele","C128945","Human IFT88 wild-type allele is located in the vicinity of 13q12.1 and is approximately 125 kb in length. This allele, which encodes intraflagellar transport protein 88 homolog, plays a role in the assembly of both cilia and autophagosomes.","IFT88 wt Allele | D13S1056E | DAF19 | DAF19, C. elegans, Homolog of Gene | Intraflagellar Transport 88 Homolog (Chlamydomonas) Gene | Intraflagellar Transport 88 Homolog Gene | Intraflagellar Transport 88 wt Allele | MGC26259 | Polaris Homolog Gene | Polaris, Mouse, Homolog of Gene | Probe HTg737 (Polycystic Kidney Disease, Autosomal Recessive) Gene | TG737 | TG737, Mouse, Homolog of Gene | TTC10 | hTg737",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512163","IFT88 protein, human","C128946","Intraflagellar transport protein 88 homolog (833 aa, ~94 kDa) is encoded by the human IFT88 gene. This protein is involved in cilium and autophagosome assembly.","Intraflagellar Transport Protein 88 Homolog | IFT88 | Recessive Polycystic Kidney Disease Protein Tg737 Homolog | TPR Repeat Protein 10 | Testicular Tissue Protein Li 93 | Tetratricopeptide Repeat Domain 10 | Tetratricopeptide Repeat Protein 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512227","Name of Fixative","C128948","The name of the compound that preserves tissues and cells for microscopic study.","Name of Fixative | FIXNAM | Fixative Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512385","Kirchner Growth Medium","C128949","A liquid growth medium mainly consisting of sodium dihydrogen phosphate, potassium dihydrogen phosphate, magnesium sulphate, trisodium citrate, L-asparagine and phenol red, which is developed for the culture and recovery of Mycobacteria.","Kirchner Growth Medium | KIRCHNER MEDIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0446021","Kluyveromyces lactis","C127724","A species of yeasts in the family Saccharomycetaceae and phylum Ascomycota with the ability to utilize lactose and convert it into lactic acid. The species is heterothallic, with a predominantly haploid life cycle. K. lactis has emerged as an important yeast species for research and industrial biotechnology.","Kluyveromyces lactis | Candida sphaerica | KLUYVEROMYCES LACTIS | Kluyveromyces drosophilarum | Kluyveromyces lactis var. drosophilarum | Kluyveromyces lactis var. lactis | Kluyveromyces marxianus lactis | Kluyveromyces marxianus var. drosophilarum | Kluyveromyces marxianus var. lactis | Saccharomyces lactis",,,,,,,,,,,,,,,"4348449","Kluyveromyces lactis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319554","Kodamaea ohmeri","C127725","A species of yeast-like fungi in the phylum Ascomycota. K. ohmeri is a causative agent of fungemia in immunocompromised patients. This species is widely used in the food industry for fermentation of fruits, pickles and rinds.","Kodamaea ohmeri | Candida guilliermondii var. membranifaciens | KODAMAEA OHMERI | Pichia ohmeri | Yamadazyma ohmeri",,,,,,,,,,,,,,,"40492867","Kodamaea ohmeri",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1947862","Lysinibacillus","C127727","A genus of gram-positive, rod-shaped, non-motile bacteria in the phylum Firmicutes.","Lysinibacillus | LYSINIBACILLUS",,,,,,,,,,,,,,,"40480223","Lysinibacillus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320105","Madurella mycetomatis","C127728","A species of fungi in the phylum ascomycota characterized by brown diffusible pigment that is produced in primary cultures and the occasional presence of phialides. This species is a causative agent of eumycetoma.","Madurella mycetomatis | MADURELLA MYCETOMATIS | Madurella ikedae | Madurella mycetomi | Streptotrix mycetomatis",,,,,,,,,,,,,,,"4089381","Madurella mycetomatis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032030","Malassezia furfur","C127729","A species of obligatory lipophilic, anthropophilic yeast in the phylum Basidiomycota that is part of the normal human skin flora. This species is the causative agent of pityriasis versicolor.","Malassezia furfur | MALASSEZIA FURFUR | Pityrosporum orbiculare | Pityrosporum ovale | Saccharomyces ovalis",,,,,,,,,,,,,,,"4106082","Malassezia furfur",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032008","Anterior Lobe of the Pituitary Gland","C12772","The glandular or anterior lobe of the pituitary gland which secretes several hormones.","Anterior Lobe of the Pituitary Gland | Adenohypophysis | Anterior Lobe of Pituitary | Anterior Lobe of Pituitary Gland | Anterior Pituitary Gland | Gland, Anterior Pituitary | Glands, Anterior Pituitary | Pars Anterior Pituitary Gland | Pituitary Anterior Lobe | Pituitary Gland, Anterior",,,,,,,,,,,,,,,"4270353","Adenohypophysis structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319894","Malassezia pachydermatis","C127730","A zoophilic species of lipophilic yeast in the phylum Basidiomycota that can be found within the microflora of healthy mammals. M. pachydermatis can be distinguished from other species in the genus by its ability to grow on Sabouraud agar.","Malassezia pachydermatis | MALASSEZIA PACHYDERMATIS | Pityrosporum pachydermatis",,,,,,,,,,,,,,,"4198244","Malassezia pachydermatis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319949","Microsporum audouinii","C127732","A species of anthropophilic fungi in the phylum Ascomycota that is characterized by spindle shaped macroconidia, clavate microconidia, and pitted or spiny external walls. This species is a causative agent of tinea capitis and tinea corporis.","Microsporum audouinii | MICROSPORUM AUDOUINII",,,,,,,,,,,,,,,"4286331","Microsporum audouinii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0446071","Microsporum distortum","C127733","A species of fungi in the phylum Ascomycota characterized by thick-walled, roughened macroconidia with a distorted shape. This species is a causative agent of tinea capitis and tinea corporis.","Microsporum distortum | MICROSPORUM DISTORTUM | Microsporum canis var. distortum",,,,,,,,,,,,,,,"4020934","Microsporum canis var. distortum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319952","Microsporum equinum","C127734","A species of fungi in the phylum Ascomycota with macroconidia that are small, broad, irregular, and spindle-shaped with rough thick walls and few septa. This species is a causative agent of ringworm in horses and humans.","Microsporum equinum | MICROSPORUM EQUINUM",,,,,,,,,,,,,,,"4322981","Microsporum equinum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319953","Microsporum ferrugineum","C127735","A species of anthropophilic fungi in the phylum Ascomycota characterized by 'bamboo hyphae'. This species is a causative agent of juvenile tinea capitis in humans.","Microsporum ferrugineum | MICROSPORUM FERRUGINEUM",,,,,,,,,,,,,,,"4067550","Microsporum ferrugineum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3279069","Cutaneous Neurofibroma","C128451","A neurofibroma that grows along small branches of nerves in the dermis in patients with neurofibromatosis. It presents as a solid cutaneous tumor.","Skin Neurofibroma | Cutaneous (Skin) Neurofibroma | Cutaneous Neurofibroma | Cutaneous Neurofibroma | Dermal Neurofibroma",,,,,,,,,,,,,,,"4110732","Cutaneous neurofibroma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508958","Pediatric Infectious Disease Terminology","C128453","Terminology developed by a collaborative effort of the National Cancer Institute's Enterprise Vocabulary Services, the National Institute of Child Health and Human Development, and an international group of clinicians and informaticists to support the reporting of events in the pediatric population with issues pertaining to infectious diseases.","Pediatric Infectious Disease Terminology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509174","GAIA Level 2 Maternal Death","C127998","GAIA Level 2 Maternal Death is defined by three criteria: first, diagnosis of a pregnancy, in the absence of level 1 criteria, as established by either of the following requirements: a) last menstrual period date; b) Serial symphysio fundal height examinations; second, death of the mother while pregnant or within 42 days of termination of pregnancy, irrespective of the duration and the site of the pregnancy; third, documentation of the maternal cause of death wherein one of the following requirements must be met: a) Direct: abortive outcome, hypertensive disorder, obstetric hemorrhage, pregnancy related infection, other obstetric complications, unanticipated complications; b) Indirect: non obstetric complications; c) Death during pregnancy, childbirth, and the puerperium: other or coincidental; d) Unspecified: unknown or undetermined.","GAIA Level 2 Maternal Death | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Maternal Death | Level 2 Maternal Death",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509194","GAIA Level 3 Maternal Death","C127999","GAIA Level 3 Maternal Death is defined by three criteria: first, the absence of level 1 or level 2 criteria for establishing diagnosis of pregnancy, and both the uncertainty of the individual's last menstrual period date and no documented clinical examination; second, death of the mother temporal to pregnancy, childbirth, or the postpartum period when exact timing of death is unknown; third, documentation of the maternal cause of death wherein one of the following requirements must be met: a) Direct: abortive outcome, hypertensive disorder, obstetric hemorrhage, pregnancy related infection, other obstetric complications, unanticipated complications; b) Indirect: non-obstetric complications; c) Death during pregnancy, childbirth, and the puerperium: other or coincidental; d) Unspecified: unknown or undetermined.","GAIA Level 3 Maternal Death | Global Alignment of Immunization safety Assessment in pregnancy Level 3 Maternal Death | Level 3 Maternal Death",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0053847","Pingyangmycin","C1279","The naturally-occurring bleomycin antineoplastic antibiotic isolated from the bacterium Streptomyces pingyangensisn.  Pingyangmycin induces tumor cell apoptosis, possibly via a mechanism mediated by the mitogen-activated protein kinase (MAPK) pathway. (NCI04)","Pingyangmycin | BLEOMYCIN A5 | Bleomycetin | Bleomycin A5 | N1-(3-((4-Aminobutyl)amino)propyl)bleomycinamide | Zhengguangmycin A5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509161","GAIA Level 1 Postpartum Hemorrhage","C128000","GAIA Level 1 Postpartum Hemorrhage is the presence of genital bleeding after delivery, leading to severe maternal outcome (maternal death or maternal near miss) as defined by WHO.","GAIA Level 1 Postpartum Hemorrhage | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Postpartum Hemorrhage | Level 1 Postpartum Haemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509180","GAIA Level 2 Postpartum Hemorrhage","C128001","GAIA Level 2 Postpartum Hemorrhage is defined by the presence of the following criteria: genital bleeding after delivery with at least one of the following: a) Measured abnormal bleeding (1000ml or more); or b) Any bleeding leading to hypotension or blood transfusion.","GAIA Level 2 Postpartum Hemorrhage | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Postpartum Hemorrhage | Level 2 Postpartum Haemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509200","GAIA Level 3 Postpartum Hemorrhage","C128002","GAIA Level 3 Postpartum Hemorrhage is defined by the presence of genital bleeding after delivery that is estimated at 1000ml or more.","GAIA Level 3 Postpartum Hemorrhage | Global Alignment of Immunization safety Assessment in pregnancy Level 3 Postpartum Hemorrhage | Level 3 Postpartum Haemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508999","MT-RNR1 wt Allele","C128261","Human MT-RNR1 wild-type allele is located within the circular mitochondrial (MT) chromosome and is approximately 1 kb in length. This allele, which encodes both 12S mitochondrial ribosomal RNA and mitochondrial-derived peptide MOTS-c protein, plays a role in cellular metabolism and the translation of mitochondrial proteins.","MT-RNR1 wt Allele | 12S Mitochondrial Ribosomal RNA wt Allele | MTRNR1 | RNR1 | Ribosomal RNA, Mitochondrial, 12S Gene | rRNA, 12S, Mitochondrial Gene | s-rRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509635","Mitochondrial-Derived Peptide MOTS-c","C128262","Mitochondrial-derived peptide MOTS-c (16 aa, ~2 kDa) is encoded by the human MT-RNR1 gene. This protein may be involved in cellular homeostasis.","Mitochondrial-Derived Peptide MOTS-c | MOTS-c | Mitochondrial Open Reading Frame of the 12S rRNA-c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508650","12S Mitochondrial Ribosomal RNA, Human","C128263","12S mitochondrial ribosomal RNA is encoded by the human MT-RNR1 gene. This ribonucleotide is involved in mitochondrial protein translation.","12S Mitochondrial Ribosomal RNA | 12S Mitochondrial rRNA | 12S RNA | Mitochondrially Encoded 12S RNA | s-rRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272352","Vitamin D3 Deficiency","C128265","Abnormally low concentration of vitamin D3 (cholecalciferol) in the blood.","Vitamin D3 Deficiency | ",,,,,,,,,,,,,,,"4300955","Deficiency of vitamin D3",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL507865","BAY1251152","C128266","An inhibitor of cyclin-dependent kinase 9 (CDK9), the catalytic subunit of the RNA polymerase II (RNA Pol II) elongation factor positive transcription elongation factor b (PTEF- b; PTEFb), with potential antineoplastic activity. Upon administration, enitociclib binds to and blocks the phosphorylation and kinase activity of CDK9, thereby preventing PTEFb-mediated activation of RNA Pol II and leading to the inhibition of gene transcription of various anti-apoptotic proteins. This may cause cell cycle arrest and induce apoptosis, which may lead to a reduction in tumor cell proliferation. The protein complex PTEF-b, a heterodimer consisting of CDK9 and a regulatory cyclin subunit of the T family, is over-activated in various tumor cell types; it plays a key role in the regulation of Pol II-mediated transcription of anti-apoptotic proteins. Tumor cells are dependent on anti-apoptotic proteins for their survival.","Enitociclib | BAY 1251152 | BAY1251152 | ENITOCICLIB | PTEF-b/CDK9 Inhibitor BAY1251152 | PTEF-b/CDK9 Inhibitor VIP152 | PTEF-b/CDK9 Inhibitor VIP152 | VIP 152 | VIP-152 | VIP152",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1540031","TMSB15A Gene","C128267","This gene plays a role in both actin binding and cytoskeletal remodeling.","TMSB15A Gene | TMSB15A | Thymosin Beta 15a Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508995","TNFRSF13B wt Allele","C127902","Human TNFRSF13B wild-type allele is located in the vicinity of 17p11.2 and is approximately 42 kb in length. This allele, which encodes tumor necrosis factor receptor superfamily member 13B protein, is involved in ligand-mediated signaling and immunity.","TNFRSF13B wt Allele | CD267 | CVID | CVID2 | IGAD2 | RYZN | TACI | TNFRSF14B | Tumor Necrosis Factor Receptor Superfamily Member 13B wt Allele | Tumor Necrosis Factor Receptor Superfamily, Member 13B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509708","Cervical Transitional Metaplasia","C127904","Cervical metaplasia in which the cervical squamous epithelium resembles benign urothelium as a result of a lack of cellular maturation.","Cervical Transitional Metaplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512301","MB Redox Broth Growth Medium","C128950","A liquid and selective growth medium that is modified based on the Kirchner medium by the addition of a mixture of antimicrobial agents (typically polymyxin B, amphotericin B, carbenicillin, and trimethoprim) and colorless tetrazolium salt as a growth indicator, which is developed for the cultivation of mycobacterium.","MB Redox Broth Growth Medium | MB REDOX BROTH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512193","NCCN-FACT FKSI-19 Version 2 - I Feel Weak All Over","C129159","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I feel weak all over.","NCCN-FACT FKSI-19 Version 2 - I Feel Weak All Over | FAC042-I Feel Weak All Over | FAC04209",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333855","Small Cleaved Follicle Center Cell","C12915","A lymphoid cell of follicular center cell origin that has an irregularly shaped nucleus with clumped chromatin, absent nucleoli, and one or more clefts in the nuclear membrane.","Small Cleaved Follicle Center Cell | ",,,,,,,,,,,,,,,"4232608","Small cleaved cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512198","NCCN-FACT FKSI-19 Version 2 - I Have Had Blood in My Urine","C129160","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I have had blood in my urine.","NCCN-FACT FKSI-19 Version 2 - I Have Had Blood in My Urine | FAC042-I Have Had Blood in My Urine | FAC04210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0300804","interleukin-15 receptor","C128303","A heterotrimeric complex comprised of interleukin-15 receptor subunit alpha, interleukin-2 receptor subunit beta, and cytokine receptor common subunit gamma. This receptor complex has high affinity for interleukin-15 and modulates interleukin signaling.","Interleukin-15 Receptor | High-Affinity Interleukin-15 Receptor | IL-15 Receptor | IL-15R | IL15 Receptor | IL15R | Interleukin 15 Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509615","HLA-B Gene Product","C128308","A protein encoded by the HLA-B gene.","HLA-B Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509163","GAIA Level 1 Preeclampsia","C128003","GAIA Level 1 Preeclampsia is defined by three criteria: first, the gestational age of the pregnancy must be greater than or equal to 20 weeks; second, a diagnosis of new onset maternal hypertension (systolic blood pressure greater than or equal to 140mmHg and/or diastolic blood pressure greater than or equal to 90mmHg) that is sustained on two measurements over a minimum of one hour; third, a diagnosis of new onset proteinuria that is a level one diagnostic certainty (proteinuria diagnosed with greater than or equal to 300 mg of protein during 24 hour urine collection OR greater than or equal to 0.3 for spot protein:creatinine ratio.)","GAIA Level 1 Preeclampsia | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Preeclampsia | Level 1 Preeclampsia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509182","GAIA Level 2 Preeclampsia","C128004","GAIA Level 2 Preeclampsia is defined by three criteria: first, the gestational age of the pregnancy must be greater than or equal to 20 weeks; second, a diagnosis of new onset maternal hypertension (systolic blood pressure greater than or equal to 140mmHg and/or diastolic blood pressure greater than or equal to 90mmHg) that is sustained on two measurements for a minimum of one hour; third, a diagnosis of new onset proteinuria that is a level 2 diagnostic certainty (proteinuria diagnosed with greater than or equal to 1+ protein on urine dipstick).","GAIA Level 2 Preeclampsia | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Preeclampsia | Level 2 Preeclampsia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509214","GAIA Insufficient Evidence for Diagnosis of Preeclampsia","C128005","GAIA Insufficient Evidence for Diagnosis of Preeclampsia is defined as a pregnancy with gestational age greater than or equal to 20 weeks and either a) The inability to measure blood pressure OR b) The inability to evaluate for proteinuria.","GAIA Insufficient Evidence for Diagnosis of Preeclampsia | Global Alignment of Immunization safety Assessment in pregnancy Insufficient Evidence for Diagnosis of Preeclampsia | Insufficient Evidence for Preeclampsia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507929","Anti-Met Monoclonal Antibody Mixture Sym015","C127906","A mixture of two humanized immunoglobulin G1 (IgG1) monoclonal antibodies, Hu9006 and Hu9338, which recognize non-overlapping epitopes in the extracellular domain of the human hepatocyte growth factor receptor (MET; HGFR; c-Met), with potential antineoplastic activity. Upon administration, anti-MET monoclonal antibody mixture Sym015 targets and binds to the extracellular domain of MET, thereby preventing the binding of its ligand, hepatocyte growth factor (HGF). This may prevent activation of the receptor and MET-mediated signal transduction pathways. This inhibits MET-dependent tumor cell proliferation. MET, a receptor tyrosine kinase, is overexpressed on the cell surfaces of various solid tumor cell types; it plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.","Anti-Met Monoclonal Antibody Mixture Sym015 | Hu9006-Hu9338 | Hu9006/Hu9338 | Sym 015 | Sym-015 | Sym015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266079","Endocervical Adenocarcinoma, Usual-Type","C127907","A cervical adenocarcinoma in which 0-50% of malignant cells contain intracytoplasmic mucin. It is the most common subtype of cervical adenocarcinoma and represents 75% of all invasive cervical adenocarcinomas. The neoplastic epithelium shows a pseudostratified architecture and the malignant cells have enlarged, elongated, and hyperchromatic nuclei. Historically, usual-type cervical adenocarcinomas were termed 'endocervical-type'.","Endocervical Adenocarcinoma, Usual-Type | Adenocarcinoma, Endocervical Type | Adenocarcinoma, endocervical type | Cervical Adenocarcinoma, Usual Type | Cervical Adenocarcinoma, Usual-Type | Cervical Mucinous Adenocarcinoma, Endocervical Type | Cervical Mucinous Adenocarcinoma, Endocervical-Type | Endocervical Adenocarcinoma, Usual Type | Endocervical adenocarcinoma usual type | Mucinous adenocarcinoma, endocervical type | UEA","8384/3","Adenocarcinoma, endocervical type, NOS",,,,,,,,,,,,,"4030118","Mucinous adenocarcinoma, endocervical type",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"C0051080","Alanylglutamine","C127908","A nutritional supplement containing a stable, water-soluble dipeptide comprised of the amino acids L-glutamine and L-alanine, with potential protective and absorption enhancing activities. Upon oral or enteral administration, alanylglutamine works locally in the gastrointestinal (GI) tract to both protect the integrity of the intestinal mucosa and maintain intestinal barrier functions. This reduces bacterial translocation, the risk of infection, infection-induced inflammatory damage and infection-associated symptoms, such as diarrhea, dehydration, malabsorption and electrolyte imbalances. Alanylglutamine also increases absorption of other chemicals, enhances epithelial repair, and inhibits apoptosis due to cellular damage, and stimulates cellular proliferation. Altogether, this improves absorption of nutrients, decreases weight loss, reduces diarrhea, decreases the risk of GI-associated infections and improves recovery. Upon absorption, alanylglutamine may also help inhibit muscle protein catabolism.","Alanylglutamine | AG | ALANYL GLUTAMINE | Ala-Gln | Alanyl-glutamine | L-alanyl-L-glutamine | L-alanyl/L-glutamine | N(2)-L-Alanyl-L-glutamine | Sustamine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507933","pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine","C127910","A polyepitope plasmid DNA vaccine containing the mammalian expression vector pUMVC3 encoding epitopes derived from three tumor-associated antigens (TAAs): human insulin-like growth factor-binding protein 2 (IGFBP2), human epidermal growth factor receptor 2 (HER2; ERBB2) and insulin-like growth factor 1 receptor (IGF1R), with potential immunostimulating and antineoplastic activities. Upon intradermal vaccination, pUMVC3-IGFBP2-HER2-IGF1R plasmid DNA vaccine transfects local keratinocytes, which process the plasmid, express the epitopes and present them to antigen-presenting cells (APCs). This activates the immune system to mount a combined response from specific T helper type 1 (Th1) cells, memory T-cells and cytotoxic T-lymphocytes (CTL) against IGFBP2-, HER2-, and IGF1R-expressing tumor cells. IGFBP2, HER2, and IGF1R are tumor-associated proteins overexpressed in certain tumor cell types, and play key roles in cellular proliferation and survival.","pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine | WOKVAC | WOKVAC Vaccine | pUMVC3-IGFBP2-HER2-IGF1R | pUMVC3-IGFBP2-HER2-IGF1R Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512201","NCCN-FACT FKSI-19 Version 2 - I Have a Good Appetite","C129161","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I have a good appetite.","NCCN-FACT FKSI-19 Version 2 - I Have a Good Appetite | FAC042-I Have a Good Appetite | FAC04211",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512191","NCCN-FACT FKSI-19 Version 2 - I Am Sleeping Well","C129162","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I am sleeping well.","NCCN-FACT FKSI-19 Version 2 - I Am Sleeping Well | FAC042-I Am Sleeping Well | FAC04212",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512199","NCCN-FACT FKSI-19 Version 2 - I Have Nausea","C129164","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I have nausea.","NCCN-FACT FKSI-19 Version 2 - I Have Nausea | FAC042-I Have Nausea | FAC04214",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512197","NCCN-FACT FKSI-19 Version 2 - I Have Diarrhea","C129165","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I have diarrhea (diarrhoea).","NCCN-FACT FKSI-19 Version 2 - I Have Diarrhea | FAC042-I Have Diarrhea | FAC04215",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512185","NCCN-FACT FKSI-19 Version 2 - Bothered by Treatment Side Effect","C129166","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I am bothered by side effects of treatment.","NCCN-FACT FKSI-19 Version 2 - Bothered by Treatment Side Effect | FAC042-Bothered by Treatment Side Effect | FAC04216",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512188","NCCN-FACT FKSI-19 Version 2 - I Am Able to Work","C129167","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I am able to work (include work at home).","NCCN-FACT FKSI-19 Version 2 - I Am Able to Work | FAC042-I Am Able to Work | FAC04217",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512187","NCCN-FACT FKSI-19 Version 2 - I Am Able to Enjoy Life","C129168","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I am able to enjoy life.","NCCN-FACT FKSI-19 Version 2 - I Am Able to Enjoy Life | FAC042-I Am Able to Enjoy Life | FAC04218",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512186","NCCN-FACT FKSI-19 Version 2 - Content With Quality of My Life","C129169","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I am content with the quality of my life right now.","NCCN-FACT FKSI-19 Version 2 - Content With Quality of My Life | FAC042-Content With Quality of My Life | FAC04219",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3550864","Micromegakaryocyte","C12916","No value exists.","Micromegakaryocyte | Atypically Small Megakaryocyte",,,,,,,,,,,,,,,"4141449","Micromegakaryocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512179","NCCN-FACT FBLSI-18 Version 2 - I Have Pain","C129170","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I have pain.","NCCN-FACT FBLSI-18 Version 2 - I Have Pain | FAC028-I Have Pain | FAC02801",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512171","NCCN-FACT FBLSI-18 Version 2 - I Am Losing Weight","C129171","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I am losing weight.","NCCN-FACT FBLSI-18 Version 2 - I Am Losing Weight | FAC028-I Am Losing Weight | FAC02802",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512169","NCCN-FACT FBLSI-18 Version 2 - Have Trouble Controlling My Urine","C129172","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I have trouble controlling my urine.","NCCN-FACT FBLSI-18 Version 2 - Have Trouble Controlling My Urine | FAC028-Have Trouble Controlling My Urine | FAC02803",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509166","GAIA Level 2 Assessment of Premature Preterm Rupture of Membranes","C127945","GAIA Level 2 Assessment of Premature Preterm Rupture of Membranes is defined by four criteria: first, presentation between 24 0/7 and 36 6/7 weeks gestation with a clinical history of rupture of membranes, the fluid from which may be any color, including clear, blood-tinged, meconium-tinged (fetal stool), or purulent-tinged (yellowish, suggesting infection); second, the patient is determined to not be in preterm labor (having less than or equal to 4 contractions per hour documented clinically or on tocodynometer, with less than 2cm cervical dilation); third, visible leakage of fluid on vaginal speculum exam; fourth, one of the three following requirements must be met: a) Visible arborization (ferning) on microscopy of amniotic fluid; OR b) Ultrasound with oligohydramnios (amniotic fluid index (AFI) less than 5, or maximum vertical pocket (MVP) less than; OR c) documentation of the membrane rupture by one of the following diagnostic tests: 1) Positive intra-amniotic dye-injection method; 2) Positive result on amniotic fluid alpha-fetoprotein test kit; 3) Amniotic fluid pH measurement (nitrazine paper test); 4) Amniotic fluid placental alpha macroglobulin-1 protein assay (PAMG-1) test (AmniSure test); 5) Amniotic fluid insulin-like growth factor binding protein (IGFBP-1) test (Actim PROM test).","GAIA Level 2 Assessment of Premature Preterm Rupture of Membranes | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Assessment of Premature Preterm Rupture of Membranes | Level 2 Assessment of Premature Preterm Rupture of Membranes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509187","GAIA Level 3 Assessment of Premature Preterm Rupture of Membranes","C127946","GAIA Level 3 Assessment of Premature Preterm Rupture of Membranes is defined by three criteria: first, presentation between 24 0/7 and 36 6/7 weeks gestation with a clinical history of rupture of membranes, the fluid from which may be any color, including clear, blood-tinged, meconium-tinged (fetal stool), or purulent-tinged (yellowish, suggesting infection); second, the patient is determined to not be in preterm labor (having less than or equal to 4 contractions per hour documented clinically or on tocodynometer, with less than 2cm cervical dilation); third, visible leakage of presumed amniotic fluid, which may be on vaginal speculum examination (pooling in the vagina), on inspection of the perineum (wet perineum due to leakage of fluid from the vagina), or fluid soaked cloth/clothes/sanitary pad.","GAIA Level 3 Assessment of Premature Preterm Rupture of Membranes | Global Alignment of Immunization safety Assessment in pregnancy Level 3 Assessment of Premature Preterm Rupture of Membranes | Level 3 Assessment of Premature Preterm Rupture of Membranes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509148","GAIA Level 1 Assessment of Preterm Labor","C127947","GAIA Level 1 Assessment of Preterm Labor is defined by three criteria: first, confirmed delivery of a fetus between 24 0/7 and 36 6/7 weeks gestation; second, greater than four uterine contractions per hour as determined by a tocodynometer OR transvaginal ultrasound during a two hour period; third, documented change in length or dilation of the cervix by physical examination, with clinical criteria obtained by digital examination, including: a) Cervical dilation of two centimeters or more at the internal os; b) Cervical length of one centimeter or less; c) greater than or equal to 50% effacement of the cervix.","GAIA Level 1 Assessment of Preterm Labor | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Assessment of Preterm Labor | Level 1 Assessment of Preterm Labor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509167","GAIA Level 2 Assessment of Preterm Labor","C127948","GAIA Level 2 Assessment of Preterm Labor is defined by three criteria: first, confirmed delivery of a fetus between 24 0/7 and 36 6/7 weeks gestation; second, greater than four uterine contractions per hour as determined by a tocodynometer OR by clinical assessment; third, documented change in length or dilation of the cervix by physical examination, with clinical criteria obtained by digital examination, including: a) Cervical dilation of two centimeters or more at the internal os; b) Cervical length of one centimeter or less; c) greater than or equal to 50% effacement of the cervix.","GAIA Level 2 Assessment of Preterm Labor | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Assessment of Preterm Labor | Level 2 Assessment of Preterm Labor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509188","GAIA Level 3 Assessment of Preterm Labor","C127949","GAIA Level 3 Assessment of Preterm Labor is defined by three criteria: first, confirmed delivery of a fetus between 24 0/7 and 36 6/7 weeks gestation; second, greater than four uterine contractions per hour as determined by clinical assessment; third, documented changes in cervical dilation or effacement during a two hour period.","GAIA Level 3 Assessment of Preterm Labor | Global Alignment of Immunization safety Assessment in pregnancy Level 3 Assessment of Preterm Labor | Level 3 Assessment of Preterm Labor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509190","GAIA Level 3 Intrapartum Stillbirth","C128024","GAIA Level 3 Intrapartum Stillbirth is defined by four criteria: first, delivery of an infant who is reported to have no of signs of life at birth, including the following: no spontaneous movements, no umbilical cord pulse, no heartbeat, no crying, no spontaneous respirations or chest movement, and full body cyanosis; second, evidence of a live fetus prior to the onset of labor (maternal report of fetal movement prior to the onset of labor OR auscultation of fetal heart tones). NOTE: in the absence of evidence of a live fetus prior to the onset of labor, the fetal death should be reported as a stillbirth or an antepartum stillbirth; third, a non-attended delivery followed by a post-delivery physical examination that is performed by a health care professional who meets the standard of care in the immediate health care setting, and that is consistent with intrapartum death, or a verbal history that is provided by a trained health care provider, a non-medical witness, or the mother of the fetus that documents a fetus born with no signs of life and who was unresponsive to resuscitation efforts immediately after birth; fourth, gestational age within the pre-defined range for selected stillbirth definition as assessed by maternal and/or fetal parameters (level 2-3 in GA assessment algorithm).","GAIA Level 3 Intrapartum Stillbirth | Global Alignment of Immunization safety Assessment in pregnancy Level 3 Intrapartum Stillbirth | Level 3 Intrapartum Stillbirth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509204","GAIA Level 4 Intrapartum Stillbirth","C128025","GAIA Level 4 Intrapartum Stillbirth is defined by two criteria: first, a report of stillbirth, but the fetus is unavailable for physical examination after birth so no objective assessment can be made; second, maternal information is insufficient to assess gestational age.","GAIA Level 4 Intrapartum Stillbirth | Global Alignment of Immunization safety Assessment in pregnancy Level 4 Intrapartum Stillbirth | Level 4 Intrapartum Stillbirth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507919","Anti-OX40 Antibody BMS 986178","C128026","An agonistic monoclonal antibody against the co-stimulatory receptor OX40 (CD134; TNFRSF4), with potential immunostimulatory activity. Upon administration, anti-OX40 monoclonal antibody BMS 986178 selectively binds to and activates the OX40 receptor, by mimicking the action of the endogenous OX40 ligand (OX40L). OX40 receptor activation induces proliferation of memory and effector T-lymphocytes. In the presence of tumor-associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor family (TNFRSF), is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T-cells.","Anti-OX40 Antibody BMS 986178 | BMS 986178 | BMS-986178",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2366045","Gluten-free DHA/EPA/GLA/Antioxidant-rich Nutritional Liquid","C128027","A gluten- and lactose-free, energy-rich, calorie-dense, non-complete liquid nutritional supplement enriched with eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), gamma-linolenic acid (GLA) and antioxidants, with potential anti-cachexic and anti-inflammatory activities. The nutritional liquid also contains protein, in the form of sodium and calcium caseinates, carbohydrates, as maltodextrin and sucrose, fat, as canola, borage, and marine oils, L-carnitine, taurine, and several other vitamins and minerals. Upon oral intake of the gluten-free DHA/EPA/GLA/antioxidant-rich nutritional liquid, the essential omega-3 polyunsaturated fatty acids EPA and DHA, derived from refined marine oil, and GLA, derived from borage oil, are incorporated into cell membranes and affect the production of pro-inflammatory mediators, which elicits an anti-inflammatory effect and may also prevent infections. The antioxidants, including ascorbic acid, beta-carotene, and tocopherols, neutralize free radicals, thereby protecting tissues and organs from oxidative damage. Medium chain triglycerides (MCT) and large chain triglycerides (LCT) in this supplement enhance fat absorption and increase calorie intake. Additionally, this nutritional supplement may prevent malnutrition and weight loss.","Gluten-free DHA/EPA/GLA/Antioxidant-rich Nutritional Liquid | Oxepa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507922","Anti-GITR Monoclonal Antibody GWN 323","C128028","An anti-human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor superfamily, member 18; TNFRSF18; GITR; CD357) agonistic monoclonal antibody, with potential immune checkpoint modulating activity. Anti-GITR antibody GWN 323 binds to and activates GITRs found on multiple types of T-cells. This stimulates the immune system, induces both the activation and proliferation of tumor-antigen-specific T effector cells (Teff), and suppresses the function of activated T regulatory cells (Tregs). This leads to tumor cell eradication. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B-cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress both Teffs and T-cell receptor (TCR) signaling.","Anti-GITR Monoclonal Antibody GWN 323 | GWN 323 | GWN-323 | GWN323",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520316","Whole Blood or Product Procurement","C133294","The procurement of whole blood or blood products for transfusion or further manufacturing into injectable or non-injectable products.","Whole Blood or Product Procurement | Collect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3713057","Caplacizumab","C128625","A humanized, bivalent anti-von Willebrand factor (VWF) nanobody, with potential anti-platelet and anti-thrombotic activities. Upon administration, caplacizumab specifically binds, with its two identical monovalent moieties, to the A1 domain of the adhesive glycoprotein VWF, thereby inhibiting and neutralizing VWF activity. This prevents the interaction of ultra-large VWF (ULVWF) with the platelet glycoprotein (GP)Ib-IX-V receptor complex, and prevents ULVWF-mediated platelet adhesion, and aggregation, which reduces thrombus formation. VWF is a glycoprotein and plays a key role in blood coagulation. Increased VWF, which is seen in a number of diseases, is associated with an increased risk in thrombosis; in thrombotic thrombocytopenic purpura (TTP), increased levels of ULVWF and thus increased and abnormal platelet aggregation are seen due to impaired breakdown of ULVWF. The nanobody formulation allows for rapid distribution, onset of action and clearance. The nanobody is based on the smallest functional fragments of the immunoglobulin heavy-chain variable domains that occur naturally in the Camelidae family.","Caplacizumab | ALX 0081 | ALX 0681 | ALX-0081 | ALX-0681 | ALX0081 | ALX0681 | CAPLACIZUMAB | Cablivi | Caplacizumab-yhdp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509742","MRI-Guided Transurethral Ultrasound Ablation","C128626","The use of high-intensity ultrasound, via a transurethral approach and using MRI-guidance, to destroy tissue.","MRI-Guided Transurethral Ultrasound Ablation | MRI-TULSA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509686","Anti-TIM3 Checkpoint Inhibitor TSR-022","C128627","A monoclonal antibody against the inhibitory T-cell receptor, T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, cobolimab binds to TIM-3 expressed on certain T-cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.","Cobolimab | Anti-TIM3 Checkpoint Inhibitor TSR-022 | Anti-TIM3 Monoclonal Antibody TSR-022 | COBOLIMAB | Immunoglobulin G4, Anti-(Hepatitis A Virus Cellular Receptor 2 (havcr2)) (Humanized Clone ABT2 Gamma4-chain), Disulfide with Humanized Clone ABT2 Kappa-chain, Dimer | TSR-022",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508962","Ph Unknown","C128628","Philadelphia chromosome abnormality, t(9;22)(q34;q11) was not tested; therefore it is not known whether it is present or not.","Ph Unknown | Philadelphia Chromosome Status Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509011","B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","C128629","A B acute lymphoblastic leukemia (B-ALL) that does not have the cytogenetic abnormality t(9;22)(q34;q11.2). Most cases of B-ALL do not have this translocation.","B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | B-Cell Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Ph1-Negative ALL | Ph1-Negative Acute Lymphoblastic Leukemia | Philadelphia Chromosome Negative ALL | Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia | Philadelphia-Negative ALL | Philadelphia-Negative Acute Lymphoblastic Leukemia | Precursor B Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Precursor B-Lymphoblastic Leukemia, Philadelphia Chromosome Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3492864","mTOR Kinase Inhibitor PP242","C128632","No value exists.","mTOR Kinase Inhibitor PP242 | 2-(4-Amino-1-isopropyl-1H-pyrazolo(3,4-d)pyrimidin-3-yl)-1H-indol-5-ol | PP-242 | PP242",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0105729","Proteasome Inhibitor MG-132","C128633","No value exists.","Proteasome Inhibitor MG-132 | Benzyloxycarbonylleucyl-leucyl-leucine Aldehyde | MG 132 | MG-132 | S)-N-((Phenylmethoxy)carbonyl)-L-leucyl-N-(1-formyl-3-methylbutyl)-L-leucinamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0076374","Thapsigargin","C128634","No value exists.","Thapsigargin | Octanoic Acid, 6-(Acetyloxy)-2,3,3a,4,5,6,6a,7,8,9b-decahydro-3,3a-dihydroxy-3,6,9-trimethyl-8-((2-methyl-1-oxo-2-butenyl)oxy)-2-oxo-4-(1-oxobutoxy)azuleno(4,5-b)furan-7-yl Ester, (3S-(3alpha,3abeta,4alpha,6beta,6abeta,7beta,8alpha(Z),9balpha))- | THAPSIGARGIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509149","GAIA Level 1 Assessment of Provider Initiated Preterm Delivery","C127950","GAIA Level 1 Assessment of Provider-Initiated Preterm Delivery is defined by three criteria: first, the patient is determined to be between 24 0/7 and 36 6/7 weeks gestation; second, documentation in the healthcare record as noted by the delivering provider of the absence of any signs or symptoms of spontaneous onset of preterm labor; third, additional documentation of the need to induce labor or to perform a cesarean delivery, resulting in a preterm delivery.","GAIA Level 1 Assessment of Provider Initiated Preterm Delivery | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Assessment of Provider-Initiated Preterm Delivery | Level 1 Assessment of Provider-Initiated Preterm Delivery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2363961","Vaginal Tubulosquamous Polyp","C128061","A rare benign lesion that arises from the vagina. It is characterized by the presence of squamous epithelial and tubular structures in a fibrovascular stroma.","Vaginal Tubulosquamous Polyp | Skene Duct Cyst | Vaginal Ectopic Prostatic Tissue",,,,,,,,,,,,,,,"36717631","Cyst of Skene's duct",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509797","Vaginal Transitional Cell Metaplasia","C128062","Vaginal metaplasia in which the vaginal surface squamous epithelium resembles benign transitional urothelium.","Vaginal Transitional Cell Metaplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0269214","Vaginal Adenosis","C128063","The presence of glandular structures in the vagina.","Vaginal Adenosis | ",,,,,,,,,,,,,,,"4242227","Vaginal adenosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0156346","Vaginal Endometriosis","C128064","Endometriosis that affects the vagina. It is characterized by the presence of endometrial stroma with or without endometrial-type glands in the vagina.","Vaginal Endometriosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509793","Vaginal Endocervicosis","C128066","A rare benign lesion characterized by the presence of endocervical-type glands in the vaginal wall.","Vaginal Endocervicosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1139952","Actigraph","C128069","A continuous record of body movement obtained from a monitor worn by an individual and that is used to measure rest-activity (sleep-wake) cycles.","Actigraph | Actigram",,,,,,,,,,,,,,,"607185","Actigraph",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509356","Vaginal Neuroendocrine Carcinoma","C128073","A rare neuroendocrine carcinoma that arises from the vagina. This category includes small cell and large cell neuroendocrine carcinoma.","Vaginal Neuroendocrine Carcinoma | Vaginal High Grade Neuroendocrine Carcinoma | Vaginal High Grade Neuroendocrine Neoplasm | Vaginal Neuroendocrine Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042598","Vestibular Nerve","C12820","One of the two branches of cranial nerve VIII (vestibulocochlear nerve), which transmits sensory information transmitted from vestibular hair cells located in the utricle, the saccule, and the three semicircular canals.","Vestibular Nerve | Vestibular Nerve (VIII) | Vestibular Root of Eighth Cranial Nerve",,,,,,,,,,,,,,,"4305167","Vestibular nerve structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0042600","Vestibular Nucleus","C12821","The cranial nuclei, located in both the pons and the medulla, for the vestibular nerve.","Vestibular Nucleus | Vestibular Nuclei",,,,,,,,,,,,,,,"4069764","Vestibular nucleus structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509350","SMN1 wt Allele","C127864","Human SMN1 wild-type allele is located in the vicinity of 5q13.2 and is approximately 29 kb in length. This allele, which encodes survival motor neuron protein, is involved in the modulation of spliceosome assembly. Mutation of the gene is associated with spinal muscular atrophy types 1 through 4.","SMN1 wt Allele | BCD541 | GEMIN1 | SMA | SMA1 | SMA2 | SMA3 | SMA4 | SMN | SMNT | Spinal Muscular Atrophy (Werdnig-Hoffmann Disease, Kugelberg-Welander Disease) Gene | Survival Motor Neuron 1 Protein Gene | Survival of Motor Neuron 1 Gene | Survival of Motor Neuron 1, Telomeric wt Allele | Survival of Motor Neuron, Telomeric Copy Gene | T-BCD541 | TDRD16A | Tudor Domain Containing 16A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2614692","Acidaminococcus intestini","C127680","A species of anaerobic, Gram negative, non-spore-forming and non-motile coccobacilli shaped bacterium in the family Veillonellaceae isolated from the human gastrointestinal tract. A. intestini is oxidase- and catalase-negative and negative for gelatinase and nitrate-reduction tests.","Acidaminococcus intestini | ACIDAMINOCOCCUS INTESTINI",,,,,,,,,,,,,,,"37016249","Acidaminococcus intestini",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319532","Apophysomyces elegans","C127681","A species of filamentous fungi in the order Mucorales that is one of the causative agents of mucormycosis in humans.","Apophysomyces elegans | APOPHYSOMYCES ELEGANS",,,,,,,,,,,,,,,"4324674","Apophysomyces elegans",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1053049","Arthrinium phaeospermum","C127682","A species of dematiaceous anamorphic fungi in the phylum Ascomycota with smooth, hyaline, branched, septate hyphae.","Arthrinium phaeospermum | ARTHRINIUM PHAEOSPERMUM",,,,,,,,,,,,,,,"4212753","Arthrinium phaeospermum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319577","Arthroderma fulvum","C127683","A species of geophilic fungi in the phylum Ascomycota with thin-walled, elongate, ellipsoidal macroconidia having 3 to 6 septa.","Arthroderma fulvum | ARTHRODERMA FULVUM | Microsporum fulvum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0319581","Arthroderma obtusum","C127684","A species of heterothallic fungi in the phylum Ascomycota with small, clavate, thick-walled conidia and usually one septa.","Arthroderma obtusum | ARTHRODERMA OBTUSUM | Microsporum nanum",,,,,,,,,,,,,,,"4032636","Arthroderma obtusum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319582","Arthroderma otae","C127685","A species of zoophilic dermatophyte fungi in the phylum Ascomycota. This species causes superficial infections of the scalp (tinea capitis) in humans.","Arthroderma otae | ARTHRODERMA OTAE | Microsporum canis | Nannizzia otae",,,,,,,,,,,,,,,"4286438","Arthroderma otae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319570","Arthroderma simii","C127687","A species of dermatophyte fungi in the phylum Ascomycota with smooth, thin-walled, cylindrical to fusiform macroconidia. This species causes skin infections in monkeys, chickens, and humans.","Arthroderma simii | ARTHRODERMA SIMII | Trichophyton simii",,,,,,,,,,,,,,,"4185048","Arthroderma simii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319924","Aspergillus versicolor","C127688","A species of slow-growing filamentous fungi in the phylum Ascomycota with long, septate hyphae and conidiophores that terminate in small vesicles. This species is commonly isolated from soil and plant debris and is among the most common of indoor molds.","Aspergillus versicolor | ASPERGILLUS VERSICOLOR | Sterigmatocystis versicolor",,,,,,,,,,,,,,,"4167527","Aspergillus versicolor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0997626","Asterotremella humicola","C127689","A species of psychrotrophic, dimorphic yeast-like fungi in the phylum Basidiomycota and genus Asterotremella found in soil and water. This species has no sexual form.","Asterotremella humicola | ASTEROTREMELLA HUMICOLA | Apiotrichum humicola | Azymoprocandida humicola | Candida humicola | Cryptococcus humicola | Mycotorula humicola | Torula humicola | Vanrija humicola | Vanrijia humicola",,,,,,,,,,,,,,,"4171727","Vanrija humicola",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509102","GAIA Level 4 First Trimester Spontaneous Abortion","C128779","GAIA Level 4 First Trimester Spontaneous Abortion is defined by two criteria: first, it does not qualify as a Level 1, a Level 2, or a Level 3 First Trimester Spontaneous Abortion; second, a maternal self-report or documentation in the medical record of a pregnancy loss without sufficient ultrasound or laboratory evidence to confirm.","GAIA Level 4 First Trimester Spontaneous Abortion | Global Alignment of Immunization safety Assessment in pregnancy Level 4 First Trimester Spontaneous Abortion | Level 4 First Trimester Spontaneous Abortion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0269389","Second Trimester Spontaneous Abortion","C128780","Pregnancy loss between 14 weeks 0 days and 21 weeks 6 days gestation.","Second Trimester Spontaneous Abortion | 2nd Trimester Spontaneous Abortion",,,,,,,,,,,,,,,"4224646","Miscarriage in second trimester",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509083","GAIA Level 1 Second Trimester Spontaneous Abortion","C128781","GAIA Level 1 Second Trimester Spontaneous Abortion is defined by two criteria: first, gestational age is within the pre-defined range for the selected abortion definition as assessed by maternal and/or fetal parameters (Level 1-2) (Brighton Preterm Birth Gestational Age algorithm); second, at least one of the following requirements must be met: a) No visible heartbeat on ultrasound; OR b) Visible expulsion of pregnancy tissues/products of conception on examination of the cervix; OR c) Products of conception found on histopathological evaluation of uterine contents.","GAIA Level 1 Second Trimester Spontaneous Abortion | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Second Trimester Spontaneous Abortion | Level 1 Second Trimester Spontaneous Abortion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509095","GAIA Level 2 Second Trimester Spontaneous Abortion","C128782","GAIA Level 2 Second Trimester Spontaneous Abortion is defined by three criteria: first, it does not qualify as a Level 1 Second Trimester Spontaneous Abortion; second, gestational age is within the pre-defined range for the selected abortion definition as assessed by maternal and/or fetal parameters (Level 3) (Brighton Preterm Birth Gestational Age algorithm); third, one of the following three requirements must be met: a) No visible heartbeat on ultrasound; b) Visible expulsion of pregnancy tissues/products of conception on examination of the cervix; c) Products of conception found on histopathological evaluation of uterine contents.","GAIA Level 2 Second Trimester Spontaneous Abortion | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Second Trimester Spontaneous Abortion | Level 2 Second Trimester Spontaneous Abortion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509103","GAIA Level 4 Second Trimester Spontaneous Abortion","C128783","GAIA Level 4 Second Trimester Spontaneous Abortion is defined by two criteria: first, it does not qualify as either a Level 1 or a Level 2 Second Trimester Spontaneous Abortion; second, a maternal self-report or documentation in the medical record of a pregnancy loss without sufficient ultrasound or laboratory evidence to confirm.","GAIA Level 4 Second Trimester Spontaneous Abortion | Global Alignment of Immunization safety Assessment in pregnancy Level 4 Second Trimester Spontaneous Abortion | Level 4 Second Trimester Spontaneous Abortion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509500","NCIt Antineoplastic Agent Terminology","C128784","A terminology subset in NCI Thesaurus (NCIt) containing any agent that has known or potential antineoplastic activity. The subset includes FDA approved antineoplastic agents, agents that either are or once were in clinical trial (CT) specifically for their antineoplastic activity as well as some additional investigational agents that may have antineoplastic activity. Included in this list are conventional antineoplastic agents, specific tumor-targeting agents, and cancer immunotherapeutics. Excluded from this list are: agents that treat cancer-related conditions; cancer diagnostics or agents used for tumor imaging; agents that treat drug-related adverse effects; any agent that increases an antineoplastic agent's efficacy or pharmacokinetic profile but does not have an antineoplastic effect by itself, including immunoadjuvants that boost efficacy of antineoplastic vaccines; and antineoplastic agents that are conjugated with a radioisotope and are in CT for efficacy and/or ADME studies.","NCIt Antineoplastic Agent Terminology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1039767","Monascus ruber","C127737","A genus of salt- and acid-tolerant fungi in the phylum Ascomycota. This species is used in the production of pigments.","Monascus ruber | MONASCUS RUBER",,,,,,,,,,,,,,,"4218830","Monascus ruber",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319504","Mucor ramosissimus","C127738","A species of saprobic fungi in the phylum Zygomycota with sporangiophores that are hyaline, slightly roughened, tapering towards the apex, and erect with repeated sympodial branching.","Mucor ramosissimus | MUCOR RAMOSISSIMUS",,,,,,,,,,,,,,,"4194782","Mucor ramosissimus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0031524","Phialophora verrucosa","C127739","A species of dematiaceous fungi in the phylum Ascomycota that produces conidia from phialides with conspicuous darkened collarettes. This species is a causative agent of chromoblastomycosis.","Phialophora verrucosa | PHIALOPHORA VERRUCOSA",,,,,,,,,,,,,,,"4284838","Phialophora verrucosa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0032009","Posterior Lobe of the Pituitary Gland","C12773","The neural or post-neural lobe of the pituitary gland which stores and releases vasopressin, oxytocin, and neurophysins.","Posterior Lobe of the Pituitary Gland | Neurohypophysis | Posterior Lobe of Pituitary | Posterior Lobe of Pituitary Gland | Posterior Pituitary Gland",,,,,,,,,,,,,,,"4292400","Neurohypophysis structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4048606","Pichia fermentans","C127740","A species of yeast in the phylum Ascomycota that occurs singly, in pairs, or in short chains and that produces 2-4 hat-shaped ascospores per ascus. This species is a normal member of the flora of skin, mouth, and vagina, and is also found in the environment.","Pichia fermentans | Candida fimetaria | Candida lambica | Mycoderma lambica | PICHIA FERMENTANS",,,,,,,,,,,,,,,"37018625","Pichia fermentans",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319613","Piedraia hortae","C127741","A species of dermatophytic fungi in the phylum Ascomycota. This species is a causative agent of black piedra.","Piedraia hortae | PIEDRAIA HORTAE",,,,,,,,,,,,,,,"4232464","Piedraia hortae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0260109","Purpureocillium lilacinum","C127742","A species of saprobic, filamentous fungi in the phylum Ascomycota. Depending upon available nutrients in the environment P. lilacinum may be entomopathogenic, mycoparasitic, saprophytic, or nematophagous. Human infections are rare, but may occur in patients with compromised immune systems or intraocular lens implants.","Purpureocillium lilacinum | PURPUREOCILLIUM LILACINUM | Paecilomyces lilacinus | Penicillium lilacinum | Purpureocillium lilacinus",,,,,,,,,,,,,,,"4348151","Purpureocillium lilacinum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1189268","Rhizopus oryzae","C127743","A species of filamentous fungi in the phylum Zygomycota characterized by sporangiophores that arise from nodes at the point where the rhizoids are formed. R. oryzae is a causative agent of mucormycosis in immunocompromised individuals. This species is used in the fermentation of tempeh.","Rhizopus oryzae | RHIZOPUS ORYZAE | Rhizopus arrhizus | Rhizopus chiuniang | Rhizopus formosaensis | Rhizopus hangchow | Rhizopus javanicus Y. Takeda | Rhizopus liquefaciens | Rhizopus peka | Rhizopus pseudochinensis | Rhizopus suinus | Rhizopus tamarii | Rhizopus thermosus | Rhizopus tritici",,,,,,,,,,,,,,,"4337256","Rhizopus arrhizus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026501","Scedosporium boydii","C127744","A species of saprophytic fungi in the phylum frequently isolated from agricultural soil and polluted water. It is the causative agent of human scedosporiosis.","Scedosporium boydii | Allescheria boydii | Petriellidium boydii | Pseudallescheria boydii | SCEDOSPORIUM BOYDII",,,,,,,,,,,,,,,"4087582","Scedosporium boydii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1677664","Scolecobasidium terreum","C127745","A species of soil-borne, saprotrophic fungi in the phylum Ascomycota. S. terreum is the type species for Scolecobasidium.","Scolecobasidium terreum | SCOLECOBASIDIUM TERREUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420258","SMN2 Gene","C127867","This gene plays a role in the modulation of spliceosome formation.","SMN2 Gene | SMN2 | Survival of Motor Neuron 2, Centromeric Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509024","SMN2 wt Allele","C127869","Human SMN2 wild-type allele is located in the vicinity of 5q13.2 and is approximately 29 kb in length. This allele, which encodes survival motor neuron protein, is involved in the assembly of small nuclear ribonucleoproteins. Mutation of the gene is associated with sporadic adult-onset lower motor neuron disease (LMND) and a modified form of spinal muscular atrophy type 3.","SMN2 wt Allele | BCD541 | C-BCD541 | GEMIN1 | SMNC | Survival of Motor Neuron 2, Centromeric wt Allele | Survival of Motor Neuron, Centromeric Copy Gene | TDRD16B | Tudor Domain Containing 16B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1568617","Survival Motor Neuron Protein, Human","C127871","Survival motor neuron protein (294 aa, ~32 kDa) is encoded by the human SMN1 and SMN2 genes. This protein plays a role in the assembly of small nuclear ribonucleoproteins.","Survival Motor Neuron Protein | Component of Gems 1 | Gemin-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2681845","MSLNL Gene","C127874","This gene may be involved in cell-matrix adhesion.","MSLNL Gene | MSLNL | Mesothelin-Like Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509025","MSLNL wt Allele","C127876","Human MSLNL wild-type allele is located in the vicinity of 16p13.3 and is approximately 14 kb in length. This allele, which encodes mesothelin-like protein, may play a role in cell adhesion.","MSLNL wt Allele | C16orf37 | Chromosome 16 Open Reading Frame 37 Gene | MPFL | Mesothelin-Like wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509162","GAIA Level 1 Preeclampsia with Severe Features","C128006","GAIA Level 1 Preeclampsia with Severe Features is defined by three criteria: first, the gestational age of the pregnancy must be greater than or equal to 20 weeks; second, a diagnosis of new onset maternal hypertension (systolic blood pressure greater than or equal to 140mmHg and/or diastolic blood pressure greater than or equal to 90mmHg) that is sustained on two measurements over a minimum of one hour); third, the presence of one or more of the following requirements: a) Systolic blood pressure greater than or equal to 160mmHg and/or diastolic blood pressure greater than or equal to 110mmHg, which is confirmed after only minutes; b) Development of severe, persistent headache; c) Development of visual changes; d) Eclampsia; e) New onset thrombocytopenia (platelets less than 100,000/microliter); f) New onset unremitting epigastric pain; g) AST and ALT elevated to twice the upper limit of normal; h) Evidence of liver capsular hematoma or liver rupture (diagnosed on clinical exam or with imaging); i) Worsening renal function, as evidenced by serum creatinine level greater than 1.1 mg/dL, a doubling of the serum creatinine (absent other renal disease), or oliguria (less than 500 cc/24 hours); j) Pulmonary edema (confirmed on either imaging with chest x-ray or on clinical exam).","GAIA Level 1 Preeclampsia with Severe Features | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Preeclampsia with Severe Features | Level 1 Preeclampsia with Severe Features",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0320069","Aureobasidium pullulans","C127690","A species of yeast-like saprophytic fungi in the phylum Ascomycota with slimy masses of conidia and chains of one to two-celled, thick-walled, darkly pigmented arthroconidia.","Aureobasidium pullulans | AUREOBASIDIUM PULLULANS | Aureobasidium pullulans var. pullulans",,,,,,,,,,,,,,,"4307325","Aureobasidium pullulans",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1641393","Bocaparvovirus","C127691","A genus of non-enveloped single-stranded DNA viruses in the family Parvoviridae with a 21-22 nm diameter capsid and a genome of about 5.5kb. Bocaparvoviruses encode a novel protein called NP1 that is not present in parvoviruses from other genera.","Bocaparvovirus | BOCAPARVOVIRUS | Bocavirus",,,,,,,,,,,,,,,"4330091","Genus Bocavirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509573","Vulvar Lipoma","C128270","An uncommon benign neoplasm of the vulva, composed of lobules of mature adipocytes.","Vulvar Lipoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509569","Vulvar Fibrolipoma","C128271","A lipoma of the vulva with a predominant fibrous component.","Vulvar Fibrolipoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509367","Vulvar Superficial Myofibroblastoma","C128272","An uncommon benign polypoid or nodular mesenchymal neoplasm that arises in the vulvar region. It is characterized by the presence of oval or spindle-shaped cells in a collagenous stroma and is separated from the epidermis by a variably thick Grenz zone.","Vulvar Superficial Myofibroblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509567","Vulvar Alveolar Rhabdomyosarcoma","C128273","An extremely rare malignant mesenchymal neoplasm of the vulva exhibiting skeletal muscle differentiation with an alveolar pattern.","Vulvar Alveolar Rhabdomyosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509371","CASP3 Gene Product","C128276","A protein encoded by the CASP3 gene.","CASP3 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0319945","Scopulariopsis brevicaulis","C127746","A genus of anamorphic fungi in the family Microascaceae. This species is a causative agent of human nail infections and deep fungal infections.","Scopulariopsis brevicaulis | Microascus brevicaulis | SCOPULARIOPSIS BREVICAULIS",,,,,,,,,,,,,,,"4138373","Scopulariopsis brevicaulis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1011787","Setosphaeria rostrata","C127747","A species of fungi in the phylum Ascomycota characterized by mature conidia with a distinct protruding hilum. This species is commonly found in soils, but is an opportunistic agent of sinusitis, keratitis, and CNS vasculitis as well as cutaneous and subcutaneous mycoses.","Setosphaeria rostrata | Exserohilum rostratum | SETOSPHAERIA ROSTRATA",,,,,,,,,,,,,,,"4330857","Setosphaeria rostrata",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0446018","Sporidiobolus salmonicolor","C127748","A species of yeast-like fungus in the phylum Basidiomycota. The asexual form of S. salmonicolor is characterized by pink, ballistosporic yeast that are forcibly ejected into the air upon maturity. This species is considered an opportunistic fungal pathogen of immunocompromised individuals.","Sporidiobolus salmonicolor | Aessosporon salmonicolor | SPORIDIOBOLUS SALMONICOLOR | Sporobolomyces salmonicolor",,,,,,,,,,,,,,,"4348452","Sporobolomyces salmonicolor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038033","Sporothrix schenckii","C127749","A species of thermally dimorphic fungi in the phylum Ascomycota. In the environment S. schenckii is found growing as filamentous hyphae; in host tissue it is found as a yeast. This species is the causative agent of sporotrichosis.","Sporothrix schenckii | SPOROTHRIX SCHENCKII",,,,,,,,,,,,,,,"4139132","Sporothrix schenkii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0149566","Middle Cerebral Artery","C12830","The largest terminal branch of the internal carotid artery that runs along the fissure of Sylvius with branches supplying parts of the fontal, parietal and temporal lobes as well as the basal ganglia and internal capsule.","Middle Cerebral Artery | MCA | MIDDLE CEREBRAL ARTERY | Middle Cerebral Arteries",,,,,,,,,,,,,,,"4066167","Structure of middle cerebral artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508927","PGR Gene Product","C128314","A protein encoded by the PGR gene.","PGR Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509743","MSLN Gene Product","C128316","A protein encoded by the MSLN gene.","MSLN Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509181","GAIA Level 2 Preeclampsia with Severe Features","C128007","GAIA Level 2 Preeclampsia with Severe Features is defined by three criteria: first, the gestational age of the pregnancy must be greater than or equal to 20 weeks; second, a diagnosis of new onset maternal hypertension (systolic blood pressure greater than or equal to 140mmHg and/or diastolic blood pressure greater than or equal to 90mmHg) that is sustained on two measurements for a minimum of one hour; third, the diagnosis of new onset nausea and vomiting.","GAIA Level 2 Preeclampsia with Severe Features | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Preeclampsia with Severe Features | Level 2 Preeclampsia with Severe Features",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509143","GAIA Insufficient Evidence for Diagnosis of Preeclampsia with Severe Features","C128008","GAIA Insufficient Evidence for Diagnosis of Preeclampsia with Severe Features is a pregnancy with a gestational age greater than or equal to 20 weeks and the inability to measure blood pressure.","GAIA Insufficient Evidence for Diagnosis of Preeclampsia with Severe Features | Global Alignment of Immunization safety Assessment in pregnancy Insufficient Evidence for Diagnosis of Preeclampsia with Severe Features | Insufficient Evidence for Preeclampsia with Severe Features",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509150","GAIA Level 1 Gestational Hypertension","C128009","GAIA Level 1 Gestational Hypertension is defined by four criteria: first, the gestational age of the pregnancy must be greater than or equal to 20 weeks; second, a diagnosis of new onset maternal hypertension (systolic blood pressure greater than or equal to 140mmHg and/or diastolic blood pressure greater than or equal to 90mmHg) that is sustained on two measurements over a minimum of one hour; third, the absence of any severe features (see preeclampsia with severe features category); fourth, the absence of proteinuria (as defined by 24 hour urine collection less than 300 mg, and spot protein:creatinine ratio less than 0.3).","GAIA Level 1 Gestational Hypertension | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Gestational Hypertension | Level 1 Gestational Hypertension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509169","GAIA Level 2 Gestational Hypertension","C128010","GAIA Level 2 Gestational Hypertension is defined by four criteria: first, the gestational age of the pregnancy must be greater than or equal to 20 weeks; second, a diagnosis of new onset maternal hypertension (systolic blood pressure greater than or equal to 140mmHg and/or diastolic blood pressure greater than or equal to 90mmHg) that is sustained on two measurements for a minimum of one hour; third, the absence of any severe features (see preeclampsia with severe features category); fourth, the absence of proteinuria (as defined by urine dipstick result of negative or trace).","GAIA Level 2 Gestational Hypertension | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Gestational Hypertension | Level 2 Gestational Hypertension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509073","GAIA Insufficient Evidence for Diagnosis of Gestational Hypertension","C128011","GAIA Insufficient Evidence for Diagnosis of Gestational Hypertension is defined by two criteria: first, a pregnancy with gestational age greater than or equal to 20 weeks; second, one or more of the following requirements: a) The inability to measure blood pressure; b) The inability to evaluate for proteinuria.","GAIA Insufficient Evidence for Diagnosis of Gestational Hypertension | Global Alignment of Immunization safety Assessment in pregnancy Insufficient Evidence for Diagnosis of Gestational Hypertension | Insufficient Evidence for Gestational Hypertension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509141","GAIA Gestational Age Levels of Diagnostic Certainty","C128012","A classification of gestational age levels developed by the Global Alignment of Immunization safety Assessment in pregnancy.","GAIA Gestational Age Levels of Diagnostic Certainty | Global Alignment of Immunization safety Assessment in pregnancy Gestational Age Levels of Diagnostic Certainty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509145","GAIA Level 1 Assessment of Gestational Age","C128013","GAIA Level 1 Assessment of Gestational Age is defined by the presence of at least one of the following criteria: a) the last menstrual period (LMP) or intrauterine insemination (IUI) date or embryo transfer (ET) date with confirmatory first trimester scan (less than or equal to 13 6/7 weeks); OR b) first trimester scan (less than or equal to 13 6/7 weeks).","GAIA Level 1 Assessment of Gestational Age | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Assessment of Gestational Age | Level 1 Assessment of Prematurity and Gestational Age",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507934","Selective Estrogen Receptor Degrader LSZ102","C128280","An selective estrogen receptor (ER) degrader (SERD), with potential antineoplastic activity. Upon administration of LSZ102, this agent binds to the ER and induces the degradation of the receptor. This prevents ER activation and ER-mediated signaling, and inhibits the growth and survival of ER-expressing cancer cells.","Selective Estrogen Receptor Degrader LSZ102 | LSZ 102 | LSZ-102 | LSZ102 | SERD LSZ 102 | SERD LSZ102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507935","PDCD-1 Knockout Autologous T-lymphocytes","C128281","A population of engineered autologous T-lymphocytes in which the gene encoding for the programmed cell death protein 1 (PDCD-1) is deleted, with potential immunomodulating activity. Following collection of peripheral blood lymphocytes and selection of T-cells, the PDCD-1 gene was knocked out and the T-cells were expanded. Upon reinfusion of the PDCD-1 knockout T-lymphocytes, these T-cells target and lyse cancer cells. The PDCD-1 protein, found on activated T-cells and often overexpressed on T-cells in cancer patients, negatively regulates T-cell activity; it plays a key role in immune evasion and prevents tumor cell lysis. PDCD-1 knockout enhances cytotoxicity and T-cell-mediated anti-tumor immune responses.","PDCD-1 Knockout Autologous T-lymphocytes | PD-1 Knockout Autologous T-cells | PD-1-disrupted Autologous T-lymphocytes | PDCD-1 Knockout Autologous T Lymphocytes | PDCD1 Gene Knockout Autologous T-cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508997","TRAP1 wt Allele","C127911","Human TRAP1 wild-type allele is located in the vicinity of 16p13.3 and is approximately 66 kb in length. This allele, which encodes heat shock protein 75 kDa, mitochondrial, plays a role in both ATPase activity and protein folding.","TRAP1 wt Allele | HSP 75 | HSP75 | HSP90L | TNF Receptor Associated Protein 1 wt Allele | TNFR-Associated Protein 1 Heat-Shock Protein, 75-kD Gene | TRAP-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1430180","Heat Shock Protein 75 kDa, Mitochondrial, Human","C127912","Heat shock protein 75 kDa, mitochondrial (704 aa, ~80 kDa) is encoded by the human TRAP1 gene. This protein is involved in mitochondrial protein folding.","Heat Shock Protein 75 kDa, Mitochondrial | HSP 75 | HSP90-Like Protein | TNF Receptor-Associated Protein 1 | TNFR-Associated Protein 1 | TRAP-1 | TRAP1 | Tumor Necrosis Factor Type 1 Receptor-Associated Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508998","TWIST2 wt Allele","C127914","Human TWIST2 wild-type allele is located in the vicinity of 2q37.3 and is approximately 63 kb in length. This allele, which encodes twist-related protein 2, is involved in the modulation of osteogenesis. Mutation of the gene is associated with Ablepharon-macrostomia syndrome, Barber-Say syndrome, and Setleis type focal facial dermal dysplasia 3.","TWIST2 wt Allele | AMS | BBRSAY | BHLHA39 | DERMO1 | Dermis-Expressed Protein 1, Mouse, Homolog of Gene | FFDD3 | SETLSS | Twist Family bHLH Transcription Factor 2 wt Allele | Twist Homolog 2 (Drosophila) Gene | Twist, Drosophila, Homolog of, 2 Gene | bHLHa39",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1435014","Twist-Related Protein 2, Human","C127916","Twist-related protein 2 (160 aa, ~18 kDa) is encoded by the human TWIST2 gene. This protein plays a role in transcriptional regulation and osteogenesis.","Twist-Related Protein 2 | Class A Basic Helix-Loop-Helix Protein 39 | Dermis-Expressed Protein 1 | Dermo-1 | Twist Basic Helix-Loop-Helix Transcription Factor 2 | Twist Homolog 2 | Twist Related Protein 2 | Twist-Related bHLH Protein Dermo1 | bHLHa39",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509062","UGCG wt Allele","C127918","Human UGCG wild-type allele is located in the vicinity of 9q31 and is approximately 39 kb in length. This allele, which encodes ceramide glucosyltransferase protein, plays a role in glycosphingolipid synthesis.","UGCG wt Allele | GCS | GLCT1 | UDP-Glucose Ceramide Glucosyltransferase wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0163410","Ceramide Glucosyltransferase","C127919","Ceramide glucosyltransferase (394 aa, ~45 kDa) is encoded by the human UGCG gene. This protein is involved in the glycosylation of N-acylsphingosine.","Ceramide Glucosyltransferase | CERAMIDE GLUCOSYLTRANSFERASE | EC 2.4.1.80 | GCS | GLCT-1 | Glucosylceramide Synthase | UDP-Glucose Ceramide Glucosyltransferase | UDP-Glucose:N-Acylsphingosine D-Glucosyltransferase | UGCG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512176","NCCN-FACT FBLSI-18 Version 2 - I Feel Weak All Over","C129173","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I feel weak all over.","NCCN-FACT FBLSI-18 Version 2 - I Feel Weak All Over | FAC028-I Feel Weak All Over | FAC02804",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512174","NCCN-FACT FBLSI-18 Version 2 - I Feel Light-headed","C129174","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I feel light-headed (dizzy).","NCCN-FACT FBLSI-18 Version 2 - I Feel Light-headed | FAC028-I Feel Light-headed | FAC02805",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512182","NCCN-FACT FBLSI-18 Version 2 - Trouble Meeting Needs of Family","C129175","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) Because of my physical condition, I have trouble meeting the needs of my family.","NCCN-FACT FBLSI-18 Version 2 - Trouble Meeting Needs of Family | FAC028-Trouble Meeting Needs of Family | FAC02806",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512180","NCCN-FACT FBLSI-18 Version 2 - I Have a Good Appetite","C129176","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I have a good appetite.","NCCN-FACT FBLSI-18 Version 2 - I Have a Good Appetite | FAC028-I Have a Good Appetite | FAC02807",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512166","NCCN-FACT FBLSI-18 Version 2 - Able to Have, Maintain Erection","C129177","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) (For men only) I am able to have and maintain an erection.","NCCN-FACT FBLSI-18 Version 2 - Able to Have, Maintain Erection | FAC028-Able to Have/Maintain Erection | FAC02808",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512172","NCCN-FACT FBLSI-18 Version 2 - I Am Sleeping Well","C129178","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I am sleeping well.","NCCN-FACT FBLSI-18 Version 2 - I Am Sleeping Well | FAC028-I Am Sleeping Well | FAC02809",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512183","NCCN-FACT FBLSI-18 Version 2 - Worry My Condition Will Get Worse","C129179","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I worry that my condition will get worse.","NCCN-FACT FBLSI-18 Version 2 - Worry My Condition Will Get Worse | FAC028-Worry My Condition Will Get Worse | FAC02810",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509710","Childhood Infectious Disorder","C128321","An infectious disorder that occurs in childhood.","Childhood Infectious Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031157","Peritonsillar Abscess","C128322","An abscess that develops in the space surrounding one or both palatine tonsils.","Peritonsillar Abscess | Quinsy",,,,,,,,,,,,,,,"440751","Peritonsillar abscess",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0155842","Parapharyngeal Abscess","C128323","An abscess that develops in the soft tissues of the lateral pharyngeal space.","Parapharyngeal Abscess | Lateral Pharyngeal Abscess",,,,,,,,,,,,,,,"257008","Parapharyngeal abscess",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0155843","Retropharyngeal Abscess","C128324","An abscess that develops in the soft tissues behind the posterior pharyngeal wall.","Retropharyngeal Abscess | ",,,,,,,,,,,,,,,"437580","Retropharyngeal abscess",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509767","Prevertebral Abscess","C128325","An abscess that develops in the tissues within the prevertebral fascia.","Prevertebral Abscess | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0243001","Intra-abdominal Abscess","C128326","An abscess within the abdomen.","Intra-abdominal Abscess | ",,,,,,,,,,,,,,,"4326255","Abdominal abscess",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509168","GAIA Level 2 Assessment of Provider Initiated Preterm Delivery","C127951","GAIA Level 2 Assessment of Provider-Initiated Preterm Delivery is defined by three criteria: first, the patient is determined to be between 24 0/7 and 36 6/7 weeks gestation; second, a report from the delivering provider, based on recall, that there were no signs or symptoms of the spontaneous onset of preterm labor; third, additional documentation of the need to induce labor or to perform a cesarean delivery, resulting in a preterm delivery.","GAIA Level 2 Assessment of Provider Initiated Preterm Delivery | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Assessment of Provider-Initiated Preterm Delivery | Level 2 Assessment of Provider-Initiated Preterm Delivery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509189","GAIA Level 3 Assessment of Provider Initiated Preterm Delivery","C127952","GAIA Level 3 Assessment of Provider-Initiated Preterm Delivery is defined by three criteria: first, the patient is determined to be between 24 0/7 and 36 6/7 weeks gestation; second, from recall, the patient reports that there were no signs or symptoms of spontaneous onset of preterm labor; third, from recall, the patient reports that the healthcare provider indicated the need to induce labor or to perform a cesarean delivery between, resulting in preterm delivery.","GAIA Level 3 Assessment of Provider Initiated Preterm Delivery | Global Alignment of Immunization safety Assessment in pregnancy Level 3 Assessment of Provider-Initiated Preterm Delivery | Level 3 Assessment of Provider-Initiated Preterm Delivery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509146","GAIA Level 1 Assessment of Insufficient Cervix","C127953","GAIA Level 1 Assessment of Insufficient Cervix is defined by two criteria: first, the following three requirements must all be met: a) Presentation between 16 and 23 6/7 weeks gestation; b) Advanced cervical dilation greater than two centimeters, resulting in either treatment with a cerclage (cervical stitch) or with preterm delivery; c) Less than or equal to four contractions per hour as documented by a tocodynometer, meaning the patient is not in preterm labor; second, dilation of the internal cervical os greater than two centimeters as determined by transvaginal ultrasound or digital examination.","GAIA Level 1 Assessment of Insufficient Cervix | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Assessment of Insufficient Cervix | Level 1 Assessment of Insufficient Cervix",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509165","GAIA Level 2 Assessment of Insufficient Cervix","C127954","GAIA Level 2 Assessment of Insufficient Cervix is defined by two criteria: first, the following three requirements must be met: a) Presentation between 16 and 23 6/7 weeks gestation; b) Advanced cervical dilation greater than two centimeters, resulting in either treatment with a cerclage (cervical stitch) or preterm delivery; c) less than or equal to four contractions per hour as documented by a tocodynometer, meaning the patient is not in preterm labor; second, dilation of the internal cervical os greater than two centimeters as determined by digital examination.","GAIA Level 2 Assessment of Insufficient Cervix | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Assessment of Insufficient Cervix | Level 2 Assessment of Insufficient Cervix",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037940","Spinal Nerve Root","C12791","Either of the two initial segments of a spinal nerve, the dorsal sensory nerve root or the ventral motor nerve root; once emerged, the two fuse to form a single spinal nerve.","Spinal Nerve Root | Spinal Nerve Roots | Spinal Roots",,,,,,,,,,,,,,,"4288993","Spinal nerve root structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509787","Tunnel Clusters","C127920","A benign lesion characterized by the presence of rounded, lobular aggregates of endocervical glands in the cervical wall.","Tunnel Clusters | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509369","WNT5B wt Allele","C127922","Human WNT5B wild-type allele is located in the vicinity of 12p13.3 and is approximately 117 kb in length. This allele, which encodes protein Wnt-5b, is involved in G protein-coupled receptor signaling.","WNT5B wt Allele | Wingless-Type MMTV Integration Site Family, Member 5B Gene | Wnt family member 5B wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509249","IL32 wt Allele","C127925","Human IL32 wild-type allele is located in the vicinity of 16p13.3 and is approximately 17 kb in length. This allele, which encodes interleukin-32 protein, plays a role in cytokine signaling.","IL32 wt Allele | IL-32alpha | IL-32beta | IL-32delta | IL-32gamma | Interleukin 32 wt Allele | NK4 | Natural Killer Cell Transcript 4 Gene | TAIF | TAIFa | TAIFb | TAIFc | TAIFd",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507923","PRAME-targeting T-cell Receptor/Inducible Caspase 9 BPX-701","C128029","Human allogeneic T-lymphocytes transduced with a retroviral vector encoding a high-affinity T-cell receptor (TCR) specific for human leukocyte antigen (HLA)-A2-01-restricted, preferentially-expressed antigen in melanoma (PRAME) and containing the chemical induction of dimerization (CID) suicide/safety switch, composed of a drug binding domain coupled to the signaling domain of the suicide enzyme caspase-9, with potential antineoplastic activity. Peripheral blood mononuclear cells (PBMCs) are isolated from a patient, transduced with an anti-PRAME-HLA-A2 restricted TCR, expanded ex vivo, and reintroduced into the HLA-A2-positive patient. Upon reintroduction, PRAME-targeting T-cell receptor-based therapy BPX-701 binds to tumor cells expressing PRAME, which may induce cell death in and halt the growth of PRAME-expressing cancer cells. The tumor-associated antigen PRAME is overexpressed by a variety of cancer cell types. If potential T-cell toxicity due to graft-versus-host disease (GvHD) occurs, the chemical dimerizer rimiducid (AP1903) can be adminstered. Rimiducid binds to the drug binding domain expressed by the BPX-701 T-cells, and triggers activation of the caspase-9 domain, which leads to caspase 9-mediated signaling, the induction of apoptosis and to selective and complete elimination of BPX-701 cells.","PRAME-targeting T-cell Receptor/Inducible Caspase 9 BPX-701 | BPX-701 | CaspaCID-based PRAME-TCR Allogeneic T-lymphocytes BPX-701",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507924","MetAP2 inhibitor SDX-7320","C128030","A synthetic copolymer-drug conjugate of a fumagillin-derived methionine aminopeptidase 2 (MetAP2) inhibitor conjugated to the bio-compatible polymer poly(N-(hydroxypropyl)methacrylamide) (HPMA), with potential antineoplastic activity. Upon administration of SDX-7320, the active moiety SDX7539 is released inside the tumor cells. SDX7539 binds to and inhibits MetAP2, which prevents MetAP2-mediated signal transduction pathways and results in tumor cell death. MetAP2, a member of the dimetallohydrolase family upregulated in certain tumor cell types, plays a key role in angiogenesis, proliferation and survival. Polymer conjugation reduces systemic drug exposure and increases this agent's efficacy as compared to non-polymer conjugates.","Evexomostat | EVEXOMOSTAT | MetAP2 Inhibitor SDX-7320 | Methionine aminopeptidase type II Inhibitor SDX-7320 | SDX-7320",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512175","NCCN-FACT FBLSI-18 Version 2 - I Feel Sad","C129180","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I feel sad.","NCCN-FACT FBLSI-18 Version 2 - I Feel Sad | FAC028-I Feel Sad | FAC02811",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512178","NCCN-FACT FBLSI-18 Version 2 - I Have Nausea","C129181","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I have nausea.","NCCN-FACT FBLSI-18 Version 2 - I Have Nausea | FAC028-I Have Nausea | FAC02812",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512181","NCCN-FACT FBLSI-18 Version 2 - I Have a Lack of Energy","C129182","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I have a lack of energy.","NCCN-FACT FBLSI-18 Version 2 - I Have a Lack of Energy | FAC028-I Have a Lack of Energy | FAC02813",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512177","NCCN-FACT FBLSI-18 Version 2 - I Have Control of My Bowels","C129184","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I have control of my bowels.","NCCN-FACT FBLSI-18 Version 2 - I Have Control of My Bowels | FAC028-I Have Control of My Bowels | FAC02815",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512167","NCCN-FACT FBLSI-18 Version 2 - Bothered by Treatment Side Effect","C129185","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I am bothered by side effects of treatment.","NCCN-FACT FBLSI-18 Version 2 - Bothered by Treatment Side Effect | FAC028-Bothered by Treatment Side Effect | FAC02816",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512170","NCCN-FACT FBLSI-18 Version 2 - I Am Able to Enjoy Life","C129186","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I am able to enjoy life.","NCCN-FACT FBLSI-18 Version 2 - I Am Able to Enjoy Life | FAC028-I Am Able to Enjoy Life | FAC02817",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1168198","Recurrent Respiratory Papillomatosis","C128637","A rare disease caused by the human papillomavirus (HPV), most commonly types 6 and 11, that affects tissue along the respiratory tract with the majority of cases affecting the larynx. The disease has a bimodal distribution and manifests in those younger than age 5, juvenile-onset recurrent respiratory papillomatosis (JORRP), and those older than age 40, adult-onset recurrent respiratory papillomatosis (AORRP). JORRP is more common and more severe in presentation than AORRP. In a small percentage of patients, respiratory papillomas may undergo malignant transformation to squamous cell carcinomas that have a poor prognosis.","Recurrent Respiratory Papillomatosis | RRP",,,,,,,,,,,,,,,"43021940","Recurrent respiratory papillomatosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0223828","Middle Phalanx of Hand","C12863","One of four finger bones located between, and articulating with, a proximal phalange and a distal phalange.","Middle Phalanx of Hand | Middle Phalanx of Finger | Middle Phalanx of the Hand | hand middle phalanx | middle manual phalanx | middle phalanx of finger | middle phalanx of hand | middle phalanx of manual digit | middle phalanx of manus | phalanx media manus",,,,,,,,,,,,,"UBERON:0003864","middle phalanx of manus","4216860","Structure of phalanx of middle finger",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509066","P03277","C128640","A gadolinium-based paramagnetic contrast agent, with potential imaging enhancing activity upon magnetic resonance imaging (MRI). Upon administration of gadopiclenol and placement in a magnetic field, this agent produces a large magnetic moment and creates a large local magnetic field, which can enhance the relaxation rate of nearby protons. This change in proton relaxation dynamics, increases the MRI signal intensity of tissues in which this agent has accumulated; therefore, contrast and visualization of those tissues is enhanced compared to unenhanced MRI.","Gadopiclenol | (alpha3,alpha6,alpha9-Tris(3-((2,3-dihydroxypropyl)amino)-3-oxopropyl)-3,6,9,15-tetraazabicyclo(9.3.1)pentadeca-1(15),11,13-triene-3,6,9-triacetato(3-)-kappaN3,kappaN6,kappaN9,kappaN15,kappaO3,kappaO6,kappaO9)gadolinium | Elucirem | GADOPICLENOL | GBCA P03277 | Gadolinium-based Magnetic Resonance Contrast Agent P03277 | P 03277 | P03277 | WHO 10744",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509186","GAIA Level 3 Assessment of Insufficient Cervix","C127955","GAIA Level 3 Assessment of Insufficient Cervix is defined by three criteria: first, the following three requirements must be met: a) Presentation between 16 and 23 6/7 weeks gestation; b) Advanced cervical dilation greater than two centimeters, resulting in either treatment with a cerclage (cervical stitch) or preterm delivery; c) less than or equal to four contractions per hour as documented by a tocodynometer, meaning the patient is not in preterm labor; second, patient reported fetal delivery without painful contractions; third, the patient's history excludes other causes of mid-second trimester delivery.","GAIA Level 3 Assessment of Insufficient Cervix | Global Alignment of Immunization safety Assessment in pregnancy Level 3 Assessment of Insufficient Cervix | Level 3 Assessment of Insufficient Cervix",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509747","Major Congenital Anomaly","C127956","A major congenital anomaly is a structural or functional defect with the following three characteristics: 1) Of prenatal origin; 2) Present at the time of live birth or fetal demise, or in utero; 3) Affecting (or has the propensity to affect) the health, survival, or physical or cognitive functioning of the individual.","Major Congenital Anomaly | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509152","GAIA Level 1 Major External Structural Defect","C127957","GAIA Level 1 Major External Structural Defect is defined by four criteria: first, the defects are of a prenatal origin; second, at least one of the following requirements must be met: a) Alterations in the external anatomy that are present and visible at the time of live birth, and that persist beyond the immediate peripartum period unless surgically repaired OR b) Alterations in the external anatomy that are present and visible in a stillbirth or in the products of conception of a spontaneous or therapeutic abortion; third, the defect(s) affect (or have the propensity to affect) the health, survival, or physical or cognitive functioning of the individual; fourth, there must be documented confirmation of a diagnosis made by a clinician who is both experienced in diagnosing congenital anomalies and who has the highest level of morphology training for the specific setting.","GAIA Level 1 Major External Structural Defect | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Major External Structural Defect | Level 1 Major External Structural Defect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509348","Superficial Myofibroblastoma of the Lower Female Genital Tract","C128079","An uncommon, benign, well circumscribed mesenchymal neoplasm that grows beneath the vaginal epithelium. It is characterized by the presence of cells containing bland ovoid, spindle, or stellate-shaped nuclei in a collagenous stroma.","Vaginal Superficial Myofibroblastoma | Superficial Myofibroblastoma of the Lower Female Genital Tract | Vaginal Myofibroblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040999","Trigeminal Nucleus","C12807","Any one of the four nuclei of the fifth cranial nerve located in the brain stem, which includes the principal sensory nucleus, the mesencephalic nucleus, the spinal trigeminal tract, and the motor nucleus.","Trigeminal Nucleus | Nucleus of Fifth Nerve | Nucleus of the Fifth Nerve | Trigeminal Nuclei",,,,,,,,,,,,,,,"4090142","Trigeminal nucleus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509796","Vaginal Rhabdomyosarcoma","C128080","A malignant mesenchymal neoplasm with skeletal muscle differentiation arising from the vagina.","Vaginal Rhabdomyosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085376","Corneoscleral Limbus","C12823","The transitional zone where the cornea becomes continuous with the sclera.","Corneoscleral Limbus | Corneal Limbus",,,,,,,,,,,,,,,"4245981","Limbus corneae structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL507925","Autologous Prostate Stem Cell Antigen-specific CAR T Cells BPX-601","C128031","A preparation of autologous T-lymphocytes expressing a chimeric antigen receptor (CAR) consisting of an anti-human prostate stem cell antigen (PSCA) scFv (single chain variable fragment) coupled to the zeta chain of the T-cell receptor (TCRzeta) and a drug-induced co-stimulatory molecule, composed of an inducible, chimeric MyD88/CD40 (inducible MC; iMC) co-stimulatory domain, in which both the MyD88 and CD40 lack their extracellular domains, with potential antineoplastic activity. Upon administration of BPX-601, the T-cells target and bind to PSCA-expressing cancer cells. Upon subsequent administration of the chemical inducer of dimerization (CID) agent rimiducid, this agent targets and binds to the drug binding domain, which leads to iMC expression, activation of both CD40- and MyD88-mediated signal transduction pathways, and an induction of selective cytotoxicity in, and eradication of PSCA-expressing cancer cells. iMC activation by rimiducid increases T-cell survival and anti-tumor activity of the administered T-cells, compared to T-cells without the drug iMC activation-switch. As these T-cells are engineered to only be fully activated by binding to both antigen and rimiducid, T-cell proliferation, activity and toxicity can be controlled by adjusting the dose of rimiducid, thereby preventing uncontrolled T-cell activation which increases the safety of the administered T-cells. PSCA is a glycosylphosphatidylinositol (GPI)-anchored cell surface antigen overexpressed in many cancer cell types.","Autologous Prostate Stem Cell Antigen-specific CAR T Cells BPX-601 | Autologous PSCA-Specific Chimeric Antigen Receptor Engineered T Cells BPX-601 | Autologous PSCA-specific CAR T Cells BPX-601 | BPX-601 | GoCART BPX-601 | iMC/PSCA-zeta CAR BPX-601",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507926","Hyperpolarized Helium 3","C128033","A contrast agent composed of hyperpolarized helium He 3 gas (HP3He), with potential usage in diagnostic nuclear magnetic resonance (NMR)-based imaging (MRI). Upon inhalation, the hyperpolarized helium He 3 gas is distributed throughout the lungs. MRI, immediately following HP3He administration, allows for the visualization of lung structures based on the distribution pattern of the gas. This may aid in the diagnosis of certain lung abnormalities. Hyperpolarization of He 3 enhances NMR signals and thus improves imaging and assessment of lung function.","Hyperpolarized Helium 3 | HP3He | Hyperpolarized He-3 | Hyperpolarized He3 | Hyperpolarized Helium-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507927","Hyperpolarized Xenon 129","C128034","A contrast agent composed of hyperpolarized xenon Xe 129 gas (HP129Xe), with potential usage in diagnostic nuclear magnetic resonance (NMR)-based imaging (MRI). Upon inhalation, the hyperpolarized xenon 129 gas is distributed throughout the lungs. MRI, immediately following HP129Xe administration, allows for the visualization of lung structures based on the distribution pattern of the gas. This may aid in the diagnosis of certain lung abnormalities. Hyperpolarization of Xe 129 enhances NMR signals and thus improves imaging and assessment of lung function.","Hyperpolarized Xenon 129 | HP 129Xe | Hyperpolarized Xe-129 | Hyperpolarized Xe129 | Hyperpolarized Xenon-129 | XENON XE-129, HYPERPOLARIZED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1047984","Bordetella hinzii","C127692","A species of Gram-negative, oxidase- and catalase-positive, nonsporulating, short motile rod-shaped bacteria in the family Alcaligenaceae. Poultry species act as a reservoir for B. hinzii. Transmission to humans is rare, mostly occurring through occupational exposure.","Bordetella hinzii | BORDETELLA HINZII",,,,,,,,,,,,,,,"4014276","Bordetella hinzii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1087404","Bordetella petrii","C127693","A species of Gram-negative, coccobacillus-shaped, non-spore-forming, non-motile, facultatively anaerobic bacteria in the family Alcaligenaceae that is able to reduce selenate to elemental selenium. B. petrii is unable to utilize carbohydrates as a carbon source.","Bordetella petrii | BORDETELLA PETRII",,,,,,,,,,,,,,,"4211938","Bordetella petrii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319966","Byssochlamys spectabilis","C127694","A species of fungi in the family Trichocomacae characterized by broadly ellipsoidal to lemon-shaped conidia, loosely branched conidiophores and phialides with pointed tips. B. spectabilis is strongly heat-resistant and is a common contaminant of heat-treated foods and juices.","Byssochlamys spectabilis | BYSSOCHLAMYS SPECTABILIS | Paecilomyces spectabilis | Paecilomyces variotii | Talaromyces spectabilis",,,,,,,,,,,,,,,"4066245","Paecilomyces variotii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0997658","Candida boidinii","C127695","A species of yeast in the family Trichocomacae that is capable of utilizing methanol as a carbon source.","Candida boidinii | CANDIDA BOIDINII | Hansenula alcolica",,,,,,,,,,,,,,,"40487408","Candida boidinii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319631","Candida famata","C127696","A species of commensal yeast in the family Trichocomaca that are found in cheese, dairy products and the environment. It is rarely recovered from clinical specimens, usually associated with skin. C. famata is negative for fermentation on lactose and galactose.","Candida famata | CANDIDA FAMATA | Debaryomyces hansenii | Torulopsis candida",,,,,,,,,,,,,,,"4348448","Debaryomyces hansenii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0446049","Candida inconspicua","C127697","A species of yeast in the family Trichocomaceae. Clinical isolates of C. inconspicua has been obtained from human immunodeficiency virus-infected patients with either oral or esophageal infections, women with vaginal infections, and patients with diabetes mellitus.","Candida inconspicua | CANDIDA INCONSPICUA | Torulopsis inconspicua",,,,,,,,,,,,,,,"4152486","Candida inconspicua",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3885063","Idarucizumab","C128646","A humanized monoclonal antibody fragment directed against the thrombin-binding site of dabigatran, that may be used as a specific reversal agent for dabigatran. Upon intravenous administration, idarucizumab binds to dabigatran and its acylglucuronide metabolites with a higher affinity than the binding affinity of dabigatran to thrombin, thereby neutralizing the anticoagulant effect of dabigatran.","Idarucizumab | BI 655075 | BI-655075 | BI655075 | IDARUCIZUMAB | Praxbind",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508919","PAK3 wt Allele","C127850","Human PAK3 wild-type allele is located in the vicinity of Xq23 and is approximately 283 kb in length. This allele, which encodes serine/threonine-protein kinase PAK 3 protein, plays a role in small G protein-mediated signaling. Mutation of the gene is associated with X-linked mental retardation type 30/47.","PAK3 wt Allele | ARA | MRX30 | MRX47 | Mental Retardation, X-Linked 47 Gene | OPHN3 | PAK-3 | PAK3beta | bPAK | beta-PAK | p21 (CDKN1A)-Activated Kinase 3 Gene | p21 (RAC1) Activated Kinase 3 wt Allele | p21 Protein (Cdc42/Rac)-Activated Kinase 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1568884","Serine/Threonine-Protein Kinase PAK 3, Human","C127851","Serine/threonine-protein kinase PAK 3 (559 aa, ~62 kDa) is encoded by the human PAK3 gene. This protein is involved in the phosphorylation-dependent modulation of signal transduction.","Serine/Threonine-Protein Kinase PAK 3 | Beta-PAK | EC 2.7.11.1 | Oligophrenin 3 | Oligophrenin-3 | PAK-3 | PAK3 | PAK3beta | p21 CDC42/RAC1-Activated Kinase 3 | p21-Activated Kinase 3 | p21-Activated Kinase-3 | p21-Activated Protein Kinase 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0320104","Trematosphaeria grisea","C127750","A species of fungi in the phylum Ascomycota. T. grisea is a causative agent of black-grain mycetoma.","Trematosphaeria grisea | Madurella grisea | TREMATOSPHAERIA GRISEA",,,,,,,,,,,,,,,"4221560","Madurella grisea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0561724","Trichomonascus ciferrii","C127751","A species of yeast-like fungi in the phylum Ascomycota that is associated with otitis externa in humans and animals.","Trichomonascus ciferrii | Candida ciferrii | Stephanoascus ciferrii | TRICHOMONASCUS CIFERRII",,,,,,,,,,,,,,,"4218840","Trichomonascus ciferrii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319992","Trichophyton equinum","C127752","A species of zoophilic fungi in the phylum Ascomycota that causes ringworm in horses, but rare infections in humans.","Trichophyton equinum | TRICHOPHYTON EQUINUM",,,,,,,,,,,,,,,"4213859","Trichophyton equinum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040935","Trichophyton rubrum","C127754","A species of anthropophilic and dermatophytic fungi in the phylum Ascomycota. This species causes chronic infections of skin, nails, and rarely scalp.","Trichophyton rubrum | Epidermophyton rubrum | TRICHOPHYTON RUBRUM | Trichophyton fischeri | Trichophyton kanei | Trichophyton megninii | Trichophyton raubitschekii",,,,,,,,,,,,,,,"4290329","Trichophyton rubrum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040936","Trichophyton schoenleinii","C127755","A species of anthropophilic fungi in the phylum Ascomycota with a geographic distribution limited to certain areas of Africa. This species causes favus in humans.","Trichophyton schoenleinii | TRICHOPHYTON SCHOENLEINII",,,,,,,,,,,,,,,"4206891","Trichophyton schoenleinii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320000","Trichophyton soudanense","C127756","A species of anthropophilic and dermatophytic fungi in the phylum Ascomycota with a geographic distribution limited to areas of Africa. This species causes tinea of the scalp.","Trichophyton soudanense | TRICHOPHYTON SOUDANENSE",,,,,,,,,,,,,,,"4175971","Trichophyton soudanense",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040937","Trichophyton tonsurans","C127757","A species of anthropophilic fungi in the phylum Ascomycota with a worldwide distribution. This species causes inflammatory, or chronic non-inflammatory, finely scaling lesions of skin, nails and scalp.","Trichophyton tonsurans | TRICHOPHYTON TONSURANS",,,,,,,,,,,,,,,"4324138","Trichophyton tonsurans",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509365","Vulvar Hidradenoma Papilliferum","C128240","A benign glandular neoplasm that arises from the vulva. It presents as a mass or cystic lesion in or adjacent to the interlabial sulcus. It is characterized by the presence of complex branching papillae with fibrovascular stalks, lined by uniform columnar epithelial secretory cells and myoepithelial cells.","Vulvar Hidradenoma Papilliferum | Vulvar Papillary Hidradenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509513","Bartholin Gland Hyperplasia","C128241","Nodular/lobular proliferation of normal Bartholin gland tissue and ducts.","Bartholin Gland Hyperplasia | Bartholin Gland Nodular Hyperplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509757","Mesothelin-Like Protein","C127878","Mesothelin-like protein (702 aa, ~75 kDa) is encoded by the human MSLNL gene. This protein may be involved in cell adhesion.","Mesothelin-Like Protein | MPF-Like | Pre-Pro-Megakaryocyte-Potentiating-Factor-Like",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509315","SNAP25 wt Allele","C127883","Human SNAP25 wild-type allele is located within 20p12-p11.2 and is approximately 89 kb in length. This allele, which encodes synaptosomal-associated protein 25, is involved in vesicular trafficking, neurotransmitter release and plasma membrane recycling. Mutation of the gene may be associated with congenital myasthenic syndrome-18 and certain polymorphisms may be linked to attention deficit-hyperactivity disorder.","SNAP25 wt Allele | CMS18 | RIC-4 | RIC4 | Resistance To Inhibitors of Cholinesterase 4 Homolog Gene | SEC9 | SNAP | SNAP-25 | SUP | Synaptosomal Associated Protein 25kDa wt Allele | Synaptosomal-Associated Protein, 25-kD Gene | Synaptosomal-Associated Protein, 25kD Gene | Synaptosomal-Associated Protein, 25kDa Gene | bA416N4.2 | dJ1068F16.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1451765","Synaptosomal-Associated Protein 25, Human","C127884","Synaptosomal-associated protein 25 (206 aa, ~23 kDa) is encoded by the human SNAP25 gene. This protein plays a role in vesicular transport.","Synaptosomal-Associated Protein 25 | SNAP-25 | SUP | Super Protein | Synaptosomal-Associated 25 kDa Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509548","SPHKAP wt Allele","C127886","Human SPHKAP wild-type allele is located in the vicinity of 2q36 and is approximately 202 kb in length. This allele, which encodes A-kinase anchor protein SPHKAP, plays a role in the regulation of protein kinase A-dependent signaling.","SPHKAP wt Allele | KIAA1678 | SKIP | SPHK1 (Sphingosine Kinase Type 1) Interacting Protein Gene | SPHK1 Interactor, AKAP Domain Containing wt Allele | SPHK1 Interactor, AKAP Domain-Containing Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1144343","A-Kinase Anchor Protein SPHKAP, Human","C127887","A-kinase anchor protein SPHKAP (1700 aa, ~186 kDa) is encoded by the human SPHKAP gene. This protein is involved in the regulation of signaling mediated by protein kinase A and by sphingosine kinase 1.","A-Kinase Anchor Protein SPHKAP | SPHK1-Interacting Protein | SPHK1-Interactor and AKAP Domain-Containing Protein | Sphingosine Kinase Type 1-Interacting Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1008183","Candida sake","C127698","A species of yeast in the family Trichocomaceae. C. sake is rarely pathogenic but has been identified as a causative agent of spondylodiscitis, fungal endocarditis, peritonitis, and bloodstream infection.","Candida sake | CANDIDA SAKE",,,,,,,,,,,,,,,"40487001","Candida sake",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1028869","Coprinellus radians","C127699","A species of saprobic mushroom-forming fungi in the family Psathyrellaceae.","Coprinellus radians | COPRINELLUS RADIANS | Coprinus radians",,,,,,,,,,,,,,,"45765404","Coprinellus radians",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0078282","Vinzolidine","C1276","An orally active semisynthetic vinca alkaloid with potential antineoplastic activity. Like other vinca alkaloid compounds, vinzolidine binds to and stabilizes tubulin molecules, thereby interfering with microtubule assembly/disassembly dynamics. As a result, vinzolidine prevents mitotic spindle formation and leads to cell cycle arrest in metaphase.","Vinzolidine | 2H-3,7-Methanoazacycloundecino(5,4-b)indole-9-carboxylic acid, 9-((2-beta,3-beta,4-beta,5-alpha,12-beta,19-alpha)-4-(acetyloxy)-3'-(2-chloroethyl)-6,7-didehydro-16-methoxy-1-methyl-2',4'-dioxospiro(aspidospermidine-3,5'-oxazolidin)-15-yl)-5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-, methyl ester, (3R-(3R*,5S*,7R*,9S*))- | VINZOLIDINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1197463","Corynebacterium aurimucosum","C127700","A species of non-motile, catalase-positive, non-lipophilic, pleomorphic coryneform bacteria in the family Corynebacteriaceae that are aerobic or facultatively anaerobic. The species is positive for utilization of fructose, glucose, maltose, and sucrose. C. aurimucosum is positive for alkaline phosphatase but negative for acid phosphatase, lipase, alpha- and beta-glucosidase, and alpha- and beta-galactosidase.","Corynebacterium aurimucosum | CORYNEBACTERIUM AURIMUCOSUM | Corynebacterium nigricans",,,,,,,,,,,,,,,"4300249","Corynebacterium aurimucosum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4076277","Cryptococcus albidus Var. albidus","C127701","A variety of Cryptococcus albidus that is characterized by its ability to assimilate lactose, but not galactose.","Cryptococcus albidus Var. albidus | CRYPTOCOCCUS ALBIDUS VAR. ALBIDUS | Torulopsis albida var. albida",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1040031","Cryptococcus diffluens","C127702","A species of yeast in the phylum Basidiomycota. Colonies white to cream, and fluid to mucoid. C.diffluens is associated with rare cases of skin, nail, and subcutaneous infection.","Cryptococcus diffluens | CRYPTOCOCCUS DIFFLUENS | Cryptococcus albidus var. diffluens | Cryptococcus diffluens var. diffluens | Naganishia diffluens | Torulopsis diffluens",,,,,,,,,,,,,,,"37017001","Naganishia diffluens",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0319890","Cryptococcus terreus","C127703","A species of yeast in the phylum Basidiomycota. This species is characterized by its ability to utilize glucose, lactose, galactose, and potassium nitrate and its inability to ferment sucrose.","Cryptococcus terreus | CRYPTOCOCCUS TERREUS | Cryptococcus elinovii | Cryptococcus himalayensis | Solicoccozyma terreus",,,,,,,,,,,,,,,"4214177","Solicoccozyma terrea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1002921","Cystobasidium minutum","C127704","A species of saprobic yeast in the phylum Basidiomycota and the family Cystobasidiaceae.","Cystobasidium minutum | CYSTOBASIDIUM MINUTUM | Cystobasidium minuta | Rhodotorula minuta | Torula minuta",,,,,,,,,,,,,,,"4215534","Cystobasidium minutum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508920","PCSK1 wt Allele","C127853","Human PCSK1 wild-type allele is located within 5q15-q21 and is approximately 44 kb in length. This allele, which encodes neuroendocrine convertase 1 protein, is involved in the activation of neuropeptides and protein hormones. Mutation of the gene is associated with proprotein convertase 1/3 deficiency and increased susceptibility to obesity.","PCSK1 wt Allele | BMIQ12 | NEC1 | PC1 | PC3 | Proprotein Convertase Subtilisin/Kexin Type 1 wt Allele | SPC3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3849253","Neuroendocrine Convertase 1, Human","C127854","Neuroendocrine convertase 1 (753 aa, ~84 kDa) is encoded by the human PCSK1 gene. This protein plays a role in the proteolytic activation of protein hormones and neuropeptides.","Neuroendocrine Convertase 1 | EC 3.4.21.93 | NEC 1 | PC1 | PCSK1 | Prohormone Convertase 1 | Proprotein Convertase 1 | Proprotein Convertase Subtilisin/Kexin Type 1 | Proprotein Convertase Subtilisin/Kexin-Type 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508930","PRMT5 wt Allele","C127856","Human PRMT5 wild-type allele is located in the vicinity of 14q11.2 and is approximately 9 kb in length. This allele, which encodes protein arginine N-methyltransferase 5 protein, plays a role in arginine metabolism.","PRMT5 wt Allele | HRMT1L5 | Histone Synthetic Lethal 7, S. cerevisiae, Homolog of Gene | IBP72 | ICLN-Binding Protein, 72-kD Gene | JBP1 | Protein Arginine Methyltransferase 5 wt Allele | SHK1 Kinase-Binding Protein 1, S. pombe, Homolog of Gene | SKB1 | SKB1 Homolog (S. pombe) Gene | SKB1Hs | Skb1 (S. pombe) Homolog Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1449307","Protein Arginine N-Methyltransferase 5, Human","C127857","Protein arginine N-methyltransferase 5 (637 aa, ~73 kDa) is encoded by the human PRMT5 gene. This protein is involved in the methylation of arginine.","Protein Arginine N-Methyltransferase 5 | 72 kDa ICln-Binding Protein | EC 2.1.1.125 | EC 2.1.1.320 | HMT1 HnRNP Methyltransferase-Like 5 | Histone-Arginine N-Methyltransferase PRMT5 | Jak-Binding Protein 1 | Protein Arginine Methyltransferase 5 | SKB1 Homolog | SKB1Hs | Shk1 Kinase-Binding Protein 1 Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509546","SLC31A1 wt Allele","C127859","Human SLC31A1 wild-type allele is located in the vicinity of 9q32 and is approximately 43 kb in length. This allele, which encodes high affinity copper uptake protein 1, is involved in transmembrane copper ion transport.","SLC31A1 wt Allele | COPT1 | CTR1 | Copper Transport 1 Homolog (S. cerevisiae) Gene | Solute Carrier Family 31 (Copper Transporter), Member 1 Gene | Solute Carrier Family 31 (Copper Transporters), Member 1 Gene | Solute Carrier Family 31 Member 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0962796","High Affinity Copper Uptake Protein 1, Human","C127860","High affinity copper uptake protein 1 (190 aa, ~21 kDa) is encoded by the human SLC31A1 gene. This protein plays a role in copper ion transport.","High Affinity Copper Uptake Protein 1 | Copper Transport 1 Homolog | Copper Transporter 1 | Solute Carrier Family 31 Member 1 | hCTR1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1827301","Extensively Drug-Resistant Tuberculosis","C128417","Tuberculosis disease that is caused by an extensively drug-resistant strain of Mycobacterium tuberculosis.","Extensively Drug-Resistant Tuberculosis | Extensively Drug-Resistant TB | XDR-TB",,,,,,,,,,,,,,,"4308319|46273571","Extreme drug resistant tuberculosis|Extensively drug resistant tuberculosis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0023092","Lassa Fever","C128418","A viral hemorrhagic fever that is caused by the Lassa virus, which is transmitted by contact with infected rodents; it is characterized by fever, headache, malaise, myalgia, and hearing loss.","Lassa Fever | ",,,,,,,,,,,,,,,"4078535","Lassa fever",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0035613","Rift Valley Fever","C128419","A viral hemorrhagic fever that is caused by the Rift Valley fever virus, which is transmitted by mosquitoes and infected animals. The infection is typically asymptomatic or causes only mild illness, but can be associated with retinitis.","Rift Valley Fever | RVF",,,,,,,,,,,,,,,"4300216","Rift valley fever",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320003","Trichophyton verrucosum","C127758","A species of zoophilic and dermatophytic fungi in the phylum Ascomycota. This species causes ringworm in cattle.","Trichophyton verrucosum | TRICHOPHYTON VERRUCOSUM",,,,,,,,,,,,,,,"4131819","Trichophyton verrucosum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0320009","Trichophyton yaoundei","C127760","A species of anthropophilic and dermatophytic fungi in the phylum Ascomycota that is endemic to equatorial Africa. This species causes tinea of the scalp, but is capable of infecting the glabrous skin, nails, and the soles of the feet.","Trichophyton yaoundei | TRICHOPHYTON YAOUNDEI",,,,,,,,,,,,,,,"4009778","Trichophyton yaoundei",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040944","Trichosporon beigelii","C127761","A species of urease-positive, non-encapsulated yeasts in the phylum Basidiomycota characterized by the development of hyaline, septate hyphae that fragment into oval or rectangular arthroconidia.","Trichosporon beigelii | TRICHOSPORON BEIGELII",,,,,,,,,,,,,,,"4214443","Trichosporon beigelii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038565","Subdiaphragmatic Abscess","C128327","An abscess that is located in the anatomical space between the diaphragm and the liver and/or spleen.","Subdiaphragmatic Abscess | Subphrenic Abscess",,,,,,,,,,,,,,,"4199144","Subdiaphragmatic abscess",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0267760","Mesenteric Abscess","C128328","An abscess that is located in any part of the tissue composing the mesentery, and that generally arises from an infection in an adjacent area of the intestine.","Mesenteric Abscess | ",,,,,,,,,,,,,,,"4137771","Mesenteric abscess",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1963776","Perihepatic Abscess","C128329","An abscess that is located in the anatomical space surrounding the liver, but which is outside of the liver capsule itself.","Perihepatic Abscess | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0237962","Retroperitoneal Abscess","C128330","An abscess that is located in the abdominal cavity posterior to the peritoneum.","Retroperitoneal Abscess | ",,,,,,,,,,,,,,,"200761","Retroperitoneal abscess",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0030785","Pelvic Abscess","C128331","An abscess that is located in the pelvic cavity.","Pelvic Abscess | ",,,,,,,,,,,,,,,"4009635","Pelvic abscess",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085435","Reactive Arthritis","C128332","A form of inflammatory arthritis that results as a reaction to a bacterial infection outside the joint.","Reactive Arthritis | ",,,,,,,,,,,,,,,"40399768","Reactive arthritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0694577","Migratory Arthritis","C128333","A form of reactive arthritis in which the inflammation moves between joints.","Migratory Arthritis | ",,,,,,,,,,,,,,,"4009504","Migratory polyarthritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509549","SPTLC1 wt Allele","C127889","Human SPTLC1 wild-type allele is located in the vicinity of 9q22.2 and is approximately 84 kb in length. This allele, which encodes serine palmitoyltransferase 1 protein, is involved in the metabolism of lipids. Mutation of the gene is associated with hereditary sensory neuropathy type IA.","SPTLC1 wt Allele | HSAN1 | HSN1 | Hereditary Sensory Neuropathy, Type 1 Gene | LBC1 | LCB1 | SPT1 | SPTI | Serine Palmitoyltransferase, Long Chain Base Subunit 1 wt Allele | Serine Palmitoyltransferase, Long-Chain Base Subunit 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509183","GAIA Level 2a Assessment of Gestational Age","C128014","GAIA Level 2a Assessment of Gestational Age is defined by the presence of at least one of the following criteria: a) Certain last menstrual period (LMP) date with second trimester scan (14 0/7 weeks to 27 6/7 weeks), (If LMP and ultrasound (U/S) do not correlate, default to U/S GA assessment); OR b) Certain LMP date with first trimester physical examination.","GAIA Level 2a Assessment of Gestational Age | Global Alignment of Immunization safety Assessment in pregnancy Level 2a Assessment of Gestational Age | Level 2a Assessment of Prematurity and Gestational Age",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509184","GAIA Level 2b Assessment of Gestational Age","C128015","GAIA Level 2b Assessment of Gestational Age is defined by the following criteria: uncertain last menstrual period (LMP) date with second trimester scan (14 0/7 weeks to 27 6/7 weeks).","GAIA Level 2b Assessment of Gestational Age | Global Alignment of Immunization safety Assessment in pregnancy Level 2b Assessment of Gestational Age | Level 2b Assessment of Prematurity and Gestational Age",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509201","GAIA Level 3a Assessment of Gestational Age","C128016","GAIA Level 3a Assessment of Gestational Age is defined by the presence at least one of the following criteria: a) Certain last menstrual period (LMP) date with third trimester scan (28 0/7 weeks or more); OR b) Certain LMP date with confirmatory second trimester fundal height (FH); OR c) Certain LMP date with birth weight; OR d) Uncertain LMP date with first trimester physical examination.","GAIA Level 3a Assessment of Gestational Age | Global Alignment of Immunization safety Assessment in pregnancy Level 3a Assessment of Gestational Age | Level 3a Assessment of Prematurity and Gestational Age",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509202","GAIA Level 3b Assessment of Gestational Age","C128017","GAIA Level 3b Assessment of Gestational Age is defined by the presence of at least one of the following criteria: a) Uncertain last menstrual period (LMP) date with fundal height (FH); OR b) Uncertain LMP date with newborn physical assessment; OR c) Uncertain LMP date with birth weight.","GAIA Level 3b Assessment of Gestational Age | Global Alignment of Immunization safety Assessment in pregnancy Level 3b Assessment of Gestational Age | Level 3b Assessment of Prematurity and Gestational Age",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509144","GAIA Level 1 Antepartum Stillbirth","C128018","GAIA Level 1 Antepartum Stillbirth is defined by four criteria: first, one or more of the following three requirements must be met: a) Prenatal ultrasound examination (e.g. basic ultrasound or special ultrasound with Doppler) documenting an absence of fetal cardiac activity or movement before the onset of labor; b) Radiology findings consistent with intrauterine fetal death; c) Delivery of an infant with no of signs of life at birth, including no spontaneous movements, no umbilical cord pulse, no heartbeat, no respirations, and Apgar scores of 0 at both 1 and 5 minutes. The determination of the absence of signs of life is made by physical examination after delivery, with or without electronic monitoring of heart rate, respiratory rate, and pulse oximetry; second, the following three criteria must be met: a) Maternal report of the absence of fetal movement for 24 hours or more; b) Maternal physical examination confirming the absence of fetal movement; c) Auscultation for fetal heart tones using electronic devices (e.g. handheld Doppler or fetal heart rate monitor) OR non-electronic devices (e.g. stethoscope, fetoscope, or Pinard horn) that documents the absence of a fetal heartbeat; third, one of the following two requirements must be met: a) Attended delivery, followed by a post-delivery physical examination of the fetus by an obstetrician, a neonatologist, a pediatrician, a maternal-fetal medicine specialist, or a pathologist that is consistent with antepartum death. In a setting where access to a specialist is not feasible, diagnosis by a health care provider trained or experienced to make the diagnosis is acceptable (e.g. general practice physician, mid-wife, nurse practitioner, a physician's assistant, or other qualified trained practitioner); OR b) fetal/placental pathology report that is consistent with antepartum death; fourth, gestational age within the pre-defined range for selected stillbirth definition, as assessed by maternal and/or fetal parameters (level 1 in GA assessment algorithm).","GAIA Level 1 Antepartum Stillbirth | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Antepartum Stillbirth | Level 1 Antepartum Stillbirth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507937","HER-2-positive B-cell Peptide Antigen P467-DT-CRM197/Montanide Vaccine IMU-131","C128283","A cancer vaccine consisting of a fusion peptide, composed of three peptides derived from the extracellular domain (ECD) of the HER2 peptide antigen found on B-cells (P4, P6 and P7; P467), conjugated to the carrier protein DT-CRM197, a non-toxic, mutated form of diphtheria toxin (DT), and combined with the immunoadjuvant montanide ISA 51, with potential immunostimulatory and antineoplastic activities. Upon administration, IMU-131 vaccine induces the production of polyclonal antibodies against the HER2 protein. In turn, the antibodies bind to three separate binding sites on HER2 expressed on tumor cells and inhibit HER2 dimerization and activity, which leads to the inhibition of HER2-mediated signal transduction pathways. This induces apoptosis in and reduces cellular proliferation of HER2-overexpressing tumor cells. In addition, IMU-131 induces a cytotoxic T-lymphocyte (CTL) response against the HER2-expressing tumor cells. The tumor-associated antigen (TAA) HER2, also called Neu or ErbB2, is a tyrosine kinase receptor for epidermal growth factor (EGF) and is often overexpressed by a variety of tumor cell types. Montanide ISA 51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil (w/o) emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens. DT-CRM197 is used to increase the immunogenicity of the HER2/neu peptide antigen. In P467, the three B-cell epitopes were combined in a specific order into a single 49 amino acid peptide antigen.","HER-2-positive B-cell Peptide Antigen P467-DT-CRM197/Montanide Vaccine IMU-131 | HER-Vaxx | HER-Vaxx Peptide Vaccine | IMU-131 | IMU-131 HER2/Neu Peptide Vaccine | IMU-131 Vaccine | P467-CRM197/Montanide Vaccine IMU-131",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507939","threonine tyrosine kinase inhibitor CFI-402257","C128288","An orally bioavailable, selective inhibitor of the dual specificity protein kinase TTK (monopolar spindle 1 kinase, Mps1), with potential antineoplastic activity. Upon administration, luvixasertib selectively binds to and inhibits the activity of Mps1. This inactivates the spindle assembly checkpoint (SAC) and accelerates mitosis, which results in chromosomal misalignment and missegregation, and mitotic checkpoint complex destabilization. This induces cell death in Mps1-overexpressing cancer cells. Mps1, a tyrosine and serine/threonine kinase expressed in proliferating normal tissues, is essential for proper SAC functioning and chromosome alignment. Overexpressed in various human tumors, Mps1 plays a key role in uncontrolled tumor cell growth.","Luvixasertib | CFI-402257 | LUVIXASERTIB | MSP1 Inhibitor CFI-402257 | N-cyclopropyl-4-(7-((((1s,3s)-3-hydroxy-3-methylcyclobutyl)methyl)amino)-5-(pyridin-2-yloxy)pyrazolo[1,5-a]pyridin-3-yl)-2-methylbenzamide | TTK Inhibitor CFI-402257 | Threonine Tyrosine Kinase Inhibitor CFI-402257 | Threonine Tyrosine Kinase Inhibitor CFI-402257",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509574","Vulvar Melanocytic Nevus","C128289","A benign, atypical, or dysplastic melanocytic nevus that arises from the vulva.","Vulvar Melanocytic Nevus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0595993","Roseola Infantum","C128420","An infection that is due to human herpesvirus (HHV) types 6 or 7; it is characterized by 3-5 days of high fever followed by the acute onset of a rosy, pink, non-pruritic, macular rash that is predominantly on the neck and trunk.","Roseola Infantum | Exanthem Subitum | Roseola",,,,,,,,,,,,,,,"135745","Exanthema subitum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0276180","Monkeypox","C128421","An infection that is caused by an Orthopoxvirus, which is transmitted by primates or rodents, and which is characterized by a prodromal syndrome of fever, chills, headache, myalgia, and lymphedema; initial symptoms are followed by a generalized papular rash that typically progresses from vesiculation through crusting over the course of two weeks.","Monkeypox | Monkeypox Infection | Mpox",,,,,,,,,,,,,,,"4234275","Mpox",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0008055","Chikungunya","C128422","An infection that is caused by the Chikungunya virus, which is transmitted by mosquitoes; it is characterized by fever and severe arthralgia.","Chikungunya | ",,,,,,,,,,,,,,,"4009926","Chikungunya fever",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0276289","Zika Virus Infection","C128423","An infection that is caused by the Zika virus, which is primarily transmitted via mosquitoes; it is characterized by fever, skin rash, arthralgia, and conjunctivitis.","Zika Virus Infection | Zika",,,,,,,,,,,,,,,"4214984","Zika virus disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3694279","Middle East Respiratory Syndrome","C128424","A viral respiratory infection that is caused by the MERS coronavirus (MERS-CoV), which most often manifests with moderate to severe respiratory symptoms, including productive cough and shortness of breath, which can progress to pneumonia and acute respiratory distress syndrome.","Middle East Respiratory Syndrome | MERS",,,,,,,,,,,,,,,"45763594","Middle East respiratory syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152061","Louse-Borne Relapsing Fever","C128426","An infection that is caused by certain species of Rickettsia or Borrelia, which are transmitted to humans from infected lice; it is characterized by sudden fever, chills, headaches, myalgia, arthralgia, nausea, and possibly a rash. Symptoms usually persist for two to nine days, then disappear, with recurrence after several weeks if the patient remains untreated.","Louse-Borne Relapsing Fever | ",,,,,,,,,,,,,,,"443908","Louse-borne relapsing fever",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2733483","Southern Tick-Associated Rash Illness","C128427","A putative Borrelia infection causing acute manifestations similar to Lyme disease, particularly erythema migrans, following the bite of the lone star tick, Amblyomma americanum.","Southern Tick-Associated Rash Illness | Masters Disease | STARI",,,,,,,,,,,,,,,"40485009","Southern tick-associated rash illness",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509470","Infectious Hidradenitis","C128428","Hidradenitis that is caused by an infectious agent, usually a bacterium.","Infectious Hidradenitis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2677867","Hidradenitis Suppurativa","C128429","A chronic, suppurative inflammation of the apocrine sweat glands, that is characterized by clusters of bumps or sores.","Hidradenitis Suppurativa | ",,,,,,,,,,,,,,,"4241223","Hidradenitis suppurativa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0181078","Skin Graft","C12842","No value exists.","Skin Graft | skin graft",,,,,,,,,,,,,,,"4029137","Transplanted skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0275842","Early Latent Syphilis","C128430","Latent syphilis when infection was acquired less than twelve months previously.","Early Latent Syphilis | ",,,,,,,,,,,,,,,"4092828|441507","Latent early syphilis|Early latent syphilis, positive serology, negative cerebrospinal fluid, less than 2 years after infection",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL509479","Multidrug-Resistant Mycobacterium tuberculosis","C128431","A strain of Mycobacterium tuberculosis that is resistant to isoniazid and rifampin.","Multidrug-Resistant Mycobacterium tuberculosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509764","Pre-Extensively Drug-Resistant Mycobacterium tuberculosis","C128432","A strain of Mycobacterium tuberculosis that is characterized by resistance to isoniazid, rifampin, and one of the following: a) any of the fluoroquinolone antibiotics or b) one or more of three injectable drugs (kanamycin, capreomycin, amikacin).","Pre-Extensively Drug-Resistant Mycobacterium tuberculosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509229","GAIA Level 1 Neonatal Respiratory Tract Infection","C127991","GAIA Level 1 Neonatal Respiratory Tract Infection is defined by two criteria: first, a new or progressive or persistent infiltrate or shadowing or fluid in the intrapleural cavity or interlobar fissure on chest X-ray OR a recognized virus identified using a validated assay from an upper respiratory sample OR a recognized pathogen identified, using a validated method, from a normally sterile site; second, three or more of the following requirements must be met: a) Temperature greater than or equal to 37.5 degrees C or less than 35.5 degrees C; b) Tachypnea or nasal flaring or chest indrawing or grunting; c) Desaturations or increased oxygen requirements or increased ventilator requirements or oxygen saturation less than 95%; d) Apnea; e) Increased respiratory secretions or increased suctioning requirements; f) Cough, wheeze, or crepitations; g) Increased CRP or procalcitonin.","GAIA Level 1 Neonatal Respiratory Tract Infection | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Neonatal Respiratory Tract Infection | Level 1 Neonatal Respiratory Tract Infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023240","Legionellosis","C128334","Any disease caused by Legionella bacteria.","Legionellosis | ",,,,,,,,,,,,,,,"4097550","Legionella infection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0343528","Pontiac Fever","C128335","A self-limited, febrile illness without pneumonia that occurs in epidemics, and that is caused by Legionella species.","Pontiac Fever | ",,,,,,,,,,,,,,,"4347535","Pontiac fever",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0025229","Melioidosis","C128336","An infection that is caused by Burkholderia pseudomallei, which is found in soil and water; symptoms vary widely, but most commonly include fever, cough, pneumonia, arthralgia, myalgia, and skin ulceration.","Melioidosis | Whitmore Disease",,,,,,,,,,,,,,,"443542","Melioidosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043407","Yersiniosis","C128337","An infection that is caused by Yersinia enterocolitica or Yersinia pseudotuberculosis, and that is usually acquired by consumption of contaminated meat, water, or unpasteurized milk. It can also be transmitted vertically, pre- or perinatally, from mother to infant. Manifestation of symptoms depends on the infecting species and mode of acquisition, and can range from gastrointestinal syndromes to septicemia.","Yersiniosis | ",,,,,,,,,,,,,,,"4308864","Yersiniosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0857946","Atypical Pneumonia","C128338","Historical term that references a form of pneumonia caused by Mycoplasma pneumoniae, Chlamydophila pneumoniae, or Legionella species.","Atypical Pneumonia | Walking Pneumonia",,,,,,,,,,,,,,,"4050869","Atypical pneumonia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023241","Legionella Pneumonia","C128339","A pneumonia caused by Legionella pneumophila and other Legionella species, which is characterized by fever, cough, progressive respiratory distress, and which is often accompanied by extrapulmonary manifestations.","Legionella Pneumonia | Legionnaires' Disease",,,,,,,,,,,,,,,"4112820","Legionella pneumonia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0149603","Anterior Spinal Artery","C12833","The artery that delivers blood to the anterior portion of the spinal cord.","Anterior Spinal Artery | ",,,,,,,,,,,,,,,"4066409","Structure of anterior spinal artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0343770","Bacillary Peliosis","C128340","An infection that is caused by Bartonella henselae, which occurs primarily in immunocompromised persons; it is characterized by blood-filled cysts in the liver and spleen.","Bacillary Peliosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1739094","Foodborne Botulism","C128341","Botulism that is caused by consuming food or beverage that contains the botulinum toxin.","Foodborne Botulism | ",,,,,,,,,,,,,,,"443444","Foodborne botulism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1306794","Wound Botulism","C128342","Botulism that is caused by toxin that is produced in a wound contaminated with Clostridium botulinum.","Wound Botulism | ",,,,,,,,,,,,,,,"438958","Wound botulism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0238027","Infant Botulism","C128343","Botulism that is caused by contact with spores of Clostridial bacteria, which subsequently grow in the intestine and release toxin.","Infant Botulism | ",,,,,,,,,,,,,,,"435468","Infantile botulism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508664","Adult Intestinal Botulism","C128344","A rare form of botulism that occurs among adults by the same mechanism as infant botulism.","Adult Intestinal Botulism | Adult Intestinal Toxemia Botulism",,,,,,,,,,,,,,,"608055","Adult intestinal botulism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509010","Iatrogenic Botulism","C128345","Botulism that occurs following injection of botulinum toxin.","Iatrogenic Botulism | Accidental Botulism",,,,,,,,,,,,,,,"608083","Iatrogenic infection caused by Clostridium botulinum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL509171","GAIA Level 2 Major External Structural Defect","C127958","GAIA Level 2 Major External Structural Defect is defined by four criteria: first, the defects are of a prenatal origin; second, at least one of the following requirements must be met: a) Alterations in the external anatomy that are present and visible at the time of live birth, and that persist beyond the immediate peripartum period unless surgically repaired OR b) Alterations in the external anatomy that are present and visible in a stillbirth or in the products of conception of a spontaneous or therapeutic abortion; third, the defect(s) affect (or have the propensity to affect) the health, survival, or physical or cognitive functioning of the individual; fourth,  there must be documented confirmation of a diagnosis made by a clinician with some experience diagnosing congenital anomalies.","GAIA Level 2 Major External Structural Defect | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Major External Structural Defect | Level 2 Major External Structural Defect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509164","GAIA Level 2 Antepartum Stillbirth","C128019","GAIA Level 2 Antepartum Stillbirth is defined by four criteria: first, delivery of an infant with no of signs of life at birth, including the following: no spontaneous movements, no umbilical cord pulse, no heartbeat, no respirations, and an Apgar score of 0 at both 1 and 5 minutes. Determination of the absence of signs of life is made by physical examination after delivery, with or without electronic monitoring of heart rate, respiratory rate, and pulse oximetry; second, one or more of the following three requirements must be met: a) Maternal report of the absence of fetal movement for 24 hours or more; b) Maternal physical examination confirming the absence of fetal movement; c) Auscultation for fetal heart tones using electronic devices (e.g. handheld Doppler or fetal heart rate monitor) or non-electronic devices (e.g. stethoscope, fetoscope or Pinard horn) that documents the absence of a fetal heartbeat; third, one or more of the following two requirements must be met: a) Attended delivery followed by a post-delivery physical examination of the fetus that is performed by specialist or qualified trained practitioner appropriate to the health care setting, and that is consistent with antepartum death; b) fetal/placental pathology report that is consistent with antepartum death; fourth, gestational age within the pre-defined range for selected stillbirth definition, as assessed by maternal and/or fetal parameters (level 1-2 in GA assessment algorithm).","GAIA Level 2 Antepartum Stillbirth | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Antepartum Stillbirth | Level 2 Antepartum Stillbirth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030510","Parasympathetic Nervous System","C12764","The division of the autonomic nervous system responsible for conserving and restoring energy (opposing the sympathetic nervous system), which arises from preganglionic cell bodies in the gray matter of the brain stem and the middle three segments of the sacral cord.","Parasympathetic Nervous System | ",,,,,,,,,,,,,,,"4052081","Parasympathetic nervous system structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL508658","AR Gene Product","C128290","A protein encoded by the AR gene.","AR Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1566219","Interleukin-32, Human","C127926","Interleukin-32 (234 aa, ~27 kDa) is encoded by the human IL32 gene. This protein is involved in interleukin-dependent signaling.","Interleukin-32 | IL-32 | IL32 | Interleukin 32 | Natural Killer Cells Protein 4 | Tumor Necrosis Factor Alpha-Inducing Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037941","Spinal Nerve","C12792","Paired nerves that arise from the spinal cord. In all, there are 31 pairs of spinal nerves located in the human body.","Spinal Nerve | NERVE, SPINAL | Spinal Nerves | Spinal Roots",,,,,,,,,,,,,,,"4136497","Spinal nerve structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1438798","Melanoma Antigen Preferentially Expressed in Tumors, Human","C127930","Melanoma antigen preferentially expressed in tumors (509 aa, ~58 kDa) is encoded by the human PRAME gene. This protein plays a role in the repression of retinoic acid receptor-dependent gene expression.","Melanoma Antigen Preferentially Expressed in Tumors | Cancer/Testis Antigen 130 | OIP-4 | Opa-Interacting Protein 4 | Opa-Interacting Protein OIP4 | PRAME | Preferentially Expressed Antigen in Melanoma | Preferentially Expressed Antigen of Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509704","Cervical Microglandular Hyperplasia","C127931","A benign endocervical gland proliferation characterized by the presence of closely packed glands composed of columnar to cuboidal cells with subnuclear mucin vacuoles. It is associated with progestins or pregnancy.","Cervical Microglandular Hyperplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508904","Lobular Endocervical Glandular Hyperplasia","C127932","Lobular proliferations of benign-appearing small to moderate sized endocervical glands in the inner half of the cervical stroma. The glands are lined by columnar epithelial cells which contain pyloric gland-type mucin. There is minimal atypia and mitotic figures are rare. Some cases have been associated with adenocarcinoma in situ/high grade cervical glandular intraepithelial neoplasia and gastric-type adenocarcinomas.","Lobular Endocervical Glandular Hyperplasia | Pyloric Gland Metaplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509438","Diffuse Laminar Endocervical Hyperplasia","C127933","A benign band-like proliferation of tightly-packed, small to medium sized endocervical glands below the surface of the endocervical canal.","Diffuse Laminar Endocervical Hyperplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509233","GAIA Level 2 Neonatal Respiratory Tract Infection","C127992","GAIA Level 2 Neonatal Respiratory Tract Infection is defined by two criteria: first, new or progressive or persistent infiltrate or shadowing or fluid in the intrapleural cavity or interlobar fissure on chest X-ray; second, four or more of the following requirements must be met: a) Temperature greater than or equal to 37.5 degrees C or less than 35.5 degrees C; b) Tachypnea or nasal flaring or chest indrawing or grunting; c) Desaturations or increased oxygen requirements or increased ventilator requirements or oxygen saturation less than 95%; d) Apnea; e) Increased respiratory secretions or increased suctioning requirements; f) Cough, wheeze, or crepitations; g) Increased CRP or procalcitonin.","GAIA Level 2 Neonatal Respiratory Tract Infection | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Neonatal Respiratory Tract Infection | Level 2 Neonatal Respiratory Tract Infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509236","GAIA Level 3 Neonatal Respiratory Tract Infection","C127993","GAIA Level 3 Neonatal Respiratory Tract Infection is defined by the presence of two or more of the following criteria: a) Difficulty in breathing/tachypnea; b) Severe chest indrawing; c) Nasal flaring; d) Grunting; e) Wheeze; f) Stridor.","GAIA Level 3 Neonatal Respiratory Tract Infection | Global Alignment of Immunization safety Assessment in pregnancy Level 3 Neonatal Respiratory Tract Infection | Level 3 Neonatal Respiratory Tract Infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509230","GAIA Level 1 Non-reassuring Fetal Status","C127994","GAIA Level 1 Non-reassuring Fetal Status is defined by two criteria: first, a Category III fetal heart rate tracing detected via continuous cardiotocography as defined by the NICHD; second, one of the following two conditions must be met: a) an absent baseline fetal heart rate variability AND any of the following: recurrent late decelerations, recurrent variable deceleration, bradycardia (less than 110 bpm); OR b) a sinusoidal pattern; third, umbilical cord blood analysis that is consistent with metabolic acidosis (pH less than 7.0 and a base deficit greater than 12mmol/L).","GAIA Level 1 Non-reassuring Fetal Status | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Non-reassuring Fetal Status | Level 1 Non-reassuring Fetal Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509234","GAIA Level 2 Non-reassuring Fetal Status","C127995","GAIA Level 2 Non-reassuring Fetal Status is defined by the presence of at least one of the following two criteria: first, a category III fetal heart rate tracing detected via continuous cardiotocography as defined by NICHD; second, one of the following two conditions must be met: a) an absent baseline fetal heart rate variability AND any of the following: recurrent late decelerations, recurrent variable deceleration, bradycardia (less than 110 bpm); OR b) a sinusoidal pattern.","GAIA Level 2 Non-reassuring Fetal Status | Global Alignment of Immunization safety Assessment in pregnancy Level 2 Non-reassuring Fetal Status | Level 2 Non-reassuring Fetal Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509237","GAIA Level 3 Non-reassuring Fetal Status","C127996","GAIA Level 3 Non-reassuring Fetal Status is defined by the presence of the following criteria: A fetal heart pattern that is detected via intermittent auscultation, and that is suggestive of fetal hypoxia, including the following requirements that must be met: a) Baseline fetal heart rate less than 110 bpm or greater than 160 bpm; b) Presence of repetitive or prolonged (greater than 3 minutes) decelerations; c) More than five contractions in a ten minute period.","GAIA Level 3 Non-reassuring Fetal Status | Global Alignment of Immunization safety Assessment in pregnancy Level 3 Non-reassuring Fetal Status | Level 3 Non-reassuring Fetal Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509155","GAIA Level 1 Maternal Death","C127997","GAIA Level 1 Maternal Death is defined by three criteria: first, diagnosis of a pregnancy as established by any one of the following documented requirements: a) Ultrasound examination; b) Fetal heart tones; c) Positive serum or urine human chorionic gonadotropin pregnancy test; d) Delivery of a neonate or other products of conception (abortus, stillborn); second, the death of the mother while pregnant or within 42 days of the termination of a pregnancy, irrespective of the duration and the site of the pregnancy; third, documentation of the maternal cause of death as one of the following: a) Direct: abortive outcome, hypertensive disorder, obstetric hemorrhage, pregnancy related infection, other obstetric complications, unanticipated complications; b) Indirect: non obstetric complications; c) Death during pregnancy, childbirth, and the puerperium: other or coincidental.","GAIA Level 1 Maternal Death | Global Alignment of Immunization safety Assessment in pregnancy Level 1 Maternal Death | Level 1 Maternal Death",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL509263","Indirect Transmission","C128170","The transmission of an infectious agent from a source to a host through an intermediary such as inanimate objects (vehicles) or living organisms (vectors).","Indirect Transmission | Indirect Contact Transmission",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008266","Chloroplast","C13199","Photosynthetic organelle containing chlorophyll, the photosynthetic pigment, in cells of leaves and young stems of higher plants. Lens-shaped and rather variable in size but approximately 5 m long. Surrounded by a double membrane and contains circular DNA (though not enough to code for all proteins in the chloroplast). Like the mitochondrion, it is semi-autonomous. It resembles a cyanobacterium from which, on the endosymbiont hypothesis, it might be derived. Chlorophyll is associated with the membrane of vesicles (thylakoids) that are stacked to form grana.","Chloroplast | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021032","Immunoglobulin Fc","C13247","A protein product that results from the digestion of antibodies with papain and is comprised of the second and third constant regions of the antibody heavy chain.","Immunoglobulin Fc | Fc Fragment | Fragment Crystallizable Region | IGG FC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520317","Adipocyte Accumulation","C132483","An increase of adipocytes in the extracellular space.","Adipocyte Accumulation | ACCUMULATION, ADIPOCYTES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519960","Hemangiectasis","C132484","Dilatation of the blood vessels.","Hemangiectasis | ANGIECTASIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520349","Apoptosis and Necrosis","C132485","A finding that generally has features of degeneration and necrosis.","Apoptosis and Necrosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521025","Eosinophilic Globules","C132487","A cellular droplet comprising fibrin degradation products or intracytoplasmic proteinaceous accumulations that can be stained by eosin.","Eosinophilic Globules | EOSINOPHILIC GLOBULES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519959","Helicobacter Present","C132488","The presence of any species of Helicobacter.","Helicobacter Present | HELICOBACTER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521021","Non-clinical Contributing Scientist Name","C132489","The name of a scientist involved in study activities, which may include but is not limited to preparation of a contributor report. This role does not imply regulatory responsibilities or oversight. (CDISC)","Non-clinical Contributing Scientist Name | CNTRBSC | Contributing Scientist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519752","Contract FDF Manufacturing","C132491","Manufacturing of a part or all of final dosage form (FDF) that takes place in a contract facility and the contract facility is not identified in an approved ANDA owned by that facility or its affiliates.","Contract FDF Manufacturing | Contract Manufacturing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0872076","Pluripotent Stem Cells","C12977","A cell that can differentiate to cells derived from any of the three germ layers. --2005","Pluripotent Stem Cell | pluripotent stem cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596508","Embryonic Stem Cell","C12935","Embryonic stem (ES) cells are cells derived from the inner cell mass of the early embryo that can be propagated indefinitely in the primitive undifferentiated state while remaining pluripotent.","Embryonic Stem Cell | Embryonic Stem Cells",,,,,,,,,,,,,,,"4169777","Embryonic stem cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513400","Burixafor Hydrobromide","C130049","The hydrobromide salt form of burixafor, an orally bioavailable inhibitor of CXC chemokine receptor 4 (CXCR4) with hematopoietic stem cell (HSC)-mobilization and chemosensitizing activities. Upon administration, burixafor binds to the chemokine receptor CXCR4, thereby preventing the binding of stromal cell-derived factor-1 (SDF-1 or CXCL12) to the CXCR4 receptor and subsequent receptor activation. This may induce the mobilization of hematopoietic stem and progenitor cells from the bone marrow into the peripheral circulation. Additionally, burixafor-mediated mobilization of disseminated tumor cells (DTCs) from the bone marrow into the blood may make these metastatic tumor cells more susceptible to the actions of chemotherapeutic agents. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types. CXCL12/CXCR4 interaction induces retention of hematopoietic cells in the bone marrow.","Burixafor Hydrobromide | Burixafor HBr | TG-0054 HBr | TG-0054 Hydrobromide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514016","XmAb13676","C130050","A bispecific, Fc domain-containing, monoclonal antibody with potential antineoplastic activity. Plamotamab contains two antigen-recognition sites: one for human CD3, a T cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, plamotamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells. Inclusion of an Fc domain on the antibody prolongs the half-life of the bispecific antibody and enhances T-cell-mediated tumor cell killing because the agent is able to bind to Fc receptors.","Plamotamab | PLAMOTAMAB | XmAb13676",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514049","Estimated Mean Atrial Pressure","C130056","The estimated arithmetic average of atrial pressure.","Estimated Mean Atrial Pressure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513968","Number of Events","C130057","A measurement of the total number of events that have occurred.","Number of Events | EVENTNUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514005","2-Dimensional Biplane Ultrasound Mode","C130058","A method of ultrasound imaging that uses a probe with two 2D planes set perpendicularly to each other, allowing for better detection and localization of objects/structures.","2-Dimensional Biplane Ultrasound Mode | 2-DIMENSIONAL BIPLANE MODE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520485","Pediatric Hematology-Oncology Terminology","C132009","Terminology developed by a collaborative effort of the National Cancer Institute's Enterprise Vocabulary Services, the National Institute of Child Health and Human Development, and an international group of clinicians and informaticists to support the reporting of events observed in clinical care and research in children and adolescents seen by experts in blood disorders and cancer.","Pediatric Hematology-Oncology Terminology | Pediatric Heme-Onc Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520194","Probody CX-072","C132192","A recombinant antibody prodrug composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) programmed cell death 1 ligand 1 (PD-L1; B7-H1; CD274) that is linked to a proprietary masking peptide through a protease-cleavable linker on the amino terminus of the light chain domain of the antibody, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of pacmilimab, the linkage system is stable in the circulation and, upon extravasation into the tumor microenvironment, the peptide mask is cleaved by tumor-associated proteases. These proteases are present in high concentrations and aberrantly activated in the tumor microenvironment, while expressed as inactive forms, at much lower concentrations, in normal, healthy tissue. Protease cleavage of the linker enables binding of the unmasked, fully active monoclonal antibody moiety of CX-072 to PD-L1, which is over expressed on certain cancer cells. This blocks the binding to and activation of its receptor programmed cell death 1 (PD-1) on T-lymphocytes, thereby enhancing the T-cell-mediated anti-tumor immune response and reversing PD-L1/PD-1-mediated T-cell suppression. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. Compared to the unmodified PD-L1 antibody, peptide masking of CX-072 minimizes binding to PD-L1 in normal tissues, thereby decreasing autoimmune-based side effects while retaining anti-tumor activity.","Pacmilimab | CX 072 | CX-072 | PACMILIMAB | PD-L1 Probody Therapeutic CX-072 | Probody CX-072",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1177020","Adenovirus-expressing TLR5/TLR5 Agonist Nanoformulation M-VM3","C131825","A nanoparticle-based formulation containing a recombinant non-replicating adenovirus (Ad) encoding toll-like receptor 5 (TLR5) and its specific ligand protein 502S, with potential antineoplastic and immunomodulating activities. Upon administration, the Ad preferentially and specifically infects cells expressing the Coxsackievirus and adenovirus receptor (CAR), which is highly expressed in certain human tumors, and expresses both TLR5 and a specific agonistic ligand in the same cell. 502S binds to and activates TLR5, thereby allowing for continuous TLR5 signaling. This stimulates dendritic cells (DCs), monocytes, macrophages and the nuclear factor-kappa B (NF-kappaB) signaling cascade. This activation results in the production of pro-inflammatory cytokines, including interferon alpha, tumor necrosis factor-alpha and the interleukins (IL), IL-1 beta, -6 and -12. This may induce a T helper cell-1 (Th1) immune response and activate a cytotoxic T-lymphocyte (CTL) response against tumor associated antigens (TAAs). TLR5, a member of the TLR family, plays a key role in the activation of innate immunity.","Adenovirus-expressing TLR5/TLR5 Agonist Nanoformulation M-VM3 | M-VM3 | Mobilan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514459","VDAC/HK2 Modulator Ointment VDA-110","C131826","A topical ointment formulation containing a voltage-dependent anion channel (VDAC)/hexokinase 2 (HK2) modulator, with potential activity against certain skin cancers. Upon topical application, VDA-1102, as a protein-protein interaction (PPI) disrupter, allosterically binds to HK2, and causes HK2 to dissociate from VDAC, which prevents glycolysis and triggers apoptosis, thereby inhibiting tumor cell growth in VDAC/HK2-expressing tumor cells without affecting the surrounding healthy skin tissue. The VDAC/HK2 system, over-activated in cancer cells, plays a key role in tumor cell proliferation. The VDAC/HK2 association protects cancer cells from apoptosis. HK2 is overexpressed in many malignant cancer tissues that rely on glycolysis, while its expression is limited in normal healthy cells.","VDAC/HK2 Modulator Ointment VDA-110 | VDA-1102 | VDA-1102 Ointment | VDA-1102 Topical Dermal Ointment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514400","LSD-1 Inhibitor IMG-7289","C131827","An orally available, irreversible inhibitor of lysine-specific demethylase 1 (LSD1), with potential antineoplastic activity. Upon administration, bomedemstat binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor suppressor genes. In addition, LSD1 demethylates mono- or di-methylated H3K9 which increases gene expression of tumor promoting genes; thus, inhibition of LSD1 also promotes H3K9 methylation and decreases transcription of these genes. Altogether, this may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. LSD1, an enzyme belonging to the flavin adenine dinucleotide (FAD)-dependent amine oxidase family is overexpressed in certain tumor cells and plays a key role in the regulation of gene expression, tumor cell growth and survival.","Bomedemstat | BOMEDEMSTAT | IMG 7289 | IMG-7289 | LSD-1 Inhibitor IMG-7289 | Lysine-specific Demethylase 1 Inhibitor IMG-7289",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514240","Anti-CD133-PE38-KDEL Fusion Protein","C131828","A fusion protein consisting of an anti-single-chain variable fragment (scFv) peptide sequence targeting the extracellular domain of human CD133 (prominin-1) (anti-CD133scFV) and a deimmunized truncated form of Pseudomonas exotoxin A (38-kDa derivative of PE; PE38) where the five C-terminal amino acid residues have been replaced with the endoplasmic reticulum (ER) retention signal, KDEL, with potential antineoplastic activity. Upon administration of the anti-CD133-PE38-KDEL fusion protein, the anti-CD133 scFV moiety targets and binds to CD133, which is expressed on a variety of tumor cells. Upon internalization of the receptor-fusion protein complex, the KDEL sequence targets the fusion protein to the ER, where the PE38 exotoxin portion then inhibits protein synthesis, which results in a reduction of proliferation of CD133-expressing tumor cells. CD133, a glycoprotein expressed by a variety of cancers and especially by cancer stem cells (CSCs), plays a key role in tumor initiation, proliferation and progression.","Anti-CD133-PE38-KDEL Fusion Protein | Anti-CD133-Deimmunized Pseudomonas Exotoxin A-KDEL Fusion Protein | Deimmunized CD133KDEL | Deimmunized CD133KDEL Toxin | dCD133KDEL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225337","Columnar Epithelium","C13182","Epithelium that is composed of columnar glandular cells.","Columnar Epithelium | ",,,,,,,,,,,,,,,"4136204","Columnar epithelium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514286","Focal KATP-Associated Hyperinsulinism","C131830","KATP-associated hyperinsulinism in which there is an area of adenomatous beta-cell hyperplasia. This condition results from paternal recessive mutation(s) in either the ABCC8 or the KCNJ11 gene and paternal uniparental isodisomy of chromosome region 11p15 with loss of tumor suppressor genes expressed from the maternally inherited chromosome.","Focal KATP-Associated Hyperinsulinism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514017","ZW25","C130010","An engineered immunoglobulin G1 (IgG1) bi-specific monoclonal antibody that targets two different non-overlapping epitopes of the human tumor-associated antigen (TAA) epidermal growth factor receptor 2 (HER2), ECD2 and ECD4, with potential immunomodulating and antineoplastic activities. Upon administration, zanidatamab targets and binds to the two distinct HER2 domains on the tumor cell surface. This results in dual HER2 signal blockade, HER2 clustering, receptor internalization and downregulation. This also induces a cytotoxic T-lymphocyte (CTL) response and antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER2. Antibody-dependent cellular phagocytosis (ADCP) is also induced and further stimulates the immune system to kill HER2-overexpressing tumor cells. The HER2 receptor internalization also further inhibits HER2 activation, HER2-mediated signaling and HER2-mediated tumor cell growth. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","Zanidatamab | Anti-HER2/HER2 Bispecific Antibody ZW25 | HER2 x HER2 Bispecific Antibody ZW25 | ZANIDATAMAB | ZW-25 | ZW25",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514007","3-Dimensional Ultrasound Mode","C130060","A method of ultrasound imaging that allows for the construction of three dimensional images of a given object/structure.","3-Dimensional Ultrasound Mode | 3-DIMENSIONAL MODE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513817","Color Tissue Doppler Ultrasound Mode","C130061","A method of ultrasound imaging that uses pulsed wave Doppler signals to depict tissue motion direction and velocity in color images that are superimposed over normal, 2D images.","Color Tissue Doppler Ultrasound Mode | COLOR TISSUE DOPPLER MODE | Color Flow Tissue Doppler Mode",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513819","Continuous-Wave Doppler Ultrasound Mode","C130062","A method of ultrasound imaging that uses Doppler signals that are continuously sent and received along a single line to measure both direction and velocity of blood flow.","Continuous-Wave Doppler Ultrasound Mode | CONTINUOUS-WAVE DOPPLER MODE | CW Doppler | Continuous Doppler Mode",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0302191","Trachea and Bronchus","C12961","Trachea -The cartilaginous and membranous tube descending from the larynx and branching into the right and left main bronchi. Bronchi-The larger air passages of the lungs arising from the terminal bifurcation of the trachea.","Trachea and Bronchus | Respiratory System, Trachea, Bronchus | Trachea / Major Bronchi | Trachea, Bronchus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520651","Feline Lymphoma","C132193","A lymphoma that occurs in cats. It is associated with exposure to feline leukemia virus and feline immunodeficiency virus.","Feline Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520215","Rat Pituitary Gland Neoplasm","C132194","A benign or malignant neoplasm that affects the pituitary gland of a rat.","Rat Pituitary Gland Neoplasm | Rat Pituitary Gland Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0795949","Galloway-Mowat Syndrome","C132195","An autosomal recessive neurodegenerative condition caused by mutation(s) in the WDR73 gene, encoding WD repeat-containing protein 73. It is characterized by microcephaly and severely delayed psychomotor development.","Galloway-Mowat Syndrome | GAMOS",,,,,,,,,,,,,,,"36715581","Galloway Mowat syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0398782","Carboxypeptidase N Deficiency","C132196","An autosomal recessive condition caused by mutation(s) in the CPN1 gene, encoding carboxypeptidase N catalytic chain. It may be characterized by episodic angioedema, chronic urticaria, asthma and/or allergic hypersensitivity.","Carboxypeptidase N Deficiency | ",,,,,,,,,,,,,,,"4122333","Anaphylotoxin inactivator deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514298","Glucokinase-Associated Hyperinsulinism","C131831","Hyperinsulinism due to activating mutation(s) in the gene GCK, encoding glucokinase.","Glucokinase-Associated Hyperinsulinism | GCK-Associated Hyperinsulinism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1847555","Glutamate Dehydrogenase 1 Hyperinsulinism","C131832","Hyperinsulinism due to activating mutation(s) in the GLUD1 gene, encoding glutamate dehydrogenase 1. This condition is characterized by protein induced hypoglycemia and hyperammonemia, which is presumed to be due to increased ammonia production in the kidney.","Glutamate Dehydrogenase 1 Hyperinsulinism | GDH Hyperinsulinism | GLUD1 Hyperinsulinism | Hyperinsulinism/Hyperammonemia Syndrome",,,,,,,,,,,,,,,"37397460","Hyperinsulinism and hyperammonemia syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514651","Hepatocyte Nuclear Factor 1-Alpha Hyperinsulinism","C131833","Hyperinsulinism due to mutation(s) in the gene HNF1A, encoding the transcription factor hepatocyte nuclear factor 1-alpha. This condition may progress to diabetes later in life.","Hepatocyte Nuclear Factor 1-Alpha Hyperinsulinism | HNF1A-Associated Hyperinsulinism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520318","PDE4D wt Allele","C132038","Human PDE4D wild-type allele is located in the vicinity of 5q12 and is approximately 1553 kb in length. This allele, which encodes cAMP-specific 3',5'-cyclic phosphodiesterase 4D protein, plays a role in the modulation of second messenger signaling. Mutation of the gene is associated with acrodysostosis 2 and increased susceptibility to stroke.","PDE4D wt Allele | ACRDYS2 | DPDE3 | HSPDE4D | PDE43 | PDE4DN2 | Phosphodiesterase 4D wt Allele | Phosphodiesterase 4D, cAMP-Specific (Dunce (Drosophila)-Homolog Phosphodiesterase E3) Gene | Phosphodiesterase 4D, cAMP-Specific (Phosphodiesterase E3 Dunce Homolog, Drosophila) Gene | Phosphodiesterase 4D, cAMP-Specific Gene | Phosphodiesterase E3 Dunce Homolog (Drosophila) Gene | STRK1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1313282","PDE4D protein, human","C132039","cAMP-specific 3',5'-cyclic phosphodiesterase 4D (809 aa, ~91 kDa) is encoded by the human PDE4D gene. This protein is involved in the conversion of cyclic adenosine monophosphate (cAMP) to AMP.","cAMP-Specific 3',5'-Cyclic Phosphodiesterase 4D | DPDE3 | Dunce-Like Phosphodiesterase E3 | EC 3.1.4.53 | PDE43 | PDE4D | cAMP-Specific Phosphodiesterase PDE4D6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008643","Human Chromosome","C13203","A structure found in the nucleus of human cells that is comprised of a strand of linearized double-stranded DNA plus proteins that package the DNA in a condensed coil form and regulate chromosomal function.","Human Chromosome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420291","SNRPD3 Gene","C132040","This gene plays a role in spliceosome formation.","SNRPD3 Gene | SNRPD3 | Small Nuclear Ribonucleoprotein D3 Polypeptide Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521140","SNRPD3 wt Allele","C132041","Human SNRPD3 wild-type allele is located in the vicinity of 22q11.23 and is approximately 54 kb in length. This allele, which encodes small nuclear ribonucleoprotein Sm D3 protein, is involved in spliceosome activity.","SNRPD3 wt Allele | SMD3 | Sm-D3 | Small Nuclear Ribonucleoprotein D3 Polypeptide (18kD) Gene | Small Nuclear Ribonucleoprotein D3 Polypeptide 18kDa Gene | Small Nuclear Ribonucleoprotein D3 Polypeptide wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521349","Small Nuclear Ribonucleoprotein Sm D3","C132042","Human SNRPD3 wild-type allele is located in the vicinity of 22q11.23 and is approximately 54 kb in length. This allele, which encodes small nuclear ribonucleoprotein Sm D3 protein, is involved in spliceosome activity.","Small Nuclear Ribonucleoprotein Sm D3 | Sm-D3 | Small Nuclear Ribonucleoprotein Polypeptide D3 | SnRNP Core Protein D3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424862","PASK Gene","C132043","This gene is involved in energy homeostasis.","PASK Gene | PAS Domain Containing Serine/Threonine Kinase Gene | PASK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521124","PASK wt Allele","C132044","Human PASK wild-type allele is located in the vicinity of 2q37.3 and is approximately 44 kb in length. This allele, which encodes PAS domain-containing serine/threonine-protein kinase protein, plays a role in serine/threonine protein phosphorylation.","PASK wt Allele | KIAA0135 | PAS Domain Containing Serine/Threonine Kinase wt Allele | PASKIN | STK37",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1312481","Paskin protein, human","C132045","PAS domain-containing serine/threonine-protein kinase (1323 aa, ~143 kDa) is encoded by the human PASK gene. This protein is involved in the phosphorylation of proteins that play a role in energy homeostasis.","PAS Domain-Containing Serine/Threonine-Protein Kinase | EC 2.7.11.1 | PAS Domain-Containing Serine/Threonine Kinase | PAS-Kinase | Per-Arnt-Sim (PAS) Domain Kinase | hPASK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1136571","Nelivaptan","C132046","No value exists.","Nelivaptan | (2S,4R)-1-((3R)-5-Chloro-1-((2,4-dimethoxybenzene)sulfonyl)-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl)-4-hydroxy-N,N-dimethylpyrrolidine-2-carboxamide | NELIVAPTAN | SSR 149415 | SSR149415",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513977","Oxidative Phosphorylation Inhibitor IACS-010759","C130012","An orally bioavailable oxidative phosphorylation (OxPhos) inhibitor, with potential antineoplastic activity. Upon administration of the OxPhos inhibitor IACS-010759, this agent binds to and inhibits complex I of the electron transport chain (NADH ubiquinone oxidoreductase), thereby selectively depriving tumor cells of nutrients, and energy, and inhibiting nucleotide and amino acid production, which induces autophagy, causes tumor cell death and inhibits cell proliferation. Mitochondrial complex I, which is hyperactivated in cancer cells to meet their increased demands for energy, plays a key role in the promotion of cancer cell proliferation.","Oxidative Phosphorylation Inhibitor IACS-010759 | IACS-010759 | OXPHOS Inhibitor IACS-010759",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514004","Carbon C 11 Metformin","C130014","A radiopharmaceutical tracer containing the anti-diabetic agent metformin, a biguanide and hydrophilic organic cation, and labeled with carbon 11 (11C), used to measure metformin uptake by cancer cells using positron emission tomography (PET). Upon administration of carbon C 11 metformin, the metformin moiety targets and binds to cancer cells; in turn, the compound is taken up by cancer cells. Upon PET, metformin distribution into cancer cells can be visualized, which allows for a prediction of the anti-cancer efficacy of metformin, based on tumor cell uptake. Metformin transport, such as uptake into cancer cells, appears to be correlated with the expression of organic cation transporters (OCT) 1-3, multidrug and toxin extrusion (MATE) 1 and 2, and plasma membrane monoamine transporter (PMAT). OCTs, MATEs and PMAT play a key role in the distribution and excretion of organic cationic compounds.","Carbon C 11 Metformin | 11C-metformin | Carbon-11 Metformin | METFORMIN C-11 | [11C]-metformin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514078","Carbon C 13 Idasanutlin","C130020","A radiopharmaceutical agent composed of an orally available, small-molecule antagonist of MDM2 (mouse double minute 2; Mdm2 p53 binding protein homolog), and labeled with the radioisotope carbon C 13, with potential use for evaluating the distribution patterns, metabolism and excretion of idasanutlin using nuclear magnetic resonance (NMR) spectroscopy. Upon administration, idasanutlin binds to MDM2 blocking the interaction between the MDM2 protein and the transcriptional activation domain of the tumor suppressor protein p53. By preventing the MDM2-p53 interaction, p53 is not enzymatically degraded and the transcriptional activity of p53 is restored. This may lead to p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger nuclear phosphoprotein and negative regulator of the p53 pathway, is often overexpressed in cancer cells and has been implicated in cancer cell proliferation and survival. . Labeling of idasanutlin with the radioactive tracer carbon C 13 permits the evaluation of idasanutlin's distribution patterns, including binding to and uptake by tumors, metabolism and excretion. This may aid in the understanding of the bioactivity of this agent.","Carbon C 13 Idasanutlin | C13 Idasanutlin | [13C]-radiolabeled Idasanutlin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512577","Rou Cong Rong","C129586","A Chinese herbal medicine (CHM) derived from the stems of the herbaceous plant Cistanche deserticola Y. C. Ma (Ginseng of the desert) belonging to the Orobanchaceae family. Rou Cong Rong may have antioxidative and neuroprotective activities. This traditional Chinese medicine (TCM) is used to help with pain, deficiency of kidney yang and may relieve constipation by moistening and smoothing stool.","Rou Cong Rong | CISTANCHE DESERTICOLA STEM | Herba Cistanche | Rou Cong-Rong | RouCongRong",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512905","Antineoplastic Antibody","C129822","Any type of antibody that exerts antineoplastic activity.","Antineoplastic Antibody | Anti-cancer Antibody | Anticancer Antibody | Antineoplastic Ab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512911","Antineoplastic Antibody-Drug Conjugate","C129823","Any tumor-targeting antibody conjugated to a cytotoxic agent that exerts an antineoplastic effect.","Antineoplastic Antibody-Drug Conjugate | ADC | Antibody-Drug Conjugate | Antineoplastic ADC | Antineoplastic Antibody-drug Conjugate | Cancer-targeted Antibody Drug Conjugate | Drug-conjugated Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512910","Antineoplastic Protein Inhibitor","C129824","Any agent that inhibits the activity of any protein that is involved in cancer-specific pathways. An antineoplastic protein inhibitor is a specific cancer cell-targeting agent.","Antineoplastic Protein Inhibitor | Anti-cancer Protein Inhibitor | Antineoplastic Protein Antagonist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512908","Antineoplastic Immune Cell","C129826","Any immune cell-based preparation that can be used or may potentially be used for its cytotoxic activity against cancer cells.","Antineoplastic Immune Cell | Anti-cancer Immune Cell | Antineoplastic Immune Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513045","Unresectable Transitional Cell Carcinoma","C129827","A transitional cell carcinoma which is not amenable to surgical resection.","Unresectable Transitional Cell Carcinoma | Unresectable Transitional Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3160869","Metastatic Transitional Cell Carcinoma","C129828","A carcinoma that arises from transitional cells and has spread from its original site of growth to another anatomic site.","Metastatic Transitional Cell Carcinoma | Metastatic Transitional Cell Cancer",,,,,,,,,,,,,,,"37155955","Metastatic transitional cell carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512915","CALR Exon 9 Mutation","C129831","A molecular genetic abnormality indicating the presence of a mutation in exon 9 of the CALR gene.","CALR Exon 9 Mutation | Autoantigen Ro Gene Exon 9 Mutation | CALR Exon 9 Gene Mutation | CRT Exon 9 Mutation | Calreticulin Gene Exon 9 Mutation | RO Exon 9 Mutation | cC1qR Exon 9 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021008","Immunoglobulin Constant Region","C13242","The portion of an antibody that is invariant within a class of immunoglobulins. It is comprised of the carboxyl terminal half of both light chains and at least three quarters of each heavy chain starting from the carboxyl terminus and excludes the variable regions of the heavy and light chains.","Immunoglobulin Constant Region | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021018","Immunoglobulin Joining Region","C13243","The portion of the light and heavy chains of immunoglobulin molecules where the variable and constant regions meet.","Immunoglobulin Joining Region | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519002","Peripheral Nerve Sheath","C12972","The protective covering surrounding the axon of neurons in the peripheral nervous system.","Peripheral Nerve Sheath | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513020","Autosomal Dominant Hypoparathyroidism","C129730","Hypoparathyroidism associated with heterozygous mutation(s) in the PTH gene, which encodes parathyroid hormone, or in the GCM2 gene, which encodes chorion-specific transcription factor GCMb.","Autosomal Dominant Hypoparathyroidism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1840334","Autosomal Recessive Hypoparathyroidism","C129731","Hypoparathyroidism associated with homozygous mutation(s) in the PTH gene, which encodes parathyroid hormone, or in the GCM2 gene, which encodes chorion-specific transcription factor GCMb.","Autosomal Recessive Hypoparathyroidism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512306","Tesidolumab","C129315","A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the complement pathway protein C5, with complement pathway inhibitory activity and potential immunomodulating activity. Upon administration, tesidolumab targets and binds to C5, thereby preventing both C5 convertase-mediated cleavage of C5 and the formation of C5a and C5b. This inhibits C5-mediated signal transduction, the formation of the membrane attack complex (MAC) and the activation of the terminal complement pathway, and results in the prevention and/or inhibition of both complement-mediated inflammation and cell destruction. C5 plays a key role in the activation of the complement cascade.","Tesidolumab | LFG-316 | LFG316 | NOV-4 | TESIDOLUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512373","ACTOplus Met XR","C129316","An extended-release (ER) tablet composed of the hydrochloride salt form of the biguanide metformin and the hydrochloride salt form of the thiazolidinedione pioglitazone, with antihyperglycemic activity. Upon oral administration and although the exact mechanism of action has yet to be fully elucidated, metformin inhibits complex I (NADPH:ubiquinone oxidoreductase) of the mitochondrial respiratory chain and increases the cellular AMP to ATP ratio leading to activation of AMP-activated protein kinase (AMPK). This modulates AMPK-mediated transcription of target genes, which prevents hepatic gluconeogenesis, decreases intestinal absorption of glucose, enhances insulin sensitivity and fatty acid oxidation, and increases glucose uptake and utilization in target tissues. Pioglitazone binds to and activates the transcription factor peroxisome proliferator-activated receptor gamma (PPAR-gamma), thereby increasing the transcription of insulin-responsive genes. This enhances insulin sensitivity of insulin-dependent tissues, decreases insulin resistance, enhances peripheral glucose utilization, and decreases hepatic glucose output. Altogether, this lowers blood glucose levels.","Metformin Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet | ACTOplus Met XR | Metformin HCl/Pioglitazone HCl ER Tablet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0521400","Meningeal","C12931","No value exists.","Meningeal | meningeal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512391","1p/19q Codeletion Status Unknown","C129320","A finding indicating that there is no information regarding the presence or absence of 1p/19q codeletion in a tumor sample.","1p/19q Codeletion Status Unknown | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512570","Niu Xi","C129587","A Chinese herbal medicine (CHM) composed of the dried root from the herbaceous plant Ox-Knee (Achyranthes bidentata Blume) belonging to the Amaranthaceae family. Niu Xi may regulate the blood, may help relieve certain pains, and it may tonify the liver and kidneys.","Niu Xi | ACHYRANTHES BIDENTATA ROOT | Achyranthes Root | Huai Niu Xi | Niuxi | Ox-Knee Root | Radix Achyranthis Bidentatae",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512593","Zinc Finger Nuclease ZFN-603","C129588","A zinc finger nuclease (ZFN) targeting the human papillomavirus (HPV) type 16 (HPV16) oncoprotein E7, with potential antineoplastic activity. Upon transfection of ZFN-603 into HPV16-positive cells, ZFN-603 targets, binds to and cleaves the HPV16 E7 oncogene in HPV16-infected cells. By cleaving the HPV16 E7 DNA, the E7 oncoprotein is not expressed. This results in an inhibition of E7-mediated signaling, an induction of apoptosis, and inhibition of tumor cell proliferation in HPV16-expressing cells. In addition, preventing E7 expression induces the expression of tumor suppressor genes, thereby further preventing HPV-induced cancer cell formation and proliferation. E7 plays a key role in promoting both viral infection and carcinogenesis. ZFN, an engineered endonuclease in which a DNA-binding zinc finger protein is fused to a DNA-cleavable domain, cleaves specific DNA sites.","Zinc Finger Nuclease ZFN-603 | ZFN ZFN-603 | ZFN-603 | ZFN603",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512594","Zinc Finger Nuclease ZFN-758","C129589","A zinc finger nuclease (ZFN) targeting the human papillomavirus (HPV) type 18 (HPV18) oncoprotein E7, with potential antineoplastic activity. Upon transfection of ZFN-758 into HPV18-positive cells, ZFN-758 targets, binds to and cleaves the HPV18 E7 oncogene in HPV18-infected cells. By cleaving the HPV18 E7 DNA, the E7 oncoprotein is not expressed. This results in an inhibition of E7-mediated signaling, an induction of apoptosis, and an inhibition of tumor cell proliferation in HPV18-expressing cells. In addition, preventing E7 expression induces the expression of tumor suppressor genes, thereby further preventing HPV-induced cancer cell formation and proliferation. E7 plays a key role in promoting both viral infection and carcinogenesis. ZFN, an engineered endonuclease in which a DNA-binding zinc finger protein is fused to a DNA-cleavable domain, cleaves specific DNA sites.","Zinc Finger Nuclease ZFN-758 | ZFN ZFN-758 | ZFN-758 | ZFN758",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512977","Mammalian Cell Specimen","C12958","A biospecimen consisting of cells originating from or isolated from an animal of class Mammalia.","Mammalian Cell Specimen | Mammalian Cell | Mammalian Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512635","Fluorescent Dye LS301","C129590","A hydrophobic near-infrared (NIR) fluorescent probe composed of a NIR fluorescent dye cypate linked to an unnatural D-cysteine-containing cyclic octapeptide (D-Cys-Gly-Arg--Asp-Ser-Pro-Cys)-Lys-OH, with potential cancer imaging activity. Upon administration during tumor resection, the peptide component of LS301 specifically targets and binds integrin receptors expressed on tumor cells, which are not expressed on normal, healthy cells. Upon receptor-mediated endocytosis and fluorescence imaging using infrared light that is visualized by the surgeon with special Cancer Vision Goggles (CVG), tumor cells can be detected, identified, and removed accordingly. This enhances the accuracy of cancer cell removal during surgery. The D-cysteine on the peptide prevents degradation by endogenous proteases.","Fluorescent Dye LS301 | Cypate-cyclo (D-Cys-Gly-Arg--Asp-Ser-Pro-Cys)-Lys-OH | LS 301 | LS-301 | LS301 | NIR Fluorescent Probe LS301",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512560","Monoclonal Antibody AK 002","C129591","A humanized, nonfucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against the inhibitory receptor sialic acid-binding immunoglobulin-like lectin 8 (Siglec-8) expressed on human mast cells and eosinophils, with potential anti-inflammatory activity. Upon administration, lirentelimab targets and binds to Siglec-8 expressed on the surface of mast cells and eosinophils. This may inhibit mast cell activation and deplete eosinophils through antibody-dependent cell-mediated cytotoxicity (ADCC) and apoptosis. This may reduce abnormal proliferation of mast cells and eosinophils, which plays a key role in allergic and inflammatory responses.","Lirentelimab | AK 002 | AK002 | LIRENTELIMAB | Monoclonal Antibody AK 002",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512614","Topical Naloxone Hydrochloride","C129592","A topical lotion formulation of the dehydrated, hydrochloride salt form of naloxone, an opiate antagonist, with potential anti-pruritic activity. Upon topical application of the naloxone lotion, naloxone binds to and blocks epidermal mu-opiate receptors. This may suppress or diminish pruritus.","Topical Naloxone Hydrochloride | E-0316 | Naloxone Hydrochloride Dehydrate Lotio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512913","CALR Exon 9 Deletion Mutation","C129832","A molecular genetic abnormality indicating the presence of a deletion mutation in exon 9 of the CALR gene. These deletion mutations are associated with primary myelofibrosis and may be predicative of a favorable survival prognosis.","CALR Exon 9 Deletion Mutation | Autoantigen Ro Gene Exon 9 Deletion Mutation | CRT Exon 9 Deletion Mutation | Calreticulin Gene Exon 9 Deletion Mutation | RO Exon 9 Deletion Mutation | cC1qR Exon 9 Deletion Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512914","CALR Exon 9 Insertion Mutation","C129833","A molecular genetic abnormality indicating the presence of an insertion mutation in exon 9 of the CALR gene. These insertion mutations are associated with primary myelofibrosis and may be predicative of shortened survival.","CALR Exon 9 Insertion Mutation | Autoantigen Ro Gene Exon 9 Insertion Mutation | CRT Exon 9 Insertion Mutation | Calreticulin Gene Exon 9 Insertion Mutation | RO Exon 9 Insertion Mutation | cC1qR Exon 9 Insertion Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512928","CALR Protein Variant","C129836","A variation in the amino acid sequence for the calreticulin protein.","CALR Protein Variant | CRP55 Protein Variant | Calregulin Protein Variant | Calreticulin Protein Variant | ERp60 Protein Variant | Endoplasmic Reticulum Resident Protein 60 Protein Variant | HACBP Protein Variant | grp60 Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507844","Human Placenta-derived Stem Cell Transplantation","C129407","An adjunctive therapy to umbilical cord blood (UCB) transplantation that is used to augment stem cell engraftment in hematopoietic reconstitution. The process to extract human placenta-derived stem cells (HPDSCs) yields an enriched population of CD34-positive hematopoietic stem cells that, when transplanted in conjunction with UCB stem cells, may provide a novel source for natural killer (NK) cells.","Human Placenta-derived Stem Cell Transplantation | HPDSC Transplantation | Human Placental-derived Stem Cell Transplantation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510985","Autologous Tumor Cell","C12940","No value exists.","Autologous Tumor Cell | Autologous Tumor Cells | autologous tumor cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0836133","Simple Squamous Epithelium","C13178","Epithelium composed of a single layer of flat cells wider than they are tall. This epithelium is found in anatomic sites where exchange of nutrients, wastes and gases occur.","Simple Squamous Epithelium | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004816","Basilar Membrane","C13179","A sheet of amorphous extracellular material upon which the basal surfaces of epithelial cells rest. It is made up of two layers, the basal lamina and the reticular lamina. It is also associated with muscle cells, Schwann cells, fat cells, and capillaries; and is interposed between the cellular elements and the underlying connective tissue.","Basilar Membrane | ",,,,,,,,,,,,,,,"4175608","Structure of basilar membrane of cochlea",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512143","Diffuse Glioma","C129325","A glioma that has diffusely infiltrated the surrounding central nervous system tissues.","Diffuse Glioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512231","Resting State Functional Connectivity Magnetic Resonance Imaging","C129326","A technique that monitors blood oxygen level dependent (BOLD) signals to map brain regions that active while not performing any specific task.","Resting State Functional Connectivity Magnetic Resonance Imaging | RS-fcMRI | Resting State Functional Connectivity MRI | Resting fcMRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512862","Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949","C129967","An agonistic human immunoglobulin G1 (IgG1) monoclonal antibody that recognizes the co-stimulatory receptor OX40 (CD134; TNFRSF4), with potential immunostimulatory and antineoplastic activities. Upon administration, agonistic anti-OX40 monoclonal antibody INCAGN01949 selectively binds to and activates OX40 on activated T-cells, thereby potentiating T-cell receptor (TCR) signaling. OX40 activation inhibits regulatory T-cell (Treg)-mediated suppression of effector T-cells, induces the proliferation of memory and effector T-lymphocytes and modulates cytokine production. In the presence of tumor-associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells. In addition, the IgG1 Fc region of INCAGN01949 binds to and co-engages with the IgG Fc-gamma receptor III (FcgammaRIII; CD16) expressed by immune effector cells; thus, binding activates FcgammaRIII-mediated signaling and facilitates the selective depletion of intratumoral Tregs, thereby further enhancing the cytotoxic T-lymphocyte (CTL)-mediated tumor cell response. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T-cells; OX40 stimulation abrogates the immunosuppressive tumor microenvironment.","Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949 | Anti-OX40 Agonist Antibody INCAGN01949 | Anti-OX40 Monoclonal Antibody INCAGN0194 | INCAGN 1949 | INCAGN-1949 | INCAGN1949 | Monoclonal Antibody INCAGN01949 | NCAGN01949",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0393590","Idiopathic Basal Ganglia Calcification 1","C129973","An autosomal dominant condition caused by mutation(s) in the SLC20A2 gene, encoding sodium-dependent phosphate transporter 2. It is characterized by calcification of the basal ganglia.","Idiopathic Basal Ganglia Calcification 1 | BSPDC | Bilateral Striopallidodentate Calcinosis | IBGC1",,,,,,,,,,,,,,,"4006783","Fahr's syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512857","Acute Myeloid Leukemia with Monoallelic CEBPA Mutation","C129783","An acute myeloid leukemia with single mutations of the CEBPA gene.","Acute Myeloid Leukemia with Monoallelic CEBPA Mutation | Acute Myeloid Leukemia with Monoallelic Mutations of CEBPA | Acute Myeloid Leukemia with Monoallelic Mutations of CEBPA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513044","Unresectable Thyroid Gland Carcinoma","C129784","A carcinoma that arises from the thyroid gland and is not amenable to surgical resection.","Unresectable Thyroid Gland Carcinoma | Unresectable Thyroid Gland Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513042","Translocations Involving Tyrosine Kinases or Cytokine Receptors Present","C129789","A cytogenetic finding indicating the presence of translocations involving either tyrosine kinases or cytokine receptors.","Translocations Involving Tyrosine Kinases or Cytokine Receptors Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0872372","Totipotent Stem Cell","C12978","Totipotent stem cells, such as the product of fertilization of an ovum and its progeny, are stem cells that have total potency to form an entire mature organism, e.g., a human being, although only if placed in a woman's uterus.","Totipotent Stem Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512931","IDO1 Inhibitor KHK2455","C129790","An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1 inhibitor KHK2455 targets and binds to IDO1, an enzyme responsible for the oxidation of tryptophan into kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, KHK2455 increases and restores the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes. KHK2455 also induces increased interferon (IFN) production, and causes a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may inhibit the growth of IDO1-expressing tumor cells. IDO1, a cytosolic enzyme responsible for tryptophan catabolism and the conversion of tryptophan into kynurenine, is overexpressed by a variety of tumor cell types and antigen presenting cells (APCs); it plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system.","IDO1 Inhibitor KHK2455 | IDO-1 Inhibitor KHK2455 | KHK 2455 | KHK2455",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512696","Clostridium Cluster","C129411","A set of non-taxonomic groups of bacterial species in either the Clostridium genus or another related genus. The members of the groups were chosen based on comparative sequence analysis of their 16S ribosomal RNA gene sequences.","Clostridium Cluster | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512695","Clostridium Cluster XVI","C129414","A group that includes Clostridium innocuum, Eubacterium biforme and Streptococcus pleomorphus, which are within the mycoplasma supercluster. This grouping is based on comparative sequence analysis of their 16S ribosomal RNA gene sequences. Some of these species are commensal in humans.","Clostridium Cluster XVI | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520238","Resectable Head and Neck Squamous Cell Carcinoma","C132012","Squamous cell carcinoma of the head and neck that is amenable to surgical resection.","Resectable Head and Neck Squamous Cell Carcinoma | Resectable Head and Neck Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520999","TGFbeta Inhibitor LY3200882","C132013","An orally bioavailable agent that targets transforming growth factor-beta (TGFb), with potential antineoplastic activity. Upon administration, LY3200882 specifically targets and binds to TGFb, which prevents both the binding of TGFb to its receptor TGFbR and TGFb-mediated signal transduction. This may lead to a reduction in TGFb-dependent proliferation of cancer cells. The TGFb signaling pathway is often deregulated in tumors, and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, angiogenesis, and various immune responses.","TGFbeta Inhibitor LY3200882 | LY 3200882 | LY-3200882 | LY3200882 | TGFb Inhibitor LY 3200882",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520548","Sustained-Exposure Dexamethasone Formulation OTO-104","C132014","A sustained-release (SR) poloxamer hydrogel formulation containing the glucocorticoid dexamethasone (DXM), with potential otoprotective and anti-apoptotic activities. Prior to the administration of an ototoxic drug and upon intratympanic (IT) injection of the DXM sustained-exposure formulation OTO-104, DXM is slowly released from the hydrogel over time; DMX then binds to glucocorticoid nuclear receptors, and activates cell survival pathways. This prevents ototoxic drug-induced generation of reactive oxygen species (ROS) by activating anti-oxidant enzymes, blocking the activation of inflammatory cytokines and inducing stress signaling pathways, which ultimately prevents apoptosis of auditory hair cells in the inner ear compartment. This prevents or reduces drug-induced ototoxicity caused by certain therapeutic agents, such as platinum-based anticancer agents. This may reduce or prevent hearing loss, tinnitus, and vertigo. The SR formulation provides increased concentrations of DXM in the inner ear and maintains the elevated levels for a longer time without the need of the multiple IT injections needed when using non-SR DXM formulations. This agent also reduces the symptoms of certain ear-related disorders.","Sustained-Exposure Dexamethasone Formulation OTO-104 | Dexamethasone Sustained-exposure Formulation OTO-104 | OTO-104 | SR DXM Formulation OTO-104 | Sustained Release Dexamethasone Formulation OTO-104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520298","Untreated Chronic Lymphocytic Leukemia","C132015","A finding of chronic lymphocytic leukemia that has not been treated.","Untreated Chronic Lymphocytic Leukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520299","Untreated Small Lymphocytic Lymphoma","C132016","A finding of small lymphocytic lymphoma that has not been treated.","Untreated Small Lymphocytic Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520570","HuMax-AXL-ADC","C132017","An antibody-drug conjugate (ADC), consisting of a human monoclonal antibody directed against AXL receptor tyrosine kinase (AXL; UFO) and conjugated, through a protease-cleavable linker, to the cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of enapotamab vedotin binds to AXL, which is expressed on the surfaces of a variety of cancer cell types. Upon endocytosis and enzymatic cleavage, MMAE is released into the tumor cell cytosol, where it binds to tubulin and inhibits tubulin polymerization; this may result in G2/M phase arrest and apoptosis. AXL, a member of the TAM (TYRO3, AXL and MER) family of receptor tyrosine kinases and overexpressed by many tumor cell types, plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance and poor prognosis.","Enapotamab Vedotin | Anti-AXL/MMAE ADC | Anti-AXL/MMAE Antibody-Drug Conjugate | ENAPOTAMAB VEDOTIN | HuMax-AXL-ADC | Immunoglobulin G1, Anti-(Human Growth Factor Receptor axl)(Human Humax-axl Gamma1-chain), Disulfide with Human Humax-axl Kappa-chain, Dimer Tetrakis(thioether) with Vedotin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342800","Inosine Triphosphatase Deficiency","C129974","An inherited condition caused by mutation(s) in the ITPA gene, encoding inosine triphosphate pyrophosphatase. It is characterized by elevated concentrations of inosine triphosphate in erythrocytes.","Inosine Triphosphatase Deficiency | ",,,,,,,,,,,,,,,"4079870","Inosine triphosphate pyrophosphohydrolase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1969809","Isobutyryl-CoA Dehydrogenase Deficiency","C129975","An inherited condition caused by mutation(s) in the ACAD8 gene, encoding isobutyryl-CoA dehydrogenase, mitochondrial. It is characterized by decreased concentrations of carnitine in the blood, encephalopathy, dilated cardiomyopathy, and anemia.","Isobutyryl-CoA Dehydrogenase Deficiency | ",,,,,,,,,,,,,,,"40482899","Deficiency of isobutyryl-CoA dehydrogenase",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0795833","Kleefstra Syndrome","C129976","A condition caused by mutation or deletion of the EHMT1 gene, encoding histone-lysine N-methyltransferase EHMT1. It is characterized by severe intellectual disability, hypotonia, cardiac defects, and characteristic facial features.","Kleefstra Syndrome | Chromosome 9q34.3 Deletion Syndrome",,,,,,,,,,,,,,,"37110119","Kleefstra syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513034","Mitochondrial DNA Depletion Syndrome 12","C129977","An inherited condition caused by mutation(s) in the SLC25A4 gene, encoding ADP/ATP translocase 1. It is characterized by hypertrophic cardiomyopathy.","Mitochondrial DNA Depletion Syndrome 12 | MTDPS12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1854896","Mucolipidosis Type III Gamma","C129978","An autosomal recessive condition caused by mutation(s) in the GNPTAG gene, encoding N-acetylglucosamine-1-phosphotransferase subunit gamma. It is characterized by a slowing of the growth rate in childhood, joint stiffness, mild cognitive impairment, and cardiorespiratory insufficiency.","Mucolipidosis Type III Gamma | Mucolipidosis III Gamma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268059","Neonatal Hemochromatosis","C129980","An idiopathic form of neonatal hemochromatosis, characterized by liver failure and iron accumulation in the tissues.","Neonatal Hemochromatosis | ",,,,,,,,,,,,,,,"4189359","Neonatal hemochromatosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512654","Splicing Inhibitor H3B-8800","C129546","An orally bioavailable inhibitor of the splicing factor 3B subunit 1 (SF3B1), with potential antineoplastic activity. Upon administration, H3B-8800 binds to and blocks the activity of SF3B1, a core spliceosome protein that is mutated in various cancer cells. This modulates RNA splicing by preventing aberrant mRNA splicing by the spliceosome, blocks RNA mis-splicing, enhances proper RNA splicing and prevents the expression of certain tumor-associated genes. This leads to an induction of apoptosis and prevents tumor cell proliferation. In many cancer cells, core spliceosome proteins, including SF3B1, U2 small nuclear ribonucleoprotein auxiliary factor 1 (U2AF1), serine/arginine-rich splicing factor 2 (SRSF2) and U2 small nuclear ribonucleoprotein auxiliary factor subunit-related protein 2 (ZRSR2), are mutated and aberrantly activated leading to a dysregulation of mRNA splicing.","Splicing Inhibitor H3B-8800 | H3B 8800 | H3B-8800 | Splicing Factor Inhibitor H3B-8800 | Splicing Modulator H3B-8800",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512777","Intracranial Fibrous Histiocytoma","C129549","A benign fibrous histiocytoma involving the dura or cranial bone.","Intracranial Fibrous Histiocytoma | Intracranial Benign Fibrous Histiocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512344","Baltaleucel-T","C129374","A preparation of autologous Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes (CTLs), which have specific reactivity to the EBV antigens, latent membrane proteins (LMP) 1 (LMP1) and 2 (LMP2), EBV nuclear antigen (EBNA) and BamHI-A rightward frame-1 (BARF1), with potential immunomodulating and antineoplastic activities. Upon administration, baltaleucel-T targets and binds to EBV-expressing cancer cells specifically expressing the targeted antigens. This may kill LMP1/LMP2/EBNA/BARF1-expressing EBV-associated cancer cells. LMP1, LMP2, EBNA and BARF1 are tumor-associated antigens (TAAs) that are specifically associated with EBV infection, and play key roles in the proliferation of a variety of tumors.","Baltaleucel-T | BALTALEUCEL-T | Baltaleucel T | CMD-003 | Epstein Barr Virus-specific LMP1/LMP2/EBNABARF1-targeting Autologous Cytotoxic T-lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512154","IDO1 Inhibitor PF-06840003","C129375","An orally available hydroxyamidine and inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1 inhibitor PF-06840003 targets and binds to IDO1, an enzyme responsible for the oxidation of tryptophan into kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, PF-06840003 increases and restores the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes; PF-06840003 also induces increased interferon (IFN) production, and causes a reduction in tumor-associated regulatory T cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may inhibit the growth of IDO1-expressing tumor cells. IDO1, a cytosolic enzyme responsible for tryptophan catabolism and the conversion of tryptophan into kynurenine, is overexpressed by a variety of tumor cell types and antigen presenting cells (APCs); it plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system.","IDO1 Inhibitor PF-06840003 | IDO-1 Inhibitor PF-06840003 | Indoleamine 2,3-Dioxygenase Inhibitor PF-06840003 | PF 06840003 | PF-06840003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596882","Mammary Epithelium","C12937","The epithelium that lines the lactiferous ducts and the secretory alveoli. The mammary epithelium in the lactiferous duct is a two layered epithelium. The basal cells are cuboidal and the superficial cells are columnar. Branches of the lactiferous duct are lined with a simple cuboidal epithelium. The secretory alveoli are lined by a cuboidal or columnar epithelium. During the first half of pregnancy, the epithelium undergoes considerable growth leading to the formation of new terminal branches of ducts and of alveoli. The mammary glands continue to grow during the second half of pregnancy due to increases in the height of epithelial cells and an expansion of the lumen of the alveoli.","Mammary Epithelium | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512723","TPM3 Gene Product","C129381","A protein encoded by the TPM3 gene.","TPM3 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519882","HAQ-DI Without VAS - Help: Gripping and Opening Things","C132616","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Usually need help from another person: Gripping and opening things.","HAQ-DI Without VAS - Help: Gripping and Opening Things | HAQ02-Help: Gripping and Opening Things | HAQ0244",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521009","TSQM Version 1.4 - Medication to Prevent or Treat Condition","C132618","Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) How satisfied or dissatisfied are you with the ability of the medication to prevent or treat your condition?","TSQM Version 1.4 - Medication to Prevent or Treat Condition | TSQM01-Med to Prevent/Treat Condition | TSQM0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521013","TSQM Version 1.4 - Way Medication Relieves Symptoms","C132619","Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) How satisfied or dissatisfied are you with the way the medication relieves your symptoms?","TSQM Version 1.4 - Way Medication Relieves Symptoms | TSQM01-Way Medication Relieves Symptoms | TSQM0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512687","Central Nervous System Myofibroblastoma","C129551","A rare myofibroblastoma affecting the central nervous system.","Central Nervous System Myofibroblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513023","Autosomal Recessive Osteopetrosis","C129733","An autosomal recessive form of osteopetrosis caused by mutation(s) in at least 8 genes related to osteoclast function. This condition is characterized by the failure of osteoclasts to resorb bone, resulting in impaired bone modeling/remodeling, and skeletal fragility despite increased bone mass; it is also associated with hematopoietic insufficiency, hypocalcemia, disturbed tooth eruption, nerve entrapment syndromes, and growth impairment. Some cases are also associated with progressive neurological deterioration.","Autosomal Recessive Osteopetrosis | Malignant Osteopetrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513022","Autosomal Recessive Infantile Hypercalcemia","C129734","A condition caused by autosomal recessive loss-of-function mutation(s) in the CYP24A1 or SLC34A1 gene, encoding mitochondrial 1,25-dihydroxyvitamin D(3) 24-hydroxylase, and sodium-dependent phosphate transport protein 2A, respectively. This condition is characterized by vomiting, polyuria, dehydration, and failure to thrive, accompanied by hypercalcemia, suppressed parathyroid hormone, and nephrocalcinosis.","Autosomal Recessive Infantile Hypercalcemia | Idiopathic Infantile Hypercalcemia",,,,,,,,,,,,,,,"36675119","Autosomal recessive infantile hypercalcemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268813","Dipsogenic Diabetes Insipidus","C129735","Diabetes insipidus caused by excessive intake of water due to psychological factors or damage to the thirst-regulating mechanism.","Dipsogenic Diabetes Insipidus | Primary Polydipsia",,,,,,,,,,,,,,,"4221532","Dipsogenic diabetes insipidus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513021","Autosomal Dominant Neurohypophyseal Diabetes Insipidus","C129736","An autosomal dominant form of diabetes insipidus caused by mutation(s) in the AVP gene encoding arginine vasopressin.","Autosomal Dominant Neurohypophyseal Diabetes Insipidus | ADNDI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3888631","Monogenic Diabetes","C129739","Diabetes mellitus caused by mutation(s) in a single gene, usually presenting in childhood or early adulthood.","Monogenic Diabetes | MODY | Maturity Onset Diabetes of the Young",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512626","Tropomyosin Alpha-3 Chain Isoform 2","C129382","Tropomyosin alpha-3 chain isoform 2 (248 aa, ~30 kDa) is encoded by the hTM5 allele of the human TPM3 gene. This protein plays a role in the stabilization of the actin cytoskeleton.","Tropomyosin Alpha-3 Chain Isoform 2 | Cytoskeletal Tropomyosin TM30 | Heat-Stable Cytoskeletal Protein 30 kDa | Human Tropomyosin Isoform 5 | TM30nm | Tropomyosin Alpha-3 Chain Cytoskeletal Isoform | Tropomyosin Alpha-3 Chain Low Molecular Weight Isoform hTM5 | Tropomyosin Alpha-3 Chain Non-Muscle Isoform | Tropomyosin-5 | hTM5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514081","Carbon C 14 Idasanutlin","C130024","A radiopharmaceutical agent composed of an orally available, small-molecule antagonist of MDM2 (mouse double minute 2; Mdm2 p53 binding protein homolog), and labeled with the radioisotope carbon C 14, with potential use for evaluating the pharmacokinetics of idasanutlin. Upon oral administration, idasanutlin binds to MDM2 blocking the interaction between the MDM2 protein and the transcriptional activation domain of the tumor suppressor protein p53. By preventing the MDM2-p53 interaction, p53 is not enzymatically degraded and the transcriptional activity of p53 is restored. This may lead to p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger nuclear phosphoprotein and negative regulator of the p53 pathway, is often overexpressed in cancer cells and has been implicated in cancer cell proliferation and survival. . Labeling of idasanutlin with the radioactive tracer carbon C 14 permits the evaluation of idasanutlin's pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME).","Carbon C 14 Idasanutlin | C14 Idasanutlin | [14C]-radiolabeled Idasanutlin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514018","Anti-inflammatory/Antimicrobial/Analgesic Aqueous Mouth Rinse","C130029","A water-based proprietary mouthwash with anti-inflammatory, antimicrobial and analgesic activities. Upon rinsing with this mouthwash, the unspecified ingredients may help prevent or reduce the symptoms and severity of mucositis.","Anti-inflammatory/Antimicrobial/Analgesic Aqueous Mouth Rinse | Dentoxol | Dentoxol Mouthrinse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225828","Cardiomyocyte","C13002","A muscle cell in heart tissue (myocardium).","Cardiomyocyte | Cardiocyte | Heart Muscle Cell",,,,,,,,,,,,,,,"4313561","Cardiac myocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026973","Myelin Sheath","C13261","A layer of phospholipids and protein found on neuronal axons. This structure acts as an electrical insulator that allows nerve impulses to travel faster by increasing the resistance and decreasing the capacitance over that found in unmyelinated nerve fibers.","Myelin Sheath | Myelin | Myelinated | myelin",,,,,,,,,,,,,,,"4081099","Myelin sheath structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521012","TSQM Version 1.4 - Time Takes Medication to Start Working","C132620","Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) How satisfied or dissatisfied are you with the amount of time it takes the medication to start working?","TSQM Version 1.4 - Time Takes Medication to Start Working | TSQM01-Time Takes Med to Start Working | TSQM0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521005","TSQM Version 1.4 - Experience Any Side Effect at All","C132621","Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) As a result of taking this medication, do you experience any side effects at all?","TSQM Version 1.4 - Experience Any Side Effect at All | TSQM01-Experience Any Side Effect at All | TSQM0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521006","TSQM Version 1.4 - How Bothersome Are Side Effects","C132622","Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) How bothersome are the side effects of the medication you take to treat your condition?","TSQM Version 1.4 - How Bothersome Are Side Effects | TSQM01-How Bothersome Are Side Effects | TSQM0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521008","TSQM Version 1.4 - Interfere With Physical Health","C132623","Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) To what extent do the side effects interfere with your physical health and ability to function (i.e., strength, energy levels, etc.)?","TSQM Version 1.4 - Interfere With Physical Health | TSQM01-Interfere With Physical Health | TSQM0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521007","TSQM Version 1.4 - Interfere With Mental Function","C132624","Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) To what extent do the side effects interfere with your mental function (i.e., ability to think clearly, stay awake, etc.)?","TSQM Version 1.4 - Interfere With Mental Function | TSQM01-Interfere With Mental Function | TSQM0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521011","TSQM Version 1.4 - Side Effect Affect Overall Satisfaction","C132625","Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) To what degree have medication side effects affected your overall satisfaction with the medication?","TSQM Version 1.4 - Side Effect Affect Overall Satisfaction | TSQM01-Side Effect Affect Overall Satisf | TSQM0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521003","TSQM Version 1.4 - Easy or Difficult Use Medication","C132626","Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) How easy or difficult is it to use the medication in its current form?","TSQM Version 1.4 - Easy or Difficult Use Medication | TSQM01-Easy/Difficult Use Medication | TSQM0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521004","TSQM Version 1.4 - Easy or Difficult to Plan Use of Medication","C132627","Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) How easy or difficult is it to plan when you will use the medication each time?","TSQM Version 1.4 - Easy or Difficult to Plan Use of Medication | TSQM01-Easy/Difficult to Plan Use of Med | TSQM0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521001","TSQM Version 1.4 - Confident Medication Is Good for You","C132629","Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) Overall, how confident are you that taking this medication is a good thing for you?","TSQM Version 1.4 - Confident Medication Is Good for You | TSQM01-Confident Med Is Good for You | TSQM0112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520180","Nausea Scale","C131959","A scale for the subjective scoring of nausea that ranges from 0: None to 10: The worst you can think of.","Nausea Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021021","Immunoglobulin Switch Region","C13244","Nucleotide sequences found upstream of exons encoding the constant regions of immunoglobulin heavy chains where exon rearrangement can occur. The combination of exons selected in a B-cell determines the immunoglobulin isotype produced by that cell.","Immunoglobulin Switch Region | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516438","Cervicomedullary Junction","C12973","The point at the base of the skull where the brainstem and cervical spine intersect.","Cervicomedullary Junction | Cervico-medullary Junction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342277","Glucokinase-Associated Diabetes Mellitus","C129741","Monogenic diabetes caused by inactivating mutation(s) in the GCK gene, encoding glucokinase. Heterozygous GCK mutations may manifest as mild hyperglycemia, which is not progressive, and usually requires no treatment. Homozygous GCK mutations result in permanent neonatal diabetes.","Glucokinase-Associated Diabetes Mellitus | GCK-Associated Diabetes Mellitus | MODY2 | Maturity-Onset Diabetes of the Young, Type 2",,,,,,,,,,,,,,,"4130164","Maturity onset diabetes of the young, type 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1852093","Hepatocyte Nuclear Factor 4-Alpha Associated Monogenic Diabetes","C129744","Monogenic diabetes caused by inactivating mutation(s) in the gene HNF4A, encoding hepatocyte nuclear factor 4-alpha.","Hepatocyte Nuclear Factor 4-Alpha Associated Monogenic Diabetes | HNF4a-Associated Monogenic Diabetes | MODY1 | Maturity-Onset Diabetes of the Young, Type 1",,,,,,,,,,,,,,,"43531006","Maturity onset diabetes of the young, type 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1853371","Neurogenic Differentiation Factor 1-Associated Monogenic Diabetes","C129745","Monogenic diabetes caused by inactivating mutation(s) in the gene NEUROD1, encoding neurogenic differentiation 1. In addition to diabetes, this condition may be associated with neurogenic anomalies. Homozygous NEUROD1 mutations result in permanent neonatal diabetes.","Neurogenic Differentiation Factor 1-Associated Monogenic Diabetes | MODY6 | Maturity Onset Diabetes of the Young, Type 6 | NEUROD1-Associated Monogenic Diabetes",,,,,,,,,,,,,,,"43531643","Maturity-onset diabetes of the young, type 6",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1833382","PDX1-Associated Monogenic Diabetes","C129746","Monogenic diabetes caused by inactivating mutation(s) in the PDX1 gene, encoding pancreas/duodenum homeobox protein 1. Homozygous PDX1 mutations result in permanent neonatal diabetes.","PDX1-Associated Monogenic Diabetes | MODY4 | Maturity Onset Diabetes of the Young, Type 4",,,,,,,,,,,,,,,"43531013","Maturity-onset diabetes of the young, type 4",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512989","SUR1-Associated Diabetes Mellitus","C129747","Diabetes mellitus caused by activating mutation(s) in the ABCC8 gene, encoding the sulfonylurea receptor 1 (SUR1) subunit of the pancreatic beta cell adenosine triphosphate-sensitive potassium channel. Note: Inactivating mutation(s) in the ABCC8 gene result in hyperinsulinism.","SUR1-Associated Diabetes Mellitus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513041","Transcription Factor-Associated Monogenic Diabetes","C129748","Monogenic diabetes caused by inactivating mutation(s) in transcription factors regulating expression of pancreatic beta cell genes.","Transcription Factor-Associated Monogenic Diabetes | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4043268","PF-114","C130033","An orally bioavailable, Bcr-Abl tyrosine kinase inhibitor, with potential antineoplastic activity. Designed to overcome resistance of tumor cells to second generation Bcr-Abl inhibitors, vamotinib targets and binds to the Bcr-Abl fusion oncoprotein, including those fusion proteins with the 'gatekeeper' resistance mutation T315I, an amino acid substitution at position 315 in Bcr-Abl from a threonine (T) to an isoleucine (I). This inhibits Bcr-Abl-mediated proliferation of, and enhances apoptosis in, Philadelphia chromosome-positive (Ph+) hematologic malignancies. The Bcr-Abl fusion protein is an aberrantly activated tyrosine kinase produced by leukemia cells that contain the Philadelphia chromosome.","Vamotinib | Bcr-Abl Inhibitor PF-114 | Bcr-Abl Kinase Inhibitor PF-114 | Bcr-Abl Kinase Inhibitor PF-114 | PF-114 | VAMOTINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513815","Chronic Myelomonocytic Leukemia-0","C130035","A chronic myelomonocytic leukemia characterized by the presence of less than 5 percent blasts in the bone marrow and less than 2 percent blasts in the peripheral blood.","Chronic Myelomonocytic Leukemia-0 | CMML-0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512669","Anti-hCD70-CAR Retroviral Vector-transduced Autologous PBLs","C129593","A preparation of autologous human peripheral blood lymphocytes (PBLs) transduced with a retroviral vector encoding for a T-cell chimeric antigen receptor (CAR) gene specific for the human cluster of differentiation 70 (CD70), with potential immunostimulatory and antineoplastic activities. Autologous PBLs from a patient with CD70-positive cancer are transduced with a retroviral vector that encodes the CAR gene specific for CD70. After expansion in culture and reintroduction into the patient, anti-hCD70-CAR retroviral vector-transduced autologous PBLs bind to the CD70 antigen on tumor cell surfaces; subsequently, CD70-expressing tumor cells are lysed. CD70, the ligand for the costimulatory receptor CD27, is overexpressed on the surfaces of various cancer cell types.","Anti-hCD70-CAR Retroviral Vector-transduced Autologous PBLs | Anti-hCD70 Autologous CAR-transduced T Cells | Anti-hCD70 CAR autologous PBLs | Anti-hCD70-CAR Retroviral Vector-transduced Autologous Peripheral Blood Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512601","PD-L1/PD-L2/VISTA Antagonist CA-170","C129594","An orally bioavailable small molecule inhibitor of the immune checkpoint regulatory proteins programmed cell death ligand-1 (PD-L1; B7-H1; CD274), PD-L2, and V-domain immunoglobulin (Ig) suppressor of T-cell activation (VISTA; programmed death 1 homolog; PD1H; PD-1H), with potential negative immune checkpoint regulatory and antineoplastic activities. Upon oral administration, PD-L1/PD-L2/VISTA antagonist CA-170 targets and binds to PD-L1, PD-L2 and VISTA. This inhibits PD-L1/PD-L2/VISTA-mediated signaling, abrogates the PD-L1-, PD-L2- and VISTA-induced suppression of T-lymphocyte immune responses, enhances cytotoxic T-cell proliferation and activation against tumor cells, increases cytokine production by T-cells, and inhibits tumor cell growth. PD-L1, PD-L2 and VISTA, negative checkpoint molecules of immune activation, play key roles in the suppression of T-cell functions.","PD-L1/PD-L2/VISTA Antagonist CA-170 | AUPM 170 | Aurigene 1 | CA-170 | PD-L1/PD-L2/VISTA Checkpoint Antagonist CA-170",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1614561","Polypodium leucotomos Extract","C129595","A nutritional supplement composed of an aqueous extract derived from the leaves of the tropical fern belonging to the Polypodiaceae family, Polypodium leucotomos (PL; Phlebodium aureum), with potential photoprotective, skin protective, anti-inflammatory, immunomodulating and antioxidant activities. This extract contains many phenolic compounds, such as ferulic, caffeic, coumaric and vanillic acid, which are mainly responsible for this extract's effects. Upon administration, Polypodium leucotomos extract (PLE) exerts antioxidant activity by scavenging free radicals and inhibiting the generation and release of reactive oxygen species (ROS), thereby preventing ultraviolet (UV)-induced as well as ROS-induced DNA damage. In addition, the chemicals in this extract protect antioxidant enzymes and modulate expression of cancer and inflammation-related genes, including the induction of the expression of tumor suppressor genes and the inhibition of the expression of pro-inflammatory cytokines and inflammatory enzymes, thereby inhibiting the activation of signal transduction pathways involved in carcinogenesis and inflammation, respectively. PLE also stimulates tissue inhibitors of metalloproteinases (TIMPs) and inhibits matrix metalloproteinases (MMPs).","Polypodium leucotomos Extract | Fernblock | PL Extract | PLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512660","CD4-specific Telomerase Peptide Vaccine UCPVax","C129596","A therapeutic peptide vaccine containing the human telomerase reverse transcriptase catalytic subunit (hTERT)-derived universal cancer peptides 2 (UCP2) and 4 (UCP4), and combined with the immunoadjuvant Montanide ISA 51 VG, with potential immunostimulating and antineoplastic activities. Vaccination with the CD4-specific telomerase peptide vaccine UCPVax activates the immune system to mount a T-helper 1 (TH1) CD4-positive T-lymphocyte immune response against and ultimately killing telomerase-expressing cells. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation.","CD4-specific Telomerase Peptide Vaccine UCPVax | UCP2/UCP4 CD4-specific Telomerase Peptide Vaccine UCPVax | UCPVax",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007609","Nucleolus","C13196","The region within a cell nucleus where ribosomal DNA is clustered, ribosomal RNA is synthesized and ribosomes are assembled.","Nucleolus | ",,,,,,,,,,,,,,,"4050517","Nucleolus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514433","POLQ wt Allele","C131802","Human POLQ wild-type allele is located in the vicinity of 3q13.33 and is approximately 115 kb in length. This allele, which encodes DNA polymerase theta protein, plays a role in both the repair and synthesis of DNA.","POLQ wt Allele | DNA Polymerase Theta wt Allele | PRO0327 | Polymerase (DNA Directed), Theta Gene | Polymerase (DNA) Theta Gene | Polymerase, DNA, Theta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1568393","DNA polymerase theta, human","C131803","DNA polymerase theta (2590 aa, ~290 kDa) is encoded by the human POLQ gene. This protein is involved in microhomology-mediated end-joining and low-fidelity DNA synthesis.","DNA Polymerase Theta | EC 2.7.7.7 | POLQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3711371","Spastic Paraplegia 4","C129981","An autosomal dominant condition caused by mutation(s) in the SPAST gene, encoding spastin. It is characterized by progressive lower extremity spasticity and weakness.","Spastic Paraplegia 4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0752120","Spinocerebellar Ataxia Type 1","C129982","An autosomal dominant neurodegenerative disorder caused by mutations in the ATXN1 gene, encoding ataxin-1. It is characterized by progressive cerebellar ataxia, dysarthria and saccadic abnormalities.","Spinocerebellar Ataxia Type 1 | SCA1",,,,,,,,,,,,,,,"37396073","Spinocerebellar ataxia type 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513766","Anti-EGFR Fluorescence Imaging Agent ABY-029","C129983","A fluorescence imaging and contrast agent composed of an epidermal growth factor receptor (EGFR)-targeting affibody tracer molecule and labeled, through maleimide, with a near-infrared (NIR) fluorescent probe, IRDye 800CW, with potential use in the imaging of EGFR-overexpressing cells. Upon administration, ABY-029 targets and binds to EGFR-overexpressing tumor cells. Upon fluorescent imaging, the fluorescent dye can be visualized and EGFR-positive tumor cells can be detected.","Anti-EGFR Fluorescence Imaging Agent ABY-029 | ABY-029 | ABY-029 Trifluoroacetate Salt | Fluorescently-labeled Anti-EGFR Affibody Molecule ABY-029 | IRDye 800CW Maleimide-labeled Affibody Peptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512703","Gene_Product_Variant_Of_Gene_Product","C129597","A role used to indicate that a gene product sequence variation is related to a wild-type gene product. The domain and range for this role are 'Gene Product Sequence Variation' and 'Gene Product', respectively.","Gene_Product_Variant_Of_Gene_Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512678","Central Nervous System Anaplastic Large Cell Lymphoma, ALK-Positive","C129598","An anaplastic large cell lymphoma, ALK-positive, arising from the central nervous system.","Central Nervous System Anaplastic Large Cell Lymphoma, ALK-Positive | Primary Central Nervous System Anaplastic Large Cell Lymphoma, ALK-Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512677","Central Nervous System Anaplastic Large Cell Lymphoma, ALK-Negative","C129599","An anaplastic large cell lymphoma, ALK-negative, arising from the central nervous system.","Central Nervous System Anaplastic Large Cell Lymphoma, ALK-Negative | Primary Central Nervous System Anaplastic Large Cell Lymphoma, ALK-Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512505","Breast Cancer Cell","C12959","Cells found in human breast cancers or extracted from cancers as established cell lines","Breast Cancer Cell | Human Breast Cancer Cell | Human Breast Cancer Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0080320","Streptogramin A","C1295","A streptomycin A-related cyclic depsipeptide isolated from the bacterium Streptomyces virginiae and other Streptomyces bacterial species.  Virginiamycin M1 binds to and inhibits assembly of 50S and 30S ribosomes, thereby preventing protein synthesis. (NCI04)","Streptogramin A | OSTREOGRYCIN A | VERNAMYCIN A | VIRGINIAMYCIN M1 | Virginiamycin M1 | mikamycin A | ostreogrycin A | pristinamycin IIA | staphylomycin M1 | vernamycin A | virginiamycin factor M1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521134","RG6114","C132166","An orally available inhibitor of phosphatidylinositol 3-kinase (PI3K), with potential antineoplastic activity. Upon administration, inavolisib binds to and inhibits various members of the PI3K family, including activating mutations in the catalytic alpha isoform PIK3CA. PI3K inhibition prevents the activation of the PI3K-mediated signaling pathway and results in the inhibition of growth and survival of PI3K-overexpressing tumor cells. Dysregulation of the PI3K signaling pathway is frequently associated with tumorigenesis and tumor resistance to a variety of antineoplastic agents and radiotherapy. PIK3CA, which encodes the p110-alpha catalytic subunit of the class I PI3K, is frequently mutated in a variety of cancer cell types and plays a key role in cancer cell growth and invasion.","Inavolisib | GDC 0077 | GDC-0077 | GDC0077 | INAVOLISIB | Itovebi | PI3K Inhibitor GDC0077 | RG 6114 | RG-6114 | RG6114 | RO 7113755",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423908","ASB2 Gene","C132167","This gene is involved in substrate recognition of ubiquitin ligase complexes.","ASB2 Gene | ASB2 | Ankyrin Repeat and SOCS Box Containing 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520356","ASB2 wt Allele","C132168","Human ASB2 wild-type allele is located in the vicinity of 14q32.12 and is approximately 43 kb in length. This allele, which encodes ankyrin repeat and SOCS box protein 2, plays a role in promoting the ubiquitination of substrate proteins.","ASB2 wt Allele | ASB-2 | Ankyrin Repeat and SOCS Box Containing 2 wt Allele | Ankyrin Repeat and SOCS Box-Containing 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1432311","ASB2 protein, human","C132169","Ankyrin repeat and SOCS box protein 2 (587 aa, ~65 kDa) is encoded by the human ASB2 gene. This protein is involved in the recognition of substrates by the Elongin-Cullin-SOCS-box protein (ECS) E3 ubiquitin-protein ligase complex.","Ankyrin Repeat and SOCS Box Protein 2 | ASB-2 | Ankyrin Repeat and SOCS Box-Containing Protein 2 | Ankyrin Repeat- and SOCS Box-Containing Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520453","MB21D2 wt Allele","C132171","Human MB21D2 wild-type allele is located in the vicinity of 3q29 and is approximately 121 kb in length. This allele, which encodes protein MB21D2, may be involved in adherens junction functions.","MB21D2 wt Allele | C3orf59 | Chromosome 3 Open Reading Frame 59 Gene | Mab-21 Domain Containing 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520195","Protein MB21D2","C132172","Protein MB21D2 (491 aa, ~56 kDa) is encoded by the human MB21D2 gene. This protein may play a role in cadherin-dependent cell-cell adhesion.","Protein MB21D2 | Mab-21 Domain-Containing Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2240044","SPNS2 Gene","C132174","This gene plays a role in lipid transport.","SPNS2 Gene | SPNS2 | Sphingolipid Transporter 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521146","SPNS2 wt Allele","C132175","Human SPNS2 wild-type allele is located in the vicinity of 17p13.2 and is approximately 41 kb in length. This allele, which encodes protein spinster homolog 2, is involved in sphingolipid transport. Mutation of the gene may be involved in early onset progressive hearing loss.","SPNS2 wt Allele | Sphingolipid Transporter 2 wt Allele | Spinster Homolog 2 (Drosophila) Gene | Spinster, Drosophila, Homolog of, 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520196","Protein Spinster Homolog 2","C132176","Protein spinster homolog 2 (549 aa, ~58 kDa) is encoded by the human SPNS2 gene. This protein plays a role in the transport of sphingosine 1-phosphate (S1P).","Protein Spinster Homolog 2 | SPNS2 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826416","BCAR4 Gene","C132177","This gene may involved in breast cancer metastasis and resistance to antiestrogens.","BCAR4 Gene | BCAR4 | Breast Cancer Anti-Estrogen Resistance 4 (Non-Protein Coding) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520594","BCAR4 wt Allele","C132178","Human BCAR4 wild-type allele is located in the vicinity of 16p13.13 and is approximately 9 kb in length. This allele, which encodes breast cancer anti-estrogen resistance 4 long non-coding RNA, plays a role in both metastasis and antiestrogen resistance in breast carcinoma. Focal amplification and chromosomal rearrangement involving the gene may be associated with cervical cancer.","BCAR4 wt Allele | Breast Cancer Anti-Estrogen Resistance 4 (Non-Protein Coding) wt Allele | Breast Cancer Anti-Estrogen Resistance 4 Gene | Breast Cancer Antiestrogen Resistance 4 Gene | hCG_1814062",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0836131","Stratified Squamous Epithelium","C13180","Epithelium consisting of multiple layers of cells that are flattened and more cuboidal toward the base. Its function is protection. Outer layers may be dead and hardened (keratinized) such as with skin or on top of wet, mucous surfaces such as the cornea","Stratified Squamous Epithelium | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514491","Eiken Type Chondrodysplasia","C131811","An autosomal recessive skeletal dysplasia caused by mutation(s) in the PTH1R gene, encoding parathyroid hormone/parathyroid hormone-related peptide receptor. This condition is characterized by severely delayed skeletal maturation, as well as by abnormal modeling of the bones in the hands and feet, abnormal persistence of cartilage in the pelvis, and mild growth retardation. Calcium and phosphate concentrations are normal.","Eiken Type Chondrodysplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0432271","Endosteal Hyperostosis","C131812","An autosomal recessive form of craniotubular hyperostosis due to a 52-kb deletion in the SOST gene, encoding sclerostin. Clinical features include normal stature, enlarged jaw and facial bones, hearing loss, and facial palsy due to cranial nerve deficits. The absence of syndactyly distinguishes this condition from sclerosteosis.","Endosteal Hyperostosis | van Buchem Disease | van Buchem Disease Type 1",,,,,,,,,,,,,,,"4113735","Endosteal hyperostoses",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0342185","Familial Dysalbuminemic Hyperthyroidism","C131813","A genetic condition caused by a variant in the ALB gene, associated with increased affinity of albumin for thyroxine.","Familial Dysalbuminemic Hyperthyroidism | Familial Dysalbuminemic Hyperthyroxinemia",,,,,,,,,,,,,,,"4030051","Familial dysalbuminemic hyperthyroxinemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521020","EGFR Mutant-specific Inhibitor CK-101","C132023","An orally available third-generation and selective inhibitor of certain epidermal growth factor receptor (EGFR) activating mutations, including the resistance mutation T790M, and the L858R and del 19 mutations, with potential antineoplastic activity. Upon administration, the EGFR mutant-specific inhibitor CK-101 specifically and covalently binds to and inhibits selective EGFR mutations, with particularly high selectivity against the T790M mutation, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Compared to some other EGFR inhibitors, CK-101 may have therapeutic benefits in tumors with T790M-mediated drug resistance. This agent shows minimal activity against wild-type EGFR (WT EGFR), and does not cause dose-limiting toxicities that occur during the use of non-selective EGFR inhibitors, which also inhibit WT EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","EGFR Mutant-specific Inhibitor CK-101 | CK 101 | CK-101 | CK101 | OLAFERTINIB | RX-518",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2355396","Yang Yin Fu Zheng","C132024","A traditional Chinese medicine (TCM)-based formulation, with potential immuno-enhancing, detoxifying and antineoplastic activities. Upon administration, Yang Yin Fu Zheng may activate the immune system and may help inhibit tumor cell proliferation. This TCM may also help remove toxic substances.","Yang Yin Fu Zheng | Fu Zheng Yang Yin | Fu Zheng Yang Yin Decoction | TCM Yang Yin Fu Zheng | Yang Yin Fu Zheng Jie Du | Yangyin Fuzheng Jiedu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513383","Truncated Tissue Factor/NGR Peptide","C129984","A vascular-targeting agent composed of the extracellular domain of the trunctated form of issue factor (tTF) conjugated to the C-terminal peptide GNGRAHA (NGR), with potential procoagulatory and antineoplastic activities. Upon administration, the NGR peptide moiety of tTF-NGR targets and binds to the surface protein aminopeptidase N (CD13) expressed on endothelial cells in tumor vessels. Upon deamidation of the NGR peptide moiety, this agent also binds to integrin alphaVbeta3 (aVb3; CD51/CD61) in the tumor vasculature. In turn, the tTF causes occlusion of the tumor blood vessels, which causes an inhibition of blood supply and flow in the tumor, nutrition and induced tumor cell death and an inhibition of tumor cell proliferation. TF plays a key role in the coagulation cascade. NGR is a asparagine-glycine-arginine containing peptide and ligand of CD13. Both aVb3 and CD13 are surface proteins that are upregulated on endothelial cells of tumor vessels.","Truncated Tissue Factor/NGR Peptide | tTF-NGR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513376","Traditional Chinese Medicine Formulation","C129986","Any pharmaceutical formulation that contains agents used in traditional Chinese medicine (TCM).","Traditional Chinese Medicine Formulation | Chinese Medicinal Formulation | Pharmaceutical TCM Preparation | TCM Formula | TCM Formulation | TCM Preparation | TCM Product | TCM-based Pharmaceutical Preparation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513504","Yi Qi Fang","C129988","A traditional Chinese medicine (TCM) based that may benefit Qi and Yin, and may help with the detoxification process.","Yi Qi Fang | TCM YiQiFang | Traditional Chinese Medicine Yi Qi Fang | Traditional Chinese Medicine YiQiFang | Yi-Qi-Fang | YiQiFang",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513502","Yang Yin Fang","C129993","A traditional Chinese medicine (TCM) based formulated may benefit Qi and Yin, and may help with the detoxification process.","Yang Yin Fang | TCM Yang Yin Fang | Traditional Chinese Medicine Yang Yin Fang | Yang-Yin-Fang",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518253","Nervous System, Ear","C12955","Of or related to the peripheral or central auditory system.","Nervous System, Ear | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513026","Central Nervous System Langerhans Cell Histiocytosis","C129806","Rare involvement of the central nervous system by Langerhans cell histiocytosis.","Central Nervous System Langerhans Cell Histiocytosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512652","aFAP-IL2v RO6874281","C129383","A recombinant fusion protein comprised of a human monoclonal antibody directed against fibroblast activation protein-alpha (FAP) linked to an engineered, variant form of interleukin-2 (IL-2v), with potential immunostimulating and antineoplastic activities. Upon administration of simlukafusp alfa, the monoclonal antibody moiety recognizes and binds to FAP, thereby concentrating IL-2 in FAP-expressing tumor tissue. Subsequently, the IL-2 moiety of this fusion protein may stimulate a local immune response and activate natural killer (NK) cells and cytotoxic T-cells. FAP is a cell surface protein that is expressed on a wide variety of cancer cells. IL-2v cannot bind to IL-2 receptor-alpha (CD25, IL2Ra) and does not activate regulatory T-cells (Tregs).","Simlukafusp Alfa | Anti-FAP/Interleukin-2 Fusion Protein RO6874281 | FAP-IL2v FP RO6874281 | FAP-IL2v RO6874281 | RG 7461 | RG-7461 | RG7461 | RO 6874281 | RO-6874281 | RO6874281 | SIMLUKAFUSP ALFA | aFAP-IL2v RO6874281",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512656","Tropomyosin Alpha-3 Chain Isoform 3","C129384","Tropomyosin alpha-3 chain isoform 3 (247 aa, ~92 kDa) is encoded by the TC22 allele of the human TPM3 gene. This protein may play a role in tumorigenesis.","Tropomyosin Alpha-3 Chain Isoform 3 | Tropomyosin Alpha-3 Chain Low Molecular Weight Isoform TC22 | hTM Isoform TC22 | hTM5 Isoform TC22",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512558","Hydrogen Peroxide-hyaluronic Acid Tumor Injectable Formulation","C129385","A gel-based formulation composed of a very dilute solution of hydrogen peroxide (H2O2) combined with hyaluronic acid (HA), with potential radiosensitizing activity. Upon intratumoral injection and slow-release (SR) of H2O2 from the gel, H2O2 releases oxygen and inactivates anti-oxidative enzymes, thereby increasing the oxygen concentration in the tumor environment, which increases the efficacy of radiotherapeutic treatment. HA increases viscosity of the formulation and allows for the SR of H2O2; as compared to the injection of H2O2 alone, the addition of HA decreases diffusion of H2O2 to surrounding areas and enhances intratumoral H2O2 concentration over an increased period of time. Hypoxic tumors show a decreased response to radiotherapy; thus, increasing oxygen content increases tumor response to radiotherapy.","Hydrogen Peroxide-hyaluronic Acid Tumor Injectable Formulation | H2O2-HA Tumor Injectable Formulation | Hydrogen Peroxide-hyaluronic Acid Intratumoral Injectable Formulation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519698","Breast Cancer Anti-Estrogen Resistance 4 Long Non-Coding RNA","C132179","Breast cancer anti-estrogen resistance 4 long non-coding RNA (~1.3 kb) is encoded by the human BCAR4 gene. This non-coding RNA is involved in both metastasis and antiestrogen resistance in breast carcinoma.","Breast Cancer Anti-Estrogen Resistance 4 Long Non-Coding RNA | BCAR4 LincRNA | BCAR4 LncRNA | Breast Cancer Anti-Estrogen Resistance 4 Long Noncoding RNA | Breast Cancer Antiestrogen Resistance 4 Long Non-Coding RNA | Breast Cancer Antiestrogen Resistance 4 Long Noncoding RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018042","Golgi Apparatus","C13238","A stack of flattened vesicles located between the nucleus and the secretory pole or surface of a cell. Functions in posttranslational processing and sorting of proteins, receiving them from the rough endoplasmic reticulum and directing them to secretory vesicles, lysosomes, or the cell membrane. The movement of proteins takes place by transfer vesicles that bud off from the rough endoplasmic reticulum or golgi apparatus and fuse with the golgi, lysosomes or cell membrane.","Golgi Apparatus | Golgi | Golgi Complex",,,,,,,,,,,,,,,"4276328","Golgi complex",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018593","Hapten","C13239","A substance that can act as an epitope for an antibody but that lacks immunogenicity unless coupled to a larger carrier molecule.","Hapten | Haptens",,,,,,,,,,,,,,,"4008248","Hapten",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL520367","AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M","C132025","An orally available inhibitor of the AXL receptor tyrosine kinase (AXL; UFO) and the receptor tyrosine kinase c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Upon administration, AXL receptor tyrosine kinase/cMET inhibitor BPI-9016M, binds to both AXL and cMet, thereby disrupting both AXL- and c-Met-mediated signaling pathways. Altogether, this agent inhibits growth in AXL and cMet-overexpressing tumor cells. AXL, a member of the TAM (TYRO3, AXL and MER) family of receptor tyrosine kinases, and cMet, both overexpressed by many tumor cell types, play key roles in tumor cell proliferation, survival, invasion and metastasis.","AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M | AXL/cMET Inhibitor BPI-9016M | BPI 9016 | BPI-9016 | BPI-9016M",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521287","Yiqi-yangyin-jiedu Herbal Decoction","C132026","A traditional Chinese medicine (TCM) based formulation consisting of milkvetch root, glehnia root, asparagus root, lilyturf root, grossy privet fruit, spikemoss herb, Chinese sage herb, and manyleaf paris rhizome, with potential immuno-enhancing, detoxifying and antineoplastic activities. Upon administration, yiqi-yangyin-jiedu decoction (YYJD) may activate the immune system by enhancing T-lymphocyte activity, and inhibiting tumor cell proliferation. YYJD may also ameliorate the qi-yin deficiency syndrome by strengthening qi and nourishing yin. YYJD may help remove toxic substance.","Yiqi-yangyin-jiedu Herbal Decoction | TCM Yiqi-yangyin-jiedu Decoction | YYJ Decoction | YYJD | Yiqi Yangyin Jiedu Decoction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519709","CD8+NKG2D+ AKT Cell","C132027","A preparation of human CD8-positive tumor-specific T-lymphocytes engineered to express the natural killer cell activating receptor group 2D (NKG2D) and the serine/threonine kinase AKT, with potential immunomodulating and antineoplastic activities. Upon administration of CD8+NKG2D+ AKT cells, these cells target and kill tumor cells. AKT-mediated signaling enhances the activation, differentiation, proliferation and cytokine production of tumor specific T-cells, which enhances their anti-tumor effects; AKT activity in T-cells is often downregulated in the tumor environment. NKG2D, a stimulatory lymphocyte receptor, mediates the recognition of tumors cells and promotes T-cell activation and T-cell-mediated tumor cell killing; NKG2D ligands are expressed on cancer cells, while they are minimally expressed by or absent from normal, healthy cells.","CD8+NKG2D+ AKT Cell | NKG2D/AKT-expressing CD8-positive T-cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520372","CTT 1057 F18","C132028","A radioconjugate composed of the phosphoramidate agent vidoflufolastat, a human prostate specific membrane antigen (PSMA) inhibitor, and labeled with the radioisotope fluorine F 18, with potential use as a tracer for PSMA-expressing tumors during positron emission tomography (PET). Upon intravenous administration, vidoflufolastat (18F) targets and irreversibly binds to the extracellular domain of PSMA-expressing tumor cells. Upon rapid internalization, and following PET imaging, PSMA-expressing tumor cells can be detected. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.","Vidoflufolastat (18F) | 18F-CTT-1057 | 18F-CTT1057 | CTT 1057 18F | CTT 1057 F18 | Fluorine F 18 CTT1057 | Fluorine-18-CTT 1057 | PSMA-targeted PET Imaging Agent Fluorine F 18 CTT-1057 | PSMA-targeted PET Imaging Agent Fluorine F 18 CTT-1057 | VIDOFLUFOLASTAT (18F)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512612","Central Nervous System Undifferentiated Pleomorphic Sarcoma","C129566","A rare undifferentiated pleomorphic sarcoma (formerly known as malignant fibrous histiocytoma) involving the central nervous system.","Central Nervous System Undifferentiated Pleomorphic Sarcoma | Central Nervous System Malignant Fibrous Histiocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1828336","Skull Osteoma","C129569","A benign, well-circumscribed bone-forming neoplasm that is predominantly composed of lamellar bone and arises in the skull.","Skull Osteoma | ",,,,,,,,,,,,,,,"4311145","Osteoma of skull",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518266","Neuro-Ocular System","C12956","The components of the eye that are also part of the nervous system, including the retina and optic nerve.","Neuro-Ocular System | Nervous System, Eye",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4043276","Proxalutamide","C130036","An orally bioavailable androgen receptor (AR) antagonist with potential antineoplastic activity. Upon oral administration, proxalutamide binds to AR in target tissues, inhibits androgen-induced receptor activation, and facilitates the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes that regulate prostate cancer cell proliferation. In addition, proxalutamide induces AR downregulation, thereby further preventing AR-mediated signaling. This ultimately leads to an inhibition of growth in AR-expressing prostate cancer cells. AR is overexpressed in prostate cancer and plays a key role in prostate cancer cell proliferation.","Proxalutamide | GT-0918 | GT0918 | PRUXELUTAMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521000","TSQM Version 1.4 - Certain Good Things Outweigh Bad","C132630","Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) How certain are you that the good things about your medication outweigh the bad things?","TSQM Version 1.4 - Certain Good Things Outweigh Bad | TSQM01-Certain Good Things Outweigh Bad | TSQM0113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521010","TSQM Version 1.4 - Satisfied or Dissatisfied With Medication","C132631","Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) Taking all things into account, how satisfied or dissatisfied are you with this medication?","TSQM Version 1.4 - Satisfied or Dissatisfied With Medication | TSQM01-Satisfied/Dissatisfied With Med | TSQM0114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519938","Head and Neck Cancer TNM Finding v8","C132632","A finding about one or more characteristics of head and neck cancer, following the rules of the TNM AJCC v8 classification system.","Head and Neck Cancer TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519935","Head and Neck Cancer Clinical TNM Finding v8","C132633","A clinical finding about one or more characteristics of head and neck cancer, following the rules of the TNM AJCC v8 classification system.","Head and Neck Cancer Clinical TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519939","Head and Neck Cancer cN2 TNM Finding v8","C132635","Head and neck cancer with metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE (extranodal extension)(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, ENE(-). (from AJCC 8th Ed.)","Head and Neck Cancer cN2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519940","Head and Neck Cancer cN2a TNM Finding v8","C132636","Head and neck cancer with metastasis in a single ipsilateral or contralateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Head and Neck Cancer cN2a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519941","Head and Neck Cancer cN2b TNM Finding v8","C132637","Head and neck cancer with metastasis in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Head and Neck Cancer cN2b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519943","Head and Neck Cancer cN3 TNM Finding v8","C132639","Head and neck cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastases in a single ipsilateral lymph node ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes, any with ENE(+). (from AJCC 8th Ed.)","Head and Neck Cancer cN3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027834","Neurofilament","C13263","An intermediate filament that is found in the axons of neurons.","Neurofilament | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519944","Head and Neck Cancer cN3a TNM Finding v8","C132640","Head and neck cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Head and Neck Cancer cN3a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519945","Head and Neck Cancer cN3b TNM Finding v8","C132641","Head and neck cancer with metastasis in a single ipsilateral lymph node ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes, any with ENE(+). (from AJCC 8th Ed.)","Head and Neck Cancer cN3b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0500464","Venous Segment","C132225","A segment of a blood vessel that is part of the venous system.","Venous Segment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512873","Kir6.2-Associated Diabetes Mellitus","C129760","Diabetes mellitus caused by activating mutation(s) in the KCNJ11 gene, encoding the inwardly rectifying Kir6.2 subunit of the pancreatic beta cell adenosine triphosphate-sensitive potassium channel. Note: Inactivating mutation(s) in the KCNJ11 gene result in hyperinsulinism.","Kir6.2-Associated Diabetes Mellitus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514174","Indolent T-Lymphoblastic Proliferation","C130041","A non-neoplastic T-cell lymphoproliferation that may mimic T-lymphoblastic lymphoma. It usually involves the lymphoid tissues of the upper aerodigestive tract. It recurs locally, but systemic dissemination is rare.","Indolent T-Lymphoblastic Proliferation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514042","Contrast Enhanced Digital Mammography","C130042","A digital mammography technique that incorporates the administration of an iodinated contrast agent to enhance lesions that are not visible on standard mammograms.","Contrast Enhanced Digital Mammography | CEDM | Contrast Enhanced Spectral Mammography | Contrast-Enhanced Digital Mammography",,,,,,,,,,,,,,,"37111540","Contrast enhanced spectral mammography",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513966","Limited Early T-Cell Differentiation","C130044","A finding indicating the presence of neoplastic cells with immunophenotypic and genetic characteristics suggesting limited early T-cell differentiation.","Limited Early T-Cell Differentiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513391","Ultrasound Mode","C130045","The type of ultrasound image that is being recorded on any ultrasound-based device. Examples include 2-dimensional mode, tissue Doppler mode, or motion mode.","Ultrasound Mode | ULTRMODE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514177","Multilineage Dysplasia Present","C130048","A hematologic test result indicating dysplastic changes in two or more of the myeloid cell lineages in the bone marrow.","Multilineage Dysplasia Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512685","Central Nervous System Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","C129600","A primary central nervous system non-Hodgkin lymphoma derived from mature or post-thymic T-cells or NK-cells.","Central Nervous System Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma of the Central Nervous System | Primary Central Nervous System Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512574","Related_To_Genetic_Biomarker","C129601","Indicates that a finding or lab test is related to a gene, possibly through a variant or product.","Related_To_Genetic_Biomarker | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512684","Central Nervous System Intravascular Large B-Cell Lymphoma","C129602","A rare extranodal B-cell non-Hodgkin lymphoma that affects the central nervous system.  It is characterized by the presence of lymphoma cells exclusively in the lumina of small vessels, particularly capillaries.","Central Nervous System Intravascular Large B-Cell Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519937","Head and Neck Cancer Pathologic TNM Finding v8","C132642","A pathologic finding about one or more characteristics of head and neck cancer, following the rules of the TNM AJCC v8 classification system.","Head and Neck Cancer Pathologic TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519936","Head and Neck Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C132643","A pathologic finding about one or more characteristics of head and neck cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Head and Neck Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL494821","Focal Lipodystrophy","C131814","Loss of subcutaneous fat confined to small area(s) of the body.","Focal Lipodystrophy | Localized Lipodystrophy",,,,,,,,,,,,,,,"37311920","Localized lipodystrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514297","Generalized Lipodystrophy","C131815","Almost complete absence of subcutaneous and/or visceral adipose tissue.","Generalized Lipodystrophy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968863","Generalized Thyroid Hormone Resistance","C131816","Decreased response to thyroid hormones in peripheral tissues and in the pituitary gland.","Generalized Thyroid Hormone Resistance | GTHR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342219","Glucagon Deficiency","C131817","Impaired pancreatic secretion of glucagon that results in severely low blood glucose.","Glucagon Deficiency | ",,,,,,,,,,,,,,,"4267268","Glucagon deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514660","Iatrogenic Central Hypothyroidism","C131818","Central hypothyroidism due to medical or surgical treatment.","Iatrogenic Central Hypothyroidism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512399","Supratentorial Ependymoma, ZFTA-RELA Fusion-Positive","C129351","A supratentorial ependymoma characterized by a gene fusion involving ZFTA and RELA genes. It accounts for the majority of supratentorial ependymomas in children. It has an unfavorable outcome when compared to other ependymoma subtypes.","Supratentorial Ependymoma, ZFTA-RELA Fusion-Positive | Ependymoma, RELA Fusion-Positive | Ependymoma, RELA fusion-positive | Ependymoma, ZFTA-RELA Fusion-Positive | Supratentorial Ependymoma, RELA Fusion-Positive | Supratentorial Ependymoma, ZFTA::RELA Fusion-Positive",,,,,,,,,,,,,,,"37116852|37163595","RELA fusion-positive ependymoma|RELA fusion-positive supratentorial ependymoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL512099","ZFTA-RELA Fusion Protein Expression","C129352","Expression of a fusion protein that results from the fusion of RELA and ZFTA genes. It is present in the majority of supratentorial ependymomas in children.","ZFTA-RELA Fusion Protein Expression | C11orf95-RELA Fusion Protein Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810323","C11ORF95/RELA FUSION GENE","C129353","A fusion gene that results from chromothripsis involving chromosome 11q13.1, which fuses the first 2, 3 or 4 exons of the ZFTA gene to sequences that are located 5' of either exon 2 or 3 of the RELA gene. This rearrangement is associated with supratentorial ependymoma.","ZFTA/RELA Fusion Gene | C11orf95-RELA Fusion Gene | C11orf95/RELA Fusion Gene | ZFTA-RELA Fusion Gene | ZFTA::RELA Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512639","GAIA Level 3a Postnatally Diagnosed Congenital Microcephaly","C129604","GAIA Level 3a Postnatally Diagnosed Congenital Microcephaly is defined by three criteria: first, a live birth, stillbirth, or spontaneous or therapeutic abortion of at least 24 weeks GA based on LMP without confirmatory 1st or 2nd trimester ultrasound; second, a head circumference (HC) measurement either 2 standard deviations (SD) below the mean or less than the third percentile as assessed by GA and gender, using appropriate, standardized reference charts for the population (e.g. WHO growth reference charts if GA greater than or equal to 37 weeks and Intergrowth-21st reference charts for GA 24 to 36 weeks); third, the measurement is taken up to 6 weeks after birth or end of pregnancy, with no apparent post-natal insult resulting in microcephaly.","GAIA Level 3a Postnatally Diagnosed Congenital Microcephaly | Global Alignment of Immunization safety Assessment in pregnancy Level 3a Postnatally Diagnosed Congenital Microcephaly | Level 3a Postnatally Diagnosed Congenital Microcephaly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512640","GAIA Level 3a Prenatally Diagnosed Congenital Microcephaly","C129605","GAIA Level 3A Prenatally Diagnosed Congenital Microcephaly is defined by three criteria: first, the fetus is at least 24 weeks gestational age (GA), with GA based on certain last menstrual period (LMP) date, with confirmatory first or second trimester ultrasound (US) scan, OR uncertain LMP with second trimester ultrasound, intrauterine insemination (IUI) OR embryo transfer date; second, a head circumference (HC) measurement either 2 standard deviations (SD) below the mean or less than the third percentile according to fetal US examination, using appropriate, standardized reference charts according to GA and gender for the population (e.g. WHO growth reference charts if GA greater than or equal to 37 weeks and Intergrowth-21st reference charts for GA 24 to 36 weeks); third, no confirmation of microcephaly with any additional US or by HC measurement at either birth or autopsy.","GAIA Level 3a Prenatally Diagnosed Congenital Microcephaly | Global Alignment of Immunization safety Assessment in pregnancy Level 3a Prenatally Diagnosed Congenital Microcephaly | Level 3a Prenatally Diagnosed Congenital Microcephaly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512643","GAIA Level 5 Small for Gestational Age","C129606","GAIA Level 5 Small for Gestational Age is defined by either no evidence of Small for Gestational Age (SGA) or a confirmed diagnosis other than SGA.","GAIA Level 5 Small for Gestational Age | Global Alignment of Immunization safety Assessment in pregnancy Level 5 Small for Gestational Age | Level 5 Small for Gestational Age",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517917","Liver Stem Cell","C12960","An undifferentiated cell found in the liver.","Liver Stem Cell | Liver Stem Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513025","Central Nervous System Histiocytic Sarcoma","C129807","Rare involvement of the central nervous system by histiocytic sarcoma.","Central Nervous System Histiocytic Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513024","Central Nervous System Erdheim-Chester Disease","C129808","Erdheim-Chester disease that affects the central nervous system.","Central Nervous System Erdheim-Chester Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0447028","Intracranial Artery","C12980","Arteries which have their origins within the intracranial cavity.","Intracranial Artery | INTRACRANIAL ARTERY",,,,,,,,,,,,,,,"4027912","Structure of intracranial artery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL520662","GLMN Gene Product","C131993","A protein encoded by the GLMN gene.","GLMN Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1822800","SNHG5 Gene","C132180","This gene plays a role in small nucleolar RNA synthesis.","SNHG5 Gene | SNHG5 | Small Nucleolar RNA Host Gene 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520446","SNHG5 wt Allele","C132181","Human SNHG5 wild-type allele is located in the vicinity of 6q14.3 and is approximately 18 kb in length. This allele, which encodes long intergenic non-protein coding RNA 44, is involved in the synthesis of small nucleolar RNAs U50 and U50'. Translocation t(3;6)(q27;q15) involving the SNHG5 and BCL6 genes is associated with B-cell lymphoma.","SNHG5 wt Allele | C6orf160 | Chromosome 6 Open Reading Frame 160 Gene | LINC00044 | MGC16362 | NCRNA00044 | Small Nucleolar RNA Host Gene (Non-Protein Coding) 5 Gene | Small Nucleolar RNA Host Gene 5 (Non-Protein Coding) Gene | Small Nucleolar RNA Host Gene 5 wt Allele | U50 Host Gene | U50/U50B Host Gene | U50HG | bA33E24.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520454","Long Intergenic Non-Protein Coding RNA 44","C132182","Long intergenic non-protein coding RNA 44 (~0.5 kb) is encoded by the human SNHG5 gene. This non-coding RNA plays a role in the synthesis of small nucleolar RNAs U50 and U50'.","Long Intergenic Non-Protein Coding RNA 44 | LINC00044 | NCRNA00044 | Non-Protein Coding RNA 44 | SNHG5 LincRNA | Small Nucleolar RNA Host Gene 5 LincRNA | Small Nucleolar RNA Host Gene 5 Long Non-Coding RNA | U50 Host LincRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538637","PHLDB3 Gene","C132183","This gene may be involved in enzyme binding.","PHLDB3 Gene | PHLDB3 | Pleckstrin Homology Like Domain Family B Member 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520393","PHLDB3 wt Allele","C132184","Human PHLDB3 wild-type allele is located in the vicinity of 19q13.31 and is approximately 31 kb in length. This allele, which encodes pleckstrin homology-like domain family B member 3 protein, may play a role in protein-protein interactions.","PHLDB3 wt Allele | FLJ40193 | Pleckstrin Homology Like Domain Family B Member 3 wt Allele | Pleckstrin Homology-Like Domain, Family B, Member 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521317","Pleckstrin Homology-Like Domain Family B Member 3","C132185","Pleckstrin homology-like domain family B member 3 (640 aa, ~72 kDa) is encoded by the human PHLDB3 gene. This protein may be involved in interacting with enzymes.","Pleckstrin Homology-Like Domain Family B Member 3 | PHLDB3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422155","GPR182 Gene","C132186","This gene may play a role in adrenomedullin-mediated signaling.","GPR182 Gene | G Protein-Coupled Receptor 182 Gene | GPR182",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514663","Iatrogenic Primary Hypothyroidism","C131819","Primary hypothyroidism due to medical or surgical treatment.","Iatrogenic Primary Hypothyroidism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0506992","Pseudostratified Columnar Ciliated Epithelium","C13181","Epithelium composed of a single layer of cells, appearing as layered because the column-shaped cells vary in height so the nuclei are at different levels. The basal portions of all the cells are in contact with the basement membrane. It lines the respiratory system and the male reproductive tract. The cilia in the respiratory tract are motile, while the stereocilia in the male reproductive tract are immobile.","Pseudostratified Columnar Ciliated Epithelium | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514659","Hypothyroxinemia","C131820","Decreased concentration of thyroxine.","Hypothyroxinemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514422","Iodine I 131 MIP-1095","C131821","A radioconjugate composed of MIP-1095, a urea-based ligand for the tumor-associated antigen (TAA) prostate-specific membrane antigen (PSMA) radiolabeled with iodine I 131 (I131), with potential antineoplastic activity. Upon administration of iodine I 131 MIP-1095, the MIP-1095 moiety selectively targets and binds to the extracellular domain of PSMA, thereby delivering cytotoxic iodine I 131 specifically to PSMA-expressing cancer cells. PSMA is a transmembrane glycoprotein that is highly expressed by malignant prostate epithelial cells and certain other tumor cells.","Iodine I 131 MIP-1095 | ((S)-2-(3-((S)-1-carboxy-5-(3-(4-[(131)I]iodophenyl)ureido)pentyl)ureido)pentanedioic Acid | (131) I-MIP-1095 | 131I-MIP-1095 | I-131 MIP-1095 | MIP-1095 I-131",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514312","Malva sylvestris/Alcea digitata Herbal Compound","C131822","A traditional Persian medicine composed of Malva sylvestris (M. sylvestris) and Alcea digitata (A. digitata; Boiss), with potential use for the treatment of radiation- and chemotherapy-induced xerostomia, and potential immunomodulating, anti-oxidant and antimicrobial activities. Upon administration to the mouth, M. sylvestris/A. digitata herbal compound may lubricate the mouth and throat, and may improve the symptoms of dry mouth, thereby preventing tooth decay and improving chewing, eating, tasting, swallowing, and speaking. M. sylvestris/A. digitata herbal compound may also improve mucositis by modulating the immune system, thereby preventing infection, reducing inflammation and promoting wound healing.","Malva sylvestris/Alcea digitata Herbal Compound | M. sylvestris/A. digitata Herbal Compound | Traditional Persian Medicine Preparation M. sylvestris/A. digitata",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514550","Sodium Nitrate Supplement","C131823","A dietary supplement containing sodium nitrate, that can be used for nitrate supplementation purposes. Upon oral administration, nitrate is absorbed by the body and is partially converted to nitrite, which is stored and circulated in the blood, leading to an increase in nitrite levels. Nitrate, and to some extent nitrite, accumulates in saliva and may enhance salivary flow, which may help to treat dry mouth and chemo- and radiation-induced oropharyngeal problems.","Sodium Nitrate Supplement | Dietary Supplement Sodium Nitrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514564","Modified Vitamin D Binding Protein Macrophage Activator EF-022","C131824","A modified version of vitamin D binding protein (VDBP; Gc protein) macrophage activator, with potential antineoplastic and anti-angiogenic activities. Upon administration, modified VDBP-macrophage activator EF-022, acting in a similar manner as VDBP-macrophage activating factor (GcMAF), is able to activate tumoricidal macrophages, thereby enhancing the killing and eradication of cancer cells. In addition, EF-022 may inhibit tumor cell proliferation, migration and angiogenesis. VDBP is a glycoprotein and precursor for macrophage activating factor (MAF), which promotes macrophage activation; however VDBP can be deglycosylated by serum alpha-N-acetylgalactosaminidase, which is secreted from cancerous cells, and cannot be converted to MAF. Thus, the macrophage activation cascade is often impaired in tumor cells and plays a key role in tumor immunosuppression. Modification of VDBP stabilizes MAF.","Modified Vitamin D Binding Protein Macrophage Activator EF-022 | EF-022 | MVDP-Macrophage Activator | Modified VDBP-Macrophage Activator EF-022",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520663","Gallium Ga 68-NODAGA-Ac-Cys-ZEGFR:1907","C132029","A radiolabeled recombinant EGFR-specific affibody molecule composed of an epidermal growth factor receptor (EGFR)-targeting protein, the anti-EGFR affibody ZEGFR:1907 with an acetylated cysteine (Ac-Cys) at the N terminal of the affibody, and conjugated to the radioisotope gallium Ga 68, via the chelating agent NODAGA (1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid), with potential use for imaging EGFR-expressing tumor cells upon positron emission tomography (PET). Upon administration of gallium Ga 68-NODAGA-Ac-Cys-ZEGFR:1907, the ZEGFR:1907 affibody molecule moiety targets and binds to the extracellular domain (ECD) of EGFR expressed on various tumor cell types. Upon PET, EGFR-expressing tumor cells can be visualized. EGFR, frequently overexpressed in cancers, plays important roles in cell proliferation, survival, adhesion, migration, and differentiation. The affibody protein scaffold is based on the Z-domain, which is derived from one of the immunoglobulin (Ig) G-binding domains of staphylococcal protein A.","Gallium Ga 68-NODAGA-Ac-Cys-ZEGFR:1907 | 68Ga-NODAGA-Ac-Cys-ZEGFR:1907 | Gallium Ga 68-NODAGA-Ac-Cys-Z(EGFR:1907) | [68Ga]-labeled Anti-EGFR Affibody Molecule Ac-Cys-ZEGFR:1907",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512100","C11orf95-RELA Fusion Protein","C129354","A fusion protein encoded by the ZFTA/RELA fusion gene. This protein is comprised of the N-terminal domain of uncharacterized protein C11orf95 fused to most of the transcription factor p65 protein, including the transactivation domain.","ZFTA/RELA Fusion Protein | C11orf95-RELA Fusion Protein | C11orf95/RELA Fusion Protein | Uncharacterized Protein C11orf95/NF-Kappa B p65 Fusion Protein | Uncharacterized Protein C11orf95/Transcription Factor p65 Fusion Protein | ZFTA-RELA Fusion Protein | ZFTA::RELA Fusion Protein | Zinc Finger Translocation-Associated Protein-NF-Kappa B p65 Fusion Protein | Zinc Finger Translocation-Associated Protein/NF-Kappa B p65 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4277538","Chromothripsis","C129355","A cytogenetic abnormality characterized by the occurrence of a large number of chromosomal rearrangements that are restricted to sites in one or a few chromosomes. Chromothripsis may result from a single catastrophic event that causes multiple double-strand breaks, which are subsequently repaired or reassembled by error-prone DNA repair pathways or through aberrant DNA replication mechanisms.","Chromothripsis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513503","Yi Qi Yang Yin Fang","C129996","A traditional Chinese medicine (TCM)-based formulation that may benefit Qi, and boost Yin.","Yi Qi Yang Yin Fang | TCM Yi-qi-yang-yin Fang | Traditional Chinese Medicine Yi-qi-yang-yin Fang | Yi-qi-yang-yin Fang | YiQiYangYinFang",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0081549","Disulfonated Aluminum Phthalocyanine","C1299","An amphiphilic compound that exhibits a direct phototoxic effect, thereby inducing tumor necrosis. (NCI)","Disulfonated Aluminum Phthalocyanine | AlS2Pc | Aluminum Phthalocyanine Disulfonate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513821","BTK Inhibitor DTRMWXHS-12","C130001","An orally available inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), with potential antineoplastic activity. Upon administration, DTRMWXHS-12 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.","BTK Inhibitor DTRMWXHS-12 | DTRMWXHS 12 | DTRMWXHS-12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227149","Wall of the Pharynx","C129816","The walls of the swallowing passage.","Wall of the Pharynx | Pharyngeal Wall",,,,,,,,,,,,,,,"4206462","Pharyngeal wall structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0282559","Antineoplastic Hormonal/Endocrine Agent","C129818","Any agent that affects hormone levels and exerts antineoplastic effects. Antineoplastic hormonal/endocrine agents treat either hormone-dependent or hormone-sensitive cancers by modulating hormone levels and manipulating the endocrine system.","Antineoplastic Hormonal/Endocrine Agent | Antineoplastic Endocrinal Agent | Antineoplastic Hormonal Agent | Antineoplastic Hormonal Therapeutic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1874310","Antineoplastic Radiopharmaceutical Agent","C129819","Any radiopharmaceutical agent that targets cancer cells and exerts an antineoplastic effect through radiotoxicity.","Antineoplastic Radiopharmaceutical Agent | Anti-cancer Radiopharmaceutical | Antineoplastic Radiopharmaceutical",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512909","Antineoplastic Immunomodulating Agent","C129820","Any agent that is capable of modulating the immune system in order to exert antineoplastic effects. Antineoplastic immunomodulating agents either activate the immune system, restore certain immune system activators or abrogate immunosuppression.","Antineoplastic Immunomodulating Agent | Anti-cancer Immunotherapeutic | Antineoplastic BRM | Antineoplastic Biological Response Modifier | Antineoplastic Immunotherapeutic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512906","Antineoplastic Biological Agent","C129821","Any agent that has a biological nature, such as agents containing living organisms, derived from living organisms, or comprised of ex vivo synthesized analogs of substances derived from living organisms, and that exerts antineoplastic activity.","Antineoplastic Biological Agent | Anti-cancer Biological Agent | Anticancer Biological | Antineoplastic Biological | Antineoplastic Biotherapeutic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520320","GPR182 wt Allele","C132187","Human GPR182 wild-type allele is located in the vicinity of 12q13.3 and is approximately 6 kb in length. This allele, which encodes G-protein coupled receptor 182 protein, may be involved in adrenomedullin-dependent signaling pathways.","GPR182 wt Allele | 7TMR | ADMR | AM-R | AMR | Adrenomedullin Receptor Gene | G Protein-Coupled Receptor 182 wt Allele | G10D | gamrh | hrhAMR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0296735","adrenomedullin receptor","C132188","G-protein coupled receptor 182 (404 aa, ~45 kDa) is encoded by the human GPR182 gene. This protein plays a role in G protein-coupled receptor signaling.","G-Protein Coupled Receptor 182 | Adrenomedullin Receptor | G Protein-Coupled Receptor 182 | Gpr182",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538703","PORCN Gene","C132189","This gene is involved in the lipidation of Wnt family proteins.","PORCN Gene | PORCN | Porcupine Homolog (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520374","PORCN wt Allele","C132190","Human PORCN wild-type allele is located in the vicinity of Xp11.23 and is approximately 12 kb in length. This allele, which encodes protein-serine O-palmitoleoyltransferase porcupine protein, plays a role in post-translational modification of Wnt family proteins. Mutation of the gene is associated with focal dermal hypoplasia.","PORCN wt Allele | DHOF | Dermal Hypoplasia, Focal Gene | FODH | MG61 | PORC | PPN | Porcupine Homolog (Drosophila) wt Allele | Porcupine, Drosophila, Homolog of Gene | por",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1452435","PORCN protein, human","C132191","Protein-serine O-palmitoleoyltransferase porcupine (461 aa, ~52 kDa) is encoded by the human PORCN gene. This protein is involved in serine palmitoylation of Wnt family proteins.","Protein-Serine O-Palmitoleoyltransferase Porcupine | EC 2.3.1.- | PORCN | Probable Protein-Cysteine N-Palmitoyltransferase Porcupine | Protein MG61",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520665","Gallium Ga 68-NODAGA-ZIGF-1R:4:40","C132030","A radiolabeled recombinant insulin-like growth factor 1 receptor (IGF-1R; IGF1R)-specific affibody ligand composed of an IGF1R-targeting protein, the anti-IGF1R affibody ZIGF-1R:4:40 with an acetylated cysteine (Ac-Cys) at the N terminal of the affibody, that is site-specifically conjugated with the chelating agent NODAGA (1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid), and labeled with the radioisotope gallium Ga 68, with potential use for imaging IGF1R-expressing tumor cells upon positron emission tomography (PET). Upon administration of gallium Ga 68-NODAGA-ZIGF-1R:4:40, the ZIGF-1R:4:40 affibody molecule moiety targets and binds to IGF1R expressed on various tumor cell types. Upon PET, IGF1R-expressing tumor cells can be visualized. IGF1R, frequently overexpressed in cancers, plays important roles in cell proliferation, survival, adhesion, migration, and differentiation. The affibody protein scaffold is based on the Z-domain, which is derived from one of the immunoglobulin (Ig) G-binding domains of staphylococcal protein A.","Gallium Ga 68-NODAGA-ZIGF-1R:4:40 | 68Ga-NODAGA-ZIGF-1R:4:40 | [68Ga]-labeled Anti-IGF-1R Affibody Molecule ZIGF-1R:4:40",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826434","NLRC5 Gene","C132031","This gene is involved in innate immunity and antiviral responses.","NLRC5 Gene | NLR Family CARD Domain Containing 5 Gene | NLRC5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520089","NLRC5 wt Allele","C132032","Human NLRC5 wild-type allele is located in the vicinity of 16q13 and is approximately 94 kb in length. This allele, which encodes protein NLRC5, plays a role in signaling, immunity and antiviral processes.","NLRC5 wt Allele | CLR16.1 | FLJ21709 | NLR Family CARD Domain Containing 5 wt Allele | NLR Family, CARD Domain Containing 5 Gene | NLR Family, CARD-Containing 5 Gene | NLR Family, Caspase Recruitment Domain-Containing 5 Gene | NOD27 | NOD4 | Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat and CARD Domain Containing 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2932687","NLRC5 protein, human","C132033","Protein NLRC5 (1866 aa, ~205 kDa) is encoded by the human NLRC5 gene. This protein is involved in signaling pathways and antiviral responses.","Protein NLRC5 | CLR16.1 | Caterpiller Protein 16.1 | NOD-Like Receptor C5 | Nucleotide-Binding Oligomerization Domain Protein 27 | Nucleotide-Binding Oligomerization Domain Protein 4 | Nucleotide-Binding Oligomerization Domains 27",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2681537","CMTR2 Gene","C132034","This gene plays a role in the methylation of the 5' mRNA cap.","CMTR2 Gene | CMTR2 | Cap Methyltransferase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519749","CMTR2 wt Allele","C132035","Human CMTR2 wild-type allele is located in the vicinity of 16q22.2 and is approximately 8 kb in length. This allele, which encodes cap-specific mRNA (nucleoside-2-O-)-methyltransferase 2 protein, is involved in modification of mRNA.","CMTR2 wt Allele | AFT | Adrift Homolog (Drosophila) Gene | Cap Methyltransferase 2 wt Allele | FLJ11171 | FTSJD1 | HMTr2 | MTr2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3178372","FTSJD1 protein, human","C132036","Cap-specific mRNA (nucleoside-2-O-)-methyltransferase 2 (770 aa, ~88 kDa) is encoded by the human CMTR2 gene. This protein plays a role in mRNA maturation.","Cap-Specific mRNA (Nucleoside-2-O-)-Methyltransferase 2 | Adrift Homolog | CMTR2 | Cap2 2'O-Ribose Methyltransferase 2 | EC 2.1.1.296 | FtsJ Methyltransferase Domain Containing 1 | FtsJ Methyltransferase Domain-Containing Protein 1 | HMTr2 | MTr2 | Protein Adrift Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418423","PDE4D Gene","C132037","This gene is involved in the metabolism of the second messenger, cyclic adenosine monophosphate (cAMP).","PDE4D Gene | PDE4D | Phosphodiesterase 4D Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1704336","Rhabdomyocyte","C13000","A large cylindrical- or prismatic-shaped cell that is the basic unit of striated muscle tissue.","Rhabdomyocyte | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512608","CEV","C129579","A regimen containing carboplatin, etoposide, and vincristine which may be used in the treatment of pediatric retinoblastoma (RB).","CEV Regimen | CEV | CEV (Carboplatin/Etoposide) | Carboplatin-Etoposide-Vincristine | Carboplatin-Etoposide-Vincristine Regimen | Carboplatin/Etoposide/Vincristine | Carboplatin/Etoposide/Vincristine Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516995","Exocrine System","C12957","A system of glands that secrete fluids delivered via ducts and tubes directly to organs including the skin. Examples include the exocrine pancreas and the prostate gland.","Exocrine System | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512598","Checkpoint Kinase 1 Inhibitor CCT245737","C129580","An orally bioavailable inhibitor of checkpoint kinase 1 (chk1), with potential antineoplastic and chemosensitization activities. Upon oral administration, chk1 inhibitor SRA737 selectively binds to chk1, thereby preventing chk1 activity and abrogating the repair of damaged DNA. This may lead to an accumulation of damaged DNA, inhibition of cell cycle arrest, and induction of apoptosis. SRA737 may potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapeutic agents. Chk1, an adenosine triphosphate (ATP)-dependent serine/threonine kinase overexpressed in a variety of cancer cell types, mediates cell cycle checkpoint control and is essential for DNA repair; it plays a key role in resistance to chemotherapeutic agents by repairing DNA damage.","Chk1 Inhibitor SRA737 | (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile | CCT245737 | Checkpoint Kinase 1 Inhibitor CCT245737 | Chk1 Inhibitor CCT245737 | Chk1 Inhibitor CCT245737 | PNT-737 | SRA 737 | SRA-737 | SRA737",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016762","Fructose-Bisphosphate Aldolase","C129394","A family of enzymes that catalyzes interconversion between aldol phosphates and triose phosphates, the primary reaction for these enzymes is the reversible conversion of fructose 1,6-bisphosphate into dihydroxyacetone phosphate (DHAP) and glyceraldehyde 3-phosphate (G3P). Glycolysis uses the forward reaction while gluconeogenesis uses the reverse reaction.","Fructose-Bisphosphate Aldolase | 1,6-Diphosphofructose Aldolase | ALDO | Aldolase | D-Fructose-1,6-Bisphosphate D-Glyceraldehyde-3-Phosphate-Lyase | D-Fructose-1,6-Bisphosphate D-Glyceraldehyde-3-Phosphate-Lyase (Glycerone-Phosphate-Forming) | Diphosphofructose Aldolase | EC 4.1.2.13 | Fructoaldolase | Fructose 1,6-Diphosphate Aldolase | Fructose 1-Monophosphate Aldolase | Fructose 1-Phosphate Aldolase | Fructose Diphosphate Aldolase | Fructose-1,6-Bisphosphate Triosephosphate-Lyase | Ketose 1-Phosphate Aldolase | Phosphofructoaldolase | SMALDO | Zymohexase",,,,,,,,,,,,,,,"4102625","Aldolase",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1515406","Recombinant Transforming Growth Factor-Beta 1","C1293","A recombinant form of the endogenous Transforming Growth Factor-Beta 1, a protein involved with the regulation of cell proliferation and differentiation.","Recombinant Transforming Growth Factor-Beta 1 | HUMAN TRANSFORMING GROWTH FACTOR .BETA.-1 | TGFbeta1 | Transforming Growth Factor Beta-1 | Transforming Growth Factor-Beta 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512670","Antibody-drug Conjugate Anti-TIM-1-vcMMAE CDX-014","C129401","A monoclonal antibody-drug conjugate (ADC) comprised of human immunoglobulin G1 (IgG1) clone CR014, which targets the extracellular domain of T-cell immunoglobulin mucin-1 (TIM-1; HAVCR1), that is linked, via a valine-citrulline (VC) peptide linker, to the potent cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of ADC anti-TIM-1-vcMMAE CDX-014, the monoclonal antibody moiety targets and binds to TIM-1. Upon internalization and proteolytic cleavage, MMAE is released into the cytosol of TIM-1-expressing tumor cells, binds to tubulin, and inhibits microtubule polymerization, which induces both G2/M phase arrest and tumor cell apoptosis. TIM-1 is upregulated in a variety of cancer cell types while only minimally expressed in healthy tissue. The linkage system in CDX-014 is highly stable in plasma, resulting in increased specificity and cytotoxic efficacy towards TIM-1-positive cells.","Antibody-drug Conjugate Anti-TIM-1-vcMMAE CDX-014 | ADC Anti-TIM-1-vcMMAE CDX-014 | ADC CDX-014 | Antibody-drug Conjugate CDX-014 | CDX-014 | CR014-vc-MMAE | CR014-vcMMAE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019397","Heterochromatin","C13241","A tightly packed area of chromatin that may function to protect chromosome integrity and regulate gene expression.","Heterochromatin | ",,,,,,,,,,,,,,,"4238877","Heterochromatin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1825918","LYPD3 Gene","C132240","This gene is involved in cell migration.","LYPD3 Gene | LY6/PLAUR Domain Containing 3 Gene | LYPD3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520549","LYPD3 wt Allele","C132241","Human LYPD3 wild-type allele is located in the vicinity of 19q13.31 and is approximately 5 kb in length. This allele, which encodes Ly6/PLAUR domain-containing protein 3, plays a role in cell-matrix interactions.","LYPD3 wt Allele | C4.4A | LY6/PLAUR Domain Containing 3 wt Allele | Matrigel-Induced Gene C4 | UNQ491/PRO1007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1175291","LYPD3 protein, human","C132242","Ly6/PLAUR domain-containing protein 3 (346 aa, ~36 kDa) is encoded by the human LYPD3 gene. This protein is involved in cell-matrix interactions during cell migration.","Ly6/PLAUR Domain-Containing Protein 3 | 2310061G07Rik | C4.4A | GPI-Anchored Metastasis-Associated Protein C4.4A | GPI-Anchored Metastasis-Associated Protein C4.4A Homolog | GPI-Anchored Metastasis-Associated Protein Homolog | LYPD3 | MIG-C4 | Matrigel-Induced Gene C4 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3884847","Ma Zi Ren Wan","C129581","A proprietary, traditional Chinese herbal (TCH) formula composed of six different herbs: Semen Cannabis Sativae (Huo Ma Ren, cannabis seed), Semen Pruni Armeniacae (Xing Ren, apricot seed), Radix Paeoniae Alba (Bai Shao, white peony root), Fructus Immaturus Citri Aurantii (Zhi Shi, immature bitter orange), Cortex Magnoliae Officinalis (Hou Po, magnolia bark and Radix et Rhizoma Rhei (Da Huang, rhubarb root and rhizome). Ma Zi Ren Wan (MZRW) may help with intestinal dryness and constipation by lubricating and moistening the intestines and the stool. MZRW may also stimulate intestinal movement; it is believed to drain heat, promote the movement of Qi and unblock the bowels.","Ma Zi Ren Wan | Hemp Seed Formula | MZRW | MaZiRenWan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0696679","Huang Qi","C129582","A Chinese herbal medicine (CHM) containing the root of the perennial herbaceous plant Astragalus (Radix Astragali) belonging to the family Leguminosae. Huang Qi is believed to tonify Qi, induce diuresis, relieve edema and nourish blood. It may also replenish body fluids and help relieve pain.","Huang Qi | ASTRAGALUS MONGHOLICUS ROOT | ASTRAGALUS PROPINQUUS ROOT | Astragalus Root | HuangQi | Milk Vetch Root | Milkvetch Root | Radix Astragali",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512578","Shu Di Huang","C129583","A Chinese herbal medicine (CHM) containing the cooked or steamed root of the herbaceous plant Rehmannia glutinosa Libosch of the Scrophulariaceae family. Shu Di Huang is believed to treat deficiency of yin and body fluid by nourishing yin. It may tonify and nourish blood.","Shu Di Huang | Cooked Rehmannia Root | Processed Rehmannia Glutinosa Libosch Root | Processed Rehmannia Root | Radix Rehmanniae Preparata | ShuDiHuang | Steamed Chinese Foxglove Root",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1046250","Mai Dong","C129584","The root of the perennial herbaceous plant Ophiopogon belonging to the Liliaceae family. Mai Dong is believed to tonify yin. This traditional Chinese medicine (TCM) may replenish fluids, moisten the intestines and thereby help relieve constipation. It may also have antipyretic and antitussive effects; it may be used as an expectorant and may moisten the lungs, throat and nose.","Mai Dong | Mai Men Dong | Maidong | OPHIOPOGON JAPONICUS ROOT | Ophiopogon | Radix Ophiopogonis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1094557","Sheng Di Huang","C129585","A Chinese herbal medicine (CHM) derived from the root tuber of perennial herbaceous plant Rehmannia glutinosa Libosch (Chinese foxglove root, Radix Rehmanniae Glutinosae) belonging to the Scrophulariaceae family. This traditional Chinese medicine (TCM) is believed to nourish yin and may help relieve any symptoms due to yin deficiency. It may replenish fluids and help with constipation and fever.","Sheng Di Huang | Radix Rehmanniae Glutinosae | Rehmannia Glutinosa | ShengDiHuang",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513011","MYB/NFIB Fusion Protein","C129773","A fusion protein encoded by the MYB/NFIB fusion gene. This protein is comprised of most of transcriptional activator Myb protein fused to the amino acids comprising the extreme C-terminus of nuclear factor 1 B-type protein.","MYB/NFIB Fusion Protein | MYB-NF-IB Fusion Protein | MYB-NF1-B Fusion Protein | MYB-NFI-B Fusion Protein | MYB-NFIB Fusion Protein | MYB/NF-IB Fusion Protein | MYB/NF1-B Fusion Protein | MYB/NFI-B Fusion Protein | MYB::NFIB Fusion Protein | Transcriptional Activator Myb/Nuclear Factor 1 B-Type Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513203","Q-LES-Q - Concentrate on Leisure Activities","C130675","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) How often did you concentrate on the leisure activities and pay attention to them?","Q-LES-Q - Concentrate on Leisure Activities | QLES1-Concentrate on Leisure Activities | QLES167",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513275","Q-LES-Q - Solve or Deal Without Undue Stress","C130676","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) If a problem arose in your leisure activities, how often did you solve it or deal with it without undue stress?","Q-LES-Q - Solve or Deal Without Undue Stress | QLES1-Solve or Deal Without Undue Stress | QLES168",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513249","Q-LES-Q - Leisure Activity Sustain Interest","C130677","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) How often did the leisure activities sustain your interest?","Q-LES-Q - Leisure Activity Sustain Interest | QLES1-Leisure Activity Sustain Interest | QLES169",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513567","WHODAS 2.0 12+24-item Version Interviewer-administered - Current Marital Status","C130853","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) What is your current marital status?","WHODAS 2.0 12+24-item Version Interviewer-administered - Current Marital Status | WD4-Current Marital Status | WD4A4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513570","WHODAS 2.0 12+24-item Version Interviewer-administered - Describes Main Work Status Best","C130854","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) Which describes your main work status best?","WHODAS 2.0 12+24-item Version Interviewer-administered - Describes Main Work Status Best | WD4-Describes Main Work Status Best | WD4A5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513605","WHODAS 2.0 12+24-item Version Interviewer-administered - Standing for Long Periods","C130855","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Standing for long periods such as 30 minutes?","WHODAS 2.0 12+24-item Version Interviewer-administered - Standing for Long Periods | WD4-Standing for Long Periods | WD4S1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513565","WHODAS 2.0 12+24-item Version Interviewer-administered - Care of Household Responsibilities","C130856","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Taking care of your household responsibilities?","WHODAS 2.0 12+24-item Version Interviewer-administered - Care of Household Responsibilities | WD4-Care of Household Responsibilities | WD4S2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513589","WHODAS 2.0 12+24-item Version Interviewer-administered - Learning a New Task","C130857","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Learning a new task, for example, learning how to get to a new place?","WHODAS 2.0 12+24-item Version Interviewer-administered - Learning a New Task | WD4-Learning a New Task | WD4S3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513598","WHODAS 2.0 12+24-item Version Interviewer-administered - Problem Joining Community Activities","C130858","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Joining in community activities (for example, festivities, religious or other activities) in the same way as anyone else can?","WHODAS 2.0 12+24-item Version Interviewer-administered - Problem Joining Community Activities | WD4-Problem Joining Community Activities | WD4S4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513576","WHODAS 2.0 12+24-item Version Interviewer-administered - Emotionally Affected by Health","C130859","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: How much have you been emotionally affected by your health problems?","WHODAS 2.0 12+24-item Version Interviewer-administered - Emotionally Affected by Health | WD4-Emotionally Affected by Health | WD4S5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225695","Alveolar Wall","C13085","The alveolar structure that contains alveolar cells type I and II and macrophages.","Alveolar Wall | ",,,,,,,,,,,,,,,"4275267","Alveolar wall structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519456","Spinal Cord Tract","C12995","White matter in the spinal cord comprising longitudinally oriented nerve fibers (axons) that transmit impulses in both directions: ascending tracts transmit sensory information to the brain from the body, and descending tracts transmit impulses from the brain to the muscles.","Spinal Cord Tract | Ascending and Descending Tracts of Spinal Cord | Spinal Cord Tracts | Tracts of Spinal Cord",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512682","Central Nervous System Epithelioid Hemangioendothelioma","C129536","A low-grade malignant blood vessel neoplasm that arises from the central nervous system.  It is characterized by the presence of epithelioid endothelial cells.","Central Nervous System Epithelioid Hemangioendothelioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512619","FloTrac System","C129634","A proprietary device system comprising a sensor and a monitor for continuous determination of a patient's fluid status and cardiac output directly from the arterial line.","FloTrac System | Edwards FloTrac Monitoring Device | FloTrac | FloTrac Sensor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512767","Acquired Hyperthyroidism","C129635","Hyperthyroidism, the cause of which is not present from birth.","Acquired Hyperthyroidism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512770","Adipsic Diabetes Insipidus","C129637","Diabetes insipidus complicated by a deficient or absent thirst response to hyperosmolality, usually as a result of hypothalamic damage or dysfunction.","Adipsic Diabetes Insipidus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512689","Cerium-144 Beta Radiation","C129639","Beta radiation produced by the decay of cerium-144.","Cerium-144 Beta Radiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0836205","Gut Epithelium","C12963","The epithelium that lines the gastrointestinal tract.","Gut Epithelium | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512697","Cobalt-60 Gamma Radiation","C129640","Gamma rays produced by the decay of cobalt-60.","Cobalt-60 Gamma Radiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512778","Iron-56 Ion Irradiation","C129641","Irradiation with heavy, charged nuclei of iron-56.","Iron-56 Ion Irradiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512690","Cesium-137 Gamma Radiation","C129643","Gamma rays produced by the decay of cesium-137.","Cesium-137 Gamma Radiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512769","Acquired Hypothyroidism","C129644","Hypothyroidism, the cause of which is not present at birth.","Acquired Hypothyroidism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512927","CALR NP_004334.1:p.L367fs*46","C129837","A change in the amino acid composition of the calreticulin protein where a frameshift mutation results in the insertion of 45 non-canonic amino acids followed by a stop codon immediately after the leucine residue at position 367.","CALR NP_004334.1:p.L367fs*46 | CALR L367fs*46 | CALR Leu367fs*46 | CALR NP_004334.1:p.Leu367fs*46 | CALR Type 1 Protein Variant | CALR p.L367fs*46 | CALR p.Leu367fs*46 | CALR1 Protein Variant | CRP55 L367fs*46 | CRP55 Leu367fs*46 | Calregulin L367fs*46 | Calregulin Leu367fs*46 | Calreticulin L367fs*46 | Calreticulin Leu367fs*46 | ERp60 L367fs*46 | ERp60 Leu367fs*46 | Endoplasmic Reticulum Resident Protein 60 L367fs*46 | Endoplasmic Reticulum Resident Protein 60 Leu367fs*46 | HACBP L367fs*46 | HACBP Leu367fs*46 | NP_004334.1:p.L367fs*46 | NP_004334.1:p.Leu367fs*46 | NP_004334.1p.Leu367Thrfs*46 | Type 1 CALR Protein Variant | grp60 L367fs*46 | grp60 Leu367fs*46",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512926","CALR NP_004334.1:p.K385fs*47","C129838","A change in the amino acid composition of the calreticulin protein where a frameshift mutation results in the insertion of 46 non-canonic amino acids followed by a stop codon immediately after the lysine residue at position 385.","CALR NP_004334.1:p.K385fs*47 | CALR K385fs*47 | CALR Lys385fs*47 | CALR NP_004334.1:p.Lys385fs*47 | CALR Type 2 Protein Variant | CALR p.K385fs*47 | CALR p.Lys385fs*47 | CALR2 Protein Variant | CRP55 K385fs*47 | CRP55 Lys385fs*47 | Calregulin K385fs*47 | Calregulin Lys385fs*47 | Calreticulin K385fs*47 | Calreticulin Lys385fs*47 | ERp60 K385fs*47 | ERp60 Lys385fs*47 | Endoplasmic Reticulum Resident Protein 60 K385fs*47 | Endoplasmic Reticulum Resident Protein 60 Lys385fs*47 | HACBP K385fs*47 | HACBP Lys385fs*47 | NP_004334.1:p.K385fs*47 | NP_004334.1:p.Lys385fs*47 | Type 2 CALR Protein Variant | grp60 K385fs*47 | grp60 Lys385fs*47",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512912","Apoptotic Pathway-targeting Antineoplastic Agent","C129839","Any agent that directly targets the apoptotic pathway and has an antineoplastic effect.","Apoptotic Pathway-targeting Antineoplastic Agent | Apoptotic Pathway-targeting Cancer Therapeutic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003793","Bone of the Upper Extremity","C12983","A bone of the arm (upper extremity).","Bone of the Upper Extremity | Bone of Upper Extremity | Bones of Upper Extremity",,,,,,,,,,,,,,,"4159296","Bone structure of upper limb",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL507868","CSF1R Inhibitor PLX73086","C129688","An inhibitor of colony stimulating factor 1 receptor (CSF1R; CSF-1R), with potential antineoplastic activity. Upon administration, CSF1R inhibitor PLX73086 targets and binds to CSF1R, thereby blocking CSF1R activation and CSF1R-mediated signaling. This inhibits the activity of tumor-associated macrophages (TAMs) in the tumor tissue and prevents TAM-related tumor cell growth. CSF1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), is a cell-surface receptor for its ligand colony stimulating factor 1 (CSF1) and plays major roles in tumor cell proliferation and metastasis.","CSF1R Inhibitor PLX73086 | AC-708 | AC708 | PLX7 3086 | PLX73086",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507851","E7046","C129689","An orally bioavailable antagonist of the prostaglandin E2 (PGE2) receptor type 4 (EP4; EP-4), with potential immunomodulating and antineoplastic activities. Upon oral administration, palupiprant selectively targets, binds to and blocks the activity of immunosuppressive tumor-associated myeloid cells (TAMCs) in the microenvironment. This abolishes TAMC-dependent immunosuppression and reduces tumor cell proliferation. The presence of immunosuppressive myeloid cells in certain tumors is associated with a poor prognosis.","Palupiprant | AN 0025 | AN-0025 | AN0025 | E 7046 | E-7046 | E7046 | EP4 Antagonist E7046 | EP4 Inhibitor E7046 | ER-886046 | PALUPIPRANT | Prostaglandin E EP4 Receptor Antagonist E7046 | Prostaglandin E2 EP4 Receptor Inhibitor AN0025 | Prostaglandin E2 EP4 Receptor Inhibitor AN0025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519666","Tumor-Associated Vasculature","C12968","New blood vessels formed by solid tumors.","Tumor-Associated Vasculature | Neovasculature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418648","SERPINF2 Gene","C129261","This gene plays a role in the inhibition of serine proteinases.","SERPINF2 Gene | SERPINF2 | Serpin Family F Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512234","SERPINF2 wt Allele","C129262","Human SERPINF2 wild-type allele is located in the vicinity of 17p13 and is approximately 12 kb in length. This allele, which encodes alpha-2-antiplasmin protein, is involved in the regulation of blood coagulation. Mutation of the gene is associated with alpha-2-plasmin inhibitor deficiency.","SERPINF2 wt Allele | A2AP | AAP | ALPHA-2-PI | API | PLI | Serine (Or Cysteine) Proteinase Inhibitor, Clade F (Alpha-2 Antiplasmin, Pigment Epithelium Derived Factor), Member 2 Gene | Serpin Family F Member 2 wt Allele | Serpin Peptidase Inhibitor, Clade F (Alpha-2 Antiplasmin, Pigment Epithelium Derived Factor), Member 2 Gene | Serpin Peptidase Inhibitor, Clade F, Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2713682","Alpha-2-Antiplasmin, Human","C129263","Alpha-2-antiplasmin (491 aa, ~55 kDa) is encoded by the human SERPINF2 gene. This protein plays a role in the regulation of plasmin-mediated processes during blood coagulation.","Alpha-2-Antiplasmin | ALPHA-2-PI | Alpha-2-AP | Alpha-2-Plasmin Inhibitor | SERPINF2 | Serpin F2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419718","RPS2 Gene","C129265","This gene is involved in ribosomal function.","RPS2 Gene | RPS2 | Ribosomal Protein S2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512328","RPS2 wt Allele","C129267","Human RPS2 wild-type allele is located in the vicinity of 16p13.3 and is approximately 3 kb in length. This allele, which encodes 40S ribosomal protein S2, plays a role in ribosome assembly.","RPS2 wt Allele | LLREP3 | RPS4 | Ribosomal Protein S2 wt Allele | S2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512387","40S Ribosomal Protein S4","C129268","40S ribosomal protein S2 (293 aa, ~31 kDa) is encoded by the human RPS2 gene. This protein is involved in ribosome formation.","40S Ribosomal Protein S2 | 40S Ribosomal Protein S4 | OK/KNS-Cl.6 | Protein LLRep3 | RPS2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512611","Central Nervous System Hemangiopericytoma","C129528","A solitary fibrous tumor that arises from the central nervous system. It corresponds to the more cellular, less collagenous tumor with plump cells and staghorn vasculature which was diagnosed as central nervous system hemangiopericytoma in the past.","Central Nervous System Solitary Fibrous Tumor, Grade 2 | CNS Solitary Fibrous Tumor, Grade 2 | CNS Solitary Fibrous Tumor/Hemangiopericytoma, Grade 2 | Central Nervous System Hemangiopericytoma | Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 2 | Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 2 | Solitary fibrous tumor/hemangiopericytoma Grade 2 (CNS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512613","Central Nervous System Solitary Fibrous Tumor","C129530","A solitary fibrous tumor that arises from the central nervous system. It corresponds most often to the collagenous and low cellularity spindle cell tumor which was diagnosed as central nervous system solitary fibrous tumor in the past.","Central Nervous System Solitary Fibrous Tumor, Grade 1 | CNS Solitary Fibrous Tumor, Grade 1 | CNS Solitary Fibrous Tumor/Hemangiopericytoma, Grade 1 | Central Nervous System Solitary Fibrous Tumor | Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 1 | Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 1 | Solitary fibrous tumor/hemangiopericytoma Grade 1 (CNS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512686","Central Nervous System Mesenchymal Chondrosarcoma","C129534","A mesenchymal chondrosarcoma that arises from the central nervous system.","Central Nervous System Mesenchymal Chondrosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512774","Surface Guided Radiation Therapy","C129535","A form of image-guided radiation therapy for high-accuracy patient positioning and motion monitoring. SGRT tracks the patient's skin surface in 3 dimensions; motion that exceeds clinically acceptable tolerances can be detected and the beam can be held automatically or gated according to the patient's breathing cycle.","Surface Guided Radiation Therapy | SGRT | SURF | VisionRT-Mediated Radiation Therapy | VisionRT-assisted Deep Inspiration Breath-hold Beam Delivery | VisionRT-based Deep Inspiration Breath-hold Beam Delivery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512679","Central Nervous System Angiolipoma","C129538","An angiolipoma that arises from the central nervous system.","Central Nervous System Angiolipoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518254","Nervous System Fluids and Secretions","C12953","Fluids and secretions related to the nervous system. The entire nerve apparatus, composed of a central part, the brain and spinal cord, and a peripheral part, the cranial and spinal nerves, autonomic ganglia, and plexuses.","Nervous System Fluids and Secretions | Nervous System-Fluids, Secretions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512921","CGA wt Allele","C129841","Human CGA wild-type allele is located in the vicinity of 6q14.3 and is approximately 10 kb in length. This allele, which encodes glycoprotein hormones alpha chain protein, is involved in protein hormone-dependent signaling.","CGA wt Allele | CG-ALPHA | FSHA | GPHA1 | GPHa | Glycoprotein Hormones, Alpha Polypeptide wt Allele | HCG | LHA | TSHA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018664","Glycoprotein Hormones Alpha Chain Protein, Human","C129842","Glycoprotein hormones alpha chain (116 aa, ~13 kDa) is encoded by the human CGA gene. This protein plays a role in hormone signaling.","Glycoprotein Hormones Alpha Chain Protein | Anterior Pituitary Glycoprotein Hormones Common Subunit Alpha | CG-ALPHA | CGA | Choriogonadotropin Alpha Chain | Chorionic Gonadotrophin Subunit Alpha | Chorionic Gonadotropin, Alpha Polypeptide | FSH-Alpha | Follicle-Stimulating Hormone Alpha Chain | Follicle-Stimulating Hormone Alpha Subunit | Follicle-Stimulating Hormone, Alpha Chain | Follitropin Alpha Chain | Glycoprotein Hormones Alpha Chain | Glycoprotein Hormones Alpha Polypeptide | Glycoprotein Hormones, Alpha Chain | Glycoprotein Hormones, Alpha Polypeptide | LSH-Alpha | Luteinizing Hormone Alpha Chain | Luteinizing Hormone, Alpha Chain | Lutropin Alpha Chain | TSH-Alpha | Thyroid-Stimulating Hormone Alpha Chain | Thyroid-Stimulating Hormone, Alpha Chain | Thyrotropin Alpha Chain | Thyrotropin, Alpha Chain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512938","NAT1 wt Allele","C129844","Human NAT1 wild-type allele is located in the vicinity of 8p22 and is approximately 53 kb in length. This allele, which encodes arylamine N-acetyltransferase 1 protein, plays a role in the metabolism of arylamines.","NAT1 wt Allele | AAC1 | MNAT | N-Acetyltransferase 1 (Arylamine N-Acetyltransferase) Gene | N-Acetyltransferase 1 wt Allele | NAT-1 | NATI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0673024","Arylamine N-Acetyltransferase 1, Human","C129845","Arylamine N-acetyltransferase 1 (290 aa, ~34 kDa) is encoded by the human NAT1 gene. This protein is involved in arylamine detoxification.","Arylamine N-Acetyltransferase 1 | Acetyl-CoA:Arylamine N-Acetyltransferase | Arylamide Acetylase 1 | Arylamine N-Acetyltransferase | EC 2.3.1.5 | Monomorphic Arylamine N-Acetyltransferase | N-Acetyltransferase 1 | N-Acetyltransferase Type 1 | NAT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512933","INHBE wt Allele","C129847","Human INHBE wild-type allele is located in the vicinity of 12q13.3 and is approximately 7 kb in length. This allele, which encodes inhibin beta E chain protein, is involved in the modulation of hormone secretion.","INHBE wt Allele | Inhibin Beta E Subunit wt Allele | Inhibin, Beta E Gene | MGC4638",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1608817","Inhibin Beta E Chain, Human","C129848","Inhibin beta E chain (350 aa, ~39 kDa) is encoded by the human INHBE gene. This protein plays a role in the secretion of hormones.","Inhibin Beta E Chain | Activin Beta-E | Activin Beta-E Chain | INHBE | Inhibin Beta E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426584","CYCS Gene","C129849","This gene is involved in electron transport.","CYCS Gene | CYCS | Cytochrome C, Somatic Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512904","Interval Lymph Node","C12984","One of the nodes that lie along the course of a lymphatic vessel between a primary melanoma site and a recognized node field. (from Medscape)","Interval Lymph Node | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512863","CYCS wt Allele","C129850","Human CYCS wild-type allele is located in the vicinity of 7p15.3 and is approximately 7 kb in length. This allele, which encodes cytochrome c protein, plays a role in the mitochondrial electron transport chain. Mutation of the gene is associated with thrombocytopenia 4.","CYCS wt Allele | CYC | Cytochrome C, Somatic wt Allele | HCS | THC4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512922","Chronic Myelomonocytic Leukemia with Eosinophilia Associated with t(5;12)(q31;p12)","C129852","Chronic myelomonocytic leukemia characterized by the presence of eosinophilia, PDGFRB gene rearrangement, and t(5;12)(q31;p12).","Chronic Myelomonocytic Leukemia with Eosinophilia Associated with t(5;12)(q31;p12) | Chronic Myelomonocytic Leukemia with Eosinophilia Associated with t(5;12)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1282010","Ascending Spinal Cord Tract","C12967","A nervous tract that transmits pain, temperature, and touch sensations and position and vibratory sense to the brain.","Ascending Spinal Cord Tract | Ascending Spinal Cord Tracts | Ascending Spinal Tracts | Ascending Tracts of Spinal Cord",,,,,,,,,,,,,,,"4197000","Ascending spinal cord tract",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512592","Xp11.2 Translocations/TFE3 Gene Fusions Present","C129686","A genetic finding indicating the presence of translocations involving the chromosome Xp11.2. These translocations result in the creation of gene fusions involving the TFE3 gene.","Xp11.2 Translocations/TFE3 Gene Fusions Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507891","FT-2102","C129687","An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1; IDH-1; IDH1 [NADP+] soluble) with a mutation at arginine (R) 132, IDH1(R132), with potential antineoplastic activity. Upon administration, olutasidenib specifically inhibits IDH1(R132), thereby inhibiting the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing IDH(R132). IDH1(R132) mutations are highly expressed in certain malignancies, including gliomas; they initiate and drive cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.","Olutasidenib | 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo- | FT 2102 | FT-2102 | FT2102 | IDH1-R132 Inhibitor FT-2102 | OLUTASIDENIB | Rezlidhia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418856","PPY Gene","C129909","This gene plays a role in the modulation of gastrointestinal functions and appetite.","PPY Gene | PPY | Pancreatic Polypeptide Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512884","PPY wt Allele","C129910","Human PPY wild-type allele is located in the vicinity of 17q21.31 and is approximately 3 kb in length. This allele, which encodes pancreatic prohormone protein, is involved in the regulation of pancreatic and gastrointestinal functions.","PPY wt Allele | PNP | PP | Pancreatic Polypeptide Y Gene | Pancreatic Polypeptide wt Allele | Pancreatic Polypeptide/Pancreatic Icosapeptide Gene | Prepro-PP (Prepropancreatic Polypeptide) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0063017","Pancreatic Prohormone, Human","C129912","Pancreatic prohormone (95 aa, ~10 kDa) is encoded by the human PPY gene. This protein plays a role in the regulation of appetite, food intake and digestion.","Pancreatic Prohormone | PP | PPY | Pancreatic Polypeptide | Prepro-PP | Prepropancreatic Polypeptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513047","Pancreatic Hormone, Human","C129913","Pancreatic hormone (36 aa, ~4 kDa) is encoded by the human PPY gene. This protein plays a role in the modulation of appetite and digestion.","Pancreatic Hormone | PH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0122626","Pancreatic Icosapeptide, Human","C129914","Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.","Pancreatic Icosapeptide | PI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0175701","Aarskog Syndrome","C129720","An X-linked condition associated in a subset of cases with mutation(s) in the FGD1 gene, encoding a complex signaling protein containing FYVE, RhoGEF, and PH domains. The condition is usually characterized by distinctive facial features, short stature, skeletal anomalies, shawl scrotum (altered anatomical relationship between the penis and the scrotum) cryptorchidism, and developmental delay.","Aarskog Syndrome | Aarskog-Scott Syndrome | FGD | Faciogenital Dysplasia",,,,,,,,,,,,,,,"4032940","Aarskog syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3494506","Albright Hereditary Osteodystrophy with Multiple Hormone Resistance","C129721","Parathyroid hormone (PTH) resistance caused by heterozygous inactivating mutation(s) of the maternal allele of the GNAS gene encoding Gs-alpha, resulting in expression of PTH from only the paternal allele. Clinical manifestations include Albright hereditary osteodystrophy, early-onset obesity, and, in some cases, resistance to thyroid-stimulating hormone, gonadotropins, and growth hormone-releasing hormone, reflecting additional manifestations of Gs-alpha deficiency.","Albright Hereditary Osteodystrophy with Multiple Hormone Resistance | PHP1a | Pseudohypoparathyroidism Type 1a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033835","Albright Hereditary Osteodystrophy without Multiple Hormone Resistance","C129722","A condition caused by inactivating mutation(s) in the paternal allele of the GNAS gene, encoding Gs-alpha, resulting in expression of the Gs-alpha protein from only the maternal allele. Affected individuals have the clinical phenotype of Albright hereditary osteodystrophy without hormone resistance.","Albright Hereditary Osteodystrophy without Multiple Hormone Resistance | Albright Hereditary Osteodystrophy with Multiple Hormone Resistance | PPHP | Pseudopseudohypoparathyroidism",,,,,,,,,,,,,,,"4030185","Pseudopseudohypoparathyroidism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0220989","Acquired Partial Lipodystrophy","C129723","Partial lipodystrophy, the cause of which is not present at birth. Examples include lipodystrophy associated with human immunodeficiency virus (HIV) therapy, and Barraquer-Simons syndrome, associated with C3 nephritic factor.","Acquired Partial Lipodystrophy | ",,,,,,,,,,,,,,,"4192633","Acquired partial lipodystrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0040150","Acute Suppurative Thyroiditis","C129724","Thyroiditis due to a bacterial infection.","Acute Suppurative Thyroiditis | ",,,,,,,,,,,,,,,"4102064","Acute suppurative thyroiditis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0429468","Anovulatory Cycle","C129725","A menstrual cycle in which no ovulation occurs.","Anovulatory Cycle | Anovulation",,,,,,,,,,,,,,,"4090070","Anovulatory",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513017","Autoimmune Polyglandular Syndrome","C129726","A group of diverse conditions that are characterized by spontaneous, multi-organ autoimmunity, which target both endocrine (adrenal, gonad, pancreatic islet cells, parathyroid, pituitary, thyroid) and non-endocrine (gastrointestinal, integumentary, lymphatic) tissues.","Autoimmune Polyglandular Syndrome | Autoimmune Polyendocrine Syndrome | Autoimmune Polyglandular Syndrome(s) | Polyglandular Autoimmune Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085859","Autoimmune Polyglandular Syndrome Type 1","C129727","Autoimmune polyglandular syndrome caused by homozygous, compound heterozygous, or heterozygous mutation(s) in the AIRE gene, encoding autoimmune regulator protein. Diagnosis requires at least 2 of the 3 major clinical features: chronic mucocutaneous candidiasis, primary adrenal insufficiency, or primary hypoparathyroidism. Antibodies against type 1 interferons and interleukin 17 cytokines are almost always present. Heterozygous AIRE mutation(s) typically result in a narrower disease spectrum.","Autoimmune Polyglandular Syndrome Type 1 | APECED Syndrome | APS1 | Autoimmune Polyendocrine Syndrome Type 1 | Autoimmune Polyendocrinopathy-candidiasis-ectodermal Dystrophy Syndrome | Polyglandular Autoimmune Syndrome Type 1",,,,,,,,,,,,,,,"4008545","Polyglandular autoimmune syndrome, type 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0085860","Autoimmune Polyglandular Syndrome Type 2","C129728","Autoimmune polyglandular syndrome of likely polygenic etiology characterized by the presence of primary adrenal insufficiency in association with autoimmune thyroiditis and/or type 1 diabetes mellitus; this condition is not associated with mucocutaneous candidiasis.","Autoimmune Polyglandular Syndrome Type 2 | APS2 | Schmidt Syndrome",,,,,,,,,,,,,,,"4308266","Polyglandular autoimmune syndrome, type 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513019","Autonomous Ovarian Follicular Cyst","C129729","A cyst arising from an ovarian follicle that produces hormones independent of gonadotropin stimulation.","Autonomous Ovarian Follicular Cyst | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512998","t(8;9)(p22;p24.1)","C129854","A cytogenetic abnormality that refers to the translocation of 8p22 and 9p24.1. This translocation results in the fusion of the PCM1 gene and the JAK2 gene.","t(8;9)(p22;p24.1) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512881","PCM1/JAK2 Fusion Gene","C129855","A fusion gene that results from a chromosomal translocation t(8;9)(p22;p24.1) which fuses most of the PCM1 gene to the upstream side of the exons of the JAK2 gene encoding the tyrosine kinase domain. This fusion is associated with myeloproliferative disorders and some rare myeloid and lymphoid neoplastic diseases.","PCM1/JAK2 Fusion Gene | PCM1-JAK2 Fusion Gene | PCM1::JAK2 Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512882","PCM1/JAK2 Fusion Protein","C129856","A fusion protein that is encoded by the PCM1/JAK2 fusion gene. This protein contains the predicted coiled-coil domains and the ATP/GTP binding domain from pericentriolar material 1 protein and the entire tyrosine kinase domain of the tyrosine-protein kinase JAK2 protein.","PCM1/JAK2 Fusion Protein | PCM-1/JAK-2 Fusion Protein | PCM1-JAK2 Fusion Protein | PCM1::JAK2 Fusion Protein | Pericentriolar Material 1 Protein/Tyrosine-Protein Kinase JAK2 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512930","Gingival Squamous Cell Carcinoma","C129857","A squamous cell carcinoma that arises from the gingival mucosa. It presents as an ulcerated lesion or exophytic mass. The prognosis is usually poor.","Gingival Squamous Cell Carcinoma | Gingival SCC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512859","Rat Ovarian Adenocarcinoma","C129858","Adenocarcinoma that arises from the ovary of a rat.","Rat Ovarian Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512983","Mouse Teratocarcinoma","C129859","A malignant germ-cell neoplasm arising from pluripotent cells, including components from the epithelial germ-cell layer, which occurs in a mouse.","Mouse Teratocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1113654","Neural Stem Cell","C12985","A stem cell derived from embryonic sources or found in adult neural tissue. It has the capacity to generate all the multiple cell types found in the brain and spinal cord.","Neural Stem Cell | Neural Stem Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513009","Time of Bowel Movement","C129860","A question about the time of day when a bowel movement occurred.","Time of Bowel Movement | Time of This Bowel Movement | Time when this bowel movement occurred.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3850024","Transcranial Direct Current Stimulation","C129862","A noninvasive technique to alter cortical brain activity by direct current polarization. This technique is being applied in human for modification of perceptual, cognitive, and behavioral functions.","Transcranial Direct Current Stimulation | tDCS",,,,,,,,,,,,,,,"37158172","Transcranial direct current stimulation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512879","Oral Epithelial Dysplasia","C129863","A morphologic finding of dysplastic epithelial cells in the oral cavity.","Oral Epithelial Dysplasia | OED | Oral Dysplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513218","Q-LES-Q - Felt Able to Make Decisions","C130625","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: felt able to make decisions?","Q-LES-Q - Felt Able to Make Decisions | QLES1-Felt Able to Make Decisions | QLES122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513231","Q-LES-Q - Felt Relaxed","C130626","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: felt relaxed?","Q-LES-Q - Felt Relaxed | QLES1-Felt Relaxed | QLES123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513225","Q-LES-Q - Felt Good About Your Life","C130627","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: felt good about your life?","Q-LES-Q - Felt Good About Your Life | QLES1-Felt Good About Your Life | QLES124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513195","Q-LES-Q - Able to Travel About to Get Things Done When Needed","C130628","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: felt able to travel about to get things done when needed (walk, use car, bus, train, or whatever is available as needed)?","Q-LES-Q - Able to Travel About to Get Things Done When Needed | QLES1-Able to Travel About When Needed | QLES125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513194","Q-LES-Q - Able to Take Care of Yourself","C130630","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: felt able to take care of yourself?","Q-LES-Q - Able to Take Care of Yourself | QLES1-Able to Take Care of Yourself | QLES127",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513242","Q-LES-Q - Have a Job","C130631","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Do you have a job?","Q-LES-Q - Have a Job | QLES1-Have a Job | QLES128A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513287","Q-LES-Q - Work for Yourself","C130632","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Do you work for yourself?","Q-LES-Q - Work for Yourself | QLES1-Work for Yourself | QLES128B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513728","WHODAS 2.0 36-item Version Self-administered - Moving Around Inside Your Home","C130818","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Moving around inside your home?","WHODAS 2.0 36-item Version Self-administered - Moving Around Inside Your Home | WD7-Moving Around Inside Your Home | WD7D2_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513721","WHODAS 2.0 36-item Version Self-administered - Getting Out of Your Home","C130819","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Getting out of your home?","WHODAS 2.0 36-item Version Self-administered - Getting Out of Your Home | WD7-Getting Out of Your Home | WD7D2_4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013681","Efferent Pathway","C13081","A sensory pathway that conducts impulses away from the central nervous system.","Efferent Pathway | Efferent Pathways",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513742","WHODAS 2.0 36-item Version Self-administered - Walking a Long Distance","C130820","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Walking a long distance such as a kilometre [or equivalent]?","WHODAS 2.0 36-item Version Self-administered - Walking a Long Distance | WD7-Walking a Long Distance | WD7D2_5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513743","WHODAS 2.0 36-item Version Self-administered - Washing Your Whole Body","C130821","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Washing your whole body?","WHODAS 2.0 36-item Version Self-administered - Washing Your Whole Body | WD7-Washing Your Whole Body | WD7D3_1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512850","ATXN1 wt Allele","C129916","Human ATXN1 wild-type allele is located in the vicinity of 6p22.3 and is approximately 462 kb in length. This allele, which encodes ataxin-1 protein, plays a role in Notch signaling, chromatin binding and RNA metabolism. CGA repeat expansion within the coding region of the gene is associated with spinocerebellar ataxia 1.","ATXN1 wt Allele | ATX1 | Ataxin 1 wt Allele | D6S504E | SCA1 | Spinocerebellar Ataxia 1 (Olivopontocerebellar Ataxia 1, Autosomal Dominant, Ataxin 1) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1568182","Ataxin-1, Human","C129917","Ataxin-1 (815 aa, ~87 kDa) is encoded by the human ATXN1 gene. This protein is involved in chromatin binding, RNA metabolism and Notch signaling.","Ataxin-1 | ATXN1 | Ataxin 1 | Spinocerebellar Ataxia Type 1 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512903","Human Anti-Idiotype Antibody","C129918","A human anti-mouse antibody that binds to the antigen-combining site of another antibody.","Human Anti-Idiotype Antibody | Ab2 | Anti-Id | Anti-Idiotype Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512899","Human Anti-Anti-Idiotype Antibody","C129919","A human antibody that recognizes human anti-mouse anti-idiotype antibodies.","Human Anti-Anti-Idiotype Antibody | Ab3 | Anti-Anti-Id | Anti-Anti-Idiotype Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512932","Induced Anti-Tumor Antigen-specific Antibody","C129920","An antibody that recognizes a tumor-associated antigen (TAA) and is induced and expressed following immunization by a therapeutic antibody targeting the same TAA.","Induced Anti-Tumor Antigen-specific Antibody | Ab3 Prime | Ab3' | Induced Anti-TAA Antibody | Induced Anti-Tumor-Associated Antigen Antibody | Induced Tumor Antigen-specific Antibody | Induced Tumor-Associated Antigen Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1567114","Nuclear Factor NF-kappa-B p52 Subunit, Human","C129923","Nuclear factor NF-kappa-B p52 subunit (454 aa, ~49 kDa) is encoded by the human NFKB2 gene. This protein is involved in both transcriptional regulation and signal transduction.","Nuclear Factor NF-kappa-B p52 Subunit | NF-Kappa B p52 | NF-kB Subunit 2 p52 | NF-kappaB(p52) | NFKB p52 Subunit | Nuclear Factor Kappa-B Subunit 2 p52",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513566","WHODAS 2.0 12+24-item Version Interviewer-administered - Concentrating for Ten Minutes","C130860","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Concentrating on doing something for ten minutes?","WHODAS 2.0 12+24-item Version Interviewer-administered - Concentrating for Ten Minutes | WD4-Concentrating for Ten Minutes | WD4S6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513611","WHODAS 2.0 12+24-item Version Interviewer-administered - Washing Your Whole Body","C130862","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Washing your whole body?","WHODAS 2.0 12+24-item Version Interviewer-administered - Washing Your Whole Body | WD4-Washing Your Whole Body | WD4S8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513580","WHODAS 2.0 12+24-item Version Interviewer-administered - Getting Dressed","C130863","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Getting dressed?","WHODAS 2.0 12+24-item Version Interviewer-administered - Getting Dressed | WD4-Getting Dressed | WD4S9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513404","CDISC Clinical Classification BUERS Test Name Terminology","C130238","Test names of clinical classification questions associated with the Brooke Upper Extremity Rating Scale (BUERS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification BUERS Test Name Terminology | BUERS1TN | Brooke Upper Extremity Rating Scale Clinical Classification Test Name | CC-BUERS TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513403","CDISC Clinical Classification BUERS Test Code Terminology","C130239","Test codes of clinical classification questions associated with the Brooke Upper Extremity Rating Scale (BUERS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification BUERS Test Code Terminology | BUERS1TC | Brooke Upper Extremity Rating Scale Clinical Classification Test Code | CC-BUERS TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1268110","Heart Part","C13023","Any component of the organ which receives blood from the veins and ejects it into the arteries.","Heart Part | ",,,,,,,,,,,,,,,"4000501","Heart part",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513416","CDISC Clinical Classification VLERS Test Name Terminology","C130240","Test names of clinical classification questions associated with the Vignos Lower Extremity Rating Scale (VLERS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification VLERS Test Name Terminology | CC-VLERS TEST | VLERS1TN | Vignos Lower Extremity Rating Scale Clinical Classification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513406","CDISC Clinical Classification HAM-D6 Clinician Version Test Name Terminology","C130242","Test names of clinical classification questions associated with the Hamilton Depression Rating Scale 6 Clinician Version (HAM-D6 Clinician Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification HAM-D6 Clinician Version Test Name Terminology | CC-HAM-D6 Clinician Version TEST | HAMD4TN | Hamilton Depression Rating Scale - 6 Clinician Version Clinical Classification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513405","CDISC Clinical Classification HAM-D6 Clinician Version Test Code Terminology","C130243","Test codes of clinical classification questions associated with the Hamilton Depression Rating Scale 6 Clinician Version (HAM-D6 Clinician Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification HAM-D6 Clinician Version Test Code Terminology | CC-HAM-D6 Clinician Version TESTCD | HAMD4TC | Hamilton Depression Rating Scale - 6 Clinician Version Clinical Classification Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513408","CDISC Clinical Classification HAMD 24 Test Name Terminology","C130244","Test names of clinical classification questions associated with the Hamilton Depression Rating Scale-24 Item (HAMD 24) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification HAMD 24 Test Name Terminology | CC-HAMD 24 TEST | HAMD3TN | Hamilton Depression Rating Scale - 24 Item Clinical Classification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513407","CDISC Clinical Classification HAMD 24 Test Code Terminology","C130245","Test codes of clinical classification questions associated with the Hamilton Depression Rating Scale-24 Item (HAMD 24) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification HAMD 24 Test Code Terminology | CC-HAMD 24 TESTCD | HAMD3TC | Hamilton Depression Rating Scale - 24 Item Clinical Classification Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513718","WHODAS 2.0 36-item Version Self-administered - Getting Dressed","C130822","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Getting dressed?","WHODAS 2.0 36-item Version Self-administered - Getting Dressed | WD7-Getting Dressed | WD7D3_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513713","WHODAS 2.0 36-item Version Self-administered - Eating","C130823","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Eating?","WHODAS 2.0 36-item Version Self-administered - Eating | WD7-Eating | WD7D3_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513739","WHODAS 2.0 36-item Version Self-administered - Staying by Yourself for a Few Days","C130824","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Staying by yourself for a few days?","WHODAS 2.0 36-item Version Self-administered - Staying by Yourself for a Few Days | WD7-Staying by Yourself for a Few Days | WD7D3_4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513709","WHODAS 2.0 36-item Version Self-administered - Dealing With People You Do Not Know","C130825","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Dealing with people you do not know?","WHODAS 2.0 36-item Version Self-administered - Dealing With People You Do Not Know | WD7-Dealing With People You Do Not Know | WD7D4_1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513726","WHODAS 2.0 36-item Version Self-administered - Maintaining a Friendship","C130826","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Maintaining a friendship?","WHODAS 2.0 36-item Version Self-administered - Maintaining a Friendship | WD7-Maintaining a Friendship | WD7D4_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513716","WHODAS 2.0 36-item Version Self-administered - Get Along With People Close to You","C130827","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Getting along with people who are close to you?","WHODAS 2.0 36-item Version Self-administered - Get Along With People Close to You | WD7-Get Along With People Close to You | WD7D4_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513727","WHODAS 2.0 36-item Version Self-administered - Making New Friends","C130828","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Making new friends?","WHODAS 2.0 36-item Version Self-administered - Making New Friends | WD7-Making New Friends | WD7D4_4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512738","PROMIS Short Form v1.0 - Fatigue 8a","C129493","A self-report tool that evaluates fatigue over a range of symptoms, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. The fatigue short form is generic rather than disease specific and assesses fatigue over the past seven days.","PROMIS Short Form v1.0 - Fatigue 8a | PROMIS Fatigue Short Form | PROMIS Item Bank v1.0 - Fatigue - Short Form 8a | Promis Fatigue Item Bank Short Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512662","C19MC Amplification","C129498","A genetic finding indicating the presence of amplification of the C19MC region on chromosome 19 (19q13.42).","C19MC Amplification | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1257909","Somatic Cell","C12949","No value exists.","Somatic Cell | Somatic Cells | somatic cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0080225","Thymopentin","C1294","A synthetic pentapeptide which is the active site of the naturally occurring hormone thymopoietin with immunomodulating properties. Thymopentin enhances the production of thymic T cells and may help restore immunocompetence in immunosuppressed subjects. This agent also augments the effects of ionizing radiation by arresting cancer cells in the G2/M phase of the cell cycle. (NCI04)","Thymopentin | Immunox | Mepentil | N-(N-(N-(N(2)-L-Arginyl-L-Lysyl)-L-alpha-Aspartyl)-L-Valyl)-L-Tyrosine | N-[N-[N-(N{2}-L-Arginyl-L-lysyl)-L-alpha-aspartyl]-L-valyl]-L-tyrosine | ORF-15244 | Sintomodulina | THYMOPENTIN | Timunox",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507850","BTCT4465A","C129691","A bispecific, humanized monoclonal antibody with potential antineoplastic activity. Mosunetuzumab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, mosunetuzumab binds to both T-cells and CD20-expressing tumor B-cells; this cross-links T-cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B-cells.","Mosunetuzumab | Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A | BTCT 4465A | BTCT-4465A | BTCT4465A | CD20/CD3 BiMAb BTCT4465A | Lunsumio | MOSUNETUZUMAB | Mosunetuzumab-axgb | RG 7828 | RG-7828 | RG7828 | RO7030816",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513410","CDISC Clinical Classification IDS-C Test Name Terminology","C130246","Test names of clinical classification questions associated with the Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification IDS-C Test Name Terminology | CC-IDS-C TEST | IDSC1TN | Inventory of Depressive Symptomatology Clinician-Rated Version Clinical Classification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513409","CDISC Clinical Classification IDS-C Test Code Terminology","C130247","Test codes of clinical classification questions associated with the Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification IDS-C Test Code Terminology | CC-IDS-C TESTCD | IDSC1TC | Inventory of Depressive Symptomatology Clinician-Rated Version Clinical Classification Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513414","CDISC Clinical Classification QIDS-C Test Name Terminology","C130248","Test names of clinical classification questions associated with the Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification QIDS-C Test Name Terminology | CC-QIDS-C TEST | QIDSC1TN | Quick Inventory of Depressive Symptomatology Clinician-Rated Version Clinical Classification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513413","CDISC Clinical Classification QIDS-C Test Code Terminology","C130249","Test codes of clinical classification questions associated with the Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification QIDS-C Test Code Terminology | CC-QIDS-C TESTCD | QIDSC1TC | Quick Inventory of Depressive Symptomatology Clinician-Rated Version Clinical Classification Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513857","FACT-HEP Version 4 - I Have a Lack of Energy","C130458","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Physical Well-Being: I have a lack of energy.","FACT-HEP Version 4 - I Have a Lack of Energy | FAC015-I Have a Lack of Energy | FAC01501",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513853","FACT-HEP Version 4 - I Have Nausea","C130459","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Physical Well-Being: I have nausea.","FACT-HEP Version 4 - I Have Nausea | FAC015-I Have Nausea | FAC01502",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513866","FACT-HEP Version 4 - Trouble Meeting Needs of Family","C130460","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Physical Well-Being: Because of my physical condition, I have trouble meeting the needs of my family.","FACT-HEP Version 4 - Trouble Meeting Needs of Family | FAC015-Trouble Meeting Needs of Family | FAC01503",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513855","FACT-HEP Version 4 - I Have Pain","C130461","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Physical Well-Being: I have pain.","FACT-HEP Version 4 - I Have Pain | FAC015-I Have Pain | FAC01504",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513826","FACT-HEP Version 4 - Bothered by Treatment Side Effect","C130462","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Physical Well-Being: I am bothered by side effects of treatment.","FACT-HEP Version 4 - Bothered by Treatment Side Effect | FAC015-Bothered by Treatment Side Effect | FAC01505",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513835","FACT-HEP Version 4 - I Am Forced to Spend Time in Bed","C130464","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Physical Well-Being: I am forced to spend time in bed.","FACT-HEP Version 4 - I Am Forced to Spend Time in Bed | FAC015-I Am Forced to Spend Time in Bed | FAC01507",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513840","FACT-HEP Version 4 - I Feel Close to My Friends","C130465","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Social/Family Well-Being: I feel close to my friends.","FACT-HEP Version 4 - I Feel Close to My Friends | FAC015-I Feel Close to My Friends | FAC01508",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512698","Continued Complete Hematologic Response","C129648","Durable or long-term complete hematologic response. Time frames that define durability of complete hematologic response vary for different hematologic malignancies.","Continued Complete Hematologic Response | Continued CHR | Durable Complete Hematologic Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512602","Bifidobacterium animalis/Lactobacillus rhamnosus Probiotic Supplement","C129649","An orally bioavailable, probiotic supplement containing the non-pathogenic microorganisms Bifidobacterium animalis and Lactobacillus rhamnosus subspecies lactis with potential immunomodulating, anti-diarrheal and mucosal protective activities. Upon oral ingestion, the naturally-occurring bacterial components in Bifidobacterium animalis/Lactobacillus rhamnosus subspecies lactis probiotic supplement may improve digestion and help to maintain adequate colonization of the gastrointestinal (GI) tract by modulating the composition of the normal microflora. They produce lactic acid, hydrogen peroxide and other substances during fermentation, thereby creating an acidic environment that is unfavorable for pathogens. During colonization in the GI tract, the bacteria may also form a protective intestinal barrier, which may prevent damage to the mucosal epithelium, maintains the integrity of the epithelial barrier from potential damage by toxins and certain chemicals, and reduces the potential for attachment of pathogens. This further protects against bacterial translocation and infection. In addition, this agent may reduce the secretion of pro-inflammatory cytokines and may potentiate natural and acquired immunity. Altogether, this may increase immunity, prevent GI mucosal damage, malabsorption, inflammation, and reduce diarrhea, such as diarrhea induced by inflammation and GI mucosa-damaging agents.","Bifidobacterium animalis/Lactobacillus rhamnosus Probiotic Supplement | BB-12/LGG | Bifidobacterium animalis/Lactobacillus rhamnosus Probiotic | Lactobacillus rhamnosus GG/ Bifidobacterium animalis subsp. lactis BB-12 | Lactobacillus rhamnosus/Bifidobacterium animalis subsp. lactis | PROBIO-FIX INUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516798","Connective and Soft Tissue","C12964","The supporting connective tissue of an organ.","Connective and Soft Tissue | ","C49.9","Connective, subcutaneous and other soft tissues, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"CL512625","Polysiloxane/Gadolinium Chelates-based Nanoparticles","C129651","A nanoparticle formulation composed of a polysiloxane-based inorganic matrix bound to cyclic chelates composed of the chelating agent DOTA (1,4,7,10-tetra-azacyclododecane-1-glutaric anhydride-4,7,10-triacetic acid) covalently bound to the paramagnetic contrast enhancer gadolinium (Gd), a high-Z material, with potential use in enhancing diagnostic images upon magnetic resonance imaging (MRI) and potential radiosensitizing activity. Upon intravenous administration of polysiloxane matrix-gadolinium chelates-based nanoparticles, the nanoparticles extravasate to tumor sites due to the unique, hyperpermeable environment of the tumor vasculature. In addition, the small nanoparticles allow for deep penetration into the tumor, where they subsequently accumulate. Upon placement in a magnetic field, this agent produces a large magnetic moment and creates a large local magnetic field, which can enhance the relaxation rate of nearby protons. This change in proton relaxation dynamics increases the MRI signal intensity of tissues in which this agent has accumulated; therefore, contrast and visualization of those tissues are enhanced compared to unenhanced MRI. The ultra-small nanoparticles, less than 5 nm in diameter, allow for rapid renal clearance and reduced toxicity. Due to their magnetic properties, these nanoparticles make tumor cells more sensitive to radiation therapy.","Polysiloxane/Gadolinium Chelates-based Nanoparticles | AGuIX | AGuIX-NP | Gadolinium-Based Nanoparticle | Polysiloxane Matrix-gadolinium Chelates-based Nanoparticles | Polysiloxane/Gadolinium-DOTA Chelates-based Nanoparticles",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512474","FACT-B Version 4 - Self-conscious About Way I Dress","C129216","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Additional Concerns: I am self-conscious about the way I dress.","FACT-B Version 4 - Self-conscious About Way I Dress | FAC005-Self-conscious About Way I Dress | FAC00529",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513809","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.895G>T Mutation","C130214","A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where guanine has been substituted with thymine at nucleotide position 895 of the ABL1 gene. This mutation is associated with imatinib- and dasatinib-resistant leukemias.","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.895G>T Mutation | BCR/ABL Fusion Gene with NM_005157.4:c.895G>T | BCR/ABL Fusion Gene with NM_005157.5:c.895G>T | BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.895G>T | BCR/ABL1 Fusion Gene with NM_005157.4:c.895G>T | BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.895G>T Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513811","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.951C>A Mutation","C130216","A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where cytosine has been substituted with adenine at nucleotide position 951 of the ABL1 gene. This mutation is associated with imatinib- and dasatinib-resistant leukemias.","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.951C>A Mutation | BCR/ABL Fusion Gene with NM_005157.4:c.951C>A | BCR/ABL Fusion Gene with NM_005157.5:c.951C>A | BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.951C>A | BCR/ABL1 Fusion Gene with NM_005157.4:c.951C>A | BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.951C>A Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513810","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.949T>C Mutation","C130217","A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where thymine has been substituted with cytosine at nucleotide position 949 of the ABL1 gene. This mutation is associated with imatinib- and dasatinib-resistant leukemias.","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.949T>C Mutation | BCR/ABL Fusion Gene with NM_005157.4:c.949T>C | BCR/ABL Fusion Gene with NM_005157.5:c.949T>C | BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.949T>C | BCR/ABL1 Fusion Gene with NM_005157.4:c.949T>C | BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.949T>C Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513812","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.951C>G Mutation","C130218","A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where cytosine has been substituted with guanine at nucleotide position 951 of the ABL1 gene. This mutation is associated with imatinib- and dasatinib-resistant leukemias.","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.951C>G Mutation | BCR/ABL Fusion Gene with NM_005157.4:c.951C>G | BCR/ABL Fusion Gene with NM_005157.5:c.951C>G | BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.951C>G | BCR/ABL1 Fusion Gene with NM_005157.4:c.951C>G | BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.951C>G Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513316","QIDS-C - Highest Score Sleep Items","C130410","Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Enter the highest score on any 1 of the 4 sleep items.","QIDS-C - Highest Score Sleep Items | QIDSC1-Highest Score Sleep Items | QIDSC117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513314","QIDS-C - High Score Appetite or Weight Items","C130411","Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Enter the highest score on any 1 of the 4 appetite/weight change items.","QIDS-C - High Score Appetite or Weight Items | QIDSC1-High Score Appetite/Weight Items | QIDSC118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507788","VX-803","C129693","An orally available inhibitor of ataxia telangiectasia and Rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration,gartisertib selectively inhibits ATR activity and blocks the downstream phosphorylation of the serine/threonine protein kinase CHK1. This prevents ATR-mediated signaling, which results in the inhibition of DNA damage checkpoint activation, the disruption of DNA damage repair, and the induction of tumor cell apoptosis. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression and survival; it is activated by DNA damage caused during DNA replication-associated stress.","Gartisertib | ATR Kinase Inhibitor VX-803 | GARTISERTIB | M 4344 | M-4344 | M4344 | VX 803 | VX-803 | VX803",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512894","Anti-human GITR Monoclonal Antibody AMG 228","C129694","An agonistic anti-human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor receptor superfamily, member 18; TNFRSF18; GITR; CD357) humanized monoclonal antibody, with potential immune checkpoint modulating activity. Anti-human GITR monoclonal antibody AMG 228 binds to and activates GITRs found on multiple types of T-cells. This stimulates the immune system, induces both the activation and proliferation of tumor-antigen-specific T effector cells (Teffs), and suppresses the function of activated T regulatory cells (Tregs). This leads to immune-mediated tumor cell eradication though a cytotoxic T-lymphocyte (CTL) response. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B-cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress Teffs and suppress T-cell receptor (TCR) signaling.","Anti-human GITR Monoclonal Antibody AMG 228 | AMG 228 | AMG-228 | AMG228 | Agonistic GITR Antibody AMG 228",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512924","Beta Thalassemia Major","C129699","The most severe form of beta thalassemia that is characterized by the lack of functional beta-globin chain production resulting in the absence of hemoglobin A.","Beta Thalassemia Major | Cooley Anemia | Cooley's Anemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1282011","Descending Spinal Cord Tract","C12969","Neural fibers of the spinal cord, that are grouped into tracts or fasciculi, and send motor signals from the brain to lower motor neurons. These tracts function to control muscle tone, posture, precise motor movements, spinal reflexes, and spinal autonomic functions.","Descending Spinal Cord Tract | Descending Spinal Cord Tracts | Descending Spinal Tracts",,,,,,,,,,,,,,,"4200116","Descending spinal cord tract",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0080321","virginiamycin factor S1","C1296","A streptomycin B-related cyclic depsipeptide isolated from the bacterium Streptomyces virginiae and other Streptomyces bacterial species.  Virginiamycin S1 binds to and inhibits the formation of 50S ribosomes, thereby preventing protein synthesis. (NCI04)","Virginiamycin S1 | Staphylomycin S | VIRGINIAMYCIN S1 | Virginiamycin Factor S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513830","FACT-HEP Version 4 - Get Emotional Support From Family","C130466","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Social/Family Well-Being: I get emotional support from my family.","FACT-HEP Version 4 - Get Emotional Support From Family | FAC015-Get Emotional Support From Family | FAC01509",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513846","FACT-HEP Version 4 - I Get Support From My Friends","C130467","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Social/Family Well-Being: I get support from my friends.","FACT-HEP Version 4 - I Get Support From My Friends | FAC015-I Get Support From My Friends | FAC01510",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513860","FACT-HEP Version 4 - My Family Has Accepted My Illness","C130468","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Social/Family Well-Being: My family has accepted my illness.","FACT-HEP Version 4 - My Family Has Accepted My Illness | FAC015-My Family Has Accepted My Illness | FAC01511",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513863","FACT-HEP Version 4 - Satisfied With Communication About Illness","C130469","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Social/Family Well-Being: I am satisfied with family communication about my illness.","FACT-HEP Version 4 - Satisfied With Communication About Illness | FAC015-Satisfied Communication Illness | FAC01512",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513841","FACT-HEP Version 4 - I Feel Close to My Partner","C130470","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Social/Family Well-Being: I feel close to my partner (or the person who is my main support).","FACT-HEP Version 4 - I Feel Close to My Partner | FAC015-I Feel Close to My Partner | FAC01513",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513845","FACT-HEP Version 4 - I Feel Sad","C130472","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Emotional Well-Being: I feel sad.","FACT-HEP Version 4 - I Feel Sad | FAC015-I Feel Sad | FAC01515",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513213","Q-LES-Q - Enjoyed Being With Friends","C130678","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how often have you: enjoyed talking with or being with friends or relatives?","Q-LES-Q - Enjoyed Being With Friends | QLES1-Enjoyed Being With Friends | QLES170",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513240","Q-LES-Q - Getting Together With Friends","C130679","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how often have you: looked forward to getting together with friends or relatives?","Q-LES-Q - Getting Together With Friends | QLES1-Getting Together With Friends | QLES171",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0175518","Solitary Nucleus","C13067","A cluster of nerve cell bodies that form a column of gray matter in the dorsomedial region of the medulla oblongata. The solitary nucleus comprises the gustatory and visceral sensory nuclei of the brainstem, processing impulses from the taste buds, pharynx, larynx, intestinal and respiratory tracts, heart, and large blood vessels.","Solitary Nucleus | Nucleus Tractus Solitarius | Nucleus of the Solitary Tract | Nucleus of the Tractus Solitarius",,,,,,,,,,,,,,,"4266495","Structure of nucleus of tractus solitarius",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513255","Q-LES-Q - Made Social Plans With Friends","C130680","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how often have you: made social plans with friends or relatives for future activities?","Q-LES-Q - Made Social Plans With Friends | QLES1-Made Social Plans With Friends | QLES172",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513215","Q-LES-Q - Enjoyed Talking With Co-workers","C130681","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how often have you: enjoyed talking with co-workers or neighbors?","Q-LES-Q - Enjoyed Talking With Co-workers | QLES1-Enjoyed Talking With Co-workers | QLES173",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513261","Q-LES-Q - Patient With Others","C130682","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how often have you: been patient with others when others were irritating in their actions or words?","Q-LES-Q - Patient With Others | QLES1-Patient With Others | QLES174",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512471","FACT-B Version 4 - One or Both Arms Are Swollen or Tender","C129217","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Additional Concerns: One or both of my arms are swollen or tender.","FACT-B Version 4 - One or Both Arms Are Swollen or Tender | FAC005-One/Both Arms Are Swollen/Tender | FAC00530",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512460","FACT-B Version 4 - I Feel Sexually Attractive","C129218","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Additional Concerns: I feel sexually attractive.","FACT-B Version 4 - I Feel Sexually Attractive | FAC005-I Feel Sexually Attractive | FAC00531",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512451","FACT-B Version 4 - I Am Bothered by Hair Loss","C129219","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Additional Concerns: I am bothered by hair loss.","FACT-B Version 4 - I Am Bothered by Hair Loss | FAC005-I Am Bothered by Hair Loss | FAC00532",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512477","FACT-B Version 4 - Worry Family Will Get Illness","C129220","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Additional Concerns: I worry that other members of my family might someday get the same illness I have.","FACT-B Version 4 - Worry Family Will Get Illness | FAC005-Worry Family Will Get Illness | FAC00533",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512476","FACT-B Version 4 - Worry About the Effect of Stress","C129221","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Additional Concerns: I worry about the effect of stress on my illness.","FACT-B Version 4 - Worry About the Effect of Stress | FAC005-Worry About the Effect of Stress | FAC00534",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512450","FACT-B Version 4 - I Am Bothered by Change in Weight","C129222","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Additional Concerns: I am bothered by a change in weight.","FACT-B Version 4 - I Am Bothered by Change in Weight | FAC005-I Am Bothered by Change in Weight | FAC00535",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512448","FACT-B Version 4 - I Am Able to Feel Like a Woman","C129223","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Additional Concerns: I am able to feel like a woman.","FACT-B Version 4 - I Am Able to Feel Like a Woman | FAC005-I Am Able to Feel Like a Woman | FAC00536",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512443","FACT-B Version 4 - Certain Parts of Body Have Pain","C129224","Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Additional Concerns: I have certain parts of my body where I experience pain.","FACT-B Version 4 - Certain Parts of Body Have Pain | FAC005-Certain Parts of Body Have Pain | FAC00537",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512481","FOSI - I Have Been Vomiting","C129226","Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) I have been vomiting.","FOSI - I Have Been Vomiting | FAC049-I Have Been Vomiting | FAC04902",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512484","FOSI - I Have Pain","C129227","Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) I have pain.","FOSI - I Have Pain | FAC049-I Have Pain | FAC04903",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512483","FOSI - I Have Nausea","C129228","Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) I have nausea.","FOSI - I Have Nausea | FAC049-I Have Nausea | FAC04904",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512485","FOSI - I Have Swelling in Stomach Area","C129229","Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) I have swelling in my stomach area.","FOSI - I Have Swelling in Stomach Area | FAC049-I Have Swelling in Stomach Area | FAC04905",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513315","QIDS-C - Highest Score Psychomotor Items","C130412","Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Enter the highest score on either of the 2 psychomotor items.","QIDS-C - Highest Score Psychomotor Items | QIDSC1-Highest Score Psychomotor Items | QIDSC119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513326","QIDS-C - Total Score","C130413","Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Total score.","QIDS-C - Total Score | QIDSC1-Total Score | QIDSC120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513901","FACT-LEU Version 4 - I Have a Lack of Energy","C130414","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Physical Well-Being: I have a lack of energy.","FACT-LEU Version 4 - I Have a Lack of Energy | FAC017-I Have a Lack of Energy | FAC01701",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513897","FACT-LEU Version 4 - I Have Nausea","C130415","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Physical Well-Being: I have nausea.","FACT-LEU Version 4 - I Have Nausea | FAC017-I Have Nausea | FAC01702",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513899","FACT-LEU Version 4 - I Have Pain","C130417","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Physical Well-Being: I have pain.","FACT-LEU Version 4 - I Have Pain | FAC017-I Have Pain | FAC01704",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513871","FACT-LEU Version 4 - Bothered by Treatment Side Effect","C130418","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Physical Well-Being: I am bothered by side effects of treatment.","FACT-LEU Version 4 - Bothered by Treatment Side Effect | FAC017-Bothered by Treatment Side Effect | FAC01705",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513889","FACT-LEU Version 4 - I Feel Ill","C130419","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Physical Well-Being: I feel ill.","FACT-LEU Version 4 - I Feel Ill | FAC017-I Feel Ill | FAC01706",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513881","FACT-LEU Version 4 - I Am Forced to Spend Time in Bed","C130420","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Physical Well-Being: I am forced to spend time in bed.","FACT-LEU Version 4 - I Am Forced to Spend Time in Bed | FAC017-I Am Forced to Spend Time in Bed | FAC01707",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513887","FACT-LEU Version 4 - I Feel Close to My Friends","C130421","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Social/Family Well-Being: I feel close to my friends.","FACT-LEU Version 4 - I Feel Close to My Friends | FAC017-I Feel Close to My Friends | FAC01708",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513876","FACT-LEU Version 4 - Get Emotional Support From Family","C130422","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Social/Family Well-Being: I get emotional support from my family.","FACT-LEU Version 4 - Get Emotional Support From Family | FAC017-Get Emotional Support From Family | FAC01709",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513893","FACT-LEU Version 4 - I Get Support From My Friends","C130423","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Social/Family Well-Being: I get support from my friends.","FACT-LEU Version 4 - I Get Support From My Friends | FAC017-I Get Support From My Friends | FAC01710",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513905","FACT-LEU Version 4 - My Family Has Accepted My Illness","C130424","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Social/Family Well-Being: My family has accepted my illness.","FACT-LEU Version 4 - My Family Has Accepted My Illness | FAC017-My Family Has Accepted My Illness | FAC01711",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513907","FACT-LEU Version 4 - Satisfied Communication Illness","C130425","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Social/Family Well-Being: I am satisfied with family communication about my illness.","FACT-LEU Version 4 - Satisfied Communication Illness | FAC017-Satisfied Communication Illness | FAC01712",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0022651","Renal Calyx","C12927","An intrarenal space located in the renal medulla that serves to collect and transport urine.","Renal Calyx | Renal Calix | Renal Calyces",,,,,,,,,,,,,,,"4052263","Renal calyx",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513244","Q-LES-Q - Interested in Problems of People","C130683","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how often have you: been interested in the problems of other people?","Q-LES-Q - Interested in Problems of People | QLES1-Interested in Problems of People | QLES175",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513219","Q-LES-Q - Felt Affection Toward People","C130684","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how often have you: felt affection toward one or more people?","Q-LES-Q - Felt Affection Toward People | QLES1-Felt Affection Toward People | QLES176",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513241","Q-LES-Q - Gotten Along Well With People","C130685","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how often have you: gotten along well with other people?","Q-LES-Q - Gotten Along Well With People | QLES1-Gotten Along Well With People | QLES177",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513246","Q-LES-Q - Joked or Laughed With Other People","C130686","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how often have you: joked or laughed with other people?","Q-LES-Q - Joked or Laughed With Other People | QLES1-Joked or Laughed With Other People | QLES178",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513270","Q-LES-Q - Relationships Without Problems","C130688","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how often have you: felt your relationships with your friends or relatives were without major problems or conflicts?","Q-LES-Q - Relationships Without Problems | QLES1-Relationships Without Problems | QLES180",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513262","Q-LES-Q - Physical Health","C130689","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Taking everything into consideration, during the past week how satisfied have you been with your: physical health?","Q-LES-Q - Physical Health | QLES1-Physical Health | QLES181",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513258","Q-LES-Q - Mood","C130690","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Taking everything into consideration, during the past week how satisfied have you been with your: mood?","Q-LES-Q - Mood | QLES1-Mood | QLES182",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513290","Q-LES-Q - Work","C130691","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Taking everything into consideration, during the past week how satisfied have you been with your: work?","Q-LES-Q - Work | QLES1-Work | QLES183",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513569","WHODAS 2.0 12+24-item Version Interviewer-administered - Dealing With People You Do Not Know","C130864","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Dealing with people you do not know?","WHODAS 2.0 12+24-item Version Interviewer-administered - Dealing With People You Do Not Know | WD4-Dealing With People You Do Not Know | WD4S10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513591","WHODAS 2.0 12+24-item Version Interviewer-administered - Maintaining a Fiendship","C130865","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Maintaining a friendship?","WHODAS 2.0 12+24-item Version Interviewer-administered - Maintaining a Fiendship | WD4-Maintaining a Fiendship | WD4S11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513613","WHODAS 2.0 12+24-item Version Interviewer-administered - Your Day-to-Day Work","C130866","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Your day-to-day work?","WHODAS 2.0 12+24-item Version Interviewer-administered - Your Day-to-Day Work | WD4-Your Day-to-Day Work | WD4S12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513601","WHODAS 2.0 12+24-item Version Interviewer-administered - Remembering to Do Important Things","C130867","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Remembering to do important things?","WHODAS 2.0 12+24-item Version Interviewer-administered - Remembering to Do Important Things | WD4-Remembering to Do Important Things | WD4D1_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512487","FOSI - Worry My Condition Will Get Worse","C129230","Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) I worry that my condition will get worse.","FOSI - Worry My Condition Will Get Worse | FAC049-Worry My Condition Will Get Worse | FAC04906",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1866636","Charcot-Marie-Tooth Disease Type 4C","C129864","An autosomal recessive form of demyelinating Charcot-Marie-Tooth disease caused by mutations in the SH3TC2 gene, encoding SH3 domain and tetratricopeptide repeat-containing protein 2.","Charcot-Marie-Tooth Disease Type 4C | CMT4C",,,,,,,,,,,,,,,"37396107","Charcot-Marie-Tooth disease type 4C",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0220668","Congenital Contractural Arachnodactyly","C129865","An autosomal dominant connective tissue disorder caused by mutation(s) in the FBN2 gene, encoding fibrillin-2. It is characterized by contractures, arachnodactyly, scoliosis, micrognathia, and crumpled ears.","Congenital Contractural Arachnodactyly | Arthrogryposis, Distal, Type 9 | Beals Syndrome | CCA",,,,,,,,,,,,,,,"4007586","Congenital contractural arachnodactyly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2751067","Dopamine Transporter Deficiency Syndrome","C129866","An autosomal recessive condition caused by mutation(s) in the SLC6A3 gene, encoding sodium-dependent dopamine transporter. It is characterized by Parkinsonian features and has an onset in early infancy.","Dopamine Transporter Deficiency Syndrome | PKDYS | Parkinsonism-Dystonia, Infantile",,,,,,,,,,,,,,,"36716653","Dopamine transporter deficiency syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0271568","Growth Hormone Insensitivity Syndrome","C129867","A group of inherited syndromes in which there is impaired growth hormone signaling, despite normal or increased growth hormone concentrations. The syndromes are characterized by some or all of the following: prenatal and/or postnatal growth failure, immature facial features, microcephaly, neurocognitive deficiencies, sensorineural hearing loss, immune dysregulation, and delayed puberty.","Growth Hormone Insensitivity Syndrome | Growth Hormone Insensitivity Syndromes",,,,,,,,,,,,,,,"4243014","Laron-type isolated somatotropin defect",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512872","Juvenile Absence Epilepsy","C129868","A subtype of idiopathic generalized epilepsy, whose manifestations occur around puberty, associated with mutation(s) in the EFHC1 gene, encoding EF-hand domain-containing protein 1.","Juvenile Absence Epilepsy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512984","Multiple Vascular Disruption Syndrome","C129869","A rare syndrome that refers to a constellation of anomalies resulting from multiple vascular disruption.","Multiple Vascular Disruption Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1834336","Nemaline Myopathy 3","C129870","An inherited myopathy caused by mutations in the ACTA1 gene, encoding actin, alpha skeletal muscle. The phenotype is highly variable, and as such attempts at classification by clinical features is not optimal. Generally, affected individuals have generalized muscle weakness, typically involving proximal muscles, the face, bulbar and respiratory muscles.","Nemaline Myopathy 3 | NEM3",,,,,,,,,,,,,,,"45765416","Actin accumulation myopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3809209","NEMALINE MYOPATHY 8","C129871","An autosomal recessive myopathy caused by mutations in the KLHL40 gene, encoding Kelch-like protein 40. The phenotype is highly variable, and as such attempts at classification by clinical features is not optimal. Generally, affected individuals have generalized muscle weakness, and typically involves proximal muscles, the face, bulbar and respiratory muscles.","Nemaline Myopathy 8 | NEM8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1970431","Pitt-Hopkins Syndrome","C129872","An autosomal dominant condition caused by mutation(s) on the TCF4 gene, encoding transcription factor 4. It is characterized by intellectual disability, developmental delay, breathing problems and seizures.","Pitt-Hopkins Syndrome | PTHS",,,,,,,,,,,,,,,"45765412","Pitt-Hopkins syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513002","Floor of Mouth Basaloid Squamous Cell Carcinoma","C129873","An aggressive variant of squamous cell carcinoma that arises from the floor of the mouth. It is characterized by the presence of small malignant cells with hyperchromatic nuclei and scant amount of cytoplasm forming lobules with peripheral palisading.","Floor of Mouth Basaloid Squamous Cell Carcinoma | Floor of Mouth BSCC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1842342","DEAFNESS, AUTOSOMAL RECESSIVE 39 (disorder)","C129874","An autosomal recessive disorder caused by mutations in the HGF gene, encoding hepatocyte growth factor. It is characterized by profound deafness.","Deafness, Autosomal Recessive 39 | DFNB39",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3149276","Chromosome 16p12.1 Deletion Syndrome","C129875","A condition caused by a 520 kb deletion at 16p12.1. It is characterized by developmental delay, craniofacial dysmorphology and congenital heart defects.","Chromosome 16p12.1 Deletion Syndrome | Chromosome 16p12.1 Deletion Syndrome, 520-KB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513210","Q-LES-Q - Do Volunteer Work","C130633","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Do you do volunteer work?","Q-LES-Q - Do Volunteer Work | QLES1-Do Volunteer Work | QLES128C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513269","Q-LES-Q - Reason for Not Working","C130634","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Reason not having a job, working for yourself, and not doing volunteer work?","Q-LES-Q - Reason for Not Working | QLES1-Reason for Not Working | QLES128D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513216","Q-LES-Q - Enjoyed Your Work","C130635","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: enjoyed your work?","Q-LES-Q - Enjoyed Your Work | QLES1-Enjoyed Your Work | QLES129",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513277","Q-LES-Q - Solved Work Problem Without Stress","C130636","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: solved work problems or dealt with them without undue stress?","Q-LES-Q - Solved Work Problem Without Stress | QLES1-Solved Work Problem Without Stress | QLES130",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513208","Q-LES-Q - Decisive About Work or Made Decisions","C130638","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: been decisive about work, or made decisions when needed?","Q-LES-Q - Decisive About Work or Made Decisions | QLES1-Decisive About Work/Made Decisions | QLES132",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513197","Q-LES-Q - Accomplished What You Wanted to Do","C130639","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: accomplished what you wanted to do?","Q-LES-Q - Accomplished What You Wanted to Do | QLES1-Accomplished What You Wanted to Do | QLES133",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513264","Q-LES-Q - Pleased With Work Accomplishments","C130640","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: been pleased with your work accomplishments?","Q-LES-Q - Pleased With Work Accomplishments | QLES1-Pleased With Work Accomplishments | QLES134",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513200","Q-LES-Q - Been Interested in Your Work","C130642","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: been interested in your work?","Q-LES-Q - Been Interested in Your Work | QLES1-Been Interested in Your Work | QLES136",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513205","Q-LES-Q - Concentrated on Work","C130643","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: concentrated on work?","Q-LES-Q - Concentrated on Work | QLES1-Concentrated on Work | QLES137",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513288","Q-LES-Q - Worked Carefully","C130644","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: worked carefully?","Q-LES-Q - Worked Carefully | QLES1-Worked Carefully | QLES138",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513248","Q-LES-Q - Kept Up With Expected Work","C130645","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: kept up with expected work?","Q-LES-Q - Kept Up With Expected Work | QLES1-Kept Up With Expected Work | QLES139",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513279","Q-LES-Q - Taken Care of Work by Yourself","C130646","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: taken care of work by yourself when it was necessary?","Q-LES-Q - Taken Care of Work by Yourself | QLES1-Taken Care of Work by Yourself | QLES140",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512957","CASP9 Gene Product","C129924","A protein encoded by the CASP9 gene.","CASP9 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512851","Activated Caspase-9","C129925","Activated caspase-9 (~400 aa, ~45 kDa) is encoded by the human CASP9 gene. This protein is involved in the induction of caspase-dependent apoptosis.","Activated Caspase-9 | Activated CASP-9 | Activated CASP9 | Activated Caspase 9 | EC 3.4.22.62",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512990","Sacral Chordoma","C129927","A chordoma that arises from the sacral area.","Sacral Chordoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268233","Galactosialidosis","C129928","An autosomal recessive lysosomal storage disease caused by mutation(s) in the CTSA gene, encoding lysosomal protective protein. It is characterized by a combined deficiency of neuraminidase and beta-galactosidase.","Galactosialidosis | GSL | Goldberg Syndrome | Neuraminidase Deficiency with Beta-Galactosidase Deficiency",,,,,,,,,,,,,,,"4262271","Combined deficiency of sialidase AND beta galactosidase",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512876","Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency","C129929","An inherited condition caused by mutation(s) in the HADHA gene, encoding trifunctional enzyme subunit alpha, mitochondrial. It is characterized by hypoglycemia, hypotonia, neuropathy, cardiomyopathy, pigmentary retinopathy and may be associated with sudden death.","Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency | LCHAD Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229687","Splenic Red Pulp","C12992","Splenic pulp seen grossly as a reddish brown substance, due to its abundance of red blood cells, consisting of splenic sinuses and the tissue intervening between them (splenic cords).","Splenic Red Pulp | Red Pulp",,,,,,,,,,,,,,,"4100329","Splenic red pulp",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0795953","MASA Syndrome","C129930","An X-linked recessive condition caused by mutation(s) in the L1CAM gene, encoding neural cell adhesion molecule L1. It is characterized by mental retardation, aphasia, shuffling gait and adducted thumbs.","MASA Syndrome | CRASH Syndrome | Gareis-Mason Syndrome | Mental retardation, Aphasia, Shuffling Gait, and Adducted Thumbs | SPG1 | Spastic Paraplegia, X-linked",,,,,,,,,,,,,,,"3654718","MASA syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4085582","MENTAL RETARDATION, X-LINKED 102","C129931","An inherited condition caused by mutation(s) in the DDX3X gene, encoding ATP-dependent RNA helicase DDX3X. It is characterized by severe intellectual disability and variable neurologic features.","Mental Retardation, X-linked 102 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2931187","Nephropathic Cystinosis","C129932","An autosomal recessive condition caused by mutation(s) in the CTNS gene, encoding cystinosin. It is a sub-type of cystinosis, in which accumulation of cystine in the kidney results in renal dysfunction.","Nephropathic Cystinosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0154682","Primary Lateral Sclerosis","C129933","A progressive neurodegenerative disorder affecting upper motor neurons, characterized by progressive muscle weakness.","Primary Lateral Sclerosis | Primary lateral sclerosis",,,,,,,,,,,,,,,"381003","Primary lateral sclerosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4228298","Pseudobulbar Palsy","C129934","A condition affecting cranial nerves IX-XII resulting from upper motor neuron damage arising from a variety of causes.","Pseudobulbar Palsy | ",,,,,,,,,,,,,,,"373190","Pseudobulbar palsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512888","Personalized Peptide Cancer Vaccine NEO-PV-01","C129935","A synthetic peptide-based, personalized cancer vaccine consisting of patient-specific mutated peptide epitopes, which are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-based anti-cancer vaccine NEO-PV-01 stimulates the host immune system to mount a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis.","Personalized Peptide Cancer Vaccine NEO-PV-01 | NEO PV 01 | NEO-PV 01 | NEO-PV-01 | Neoantigen-based Anticancer Vaccine NEO-PV-01 | Neoantigen-based Peptide Vaccine NEO-PV-01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513577","WHODAS 2.0 12+24-item Version Interviewer-administered - Finding Solutions to Problems","C130868","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Analysing and finding solutions to problems in day-to-day life?","WHODAS 2.0 12+24-item Version Interviewer-administered - Finding Solutions to Problems | WD4-Finding Solutions to Problems | WD4D1_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513609","WHODAS 2.0 12+24-item Version Interviewer-administered - Understanding What People Say","C130869","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Generally understanding what people say?","WHODAS 2.0 12+24-item Version Interviewer-administered - Understanding What People Say | WD4-Understanding What People Say | WD4D1_5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513606","WHODAS 2.0 12+24-item Version Interviewer-administered - Starting or Maintaining Conversation","C130870","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Starting and maintaining a conversation?","WHODAS 2.0 12+24-item Version Interviewer-administered - Starting or Maintaining Conversation | WD4-Starting/Maintaining Conversation | WD4D1_6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513604","WHODAS 2.0 12+24-item Version Interviewer-administered - Standing Up From Sitting Down","C130871","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Standing up from sitting down?","WHODAS 2.0 12+24-item Version Interviewer-administered - Standing Up From Sitting Down | WD4-Standing Up From Sitting Down | WD4D2_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513575","WHODAS 2.0 12+24-item Version Interviewer-administered - Eating","C130874","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Eating?","WHODAS 2.0 12+24-item Version Interviewer-administered - Eating | WD4-Eating | WD4D3_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513607","WHODAS 2.0 12+24-item Version Interviewer-administered - Staying By Yourself for a Few Days","C130875","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Staying by yourself for a few days?","WHODAS 2.0 12+24-item Version Interviewer-administered - Staying By Yourself for a Few Days | WD4-Staying By Yourself for a Few Days | WD4D3_4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513412","CDISC Clinical Classification KDPI Test Name Terminology","C130250","Test names of clinical classification questions associated with the Kidney Donor Profile Index (KDPI) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification KDPI Test Name Terminology | CC-KDPI TEST | KDPI01TN | Kidney Donor Profile Index Clinical Classification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513411","CDISC Clinical Classification KDPI Test Code Terminology","C130251","Test codes of clinical classification questions associated with the Kidney Donor Profile Index (KDPI) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification KDPI Test Code Terminology | CC-KDPI TESTCD | KDPI01TC | Kidney Donor Profile Index Clinical Classification Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513420","CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology","C130252","Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology | FAC017TN | Functional Assessment of Cancer Therapy-Leukemia Version 4 Questionnaire Test Name | QS-FACT-LEU Version 4 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512902","ICOS Agonist Monoclonal Antibody JTX-2011","C129876","An agonistic humanized monoclonal antibody that recognizes inducible T-cell co-stimulator (ICOS; CD278), with potential antineoplastic activity. Upon administration, anti-ICOS agonist monoclonal antibody JTX-2011 targets and binds to ICOS expressed on certain T-cells. This stimulates ICOS-mediated signaling, induces proliferation of ICOS-positive T-cells, enhances cytotoxic T-lymphocyte (CTL) survival and augments the CTL-mediated immune response against tumor cells. ICOS, a T-cell specific, CD28-superfamily co-stimulatory molecule and immune checkpoint protein, is normally expressed on certain activated T-cells and plays a key role in the proliferation and activation of T-cells.","Vopratelimab | Anti-ICOS Agonist MAb JTX-2011 | Anti-ICOS Agonist Monoclonal Antibody JTX-2011 | ICOS Agonist Monoclonal Antibody JTX-2011 | JTX-2011 | VOPRATELIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512691","Chromosome 17 Abnormality","C129438","An irregularity in the structure of chromosome 17.","Chromosome 17 Abnormality | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512710","medulloblastoma molecular classification","C129439","A term that refers to the classification of medulloblastomas based on their molecular characteristics.","Medulloblastoma Molecular Subtypes | Medulloblastoma, Genetically Defined | Medulloblastoma, Genetically Defined | Medulloblastoma, Molecularly Defined | Medulloblastoma, Molecularly Defined | Molecular Subtypes of Medulloblastoma | medulloblastoma molecular classification | medulloblastoma_molecular_classification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512715","Medulloblastoma, SHH-Activated, TP53-Mutant","C129442","Medulloblastoma associated with activation of the sonic hedgehog (SHH) pathway and the presence of TP53 mutations.","Medulloblastoma, SHH-Activated, TP53-Mutant | Medulloblastoma, SHH-activated and TP53-mutant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512716","Medulloblastoma, SHH-Activated, TP53-Wildtype","C129443","Medulloblastoma associated with activation of the sonic hedgehog (SHH) pathway and the absence of TP53 mutations.","Medulloblastoma, SHH-Activated, TP53-Wildtype | Medulloblastoma, SHH-activated and TP53-wildtype",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513202","Q-LES-Q - Communicated and Interacted With Ease","C130647","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: communicated and interacted with ease with others while working?","Q-LES-Q - Communicated and Interacted With Ease | QLES1-Communicated/Interacted With Ease | QLES141",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513271","Q-LES-Q - Responsible for Household","C130648","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Are you responsible for any household duties/housework/homemaker activities (e.g., cleaning, shopping, doing dishes, food shopping or preparation) for your-self or for other people?","Q-LES-Q - Responsible for Household | QLES1-Responsible for Household | QLES142",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513706","WHODAS 2.0 36-item Version Self-administered - Care of Household Responsibilities","C130830","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Taking care of your household responsibilities?","WHODAS 2.0 36-item Version Self-administered - Care of Household Responsibilities | WD7-Care of Household Responsibilities | WD7D5_1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513719","WHODAS 2.0 36-item Version Self-administered - Getting Household Work Done Needed","C130832","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Getting all the household work done that you needed to do?","WHODAS 2.0 36-item Version Self-administered - Getting Household Work Done Needed | WD7-Getting Household Work Done Needed | WD7D5_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513720","WHODAS 2.0 36-item Version Self-administered - Getting Household Work Done Quickly","C130833","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Getting your household work done as quickly as needed?","WHODAS 2.0 36-item Version Self-administered - Getting Household Work Done Quickly | WD7-Getting Household Work Done Quickly | WD7D5_4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513744","WHODAS 2.0 36-item Version Self-administered - Your Day-to-Day Work or School","C130834","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) Because of your health condition, in the past 30 days, how much difficulty did you have in: Your day-to-day work/school?","WHODAS 2.0 36-item Version Self-administered - Your Day-to-Day Work or School | WD7-Your Day-to-Day Work/School | WD7D5_5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513711","WHODAS 2.0 36-item Version Self-administered - Doing Important Work or School Tasks","C130835","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) Because of your health condition, in the past 30 days, how much difficulty did you have in: Doing your most important work/school tasks well?","WHODAS 2.0 36-item Version Self-administered - Doing Important Work or School Tasks | WD7-Doing Important Work/School Tasks | WD7D5_6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513717","WHODAS 2.0 36-item Version Self-administered - Getting All Work Done You Need","C130836","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) Because of your health condition, in the past 30 days, how much difficulty did you have in: Getting all the work done that you need to do?","WHODAS 2.0 36-item Version Self-administered - Getting All Work Done You Need | WD7-Getting All Work Done You Need | WD7D5_7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513722","WHODAS 2.0 36-item Version Self-administered - Getting Work Done Quickly as Needed","C130837","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) Because of your health condition, in the past 30 days, how much difficulty did you have in: Getting your work done as quickly as needed?","WHODAS 2.0 36-item Version Self-administered - Getting Work Done Quickly as Needed | WD7-Getting Work Done Quickly as Needed | WD7D5_8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513732","WHODAS 2.0 36-item Version Self-administered - Problem Joining Community Activities","C130838","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days: How much of a problem did you have in joining in community activities (for example, festivities, religious or other activities) in the same way as anyone else can?","WHODAS 2.0 36-item Version Self-administered - Problem Joining Community Activities | WD7-Problem Joining Community Activities | WD7D6_1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512901","Anti-Glypican 3/CD3 Bispecific Antibody ERY974","C129936","An anti-glypican 3 (GPC3; GPC-3)/anti-CD3 bispecific monoclonal antibody, with potential immunostimulating and antineoplastic activities. Anti-GPC3/CD3 bispecific antibody ERY974 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for GPC3, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of ERY974, this bispecific antibody simultaneously binds to both CD3-expressing and GPC3-expressing cells, thereby crosslinking GPC3-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated lysis of GPC3-expressing tumor cells. GPC3, a heparan sulfate proteoglycan and an oncofetal antigen protein, is overexpressed in a variety of cancers; it plays a role in cell division and growth regulation.","Anti-Glypican 3/CD3 Bispecific Antibody ERY974 | Anti-GPC3/CD3 BiAb ERY974 | Anti-GPC3/CD3 Bispecific Antibody ERY974 | ERY-974 | ERY974",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512681","Central Nervous System Embryonal Tumor with Rhabdoid Features","C129501","A central nervous system embryonal neoplasm characterized by the presence of histological features consistent with atypical teratoid/rhabdoid tumor and absence of mutations of the INI1 gene or SMARCA4 (BRG1) gene.","Central Nervous System Embryonal Tumor with Rhabdoid Features | CNS Embryonal Tumor with Rhabdoid Features | CNS Embryonal tumor with rhabdoid features",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512784","PRKAR1A Gene Mutation","C129503","A change in the nucleotide sequence of the PRKAR1A gene.","PRKAR1A Gene Mutation | PKR1 Gene Mutation | PRKAR1 Gene Mutation | Protein Kinase cAMP-Dependent Type I Regulatory Subunit Alpha Gene Mutation | TSE1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225331","Fibrous Tissue","C129504","A tissue composed of bundles of collagenous white fibers between which are rows of connective tissue cells.","Fibrous Tissue | ",,,,,,,,,,,,,,,"4144549","Fibrous tissue",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512720","Placement of Surgical Mesh","C129506","A surgical procedure in which a surgical mesh is implanted, usually for repair of abdominal wall hernias or pelvic organ prolapse.","Placement of Surgical Mesh | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038930","Surgical Mesh Implant","C129507","A surgically implanted medical device composed of woven material, often used for support of weakened or damaged organs or tissues. A surgical mesh can be used for either permanent or temporary support.","Surgical Mesh Implant | Surgical Mesh",,,,,,,,,,,,,,,"45768044","Surgical mesh",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513419","CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology","C130253","Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology | FAC017TC | Functional Assessment of Cancer Therapy-Leukemia Version 4 Questionnaire Test Code | QS-FACT-LEU Version 4 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513418","CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology","C130254","Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology | FAC015TN | Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 Questionnaire Test Name | QS-FACT-HEP Version 4 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513417","CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology","C130255","Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology | FAC015TC | Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 Questionnaire Test Code | QS-FACT-HEP Version 4 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513422","CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology","C130256","Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology | FAC018TN | Functional Assessment of Cancer Therapy-Lymphoma Version 4 Questionnaire Test Name | QS-FACT-LYM Version 4 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513421","CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology","C130257","Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology | FAC018TC | Functional Assessment of Cancer Therapy-Lymphoma Version 4 Questionnaire Test Code | QS-FACT-LYM Version 4 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513424","CDISC Questionnaire HAM-D6 Self-Report Version Test Name Terminology","C130258","Test names of questionnaire questions associated with the Hamilton Depression Rating Scale 6 Self-Report Version (HAM-D6 Self-Report Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire HAM-D6 Self-Report Version Test Name Terminology | HAMDS1TN | Hamilton Depression Rating Scale - 6 Self-Report Questionnaire Test Name | QS-HAM-D6 Self-Report Version TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513423","CDISC Questionnaire HAM-D6 Self-Report Version Test Code Terminology","C130259","Test codes of questionnaire questions associated with the Hamilton Depression Rating Scale 6 Self-Report Version (HAM-D6 Self-Report Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire HAM-D6 Self-Report Version Test Code Terminology | HAMDS1TC | Hamilton Depression Rating Scale - 6 Self-Report Questionnaire Test Code | QS-HAM-D6 Self-Report Version TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513426","CDISC Questionnaire IDS-SR Test Name Terminology","C130260","Test names of questionnaire questions associated with the Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire IDS-SR Test Name Terminology | IDSR1TN | Inventory of Depressive Symptomatology Self-Report Version Questionnaire Test Name | QS-IDS-SR TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513864","FACT-HEP Version 4 - Satisfied With How I Am Coping","C130473","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Emotional Well-Being: I am satisfied with how I am coping with my illness.","FACT-HEP Version 4 - Satisfied With How I Am Coping | FAC015-Satisfied With How I Am Coping | FAC01516",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513859","FACT-HEP Version 4 - Losing Hope Against Illness","C130474","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Emotional Well-Being: I am losing hope in the fight against my illness.","FACT-HEP Version 4 - Losing Hope Against Illness | FAC015-Losing Hope Against Illness | FAC01517",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513844","FACT-HEP Version 4 - I Feel Nervous","C130475","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Emotional Well-Being: I feel nervous.","FACT-HEP Version 4 - I Feel Nervous | FAC015-I Feel Nervous | FAC01518",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512713","Medulloblastoma, Non-WNT/Non-SHH","C129444","Medulloblastoma not associated with activation of the WNT pathway or sonic hedgehog (SHH) pathway. TP53 mutations are absent. This molecular subtype includes medulloblastomas numerically designated as 'group 3' and 'group 4'.","Medulloblastoma, Non-WNT/Non-SHH | Medulloblastoma, non-WNT/non-SHH | Non-WNT/Non-SHH Medulloblastoma | Non-WNT/non-SHH Activated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512714","Medulloblastoma, Not Otherwise Specified","C129447","A medulloblastoma which has not been further characterized.","Medulloblastoma, Not Otherwise Specified | Medulloblastoma, NOS | Not Determined","9470/3","Medulloblastoma, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"CL512627","Synthetic Long E6 Peptide-Toll-like Receptor Ligand Conjugate Vaccine ISA201","C129652","A therapeutic peptide vaccine consisting of two highly immunogenic synthetic long peptides (SLPs), which are 25-35 amino acids in size, derived from the human papillomavirus (HPV) type 16 oncoprotein E6, and conjugated to a proprietary toll-like receptor 2 (TLR2) ligand (TLR2-L) immunoadjuvant, with potential immunostimulating and antitumor activities. Upon administration, the TLR2-L moiety of the synthetic long E6 peptides TLR ligand conjugate vaccine targets and binds to TLRs expressed on antigen-presenting cells (APCs), particularly dendritic cells (DCs). This increases the direct targeting of, binding to, uptake by, and processing of the SLPs into small pieces by the DCs. The processed viral epitopes are presented by DCs, which activate and stimulate the host immune system to mount specific cytotoxic T-lymphocyte (CTL) and helper T (Th) cell responses against HPV E6-expressing tumor cells. This results in the destruction of tumor cells and leads to decreased growth of HPV E6-expressing tumor cells. The E6 oncoprotein is implicated in tumorigenesis in a variety of cancers. The TLR2-L improves antigen processing and presentation by, and activation of APCs, thereby improving the immunostimulatory effect of the vaccine. The two peptides cover the most immunodominant regions of the HPV16 E6 oncogenic protein and contain both Th and CTL epitopes.","Synthetic Long E6 Peptide-Toll-like Receptor Ligand Conjugate Vaccine ISA201 | HPV E Six Peptide Conjugated to Amplivant | HPV16 peptides AMPLIVANT Vaccine | Hespecta | ISA201 | PV E6 Peptides-Amplivant | PV16 E6 Peptide Conjugated to Amplivant | SLP HPV16 E6/Amplivant Vaccine ISA201 | SLP-Amplivant ISA201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3252423","BLZ 945","C129653","An orally bioavailable inhibitor of colony stimulating factor 1 receptor (CSF-1R; CSF1R), with potential antineoplastic activity. CSF1R inhibitor BLZ945 selectively binds to CSF1R expressed on tumor-associated macrophages (TAMs), blocks the activity of CSF1R, and inhibits CSF1R-mediated signal transduction pathways. This inhibits the activity and proliferation of TAMs, and reprograms the immunosuppressive nature of existing TAMs. Altogether, this reduces TAM-mediated immune suppression in the tumor microenvironment, re-activates the immune system, and improves anti-tumor cell responses mediated by T-cells.  CSF1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), is a cell-surface receptor for its ligand, colony stimulating factor 1 (CSF1); this receptor is overexpressed by TAMs in the tumor microenvironment, and plays a major role in both immune suppression and the induction of tumor cell proliferation.","Sotuletinib | 4-((2-(((1R,2R)-2-hydroxycyclohexyl)amino)benzo[d]thiazol-6-yl)oxy)-N-methylpicolinamide | 4-[2((1R,2R)-2-Hydroxycyclohexylamino)-benzothiazol-6-yloxyl]-pyridine- 2-carboxylic Acid Methylamide | BLZ 945 | BLZ-945 | BLZ945 | CSF-1R Inhibitor BLZ945 | SOTULETINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512661","Unresectable Digestive System Adenocarcinoma","C129654","An adenocarcinoma that arises from the gastrointestinal system and is not amenable to surgical resection.","Unresectable Digestive System Adenocarcinoma | Unresectable Gastrointestinal System Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513729","WHODAS 2.0 36-item Version Self-administered - Problem Because of Barriers in World","C130839","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days: How much of a problem did you have because of barriers or hindrances in the world around you?","WHODAS 2.0 36-item Version Self-administered - Problem Because of Barriers in World | WD7-Problem Because of Barriers in World | WD7D6_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025055","Medial Forebrain Bundle","C13083","A complex tract of nerve fibers that connects the basal telencephalon, the hypothalamus, and the midbrain reticular formation. The medial forebrain bundle contains fibers involved in the reward pathway of the brain.","Medial Forebrain Bundle | ",,,,,,,,,,,,,,,"4242855","Structure of median forebrain bundle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513733","WHODAS 2.0 36-item Version Self-administered - Problem Living with Dignity","C130840","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days: How much of a problem did you have living with dignity because of the attitudes and actions of others?","WHODAS 2.0 36-item Version Self-administered - Problem Living with Dignity | WD7-Problem Living with Dignity | WD7D6_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513793","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.1052T>C Mutation","C130220","A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where thymine has been substituted with cytosine at nucleotide position 1052 of the ABL1 gene.","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.1052T>C Mutation | BCR/ABL Fusion Gene with NM_005157.4:c.1052T>C | BCR/ABL Fusion Gene with NM_005157.5:c.1052T>C | BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.1052T>C | BCR/ABL1 Fusion Gene with NM_005157.4:c.1052T>C | BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.1052T>C Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513794","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.1075T>G Mutation","C130222","A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where thymine has been substituted with guanine at nucleotide position 1075 of the ABL1 gene. This mutation is associated with imatinib- and nilotinib-resistant leukemias.","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.1075T>G Mutation | BCR/ABL Fusion Gene with NM_005157.4:c.1075T>G | BCR/ABL Fusion Gene with NM_005157.5:c.1075T>G | BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.1075T>G | BCR/ABL1 Fusion Gene with NM_005157.4:c.1075T>G | BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.1075T>G Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513795","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.1150C>A Mutation","C130224","A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where cytosine has been substituted with adenine at nucleotide position 1150 of the ABL1 gene.","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.1150C>A Mutation | BCR/ABL Fusion Gene with NM_005157.4:c.1150C>A | BCR/ABL Fusion Gene with NM_005157.5:c.1150C>A | BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.1150C>A | BCR/ABL1 Fusion Gene with NM_005157.4:c.1150C>A | BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.1150C>A Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512875","Liquid Component Present","C129709","A finding indicating the formation of liquid areas in a tissue sample.","Liquid Component Present | Liquid Change",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513858","FACT-HEP Version 4 - I Worry About Dying","C130476","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Emotional Well-Being: I worry about dying.","FACT-HEP Version 4 - I Worry About Dying | FAC015-I Worry About Dying | FAC01519",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513868","FACT-HEP Version 4 - Worry My Condition Will Get Worse","C130477","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Emotional Well-Being: I worry that my condition will get worse.","FACT-HEP Version 4 - Worry My Condition Will Get Worse | FAC015-Worry My Condition Will Get Worse | FAC01520",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513833","FACT-HEP Version 4 - I Am Able to Work","C130478","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Functional Well-Being: I am able to work (include work at home).","FACT-HEP Version 4 - I Am Able to Work | FAC015-I Am Able to Work | FAC01521",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513862","FACT-HEP Version 4 - My Work Is Fulfilling","C130479","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Functional Well-Being: My work (include work at home) is fulfilling.","FACT-HEP Version 4 - My Work Is Fulfilling | FAC015-My Work Is Fulfilling | FAC01522",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0036630","Seminiferous Tubule","C13047","A hollow tube located in the testes, which is the site of germination, maturation, and transportation of the sperm cells in a sexually mature male.","Seminiferous Tubule | Seminiferous Tubules",,,,,,,,,,,,,,,"4198988","Seminiferous tubule structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513832","FACT-HEP Version 4 - I Am Able to Enjoy Life","C130480","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Functional Well-Being: I am able to enjoy life.","FACT-HEP Version 4 - I Am Able to Enjoy Life | FAC015-I Am Able to Enjoy Life | FAC01523",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513847","FACT-HEP Version 4 - I Have Accepted My Illness","C130481","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Functional Well-Being: I have accepted my illness.","FACT-HEP Version 4 - I Have Accepted My Illness | FAC015-I Have Accepted My Illness | FAC01524",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513838","FACT-HEP Version 4 - I Am Sleeping Well","C130482","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Functional Well-Being: I am sleeping well.","FACT-HEP Version 4 - I Am Sleeping Well | FAC015-I Am Sleeping Well | FAC01525",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513827","FACT-HEP Version 4 - Content With Quality of My Life","C130484","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Functional Well-Being: I am content with the quality of my life right now.","FACT-HEP Version 4 - Content With Quality of My Life | FAC015-Content With Quality of My Life | FAC01527",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513865","FACT-HEP Version 4 - Swelling or Cramps in Stomach Area","C130485","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I have swelling or cramps in my stomach area.","FACT-HEP Version 4 - Swelling or Cramps in Stomach Area | FAC015-Swelling/Cramps in Stomach Area | FAC01528",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513836","FACT-HEP Version 4 - I Am Losing Weight","C130486","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I am losing weight.","FACT-HEP Version 4 - I Am Losing Weight | FAC015-I Am Losing Weight | FAC01529",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513848","FACT-HEP Version 4 - I Have Control of My Bowels","C130487","Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I have control of my bowels.","FACT-HEP Version 4 - I Have Control of My Bowels | FAC015-I Have Control of My Bowels | FAC01530",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513243","Q-LES-Q - Household Activities","C130692","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Taking everything into consideration, during the past week how satisfied have you been with your: household activities?","Q-LES-Q - Household Activities | QLES1-Household Activities | QLES184",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513274","Q-LES-Q - Social Relationships","C130693","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Taking everything into consideration, during the past week how satisfied have you been with your: social relationships?","Q-LES-Q - Social Relationships | QLES1-Social Relationships | QLES185",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512480","FOSI - Content With Quality of My Life","C129231","Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) I am content with the quality of my life right now.","FOSI - Content With Quality of My Life | FAC049-Content With Quality of My Life | FAC04907",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512482","FOSI - I Have Cramps in My Stomach Area","C129232","Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) I have cramps in my stomach area.","FOSI - I Have Cramps in My Stomach Area | FAC049-I Have Cramps in My Stomach Area | FAC04908",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512221","NCCN-FACT FOSI-18 Version 2 - I Have a Lack of Energy","C129233","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I have a lack of energy.","NCCN-FACT FOSI-18 Version 2 - I Have a Lack of Energy | FAC050-I Have a Lack of Energy | FAC05001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512219","NCCN-FACT FOSI-18 Version 2 - I Have Pain","C129234","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I have pain.","NCCN-FACT FOSI-18 Version 2 - I Have Pain | FAC050-I Have Pain | FAC05002",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512214","NCCN-FACT FOSI-18 Version 2 - I Feel Ill","C129235","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I feel ill.","NCCN-FACT FOSI-18 Version 2 - I Feel Ill | FAC050-I Feel Ill | FAC05003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512217","NCCN-FACT FOSI-18 Version 2 - I Have Cramps in My Stomach Area","C129236","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I have cramps in my stomach area.","NCCN-FACT FOSI-18 Version 2 - I Have Cramps in My Stomach Area | FAC050-I Have Cramps in My Stomach Area | FAC05004",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512209","NCCN-FACT FOSI-18 Version 2 - I Am Bothered by Constipation","C129238","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I am bothered by constipation.","NCCN-FACT FOSI-18 Version 2 - I Am Bothered by Constipation | FAC050-I Am Bothered by Constipation | FAC05006",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512220","NCCN-FACT FOSI-18 Version 2 - I Have Swelling in Stomach Area","C129239","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I have swelling in my stomach area.","NCCN-FACT FOSI-18 Version 2 - I Have Swelling in Stomach Area | FAC050-I Have Swelling in Stomach Area | FAC05007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513796","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.1187A>C Mutation","C130226","A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where adenine has been substituted with cytosine at nucleotide position 1187 of the ABL1 gene.","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.1187A>C Mutation | BCR/ABL Fusion Gene with NM_005157.4:c.1187A>C | BCR/ABL Fusion Gene with NM_005157.5:c.1187A>C | BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.1187A>C | BCR/ABL1 Fusion Gene with NM_005157.4:c.1187A>C | BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.1187A>C Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513888","FACT-LEU Version 4 - I Feel Close to My Partner","C130426","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Social/Family Well-Being: I feel close to my partner (or the person who is my main support).","FACT-LEU Version 4 - I Feel Close to My Partner | FAC017-I Feel Close to My Partner | FAC01713",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513883","FACT-LEU Version 4 - I Am Satisfied With My Sex Life","C130427","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Social/Family Well-Being: I am satisfied with my sex life.","FACT-LEU Version 4 - I Am Satisfied With My Sex Life | FAC017-I Am Satisfied With My Sex Life | FAC01714",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513891","FACT-LEU Version 4 - I Feel Sad","C130428","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Emotional Well-Being: I feel sad.","FACT-LEU Version 4 - I Feel Sad | FAC017-I Feel Sad | FAC01715",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513890","FACT-LEU Version 4 - I Feel Nervous","C130431","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Emotional Well-Being: I feel nervous.","FACT-LEU Version 4 - I Feel Nervous | FAC017-I Feel Nervous | FAC01718",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513902","FACT-LEU Version 4 - I Worry About Dying","C130432","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Emotional Well-Being: I worry about dying.","FACT-LEU Version 4 - I Worry About Dying | FAC017-I Worry About Dying | FAC01719",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513912","FACT-LEU Version 4 - Worry My Condition Will Get Worse","C130433","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Emotional Well-Being: I worry that my condition will get worse.","FACT-LEU Version 4 - Worry My Condition Will Get Worse | FAC017-Worry My Condition Will Get Worse | FAC01720",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513878","FACT-LEU Version 4 - I Am Able to Work","C130434","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Functional Well-Being: I am able to work (include work at home).","FACT-LEU Version 4 - I Am Able to Work | FAC017-I Am Able to Work | FAC01721",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0228427","Pontine Base","C12970","The portion of the pons, located ventral to the medial lemnisci, that contains the pontine nuclei and the cortocobulbar, corticospinal, corticopontine, and transverse pontocerebellar fibers.","Pontine Base | Base of Pons | Basis Pontis",,,,,,,,,,,,,,,"4245263","Structure of pars basalis of pons",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512935","BTK Inhibitor M7583","C129710","An orally bioavailable, selective inhibitor of Bruton's tyrosine kinase (BTK), with potential antineoplastic activity. Upon oral administration, BTK inhibitor TL-895 targets and covalently binds to BTK, thereby preventing its activity. This leads to an inhibition of B cell receptor (BCR) signaling and inhibits cell proliferation of B-cell malignancies. BTK, a cytoplasmic tyrosine kinase and member of the Tec family of kinases, plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.","BTK Inhibitor TL-895 | BTK Inhibitor M7583 | Bruton's Tyrosine Kinase Inhibitor M7583 | M 7583 | M-7583 | M7583 | TL 895 | TL-895 | TL895",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512955","Botanical Agent LEAC-102","C129711","A botanical-based formulation derived from the Taiwanese mushroom Antrodia cinnamomea, with potential antineoplastic activity, Upon administration, the components in LEAC-102 may exert cytotoxic effects against cancer cells.","Botanical Agent LEAC-102 | LEAC 102 | LEAC-102 | TAIWANOFUNGUS CAMPHORATUS FRUITING BODY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3712398","Etelcalcetide","C129712","A calcimimetic and calcium-sensing receptor (CaSR) agonist composed of a synthetic peptide comprised of seven D-amino acids that can be used to treat secondary hyperparathyroidism (sHPT) in hemodialysis patients with chronic kidney disease (CKD). Upon intravenous administration, etelcalcetide mimics calcium and allosterically binds to and activates the CaSR expressed by the parathyroid gland. This suppresses the synthesis and secretion of parathyroid hormone (PTH), thereby reducing PTH levels and lowering serum calcium and phosphorus levels. Elevated PTH is often observed in patients with CKD and is associated with dysregulated calcium-phosphate homeostasis.","Etelcalcetide | AMG 416 | AMG416 | ETELCALCETIDE | KAI 4169 | KAI-4169 | KAI4169 | N-acetyl-D-cysteinyl-S-(L-cysteine disulfide)-D-alanyl-D-arginyl-D-arginyl-D-arginyl-D-alanyl-D-argininamide | Parsabiv | Velcalcetide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512149","IDH Gene Family Mutation Status Unknown","C129288","A finding indicating that there is no information regarding the presence or absence of IDH1 or IDH2 gene mutations in a tumor sample.","IDH Gene Family Mutation Status Unknown | Cannot be determined | Unknown: Could not be determined or unsure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512355","Gingival Spindle Cell Carcinoma","C129289","A poorly differentiated squamous cell carcinoma that arises from the gingiva. It is characterized by the presence of malignant pleomorphic spindle cells.","Gingival Spindle Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512241","Semmes Weinstein Monofilament Examination","C129294","A noninvasive screening tool for peripheral neuropathy. A monofilament strand is pressed on a test site perpendicularly until it bends. If a patient fails to sense the monofilament after it bends, the test site is considered to be insensate.","Semmes Weinstein Monofilament Examination | SWME",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512282","Glioblastoma with Primitive Neuronal Component","C129296","A glioblastoma characterized by the presence of well-demarcated nodules which contain primitive cells exhibiting neuronal differentiation.","Glioblastoma with Primitive Neuronal Component | Glioblastoma with PNET-Like Component",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513217","Q-LES-Q - Family Relationships","C130694","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Taking everything into consideration, during the past week how satisfied have you been with your: family relationships?","Q-LES-Q - Family Relationships | QLES1-Family Relationships | QLES186",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513250","Q-LES-Q - Leisure Time Activities","C130695","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Taking everything into consideration, during the past week how satisfied have you been with your: leisure time activities?","Q-LES-Q - Leisure Time Activities | QLES1-Leisure Time Activities | QLES187",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513190","Q-LES-Q - Ability to Function in Daily Life","C130696","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Taking everything into consideration, during the past week how satisfied have you been with your: ability to function in daily life?","Q-LES-Q - Ability to Function in Daily Life | QLES1-Ability to Function in Daily Life | QLES188",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513272","Q-LES-Q - Sex Drive, Interest, Performance","C130697","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Taking everything into consideration, during the past week how satisfied have you been with your: sexual drive, interest and/or performance?","Q-LES-Q - Sex Drive, Interest, Performance | QLES1-Sex Drive, Interest, Performance | QLES189",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513211","Q-LES-Q - Economic Status","C130698","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Taking everything into consideration, during the past week how satisfied have you been with your: economic status?","Q-LES-Q - Economic Status | QLES1-Economic Status | QLES190",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513251","Q-LES-Q - Living or Housing Situation","C130699","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Taking everything into consideration, during the past week how satisfied have you been with your: living/housing situation?","Q-LES-Q - Living or Housing Situation | QLES1-Living/Housing Situation | QLES191",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038369","Stomatognathic System","C13069","The mouth, jaws, and other related structures that are involved in speech, mastication, and deglutition.","Stomatognathic System | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513191","Q-LES-Q - Ability to Get Around Physically","C130700","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Taking everything into consideration, during the past week how satisfied have you been with your: ability to get around physically without feeling dizzy or unsteady or falling?","Q-LES-Q - Ability to Get Around Physically | QLES1-Ability to Get Around Physically | QLES192",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513286","Q-LES-Q - Vision Ability to Do Work or Hobbies","C130701","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Taking everything into consideration, during the past week how satisfied have you been with your: your vision in terms of ability to do work or hobbies?","Q-LES-Q - Vision Ability to Do Work or Hobbies | QLES1-Vision Ability to Do Work/Hobbies | QLES193",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513259","Q-LES-Q - Overall Sense of Well Being","C130702","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Taking everything into consideration, during the past week how satisfied have you been with your: overall sense of well being?","Q-LES-Q - Overall Sense of Well Being | QLES1-Overall Sense of Well Being | QLES194",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513256","Q-LES-Q - Medication","C130703","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Taking everything into consideration, during the past week how satisfied have you been with your: medication?","Q-LES-Q - Medication | QLES1-Medication | QLES195",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513266","Q-LES-Q - Rate Overall Life Satisfaction","C130704","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) How would you rate your overall life satisfaction and contentment during the past week?","Q-LES-Q - Rate Overall Life Satisfaction | QLES1-Rate Overall Life Satisfaction | QLES196",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513578","WHODAS 2.0 12+24-item Version Interviewer-administered - Get Along with People Close to You","C130876","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Getting along with people who are close to you?","WHODAS 2.0 12+24-item Version Interviewer-administered - Get Along with People Close to You | WD4-Get Along with People Close to You | WD4D4_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512216","NCCN-FACT FOSI-18 Version 2 - I Have Control of My Bowels","C129240","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I have control of my bowels.","NCCN-FACT FOSI-18 Version 2 - I Have Control of My Bowels | FAC050-I Have Control of My Bowels | FAC05008",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512212","NCCN-FACT FOSI-18 Version 2 - I Am Sleeping Well","C129241","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I am sleeping well.","NCCN-FACT FOSI-18 Version 2 - I Am Sleeping Well | FAC050-I Am Sleeping Well | FAC05009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512222","NCCN-FACT FOSI-18 Version 2 - Worry My Condition Will Get Worse","C129242","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I worry that my condition will get worse.","NCCN-FACT FOSI-18 Version 2 - Worry My Condition Will Get Worse | FAC050-Worry My Condition Will Get Worse | FAC05010",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512218","NCCN-FACT FOSI-18 Version 2 - I Have Nausea","C129243","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I have nausea.","NCCN-FACT FOSI-18 Version 2 - I Have Nausea | FAC050-I Have Nausea | FAC05011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512210","NCCN-FACT FOSI-18 Version 2 - I Am Bothered by Hair Loss","C129244","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I am bothered by hair loss.","NCCN-FACT FOSI-18 Version 2 - I Am Bothered by Hair Loss | FAC050-I Am Bothered by Hair Loss | FAC05012",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512205","NCCN-FACT FOSI-18 Version 2 - Bothered by Treatment Side Effect","C129245","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I am bothered by side effects of treatment.","NCCN-FACT FOSI-18 Version 2 - Bothered by Treatment Side Effect | FAC050-Bothered by Treatment Side Effect | FAC05013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513018","Autologous Monocytes","C129877","A preparation of autologous monocytes, with potential immunomodulating activity. Following isolation and administration, the autologous monocytes may differentiate into classic M1 macrophages, which are able to directly attack and kill tumor cells. The stimulated monocytes also promote natural killer (NK) cell differentiation, which further enhances tumor cell killing through NK-mediated cytotoxicity.","Autologous Monocytes | Therapeutic Autologous Monocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513906","FACT-LEU Version 4 - My Work Is Fulfilling","C130435","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Functional Well-Being: My work (include work at home) is fulfilling.","FACT-LEU Version 4 - My Work Is Fulfilling | FAC017-My Work Is Fulfilling | FAC01722",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513877","FACT-LEU Version 4 - I Am Able to Enjoy Life","C130436","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Functional Well-Being: I am able to enjoy life.","FACT-LEU Version 4 - I Am Able to Enjoy Life | FAC017-I Am Able to Enjoy Life | FAC01723",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513895","FACT-LEU Version 4 - I Have Accepted My Illness","C130437","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Functional Well-Being: I have accepted my illness.","FACT-LEU Version 4 - I Have Accepted My Illness | FAC017-I Have Accepted My Illness | FAC01724",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513884","FACT-LEU Version 4 - I Am Sleeping Well","C130438","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Functional Well-Being: I am sleeping well.","FACT-LEU Version 4 - I Am Sleeping Well | FAC017-I Am Sleeping Well | FAC01725",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513874","FACT-LEU Version 4 - Enjoy Things I Usually Do for Fun","C130439","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Functional Well-Being: I am enjoying the things I usually do for fun.","FACT-LEU Version 4 - Enjoy Things I Usually Do for Fun | FAC017-Enjoy Things I Usually Do for Fun | FAC01726",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1268160","Ear Part","C13043","Any component pertaining to the organ for hearing including the external, middle, and inner ear.","Ear Part | ",,,,,,,,,,,,,,,"4002725","Ear part",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513873","FACT-LEU Version 4 - Content With Quality of My Life","C130440","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Functional Well-Being: I am content with the quality of my life right now.","FACT-LEU Version 4 - Content With Quality of My Life | FAC017-Content With Quality of My Life | FAC01727",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513268","Q-LES-Q - Reason for No Household Activities","C130649","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Reason for no household duties/housework/homemaker activities (e.g., cleaning, shopping doing dishes, food shopping or preparation) for your-self or for other people?","Q-LES-Q - Reason for No Household Activities | QLES1-Reason for No Household Activities | QLES142A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513247","Q-LES-Q - Kept Room Clean to Satisfaction","C130650","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: kept your room/apartment/house cleaned to your satisfaction?","Q-LES-Q - Kept Room Clean to Satisfaction | QLES1-Kept Room Clean to Satisfaction | QLES143",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513260","Q-LES-Q - Paid Bills, Done Banking","C130651","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: paid the bills, done the banking to your satisfaction?","Q-LES-Q - Paid Bills, Done Banking | QLES1-Paid Bills, Done Banking | QLES144",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513273","Q-LES-Q - Shopped for Food or Household Items","C130652","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: shopped for food or other household items to your satisfaction?","Q-LES-Q - Shopped for Food or Household Items | QLES1-Shopped for Food/Household Items | QLES145",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513265","Q-LES-Q - Prepared Food or Obtained Food","C130653","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: prepared food or obtained food to your satisfaction?","Q-LES-Q - Prepared Food or Obtained Food | QLES1-Prepared Food or Obtained Food | QLES146",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513278","Q-LES-Q - Taken Care of Laundry or Cleaning","C130654","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: taken care of the laundry/cleaning to your satisfaction?","Q-LES-Q - Taken Care of Laundry or Cleaning | QLES1-Taken Care of Laundry/Cleaning | QLES147",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512393","Canine Glioma","C129297","A brain or spinal cord tumor arising from glial cells that occurs in dogs.","Canine Glioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512394","Canine Hepatocellular Carcinoma","C129298","A malignant tumor arising from hepatocytes that occurs in dogs.","Canine Hepatocellular Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512395","Canine Lung Adenocarcinoma","C129299","A carcinoma that arises from the lung in dogs and is characterized by the presence of malignant glandular epithelial cells.","Canine Lung Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0501403","Nerve Plexus","C12929","A network of intersecting nerve fibers that link peripheral nerves with specific areas of the body.","Nerve Plexus | Nerve Plexi",,,,,,,,,,,,,,,"4046729","Structure of nerve plexus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0080125","Catalytic RNA","C1292","RNA that contains an intron sequence which has an enzyme-like catalytic activity. This intron sequence has been shown to fold up to form a complex surface that can function like an enzyme in reactions with other RNA molecules and thus synthesize new molecules even in the absence of protein. Synthetic ribozymes can be engineered to specifically cleave a target RNA sequence causing expression down regulation.","Ribozyme | Catalytic RNA | RIBOZYME | RNA, Catalytic | Ribonucleic Enzyme",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512397","Canine Rhabdomyosarcoma","C129300","A malignant mesenchymal neoplasm arising from skeletal muscle that occurs in dogs.","Canine Rhabdomyosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342471","Adrenal Gland Hyperplasia II","C129301","Decreased activity of the enzyme 3-beta-hydroxysteroid dehydrogenase, associated with mutation(s) in the HSD3B2 gene. The lack of activity of this enzyme produces a type of congenital adrenal hyperplasia.","Adrenal Gland Hyperplasia II | 3-Beta-Hydroxysteroid Dehydrogenase Deficiency | Adrenal Gland Hyperplasia, Congenital, due to 3-Beta-Hydroxysteroid Dehydrogenase 2 Deficiency | HSDB",,,,,,,,,,,,,,,"4182535","3 beta-Hydroxysteroid dehydrogenase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2936858","Congenital adrenal hyperplasia due to 21 hydroxylase deficiency","C129302","Decreased activity of the enzyme 21-hydroxylase, associated with mutation(s) in the CYP21A2 gene. The lack of activity of this enzyme produces a type of congenital adrenal hyperplasia (CAH) and is the cause of approximately 95% of CAH.","Adrenal Gland Hyperplasia III | 21-Hydroxylase Deficieny | Adrenal Gland Hyperplasia, Congenital, due to 21-Hydroxylase Deficiency | CAH1 | CYP21 Deficiency | Congenital Adrenal Hyperplasia 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513016","Anti-FLT3 Antibody-drug Conjugate AGS62P1","C129937","An antibody-drug conjugate (ADC) composed of a human monoclonal antibody directed against the extracellular domain of receptor-type tyrosine-protein kinase FLT3 (FLT-3; FMS-like tyrosine kinase 3; CD135; fetal-liver kinase 2; FLK2) and conjugated, via an oxime linker and the site-directed non-natural amino acid linker para-acetyl-phenylalanine (pAcF), to a microtubule-disrupting cytotoxic agent, with potential antineoplastic activity. Upon administration of ADC AGS62P1, the antibody moiety targets and binds to FLT3. Upon antibody/antigen binding and internalization, the microtubule-targeting agent binds to and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. The site-specific conjugation of the cytotoxic agent to the antibody, through pAcF, improves the biophysical properties of AGS62P1, increases payload distribution and stability, and optimizes its efficacy. FLT3, a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage, acute lymphoblastic leukemias and acute myeloid leukemias.","Anti-FLT3 Antibody-drug Conjugate AGS62P1 | ADC AGS62P1 | AGS62P1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513048","CDISC SDTM Device-In-Use Response Terminology","C129938","Terminology associated with the device-in-use response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Device-In-Use Response Terminology | DURS | Device-In-Use Response | SDTM-DURS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512946","CDISC SDTM Diabetic Kidney Findings About Test Name Terminology","C129939","Terminology associated with the diabetic kidney disease findings about test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Diabetic Kidney Findings About Test Name Terminology | DKFATS | Diabetic Kidney Disease Findings About Test Name | SDTM-DKFATS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229686","Splenic White Pulp","C12993","The part of the spleen that consists of nodules and other lymphatic concentrations.","Splenic White Pulp | White Pulp",,,,,,,,,,,,,,,"4262110","Lymphatic follicle of spleen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512945","CDISC SDTM Diabetic Kidney Findings About Test Code Terminology","C129940","Terminology associated with the diabetic kidney disease findings about test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Diabetic Kidney Findings About Test Code Terminology | DKFATSCD | Diabetic Kidney Disease Findings About Test Code | SDTM-DKFATSCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513592","WHODAS 2.0 12+24-item Version Interviewer-administered - Making New Friends","C130877","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Making new friends?","WHODAS 2.0 12+24-item Version Interviewer-administered - Making New Friends | WD4-Making New Friends | WD4D4_4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513603","WHODAS 2.0 12+24-item Version Interviewer-administered - Sexual Activities","C130878","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Sexual activities?","WHODAS 2.0 12+24-item Version Interviewer-administered - Sexual Activities | WD4-Sexual Activities | WD4D4_5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513571","WHODAS 2.0 12+24-item Version Interviewer-administered - Doing Important Household Tasks","C130879","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) Because of your health condition, in the past 30 days, how much difficulty did you have in: Doing your most important household tasks well?","WHODAS 2.0 12+24-item Version Interviewer-administered - Doing Important Household Tasks | WD4-Doing Important Household Tasks | WD4D5_2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513581","WHODAS 2.0 12+24-item Version Interviewer-administered - Getting Household Work Done Needed","C130880","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) Because of your health condition, in the past 30 days, how much difficulty did you have in: Getting all the household work done that you needed to do?","WHODAS 2.0 12+24-item Version Interviewer-administered - Getting Household Work Done Needed | WD4-Getting Household Work Done Needed | WD4D5_3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513582","WHODAS 2.0 12+24-item Version Interviewer-administered - Getting Household Work Done Quickly","C130881","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) Because of your health condition, in the past 30 days, how much difficulty did you have in: Getting your household work done as quickly as needed?","WHODAS 2.0 12+24-item Version Interviewer-administered - Getting Household Work Done Quickly | WD4-Getting Household Work Done Quickly | WD4D5_4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513600","WHODAS 2.0 12+24-item Version Interviewer-administered - Reduce or Miss Household Work","C130882","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, on how many days did you reduce or completely miss household work because of your health condition?","WHODAS 2.0 12+24-item Version Interviewer-administered - Reduce or Miss Household Work | WD4-Reduce or Miss Household Work | WD4D5_01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513572","WHODAS 2.0 12+24-item Version Interviewer-administered - Doing Important Work or School Tasks","C130883","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) Because of your health condition, in the past 30 days how much difficulty did you have in: Doing your most important work/school tasks well?","WHODAS 2.0 12+24-item Version Interviewer-administered - Doing Important Work or School Tasks | WD4-Doing Important Work/School Tasks | WD4D5_6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513579","WHODAS 2.0 12+24-item Version Interviewer-administered - Getting All Work Done You Need","C130884","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) Because of your health condition, in the past 30 days how much difficulty did you have in: Getting all the work done that you need to do?","WHODAS 2.0 12+24-item Version Interviewer-administered - Getting All Work Done You Need | WD4-Getting All Work Done You Need | WD4D5_7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513585","WHODAS 2.0 12+24-item Version Interviewer-administered - Had to Work at a Lower Level","C130886","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) Because of your health condition, in the past 30 days how much difficulty did you have in: Have you had to work at a lower level because of a health condition?","WHODAS 2.0 12+24-item Version Interviewer-administered - Had to Work at a Lower Level | WD4-Had to Work at a Lower Level | WD4D5_9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512668","JNJ63723283","C129448","A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 protein (PD-1, PCDC-1), with potential immune checkpoint inhibitory and antineoplastic activity. Upon administration, cetrelimab binds to PD-1, and inhibits the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation.","Cetrelimab | CETRELIMAB | JNJ 63723283 | JNJ-63723283 | JNJ63723283 | WHO 10757",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513048","Medial Supraclavicular Lymph Node","C12944","A cervical lymph node located above the medial region of the clavicle.","Medial Supraclavicular Lymph Node | Medial Supraclavicular Lymph Nodes | medial supraclavicular lymph node",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513196","Q-LES-Q - Accomplish Household Activities","C130655","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: had a feeling of accomplishment with regard to household activities?","Q-LES-Q - Accomplish Household Activities | QLES1-Accomplish Household Activities | QLES148",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513284","Q-LES-Q - Thought Clearly Household Activities to be Done","C130656","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: concentrated and thought clearly about what household activities needed to be done?","Q-LES-Q - Thought Clearly Household Activities to be Done | QLES1-Thought Clearly Household Activ | QLES149",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513276","Q-LES-Q - Solved House Problems Without Stress","C130657","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: solved household problems or dealt with them without undue stress?","Q-LES-Q - Solved House Problems Without Stress | QLES1-Solved House Problems w/o Stress | QLES150",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513254","Q-LES-Q - Made Repairs or Household Maintenance","C130659","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: made repairs or taken care of household maintenance as needed?","Q-LES-Q - Made Repairs or Household Maintenance | QLES1-Made Repairs Household Maintenance | QLES152",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028872","Sphincter of Oddi","C13065","The muscle fibres around the opening of the common bile duct (ductus choledochus) into the duodenum at the papilla of Vater.","Sphincter of Oddi | Glisson's Sphincter | Oddi's Sphincter","C24.0","Sphincter of Oddi",,,,,,,,,,,,,"4197959","Sphincter of Oddi structure",,,,,,,,,,,,,"--","--",,,,,,,,"--"
"CL513280","Q-LES-Q - Taken Courses or Going to Class","C130660","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Have you been taking any courses, going to class, or been involved in any type of course work, school or college studies during the past week?","Q-LES-Q - Taken Courses or Going to Class | QLES1-Taken Courses/Going to Class | QLES153",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513267","Q-LES-Q - Reason for No Courses","C130661","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Reason not taking any courses, going to class, or been involved in any type of course work, school or college studies during the past week.","Q-LES-Q - Reason for No Courses | QLES1-Reason for No Courses | QLES153A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513214","Q-LES-Q - Enjoyed Course or Class Work","C130662","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: enjoyed the course/class work?","Q-LES-Q - Enjoyed Course or Class Work | QLES1-Enjoyed Course/Class Work | QLES154",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513740","WHODAS 2.0 36-item Version Self-administered - Time Spend on Your Health Condition","C130841","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days: How much time did you spend on your health condition, or its consequences?","WHODAS 2.0 36-item Version Self-administered - Time Spend on Your Health Condition | WD7-Time Spend on Your Health Condition | WD7D6_4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513714","WHODAS 2.0 36-item Version Self-administered - Emotionally Affected by Health","C130842","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days: How much have you been emotionally affected by your health condition?","WHODAS 2.0 36-item Version Self-administered - Emotionally Affected by Health | WD7-Emotionally Affected by Health | WD7D6_5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513712","WHODAS 2.0 36-item Version Self-administered - Drain on Financial Resources","C130843","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days: How much has your health been a drain on the financial resources of you or your family?","WHODAS 2.0 36-item Version Self-administered - Drain on Financial Resources | WD7-Drain on Financial Resources | WD7D6_6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513730","WHODAS 2.0 36-item Version Self-administered - Problem Did Your Family Have","C130844","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days: How much of a problem did your family have because of your health problems?","WHODAS 2.0 36-item Version Self-administered - Problem Did Your Family Have | WD7-Problem Did Your Family Have | WD7D6_7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512986","Non-Clinical Principal Investigator Name","C129943","The name of the investigator who is responsible for defined aspects of a nonclinical study, as specified in the study protocol.","Non-Clinical Principal Investigator Name | PINV | Principal Investigator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512891","Study Chair Name","C129944","The name of the person who has overall responsibility for the technical conduct of a study, as well as for the interpretation, analysis, documentation and reporting of results, and represents the single point of study control. (FDA)","Study Chair Name | STDIR | Study Director",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512987","Nonclinical Study Sponsor Name","C129946","The name of the entity that is responsible for the initiation, management, and/or financing of a nonclinical study. (NCI)","Nonclinical Study Sponsor Name | SSPONSOR | Sponsoring Organization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513046","Untreated Extensive Stage Small Cell Lung Carcinoma","C129947","A finding of small cell carcinoma which has spread beyond one hemi-thorax and the regional lymph nodes and has not been treated.","Untreated Extensive Stage Small Cell Lung Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512958","CDKN2A Gene Product","C129948","A protein encoded by the CDKN2A gene.","CDKN2A Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0814999","Thymocyte","C12994","A cell that develops in the thymus, seemingly from a stem cell of bone marrow and of fetal liver, and is the precursor of the thymus-derived lymphocyte (T lymphocyte) that effects cell-mediated (delayed type) sensitivity.","Thymocyte | Thymocytes | thymocyte",,,,,,,,,,,,,,,"4310041","Thymic lymphocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519477","Splenocyte","C12951","A vague term that usually refers to the phagocytic cells (macrophages) of the spleen.","Splenocyte | Splenocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513425","CDISC Questionnaire IDS-SR Test Code Terminology","C130261","Test codes of questionnaire questions associated with the Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire IDS-SR Test Code Terminology | IDSR1TC | Inventory of Depressive Symptomatology Self-Report Version Questionnaire Test Code | QS-IDS-SR TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513432","CDISC Questionnaire QIDS-SR Test Name Terminology","C130262","Test names of questionnaire questions associated with the Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire QIDS-SR Test Name Terminology | QIDSR1TN | QS-QIDS-SR TEST | Quick Inventory of Depressive Symptomatology Self-Report Version Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513431","CDISC Questionnaire QIDS-SR Test Code Terminology","C130263","Test codes of questionnaire questions associated with the Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire QIDS-SR Test Code Terminology | QIDSR1TC | QS-QIDS-SR TESTCD | Quick Inventory of Depressive Symptomatology Self-Report Version Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513428","CDISC Questionnaire Q-LES-Q Test Name Terminology","C130264","Test names of questionnaire questions associated with the Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire Q-LES-Q Test Name Terminology | QLES1TN | QS-Q-LES-Q TEST | Quality Of Life Enjoyment And Satisfaction Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513427","CDISC Questionnaire Q-LES-Q Test Code Terminology","C130265","Test codes of questionnaire questions associated with the Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire Q-LES-Q Test Code Terminology | QLES1TC | QS-Q-LES-Q TESTCD | Quality Of Life Enjoyment And Satisfaction Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513430","CDISC Questionnaire Q-LES-Q-SF Test Name Terminology","C130266","Test names of questionnaire questions associated with the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire Q-LES-Q-SF Test Name Terminology | QLES2TN | QS-Q-LES-Q-SF TEST | Quality Of Life Enjoyment And Satisfaction Questionnaire - Short Form Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513429","CDISC Questionnaire Q-LES-Q-SF Test Code Terminology","C130267","Test codes of questionnaire questions associated with the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire Q-LES-Q-SF Test Code Terminology | QLES2TC | QS-Q-LES-Q-SF TESTCD | Quality Of Life Enjoyment And Satisfaction Questionnaire - Short Form Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513442","CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology","C130268","Test names of questionnaire questions associated with the World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology | QS-WHODAS 2.0 36-item Version Interviewer-administered TEST | WD5TN | World Health Organization Disability Assessment Schedule 2.0 - 36-Item Interviewer Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513441","CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology","C130269","Test codes of questionnaire questions associated with the World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology | QS-WHODAS 2.0 36-item Version Interviewer-administered TESTCD | WD5TC | World Health Organization Disability Assessment Schedule 2.0 - 36-Item Interviewer Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513444","CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology","C130270","Test names of questionnaire questions associated with the World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology | QS-WHODAS 2.0 36-item Version Proxy-administered TEST | WD6TN | World Health Organization Disability Assessment Schedule 2.0 - 36-Item Proxy Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512667","Anti-CD123-Pyrrolobenzodiazepine Dimer Antibody Drug Conjugate SGN-CD123A","C129457","An antibody-drug conjugate (ADC) consisting of an anti-CD123 humanized monoclonal antibody conjugated, via a stable maleimidocaproyl-valine-alanine dipeptide protease-cleavable linker, to the cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of anti-CD123 ADC SGN-CD123A, the antibody moiety targets the cell surface antigen CD123. Upon antibody/antigen binding, internalization, and lysosome uptake, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of CD123-overexpressing tumor cells. CD123, the alpha subunit of the IL-3 receptor, regulates the proliferation, survival and differentiation of hematopoietic cells. CD123 is overexpressed on a variety of cancers, including myeloid leukemia, and increased expression of CD123 on leukemic stem cells is associated with poor prognosis. Cysteine engineering of the monoclonal antibody (EC-mAb) allows for a site-specific, stable conjugation and uniform loading of the PBD agent to the antibody.","Anti-CD123-Pyrrolobenzodiazepine Dimer Antibody Drug Conjugate SGN-CD123A | ADC SGN-CD123A | Anti-CD123 ADC SGN-CD123A | Anti-CD123-PBD ADC SGN-CD123A | Antibody-drug Conjugate SGN-CD123A | SGN CD123A | SGN-CD123A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513723","WHODAS 2.0 36-item Version Self-administered - How Many Days Difficulties Present","C130846","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) Overall, in the past 30 days, how many days were these difficulties present?","WHODAS 2.0 36-item Version Self-administered - How Many Days Difficulties Present | WD7-How Many Days Difficulties Present | WD7H1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513708","WHODAS 2.0 36-item Version Self-administered - Days Unable to Carry Out Activities","C130847","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, for how many days were you totally unable to carry out your usual activities or work because of any health condition?","WHODAS 2.0 36-item Version Self-administered - Days Unable to Carry Out Activities | WD7-Days Unable to Carry Out Activities | WD7H2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513724","WHODAS 2.0 36-item Version Self-administered - How Many Days Reduce Activities","C130848","World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, not counting the days that you were totally unable, for how many days did you cut back or reduce your usual activities or work because of any health condition?","WHODAS 2.0 36-item Version Self-administered - How Many Days Reduce Activities | WD7-How Many Days Reduce Activities | WD7H3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513590","WHODAS 2.0 12+24-item Version Interviewer-administered - Living Situation at Interview","C130849","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) Living situation at time of interview.","WHODAS 2.0 12+24-item Version Interviewer-administered - Living Situation at Interview | WD4-Living Situation at Interview | WD4F5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524810","Perforant Pathway","C13084","The route of neural fibers originating in the entorhinal cortex that project through the hippocampal formation to granule cells of the dentate gyrus, providing the major input to the hippocampus.","Perforant Pathway | Perforating Fasciculus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513602","WHODAS 2.0 12+24-item Version Interviewer-administered - Observed Sex","C130850","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) Record sex as observed.","WHODAS 2.0 12+24-item Version Interviewer-administered - Observed Sex | WD4-Sex as Observed | WD4A1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513588","WHODAS 2.0 12+24-item Version Interviewer-administered - How Old Are You Now","C130851","World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) How old are you now?","WHODAS 2.0 12+24-item Version Interviewer-administered - How Old Are You Now | WD4-How Old Are You Now | WD4A2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513797","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.1187A>G Mutation","C130229","A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where adenine has been substituted with guanine at nucleotide position 1187 of the ABL1 gene.","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.1187A>G Mutation | BCR/ABL Fusion Gene with NM_005157.4:c.1187A>G | BCR/ABL Fusion Gene with NM_005157.5:c.1187A>G | BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.1187A>G | BCR/ABL1 Fusion Gene with NM_005157.4:c.1187A>G | BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.1187A>G Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1268090","Skin Part","C13022","Any component of the organ that constitutes the external surface of the body, including the epidermis, dermis, and skin appendages.","Skin Part | ",,,,,,,,,,,,,,,"4002704","Skin part",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512599","Autologous Bladder Cell Carcinoma RNAs/CD40L RNA Electroporated Autologous Matured Dendritic Cells","C129522","A cell-based preparation in which autologous, mature dendritic cells (DCs) are electroporated with in vitro transcribed (IVT) RNAs encoding for a synthetic form of T-cell protein CD40 ligand (CD40L) and IVT RNA encoding for autologous tumor-associated antigens (TAAs) derived from patient-specific bladder cell carcinoma (BCC) cells, with potential immunostimulatory and antineoplastic activities. Upon electroporation into autologous DCs, the RNA is translated and processed. BCC-specific antigenic peptides are subsequently presented via major histocompatibility complex (MHC) Class I molecules on the DCs surface. When AGS-003-BLD is reintroduced to the patient, the MHC-presented peptides interact with and activate CD8-positive T-cells, which elicits a highly specific cytotoxic T-cell (CTL) response against tumor cells expressing the patient-specific BCC TAAs. The signal cascade initiated by expression of the co-stimulatory molecule CD40L results in the secretion of the inflammatory cytokine IL-12, which further stimulates CTLs.","Autologous Bladder Cell Carcinoma RNAs/CD40L RNA Electroporated Autologous Matured Dendritic Cells | AGS-003-BLD | Autologous DCs Electroporated with Autologous Tumor-derived IVT RNAs/CD40L IVT RNA | Autologous DCs Electroporated with Autologous Tumor-derived RNAs/CD40L RNA | Bladder Cell Carcinoma RNAs/CD40L RNA-transfected Autologous Dendritic Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512688","CNS Solitary Fibrous Tumor/Hemangiopericytoma","C129526","A mesenchymal, non-meningothelial neoplasm arising from the central nervous system. It is characterized by a collagenous and low cellularity spindle cell and/or hemangiopericytomatous histopathological pattern, recurrent intrachromosomal rearrangement on chromosome 12q that results in the fusion of the NAB2 and STAT6 genes, high recurrence rates, and long-term risk of systemic metastasis.","Central Nervous System Solitary Fibrous Tumor | CNS Solitary Fibrous Tumor | CNS Solitary Fibrous Tumor/Hemangiopericytoma | Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma | Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512610","CNS Solitary Fibrous Tumor/Hemangiopericytoma, Grade 3","C129527","A solitary fibrous tumor that arises from the central nervous system. It most often corresponds to the tumor previously diagnosed as anaplastic hemangiopericytoma.","Central Nervous System Solitary Fibrous Tumor, Grade 3 | CNS Solitary Fibrous Tumor, Grade 3 | CNS Solitary Fibrous Tumor/Hemangiopericytoma, Grade 3 | Central Nervous System Anaplastic Hemangiopericytoma | Central Nervous System Malignant Hemangiopericytoma | Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 3 | Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 3 | Solitary fibrous tumor/hemangiopericytoma Grade 3 (CNS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512929","Gallium Ga 68 P15-041","C129713","A radiotracer composed of a bone targeting agent P15-041 linked to the radioisotope gallium Ga 68, with potential imaging activity upon positron emission tomography (PET)/computed tomography (CT). Upon administration, the P15-041 moiety targets, through an as of yet unknown mechanism of action, a certain target expressed by bone and, upon PET/CT, bone metastases can be imaged.","Gallium Ga 68 P15-041 | Gallium Ga 68 P15 041 | [68Ga]P15-041",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512904","KN035","C129714","An injectable formulation of a monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with immune checkpoint inhibitory and potential antineoplastic activities. Upon subcutaneous administration, envafolimab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells.","Envafolimab | Anti-PD-L1 MoAb KN035 | ENVAFOLIMAB | Enweida | KN 035 | KN-035 | KN035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513443","CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology","C130271","Test codes of questionnaire questions associated with the World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology | QS-WHODAS 2.0 36-item Version Proxy-administered TESTCD | WD6TC | World Health Organization Disability Assessment Schedule 2.0 - 36-Item Proxy Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516687","Coactivated T Cell","C12941","No value exists.","Coactivated T Cell | Coactivated T Cells | coactivated T cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596043","ADP Ribosylation","C129423","The transfer of ADP-ribose to amino acids within proteins or to the amino group at N2 of a 2'-deoxyguanosine residue in double-stranded DNA.","ADP Ribosylation | ADP-Ribosylation | Adenosine Diphosphate Ribosylation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512526","Diffuse Leptomeningeal Glioneuronal Tumor","C129424","A relatively slow growing diffuse leptomeningeal neoplasm usually affecting children and adolescents. It is characterized by the presence of clear glial neoplastic cells reminiscent of oligodendroglioma. A neuronal component may be present. The prognosis is variable.","Diffuse Leptomeningeal Glioneuronal Tumor | DLGNT | Diffuse leptomeningeal glioneuronal tumor | Disseminated Oligodendroglial-Like Leptomeningeal Tumor of Childhood",,,,,,,,,,,,,,,"37116418","Diffuse leptomeningeal glioneuronal neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512600","Onalespib Lactate","C129425","The lactate form of onalespib, a synthetic, orally bioavailable, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Onalespib selectively binds to Hsp90, thereby inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability and degradation of many oncogenic signaling proteins.","Onalespib Lactate | AT-13387 Lactate | ATI-13387A | ATI-13387AU | ONALESPIB LACTATE | Propanoic Acid, 2-Hydroxy-, (2S)-, Compound with (1,3-Dihydro-5-((4-methyl-1-piperazinyl)methyl)-2H-isoindol-2-yl)(2,4-dihydroxy-5-(1-methylethyl)phenyl)methanone (1:1)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512564","Multinodular and Vacuolated Pattern","C129426","An architectural pattern characterized by the presence of neoplastic cells forming multiple nodules with prominent vacuolation.","Multinodular and Vacuolated Pattern | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512915","Intracarotid","C12942","The inside of the common, external, or internal carotid arteries.","Intracarotid | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512630","CMV UL38 Gene","C129673","CMV UL38, which encodes apoptosis inhibitor UL38 protein, plays a role in the modulation of host cell apoptosis.","CMV UL38 Gene | CMV Involved in Apoptosis Gene | CMV UL38 | HHV-5 Involved in Apoptosis Gene | HHV-5 UL38 | HHV-5 UL38 Gene | HHV5 Involved in Apoptosis Gene | HHV5 UL38 | HHV5 UL38 Gene | Human Cytomegalovirus Involved in Apoptosis Gene | Human Cytomegalovirus UL38 | Human Cytomegalovirus UL38 Gene | Human Herpesvirus 5 Involved in Apoptosis Gene | Human Herpesvirus 5 UL38 | Human Herpesvirus 5 UL38 Gene | Human Herpesvirus-5 Involved in Apoptosis Gene | Human Herpesvirus-5 UL38 | Human Herpesvirus-5 UL38 Gene | Involved in Apoptosis Gene | UL38 | UL38 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2715021","UL38 protein, human herpesvirus-5","C129674","Apoptosis inhibitor UL38 (331 aa, ~37 kDa) is encoded by the cytomegalovirus UL38 gene. This protein plays a role in the inhibition of host cell apoptosis.","Apoptosis Inhibitor UL38 | CMV UL38 | HHV-5 UL38 | HHV5 UL38 | Human Cytomegalovirus UL38 | Human Herpesvirus 5 UL38 | Human Herpesvirus-5 UL38 | Protein UL38 | pUL38",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512215","NCCN-FACT FOSI-18 Version 2 - I Have Been Vomiting","C129246","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I have been vomiting.","NCCN-FACT FOSI-18 Version 2 - I Have Been Vomiting | FAC050-I Have Been Vomiting | FAC05014",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512211","NCCN-FACT FOSI-18 Version 2 - I Am Bothered by Skin Problems","C129247","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I am bothered by skin problems.","NCCN-FACT FOSI-18 Version 2 - I Am Bothered by Skin Problems | FAC050-I Am Bothered by Skin Problems | FAC05015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513798","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.1457T>C Mutation","C130232","A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where thymine has been substituted with cytosine at nucleotide position 1457 of the ABL1 gene.","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.1457T>C Mutation | BCR/ABL Fusion Gene with NM_005157.4:c.1457T>C | BCR/ABL Fusion Gene with NM_005157.5:c.1457T>C | BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.1457T>C | BCR/ABL1 Fusion Gene with NM_005157.4:c.1457T>C | BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.1457T>C Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514032","Castration Resistance","C130235","A finding indicating that a prostate carcinoma continues to grow despite the surgical removal of the testes or medical intervention to block androgen production.","Castration Resistance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514001","Stage IB Mycosis Fungoides AJCC v7","C130237","Stage IB includes: T2, N0, M0, B0-1. T2: Patches, papules, or plaques covering 10% or more of the skin surface.  May further stratify into T2a (patch only) vs. T2b (plaque +/- patch).  N0: No clinically abnormal peripheral lymph nodes; biopsy not required.  M0: No visceral organ involvement.  B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells).  B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2.  (AJCC 7th ed.)","Stage IB Mycosis Fungoides AJCC v7 | Stage IB Mycosis Fungoides",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513872","FACT-LEU Version 4 - Certain Parts of Body Have Pain","C130442","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I have certain parts of my body where I experience pain.","FACT-LEU Version 4 - Certain Parts of Body Have Pain | FAC017-Certain Parts of Body Have Pain | FAC01729",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512898","Anti-ACTR/4-1BB/CD3zeta-Viral Vector-transduced Autologous T-Lymphocytes ACTR087","C129715","Autologous T-lymphocytes that are genetically modified and transfected with a viral vector expressing the ACTR gene, a proprietary gene encoding for an antibody-coupled T-cell receptor (ATCR), with potential antineoplastic activity. The ACTR contains the extracellular Fc receptor CD16 domain, normally found on certain immune cells, such as natural killer (NK) cells, coupled to the co-immunostimulatory signaling domain 4-1BB, normally expressed on T-cells, and linked to the intracellular CD3 zeta domain (CD3z), which is needed for TCR signaling. Upon reintroduction into the patient and co-administration of a cancer-specific antibody, the co-administered antibody targets and binds to the tumor-associated antigen (TAA) expressed on the tumor cell. In turn, this induces the activation of the ACTR087 cells and destruction of the tumor cells by a) releasing cytotoxins that directly kill cancer cells; b) releasing cytokines that trigger an immune response and recruit other immune-mediated killer cells to kill the tumor cells; b) targeting and killing adjacent tumor cells that are not bound to the antibody; c) inducing T-cell proliferation and thereby further enhancing the T-cell mediated tumor cell attack. CD3 zeta is one of several membrane-bound polypeptides found in the TCR/CD3 complex; it enhances the survival and persistence of T-lymphocytes. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of the TAA.","Anti-ACTR/4-1BB/CD3zeta-Viral Vector-transduced Autologous T-Lymphocytes ACTR087 | ACTR-087 | ACTR087 | Anti-ACTR Viral Vector-transduced Autologous T-lymphocytes ACTR087 | CD16-41BB-CD3zeta ACTR Autologous T-cells | Virally-delivered Antibody-coupled TCR ACTR087",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512897","Amino Acid/Electrolyte Mixture-based Dietary Supplement","C129716","A nutritional supplement containing a proprietary mix of amino acids and electrolytes, with potential rehydrating and gastrointestinal (GI) supportive activities. Upon oral administration of the amino acid-electrolyte dietary supplement, the electrolytes are transported by amino acid-coupled transporters across the intestinal epithelial barriers. This helps rehydrate the intestinal epithelial cells, helps restore normal bowel function, prevents fluid loss and improves symptoms of diarrhea. In addition, the supplement helps restore the size and functioning of the damaged villi and facilitates the restoration of the intestinal cells, thereby helping to restore and increase nutrient absorption, restoring normal bowel function and supporting healthy immune function.","Amino Acid/Electrolyte Mixture-based Dietary Supplement | Amino Acid/electrolyte-Coupled Transport Supplement | Enterade | Proprietary Amino Acid Mixture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512997","PLB1001","C129717","An orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) with potential antineoplastic activity. Upon administration, vebreltinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","Vebreltinib | 6-(1-Cyclopropyl-1h-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5-yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine | APL-101 | APL101 | Bozitinib | CBI-3103 | CBT-101 | PLB-1001 | PLB1001 | VEBRELTINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0221033","47,XXX Syndrome","C129718","A condition caused by the presence of an extra X chromosome resulting in 47,XXX karyotype in an individual with female phenotype. The condition is characterized by tall stature, increased risk of learning disabilities, and delayed development of speech and language.","47,XXX Syndrome | 47,XXX | Triple X Syndrome | Trisomy X",,,,,,,,,,,,,,,"4148557","Trisomy X syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0403814","Congenital Bilateral Aplasia of the Vas Deferens","C129303","An autosomal recessive disorder that is associated with mutation(s) in the CFTR gene, encoding cystic fibrosis transmembrane conductance regulator. Mutation(s) in the same gene are associated with cystic fibrosis.","Congenital Bilateral Aplasia of the Vas Deferens | CAVD",,,,,,,,,,,,,,,"4170455|45765627","Congenital bilateral aplasia of vas deferens|Congenital aplasia of vas deferens",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1864233","ENDPLATE ACETYLCHOLINESTERASE DEFICIENCY (disorder)","C129304","Congenital myasthenic syndrome caused by mutation(s) in the COLQ gene, encoding acetylcholinesterase collagenic tail peptide. It is inherited in an autosomal recessive manner.","Congenital Myasthenic Syndrome 5 | CMS5 | EAD | Endplate Acetylcholinesterase Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0432235","Cranioectodermal Dysplasia","C129305","An autosomal recessive disorder associated with mutation(s) in at least one of four genes (WDR35, IFT122, WDR19, or IFT43). It is characterized by distinctive abnormalities of the face and skull, in association with developmental abnormalities of the structures derived from ectodermal tissues.","Cranioectodermal Dysplasia | Sensenbrenner Syndrome",,,,,,,,,,,,,,,"4109974","Cranioectodermal dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL497922","Rosette-Forming Glioneuronal Tumor","C129431","A central nervous system neoplasm mostly occurring in the fourth ventricle region. It is characterized by the presence of neurocytes forming pseudorosettes and astrocytes which contain Rosenthal fibers. Cytologic atypia is minimal.","Rosette-Forming Glioneuronal Tumor | RGNT | Rosette-forming glioneuronal tumor",,,,,,,,,,,,,,,"36674829|37116883","Rosette-forming glioneuronal neoplasm|Rosette-forming glioneuronal neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL382087","M-Mode Ultrasound Mode","C130063","A method of ultrasound imaging that uses a single ultrasound beam to provide high temporal resolution of tissue motion.","M-Mode Ultrasound Mode | M-MODE | Motion Mode",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL382084","Pulsed-Wave Doppler Ultrasound Mode","C130064","A method of ultrasound imaging that uses intermittent Doppler signals to measure both direction and velocity of blood flow.","Pulsed-Wave Doppler Ultrasound Mode | PULSED-WAVE DOPPLER MODE | PW Doppler | Pulsed Doppler Mode",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513189","Pulsed-Wave Tissue Doppler Ultrasound Mode","C130065","A method of ultrasound imaging that uses pulsed wave Doppler signals to measure velocities of tissue movement.","Pulsed-Wave Tissue Doppler Ultrasound Mode | PULSED-WAVE TISSUE DOPPLER MODE | Pulsed Tissue Doppler Mode",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519442","Specialized Epithelial Cell","C13006","A cell that covers the surface of the body and lines its cavities that has a specific function to perform.","Specialized Epithelial Cell | Specialized Epithelial Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512208","NCCN-FACT FOSI-18 Version 2 - I Am Able to Get Around by Myself","C129248","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I am able to get around by myself.","NCCN-FACT FOSI-18 Version 2 - I Am Able to Get Around by Myself | FAC050-I Am Able to Get Around by Myself | FAC05016",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512207","NCCN-FACT FOSI-18 Version 2 - I Am Able to Enjoy Life","C129249","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I am able to enjoy life.","NCCN-FACT FOSI-18 Version 2 - I Am Able to Enjoy Life | FAC050-I Am Able to Enjoy Life | FAC05017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512206","NCCN-FACT FOSI-18 Version 2 - Content With Quality of My Life","C129250","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I am content with the quality of my life right now.","NCCN-FACT FOSI-18 Version 2 - Content With Quality of My Life | FAC050-Content With Quality of My Life | FAC05018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512256","ASEX-Female Version - Comments","C129254","Arizona Sexual Experiences Scale-Female Version (ASEX-Female Version) Comments.","ASEX-Female Version - Comments | ASEX01-Comments | ASEX0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512257","ASEX-Male Version - Comments","C129256","Arizona Sexual Experiences Scale-Male Version (ASEX-Male Version) Comments.","ASEX-Male Version - Comments | ASEX02-Comments | ASEX0206",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513880","FACT-LEU Version 4 - I Am Bothered by the Chills","C130443","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I am bothered by the chills.","FACT-LEU Version 4 - I Am Bothered by the Chills | FAC017-I Am Bothered by the Chills | FAC01730",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513898","FACT-LEU Version 4 - I Have Night Sweats","C130444","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I have night sweats.","FACT-LEU Version 4 - I Have Night Sweats | FAC017-I Have Night Sweats | FAC01731",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513885","FACT-LEU Version 4 - I Bleed Easily","C130446","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I bleed easily.","FACT-LEU Version 4 - I Bleed Easily | FAC017-I Bleed Easily | FAC01733",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513886","FACT-LEU Version 4 - I Bruise Easily","C130447","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I bruise easily.","FACT-LEU Version 4 - I Bruise Easily | FAC017-I Bruise Easily | FAC01734",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513892","FACT-LEU Version 4 - I Feel Weak All Over","C130448","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I feel weak all over.","FACT-LEU Version 4 - I Feel Weak All Over | FAC017-I Feel Weak All Over | FAC01735",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513894","FACT-LEU Version 4 - I Get Tired Easily","C130449","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I get tired easily.","FACT-LEU Version 4 - I Get Tired Easily | FAC017-I Get Tired Easily | FAC01736",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513882","FACT-LEU Version 4 - I Am Losing Weight","C130450","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I am losing weight.","FACT-LEU Version 4 - I Am Losing Weight | FAC017-I Am Losing Weight | FAC01737",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513900","FACT-LEU Version 4 - I Have a Good Appetite","C130451","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I have a good appetite.","FACT-LEU Version 4 - I Have a Good Appetite | FAC017-I Have a Good Appetite | FAC01738",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513869","FACT-LEU Version 4 - Able to Do My Usual Activities","C130452","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I am able to do my usual activities.","FACT-LEU Version 4 - Able to Do My Usual Activities | FAC017-Able to Do My Usual Activities | FAC01739",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513903","FACT-LEU Version 4 - I Worry About Getting Infections","C130453","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I worry about getting infections.","FACT-LEU Version 4 - I Worry About Getting Infections | FAC017-I Worry About Getting Infections | FAC01740",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513910","FACT-LEU Version 4 - Uncertain About My Future Health","C130454","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I feel uncertain about my future health.","FACT-LEU Version 4 - Uncertain About My Future Health | FAC017-Uncertain About My Future Health | FAC01741",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513911","FACT-LEU Version 4 - Worry I Might Get New Symptoms","C130455","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I worry that I might get new symptoms of my illness.","FACT-LEU Version 4 - Worry I Might Get New Symptoms | FAC017-Worry I Might Get New Symptoms | FAC01742",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513896","FACT-LEU Version 4 - I Have Emotional Ups and Downs","C130456","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I have emotional ups and downs.","FACT-LEU Version 4 - I Have Emotional Ups and Downs | FAC017-I Have Emotional Ups and Downs | FAC01743",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3278481","MICROCEPHALY AND CHORIORETINOPATHY, AUTOSOMAL RECESSIVE, 1","C129306","An autosomal recessive disorder caused by mutation(s) in the TUBGCP6 gene, encoding gamma-tubulin complex component 6. It is characterized by microcephaly and chorioretinopathy.","Microcephaly and Chorioretinopathy, Autosomal Recessive, Type 1 | MCCRP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268543","N-Acetylglutamate Synthase Deficiency","C129307","An autosomal recessive disorder caused by mutation(s) in the NAGS gene, encoding N-acetylglutamate synthase, mitochondrial. It may be characterized by failure to thrive, hyperammonemia, lethargy, seizures, and coma.","N-Acetylglutamate Synthase Deficiency | NAGSD",,,,,,,,,,,,,,,"4237926","Hyperammonemia, type III",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265227","Schinzel-Giedion Midface-Retraction Syndrome","C129308","An autosomal dominant disorder associated with mutation(s) in the SETBP1 gene, encoding SET-binding protein. It is characterized by unique facial features, including midface hypoplasia, skeletal abnormalities, and mental retardation.","Schinzel-Giedion Midface-Retraction Syndrome | Schinzel-Giedion Syndrome",,,,,,,,,,,,,,,"4077897","Schinzel-Giedion syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL512286","H3 Protein Variant","C129311","A variation in the amino acid sequence for the histone h3 protein.","H3 Protein Variant | Histone H3 Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512347","Chitin Oligosaccharides Supplement T-ChOS","C129312","A proprietary, nutritional supplement comprised of chitooligosaccharides extracted from deproteinized and demineralized crustacean shell. Upon administration, chitin oligosaccharides supplement T-ChOS may increase stamina and boost energy. In addition, the chitooligosaccharides may stimulate chondrocyte growth.","Chitin Oligosaccharides Supplement T-ChOS | Benecta | T-ChOs | Therapeutic CHOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512298","Factor VII-targeting Immunoconjugate Protein ICON-1","C129313","A human immunoconjugate (ICON) fusion protein composed of a modified version of human factor VII (FVII) which targets tissue factor (TF) that is fused to the Fc domain of the human immunoglobulin G1, with potential anti-thrombotic and antineoplastic activities. Acting in a similar manner as plasma FVII, the natural ligand of TF, ICON-1 targets and binds to TF expressed on neovascular endothelia, thereby preventing TF-mediated signaling pathways, and leading to the initiation of an immune response and the destruction of neovascular tissue. This prevents angiogenesis, inflammation and blood coagulation. Upon intravitreal administration, ICON-1 may block TF-induced angiogenesis and treat wet age-related macular degeneration (AMD) and ocular melanoma. TF, a naturally occurring glycoprotein in humans, regulates blood clotting, angiogenesis, and inflammation.","Factor VII-targeting Immunoconjugate Protein ICON-1 | FVII Modified Conjugate ICON-1 | FVII-targeting Immunoconjugate Protein ICON-1 | Human Immuno-conjugate 1 | ICON-1 | VII-Fc Fusion Protein ICON-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512253","c-Met Inhibitor AL2846","C129314","An orally bioavailable small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration vilzemetkib targets and binds to the c-Met protein, prevents c-Met phosphorylation and disrupts c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","Vilzemetkib | AL 2846 | AL-2846 | AL2846 | VILZEMETKIB | c-Met Inhibitor AL2846 | c-Met Inhibitor AL2846",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229109","Episclera","C12989","A thin fibrous membrane that covers the outer surface of the anteriors sclera and contains blood vessels which supply the sclera.","Episclera | Episcleral Layer",,,,,,,,,,,,,,,"4026776","Structure of lamina episcleralis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513875","FACT-LEU Version 4 - Feel Isolated Because of Illness","C130457","Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I feel isolated from others because of my illness or treatment.","FACT-LEU Version 4 - Feel Isolated Because of Illness | FAC017-Feel Isolated Because of Illness | FAC01744",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513253","Q-LES-Q - Looked Forward to Course Work","C130663","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: looked forward to getting to work on the course/class work?","Q-LES-Q - Looked Forward to Course Work | QLES1-Looked Forward to Course Work | QLES155",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513206","Q-LES-Q - Dealt With Course or Class Work Without Stress","C130664","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: dealt with the course/class work without undue stress?","Q-LES-Q - Dealt With Course or Class Work Without Stress | QLES1-Course/Class Work Without Stress | QLES156",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513282","Q-LES-Q - Thought Clearly About Course Work","C130665","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: thought clearly about the course/class work?","Q-LES-Q - Thought Clearly About Course Work | QLES1-Thought Clearly About Course Work | QLES157",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513207","Q-LES-Q - Decisive About Course Work","C130666","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: been decisive about the course/class work when needed?","Q-LES-Q - Decisive About Course Work | QLES1-Decisive About Course Work | QLES158",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513263","Q-LES-Q - Pleased With Course Accomplishment","C130667","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: been pleased with your course/class work accomplishments?","Q-LES-Q - Pleased With Course Accomplishment | QLES1-Pleased With Course Accomplishment | QLES159",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513245","Q-LES-Q - Interested in Your Course Work","C130668","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: been interested in your course/class work?","Q-LES-Q - Interested in Your Course Work | QLES1-Interested in Your Course Work | QLES160",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513226","Q-LES-Q - Felt Good Doing Course Work","C130670","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: felt good while doing your course/class work?","Q-LES-Q - Felt Good Doing Course Work | QLES1-Felt Good Doing Course Work | QLES162",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513201","Q-LES-Q - Communicated With Ease at Course","C130671","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: communicated and interacted with ease with others at your course/class?","Q-LES-Q - Communicated With Ease at Course | QLES1-Communicated With Ease at Course | QLES163",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513285","Q-LES-Q - Use Time for a Leisure Activity","C130672","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) When you had time, how often did you use that time for a leisure time activity?","Q-LES-Q - Use Time for a Leisure Activity | QLES1-Use Time for a Leisure Activity | QLES164",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513212","Q-LES-Q - Enjoy the Leisure Activities","C130673","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) How often did you enjoy the leisure activities?","Q-LES-Q - Enjoy the Leisure Activities | QLES1-Enjoy the Leisure Activities | QLES165",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513252","Q-LES-Q - Look Forward to Leisure Activities","C130674","Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) How often did you look forward to the leisure activities before spending time at them?","Q-LES-Q - Look Forward to Leisure Activities | QLES1-Look Forward to Leisure Activities | QLES166",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020640","Factor II Deficiency","C131737","A coagulation disorder characterized by the partial or complete absence of prothrombin (factor II) activity in the blood.","Factor II Deficiency | ",,,,,,,,,,,,,,,"4253058","Factor II deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514504","Factor V Deficiency","C131738","A coagulation disorder characterized by the partial or complete absence of factor V activity in the blood.","Factor V Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514510","Factor XI Deficiency","C131739","A coagulation disorder characterized by the partial or complete absence of factor XI activity in the blood.","Factor XI Deficiency | ",,,,,,,,,,,,,,,"35624800","Factor XI deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2331260","Merkel's Corpuscle","C13173","A specialized tactile sensory nerve ending in the epidermis, characterized by a terminal cuplike expansion of an intraepidermal axon in contact with the base of a single modified keratinocyte. SYN meniscus tactus, Merkel's corpuscle, Merkel's tactile cell, Merkel's tactile disk, tactile disk.","Merkel's Corpuscle | Meniscus Tactus | Merkel's Disc | Merkel's Disk | Merkel's Tactile Cell | Tactile Disc | Tactile Disk | Tactile Meniscus",,,,,,,,,,,,,,,"4246467","Merkel's tactile disc",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0015526","Factor XII Deficiency","C131740","A coagulation disorder characterized by the partial or complete absence of factor XII activity in the blood. It is not associated with increased bleeding risk.","Factor XII Deficiency | ",,,,,,,,,,,,,,,"4188355","Factor XII deficiency disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514467","SNORD50A wt Allele","C131744","Human SNORD50A wild-type allele is located in the vicinity of 6q14.3 and is approximately 2 kb in length. This allele, which encodes U50 small nucleolar RNA, plays a role in the metabolism of preribosomal RNA. Somatic loss of the gene may be associated with several cancers.","SNORD50A wt Allele | RNA, U50 Small Nuclear Gene | RNU50 | Small Nucleolar RNA, C/D Box 50A wt Allele | Small Nucleolar RNA, C/D Box, 50A Gene | U50 | snoRNA, U50 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514591","U50 Small Nucleolar RNA","C131745","U50 small nucleolar RNA (75 bases) is encoded by the human SNORD50A gene. This oligoribonucleotide plays a role in the methylation of ribose in preribosomal RNA.","U50 Small Nucleolar RNA | SNORD50A | U50 snoRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1822956","SNORD50B Gene","C131746","This gene plays a role in the methylation of 28S ribosomal RNA.","SNORD50B Gene | SNORD50B | Small Nucleolar RNA, C/D Box 50B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514576","LYC-55716","C131294","An orally bioavailable agonist of retinoic acid-related orphan receptor gamma (RORg), with potential immunomodulatory and antineoplastic activities. Upon oral administration of cintirorgon, this agent selectively binds to the nuclear receptor transcription factor RORg, forming a receptor complex that translocates to the nucleus, and binds to ROR response elements (ROREs), enhancing the function, proliferation and survival of type 17 T-cells, including Th17 (helper T-cells) and Tc17 (cytotoxic T-cells). This may increase the expression of co-stimulatory molecules and decrease the expression of co-inhibitory molecules on T-cells leading to increased production of cytokines and chemokines by T-cells, decreased proliferation of regulatory T-cells (Tregs), and abrogation of tumor-induced immunosuppression. This ultimately induces a T-cell-mediated immune response against cancer cells and leads to a reduction in tumor cell growth. RORg, the nuclear receptor transcription factor that is involved in Th17/Tc17 differentiation, plays a key role in immune activation.","Cintirorgon | CINTIRORGON | LYC-55716 | LYC55716 | RORg Agonist LYC-55716",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0598180","coated pit","C13366","Specialized depressions on the cell surface involved in receptor-mediated endocytosis; the visible proteinaceous layer on the cytosolic side of the depression provides the coated appearance.","Coated Pit | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521771","Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Conformance to Criteria Terminology","C133851","A category of terminology used to qualify the information pertaining to conformance to criteria in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.","PQ/CMC Conformance to Criteria Terminology | Pharmaceutical Quality/CMC Conformance to Criteria Terminology | Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Conformance to Criteria Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521772","Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Container Orientation Terminology","C133852","A category of terminology used to qualify the information pertaining to container orientation in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.","PQ/CMC Container Orientation Terminology | Pharmaceutical Quality/CMC Container Orientation Terminology | Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Container Orientation Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521773","Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Container Type Terminology","C133853","A category of terminology used to qualify the information pertaining to container types in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.","PQ/CMC Container Type Terminology | Pharmaceutical Quality/CMC Container Type Terminology | Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Container Type Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521776","Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Impurity Classification Terminology","C133856","A category of terminology used to qualify the information pertaining to impurity classification in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.","PQ/CMC Impurity Classification Terminology | Pharmaceutical Quality/CMC Impurity Classification Terminology | Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Impurity Classification Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513500","SAMMSON wt Allele","C131207","Human SAMMSON wild-type allele is located in the vicinity of 3p13 and is approximately 16 kb in length. This allele, which encodes survival associated mitochondrial melanoma specific oncogenic non-coding RNA, is involved in the positive regulation of melanoma cell survival.","SAMMSON wt Allele | LINC01212 | LincRNA 1212 | Long Intergenic Non-Protein Coding RNA 1212 Gene | Long Intergenic Noncoding RNA 1212 Gene | Survival Associated Mitochondrial Melanoma Specific Oncogenic Non-Coding RNA (Sammson), Long Non-Coding RNA Gene | Survival Associated Mitochondrial Melanoma Specific Oncogenic Non-Coding RNA wt Allele | Survival-Associated Mitochondrial Melanoma-Specific Oncogenic Noncoding RNA Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514233","Survival Associated Mitochondrial Melanoma Specific Oncogenic Non-Coding RNA","C131208","Survival associated mitochondrial melanoma specific oncogenic non-coding RNA (~2 kb) is encoded by the human SAMMSON gene. This plays a role in the maintenance of mitochondria in melanoma cells.","Survival Associated Mitochondrial Melanoma Specific Oncogenic Non-Coding RNA | LINC01212 | LincRNA 1212 | Long Intergenic Non-Protein Coding RNA 1212 | Long Intergenic Noncoding RNA 1212 | SAMMSON | Survival-Associated Mitochondrial Melanoma-Specific Oncogenic Noncoding RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514181","Recurrent Gliosarcoma","C131209","The reemergence of gliosarcoma after a period of remission.","Recurrent Gliosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514003","Pittsburgh Compound B","C131211","A radioconjugate composed of the beta-amyloid binding agent Pittsburgh compound B (PiB), a derivative of the amyloid-binding dye thioflavin T (ThT), that is conjugated to the radioisotope carbon C11, with potential amyloid imaging activity upon positron emission tomography (PET). Upon administration of carbon C 11 PiB, the PiB moiety targets and binds to beta-amyloid plaques in the brain, which can then be detected and analyzed using PET imaging. Increased production and concentration of amyloid beta protein and the deposition of amyloid plaques in the brain are correlated with the cognitive decline seen in neurodegenerative diseases, such as dementia, Alzheimer's disease (AD) and chemotherapy-induced cognitive impairment (CICI).","Carbon C 11 Pittsburgh Compound B | 11 Carbon Pittsburgh Compound B | 11C-PIB | 11C-PiB | C11 Pittsburgh Compound B | C11-PiB | [11C]PiB | [N-methyl-11C]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514179","Nab-paclitaxel/Rituximab-coated Nanoparticle AR160","C131213","A formulation composed of nanoparticle albumin-bound (nab) paclitaxel, which is an albumin-stabilized nanoparticle containing the natural taxane paclitaxel, non-covalently coated with rituximab, a recombinant chimeric murine/human antibody directed against the CD20 antigen found on B-lymphocytes, with potential antineoplastic activity. Upon administration of nab-paclitaxel/rituximab nanoparticle AR160, the rituximab moiety specifically binds to CD20 and targets this formulation to CD20-positive tumor cells. Paclitaxel binds to and stabilizes microtubules, which prevents depolymerization and inhibits cellular motility, mitosis, and replication. This leads to cell death of the CD20-expressing tumor cells that were targeted by this agent. The combination of albumin-stabilization and rituximab-targeting allows for higher efficacy and decreased paclitaxel-induced toxicity as it specifically targets CD20-expressing tumor cells. Rituximab may also induce complement-dependent cytotoxicity and antibody-dependent cellular toxicity.","Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 | AR160 | Abraxane Coated with Rituximab 160nm Nanoparticle | Abraxane coated with Rituximab | Abraxane/Rituxan 160 Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376408","Bovine leukemia","C131469","A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood which occurs in cattle","Bovine Leukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519718","Intercalated Cell","C13146","The intercalated cell is an epithelial cell of the renal collecting tubule that is specialized for H+ and HCO3 transport. These cells exist in two types, [alpha] and [beta]. The [alpha] cell secretes H+ into the lumen by an apical H+ ATPase and a basolateral Cl:HCO3. The [beta] cell secretes HCO3- into the lumen by an apical Cl:HCO3 and a basolateral H+ ATPase.","Intercalated Cell | Dark Cell | Intercalated Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514618","Bovine Congenital Erythropoietic Porphyria","C131470","A congenital metabolic disorder characterized by a deficiency in the enzyme uroporphyrinogen III synthase, which occurs in cattle.","Bovine Congenital Erythropoietic Porphyria | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514619","Bovine Protoporphyria","C131472","A congenital metabolic disorder characterized by a deficiency in the enzyme ferrochelatase, which occurs in cattle.","Bovine Protoporphyria | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3493776","HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 1","C131046","Reduced response to thyroid stimulating hormone resulting in low thyroid hormone production despite elevated thyroid stimulating hormone, associated with mutation(s) in the TSHR gene.","Thyroid Stimulating Hormone Resistance | TSH Resistance | TSH Unresponsiveness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521760","Prostatic Stroma","C13104","The non-glandular tissue of the prostate gland, consisting of two major cell types, smooth muscle cells and fibroblasts. Stromal cells are key regulators of growth and differentiation in the prostate.","Prostatic Stroma | Stroma of the Prostate Gland",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514244","Anti-HA Epitope Monoclonal Antibody MEDI8852","C131295","A human immunoglobulin (Ig) G1 kappa monoclonal antibody (mAb) targeting a unique epitope in the stalk of the influenza A hemagglutinin (HA) protein, with broad influenza A virus neutralization activity. MEDI8852 was derived from an antibody isolated from human memory B-cells from patients previously infected with influenza caused by type A strains that was further optimized to increase neutralization potential. Upon infusion, MEDI8852 targets and binds to a region within the stalk of the HA protein that is highly conserved amongst all influenza A virus subtypes. This neutralizes and prevents essential steps of the viral lifecycle, thereby blocking infectivity of all influenza A virus subtypes. HA, a glycoprotein found on the surface of the influenza virus, plays a key role in viral attachment and cell entry.","Anti-HA Epitope Monoclonal Antibody MEDI8852 | Anti-Influenza A Hemagglutinin Epitope mAb MEDI8852 | MEDI 8852 | MEDI-8852 | MEDI8852 | pan-Influenza A mAb MEDI8852",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514545","Partial Lipodystrophy","C131296","Loss and redistribution of subcutaneous and/or visceral adipose tissue from specific regions of the body.","Partial Lipodystrophy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417064","MC4R Gene","C131297","This gene plays a role in neuropeptide-dependent G protein-coupled receptor signaling.","MC4R Gene | MC4R | Melanocortin 4 Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514542","Parathyroid Hormone Resistance","C131298","A finding indicating decreased tissue sensitivity to parathyroid hormone.","Parathyroid Hormone Resistance | Pseudohypoparathyroidism | Pseudoparathyroidism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514303","MC4R wt Allele","C131299","Human MC4R wild-type allele is located in the vicinity of 18q22 and is approximately 2 kb in length. This allele, which encodes melanocortin receptor 4 protein, is involved in ligand-stimulated signaling. Mutation of the gene is associated with autosomal dominant obesity.","MC4R wt Allele | Melanocortin 4 Receptor wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0527721","MC4R protein, human","C131300","Melanocortin receptor 4 (332 aa, ~37 kDa) is encoded by the human MC4R gene. This protein plays a role in G protein-coupled receptor signaling.","Melanocortin Receptor 4 | MC4-R | MC4R | MCR Receptor | Melanocortin 4 Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514242","Anti-CSF1 Monoclonal Antibody PD-0360324","C131301","A humanized immunoglobulin (Ig) G2 monoclonal antibody (mAb) directed against the cytokine colony stimulating factor 1 (CSF1; CSF-1; macrophage colony-stimulating factor; M-CSF), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CSF1 monoclonal antibody PD-0360324 targets, binds to and neutralizes CSF1. This prevents the binding of CSF1 to its receptor CSF1R (CD115; M-CSFR), which is expressed on various immune cells, such as monocytes and macrophages. This prevents CSF1R activation and CSF1R-mediated signaling in these cells; this inhibits monocyte differentiation, blocks the activity of macrophages, and reduces their production of inflammatory mediators, which reduces inflammation. By blocking the activity and proliferation of CSF1R-dependent tumor-associated macrophages (TAMs) in the tumor microenvironment, PD-0360324 reduces TAM-mediated immune suppression, decreases regulatory T-cells (Tregs), re-activates the immune system, and improves anti-tumor cell responses mediated by increasing infiltration by cytotoxic T-cells. TAMs play key roles in immune suppression, and tumor cell proliferation and survival. CSF-1 plays a key role in the regulation of the proliferation, differentiation and survival of monocytes and macrophages.","Anti-CSF1 Monoclonal Antibody PD-0360324 | Anti-M-CSF mAb PD-0360324 | PD 0360324 | PD 360324 | PD-0360324 | PD-360,324",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514537","P450 Oxidoreductase Deficiency","C131302","Decreased or absent activity of P450 oxidoreductase due to mutation(s) in the POR gene.","P450 Oxidoreductase Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521778","PQ/CMC Interpretation Code (numeric) Terminology","C133858","A category of terminology used to qualify the information pertaining to numeric interpretation codes in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.","PQ/CMC Interpretation Code (numeric) Terminology | Pharmaceutical Quality/CMC Interpretation Code (numeric) Terminology | Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Interpretation Code (numeric) Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521779","PQ/CMC Manufacturing Site Unique Identifier Type Terminology","C133859","A category of terminology used to qualify the information pertaining to manufacturing site unique identifier types in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.","PQ/CMC Manufacturing Site Unique Identifier Type Terminology | Pharmaceutical Quality/CMC Manufacturing Site Unique Identifier Type Terminology | Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Manufacturing Site Unique Identifier Type Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521782","Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Source Type Terminology","C133862","A category of terminology used to qualify the information pertaining to source types in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.","PQ/CMC Source Type Terminology | Pharmaceutical Quality/CMC Source Type Terminology | Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Source Type Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521783","Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Specification Status Terminology","C133863","A category of terminology used to qualify the information pertaining to specification statuses in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.","PQ/CMC Specification Status Terminology | Pharmaceutical Quality/CMC Specification Status Terminology | Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Specification Status Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513750","Multiple Cancer Sites","C13419","More than one cancer site.","Multiple Cancer Sites | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0101807","Tyrphostin A51","C1341","A kind of Protein tyrosine kinase inhibitor involved in cell proliferation and differentiation. (NCI)","Tyrphostin A51 | AG 183",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513749","Multiple Anatomic Sites","C13420","Present at many sites of the body.","Multiple Anatomic Sites | Multiple Sites, Person",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512475","Histone Fold","C13421","A protein structural element originally identified in the core histones.  It is of the helix-loop-helix type and is involved in protein-protein interactions via a 'handshake' motif with a histone fold partner.  Also involved in protein-DNA interactions.","Histone Fold | Histone-Fold",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512313","HMG Domain","C13422","Each HMG subfamily is a distinct set of proteins with identifiable structural characteristics and a specific type of targets to induce characteristic changes in the structure of its binding site.","HMG Domain | HMG Box | High Mobility Group Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518803","POU Domain","C13423","The POU domain is a bipartite DNA binding domain recognized originally as a shared structural motif in the Pit-1, Oct-1/Oct-2, and Unc-86 transcription factors (POU).  It is comprised by a C-terminal homeo domain, and an N-terminal POU-specific domain, separated by a non-conserved linker.  The POU-specific domain, like the homeo domain, is folded in a helix-turn-helix motif.","POU Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521975","Analytical Procedure Accuracy","C134242","The closeness of agreement between the value which is accepted either as a conventional true value or an accepted reference value and the value found.","Analytical Procedure Accuracy | Accuracy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521976","Analytical Procedure Precision","C134243","The closeness of agreement (degree of scatter) between a series of measurements obtained from multiple sampling of the same homogeneous sample under the prescribed conditions. Precision may be considered at three levels: repeatability, intermediate precision and reproducibility.","Analytical Procedure Precision | Precision",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1859148","Blomstrand Type Chondrodysplasia","C131420","An autosomal recessive lethal condition caused by inactivating mutation(s) in the PTH1R gene, encoding parathyroid hormone/parathyroid hormone-related peptide receptor. This condition is characterized by short limbs, polyhydramnios, hydrops fetalis, facial anomalies, increased bone density, and advanced skeletal maturation.","Blomstrand Type Chondrodysplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514483","Calcium Deficiency Rickets","C131421","Rickets due to low calcium concentrations, the cause of which can be nutritional or genetic.","Calcium Deficiency Rickets | Calciopenic Rickets",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3151055","Cholesterol Side-Chain Cleavage Deficiency","C131422","CLAH due to loss-of-function mutations in the CYP11A1 gene, resulting in decreased or absent activity of the enzyme P450scc, which leads to reduced conversion of cholesterol to pregnenolone, the first step in steroidogenesis.","Cholesterol Side-Chain Cleavage Deficiency | P450scc Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521303","Congenital Hyperinsulinism","C131425","An etiologically heterogenous condition resulting in dysregulated insulin secretion whose cause is present from birth. It is the most common cause of persistent hypoglycemia in neonates, infants and children.","Congenital Hyperinsulinism | HHI | Hyperinsulinemia of Infancy | Hyperinsulinemic Hypoglycemia | Neonatal Hyperinsulinism | Nesidioblastosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342474","Congenital Lipoid Adrenal Hyperplasia","C131426","Congenital adrenal hyperplasia resulting from the deposition of lipid in the adrenal glands due to a defect of intracellular cholesterol transport or metabolism. The condition is characterized by deficiencies of glucocorticoids, mineralocorticoids, and sex steroids: 46,XY infants are undervirilized, whereas 46,XX infants have no genital manifestations.","Congenital Lipoid Adrenal Hyperplasia | CLAH",,,,,,,,,,,,,,,"4195771","Cholesterol monooxygenase (side-chain cleaving) deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514276","Congenital Ovarian Failure","C131427","Ovarian failure, the cause of which is present at birth.","Congenital Ovarian Failure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514277","Congenital Testicular Failure","C131428","Testicular failure, the cause of which is present at birth.","Congenital Testicular Failure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0410539","Craniodiaphyseal Dysplasia","C131429","An autosomal dominant or recessive form of craniotubular hyperostosis due to mutation(s) in the SOST gene, encoding sclerostin. This condition is characterized by massive generalized hyperostosis and sclerosis, especially involving the skull and facial bones, which is so severe that the resulting facial distortion is referred to as 'leontiasis ossea'; the bone deposition results in progressive stenosis of craniofacial foramina and can lead to severe neurologic impairment in childhood.","Craniodiaphyseal Dysplasia | CDD | Lionitis",,,,,,,,,,,,,,,"4006941","Craniodiaphyseal dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1513729","Mucus-Secreting Cell","C13142","It is the epithelium cell that produces mucin gel adherent to the mucosal surface. Mucus-secreting cells are widely distributed through the body. (NCI)","Mucus-Secreting Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514621","Craniotubular Hyperostosis","C131430","A group of sclerosing bone dysplasias characterized by pronounced sclerosis of the cranial vault and the long bones, resulting in increased cortical bone density. Most cases are caused by mutation(s) in the SOST or LRP5 genes, encoding sclerostin and low-density lipoprotein receptor-related protein 5, respectively. Other genes have been implicated, and some cases have been described, but do not yet have identified genetic mutations.","Craniotubular Hyperostosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514624","Defective Thyroglobulin Synthesis","C131431","Impairment in the intracellular synthesis of thyroglobulin.","Defective Thyroglobulin Synthesis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0432217","Wolcott-Rallison Syndrome","C131007","A rare, autosomal recessive condition caused by mutation(s) in the EIF2AK3 gene, which encodes translation initiation factor 2-alpha kinase-3. The condition is characterized by the following: permanent insulin-dependent diabetes, with onset in the neonatal period or infancy; epiphyseal dysplasia; deficient bone mineralization, diagnosed in the first year or two of life; and liver dysfunction, occurring in early childhood. Other features may include intellectual deficit, hypothyroidism, renal dysfunction, neutropenia, and thyroid dysfunction. The manifestations and clinical course are variable.","Wolcott-Rallison Syndrome | ",,,,,,,,,,,,,,,"4111314","Wolcott-Rallison dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513364","TXNRD2-Associated Familial Glucocorticoid Deficiency","C131059","Familial glucocorticoid deficiency caused by mutation(s) in the TXNRD2 gene encoding thioredoxin reductase 2.","TXNRD2-Associated Familial Glucocorticoid Deficiency | TXNRD2-Associated FGD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514038","Checkpoint Blockade Immunotherapy","C131060","Any type of immunotherapy that targets and blocks the immune checkpoint pathways to activate immune responses against tumor cells.","Checkpoint Blockade Immunotherapy | ICB Therapy | Immune Checkpoint Blockade Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0238478","Transient Erythroblastopenia of Childhood","C131683","An acquired pure red cell aplasia that is self-limited. It is the most common cause of decreased red blood cell production in the pediatric population, and typically presents as a normocytic anemia with reticulocytopenia in an otherwise asymptomatic and normal child with no evidence of other causes for anemia, including blood loss, hemolysis, nutritional deficiency, or malignancy.","Transient Erythroblastopenia of Childhood | TEC",,,,,,,,,,,,,,,"4125499","Transient erythroblastopenia of childhood",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3553284","Vitamin B12 Deficiency","C131684","Low serum levels of vitamin B12 (cobalamin) due to poor intestinal absorption, decreased dietary intake, or increased physiologic requirement.","Vitamin B12 Deficiency | Hypocobalaminemia",,,,,,,,,,,,,,,"4100822","Cobalamin deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1264039","von Willebrand Disease, Type 1","C131685","An autosomally inherited (generally dominant) coagulation disorder characterized by quantitative partial deficiency of circulating von Willebrand factor (VWF) which account for 60 to 80% of cases of von Willebrand disease. It is characterized by mild to moderate quantitative deficiencies of VWF and factor VIII, which are coordinately reduced from normal plasma levels.","von Willebrand Disease, Type 1 | ",,,,,,,,,,,,,,,"4027379","Hereditary von Willebrand disease type 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1282968","von Willebrand Disease, Type 2A","C131686","An autosomally inherited (generally dominant) coagulation disorder characterized by qualitative abnormalities of the von Willebrand factor (VWF). The mutant VWF causes decreased platelet adhesion due to a selective deficiency of high molecular weight multimers. The decrease in large multimers can be due to a failure to synthesize the multimers ('group 1') or enhanced ADAMTS13-mediated proteolysis of the secreted high molecular weight protein ('group 2').","von Willebrand Disease, Type 2A | ",,,,,,,,,,,,,,,"4234868","Hereditary von Willebrand disease type 2A",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1282971","von Willebrand Disease, Type 2B","C131687","An autosomally inherited (generally dominant) coagulation disorder characterized by qualitative abnormalities of the von Willebrand factor (VWF). The mutant VWF shows increased affinity to platelet glycoprotein Ib alpha, resulting in increased platelet aggregation, and increased proteolysis of VWF subunits causing a decrease of large VWF multimers; patients often have secondary thrombocytopenia due to platelet consumption.","von Willebrand Disease, Type 2B | ",,,,,,,,,,,,,,,"4231757","Hereditary von Willebrand disease type 2B",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514348","Zirconium Zr 89 Nanocolloidal Albumin","C131498","A radioimmunoconjugate composed of a nanoformulation of colloidal human serum albumin (HSA) labeled with zirconium Zr 89 (Zr89), via the bifunctional chelate p-isothiocyanatobenzyldesferrioxamine B, with potential imaging activity using positron emission tomography (PET). Upon administration, the zirconium Zr 89 nanocolloidal albumin travels through the bloodstream and into the lymphatic system. Using PET, the draining pattern of the lymph nodes can be visualized and lymph node status, including that of the sentinel lymph node (SLN), can be detected and analyzed. Compared to some other formulations, the smaller particle size of nanocolloidal albumin allows for enhanced imaging of the lymphatic system.","Zirconium Zr 89 Nanocolloidal Albumin | 89-Zirconium-Nanocoll | 89Zr Nanocolloidal Albumin | 89Zr-Colloidal Albumin | 89Zr-labeled Albumin Nanocolloid | 89Zr-labeled Nanocolloid Human Serum Albumin | 89Zr-nanocoll",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0336563","Artificial Pancreas","C131499","A system that connects an insulin pump with a continuous glucose monitor via a software control algorithm to automate insulin delivery.","Artificial Pancreas | Artificial Pancreas Device System | Automated Insulin Delivery System | Autonomous System for Glycemic Control",,,,,,,,,,,,,,,"4297877","Artificial pancreas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519712","Type III Epithelial Receptor Cell","C13149","A light cell found in taste buds, characterized by afferent synaptic specializations to intragemminal nerve endings including increased density of the plasma membrane along the nerve and aggregations of synaptic vesicles, and by the presence of cored vesicles of 80-150 nm in diameter. The core is dense and the cell is immunoreactive for 5-hydroxytryptamine, neural cell adhesion molecule, and PGP 9.5.","Type III Epithelial Receptor Cell | Type III Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085176","Trimetrexate","C1314","A methotrexate derivative with potential antineoplastic activity.  Trimetrexate inhibits the enzyme dihydrofolate reductase, thereby preventing the synthesis of purine nucleotides and thymidylate, with subsequent inhibition of DNA and RNA synthesis.  Trimetrexate also exhibits antiviral activity. (NCI04)","Trimetrexate | 2,4-Quinazolinediamine, 5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]- | 5-Methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediamine | CI-898 | TMQ | TRIMETREXATE | Trimexate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514679","Recurrent Primary Malignant Neoplasm","C131500","The reemergence of a primary malignant neoplasm after a period of remission.","Recurrent Primary Malignant Neoplasm | Recurrent Primary Malignancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514445","Recurrent Subsequent Malignant Neoplasm","C131501","The reemergence of a malignant neoplasm other than the original one, after a period of remission.","Recurrent Subsequent Malignant Neoplasm | Recurrent Secondary Malignancy | Recurrent Secondary Malignant Neoplasm | Recurrent Subsequent Malignancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514481","Acute Myeloid Leukemia with t(5;11)(q35;p15); NUP98-NSD1","C131502","Acute myeloid leukemia with often cytogenetically cryptic fusion of NUP98 (chromosome 11p15) with NSD1 (chromosome 5q35). This alteration occurs in 4% of pediatric AML cases.","Childhood Acute Myeloid Leukemia with t(5;11)(q35;p15); NUP98-NSD1 | AML with t(5;11)(q35;p15); NUP98-NSD1 | AML with t(5;11)(q35;p15); NUP98::NSD1 | Acute Myeloid Leukemia with t(5;11)(q35;p15); NUP98-NSD1 | Acute Myeloid Leukemia with t(5;11)(q35;p15); NUP98-NSD1 | Childhood AML with t(5;11)(q35;p15); NUP98-NSD1 | Childhood AML with t(5;11)(q35;p15); NUP98::NSD1 | Childhood Acute Myeloid Leukemia with t(5;11)(q35;p15); NUP98-NSD1 Fusion | Childhood Acute Myeloid Leukemia with t(5;11)(q35;p15); NUP98::NSD1 Fusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514691","t(5;11)(q35;p15)","C131503","A cytogenetic abnormality that refers to the translocation of chromosome 11p15 with chromosome 5q35. It results in the formation of NUP98/NSD1 fusion gene. It is associated with the development of acute myeloid leukemia with t(5;11)(q35;p15); NUP98-NSD1.","t(5;11)(q35;p15) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514480","Acute Myeloid Leukemia with t(11;15)(p15;q35); NUP98-JARID1A","C131504","Acute myeloid leukemia with a cytogenetically cryptic fusion of NUP98 to JARID1A, t(11;15)(p15;q35). It typically has a megakaryocytic phenotype and occurs in 10% of pediatric, non-Down syndrome-related acute megakaryoblastic leukemia cases.","Childhood Acute Myeloid Leukemia with t(11;15)(p15;q35); NUP98-JARID1A | AML with t(11;15)(p15;q35); NUP98-JARID1A | AML with t(11;15)(p15;q35); NUP98::JARID1A | Acute Myeloid Leukemia with t(11;15)(p15;q35); NUP98-JARID1A | Acute Myeloid Leukemia with t(11;15)(p15;q35); NUP98-JARID1A | Childhood AML with t(11;15)(p15;q35); NUP98-JARID1A | Childhood AML with t(11;15)(p15;q35); NUP98::JARID1A | Childhood Acute Myeloid Leukemia with t(11;15)(p15;q35); NUP98-JARID1A Fusion | Childhood Acute Myeloid Leukemia with t(11;15)(p15;q35); NUP98::JARID1A Fusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514689","t(11;15)(p15;q35)","C131505","A cytogenetic abnormality that refers to the translocation of chromosome 11p15 with chromosome 15q35. It results in the formation of NUP98/JARID1A fusion gene. It is associated with the development of acute myeloid leukemia with t(11;15)(p15;q35); NUP98-JARID1A.","t(11;15)(p15;q35) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539223","DCHS1 Gene","C131507","This gene plays a role in neuroprogenitor cell proliferation and differentiation.","DCHS1 Gene | DCHS1 | Dachsous Cadherin-Related 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521977","Analytical Procedure Detection Limit","C134244","The lowest amount of analyte in a sample which can be detected but not necessarily quantitated as an exact value.","Analytical Procedure Detection Limit | Detection Limit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521979","System Suitability","C134246","The tests are based on the concept that the equipment, electronics, analytical operations, and samples to be analyzed constitute an integral system that can be evaluated as such. System suitability test parameters to be established for a particular procedure depend on the type of procedure being validated.","System Suitability | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521980","Analytical Procedure Quantitation Limit","C134248","The lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy.","Analytical Procedure Quantitation Limit | Quantitation Limit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521981","Container Closure Integrity Testing","C134249","An assessment of the structural characteristics of the container closure system to ensure the required specifications for integrity are met.","Container Closure Integrity Testing | Container Closure Integrity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520153","Winged Helix","C13424","The winged helix is a common, 100 amino acid DNA-binding domain which is a variant of the helix-turn-helix motif found in the 'forkhead' transcription factor gene family.","Winged Helix | Winged Helix-Turn-Helix | wHTH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521982","Content Uniformity","C134250","An assessment of the quality of the sameness of the contents of a substance.","Content Uniformity Test | Content Uniformity | Uniformity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521983","Colon Cancer by AJCC v8 Stage","C134251","A term that refers to the staging of colon cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to adenocarcinomas, high-grade neuroendocrine carcinomas, and squamous cell carcinomas of the colon. (from AJCC 8th Ed.)","Colon Cancer by AJCC v8 Stage | Colon Carcinoma by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521984","Pharmaceutical Disintegration","C134252","Test to determine whether tablets or capsules disintegrate within the prescribed time when placed in a liquid medium at the experimental conditions.","Pharmaceutical Disintegration Test | Disintegration | Pharmaceutical Disintegration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL434044","dissolution","C134253","Test to determine compliance with the requirements of the material of interest dissolving into solution.","Pharmaceutical Dissolution Test | Dissolution | Pharmaceutical Dissolution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520928","Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma AJCC v8","C133455","Stage II includes: T3, N0, M0. T3: Tumor invades adventitia. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma AJCC v8 | Stage II Esophageal Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520932","Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8","C133456","Stage III includes: IIIA: (T0-2, N1, M0); IIIB: (T3, N1, M0); (T0-3, N2, M0); (T4a, N0, M0). T0: No evidence of primary tumor. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8 | Stage III Esophageal Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520936","Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8","C133457","Stage IIIA includes: T0-2, N1, M0. T0: No evidence of primary tumor. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8 | Stage IIIA Esophageal Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1963745","Hyperandrogenism, Insulin Resistance, Acanthosis Nigricans Syndrome","C131008","A condition characterized by hyperandrogenism, insulin resistance, and acanthosis nigricans, typically associated with obesity in teenage girls. It is considered to be a subtype of polycystic ovarian syndrome, but may occur in male individuals. Etiology is unclear, but some cases may be associated with mutations affecting the tyrosine kinase domain of the insulin receptor.","Hyperandrogenism, Insulin Resistance, Acanthosis Nigricans Syndrome | HAIR-AN Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1183911","Prostatic Muscular Tissue","C13100","The supporting structure for the prostate. A dense layer of smooth muscle tissue lies directly underneath the fibrous capsule and another dense layer of circular fibers surrounds the urethra (striated and smooth). In between these two layers is a mesh of smooth muscle tissue in which the prostatic glands are embedded.","Prostatic Muscular Tissue | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514176","Mullerian-Renal-Cervical Spine Syndrome","C131010","A condition characterized by Mullerian duct aplasia, unilateral renal dysplasia, and cervicothoracic anomalies. Other associated findings may include skeletal abnormalities (scoliosis, vertebral anomalies, rib malformations, spina bifida), and face and limb malformations (brachymesophalangy, ectrodactyly). Heart malformations may include valvular pulmonary stenosis, aortopulmonary window, atrial septal defect, and/or tetralogy of Fallot. Putative candidate genes such as HNF1B (17q12), LHX1 (17q12), SHOX (Xp22.33 and Yp11.32), TBX6 ( 16p11.2), and ITIH5 (10p14) may be implicated.","Mullerian-Renal-Cervical Spine Syndrome | MRKH Type 2 | MURCS Syndrome | Mullerian Duct Aplasia | Unilateral Renal Dysplasia and Cervicothoracic Somite Anomalies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513805","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.764A>T Mutation","C131012","A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where adenine has been substituted with thymine at nucleotide position 764 of the ABL1 gene. This mutation is associated with imatinib- and nilotinib-resistant leukemias.","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.764A>T Mutation | BCR/ABL Fusion Gene with NM_005157.4:c.764A>T | BCR/ABL Fusion Gene with NM_005157.5:c.764A>T | BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.764A>T | BCR/ABL1 Fusion Gene with NM_005157.4:c.764A>T | BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.764A>T Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513806","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.827A>G Mutation","C131013","A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where adenine has been substituted with guanine at nucleotide position 827 of the ABL1 gene.","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.827A>G Mutation | BCR/ABL Fusion Gene with NM_005157.4:c.827A>G | BCR/ABL Fusion Gene with NM_005157.5:c.827A>G | BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.827A>G | BCR/ABL1 Fusion Gene with NM_005157.4:c.827A>G | BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.827A>G Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513807","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.835G>A Mutation","C131014","A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where guanine has been substituted with adenine at nucleotide position 835 of the ABL1 gene.","BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.835G>A Mutation | BCR/ABL Fusion Gene with NM_005157.4:c.835G>A | BCR/ABL Fusion Gene with NM_005157.5:c.835G>A | BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.835G>A | BCR/ABL1 Fusion Gene with NM_005157.4:c.835G>A | BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.835G>A Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1282974","von Willebrand Disease, Type 2M","C131688","An autosomally inherited (generally dominant) coagulation disorder characterized by qualitative abnormalities of the von Willebrand factor (VWF). The mutant VWF shows decreased platelet adhesion without a deficiency of high molecular weight multimers; this functional defect is caused by mutations that disrupt VWF binding to platelets or to subendothelium.","von Willebrand Disease, Type 2M | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1282975","von Willebrand Disease, Type 2N","C131689","An autosomally inherited (generally recessive) coagulation disorder characterized by qualitative abnormalities of the von Willebrand factor (VWF). The mutant VWF shows markedly decreased binding affinity for factor VIII, which can be confused with mild hemophilia A. The phenotype is characterized by a disproportionate decrease in factor VIII compared to VWF.","von Willebrand Disease, Type 2N | von Willebrand Disease Normandy Variant",,,,,,,,,,,,,,,"4234870","Hereditary von Willebrand disease type 2N",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514346","Pan-Mutant-IDH1 Inhibitor Bay-1436032","C131690","An orally available pan-inhibitor of mutant forms of the metabolic enzyme isocitrate dehydrogenase type 1 (IDH1; IDH-1; IDH1 [NADP+] soluble), including forms with mutations of arginine 132 (IDH1(R132)), with potential antineoplastic activity. Upon administration, pan-mutant-IDH-1 inhibitor BAY-1436032 specifically inhibits the activity of IDH1 mutant forms, which prevents the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing IDH1 mutant forms. IDH1 mutations, including IDH1(R132) mutations, are highly expressed in certain malignancies; they initiate and drive cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.","Pan-Mutant-IDH1 Inhibitor Bay-1436032 | 3-(2-((4-(Trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic Acid | BAY 1436032 | BAY-1436032 | BAY1436032",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537997","MT-RNR2 Gene","C131258","This gene plays a role in both mitochondrial protein translation and apoptosis regulation.","MT-RNR2 Gene | MT-RNR2 | Mitochondrially Encoded 16S RNA Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514311","MT-RNR2 wt Allele","C131259","Human MT-RNR2 wild-type allele is located within the circular mitochondrial (MT) chromosome and is approximately 2 kb in length. This allele, which encodes both 16S mitochondrial ribosomal RNA and humanin protein, is involved in mitochondrial protein translation and the negative regulation of apoptosis.","MT-RNR2 wt Allele | HN | HNM | Humanin, Mitochondrial Gene | MTRNR2 | Mitochondrially Encoded 16S RNA wt Allele | RNR2 | Ribosomal RNA, Mitochondrial, 16S Gene | l-rRNA | rRNA, 16S, Mitochondrial Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0966511","Humanin","C131260","Humanin (24 aa, ~3 kDa) is encoded by the human MT-RNR2 gene. This protein plays a role in the inhibition of apoptosis.","Humanin | Formyl-Humanin | HNM | Humanin Mitochondrial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1456376","COMP Gene","C131262","This gene plays a role in the structure of cartilage.","COMP Gene | COMP | Cartilage Oligomeric Matrix Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514460","DCHS1 wt Allele","C131508","Human DCHS1 wild-type allele is located in the vicinity of 11p15.4 and is approximately 43 kb in length. This allele, which encodes protocadherin-16 protein, is involved in calcium-mediated cell-cell adhesion and neuroprogenitor cell proliferation and differentiation. Mutation of the gene is associated with mitral valve prolapse 2 and Van Maldergem syndrome 1.","DCHS1 wt Allele | CDH19 | CDH25 | CDHR6 | Cadherin, Fibroblast, 1 Gene | Dachsous 1 (Drosophila) Gene | Dachsous Cadherin-Related 1 wt Allele | Dachsous, Drosophila, Homolog of, 1 Gene | FIB1 | FLJ11790 | KIAA1773 | PCDH16 | VMLDS1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513482","IDH1 NP_005887.2:p.R119Q","C131103","A change in the amino acid residue at position 119 in the isocitrate dehydrogenase [NADP] cytoplasmic protein where arginine has been replaced by glutamine.","IDH1 NP_005887.2:p.R119Q | Cytosolic NADP-Isocitrate Dehydrogenase Protein Arg119Gln | Cytosolic NADP-Isocitrate Dehydrogenase Protein R119Q | IDH1 Arg119Gln | IDH1 NP_005887.2:p.Arg119Gln | IDH1 R119Q | IDH1 p.Arg119Gln | IDH1 p.R119Q | Isocitrate Dehydrogenase [NADP] Cytoplasmic Arg119Gln | Isocitrate Dehydrogenase [NADP] Cytoplasmic R119Q | NP_005887.2:p.Arg119Gln | NP_005887.2:p.R119Q",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513355","Quite a Bit of Strain","C131105","A response indicating that an individual needed quite a bit of strain to do something.","Quite a Bit of Strain | Quite a Bit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513501","Anti-EGFR/HER2/HER3 Monoclonal Antibody Mixture Sym013","C131175","An antibody mixture composed of six humanized, immunoglobulin G1 (IgG1) monoclonal antibodies directed against three members of the human epidermal growth factor receptor (EGFR; HER) family: EGFR (HER1; ErbB1), HER2 (ErbB2) and HER3 (ErbB3), with potential antineoplastic activity. Upon administration of anti-EGFR/HER2/HER3 monoclonal antibody mixture Sym013, the six antibodies bind to non-overlapping epitopes on EGFR, HER2 and HER3, which prevents both ligand binding and receptor activation, and induce simultaneous down-modulation of EGFR, HER2 and HER3.  This inhibits the activation of HER-dependent signaling pathways and HER-dependent tumor cell proliferation. Overexpression of the HER family plays a key role in many cancers; targeting multiple HER family members simultaneously may increase therapeutic efficacy.","Anti-EGFR/HER2/HER3 Monoclonal Antibody Mixture Sym013 | Pan-HER mAb Mixture Sym013 | Sym-013 | Sym013 | pan-HER Antibody Mixture Sym013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514037","CC 90009","C131177","A modulator of cereblon (CRBN), which is part of the cullin 4-RING E3 ubiquitin ligase complex (CRL4-CRBN E3 ubiquitin ligase; CUL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and pro-apoptotic activities. Upon administration, eragidomide specifically binds to CRBN, thereby affecting the activity of the ubiquitin E3 ligase complex. This leads to the ubiquitination of certain substrate proteins and induces the proteasome-mediated degradation of certain transcription factors, including Ikaros (IKZF1) and Aiolos (IKZF3), which are transcriptional repressors in T-cells. This reduces the levels of these transcription factors, and modulates the activity of the immune system, which may include the activation of T-lymphocytes. In addition, this downregulates the expression of other proteins, including interferon regulatory factor 4 (IRF4) and c-myc, which plays a key role in the proliferation of certain cancer cell types. CRBN, the substrate recognition component of the E3 ubiquitin ligase complex, plays a key role in the ubiquitination of certain proteins.","Eragidomide | CC 90009 | CC-90009 | Cereblon Modulator CC-90009 | ERAGIDOMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514562","CDKAL1 wt Allele","C131363","Human CDKAL1 wild-type allele is located in the vicinity of 6p22.3 and is approximately 698 kb in length. This allele, which encodes threonylcarbamoyladenosine tRNA methylthiotransferase protein, is involved in tRNA modification. Mutation of the gene is associated with increased susceptibility to type 2 diabetes.","CDKAL1 wt Allele | CDK5 Regulatory Subunit Associated Protein 1 Like 1 wt Allele | CDK5 Regulatory Subunit Associated Protein 1-Like 1 Gene | FLJ20342",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1999321","CDKAL1 protein, human","C131364","Threonylcarbamoyladenosine tRNA methylthiotransferase (579 aa, ~65 kDa) is encoded by the human CDKAL1 gene. This protein plays a role in the methylthiolation of transfer RNA.","Threonylcarbamoyladenosine tRNA Methylthiotransferase | CDK5 Regulatory Subunit-Associated Protein 1-Like 1 | CDKAL1 | EC 2.8.4.5 | tRNA-t(6)A37 Methylthiotransferase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1836117","AGR3 Gene","C131365","This gene may be involved in cilia movement.","AGR3 Gene | AGR3 | Anterior Gradient 3, Protein Disulphide Isomerase Family Member Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514360","AGR3 wt Allele","C131366","Human AGR3 wild-type allele is located in the vicinity of 7p21.1 and is approximately 23 kb in length. This allele, which encodes anterior gradient protein 3 homolog, plays a role in the rate of cilia movement.","AGR3 wt Allele | AG-3 | AG3 | Anterior Gradient 3 Homolog (Xenopus laevis) Gene | Anterior Gradient 3, Protein Disulphide Isomerase Family Member wt Allele | Anterior Gradient 3, Xenopus, Homolog of Gene | BCMP11 | HAG3 | PDIA18 | UNQ642/PRO1272 | hAG-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1175290","AGR3 protein, human","C131367","Anterior gradient protein 3 homolog (166 aa, ~19 kDa) is encoded by the human AGR3 gene. This protein may involved in the regulation of cilia motion.","Anterior Gradient Protein 3 Homolog | AG-3 | AG3 | AGR3 | Anterior Gradient 3 | Anterior Gradient Homolog 3 | Breast Cancer Membrane Protein 11 | Protein Disulfide Isomerase Family A, Member 18 | hAG-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514431","Spherical Nucleic Acid Nanoparticle NU-0129","C131368","A spherical nucleic acid (SNA) gold nanoparticle formulation composed of small interfering RNAs (siRNAs) targeting the Bcl-2-like protein 12 (BCL2L12) sequence and conjugated to gold nanoparticles, with potential antineoplastic activity. Upon administration of SNA NU-0129, the siRNA prevents the translation of the BCL2L12 gene. Inhibiting the expression of BCL2L12 by NU-0129 induces tumor cell apoptosis. Bcl2L12, a protein belonging to the Bcl-2 protein family, is overexpressed in glioblastoma multiforme (GBM) and plays a role in tumor cell progression and tumor cell resistance to apoptosis. NU-0129 is able to cross the blood brain barrier (BBB).","Spherical Nucleic Acid Nanoparticle NU-0129 | NU-0129 | SNA Gold Nanoparticle NU-0129 | SNA NU-0129",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514479","Acquired Factor XII Deficiency","C131628","An acquired coagulation disorder characterized by the partial or complete absence of factor XII activity in the blood.","Acquired Factor XII Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0238120","Acquired Factor XIII Deficiency","C131629","An acquired coagulation disorder characterized by the partial or complete absence of factor XIII activity in the blood.","Acquired Factor XIII Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514238","Anemia due to Erythrocyte Enzyme Disorder","C131630","Any form of anemia that results from the absence of, or the defective action of, any enzyme involved in erythropoiesis.","Anemia due to Erythrocyte Enzyme Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015503","Factor VII Deficiency","C131631","A coagulation disorder characterized by the partial or complete absence of factor VII activity in the blood.","Factor VII Deficiency | ",,,,,,,,,,,,,,,"4290160","Factor VII deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514508","Factor X Deficiency","C131632","A coagulation disorder characterized by the partial or complete absence of factor X activity in the blood.","Factor X Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514323","Platelet Disorder","C131634","A disorder of platelet function or platelet production that may cause increased bleeding.","Platelet Disorder | Platelet Abnormality",,,,,,,,,,,,,,,"4332151","Platelet disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1291620","Bisphosphoglycerate Mutase Deficiency","C131638","A rare, autosomal recessive, inherited disorder caused by mutation of the BPGM gene. It is characterized by hemolytic anemia and splenomegaly.","Bisphosphoglycerate Mutase Deficiency | Diphosphoglycerate Phosphatase Deficiency",,,,,,,,,,,,,,,"4052597","Deficiency of bisphosphoglycerate mutase",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0398641","Epstein syndrome (disorder)","C131639","An autosomal dominant disorder characterized by thrombocytopenia, giant platelets, nephritis, and deafness; it is associated with mutation of the MYH9 gene.","Epstein Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3278252","Erythrocyte Adenylate Kinase Deficiency","C131640","An autosomal recessive disorder caused by mutation of the AK1 gene. It is associated with moderate to severe non-spherocytic hemolytic anemia and, in some cases, with intellectual disability and psychomotor impairment.","Erythrocyte Adenylate Kinase Deficiency | Red Cell Adenylate Kinase Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1291579","Erythrocyte Enolase Deficiency","C131641","A rare, autosomal dominant, inherited disorder caused by mutation of the ENO1 gene. It is associated with spherocytic hemolytic anemia, exercise-induced myalgia and weakness.","Erythrocyte Enolase Deficiency | Alpha-Enolase Deficiency | Phosphopyruvate Hydratase Deficiency",,,,,,,,,,,,,,,"4052587","Deficiency of enolase",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0403445","Fechtner Syndrome","C131642","An autosomal dominant disorder characterized by the triad of thrombocytopenia, giant platelets, and characteristic inclusions in peripheral blood leukocytes, with the additional features of nephritis, hearing loss, and eye abnormalities, mostly cataracts; it is associated with mutation of the MYH9 gene.","Fechtner Syndrome | ",,,,,,,,,,,,,,,"37016797","MYH9 related disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0398561","Glucose Phosphate Isomerase Deficiency","C131643","A rare, autosomal recessive, inherited disorder caused by mutation of the GPI gene. It is characterized by chronic, non-spherocytic hemolytic anemia.","Glucose Phosphate Isomerase Deficiency | Glucose-6-Phosphate Isomerase Deficiency",,,,,,,,,,,,,,,"4121117","Glucose phosphate isomerase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514653","Hereditary Factor III Deficiency","C131644","An autosomal recessive, inherited coagulation disorder characterized by the partial or complete absence of tissue factor (factor III) activity in the blood.","Hereditary Factor III Deficiency | Hereditary Tissue Factor Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514421","COMP wt Allele","C131263","Human COMP wild-type allele is located in the vicinity of 19p13.1 and is approximately 9 kb in length. This allele, which encodes cartilage oligomeric matrix protein, is involved in cartilage structural integrity. Mutation of the gene is associated with pseudoachondroplasia and multiple epiphyseal dysplasia 1.","COMP wt Allele | Cartilage Oligomeric Matrix Protein (Pseudoachondroplasia, Epiphyseal Dysplasia 1, Multiple) Gene | Cartilage Oligomeric Matrix Protein wt Allele | Cartilage Oligomeric Matrix Protein(Pseudoachondroplasia, Epiphyseal Dysplasia 1, Multiple) Gene | EDM1 | EPD1 | MED | PSACH | Pseudoachondroplasia (Epiphyseal Dysplasia 1, Multiple) Gene | THBS5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3711580","COMP protein, human","C131264","Cartilage oligomeric matrix protein (757 aa, ~83 kDa) is encoded by the human COMP gene. This protein plays a role in the formation and maintenance of cartilage.","Cartilage Oligomeric Matrix Protein | COMP | TSP5 | Thrombospondin 5 | Thrombospondin V | Thrombospondin-5 | Thrombospondin-V",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418676","PMP2 Gene","C131265","This gene is involved in myelin formation.","PMP2 Gene | PMP2 | Peripheral Myelin Protein 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514395","PMP2 wt Allele","C131266","Human PMP2 wild-type allele is located within 8q21.3-q22.1 and is approximately 7 kb in length. This allele, which encodes myelin P2 protein, plays a role in lipid transport.","PMP2 wt Allele | FABP8 | M-FABP | MP2 | P2 | Peripheral Myelin Protein 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514251","BCORL1 wt Allele","C131269","Human BCORL1 wild-type allele is located in the vicinity of Xq26.1 and is approximately 78 kb in length. This allele, which encodes BCL-6 corepressor-like protein 1, is involved in the inhibition of transcription. Mutation of the gene may be associated with acute myeloid leukemia and head and neck squamous cell carcinoma","BCORL1 wt Allele | BCL6 Corepressor-Like 1 wt Allele | BCoR-L1 | CXorf10 | Chromosome X Open Reading Frame 10 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512639","Immature Platelet","C13126","A young platelet that contains residual mRNA and rRNA when released from the bone marrow into the peripheral circulation as a result of thrombopoiesis. Immature platelets normally make up a small percentage of the total circulating platelets (1.1-6.1%, with a mean of 3.4%.). An increased proportion of immature platelets in blood indicates increased thrombopoiesis. The relationship between the percent of immature platelets and the platelet count can be used to determine the rate of platelet turnover.","Immature Platelet | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1958398","BCORL1 protein, human","C131270","BCL-6 corepressor-like protein 1 (78 aa, ~183 kDa) is encoded by the human BCORL1 gene. This protein plays a role in the repression of gene transcription.","BCL-6 Corepressor-Like Protein 1 | BCL6 Co-Repressor-Like 1 | BCL6 Corepressor-Like 1 | BCORL1 | BCoR-L1 | BCoR-Like Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513472","Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial c.515_516delGGinsAA","C131111","A complex substitution where the nucleotide sequence at positions 515 and 516 of the coding sequence of the IDH1 gene has changed from guanine-guanine to adenine-adenine.","IDH2 NM_002168.3:c.515_516delinsAA | IDH c.515_516GG>AA | IDH c.515_516delGGinsAA | IDH2 NM_002168.3:c.515_516GG>AA | IDH2 NM_002168.3:c.515_516delGGinsAA | IDH2 NM_002168.3:c.515_516delGGinsAA | IDH2 c.515_516GG>AA | IDH2 c.515_516delGGinsAA | Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial c.515_516GG>AA | Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial c.515_516delGGinsAA | Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial c.515_516GG>AA | Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial c.515_516delGGinsAA | NM_002168.3:c.515_516GG>AA | NM_002168.3:c.515_516delGGinsAA | NM_002168.3:c.515_516delinsAA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521944","Colorectal Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C134166","A pathologic finding about one or more characteristics of colorectal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Colorectal Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | Colorectal Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521946","Refractory Histiocytic and Dendritic Cell Neoplasm","C134168","A histiocytic and dendritic cell neoplasm that does not respond to treatment.","Refractory Histiocytic and Dendritic Cell Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515887","Adrenal Fluid or Secretion","C13416","Epinephrine and norepinephrine from the medulla and steroid hormones from the cortex.","Adrenal Fluid or Secretion | Adrenal Fluids and Secretions | Adrenal-Fluids, Secretions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521950","Recurrent Histiocytic and Dendritic Cell Neoplasm","C134172","The reemergence of a histiocytic and dendritic cell neoplasm after a period of remission.","Recurrent Histiocytic and Dendritic Cell Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520861","19q13.2-q13.3","C13136","A chromosome band present on 19q","19q13.2-q13.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0340978","May-Hegglin Anomaly","C131646","An autosomal dominant disorder characterized by the triad of thrombocytopenia, giant platelets, and characteristic inclusions in peripheral blood leukocytes. It is characterized by varying degrees of thrombocytopenia that may be associated with purpura and bleeding; it is associated with mutation of the MYH9 gene.","May-Hegglin Anomaly | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513770","Autologous iC9.2A.deltaNGFR.2A.CAR.CD19 T Cells","C131214","A preparation of autologous T-lymphocytes that are transduced with a retroviral vector encoding a chimeric antigen receptor (CAR) specific for the CD19 antigen, the suicide gene, inducible human caspase 9 (iCasp9 or iC9), and a truncated low-affinity nerve growth factor receptor (deltaNGFR), with potential immunomodulating and antineoplastic activities. The iCasp9 construct consists of the entire coding sequence for the human FK506-drug binding protein (FKBP12) with an F36V mutation (FKBP12-F36V) that is linked to the gene encoding human caspase 9, which is deleted of its endogenous caspase activation and recruitment domains. Upon intravenous administration, autologous iCasp9-deltaNGFR-CD19CAR-expressing T cells are selectively toxic to CD19-expressing tumor cells. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered, which binds to the FKBP12-F36V drug binding domain, activates caspase 9, and results in apoptosis of the administered CAR19 T-cells. The CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Prior to administration, deltaNGFR, is used to select the CAR19-transduced T-cells for further enrichment by flow cytometry using an anti-NGFR antibody.","Autologous iCasp9-deltaNGFR-CD19CAR-expressing T Cells | Autologous ICASP9-deltaNGFR-CD19CAR-expressing T-Lymphocytes | Autologous iC9.2A.deltaNGFR.2A.CAR.CD19 T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513488","Montanide ISA-51 VG/KLH/NY-ESO-1/MART-1 Peptide Vaccine","C131215","A cancer vaccine consisting of two immunogenic peptides derived from the cancer-testis antigen NY-ESO-1 and the melanoma differentiation antigen Melan-A (MART-1; Melanoma Antigen Recognized by T-cells 1), which are conjugated with the immunostimulant keyhole limpet hemocyanin (KLH) and emulsified in the immunoadjuvant Montanide ISA-51 VG, with potential immunomodulating and antineoplastic activities. Upon subcutaneous vaccination, the Montanide ISA-51 VG/KLH/NY-ESO-1/MART-1 peptide vaccine stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the NY-ESO-1 and Melan-A antigens, resulting in tumor cell lysis. NY-ESO-1 and Melan-A are overexpressed in a variety of tumor cell types. The surfactant mannide monooleate in Montanide ISA 51 VG is derived from vegetable-grade (VG) oleic acid that was purified from olive oil. KLH is a hapten carrier and serves as an immunostimulant to improve immune recognition.","Montanide ISA-51 VG/KLH/NY-ESO-1/MART-1 Peptide Vaccine | Montanide ISA-51 VG/KLH/NY-ESO-1/MART-1 Vaccine | NY-ESO-1/MART-1/KLH/Montanide ISA-51 VG Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342198","Pituitary Resistance to Thyroid Hormone","C131216","Decreased response to thyroid hormones in the pituitary gland with normal response in peripheral tissues.","Pituitary Resistance to Thyroid Hormone | PitRTH",,,,,,,,,,,,,,,"4232833","Pituitary thyroid hormone resistance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0862468","Recurrent Urethral Urothelial Carcinoma","C131218","The reemergence of urethral urothelial carcinoma after a period of remission.","Recurrent Urethral Urothelial Carcinoma | Recurrent Urethral Urothelial Cancer | Recurrent Urothelial Carcinoma of the Urethra",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420246","SLK Gene","C131219","This gene is involved in protein phosphorylation and apoptosis.","SLK Gene | SLK | STE20 Like Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514466","SLK wt Allele","C131220","Human SLK wild-type allele is located in the vicinity of 10q25.1 and is approximately 62 kb in length. This allele, which encodes STE20-like serine/threonine-protein kinase protein, plays a role in both apoptosis and protein phosphorylation.","SLK wt Allele | KIAA0204 | LOSK | SNF1 (Sucrose Nonfermenting, Yeast, Homolog)-Like Kinase Gene | SNF1 (Sucrose Nonfermenting, Yeast, Homolog)-Like Kinase, SNF1 Sucrose Nonfermenting Like Kinase (Yeast) Gene | SNF1 (Sucrose Nonfermenting, Yeast, Homolog)-Like Kinase, SNF1 Sucrose Nonfermenting Like Kinase Gene | SNF1 Sucrose Nonfermenting Like Kinase (Yeast) Gene | SNF1 Sucrose Nonfermenting Like Kinase Gene | STE20 Like Kinase wt Allele | STE20-Like Kinase (Yeast) Gene | STK2 | bA16H23.1 | se20-9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1180350","Taste bud cell","C13147","Any of the three types of the cells that constitute the taste bud. They are classified as neuroepithelial (sensory) cells, supporting cells, and basal cells.","Taste Bud Cell | Taste Bud Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521953","Recurrent Langerhans Cell Histiocytosis","C134175","The reemergence of Langerhans cell histiocytosis after a period of remission.","Recurrent Langerhans Cell Histiocytosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521955","Refractory Langerhans Cell Histiocytosis","C134177","Langerhans cell histiocytosis that does not respond to treatment.","Refractory Langerhans Cell Histiocytosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521801","Canine Neoplasm","C134526","A neoplasm that occurs in dogs.","Canine Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522108","Bovine Neoplasm","C134527","A neoplasm that occurs in cattle.","Bovine Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522109","Feline Experimental Organism Diagnosis","C134528","A condition that is relevant to either disease states or models of disease in cats.","Feline Experimental Organism Diagnosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518645","Other Body Fluids and Secretions","C13452","Liquid substances produced by living organisms to fulfill specific functions or excreted as waste. Secretions do not include hormones or enzymes.","Other Body Fluids and Secretions | Other Body Fluids, Secretions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522110","Leporine Experimental Organism Diagnosis","C134530","A condition that is relevant to either disease states or models of disease in rabbits.","Leporine Experimental Organism Diagnosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522112","Non-Human or Experimental Organism Neoplasm by Organism","C134533","A neoplasm grouping that is based on the classification of the affected non-human organism; this includes neoplasms occurring in organisms used in research settings.","Non-Human or Experimental Organism Neoplasm by Organism | Experimental Organism Neoplasm by Organism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522113","Galline Experimental Organism Diagnosis","C134534","A condition that is relevant to either disease states or models of disease in chickens.","Galline Experimental Organism Diagnosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522114","Equine Experimental Organism Diagnosis","C134535","A condition that is relevant to either disease states or models of disease in horses.","Equine Experimental Organism Diagnosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517887","Linear Sequence Epitope","C13454","An epitope composed of adjacent amino acids","Linear Sequence Epitope | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522115","Chicken Bursal Lymphoma","C134556","A malignant lymphoma that arises in the bursa of Fabricius in a chicken.","Chicken Bursal Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522116","Chicken Fibrosarcoma","C134557","Fibrosarcoma that occurs in a chicken.","Chicken Fibrosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522117","Chicken Hepatoma","C134558","Hepatoma that occurs in a chicken.","Chicken Hepatoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227967","Prostatic Glandular Tissue","C13096","No value exists.","Prostatic Glandular Tissue | ",,,,,,,,,,,,,,,"4142649","Structure of prostatic glandular tissue",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514461","VSV-expressing hIFNb and NIS","C131580","A recombinant, replication competent form of the oncolytic RNA virus vesicular stomatitis virus (VSV), based on the Indiana strain of VSV, that is genetically engineered to express the genes for the human cytokine interferon beta (IFNbeta) and the human thyroidal sodium-iodide symporter (NIS), with potential oncolytic and imaging activities. Upon intravenous administration, VSV-hIFNbeta-NIS is preferentially taken up by tumor cells, resulting in tumor cell infection, viral replication and a direct virus-mediated cytolytic effect against the infected tumor cells. IFN-mediated signaling is defective in tumor cells and tumor cells are unable to exert an anti-viral response against VSV. As normal, healthy cells secrete and respond normally to IFNbeta and are able to activate IFN-mediated anti-viral pathways, the expressed IFNbeta from the VSV-infected tumor cells helps protect normal cells from VSV infection. Upon subsequent administration of certain isotope-containing imaging agents, NIS expression by the infected tumor cells allows visualization and tracking of VSV biodistribution, and analysis and quantification of VSV-infected tumor cells by positron emission tomography (PET). Also, upon subsequent administration of the radioisotope iodine I 131 (I131), I131 can be taken up by NIS and allows for a cytotoxic dose of radiation to accumulate in the NIS-expressing VSV-infected tumor cells, which also leads to tumor cell death.","Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter | Oncolytic VSV-hIFNbeta-NIS | VSV-expressing hIFNb and NIS | VSV-hIFNb-NIS | VSV-hIFNbeta-NIS | VV1 | Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter | Voyager-V1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514544","Parietal Lobe and Occipital Lobe Ependymal Tumor","C131581","A finding indicating the presence of an ependymal tumor in the parietal and occipital lobes of the brain.","Parietal Lobe and Occipital Lobe Ependymal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1436751","SLK protein, human","C131221","STE20-like serine/threonine-protein kinase (1235 aa, ~143 kDa) is encoded by the human SLK gene. This protein is involved in both serine/threonine phosphorylation and apoptosis regulation.","STE20-Like Serine/Threonine-Protein Kinase | CTCL Tumor Antigen Se20-9 | EC 2.7.11.1 | Long Ste20-Like Kinase | SNF1 Sucrose Nonfermenting Like Kinase | STE20-Like Kinase | STE20-Like Protein Kinase | STE20-Related Kinase | STE20-Related Serine/Threonine-Protein Kinase | Serine/Threonine-Protein Kinase 2 | Ste20-Related Serine/Threonine Kinase | hSLK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514625","Defective Thyroglobulin Transport","C131432","Impairment in the intracellular transport of thyroglobulin.","Defective Thyroglobulin Transport | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0271767","Neonatal Graves Disease","C131433","Graves disease in the neonate resulting from transplacental passage of thyrotropin receptor antibody.","Neonatal Graves Disease | ",,,,,,,,,,,,,,,"4243042","Neonatal Graves' disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514701","Ceramide Nanoliposome","C131434","A lipid-based nanoparticle formulation composed of the apoptosis-inducing sphingolipid ceramide encapsulated within nanoliposomes, with potential apoptotic and antineoplastic activities. Upon administration, ceramide nanoliposomes accumulate in the tumor environment, due to the unique properties of the tumor vasculature, and easily enter tumor cells. This delivers ceramide inside the tumor cells, where ceramide induces apoptosis. Although the process is not completely understood, ceramide-dependent apoptosis most likely results from the downregulation of nutrient transporter proteins, which prevents cellular access to extracellular nutrients and causes tumor cell starvation. This selectively destroys tumor cells. Ceramide alone is insoluble and has a very short half-life; therefore, the nanoliposome formulation increases its solubility and half-life. Ceramide plays a key role in the regulation of autophagy, apoptosis, survival and proliferation. Serving as a tumor suppressor lipid, the expression of ceramide is inversely correlated with tumor cell growth, survival and metastasis.","Ceramide Nanoliposome | CNL | KN 001 | KN-001 | KN-01 | Nanoliposomal Ceramide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342195","Deiodinase Deficiency","C131435","Presumed loss-of-function mutation(s) in the IYD gene, resulting in reduced activity of the enzyme iodotyrosine deiodinase.","Deiodinase Deficiency | Dehalogenase Deficiency",,,,,,,,,,,,,,,"4076302","Iodotyrosine deiodination defect",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0342114","Diffuse Goiter","C131436","Enlargement of the entire thyroid gland without discrete mass(es).","Diffuse Goiter | ",,,,,,,,,,,,,,,"4030040","Diffuse goiter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0342208","Multinodular Goiter","C131438","Nodular goiter characterized by more than one discrete tissue mass.","Multinodular Goiter | ",,,,,,,,,,,,,,,"4034825","Multinodular goiter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514241","Anti-CDH6 Antibody-drug Conjugate HKT288","C131439","An immunoconjugate consisting of a human monoclonal antibody directed against the tumor-associated antigen (TAA) cadherin-6 (CDH6; CDH-6) conjugated to a maytansine-based cytotoxic agent, with potential antineoplastic activity. The monoclonal antibody moiety of HKT288 targets and binds to CDH6 located on tumor cell surfaces. After internalization, the maytansine moiety binds to tubulin, which disrupts microtubule assembly/disassembly dynamics and inhibits both division and proliferation of CDH6-expressing tumor cells. CDH6, a member of the cadherin family and overexpressed by a variety of cancers, plays a key role in tumor cell proliferation.","Anti-CDH6 Antibody-drug Conjugate HKT288 | Anti-CDH6 ADC HKT288 | HKT 288 | HKT-288 | HKT288 | Maytansine-based ADC HKT-288",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225668","Club Cell","C13143","A rounded, club-shaped, nonciliated cell found in between ciliated cells in the epithelium of respiratory and terminal bronchioles. It has a secretory function.","Club Cell | Clara Cell | Nonciliated Bronchiolar Epithelial Cell",,,,,,,,,,,,,,,"4300402","Clara cell of bronchiole",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514658","Hypothyroid Goiter","C131440","Goiter associated with reduced thyroid hormone secretion.","Hypothyroid Goiter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1708392","Human Verumontanum","C13106","A ridge of urothelium in the prostatic urethra that serves as an important anatomical landmark that is important in the classification of several urethral disorders, including posterior urethral valves, urethral carcinoid tumors, and hypospadias.","Human Verumontanum | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342205","Uninodular Goiter","C131072","Nodular goiter characterized by one discrete tissue mass.","Uninodular Goiter | ",,,,,,,,,,,,,,,"4030055","Uninodular goiter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1838657","Vitamin D 25-Hydroxylase Deficiency","C131074","An autosomal recessive form of rickets caused by inactivating mutation(s) in the CYP2R1 gene, encoding vitamin D 25-hydroxylase, the hepatic enzyme that converts vitamin D to 25-hydroxyvitamin D, the precursor of 1,25-dihydroxyvitamin D (calcitriol). The condition is characterized by reduced serum concentrations of 25-hydroxyvitamin D, hypophosphatemia, hypocalcemia with secondary hyperparathyroidism and elevated serum alkaline phosphatase, and by failure to thrive, seizures, muscle weakness, and rickets.","Vitamin D 25-Hydroxylase Deficiency | Vitam D Hydroxylation-Deficient Rickets Type 1b | Vitamin D Hydroxylation-deficient Rickets Type 1b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342646","Vitamin D Dependent Rickets 2a","C131075","Rickets caused by a defect in the VDR gene, encoding the vitamin D receptor. This form of rickets is characterized by hypocalcemia, elevated 1,25-dihydroxyvitamin D (calcitriol) concentrations and may also manifest with alopecia.","Vitamin D Dependent Rickets 2a | Hereditary 1,25 Dihydroxyvitamin D-Resistant Rickets with Abnormal Vitamin D Receptor with Alopecia | VDDR2a | Vitamin D Receptor Deficiency Rickets",,,,,,,,,,,,,,,"4029604","Vitamin D-dependent rickets type II with alopecia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL522118","Feline Bronchioloalveolar Lung Carcinoma","C134559","Bronchioloalveolar lung carcinoma that occurs in a cat.","Feline Bronchioloalveolar Lung Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519334","Sister Chromatid","C13455","Sister chromatids are the two newly synthesized daughter chromatids derived from the same chromosome parent.  During chromosomal pairing in meiosis, recombination occurs exclusively between non-sister chromatids.","Sister Chromatid | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522119","Feline Fibrosarcoma","C134560","Fibrosarcoma that occurs in a cat.","Feline Fibrosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522121","Goldfish Erythrophoroma","C134562","A red-pigmented tumor that occurs in a goldfish.","Goldfish Erythrophoroma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522122","Guinea Pig Colon Adenocarcinoma","C134563","Adenocarcinoma that occurs in a guinea pig.","Guinea Pig Colon Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522123","Guinea Pig Leukemia","C134564","Leukemia that occurs in a guinea pig.","Guinea Pig Leukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522124","Hamster Buccal Pouch Carcinoma","C134565","Buccal pouch carcinoma that occurs in a hamster.","Hamster Buccal Pouch Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522125","Hamster Cholangiocarcinoma","C134566","Cholangiocarcinoma that occurs in a hamster.","Hamster Cholangiocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522127","Hamster Uterine Leiomyosarcoma","C134568","Uterine leiomyosarcoma that occurs in a hamster.","Hamster Uterine Leiomyosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522128","Horse Melanoma","C134569","Melanoma that occurs in a horse.","Horse Melanoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520399","Illegible Information","C133642","Problem associated with information unable to be read or deciphered.","Illegible Information | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520425","Inaccurate Information","C133643","Problem associated with imprecise, inexact information.","Inaccurate Information | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520551","Unclear Information","C133644","Problem associated with ambiguous, confusing information.","Unclear Information | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520832","Missing Information","C133645","Absence of information e.g. labeling, instruction for use.","Missing Information | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520831","Misassembly during Maintenance/Repair","C133646","Problem associated with incorrect assembly of the device or constituents during maintenance or repair.","Misassembly during Maintenance/Repair | Misassembly During Maintenance/Repair",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514335","Temporal Lobe and Parietal Lobe Ependymal Tumor","C131582","A finding indicating the presence of an ependymal tumor in the temporal and parietal lobes of the brain.","Temporal Lobe and Parietal Lobe Ependymal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514266","Cerebellar and Ventricular Ependymal Tumor","C131583","A finding indicating the presence of an ependymal tumor in the cerebellum and a brain ventricle.","Cerebellar and Ventricular Ependymal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514294","Frontal Lobe and Parietal Lobe Ependymal Tumor","C131584","A finding indicating the presence of an ependymal tumor in the frontal and parietal lobes of the brain.","Frontal Lobe and Parietal Lobe Ependymal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514264","Cerebellar and Brain Stem Ependymal Tumor","C131585","A finding indicating the presence of an ependymal tumor in the cerebellum and brain stem.","Cerebellar and Brain Stem Ependymal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514268","Cerebellar, Fourth Ventricle, and Brain Stem Ependymal Tumor","C131586","A finding indicating the presence of an ependymal tumor in the cerebellum, fourth ventricle, and brain stem.","Cerebellar, Fourth Ventricle, and Brain Stem Ependymal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514324","Posterior Fossa Ependymal Tumor","C131587","A finding indicating the presence of an ependymal tumor in the posterior cranial fossa.","Posterior Fossa Ependymal Tumor | Posterior Cranial Fossa Ependymal Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538696","POLR3B Gene","C131588","This gene is involved in the synthesis of small RNAs.","POLR3B Gene | POLR3B | RNA Polymerase III Subunit B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514401","POLR3B wt Allele","C131590","Human POLR3B wild-type allele is located in the vicinity of 12q23.3 and is approximately 153 kb in length. This allele, which encodes DNA-directed RNA polymerase III subunit RPC2 protein, plays a role in the synthesis of ribosomal and transfer RNAs. Mutation of the gene is associated with hypomyelinating leukodystrophy-8.","POLR3B wt Allele | C128 | C128, S. cerevisiae, Homolog of Gene | FLJ10388 | HLD8 | INMAP | Polymerase (RNA) III (DNA Directed) Polypeptide B Gene | Polymerase III, RNA, Subunit B Gene | RNA Polymerase III Subunit B wt Allele | RPC2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1172354","POLR3B protein, human","C131591","DNA-directed RNA polymerase III subunit RPC2 (1133 aa, ~128 kDa) is encoded by the human POLR3B gene. This protein is involved in small RNA synthesis.","DNA-Directed RNA Polymerase III Subunit RPC2 | DNA-Directed RNA Polymerase III 127.6 kDa Polypeptide | DNA-Directed RNA Polymerase III Subunit B | EC 2.7.7.6 | Interphase Nucleus and Mitotic Apparatus Associated Protein | POLR3B | RNA Polymerase III Subunit C2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514267","Cerebellar, Brain Stem, and Cervical Spinal Cord Ependymal Tumor","C131592","A finding indicating the presence of an ependymal tumor in the cerebellum, brain stem, and the cervical region of spinal cord.","Cerebellar, Brain Stem, and Cervical Spinal Cord Ependymal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514291","Fourth Ventricle Ependymal Tumor","C131593","A finding indicating the presence of an ependymal tumor in the fourth ventricle of the brain.","Fourth Ventricle Ependymal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342467","Non-Classic Congenital Adrenal Hyperplasia","C131442","A milder form of congenital adrenal hyperplasia characterized by decreased activity of an enzyme in the steroidogenic pathway, typically presenting later in life, that does not require life-long cortisol replacement.","Non-Classic Congenital Adrenal Hyperplasia | Late-onset Congenital Adrenal Hyperplasia",,,,,,,,,,,,,,,"4035120","Late onset congenital adrenal hyperplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514527","Nutritional Calcium Deficient Rickets","C131445","Nutritional rickets due to dietary deficiency of calcium.","Nutritional Calcium Deficient Rickets | Nutritional Calciopenic Rickets",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514528","Nutritional Hypophosphatemic Rickets","C131446","Hypophosphatemic rickets due to insufficient dietary phosphate intake or absorption.","Nutritional Hypophosphatemic Rickets | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514529","Nutritional Rickets","C131447","Rickets due to dietary deficiency of calcium, phosphate, or vitamin D.","Nutritional Rickets | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514530","Nutritional Vitamin D Deficiency Rickets","C131448","Nutritional rickets due to dietary deficiency of vitamin D.","Nutritional Vitamin D Deficiency Rickets | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514072","Recombinant Human Bone Morphogenetic Protein 4","C131018","A recombinant form of human bone morphogenetic protein 4 (rhBMP4; rhBMP-4), with potential antineoplastic activity. Upon administration, rhBMP4 binds to BMP receptors (BMPRs) and activates BMP-mediated signal transduction pathways. This may lead to the transcription of BMP4-target genes and to inhibition of the proliferation of certain tumor cell types. Additionally, rhBMP4 binding promotes the differentiation of normal stem cells and decreases both differentiation and renewal of cancer stem cells (CSCs). BMP4, an extracellular signaling molecule belonging to the transforming growth factor beta (TGFb) superfamily, plays a key role in bone formation. It also plays a role in the pathogenesis of certain cancers; BMP4 suppresses growth of certain types of cancer cells, and is also able to induce migration, invasion, and epithelial-mesenchymal transition (EMT), which may promote cancer metastasis and progression.","Recombinant Human Bone Morphogenetic Protein 4 | HUMAN RECOMBINANT BONE MORPHOGENETIC PROTEIN 4 | Recombinant Human BMP4 | hrBMP-4 | hrBMP4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514314","Manufactures Human Over-the-Counter Drug Products Produced Under a Monograph","C131708","The process of manufacturing non-prescription medications under a monograph (as opposed to under an approved drug application), for humans by a pharmaceutical company.","Manufactures Human Over-the-Counter Drug Products Produced Under a Monograph | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514315","Manufactures Human Over-the-Counter Drug Products Produced Under an Approved Drug Application","C131709","The process of manufacturing non-prescription medications under an approved drug application (as opposed to under a monograph), for humans by a pharmaceutical company.","Manufactures Human Over-the-Counter Drug Products Produced Under an Approved Drug Application | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229950","Hassall's Corpuscle","C13170","A small spherical body composed of keratinized squamous epithelial cells arranged in a concentric pattern in the medullary portion of the thymus.","Hassall's Corpuscle | Hassall's Body | Hassall's Concentric Corpuscle | Thymic Corpuscle | Virchow-Hassall Body",,,,,,,,,,,,,,,"4145622","Hassall's corpuscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0596138","Autocrine Systems","C13364","Organ systems involved in self-stimulation through cellular production of a factor and a specific receptor for it.","Autocrine Systems | Autocrine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520632","Clinical Stage IV Gastric Cancer AJCC v8","C133651","Stage IV includes: IVA: (T4b, Any N, M0); IVB: (Any T, Any N, M1). T4b: Tumor invades adjacent structures/organs. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)","Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastric Carcinoma AJCC v8 | Stage IV Gastric (Stomach) Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521744","3D-expanded Placenta-derived Cells PLX-R18","C133823","A population of proprietary, off-the-shelf, three-dimensional (3D)-expanded, allogeneic placenta-derived stromal cells that can potentially be used to increase hematopoietic recovery from hematological disorders or after a hematopoietic stem cell transplant (HSCT). Upon intramuscular (IM) injection of placental expanded (PLX)-R18, these cells secrete a range of specific hematopoietic, regenerative proteins depending on their in vivo environment. The secreted proteins are involved in maintenance, renewal, proliferation, differentiation, and mobilization of hematopoietic progenitor cells (HPCs), and include, but are not limited to, granulocyte colony-stimulating factor (GCSF), monocyte chemoattractant protein-1 (MCP-1/CCL2), MCP-3 (CCL7), interleukin-6 (IL-6), and IL-8. This increases the number of colony-forming hematopoietic progenitors in the bone marrow, regenerates the bone marrow hematopoietic cells, and elevates and restores blood cell production.","3D-expanded Placenta-derived Cells PLX-R18 | PLX R18 | PLX RAD | PLX-R18 | PLX-R18 Cells | PLacental eXpanded-R18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521745","Copper Chloride Formulation","C133824","A formulation containing the compound copper chloride (CuCl2), that can potentially be used to enhance Cu levels in cancer cells in order to elevate the antitumor activity of chemotherapeutic agents that are dependent on Cu for their activity. Upon intravenous administration of CuCl2, the mineral Cu is selectively taken up by and accumulates in cancer cells. In the presence of certain chemotherapeutic agents whose mechanism of action (MoA) is dependent on Cu, this formulation may enhance their cytotoxic activity.","Copper Chloride Formulation | CuCl2 Formulation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521747","Small Intestine Cancer Clinical TNM Finding v8","C133826","A clinical finding about one or more characteristics of small intestine cancer, following the rules of the TNM AJCC v8 classification system.","Small Intestine Cancer Clinical TNM Finding v8 | Small Intestine Carcinoma Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415229","GPR35 Gene","C131180","This gene plays a role in kynurenic acid-dependent signaling.","GPR35 Gene | G Protein-Coupled Receptor 35 Gene | GPR35",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513094","GPR35 wt Allele","C131182","Human GPR35 wild-type allele is located in the vicinity of 2q37.3 and is approximately 26 kb in length. This allele, which encodes G-protein coupled receptor 35 protein, is involved in kynurenic acid binding.","GPR35 wt Allele | CXCR8 | Chemokine, CXC Motif, Receptor 8 Gene | G Protein-Coupled Receptor 35 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0673011","G-Protein Coupled Receptor 35, Human","C131184","G-protein coupled receptor 35 (309 aa, ~34 kDa) is encoded by the human GPR35 gene. This protein plays a role in kynurenic acid-dependent G protein-coupled receptor signaling.","G-Protein Coupled Receptor 35 | G Protein-Coupled Receptor 35 | KYNA Receptor | Kynurenic Acid Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826769","RAVER1 Gene","C131185","This gene is involved in alternative splicing.","RAVER1 Gene | RAVER1 | Ribonucleoprotein, PTB Binding 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513356","RAVER1 wt Allele","C131186","Human RAVER1 wild-type allele is located in the vicinity of 19p13.2 and is approximately 17 kb in length. This allele, which encodes ribonucleoprotein PTB-binding 1 protein, plays a role in the regulation of alternative splicing.","RAVER1 wt Allele | KIAA1978 | RAVER1, Mouse, Homolog of Gene | Ribonucleoprotein, PTB Binding 1 wt Allele | Ribonucleoprotein, PTB-Binding 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0238402","Pycnodysostosis","C131187","An autosomal recessive disorder caused by loss-of-function mutation(s) in the CTSK gene, encoding cathepsin K, an enzyme involved in bone resorption by osteoclasts. This condition is characterized by some or all of the following: osteosclerosis, short stature, pituitary hypoplasia with growth hormone deficiency, and cerebral demyelination.","Pycnodysostosis | ",,,,,,,,,,,,,,,"4232315","Pyknodysostosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1432943","Ribonucleoprotein PTB-Binding 1, Human","C131188","Ribonucleoprotein PTB-binding 1 (606 aa, ~64 kDa) is encoded by the human RAVER1 gene. This protein is involved in RNA binding and alternative splicing.","Ribonucleoprotein PTB-Binding 1 | Protein Raver-1 | RAVER1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425371","ZNF365 Gene","C131189","This gene may play a role in uric acid excretion and gamma-tubulin localization.","ZNF365 Gene | ZNF365 | Zinc Finger Protein 365 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513468","NKTR-214","C131019","A recombinant form of the endogenous cytokine interleukin-2 (IL-2) conjugated to six releasable polyethylene glycol (PEG) chains, with potential immunostimulating activity. Upon administration of bempegaldesleukin, the IL-2 moiety binds to the IL-2 receptor beta subunit (IL2Rb; IL2Rbeta; CD122). The binding of IL-2 to IL2Rb activates IL2Rb-mediated signaling, which activates cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells, and induces expression of certain cytotoxic cytokines, such as interferon-gamma (IFNg) and transforming growth factor-beta (TGFb). The specific induction of T-cell-mediated cytotoxic immune responses against tumor cells primarily causes tumor cell destruction. IL2Rb plays a key role in the proliferation and activation of effector T-cells. PEG conjugation prevents IL-2 binding to the IL2Ralpha subunit (IL2Ra) because signaling through IL2Ra activates CD4-positive regulatory, immunosuppressive T-cells (Tregs), which would suppress tumor cell killing.","Bempegaldesleukin | Aldesleukin Prodrug NKTR-214 | BEMPEGALDESLEUKIN | NKTR-214",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513823","Arugula Seed Powder","C131020","A dietary supplement containing an extract powder derived from the seeds of the cruciferous vegetable arugula (Eruca sativa), with potential chemopreventive and antioxidant activities. Arugula seed powder contains numerous vitamins and minerals, and is rich in phytonutrients, such as sulforaphane and indole-3-carbinol. Although the exact mechanism of action through which arugula seed powder may exert its anti-tumor effect has yet to be fully elucidated, the effects of this powder on cancer cells may be attributable to the antioxidant and pro-apoptotic activities of the phytonutrients.","Arugula Seed Powder | Eruca sativa Seed Powder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513363","TSHR Gene Mutation","C131021","A change in the nucleotide sequence of the TSHR gene.","TSHR Gene Mutation | TSH Receptor Defect | Thyroid Simulating Hormone Receptor Gene Mutation | Thyroid Stimulating Hormone Receptor Gene Mutation | Thyrotropin Receptor Defect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514211","Thyroid-Binding Globulin Deficiency","C131022","Subnormal concentration of thyroid-binding globulin.","Thyroid-Binding Globulin Deficiency | TBG Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513369","Thyroid-Binding Globulin Excess","C131023","Supranormal concentration of thyroid-binding globulin.","Thyroid-Binding Globulin Excess | TBG Excess",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1291617","Phosphoglycerate Mutase Deficiency","C131647","A rare, autosomal recessive, inherited disorder caused by mutation of the PGAM2 gene. It is characterized by non-spherocytic hemolytic anemia, exercise-induced cramping, myoglobinuria, and presence of tubular aggregates on muscle biopsy.","Phosphoglycerate Mutase Deficiency | Glycogen Storage Disease X | Muscle Phosphoglycerate Mutase Deficiency",,,,,,,,,,,,,,,"4052132","Deficiency of phosphoglycerate mutase",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514322","Plasma Kallikrein Deficiency","C131648","A coagulation disorder characterized by the partial or complete absence of plasma-type kallikrein activity in the blood.","Plasma Kallikrein Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0340969","Pyrimidine-5'-Nucleotidase Deficiency","C131649","An autosomal recessive disorder caused by mutation of the NT5C3A gene. It is the most frequent abnormality of red cell nucleotide metabolism, causing chronic, non-spherocytic hemolytic anemia. Most affected individuals have Mediterranean, Jewish, or African ancestry. Basophilic stippling and accumulation of pyrimidines within erythrocytes are hallmarks of this disorder.","Pyrimidine-5'-Nucleotidase Deficiency | ",,,,,,,,,,,,,,,"4121119","Uridine monophosphate hydrolase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1854520","Sebastian syndrome","C131650","An autosomal dominant disorder characterized by the triad of thrombocytopenia, giant platelets, and characteristic inclusions in peripheral blood leukocytes, without other organ dysfunction; it is associated with mutation of the MYH9 gene.","Sebastian Syndrome | Sebastian Platelet Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514344","Tissue Kallikrein Deficiency","C131651","A disorder characterized by the partial or complete absence of tissue-type kallikrein activity in the tissues and glandular secretions where it is normally present.","Tissue Kallikrein Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824726","CEP350 Gene","C131272","This gene is involved in anchoring microtubules to the centrosome.","CEP350 Gene | CEP350 | Centrosomal Protein 350 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514561","CEP350 wt Allele","C131273","Human CEP350 wild-type allele is located in the vicinity of 1q25.2 and is approximately 160 kb in length. This allele, which encodes centrosome-associated protein 350, plays a role in centriole assembly.","CEP350 wt Allele | CAP350 | Centrosomal Protein 350 wt Allele | Centrosomal Protein 350kDa Gene | Centrosome-Associated Protein, 350-kDa Gene | GM133 | KIAA0480",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1701727","CEP350 protein, human","C131274","Centrosome-associated protein 350 (3117 aa, ~351 kDa) is encoded by the human CEP350 gene. This protein is involved in centriole growth.","Centrosome-Associated Protein 350 | Centrosomal Protein 350 | Centrosomal Protein of 350 kDa | Centrosome Associated Protein 350 | Centrosome-Associated Protein of 350 kDa | Cep350",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4273673","Peripheral Resistance to Thyroid Hormone","C131275","Decreased response to thyroid hormones in peripheral tissues, with normal response in the pituitary gland.","Peripheral Resistance to Thyroid Hormone | PRTH",,,,,,,,,,,,,,,"37397534","Peripheral resistance to thyroid hormone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1540083","TSPAN3 Gene","C131276","This gene plays a role in receptor signaling pathways.","TSPAN3 Gene | TSPAN3 | Tetraspanin 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514321","Perinatal-Stress Induced Hyperinsulinism","C131277","Transient hyperinsulinism that occurs in response to neonatal stress resulting in prolonged neonatal hypoglycemia, which is distinct from transitional hypoglycemia of typical infants.","Perinatal-Stress Induced Hyperinsulinism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514332","TSPAN3 wt Allele","C131278","Human TSPAN3 wild-type allele is located in the vicinity of 15q24.3 and is approximately 43 kb in length. This allele, which encodes tetraspanin-3 protein, is involved in signal transduction.","TSPAN3 wt Allele | TM4-A | TM4SF8 | TSPAN-3 | Tetraspanin 3 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4276912","Tspan3 protein, human","C131279","Tetraspanin-3 (253 aa, ~28 kDa) is encoded by the human TSPAN3 gene. This protein plays a role in the modulation of signal transduction.","Tetraspanin-3 | TSPAN-3 | Tetraspan 3 | Tetraspan TM4SF8 | Tetraspanin TM4-A | Transmembrane 4 Superfamily Member 8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521623","7p15-p14","C13127","A chromosome band present on 7p","7p15-p14 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414609","FGL2 Gene","C131280","This gene may be involved in memory T-cell function.","FGL2 Gene | FGL2 | Fibrinogen Like 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514454","FGL2 wt Allele","C131281","Human FGL2 wild-type allele is located in the vicinity of 7q11.23 and is approximately 6 kb in length. This allele, which encodes fibroleukin protein, may play a role in the activity of memory T-cells.","FGL2 wt Allele | Fibrinogen Like 2 wt Allele | Fibrinogen-Like 2 Gene | T49 | pT49",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1451210","FGL2 protein, human","C131282","Fibroleukin (439 aa, ~50 kDa) is encoded by the human FGL2 gene. This protein may be involved in memory T-cell functionality.","Fibroleukin | Fibrinogen-Like Protein 2 | pT49",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514262","Battlefield Acupuncture","C131283","A form of acupuncture that uses needles placed in the ear as a protocol for pain management.","Battlefield Acupuncture | BFA | Battle Field Acupuncture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424058","TRPC4AP Gene","C131284","This gene may play a role in the regulation of both ion channels and ubiquitination.","TRPC4AP Gene | TRPC4AP | Transient Receptor Potential Cation Channel Subfamily C Member 4 Associated Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514331","TRPC4AP wt Allele","C131285","Human TRPC4AP wild-type allele is located in the vicinity of 20q11.22 and is approximately 90 kb in length. This allele, which encodes short transient receptor potential channel 4-associated protein, may be involved in the modulation of both protein ubiquitination and ion transport.","TRPC4AP wt Allele | C20orf188 | Chromosome 20 Open Reading Frame 188 Gene | DKFZP727M231 | DKFZp586C1223 | PPP1R158 | Protein Phosphatase 1, Regulatory Subunit 158 Gene | TRRP4AP | TRUSS | Transient Receptor Potential Cation Channel, Subfamily C, Member 4 Associated Protein Gene | Transient Receptor Potential Cation Channel, Subfamily C, Member 4 Associated Protein wt Allele | dJ756N5.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521748","Small Intestine Cancer Clinical Distant Metastasis TNM Finding v8","C133827","A clinical finding about one or more characteristics of small intestine cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Small Intestine Cancer Clinical Distant Metastasis TNM Finding v8 | Small Intestine Carcinoma Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521749","Small Intestine Cancer cM0 TNM Finding v8","C133828","Small intestine cancer without evidence of distant metastasis. (from AJCC 8th Ed.)","Small Intestine Cancer cM0 TNM Finding v8 | Small Intestine Carcinoma cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521750","Small Intestine Cancer cM1 TNM Finding v8","C133829","Small intestine cancer with distant metastasis. (from AJCC 8th Ed.)","Small Intestine Cancer cM1 TNM Finding v8 | Small Intestine Carcinoma cM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521751","Small Intestine Cancer Pathologic TNM Finding v8","C133830","A pathologic finding about one or more characteristics of small intestine cancer, following the rules of the TNM AJCC v8 classification system.","Small Intestine Cancer Pathologic TNM Finding v8 | Small Intestine Carcinoma Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521752","Small Intestine Cancer Pathologic Distant Metastasis TNM Finding v8","C133831","A pathologic finding about one or more characteristics of small intestine cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Small Intestine Cancer Pathologic Distant Metastasis TNM Finding v8 | Small Intestine Carcinoma Pathologic Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521753","Small Intestine Cancer pM1 TNM Finding v8","C133832","Small intestine cancer with distant metastasis. (from AJCC 8th Ed.)","Small Intestine Cancer pM1 TNM Finding v8 | Small Intestine Carcinoma pM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521754","Small Intestine Cancer Pathologic Primary Tumor TNM Finding v8","C133833","A pathologic finding about one or more characteristics of small intestine cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Small Intestine Cancer Pathologic Primary Tumor TNM Finding v8 | Small Intestine Carcinoma Pathologic Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521755","Small Intestine Cancer pTX TNM Finding v8","C133834","Small intestine cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Small Intestine Cancer pTX TNM Finding v8 | Small Intestine Carcinoma pTX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521756","Small Intestine Cancer pT0 TNM Finding v8","C133835","Small intestine cancer with no evidence of primary tumor. (from AJCC 8th Ed.)","Small Intestine Cancer pT0 TNM Finding v8 | Small Intestine Carcinoma pT0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412533","ARIH1 Gene","C134183","This gene is involved in the ubiquitination of protein substrates.","ARIH1 Gene | ARIH1 | Ariadne RBR E3 Ubiquitin Protein Ligase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520554","13q33","C13137","A chromosome band present on 13q","13q33 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520689","16p13.3-p13.11","C13138","A chromosome band present on 16p","16p13.3-p13.11 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1860808","Triosephosphate Isomerase Deficiency","C131652","An autosomal recessive condition caused by mutation(s) in the TPI1 gene, encoding triosephosphate isomerase. It is characterized by congenital hemolytic anemia and progressive neuromuscular dysfunction.","Triosephosphate Isomerase Deficiency | TP1 Deficiency | Triosephosphate-Isomerase Deficiency",,,,,,,,,,,,,,,"4125631","Triose phosphate isomerase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2584778","Acquired Thrombotic Thrombocytopenic Purpura","C131653","Thrombotic thrombocytopenic purpura for which the cause is not present at birth.","Acquired Thrombotic Thrombocytopenic Purpura | Acquired ADAMTS13 Deficiency | Acquired TTP",,,,,,,,,,,,,,,"4204900","Acquired thrombotic thrombocytopenic purpura",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514235","Alpha-Beta T-Cell Depletion","C131654","Restriction of the T-cell population in stem cell transplants to those expressing only the gamma-delta receptor. Alpha-beta receptors are expressed on the majority of peripheral blood T-cells and are the primary mediators of graft versus host disease.","Alpha-Beta T-Cell Depletion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514239","Anemia due to Increased Destruction","C131656","Anemia that results from an increased rate of erythrocyte destruction.","Anemia due to Increased Destruction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL496074","Congenital Thrombotic Thrombocytopenic Purpura","C131657","Thrombotic thrombocytopenic purpura for which the cause is present from birth.","Congenital Thrombotic Thrombocytopenic Purpura | Congenital ADAMTS-13 Deficiency | Congenital ADAMTS13 Deficiency | Congenital TTP",,,,,,,,,,,,,,,"4159966","Upshaw-Schulman syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514278","Consumptive Coagulopathy","C131658","Disorders of coagulation caused by the depletion of coagulation factors in the peripheral blood.","Consumptive Coagulopathy | Consumption Coagulopathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1260903","Dysfibrinogenemia","C131659","A coagulation disorder caused by abnormalities in fibrin that result in defective clot formation. This disorder may be inherited or acquired.","Dysfibrinogenemia | ",,,,,,,,,,,,,,,"4006470","Dysfibrinogenemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514500","Factor I Inactivation","C131660","Presence of inactivating antibodies to fibrinogen (factor I) in the blood.","Factor I Inactivation | Factor I Inhibitor Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514501","Factor II Inactivation","C131661","Presence of inactivating antibodies to prothrombin (factor II) in the blood.","Factor II Inactivation | Factor II Inhibitor Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514502","Factor III Inactivation","C131662","Presence of inactivating antibodies to tissue factor (factor III) in the blood.","Factor III Inactivation | Factor III Inhibitor Present | Tissue Factor Inhibitor Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514505","Factor V Inactivation","C131664","Presence of inactivating antibodies to factor V in the blood.","Factor V Inactivation | Factor V Inhibitor Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514506","Factor VII Inactivation","C131665","Presence of inactivating antibodies to factor VII in the blood.","Factor VII Inactivation | Factor VII Inhibitor Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514452","STAG1 wt Allele","C131226","Human STAG1 wild-type allele is located in the vicinity of 3q22.3 and is approximately 416 kb in length. This allele, which encodes cohesin subunit SA-1 protein, is involved in sister chromatid cohesion.","STAG1 wt Allele | SA-1 | SA1 | SCC3A | Stromal Antigen 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1308265","STAG1 protein, human","C131228","Cohesin subunit SA-1 (1258 aa, ~144 kDa) is encoded by the human STAG1 gene. This protein plays a role in the cohesion of sister chromatids.","Cohesin Subunit SA-1 | Nuclear Protein Stromal Antigen 1 | SCC3 Homolog 1 | STAG1 | Stromal Antigen 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2934853","TRPC4AP protein, human","C131286","Short transient receptor potential channel 4-associated protein (797 aa, ~91 kDa) is encoded by the human TRPC4AP gene. This protein may play a role in both ion channel-dependent transport and protein ubiquitination.","Short Transient Receptor Potential Channel 4-Associated Protein | Protein TAP1 | Protein TRUSS | Short Transient Receptor Potential Channel 4 Associated Protein | TNF-Receptor Ubiquitous Scaffolding/Signaling Protein | TNFR1-Associated Ubiquitous Scaffolding and Signaling Protein | Transient Receptor Potential Channel 4-Associated Protein | Trp4-Associated Protein | Trpc4-Associated Protein | Tumor Necrosis Factor Receptor-Associated Ubiquitous Scaffolding and Signaling Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517881","Light Cell","C13148","A cell located in the collecting tube of the nephron..","Light Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521960","ARIH1 wt Allele","C134184","Human ARIH1 wild-type allele is located in the vicinity of 15q24.1 and is approximately 129 kb in length. This allele, which encodes E3 ubiquitin-protein ligase ARIH1 protein, plays a role in the modulation of ubiquitination.","ARIH1 wt Allele | ARI | Ariadne (Drosophila) Homolog, Ubiquitin-Conjugating Enzyme E2-Binding Protein, 1 Gene | Ariadne Homolog, Ubiquitin-Conjugating Enzyme E2 Binding Protein, 1 (Drosophila) Gene | Ariadne Homolog, Ubiquitin-Conjugating Enzyme E2 Binding Protein, 1 Gene | Ariadne RBR E3 Ubiquitin Protein Ligase 1 wt Allele | Ariadne, Drosophila, Homolog Of Gene | Ariadne, Drosophila, Homolog Of, 1 Gene | HARI | HHARI | HUSSY-27 | MOP6 | UBCH7BP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521965","E3 Ubiquitin-Protein Ligase ARIH1","C134189","E3 ubiquitin-protein ligase ARIH1 (557 aa, ~64 kDa) is encoded by the human ARIH1 gene. This protein is involved in protein ubiquitination.","E3 Ubiquitin-Protein Ligase ARIH1 | ARI-1 | EC 2.3.2.31 | H7-AP2 | MOP-6 | Monocyte Protein 6 | Protein Ariadne-1 Homolog | UbcH7-Binding Protein | UbcM4-Interacting Protein | Ubiquitin-Conjugating Enzyme E2-Binding Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512339","Head and Neck Fluids and Secretions","C13418","Secretions and fluids from the area of the body generally construed to comprise base of skull and facial bones, sinuses, orbits, salivary glands, oral cavity, oropharynx, larynx, thyroid, facial and neck musculature and lymph nodes draining these areas.","Head and Neck Fluids and Secretions | Head and Neck, Fluids, Secretions | Head and Neck-Fluids, Secretions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522129","Mouse Basal Cell Carcinoma","C134570","Basal Cell carcinoma that occurs in a mouse.","Mouse Basal Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522130","Medaka Hepatoma","C134571","Hepatoma that occurs in Oryzias latipes.","Medaka Hepatoma | Oryzias latipes Hepatoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522131","Medaka Melanoma","C134572","Melanoma that occurs in Oryzias latipes.","Medaka Melanoma | Oryzias latipes Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522132","Rainbow Trout Hepatoma","C134573","Hepatoma that occurs in Oncorhynchus mykiss.","Rainbow Trout Hepatoma | Oncorhynchus mykiss Hepatoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1832431","10p13-p14 Deletion Syndrome","C130982","A congenital condition caused by a deletion on the short arm of chromosome 10p13-p14. The NEBL gene, encoding nebulette, a heart-specific component of the sarcomere, may be responsible for the clinical findings. The condition is characterized by immunodeficiency, unusual facies, congenital heart anomalies (tetralogy of Fallot, pulmonary atresia with ventricular septal defect, truncus arteriosus, interrupted aortic arch, isolated anomalies of the aortic arch, and ventricular septal defect), hypoparathyroidism, and increased susceptibility to infections.","10p13-p14 Deletion Syndrome | DGS2 | DiGeorge Syndrome Type 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1840333","Barakat Syndrome","C130983","A condition characterized by hypoparathyroidism, sensorineural deafness, and renal failure. It is related to autosomal dominant inactivating mutation(s) in GATA3, encoding a transcription factor important for the embryonic development of the parathyroid gland, the auditory stem, and the kidneys.","Barakat Syndrome | Hypoparathyroidism, Deafness, and Renal Anomalies Syndrome",,,,,,,,,,,,,,,"37119067","Hypoparathyroidism, deafness, renal disease syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1862178","Cole-Carpenter Syndrome","C130985","Bone dysplasia due to autosomal dominant mutation(s) in the P4HB gene, encoding prolyl 4-hydroxylase subunit beta, or autosomal recessive mutation(s) in the SEC24D gene, encoding SEC24 homolog D, COPII coat complex component. This condition is characterized by bone fragility, growth failure, craniosynostosis, hydrocephalus, and distinctive facial features, including marked frontal bossing, blue sclerae, ocular proptosis, midface hypoplasia, and micrognathia.","Cole-Carpenter Syndrome | ",,,,,,,,,,,,,,,"4305428","Cole-Carpenter dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL496025","Distal 18q Deletion Syndrome","C130986","A contiguous gene deletion syndrome involving deletion of the distal portion of the long arm of chromosome 18. The clinically heterogenous condition is characterized by some or all of the following: growth hormone deficiency with resulting short stature; hand, foot, skull, facial, and genital anomalies; hypotonia; and developmental delay.","Distal 18q Deletion Syndrome | ",,,,,,,,,,,,,,,"35622930","Distal chromosome 18q deletion syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1846009","IMAGe Syndrome","C130988","A condition caused by heterozygous mutation(s) in the CDKN1C gene, encoding cyclin-dependent kinase inhibitor 1C, and characterized by intrauterine growth restriction, metaphyseal dysplasia, congenital adrenal hypoplasia, and genital anomalies.","IMAGe Syndrome | ",,,,,,,,,,,,,,,"45765446","Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3550963","Immunoglobulin Superfamily Member 1 Deficiency Syndrome","C130989","An X-linked recessive syndrome caused by loss-of-function mutation(s) in IGSF1, encoding immunoglobulin superfamily member 1. This condition can result in central hypothyroidism, macroorchidism, delayed puberty, and variable prolactin deficiency.","Immunoglobulin Superfamily Member 1 Deficiency Syndrome | Hypothyroidism Central and Testicular Enlargement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514175","Insulin Receptor Mutation - Associated Insulin Resistance Syndromes","C130990","Insulin resistance caused by inactivating mutation(s) in the INSR gene encoding the insulin receptor.","Insulin Receptor Mutation - Associated Insulin Resistance Syndromes | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0265291","Kenny-Caffey Syndrome","C130991","A genetic condition characterized by long bone sclerosis and thickening, short stature, and head and eye anomalies. Many affected individuals have hypoparathyroidism with hypocalcemia.","Kenny-Caffey Syndrome | ",,,,,,,,,,,,,,,"4221110","Kenny syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0229650","Megakaryoblast","C13122","The precursor of a megakaryocyte.","Megakaryoblast | Megacaryoblast",,,,,,,,,,,,,,,"4101236","Megakaryoblast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1425030","PITRM1 Gene","C131237","This gene is involved in mitochondrial peptide degradation.","PITRM1 Gene | PITRM1 | Pitrilysin Metallopeptidase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514426","PITRM1 wt Allele","C131238","Human PITRM1 wild-type allele is located in the vicinity of 10p15.2 and is approximately 35 kb in length. This allele, which encodes presequence protease, mitochondrial protein, plays a role in peptide degradation.","PITRM1 wt Allele | KIAA1104 | MP1 | Metalloprotease 1 (Pitrilysin Family) Gene | Pitrilysin Metallopeptidase 1 wt Allele | PreP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3280934","Hypophosphatemic Rickets","C131449","Rickets due to low serum phosphate concentrations, the cause of which can be nutritional or genetic. This condition is characterized by normal parathyroid hormone concentrations, usually caused by renal phosphate wasting occurring in isolation or as part of a renal tubular disorder, and characterized by resistance to treatment with ultraviolet radiation or vitamin D.","Hypophosphatemic Rickets | Phosphopenic Rickets",,,,,,,,,,,,,,,"4282303","Phosphopenic type rickets",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448493","Alveolar Cell Type I","C13144","A squamous cell that forms the inner lining of the alveoli and is distinguished by its greatly attenuated cytoplasm and paucity of organelles.","Alveolar Cell Type I | Squamous Alveolar Lining Cell | Type I Pneumocyte",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521299","Vitamin D Dependent Rickets 2b","C131076","Rickets caused by a post-receptor defect in the vitamin D signaling pathway producing vitamin D resistance due to constitutive overexpression of a nuclear ribonucleoprotein that competes with the vitamin D receptor-retinoid X receptor dimer binding with DNA vitamin D response elements. This condition has a similar phenotype to vitamin D receptor deficiency rickets including elevated 1,25-dihydroxyvitamin D (calcitriol) concentrations.","Vitamin D Dependent Rickets 2b | Hereditary 1,25 Dihydroxyvitamin D-Resistant Rickets with Abnormal Vitamin D Receptor without Alopecia | Vitamin D Receptor Signaling Defect Rickets | Vitamin D Resistant Rickets",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514185","Vitamin D Dependent Rickets 2","C131077","An autosomal recessive form of rickets caused by mutation(s) in the VDR gene, encoding the vitamin D receptor. The condition is characterized by hypocalcemia, increased concentrations of calcitriol, secondary hyperparathyroidism, early-onset rickets and alopecia.","Vitamin D Dependent Rickets 2 | Hereditary 1,25 Dihydroxyvitamin D-resistant Rickets with Abnormal Vitamin D Receptor | VDDR2 | Vitamin D Receptor Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514194","Wolff-Chaikoff Phenomenon","C131078","Hypothyroidism induced by excessive levels of iodine in the blood.","Wolff-Chaikoff Phenomenon | Wolff-Chaikoff | Wolff-Chaikoff Syndrome/Phenomenon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342344","X-Linked Hypoparathyroidism","C131079","Hypoparathyroidism in which the inheritance is recessive and linked to the q26-q27 region of the X chromosome. The parathyroid glands are usually incompletely developed (parathyroid dysgenesis) or absent (parathyroid agenesis).","X-Linked Hypoparathyroidism | X-linked Hypoparathyroidism",,,,,,,,,,,,,,,"4029431","X-linked hypoparathyroidism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1183855","Wall of Prostatic Duct","C13107","A layer of epithelium comprising both columnar and small cuboidal cells.","Wall of Prostatic Duct | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513367","Testicular Failure","C131080","The failure of testicular hormone production and spermatogenesis.","Testicular Failure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514002","Steroidogenic Acute Regulatory Protein Deficiency","C131081","Congenital lipoid adrenal hyperplasia (CLAH) due to loss-of-function mutations in the STAR gene, resulting in decreased or absent production of steroidogenic acute regulatory protein (StAR), which leads to deficient transport of cholesterol from the outer to the inner mitochondrial membrane.","Steroidogenic Acute Regulatory Protein Deficiency | StAR Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514198","11-Beta-Hydroxysteroid Dehydrogenase Type 1 Deficiency","C131084","Decreased activity of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 due to inactivating mutation(s) in the HSD11B1 gene. The condition is characterized by hyperandrogenism as a result of increased adrenocorticotropic hormone stimulation of the adrenal gland due to failure of cortisol-mediated down-regulation, and is clinically indistinguishable from H6PD deficiency.","11-Beta-Hydroxysteroid Dehydrogenase Type 1 Deficiency | Cortisone Reductase Deficiency Type 2",,,,,,,,,,,,,,,"37204799","Hyperandrogenism due to cortisone reductase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268292","11-Beta-Hydroxylase Deficiency","C131085","Decreased or absent activity of the enzyme 11-beta-hydroxylase caused by loss-of-function mutations in the CYP11B1 gene, resulting in congenital adrenal hyperplasia. Clinical manifestations of this condition include virilization in 46XX infants and hypertension.","11-Beta-Hydroxylase Deficiency | ",,,,,,,,,,,,,,,"4051374","Deficiency of steroid 11-beta-monooxygenase",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL522133","Xenopus Neoplasm","C134574","A neoplasm that occurs in Xenopus.","Xenopus Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522134","Xiphophorus Melanoma","C134575","Melanoma that occurs in Xiphophorus.","Xiphophorus Melanoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522135","Non-Human or Experimental Organism Neoplasm","C134576","A neoplastic condition occurring in a non-human organism; this includes neoplasms occurring in organisms used in research settings.","Non-Human or Experimental Organism Neoplasm | Experimental Organism Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522137","Intrahepatic Bile Duct Cancer Clinical TNM Finding v8","C134578","A clinical finding about one or more characteristics of intrahepatic bile duct cancer, following the rules of the TNM AJCC v8 classification system.","Intrahepatic Bile Duct Cancer Clinical TNM Finding v8 | Intrahepatic Bile Duct Carcinoma Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522138","Intrahepatic Bile Duct Cancer Clinical Distant Metastasis TNM Finding v8","C134579","A clinical finding about one or more characteristics of intrahepatic bile duct cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Intrahepatic Bile Duct Cancer Clinical Distant Metastasis TNM Finding v8 | Intrahepatic Bile Duct Cancer Clinical Distant Metastasis (cM) | Intrahepatic Bile Duct Carcinoma Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511625","Cytoplasmic Domain","C13457","The part of a transmembrane protein which projects into the cytoplasm.","Cytoplasmic Domain | Cytoplasmic Tail | Cytosolic Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522141","Intrahepatic Bile Duct Cancer Pathologic TNM Finding v8","C134582","A pathologic finding about one or more characteristics of intrahepatic bile duct cancer, following the rules of the TNM AJCC v8 classification system.","Intrahepatic Bile Duct Cancer Pathologic TNM Finding v8 | Intrahepatic Bile Duct Carcinoma Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522142","Intrahepatic Bile Duct Cancer Pathologic Distant Metastasis TNM Finding v8","C134584","A pathologic finding about one or more characteristics of intrahepatic bile duct cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Intrahepatic Bile Duct Cancer Pathologic Distant Metastasis TNM Finding v8 | Intrahepatic Bile Duct Cancer Pathologic Distant Metastasis (pM) | Intrahepatic Bile Duct Carcinoma Pathologic Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412318","AKAP6 Gene","C134587","This gene is involved in the regulation of protein kinase A-dependent signaling.","AKAP6 Gene | A-Kinase Anchoring Protein 6 Gene | AKAP6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1855648","KENNY-CAFFEY SYNDROME, TYPE 1","C130992","An autosomal recessive form of Kenny-Caffey syndrome due to mutation(s) in the TBCE gene, encoding tubulin-specific chaperone E. This condition is characterized by hypoparathyroidism with hypocalcemia, marked growth retardation, craniofacial anomalies, absent diploic space in the skull, cortical thickening of long bones with medullary stenosis, and small hands and feet.","Kenny-Caffey Syndrome Type 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514524","Lateral Ventricle Ependymal Tumor","C131594","A finding indicating the presence of an ependymal tumor in a lateral ventricle of the brain.","Lateral Ventricle Ependymal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514338","Third Ventricle Ependymal Tumor","C131595","A finding indicating the presence of an ependymal tumor in the third ventricle of the brain.","Third Ventricle Ependymal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514292","Fourth Ventricle and Brain Stem Ependymal Tumor","C131596","A finding indicating the presence of an ependymal tumor in the fourth ventricle and the brain stem.","Fourth Ventricle and Brain Stem Ependymal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514265","Cerebellar and Fourth Ventricle Ependymal Tumor","C131597","A finding indicating the presence of an  ependymal tumor in the cerebellum and fourth ventricle.","Cerebellar and Fourth Ventricle Ependymal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514336","Temporal Lobe, Parietal Lobe, and Lateral Ventricle Ependymal Tumor","C131598","A finding indicating the presence of an ependymal tumor in the temporal and parietal lobes, and a lateral ventricle of the brain.","Temporal Lobe, Parietal Lobe, and Lateral Ventricle Ependymal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426380","SRGAP2 Gene","C131599","This gene is involved in remodeling of the actin cytoskeleton.","SRGAP2 Gene | SLIT-ROBO Rho GTPase Activating Protein 2 Gene | SRGAP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0227651","Mesangial Cell","C13159","Cell found within the glomerular lobules of mammalian kidney. Mesangial cells serve as structural supports, may regulate blood flow, are phagocytic and may act as accessory cells, presenting antigen in immune responses.","Mesangial Cell | ",,,,,,,,,,,,,,,"4087095","Mesangial cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514680","SRGAP2 wt Allele","C131600","Human SRGAP2 wild-type allele is located in the vicinity of 1q32.1 and is approximately 261 kb in length. This allele, which encodes SLIT-ROBO Rho GTPase-activating protein 2, plays a role in cytoskeletal remodeling in cell differentiation, cell migration and neuronal morphogenesis.","SRGAP2 wt Allele | ARHGAP34 | FNBP2 | KIAA0456 | SLIT-ROBO GAP 2 | SLIT-ROBO GTPase Activating Protein 2, Rho, 2 Gene | SLIT-ROBO Rho GTPase Activating Protein 2 wt Allele | SRGAP2A | SRGAP3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514269","Cervical Spinal Cord Ependymal Tumor","C131601","A finding indicating the presence of an ependymal tumor in the cervical region of spinal cord.","Cervical Spinal Cord Ependymal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1454788","SRGAP2 protein, human","C131602","SLIT-ROBO Rho GTPase-activating protein 2 (1071 aa, ~121 kDa) is encoded by the human SRGAP2 gene. This protein is involved in cell differentiation, cell migration and neuronal morphogenesis.","SLIT-ROBO Rho GTPase-Activating Protein 2 | Formin Binding Protein 2 | Formin-Binding Protein 2 | Rho GTPase-Activating Protein 34 | srGAP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514339","Thoracic Spinal Cord Ependymal Tumor","C131603","A finding indicating the presence of an ependymal tumor in the thoracic region of spinal cord.","Thoracic Spinal Cord Ependymal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514271","Cervical and Thoracic Spinal Cord Ependymal Tumor","C131605","A finding indicating the presence of an ependymal tumor in the cervical and thoracic regions of spinal cord.","Cervical and Thoracic Spinal Cord Ependymal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514340","Thoracic and Lumbosacral Spinal Cord Ependymal Tumor","C131606","A finding indicating the presence of an ependymal tumor in the thoracic and lumbosacral regions of spinal cord.","Thoracic and Lumbosacral Spinal Cord Ependymal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1853271","Hereditary Hypophosphatemic Rickets with Hypercalciuria","C131450","An autosomal recessive form of hypophosphatemic rickets caused by inactivating mutation(s) in the SLC34A3 gene, encoding sodium-dependent phosphate transport protein 2C, a protein involved in maintenance of inorganic phosphate concentration in the kidney. The condition is characterized by elevated 1,25-dihydroxyvitamin D (calcitriol) concentrations, resulting in increased intestinal calcium absorption and hypercalciuria. This form of hypophosphatemic rickets is also distinguished by the lack of elevated fibroblast growth factor 23 (FGF23) concentrations.","Hereditary Hypophosphatemic Rickets with Hypercalciuria | HHRH | Hypercalciuric Hypophosphatemic Rickets | Hypophosphatemic Hypercalciuric Rickets",,,,,,,,,,,,,,,"37111357","Hereditary hypophosphatemic rickets with hypercalciuria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1836621","GLUCOCORTICOID DEFICIENCY 3 (disorder)","C131451","A variant of familial glucocorticoid deficiency caused by a defect in the steroidogenic acute regulatory protein; it may mimic lipoid congenital adrenal hyperplasia.","Familial Glucocorticoid Deficiency Type 3 | GCCD3 | Non-classic CLAH (FGD variant)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3553587","Familial Glucocorticoid Deficiency Type 4","C131452","Familial glucocorticoid deficiency caused by mutation(s) in the NNT gene encoding nicotinamide nucleotide transhydrogenase.","Familial Glucocorticoid Deficiency Type 4 | GCCD4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516943","Epithelial Receptor Cell","C13145","A cell on the surface of the body or lining a body cavity that responds to physical and chemical stimuli by sending information to the central nervous system.","Epithelial Receptor Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514199","17-Alpha-Hydroxylase/17,20 Lyase Deficiency","C131086","Decreased or absent activity of the enzyme 17-alpha-hydroxylase/17,20 lyase due to loss-of-function mutation(s) in the CYP17A1 gene. The clinical manifestations of the deficiency are dependent on whether one or both activities of the enzyme are affected, and may include hypertension due to reduced 17-hydroxylase activity and incomplete genital masculinization in 46,XY infants due to reduced 17,20 lyase activity.","17-Alpha-Hydroxylase/17,20 Lyase Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0852654","21-Hydroxylase Deficiency","C131087","A classic form of congenital adrenal hyperplasia that is characterized by severe 21-hydroxylase deficiency, resulting in glucocorticoid and mineralocorticoid deficiency, without clinically significant salt wasting, and androgen excess, which causes virilization in female infants.","21-Hydroxylase Deficiency | 21-OHD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2931782","Adrenal hyperplasia 2","C131088","Congenital adrenal hyperplasia due to presumed mutation(s) in the HSD3B2 gene, which results in decreased activity of the enzyme 3-beta-hydroxysteroid dehydrogenase. The clinical manifestations of the deficiency are dependent on the degree of reduction in enzymatic activity: 46,XY infants may have incomplete development of the genitalia, while 46,XX infants may have virilization.","3-Beta-Hydroxysteroid Dehydrogenase Deficiency | 3-beta HSD Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0271693","Acquired Generalized Lipodystrophy","C131089","Generalized lipodystrophy, the cause of which is not present at birth.","Acquired Generalized Lipodystrophy | ",,,,,,,,,,,,,,,"4336665","Acquired generalized lipodystrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514313","Manufactures Human Over-the-Counter Drug Products Neither Produced Under an Approved Application nor Under a Monograph","C131710","The process of manufacturing non-prescription medications under neither a monograph nor an approved drug application, for humans by a pharmaceutical company.","Manufactures Human Over-the-Counter Drug Products Neither Produced Under an Approved Application nor Under a Monograph | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205831","Meissner Corpuscle","C13171","One of numerous oval bodies found in the papillae of the skin, especially those of the fingers and toes; they consist of a connective tissue capsule in which the axon fibrils terminate around and between a pile of wedge-shaped epithelioid cells. SYN corpusculum tactus, oval corpuscle, touch corpuscle.","Meissner Corpuscle | Corpusculum Tactus | Meissner's Corpuscle | Oval Corpuscle | Tactile Corpuscle | Touch Corpuscle",,,,,,,,,,,,,,,"4190239","Meissner's corpuscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL520474","Pathologic Stage I Gastric Cancer AJCC v8","C133655","Stage I includes: IA: (T1, N0, M0); IB: (T1, N1, M0); (T2, N0, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Pathologic Stage I Gastric Cancer AJCC v8 | Pathologic Stage I Gastric Carcinoma AJCC v8 | Stage I Gastric (Stomach) Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520477","Pathologic Stage II Gastric Cancer AJCC v8","C133659","Stage II includes: IIA: (T1, N2, M0); (T2, N1, M0); (T3, N0, M0); IIB: (T1, N3a, M0); (T2, N2, M0); (T3, N1, M0); (T4a, N0, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. T4a: Tumor invades the serosa (visceral peritoneum). N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3a: Tumor with metastasis in seven to fifteen regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Pathologic Stage II Gastric Cancer AJCC v8 | Pathologic Stage II Gastric Carcinoma AJCC v8 | Stage II Gastric (Stomach) Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0597729","Spindle Pole Body","C13365","The spindle pole body (SPB) is the microtubule organizing center (MTOC) in the yeast Saccharomyces that plays a pivotal role in such diverse processes as mitosis, budding, and mating. (from Cell. 1997;89:1077-86)","Spindle Pole Body | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519814","DLX1 wt Allele","C133661","Human DLX1 wild-type allele is located in the vicinity of 2q31.1 and is approximately 5 kb in length. This allele, which encodes homeobox protein DLX-1, may play a role in brain and facial morphogenesis.","DLX1 wt Allele | Distal-Less Homeo Box 1 Gene | Distal-Less Homeobox 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521758","Small Intestine Cancer pT1 TNM Finding v8","C133837","Small intestine cancer with tumor invading the lamina propria or submucosa. (from AJCC 8th Ed.)","Small Intestine Cancer pT1 TNM Finding v8 | Small Intestine Carcinoma pT1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514482","Albumin-binding Cisplatin Prodrug BTP-114","C131607","A proprietary, albumin-binding platinum (Pt)-based complex containing a prodrug form of the platinum compound cisplatin and a maleimide moiety, with an ability to strongly and selectively bind human serum albumin (HSA), and with potential antineoplastic activity.  Upon intravenous administration, the maleimide group of BTP-114 rapidly conjugates with HSA in the bloodstream; this prolongs the blood circulation, enhances the half-life, and alters the biodistribution of BTP-114, as compared to cisplatin alone. Thus, BTP-114 demonstrates enhanced extravasation to the tumor, an increased accumulation in the tumor tissue and enhanced uptake by cancer cells. The prodrug form is reduced in the hypoxic tumor cell environment, which releases the highly cytotoxic active metabolite cisplatin. Once inside the tumor cell, cisplatin binds to nucleophilic groups, such as GC-rich sites, in DNA and induces intrastrand and interstrand DNA cross-links, resulting in apoptosis and cell growth inhibition. Compared to cisplatin alone, BTP-114 has improved selectivity towards tumor tissue, thereby enhancing efficacy while reducing systemic toxicities.","Albumin-binding Cisplatin Prodrug BTP-114 | Albumin-conjugating Platinum-prodrug BTP-114 | BTP 114 | BTP-114 | Cisplatin Prodrug BTP-114 | Cisplatin/Maleimide-based Complex BTP-114 | Platinum-Prodrug BTP-114 | Prodrug BTP 114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1440938","Immature Lymphocyte","C13118","A cell that develops from hematopoietic stem cells. An immature lymphocyte represents of one of five stages of lymphocyte maturation. It is estimated 90% of immature lymphocytes die in the thymus and bone marrow.","Immature Lymphocyte | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513499","ZNF365 wt Allele","C131190","Human ZNF365 wild-type allele is located in the vicinity of 10q21.2 and is approximately 298 kb in length. This allele, which encodes both protein ZNF365 and talanin protein, may be involved in gamma-tubulin localization and uric acid secretion. Mutation of the gene is associated with increased susceptibility to uric acid nephrolithiasis.","ZNF365 wt Allele | KIAA0844 | Su48 | TALN | UAN | ZNF365A | ZNF365B | ZNF365C | ZNF365D | Zinc Finger Protein 365 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514195","ZNF365 Gene Product","C131191","A protein encoded by the ZNF365 gene.","ZNF365 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1529112","Talanin, Human","C131192","Talanin (216 aa, ~24 kDa) is encoded by the human ZNF365 gene. This protein may play a role in the excretion of uric acid and the localization of gamma-tubulin.","Talanin | ZNF365D | Zinc Finger Protein 365 Isoform 4 | Zinc Finger Protein 365 Isoform D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0334041","Progressive Heterotopic Heteroplasia","C131193","Loss of function mutation(s) in the paternal allele of the GNAS gene, encoding guanine nucleotide-binding protein G(s) subunit alpha isoforms short resulting in dermal ossification beginning in infancy, followed by increasing and extensive heterotopic bone formation in deep muscle and fascia.","Progressive Heterotopic Heteroplasia | Osteoma Cutis | Progressive Osseous Heteroplasia",,,,,,,,,,,,,,,"36714156","Progressive osseous heteroplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1529113","Zinc Finger Protein 365 Isoform A, Human","C131194","Protein ZNF365 (407 aa, ~47 kDa) is encoded by the human ZNF365 gene. This protein may be involved in the localization of gamma-tubulin.","Protein ZNF365 | Protein Su48 | ZNF365A | Zinc Finger Protein 365 | Zinc Finger Protein 365 Isoform 1 | Zinc Finger Protein 365 Isoform A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0238117","Primary Testicular Failure","C131195","Testicular failure due to a condition directly affecting the testes.","Primary Testicular Failure | Hypergonadotropic Hypogonadism (Male) | Male Hypergonadotropic Hypogonadism",,,,,,,,,,,,,,,"4154689","Primary testicular failure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514227","Primary pigmented nodular adrenocortical disease","C131196","A subtype of micronodular adrenal hyperplasia, characterized by multiple pigmented nodules, which may occur in isolation or as part of the Carney complex.","Primary Pigmented Nodular Adrenal Dysplasia | PPNAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537541","LCE3B Gene","C131197","This gene is involved in epidermal keratinization.","LCE3B Gene | LCE3B | Late Cornified Envelope 3B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513964","LCE3B wt Allele","C131198","Human LCE3B wild-type allele is located in the vicinity of 1q21.3 and is approximately 1 kb in length. This allele, which encodes late cornified envelope protein 3B, plays a role in the keratinization of the epidermis. Variation of the gene may be associated with psoriatic arthritis.","LCE3B wt Allele | LEP14 | Late Cornified Envelope 3B wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2934278","Late Cornified Envelope Protein 3B, Human","C131199","Late cornified envelope protein 3B (95 aa, ~10 kDa) is encoded by the human LCE3B gene. This protein is involved in keratin formation in the epidermis.","Late Cornified Envelope Protein 3B | Late Envelope Protein 14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513377","Transient Hyperinsulinism","C131030","Hyperinsulinism that resolves spontaneously. This is the most common cause of neonatal hypoglycemia.","Transient Hyperinsulinism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0349486","Transient Hypothyroxinemia","C131031","Reduced concentration of thyroid hormone(s), usually associated with a non-thyroidal illness, that resolves spontaneously.","Transient Hypothyroxinemia | ",,,,,,,,,,,,,,,"4173327","Transient hypothyroxinemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1300287","Transient Neonatal Hyperparathyroidism","C131032","Hyperparathyroidism in an infant less than one month of age that resolves spontaneously.","Transient Neonatal Hyperparathyroidism | ",,,,,,,,,,,,,,,"4305429","Transient neonatal hyperparathyroidism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1179826","Prostatic Epithelium","C13103","Tissue composed of one or more layers of epithelial cells and a basement membrane. It lines the secretory alveoli and secretory ducts of the prostate. The secretory epithelium consists mostly of pseudostratified columnar cells and basal cells with areas of cuboidal and squamous epithelial cells. The walls of the prostatic urethra and the distal regions of the longer ducts are lined with transitional epithelium.","Prostatic Epithelium | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514432","KLH/NY-ESO-1/MART-1 Peptide-pulsed Dendritic Cell Vaccine","C131287","A cell-based cancer vaccine composed dendritic cells (DC) that were matured in the presence of a synthetic complex comprised of polyinosinic-polycytidylic acid, poly-L-lysine double-stranded RNA, and carboxymethylcellulose (poly-ICLC), and then pulsed with peptides derived from the tumor-associated antigens (TAAs) cancer/testis antigen NY-ESO-1 and melanoma antigen recognized by T-cells (MART-1/Melan-A), which are linked to the immunostimulant and carrier protein keyhole limpet hemocyanin (KLH), with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, the KLH/NY-ESO-1/MART-1 peptide-pulsed DC vaccine stimulates the immune system to mount an anti-tumor cytotoxic T-lymphocyte (CTL) response against NY-ESO-1/MART-1-expressing tumor cells, which may result in tumor cell lysis. NY-ESO-1 is expressed both in normal testes and on the surfaces of various tumor cells. MART-1 is expressed by melanoma cells. The adjuvant poly-ICLC, a ligand for toll-like receptor-3 (TLR-3), induces the release of cytokines that may help boost the immune response against the TAAs. KLH boosts the immune response against the TAA-expressing tumor cells.","KLH/NY-ESO-1/MART-1 Peptide-pulsed Dendritic Cell Vaccine | KLH/NY-ESO-1/MART-1 Peptide-pulsed DC Vaccine | KLH/NY-ESO-1/Melan-A Peptide-pulsed DC Vaccine | NY-ESO-1/MART-1 Peptide/KLH-pulsed Dendritic Cell Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514486","Carbon C14 EGFR Inhibitor ASP8273","C131288","A radioconjugate composed of ASP8273, an orally available, third-generation, mutant-selective, irreversible epidermal growth factor receptor (EGFR) inhibitor, labeled with the radioisotope carbon C 14, with potential use for evaluating the pharmacokinetic profile of ASP8273 during positron emission tomography (PET). Upon administration of carbon C 14 ASP8273, ASP8273 targets, covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M mutant form. Labeling of ASP8273 with the radioactive tracer carbon C 14 permits the evaluation of this agent's pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME) using PET.","Carbon C14 EGFR Inhibitor ASP8273 | 14C ASP8273 | 14C EGFR Inhibitor ASP8273 | [14C] EGFR Inhibitor ASP8273 | [14C]ASP8273",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514470","2-FF Containing SGN-2FF","C131289","An orally bioavailable fluorinated analog of fucose that is a protein fucosylation inhibitor, with potential antineoplastic and immunomodulating activities. Upon administration, 2-fluorofucose (2-FF) mimics fucose and is converted to guanosine diphosphate (GDP)-2FF, which prevents the formation of the fucosylation substrate GDP-fucose, and the incorporation of fucose into glycoproteins by fucosyltransferase. As fucosylation of glycoproteins plays a key role in many biological processes, such as protein function, receptor binding, cell signaling and cellular adhesion, and is essential for tumor progression, blocking fucosylation decreases tumor cell growth. In addition, blocking fucosylation of monoclonal antibodies generates fucose-deficient antibodies that exert enhanced antibody-dependent cell-mediated cytotoxicity (ADCC).","2-Fluorofucose | 2-FF Containing SGN-2FF | 2-FLUOROFUCOSE | 2FF-containing SGN-2FF | SGN-2FF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521759","Small Intestine Cancer pT1a TNM Finding v8","C133838","Small intestine cancer with tumor invading the lamina propria. (from AJCC 8th Ed.)","Small Intestine Cancer pT1a TNM Finding v8 | Small Intestine Carcinoma pT1a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521760","Metastatic Gastrointestinal System Cancer","C133839","A carcinoma that arises from the gastrointestinal system and has metastasized to other anatomic sites.","Metastatic Digestive System Carcinoma | Metastatic Digestive System Cancer | Metastatic Gastrointestinal Carcinoma | Metastatic Gastrointestinal System Cancer | Metastatic Gastrointestinal System Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521761","Small Intestine Cancer pT1b TNM Finding v8","C133840","Small intestine cancer with tumor invading the submucosa. (from AJCC 8th Ed.)","Small Intestine Cancer pT1b TNM Finding v8 | Small Intestine Carcinoma pT1b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521762","Small Intestine Cancer pT2 TNM Finding v8","C133841","Small intestine cancer with tumor invading the muscularis propria. (from AJCC 8th Ed.)","Small Intestine Cancer pT2 TNM Finding v8 | Small Intestine Carcinoma pT2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521763","Small Intestine Cancer pT3 TNM Finding v8","C133842","Small intestine cancer with tumor invading through the muscularis propria into the subserosa, or extending into nonperitonealized perimuscular tissue (mesentery or retroperitoneum) without serosal penetration. For T3 tumors, the nonperitonealized perimuscular tissue is, for the jejunum and ileum, part of the mesentery and, for the duodenum in areas where serosa is lacking, part of the interface with the pancreas. (from AJCC 8th Ed.)","Small Intestine Cancer pT3 TNM Finding v8 | Small Intestine Carcinoma pT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521764","Small Intestine Cancer pT4 TNM Finding v8","C133843","Small intestine cancer with tumor perforating the visceral peritoneum or directly invading other organs or structures (e.g., other loops of small intestine, mesentery of adjacent loops of bowel, and abdominal wall by way of serosa; for duodenum only, invasion of pancreas or bile duct). (from AJCC 8th Ed.)","Small Intestine Cancer pT4 TNM Finding v8 | Small Intestine Carcinoma pT4 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418759","POU1F1 Gene","C133844","This gene is involved in the regulation of genes associated with pituitary development.","POU1F1 Gene | POU Class 1 Homeobox 1 Gene | POU1F1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521765","POU1F1 wt Allele","C133845","Human POU1F1 wild-type allele is located in the vicinity of 3p11.2 and is approximately 17 kb in length. This allele, which encodes pituitary-specific positive transcription factor 1 protein, plays a role in pituitary development and hormone expression. Mutations in this gene results in combined pituitary hormone deficiency.","POU1F1 wt Allele | CPHD1 | GHF-1 | PIT1 | POU Class 1 Homeobox 1 wt Allele | POU Domain Class 1, Transcription Factor 1 Gene | POU Domain, Class 1, Transcription Factor 1 Gene | POU1F1a | Pit-1 | Pituitary Transcript Factor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521766","Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Batch Utilization Terminology","C133846","A category of terminology used to qualify the information pertaining to batch utilization in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.","PQ/CMC Batch Utilization Terminology | Pharmaceutical Quality/CMC Batch Utilization Terminology | Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Batch Utilization Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521768","Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Chemical Structure Data File Type Terminology","C133848","A category of terminology used to qualify the information pertaining to chemical structure data file types in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.","PQ/CMC Chemical Structure Data File Type Terminology | Pharmaceutical Quality/CMC Chemical Structure Data File Type Terminology | Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Chemical Structure Data File Type Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521769","Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Closure Type Terminology","C133849","A category of terminology used to qualify the information pertaining to closure types in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.","PQ/CMC Closure Type Terminology | Pharmaceutical Quality/CMC Closure Type Terminology | Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Closure Type Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539460","NXPE1 Gene","C131200","This gene may play a role in lipid metabolism.","NXPE1 Gene | NXPE1 | Neurexophilin and PC-Esterase Domain Family Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513489","NXPE1 wt Allele","C131201","Human NXPE1 wild-type allele is located in the vicinity of 11q23.2 and is approximately 42 kb in length. This allele, which encodes NXPE family member 1 protein, may be involved in lipid metabolism.","NXPE1 wt Allele | FAM55A | Family With Sequence Similarity 55, Member A Gene | Neurexophilin and PC-Esterase Domain Family Member 1 wt Allele | Neurexophilin and PC-Esterase Domain Family, Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514178","NXPE Family Member 1","C131202","NXPE family member 1 (547 aa, ~63 kDa) is encoded by the human NXPE1 gene. This protein may play a role in the metabolism of lipids.","NXPE Family Member 1 | Protein FAM55A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521312","3q22-q24","C13139","A chromosome band present on 3q","3q22-q24 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514507","Factor VIII Inactivation","C131666","Presence of inactivating antibodies to factor VIII in the blood.","Factor VIII Inactivation | Factor VIII Inhibitor Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514509","Factor X Inactivation","C131667","Presence of inactivating antibodies to factor X in the blood.","Factor X Inactivation | Factor X Inhibitor Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514511","Factor XI Inactivation","C131668","Presence of inactivating antibodies to factor XI in the blood.","Factor XI Inactivation | Factor XI Inhibitor Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514512","Factor XII Inactivation","C131669","Presence of inactivating antibodies to factor XII in the blood.","Factor XII Inactivation | Factor XII Inhibitor Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514514","Factor XIII Inactivation","C131670","Presence of inactivating antibodies to factor XIII in the blood.","Factor XIII Inactivation | Factor XIII Inhibitor Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514296","Gamma-Delta T-Cell Depletion","C131671","Restriction of the T-cell population in stem cell transplants to those expressing only the alpha-beta receptor.","Gamma-Delta T-Cell Depletion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514666","Immune-Mediated Coagulopathy","C131673","Disorders of coagulation caused by autoantibodies generated against native coagulation factors or therapeutically-administered hemostatic agents.","Immune-Mediated Coagulopathy | IMC | Immune-Mediated Coagulation Disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0398554","Infantile Pyknocytosis","C131674","A rare, neonatal syndrome characterized by early jaundice that becomes rapidly associated with severe hemolytic anemia. The peripheral blood smear is remarkable for small irregular, contracted red blood cells with hyper-dense spikes (pyknocytes), that progressively increase in number and then spontaneously disappear.","Infantile Pyknocytosis | Hereditary Pyknocytosis",,,,,,,,,,,,,,,"4098759","Infantile pyknocytosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1306856","Megaloblastic Anemia 1","C131677","An autosomal recessive disorder caused by mutations in the CUBN or AMN genes. It is characterized by vitamin B12 deficiency due to selective malabsorption of the vitamin, and usually results in megaloblastic anemia appearing in childhood (but not immediately after birth).","Megaloblastic Anemia 1 | Imerslund-Gräsbeck Syndrome | Juvenile Megaloblastic Anemia | MGA-1",,,,,,,,,,,,,,,"4121110|4147911|4171201|4235788","Selective malabsorption of cyanocobalamin|Megaloblastic anemia due to inborn errors of metabolism|Juvenile type megaloblastic anemia|Familial megaloblastic anemia",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--|--"
"C1521661","7q35","C13128","A chromosome band present on 7q","7q35 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415193","GPC1 Gene","C131290","This gene is involved in heparan sulfate binding and metabolism.","GPC1 Gene | GPC1 | Glypican 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507941","MTIG7192A","C131291","A human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, tiragolumab binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells, and leads to CD226 dimerization and CD226-mediated signaling. This activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family and immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","Tiragolumab | MTIG7192A | RG6058 | TIRAGOLUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514295","GPC1 wt Allele","C131292","Human GPC1 wild-type allele is located in the vicinity of 2q37.3 and is approximately 32 kb in length. This allele, which encodes glypican-1 protein, plays a role in the mediation of heparan sulfate binding.","GPC1 wt Allele | Glypican 1 wt Allele | Glypican Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1706284","Glypican-1","C131293","Glypican-1 (558 aa, ~62 kDa) is encoded by the human GPC1 gene. This protein is involved in the regulation of heparan sulfate metabolism.","Glypican-1 | GPC1 | Glypican 1 | Glypican Proteoglycan 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3501119","SKLB1028","C131492","An orally available inhibitor of epidermal growth factor receptor (EGFR), FMS-related tyrosine kinase 3 (FLT3, STK1, CD135 or FLK2), and the non-receptor tyrosine kinase ABL (Abl), with potential antineoplastic activity. Upon administration, ruserontinib specifically binds to and inhibits EGFR, FLT3 and Abl, which interferes with the activation of EGFR-, FLT3- and Abl-mediated signal transduction pathways and reduces cell proliferation in cancer cells that overexpress EGFR, FLT3 and/or Abl. EGFR, EGFR and Abl are all overexpressed in a variety of cancers and play key roles in tumor cell proliferation.","Ruserontinib | 9-Isopropyl-N2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-(pyridin-3-yl)-9H-purine-2,8-diamine | 9H-Purine-2,8-diamine, 9-(1-Methylethyl)-N2-[4-(4-methyl-1-piperazinyl)phenyl]-N8-3-pyridinyl- | EGFR/FLT3/Abl Inhibitor SKLB1028 | EGFR/FLT3/Abl Inhibitor SKLB1028 | Multikinase Inhibitor SKLB1028 | RUSERONTINIB | SKLB 1028 | SKLB-1028 | SKLB1028",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514248","Autologous Anti-MG7-CAR T-Lymphocytes","C131493","A preparation of autologous, engineered T-lymphocytes that express both a second-generation chimeric antigen receptor (CAR) specific for the human gastric carcinoma-associated antigen MG7, and the co-stimulatory molecule 4-1BB (CD137), with potential antineoplastic activity. Upon intratumoral injection, the autologous anti-MG7-CAR T-lymphocytes target and attach to cancer cells expressing MG7. This induces selective toxicity in and causes lysis of MG7-expressing tumor cells. MG7, a glycosylated protein sequence from the tumor-associated antigen (TAA) carcinoembryonic antigen (CEA), plays a key role in the development of certain tumor cell types. 4-1BB enhances T-cell activation and signaling after recognition of MG7.","Autologous Anti-MG7-CAR T-Lymphocytes | Autologous Anti-MG7 CAR-T Cells | Autologous Anti-MG7-CAR T Lymphocytes | Autologous MG7-CART | Autologous MG7-CART Cells | MG7-targeted Chimeric Antigen Receptor T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514623","DPX-E7 HPV Vaccine","C131494","A therapeutic vaccine composed of a synthetic peptide consisting of amino acids 11 through 19 of the viral oncoprotein human papillomavirus (HPV) subtype 16 E7 (HPV16-E7 11-19), with potential antineoplastic and immunostimulating activities. Immunization with the DPX-E7 HPV vaccine may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the HPV16-E7 protein. HPV type 16 plays a key role in the carcinogenesis of certain cancers.","DPX-E7 HPV Vaccine | DPX E7 | DPX-E7 | DPX-E7 Vaccine | HPV16-E7 11-19 Nanomer Vaccine DPX-E7 | HPV16-E7 11-19 Vaccine | HPV16-E711-19 Peptide Vaccine DPX-E7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521971","Stage IV Colorectal Cancer AJCC v8","C134195","Stage IV includes: IVA: (Any T, Any N, M1a); IVB: (Any T, Any N, M1b); IVC: (Any T, Any N, M1c). M1a: Metastasis to one site or organ without peritoneal metastasis. M1b: Metastasis to two or more sites or organs without peritoneal metastasis. M1c: Metastasis to the peritoneal surface alone or with other site or organ metastases. (AJCC 8th ed.)","Stage IV Colorectal Cancer AJCC v8 | Stage IV Colorectal (Colon or Rectal) Cancer | Stage IV Colorectal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521635","7q11-q22","C13140","A chromosome band present on 7q","7q11-q22 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519129","Kenny-Caffey Syndrome Type 2","C130993","An autosomal dominant form of Kenny-Caffey Syndrome due to mutation(s) in the FAM111A gene, encoding protein FAM111A. This condition is characterized by transient hypocalcemia, delayed closure of the anterior fontanel, eye anomalies, including microphthalmia, proportionate short stature, and cortical thickening and medullary stenosis of the tubular bones.","Kenny-Caffey Syndrome Type 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513965","Laron Syndrome","C130994","Growth hormone insensitivity syndrome caused by mutation(s) and/or deletion(s) in the GHR gene, encoding the growth hormone receptor.","Laron Syndrome | Growth Hormone Receptor Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024043","Low T3 Syndrome","C130995","Reduced serum concentration of tri-iodothyronine caused by a variety of non-thyroidal conditions in which there is no dysfunction in the thyroid gland or the hypothalamic-pituitary axis.","Low T3 Syndrome | Low Triiodothyronine Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513175","Maternal Diabetes and Deafness Syndrome","C130996","A maternally inherited condition characterized by diabetes and sensorineural deafness with onset after the age of 20, caused by mutation(s) in one of several mitochondrial genes, most frequently the MT-TL1 gene, which encodes the mitochondrial transfer RNA for leucine. Some patients may have additional features observed in mitochondrial disorders, including pigmentary retinopathy, ptosis, cardiomyopathy, myopathy, renal problems, and neuropsychiatric symptoms.","Maternal Diabetes and Deafness Syndrome | MIDD Syndrome | Maternally Inherited Diabetes and Deafness | Maternally Transmitted Diabetes with Deafness",,,,,,,,,,,,,,,"4129516","Diabetes-deafness syndrome maternally transmitted",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0221005","Mauriac Syndrome","C130997","A complication of poorly controlled type 1 diabetes mellitus in children characterized by linear growth impairment, glycogenic hepatopathy, and Cushingoid features.","Mauriac Syndrome | ",,,,,,,,,,,,,,,"4216214","Mauriac's syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0432252","Osteoporosis Pseudoglioma Syndrome","C130998","An autosomal recessive condition caused by homozygous or compound heterozygous inactivating mutation(s) in the gene LRP5, encoding low-density lipoprotein receptor-related protein 5. This condition is characterized by severe juvenile-onset osteoporosis and congenital or juvenile-onset blindness due to a vascularized retinal mass that resembles a glioma.","Osteoporosis Pseudoglioma Syndrome | ",,,,,,,,,,,,,,,"4109181","Osteoporosis with pseudoglioma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1524098","Recombinant Fibroblast Growth Factor 4","C1309","A recombinant therapeutic agent which is chemically identical to or similar to endogenous fibroblast growth factor 4 (FGF-4). Therapeutic FGF-4 induces vascular permeability, angiogenesis, and arteriogenesis and has potential uses in the treatment of peripheral vascular disease. (NCI04)","Recombinant Fibroblast Growth Factor 4 | FGF4 | Fibroblast Growth Factor 4 | HBGF-4 | Transforming Protein KS3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1280798","Platelet-Type von Willebrand Disease","C131681","A rare autosomal dominant bleeding disorder characterized by abnormally enhanced binding of von Willebrand factor (VWF) by the platelet glycoprotein Ib receptor complex. Hemostatic function is impaired due to the removal of VWF multimers from the circulation. It is due to a mutation in the gene encoding for platelet glycoprotein Ib alpha, resulting in enhanced affinity for VWF. It is often misdiagnosed as type 2B von Willebrand disease due to similarities between these two conditions. Patients present with a mild thrombocytopenia with large platelets. Platelet aggregates are often visible in blood smears.","Platelet-Type von Willebrand Disease | Pseudo-von Willebrand Disease",,,,,,,,,,,,,,,"4133988","Pseudo von Willebrand disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1721286","PITRM1 protein, human","C131240","Presequence protease, mitochondrial (1037 aa, ~117 kDa) is encoded by the human PITRM1 gene. This protein is involved in the catabolism of mitochondrial peptides.","Presequence Protease, Mitochondrial | EC 3.4.24.- | Metalloendoprotease 1 | Metalloprotease 1 | PITRM1 | Pitrilysin Metallopeptidase 1 | Pitrilysin Metalloproteinase 1 | PreP Peptidasome | Presequence Protease | hMP1 | hPreP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516944","Epithelial Reticular Cell","C13124","A branched epithelial cell that supports epithelial structures.","Epithelial Reticular Cell | Epithelial Reticular Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514359","HPV Types 16/18 E6/E7-Adenoviral Transduced Autologous Lymphocytes/alpha-Galactosylceramide Vaccine BVAC-C","C131495","An immunotherapeutic vaccine composed of the immunoadjuvant alpha-galactosylceramide (a-GC) and autologous antigen presenting cells (APCs), specifically B-lymphocytes and monocytes transfected with an adenoviral vector that expresses the tumor-associated antigens (TAAs) E6 and E7 derived from human papillomavirus (HPV) types 16 and 18 (HPV-16/18 E6/E7), with potential immunostimulating and antineoplastic activities. Upon administration of BVAC-C, the APCs stimulate the immune system to mount a TAA-specific cytotoxic T-lymphocyte (CTL) response, as well as natural killer (NK) cell, NK T-cell (NKT), helper T-cell and antibody-mediated immune responses, against the tumor cells. This directly or indirectly kills the TAA-expressing tumor cells. HPV-16/18 E6/E7 are overexpressed on certain tumor cell types and play key roles in tumor cell proliferation. a-GC, an NKT cell ligand, is used to specifically stimulate NKT cells and to further stimulate an anti-tumor immune response.","HPV Types 16/18 E6/E7-Adenoviral Transduced Autologous Lymphocytes/alpha-Galactosylceramide Vaccine BVAC-C | Autologous Lymphocyte/Tumor Antigen Gene Vaccine BVAC-C | BVAC-C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514247","Anti-androgen siRNA SXL01","C131496","A small-interfering RNA (siRNA) directed against androgen receptor (AR), with potential antineoplastic activity. Upon administration of anti-AR siRNA SXL01, the siRNAs bind to AR mRNAs, which may result in the inhibition of translation of the AR protein. By preventing AR expression, AR-mediated signaling is decreased, which leads to growth inhibition for AR-expressing tumor cells. AR, overexpressed in a variety of cancers, is involved in cellular proliferation and survival.","Anti-androgen siRNA SXL01 | SXL 01 | SXL-01 | SXL01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514285","Fluorine F 18 ODS2004436","C131497","A radioconjugate containing the epidermal growth factor receptor (EGFR) kinase tracer ODS2004436 labeled with fluorine F 18 for potential tumor imaging using positron emission tomography (PET). Upon administration of fluorine F 18 ODS2004436, the ODS2004436 moiety selectively targets and binds to forms of EGFR that contain activating mutations. This allows the visualization of tumor cells expressing activating EGFR mutations using PET. This agent can also be utilized in the prediction of responsiveness to EGFR tyrosine kinase inhibitors (TKIs) and the selection of patients that respond well to those kinase inhibitors that specifically target forms of EGFR with activating mutations. EGFR-activating mutations play a key role in the development of certain tumors and in tumor resistance to a variety of antineoplastic agents.","Fluorine F 18 ODS2004436 | 18F-ODS2004436 | [18F]-ODS2004436",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514206","Acquired Ovarian Failure","C131090","Ovarian failure, the cause of which is not present at birth.","Acquired Ovarian Failure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0403818","Acquired Testicular Failure","C131091","Testicular failure, the cause of which is not present at birth.","Acquired Testicular Failure | ",,,,,,,,,,,,,,,"4127867","Acquired testicular failure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521049","Esophageal Squamous Cell Carcinoma by AJCC v7 Stage","C133442","A term that refers to the staging of esophageal squamous cell carcinoma according to the American Joint Committee on Cancer, 7th edition.","Esophageal Squamous Cell Carcinoma by AJCC v7 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521053","Esophageal Squamous Cell Carcinoma by AJCC v8 Stage","C133443","A term that refers to the staging of esophageal squamous cell carcinoma according to the American Joint Committee on Cancer, 8th edition.","Esophageal Squamous Cell Carcinoma by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521052","Esophageal Squamous Cell Carcinoma by AJCC v8 Postneoadjuvant Therapy Stage","C133446","A term that refers to the postneoadjuvant therapy staging of esophageal squamous cell carcinoma according to the American Joint Committee on Cancer, 8th edition.","Esophageal Squamous Cell Carcinoma by AJCC v8 Postneoadjuvant Therapy Stage | Esophageal Squamous Cell Carcinoma by AJCC v8 ypTNM Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520631","Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8","C133451","Stage IV includes: IVA: (T4, N0-2, M0); (Any T, N3, M0); IVB: (Any T, Any N, M1). T4: Tumor invades adjacent structures. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)","Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8 | Stage IV Esophageal Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0271695","Rabson-Mendenhall Syndrome","C131000","An autosomal recessive condition caused by mutation(s) in the INSR gene, encoding the insulin receptor, and characterized by insulin resistance, intrauterine growth restriction (IUGR) and/or failure to thrive, muscle atrophy, hypertrichosis, and distinctive facial features; the condition is typically diagnosed early in life, with death usually occurring before the third decade of life. The symptoms and course of this syndrome are moderately severe as compared to the other two syndromes on the spectrum: Insulin Resistant Diabetes Mellitus with Acanthosis Nigricans and Hyperandrogenism, and Donohue Syndrome.","Rabson-Mendenhall Syndrome | ",,,,,,,,,,,,,,,"4140808","Rabson-Mendenhall syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3495488","Rieger Syndrome","C131001","A congenital condition associated with mutation(s) in the PITX2 and/or FOXC1 genes, encoding pituitary homeobox 2 and forkhead box protein C1, respectively. The condition is characterized by anterior segment dysgenesis of the eye(s), iris and corneal anomalies, glaucoma, craniofacial anomalies, hypodontia, and pituitary hypoplasia with hypopituitarism, and hypospadius.","Rieger Syndrome | Axenfeldt-Rieger Syndrome",,,,,,,,,,,,,,,"4171022","Rieger syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513991","Simpson-Golabi-Behmel Syndrome","C131002","An X-linked recessive syndrome caused by mutation(s) in the GPC3, OFD1, or rarely the GPC4 gene, encoding glypican 3, oral-facial-digital syndrome 1 protein, and glypican 4, respectively. The condition is characterized by macrosomia, coarse facies, cryptorchidism, congenital heart, kidney, liver, spleen, and musculoskeletal abnormalities.","Simpson-Golabi-Behmel Syndrome | Simpson Dysmorphia Syndrome",,,,,,,,,,,,,,,"4230703","Simpson-Golabi-Behmel syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL513992","Single Central Incisor Syndrome","C131003","An autosomal dominant condition usually caused by mutation(s) in the SHH gene, encoding sonic hedgehog, a secreted protein involved in the organization and morphology of the developing embryo. This condition is characterized by multiple, mainly midline, developmental variations, including the presence of a tooth in the center of the maxillary dental arch in both primary and permanent dentition, and any combination of the following: holoprosencephaly, congenital nasal malformation (choanal atresia, midnasal stenosis, or congenital pyriform aperture stenosis), cleft lip and/or palate, hypopituitarism (including hypothyroidism and hypogonadism, resulting in variations in genital development including small penis or incomplete masculinization in male infants), congenital heart anomalies, and developmental delay.","Single Central Incisor Syndrome | Single Central Maxillary Incisor Syndrome | Solitary Central Maxillary Incisor Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514193","Wilms Tumor 1 Gene Syndromes","C131006","A group of syndromes caused by autosomal dominant mutation(s) in the WT1 gene, encoding Wilms tumor protein. Patients with this mutation may have a predisposition to developing Wilms tumors.","Wilms Tumor 1 Gene Syndromes | WT1 Gene Syndromes | WT1 Syndromes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514270","Cervical and Lumbosacral Spinal Cord Ependymal Tumor","C131608","A finding indicating the presence of an ependymal tumor in the cervical and lumbosacral regions of spinal cord.","Cervical and Lumbosacral Spinal Cord Ependymal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514272","Cervical, Thoracic, and Lumbosacral Spinal Cord Ependymal Tumor","C131609","A finding indicating the presence of an ependymal tumor in the cervical, thoracic, and lumbosacral regions of spinal cord.","Cervical, Thoracic, and Lumbosacral Spinal Cord Ependymal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514492","Ependymal Tumor of Brain and Spinal Cord","C131610","A finding indicating the presence of an ependymal tumor in the brain and spinal cord.","Ependymal Tumor of Brain and Spinal Cord | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514329","Supratentorial Ependymal Tumor","C131611","A finding indicating the presence of an ependymal tumor in the supratentorial region of the brain.","Supratentorial Ependymal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514516","Infratentorial and Spinal Cord Ependymal Tumor","C131613","A finding indicating the presence of an ependymal tumor in the infratentorial region of the brain and spinal cord.","Infratentorial and Spinal Cord Ependymal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824529","GOLM2 Gene","C131614","This gene may play a role in Golgi apparatus activity and tumor growth.","GOLM2 Gene | CASC4 | GOLM2 | Golgi Membrane Protein 2  Gene | Golgi Membrane Protein 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514253","BLM Protein Variant","C131465","A variation in the amino acid sequence for Bloom syndrome protein.","BLM Protein Variant | Bloom Syndrome Protein Variant | DNA Helicase, RecQ-Like Type 2 Protein Variant | RecQ Protein-Like 3 Protein Variant | RecQ2 Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0084393","Ro 31-8220","C1310","A methanesulfonate salt form, a staurosporine analog that inhibits protein kinase C and induces apoptosis. (NCI)","Ro 31-8220 | Bisindolylmaleimide IX Methanesulfonate | RO-31-8220 | Ro-31-8220",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030173","Vater-Pacini Corpuscle","C13172","A specialized bulblike nerve ending located in the subcutaneous tissue of the skin; occurs abundantly in the skin of palms and soles and joints and genitals.","Vater-Pacini Corpuscle | Corpuscula Lamellosa | Lamellated Corpuscle | Pacinian Corpuscle | Vater's Corpuscle",,,,,,,,,,,,,,,"4329984","Corpuscula lamellosa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL520924","Postneoadjuvant Therapy Stage I Esophageal Squamous Cell Carcinoma AJCC v8","C133454","Stage I includes: T0-2, N0, M0. T0: No evidence of primary tumor. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Postneoadjuvant Therapy Stage I Esophageal Squamous Cell Carcinoma AJCC v8 | Stage I Esophageal Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520480","Pathologic Stage III Gastric Cancer AJCC v8","C133663","Stage III includes: IIIA: (T2, N3a, M0); (T3, N2, M0); (T4a, N1, M0); (T4a, N2, M0); (T4b, N0, M0); IIIB: (T1, N3b, M0); (T2, N3b, M0); (T3, N3a, M0); (T4a, N3a, M0); (T4b, N1, M0); (T4b, N2, M0); IIIC: (T3, N3b, M0); (T4a, N3b, M0); (T4b, N3a, M0); (T4b, N3b, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. T4a: Tumor invades the serosa (visceral peritoneum). T4b: Tumor invades adjacent structures/organs. N0: No regional lymph node metastasis.  N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3a: Tumor with metastasis in seven to fifteen regional lymph nodes. N3b: Tumor with metastasis in sixteen or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Pathologic Stage III Gastric Cancer AJCC v8 | Pathologic Stage III Gastric Carcinoma AJCC v8 | Stage III Gastric (Stomach) Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521353","Homeobox Protein DLX-1","C133664","Homeobox protein DLX-1 (255 aa, ~27 kDa) is encoded by the human DLX1 gene. This protein may be involved in the development of the brain, skull and face.","Homeobox Protein DLX-1 | DLX1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514326","Cancer Susceptibility Candidate Gene 4 Protein","C131616","Protein GOLM2 (436 aa, ~49 kDa) is encoded by the human GOLM2 gene. This protein may play a role in protein maturation and tumorigenesis.","Protein GOLM2 | Cancer Susceptibility Candidate Gene 4 Protein | GOLM2 | Golgi Membrane Protein 2 | Protein CASC4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514678","Recurrent Ependymal Tumor","C131617","The reemergence of an ependymal tumor after a period of remission.","Recurrent Ependymal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514684","Ventricular Involvement Only","C131618","A finding indicating that a neoplasm affects exclusively a brain ventricle.","Ventricular Involvement Only | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514628","Deleterious Germline Mutation","C131620","A mutation that appears in the genome of the germ cells and is associated with increased risk of disease.","Deleterious Germline Mutation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514474","Acquired Factor I Deficiency","C131621","An acquired coagulation disorder characterized by the partial or complete absence of fibrinogen (factor I) activity in the blood.","Acquired Factor I Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0392610","Acquired Factor II Deficiency","C131622","An acquired coagulation disorder characterized by the partial or complete absence of prothrombin (factor II) activity in the blood.","Acquired Factor II Deficiency | ",,,,,,,,,,,,,,,"4101597","Acquired factor II deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514475","Acquired Factor III Deficiency","C131623","An acquired coagulation disorder characterized by the partial or complete absence of tissue factor (factor III) activity in the blood.","Acquired Factor III Deficiency | Acquired Tissue Factor Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514476","Acquired Factor V Deficiency","C131624","An acquired coagulation disorder characterized by the partial or complete absence of factor V activity in the blood.","Acquired Factor V Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514477","Acquired Factor VII Deficiency","C131625","An acquired coagulation disorder characterized by the partial or complete absence of factor VII activity in the blood.","Acquired Factor VII Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0272328","Acquired Factor X Deficiency","C131626","An acquired coagulation disorder characterized by the partial or complete absence of factor X activity in the blood.","Acquired Factor X Deficiency | ",,,,,,,,,,,,,,,"4141269","Acquired factor X deficiency disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514478","Acquired Factor XI Deficiency","C131627","An acquired coagulation disorder characterized by the partial or complete absence of factor XI activity in the blood.","Acquired Factor XI Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810296","BECN2 Gene","C131203","This gene is involved in autophagy and G protein-coupled receptor turnover.","BECN2 Gene | BECN2 | Beclin 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513813","BECN2 wt Allele","C131204","Human BECN2 wild-type allele is located in the vicinity of 1q43 and is approximately 1 kb in length. This allele, which encodes beclin-2 protein, plays a role in the regulation of both G protein-coupled receptor catabolism and autophagy.","BECN2 wt Allele | BECN1L1 | BECN1P1 | Beclin 1, Autophagy Related, Pseudogene 1 Gene | Beclin 2 wt Allele | Beclin-1 Autophagy-Related Pseudogene 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3712212","Beclin-2, Human","C131205","Beclin-2 (431 aa, ~48 kDa) is encoded by the human BECN2 gene. This protein is involved in both autophagy and the catabolism of G protein-coupled receptors.","Beclin-2 | Beclin 1-Like Protein 1 | Beclin 2 | Beclin-1 Autophagy-Related Pseudogene 1 Protein | Beclin-1-Like Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3815310","SAMMSON Gene","C131206","This gene plays a role in melanoma cell survival.","SAMMSON Gene | SAMMSON | Survival Associated Mitochondrial Melanoma Specific Oncogenic Non-Coding RNA Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519905","HOXA5 wt Allele","C132094","Human HOXA5 wild-type allele is located in the vicinity of 7p15.2 and is approximately 3 kb in length. This allele, which encodes homeobox protein Hox-A5, is involved in transcriptional regulation.","HOXA5 wt Allele | HOX1 | HOX1.3 | HOX1C | Homeo Box 1C Gene | Homeo Box A5 Gene | Homeobox 1C Gene | Homeobox A5 wt Allele | Hox-1.3, Mouse, Homolog of Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1448586","HOXA5 protein, human","C132095","Homeobox protein Hox-A5 (270 aa, ~29 kDa) is encoded by the human HOXA5 gene. This protein plays a role in the regulation of gene expression.","Homeobox Protein Hox-A5 | HOXA5 | Homeobox Protein HOXA5 | Homeobox Protein Hox-1C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521137","Simple Virilizing 21-Hydroxylase Deficiency","C132096","A classic form of congenital adrenal hyperplasia that is characterized by severe 21-hydroxylase deficiency, resulting in glucocorticoid and mineralocorticoid deficiency, but without clinically significant salt wasting, and with androgen excess, which causes virilization in female infants.","Simple Virilizing 21-Hydroxylase Deficiency | Simple Virilizing 21-OHD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427738","SOSTDC1 Gene","C132097","This gene is involved in the negative regulation of bone morphogenic protein signaling.","SOSTDC1 Gene | SOSTDC1 | Sclerostin Domain Containing 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521273","Sothrombomodulin Alfa","C132278","No value exists.","Sothrombomodulin Alfa | SOTHROMBOMODULIN ALFA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520115","Napsagatran Anhydrous","C132279","No value exists.","Napsagatran Anhydrous | NAPSAGATRAN ANHYDROUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010853","Cytoskeleton","C13227","The protein scaffolding (the network of filaments microfilaments, microtubules, intermediate filaments, and their associated proteins) that gives shape, structure, and organization to the cytoplasm and a cell its shape.","Cytoskeleton | Cellular Matrix | Cytoskeletal | Cytoskeletal System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520703","Gatifloxacin Mesylate","C132281","The mesylate salt form of gatifloxacin, a synthetic 8-methoxyfluoroquinolone with antibacterial activity against a wide range of gram-negative and gram-positive microorganisms. Gatifloxacin exerts its effect through inhibition of DNA gyrase, an enzyme involved in DNA replication, transcription and repair, and inhibition of topoisomerase IV, an enzyme involved in partitioning of chromosomal DNA during bacterial cell division.","Gatifloxacin Mesylate | 3-Quinolinecarboxylic Acid, 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-, Monomethanesulfonate | GATIFLOXACIN MESYLATE | Gemifloxacin Mesilate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520438","Iodocetylic Acid I 123","C132283","No value exists.","Iodocetylic Acid I 123 | 16-Iodo-(sup 123)I-hexadecanoic Acid | IODOCETYLIC ACID I-123 | Iodocetylic Acid (123I)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519957","Health Assessment Questionnaire Disability Index","C132288","A questionnaire for the assessment of rheumatoid arthritis.","Health Assessment Questionnaire Disability Index | HAQ-DI | Health Assessment Questionnaire Disability Index (HAQ-DI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012934","Satellite DNA","C13228","DNA that contains many tandem highly repetitive sequences, that have a base composition (and thus density) sufficiently different from that of normal DNA that it sediments as a distinct band in cesium chloride density gradients.  Satellite DNA is located at very specific spots in the genome (on chromosomes 1, 9, 16 and the Y chromosome, the tiny short arms of chromosomes 13-15 and 21 and 22, and near the centromeres of chromosomes).","Satellite DNA | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514681","STN1 Gene","C131359","This gene is involved in DNA replication and telomere maintenance.","STN1 Gene | OBFC1 | STN1 | STN1 Subunit of CST Complex Gene | STN1, CST Complex Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520173","Xp11.23","C13135","A chromosome band present on Xp","Xp11.23 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514350","STN1 wt Allele","C131360","Human STN1 wild-type allele is located in the vicinity of 10q24.33 and is approximately 48 kb in length. This allele, which encodes CST complex subunit STN1 protein, plays a role in both telomere maintenance and DNA replication.","STN1 wt Allele | AAF-44 | AAF44 | Alpha Accessory Factor, 44-kD Subunit Gene | FLJ22559 | OBFC1 | Oligonucleotide/Oligosaccharide-Binding Fold Containing 1 Gene | RPA-32 | STN1 Subunit of CST Complex wt Allele | STN1, CST Complex Subunit Gene | STN1, CST Complex Subunit wt Allele | STN1, S. pombe, Homolog of Gene | bA541N10.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2742696","Stn1 protein, human","C131361","CST complex subunit STN1 (368 aa, ~42 kDa) is encoded by the human STN1 gene. This protein is involved in DNA binding, telomere homeostasis and DNA replication.","CST Complex Subunit STN1 | Alpha Accessory Factor 44 | Oligonucleotide/Oligosaccharide-Binding Fold-Containing Protein 1 | Replication Protein A 32 kDa Subunit | STN1 | Suppressor of cdc Thirteen Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427272","CDKAL1 Gene","C131362","This gene plays a role in transfer RNA methylthiolation.","CDKAL1 Gene | CDK5 Regulatory Subunit Associated Protein 1 Like 1 Gene | CDKAL1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513562","WHODAS 2.0 12-item Version Self-administered - Washing Your Whole Body","C130942","World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Washing your whole body?","WHODAS 2.0 12-item Version Self-administered - Washing Your Whole Body | WD3-Washing Your Whole Body | WD3S8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513554","WHODAS 2.0 12-item Version Self-administered - Getting Dressed","C130943","World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Getting dressed?","WHODAS 2.0 12-item Version Self-administered - Getting Dressed | WD3-Getting Dressed | WD3S9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513552","WHODAS 2.0 12-item Version Self-administered - Dealing With People You Do Not Know","C130944","World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Dealing with people you do not know?","WHODAS 2.0 12-item Version Self-administered - Dealing With People You Do Not Know | WD3-Dealing With People You Do Not Know | WD3S10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513563","WHODAS 2.0 12-item Version Self-administered - Your Day-to-Day Work or School","C130946","World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Your day-to-day work?","WHODAS 2.0 12-item Version Self-administered - Your Day-to-Day Work or School | WD3-Your Day-to-Day Work/School | WD3S12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513555","WHODAS 2.0 12-item Version Self-administered - How Many Days Difficulties Present","C130947","World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) Overall, in the past 30 days, how many days were these difficulties present?","WHODAS 2.0 12-item Version Self-administered - How Many Days Difficulties Present | WD3-How Many Days Difficulties Present | WD3H1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513551","WHODAS 2.0 12-item Version Self-administered - Days Unable to Carry Out Activities","C130948","World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) In the past 30 days, for how many days were you totally unable to carry out your usual activities or work because of any health condition?","WHODAS 2.0 12-item Version Self-administered - Days Unable to Carry Out Activities | WD3-Days Unable to Carry Out Activities | WD3H2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513556","WHODAS 2.0 12-item Version Self-administered - How Many Days Reduce Activities","C130949","World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) In the past 30 days, not counting the days that you were totally unable, for how many days did you cut back or reduce your usual activities or work because of any health condition?","WHODAS 2.0 12-item Version Self-administered - How Many Days Reduce Activities | WD3-How Many Days Reduce Activities | WD3H3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0015350","Extracellular Matrix","C13232","The extracellular matrix is a network of fibers that hold cells together. It is found within the extracellular space and in association with the basement membrane of the cell surface. It promotes cellular proliferation and provides a supporting structure to which cells or cell lysates in culture dishes adhere. It is broken down during normal physiological and disease processes such as bone remodeling, embryogenesis, cancer, and arthritis.","Extracellular Matrix | Cell-Extracellular Matrix | ECM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520593","BCL9L protein, human","C132330","B-cell CLL/lymphoma 9-like protein (1499 aa, ~157 kDa) is encoded by the human BCL9L gene. This protein plays a role in the promotion of beta-catenin transcriptional activity.","B-Cell CLL/Lymphoma 9-Like Protein | B-Cell Lymphoma 9-Like Protein | BCL9-Like Protein | BCL9L | Nuclear Co-Factor of Beta-Catenin Signaling | Nuclear Co-Factor of Beta-Catenin Signalling | Protein BCL9-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520578","Approved Drug Product Manufactured Under Contract","C132333","A marketing category specifying that an approved drug product is manufactured by a contract manufacturer and not marketed by the contract manufacturer.","Approved Drug Product Manufactured Under Contract | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521222","OTC Monograph Drug Product Manufactured Under Contract","C132334","A marketing category specifying that an OTC monograph drug product is manufactured by a contract manufacturer and not marketed by the contract manufacturer.","OTC Monograph Drug Product Manufactured Under Contract | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520269","Unapproved Drug Product Manufactured Under Contract","C132335","A marketing category specifying that an unapproved drug product is manufactured by a contract manufacturer and not marketed by the contract manufacturer.","Unapproved Drug Product Manufactured Under Contract | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519855","Guideline Concordant Care","C132336","Treatment that is in compliance with established guidelines.","Guideline Concordant Care | GCC | Guideline-concordant Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521162","ARHGEF5 Gene Product","C132337","A protein encoded by the ARHGEF5 gene.","ARHGEF5 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420737","Oncogene TIM Protein","C132338","Oncogene TIM protein (519 aa, ~60 kDa) is encoded by the human ARHGEF5 gene. This protein is involved in the activation of Rho family small GTPases and may induce cellular transformation.","Oncogene TIM Protein | Oncoprotein TIM | Rho Guanine Nucleotide Exchange Factor 5 Isoform 2 | Rho Guanine Nucleotide Exchange Factor 5 p60 Isoform | TIM | TIM1 | Transforming Immortalized Mammary Oncogene Protein | Transforming Immortalized Mammary Protein | p60 | p60 TIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520574","REGN 3767","C132339","A monoclonal antibody directed against the inhibitory receptor lymphocyte activation gene-3 protein (LAG-3; LAG3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, fianlimab binds to LAG-3 expressed by tumor infiltrating lymphocytes (TILs) and blocks LAG-3 binding to tumor cells expressing major histocompatibility complex (MHC) class II molecules. This may activate antigen-specific T-lymphocytes and enhance cytotoxic T-lymphocyte (CTL)-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells; its expression on TILs is associated with tumor-mediated immune suppression and the negative regulation of both cellular proliferation and T-cell activation.","Fianlimab | Anti-LAG-3 MoAb REGN3767 | FIANLIMAB | REGN 3767 | REGN3767 | WHO 11182",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519875","HAQ-DI Without VAS - Get In and Out of Bed","C132576","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Arising: Are you able to get in and out of bed?","HAQ-DI Without VAS - Get In and Out of Bed | HAQ02-Get In and Out of Bed | HAQ0204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514307","MIR483 wt Allele","C131517","Human MIR483 wild-type allele is located in the vicinity of 11p15.5 and is approximately 80 bases in length. This allele, which encodes MIR483 pre-miRNA, may play a role in the negative regulation of mRNA translation. Alteration in the expression of this gene may be associated with development of non small lung cell carcinoma.","MIR483 wt Allele | MIRN483 | MIRNA438 | Micro RNA 483 Gene | MicroRNA 483 wt Allele | hsa-mir-483 | mir-483",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514306","MIR483 Pre-miRNA","C131518","MIR483 pre-miRNA (76 bases) is encoded by the human MIR483 gene. This oligoribonucleotide may be involved in the negative regulation of gene expression.","MIR483 Pre-miRNA | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514318","MicroRNA 483-5p","C131519","A 22 ribonucleotide sequence that is a final product of the processing of MIR483 pre-miRNA. This oligonucleotide may be involved in the negative regulation of gene expression.","MicroRNA 483-5p | hsa-miR-483-5p | miR-483-5p",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518565","Olfactory Receptor Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514317","MicroRNA 193a-5p","C131520","A 22 ribonucleotide sequence that is a final product of the processing of MIR193A pre-miRNA. This oligonucleotide may be involved in the negative regulation of gene expression.","MicroRNA 193a-5p | hsa-miR-193a-5p",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2933797","MicroRNA 7","C131521","A 23 ribonucleotide sequence that is a final product of the processing of MIR7-1, MIR7-2 or MIR7-3 pre-miRNA. This oligonucleotide may be involved in the negative regulation of gene expression.","MicroRNA 7 | hsa-miR-7 | hsa-miR-7-5p | miR-7 | miR-7-5p",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1540147","UBE2T Gene","C131522","This gene plays a role in monoubiquitination of the Fanconi anemia complex.","UBE2T Gene | UBE2T | Ubiquitin-Conjugating Enzyme E2T Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514399","UBE2T wt Allele","C131523","Human UBE2T wild-type allele is located in the vicinity of 1q32.1 and is approximately 10 kb in length. This allele, which encodes ubiquitin-conjugating enzyme E2 T protein, is involved in both protein ubiquitination and DNA repair. Mutation of the gene is associated with Fanconi anemia complementation group T.","UBE2T wt Allele | Cell Proliferation-Inducing Gene 50 | FANCT | HSPC150 | PIG50 | Ubiquitin Conjugating Enzyme E2T wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1741097","UBE2T protein, human","C131524","Ubiquitin-conjugating enzyme E2 T (197 aa, ~23 kDa) is encoded by the human UBE2T gene. This protein plays a role in the modulation of Fanconi anemia complex DNA repair activity.","Ubiquitin-Conjugating Enzyme E2 T | Cell Proliferation-Inducing Gene 50 Protein | E2 Ubiquitin-Conjugating Enzyme T | EC 2.3.2.23 | EC 6.3.2.19, Formerly | HSPC150 Protein Similar To Ubiquitin-Conjugating Enzyme | UBE2T | Ubiquitin Carrier Protein T | Ubiquitin-Conjugating Enzyme E2T | Ubiquitin-Protein Ligase T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514493","Ependymal Tumor of Spinal Cord","C131526","A finding indicating the presence of an ependymal tumor in the spinal cord.","Ependymal Tumor of Spinal Cord | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3660488","ARHGAP22 protein, human","C131766","Rho GTPase-activating protein 22 (698 aa, ~77 kDa) is encoded by the human ARHGAP22 gene. This protein plays a role in the activation of Ras-related C3 botulinum toxin substrate 1.","Rho GTPase-Activating Protein 22 | ARHGAP22 | Rho GTPase Activating Protein 22 | Rho-Type GTPase-Activating Protein 22",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426749","NYNRIN Gene","C131767","This gene may be involved in DNA transposition.","NYNRIN Gene | NYN Domain and Retroviral Integrase Containing Gene | NYNRIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514374","NYNRIN wt Allele","C131768","Human NYNRIN wild-type allele is located in the vicinity of 14q12 and is approximately 21 kb in length. This allele, which encodes protein NYNRIN, may play a role in DNA integration.","NYNRIN wt Allele | CGIN1 | Cousin of GIN1 Gene | FLJ11811 | KIAA1305 | NYN Domain and Retroviral Integrase Containing wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514328","Protein NYNRIN","C131769","Protein NYNRIN (208 aa, ~208 kDa) is encoded by the human NYNRIN gene. This protein may be involved in the mediation of DNA transposition.","Protein NYNRIN | NYN Domain and Retroviral Integrase Catalytic Domain-Containing Protein | Protein Cousin of GIN1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823912","ZBTB46 Gene","C131771","This gene plays a role in the regulation of PRDM1 gene transcription.","ZBTB46 Gene | ZBTB46 | Zinc Finger and BTB Domain Containing 46 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514582","ZBTB46 wt Allele","C131772","Human ZBTB46 wild-type allele is located in the vicinity of 20q13.33 and is approximately 89 kb in length. This allele, which encodes zinc finger and BTB domain-containing protein 46, is involved in the negative regulation of PRDM1 gene expression.","ZBTB46 wt Allele | BTB (POZ) Domain Containing 4 Gene | BTBD4 | BZEL | FLJ13502 | RINZF | ZNF340 | Zinc Finger and BTB Domain Containing 46 wt Allele | dJ583P15.7 | dJ583P15.8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3493869","Zbtb46 protein, human","C131773","Zinc finger and BTB domain-containing protein 46 (589 aa, ~64 kDa) is encoded by the human ZBTB46 gene. This protein plays a role in the negative regulation of PR domain zinc finger protein 1 expression.","Zinc Finger and BTB Domain-Containing Protein 46 | BTB-ZF Protein Expressed In Effector Lymphocytes | BTB-Zinc Finger Protein Expressed In Effector Lymphocytes | BTB/POZ Domain-Containing Protein 4 | ZBTB46 | Zinc Finger Protein 340 | Zinc Finger- and BTB Domain-Containing Protein 46",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514366","EGR2 wt Allele","C131313","Human EGR2 wild-type allele is located in the vicinity of 10q21.1 and is approximately 108 kb in length. This allele, which encodes E3 SUMO-protein ligase EGR2 protein, is involved in the regulation of both gene transcription and protein modification. Mutation of the gene is associated with Charcot-Marie-Tooth disease type 1D (CMT1D), Charcot-Marie-Tooth disease type 4E (CMT4E), and with Dejerine-Sottas syndrome (DSS).","EGR2 wt Allele | AT591 | CMT1D | CMT4E | Early Growth Response 2 (Krox-20 Homolog, Drosophila) Gene | Early Growth Response 2 wt Allele | KROX-20, Drosophila, Homolog (Early Growth Response-2) Gene | KROX20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1505738","EGR2 protein, human","C131314","E3 SUMO-protein ligase EGR2 (476 aa, ~50 kDa) is encoded by the human EGR2 gene. This protein plays a role in both protein sumoylation and sequence-specific DNA binding.","E3 SUMO-Protein Ligase EGR2 | AT591 | E3 SUMO-Protein Transferase ERG2 | EC 2.3.2.- | EC 6.3.2.-, Formerly | EGR-2 | EGR2 | Early Growth Response Protein 2 | Krox-20 Homolog | Zinc Finger Protein Krox-20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513187","Posterior Cranial Fossa Tumor","C130950","A neoplasm that arises from the posterior cranial fossa. Examples include meningiomas and medulloblastomas.","Posterior Fossa Neoplasm | Posterior Cranial Fossa Neoplasm | Posterior Cranial Fossa Tumor | Posterior Fossa Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514000","Stage IA Mycosis Fungoides AJCC v7","C130951","Stage IA includes: T1, N0, M0, B0-1.  T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface.  May further stratify into T1a (patch only) vs. T1b (plaque +/- patch).  N0: No clinically abnormal peripheral lymph nodes; biopsy not required.  M0: No visceral organ involvement.  B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells).  B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2.  (AJCC 7th ed.)","Stage IA Mycosis Fungoides AJCC v7 | Stage IA Mycosis Fungoides",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414471","ETFA Gene","C131569","This gene plays a role in the electron transport chain.","ETFA Gene | ETFA | Electron Transfer Flavoprotein Alpha Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514760","Receptor Cell","C13156","Specialized cells located in sense organs that respond to physical and chemical stimuli by sending information to the central nervous system.","Receptor Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514418","ETFA wt Allele","C131570","Human ETFA wild-type allele is located within 15q24.2-q24.3 and is approximately 96 kb in length. This allele, which encodes electron transfer flavoprotein subunit alpha, mitochondrial protein, is involved in cellular respiration. Mutation of the gene is associated with glutaric aciduria 2A.","ETFA wt Allele | EMA | Electron Transfer Flavoprotein Alpha Subunit wt Allele | Electron Transfer Flavoprotein, Alpha Polypeptide Gene | Electron-Transfer-Flavoprotein, Alpha Polypeptide Gene | GA2 | MADD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL358695","ETFA protein, human","C131571","Electron transfer flavoprotein subunit alpha, mitochondrial (333 aa, ~35 kDa) is encoded by the human ETFA gene. This protein plays a role in electron transport.","Electron Transfer Flavoprotein Subunit Alpha, Mitochondrial | Alpha-ETF | Electron Transfer Flavoprotein Alpha-Subunit | Electron Transfer Flavoprotein, Alpha Polypeptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514243","Anti-CXCR4 Monoclonal Antibody PF-06747143","C131572","A humanized immunoglobulin (Ig) G1 monoclonal antibody (mAb) against C-X-C chemokine receptor type 4 (CXCR4), with potential antineoplastic activity. Upon administration, anti-CXCR4 mAb PF-06747143 binds to CXCR4, thereby preventing the binding of stromal cell-derived factor-1 (SDF-1 or CXCL12) to CXCR4 and inhibiting CXCR4 activation. This results in decreased proliferation and migration of CXCR4-expressing tumor cells. In addition, PF-06747143 promotes cell death through the induction of both complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) family, is upregulated in several tumor cell types and plays an important role in cancer cell proliferation, survival, and chemotaxis, and in tumor angiogenesis.","Anti-CXCR4 Monoclonal Antibody PF-06747143 | Anti-CXCR4 IgG1 Antibody PF-06747143 | PF 06747143 | PF-06747143",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514293","Frontal Lobe Ependymal Tumor","C131573","A finding indicating the presence of an ependymal tumor in the frontal lobe of the brain.","Frontal Lobe Ependymal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514334","Temporal Lobe Ependymal Tumor","C131574","A finding indicating the presence of an ependymal tumor in the temporal lobe of the brain.","Temporal Lobe Ependymal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519873","HAQ-DI Without VAS - Cut Your Meat","C132577","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Eating: Are you able to cut your meat?","HAQ-DI Without VAS - Cut Your Meat | HAQ02-Cut Your Meat | HAQ0205",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519886","HAQ-DI Without VAS - Lift a Full Cup or Glass to Mouth","C132578","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Eating: Are you able to lift a full cup or glass to your mouth?","HAQ-DI Without VAS - Lift a Full Cup or Glass to Mouth | HAQ02-Lift a Full Cup or Glass to Mouth | HAQ0206",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519900","HAQ-DI Without VAS - Walk Outdoors on Flat Ground","C132580","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Walking: Are you able to walk outdoors on flat ground?","HAQ-DI Without VAS - Walk Outdoors on Flat Ground | HAQ02-Walk Outdoors on Flat Ground | HAQ0208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519872","HAQ-DI Without VAS - Climb Up Five Steps","C132581","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Walking: Are you able to climb up five steps?","HAQ-DI Without VAS - Climb Up Five Steps | HAQ02-Climb Up Five Steps | HAQ0209",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519861","HAQ-DI Without VAS - Aid: Cane","C132582","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Cane.","HAQ-DI Without VAS - Aid: Cane | HAQ02-Aid: Cane | HAQ0210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519869","HAQ-DI Without VAS - Aid: Walker","C132583","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Walker.","HAQ-DI Without VAS - Aid: Walker | HAQ02-Aid: Walker | HAQ0211",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519862","HAQ-DI Without VAS - Aid: Crutches","C132584","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Crutches.","HAQ-DI Without VAS - Aid: Crutches | HAQ02-Aid: Crutches | HAQ0212",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519870","HAQ-DI Without VAS - Aid: Wheelchair","C132585","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Wheelchair.","HAQ-DI Without VAS - Aid: Wheelchair | HAQ02-Aid: Wheelchair | HAQ0213",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519863","HAQ-DI Without VAS - Aid: Devices Used for Dressing","C132586","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Devices used for Dressing (button hook, zipper pull, long-handled shoe horn, etc.).","HAQ-DI Without VAS - Aid: Devices Used for Dressing | HAQ02-Aid: Devices Used for Dressing | HAQ0214",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519860","HAQ-DI Without VAS - Aid: Built Up or Special Utensils","C132587","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Built up or special utensils.","HAQ-DI Without VAS - Aid: Built Up or Special Utensils | HAQ02-Aid: Built Up or Special Utensils | HAQ0215",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519868","HAQ-DI Without VAS - Aid: Special or Built Up Chair","C132588","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Special or built up chair.","HAQ-DI Without VAS - Aid: Special or Built Up Chair | HAQ02-Aid: Special or Built Up Chair | HAQ0216",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515077","Olfactory Supporting Cell","C13152","A cell that serves to provide support and protection to the olfactory epithelium.","Olfactory Supporting Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796232","Bohring-Opitz Syndrome","C131533","An autosomal dominant condition caused by mutation(s) in the ASXL1 gene, encoding putative polycomb group protein ASXL1. It is characterized by severe intrauterine growth retardation, profound mental retardation, craniofacial dysmorphisms, and flexion deformities of the upper limbs.","Bohring-Opitz Syndrome | ",,,,,,,,,,,,,,,"36717129","Bohring Opitz syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514236","Anastomosing Hemangioma","C131760","An unusual variant of capillary hemangioma. It is characterized by a unique anastomosing sinusoidal-like architecture which may mimic angiosarcoma. It was originally described in the kidney but rare cases have been reported in other sites.","Anastomosing Hemangioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414146","DPYSL3 Gene","C131761","This gene is involved in semaphorin signaling and neuronal development.","DPYSL3 Gene | DPYSL3 | Dihydropyrimidinase Like 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514372","DPYSL3 wt Allele","C131762","Human DPYSL3 wild-type allele is located in the vicinity of 5q32 and is approximately 119 kb in length. This allele, which encodes dihydropyrimidinase-related protein 3, plays a role in neuronal development and semaphorin signaling.","DPYSL3 wt Allele | CRMP-4 | CRMP4 | DRP-3 | DRP3 | Dihydropyrimidinase Like 3 wt Allele | Dihydropyrimidinase-Like 3 Gene | LCRMP | ULIP | ULIP-1 | ULIP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0538764","DPYSL3 protein, human","C131763","Dihydropyrimidinase-related protein 3 (570 aa, ~62 kDa) is encoded by the human DPYSL3 gene. This protein is involved in the regulation of both semaphorin signaling and the development of neurons.","Dihydropyrimidinase-Related Protein 3 | CRMP-4 | Collapsin Response Mediator Protein 4 | DPYSL3 | DRP-3 | Testicular Secretory Protein Li 7 | ULIP-1 | Unc-33 Like Phosphoprotein 1 | Unc-33-Like Phosphoprotein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1428960","ARHGAP22 Gene","C131764","This gene plays a role in RAC1 activation.","ARHGAP22 Gene | ARHGAP22 | Rho GTPase Activating Protein 22 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514448","ARHGAP22 wt Allele","C131765","Human ARHGAP22 wild-type allele is located within 10q11.22-q11.23 and is approximately 226 kb in length. This allele, which encodes Rho GTPase-activating protein 22, is involved in the conversion of GTP to GDP.","ARHGAP22 wt Allele | Rho GTPase Activating Protein 22 wt Allele | RhoGAP2 | RhoGap22",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514384","EIF1AX wt Allele","C131316","Human EIF1AX wild-type allele is located in the vicinity of Xp22.13 and is approximately 17 kb in length. This allele, which encodes eukaryotic translation initiation factor 1A, X-chromosomal protein, plays a role in regulating the efficiency of the translation machinery.","EIF1AX wt Allele | EIF1A | EIF1AP1 | EIF4C | Eukaryotic Translation Initiation Factor 1A X-Linked wt Allele | Eukaryotic Translation Initiation Factor 1A, X Chromosome Gene | Eukaryotic Translation Initiation Factor 1A, X-Linked Gene | eIF-1A | eIF-4C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1611071","eukaryotic translation initiation factor 4C, human","C131317","Eukaryotic translation initiation factor 1A, X-chromosomal (144 aa, ~16 kDa) is encoded by the human EIF1AX gene. This protein is involved in the modulation of translation.","Eukaryotic Translation Initiation Factor 1A, X-Chromosomal | EIF1AX | Eukaryotic Translation Initiation Factor 1A | Eukaryotic Translation Initiation Factor 4C | Putative Eukaryotic Translation Initiation Factor 1A | eIF-1A X Isoform | eIF-4C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824418","CEP20 Gene","C131318","This gene plays a role in the formation of cilia and in S phase progression.","CEP20 Gene | CEP20 | Centrosomal Protein 20 Gene | FOPNL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514383","DKFZp686N1651","C131319","Human CEP20 wild-type allele is located in the vicinity of 16p13.11 and is approximately 23 kb in length. This allele, which encodes centrosomal protein 20, is involved in S phase progression and cilia formation.","CEP20 wt Allele | C16orf63 | Centrosomal Protein 20 wt Allele | Chromosome 16 Open Reading Frame 63 Gene | DKFZp686N1651 | FGFR1OP N-Terminal Like Gene | FLJ31153 | FOP-Related Protein, 20-kD Gene | FOPNL | FOR20 | PHSECRG2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229629","Polychromatic Erythroblast","C13131","No value exists.","Polychromatic Erythroblast | Polychromatophilic Erythroblast",,,,,,,,,,,,,,,"4043275","Polychromatophilic erythroblast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514525","FOP-Related Protein of 20 kDa","C131320","Centrosomal protein 20 (174 aa, ~20 kDa) is encoded by the human CEP20 gene. This protein plays a role in ciliogenesis and progression of the S phase of the cell cycle.","Centrosomal Protein 20 | CEP20 | FGFR1OP N-Terminal Domain-Like Protein | FGFR1OP N-Terminal-Like Protein | FOP-Related Protein of 20 kDa | LisH Domain-Containing Protein C16orf63 | LisH Domain-Containing Protein FOPNL | Pluripotent Embryonic Stem Cell-Related Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419333","REG1A Gene","C131322","This gene may be involved in cell proliferation in the brain and pancreas.","REG1A Gene | REG1A | Regenerating Family Member 1 Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514434","REG1A wt Allele","C131323","Human REG1A wild-type allele is located in the vicinity of 2p12 and is approximately 3 kb in length. This allele, which encodes lithostathine-1-alpha protein, may play a role in the modulation of the proliferation of both islet cells and neurons. Gene expression may be associated with both diabetogenesis and pancreatic lithogenesis.","REG1A wt Allele | ICRF | P19 | PSP | PSPS | PSPS1 | PTP | Pancreatic Stone Protein, Secretory Gene | REG | Regenerating Family Member 1 Alpha wt Allele | Regenerating Islet-Derived 1 Alpha (Pancreatic Stone Protein, Pancreatic Thread Protein) Gene | Regenerating Islet-Derived, Rat, Homolog of Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0208940","REG1A protein, human","C131324","Lithostathine-1-alpha (166 aa, ~19 kDa) is encoded by the human REG1A gene. This protein may be involved in the modulation of neuronal and pancreatic cell proliferation.","Lithostathine-1-Alpha | ICRF | Islet Cells Regeneration Factor | Islet of Langerhans Regenerating Protein | Lithostathine | Lithostathine 1 Alpha | PSP | PTP | Pancreatic Stone Protein | Pancreatic Thread Protein | Protein-X | REG | REG1A | Reg-1-Alpha | Regenerating Islet-Derived 1 Alpha | Regenerating Islet-Derived 1-Alpha | Regenerating Islet-Derived Protein 1-Alpha | Regenerating Protein I Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513511","WHODAS 2.0 12-item Version Interviewer-administered - Concentrating for Ten Minutes","C130909","World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Concentrating on doing something for ten minutes?","WHODAS 2.0 12-item Version Interviewer-administered - Concentrating for Ten Minutes | WD1-Concentrating for Ten Minutes | WD1S6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514543","Parietal Lobe Ependymal Tumor","C131575","A finding indicating the presence of an ependymal tumor in the parietal lobe of the brain.","Parietal Lobe Ependymal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514263","Cerebellar Ependymal Tumor","C131576","A finding indicating the presence of an ependymal tumor in the cerebellum.","Cerebellar Ependymal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514683","Ventricular Ependymal Tumor","C131577","A finding indicating the presence of an ependymal tumor in a brain ventricle.","Ventricular Ependymal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514685","Ventricular and Brain Stem Ependymal Tumor","C131578","A finding indicating the presence of an ependymal tumor in a brain ventricle and the brain stem.","Ventricular and Brain Stem Ependymal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0935440","Cuboidal Cell","C13157","A cube-shaped epithelial cell. Because a cuboidal cell has a relatively large cytoplasmic volume, it can undertake more complex functions such as absorption and secretion. Most glandular secretory cells are cuboidal epithelial cells and the ducts of most exocrine glands and kidney tubules are lined by cuboidal cells.","Cuboidal Cell | Cuboidal Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421261","UBASH3A Gene","C131171","This gene may be involved in the negative regulation of T-cell receptor signaling.","UBASH3A Gene | UBASH3A | Ubiquitin Associated and SH3 Domain Containing A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513390","UBASH3A wt Allele","C131172","Human UBASH3A wild-type allele is located in the vicinity of 21q22.3 and is approximately 44 kb in length. This allele, which encodes ubiquitin-associated and SH3 domain-containing protein A, may play a role in the modulation of T-cell receptor signaling pathways.","UBASH3A wt Allele | CLIP4 | STS-2 | STS2 | TULA | TULA-1 | Ubiquitin Associated and SH3 Domain Containing A wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0965248","Ubiquitin-Associated and SH3 Domain-Containing Protein A, Human","C131173","Ubiquitin-associated and SH3 domain-containing protein A (661 aa, ~74 kDa) is encoded by the human UBASH3A gene. This protein may be involved in the inhibition of T-cell receptor signaling.","Ubiquitin-Associated and SH3 Domain-Containing Protein A | CLIP4 | Cbl-Interacting Protein 4 | STS-2 | Suppressor of T-Cell Receptor Signaling | T-Cell Ubiquitin Ligand 1 | T-Cell Ubiquitin Ligand Protein | TULA-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513495","Anti-CD352 Antibody-drug Conjugate SGN-CD352A","C131174","An antibody-drug conjugate (ADC) consisting of an engineered cysteine humanized monoclonal antibody (EC-mAb) targeting CD352 (SLAM family member 6; SLAM6) that is conjugated to the cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of anti-CD352 ADC SGN-CD352A, the antibody moiety targets the cell surface antigen CD352. Upon antibody/antigen binding, internalization, and lysosome uptake, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of CD352-overexpressing tumor cells. CD352, a tumor-associated antigen (TAA), is overexpressed on a variety of cancers. Cysteine engineering of the monoclonal antibody allows for a site-specific, stable conjugation and uniform loading of the PBD agent to the antibody.","Anti-CD352 Antibody-drug Conjugate SGN-CD352A | ADC SGN-CD352A | PBD Dimer ADC SGN-CD352A | PBD-based Anti-CD352 ADC SGN-CD352A | PBD-based Anti-CD352 Antibody-drug Conjugate SGN-CD352A | SGN-CD352A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519890","HAQ-DI Without VAS - Other Aid (Dress or Arising or Eat or Walk)","C132589","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Other (for dressing and grooming, arising, eating and walking).","HAQ-DI Without VAS - Other Aid (Dress or Arising or Eat or Walk) | HAQ02-Othr Aid (Dress/Arising/Eat/Walk) | HAQ0217",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520366","EGFR T790M Antagonist BPI-15086","C131909","An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. EGFR T790M antagonist BPI-15086 specifically binds to and inhibits EGFR T790M, a secondarily acquired resistance mutation, which prevents EGFR-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells. EGFR, a receptor tyrosine kinase that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","EGFR T790M Antagonist BPI-15086 | BPI 15086 | BPI-15086 | BPI15086 | EGFR T790M Inhibitor BPI-15086",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520758","LXR-b Agonist RGX-104","C131910","An orally bioavailable agonist of the nuclear receptor liver X receptor beta (LXRbeta; NR1H2; LXR-b), with potential immunomodulating and antineoplastic activities. Upon oral administration, abequolixron selectively targets and binds to LXRbeta, thereby activating LXRbeta-mediated signaling, leading to the transcription of certain tumor suppressor genes and the downregulation of certain tumor promoter genes. This particularly activates the expression of apolipoprotein E (ApoE), a tumor suppressor protein, in tumor cells and certain immune cells. This activates the innate immune system, resulting in depletion of immunosuppressive myeloid-derived suppressor cells (MDSCs), tumor cells and endothelial cells in the tumor microenvironment. This reverses immune evasion, enhances anti-tumor immune responses and inhibits proliferation of tumor cells. LXRbeta, a member of the oxysterol receptor family, which is in the nuclear receptor family of transcription factors, plays a key role in cholesterol transport, glucose metabolism and the modulation of inflammatory responses; activation of LXRbeta suppresses tumor cell invasion, angiogenesis, tumor progression, and metastasis in a variety of tumor cell types. The expression of the ApoE protein becomes silenced in human cancers as they grow, become invasive, and metastasize; ApoE silencing is related to reduced survival in cancer patients. The LXR-ApoE pathway regulates the ability of cancers to evade the immune system and recruit blood vessels.","Abequolixron | ABEQUOLIXRON | LXR-b Agonist RGX-104 | Liver X Receptor beta Agonist RGX-104 | RGX 104 | RGX-104 | RGX104 | SB-742881",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520066","Mozavaptan Hydrochloride","C132047","No value exists.","Mozavaptan Hydrochloride | MOZAVAPTAN HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520308","Volumetric Contrast-Enhanced Ultrasound Imaging","C132048","A type of contrast-enhanced ultrasound imaging that captures the nonlinear second harmonic signal from microbubble contrast agents flowing in the vasculature to create a 3-dimensional image.","Volumetric Contrast-Enhanced Ultrasound Imaging | VCEUS | VCEUS Imaging | Volumetric Contrast-Enhanced Ultrasound",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520254","Tramiprosate Sodium","C132049","No value exists.","Tramiprosate Sodium | Sodium 3-Aminopropanesulphonate | TRAMIPROSATE SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1260616","Ectopic Thyroid Gland","C132051","Location of the thyroid gland somewhere other than at the base of the neck.","Ectopic Thyroid Gland | Thyroid Ectopy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1179819","Lingual Thyroid Gland","C132052","Ectopic thyroid gland located at the base of the tongue.","Lingual Thyroid Gland | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1445578","Dibotermin Alfa","C132249","A recombinant form of human bone morphogenetic protein 2 (rhBMP-2), with potential bone remodeling and osteoinductive activities. Following administration, dibotermin alfa induces signaling cascades, which leads to osteoblast differentiation, enhancement of bone repair and formation, and improvement of re-vascularization. This promotes bone healing. BMP-2, a protein belonging to the transforming growth factor beta (TGFb) superfamily of proteins, plays a key role in bone and cartilage formation.","Dibotermin Alfa | DIBOTERMIN ALFA | Diotermin | Nebotermin | rhBMP-2 | rhBMP2",,,,,,,,,,,,,,,"4225658","Dibotermin alfa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL520460","NIS793","C132250","A monoclonal antibody directed against human transforming growth factor beta (TGF-beta), with potential antineoplastic activity. Upon administration, nisevokitug targets and binds to TGF-beta, thereby preventing the activation of TGF-beta-mediated signaling pathways. TGF-beta, a pro-inflammatory mediator that is mutated and/or overexpressed in a number of cancer cell types, is involved in cancer cell proliferation and migration, and tumor progression.","Nisevokitug | Anti-TGF-beta Monoclonal Antibody NIS793 | Anti-TGF-beta Monoclonal Antibody NIS793 | NIS-793 | NIS793 | NISEVOKITUG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513527","WHODAS 2.0 12-item Version Interviewer-administered - Walking a Long Distance","C130910","World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Walking a long distance such as a kilometre [or equivalent]?","WHODAS 2.0 12-item Version Interviewer-administered - Walking a Long Distance | WD1-Walking a Long Distance | WD1S7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513528","WHODAS 2.0 12-item Version Interviewer-administered - Washing Your Whole Body","C130911","World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Washing your whole body?","WHODAS 2.0 12-item Version Interviewer-administered - Washing Your Whole Body | WD1-Washing Your Whole Body | WD1S8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513517","WHODAS 2.0 12-item Version Interviewer-administered - Getting Dressed","C130912","World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Getting dressed?","WHODAS 2.0 12-item Version Interviewer-administered - Getting Dressed | WD1-Getting Dressed | WD1S9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513514","WHODAS 2.0 12-item Version Interviewer-administered - Dealing With People You Do Not Know","C130913","World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Dealing with people you do not know?","WHODAS 2.0 12-item Version Interviewer-administered - Dealing With People You Do Not Know | WD1-Dealing With People You Do Not Know | WD1S10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513523","WHODAS 2.0 12-item Version Interviewer-administered - Maintaining a Friendship","C130914","World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Maintaining a friendship?","WHODAS 2.0 12-item Version Interviewer-administered - Maintaining a Friendship | WD1-Maintaining a Friendship | WD1S11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513530","WHODAS 2.0 12-item Version Interviewer-administered - Your Day-to-Day Work or School","C130915","World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Your day-to-day work/school?","WHODAS 2.0 12-item Version Interviewer-administered - Your Day-to-Day Work or School | WD1-Your Day-to-Day Work/School | WD1S12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513518","WHODAS 2.0 12-item Version Interviewer-administered - How Many Days Difficulties Present","C130916","World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) Overall, in the past 30 days, how many days were these difficulties present?","WHODAS 2.0 12-item Version Interviewer-administered - How Many Days Difficulties Present | WD1-How Many Days Difficulties Present | WD1H1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513513","WHODAS 2.0 12-item Version Interviewer-administered - Days Unable to Carry Out Activities","C130917","World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) In the past 30 days, for how many days were you totally unable to carry out your usual activities or work because of any health condition?","WHODAS 2.0 12-item Version Interviewer-administered - Days Unable to Carry Out Activities | WD1-Days Unable to Carry Out Activities | WD1H2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513540","WHODAS 2.0 12-item Version Proxy-administered - I Am the (Fill in the Blank) of This Person","C130919","World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) I am the (Fill in the Blank) of this person.","WHODAS 2.0 12-item Version Proxy-administered - I Am the (Fill in the Blank) of This Person | WD2-I Am (Fill in Blank) of This Person | WD2H4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0426735","Surface of the Prostate","C13091","The external portion of the prostate including the anterior, inferolateral, lateral and posterior surfaces.","Surface of the Prostate | ",,,,,,,,,,,,,,,"4087209","Surface of prostate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4015932","Carbonic Anhydrase I Deficiency","C132290","Decreased or absent activity of the enzyme carbonic anhydrase 1, due to loss-of-function mutation(s) in the gene CA1.","Carbonic Anhydrase I Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0301550","Procaine Merethoxylline","C132291","No value exists.","Procaine Merethoxylline | PROCAINE MERETHOXYLLINE | Procaine Merethoxylline Component of Dicurin Procaine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0393929","Presynaptic Congenital Myasthenic Syndrome 6","C132292","Congenital myasthenic syndrome caused by mutation(s) in the CHAT gene, encoding choline O-acetyltransferase. It is inherited in an autosomal recessive manner.","Presynaptic Congenital Myasthenic Syndrome 6 | CMS6",,,,,,,,,,,,,,,"4048654","Familial infantile myasthenia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL520226","Recurrent Endometrial Serous Adenocarcinoma","C132294","The reemergence of endometrial serous adenocarcinoma after a period of remission.","Recurrent Endometrial Serous Adenocarcinoma | Recurrent Uterine Corpus Serous Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520212","Pralsetinib","C132295","An orally bioavailable selective inhibitor of mutant forms of and fusion products involving the proto-oncogene receptor tyrosine kinase RET, with potential antineoplastic activity. Upon administration, pralsetinib binds to and targets various RET mutants and RET-containing fusion product. RET gene mutations and translocations result in the upregulation and/or activation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role in the development and regression of these cancers.","Pralsetinib | (cis)-N-((S)-1-(6-(4-Fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-1-methoxy-4-(4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-yl)cyclohexanecarboxamide | BLU 667 | BLU-667 | BLU667 | Gavreto | PRALSETINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519902","HAQ-DI Without VAS Questionnaire Question","C132529","A question associated with the HAQ-DI without VAS questionnaire.","HAQ-DI Without VAS Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521014","TSQM Version 1.4 Questionnaire Question","C132530","A question associated with the TSQM Version 1.4 questionnaire.","TSQM Version 1.4 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1610219","WDR5 protein, human","C132136","WD repeat-containing protein 5 (334 aa, ~37 kDa) is encoded by the human WDR5 gene. This protein plays a role in post-translational modification of histone proteins.","WD Repeat-Containing Protein 5 | BMP2-Induced 3-kb Gene Protein | Cilia and Flagella Associated Protein 89 | WDR5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520258","Tutocaine","C132137","No value exists.","Tutocaine | 4-(Dimethylamino)-3-methyl-2-butanol p-Aminobenzoate (Ester) | TUTOCAINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520385","Fenoprofen Sodium","C132138","No value exists.","Fenoprofen Sodium | FENOPROFEN SODIUM | Fenoprofen Na | Propionic Acid, 2-(3-Phenoxyphenyl)-, Sodium Salt, (+-)- | d,l-2-(3-Phenoxyphenyl)propionic Acid, Sodium Salt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520257","Tutocaine Hydrochloride","C132139","No value exists.","Tutocaine Hydrochloride | 4-(Dimethylamino)-3-methyl-2-butanol p-Aminobenzoate (Ester) Hydrochloride | TUTOCAINE HYDROCHLORIDE | Tutocaine HCl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422243","SH3KBP1 Gene","C132140","This gene is involved in the regulation of protein-protein interactions in signaling pathways.","SH3KBP1 Gene | SH3 Domain Containing Kinase Binding Protein 1 Gene | SH3KBP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520447","SH3KBP1 wt Allele","C132141","Human SH3KBP1 wild-type allele is located in the vicinity of Xp22.12 and is approximately 354 kb in length. This allele, which encodes SH3 domain-containing kinase-binding protein 1, plays a role in adaptor signaling protein activity.","SH3KBP1 wt Allele | CD2BP3 | CIN85 | Cbl-Interacting Protein, 85-kD Gene | GIG10 | HSB-1 | HSB1 | MIG18 | SH3 Domain Containing Kinase Binding Protein 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0293666","Terdecamycin","C132142","No value exists.","Terdecamycin | 1-Pipeprazinecarboxylic Acid, 4-Methyl-, 7-Ester with (-)-N-(1S,2R,3E,5E,7S,9E,11E,13S,15R,19R)-7,13-dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo(13.2.2)nonadeca-3,5,9,11-tetraen-2-yl)pyruvamide | TERDECAMYCIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1432707","SH3 Domain-Containing Kinase-Binding Protein 1","C132143","SH3 domain-containing kinase-binding protein 1 (665 aa, ~73 kDa) is encoded by the human SH3KBP1 gene. This protein is involved in the modulation of protein-protein interactions.","SH3 Domain-Containing Kinase-Binding Protein 1 | C-Cbl-Interacting Protein | CD2-Binding Protein 3 | CD2BP3 | Cbl-Interacting Protein of 85 kDa | HSB-1 | Human Src Family Kinase-Binding Protein 1 | SH3 Domain Containing Kinase Binding Protein 1 | SH3-Domain Kinase Binding Protein 1 | SH3KBP1 | Src Family Kinase-Binding Protein 1 | Src-Related Kinase Binding Protein-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0957938","Roxindole Hydrochloride","C132144","No value exists.","Roxindole Hydrochloride | 1H-Indol-5-ol, 3-(4-(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)butyl)-, Monohydrochloride | ROXINDOLE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2350692","Pocapavir","C132145","No value exists.","Pocapavir | 4-Amino-1-(4-C-Azido-2',3',5'-Tri-O-(2-Methylpropanoyl)-Beta-D-Ribofuranosyl)Pyrimidin- 2(1H)-One | Benzene, 1-((2-Chloro-4-methoxyphenoxy)methyl)-4-((2,6-dichlorophenoxy)methyl)- | POCAPAVIR | Sch-48973 | V-073",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520586","Autologous PD-1-targeted Chimeric Switch Receptor-modified T Lymphocytes","C132251","Autologous human T-lymphocytes that are genetically engineered to express a chimeric switch receptor (CSR) composed of the extracellular ligand binding domain of the human inhibitory receptor programmed cell death protein 1 (PD-1; PDCD1) fused to the transmembrane and cytoplasmic co-stimulatory signaling domains of CD28 (PD1CD28; PD-1:CD28 switch receptor), with potential immunomodulating and antineoplastic activities. Upon reintroduction of autologous PD-1-targeted CSR-modified T-lymphocytes into the patient, the switch receptor expressed by the engineered T-cells targets and binds to the PD-1 ligands, programmed cell death ligand 1 (PD-L1) and 2 (PD-L2) expressed, on tumor cells. The nature of the PD-1/CD28 switch receptor fusion protein prevents the normal PD1/PD-L1-mediated T-cell suppression and, instead, promotes signaling through the CD28 domain, which results in the stimulation of T-lymphocytes. This induces enhanced toxicity against PD-L1-expressing tumor cells. PD-1 protein, found on activated T-cells, negatively regulates T-cell activity; it plays a key role in immune evasion and prevents tumor cell lysis. Exchanging the transmembrane and intracellular domain of PD-1 with that of CD28 converts PD-L1 into a co-stimulation ligand of primary human CD8+ cytotoxic T-lymphocytes (CTLs). CD28, is a molecule expressed by T-cells that stimulates increased T-lymphocyte proliferation and activity.","Autologous PD-1-targeted Chimeric Switch Receptor-modified T Lymphocytes | Autologous Chimeric Switch Receptor PD-1:CD28 Modified T Cells | Autologous PD-1-targeted CSR T Cells | Chimeric Switch Receptor PD1CD28 Modified T Cells | PD1CD28 CSR T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520361","BI 754091","C132252","A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death protein 1 (PD-1; PDCD1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, ezabenlimab selectively binds to and blocks the activation of PD-1, an immunoglobulin (Ig) superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and T-cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","Ezabenlimab | Anti-PD-1 Monoclonal Antibody BI 754091 | BI 754091 | EZABENLIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520467","Neck Lymph Node Boundary Levels and Sublevels","C132494","The anatomical structures that define the neck lymph node boundaries.","Neck Lymph Node Boundary Levels and Sublevels | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514455","CXCR4 Antagonist USL311","C131534","An orally bioavailable inhibitor of C-X-C chemokine receptor type 4 (CXCR4), with potential antineoplastic activity. Upon administration, USL311 binds to CXCR4, thereby preventing the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4 and inhibiting CXCR4 activation, which may result in decreased proliferation and migration of CXCR4-expressing tumor cells. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) family, plays an important role in chemotaxis and angiogenesis, and is upregulated in several tumor cell types.","CXCR4 Antagonist USL311 | CXCR4 Inhibitor USL311 | USL 311 | USL-311 | USL311",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2976005","Osilodrostat","C131535","An orally bioavailable inhibitor of both steroid 11beta-hydroxylase (cytochrome P450 (CYP) 11B1) and aldosterone synthase (CYP11B2; steroid 18-hydroxylase), with potential anti-adrenal activity and ability to treat Cushing disease (CD). Upon administration, osilodrostat binds to and inhibits the activity of CYP11B1, the enzyme that catalyzes the final step of cortisol synthesis from the precursor 11-deoxycortisol, and CYP11B2, the enzyme that catalyzes aldosterone synthesis from corticosterone and 11-deoxycorticosterone in the adrenal gland. The inhibition of CYP11B1 prevents the production of excess cortisol, thereby decreasing and normalizing the levels of cortisol. CD is most often caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary tumor.","Osilodrostat | (R)-4-(6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluorobenzonitrile | LCI 699 | LCI-699 | LCI699 | OSILODROSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514526","Non-Fucosylated Umbilical Cord Blood Regulatory T-cells","C131536","A preparation of non-fucosylated regulatory T-lymphocytes (Tregs) allogeneically derived from umbilical cord blood (UCB), with potential immunomodulating activity. Tregs are essential in maintaining immunologic homeostasis, preventing autoimmunity, through the suppression of self-reactive T-cells, and they may induce tolerance to allogeneic organ transplants, including hematopoetic stem cell transplants (HSCTs). Administration of the non-fucosylated UCB Tregs upon HSCT may prevent or reduce graft-versus host disease (GVHD).","Non-Fucosylated Umbilical Cord Blood Regulatory T-cells | Non-Fucosylated UCB Regulatory T-cells | Non-Fucosylated UCB Tregs | Non-Fucosylated Umbilical Cord Blood Tregs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514246","Anti-PD-L1 Monoclonal Antibody FAZ053","C131537","A monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1), with immune checkpoint inhibitory and potential antineoplastic activities. Upon administration, anti-PD-L1 monoclonal antibody FAZ053 binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated anti-tumor immune response and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T-cells.","Anti-PD-L1 Monoclonal Antibody FAZ053 | FAZ 053 | FAZ-053 | FAZ053",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422819","EGLN2 Gene","C131538","This gene is involved in the response to hypoxia.","EGLN2 Gene | EGLN2 | Egl-9 Family Hypoxia-Inducible Factor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514488","EGLN2 wt Allele","C131539","Human EGLN2 wild-type allele is located in the vicinity of 19q13.2 and is approximately 9 kb in length. This allele, which encodes egl nine homolog 2 protein, plays a role in the cellular response to hypoxia.","EGLN2 wt Allele | EGL Nine (C.elegans) Homolog 2 Gene | EGL9, C. elegans, Homolog of, 2 Gene | EIT6 | Egl Nine Homolog 2 (C. elegans) Gene | Egl-9 Family Hypoxia-Inducible Factor 2 wt Allele | HIF-PH1 | HIFP4H1 | HIFPH1 | HPH-1 | HPH-3 | PHD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1179114","Olfactory Basal Cell","C13153","A cell found in the pseudostratified epithelium lining the olfactory region of the nasal cavity. It gives rise to olfactory receptor cells and sustentacular cells.","Olfactory Basal Cell | Olfactory Basal Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1310406","EGLN2 protein, human","C131540","Egl nine homolog 2 (407 aa, ~44 kDa) is encoded by the human EGLN2 gene. This protein is involved in the hydroxylation of hypoxia-inducible factor alpha proteins.","Egl Nine Homolog 2 | EC 1.14.11.29 | EGLN2 | Estrogen-Induced Tag 6 | HIF Prolyl 4-Hydroxylase 1 | HIF Prolyl Hydroxylase 1 | HIF-PH1 | HIF-Prolyl Hydroxylase 1 | HPH-1 | HPH-3 | Hypoxia-Inducible Factor Prolyl 4-Hydroxylase 1 | Hypoxia-Inducible Factor Prolyl Hydroxylase 1 | PHD1 | Prolyl Hydroxylase Domain-Containing Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514343","Timolumab","C131541","No value exists.","Timolumab | BTT 1023 | BTT-1023 | SI-3106 | TIMOLUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414668","FOXC1 Gene","C131542","This gene plays a role in the regulation of both embryonic and ocular development.","FOXC1 Gene | FOXC1 | Forkhead Box C1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520109","NSAA - Stand","C132536","North Star Ambulatory Assessment (NSAA) Can you stand up tall for me for as long as you can and as still as you can.","NSAA - Stand | NSAA1-Stand | NSAA101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520111","NSAA - Walk","C132537","North Star Ambulatory Assessment (NSAA) Can you walk from A to B (state to and where from) for me.","NSAA - Walk | NSAA1-Walk | NSAA102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520105","NSAA - Stand Up From Chair","C132538","North Star Ambulatory Assessment (NSAA) Stand up from the chair keeping your arms folded if you can.","NSAA - Stand Up From Chair | NSAA1-Stand Up From Chair | NSAA103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520107","NSAA - Stand on One Leg - Right","C132539","North Star Ambulatory Assessment (NSAA) Can you stand on your right leg for as long as you can?","NSAA - Stand on One Leg - Right | NSAA1-Stand on One Leg - Right | NSAA104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520106","NSAA - Stand on One Leg - Left","C132540","North Star Ambulatory Assessment (NSAA) Can you stand on your left leg for as long as you can?","NSAA - Stand on One Leg - Left | NSAA1-Stand on One Leg - Left | NSAA105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520294","Unresectable Leiomyosarcoma","C132147","A leiomyosarcoma which is not amenable to surgical resection.","Unresectable Leiomyosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520295","Unresectable Liposarcoma","C132148","A liposarcoma which is not amenable to surgical resection.","Unresectable Liposarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425460","PADI2 Gene","C132149","This gene plays a role in post-translational deimination of proteins.","PADI2 Gene | PADI2 | Peptidyl Arginine Deiminase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520486","PADI2 wt Allele","C132150","Human PADI2 wild-type allele is located in the vicinity of 1p36.13 and is approximately 53 kb in length. This allele, which encodes protein-arginine deiminase type-2 protein, is involved in arginine residue metabolism.","PADI2 wt Allele | KIAA0994 | PAD-H19 | PAD2 | PDI2 | Peptidyl Arginine Deiminase 2 wt Allele | Peptidyl Arginine Deiminase, Type II Gene | Peptidylarginine Deiminase, Type II Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520197","Protein-Arginine Deiminase Type-2","C132151","Protein-arginine deiminase type-2 (665 aa, ~76 kDa) is encoded by the human PADI2 gene. This protein plays a role in the conversion of arginine residues to citrulline.","Protein-Arginine Deiminase Type-2 | EC 3.5.3.15 | PAD-H19 | PADI2 | Peptidyl Arginine Deiminase 2 | Peptidylarginine Deiminase II | Protein-Arginine Deiminase Type II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521665","Best Observed Case Imputation Technique","C132340","A data imputation technique that populates analysis values with the best outcome recorded within a subject.","Best Observed Case Imputation Technique | BOC | Best Observed Case",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521196","Last Observed Value Imputation Technique","C132341","A data imputation technique that populates analysis values with the subject's last recorded nonmissing observation.","Last Observed Value Imputation Technique | LOV | Last Observed Value",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521197","Last Value Prior to Dosing Imputation Technique","C132342","A data imputation technique that populates missing values with the subject's last observed value prior to the start of study treatment.","Last Value Prior to Dosing Imputation Technique | LVPD | Last Value Prior to Dosing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520568","Alternate Protocol Identifier","C132344","A unique code that identifies a specific protocol assigned by an affiliated governing body or other organization.","Alternate Protocol Identifier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519700","Brief Protocol Title","C132345","The short, descriptive name for the protocol.","Brief Protocol Title | Abbreviated Protocol Title",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521224","Official Protocol Title","C132346","The formal, descriptive name of the protocol.","Official Protocol Title | official protocol title | scientific protocol title",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520199","Protocol Amendment","C132347","A written description of a change(s) to, or formal clarification of, a protocol. (ICH E6)","Protocol Amendment | Study Protocol Amendment | protocol amendment(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520232","Registry Protocol Identifier","C132348","A unique code, which is assigned by the clinical trial registry, that identifies a specific protocol.","Registry Protocol Identifier | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521320","Schedule of Activities","C132349","A planned list of clinical trial activities to include interventions, assessments, and study administrative activities.","Schedule of Activities | Schedule of Events | SoA | schedule of activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522551","Recombinant Interleukin-9","C1324","A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin-9 (IL-9). Produced by CD4+ lymphocytes, IL-9 stimulates the proliferation of T-helper cells and the growth of mast cells and megakaryoblasts.  This agent also enhances the growth of some leukemia cell lines and may play a role in the pathogenesis of Hodgkin disease and large cell anaplastic lymphoma. (NCI04)","Recombinant Interleukin-9 | IL-9 | INTERLEUKIN-9 | Interleukin 9 | P40 T-Cell Growth Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520717","Grade II Glioma","C132505","A category of low grade gliomas that includes diffuse astrocytoma, ependymoma, oligodendroglioma, and oligoastrocytoma.","WHO Grade 2 Glioma | Grade 2 Glioma | Grade II Glioma | WHO Grade II Glioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514652","Hepatocyte Nuclear Factor 4-Alpha Hyperinsulinism","C131834","Hyperinsulinism due to mutation(s) in the gene HNF4A, encoding the transcription factor hepatocyte nuclear factor 4-alpha. This condition may progress to diabetes later in life.","Hepatocyte Nuclear Factor 4-Alpha Hyperinsulinism | HNF4A-Associated Hyperinsulinism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514656","Hyperinsulinism in the Infant of a Diabetic Mother","C131835","Transient hypoglycemia that occurs in the infant of a diabetic mother due to increased postnatal insulin release as a result of in utero exposure to maternal hyperglycemia.","Hyperinsulinism in the Infant of a Diabetic Mother | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342278","Insulin Resistant Diabetes Mellitus with Acanthosis Nigricans and Hyperandrogenism","C131836","A syndrome of insulin resistance caused by mutation(s) in the INSR gene, encoding the insulin receptor. This condition is characterized by a clinical triad of hyperinsulinemia, acanthosis nigricans, and hyperandrogenism without lipodystrophy. This is the least severe of a spectrum of disorders; the other two conditions are Rabson-Mendenhall Syndrome and Donohoe Syndrome.","Insulin Resistant Diabetes Mellitus with Acanthosis Nigricans and Hyperandrogenism | Type A Insulin Resistance Syndrome",,,,,,,,,,,,,,,"4030063|4321756","Hereditary benign acanthosis nigricans with insulin resistance|Acanthosis nigricans due to type 2 diabetes mellitus",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL514403","FOXC1 wt Allele","C131543","Human FOXC1 wild-type allele is located in the vicinity of 6p25 and is approximately 4 kb in length. This allele, which encodes forkhead box protein C1, is involved in both embryogenesis and eye development. Mutations in this gene are associated with Peters anomaly, primary congenital glaucoma, autosomal dominant iridogoniodysgenesis type 1, and Axenfeld Rieger syndrome 3.","FOXC1 wt Allele | ARA | FKHL7 | FREAC-3 | FREAC3 | Forkhead Box C1 wt Allele | Forkhead, Drosophila, Homolog-Like 7 Gene | IGDA | IHG1 | IRID1 | RIEG3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0333805","Macrocytic Red Blood Cell","C13112","An abnormally large red blood cell occurring mainly in anemias (as pernicious anemia), also called megalocyte.  Lack of vitamin B12 and folic acid could also cause macrocytes. (NCI)","Macrocytic Red Blood Cell | Macrocyte | Macrocytes",,,,,,,,,,,,,,,"4127153","Macrocytic erythrocyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514182","STAT5B Deficiency","C131130","Growth hormone insensitivity syndrome caused by mutation(s) in the STAT5B gene, encoding signal transducer and activator of transcription 5B, a protein critical for the transcription of growth hormone-dependent genes.","STAT5B Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2932717","Secondary Parathyroid Hormone Resistance","C131132","Parathyroid hormone (PTH) resistance caused by vitamin D deficiency and characterized by clinically increased PTH concentrations with relative hyperphosphatemia. The diagnosis can be confirmed by finding of a normal cyclic adenosine monophosphate (cAMP) response to PTH infusion, but deficient phosphaturic response, indicating a defect distal to cAMP generation in renal cells.","Secondary Parathyroid Hormone Resistance | Acquired Parathyroid Hormone Resistance | Pseudohypoparathyroidism, Type 2",,,,,,,,,,,,,,,"4171210","Pseudohypoparathyroidism type II",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0265301","Sclerosteosis","C131133","An autosomal recessive form of craniotubular hyperostosis due to loss-of-function mutation(s) in the SOST gene, encoding sclerostin. Clinical features include tall stature, enlarged jaw and facial bones, and cranial nerve compression leading to hearing loss and facial palsy. About two-thirds of patients have syndactyly and/or nail malformations. Increased intracranial pressure due to the thickened calvaria and skull base can occur.","Sclerosteosis | Cortical Hyperostosis with Syndactyly",,,,,,,,,,,,,,,"4069829","Sclerosteosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514183","Salt-Wasting 21-Hydroxylase Deficiency","C131134","A classic form of congenital adrenal hyperplasia characterized by complete absence of 21-hydroxylase activity resulting in deficiency of glucocorticoids and mineralocorticoids accompanied by androgen excess causing virilization in female infants. Mineralocorticoid deficiency results in renal salt-wasting, and if untreated, hyponatremia, hyperkalemia, and shock.","Salt-Wasting 21-Hydroxylase Deficiency | Salt-wasting 21-OHD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2932715","Renal Parathyroid Hormone Resistance","C131135","Parathyroid hormone resistance caused by defects in methylation in the GNAS gene that cause loss of expression of Gs-alpha from the maternal allele in renal tissue, resulting in decreased phosphate excretion and increased calcium excretion. Individuals with this condition may also have brachydactyly and partial resistance to thyroid-stimulating hormone.","Renal Parathyroid Hormone Resistance | Pseudohypoparathyroidism Type 1b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520373","SOSTDC1 wt Allele","C132098","Human SOSTDC1 wild-type allele is located in the vicinity of 7p21.2 and is approximately 69 kb in length. This allele, which encodes sclerostin domain-containing protein 1, plays a role in the modulation of bone morphogenic protein-dependent signaling pathways.","SOSTDC1 wt Allele | CDA019 | DAND7 | DKFZp564D206 | ECTODIN | Sclerostin Domain Containing 1 wt Allele | USAG1 | Uterine Sensitization-Associated Gene 1 | WISE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1434090","Sclerostin Domain-Containing Protein 1, Human","C132099","Sclerostin domain-containing protein 1 (206 aa, ~23 kDa) is encoded by the human SOSTDC1 gene. This protein is involved in the inhibition of bone morphogenic proteins.","Sclerostin Domain-Containing Protein 1 | Cystine-Knot Containing Secreted Protein | Ectodermal BMP Inhibitor | Ectodin | USAG-1 | Uterine Sensitization-Associated Gene 1 Protein | Uterine Sensitization-Associated Protein-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522550","Recombinant Interleukin-10","C1320","A recombinant cytokine chemically identical to or similar to interleukin-10 (IL-10) secreted by certain leukocytes with immunomodulatory activities. IL-10 is an anti-inflammatory cytokine, capable of inhibiting synthesis of pro-inflammatory cytokines, such as Interferon-gamma, IL-2, IL-3, TNF-alpha, and GM-CSF. However, it also has stimulatory effects on certain T cells, mast cells, and B cells, as well as inducing expression of class II major histocompatibility complex.","Recombinant Interleukin 10 | B cell-derived T cell growth factor | CSIF | Cytokine Synthesis Inhibitory Factor | IL-10 | Interleukin-10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521271","Scientific Protocol Title","C132350","The descriptive name of the protocol that is intended for medical professionals, and which is written using medical and scientific language.","Scientific Protocol Title | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521147","Sponsor Protocol Identifier","C132351","A unique code, which is assigned by the sponsor, that identifies a specific protocol.","Sponsor Protocol Identifier | Sponsor Protocol Code | Sponsor Protocol Number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520200","Study Protocol Version Approval Date","C132352","Date protocol that was finalized or approved internally by the sponsor.","Protocol Approval by Sponsor Date | Protocol Amendment Approval by Sponsor Date | Sponsor Approval Date | Study Protocol Version Approval Date | Study Protocol Version Approval by Sponsor Date",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521083","Induced Expectoration Technique","C132353","A type of expectoration procedure in which hypotonic saline is inhaled, making lung secretions easier to cough up.","Induced Expectoration Technique | INDUCED EXPECTORATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520347","Associated Persons Demographics Submission Domain","C132354","An associated persons domain utilized for the submission of information encompassing and representing data, vocabulary, or records related to demographics.","Associated Persons Demographics Submission Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519895","HAQ-DI Without VAS - Special Aid (Dress or Arising or Eat or Walk)","C132590","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Other (specify) - for dressing and grooming, arising, eating and walking.","HAQ-DI Without VAS - Special Aid (Dress or Arising or Eat or Walk) | HAQ02-Spec Aid (Dress/Arising/Eat/Walk) | HAQ0218",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519879","HAQ-DI Without VAS - Help: Dressing and Grooming","C132591","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Usually need help from another person: Dressing and grooming.","HAQ-DI Without VAS - Help: Dressing and Grooming | HAQ02-Help: Dressing and Grooming | HAQ0219",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519878","HAQ-DI Without VAS - Help: Arising","C132592","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Usually need help from another person: Arising.","HAQ-DI Without VAS - Help: Arising | HAQ02-Help: Arising | HAQ0220",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519880","HAQ-DI Without VAS - Help: Eating","C132593","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Usually need help from another person: Eating.","HAQ-DI Without VAS - Help: Eating | HAQ02-Help: Eating | HAQ0221",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519885","HAQ-DI Without VAS - Help: Walking","C132594","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Usually need help from another person: Walking.","HAQ-DI Without VAS - Help: Walking | HAQ02-Help: Walking | HAQ0222",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514669","Mitochondrial Hydroxyacyl-Coenzyme A Dehydrogenase Hyperinsulinism","C131837","Hyperinsulinism due to inactivating mutation(s) in the gene HADH, encoding mitochondrial (short-chain) hydroxyacyl-coenzyme A dehydrogenase, resulting in loss of inhibition of glutamate dehydrogenase (GDH). This condition is also characterized by protein-induced hypoglycemia, but in contrast to GLUD1-associated hyperinsulinism, hyperammonemia is absent.","Mitochondrial Hydroxyacyl-Coenzyme A Dehydrogenase Hyperinsulinism | HADH-Associated Hyperinsulinism | SCHAD Hyperinsulinism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514670","Mitochondrial Uncoupling Protein 2 Hyperinsulinism","C131838","Hyperinsulinism due to mutation(s) in the gene UCP2, encoding mitochondrial uncoupling protein 2, which plays a role in attenuating insulin secretion.","Mitochondrial Uncoupling Protein 2 Hyperinsulinism | UCP2 Hyperinsulinism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1864902","Monocarboxylate Transporter 1 Hyperinsulinism","C131839","Hyperinsulinism due to mutation(s) in the regulatory region of the SLC16A1 gene, encoding monocarboxylate transporter 1 (MCT1). The mutation(s) result in aberrant expression of MCT1 in the beta cell, leading to inappropriate insulin secretion and hypoglycemia triggered by anaerobic exercise.","Monocarboxylate Transporter 1 Hyperinsulinism | Exercise-induced Hyperinsulinism | MCT1 Hyperinsulinism",,,,,,,,,,,,,,,"37396132","Exercise-induced hyperinsulinism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0222658","Endosteum","C13183","A thin vascular connective tissue membrane that lines the medullary cavities of bone.","Endosteum | ",,,,,,,,,,,,,,,"4238225","Endosteum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514671","Monogenic Hyperinsulinism","C131840","A genetically heterogenous group of hyperinsulinemic conditions caused by mutation(s) in one of the many genes involved in the regulation of insulin secretion.","Monogenic Hyperinsulinism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514531","Obesity-Associated Insulin Resistance","C131841","Insulin resistance associated with obesity, which may be attributed in part to impaired insulin signaling in target tissues, or impaired insulin-stimulated glucose transport due to reduced expression of the glucose transporter protein 4.","Obesity-Associated Insulin Resistance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514522","KATP-Associated Hyperinsulinism","C131842","Hyperinsulinism caused by non-functional beta-cell ATP-sensitive potassium channels due to inactivating mutation(s) in either the ABCC8 or KCNJ11 gene.","KATP-Associated Hyperinsulinism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514635","Diffuse KATP-Associated Hyperinsulinism","C131843","KATP-associated hyperinsulinism affecting all pancreatic beta cells.","Diffuse KATP-Associated Hyperinsulinism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514519","K ATP Associated Developmental Delay, Epilepsy and Neonatal Diabetes","C131845","A condition characterized by K ATP channel-associated permanent neonatal diabetes mellitus accompanied by neurological manifestations of developmental delay and epilepsy that may be associated with the severity of the mutation(s).","K ATP Associated Developmental Delay, Epilepsy and Neonatal Diabetes | DEND Syndrome",,,,,,,,,,,,,,,"36715417","DEND syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1832386","K ATP Associated Transient Neonatal Diabetes Mellitus","C131846","K ATP channel-associated neonatal diabetes mellitus that resolves spontaneously.","K ATP Associated Transient Neonatal Diabetes Mellitus | TNDM",,,,,,,,,,,,,,,"43531645","Diabetes mellitus, transient neonatal 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514520","K ATP Channel-Associated Diabetes Mellitus","C131847","Diabetes mellitus caused by activating mutation(s) in genes (KNCJ11 and/or ABCC8) encoding either of the 2 proteins (Kir6.2 and/or SUR1) that make up the pancreatic beta cell adenosine triphosphate-sensitive potassium channel, which is crucial for the regulation of glucose-induced insulin secretion.","K ATP Channel-Associated Diabetes Mellitus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514521","K ATP Permanent Neonatal Diabetes","C131848","K ATP channel-associated neonatal diabetes mellitus that does not resolve spontaneously.","K ATP Permanent Neonatal Diabetes | PNDM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520437","Iodine Deficiency Hypothyroidism","C132053","Hypothyroidism due to insufficient intake of iodine.","Iodine Deficiency Hypothyroidism | Hypothyroidism due to Iodine Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520381","Euthyroid Condition","C132054","Derangement of the thyroid gland or thyroid hormone metabolism that is unaccompanied by signs or symptoms of hypothyroidism or hyperthyroidism.","Euthyroid Condition | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1837895","ARHGAP32 Gene","C131139","This gene is involved in both small GTPase activity and NMDA receptor signaling.","ARHGAP32 Gene | ARHGAP32 | Rho GTPase Activating Protein 32 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514539","POLE Exonuclease Domain Mutation","C131329","A missense mutation in the POLE gene located in the region that encodes the exonuclease domain of the DNA polymerase epsilon catalytic subunit A protein (POLE protein). These mutations lead to defective DNA proof-reading by POLE protein during DNA replication and have been reported in patients with colorectal carcinoma and certain subtypes of endometrial carcinoma.","POLE Exonuclease Domain Mutation | DNA Polymerase Epsilon Catalytic Subunit A Exonuclease Domain Mutation | DNA Polymerase Epsilon, Catalytic Subunit Exonuclease Domain Mutation | POLE1 Exonuclease Domain Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518620","Orthochromatic Erythroblast","C13132","A cell derived from a polychromatophilic erythroblast in bone marrow. It has a dense nucleus and its cytoplasm is approaching the color of a mature erythrocyte. It differentiates into a reticulocyte when it extrudes its nucleus.","Orthochromatic Erythroblast | Acidophilic Erythroblast | Orthochromatophilic Erythroblast | Oxyphilic Erythroblast",,,,,,,,,,,,,,,"4034506","Orthochromic normoblast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521169","Acute Myeloid Leukemia with t(10;11)(p12.3;q23.3); MLLT10-KMT2A","C132101","An acute myeloid leukemia characterized by t(10;11)(p12.3;q23.3) resulting in MLLT10-KMT2A gene fusion. It is associated with an unfavorable prognosis.","Acute Myeloid Leukemia with t(10;11)(p12.3;q23.3); MLLT10-KMT2A | Acute Myeloid Leukemia (AML) with t(10;11)(p12.3;q23.3); KMT2A::MLLT10 | Acute Myeloid Leukemia (AML) with t(10;11)(p12.3;q23.3); MLL-MLLT10 | Acute Myeloid Leukemia (AML) with t(10;11)(p12;q23); KMT2A::MLLT10 | Acute Myeloid Leukemia (AML) with t(10;11)(p12;q23); MLL-MLLT10 | Acute Myeloid Leukemia with t(10;11)(p12.3;q23.3); MLL-MLLT10 | Acute Myeloid Leukemia with t(10;11)(p12.3;q23.3); MLLT10- KMT2A | Acute Myeloid Leukemia with t(10;11)(p12.3;q23.3); MLLT10-KMT2A Fusion | Acute Myeloid Leukemia with t(10;11)(p12.3;q23.3); MLLT10-MLL | Acute Myeloid Leukemia with t(10;11)(p12.3;q23.3); MLLT10::KMT2A Fusion | Acute Myeloid Leukemia with t(10;11)(p12;q23); MLL-MLLT10 | Acute Myeloid Leukemia with t(10;11)(p12;q23); MLLT10-MLL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521170","Acute Myeloid Leukemia with t(6;11)(q27;q23); KMT2A-MLLT4","C132105","An acute myeloid leukemia characterized by t(6;11)(q27;q23.3) resulting in MLLT4-KMT2A gene fusion. It is associated with an unfavorable prognosis.","Acute Myeloid Leukemia with t(6;11)(q27;q23.3); MLLT4-KMT2A | Acute Myeloid Leukemia (AML) with t(6;11)(q27;q23); KMT2A-MLLT4 | Acute Myeloid Leukemia (AML) with t(6;11)(q27;q23.3); KMT2A-MLLT4 | Acute Myeloid Leukemia with t(6;11)(q27;q23); KMT2A-MLLT4 | Acute Myeloid Leukemia with t(6;11)(q27;q23); KMT2A::MLLT4 | Acute Myeloid Leukemia with t(6;11)(q27;q23); MLL-MLLT4 | Acute Myeloid Leukemia with t(6;11)(q27;q23); MLLT4-MLL | Acute Myeloid Leukemia with t(6;11)(q27;q23.3); KMT2A-MLLT4 | Acute Myeloid Leukemia with t(6;11)(q27;q23.3); KMT2A::MLLT4 | Acute Myeloid Leukemia with t(6;11)(q27;q23.3); MLLT4- KMT2A | Acute Myeloid Leukemia with t(6;11)(q27;q23.3); MLLT4-KMT2A Fusion | Acute Myeloid Leukemia with t(6;11)(q27;q23.3); MLLT4-MLL | Acute Myeloid Leukemia with t(6;11)(q27;q23.3); MLLT4::KMT2A Fusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423286","OR51E2 Gene","C132106","This gene may play a role in olfactory chemosensation.","OR51E2 Gene | OR51E2 | Olfactory Receptor Family 51 Subfamily E Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520470","OR51E2 wt Allele","C132107","Human OR51E2 wild-type allele is located in the vicinity of 11p15.4 and is approximately 18 kb in length. This allele, which encodes olfactory receptor 51E2 protein, may be involved in olfaction.","OR51E2 wt Allele | OR51E3P | OR52A2 | Olfactory Receptor Family 51 Subfamily E Member 2 wt Allele | Olfactory Receptor Family 52 Subfamily A Member 2 Gene | Olfactory Receptor, Family 51, Subfamily E, Member 2 Gene | Olfactory Receptor, Family 51, Subfamily E, Member 3 Pseudogene Gene | Olfactory Receptor, Family 52, Subfamily A, Member 2 Gene | PSGR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521225","Olfactory Receptor 51E2","C132108","Olfactory receptor 51E2 (320 aa, ~35 kDa) is encoded by the human OR51E2 gene. This protein may play a role in binding odorant molecules.","Olfactory Receptor 51E2 | HPRAJ | Olfactory Receptor OR11-16 | Prostate Specific G Protein-Coupled Receptor | Prostate Specific G-Protein Coupled Receptor | Prostate-Specific G-Protein Coupled Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520582","Atypical Pituitary Neuroendocrine Tumor","C132296","A usually aggressive and invasive pituitary neuroendocrine tumor characterized by excessive p53 immunoreactivity, increased mitotic activity, and MIB-1 proliferative index greater than 3%.","Atypical Pituitary Neuroendocrine Tumor | Atypical PitNET/Adenoma | Atypical Pituitary Gland Adenoma | Atypical Pituitary Gland Adenoma | Atypical Pituitary Neuroendocrine Tumor/Adenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519719","CDISC Protocol Terminology","C132298","The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) protocol group.","CDISC Protocol Terminology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013948","Embryonic Structure","C13229","A body part, organ or organ component that is formed during the embryonic stage of life of an organism.","Embryonic Structure | Embryologic Structure",,,,,,,,,,,,,,,"4280957","Embryonic structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL519901","HAQ-DI Without VAS - Wash and Dry Your Body","C132595","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Hygiene: Are you able to wash and dry your body?","HAQ-DI Without VAS - Wash and Dry Your Body | HAQ02-Wash and Dry Your Body | HAQ0223",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519898","HAQ-DI Without VAS - Take a Tub Bath","C132596","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Hygiene: Are you able to take a tub bath?","HAQ-DI Without VAS - Take a Tub Bath | HAQ02-Take a Tub Bath | HAQ0224",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519877","HAQ-DI Without VAS - Get On and Off The Toilet","C132597","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Hygiene: Are you able to get on and off the toilet?","HAQ-DI Without VAS - Get On and Off The Toilet | HAQ02-Get On and Off The Toilet | HAQ0225",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519892","HAQ-DI Without VAS - Reach-Get Down 5 Lb Object Above Head","C132598","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Reach: Are you able to reach and get down a 5-pound object (such as a bag of sugar) from just above your head?","HAQ-DI Without VAS - Reach-Get Down 5 Lb Object Above Head | HAQ02-Reach-Get Down 5 Lb Obj Above Head | HAQ0226",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086413","HIV Vaccine","C1325","A vaccine intended to prevent or treat infections caused by human immunodeficiency viruses (HIVs).","HIV Vaccine | AIDS Vaccines | HIV/AIDS Vaccines",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519887","HAQ-DI Without VAS - Open Car Doors","C132600","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Grip: Are you able to open car doors?","HAQ-DI Without VAS - Open Car Doors | HAQ02-Open Car Doors | HAQ0228",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519888","HAQ-DI Without VAS - Open Jars Previously Opened","C132601","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Grip: Are you able to open jars which have been previously opened?","HAQ-DI Without VAS - Open Jars Previously Opened | HAQ02-Open Jars Previously Opened | HAQ0229",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342410","Autoimmune Hypophysitis","C132055","An autoimmune condition affecting the pituitary gland, characterized by lymphocytic infiltration, commonly presenting with pituitary hormone deficiencies.","Autoimmune Hypophysitis | Lymphocytic Hypophysitis",,,,,,,,,,,,,,,"4030201","Autoimmune hypophysitis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1421400","USP22 Gene","C132056","This gene plays a role in the deubiquitination of histone H2 proteins.","USP22 Gene | USP22 | Ubiquitin Specific Peptidase 22 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520264","USP22 wt Allele","C132057","Human USP22 wild-type allele is located in the vicinity of 17p11.2 and is approximately 44 kb in length. This allele, which encodes ubiquitin carboxyl-terminal hydrolase 22 protein, is involved in the removal of ubiquitin from histone H2 proteins.","USP22 wt Allele | KIAA1063 | USP3L | Ubiquitin Specific Peptidase 22 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2352015","Ubiquitin Carboxyl-Terminal Hydrolase 22, Human","C132058","Ubiquitin carboxyl-terminal hydrolase 22 (525 aa, ~60 kDa) is encoded by the human USP22 gene. This protein plays a role in the deubiquitination of histones H2A and H2B.","Ubiquitin Carboxyl-Terminal Hydrolase 22 | Deubiquitinating Enzyme 22 | EC 3.4.19.12 | USP22 | Ubiquitin Specific Peptidase 22 | Ubiquitin Specific Peptidase 3-Like | Ubiquitin Specific Protease 22 | Ubiquitin Thioesterase 22 | Ubiquitin Thiolesterase 22 | Ubiquitin-Specific Processing Protease 22 | Ubiquitin-Specific Protease 22 | Ubiquitin-Specific-Processing Protease 22",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521087","Lack of Adrenarche","C132059","Absent or incomplete development of adrenal androgen-mediated secondary sexual characteristics.","Lack of Adrenarche | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521165","Activating TSHR Gene Mutation","C132060","Mutation(s) in the TSHR gene resulting in increased function of the thyroid stimulating hormone receptor.","Activating TSHR Gene Mutation | Activating Thyroid Stimulating Hormone Receptor Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520426","Inactivating TSHR Gene Mutation","C132061","Mutation(s) in the TSHR gene, resulting in decreased function of the thyroid stimulating hormone receptor.","Inactivating TSHR Gene Mutation | Inactivating Thyroid Stimulating Hormone Receptor Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521270","Osteoma Cutis","C132062","Heterotopic ossification of the skin not associated with a preexisting lesion or process, such as inflammation or neoplasia.","Osteoma Cutis | ",,,,,,,,,,,,,,,"4301653|4322949","Osteoma cutis|Osteoma cutis",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL521191","Kataegis","C132063","Regions of hypermutation that are found in clusters and are localized to one or more hot spots in the genome.","Kataegis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520062","Minocycline Hydrochloride Dihydrate","C132064","No value exists.","Minocycline Hydrochloride Dihydrate | 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide Monohydrochloride Dihydrate | MINOCYCLINE HYDROCHLORIDE DIHYDRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520306","Valnemulin Hydrochloride","C132065","No value exists.","Valnemulin Hydrochloride | ((2-((R)-2-Amino-3-methylbutyramido)-1,1-dimethylethyl)thio)acetic Acid, 8-ester with (3aS,4R,5S,6S,8R,9R,9aR,10R)-octahydro-5,8- dihydroxy-4,6,9,10-tetramethyl-6-vinyl-3a,9-propano-3ah- cyclopentacycloocten-1(4H)-one Hydrochloride | VALNEMULIN HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0752615","Eukaryotic Initiation Factor-3","C132066","A protein complex comprised of 13 nonidentical subunits (EIF3A-M) that is involved in translation initiation and the disassembly and recycling of post-termination ribosomal complexes.","Eukaryotic Initiation Factor 3 | EIF3 | Eukaryotic Translation Initiation Factor 3 | eIF-3 Complex | eIF3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514533","Oligomeric Procyanidin Complex","C131333","A preparation containing plant-derived polyphenolic bioflavonoids composed of multimers (dimers, trimers, or higher order polymers) of the flavan-3-ol-based monomers catechin and epicatechin, which are extracted from sources rich in these chemicals, such as grape seeds, grape skin and pine bark, with potential anti-oxidant, anti-inflammatory, anti-microbial, anti-cancer and protective activities. Upon oral administration of oligomeric procyanidin complex (OPC), the polyphenols exert anti-oxidant activity by scavenging free radicals, which prevents both the formation of reactive oxygen species (ROS), particularly nitrous oxide (NO), and DNA damage. OPC also inhibits chemical-induced lipid peroxidation. In addition, OPC reduces the production advanced glycation end-products (AGE), decreases AGE accumulation in tissues, and inhibits the progression of AGE/receptor for AGE (RAGE)-mediated inflammatory transduction pathways, which inhibits the activation of pro-inflammatory transcriptional regulators and prevents the secretion of pro-inflammatory cytokines/chemokines. This ultimately prevents inflammatory-driven damage to end organs and may reduce inflammation-induced cancer formation and progression. In addition, OPC inhibits the activity of a variety of enzymes, including xanthine oxidase, collagenase, elastase hyaluronidase and beta-glucuronidase.","Oligomeric Procyanidin Complex | OPC | Oligomeric Flavanols | Oligomeric Proanthocyanidins | Oligomeric Procyanidolic Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514245","JS001","C131334","A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (programmed death-1; PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, toripalimab binds to PD-1 and inhibits the binding of PD-1 to its ligands, programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the Ig superfamily that is expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.","Toripalimab | Anti-PD-1 Monoclonal Antibody JS001 | JS 001 | JS-001 | JS001 | Loqtorz | Loqtorzi | TAB 001 | TAB-001 | TORIPALIMAB | Toripalimab-tpzi | Tuoyi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513544","WHODAS 2.0 12-item Version Proxy-administered - Standing for Long Periods","C130920","World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Standing for long periods such as 30 minutes?","WHODAS 2.0 12-item Version Proxy-administered - Standing for Long Periods | WD2-Standing for Long Periods | WD2S1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513532","WHODAS 2.0 12-item Version Proxy-administered - Care of Household Responsibilities","C130921","World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Taking care of his or her household responsibilities?","WHODAS 2.0 12-item Version Proxy-administered - Care of Household Responsibilities | WD2-Care of Household Responsibilities | WD2S2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513541","WHODAS 2.0 12-item Version Proxy-administered - Learning a New Task","C130922","World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Learning a new task, for example, learning how to get to a new place?","WHODAS 2.0 12-item Version Proxy-administered - Learning a New Task | WD2-Learning a New Task | WD2S3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513543","WHODAS 2.0 12-item Version Proxy-administered - Problem Joining Community Activities","C130923","World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: How much of a problem did your relative have joining in community activities (for example, festivities, religious or other activities) in the same way as anyone else can?","WHODAS 2.0 12-item Version Proxy-administered - Problem Joining Community Activities | WD2-Problem Joining Community Activities | WD2S4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513536","WHODAS 2.0 12-item Version Proxy-administered - Emotionally Affected by Health","C130924","World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: How much has your relative been emotionally affected by his or her health condition?","WHODAS 2.0 12-item Version Proxy-administered - Emotionally Affected by Health | WD2-Emotionally Affected by Health | WD2S5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085385","Lipoxygenase Inhibitors","C1322","Any substance that inhibits lipooxygenase, an enzyme that catalyses the dioxygenation of polyunsaturated fatty acids in lipids. Lipooxygenase is involved in the metabolism of eicosanoids (such as prostaglandins and leukotrienes) and its inhibition can suppress hypersensitivity reactions.","Lipooxygenase Inhibitor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520202","Protocol Title","C132300","The name of a study protocol.","Protocol Title | protocol title",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519717","CDISC Protocol Entities Study Protocol Attribute Terminology","C132309","Terminology associated with the protocol entity study protocol attribute codelist of the Clinical Data Interchange Standards Consortium (CDISC).","CDISC Protocol Entities Study Protocol Attribute Terminology | PROT-Att Study Protocol | Study Protocol Attribute Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014239","Endoplasmic Reticulum","C13230","The endoplasmic reticulum is a network of tubular membranes within the cytoplasm of the cell, occurring either with a smooth surface (smooth endoplasmic reticulum) or studded with ribosomes (rough endoplasmic reticulum), involved in the transport of materials. (Infoplease Dictionary)","Endoplasmic Reticulum | ER",,,,,,,,,,,,,,,"4142911","Endoplasmic reticulum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL519718","CDISC Protocol Entities Terminology","C132310","Terminology associated with the protocol entity codelist of the Clinical Data Interchange Standards Consortium (CDISC).","CDISC Protocol Entities Terminology | PROT-Prot Entities | Protocol Entity Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520093","NSAA - Climb Box Step - Right","C132541","North Star Ambulatory Assessment (NSAA) Can you step onto the top of the box using your right leg first?","NSAA - Climb Box Step - Right | NSAA1-Climb Box Step - Right | NSAA106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520092","NSAA - Climb Box Step - Left","C132542","North Star Ambulatory Assessment (NSAA) Can you step onto the top of the box using your left leg first?","NSAA - Climb Box Step - Left | NSAA1-Climb Box Step - Left | NSAA107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520095","NSAA - Descend Box Step - Right","C132543","North Star Ambulatory Assessment (NSAA) Can you step down from the box using your right leg first?","NSAA - Descend Box Step - Right | NSAA1-Descend Box Step - Right | NSAA108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005457","Antibody Binding Site","C13193","The site at which an antibody makes direct physical contact with a corresponding epitope on an antigen.","Antibody Binding Site | Antibody Combining Site",,,,,,,,,,,,,,,"4190325","Antibody binding site",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1421477","WARS2 Gene","C132152","This gene is involved in tRNA maturation.","WARS2 Gene | Tryptophanyl tRNA Synthetase 2, Mitochondrial Gene | WARS2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520309","WARS2 wt Allele","C132153","Human WARS2 wild-type allele is located in the vicinity of 1p12 and is approximately 40 kb in length. This allele, which encodes tryptophan-tRNA ligase, mitochondrial protein, plays a role in tRNA aminoacylation.","WARS2 wt Allele | NEMMLAS | PKDYS3 | TrpRS | Tryptophan tRNA Ligase 2, Mitochondrial Gene | Tryptophanyl tRNA Synthetase 2, Mitochondrial wt Allele | Tryptophanyl-tRNA Synthetase 2, Mitochondrial Gene | mtTrpRS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521338","Tryptophan-tRNA Ligase, Mitochondrial","C132154","Tryptophan-tRNA ligase, mitochondrial (360 aa, ~110 kDa) is encoded by the human WARS2 gene. This protein is involved in the synthesis of tryptophyl-tRNA.","Tryptophan-tRNA Ligase, Mitochondrial | (Mt)TrpRS | EC 6.1.1.2 | Mitochondrial TrpRS | TrpRS | Tryptophan tRNA Ligase 2, Mitochondrial | Tryptophan--tRNA Ligase, Mitochondrial | Tryptophanyl-tRNA Synthetase | Tryptophanyl-tRNA Synthetase 2 | Tryptophanyl-tRNA Synthetase, Mitochondrial | Tryptophan—tRNA Ligase, Mitochondrial | WARS2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2829141","VSIG10L Gene","C132155","This gene may play a role in intercellular junction formation.","VSIG10L Gene | V-Set and Immunoglobulin Domain Containing 10 Like Gene | VSIG10L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521142","SmartPill","C132255","A proprietary ingestible capsule for gastrointestinal tract functional assessment that measures pressure, pH, temperature, and transit time as it travels through the entire gastrointestinal tract.","SmartPill | SmartPill Motility Monitoring System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1550665","Unspecified Tissue","C132256","A tissue specimen whose anatomic origin is not known or reported.","Unspecified Tissue | TISSUE, UNSPECIFIED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520045","Idronoxil Suppository NOX66","C132257","A proprietary, suppository-based formulation composed of idronoxil, a synthetic flavonoid derivative, surrounded by a proprietary lipid that protects idronoxil from phase 2 degradation, with potential chemo- and radio-sensitizing activities. Upon administration, idronoxil blocks the activity of ecto-NOX disulfide-thiol exchanger 2 (ENOX2; tNOX), a tumor-specific external NADH oxidase that maintains the transmembrane electron potential across the plasma membrane and is overexpressed in certain cancer cell types while absent in normal, healthy cells. Loss of this potential directly inhibits certain pro-survival signal transduction pathways, such as the PARP1/PI3 kinase/Akt signaling pathway. The inhibition of these pathways prevents resistance to standard chemo- and radio-therapy and makes tumor cells more susceptible to the anti-tumor activity of conventional chemotherapeutic agents and radiotherapy. The formulation prevents detoxification of idronoxil to an inactive form by bypassing phase 2 metabolism; this increases idronoxil's bioavailability as compared to idronoxil alone.","Idronoxil Suppository NOX66 | NOX66",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520450","MK 1454","C132258","A synthetic cyclic dinucleotide (CDN) and agonist of stimulator of interferon genes protein (STING), with potential immunoactivating and antineoplastic activities. Upon intratumoral (IT) administration,ulevostinag binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor microenvironment; this leads to the production of pro-inflammatory cytokines, including interferons (IFNs). Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens by CD8alpha-positive and CD103-positive dendritic cells (DCs) to cytotoxic T-lymphocytes (CTLs). This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis.","Ulevostinag | MK 1454 | MK-1454 | STING Agonist MK-1454 | ULEVOSTINAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513533","WHODAS 2.0 12-item Version Proxy-administered - Concentrating for Ten Minutes","C130925","World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Concentrating on doing something for ten minutes?","WHODAS 2.0 12-item Version Proxy-administered - Concentrating for Ten Minutes | WD2-Concentrating for Ten Minutes | WD2S6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513545","WHODAS 2.0 12-item Version Proxy-administered - Walking a Long Distance","C130926","World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Walking a long distance such as a kilometre [or equivalent]?","WHODAS 2.0 12-item Version Proxy-administered - Walking a Long Distance | WD2-Walking a Long Distance | WD2S7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513546","WHODAS 2.0 12-item Version Proxy-administered - Washing His or Her Whole Body","C130927","World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Washing his or her whole body?","WHODAS 2.0 12-item Version Proxy-administered - Washing His or Her Whole Body | WD2-Washing His/Her Whole Body | WD2S8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513537","WHODAS 2.0 12-item Version Proxy-administered - Getting Dressed","C130928","World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Getting dressed?","WHODAS 2.0 12-item Version Proxy-administered - Getting Dressed | WD2-Getting Dressed | WD2S9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513542","WHODAS 2.0 12-item Version Proxy-administered - Maintaining a Friendship","C130930","World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Maintaining a friendship?","WHODAS 2.0 12-item Version Proxy-administered - Maintaining a Friendship | WD2-Maintaining a Friendship | WD2S11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL360833","FOXC1 protein, human","C131544","Forkhead box protein C1 (553 aa, ~57 kDa) is encoded by the human FOXC1 gene. This protein plays a role in transcriptional regulation during both embryonic development and ocular development.","Forkhead Box Protein C1 | FOXC1 | FREAC-3 | Forkhead Box C1 Protein | Forkhead-Related Activator 3 | Forkhead-Related Protein FKHL | Forkhead-Related Transcription Factor 3 | Forkhead/Winged Helix-Like Transcription Factor 7 | Myeloid Factor-Delta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414831","FSTL1 Gene","C131545","This gene is involved in both heparin binding and signaling.","FSTL1 Gene | FSTL1 | Follistatin Like 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514499","FSTL1 wt Allele","C131546","Human FSTL1 wild-type allele is located in the vicinity of 3q13.33 and is approximately 59 kb in length. This allele, which encodes follistatin-related protein 1, plays a role in both signal transduction and heparin binding.","FSTL1 wt Allele | FRP | FSL1 | Follistatin Like 1 wt Allele | Follistatin-Like 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1136226","FSTL1 protein, human","C131547","Follistatin-related protein 1 (308 aa, ~35 kDa) is encoded by the human FSTL1 gene. This protein is involved in both signaling pathways and binding to heparin.","Follistatin-Related Protein 1 | FSTL1 | Follistatin-Like Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421525","WWOX Gene","C131548","This gene plays a role in oxidation/reduction, tumor suppression and the regulation of apoptosis.","WWOX Gene | WW Domain Containing Oxidoreductase Gene | WWOX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514380","WWOX wt Allele","C131549","Human WWOX wild-type allele is located in the vicinity of 16q23 and is approximately 1113 kb in length. This allele, which encodes WW domain-containing oxidoreductase protein, is involved in tumor suppression, apoptosis and oxidation/reduction. Mutation of the gene is associated with early infantile epileptic encephalopathy 28, somatic esophageal squamous cell carcinoma, and autosomal recessive spinocerebellar ataxia 12.","WWOX wt Allele | D16S432E | EIEE28 | FOR | FRA16D | HHCMA56 | PRO0128 | SCAR12 | SDR41C1 | Short Chain Dehydrogenase/Reductase Family 41C, Member 1 Gene | WOX1 | WW Domain Containing Oxidoreductase wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511178","Bipolar Neuron","C13154","A nerve cell with two processes.","Bipolar Neuron | Bipolar Neurons",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520094","NSAA - Descend Box Step - Left","C132544","North Star Ambulatory Assessment (NSAA) Can you step down from the box using your left leg first?","NSAA - Descend Box Step - Left | NSAA1-Descend Box Step - Left | NSAA109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520096","NSAA - Gets to Sitting","C132545","North Star Ambulatory Assessment (NSAA) Can you get from lying to sitting?","NSAA - Gets to Sitting | NSAA1-Gets to Sitting | NSAA110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520102","NSAA - Rise From Floor","C132546","North Star Ambulatory Assessment (NSAA) Get up from the floor using as little support as possible and as fast as you can (from supine).","NSAA - Rise From Floor | NSAA1-Rise From Floor | NSAA111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520101","NSAA - Rise From Floor Time","C132547","North Star Ambulatory Assessment (NSAA) Time to get up from the floor using as little support as possible and as fast as you can (from supine) (seconds).","NSAA - Rise From Floor Time | NSAA1-Rise From Floor Time | NSAA111A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520108","NSAA - Stands on Heels","C132549","North Star Ambulatory Assessment (NSAA) Can you stand on your heels?","NSAA - Stands on Heels | NSAA1-Stands on Heels | NSAA113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025954","Peroxisome","C13254","Subcellular respiratory organelles containing catalase and hydrogen peroxide-producing flavin oxidases among its enzymatic constituents, which carry out an essentially oxidative type of metabolism","Peroxisome | Microbody",,,,,,,,,,,,,,,"4009934","Microbody",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL520099","NSAA - Jump","C132550","North Star Ambulatory Assessment (NSAA) How high can you jump?","NSAA - Jump | NSAA1-Jump | NSAA114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520098","NSAA - Hop Right Leg","C132551","North Star Ambulatory Assessment (NSAA) Can you hop on your right leg?","NSAA - Hop Right Leg | NSAA1-Hop Right Leg | NSAA115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520097","NSAA - Hop Left Leg","C132552","North Star Ambulatory Assessment (NSAA) Can you hop on your left leg?","NSAA - Hop Left Leg | NSAA1-Hop Left Leg | NSAA116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520104","NSAA - Run (10m)","C132553","North Star Ambulatory Assessment (NSAA) Run as fast as you can to...(give point).","NSAA - Run (10m) | NSAA1-Run (10m) | NSAA117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520103","NSAA - Run (10m) Time","C132554","North Star Ambulatory Assessment (NSAA) Time to run as fast as you can (seconds).","NSAA - Run (10m) Time | NSAA1-Run (10m) Time | NSAA117A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520110","NSAA - Total","C132555","North Star Ambulatory Assessment (NSAA) Total.","NSAA - Total | NSAA1-Total | NSAA118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519747","CES - Were You Ever Under Enemy Fire","C132557","Combat Exposure Scale (CES) Were you ever under enemy fire?","CES - Were You Ever Under Enemy Fire | CES01-Were You Ever Under Enemy Fire | CES0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519742","CES - Ever Surrounded by the Enemy","C132558","Combat Exposure Scale (CES) Were you ever surrounded by the enemy?","CES - Ever Surrounded by the Enemy | CES01-Ever Surrounded by the Enemy | CES0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519746","CES - Soldiers in Unit Killed (KIA), Wounded, Missing (MIA)","C132559","Combat Exposure Scale (CES) What percentage of the soldiers in your unit were killed (KIA), wounded or missing in action (MIA)?","CES - Soldiers in Unit Killed (KIA), Wounded, Missing (MIA) | CES01-Soldiers in Unit KIA, Wounded, MIA | CES0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025979","Actin Filament","C13255","The finest filamentous element of the cytoskeleton, having a diameter of about 5 nm and consisting primarily of actin.","Actin Filament | Microfilament",,,,,,,,,,,,,,,"4240537","Filaments of contractile apparatus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL520305","VSIG10L wt Allele","C132156","Human VSIG10L wild-type allele is located in the vicinity of 19q13.41 and is approximately 11 kb in length. This allele, which encodes V-set and immunoglobulin domain-containing protein 10-like, may be involved in cell-cell adhesion. Mutation or loss of expression of the gene may be associated with neoplastic or pre-neoplastic diseases.","VSIG10L wt Allele | V-Set and Immunoglobulin Domain Containing 10 Like wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520304","V-Set and Immunoglobulin-Domain Containing Protein 10-Like, Human","C132157","V-set and immunoglobulin domain-containing protein 10-like (867 aa, ~92 kDa) is encoded by the human VSIG10L gene. This protein may play a role in cell-cell junction formation.","V-Set and Immunoglobulin Domain-Containing Protein 10-Like | V-Set and Immunoglobulin Domain Containing 10 Like | V-Set and Immunoglobulin Domains-Containing Protein 10-Like | V-Set and Immunoglobulin-Domain Containing Protein 10-Like | V-Set and Immunoglobulin-Domains Containing Protein 10-Like | VSIG10-Like Protein | VSIG10L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3471356","PCAT1 Gene","C132158","This gene may be involved in cancer progression.","PCAT1 Gene | PCAT1 | Prostate Cancer Associated Transcript 1 (Non-Protein Coding) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521126","PCAT1 wt Allele","C132159","Human PCAT1 wild-type allele is located in the vicinity of 8q24.21 and is approximately 174 kb in length. This allele, which encodes prostate cancer associated transcript 1 non-coding RNA, may be involved in carcinogenesis.","PCAT1 wt Allele | PCA1 | PCAT-1 | Prostate Cancer Associated Transcript 1 (Non-Protein Coding) wt Allele | Prostate Cancer Associated Transcript 1, Noncoding Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521330","Prostate Cancer Associated Transcript 1","C132160","Prostate cancer associated transcript 1 (~2 kb) is encoded by the human PCAT1 gene. This non-coding RNA may play a role in tumorigenesis.","Prostate Cancer Associated Transcript 1 | Long Non-Coding RNA PCAT-1 | Long Noncoding RNA PCAT-1 | PCA1 | PCAT-1 | PCAT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519812","DINOL Gene","C132161","This gene plays a role in p53-dependent responses to DNA damage.","DINOL Gene | DINO | DINOL | Damage Induced Long Noncoding RNA Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519813","DINOL wt Allele","C132162","Human DINOL wild-type allele is located in the vicinity of 6p21.2 and is approximately 1 kb in length. This allele, which encodes damage induced long noncoding RNA, plays a role in stabilization of cellular tumor antigen p53.","DINOL wt Allele | DINO | DNA Damage, p53 is Stabilized and p53-Responsive Gene | Damage Induced Long Noncoding RNA wt Allele | Damage Induced Noncoding RNA Gene | Damage-Induced Non-Coding RNA Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519713","CDISC Integrated Basic Data Structure Dataset","C132357","IBDS is the ADaM Model for the Integrated Basic Data Structure. The structure includes per pool as defined in the integrated SAP when multiple records per subject are included in integrated ADSL. (CDISC)","CDISC Integrated Basic Data Structure Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520468","Neck Lymph Node Groups","C132507","Lymph node groups found within the seven levels and sublevels of the neck. (AJCC 8th ed.)","Neck Lymph Node Groups | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520991","Submental Lymph Node Group (Sublevel IA)","C132508","Lymph nodes within the triangular boundary of the anterior belly of the digastric muscles and the hyoid bone. These nodes are at greatest risk for harboring metastases from cancers arising from the floor of mouth, anterior oral tongue, anterior mandibular alveolar ridge, and lower lip. (AJCC 8th ed.)","Submental Lymph Node Group (Sublevel IA) | Lymph node level IA (qualifier value)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520990","Submandibular Lymph Node Group (Sublevel IB)","C132509","Lymph nodes within the boundaries of the anterior and posterior bellies of the digastric muscle, the stylohyoid muscle, and the body of the mandible. These include the preglandular and the postglandular nodes and the prevascular and postvascular nodes. The submandibular gland is included in the specimen when the lymph nodes within the triangle are removed. These nodes are at greatest risk for harboring metastases from cancers arising from the oral cavity, anterior nasal cavity, skin, and soft tissue structures of the midface, as well as from the submandibular gland. (AJCC 8th ed.)","Submandibular Lymph Node Group (Sublevel IB) | Lymph node level IB (qualifier value)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520301","Upper Jugular Lymph Node Group (Sublevels IIA and IIB)","C132510","Lymph nodes located around the upper third of the internal jugular vein and adjacent spinal accessory nerve, extending from the level of the skull base (above) to the level of the inferior border of the hyoid bone (below). The anterior (medial) boundary is the stylohyoid muscle (the radiologic correlate is the vertical plane defined by the posterior surface of the submandibular gland) and the posterior (lateral) boundary is the posterior border of the sternocleidomastoid muscle. Sublevel IIA nodes are located anterior (medial) to the vertical plain defined by the spinal accessory nerve. Sublevel IIB nodes are located posterior (lateral) to the vertical plane defined by the spinal accessory nerve (the radiologic correlate is the lateral border of the internal jugular on a contrast-enhanced CT scan). The upper jugular nodes are at greatest risk for harboring metastases from cancers arising from the oral cavity, nasal cavity, nasopharynx, oropharynx, hypopharynx, larynx, and parotid gland. (AJCC 8th ed.)","Upper Jugular Lymph Node Group (Sublevels IIA and IIB) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1450179","WWOX protein, human","C131550","WW domain-containing oxidoreductase (414 aa, ~47 kDa) is encoded by the human WWOX gene. This protein plays a role in apoptosis, oxidation/reduction and tumor suppression.","WW Domain-Containing Oxidoreductase | EC 1.1.1.- | Fragile Site FRA16D Oxidoreductase | Short Chain Dehydrogenase/Reductase Family 41C Member 1 | WW Domain-Containing Protein WWOX | WWOX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424025","MCM8 Gene","C131551","This gene is involved in the repair of DNA interstrand cross-links.","MCM8 Gene | MCM8 | Minichromosome Maintenance 8 Homologous Recombination Repair Factor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514304","MCM8 wt Allele","C131552","Human MCM8 wild-type allele is located in the vicinity of 20p12.3 and is approximately 45 kb in length. This allele, which encodes DNA helicase MCM8 protein, plays a role in homologous recombination repair. Mutation of the gene is associated with premature ovarian failure 10.","MCM8 wt Allele | C20orf154 | Chromosome 20 Open Reading Frame 154 Gene | MGC119522 | MGC119523 | MGC12866 | MGC4816 | Minichromosome Maintenance 8 Homologous Recombination Repair Factor wt Allele | POF10 | REC Homolog (Drosophila) Gene | REC Homolog Gene | dJ967N21.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1174540","MCM8 protein, human","C131553","DNA helicase MCM8 (840 aa, ~94 kDa) is encoded by the human MCM8 gene. This protein is involved in DNA repair.","DNA Helicase MCM8 | DNA Replication Licensing Factor MCM8 | EC 3.6.4.12 | MCM8 | MCM8 Minichromosome Maintenance Deficient 8 | Minichromosome Maintenance 8 | Minichromosome Maintenance Complex Component 8 | Minichromosome Maintenance Protein 8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427573","MCM9 Gene","C131554","This gene plays a role in homologous recombination repair.","MCM9 Gene | MCM9 | Minichromosome Maintenance 9 Homologous Recombination Repair Factor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514305","MCM9 wt Allele","C131555","Human MCM9 wild-type allele is located in the vicinity of 6q22.31 and is approximately 122 kb in length. This allele, which encodes DNA helicase MCM9 protein, is involved in DNA repair.","MCM9 wt Allele | C6orf61 | Chromosome 6 Open Reading Frame 61 Gene | FLJ20170 | MCMDC1 | MGC35304 | Minichromosome Maintenance 9 Homologous Recombination Repair Factor wt Allele | ODG4 | dJ329L24.1 | dJ329L24.3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1570815","MCM9 protein, human","C131556","DNA helicase MCM9 (1143 aa, ~127 kDa) is encoded by the human MCM9 gene. This protein plays a role in homologous recombination repair of replication forks.","DNA Helicase MCM9 | DNA Replication Licensing Factor MCM9 | EC 3.6.4.12 | MCM9 | Mini-Chromosome Maintenance Deficient Domain-Containing Protein 1 | Minichromosome Maintenance 9 | Minichromosome Maintenance Complex Component 9 | Minichromosome Maintenance Deficient Domain Containing 1 | Minichromosome Maintenance Protein 9 | hMCM9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513464","ARHGAP32 wt Allele","C131140","Human ARHGAP32 wild-type allele is located in the vicinity of 11q24.3 and is approximately 314 kb in length. This allele, which encodes Rho GTPase-activating protein 32, plays a role in the modulation of both NMDA receptor signaling and small GTPase activity. Deletion of the chromosomal region containing the gene is associated with a subset of Jacobsen syndrome patients that exhibit autism spectrum disorder.","ARHGAP32 wt Allele | GC-GAP | GRIT | KIAA0712 | MGC1892 | PX-RICS | RICS | Rho GTPase Activating Protein 32 wt Allele | p200RhoGAP | p250GAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1312027","p200RhoGAP protein, human","C131141","Rho GTPase-activating protein 32 (2087 aa, ~231 kDa) is encoded by the human ARHGAP32 gene. This protein is involved in the regulation of signaling mediated by both Rho family GTPases and the NMDA receptor.","Rho GTPase-Activating Protein 32 | Brain-Specific Rho GTP-Ase-Activating Protein | Brain-Specific Rho GTPase-Activating Protein | GAB-Associated CDC42 | GAB-Associated Cdc42/Rac GTPase-Activating Protein | GC-GAP | GTPase Interacting With TrkA | GTPase Regulator Interacting With TrkA | GTPase-Activating Protein For Cdc42 and Rac1 | PX-RICS | Rho GTPase Involved In Beta-Catenin, N-Cadherin, and NMDA Receptor Signaling | Rho-Type GTPase-Activating Protein 32 | Rho/Cdc42/Rac GTPase-Activating Protein RICS | RhoGAP Involved in the Beta-Catenin-N-Cadherin and NMDA Receptor Signaling | p200RhoGAP | p250GAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521163","AVP Gene Product","C131899","A protein encoded by the AVP gene.","AVP Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520579","Artificial Saliva Spray","C131900","A spray formulation containing a saliva substitute, composed of potassium chloride, sodium chloride, magnesium chloride, calcium chloride, dipotassium phosphate and monopotassium phosphate, that has potential anti-xerostomia activity. Upon direct oral application of the artificial saliva spray, a protective film of moisture is deposited over the mucous membranes of the mouth, which relieves dryness of the mucous membranes and increases salivary flow. In addition, artificial saliva may help prevent chemotherapy- or radiotherapy-induced oral mucositis.","Artificial Saliva Spray | Hypozalix Spray",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520557","Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells","C131901","A preparation of human cytokine interleukin-21 (IL-21) primed, tumor-activated allogeneic human leukocyte antigen (HLA) haploidentical natural killer (NK) cells, with potential cytolytic and immunoregulatory activities. Allogeneic leukemia cells are genetically modified to express membrane-bound interleukin-21 (mbIL-21) on their cell surfaces. When human peripheral blood mononuclear cells (PBMCs) from an HLA-haploidentical donor are subsequently exposed to these cells, the donor PBMC differentiate into mature, highly cytotoxic NK cells, which are subsequently expanded in ex vivo culture.  Upon infusion of the mbIL-21-expanded haploidentical NK cells, the NK cells target, lyse and destroy tumor cells. mbIL-21 promotes sustained ex vivo proliferation of human NK cells and enhances its cytotoxic activity.","Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells | (mbIL21)-expanded Haploidentical NK Cells | Donor mbIL21-expanded NK Cells | mbIL21-expanded Haploidentical NK Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519714","CDISC Integrated Occurrence Data Structure Dataset","C132358","IOCCDS is the ADaM Model for Integrated Occurrence Data structure. The structure includes per pool as defined in the integrated SAP when multiple records per subject are included in integrated ADSL. (CDISC)","CDISC Integrated Occurrence Data Structure Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519715","CDISC Integrated Subject Level Dataset","C132359","IADSL is the ADaM Model for Integrated Subject Level Analysis Dataset. The structure is one record per subject per pool as defined in the integrated SAP. Multiple records per subject are required in an integrated ADSL dataset when any subject's data is used in more than one pool and the values for subject-level variables differ across pools. (CDISC)","CDISC Integrated Subject Level Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519899","HAQ-DI Without VAS - Turn Faucets On And Off","C132602","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Grip: Are you able to turn faucets on and off?","HAQ-DI Without VAS - Turn Faucets On And Off | HAQ02-Turn Faucets On And Off | HAQ0230",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520922","Posterior Triangle Lymph Node Group (Sublevels VA and VB)","C132513","This group is composed predominantly of the lymph nodes located along the lower half of the spinal accessory nerve and the transverse cervical artery. The supraclavicular nodes also are included in the posterior triangle group. The superior boundary is the apex formed by the convergence of the sternocleidomastoid and trapezius muscles; the inferior boundary is the clavicle; the anterior (medial) boundary is the posterior border of the sternocleidomastoid muscle; and the posterior (lateral) boundary is the anterior border of the trapezius muscle. Thus, sublevel VA includes the spinal accessory nodes, whereas sublevel VB includes the nodes following the transverse cervical vessels and the supraclavicular nodes, with the exception of the Virchow node, which is located in level IV. The posterior triangle nodes are at greatest risk for harboring metastases from cancers arising from the nasopharynx, oropharynx, and cutaneous structures of the posterior scalp and neck. (AJCC 8th ed.)","Posterior Triangle Lymph Node Group (Sublevels VA and VB) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520569","Anterior Compartment Lymph Node Group (Level VI)","C132514","Lymph nodes in this compartment include the pretracheal and paratracheal nodes, precricoid (Delphian) node, and the perithyroidal nodes, including the lymph nodes along the recurrent laryngeal nerves. The superior boundary is the hyoid bone; the inferior boundary is the suprasternal notch; and the lateral boundaries are the common carotid arteries. These nodes are at greatest risk for harboring metastases from cancers arising from the thyroid gland, glottic and subglottic larynx, apex of the piriform sinus, and cervical esophagus. (AJCC 8th ed.)","Anterior Compartment Lymph Node Group (Level VI) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514654","Hexose-6-phosphate Dehydrogenase Deficiency","C131849","Decreased activity of hexose-6-phosphatase due to autosomal recessive mutation(s) in the H6PD gene. This enzyme is necessary to generate NADPH, a cofactor in the 11-beta-hydroxysteroid dehydrogenase pathway required for conversion of cortisone to cortisol. The condition is characterized by hyperandrogenism as a result of increased adrenocorticotropic hormone stimulation of the adrenal gland due to failure of cortisol-mediated down-regulation, and is clinically indistinguishable from 11-beta HSD type 1 deficiency.","Hexose-6-phosphate Dehydrogenase Deficiency | Cortisone Reductase Deficiency Type 1 | Hexose-6-Phosphate Dehydrogenase Deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020551","Hyperthyroxinemia","C131850","Supranormal concentration of thyroxine in the blood.","Hyperthyroxinemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1876187","Hyperphosphatemic Familial Tumoral Calcinosis","C131851","An autosomal recessive disorder caused by loss-of-function mutation(s) in the GALNT3, FGF23, or KL gene, which encode polypeptide N-acetylgalactosaminyltransferase 3, fibroblast growth factor 23, and klotho, respectively. This condition, the biochemical hallmark of which is hyperphosphatemia caused by increased renal phosphate absorption, is characterized by the progressive deposition of calcium phosphate crystals in periarticular spaces, soft tissues, and/or bone.","Hyperphosphatemic Familial Tumoral Calcinosis | ",,,,,,,,,,,,,,,"3655267","Hyperphosphatemic familial tumoral calcinosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1262098","Congenital Hyperthyroidism","C131852","Hyperthyroidism, the cause of which is present at birth.","Congenital Hyperthyroidism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1832615","Neonatal Severe Primary Hyperparathyroidism","C131853","A genetic condition caused by loss-of-function mutation(s) in the CASR gene, encoding extracellular calcium-sensing receptor. It is characterized by severe hypercalcemia and metabolic bone disease occurring in the first six months of life.","Neonatal Severe Primary Hyperparathyroidism | ",,,,,,,,,,,,,,,"37395693","Neonatal severe primary hyperparathyroidism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0271713","Ketotic Hypoglycemia","C131854","A condition in which hypoglycemia is accompanied by ketosis. This condition may be a manifestation of another condition such as glycogen storage disease, ketone utilization defects, growth hormone deficiency, or cortisol deficiency.","Ketotic Hypoglycemia | ",,,,,,,,,,,,,,,"4049629","Ketotic hypoglycemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514665","Idiopathic Ketotic Hypoglycemia","C131855","Ketotic hypoglycemia that usually occurs in young, thin children in association with infection or fasting, and which typically resolves by age 6-8 years.","Idiopathic Ketotic Hypoglycemia | Accelerated Starvation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514662","Iatrogenic Hypoparathyroidism","C131856","Hypoparathyroidism resulting from medical treatment or intervention.","Iatrogenic Hypoparathyroidism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420831","TNP2 Gene","C131145","This gene plays a role in spermatid differentiation.","TNP2 Gene | TNP2 | Transition Protein 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513362","TNP2 wt Allele","C131146","Human TNP2 wild-type allele is located in the vicinity of 16p13.13 and is approximately 2 kb in length. This allele, which encodes nuclear transition protein 2, is involved in chromatin packaging during spermatogenesis.","TNP2 wt Allele | TP2 | Transition Protein 2 (During Histone To Protamine Replacement) Gene | Transition Protein 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1504710","Nuclear Transition Protein 2, Human","C131147","Nuclear transition protein 2 (138 aa, ~16 kDa) is encoded by the human TNP2 gene. This protein plays a role in chromatid packaging during spermatid differentiation.","Nuclear Transition Protein 2 | TP-2 | TP2 | Transition Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513401","CARD9 wt Allele","C131149","Human CARD9 wild-type allele is located in the vicinity of 9q34 and is approximately 12 kb in length. This allele, which encodes caspase recruitment domain-containing protein 9, plays a role in both the regulation of apoptosis and innate immune responses..","CARD9 wt Allele | CANDF2 | Caspase Recruitment Domain Family Member 9 wt Allele | Caspase Recruitment Domain Family, Member 9 Gene | hCARD9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1667071","Caspase Recruitment Domain-Containing Protein 9, Human","C131150","Caspase recruitment domain-containing protein 9 (536 aa, ~62 kDa) is encoded by the human CARD9 gene. This protein is involved in both the modulation of pathogen-triggered signaling pathways and the regulation of apoptosis.","Caspase Recruitment Domain-Containing Protein 9 | CARD9 | hCARD9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513171","MST1 wt Allele","C131152","Human MST1 wild-type allele is located in the vicinity of 3p21 and is approximately 6 kb in length. This allele, which encodes hepatocyte growth factor-like protein, is involved in the regulation of both ciliary motility and macrophage activation. Variation in the gene may be associated with inflammatory bowel disease.","MST1 wt Allele | D3F15S2 | DNF15S2 | HGFL | MSP | Macrophage Stimulating 1 (Hepatocyte Growth Factor-Like) Gene | Macrophage Stimulating 1 wt Allele | NF15S2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514490","LY3214996","C131335","An orally available inhibitor of extracellular signal-regulated kinase (ERK) 1 and 2, with potential antineoplastic activity. Upon oral administration, temuterkib inhibits both ERK 1 and 2, thereby preventing the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The MAPK/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.","Temuterkib | ERK1/2 Inhibitor LY3214996 | LY 3214996 | LY-3214996 | LY3214996 | TEMUTERKIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514420","Multiple TAA-loaded Dendritic Cell Vaccine","C131336","A dendritic cell (DC) vaccine in which autologous DCs are loaded with multiple tumor-associated antigens (TAAs), with potential immunostimulating and antineoplastic activities. Upon re-infusion into the patient, the antigen-pulsed DCs stimulate the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against the TAA-expressing tumor cells.","Multiple TAA-loaded Dendritic Cell Vaccine | Antigen-pulsed DCs MASCT-I | MASCT-I | Multiple TAA-loaded DC Vaccine | Multiple Target Antigen-stimulating Cells-I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521167","Acute Megakaryoblastic Leukemia with CBFA2T3-GLIS2","C132109","A non-Down syndrome acute megakaryoblastic leukemia that occurs in children. It is associated with CBFA2T3-GLIS2 chimeric oncogene and has an unfavorable prognosis.","Acute Megakaryoblastic Leukemia with CBFA2T3-GLIS2 | Acute Megakaryoblastic Leukemia with CBFA2T3::GLIS2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521288","t(11;12)(p15;p13)","C132110","A cytogenetic abnormality that refers to the translocation of chromosome 11p15 with chromosome 12p13. It results in NUP98-KDM5A fusion and is associated with acute megakaryoblastic leukemia in childhood.","t(11;12)(p15;p13) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521168","Acute Megakaryoblastic Leukemia with NUP98-KDM5A","C132111","A non-Down syndrome acute megakaryoblastic leukemia that occurs in childhood. It is associated with t(11;12)(p15;p13) which results in the presence of NUP98-KDM5A chimeric oncogene.","Childhood Acute Megakaryoblastic Leukemia with NUP98-KDM5A | Acute Megakaryoblastic Leukemia with NUP98-KDM5A | Acute Megakaryoblastic Leukemia with NUP98-KDM5A | Acute Megakaryoblastic Leukemia with NUP98::KDM5A | Childhood Acute Megakaryoblastic Leukemia with NUP98-KDM5A Fusion | Childhood Acute Megakaryoblastic Leukemia with NUP98::KDM5A | Childhood Acute Megakaryoblastic Leukemia with NUP98::KDM5A Fusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520319","Anti-HER2/Auristatin Payload Antibody-drug Conjugate XMT-1522","C132112","An antibody-drug conjugate (ADC) composed of HT-19, a monoclonal antibody directed against the human epidermal growth factor receptor 2 (ERBB2; HER2), conjugated, via a proprietary biodegradable, hydrophilic polymer backbone and various linkers, to proprietary auristatin-derived payload molecules (about 15 per antibody), with potential antineoplastic activity. Upon administration of anti-HER2/auristatin payload ADC XMT-1522, the antibody moiety targets and binds to a unique epitope in the extracellular domain (ECD) of HER2. Upon internalization, cleavage and release of the cytotoxic molecules, the auristatin-derived molecules bind to tubulin and inhibit its polymerization, which results in G2/M phase arrest and induces apoptosis of HER2-expressing tumor cells. The attachment of multiple auristatin molecules to the backbone enables XMT-1522 to effectively kill tumors that express relatively low amounts of the HER2 protein; therefore, this agent shows increased therapeutic potential in tumors with low HER2 expression compared to other anti-HER2 antibody-based therapies. The polymer-based proprietary platform optimizes delivery of the cytotoxic drug payload and improves drug solubility.","Anti-HER2/Auristatin Payload Antibody-drug Conjugate XMT-1522 | ADC XMT-1522 | Anti-HER2 ADC XMT-1522 | XMT-1522",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417824","NR1H3 Gene","C132113","This gene is involved in the regulation of retinoid responses and cholesterol homeostasis.","NR1H3 Gene | NR1H3 | Nuclear Receptor Subfamily 1 Group H Member 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520090","NR1H3 wt Allele","C132114","Human NR1H3 wild-type allele is located in the vicinity of 11p11.2 and is approximately 21 kb in length. This allele, which encodes oxysterols receptor LXR-alpha protein, plays a role in both cholesterol homeostasis and the expression of retinoid-responsive genes.","NR1H3 wt Allele | LX Receptor, Alpha Gene | LXR-a | LXRA | Liver X Receptor, Alpha Gene | Nuclear Receptor Subfamily 1 Group H Member 3 wt Allele | Nuclear Receptor Subfamily 1, Group H, Member 3 Gene | RLD-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0297439","nuclear receptor subfamily 1, group H, member 3","C132115","Oxysterols receptor LXR-alpha (447 aa, ~50 kDa) is encoded by the human NR1H3 gene. This protein is involved in transcriptional regulation and cholesterol homeostasis.","Oxysterols Receptor LXR-Alpha | Liver X Nuclear Receptor Alpha | Liver X Receptor Alpha | Liver X Receptor-Alpha | NR1H3 | Nuclear Receptor Subfamily 1 Group H Member 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417671","NEK1 Gene","C132116","This gene plays a role in protein phosphorylation and the modulation of cilia assembly and cell division.","NEK1 Gene | NEK1 | NIMA Related Kinase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520088","NEK1 wt Allele","C132117","Human NEK1 wild-type allele is located in the vicinity of 4q33 and is approximately 219 kb in length. This allele, which encodes serine/threonine-protein kinase Nek1 protein, is involved in cell division, cilia assembly and protein phosphorylation. Mutation of the gene is associated with short-rib thoracic dysplasia 6 with or without polydactyly.","NEK1 wt Allele | KIAA1901 | NIMA (Never In Mitosis Gene A)-Related Kinase 1 Gene | NIMA Related Kinase 1 wt Allele | NY-REN-55 | SRPS2 | SRPS2A | SRTD6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523875","Serine/Threonine-Protein Kinase Nek1","C132118","Serine/threonine-protein kinase Nek1 (1258 aa, ~143 kDa) is encoded by the human NEK1 gene. This protein plays a role in cilia assembly, protein phosphorylation and cell division.","Serine/Threonine-Protein Kinase Nek1 | EC 2.7.11.1 | NIMA-Related Kinase 1 | Never In Mitosis A-Related Kinase 1 | NimA-Related Protein Kinase 1 | Renal Carcinoma Antigen NY-REN-55",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519893","HAQ-DI Without VAS - Run Errands and Shop","C132603","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Activities: Are you able to run errands and shop?","HAQ-DI Without VAS - Run Errands and Shop | HAQ02-Run Errands and Shop | HAQ0231",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519876","HAQ-DI Without VAS - Get In and Out of a Car","C132604","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Activities: Are you able to get in and out of a car?","HAQ-DI Without VAS - Get In and Out of a Car | HAQ02-Get In and Out of a Car | HAQ0232",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519857","HAQ-DI Without VAS - Able to Do Chores","C132605","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Activities: Are you able to do chores such as vacuuming or yardwork?","HAQ-DI Without VAS - Able to Do Chores | HAQ02-Able to Do Chores | HAQ0233",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519867","HAQ-DI Without VAS - Aid: Raised Toilet Seat","C132606","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Raised toilet seat.","HAQ-DI Without VAS - Aid: Raised Toilet Seat | HAQ02-Aid: Raised Toilet Seat | HAQ0234",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519859","HAQ-DI Without VAS - Aid: Bathtub Seat","C132607","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Bathtub seat.","HAQ-DI Without VAS - Aid: Bathtub Seat | HAQ02-Aid: Bathtub Seat | HAQ0235",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519864","HAQ-DI Without VAS - Aid: Jar Opener (Previously Open)","C132608","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Jar opener (for jars previously opened).","HAQ-DI Without VAS - Aid: Jar Opener (Previously Open) | HAQ02-Aid: Jar Opener (Previously Open) | HAQ0236",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519858","HAQ-DI Without VAS - Aid: Bathtub Bar","C132609","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Bathtub bar.","HAQ-DI Without VAS - Aid: Bathtub Bar | HAQ02-Aid: Bathtub Bar | HAQ0237",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026732","Mullerian Duct","C13260","A pair of embryonic tubular structures that extend along the genital ridge and continue toward the cloaca, which in females will develop into the vagina, uterus, and fallopian tubes, and which will degenerate and be resorbed in males.","Mullerian Duct | Müllerian Duct | Paramesonephric Duct",,,,,,,,,,,,,,,"4097526","Structure of paramesonephric duct",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL519866","HAQ-DI Without VAS - Aid: Long-Handled Appliances Reach","C132610","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Long-handled appliances for reach.","HAQ-DI Without VAS - Aid: Long-Handled Appliances Reach | HAQ02-Aid: Long-Handled Appl Reach | HAQ0238",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519891","HAQ-DI Without VAS - Other Aid (Hygiene or Reach or Grip or Act)","C132612","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Other (for hygiene, reach, grip and activities).","HAQ-DI Without VAS - Other Aid (Hygiene or Reach or Grip or Act) | HAQ02-Othr Aid (Hygiene/Reach/Grip/Act) | HAQ0240",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519896","HAQ-DI Without VAS - Special Aid (Hygiene or Reach or Grip or Act)","C132613","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Other (specify) - for hygiene, reach, grip and activities.","HAQ-DI Without VAS - Special Aid (Hygiene or Reach or Grip or Act) | HAQ02-Spec Aid (Hygiene/Reach/Grip/Act) | HAQ0241",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519883","HAQ-DI Without VAS - Help: Hygiene","C132614","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Usually need help from another person: Hygiene.","HAQ-DI Without VAS - Help: Hygiene | HAQ02-Help: Hygiene | HAQ0242",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519884","HAQ-DI Without VAS - Help: Reach","C132615","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Usually need help from another person: Reach.","HAQ-DI Without VAS - Help: Reach | HAQ02-Help: Reach | HAQ0243",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514657","Hypogonadotropic Hypogonadism with Adrenal Hypoplasia Congenita","C131857","Hypogonadotropic hypogonadism with congenital adrenal hypoplasia associated with mutation(s) in the NR0B1 gene (on the X chromosome).","Hypogonadotropic Hypogonadism with Adrenal Hypoplasia Congenita | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521333","Mitochondrial Diabetes","C131859","Diabetes mellitus caused by mutation(s) in mitochondrial DNA.","Mitochondrial Diabetes | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1179135","Taste Bud Basal Cell","C13185","A small, round cell found in the lower part of the epidermis of the taste bud. It differentiates into a new receptor cell and renewed about every 10 days.","Taste Bud Basal Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268414","Juvenile Paget Disease","C131861","A bone disorder caused by autosomal recessive mutation(s) of the gene TNFRSF11B, which encodes tumor necrosis factor receptor superfamily member 11B. This condition is characterized by excessive osteoclastic resorption of bone followed by deposition of weak, disorganized woven bone. Clinical characteristics include short stature, enlarged skull, bony deformities, bone pain, warm skin over the affected bone, joint stiffness, headaches, hearing loss, and elevated serum alkaline phosphatase.","Juvenile Paget Disease | Familial Hyperphosphatasia | PDB5 | Paget Disease of Bone-5",,,,,,,,,,,,,,,"4319896","Hyperphosphatasemia with bone disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0086367","Gonadotropin-Resistant Ovary Syndrome","C131862","Ovarian dysfunction due to a defect at the receptor or post receptor level, or due to the presence of antibodies against gonadotropin receptors, resulting in deficient gonadotropin signaling that causes elevated concentrations of follicle stimulating hormone and/or luteinizing hormone. A distinguishing feature is the presence of normal numbers of ova.","Gonadotropin-Resistant Ovary Syndrome | ROS | Resistant Ovary Syndrome | Savage Syndrome",,,,,,,,,,,,,,,"4214899","Resistant ovary syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514661","Iatrogenic Contrasexual Pubertal Development","C131863","Contrasexual pubertal development caused by medical intervention.","Iatrogenic Contrasexual Pubertal Development | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520497","Sarpogrelate Hydrochloride","C132071","No value exists.","Sarpogrelate Hydrochloride | Butanedioic Acid, Mono(2-(dimethylamino)-1-((2-(2-(3-methoxyphenyl)ethyl)phenoxy)methyl)ethyl) ester, Hydrochloride, (+-)- | SARPOGRELATE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1413123","CAPZA2 Gene","C132072","This gene is involved in the regulation of actin polymerization.","CAPZA2 Gene | CAPZA2 | Capping Actin Protein of Muscle Z-Line Alpha Subunit 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519701","CAPZA2 wt Allele","C132073","Human CAPZA2 wild-type allele is located in the vicinity of 7q31.2 and is approximately 111 kb in length. This allele, which encodes F-actin-capping protein subunit alpha-2 protein, plays a role in the modulation of actin polymerization.","CAPZA2 wt Allele | CAPPA2 | CAPZ | Cap Protein, Actin, Alpha-2 Subunit Gene | Capping Actin Protein of Muscle Z-Line Alpha Subunit 2 wt Allele | Capping Protein (Actin Filament) Muscle Z-Line, Alpha 2 Gene | Capping Protein, Alpha-2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1565245","F-Actin-Capping Protein Subunit Alpha-2, Human","C132074","F-actin-capping protein subunit alpha-2 (286 aa, ~33 kDa) is encoded by the human CAPZA2 gene. This protein is involved in the inhibition of actin polymerization and depolymerization.","F-Actin-Capping Protein Subunit Alpha-2 | CAPZA2 | CapZ Alpha-2 | F-Actin Capping Protein Alpha-2 Subunit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416649","KIR2DS3 Gene","C132075","This gene is involved in the regulation of natural killer cell-dependent immune responses.","KIR2DS3 Gene | KIR2DS3 | Killer Cell Immunoglobulin Like Receptor, Two Ig Domains and Short Cytoplasmic Tail 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1423519","DIAPH3 Gene","C131337","This gene plays a role in actin dynamics, Rho and Src localization, and cytokinesis.","DIAPH3 Gene | DIAPH3 | Diaphanous-Related Formin 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514358","DIAPH3 wt Allele","C131338","Human DIAPH3 wild-type allele is located in the vicinity of 13q21.2 and is approximately 498 kb in length. This allele, which encodes protein diaphanous homolog 3, is involved in cytoskeletal dynamics, signaling molecule localization and cell division. Mutation of the gene is associated with autosomal dominant auditory neuropathy 1.","DIAPH3 wt Allele | AN | AUNA1 | Auditory Neuropathy, Autosomal Dominant 1 Gene | DIA2 | DIAP3 | DRF3 | Diaphanous (Drosophila, Homolog) 3 Gene | Diaphanous Homolog 3 (Drosophila) Gene | Diaphanous Homolog 3 Gene | Diaphanous, Drosophila, Homolog of, 3 Gene | Diaphanous-Related Formin 3 wt Allele | FLJ34705 | NSDAN | diap3 | mDia2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1450901","DIAPH3 protein, human","C131339","Protein diaphanous homolog 3 (1193 aa, ~137 kDa) is encoded by the human DIAPH3 gene. This protein plays a role in Rho and Src coupling, cytokinesis and actin polymerization.","Protein Diaphanous Homolog 3 | DIAP3 | DRF3 | Diaphanous-Related Formin-3 | MDia2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412581","ASIP Gene","C131341","This gene is involved in the modulation of melanogenesis.","ASIP Gene | ASIP | Agouti Signaling Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514471","ASIP wt Allele","C131342","Human ASIP wild-type allele is located within 20q11.2-q12 and is approximately 75 kb in length. This allele, which encodes agouti-signaling protein, plays a role in the regulation of melanogenesis. Homozygous polymorphism in the 3' untranslated region of the gene is associated with an increased likelihood of having dark hair and brown eyes.","ASIP wt Allele | AGSW | AGTI | AGTIL | ASP | Agouti (Mouse)-Signaling Protein Gene | Agouti Signaling Protein wt Allele | Agouti Signaling Protein, Nonagouti Homolog (Mouse) Gene | Agouti Signaling Protein, Nonagouti Homolog Gene | Agouti, Mouse, Homolog of Gene | SHEP9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1528298","ASIP protein, human","C131343","Agouti-signaling protein (132 aa, ~15 kDa) is encoded by the human ASIP gene. This protein is involved in the inhibition of melanin synthesis and the promotion of pheomelanin synthesis.","Agouti-Signaling Protein | ASIP | ASP | Agouti Switch Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417925","OCA2 Gene","C131349","This gene plays a role in transport and melanin synthesis.","OCA2 Gene | OCA2 | OCA2 Melanosomal Transmembrane Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513547","WHODAS 2.0 12-item Version Proxy-administered - Your Day-to-Day Work or School","C130931","World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: His or her day-to-day work?","WHODAS 2.0 12-item Version Proxy-administered - Your Day-to-Day Work or School | WD2-Your Day-to-Day Work/School | WD2S12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519728","CDISC SDTM Administration Technique Response Terminology","C132311","Terminology associated with the administration technique response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Administration Technique Response Terminology | ADTNQRS | Administration Technique Response | SDTM-ADTNQRS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519730","CDISC SDTM Asthma Findings About Test Name Terminology","C132312","Terminology associated with the asthma findings about test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Asthma Findings About Test Name Terminology | ASFATS | Asthma Findings About Test Name | SDTM-ASFATS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519729","CDISC SDTM Asthma Findings About Test Code Terminology","C132313","Terminology associated with the asthma findings about test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Asthma Findings About Test Code Terminology | ASFATSCD | Asthma Findings About Test Code | SDTM-ASFATSCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521336","CDISC SDTM Specimen Collection Method Terminology","C132314","Terminology associated with the specimen collection method codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Specimen Collection Method Terminology | CLMETH | SDTM-CLMETH | Specimen Collection Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519732","CDISC SDTM Ebola Virus Findings About Test Name Terminology","C132315","Terminology associated with the Ebola virus findings about test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Ebola Virus Findings About Test Name Terminology | EBFATS | Ebola Virus Findings About Test Name | SDTM-EBFATS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519731","CDISC SDTM Ebola Virus Findings About Test Code Terminology","C132316","Terminology associated with the Ebola virus findings about test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Ebola Virus Findings About Test Code Terminology | EBFATSCD | Ebola Virus Findings About Test Code | SDTM-EBFATSCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519735","CDISC SDTM Malaria Findings About Test Name Terminology","C132319","Terminology associated with the malaria findings about test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Malaria Findings About Test Name Terminology | MRFATS | Malaria Findings About Test Name | SDTM-MRFATS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519734","CDISC SDTM Malaria Findings About Test Code Terminology","C132320","Terminology associated with the malaria findings about test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Malaria Findings About Test Code Terminology | MRFATSCD | Malaria Findings About Test Code | SDTM-MRFATSCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519738","CDISC SEND Within Normal Limits Results Terminology","C132321","Terminology associated with the within normal limits results codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).","CDISC SEND Within Normal Limits Results Terminology | NORMRS | SEND-NORMRS | Within Normal Limits Results",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826825","RHBDF2 Gene","C132322","This gene plays a role in modulation of epidermal growth factor receptor signaling pathways.","RHBDF2 Gene | RHBDF2 | Rhomboid 5 Homolog 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520600","Chemotherapy-induced Nausea and Vomiting Questionnaire","C131956","A questionnaire designed to assess the extent of nausea on vomiting in individuals undergoing chemotherapy.","Chemotherapy-induced Nausea and Vomiting Questionnaire | CINV | CINV Questionnaire",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520461","KIR2DS3 wt Allele","C132076","Human KIR2DS3 wild-type allele is located in the vicinity of 19q13.4 and is approximately 14 kb in length. This allele, which encodes killer cell immunoglobulin-like receptor 2DS3 protein, plays a role in HLA-C binding and immunity.","KIR2DS3 wt Allele | Killer Cell Immunoglobulin Like Receptor, Two Ig Domains and Short Cytoplasmic Tail 3 wt Allele | Killer Cell Immunoglobulin-Like Receptor, Two Domains, Short Cytoplasmic Tail, 3 Gene | NK-Associated Transcript 7 Gene | NKAT-7 | NKAT7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2716494","Killer Cell Immunoglobulin-Like Receptor 2DS3, Human","C132077","Killer cell immunoglobulin-like receptor 2DS3 (304 aa, ~34 kDa) is encoded by the human KIR2DS3 gene. This protein is involved in the positive regulation of natural killer cell-mediated immunity.","Killer Cell Immunoglobulin-Like Receptor 2DS3 | KIR2DS3 | MHC Class I NK Cell Receptor | NKAT-7 | Natural Killer-Associated Transcript 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520920","Positive Para-Aortic Lymph Node","C132078","A laboratory test result indicating the presence of a pathologic process in a para-aortic lymph node.","Positive Para-Aortic Lymph Node | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520921","Positive Pelvic Lymph Node","C132079","A laboratory test result indicating the presence of a pathologic process in a pelvic lymph node.","Positive Pelvic Lymph Node | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0265661","Congenital Pseudarthrosis of Tibia","C132080","A condition characterized by non-union of the tibia, which is present at birth. It is usually associated with neurofibromatosis type 1.","Congenital Pseudarthrosis of Tibia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520398","SPTBN1 wt Allele","C132082","Human SPTBN1 wild-type allele is located in the vicinity of 2p21 and is approximately 215 kb in length. This allele, which encodes spectrin beta chain, non-erythrocytic 1 protein, is involved in the modulation of both cell shape and calcium-dependent secretory pathways.","SPTBN1 wt Allele | Beta-Spectrin, General Form Gene | ELF | Fodrin, Beta Gene | HEL102 | SPTB2 | Spectrin Beta, Non-Erythrocytic 1 wt Allele | Spectrin, Beta, Non-Erythrocytic 1 Gene | Spectrin, Beta, Nonerythrocytic, 1 Gene | Spectrin, Beta-II Gene | Spectrin, Nonerythroid, Beta Subunit Gene | betaSpII",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1121863","SPTBN1 protein, human","C132083","Spectrin beta chain, non-erythrocytic 1 (2364 aa, ~275 kDa) is encoded by the human SPTBN1 gene. This protein plays a role in both calcium-dependent intercellular transport and cell morphology.","Spectrin Beta Chain, Non-Erythrocytic 1 | Beta-Fodrin | Beta-G Spectrin | Beta-II Spectrin | Beta-Spectrin | Beta-Spectrin II | Beta-Spectrin Non-Erythrocytic 1 | Embryonic Liver Beta-Fodrin | Epididymis Luminal Protein 102 | Fodrin Beta Chain | Spectrin Beta Chain, Brain 1 | Spectrin, Non-Erythroid Beta Chain 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520363","Anti-CD73 Monoclonal Antibody BMS-986179","C132266","A monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD73 monoclonal antibody BMS-986179 targets and binds to CD73, leading to clustering and internalization of CD73. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine and decreases the amount of free adenosine. This prevents adenosine-mediated suppression of lymphocyte activity and increases the activity of CD8-positive effector cells. This also activates macrophages, and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes. By abrogating the inhibitory effect on the immune system and enhancing the cytotoxic T-cell-mediated immune response against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, is upregulated on a number of cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment.","Anti-CD73 Monoclonal Antibody BMS-986179 | BMS 986179 | BMS-986179",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513538","WHODAS 2.0 12-item Version Proxy-administered - How Many Days Difficulties Present","C130932","World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) Overall, in the past 30 days, how many days were these difficulties present?","WHODAS 2.0 12-item Version Proxy-administered - How Many Days Difficulties Present | WD2-How Many Days Difficulties Present | WD2H1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513534","WHODAS 2.0 12-item Version Proxy-administered - Days Unable to Carry Out Activities","C130933","World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) In the past 30 days, for how many days were you totally unable to carry out your usual activities or work because of any health condition?","WHODAS 2.0 12-item Version Proxy-administered - Days Unable to Carry Out Activities | WD2-Days Unable to Carry Out Activities | WD2H2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513539","WHODAS 2.0 12-item Version Proxy-administered - How Many Days Reduce Activities","C130934","World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) In the past 30 days, not counting the days that you were totally unable, for how many days did you cut back or reduce your usual activities or work because of any health condition?","WHODAS 2.0 12-item Version Proxy-administered - How Many Days Reduce Activities | WD2-How Many Days Reduce Activities | WD2H3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513560","WHODAS 2.0 12-item Version Self-administered - Standing for Long Periods","C130935","World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Standing for long periods such as 30 minutes?","WHODAS 2.0 12-item Version Self-administered - Standing for Long Periods | WD3-Standing for Long Periods | WD3S1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513549","WHODAS 2.0 12-item Version Self-administered - Care of Household Responsibilities","C130936","World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Taking care of your household responsibilities?","WHODAS 2.0 12-item Version Self-administered - Care of Household Responsibilities | WD3-Care of Household Responsibilities | WD3S2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513557","WHODAS 2.0 12-item Version Self-administered - Learning a New Task","C130937","World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Learning a new task, for example, learning how to get to a new place?","WHODAS 2.0 12-item Version Self-administered - Learning a New Task | WD3-Learning a New Task | WD3S3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513553","WHODAS 2.0 12-item Version Self-administered - Emotionally Affected by Health","C130939","World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) In the past 30 days, how much difficulty did you have in: How much have you been emotionally affected by your health problems?","WHODAS 2.0 12-item Version Self-administered - Emotionally Affected by Health | WD3-Emotionally Affected by Health | WD3S5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513550","WHODAS 2.0 12-item Version Self-administered - Concentrating for Ten Minutes","C130940","World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Concentrating on doing something for ten minutes?","WHODAS 2.0 12-item Version Self-administered - Concentrating for Ten Minutes | WD3-Concentrating for Ten Minutes | WD3S6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513561","WHODAS 2.0 12-item Version Self-administered - Walking a Long Distance","C130941","World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Walking a long distance such as a kilometre [or equivalent]?","WHODAS 2.0 12-item Version Self-administered - Walking a Long Distance | WD3-Walking a Long Distance | WD3S7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520213","RHBDF2 wt Allele","C132323","Human RHBDF2 wild-type allele is located in the vicinity of 17q25.3 and is approximately 31 kb in length. This allele, which encodes inactive rhomboid protein 2, is involved in the regulation of the secretion of various ligands of the epidermal growth factor receptor. Mutation of the gene is associated with tylosis with esophageal cancer.","RHBDF2 wt Allele | FLJ22341 | IRHOM2 | RHBDL5 | RHBDL6 | Rhomboid 5 Homolog 2 (Drosophila) Gene | Rhomboid 5 Homolog 2 wt Allele | Rhomboid 5, Drosophila, Homolog of, 2 Gene | Rhomboid, Veinlet-Like 6 (Drosophila) Gene | TEC | TOC | TOCG | Tylosis With Esophageal Cancer Gene | iRhom2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3657556","RHBDF2 protein, human","C132324","Inactive rhomboid protein 2 (856 aa, ~97 kDa) is encoded by the human RHBDF2 gene. This protein plays a role in the modulation of both epidermal growth factor receptor (EGFR) ligand secretion and EGFR-dependent signaling.","Inactive Rhomboid Protein 2 | Rhomboid 5 Homolog 2 | Rhomboid Family Member 2 | Rhomboid Veinlet-Like Protein 5 | Rhomboid Veinlet-Like Protein 6 | iRhom2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418501","PGAM1 Gene","C132325","This gene is involved in glycolysis.","PGAM1 Gene | PGAM1 | Phosphoglycerate Mutase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520397","PGAM1 wt Allele","C132326","Human PGAM1 wild-type allele is located in the vicinity of 10q24.1 and is approximately 7 kb in length. This allele, which encodes phosphoglycerate mutase 1 protein, plays a role in the glycolytic pathway.","PGAM1 wt Allele | CDABP0006 | HEL-S-35 | PGAM-B | PGAMA | Phosphoglycerate Mutase 1 (Brain) Gene | Phosphoglycerate Mutase 1 wt Allele | Phosphoglycerate Mutase A, Nonmuscle Form Gene | Phosphoglycerate Mutase, Brain Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519743","CES - How Often Fire Rounds at Enemy","C132560","Combat Exposure Scale (CES) How often did you fire rounds at the enemy?","CES - How Often Fire Rounds at Enemy | CES01-How Often Fire Rounds at Enemy | CES0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519745","CES - See Someone Hit by Rounds","C132561","Combat Exposure Scale (CES) How often did you see someone hit by incoming or outgoing rounds?","CES - See Someone Hit by Rounds | CES01-See Someone Hit by Rounds | CES0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519744","CES - In Danger of Being Injured or Killed","C132562","Combat Exposure Scale (CES) How often were you in danger of being injured or killed (i.e., being pinned down, overrun, ambushed, near miss, etc.)?","CES - In Danger of Being Injured or Killed | CES01-In Danger of Being Injured/Killed | CES0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521026","EPDS - Able to Laugh and See Funny Side","C132563","Edinburgh Postnatal Depression Scale (EPDS) I have been able to laugh and see the funny side of things.","EPDS - Able to Laugh and See Funny Side | EPDS01-Able to Laugh and See Funny Side | EPDS0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521030","EPDS - Looked Forward With Enjoyment","C132564","Edinburgh Postnatal Depression Scale (EPDS) I have looked forward with enjoyment to things.","EPDS - Looked Forward With Enjoyment | EPDS01-Looked Forward With Enjoyment | EPDS0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521028","EPDS - Blamed Myself Unnecessarily","C132565","Edinburgh Postnatal Depression Scale (EPDS) I have blamed myself unnecessarily when things went wrong.","EPDS - Blamed Myself Unnecessarily | EPDS01-Blamed Myself Unnecessarily | EPDS0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521027","EPDS - Anxious or Worried No Good Reason","C132566","Edinburgh Postnatal Depression Scale (EPDS) I have been anxious or worried for no good reason.","EPDS - Anxious or Worried No Good Reason | EPDS01-Anxious/Worried No Good Reason | EPDS0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521031","EPDS - Scared or Panicky for No Good Reason","C132567","Edinburgh Postnatal Depression Scale (EPDS) I have felt scared or panicky for no very good reason.","EPDS - Scared or Panicky for No Good Reason | EPDS01-Scared/Panicky for No Good Reason | EPDS0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521035","EPDS - Unhappy Had Difficulty Sleeping","C132569","Edinburgh Postnatal Depression Scale (EPDS) I have been so unhappy that I have had difficulty sleeping.","EPDS - Unhappy Had Difficulty Sleeping | EPDS01-Unhappy Had Difficulty Sleeping | EPDS0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519828","Difficulty Falling Asleep Scale","C131957","A scale for the subjective scoring of difficulty faling asleep that ranges from 0: No difficulty to 10: Didn't fall asleep.","Difficulty Falling Asleep Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520897","Percentage Food Eaten Scale","C131958","A scale for the subjective scoring of percentage of food eaten that ranges from 0%: None to 100%: All of my food.","Percentage Food Eaten Scale | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL513185","Poliovirus Receptor Staining Finding","C131115","The results of staining for poliovirus receptor in a sample.","Poliovirus Receptor Staining Finding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514053","FDA Terminology","C131123","Terminology subsets associated with the Food and Drug Administration.","FDA Terminology | Food and Drug Administration Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514041","Continuous Temperature Monitoring Device","C131124","A device designed to take a temperature reading at preset intervals over an extended period of time.","Continuous Temperature Monitoring Device | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1452413","NFKB1 Gene Product, Human","C131126","A protein encoded by the NFKB1 gene.","NFKB1 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507899","Anti-GITR Agonistic Monoclonal Antibody BMS-986156","C132267","An anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR; tumor necrosis factor superfamily member 18; TNFRSF18; CD357) agonistic monoclonal antibody, with potential immune checkpoint modulating activity. Anti-GITR antibody BMS-986156 binds to and activates GITR, which is expressed on the cell surface of multiple types of T-cells. This stimulates the immune system, induces both the activation and proliferation of tumor antigen-specific T-effector cells (Teffs), and suppresses the function of activated T-regulatory cells (Tregs). This leads to tumor cell eradication. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B-cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress both Teffs and T-cell receptor (TCR) signaling.","Anti-GITR Agonistic Monoclonal Antibody BMS-986156 | Anti-GITR MoAb BMS-986156 | BMS 986156 | BMS-986156 | GITR Agonist BMS-986156 | TNFRSF18 Agonist BMS-986156",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1646276","Funisolide Anhydrous","C132268","No value exists.","Funisolide Anhydrous | FLUNISOLIDE ANHYDROUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0674350","Sampatrilat","C132269","No value exists.","Sampatrilat | Beta-Alanine, 2-((1-(((1-Carboxy-2-(4-hydroxyphenyl)ethyl)amino)carbonyl)cyclopentyl)methyl)-N-(N2-(methylsulfonyl)-L-lysyl)-, (S-(R*,R*))- | SAMPATRILAT | UK 81,252",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2752149","46,XY Sex Reversal 4","C132270","Sex reversal in an individual associated with a 9p24.3 deletion.","46,XY Sex Reversal 4 | SRXY4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0170835","Oxeclosporin","C132271","No value exists.","Oxeclosporin | Cyclo(((2S,3R,4R,6E)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl)-L-2-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-O-(2-hydroxyethyl)-D-seryl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl) | Cyclosporin A, 2-(O-(2-hydroxyethyl)-D-serine)- | OXECLOSPORIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520439","Iometopane I 123","C132272","No value exists.","Iometopane I 123 | (123I)-RTI 55 | (123I)-beta-CIT | 8-Azabicyclo(3.2.1)-octane-2-carboxylic acid, 3-(4-(Iodo-I)phenyl)-8-methyl-, Methyl Ester (1R-(exo,exo))- | IOMETOPANE I-123 | Iometopane (123I) | Methyl 3beta-(p-(123I)iodophenyl)-1alphaH,5alphaH-tropane-2beta- Carboxylate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0906020","Milameline","C132273","No value exists.","Milameline | 3-Pyridinecarboxaldehyde, 1,2,5,6-Tetrahydro-1-methyl-, O-methyloxime, (E)- | E)-1,2,5,6-Tetrahydro-1-methyl-3-pyridinecarboxaldehyde O-methyloxime | MILAMELINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520652","Feline Mammary Carcinoma","C132274","Mammary carcinoma occurring in a cat.","Feline Mammary Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521174","Canine Thyroid Adenocarcinoma","C132275","Adeonocarcinoma of the thyroid gland occurring in a dog.","Canine Thyroid Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521173","Canine Soft Tissue Sarcoma","C132276","Soft tissue sarcoma occurring in a dog.","Canine Soft Tissue Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0249057","Teverelix","C132277","A synthetic decapeptide and antagonist of the naturally occurring gonadotropin-releasing hormone (GnRH), with potential hormone production inhibitory and antineoplastic activities. Upon administration, teverelix directly competes with GnRH for receptor binding in the anterior pituitary gland, thereby inhibiting GnRH receptor signaling. This inhibits the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation. In females, this prevents the production of estrogen by the ovaries and may relieve symptoms from sex-hormone dependent diseases.","Teverelix | ANB019 | Ac-D-Nal-D-cpa-D-pal-ser-tyr-D-hci-leu-lys(ipr)-pro-D-ala-NH2 | D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-(aminocarbonyl)-D-lysyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl- | EP 24332 | TEVERELIX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520993","Superior Mediastinal Lymph Node Group (Level VII)","C132515","Lymph nodes in this group include pretracheal, paratracheal, and esophageal groove lymph nodes, extending from the level of the suprasternal notch cephalad and up to the innominate artery caudad. These nodes are at greatest risk of involvement by thyroid cancer and cancer of the esophagus. (AJCC 8th ed.)","Superior Mediastinal Lymph Node Group (Level VII) | SUPERIOR MEDIASTINAL LYMPH NODE LEVEL VII",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537655","MAPK15 Gene","C131559","This gene is involved in both protein phosphorylation and telomere maintenance.","MAPK15 Gene | MAPK15 | Mitogen-Activated Protein Kinase 15 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0228071","Ganglion Cell","C13155","A type of interneuron that conveys information to the brain.","Ganglion Cell | Ganglion Cells",,,,,,,,,,,,,,,"4200390","Ganglion cell",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514302","MAPK15 wt Allele","C131560","Human MAPK15 wild-type allele is located in the vicinity of 8q24.3 and is approximately 6 kb in length. This allele, which encodes mitogen-activated protein kinase 15 protein, plays a role in both telomere maintenance and protein phosphorylation.","MAPK15 wt Allele | ERK7 | ERK8 | Mitogen-Activated Protein Kinase 15 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514703","Mitogen-Activated Protein Kinase 15","C131561","Mitogen-activated protein kinase 15 (544 aa, ~60 kDa) is encoded by the human MAPK15 gene. This protein is involved in serine/threonine protein phosphorylation and telomere maintenance.","Mitogen-Activated Protein Kinase 15 | EC 2.7.11.24 | ERK-7 | ERK-8 | Extracellular Signal Regulated Kinase 8 | Extracellular Signal-Regulated Kinase 7 | Extracellular Signal-Regulated Kinase 8 | MAP Kinase 15 | MAPK 15 | MAPK15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514580","PEN 221","C131562","A miniaturized drug conjugate composed of a peptide analog of somatostatin that targets the somatostatin receptor 2 (SSTR2) and is conjugated, through a cleavable linker, to the microtubule-binding cytotoxic maytansinoid DM1 (mertansine), with potential anti-tumor activity. Upon administration, the peptide ligand moiety of nendratareotide uzatansine targets and binds to SSTR2, which is overexpressed on certain tumor cell types. Binding stimulates SSTR2-mediated endocytosis of the agent; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics. This inhibits both cell division and the proliferation of SSTR2-expressing cancer cells. Compared to antibody-drug conjugates (ADCs), miniaturized drug conjugates are much smaller and can more easily penetrate and distribute in dense tumor tissue.","Nendratareotide Uzatansine | NENDRATAREOTIDE UZATANSINE | PEN 221 | PEN-221 | PEN221 | SSTR2-targeting Protein/DM1 Conjugate PEN-221 | SSTR2PEN-221",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826473","NSMCE2 Gene","C131563","This gene plays a role in protein sumoylation, DNA repair and the inhibition of apoptosis.","NSMCE2 Gene | NSE2/MMS21 Homolog, SMC5-SMC6 Complex SUMO Ligase Gene | NSMCE2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514425","NSMCE2 wt Allele","C131564","Human NSMCE2 wild-type allele is located in the vicinity of 8q24.13 and is approximately 275 kb in length. This allele, which encodes E3 SUMO-protein ligase NSE2 protein, is involved in the negative regulation of apoptosis, protein sumoylation, and the promotion of DNA repair. Mutation of the gene is associated with Seckel syndrome 10.","NSMCE2 wt Allele | C8orf36 | Chromosome 8 Open Reading Frame 36 Gene | FLJ32440 | MMS21 | MMS21, S. cerevisiae, Homolog of Gene | Methyl Methanesulfonate Sensitivity Gene 21 | NSE2 | NSE2/MMS21 Homolog, SMC5-SMC6 Complex SUMO Ligase wt Allele | Non-SMC Element 2 Homolog (MMS21, S. cerevisiae) Gene | Non-SMC Element 2, MMS21 Homolog (S. cerevisiae) Gene | Non-SMC Element 2, S. cerevisiae, Homolog of Gene | ZMIZ7 | Zinc Finger, MIZ-Type Containing 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1612005","NSMCE2 protein, human","C131565","E3 SUMO-protein ligase NSE2 (247 aa, ~28 kDa) is encoded by the human NSMCE2 gene. This protein plays a role in DNA double-strand break repair by homologous recombination, the prevention of DNA damage-induced apoptosis, and the sumolyation of protein substrates.","E3 SUMO-Protein Ligase NSE2 | E3 SUMO-Protein Transferase NSE2 | EC 2.3.2.- | EC 6.3.2.-, Formerly | MMS21 Homolog | NSMCE2 | Non-SMC Element 2 Homolog | Non-Structural Maintenance Of Chromosomes Element 2 Homolog | SMC5/SMC6 Complex SUMO Ligase NSMCE2 | hMMS21",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419864","SCN5A Gene","C131566","This gene is involved in voltage-dependent sodium ion transport.","SCN5A Gene | SCN5A | Sodium Voltage-Gated Channel Alpha Subunit 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514365","SCN5A wt Allele","C131567","Human SCN5A wild-type allele is located in the vicinity of 3p21 and is approximately 102 kb in length. This allele, which encodes sodium channel protein type 5 subunit alpha protein, plays a role in voltage-dependent sodium transport. Mutation of the gene is associated with long QT syndrome-3, sick sinus syndrome 1, Brugada syndrome 1, familial atrial fibrillation 10, familial ventricular fibrillation 1, dialated cardiomyopathy 1E, progressive heart block type 1A and non-progressive heart block.","SCN5A wt Allele | CDCD2 | CMD1E | CMPD2 | HB1 | HB2 | HBBD | HH1 | ICCD | IVF | LQT3 | Nav1.5 | PFHB1 | SSS1 | Sodium Channel, Voltage Gated, Type V Alpha Subunit Gene | Sodium Channel, Voltage-Gated, Type V, Alpha (Long QT Syndrome 3) Gene | Sodium Channel, Voltage-Gated, Type V, Alpha Subunit Gene | Sodium Voltage-Gated Channel Alpha Subunit 5 wt Allele | VF1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026046","Microtubule","C13256","Microtubules of the eukaryotic cytoskeleton perform essential and diverse functions and are composed of a heterodimer of alpha and beta tubulin. The genes encoding these microtubule constituents are part of the tubulin superfamily, which is composed of six distinct families. Genes from the alpha, beta and gamma tubulin families are found in all eukaryotes. The alpha and beta tubulins represent the major components of microtubules, while gamma tubulin plays a critical role in the nucleation of microtubule assembly. There are multiple alpha and beta tubulin genes and they are highly conserved among and between species. (from LocusLink)","Microtubule | Micro Tubule | Micro-tubule",,,,,,,,,,,,,,,"4143935","Cytoplasmic microtubule",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521029","EPDS - I Have Felt Sad or Miserable","C132570","Edinburgh Postnatal Depression Scale (EPDS) I have felt sad or miserable.","EPDS - I Have Felt Sad or Miserable | EPDS01-I Have Felt Sad or Miserable | EPDS0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521032","EPDS - So Unhappy I Have Been Crying","C132571","Edinburgh Postnatal Depression Scale (EPDS) I have been so unhappy that I have been crying.","EPDS - So Unhappy I Have Been Crying | EPDS01-So Unhappy I Have Been Crying | EPDS0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521034","EPDS - Thought of Harming Myself","C132572","Edinburgh Postnatal Depression Scale (EPDS) The thought of harming myself has occurred to me.","EPDS - Thought of Harming Myself | EPDS01-Thought of Harming Myself | EPDS0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519874","HAQ-DI Without VAS - Dress Yourself","C132573","Dressing & Grooming: Are you able to dress yourself, including tying shoelaces and doing buttons?","HAQ-DI Without VAS - Dress Yourself | HAQ02-Dress Yourself | HAQ0201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519894","HAQ-DI Without VAS - Shampoo Your Hair","C132574","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Dressing & Grooming: Are you able to shampoo your hair?","HAQ-DI Without VAS - Shampoo Your Hair | HAQ02-Shampoo Your Hair | HAQ0202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519897","HAQ-DI Without VAS - Stand Up From a Straight Chair","C132575","Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Arising: Are you able to stand up from a straight chair?","HAQ-DI Without VAS - Stand Up From a Straight Chair | HAQ02-Stand Up From a Straight Chair | HAQ0203",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521226","Oral Docetaxel","C131903","An oral proprietary P-glycoprotein (P-gp) pump inhibitor-based formulation containing the taxane docetaxel, a semisynthetic analogue of paclitaxel, and a P-gp pump inhibitor, with potential antineoplastic activity. Upon administration of oral docetaxel, the P-gp pump inhibitor moiety, which is not absorbed, binds to the P-gp pump in the gastrointestinal (GI) tract and prevents the P-gp pump-mediated efflux of docetaxel from cells the docetaxel has been internalized by back into the GI tract. This decreases P-gp-mediated excretion and enhances absorption of docetaxel. Upon absorption, docetaxel binds specifically to the beta-tubulin subunit of the microtubule, stabilizes tubulin and inhibits microtubule disassembly, which results in cell-cycle arrest at the G2/M phase and cell death. The P-gp pump inhibitor enhances the bioavailability of certain poorly bioavailable agents and thereby allows oral administration of those agents. P-gp, an efflux membrane transporter, plays a key role in active drug export, and prevents cellular uptake and accumulation of certain substances.","Oral Docetaxel | Docetaxel-P-glycoprotein Inhibitor | Docetaxel-P-gp Inhibitor | Oradoxel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520666","Gallium Ga 68-NOTA-3PTATE-RGD","C131904","A radiopharmaceutical agent composed of a modified form of the somatostatin analogue octreotate (TATE), linked, via a glutamate linker, to the cyclic tri-amino acid arginine-glycine-aspartic acid (RGD) motif (3PTATE-RGD), and labeled, via the macrocyclic chelating agent 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA) with the radioisotope gallium Ga 68, with potential somatostatin receptor type 2 (SSTR2) and alphaVbeta3 (aVb3) integrin imaging activity upon positron emission topography (PET) or single photon emission computed tomography (SPECT). After intravenous administration, gallium Ga 68-NOTA-3PTATE-RGD simultaneously binds to SSTR, with its TATE moiety (with a preference for SSTR2), and to the integrin receptor aVb3 with its RGD moiety. Both SSTR2 and aVb3 are expressed on the membrane of certain tumor cells while minimally or not expressed on healthy, normal cells. Upon PET imaging, SSTR2- and aVb3 integrin-expressing tumor cells can be visualized and expression levels can be quantified. SSTR2 and aVb3 play key roles in tumor proliferation and survival.","Gallium Ga 68-NOTA-3PTATE-RGD | 68Ga-NOTA-3PTATE-RGD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514468","SNORD50B wt Allele","C131747","Human SNORD50B wild-type allele is located in the vicinity of 6q14.3 and is approximately 2 kb in length. This allele, which encodes U50' small nucleolar RNA, is involved in the metabolism of ribosomal RNA. Somatic loss of the gene may be associated with various neoplastic diseases.","SNORD50B wt Allele | RNA, U50' Small Nuclear Gene | RNA, U50-Prime Small Nuclear Gene | Small Nucleolar RNA, C/D Box 50B wt Allele | Small Nucleolar RNA, C/D Box, 50B Gene | U50' | U50-Prime | U50B | snoRNA, U50' Gene | snoRNA, U50-Prime Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514592","U50' Small Nucleolar RNA","C131748","U50' small nucleolar RNA (75 bases) is encoded by the human SNORD50B gene. This oligoribonucleotide plays a role in ribosomal RNA methylation.","U50' Small Nucleolar RNA | SNORD50B | U50' snoRNA | U50-Prime Small Nucleolar RNA | U50-Prime snoRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828935","SMIM24 Gene","C131749","This gene encodes a membrane protein of unknown function.","SMIM24 Gene | SMIM24 | Small Integral Membrane Protein 24 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0228107","Free Nerve Ending","C13174","Free nerve endings are widely distributed throughout the body, and are found as branches of unmyelinated, or lightly myelinated fibres grouped in bundles beneath the epithelium. As they penetrate the epithelium, they lose their myelin, and branch among the epithelial cells. Branches of one nerve may cover a wide area and overlap the territories of other nerves. The free nerve endings detect pain, touch, pressure and temperature, and are associated with C fibres.","Free Nerve Ending | Free Nerve Endings",,,,,,,,,,,,,,,"4244213","Free nerve ending",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514419","SMIM24 wt Allele","C131750","Human SMIM24 wild-type allele is located in the vicinity of 19p13.3 and is approximately 7 kb in length. This allele, which encodes small integral membrane protein 24, has no known function.","SMIM24 wt Allele | C19orf77 | Chromosome 19 Open Reading Frame 77 Gene | HSPC323 | MARDI | Small Integral Membrane Protein 24 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824787","CPXM1 Gene","C131752","This gene may be involved in cell-cell interactions.","CPXM1 Gene | CPXM1 | Carboxypeptidase X, M14 Family Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514369","CPXM1 wt Allele","C131753","Human CPXM1 wild-type allele is located in the vicinity of 20p13 and is approximately 7 kb in length. This allele, which encodes probable carboxypeptidase X1 protein, may play a role in cell interactions.","CPXM1 wt Allele | CPX1 | CPXM | Carboxypeptidase X (M14 Family), Member 1 Gene | Carboxypeptidase X, M14 Family Gene | Carboxypeptidase X, M14 Family Member 1 wt Allele | UNQ3015/PRO9782",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514325","Probable Carboxypeptidase X1","C131754","Probable carboxypeptidase X1 (734 aa, ~82 kDa) is encoded by the human CPXM1 gene. This protein may be involved in the interactions between cells.","Probable Carboxypeptidase X1 | CPXM1 | Carboxypeptidase-Like Protein X1 | EC 3.4.17.- | Metallocarboxypeptidase CPX-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426557","FAM30A Gene","C131755","This gene may play a role in both cell migration and epithelial-mesenchymal transition.","FAM30A Gene | FAM30A | Family With Sequence Similarity 30, Member A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514497","FAM30A wt Allele","C131756","Human FAM30A wild-type allele is located in the vicinity of 14q32.33 and is approximately 15 kb in length. This allele, which encodes FAM30A protein and long non-coding RNA KIAA0125, may be involved in the promotion of both cell migration and cell differentiation.","FAM30A wt Allele | C14orf110 | Chromosome 14 Open Reading Frame 110 Gene | Family With Sequence Similarity 30, Member A wt Allele | HSPC053 | KIAA0125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519712","CDISC Clinical Classification NSAA Test Name Terminology","C132516","Test names of clinical classification questions associated with the North Star Ambulatory Assessment (NSAA) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification NSAA Test Name Terminology | CC-NSAA TEST | NSAA1TN | North Star Ambulatory Assessment Clinical Classification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519711","CDISC Clinical Classification NSAA Test Code Terminology","C132517","Test codes of clinical classification questions associated with the North Star Ambulatory Assessment (NSAA) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification NSAA Test Code Terminology | CC-NSAA TESTCD | NSAA1TC | North Star Ambulatory Assessment Clinical Classification Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519721","CDISC Questionnaire CES Test Name Terminology","C132518","Test names of questionnaire questions associated with the Combat Exposure Scale (CES) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire CES Test Name Terminology | CES01TN | Combat Exposure Scale Questionnaire Test Name | QS-CES TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519720","CDISC Questionnaire CES Test Code Terminology","C132519","Test codes of questionnaire questions associated with the Combat Exposure Scale (CES) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire CES Test Code Terminology | CES01TC | Combat Exposure Scale Questionnaire Test Code | QS-CES TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023978","Long Terminal Repeat","C13251","Identical DNA sequences found at either end of retrovirus proviral DNA, formed by reverse transcription of viral RNA.","Long Terminal Repeat | LTR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519723","CDISC Questionnaire EPDS Test Name Terminology","C132520","Test names of questionnaire questions associated with the Edinburgh Postnatal Depression Scale (EPDS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire EPDS Test Name Terminology | EPDS01TN | Edinburgh Postnatal Depression Scale Questionnaire Test Name | QS-EPDS TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519722","CDISC Questionnaire EPDS Test Code Terminology","C132521","Test codes of questionnaire questions associated with the Edinburgh Postnatal Depression Scale (EPDS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire EPDS Test Code Terminology | EPDS01TC | Edinburgh Postnatal Depression Scale Questionnaire Test Code | QS-EPDS TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519724","CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology","C132523","Test codes of questionnaire questions associated with the Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology | HAQ02TC | Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale Questionnaire Test Code | QS-HAQ-DI Without VAS TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519727","CDISC Questionnaire TSQM Version 1.4 Test Name Terminology","C132524","Test names of questionnaire questions associated with the Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire TSQM Version 1.4 Test Name Terminology | QS-TSQM Version 1.4 TEST | TSQM01TN | Treatment Satisfaction Questionnaire for Medication Version 1.4 Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519726","CDISC Questionnaire TSQM Version 1.4 Test Code Terminology","C132525","Test codes of questionnaire questions associated with the Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire TSQM Version 1.4 Test Code Terminology | QS-TSQM Version 1.4 TESTCD | TSQM01TC | Treatment Satisfaction Questionnaire for Medication Version 1.4 Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520112","NSAA Clinical Classification Question","C132526","A question associated with the NSAA clinical classification.","NSAA Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519748","CES Questionnaire Question","C132527","A question associated with the CES questionnaire.","CES Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521178","EPDS Questionnaire Question","C132528","A question associated with the EPDS questionnaire.","EPDS Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1143897","SCN5A protein, human","C131568","Sodium channel protein type 5 subunit alpha (2016 aa, ~227 kDa) is encoded by the human SCN5A gene. This protein is involved in voltage-gated transport of sodium ions.","Sodium Channel Protein Type 5 Subunit Alpha | Cardiac Tetrodotoxin-Insensitive Voltage-Dependent Sodium Channel Alpha Subunit | HH1 | SCN5A | Sodium Channel Protein Cardiac Muscle Subunit Alpha | Sodium Channel Protein Type V Subunit Alpha | Voltage-Gated Sodium Channel Alpha Subunit Nav1.5 | Voltage-Gated Sodium Channel Subunit Alpha Nav1.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1567781","Hepatocyte Growth Factor-Like Protein, Human","C131153","Hepatocyte growth factor-like protein (711 aa, ~80 kDa) is encoded by the human MST1 gene. This protein plays a role in the positive regulation of both macrophage activation and ciliary motility.","Hepatocyte Growth Factor-Like Protein | Hepatocyte Growth Factor-Like | Hepatocyte Growth Factor-Like Protein Homolog | MSP | Macrophage Stimulating Protein | Macrophage Stimulatory Protein | Macrophage-Stimulating Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3490787","BF-200 Gel Formulation","C131905","A topical nanoemulsion-based gel formulation containing 5-aminolevulinic acid (ALA), a metabolic precursor of the photosensitizer protoporphyrin IX, with a potential application for enhanced photodynamic therapy (PDT) for various precancerous and malignant skin lesions. After topical administration of a thick layer of the ALA-based BF-200 gel formulation to the affected area, ALA penetrates the skin and is intracellularly converted to protoporphyrin IX (PpIX). Exposure of PpIX to the proper excitation wavelength of light generates singlet oxygen molecules, resulting in a local cytotoxic effect.","BF-200 Gel Formulation | BF-200 | BF-200 ALA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520364","BMS-986207","C131907","A human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, renvistobart binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells, and leads to CD226 dimerization and CD226-mediated signaling. This activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","Renvistobart | Anti-TIGIT Monoclonal Antibody BMS-986207 | Anti-TIGIT Monoclonal Antibody BMS-986207 | BMS-986207 | RENVISTOBART",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521133","RG 6016","C131908","An orally available inhibitor of lysine specific histone demethylase 1 (KDM1A; LSD1), with potential antineoplastic activity. Upon administration, iadademstat binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4, respectively. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. In addition, LSD1 demethylates mono- or di-methylated H3K9, which increases gene expression of tumor promoting genes; inhibition of LSD1 promotes H3K9 methylation and decreases transcription of these genes. LSD1, an enzyme belonging to the flavin adenine dinucleotide (FAD)-dependent amine oxidase family, is overexpressed in certain tumor cells and plays a key role in in the regulation of gene expression, tumor cell growth and survival.","Iadademstat | 1,4-Cyclohexanediamine, N1-((1R,2S)-2-Phenylcyclopropyl)-, trans- | IADADEMSTAT | ORY 1001 | ORY-1001 | RG 6016 | RG6016 | RO 7051790 | RO7051790 | trans-N1-((1R,2S)-2-Phenylcyclopropyl)-1,4-cyclohexanediamine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825392","GON4L Gene","C132120","This gene may play a role in the negative regulation of gene transcription.","GON4L Gene | GON4L | Gon-4 Like Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520391","GON4L wt Allele","C132121","Human GON4L wild-type allele is located in the vicinity of 1q22 and is approximately 110 kb in length. This allele, which encodes GON-4-like protein, is involved in transcriptional repression.","GON4L wt Allele | FLJ20203 | GON-4 | GON4 | Gon-4 Homolog (C.elegans) Gene | Gon-4 Like wt Allele | Gon-4-Like (C. elegans) Gene | KIAA1606 | YARP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2351402","GON4L protein, human","C132122","GON-4-like protein (2241 aa, ~249 kDa) is encoded by the human GON4L gene. This protein plays a role in the repression of gene transcription.","GON-4-Like Protein | GON-4 Homolog | GON4-Like Protein | GON4L | Gon-4 Homolog | YY1AP Related Protein | YY1AP-Related Protein1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418730","POLE2 Gene","C132123","This gene is involved in both chromosomal DNA replication and DNA repair.","POLE2 Gene | DNA Polymerase Epsilon 2, Accessory Subunit Gene | POLE2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520376","POLE2 wt Allele","C132124","Human POLE2 wild-type allele is located in the vicinity of 14q21.3 and is approximately 45 kb in length. This allele, which encodes DNA polymerase epsilon subunit 2 protein, plays a role in DNA-dependent replication.","POLE2 wt Allele | DNA Polymerase Epsilon 2, Accessory Subunit wt Allele | DPE2 | Polymerase (DNA Directed), Epsilon 2 (p59 Subunit) Gene | Polymerase (DNA Directed), Epsilon 2, Accessory Subunit Gene | Polymerase (DNA) Epsilon 2, Accessory Subunit Gene | Polymerase, DNA, Epsilon-2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514496","FAM30A Protein","C131757","FAM30A protein (136 aa, ~15 kDa) is encoded by the human FAM30A gene. This protein may play a role in the regulation of both epithelial-mesenchymal transition and cell migration.","FAM30A Protein | HCG2029388, Isoform CRA_d | Putative Uncharacterized Protein KIAA0125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514713","Long Noncoding RNA KIAA0125","C131758","Long noncoding RNA KIAA0125 (~10 kb) is encoded by the human FAM30A gene. This non-coding RNA may be involved in the modulation of both cell migration and epithelial-mesenchymal transition.","Long Noncoding RNA KIAA0125 | FAM30A, Long Non-Coding RNA | Family With Sequence Similarity 30, Member A, Long Non-Coding RNA | Long Non-Coding RNA KIAA0125 | lncRNA KIAA0125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035943","Ruffini Corpuscle","C13175","Mechanoreceptors located in subcutaneous tissue, which are enlarged dendritic endings with elongated capsules, and which respond to sustained pressure.","Ruffini Corpuscle | Ruffini's Corpuscle | Ruffini's Ending",,,,,,,,,,,,,,,"4204216","Ruffini's corpuscle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514523","Lysine-specific Demethylase 1 Inhibitor CC-90011","C131303","An orally available inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity. Upon administration, pulrodemstat binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4, respectively. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor (remove hyphen) suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. In addition, LSD1 demethylates mono- or di-methylated H3K9 which increases gene expression of tumor promoting genes; inhibition of LSD1 promotes H3K9 methylation and decreases transcription of these genes. LSD1, an enzyme belonging to the flavin adenine dinucleotide (FAD)-dependent amine oxidase family that is overexpressed in certain tumor cells, plays a key role in tumor cell growth and survival.","Pulrodemstat | CC 90011 | CC-90011 | CC90011 | LSD1 Inhibitor CC-90011 | Lysine-specific Demethylase 1 Inhibitor CC-90011 | PULRODEMSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514718","Interleukin-35","C131304","A heterodimeric cytokine that is comprised of interleukin-12 subunit alpha and interleukin-27 subunit beta. This protein complex is reported to be secreted by regulatory T-cells and may suppress inflammation.","Interleukin-35 | IL-35 | IL35 | Interleukin 35",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514353","Ex Vivo-expanded Autologous T Cells IMA101","C131305","A preparation of autologous cytotoxic T-lymphocytes, specifically recognizing certain tumor-associated antigens (TAAs), with potential antineoplastic activity. The endogenous T-cells are isolated, expanded ex vivo, and reintroduced back into the patient. Upon administration, the ex vivo-expanded autologous T-cells IMA101 target and kill tumor cells. The T-cells are analyzed beforehand for their ability to specifically recognize certain TAAs, based on a proprietary antigen warehouse.","Ex Vivo-expanded Autologous T Cells IMA101 | ACTolog IMA101 | IMA101 | IMA101 T-Cells | IMA101 T-cell Product",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514450","Risperidone Formulation in Rumenic Acid","C131306","An orally bioavailable capsule formulation containing the antipsychotic agent risperidone suspended in the lipid rumenic acid, with potential antineoplastic activity. Upon administration of VAL401, risperidone may, through an as of yet not elucidated mechanism of action, reduce cellular activity and tumor cell proliferation in multiple cancers.","Risperidone Formulation in Rumenic Acid | Risperidone Lipid Formulation VAL401 | VAL-401 | VAL401",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514320","Pegylated Liposomal Mitoxantrone Hydrochloride","C131307","A pegylated liposomal mitoxantrone formulation composed of the hydrochloride salt form of the anthracenedione antibiotic mitoxantrone encapsulated within pegylated small unilamellar vesicles (SUVs), with potential antineoplastic activity. Upon intravenous administration, mitoxantrone intercalates into and forms crosslinks with DNA, thereby disrupting DNA and RNA replication. This agent also binds to topoisomerase II, which both results in DNA strand breaks and prevents DNA synthesis. This leads to the induction of apoptosis in rapidly dividing cancer cells. The pegylated liposomal formulation improves drug penetration into tumors and decreases drug clearance, thereby increasing drug circulation and therapeutic efficacy while lowering toxic effects.","Pegylated Liposomal Mitoxantrone Hydrochloride | PLM60",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514534","Osteoclast-Rich Osteopetrosis","C131308","A form of osteopetrosis in which osteoclasts are abundant but have severely impaired resorptive function.","Osteoclast-Rich Osteopetrosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1840322","Odontohypophosphatasia","C131309","Hypophosphastasia characterized by the premature loss of deciduous teeth, but without accompanying bony abnormalities.","Odontohypophosphatasia | ",,,,,,,,,,,,,,,"46270714","Odontohypophosphatasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514664","Idiopathic 46,XY Differences of Sex Development","C131864","Conditions affecting individuals whose karyotype is 46,XY that is characterized by atypical development of the internal or external sex structures, or the gonads, and in whom no genetic, environmental, or biochemical causation can be established.","Idiopathic 46,XY Differences of Sex Development | Idiopathic 46,XY Disorder of Sex Development",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342387","Luteinizing Hormone Deficiency","C131865","Subnormal concentration of luteinizing hormone.","Luteinizing Hormone Deficiency | LH deficiency | Lutropin Deficiency",,,,,,,,,,,,,,,"4099782","LH - luteinizing hormone deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514517","Isolated Non-Pigmented Micronodular Adrenal Hyperplasia","C131866","A subtype of micronodular adrenal hyperplasia, characterized by multiple non-pigmented nodules.","Isolated Non-Pigmented Micronodular Adrenal Hyperplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514667","Miniature Adult Form of AHC","C131867","An autosomal recessive or sporadic form of adrenal hypoplasia congenita frequently associated with central nervous system anomalies including anencephaly and pituitary defects. Histologically the adrenal gland is distinguished by the absence of fetal adrenal cortex and the presence of a small amount of normal, permanent adult adrenal cortex.","Miniature Adult Form of AHC | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0265295","Metaphyseal Chondrodysplasia, Jansen Type","C131868","A form of metaphyseal chondrodysplasia caused by mutation(s) in the PTH1R gene, encoding parathyroid hormone/parathyroid hormone-related peptide receptor. This condition is characterized by severe short stature, short bowed limbs, clinodactyly, prominent upper face, and a small mandible. Hypercalcemia and hypophosphatemia due to PTH resistance can appear later in childhood.","Metaphyseal Chondrodysplasia, Jansen Type | ",,,,,,,,,,,,,,,"4078643","Metaphyseal chondrodysplasia, Jansen type",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0000702","A-DNA","C13186","A-DNA is a shorter and wider helix than B-DNA. Most RNA and RNA-DNA duplex are in this form. While deep, narrow major groove is not easily accessible to proteins but wide, shallow minor groove is accessible to proteins but with lower information content than major groove. A-DNA is the favored conformation at low water concentrations. Base pairs are tilted to helix axis and displaced from axis and sugar pucker is C3'-endo (in RNA 2'-OH inhibits C2'-endo conformation). When examined from the top of the helix, there is a large hole in the middle, the sugar phosphate backbone is at the edge of the helix, and the bases are displaced towards the edge.","A-DNA | A-Form DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520224","Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","C131873","The reemergence of chronic lymphocytic leukemia/small lymphocytic lymphoma after a period of remission.","Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520350","Androgen Receptor Antagonist TRC253","C131874","An orally bioavailable androgen receptor (AR) antagonist, with potential antineoplastic activity. Upon oral administration, AR antagonist TRC253 specifically binds to both wild-type and certain mutant forms of AR, thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes, inhibits the expression of genes that regulate prostate cancer cell proliferation, and may lead to an inhibition of growth of tumor cells in which AR is overexpressed and/or mutated. AR is often overexpressed and/or mutated in prostate cancers and plays a key role in proliferation, survival and chemoresistance of tumor cells.","Androgen Receptor Antagonist TRC253 | AR Antagonist TRC253 | JNJ 63576253 | JNJ-63576253 | JNJ63576253 | TRC 253 | TRC-253 | TRC253",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520223","Recurrent Childhood T Acute Lymphoblastic Leukemia","C131875","The reemergence of T acute lymphoblastic leukemia in childhood after a period of remission.","Recurrent Childhood T Acute Lymphoblastic Leukemia | Recurrent Childhood T-Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521234","2q37","C13134","A chromosome band present on 2q","2q37 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514361","OCA2 wt Allele","C131354","Human OCA2 wild-type allele is located within 15q12-q13.1 and is approximately 344 kb in length. This allele, which encodes P protein, is involved in eye and skin color. Mutations in this gene are associated with type 2 oculocutaneous albinism.","OCA2 wt Allele | BEY | BEY1 | BEY2 | BOCA | D15S12 | EYCL | EYCL2 | EYCL3 | Eye Color 2 (Central Brown) Gene | Eye Color 3 (Brown) Gene | HCL3 | Hair Color 3 (Brown) Gene | OCA2 Melanosomal Transmembrane Protein wt Allele | Oculocutaneous Albinism II (Pink-Eye Dilution Homolog, Mouse) Gene | Oculocutaneous Albinism II Gene | P | P Gene | PED | Pink-Eyed Dilution Gene | SHEP1 | Total Brown Iris Pigmentation Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0212578","OCA2 protein, human","C131356","P protein (838 aa, ~93 kDa) is encoded by the human OCA2 gene. This protein plays a role in melanogenesis and transmembrane transport of tyrosine and hydrogen ions.","P Protein | Melanocyte-Specific Transporter Protein | OCA2 | P-Protein | Pink-Eyed Dilution Protein Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519815","POLE2 protein, human","C132125","DNA polymerase epsilon subunit 2 (527 aa, ~60 kDa) is encoded by the human POLE2 gene. This protein is involved in the replication and repair of chromosomal DNA.","DNA Polymerase Epsilon Subunit 2 | DNA Polymerase Epsilon Subunit B | DNA Polymerase II Subunit 2 | EC 2.7.7.7 | POLE2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414988","GARS1 Gene","C132127","This gene plays a role in the attachment of glycine to the appropriate tRNA.","GARS1 Gene | GARS | GARS1 | Glycyl-tRNA Synthetase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520378","CMT2D","C132128","Human GARS1 wild-type allele is located in the vicinity of 7p14.3 and is approximately 39 kb in length. This allele, which encodes glycine-tRNA ligase protein, is involved in the synthesis of glycyl-tRNA. Mutation of the gene is associated with type 2D Charcot-Marie-Tooth disease and distal hereditary motor neuropathy, type Va.","GARS1 wt Allele | CMT2D | Charcot-Marie-Tooth Neuropathy 2D Gene | Charcot-Marie-Tooth Neuropathy, Neuronal Type, D Gene | DSMAV | GARS | GlyRS | Glycine tRNA Ligase Gene | Glycyl-tRNA Synthetase 1 wt Allele | Glycyl-tRNA Synthetase Gene | HMN5 | SMAD1 | SMAJI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521332","Glycine-tRNA Ligase","C132129","Glycine-tRNA ligase (739 aa, ~83 kDa) is encoded by the human GARS1 gene. This protein plays a role in tRNA aminoacylation.","Glycine-tRNA Ligase | AP-4-A Synthetase | Ap4A Synthetase | Diadenosine Tetraphosphate Synthetase | EC 6.1.1.14 | EJ ANTIGEN | GARS | GARS1 | GlyRS | Glycine tRNA Ligase | Glycine--tRNA Ligase | Glycine—tRNA Ligase | Glycyl-tRNA Synthetase | Glycyl-tRNA Synthetase 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416863","LIMK2 Gene","C132130","This gene is involved in serine/threonine phosphorylation of protein substrates.","LIMK2 Gene | LIM Domain Kinase 2 Gene | LIMK2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521194","LIMK2 wt Allele","C132131","Human LIMK2 wild-type allele is located in the vicinity of 22q12.2 and is approximately 68 kb in length. This allele, which encodes LIM domain kinase 2 protein, plays a role in serine/threonine phosphorylation.","LIMK2 wt Allele | LIM Domain Kinase 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1430543","LIMK2 protein, human","C132132","LIM domain kinase 2 (638 aa, ~72 kDa) is encoded by the human LIMK2 gene. This protein is involved in the phosphorylation of serines or threonines in protein substrates.","LIM Domain Kinase 2 | EC 2.7.11.1 | LIMK-2 | LIMK2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0062076","Hachimycin","C132133","No value exists.","Hachimycin | HACHIMYCIN | Trichomycin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520310","WDR5 wt Allele","C132135","Human WDR5 wild-type allele is located in the vicinity of 9q34.2 and is approximately 25 kb in length. This allele, which encodes WD repeat-containing protein 5, is involved in the acetylation and methylation of histones.","WDR5 wt Allele | BIG-3 | BIG3 | BMP2-Induced 3-kb Gene | BMP2-Induced Gene | CFAP89 | SWD3 | SWD3, Set1c WD40 Repeat Protein, Homolog (S. cerevisiae) 2 Gene | Set1c WD40 Repeat Protein, Homolog Gene | WD Repeat Domain 5 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521645","Phosphoglycerate Mutase 1, Human","C132327","Phosphoglycerate mutase 1 (254 aa, ~29 kDa) is encoded by the human PGAM1 gene. This protein is involved in the interconversion of 3- and 2-phosphoglycerate during glycolysis.","Phosphoglycerate Mutase 1 | BPG-Dependent PGAM 1 | EC 5.4.2.11 | Epididymis Secretory Protein Li 35 | PGAM-B | PGAM1 | Phosphoglycerate Mutase A | Phosphoglycerate Mutase Isozyme B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520375","BCL9L wt Allele","C132329","Human BCL9L wild-type allele is located in the vicinity of 11q23.3 and is approximately 32 kb in length. This allele, which encodes B-cell CLL/lymphoma 9-like protein, is involved in transcriptional activation.","BCL9L wt Allele | B-Cell CLL/Lymphoma 9-Like wt Allele | BCL9-2 | DLNB11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0229628","Basophilic Erythroblast","C13130","A nucleated red blood cell that stains readily with basic dye.","Basophilic Erythroblast | ",,,,,,,,,,,,,,,"4187943","Basophilic normoblast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL514249","Autologous Cytokine-induced Killer Cells","C131310","A proprietary formulation of autologous cytokine-induced killer (CIK) T-lymphocytes, with immunopotentiating and antineoplastic activities. These CIK cells are generated by ex vivo incubation of autologous peripheral blood lymphocytes with an undisclosed mixture of compounds to stimulate killer T-cell differentiation; this is followed by expansion of the cells. Upon reintroduction into the patient, the autologous CIK cells are able to target and kill tumor cells.","Autologous Cytokine-induced Killer Cells | Immuncell-LC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0083104","Sipjeondaebo-tang","C131311","An orally bioavailable east Asian herbal supplement, with potential gastro- and neuro-protective, immunostimulatory, anti-inflammatory, anti-cancer, anti-cachexic and antioxidant activities. Sipjeondaebo-tang is comprised of various components, including Angelica root (Angelicae Gigantis Radix), the rhizome of Cnidium officinale Makino (Cnidii Rhizoma), Radix Paeoniae, Rehmannia glutinosa root (Rehmanniae Radix Preparata), Ginseng root (Ginseng Radix Alba), Atractylodes lancea root (Atractylodis Rhizoma Alba), the dried sclerotia of Poria cocos (Poria cocos Sclerotium), Licorice root (Glycyrrhizae Radix), Astragalus root (Astragali Radix), and the dried bark of Cinnamomum verum (Cinnamomi Cortex). Upon administration, and although the exact mechanism of action has yet to be fully elucidated, sipjeondaebo-tang may exert its effect through the various mechanism of actions that may be attributed to the different herbs.","Sipjeondaebo-tang | Deciten Granule | Juzen-taiho-to | SJDBT | Shi-Quan-Da-Bu-Tang",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414315","EGR2 Gene","C131312","This gene plays a role in both transcriptional regulation and protein sumoylation.","EGR2 Gene | EGR2 | Early Growth Response 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1310306","protocadherin 16 dachsous-like (Drosophila) protein, human","C131509","Protocadherin-16 (3298 aa, ~346 kDa) is encoded by the human DCHS1 gene. This protein plays a role in both neurogenesis and cell-cell adhesion.","Protocadherin-16 | Cadherin 19 | Cadherin 25 | Cadherin-19 | Cadherin-25 | Cadherin-Like 27 | Cadherin-Related Family Member 6 | DCHS1 | Fibroblast Cadherin 1 | Fibroblast Cadherin FIB1 | Fibroblast Cadherin-1 | Protein Dachsous Homolog 1 | Protocadherin 16",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1180326","Olfactory Epithelial Cell","C13150","A cell found in the pseudostratified epithelium lining the olfactory region of the nasal cavity. The olfactory epithelium has three major cell types - olfactory receptor cells, basal cell and sustentacular cells.","Olfactory Epithelial Cell | Olfactory Epithelial Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425534","ZDHHC2 Gene","C131510","This gene is involved in protein palmitoylation.","ZDHHC2 Gene | ZDHHC2 | Zinc Finger DHHC-Type Palmitoyltransferase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514381","ZDHHC2 wt Allele","C131511","Human ZDHHC2 wild-type allele is located in the vicinity of 8p22 and is approximately 69 kb in length. This allele, which encodes palmitoyltransferase ZDHHC2 protein, plays a role in post-translational protein modification.","ZDHHC2 wt Allele | DHHC2 | ZNF372 | Zinc Finger DHHC-Type Containing 2 Gene | Zinc Finger DHHC-Type Palmitolytransferase 2 wt Allele | Zinc Finger, DHHC Domain Containing 2 Gene | Zinc Finger, DHHC-Type Containing 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2606415","ZDHHC2 protein, human","C131512","Palmitoyltransferase ZDHHC2 (367 aa, ~42 kDa) is encoded by the human ZDHHC2 gene. This protein is involved in the palmitoylation of protein substrates.","Palmitoyltransferase ZDHHC2 | DHHC Domain-Containing Protein 2 | DHHC-2 | EC 2.3.1.225 | Ream | Rec | Reduced Expression Associated with Metastasis Protein | Reduced Expression in Cancer Protein | Zinc Finger DHHC Domain-Containing Protein 2 | Zinc Finger DHHC-Type Palmitoyltransferase 2 | Zinc Finger Protein 372",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419945","SEMA3D Gene","C131513","This gene plays a role in the inhibition of axonal growth.","SEMA3D Gene | SEMA3D | Semaphorin 3D Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL514584","SEMA3D wt Allele","C131514","Semaphorin-3D (777 aa, ~90 kDa) is encoded by the human SEMA3D gene. This protein plays a role in the negative regulation of axon migration.","SEMA3D wt Allele | Sema Domain, Immunoglobulin Domain (Ig), Short Basic Domain, Secreted, (Semaphorin) 3D Gene | Sema-Z2 | Semaphorin 3D wt Allele | UNQ760/PRO1491 | coll-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3883862","Sema3D protein, human","C131515","Semaphorin-3D (777 aa, ~90 kDa) is encoded by the human SEMA3D gene. This protein plays a role in the negative regulation of axon migration.","Semaphorin-3D | Collapsin 2 | Collapsin-2 | Sema3D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826036","MIR483 Gene","C131516","This gene may be involved in the negative regulation of translation.","MIR483 Gene | MIR483 | MicroRNA 483 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520601","Childhood T Acute Lymphoblastic Leukemia in Remission","C131876","A finding of T acute lymphoblastic leukemia in childhood that is not growing and responds to treatment.","Childhood T Acute Lymphoblastic Leukemia in Remission | T Acute Lymphoblastic Leukemia in Remission",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414394","EMX2 Gene","C132084","This gene is involved in development and transcriptional regulation.","EMX2 Gene | EMX2 | Empty Spiracles Homeobox 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521041","EMX2 wt Allele","C132085","Human EMX2 wild-type allele is located in the vicinity of 10q26.11 and is approximately 7 kb in length. This allele, which encodes homeobox protein EMX2, plays a role in transcriptional regulation. Mutation of the gene may be associated with schizencephaly, endometrioid adenocarcinomas and Mullerian mesodermal tumors.","EMX2 wt Allele | Empty Spiracles Homeobox 2 wt Allele | Empty Spiracles Homolog 2 (Drosophila) Gene | Empty Spiracles, Drosophila, Homolog of, 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519966","Homeobox Protein EMX2","C132086","Homeobox protein EMX2 (252 aa, ~28 kDa) is encoded by the human EMX2 gene. This protein is involved in the development of the nervous system and the urogenital system.","Homeobox Protein EMX2 | Empty Spiracles Homolog 2 | Empty Spiracles-Like Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412633","ATP1B3 Gene","C132087","This gene plays a role in ion exchange activity.","ATP1B3 Gene | ATP1B3 | ATPase Na+/K+ Transporting Subunit Beta 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520392","ATP1B3 wt Allele","C132088","Human ATP1B3 wild-type allele is located in the vicinity of 3q23 and is approximately 50 kb in length. This allele, which encodes sodium/potassium-transporting ATPase subunit beta-3 protein, is involved in sodium/potassium ion exchange.","ATP1B3 wt Allele | ATPB-3 | ATPase Na+/K+ Transporting Subunit Beta 3 wt Allele | ATPase, Na+/K+ Transporting, Beta 3 Polypeptide 2 Gene | CD298 | FLJ29027 | Na, K-ATPase Beta-3 Polypeptide Gene | Sodium-Potassium ATPase Subunit Beta 3 (Non-Catalytic) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1956574","ATP1B3 protein, human","C132089","Sodium/potassium-transporting ATPase subunit beta-3 (279 aa, ~32 kDa) is encoded by the human ATP1B3 gene. This protein plays a role in sodium ion import and potassium ion export.","Sodium/Potassium-Transporting ATPase Subunit Beta-3 | ATP1B3 | ATPB-3 | CD298 Antigen | Sodium Pump Subunit Beta-3 | Sodium/Potassium-Dependent ATPase Beta-3 Subunit | Sodium/Potassium-Dependent ATPase Subunit Beta-3 | Sodium/Potassium-Transporting ATPase Beta-3 Chain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421391","USP14 Gene","C132090","This gene is involved in ubiquitin recycling.","USP14 Gene | USP14 | Ubiquitin Specific Peptidase 14 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520263","USP14 wt Allele","C132091","Human USP14 wild-type allele is located in the vicinity of 18p11.32 and is approximately 56 kb in length. This allele, which encodes ubiquitin carboxyl-terminal hydrolase 14 protein, plays a role in the removal of ubiquitin from protein substrates.","USP14 wt Allele | TGT | TGT, 60-kD Subunit Gene | Ubiquitin Specific Peptidase 14 (tRNA-Guanine Transglycosylase) Gene | Ubiquitin Specific Peptidase 14 wt Allele | Ubiquitin Specific Protease 14 (tRNA-Guanine Transglycosylase) Gene | tRNA-Guanine Transglycosylase, 60-kD Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1698205","Ubiquitin Carboxyl-Terminal Hydrolase 14, Human","C132092","Ubiquitin carboxyl-terminal hydrolase 14 (494 aa, ~56 kDa) is encoded by the human USP14 gene. This protein is involved in the regulation of both ubiquitinated protein degradation and endoplasmic reticulum-associated degradation.","Ubiquitin Carboxyl-Terminal Hydrolase 14 | Deubiquitinating Enzyme 14 | EC 3.4.19.12 | USP14 | Ubiquitin Thioesterase 14 | Ubiquitin Thiolesterase 14 | Ubiquitin-Specific Processing Protease 14 | Ubiquitin-Specific Protease 14 | Ubiquitin-Specific-Processing Protease 14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1415659","HOXA5 Gene","C132093","This gene plays a role in the regulation of gene transcription during embryogenesis.","HOXA5 Gene | HOXA5 | Homeobox A5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3180560","Fasiglifam","C132780","No value exists.","Fasiglifam | ((3S)-6-((3-(4-(3-Methanesulfonylpropoxy)-2,6-dimethylphenyl]phenyl}methoxy)-2,3-dihydro-1-benzofuran-3-yl)acetic Acid | FASIGLIFAM | TAK 875 | TAK-875",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521152","Stage I Major Salivary Gland Cancer AJCC v8","C132781","Stage I includes: T1, N0, M0. T1: Tumor measuring 2 cm or less in greatest dimension without extraparenchymal extension. Extraparenchymal extension is clinical or macroscopic evidence of invasion of soft tissues. Microscopic evidence alone does not constitute extraparenchymal extension for classification purposes. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Major Salivary Gland Cancer AJCC v8 | Stage I Major Salivary Gland Cancer | Stage I Major Salivary Gland Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521149","Stage 0 Major Salivary Gland Cancer AJCC v8","C132783","Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0 Major Salivary Gland Cancer AJCC v8 | Stage 0 Major Salivary Gland Cancer | Stage 0 Major Salivary Gland Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521056","Esophagus and Esophagogastric Junction Cancer Pathologic Distant Metastasis TNM Finding v8","C133370","A pathologic finding about one or more characteristics of esophagus and esophagogastric junction cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Esophagus and Esophagogastric Junction Cancer Pathologic Distant Metastasis TNM Finding v8 | Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) Pathologic Distant Metastasis TNM Finding v8 | Pathologic Distant Metastasis Status (pM)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521054","Esophagus and Esophagogastric Junction Cancer Clinical Distant Metastasis TNM Finding v8","C133371","A clinical finding about one or more characteristics of esophagus and esophagogastric junction cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Esophagus and Esophagogastric Junction Cancer Clinical Distant Metastasis TNM Finding v8 | Clinical Distant Metastasis Status (cM) | Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521057","Esophagus and Esophagogastric Junction Cancer Pathologic Primary Tumor TNM Finding v8","C133373","A pathologic finding about one or more characteristics of esophagus and esophagogastric junction cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Esophagus and Esophagogastric Junction Cancer Pathologic Primary Tumor TNM Finding v8 | Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) Pathologic Primary Tumor TNM Finding v8 | Pathologic Primary Tumor Status (pT)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0225339","Transitional Epithelium","C13318","Stratified epithelium that changes shape from cuboidal to squamous when stretched without losing strength or consistency. This type of epithelium is found in the urinary tract.","Transitional Epithelium | ",,,,,,,,,,,,,,,"4146911","Transitional epithelium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL520581","Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10","C133190","A radioimmunoconjugate containing the murine IgG1 anti-CD45 monoclonal antibody (MAb) BC8 where the lysine side groups have been conjugated with decaborate (closo-decaborate; B10) and labeled with astatine (At) 211, with potential immunotherapeutic activity. Astatine At 211 anti-CD45 monoclonal antibody BC8-B10 binds to CD45 antigen, a receptor protein-tyrosine phosphatase expressed on the surface of both normal and malignant hematopoietic cells. After binding and internalization by CD45-expressing tumor cells, this agent may deliver a cytotoxic dose of alpha radiation. Additionally, the radiolabel can be leveraged to assay the biodistribution and/or pharmacokinetics (absorption, distribution, metabolism and excretion) for this agent. The use of B10 rather than other labeling methods increases the therapeutic efficacy while decreasing the toxicity of the radioconjugate.","Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10 | APAMISTAMAB-B10-ASTATINE AT-211 | Astatine 211-Labeled Anti-CD45 Monoclonal Antibody BC8-B10 | Astatine At 211 MAb BC8-B10 | At 211 Anti-CD45 Monoclonal Antibody BC8-B10 | At 211 MAb BC8-B10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521227","Oral Intraepithelial Neoplasia","C133192","A precancerous neoplastic process affecting the oral mucosa. It is characterized by the presence of dysplasia in the mucosal epithelium.","Oral Intraepithelial Neoplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520053","Metastatic Thyroid Gland Carcinoma","C133193","Thyroid gland carcinoma that has spread from its original site of growth to another anatomic site.","Metastatic Thyroid Gland Carcinoma | Metastatic Thyroid Gland Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521296","Other Blood Form Product","C133277","Another blood form product type other than the ones that are explicitly identified in this value set.","Other Blood Form Product | Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443116","Platelets Product","C133278","Platelets collected from a single donor and suspended in a specified volume of original plasma.","Platelets Product | Platelets",,,,,,,,,,,,,,,"4103615","Platelet product",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521304","Pooled Blood Products","C133279","Individual components, e.g. cryoprecipitated antihemophilic factor (AHF), whole blood-derived platelet concentrates, that are combined using an aseptic technique.","Pooled Blood Products | Pooled",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520540","Supraglottic Cancer pT1 TNM Finding v8","C133102","Supraglottic cancer with tumor limited to one subsite of supraglottis with normal vocal cord mobility. (from AJCC 8th Ed.)","Supraglottic Cancer pT1 TNM Finding v8 | Supraglottic Carcinoma pT1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520542","Supraglottic Cancer pT3 TNM Finding v8","C133104","Supraglottic cancer with tumor limited to larynx with vocal cord fixation and/or invading any of the following: postcricoid area, preepiglottic space, paraglottic space, and/or inner cortex of thyroid cartilage. (from AJCC 8th Ed.)","Supraglottic Cancer pT3 TNM Finding v8 | Supraglottic Carcinoma pT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520543","Supraglottic Cancer pT4 TNM Finding v8","C133105","Supraglottic cancer with moderately advanced or very advanced disease. (from AJCC 8th Ed.)","Supraglottic Cancer pT4 TNM Finding v8 | Supraglottic Carcinoma pT4 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520544","Supraglottic Cancer pT4a TNM Finding v8","C133106","Supraglottic cancer with moderately advanced local disease. Tumor invades through the outer cortex of the thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck including deep extrinsic muscle of the tongue, strap muscles, thyroid, or esophagus). (from AJCC 8th Ed.)","Supraglottic Cancer pT4a TNM Finding v8 | Supraglottic Carcinoma pT4a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520545","Supraglottic Cancer pT4b TNM Finding v8","C133107","Supraglottic cancer with very advanced local disease. Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures. (from AJCC 8th Ed.)","Supraglottic Cancer pT4b TNM Finding v8 | Supraglottic Carcinoma pT4b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520706","Glottic Cancer Pathologic Primary Tumor TNM Finding v8","C133108","A pathologic finding about one or more characteristics of glottic cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Glottic Cancer Pathologic Primary Tumor TNM Finding v8 | Glottic Carcinoma Pathologic Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520715","Glottic Cancer pTX TNM Finding v8","C133109","Glottic cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Glottic Cancer pTX TNM Finding v8 | Glottic Carcinoma pTX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520707","Glottic Cancer pT1 TNM Finding v8","C133111","Glottic cancer with tumor limited to the vocal cord(s) (may involve anterior or posterior commissure) with normal mobility. (from AJCC 8th Ed.)","Glottic Cancer pT1 TNM Finding v8 | Glottic Carcinoma pT1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520708","Glottic Cancer pT1a TNM Finding v8","C133112","Glottic cancer with tumor limited to one vocal cord. (from AJCC 8th Ed.)","Glottic Cancer pT1a TNM Finding v8 | Glottic Carcinoma pT1a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282491","Germinal Center","C13337","Sites in secondary lymphoid tissue where follicular dendritic cells present antigens to B-cells and follicular helper T-cells.","Germinal Center | ",,,,,,,,,,,,,,,"4055412","Structure of germinal center of lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL520008","Hypopharyngeal Cancer cM0 TNM Finding v8","C132985","Hypopharyngeal cancer without evidence of distant metastasis. (from AJCC 8th Ed.)","Hypopharyngeal Cancer cM0 TNM Finding v8 | Hypopharyngeal Carcinoma cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520009","Hypopharyngeal Cancer cM1 TNM Finding v8","C132986","Hypopharyngeal cancer with distant metastasis. (from AJCC 8th Ed.)","Hypopharyngeal Cancer cM1 TNM Finding v8 | Hypopharyngeal Carcinoma cM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520020","Hypopharyngeal Cancer pM1 TNM Finding v8","C132988","Hypopharyngeal cancer with distant metastasis. (from AJCC 8th Ed.)","Hypopharyngeal Cancer pM1 TNM Finding v8 | Hypopharyngeal Carcinoma pM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520573","Anti-Glypican 3-scFvGC33-CAR-expressing T Lymphocytes","C132989","A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) derived from the anti-glypican-3 (GPC3) monoclonal antibody GC33 (scFvGC33), with potential immunostimulating and antineoplastic activities. Upon administration, anti-GPC3-scFvGC33-CAR autologous T-lymphocytes specifically target and bind to GPC3-expressing tumor cells, resulting in tumor cell lysis. GPC3, a heparan sulfate proteoglycan and a member of the glypican family, is overexpressed on certain tumor cell types while minimally expressed in normal, healthy cells.. GPC3 plays an important role in cellular proliferation and differentiation.","Anti-Glypican 3-scFvGC33-CAR-expressing T Lymphocytes | Anti-GPC3-scFvGC33-CAR Autologous T Lymphocytes | Autologous GAP T Cells | Autologous GPC3-CAR T Cells | GPC3-CAR Transduced Autologous T Cells | Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells | Glypican 3-specific Chimeric Antigen Receptor-expressing Autologous T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039062","Synapse","C13281","A cell-cell junction between a neuron and another neuron or a cell in a target organ. At this interface, the presynaptic neuron can transmit chemical (neurotransmitter) or electical signals (nerve impulses) to the postsynaptic target.","Synapse | synapse",,,,,,,,,,,,,,,"4289438","Synapse structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL520963","Stage IV Nasopharyngeal Carcinoma AJCC v8","C132820","Stage IV includes: IVA: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0); (Any T, N3, M0); IVB (Any T, Any N, M1). T4: Tumor with intracranial extension, involvement of cranial nerves, hypopharynx, orbit, parotid gland, and/or extensive soft tissue infiltration beyond the lateral surface of the lateral pterygoid muscle.  N0: No regional lymph node metastasis. N1: Tumor with unilateral metastasis in cervical lymph node(s), and/or unilateral or bilateral metastasis in retropharyngeal lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage. N2: Tumor with bilateral metastasis in cervical lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage. N3: Tumor with unilateral or bilateral metastasis in cervical lymph node(s), larger than 6 cm in greatest dimension, and/or extension below the caudal border of cricoid cartilage. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Nasopharyngeal Carcinoma AJCC v8 | Stage IV Nasopharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521172","Canine Oral Squamous Cell Carcinoma","C132823","Oral squamous cell carcinoma that occurs in a dog.","Canine Oral Squamous Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520653","Feline Oral Squamous Cell Carcinoma","C132824","Oral squamous cell carcinoma that occurs in a cat.","Feline Oral Squamous Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520654","Feline Osteosarcoma","C132825","Osteosarcoma that occurs in a cat.","Feline Osteosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1866784","Distal Hereditary Motor Neuronopathy Type I","C132826","An autosomal dominant neurodegenerative disorder characterized by juvenile onset, distal motor weakness without sensory impairment, and anterior horn cell degeneration.","Distal Hereditary Motor Neuronopathy Type I | Charcot-Marie-Tooth Disease, Spinal, I | DHMN1 | Distal HMN I | HMN1 | Spinal CMT I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1855792","ICHTHYOSIFORM ERYTHRODERMA, CONGENITAL, NONBULLOUS, 1","C132827","An autosomal recessive condition caused by mutation(s) in the ALOX12B gene, encoding arachidonate 12-lipoxygenase, 12R-type. It is characterized by dry, thickened, scaly skin.","Autosomal Recessive Congenital Ichthyosis 2 | ARCI2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0729605","Subcellular Structure","C13282","An anatomical element found within cells or tissues that are smaller than cells and are at or below the size that can be resolved by light microscopy.","Subcellular Structure | Intracellular Structure",,,,,,,,,,,,,,,"4284814","Subcellular structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0059882","Euchromatin","C13289","Euchromatin. The parts of chromosomes that, during interphase, are uncoiled dispersed threads and not stained by ordinary dyes; metabolically active, in contrast to the inert heterochromatin.","Euchromatin | ",,,,,,,,,,,,,,,"4306938","Euchromatin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL519704","CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes","C133073","A preparation of genetically modified lymphocytes comprised of CD62L-positive naïve and memory T-cells (Tn/mem), that are transduced ex vivo with a self-inactivating (SIN) lentiviral vector expressing a hinge-optimized chimeric antigen receptor (CAR) specific for the CD19 antigen and containing CD28 and CD3 zeta signaling domains, and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon isolation of peripheral blood lymphocytes (PBLs), transduction of the CD62L-positive T-lymphocytes, expansion ex vivo and administration, the CD19R(EQ)-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-cells target CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.  Devoid of both ligand binding domains and tyrosine kinase activity, EGFRt both facilitates in vivo detection of the administered T-cells and can promote elimination of those cells upon a cetuximab-induced antibody dependent cellular cytotoxicity response. Tn/mem T-cells include naïve T-cells, central memory T-cells (Tcm) and stem cell memory T-cells (Tscm). CD19R(EQ) contains two point mutations in the immunoglobulin (Ig) G4 spacer region, thereby preventing recognition of the CAR by Fc receptors (FcRs).","CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes | CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T Cells | CD19R(EQ)28zeta/EGFRt+ Naive and Memory T Cells | CD19R(EQ)28zetaEGFRt+ Tn/mem Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520125","Nasal Cavity and Paranasal Sinus Carcinoma by AJCC v8 Stage","C133074","A term that refers to the staging of nasal cavity and paranasal sinus carcinoma according to the American Joint Committee on Cancer, 8th edition.","Sinonasal Cancer by AJCC v8 Stage | Nasal Cavity and Paranasal Sinus Cancer by AJCC v8 Stage | Nasal Cavity and Paranasal Sinus Carcinoma by AJCC v8 Stage | Sinonasal Carcinoma by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521153","Stage I Nasal Cavity and Paranasal Sinus Carcinoma AJCC v8","C133076","Stage I includes: T1, N0, M0. T1: Maxillary sinus: Tumor limited to the maxillary sinus mucosa with no erosion or destruction of bone. Nasal cavity and ethmoid sinus: Tumor restricted to any one subsite, with or without bony invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Sinonasal Cancer AJCC v8 | Stage I Nasal Cavity and Paranasal Sinus Cancer | Stage I Nasal Cavity and Paranasal Sinus Cancer AJCC v8 | Stage I Nasal Cavity and Paranasal Sinus Carcinoma AJCC v8 | Stage I Sinonasal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520504","Stage II Nasal Cavity and Paranasal Sinus Carcinoma AJCC v8","C133077","Stage II includes: T2, N0, M0. T2: Maxillary sinus: Tumor causing bone erosion or destruction including extension into the hard palate and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and pterygoid plates. Nasal cavity and ethmoid sinus: Tumor invading two subsites in a single region or extending to involve an adjacent region within the nasoethmoidal complex, with or without bony invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Sinonasal Cancer AJCC v8 | Stage II Nasal Cavity and Paranasal Sinus Cancer | Stage II Nasal Cavity and Paranasal Sinus Cancer AJCC v8 | Stage II Nasal Cavity and Paranasal Sinus Carcinoma AJCC v8 | Stage II Sinonasal Cancer AJCC  v8 | Stage II Sinonasal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520510","Stage IV Lip and Oral Cavity Cancer AJCC v8","C132732","Stage IV includes: IVA (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB (Any T, N3, M0); (T4b, Any N, M0); IVC (Any T, Any N, M1). T4a (lip): Tumor invades through cortical bone or involves the inferior alveolar nerve, floor of mouth, or skin of face (i.e., chin or nose).  T4a (oral cavity): Tumor invades adjacent structures only (e.g., through cortical bone of the mandible or maxilla, or involves the maxillary sinus or skin of face). Note: Superficial erosion of bone/tooth socket (alone) by a gingival primary is not sufficient to classify a tumor as T4. T1: Tumor size 2 cm or less in greatest dimension and 5 mm or less DOI. T2: Tumor size 2 cm or less in greatest dimension, DOI greater than 5 mm and equal or less than 10 mm or tumor greater than 2 cm but 4 cm or less in greatest dimension and 10 mm or less DOI. T3: Tumor size greater than 4 cm or any tumor greater than 10 mm DOI. T4b: Tumor invades masticator space, pterygoid plates, or skull base and/or encases the internal carotid artery. N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-). N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE (-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, ENE(-). N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE (-); or in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral or bilateral lymph nodes any with ENE(+). M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th Ed.)","Stage IV Lip and Oral Cavity Cancer AJCC v8 | Stage IV Lip and Oral Cavity Cancer | Stage IV Lip and Oral Cavity Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520514","Stage IVA Lip and Oral Cavity Cancer AJCC v8","C132733","Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0). T4a (lip): Tumor invades through cortical bone or involves the inferior alveolar nerve, floor of mouth, or skin of face (i.e., chin or nose).  T4a (oral cavity): Tumor invades adjacent structures only (e.g., through cortical bone of the mandible or maxilla, or involves the maxillary sinus or skin of face). Note: Superficial erosion of bone/tooth socket (alone) by a gingival primary is not sufficient to classify a tumor as T4. T1: Tumor size 2 cm or less in greatest dimension and 5 mm or less DOI. T2: Tumor size 2 cm or less in greatest dimension, DOI greater than 5 mm and equal or less than 10 mm or tumor greater than 2 cm but 4 cm or less in greatest dimension and 10 mm or less DOI. T3: Tumor size greater than 4 cm or any tumor greater than 10 mm DOI. N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-). N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE (-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, ENE(-). M0: No distant metastasis. (AJCC 8th Ed.)","Stage IVA Lip and Oral Cavity Cancer AJCC v8 | Stage IVA Lip and Oral Cavity Cancer | Stage IVA Lip and Oral Cavity Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520518","Stage IVB Lip and Oral Cavity Cancer AJCC v8","C132734","Stage IVB includes: (Any T, N3, M0); (T4b, Any N, M0). T4b: Tumor invades masticator space, pterygoid plates, or skull base and/or encases the internal carotid artery. N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE (-); or in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral or bilateral lymph nodes any with ENE(+). M0: No distant metastasis. (AJCC 8th Ed.)","Stage IVB Lip and Oral Cavity Cancer AJCC v8 | Stage IVB Lip and Oral Cavity Cancer | Stage IVB Lip and Oral Cavity Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520522","Stage IVC Lip and Oral Cavity Cancer AJCC v8","C132735","Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th Ed.)","Stage IVC Lip and Oral Cavity Cancer AJCC v8 | Stage IVC Lip and Oral Cavity Cancer | Stage IVC Lip and Oral Cavity Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520728","Lip and Oral Cavity Cancer by AJCC v6 and v7 Stage","C132736","A term that refers to the staging of lip and oral cavity carcinoma according to the American Joint Committee on Cancer, 6th and 7th editions.","Lip and Oral Cavity Cancer by AJCC v6 and v7 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520436","Intracanalicular Route of Administration","C132737","Administration to, or situated within, a tubular passage or channel of the body.","Intracanalicular Route of Administration | Intracanalicular",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3529991","Abediterol","C132738","No value exists.","Abediterol | 5-((1R)-2-((6-(2,2-Difluoro-2-phenylethoxy)hexyl)amino)-1-hydroxyethyl)-8- hydroxyquinolin-2(1H)-one | ABEDITEROL | LAS 100977",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520348","APG 115","C132991","An orally available inhibitor of human homolog of double minute 2 (HDM2; mouse double minute 2 homolog; MDM2), with potential antineoplastic activity. Upon oral administration,alrizomadlin binds to HDM2, preventing the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This may result in the restoration of p53 signaling and lead to the p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger protein and a negative regulator of the p53 pathway, is often overexpressed in cancer cells. It has been implicated in cancer cell proliferation and survival.","Alrizomadlin | AA-115 | ALRIZOMADLIN | APG 115 | APG-115 | MDM2-p53 Inhibitor APG-115 | p53-HDM2 Protein-protein Interaction Inhibitor APG-115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520501","Stage II Laryngeal Cancer AJCC v8","C133159","Stage II includes: T2, N0, M0. T2: Supraglottis: Tumor invades the mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis (e.g., mucosa of base of the tongue, vallecula, medial wall of pyriform sinus) without fixation of the larynx. Glottis: Tumor extends to supraglottis and/or subglottis, and/or with impaired vocal cord mobility. Subglottis: Tumor extends to vocal cord(s) with normal or impaired mobility. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Laryngeal Cancer AJCC v8 | Stage II Laryngeal Carcinoma AJCC v8 | Stage II Laryngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520505","Stage III Laryngeal Cancer AJCC v8","C133160","Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T3: Supraglottis: Tumor is limited to larynx with vocal cord fixation and/or invades any of the following: postcricoid area, preepiglottic space, paraglottic space, and/or inner cortex of thyroid cartilage. Glottis: Tumor is limited to the larynx with vocal cord fixation and /or invades the paraglottic space, and/or inner cortex of the thyroid cartilage. Subglottis: Tumor is limited to the larynx with vocal cord fixation and/or invades the paraglottic space and/or inner cortex of the thyroid cartilage. T1: Supraglottis: Tumor is limited to one subsite of supraglottis with normal vocal cord mobility. Glottis: Tumor is limited to the vocal cord(s) (may involve anterior or posterior commissure) with normal mobility. Subglottis: Tumor is limited to the subglottis. T2: Supraglottis: Tumor invades the mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis (e.g., mucosa of base of the tongue, vallecula, medial wall of pyriform sinus) without fixation of the larynx. Glottis: Tumor extends to supraglottis and/or subglottis, and/or with impaired vocal cord mobility. Subglottis: Tumor extends to vocal cord(s) with normal or impaired mobility. N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(-). M0: No distant metastasis. (AJCC 8th ed.)","Stage III Laryngeal Cancer AJCC v8 | Stage III Laryngeal Carcinoma AJCC v8 | Stage III Laryngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514917","Retinoic Acid Response Element","C13634","A cis-acting transcription regulatory element.  It is bound by the retinoic acid receptors.","Retinoic Acid Response Element | RARE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523657","Stage III Thymoma AJCC v8","C136350","Stage III includes: IIIA: (T3, N0, M0); IIIB: (T4, N0, M0). T3: Tumor with direct invasion into any of the following: lung, brachiocephalic vein, superior vena cava, phrenic nerve, chest wall, or extrapericardial pulmonary artery or veins. T4: Tumor with invasion into any of the following: aorta (ascending, arch, or descending), arch vessels, intrapericardial pulmonary artery, myocardium, trachea, esophagus. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Thymoma AJCC v8 | Stage III Thymoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523658","Stage IIIA Thymoma AJCC v8","C136351","Stage IIIA includes: T3, N0, M0. T3: Tumor with direct invasion into any of the following: lung, brachiocephalic vein, superior vena cava, phrenic nerve, chest wall, or extrapericardial pulmonary artery or veins. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIA Thymoma AJCC v8 | Stage IIIA Thymoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523659","Stage IIIB Thymoma AJCC v8","C136352","Stage IIIB includes: T4, N0, M0. T4: Tumor with invasion into any of the following: aorta (ascending, arch, or descending), arch vessels, intrapericardial pulmonary artery, myocardium, trachea, esophagus. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIB Thymoma AJCC v8 | Stage IIIB Thymoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523660","Stage IV Thymoma AJCC v8","C136353","Stage IV includes: IVA: (Any T, N1, M0); (Any T, N0,1, M1a); IVB: (Any T, N2, M0, M1a); (Any T, Any N, M1b). N0: No regional lymph node metastasis. N1: Metastasis in anterior (perithymic) lymph nodes. N2: Metastasis in deep intrathoracic or cervical lymph nodes. M0: No distant metastasis. M1a: Separate pleural or pericardial nodule(s). M1b: Pulmonary intraparenchymal nodule or distant organ metastasis. (AJCC 8th ed.)","Stage IV Thymoma AJCC v8 | Stage IV Thymoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523661","Stage IVA Thymoma AJCC v8","C136354","Stage IVA includes: (Any T, N1, M0); (Any T, N0,1, M1a). N0: No regional lymph node metastasis. N1: Metastasis in anterior (perithymic) lymph nodes. M0: No distant metastasis. M1a: Separate pleural or pericardial nodule(s). (AJCC 8th ed.)","Stage IVA Thymoma AJCC v8 | Stage IVA Thymoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523663","Stage IVB Thymoma AJCC v8","C136356","Stage IVB includes: (Any T, N2, M0, M1a); (Any T, Any N, M1b). N2: Metastasis in deep intrathoracic or cervical lymph nodes. M0: No distant metastasis. M1a: Separate pleural or pericardial nodule(s). M1b: Pulmonary intraparenchymal nodule or distant organ metastasis. (AJCC 8th ed.)","Stage IVB Thymoma AJCC v8 | Stage IVB Thymoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515555","bHLH-Zip Domain","C13635","Tripartite DNA binding domain containing a basic region, a helix-loop-helix, and a leucine zipper.","bHLH-Zip Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520508","Stage III Nasal Cavity and Paranasal Sinus Carcinoma AJCC v8","C133078","Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T3: Maxillary sinus: Tumor invading any of the following: bone of the posterior wall of maxillary sinus, subcutaneous tissues, floor or medial wall of orbit, pterygoid fossa, or ethmoid sinuses. Nasal cavity and ethmoid sinus: Tumor invading the medial wall or floor of the orbit, maxillary sinus, palate, or cribriform plate.  T1: Maxillary sinus: Tumor limited to the maxillary sinus mucosa with no erosion or destruction of bone. Nasal cavity and ethmoid sinus: Tumor restricted to any one subsite, with or without bony invasion. T2: Maxillary sinus: Tumor causing bone erosion or destruction including extension into the hard palate and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and pterygoid plates. Nasal cavity and ethmoid sinus: Tumor invading two subsites in a single region or extending to involve an adjacent region within the nasoethmoidal complex, with or without bony invasion. N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(-). M0: No distant metastasis. (AJCC 8th ed.)","Stage III Sinonasal Cancer AJCC v8 | Stage III Nasal Cavity and Paranasal Sinus Cancer | Stage III Nasal Cavity and Paranasal Sinus Cancer AJCC v8 | Stage III Nasal Cavity and Paranasal Sinus Carcinoma AJCC v8 | Stage III Sinonasal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521300","Human Cells, Tissues, and Cellular and Tissue-Based Products Packing","C133284","Placing Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) in containers that may or may not be in direct contact with the product.","Human Cells, Tissues, and Cellular and Tissue-Based Products Packing | HCT/P Packing | Package",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520750","Lip and Oral Cavity Cancer pT1 TNM Finding v8","C132695","Lip and oral cavity cancer with tumor size 2 cm or less in greatest dimension and 5 mm or less depth of invasion (DOI). DOI is depth of invasion and not tumor thickness. (from AJCC 8th Ed.)","Lip and Oral Cavity Cancer pT1 TNM Finding v8 | Lip and Oral Cavity Carcinoma pT1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520751","Lip and Oral Cavity Cancer pT2 TNM Finding v8","C132696","Lip and oral cavity cancer with tumor size 2 cm or less in greatest dimension, DOI greater than 5 mm and equal or less than 10 mm or tumor greater than 2 cm but 4 cm or less in greatest dimension and 10 mm or less DOI. (from AJCC 8th Ed.)","Lip and Oral Cavity Cancer pT2 TNM Finding v8 | Lip and Oral Cavity Carcinoma pT2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520752","Lip and Oral Cavity Cancer pT3 TNM Finding v8","C132697","Lip and oral cavity cancer with tumor size greater than 4 cm or any tumor greater than 10 mm DOI. (from AJCC 8th Ed.)","Lip and Oral Cavity Cancer pT3 TNM Finding v8 | Lip and Oral Cavity Carcinoma pT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520753","Lip and Oral Cavity Cancer pT4 TNM Finding v8","C132698","Lip and oral cavity cancer with moderately advanced or very advanced local disease. (from AJCC 8th Ed.)","Lip and Oral Cavity Cancer pT4 TNM Finding v8 | Lip and Oral Cavity Carcinoma pT4 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520754","Lip and Oral Cavity Cancer pT4a TNM Finding v8","C132699","Lip and oral cavity cancer with moderately advanced local disease. For lip: Tumor invades through cortical bone or involves the inferior alveolar nerve, floor of mouth, or skin of face (i.e., chin or nose). For oral cavity: Tumor invades adjacent structures only (e.g., through cortical bone of the mandible or maxilla, or involves the maxillary sinus or skin of face). Note: Superficial erosion of bone/tooth socket (alone) by a gingival primary is not sufficient to classify a tumor as T4. (from AJCC 8th Ed.)","Lip and Oral Cavity Cancer pT4a TNM Finding v8 | Lip and Oral Cavity Carcinoma pT4a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520776","Major Salivary Gland Cancer TNM Finding v8","C132739","A finding about one or more characteristics of major salivary gland cancer, following the rules of the TNM AJCC v8 classification system.  This classification does not apply to lymphomas and minor salivary gland cancers. (from AJCC 8th Ed.)","Major Salivary Gland Cancer TNM Finding v8 | Major Salivary Gland Carcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519961","Hematopoietic Progenitor Cells from Apheresis","C133328","Peripheral blood collected by apheresis as a source of hematopoietic progenitor cells.","Hematopoietic Progenitor Cells from Apheresis | Human HPC, Apheresis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519962","Hematopoietic Progenitor Cells from Cord Blood","C133329","Blood collected from the umbilical cord as a source of hematopoietic progenitor cells.","Hematopoietic Progenitor Cells from Cord Blood | Human HPC, Cord Blood",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520645","Community or Hospital Associated Blood Products Testing Facility","C133330","A separately operated and owned establishment that performs routine blood and plasma donor testing for a community or hospital blood bank.","Community or Hospital Associated Blood Products Testing Facility | Product Testing Laboratory - Associated with Community or Hospital Blood Bank",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521189","Independently Owned Blood Products Testing Facility","C133331","A separately operated and owned facility that performs routine blood and plasma donor testing.","Independently Owned Blood Products Testing Facility | Product Testing Laboratory - Independent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521176","Donor Retested Negative","C133332","A test result of negative infectious disease markers at subsequent testing of blood products that have been stored for a minimum of 112 days.","Donor Retested Negative | Donor Retested",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520587","Automated Pheresis","C133333","The procurement of red blood cells, platelets, leukocytes, granulocytes, or plasma by automated equipment.","Automated Pheresis | Automated Apheresis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520810","Manual Pheresis","C133334","Procedures such as plasmapheresis, plateletpheresis, and leukapheresis, in which unneeded portions of the whole blood are returned to the donor.","Manual Pheresis | Manual Apheresis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519687","Blood Bank Reagent","C133335","Diagnostic substances manufactured for commercial distribution used to characterize and determine the acceptability of blood products for transfusion purposes. These include reagent red blood cells, blood grouping reagents, antibody to HBsAg, etc.","Blood Bank Reagent | Blood Bank Reagents",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520918","Platelets Additive Solution","C133336","Isotonic crystalloid nutrient media solution designed to replace a portion of plasma for the storage of apheresis platelet products, allowing the volume of plasma transfused to be decreased.","Platelets Additive Solution | PAS | Platelets PAS (Platelets Additive Solution)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272575","Cardiac Tissue","C133337","No value exists.","Cardiac Tissue | ",,,,,,,,,,,,,,,"4300965","Heart tissue",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1306535","Heart Valve Tissue","C133338","Tissue derived from the heart valves that allow blood flow through the heart.","Heart Valve Tissue | Human Heart Valve",,,,,,,,,,,,,,,"4303141","Heart valve tissue",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521081","Ocular Tissue","C133340","Different types of tissues from the human eye.","Ocular Tissue | Human Ocular Tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520509","Stage IV Laryngeal Cancer AJCC v8","C133161","Stage IV includes: IVA: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB: (Any T, N3, M0); (T4b, Any N, M0); IVC: (Any T, Any N, M1). T4a: Supraglottis: Moderately advanced local disease. Tumor invades through the outer cortex of the thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck including deep extrinsic muscle of the tongue, strap muscles, thyroid, or esophagus). Glottis: Moderately advanced local disease. Tumor invades through the outer cortex of the thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, cricoid cartilage, soft tissues of neck including deep extrinsic muscle of the tongue, strap muscles, thyroid, or esophagus). Subglottis: Moderately advanced local disease. Tumor invades cricoid or thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck including deep extrinsic muscles of the tongue, strap muscles, thyroid, or esophagus). T3: Supraglottis: Tumor is limited to larynx with vocal cord fixation and/or invades any of the following: postcricoid area, preepiglottic space, paraglottic space, and/or inner cortex of thyroid cartilage. Glottis: Tumor is limited to the larynx with vocal cord fixation and /or invades the paraglottic space, and/or inner cortex of the thyroid cartilage. Subglottis: Tumor is limited to the larynx with vocal cord fixation and/or invades the paraglottic space and/or inner cortex of the thyroid cartilage. T1: Supraglottis: Tumor is limited to one subsite of supraglottis with normal vocal cord mobility. Glottis: Tumor is limited to the vocal cord(s) (may involve anterior or posterior commissure) with normal mobility. Subglottis: Tumor is limited to the subglottis. T2: Supraglottis: Tumor invades the mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis (e.g., mucosa of base of the tongue, vallecula, medial wall of pyriform sinus) without fixation of the larynx. Glottis: Tumor extends to supraglottis and/or subglottis, and/or with impaired vocal cord mobility. Subglottis: Tumor extends to vocal cord(s) with normal or impaired mobility. T4b: Supraglottis: Very advanced local disease. Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures. Glottis: Very advanced local disease. Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures. Subglottis: Very advanced local disease. Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures. N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(-). N2: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(+); or metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-); or metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-). N3: metastasis in a lymph node, more than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral lymph node, more than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+). M0: No distant metastasis. M1: distant metastasis. (AJCC 8th ed.)","Stage IV Laryngeal Cancer AJCC v8 | Stage IV Laryngeal Carcinoma AJCC v8 | Stage IV Laryngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520503","Stage II Major Salivary Gland Cancer AJCC v8","C132785","Stage II includes: T2, N0, M0. T2: Tumor measuring more than 2 cm, but not more than 4 cm in greatest dimension without extraparenchymal extension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Major Salivary Gland Cancer AJCC v8 | Stage II Major Salivary Gland Cancer | Stage II Major Salivary Gland Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520507","Stage III Major Salivary Gland Cancer AJCC v8","C132786","Stage III includes: (T3, N0, M0); (T0, N1, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0).  T3: Tumor measuring more than 4 cm in greatest dimension, and/or tumor having extraparenchymal extension.  T0: No evidence of primary tumor. T1: Tumor measuring 2 cm or less in greatest dimension without extraparenchymal extension. T2: Tumor measuring more than 2 cm, but not more than 4 cm in greatest dimension without extraparenchymal extension.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(-). M0: No distant metastasis. (AJCC 8th ed.)","Stage III Major Salivary Gland Cancer AJCC v8 | Stage III Major Salivary Gland Cancer | Stage III Major Salivary Gland Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520227","Recurrent Germ Cell Neoplasm","C132853","The reemergence of a malignant germ cell tumor after a period of remission.","Recurrent Malignant Germ Cell Tumor | Recurrent Germ Cell Neoplasm | Recurrent Germ Cell Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520050","Metastatic Germ Cell Neoplasm","C132854","A malignant germ cell tumor that has spread from its original site of growth to another anatomic site.","Metastatic Malignant Germ Cell Tumor | Metastatic Germ Cell Neoplasm | Metastatic Germ Cell Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4264732","HSV1 DNA CSF Ql Non-probe PCR","C132855","This assay detects the presence of nucleic acid sequences from the Herpes simplex virus 1 DNA in cerebrospinal fluid (CSF) using PCR and non-probe based detection methods, such as melt curve analysis. (LOINC)","HSV1 DNA CSF Ql Non-probe PCR | HSV1 DNA CSF Ql Non-probe PCR | Herpes Simplex Virus 1 DNA (Presence) | Herpes Simplex Virus 1 DNA (Presence) | Herpes simplex virus 1 DNA | Herpes simplex virus 1 DNA [Presence] in Cerebral spinal fluid by Target amplification with non-probe based detection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4264731","Herpes simplex virus 2 DNA","C132856","This assay detects the presence of nucleic acid sequences from the Herpes simplex virus 2 DNA in cerebrospinal fluid (CSF) using PCR and non-probe based detection methods, such as melt curve analysis. (LOINC)","HSV2 DNA CSF Ql Non-probe PCR | HSV2 DNA CSF Ql Non-probe PCR | Herpes Simplex Virus 2 DNA (Presence) | Herpes Simplex Virus 2 DNA (Presence) | Herpes simplex virus 2 DNA | Herpes simplex virus 2 DNA [Presence] in Cerebral spinal fluid by Target amplification with non-probe based detection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521644","Herpes virus 6 DNA","C132857","This assay detects the presence of nucleic acid sequences from the Herpes virus 6 DNA in cerebrospinal fluid (CSF) using PCR and non-probe based detection methods, such as melt curve analysis. (LOINC)","HHV6 DNA CSF Ql Non-probe PCR | HHV6 DNA CSF Ql Non-probe PCR | Herpes Virus 6 DNA (Presence) | Herpes Virus 6 DNA (Presence) | Herpes virus 6 DNA | Herpes virus 6 DNA [Presence] in Cerebral spinal fluid by Target amplification with non-probe based detection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519908","HPV-Mediated (p16-Positive) Oropharyngeal Cancer Clinical TNM Finding v8","C132860","A clinical finding about one or more characteristics of HPV-mediated (p16-positive) oropharyngeal cancer, following the rules of the TNM AJCC v8 classification system.","HPV-Mediated (p16-Positive) Oropharyngeal Cancer Clinical TNM Finding v8 | HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519910","HPV-Mediated (p16-Positive) Oropharyngeal Cancer Pathologic Primary Tumor TNM Finding v8","C132861","A pathologic finding about one or more characteristics of HPV-mediated (p16-positive) oropharyngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","HPV-Mediated (p16-Positive) Oropharyngeal Cancer Pathologic Primary Tumor TNM Finding v8 | HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma Pathologic Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520755","Lip and Oral Cavity Cancer pT4b TNM Finding v8","C132700","Lip and oral cavity cancer with very advanced local disease. Tumor invades masticator space, pterygoid plates, or skull base and/or encases the internal carotid artery. (from AJCC 8th Ed.)","Lip and Oral Cavity Cancer pT4b TNM Finding v8 | Lip and Oral Cavity Carcinoma pT4b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520725","Lip and Oral Cavity Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C132701","A pathologic finding about one or more characteristics of lip and oral cavity cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Lip and Oral Cavity Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | Lip and Oral Cavity Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520749","Lip and Oral Cavity Cancer pNX TNM Finding v8","C132702","Lip and oral cavity cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Lip and Oral Cavity Cancer pNX TNM Finding v8 | Lip and Oral Cavity Carcinoma pNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520740","Lip and Oral Cavity Cancer pN0 TNM Finding v8","C132703","Lip and oral cavity cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","Lip and Oral Cavity Cancer pN0 TNM Finding v8 | Lip and Oral Cavity Carcinoma pN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520741","Lip and Oral Cavity Cancer pN1 TNM Finding v8","C132704","Lip and oral cavity cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Lip and Oral Cavity Cancer pN1 TNM Finding v8 | Lip and Oral Cavity Carcinoma pN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230616","Hemidesmosome","C13327","Half desmosomes that occur on the basal surface of the stratum basalis of stratified squamous epithelium.","Hemidesmosome | ",,,,,,,,,,,,,,,"4129717","Hemidesmosome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521144","Source Leukocytes","C133281","White blood cells intended as source material for further manufacturing use.","Source Leukocytes | WBC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519688","Blood Product Pathogen Reduction","C133282","Exposure to a chemical and/or radiation based processing system intended to reduce the risk of transfusion-transmitted infections in blood and blood components.","Blood Product Pathogen Reduction | Pathogen Reduced",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519990","Human Cells, Tissues, and Cellular and Tissue-Based Products Communicable Disease Testing","C133283","Testing Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) donors for infectious diseases.","Human Cells, Tissues, and Cellular and Tissue-Based Products Communicable Disease Testing | HCT/P Communicable Disease Testing | Testing for Relevant Communicable Disease Agents and Diseases",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520910","Placenta Tissue without Amniotic Elements","C133341","The placenta and tissue derived from the placenta (other than amniotic membrane).","Placenta Tissue without Amniotic Elements | Human Placenta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521129","PF24 Plasma","C133342","The fluid portion of one unit of human blood intended for transfusion which has been separated from whole blood and placed at -18 degrees C or colder within 24 hours from whole blood collection. When prepared by automated apheresis the product is stored at 1 degree to 6 degrees C within 8 hours of collection and frozen at -18 degrees C or colder within 24 hours of collection.","PF24 Plasma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521130","PF24RT24 Plasma","C133343","Plasma Frozen within 24 Hours after Phlebotomy held at Room Temperature Up To 24 Hours after Phlebotomy (PF24RT24). Plasma prepared from automated apheresis collections can be held at room temperature for up 24 hours after collection and then frozen at -18 degrees C or colder.","PF24RT24 Plasma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520220","Recovered Plasma","C133344","Plasma that has been collected from whole blood and is intended for further manufacture.","Recovered Plasma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520010","Hypopharyngeal Cancer cN0 TNM Finding v8","C132942","Hypopharyngeal cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","Hypopharyngeal Cancer cN0 TNM Finding v8 | Hypopharyngeal Carcinoma cN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520011","Hypopharyngeal Cancer cN1 TNM Finding v8","C132944","Hypopharyngeal cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (-). (from AJCC 8th Ed.)","Hypopharyngeal Cancer cN1 TNM Finding v8 | Hypopharyngeal Carcinoma cN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520012","Hypopharyngeal Cancer cN2 TNM Finding v8","C132946","Hypopharyngeal cancer with metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Hypopharyngeal Cancer cN2 TNM Finding v8 | Hypopharyngeal Carcinoma cN2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520013","Hypopharyngeal Cancer cN2a TNM Finding v8","C132948","Hypopharyngeal cancer with metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Hypopharyngeal Cancer cN2a TNM Finding v8 | Hypopharyngeal Carcinoma cN2a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520511","Stage IV Major Salivary Gland Cancer AJCC v8","C132787","Stage IV includes: IVA (T4a, N0, M0); (T4a, N1, M0); (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB (T4b, Any N, M0); (Any T, N3, M0); IVC (Any T, Any N, M1). T4a: Moderately advanced disease.  Tumor invades skin, mandible, ear canal, and/or facial nerve. T0: No evidence of primary tumor. T1: Tumor measuring 2 cm or less in greatest dimension without extraparenchymal extension. T2: Tumor measuring more than 2 cm, but not more than 4 cm in greatest dimension without extraparenchymal extension. T3: Tumor measuring more than 4 cm in greatest dimension, and/or tumor having extraparenchymal extension. T4b: Very advanced disease.  Tumor invades skull base and/or pterygoid plates and/or encases carotid artery. N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. N2: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(+); or more than 3 cm but not more than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-), or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-). N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+). M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Major Salivary Gland Cancer AJCC v8 | Stage IV Major Salivary Gland Cancer | Stage IV Major Salivary Gland Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520515","Stage IVA Major Salivary Gland Cancer AJCC v8","C132788","Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0). T4a: Moderately advanced disease.  Tumor invades skin, mandible, ear canal, and/or facial nerve. T0: No evidence of primary tumor. T1: Tumor measuring 2 cm or less in greatest dimension without extraparenchymal extension. T2: Tumor measuring more than 2 cm, but not more than 4 cm in greatest dimension without extraparenchymal extension. T3: Tumor measuring more than 4 cm in greatest dimension, and/or tumor having extraparenchymal extension. N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. N2: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(+); or more than 3 cm but not more than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-), or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-). M0: No distant metastasis. (AJCC 8th ed.)","Stage IVA Major Salivary Gland Cancer AJCC v8 | Stage IVA Major Salivary Gland Cancer | Stage IVA Major Salivary Gland Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520519","Stage IVB Major Salivary Gland Cancer AJCC v8","C132789","Stage IVB includes: (T4b, Any N, M0); (Any T, N3, M0). T4b: Very advanced disease.  Tumor invades skull base and/or pterygoid plates and/or encases carotid artery. N0: No regional lymph node metastasis. N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+). M0: No distant metastasis. (AJCC 8th ed.)","Stage IVB Major Salivary Gland Cancer AJCC v8 | Stage IVB Major Salivary Gland Cancer | Stage IVB Major Salivary Gland Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520523","Stage IVC Major Salivary Gland Cancer AJCC v8","C132790","Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","Stage IVC Major Salivary Gland Cancer AJCC v8 | Stage IVC Major Salivary Gland Cancer | Stage IVC Major Salivary Gland Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521058","Esophagus and Esophagogastric Junction Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C133385","A pathologic finding about one or more characteristics of esophagus and esophagogastric junction cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Esophagus and Esophagogastric Junction Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) Pathologic Regional Lymph Nodes TNM Finding v8 | Pathologic Regional Lymph Node Status (pN)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520813","Maxillary Sinus Cancer pT2 TNM Finding v8","C133036","Maxillary sinus cancer with tumor causing bone erosion or destruction including extension into the hard palate and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and pterygoid plates. (from AJCC 8th Ed.)","Maxillary Sinus Cancer pT2 TNM Finding v8 | Maxillary Sinus Carcinoma pT2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520814","Maxillary Sinus Cancer pT3 TNM Finding v8","C133037","Maxillary sinus cancer with tumor invading any of the following: bone of the posterior wall of maxillary sinus, subcutaneous tissues, floor or medial wall of orbit, pterygoid fossa, or ethmoid sinuses. (from AJCC 8th Ed.)","Maxillary Sinus Cancer pT3 TNM Finding v8 | Maxillary Sinus Carcinoma pT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520815","Maxillary Sinus Cancer pT4 TNM Finding v8","C133038","Maxillary sinus cancer with moderately advanced or very advanced local disease. (from AJCC 8th Ed.)","Maxillary Sinus Cancer pT4 TNM Finding v8 | Maxillary Sinus Carcinoma pT4 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520817","Maxillary Sinus Cancer pT4b TNM Finding v8","C133040","Maxillary sinus cancer with very advanced local disease.  Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than maxillary division of trigeminal nerve (V2), nasopharynx, or clivus. (from AJCC 8th Ed.)","Maxillary Sinus Cancer pT4b TNM Finding v8 | Maxillary Sinus Carcinoma pT4b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520123","Nasal Cavity and Ethmoid Sinus Cancer pTX TNM Finding v8","C133041","Nasal cavity and ethmoid sinus cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Nasal Cavity and Ethmoid Sinus Cancer pTX TNM Finding v8 | Nasal Cavity and Ethmoid Sinus Carcinoma pTX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520124","Nasal Cavity and Ethmoid Sinus Cancer pTis TNM Finding v8","C133042","Nasal cavity and ethmoid sinus cancer with a finding of carcinoma in situ. (from AJCC 8th Ed.)","Nasal Cavity and Ethmoid Sinus Cancer pTis TNM Finding v8 | Nasal Cavity and Ethmoid Sinus Carcinoma pTis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520117","Nasal Cavity and Ethmoid Sinus Cancer pT1 TNM Finding v8","C133043","Nasal cavity and ethmoid sinus cancer with tumor restricted to any one subsite, with or without bony invasion. (from AJCC 8th Ed.)","Nasal Cavity and Ethmoid Sinus Cancer pT1 TNM Finding v8 | Nasal Cavity and Ethmoid Sinus Carcinoma pT1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520119","Nasal Cavity and Ethmoid Sinus Cancer pT3 TNM Finding v8","C133045","Nasal cavity and ethmoid sinus cancer with tumor invading the medial wall or floor of the orbit, maxillary sinus, palate, or cribriform plate. (from AJCC 8th Ed.)","Nasal Cavity and Ethmoid Sinus Cancer pT3 TNM Finding v8 | Nasal Cavity and Ethmoid Sinus Carcinoma pT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520120","Nasal Cavity and Ethmoid Sinus Cancer pT4 TNM Finding v8","C133046","Nasal cavity and ethmoid sinus cancer with moderately advanced or very advanced local disease. (from AJCC 8th Ed.)","Nasal Cavity and Ethmoid Sinus Cancer pT4 TNM Finding v8 | Nasal Cavity and Ethmoid Sinus Carcinoma pT4 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520121","Nasal Cavity and Ethmoid Sinus Cancer pT4a TNM Finding v8","C133047","Nasal cavity and ethmoid sinus cancer with moderately advanced local disease. Tumor invades any of the following: anterior orbital contents, skin of nose or cheek, minimal extension to anterior cranial fossa, pterygoid plates, sphenoid or frontal sinuses. (from AJCC 8th Ed.)","Nasal Cavity and Ethmoid Sinus Cancer pT4a TNM Finding v8 | Nasal Cavity and Ethmoid Sinus Carcinoma pT4a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521298","Human Cells, Tissues, and Cellular and Tissue-Based Products Processing","C133285","Activities performed on Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) other than recovery, donor screening and testing, storage, labeling, packaging or distribution.","Human Cells, Tissues, and Cellular and Tissue-Based Products Processing | HCT/P Processing | Process",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521339","Human Cells, Tissues, and Cellular and Tissue-Based Products Recovery","C133286","Obtaining Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) from a human donor for use in a human recipient.","Human Cells, Tissues, and Cellular and Tissue-Based Products Recovery | HCT/P Recovery | Recover",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521294","Human Cells, Tissues, and Cellular and Tissue-Based Products Screening","C133287","To evaluate and screen Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) donors for communicable disease risks.","Human Cells, Tissues, and Cellular and Tissue-Based Products Screening | HCT/P Screening | Screen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521315","Human Cells, Tissues, and Cellular and Tissue-Based Products Storage","C133288","Holding Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) for future processing and/or distribution.","Human Cells, Tissues, and Cellular and Tissue-Based Products Storage | HCT/P Storage | Store",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519991","Human Cells, Tissues, and Cellular and Tissue-Based Products Distribution","C133289","Conveyance or shipment of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) that has met all release criteria.","Human Cells, Tissues, and Cellular and Tissue-Based Products Distribution | Distribute | HCT/P Distribution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230653","Caveola","C13328","A small pocket, vesicle, cave, or recess communicating with the outside of a cell and extending inward, indenting the cytoplasm and the cell membrane. Such caveolae may be pinched off to form free vesicles within the cytoplasm. They are considered to be sites of uptake of materials into the cell, expulsion of materials from the cell, or sites of addition or removal of cell (unit) membrane to or from the cell surface.","Caveola | Caveolae",,,,,,,,,,,,,,,"4279124","Micropinocytotic vesicle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL370635","Human Cells, Tissues, and Cellular and Tissue-Based Products Labeling","C133290","Written information on the container or records that accompany Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps).","Human Cells, Tissues, and Cellular and Tissue-Based Products Labeling | HCT/P Labeling | Label",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519992","Human Cells, Tissues, and Cellular and Tissue-Based Products Microorganism Testing Only","C133291","Testing a representative sample of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) to detect microorganisms is the only function performed by the establishment.","Human Cells, Tissues, and Cellular and Tissue-Based Products Microorganism Testing Only | HCT/P Microorganism Testing Only | Testing for Microorganisms Only",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520527","Store and Distribute to Others","C133292","Storage of products under controlled conditions for distribution to other firms.","Store and Distribute to Others | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521311","Whole Blood or Product Preparation","C133293","The preparation of whole blood or any of its components.","Whole Blood or Product Preparation | Prepare",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519822","Demineralized Bone Tissue","C133295","Bone that has had most of the mineralized components removed while retaining collagen and noncollagenous proteins.","Demineralized Bone Tissue | Human Demineralized Bone Matrix",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520014","Hypopharyngeal Cancer cN2b TNM Finding v8","C132950","Hypopharyngeal cancer with metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Hypopharyngeal Cancer cN2b TNM Finding v8 | Hypopharyngeal Carcinoma cN2b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520016","Hypopharyngeal Cancer cN3 TNM Finding v8","C132954","Hypopharyngeal cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in any node(s) and clinically overt ENE(+). (from AJCC 8th Ed.)","Hypopharyngeal Cancer cN3 TNM Finding v8 | Hypopharyngeal Carcinoma cN3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520709","Glottic Cancer pT1b TNM Finding v8","C133113","Glottic cancer with tumor involving both vocal cords. (from AJCC 8th Ed.)","Glottic Cancer pT1b TNM Finding v8 | Glottic Carcinoma pT1b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520710","Glottic Cancer pT2 TNM Finding v8","C133114","Glottic cancer with tumor extending to supraglottis and/or subglottis, and/or with impaired vocal cord mobility. (from AJCC 8th Ed.)","Glottic Cancer pT2 TNM Finding v8 | Glottic Carcinoma pT2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520711","Glottic Cancer pT3 TNM Finding v8","C133115","Glottic cancer with tumor limited to the larynx with vocal cord fixation and /or invasion of paraglottic space, and/or inner cortex of the thyroid cartilage. (from AJCC 8th Ed.)","Glottic Cancer pT3 TNM Finding v8 | Glottic Carcinoma pT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520712","Glottic Cancer pT4 TNM Finding v8","C133116","Glottic cancer with moderately advanced or very advanced disease. (from AJCC 8th Ed.)","Glottic Cancer pT4 TNM Finding v8 | Glottic Carcinoma pT4 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520714","Glottic Cancer pT4b TNM Finding v8","C133118","Glottic cancer with very advanced local disease. Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures. (from AJCC 8th Ed.)","Glottic Cancer pT4b TNM Finding v8 | Glottic Carcinoma pT4b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520528","Subglottic Cancer Pathologic Primary Tumor TNM Finding v8","C133119","A pathologic finding about one or more characteristics of subglottic cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Subglottic Cancer Pathologic Primary Tumor TNM Finding v8 | Subglottic Carcinoma Pathologic Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520535","Subglottic Cancer pTX TNM Finding v8","C133120","Subglottic cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Subglottic Cancer pTX TNM Finding v8 | Subglottic Carcinoma pTX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520536","Subglottic Cancer pTis TNM Finding v8","C133121","Subglottic cancer with a finding of carcinoma in situ. (from AJCC 8th Ed.)","Subglottic Cancer pTis TNM Finding v8 | Subglottic Carcinoma pTis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520529","Subglottic Cancer pT1 TNM Finding v8","C133122","Subglottic cancer in which the tumor is limited to the subglottis. (from AJCC 8th Ed.)","Subglottic Cancer pT1 TNM Finding v8 | Subglottic Carcinoma pT1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520530","Subglottic Cancer pT2 TNM Finding v8","C133123","Subglottic cancer with tumor extending to vocal cord(s) with normal or impaired mobility. (from AJCC 8th Ed.)","Subglottic Cancer pT2 TNM Finding v8 | Subglottic Carcinoma pT2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521185","Esophageal Squamous Cell Carcinoma Location Category X","C133392","Esophageal squamous cell carcinoma with unknown location. (from AJCC 8th Ed.)","Esophageal Squamous Cell Carcinoma Location Category X | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521184","Esophageal Squamous Cell Carcinoma Location Category Upper","C133393","Esophageal squamous cell carcinoma located in the cervical esophagus to lower border of azygos vein. (from AJCC 8th Ed.)","Esophageal Squamous Cell Carcinoma Location Category Upper | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521183","Esophageal Squamous Cell Carcinoma Location Category Middle","C133394","Esophageal squamous cell carcinoma located in the lower border of azygos vein to lower border of inferior pulmonary vein. (from AJCC 8th Ed.)","Esophageal Squamous Cell Carcinoma Location Category Middle | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521182","Esophageal Squamous Cell Carcinoma Location Category Lower","C133395","Esophageal squamous cell carcinoma located in the lower border of inferior pulmonary vein to stomach, including gastroesophageal junction. (from AJCC 8th Ed.)","Esophageal Squamous Cell Carcinoma Location Category Lower | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282534","SH2 Domain","C13339","A region of protein sequence similarity among members of the SRC family of cytoplasmic tyrosine kinases, and other proteins. The SH2 domain usually mediates binding to phosphotyrosine and neighboring residues of target proteins.","SH2 Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520122","Nasal Cavity and Ethmoid Sinus Cancer pT4b TNM Finding v8","C133048","Nasal cavity and ethmoid sinus cancer with very advanced local disease. Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than maxillary division of trigeminal nerve (V2), nasopharynx, or clivus. (from AJCC 8th Ed.)","Nasal Cavity and Ethmoid Sinus Cancer pT4b TNM Finding v8 | Nasal Cavity and Ethmoid Sinus Carcinoma pT4b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520144","Nasal Cavity and Paranasal Sinuses Cancer cNX TNM Finding v8","C133049","Nasal cavity and paranasal sinuses cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Nasal Cavity and Paranasal Sinuses Cancer cNX TNM Finding v8 | Nasal Cavity and Paranasal Sinuses Carcinoma cNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520277","Unknown Primary Tumor cN2b TNM Finding v8","C132660","Unknown primary tumor with metastases in multiple ipsilateral cervical lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Unknown Primary Tumor cN2b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520278","Unknown Primary Tumor cN2c TNM Finding v8","C132661","Unknown primary tumor with metastases in bilateral or contralateral cervical lymph nodes, none larger than 6 cm in greatest dimension, ENE(-). (from AJCC 8th Ed.)","Unknown Primary Tumor cN2c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520279","Unknown Primary Tumor cN3 TNM Finding v8","C132662","Unknown primary tumor with metastasis in a cervical lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in any cervical node(s) with clinically overt ENE(+) (ENEc). ENEc is defined as invasion of skin, infiltration of musculature, dense tethering or fixation to adjacent structures, or cranial nerve, brachial plexus, sympathetic trunk, or phrenic nerve invasion with dysfunction. (from AJCC 8th Ed.)","Unknown Primary Tumor cN3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520280","Unknown Primary Tumor cN3a TNM Finding v8","C132663","Unknown primary tumor with metastasis in a cervical lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Unknown Primary Tumor cN3a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520281","Unknown Primary Tumor cN3b TNM Finding v8","C132664","Unknown primary tumor with metastasis in any cervical node(s) with clinically overt ENE(+) (ENEc). ENEc is defined as invasion of skin, infiltration of musculature, dense tethering or fixation to adjacent structures, or cranial nerve, brachial plexus, sympathetic trunk, or phrenic nerve invasion with dysfunction. (from AJCC 8th Ed.)","Unknown Primary Tumor cN3b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520274","Unknown Primary Tumor Pathologic Cervical Lymph Nodes TNM Finding v8","C132665","A pathologic finding about one or more characteristics of an unknown primary tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of cervical lymph nodes. It applies to patients who are treated surgically with a cervical lymph node dissection. (from AJCC 8th Ed.)","Unknown Primary Tumor Pathologic Cervical Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520291","Unknown Primary Tumor pNX TNM Finding v8","C132666","Unknown primary tumor in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)","Unknown Primary Tumor pNX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520282","Unknown Primary Tumor pN0 TNM Finding v8","C132667","Unknown primary tumor in which no regional lymph node metastases are detected. (from AJCC 8th Ed.)","Unknown Primary Tumor pN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520283","Unknown Primary Tumor pN1 TNM Finding v8","C132668","Unknown primary tumor with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (extranodal extension)(-). (from AJCC 8th Ed.)","Unknown Primary Tumor pN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028587","Nuclear Pore","C13266","An octagonal opening, about 70 nm across, where the inner and outer membranes of the nuclear envelope are continuous.","Nuclear Pore | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520285","Unknown Primary Tumor pN2a TNM Finding v8","C132670","Unknown primary tumor with metastasis in a single ipsilateral or contralateral cervical lymph node 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral cervical lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Unknown Primary Tumor pN2a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520767","MGMT-Unmethylated Glioblastoma","C132902","A glioblastoma characterized by the absence of DNA methylation in the promoter region of the MGMT gene. It is associated with a poor outcome.","MGMT-Unmethylated Glioblastoma | Unmethylated MGMT Glioblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521269","Oropharyngeal (p16-Negative) and Hypopharyngeal Cancer TNM Finding v8","C132908","A finding about one or more characteristics of p16-negative oropharyngeal and hypopharyngeal cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to p16-negative squamous cell carcinomas of the oropharynx, oropharyngeal cancers without p16 immunostaining performed, and all cancers of the hypopharynx. Minor salivary gland cancers and neuroendocrine carcinomas of the oropharynx and hypopharynx are included in this classification. Oropharyngeal cancers which are p16-positive are staged according to the classification for p16-positive oropharyngeal cancers. (from AJCC 8th Ed.)","Oropharyngeal (p16-Negative) and Hypopharyngeal Cancer TNM Finding v8 | Oropharyngeal (p16-Negative) and Hypopharyngeal Carcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0064417","Kringle Domain","C13290","Kringles are autonomous structural domains, found throughout the blood clotting and fibrinolytic proteins. Kringle domains are believed to play a role in binding mediators (e.g., membranes, other proteins or phospholipids), and in the regulation of proteolytic activity. Kringle domains are characterised by a triple loop, 3-disulphide bridge structure, whose conformation is defined by a number of hydrogen bonds and small pieces of anti-parallel beta-sheet. They are found in a varying number of copies, in some serine proteases and plasma proteins.","Kringle Domain | Kringle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520007","Hypopharyngeal Cancer TNM Finding v8","C132910","A finding about one or more characteristics of hypopharyngeal cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to all cancers of the hypopharynx. Minor salivary gland carcinomas and neuroendocrine carcinomas of the hypopharynx are included in this classification. (from AJCC 8th Ed.)","Hypopharyngeal Cancer TNM Finding v8 | Hypopharyngeal Carcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520531","Subglottic Cancer pT3 TNM Finding v8","C133124","Subglottic cancer with tumor limited to the larynx with vocal cord fixation and/or invasion of paraglottic space and/or inner cortex of the thyroid cartilage. (from AJCC 8th Ed.)","Subglottic Cancer pT3 TNM Finding v8 | Subglottic Carcinoma pT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520532","Subglottic Cancer pT4 TNM Finding v8","C133125","Subglottic cancer with moderately advanced or very advanced disease. (from AJCC 8th Ed.)","Subglottic Cancer pT4 TNM Finding v8 | Subglottic Carcinoma pT4 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520533","Subglottic Cancer pT4a TNM Finding v8","C133126","Subglottic cancer with moderately advanced local disease. Tumor invades cricoid or thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck including deep extrinsic muscles of the tongue, strap muscles, thyroid, or esophagus). (from AJCC 8th Ed.)","Subglottic Cancer pT4a TNM Finding v8 | Subglottic Carcinoma pT4a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520534","Subglottic Cancer pT4b TNM Finding v8","C133127","Subglottic cancer with very advanced local disease. Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures. (from AJCC 8th Ed.)","Subglottic Cancer pT4b TNM Finding v8 | Subglottic Carcinoma pT4b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521090","Laryngeal Cancer Clinical Regional Lymph Nodes TNM Finding v8","C133128","A clinical finding about one or more characteristics of laryngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Laryngeal Cancer Clinical Regional Lymph Nodes TNM Finding v8 | Laryngeal Carcinoma Clinical Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521107","Laryngeal Cancer cNX TNM Finding v8","C133129","Laryngeal cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Laryngeal Cancer cNX TNM Finding v8 | Laryngeal Carcinoma cNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4045834","Decernotinib","C132740","No value exists.","Decernotinib | (2R)-2-Methyl-2-((2-(1H-pyrrolo(2,3-b)pyridin-3-yl)pyrimidin- 4-yl)amino)-N-(2,2,2-trifluoroethyl)butanamide | Adelatinib | DECERNOTINIB | VRT 831509 | VX 509 | VX-509 | VX509",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520771","Major Salivary Gland Cancer Clinical TNM Finding v8","C132741","A clinical finding about one or more characteristics of major salivary gland cancer, following the rules of the TNM AJCC v8 classification system.","Major Salivary Gland Cancer Clinical TNM Finding v8 | Major Salivary Gland Carcinoma Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520775","Major Salivary Gland Cancer Pathologic TNM Finding v8","C132742","A pathologic finding about one or more characteristics of major salivary gland cancer, following the rules of the TNM AJCC v8 classification system.","Major Salivary Gland Cancer Pathologic TNM Finding v8 | Major Salivary Gland Carcinoma Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520773","Major Salivary Gland Cancer Pathologic Primary Tumor TNM Finding v8","C132743","A pathologic finding about one or more characteristics of major salivary gland cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Major Salivary Gland Cancer Pathologic Primary Tumor TNM Finding v8 | Major Salivary Gland Carcinoma Pathologic Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520806","Major Salivary Gland Cancer pTX TNM Finding v8","C132744","Major salivary gland cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Major Salivary Gland Cancer pTX TNM Finding v8 | Major Salivary Gland Carcinoma pTX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520799","Major Salivary Gland Cancer pT0 TNM Finding v8","C132745","Major salivary gland cancer with no evidence of a primary tumor. (from AJCC 8th Ed.)","Major Salivary Gland Cancer pT0 TNM Finding v8 | Major Salivary Gland Carcinoma pT0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520807","Major Salivary Gland Cancer pTis TNM Finding v8","C132746","Major salivary gland cancer with a finding of carcinoma in situ. (from AJCC 8th Ed.)","Major Salivary Gland Cancer pTis TNM Finding v8 | Major Salivary Gland Carcinoma pTis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520800","Major Salivary Gland Cancer pT1 TNM Finding v8","C132747","Major salivary gland cancer with tumor 2 cm or less in greatest dimension without extraparenchymal extension. Extraparenchymal extension is clinical or macroscopic evidence of invasion of soft tissues. Microscopic evidence alone does not constitute extraparenchymal extension for classification purposes. (from AJCC 8th Ed.)","Major Salivary Gland Cancer pT1 TNM Finding v8 | Major Salivary Gland Carcinoma pT1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520576","Anti-PDCD1 Monoclonal Antibody IBI308","C132992","A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PDCD1; PD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sintilimab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.","Sintilimab | Anti-PD-1 Monoclonal Antibody IBI308 | Anti-PDCD1 Monoclonal Antibody IBI308 | Daboshu | IBI 308 | IBI-308 | IBI308 | SINTILIMAB | Tyvyt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520664","Gallium Ga 68-NODAGA-E(c[RGDyK])2","C132993","A radiopharmaceutical agent composed of a dimeric cyclic arginine-glycine-aspartic acid (RGD)-based peptide (c[RGDyK]) and labeled, via the chelating agent 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA), with gallium Ga 68, with potential alphaVbeta3 (aVb3) integrin imaging activity upon positron emission topography (PET) or single photon emission computed tomography (SPECT). After intravenous administration of gallium Ga 68-NODAGA-E(c[RGDyK])2, the cyclic RGD moiety targets and binds to aVb3 integrin which is expressed on the cell membrane of tumor cells and tumor-resident endothelial cells. Upon imaging, aVb3 integrin-expressing cells can be visualized and expression levels can be quantified. This can be used to assess response to anti-angiogenic treatment. aVb3 integrin is overexpressed on certain tumor cells and tumor-resident endothelial cells, while minimally or not expressed on healthy, normal cells; aVb3 integrin plays a key role in angiogenesis, tumor proliferation and survival.","Gallium Ga 68-NODAGA-E(c[RGDyK])2 | 68Ga-NODAGA-E(c[RGDyK])2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520286","Unknown Primary Tumor pN2b TNM Finding v8","C132671","Unknown primary tumor with metastases in multiple ipsilateral cervical lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Unknown Primary Tumor pN2b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520287","Unknown Primary Tumor pN2c TNM Finding v8","C132672","Unknown primary tumor with metastases in bilateral or contralateral cervical lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Unknown Primary Tumor pN2c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520288","Unknown Primary Tumor pN3 TNM Finding v8","C132673","Unknown primary tumor with metastasis in a cervical lymph node larger than 6 cm in greatest dimension and ENE(-); or metastases in a single ipsilateral cervical lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral cervical lymph nodes, any size and ENE(+) in any node. (from AJCC 8th Ed.)","Unknown Primary Tumor pN3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520289","Unknown Primary Tumor pN3a TNM Finding v8","C132674","Unknown primary tumor with metastasis in a cervical lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Unknown Primary Tumor pN3a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520977","SPL Blood Form Donor Type Terminology","C133240","Terminology used to qualify the information pertaining to blood form donor types in the framework of the Structured Product Labeling documents.","SPL Blood Form Donor Type Terminology | Structured Product Labeling Blood Form Donor Type Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520978","SPL Blood Form Establishment Functions Terminology","C133241","Terminology used to qualify the information pertaining to establishment functions in the framework of the Structured Product Labeling documents.","SPL Blood Form Establishment Functions Terminology | Structured Product Labeling Blood Form Establishment Functions Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520512","Stage IV Nasal Cavity and Paranasal Sinus Carcinoma AJCC v8","C133079","Stage IV includes: IVA: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB: (T4b, Any N, M0); (Any T, N3, M0); IVC: (Any T, Any N, M1). T4a: Maxillary sinus: Moderately advanced local disease. Tumor invades anterior orbital contents, skin of cheek, pterygoid plates, infratemporal fossa, cribriform plate, sphenoid or frontal sinuses. Nasal cavity and ethmoid sinus: Moderately advanced local disease. Tumor invades any of the following: anterior orbital contents, skin of nose or cheek, minimal extension to anterior cranial fossa, pterygoid plates, sphenoid or frontal sinuses. T4b: Very advanced local disease.  Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than maxillary division of trigeminal nerve (V2), nasopharynx, or clivus. T1: Maxillary sinus: Tumor limited to the maxillary sinus mucosa with no erosion or destruction of bone. Nasal cavity and ethmoid sinus: Tumor restricted to any one subsite, with or without bony invasion. T2: Maxillary sinus: Tumor causing bone erosion or destruction including extension into the hard palate and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and pterygoid plates. Nasal cavity and ethmoid sinus: Tumor invading two subsites in a single region or extending to involve an adjacent region within the nasoethmoidal complex, with or without bony invasion. T3: Maxillary sinus: Tumor invading any of the following: bone of the posterior wall of maxillary sinus, subcutaneous tissues, floor or medial wall of orbit, pterygoid fossa, or ethmoid sinuses. Nasal cavity and ethmoid sinus: Tumor invading the medial wall or floor of the orbit, maxillary sinus, palate, or cribriform plate. N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(-). N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes , none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral or bilateral nodes, any with ENE(+). M0: No distant metastasis. M1: Distant metastasis.  (AJCC 8th ed.)","Stage IV Sinonasal Cancer AJCC v8 | Stage IV Nasal Cavity and Paranasal Sinus Cancer | Stage IV Nasal Cavity and Paranasal Sinus Cancer AJCC v8 | Stage IV Nasal Cavity and Paranasal Sinus Carcinoma AJCC v8 | Stage IV Sinonasal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520516","Stage IVA Nasal Cavity and Paranasal Sinus Carcinoma AJCC v8","C133080","Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0). T4a: Maxillary sinus: Moderately advanced local disease. Tumor invades anterior orbital contents, skin of cheek, pterygoid plates, infratemporal fossa, cribriform plate, sphenoid or frontal sinuses. Nasal cavity and ethmoid sinus: Moderately advanced local disease. Tumor invades any of the following: anterior orbital contents, skin of nose or cheek, minimal extension to anterior cranial fossa, pterygoid plates, sphenoid or frontal sinuses. T1: Maxillary sinus: Tumor limited to the maxillary sinus mucosa with no erosion or destruction of bone. Nasal cavity and ethmoid sinus: Tumor restricted to any one subsite, with or without bony invasion. T2: Maxillary sinus: Tumor causing bone erosion or destruction including extension into the hard palate and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and pterygoid plates. Nasal cavity and ethmoid sinus: Tumor invading two subsites in a single region or extending to involve an adjacent region within the nasoethmoidal complex, with or without bony invasion. T3: Maxillary sinus: Tumor invading any of the following: bone of the posterior wall of maxillary sinus, subcutaneous tissues, floor or medial wall of orbit, pterygoid fossa, or ethmoid sinuses. Nasal cavity and ethmoid sinus: Tumor invading the medial wall or floor of the orbit, maxillary sinus, palate, or cribriform plate. N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(-). N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes , none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). M0: No distant metastasis. (AJCC 8th ed.)","Stage IVA Sinonasal Cancer AJCC v8 | Stage IVA Nasal Cavity and Paranasal Sinus Cancer | Stage IVA Nasal Cavity and Paranasal Sinus Cancer AJCC v8 | Stage IVA Nasal Cavity and Paranasal Sinus Carcinoma AJCC v8 | Stage IVA Sinonasal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520520","Stage IVB Nasal Cavity and Paranasal Sinus Carcinoma AJCC v8","C133081","Stage IVB includes: (T4b, Any N, M0); (Any T, N3, M0). T4b: Very advanced local disease. Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than maxillary division of trigeminal nerve (V2), nasopharynx, or clivus. N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral or bilateral nodes, any with ENE(+). M0: No distant metastasis. (AJCC 8th ed.)","Stage IVB Sinonasal Cancer AJCC v8 | Stage IVB Nasal Cavity and Paranasal Sinus Cancer | Stage IVB Nasal Cavity and Paranasal Sinus Cancer AJCC v8 | Stage IVB Nasal Cavity and Paranasal Sinus Carcinoma AJCC v8 | Stage IVB Sinonasal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520802","Major Salivary Gland Cancer pT3 TNM Finding v8","C132749","Major salivary gland cancer with tumor more than 4 cm in greatest dimension, and/or tumor having extraparenchymal extension. Extraparenchymal extension is clinical or macroscopic evidence of invasion of soft tissues. Microscopic evidence alone does not constitute extraparenchymal extension for classification purposes. (from AJCC 8th Ed.)","Major Salivary Gland Cancer pT3 TNM Finding v8 | Major Salivary Gland Carcinoma pT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035553","Ribosome","C13274","Ribosomes are small organelles composed of ribosomal RNA (rRNA) and 80 some different proteins. rRNA is synthesized in the nucleolus and the ribosomal subunits are assembled there from rRNA and imported cytoplasmic made proteins. Once assembled, the subunits pass through the nuclear pores to the cytoplasm where they take part in protein synthesis. Some ribosomes are free in the cytoplasm and can be recruited to a polyribosomal structure when a messenger RNA (mRNA) strand is to be translated into a cytoplasmic protein. Other ribosomes are attached to the endoplasmic reticulum where the protein is formed within the interior to the endoplasmic reticulum. These proteins are destined for secretion, storage or incorporation into membranes.","Ribosome | Ribosomal | ribosome",,,,,,,,,,,,,,,"4097401","Ribosome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL520803","Major Salivary Gland Cancer pT4 TNM Finding v8","C132750","Moderately advanced or very advanced major salivary gland cancer. (from AJCC 8th Ed.)","Major Salivary Gland Cancer pT4 TNM Finding v8 | Major Salivary Gland Carcinoma pT4 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520804","Major Salivary Gland Cancer pT4a TNM Finding v8","C132751","Moderately advanced major salivary gland cancer. Tumor invades skin, mandible, ear canal, and/or facial nerve. (from AJCC 8th Ed.)","Major Salivary Gland Cancer pT4a TNM Finding v8 | Major Salivary Gland Carcinoma pT4a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520805","Major Salivary Gland Cancer pT4b TNM Finding v8","C132752","Very advanced major salivary gland cancer. Tumor invades skull base and/or pterygoid plates and/or encases carotid artery. (from AJCC 8th Ed.)","Major Salivary Gland Cancer pT4b TNM Finding v8 | Major Salivary Gland Carcinoma pT4b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520774","Major Salivary Gland Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C132753","A pathologic finding about one or more characteristics of major salivary gland cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Major Salivary Gland Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | Major Salivary Gland Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520915","Plasma, Cryoprecipitated Reduced","C133345","Plasma from which cryoprecipitated antihemophilic factor (AHF) has been removed.","Plasma, Cryoprecipitated Reduced | Plasma Cryoprecipitated Reduced",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521120","Single Donor Plasma","C133346","Single donor plasma separated from red donor cells within 26 days after phlebotomy (40 days when citrate phosphate dextrose adenine (CPDA-1) is used as the anticoagulant) and stored at 1-6 degrees C.","Single Donor Plasma | Liquid Plasma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521145","Source Plasma","C133347","Plasma collected by apheresis and is intended for further manufacturing to prepare plasma derivatives.","Source Plasma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521187","Extended Dating Platelets","C133349","Platelets that have been tested for bacteria using an FDA-cleared rapid bacterial detection device labeled as a safety measure, following testing with a growth-based quality control test cleared by the FDA for platelet components, that can support extending the expiration date of platelets past 5 days.","Extended Dating Platelets | Platelets Extended Dating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520312","Washed Platelets","C133350","Whole blood derived or apheresis collected platelets washed with normal saline or saline-buffered with acid citrate dextrose formula-A (ACD-A) or citrate using manual or automated methods. The washed platelets are stored at 20-24 degrees C for up to 4 hours.","Washed Platelets | Platelets Washed | Platelets, Washed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520513","Stage IVA Laryngeal Cancer AJCC v8","C133162","Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0). T4a: Supraglottis: Moderately advanced local disease. Tumor invades through the outer cortex of the thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck including deep extrinsic muscle of the tongue, strap muscles, thyroid, or esophagus). Glottis: Moderately advanced local disease. Tumor invades through the outer cortex of the thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, cricoid cartilage, soft tissues of neck including deep extrinsic muscle of the tongue, strap muscles, thyroid, or esophagus). Subglottis: Moderately advanced local disease. Tumor invades cricoid or thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck including deep extrinsic muscles of the tongue, strap muscles, thyroid, or esophagus). T3: Supraglottis: Tumor is limited to larynx with vocal cord fixation and/or invades any of the following: postcricoid area, preepiglottic space, paraglottic space, and/or inner cortex of thyroid cartilage. Glottis: Tumor is limited to the larynx with vocal cord fixation and /or invades the paraglottic space, and/or inner cortex of the thyroid cartilage. Subglottis: Tumor is limited to the larynx with vocal cord fixation and/or invades the paraglottic space and/or inner cortex of the thyroid cartilage. T1: Supraglottis: Tumor is limited to one subsite of supraglottis with normal vocal cord mobility. Glottis: Tumor is limited to the vocal cord(s) (may involve anterior or posterior commissure) with normal mobility. Subglottis: Tumor is limited to the subglottis. T2: Supraglottis: Tumor invades the mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis (e.g., mucosa of base of the tongue, vallecula, medial wall of pyriform sinus) without fixation of the larynx. Glottis: Tumor extends to supraglottis and/or subglottis, and/or with impaired vocal cord mobility. Subglottis: Tumor extends to vocal cord(s) with normal or impaired mobility. N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(-). N2: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(+); or metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-); or metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-). M0: No distant metastasis. (AJCC 8th ed.)","Stage IVA Laryngeal Cancer AJCC v8 | Stage IVA Laryngeal Carcinoma AJCC v8 | Stage IVA Laryngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520517","Stage IVB Laryngeal Cancer AJCC v8","C133163","Stage IVB includes: (Any T, N3, M0); (T4b, Any N, M0). T4b: Supraglottis: Very advanced local disease. Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures. Glottis: Very advanced local disease. Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures. Subglottis: Very advanced local disease. Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures. N3: metastasis in a lymph node, more than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral lymph node, more than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+). M0: No distant metastasis. (AJCC 8th ed.)","Stage IVB Laryngeal Cancer AJCC v8 | Stage IVB Laryngeal Carcinoma AJCC v8 | Stage IVB Laryngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520521","Stage IVC Laryngeal Cancer AJCC v8","C133164","Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","Stage IVC Laryngeal Cancer AJCC v8 | Stage IVC Laryngeal Carcinoma AJCC v8 | Stage IVC Laryngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520073","Mucosal Melanoma of the Head and Neck TNM Finding v8","C133168","A finding about one or more characteristics of mucosal melanoma of the head and neck, following the rules of the TNM AJCC v8 classification system. It applies to mucosal melanomas arising in the nasal cavity, paranasal sinuses, oral cavity, oropharynx, nasopharynx, larynx, and hypopharynx. No prognostic stage grouping is proposed in AJCC 8th edition. (from AJCC 8th Ed.)","Mucosal Melanoma of the Head and Neck TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520068","Mucosal Melanoma of the Head and Neck Clinical TNM Finding v8","C133169","A clinical finding about one or more characteristics of mucosal melanoma of the head and neck, following the rules of the TNM AJCC v8 classification system.","Mucosal Melanoma of the Head and Neck Clinical TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520980","SPL Blood Form Product Type Terminology","C133243","Terminology used to qualify the information pertaining to blood form product types in the framework of the Structured Product Labeling documents.","SPL Blood Form Product Type Terminology | Structured Product Labeling Blood Form Product Type Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520982","SPL Blood Form Type of Ownership Terminology","C133245","Terminology used to qualify the information pertaining to blood forms types of ownership in the framework of the Structured Product Labeling documents.","SPL Blood Form Type of Ownership Terminology | Structured Product Labeling Blood Form Type of Ownership Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520984","SPL Tissue Form Donor Type Terminology","C133247","Terminology used to qualify the information pertaining to tissue form donor types in the framework of the Structured Product Labeling documents.","SPL Tissue Form Donor Type Terminology | Structured Product Labeling Tissue Form Donor Type Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521667","SPL Tissue Form Establishment Functions Terminology","C133248","Terminology used to qualify the information pertaining to tissue form establishment functions in the framework of the Structured Product Labeling documents.","SPL Tissue Form Establishment Functions Terminology | Structured Product Labeling Blood Form Establishment Functions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520985","SPL Tissue Form Establishment Type Terminology","C133249","Terminology used to qualify the information pertaining to tissue form establishment types in the framework of the Structured Product Labeling documents.","SPL Tissue Form Establishment Type Terminology | Structured Product Labeling Tissue Form Establishment Type Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520743","Lip and Oral Cavity Cancer pN2a TNM Finding v8","C132706","Lip and oral cavity cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE (-). (from AJCC 8th Ed.)","Lip and Oral Cavity Cancer pN2a TNM Finding v8 | Lip and Oral Cavity Carcinoma pN2a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520744","Lip and Oral Cavity Cancer pN2b TNM Finding v8","C132707","Lip and oral cavity cancer with metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Lip and Oral Cavity Cancer pN2b TNM Finding v8 | Lip and Oral Cavity Carcinoma pN2b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520746","Lip and Oral Cavity Cancer pN3 TNM Finding v8","C132709","Lip and oral cavity cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE (-); or in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral or bilateral lymph nodes any with ENE(+). (from AJCC 8th Ed.)","Lip and Oral Cavity Cancer pN3 TNM Finding v8 | Lip and Oral Cavity Carcinoma pN3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030296","Pancreatic Secretion","C13270","No value exists.","Pancreatic Secretion | ",,,,,,,,,,,,,,,"4067914","Pancreatic fluid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL520747","Lip and Oral Cavity Cancer pN3a TNM Finding v8","C132710","Lip and oral cavity cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE (-). (from AJCC 8th Ed.)","Lip and Oral Cavity Cancer pN3a TNM Finding v8 | Lip and Oral Cavity Carcinoma pN3a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520748","Lip and Oral Cavity Cancer pN3b TNM Finding v8","C132711","Lip and oral cavity cancer with metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral or bilateral lymph nodes any with ENE(+). (from AJCC 8th Ed.)","Lip and Oral Cavity Cancer pN3b TNM Finding v8 | Lip and Oral Cavity Carcinoma pN3b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520721","Lip and Oral Cavity Cancer Clinical Regional Lymph Nodes TNM Finding v8","C132712","A clinical finding about one or more characteristics of lip and oral cavity cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Lip and Oral Cavity Cancer Clinical Regional Lymph Nodes TNM Finding v8 | Lip and Oral Cavity Carcinoma Clinical Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520732","Lip and Oral Cavity Cancer cN2 TNM Finding v8","C132713","Lip and oral cavity cancer with metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, and ENE(-). (from AJCC 8th Ed.)","Lip and Oral Cavity Cancer cN2 TNM Finding v8 | Lip and Oral Cavity Carcinoma cN2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520733","Lip and Oral Cavity Cancer cN2a TNM Finding v8","C132714","Lip and oral cavity cancer with metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-).  (from AJCC 8th Ed.)","Lip and Oral Cavity Cancer cN2a TNM Finding v8 | Lip and Oral Cavity Carcinoma cN2a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520734","Lip and Oral Cavity Cancer cN2b TNM Finding v8","C132715","Lip and oral cavity cancer with metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Lip and Oral Cavity Cancer cN2b TNM Finding v8 | Lip and Oral Cavity Carcinoma cN2b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520735","Lip and Oral Cavity Cancer cN2c TNM Finding v8","C132716","Lip and oral cavity cancer with metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, and ENE(-). (from AJCC 8th Ed.)","Lip and Oral Cavity Cancer cN2c TNM Finding v8 | Lip and Oral Cavity Carcinoma cN2c TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520736","Lip and Oral Cavity Cancer cN3 TNM Finding v8","C132717","Lip and oral cavity cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in any node(s) and clinically overt ENE(+). (from AJCC 8th Ed.)","Lip and Oral Cavity Cancer cN3 TNM Finding v8 | Lip and Oral Cavity Carcinoma cN3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519820","Deglycerolized Red Blood Cells","C133351","Red blood cells washed free of the glycerol in which they have been stored.","Deglycerolized Red Blood Cells | Red Blood Cells Deglycerolized | Red Blood Cells, Deglycerolized",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520495","Frozen Red Blood Cells","C133352","Red blood cells stored at an ultra-low temperature in the presence of a cryoprotective agent. These may be preserved for long periods of time.","Frozen Red Blood Cells | Red Blood Cells Frozen | Red Blood Cells, Frozen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520234","Rejuvenated Frozen Red Blood Cells","C133353","Red blood cells treated with a rejuvenating solution, then frozen and stored at ultra-low temperatures in the presence of a cryoprotective agent.","Rejuvenated Frozen Red Blood Cells | Red Blood Cells Rejuvenated Frozen | Red Blood Cells, Rejuvenated, Frozen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520219","Reconstituted Red Blood Cells","C133354","Red blood cells to which plasma is added to prepare a whole blood product, often with a designated specific hematocrit.","Reconstituted Red Blood Cells | Red Blood Cells Reconstituted | Red Blood Cells, Reconstituted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520236","Rejuvenated, Frozen, Deglycerolized Red Blood Cells","C133355","Red blood cells treated with a rejuvenating solution, then frozen using a cryoprotective agent, and finally, washed free of the rejuvenating solution and glycerol.","Rejuvenated, Frozen, Deglycerolized Red Blood Cells | Red Blood Cells Rejuvenated Frozen Deglycerolized | Red Blood Cells, Rejuvenated, Frozen, Deglycerolized",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520235","Rejuvenated Red Blood Cells","C133356","Red blood cells treated to restore cell integrity with a rejuvenating solution, such as pyruvate inosine.","Rejuvenated Red Blood Cells | Red Blood Cells Rejuvenated | Red Blood Cells, Rejuvenated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520313","Washed Red Blood Cells","C133357","Red blood cells typically washed using normal saline with or without small amounts of dextrose using manual or automated methods. The washed red blood cells are stored at 1-6 degrees C for up to 24 hours.","Washed Red Blood Cells | Red Blood Cells Washed | Red Blood Cells, Washed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520261","U.S. Military Ownership","C133358","Operated by the U.S. Military and receives federal government funding.","U.S. Military Ownership | U.S. Military",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520017","Hypopharyngeal Cancer cN3a TNM Finding v8","C132956","Hypopharyngeal cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Hypopharyngeal Cancer cN3a TNM Finding v8 | Hypopharyngeal Carcinoma cN3a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520018","Hypopharyngeal Cancer cN3b TNM Finding v8","C132958","Hypopharyngeal cancer with metastasis in any node(s) and clinically overt ENE(+). (from AJCC 8th Ed.)","Hypopharyngeal Cancer cN3b TNM Finding v8 | Hypopharyngeal Carcinoma cN3b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520030","Hypopharyngeal Cancer pNX TNM Finding v8","C132960","Hypopharyngeal cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Hypopharyngeal Cancer pNX TNM Finding v8 | Hypopharyngeal Carcinoma pNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520021","Hypopharyngeal Cancer pN0 TNM Finding v8","C132962","Hypopharyngeal cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","Hypopharyngeal Cancer pN0 TNM Finding v8 | Hypopharyngeal Carcinoma pN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520067","Mucosal Melanoma of the Head and Neck Clinical Distant Metastasis TNM Finding v8","C133170","A clinical finding about one or more characteristics of mucosal melanoma of the head and neck, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Mucosal Melanoma of the Head and Neck Clinical Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520489","Pharyngeal Cancer TNM Finding v8","C132791","A finding about one or more characteristics of pharyngeal cancer, following the rules of the TNM AJCC v8 classification system. (from AJCC 8th Ed.)","Pharyngeal Cancer TNM Finding v8 | Pharyngeal Carcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520157","Nasopharyngeal Cancer Clinical TNM Finding v8","C132793","A clinical finding about one or more characteristics of nasopharyngeal cancer, following the rules of the TNM AJCC v8 classification system.","Nasopharyngeal Cancer Clinical TNM Finding v8 | Nasopharyngeal Carcinoma Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520161","Nasopharyngeal Cancer Pathologic TNM Finding v8","C132794","A pathologic finding about one or more characteristics of nasopharyngeal cancer, following the rules of the TNM AJCC v8 classification system.","Nasopharyngeal Cancer Pathologic TNM Finding v8 | Nasopharyngeal Carcinoma Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520159","Nasopharyngeal Cancer Pathologic Primary Tumor TNM Finding v8","C132795","A pathologic finding about one or more characteristics of nasopharyngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Nasopharyngeal Cancer Pathologic Primary Tumor TNM Finding v8 | Nasopharyngeal Carcinoma Pathologic Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520160","Nasopharyngeal Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C132803","A pathologic finding about one or more characteristics of nasopharyngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Nasopharyngeal Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | Nasopharyngeal Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519909","HPV-Mediated (p16-Positive) Oropharyngeal Cancer Pathologic Distant Metastasis TNM Finding v8","C132876","A pathologic finding about one or more characteristics of HPV-mediated (p16-positive) oropharyngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","HPV-Mediated (p16-Positive) Oropharyngeal Cancer Pathologic Distant Metastasis TNM Finding v8 | HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma Pathologic Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519906","HPV-Mediated (p16-Positive) Oropharyngeal Cancer Clinical Distant Metastasis TNM Finding v8","C132878","A clinical finding about one or more characteristics of HPV-mediated (p16-positive) oropharyngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","HPV-Mediated (p16-Positive) Oropharyngeal Cancer Clinical Distant Metastasis TNM Finding v8 | HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520135","Nasal Cavity and Paranasal Sinuses Cancer cN0 TNM Finding v8","C133050","Nasal cavity and paranasal sinuses cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","Nasal Cavity and Paranasal Sinuses Cancer cN0 TNM Finding v8 | Nasal Cavity and Paranasal Sinuses Carcinoma cN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520136","Nasal Cavity and Paranasal Sinuses Cancer cN1 TNM Finding v8","C133051","Nasal cavity and paranasal sinuses cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Nasal Cavity and Paranasal Sinuses Cancer cN1 TNM Finding v8 | Nasal Cavity and Paranasal Sinuses Carcinoma cN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520137","Nasal Cavity and Paranasal Sinuses Cancer cN2 TNM Finding v8","C133052","Nasal cavity and paranasal sinuses cancer with metastasis in a single ipsilateral lymph node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes , none larger than 6 cm in greatest dimension and ENE(-); or in in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-) . (from AJCC 8th Ed.)","Nasal Cavity and Paranasal Sinuses Cancer cN2 TNM Finding v8 | Nasal Cavity and Paranasal Sinuses Carcinoma cN2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520138","Nasal Cavity and Paranasal Sinuses Cancer cN2a TNM Finding v8","C133053","Nasal cavity and paranasal sinuses cancer with metastasis in a single ipsilateral lymph node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Nasal Cavity and Paranasal Sinuses Cancer cN2a TNM Finding v8 | Nasal Cavity and Paranasal Sinuses Carcinoma cN2a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520139","Nasal Cavity and Paranasal Sinuses Cancer cN2b TNM Finding v8","C133054","Nasal cavity and paranasal sinuses cancer with metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Nasal Cavity and Paranasal Sinuses Cancer cN2b TNM Finding v8 | Nasal Cavity and Paranasal Sinuses Carcinoma cN2b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520141","Nasal Cavity and Paranasal Sinuses Cancer cN3 TNM Finding v8","C133056","Nasal cavity and paranasal sinuses cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in any node(s) with clinically overt ENE(+) . (from AJCC 8th Ed.)","Nasal Cavity and Paranasal Sinuses Cancer cN3 TNM Finding v8 | Nasal Cavity and Paranasal Sinuses Carcinoma cN3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520738","Lip and Oral Cavity Cancer cN3b TNM Finding v8","C132719","Lip and oral cavity cancer with metastasis in any node(s) and clinically overt ENE(+). (from AJCC 8th Ed.)","Lip and Oral Cavity Cancer cN3b TNM Finding v8 | Lip and Oral Cavity Carcinoma cN3b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520655","Fertility Clinic that Manufactures Human Cells, Tissues, and Cellular and Tissue-Based Products","C133297","Clinics that perform assisted reproductive technologies and manufacture reproductive Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps).","Fertility Clinic that Manufactures Human Cells, Tissues, and Cellular and Tissue-Based Products | Fertility Clinic that Manufactures HCT/P | Fertility clinic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521207","Licensed Biologics Manufacturer","C133299","A licensed biologics manufacturing facility responsible for production and distribution of medical devices intended for use in the US.","Licensed Biologics Manufacturer | Manufacturer of Licensed Device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230779","Rough Endoplasmic Reticulum","C13329","Membrane organelle of eukaryotes that forms sheets and tubules. Contains the receptor for the signal receptor particle and binds ribosomes engaged in translating mRNA for secreted proteins and the majority of transmembrane proteins. Also a site of membrane lipid synthesis. The membrane is very similar to the nuclear outer membrane. The lumen contains a number of proteins that possess the C terminal signal KDEL.","Rough Endoplasmic Reticulum | Ergastoplasm | Granular Endoplasmic Reticulum | Rough ER | Rough-Surfaced Endoplasmic Reticulum | rER",,,,,,,,,,,,,,,"4082970","Granular endoplasmic reticulum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0086268","Etidronic Acid","C1332","As a member of the family of drugs known as bisphosphonates, etidronate differs from endogenous pyrophosphate in its resistance to enzymatic hydrolysis.  This agent adsorbs to hydroxyapatite cells and reduces the number of osteoclasts, thereby inhibiting abnormal bone resorption.  Etidronate may also directly stimulate bone formation by osteoblasts. (NCI)","Etidronic Acid | (1-Hydroxyethylidene)bisphosphonic Acid | (1-Hydroxyethylidene)diphosphonic Acid | EHDP | ETIDRONIC ACID | Ethane-1-hydroxy-1,1-diphosphonic Acid | Ethane-1-hydroxy-1,1-diphosphonic acid | Etidronate | etidronate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519689","Blood Products Broker, Distributor, Warehouse","C133300","A broker, distributor, or warehouse that stores and redistributes source material for further manufacture, such as recovered plasma, source plasma, and whole blood, red blood cells, or platelets for diagnostic product use.","Blood Products Broker, Distributor, Warehouse | Broker/Warehouse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519690","Blood Products Collection Facility","C133301","A facility that performs blood collections or apheresis.","Blood Products Collection Facility | Collection Facility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519691","Blood Products Component Preparation Facility","C133302","An intermediate processing facility that prepares components from blood collected by a mobile or fixed collection site but does not perform product testing.","Blood Products Component Preparation Facility | Component Preparation Facility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519692","Blood Products Distribution Center","C133303","A facility that stores blood or blood products for transfusion under specific controlled conditions prior to shipping it to the final user.","Blood Products Distribution Center | Distribution Center",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519693","Blood Products Irradiation Facility","C133304","A facility that performs the irradiation of blood components.","Blood Products Irradiation Facility | Irradiation Facility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520842","Medicare Approved Hospital Transfusion Service","C133305","A facility in compliance with the Clinical Laboratory Improvement Amendments Act of 1988 (42 U.S.C. 236a), that performs compatibility testing and transfusion of blood and blood components, but which neither routinely collect nor process blood and blood components. The facility has met equivalent requirements as determined by the Centers for Medicare and Medicaid Services.","Medicare Approved Hospital Transfusion Service | Hospital Transfusion Service - Approved Medicare",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519754","Cooperative Association","C133307","Business organization formed by a group of individuals for their mutual benefit.","Cooperative Association | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519757","County Municipal Hospital Authority","C133308","Owned by a territorial division of the local government within a state and has corporate status and powers of self-government.","County Municipal Hospital Authority | County/Municipal/Hospital Authority",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520022","Hypopharyngeal Cancer pN1 TNM Finding v8","C132964","Hypopharyngeal cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (-). (from AJCC 8th Ed.)","Hypopharyngeal Cancer pN1 TNM Finding v8 | Hypopharyngeal Carcinoma pN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520023","Hypopharyngeal Cancer pN2 TNM Finding v8","C132967","Hypopharyngeal cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Hypopharyngeal Cancer pN2 TNM Finding v8 | Hypopharyngeal Carcinoma pN2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521098","Laryngeal Cancer cN0 TNM Finding v8","C133130","Laryngeal cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","Laryngeal Cancer cN0 TNM Finding v8 | Laryngeal Carcinoma cN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521099","Laryngeal Cancer cN1 TNM Finding v8","C133131","Laryngeal cancer with metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Laryngeal Cancer cN1 TNM Finding v8 | Laryngeal Carcinoma cN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521100","Laryngeal Cancer cN2 TNM Finding v8","C133132","Laryngeal cancer with metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-); or metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Laryngeal Cancer cN2 TNM Finding v8 | Laryngeal Carcinoma cN2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521101","Laryngeal Cancer cN2a TNM Finding v8","C133133","Laryngeal cancer with metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Laryngeal Cancer cN2a TNM Finding v8 | Laryngeal Carcinoma cN2a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521102","Laryngeal Cancer cN2b TNM Finding v8","C133134","Laryngeal cancer with metastases in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Laryngeal Cancer cN2b TNM Finding v8 | Laryngeal Carcinoma cN2b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521046","Esophageal Adenocarcinoma by AJCC v8 Stage","C133400","A term that refers to the staging of esophageal adenocarcinoma according to the American Joint Committee on Cancer, 8th edition.","Esophageal Adenocarcinoma by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520142","Nasal Cavity and Paranasal Sinuses Cancer cN3a TNM Finding v8","C133057","Nasal cavity and paranasal sinuses cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Nasal Cavity and Paranasal Sinuses Cancer cN3a TNM Finding v8 | Nasal Cavity and Paranasal Sinuses Carcinoma cN3a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520143","Nasal Cavity and Paranasal Sinuses Cancer cN3b TNM Finding v8","C133058","Nasal cavity and paranasal sinuses cancer with metastasis in any node(s) with clinically overt ENE(+) (ENEc). (from AJCC 8th Ed.)","Nasal Cavity and Paranasal Sinuses Cancer cN3b TNM Finding v8 | Nasal Cavity and Paranasal Sinuses Carcinoma cN3b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520155","Nasal Cavity and Paranasal Sinuses Cancer pNX TNM Finding v8","C133059","Nasal cavity and paranasal sinuses cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Nasal Cavity and Paranasal Sinuses Cancer pNX TNM Finding v8 | Nasal Cavity and Paranasal Sinuses Carcinoma pNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520146","Nasal Cavity and Paranasal Sinuses Cancer pN0 TNM Finding v8","C133060","Nasal cavity and paranasal sinuses cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","Nasal Cavity and Paranasal Sinuses Cancer pN0 TNM Finding v8 | Nasal Cavity and Paranasal Sinuses Carcinoma pN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520147","Nasal Cavity and Paranasal Sinuses Cancer pN1 TNM Finding v8","C133061","Nasal cavity and paranasal sinuses cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Nasal Cavity and Paranasal Sinuses Cancer pN1 TNM Finding v8 | Nasal Cavity and Paranasal Sinuses Carcinoma pN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520148","Nasal Cavity and Paranasal Sinuses Cancer pN2 TNM Finding v8","C133062","Nasal cavity and paranasal sinuses cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes , none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Nasal Cavity and Paranasal Sinuses Cancer pN2 TNM Finding v8 | Nasal Cavity and Paranasal Sinuses Carcinoma pN2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520149","Nasal Cavity and Paranasal Sinuses Cancer pN2a TNM Finding v8","C133063","Nasal cavity and paranasal sinuses cancer with metastasis in a single ipsilateral or contralateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-).  (from AJCC 8th Ed.)","Nasal Cavity and Paranasal Sinuses Cancer pN2a TNM Finding v8 | Nasal Cavity and Paranasal Sinuses Carcinoma pN2a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520290","Unknown Primary Tumor pN3b TNM Finding v8","C132675","Unknown primary tumor with metastases in a single ipsilateral cervical lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral cervical lymph nodes, any size and ENE(+) in any node. (from AJCC 8th Ed.)","Unknown Primary Tumor pN3b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520272","Unknown Primary Tumor (Except for EBV-Related and HPV-Related Tumors) and Metastatic Cervical Adenopathy by AJCC v8 Stage","C132676","A term that refers to the staging of unknown primary tumor (except for EBV-related and HPV-related tumors) and metastatic cervical adenopathy according to the American Joint Committee on Cancer, 8th edition.","Unknown Primary Tumor (Except for EBV-Related and HPV-Related Tumors) and Metastatic Cervical Adenopathy by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520960","Stage III Unknown Primary Tumor (Except for EBV-Related and HPV-Related Tumors) and Metastatic Cervical Adenopathy AJCC v8","C132677","Stage III includes: T0, N1, M0. T0: No evidence of primary tumor. N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (extranodal extension)(-). M0: No distant metastasis. (AJCC 8th Ed.)","Stage III Unknown Primary Tumor (Except for EBV-Related and HPV-Related Tumors) and Metastatic Cervical Adenopathy AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520650","Federal Non-Military Ownership","C133309","Owned by the federal government and receives federal government funding.","Federal Non-Military Ownership | Federal (non-military)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230839","Outer Mitochondrial Membrane","C13330","The mitochondrial outer membrane contains the multi-subunit machinery responsible for the specific recognition and translocation of precursor proteins.","Outer Mitochondrial Membrane | Mitochondrial Outer Membrane",,,,,,,,,,,,,,,"4280497","Outer mitochondrial membrane",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521231","Oropharyngeal (p16-Negative) Cancer Clinical TNM Finding v8","C132911","A clinical finding about one or more characteristics of p16-negative oropharyngeal cancer, following the rules of the TNM AJCC v8 classification system.","Oropharyngeal (p16-Negative) Cancer Clinical TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521235","Oropharyngeal (p16-Negative) Cancer Pathologic TNM Finding v8","C132912","A pathologic finding about one or more characteristics of p16-negative oropharyngeal cancer, following the rules of the TNM AJCC v8 classification system.","Oropharyngeal (p16-Negative) Cancer Pathologic TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520002","Hypopharyngeal Cancer Clinical TNM Finding v8","C132913","A clinical finding about one or more characteristics of hypopharyngeal cancer, following the rules of the TNM AJCC v8 classification system.","Hypopharyngeal Cancer Clinical TNM Finding v8 | Hypopharyngeal Carcinoma Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520006","Hypopharyngeal Cancer Pathologic TNM Finding v8","C132914","A pathologic finding about one or more characteristics of hypopharyngeal cancer, following the rules of the TNM AJCC v8 classification system.","Hypopharyngeal Cancer Pathologic TNM Finding v8 | Hypopharyngeal Carcinoma Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521233","Oropharyngeal (p16-Negative) Cancer Pathologic Primary Tumor TNM Finding v8","C132915","A pathologic finding about one or more characteristics of p16-negative oropharyngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Oropharyngeal (p16-Negative) Cancer Pathologic Primary Tumor TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma Pathologic Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079686","Leucine Zipper","C13291","Domains in DNA-binding proteins that contain amino acid sequences that show periodic arrays of leucine residues. These residues exist in an alpha-helical conformation, with the leucine side chains extending from one alpha helix interdigitating with those displayed from a similar alpha helix of a second polypeptide, facilitating dimerization.","Leucine Zipper | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520719","Linear Structural Repeat Unit Connection Points","C132921","The head and the tail of a repeating structural unit in a polymer.","Linear Structural Repeat Unit Connection Points | LINEAR STRUCTURAL REPEAT UNIT CONNECTION POINTS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521103","Laryngeal Cancer cN2c TNM Finding v8","C133135","Laryngeal cancer with metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Laryngeal Cancer cN2c TNM Finding v8 | Laryngeal Carcinoma cN2c TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521104","Laryngeal Cancer cN3 TNM Finding v8","C133136","Laryngeal cancer with metastasis in a lymph node, more than 6 cm in greatest dimension and ENE(-); or metastasis in any lymph node(s) with clinically overt ENE(+). (from AJCC 8th Ed.)","Laryngeal Cancer cN3 TNM Finding v8 | Laryngeal Carcinoma cN3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521105","Laryngeal Cancer cN3a TNM Finding v8","C133137","Laryngeal cancer with metastasis in a lymph node, more than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Laryngeal Cancer cN3a TNM Finding v8 | Laryngeal Carcinoma cN3a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521106","Laryngeal Cancer cN3b TNM Finding v8","C133138","Laryngeal cancer with metastasis in any lymph node(s) with clinically overt ENE(+). (from AJCC 8th Ed.)","Laryngeal Cancer cN3b TNM Finding v8 | Laryngeal Carcinoma cN3b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521093","Laryngeal Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C133139","A pathologic finding about one or more characteristics of laryngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Laryngeal Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | Laryngeal Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206678","Helix-Loop-Helix Domain","C13313","In transcription regulators of cell cycle control, cell determination, and cell differentiation, the conserved HLH (Helix-Loop-Helix) Domain of 40-50 amino acids forms amphipathic helixes between a variable loop. HLHs typically mediate homo- or heterodimerization through interactions with self or other motifs to activate or inactivate trans-activating function. The N-helix often contains DNA-interacting basic residues; the C-helix typically contains characteristically spaced hydrophobic residues. An adjacent basic region of 15 amino acids in most HLH proteins binds to DNA. Basic (b)HLH proteins bind variants of the 'CANNTG' E-box. Proteins lacking the basic domain act as inhibitors, failing to bind DNA. bHLH proteins exhibit specific dimerization partner combinations. In calcium-binding proteins, certain invariant hydrophilic loop residues in the HLH motif bind calcium. (NCI)","Helix-Loop-Helix Domain | HLH Domain | HLH Motif | Helix-Loop-Helix Motif",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521118","Laryngeal Cancer pNX TNM Finding v8","C133140","Laryngeal cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Laryngeal Cancer pNX TNM Finding v8 | Laryngeal Carcinoma pNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521109","Laryngeal Cancer pN0 TNM Finding v8","C133141","Laryngeal cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","Laryngeal Cancer pN0 TNM Finding v8 | Laryngeal Carcinoma pN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521110","Laryngeal Cancer pN1 TNM Finding v8","C133142","Laryngeal cancer with metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Laryngeal Cancer pN1 TNM Finding v8 | Laryngeal Carcinoma pN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521111","Laryngeal Cancer pN2 TNM Finding v8","C133143","Laryngeal cancer with metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(+); or metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-); or metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Laryngeal Cancer pN2 TNM Finding v8 | Laryngeal Carcinoma pN2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520798","Major Salivary Gland Cancer pNX TNM Finding v8","C132754","Major salivary gland cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Major Salivary Gland Cancer pNX TNM Finding v8 | Major Salivary Gland Carcinoma pNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520790","Major Salivary Gland Cancer pN1 TNM Finding v8","C132756","Major salivary gland cancer with metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Major Salivary Gland Cancer pN1 TNM Finding v8 | Major Salivary Gland Carcinoma pN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520968","Stage IVA Unknown Primary Tumor (Except for EBV-Related and HPV-Related Tumors) and Metastatic Cervical Adenopathy AJCC v8","C132678","Stage IVA includes: T0, N2, M0. T0: No evidence of primary tumor. N2: Metastasis in a single ipsilateral or contralateral cervical lymph node 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral cervical lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral cervical lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral cervical lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). M0: No distant metastasis. (AJCC 8th Ed.)","Stage IVA Unknown Primary Tumor (Except for EBV-Related and HPV-Related Tumors) and Metastatic Cervical Adenopathy AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520972","Stage IVB Unknown Primary Tumor (Except for EBV-Related and HPV-Related Tumors) and Metastatic Cervical Adenopathy AJCC v8","C132679","Stage IVB includes: T0, N3, M0. T0: No evidence of primary tumor. N3: Metastasis in a cervical lymph node larger than 6 cm in greatest dimension and ENE(-); or metastases in a single ipsilateral cervical lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral cervical lymph nodes, any size and ENE(+) in any node. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IVB Unknown Primary Tumor (Except for EBV-Related and HPV-Related Tumors) and Metastatic Cervical Adenopathy AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028609","Nucleolar Organizer Region","C13267","Nucleolar organizer regions (NORs), which are loops of DNA containing ribosomal RNA genes, have been shown to correlate with cell proliferation and malignant transformation.","Nucleolar Organizer Region | ",,,,,,,,,,,,,,,"4216999","Nucleolus organizer region",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL520975","Stage IVC Unknown Primary Tumor (Except for EBV-Related and HPV-Related Tumors) and Metastatic Cervical Adenopathy AJCC v8","C132680","Stage IVC includes: T0, Any N, M1. T0: No evidence of primary tumor. M1: Distant metastasis. (AJCC 8th Ed.)","Stage IVC Unknown Primary Tumor (Except for EBV-Related and HPV-Related Tumors) and Metastatic Cervical Adenopathy AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520571","Anti-CD40/Anti-TAA Bispecific Monoclonal Antibody ABBV-428","C132681","A bispecific antibody directed against both the cell-surface receptor CD40 and the tumor-associated antigen (TAA) mesothelin (MSLN), with potential immunostimulatory and antineoplastic activities. Upon administration of anti-CD40/anti-MSLN bispecific antibody ABBV-428, the anti-MSLN moiety targets and binds to MSLN expressed on tumor cells. The agonistic anti-CD40 moiety targets and binds to various CD40-expressing immune cells in the tumor microenvironment (TME) and induces CD40-dependent signaling pathways, which triggers the proliferation and activation of antigen-presenting cells (APCs) and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD40, a stimulatory receptor and a member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells, such as macrophages, B-lymphocytes, and dendritic cells (DCs); it plays a key role in the activation of the immune system. MSLN, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types.","Anti-CD40/Anti-mesothelin Bispecific Antibody ABBV-428 | ABBV 428 | ABBV-428 | Anti-CD40 x Anti-TAA Bispecific Monoclonal Antibody ABBV-428 | Anti-CD40 x Anti-mesothelin Bispecific Antibody ABBV-428 | Anti-CD40/Anti-MSLN Bispecific Antibody ABBV-428 | Anti-CD40/Anti-TAA Bispecific Monoclonal Antibody ABBV-428",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2369991","Lidocaine Hydrochloride Ophthalmic Gel","C132682","An ophthalmic gel formulation containing the synthetic amide-type anesthetic lidocaine, with potential analgesic activity. Upon ophthalmic application, the active ingredient lidocaine binds to and blocks voltage-gated sodium channels in neuronal cell membranes. Lidocaine-mediated stabilization of neuronal membranes inhibits the initiation and conduction of nerve impulses, which numbs the nerves, prevents the trigemino-cardiac reflex and produces a reversible local anesthesia.","Lidocaine Hydrochloride Ophthalmic Gel | Akten | Lidocaine HCl Ophthalmic Gel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520987","SPL Tissue Form Product Type Terminology","C133250","Terminology used to qualify the information pertaining to tissue form product types in the framework of the Structured Product Labeling documents.","SPL Tissue Form Product Type Terminology | Structured Product Labeling Tissue Form Product Type Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520986","SPL Tissue Form Product Group Terminology","C133251","Terminology used to qualify the information pertaining to tissue form product groups in the framework of the Structured Product Labeling documents.","SPL Tissue Form Product Group Terminology | Structured Product Labeling Tissue Form Product Group Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520976","Structural Repeat Unit Substitution Point","C132923","The location of a substituted repeating structural unit in a polymer.","Structural Repeat Unit Substitution Point | STRUCTURAL REPEAT UNIT SUBSTITUTION POINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520524","Stage IVC Nasal Cavity and Paranasal Sinus Carcinoma AJCC v8","C133082","Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","Stage IVC Sinonasal Cancer AJCC v8 | Stage IVC Nasal Cavity and Paranasal Sinus Cancer | Stage IVC Nasal Cavity and Paranasal Sinus Cancer AJCC v8 | Stage IVC Nasal Cavity and Paranasal Sinus Carcinoma AJCC v8 | Stage IVC Sinonasal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521086","LORETA Neurofeedback Training","C133083","A type of operant conditioning that uses real-time displays of EEG to illustrate brain activity and allow a subject to self-regulate brain EEG activity. The use of low resolution electromagnetic tomography allows neurofeedback directly on deep brain areas and functions.","LORETA Neurofeedback Training | LNFB Training | LORETA Neurofeedback | LORETA Z-score NFT | LORETA Z-score Neurofeedback Training | LORETA Z-score Training | LORETA-EEG-NFB | LZNFT | Low Resolution Electromagnetic Tomography Neurofeedback Training",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268275","GM2-Gangliosidosis, AB Variant","C133084","An autosomal recessive lysosomal storage disease caused by mutation(s) in the GM2A gene, encoding ganglioside GM2 activator. It is characterized by GM2-ganglioside accumulation in tissues resulting in hypotonia, cherry-red macular spots, and neurocognitive dysfunction.","GM2-Gangliosidosis, AB Variant | Tay-Sachs Disease, AB Variant",,,,,,,,,,,,,,,"4324845","Tay-Sachs disease, variant AB",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL519697","Brachial Amyotrophic Diplegia","C133085","A neurodegenerative condition characterized by asymmetric weakness in the upper extremities resulting from segmental lower motor neuron dysfunction.","Brachial Amyotrophic Diplegia | BAD | FAS | Flail Arm Syndrome | MIBS | Man-in-barrel Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342791","Carnitine-Acylcarnitine Translocase Deficiency","C133086","An autosomal recessive condition caused by mutation(s) in the SLC25A20 gene, encoding mitochondrial carnitine/acylcarnitine carrier protein. It is characterized by cardiomyopathy, skeletal muscle damage, and liver dysfunction that results from derangement of long-chain fatty acid oxidation.","Carnitine-Acylcarnitine Translocase Deficiency | ",,,,,,,,,,,,,,,"4079869","Carnitine acylcarnitine translocase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0011195","Dejerine-Sottas Neuropathy","C133087","A demyelinating peripheral neuropathy characterized by delayed motor development.","Dejerine-Sottas Neuropathy | CMT3 | Charcot-Marie-Tooth Disease, Type 3 | HMSN3 | Hereditary Motor and Sensory Neuropathy Type III | Hypertrophic Neuropathy of Dejerine-Sottas",,,,,,,,,,,,,,,"4009656","Déjérine-Sottas disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521171","Canine Globoid Cell Leukodystrophy","C133088","Globoid cell leukodystrophy that occurs in a dog.","Canine Globoid Cell Leukodystrophy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519932","Hamster Melanoma","C133089","Melanoma that occurs in a hamster.","Hamster Melanoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519933","Hamster Pancreatic Ductal Adenocarcinoma","C133090","Pancreatic ductal carcinoma that occurs in a hamster.","Hamster Pancreatic Ductal Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520765","Lung Adenofibroma","C133091","A very rare benign neoplasm that arises from the lung. It is characterized by the presence of a stromal and an epithelial component. It resembles the adenofibromas that arise from the organs of the female reproductive system.","Lung Adenofibroma | Pulmonary Adenofibroma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520791","Major Salivary Gland Cancer pN2 TNM Finding V8","C132757","Major salivary gland cancer with metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(+); or more than 3 cm but not more than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-), or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Major Salivary Gland Cancer pN2 TNM Finding V8 | Major Salivary Gland Carcinoma pN2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520792","Major Salivary Gland Cancer pN2a TNM Finding V8","C132758","Major salivary gland cancer with metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(+); or a single ipsilateral node more than 3 cm but not more than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Major Salivary Gland Cancer pN2a TNM Finding V8 | Major Salivary Gland Carcinoma pN2a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520793","Major Salivary Gland Cancer pN2b TNM Finding V8","C132759","Major salivary gland cancer with metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-).  (from AJCC 8th Ed.)","Major Salivary Gland Cancer pN2b TNM Finding V8 | Major Salivary Gland Carcinoma pN2b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520794","Major Salivary Gland Cancer pN2c TNM Finding V8","C132760","Major salivary gland cancer with metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Major Salivary Gland Cancer pN2c TNM Finding V8 | Major Salivary Gland Carcinoma pN2c TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520795","Major Salivary Gland Cancer pN3 TNM Finding v8","C132761","Major salivary gland cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+). (from AJCC 8th Ed.)","Major Salivary Gland Cancer pN3 TNM Finding v8 | Major Salivary Gland Carcinoma pN3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520796","Major Salivary Gland Cancer pN3a TNM Finding v8","C132762","Major salivary gland cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Major Salivary Gland Cancer pN3a TNM Finding v8 | Major Salivary Gland Carcinoma pN3a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520797","Major Salivary Gland Cancer pN3b TNM Finding v8","C132763","Major salivary gland cancer with metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+). (from AJCC 8th Ed.)","Major Salivary Gland Cancer pN3b TNM Finding v8 | Major Salivary Gland Carcinoma pN3b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520781","Major Salivary Gland Cancer cN2 TNM Finding V8","C132765","Major salivary gland cancer with metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-), or in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Major Salivary Gland Cancer cN2 TNM Finding V8 | Major Salivary Gland Carcinoma cN2 TNM Finding V8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520782","Major Salivary Gland Cancer cN2a TNM Finding V8","C132766","Major salivary gland cancer with metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Major Salivary Gland Cancer cN2a TNM Finding V8 | Major Salivary Gland Carcinoma cN2a TNM Finding V8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520783","Major Salivary Gland Cancer cN2b TNM Finding V8","C132767","Major salivary gland cancer with metastasis in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Major Salivary Gland Cancer cN2b TNM Finding V8 | Major Salivary Gland Carcinoma cN2b TNM Finding V8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520784","Major Salivary Gland Cancer cN2c TNM Finding V8","C132768","Major salivary gland cancer with metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Major Salivary Gland Cancer cN2c TNM Finding V8 | Major Salivary Gland Carcinoma cN2c TNM Finding V8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520039","Hypopharyngeal Carcinoma by AJCC v8 Stage","C133003","A term that refers to the staging of hypopharyngeal carcinoma according to the American Joint Committee on Cancer, 8th edition.","Hypopharyngeal Carcinoma by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521277","Stage I Hypopharyngeal Carcinoma AJCC v8","C133005","Stage I includes: T1, N0, M0. T1: Tumor limited to one subsite of hypopharynx and/or 2 cm or smaller in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Hypopharyngeal Carcinoma AJCC v8 | Stage I Hypopharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520075","Mucosal Melanoma of the Head and Neck cM0 TNM Finding v8","C133171","Mucosal melanoma of the head and neck without evidence of distant metastasis. (from AJCC 8th Ed.)","Mucosal Melanoma of the Head and Neck cM0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520076","Mucosal Melanoma of the Head and Neck cM1 TNM Finding v8","C133172","Mucosal melanoma of the head and neck with distant metastasis. (from AJCC 8th Ed.)","Mucosal Melanoma of the Head and Neck cM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520072","Mucosal Melanoma of the Head and Neck Pathologic TNM Finding v8","C133173","A pathologic finding about one or more characteristics of mucosal melanoma of the head and neck, following the rules of the TNM AJCC v8 classification system.","Mucosal Melanoma of the Head and Neck Pathologic TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520448","Mcl-1 Inhibitor MIK665","C133174","An inhibitor of induced myeloid leukemia cell differentiation protein (Mcl-1; Bcl2-L-3), with potential pro-apoptotic and antineoplastic activities. Upon administration, MIK665 binds to and inhibits the activity of Mcl-1, which promotes apoptosis of cells overexpressing Mcl-1. Mcl-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival.","Mcl-1 Inhibitor MIK665 | MIK 665 | MIK-665 | MIK665 | S 64315 | S-64315 | S64315",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520077","Mucosal Melanoma of the Head and Neck pM1 TNM Finding v8","C133176","Mucosal melanoma of the head and neck with distant metastasis. (from AJCC 8th Ed.)","Mucosal Melanoma of the Head and Neck pM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520070","Mucosal Melanoma of the Head and Neck Pathologic Primary Tumor TNM Finding v8","C133177","A pathologic finding about one or more characteristics of mucosal melanoma of the head and neck, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Mucosal Melanoma of the Head and Neck Pathologic Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520081","Mucosal Melanoma of the Head and Neck pT3 TNM Finding v8","C133178","Mucosal melanoma of the head and neck with tumor limited to the mucosa and immediately underlying soft tissue, regardless of thickness or greatest dimension; for example, polypoid nasal disease, pigmented or nonpigmented lesions of the oral cavity, pharynx, or larynx. (from AJCC 8th Ed.)","Mucosal Melanoma of the Head and Neck pT3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520082","Mucosal Melanoma of the Head and Neck pT4 TNM Finding v8","C133179","Mucosal melanoma of the head and neck with moderately advanced or very advanced disease. (from AJCC 8th Ed.)","Mucosal Melanoma of the Head and Neck pT4 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521148","Lung Non-Small Cell Squamous Carcinoma","C133254","A squamous cell carcinoma that arises from the lung. It is characterized by the presence of large malignant cells. It includes the clear cell and papillary variants of squamous cell carcinoma.","Lung Non-Small Cell Squamous Carcinoma | Non-Small Cell Squamous Lung Cancer | Non-Small Cell Squamous Lung Carcinoma | Squamous Non-Small Cell Lung Carcinoma",,,,,,,,,,,,,,,"37109576","Squamous non-small cell lung cancer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043442","Z-DNA","C13287","Z-DNA can be obtained for certain sequences such as CGCGCG by increasing the salt concentration of the solution containing the sample to 4 molar NaCl. Z-DNA is left-handed and the thinnest & tallest with a diameter of about 18 Angstrom. The sugar pucker is both C(3')-endo and C(2')-endo. In Z-DNA, the Watson-Crick base pairs are perpendicular to the helix axis. When examined from the top of the helix, bases are present throughout the matrix of the helix with no exclusive domains for either the bases or the backbone. At times the sugar phosphate backbone travels very close to the center of the helix, and the bases to the very edge of the helix.","Z-DNA | zDNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520222","Recurrent Breast Angiosarcoma","C133092","The reemergence of breast angiosarcoma after a period of remission.","Recurrent Breast Angiosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520760","Locally Advanced Solid Tumor","C133093","A malignant solid neoplasm that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Tumor | Locally Advanced Solid Neoplasm | Locally Advanced Solid Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520657","Fluorine F 18 alphaVbeta6-Binding Peptide","C133094","A radiotracer composed of a 20 amino acid peptide derived from the GH loop of an envelope protein (VP1) of the foot-and-mouth disease virus (FMDV), where the N-terminal lysine has been substituted with arginine, conjugated with two polyethylene glycol units and radiolabeled with fluorine 18, for potential positron emission tomography (PET) imaging of alphaVbeta6 integrin expression. Upon administration, the arginine-glycine-aspartic acid (RGD) motif within the peptide moiety of the fluorine 18 F alphaVbeta6-binding peptide selectively binds to alphaVbeta6 integrin. During PET imaging, alphaVbeta6-expressing tumor cells can be visualized and the degree of tumor growth can be determined. AlphaVbeta6 integrin, a cell adhesion and signaling receptor, is upregulated in certain cancers and has been associated with proliferation, migration and invasion of tumor cells.","Fluorine F 18 alphaVbeta6-Binding Peptide | 18F-aVb6-BP | 18F-alphaVbeta6-Binding Peptide | 18F-alphaVbeta6-Binding-Peptide | Fluorine F 18-alphaVbeta6-Binding-Peptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521160","AIDS-Related Anal Canal Carcinoma","C133095","A carcinoma arising from the anal canal and occurring in HIV-positive patients.","AIDS-Related Anal Canal Carcinoma | AIDS-Related Anal Canal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520723","Lip and Oral Cavity Cancer Pathologic Distant Metastasis TNM Finding v8","C132720","A pathologic finding about one or more characteristics of lip and oral cavity cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.  There is no pathologic M0 for lip and oral cavity cancer.","Lip and Oral Cavity Cancer Pathologic Distant Metastasis TNM Finding v8 | Lip and Oral Cavity Carcinoma Pathologic Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520739","Lip and Oral Cavity Cancer pM1 TNM Finding v8","C132721","Lip and oral cavity cancer with distant metastasis. (from AJCC 8th Ed.)","Lip and Oral Cavity Cancer pM1 TNM Finding v8 | Lip and Oral Cavity Carcinoma pM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520720","Lip and Oral Cavity Cancer Clinical Distant Metastasis TNM Finding v8","C132722","A clinical finding about one or more characteristics of lip and oral cavity cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Lip and Oral Cavity Cancer Clinical Distant Metastasis TNM Finding v8 | Lip and Oral Cavity Carcinoma Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520730","Lip and Oral Cavity Cancer cM0 TNM Finding v8","C132723","Lip and oral cavity cancer without evidence of distant metastasis. (from AJCC 8th Ed.)","Lip and Oral Cavity Cancer cM0 TNM Finding v8 | Lip and Oral Cavity Carcinoma cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520731","Lip and Oral Cavity Cancer cM1 TNM Finding v8","C132724","Lip and oral cavity cancer with distant metastasis. (from AJCC 8th Ed.)","Lip and Oral Cavity Cancer cM1 TNM Finding v8 | Lip and Oral Cavity Carcinoma cM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3180121","Vabicaserin","C132725","No value exists.","Vabicaserin | Cyclopenta(4,5)pyrido(3,2,1-jk)(1,4)benzodiazepine, 4,5,6,7,9,9a,10,11,12,12a-Decahydro-, (9aR,12aS)-rel-(-)- | SCA-136 | VABICASERIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520729","Lip and Oral Cavity Cancer by AJCC v8 Stage","C132728","A term that refers to the staging of lip and oral cavity carcinoma according to the American Joint Committee on Cancer, 8th edition.","Lip and Oral Cavity Cancer by AJCC v8 Stage | Lip and Oral Cavity Carcinoma by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521128","Iodinated Polyethylene Glycol-based Hydrogel Tissue Marker","C133359","A radiopaque hydrogel containing cross-linked, iodinated polyethylene glycol (PEG) particles in a viscous carrier, with potential use as a contrast agent to enhance marking of soft tissue during a surgical procedure and concomitant radiotherapy upon computed tomography (CT), magnetic resonance (MR) and ultrasound imaging. Upon intratumoral injection, iodinated PEG-based hydrogel tissue marker localizes to and is maintained in soft tissue. Upon MR, ultrasound and/or CT imaging, the visualization of the tumor tissue is enhanced, which can facilitate tumor removal and image-guided radiotherapeutic treatment. The hydrogel particles are stable and visible through 3 months, after which they liquefy, and are absorbed by the body and cleared in the urine.","Iodinated Polyethylene Glycol-based Hydrogel Tissue Marker | PEG-based Hydrogel Tissue Marker | Radiopaque Polymer Hydrogel Imaging Agent | TraceIT | TraceIT Hydrogel | TraceIT Tissue Marker",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242961","Replication Origin","C13335","A DNA sequence necessary and sufficient for initiation of DNA replication.","Origin of Replication | ARS | Autonomously Replicating Sequence | ORI | Replication Origin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519995","Human Cells, Tissues, and Cellular and Tissue-Based Products from Blood Vessel Tissue","C133360","Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) from the human circulatory or vascular system.","Human Cells, Tissues, and Cellular and Tissue-Based Products from Blood Vessel Tissue | HCT/P from Blood Vessel Tissue | Human Vascular Tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519840","Digestive System Cancer TNM Finding v8","C133361","A finding about one or more characteristics of digestive system cancer, following the rules of the TNM AJCC v8 classification system.","Digestive System Cancer TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519996","Human Cells, Tissues, and Cellular and Tissue-Based Products from Cardiac Tissue","C133362","Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) from the human heart.","Human Cells, Tissues, and Cellular and Tissue-Based Products from Cardiac Tissue | Human Cardiac Tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520300","Upper Gastrointestinal Tract Cancer TNM Finding v8","C133363","A finding about one or more characteristics of upper gastrointestinal tract cancer, following the rules of the TNM AJCC v8 classification system.","Upper Gastrointestinal Tract Cancer TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519997","Human Cells, Tissues, and Cellular and Tissue-Based Products from Musculoskeletal Tissue","C133364","Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) from the human muscular and skeletal system.","Human Cells, Tissues, and Cellular and Tissue-Based Products from Musculoskeletal Tissue | Human Musculoskeletal Tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521055","Esophagus and Esophagogastric Junction Cancer Clinical TNM Finding v8","C133366","A clinical finding about one or more characteristics of esophagus and esophagogastric junction cancer, following the rules of the TNM AJCC v8 classification system.","Esophagus and Esophagogastric Junction Cancer Clinical TNM Finding v8 | Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520083","Mucosal Melanoma of the Head and Neck pT4a TNM Finding v8","C133180","Mucosal melanoma of the head and neck with moderately advanced disease. Tumor involves deep soft tissue, cartilage, bone, or overlying skin. (from AJCC 8th Ed.)","Mucosal Melanoma of the Head and Neck pT4a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520084","Mucosal Melanoma of the Head and Neck pT4b TNM Finding v8","C133181","Mucosal melanoma of the head and neck with very advanced disease. Tumor involves brain, dura, skull base, lower cranial nerves (IX, X, XI, XII), masticator space, carotid artery, prevertebral space, or mediastinal structures. (from AJCC 8th Ed.)","Mucosal Melanoma of the Head and Neck pT4b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520071","Mucosal Melanoma of the Head and Neck Pathologic Regional Lymph Nodes TNM Finding v8","C133182","A pathologic finding about one or more characteristics of mucosal melanoma of the head and neck, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Mucosal Melanoma of the Head and Neck Pathologic Regional Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520080","Mucosal Melanoma of the Head and Neck pNX TNM Finding v8","C133183","Mucosal melanoma of the head and neck in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)","Mucosal Melanoma of the Head and Neck pNX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520079","Mucosal Melanoma of the Head and Neck pN1 TNM Finding v8","C133185","Mucosal melanoma of the head and neck with regional lymph node metastases. (from AJCC 8th Ed.)","Mucosal Melanoma of the Head and Neck pN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520074","Mucosal Melanoma of the Head and Neck by AJCC v7 Stage","C133186","A term that refers to the staging of mucosal melanoma of the head and neck according to the American Joint Committee on Cancer, 7th edition. No prognostic stage grouping is proposed in the 8th edition.","Mucosal Melanoma of the Head and Neck by AJCC v7 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520085","Mucosal Melanoma of the Head and Neck","C133187","A melanoma that arises in the mucosa of the nasal cavity, paranasal sinuses, oral cavity, oropharynx, nasopharynx, larynx, and hypopharynx.","Mucosal Melanoma of the Head and Neck | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520158","Nasopharyngeal Cancer Pathologic Distant Metastasis TNM Finding v8","C132809","A pathologic finding about one or more characteristics of nasopharyngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Nasopharyngeal Cancer Pathologic Distant Metastasis TNM Finding v8 | Nasopharyngeal Carcinoma Pathologic Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520156","Nasopharyngeal Cancer Clinical Distant Metastasis TNM Finding v8","C132811","A clinical finding about one or more characteristics of nasopharyngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Nasopharyngeal Cancer Clinical Distant Metastasis TNM Finding v8 | Nasopharyngeal Carcinoma Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520052","Metastatic Prostate Cancer in the Soft Tissue","C132881","A carcinoma that arises from the prostate gland and has spread to the soft tissues.","Prostate Carcinoma Metastatic in the Soft Tissue | Metastatic Prostate Cancer in the Soft Tissue | Metastatic Prostate Carcinoma in the Soft Tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519931","HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma by AJCC v8 Stage","C132882","A term that refers to the staging of HPV-mediated (p16-positive) oropharyngeal carcinoma according to the American Joint Committee on Cancer, 8th edition.","HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520449","MIR124-2 wt Allele","C132888","Human MIR124-2 wild-type allele is located in the vicinity of 8q12.3 and is approximately 109 bases in length. This allele, which encodes MIR124-2 pre-miRNA, may play a role in neuronal differentiation.","MIR124-2 wt Allele | MIRN124-2 | MIRN124A2 | MicroRNA 124-2 wt Allele | MicroRNA 124a-2 Gene | hsa-mir-124-2 | hsa-mir-124a-2 | mir-124-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520768","MIR124-2 Pre-miRNA","C132889","MIR124-2 pre-miRNA (109 bases) is encoded by the human MIR124-2 gene. This oligonucleotide may be involved in the regulation of neuronal gene expression.","MIR124-2 Pre-miRNA | Pre-MIR124-2 | Pre-MicroRNA 124-2 | Pre-miRNA MIR124-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0052350","arginyl-glycyl-aspartic acid","C13288","A consensus tripeptide that is recognized by and for binding to proteins of the integrin family, including many cell adhesion molecules. The one-letter codes for arginine - glycine - aspartic acid. This motif can be found in proteins of the extracellular matrix and it is recognized by different members of the integrin family. The structure of the tenth type III module of fibronectin has shown that the RGD motif lies on a flexible loop.","RGD Motif | Arginine-Glycine-Aspartic Acid Cell Adhesion Domain | RGD | RGD Cell Adhesion Domain | RGD Domain | RGD Peptide | RGD Tripeptide Sequence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521151","Stage I Lip and Oral Cavity Cancer AJCC v8","C132729","Stage I includes: T1, N0, M0.  T1: Tumor size 2 cm or less in greatest dimension and 5 mm or less depth of invasion (DOI).  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 8th Ed.)","Stage I Lip and Oral Cavity Cancer AJCC v8 | Stage I Lip and Oral Cavity Cancer | Stage I Lip and Oral Cavity Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520502","Stage II Lip and Oral Cavity Cancer AJCC v8","C132730","Stage II includes: T2, N0, M0. T2: Tumor size 2 cm or less in greatest dimension, DOI greater than 5 mm and equal or less than 10 mm or tumor greater than 2 cm but 4 cm or less in greatest dimension and 10 mm or less DOI.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 8th Ed.)","Stage II Lip and Oral Cavity Cancer AJCC v8 | Stage II Lip and Oral Cavity Cancer | Stage II Lip and Oral Cavity Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520506","Stage III Lip and Oral Cavity Cancer AJCC v8","C132731","Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T3: Tumor size greater than 4 cm or any tumor greater than 10 mm DOI. T1: Tumor size 2 cm or less in greatest dimension and 5 mm or less DOI. T2: Tumor size 2 cm or less in greatest dimension, DOI greater than 5 mm and equal or less than 10 mm or tumor greater than 2 cm but 4 cm or less in greatest dimension and 10 mm or less DOI N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (extranodal extension)(-). M0: No distant metastasis. (AJCC 8th Ed.)","Stage III Lip and Oral Cavity Cancer AJCC v8 | Stage III Lip and Oral Cavity Cancer | Stage III Lip and Oral Cavity Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520658","For-Profit Corporation","C133310","An organization which aims to earn profit through its operations and is concerned with its own interests.","For-Profit Corporation | Corporation (for Profit)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521138","Single Proprietorship","C133312","An unincorporated business with a single owner who pays personal income tax on profits earned from the business. Ownership of a business establishment by one individual.","Single Proprietorship | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520526","State Ownership","C133313","Owned by the state and receives state government funding.","State Ownership | State",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521313","Reproductive Human Cells, Tissues, and Cellular and Tissue-Based Products from Anonymous Donor","C133314","Reproductive Human Cells, Tissues and Tissue based Products (HCT/Ps) donated by a donor to a recipient who doesn't know and isn't known by the recipient before donation.","Reproductive Human Cells, Tissues, and Cellular and Tissue-Based Products from Anonymous Donor | Anonymous | Reproductive HCT/P from Anonymous Donor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521306","Reproductive Human Cells, Tissues, and Cellular and Tissue-Based Products from Known Donor to Directed Recipient","C133315","Reproductive Human Cells, Tissues and Tissue based Products (HCT/Ps) donated by a donor to a specific recipient who knows and is known by the recipient before donation.","Reproductive Human Cells, Tissues, and Cellular and Tissue-Based Products from Known Donor to Directed Recipient | Directed | Reproductive HCT/P from Known Donor to Directed Recipient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520237","Reproductive Human Cells, Tissues, and Cellular and Tissue-Based Products from Sexually Intimate Partner","C133316","Reproductive Human Cells, Tissues and Tissue based Products (HCT/Ps) donated by a donor to a recipient who is a sexually intimate partner.","Reproductive Human Cells, Tissues, and Cellular and Tissue-Based Products from Sexually Intimate Partner | Reproductive HCT/P from Sexually Intimate Partner | Sexually intimate partner",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521079","Inner Membrane Amniotic Membrane Tissue","C133317","Tissue derived from the inner membrane of amniotic sac.","Inner Membrane Amniotic Membrane Tissue | Human Amniotic Membrane",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521334","Umbilical Cord Tissue","C133318","Tissue derived from the umbilical cord.","Umbilical Cord Tissue | Human Umbilical Cord Tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520577","Apheresis Collection Facility","C133319","A facility whose primary operation is peripheral blood stem cells and mononuclear cell collection by apheresis.","Apheresis Collection Facility | Apheresis collection facility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0251851","PA700 Regulatory Module","C13336","Ubiquitinated proteins are degraded by a 26S ATP-dependent protease complex, composed of a 20S catalytic proteasome and two 19S PA700 regulatory modules.  The multi-subunit PA700 complex binds two sites of the 20S proteasome and is composed of at least six related ATPases and approximately fifteen non-ATPase polypeptides.  Each of the ATPases, PSMC1-6, contains an AAA (ATPases associated with diverse cellular activities) domain.  A protein complex containing p42 and p50 enhances PA700 activation of the proteasome.","PA700 Regulatory Module | 19S Proteasome Regulatory Particle | 19S Regulatory Particle | PA700 Protein | PA700 Protein Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520025","Hypopharyngeal Cancer pN2b TNM Finding v8","C132970","Hypopharyngeal cancer with metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Hypopharyngeal Cancer pN2b TNM Finding v8 | Hypopharyngeal Carcinoma pN2b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520027","Hypopharyngeal Cancer pN3 TNM Finding v8","C132974","Hypopharyngeal cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+). (from AJCC 8th Ed.)","Hypopharyngeal Cancer pN3 TNM Finding v8 | Hypopharyngeal Carcinoma pN3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520028","Hypopharyngeal Cancer pN3a TNM Finding v8","C132976","Hypopharyngeal cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Hypopharyngeal Cancer pN3a TNM Finding v8 | Hypopharyngeal Carcinoma pN3a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520029","Hypopharyngeal Cancer pN3b TNM Finding v8","C132978","Hypopharyngeal cancer with metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+). (from AJCC 8th Ed.)","Hypopharyngeal Cancer pN3b TNM Finding v8 | Hypopharyngeal Carcinoma pN3b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521229","Oropharyngeal (p16-Negative) Cancer Clinical Distant Metastasis TNM Finding v8","C132979","A clinical finding about one or more characteristics of oropharyngeal (p16-negative) cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Oropharyngeal (p16-Negative) Cancer Clinical Distant Metastasis TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520000","Hypopharyngeal Cancer Clinical Distant Metastasis TNM Finding v8","C132980","A clinical finding about one or more characteristics of hypopharyngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Hypopharyngeal Cancer Clinical Distant Metastasis TNM Finding v8 | Hypopharyngeal Carcinoma Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520490","Pharyngeal Carcinoma by AJCC v8 Stage","C132814","A term that refers to the staging of pharyngeal carcinoma according to the American Joint Committee on Cancer, 8th edition.","Pharyngeal Carcinoma by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282535","SH3 Domain","C13340","A region of protein sequence similarity among members of the SRC family of cytoplasmic tyrosine kinases, and other proteins. The SH3 domain is a protein-binding domain that interacts with cytoskeletal proteins.","SH3 Domain | SRC Homology Region 3 Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521042","Esophageal Adenocarcinoma by AJCC v7 Stage","C133411","A term that refers to the staging of esophageal adenocarcinoma according to the American Joint Committee on Cancer, 7th edition.","Esophageal Adenocarcinoma by AJCC v7 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520150","Nasal Cavity and Paranasal Sinuses Cancer pN2b TNM Finding v8","C133064","Nasal cavity and paranasal sinuses cancer with metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Nasal Cavity and Paranasal Sinuses Cancer pN2b TNM Finding v8 | Nasal Cavity and Paranasal Sinuses Carcinoma pN2b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520151","Nasal Cavity and Paranasal Sinuses Cancer pN2c TNM Finding v8","C133065","Nasal cavity and paranasal sinuses cancer with metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Nasal Cavity and Paranasal Sinuses Cancer pN2c TNM Finding v8 | Nasal Cavity and Paranasal Sinuses Carcinoma pN2c TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520152","Nasal Cavity and Paranasal Sinuses Cancer pN3 TNM Finding v8","C133066","Nasal cavity and paranasal sinuses cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral or bilateral nodes, any with ENE(+) . (from AJCC 8th Ed.)","Nasal Cavity and Paranasal Sinuses Cancer pN3 TNM Finding v8 | Nasal Cavity and Paranasal Sinuses Carcinoma pN3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520153","Nasal Cavity and Paranasal Sinuses Cancer pN3a TNM Finding v8","C133067","Nasal cavity and paranasal sinuses cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Nasal Cavity and Paranasal Sinuses Cancer pN3a TNM Finding v8 | Nasal Cavity and Paranasal Sinuses Carcinoma pN3a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520154","Nasal Cavity and Paranasal Sinuses Cancer pN3b TNM Finding v8","C133068","Nasal cavity and paranasal sinuses cancer with metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral or bilateral nodes, any with ENE(+) . (from AJCC 8th Ed.)","Nasal Cavity and Paranasal Sinuses Cancer pN3b TNM Finding v8 | Nasal Cavity and Paranasal Sinuses Carcinoma pN3b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520133","Nasal Cavity and Paranasal Sinuses Cancer cM0 TNM Finding v8","C133069","Nasal cavity and paranasal sinuses cancer without evidence of distant metastasis. (from AJCC 8th Ed.)","Nasal Cavity and Paranasal Sinuses Cancer cM0 TNM Finding v8 | Nasal Cavity and Paranasal Sinuses Carcinoma cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520134","Nasal Cavity and Paranasal Sinuses Cancer cM1 TNM Finding v8","C133070","Nasal cavity and paranasal sinuses cancer with distant metastasis. (from AJCC 8th Ed.)","Nasal Cavity and Paranasal Sinuses Cancer cM1 TNM Finding v8 | Nasal Cavity and Paranasal Sinuses Carcinoma cM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520145","Nasal Cavity and Paranasal Sinuses Cancer pM1 TNM Finding v8","C133071","Nasal cavity and paranasal sinuses cancer with distant metastasis. (from AJCC 8th Ed.)","Nasal Cavity and Paranasal Sinuses Cancer pM1 TNM Finding v8 | Nasal Cavity and Paranasal Sinuses Carcinoma pM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519703","CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes","C133072","A preparation of genetically modified central memory (Tcm) enriched T-cells transduced with a replication incompetent lentiviral vector expressing a chimeric antigen receptor (CAR), containing a CD28 signaling domain fused to both CD3 zeta, which targets the CD19 antigen, and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells are directed to CD19-expressing tumor cells, thereby inducing a selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.  Devoid of both ligand binding domains and tyrosine kinase activity, EGFRt both facilitates in vivo detection of the administered T-cells and can promote elimination of those cells upon a cetuximab-induced antibody dependent cellular cytotoxicity response. The costimulatory signaling domain enhances proliferation of T cells and antitumor activity.","CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes | CD19-CAR-specific/truncated EGFR Lentiviral Vector-transduced T Cells | CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T Cells | CD19R(EQ)28zeta/EGFRt+ TCM | CD19R(EQ)28zeta/truncated Human EGFR+ Central Memory T Cells | CD19R:CD28:lentiviral/EGFRt+ T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0057576","Detirelix","C132693","No value exists.","Detirelix | BRN 6564671 | D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-D-tryptophyl-L-seryl-L-tyrosyl-N(sup 6)-(bis(ethylamino)methylene)-D-lysyl-L-leucyl-L-arginyl-L-prolyl- | DETIRELIX | N-Ac-D-Nal(2)1,D-pCl-Phe2,D-Trp3,D-hArg(Et2)6,D-Ala(10)-GnRH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230840","Inner Mitochondrial Membrane","C13331","The inner mitochondrial membrane encloses a fluid-filled matrix and is elaborately folded with shelf-like cristae projecting into the matrix. The components of electron transport chain are integral part of the inner membrane.","Inner Mitochondrial Membrane | Mitochondrial Inner Membrane",,,,,,,,,,,,,,,"4047856","Inner mitochondrial membrane",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL519994","Human Cells, Tissues, and Cellular and Tissue-Based Products Satellite Recovery Facility","C133321","A facility with Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) recovery as the primary operation and a parent establishment that has a registration number.","Human Cells, Tissues, and Cellular and Tissue-Based Products Satellite Recovery Facility | HCT/P Satellite Recovery Facility | Satellite recovery establishment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521219","Non-Hospital Based Cell or Tissue Processing Facility","C133323","A cell or tissue processing facility that is not located within a hospital.","Non-Hospital Based Cell or Tissue Processing Facility | Non-hospital based cell or tissue processing facility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521228","Organ and Tissue Procurement Facility","C133324","An organ procurement organization that also recovers tissues.","Organ and Tissue Procurement Facility | Organ and tissue procurement organization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520916","Plasmapheresis Center","C133325","A facility licensed by the FDA/CBER that collects source plasma or therapeutic exchange plasma for commercial distribution.","Plasmapheresis Center | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520440","Tissue Irradiation Facility","C133326","A facility that irradiates body tissue products.","Tissue Irradiation Facility | Irradiation facility only",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521341","Blood Product Bacterial Testing 24 Hours Prior to Transfusion","C133327","A qualitative immunoassay for the detection of aerobic and anaerobic gram-positive and gram-negative bacteria in leukocyte reduced apheresis platelets or pre-storage pools of up to six (6) leukocyte reduced whole blood derived platelets within 24 hours prior to transfusion.","Blood Product Bacterial Testing 24 Hours Prior to Transfusion | Bacterial Testing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520037","Hypopharyngeal Cancer pTX TNM Finding v8","C132927","Hypopharyngeal cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Hypopharyngeal Cancer pTX TNM Finding v8 | Hypopharyngeal Carcinoma pTX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520038","Hypopharyngeal Cancer pTis TNM Finding v8","C132928","Hypopharyngeal cancer with a finding of carcinoma in situ. (from AJCC 8th Ed.)","Hypopharyngeal Cancer pTis TNM Finding v8 | Hypopharyngeal Carcinoma pTis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520031","Hypopharyngeal Cancer pT1 TNM Finding v8","C132929","Hypopharyngeal cancer with tumor limited to one subsite of hypopharynx and/or 2 cm or smaller in greatest dimension. (from AJCC 8th Ed.)","Hypopharyngeal Cancer pT1 TNM Finding v8 | Hypopharyngeal Carcinoma pT1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520033","Hypopharyngeal Cancer pT3 TNM Finding v8","C132931","Hypopharyngeal cancer with tumor larger than 4 cm in greatest dimension or with fixation of hemilarynx or extension to esophagus. (from AJCC 8th Ed.)","Hypopharyngeal Cancer pT3 TNM Finding v8 | Hypopharyngeal Carcinoma pT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520034","Hypopharyngeal Cancer pT4 TNM Finding v8","C132932","Hypopharyngeal cancer with moderately advanced or very advanced local disease. (from AJCC 8th Ed.)","Hypopharyngeal Cancer pT4 TNM Finding v8 | Hypopharyngeal Carcinoma pT4 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520035","Hypopharyngeal Cancer pT4a TNM Finding v8","C132933","Hypopharyngeal cancer with moderately advanced local disease. Tumor invades thyroid/cricoid cartilage, hyoid bone, thyroid gland, or central compartment soft tissue. Central compartment soft tissue includes prelaryngeal strap muscles and subcutaneous fat.  (from AJCC 8th Ed.)","Hypopharyngeal Cancer pT4a TNM Finding v8 | Hypopharyngeal Carcinoma pT4a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521232","Oropharyngeal (p16-Negative) Cancer Pathologic Distant Metastasis TNM Finding v8","C132981","A pathologic finding about one or more characteristics of oropharyngeal (p16-negative) cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Oropharyngeal (p16-Negative) Cancer Pathologic Distant Metastasis TNM Finding v8 | Oropharyngeal (p16-Negative) Carcinoma Pathologic Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521112","Laryngeal Cancer pN2a TNM Finding v8","C133144","Laryngeal cancer with metastasis in a single ipsilateral or contralateral lymph node, 3 cm or less in greatest dimension and ENE(+); or metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Laryngeal Cancer pN2a TNM Finding v8 | Laryngeal Carcinoma pN2a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521113","Laryngeal Cancer pN2b TNM Finding v8","C133145","Laryngeal cancer with metastases in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Laryngeal Cancer pN2b TNM Finding v8 | Laryngeal Carcinoma pN2b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521114","Laryngeal Cancer pN2c TNM Finding v8","C133146","Laryngeal cancer with metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Laryngeal Cancer pN2c TNM Finding v8 | Laryngeal Carcinoma pN2c TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521115","Laryngeal Cancer pN3 TNM Finding v8","C133147","Laryngeal cancer with metastasis in a lymph node, more than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral lymph node, more than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+). (from AJCC 8th Ed.)","Laryngeal Cancer pN3 TNM Finding v8 | Laryngeal Carcinoma pN3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521116","Laryngeal Cancer pN3a TNM Finding v8","C133148","Laryngeal cancer with metastasis in a lymph node, more than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Laryngeal Cancer pN3a TNM Finding v8 | Laryngeal Carcinoma pN3a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521117","Laryngeal Cancer pN3b TNM Finding v8","C133149","Laryngeal cancer with metastasis in a single ipsilateral lymph node, more than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+). (from AJCC 8th Ed.)","Laryngeal Cancer pN3b TNM Finding v8 | Laryngeal Carcinoma pN3b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521089","Laryngeal Cancer Clinical Distant Metastasis TNM Finding v8","C133150","A clinical finding about one or more characteristics of laryngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Laryngeal Cancer Clinical Distant Metastasis TNM Finding v8 | Laryngeal Carcinoma Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521096","Laryngeal Cancer cM0 TNM Finding v8","C133151","Laryngeal cancer without evidence of distant metastasis. (from AJCC 8th Ed.)","Laryngeal Cancer cM0 TNM Finding v8 | Laryngeal Carcinoma cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521097","Laryngeal Cancer cM1 TNM Finding v8","C133152","Laryngeal cancer with distant metastasis. (from AJCC 8th Ed.)","Laryngeal Cancer cM1 TNM Finding v8 | Laryngeal Carcinoma cM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520848","Pathologic Stage I Esophageal Adenocarcinoma AJCC v8","C133414","Stage I includes: IA: (T1a, N0, M0, G1); (T1a, N0, M0, GX); IB: (T1a, N0, M0, G2); (T1b, N0, M0, G1-2); (T1b, N0, M0, GX); IC: (T1, N0, M0, G3); (T2, N0, M0, G1-2). T1a: Tumor invades the lamina propria or muscularis mucosae. T1b: Tumor invades the submucosa. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well-differentiated. GX: Grade cannot be assessed. G2: Moderately differentiated. G3: Poorly differentiated, undifferentiated. (AJCC 8th ed.)","Pathologic Stage I Esophageal Adenocarcinoma AJCC v8 | I | Stage I Esophageal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520860","Pathologic Stage II Esophageal Adenocarcinoma AJCC v8","C133418","Stage II includes: IIA: (T2, N0, M0, G3); (T2, N0, M0, GX); IIB: (T1, N1, M0, Any G); (T3, N0, M0, Any G). T2: Tumor invades the muscularis propria. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T3: Tumor invades adventitia. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. GX: Grade cannot be assessed. G3: Poorly differentiated, undifferentiated. (AJCC 8th ed.)","Pathologic Stage II Esophageal Adenocarcinoma AJCC v8 | II | Stage II Esophageal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282642","Helix-Turn-Helix Motif","C13341","A DNA binding domain comprised of two or more alpha helical amino acid sequences that are linked by short flexible chains of amino acids. The interactions between the helices determine the domain structure and its DNA binding specificity.","Helix-Turn-Helix Motif | HTH DNA Binding Domain | Helix-Turn-Helix",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521281","Stage II Hypopharyngeal Carcinoma AJCC v8","C133006","Stage II includes: T2, N0, M0. T2: Tumor invading more than one subsite of hypopharynx or an adjacent site, or measuring more than 2 cm but not more than 4 cm in greatest dimension without fixation of hemilarynx. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Hypopharyngeal Carcinoma AJCC v8 | Stage II Hypopharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520957","Stage III Hypopharyngeal Carcinoma AJCC v8","C133007","Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T3: Tumor larger than 4 cm in greatest dimension or with fixation of hemilarynx or extension to esophagus. T1: Tumor limited to one subsite of hypopharynx and/or 2 cm or smaller in greatest dimension. T2: Tumor invading more than one subsite of hypopharynx or an adjacent site, or measuring more than 2 cm but not more than 4 cm in greatest dimension without fixation of hemilarynx. N0: No regional lymph node metastasis. N1: Tumor with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (-). M0: No distant metastasis. (AJCC 8th ed.)","Stage III Hypopharyngeal Carcinoma AJCC v8 | Stage III Hypopharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519856","H3.3K27M-specific Peptide Vaccine","C132684","A vaccine composed of a peptide derived from histone H3.3 containing the amino acid substitution mutation lysine (Lys) 27-to-methionine (H3.3K27M), with potential immunoactivating and antineoplastic activities. Upon administration of the H3.3K27M-specific peptide vaccine, the immune system may exert a cytotoxic T-lymphocyte (CTL)-mediated immune response against H3.3K27M-expressing tumor cells. The H3.3K27M mutation alters the methylation and acetylation profile of the histone H3 variant H3.3 at Lys 27. Modification of H3.3 at Lys 27 regulates gene expression, and the H3.3K27M mutation occurs in a variety of cancer cell types.","H3.3K27M-specific Peptide Vaccine | H3.3K27M Peptide Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519824","Deuteporfin","C132685","A photosensitizing agent composed of four sub-porphyrin derivatives, methoxyethy-hydroxyethyl-dipropionic, di-methoxyethyl-dipropionic, hydroxyethy-vinyl-dipropionic and methoxyethy-vinyl-dipropionic, with potential photosensitizing activity upon photodynamic therapy (PDT) and potential diagnostic imaging activity. Upon intravenous administration, deuteporfin preferentially targets and accumulates in cancer cells, especially those in the lymphatic system. Following photoactivation with an appropriate wavelength, deuteporfin generates highly cytotoxic singlet oxygen species, and induces oxidative stress that results in the damage and death of cancer cells. In addition, deuteporfin could be used as a tracer in near-infrared (NIR) fluorescence lymph node mapping.","Deuteporfin | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3818757","Florbetaben (18F)","C132687","A stilbene derivative labeled with the positron-emitting isotope fluorine F 18, that may be used for positron emission tomography (PET) detection of beta-amyloid neuritic plaques and other amyloid protein deposits. Upon administration, F 18-florbetaben exhibits differential retention in regions that contain certain amyloid deposits. Differences in signal intensity between tissues showing specific and non-specific uptake of F 18-florbetaben allows for the detection of amyloid neuritic plaques in patients being evaluated for Alzheimer's disease, and potentially the detection of amyloid deposits in amyloidosis.","Florbetaben (18F) | 18F-BAY94-9172 | 18F-Florbetaben | 4-((1E)-2-(4-(2-(2-(2-((sup 18(f))fluoroethoxy)ethoxy)ethoxy)phenyl)eth-1-en-1-yl)-N-methylaniline | FLORBETABEN F-18 | Florbetaben 18F | Neuraceq",,,,,,,,,,,,,,,"37016650","Florbetaben (18-F)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL520727","Lip and Oral Cavity Cancer TNM Finding v8","C132688","A finding about one or more characteristics of lip and oral cavity cancer, following the rules of the TNM AJCC v8 classification system.  Cutaneous squamous cell carcinoma of the vermilion lip, nonepithelial tumors such as those of lymphoid tissue, soft tissue, bone, cartilage, and mucosal melanoma are not included in this classification. (from AJCC 8th Ed.)","Lip and Oral Cavity Cancer TNM Finding v8 | Lip and Oral Cavity Carcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520722","Lip and Oral Cavity Cancer Clinical TNM Finding v8","C132689","A clinical finding about one or more characteristics of lip and oral cavity cancer, following the rules of the TNM AJCC v8 classification system.  The assessment of the primary tumor is based on inspection and palpation of the oral cavity and neck.  Additional studies may include CT, MRI, or ultrasound.  (from AJCC 8th Ed.)","Lip and Oral Cavity Cancer Clinical TNM Finding v8 | Lip and Oral Cavity Carcinoma Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028623","Nucleosomes","C13268","A DNA packaging complex comprised of approximately 200 base pairs of DNA wound around a protein core, which is formed by an octomer of histones. The histone octomer includes two dimers of histones H2A and H2B that surround a tetramer consisting of two molecules of histone H3 and two molecules of histone H4.","Nucleosome | NUCLEOSOME",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520726","Lip and Oral Cavity Cancer Pathologic TNM Finding v8","C132690","A pathologic finding about one or more characteristics of lip and oral cavity cancer, following the rules of the TNM AJCC v8 classification system.  The pathologic staging is determined after the complete resection of the primary site and/or regional nodal dissection, followed by pathologic examination of the resected specimen(s).  (from AJCC 8th Ed.)","Lip and Oral Cavity Cancer Pathologic TNM Finding v8 | Lip and Oral Cavity Carcinoma Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520724","Lip and Oral Cavity Cancer Pathologic Primary Tumor TNM Finding v8","C132691","A pathologic finding about one or more characteristics of lip and oral cavity cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Lip and Oral Cavity Cancer Pathologic Primary Tumor TNM Finding v8 | Lip and Oral Cavity Carcinoma Pathologic Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520756","Lip and Oral Cavity Cancer pTX TNM Finding v8","C132692","Lip and oral cavity cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Lip and Oral Cavity Cancer pTX TNM Finding v8 | Lip and Oral Cavity Carcinoma pTX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520036","Hypopharyngeal Cancer pT4b TNM Finding v8","C132934","Hypopharyngeal cancer with very advanced local disease. Tumor invades prevertebral fascia, encases carotid artery, or involves mediastinal structures.  (from AJCC 8th Ed.)","Hypopharyngeal Cancer pT4b TNM Finding v8 | Hypopharyngeal Carcinoma pT4b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520001","Hypopharyngeal Cancer Clinical Regional Lymph Nodes TNM Finding v8","C132936","A clinical finding about one or more characteristics of hypopharyngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Hypopharyngeal Cancer Clinical Regional Lymph Nodes TNM Finding v8 | Hypopharyngeal Carcinoma Clinical Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520005","Hypopharyngeal Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C132938","A pathologic finding about one or more characteristics of hypopharyngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Hypopharyngeal Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | Hypopharyngeal Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0080206","TATA Box","C13293","A consensus sequence found in the promoter region of most genes transcribed by eukaryotic RNA polymerase II. It is found about 25 nucleotides before the site of initiation of transcription and has the consensus sequence: 5' TATAAAA 3'. This sequence seems to be important in determining accurately the position at which transcription is initiated.","TATA Box | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520019","Hypopharyngeal Cancer cNX TNM Finding v8","C132940","Hypopharyngeal cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Hypopharyngeal Cancer cNX TNM Finding v8 | Hypopharyngeal Carcinoma cNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521095","Laryngeal Cancer TNM Finding v8","C133096","A finding about one or more characteristics of laryngeal cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to the supraglottic, glottic, and subglottic laryngeal cancers. Nonepithelial cancers such as those of lymphoid tissue, soft tissue, bone, and cartilage are not included in this classification. (from AJCC 8th Ed.)","Laryngeal Cancer TNM Finding v8 | Laryngeal Carcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521091","Laryngeal Cancer Clinical TNM Finding v8","C133097","A clinical finding about one or more characteristics of laryngeal cancer, following the rules of the TNM AJCC v8 classification system.","Laryngeal Cancer Clinical TNM Finding v8 | Laryngeal Carcinoma Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521094","Laryngeal Cancer Pathologic TNM Finding v8","C133098","A pathologic finding about one or more characteristics of laryngeal cancer, following the rules of the TNM AJCC v8 classification system.","Laryngeal Cancer Pathologic TNM Finding v8 | Laryngeal Carcinoma Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520546","Supraglottic Cancer pTX TNM Finding v8","C133100","Supraglottic cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Supraglottic Cancer pTX TNM Finding v8 | Supraglottic Carcinoma pTX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520547","Supraglottic Cancer pTis TNM Finding v8","C133101","Supraglottic cancer with a finding of carcinoma in situ. (from AJCC 8th Ed.)","Supraglottic Cancer pTis TNM Finding v8 | Supraglottic Carcinoma pTis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521092","Laryngeal Cancer Pathologic Distant Metastasis TNM Finding v8","C133153","A pathologic finding about one or more characteristics of laryngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Laryngeal Cancer Pathologic Distant Metastasis TNM Finding v8 | Laryngeal Carcinoma Pathologic Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521108","Laryngeal Cancer pM1 TNM Finding v8","C133154","Laryngeal cancer with distant metastasis. (from AJCC 8th Ed.)","Laryngeal Cancer pM1 TNM Finding v8 | Laryngeal Carcinoma pM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521150","Stage I Laryngeal Cancer AJCC v8","C133158","Stage I includes: T1, N0, M0. T1: Supraglottis: Tumor is limited to one subsite of supraglottis with normal vocal cord mobility. Glottis: Tumor is limited to the vocal cord(s) (may involve anterior or posterior commissure) with normal mobility. Subglottis: Tumor is limited to the subglottis. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Laryngeal Cancer AJCC v8 | Stage I Laryngeal Carcinoma AJCC v8 | Stage I Laryngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520785","Major Salivary Gland Cancer cN3 TNM Finding v8","C132769","Major salivary gland cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in any node(s) with clinically overt ENE(+). (from AJCC 8th Ed.)","Major Salivary Gland Cancer cN3 TNM Finding v8 | Major Salivary Gland Carcinoma cN3 TNM Finding V8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520786","Major Salivary Gland Cancer cN3a TNM Finding v8","C132770","Major salivary gland cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Major Salivary Gland Cancer cN3a TNM Finding v8 | Major Salivary Gland Carcinoma cN3a TNM Finding V8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520787","Major Salivary Gland Cancer cN3b TNM Finding v8","C132771","Major salivary gland cancer with metastasis in any node(s) with clinically overt ENE(+). (from AJCC 8th Ed.)","Major Salivary Gland Cancer cN3b TNM Finding v8 | Major Salivary Gland Carcinoma cN3b TNM Finding V8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520769","Major Salivary Gland Cancer Clinical Distant Metastasis TNM Finding v8","C132772","A clinical finding about one or more characteristics of major salivary gland cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Major Salivary Gland Cancer Clinical Distant Metastasis TNM Finding v8 | Major Salivary Gland Carcinoma Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520779","Major Salivary Gland Cancer cM0 TNM Finding v8","C132773","Major salivary gland cancer without evidence of distant metastasis. (from AJCC 8th Ed.)","Major Salivary Gland Cancer cM0 TNM Finding v8 | Major Salivary Gland Carcinoma cM0 TNM Finding V8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520780","Major Salivary Gland Cancer cM1 TNM Finding v8","C132774","Major salivary gland cancer with distant metastasis. (from AJCC 8th Ed.)","Major Salivary Gland Cancer cM1 TNM Finding v8 | Major Salivary Gland Carcinoma cM1 TNM Finding V8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520772","Major Salivary Gland Cancer Pathologic Distant Metastasis TNM Finding v8","C132775","A pathologic finding about one or more characteristics of major salivary gland cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Major Salivary Gland Cancer Pathologic Distant Metastasis TNM Finding v8 | Major Salivary Gland Carcinoma Pathologic Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520788","Major Salivary Gland Cancer pM1 TNM Finding v8","C132776","Major salivary gland cancer with distant metastasis. (from AJCC 8th Ed.)","Major Salivary Gland Cancer pM1 TNM Finding v8 | Major Salivary Gland Carcinoma pM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0937843","Parnaparin Sodium","C132777","No value exists.","Parnaparin Sodium | PARNAPARIN SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520777","Major Salivary Gland Cancer by AJCC v7 Stage","C132778","A term that refers to the staging of major salivary gland cancer according to the American Joint Committee on Cancer, 7th edition.","Major Salivary Gland Cancer by AJCC v7 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520962","Stage IV Hypopharyngeal Carcinoma AJCC v8","C133008","Stage IV includes: IVA: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB: (Any T, N3, M0); (T4b, Any N, M0); IVC: (Any T, Any N, M1). T4a: Moderately advanced local disease. Tumor invades thyroid/cricoid cartilage, hyoid bone, thyroid gland, or central compartment soft tissue. Central compartment soft tissue includes prelaryngeal strap muscles and subcutaneous fat. T1: Tumor limited to one subsite of hypopharynx and/or 2 cm or smaller in greatest dimension. T2: Tumor invading more than one subsite of hypopharynx or an adjacent site, or measuring more than 2 cm but not more than 4 cm in greatest dimension without fixation of hemilarynx. T3: Tumor larger than 4 cm in greatest dimension or with fixation of hemilarynx or extension to esophagus. T4b: Very advanced local disease. Tumor invades prevertebral fascia, encases carotid artery, or involves mediastinal structures.  N0: No regional lymph node metastasis. N1: Tumor with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (-). N2: Tumor with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). N3: Tumor with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+). M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Hypopharyngeal Carcinoma AJCC v8 | Stage IV Hypopharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520965","Stage IVA Hypopharyngeal Carcinoma AJCC v8","C133009","Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0). T4a: Moderately advanced local disease. Tumor invades thyroid/cricoid cartilage, hyoid bone, thyroid gland, or central compartment soft tissue. Central compartment soft tissue includes prelaryngeal strap muscles and subcutaneous fat. T1: Tumor limited to one subsite of hypopharynx and/or 2 cm or smaller in greatest dimension. T2: Tumor invading more than one subsite of hypopharynx or an adjacent site, or measuring more than 2 cm but not more than 4 cm in greatest dimension without fixation of hemilarynx. T3: Tumor larger than 4 cm in greatest dimension or with fixation of hemilarynx or extension to esophagus. N0: No regional lymph node metastasis. N1: Tumor with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-). N2: Tumor with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). M0: No distant metastasis. (AJCC 8th ed.)","Stage IVA Hypopharyngeal Carcinoma AJCC v8 | Stage IVA Hypopharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520969","Stage IVB Hypopharyngeal Carcinoma AJCC v8","C133010","Stage IVB includes: (Any T, N3, M0); (T4b, Any N, M0). T4b: Very advanced local disease. Tumor invades prevertebral fascia, encases carotid artery, or involves mediastinal structures. N3: Tumor with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+). M0: No distant metastasis. (AJCC 8th ed.)","Stage IVB Hypopharyngeal Carcinoma AJCC v8 | Stage IVB Hypopharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520973","Stage IVC Hypopharyngeal Carcinoma AJCC v8","C133011","Stage IVC includes: Any T, Any N, M1. M1: distant metastasis. (AJCC 8th ed.)","Stage IVC Hypopharyngeal Carcinoma AJCC v8 | Stage IVC Hypopharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520757","Lip and Oral Cavity Cancer pTis TNM Finding v8","C132694","Lip and oral cavity cancer with a finding of carcinoma in situ. (from AJCC 8th Ed.)","Lip and Oral Cavity Cancer pTis TNM Finding v8 | Lip and Oral Cavity Carcinoma pTis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520911","Derived Placental Blood Cell","C133262","Cells collected from placental blood.","Derived Placental Blood Cell | Human Placental Blood Derived Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519969","Hospital Blood Bank","C133264","A hospital (or facility located within a hospital) that routinely collects or processes whole blood or blood components.","Hospital Blood Bank | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520567","Allogeneic Blood Product Donation","C133267","Blood or blood product donations intended for transfusion to other than the donor.","Allogeneic Blood Product Donation | Allogeneic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519819","Dedicated Blood Product Donation","C133269","Donations arranged by the collecting facility to support a specific recipient on a frequent basis.","Dedicated Blood Product Donation | Dedicated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230532","Metaphase Plate","C13326","The plane of the spindle approximately equidistant from the two poles along which the chromosomes are lined up during mitosis or meiosis.","Metaphase Plate | ",,,,,,,,,,,,,,,"4167677","Metaphase plate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL519823","Designated Blood Product Donation","C133270","Donations from a donor called by the collecting facility to provide products for a specific recipient in some future therapeutic procedure, e.g. specifically matched blood for patients with antibodies.","Designated Blood Product Donation | Designated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519825","Diagnostic Use Designated Blood Product","C133271","Whole blood, red blood cells, or platelets intended for diagnostic use.","Diagnostic Use Designated Blood Product | Blood Products for Diagnostic Use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521305","Directed Blood Product Donation","C133272","Donations from a donor who presents to the collecting facility at the request of another person intending to provide products to be used by that person during some future therapeutic procedure.","Directed Blood Product Donation | Directed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519854","Granulocytes Product","C133273","Granulocytes collected from a single donor and suspended in a specific volume of original plasma intended for patient infusion.","Granulocytes Product | Granulocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519998","Human Peripheral or Cord Blood Cell Product","C133274","Cells from human blood or umbilical cord blood for transplantation or infusion.","Human Peripheral or Cord Blood Cell Product | Human Peripheral And Cord Blood Cell Product",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520843","Melanoma Metastatic in the Central Nervous System","C133504","A melanoma that has spread to the central nervous system from its original site of growth, through the hematogenous route.","Metastatic Melanoma in the Central Nervous System | Melanoma Metastatic in the CNS | Melanoma Metastatic in the Central Nervous System | Melanoma Metastatic in the Central Nervous System | Metastatic Melanoma in the Central Nervous System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521314","Explosion","C133505","Problem with the device associated with the violent bursting due to the sudden expansion of air, gas or fluid.","Device Explosion | Explosion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520829","Material Too Soft or Flexible","C133507","Problem associated with the device material that results in the material's inability to maintain the desired shape or support function.","Material Too Soft or Flexible | Material Too Soft/Flexible",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520828","Material Split, Cut or Torn","C133509","Problem associated with materials comprising the device are split, cut or torn due to external forces (e.g. wrenching or laceration) or internal forces (e.g. exceeding the tensile stress limits belonging to the materials used in the device construction).","Material Split, Cut or Torn | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421270","Ubiquitin-Conjugating Enzyme Gene","C133708","Genes encoding enzymes that catalyze the second step in the ubiquitination reaction via the transfer of ubiquitin from E1 ubiquitin-activating enzymes to themselves.","Ubiquitin-Conjugating Enzyme Gene | E2 Ubiquitin-Conjugating Enzyme Gene | UBC | UBE2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520229","Recurrent Head and Neck Squamous Cell Carcinoma","C133709","The reemergence of squamous cell carcinoma in the head and neck region after a period of remission.","Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Cancer | Recurrent Squamous Cell Carcinoma of the Head and Neck",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0599780","Cis-Acting Sequence","C13370","Cis-acting locus is a section of DNA that affects the activity of DNA sequences on that same molecule of DNA.","Cis-Acting Sequence | Cis-Acting Locus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520266","Ubiquitin-Transferase Gene","C133710","Genes encoding enzymes that catalyze the third step in the ubiquitination reaction via the transfer of ubiquitin from E2 ubiquitin-conjugating enzymes to the final protein substrate.","Ubiquitin-Transferase Gene | E3 Ubiquitin-Transferase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0077670","ubiquitin carrier proteins","C133711","An aminoacyltransferase that catalyzes the second step in the ubiquitination reaction via the transfer of activated ubiquitin from an E1 ubiquitin-activating enzyme to itself via transthioesterification.","E2 Ubiquitin-Conjugating Enzyme | Ubiquitin Carrier Enzyme | Ubiquitin Carrier Protein | Ubiquitin-Conjugating Enzyme | Ubiquitin-Conjugating Enzyme E2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520759","Locally Advanced Paraganglioma","C133713","A paraganglioma that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Paraganglioma | Locally Advanced Malignant Paraganglioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0163974","E1 Ubiquitin-Activating Enzyme","C133714","A ligase that catalyzes the first step in the ubiquitination reaction via the ligation of the C-terminal lysine of ubiquitin to the E1 enzyme in an ATP-dependent reaction.","E1 Ubiquitin-Activating Enzyme | EC 6.2.1.45 | EC 6.3.2.19, Formerly | Ubiquitin-Activating Enzyme",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521285","YEATS Domain","C133715","A protein domain whose structure is comprised of an immunoglobulin-like fold that is found in various chromatin modification factors and may bind to modified lysines in other proteins.","YEATS Domain | YNK7, ENL, AF-9 and TFIIF Small Subunit Domain | Yaf9, ENL, AF9, Taf14, and Sas5 Homology Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520132","Nasal Cavity and Paranasal Sinuses Cancer TNM Finding v8","C133024","A finding about one or more characteristics of nasal cavity and paranasal sinuses cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to malignancies that arise in the epithelial lining of the nasal cavity and paranasal sinuses, with the exception of lymphoma and sarcoma. Mucosal melanoma of the nasal cavity and paranasal sinuses is staged according to the classification for mucosal melanoma of the head and neck. (from AJCC 8th Ed.)","Nasal Cavity and Paranasal Sinuses Cancer TNM Finding v8 | Nasal Cavity and Paranasal Sinuses Carcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520128","Nasal Cavity and Paranasal Sinuses Cancer Clinical TNM Finding v8","C133025","A clinical finding about one or more characteristics of nasal cavity and paranasal sinuses cancer, following the rules of the TNM AJCC v8 classification system.","Nasal Cavity and Paranasal Sinuses Cancer Clinical TNM Finding v8 | Nasal Cavity and Paranasal Sinuses Carcinoma Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520131","Nasal Cavity and Paranasal Sinuses Cancer Pathologic TNM Finding v8","C133026","A pathologic finding about one or more characteristics of nasal cavity and paranasal sinuses cancer, following the rules of the TNM AJCC v8 classification system.","Nasal Cavity and Paranasal Sinuses Cancer Pathologic TNM Finding v8 | Nasal Cavity and Paranasal Sinuses Carcinoma Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520811","Maxillary Sinus Cancer Pathologic Primary Tumor TNM Finding v8","C133027","A pathologic finding about one or more characteristics of maxillary sinus cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Maxillary Sinus Cancer Pathologic Primary Tumor TNM Finding v8 | Maxillary Sinus Carcinoma Pathologic Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520116","Nasal Cavity and Ethmoid Sinus Cancer Pathologic Primary Tumor TNM Finding v8","C133028","A pathologic finding about one or more characteristics of nasal cavity and ethmoid sinus cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Nasal Cavity and Ethmoid Sinus Cancer Pathologic Primary Tumor TNM Finding v8 | Nasal Cavity and Ethmoid Sinus Carcinoma Pathologic Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520130","Nasal Cavity and Paranasal Sinuses Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C133029","A pathologic finding about one or more characteristics of nasal cavity and paranasal sinuses cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Nasal Cavity and Paranasal Sinuses Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | Nasal Cavity and Paranasal Sinuses Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520127","Nasal Cavity and Paranasal Sinuses Cancer Clinical Regional Lymph Nodes TNM Finding v8","C133030","A clinical finding about one or more characteristics of nasal cavity and paranasal sinuses cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Nasal Cavity and Paranasal Sinuses Cancer Clinical Regional Lymph Nodes TNM Finding v8 | Nasal Cavity and Paranasal Sinuses Carcinoma Clinical Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520126","Nasal Cavity and Paranasal Sinuses Cancer Clinical Distant Metastasis TNM Finding v8","C133032","A clinical finding about one or more characteristics of nasal cavity and paranasal sinuses cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Nasal Cavity and Paranasal Sinuses Cancer Clinical Distant Metastasis TNM Finding v8 | Nasal Cavity and Paranasal Sinuses Carcinoma Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520818","Maxillary Sinus Cancer pTX TNM Finding v8","C133033","Maxillary sinus cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Maxillary Sinus Cancer pTX TNM Finding v8 | Maxillary Sinus Carcinoma pTX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520819","Maxillary Sinus Cancer pTis TNM Finding v8","C133034","Maxillary sinus cancer with a finding of carcinoma in situ. (from AJCC 8th Ed.)","Maxillary Sinus Cancer pTis TNM Finding v8 | Maxillary Sinus Carcinoma pTis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521857","Release and Stability Determination","C134031","For determination at release and on stability when test and acceptance criteria are the same in both cases.","Release and Stability Determination | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037791","Specificity","C134032","The ability to assess unequivocally the analyte in the presence of other components which may be expected to be present.","Analyte Specificity | Specificity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424905","WAC Gene","C134034","This gene is involved in chromatin remodeling and DNA damage responses.","WAC Gene | WAC | WW Domain Containing Adaptor With Coiled-Coil Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521859","WAC wt Allele","C134035","Human WAC wild-type allele is located in the vicinity of 10p12.1 and is approximately 91 kb in length. This allele, which encodes WW domain-containing adapter protein with coiled-coil, plays a role in both DNA damage responses and chromatin remodeling. Mutation of the gene is associated with Desanto-Shinawi syndrome.","WAC wt Allele | BM-016 | DESSH | FLJ31290 | KIAA1844 | MGC10753 | PRO1741 | WW Domain Containing Adaptor With Coiled-Coil wt Allele | WW Domain-Containing Adaptor With Coiled Coil Gene | Wwp4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521860","WW Domain-Containing Adapter Protein With Coiled-Coil","C134036","WW domain-containing adapter protein with coiled-coil (647 aa, ~71 kDa) is encoded by the human WAC gene. This protein is involved in chromatin modification.","WW Domain-Containing Adapter Protein With Coiled-Coil | WW Domain Containing Adaptor With Coiled-Coil | WW Domain-Containing Adapter With Coiled-Coil | WW Domain-Containing Adaptor With Coiled Coil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521861","Appendiceal Cancer TNM Finding v8","C134037","A finding about one or more characteristics of appendiceal cancer, following the rules of the TNM AJCC v8 classification system. Carcinomas and well-differentiated neuroendocrine tumors (carcinoids) are separately categorized. (from AJCC 8th Ed.)","Appendiceal Cancer TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520944","Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8","C133589","Stage IV includes: IVA: (T4a, N1-2, M0); (T4a, NX, M0); (T4b, N0-2, M0); (Any T, N3, M0); IVB: (Any T, Any N, M1). T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. NX: Regional lymph nodes cannot be assessed. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)","Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520947","Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8","C133590","Stage IVA includes: (T4a, N1-2, M0); (T4a, NX, M0); (T4b, N0-2, M0); (Any T, N3, M0). T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. NX: Regional lymph nodes cannot be assessed. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520950","Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8","C133591","Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520225","Recurrent Classic Hodgkin Lymphoma","C133592","The reemergence of classic Hodgkin lymphoma after a period of remission.","Recurrent Classic Hodgkin Lymphoma | Recurrent Classical Hodgkin Lymphoma | Relapsed Classical Hodgkin Lymphoma",,,,,,,,,,,,,,,"3654298","Relapsing classical Hodgkin lymphoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL520835","Program or Algorithm Execution Problem","C133593","Problem associated with execution problems relating to program or algorithm.","Program or Algorithm Execution Problem | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520554","Unintended Application Program Shut Down","C133594","Problem associated with an unintended shut down by malfunction of the application program.","Unintended Application Program Shut Down | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520668","Gastric Cancer Clinical TNM Finding v8","C133596","A clinical finding about one or more characteristics of gastric cancer, following the rules of the TNM AJCC v8 classification system.","Gastric Cancer Clinical TNM Finding v8 | Gastric Carcinoma Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520667","Gastric Cancer Clinical Distant Metastasis TNM Finding v8","C133597","A clinical finding about one or more characteristics of gastric cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Gastric Cancer Clinical Distant Metastasis TNM Finding v8 | Clinical Distant Metastasis Status (cM) | Gastric Carcinoma Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520379","Delayed Program or Algorithm Execution","C133599","Problem associated with a delayed execution relating to program or algorithm.","Delayed Program or Algorithm Execution | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521733","AKR1B1 wt Allele","C133810","Human AKR1B1 wild-type allele is located in the vicinity of 7q33 and is approximately 17 kb in length. This allele, which encodes aldose reductase protein, is involved in the metabolism of glucose, toxic aldehydes and steroids. This gene is associated with the development of diabetic complications.","AKR1B1 wt Allele | ADR | ALDR1 | ALR2 | AR | Aldo-Keto Reductase Family 1 Member B wt Allele | Aldo-Keto Reductase Family 1, Member B1 (Aldose Reductase) Gene | Aldo-Keto Reductase Family 1, Member B1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1436327","AKR1B1 protein, human","C133811","Aldose reductase (316 aa, ~36 kDa) is encoded by the human AKR1B1 gene. This protein plays a role in glucose metabolism.","Aldose Reductase | AKR1B1 | AR | Aldehyde Reductase | Aldehyde Reductase 1 | Aldo-Keto Reductase Family 1 Member B1 | EC 1.1.1.21 | Lii5-2 CTCL Tumor Antigen | Low Km Aldose Reductase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521910","Stage IIIB Appendix Carcinoma AJCC v8","C134127","Stage IIIB includes: (T3, N1, M0); (T4, N1, M0). T3: Tumor invades through the muscularis propria into the subserosa or the mesoappendix. T4: Tumor invades the visceral peritoneum, including the acellular mucin or mucinous epithelium involving the serosa of the appendix or mesoappendix, and/or directly invades adjacent organs or structures. N1: One to three regional lymph nodes are positive (tumor in lymph node measuring 0.2 mm or more) or any number of tumor deposits is present, and all identifiable lymph nodes are negative. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIB Appendix Carcinoma AJCC v8 | Stage IIIB Appendiceal Carcinoma AJCC v8 | Stage IIIB Appendix Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521911","Stage IIIC Appendix Carcinoma AJCC v8","C134128","Stage IIIC includes: Any T, N2, M0. N2: Four or more regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIC Appendix Carcinoma AJCC v8 | Stage IIIC Appendiceal Carcinoma AJCC v8 | Stage IIIC Appendix Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521912","Stage IV Appendix Carcinoma AJCC v8","C134129","Stage IV includes: IVA: (Any T, N0, M1a); (Any T, Any N, M1b, G1); IVB: (Any T, Any N, M1b, G2, G3, or GX); IVC: (Any T, Any N, M1c, Any G). N0: No regional lymph node metastasis. M1a: Intraperitoneal acellular mucin, without identifiable tumor cells in the disseminated peritoneal mucinous deposits. M1b: Intraperitoneal metastasis only, including peritoneal mucinous deposits containing tumor cells. M1c: Metastasis to sites other than peritoneum. G1: Well differentiated. G2: Moderately differentiated. G3: Poorly differentiated. GX: Grade cannot be assessed. (AJCC 8th ed.)","Stage IV Appendix Carcinoma AJCC v8 | Stage IV Appendiceal Carcinoma AJCC v8 | Stage IV Appendix Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519878","V3 Loop","C13412","Third hypervariable region (V3) of the gp120 HIV envelope protein.","V3 Loop | V3 Loop of HIV-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521913","Stage IVA Appendix Carcinoma AJCC v8","C134130","Stage IVA includes: (Any T, N0, M1a); (Any T, Any N, M1b, G1). N0: No regional lymph node metastasis. M1a: Intraperitoneal acellular mucin, without identifiable tumor cells in the disseminated peritoneal mucinous deposits. M1b: Intraperitoneal metastasis only, including peritoneal mucinous deposits containing tumor cells. G1: Well differentiated. (AJCC 8th ed.)","Stage IVA Appendix Carcinoma AJCC v8 | Stage IVA Appendiceal Carcinoma AJCC v8 | Stage IVA Appendix Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521914","Stage IVB Appendix Carcinoma AJCC v8","C134131","Stage IVB includes: Any T, Any N, M1b, G2, G3, or GX. M1b: Intraperitoneal metastasis only, including peritoneal mucinous deposits containing tumor cells. G2: Moderately differentiated. G3: Poorly differentiated. GX: Grade cannot be assessed.  (AJCC 8th ed.)","Stage IVB Appendix Carcinoma AJCC v8 | Stage IVB Appendiceal Carcinoma AJCC v8 | Stage IVB Appendix Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521915","Stage IVC Appendix Carcinoma AJCC v8","C134132","Stage IVC includes: Any T, Any N, M1c, Any G. M1c: Metastasis to sites other than peritoneum. (AJCC 8th ed.)","Stage IVC Appendix Carcinoma AJCC v8 | Stage IVC Appendiceal Carcinoma AJCC v8 | Stage IVC Appendix Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521917","Colorectal Cancer Clinical TNM Finding v8","C134134","A clinical finding about one or more characteristics of colorectal cancer, following the rules of the TNM AJCC v8 classification system.","Colorectal Cancer Clinical TNM Finding v8 | Colorectal Carcinoma Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028581","Nuclear Matrix","C13264","A network of fibrillar structures within cell nuclei that may play a role in chromatin organization and the localization of proteins within the nucleus.","Nuclear Matrix | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520599","Cervical Lymph Nodes and Unknown Primary Tumors TNM Finding v8","C132656","A finding about one or more characteristics of cervical lymph nodes and unknown primary tumors, following the rules of the TNM AJCC v8 classification system. It applies to squamous cell carcinoma and salivary gland carcinoma of all head and neck sites except HPV-related oropharynx cancer, nasopharynx cancer, melanoma, thyroid carcinoma, and sarcoma. Staging of the patient who presents with an occult primary tumor and EBV-unrelated and HPV-unrelated metastatic cervical lymphadenopathy is also included. (from AJCC 8th Ed.)","Cervical Lymph Nodes and Unknown Primary Tumors TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520273","Unknown Primary Tumor Clinical Cervical Lymph Nodes TNM Finding v8","C132657","A clinical finding about one or more characteristics of an unknown primary tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of cervical lymph nodes. It applies to patients who are treated with primary nonsurgical treatment without a cervical lymph node dissection. (from AJCC 8th Ed.)","Unknown Primary Tumor Clinical Cervical Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520275","Unknown Primary Tumor cN2 TNM Finding v8","C132658","Unknown primary tumor with metastasis in a single ipsilateral cervical lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE (extranodal extension)(-); or metastases in multiple ipsilateral cervical lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral cervical lymph nodes, none larger than 6 cm in greatest dimension, ENE(-). (from AJCC 8th Ed.)","Unknown Primary Tumor cN2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520276","Unknown Primary Tumor cN2a TNM Finding v8","C132659","Unknown primary tumor with metastasis in a single ipsilateral cervical lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","Unknown Primary Tumor cN2a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521862","Appendiceal Carcinoma TNM Finding v8","C134039","A finding about one or more characteristics of appendiceal carcinoma, following the rules of the TNM AJCC v8 classification system. This staging system applies to carcinomas of the appendix, including high-grade neuroendocrine carcinomas, mixed adenoneuroendocrine carcinomas, and goblet cell carcinoids. Well-differentiated neuroendocrine tumors (carcinoids) are staged according to the classification for neuroendocrine tumors of the appendix. (from AJCC 8th Ed.)","Appendiceal Carcinoma TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521863","Appendiceal Carcinoma Clinical TNM Finding v8","C134040","A clinical finding about one or more characteristics of appendiceal carcinoma, following the rules of the TNM AJCC v8 classification system.","Appendiceal Carcinoma Clinical TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521864","Appendiceal Carcinoma Clinical Distant Metastasis TNM Finding v8","C134041","A clinical finding about one or more characteristics of appendiceal carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Appendiceal Carcinoma Clinical Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521865","Appendiceal Carcinoma cM0 TNM Finding v8","C134042","Appendiceal carcinoma without evidence of distant metastasis. (from AJCC 8th Ed.)","Appendiceal Carcinoma cM0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521866","Appendiceal Carcinoma cM1 TNM Finding v8","C134043","Appendiceal carcinoma with distant metastasis. (from AJCC 8th Ed.)","Appendiceal Carcinoma cM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521867","Appendiceal Carcinoma cM1a TNM Finding v8","C134044","Appendiceal carcinoma with intraperitoneal acellular mucin, without identifiable tumor cells in the disseminated peritoneal mucinous deposits. (from AJCC 8th Ed.)","Appendiceal Carcinoma cM1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521868","Appendiceal Carcinoma cM1b TNM Finding v8","C134045","Appendiceal carcinoma with intraperitoneal metastasis only, including peritoneal mucinous deposits containing tumor cells. (from AJCC 8th Ed.)","Appendiceal Carcinoma cM1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521869","Appendiceal Carcinoma cM1c TNM Finding v8","C134046","Appendiceal carcinoma with metastasis to sites other than peritoneum. (from AJCC 8th Ed.)","Appendiceal Carcinoma cM1c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521870","Appendiceal Carcinoma Pathologic TNM Finding v8","C134047","A pathologic finding about one or more characteristics of appendiceal carcinoma, following the rules of the TNM AJCC v8 classification system.","Appendiceal Carcinoma Pathologic TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521871","Appendiceal Carcinoma Pathologic Distant Metastasis TNM Finding v8","C134048","A pathologic finding about one or more characteristics of appendiceal carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Appendiceal Carcinoma Pathologic Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4044757","TAS-116","C134448","A specific inhibitor of heat shock protein 90 (Hsp90) subtypes alpha and beta, with potential antineoplastic and chemo/radiosensitizing activities. Upon oral administration, pimitespib specifically binds to and inhibits the activity of Hsp90 alpha and beta; this results in the proteasomal degradation of oncogenic client proteins, which inhibits client protein dependent-signaling, induces apoptosis, and inhibits the proliferation of cells overexpressing HSP90alpha/beta. Hsp90, a family of molecular chaperone proteins that are upregulated in a variety of tumor cells, plays a key role in the conformational maturation, stability, and function of 'client' proteins within the cell,; many of which are involved in signal transduction, cell cycle regulation and apoptosis, including kinases, cell-cycle regulators, transcription factors and hormone receptors. As TAS-116 selectively inhibits cytosolic HSP90alpha and beta only and does not inhibit HSP90 paralogs, such as endoplasmic reticulum GRP94 or mitochondrial TRAP1, this agent may have less off-target toxicity as compared to non-selective HSP90 inhibitors.","Pimitespib | 3-Ethyl-4-(3-(1-methylethyl)-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo(3,4-b)pyridin-1-yl)benzamide | HSP90alpha/beta Inhibitor TAS-116 | Heat Shock Protein 90 alpha/beta Inhibitor TAS-116 | PIMITESPIB | TAS 116 | TAS-116 | TAS116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2979928","Bone and Cartilage Funding","C13444","Research dollars spent on bone or cartilage research.","Bone and Cartilage Funding | Bone and Cartilage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520672","Gastric Cancer Pathologic TNM Finding v8","C133601","A pathologic finding about one or more characteristics of gastric cancer, following the rules of the TNM AJCC v8 classification system.","Gastric Cancer Pathologic TNM Finding v8 | Gastric Carcinoma Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0874063","Cevimeline Hydrochloride","C1337","A cholinergic analogue with glandular secretion stimulatory activity. Cevimeline binds to and activates muscarinic receptors, thereby increasing the secretions in exocrine salivary and sweat glands. This cholinergic agonist also increases the tone of smooth muscle in the gastrointestinal and urinary tracts. Cevimeline is being studied as a treatment for dry mouth caused by radiation therapy to the head and neck.","Cevimeline Hydrochloride | AF-102B | CEVIMELINE HYDROCHLORIDE | Evoxac | cevimeline hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521725","Stage III Anal Cancer AJCC v8","C133800","Stage III includes: IIIA: (T1, N1, M0); (T2, N1, M0); IIIB: (T4, N0, M0); IIIC: (T3, N1, M0); (T4, N1, M0). T1: Tumor 2 cm or smaller. T2: Tumor larger than 2 cm but equal to or smaller than 5 cm. T3: Tumor larger than 5 cm. T4: Tumor of any size invading adjacent organ(s), such as the vagina, urethra, or bladder. N0: No regional lymph node metastasis. N1: Metastasis in inguinal, mesorectal, internal iliac, or external iliac nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Anal Cancer AJCC v8 | Stage III Anal Canal and Perianal (Anal Margin) Carcinoma AJCC v8 | Stage III Anal Cancer | Stage III Anal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537791","FDA Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Terminology","C133805","A category of terminology used to qualify the information pertaining to Pharmaceutical Quality/Chemistry, Manufacturing and Controls.","FDA Pharmaceutical Quality/CMC Terminology | FDA Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Terminology | PQ/CMC Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537790","Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Test Category Terminology","C133807","A category of terminology used to qualify the information pertaining to test categories in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.","PQ/CMC Test Category Terminology | Pharmaceutical Quality/CMC Test Category Terminology | Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Test Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412322","AKR1B1 Gene","C133809","This gene plays a role in the NADPH-dependent metabolism of aldehydes.","AKR1B1 Gene | AKR1B1 | Aldo-Keto Reductase Family 1 Member B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825939","MAGI3 Gene","C134139","This gene plays a role in protein-protein interactions that regulate signaling.","MAGI3 Gene | MAGI3 | Membrane Associated Guanylate Kinase, WW and PDZ Domain Containing 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522088","PPP2R2A wt Allele","C134507","Human PPP2R2A wild-type allele is located in the vicinity of 8p21.2 and is approximately 81 kb in length. This allele, which encodes serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform protein, plays a role in the regulation of protein phosphatase 2 activity.","PPP2R2A wt Allele | B55-Alpha Gene | B55A | B55ALPHA | PR52A | PR55-Alpha Gene | PR55A | PR55alpha | Protein Phosphatase 2 (Formerly 2A), Regulatory Subunit B (PR 52), Alpha Isoform Gene | Protein Phosphatase 2 Regulatory Subunit Balpha wt Allele | Protein Phosphatase 2, Regulatory Subunit B, Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522089","Serine/Threonine-Protein Phosphatase 2A 55 kDa Regulatory Subunit B Alpha Isoform","C134508","Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform (447 aa, ~52 kDa) is encoded by the human PPP2R2A gene. This protein is involved in the modulation of protein phosphatase 2 activity.","Serine/Threonine-Protein Phosphatase 2A 55 kDa Regulatory Subunit B Alpha Isoform | PP2A Subunit B Isoform Alpha | PP2A Subunit B Isoform B55-Alpha | PP2A Subunit B Isoform PR55-Alpha | PP2A Subunit B Isoform R2-Alpha | PPP2R2A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4045761","17beta-Hydroxysteroid Dehydrogenase Type 5 Inhibitor ASP9521","C133224","A selective, orally bioavailable inhibitor of 17beta-hydroxysteroid dehydrogenase type 5 (17bHSD5, aldo-keto reductase 1C3; AKR1C3), with potential antineoplastic activity. Upon administration, ASP9521 selectively binds to and inhibits the activity of 17bHSD5. This prevents the conversion of the adrenal androgens dehydroepiandrosterone and androstenedione into 5-androstenediol and testosterone. By blocking testosterone production, ASP9521 may inhibit the growth of testosterone-dependent cancers such as castration-resistant prostate cancer (CRPC). 17bHSD5, expressed both in normal prostate tissue and in prostate cancer (PC), plays a crucial role in persistent production of androgens despite castration; its expression is associated with increased malignancy of PC.","17beta-Hydroxysteroid Dehydrogenase Type 5 Inhibitor ASP9521 | (4-(2-Hydroxy-2-methylpropyl)piperidin-1-yl)(5-methoxy-1H-indol-2-yl)methanone | 17bHSD5 Inhibitor ASP9521 | ASP 9521 | ASP-9521 | ASP9521",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433839","mTOR Inhibitor GDC-0349","C133227","An orally bioavailable, ATP-competitive, tetrahydroquinazoline (THQ)-based inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. Upon administration, GDC-0349 selectively binds to and inhibits the activity of mTOR, which may result in both the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase belonging to the phosphatidylinositol-3 (PI3K) kinase-related kinase (PIKK) family, plays an important role in the PI3K/Akt/mTOR signaling pathway that regulates cell growth and proliferation, and its expression or activity is frequently dysregulated in human cancers.","mTOR Inhibitor GDC-0349 | (S)-1-ethyl-3-(4-(4-(3-methylmorpholino)-7-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)phenyl)urea | GDC 0349 | GDC-0349 | GDC0349 | RG7603",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0292832","exendin (9-39)","C133230","A truncated form of the glucagon-like peptide 1 receptor (GLP-1R) agonist exendin-4 peptide, with GLP-1 receptor (GLP-1R) antagonistic and GLP-1R-mediated signaling inhibiting activities. Upon administration, avexitide competitively binds to and inhibits the activity of GLP-1R, thereby inhibiting GLP-1/GLP-1R-mediated signaling. This antagonizes the glucagonostatic and the insulinotropic effects of GLP-1. By abrogating GLP-1-mediated simulation of insulin release and reduction of glucagon secretion after food intake, exendin 9-39 may be used to help study the potential effects of overproduction of GLP-1 on food intake, weight loss and glucose levels. GLP-1R, located on pancreatic beta cells, is overexpressed on certain tumor cell types. GLP-1 is a gastrointestinal (GI) and insulinotropic hormone that is released after a meal and plays a key role in the regulation of blood glucose levels.","Avexitide | 9-39-Exendin 4 | AVEXITIDE | Ex(9-39)NH2 | Exendin (9-39) | Exendin 3, 1-de-L-histidine-2-de-L-serine-3-de-L-aspartic acid-4-deglycine-5-de-L-threonine-6-de-L-phenylalanine-7-de-L-threonine-8-de-L-serine- | Exendin(9-39)amide | LYS-ASN-GIY-GIY-PRO-SER-SER-GIY-ALA-PRO-PRO-PRO-SER-NH2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522041","Hepatobiliary System Cancer TNM Finding v8","C134455","A finding about one or more characteristics of hepatobiliary system cancer, following the rules of the TNM AJCC v8 classification system. (from AJCC 8th Ed.)","Hepatobiliary System Cancer TNM Finding v8 | Hepatobiliary System Carcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522045","Hepatocellular Carcinoma Clinical TNM Finding v8","C134459","A clinical finding about one or more characteristics of hepatocellular carcinoma, following the rules of the TNM AJCC v8 classification system.","Hepatocellular Carcinoma Clinical TNM Finding v8 | Liver Cell Carcinoma Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520427","Inappropriate Tactile Prompt/Feedback","C133551","Problem with tactile feedback which does not guide a device user to the correct action.","Inappropriate Tactile Prompt/Feedback | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520612","Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8","C133552","Stage I includes: T1, N0, M0. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520617","Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8","C133553","Stage II includes: IIA: T1, N1, M0; IIB: T2, N0, M0. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520621","Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8","C133554","Stage IIA includes: T1, N1, M0. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520939","Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8","C133458","Stage IIIB includes: (T3, N1, M0); (T0-3, N2, M0); (T4a, N0, M0). T0: No evidence of primary tumor. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8 | Stage IIIB Esophageal Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520942","Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8","C133459","Stage IV includes: IVA: (T4a, N1-2, M0); (T4a, NX, M0); (T4b, N0-2, M0); (Any T, N3, M0); IVB: (Any T, Any N, M1). T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. NX: Regional lymph nodes cannot be assessed. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)","Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8 | Stage IV Esophageal Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520949","Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8","C133461","Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8 | Stage IVB Esophageal Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515556","bHLH Domain","C13450","The bHLH domain is a bipartite DNA-binding domain containing a basic region upstream of an amphipathic helix-loop-helix region. The basic region interacts with DNA and the HLH motif mediates protein dimerization.","bHLH Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520669","Gastric Cancer Pathologic Distant Metastasis TNM Finding v8","C133602","A pathologic finding about one or more characteristics of gastric cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Gastric Cancer Pathologic Distant Metastasis TNM Finding v8 | Gastric Carcinoma Pathologic Distant Metastasis TNM Finding v8 | Pathologic Distant Metastasis Status (pM)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520434","Intermittent Program or Algorithm Execution","C133603","Problem associated with intermittent execution relating to program or algorithm.","Intermittent Program or Algorithm Execution | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520670","Gastric Cancer Pathologic Primary Tumor TNM Finding v8","C133605","A pathologic finding about one or more characteristics of gastric cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Gastric Cancer Pathologic Primary Tumor TNM Finding v8 | Gastric Carcinoma Pathologic Primary Tumor TNM Finding v8 | Pathologic Primary Tumor Status (pT)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521141","Small Intestinal Cancer by AJCC v7 Stage","C133716","A term that refers to the staging of small intestinal cancer according to the American Joint Committee on Cancer, 7th edition.","Small Intestinal Cancer by AJCC v7 Stage | Small Intestinal Carcinoma by AJCC v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519696","Boron-dipyrromethene-modified Olaparib Fluorescent Imaging Agent","C133717","A poly (ADP-ribose) polymerase type 1 (PARP1) fluorescence imaging agent based on the PARP1 inhibitor olaparib, in which the cyclopropane group of olaparib is replaced by the green fluorescent dye boron-dipyrromethene (BODIPY) fluorophore (FL), with potential fluorescent imaging activity. Upon administration of the fluorescent PARP1 inhibitor PARPi-FL, the olaparib binding moiety specifically targets and binds to PARP1, which is often overexpressed on cancer cells. Upon fluorescent imaging, the PARP1-expressing cancer cells can be visualized. PARP1, the nuclear enzyme that catalyzes post-translational ADP-ribosylation of nuclear proteins, is activated by single-strand (SS) DNA breaks and overexpressed in certain tumor cells; it plays a key role in DNA repair, tumor cell resistance and survival.","Boron-dipyrromethene-modified Olaparib Fluorescent Imaging Agent | ABY-029 | AZD2281-BODIPY FL | BODIPY-modified Olaparib Fluorescent Imaging Agent | Boron, (4-((3-((4-(3-(5-((3,5-dimethyl-2H-pyrrol-2-ylidene-kappaN)methyl)-1H-pyrrol-2-yl-kappaN)-1-oxopropyl)-1-piperazinyl)carbonyl)-4-fluorophenyl)methyl)-1(2H)-phthalazinonato)difluoro-, (T-4)- | Fluorescent PARP1 Inhibitor PARPi-FL | Fluorescent PARPi Binding Imaging Agent PARPi-FL | OLAPARIB-BODIPY FL | Olaparib-BODIPY FL | PARPi-FL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521816","Raw Materials/Excipients/Intermediates/Reagents Specification","C133931","The specification which is applied to the raw materials, excipients, intermediates or reagents.","Raw Materials/Excipients/Intermediates/Reagents Specification | Raw Materials/Excipients/Intermediates/Reagents",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521817","Temperature 5 (+/-) 3 Degrees C","C133935","Storage at 5 degrees C (+/-) 3 degrees C.","Temperature 5 (+/-) 3 Degrees C | 5 +/- 3 degrees C | 5 Degrees C (+/-) 3 Degrees C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521818","Temperature -20 (+/-) 5 Degrees C","C133936","Storage at -20 degrees C (+/-) 5 degrees C.","Temperature -20 (+/-) 5 Degrees C | -20 +/- 5 degrees C | -20 Degrees C (+/-) 5 Degrees C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521819","Temperature 40 (+/-) 2 Degrees C and Relative Humidity Not More Than 25%","C133940","Storage at 40 degrees C (+/-) 2 degrees C and Relative Humidity not more than 25%.","Temperature 40 (+/-) 2 Degrees C and Relative Humidity Not More Than 25% | 40 Degrees C (+/-) 2 Degrees C and Relative Humidity Not More Than 25% | 40 degrees C +/- 2 degrees C/not more than (NMT) 25%RH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521820","Deliverable Volume/Fill Volume","C133961","Tests designed to provide assurance that the liquids will, when transferred from the original container, deliver the volume of dosage form that is declared on the label of the article.","Deliverable Volume/Fill Volume Test | Deliverable Volume/Fill Volume | Deliverable Volume/Fill Volume",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521821","Heavy Metals/Elemental Impurities Analysis","C133964","Analytical procedures that determine the amount of elemental impurities in drug products or drug product components.","Heavy Metals/Elemental Impurities Analysis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0879438","Allogeneic Lymphocyte","C13396","A cell that is antigenically distinct from other lymphocytes.","Allogeneic Lymphocyte | Lymphocytes, Allogeneic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521822","Crystallinity","C133974","The detection and quantification of the amount of amorphous material within a highly crystalline substance.","Crystallinity Analysis | Crystallinity | Crystallinity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521823","Viscosity/Rheological Properties","C133979","The determination of the thickness of a fluid and other properties related to the flow of a material.","Viscosity/Rheological Property Analysis | Viscosity/Rheological Properties | Viscosity/Rheological Properties",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520624","Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8","C133555","Stage IIB includes: T2, N0, M0. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520628","Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8","C133556","Stage III includes: (T2, N1, M0); (T3, N0-1, M0); (T4a, N0-1, M0). T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520633","Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8","C133557","Stage IV includes: IVA: (T1-4a, N2, M0); (T4b, N0-2, M0); (Any T, N3, M0); IVB: (Any T, Any N, M1). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)","Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520833","No Tactile Prompts/Feedback","C133559","Problem associated with the device ceasing to provide tactile feedback.","No Tactile Prompts/Feedback | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520642","Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8","C133560","Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520432","Intermittent Energy Output","C133561","Problem associated with the energy output from the device being inconsistent over time.","Intermittent Energy Output | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520838","Radiation Output Problem","C133562","Problem with the device's intended output of radiation.","Radiation Output Problem | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520700","Gastroesophageal Junction Adenocarcinoma by AJCC v8 Pathologic Stage","C133563","A term that refers to the pathologic staging of gastroesophageal junction adenocarcinoma according to the American Joint Committee on Cancer, 8th edition.","Gastroesophageal Junction Adenocarcinoma by AJCC v8 Pathologic Stage | Gastroesophageal Junction Adenocarcinoma by AJCC v8 pTNM Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520847","Pathologic Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8","C133564","Stage 0 includes: Tis, N0, M0, GN/A. Tis: High-grade dysplasia, defined as malignant cells confined to the epithelium by the basement membrane. N0: No regional lymph node metastasis. M0: No distant metastasis. GN/A: Grade non-applicable. (AJCC 8th ed.)","Pathologic Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521690","Lower Gastrointestinal Tract Cancer TNM Finding v8","C133761","A finding about one or more characteristics of lower gastrointestinal tract cancer, following the rules of the TNM AJCC v8 classification system.","Lower Gastrointestinal Tract Cancer TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0598306","Homeo Domain","C13367","The DNA-binding homeo domain was originally identified in transcription factor proteins encoded by homeobox genes (homeotic genes).  The homeo domain is structurally similar to the helix-turn-helix DNA-binding domain of CRO and Lambda repressor.","Homeo Domain | Homeo Box | Homeobox | Homeodomain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521784","Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Specification Type Terminology","C133864","A category of terminology used to qualify the information pertaining to specification types in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.","PQ/CMC Specification Type Terminology | Pharmaceutical Quality/CMC Specification Type Terminology | Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Specification Type Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521785","Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Storage Conditions Terminology","C133865","A category of terminology used to qualify the information pertaining to storage conditions in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.","PQ/CMC Storage Conditions Terminology | Pharmaceutical Quality/CMC Storage Conditions Terminology | Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Storage Conditions Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520671","Gastric Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C133617","A pathologic finding about one or more characteristics of gastric cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Gastric Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | Gastric Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8 | Pathologic Regional Lymph Node Status (pN)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0919262","B-DNA","C13397","A duplex of DNA is formed by two complementary chains that are arranged in an anti-parallel manner. B-DNA is about 20 Angstrom in diameter and a right-handed double helix with a wide major groove easily accessible to proteins and narrow minor groove. B-DNA is the most common DNA conformation in vivo and the favored conformation at high water concentrations. Base pairs are nearly perpendicular to the helix axis and sugar pucker is C2'-endo.","B-DNA | B-Form DNA | Right-Handed DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521825","Redispersibility","C133985","A measurement of the time necessary for settled components to remix uniformly.","Redispersibility Measurement | Redispersibility | Redispersibility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516820","Embryonic Fluid","C13398","Fluids surrounding or related to an embryo.","Embryonic Fluid | Embryonic Fluids | Embryonic Tissue, Fluids, Secretions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521826","Commercial Batch","C133990","A product batch intended for marketing.","Commercial Batch | Commercial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523827","Development Batch","C133991","A batch produced during the characterization and process definition for the desired product.","Development Batch | Development",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521827","Validation Batch","C133993","A batch intended for use in verification and demonstration of suitability of the designed process.","Validation Batch | Validation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521828","Bioequivalence Batch","C133994","A batch produced and used for the purposes of determining bioequivalence of the product.","Bioequivalence Batch | Bioequivalence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522021","Stage IIB Rectal Cancer AJCC v8","C134295","Stage IIB includes: T4a, N0, M0. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIB Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522022","Stage IIC Rectal Cancer AJCC v8","C134296","Stage IIC includes: T4b, N0, M0. T4b: Tumor directly invades or adheres to adjacent organs or structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIC Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522024","Stage IIIA Rectal Cancer AJCC v8","C134298","Stage IIIA includes: (T1-T2, N1/N1c, M0); (T1, N2a, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N1c: No regional lymph nodes are positive, but there are tumor deposits in the subserosa, mesentery, or nonperitonealized pericolic, or perirectal/mesorectal tissues. N2a: Four to six regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIA Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521692","Anal Cancer Clinical TNM Finding v8","C133763","A clinical finding about one or more characteristics of anal cancer, following the rules of the TNM AJCC v8 classification system.","Anal Cancer Clinical TNM Finding v8 | Anal Canal and Perianal (Anal Margin) Carcinoma Clinical TNM Finding v8 | Anal Carcinoma Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521693","Anal Cancer Clinical Distant Metastasis TNM Finding v8","C133764","A clinical finding about one or more characteristics of anal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Anal Cancer Clinical Distant Metastasis TNM Finding v8 | Anal Canal and Perianal (Anal Margin) Carcinoma Clinical Distant Metastasis TNM Finding v8 | Anal Carcinoma Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521696","Anal Cancer Pathologic TNM Finding v8","C133767","A pathologic finding about one or more characteristics of anal cancer, following the rules of the TNM AJCC v8 classification system.","Anal Cancer Pathologic TNM Finding v8 | Anal Canal and Perianal (Anal Margin) Carcinoma Pathologic TNM Finding v8 | Anal Carcinoma Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521697","Anal Cancer Pathologic Distant Metastasis TNM Finding v8","C133768","A pathologic finding about one or more characteristics of anal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Anal Cancer Pathologic Distant Metastasis TNM Finding v8 | Anal Canal and Perianal (Anal Margin) Carcinoma Pathologic Distant Metastasis TNM Finding v8 | Anal Carcinoma Pathologic Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521699","Anal Cancer Pathologic Primary Tumor TNM Finding v8","C133770","A pathologic finding about one or more characteristics of anal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Anal Cancer Pathologic Primary Tumor TNM Finding v8 | Anal Canal and Perianal (Anal Margin) Carcinoma Pathologic Primary Tumor TNM Finding v8 | Anal Carcinoma Pathologic Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521872","Appendiceal Carcinoma pM1 TNM Finding v8","C134049","Appendiceal carcinoma with distant metastasis. (from AJCC 8th Ed.)","Appendiceal Carcinoma pM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521786","Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Study Type Terminology","C133866","A category of terminology used to qualify the information pertaining to study types in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.","PQ/CMC Study Type Terminology | Pharmaceutical Quality/CMC Study Type Terminology | Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Study Type Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521787","Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Test Method Origin Terminology","C133867","A category of terminology used to qualify the information pertaining to test method origins in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.","PQ/CMC Test Method Origin Terminology | Pharmaceutical Quality/CMC Test Method Origin Terminology | Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Test Method Origin Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521788","Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Test Usage Terminology","C133868","A category of terminology used to qualify the information pertaining to test usage in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.","PQ/CMC Test Usage Terminology | Pharmaceutical Quality/CMC Test Usage Terminology | Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Test Usage Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521789","Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Testing Site Unique Identifier Terminology","C133869","A category of terminology used to qualify the information pertaining to testing site unique identifiers in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.","PQ/CMC Testing Site Unique Identifier Type Terminology | Pharmaceutical Quality/CMC Testing Site Unique Identifier Type Terminology | Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Testing Site Unique Identifier Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796363","Chromosome 7q31","C13386","A chromosome band present on 7q","7q31 | Chromosome 7q31",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523823","Pituitary-Specific Positive Transcription Factor 1","C133871","Pituitary-specific positive transcription factor 1 (291 aa, ~33 kDa) is encoded by the human POU1F1 gene. This protein is involved in both the development and function of the pituitary gland.","Pituitary-Specific Positive Transcription Factor 1 | GHF-1 | Growth Hormone Factor 1 | POU Domain, Class 1, Transcription Factor 1 | POU1F1 | Pit-1 | Pituitary-Specific Transcription Factor 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521792","Small Intestine Cancer pNX TNM Finding v8","C133873","Small intestine cancer in which the regional lymph node(s) cannot be assessed.  (from AJCC 8th Ed.)","Small Intestine Cancer pNX TNM Finding v8 | Small Intestine Carcinoma pNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521793","Small Intestine Cancer pN0 TNM Finding v8","C133874","Small intestine cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","Small Intestine Cancer pN0 TNM Finding v8 | Small Intestine Carcinoma pN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521794","Small Intestine Cancer pN1 TNM Finding v8","C133875","Small intestine cancer with metastasis in one or two regional lymph nodes. (from AJCC 8th Ed.)","Small Intestine Cancer pN1 TNM Finding v8 | Small Intestine Carcinoma pN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521795","Small Intestine Cancer pN2 TNM Finding v8","C133876","Small intestine cancer with metastasis in three or more regional lymph nodes. (from AJCC 8th Ed.)","Small Intestine Cancer pN2 TNM Finding v8 | Small Intestine Carcinoma pN2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521796","Anti-CD40 Monoclonal Antibody","C133877","Any monoclonal antibody directed against the antigen cluster of differentiation 40 (CD40).","Anti-CD40 Monoclonal Antibody | Anti-CD40 MoAb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521797","Anti-EGFR Monoclonal Antibody","C133878","Any monoclonal antibody directed against epidermal growth factor receptor (EGFR).","Anti-EGFR Monoclonal Antibody | Anti-EGFR MoAb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521985","Impurities/Degradation Products/Related Substances Assessment","C134254","Analytical procedures that determine the presence of a component of the material that is not the chemical entity defined as the material.","Impurities/Degradation Products/Related Substances Test | Impurities/Degradation Products/Related Substances | Impurities/Degradation Products/Related Substances Assessment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521740","Anti-AG7 Antibody Drug Conjugate AbGn-107","C133818","An antibody drug conjugate (ADC) composed of a monoclonal antibody that targets the tumor-associated antigen (TAA) AG7 and is linked, through a hydrophilic, self-immolative linker, to a proprietary cytotoxic payload, with potential antineoplastic activity. Upon administration of AbGn-107 the antibody moiety targets and binds to the AG7 antigen expressed on a variety of cancer cells. Upon binding and internalization, the linker is cleaved and the payload is released, binds to tubulin, inhibits tubulin polymerization and kills the AG7-expressing tumor cells.","Anti-AG7 Antibody Drug Conjugate AbGn-107 | ADC AbGn-107 | Ab1-18Hr1 | AbGn-107 | AbGn107 | Anti-AG7 ADC AbGn-107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521741","EED Inhibitor MAK683","C133819","An inhibitor of embryonic ectoderm development protein (EED) and allosteric inhibitor of polycomb repressive complex 2 (PRC2), with potential antineoplastic activity. Upon administration, MAK683 selectively binds to the domain of EED that interacts with trimethylated lysine 27 on histone 3 (H3K27me3), which leads to a conformational change in the EED H3K27me3-binding pocket and prevents the interaction of EED with the histone methyltransferase enhancer zeste homolog 2 (EZH2). Disruption of the EED-EZH2 protein-protein interaction (PPI) results in a loss of H3K27me3-stimulated PRC2 activity and prevents H3K27 trimethylation. This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased tumor cell proliferation in EZH2-mutated and PRC2-dependent cancer cells. PRC2, a histone H3 lysine 27 methyltransferase and multi-protein complex comprised of EZH2, EED and suppressor of zeste 12 (SUZ12), plays a key role in gene regulation, especially during embryonic development. EZH2, the catalytic subunit of PRC2, is overexpressed or mutated in a variety of cancer cells. EED is essential for the histone methyltransferase activity of PRC2 because EED directly binds to H3K27me3.","EED Inhibitor MAK683 | EED PPI Inhibitor MAK683 | EED Protein-protein Interaction Inhibitor MAK683 | Ectodermal Embryonic Development Inhibitor MAK683 | MAK 683 | MAK-683 | MAK683",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521742","TPX-0005","C133821","An orally available inhibitor of multiple kinases, including the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), the neurotrophic tyrosine receptor kinase (NTRK) types 1, 2 and 3, the proto-oncogene SRC, and focal adhesion kinase (FAK), with potential antineoplastic activity. Upon oral administration, repotrectinib binds to and inhibits wild-type, point mutants and fusion proteins of ALK, ROS1, NTRK1-3, SRC, FAK and, to a lesser extent, other kinases. Inhibition of these kinases leads to the disruption of downstream signaling pathways and the inhibition of cell growth of tumors in which these kinases are overexpressed, rearranged or mutated.","Repotrectinib | ALK/ROS1/NTRK/SRC/FAK Multikinase Inhibitor TPX-0005 | Augtyro | Multi-kinase Inhibitor TPX-0005 | Multikinase Inhibitor TPX-0005 | REPOTRECTINIB | TPX 0005 | TPX-0005 | TPX0005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521743","Zirconium Zr 89 DFO-Pertuzumab","C133822","A radioimmunoconjugate composed of pertuzumab, a humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the tyrosine kinase receptor human epidermal growth factor-2 (HER2; HER-2), and linked, via the chelator desferrioxamine (DFO), to the radioisotope zirconium Zr 89 (Zr89), with potential use in imaging of HER-2-expressing tumor cells upon positron emission tomography (PET). Upon administration of zirconium Zr 89-DFO-pertuzumab, the pertuzumab moiety targets and binds to HER-2. After binding and internalization into HER-2-expressing tumor cells, Zr89 facilitates the visualization and detection of HER-2-expressing tumor cells using PET. This assesses HER2-expression and may predict or evaluate the tumor's response to certain HER-2-targeting chemotherapeutics.","Zirconium Zr 89 DFO-Pertuzumab | (89)Zr-pertuzumab | 89Zr-DFO-pertuzumab | PERTUZUMAB DEFEROXAMINE ZIRCONIUM ZR-89 | Zr 89-DFO-pertuzumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521921","MAGI3 wt Allele","C134140","Human MAGI3 wild-type allele is located in the vicinity of 1p13.2 and is approximately 295 kb in length. This allele, which encodes membrane-associated guanylate kinase, WW and PDZ domain-containing protein 3, is involved in the modulation of signal transduction.","MAGI3 wt Allele | KIAA1634 | MAGI-3 | Membrane Associated Guanylate Kinase, WW and PDZ Domain Containing 3 wt Allele | Membrane-Associated Guanylate Kinase, WW and PDZ Domains-Containing, 3 Gene | dJ730K3.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522025","Stage IIIB Rectal Cancer AJCC v8","C134299","Stage IIIB includes: (T3-T4a, N1/N1c, M0); (T2-T3, N2a, M0); (T1-T2, N2b, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N1c: No regional lymph nodes are positive, but there are tumor deposits in the subserosa, mesentery, or nonperitonealized pericolic, or perirectal/mesorectal tissues. N2a: Four to six regional lymph nodes are positive. N2b: Seven or more regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIB Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520222","Zinc Cluster","C13429","The zinc cluster is one of three structural motifs observed in the DNA-binding domains of zinc proteins.  In the 'zinc cluster' two zinc atoms are liganded by six cysteine residues.  Originally identified in the GAL4 transactivator, it is also known as the C6 zinc cluster, binuclear cluster, and the Zn(II)2Cys6 motif.","Zinc Cluster | C6 Zinc Cluster",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0102923","ametantrone","C1342","A topoisomerase II inhibitor of the anthrapyrazole family that causes covalent cross-links in DNA of tumor cells.","Ametantrone | 1,4-bis[[2-[(2-Hydroxyethyl)amino]ethyl]amino]9,10-anthracenedione | 9, 10-Anthracenedione, 1, 4-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]- | AMETANTRONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522026","Stage IIIC Rectal Cancer AJCC v8","C134300","Stage IIIC includes: (T4a, N2a, M0); (T3-T4a, N2b, M0); (T4b, N1-N2, M0). T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). T4b: Tumor directly invades or adheres to adjacent organs or structures. N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N2: Four or more regional lymph nodes are positive. N2a: Four to six regional lymph nodes are positive. N2b: Seven or more regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIC Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520824","Ejection Problem","C133510","Problems associated with the inability of or unexpected removal or separation of the device from its physical location.","Ejection Problem | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520825","Failure to Eject","C133511","Problem associated with the inability to remove or discharge device from the location of use.","Failure to Eject | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520827","Firing Problem","C133512","Problem associated with the device not discharging as intended.","Firing Problem | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520494","Physical Resistance/Sticking","C133513","Problem associated with the lack of movement in the device due parts sticking or seizing.","Physical Resistance/Sticking | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520840","Sharp Edges","C133514","The device has undesirable sharp edges which can cause harm or damage.","Sharp Edges | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520826","Device Fell","C133516","Problem associated with the device or a component unexpectedly being dropped or moving down from an intended place.","Device Fell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521873","Appendiceal Carcinoma pM1a TNM Finding v8","C134050","Appendiceal carcinoma with intraperitoneal acellular mucin, without identifiable tumor cells in the disseminated peritoneal mucinous deposits. (from AJCC 8th Ed.)","Appendiceal Carcinoma pM1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521874","Appendiceal Carcinoma pM1b TNM Finding v8","C134052","Appendiceal carcinoma with intraperitoneal metastasis only, including peritoneal mucinous deposits containing tumor cells. (from AJCC 8th Ed.)","Appendiceal Carcinoma pM1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521875","Appendiceal Carcinoma pM1c TNM Finding v8","C134053","Appendiceal carcinoma with metastasis to sites other than peritoneum. (from AJCC 8th Ed.)","Appendiceal Carcinoma pM1c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521876","Appendiceal Carcinoma Pathologic Primary Tumor TNM Finding v8","C134054","A pathologic finding about one or more characteristics of appendiceal carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Appendiceal Carcinoma Pathologic Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521877","Appendiceal Carcinoma pTX TNM Finding v8","C134055","Appendiceal carcinoma in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Appendiceal Carcinoma pTX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521878","Appendiceal Carcinoma pT0 TNM Finding v8","C134056","Appendiceal carcinoma with no evidence of primary tumor. (from AJCC 8th Ed.)","Appendiceal Carcinoma pT0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512067","Drug Binding Site","C13405","The reactive parts of a macromolecule that directly participate in its specific combination with a drug.","Drug Binding Site | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518145","MYC Box","C13406","MYC boxes I and II, found in the N termini of all members of the MYC protein family, function to direct the degradation of the c-MYC protein. Both MYC boxes I and II contain sufficient information to independently direct the degradation of otherwise stably expressed proteins to which they are fused. At least part of the MYC box-directed degradation occurs via the proteasome.","MYC Box | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518960","Peptide Conformation","C13407","The 3-D structure of peptides.","Peptide Conformation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1321892","Lysine-Specific Demethylase 5B, Human","C13408","Lysine-specific demethylase 5B (1544 aa, ~176 kDa) is encoded by the human KDM5B gene. This protein plays a role in both histone modification and transcriptional regulation.","Lysine-Specific Demethylase 5B | AT Rich Interactive Domain 1B Protein | CT31 | Cancer/Testis Antigen 31 | EC 1.14.11.- | Histone Demethylase JARID1B | JARID1B | Jumonji Protein | Jumonji/ARID Domain-Containing Protein 1B | KDM5B | PLU-1 | PLU-1 Protein | PUT 1 | PUT1 | Putative DNA/Chromatin Binding Motif 1 | RBBP2H1A | RBP2-H1 | RBP2-Like Protein | Retinoblastoma-Binding Protein 2 Homolog 1 | Retinoblastoma-Binding Protein 2 Homolog 1A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521879","Appendiceal Carcinoma pTis TNM Finding v8","C134095","Appendiceal carcinoma with a finding of carcinoma in situ (intramucosal carcinoma; invasion of the lamina propria or extension into but not through the muscularis mucosae). (from AJCC 8th Ed.)","Appendiceal Carcinoma pTis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521880","Low-Grade Appendiceal Mucinous Neoplasm (LAMN) pTis TNM Finding v8","C134096","Low-grade appendiceal mucinous neoplasm confined by the muscularis propria. Acellular mucin or mucinous epithelium may invade into the muscularis propria. T1 and T2 are not applicable to LAMN. Acellular mucin or mucinous epithelium that extends into the subserosa or serosa should be classified as T3 or T4a, respectively. (from AJCC 8th Ed.)","Low-Grade Appendiceal Mucinous Neoplasm (LAMN) pTis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521881","Appendiceal Carcinoma pT1 TNM Finding v8","C134097","Appendiceal carcinoma with tumor invading the submucosa (through the muscularis mucosa but not into the muscularis propria). (from AJCC 8th Ed.)","Appendiceal Carcinoma pT1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521882","Appendiceal Carcinoma pT2 TNM Finding v8","C134098","Appendiceal carcinoma with tumor invading the muscularis propria. (from AJCC 8th Ed.)","Appendiceal Carcinoma pT2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521883","Appendiceal Carcinoma pT3 TNM Finding v8","C134099","Appendiceal carcinoma with tumor invading through the muscularis propria into the subserosa or the mesoappendix. (from AJCC 8th Ed.)","Appendiceal Carcinoma pT3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521986","Loss on Drying","C134255","The determination of the total change in weight of a material as a result of drying. It determines the moisture content of a sample","Loss on Drying Measurement | LOD | Loss on Drying | Loss on Drying",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521987","Microbial Limit","C134256","An assessment of the total number of viable aerobic microorganisms present in a product and the semi-quantitative estimation of the relative number of specific types of microbes present based on an established specification for production quality.","Microbial Limit Determination | Microbial Limit | Microbial Limits",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL422321","Particle Size Distribution","C134257","Analytical procedures that utilize mechanical sieving for deducing the particle-size distribution of a powdered solid.","Particle Size Distribution Analysis | PSD | Particle Size Distribution | Particle Size Distribution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521988","Rectal Cancer by AJCC v8 Stage","C134258","A term that refers to the staging of rectal cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to adenocarcinomas, high-grade neuroendocrine carcinomas, and squamous cell carcinomas of the rectum. (from AJCC 8th Ed.)","Rectal Cancer by AJCC v8 Stage | Rectal Carcinoma by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521989","Physicochemical Property Analysis","C134259","The tests performed to assess/determine physical and chemical characteristics of the  drug substance.","Physicochemical Property Analysis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521990","Powder Bulk Density","C134260","The ratio of the mass of an untapped powder sample and its volume including the contribution of the interparticulate void volume.","Powder Bulk Density Measurement | Bulk Density | Powder Bulk Density",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521991","Clarity of Solution","C134261","Measurement of the turbidity of the solution.","Clarity of Solution Measurement | Clarity of Solution | Clarity of Solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521992","Color of Solution","C134262","The color of a solution compared to that of a standard solution.","Color of Solution Measurement | Color of Solution | Color of Solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521994","Tablet Properties","C134265","Characteristics of a tablet, which include weight, length, thickness, diameter, color and shape.","Tablet Property Analysis | Tablet Properties",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521995","Tap Density","C134266","Determination of the density, compared to the bulk density, of dry particles, expressed in mass/volume, obtained by mechanically tapping a cylinder containing the powder sample until no more change in volume occurs.","Tap Density Determination | Tap Density | Tap Density",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521996","Plume Geometry","C134267","A test that measures the spray pattern characteristics, including shape and size of the evolving spray cloud under defined experimental and instrumental test conditions.","Plume Geometry Test | Plume Geometry | Plume Geometry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521997","Polymorphic Form Determination","C134269","Tests to determine the crystalline form of a particular solid material.","Polymorphic Form Determination | Polymorphism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514535","Protein Binding Motif","C13426","Protein Binding Domains are structural motifs responsible for the peptide/protein binding activity of proteins.","Protein Binding Domain | Protein Binding Motif | Protein-Protein Interaction Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521998","Potency Assay","C134270","The determination of the strength of a material, as measured by the ability to produce a specific response. The potency of a pharmacologic substance is measured by the amount needed to produce a certain effect.","Potency Assay | Potency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521999","Stage 0 Colon Cancer AJCC v8","C134271","Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ, intramucosal carcinoma (involvement of lamina propria with no extension through muscularis mucosae). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0 Colon Cancer AJCC v8 | Stage 0 Colon Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521925","Colorectal Cancer Pathologic TNM Finding v8","C134145","A pathologic finding about one or more characteristics of colorectal cancer, following the rules of the TNM AJCC v8 classification system.","Colorectal Cancer Pathologic TNM Finding v8 | Colorectal Carcinoma Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521931","Colorectal Cancer Pathologic Primary Tumor TNM Finding v8","C134152","A pathologic finding about one or more characteristics of colorectal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Colorectal Cancer Pathologic Primary Tumor TNM Finding v8 | Colorectal Carcinoma Pathologic Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521932","Refractory Neuroblastoma","C134153","A neuroblastoma that does not respond to treatment.","Refractory Neuroblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523835","Membrane-Associated Guanylate Kinase, WW and PDZ Domain-Containing Protein 3","C134155","Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 3 (1506 aa, ~166 kDa) is encoded by the human MAGI3 gene. This protein plays a role in adaptor signaling protein activity.","Membrane-Associated Guanylate Kinase, WW and PDZ Domain-Containing Protein 3 | MAGI-3 | MAGI3 | Membrane-Associated Guanylate Kinase Inverted 3 | Membrane-Associated Guanylate Kinase with Inverted Structure 3 | Membrane-Associated Guanylate Kinase-Related 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522095","Intrahepatic Cholangiocarcinoma by AJCC v7 Stage","C134514","A term that refers to the staging of intrahepatic cholangiocarcinoma according to the American Joint Committee on Cancer, 7th edition.","Intrahepatic Cholangiocarcinoma by AJCC v7 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520433","Intermittent Loss of Power","C133520","Problem associated with an intermittent disruption to the power to run the device.","Intermittent Loss of Power | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520849","Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC v8","C133521","Stage I includes: IA: (T1a, N0, M0, G1, Tumor location: Any); (T1a, N0, M0, GX, Tumor location: Any); IB: (T1a, N0, M0, G2-3, Tumor location: Any); (T1b, N0, M0, G1-3, Tumor location: Any); (T1b, N0, M0, GX, Tumor location: Any); (T2, N0, M0, G1, Tumor location: Any). T1a: Tumor invades the lamina propria or muscularis mucosae. T1b: Tumor invades the submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well-differentiated. GX: Grade cannot be assessed. G2: Moderately differentiated. G3: Poorly differentiated, undifferentiated. (AJCC 8th ed.)","Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC v8 | Stage I Esophageal Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520435","Interrogation Problem","C133523","Problems associated with the device's ability to respond to signals from a system designed to interrogate its status.","Interrogation Problem | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521139","Sixth-Line Therapy","C133526","Treatment that is given when the first five treatments don't work, or stop working.","Sixth-Line Therapy | Sixth Line Treatment | Sixth line of therapy | Sixth-Line Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520555","Unintended Electrical Shock","C133527","The device delivers unintended electrical shock.","Unintended Electrical Shock | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521136","Seventh-Line Therapy","C133528","Treatment that is given when the first six treatments don't work, or stop working.","Seventh-Line Therapy | Seventh Line Treatment | Seventh line of therapy | Seventh-Line Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521040","Eighth-Line Therapy","C133529","Treatment that is given when the first seven treatments don't work, or stop working.","Eighth-Line Therapy | Eighth Line Treatment | Eighth line of therapy | Eighth-Line Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520442","Anti-CD19/CD28/zeta Modified CAR CD3+ T Lymphocytes JCAR015","C133718","Genetically modified CD3-positive-enriched autologous T-lymphocytes transduced with a replication incompetent gamma retroviral vector expressing a chimeric T-cell antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv), fused to the extracellular, transmembrane and intracellular signaling domains of the T-cell co-stimulatory receptor CD28 and the cytoplasmic signaling domain of the zeta chain of the TCR/CD3 complex (CD3-zeta) (CAR19-28z), with potential antineoplastic activities. Upon intravenous administration, vadacabtagene leraleucel,is directed to CD19-expressing tumor cells, and, upon binding to the T-cells, induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. The CD28 co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19. The inclusion of the CD28 signaling domain may increase proliferation of T-cells and antitumor activity compared to the inclusion of the CD3-zeta chain alone.","Vadacabtagene Leraleucel | Anti-CD19/CD28/zeta Modified CAR CD3+ T Lymphocytes JCAR015 | JCAR 015 | JCAR 15 | JCAR015 | VADACABTAGENE LERALEUCEL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520357","Alflutinib Mesylate","C133719","The mesylate salt form of alflutinib, an orally available selective inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. Upon administration, alflutinib specifically binds to and inhibits the tyrosine kinase activity of EGFR T790M, a secondarily acquired resistance mutation. This prevents EGFR T790M-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells. EGFR, a receptor tyrosine kinase that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. Compared to some other EGFR inhibitors, alflutinib may have therapeutic benefits in tumors with T790M-mediated drug resistance.","Alflutinib Mesylate | ASK 120067 | ASK-120067 | ASK120067 | AST 2818 Mesylate | AST2818 Mesylate | FIRMONERTINIB MESYLATE | FURMONERTINIB MESILATE | Furmonertinib Mesylate | Ivesa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519349","Skin Fluid or Secretion","C13409","Secretions of the skin.","Skin Fluid or Secretion | Skin Fluid and Secretion | Skin Fluids and Secretions | Skin-Fluids, Secretions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522046","Hepatocellular Carcinoma Clinical Distant Metastasis TNM Finding v8","C134460","A clinical finding about one or more characteristics of hepatocellular carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Hepatocellular Carcinoma Clinical Distant Metastasis TNM Finding v8 | Clinical Distant Metastasis Status (cM) | Liver Cell Carcinoma Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522050","Hepatocellular Carcinoma Pathologic TNM Finding v8","C134464","A pathologic finding about one or more characteristics of hepatocellular carcinoma, following the rules of the TNM AJCC v8 classification system.","Hepatocellular Carcinoma Pathologic TNM Finding v8 | Liver Cell Carcinoma Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522052","Hepatocellular Carcinoma Pathologic Distant Metastasis TNM Finding v8","C134466","A pathologic finding about one or more characteristics of hepatocellular carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Hepatocellular Carcinoma Pathologic Distant Metastasis TNM Finding v8 | Liver Cell Carcinoma Pathologic Distant Metastasis TNM Finding v8 | Pathologic Distant Metastasis Status (pM)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522055","Hepatocellular Carcinoma Pathologic Primary Tumor TNM Finding v8","C134469","A pathologic finding about one or more characteristics of hepatocellular carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Hepatocellular Carcinoma Pathologic Primary Tumor TNM Finding v8 | Liver Cell Carcinoma Pathologic Primary Tumor TNM Finding v8 | Pathologic Primary Tumor Status (pT)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522000","Reconstitution Time","C134272","Measurement of how long it takes to restore something dried to its original state of liquid.","Reconstitution Time Measurement | Reconstitution Time | Reconstitution Time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520335","ALK NM_004304.4:c.3509T>A","C133476","A nucleotide substitution at position 3509 of the coding sequence of the ALK gene where thymine has been mutated to adenine.","ALK NM_004304.4:c.3509T>A | ALK Receptor Tyrosine Kinase c.3509T>A | ALK c.3509T>A | Anaplastic Lymphoma Kinase (Ki-1) c.3509T>A | Anaplastic Lymphoma Receptor Tyrosine Kinase c.3509T>A | CD246 c.3509T>A | NM_004304.4:c.3509T>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520336","ALK NM_004304.4:c.3509T>G","C133479","A nucleotide substitution at position 3509 of the coding sequence of the ALK gene where thymine has been mutated to guanine.","ALK NM_004304.4:c.3509T>G | ALK Receptor Tyrosine Kinase c.3509T>G | ALK c.3509T>G | Anaplastic Lymphoma Kinase (Ki-1) c.3509T>G | Anaplastic Lymphoma Receptor Tyrosine Kinase c.3509T>G | CD246 c.3509T>G | NM_004304.4:c.3509T>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522097","Stage I Hepatocellular Carcinoma AJCC v8","C134516","Stage I includes: IA (T1a, N0, M0); IB (T1b, N0, M0). T1a: Solitary tumor equal to or less than 2 cm.  T1b: Solitary tumor larger than 2 cm without vascular invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Hepatocellular Carcinoma AJCC v8 | Stage I Hepatocellular Cancer | Stage I Liver Cell Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514293","Pre-Condensed Chromosomes","C13451","It refers to the chromosome status during the prophase of mitotic division. (NCI)","Pre-Condensed Chromosomes | Genetics, Pre-Condensed Chromosomes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522101","Stage III Hepatocellular Carcinoma AJCC v8","C134520","Stage III includes: IIIA: (T3, N0, M0); IIIB: (T4, N0, M0). T3: Multiple tumors, at least one of which is larger than 5 cm. T4: Single tumor or multiple tumors of any size involving a major branch of the portal vein or hepatic vein, or tumor(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of visceral peritoneum. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Hepatocellular Carcinoma AJCC v8 | Stage III Hepatocellular Cancer | Stage III Liver Cell Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522104","Stage IV Hepatocellular Carcinoma AJCC v8","C134523","Stage IV includes: IVA: (Any T, N1, M0); IVB: (Any T, Any N, M1). N1: Regional lymph node metastasis. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Cancer | Stage IV Liver Cell Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520496","Arsenic Trioxide Capsule Formulation ORH 2014","C133720","An orally bioavailable capsule formulation of the inorganic toxic compound arsenic trioxide (As2O3), with potential antineoplastic activity. Although the mechanism of action (MoA) of As2O3 is not well understood, upon oral administration of ORH 2014, As2O3 appears to bind to DNA, prevent DNA synthesis, and cause DNA fragmentation, which leads to an induction of apoptosis in proliferating cells, including tumor cells. In addition, As2O3 causes damage to and induces degradation of the promyelocytic leukemia protein/retinoic acid receptor-alpha (PML/RARa) fusion protein, and inhibits the activity of the enzyme thioredoxin reductase.","Arsenic Trioxide Capsule Formulation ORH 2014 | Arsenic Trioxide Formulation ORH 2014 | As2O3 Formulation ORH 2014 | ORH 2014 | Oral Arsenic Trioxide Formulation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520830","Misassembled During Installation","C133721","Problem associated with the use of the device characterized by incorrect assembly of device components, parts or constituents.","Misassembled During Installation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521301","Migration","C133722","Problem with all or part of an implanted or invasive device moving from its intended location within the body.","Device Migration Problem | Migration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519753","Contrast-Enhanced Subharmonic Ultrasound Imaging","C133723","A variation of contrast-enhanced ultrasound imaging that centers the receiving bandwidth at half the transmitting frequency in order to suppress tissue signals during vascular imaging studies.","Contrast-Enhanced Subharmonic Ultrasound Imaging | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796274","Brown-Vialetto-Van Laere Syndrome 1","C133724","An autosomal recessive neurologic condition caused by mutation(s) in the SLC52A3 gene, encoding solute carrier family 52, riboflavin transporter, member 3. It is characterized by sensorineural hearing loss and varying cranial nerve palsies, usually affecting the motor components of the seventh and ninth to twelfth cranial nerves. Spinal motor nerves are often affected. Mutations in SLC52A3 may result in Faxio-Lone disease, which is a similar condition, but sensorineural deafness is not present.","Brown-Vialetto-Van Laere Syndrome 1 | BVVLS1 | Bulbar Palsy, Progressive, with Sensorineural Deafness",,,,,,,,,,,,,,,"44783873","Brown-Vialetto-Van Laere syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1861862","Cardiomyopathy, Familial Hypertrophic, 4","C133725","An autosomal dominant condition caused by mutation(s) in the MYBPC3 gene, encoding MYBPC3 protein. It is characterized by severe neonatal hypertrophic cardiomyopathy.","Familial Hypertrophic Cardiomyopathy Type 4 | CMH4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1855840","Hypoparathyroidism-Retardation-Dysmorphism Syndrome","C133727","An autosomal recessive condition caused by mutation(s) in the TBCE gene, encoding tubulin-specific chaperone E. It is characterized by congenital hypoparathyroidism, mental retardation, seizures and developmental delay.","Hypoparathyroidism-Retardation-Dysmorphism Syndrome | HRDS | Hypoparathyroidism with Short Stature, Mental Retardation, and Seizures | Hypoparathyroidism, Congenital, Associated with Dysmorphism, Growth Retardation, and Developmental Delay | Sanjad-Sakati Syndrome",,,,,,,,,,,,,,,"37162666","Sanjad Sakati syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521830","Molecular Design Limited Structure-data File","C133996","A family of chemical text file formats developed by Molecular Design Limited (MDL) that represent multiple chemical structural records and associated data fields. The file extension is .sd or .sdf.","MDL Structure-data File Format | MDL SDF | MDL Structure-data File | MDL Structure-data File | Molecular Design Limited Structure-data File | SDF | Structure Data File",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521831","Macromolecular CIF","C133997","A standard text file format for representing crystallographic information of large molecules. The file extension is .mcif.","Macromolecular CIF | macromolecular Crystallographic Information File | mmCIF | mmCIF (large molecules)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521832","Does Not Conform","C133998","An observation that the item of interest does not match required specifications.","Does Not Conform | Does not conform",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520850","Pathologic Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8","C133565","Stage I includes: IA: (T1a, N0, M0, G1); (T1a, N0, M0, GX); IB: (T1a, N0, M0, G2); (T1b, N0, M0, G1-2); (T1b, N0, M0, GX); IC: (T1, N0, M0, G3); (T2, N0, M0, G1-2). T1a: Tumor invades the lamina propria or muscularis mucosae. T1b: Tumor invades the submucosa. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well-differentiated. GX: Grade cannot be assessed. G2: Moderately differentiated. G3: Poorly differentiated, undifferentiated. (AJCC 8th ed.)","Pathologic Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520854","Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8","C133566","Stage IA includes: (T1a, N0, M0, G1); (T1a, N0, M0, GX). T1a: Tumor invades the lamina propria or muscularis mucosae. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well-differentiated. GX: Grade cannot be assessed. (AJCC 8th ed.)","Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520859","Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8","C133568","Stage IC includes: (T1, N0, M0, G3); (T2, N0, M0, G1-2). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well-differentiated. G2: Moderately differentiated. G3: Poorly differentiated, undifferentiated. (AJCC 8th ed.)","Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520837","Radiation Output Failure","C133569","Problem associated with the absence of radiation output from radiological or diagnostic devices.","Radiation Output Failure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520862","Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8","C133570","Stage II includes: IIA: (T2, N0, M0, G3); (T2, N0, M0, GX); IIB: (T1, N1, M0, Any G); (T3, N0, M0, Any G). T2: Tumor invades the muscularis propria. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T3: Tumor invades adventitia. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. GX: Grade cannot be assessed. G3: Poorly differentiated, undifferentiated. (AJCC 8th ed.)","Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520553","Unexpected/Unintended Radiation Output","C133571","Device-emitted radiation when it was not supposed to. This applies to devices which are intended to emit radiation, and the radiation being emitted from the correct part of the device, but at an incorrect time.","Unexpected/Unintended Radiation Output | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520866","Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8","C133572","Stage IIA includes: (T2, N0, M0, G3); (T2, N0, M0, GX). T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. GX: Grade cannot be assessed. G3: Poorly differentiated, undifferentiated. (AJCC 8th ed.)","Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520869","Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8","C133573","Stage IIB includes: (T1, N1, M0, Any G); (T3, N0, M0, Any G). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T3: Tumor invades adventitia. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520841","Non Reproducible Results","C133574","Device results that cannot be reliably reproduced.","Non-Reproducible Results | Non Reproducible Results",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520337","ALK NM_004304.4:c.3512T>A","C133481","A nucleotide substitution at position 3512 of the coding sequence of the ALK gene where thymine has been mutated to adenine.","ALK NM_004304.4:c.3512T>A | ALK Receptor Tyrosine Kinase c.3512T>A | ALK c.3512T>A | Anaplastic Lymphoma Kinase (Ki-1) c.3512T>A | Anaplastic Lymphoma Receptor Tyrosine Kinase c.3512T>A | CD246 c.3512T>A | NM_004304.4:c.3512T>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1268448","Keratin Filament","C13368","A class of intermediate filaments that form a network within epithelial cells and anchor to desmosomes, thus imparting tensile strength to the tissue","Keratin Filament | ",,,,,,,,,,,,,,,"4019735","Cytokeratin filaments",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521177","HS-10296","C133691","An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. Upon administration, aumolertinib binds to and inhibits EGFR T790M, a secondarily acquired resistance mutation, inhibits the tyrosine kinase activity of EGFR T790M, prevents EGFR T790M-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells. EGFR, a receptor tyrosine kinase that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","Aumolertinib | AUMOLERTINIB | Almonertinib | EGFR Tyrosine Kinase Inhibitor HS-10296 | EQ143 | HS 10296 | HS-10296 | HS10296",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520836","Program or Algorithm Execution Failure","C133625","Problem associated with the failure of a program or algorithm to execute. Sudden /unexpected interruption to a program's execution.","Program or Algorithm Execution Failure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520428","Incomplete or Inadequate Connection","C133626","Problem associated with a partial linking of the device whereby the device may appear to be connected however only a partial, intermittent or no transfer of liquid, gas, electricity, or information can be accomplished.","Incomplete or Inadequate Connection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520431","Intermittent Communication Failure","C133627","Inconsistent or lack of intended communication of data among internal components or with other external devices.","Intermittent Communication Failure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520537","Suction Failure","C133628","Problem associated with the complete inability to provide suction.","Suction Failure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520429","Incomplete or Inadequate Priming","C133630","Problem associated with not adequately preparing the device.","Incomplete or Inadequate Priming | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521166","Activation Problem","C133631","Problem associated with the activation of a device.","Activation Problem | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521135","Separation Problem","C133632","Problem associated with the detachment or separation of device.","Separation Problem | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519827","Difficult or Delayed Separation","C133633","Problem associated with users experiencing difficulty or delay with detachment or separation of the device.","Difficult or Delayed Separation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520647","Fail-Safe Did Not Operate","C133635","Problem associated with the device fail-safe mechanism, which did not function or function in a non effective way, compromising safe use of the device.","Fail Safe did not Operate | Fail-Safe Did Not Operate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520270","Unintended Compatability Medical Device Problem","C133636","Problem associated with the ability of two or more devices which are intended to be incompatible but are able to work or fit together.","Unintended Compatibility Problem | Unintended Compatibility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0443241","Inverted","C133999","To place upside down.","Inverted | ",,,,,,,,,,,,,,,"4137045","Inverted",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1510853","All Sites","C13399","Anything relevant to all anatomic sites - non-specific.","All Sites | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0100007","BW A773U","C1339","The hydrochloride salt form of 73U82, a three substituted fluoranthene derivative of the 2-(arylmethylamino)-1,3-propanediol family, with potential antineoplastic activity. Upon administration, BW-A-773U intercalates with DNA, causing inhibition of DNA synthesis.","BW A773U | 1,3-Propanediol, 2-((3-fluoranthenylmethyl)amino)-2-methyl-, Hydrochloride | 773U82 HYDROCHLORIDE | 773U82 Hydrochloride | BW 773U82 | BW-A 773U | BW-A-773U",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521833","Organic Impurity","C134000","Any unwanted organic compound that is present in specifically defined substances or products and is generated during the manufacturing process or is created upon degradation during storage.","Organic Impurity | Organic Impurities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521834","Inorganic Impurity","C134001","Any unwanted inorganic compound generated during the manufacturing process of a particular substance or product.","Inorganic Impurity | Inorganic | Inorganic Impurities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521835","Residual Solvents","C134002","Tests performed to determine if organic volatile chemicals that are used or produced in manufacture of drug substance or excipients, or in the preparation of drug products are present in the pharmaceuticals.","Residual Solvent Test | Residual Solvent | Residual Solvents",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521836","Data Universal Numbering System","C134003","A proprietary system developed and regulated by Dun & Bradstreet that assigns a unique nine digit numeric identifier to a single business entity location.","Data Universal Numbering System | D-U-N-S | D-U-N-S NUMBER | D-U-N-S Number | DUNS | DUNS Numbers | Data Universal Number System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521837","Facility FDA Establishment Identifier","C134004","A unique identifier assigned by the Food and Drug Administration (FDA) to track inspections of a regulated establishment or facility. They are also used to track generic drug user fee acts (GDUFA) facility fee payments.","Facility FDA Establishment Identifier | FEI | Facility FEI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521839","United States Pharmacopeia-National Formulary","C134006","An official publication managed and maintained by the US Pharamacopeial Convention, that gives the composition, description, method of preparation, and dosage for drugs.","United States Pharmacopeia-National Formulary | USP-NF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523870","European Pharmacopeia","C134007","A European reference publication from that is a legal and scientific benchmark for pharmacopoeial standards.","European Pharmacopeia | EP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523871","Japanese Pharmacopeia","C134008","A reference publication considered the official pharmacopoeia of Japan that is published under the authority of the Ministry of Health, Labour and Welfare.","Japanese Pharmacopeia | JP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521840","Company Standard","C134009","A trademarked, copyrighted standard belonging to an organization.","Company Standard | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521841","Tentative Approval","C134010","Provisional approval of a specification.","Tentative Approval | Tentatively Approved",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521842","Not Approved","C134011","A specification that has not yet been approved.","Not Approved | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522027","Stage IV Rectal Cancer AJCC v8","C134301","Stage IV includes: IVA: (Any T, Any N, M1a); IVB: (Any T, Any N, M1b); IVC: (Any T, Any N, M1c). M1a: Metastasis to one site or organ without peritoneal metastasis. M1b: Metastasis to two or more sites or organs without peritoneal metastasis. M1c: Metastasis to the peritoneal surface alone or with other site or organ metastases. (AJCC 8th ed.)","Stage IV Rectal Cancer AJCC v8 | Stage IV Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522028","Stage IVA Rectal Cancer AJCC v8","C134302","Stage IVA includes: Any T, Any N, M1a. M1a: Metastasis to one site or organ without peritoneal metastasis. (AJCC 8th ed.)","Stage IVA Rectal Cancer AJCC v8 | Stage IVA Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520872","Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8","C133575","Stage III includes: IIIA: (T1, N2, M0, Any G); (T2, N1, M0, Any G); IIIB: (T2, N2, M0, Any G); (T3, N1-2, M0, Any G); (T4a, N0-1, M0, Any G). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521347","Excessive Heating","C133576","Problem associated with the device which has a warming or heating function, and is producing excessive heat.","Excessive Heating | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520876","Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8","C133577","Stage IIIA includes: (T1, N2, M0, Any G); (T2, N1, M0, Any G). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521708","Anal Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C133779","A pathologic finding about one or more characteristics of anal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Anal Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | Anal Canal and Perianal (Anal Margin) Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8 | Anal Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0729606","Chromosome Structure","C13377","The 3-D organization of histones and other proteins on chromosomal DNA in the nucleus and allow for its form and function during cellular growth and division.","Chromosome Structure | Chromosomal Organization | Chromosomal Structure | Chromosome Organization",,,,,,,,,,,,,,,"4193189","Chromosome structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521798","Anti-FGFR Monoclonal Antibody","C133879","Any monoclonal antibody directed against te antigen fibroblast growth factor receptor (FGFR).","Anti-FGFR Monoclonal Antibody | Anti-FGFR MoAb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796364","17p12","C13387","A chromosome band present on 17p","17p12 | Chromosome 17p12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823478","TANK Gene","C133880","This gene plays a role in the inhibition of tumor necrosis factor receptor family-dependent signaling.","TANK Gene | TANK | TRAF Family Member Associated NFKB Activator Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521799","TANK wt Allele","C133881","Human TANK wild-type allele is located in the vicinity of 2q24.2 and is approximately 99 kb in length. This allele, which encodes TRAF family member-associated NF-kappa-B activator protein, is involved in the regulation of tumor necrosis factor receptor-associated factor- and I-kappa-B-kinase-dependent signaling.","TANK wt Allele | I-TRAF | ITRAF | TRAF Family Member Associated NFKB Activator wt Allele | TRAF2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523836","TRAF Family Member-Associated NF-Kappa-B Activator","C133882","TRAF family member-associated NF-kappa-B activator (425 aa, ~48 kDa) is encoded by the human TANK gene. This protein plays a role in the sequestration of tumor necrosis factor receptor-associated factors.","TRAF Family Member-Associated NF-Kappa-B Activator | I-TRAF | TANK | TRAF Family Member-Associated NFKB Activator | TRAF-Associated NF-Kappa-B Activator | TRAF-Interacting Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521800","Rabbit Uterine Carcinoma","C133883","Uterine carcinoma that occurs in a rabbit.","Rabbit Uterine Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2750067","Plasminogen Activator Inhibitor-1 Deficiency","C133884","An autosomal recessive condition caused by mutation(s) in the PAI1 gene, encoding plasminogen activator inhibitor 1. It is characterized by increased bleeding following trauma, injury, or surgery and in women, menorrhagia.","Plasminogen Activator Inhibitor-1 Deficiency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1288283","Anetoderma","C133885","A dermatologic condition characterized by focal loss of elastic tissue. Clinically it presents with atrophic depressions or saccular outpouchings of the skin.","Anetoderma | ",,,,,,,,,,,,,,,"4032902","Anetoderma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1842983","Charcot-Marie-Tooth Disease Type 2K","C133886","No value exists.","Charcot-Marie-Tooth Disease Type 2K | CMT2K",,,,,,,,,,,,,,,"37110720","Autosomal recessive Charcot-Marie-Tooth disease with hoarseness",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268328","Acute Hepatic Porphyria","C133887","No value exists.","Acute Hepatic Porphyria | ALAD Deficiency | Delta-Aminolevulinate Dehydratase Deficiency | Porphobilinogen Synthase Deficiency",,,,,,,,,,,,,,,"4272337","Porphobilinogen synthase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1416677","KLK6 Gene","C133889","This gene is involved in protein processing.","KLK6 Gene | KLK6 | Kallikrein Related Peptidase 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796365","8p22","C13388","A chromosome band present on 8p","8p22 | Chromosome 8p22",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521802","KLK6 wt Allele","C133890","Human KLK6 wild-type allele is located in the vicinity of 19q13.41 and is approximately 11 kb in length. This allele, which encodes kallikrein-6 protein, plays a role in post-translational protein processing.","KLK6 wt Allele | Bssp | Kallikrein 6 (Neurosin, Zyme) Gene | Kallikrein Related Peptidase 6 wt Allele | Klk7 | PRSS18 | PRSS9 | Protease, Serine, 18 Gene | Protease, Serine, 9 Gene | SP59 | hK6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520648","Failure to Clean Adequately","C133637","Problem associated with the failure of the device or operator to remove any visible soil, foreign material or organism deposits on the external surfaces, crevices, and joints of the device.","Failure to Adequately Clean | Failure to Clean Adequately",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520677","Gastric Cancer by AJCC v8 Stage","C133638","A term that refers to the staging of gastric cancer according to the American Joint Committee on Cancer, 8th edition.","Gastric Cancer by AJCC v8 Stage | Gastric Carcinoma by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3501765","Imeglimin","C132841","No value exists.","Imeglimin | (4R)-6-(Dimethylamino)-4-methyl-4,5-dihydro-1,3,5-triazin-2-amine | IMEGLIMIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3178683","Auriclosene","C132842","No value exists.","Auriclosene | 1-Propanesulfonic Acid, 2-(Dichloroamino)-2-methyl- | AURICLOSENE | CD0722 | NVC 422 | NVC-422",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520891","Pentiapine","C132843","No value exists.","Pentiapine | PENTIAPINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0075958","Technetium Tc 99m Lidofenin","C132844","No value exists.","Technetium Tc 99m Lidofenin | TECHNETIUM TC-99M LIDOFENIN | Tc-99m HIDA | Technetate(1-)-99tc, bis(N-(carboxymethyl)-N-(2-((2,6-dimethylphenyl)amino)-2-oxoethyl)glycinato(2-))-, (oc-6-11')- | Technetium tc-99m Lidofenin",,,,,,,,,,,,,,,"4217834","Technetium (99m-Tc) lidofenin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521018","6,7-Epidrospirenone","C132845","No value exists.","6,7-Epidrospirenone | 6,7-EPIDROSPIRENONE | 6alpha,7alpha-Drospirenone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520344","Almagodrate","C132846","No value exists.","Almagodrate | ALMAGODRATE | Almagodrate Hydrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520293","Unresectable Ewing Sarcoma","C132849","A Ewing sarcoma which is not amenable to surgical resection.","Unresectable Ewing Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520296","Unresectable Osteosarcoma","C132850","An osteosarcoma which is not amenable to surgical resection.","Unresectable Osteosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522029","Stage IVB Rectal Cancer AJCC v8","C134303","Stage IVB includes: Any T, Any N, M1b. M1b: Metastasis to two or more sites or organs without peritoneal metastasis.  (AJCC 8th ed.)","Stage IVB Rectal Cancer AJCC v8 | Stage IVB Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522030","Stage IVC Rectal Cancer AJCC v8","C134304","Stage IVC includes: Any T, Any N, M1c. M1c: Metastasis to the peritoneal surface alone or with other site or organ metastases. (AJCC 8th ed.)","Stage IVC Rectal Cancer AJCC v8 | Stage IVC Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522031","Anti-LAG-3 Monoclonal Antibody","C134305","Any monoclonal antibody directed against the antigen lymphocyte-activation gene 3 (LAG-3; CD223).","Anti-LAG-3 Monoclonal Antibody | Anti LAG-3 MoAb | Anti-LAG3 Monoclonal Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1540036","TNRC6B Gene","C134308","This gene plays a role in RNA binding and RNA-mediated gene silencing.","TNRC6B Gene | TNRC6B | Trinucleotide Repeat Containing 6B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522032","TNRC6B wt Allele","C134309","Human TNRC6B wild-type allele is located in the vicinity of 22q13.1 and is approximately 291 kb in length. This allele, which encodes trinucleotide repeat-containing gene 6B protein is involved in translational repression.","TNRC6B wt Allele | KIAA1093 | Trinucleotide Repeat Containing 6B wt Allele | Trinucleotide Repeat-Containing 6B Gene | Trinucleotide Repeat-Containing Gene 6B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1166688","Mitotic Chromosome","C13430","Condensed chromosomes observed during the M phase of the cell cycle.  Individual chromosomes can be discerned and differentiated morphologically.","Mitotic Chromosome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523819","Trinucleotide Repeat-Containing Gene 6B Protein","C134310","Trinucleotide repeat-containing gene 6B protein (1833 aa, ~194 kDa) is encoded by the human TNRC6B gene. This protein plays a role in RNA-mediated repression of translation.","Trinucleotide Repeat-Containing Gene 6B Protein | TNRC6B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427145","KDM3A Gene","C134311","This gene is involved in the negative regulation of histone H3 methylation.","KDM3A Gene | KDM3A | Lysine Demethylase 3A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522033","KDM3A wt Allele","C134312","Human KDM3A wild-type allele is located in the vicinity of 2p11.2 and is approximately 52 kb in length. This allele, which encodes lysine-specific demethylase 3A protein, plays a role in the metabolism of histone H3.","KDM3A wt Allele | JHDM2A | JHMD2A | JMJD1 | JMJD1A | Jumonji Domain Containing 1 Gene | Jumonji Domain Containing 1A Gene | KIAA0742 | Lysine (K)-Specific Demethylase 3A Gene | Lysine Demethylase 3A wt Allele | TSGA | Testis-Specific Gene A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2355222","KDM3A protein, human","C134313","Lysine-specific demethylase 3A (1321 aa, ~147 kDa) is encoded by the human KDM3A gene. This protein is involved in the demethylation of lysine-9 of histone H3 (H3K9).","Lysine-Specific Demethylase 3A | EC 1.14.11.- | JmjC Domain-Containing Histone Demethylase 2A | JmjC Domain-Containing Histone Demethylation Protein 2A | Jumonji C Domain-Containing Histone Demethylase 2A | Jumonji Domain-Containing Protein 1A | K-Specific Demethylase 3A | KDM3A | Testis-Specific Protein A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521716","Anal Canal Cancer by AJCC v6 and v7 Stage","C133787","A term that refers to the staging of anal canal cancer according to the American Joint Committee on Cancer, 6th and 7th editions. This staging system applies to carcinomas arising in the anal canal only; melanomas, carcinoid tumors, sarcomas, and perianal tumors are not included. (from AJCC 6th and 7th Eds.)","Anal Canal Cancer by AJCC v6 and v7 Stage | Anal Canal Carcinoma by AJCC v6 and v7 Stage | Anal Carcinoma by AJCC v6 and v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420817","TNFSF14 Gene","C133788","This gene is involved in both T-cell proliferation and tumor cell apoptosis.","TNFSF14 Gene | TNFSF14 | Tumor Necrosis Factor Superfamily Member 14 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521884","Appendiceal Carcinoma pT4 TNM Finding v8","C134100","Appendiceal carcinoma with tumor invading the visceral peritoneum, including the acellular mucin or mucinous epithelium involving the serosa of the appendix or mesoappendix, and/or directly invading adjacent organs or structures. (from AJCC 8th Ed.)","Appendiceal Carcinoma pT4 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521885","Appendiceal Carcinoma pT4a TNM Finding v8","C134101","Appendiceal carcinoma with tumor invading through the visceral peritoneum, including the acellular mucin or mucinous epithelium involving the serosa of the appendix or serosa of the mesoappendix. (from AJCC 8th Ed.)","Appendiceal Carcinoma pT4a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521886","Appendiceal Carcinoma pT4b TNM Finding v8","C134102","Appendiceal carcinoma with tumor directly invading or adhering to adjacent organs or structures. (from AJCC 8th Ed.)","Appendiceal Carcinoma pT4b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521887","Appendiceal Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8","C134103","A pathologic finding about one or more characteristics of appendiceal carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Appendiceal Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521888","Appendiceal Carcinoma pNX TNM Finding v8","C134104","Appendiceal carcinoma in which the regional lymph node(s) cannot be assessed.  (from AJCC 8th Ed.)","Appendiceal Carcinoma pNX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521889","Appendiceal Carcinoma pN0 TNM Finding v8","C134105","Appendiceal carcinoma with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","Appendiceal Carcinoma pN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0534101","KLK6 protein, human","C133891","Kallikrein-6 (244 aa, ~27 kDa) is encoded by the human KLK6 gene. This protein is involved in the proteolytic processing of substrates.","Kallikrein-6 | EC 3.4.21.- | KLK6 | Kallikrein 6 | Neurosin | Protease M | SP59 | Serine Protease 18 | Serine Protease 9 | Zyme",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521803","Small Intestinal Adenocarcinoma by AJCC v8 Stage","C133893","A term that refers to the staging of small intestinal adenocarcinoma according to the American Joint Committee on Cancer, 8th edition. Nonadenocarcinomas arising in the small intestine should have a TNM assigned but are not assigned a stage classification. (from AJCC 8th Ed.)","Small Intestinal Adenocarcinoma by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521804","Stage 0 Small Intestinal Adenocarcinoma AJCC v8","C133894","Stage 0 includes: Tis, N0, M0. Tis: High grade dysplasia/carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0 Small Intestinal Adenocarcinoma AJCC v8 | Stage 0 Small Intestinal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521805","Stage I Small Intestinal Adenocarcinoma AJCC v8","C133895","Stage I includes: T1-2, N0, M0. T1: Tumor invading the lamina propria or submucosa. T2: Tumor invading the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Small Intestinal Adenocarcinoma AJCC v8 | Stage I Small Intestinal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522001","Stage I Colon Cancer AJCC v8","C134273","Stage I includes: (T1, N0, M0); (T2, N0, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Colon Cancer AJCC v8 | Stage I Colon Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522002","Stage II Colon Cancer AJCC v8","C134274","Stage II includes: IIA: T3, N0, M0; IIB: T4a, N0, M0; IIC: T4b, N0, M0. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). T4b: Tumor directly invades or adheres to adjacent organs or structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Colon Cancer AJCC v8 | Stage II Colon Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522003","Residue on Ignition","C134276","The amount of residual substance not volatilized after a sample is ignited.","Residue on Ignition Measurement | Residue on Ignition | Residue on Ignition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522004","Spray Pattern Assessment","C134277","Tests to determine the size of the mist formed by spraying. The measurement is made for the longest axis (x axis), and the ratio of longest to shortest axes (x/y ratio).","Spray Pattern Assessment | Spray Pattern",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523830","Sterility Test","C134278","Tests done under aseptic conditions to ensure that there are no contaminating micro-organism present in the sample.","Sterility Test | Sterility",,,,,,,,,,,,,,,"4314552","Sterility testing",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL522005","Sub-Visible Particle","C134279","Insoluble, unintentionally present particulate matter usually in the range of 1-100 microns.","Sub-Visible Particle | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522006","Stage IIA Colon Cancer AJCC v8","C134280","Stage IIA includes: T3, N0, M0. T3: Tumor invades through the muscularis propria into pericolorectal tissues. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIA Colon Cancer AJCC v8 | Stage IIA Colon Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522007","Stage IIB Colon Cancer AJCC v8","C134281","Stage IIB includes: T4a, N0, M0. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIB Colon Cancer AJCC v8 | Stage IIB Colon Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520870","Pathologic Stage III Esophageal Adenocarcinoma AJCC v8","C133421","Stage III includes: IIIA: (T1, N2, M0, Any G); (T2, N1, M0, Any G); IIIB: (T2, N2, M0, Any G); (T3, N1-2, M0, Any G); (T4a, N0-1, M0, Any G). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Pathologic Stage III Esophageal Adenocarcinoma AJCC v8 | III | Stage III Esophageal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520880","Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8","C133424","Stage IV includes: IVA: (T4a, N2, M0, Any G); (T4b, N0-2, M0, Any G); (Any T, N3, M0, Any G); IVB: (Any T, Any N, M1, Any G). T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)","Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8 | IV | Stage IV Esophageal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205441","Seventh","C133531","Following the sixth position in an ordering or series; coming next after the sixth and just before the eighth in position.","Seventh | 7th",,,,,,,,,,,,,,,"4336538","Seventh",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL520861","Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8","C133532","Stage II includes: IIA: (T2, N0, M0, G2-3, Tumor location: Any); (T2, N0, M0, GX, Tumor location: Any); (T3, N0, M0, Any G, Tumor location: Lower); (T3, N0, M0, G1, Tumor location: Upper/middle); IIB: (T3, N0, M0, G2-3, Tumor location: Upper/middle); (T3, N0, M0, GX, Tumor location: Any); (T3, N0, M0, Any G, Tumor location: Unknown); (T1, N1, M0, Any G, Tumor location: Any). T2: Tumor invades the muscularis propria. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T3: Tumor invades adventitia. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. GX: Grade cannot be assessed. G1: Well-differentiated. G2: Moderately differentiated. G3: Poorly differentiated, undifferentiated. (AJCC 8th ed.)","Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8 | Stage II Esophageal Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521180","Eighth","C133533","Following the seventh position in an ordering or series; coming next after the seventh and just before the ninth in position.","Eighth | 8th",,,,,,,,,,,,,,,"4197569","Eighth",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL520871","Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8","C133536","Stage III includes: IIIA: (T1, N2, M0, Any G, Tumor location: Any); (T2, N1, M0, Any G, Tumor location: Any); IIIB: (T2, N2, M0, Any G, Tumor location: Any); (T3, N1-2, M0, Any G, Tumor location: Any); (T4a, N0-1, M0, Any G, Tumor location: Any). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8 | Stage III Esophageal Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521890","Appendiceal Carcinoma pN1 TNM Finding v8","C134106","Appendiceal carcinoma in which one to three regional lymph nodes are positive (tumor in lymph node measuring 0.2 mm or more) or any number of tumor deposits is present, and all identifiable lymph nodes are negative. (from AJCC 8th Ed.)","Appendiceal Carcinoma pN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521891","Appendiceal Carcinoma pN1a TNM Finding v8","C134107","Appendiceal carcinoma in which one regional lymph node is positive. (from AJCC 8th Ed.)","Appendiceal Carcinoma pN1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521892","Appendiceal Carcinoma pN1b TNM Finding v8","C134108","Appendiceal carcinoma in which two to three regional lymph nodes are positive. (from AJCC 8th Ed.)","Appendiceal Carcinoma pN1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521893","Appendiceal Carcinoma pN1c TNM Finding v8","C134109","Appendiceal carcinoma in which no regional lymph nodes are positive, but there are tumor deposits in the subserosa or mesentery. (from AJCC 8th Ed.)","Appendiceal Carcinoma pN1c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521894","Appendiceal Carcinoma pN2 TNM Finding v8","C134110","Appendiceal carcinoma in which four or more regional lymph nodes are positive. (from AJCC 8th Ed.)","Appendiceal Carcinoma pN2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521895","Sub-Visible Particulates","C134112","No value exists.","Sub-Visible Particulates | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521897","Total Organic Carbon","C134114","An indirect measure of organic molecules present in pharmaceutical waters measured as carbon.","Total Organic Carbon Measurement | Total Organic Carbon | Total Organic Carbon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521898","Uniformity of Dosage Units","C134115","An evaluation of the content uniformity in terms of amount of drug substance among dosage units.","Uniformity of Dosage Units Analysis | Uniformity of Dosage Unit | Uniformity of Dosage Units",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521899","Water Content Determination","C134116","Determining the quantity of water contained in a material.","Water Content Determination | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426335","NECTIN4 Gene","C134478","This gene is involved in the modulation of cell-cell adhesion.","NECTIN4 Gene | NECTIN4 | Nectin Cell Adhesion Molecule 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518405","Nonexchangeable Site","C13447","A binding site where a ligand is permanently bound.","Nonexchangeable Site | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522065","NECTIN4 wt Allele","C134480","Human NECTIN4 wild-type allele is located in the vicinity of 1q23.3 and is approximately 19 kb in length. This allele, which encodes nectin-4 protein, plays a role in cell-cell adhesion. Mutation of the gene is associated with ectodermal dysplasia-syndactyly syndrome 1.","NECTIN4 wt Allele | EDSS1 | LNIR | Nectin Cell Adhesion Molecule 4 wt Allele | PRR4 | PVRL4 | Poliovirus Receptor-Like 4 Gene | Poliovirus Receptor-Related 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522066","Hepatocellular Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8","C134481","A pathologic finding about one or more characteristics of hepatocellular carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Hepatocellular Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8 | Liver Cell Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8 | Pathologic Regional Lymph Node Status (pN)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522008","Stage IIC Colon Cancer AJCC v8","C134282","Stage IIC includes: T4b, N0, M0. T4b: Tumor directly invades or adheres to adjacent organs or structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIC Colon Cancer AJCC v8 | Stage IIC Colon Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522009","Stage III Colon Cancer AJCC v8","C134283","Stage III includes: IIIA: (T1-T2, N1/N1c, M0); (T1, N2a, M0); IIIB: (T3-T4a, N1/N1c, M0); (T2-T3, N2a, M0); (T1-T2, N2b, M0); IIIC: (T4a, N2a, M0); (T3-T4a, N2b, M0); (T4b, N1-N2, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). T4b: Tumor directly invades or adheres to adjacent organs or structures. N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N1c: No regional lymph nodes are positive, but there are tumor deposits in the subserosa, mesentery, or nonperitonealized pericolic, or perirectal/mesorectal tissues. N2: Four or more regional lymph nodes are positive. N2a: Four to six regional lymph nodes are positive. N2b: Seven or more regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Colon Cancer AJCC v8 | Stage III Colon Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522010","Stage IIIA Colon Cancer AJCC v8","C134284","Stage IIIA includes: (T1-T2, N1/N1c, M0); (T1, N2a, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N1c: No regional lymph nodes are positive, but there are tumor deposits in the subserosa, mesentery, or nonperitonealized pericolic, or perirectal/mesorectal tissues. N2a: Four to six regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Colon Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520338","Anaplastic Lymphoma Kinase (Ki-1) c.3512_3513TC>AT","C133482","A complex nucleotide substitution where the nucleotide sequence at positions 3512 and 3513 of the coding sequence of the ALK gene where thymine-cytosine has been mutated to adenine-thymine.","ALK NM_004304.4:c.3512_3513delinsAT | ALK NM_004304.4:c.3512_3513TC>AT | ALK NM_004304.4:c.3512_3513delTCinsAT | ALK NM_004304.4:c.3512_3513delTCinsAT | ALK Receptor Tyrosine Kinase c.3512_3513TC>AT | ALK c.3512_3513TC>AT | ALK c.3512_3513delTCinsAT | Anaplastic Lymphoma Kinase (Ki-1) c.3512_3513TC>AT | Anaplastic Lymphoma Receptor Tyrosine Kinase c.3512_3513TC>AT | CD246 c.3512_3513TC>AT | CD246 c.3512_3513delTCinsAT | NM_004304.4:c.3512_3513TC>AT | NM_004304.4:c.3512_3513delTCinsAT | NM_004304.4:c.3512_3513delinsAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520341","ALK NM_004304.4:c.3833A>C","C133484","A nucleotide substitution at position 3833 of the coding sequence of the ALK gene where adenine has been mutated to cytosine.","ALK NM_004304.4:c.3833A>C | ALK Receptor Tyrosine Kinase c.3833A>C | ALK c.3833A>C | Anaplastic Lymphoma Kinase (Ki-1) c.3833A>C | Anaplastic Lymphoma Receptor Tyrosine Kinase c.3833A>C | CD246 c.3833A>C | NM_004304.4:c.1278",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520339","ALK NM_004304.4:c.3575G>C","C133486","A nucleotide substitution at position 3575 of the coding sequence of the ALK gene where guanine has been mutated to cytosine.","ALK NM_004304.4:c.3575G>C | ALK Receptor Tyrosine Kinase c.3575G>C | ALK c.3575G>C | Anaplastic Lymphoma Kinase (Ki-1) c.3575G>C | Anaplastic Lymphoma Receptor Tyrosine Kinase c.3575G>C | CD246 c.3575G>C | NM_004304.4:c.3575G>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021024","Immunoglobulin Hypervariable Region","C13342","Within the variable domain of an antibody molecule are three regions called hypervariable regions, areas of high sequence diversity.  These regions form the surfaces that are responsible for antigen binding interactions.  Also known as complementarity determining region or hypervariable loop.","Immunoglobulin Hypervariable Region | CDR | Complementarity Determining Region | Complementarity-Determining Region | Hypervariable Loop",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520297","Untreated Adult Rhabdomyosarcoma","C133018","A finding of rhabdomyosarcoma in adulthood that has not been treated.","Untreated Adult Rhabdomyosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1101538","Proapoptotic Sulindac Analog CP-461","C133019","An orally bioavailable second-generation selective apoptotic antineoplastic drug (SAAND) and analog of the nonsteroidal anti-inflammatory drug (NSAID) sulindac, with potential pro-apoptotic and antineoplastic activities. Upon administration, CP-461 specifically binds to and blocks the activity of cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway. Inhibition of cGMP-PDE permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death. cGMP-PDE is overexpressed in a variety of cancer cell types; therefore, CP-461 selectively induces apoptosis in cancer cells, with minimal or no effect in healthy cells.","Proapoptotic Sulindac Analog CP-461 | 1H-Indene-3-acetamide, 5-Fluoro-2-methyl-N-(phenylmethyl)-1-(4-pyridinylmethylene)-, Monohydrochloride, (1Z)- | CEL 031 | CP 461 | CP-461 | CP461 | OSI 461",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2931498","MRX18","C133729","An X-linked dominant condition caused by mutation(s) in the IQSEC2 gene, encoding IQ motif and SEC7 domain-containing protein 2. It is characterized by substantially impaired intellectual functioning and behavioral abnormalities.","Mental Retardation, X-linked 1 | MRX1 | Nonsyndromic X-Linked Cognitive Disability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600508","Response Element","C13372","A nucleotide sequence that plays a role in the expression of a nearby gene because it can be recognized by specific transcription factors or coregulatory proteins.","Response Element | Response Elements",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1836373","Muscular Dystrophy-Dystroglycanopathy (Limb-Girdle) Type C, 1","C133730","An autosomal recessive limb-girdle muscular dystrophy caused by mutations in the POMT1 gene, encoding protein O-mannosyl-transferase 1. It is characterized by mental retardation without structural brain abnormalities and limb-girdle muscular dystrophy.","Muscular Dystrophy-Dystroglycanopathy (Limb-Girdle) Type C, 1 | LGMD2K | Limb-Girdle Muscular Dystrophy Type 2K | MDDGC1",,,,,,,,,,,,,,,"36715055","Autosomal recessive limb girdle muscular dystrophy type 2K",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521670","Refractory Primary Amyloidosis","C133731","Primary amyloidosis that does not respond to treatment.","Refractory Primary Amyloidosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521671","Recurrent Primary Amyloidosis","C133732","The reemergence of primary amyloidosis after a period of remission.","Recurrent Primary Amyloidosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521672","Appendix Carcinoma by AJCC v7 Stage","C133733","A term that refers to the staging of appendiceal carcinoma according to the American Joint Committee on Cancer, 7th edition. Carcinoid tumors are staged separately. (from AJCC 7th Ed.)","Appendix Carcinoma by AJCC v7 Stage | Appendiceal Carcinoma by AJCC v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1956036","PDZ Domain","C133734","A globular protein domain of 80 to 90 amino acids comprising six beta-strands and two alpha-helices that plays a role in anchoring receptor proteins in the membrane to cytoskeletal components.","PDZ Domain | DHR Domain | Discs-Large Homologous Region | GLGF Domain | Gly-Leu-Gly-Phe Domain | Glycine-Leucine-Glycine-Phenylalanine Domain | PSD95, Dlg1, Zo-1 Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521675","Refractory Malignant Solid Neoplasm","C133737","A malignant solid neoplasm that does not respond to treatment.","Refractory Malignant Solid Neoplasm | Refractory Malignant Solid Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521676","Rabbit Plasmacytoma","C133738","Plasmacytoma that occurs in a rabbit.","Rabbit Plasmacytoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521677","Rabbit Oral Cavity Squamous Cell Carcinoma","C133739","Oral cavity squamous cell carcinoma that occurs in a rabbit.","Rabbit Oral Cavity Squamous Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521678","Rabbit Fibroma","C133740","Fibroma that occurs in a rabbit.","Rabbit Fibroma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521679","Rabbit Cutaneous Lymphoma","C133741","Cutaneous lymphoma that occurs in a rabbit.","Rabbit Cutaneous Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3280283","Mental Retardation, Autosomal Dominant 9","C133742","An autosomal dominant condition caused by mutation(s) in the KIF1A gene, encoding kinesin-like protein KIF1A. It is characterized by microcephaly, intellectual disability, and delayed psychomotor development. The condition is progressive, occurs in early infancy, and is of variable severity.","Mental Retardation, Autosomal Dominant 9 | MRD9 | NESCAV Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522068","nectin 4 protein, human","C134483","Nectin-4 (510 aa, ~55 kDa) is encoded by the human NECTIN4 gene. This protein is involved in cell-cell adhesion.","Nectin-4 | Ig Superfamily Receptor LNIR | NECTIN4 | Nectin 4 | Nectin Cell Adhesion Molecule 4 | Poliovirus Receptor-Related 4 | Poliovirus Receptor-Related Protein 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522074","BTK Protein Variant","C134489","A variation in the amino acid sequence of the tyrosine-protein kinase BTK protein.","BTK Protein Variant | ATK Protein Variant | Agammaglobulinaemia Tyrosine Kinase Protein Variant | B-Cell Progenitor Kinase Protein Variant | BPK Protein Variant | Bruton Tyrosine Kinase Protein Variant | Tyrosine-Protein Kinase BTK Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448290","Microtubule Bundle","C13448","It is the aggregated products of microtubules during mitosis where chromosomes line up prior to the segregation process. Many antineoplastic agents cause cytotoxicity by inducing microtubular bundle formation irreversibly. (NCI)","Microtubule Bundle | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520820","Application Program Freezes, Becomes Nonfunctional","C133578","Problem associated with freezing and/or becoming nonfunctional of an application program.","Application Program Freezes, Becomes Nonfunctional | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520879","Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8","C133579","Stage IIIB includes: (T2, N2, M0, Any G); (T3, N1-2, M0, Any G); (T4a, N0-1, M0, Any G). T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520882","Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8","C133580","Stage IV includes: IVA: (T4a, N2, M0, Any G); (T4b, N0-2, M0, Any G); (Any T, N3, M0, Any G); IVB: (Any T, Any N, M1, Any G). T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)","Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520334","ALK NM_004304.4:c.3497T>G","C133488","A nucleotide substitution at position 3497 of the coding sequence of the ALK gene where thymine has been mutated to guanine.","ALK NM_004304.4:c.3497T>G | ALK Receptor Tyrosine Kinase c.3497T>G | ALK c.3497T>G | Anaplastic Lymphoma Kinase (Ki-1) c.3497T>G | Anaplastic Lymphoma Receptor Tyrosine Kinase c.3497T>G | CD246 c.3497T>G | NM_004304.4:c.3497T>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520340","ALK NM_004304.4:c.3586C>A","C133490","A nucleotide substitution at position 3586 of the coding sequence of the ALK gene where cytosine has been mutated to adenine.","ALK NM_004304.4:c.3586C>A | ALK Receptor Tyrosine Kinase c.3586C>A | ALK c.3586C>A | Anaplastic Lymphoma Kinase (Ki-1) c.3586C>A | Anaplastic Lymphoma Receptor Tyrosine Kinase c.3586C>A | CD246 c.3586C>A | NM_004304.4:c.3586C>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520333","ALK NM_004304.4:c.3383G>C","C133492","A nucleotide substitution at position 3383 of the coding sequence of the ALK gene where guanine has been mutated to cytosine.","ALK NM_004304.4:c.3383G>C | ALK Receptor Tyrosine Kinase c.3383G>C | ALK c.3383G>C | Anaplastic Lymphoma Kinase (Ki-1) c.3383G>C | Anaplastic Lymphoma Receptor Tyrosine Kinase c.3383G>C | CD246 c.3383G>C | NM_004304.4:c.3383G>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162805","Alpha Helix","C13369","A right-handed spiral conformation; the a-helix has a pitch of 5.4 A and has 3.6 amino acid residues per turn; every main chain C=O and N-H group is hydrogen-bonded to a peptide bond 4 residues away; the peptide planes are roughly parallel with the helix axis and the dipoles within the helix are aligned, i.e. all C=O groups point in the same direction and all N-H groups point the other way; side chains point outward from helix axis and are generally oriented towards its amino-terminal end.  (from expasy.org)","Alpha Helix | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1328202","Gallium Maltolate","C133020","An orally bioavailable form of the element gallium (Ga) composed of a trivalent gallium cation (Ga3+) coordinated to three maltolate ligands, with anti-inflammatory, anti-proliferative, antineoplastic, analgesic, antiresorptive and antibacterial activities. Upon administration of gallium maltolate, Ga3+, which is structurally similar to the ferric ion (Fe3+), competes with and replaces Fe3+ in many vital Fe 3+-mediated biological reactions.. Unlike Fe3+, Ga3+ cannot be reduced, cannot participate in redox reactions and cannot mimic Fe3+ functions. In rapidly proliferating cells, such as cancer cells, high amounts of iron are needed for DNA synthesis. The incorporation of Ga3+ inactivates the Fe3+-dependent enzyme ribonucleotide reductase (RR), an enzyme essential for DNA synthesis, leading to an inhibition of DNA synthesis and induction of cell death in rapidly proliferating cells. Gallium similarly reduces bacterial cell growth. In addition, Ga3+ is able to suppress inflammation through the down-regulation of pro-inflammatory cells and the inhibition of pro-inflammatory cytokine secretion. Gallium also exerts analgesic effects due to the inhibition of Fe3+-dependent enzymes involved in inflammation and may interfere with the activity of certain metalloproteinases and neuropeptides that are implicated in pain. Also, gallium is able to inhibit bone resorption by osteoclasts, may inhibit metastasis to bone and may prevent the destruction of bone by tumors.","Gallium Maltolate | GALLIUM MALTOLATE | GaM | Tris(3-hydroxy-2-methyl-4H-pyran-4-onato)gallium(III)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0061184","GEL protein, Gelonium multiflorum","C133021","A class I ribosome-inactivating protein (RIP) and toxin derived from the seeds of the plant Gelonium multiflorum. Gelonin (rGel) exerts N-glycosidase activity on the 28S ribosomal RNA (rRNA) unit of eukaryotic ribosomes by cleaving out adenine at the 4324 site, which depurinates rRNA, inactivates ribosomes, inhibits protein synthesis, and results in cell death. Used as the toxin moiety of certain immunotoxins and linked to antibodies specific for a tumor-associated antigen (TAA), gelonin can be targeted to and induce specific cytotoxicity in tumor cells expressing the TAA.","Gelonin | GEL Protein, Gelonium multiflorum | LGK974 | Ribosome-inactivating Protein Gelonin, Gelonium multiflorum | rGel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1328238","monoclonal antibody ING-1","C133022","An engineered monoclonal antibody (MAb) directed against the tumor-associated antigen (TAA) human epithelial cell adhesion molecule (Ep-CAM; EpCAM; CD326), with potential antitumor activity. Upon administration, anti-Ep-CAM monoclonal antibody ING-1 binds to Ep-CAM, which may result in a cytotoxic T-lymphocyte (CTL)-mediated immune response against Ep-CAM-expressing tumor cells. Ep-CAM, a cell surface protein upregulated on many tumor cell types, promotes the proliferation, migration and invasiveness of tumor cells.","Anti-Ep-CAM Monoclonal Antibody ING-1 | ING 1 | ING-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520444","Post Mastectomy Recovery Jacket","C133197","A type of functional clothing designed to be worn over the torso during the recovery period following surgical removal of the breast, typically with built-in features to manage post-surgical drains and discomfort.","Post Mastectomy Recovery Jacket | Jacki Recovery Jacket",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1864887","Cortical Dysplasia-Focal Epilepsy Syndrome","C133743","An autosomal recessive condition caused by mutation(s) in the CNTNAP2 gene, encoding contactin-associated protein-like 2. It is characterized by normal development until the onset of intractable focal seizures at age 1-9. After the onset of seizures, language regression, intellectual disability, hyperactivity, and impulsive behaviors begin to occur. The majority of children eventually fulfill the criteria for autism spectrum disorder.","Cortical Dysplasia-Focal Epilepsy Syndrome | CDFE Syndrome",,,,,,,,,,,,,,,"37164436","CNTNAP2-related developmental and epileptic encephalopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521844","Temperature 25 (+/-) 2 Degrees C and Relative Humidity 60% (+/-) 5%","C134014","Storage at 25 degrees C (+/-) 2 degrees C and 60% Relative Humidity (+/-) 5% Relative Humidity.","Temperature 25 (+/-) 2 Degrees C and Relative Humidity 60% (+/-) 5% | 25 +/- 2 degrees C/60% +/- 5%RH | 25 Degrees C (+/-) 2 Degrees C and 60% Relative Humidity (+/-) 5% Relative Humidity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521845","Temperature 30 (+/-) 2 Degrees C and Relative Humidity 65% (+/-) 5%","C134015","Storage at 30 degrees C (+/-) 2 degrees C and 65% Relative Humidity (+/-) 5% Relative Humidity.","Temperature 30 (+/-) 2 Degrees C and Relative Humidity 65% (+/-) 5% | 30 +/- 2 degrees C/65% +/- 5%RH | 30 Degrees C (+/-) 2 Degrees C and 65% Relative Humidity (+/-) 5% Relative Humidity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521846","Temperature 40 (+/-) 2 Degrees C and Relative Humidity 75% (+/-) 5%","C134016","Storage at 40 degrees C (+/-) 2 degrees C and 75% Relative Humidity (+/-) 5% Relative Humidity.","Temperature 40 (+/-) 2 Degrees C and Relative Humidity 75% (+/-) 5% | 40 +/- 2 degrees C/75% +/- 5%RH | 40 Degrees C (+/-) 2 Degrees C and 75% Relative Humidity (+/-) 5% Relative Humidity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521847","Temperature 30 (+/-) 2 Degrees C and Relative Humidity 75% (+/-) 5%","C134017","Storage at 30 degrees C (+/-) 2 degrees C and 75% Relative Humidity (+/-) 5% Relative Humidity.","Temperature 30 (+/-) 2 Degrees C and Relative Humidity 75% (+/-) 5% | 30 +/- 2 degrees C/75% +/- 5%RH | 30 Degrees C (+/-) 2 Degrees C and 75% Relative Humidity (+/-) 5% Relative Humidity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521848","Temperature 25 (+/-) 2 Degrees C and Relative Humidity 40% (+/-) 5%","C134018","Storage at 25 degrees C (+/-) 2 degrees C and 40% Relative Humidity (+/-) 5% Relative Humidity.","Temperature 25 (+/-) 2 Degrees C and Relative Humidity 40% (+/-) 5% | 25 +/- 2 degrees C/40% +/- 5%RH | 25 Degrees C (+/-) 2 Degrees C and 40% Relative Humidity (+/-) 5% Relative Humidity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521849","Temperature 30 (+/-) 2 Degrees C and Relative Humidity 35% (+/-) 5%","C134019","Storage at 30 degrees C (+/-) 2 degrees C and 35% Relative Humidity (+/-) 5% Relative Humidity.","Temperature 30 (+/-) 2 Degrees C and Relative Humidity 35% (+/-) 5% | 30 Degrees C (+/-) 2 Degrees C and 35% Relative Humidity (+/-) 5% Relative Humidity | 30 degrees C +/- 2 degrees C/35%RH +/- 5%RH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511310","Breast Fluid or Secretion","C13401","Any of the secretions of the breast.","Breast Fluid or Secretion | Breast Fluids and Secretions | Mammary Gland Fluids and Secretions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538150","ZBTB20 Gene","C134020","This gene may play a role in gene transcription.","ZBTB20 Gene | ZBTB20 | Zinc Finger and BTB Domain Containing 20 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521851","Drug Substance Specification","C134022","The specification which is applied to the drug substance.","Drug Substance Specification | Drug Substance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521852","ZBTB20 wt Allele","C134024","Human ZBTB20 wild-type allele is located in the vicinity of 3q13.31 and is approximately 833 kb in length. This allele, which encodes zinc finger and BTB domain-containing protein 20, may be involved in transcriptional regulation. Mutation of the gene is associated with Primrose syndrome.","ZBTB20 wt Allele | DKFZp566F123 | DPZF | HOF | ODA-8S | PRIMS | ZNF288 | Zinc Finger and BTB Domain Containing 20 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521853","ZBTB20 protein, human","C134025","Zinc finger and BTB domain-containing protein 20 (741 aa, ~81 kDa) is encoded by the human ZBTB20 gene. This protein may play a role in the regulation of gene expression.","Zinc Finger and BTB Domain-Containing Protein 20 | BTB/POZ Zinc Finger Protein DPZF | Dendritic Cell-Derived BTB/POZ Zinc Finger | Dendritic-Derived BTB/POZ Zinc Finger Protein | ZBTB20 | Zinc Finger Protein 288 | Zinc Finger- and BTB Domain-Containing Protein 20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523829","Standard Environmental Condition","C134026","A single set of environmental conditions.","Standard Environmental Condition | Standard",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521854","Cycled-Simple Environmental Condition","C134027","A set of two alternating environmental conditions.","Cycled-Simple Environmental Condition | Cycled-Simple",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520886","Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8","C133581","Stage IVA includes: (T4a, N2, M0, Any G); (T4b, N0-2, M0, Any G); (Any T, N3, M0, Any G). T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520889","Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8","C133582","Stage IVB includes: Any T, Any N, M1, Any G. M1: Distant metastasis. (AJCC 8th ed.)","Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520701","Gastroesophageal Junction Adenocarcinoma by AJCC v8 Postneoadjuvant Therapy Stage","C133583","A term that refers to the postneoadjuvant therapy staging of gastroesophageal junction adenocarcinoma according to the American Joint Committee on Cancer, 8th edition.","Gastroesophageal Junction Adenocarcinoma by AJCC v8 Postneoadjuvant Therapy Stage | Gastroesophageal Junction Adenocarcinoma by AJCC v8 ypTNM Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520926","Postneoadjuvant Therapy Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8","C133584","Stage I includes: T0-2, N0, M0. T0: No evidence of primary tumor. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Postneoadjuvant Therapy Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520930","Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8","C133585","Stage II includes: T3, N0, M0. T3: Tumor invades adventitia. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520934","Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8","C133586","Stage III includes: IIIA: (T0-2, N1, M0); IIIB: (T3, N1, M0); (T0-3, N2, M0); (T4a, N0, M0). T0: No evidence of primary tumor. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520937","Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8","C133587","Stage IIIA includes: T0-2, N1, M0. T0: No evidence of primary tumor. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520940","Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8","C133588","Stage IIIB includes: (T3, N1, M0); (T0-3, N2, M0); (T4a, N0, M0). T0: No evidence of primary tumor. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521717","TNFSF14 wt Allele","C133789","Tumor necrosis factor ligand superfamily member 14 (240 aa, ~26 kDa) is encoded by the human TNFSF14 gene. This protein is involved in the regulation of both T-cell proliferation and apoptosis.","TNFSF14 wt Allele | CD258 | HVEML | LIGHT | LTg | Tumor Necrosis Factor (Ligand) Superfamily, Member 14 Gene | Tumor Necrosis Factor Superfamily Member 14 wt Allele | Tumor Necrosis Factor Superfamily, Member 14 Gene | UNQ391/PRO726",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1570446","TNFSF14 protein, human","C133790","Tumor necrosis factor ligand superfamily member 14 (240 aa, ~26 kDa) is encoded by the human TNFSF14 gene. This protein is involved in the regulation of both T-cell proliferation and apoptosis.","Tumor Necrosis Factor Ligand Superfamily Member 14 | CD258 | CD258 Antigen | HVEM-L | Herpes Virus Entry Mediator Ligand | Herpesvirus Entry Mediator Ligand | LIGHT | TNFSF14 | Tumor Necrosis Factor Ligand 1D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521806","Stage II Small Intestinal Adenocarcinoma AJCC v8","C133896","Stage II includes: IIA: T3, N0, M0; IIB: T4, N0, M0. T3: Tumor invading through the muscularis propria into the subserosa, or extending into nonperitonealized perimuscular tissue (mesentery or retroperitoneum) without serosal penetration. For T3 tumors, the nonperitonealized perimuscular tissue is, for the jejunum and ileum, part of the mesentery and, for the duodenum in areas where serosa is lacking, part of the interface with the pancreas. T4: Tumor perforating the visceral peritoneum or directly invading other organs or structures (e.g., other loops of small intestine, mesentery of adjacent loops of bowel, and abdominal wall by way of serosa; for duodenum only, invasion of pancreas or bile duct). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Small Intestinal Adenocarcinoma AJCC v8 | Stage II Small Intestinal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521807","Stage IIA Small Intestinal Adenocarcinoma AJCC v8","C133897","Stage IIA includes: T3, N0, M0. T3: Tumor invading through the muscularis propria into the subserosa, or extending into nonperitonealized perimuscular tissue (mesentery or retroperitoneum) without serosal penetration. For T3 tumors, the nonperitonealized perimuscular tissue is, for the jejunum and ileum, part of the mesentery and, for the duodenum in areas where serosa is lacking, part of the interface with the pancreas. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIA Small Intestinal Adenocarcinoma AJCC v8 | Stage IIA Small Intestinal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521855","Complex Environmental Condition","C134028","Multiple phases with different sets of environmental conditions.","Complex Environmental Condition | Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523826","Release Determination","C134029","For determination of acceptability for use of a material, drug or a drug substance.","Release Determination | Release",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521856","Stability Determination","C134030","For determination of maintained performance parameters on storage over time, of a material, drug or a drug substance.","Stability Determination | Stability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826770","RAVER2 Gene","C134316","This gene plays a role in binding single stranded RNA.","RAVER2 Gene | RAVER2 | Ribonucleoprotein, PTB Binding 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522036","RAVER2 wt Allele","C134317","Human RAVER2 wild-type allele is located in the vicinity of 1p31.3 and is approximately 88 kb in length. This allele, which encodes ribonucleoprotein PTB-binding 2 protein, is involved in RNA binding.","RAVER2 wt Allele | FLJ10770 | KIAA1579 | Raver2, Mouse, Homolog of Gene | Ribonucleoprotein, PTB Binding 2 wt Allele | Ribonucleoprotein, PTB-Binding 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523822","Ribonucleoprotein PTB-Binding 2","C134318","Ribonucleoprotein PTB-binding 2 (691 aa, ~74 kDa) is encoded by the human RAVER2 gene. This protein plays a role in RNA binding and may affect RNA processing.","Ribonucleoprotein PTB-Binding 2 | Protein Raver-2 | RAVER2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522037","Refractory Acute Myeloid Leukemia","C134319","Acute myeloid leukemia that does not respond to treatment.","Refractory Acute Myeloid Leukemia | Refractory AML | Refractory Acute Myeloid Leukemia (AML)",,,,,,,,,,,,,,,"3572256","Refractory acute myeloid leukemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1166680","Interphase Chromosome","C13431","Interphase chromosomes are decondensed chromosomes that reside in the interphase nucleus in the form of chromatin. Two types of chromatin, euchromatin and heterochromatin, can be discerned microscopically.","Interphase Chromosome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516507","30 nm Chromatin Fiber","C13433","A level of DNA packaging in chromatin above that of the nucleosome, the fundamental subunit of chromatin structure.  The chromatin fiber has a thickness of about 30 nanometers and results from the folding of a linear array of nucleosomes (thickness about 10 nm) into a more compact fiber.","Chromatin Fiber | 30 nm Chromatin Fiber | 30 nm Fiber | Chromatin Fibril",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512460","Higher Order Chromatin Structure","C13434","Refers to various levels of DNA packaging in the chromosomes above that of the nucleosome.  Includes the chromatin fiber and higher levels of folding such as loops.","Higher Order Chromatin Structure | Higher Order Chromatin Folding | Higher Order Structure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516509","Chromatin Loop","C13435","A higher order chromatin structure above the level of the chromatin fiber.  The organization of chromatin into loops permits the partitioning of chromatin into topologically independent domains, and is thought to facilitate its compartmentation into functionally independent regions.","Chromatin Loop | Chromatin Loop Domains | DNA Loop",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516545","Chromosome Territory","C13436","The physical volume occupied by a specific chromosome in the interphase nucleus.  The territories from distinct chromosomes do not appear to overlap, preventing an intermingling of the decondensed chromatin.  Relative to a nuclear landmark (e.g. nucleolus), chromosome territories appear to differ from cell to cell.","Chromosome Territory | Chromosomal Territory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1257994","Matrix Attachment Regions","C13437","Regions of chromosomal DNA attached to a structural component of the interphase nucleus termed the nuclear matrix, permitting the partitioning of DNA in the chromosomes into looped chromatin domains.","Matrix Attachment Region | MAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511738","Death Domain","C13438","The death domain is a protein region, approximately 80 amino acids long, that is required for transmission of the cytotoxic signal of apoptosis and is present in the TNF receptor, FAS, and several downstream signaling molecules.  Transmission of the apoptotic signal requires the functional interaction of proteins via the death domain.","Death Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420821","TNFSF9 Gene","C133791","This gene plays a role in T-lymphocyte activation.","TNFSF9 Gene | TNFSF9 | Tumor Necrosis Factor Superfamily Member 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521718","TNFSF9 wt Allele","C133792","Human TNFSF9 wild-type allele is located in the vicinity of 19p13.3 and is approximately 7 kb in length. This allele, which encodes tumor necrosis factor ligand superfamily member 9 protein, is involved in antigen presentation, T-lymphocyte proliferation and cytotoxic T-cell stimulation.","TNFSF9 wt Allele | 4-1BB-L | 4-1BB-L, Mouse, Homolog of Gene | CD137L | Homolog of Mouse 4-1BB-L Gene | TNLG5A | Tumor Necrosis Factor (Ligand) Superfamily, Member 9 Gene | Tumor Necrosis Factor Ligand Superfamily, Member 9 Gene | Tumor Necrosis Factor Superfamily Member 9 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1676759","TNFSF9 protein, human","C133793","Tumor necrosis factor ligand superfamily member 9 (254 aa, ~27 kDa) is encoded by the human TNFSF9 gene. This protein plays a role in the costimulation of T-cells.","Tumor Necrosis Factor Ligand Superfamily Member 9 | 4-1BB Ligand | 4-1BB-L | 4-1BBL | Receptor 4-1BB Ligand | TNFSF9 | Tumor Necrosis Factor Ligand 5A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521722","Stage II Anal Cancer AJCC v8","C133797","Stage II includes: IIA: T2, N0, M0; IIB: T3, N0, M0. T2: Tumor larger than 2 cm but equal to or smaller than 5 cm. T3: Tumor larger than 5 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Anal Cancer AJCC v8 | Stage II Anal Canal and Perianal (Anal Margin) Carcinoma AJCC v8 | Stage II Anal Cancer | Stage II Anal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521808","Stage IIB Small Intestinal Adenocarcinoma AJCC v8","C133898","Stage IIB includes: T4, N0, M0. T4: Tumor perforating the visceral peritoneum or directly invading other organs or structures (e.g., other loops of small intestine, mesentery of adjacent loops of bowel, and abdominal wall by way of serosa; for duodenum only, invasion of pancreas or bile duct). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIB Small Intestinal Adenocarcinoma AJCC v8 | Stage IIB Small Intestinal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521809","Stage III Small Intestinal Adenocarcinoma AJCC v8","C133899","Stage III includes: IIIA: Any T, N1, M0; IIIB: Any T, N2, M0. N1: Metastasis in one or two regional lymph nodes. N2: Metastasis in three or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Small Intestinal Adenocarcinoma AJCC v8 | Stage III Small Intestinal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0094556","Didox","C1338","A ribonucleotide reductase inhibitor with activity against retroviruses. Didox inhibits retrovirus replication by depleting the deoxynucleotides obligatory for synthesis of the proviral DNA intermediate of retrovirus replication.","Didox | 3,4-Dihydroxybenzohydroxamic Acid | 3,4-Dihydroxybenzohydroxamic acid | DIDOX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521810","Stage IIIA Small Intestinal Adenocarcinoma AJCC v8","C133900","Stage IIIA includes: Any T, N1, M0. N1: Metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIA Small Intestinal Adenocarcinoma AJCC v8 | Stage IIIA Small Intestinal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521811","Stage IIIB Small Intestinal Adenocarcinoma AJCC v8","C133901","Stage IIIB includes: Any T, N2, M0. N2: Metastasis in three or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIB Small Intestinal Adenocarcinoma AJCC v8 | Stage IIIB Small Intestinal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521812","Stage IV Small Intestinal Adenocarcinoma AJCC v8","C133902","Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Small Intestinal Adenocarcinoma AJCC v8 | Stage IV Small Intestinal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521813","Molfile","C133910","A chemical text file format developed by Molecular Design Limited (MDL) that represent information about molecular atoms, bonds, connectivity and coordinates. The file extension is .mol.","MDL Molfile Format | MDL Molfile | MDL Molfile | MOLFILE | Molecular Design Limited Molefile | Molfile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521814","Valve-up","C133914","A position in which the valve indicator is pointing up.","Valve-up | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521815","Valve-down","C133915","A position in which the valve indicator is pointing down.","Valve-down | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0226884","Gastrointestinal Fluid or Secretion","C13321","Fluids and secretions within the passage leading from the mouth to the anus through the pharynx, esophagus, stomach, and intestine which cause digestion.","Gastrointestinal Fluid or Secretion | Gastrointestinal Fluids and Secretions",,,,,,,,,,,,,,,"4274793","Digestive system fluid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521045","Esophageal Adenocarcinoma by AJCC v8 Postneoadjuvant Therapy Stage","C133432","A term that refers to the postneoadjuvant therapy staging of esophageal adenocarcinoma according to the American Joint Committee on Cancer, 8th edition.","Esophageal Adenocarcinoma by AJCC v8 Postneoadjuvant Therapy Stage | Esophageal Adenocarcinoma by AJCC v8 ypTNM Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520923","Postneoadjuvant Therapy Stage I Esophageal Adenocarcinoma AJCC v8","C133433","Stage I includes: T0-2, N0, M0. T0: No evidence of primary tumor. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Postneoadjuvant Therapy Stage I Esophageal Adenocarcinoma AJCC v8 | Stage I Esophageal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515174","TRAF Domain","C13439","The TRAF domain is the portion of TRAF family adaptor proteins which bind to TNF receptor cytoplasmic domain. It is the C-terminal homology region of 230 amino acids of signal-transducing proteins associated with members of the TNFR superfamily. This domain is involved in a variety of specific protein-protein interactions.","TRAF Domain | TNF Receptor-Associated Factor Motif | TRAF Motif",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520881","Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8","C133539","Stage IV includes: IVA: (T4a, N2, M0, Any G, Tumor location: Any); (T4b, N0-2, M0, Any G, Tumor location: Any); (Any T, N3, M0, Any G, Tumor location: Any); IVB: (Any T, Any N, M1, Any G, Tumor location: Any). T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)","Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8 | Stage IV Esophageal Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520500","PIM/FLT3 Kinase Inhibitor SEL24","C133540","An orally available inhibitor of PIM family serine/threonine protein kinases and mutant forms of FMS-related tyrosine kinase 3 (FLT3; STK1) with potential antineoplastic activity. Upon oral administration, dapolsertib binds to and inhibits the kinase activities of PIM-1, -2 and -3, and mutant forms of FLT3, which may result in the interruption of the G1/S phase cell cycle transition, an inhibition of cell proliferation, and an induction of apoptosis in tumor cells that overexpress PIMs or express mutant forms of FLT3. FLT3, a tyrosine kinase receptor that is overexpressed or mutated in various cancers, plays a role in signaling pathways that regulate hematopoietic progenitor cell proliferation, and in leukemic cell proliferation and survival. PIM kinases, downstream effectors of many cytokine and growth factor signaling pathways, including the FLT3 signaling pathway, play key roles in cell cycle progression and apoptosis inhibition and may be overexpressed in various malignancies.","Dapolsertib | DAPOLSERTIB | Dual PIM/FLT3 Kinase Inhibitor | PIM/FLT3 Kinase Inhibitor SEL24 | PIM/FLT3 Kinase Inhibitor SEL24 | SEL 24 | SEL-24 | SEL-24 FREE BASE | SEL24 | SEL24-B489",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521901","Stage 0 Appendix Carcinoma AJCC v8","C134118","Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ (intramucosal carcinoma; invasion of the lamina propria or extension into but not through the muscularis mucosae). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0 Appendix Carcinoma AJCC v8 | Stage 0 Appendiceal Carcinoma AJCC v8 | Stage 0 Appendix Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521902","Stage 0 Low Grade Appendix Mucinous Neoplasm (LAMN) AJCC v8","C134119","Stage 0 includes: Tis(LAMN), N0, M0. Tis(LAMN): Low-grade appendiceal mucinous neoplasm confined by the muscularis propria. Acellular mucin or mucinous epithelium may invade into the muscularis propria. T1 and T2 are not applicable to LAMN. Acellular mucin or mucinous epithelium that extends into the subserosa or serosa should be classified as T3 or T4a, respectively. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0 Low Grade Appendix Mucinous Neoplasm (LAMN) AJCC v8 | Stage 0 Low Grade Appendiceal Mucinous Neoplasm (LAMN) | Stage 0 Low-Grade Appendix Mucinous Neoplasm (LAMN) AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519812","Unspecified Anatomic Sites","C13411","Research that isn't focused on a specific site.","Unspecified Anatomic Sites | Unspecified Site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521903","Stage I Appendix Carcinoma AJCC v8","C134120","Stage I includes: (T1, N0, M0); (T2, N0, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Appendix Carcinoma AJCC v8 | Stage I Appendiceal Carcinoma AJCC v8 | Stage I Appendix Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521904","Stage II Appendix Carcinoma AJCC v8","C134121","Stage II includes: IIA: T3, N0, M0; IIB: T4a, N0, M0; IIC: T4b, N0, M0. T3: Tumor invades through the muscularis propria into the subserosa or the mesoappendix. T4a: Tumor invades through the visceral peritoneum, including the acellular mucin or mucinous epithelium involving the serosa of the appendix or serosa of the mesoappendix. T4b: Tumor directly invades or adheres to adjacent organs or structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Appendix Carcinoma AJCC v8 | Stage II Appendiceal Carcinoma AJCC v8 | Stage II Appendix Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521905","Stage IIA Appendix Carcinoma AJCC v8","C134122","Stage IIA includes: T3, N0, M0. T3: Tumor invades through the muscularis propria into the subserosa or the mesoappendix. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIA Appendix Carcinoma AJCC v8 | Stage IIA Appendiceal Carcinoma AJCC v8 | Stage IIA Appendix Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521906","Stage IIB Appendix Carcinoma AJCC v8","C134123","Stage IIB includes: T4a, N0, M0. T4a: Tumor invades through the visceral peritoneum, including the acellular mucin or mucinous epithelium involving the serosa of the appendix or serosa of the mesoappendix. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIB Appendix Carcinoma AJCC v8 | Stage IIB Appendiceal Carcinoma AJCC v8 | Stage IIB Appendix Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521907","Stage IIC Appendix Carcinoma AJCC v8","C134124","Stage IIC includes: T4b, N0, M0. T4b: Tumor directly invades or adheres to adjacent organs or structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIC Appendix Carcinoma AJCC v8 | Stage IIC Appendiceal Carcinoma AJCC v8 | Stage IIC Appendix Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521908","Stage III Appendix Carcinoma AJCC v8","C134125","Stage III includes: IIIA: (T1, N1, M0); (T2, N1, M0); IIIB: (T3, N1, M0); (T4, N1, M0); IIIC: (Any T, N2, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. T3: Tumor invades through the muscularis propria into the subserosa or the mesoappendix. T4: Tumor invades the visceral peritoneum, including the acellular mucin or mucinous epithelium involving the serosa of the appendix or mesoappendix, and/or directly invades adjacent organs or structures. N1: One to three regional lymph nodes are positive (tumor in lymph node measuring 0.2 mm or more) or any number of tumor deposits is present, and all identifiable lymph nodes are negative. N2: Four or more regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Appendix Carcinoma AJCC v8 | Stage III Appendiceal Carcinoma AJCC v8 | Stage III Appendix Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522011","Stage IIIB Colon Cancer AJCC v8","C134285","Stage IIIB includes: (T3-T4a, N1/N1c, M0); (T2-T3, N2a, M0); (T1-T2, N2b, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N1c: No regional lymph nodes are positive, but there are tumor deposits in the subserosa, mesentery, or nonperitonealized pericolic, or perirectal/mesorectal tissues. N2a: Four to six regional lymph nodes are positive. N2b: Seven or more regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Colon Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522012","Stage IIIC Colon Cancer AJCC v8","C134286","Stage IIIC includes: (T4a, N2a, M0); (T3-T4a, N2b, M0); (T4b, N1-N2, M0). T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). T4b: Tumor directly invades or adheres to adjacent organs or structures. N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N2: Four or more regional lymph nodes are positive. N2a: Four to six regional lymph nodes are positive. N2b: Seven or more regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIC Colon Cancer AJCC v8 | Stage IIIC Colon Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522013","Stage IV Colon Cancer AJCC v8","C134287","Stage IV includes: IVA: (Any T, Any N, M1a); IVB: (Any T, Any N, M1b); IVC: (Any T, Any N, M1c). M1a: Metastasis to one site or organ without peritoneal metastasis. M1b: Metastasis to two or more sites or organs without peritoneal metastasis. M1c: Metastasis to the peritoneal surface alone or with other site or organ metastases. (AJCC 8th ed.)","Stage IV Colon Cancer AJCC v8 | Stage IV Colon Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522014","Stage IVA Colon Cancer AJCC v8","C134288","Stage IVA includes: Any T, Any N, M1a. M1a: Metastasis to one site or organ without peritoneal metastasis. (AJCC 8th ed.)","Stage IVA Colon Cancer AJCC v8 | Stage IVA Colon Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522015","Stage IVB Colon Cancer AJCC v8","C134289","Stage IVB includes: Any T, Any N, M1b. M1b: Metastasis to two or more sites or organs without peritoneal metastasis.  (AJCC 8th ed.)","Stage IVB Colon Cancer AJCC v8 | Stage IVB Colon Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512495","Hormone Receptor DNA-Binding Domain","C13428","One of three structural motifs observed in DNA binding domains of zinc proteins.  Originally identified in the glucocorticoid receptor, it's also known as the C4 zinc finger, or the zinc twist.  Each of two zinc atoms is bound to four cysteine residues; the zinc twist is represented by a helical DNA recognition site located between the two zinc atoms.","Hormone Receptor DNA-Binding Domain | C4 Zinc Finger | Zinc Twist Motif",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522016","Stage IVC Colon Cancer AJCC v8","C134290","Stage IVC includes: Any T, Any N, M1c. M1c: Metastasis to the peritoneal surface alone or with other site or organ metastases. (AJCC 8th ed.)","Stage IVC Colon Cancer AJCC v8 | Stage IVC Colon Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522017","Stage 0 Rectal Cancer AJCC v8","C134291","Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ, intramucosal carcinoma (involvement of lamina propria with no extension through muscularis mucosae). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0 Rectal Cancer AJCC v8 | Stage 0 Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522018","Stage I Rectal Cancer AJCC v8","C134292","Stage I includes: (T1, N0, M0); (T2, N0, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Rectal Cancer AJCC v8 | Stage I Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520927","Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8","C133434","Stage II includes: T3, N0, M0. T3: Tumor invades adventitia. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8 | Stage II Esophageal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520931","Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8","C133435","Stage III includes: IIIA: (T0-2, N1, M0); IIIB: (T3, N1, M0); (T0-3, N2, M0); (T4a, N0, M0). T0: No evidence of primary tumor. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8 | Stage III Esophageal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520935","Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8","C133436","Stage IIIA includes: T0-2, N1, M0. T0: No evidence of primary tumor. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8 | Stage IIIA Esophageal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520941","Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8","C133438","Stage IV includes: IVA: (T4a, N1-2, M0); (T4a, NX, M0); (T4b, N0-2, M0); (Any T, N3, M0); IVB: (Any T, Any N, M1). T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. NX: Regional lymph nodes cannot be assessed. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)","Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8 | Stage IV Esophageal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520945","Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8","C133439","Stage IVA includes: (T4a, N1-2, M0); (T4a, NX, M0); (T4b, N0-2, M0); (Any T, N3, M0). T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. NX: Regional lymph nodes cannot be assessed. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8 | Stage IVA Esophageal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0312783","Immunoglobulin Hinge Region","C13343","A region of relative flexibility between the variable and constant regions of an antibody molecule.","Immunoglobulin Hinge Region | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520948","Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8","C133440","Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8 | Stage IVB Esophageal Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0304983","Iodine I 131 Iodocholesterol","C133023","A radioiodine-labeled cholesterol analogue with diagnostic imaging activity upon scintigraphy. Upon administration, iodine I 131 iodocholesterol accumulates in tissues where steroid hormones are produced, including the adrenal glands and, to a lesser extent, the ovaries and the testes. After binding to low-density lipoprotein (LDL) receptors on adrenocortical cells, this agent is internalized. As cholesterol is the precursor for all adrenocortical steroid hormones, areas of hormonal hypersecretion, can be visualized using scintigraphy and the adrenocortical function can be assessed.","Iodine I 131 Iodocholesterol | Cholest-5-en-3-ol, 19(Iodo-(sup 131)I)-, (3beta)- | I-131 Iodocholesterol | IODOCHOLESTEROL I-131 | Iodine 131 Iodocholesterol | Iodine I-131 Iodocholesterol | Iodocholesterol (131 I) | Iodocholesterol (131I) | Iodocholesterol I 131",,,,,,,,,,,,,,,"4286787","Iodocholesterol (131-I)",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL520552","Unexpected Shutdown","C133544","Problem associated with the device unexpectedly powering down.","Unexpected Shutdown | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520821","Audible Prompt/Feedback","C133545","Problem with any deviation from the documented specifications of a device that relates to audible feedback.","Audible Prompt/Feedback | Audible Prompt/Feedback Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520839","Tactile Prompts/Feedback","C133547","Problem with any deviation from the documented specifications of the device that relates to tactile feedback, e.g. device vibrational prompt.","Tactile Prompts/Feedback | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520702","Gastroesophageal Junction Adenocarcinoma by AJCC v8 Stage","C133548","A term that refers to the staging of gastroesophageal junction adenocarcinoma according to the American Joint Committee on Cancer, 8th edition.","Gastroesophageal Junction Adenocarcinoma by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520699","Gastroesophageal Junction Adenocarcinoma by AJCC v8 Clinical Stage","C133549","A term that refers to the clinical staging of gastroesophageal junction adenocarcinoma according to the American Joint Committee on Cancer, 8th edition.","Gastroesophageal Junction Adenocarcinoma by AJCC v8 Clinical Stage | Gastroesophageal Junction Adenocarcinoma by AJCC v8 cTNM Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520608","Clinical Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8","C133550","Stage 0 includes: Tis, N0, M0. Tis: High-grade dysplasia, defined as malignant cells confined to the epithelium by the basement membrane. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Clinical Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033999","Pterygium","C133744","A wedge-shaped, benign, degenerative fibrovascular lesion arising from the bulbar conjunctiva and extending to the cornea. It is caused by chronic exposure to solar ultraviolet radiation, heat, and dust. It may cause severe vision loss.","Pterygium | Pterygium of Conjunctiva and Cornea",,,,,,,,,,,,,,,"375552","Pterygium",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL521681","Packs per Day","C133746","The number of cigarettes smoked in a 24 hour period, considered in 20-cigarette units.","Packs per Day | Pack a Day | Pack/Day",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521682","Treatment Based on Genomic Alteration","C133747","A question to determine if any therapeutic interventions, planned or performed, are tailored to an individual's specific genetic change or defect.","Treatment Based on Genomic Alteration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521683","Is Patient Eligible for Systemic Therapy in Provider's Opinion","C133748","A question regarding the eligibility of a patient for systemic therapy, based on the medical provider's opinion.","Is Patient Eligible for Systemic Therapy in Provider's Opinion | Eligibility for Systemic Therapy | Is the patient eligible to receive systemic therapy in provider's opinion | Patient Eligibility for Systemic Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521684","Treatment Planned Prior to Return of Genomic Testing Not Already Recorded","C133749","A question to determine if there are plans for treatment prior to the results of genetic testing that have not yet been recorded.","Treatment Planned Prior to Return of Genomic Testing Not Already Recorded | Is there any treatment planned to take place prior to return of genomic testing results that has not already been recorded",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600253","Intracisternal A-Particle Elements","C13374","Retroviral-like intracisternal A particles.  High copy number family of repeated elements in the mouse with a typical proviral organization.  Expressed very early in mouse development (2-8 cell stage) and in transformed cells.  Mutant alleles of various genes contain newly-integrated IAP genes.","Intracisternal A-Particle | IAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032859","Powassan Virus","C134498","A positive-sense single-stranded RNA virus in the genus Flavivirus. It is the causative agent of Powassan Disease, an infection of the central nervous system associated with encephalitis and/or meningitis. The virus is maintained in a cycle between ticks and small-to-medium-sized rodents.","Powassan Virus | POW",,,,,,,,,,,,,,,"4164452","Powassan virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1514663","RNA Conformation","C13449","Related to the secondary level of structural organization of RNA.  RNA can be found in various conformations, including double- as well as single-stranded, and in loops.","RNA Conformation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0137152","Pivaloyloxymethylbutyrate","C1344","An acyloxyalkyl ester prodrug of butyric acid. Pivaloyloxymethylbutyrate inhibits histone deacetylase, resulting in cell differentiation, cell growth inhibition, and apoptosis. (NCI04)","Pivaloyloxymethylbutyrate | AN-9 | Pivanex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522019","Stage II Rectal Cancer AJCC v8","C134293","Stage II includes: IIA: T3, N0, M0; IIB: T4a, N0, M0; IIC: T4b, N0, M0. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). T4b: Tumor directly invades or adheres to adjacent organs or structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Rectal Cancer AJCC v8 | Stage II Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522020","Stage IIA Rectal Cancer AJCC v8","C134294","Stage IIA includes: T3, N0, M0. T3: Tumor invades through the muscularis propria into pericolorectal tissues. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIA Rectal Cancer AJCC v8 | Stage IIA Rectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520890","Patient-Device Interaction Problem","C133496","Problem related to the interaction between the patient and a medical device.","Patient-Device Interaction Problem | Patient Device Interaction Problem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520763","Loosening of Implant Not Related to Bone-Ingrowth","C133497","Problem associated with the loss of direct anchorage of an implanted device over time or due to an injury.","Loosening of Implant Not Related to Bone-Ingrowth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520823","Component Misassembled","C133498","A device is found to have one or more components incorrectly assembled when delivered to the user facility.","Component Misassembled | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520221","Recurrent Atypical Teratoid/Rhabdoid Tumor","C133499","The reemergence of an atypical teratoid/rhabdoid tumor after a period of remission.","Recurrent Atypical Teratoid/Rhabdoid Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521348","Low pH","C133500","pH lower than expected and/or anticipated.","Low pH | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL520766","Lung Carcinoma Metastatic in the Central Nervous System","C133503","A carcinoma that has spread to the central nervous system from its original site in the lung, through the hematogenous route.","Metastatic Lung Carcinoma in the Central Nervous System | Lung Carcinoma Metastatic in the CNS | Lung Carcinoma Metastatic in the Central Nervous System | Lung Carcinoma Metastatic in the Central Nervous System | Metastatic Lung Cancer in the Central Nervous System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522762","Colorectal Neuroendocrine Tumor Pathologic Primary Tumor TNM Finding v8","C135183","A pathologic finding about one or more characteristics of a colorectal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Colorectal Neuroendocrine Tumor Pathologic Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521001","1q24-q25","C13468","A chromosome band present on 1q","1q24-q25 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522228","Olfactory Receptor 51B4","C134690","Olfactory receptor 51B4 (310 aa, ~35 kDa) is encoded by the human OR51B4 gene. This protein is involved in G protein-coupled receptor-mediated signaling following exposure to odorant molecules.","Olfactory Receptor 51B4 | OR51B4 | Odorant Receptor HOR5'beta1 | Odorant Receptor HOR5beta1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417562","MYO1E Gene","C134691","This gene plays a role in lipid localization and vesicular transport.","MYO1E Gene | MYO1E | Myosin IE Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522229","MYO1E wt Allele","C134692","Human MYO1E wild-type allele is located in the vicinity of 15q22.2 and is approximately 240 kb in length. This allele, which encodes unconventional myosin-Ie protein, is involved in the transport of lipids and cytoplasmic vesicles. Mutation of the gene is associated with focal segmental glomerulosclerosis type 6.","MYO1E wt Allele | FSGS6 | HuncM-IC | MGC104638 | MYO1C | Myosin IC Gene | Myosin IE wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523834","Unconventional Myosin-Ie","C134693","Unconventional myosin-Ie (1108 aa, ~127 kDa) is encoded by the human MYO1E gene. This protein plays a role in the intracellular movement of lipids and vesicles.","Unconventional Myosin-Ie | MYO1E | Myosin-Ic | Unconventional Myosin 1E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419257","RAN Gene","C134694","This gene is involved in nucleocytoplasmic transport.","RAN Gene | RAN | RAN, Member RAS Oncogene Family Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522230","RAN wt Allele","C134695","Human RAN wild-type allele is located in the vicinity of 12q24.33 and is approximately 6 kb in length. This allele, which encodes GTP-binding nuclear protein Ran, plays a role in nuclear import and export of proteins and RNAs.","RAN wt Allele | ARA24 | Gsp1 | OK/SW-cl.81 | RAN, Member RAS Oncogene Family wt Allele | TC4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523869","GTP-Binding Nuclear Protein Ran","C134696","GTP-binding nuclear protein Ran (216 aa, ~24 kDa) is encoded by the human RAN gene. This protein is involved in nucleocytoplasmic transport of proteins and RNAs.","GTP-Binding Nuclear Protein Ran | Androgen Receptor-Associated Protein 24 | GTPase Ran | Guanosine Triphosphatase Ran | RAN | Ras-Like Protein TC4 | Ras-Related Nuclear Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522231","PDC CX-2009","C134697","A probody drug conjugate (PDC) composed of a recombinant antibody targeting the tumor-associated antigen (TAA) CD166, which is masked by a cleavable masking peptide, and conjugated to the cytotoxic agent maytansinoid DM4, with potential antineoplastic activity. Upon administration of praluzatamab ravtansine and migration to the tumor microenvironment (TME), the cleavable masking peptide, which prevent anti-CD166 antibody binding to the CD166 expressed on both normal cells and tumor cells, is proteolytically cleaved by tumor-associated proteases that are specifically present in the TME. This enables the anti-CD166 antibody moiety of CX-2009 to selectively bind to, be internalized by, and deliver DM4 into CD166-expressing tumor cells. Following internalization, DM4 is released, binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of CD166-expressing tumor cells. The masking peptide prevents binding of the anti-CD166 antibody to CD166 in normal tissues, thereby minimizing toxicities.","Praluzatamab Ravtansine | ADC CX-2009 | Anti-CD166-DM4 CX-2009 | CX-2009 | PDC CX-2009 | PRALUZATAMAB RAVTANSINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424606","MELK Gene","C134698","This gene plays a role in cell cycle regulation, stem cell renewal, apoptosis, splicing regulation and the proliferation of neural progenitors.","MELK Gene | MELK | Maternal Embryonic Leucine Zipper Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522497","Selpercatinib","C134987","An orally bioavailable selective inhibitor of wild-type, mutant and fusion products involving the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET), with potential antineoplastic activity. Upon oral administration, selpercatinib selectively binds to and targets wild-type RET as well as various RET mutants and RET-containing fusion products. This results in an inhibition of cell growth of tumors cells that exhibit increased RET activity. In addition, selpercatinib targets, binds to and inhibits vascular endothelial growth factor receptor 1 (VEGFR1) and 3 (VEGFR3), and fibroblast growth factor receptor 1 (FGFR1), 2 (FGFR2), and 3 (FGFR3). RET overexpression, activating mutations, and fusions result in the upregulation and/or overactivation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role in the development and progression of these cancers.","Selpercatinib | 6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitril | 6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitrile | LOXO 292 | LOXO-292 | LOXO292 | RET Inhibitor LOXO-292 | RET Kinase Inhibitor LOXO-292 | Retevmo | Retsevmo | SELPERCATINIB | WHO 10967",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522498","Hamster Neoplasm","C134988","A neoplasm occurring in a hamster.","Hamster Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522499","Rabbit Neoplasm","C134989","A neoplasm occurring in a rabbit.","Rabbit Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520169","Xp11.2","C13498","A chromosome band present on Xp","Xp11.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522501","Hamster Lung Carcinoma","C134991","Carcinoma arising from the lung and occurring in a hamster.","Hamster Lung Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522502","Hamster Fibrosarcoma","C134992","Fibrosarcoma that occurs in a hamster.","Hamster Fibrosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522503","Hamster Pituitary Carcinoma","C134993","Carcinoma arising in the pituitary gland and occurring in a hamster.","Hamster Pituitary Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522504","Hamster Small Intestinal Neoplasm","C134994","A neoplasm that occurs in the small intestine of a hamster.","Hamster Small Intestinal Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522505","Horse Sarcoid","C134995","A fibroblastic tumor that occurs in the skin of a horse.","Horse Sarcoid | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522506","Mouse Histiocytic and Dendritic Cell Neoplasm","C134996","A tumor arising from histiocytes and dendritic cells and occurring in a mouse.","Mouse Histiocytic and Dendritic Cell Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030357","Rabbit Papilloma","C134998","A rabbit papilloma that is associated with infection by the Shope papilloma virus.","Rabbit Papilloma | Shope Papilloma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522852","Genetic Sub-Region Sequence","C135485","The determination of the sequence of nucleotide residues along a genetic sub-region of interest.","Genetic Sub-Region Sequence | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522853","Predicted Single Nucleotide Polymorphism Frequency","C135486","The determination of the anticipated or extrapolated frequency of a single nucleotide polymorphism within a single interbreeding population.","Predicted Single Nucleotide Polymorphism Frequency | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522854","Genetic Sequence Length","C135487","The determination of the number of base pairs that compose a nucleotide sequence.","Genetic Sequence Length | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522855","Genetic Sequence Start Location","C135488","The determination of the location on a nucleotide sequence that is considered to be the beginning of a genetic region of interest.","Genetic Sequence Start Location | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522390","Stage IIIB Ampulla of Vater Cancer AJCC v8","C134874","Stage IIIB includes: (T4, Any N, M0); (Any T, N2, M0). T4: Tumor involving the celiac axis, superior mesenteric artery, and/or common hepatic artery, irrespective of size. N2: Metastasis to four or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIB Ampulla of Vater Cancer AJCC v8 | Stage IIIB Ampulla of Vater Cancer | Stage IIIB Ampulla of Vater Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522391","Stage IV Ampulla of Vater Cancer AJCC v8","C134875","Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Ampulla of Vater Cancer AJCC v8 | Stage IV Ampulla of Vater Cancer | Stage IV Ampulla of Vater Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522394","Exocrine Pancreatic Cancer Clinical TNM Finding v8","C134878","A clinical finding about one or more characteristics of pancreatic cancer, following the rules of the TNM AJCC v8 classification system.","Pancreatic Cancer Clinical TNM Finding v8 | Exocrine Pancreatic Cancer Clinical TNM Finding v8 | Exocrine Pancreatic Carcinoma Clinical TNM Finding v8 | Pancreatic Carcinoma Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521538","6p21.2","C13487","A chromosome band present on 6p","6p21.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522710","Stage IV Jejunal Neuroendocrine Tumor AJCC v8","C135123","Stage IV includes: (T1, N0, N1, N2, M1); (T2, N0, N1, N2, M1); (T3, N0, N1, N2, M1); (T4, N0, N1, N2, M1). T1: Tumor invading lamina propria or submucosa and measuring 1 cm or less in size. T2: Tumor invading muscularis propria or measuring more than 1 cm in size. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. T4: Tumor invading visceral peritoneum (serosa) or other organs or adjacent structures. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis in less than 12 nodes. N2: Large mesenteric masses (larger than 2 cm) and/or extensive nodal deposits (12 or greater), especially those that encase the superior mesenteric vessels. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Jejunal Neuroendocrine Tumor AJCC v8 | Stage IV Jejunal Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522531","Ileal Neuroendocrine Tumor by AJCC v8 Stage","C135124","A term that refers to the staging of an ileal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system. This classification system applies to small bowel 'carcinoid' tumors (NET G1 and G2, and rare well-differentiated G3) arising in the ileum. This classification system does not apply to high-grade neuroendocrine carcinomas, mixed adenoneuroendocrine carcinomas, and neuroendocrine tumors of the duodenum. (from AJCC 8th Ed.)","Ileal Neuroendocrine Tumor by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522232","MELK wt Allele","C134699","Human MELK wild-type allele is located in the vicinity of 9p13.2 and is approximately 105 kb in length. This allele, which encodes maternal embryonic leucine zipper kinase, is involved in protein phosphorylation. Mutation of the gene may be associated with neoplastic diseases.","MELK wt Allele | HPK38 | Maternal Embryonic Leucine Zipper Kinase wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520603","14q32.3","C13469","A chromosome band present on 14q","14q32.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0064791","Asaley","C1346","An L-leucine derivative of melphalan with antineoplastic activity. Asaley alkylates and crosslinks DNA, resulting in disruption of DNA synthesis. (NCI04)","Asaley | Asalex | Ethyl ester of N-acetyl-DL-sarcolysyl-L-leucine | L-Leucine, N-[N-acetyl-4-[bis(2-chloroethyl)amino]-DL-phenylalanyl]-, ethyl ester (9CI) | L-Leucine, N-[N-acetyl-4-[bis-(2-chloroethyl)amino]-DL-phenylalanyl]-, ethylester | L-leucine, N-[N-acetyl-4-[bis(2-chloroethyl)amino]-DL-phenylalanyl]-, ethyl ester (9CI) | L-leucine, N-[N-acetyl-4-[bis-(2-chloroethyl)amino]-DL-phenylalanyl]-, ethylester | Leucine, N-[N-acetyl-3-[p-[bis(2-chloroethyl)amino]phenyl]-DL-alanyl]-, ethyl ester, L- (8CI) | ethyl ester of N-acetyl-DL-sarcolysyl-L-leucine | leucine, N-[N-acetyl-3-[p-[bis(2-chloroethyl)amino]phenyl]-DL-alanyl]-, ethyl ester, L- (8CI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3871462","Balugrastim","C134828","No value exists.","Balugrastim | BALUGRASTIM | CG-10639 | CG10639 | Human serum albumin (585 residues) fusion protein with des-(1-alanine,37-valine,38-serine,39-gutamic acid)-human granulocyte colony-stimulating factor (pluripoietin) | Serum albumin (human), fusion protein with granulocyte colony-stimulating factor (human)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522347","Empegfilgrastim","C134829","A long-acting form and covalent conjugate of recombinant human granulocyte colony-stimulating factor (G-CSF) filgrastim with 30 kDa polyethylene glycol (PEG), with potential hematopoietic activity. Upon administration, empegfilgrastim acts similarly to endogenous G-CSF and binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. Therefore, this agent may prevent the incidence and shorten the duration of chemotherapy-induced neutropenia. Conjugation of the cytokine with a PEG molecule significantly increases this agent's therapeutic half-life compared to filgrastim.","Empegfilgrastim | 1-(N-(4-(omega-Methoxypoly(oxyethylene))butyl)-L-methionine))human granulocyte colony-stimulating factor (pluripoietin) | BCD 017 | BCD-017 | BCD017 | EMPEGFILGRASTIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520542","13q12.3","C13482","A chromosome band present on 13q","13q12.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522348","Eyelid Sebaceous Gland Carcinoma","C134831","A sebaceous gland carcinoma affecting the eyelid. It arises from the meibomian glands, glands of Zeis, or glands associated with the caruncle. It usually affects elderly women and is characterized by high rate of local recurrence, regional, and distant metastases.","Eyelid Sebaceous Gland Carcinoma | Eyelid SGC | Sebaceous Gland Carcinoma of the Eyelid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522350","Recurrent Ph-Like Acute Lymphoblastic Leukemia","C134834","The reemergence of  B acute lymphoblastic leukemia, BCR-ABL1-like after a period of remission.","Recurrent B Acute Lymphoblastic Leukemia, BCR-ABL1-Like | Recurrent B Acute Lymphoblastic Leukemia with BCR-ABL1-Like Features | Recurrent B Acute Lymphoblastic Leukemia with BCR-ABL1-Like Features | Recurrent B Acute Lymphoblastic Leukemia with BCR::ABL1-Like Features | Recurrent B Acute Lymphoblastic Leukemia, BCR::ABL1-Like | Recurrent B-Acute Lymphoblastic Leukemia, BCR-ABL1-Like | Recurrent B-Acute Lymphoblastic Leukemia, BCR::ABL1-Like | Recurrent Ph-Like Acute Lymphoblastic Leukemia | Recurrent Ph-Like Acute Lymphoblastic Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522351","Refractory Ph-Like Acute Lymphoblastic Leukemia","C134835","B acute lymphoblastic leukemia, BCR-ABL1-like that does not respond to treatment.","Refractory B Acute Lymphoblastic Leukemia, BCR-ABL1-Like | Refractory B Acute Lymphoblastic Leukemia with BCR-ABL1-Like Features | Refractory B Acute Lymphoblastic Leukemia with BCR-ABL1-Like Features | Refractory B Acute Lymphoblastic Leukemia, BCR::ABL1-Like | Refractory B-Acute Lymphoblastic Leukemia with BCR::ABL1-Like Features | Refractory B-Acute Lymphoblastic Leukemia, BCR::ABL1-Like | Refractory Ph-Like Acute Lymphoblastic Leukemia | Refractory Ph-Like Acute Lymphoblastic Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522352","Ampulla of Vater Cancer TNM Finding v8","C134836","A finding about one or more characteristics of ampulla of Vater cancer, following the rules of the TNM AJCC v8 classification system. This staging system and classification does not apply to well-differentiated neuroendocrine (carcinoid) tumors but does apply to high-grade neuroendocrine carcinomas, such as small cell carcinoma and large cell neuroendocrine carcinoma. (from AJCC 8th Ed.)","Ampulla of Vater Cancer TNM Finding v8 | Ampulla of Vater Carcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522354","Alloantigen-specific Allogeneic Type 1 Regulatory T Cells T-allo10","C134838","A preparation of allogeneic CD4+ cells that were ex vivo stimulated with alloantigens, which involves exposing the cells to host antigen-presenting cells (APCs), in the presence of the immunomodulatory cytokine interleukin-10 (IL-10), with potential to prevent graft-versus-host disease (GvHD). The stimulation of the CD4+ cells by exposure to alloantigens plus IL-10 induces the differentiation of alloantigen-specific type 1 T regulatory (TR1) cells, which are hyporesponsive to the alloantigens. Upon infusion of T-allo10 and prior to donor hematopoietic stem cell transplantation (HSCT), the alloantigen-specific type 1 regulatory T-cells are tolerant to the alloantigens and suppress alloreactive immune responses by donor CD4+ and CD8+ T-cells. This may ultimately prevent GvHD. IL-10 plays a key role in controlling inflammation, down-regulating immune responses, and inducing immunological tolerance. IL-10 induces both a long lasting antigen specific T-cell anergy and the differentiation of TR1 cells.","Alloantigen-specific Allogeneic Type 1 Regulatory T Cells T-allo10 | Alloantigen-specific TR1 Cells Allo10 | Alloantigen-specific Type 1 Tregs T-allo10 | Donor-derived Host Alloantigen-specific IL-10 Anergized T Cells | T-allo10 | T-allo10 Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522711","Stage I Ileal Neuroendocrine Tumor AJCC v8","C135125","Stage I includes: T1, N0, M0. T1: Tumor invading lamina propria or submucosa and measuring 1 cm or less in size. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Ileal Neuroendocrine Tumor AJCC v8 | Stage I Ileal Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522712","Stage II Ileal Neuroendocrine Tumor AJCC v8","C135126","Stage II includes: (T2, N0, M0); (T3, N0, M0). T2: Tumor invading muscularis propria or measuring more than 1 cm in size. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Ileal Neuroendocrine Tumor AJCC v8 | Stage II Ileal Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522713","Stage III Ileal Neuroendocrine Tumor AJCC v8","C135127","Stage III includes: (T1, N1, N2, M0); (T2, N1, N2, M0); (T3, N1, N2, M0); (T4, N0, M0); (T4, N1, N2, M0). T1: Tumor invading lamina propria or submucosa and measuring 1 cm or less in size. T2: Tumor invading muscularis propria or measuring more than 1 cm in size. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. T4: Tumor invading visceral peritoneum (serosa) or other organs or adjacent structures. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis in less than 12 nodes. N2: Large mesenteric masses (larger than 2 cm) and/or extensive nodal deposits (12 or greater), especially those that encase the superior mesenteric vessels. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Ileal Neuroendocrine Tumor AJCC v8 | Stage III Ileal Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522714","Stage IV Ileal Neuroendocrine Tumor AJCC v8","C135128","Stage IV includes: (T1, N0, N1, N2, M1); (T2, N0, N1, N2, M1); (T3, N0, N1, N2, M1); (T4, N0, N1, N2, M1). T1: Tumor invading lamina propria or submucosa and measuring 1 cm or less in size. T2: Tumor invading muscularis propria or measuring more than 1 cm in size. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. T4: Tumor invading visceral peritoneum (serosa) or other organs or adjacent structures. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis in less than 12 nodes. N2: Large mesenteric masses (larger than 2 cm) and/or extensive nodal deposits (12 or greater), especially those that encase the superior mesenteric vessels. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Ileal Neuroendocrine Tumor AJCC v8 | Stage IV Ileal Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522532","Digestive System Neuroendocrine Tumor by AJCC v7 Stage","C135129","A term that refers to the staging of a digestive system neuroendocrine tumor, following the rules of the TNM AJCC v7 classification system.","Digestive System Neuroendocrine Tumor by AJCC v7 Stage | Digestive System Neuroendocrine Neoplasm by AJCC v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521417","4q34-q35","C13512","A chromosome band present on 4q","4q34-q35 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522715","Appendix Neuroendocrine Tumor TNM Finding v8","C135130","A finding about one or more characteristics of an appendiceal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system. This classification system applies to appendiceal NETs (carcinoid tumors) (NET G1 and G2, and rare well-differentiated G3). It does not apply to high-grade neuroendocrine carcinomas (NEC), goblet cell carcinoids, mixed adenocarcinomas, and adenocarcinomas of the appendix. (from AJCC 8th Ed.)","Appendix Neuroendocrine Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522716","Appendix Neuroendocrine Tumor Clinical TNM Finding v8","C135131","A clinical finding about one or more characteristics of an appendiceal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system.","Appendix Neuroendocrine Tumor Clinical TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522717","Appendix Neuroendocrine Tumor Clinical Distant Metastasis TNM Finding v8","C135132","A clinical finding about one or more characteristics of an appendiceal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Appendix Neuroendocrine Tumor Clinical Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520754","17p13.3","C13492","A chromosome band present on 17p","17p13.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522274","Stage III Hilar Cholangiocarcinoma AJCC v8","C134747","Stage III includes: IIIA: (T3, N0, M0); IIIB: (T4, N0, M0); IIIC: (Any T, N1, M0). T3: Tumor invading unilateral branches of the portal vein or hepatic artery. T4: Tumor invading the main portal vein or its branches bilaterally, or the common hepatic artery; or unilateral second-order biliary radicals with contralateral portal vein or hepatic artery involvement. N0: No regional lymph node metastasis. N1: One to three positive lymph nodes typically involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Hilar Cholangiocarcinoma AJCC v8 | III | Stage III Hilar Cholangiocarcinoma | Stage III Perihilar Cholangiocarcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520856","19q13.1","C13474","A chromosome band present on 19q","19q13.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522278","Stage IV Hilar Cholangiocarcinoma AJCC v8","C134751","Stage IV includes: IVA: (Any T, N2, M0); IVB: (Any T, Any N, M1). N2: Four or more positive lymph nodes involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Hilar Cholangiocarcinoma AJCC v8 | IV | Stage IV Hilar Cholangiocarcinoma | Stage IV Perihilar Cholangiocarcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522281","Intrahepatic Cholangiocarcinoma by AJCC v8 Stage","C134755","A term that refers to the staging of intrahepatic cholangiocarcinoma according to the American Joint Committee on Cancer, 8th edition.","Intrahepatic Cholangiocarcinoma by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522282","Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8","C134756","Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ (intraductal tumor). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8 | 0 | Stage 0 Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522283","Stage I Intrahepatic Cholangiocarcinoma AJCC v8","C134757","Stage I includes: IA (T1a, N0, M0); IB (T1b, N0, M0). T1a: Solitary tumor equal or less than 5 cm without vascular invasion.  T1b: Solitary tumor larger than 5 cm without vascular invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Intrahepatic Cholangiocarcinoma AJCC v8 | I | Stage I Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522355","Ampulla of Vater Cancer Clinical Distant Metastasis TNM Finding v8","C134839","A clinical finding about one or more characteristics of ampulla of Vater cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Ampulla of Vater Cancer Clinical Distant Metastasis TNM Finding v8 | Ampulla of Vater Carcinoma Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522675","Stage I Ampulla of Vater Neuroendocrine Tumor AJCC v8","C135082","Stage I includes: T1, N0, M0. T1: Tumor measuring 1 cm or less and is confined within the sphincter of Oddi. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Ampulla of Vater Neuroendocrine Tumor AJCC v8 | Stage I Ampulla of Vater Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522676","Stage II Ampulla of Vater Neuroendocrine Tumor AJCC v8","C135083","Stage II includes: (T2, N0, M0); (T3, N0, M0). T2: Tumor invading through the sphincter of Oddi into duodenal submucosa or muscularis propria, or measuring more than 1 cm. T3: Tumor invading the pancreas or peripancreatic adipose tissue. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Ampulla of Vater Neuroendocrine Tumor AJCC v8 | Stage II Ampulla of Vater Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522677","Stage III Ampulla of Vater Neuroendocrine Tumor AJCC v8","C135084","Stage III includes: (T4, N0, M0); (Any T, N1, M0). T4: Tumor invading the visceral peritoneum (serosa) or other organs. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Ampulla of Vater Neuroendocrine Tumor AJCC v8 | Stage III Ampulla of Vater Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522678","Stage IV Ampulla of Vater Neuroendocrine Tumor AJCC v8","C135085","Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Ampulla of Vater Neuroendocrine Tumor AJCC v8 | Stage IV Ampulla of Vater Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0877024","Schimke Immunoosseous Dysplasia","C135087","An autosomal recessive condition caused by mutation(s) in the SMARCAL1 gene, encoding SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A-like protein 1. It is characterized by short stature, intrauterine growth restriction, microdontia, depressed nasal bridge, skeletal dysplasia, immune complex nephritis and immune deficiency.","Schimke Immunoosseous Dysplasia | Schimke Immuno-Osseous Dysplasia",,,,,,,,,,,,,,,"37109992","Schimke immuno-osseous dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0796173","Spondyloperipheral Dysplasia","C135088","An autosomal dominant condition caused by mutation(s) in the COL2A1 gene, encoding collagen alpha-1(II) chain. It is characterized by short stature, pugilistic facies, midface hypoplasia, spondyloepiphyseal dysplasia, kyphosis, short ulna, and absent styloid process. Mutation(s) in the same gene are responsible for Kniest dysplasia.","Spondyloperipheral Dysplasia | ",,,,,,,,,,,,,,,"45773359","Spondyloperipheral dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1520990","1q21-q23","C13508","A chromosome band present on 1q","1q21-q23 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522679","Jejunal Neuroendocrine Tumor","C135090","A well-differentiated, low-, intermediate-, or high-grade neoplasm with neuroendocrine differentiation that arises from the jejunum.","Jejunal Neuroendocrine Tumor | Jejunal Well Differentiated Neuroendocrine Neoplasm | Jejunal Well-Differentiated Neuroendocrine Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519938","Vaginal and Other Genital","C13464","An anatomical qualifier that describes any part of the vagina or female genitalia.","Vaginal and Other Genital | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522202","Gallbladder Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C134655","A pathologic finding about one or more characteristics of gallbladder cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Gallbladder Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | Gallbladder Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511332","Bronchial Secretion","C13465","No value exists.","Bronchial Secretion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422418","POLR3K Gene","C134661","This gene is involved in the transcription of DNA into small RNAs.","POLR3K Gene | POLR3K | RNA Polymerase III Subunit K Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521492","5q33-q35","C13493","A chromosome band present on 5q","5q33-q35 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1839161","X-Linked Thrombocytopenia with Beta-Thalassemia","C134941","An X-linked recessive condition caused by mutation(s) in the GATA1 gene encoding erythroid transcription factor. It is characterized by thrombocytopenia, hemolytic anemia, and impairment of hemoglobin chain synthesis.","X-Linked Thrombocytopenia with Beta-Thalassemia | XLTT",,,,,,,,,,,,,,,"37397537","Beta thalassemia X-linked thrombocytopenia syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL522456","Rat Neoplasms","C134942","A neoplasm arising in a rat.","Rat Neoplasms | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522457","Budgerigar Fibrosarcoma","C134943","Fibrosarcoma that occurs in a budgerigar.","Budgerigar Fibrosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522458","Canine Pancreatic Carcinoma","C134944","Pancreatic carcinoma that occurs in a dog.","Canine Pancreatic Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522459","Chicken Monocytic Leukemia","C134945","Monocytic leukemia that occurs in a chicken.","Chicken Monocytic Leukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522460","Hamster Insulinoma","C134946","Insulinoma that occurs in a hamster.","Hamster Insulinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520539","13q12","C13518","A chromosome band present on 13q","13q12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523443","PODCI Adolescent Self-Reported Version - Comb Your Hair","C136130","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, was it easy or hard for you to: Comb your hair?","PODCI Adolescent Self-Reported Version - Comb Your Hair | PODCI3-Comb Your Hair | PODCI305",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523444","PODCI Adolescent Self-Reported Version - Button Buttons","C136131","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, was it easy or hard for you to: Button buttons?","PODCI Adolescent Self-Reported Version - Button Buttons | PODCI3-Button Buttons | PODCI306",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523445","PODCI Adolescent Self-Reported Version - Put on Your Coat","C136132","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, was it easy or hard for you to: Put on your coat?","PODCI Adolescent Self-Reported Version - Put on Your Coat | PODCI3-Put on Your Coat | PODCI307",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523446","PODCI Adolescent Self-Reported Version - Write With a Pencil","C136133","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, was it easy or hard for you to: Write with a pencil?","PODCI Adolescent Self-Reported Version - Write With a Pencil | PODCI3-Write With a Pencil | PODCI308",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523447","PODCI Adolescent Self-Reported Version - Miss School Because of Health","C136134","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) On average, over the last 12 months, how often did you miss school (camp, etc.) because of your health?","PODCI Adolescent Self-Reported Version - Miss School Because of Health | PODCI3-Miss School Because of Health | PODCI309",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523448","PODCI Adolescent Self-Reported Version - How You Look","C136135","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, how happy have you been with: How you look?","PODCI Adolescent Self-Reported Version - How You Look | PODCI3-How You Look | PODCI310",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523449","PODCI Adolescent Self-Reported Version - Your Body","C136136","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, how happy have you been with: Your body?","PODCI Adolescent Self-Reported Version - Your Body | PODCI3-Your Body | PODCI311",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523450","PODCI Adolescent Self-Reported Version - What Clothes or Shoes You Can Wear","C136137","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, how happy have you been with: What clothes or shoes you can wear?","PODCI Adolescent Self-Reported Version - What Clothes or Shoes You Can Wear | PODCI3-What Clothes/Shoes You Can Wear | PODCI312",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523452","PODCI Adolescent Self-Reported Version - Your Health in General","C136139","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, how happy have you been with: Your health in general?","PODCI Adolescent Self-Reported Version - Your Health in General | PODCI3-Your Health in General | PODCI314",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523639","Stage IVA Thymus Epithelial Neoplasm","C136330","Stage IVA includes: (Any T, N1, M0); (Any T, N0,1, M1a). N0: No regional lymph node metastasis. N1: Metastasis in anterior (perithymic) lymph nodes. M0: No distant metastasis. M1a: Separate pleural or pericardial nodule(s). (AJCC 8th ed.)","Stage IVA Thymus Epithelial Neoplasm AJCC v8 | Stage IVA Thymic Epithelial Neoplasm AJCC v8 | Stage IVA Thymic Epithelial Neoplasm AJCC v8 | Stage IVA Thymus Epithelial Neoplasm | Stage IVA Thymus Epithelial Neoplasm AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523640","Stage IVB Thymus Epithelial Neoplasm","C136331","Stage IVB includes: (Any T, N2, M0, M1a); (Any T, Any N, M1b). N2: Metastasis in deep intrathoracic or cervical lymph nodes. M0: No distant metastasis. M1a: Separate pleural or pericardial nodule(s). M1b: Pulmonary intraparenchymal nodule or distant organ metastasis. (AJCC 8th ed.)","Stage IVB Thymus Epithelial Neoplasm AJCC v8 | Stage IVB Thymic Epithelial Neoplasm AJCC v8 | Stage IVB Thymic Epithelial Neoplasm AJCC v8 | Stage IVB Thymus Epithelial Neoplasm | Stage IVB Thymus Epithelial Neoplasm AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522529","TLR 2/6/9 Agonist PUL-042","C135091","A solution consisting of a combination of two toll-like receptor (TLR) ligands: Pam2CSK4 acetate (Pam2), a synthetic diacylated lipopeptide (LP) that is an agonist of TLR2 and TLR6 (TLR2/6) and the TLR9 agonist oligodeoxynucleotide (ODN) M362, which contains unmethylated CpG-based dinucleotides, with potential immunostimulating activity. Upon administration via inhalation of the PUL-042 solution, the components in PUL-042 bind to and activate TLRs on lung epithelial cells. This induces the epithelial cells to produce peptides and reactive oxygen species (ROS) against pathogens, including bacteria, fungi and viruses, that are present in the lungs. M362, through binding of the CpG motifs to TLR9 and subsequent TLR9-mediated signaling, initiates the innate immune system and activates macrophages, natural killer (NK) cells, B-cells, and plasmacytoid dendritic cells (pDCs), stimulates interferon-alpha (IFN-a) production and induces a T-helper 1 cells (Th1)-mediated immune response. Pam2CSK4, through TLR2/6, activates the production of T-helper 2 cells (Th2), leading to the production of Th2-specific cytokines. Altogether, this protects against and kills the pathogens present in the lungs and prevents pulmonary infection. TLRs play fundamental roles in both pathogen recognition and the activation of innate immunity.","TLR 2/6/9 Agonist PUL-042 | Inhalation Solution PUL-042 | PUL 042 | PUL-042 | Pam2/M362 | Pam2/M362 Combination | Pam2CSK4 Acetate/ODN M362 | Pam2CSK4 Acetate/ODN M362 Combination | Solution PUL-042 | TLR Agonist PUL-042 | Toll-like Receptor Agonist PUL-042",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522680","Ileal Neuroendocrine Tumor","C135092","A well-differentiated, low-, intermediate-, or high-grade neoplasm with neuroendocrine differentiation that arises from the ileum.","Ileal Neuroendocrine Tumor | Ileal Well Differentiated Neuroendocrine Neoplasm | Ileal Well-Differentiated Neuroendocrine Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522681","Jejunum and Ileum Neuroendocrine Tumor TNM Finding v8","C135093","A finding about one or more characteristics of a jejunum and ileum neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system. This classification system applies to small bowel 'carcinoid' tumors (NET G1 and G2, and rare well-differentiated G3) arising in the jejunum and ileum. This classification system does not apply to high-grade neuroendocrine carcinomas, mixed adenoneuroendocrine carcinomas, and neuroendocrine tumors of the duodenum. (from AJCC 8th Ed.)","Jejunum and Ileum Neuroendocrine Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522159","Intrahepatic Bile Duct Cancer by AJCC v8 Stage","C134604","A term that refers to the staging of intrahepatic bile duct cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to intrahepatic cholangiocarcinomas, combined hepatocellular-cholangiocarcinomas (mixed hepatocholangiocarcinomas), and primary neuroendocrine tumors of the liver. Primary sarcomas of the liver, pure hepatocellular carcinomas, hilar cholangiocarcinomas, and gallbladder carcinomas are not staged using this staging system. (from AJCC 8th Ed.)","Intrahepatic Bile Duct Cancer by AJCC v8 Stage | Intrahepatic Bile Duct Cancer Tumor Stage (Pathologic) | Intrahepatic Bile Duct Carcinoma by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1823374","LMF1 Gene","C134605","This gene plays a role in protein maturation.","LMF1 Gene | LMF1 | Lipase Maturation Factor 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522160","LMF1 wt Allele","C134607","Human LMF1 wild-type allele is located in the vicinity of 16p13.3 and is approximately 128 kb in length. This allele, which encodes lipase maturation factor 1 protein, is involved in the activation of lipoprotein lipase. Mutation of the gene is associated with combined lipase deficiency.","LMF1 wt Allele | C16orf26 | Chromosome 16 Open Reading Frame 26 Gene | FLJ12681 | FLJ22302 | HMFN1876 | JFP11 | Lipase Maturation Factor 1 wt Allele | TMEM112 | TMEM112A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522161","Lipase Maturation Factor 1","C134608","Lipase maturation factor 1 (567 aa, ~65 kDa) is encoded by the human LMF1 gene. This protein plays a role in the maturation of lipoprotein lipase.","Lipase Maturation Factor 1 | LMF1 | Transmembrane Protein 112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514581","Proximal Enhancer Element","C13460","Enhancer sequences found nearby to the gene it regulates.","Proximal Enhancer Element | Proximal Enhancer Elements",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522905","Pancreatic Neuroendocrine Tumor Pathologic TNM Finding v8","C135544","A pathologic finding about one or more characteristics of a pancreatic neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system.","Pancreatic Neuroendocrine Tumor Pathologic TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522911","Pancreatic Neuroendocrine Tumor Pathologic Primary Tumor TNM Finding v8","C135550","A pathologic finding about one or more characteristics of a pancreatic neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Pancreatic Neuroendocrine Tumor Pathologic Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0106556","Bismuth Subcitrate","C1351","A mineral compound that is used to treat duodenal and gastric ulcers associated with Helicobacter pylori.","Bismuth Subcitrate | BISMUTH SUBCITRATE | Bismuth Tripotassium Dicitrate | Bismuth subcitrate | Colloidal Bismuth Subcitrate | De-Noltab | Tripotassium Dicitratobismuthate | Tripotassium dicitratobismuthate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522234","Capecitabine/Methotrexate/Vinorelbine Regimen","C134702","A regimen composed of capecitabine, methotrexate and vinorelbine that can potentially be used in the treatment of breast cancer.","Capecitabine/Methotrexate/Vinorelbine Regimen | Capecitabine-Methotrexate-Vinorelbine Regimen | Capecitabine/Methotrexate/Vinorelbine Tartrate Regimen | Xeloda-Methotrexate-Navelbine Regimen | Xeloda/Methotrexate/Navelbine Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826060","MIR506 Gene","C134703","This gene may be involved in RNA silencing.","MIR506 Gene | MIR506 | MicroRNA 506 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523643","Colectomy with En Bloc Removal of Regional Lymph Nodes","C136336","Surgical removal of the colon and regional lymph nodes.","Colectomy with En Bloc Removal of Regional Lymph Nodes | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520797","18p11.31-p11.21","C13633","A chromosome band present on 18p","18p11.31-p11.21 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523649","Colonoscopy with Marking of Cancerous Polyp","C136342","A procedure in which the location of a cancerous polyp is marked with a dye during colonoscopy, for the purpose of identifying the site for later, possible resection.","Colonoscopy with Marking of Cancerous Polyp | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523652","Thymoma by AJCC v8 Stage","C136345","A term that refers to the staging of thymoma, following the rules of the TNM AJCC v8 classification system.","Thymoma by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523655","Stage I Thymoma AJCC v8","C136348","Stage I includes: T1a, b, N0, M0. T1a: Tumor with no mediastinal pleura involvement. T1b: Tumor with direct invasion of mediastinal pleura. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Thymoma AJCC v8 | Stage I Thymoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523656","Stage II Thymoma AJCC v8","C136349","Stage II includes: T2, N0, M0. T2: Tumor with direct invasion of the pericardium (either partial or full thickness). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Thymoma AJCC v8 | Stage II Thymoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522163","Stage I Intrahepatic Bile Duct Cancer AJCC v8","C134610","Stage I includes: IA (T1a, N0, M0); IB (T1b, N0, M0). T1a: Solitary tumor equal to or less than 5 cm without vascular invasion.  T1b: Solitary tumor larger than 5 cm without vascular invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Intrahepatic Bile Duct Cancer AJCC v8 | Stage I Intrahepatic Bile Duct Cancer | Stage I Intrahepatic Bile Duct Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1825455","HEATR3 Gene","C134613","This gene is involved in nuclear import and assembly of ribonucleoproteins.","HEATR3 Gene | HEAT Repeat Containing 3 Gene | HEATR3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522167","Stage III Intrahepatic Bile Duct Cancer AJCC v8","C134615","Stage III includes: IIIA: (T3, N0, M0); IIIB: (T4, N0, M0); (Any T, N1, M0). T3: Tumor perforating the visceral peritoneum. T4: Tumor involving local extrahepatic structures by direct invasion. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Intrahepatic Bile Duct Cancer AJCC v8 | Stage III Intrahepatic Bile Duct Cancer | Stage III Intrahepatic Bile Duct Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0107606","Crisnatol Mesylate","C1354","No value exists.","Crisnatol Mesylate | BW A770U Mesylate | CRISNATOL MESYLATE | Crisnatol | crisnatol mesylate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522401","Exocrine Pancreatic Cancer Pathologic Primary Tumor TNM Finding v8","C134885","A pathologic finding about one or more characteristics of pancreatic cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Pancreatic Cancer Pathologic Primary Tumor TNM Finding v8 | Exocrine Pancreatic Cancer Pathologic Primary Tumor TNM Finding v8 | Exocrine Pancreatic Carcinoma Pathologic Primary Tumor TNM Finding v8 | Pancreatic Carcinoma Pathologic Primary Tumor TNM Finding v8 | Pathologic Staging: Primary Tumor (pT)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520373","11p15.5","C13488","A chromosome band present on 11p","11p15.5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522235","MIR506 wt Allele","C134704","Human MIR506 wild-type allele is located in the vicinity of Xq27.3 and is 124 bp in length. This allele, which encodes MIR506 pre-miRNA, may play a role in the regulation of gene expression.","MIR506 wt Allele | MIRN506 | Micro RNA 506 Gene | MicroRNA 506 wt Allele | hsa-mir-506 | miRNA506 | mir-506",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522236","MIR506 Pre-miRNA","C134705","MIR506 pre-miRNA (124 bases) is encoded by the human MIR506 gene. This oligoribonucleotide may be involved in the post-transcriptional regulation of gene expression.","MIR506 Pre-miRNA | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4085399","USF3 Gene","C134706","This gene may play a role in gene transcription or glycan metabolism.","USF3 Gene | USF3 | Upstream Transcription Factor Family Member 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522237","USF3 wt Allele","C134707","Human USF3 wild-type allele is located in the vicinity of 3q13.2 and is approximately 48 kb in length. This allele, which encodes basic helix-loop-helix domain-containing protein USF3, may be involved in transcription regulation.","USF3 wt Allele | KIAA2018 | Upstream Transcription Factor Family Member 3 wt Allele | Upstream Transcription Factor Family, Member 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522238","Basic Helix-Loop-Helix Domain-Containing Protein USF3","C134708","Basic helix-loop-helix domain-containing protein USF3 (2245 aa, ~242 kDa) is encoded by the human USF3 gene. This protein may play a role in the regulation of gene transcription.","Basic Helix-Loop-Helix Domain-Containing Protein USF3 | USF3 | Upstream Transcription Factor 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520170","Xp11.2-p11.4","C13470","A chromosome band present on Xp","Xp11.2-p11.4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523860","Mixed Lineage Kinase Domain-Like Protein","C134711","Mixed lineage kinase domain-like protein (471 aa, ~54 kDa) is encoded by the human MLKL gene. This protein is involved in tumor necrosis factor-dependent necroptosis.","Mixed Lineage Kinase Domain-Like Protein | MLKL | Mixed Lineage Kinase Domain Like | Mixed Lineage Kinase Domain-Like | hMLKL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522241","Perihilar Bile Duct Cancer Clinical TNM Finding v8","C134714","A clinical finding about one or more characteristics of perihilar bile duct cancer, following the rules of the TNM AJCC v8 classification system.","Perihilar Bile Duct Cancer Clinical TNM Finding v8 | Hilar Cholangiocarcinoma Clinical TNM Finding v8 | Perihilar Cholangiocarcinoma Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522242","Perihilar Bile Duct Cancer Clinical Distant Metastasis TNM Finding v8","C134715","A clinical finding about one or more characteristics of perihilar bile duct cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Perihilar Bile Duct Cancer Clinical Distant Metastasis TNM Finding v8 | Hilar Cholangiocarcinoma Clinical Distant Metastasis TNM Finding v8 | Perihilar Bile Duct Cancer Clinical Distant Metastasis (cM) | Perihilar Cholangiocarcinoma Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521559","6q14.3-16.1","C13653","A chromosome band present on 6q","6q14.3-16.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520488","12q12-12q14","C13654","A chromosome band present on 12q","12q12-12q14 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521191","2p24.1","C13593","A chromosome band present on 2p","2p24.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520405","11q23.3","C13483","A chromosome band present on 11q","11q23.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522356","Ampulla of Vater Cancer cM0 TNM Finding v8","C134840","Ampulla of Vater cancer without evidence of distant metastasis. (from AJCC 8th Ed.)","Ampulla of Vater Cancer cM0 TNM Finding v8 | Ampulla of Vater Carcinoma cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522357","Ampulla of Vater Cancer cM1 TNM Finding v8","C134841","Ampulla of Vater cancer with distant metastasis. (from AJCC 8th Ed.)","Ampulla of Vater Cancer cM1 TNM Finding v8 | Ampulla of Vater Carcinoma cM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522358","Ampulla of Vater Cancer Pathologic TNM Finding v8","C134842","A pathologic finding about one or more characteristics of ampulla of Vater cancer, following the rules of the TNM AJCC v8 classification system.","Ampulla of Vater Cancer Pathologic TNM Finding v8 | Ampulla of Vater Carcinoma Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522359","Ampulla of Vater Cancer Pathologic Distant Metastasis TNM Finding v8","C134843","A pathologic finding about one or more characteristics of ampulla of Vater cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Ampulla of Vater Cancer Pathologic Distant Metastasis TNM Finding v8 | Ampulla of Vater Carcinoma Pathologic Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522718","Appendix Neuroendocrine Tumor cM0 TNM Finding v8","C135133","Appendix neuroendocrine tumor without evidence of distant metastasis. (from AJCC 8th Ed.)","Appendix Neuroendocrine Tumor cM0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522720","Appendix Neuroendocrine Tumor cM1a TNM Finding v8","C135135","Appendix neuroendocrine tumor with metastasis confined to liver. (from AJCC 8th Ed.)","Appendix Neuroendocrine Tumor cM1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522721","Appendix Neuroendocrine Tumor cM1b TNM Finding v8","C135136","Appendix neuroendocrine tumor with metastasis in at least one extrahepatic site (e.g., lung, ovary, nonregional lymph node, peritoneum, bone). (from AJCC 8th Ed.)","Appendix Neuroendocrine Tumor cM1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522722","Appendix Neuroendocrine Tumor cM1c TNM Finding v8","C135137","Appendix neuroendocrine tumor with both hepatic and extrahepatic metastases. (from AJCC 8th Ed.)","Appendix Neuroendocrine Tumor cM1c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522723","Appendix Neuroendocrine Tumor Pathologic TNM Finding v8","C135138","A pathologic finding about one or more characteristics of an appendiceal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system.","Appendix Neuroendocrine Tumor Pathologic TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522724","Appendix Neuroendocrine Tumor Pathologic Distant Metastasis TNM Finding v8","C135139","A pathologic finding about one or more characteristics of an appendiceal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Appendix Neuroendocrine Tumor Pathologic Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520650","15q26.1","C13513","A chromosome band present on 15q","15q26.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522726","Appendix Neuroendocrine Tumor pM1a TNM Finding v8","C135141","Appendix neuroendocrine tumor with metastasis confined to liver. (from AJCC 8th Ed.)","Appendix Neuroendocrine Tumor pM1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522727","Appendix Neuroendocrine Tumor pM1b TNM Finding v8","C135142","Appendix neuroendocrine tumor with metastasis in at least one extrahepatic site (e.g., lung, ovary, nonregional lymph node, peritoneum, bone). (from AJCC 8th Ed.)","Appendix Neuroendocrine Tumor pM1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522728","Appendix Neuroendocrine Tumor pM1c TNM Finding v8","C135143","Appendix neuroendocrine tumor with both hepatic and extrahepatic metastases. (from AJCC 8th Ed.)","Appendix Neuroendocrine Tumor pM1c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522729","Appendix Neuroendocrine Tumor Pathologic Primary Tumor TNM Finding v8","C135144","A pathologic finding about one or more characteristics of an appendiceal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Appendix Neuroendocrine Tumor Pathologic Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522730","Appendix Neuroendocrine Tumor pTX TNM Finding v8","C135145","Appendix neuroendocrine tumor in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Appendix Neuroendocrine Tumor pTX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522731","Appendix Neuroendocrine Tumor pT0 TNM Finding v8","C135146","Appendix neuroendocrine tumor with no evidence of primary tumor. (from AJCC 8th Ed.)","Appendix Neuroendocrine Tumor pT0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522968","Neural Stem Cells-expressing CRAd-S-pk7","C135612","Neural stem cells (NSCs) that are transfected with the gliomatropic oncolytic adenovirus (OV) CRAd-S-pk7, a conditionally replicative oncolytic adenoviral (CRAd) vector that contains the tumor-specific survivin promoter (S) and a fiber protein polylysine modification (pk7), with potential antineoplastic activity. Upon intracerebral administration of NSC loaded with CRAd-S-pk7, the NSCs preferentially migrate towards tumor cells, and the polylysine moiety of the modified fiber protein expressed by the viral vector specifically targets and binds to tumor-specific heparan sulfate proteoglycans. Subsequently, the virus can infect the tumor cells and viral replication is initiated because E1 gene expression is controlled by the tumor-specific promoter for survivin. This results in the specific lysis of the glioma cells. The pk7 fiber modification and the survivin promoter enable tumor-specific infectivity, and transcriptional targeting and preferential replication in glioma cells, while sparing the surrounding normal brain parenchyma. The pK7 is comprised of a heparan sulfate binding domain incorporated into the fiber protein of the adenovirus.","Neural Stem Cells-expressing CRAd-S-pk7 | CRAd-S-pk7 loaded NSCs | NSC-CRAd-S-pk7 | NSC-CRAd-S-pk7 Virotherapeutic | NSCs loaded with CRAd-S-pk7 | SC-CRAd-Survivin-pk7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522969","Amikacin Inhalation Solution","C135613","A solution for inhalation containing the aminoglycoside antibiotic amikacin, with anti-bacterial activity. Upon aerosolized administration using the Pulmonary Drug Delivery System (PDDS), amikacin irreversibly binds to the 30S ribosomal subunit of susceptible organisms, thereby interfering with the activity of the translation initiation complex, which leads to both the misreading of mRNA and the production of non-functional or toxic peptides, and prevents normal protein synthesis. This kills susceptible bacteria.","Amikacin Inhalation Solution | BAY41 6551 | BAY41-6551",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522461","Mouse Leydig Cell Tumor","C134947","A Leydig cell tumor that occurs in a mouse.","Mouse Leydig Cell Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522462","Pike Sarcoma","C134949","Sarcoma that occurs in a pike.","Pike Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523253","PCL-5 - Having Difficulty Concentrating","C135940","The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Having difficulty concentrating?","PCL-5 - Having Difficulty Concentrating | PCL01-Having Difficulty Concentrating | PCL0119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523254","PCL-5 - Trouble Falling or Staying Asleep","C135941","The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Trouble falling or staying asleep?","PCL-5 - Trouble Falling or Staying Asleep | PCL01-Trouble Falling or Staying Asleep | PCL0120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523255","PODCI Pediatric Parent-Reported Version - Lift Heavy Books","C135942","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, was it easy or hard for your child to: Lift heavy books?","PODCI Pediatric Parent-Reported Version - Lift Heavy Books | PODCI1-Lift Heavy Books | PODCI101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523256","PODCI Pediatric Parent-Reported Version - Pour a Half Gallon of Milk","C135943","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, was it easy or hard for your child to: Pour a half gallon of milk?","PODCI Pediatric Parent-Reported Version - Pour a Half Gallon of Milk | PODCI1-Pour a Half Gallon of Milk | PODCI102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523257","PODCI Pediatric Parent-Reported Version - Open a Jar Been Opened Before","C135944","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, was it easy or hard for your child to: Open a jar that has been opened before?","PODCI Pediatric Parent-Reported Version - Open a Jar Been Opened Before | PODCI1-Open a Jar Been Opened Before | PODCI103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523258","PODCI Pediatric Parent-Reported Version - Use a Fork and Spoon","C135945","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, was it easy or hard for your child to: Use a fork and spoon?","PODCI Pediatric Parent-Reported Version - Use a Fork and Spoon | PODCI1-Use a Fork and Spoon | PODCI104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523259","PODCI Pediatric Parent-Reported Version - Comb His or Her Hair","C135946","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, was it easy or hard for your child to: Comb his/her hair?","PODCI Pediatric Parent-Reported Version - Comb His or Her Hair | PODCI1-Comb His/Her Hair | PODCI105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523260","PODCI Pediatric Parent-Reported Version - Button Buttons","C135947","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, was it easy or hard for your child to: Button buttons?","PODCI Pediatric Parent-Reported Version - Button Buttons | PODCI1-Button Buttons | PODCI106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523261","PODCI Pediatric Parent-Reported Version - Put on His or Her Coat","C135948","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, was it easy or hard for your child to: Put on his/her coat?","PODCI Pediatric Parent-Reported Version - Put on His or Her Coat | PODCI1-Put on His/Her Coat | PODCI107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523262","PODCI Pediatric Parent-Reported Version - Write With a Pencil","C135949","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, was it easy or hard for your child to: Write with a pencil?","PODCI Pediatric Parent-Reported Version - Write With a Pencil | PODCI1-Write With a Pencil | PODCI108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523263","PODCI Pediatric Parent-Reported Version - Miss School Because of Health","C135950","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) On average, over the last 12 months, how often did your child miss school (preschool, day care, camp, etc.) because of his/her health?","PODCI Pediatric Parent-Reported Version - Miss School Because of Health | PODCI1-Miss School Because of Health | PODCI109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523264","PODCI Pediatric Parent-Reported Version - How He or She Looks","C135951","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, how happy has your child been with: How he/she looks?","PODCI Pediatric Parent-Reported Version - How He or She Looks | PODCI1-How He/She Looks | PODCI110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522361","Ampulla of Vater Cancer Pathologic Primary Tumor TNM Finding v8","C134845","A pathologic finding about one or more characteristics of ampulla of Vater cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Ampulla of Vater Cancer Pathologic Primary Tumor TNM Finding v8 | Ampulla of Vater Carcinoma Pathologic Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522362","Ampulla of Vater Cancer pTX TNM Finding v8","C134846","Ampulla of Vater cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Ampulla of Vater Cancer pTX TNM Finding v8 | Ampulla of Vater Carcinoma pTX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522363","Ampulla of Vater Cancer pT0 TNM Finding v8","C134847","Ampulla of Vater cancer with no evidence of primary tumor. (from AJCC 8th Ed.)","Ampulla of Vater Cancer pT0 TNM Finding v8 | Ampulla of Vater Carcinoma pT0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522364","Ampulla of Vater Cancer pTis TNM Finding v8","C134848","Ampulla of Vater cancer with a finding of carcinoma in situ. (from AJCC 8th Ed.)","Ampulla of Vater Cancer pTis TNM Finding v8 | Ampulla of Vater Carcinoma pTis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522365","Ampulla of Vater Cancer pT1 TNM Finding v8","C134849","Ampulla of Vater cancer with tumor limited to ampulla of Vater or sphincter of Oddi or tumor invading beyond the sphincter of Oddi (perisphincteric invasion) and/or into the duodenal submucosa. (from AJCC 8th Ed.)","Ampulla of Vater Cancer pT1 TNM Finding v8 | Ampulla of Vater Carcinoma pT1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522366","Ampulla of Vater Cancer pT1a TNM Finding v8","C134850","Ampulla of Vater cancer with tumor limited to ampulla of Vater or sphincter of Oddi. (from AJCC 8th Ed.)","Ampulla of Vater Cancer pT1a TNM Finding v8 | Ampulla of Vater Carcinoma pT1a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522367","Ampulla of Vater Cancer pT1b TNM Finding v8","C134851","Ampulla of Vater cancer with tumor invading beyond the sphincter of Oddi (perisphincteric invasion) and/or into the duodenal submucosa. (from AJCC 8th Ed.)","Ampulla of Vater Cancer pT1b TNM Finding v8 | Ampulla of Vater Carcinoma pT1b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522369","Ampulla of Vater Cancer pT3 TNM Finding v8","C134853","Ampulla of Vater cancer with tumor directly invading the pancreas (up to 0.5 cm) or tumor extending more than 0.5 cm into the pancreas, or extending into peripancreatic or periduodenal tissue or duodenal serosa without involvement of the celiac axis or superior mesenteric artery. (from AJCC 8th Ed.)","Ampulla of Vater Cancer pT3 TNM Finding v8 | Ampulla of Vater Carcinoma pT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522370","Ampulla of Vater Cancer pT3a TNM Finding v8","C134854","Ampulla of Vater cancer with tumor directly invading the pancreas (up to 0.5 cm). (from AJCC 8th Ed.)","Ampulla of Vater Cancer pT3a TNM Finding v8 | Ampulla of Vater Carcinoma pT3a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522371","Ampulla of Vater Cancer pT3b TNM Finding v8","C134855","Ampulla of Vater cancer with tumor extending more than 0.5 cm into the pancreas, or extending into peripancreatic tissue or duodenal serosa without involvement of the celiac axis or superior mesenteric artery. (from AJCC 8th Ed.)","Ampulla of Vater Cancer pT3b TNM Finding v8 | Ampulla of Vater Carcinoma pT3b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522372","Ampulla of Vater Cancer pT4 TNM Finding v8","C134856","Ampulla of Vater cancer with tumor involving the celiac axis, superior mesenteric artery, and/or common hepatic artery, irrespective of size. (from AJCC 8th Ed.)","Ampulla of Vater Cancer pT4 TNM Finding v8 | Ampulla of Vater Carcinoma pT4 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522683","Jejunum and Ileum Neuroendocrine Tumor Clinical Distant Metastasis TNM Finding v8","C135095","A clinical finding about one or more characteristics of a jejunum and ileum neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Jejunum and Ileum Neuroendocrine Tumor Clinical Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522684","Jejunum and Ileum Neuroendocrine Tumor cM0 TNM Finding v8","C135096","Jejunum and ileum neuroendocrine tumor without evidence of distant metastasis. (from AJCC 8th Ed.)","Jejunum and Ileum Neuroendocrine Tumor cM0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522685","Jejunum and Ileum Neuroendocrine Tumor cM1 TNM Finding v8","C135097","Jejunum and ileum neuroendocrine tumor with distant metastasis. (from AJCC 8th Ed.)","Jejunum and Ileum Neuroendocrine Tumor cM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522732","Appendix Neuroendocrine Tumor pT1 TNM Finding v8","C135147","Appendix neuroendocrine tumor measuring 2 cm or less in greatest dimension. (from AJCC 8th Ed.)","Appendix Neuroendocrine Tumor pT1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522734","Appendix Neuroendocrine Tumor pT3 TNM Finding v8","C135149","Appendix neuroendocrine tumor measuring more than 4 cm or with subserosal invasion or involvement of the mesoappendix. (from AJCC 8th Ed.)","Appendix Neuroendocrine Tumor pT3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520385","11q13.3","C13514","A chromosome band present on 11q","11q13.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522736","Appendix Neuroendocrine Tumor Pathologic Regional Lymph Nodes TNM Finding v8","C135151","A pathologic finding about one or more characteristics of an appendiceal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Appendix Neuroendocrine Tumor Pathologic Regional Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522737","Appendix Neuroendocrine Tumor pNX TNM Finding v8","C135152","Appendix neuroendocrine tumor in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)","Appendix Neuroendocrine Tumor pNX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522208","POLR3K wt Allele","C134662","Human POLR3K wild-type allele is located in the vicinity of 16p13.3 and is approximately 7 kb in length. This allele, which encodes DNA-directed RNA polymerase III subunit RPC10 protein, plays a role in the synthesis of small RNAs and in immunity.","POLR3K wt Allele | C11 | C11-RNP3 | My010 | Polymerase (RNA) III (DNA Directed) Polypeptide K, 12.3 kDa Gene | Polymerase (RNA) III Subunit K Gene | Polymerase III, RNA, Subunit K Gene | RNA Polymerase III Subunit K wt Allele | RNA Polymerase III, 12.3-kD Subunit Gene | RPC10 | RPC11 | RPC11, S. cerevisiae, Homolog of Gene | RPC12.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522212","DNA-Directed RNA Polymerase III Subunit RPC10","C134668","DNA-directed RNA polymerase III subunit RPC10 (108 aa, ~12 kDa) is encoded by the human POLR3K gene. This protein is involved in innate immunity and small RNA synthesis.","DNA-Directed RNA Polymerase III Subunit RPC10 | DNA-Directed RNA Polymerase III Subunit K | DNA-Directed RNA Polymerases III 12.5 kDa Polypeptide | HsC11p | POLR3K | RNA Polymerase III 12.5 kDa Subunit | RNA Polymerase III Subunit C10 | RNA Polymerase III Subunit C11 | RNA Polymerase III Subunit CII | RPC11 | RPC12.5 | hRPC11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520269","10q11-q12","C13494","A chromosome band present on 10q","10q11-q12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522463","Quail Fibrosarcoma","C134950","Fibrosarcoma that occurs in a quail.","Quail Fibrosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522464","Suncus Murinus Mammary Tumor","C134951","A mammary tumor that occurs in Suncus murinus.","Suncus Murinus Mammary Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2079538","Charcot-Marie-Tooth Disease Type 2A","C134952","A sub-type of Charcot-Marie-Tooth caused by mutation(s) in the MFN2 gene, encoding mitofusin-2. It results in peripheral axonal neuropathy.","Charcot-Marie-Tooth Disease Type 2A | CMT2A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1843225","Charcot-Marie-Tooth Disease Type 2E","C134953","A form of Charcot-Marie-Tooth disease which is inherited in an autosomal dominant manner. It is caused by mutation(s) in the NEFL gene, encoding neurofilament light polypeptide. It results in peripheral axonal neuropathy.","Charcot-Marie-Tooth Disease Type 2E | CMT2E",,,,,,,,,,,,,,,"37397003","Autosomal dominant Charcot-Marie-Tooth disease type 2E",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1970011","Charcot-Marie-Tooth Disease Type 4J","C134954","A form of Charcot-Marie-Tooth disease which is inherited in an autosomal recessive manner. It is caused by mutation(s) in the FIG4 gene, encoding polyphosphoinositide phosphatase. It results in peripheral demyelinating motor and sensory neuropathy.","Charcot-Marie-Tooth Disease Type 4J | CMT4J",,,,,,,,,,,,,,,"36717404","Charcot-Marie-Tooth disease type 4J",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL522465","Bat Skin Tumor","C134955","A skin tumor that occurs in a bat.","Bat Skin Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522466","Canine Acanthomatous Epulis","C134956","A tumor arising from odontogenic epithelium and occurs in a dog.","Canine Acanthomatous Epulis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522467","Hamster Chondrosarcoma","C134957","A chondrosarcoma that occurs in a hamster.","Hamster Chondrosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522468","Hemangioendothelioma of the Mouse Thyroid Gland","C134958","A neoplasm that arises from vascular endothelium and occurs in the thyroid gland of a mouse.","Hemangioendothelioma of the Mouse Thyroid Gland | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522469","Marmoset Lymphoma","C134959","Lymphoma that occurs in a marmoset.","Marmoset Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521052","20q11.2","C13495","A chromosome band present on 20q","20q11.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522470","Mouse Adrenal Gland Pheochromocytoma","C134960","A pheochromocytoma that occurs in the adrenal gland of a mouse.","Mouse Adrenal Gland Pheochromocytoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522471","Mouse Submandibular Gland Neoplasm","C134961","A tumor arising in the submandibular gland of a mouse.","Mouse Submandibular Gland Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522472","Poeciliopsis Lucida Hepatocellular Carcinoma","C134962","Hepatocellular carcinoma that occurs in Poeciliopsis lucida.","Poeciliopsis Lucida Hepatocellular Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522473","Seal Lymphoma","C134963","A lymphoma that occurs in a seal.","Seal Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522474","Tamarin Colon Adenocarcinoma","C134964","Adenocarcinoma arising in the colon of a tamarin.","Tamarin Colon Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522476","MSAS Frequency Score Likert Scale","C134966","A scale for the subjective scoring of event frequency that ranges from 1: Almost Never to 4: Almost Always designed for use with the Memorial Symptom Assessment Scale (MSAS) 10-18.","MSAS Frequency Score Likert Scale | Memorial Symptom Assessment Scale (Pediatrics 10-18) Frequency Score 4 Point Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523265","PODCI Pediatric Parent-Reported Version - His or Her Body","C135952","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, how happy has your child been with: His/her body?","PODCI Pediatric Parent-Reported Version - His or Her Body | PODCI1-His/Her Body | PODCI111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522335","Stage II Distal Bile Duct Cancer AJCC v8","C134814","Stage II includes: IIA: (T1, N1, M0); (T2, N0, M0); IIB: (T2, N1, M0); (T3, N0, M0); (T3, N1, M0). T1: Tumor invading the bile duct wall with a depth less than 5 mm. T2: Tumor invading the bile duct wall with a depth of 5-12 mm. T3: Tumor invading the bile duct wall with a depth greater than 12 mm. N0: No regional lymph node metastasis. N1: Metastasis in one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Distal Bile Duct Cancer AJCC v8 | II | Stage II Distal Bile Duct Carcinoma AJCC v8 | Stage II Extrahepatic (Distal) Bile Duct Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522338","Stage III Distal Bile Duct Cancer AJCC v8","C134817","Stage III includes: IIIA: (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); IIIB: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T1: Tumor invading the bile duct wall with a depth less than 5 mm. T2: Tumor invading the bile duct wall with a depth of 5-12 mm. T3: Tumor invading the bile duct wall with a depth greater than 12 mm. T4: Tumor involving the celiac axis, superior mesenteric artery, and/or common hepatic artery. N0: No regional lymph node metastasis. N1: Metastasis in one to three regional lymph nodes. N2: Metastasis in four or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Distal Bile Duct Cancer AJCC v8 | III | Stage III Distal Bile Duct Carcinoma AJCC v8 | Stage III Extrahepatic (Distal) Bile Duct Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520768","17q21","C13481","A chromosome band present on 17q","17q21 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0937851","Tasonermin","C134821","No value exists.","Tasonermin | 1-157-Tumor Necrosis Factor Alfa-1a (Human) | TASONERMIN | Tumor Necrosis Factor, Human Recombinant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522686","Jejunum and Ileum Neuroendocrine Tumor cM1a TNM Finding v8","C135098","Jejunum and ileum neuroendocrine tumor with metastasis confined to liver. (from AJCC 8th Ed.)","Jejunum and Ileum Neuroendocrine Tumor cM1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522687","Jejunum and Ileum Neuroendocrine Tumor cM1b TNM Finding v8","C135099","Jejunum and ileum neuroendocrine tumor with metastasis in at least one extrahepatic site (e.g., lung, ovary, nonregional lymph node, peritoneum, bone). (from AJCC 8th Ed.)","Jejunum and Ileum Neuroendocrine Tumor cM1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520474","12p13","C13509","A chromosome band present on 12p","12p13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522688","Jejunum and Ileum Neuroendocrine Tumor cM1c TNM Finding v8","C135100","Jejunum and ileum neuroendocrine tumor with both hepatic and extrahepatic metastases. (from AJCC 8th Ed.)","Jejunum and Ileum Neuroendocrine Tumor cM1c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522689","Jejunum and Ileum Neuroendocrine Tumor Pathologic TNM Finding v8","C135101","A pathologic finding about one or more characteristics of a jejunum and ileum neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system.","Jejunum and Ileum Neuroendocrine Tumor Pathologic TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522690","Jejunum and Ileum Neuroendocrine Tumor Pathologic Distant Metastasis TNM Finding v8","C135102","A pathologic finding about one or more characteristics of a jejunum and ileum neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Jejunum and Ileum Neuroendocrine Tumor Pathologic Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522692","Jejunum and Ileum Neuroendocrine Tumor pM1a TNM Finding v8","C135104","Jejunum and ileum neuroendocrine tumor with metastasis confined to liver. (from AJCC 8th Ed.)","Jejunum and Ileum Neuroendocrine Tumor pM1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522693","Jejunum and Ileum Neuroendocrine Tumor pM1b TNM Finding v8","C135105","Jejunum and ileum neuroendocrine tumor with metastasis in at least one extrahepatic site (e.g., lung, ovary, nonregional lymph node, peritoneum, bone). (from AJCC 8th Ed.)","Jejunum and Ileum Neuroendocrine Tumor pM1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522694","Jejunum and Ileum Neuroendocrine Tumor pM1c TNM Finding v8","C135106","Jejunum and ileum neuroendocrine tumor with both hepatic and extrahepatic metastases. (from AJCC 8th Ed.)","Jejunum and Ileum Neuroendocrine Tumor pM1c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522695","Jejunum and Ileum Neuroendocrine Tumor Pathologic Primary Tumor TNM Finding v8","C135107","A pathologic finding about one or more characteristics of a jejunum and ileum neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Jejunum and Ileum Neuroendocrine Tumor Pathologic Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522696","Jejunum and Ileum Neuroendocrine Tumor pTX TNM Finding v8","C135108","Jejunum and ileum neuroendocrine tumor in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Jejunum and Ileum Neuroendocrine Tumor pTX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522169","HEATR3 wt Allele","C134617","Human HEATR3 wild-type allele is located in the vicinity of 16q12.1 and is approximately 40 kb in length. This allele, which encodes HEAT repeat-containing protein 3, plays a role in transporting ribosomal proteins and RNAs into the nucleus.","HEATR3 wt Allele | FLJ20718 | HEAT Repeat Containing 3 wt Allele | SYO1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0341253","Brunner's Gland Hyperplasia","C135565","A rare hyperplastic lesion of Brunner's gland in the duodenum. Although it is usually asymptomatic and discovered incidentally during upper gastrointestinal endoscopy, it may cause hemorrhage.","Brunner's Gland Hyperplasia | ",,,,,,,,,,,,,,,"4342652","Hyperplasia of Brunner glands of duodenum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0150618","History and Physical Exam","C135566","A record of the medical history and physical examination findings for a patient collected at the time of admission.","History and Physical Exam | H&P | History and Physical | History and Physical Examination",,,,,,,,,,,,,,,"4268628","History AND physical examination",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL522630","Gastric Neuroendocrine Tumor Pathologic Primary Tumor TNM Finding v8","C135034","A pathologic finding about one or more characteristics of a gastric neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Gastric Neuroendocrine Tumor Pathologic Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521187","2p23-p22","C13520","A chromosome band present on 2p","2p23-p22 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522789","Colon Neuroendocrine Tumor","C135212","A well-differentiated, low-, intermediate-, or high-grade neoplasm with neuroendocrine differentiation that arises from the colon.","Colon Neuroendocrine Tumor | Colon Well Differentiated Neuroendocrine Neoplasm | Colon Well-Differentiated Neuroendocrine Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522790","Rectal Neuroendocrine Tumor","C135213","A well-differentiated, low-, intermediate-, or high-grade neoplasm with neuroendocrine differentiation that arises from the rectum.","Rectal Neuroendocrine Tumor | Rectal Well Differentiated Neuroendocrine Neoplasm | Rectal Well-Differentiated Neuroendocrine Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522536","Colon Neuroendocrine Tumor by AJCC v8 Stage","C135214","A term that refers to the staging of a colon neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system. This staging system applies to colon 'carcinoid' tumors (neuroendocrine tumor G1 and G2, and rare-well differentiated G3). High-grade neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas of the colon are not staged using this staging system. (from AJCC 8th Ed.)","Colon Neuroendocrine Tumor by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521382","4q11-q12","C13571","A chromosome band present on 4q","4q11-q12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523038","Mouse Erythroleukemia","C135721","Erythroleukemia that occurs in a mouse.","Mouse Erythroleukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523039","Rat Erythroleukemia","C135722","Erythroleukemia that occurs in a rat.","Rat Erythroleukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523040","Hamster Mammary Carcinoma","C135723","Carcinoma of the mammary gland that occurs in a hamster.","Hamster Mammary Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523041","Feline Large Granular Lymphocyte Lymphoma","C135724","A T-cell leukemia in which there is a persistent increase in the number of large granular lymphocytes in the peripheral blood and occurring in a cat.","Feline Large Granular Lymphocyte Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0751039","Cockayne Syndrome Type A","C135725","Cockayne syndrome caused by mutation(s) in the ERCC8 gene, encoding DNA excision repair protein ERCC-8.","Cockayne Syndrome Type A | ",,,,,,,,,,,,,,,"619272","Cockayne syndrome type 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL523043","Mammoplasty Patient","C135728","A person who is undergoing mammoplasty.","Mammoplasty Patient | Breast Mammoplasty Patient | Breast Reconstruction Patient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511993","Distal Enhancer Elements","C13461","Enhancer sequences found at a distance from the gene it regulates.","Distal Enhancer Elements | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522173","HEAT Repeat-Containing Protein 3","C134621","HEAT repeat-containing protein 3 (680 aa, ~75 kDa) is encoded by the human HEATR3 gene. This protein is involved in nuclear import of RNAs and RNA-binding proteins.","HEAT Repeat-Containing Protein 3 | HEATR3 | Symportin | Symportin 1 | Synchronized Import Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1424140","SLC16A8 Gene","C134625","This gene plays a role in lactate transport in the retina.","SLC16A8 Gene | SLC16A8 | Solute Carrier Family 16 Member 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522177","SLC16A8 wt Allele","C134626","Human SLC16A8 wild-type allele is located in the vicinity of 22q13.1 and is approximately 6 kb in length. This allele, which encodes monocarboxylate transporter 3 protein, is involved in the transport of lactate and other monocarboxylates.","SLC16A8 wt Allele | MCT3 | REMP | Solute Carrier 16 (Monocarboxylic Acid Transporters), Member 8 Gene | Solute Carrier Family 16 (Monocarboxylate Transporter), Member 8 Gene | Solute Carrier Family 16 Member 8 wt Allele | Solute Carrier Family 16, Member 8 (Monocarboxylic Acid Transporter 3) Gene | Solute Carrier Family 16, Member 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824551","CCDC26 Gene","C134628","This gene may be involved in the modulation of cellular responses to retinoic acid.","CCDC26 Gene | CCDC26 | CCDC26 Long Non-Coding RNA Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522179","CCDC26 wt Allele","C134629","Human CCDC26 wild-type allele is located in the vicinity of 8q24.21 and is approximately 329 kb in length. This allele, which encodes CCDC26 long non-coding RNA and/or putative coiled-coil domain-containing protein 26, may play a role in the cellular response to retinoic acid.","CCDC26 wt Allele | CCDC26 Long Non-Coding RNA wt Allele | MGC27434 | RAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0365274","Serum Viscosity","C135572","A measurement of the resistance of a serum sample to flow because of shear stress.","Serum Viscosity | Serum Viscosity Measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0105764","Atrimustine","C1348","The benzoate of a estradiol-chlorambucil conjugate. (NCI)","Atrimustine | ATRIMUSTINE | Bestrabucil | Estradiol 3-benzoate 17-glycolate, 4-(p-(bis(2-chloroethyl)amino)phenyl)butyrate | KM2210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522418","Pancreatic Cancer by AJCC v6 and v7 Stage","C134902","A term that refers to the staging of exocrine and endocrine pancreatic cancer including well-differentiated neuroendocrine tumors according to the American Joint Committee on Cancer, 6th and 7th editions.","Pancreatic Cancer by AJCC v6 and v7 Stage | Exocrine and Endocrine Pancreatic Cancer by AJCC v6 and v7 Stage | Exocrine and Endocrine Pancreatic Carcinoma by AJCC v6 and v7 Stage | Pancreatic Carcinoma by AJCC v6 and v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520497","12q13.2-q13.3","C13522","A chromosome band present on 12q","12q13.2-q13.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521204","2q14","C13523","A chromosome band present on 2q","2q14 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521616","7p13","C13524","A chromosome band present on 7p","7p13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521392","4q21","C13525","A chromosome band present on 4q","4q21 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522245","Perihilar Bile Duct Cancer Pathologic TNM Finding v8","C134718","A pathologic finding about one or more characteristics of perihilar bile duct cancer, following the rules of the TNM AJCC v8 classification system.","Perihilar Bile Duct Cancer Pathologic TNM Finding v8 | Hilar Cholangiocarcinoma Pathologic TNM Finding v8 | Perihilar Cholangiocarcinoma Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522246","Perihilar Bile Duct Cancer Pathologic Distant Metastasis TNM Finding v8","C134719","A pathologic finding about one or more characteristics of perihilar bile duct cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Perihilar Bile Duct Cancer Pathologic Distant Metastasis TNM Finding v8 | Hilar Cholangiocarcinoma Pathologic Distant Metastasis TNM Finding v8 | Perihilar Bile Duct Cancer Pathologic Distant Metastasis (pM) | Perihilar Cholangiocarcinoma Pathologic Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521285","3p21.3","C13471","A chromosome band present on 3p","3p21.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522248","Perihilar Bile Duct Cancer Pathologic Primary Tumor TNM Finding v8","C134721","A pathologic finding about one or more characteristics of perihilar bile duct cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Perihilar Bile Duct Cancer Pathologic Primary Tumor TNM Finding v8 | Hilar Cholangiocarcinoma Pathologic Primary Tumor TNM Finding v8 | Perihilar Bile Duct Cancer Pathologic Primary Tumor Status (pT) | Perihilar Cholangiocarcinoma Pathologic Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523044","EGFR NM_005228.3:c.1474A>C","C135729","A nucleotide substitution at position 1474 of the coding sequence of the EGFR gene where adenine has been mutated to cytosine.","EGFR NM_005228.3:c.1474A>C | EGFR S492R Gene Mutation | EGFR c.1474A>C | ERBB c.1474A>C | ERBB1 c.1474A>C | Epidermal Growth Factor Receptor Gene c.1474A>C | HER1 c.1474A>C | NM_005228.3:c.1474A>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520471","12p12.1","C13572","A chromosome band present on 12p","12p12.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523045","EGFR NM_005228.3:c.1476C>A","C135730","A nucleotide substitution at position 1476 of the coding sequence of the EGFR gene where cytosine has been mutated to adenine.","EGFR NM_005228.3:c.1476C>A | EGFR S492R Gene Mutation | EGFR c.1476C>A | ERBB c.1476C>A | ERBB1 c.1476C>A | Epidermal Growth Factor Receptor Gene c.1476C>A | HER1 c.1476C>A | NM_005228.3:c.1476C>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522645","Duodenum and Ampulla of Vater Neuroendocrine Tumor TNM Finding v8","C135050","A finding about one or more characteristics of a duodenum and ampulla of Vater neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system. This classification system applies to well-differentiated neuroendocrine tumors of the duodenum and ampulla of Vater. Carcinomas of the duodenum, including high-grade (grade 3), poorly differentiated neuroendocrine carcinomas and carcinomas of the ampulla of Vater, including high-grade (grade 3), poorly differentiated neuroendocrine carcinomas are not included in this classification system. (from AJCC 8th Ed.)","Duodenal and Ampulla of Vater Neuroendocrine Tumor TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522646","Duodenum and Ampulla of Vater Neuroendocrine Tumor Clinical TNM Finding v8","C135051","A clinical finding about one or more characteristics of a duodenum and ampulla of Vater neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system.","Duodenal and Ampulla of Vater Neuroendocrine Tumor Clinical TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor Clinical TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522647","Duodenum and Ampulla of Vater Neuroendocrine Tumor Clinical Distant Metastasis TNM Finding v8","C135052","A clinical finding about one or more characteristics of a duodenum and ampulla of Vater neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Duodenal and Ampulla of Vater Neuroendocrine Tumor Clinical Distant Metastasis TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor Clinical Distant Metastasis TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522648","Duodenum and Ampulla of Vater Neuroendocrine Tumor cM0 TNM Finding v8","C135053","Duodenum and ampulla of Vater neuroendocrine tumor without evidence of distant metastasis. (from AJCC 8th Ed.)","Duodenal and Ampulla of Vater Neuroendocrine Tumor cM0 TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor cM0 TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522650","Duodenum and Ampulla of Vater Neuroendocrine Tumor cM1a TNM Finding v8","C135055","Duodenum and ampulla of Vater neuroendocrine tumor with metastasis confined to liver. (from AJCC 8th Ed.)","Duodenal and Ampulla of Vater Neuroendocrine Tumor cM1a TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor cM1a TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor cM1a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522651","Duodenum and Ampulla of Vater Neuroendocrine Tumor cM1b TNM Finding v8","C135056","Duodenum and ampulla of Vater neuroendocrine tumor with metastasis in at least one extrahepatic site (e.g., lung, ovary, nonregional lymph node, peritoneum, bone). (from AJCC 8th Ed.)","Duodenal and Ampulla of Vater Neuroendocrine Tumor cM1b TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor cM1b TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor cM1b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522652","Duodenum and Ampulla of Vater Neuroendocrine Tumor cM1c TNM Finding v8","C135057","Duodenum and ampulla of Vater neuroendocrine tumor with both hepatic and extrahepatic metastases. (from AJCC 8th Ed.)","Duodenal and Ampulla of Vater Neuroendocrine Tumor cM1c TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor cM1c TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor cM1c TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522526","Autologous Peripheral Blood Mononuclear Cells","C135058","A preparation of autologous peripheral blood mononuclear cells (PBMCs).","Autologous Peripheral Blood Mononuclear Cells | Autologous PBMC | Autologous PBMCs | Autologous Peripheral Blood Mononuclear Cell | Therapeutic PBMCs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522653","Duodenum and Ampulla of Vater Neuroendocrine Tumor Pathologic TNM Finding v8","C135059","A pathologic finding about one or more characteristics of a duodenum and ampulla of Vater neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system.","Duodenal and Ampulla of Vater Neuroendocrine Tumor Pathologic TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor Pathologic TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521074","Chromosome 21 Short Arm","C13551","Proximal (short) arm of chromosome 21","21p | Chromosome 21 Proximal Arm | Chromosome 21 Short Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522885","Femur/Femorotibial Joint","C135523","A tissue sample that contains the femur and femorotibial joint.","Femur/Femorotibial Joint | BONE, FEMUR/JOINT, FEMOROTIBIAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522886","Stage IIIA Colon Neuroendocrine Tumor AJCC v8","C135524","Stage IIIA includes: T4, N0, M0. T4: Tumor invading the visceral peritoneum (serosa) or other organs or adjacent structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIA Colon Neuroendocrine Tumor AJCC v8 | Stage IIIA Colon Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522887","Stage IIIB Colon Neuroendocrine Tumor AJCC v8","C135525","Stage IIIB includes: (T1, N1, M0); (T2, N1, M0); (T3, N1, M0); (T4, N1, M0). T1: Tumor invading the lamina propria or submucosa and measuring 2 cm or less. T2: Tumor invading the muscularis propria or measuring more than 2 cm with invasion of the lamina propria or submucosa. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. T4: Tumor invading the visceral peritoneum (serosa) or other organs or adjacent structures. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIB Colon Neuroendocrine Tumor AJCC v8 | Stage IIIB Colon Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522888","Stage IV Colon Neuroendocrine Tumor AJCC v8","C135526","Stage IV includes: (T1, Any N, M1); (T2, Any N, M1); (T3, Any N, M1); (T4, Any N, M1). T1: Tumor invading the lamina propria or submucosa and measuring 2 cm or less. T2: Tumor invading the muscularis propria or measuring more than 2 cm with invasion of the lamina propria or submucosa. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. T4: Tumor invading the visceral peritoneum (serosa) or other organs or adjacent structures. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Colon Neuroendocrine Tumor AJCC v8 | Stage IV Colon Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520595","14q24.3-q31","C13490","A chromosome band present on 14q","14q24.3-q31 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522738","Appendix Neuroendocrine Tumor pN0 TNM Finding v8","C135153","Appendix neuroendocrine tumor without regional lymph node metastasis. (from AJCC 8th Ed.)","Appendix Neuroendocrine Tumor pN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522739","Appendix Neuroendocrine Tumor pN1 TNM Finding v8","C135154","Appendix neuroendocrine tumor with regional lymph node metastasis. (from AJCC 8th Ed.)","Appendix Neuroendocrine Tumor pN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522533","Appendix Neuroendocrine Tumor by AJCC v7 Stage","C135155","A term that refers to the staging of an appendiceal neuroendocrine tumor, following the rules of the TNM AJCC v7 classification system.","Appendix Neuroendocrine Tumor by AJCC v7 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522534","Appendix Neuroendocrine Tumor by AJCC v8 Stage","C135156","A term that refers to the staging of an appendiceal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system. This staging system applies to appendiceal NETs (carcinoid tumors) (NET G1 and G2, and rare well-differentiated G3). High-grade neuroendocrine carcinomas (NEC), goblet cell carcinoids, mixed adenocarcinomas, and adenocarcinomas of the appendix are not staged using this staging system. (from AJCC 8th Ed.)","Appendix Neuroendocrine Tumor by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522740","Stage I Appendix Neuroendocrine Tumor AJCC v8","C135157","Stage I includes: T1, N0, M0. T1: Tumor measuring 2 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Appendix Neuroendocrine Tumor AJCC v8 | Stage I Appendix Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521196","2pter-p12","C13472","A chromosome band present on 2p","2pter-p12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522258","Perihilar Bile Duct Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C134731","A pathologic finding about one or more characteristics of perihilar bile duct cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Perihilar Bile Duct Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | Hilar Cholangiocarcinoma Pathologic Regional Lymph Nodes TNM Finding v8 | Perihilar Bile Duct Cancer Pathologic Regional Lymph Node Status (pN) TNM Finding v8 | Perihilar Cholangiocarcinoma Pathologic Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522971","Polymyxin-B Immobilized Fiber PMX-20R","C135615","A cartridge containing a polystyrene-based composite woven fiber that is covalently attached to the anti-microbial cyclic cationic polypeptide antibiotic polymyxin-B (PMX) and can potentially be used for hemoperfusion purposes. Upon extracorporeal treatment, a patient's blood flows through the fibers in the polymyxin-B immobilized fiber PMX-20R cartridge and the circulating endotoxins from the blood are selectively adsorbed by PMX, which has positively charged amino groups that bind to the negatively charged site in the lipid A portion of the lipopolysaccharide (LPS) layer of the bacterial cell membrane. This removes endotoxins from the blood and, upon administration of the blood back into the patient, helps treat or reduce the incidence of endotoxemia and sepsis.","Polymyxin-B Immobilized Fiber PMX-20R | PMX Cartridge | PMX-20R | Toraymyxin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522975","Liposomal Vinorelbine Tartrate","C135619","A formulation of the tartrate salt form of vinorelbine, a semisynthetic vinca alkaloid, encapsulated within liposomes, with potential antineoplastic activity. Upon intravenous administration, vinorelbine binds to tubulin within tumor cells and prevents the formation of the mitotic spindle, resulting in cell cycle arrest, induction of apoptosis and an inhibition of tumor cell growth. Compared to the administration of vinorelbine alone, the liposomal formulation improves drug penetration into tumors and decreases drug clearance, thereby increasing vinorelbine's efficacy while lowering the toxicity profile.","Liposomal Vinorelbine Tartrate | TLC-178 | TLC178",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520491","12q13","C13505","A chromosome band present on 12q","12q13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522654","Duodenum and Ampulla of Vater Neuroendocrine Tumor Pathologic Distant Metastasis TNM Finding v8","C135060","A pathologic finding about one or more characteristics of a duodenum and ampulla of Vater neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Duodenal and Ampulla of Vater Neuroendocrine Tumor Pathologic Distant Metastasis TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor Pathologic Distant Metastasis TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor Pathologic Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522655","Duodenum and Ampulla of Vater Neuroendocrine Tumor pM1 TNM Finding v8","C135061","Duodenum and ampulla of Vater neuroendocrine tumor with distant metastasis. (from AJCC 8th Ed.)","Duodenal and Ampulla of Vater Neuroendocrine Tumor pM1 TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor pM1 TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor pM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522656","Duodenum and Ampulla of Vater Neuroendocrine Tumor pM1a TNM Finding v8","C135062","Duodenum and ampulla of Vater neuroendocrine tumor with metastasis confined to liver. (from AJCC 8th Ed.)","Duodenal and Ampulla of Vater Neuroendocrine Tumor pM1a TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor pM1a TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor pM1a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522659","Duodenum and Ampulla of Vater Neuroendocrine Tumor Pathologic Primary Tumor TNM Finding v8","C135065","A pathologic finding about one or more characteristics of a duodenum and ampulla of Vater neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Duodenal and Ampulla of Vater Neuroendocrine Tumor Pathologic Primary Tumor TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor Pathologic Primary Tumor TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor Pathologic Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522660","Duodenum and Ampulla of Vater Neuroendocrine Tumor pTX TNM Finding v8","C135066","Duodenum and ampulla of Vater neuroendocrine tumor in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Duodenal and Ampulla of Vater Neuroendocrine Tumor pTX TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor pTX TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor pTX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522889","Rectal Neuroendocrine Tumor by AJCC v8 Stage","C135527","A term that refers to the staging of a rectal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system. This staging system applies to rectal 'carcinoid' tumors (neuroendocrine tumor G1 and G2, and rare-well differentiated G3). High-grade neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas of the rectum are not staged using this staging system. (from AJCC 8th Ed.)","Rectal Neuroendocrine Tumor by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522373","Ampulla of Vater Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C134857","A pathologic finding about one or more characteristics of ampulla of Vater cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Ampulla of Vater Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | Ampulla of Vater Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522374","Ampulla of Vater Cancer pNX TNM Finding v8","C134858","Ampulla of Vater cancer in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)","Ampulla of Vater Cancer pNX TNM Finding v8 | Ampulla of Vater Carcinoma pNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522375","Ampulla of Vater Cancer pN0 TNM Finding v8","C134859","Ampulla of Vater cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","Ampulla of Vater Cancer pN0 TNM Finding v8 | Ampulla of Vater Carcinoma pN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520701","16q22.1","C13485","A chromosome band present on 16q","16q22.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522376","Ampulla of Vater Cancer pN1 TNM Finding v8","C134860","Ampulla of Vater cancer with metastasis to one to three regional lymph nodes. (from AJCC 8th Ed.)","Ampulla of Vater Cancer pN1 TNM Finding v8 | Ampulla of Vater Carcinoma pN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522379","Ampulla of Vater Cancer by AJCC v7 Stage","C134863","A term that refers to the staging of ampulla of Vater cancer according to the American Joint Committee on Cancer, 7th edition.","Ampulla of Vater Cancer by AJCC v7 Stage | Ampulla of Vater Carcinoma by AJCC v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522380","Ampulla of Vater Cancer by AJCC v8 Stage","C134864","A term that refers to the staging of ampulla of Vater cancer according to the American Joint Committee on Cancer, 8th edition. This staging system does not apply to well-differentiated neuroendocrine (carcinoid) tumors but does apply to high-grade neuroendocrine carcinomas, such as small cell carcinoma and large cell neuroendocrine carcinoma. (from AJCC 8th Ed.)","Ampulla of Vater Cancer by AJCC v8 Stage | Ampulla of Vater Carcinoma by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522381","Stage 0 Ampulla of Vater Cancer AJCC v8","C134865","Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0 Ampulla of Vater Cancer AJCC v8 | Stage 0 Ampulla of Vater Cancer | Stage 0 Ampulla of Vater Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522382","Stage I Ampulla of Vater Cancer AJCC v8","C134866","Stage I includes: IA: (T1a, N0, M0); IB: (T1b, N0, M0); (T2, N0, M0). T1a: Tumor limited to ampulla of Vater or sphincter of Oddi. T1b: Tumor invading beyond the sphincter of Oddi (perisphincteric invasion) and/or into the duodenal submucosa. T2: Tumor invading into the muscularis propria of the duodenum. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Ampulla of Vater Cancer AJCC v8 | Stage I Ampulla of Vater Cancer | Stage I Ampulla of Vater Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522383","Stage IA Ampulla of Vater Cancer AJCC v8","C134867","Stage IA includes: T1a, N0, M0. T1a: Tumor limited to ampulla of Vater or sphincter of Oddi. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IA Ampulla of Vater Cancer AJCC v8 | Stage IA Ampulla of Vater Cancer | Stage IA Ampulla of Vater Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522384","Stage IB Ampulla of Vater Cancer AJCC v8","C134868","Stage IB includes: (T1b, N0, M0); (T2, N0, M0). T1b: Tumor invading beyond the sphincter of Oddi (perisphincteric invasion) and/or into the duodenal submucosa. T2: Tumor invading into the muscularis propria of the duodenum. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IB Ampulla of Vater Cancer AJCC v8 | Stage IB Ampulla of Vater Cancer | Stage IB Ampulla of Vater Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522741","Stage II Appendix Neuroendocrine Tumor AJCC v8","C135158","Stage II includes: (T2, N0, M0); (T3, N0, M0). T2: Tumor measuring more than 2 cm but less than or equal to 4 cm. T3: Tumor measuring more than 4 cm or with subserosal invasion or involvement of the mesoappendix. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Appendix Neuroendocrine Tumor AJCC v8 | Stage II Appendix Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522742","Stage III Appendix Neuroendocrine Tumor AJCC v8","C135159","Stage III includes: (T1, N1, M0); (T2, N1, M0); (T3, N1, M0); (T4, N0, M0); (T4, N1, M0). T1: Tumor measuring 2 cm or less in greatest dimension. T2: Tumor measuring more than 2 cm but less than or equal to 4 cm. T3: Tumor measuring more than 4 cm or with subserosal invasion or involvement of the mesoappendix. T4: Tumor perforating the peritoneum or directly invading other adjacent organs or structures (excluding direct mural extension to adjacent subserosa of adjacent bowel), e.g., abdominal wall and skeletal muscle. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Appendix Neuroendocrine Tumor AJCC v8 | Stage III Appendix Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522743","Stage IV Appendix Neuroendocrine Tumor AJCC v8","C135160","Stage IV includes: (T1, N0, N1, M1); (T2, N0, N1, M1); (T3, N0, N1, M1); (T4, N0, N1, M1). T1: Tumor measuring 2 cm or less in greatest dimension. T2: Tumor measuring more than 2 cm but less than or equal to 4 cm. T3: Tumor measuring more than 4 cm or with subserosal invasion or involvement of the mesoappendix. T4: Tumor perforating the peritoneum or directly invading other adjacent organs or structures (excluding direct mural extension to adjacent subserosa of adjacent bowel), e.g., abdominal wall and skeletal muscle. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Appendix Neuroendocrine Tumor AJCC v8 | Stage IV Appendix Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522745","Colorectal Neuroendocrine Tumor Clinical TNM Finding v8","C135162","A clinical finding about one or more characteristics of a colorectal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system.","Colorectal Neuroendocrine Tumor Clinical TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522982","PT2977","C135627","An orally active, small molecule inhibitor of hypoxia inducible factor (HIF)-2alpha (HIF-2a), with potential antineoplastic activity. Upon oral administration, belzutifan binds to and blocks the function of HIF-2alpha, thereby preventing HIF-2alpha heterodimerization and its subsequent binding to DNA. This results in decreased transcription and expression of HIF-2alpha downstream target genes, many of which regulate hypoxic signaling. This inhibits cell growth and survival of HIF-2alpha-expressing tumor cells. HIF-2alpha, the alpha subunit for the heterodimeric transcription factor HIF-2, is overexpressed in many cancers and promotes tumorigenesis.","Belzutifan | BELZUTIFAN | HIF-2alpha Inhibitor PT2977 | MK 6482 | MK-6482 | MK6482 | PT 2977 | PT-2977 | PT2977 | Welireg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522477","BRAFV600/PI3K Inhibitor ASN003","C134967","A selective inhibitor of mutated forms of B-RAF kinase at amino acid position 600 (BRAFV600), including BRAFV600E, the alpha, delta and, to a lesser extent, beta isoforms of phosphatidylinositide 3-kinase (PI3K), including mutated forms of PI3KCA, which encodes the p110-alpha catalytic subunit of the class I PI3K, and the phosphatase and tensin homologs (PTEN) with loss-of-function mutation, with potential antineoplastic activity. Upon administration of ASN003, this agent selectively targets, binds to and inhibits the activity of BRAFV600 mutants as well as mutated isoforms of PI3K. This inhibits signaling through B-RAF- and PI3K/mechanistic target of rapamycin (mTOR)-mediated pathways and inhibits cellular proliferation in tumor cells with BRAFV600 mutations, those expressing PI3K and/or those driven by PTEN. Dysregulation of the B-RAF- and PI3K-mediated pathways is frequently seen in a variety of tumors and results in increased tumor cell growth and survival. Dual targeting of both pathways may increase efficacy and anti-tumor potential compared to the targeting of just one pathway by a selective B-RAF inhibitor or selective PI3K pathway inhibitor alone.","BRAFV600/PI3K Inhibitor ASN003 | ASN 003 | ASN-003 | ASN003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1005839","Bordetella holmesii","C135460","No value exists.","Bordetella holmesii | BORDETELLA HOLMESII | CDC Nonoxidizer Group 2",,,,,,,,,,,,,,,"4023385","Bordetella holmesii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL522385","Stage II Ampulla of Vater Cancer AJCC v8","C134869","Stage II includes: IIA: T3a, N0, M0; IIB: T3b, N0, M0. T3a: Tumor directly invading the pancreas (up to 0.5 cm). T3b: Tumor extending more than 0.5 cm into the pancreas, or extending into peripancreatic tissue or duodenal serosa without involvement of the celiac axis or superior mesenteric artery. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Ampulla of Vater Cancer AJCC v8 | Stage II Ampulla of Vater Cancer | Stage II Ampulla of Vater Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520499","12q14","C13486","A chromosome band present on 12q","12q14 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522697","Jejunum and Ileum Neuroendocrine Tumor pT0 TNM Finding v8","C135109","Jejunum and ileum neuroendocrine tumor with no evidence of primary tumor. (from AJCC 8th Ed.)","Jejunum and Ileum Neuroendocrine Tumor pT0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521318","3q24-q28","C13510","A chromosome band present on 3q","3q24-q28 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522698","Jejunum and Ileum Neuroendocrine Tumor pT1 TNM Finding v8","C135110","Jejunum and ileum neuroendocrine tumor invading lamina propria or submucosa and measuring 1 cm or less in size. (from AJCC 8th Ed.)","Jejunum and Ileum Neuroendocrine Tumor pT1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522699","Jejunum and Ileum Neuroendocrine Tumor pT2 TNM Finding v8","C135111","Jejunum and ileum neuroendocrine tumor invading muscularis propria or measuring more than 1 cm in size.  (from AJCC 8th Ed.)","Jejunum and Ileum Neuroendocrine Tumor pT2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522700","Jejunum and Ileum Neuroendocrine Tumor pT3 TNM Finding v8","C135112","Jejunum and ileum neuroendocrine tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. (from AJCC 8th Ed.)","Jejunum and Ileum Neuroendocrine Tumor pT3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522701","Jejunum and Ileum Neuroendocrine Tumor pT4 TNM Finding v8","C135113","Jejunum and ileum neuroendocrine tumor invading visceral peritoneum (serosa) or other organs or adjacent structures. (from AJCC 8th Ed.)","Jejunum and Ileum Neuroendocrine Tumor pT4 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522702","Jejunum and Ileum Neuroendocrine Tumor Pathologic Regional Lymph Nodes TNM Finding v8","C135114","A pathologic finding about one or more characteristics of a jejunum and ileum neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Jejunum and Ileum Neuroendocrine Tumor Pathologic Regional Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522703","Jejunum and Ileum Neuroendocrine Tumor pNX TNM Finding v8","C135115","Jejunum and ileum neuroendocrine tumor in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)","Jejunum and Ileum Neuroendocrine Tumor pNX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522704","Jejunum and Ileum Neuroendocrine Tumor pN0 TNM Finding v8","C135116","Jejunum and ileum neuroendocrine tumor without regional lymph node metastasis. (from AJCC 8th Ed.)","Jejunum and Ileum Neuroendocrine Tumor pN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522705","Jejunum and Ileum Neuroendocrine Tumor pN1 TNM Finding v8","C135117","Jejunum and ileum neuroendocrine tumor with regional lymph node metastasis in less than 12 nodes. (from AJCC 8th Ed.)","Jejunum and Ileum Neuroendocrine Tumor pN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522706","Jejunum and Ileum Neuroendocrine Tumor pN2 TNM Finding v8","C135118","Jejunum and ileum neuroendocrine tumor with large mesenteric masses (larger than 2 cm) and/or extensive nodal deposits (12 or greater), especially those that encase the superior mesenteric vessels. (from AJCC 8th Ed.)","Jejunum and Ileum Neuroendocrine Tumor pN2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521108","22q12","C13511","A chromosome band present on 22q","22q12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522707","Stage I Jejunal Neuroendocrine Tumor AJCC v8","C135120","Stage I includes: T1, N0, M0. T1: Tumor invading lamina propria or submucosa and measuring 1 cm or less in size. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Jejunal Neuroendocrine Tumor AJCC v8 | Stage I Jejunal Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2680426","SNRNP25 Gene","C134679","This gene plays a role in pre-mRNA processing.","SNRNP25 Gene | SNRNP25 | Small Nuclear Ribonucleoprotein U11/U12 Subunit 25 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515530","9q34.1","C13467","A chromosome band present on 9q","9q34.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522221","SNRNP25 wt Allele","C134680","Human SNRNP25 wild-type allele is located in the vicinity of 16p13.3 and is approximately 5 kb in length. This allele, which encodes U11/U12 small nuclear ribonucleoprotein 25 kDa protein, is involved in mRNA processing.","SNRNP25 wt Allele | C16orf33 | Chromosome 16 Open Reading Frame 33 Gene | Small Nuclear Ribonucleoprotein 25kDa (U11/U12) Gene | Small Nuclear Ribonucleoprotein U11/U12 Subunit 25 wt Allele | U11/U12 25kDa Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522222","U11/U12 Small Nuclear Ribonucleoprotein 25 kDa Protein","C134681","U11/U12 small nuclear ribonucleoprotein 25 kDa protein (132 aa, ~15 kDa) is encoded by the human SNRNP25 gene. This protein plays a role in the removal of U2- and U12-type introns from pre-mRNAs.","U11/U12 Small Nuclear Ribonucleoprotein 25 kDa Protein | Minus-99 Protein | SNRNP25 | U11/U12 SnRNP 25 kDa Protein | U11/U12 SnRNP 25K | U11/U12-25K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826583","PICK1 Gene","C134682","This gene is involved in the regulation of receptor signaling, localization and internalization.","PICK1 Gene | PICK1 | Protein Interacting with PRKCA 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522223","PICK1 wt Allele","C134683","Human PICK1 wild-type allele is located in the vicinity of 22q13.1 and is approximately 19 kb in length. This allele, which encodes PRKCA-binding protein, plays a role in the trafficking and internalization of signaling receptors.","PICK1 wt Allele | MGC15204 | PICK | PRKCABP | Protein Interacting with PRKCA 1 wt Allele | Protein Kinase C, Alpha Binding Protein Gene | dJ1039K5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522224","PRKCA-Binding Protein","C134684","PRKCA-binding protein (415 aa, ~47 kDa) is encoded by the human PICK1 gene. This protein is involved in the modulation of receptor signaling, localization and internalization.","PRKCA-Binding Protein | PICK1 | Protein Interacting with C Kinase 1 | Protein Interacting with PRKCA | Protein Kinase C-Alpha-Binding Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826697","PRMT1 Gene","C134685","This gene plays a role in the regulation of transcription via the methylation of histones and chromatin.","PRMT1 Gene | PRMT1 | Protein Arginine Methyltransferase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522225","PRMT1 wt Allele","C134686","Human PRMT1 wild-type allele is located in the vicinity of 19q13.33 and is approximately 13 kb in length. This allele, which encodes protein arginine N-methyltransferase 1 protein, is involved in the methylation of histone H4 and chromatin.","PRMT1 wt Allele | ANM1 | HCP1 | HMT1 (HnRNP Methyltransferase, S. cerevisiae)-Like 2 Gene | HMT1 HnRNP Methyltransferase-Like 2 (S. cerevisiae) Gene | HMT1-Like 2 | HRMT1L2 | IR1B4 | Protein Arginine Methyltransferase 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522226","Protein Arginine N-Methyltransferase 1","C134687","Protein arginine N-methyltransferase 1 (361 aa, ~42 kDa) is encoded by the human PRMT1 gene. This protein plays a role in the methylation of the guanidino nitrogens of arginyl residues in substrate proteins.","Protein Arginine N-Methyltransferase 1 | EC 2.1.1.319 | Heterogeneous Nuclear Ribonucleoprotein Methyltransferase 1-Like 2 | Histone-Arginine N-Methyltransferase PRMT1 | Interferon Receptor 1-Bound Protein 4 | PRMT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422862","OR51B4 Gene","C134688","This gene is involved in the perception of a smell.","OR51B4 Gene | OR51B4 | Olfactory Receptor Family 51 Subfamily B Member 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515460","8q22-q23","C13497","A chromosome band present on 8q","8q22-q23 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520982","1p36.3","C13527","A chromosome band present on 1p","1p36.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522561","Recombinant Brain-Derived Growth Factors","C1352","Recombinant therapeutic agents chemically identical to or similar to endogenous nerve growth factors (neurotrophins) that play vital roles in the development of the nervous system.  Brain-derived growth factors may also regulate hematopoiesis and immune cell function.  Examples of brain-derived growth factors include nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). (NCI04)","Recombinant Brain-Derived Growth Factors | BDNF | Brain-Derived Neurotrophic Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523047","Colectomy with Diversion","C135732","Surgical diversion of the gastrointestinal tract performed in conjunction with a colectomy.","Colectomy with Diversion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523048","Bypass of Impending Intestinal Obstruction","C135733","Surgical bypass of an impending intestinal obstruction.","Bypass of Impending Intestinal Obstruction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522709","Stage III Jejunal Neuroendocrine Tumor AJCC v8","C135122","Stage III includes: (T1, N1, N2, M0); (T2, N1, N2, M0); (T3, N1, N2, M0); (T4, N0, M0); (T4, N1, N2, M0). T1: Tumor invading lamina propria or submucosa and measuring 1 cm or less in size. T2: Tumor invading muscularis propria or measuring more than 1 cm in size. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. T4: Tumor invading visceral peritoneum (serosa) or other organs or adjacent structures. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis in less than 12 nodes. N2: Large mesenteric masses (larger than 2 cm) and/or extensive nodal deposits (12 or greater), especially those that encase the superior mesenteric vessels. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Jejunal Neuroendocrine Tumor AJCC v8 | Stage III Jejunal Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519818","Upstream Enhancer","C13462","An enhancer which is located 5' of the gene it regulates.","Upstream Enhancer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522180","Putative Coiled-Coil Domain-Containing Protein 26","C134630","Putative coiled-coil domain-containing protein 26 (109 aa, ~13 kDa) is encoded by the human CCDC26 gene. This protein may play a role in the cellular response to retinoic acid.","Putative Coiled-Coil Domain-Containing Protein 26 | CCDC26 | Coiled-Coil Domain-Containing Protein 26 | Retinoic Acid Modulator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523843","CCDC26 Long Non-Coding RNA","C134631","CCDC26 long non-coding RNA (~1.7 kb) is encoded by the human CCDC26 gene. This long non-coding RNA may be involved in retinoic acid-mediated cellular processes.","CCDC26 Long Non-Coding RNA | CCDC26 | CCDC26 LincRNA | CCDC26 LncRNA | CCDC26 Long Noncoding RNA | RAM LincRNA | RAM LncRNA | Retinoic Acid Modulator Long Non-Coding RNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539711","RTEL1 Gene","C134632","This gene plays a role in telomere maintenance and the regulation of meiotic crossover recombination.","RTEL1 Gene | RTEL1 | Regulator of Telomere Elongation Helicase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522181","RTEL1 wt Allele","C134633","Human RTEL1 wild-type allele is located in the vicinity of 20q13.33 and is approximately 38 kb in length. This allele, which encodes regulator of telomere elongation helicase 1 protein, is involved in telomere and chromosome maintenance. Mutation of the gene is associated with telomere-related pulmonary fibrosis and/or bone marrow failure 3 and dyskeratosis congenita types autosomal dominant 4 and autosomal recessive 5.","RTEL1 wt Allele | C20orf41 | Chromosome 20 Open Reading Frame 41 Gene | DKCA4 | DKCB5 | DKFZP434C013 | KIAA1088 | NHL | PFBMFT3 | RTEL | Regulator of Telomere Elongation Helicase 1 wt Allele | bK3184A7.3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2605651","RTEL1 protein, human","C134634","Regulator of telomere elongation helicase 1 (1219 aa, ~134 kDa) is encoded by the human RTEL1 gene. This protein plays a role in the maintenance of chromosomes and telomeres.","Regulator of Telomere Elongation Helicase 1 | EC 3.6.4.12 | Novel Helicase-Like | Novel Helicase-Like Protein | RTEL1 | Regulator of Telomere Length | Telomere Length Regulator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522183","Gallbladder Cancer Clinical TNM Finding v8","C134636","A clinical finding about one or more characteristics of gallbladder cancer, following the rules of the TNM AJCC v8 classification system.","Gallbladder Cancer Clinical TNM Finding v8 | Gallbladder Carcinoma Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520535","Chromosome 13 Short Arm","C13535","Proximal (short) arm of chromosome 13","13p | Chromosome 13 Proximal Arm | Chromosome 13 Short Arm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522791","Stage I Colon Neuroendocrine Tumor AJCC v8","C135368","Stage I includes: T1, N0, M0. T1: Tumor invading the lamina propria or submucosa and measuring 2 cm or less. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Colon Neuroendocrine Tumor AJCC v8 | Stage I Colon Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522792","Stage IIA Colon Neuroendocrine Tumor AJCC v8","C135369","Stage IIA includes: T2, N0, M0. T2: Tumor invading the muscularis propria or measuring more than 2 cm with invasion of the lamina propria or submucosa. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIA Colon Neuroendocrine Tumor AJCC v8 | Stage IIA Colon Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521049","20q11-q12","C13536","A chromosome band present on 20q","20q11-q12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522793","Stage IIB Colon Neuroendocrine Tumor AJCC v8","C135370","Stage IIB includes: T3, N0, M0. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIB Colon Neuroendocrine Tumor AJCC v8 | Stage IIB Colon Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522263","Bismuth-Corlette Hilar Cholangiocarcinoma Classification","C134736","A classification system of hilar cholangiocarcinoma that describes the location and extent of biliary infiltration by tumor. (AJCC 8th ed.)","Bismuth-Corlette Hilar Cholangiocarcinoma Classification | Bismuth-Corlette Perihilar Cholangiocarcinoma Classification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520968","1p35-p34.3","C13573","A chromosome band present on 1p","1p35-p34.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522661","Duodenum and Ampulla of Vater Neuroendocrine Tumor pT1 TNM Finding v8","C135067","Duodenum neuroendocrine tumor invading the mucosa or submucosa only and is equal or less than 1 cm; Ampulla of Vater neuroendocrine tumor measuring 1 cm or less and is confined within the sphincter of Oddi. (from AJCC 8th Ed.)","Duodenal and Ampulla of Vater Neuroendocrine Tumor pT1 TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor pT1 TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor pT1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522663","Duodenum and Ampulla of Vater Neuroendocrine Tumor pT3 TNM Finding v8","C135069","Duodenum and ampulla of Vater neuroendocrine tumor invading the pancreas or peripancreatic adipose tissue. (from AJCC 8th Ed.)","Duodenal and Ampulla of Vater Neuroendocrine Tumor pT3 TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor pT3 TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor pT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521224","2q33.3-q34","C13506","A chromosome band present on 2q","2q33.3-q34 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522664","Duodenum and Ampulla of Vater Neuroendocrine Tumor pT4 TNM Finding v8","C135070","Duodenum and ampulla of Vater neuroendocrine tumor invading the visceral peritoneum (serosa) or other organs. (from AJCC 8th Ed.)","Duodenal and Ampulla of Vater Neuroendocrine Tumor pT4 TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor pT4 TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor pT4 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522665","Duodenum and Ampulla of Vater Neuroendocrine Tumor Pathologic Regional Lymph Nodes TNM Finding v8","C135071","A pathologic finding about one or more characteristics of a duodenum and ampulla of Vater neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Duodenal and Ampulla of Vater Neuroendocrine Tumor Pathologic Regional Lymph Nodes TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor Pathologic Regional Lymph Nodes TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor Pathologic Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512050","Downstream Enhancer","C13463","An enhancer which is located 3' of the gene it regulates.","Downstream Enhancer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522187","Gallbladder Cancer Pathologic TNM Finding v8","C134640","A pathologic finding about one or more characteristics of gallbladder cancer, following the rules of the TNM AJCC v8 classification system.","Gallbladder Cancer Pathologic TNM Finding v8 | Gallbladder Carcinoma Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522188","Gallbladder Cancer Pathologic Distant Metastasis TNM Finding v8","C134641","A pathologic finding about one or more characteristics of gallbladder cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Gallbladder Cancer Pathologic Distant Metastasis TNM Finding v8 | Gallbladder Carcinoma Pathologic Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522190","Gallbladder Cancer Pathologic Primary Tumor TNM Finding v8","C134643","A pathologic finding about one or more characteristics of gallbladder cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Gallbladder Cancer Pathologic Primary Tumor TNM Finding v8 | Gallbladder Carcinoma Pathologic Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522891","Stage IIA Rectal Neuroendocrine Tumor AJCC v8","C135529","Stage IIA includes: T2, N0, M0. T2: Tumor invading the muscularis propria or measuring more than 2 cm with invasion of the lamina propria or submucosa. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIA Rectal Neuroendocrine Tumor AJCC v8 | Stage IIA Rectal Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522892","Stage IIB Rectal Neuroendocrine Tumor AJCC v8","C135530","Stage IIB includes: T3, N0, M0. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIB Rectal Neuroendocrine Tumor AJCC v8 | Stage IIB Rectal Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522893","Stage IIIA Rectal Neuroendocrine Tumor AJCC v8","C135531","Stage IIIA includes: T4, N0, M0. T4: Tumor invading the visceral peritoneum (serosa) or other organs or adjacent structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIA Rectal Neuroendocrine Tumor AJCC v8 | Stage IIIA Rectal Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522894","Stage IIIB Rectal Neuroendocrine Tumor AJCC v8","C135532","Stage IIIB includes: (T1, N1, M0); (T2, N1, M0); (T3, N1, M0); (T4, N1, M0). T1: Tumor invading the lamina propria or submucosa and measuring 2 cm or less. T2: Tumor invading the muscularis propria or measuring more than 2 cm with invasion of the lamina propria or submucosa. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. T4: Tumor invading the visceral peritoneum (serosa) or other organs or adjacent structures. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIB Rectal Neuroendocrine Tumor AJCC v8 | Stage IIIB Rectal Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522895","Stage IV Rectal Neuroendocrine Tumor AJCC v8","C135533","Stage IV includes: (T1, Any N, M1); (T2, Any N, M1); (T3, Any N, M1); (T4, Any N, M1). T1: Tumor invading the lamina propria or submucosa and measuring 2 cm or less. T2: Tumor invading the muscularis propria or measuring more than 2 cm with invasion of the lamina propria or submucosa. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. T4: Tumor invading the visceral peritoneum (serosa) or other organs or adjacent structures. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Rectal Neuroendocrine Tumor AJCC v8 | Stage IV Rectal Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520256","10p11.2","C13491","A chromosome band present on 10p","10p11.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522264","Type I Bismuth-Corlette Hilar Cholangiocarcinoma","C134737","Tumor is limited to the common hepatic duct, below the level of the confluence of the right and left hepatic ducts. (AJCC 8th ed.)","Type I Bismuth-Corlette Hilar Cholangiocarcinoma | Type I Bismuth-Corlette Perihilar Cholangiocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522265","Type II Bismuth-Corlette Hilar Cholangiocarcinoma","C134738","Tumor involves the confluence of the right and left hepatic ducts. (AJCC 8th ed.)","Type II Bismuth-Corlette Hilar Cholangiocarcinoma | Type II Bismuth-Corlette Perihilar Cholangiocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522266","Type IIIa Bismuth-Corlette Hilar Cholangiocarcinoma","C134739","Tumor with type II involvement plus extension to the right 2nd-order ducts. (AJCC 8th ed.)","Type IIIa Bismuth-Corlette Hilar Cholangiocarcinoma | Type IIIa Bismuth-Corlette Perihilar Cholangiocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520941","1p21-p13","C13473","A chromosome band present on 1p","1p21-p13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522267","Type IIIb Bismuth-Corlette Hilar Cholangiocarcinoma","C134740","Tumor with type II involvement plus extension to the left 2nd-order ducts. (AJCC 8th ed.)","Type IIIb Bismuth-Corlette Hilar Cholangiocarcinoma | Type IIIb Bismuth-Corlette Perihilar Cholangiocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522268","Type IV Bismuth-Corlette Hilar Cholangiocarcinoma","C134741","Tumor extends into both right and left 2nd-order ducts. (AJCC 8th ed.)","Type IV Bismuth-Corlette Hilar Cholangiocarcinoma | Type IV Bismuth-Corlette Perihilar Cholangiocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522269","Hilar Cholangiocarcinoma by AJCC v7 Stage","C134742","A term that refers to the staging of hilar cholangiocarcinoma according to the American Joint Committee on Cancer, 7th edition.","Hilar Cholangiocarcinoma by AJCC v7 Stage | Perihilar Cholangiocarcinoma by AJCC v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522984","HDAC6 Inhibitor KA2507","C135629","An orally bioavailable inhibitor of histone deacetylase (HDAC) type 6 (HDAC6; HDAC-6), with potential antineoplastic activity. Upon administration, KA2507 targets, binds to and inhibits the activity of HDAC6. This results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. Specifically, inhibition of HDAC6 prevents STAT3 activity, which leads to a reduction in programmed death-1 (PD-1) expression. Eventually, this results in a selective transcription of tumor suppressor genes, tumor suppressor protein-mediated inhibition of tumor cell division and an induction of apoptosis in tumor cells that overexpress HDAC6. HDAC6, which is upregulated in many tumor cell types, deacetylates chromatin histone proteins.","HDAC6 Inhibitor KA2507 | HDAC6i KA2507 | KA-2507 | KA2507",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522666","Duodenum and Ampulla of Vater Neuroendocrine Tumor pNX TNM Finding v8","C135072","Duodenum and ampulla of Vater neuroendocrine tumor in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)","Duodenal and Ampulla of Vater Neuroendocrine Tumor pNX TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor pNX TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor pNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522667","Duodenum and Ampulla of Vater Neuroendocrine Tumor pN0 TNM Finding v8","C135073","Duodenum and ampulla of Vater neuroendocrine tumor without regional lymph node involvement. (from AJCC 8th Ed.)","Duodenal and Ampulla of Vater Neuroendocrine Tumor pN0 TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor pN0 TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor pN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522668","Duodenum and Ampulla of Vater Neuroendocrine Tumor pN1 TNM Finding v8","C135074","Duodenum and ampulla of Vater neuroendocrine tumor with regional lymph node involvement. (from AJCC 8th Ed.)","Duodenal and Ampulla of Vater Neuroendocrine Tumor pN1 TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor pN1 TNM Finding v8 | Duodenum and Ampulla of Vater Neuroendocrine Tumor pN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522527","Duodenal Neuroendocrine Tumor by AJCC v8 Stage","C135075","A term that refers to the staging of a duodenal neuroendocrine tumor according to the American Joint Committee on Cancer, 8th edition. This staging system applies to well-differentiated neuroendocrine tumors of the duodenum. Carcinomas of the duodenum, including high-grade (grade 3), poorly differentiated neuroendocrine carcinomas are not included in this staging system. (from AJCC 8th Ed.)","Duodenal Neuroendocrine Tumor by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522669","Stage I Duodenal Neuroendocrine Tumor AJCC v8","C135076","Stage I includes: T1, N0, M0. T1: Tumor invading the mucosa or submucosa only and is equal or less than 1 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Duodenal Neuroendocrine Tumor AJCC v8 | Stage I Duodenal Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522670","Stage II Duodenal Neuroendocrine Tumor AJCC v8","C135077","Stage II includes: (T2, N0, M0); (T3, N0, M0). T2: Tumor invading the muscularis propria or measuring more than 1 cm. T3: Tumor invading the pancreas or peripancreatic adipose tissue. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Duodenal Neuroendocrine Tumor AJCC v8 | Stage II Duodenal Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522671","Stage III Duodenal Neuroendocrine Tumor AJCC v8","C135078","Stage III includes: (T4, N0, M0); (Any T, N1, M0). T4: Tumor invading the visceral peritoneum (serosa) or other organs. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Duodenal Neuroendocrine Tumor AJCC v8 | Stage III Duodenal Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522672","Stage IV Duodenal Neuroendocrine Tumor AJCC v8","C135079","Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Duodenal Neuroendocrine Tumor AJCC v8 | Stage IV Duodenal Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521082","21q22.3","C13507","A chromosome band present on 21q","21q22.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522674","Ampulla of Vater Neuroendocrine Tumor by AJCC v8 Stage","C135081","A term that refers to the staging of an ampulla of Vater neuroendocrine tumor according to the American Joint Committee on Cancer, 8th edition. This staging system applies to well-differentiated neuroendocrine tumors of the ampulla of Vater. Carcinomas of the ampulla of Vater, including high-grade (grade 3), poorly differentiated neuroendocrine carcinomas are not included in this staging system. (from AJCC 8th Ed.)","Ampulla of Vater Neuroendocrine Tumor by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522146","AKAP6 wt Allele","C134589","Human AKAP6 wild-type allele is located in the vicinity of 14q12 and is approximately 508 kb in length. This allele, which encodes A-kinase anchor protein 6, plays a role in the propagation of cyclic adenosine monophosphate (cAMP)-mediated signaling.","AKAP6 wt Allele | A Kinase (PRKA) Anchor Protein 6 Gene | A-Kinase Anchor Protein, 100 kD Gene | A-Kinase Anchoring Protein 6 wt Allele | ADAP100 | ADAP6 | AKAP100 | KIAA0311 | PRKA6 | mAKAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522896","Autologous MAGE-A3/A6-specific TCR Gene-engineered Lymphocytes KITE-718","C135534","Human autologous T-lymphocytes genetically modified to express a T-cell receptor (TCR) that specifically targets human melanoma-associated antigen A3 (MAGE-A3) and MAGE-A6 (MAGEA3/A6; MAGE-A3/A6), with potential antineoplastic activity. Peripheral blood mononuclear cells (PBMCs) are isolated from a patient, transduced with a gene expressing a TCR specific for the MAGE-A3/A6 antigens, expanded ex vivo, and reintroduced into the patient. Then, the autologous MAGE-A3/A6-specific TCR gene engineered lymphocytes KITE-718 target and bind to tumor cells expressing the MAGE-A3 and/or MAGE-A6 antigens. This halts the growth of and kills MAGE-A3/A6-expressing cancer cells. The tumor-associated antigens MAGE-A3 and MAGE-A6 are overexpressed on a variety of tumor cell types.","Autologous MAGE-A3/A6-specific TCR Gene-engineered Lymphocytes KITE-718 | Autologous Anti-MAGE-A3/A6 TCR-transduced T Cells KITE-718 | KITE 718 | KITE-718 | MAGE-A3/A6 T Cell Receptor Engineered T-Cells | MAGE-A3/A6 T-Cell Receptor Engineered T-Cells KITE-718 | MAGE-A3/A6 TCR Engineered T-lymphocytes | MAGEA3/A6-targeted TCR-transduced T-Cells KITE-718 | TCR-transduced Autologous T-Cells KITE-718",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522898","Pancreatic Neuroendocrine Tumor Clinical TNM Finding v8","C135537","A clinical finding about one or more characteristics of a pancreatic neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system.","Pancreatic Neuroendocrine Tumor Clinical TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522387","Stage IIB Ampulla of Vater Cancer AJCC v8","C134871","Stage IIB includes: T3b, N0, M0. T3b: Tumor extending more than 0.5 cm into the pancreas, or extending into peripancreatic tissue or duodenal serosa without involvement of the celiac axis or superior mesenteric artery. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIB Ampulla of Vater Cancer AJCC v8 | Stage IIB Ampulla of Vater Cancer | Stage IIB Ampulla of Vater Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522388","Stage III Ampulla of Vater Cancer AJCC v8","C134872","Stage III includes: IIIA: (T1a, N1, M0); (T1b, N1, M0); (T2, N1, M0); (T3a, N1, M0); (T3b, N1, M0); IIIB: (T4, Any N, M0); (Any T, N2, M0). T1a: Tumor limited to ampulla of Vater or sphincter of Oddi. T1b: Tumor invading beyond the sphincter of Oddi (perisphincteric invasion) and/or into the duodenal submucosa. T2: Tumor invading into the muscularis propria of the duodenum. T3a: Tumor directly invading the pancreas (up to 0.5 cm). T3b: Tumor extending more than 0.5 cm into the pancreas, or extending into peripancreatic tissue or duodenal serosa without involvement of the celiac axis or superior mesenteric artery. T4: Tumor involving the celiac axis, superior mesenteric artery, and/or common hepatic artery, irrespective of size. N1: Metastasis to one to three regional lymph nodes. N2: Metastasis to four or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Ampulla of Vater Cancer AJCC v8 | Stage III Ampulla of Vater Cancer | Stage III Ampulla of Vater Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522389","Stage IIIA Ampulla of Vater Cancer AJCC v8","C134873","Stage IIIA includes: (T1a, N1, M0); (T1b, N1, M0); (T2, N1, M0); (T3a, N1, M0); (T3b, N1, M0). T1a: Tumor limited to ampulla of Vater or sphincter of Oddi. T1b: Tumor invading beyond the sphincter of Oddi (perisphincteric invasion) and/or into the duodenal submucosa. T2: Tumor invading into the muscularis propria of the duodenum. T3a: Tumor directly invading the pancreas (up to 0.5 cm). T3b: Tumor extending more than 0.5 cm into the pancreas, or extending into peripancreatic tissue or duodenal serosa without involvement of the celiac axis or superior mesenteric artery. N1: Metastasis to one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIA Ampulla of Vater Cancer AJCC v8 | Stage IIIA Ampulla of Vater Cancer | Stage IIIA Ampulla of Vater Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520582","14q13","C13516","A chromosome band present on 14q","14q13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520409","11q24.1-q24.3","C13517","A chromosome band present on 11q","11q24.1-q24.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522986","Grape Seed Extract Supplement","C135631","An orally bioavailable dietary supplement composed of an extract from grape seeds containing high amounts of polyphenols, particularly lower proanthocyanidin oligomers (OPCs) and catechins, with antioxidant and chemopreventive activities. Upon administration, the active components in the grape seed extract (GSE) scavenge free radicals, protect against oxidation of low-density lipoprotein (LDL), and inhibit cell damage due to reactive oxygen species (ROS). This inhibits oxidative stress and protects against DNA damage. GSE also inhibits enzymes involved in inflammation, cell replication and DNA synthesis, and induces the expression of anti-oxidant enzymes. This may inhibit growth and induce apoptosis of cancer cells.","Grape Seed Extract Supplement | GSE | GSE Supplement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522987","AMV564","C135632","An anti-CD33/anti-CD3 bispecific tetravalent antibody, with potential immunostimulatory and antineoplastic activities. Anti-CD33/CD3 tetravalent bispecific monoclonal antibody AMV564 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD33, a tumor-associated antigen (TAA) overexpressed on the surface of a variety of tumor cell types. Upon infusion of vixtimotamab, this bispecific antibody binds to CD3-expressing T-cells and CD33-expressing tumor cells, thereby crosslinking CD33-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in a potent CTL-mediated cell lysis of CD33-expressing cells. CD33, a glycoprotein expressed by a variety of cancers, including the majority of acute myeloid leukemias (AMLs), and normal non-pluripotent hematopoietic stem cells, plays a key role in tumor initiation, proliferation and progression.","Vixtimotamab | AMV 564 | AMV-564 | AMV564 | Anti-CD33 Antigen/CD3 Receptor Bispecific Monoclonal Antibody AMV564 | CD33 x CD3 Tandem Diabody AMV-56 | CD33/CD3 TandAbs AMV564 | CNTO-3953 | T652 | VIXTIMOTAMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522988","Anti-CTLA4 Monoclonal Antibody BMS-986218","C135633","A Fc-modified monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA4 monoclonal antibody BMS-986218 targets and binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system. Removal of the fucose sugar units from the antibody's Fc region, enhances its activity and decreases the toxicity of BMS-986218.","Anti-CTLA4 Monoclonal Antibody BMS-986218 | BMS 986218 | BMS-986218 | Monoclonal Antibody BMS-986218",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522989","Autologous Tumor Infiltrating Lymphocytes LN-145","C135634","A proprietary preparation of autologous tumor infiltrating lymphocytes (TILs), with potential immunomodulating activity. The autologous TILs are isolated from an autologous tumor sample and expanded ex vivo in the presence of interleukin-2 (IL-2). Upon infusion of the autologous TILs LN-145 back into the patient, the cells specifically recognize, target and kill the patient's tumor cells.","Autologous Tumor Infiltrating Lymphocytes LN-145 | Autologous TILs LN-145 | Autologous Tumor-infiltrating Lymphocytes LN-145 | LN-145 | LN145",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523861","A-Kinase Anchor Protein 6","C134592","A-kinase anchor protein 6 (2319 aa, ~257 kDa) is encoded by the human AKAP6 gene. This protein is involved in the positive regulation of protein kinase A-mediated signaling.","A-Kinase Anchor Protein 6 | A-Kinase Anchor Protein 100 kDa | AKAP 100 | AKAP-6 | AKAP6 | PRKA6 | Protein Kinase A Anchoring Protein 6 | Protein Kinase A-Anchoring Protein 6 | mAKAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522155","Intrahepatic Bile Duct Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C134599","A pathologic finding about one or more characteristics of intrahepatic bile duct cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Intrahepatic Bile Duct Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | Intrahepatic Bile Duct Cancer Pathologic Regional Lymph Node Status (pN) | Intrahepatic Bile Duct Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514524","Protease Domain","C13459","The portion of a proteolytic protein which causes hydrolysis and cleavage of other protein polypeptides.","Protease Domain | Proteolytic Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523082","PASI - Lower Extremities (L): Desquamation (D)","C135769","Psoriasis Area and Severity Index (PASI) Lower Extremities (L): Desquamation (D).","PASI - Lower Extremities (L): Desquamation (D) | PASI01-Low Extrem (L): Desquamation (D) | PASI0124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520801","18q21.1","C13576","A chromosome band present on 18q","18q21.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523083","PASI - Lower Extremities (L): Sum = E+I+D","C135770","Psoriasis Area and Severity Index (PASI) Lower Extremities (L): Sum = E + I + D.","PASI - Lower Extremities (L): Sum = E+I+D | PASI01-Low Extrem (L): Sum = E+I+D | PASI0125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523084","PASI - Lower Extremities (L): Area Score","C135771","Psoriasis Area and Severity Index (PASI) Lower Extremities (L): Area score.","PASI - Lower Extremities (L): Area Score | PASI01-Low Extrem (L): Area Score | PASI0126",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523085","PASI - Lower Extremities (L): Sum X Area","C135772","Psoriasis Area and Severity Index (PASI) Lower Extremities (L): Sum x area.","PASI - Lower Extremities (L): Sum X Area | PASI01-Low Extrem (L): Sum X Area | PASI0127",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523086","PASI - Lower Extremities (L): Sum X Area X 0.4","C135773","Psoriasis Area and Severity Index (PASI) Lower Extremities (L): Sum x area x 0.4.","PASI - Lower Extremities (L): Sum X Area X 0.4 | PASI01-Low Extrem (L): Sum X Area X 0.4 | PASI0128",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523087","PASI - Total Sum","C135774","Psoriasis Area and Severity Index (PASI) Total sum.","PASI - Total Sum | PASI01-Total Sum | PASI0129",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523088","BEBQ Concurrent Version - Baby Seems Contented Feeding","C135775","Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) My baby seems contented while feeding.","BEBQ Concurrent Version - Baby Seems Contented Feeding | BEBQ01-Baby Seems Contented Feeding | BEBQ0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523089","BEBQ Concurrent Version - Baby Frequently Wants More Milk","C135776","Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) My baby frequently wants more milk than I provide.","BEBQ Concurrent Version - Baby Frequently Wants More Milk | BEBQ01-Baby Frequently Wants More Milk | BEBQ0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523090","BEBQ Concurrent Version - Baby Loves Milk","C135777","Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) My baby loves milk.","BEBQ Concurrent Version - Baby Loves Milk | BEBQ01-Baby Loves Milk | BEBQ0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523303","PODCI Pediatric Parent-Reported Version - Games Limited by: Dislike","C135990","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'no' to Question 44 above, was your child's activity limited by: Dislike of pickup games or sports?","PODCI Pediatric Parent-Reported Version - Games Limited by: Dislike | PODCI1-Games Limited by: Dislike | PODCI149",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523304","PODCI Pediatric Parent-Reported Version - Games Limited by: Too Young","C135991","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'no' to Question 44 above, was your child's activity limited by: Too young?","PODCI Pediatric Parent-Reported Version - Games Limited by: Too Young | PODCI1-Games Limited by: Too Young | PODCI150",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523305","PODCI Pediatric Parent-Reported Version - Games Limited by: Season","C135992","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'no' to Question 44 above, was your child's activity limited by: Activity not in season?","PODCI Pediatric Parent-Reported Version - Games Limited by: Season | PODCI1-Games Limited by: Season | PODCI151",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523306","PODCI Pediatric Parent-Reported Version - Participate in Competitive Sports","C135993","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) Can your child participate in competitive level sports with other children the same age (For example: hockey, basketball, soccer, football, baseball, swimming, running [track or cross country], gymnastics, or dance)?","PODCI Pediatric Parent-Reported Version - Participate in Competitive Sports | PODCI1-Participate in Competitive Sports | PODCI152",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523634","Stage III Thymus Epithelial Neoplasm","C136325","Stage III includes: IIIA: (T3, N0, M0); IIIB: (T4, N0, M0). T3: Tumor with direct invasion into any of the following: lung, brachiocephalic vein, superior vena cava, phrenic nerve, chest wall, or extrapericardial pulmonary artery or veins. T4: Tumor with invasion into any of the following: aorta (ascending, arch, or descending), arch vessels, intrapericardial pulmonary artery, myocardium, trachea, esophagus. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Thymus Epithelial Neoplasm AJCC v8 | Stage III Thymic Epithelial Neoplasm AJCC v8 | Stage III Thymic Epithelial Neoplasm AJCC v8 | Stage III Thymus Epithelial Neoplasm | Stage III Thymus Epithelial Neoplasm AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523636","Stage IIIA Thymic Epithelial Neoplasm AJCC v8","C136327","Stage IIIA includes: T3, N0, M0. T3: Tumor with direct invasion into any of the following: lung, brachiocephalic vein, superior vena cava, phrenic nerve, chest wall, or extrapericardial pulmonary artery or veins. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIA Thymus Epithelial Neoplasm AJCC v8 | Stage IIIA Thymic Epithelial Neoplasm AJCC v8 | Stage IIIA Thymic Epithelial Neoplasm AJCC v8 | Stage IIIA Thymus Epithelial Neoplasm AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523637","Stage IIIB Thymic Epithelial Neoplasm AJCC v8","C136328","Stage IIIB includes: T4, N0, M0. T4: Tumor with invasion into any of the following: aorta (ascending, arch, or descending), arch vessels, intrapericardial pulmonary artery, myocardium, trachea, esophagus. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIB Thymus Epithelial Neoplasm AJCC v8 | Stage IIIB Thymic Epithelial Neoplasm AJCC v8 | Stage IIIB Thymic Epithelial Neoplasm AJCC v8 | Stage IIIB Thymus Epithelial Neoplasm AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520361","11p13","C13632","A chromosome band present on 11p","11p13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524369","Recurrent Anaplastic Astrocytoma","C136517","The reemergence of anaplastic astrocytoma after a period of remission.","Recurrent Anaplastic Astrocytoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524367","Recurrent Diffuse Intrinsic Pontine Glioma","C136518","The reemergence of diffuse intrinsic pontine glioma after a period of remission.","Recurrent Diffuse Intrinsic Pontine Glioma | Recurrent Diffuse Intrinsic Pontine Glioma (DIPG)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524368","Refractory Diffuse Intrinsic Pontine Glioma","C136519","Diffuse intrinsic pontine glioma that is resistant to treatment.","Refractory Diffuse Intrinsic Pontine Glioma | Refractory Diffuse Intrinsic Pontine Glioma (DIPG)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520840","19p13","C13651","A chromosome band present on 19p","19p13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523338","PODCI Pediatric Parent-Reported Version - Able to Do More Sports","C136025","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) As a result of my child's treatment, I expect my child: To be able to do more sports.","PODCI Pediatric Parent-Reported Version - Able to Do More Sports | PODCI1-Able to Do More Sports | PODCI184",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523339","PODCI Pediatric Parent-Reported Version - Free From Pain as Adult","C136026","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) As a result of my child's treatment, I expect my child: To be free from pain or disability as an adult.","PODCI Pediatric Parent-Reported Version - Free From Pain as Adult | PODCI1-Free From Pain as Adult | PODCI185",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523340","PODCI Pediatric Parent-Reported Version - Spend Rest of Life With Condition","C136027","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If your child had to spend the rest of his/her life with his/her bone and muscle condition as it is right now, how would you feel about it?","PODCI Pediatric Parent-Reported Version - Spend Rest of Life With Condition | PODCI1-Spend Rest of Life With Condition | PODCI186",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523341","PODCI Pediatric Parent-Reported Version - Upper Extremity and Physical Function Scale","C136028","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) Upper extremity and physical function core scale.","PODCI Pediatric Parent-Reported Version - Upper Extremity and Physical Function Scale | PODCI1-Up Extremity/Phys Function Scale | PODCI187",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523342","PODCI Pediatric Parent-Reported Version - Transfer and Basic Mobility Scale","C136029","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) Transfer and basic mobility core scale.","PODCI Pediatric Parent-Reported Version - Transfer and Basic Mobility Scale | PODCI1-Transfer/Basic Mobility Scale | PODCI188",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521112","22q12.3-q13.1","C13602","A chromosome band present on 22q","22q12.3-q13.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523343","PODCI Pediatric Parent-Reported Version - Sports and Physical Function Scale","C136030","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) Sports and physical functioning core scale.","PODCI Pediatric Parent-Reported Version - Sports and Physical Function Scale | PODCI1-Sports/Phys Function Scale | PODCI189",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523344","PODCI Pediatric Parent-Reported Version - Pain or Comfort Scale","C136031","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) Pain/comfort core scale.","PODCI Pediatric Parent-Reported Version - Pain or Comfort Scale | PODCI1-Pain/Comfort Scale | PODCI190",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523345","PODCI Pediatric Parent-Reported Version - Happiness Scale","C136032","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) Happiness core scale.","PODCI Pediatric Parent-Reported Version - Happiness Scale | PODCI1-Happiness Scale | PODCI191",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523346","PODCI Pediatric Parent-Reported Version - Global Functioning Scale","C136033","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) Global functioning scale.","PODCI Pediatric Parent-Reported Version - Global Functioning Scale | PODCI1-Global Functioning Scale | PODCI192",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523347","PODCI Adolescent Parent-Reported Version - Lift Heavy Books","C136034","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, was it easy or hard for your child to: Lift heavy books?","PODCI Adolescent Parent-Reported Version - Lift Heavy Books | PODCI2-Lift Heavy Books | PODCI201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523350","PODCI Adolescent Parent-Reported Version - Use a Fork and Spoon","C136037","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, was it easy or hard for your child to: Use a fork and spoon?","PODCI Adolescent Parent-Reported Version - Use a Fork and Spoon | PODCI2-Use a Fork and Spoon | PODCI204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523180","LEC-5 Standard Version - Sexual Assault: Not Apply","C135867","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sexual assault (rape, attempted rape, made to perform any type of sexual act through force or threat of harm): Doesn't apply.","LEC-5 Standard Version - Sexual Assault: Not Apply | LEC01-Sexual Assault: Not Apply | LEC0108F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523181","LEC-5 Standard Version - Unwanted Sex Experience: Happened","C135868","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Other unwanted or uncomfortable sexual experience: Happened to me.","LEC-5 Standard Version - Unwanted Sex Experience: Happened | LEC01-Unwanted Sex Experience: Happened | LEC0109A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520960","1p34","C13586","A chromosome band present on 1p","1p34 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523183","LEC-5 Standard Version - Unwanted Sex Experience: Learned","C135870","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Other unwanted or uncomfortable sexual experience: Learned about it.","LEC-5 Standard Version - Unwanted Sex Experience: Learned | LEC01-Unwanted Sex Experience: Learned | LEC0109C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523184","LEC-5 Standard Version - Unwanted Sex Experience: Job","C135871","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Other unwanted or uncomfortable sexual experience: Part of my job.","LEC-5 Standard Version - Unwanted Sex Experience: Job | LEC01-Unwanted Sex Experience: Job | LEC0109D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523394","PODCI Adolescent Parent-Reported Version - Games Limited by: Fear","C136081","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered 'no' to Question 44 above, was your child's activity limited by: Fear the other kids won't like him/her?","PODCI Adolescent Parent-Reported Version - Games Limited by: Fear | PODCI2-Games Limited by: Fear | PODCI248",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523395","PODCI Adolescent Parent-Reported Version - Games Limited by: Dislike","C136082","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered 'no' to Question 44 above, was your child's activity limited by: Dislike of pickup games or sports?","PODCI Adolescent Parent-Reported Version - Games Limited by: Dislike | PODCI2-Games Limited by: Dislike | PODCI249",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523396","PODCI Adolescent Parent-Reported Version - Games Limited by: Too Young","C136083","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered 'no' to Question 44 above, was your child's activity limited by: Too young?","PODCI Adolescent Parent-Reported Version - Games Limited by: Too Young | PODCI2-Games Limited by: Too Young | PODCI250",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523397","PODCI Adolescent Parent-Reported Version - Games Limited by: Season","C136084","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered 'no' to Question 44 above, was your child's activity limited by: Activity not in season?","PODCI Adolescent Parent-Reported Version - Games Limited by: Season | PODCI2-Games Limited by: Season | PODCI251",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523398","PODCI Adolescent Parent-Reported Version - Participate in Competitive Sports","C136085","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) Can your child participate in competitive level sports with other children the same age (For example: hockey, basketball, soccer, football, baseball, swimming, running [track or cross country], gymnastics, or dance)?","PODCI Adolescent Parent-Reported Version - Participate in Competitive Sports | PODCI2-Participate in Competitive Sports | PODCI252",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523399","PODCI Adolescent Parent-Reported Version - Competitive Sports Limited by: Pain","C136086","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered 'no' to Question 52 above, was your child's activity limited by: Pain?","PODCI Adolescent Parent-Reported Version - Competitive Sports Limited by: Pain | PODCI2-Comp Sports Limited by: Pain | PODCI253",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523400","PODCI Adolescent Parent-Reported Version - Competitive Sports Limited by: Health","C136087","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered 'no' to Question 52 above, was your child's activity limited by: General health?","PODCI Adolescent Parent-Reported Version - Competitive Sports Limited by: Health | PODCI2-Comp Sports Limited by: Health | PODCI254",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523401","PODCI Adolescent Parent-Reported Version - Competitive Sports Limited by: Instructions","C136088","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered 'no' to Question 52 above, was your child's activity limited by: Doctor or parent instructions?","PODCI Adolescent Parent-Reported Version - Competitive Sports Limited by: Instructions | PODCI2-Comp Sports Limited by: Instruct | PODCI255",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523580","VTD-PACE Regimen","C136269","A regimen consisting of dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide and etoposide (DT-PACE), plus bortezomib (VTD-PACE) that is used for the treatment of plasma cell myeloma.","VTD-PACE Regimen | Bortezomib-Thalidomide-Dexamethasone-Cisplatin-Doxorubicin-Cyclophosphamide-Etoposide Regimen | DT-PACE Plus Bortezomib | DT-PACE Plus Velcade | DT-PACE-Bortezomib Regimen | DT-PACE/Bortezomib Regimen | VDT-PACE | VDT-PACE Regimen | VTD-PACE | Velcade/Thalomid/Decadron/Platinol/Adriamycin/Cytoxan/Vepesid Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521308","3q21-q25","C13626","A chromosome band present on 3q","3q21-q25 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523581","Elotuzumab-Lenalidomide-Dexamethasone Regimen","C136270","A regimen consisting of elotuzumab, lenalidomide and dexamethasone that is used for the treatment of plasma cell myeloma.","Elo-Rd Regimen | Dexamethasone/Elotuzumab/Lenalidomide/ | Elo-Rd | Elotuzumab-Lenalidomide-Dexamethasone | Elotuzumab-Lenalidomide-Dexamethasone Regimen | Elotuzumab/Lenalidomide/Dexamethasone | Elotuzumab/Lenalidomide/Dexamethasone Regimen | Empliciti/Revlimid/Dexamethasone | Lenalidomide/Dexamethasone/Elotuzumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520938","1p13.3","C13652","A chromosome band present on 1p","1p13.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523238","PCL-5 - Feel Upset When Reminded","C135925","The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Feeling very upset when something reminded you of the stressful experience?","PCL-5 - Feel Upset When Reminded | PCL01-Feel Upset When Reminded | PCL0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523239","PCL-5 - Strong Physical Reactions","C135926","The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Having strong physical reactions when something reminded you of the stressful experience (for example, heart pounding, trouble breathing, sweating)?","PCL-5 - Strong Physical Reactions | PCL01-Strong Physical Reactions | PCL0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523240","PCL-5 - Avoid Memories, Thoughts or Feelings","C135927","The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Avoiding memories, thoughts, or feelings related to the stressful experience?","PCL-5 - Avoid Memories, Thoughts or Feelings | PCL01-Avoid Memories/Thoughts/Feelings | PCL0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523241","PCL-5 - Avoid External Reminders","C135928","The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Avoiding external reminders of the stressful experience (for example, people, places, conversations, activities, objects, or situations)?","PCL-5 - Avoid External Reminders | PCL01-Avoid External Reminders | PCL0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523242","PCL-5 - Trouble Remembering Important Parts","C135929","The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Trouble remembering important parts of the stressful experience?","PCL-5 - Trouble Remembering Important Parts | PCL01-Trouble Remembering Important Part | PCL0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520963","1p34.3","C13592","A chromosome band present on 1p","1p34.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523351","PODCI Adolescent Parent-Reported Version - Comb His or Her Hair","C136038","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, was it easy or hard for your child to: Comb his/her hair?","PODCI Adolescent Parent-Reported Version - Comb His or Her Hair | PODCI2-Comb His/Her Hair | PODCI205",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523528","RAND Social Support Survey - Count on to Listen to You","C136215","RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone you can count on to listen to you when you need to talk.","RAND Social Support Survey - Count on to Listen to You | RSSS01-Count on to Listen to You | RSSS0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523529","RAND Social Support Survey - Give You Info to Help Understand","C136216","RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone to give you information to help you understand a situation.","RAND Social Support Survey - Give You Info to Help Understand | RSSS01-Give You Info to Help Understand | RSSS0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523530","RAND Social Support Survey - Give You Advice About a Crisis","C136217","RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone to give you good advice about a crisis.","RAND Social Support Survey - Give You Advice About a Crisis | RSSS01-Give You Advice About a Crisis | RSSS0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523531","RAND Social Support Survey - Confide in or Talk to About Yourself","C136218","RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone to confide in or talk to about yourself or your problems.","RAND Social Support Survey - Confide in or Talk to About Yourself | RSSS01-Confide in/Talk to About Yourself | RSSS0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523532","RAND Social Support Survey - Advice You Really Want","C136219","RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone whose advice you really want.","RAND Social Support Survey - Advice You Really Want | RSSS01-Advice You Really Want | RSSS0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523533","RAND Social Support Survey - Share Your Private Worries and Fears","C136220","RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone to share your most private worries and fears with.","RAND Social Support Survey - Share Your Private Worries and Fears | RSSS01-Share Your Private Worries/Fears | RSSS0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523535","RAND Social Support Survey - Understands Your Problems","C136222","RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone who understands your problems.","RAND Social Support Survey - Understands Your Problems | RSSS01-Understands Your Problems | RSSS0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523536","RAND Social Support Survey - Help If You Were Confined to Bed","C136223","RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone to help you if you were confined to bed.","RAND Social Support Survey - Help If You Were Confined to Bed | RSSS01-Help If You Were Confined to Bed | RSSS0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523537","RAND Social Support Survey - Take You to the Doctor If Needed","C136224","RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone to take you to the doctor if you needed it.","RAND Social Support Survey - Take You to the Doctor If Needed | RSSS01-Take You to the Doctor If Needed | RSSS0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523538","RAND Social Support Survey - Prepare Your Meals If Unable","C136225","RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone to prepare your meals if you were unable to do it yourself.","RAND Social Support Survey - Prepare Your Meals If Unable | RSSS01-Prepare Your Meals If Unable | RSSS0111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523185","LEC-5 Standard Version - Unwanted Sex Experience: Not Sure","C135872","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Other unwanted or uncomfortable sexual experience: Not sure.","LEC-5 Standard Version - Unwanted Sex Experience: Not Sure | LEC01-Unwanted Sex Experience: Not Sure | LEC0109E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523187","LEC-5 Standard Version - Combat or Exposure to War-Zone: Happened","C135874","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Combat or exposure to a war-zone (in the military or as a civilian): Happened to me.","LEC-5 Standard Version - Combat or Exposure to War-Zone: Happened | LEC01-Combat/Exp to War-Zone: Happened | LEC0110A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523188","LEC-5 Standard Version - Combat or Exposure to War-Zone: Witnessed","C135875","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Combat or exposure to a war-zone (in the military or as a civilian): Witnessed it.","LEC-5 Standard Version - Combat or Exposure to War-Zone: Witnessed | LEC01-Combat/Exp to War-Zone: Witnessed | LEC0110B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523189","LEC-5 Standard Version - Combat or Exposure to War-Zone: Learned","C135876","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Combat or exposure to a war-zone (in the military or as a civilian): Learned about it.","LEC-5 Standard Version - Combat or Exposure to War-Zone: Learned | LEC01-Combat/Exp to War-Zone: Learned | LEC0110C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523190","LEC-5 Standard Version - Combat or Exposure to War-Zone: Job","C135877","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Combat or exposure to a war-zone (in the military or as a civilian): Part of my job.","LEC-5 Standard Version - Combat or Exposure to War-Zone: Job | LEC01-Combat/Exp to War-Zone: Job | LEC0110D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523191","LEC-5 Standard Version - Combat or Exposure to War-Zone: Not Sure","C135878","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Combat or exposure to a war-zone (in the military or as a civilian): Not sure.","LEC-5 Standard Version - Combat or Exposure to War-Zone: Not Sure | LEC01-Combat/Exp to War-Zone: Not Sure | LEC0110E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523192","LEC-5 Standard Version - Combat or Exposure to War-Zone: Not Apply","C135879","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Combat or exposure to a war-zone (in the military or as a civilian): Doesn't apply.","LEC-5 Standard Version - Combat or Exposure to War-Zone: Not Apply | LEC01-Combat/Exp to War-Zone: Not Apply | LEC0110F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521180","2p16","C13587","A chromosome band present on 2p","2p16 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523193","LEC-5 Standard Version - Captivity: Happened","C135880","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Captivity (for example, being kidnapped, abducted, held hostage, prisoner of war): Happened to me.","LEC-5 Standard Version - Captivity: Happened | LEC01-Captivity: Happened | LEC0111A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523390","PODCI Adolescent Parent-Reported Version - Participate in Pickup Games","C136077","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) Can your child participate in pickup games or sports with other children the same age (For example: tag, dodge ball, basketball, softball, soccer, catch, jump rope, touch football, hop scotch)?","PODCI Adolescent Parent-Reported Version - Participate in Pickup Games | PODCI2-Participate in Pickup Games | PODCI244",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523391","PODCI Adolescent Parent-Reported Version - Games Limited by: Pain","C136078","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered 'no' to Question 44 above, was your child's activity limited by: Pain?","PODCI Adolescent Parent-Reported Version - Games Limited by: Pain | PODCI2-Games Limited by: Pain | PODCI245",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523392","PODCI Adolescent Parent-Reported Version - Games Limited by: Health","C136079","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered 'no' to Question 44 above, was your child's activity limited by: General health?","PODCI Adolescent Parent-Reported Version - Games Limited by: Health | PODCI2-Games Limited by: Health | PODCI246",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521167","2cen-q13","C13607","A chromosome band present on 22q","2cen-q13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523582","Elotuzumab-Bortezomib-Dexamethasone Regimen","C136271","A regimen consisting of elotuzumab, bortezomib and dexamethasone that is used for the treatment of plasma cell myeloma.","Elo-Vd Regimen | Bortezomib/Dexamethasone/Elotuzumab | Elo-Vd | Elotuzumab-Bortezomib-Dexamethasone | Elotuzumab-Bortezomib-Dexamethasone Regimen | Elotuzumab/Bortezomib/Dexamethasone | Elotuzumab/Bortezomib/Dexamethasone Regimen | Empliciti/Velcade/Dexamethasone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523583","Ixazomib-Lenalidomide-Dexamethasone Regimen","C136272","A regimen consisting of ixazomib, lenalidomide and dexamethasone that may be used for the treatment of plasma cell (multiple) myeloma and systemic light chain (AL) amyloidosis.","IRd Regimen | IRD Regimen | IRd | Ixazomib-Lenalidomide-Dexamethasone | Ixazomib-Lenalidomide-Dexamethasone Regimen | Ixazomib/Lenalidomide/Dexamethasone | Ixazomib/Lenalidomide/Dexamethasone Regimen | Ixazomib/Revlimid/Dexamethasone | Ninlaro/Revlimid/Dexamethasone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523584","Ixazomib-Dexamethasone Regimen","C136273","A regimen consisting of ixazomib and dexamethasone that may be used for the treatment of plasma cell myeloma and systemic light chain (AL) amyloidosis.","Dexamethasone/Ixazomib Regimen | Ixazomib and Dexamethasone | Ixazomib-Dexamethasone | Ixazomib-Dexamethasone Regimen | Ixazomib/Dexamethasone | Ixazomib/Dexamethasone Regimen | Ninlaro/Dexamethasone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523585","Lenalidomide Plus Low-dose Dexamethasone Regimen","C136274","A regimen consisting of lenalidomide and low-dose dexamethasone that is used for the treatment of plasma cell myeloma.","Low-dose Dexamethasone/Lenalidomide Regimen | Lenalidomide Plus Low-dose Dexamethasone Regimen | Lenalidomide-Low-dose Dexamethasone | Lenalidomide/Low-dose Dexamethasone | Lenalidomide/Low-dose Dexamethasone Regimen | Rd Regimen | Revlimid/Low-dose Dexamethasone | Revlimid/Low-dose Dexamethasone Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523586","Panobinostat-Bortezomib-Dexamethasone Regimen","C136275","A regimen consisting of panobinostat, bortezomib and dexamethasone that is used for the treatment of plasma cell myeloma.","Bortezomib/Dexamethasone/Panobinostat Regimen | Bortezomib and Dexamethasone (Vd) and Panobinostat | Farydak/Velcade/Dexamethasone | Panobinostat-Bortezomib-Dexamethasone | Panobinostat-Bortezomib-Dexamethasone Regimen | Panobinostat/Bortezomib/Dexamethasone | Panobinostat/Bortezomib/Dexamethasone Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523587","Panobinostat-Carfilzomib Regimen","C136276","A regimen consisting of panobinostat and carfilzomib that is used for the treatment of plasma cell myeloma.","Carfilzomib/Panobinostat Regimen | Carfilzomib and Panobinostat | Farydak/Kyprolis | Panobinostat-Carfilzomib | Panobinostat-Carfilzomib Regimen | Panobinostat/Carfilzomib | Panobinostat/Carfilzomib Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523588","Pomalidomide-Dexamethasone Regimen","C136277","A regimen consisting of pomalidomide and dexamethasone that is used for the treatment of plasma cell myeloma and systemic light chain amyloidosis.","Dexamethasone/Pomalidomide Regimen | PomDex | Pomalidomide and Dexamethasone (Pd) | Pomalidomide-Dexamethasone | Pomalidomide-Dexamethasone Regimen | Pomalidomide/Dexamethasone | Pomalidomide/Dexamethasone Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523589","Pomalidomide-Bortezomib-Dexamethasone Regimen","C136278","A regimen consisting of pomalidomide, bortezomib and dexamethasone that is used for the treatment of plasma cell myeloma.","PVD Regimen | B-Pd | Bortezomib/Pomalidomide/Dexamethasone | PVD | Pomalidomide-Bortezomib-Dexamethasone | Pomalidomide-Bortezomib-Dexamethasone Regimen | Pomalidomide/Bortezomib/Dexamethasone | Pomalidomide/Bortezomib/Dexamethasone Regimen | Pomalidomide/Velcade/Dexamethasone | Pomalidomide/Velcade/Dexamethasone Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523590","Pomalidomide-Carfilzomib-Dexamethasone Regimen","C136279","A regimen consisting of pomalidomide, carfilzomib and dexamethasone that is used for the treatment of plasma cell myeloma.","KPD Regimen | CPD | Carfilzomib/Dexamethasone/Pomalidomide | Carfilzomib/Pomalidomide/Dexamethasone | KPD | Kyprolis/Pomalidomide/Dexamethasone | Pomalidomide-Carfilzomib-Dexamethasone | Pomalidomide-Carfilzomib-Dexamethasone Regimen | Pomalidomide/Carfilzomib/Dexamethasone | Pomalidomide/Carfilzomib/Dexamethasone Regimen | Pomalidomide/Kyprolis/Dexamethasone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521539","6p21.3","C13627","A chromosome band present on 6p","6p21.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523591","Pomalidomide-Cyclophosphamide-Dexamethasone Regimen","C136280","A regimen consisting of pomalidomide, cyclophosphamide and dexamethasone that is used for the treatment of plasma cell myeloma.","PCD Regimen | Cyclophosphamide/Pomalidomide/Dexamethasone | PCD | PomCyDex | Pomalidomide-Cyclophosphamide-Dexamethasone | Pomalidomide-Cyclophosphamide-Dexamethasone Regimen | Pomalidomide/Cyclophosphamide/Dexamethasone | Pomalidomide/Cyclophosphamide/Dexamethasone Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523243","PCL-5 - Strong Negative Beliefs","C135930","The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Having strong negative beliefs about yourself, other people, or the world (for example, having thoughts such as: I am bad, there is something seriously wrong with me, no one can be trusted, the world is completely dangerous)?","PCL-5 - Strong Negative Beliefs | PCL01-Strong Negative Beliefs | PCL0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523245","PCL-5 - Strong Negative Feelings","C135932","The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Having strong negative feelings such as fear, horror, anger, guilt, or shame?","PCL-5 - Strong Negative Feelings | PCL01-Strong Negative Feelings | PCL0111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523246","PCL-5 - Loss of Interest in Activities","C135933","The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Loss of interest in activities that you used to enjoy?","PCL-5 - Loss of Interest in Activities | PCL01-Loss of Interest in Activities | PCL0112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523247","PCL-5 - Feeling Distant From People","C135934","The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Feeling distant or cut off from other people?","PCL-5 - Feeling Distant From People | PCL01-Feeling Distant From People | PCL0113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523248","PCL-5 - Trouble Experiencing Positive Feelings","C135935","The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Trouble experiencing positive feelings (for example, being unable to feel happiness or have loving feelings for people close to you)?","PCL-5 - Trouble Experiencing Positive Feelings | PCL01-Trouble Experiencing Pos Feelings | PCL0114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523249","PCL-5 - Irritable Behavior or Angry Outbursts","C135936","The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Irritable behavior, angry outbursts, or acting aggressively?","PCL-5 - Irritable Behavior or Angry Outbursts | PCL01-Irritable Behavior/Angry Outbursts | PCL0115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523250","PCL-5 - Taking Too Many Risks or Cause Harm","C135937","The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Taking too many risks or doing things that could cause you harm?","PCL-5 - Taking Too Many Risks or Cause Harm | PCL01-Taking Too Many Risks/Cause Harm | PCL0116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523251","PCL-5 - Being Super Alert or Watchful","C135938","The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Being 'superalert' or watchful or on guard?","PCL-5 - Being Super Alert or Watchful | PCL01-Being Superalert/Watchful/on Guard | PCL0117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523252","PCL-5 - Feeling Jumpy or Easily Startled","C135939","The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Feeling jumpy or easily startled?","PCL-5 - Feeling Jumpy or Easily Startled | PCL01-Feeling Jumpy or Easily Startled | PCL0118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523440","PODCI Adolescent Self-Reported Version - Pour a Half Gallon of Milk","C136127","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, was it easy or hard for you to: Pour a half gallon of milk?","PODCI Adolescent Self-Reported Version - Pour a Half Gallon of Milk | PODCI3-Pour a Half Gallon of Milk | PODCI302",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523441","PODCI Adolescent Self-Reported Version - Open a Jar Been Opened Before","C136128","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, was it easy or hard for you to: Open a jar that has been opened before?","PODCI Adolescent Self-Reported Version - Open a Jar Been Opened Before | PODCI3-Open a Jar Been Opened Before | PODCI303",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523442","PODCI Adolescent Self-Reported Version - Use a Fork and Spoon","C136129","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, was it easy or hard for you to: Use a fork and spoon?","PODCI Adolescent Self-Reported Version - Use a Fork and Spoon | PODCI3-Use a Fork and Spoon | PODCI304",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520994","1q22-q24","C13612","A chromosome band present on 1q","1q22-q24 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523539","RAND Social Support Survey - Help With Daily Chores If Sick","C136226","RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone to help with daily chores if you were sick.","RAND Social Support Survey - Help With Daily Chores If Sick | RSSS01-Help With Daily Chores If Sick | RSSS0112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523540","RAND Social Support Survey - Shows You Love and Affection","C136227","RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone who shows you love and affection.","RAND Social Support Survey - Shows You Love and Affection | RSSS01-Shows You Love and Affection | RSSS0113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523734","Lung Cancer Clinical TNM Finding v8","C136431","A clinical finding about one or more characteristics of lung cancer, following the rules of the TNM AJCC v8 classification system.","Lung Cancer Clinical TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520702","16q22.2","C13643","A chromosome band present on 16q","16q22.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524431","Gerbil Experimental Organism Diagnosis","C136555","A condition that is relevant to either disease states or models of disease in gerbils (Subfamily Gerbillinae.)","Gerbil Experimental Organism Diagnosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524433","Fish Experimental Organism Diagnosis","C136559","A condition that is relevant to either disease states or models of disease in fish.","Fish Experimental Organism Diagnosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520860","19q13.2","C13655","A chromosome band present on 19q","19q13.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524414","Bone Cancer TNM Finding v8","C136561","A finding about one or more characteristics of bone cancer, following the rules of the TNM AJCC v8 classification system. This classification system applies to osteosarcoma, chondrosarcoma, Ewing sarcoma, spindle cell sarcoma, hemangioendothelioma, angiosarcoma, fibrosarcoma/myofibroid sarcoma, chordoma, adamantinoma, and other cancers arising in the bone. It does not apply to primary malignant lymphoma of the bone and multiple myeloma. (from AJCC 8th Ed.)","Bone Cancer TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524411","Bone Cancer Clinical TNM Finding v8","C136562","A clinical finding about one or more characteristics of bone cancer, following the rules of the TNM AJCC v8 classification system.","Bone Cancer Clinical TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524412","Bone Cancer Clinical Distant Metastasis TNM Finding v8","C136563","A clinical finding about one or more characteristics of bone cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Bone Cancer Clinical Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524418","Bone Cancer cM1 TNM Finding v8","C136565","Bone cancer with distant metastasis. (from AJCC 8th Ed.)","Bone Cancer cM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524415","Bone Cancer cM1a TNM Finding v8","C136566","Bone cancer with metastasis in the lung. (from AJCC 8th Ed.)","Bone Cancer cM1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521184","2p22-p21","C13647","A chromosome band present on 2p","2p22-p21 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523307","PODCI Pediatric Parent-Reported Version - Competitive Sports Limited by: Pain","C135994","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'no' to Question 52 above, was your child's activity limited by: Pain?","PODCI Pediatric Parent-Reported Version - Competitive Sports Limited by: Pain | PODCI1-Comp Sports Limited by: Pain | PODCI153",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523308","PODCI Pediatric Parent-Reported Version - Competitive Sports Limited by: Health","C135995","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'no' to Question 52 above, was your child's activity limited by: General health?","PODCI Pediatric Parent-Reported Version - Competitive Sports Limited by: Health | PODCI1-Comp Sports Limited by: Health | PODCI154",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523309","PODCI Pediatric Parent-Reported Version - Competitive Sports Limited by: Instruction","C135996","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'no' to Question 52 above, was your child's activity limited by: Doctor or parent instructions?","PODCI Pediatric Parent-Reported Version - Competitive Sports Limited by: Instruction | PODCI1-Comp Sports Limited by: Instruct | PODCI155",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523310","PODCI Pediatric Parent-Reported Version - Competitive Sports Limited by: Fear","C135997","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'no' to Question 52 above, was your child's activity limited by: Fear the other kids won't like him/her?","PODCI Pediatric Parent-Reported Version - Competitive Sports Limited by: Fear | PODCI1-Comp Sports Limited by: Fear | PODCI156",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523311","PODCI Pediatric Parent-Reported Version - Competitive Sports Limited by: Dislike","C135998","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'no' to Question 52 above, was your child's activity limited by: Dislike of pickup games or sports?","PODCI Pediatric Parent-Reported Version - Competitive Sports Limited by: Dislike | PODCI1-Comp Sports Limited by: Dislike | PODCI157",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523312","PODCI Pediatric Parent-Reported Version - Competitive Sports Limited by: Too Young","C135999","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'no' to Question 52 above, was your child's activity limited by: Too young?","PODCI Pediatric Parent-Reported Version - Competitive Sports Limited by: Too Young | PODCI1-Comp Sports Limited by: Too Young | PODCI158",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520935","1p13","C13599","A chromosome band present on 1p","1p13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523491","PODCI Adolescent Self-Reported Version - Competitive Sports Limited by: Instructions","C136178","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered 'no' to Question 50 above, was your activity limited by: Doctor or parent instructions?","PODCI Adolescent Self-Reported Version - Competitive Sports Limited by: Instructions | PODCI3-Comp Sports Limited by: Instruct | PODCI353",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523492","PODCI Adolescent Self-Reported Version - Competitive Sports Limited by: Fear","C136179","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered 'no' to Question 50 above, was your activity limited by: Fear the other kids won't like you?","PODCI Adolescent Self-Reported Version - Competitive Sports Limited by: Fear | PODCI3-Comp Sports Limited by: Fear | PODCI354",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521537","6p21.1-p21.3","C13617","A chromosome band present on 6p","6p21.1-p21.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523493","PODCI Adolescent Self-Reported Version - Competitive Sports Limited by: Dislike","C136180","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered 'no' to Question 50 above, was your activity limited by: Dislike of pickup games or sports?","PODCI Adolescent Self-Reported Version - Competitive Sports Limited by: Dislike | PODCI3-Comp Sports Limited by: Dislike | PODCI355",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523136","LEC-5 Standard Version - Natural Disaster: Job","C135823","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Natural disaster (for example, flood, hurricane, tornado, earthquake): Part of my job.","LEC-5 Standard Version - Natural Disaster: Job | LEC01-Natural Disaster: Job | LEC0101D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523137","LEC-5 Standard Version - Natural Disaster: Not Sure","C135824","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Natural disaster (for example, flood, hurricane, tornado, earthquake): Not sure.","LEC-5 Standard Version - Natural Disaster: Not Sure | LEC01-Natural Disaster: Not Sure | LEC0101E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523138","LEC-5 Standard Version - Natural Disaster: Not Apply","C135825","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Natural disaster (for example, flood, hurricane, tornado, earthquake): Doesn't apply.","LEC-5 Standard Version - Natural Disaster: Not Apply | LEC01-Natural Disaster: Not Apply | LEC0101F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523139","LEC-5 Standard Version - Fire or Explosion: Happened","C135826","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Fire or explosion: Happened to me.","LEC-5 Standard Version - Fire or Explosion: Happened | LEC01-Fire or Explosion: Happened | LEC0102A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523140","LEC-5 Standard Version - Fire or Explosion: Witnessed","C135827","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Fire or explosion: Witnessed it.","LEC-5 Standard Version - Fire or Explosion: Witnessed | LEC01-Fire or Explosion: Witnessed | LEC0102B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523141","LEC-5 Standard Version - Fire or Explosion: Learned","C135828","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Fire or explosion: Learned about it.","LEC-5 Standard Version - Fire or Explosion: Learned | LEC01-Fire or Explosion: Learned | LEC0102C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523143","LEC-5 Standard Version - Fire or Explosion: Not Sure","C135830","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Fire or explosion: Not sure.","LEC-5 Standard Version - Fire or Explosion: Not Sure | LEC01-Fire or Explosion: Not Sure | LEC0102E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523144","LEC-5 Standard Version - Fire or Explosion: Not Apply","C135831","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Fire or explosion: Doesn't apply.","LEC-5 Standard Version - Fire or Explosion: Not Apply | LEC01-Fire or Explosion: Not Apply | LEC0102F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523145","LEC-5 Standard Version - Transportation Accident: Happened","C135832","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Transportation accident (for example, car accident, boat accident, train wreck, plane crash): Happened to me.","LEC-5 Standard Version - Transportation Accident: Happened | LEC01-Transportation Accident: Happened | LEC0103A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524421","Bone Cancer cM1b TNM Finding v8","C136568","Bone cancer with metastasis in the bone or other distant sites. (from AJCC 8th Ed.)","Bone Cancer cM1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524422","Bone Cancer Pathologic TNM Finding v8","C136569","A pathologic finding about one or more characteristics of bone cancer, following the rules of the TNM AJCC v8 classification system.","Bone Cancer Pathologic TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520581","14q12","C13656","A chromosome band present on 14q","14q12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524420","Bone Cancer pM1 TNM Finding v8","C136571","Bone cancer with distant metastasis. (from AJCC 8th Ed.)","Bone Cancer pM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524425","Bone Cancer pM1a TNM Finding v8","C136572","Bone cancer with metastasis in the lung. (from AJCC 8th Ed.)","Bone Cancer pM1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524426","Bone Cancer pM1b TNM Finding v8","C136573","Bone cancer with metastasis in the bone or other distant sites. (from AJCC 8th Ed.)","Bone Cancer pM1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523266","PODCI Pediatric Parent-Reported Version - What Clothes or Shoes He or She Wear","C135953","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, how happy has your child been with: What clothes or shoes he/she can wear?","PODCI Pediatric Parent-Reported Version - What Clothes or Shoes He or She Wear | PODCI1-What Clothes/Shoes He/She Wear | PODCI112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523267","PODCI Pediatric Parent-Reported Version - Ability Do Same Things Friends Do","C135954","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, how happy has your child been with: His/her ability to do the same things his/her friends do?","PODCI Pediatric Parent-Reported Version - Ability Do Same Things Friends Do | PODCI1-Ability Do Same Things Friends Do | PODCI113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523268","PODCI Pediatric Parent-Reported Version - His or Her Health in General","C135955","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, how happy has your child been with: His/her health in general?","PODCI Pediatric Parent-Reported Version - His or Her Health in General | PODCI1-His/Her Health in General | PODCI114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523269","PODCI Pediatric Parent-Reported Version - Feel Sick and Tired","C135956","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, how much of the time: Did your child feel sick and tired?","PODCI Pediatric Parent-Reported Version - Feel Sick and Tired | PODCI1-Feel Sick and Tired | PODCI115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523271","PODCI Pediatric Parent-Reported Version - Pain or Discomfort Interfere With Activities","C135958","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, how much of the time: Did pain or discomfort interfere with your child's activities?","PODCI Pediatric Parent-Reported Version - Pain or Discomfort Interfere With Activities | PODCI1-Pain/Discom Inter With Activities | PODCI117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523272","PODCI Pediatric Parent-Reported Version - Run Short Distances","C135959","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, has it been easy or hard for your child to: Run short distances?","PODCI Pediatric Parent-Reported Version - Run Short Distances | PODCI1-Run Short Distances | PODCI118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521111","22q12.2","C13595","A chromosome band present on 22q","22q12.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523195","LEC-5 Standard Version - Captivity: Learned","C135882","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Captivity (for example, being kidnapped, abducted, held hostage, prisoner of war): Learned about it.","LEC-5 Standard Version - Captivity: Learned | LEC01-Captivity: Learned | LEC0111C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523196","LEC-5 Standard Version - Captivity: Job","C135883","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Captivity (for example, being kidnapped, abducted, held hostage, prisoner of war): Part of my job.","LEC-5 Standard Version - Captivity: Job | LEC01-Captivity: Job | LEC0111D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523197","LEC-5 Standard Version - Captivity: Not Sure","C135884","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Captivity (for example, being kidnapped, abducted, held hostage, prisoner of war): Not sure.","LEC-5 Standard Version - Captivity: Not Sure | LEC01-Captivity: Not Sure | LEC0111E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523198","LEC-5 Standard Version - Captivity: Not Apply","C135885","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Captivity (for example, being kidnapped, abducted, held hostage, prisoner of war): Doesn't apply.","LEC-5 Standard Version - Captivity: Not Apply | LEC01-Captivity: Not Apply | LEC0111F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523199","LEC-5 Standard Version - Life-threatening Illness: Happened","C135886","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Life-threatening illness or injury: Happened to me.","LEC-5 Standard Version - Life-threatening Illness: Happened | LEC01-Life-threatening Illness: Happened | LEC0112A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523200","LEC-5 Standard Version - Life-threatening Illness: Witnessed","C135887","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Life-threatening illness or injury: Witnessed it.","LEC-5 Standard Version - Life-threatening Illness: Witnessed | LEC01-Life-threatening Illness: Witness | LEC0112B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523201","LEC-5 Standard Version - Life-threatening Illness: Learned","C135888","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Life-threatening illness or injury: Learned about it.","LEC-5 Standard Version - Life-threatening Illness: Learned | LEC01-Life-threatening Illness: Learned | LEC0112C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523202","LEC-5 Standard Version - Life-threatening Illness: Job","C135889","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Life-threatening illness or injury: Part of my job.","LEC-5 Standard Version - Life-threatening Illness: Job | LEC01-Life-threatening Illness: Job | LEC0112D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521567","6q22-q23","C13588","A chromosome band present on 6q","6q22-q23 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523203","LEC-5 Standard Version - Life-threatening Illness: Not Sure","C135890","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Life-threatening illness or injury: Not sure.","LEC-5 Standard Version - Life-threatening Illness: Not Sure | LEC01-Life-threatening Illness: Not Sure | LEC0112E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523204","LEC-5 Standard Version - Life-threatening Illness: Not Apply","C135891","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Life-threatening illness or injury: Doesn't apply.","LEC-5 Standard Version - Life-threatening Illness: Not Apply | LEC01-Life-threatening Illness: No Apply | LEC0112F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523205","LEC-5 Standard Version - Severe Human Suffering: Happened","C135892","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Severe human suffering: Happened to me.","LEC-5 Standard Version - Severe Human Suffering: Happened | LEC01-Severe Human Suffering: Happened | LEC0113A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523495","PODCI Adolescent Self-Reported Version - Get Together With Friends","C136182","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) How often in the last week did you get together and do things with friends?","PODCI Adolescent Self-Reported Version - Get Together With Friends | PODCI3-Get Together With Friends | PODCI357",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523496","PODCI Adolescent Self-Reported Version - Friends Limited by: Pain","C136183","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 57 above, was your activity limited by: Pain?","PODCI Adolescent Self-Reported Version - Friends Limited by: Pain | PODCI3-Friends Limited by: Pain | PODCI358",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523497","PODCI Adolescent Self-Reported Version - Friends Limited by: Health","C136184","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 57 above, was your activity limited by: General health?","PODCI Adolescent Self-Reported Version - Friends Limited by: Health | PODCI3-Friends Limited by: Health | PODCI359",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523498","PODCI Adolescent Self-Reported Version - Friends Limited by: Instructions","C136185","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 57 above, was your activity limited by: Doctor or parent instructions?","PODCI Adolescent Self-Reported Version - Friends Limited by: Instructions | PODCI3-Friends Limited by: Instructions | PODCI360",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523499","PODCI Adolescent Self-Reported Version - Friends Limited by: Fear","C136186","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 57 above, was your activity limited by: Fear the other kids won't like you?","PODCI Adolescent Self-Reported Version - Friends Limited by: Fear | PODCI3-Friends Limited by: Fear | PODCI361",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523500","PODCI Adolescent Self-Reported Version - Friends Limited by: Not Around","C136187","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 57 above, was your activity limited by: Friends not around?","PODCI Adolescent Self-Reported Version - Friends Limited by: Not Around | PODCI3-Friends Limited by: Not Around | PODCI362",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523501","PODCI Adolescent Self-Reported Version - Participate in Gym or Recess","C136188","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) How often in the last week did you participate in gym/recess?","PODCI Adolescent Self-Reported Version - Participate in Gym or Recess | PODCI3-Participate in Gym/Recess | PODCI363",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523502","PODCI Adolescent Self-Reported Version - Gym Limited by: Pain","C136189","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 63 above, was your activity limited by: Pain?","PODCI Adolescent Self-Reported Version - Gym Limited by: Pain | PODCI3-Gym Limited by: Pain | PODCI364",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520855","19q13","C13618","A chromosome band present on 19q","19q13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523146","LEC-5 Standard Version - Transportation Accident: Witnessed","C135833","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Transportation accident (for example, car accident, boat accident, train wreck, plane crash): Witnessed it.","LEC-5 Standard Version - Transportation Accident: Witnessed | LEC01-Transportation Accident: Witnessed | LEC0103B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523148","LEC-5 Standard Version - Transportation Accident: Job","C135835","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Transportation accident (for example, car accident, boat accident, train wreck, plane crash): Part of my job.","LEC-5 Standard Version - Transportation Accident: Job | LEC01-Transportation Accident: Job | LEC0103D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523149","LEC-5 Standard Version - Transportation Accident: Not Sure","C135836","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Transportation accident (for example, car accident, boat accident, train wreck, plane crash): Not sure.","LEC-5 Standard Version - Transportation Accident: Not Sure | LEC01-Transportation Accident: Not Sure | LEC0103E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523150","LEC-5 Standard Version - Transportation Accident: Not Apply","C135837","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Transportation accident (for example, car accident, boat accident, train wreck, plane crash): Doesn't apply.","LEC-5 Standard Version - Transportation Accident: Not Apply | LEC01-Transportation Accident: Not Apply | LEC0103F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523353","PODCI Adolescent Parent-Reported Version - Put on His or Her Coat","C136040","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, was it easy or hard for your child to: Put on his/her coat?","PODCI Adolescent Parent-Reported Version - Put on His or Her Coat | PODCI2-Put on His/Her Coat | PODCI207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523354","PODCI Adolescent Parent-Reported Version - Write With a Pencil","C136041","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, was it easy or hard for your child to: Write with a pencil?","PODCI Adolescent Parent-Reported Version - Write With a Pencil | PODCI2-Write With a Pencil | PODCI208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523355","PODCI Adolescent Parent-Reported Version - Miss School Because of Health","C136042","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) On average, over the last 12 months, how often did your child miss school (camp, etc.) because of his/her health?","PODCI Adolescent Parent-Reported Version - Miss School Because of Health | PODCI2-Miss School Because of Health | PODCI209",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523356","PODCI Adolescent Parent-Reported Version - How He or She Looks","C136043","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, how happy has your child been with: How he/she looks?","PODCI Adolescent Parent-Reported Version - How He or She Looks | PODCI2-How He/She Looks | PODCI210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523357","PODCI Adolescent Parent-Reported Version - His or Her Body","C136044","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, how happy has your child been with: His/her body?","PODCI Adolescent Parent-Reported Version - His or Her Body | PODCI2-His/Her Body | PODCI211",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523358","PODCI Adolescent Parent-Reported Version - What Clothes or Shoes He or She Wear","C136045","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, how happy has your child been with: What clothes or shoes he/she can wear?","PODCI Adolescent Parent-Reported Version - What Clothes or Shoes He or She Wear | PODCI2-What Clothes/Shoes He/She Wear | PODCI212",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523359","PODCI Adolescent Parent-Reported Version - Ability Do Same Things Friends Do","C136046","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, how happy has your child been with: His/her ability to do the same things his/her friends do?","PODCI Adolescent Parent-Reported Version - Ability Do Same Things Friends Do | PODCI2-Ability Do Same Things Friends Do | PODCI213",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523273","PODCI Pediatric Parent-Reported Version - Bicycle or Tricycle","C135960","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, has it been easy or hard for your child to: Bicycle or tricycle?","PODCI Pediatric Parent-Reported Version - Bicycle or Tricycle | PODCI1-Bicycle or Tricycle | PODCI119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523274","PODCI Pediatric Parent-Reported Version - Climb Three Flights of Stairs","C135961","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, has it been easy or hard for your child to: Climb three flights of stairs?","PODCI Pediatric Parent-Reported Version - Climb Three Flights of Stairs | PODCI1-Climb Three Flights of Stairs | PODCI120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523275","PODCI Pediatric Parent-Reported Version - Climb One Flight of Stairs","C135962","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, has it been easy or hard for your child to: Climb one flight of stairs?","PODCI Pediatric Parent-Reported Version - Climb One Flight of Stairs | PODCI1-Climb One Flight of Stairs | PODCI121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523276","PODCI Pediatric Parent-Reported Version - Walk More Than a Mile","C135963","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, has it been easy or hard for your child to: Walk more than a mile?","PODCI Pediatric Parent-Reported Version - Walk More Than a Mile | PODCI1-Walk More Than a Mile | PODCI122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523277","PODCI Pediatric Parent-Reported Version - Walk Three Blocks","C135964","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, has it been easy or hard for your child to: Walk three blocks?","PODCI Pediatric Parent-Reported Version - Walk Three Blocks | PODCI1-Walk Three Blocks | PODCI123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523278","PODCI Pediatric Parent-Reported Version - Walk One Block","C135965","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, has it been easy or hard for your child to: Walk one block?","PODCI Pediatric Parent-Reported Version - Walk One Block | PODCI1-Walk One Block | PODCI124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521104","22q11.2","C13613","A chromosome band present on 22q","22q11.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523453","PODCI Adolescent Self-Reported Version - Feel Sick and Tired","C136140","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, how much of the time: Did you feel sick and tired?","PODCI Adolescent Self-Reported Version - Feel Sick and Tired | PODCI3-Feel Sick and Tired | PODCI315",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523454","PODCI Adolescent Self-Reported Version - Full of Pep and Energy","C136141","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, how much of the time: Were you full of pep and energy?","PODCI Adolescent Self-Reported Version - Full of Pep and Energy | PODCI3-Full of Pep and Energy | PODCI316",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523455","PODCI Adolescent Self-Reported Version - Pain or Discomfort Interfere With Activities","C136142","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, how much of the time: Did pain or discomfort interfere with your activities?","PODCI Adolescent Self-Reported Version - Pain or Discomfort Interfere With Activities | PODCI3-Pain/Discom Inter With Activities | PODCI317",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523457","PODCI Adolescent Self-Reported Version - Bicycle or Tricycle","C136144","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, has it been easy or hard for you to: Bicycle or tricycle?","PODCI Adolescent Self-Reported Version - Bicycle or Tricycle | PODCI3-Bicycle or Tricycle | PODCI319",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523458","PODCI Adolescent Self-Reported Version - Climb Three Flights of Stairs","C136145","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, has it been easy or hard for you to: Climb three flights of stairs?","PODCI Adolescent Self-Reported Version - Climb Three Flights of Stairs | PODCI3-Climb Three Flights of Stairs | PODCI320",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523207","LEC-5 Standard Version - Severe Human Suffering: Learned","C135894","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Severe human suffering: Learned about it.","LEC-5 Standard Version - Severe Human Suffering: Learned | LEC01-Severe Human Suffering: Learned | LEC0113C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523208","LEC-5 Standard Version - Severe Human Suffering: Job","C135895","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Severe human suffering: Part of my job.","LEC-5 Standard Version - Severe Human Suffering: Job | LEC01-Severe Human Suffering: Job | LEC0113D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523209","LEC-5 Standard Version - Severe Human Suffering: Not Sure","C135896","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Severe human suffering: Not sure.","LEC-5 Standard Version - Severe Human Suffering: Not Sure | LEC01-Severe Human Suffering: Not Sure | LEC0113E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520549","13q14.2","C13608","A chromosome band present on 13q","13q14.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523403","PODCI Adolescent Parent-Reported Version - Competitive Sports Limited by: Dislike","C136090","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered 'no' to Question 52 above, was your child's activity limited by: Dislike of pickup games or sports?","PODCI Adolescent Parent-Reported Version - Competitive Sports Limited by: Dislike | PODCI2-Comp Sports Limited by: Dislike | PODCI257",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523404","PODCI Adolescent Parent-Reported Version - Competitive Sports Limited by: Too Young","C136091","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered 'no' to Question 52 above, was your child's activity limited by: Too young?","PODCI Adolescent Parent-Reported Version - Competitive Sports Limited by: Too Young | PODCI2-Comp Sports Limited by: Too Young | PODCI258",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523405","PODCI Adolescent Parent-Reported Version - Competitive Sports Limited by: Season","C136092","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered 'no' to Question 52 above, was your child's activity limited by: Activity not in season?","PODCI Adolescent Parent-Reported Version - Competitive Sports Limited by: Season | PODCI2-Comp Sports Limited by: Season | PODCI259",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523406","PODCI Adolescent Parent-Reported Version - Get Together With Friends","C136093","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) How often in the last week did your child get together and do things with friends?","PODCI Adolescent Parent-Reported Version - Get Together With Friends | PODCI2-Get Together With Friends | PODCI260",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523407","PODCI Adolescent Parent-Reported Version - Friends Limited by: Pain","C136094","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 60 above, was your child's activity limited by: Pain?","PODCI Adolescent Parent-Reported Version - Friends Limited by: Pain | PODCI2-Friends Limited by: Pain | PODCI261",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523408","PODCI Adolescent Parent-Reported Version - Friends Limited by: Health","C136095","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 60 above, was your child's activity limited by: General health?","PODCI Adolescent Parent-Reported Version - Friends Limited by: Health | PODCI2-Friends Limited by: Health | PODCI262",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523409","PODCI Adolescent Parent-Reported Version - Friends Limited by: Instructions","C136096","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 60 above, was your child's activity limited by: Doctor or parent instructions?","PODCI Adolescent Parent-Reported Version - Friends Limited by: Instructions | PODCI2-Friends Limited by: Instructions | PODCI263",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523709","Stage III Pleural Malignant Mesothelioma AJCC v8","C136403","Stage III includes: IIIA: (T3, N1, M0); IIIB: (T1-3, N2, M0); (T4, Any N, M0). T1: Tumor limited to the ipsilateral parietal with or without involvement of visceral pleura, mediastinal pleura, and diaphragmatic pleura. T2: Tumor involving each of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of diaphragmatic muscle and/or extension of tumor from visceral pleura into the underlying pulmonary parenchyma. T3: Tumor is locally advanced but potentially resectable. The tumor involves all the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of the endothoracic fascia, extension into the mediastinal fat, solitary, completely resectable focus of tumor extending into the soft tissues of the chest wall, and/or nontransmural involvement of the pericardium. T4: Tumor is locally advanced and technically unresectable. The tumor involves all the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: diffuse extension or multifocal masses of tumor in the chest wall, with or without associated rib destruction, direct transdiaphragmatic extension of tumor to the peritoneum, direct extension of tumor to the contralateral pleura, direct extension of tumor to mediastinal organs, direct extension of tumor into the spine, and/or tumor extending through to the internal surface of the pericardium with or without a pericardial effusion; or tumor involving the myocardium. N1: Metastases in the ipsilateral bronchopulmonary, hilar, or mediastinal (including the internal mammary, peridiaphragmatic, pericardial fat pad, or intercostal) lymph nodes. N2: Metastases in the contralateral mediastinal, ipsilateral, or contralateral supraclavicular lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Pleural Malignant Mesothelioma AJCC v8 | Stage III Pleural Malignant Mesothelioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523710","Stage IIIA Pleural Malignant Mesothelioma AJCC v8","C136404","Stage IIIA includes: T3, N1, M0. T3: Tumor is locally advanced but potentially resectable. The tumor involves all the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of the endothoracic fascia, extension into the mediastinal fat, solitary, completely resectable focus of tumor extending into the soft tissues of the chest wall, and/or nontransmural involvement of the pericardium. N1: Metastases in the ipsilateral bronchopulmonary, hilar, or mediastinal (including the internal mammary, peridiaphragmatic, pericardial fat pad, or intercostal) lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIA Pleural Malignant Mesothelioma AJCC v8 | Stage IIIA Pleural Malignant Mesothelioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523711","Stage IIIB Pleural Malignant Mesothelioma AJCC v8","C136405","Stage IIIB includes: (T1-3, N2, M0); (T4, Any N, M0). T1: Tumor limited to the ipsilateral parietal with or without involvement of visceral pleura, mediastinal pleura, and diaphragmatic pleura. T2: Tumor involving each of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of diaphragmatic muscle and/or extension of tumor from visceral pleura into the underlying pulmonary parenchyma. T3: Tumor is locally advanced but potentially resectable. The tumor involves all the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of the endothoracic fascia, extension into the mediastinal fat, solitary, completely resectable focus of tumor extending into the soft tissues of the chest wall, and/or nontransmural involvement of the pericardium. T4: Tumor is locally advanced and technically unresectable. The tumor involves all the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: diffuse extension or multifocal masses of tumor in the chest wall, with or without associated rib destruction, direct transdiaphragmatic extension of tumor to the peritoneum, direct extension of tumor to the contralateral pleura, direct extension of tumor to mediastinal organs, direct extension of tumor into the spine, and/or tumor extending through to the internal surface of the pericardium with or without a pericardial effusion; or tumor involving the myocardium. N2: Metastases in the contralateral mediastinal, ipsilateral, or contralateral supraclavicular lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIB Pleural Malignant Mesothelioma AJCC v8 | Stage IIIB Pleural Malignant Mesothelioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523712","Stage IV Pleural Malignant Mesothelioma AJCC v8","C136406","Stage IV includes: Any T, Any N, M1. M1: Distant metastasis present. (AJCC 8th ed.)","Stage IV Pleural Malignant Mesothelioma AJCC v8 | Stage IV Pleural Malignant Mesothelioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523713","GNRH1 Gene Product","C136407","A protein encoded by the GNRH1 gene.","GNRH1 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523858","Gonadoliberin-1","C136408","Gonadoliberin-1 (10 aa, ~1 kDa) is encoded by the human GNRH1 gene. This protein is involved in stimulating the secretion of both luteinizing and follicle-stimulating hormones (LH and FSH, respectively).","Gonadoliberin-1 | GNRH1 | GnRH I | GnRH-Associated Peptide I | GnRH-I | Gonadoliberin 1 | Gonadoliberin I | Gonadorelin | Gonadotropin Releasing Hormone 1 | Gonadotropin-Releasing Hormone 1 | Gonadotropin-Releasing Hormone I | LH-RH I | Leutinizing-Releasing Hormone | Luliberin I | Luteinizing Hormone-Releasing Hormone I | PIF | Prolactin Release-Inhibiting Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523360","PODCI Adolescent Parent-Reported Version - His or Her Health in General","C136047","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, how happy has your child been with: His/her health in general?","PODCI Adolescent Parent-Reported Version - His or Her Health in General | PODCI2-His/Her Health in General | PODCI214",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523361","PODCI Adolescent Parent-Reported Version - Feel Sick and Tired","C136048","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, how much of the time: Did your child feel sick and tired?","PODCI Adolescent Parent-Reported Version - Feel Sick and Tired | PODCI2-Feel Sick and Tired | PODCI215",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523362","PODCI Adolescent Parent-Reported Version - Full of Pep and Energy","C136049","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, how much of the time: Were your child full of pep and energy?","PODCI Adolescent Parent-Reported Version - Full of Pep and Energy | PODCI2-Full of Pep and Energy | PODCI216",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515519","9q31","C13604","A chromosome band present on 9q","9q31 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523364","PODCI Adolescent Parent-Reported Version - Run Short Distances","C136051","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, has it been easy or hard for your child to: Run short distances?","PODCI Adolescent Parent-Reported Version - Run Short Distances | PODCI2-Run Short Distances | PODCI218",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523541","RAND Social Support Survey - Love and Make You Feel Wanted","C136228","RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone to love and make you feel wanted.","RAND Social Support Survey - Love and Make You Feel Wanted | RSSS01-Love and Make You Feel Wanted | RSSS0114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523542","RAND Social Support Survey - Hugs You","C136229","RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone who hugs you.","RAND Social Support Survey - Hugs You | RSSS01-Hugs You | RSSS0115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520763","17q11.2-q12","C13622","A chromosome band present on 17q","17q11.2-q12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523543","RAND Social Support Survey - Have a Good Time With","C136230","RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone to have a good time with.","RAND Social Support Survey - Have a Good Time With | RSSS01-Have a Good Time With | RSSS0116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523544","RAND Social Support Survey - Get Together With for Relaxation","C136231","RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone to get together with for relaxation.","RAND Social Support Survey - Get Together With for Relaxation | RSSS01-Get Together With for Relaxation | RSSS0117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523545","RAND Social Support Survey - Do Something Enjoyable With","C136232","RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone to do something enjoyable with.","RAND Social Support Survey - Do Something Enjoyable With | RSSS01-Do Something Enjoyable With | RSSS0118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523546","RAND Social Support Survey - Help You Get Your Mind Off Things","C136233","RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone to do things with to help you get your mind off things.","RAND Social Support Survey - Help You Get Your Mind Off Things | RSSS01-Help You Get Your Mind Off Things | RSSS0119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523547","MMSE - Level of Consciousness","C136234","Mini-Mental State Examination (MMSE) Assessment of level of consciousness.","MMSE - Level of Consciousness | MMS1-Level of Consciousness | MMS113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523549","Cervical/Vaginal Cytology","C136236","Cytologic evaluation of cells collected from the uterine cervix and/or vagina.","Cervical/Vaginal Cytology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523459","PODCI Adolescent Self-Reported Version - Climb One Flight of Stairs","C136146","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, has it been easy or hard for you to: Climb one flight of stairs?","PODCI Adolescent Self-Reported Version - Climb One Flight of Stairs | PODCI3-Climb One Flight of Stairs | PODCI321",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523460","PODCI Adolescent Self-Reported Version - Walk More Than a Mile","C136147","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, has it been easy or hard for you to: Walk more than a mile?","PODCI Adolescent Self-Reported Version - Walk More Than a Mile | PODCI3-Walk More Than a Mile | PODCI322",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523461","PODCI Adolescent Self-Reported Version - Walk Three Blocks","C136148","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, has it been easy or hard for you to: Walk three blocks?","PODCI Adolescent Self-Reported Version - Walk Three Blocks | PODCI3-Walk Three Blocks | PODCI323",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523462","PODCI Adolescent Self-Reported Version - Walk One Block","C136149","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, has it been easy or hard for you to: Walk one block?","PODCI Adolescent Self-Reported Version - Walk One Block | PODCI3-Walk One Block | PODCI324",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520360","11p12-p11.22","C13614","A chromosome band present on 11p","11p12-p11.22 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523463","PODCI Adolescent Self-Reported Version - Get On and Off a Bus","C136150","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, has it been easy or hard for you to: Get on and off a bus?","PODCI Adolescent Self-Reported Version - Get On and Off a Bus | PODCI3-Get On and Off a Bus | PODCI325",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523464","PODCI Adolescent Self-Reported Version - Need Help Walking and Climbing","C136151","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) How often do you need help from another person for walking and climbing?","PODCI Adolescent Self-Reported Version - Need Help Walking and Climbing | PODCI3-Need Help Walking and Climbing | PODCI326",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523465","PODCI Adolescent Self-Reported Version - Use Assistive Devices for Walking","C136152","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) How often do you use assistive devices (such as braces, crutches, or wheelchair) for walking and climbing?","PODCI Adolescent Self-Reported Version - Use Assistive Devices for Walking | PODCI3-Use Assistive Devices for Walking | PODCI327",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523411","PODCI Adolescent Parent-Reported Version - Friends Limited by: Not Around","C136098","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 60 above, was your child's activity limited by: Friends not around?","PODCI Adolescent Parent-Reported Version - Friends Limited by: Not Around | PODCI2-Friends Limited by: Not Around | PODCI265",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523412","PODCI Adolescent Parent-Reported Version - Participate in Gym or Recess","C136099","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) How often in the last week did your child participate in gym/recess?","PODCI Adolescent Parent-Reported Version - Participate in Gym or Recess | PODCI2-Participate in Gym/Recess | PODCI266",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521173","2p13-p12","C13609","A chromosome band present on 2p","2p13-p12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0111753","Cytembena","C1360","A cytostatic agent that interferes with DNA synthesis.","Cytembena | (E)-3-p-Anisoyl-3-bromoacrylic Acid Sodium Salt | 2-Butenoic Acid, 3-Bromo-4-(4-methoxyphenyl)-4-oxo-, Sodium Salt, (Z)- (9CI) | 2-Butenoic acid, 3-bromo-4-(4-methoxyphenyl)-4-oxo-, sodium salt, (Z)- (9CI) | Acrylic acid, 3-p-anisoyl-3-bromo-, sodium salt | CTB | Cytembena Spofa | SODIUM BROMEBRATE | Sodium Bromebrate | Sodium cis-Beta-4-methoxybenzoyl-beta-bromacrylate | WR-149912",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523592","Bevacizumab/Carboplatin/Pemetrexed Regimen","C136281","A regimen consisting of bevacizumab, carboplatin and pemetrexed that is used for the treatment of non-small cell lung cancer (NSCLC).","Bevacizumab/Carboplatin/Pemetrexed Regimen | Avastin/Carboplatin/Alimta | Bevacizumab-Carboplatin-Pemetrexed | Bevacizumab-Carboplatin-Pemetrexed Regimen | Bevacizumab/Carboplatin/Pemetrexed | Carboplatin, Pemetrexed, Bevacizumab | Carboplatin, Pemetrexed, Bevacizumab-adcd | Carboplatin, Pemetrexed, Bevacizumab-awwb | Carboplatin, Pemetrexed, Bevacizumab-aybi | Carboplatin, Pemetrexed, Bevacizumab-bvzr | Carboplatin, Pemetrexed, Bevacizumab-equi | Carboplatin, Pemetrexed, Bevacizumab-maly | Carboplatin, Pemetrexed, Bevacizumab-onbe | Carboplatin, Pemetrexed, Bevacizumab-tnjn",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523593","Bevacizumab/Cisplatin/Pemetrexed Regimen","C136282","A regimen consisting of bevacizumab, cisplatin and pemetrexed that is used for the treatment of non-small cell lung cancer (NSCLC).","Bevacizumab/Cisplatin/Pemetrexed Regimen | Avastin/Cisplatin/Pemetrexed | Bevacizumab-Cisplatin-Pemetrexed | Bevacizumab-Cisplatin-Pemetrexed Regimen | Bevacizumab/Cisplatin/Pemetrexed | Cisplatin, Pemetrexed, Bevacizumab | Cisplatin, Pemetrexed, Bevacizumab-adcd | Cisplatin, Pemetrexed, Bevacizumab-awwb | Cisplatin, Pemetrexed, Bevacizumab-aybi | Cisplatin, Pemetrexed, Bevacizumab-bvzr | Cisplatin, Pemetrexed, Bevacizumab-equi | Cisplatin, Pemetrexed, Bevacizumab-maly | Cisplatin, Pemetrexed, Bevacizumab-onbe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523594","Carboplatin/Nab-paclitaxel Regimen","C136283","A regimen consisting of carboplatin and nab-paclitaxel, an albumin-bound formulation of paclitaxel, that is used for the treatment of non-small cell lung cancer (NSCLC), breast, ovarian, fallopian tube and primary peritoneal cancers, and cutaneous melanoma.","Carboplatin/Nab-paclitaxel Regimen | Albumin-bound Paclitaxel/Carboplatin | Carboplatin and nab-Paclitaxel | Carboplatin-Albumin-bound Paclitaxel | Carboplatin-Albumin-bound Paclitaxel Regimen | Carboplatin/Abraxane Regimen | Carboplatin/Albumin-bound Paclitaxel | Nab-P/C Regimen | Nab-PC Regimen | Nab-paclitaxel/Carboplatin | Nab-paclitaxel/Carboplatin Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523597","MET Protein Variant","C136286","A variation in the amino acid sequence for the hepatocyte growth factor receptor protein.","MET Protein Variant | C-MET Protein Variant | HGF Receptor Protein Variant | HGFR Protein Variant | Hepatocyte Growth Factor Receptor Protein Variant | Proto-Oncogene c-Met Protein Variant | Scatter Factor Receptor Protein Variant | Tyrosine-Protein Kinase Met Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523092","BEBQ Concurrent Version - Baby Finishes Feeding Quickly","C135779","Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) My baby finishes feeding quickly.","BEBQ Concurrent Version - Baby Finishes Feeding Quickly | BEBQ01-Baby Finishes Feeding Quickly | BEBQ0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520699","16q22-q23","C13577","A chromosome band present on 16q","16q22-q23 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523093","BEBQ Concurrent Version - Baby Becomes Distressed Feeding","C135780","Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) My baby becomes distressed while feeding.","BEBQ Concurrent Version - Baby Becomes Distressed Feeding | BEBQ01-Baby Becomes Distressed Feeding | BEBQ0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523094","BEBQ Concurrent Version - Baby Gets Full Up Easily","C135781","Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) My baby gets full up easily.","BEBQ Concurrent Version - Baby Gets Full Up Easily | BEBQ01-Baby Gets Full Up Easily | BEBQ0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523095","BEBQ Concurrent Version - Baby Would Take Too Much Milk","C135782","Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) If allowed to, my baby would take too much milk.","BEBQ Concurrent Version - Baby Would Take Too Much Milk | BEBQ01-Baby Would Take Too Much Milk | BEBQ0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523096","BEBQ Concurrent Version - Baby Takes More Than 30 Minutes","C135783","Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) My baby takes more than 30 minutes to finish feeding.","BEBQ Concurrent Version - Baby Takes More Than 30 Minutes | BEBQ01-Baby Takes More Than 30 Minutes | BEBQ0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523097","BEBQ Concurrent Version - Gets Full Before Taking All Milk","C135784","Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) My baby gets full before taking all the milk I think he/she should have.","BEBQ Concurrent Version - Gets Full Before Taking All Milk | BEBQ01-Gets Full Before Taking All Milk | BEBQ0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523099","BEBQ Concurrent Version - Just Eaten Is Happy to Feed Again","C135786","Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) Even when my baby has just eaten well he/she is happy to feed again if offered.","BEBQ Concurrent Version - Just Eaten Is Happy to Feed Again | BEBQ01-Just Eaten Is Happy to Feed Again | BEBQ0112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523100","BEBQ Concurrent Version - Difficult Manage Complete Feed","C135787","Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) My baby finds it difficult to manage a complete feed.","BEBQ Concurrent Version - Difficult Manage Complete Feed | BEBQ01-Difficult Manage Complete Feed | BEBQ0113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523101","BEBQ Concurrent Version - Baby Is Always Demanding a Feed","C135788","Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) My baby is always demanding a feed.","BEBQ Concurrent Version - Baby Is Always Demanding a Feed | BEBQ01-Baby Is Always Demanding a Feed | BEBQ0114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523102","BEBQ Concurrent Version - Baby Sucks More and More Slowly","C135789","Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) My baby sucks more and more slowly during the course of a feed.","BEBQ Concurrent Version - Baby Sucks More and More Slowly | BEBQ01-Baby Sucks More and More Slowly | BEBQ0115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520789","17q25","C13578","A chromosome band present on 17q","17q25 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523103","BEBQ Concurrent Version - Baby Would Always Be Feeding","C135790","Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) If given the chance, my baby would always be feeding.","BEBQ Concurrent Version - Baby Would Always Be Feeding | BEBQ01-Baby Would Always Be Feeding | BEBQ0116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523104","BEBQ Concurrent Version - Baby Enjoys Feeding Time","C135791","Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) My baby enjoys feeding time.","BEBQ Concurrent Version - Baby Enjoys Feeding Time | BEBQ01-Baby Enjoys Feeding Time | BEBQ0117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523550","Upper Vaginectomy","C136237","The surgical removal of the upper part of the vagina.","Upper Vaginectomy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1719614","Modified Radical Hysterectomy","C136238","The surgical removal of the uterus and surrounding structures, including bilateral pelvic lymph nodes, the parametrium, and the upper one-third to one-half of the vagina. The amount of parametria and uterosacral ligament removed with the uterus is less than that removed during a radical hysterectomy.","Modified Radical Hysterectomy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521292","3p24.1-p22","C13623","A chromosome band present on 3p","3p24.1-p22 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523551","Rectal Carcinoma Metastatic in the Liver","C136240","A carcinoma that originates from the rectum and has spread to the liver.","Rectal Carcinoma Metastatic in the Liver | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523552","Cisplatin-Paclitaxel-Bevacizumab Regimen","C136241","A regimen consisting of bevacizumab, cisplatin and paclitaxel that is used for the treatment of vulvar and cervical cancer.","Bevacizumab/Cisplatin/Paclitaxel Regimen | Cisplatin, Paclitaxel, Bevacizumab | Cisplatin, Paclitaxel, Bevacizumab-adcd | Cisplatin, Paclitaxel, Bevacizumab-awwb | Cisplatin, Paclitaxel, Bevacizumab-aybi | Cisplatin, Paclitaxel, Bevacizumab-bvzr | Cisplatin, Paclitaxel, Bevacizumab-equi | Cisplatin, Paclitaxel, Bevacizumab-maly | Cisplatin, Paclitaxel, Bevacizumab-onbe | Cisplatin, Paclitaxel, Bevacizumab-tnjn | Cisplatin-Paclitaxel-Bevacizumab | Cisplatin-Paclitaxel-Bevacizumab Regimen | Cisplatin/Paclitaxel/Bevacizumab | Cisplatin/Paclitaxel/Bevacizumab Regimen | Platinol-Taxol-Avastin Regimen | Platinol/Taxol/Avastin Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523553","Topotecan-Paclitaxel-Bevacizumab Regimen","C136242","A regimen consisting of topotecan, paclitaxel and bevacizumab that is used for the treatment of cervical and vaginal cancer.","Bevacizumab/Paclitaxel/Topotecan Regimen | Hycamtin-Taxol-Avastin Regimen | Hycamtin/Taxol/Avastin Regimen | PACLTOPO+BEVA Regimen | Paclitaxel, Topotecan, Bevacizumab | Paclitaxel, Topotecan, Bevacizumab-adcd | Paclitaxel, Topotecan, Bevacizumab-awwb | Paclitaxel, Topotecan, Bevacizumab-aybi | Paclitaxel, Topotecan, Bevacizumab-bvzr | Paclitaxel, Topotecan, Bevacizumab-equi | Paclitaxel, Topotecan, Bevacizumab-maly | Paclitaxel, Topotecan, Bevacizumab-onbe | Paclitaxel, Topotecan, Bevacizumab-tnjn | TPB Regimen | Topotecan-Paclitaxel-Bevacizumab | Topotecan-Paclitaxel-Bevacizumab Regimen | Topotecan/Paclitaxel/Bevacizumab | Topotecan/Paclitaxel/Bevacizumab Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521186","2p23","C13644","A chromosome band present on 2p","2p23 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523681","Pleural Malignant Mesothelioma by AJCC v7 Stage","C136374","A term that refers to the staging of pleural malignant mesothelioma, following the rules of the TNM AJCC v7 classification system.","Pleural Malignant Mesothelioma by AJCC v7 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523682","KNG1 Gene Product","C136375","A protein encoded by the KNG1 gene.","KNG1 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006670","Calcitonin Gene-Related Peptide I","C136377","Calcitonin precursor (141 aa, ~15 kDa) is encoded by the human CALCA gene. This protein plays a role in calcium flux and bone resorption.","Calcitonin Precursor | Alpha-Type CGRP | CALCA | CGRP-I | Calcitonin | Calcitonin Gene-Related Peptide | Calcitonin Gene-Related Peptide 1 | Calcitonin Gene-Related Peptide I | Prepro-CALCA | Preprocalcitonin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523685","Pleural Malignant Mesothelioma TNM Finding v8","C136379","A finding about one or more characteristics of pleural malignant mesothelioma, following the rules of the TNM AJCC v8 classification system. This classification system applies to pleural diffuse malignant mesothelioma only. Localized pleural malignant mesotheliomas and other primary tumors of the pleura are not included in this classification. (from AJCC 8th Ed.)","Pleural Malignant Mesothelioma TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512325","HT-Zip Domain","C13637","Bipartite DNA binding domain containing a helix-turn and a leucine zipper.","HT-Zip Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523686","Pleural Malignant Mesothelioma Clinical TNM Finding v8","C136380","A clinical finding about one or more characteristics of pleural malignant mesothelioma, following the rules of the TNM AJCC v8 classification system.","Pleural Malignant Mesothelioma Clinical TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523687","Pleural Malignant Mesothelioma Clinical Distant Metastasis TNM Finding v8","C136381","A clinical finding about one or more characteristics of pleural malignant mesothelioma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Pleural Malignant Mesothelioma Clinical Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524424","Bone Cancer Pathologic Primary Tumor TNM Finding v8","C136575","A pathologic finding about one or more characteristics of bone cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Bone Cancer Pathologic Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524398","Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer pTX TNM Finding v8","C136577","Appendicular skeleton, trunk, skull, and facial bones cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer pTX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524395","Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer pT0 TNM Finding v8","C136578","Appendicular skeleton, trunk, skull, and facial bones cancer without evidence of primary tumor. (from AJCC 8th Ed.)","Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer pT0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0189488","Segmental Resection of the Lung","C136290","Surgical removal of a section of a lobe of the lung.","Segmental Resection of the Lung | Segmentectomy of the Lung",,,,,,,,,,,,,,,"4070880","Excision of segment of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL523600","Abdominal Wall Fat Pad Biopsy","C136291","Biopsy of the subcutaneous fat of the abdominal wall.","Abdominal Wall Fat Pad Biopsy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523601","Thoracic Cancer TNM Finding v8","C136292","A finding about one or more characteristics of thoracic cancer, following the rules of the TNM AJCC v8 classification system. It refers to thymic tumors, lung carcinoma, and malignant pleural mesothelioma.","Thoracic Cancer TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523602","Thymic Tumor TNM Finding v8","C136293","A finding about one or more characteristics of a thymus tumor, following the rules of the TNM AJCC v8 classification system. This classification system applies to thymomas, thymic carcinomas, thymic neuroendocrine tumors, and combined thymic carcinomas. (from AJCC 8th Ed.)","Thymus Tumor TNM Finding v8 | Thymic Tumor TNM Finding v8 | Thymic Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523603","Thymic Tumor Clinical TNM Finding v8","C136294","A clinical finding about one or more characteristics of a thymus tumor, following the rules of the TNM AJCC v8 classification system.","Thymus Tumor Clinical TNM Finding v8 | Thymic Tumor Clinical TNM Finding v8 | Thymic Tumor Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523605","Thymic Tumor cM0 TNM Finding v8","C136296","Thymus tumor without evidence of pleural, pericardial, or distant metastasis. (from AJCC 8th Ed.)","Thymus Tumor cM0 TNM Finding v8 | Thymic Tumor cM0 TNM Finding v8 | Thymic Tumor cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523791","Refractory Acute Lymphoblastic Leukemia","C136488","Acute lymphoblastic leukemia that does not respond to treatment.","Refractory Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia (ALL)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523792","Refractory Erdheim-Chester Disease","C136489","Erdheim-Chester disease that does not respond to treatment.","Refractory Erdheim-Chester Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521216","2q32","C13648","A chromosome band present on 2q","2q32 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523105","BEBQ Concurrent Version - Take a Feed Within 30 Minutes","C135792","Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) My baby can easily take a feed within 30 minutes of the last one.","BEBQ Concurrent Version - Take a Feed Within 30 Minutes | BEBQ01-Take a Feed Within 30 Minutes | BEBQ0118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523106","BEBQ Retrospective Version - Baby Seemed Contented Feeding","C135793","Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) My baby seemed contented while feeding.","BEBQ Retrospective Version - Baby Seemed Contented Feeding | BEBQ02-Baby Seemed Contented Feeding | BEBQ0201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523313","PODCI Pediatric Parent-Reported Version - Competitive Sports Limited by: Season","C136000","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'no' to Question 52 above, was your child's activity limited by: Activity not in season?","PODCI Pediatric Parent-Reported Version - Competitive Sports Limited by: Season | PODCI1-Comp Sports Limited by: Season | PODCI159",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523314","PODCI Pediatric Parent-Reported Version - Get Together With Friends","C136001","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) How often in the last week did your child get together and do things with friends?","PODCI Pediatric Parent-Reported Version - Get Together With Friends | PODCI1-Get Together With Friends | PODCI160",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523315","PODCI Pediatric Parent-Reported Version - Friends Limited by: Pain","C136002","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 60 above, was your child's activity limited by: Pain?","PODCI Pediatric Parent-Reported Version - Friends Limited by: Pain | PODCI1-Friends Limited by: Pain | PODCI161",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523316","PODCI Pediatric Parent-Reported Version - Friends Limited by: Health","C136003","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 60 above, was your child's activity limited by: General health?","PODCI Pediatric Parent-Reported Version - Friends Limited by: Health | PODCI1-Friends Limited by: Health | PODCI162",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523317","PODCI Pediatric Parent-Reported Version - Friends Limited by: Instructions","C136004","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 60 above, was your child's activity limited by: Doctor or parent instructions?","PODCI Pediatric Parent-Reported Version - Friends Limited by: Instructions | PODCI1-Friends Limited by: Instructions | PODCI163",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523318","PODCI Pediatric Parent-Reported Version - Friends Limited by: Fear","C136005","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 60 above, was your child's activity limited by: Fear the other kids won't like him/her?","PODCI Pediatric Parent-Reported Version - Friends Limited by: Fear | PODCI1-Friends Limited by: Fear | PODCI164",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523319","PODCI Pediatric Parent-Reported Version - Friends Limited by: Not Around","C136006","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 60 above, was your child's activity limited by: Friends not around?","PODCI Pediatric Parent-Reported Version - Friends Limited by: Not Around | PODCI1-Friends Limited by: Not Around | PODCI165",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523321","PODCI Pediatric Parent-Reported Version - Gym Limited by: Pain","C136008","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 66 above, was your child's activity limited by: Pain?","PODCI Pediatric Parent-Reported Version - Gym Limited by: Pain | PODCI1-Gym Limited by: Pain | PODCI167",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523322","PODCI Pediatric Parent-Reported Version - Gym Limited by: Health","C136009","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 66 above, was your child's activity limited by: General health?","PODCI Pediatric Parent-Reported Version - Gym Limited by: Health | PODCI1-Gym Limited by: Health | PODCI168",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515529","9q34","C13645","A chromosome band present on 9q","9q34 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523151","LEC-5 Standard Version - Serious Accident: Happened","C135838","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Serious accident at work, home, or during recreational activity: Happened to me.","LEC-5 Standard Version - Serious Accident: Happened | LEC01-Serious Accident: Happened | LEC0104A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523153","LEC-5 Standard Version - Serious Accident: Learned","C135840","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Serious accident at work, home, or during recreational activity: Learned about it.","LEC-5 Standard Version - Serious Accident: Learned | LEC01-Serious Accident: Learned | LEC0104C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523154","LEC-5 Standard Version - Serious Accident: Job","C135841","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Serious accident at work, home, or during recreational activity: Part of my job.","LEC-5 Standard Version - Serious Accident: Job | LEC01-Serious Accident: Job | LEC0104D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523155","LEC-5 Standard Version - Serious Accident: Not Sure","C135842","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Serious accident at work, home, or during recreational activity: Not sure.","LEC-5 Standard Version - Serious Accident: Not Sure | LEC01-Serious Accident: Not Sure | LEC0104E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524396","Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer pT1 TNM Finding v8","C136579","Appendicular skeleton, trunk, skull, and facial bones cancer with tumor measuring 8 cm or less in greatest dimension. (from AJCC 8th Ed.)","Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer pT1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518455","Nucleosomal Repeat Length","C13657","Nucleosomal repeat length is approximately 200 base pairs of DNA within which 146 base pairs are highly protected. (NCI)","Nucleosomal Repeat Length | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524401","Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer pT2 TNM Finding v8","C136580","Appendicular skeleton, trunk, skull, and facial bones cancer with tumor measuring more than 8 cm in greatest dimension. (from AJCC 8th Ed.)","Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer pT2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524402","Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer pT3 TNM Finding v8","C136581","Appendicular skeleton, trunk, skull, and facial bones cancer with discontinuous tumors in the primary bone site. (from AJCC 8th Ed.)","Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer pT3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524399","Spine Cancer Pathologic Primary Tumor TNM Finding v8","C136582","A pathologic finding about one or more characteristics of spine cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Spine Cancer Pathologic Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524400","Spine Cancer pTX TNM Finding v8","C136583","Spine cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Spine Cancer pTX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524405","Spine Cancer pT0 TNM Finding v8","C136584","Spine cancer without evidence of primary tumor. (from AJCC 8th Ed.)","Spine Cancer pT0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524406","Spine Cancer pT1 TNM Finding v8","C136585","Spine cancer with tumor confined to one vertebral segment or two adjacent vertebral segments. (from AJCC 8th Ed.)","Spine Cancer pT1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524403","Spine Cancer pT2 TNM Finding v8","C136586","Spine cancer with tumor confined to three adjacent vertebral segments. (from AJCC 8th Ed.)","Spine Cancer pT2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524404","Spine Cancer pT3 TNM Finding v8","C136587","Spine cancer with tumor confined to four or more adjacent vertebral segments, or any nonadjacent vertebral segments. (from AJCC 8th Ed.)","Spine Cancer pT3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524410","Spine Cancer pT4a TNM Finding v8","C136589","Spine cancer with tumor extending into the spinal canal. (from AJCC 8th Ed.)","Spine Cancer pT4a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524407","Spine Cancer pT4b TNM Finding v8","C136590","Spine cancer with evidence of gross vascular invasion or tumor thrombus in the great vessels. (from AJCC 8th Ed.)","Spine Cancer pT4b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524408","Pelvis Cancer Pathologic Primary Tumor TNM Finding v8","C136591","A pathologic finding about one or more characteristics of pelvis cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Pelvis Cancer Pathologic Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524381","Pelvis Cancer pTX TNM Finding v8","C136592","Pelvis cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Pelvis Cancer pTX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524382","Pelvis Cancer pT0 TNM Finding v8","C136593","Pelvis cancer without evidence of primary tumor. (from AJCC 8th Ed.)","Pelvis Cancer pT0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523279","PODCI Pediatric Parent-Reported Version - Get On and Off a Bus","C135966","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, has it been easy or hard for your child to: Get on and off a bus?","PODCI Pediatric Parent-Reported Version - Get On and Off a Bus | PODCI1-Get On and Off a Bus | PODCI125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523793","Lung Adenocarcinoma by AJCC v7 Stage","C136490","A term that refers to the staging of lung adenocarcinoma, following the rules of the TNM AJCC v7 classification system.","Lung Adenocarcinoma by AJCC v7 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523794","Lung Non-Small Cell Cancer by AJCC v7 Stage","C136491","A term that refers to the staging of non-small cell lung carcinoma, following the rules of the TNM AJCC v7 classification system.","Lung Non-Small Cell Cancer by AJCC v7 Stage | Lung Non-Small Cell Carcinoma by AJCC v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523795","Lung Adenosquamous Carcinoma by AJCC v7 Stage","C136492","A term that refers to the staging of adenosquamous lung carcinoma, following the rules of the TNM AJCC v7 classification system.","Lung Adenosquamous Carcinoma by AJCC v7 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523796","Lung Large Cell Carcinoma by AJCC v7 Stage","C136493","A term that refers to the staging of large cell lung carcinoma, following the rules of the TNM AJCC v7 classification system.","Lung Large Cell Carcinoma by AJCC v7 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523798","Lung Small Cell Carcinoma by AJCC v7 Stage","C136496","A term that refers to the staging of small cell lung carcinoma, following the rules of the TNM AJCC v7 classification system.","Lung Small Cell Carcinoma by AJCC v7 Stage | Small Cell Lung Carcinoma by AJCC v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521630","7p22","C13649","A chromosome band present on 7p","7p22 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523210","LEC-5 Standard Version - Severe Human Suffering: Not Apply","C135897","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Severe human suffering: Doesn't apply.","LEC-5 Standard Version - Severe Human Suffering: Not Apply | LEC01-Severe Human Suffering: Not Apply | LEC0113F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523211","LEC-5 Standard Version - Sudden Violent Death: Happened","C135898","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sudden violent death (for example, homicide, suicide): Happened to me.","LEC-5 Standard Version - Sudden Violent Death: Happened | LEC01-Sudden Violent Death: Happened | LEC0114A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523212","LEC-5 Standard Version - Sudden Violent Death: Witnessed","C135899","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sudden violent death (for example, homicide, suicide): Witnessed it.","LEC-5 Standard Version - Sudden Violent Death: Witnessed | LEC01-Sudden Violent Death: Witnessed | LEC0114B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520998","1q23-q31","C13600","A chromosome band present on 1q","1q23-q31 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523323","PODCI Pediatric Parent-Reported Version - Gym Limited by: Instructions","C136010","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 66 above, was your child's activity limited by: Doctor or parent instructions?","PODCI Pediatric Parent-Reported Version - Gym Limited by: Instructions | PODCI1-Gym Limited by: Instructions | PODCI169",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523324","PODCI Pediatric Parent-Reported Version - Gym Limited by: Fear","C136011","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 66 above, was your child's activity limited by: Fear the other kids won't like him/her?","PODCI Pediatric Parent-Reported Version - Gym Limited by: Fear | PODCI1-Gym Limited by: Fear | PODCI170",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523503","PODCI Adolescent Self-Reported Version - Gym Limited by: Health","C136190","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 63 above, was your activity limited by: General health?","PODCI Adolescent Self-Reported Version - Gym Limited by: Health | PODCI3-Gym Limited by: Health | PODCI365",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523504","PODCI Adolescent Self-Reported Version - Gym Limited by: Instructions","C136191","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 63 above, was your activity limited by: Doctor or parent instructions?","PODCI Adolescent Self-Reported Version - Gym Limited by: Instructions | PODCI3-Gym Limited by: Instructions | PODCI366",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523505","PODCI Adolescent Self-Reported Version - Gym Limited by: Fear","C136192","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 63 above, was your activity limited by: Fear the other kids won't like you?","PODCI Adolescent Self-Reported Version - Gym Limited by: Fear | PODCI3-Gym Limited by: Fear | PODCI367",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523506","PODCI Adolescent Self-Reported Version - Gym Limited by: Dislike","C136193","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 63 above, was your activity limited by: Dislike of gym/recess?","PODCI Adolescent Self-Reported Version - Gym Limited by: Dislike | PODCI3-Gym Limited by: Dislike | PODCI368",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523507","PODCI Adolescent Self-Reported Version - Gym Limited by: Not in Session","C136194","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 63 above, was your activity limited by: School not in session?","PODCI Adolescent Self-Reported Version - Gym Limited by: Not in Session | PODCI3-Gym Limited by: Not in Session | PODCI369",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523508","PODCI Adolescent Self-Reported Version - Gym Limited by: Not Attend School","C136195","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 63 above, was your activity limited by: I don't attend school?","PODCI Adolescent Self-Reported Version - Gym Limited by: Not Attend School | PODCI3-Gym Limited by: Not Attend School | PODCI370",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523509","PODCI Adolescent Self-Reported Version - Easy to Make Friends","C136196","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) Is it easy or hard for you to make friends with kids your own age?","PODCI Adolescent Self-Reported Version - Easy to Make Friends | PODCI3-Easy to Make Friends | PODCI371",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523156","LEC-5 Standard Version - Serious Accident: Not Apply","C135843","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Serious accident at work, home, or during recreational activity: Doesn't apply.","LEC-5 Standard Version - Serious Accident: Not Apply | LEC01-Serious Accident: Not Apply | LEC0104F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523157","LEC-5 Standard Version - Toxic Substance: Happened","C135844","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Exposure to toxic substance (for example, dangerous chemicals, radiation): Happened to me.","LEC-5 Standard Version - Toxic Substance: Happened | LEC01-Toxic Substance: Happened | LEC0105A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523158","LEC-5 Standard Version - Toxic Substance: Witnessed","C135845","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Exposure to toxic substance (for example, dangerous chemicals, radiation): Witnessed it.","LEC-5 Standard Version - Toxic Substance: Witnessed | LEC01-Toxic Substance: Witnessed | LEC0105B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523159","LEC-5 Standard Version - Toxic Substance: Learned","C135846","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Exposure to toxic substance (for example, dangerous chemicals, radiation): Learned about it.","LEC-5 Standard Version - Toxic Substance: Learned | LEC01-Toxic Substance: Learned | LEC0105C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523160","LEC-5 Standard Version - Toxic Substance: Job","C135847","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Exposure to toxic substance (for example, dangerous chemicals, radiation): Part of my job.","LEC-5 Standard Version - Toxic Substance: Job | LEC01-Toxic Substance: Job | LEC0105D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523161","LEC-5 Standard Version - Toxic Substance: Not Sure","C135848","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Exposure to toxic substance (for example, dangerous chemicals, radiation): Not sure.","LEC-5 Standard Version - Toxic Substance: Not Sure | LEC01-Toxic Substance: Not Sure | LEC0105E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523162","LEC-5 Standard Version - Toxic Substance: Not Apply","C135849","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Exposure to toxic substance (for example, dangerous chemicals, radiation): Doesn't apply.","LEC-5 Standard Version - Toxic Substance: Not Apply | LEC01-Toxic Substance: Not Apply | LEC0105F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520844","19p13.1-p13.2","C13584","A chromosome band present on 19p","19p13.1-p13.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523164","LEC-5 Standard Version - Physical Assault: Witnessed","C135851","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Physical assault (for example, being attacked, hit, slapped, kicked, beaten up): Witnessed it.","LEC-5 Standard Version - Physical Assault: Witnessed | LEC01-Physical Assault: Witnessed | LEC0106B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523165","LEC-5 Standard Version - Physical Assault: Learned","C135852","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Physical assault (for example, being attacked, hit, slapped, kicked, beaten up): Learned about it.","LEC-5 Standard Version - Physical Assault: Learned | LEC01-Physical Assault: Learned | LEC0106C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523365","PODCI Adolescent Parent-Reported Version - Bicycle or Tricycle","C136052","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, has it been easy or hard for your child to: Bicycle or tricycle?","PODCI Adolescent Parent-Reported Version - Bicycle or Tricycle | PODCI2-Bicycle or Tricycle | PODCI219",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523367","PODCI Adolescent Parent-Reported Version - Climb One Flight of Stairs","C136054","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, has it been easy or hard for your child to: Climb one flight of stairs?","PODCI Adolescent Parent-Reported Version - Climb One Flight of Stairs | PODCI2-Climb One Flight of Stairs | PODCI221",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523368","PODCI Adolescent Parent-Reported Version - Walk More Than a Mile","C136055","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, has it been easy or hard for your child to: Walk more than a mile?","PODCI Adolescent Parent-Reported Version - Walk More Than a Mile | PODCI2-Walk More Than a Mile | PODCI222",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523280","PODCI Pediatric Parent-Reported Version - Need Help Walking and Climbing","C135967","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) How often does your child need help from another person for walking and climbing?","PODCI Pediatric Parent-Reported Version - Need Help Walking and Climbing | PODCI1-Need Help Walking and Climbing | PODCI126",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523281","PODCI Pediatric Parent-Reported Version - Use Assistive Devices for Walking","C135968","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) How often does your child use assistive devices (such as braces, crutches, or wheelchair) for walking and climbing?","PODCI Pediatric Parent-Reported Version - Use Assistive Devices for Walking | PODCI1-Use Assistive Devices for Walking | PODCI127",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523282","PODCI Pediatric Parent-Reported Version - Stand Washing Hands at a Sink","C135969","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, has it been easy or hard for your child to: Stand while washing his/her hands and face at a sink?","PODCI Pediatric Parent-Reported Version - Stand Washing Hands at a Sink | PODCI1-Stand Washing Hands at a Sink | PODCI128",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520284","10q24","C13596","A chromosome band present on 10q","10q24 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523283","PODCI Pediatric Parent-Reported Version - Sit in Chair Without Holding On","C135970","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, has it been easy or hard for your child to: Sit in a regular chair without holding on?","PODCI Pediatric Parent-Reported Version - Sit in Chair Without Holding On | PODCI1-Sit in Chair Without Holding On | PODCI129",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523284","PODCI Pediatric Parent-Reported Version - Get On and Off a Toilet or Chair","C135971","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, has it been easy or hard for your child to: Get on and off a toilet or chair?","PODCI Pediatric Parent-Reported Version - Get On and Off a Toilet or Chair | PODCI1-Get On and Off a Toilet or Chair | PODCI130",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523285","PODCI Pediatric Parent-Reported Version - Get In and Out of Bed","C135972","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, has it been easy or hard for your child to: Get in and out of bed?","PODCI Pediatric Parent-Reported Version - Get In and Out of Bed | PODCI1-Get In and Out of Bed | PODCI131",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523286","PODCI Pediatric Parent-Reported Version - Turn Door Knobs","C135973","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, has it been easy or hard for your child to: Turn door knobs?","PODCI Pediatric Parent-Reported Version - Turn Door Knobs | PODCI1-Turn Door Knobs | PODCI132",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523288","PODCI Pediatric Parent-Reported Version - Need Help Sitting and Standing","C135975","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) How often does your child need help from another person for sitting and standing?","PODCI Pediatric Parent-Reported Version - Need Help Sitting and Standing | PODCI1-Need Help Sitting and Standing | PODCI134",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523289","PODCI Pediatric Parent-Reported Version - Use Assistive Devices for Sitting","C135976","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) How often does your child use assistive devices (such as braces, crutches, or wheelchair) for sitting and standing?","PODCI Pediatric Parent-Reported Version - Use Assistive Devices for Sitting | PODCI1-Use Assistive Devices for Sitting | PODCI135",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523290","PODCI Pediatric Parent-Reported Version - Participate in Outdoor Activities","C135977","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) Can your child participate in recreational outdoor activities with other children the same age (For example: bicycling, tricycling, skating, hiking, jogging)?","PODCI Pediatric Parent-Reported Version - Participate in Outdoor Activities | PODCI1-Participate in Outdoor Activities | PODCI136",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1523977","Recombinant CTAP III","C1358","Connective Tissue-Activating Peptide III is a platelet-derived growth factor that stimulates in fibroblasts mitogenesis, extracellular matrix synthesis, glucose metabolism, and plasminogen activator synthesis through interaction with a GPCR.  It is present in platelet granules, released by inducers of platelet aggregation, and is chemoattractant for fibroblasts, presumably for repair.  Pro-platelet basic protein is the precursor of platelet basic protein (PBP) and CTAP III.  Upon platelet activation they are released and processed in plasma to beta-thromboglobulin and neutrophil-activating peptide-2.  The thrombocidins TC1 and TC2 are variants of NAP2 and CTAP III, respectively.  TC1 and TC2 differ from NAP2 and CTAP III by their bactericidal and fungicidal properties, which apparently do not involve pore formation.  (from OMIM 121010 and NCI)","Recombinant CTAP III | CTAP III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523213","LEC-5 Standard Version - Sudden Violent Death: Learned","C135900","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sudden violent death (for example, homicide, suicide): Learned about it.","LEC-5 Standard Version - Sudden Violent Death: Learned | LEC01-Sudden Violent Death: Learned | LEC0114C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523214","LEC-5 Standard Version - Sudden Violent Death: Job","C135901","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sudden violent death (for example, homicide, suicide): Part of my job.","LEC-5 Standard Version - Sudden Violent Death: Job | LEC01-Sudden Violent Death: Job | LEC0114D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523215","LEC-5 Standard Version - Sudden Violent Death: Not Sure","C135902","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sudden violent death (for example, homicide, suicide): Not sure.","LEC-5 Standard Version - Sudden Violent Death: Not Sure | LEC01-Sudden Violent Death: Not Sure | LEC0114E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523217","LEC-5 Standard Version - Sudden Accidental Death: Happened","C135904","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sudden accidental death: Happened to me.","LEC-5 Standard Version - Sudden Accidental Death: Happened | LEC01-Sudden Accidental Death: Happened | LEC0115A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523218","LEC-5 Standard Version - Sudden Accidental Death: Witnessed","C135905","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sudden accidental death: Witnessed it.","LEC-5 Standard Version - Sudden Accidental Death: Witnessed | LEC01-Sudden Accidental Death: Witnessed | LEC0115B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523219","LEC-5 Standard Version - Sudden Accidental Death: Learned","C135906","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sudden accidental death: Learned about it.","LEC-5 Standard Version - Sudden Accidental Death: Learned | LEC01-Sudden Accidental Death: Learned | LEC0115C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523220","LEC-5 Standard Version - Sudden Accidental Death: Job","C135907","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sudden accidental death: Part of my job.","LEC-5 Standard Version - Sudden Accidental Death: Job | LEC01-Sudden Accidental Death: Job | LEC0115D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523221","LEC-5 Standard Version - Sudden Accidental Death: Not Sure","C135908","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sudden accidental death: Not sure.","LEC-5 Standard Version - Sudden Accidental Death: Not Sure | LEC01-Sudden Accidental Death: Not Sure | LEC0115E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523222","LEC-5 Standard Version - Sudden Accidental Death: Not Apply","C135909","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sudden accidental death: Doesn't apply.","LEC-5 Standard Version - Sudden Accidental Death: Not Apply | LEC01-Sudden Accidental Death: Not Apply | LEC0115F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521062","20q13.1","C13590","A chromosome band present on 20q","20q13.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523413","PODCI Adolescent Parent-Reported Version - Gym Limited by: Pain","C136100","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 66 above, was your child's activity limited by: Pain?","PODCI Adolescent Parent-Reported Version - Gym Limited by: Pain | PODCI2-Gym Limited by: Pain | PODCI267",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523511","PODCI Adolescent Self-Reported Version - Pain Interfere With Activities","C136198","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, how much did pain interfere with your normal activities (including at home, outside of the home, and at school)?","PODCI Adolescent Self-Reported Version - Pain Interfere With Activities | PODCI3-Pain Interfere With Activities | PODCI373",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520762","17q11.2","C13619","A chromosome band present on 17q","17q11.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0113086","Depudecin","C1361","Depudecin is a fungal metabolite that reverts the rounded phenotype of NIH 3T3 fibroblasts transformed with v-ras and v-src oncogenes to the flattened phenotype of the non-transformed parental cells. The mechanism of de-transformation induced by this agent had not been determined. However, depudecin has been demonstrated to inhibit histone deacetylase (HDAC) activity effectively both in vivo and in vitro.","Depudecin | (2R,3S,4S,5E,7S,8S,9R)-2,9- Dihydroxy-3,4;7,8-diepoxy-undeca-5,10-diene | (2S-(2R*(E(2R*(S*),3R*)),3R*(S*)))-alpha-Ethenyl-3-(2-(3-(1-hydroxyethyl)oxiranyl)ethenyl)oxiranemethanol | Oxiranemethanol, Alpha-ethenyl-3-(2-(3-(1-hydroxyethyl) oxiranyl)ethenyl)-, (2S- (2R*(E(2R*(S*),3R*)),3R*(S*)))-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523513","PODCI Adolescent Self-Reported Version - Look Better","C136200","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) As a result of my treatment, I expect: To look better.","PODCI Adolescent Self-Reported Version - Look Better | PODCI3-Look Better | PODCI375",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523714","Stage IA Pleural Malignant Mesothelioma AJCC v8","C136409","Stage IA includes: T1, N0, M0. T1: Tumor limited to the ipsilateral parietal with or without involvement of visceral pleura, mediastinal pleura, and diaphragmatic pleura. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)","Stage IA Pleural Malignant Mesothelioma AJCC v8 | Stage IA Pleural Malignant Mesothelioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521476","5q21","C13640","A chromosome band present on 5q","5q21 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523715","Malignant Peritoneal Germ Cell Tumor","C136410","A malignant germ cell tumor that affects the peritoneum.","Malignant Peritoneal Germ Cell Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523717","TRH Gene Product","C136412","A protein encoded by the TRH gene.","TRH Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040162","Thyrotropin-Releasing Hormone","C136413","Thyrotropin-releasing hormone (3 aa, ~0.4  kDa) is encoded by the human TRH gene. This protein plays a role in the positive regulation of thyrotropin (thyroid-stimulating hormone; TSH) production and release.","Thyrotropin-Releasing Hormone | TRF | TRH | TSH-Releasing Factor | Thyroliberin | Thyrotropin Releasing Hormone | Thyrotropin-Releasing Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523718","EPOCH-O Regimen","C136414","A regimen consisting of etoposide, prednisone, vincristine (Oncovin), cyclophosphamide, doxorubicin (hydroxydaunorubicin) and ofatumumab, which may be used for the treatment of various aggressive non-Hodgkin lymphomas.","EPOCH-O Regimen | DA EPOCH-O | Dose-Adjusted Etoposide-Prednisone- Vincristine-Cyclophosphamide-Ofatumumab | Dose-adjusted EPOCH-Ofatumumab | Dose-adjusted Etoposide/Vincristine/Doxorubicin/Cyclophosphamide/Prednisone Plus Ofatumumab Regimen | EPOCH Plus Arzerra | EPOCH Plus Ofatumumab | EPOCH-O | Etoposide-Prednisone-Oncovin-Cyclophosphamide-Hydroxydaunorubicin-Ofatumumab Regimen | O-EPOCH | O-EPOCH Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523369","PODCI Adolescent Parent-Reported Version - Walk Three Blocks","C136056","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, has it been easy or hard for your child to: Walk three blocks?","PODCI Adolescent Parent-Reported Version - Walk Three Blocks | PODCI2-Walk Three Blocks | PODCI223",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523370","PODCI Adolescent Parent-Reported Version - Walk One Block","C136057","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, has it been easy or hard for your child to: Walk one block?","PODCI Adolescent Parent-Reported Version - Walk One Block | PODCI2-Walk One Block | PODCI224",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523371","PODCI Adolescent Parent-Reported Version - Get On and Off a Bus","C136058","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, has it been easy or hard for your child to: Get on and off a bus?","PODCI Adolescent Parent-Reported Version - Get On and Off a Bus | PODCI2-Get On and Off a Bus | PODCI225",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523372","PODCI Adolescent Parent-Reported Version - Need Help Walking and Climbing","C136059","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) How often does your child need help from another person for walking and climbing?","PODCI Adolescent Parent-Reported Version - Need Help Walking and Climbing | PODCI2-Need Help Walking and Climbing | PODCI226",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521294","3p25","C13605","A chromosome band present on 3p","3p25 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523373","PODCI Adolescent Parent-Reported Version - Use Assistive Devices for Walking","C136060","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) How often does your child use assistive devices (such as braces, crutches, or wheelchair) for walking and climbing?","PODCI Adolescent Parent-Reported Version - Use Assistive Devices for Walking | PODCI2-Use Assistive Devices for Walking | PODCI227",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523374","PODCI Adolescent Parent-Reported Version - Stand Washing Hands at a Sink","C136061","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, has it been easy or hard for your child to: Stand while washing his/her hands and face at a sink?","PODCI Adolescent Parent-Reported Version - Stand Washing Hands at a Sink | PODCI2-Stand Washing Hands at a Sink | PODCI228",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523375","PODCI Adolescent Parent-Reported Version - Sit in Chair Without Holding On","C136062","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, has it been easy or hard for your child to: Sit in a regular chair without holding on?","PODCI Adolescent Parent-Reported Version - Sit in Chair Without Holding On | PODCI2-Sit in Chair Without Holding On | PODCI229",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523376","PODCI Adolescent Parent-Reported Version - Get On and Off a Toilet or Chair","C136063","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, has it been easy or hard for your child to: Get on and off a toilet or chair?","PODCI Adolescent Parent-Reported Version - Get On and Off a Toilet or Chair | PODCI2-Get On and Off a Toilet or Chair | PODCI230",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523377","PODCI Adolescent Parent-Reported Version - Get In and Out of Bed","C136064","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, has it been easy or hard for your child to: Get in and out of bed?","PODCI Adolescent Parent-Reported Version - Get In and Out of Bed | PODCI2-Get In and Out of Bed | PODCI231",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523555","Capecitabine/Cetuximab Regimen","C136244","A regimen consisting of capecitabine and cetuximab that is used for the treatment of colon cancer.","Capecitabine/Cetuximab Regimen | Capecitabine-Cetuximab | Capecitabine-Cetuximab Regimen | Capecitabine/Cetuximab | Xeloda/Erbitux Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523556","Capecitabine/Panitumumab Regimen","C136245","A regimen consisting of capecitabine and panitumumab that is used for the treatment of colon cancer.","Capecitabine/Panitumumab Regimen | Capecitabine-Panitumumab | Capecitabine-Panitumumab Regimen | Capecitabine/Panitumumab | Xeloda-Vectibix Regimen | Xeloda/Vectibix Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523466","PODCI Adolescent Self-Reported Version - Stand Washing Hands at a Sink","C136153","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, has it been easy or hard for you to: Stand while washing your hands and face at a sink?","PODCI Adolescent Self-Reported Version - Stand Washing Hands at a Sink | PODCI3-Stand Washing Hands at a Sink | PODCI328",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523467","PODCI Adolescent Self-Reported Version - Sit in Chair Without Holding On","C136154","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, has it been easy or hard for you to: Sit in a regular chair without holding on?","PODCI Adolescent Self-Reported Version - Sit in Chair Without Holding On | PODCI3-Sit in Chair Without Holding On | PODCI329",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523468","PODCI Adolescent Self-Reported Version - Get On and Off a Toilet or Chair","C136155","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, has it been easy or hard for you to: Get on and off a toilet or chair?","PODCI Adolescent Self-Reported Version - Get On and Off a Toilet or Chair | PODCI3-Get On and Off a Toilet or Chair | PODCI330",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523470","PODCI Adolescent Self-Reported Version - Turn Door Knobs","C136157","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, has it been easy or hard for you to: Turn door knobs?","PODCI Adolescent Self-Reported Version - Turn Door Knobs | PODCI3-Turn Door Knobs | PODCI332",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523471","PODCI Adolescent Self-Reported Version - Bend Over and Pick Up Something","C136158","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, has it been easy or hard for you to: Bend over from a standing position and pick up something off the floor?","PODCI Adolescent Self-Reported Version - Bend Over and Pick Up Something | PODCI3-Bend Over and Pick Up Something | PODCI333",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523472","PODCI Adolescent Self-Reported Version - Need Help Sitting and Standing","C136159","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) How often do you need help from another person for sitting and standing?","PODCI Adolescent Self-Reported Version - Need Help Sitting and Standing | PODCI3-Need Help Sitting and Standing | PODCI334",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523473","PODCI Adolescent Self-Reported Version - Use Assistive Devices for Sitting","C136160","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) How often do you use assistive devices (such as braces, crutches, or wheelchair) for sitting and standing?","PODCI Adolescent Self-Reported Version - Use Assistive Devices for Sitting | PODCI3-Use Assistive Devices for Sitting | PODCI335",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523474","PODCI Adolescent Self-Reported Version - Participate in Outdoor Activities","C136161","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) Can you participate in recreational outdoor activities with other kids the same age (For example: bicycling, skating, hiking, jogging)?","PODCI Adolescent Self-Reported Version - Participate in Outdoor Activities | PODCI3-Participate in Outdoor Activities | PODCI336",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523475","PODCI Adolescent Self-Reported Version - Outdoor Limited by: Pain","C136162","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered 'no' to Question 36 above, was your activity limited by: Pain?","PODCI Adolescent Self-Reported Version - Outdoor Limited by: Pain | PODCI3-Outdoor Limited by: Pain | PODCI337",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523476","PODCI Adolescent Self-Reported Version - Outdoor Limited by: Health","C136163","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered 'no' to Question 36 above, was your activity limited by: General health?","PODCI Adolescent Self-Reported Version - Outdoor Limited by: Health | PODCI3-Outdoor Limited by: Health | PODCI338",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523477","PODCI Adolescent Self-Reported Version - Outdoor Limited by: Instructions","C136164","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered 'no' to Question 36 above, was your activity limited by: Doctor or parent instructions?","PODCI Adolescent Self-Reported Version - Outdoor Limited by: Instructions | PODCI3-Outdoor Limited by: Instructions | PODCI339",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523414","PODCI Adolescent Parent-Reported Version - Gym Limited by: Health","C136101","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 66 above, was your child's activity limited by: General health?","PODCI Adolescent Parent-Reported Version - Gym Limited by: Health | PODCI2-Gym Limited by: Health | PODCI268",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523415","PODCI Adolescent Parent-Reported Version - Gym Limited by: Instructions","C136102","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 66 above, was your child's activity limited by: Doctor or parent instructions?","PODCI Adolescent Parent-Reported Version - Gym Limited by: Instructions | PODCI2-Gym Limited by: Instructions | PODCI269",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523416","PODCI Adolescent Parent-Reported Version - Gym Limited by: Fear","C136103","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 66 above, was your child's activity limited by: Fear the other kids won't like him/her?","PODCI Adolescent Parent-Reported Version - Gym Limited by: Fear | PODCI2-Gym Limited by: Fear | PODCI270",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523417","PODCI Adolescent Parent-Reported Version - Gym Limited by: Dislike","C136104","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 66 above, was your child's activity limited by: Dislike of gym/recess?","PODCI Adolescent Parent-Reported Version - Gym Limited by: Dislike | PODCI2-Gym Limited by: Dislike | PODCI271",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523418","PODCI Adolescent Parent-Reported Version - Gym Limited by: Not in Session","C136105","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 66 above, was your child's activity limited by: School not in session?","PODCI Adolescent Parent-Reported Version - Gym Limited by: Not in Session | PODCI2-Gym Limited by: Not in Session | PODCI272",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523419","PODCI Adolescent Parent-Reported Version - Gym Limited by: Not Attend School","C136106","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 66 above, was your child's activity limited by: Does not attend school?","PODCI Adolescent Parent-Reported Version - Gym Limited by: Not Attend School | PODCI2-Gym Limited by: Not Attend School | PODCI273",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523420","PODCI Adolescent Parent-Reported Version - Easy to Make Friends","C136107","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) Is it easy or hard for your child to make friends with children his/her own age?","PODCI Adolescent Parent-Reported Version - Easy to Make Friends | PODCI2-Easy to Make Friends | PODCI274",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523421","PODCI Adolescent Parent-Reported Version - Pain During the Last Week","C136108","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) How much pain has your child had during the last week?","PODCI Adolescent Parent-Reported Version - Pain During the Last Week | PODCI2-Pain During the Last Week | PODCI275",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523422","PODCI Adolescent Parent-Reported Version - Pain Interfere With Activities","C136109","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, how much did pain interfere with your child's normal activities (including at home, outside of the home, and at school)?","PODCI Adolescent Parent-Reported Version - Pain Interfere With Activities | PODCI2-Pain Interfere With Activities | PODCI276",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520271","10q11.2","C13610","A chromosome band present on 10q","10q11.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523424","PODCI Adolescent Parent-Reported Version - Look Better","C136111","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) As a result of my child's treatment, I expect my child: To look better.","PODCI Adolescent Parent-Reported Version - Look Better | PODCI2-Look Better | PODCI278",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523606","Thymic Tumor cM1 TNM Finding v8","C136297","Thymus tumor with pleural, pericardial, or distant metastasis. (from AJCC 8th Ed.)","Thymus Tumor cM1 TNM Finding v8 | Thymic Tumor cM1 TNM Finding v8 | Thymic Tumor cM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523719","SNS062","C136416","An orally available second-generation, reversible inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), with potential antineoplastic activity. Upon administration, vecabrutinib non-covalently binds to and inhibits the activity of both wild-type and the C481S mutated form of BTK, a resistance mutation in the BTK active site in which cysteine is substituted for serine at residue 481. This prevents the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B-cells that overexpress BTK. Compared to other BTK inhibitors, SNS-062 does not require interaction with the BTK C481 site and inhibits the proliferation of cells harboring the BTK C481S mutation. Other irreversible BTK inhibitors covalently bind to the C481 site to inhibit BTK's activity; the C481S mutation prevents that binding. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.","Vecabrutinib | BIIB-062 | BIIB062 | BSK-4841 | FP-182 | SNS 062 | SNS-062 | SNS062 | VECABRUTINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523721","NEDD8 Activating Enzyme E1 Inhibitor TAS4464","C136418","An inhibitor of NEDD8 (neural precursor cell expressed, developmentally down-regulated 8) activating enzyme E1 (NAE), with potential antineoplastic activity. Upon administration, TAS4464 selectively binds to and inhibits NAE, which prevents NAE/NEDD8-mediated signaling and prevents the NEDD8 conjugation of cullin-RING ligase complexes (CRLs). This inactivates the CRLs leading to an accumulation of CRL substrate proteins, such as CDT1, p27, p21 and phosphorylated IkappaB, and inactivates nuclear factor-kappaB (NF-kB) as well as downregulates anti-apoptotic proteins. This causes cell cycle dysregulation, induces apoptosis, and inhibits tumor cell proliferation and survival. NAE catalyzes the first step in the NEDD8 conjugation (neddylation) pathway which controls cancer cell growth and survival through activation of CRLs.","NEDD8 Activating Enzyme E1 Inhibitor TAS4464 | NAE Inhibitor TAS4464 | TAS4464",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523722","VEGFR Family Gene Mutation","C136419","A change in the nucleotide sequence in a VEGFR family gene.","VEGFR Family Gene Mutation | Mutant VEGFR | Mutant VEGFR Family Gene | VEGFR Family Mutation | VEGFR Mutation | Vascular Endothelial Growth Factor Receptor Family Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520293","10q24.3-10qter","C13641","A chromosome band present on 10q","10q24.3-10qter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523107","BEBQ Retrospective Version - Baby Frequently Wanted More Milk","C135794","Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) My baby frequently wanted more milk than I provided.","BEBQ Retrospective Version - Baby Frequently Wanted More Milk | BEBQ02-Baby Frequently Wanted More Milk | BEBQ0202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523108","BEBQ Retrospective Version - Baby Loved Milk","C135795","Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) My baby loved milk.","BEBQ Retrospective Version - Baby Loved Milk | BEBQ02-Baby Loved Milk | BEBQ0203",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523109","BEBQ Retrospective Version - Baby Had a Big Appetite","C135796","Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) My baby had a big appetite.","BEBQ Retrospective Version - Baby Had a Big Appetite | BEBQ02-Baby Had a Big Appetite | BEBQ0204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523110","BEBQ Retrospective Version - Baby Finished Feeding Quickly","C135797","Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) My baby finished feeding quickly.","BEBQ Retrospective Version - Baby Finished Feeding Quickly | BEBQ02-Baby Finished Feeding Quickly | BEBQ0205",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523111","BEBQ Retrospective Version - Baby Became Distressed Feeding","C135798","Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) My baby became distressed while feeding.","BEBQ Retrospective Version - Baby Became Distressed Feeding | BEBQ02-Baby Became Distressed Feeding | BEBQ0206",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523112","BEBQ Retrospective Version - Baby Got Full Up Easily","C135799","Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) My baby got full up easily.","BEBQ Retrospective Version - Baby Got Full Up Easily | BEBQ02-Baby Got Full Up Easily | BEBQ0207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521079","21q22.1","C13624","A chromosome band present on 21q","21q22.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523561","FOLFIRI-Zaltrap Regimen","C136250","A regimen consisting of leucovorin, fluorouracil and irinotecan (FOLFIRI), plus ziv-aflibercept that is used for the treatment of appendiceal adenocarcinoma and colorectal cancer.","FOLFIRI-Ziv-aflibercept Regimen | FOLFIRI | FOLFIRI Plus Zaltrap | FOLFIRI Plus Ziv-aflibercept | FOLFIRI and Ziv-aflibercept | FOLFIRI-Zaltrap Regimen | FOLFIRI/Zaltrap | FOLFIRI/Zaltrap Regimen | FOLFIRI/Ziv-aflibercept | FOLFIRI/Ziv-aflibercept Regimen | Folinic Acid-Fluorouracil-Irinotecan-Ziv-aflibercept | Folinic Acid/Fluorouracil/Irinotecan/Ziv-aflibercept",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523562","FOLFIRI Plus Cyramza","C136251","A regimen consisting of leucovorin, fluorouracil and irinotecan (FOLFIRI), plus ramucirumab that is used for the treatment of appendiceal adenocarcinoma, colon, esophageal and esophagogastric junction, gastric and rectal cancers.","FOLFIRI-Ramucirumab Regimen | FOLFIRI Plus Cyramza | FOLFIRI Plus Ramucirumab | FOLFIRI and Ramucirumab | FOLFIRI-Cyramza | FOLFIRI-Cyramza Regimen | FOLFIRI-Ramucirumab | FOLFIRI/Cyramza | FOLFIRI/Cyramza Regimen | FOLFIRI/Ramucirumab | FOLFIRI/Ramucirumab Regimen | Folinic Acid/Fluorouracil/Irinotecan/Ramucirumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523563","Folinic Acid/Fluorouracil/Oxaliplatin/Irinotecan","C136252","A regimen consisting of fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFOXIRI) that is used for the treatment of colon cancer.","FOLFOXIRI Regimen | FOLFOXIRI | Folinic Acid/Fluorouracil/Oxaliplatin/Irinotecan | Leucovorin-Fluorouracil-Oxaliplatin-Irinotecan | Leucovorin/Fluorouracil/Oxaliplatin/Irinotecan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523564","FOLFOXIRI-Avastin Regimen","C136253","A regimen consisting of fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFOXIRI), plus bevacizumab that is used for the treatment of colon cancer.","FOLFOXIRI-Bevacizumab Regimen | FOLFOXIRI Plus Avastin | FOLFOXIRI Plus Bevacizumab | FOLFOXIRI-Avastin Regimen | FOLFOXIRI/Avastin Regimen | FOLFOXIRI/Bevacizumab Regimen | Folinic Acid/Fluorouracil/Oxaliplatin/Irinotecan Plus Bevacizumab | Leucovorin-Fluorouracil-Oxaliplatin-Irinotecan Plus Avastin | Leucovorin/Fluorouracil/Oxaliplatin/Irinotecan/Bevacizumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523565","Bolus Fluorouracil/Leucovorin Regimen","C136254","A regimen consisting of bolus fluorouracil and leucovorin that is used for the treatment of colon cancer, and ampullary, appendiceal, small bowel, and pancreatic adenocarcinoma.","Bolus Fluorouracil/Leucovorin Regimen | Bolus 5-FU/LV | Bolus 5-FU/LV Regimen | Bolus 5-FU/Leucovorin | Bolus 5-Fluorouracil-Leucovorin | Bolus Fluorouracil-Leucovorin Regimen | Bolus Fluorouracil/Folinic Acid | LV5FU2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523767","Acrodysostosis 1","C136464","An autosomal dominant skeletal dysplasia caused by mutation(s) in the PRKAR1A gene, encoding cAMP-dependent protein kinase type I-alpha regulatory subunit. It is characterized by short stature, brachydactyly, and characteristic facial features.  Resistance to multiple hormones is a common finding.","Acrodysostosis 1 | ACRDYS1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523478","PODCI Adolescent Self-Reported Version - Outdoor Limited by: Fear","C136165","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered 'no' to Question 36 above, was your activity limited by: Fear the other kids won't like you?","PODCI Adolescent Self-Reported Version - Outdoor Limited by: Fear | PODCI3-Outdoor Limited by: Fear | PODCI340",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523690","Pleural Malignant Mesothelioma Pathologic TNM Finding v8","C136384","A pathologic finding about one or more characteristics of pleural malignant mesothelioma, following the rules of the TNM AJCC v8 classification system.","Pleural Malignant Mesothelioma Pathologic TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523691","Pleural Malignant Mesothelioma Pathologic Distant Metastasis TNM Finding v8","C136385","A pathologic finding about one or more characteristics of pleural malignant mesothelioma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Pleural Malignant Mesothelioma Pathologic Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523693","Pleural Malignant Mesothelioma Pathologic Primary Tumor TNM Finding v8","C136387","A pathologic finding about one or more characteristics of pleural malignant mesothelioma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Pleural Malignant Mesothelioma Pathologic Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523694","Pleural Malignant Mesothelioma pTX TNM Finding v8","C136388","Pleural malignant mesothelioma in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Pleural Malignant Mesothelioma pTX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523695","Pleural Malignant Mesothelioma pT0 TNM Finding v8","C136389","Pleural malignant mesothelioma without evidence of primary tumor. (from AJCC 8th Ed.)","Pleural Malignant Mesothelioma pT0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520631","15q21-q22","C13638","A chromosome band present on 15q","15q21-q22 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523696","Pleural Malignant Mesothelioma pT1 TNM Finding v8","C136390","Pleural malignant mesothelioma with tumor limited to the ipsilateral parietal with or without involvement of visceral pleura, mediastinal pleura, and diaphragmatic pleura. (from AJCC 8th Ed.)","Pleural Malignant Mesothelioma pT1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523697","Pleural Malignant Mesothelioma pT2 TNM Finding v8","C136391","Pleural malignant mesothelioma with tumor involving each of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of diaphragmatic muscle and/or extension of tumor from visceral pleura into the underlying pulmonary parenchyma. (from AJCC 8th Ed.)","Pleural Malignant Mesothelioma pT2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523698","Pleural Malignant Mesothelioma pT3 TNM Finding v8","C136392","Pleural malignant mesothelioma in which the tumor is locally advanced but potentially resectable. The tumor involves all the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of the endothoracic fascia, extension into the mediastinal fat, solitary, completely resectable focus of tumor extending into the soft tissues of the chest wall, and/or nontransmural involvement of the pericardium. (from AJCC 8th Ed.)","Pleural Malignant Mesothelioma pT3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523699","Pleural Malignant Mesothelioma pT4 TNM Finding v8","C136393","Pleural malignant mesothelioma in which the tumor is locally advanced and technically unresectable. The tumor involves all the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: diffuse extension or multifocal masses of tumor in the chest wall, with or without associated rib destruction, direct transdiaphragmatic extension of tumor to the peritoneum, direct extension of tumor to the contralateral pleura, direct extension of tumor to mediastinal organs, direct extension of tumor into the spine, and/or tumor extending through to the internal surface of the pericardium with or without a pericardial effusion; or tumor involving the myocardium. (from AJCC 8th Ed.)","Pleural Malignant Mesothelioma pT4 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523701","Pleural Malignant Mesothelioma pNX TNM Finding v8","C136395","Pleural malignant mesothelioma in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)","Pleural Malignant Mesothelioma pNX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523607","Thymic Tumor cM1a TNM Finding v8","C136298","Thymus tumor with separate pleural or pericardial nodule(s). (from AJCC 8th Ed.)","Thymus Tumor cM1a TNM Finding v8 | Thymic Tumor cM1a TNM Finding v8 | Thymic Tumor cM1a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523608","Thymic Tumor cM1b TNM Finding v8","C136299","Thymus tumor with pulmonary intraparenchymal nodule or distant organ metastasis. (from AJCC 8th Ed.)","Thymus Tumor cM1b TNM Finding v8 | Thymic Tumor cM1b TNM Finding v8 | Thymic Tumor cM1b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521016","1q42.1","C13629","A chromosome band present on 1q","1q42.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0113286","Dexamethasone Sodium Phosphate","C1362","A sodium phosphate salt form of Dexamethasone, a synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","Dexamethasone Sodium Phosphate | Cebedex | Corson | DEXAMETHASONE SODIUM PHOSPHATE | Dalalone | Decaject | Dekasol LA | Dexacen | Dexamethasone Sodium Phosphates | Dexasone | Dezone | ReadySharp Dexamethasone | Soludecadron | Solurex | Topidex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523609","Thymic Tumor Pathologic TNM Finding v8","C136300","A pathologic finding about one or more characteristics of a thymus tumor, following the rules of the TNM AJCC v8 classification system.","Thymus Tumor Pathologic TNM Finding v8 | Thymic Tumor Pathologic TNM Finding v8 | Thymic Tumor Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523611","Thymic Tumor pM1 TNM Finding v8","C136302","Thymus tumor with pleural, pericardial, or distant metastasis. (from AJCC 8th Ed.)","Thymus Tumor pM1 TNM Finding v8 | Thymic Tumor pM1 TNM Finding v8 | Thymic Tumor pM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523612","Thymic Tumor pM1a TNM Finding v8","C136303","Thymus tumor with separate pleural or pericardial nodule(s). (from AJCC 8th Ed.)","Thymus Tumor pM1a TNM Finding v8 | Thymic Tumor pM1a TNM Finding v8 | Thymic Tumor pM1a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523613","Thymic Tumor pM1b TNM Finding v8","C136304","Thymus tumor with pulmonary intraparenchymal nodule or distant organ metastasis. (from AJCC 8th Ed.)","Thymus Tumor pM1b TNM Finding v8 | Thymic Tumor pM1b TNM Finding v8 | Thymic Tumor pM1b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523614","Thymic Tumor Pathologic Primary Tumor TNM Finding v8","C136305","A pathologic finding about one or more characteristics of a thymus tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Thymus Tumor Pathologic Primary Tumor TNM Finding v8 | Thymic Tumor Pathologic Primary Tumor TNM Finding v8 | Thymic Tumor Pathologic Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523615","Thymic Tumor pTX TNM Finding v8","C136306","Thymus tumor in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Thymus Tumor pTX TNM Finding v8 | Thymic Tumor pTX TNM Finding v8 | Thymic Tumor pTX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523616","Thymic Tumor pT0 TNM Finding v8","C136307","Thymus tumor without evidence of primary tumor. (from AJCC 8th Ed.)","Thymus Tumor pT0 TNM Finding v8 | Thymic Tumor pT0 TNM Finding v8 | Thymic Tumor pT0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523617","Thymic Tumor pT1 TNM Finding v8","C136308","Thymus tumor which is encapsulated or extends into the mediastinal fat; may involve the mediastinal pleura. (from AJCC 8th Ed.)","Thymus Tumor pT1 TNM Finding v8 | Thymic Tumor pT1 TNM Finding v8 | Thymic Tumor pT1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523618","Thymic Tumor pT1a TNM Finding v8","C136309","Thymus tumor with no mediastinal pleura involvement. (from AJCC 8th Ed.)","Thymus Tumor pT1a TNM Finding v8 | Thymic Tumor pT1a TNM Finding v8 | Thymic Tumor pT1a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523619","Thymic Tumor pT1b TNM Finding v8","C136310","Thymus tumor with direct invasion of mediastinal pleura. (from AJCC 8th Ed.)","Thymus Tumor pT1b TNM Finding v8 | Thymic Tumor pT1b TNM Finding v8 | Thymic Tumor pT1b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523621","Thymic Tumor pT3 TNM Finding v8","C136312","Thymus tumor with direct invasion into any of the following: lung, brachiocephalic vein, superior vena cava, phrenic nerve, chest wall, or extrapericardial pulmonary artery or veins. (from AJCC 8th Ed.)","Thymus Tumor pT3 TNM Finding v8 | Thymic Tumor pT3 TNM Finding v8 | Thymic Tumor pT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523622","Thymic Tumor pT4 TNM Finding v8","C136313","Thymus tumor with invasion into any of the following: aorta (ascending, arch, or descending), arch vessels, intrapericardial pulmonary artery, myocardium, trachea, esophagus. (from AJCC 8th Ed.)","Thymus Tumor pT4 TNM Finding v8 | Thymic Tumor pT4 TNM Finding v8 | Thymic Tumor pT4 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523623","Thymic Tumor Pathologic Regional Lymph Nodes TNM Finding v8","C136314","A pathologic finding about one or more characteristics of a thymus tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Thymus Tumor Pathologic Regional Lymph Nodes TNM Finding v8 | Thymic Tumor Pathologic Regional Lymph Nodes TNM Finding v8 | Thymic Tumor Pathologic Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521575","6q24-q27","C13579","A chromosome band present on 6q","6q24-q27 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0109740","Mivobulin Isethionate","C1357","The isethionate salt of mivobulin, a synthetic colchicine analogue with potential antineoplastic activity. Mivobulin isethionate binds to tubulin, thereby inhibiting microtubule polymerization and mitosis.","Mivobulin Isethionate | CI 980 | CI-980 | CI980 | MIVOBULIN ISETHIONATE | mivobulin isethionate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523113","BEBQ Retrospective Version - Baby Would Take Too Much Milk","C135800","Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) If allowed to, my baby would take too much milk.","BEBQ Retrospective Version - Baby Would Take Too Much Milk | BEBQ02-Baby Would Take Too Much Milk | BEBQ0208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523114","BEBQ Retrospective Version - Baby Took More Than 30 Minutes","C135801","Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) My baby took more than 30 minutes to finish feeding.","BEBQ Retrospective Version - Baby Took More Than 30 Minutes | BEBQ02-Baby Took More Than 30 Minutes | BEBQ0209",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523116","BEBQ Retrospective Version - Baby Fed Slowly","C135803","Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) My baby fed slowly.","BEBQ Retrospective Version - Baby Fed Slowly | BEBQ02-Baby Fed Slowly | BEBQ0211",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523117","BEBQ Retrospective Version - Just Eaten Happy to Feed Again","C135804","Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) Even when my baby had just eaten well he/she was happy to feed again if offered.","BEBQ Retrospective Version - Just Eaten Happy to Feed Again | BEBQ02-Just Eaten Happy to Feed Again | BEBQ0212",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523118","BEBQ Retrospective Version - Difficult Manage Complete Feed","C135805","Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) My baby found it difficult to manage a complete feed.","BEBQ Retrospective Version - Difficult Manage Complete Feed | BEBQ02-Difficult Manage Complete Feed | BEBQ0213",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523119","BEBQ Retrospective Version - Baby Was Always Demanding a Feed","C135806","Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) My baby was always demanding a feed.","BEBQ Retrospective Version - Baby Was Always Demanding a Feed | BEBQ02-Baby Was Always Demanding a Feed | BEBQ0214",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523120","BEBQ Retrospective Version - Baby Sucked More and More Slowly","C135807","Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) My baby sucked more and more slowly during the course of a feed.","BEBQ Retrospective Version - Baby Sucked More and More Slowly | BEBQ02-Baby Sucked More and More Slowly | BEBQ0215",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523325","PODCI Pediatric Parent-Reported Version - Gym Limited by: Dislike","C136012","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 66 above, was your child's activity limited by: Dislike of gym/recess?","PODCI Pediatric Parent-Reported Version - Gym Limited by: Dislike | PODCI1-Gym Limited by: Dislike | PODCI171",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523326","PODCI Pediatric Parent-Reported Version - Gym Limited by: Not in Session","C136013","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'sometimes' or 'never or rarely' to Question 66 above, was your child's activity limited by: School not in session?","PODCI Pediatric Parent-Reported Version - Gym Limited by: Not in Session | PODCI1-Gym Limited by: Not in Session | PODCI172",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523328","PODCI Pediatric Parent-Reported Version - Easy to Make Friends","C136015","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) Is it easy or hard for your child to make friends with children his/her own age?","PODCI Pediatric Parent-Reported Version - Easy to Make Friends | PODCI1-Easy to Make Friends | PODCI174",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523329","PODCI Pediatric Parent-Reported Version - Pain During the Last Week","C136016","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) How much pain has your child had during the last week?","PODCI Pediatric Parent-Reported Version - Pain During the Last Week | PODCI1-Pain During the Last Week | PODCI175",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523768","AGEN2034","C136465","A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1; PDCD1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, balstilimab binds to PD-1, and thereby blocks its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-cells. PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.","Balstilimab | AGEN 2034 | AGEN-2034 | AGEN2034 | BALSTILIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523769","Personalized Genomic Vaccine 001","C136466","A synthetic peptide-based, personalized cancer vaccine consisting of multiple patient-specific tumor peptides, which are immunogenic and unique to the patient's tumor, combined with the immunostimulant polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC), with potential immunomodulating and antineoplastic activities. Upon vaccination with the personalized genomic vaccine 001 (PGV001), the peptides stimulate the host immune system to mount a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. The adjuvant Poly-ICLC is added to boost the immune response to the peptides and together will expand immune cells to target cancer. The adjuvant poly-ICLC is a ligand for toll-like receptor-3 (TLR3) and induces the release of cytokines which may help to boost the immune response against the selected neoantigens.","Personalized Genomic Vaccine 001 | Multi-Peptide Therapeutic Vaccine 001 | PGV 001 | PGV-001 | PGV001 | Personalized Peptide Vaccine 001 | Personalized Peptides Plus Poly-ICLC Vaccine 001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520688","16p13.3","C13646","A chromosome band present on 16p","16p13.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523702","Pleural Malignant Mesothelioma pN0 TNM Finding v8","C136396","Pleural malignant mesothelioma without regional lymph node metastases. (from AJCC 8th Ed.)","Pleural Malignant Mesothelioma pN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523703","Pleural Malignant Mesothelioma pN1 TNM Finding v8","C136397","Pleural malignant mesothelioma with metastases in the ipsilateral bronchopulmonary, hilar, or mediastinal (including the internal mammary, peridiaphragmatic, pericardial fat pad, or intercostal) lymph nodes. (from AJCC 8th Ed.)","Pleural Malignant Mesothelioma pN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523704","Pleural Malignant Mesothelioma pN2 TNM Finding v8","C136398","Pleural malignant mesothelioma with metastases in the contralateral mediastinal, ipsilateral, or contralateral supraclavicular lymph nodes. (from AJCC 8th Ed.)","Pleural Malignant Mesothelioma pN2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523059","PASI - Head (H): Erythema (E)","C135746","Psoriasis Area and Severity Index (PASI) Head (H): Erythema (E).","PASI - Head (H): Erythema (E) | PASI01-Head (H): Erythema (E) | PASI0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523060","PASI - Head (H): Infiltration (I)","C135747","Psoriasis Area and Severity Index (PASI) Head (H): Infiltration (I).","PASI - Head (H): Infiltration (I) | PASI01-Head (H): Infiltration (I) | PASI0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523061","PASI - Head (H): Desquamation (D)","C135748","Psoriasis Area and Severity Index (PASI) Head (H): Desquamation (D).","PASI - Head (H): Desquamation (D) | PASI01-Head (H): Desquamation (D) | PASI0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523062","PASI - Head (H): Sum = E+I+D","C135749","Psoriasis Area and Severity Index (PASI) Head (H): Sum = E + I + D.","PASI - Head (H): Sum = E+I+D | PASI01-Head (H): Sum = E+I+D | PASI0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515450","8q13","C13574","A chromosome band present on 8q","8q13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523063","PASI - Head (H): Area Score","C135750","Psoriasis Area and Severity Index (PASI) Head (H): Area score.","PASI - Head (H): Area Score | PASI01-Head (H): Area Score | PASI0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523064","PASI - Head (H): Sum X Area","C135751","Psoriasis Area and Severity Index (PASI) Head (H): Sum x area.","PASI - Head (H): Sum X Area | PASI01-Head (H): Sum X Area | PASI0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523065","PASI - Head (H): Sum X Area X 0.1","C135752","Psoriasis Area and Severity Index (PASI) Head (H): Sum x area x 0.1.","PASI - Head (H): Sum X Area X 0.1 | PASI01-Head (H): Sum X Area X 0.1 | PASI0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523067","PASI - Trunk (T): Infiltration (I)","C135754","Psoriasis Area and Severity Index (PASI) Trunk (T): Infiltration (I).","PASI - Trunk (T): Infiltration (I) | PASI01-Trunk (T): Infiltration (I) | PASI0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523068","PASI - Trunk (T): Desquamation (D)","C135755","Psoriasis Area and Severity Index (PASI) Trunk (T): Desquamation (D).","PASI - Trunk (T): Desquamation (D) | PASI01-Trunk (T): Desquamation (D) | PASI0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523624","Thymic Tumor pNX TNM Finding v8","C136315","Thymus tumor in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)","Thymus Tumor pNX TNM Finding v8 | Thymic Tumor pNX TNM Finding v8 | Thymic Tumor pNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520283","10q23.31","C13650","A chromosome band present on 10q","10q23.31 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523330","PODCI Pediatric Parent-Reported Version - Pain Interfere With Activities","C136017","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, how much did pain interfere with your child's normal activities (including at home, outside of the home, and at school)?","PODCI Pediatric Parent-Reported Version - Pain Interfere With Activities | PODCI1-Pain Interfere With Activities | PODCI176",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523331","PODCI Pediatric Parent-Reported Version - Have Pain Relief","C136018","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) As a result of my child's treatment, I expect my child: To have pain relief.","PODCI Pediatric Parent-Reported Version - Have Pain Relief | PODCI1-Have Pain Relief | PODCI177",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523332","PODCI Pediatric Parent-Reported Version - Look Better","C136019","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) As a result of my child's treatment, I expect my child: To look better.","PODCI Pediatric Parent-Reported Version - Look Better | PODCI1-Look Better | PODCI178",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520648","15q25-q26","C13601","A chromosome band present on 15q","15q25-q26 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523333","PODCI Pediatric Parent-Reported Version - Feel Better","C136020","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) As a result of my child's treatment, I expect my child: To feel better about himself/herself.","PODCI Pediatric Parent-Reported Version - Feel Better | PODCI1-Feel Better | PODCI179",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523334","PODCI Pediatric Parent-Reported Version - Sleep More Comfortably","C136021","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) As a result of my child's treatment, I expect my child: To sleep more comfortably.","PODCI Pediatric Parent-Reported Version - Sleep More Comfortably | PODCI1-Sleep More Comfortably | PODCI180",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523335","PODCI Pediatric Parent-Reported Version - Able to Do Activities at Home","C136022","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) As a result of my child's treatment, I expect my child: To be able to do activities at home.","PODCI Pediatric Parent-Reported Version - Able to Do Activities at Home | PODCI1-Able to Do Activities at Home | PODCI181",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523336","PODCI Pediatric Parent-Reported Version - Able to Do More at School","C136023","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) As a result of my child's treatment, I expect my child: To be able to do more at school.","PODCI Pediatric Parent-Reported Version - Able to Do More at School | PODCI1-Able to Do More at School | PODCI182",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523337","PODCI Pediatric Parent-Reported Version - Able to Do More Play","C136024","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) As a result of my child's treatment, I expect my child: To be able to do more play or recreational activities (biking, walking, doing things with friends).","PODCI Pediatric Parent-Reported Version - Able to Do More Play | PODCI1-Able to Do More Play | PODCI183",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523514","PODCI Adolescent Self-Reported Version - Feel Better","C136201","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) As a result of my treatment, I expect: To feel better about myself.","PODCI Adolescent Self-Reported Version - Feel Better | PODCI3-Feel Better | PODCI376",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523516","PODCI Adolescent Self-Reported Version - Able to Do Activities at Home","C136203","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) As a result of my treatment, I expect: To be able to do activities at home.","PODCI Adolescent Self-Reported Version - Able to Do Activities at Home | PODCI3-Able to Do Activities at Home | PODCI378",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523517","PODCI Adolescent Self-Reported Version - Able to Do More at School","C136204","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) As a result of my treatment, I expect: To be able to do more at school.","PODCI Adolescent Self-Reported Version - Able to Do More at School | PODCI3-Able to Do More at School | PODCI379",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523166","LEC-5 Standard Version - Physical Assault: Job","C135853","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Physical assault (for example, being attacked, hit, slapped, kicked, beaten up): Part of my job.","LEC-5 Standard Version - Physical Assault: Job | LEC01-Physical Assault: Job | LEC0106D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523167","LEC-5 Standard Version - Physical Assault: Not Sure","C135854","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Physical assault (for example, being attacked, hit, slapped, kicked, beaten up): Not sure.","LEC-5 Standard Version - Physical Assault: Not Sure | LEC01-Physical Assault: Not Sure | LEC0106E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523168","LEC-5 Standard Version - Physical Assault: Not Apply","C135855","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Physical assault (for example, being attacked, hit, slapped, kicked, beaten up): Doesn't apply.","LEC-5 Standard Version - Physical Assault: Not Apply | LEC01-Physical Assault: Not Apply | LEC0106F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523169","LEC-5 Standard Version - Assault With a Weapon: Happened","C135856","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Assault with a weapon (for example, being shot, stabbed, threatened with a knife, gun, bomb): Happened to me.","LEC-5 Standard Version - Assault With a Weapon: Happened | LEC01-Assault With a Weapon: Happened | LEC0107A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523170","LEC-5 Standard Version - Assault With a Weapon: Witnessed","C135857","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Assault with a weapon (for example, being shot, stabbed, threatened with a knife, gun, bomb): Witnessed it.","LEC-5 Standard Version - Assault With a Weapon: Witnessed | LEC01-Assault With a Weapon: Witnessed | LEC0107B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523171","LEC-5 Standard Version - Assault With a Weapon: Learned","C135858","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Assault with a weapon (for example, being shot, stabbed, threatened with a knife, gun, bomb): Learned about it.","LEC-5 Standard Version - Assault With a Weapon: Learned | LEC01-Assault With a Weapon: Learned | LEC0107C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523172","LEC-5 Standard Version - Assault With a Weapon: Job","C135859","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Assault with a weapon (for example, being shot, stabbed, threatened with a knife, gun, bomb): Part of my job.","LEC-5 Standard Version - Assault With a Weapon: Job | LEC01-Assault With a Weapon: Job | LEC0107D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515446","8q11","C13585","A chromosome band present on 8q","8q11 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523173","LEC-5 Standard Version - Assault With a Weapon: Not Sure","C135860","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Assault with a weapon (for example, being shot, stabbed, threatened with a knife, gun, bomb): Not sure.","LEC-5 Standard Version - Assault With a Weapon: Not Sure | LEC01-Assault With a Weapon: Not Sure | LEC0107E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523175","LEC-5 Standard Version - Sexual Assault: Happened","C135862","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sexual assault (rape, attempted rape, made to perform any type of sexual act through force or threat of harm): Happened to me.","LEC-5 Standard Version - Sexual Assault: Happened | LEC01-Sexual Assault: Happened | LEC0108A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523176","LEC-5 Standard Version - Sexual Assault: Witnessed","C135863","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sexual assault (rape, attempted rape, made to perform any type of sexual act through force or threat of harm): Witnessed it.","LEC-5 Standard Version - Sexual Assault: Witnessed | LEC01-Sexual Assault: Witnessed | LEC0108B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523177","LEC-5 Standard Version - Sexual Assault: Learned","C135864","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sexual assault (rape, attempted rape, made to perform any type of sexual act through force or threat of harm): Learned about it.","LEC-5 Standard Version - Sexual Assault: Learned | LEC01-Sexual Assault: Learned | LEC0108C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523069","PASI - Trunk (T): Sum = E+I+D","C135756","Psoriasis Area and Severity Index (PASI) Trunk (T): Sum = E + I + D.","PASI - Trunk (T): Sum = E+I+D | PASI01-Trunk (T): Sum = E+I+D | PASI0111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523070","PASI - Trunk (T): Area Score","C135757","Psoriasis Area and Severity Index (PASI) Trunk (T): Area score.","PASI - Trunk (T): Area Score | PASI01-Trunk (T): Area Score | PASI0112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523071","PASI - Trunk (T): Sum X Area","C135758","Psoriasis Area and Severity Index (PASI) Trunk (T): Sum x area.","PASI - Trunk (T): Sum X Area | PASI01-Trunk (T): Sum X Area | PASI0113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523072","PASI - Trunk (T): Sum X Area X 0.3","C135759","Psoriasis Area and Severity Index (PASI) Trunk (T): Sum x area x 0.3.","PASI - Trunk (T): Sum X Area X 0.3 | PASI01-Trunk (T): Sum X Area X 0.3 | PASI0114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523073","PASI - Upper Extremities (U): Erythema (E)","C135760","Psoriasis Area and Severity Index (PASI) Upper Extremities (U): Erythema (E).","PASI - Upper Extremities (U): Erythema (E) | PASI01-Up Extrem (U): Erythema (E) | PASI0115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523291","PODCI Pediatric Parent-Reported Version - Outdoor Limited by: Pain","C135978","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'no' to Question 36 above, was your child's activity limited by: Pain?","PODCI Pediatric Parent-Reported Version - Outdoor Limited by: Pain | PODCI1-Outdoor Limited by: Pain | PODCI137",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523292","PODCI Pediatric Parent-Reported Version - Outdoor Limited by: Health","C135979","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'no' to Question 36 above, was your child's activity limited by: General health?","PODCI Pediatric Parent-Reported Version - Outdoor Limited by: Health | PODCI1-Outdoor Limited by: Health | PODCI138",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521290","3p23-p21","C13597","A chromosome band present on 3p","3p23-p21 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523293","PODCI Pediatric Parent-Reported Version - Outdoor Limited by: Instructions","C135980","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'no' to Question 36 above, was your child's activity limited by: Doctor or parent instructions?","PODCI Pediatric Parent-Reported Version - Outdoor Limited by: Instructions | PODCI1-Outdoor Limited by: Instructions | PODCI139",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523294","PODCI Pediatric Parent-Reported Version - Outdoor Limited by: Fear","C135981","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'no' to Question 36 above, was your child's activity limited by: Fear the other kids won't like him/her?","PODCI Pediatric Parent-Reported Version - Outdoor Limited by: Fear | PODCI1-Outdoor Limited by: Fear | PODCI140",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523296","PODCI Pediatric Parent-Reported Version - Outdoor Limited by: Too Young","C135983","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'no' to Question 36 above, was your child's activity limited by: Too young?","PODCI Pediatric Parent-Reported Version - Outdoor Limited by: Too Young | PODCI1-Outdoor Limited by: Too Young | PODCI142",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523297","PODCI Pediatric Parent-Reported Version - Outdoor Limited by: Season","C135984","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'no' to Question 36 above, was your child's activity limited by: Activity not in season?","PODCI Pediatric Parent-Reported Version - Outdoor Limited by: Season | PODCI1-Outdoor Limited by: Season | PODCI143",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523298","PODCI Pediatric Parent-Reported Version - Participate in Pickup Games","C135985","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) Can your child participate in pickup games or sports with other children the same age (For example: tag, dodge ball, basketball, soccer, catch, jump rope, touch football, hop scotch)?","PODCI Pediatric Parent-Reported Version - Participate in Pickup Games | PODCI1-Participate in Pickup Games | PODCI144",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3713852","AIC316","C136516","A thiazolylamide and helicase-primase enzyme inhibitor that is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). Pritelivir inhibits the helicase-primase complex and prevents helicase or primase catalytic cycling of viral DNA, which interferes with DNA replication and growth. This agent does not require activation by HSV thymidine kinase and has a longer plasma half-life than nucleoside analogues.","Pritelivir | AIC-316 | AIC316 | BAY 57-1293 | Benzeneacetamide, N-(5-(Aminosulfonyl)-4-methyl-2-thiazolyl)-N-methyl-4-(2-pyridinyl)- | Benzeneacetamide, N-(5-(aminosulfonyl)-4-methyl-2-thiazolyl)-N-methyl-4-(2-pyridinyl)- | N-(5-(Aminiosulfonyl)-4-methyl-1,3-thiazol-2-yl)-N-methyl-2-(4-(2-pyridinyl)phenyl)acetamide | N-methyl-N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-(4-pyridin-2-ylphenyl)acetamide | PRITELIVIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523223","LEC-5 Standard Version - Serious Injury Caused: Happened","C135910","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Serious injury, harm, or death you caused to someone else: Happened to me.","LEC-5 Standard Version - Serious Injury Caused: Happened | LEC01-Serious Injury Caused: Happened | LEC0116A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523224","LEC-5 Standard Version - Serious Injury Caused: Witnessed","C135911","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Serious injury, harm, or death you caused to someone else: Witnessed it.","LEC-5 Standard Version - Serious Injury Caused: Witnessed | LEC01-Serious Injury Caused: Witnessed | LEC0116B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523226","LEC-5 Standard Version - Serious Injury Caused: Job","C135913","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Serious injury, harm, or death you caused to someone else: Part of my job.","LEC-5 Standard Version - Serious Injury Caused: Job | LEC01-Serious Injury Caused: Job | LEC0116D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523227","LEC-5 Standard Version - Serious Injury Caused: Not Sure","C135914","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Serious injury, harm, or death you caused to someone else: Not sure.","LEC-5 Standard Version - Serious Injury Caused: Not Sure | LEC01-Serious Injury Caused: Not Sure | LEC0116E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523228","LEC-5 Standard Version - Serious Injury Caused: Not Apply","C135915","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Serious injury, harm, or death you caused to someone else: Doesn't apply.","LEC-5 Standard Version - Serious Injury Caused: Not Apply | LEC01-Serious Injury Caused: Not Apply | LEC0116F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523229","LEC-5 Standard Version - Other Stressful Event: Happened","C135916","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Any other very stressful event or experience: Happened to me.","LEC-5 Standard Version - Other Stressful Event: Happened | LEC01-Other Stressful Event: Happened | LEC0117A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523231","LEC-5 Standard Version - Other Stressful Event: Learned","C135918","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Any other very stressful event or experience: Learned about it.","LEC-5 Standard Version - Other Stressful Event: Learned | LEC01-Other Stressful Event: Learned | LEC0117C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523232","LEC-5 Standard Version - Other Stressful Event: Job","C135919","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Any other very stressful event or experience: Part of my job.","LEC-5 Standard Version - Other Stressful Event: Job | LEC01-Other Stressful Event: Job | LEC0117D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523233","LEC-5 Standard Version - Other Stressful Event: Not Sure","C135920","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Any other very stressful event or experience: Not sure.","LEC-5 Standard Version - Other Stressful Event: Not Sure | LEC01-Other Stressful Event: Not Sure | LEC0117E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523518","PODCI Adolescent Self-Reported Version - Able to Do More Play","C136205","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) As a result of my treatment, I expect: To be able to do more play or recreational activities.","PODCI Adolescent Self-Reported Version - Able to Do More Play | PODCI3-Able to Do More Play | PODCI380",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523519","PODCI Adolescent Self-Reported Version - Able to Do More Sports","C136206","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) As a result of my treatment, I expect: To be able to do more sports.","PODCI Adolescent Self-Reported Version - Able to Do More Sports | PODCI3-Able to Do More Sports | PODCI381",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523520","PODCI Adolescent Self-Reported Version - Free From Pain as Adult","C136207","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) As a result of my treatment, I expect: To be free from pain or disability as an adult.","PODCI Adolescent Self-Reported Version - Free From Pain as Adult | PODCI3-Free From Pain as Adult | PODCI382",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523521","PODCI Adolescent Self-Reported Version - Spend Rest of Life With Condition","C136208","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you had to spend the rest of your life with your bone and muscle condition as it is right now, how would you feel about it?","PODCI Adolescent Self-Reported Version - Spend Rest of Life With Condition | PODCI3-Spend Rest of Life With Condition | PODCI383",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523522","PODCI Adolescent Self-Reported Version - Upper Extremity and Physical Function Scale","C136209","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) Upper extremity and physical function core scale.","PODCI Adolescent Self-Reported Version - Upper Extremity and Physical Function Scale | PODCI3-Up Extremity/Phys Function Scale | PODCI384",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521288","3p22","C13620","A chromosome band present on 3p","3p22 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523523","PODCI Adolescent Self-Reported Version - Transfer and Basic Mobility Scale","C136210","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) Transfer and basic mobility core scale.","PODCI Adolescent Self-Reported Version - Transfer and Basic Mobility Scale | PODCI3-Transfer/Basic Mobility Scale | PODCI385",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523524","PODCI Adolescent Self-Reported Version - Sports and Physical Function Scale","C136211","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) Sports and physical functioning core scale.","PODCI Adolescent Self-Reported Version - Sports and Physical Function Scale | PODCI3-Sports/Phys Function Scale | PODCI386",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523525","PODCI Adolescent Self-Reported Version - Pain or Comfort Scale","C136212","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) Pain/comfort core scale.","PODCI Adolescent Self-Reported Version - Pain or Comfort Scale | PODCI3-Pain/Comfort Scale | PODCI387",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523526","PODCI Adolescent Self-Reported Version - Happiness Scale","C136213","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) Happiness core scale.","PODCI Adolescent Self-Reported Version - Happiness Scale | PODCI3-Happiness Scale | PODCI388",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523527","PODCI Adolescent Self-Reported Version - Global Functioning Scale","C136214","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) Global functioning scale.","PODCI Adolescent Self-Reported Version - Global Functioning Scale | PODCI3-Global Functioning Scale | PODCI389",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523723","JAK Family Gene Mutation","C136420","A change in the nucleotide sequence in a JAK family gene.","JAK Family Gene Mutation | JAK Family Mutation | JAK Mutation | Janus Kinase Family Gene Mutation | Mutant JAK | Mutant JAK Family Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523724","STAT Family Gene Mutation","C136421","A change in the nucleotide sequence in a STAT family gene.","STAT Family Gene Mutation | Mutant STAT | Mutant STAT Family Gene | STAT Family Mutation | STAT Mutation | Signal Transducer and Activator of Transcription Family Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523178","LEC-5 Standard Version - Sexual Assault: Job","C135865","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sexual assault (rape, attempted rape, made to perform any type of sexual act through force or threat of harm): Part of my job.","LEC-5 Standard Version - Sexual Assault: Job | LEC01-Sexual Assault: Job | LEC0108D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523179","LEC-5 Standard Version - Sexual Assault: Not Sure","C135866","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sexual assault (rape, attempted rape, made to perform any type of sexual act through force or threat of harm): Not sure.","LEC-5 Standard Version - Sexual Assault: Not Sure | LEC01-Sexual Assault: Not Sure | LEC0108E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523378","PODCI Adolescent Parent-Reported Version - Turn Door Knobs","C136065","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, has it been easy or hard for your child to: Turn door knobs?","PODCI Adolescent Parent-Reported Version - Turn Door Knobs | PODCI2-Turn Door Knobs | PODCI232",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523379","PODCI Adolescent Parent-Reported Version - Bend Over and Pick Up Something","C136066","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, has it been easy or hard for your child to: Bend over from a standing position and pick up something off the floor?","PODCI Adolescent Parent-Reported Version - Bend Over and Pick Up Something | PODCI2-Bend Over and Pick Up Something | PODCI233",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523380","PODCI Adolescent Parent-Reported Version - Need Help Sitting and Standing","C136067","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) How often does your child need help from another person for sitting and standing?","PODCI Adolescent Parent-Reported Version - Need Help Sitting and Standing | PODCI2-Need Help Sitting and Standing | PODCI234",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523381","PODCI Adolescent Parent-Reported Version - Use Assistive Devices for Sitting","C136068","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) How often does your child use assistive devices (such as braces, crutches, or wheelchair) for sitting and standing?","PODCI Adolescent Parent-Reported Version - Use Assistive Devices for Sitting | PODCI2-Use Assistive Devices for Sitting | PODCI235",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523382","PODCI Adolescent Parent-Reported Version - Participate in Outdoor Activities","C136069","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) Can your child participate in recreational outdoor activities with other children the same age (For example: bicycling, skating, hiking, jogging)?","PODCI Adolescent Parent-Reported Version - Participate in Outdoor Activities | PODCI2-Participate in Outdoor Activities | PODCI236",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521631","7p22-p15","C13606","A chromosome band present on 7p","7p22-p15 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523383","PODCI Adolescent Parent-Reported Version - Outdoor Limited by: Pain","C136070","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered 'no' to Question 36 above, was your child's activity limited by: Pain?","PODCI Adolescent Parent-Reported Version - Outdoor Limited by: Pain | PODCI2-Outdoor Limited by: Pain | PODCI237",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523384","PODCI Adolescent Parent-Reported Version - Outdoor Limited by: Health","C136071","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered 'no' to Question 36 above, was your child's activity limited by: General health?","PODCI Adolescent Parent-Reported Version - Outdoor Limited by: Health | PODCI2-Outdoor Limited by: Health | PODCI238",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523386","PODCI Adolescent Parent-Reported Version - Outdoor Limited by: Fear","C136073","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered 'no' to Question 36 above, was your child's activity limited by: Fear the other kids won't like him/her?","PODCI Adolescent Parent-Reported Version - Outdoor Limited by: Fear | PODCI2-Outdoor Limited by: Fear | PODCI240",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523299","PODCI Pediatric Parent-Reported Version - Games Limited by: Pain","C135986","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'no' to Question 44 above, was your child's activity limited by: Pain?","PODCI Pediatric Parent-Reported Version - Games Limited by: Pain | PODCI1-Games Limited by: Pain | PODCI145",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523300","PODCI Pediatric Parent-Reported Version - Games Limited by: Health","C135987","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'no' to Question 44 above, was your child's activity limited by: General health?","PODCI Pediatric Parent-Reported Version - Games Limited by: Health | PODCI1-Games Limited by: Health | PODCI146",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523301","PODCI Pediatric Parent-Reported Version - Games Limited by: Instructions","C135988","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'no' to Question 44 above, was your child's activity limited by: Doctor or parent instructions?","PODCI Pediatric Parent-Reported Version - Games Limited by: Instructions | PODCI1-Games Limited by: Instructions | PODCI147",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523302","PODCI Pediatric Parent-Reported Version - Games Limited by: Fear","C135989","Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered 'no' to Question 44 above, was your child's activity limited by: Fear the other kids won't like him/her?","PODCI Pediatric Parent-Reported Version - Games Limited by: Fear | PODCI1-Games Limited by: Fear | PODCI148",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515466","8q24.1","C13598","A chromosome band present on 8q","8q24.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523479","PODCI Adolescent Self-Reported Version - Outdoor Limited by: Dislike","C136166","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered 'no' to Question 36 above, was your activity limited by: Dislike of recreational outdoor activities?","PODCI Adolescent Self-Reported Version - Outdoor Limited by: Dislike | PODCI3-Outdoor Limited by: Dislike | PODCI341",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523480","PODCI Adolescent Self-Reported Version - Outdoor Limited by: Season","C136167","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered 'no' to Question 36 above, was your activity limited by: Activity not in season?","PODCI Adolescent Self-Reported Version - Outdoor Limited by: Season | PODCI3-Outdoor Limited by: Season | PODCI342",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523481","PODCI Adolescent Self-Reported Version - Participate in Pickup Games","C136168","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) Can you participate in pickup games or sports with other kids the same age (For example: tag, dodge ball, basketball, softball, soccer, catch, jump rope, touch football, hop scotch)?","PODCI Adolescent Self-Reported Version - Participate in Pickup Games | PODCI3-Participate in Pickup Games | PODCI343",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523482","PODCI Adolescent Self-Reported Version - Games Limited by: Pain","C136169","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered 'no' to Question 43 above, was your activity limited by: Pain?","PODCI Adolescent Self-Reported Version - Games Limited by: Pain | PODCI3-Games Limited by: Pain | PODCI344",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523483","PODCI Adolescent Self-Reported Version - Games Limited by: Health","C136170","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered 'no' to Question 43 above, was your activity limited by: General health?","PODCI Adolescent Self-Reported Version - Games Limited by: Health | PODCI3-Games Limited by: Health | PODCI345",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523484","PODCI Adolescent Self-Reported Version - Games Limited by: Instructions","C136171","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered 'no' to Question 43 above, was your activity limited by: Doctor or parent instructions?","PODCI Adolescent Self-Reported Version - Games Limited by: Instructions | PODCI3-Games Limited by: Instructions | PODCI346",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523234","LEC-5 Standard Version - Other Stressful Event: Not Apply","C135921","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Any other very stressful event or experience: Doesn't apply.","LEC-5 Standard Version - Other Stressful Event: Not Apply | LEC01-Other Stressful Event: Not Apply | LEC0117F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523235","PCL-5 - Repeated Disturbing Memories","C135922","The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Repeated, disturbing, and unwanted memories of the stressful experience?","PCL-5 - Repeated Disturbing Memories | PCL01-Repeated Disturbing Memories | PCL0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523236","PCL-5 - Repeated Disturbing Dreams","C135923","The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Repeated, disturbing dreams of the stressful experience?","PCL-5 - Repeated Disturbing Dreams | PCL01-Repeated Disturbing Dreams | PCL0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523237","PCL-5 - Suddenly Feeling Happening Again","C135924","The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Suddenly feeling or acting as if the stressful experience were actually happening again (as if you were actually back there reliving it)?","PCL-5 - Suddenly Feeling Happening Again | PCL01-Suddenly Feeling Happening Again | PCL0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523426","PODCI Adolescent Parent-Reported Version - Sleep More Comfortably","C136113","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) As a result of my child's treatment, I expect my child: To sleep more comfortably.","PODCI Adolescent Parent-Reported Version - Sleep More Comfortably | PODCI2-Sleep More Comfortably | PODCI280",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523427","PODCI Adolescent Parent-Reported Version - Able to Do Activities at Home","C136114","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) As a result of my child's treatment, I expect my child: To be able to do activities at home.","PODCI Adolescent Parent-Reported Version - Able to Do Activities at Home | PODCI2-Able to Do Activities at Home | PODCI281",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523428","PODCI Adolescent Parent-Reported Version - Able to Do More at School","C136115","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) As a result of my child's treatment, I expect my child: To be able to do more at school.","PODCI Adolescent Parent-Reported Version - Able to Do More at School | PODCI2-Able to Do More at School | PODCI282",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523429","PODCI Adolescent Parent-Reported Version - Able to Do More Play","C136116","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) As a result of my child's treatment, I expect my child: To be able to do more play or recreational activities.","PODCI Adolescent Parent-Reported Version - Able to Do More Play | PODCI2-Able to Do More Play | PODCI283",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523430","PODCI Adolescent Parent-Reported Version - Able to Do More Sports","C136117","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) As a result of my child's treatment, I expect my child: To be able to do more sports.","PODCI Adolescent Parent-Reported Version - Able to Do More Sports | PODCI2-Able to Do More Sports | PODCI284",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523431","PODCI Adolescent Parent-Reported Version - Free From Pain as Adult","C136118","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) As a result of my child's treatment, I expect my child: To be free from pain or disability as an adult.","PODCI Adolescent Parent-Reported Version - Free From Pain as Adult | PODCI2-Free From Pain as Adult | PODCI285",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523432","PODCI Adolescent Parent-Reported Version - Spend Rest of Life With Condition","C136119","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If your child had to spend the rest of his/her life with his/her bone and muscle condition as it is right now, how would you feel about it?","PODCI Adolescent Parent-Reported Version - Spend Rest of Life With Condition | PODCI2-Spend Rest of Life With Condition | PODCI286",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521562","6q21-q22","C13611","A chromosome band present on 6q","6q21-q22 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523729","Anti-GD3 Antibody-drug Conjugate PF-06688992","C136426","An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the ganglioside GD3, a surface antigen expressed on many malignant melanoma cells, and linked to an as of yet not fully elucidated chemotherapeutic agent, with potential antineoplastic activity. Upon administration of the ADC PF-06688992, the antibody moiety targets and binds to GD3 expressed on melanoma cells. Upon internalization, the chemotherapeutic agent specifically kills the GD3-positive cells. GD3 represents a major surface marker on most human melanoma cells and is not expressed on most other types of normal, healthy cells.","Anti-GD3 Antibody-drug Conjugate PF-06688992 | Anti-GD3 ADC PF-06688992 | GD3 ADC PF-06688992 | PF 06688992 | PF-06688992",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523730","Unresectable Head and Neck Squamous Cell Carcinoma","C136427","A squamous cell carcinoma that arises from the head and neck region and is not amenable to surgical resection.","Unresectable Head and Neck Squamous Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523731","Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6","C136428","A formulation composed of three agents in a fixed ratio: two chemotherapeutic agents, the platinum compound cisplatin and the vinca alkaloid vinblastine, and a proprietary amphiphilic excipient that acts as a penetration enhancer, with potential antineoplastic activity. Upon intra-tumoral (IT) injection of INT230-6, the dispersion/cell penetration enhancer excipient of INT230-6 facilitates dispersion of the two drugs throughout the tumor tissue and enables increased cellular uptake of these agents into tumor cells. Once inside the cell, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, which results in apoptosis and cell growth inhibition. Vinblastine kills the tumor cells through binding to tubulin and thereby inhibits microtubule formation, resulting in disruption of the mitotic spindle assembly and cell cycle arrest of tumor. In addition, the tumor cell killing leads to recruitment of dendritic cells (DCs) and induces a tumor-specific T-cell-mediated immune response that attacks both the injected tumor and distant tumor lesions. Local administration of both cisplatin and vinblastine, without the diffusion/penetration enhancer, results in to poor diffusion and a lack of cellular uptake of the agents; INT230-6 increases the intracellular concentration of cisplatin and vinblastine, thereby improving efficacy.","Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6 | Cisplatin/Vinblastine Formulation with Cell Penetration Enhancer INT230-6 | INT 230-6 | INT230-6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523732","Extended-release Granisetron Polymer Formulation","C136429","An extended-release (ER), polymer-based injectable formulation containing the indazole derivative granisetron, a selective serotonin (5-hydroxytryptamine; 5-HT) receptor type 3 (5-HT3) antagonist, with anti-emetic activity. Upon subcutaneous administration, granisetron is released from the polymer in a sustained manner, which is based upon the controlled hydrolysis of the polymers, and selectively binds to and inhibits the activity of the 5-HT3 receptors located peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone (CTZ) of the area postrema. By preventing stimulation of 5-HT3 receptors, granisetron is able to suppress chemotherapy-induced nausea and vomiting (CINV). Compared to the injection of granisetron alone, injection of the polymer-based formulation allows for therapeutic levels of granisetron over an extended period of time.","Extended-release Granisetron Polymer Formulation | ER Granisetron Injectable Formulation | Granisetron Extended-release Injection | Granisetron Extended-release Polymer-based Injectable Formulation | Sustol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520642","15q23-15q24","C13642","A chromosome band present on 15q","15q23-15q24 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523122","BEBQ Retrospective Version - Baby Enjoyed Feeding Time","C135809","Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) My baby enjoyed feeding time.","BEBQ Retrospective Version - Baby Enjoyed Feeding Time | BEBQ02-Baby Enjoyed Feeding Time | BEBQ0217",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523387","PODCI Adolescent Parent-Reported Version - Outdoor Limited by: Dislike","C136074","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered 'no' to Question 36 above, was your child's activity limited by: Dislike of recreational outdoor activities?","PODCI Adolescent Parent-Reported Version - Outdoor Limited by: Dislike | PODCI2-Outdoor Limited by: Dislike | PODCI241",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523388","PODCI Adolescent Parent-Reported Version - Outdoor Limited by: Too Young","C136075","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered 'no' to Question 36 above, was your child's activity limited by: Too young?","PODCI Adolescent Parent-Reported Version - Outdoor Limited by: Too Young | PODCI2-Outdoor Limited by: Too Young | PODCI242",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523389","PODCI Adolescent Parent-Reported Version - Outdoor Limited by: Season","C136076","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered 'no' to Question 36 above, was your child's activity limited by: Activity not in season?","PODCI Adolescent Parent-Reported Version - Outdoor Limited by: Season | PODCI2-Outdoor Limited by: Season | PODCI243",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523568","Infusional Fluorouracil/Leucovorin/Bevacizumab Regimen","C136257","A regimen consisting of infusional fluorouracil, leucovorin and bevacizumab that is used for the treatment of colorectal cancer, and ampullary, appendiceal and small bowel adenocarcinoma.","Infusional Fluorouracil/Leucovorin/Bevacizumab Regimen | Infusional 5-FU/LV Plus Bevacizumab | Infusional Fluorouracil-Leucovorin-Bevacizumab Regimen | Infusional Fluorouracil/Leucovorin Plus Avastin | Infusional Fluorouracil/Leucovorin/Avastin | Infusional Fluorouracil/leucovorin Plus Bevacizumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523570","Irinotecan/Ziv-aflibercept Regimen","C136259","A regimen consisting of irinotecan and ziv-aflibercept that is used for the treatment of appendiceal adenocarcinoma and colorectal cancer.","Irinotecan/Ziv-aflibercept Regimen | Irinotecan-Zaltrap Regimen | Irinotecan-Ziv-aflibercept | Irinotecan-Ziv-aflibercept Regimen | Irinotecan/Zaltrap Regimen | Irinotecan/Ziv-aflibercept",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521658","7q33-q35","C13625","A chromosome band present on 7q","7q33-q35 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523571","Irinotecan/Ramucirumab Regimen","C136260","A regimen consisting of irinotecan and ramucirumab that is used for the treatment of appendiceal adenocarcinoma, colon, esophageal and esophagogastric junction, gastric and rectal cancers.","Irinotecan/Ramucirumab Regimen | Irinotecan-Cyramza Regimen | Irinotecan-Ramucirumab | Irinotecan-Ramucirumab Regimen | Irinotecan/Cyramza Regimen | Irinotecan/Ramucirumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523572","Bendamustine/Bortezomib/Dexamethasone Regimen","C136261","A regimen consisting of bendamustine, bortezomib and dexamethasone that is used for the treatment of plasma cell myeloma.","Bendamustine/Bortezomib/Dexamethasone Regimen | BBD | BVD | Bendamustine-Bortezomib-Dexamethasone | Bendamustine-Bortezomib-Dexamethasone Regimen | Bendamustine/Bortezomib/Dexamethasone | Treanda/Velcade/Dexamethasone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523573","Bendamustine-Lenalidomide-Dexamethasone Regimen","C136262","A regimen consisting of bendamustine, lenalidomide and dexamethasone that is used for the treatment of plasma cell (multiple) myeloma.","BLD Regimen | BLD | BRD | Bendamustine-Lenalidomide-Dexamethasone Regimen | Bendamustine/Dexamethasone/Lenalidomide | Bendamustine/Lenalidomide/Dexamethasone | Bendamustine/Lenalidomide/Dexamethasone Regimen | Treanda/Revlimid/Dexamethasone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523574","Bortezomib/Liposomal Doxorubicin Regimen","C136263","A regimen consisting of bortezomib and liposomal doxorubicin that is used for the treatment of plasma cell myeloma.","Bortezomib/Liposomal Doxorubicin Regimen | Bortezomib-Liposomal Doxorubicin | Bortezomib-Liposomal Doxorubicin Regimen | Bortezomib/Liposomal Doxorubicin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523485","PODCI Adolescent Self-Reported Version - Games Limited by: Fear","C136172","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered 'no' to Question 43 above, was your activity limited by: Fear the other kids won't like you?","PODCI Adolescent Self-Reported Version - Games Limited by: Fear | PODCI3-Games Limited by: Fear | PODCI347",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523486","PODCI Adolescent Self-Reported Version - Games Limited by: Dislike","C136173","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered 'no' to Question 43 above, was your activity limited by: Dislike of pickup games or sports?","PODCI Adolescent Self-Reported Version - Games Limited by: Dislike | PODCI3-Games Limited by: Dislike | PODCI348",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523488","PODCI Adolescent Self-Reported Version - Participate in Competitive Sports","C136175","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) Can you participate in competitive level sports with other kids the same age (For example: hockey, basketball, soccer, football, baseball, swimming, running [track or cross country], gymnastics, or dance)?","PODCI Adolescent Self-Reported Version - Participate in Competitive Sports | PODCI3-Participate in Competitive Sports | PODCI350",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523489","PODCI Adolescent Self-Reported Version - Competitive Sports Limited by: Pain","C136176","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered 'no' to Question 50 above, was your activity limited by: Pain?","PODCI Adolescent Self-Reported Version - Competitive Sports Limited by: Pain | PODCI3-Comp Sports Limited by: Pain | PODCI351",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523490","PODCI Adolescent Self-Reported Version - Competitive Sports Limited by: Health","C136177","Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered 'no' to Question 50 above, was your activity limited by: General health?","PODCI Adolescent Self-Reported Version - Competitive Sports Limited by: Health | PODCI3-Comp Sports Limited by: Health | PODCI352",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523705","Pleural Malignant Mesothelioma by AJCC v8 Stage","C136399","A term that refers to the staging of pleural malignant mesothelioma, following the rules of the TNM AJCC v8 classification system. This staging system applies to pleural diffuse malignant mesothelioma only. Localized pleural malignant mesotheliomas and other primary tumors of the pleura are not staged using this staging system. (from AJCC 8th Ed.)","Pleural Malignant Mesothelioma by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514192","Poly-A Addition Site","C13639","The site within the 3' untranslated region of a gene where polyadenylation of the transcribed RNA takes place.  Usually consists of the sequence AATAAA.","Poly-A Addition Site | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523434","PODCI Adolescent Parent-Reported Version - Transfer and Basic Mobility Scale","C136121","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) Transfer and basic mobility core scale.","PODCI Adolescent Parent-Reported Version - Transfer and Basic Mobility Scale | PODCI2-Transfer/Basic Mobility Scale | PODCI288",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523435","PODCI Adolescent Parent-Reported Version - Sports and Physical Function Scale","C136122","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) Sports and physical functioning core scale.","PODCI Adolescent Parent-Reported Version - Sports and Physical Function Scale | PODCI2-Sports/Phys Function Scale | PODCI289",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523436","PODCI Adolescent Parent-Reported Version - Pain or Comfort Scale","C136123","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) Pain/comfort core scale.","PODCI Adolescent Parent-Reported Version - Pain or Comfort Scale | PODCI2-Pain/Comfort Scale | PODCI290",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523437","PODCI Adolescent Parent-Reported Version - Happiness Scale","C136124","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) Happiness core scale.","PODCI Adolescent Parent-Reported Version - Happiness Scale | PODCI2-Happiness Scale | PODCI291",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523438","PODCI Adolescent Parent-Reported Version - Global Functioning Scale","C136125","Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) Global functioning scale.","PODCI Adolescent Parent-Reported Version - Global Functioning Scale | PODCI2-Global Functioning Scale | PODCI292",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523625","Thymic Tumor pN0 TNM Finding v8","C136316","Thymus tumor without regional lymph node metastasis. (from AJCC 8th Ed.)","Thymus Tumor pN0 TNM Finding v8 | Thymic Tumor pN0 TNM Finding v8 | Thymic Tumor pN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523626","Thymic Tumor pN1 TNM Finding v8","C136317","Thymus tumor with metastasis in anterior (perithymic) lymph nodes. (from AJCC 8th Ed.)","Thymus Tumor pN1 TNM Finding v8 | Thymic Tumor pN1 TNM Finding v8 | Thymic Tumor pN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523627","Thymic Tumor pN2 TNM Finding v8","C136318","Thymus tumor with metastasis in deep intrathoracic or cervical lymph nodes. (from AJCC 8th Ed.)","Thymus Tumor pN2 TNM Finding v8 | Thymic Tumor pN2 TNM Finding v8 | Thymic Tumor pN2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521282","3p21-p14","C13631","A chromosome band present on 3p","3p21-p14 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523629","Thymic Epithelial Neoplasm by AJCC v8 Stage","C136320","A term that refers to the staging of a thymus epithelial neoplasm, following the rules of the TNM AJCC v8 classification system. This staging system applies to thymomas, thymus carcinomas, thymus neuroendocrine tumors, and combined thymus carcinomas. (from AJCC 8th Ed.)","Thymus Epithelial Neoplasm by AJCC v8 Stage | Thymic Epithelial Neoplasm by AJCC v8 Stage | Thymic Epithelial Neoplasm by AJCC v8 Stage | Thymus Epithelial Neoplasm by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523631","Stage I Thymus Epithelial Neoplasm","C136322","Stage I includes: T1a, b, N0, M0. T1a: Tumor with no mediastinal pleura involvement. T1b: Tumor with direct invasion of mediastinal pleura. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Thymus Epithelial Neoplasm AJCC v8 | Stage I Thymic Epithelial Neoplasm AJCC v8 | Stage I Thymic Epithelial Neoplasm AJCC v8 | Stage I Thymus Epithelial Neoplasm | Stage I Thymus Epithelial Neoplasm AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523632","Stage II Thymus Epithelial Neoplasm","C136323","Stage II includes: T2, N0, M0. T2: Tumor with direct invasion of the pericardium (either partial or full thickness). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Thymus Epithelial Neoplasm AJCC v8 | Stage II Thymic Epithelial Neoplasm AJCC v8 | Stage II Thymic Epithelial Neoplasm AJCC v8 | Stage II Thymus Epithelial Neoplasm | Stage II Thymus Epithelial Neoplasm AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520588","14q23","C13580","A chromosome band present on 14q","14q23 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523123","BEBQ Retrospective Version - Take a Feed Within 30 Minutes","C135810","Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) My baby could easily take a feed within 30 minutes of the last one.","BEBQ Retrospective Version - Take a Feed Within 30 Minutes | BEBQ02-Take a Feed Within 30 Minutes | BEBQ0218",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523124","CGI Original Version - Severity of Illness","C135811","Clinical Global Impression Original Version (CGI Original Version) Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?","CGI Original Version - Severity of Illness | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523125","CGI Original Version - Global Improvement","C135812","Clinical Global Impression Original Version (CGI Original Version) Rate total improvement whether or not, in your judgement, it is due entirely to drug treatment. Compared to his condition at admission to the project, how much has he changed?","CGI Original Version - Global Improvement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523126","CGI Original Version - Efficacy Index","C135813","Clinical Global Impression Original Version (CGI Original Version) Rate this item on the basis of drug effect only. Select the terms which best describe the degrees of therapeutic effect and side effects.","CGI Original Version - Efficacy Index | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523127","CGI Generic Modification Version - Severity","C135814","Clinical Global Impression Generic Modification Version (CGI Generic Modification Version) Considering your total clinical experience with this particular population, how severe is the subject's condition at this time?","CGI Generic Modification Version - Severity | CGI02-Severity | CGI0201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523128","CGI Generic Modification Version - Change","C135815","Clinical Global Impression Generic Modification Version (CGI Generic Modification Version) Rate total change whether or not, in your judgement, it is due entirely to drug treatment. Compared to the subject's condition <at previously assessed protocol specified time point>, how much has the subject changed?","CGI Generic Modification Version - Change | CGI02-Change | CGI0202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523129","CGI Generic Modification Version - Improvement","C135816","Clinical Global Impression Generic Modification Version (CGI Generic Modification Version) Rate total improvement whether or not, in your judgement, it is due entirely to drug treatment. Compared to the subject's condition <at previously assessed protocol specified time point>, how much has the subject improved?","CGI Generic Modification Version - Improvement | CGI02-Improvement | CGI0203",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523130","PGI Generic Modification Version - Severity","C135817","Patient Global Impression Generic Modification Version (PGI Generic Modification Version) Considering all the ways your condition impacts you, how severe is your condition at this time?","PGI Generic Modification Version - Severity | PGI01-Severity | PGI0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523131","PGI Generic Modification Version - Change","C135818","Patient Global Impression Generic Modification Version (PGI Generic Modification Version) Compared to <previously assessed protocol specified time point> how much has your condition changed?","PGI Generic Modification Version - Change | PGI01-Change | PGI0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521477","5q21-q22","C13581","A chromosome band present on 5q","5q21-q22 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523134","LEC-5 Standard Version - Natural Disaster: Witnessed","C135821","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Natural disaster (for example, flood, hurricane, tornado, earthquake): Witnessed it.","LEC-5 Standard Version - Natural Disaster: Witnessed | LEC01-Natural Disaster: Witnessed | LEC0101B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523135","LEC-5 Standard Version - Natural Disaster: Learned","C135822","Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Natural disaster (for example, flood, hurricane, tornado, earthquake): Learned about it.","LEC-5 Standard Version - Natural Disaster: Learned | LEC01-Natural Disaster: Learned | LEC0101C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523576","Carfilzomib/Dexamethasone Regimen","C136265","A regimen consisting of carfilzomib and dexamethasone that is used for the treatment of plasma cell myeloma and systemic light chain amyloidosis.","Carfilzomib/Dexamethasone Regimen | Carfilzomib and Dexamethasone (Kd) | Carfilzomib-Dexamethasone | Carfilzomib-Dexamethasone Regimen | Carfilzomib/Dexamethasone | KD | KD Regimen | Kyprolis/Dexamethasone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523577","Cyclophosphamide-Lenalidomide-Dexamethasone Regimen","C136266","A regimen consisting of cyclophosphamide, lenalidomide and dexamethasone that can be used for the treatment of plasma cell myeloma and systemic light chain amyloidosis.","CRd Regimen | CLD | CRD | CRd | Cyclophosphamide-Lenalidomide-Dexamethasone | Cyclophosphamide-Lenalidomide-Dexamethasone Regimen | Cyclophosphamide/Dexamethasone/Lenalidomide | Cyclophosphamide/Lenalidomide/Dexamethasone | Cyclophosphamide/Lenalidomide/Dexamethasone Regimen | RdC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523579","Daratumumab-Lenalidomide-Dexamethasone Regimen","C136268","A regimen consisting of daratumumab, lenalidomide and dexamethasone that is used for the treatment of plasma cell myeloma.","Dara-Rd Regimen | Dara-Rd | Daratumumab-Lenalidomide-Dexamethasone | Daratumumab-Lenalidomide-Dexamethasone Regimen | Daratumumab/Lenalidomide/Dexamethasone | Daratumumab/Lenalidomide/Dexamethasone Regimen | Darzalex/Revlimid/Dexamethasone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523706","Stage I Pleural Malignant Mesothelioma AJCC v8","C136400","Stage I includes: IA: (T1, N0, M0); IB: (T2 or T3, N0, M0). T1: Tumor limited to the ipsilateral parietal with or without involvement of visceral pleura, mediastinal pleura, and diaphragmatic pleura. T2: Tumor involving each of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of diaphragmatic muscle and/or extension of tumor from visceral pleura into the underlying pulmonary parenchyma. T3: Tumor is locally advanced but potentially resectable. The tumor involves all the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of the endothoracic fascia, extension into the mediastinal fat, solitary, completely resectable focus of tumor extending into the soft tissues of the chest wall, and/or nontransmural involvement of the pericardium. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Pleural Malignant Mesothelioma AJCC v8 | Stage I Pleural Malignant Mesothelioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523707","Stage IB Pleural Malignant Mesothelioma AJCC v8","C136401","Stage IB includes: T2 or T3, N0, M0. T2: Tumor involving each of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of diaphragmatic muscle and/or extension of tumor from visceral pleura into the underlying pulmonary parenchyma. T3: Tumor is locally advanced but potentially resectable. The tumor involves all the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of the endothoracic fascia, extension into the mediastinal fat, solitary, completely resectable focus of tumor extending into the soft tissues of the chest wall, and/or nontransmural involvement of the pericardium. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)","Stage IB Pleural Malignant Mesothelioma AJCC v8 | Stage IB Pleural Malignant Mesothelioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523708","Stage II Pleural Malignant Mesothelioma AJCC v8","C136402","Stage II includes: (T1, N1, M0); (T2, N1, M0). T1: Tumor limited to the ipsilateral parietal with or without involvement of visceral pleura, mediastinal pleura, and diaphragmatic pleura. T2: Tumor involving each of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of diaphragmatic muscle and/or extension of tumor from visceral pleura into the underlying pulmonary parenchyma. N1: Metastases in the ipsilateral bronchopulmonary, hilar, or mediastinal (including the internal mammary, peridiaphragmatic, pericardial fat pad, or intercostal) lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Pleural Malignant Mesothelioma AJCC v8 | Stage II Pleural Malignant Mesothelioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523074","PASI - Upper Extremities (U): Infiltration (I)","C135761","Psoriasis Area and Severity Index (PASI) Upper Extremities (U): Infiltration (I).","PASI - Upper Extremities (U): Infiltration (I) | PASI01-Up Extrem (U): Infiltration (I) | PASI0116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523075","PASI - Upper Extremities (U): Desquamation (D)","C135762","Psoriasis Area and Severity Index (PASI) Upper Extremities (U): Desquamation (D).","PASI - Upper Extremities (U): Desquamation (D) | PASI01-Up Extrem (U): Desquamation (D) | PASI0117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523076","PASI - Upper Extremities (U): Sum = E+I+D","C135763","Psoriasis Area and Severity Index (PASI) Upper Extremities (U): Sum = E + I + D.","PASI - Upper Extremities (U): Sum = E+I+D | PASI01-Up Extrem (U): Sum = E+I+D | PASI0118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523077","PASI - Upper Extremities (U): Area Score","C135764","Psoriasis Area and Severity Index (PASI) Upper Extremities (U): Area score.","PASI - Upper Extremities (U): Area Score | PASI01-Up Extrem (U): Area Score | PASI0119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523078","PASI - Upper Extremities (U): Sum X Area","C135765","Psoriasis Area and Severity Index (PASI) Upper Extremities (U): Sum x area.","PASI - Upper Extremities (U): Sum X Area | PASI01-Up Extrem (U): Sum X Area | PASI0120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523079","PASI - Upper Extremities (U): Sum X Area X 0.2","C135766","Psoriasis Area and Severity Index (PASI) Upper Extremities (U): Sum x area x 0.2.","PASI - Upper Extremities (U): Sum X Area X 0.2 | PASI01-Up Extrem (U): Sum X Area X 0.2 | PASI0121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523080","PASI - Lower Extremities (L): Erythema (E)","C135767","Psoriasis Area and Severity Index (PASI) Lower Extremities (L): Erythema (E).","PASI - Lower Extremities (L): Erythema (E) | PASI01-Low Extrem (L): Erythema (E) | PASI0122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521385","4q12-q13","C13685","A chromosome band present on 4q","4q12-q13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524516","Uterine Corpus Sarcoma by AJCC v7 Stage","C136708","A term that refers to the staging of uterine corpus sarcoma, following the rules of the TNM AJCC v7 classification system.","Uterine Corpus Sarcoma by AJCC v7 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520504","12q15","C13800","A chromosome band present on 12q","12q15 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526332","PedsQL Neuromuscular Module Version 3.0 Teen Report - Long Time to Bathe or Shower","C138844","Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: It takes me a long time to bathe or shower.","PedsQL Neuromuscular Module Version 3.0 Teen Report - Long Time to Bathe or Shower | PQL03-Long Time to Bathe/Shower | PQL0313",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526339","PedsQL Neuromuscular Module Version 3.0 Teen Report - Get Hurt Accidentally","C138845","Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: I get hurt accidentally.","PedsQL Neuromuscular Module Version 3.0 Teen Report - Get Hurt Accidentally | PQL03-Get Hurt Accidentally | PQL0314",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526338","PedsQL Neuromuscular Module Version 3.0 Teen Report - Take Long Time to Eat","C138846","Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: I take a long time to eat.","PedsQL Neuromuscular Module Version 3.0 Teen Report - Take Long Time to Eat | PQL03-Take Long Time to Eat | PQL0315",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526337","PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard to Turn During Night","C138847","Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: It is hard to turn myself during the night.","PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard to Turn During Night | PQL03-Hard to Turn During Night | PQL0316",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526336","PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard to Go Places With Equipment","C138848","Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: It is hard for me to go places with my equipment.","PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard to Go Places With Equipment | PQL03-Hard to Go Places With Equipment | PQL0317",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526343","PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard Tell Doctors and Nurses How Feel","C138849","Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: It is hard for me to tell the doctors and nurses how I feel.","PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard Tell Doctors and Nurses How Feel | PQL03-Hard Tell Doctors/Nurses How Feel | PQL0318",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521047","20pter-q12","C13884","A chromosome band present on 20p","20pter-q12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526342","PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard Ask Doctors and Nurses Questions","C138850","Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: It is hard for me to ask the doctors and nurses questions.","PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard Ask Doctors and Nurses Questions | PQL03-Hard Ask Doctors/Nurses Questions | PQL0319",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525759","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Name Terminology","C138260","Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Name Terminology | PQL07TN | Pediatric Quality of Life Neuromuscular Module Version 3 Young Child Questionnaire Test Name | QS-PedsQL Neuromuscular Module Version 3.0 Young Child Report TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525758","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Code Terminology","C138261","Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Code Terminology | PQL07TC | Pediatric Quality of Life Neuromuscular Module Version 3 Young Child Questionnaire Test Code | QS-PedsQL Neuromuscular Module Version 3.0 Young Child Report TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525757","HAS-BLED Clinical Classification Question","C138262","A question associated with the HAS-BLED clinical classification.","HAS-BLED Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524482","Bone Cancer by AJCC v7 Stage","C136610","A term that refers to the staging of bone cancer, following the rules of the TNM AJCC v7 classification system.","Bone Cancer by AJCC v7 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1275581","Computed Tomography of the Brain without Contrast","C137897","Computed tomography of the brain without the use of a contrast agent.","Computed Tomography of the Brain without Contrast | Brain CT without Contrast | Brain CT without contrast | Head CT without Contrast",,,,,,,,,,,,,,,"4244986","CT of brain without contrast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL515578","Computed Tomography of the Chest without Contrast","C137898","Computed tomography of the chest without the use of a contrast agent.","Computed Tomography of the Chest without Contrast | Chest CT without Contrast",,,,,,,,,,,,,,,"36713200","CT of chest without contrast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL515577","Computed Tomography of the Chest and Abdomen without Contrast","C137899","Computed tomography of the chest and abdomen without the use of a contrast agent.","Computed Tomography of the Chest and Abdomen without Contrast | Chest/Abdominal CT without Contrast",,,,,,,,,,,,,,,"36713242","CT of chest and abdomen without contrast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1520265","10p15.1","C13789","A chromosome band present on 10p","10p15.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0122297","Antimoniotungstate","C1378","A non-nucleoside reverse transcriptase inhibitor. Antimoniotungstate is a mineral condensed ion with a cryptic structure.","Antimoniotungstate | 21-Tungsto-9-antimonate | 5-Tungsto-2-antimonate | Ammonium 5-Tungsto-2-antimonate | HPA-23 | Heteropolyanion-23 | Hexaoctacontaoxononaantimonateheneicosatungstate(19-) Heptadecaammonium Disodium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL516119","Computed Tomography of the Chest, Abdomen and Pelvis without Contrast","C137900","Computed tomography of the chest, abdomen and pelvis without the use of a contrast agent.","Computed Tomography of the Chest, Abdomen and Pelvis without Contrast | Chest/Abdominal/Pelvic CT without Contrast",,,,,,,,,,,,,,,"36713194","CT of chest, abdomen and pelvis without contrast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL524925","Computed Tomography of an Anatomical Site of Interest without Contrast","C137901","Computed tomography of an anatomical site of interest without the use of a contrast agent.","Computed Tomography of an Anatomical Site of Interest without Contrast | CT without Contrast of Area of Interest | Computed Tomography of an Area of Interest without Contrast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524924","Magnetic Resonance Imaging of a Primary Site with and without Contrast","C137902","Magnetic resonance imaging of the primary site without a contrast agent to enhance the image.","Magnetic Resonance Imaging of a Primary Site with and without Contrast | MRI with and without Contrast of Primary Site | Magnetic Resonance Imaging with and without Contrast of Primary Site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL515553","Computed Tomography of the Neck, Chest, Abdomen and Pelvis without Contrast","C137903","Computed tomography of the neck, chest, abdomen and pelvis without the use of a contrast agent.","Computed Tomography of the Neck, Chest, Abdomen and Pelvis without Contrast | CT Scan of the Neck/Chest/Abdomen/Pelvis without Contrast | Neck/Chest/Abdominal/Pelvic CT without Contrast | Neck/Chest/Abdominal/Pelvic Computed Tomography without Contrast",,,,,,,,,,,,,,,"36713232","CT of neck, chest, abdomen and pelvis without contrast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL515373","Computed Tomography of the Pelvis without Contrast","C137904","Computed tomography of the pelvis without the use of a contrast agent.","Computed Tomography of the Pelvis without Contrast | CT Scan of the Pelvis without Contrast | Pelvic CT without Contrast | Pelvic Computed Tomography without Contrast",,,,,,,,,,,,,,,"36713202","CT of pelvis without contrast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL524926","Sodium Fluoride Positron Emission Tomography/Computed Tomography of the Whole Body","C137906","Positron emission tomography combined with computed tomography of the whole body with the use of the contrast agent sodium fluoride F 18 (18F-NaF) to enhance the image.","Sodium Fluoride Positron Emission Tomography/Computed Tomography of the Whole Body | 18F-NaF Whole-body PET/CT Scan | NaF PET/CT WB | PET/CT, Whole Body, Sodium Fluoride | Sodium Fluoride WB PET-CT | WB PET/CT Scan with Sodium Fluoride | Whole Body 18F-NaF Positron Emission Tomography/Computed Tomography | Whole Body Sodium Fluoride Positron Emission Tomography/Computed Tomography",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521114","22q13.1","C13766","A chromosome band present on 22q","22q13.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524459","Recurrent Cervical Adenosquamous Carcinoma","C136650","The reemergence of cervical adenosquamous carcinoma after a period of remission.","Recurrent Cervical Adenosquamous Carcinoma | Recurrent Cervical Adenosquamous Cancer | Relapsed Cervical Adenosquamous Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524460","Recurrent Cervical Adenocarcinoma","C136651","The reemergence of cervical adenocarcinoma after a period of remission.","Recurrent Cervical Adenocarcinoma | Relapsed Cervical Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3550789","X-linked Thrombocytopenia, with or without Dyserythropoietic Anemia","C136653","An X-linked condition caused by mutation(s) in the GATA1 gene, encoding erythroid transcription factor. It is characterized by thrombocytopenia, as well as abnormal platelet function and morphology. Dyserythropoietic anemia of variable severity may also be present.","X-linked Thrombocytopenia, with or without Dyserythropoietic Anemia | XLTDA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524465","Soft Tissue Sarcoma TNM Finding v8","C136654","A finding about one or more characteristics of soft tissue sarcoma, following the rules of the TNM AJCC v8 classification system. This classification system applies to soft tissue sarcomas that arise in the following areas: head and neck, trunk and extremities, gastrointestinal tract, genitourinary tract, viscera and retroperitoneum, gynecologic sites, breast, lung, pleura, mediastinum, and other unusual histologies and sites. It does not apply to desmoid tumor/deep fibromatosis (no AJCC staging system available) and Kaposi sarcoma (no AJCC staging system available; AIDS Clinical Trials Group system TIS (tumor, immune system, systemic illness) staging may be used). (from AJCC 8th Ed.)","Soft Tissue Sarcoma TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525018","Recurrent Gray Zone Lymphoma","C138013","The reemergence of gray-zone lymphoma after a period of remission.","Recurrent Gray-Zone Lymphoma | Recurrent B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma | Recurrent B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma | Recurrent B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma | Recurrent Gray Zone Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515451","8q13-qter","C13689","A chromosome band present on 8q","8q13-qter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510510","Recombinant ENA-78","C1368","Epithelial neutrophil activating peptide-78.  A 78 amino acid member of the CXC family of chemokines, produced and secreted upon stimulation by interleukin 1 beta or tumor necrosis factor alpha.  Stimulates chemotactic migration of neutrophils, monocytes, lymphocytes, and fibroblasts.","Recombinant ENA-78 | ENA-78 | LIX | Lipopolysaccharide-Induced CXC Chemokine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525756","LPSS Clinical Classification Question","C138263","A question associated with the LPSS clinical classification.","LPSS Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525763","PUL 1.2 Functional Test Question","C138264","A question associated with the PUL 1.2 functional test.","PUL 1.2 Functional Test Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525762","PUL 2.0 Functional Test Question","C138265","A question associated with the PUL 2.0 functional test.","PUL 2.0 Functional Test Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525760","FKSI-15 Questionnaire Question","C138267","A question associated with the FKSI-15 questionnaire.","FKSI-15 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525767","FLSI Questionnaire Question","C138268","A question associated with the FLSI questionnaire.","FLSI Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525766","PedsQL Neuromuscular Module Acute Version 3.0 Child Report Questionnaire Question","C138269","A question associated with the PedsQL Neuromuscular Module Acute Version 3.0 Child Report questionnaire.","PedsQL Neuromuscular Module Acute Version 3.0 Child Report Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027929","Golgi Tendon Organ","C13826","The Golgi Tendon Organ is located within the tendons found on each end of a muscle. It responds to increased muscle tension or contraction as exerted on the tendon, by inhibiting further muscle contraction, which protects against muscle damage. The proprioceptive sensory neuron of a Golgi tendon organ, projects to the motor neurons located within the ventral horn of the spinal cord, where the inhibition occurs. Unlike the muscle spindle, Golgi tendon organs do not indicate muscle length, but rather muscle tension.","Golgi Tendon Organ | Golgi's Tendon Organ | Golgi's Tendon Spindle | Neurotendinous Organ | Neurotendinous Spindle",,,,,,,,,,,,,,,"4218455","Tendon spindle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL525765","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Questionnaire Question","C138270","A question associated with the PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler questionnaire.","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525764","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Questionnaire Question","C138271","A question associated with the PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child questionnaire.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525770","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Questionnaire Question","C138273","A question associated with the PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults questionnaire.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525769","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Questionnaire Question","C138274","A question associated with the PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child questionnaire.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525743","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Questionnaire Question","C138276","A question associated with the PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report questionnaire.","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526025","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Get Hurt Accidentally","C138503","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: My child gets hurt accidentally.","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Get Hurt Accidentally | PQL18-Get Hurt Accidentally | PQL1814",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526024","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Take Long Time to Eat","C138504","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: My child takes a long time to eat.","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Take Long Time to Eat | PQL18-Take Long Time to Eat | PQL1815",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524674","Stage I Retroperitoneal Sarcoma AJCC v8","C136812","Stage I includes: IA: (T1, N0, M0, G1, GX); IB: (T2, T3, T4, N0, M0, G1, GX). T1: Tumor measuring 5 cm or less in greatest dimension. T2: Tumor measuring more than 5 cm and less than or equal to 10 cm in greatest dimension. T3: Tumor measuring more than 10 cm and less than or equal to 15 cm in greatest dimension. T4: Tumor measuring more than 15 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. GX: Grade cannot be assessed. G1: Total differentiation, mitotic count and necrosis score of 2 or 3. (AJCC 8th ed.)","Stage I Retroperitoneal Sarcoma AJCC v8 | Stage I Retroperitoneal Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524678","Stage III Retroperitoneal Sarcoma AJCC v8","C136816","Stage III includes: IIIA: (T2, N0, M0, G2, G3); IIIB: (T3, T4, N0, M0, G2, G3); (Any T, N1, M0, Any G). T2: Tumor measuring more than 5 cm and less than or equal to 10 cm in greatest dimension. T3: Tumor measuring more than 10 cm and less than or equal to 15 cm in greatest dimension. T4: Tumor measuring more than 15 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. N1: Regional lymph node metastasis. M0: No distant metastasis. G2: Total differentiation, mitotic count and necrosis score of 4 or 5. G3: Total differentiation, mitotic count and necrosis score of 6, 7, or 8. (AJCC 8th ed.)","Stage III Retroperitoneal Sarcoma AJCC v8 | Stage III Retroperitoneal Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524437","Soft Tissue Sarcoma of the Head and Neck Clinical Distant Metastasis TNM Finding v8","C136657","A clinical finding about one or more characteristics of soft tissue sarcoma of the head and neck, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Soft Tissue Sarcoma of the Head and Neck Clinical Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520781","17q23-q24","C13665","A chromosome band present on 17q","17q23-q24 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524436","Soft Tissue Sarcoma of the Head and Neck Pathologic TNM Finding v8","C136660","A pathologic finding about one or more characteristics of soft tissue sarcoma of the head and neck, following the rules of the TNM AJCC v8 classification system.","Soft Tissue Sarcoma of the Head and Neck Pathologic TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524441","Soft Tissue Sarcoma of the Head and Neck Pathologic Distant Metastasis TNM Finding v8","C136661","A pathologic finding about one or more characteristics of soft tissue sarcoma of the head and neck, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Soft Tissue Sarcoma of the Head and Neck Pathologic Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524439","Soft Tissue Sarcoma of the Head and Neck Pathologic Primary Tumor TNM Finding v8","C136663","A pathologic finding about one or more characteristics of soft tissue sarcoma of the head and neck, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Soft Tissue Sarcoma of the Head and Neck Pathologic Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524974","Branched-Chain-Amino-Acid Aminotransferase, Cytosolic","C137956","Branched-chain-amino-acid aminotransferase, cytosolic (386 aa, ~43 kDa) is encoded by the human BCAT1 gene. This protein is involved in transamination of leucine, isoleucine, and valine.","Branched-Chain-Amino-Acid Aminotransferase, Cytosolic | BCAT(c) | BCAT1 | Branched Chain Amino-Acid Transaminase 1, Cytosolic | Branched-Chain Aminotransferase 1 | Branched-Chain Aminotransferase 1, Cytosolic | EC 2.6.1.42 | Placental Protein 18 | Protein ECA39",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3150943","Long QT Syndrome 2","C137957","An autosomal dominant condition caused by mutation(s) in the KCNH2 gene, encoding potassium voltage-gated channel subfamily H member 2. It is characterized by a prolonged QT interval that may result in torsade de pointes, ventricular fibrillation and/or sudden cardiac death.","Long QT Syndrome 2 | LQT2",,,,,,,,,,,,,,,"37163282","Long QT syndrome type 2",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1420787","TMSB4X Gene","C137958","This gene plays a role in the sequestration of actin monomers.","TMSB4X Gene | TMSB4X | Thymosin Beta 4, X-Linked Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521566","6q22","C13690","A chromosome band present on 6q","6q22 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521646","7q21.3-q22.1","C13769","A chromosome band present on 7q","7q21.3-q22.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0120715","Halichondrin B","C1376","A complex macrolide polyether from marine sponge genera, such as Halichondria, Axinella, Phakellia, and Lissodendoryx that binds to tubulin, thereby inhibiting mitosis. (NCI)","Halichondrin B | HALICHONDRIN B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526031","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard to Turn During Night","C138505","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to turn him or herself during the night.","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard to Turn During Night | PQL18-Hard to Turn During Night | PQL1816",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526030","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard to Go Places With Equipment","C138506","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to go places with his or her equipment.","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard to Go Places With Equipment | PQL18-Hard to Go Places With Equipment | PQL1817",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526029","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard Tell Doctors and Nurses How Feel","C138507","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to tell the doctors and nurses how he or she feels.","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard Tell Doctors and Nurses How Feel | PQL18-Hard Tell Doctors/Nurses How Feel | PQL1818",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526028","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard Ask Doctors and Nurses Questions","C138508","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to ask the doctors and nurses questions.","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard Ask Doctors and Nurses Questions | PQL18-Hard Ask Doctors/Nurses Questions | PQL1819",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526035","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard Explain Illness to People","C138509","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to explain his or her illness to other people.","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard Explain Illness to People | PQL18-Hard Explain Illness to People | PQL1820",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521226","2q34-q35","C13850","A chromosome band present on 2q","2q34-q35 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526034","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard for Family to Plan Activities","C138510","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: It is hard for our family to plan activities like vacations.","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard for Family to Plan Activities | PQL18-Hard for Family to Plan Activities | PQL1821",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526033","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard for Family to Rest","C138511","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: It is hard for our family to get enough rest.","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard for Family to Rest | PQL18-Hard for Family to Rest | PQL1822",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526032","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Money Problem in Our Family","C138512","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: I think money is a problem in our family.","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Money Problem in Our Family | PQL18-Money Problem in Our Family | PQL1823",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526130","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Back Feels Stiff","C138670","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: My back feels stiff.","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Back Feels Stiff | PQL16-Back Feels Stiff | PQL1606",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521694","8p11.2-p11.1","C13681","A chromosome band present on 8p","8p11.2-p11.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0119196","Girodazole","C1373","A compound isolated from the marine sponge Pseudaxinyssa cantharella exhibiting anti-tumor activity.  Studies indicate girodazole acts during the elongation/termination steps of protein synthesis, resulting in protein synthesis inhibition. (NCI)","Girodazole | 3-Amino-1-[4-(2 amino-1H-imidazolyl)]-propanol, 2HCl | Giroline | RP 49532A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1283994","Inner Cell Mass","C13740","A small group of cells found in the blastocyst cavity surrounded by a wall of trophoblast cells that eventually will form the embryo.","Inner Cell Mass | Embryoblast",,,,,,,,,,,,,,,"4158925","Inner cell mass",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0949662","AT Hook Motif","C13741","Highly conserved peptide motifs of the HMG-I(Y) proteins that preferentially bind to the AT-rich minor groove of DNA. The AT hook motif tethers and unwinds the minor groove of the DNA with very little specificity for the DNA sequence. The AT hook motif has a narrow DNA recognition surface that is devoid of hydrophobic amino acids and that does not significantly distort the B-form DNA structure.","AT Hook Motif | AT Hook Domain | ATH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513315","Minor Groove","C13742","The smaller of the two types of spiral grooves found on a right-handed DNA double helix; located between the sugar phosphate backbones of two DNA strands.","Minor Groove | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518157","Major Groove","C13743","One of the two types of grooves found in a right-handed double helix, running between the sugar phosphate backbones of each strand.","Major Groove | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512311","HMG-Box","C13744","The HMG-Box Domain binds to and bends the minor groove of the DNA. This domain can recognize and bind to altered DNA conformations, such as stem-loops, four-way junctions, and specifically kinked or underwound DNA. (Mol Cell Biol 1999 Aug;19(8):5237-46)","HMG-Box | HMG-1 Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518456","Nucleosome Binding Domain","C13745","The Nucleosomal Binding Domain anchors HMG-14 and HMG-17, two canonical HMG proteins, to nucleosomes. HMG-14 and HMG-17 are the only nuclear proteins known to specifically recognize the genetic structure of the 146-bp nucleosome, i.e., the building block of the chromatin fiber. Although the target of HMG-14/-17 is the nucleosome, the main function of these proteins is to change the architecture of the higher-order chromatin structure. These changes are mediated through the C-terminal region of the proteins. The nucleosomal binding domain anchors these HMG proteins to the nucleosome cores to facilitate HMG-14/-17-dependent changes in chromatin structure.","Nucleosome Binding Domain | NBD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521759","Ring Finger Domain","C13746","The RING finger is a specialized type of Zn-finger consisting of 40 to 60 residues, which has the consensus sequence CX2CX(9-39)CX(1-3)HX(2-3)C/HX2CX(4-48)CX2C, that binds two atoms of zinc, and is involved in mediating protein-protein interactions. The RING domain mediates the interaction with the appropriate E2 enzyme. Unlike HECT E3 enzymes that form a thiol-ester with ubiquitin, RING fingers likely mediate ubiquitination by facilitating the direct transfer of ubiquitin from E2 enzyme to lysine residues on the target substrate.","Ring Finger Domain | Ring Finger | Ring Finger Motif | Ring-Type Zinc Finger Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521287","3p21.3-p21.2","C13748","A chromosome band present on 3p","3p21.3-p21.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1859062","LONG QT SYNDROME 3","C137959","An autosomal dominant condition caused by mutation(s) in the SCN5A gene, encoding sodium channel protein type 5 subunit alpha. It is characterized by a prolonged QT interval that may result in torsade de pointes, ventricular fibrillation and/or sudden cardiac death.","Long QT Syndrome 3 | LQT3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521541","6p21.31","C13795","A chromosome band present on 6p","6p21.31 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420788","TMSB4Y Gene","C137961","This gene is involved in the downregulation of actin polymerization.","TMSB4Y Gene | TMSB4Y | Thymosin Beta 4, Y-Linked Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524959","TMSB4Y wt Allele","C137962","Human TMSB4Y wild-type allele is located in the vicinity of Yq11.221 and is approximately 2 kb in length. This allele, which encodes thymosin beta-4, Y-chromosomal protein, plays a role in G actin sequestration.","TMSB4Y wt Allele | TB4Y | Thymosin Beta 4, Y-Linked wt Allele | Thymosin, Beta 4, Y Chromosome Gene | Thymosin, Beta-4 Gene | Thymosin, Beta-4, Y Chromosome Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0076616","thymosin beta(4)","C137963","Thymosin beta-4 (44 aa, ~5 kDa) is encoded by the human TMSB4X gene. This protein plays a role in the downregulation of actin polymerization.","Thymosin Beta-4 | Fx | Prothymosin Beta-4 | T Beta-4 | TMSB4X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524962","Thymosin Beta-4, Y-Chromosomal","C137964","Thymosin beta-4, Y-chromosomal (44 aa, ~5 kDa) is encoded by the human TMSB4Y gene. This protein is involved in the inhibition of actin polymerization.","Thymosin Beta-4, Y-Chromosomal | TMSB4Y | Thymosin Beta-4, Y Isoform",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826584","PIF1 Gene","C137965","This gene plays a role in the DNA maintenance.","PIF1 Gene | PIF1 | PIF1 5'-to-3' DNA Helicase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1698285","PIF1 protein, human","C137967","ATP-dependent DNA helicase PIF1 (641 aa, ~70 kDa) is encoded by the human PIF1 gene. This protein plays a role in the unwinding of G-quadruplex DNA and RNA-DNA hybrids.","ATP-Dependent DNA Helicase PIF1 | DNA Repair and Recombination Helicase PIF1 | EC 3.6.4.12 | PIF1 | PIF1/RRM3 DNA Helicase-Like Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1826630","BPTF Gene","C137968","This gene is involved in histone-dependent regulation of transcription.","BPTF Gene | BPTF | Bromodomain PHD Finger Transcription Factor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524963","BPTF wt Allele","C137969","Human BPTF wild-type allele is located in the vicinity of 17q24.2 and is approximately 159 kb in length. This allele, which encodes nucleosome-remodeling factor subunit BPTF protein, plays a role in the regulation of gene transcription.","BPTF wt Allele | Bromodomain PHD Finger Transcription Factor wt Allele | FAC1 | FALZ | NURF301 | NURF301, Drosophila, Homolog of Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520970","1p35.2","C13796","A chromosome band present on 1p","1p35.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0300134","Nucleosome-Remodeling Factor Subunit BPTF","C137970","Nucleosome-remodeling factor subunit BPTF (3046 aa, ~338 kDa) is encoded by the human BPTF gene. This protein is involved in chromatin remodeling and transcriptional regulation.","Nucleosome-Remodeling Factor Subunit BPTF | Bromodomain and PHD Domain Transcription Factor | Bromodomain and PHD Finger-Containing Transcription Factor | Fetal Alz-50 Clone 1 Protein | Fetal Alz-50 Reactive Clone 1 | Fetal Alzheimer Antigen | Nucleosome Remodeling Factor, Large Subunit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526370","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hands Are Weak","C138814","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: My child's hands are weak.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hands Are Weak | PQL08-Hands Are Weak | PQL0808",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526369","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard to Use Bathroom","C138815","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to use the bathroom.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard to Use Bathroom | PQL08-Hard to Use Bathroom | PQL0809",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525792","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Code Terminology","C138235","Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Code Terminology | PQL11TC | Pediatric Quality of Life Neuromuscular Module Acute Version 3 Young Adult Parent Report Questionnaire Test Code | QS-PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525799","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Name Terminology","C138236","Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Name Terminology | PQL17TN | Pediatric Quality of Life Neuromuscular Module Acute Version 3 Young Child Parent Report Questionnaire Test Name | QS-PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525798","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Code Terminology","C138237","Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Code Terminology | PQL17TC | Pediatric Quality of Life Neuromuscular Module Acute Version 3 Young Child Parent Report Questionnaire Test Code | QS-PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525797","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Name Terminology","C138238","Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Name Terminology | PQL12TN | Pediatric Quality of Life Neuromuscular Module Acute Version 3 Teen Questionnaire Test Name | QS-PedsQL Neuromuscular Module Acute Version 3.0 Teen Report TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525796","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Code Terminology","C138239","Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Code Terminology | PQL12TC | Pediatric Quality of Life Neuromuscular Module Acute Version 3 Teen Questionnaire Test Code | QS-PedsQL Neuromuscular Module Acute Version 3.0 Teen Report TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0682649","Proprioceptor","C13823","A primary sensory neuron that acts as a receptor of the somatic afferent component of the nervous system. It is stimulated by the contraction of muscles, movements of joints, and changes in body position.","Proprioceptor | Proprioceptive Sensory Neuron",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526129","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Wake Up Tired","C138671","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: I wake up tired.","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Wake Up Tired | PQL16-Wake Up Tired | PQL1607",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526128","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Hands Are Weak","C138672","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: My hands are weak.","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Hands Are Weak | PQL16-Hands Are Weak | PQL1608",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526135","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Hard to Use Bathroom","C138673","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: It is hard to use the bathroom.","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Hard to Use Bathroom | PQL16-Hard to Use Bathroom | PQL1609",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526134","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Hard to Gain or Lose Weight","C138674","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: It is hard to gain or lose weight when I want to.","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Hard to Gain or Lose Weight | PQL16-Hard to Gain/Lose Weight | PQL1610",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526133","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Hard to Use Hands","C138675","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: It is hard to use my hands.","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Hard to Use Hands | PQL16-Hard to Use Hands | PQL1611",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526132","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Hard to Swallow Food","C138676","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: It is hard to swallow food.","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Hard to Swallow Food | PQL16-Hard to Swallow Food | PQL1612",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526235","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Long Time to Bathe or Shower","C138677","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: It takes me a long time to bathe or shower.","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Long Time to Bathe or Shower | PQL16-Long Time to Bathe/Shower | PQL1613",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526234","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Get Hurt Accidentally","C138678","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: I get hurt accidentally.","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Get Hurt Accidentally | PQL16-Get Hurt Accidentally | PQL1614",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526233","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Take Long Time to Eat","C138679","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: I take a long time to eat.","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Take Long Time to Eat | PQL16-Take Long Time to Eat | PQL1615",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520200","Xq28","C13749","A chromosome band present on Xq","Xq28 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521463","5q11-q12","C13750","A chromosome band present on 5q","5q11-q12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520553","13q22-q34","C13751","A chromosome band present on 13q","13q22-q34 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521474","5q13-q14","C13752","A chromosome band present on 5q","5q13-q14 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521664","7q36.1","C13753","A chromosome band present on 7q","7q36.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520397","11q22-q23","C13754","A chromosome band present on 11q","11q22-q23 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520193","Xq25","C13755","A chromosome band present on Xq","Xq25 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524488","Bone Cancer by AJCC v8 Stage","C136612","A term that refers to the staging of appendicular skeleton, trunk, skull, and facial bones cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to osteosarcoma, chondrosarcoma, Ewing sarcoma, spindle cell sarcoma, hemangioendothelioma, angiosarcoma, fibrosarcoma/myofibroid sarcoma, chordoma, adamantinoma, and other cancers arising in the bone. It does not apply to primary malignant lymphoma of the bone and multiple myeloma. There are no AJCC prognostic stage groupings for spine and pelvis. (from AJCC 8th Ed.)","Bone Cancer by AJCC v8 Stage | Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524489","Stage I Bone Cancer AJCC v8","C136613","Stage I includes: IA: (T1, N0, M0, G1 or GX); IB: (T2, N0, M0, G1 or GX); (T3, N0, M0, G1 or GX). T1: Tumor measuring 8 cm or less in greatest dimension. T2: Tumor measuring more than 8 cm in greatest dimension. T3: Discontinuous tumors in the primary bone site. N0: No regional lymph node metastasis. M0: No distant metastasis. GX: Grade cannot be assessed. G1: Well differentiated, low grade. (AJCC 8th ed.)","Stage I Bone Cancer AJCC v8 | Stage I Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer AJCC v8 | Stage I Bone Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524486","Stage IA Bone Cancer AJCC v8","C136614","Stage IA includes: T1, N0, M0, G1 or GX. T1: Tumor measuring 8 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. GX: Grade cannot be assessed. G1: Well differentiated, low grade. (AJCC 8th ed.)","Stage IA Bone Cancer AJCC v8 | Stage IA Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer AJCC v8 | Stage IA Bone Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524487","Stage IB Bone Cancer AJCC v8","C136615","Stage IB includes: (T2, N0, M0, G1 or GX); (T3, N0, M0, G1 or GX). T2: Tumor measuring more than 8 cm in greatest dimension. T3: Discontinuous tumors in the primary bone site. N0: No regional lymph node metastasis. M0: No distant metastasis. GX: Grade cannot be assessed. G1: Well differentiated, low grade. (AJCC 8th ed.)","Stage IB Bone Cancer AJCC v8 | Stage IB Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer AJCC v8 | Stage IB Bone Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524492","Stage II Bone Cancer AJCC v8","C136616","Stage II includes: IIA: (T1, N0, M0, G2 or G3); IIB: (T2, N0, M0, G2 or G3). T1: Tumor measuring 8 cm or less in greatest dimension. T2: Tumor measuring more than 8 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. G2: Moderately differentiated, high grade. G3: Poorly differentiated, high grade. (AJCC 8th ed.)","Stage II Bone Cancer AJCC v8 | Stage II Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer AJCC v8 | Stage II Bone Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524493","Stage IIA Bone Cancer AJCC v8","C136617","Stage IIA includes: T1, N0, M0, G2 or G3. T1: Tumor measuring 8 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. G2: Moderately differentiated, high grade. G3: Poorly differentiated, high grade. (AJCC 8th ed.)","Stage IIA Bone Cancer AJCC v8 | Stage IIA Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer AJCC v8 | Stage IIA Bone Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524731","Merkel Cell Carcinoma by AJCC v7 Stage","C136869","A term that refers to the staging of Merkel cell carcinoma (primary cutaneous neuroendocrine carcinoma), following the rules of the TNM AJCC v7 classification system.","Cutaneous Merkel Cell Carcinoma by AJCC v7 Stage | Cutaneous Neuroendocrine Carcinoma of the Skin by AJCC v7 Stage | Merkel Cell Carcinoma by AJCC v7 Stage | Neuroendocrine Carcinoma of the Skin by AJCC v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521325","3q26.3-q27","C13686","A chromosome band present on 3q","3q26.3-q27 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524728","Merkel Cell Carcinoma by AJCC v8 Stage","C136870","A term that refers to the staging of Merkel cell carcinoma (primary cutaneous neuroendocrine carcinoma), following the rules of the TNM AJCC v8 classification system.","Cutaneous Merkel Cell Carcinoma by AJCC v8 Stage | Merkel Cell Carcinoma by AJCC v8 Stage | Neuroendocrine Carcinoma of the Skin by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524732","Clinical Stage II Merkel Cell Carcinoma AJCC v8","C136874","Stage II includes: IIA: (T2-3, N0, M0); IIB: (T4, N0, M0). T2: Maximum clinical tumor diameter more than 2 cm but equal to or less than 5 cm. T3: Maximum clinical tumor diameter more than 5 cm. T4: Primary tumor invades fascia, muscle, cartilage, or bone. N0: No regional lymph node metastasis detected on clinical and/or radiologic examination. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)","Clinical Stage II Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage II Merkel Cell Carcinoma AJCC v8 | Clinical Stage II Neuroendocrine Carcinoma of the Skin AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525803","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Name Terminology","C138240","Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Name Terminology | PQL10TN | Pediatric Quality of Life Neuromuscular Module Acute Version 3 Young Adult Questionnaire Test Name | QS-PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525802","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Code Terminology","C138241","Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Code Terminology | PQL10TC | Pediatric Quality of Life Neuromuscular Module Acute Version 3 Young Adult Questionnaire Test Code | QS-PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525801","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Name Terminology","C138242","Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Name Terminology | PQL16TN | Pediatric Quality of Life Neuromuscular Module Acute Version 3 Young Child Questionnaire Test Name | QS-PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525956","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Legs Hurt","C138468","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: My legs hurt.","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Legs Hurt | PQL14-Legs Hurt | PQL1404",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525931","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Feel Tired","C138469","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: I feel tired.","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Feel Tired | PQL14-Feel Tired | PQL1405",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521076","21q11.2","C13846","A chromosome band present on 21q","21q11.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525930","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Back Feels Stiff","C138470","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: My back feels stiff.","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Back Feels Stiff | PQL14-Back Feels Stiff | PQL1406",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525929","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Wake Up Tired","C138471","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: I wake up tired.","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Wake Up Tired | PQL14-Wake Up Tired | PQL1407",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525928","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hands Are Weak","C138472","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: My hands are weak.","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hands Are Weak | PQL14-Hands Are Weak | PQL1408",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525934","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard to Gain or Lose Weight","C138474","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: It is hard to gain or lose weight when I want to.","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard to Gain or Lose Weight | PQL14-Hard to Gain/Lose Weight | PQL1410",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520634","15q21.2","C13867","A chromosome band present on 15q","15q21.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526341","PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard Explain Illness to People","C138851","Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: It is hard for me to explain my illness to other people.","PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard Explain Illness to People | PQL03-Hard Explain Illness to People | PQL0320",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526340","PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard for Family to Plan Activities","C138852","Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: It is hard for my family to plan activities like vacations.","PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard for Family to Plan Activities | PQL03-Hard for Family to Plan Activities | PQL0321",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526315","PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard for Family to Rest","C138853","Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: It is hard for my family to get enough rest.","PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard for Family to Rest | PQL03-Hard for Family to Rest | PQL0322",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526314","PedsQL Neuromuscular Module Version 3.0 Teen Report - Money Problem in Our Family","C138854","Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: I think money is a problem in our family.","PedsQL Neuromuscular Module Version 3.0 Teen Report - Money Problem in Our Family | PQL03-Money Problem in Our Family | PQL0323",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526313","PedsQL Neuromuscular Module Version 3.0 Teen Report - Family Has Lot of Problems","C138855","Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: I think my family has a lot of problems.","PedsQL Neuromuscular Module Version 3.0 Teen Report - Family Has Lot of Problems | PQL03-Family Has Lot of Problems | PQL0324",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526312","PedsQL Neuromuscular Module Version 3.0 Teen Report - Do Not Have Equipment Need","C138856","Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: I do not have the equipment I need.","PedsQL Neuromuscular Module Version 3.0 Teen Report - Do Not Have Equipment Need | PQL03-Do Not Have Equipment Need | PQL0325",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526319","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard to Breathe","C138857","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: It is hard to breathe.","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard to Breathe | PQL01-Hard to Breathe | PQL0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526318","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Get Sick Easily","C138858","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: I get sick easily.","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Get Sick Easily | PQL01-Get Sick Easily | PQL0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521018","1q42.1-q43","C13885","A chromosome band present on 1q","1q42.1-q43 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526316","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Legs Hurt","C138860","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: My legs hurt.","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Legs Hurt | PQL01-Legs Hurt | PQL0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526323","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Feel Tired","C138861","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: I feel tired.","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Feel Tired | PQL01-Feel Tired | PQL0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524490","Stage IIB Bone Cancer AJCC v8","C136618","Stage IIB includes: T2, N0, M0, G2 or G3. T2: Tumor measuring more than 8 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. G2: Moderately differentiated, high grade. G3: Poorly differentiated, high grade. (AJCC 8th ed.)","Stage IIB Bone Cancer AJCC v8 | Stage IIB Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer AJCC v8 | Stage IIB Bone Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524491","Stage III Bone Cancer AJCC v8","C136619","Stage III includes: T3, N0, M0, G2 or G3. T3: Discontinuous tumors in the primary bone site. N0: No regional lymph node metastasis. M0: No distant metastasis. G2: Moderately differentiated, high grade. G3: Poorly differentiated, high grade. (AJCC 8th ed.)","Stage III Bone Cancer AJCC v8 | Stage III Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer AJCC v8 | Stage III Bone Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511573","Cyclic AMP Response Element","C13661","A promoter sequence which interacts with CRE binding proteins to modulate gene expression in response to the level of cAMP in the cell.","Cyclic AMP Response Element | CRE | cAMP Response Element",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524496","Stage IV Bone Cancer AJCC v8","C136620","Stage IV includes: IVA: (Any T, N0, M1a, Any G); IVB: (Any T, N1, Any M, Any G); (Any T, Any N, M1b, Any G). N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M1a: Metastasis in the lung. M1b: Metastasis in the bone or other distant sites. (AJCC 8th ed.)","Stage IV Bone Cancer AJCC v8 | Stage IV Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer AJCC v8 | Stage IV Bone Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524497","Stage IVA Bone Cancer AJCC v8","C136621","Stage IVA includes: Any T, N0, M1a, Any G. N0: No regional lymph node metastasis. M1a: Metastasis in the lung. (AJCC 8th ed.)","Stage IVA Bone Cancer AJCC v8 | Stage IVA Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer AJCC v8 | Stage IVA Bone Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524494","Stage IVB Bone Cancer AJCC v8","C136622","Stage IVB includes: (Any T, N1, Any M, Any G); (Any T, Any N, M1b, Any G). N1: Regional lymph node metastasis. M1b: Metastasis in the bone or other distant sites. (AJCC 8th ed.)","Stage IVB Bone Cancer AJCC v8 | Stage IVB Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer AJCC v8 | Stage IVB Bone Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521068","20q13.33","C13790","A chromosome band present on 20q","20q13.33 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524928","Interruption of Chemotherapy","C137910","Discontinuation of chemotherapy, most often due to toxicity or unacceptable side effects.","Interruption of Chemotherapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524914","Magnetic Resonance Imaging of the Abdomen and Pelvis with and without Contrast","C137911","Magnetic resonance imaging of the abdomen and pelvis, with and without the use of a contrast agent to enhance the image.","Magnetic Resonance Imaging of the Abdomen and Pelvis with and without Contrast | Abdominal/Pelvic MRI with and without Contrast | MRI of the Abdomen and Pelvis with and without Contrast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1960255","Magnetic Resonance Imaging of Bone","C137912","Magnetic resonance imaging of bone.","Magnetic Resonance Imaging of Bone | Bone MRI",,,,,,,,,,,,,,,"4137868","MRI of bone",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL524912","Magnetic Resonance Imaging of the Breast with and without Contrast","C137914","Magnetic resonance imaging of the breast with and without the use of a contrast agent to enhance the image.","Magnetic Resonance Imaging of the Breast with and without Contrast | Breast MRI with and without Contrast | Breast Magnetic Resonance Imaging with and without Contrast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0412692","Magnetic Resonance Imaging of the Heart","C137915","Magnetic resonance imaging of the heart.","Magnetic Resonance Imaging of the Heart | Cardiac MRI | Heart MRI",,,,,,,,,,,,,,,"4082987","Cardiac MRI",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL515639","Magnetic Resonance Imaging of the Chest with and without Contrast","C137916","Magnetic resonance imaging of the chest with and without the use of a contrast agent to enhance the image.","Magnetic Resonance Imaging of the Chest with and without Contrast | Chest MRI with and without Contrast | Chest Magnetic Resonance Imaging with and without Contrast",,,,,,,,,,,,,,,"36713045","MRI of chest without contrast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL524851","Pathologic Stage III Cutaneous Melanoma AJCC v8","C137670","Stage III includes: IIIA: (T1a/b-T2a, N1a or N2a, M0); IIIB: (T0, N1b, N1c, M0); (T1a/b-T2a, N1b/c or N2b, M0); (T2b/T3a, N1a-N2b, M0); IIIC: (T0, N2b, N2c, N3b or N3c); (T1a-T3a, N2c or N3a/b/c, M0); (T3b/T4a, Any N greater than or equal to N1, M0); (T4b, N1a-N2c, M0); IIID: (T4b, N3a/b/c, M0). T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. T0: No evidence of primary tumor (e.g., unknown primary or completely regressed melanoma). Thickness: Not applicable. Ulceration status: Not applicable. T2b: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: With ulceration. T3a: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: Without ulceration. T3b: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: With ulceration. T4a: Tumor measuring more than 4.0 mm in thickness. Ulceration status: Without ulceration. T4b: Tumor measuring more than 4.0 mm in thickness. Ulceration status: With ulceration.  N1a: One clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No.  N2a: Two or three clinically occult nodal metastases (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. N1b: One clinically detected nodal metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: No. N1c: No regional lymph node disease. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. N2b: Two or three nodal metastases at least one of which was clinically detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. N2c: One clinically occult nodal metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. N3b: Four or more nodal metastases, at least one of which was clinically detected, or presence of any number of matted nodes. Presence of in-transit, satellite, and/or microsatellite metastases: No. N3c: Two or more clinically occult nodal metastases. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. N3a: Four or more clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","Pathologic Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage III Melanoma of the Skin AJCC v8 | Stage III Cutaneous (Skin) Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525933","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard to Use Hands","C138475","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: It is hard to use my hands.","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard to Use Hands | PQL14-Hard to Use Hands | PQL1411",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525932","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard to Swallow Food","C138476","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: It is hard to swallow food.","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard to Swallow Food | PQL14-Hard to Swallow Food | PQL1412",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525939","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Long Time to Bathe or Shower","C138477","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: It takes me a long time to bathe or shower.","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Long Time to Bathe or Shower | PQL14-Long Time to Bathe/Shower | PQL1413",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525938","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Get Hurt Accidentally","C138478","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: I get hurt accidentally.","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Get Hurt Accidentally | PQL14-Get Hurt Accidentally | PQL1414",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525937","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Take Long Time to Eat","C138479","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: I take a long time to eat.","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Take Long Time to Eat | PQL14-Take Long Time to Eat | PQL1415",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520973","1p36.1","C13847","A chromosome band present on 1p","1p36.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526157","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard for Family to Plan Activities","C138635","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: It is hard for my family to plan activities like vacations.","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard for Family to Plan Activities | PQL12-Hard for Family to Plan Activities | PQL1221",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526156","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard for Family to Rest","C138636","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: It is hard for my family to get enough rest.","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard for Family to Rest | PQL12-Hard for Family to Rest | PQL1222",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526163","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Money Problem in Our Family","C138637","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: I think money is a problem in our family.","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Money Problem in Our Family | PQL12-Money Problem in Our Family | PQL1223",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526162","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Family Has Lot of Problems","C138638","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: I think my family has a lot of problems.","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Family Has Lot of Problems | PQL12-Family Has Lot of Problems | PQL1224",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521064","20q13.13","C13863","A chromosome band present on 20q","20q13.13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526322","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Back Feels Stiff","C138862","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: My back feels stiff.","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Back Feels Stiff | PQL01-Back Feels Stiff | PQL0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525742","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Questionnaire Question","C138277","A question associated with the PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report questionnaire.","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525740","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Questionnaire Question","C138279","A question associated with the PedsQL Neuromuscular Module Version 3.0 Parent of Toddler questionnaire.","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521188","2p23.3","C13827","A chromosome band present on 2p","2p23.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525747","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Questionnaire Question","C138280","A question associated with the PedsQL Neuromuscular Module Version 3.0 Parent Report for Child questionnaire.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525746","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Questionnaire Question","C138281","A question associated with the PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen questionnaire.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525745","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Questionnaire Question","C138282","A question associated with the PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report questionnaire.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525744","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Questionnaire Question","C138283","A question associated with the PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child questionnaire.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525750","PedsQL Neuromuscular Module Version 3.0 Young Adult Report Questionnaire Question","C138285","A question associated with the PedsQL Neuromuscular Module Version 3.0 Young Adult Report questionnaire.","PedsQL Neuromuscular Module Version 3.0 Young Adult Report Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525749","PedsQL Neuromuscular Module Version 3.0 Young Child Report Questionnaire Question","C138286","A question associated with the PedsQL Neuromuscular Module Version 3.0 Young Child Report questionnaire.","PedsQL Neuromuscular Module Version 3.0 Young Child Report Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525755","Cordonnier Bacterial Complication","C138288","Any bacterially-focused infection complications occurring in allogeneic stem cell transplant recipients.","Cordonnier Bacterial Complication | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515532","9q34.3","C13828","A chromosome band present on 9q","9q34.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525753","Cordonnier Viral Complication","C138290","Any virally-focused infection complications occurring in allogeneic stem cell transplant recipients.","Cordonnier Viral Complication | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525752","Cordonnier Parasitic Complication","C138291","Any parasite-focused infection complications occurring in allogeneic stem cell transplant recipients.","Cordonnier Parasitic Complication | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525851","Cordonnier Nonmicrobially-Defined Infection","C138292","Any nonmicrobally-defined infection complications occurring in allogeneic stem cell transplant recipients.","Cordonnier Nonmicrobially-Defined Infection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524915","Magnetic Resonance Imaging of the Head and Neck with and without Contrast","C137918","Magnetic resonance imaging of the head and neck with and without the use of a contrast agent to enhance the image.","Magnetic Resonance Imaging of the Head and Neck with and without Contrast | Head and Neck Magnetic Resonance Imaging with and without Contrast | Head/Neck MRI with and without Contrast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524919","Magnetic Resonance Imaging of an Area of Interest with and without Contrast","C137919","Magnetic resonance imaging of an anatomical area of interest with and without a contrast agent to enhance the image.","Magnetic Resonance Imaging of an Area of Interest with and without Contrast | MRI with and without Contrast of Area of Interest | Magnetic Resonance Imaging with and without Contrast of Area of Interest",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520286","10q24-q25.2","C13791","A chromosome band present on 10q","10q24-q25.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524918","Magnetic Resonance Imaging of the Neck with and without Contrast","C137920","Magnetic resonance imaging of the neck with and without a contrast agent to enhance the image.","Magnetic Resonance Imaging of the Neck with and without Contrast | MRI of the Neck with and without Contrast | Neck Computed Tomography with and without Contrast | Neck MRI with and without Contrast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524917","Magnetic Resonance Imaging of the Whole Body with and without Contrast","C137921","Magnetic resonance imaging of the whole body with and without the use of a contrast agent to enhance the image.","Magnetic Resonance Imaging of the Whole Body with and without Contrast | WB-MRI with and without Contrast | Whole Body MRI with and without Contrast | Whole Body Magnetic Resonance Imaging with and without Contrast | Whole-body MRI with and without Contrast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4075962","Low Dose Computed Tomography of the Chest","C137922","Computed tomography (CT) of the chest that uses less radiation than a standard chest CT.","Low Dose Computed Tomography of the Chest | LDCT | Low Dose Chest Computed Tomography | Low-dose Chest CT | Low-dose Chest Computed Tomography",,,,,,,,,,,,,,,"37017298","Low dose computed tomography of thorax",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL524923","Low Dose Computed Tomography of the Whole Body","C137923","Computed tomography (CT) of the whole body that uses less radiation than a standard CT.","Low Dose Computed Tomography of the Whole Body | Low-dose Whole-body CT | Whole Body Low Dose CT | Whole Body Low Dose Computed Tomography | Whole-body Low-dose CT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524922","Axillary Lymph Node Ultrasound","C137924","Ultrasound of one or more lymph nodes in the axillary area.","Axillary Lymph Node Ultrasound | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524920","Regional Lymph Node Ultrasound","C137926","An ultrasound of one or more lymph nodes in an anatomical area of interest.","Regional Lymph Node Ultrasound | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524653","Axl/Mer RTK Inhibitor ONO-7475","C136822","An orally available and selective inhibitor of the receptor tyrosine kinases (RTKs) Axl (UFO) and Mer, with potential antineoplastic activity. Upon administration, tamnorzatinib targets and binds to both Axl and Mer, and prevents their activity. This blocks Axl- and Mer-mediated signal transduction pathways, and inhibits proliferation and migration of Axl- and Mer-overexpressing tumor cells. Axl and Mer, both members of the TAM (Tyro3, Axl and Mer) family of RTKs, are overexpressed by many tumor cell types. They play key roles in tumor cell proliferation, survival, invasion, angiogenesis and metastasis, and their expression is associated with drug resistance and poor prognosis.","Tamnorzatinib | Axl/Mer Inhibitor ONO-7475 | Axl/Mer Inhibitor ONO-7475 | Axl/Mer RTK Inhibitor ONO-7475 | ONO 7475 | ONO-7475 | TAMNORZATINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521320","3q25.1-q26.1","C13666","A chromosome band present on 3q","3q25.1-q26.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524447","Soft Tissue Sarcoma of the Head and Neck Pathologic Regional Lymph Nodes TNM Finding v8","C136671","A pathologic finding about one or more characteristics of soft tissue sarcoma of the head and neck, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Soft Tissue Sarcoma of the Head and Neck Pathologic Regional Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524545","Soft Tissue Sarcoma of the Trunk and Extremities Clinical Distant Metastasis TNM Finding v8","C136676","A clinical finding about one or more characteristics of soft tissue sarcoma of the trunk and extremities, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Soft Tissue Sarcoma of the Trunk and Extremities Clinical Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524548","Soft Tissue Sarcoma of the Trunk and Extremities Pathologic TNM Finding v8","C136679","A pathologic finding about one or more characteristics of soft tissue sarcoma of the trunk and extremities, following the rules of the TNM AJCC v8 classification system.","Soft Tissue Sarcoma of the Trunk and Extremities Pathologic TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521410","4q31.1-q31.2","C13667","A chromosome band present on 4q","4q31.1-q31.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524549","Soft Tissue Sarcoma of the Trunk and Extremities Pathologic Distant Metastasis TNM Finding v8","C136680","A pathologic finding about one or more characteristics of soft tissue sarcoma of the trunk and extremities, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Soft Tissue Sarcoma of the Trunk and Extremities Pathologic Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526160","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard to Breathe","C138640","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: It is hard to breathe.","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard to Breathe | PQL10-Hard to Breathe | PQL1001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526167","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Get Sick Easily","C138641","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: I get sick easily.","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Get Sick Easily | PQL10-Get Sick Easily | PQL1002",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526166","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Get Sores and/or Rashes","C138642","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: I get sores and/or rashes.","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Get Sores and/or Rashes | PQL10-Get Sores and/or Rashes | PQL1003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526165","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Legs Hurt","C138643","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: My legs hurt.","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Legs Hurt | PQL10-Legs Hurt | PQL1004",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526164","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Feel Tired","C138644","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: I feel tired.","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Feel Tired | PQL10-Feel Tired | PQL1005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526139","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Back Feels Stiff","C138645","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: My back feels stiff.","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Back Feels Stiff | PQL10-Back Feels Stiff | PQL1006",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526138","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Wake Up Tired","C138646","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: I wake up tired.","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Wake Up Tired | PQL10-Wake Up Tired | PQL1007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526368","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard to Gain or Lose Weight","C138816","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to gain or lose weight when he or she wants to.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard to Gain or Lose Weight | PQL08-Hard to Gain/Lose Weight | PQL0810",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526375","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard to Use Hands","C138817","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to use his or her hands.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard to Use Hands | PQL08-Hard to Use Hands | PQL0811",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526374","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard to Swallow Food","C138818","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to swallow food.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard to Swallow Food | PQL08-Hard to Swallow Food | PQL0812",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521400","4q25-q27","C13679","A chromosome band present on 4q","4q25-q27 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524572","Soft Tissue Sarcoma of the Retroperitoneum Pathologic Primary Tumor TNM Finding v8","C136800","A pathologic finding about one or more characteristics of soft tissue sarcoma of the retroperitoneum, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Soft Tissue Sarcoma of the Retroperitoneum Pathologic Primary Tumor TNM Finding v8 | Retroperitoneal Soft Tissue Sarcoma Pathologic Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0967625","Antibody-drug Conjugate SC-004","C136807","An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody directed against claudin-6 (CLDN6; CLDN-6) and claudin-9 (CLDN9; CLDN-9) linked to a cytotoxic pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of anti-CLDN6/9 ADC SC-004 targets and binds to CLDN6/9 expressed on tumor cells, and the PBD moiety is released. Then the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of CLDN6/9-overexpressing tumor cells. CLDN6, a transmembrane tight-junction protein and embryonic antigen, is overexpressed on a variety of tumor cells but is not expressed on normal, healthy adult cells. CLDN6 and CLDN9 differ at only 3 out of 76 residues in their extracellular loops, and CLDN9 is highly expressed in some normal tissues in addition to some tumors.","Anti-CLDN6/9 Antibody-drug Conjugate SC-004 | ADC SC-004 | Anti-CLDN6/9 ADC SC-004 | Antibody-drug Conjugate SC-004 | SC 004 | SC-004 | SC004",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0724532","Therapeutic Human Antithrombin-III","C136824","A form of the human glycoprotein antithrombin-III (AT-III), which is produced recombinantly or isolated from human plasma, with anticoagulant activity. Upon administration, antithrombin-III binds to and blocks thrombin activity, and prevents thrombus formation.","Therapeutic Human Antithrombin-III | ANTITHROMBIN III HUMAN | AT-III | AT-III (Human) | Antithrombin | Antithrombin III | Antithrombin-III | Human AT-III | Thrombate III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524657","Spitz Melanocytoma","C136825","A junctional or compound melanocytic neoplasm not fulfilling the histopathologic criteria of melanoma but with one of the following features: asymmetry, predominance of single melanocytes over nests in lesions 4 mm or larger, ulceration, large dermal sheets of melanocytes, lack of maturation in dermis, deep dermal mitotic figures, extensive involvement of subcutis, and nuclear pleomorphism. (Mod Pathol 2006;19: S21)","Spitz Melanocytoma | AST | Atypical Spitz Nevus | Atypical Spitz Nevus | Atypical Spitz Tumor | Atypical Spitz Tumor of Uncertain Malignant Potential | Melanocytic Tumor of Unknown Malignant Potential | Pagetoid Spitz Nevus | STUMP | Spindle and Epithelioid Cell Nevus with Atypia and Metastasis | Spitz Tumor with One or More Atypical Features | Spitzoid Tumor of Uncertain Malignant Potential",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524656","Regimen Used to Treat Retinoblastoma","C136826","Any regimen that can be used for the treatment of retinoblastoma.","Regimen Used to Treat Retinoblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524660","Calcium Release-activated Channels Inhibitor RP4010","C136828","A calcium (Ca2+) release-activated channel (CRAC) inhibitor, with potential antineoplastic activity. Upon administration, RP4010 binds to and inhibits CRACs, thereby preventing the transport of extracellular Ca2+ into the cell and inhibiting the subsequent activation of Ca2+-mediated signaling and transcription of target genes. CRACs, specialized plasma membrane Ca2+ ion channels composed of the plasma membrane based Orai channels and the endoplasmic reticulum (ER) stromal interaction molecules (STIMs), play key roles in calcium homeostasis and are over-activated in a number of cancer cell types. Aberrant activation of CRACs leads to increased cancer cell proliferation.","Calcium Release-activated Channels Inhibitor RP4010 | CRAC Inhibitor RP4010 | RP 4010 | RP-4010 | RP4010",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1564779","Heat-Shock Proteins, Small","C136829","A family of chaperone proteins with subunit molecular masses of 12-43 kDa. The members are characterized by the presence of a highly conserved stretch of 80-100 amino acids in their C-terminal domains called the alpha-crystallin domain (ACD). Class I small heat shock proteins (sHsps) are widely expressed and play a role in cell survival. Class II sHsps are expressed in tissue-specific patterns and may be involved in the differentiation, development and specific functionality for the tissues they are expressed in.","Small Heat Shock Protein | HSPB | Heat Shock Protein Family B | Heat Shock Protein Family B (Small) | Small Heat Shock Protein Family | sHSP Family | sHsp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521102","22q11-q13","C13757","A chromosome band present on 22q","22q11-q13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521298","3p26.2","C13758","A chromosome band present on 3p","3p26.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521015","1q42-q43","C13759","A chromosome band present on 1q","1q42-q43 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL405470","Guanidinium Cation","C1375","The cationic form and conjugate acid of the strongly basic compound guanidine.","Guanidinium Cation | Guanidinium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521471","5q12.2-q13.3","C13760","A chromosome band present on 5q","5q12.2-q13.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521313","3q22.1","C13761","A chromosome band present on 3q","3q22.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426518","RRAGD Gene","C137971","This gene plays a role in both GTP-binding and mTOR complex 1 (mTORC1) signaling.","RRAGD Gene | RRAGD | Ras Related GTP Binding D Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524967","RRAGD wt Allele","C137972","Human RRAGD wild-type allele is located in the vicinity of 6q15 and is approximately 48 kb in length. This allele, which encodes Ras-related GTP-binding protein D, is involved in both mTOR complex 1 (mTORC1) signaling and GTP-binding.","RRAGD wt Allele | DKFZP761H171 | RAGD | Ras Related GTP Binding D wt Allele | bA11D8.2.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0967699","RRAGD protein, human","C137973","Ras-related GTP-binding protein D (400 aa, ~46 kDa) is encoded by the human RRAGD gene. This protein plays a role in both GTP-binding and lysosomal localization of mTOR complex 1 (mTORC1).","Ras-Related GTP-Binding Protein D | RAS-Related GTP Binding D | RRAGD | Rag D | Rag D Protein | RagD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416777","LAMA3 Gene","C137975","This gene is involved in cell-matrix adhesion and cell migration.","LAMA3 Gene | LAMA3 | Laminin Subunit Alpha 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524950","LAMA3 wt Allele","C137976","Human LAMA3 wild-type allele is located in the vicinity of 18q11.2 and is approximately 266 kb in length. This allele, which encodes laminin subunit alpha-3 protein, plays a role in cell-matrix attachment.","LAMA3 wt Allele | BM600 | E170 | Epiligrin, 170-kD Subunit Gene | LAM3, Alpha-3 Subunit Gene | LAMNA | LOCS | Laminin 5, Alpha-3 Subunit Gene | Laminin Subunit Alpha 3 wt Allele | Laminin, Alpha 3 (Nicein (150kD), Kalinin (165kD), BM600 (150kD), Epilegrin) Gene | Laminin, Alpha 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524949","Laminin Subunit Alpha-3","C137977","Laminin subunit alpha-3 (3333 aa, ~367 kDa) is encoded by the human LAMA3 gene. This protein is involved in both cell-matrix adhesion and the organization of the extracellular matrix.","Laminin Subunit Alpha-3 | BM600 150kD Subunit | E170 | Epiligrin 170 kDa Subunit | Epiligrin Alpha 3 Subunit | Epiligrin Subunit Alpha | Kalinin 165kD Subunit | Kalinin Subunit Alpha | LAMA3 | Laminin A3 | Laminin-5 Subunit Alpha | Laminin-6 Subunit Alpha | Laminin-7 Subunit Alpha | Nicein 150kD Subunit | Nicein Subunit Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1427633","SESN1 Gene","C137978","This gene plays a role in leucine binding and the regulation of stress response signaling.","SESN1 Gene | SESN1 | Sestrin 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524953","SESN1 wt Allele","C137979","Human SESN1 wild-type allele is located in the vicinity of 6q21 and is approximately 108 kb in length. This allele, which encodes sestrin-1 protein, is involved in stress response signaling.","SESN1 wt Allele | PA26 | SEST1 | Sestrin 1 wt Allele | p53 Activated Gene 26",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520936","1p13.1","C13797","A chromosome band present on 1p","1p13.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524952","Sestrin-1","C137980","Sestrin-1 (492 aa, ~57 kDa) is encoded by the human SESN1 gene. This protein plays a role in leucine sensing.","Sestrin-1 | EC 1.11.1.- | SESN1 | Sestrin 1 | p53 Regulated PA26 Nuclear Protein | p53-Regulated Protein PA26",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420591","TAX1BP1 Gene","C137981","This gene is involved in the inhibition of apoptosis.","TAX1BP1 Gene | TAX1BP1 | Tax1 Binding Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524951","TAX1BP1 wt Allele","C137982","Human TAX1BP1 wild-type allele is located in the vicinity of 7p15.2 and is approximately 105 kb in length. This allele, which encodes Tax1-binding protein 1, plays a role in apoptosis inhibition.","TAX1BP1 wt Allele | CALCOCO3 | PRO0105 | T6BP | TXBP151 | Tax1 (Human T-Cell Leukemia Virus Type I) Binding Protein 1 Gene | Tax1 Binding Protein 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525113","Tax1-Binding Protein 1","C137983","Tax1-binding protein 1 (789 aa, ~91 kDa) is encoded by the human TAX1BP1 gene. This protein is involved in the inhibition of tumor necrosis factor-induced apoptosis.","Tax1-Binding Protein 1 | Human T-Cell Leukemia Virus Type 1-Binding Protein | TAX1BP1 | TRAF6-Binding Protein | Tax1 Binding Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810054","APELA Gene","C137984","This gene plays a role in endoderm differentiation, heart development and angiogenesis.","APELA Gene | APELA | Apelin Receptor Early Endogenous Ligand Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526373","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Long Time to Bathe or Shower","C138819","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: It takes my child a long time to bathe or shower.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Long Time to Bathe or Shower | PQL08-Long Time to Bathe/Shower | PQL0813",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526372","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Get Hurt Accidentally","C138820","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: My child gets hurt accidentally.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Get Hurt Accidentally | PQL08-Get Hurt Accidentally | PQL0814",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526347","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Take Long Time to Eat","C138821","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: My child takes a long time to eat.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Take Long Time to Eat | PQL08-Take Long Time to Eat | PQL0815",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526346","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard to Turn During Night","C138822","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to turn him or herself during the night.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard to Turn During Night | PQL08-Hard to Turn During Night | PQL0816",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526345","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard to Go Places With Equipment","C138823","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to go places with his or her equipment.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard to Go Places With Equipment | PQL08-Hard to Go Places With Equipment | PQL0817",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526351","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard Ask Doctors and Nurses Questions","C138825","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to ask the doctors and nurses questions.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard Ask Doctors and Nurses Questions | PQL08-Hard Ask Doctors/Nurses Questions | PQL0819",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526350","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard Explain Illness to People","C138826","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to explain his or her illness to other people.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard Explain Illness to People | PQL08-Hard Explain Illness to People | PQL0820",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525800","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Code Terminology","C138243","Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Code Terminology | PQL16TC | Pediatric Quality of Life Neuromuscular Module Acute Version 3 Young Child Questionnaire Test Code | QS-PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524670","Soft Tissue Sarcoma of the Retroperitoneum Pathologic Regional Lymph Nodes TNM Finding v8","C136808","A pathologic finding about one or more characteristics of soft tissue sarcoma of the retroperitoneum, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Soft Tissue Sarcoma of the Retroperitoneum Pathologic Regional Lymph Nodes TNM Finding v8 | Retroperitoneal Soft Tissue Sarcoma Pathologic Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520626","15q15-q21.1","C13680","A chromosome band present on 15q","15q15-q21.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2933578","RFWD3 protein, human","C138093","E3 ubiquitin-protein ligase RFWD3 (774 aa, ~85 kDa) is encoded by the human RFWD3 gene. This protein is involved in the ubiquitination of proteins that regulate the DNA damage checkpoint during the cell cycle.","E3 Ubiquitin-Protein Ligase RFWD3 | EC 2.3.2.27 | RFWD3 | RING Finger Protein 201 | RING Finger and WD Repeat Domain-Containing Protein 3 | RING Finger and WD Repeat Domains-Containing Protein 3 | RING-Type E3 Ubiquitin Transferase RFWD3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419320","RBP4 Gene","C138096","This gene plays a role in retinol transport.","RBP4 Gene | RBP4 | Retinol Binding Protein 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525062","RBP4 wt Allele","C138097","Human RBP4 wild-type allele is located in the vicinity of 10q23.33 and is approximately 10 kb in length. This allele, which encodes retinol-binding protein 4, is involved in the transport of retinol. Mutation of the gene is associated with both isolated microphthalmia with coloboma and retinal dystrophy, iris coloboma and comedogenic acne syndrome.","RBP4 wt Allele | MCOPCB10 | PRO2222 | RDCCAS | Retinol Binding Protein 4 wt Allele | Retinol Binding Protein 4, Plasma Gene | Retinol-Binding Protein 4, Interstitial Gene | Retinol-Binding Protein 4, Plasma Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1438309","RBP4 protein, human","C138098","Retinol-binding protein 4 (201 aa, ~23 kDa) is encoded by the human RBP4 gene. This protein plays a role in retinol transport.","Retinol-Binding Protein 4 | PRBP | Plasma Retinol-Binding Protein | RBP4 | Retinol Binding Protein 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1136039","Nuclear Lamina","C13809","The nuclear lamina is a proteinaceous filamentous meshwork of lamin proteins interacting with integral proteins of the inner nuclear membrane, including emerin, and is thought to play a role in nuclear stability, chromatin structure, and gene expression. Lamins are highly conserved in evolution and members of the intermediate filament protein family. Mammalian lamins are classified into two major types, A and B, with two subspecies of each: lamins A and C for the A type and B1 and B2 for the B type. Lamins A and C arise from one gene by alternative splicing. Pre-lamin A contains a carboxyl CAAX box that can be modified by farnesylation. During mitosis, the lamina meshwork is reversibly disassembled in parallel with phosphorylation of the lamins.","Nuclear Lamina | ",,,,,,,,,,,,,,,"4298817","Nuclear fibrous lamina",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1521227","2q35","C13763","A chromosome band present on 2q","2q35 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524751","Cutaneous Melanoma by AJCC v8 Stage","C137645","A term that refers to the staging of cutaneous melanoma, following the rules of the TNM AJCC v8 classification system. This staging system does not apply to melanoma of the conjunctiva, melanoma of the uvea, mucosal melanoma arising in the head and neck, and mucosal melanoma of the urethra, vagina, rectum, and anus. (from AJCC 8th Ed.)","Cutaneous Melanoma by AJCC v8 Stage | Melanoma of the Skin by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524468","Small Cell Lung Carcinoma Transformation","C136624","A term that usually refers to the histological transformation of EGFR mutation-positive lung non-small cell carcinoma to small cell carcinoma in response to treatment with tyrosine kinase inhibitors, resulting in resistance to first-line tyrosine kinase inhibitors. It may also refer to rare cases of lung adenocarcinoma carrying KRAS G12C mutation that are transformed into small cell carcinoma before treatment.","Small Cell Lung Carcinoma Transformation | Lung Adenocarcinoma Transformation | SCLC Transformation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524954","APELA wt Allele","C137985","Human APELA wild-type allele is located in the vicinity of 4q32.3 and is approximately 22 kb in length. This allele, which encodes apelin receptor early endogenous ligand protein, is involved in apelin receptor binding and in the development of the heart and cardiovascular system.","APELA wt Allele | Apelin Receptor Early Endogenous Ligand wt Allele | ELA | ELABELA | Ende | LOC100506013 | Toddler Gene | tdl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525114","Apelin Receptor Early Endogenous Ligand","C137986","Apelin receptor early endogenous ligand (54 aa, ~7 kDa) is encoded by the human APELA gene. This protein plays a role in heart and cardiovascular system development.","Apelin Receptor Early Endogenous Ligand | APELA | ELA | Protein Elabela | Protein Toddler",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520489","12q12-q13","C13687","A chromosome band present on 12q","12q12-q13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524741","Pathologic Stage II Merkel Cell Carcinoma AJCC v8","C136883","Stage II includes: IIA: (T2-3, N0, M0); IIB: (T4, N0, M0). T2: Maximum clinical tumor diameter more than 2 cm but equal to or less than 5 cm. T3: Maximum clinical tumor diameter more than 5 cm. T4: Primary tumor invades fascia, muscle, cartilage, or bone. N0: No regional lymph node metastasis detected on pathologic examination. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)","Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage II Merkel Cell Carcinoma AJCC v8 | Pathologic Stage II Neuroendocrine Carcinoma of the Skin AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525775","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Name Terminology","C138244","Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Name Terminology | PQL05TN | Pediatric Quality of Life Neuromuscular Module Version 3 Child Questionnaire Test Name | QS-PedsQL Neuromuscular Module Version 3.0 Child Report TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525774","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Code Terminology","C138245","Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Code Terminology | PQL05TC | Pediatric Quality of Life Neuromuscular Module Version 3 Child Questionnaire Test Code | QS-PedsQL Neuromuscular Module Version 3.0 Child Report TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525773","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Name Terminology","C138246","Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Name Terminology | PQL09TN | Pediatric Quality of Life Neuromuscular Module Version 3 Toddler Parent Report Questionnaire Test Name | QS-PedsQL Neuromuscular Module Version 3.0 Parent of Toddler TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525772","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Code Terminology","C138247","Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Code Terminology | PQL09TC | Pediatric Quality of Life Neuromuscular Module Version 3 Toddler Parent Report Questionnaire Test Code | QS-PedsQL Neuromuscular Module Version 3.0 Parent of Toddler TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525778","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Code Terminology","C138249","Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Code Terminology | PQL06TC | Pediatric Quality of Life Neuromuscular Module Version 3 Child Parent Report Questionnaire Test Code | QS-PedsQL Neuromuscular Module Version 3.0 Parent Report for Child TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027871","Muscle Spindle","C13824","The Muscle Spindle is composed of intrafusal fibers that are located within and run parallel to the extrafusal fibers of skeletal muscle. When the extrafusal fibers are stretched, the intrafusal fibers of the spindle stretch as well. When stretching occurs, the sensory neuron from the muscle spindle signals the motor neurons located within the ventral horn of the spinal cord. This signal causes the motor neurons to fire, resulting in contraction of the muscle. This reflex arc provides negative feedback. The muscular contraction induced by the stretching works against or negates further muscle stretch. This mechanism helps to maintain proper muscle tension or tone. Although the muscle spindle helps to maintain proper muscle tension, unlike the Golgi tendon organ, it is not an indicator of muscle tension, but rather of muscle length.","Muscle Spindle | Muscle Spindles",,,,,,,,,,,,,,,"4045091","Muscle spindle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL525777","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Name Terminology","C138250","Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Name Terminology | PQL04TN | Pediatric Quality of Life Neuromuscular Module Version 3 Teen Parent Report Questionnaire Test Name | QS-PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525936","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard to Turn During Night","C138480","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: It is hard to turn myself during the night.","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard to Turn During Night | PQL14-Hard to Turn During Night | PQL1416",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1524115","Recombinant Interleukin-12","C1380","A recombinant form of the endogenous heterodimeric cytokine interleukin-12 with potential antineoplastic activity.  Edodekin alfa binds to and activates its cell-surface receptor, stimulating the production of interferon-gamma (IFN) which, in turn, induces IFN-gamma-inducible protein-10 (IP-10) and so inhibits tumor angiogenesis. (NCI04)","Edodekin alfa | Cytotoxic Lymphocyte Maturation Factor | EDODEKIN ALFA | IL-12 | Interleukin 12 | Interleukin-12 | NM-IL-12 | Natural Killer Cell Stimulatory Factor | Recombinant human interleukin-12 (IL-12) cytokine | Ro 24-7472 | interleukin-12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0248241","CEF regimen","C138100","A regimen consisting of oral cyclophosphamide, epirubicin and fluorouracil, used as a treatment for recurrent and metastatic breast cancer.","CEF Regimen | CEF | Fluorouracil-Epirubicin-Oral Cytoxan Regimen | Fluorouracil/Epirubicin/Oral Cyclophosphamide | Oral CTX/EPI/5-FU | Oral Cyclophosphamide/Epirubicin/Fluorouracil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419100","PTPN2 Gene","C138101","This gene is involved in the dephosphorylation of receptor tyrosine kinases.","PTPN2 Gene | PTPN2 | Protein Tyrosine Phosphatase, Non-Receptor Type 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525063","PTPN2 wt Allele","C138102","Human PTPN2 wild-type allele is located in the vicinity of 18p11.21 and is approximately 144 kb in length. This allele, which encodes tyrosine-protein phosphatase non-receptor type 2 protein, plays a role in the modulation of receptor phosphorylation.","PTPN2 wt Allele | PTN2 | PTPT | Protein Tyrosine Phosphatase, Non-Receptor Type 2 wt Allele | Protein-Tyrosine Phosphatase, T-Cell Gene | TC-PTP | TCELLPTP | TCPTP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1869329","PTPN2 protein, human","C138103","Tyrosine-protein phosphatase non-receptor type 2 (415 aa, ~48 kDa) is encoded by the human PTPN2 gene. This protein is involved in the removal of phosphate groups from receptor tyrosine kinase proteins.","Tyrosine-Protein Phosphatase Non-Receptor Type 2 | EC 3.1.3.48 | PTPN2 | T-Cell Protein Tyrosine Phosphatase | T-Cell Protein-Tyrosine Phosphatase | TCPTP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417672","NEK2 Gene","C138104","This gene plays a role in protein phosphorylation and the cell cycle.","NEK2 Gene | NEK2 | NIMA Related Kinase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514771","Recombinant Fibroblast Growth Factor 5","C1370","A recombinant form of the heparin-binding fibroblast growth factor 5 (FGF-5).  FGF-5 may function as a growth factor during embryogenesis and may have a role in wound repair throughout adulthood because of its mitogenic effects on fibroblasts and endothelial cells.  Overexpressed in certain tumor cell types, this agent may promote tumor growth and angiogenesis. (NCI04)","Recombinant Fibroblast Growth Factor 5 | FGF5 | HBGF-5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521297","3p26-p25","C13710","A chromosome band present on 3p","3p26-p25 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521214","2q31-q33","C13712","A chromosome band present on 2q","2q31-q33 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518159","Male Genital System Fluid or Secretion","C13713","Sperm and the fluid it is suspended in.","Male Genital System Fluid or Secretion | Genital System, Male, Fluids, Secretions | Male Genital System Fluids and Secretions | Sperm, Fluids, Secretions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521500","5q35.1","C13714","A chromosome band present on 5q","5q35.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512886","Internal Ribosome Entry Site","C13716","Internal ribosome entry site (IRES) is a translational cis-acting element that directs ribosomes to the start codon by a cap-independent mechanism.  IRESs are usually about 450 nucleotides in length and were first identified in picornavirus RNAs.  IRESs can fold into a stable secondary hairpin structure to be incompatible with efficient translation by ribosomal scanning. (NCI)","Internal Ribosome Entry Site | IRES | Ribosome Entry Site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512575","Hypoxia-Responsive Elements","C13718","DNA sequences in a gene's promoter region that mediate expression during hypoxia.  Since unlike normal tissues, solid tumors frequently have regions of hypoxia, suicide genes controlled by hypoxia-responsive elements may provide a means for cancer-specific gene therapy.","Hypoxia-Responsive Elements | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524476","Bone Sarcoma by AJCC v7 Stage","C136632","A term that refers to the staging of bone sarcoma, following the rules of the TNM AJCC v7 classification system.","Bone Sarcoma by AJCC v7 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524477","Osteosarcoma by AJCC v7 Stage","C136633","A term that refers to the staging of osteosarcoma, following the rules of the TNM AJCC v7 classification system.","Osteosarcoma by AJCC v7 Stage | Primary Bone Osteosarcoma by AJCC v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524979","X-ray of an Area of Interest","C137927","An X-ray of an anatomical area of interest.","X-ray of an Area of Interest | Area of Interest X-ray | X-ray Imaging of Area of Interest",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524712","Pathologic Stage III Merkel Cell Carcinoma AJCC v8","C136886","Stage III includes: IIIA: (T1-4, N1a(sn) or N1a, M0); (T0, N1b, M0); IIIB: (T1-4, N1b-3, M0). T0: No evidence of primary tumor. T1: Maximum clinical tumor diameter equal to or less than 2 cm. T2: Maximum clinical tumor diameter more than 2 cm but equal to or less than 5 cm. T3: Maximum clinical tumor diameter more than 5 cm. T4: Primary tumor invades fascia, muscle, cartilage, or bone. N1a(sn): Clinically occult regional lymph node metastasis identified only by sentinel lymph node biopsy. N1a: Clinically occult regional lymph node metastasis following lymph node dissection. N1b: Clinically and/or radiologically detected regional lymph node metastasis, microscopically confirmed. N2: In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) without lymph node metastasis. N3: In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) with lymph node metastasis. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)","Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage III Merkel Cell Carcinoma AJCC v8 | Pathologic Stage III Neuroendocrine Carcinoma of the Skin AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524829","Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","C137673","Stage IIIC includes: (T0, N2b, N2c, N3b or N3c); (T1a-T3a, N2c or N3a/b/c, M0); (T3b/T4a, Any N greater than or equal to N1, M0); (T4b, N1a-N2c, M0). T0: No evidence of primary tumor (e.g., unknown primary or completely regressed melanoma). Thickness: Not applicable. Ulceration status: Not applicable. T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. T2b: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: With ulceration. T3a: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: Without ulceration. T3b: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: With ulceration. T4a: Tumor measuring more than 4.0 mm in thickness. Ulceration status: Without ulceration. T4b: Tumor measuring more than 4.0 mm in thickness. Ulceration status: With ulceration.  N2b: Two or three nodal metastases at least one of which was clinically detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. N2c: One clinically occult nodal metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. N3b: Four or more nodal metastases, at least one of which was clinically detected, or presence of any number of matted nodes. Presence of in-transit, satellite, and/or microsatellite metastases: No. N3c: Two or more clinically occult nodal metastases. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. N3a: Four or more clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. N1a: One clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. N1b: One clinically detected nodal metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: No. N1c: No regional lymph node disease. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. N2a: Two or three clinically occult nodal metastases (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)","Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Melanoma of the Skin AJCC v8 | Stage IIIC | Stage IIIC Cutaneous (Skin) Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525943","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard to Go Places With Equipment","C138481","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: It is hard for me to go places with my equipment.","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard to Go Places With Equipment | PQL14-Hard to Go Places With Equipment | PQL1417",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525942","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard Tell Doctors and Nurses How Feel","C138482","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: It is hard for me to tell the doctors and nurses how I feel.","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard Tell Doctors and Nurses How Feel | PQL14-Hard Tell Doctors/Nurses How Feel | PQL1418",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525941","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard Ask Doctors and Nurses Questions","C138483","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: It is hard for me to ask the doctors and nurses questions.","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard Ask Doctors and Nurses Questions | PQL14-Hard Ask Doctors/Nurses Questions | PQL1419",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525940","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard Explain Illness to People","C138484","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: It is hard for me to explain my illness to other people.","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard Explain Illness to People | PQL14-Hard Explain Illness to People | PQL1420",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526043","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard for Family to Plan Activities","C138485","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: It is hard for my family to plan activities like vacations.","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard for Family to Plan Activities | PQL14-Hard for Family to Plan Activities | PQL1421",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526042","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard for Family to Rest","C138486","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: It is hard for my family to get enough rest.","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard for Family to Rest | PQL14-Hard for Family to Rest | PQL1422",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526041","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Money Problem in Our Family","C138487","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: I think money is a problem in our family.","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Money Problem in Our Family | PQL14-Money Problem in Our Family | PQL1423",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526047","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Do Not Have Equipment Need","C138489","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: I do not have the equipment I need.","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Do Not Have Equipment Need | PQL14-Do Not Have Equipment Need | PQL1425",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520494","12q13.1","C13848","A chromosome band present on 12q","12q13.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526046","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard to Breathe","C138490","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to breathe.","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard to Breathe | PQL18-Hard to Breathe | PQL1801",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512142","ETS Domain","C13719","Usually C-terminal, the conserved ETS (Erythroblast Transformation Specific) Domain of 85-90 amino acids, rich in positively-charged and aromatic residues, binds to purine-rich DNA with a GGAA/T core. Identified in many transcription factors, many ETS-proteins modulate gene expression through protein-protein interactions with other transcriptional factors and co-factors. Most ETS-proteins are nuclear targets of RAS-MAPK signaling; some affect cell proliferation or apoptosis-related genes. Several are expressed in specific cell lineages to regulate development and differentiation. Deregulated ETS-gene expression or chimeric ETS-proteins are associated with leukemias, some tumors, invasion and metastasis. (NCI)","ETS Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0118171","Fosquidone","C1371","A water-soluble pentacyclic pyrolloquinone analogue of mitoquidone with potential antineoplastic activity. Currently, the mechanism of action of fosquidone is unknown. In vitro studies indicate that this agent does not bind to DNA or inhibit topoisomerases.","Fosquidone | FOSQUIDONE | GR 63178A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522002","RNA Recognition Motif","C13720","RNA Binding Domains (RBD) mediate the interaction of RNAs with RNA-binding proteins. RBDs of about 90 amino acids consist of a four-stranded beta sheet adjacent to two alpha helixes. Within RBDs, conserved RNP-1 and RNP-2 motifs on the central beta sheets lie side by side; their side chains contact RNA.","RNA Recognition Motif | Putative RNA-Binding Region | RBD | RNA Binding Domain | RNP Domain | RNP Motif | RNP-1 Signature | RRM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515557","bZIP Domain","C13721","Bipartite DNA binding domain containing a basic region directly interacting with DNA, and a leucine zipper mediating dimerization through contacts with a protein partner.","bZIP Domain | Basic Leucine Zipper",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514899","Respiratory System Fluid or Secretion","C13722","Fluids and secretions relating to the respiratory system.","Respiratory System Fluid or Secretion | Respiratory System Fluid and Secretion | Respiratory System Fluids and Secretions | Respiratory System-Fluids, Secretions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516385","Central DNA Flap Sequence","C13724","In Lentivirus, a central strand displacement event consecutive to central initiation and termination of plus strand synthesis creates a plus strand overlap: the central DNA flap.  This feature promotes efficient nuclear import and viral replication in non-dividing cells. (from Cell 2000;101:173-85)","Central DNA Flap Sequence | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524940","Autologous CD19 CAR+ EGFRt + CD4+ and CD8+ T Cells","C137866","A preparation of a defined ratio of CD4+ and CD8+ autologous T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-CD19 single chain variable fragment (scFv), derived from the CD19-specific murine immunoglobulin (Ig) G1 monoclonal antibody FMC63, fused to the signaling domain of CD28, the zeta chain of the TCR/CD3 complex (CD3-zeta), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, the autologous CD19 CAR+ EGFRt + CD4+ and CD8+ T-cells are directed to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a cetuximab-induced antibody dependent cellular cytotoxicity (ADCC) response.","Autologous CD19 CAR+ EGFRt + CD4+ and CD8+ T Cells | Autologous Anti-CD19CAR-CD28-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0420264","Repeat Previous Treatment","C137867","Following primary therapy, administration of a second course of therapy.","Repeat Previous Treatment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524944","FDG-Positron Emission Tomography/Computed Tomography of an Area of Interest","C137868","Positron emission tomography combined with computed tomography of an anatomical area of interest with the use of the contrast agent fludeoxyglucose F 18 (18F-FDG) to enhance the image.","FDG-Positron Emission Tomography/Computed Tomography of an Area of Interest | Area of Interest 18F FDG PET/CT | Area of Interest FDG-PET/CT | Area of Interest FDG-Positron Emission Tomography/Computed Tomography | FDG PET/CT Area of Interest | PET/CT, Area of Interest, FDG | Positron Emission Tomography/Computed Tomography, Area of Interest, FDG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524978","X-ray of Primary Site","C137928","An X-ray of the primary site.","X-ray of Primary Site | Primary Site X-ray | X-ray Imaging of Primary Site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524977","Magnetic Resonance Imaging of the Abdomen with and without Contrast","C137929","Magnetic resonance imaging of the abdomen with and without the use of a contrast agent to enhance the image.","Magnetic Resonance Imaging of the Abdomen with and without Contrast | Abdominal MRI with and without Contrast | MRI of the Abdomen with and without Contrast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524976","Multiphasic Magnetic Resonance Imaging of the Abdomen","C137930","Multiphasic magnetic resonance imaging of the abdomen.","Multiphasic Magnetic Resonance Imaging of the Abdomen | Abdominal MRI, Multiphasic | Multiphasic MRI of the Abdomen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524982","Multiphasic Magnetic Resonance imaging of the Abdomen and Pelvis","C137931","Multiphasic magnetic resonance imaging of the abdomen and pelvis.","Multiphasic Magnetic Resonance imaging of the Abdomen and Pelvis | Abdominal/Pelvic MRI, Multiphasic | Multiphasic MRI of the Abdomen and Pelvis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524981","Magnetic Resonance Imaging of Skeletal Metastatic Sites with Contrast","C137932","Magnetic resonance imaging of skeletal metastatic sites with the use of a contrast agent to enhance the image.","Magnetic Resonance Imaging of Skeletal Metastatic Sites with Contrast | MRI of Skeletal Metastatic Sites with Contrast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524980","Magnetic Resonance Imaging of the Pelvis with and without Contrast","C137933","Magnetic resonance imaging of the pelvis with and without the use of a contrast agent to enhance the image.","Magnetic Resonance Imaging of the Pelvis with and without Contrast | MRI of the Pelvis with and without Contrast | Pelvic MRI with and without Contrast | Pelvic Magnetic Resonance Imaging with and without Contrast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1300768","Supraclavicular Lymph Node Biopsy","C137935","Removal or sampling of lymph nodes in the supraclavicular area.","Supraclavicular Lymph Node Biopsy | ",,,,,,,,,,,,,,,"4288938","Supraclavicular lymph node biopsy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL524984","Superior Vena Cava Stent Placement","C137936","Placement of a stent in the superior vena cava.","Superior Vena Cava Stent Placement | SVC Stenting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524983","Bilateral Diagnostic Mammogram","C137937","Mammography of both breasts for the purpose of diagnosis of disease.","Bilateral Diagnostic Mammogram | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1960432","Status of Correlation between Radiographic Image and Pathologic Finding","C137938","A qualifier used to describe the agreement between radiographic and pathologic findings.","Status of Correlation between Radiographic Image and Pathologic Finding | Correlation between Radiological and Pathological Findings",,,,,,,,,,,,,,,"4144142","Status of correlation between radiographic image and pathologic finding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1960401","Radiographic Image Correlates with Tumor Pathology Finding","C137939","An indication that the results from radiographic and pathological testing correlate.","Radiographic Image Correlates with Tumor Pathology Finding | Rradiographic Findings Correlate with Histologic Findings",,,,,,,,,,,,,,,"4139999","Radiographic image correlates with tumor pathology finding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1521465","5q11.2-q13.1","C13793","A chromosome band present on 5q","5q11.2-q13.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524986","Risk Assessment for Hereditary Breast Cancer","C137941","Assessment of an individual's specific predispositions for hereditary breast cancer, such as presence of a gene mutation.","Risk Assessment for Hereditary Breast Cancer | Assessment of Risk of Hereditary Breast Cancer | Genetic/Familial Assessment of Risk of Breast Cancer | Hereditary Breast Cancer Risk Assessment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524985","Risk Assessment for Thromboembolism","C137942","Analysis of risk factors that affect the development of thromboembolism, such as age or comorbidities.","Risk Assessment for Thromboembolism | Assessment of Risk of Thromboembolism | Thromboembolism Risk Assessment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524968","Patient Decision","C137943","A position, opinion or judgment reached after consideration by a patient.","Patient Decision | Patient's Decision",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2586154","Patient Intends to Continue Pregnancy","C137944","An indication that a patient intends to continue pregnancy.","Patient Intends to Continue Pregnancy | Intends to Continue Pregnancy | Intent to Continue Pregnancy",,,,,,,,,,,,,,,"4231507","Intends to continue pregnancy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3846374","Stage IIID","C137676","Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites. The definition of stage IIID depends on the particular type of cancer that it refers to; for example, for cutaneous melanoma, stage IIID is defined as follows: T4b, N3a/b/c, M0. T4b: Tumor measuring more than 4.0 mm in thickness. Ulceration status: With ulceration. N3a: Four or more clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. N3b: Four or more nodal metastases, at least one of which was clinically detected, or presence of any number of matted nodes. Presence of in-transit, satellite, and/or microsatellite metastases: No. N3c: Two or more clinically occult nodal metastases. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. M0: No evidence of distant metastasis. LDH level is not applicable. (partially adapted from AJCC 8th ed.)","Stage IIID | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521206","2q21","C13767","A chromosome band present on 2q","2q21 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524530","Soft Tissue Sarcoma of the Trunk and Extremities Pathologic Regional Lymph Nodes TNM Finding v8","C136689","A pathologic finding about one or more characteristics of soft tissue sarcoma of the trunk and extremities, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Soft Tissue Sarcoma of the Trunk and Extremities Pathologic Regional Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521662","7q35-q36","C13668","A chromosome band present on 7q","7q35-q36 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524529","Soft Tissue Sarcoma by AJCC v8 Stage","C136693","A term that refers to the staging of soft tissue sarcoma, following the rules of the TNM AJCC v8 classification system.","Soft Tissue Sarcoma by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526137","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hands Are Weak","C138647","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: My hands are weak.","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hands Are Weak | PQL10-Hands Are Weak | PQL1008",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526136","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard to Use Bathroom","C138648","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: It is hard to use the bathroom.","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard to Use Bathroom | PQL10-Hard to Use Bathroom | PQL1009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526143","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard to Gain or Lose Weight","C138649","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: It is hard to gain or lose weight when I want to.","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard to Gain or Lose Weight | PQL10-Hard to Gain/Lose Weight | PQL1010",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521182","2p16.3","C13864","A chromosome band present on 2p","2p16.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526142","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard to Use Hands","C138650","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: It is hard to use my hands.","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard to Use Hands | PQL10-Hard to Use Hands | PQL1011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526141","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard to Swallow Food","C138651","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: It is hard to swallow food.","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard to Swallow Food | PQL10-Hard to Swallow Food | PQL1012",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526140","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Long Time to Bathe or Shower","C138652","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: It takes me a long time to bathe or shower.","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Long Time to Bathe or Shower | PQL10-Long Time to Bathe/Shower | PQL1013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526147","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Get Hurt Accidentally","C138653","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: I get hurt accidentally.","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Get Hurt Accidentally | PQL10-Get Hurt Accidentally | PQL1014",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526146","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Take Long Time to Eat","C138654","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: I take a long time to eat.","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Take Long Time to Eat | PQL10-Take Long Time to Eat | PQL1015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526151","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard Tell Doctors and Nurses How Feel","C138657","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: It is hard for me to tell the doctors and nurses how I feel.","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard Tell Doctors and Nurses How Feel | PQL10-Hard Tell Doctors/Nurses How Feel | PQL1018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524943","FDG-Positron Emission Tomography/Computed Tomography from the Skull Base to Mid-thigh","C137869","Positron emission tomography combined with computed tomography of the region encompassing the skull base to the mid-thigh with the use of the contrast agent fludeoxyglucose F 18 (18F-FDG) to enhance the image.","FDG-Positron Emission Tomography/Computed Tomography from the Skull Base to Mid-thigh | FDG PET/CT Skull Base to Mid-thigh | PET/CT, Skull Base to Mid-thigh, FDG | Positron Emission Tomography/Computed Tomography, Skull Base to Mid-thigh, FDG | Skull Base to Mid-thigh 18F FDG PET/CT | Skull Base to Mid-thigh FDG-PET/CT | Skull Base to Mid-thigh FDG-Positron Emission Tomography/Computed Tomography | Skull Base to Mid-thigh PET/CT Scan with FDG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520708","16q24.3","C13786","A chromosome band present on 16q","16q24.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL515656","Magnetic Resonance Imaging of the Pelvis without Contrast","C137870","Magnetic resonance imaging of the pelvis without the use of a contrast agent.","Magnetic Resonance Imaging of the Pelvis without Contrast | MRI of the Pelvis without Contrast | Pelvic MRI without Contrast | Pelvic Magnetic Resonance Imaging without Contrast",,,,,,,,,,,,,,,"36713204","MRI of pelvis without contrast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL524945","Magnetic Resonance Imaging of the Whole Body without Contrast","C137871","Magnetic resonance imaging of the entire body of a patient without the use of a contrast agent.","Magnetic Resonance Imaging of the Whole Body without Contrast | WB-MRI without Contrast | Whole Body MRI without Contrast | Whole Body Magnetic Resonance Imaging without Contrast | Whole-body MRI without Contrast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL515624","Magnetic Resonance Imaging of the Abdomen and Pelvis without Contrast","C137873","Magnetic resonance imaging of the abdomen and pelvis, without the use of a contrast agent.","Magnetic Resonance Imaging of the Abdomen and Pelvis without Contrast | Abdominal/Pelvic MRI without Contrast | MRI of the Abdomen and Pelvis without Contrast",,,,,,,,,,,,,,,"36713235","MRI of abdomen and pelvis without contrast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL515634","Magnetic Resonance Imaging of the Brain without Contrast","C137874","Magnetic resonance imaging of the brain without the use of a contrast agent.","Magnetic Resonance Imaging of the Brain without Contrast | Brain MRI without Contrast | Brain Magnetic Resonance Imaging without Contrast | Head MRI without Contrast",,,,,,,,,,,,,,,"36713262","MRI of brain without contrast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL524948","Magnetic Resonance Imaging of the Breast without Contrast","C137875","Magnetic resonance imaging of the breast without the use of a contrast agent.","Magnetic Resonance Imaging of the Breast without Contrast | Breast MRI without Contrast | Breast Magnetic Resonance Imaging without Contrast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524947","Bone Radiography","C137876","Radiographic imaging of bone.","Bone Radiography | Bone Radiograph",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524946","Staging of Lung Cancer to Rule Out Progression","C137877","Staging of lung cancer using invasive and/or imaging modalities to assess progression of disease.","Staging of Lung Cancer to Rule Out Progression | Lung Staging to Rule Out Progression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524931","Multiphasic Computed Tomography of the Abdomen","C137879","Multiphasic computed tomography of the abdomen.","Multiphasic Computed Tomography of the Abdomen | Abdominal CT, Multiphasic | Multiphasic CT of the Abdomen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515449","8q12-q13","C13787","A chromosome band present on 8q","8q12-q13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2315935","Computed Tomography of the Abdomen and Pelvis with Contrast","C137880","Computed tomography of the abdomen and pelvis with the use of a contrast agent to enhance the image.","Computed Tomography of the Abdomen and Pelvis with Contrast | Abdominal/Pelvic CT with Contrast | CT of the Abdomen and Pelvis with Contrast",,,,,,,,,,,,,,,"4335400","Computed tomography of abdomen and pelvis with contrast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2029583","Computed Tomography of the Brain with Contrast","C137882","Computed tomography of the brain with the use of a contrast agent to enhance the image.","Computed Tomography of the Brain with Contrast | Brain CT with Contrast | Head CT with Contrast",,,,,,,,,,,,,,,"46272801","CT of head with contrast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0581121","Patient Requests Pregnancy Termination","C137945","An indication that a patient requests to terminate pregnancy.","Patient Requests Pregnancy Termination | Intent to Terminate Pregnancy | Patient Intends to Terminate Pregnancy | Patients Decides to Discontinue Pregnancy | Requests Pregnancy Termination",,,,,,,,,,,,,,,"4086797","Requests pregnancy termination",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1520300","10q26","C13682","A chromosome band present on 10q","10q26 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524658","COL4A3 Gene Product","C136830","A protein encoded by the COL4A3 gene.","COL4A3 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524659","Skin Cancer TNM Finding v8","C136831","A finding about one or more characteristics of skin cancer, following the rules of the TNM AJCC v8 classification system. It applies to Merkel cell carcinoma and melanoma of the skin. (from AJCC 8th Ed.)","Skin Cancer TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524664","Merkel Cell Carcinoma Clinical TNM Finding v8","C136833","A clinical finding about one or more characteristics of Merkel cell carcinoma, following the rules of the TNM AJCC v8 classification system.","Merkel Cell Carcinoma Clinical TNM Finding v8 | Neuroendocrine Carcinoma of the Skin Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520843","19p13.1-p12","C13683","A chromosome band present on 19p","19p13.1-p12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524643","Merkel Cell Carcinoma Clinical Primary Tumor TNM Finding v8","C136840","A clinical finding about one or more characteristics of Merkel cell carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Merkel Cell Carcinoma Clinical Primary Tumor TNM Finding v8 | Neuroendocrine Carcinoma of the Skin Clinical Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524535","NUP98 Gene Product","C136695","A protein encoded by the NUP98 gene.","NUP98 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524533","Nuclear Pore Complex Protein Nup98-Nup96","C136697","Nuclear pore complex protein Nup98-Nup96 (1817 aa, ~198 kDa) is encoded by the human NUP98 gene. This protein may play a role in nuclear pore complex assembly and bidirectional transport across the nuclear pore complex.","Nuclear Pore Complex Protein Nup98-Nup96 | NUP196 | NUP98-NUP96 Precursor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515505","9p22.3","C13669","A chromosome band present on 9p","9p22.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524958","Carbon C 11 Glutamine","C137987","Upon intravenous administration of 11C-glutamine, glutamine is preferentially taken up by cancer cells. Upon PET, the biodistribution and uptake by cancer cells can be assessed. Tumor cells use the amino acid glutamine for nutritional purposes including energy production and growth; as tumor cells proliferate more rapidly than normal healthy cells, glutamine uptake is higher in certain cancer cells.","Carbon C 11 Glutamine | 11C-Gln | 11C-glutamine | GLUTAMINE 5-C-11 | [11C]-glutamine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524957","FLT3 Inhibitor FF-10101 Succinate","C137988","The succinate salt form of FF-10101, a FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2) inhibitor, with potential antineoplastic activity. Upon administration of FLT3 inhibitor FF-10101 succinate (FF-10101-01), FF-10101 irreversibly binds to and inhibits the activity of FLT3. This inhibits the proliferation of FLT3-expressing cancer cells. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B lineage neoplasms and in acute myeloid leukemias.","FLT3 Inhibitor FF-10101 Succinate | FF-10101 Succinate | FF-10101-01 | FF10101 Succinate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524956","Mcl-1 Inhibitor AZD5991","C137989","An inhibitor of induced myeloid leukemia cell differentiation protein (myeloid cell leukemia-1; Mcl-1; Bcl2-L-3), with potential pro-apoptotic and antineoplastic activities. Upon administration, AZD5991 binds to Mcl-1, thereby preventing the binding of Mcl-1 to and inactivation of certain pro-apoptotic proteins, and promoting apoptosis of cells overexpressing Mcl-1. Mcl-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival.","Mcl-1 Inhibitor AZD5991 | AZD-5991 | AZD5991 | MCL1 Inhibitor AZD5991",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521568","6q22.1-q22.3","C13798","A chromosome band present on 6q","6q22.1-q22.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524955","Mcl-1 Inhibitor","C137990","Any agent that inhibits Mcl-1.","Mcl-1 Inhibitor | Mcl1 Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526150","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard Ask Doctors and Nurses Questions","C138658","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: It is hard for me to ask the doctors and nurses questions.","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard Ask Doctors and Nurses Questions | PQL10-Hard Ask Doctors/Nurses Questions | PQL1019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526349","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard for Family to Plan Activities","C138827","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: It is hard for our family to plan activities like vacations.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard for Family to Plan Activities | PQL08-Hard for Family to Plan Activities | PQL0821",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526348","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard for Family to Rest","C138828","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: It is hard for our family to get enough rest.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard for Family to Rest | PQL08-Hard for Family to Rest | PQL0822",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526355","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Money Problem in Our Family","C138829","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: I think money is a problem in our family.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Money Problem in Our Family | PQL08-Money Problem in Our Family | PQL0823",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520759","17q11-q21.3","C13882","A chromosome band present on 17q","17q11-q21.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526353","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Do Not Have Equipment Need","C138831","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: My child does not have the equipment he or she needs.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Do Not Have Equipment Need | PQL08-Do Not Have Equipment Need | PQL0825",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526352","PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard to Breathe","C138832","Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: It is hard to breathe.","PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard to Breathe | PQL03-Hard to Breathe | PQL0301",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526359","PedsQL Neuromuscular Module Version 3.0 Teen Report - Get Sick Easily","C138833","Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: I get sick easily.","PedsQL Neuromuscular Module Version 3.0 Teen Report - Get Sick Easily | PQL03-Get Sick Easily | PQL0302",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526358","PedsQL Neuromuscular Module Version 3.0 Teen Report - Get Sores and/or Rashes","C138834","Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: I get sores and/or rashes.","PedsQL Neuromuscular Module Version 3.0 Teen Report - Get Sores and/or Rashes | PQL03-Get Sores and/or Rashes | PQL0303",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526357","PedsQL Neuromuscular Module Version 3.0 Teen Report - Legs Hurt","C138835","Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: My legs hurt.","PedsQL Neuromuscular Module Version 3.0 Teen Report - Legs Hurt | PQL03-Legs Hurt | PQL0304",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526356","PedsQL Neuromuscular Module Version 3.0 Teen Report - Feel Tired","C138836","Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: I feel tired.","PedsQL Neuromuscular Module Version 3.0 Teen Report - Feel Tired | PQL03-Feel Tired | PQL0305",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2316455","Computed Tomography of the Chest, Abdomen and Pelvis with Contrast","C137885","Computed tomography of the chest, abdomen and pelvis with the use of a contrast agent to enhance the image.","Computed Tomography of the Chest, Abdomen and Pelvis with Contrast | Chest/Abdominal/Pelvic CT with Contrast",,,,,,,,,,,,,,,"4200610","CT of thorax, abdomen and pelvis with contrast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL524932","Computed Tomography of Skeletal Metastases with Contrast","C137886","Computed tomography of sites with skeletal metastases with the use of a contrast agent to enhance the image.","Computed Tomography of Skeletal Metastases with Contrast | CT of Skeletal Metastatic Sites with Contrast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524937","Computed Tomography of a Primary Disease Site with Contrast","C137887","Computed tomography of the primary site of a disease with the use of a contrast agent to enhance the image.","Computed Tomography of a Primary Disease Site with Contrast | CT with Contrast of Primary Site | Computed Tomography of Primary Site with Contrast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524936","Computed Tomography of an Anatomical Site of Interest with Contrast","C137888","Computed tomography of an anatomical site of interest with the use of a contrast agent to enhance the image.","Computed Tomography of an Anatomical Site of Interest with Contrast | CT with Contrast of Area of Interest | Computed Tomography of an Area of Interest with Contrast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524935","Computed Tomography of the Inguinal Region with Contrast","C137889","Computed tomography of the inguinal region with the use of a contrast agent to enhance the image.","Computed Tomography of the Inguinal Region with Contrast | CT with Contrast of Inguinal Region | Inguinal Region CT with Contrast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520180","Xq11-q13","C13788","A chromosome band present on Xq","Xq11-q13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524934","Computed Tomography of a Lymph Node Basin with Contrast","C137890","Computed tomography of one or more lymphatic basins with the use of a contrast agent to enhance the image.","Computed Tomography of a Lymph Node Basin with Contrast | CT with Contrast of the Nodal Basin | Lymphatic Basin CT with Contrast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524939","Computed Tomography of the Neck, Chest, Abdomen and Pelvis with Contrast","C137893","Computed tomography of the neck, chest, abdomen and pelvis with the use of a contrast agent to enhance the image.","Computed Tomography of the Neck, Chest, Abdomen and Pelvis with Contrast | CT Scan of the Neck/Chest/Abdomen/Pelvis with Contrast | Neck/Chest/Abdominal/Pelvic CT with Contrast | Neck/Chest/Abdominal/Pelvic Computed Tomography with Contrast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL527551","Computed Tomography of the Abdomen without Contrast","C137895","Computed tomography of the abdomen without the use of a contrast agent.","Computed Tomography of the Abdomen without Contrast | Abdominal CT without Contrast | CT of the Abdomen without Contrast",,,,,,,,,,,,,,,"37109313","CT of abdomen without contrast",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL525045","NEK2 wt Allele","C138105","Human NEK2 wild-type allele is located in the vicinity of 1q32.3 and is approximately 17 kb in length. This allele, which encodes serine/threonine-protein kinase Nek2 protein, is involved in both the cell cycle and protein phosphorylation. Mutation of the gene may be associated with retinitis pigmentosa.","NEK2 wt Allele | HsPK21 | NEK2A | NIMA (Never In Mitosis Gene A)-Related Kinase 2 Gene | NIMA Related Kinase 2 wt Allele | NLK1 | Never In Mitosis Gene A-Related Kinase 2 Gene | PPP1R111 | RP67 | s Protein Phosphatase 1, Regulatory Subunit 111 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1505136","NEK2 protein, human","C138106","Serine/threonine-protein kinase Nek2 (445 aa, ~52 kDa) is encoded by the human NEK2 gene. This protein plays a role in chromosome dynamics during cell division.","Serine/Threonine-Protein Kinase Nek2 | EC 2.7.11.1 | HsPK 21 | NIMA-Related Kinase 2 | Never In Mitosis A-Related Kinase 2 | NimA-Like Protein Kinase 1 | NimA-Related Protein Kinase 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515448","8q11.2","C13765","A chromosome band present on 8q","8q11.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525031","ABBV 176","C137991","An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against the prolactin receptor (PRLR) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration of rolinsatamab talirine, rolinsatamab targets and binds to PRLR expressed on tumor cells. Upon binding and internalization, talirine is released and kills the PRLR-expressing tumor cells, through an as of yet unknown mechanism of action. PRLR, a tumor-associated antigen (TAA), is overexpressed by a variety of tumor cell types.","Rolinsatamab Talirine | ABBV 176 | ABBV-176 | ABBV176 | ADC ABBV-176 | ROLINSATAMAB TALIRINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525033","Integra Dermal Regeneration Template","C137997","A proprietary bilayer membrane system for skin replacement. It is composed of a dermal replacement layer made of a porous matrix of cross-linked bovine tendon collagen and glycosaminoglycan manufactured with a controlled porosity and defined degradation rate, and an epidermal substitute layer made of polysiloxane silicone to control moisture loss from the wound.","Integra Dermal Regeneration Template | Integra Dermal Substitute | Integra Template",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526331","PedsQL Neuromuscular Module Version 3.0 Teen Report - Back Feels Stiff","C138837","Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: My back feels stiff.","PedsQL Neuromuscular Module Version 3.0 Teen Report - Back Feels Stiff | PQL03-Back Feels Stiff | PQL0306",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526330","PedsQL Neuromuscular Module Version 3.0 Teen Report - Wake Up Tired","C138838","Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: I wake up tired.","PedsQL Neuromuscular Module Version 3.0 Teen Report - Wake Up Tired | PQL03-Wake Up Tired | PQL0307",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525783","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Name Terminology","C138252","Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Name Terminology | PQL02TN | Pediatric Quality of Life Neuromuscular Module Version 3 Young Adult Parent Report Questionnaire Test Name | QS-PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525782","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Code Terminology","C138253","Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Code Terminology | PQL02TC | Pediatric Quality of Life Neuromuscular Module Version 3 Young Adult Parent Report Questionnaire Test Code | QS-PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525781","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Name Terminology","C138254","Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Name Terminology | PQL08TN | Pediatric Quality of Life Neuromuscular Module Version 3 Young Child Parent Report Questionnaire Test Name | QS-PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525780","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Code Terminology","C138255","Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Code Terminology | PQL08TC | Pediatric Quality of Life Neuromuscular Module Version 3 Young Child Parent Report Questionnaire Test Code | QS-PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525787","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Name Terminology","C138256","Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Name Terminology | PQL03TN | Pediatric Quality of Life Neuromuscular Module Version 3 Teen Questionnaire Test Name | QS-PedsQL Neuromuscular Module Version 3.0 Teen Report TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525786","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Code Terminology","C138257","Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Code Terminology | PQL03TC | Pediatric Quality of Life Neuromuscular Module Version 3 Teen Questionnaire Test Code | QS-PedsQL Neuromuscular Module Version 3.0 Teen Report TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412475","APOC1 Gene","C138108","This gene is involved in lipid transport and metabolism.","APOC1 Gene | APOC1 | Apolipoprotein C1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525047","APOC1 wt Allele","C138109","Human APOC1 wild-type allele is located in the vicinity of 19q13.32 and is approximately 5 kb in length. This allele, which encodes apolipoprotein C-I protein, plays a role in the metabolism and transport of lipids.","APOC1 wt Allele | Apo-CI | Apo-CIB | ApoC-I | ApoC-IB | Apolipoprotein C1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0608460","human APOC1","C138110","Apolipoprotein C-I (83 aa, ~9 kDa) is encoded by the human APOC1 gene. This protein is involved in the regulation of lipid transport and metabolism.","Apolipoprotein C-I | APOC1 | Apo-CI | ApoC-I | Apolipoprotein C1 | Apolipoprotein CI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425291","TRPV4 Gene","C138111","This gene plays a role in the regulation of osmotic pressure.","TRPV4 Gene | TRPV4 | Transient Receptor Potential Cation Channel Subfamily V Member 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525046","TRPV4 wt Allele","C138112","Human TRPV4 wild-type allele is located in the vicinity of 12q24.11 and is approximately 50 kb in length. This allele, which encodes transient receptor potential cation channel subfamily V member 4 protein, is involved in calcium transport and osmotic pressure regulation. Mutation of the gene is associated with various osmotic, skeletal and neuromuscular disorders.","TRPV4 wt Allele | BCYM3 | CMT2C | HMSN2C | OTRPC4 | SMAL | SPSMA | SSQTL1 | TRP12 | Transient Receptor Potential Cation Channel Subfamily V Member 4 wt Allele | Transient Receptor Potential Cation Channel, Subfamily V, Member 4 Gene | Transient Receptor Potential, Drosophila, Homolog of, 12 Gene | VRL2 | VROAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0962567","TRPV4 protein, human","C138115","Transient receptor potential cation channel subfamily V member 4 (871 aa, ~98 kDa) is encoded by the human TRPV4 gene. This protein plays a role in the modulation of calcium transport.","Transient Receptor Potential Cation Channel Subfamily V Member 4 | OSM9-Like Transient Receptor Potential Channel 4 | Osm-9-Like TRP Channel 4 | Osmosensitive Transient Receptor Potential Channel 4 | TRPV4 | Transient Receptor Potential Channel 12 | Transient Receptor Potential Protein 12 | Vanilloid Receptor-Like Channel 2 | Vanilloid Receptor-Like Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517336","G-Quartets","C13725","G-quadruplexes are multi-stranded structures held together by square planes of four guanines ('G-quartets') interacting by forming Hoogsteen hydrogen bonds. G-quartet structures has been developed as novel anti-HIV agents. Several critical structure-activity relationships between HIV-1 integrase and G-quartet oligonucleotides have been demonstrated.","G-Quartets | G-Quadruplex | G-Quadruplexes | G-Quadruplexes DNA | G-Quartet Structures | G-Tetrads | G4-DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519125","SANT Domain","C13663","The SANT domain is found in several transcriptional regulatory proteins identified through consistent homology to the c-MYB repeat DNA binding domain, suggesting that SANT domains also bind DNA. Folded into three alpha helices as doublets or singlets in many proteins, the SANT domain family specifically recognizes the sequence YAAC(G/T)G. The SANT domain is a repeated motif in N-CoR, the nuclear receptor co-repressor. Single copies of SANT occur in yeast nuclear chromatin remodeling proteins SWI3 (SWI/SNF transcription subunit), ADA2 (ADA adaptor/HAT complex), and a TFIIIB transcription subunit. SANT domains may mediate functional interactions with histone N-terminal tails. (NCI)","SANT Domain | MYB-Like DNA-Binding Domain | SWI3/ADA2/N-CoR/TFIIIB Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521105","22q11.21","C13688","A chromosome band present on 22q","22q11.21 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524716","Neratinib Maleate","C136891","The maleate salt form of neratinib, an orally available, quinazoline-based, irreversible inhibitor of both the receptor tyrosine kinases (RTKs) human epidermal growth factor receptor 2 (HER2; ERBB2) and human epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, neratinib targets and covalently binds to the cysteine residue in the ATP-binding pockets of both HER2 and EGFR. This inhibits their activity and results in the inhibition of downstream signal transduction events, induces cell cycle arrest, apoptosis and ultimately decreases cellular proliferation in HER2- and EGFR-expressing tumor cells. EGFR and HER2, RTKs that are mutated or overactivated in many tumor cell types, play key roles in tumor cell proliferation and tumor vascularization.","Neratinib Maleate | 2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-, (2Z)-2-butenedioate (1:1) | HKI-272 Maleate | NERATINIB MALEATE | NERATINIB MALEATE ANHYDROUS | Nerlynx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524722","Cutaneous Melanoma Clinical TNM Finding v8","C136893","A clinical finding about one or more characteristics of cutaneous melanoma, following the rules of the TNM AJCC v8 classification system.","Cutaneous Melanoma Clinical TNM Finding v8 | Melanoma of the Skin Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525785","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Name Terminology","C138258","Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Name Terminology | PQL01TN | Pediatric Quality of Life Neuromuscular Module Version 3 Young Adult Questionnaire Test Name | QS-PedsQL Neuromuscular Module Version 3.0 Young Adult Report TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525784","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Code Terminology","C138259","Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Code Terminology | PQL01TC | Pediatric Quality of Life Neuromuscular Module Version 3 Young Adult Questionnaire Test Code | QS-PedsQL Neuromuscular Module Version 3.0 Young Adult Report TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520681","16p12","C13825","A chromosome band present on 16p","16p12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526045","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Get Sick Easily","C138491","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: My child gets sick easily.","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Get Sick Easily | PQL18-Get Sick Easily | PQL1802",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526044","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Get Sores and/or Rashes","C138492","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: My child gets sores and/or rashes.","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Get Sores and/or Rashes | PQL18-Get Sores and/or Rashes | PQL1803",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526051","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Legs Hurt","C138493","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: My child's legs hurt.","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Legs Hurt | PQL18-Legs Hurt | PQL1804",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526050","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Feel Tired","C138494","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: My child feels tired.","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Feel Tired | PQL18-Feel Tired | PQL1805",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526049","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Back Feels Stiff","C138495","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: My child's back feels stiff.","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Back Feels Stiff | PQL18-Back Feels Stiff | PQL1806",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526048","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Wake Up Tired","C138496","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: My child wakes up tired.","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Wake Up Tired | PQL18-Wake Up Tired | PQL1807",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526055","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hands Are Weak","C138497","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: My child's hands are weak.","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hands Are Weak | PQL18-Hands Are Weak | PQL1808",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520953","1p32-q12","C13726","A chromosome band present on 1p","1p32-q12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520644","15q23-q25","C13728","A chromosome band present on 15q","15q23-q25 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521081","21q22.2","C13729","A chromosome band present on 21q","21q22.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521387","4q13-q21","C13730","A chromosome band present on 4q","4q13-q21 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511331","Bromodomain","C13732","A motif common in chromatin remodeling factors. It consists of approximately 110 amino acids in a left-handed up-and-down four helix bundle with a left handed twist. A hydrophobic pocket in the bromodomain creates an acetyl-lysine binding domain. Bromodomain-containing proteins may recruit remodeling complexes to acetylated chromatin regions.","Bromodomain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521460","5p15.33","C13733","A chromosome band present on 5p","5p15.33 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230613","Zonula Adherens","C13736","The best understood cell-cell junction required for adhesion between cells in the epithelium. It seals adjacent epithelial cells together, preventing the passage of most dissolved molecules from one side of the epithelial sheet to the other. Adherens junctions are located most apically in insect cells and just basal to the tight junction in vertebrate cells. It is formed by the fusion of adjacent cell membranes which encircle the apical cell surface like a belt or fence based on homophilic association between molecules of the transmembrane protein E-cadherin, which is linked on its cytoplasmic side to the actin cytoskeleton via b-catenin (Drosophila Armadillo) and a-catenin. The adherens junctions and associated cytoskeleton form a continuous band (zonula adherens) around the apical circumference of each cell, thus uniting the cells of the epithelium into a coherent sheet.","Zonula Adherens | AJ | Adherens Junction | Intermediate Junction",,,,,,,,,,,,,,,"4149356","Intermediate junction",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL524462","Relapsed Cervical Squamous Cell Carcinoma","C136649","The reemergence of cervical squamous cell carcinoma after a period of remission.","Recurrent Cervical Squamous Cell Carcinoma | Recurrent Cervical Squamous Cell Cancer | Relapsed Cervical Squamous Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520267","10q11","C13664","A chromosome band present on 10q","10q11 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0437107","Breast Lump Palpated","C137946","Palpation exam confirms presence of a breast lump.","Breast Lump Palpated | Breast Lump Palpable | O/E-Breast Lump Palpated | On Examination-Breast Lump Palpable | On Examination-Breast Lump Palpated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0437108","Breast Lump Not Palpated","C137947","No lump was palpated during breast examination.","Breast Lump Not Palpated | Breast Lump Not Palpable | No Palpable Breast Lump | O/E-No Breast Lump Palpated | On Examination-Breast Lump Not Palpable | On Examination-No Breast Lump Palpable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524970","Meditation-Based Stress Reduction Program","C137948","A clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress.","Meditation-Based Stress Reduction Program | MBSR | MBSR(BC) | Meditation-Based Stress Reduction | Meditation-Based Stress Reduction (Breast Cancer) | Meditation-Based Stress Reduction for Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520370","11p15.3","C13794","A chromosome band present on 11p","11p15.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524969","RAD 140","C137950","An orally bioavailable, non-steroidal selective androgen receptor modulator (SARM), with potential tissue-selective androgenic/anti-androgenic activities. Upon oral administration, vosilasarm acts as an agonist in select tissues, such as skeletal muscle and bone, where it binds to and activates androgen receptors (ARs). In the prostate and breasts, vosilasarm acts as an antagonist and blocks AR activation and AR-mediated cellular proliferation. Therefore, this agent may improve bone formation and muscle mass and strength, and may inhibit both the growth of the prostate in males and AR-dependent breast cancer cell proliferation. Compared to anabolic agents, SARMs have reduced androgenic properties.","Vosilasarm | EP 0062 | EP-0062 | EP0062 | RAD 140 | RAD-140 | RAD140 | SARM RAD140 | Selective Androgen Receptor Modulator RAD140 | Testolone | VOSILASARM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524973","AU-011","C137951","A formulation composed of nanoparticles derived from the human papillomavirus (HPV-NPs) and conjugated to the infrared (IR)-activated fluorescent dye IR700 (IR-700), with potential antineoplastic activity. Upon intravitreal injection of belzupacap sarotalocan, the HPV-NPs target and bind to heparan-sulfated proteoglycans (HSPG) expressed by ocular melanoma cells. Upon irradiation with near-IR (NIR) light, the photosensitizer IR700 becomes activated, generates reactive oxygen species (ROS) and selectively damages the melanoma cell membrane, which induces necrosis of the melanoma cells while sparing the surrounding, healthy non-HSPG-expressing tissue, and potentially preserving vision. HSPGs are overexpressed on a variety of cancer cell types.","Belzupacap Sarotalocan | AU-011 | BELZUPACAP SAROTALOCAN | HPV-NP AU-011 | Human Papillomavirus Virus-like Particles Conjugated with IR700 Dye AU-011 | Light-activated AU-011 | VNC AU-011 | Viral Nanoparticle Conjugates AU-011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524834","ABBV 181","C137682","A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1; PDCD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody ABBV-181 targets and binds to PD-1, thereby blocking its binding to the PD-1 ligand, programmed cell death-1 ligand 1 (PD-L1), and preventing the activation of PD-1/PD-L1 downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs). PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.","Budigalimab | ABBV 181 | ABBV-181 | ABBV181 | BUDIGALIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524832","Protease Inhibitor Formulation LB1148","C137683","A proprietary formulation comprised of the serine protease inhibitor tranexamic acid (TXA), polyethylene glycol (PEG), electrolytes, and sugar, with potential GI protective activity. After reconstitution in water and upon oral or enteral administration before abdominal surgery, TXA in the protease inhibitor formulation LB1148 targets and inhibits several serine proteases in the gastrointestinal (GI) tract, thereby preventing and protecting the intestinal mucosa against degradation, which preserves gastrointestinal (GI) integrity, function and motility. By inhibiting digestive proteases, the intestinal mucosal barrier is preserved during acute physiologic shock, which may prevent multi-organ failure, postoperative ileus and surgical intra-abdominal adhesions. PEG enhances transport of TXA through the GI tract. The other components provide energy and balance dietary electrolytes, thereby promoting healing of the GI barrier.","Protease Inhibitor Formulation LB1148 | LB-1148 | LB1148",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521531","6p12","C13768","A chromosome band present on 6p","6p12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526053","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard to Gain or Lose Weight","C138499","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to gain or lose weight when he or she wants to.","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard to Gain or Lose Weight | PQL18-Hard to Gain/Lose Weight | PQL1810",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521619","7p14-p13","C13849","A chromosome band present on 7p","7p14-p13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515383","Recombinant Leukemia Inhibitory Factor","C1384","A recombinantly produced form of the leukemia inhibitory factor protein. Endogenous leukemia inhibitory factor regulates neurogenesis and hematopoiesis.","Emfilermin | EMFILERMIN | LIF | Recombinant Leukemia Inhibitory Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526052","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard to Use Hands","C138500","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to use his or her hands.","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard to Use Hands | PQL18-Hard to Use Hands | PQL1811",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526027","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard to Swallow Food","C138501","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to swallow food.","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard to Swallow Food | PQL18-Hard to Swallow Food | PQL1812",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526149","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard Explain Illness to People","C138659","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: It is hard for me to explain my illness to other people.","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard Explain Illness to People | PQL10-Hard Explain Illness to People | PQL1020",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520277","10q22-q23","C13865","A chromosome band present on 10q","10q22-q23 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526148","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard for Family to Plan Activities","C138660","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: It is hard for my family to plan activities like vacations.","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard for Family to Plan Activities | PQL10-Hard for Family to Plan Activities | PQL1021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526123","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard for Family to Rest","C138661","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: It is hard for my family to get enough rest.","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard for Family to Rest | PQL10-Hard for Family to Rest | PQL1022",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526122","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Money Problem in Our Family","C138662","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: I think money is a problem in our family.","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Money Problem in Our Family | PQL10-Money Problem in Our Family | PQL1023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526121","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Family Has Lot of Problems","C138663","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: I think my family has a lot of problems.","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Family Has Lot of Problems | PQL10-Family Has Lot of Problems | PQL1024",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524379","Pelvis Cancer pT1 TNM Finding v8","C136594","Pelvis cancer with tumor confined to one pelvic segment with no extraosseous extension. (from AJCC 8th Ed.)","Pelvis Cancer pT1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524380","Pelvis Cancer pT1a TNM Finding v8","C136595","Pelvis cancer with tumor confined to one pelvic segment with no extraosseous extension and measuring 8 cm or less in greatest dimension. (from AJCC 8th Ed.)","Pelvis Cancer pT1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524385","Pelvis Cancer pT1b TNM Finding v8","C136596","Pelvis cancer with tumor confined to one pelvic segment with no extraosseous extension and measuring more than 8 cm in greatest dimension. (from AJCC 8th Ed.)","Pelvis Cancer pT1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524386","Pelvis Cancer pT2 TNM Finding v8","C136597","Pelvis cancer with tumor confined to one pelvic segment with extraosseous extension or two segments without extraosseous extension. (from AJCC 8th Ed.)","Pelvis Cancer pT2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524383","Pelvis Cancer pT2a TNM Finding v8","C136598","Pelvis cancer with tumor confined to one pelvic segment with extraosseous extension or two segments without extraosseous extension and measuring 8 cm or less in greatest dimension. (from AJCC 8th Ed.)","Pelvis Cancer pT2a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520685","16p13.1","C13659","A chromosome band present on 16p","16p13.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0114346","Dimesna","C1365","The disodium salt form of dithio-ethane sulfonate, a dimer of mesna and a disulfide bond disrupting agent (DDA), with uroprotective, nephroprotective, chemoprotective, chemosensitizing and chemo-enhancing activities. Upon administration, dimesna is able to modify cysteine on various proteins, such as the kinases EGFR, MET and ROS1, thereby disrupting extracellular disulfide bonds and modulating the activity of these proteins. This inhibits their signaling pathways and downregulates proliferative signaling in cancer cells in which these kinases are overexpressed. This may also enhance the activity of other kinase inhibitors targeting the same proteins. In the kidneys, dimesna undergoes reduction to the free thiol compound, mesna, which reacts chemically with the urotoxic ifosfamide metabolites acrolein and 4-hydroxy-ifosfamide, resulting in their detoxification. This agent also inhibits cyclophosphamide-induced hemorrhagic cystitis. In addition, dimesna reduces toxicities associated with taxanes and platinum-based chemotherapeutic agents.","Dimesna | 2,2'-Dithio-bis-ethanesulfonate, Disodium Salt | 2,2'-Dithiobisethanesulfonic Acid, Disodium Salt | BNP7787 | DIMESNA | LP 300 | LP-300 | LP300 | Mesna Disulfide | Tavocept | dimesna",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524389","Pelvis Cancer pT3 TNM Finding v8","C136600","Pelvis cancer with tumor spanning two pelvic segments with extraosseous extension. (from AJCC 8th Ed.)","Pelvis Cancer pT3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524390","Pelvis Cancer pT3a TNM Finding v8","C136601","Pelvis cancer with tumor spanning two pelvic segments with extraosseous extension and measuring 8 cm or less in greatest dimension. (from AJCC 8th Ed.)","Pelvis Cancer pT3a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524387","Pelvis Cancer pT3b TNM Finding v8","C136602","Pelvis cancer with tumor spanning two pelvic segments with extraosseous extension and measuring more than 8 cm in greatest dimension. (from AJCC 8th Ed.)","Pelvis Cancer pT3b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524388","Pelvis Cancer pT4 TNM Finding v8","C136603","Pelvis cancer with tumor spanning three pelvic segments or crossing the sacroiliac joint. (from AJCC 8th Ed.)","Pelvis Cancer pT4 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524393","Pelvis Cancer pT4a TNM Finding v8","C136604","Pelvis cancer with tumor involving the sacroiliac joint and extending medial to the sacral neuroforamen. (from AJCC 8th Ed.)","Pelvis Cancer pT4a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524394","Pelvis Cancer pT4b TNM Finding v8","C136605","Pelvis cancer with tumor encasement of external iliac vessels or presence of gross tumor thrombus in major pelvic vessels. (from AJCC 8th Ed.)","Pelvis Cancer pT4b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524391","Bone Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C136606","A pathologic finding about one or more characteristics of bone cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Bone Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524484","Bone Cancer pN0 TNM Finding v8","C136608","Bone cancer without regional lymph node metastasis. (from AJCC 8th Ed.)","Bone Cancer pN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524485","Bone Cancer pN1 TNM Finding v8","C136609","Bone cancer with regional lymph node metastasis. (from AJCC 8th Ed.)","Bone Cancer pN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524972","Non-synonymous ALK Gene Mutation","C137952","A point mutation in the ALK gene that encodes an amino acid substitution in the ALK tyrosine kinase receptor protein.","Non-synonymous ALK Gene Mutation | ALK Missense Mutation | Non-synonymous ALK Receptor Tyrosine Kinase Gene Mutation | Non-synonymous Anaplastic Lymphoma Kinase Receptor Gene Mutation | Non-synonymous Anaplastic Lymphoma Receptor Tyrosine Kinase Gene Mutation | Non-synonymous CD246 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524971","PI3K/MTOR Pathway Mutation","C137953","A change in the sequence of one or more genes that are involved in the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) signaling pathway.","PI3K/MTOR Pathway Mutation | PI3K/ALK/MTOR Pathway Mutation | Phosphatidylinositol 3 Kinase/Anaplastic Lymphoma Kinase Receptor/Mammalian Target of Rapamycin Pathway Mutation | Phosphatidylinositol 3 Kinase/Mammalian Target of Rapamycin Pathway Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412751","BCAT1 Gene","C137954","This gene is involved in amino acid catabolism.","BCAT1 Gene | BCAT1 | BCT1 | Branched Chain Amino Acid Transaminase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524975","BCAT1 wt Allele","C137955","Human BCAT1 wild-type allele is located in the vicinity of 12p12.1 and is approximately 139 kb in length. This allele, which encodes branched-chain-amino-acid aminotransferase, cytosolic protein, plays a role in the catabolism of branched-chain amino acids. Mutation of the gene is associated with hypervalinemia and hyperleucine-isoleucinemia.","BCAT1 wt Allele | BCT1 | Branched Chain Amino Acid Transaminase 1 wt Allele | Branched Chain Aminotransferase 1, Cytosolic Gene | ECA39 | MECA39 | PNAS121 | PP18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520698","16q22","C13684","A chromosome band present on 16q","16q22 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0114882","Doxorubicin-HPMA Conjugate","C1366","A copolymer conjugate of the antineoplastic anthracycline doxorubicin and the water-soluble polymer N-(2-hydroxypropyl) methacrylamide (HPMA). Doxorubicin, an intercalator and a topoisomerase II inhibitor, prevents DNA replication and ultimately inhibits protein synthesis. This agent also generates oxygen free radicals, resulting in cytotoxic lipid peroxidation of cell membrane lipid. HPMA conjugation enhances the permeability and retention of this agent within the tumor vasculature. Poorly cleared by the lymphatic system, this formulation undergoes increased cleavage by tumor cell lysosomal proteinases, resulting in increased, sustained intracellular concentrations of free doxorubicin. Compared to other doxorubicin-containing formulations, this formulation may exhibit an improved toxicity profile due to the lower concentrations of free doxorubicin to which non-malignant tissues are exposed.","Doxorubicin-HPMA Conjugate | Doxorubicin-HPMA | Doxorubicin-HPMA Copolymer Conjugate | HPMA-Doxorubicin | P(GFLG)-ADR | PK1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524541","Soft Tissue Sarcoma by AJCC v7 Stage","C136707","A term that refers to the staging of soft tissue sarcoma, following the rules of the TNM AJCC v7 classification system.","Soft Tissue Sarcoma by AJCC v7 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526120","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Do Not Have Equipment Need","C138664","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: I do not have the equipment I need.","PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Do Not Have Equipment Need | PQL10-Do Not Have Equipment Need | PQL1025",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526127","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Hard to Breathe","C138665","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: It is hard to breathe.","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Hard to Breathe | PQL16-Hard to Breathe | PQL1601",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526126","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Get Sick Easily","C138666","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: I get sick easily.","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Get Sick Easily | PQL16-Get Sick Easily | PQL1602",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526124","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Legs Hurt","C138668","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: My legs hurt.","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Legs Hurt | PQL16-Legs Hurt | PQL1604",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526329","PedsQL Neuromuscular Module Version 3.0 Teen Report - Hands Are Weak","C138839","Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: My hands are weak.","PedsQL Neuromuscular Module Version 3.0 Teen Report - Hands Are Weak | PQL03-Hands Are Weak | PQL0308",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520639","15q22.2","C13883","A chromosome band present on 15q","15q22.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526335","PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard to Gain or Lose Weight","C138841","Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: It is hard to gain or lose weight when I want to.","PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard to Gain or Lose Weight | PQL03-Hard to Gain/Lose Weight | PQL0310",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526334","PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard to Use Hands","C138842","Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: It is hard to use my hands.","PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard to Use Hands | PQL03-Hard to Use Hands | PQL0311",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526333","PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard to Swallow Food","C138843","Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: It is hard to swallow food.","PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard to Swallow Food | PQL03-Hard to Swallow Food | PQL0312",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526238","PedsQL Neuromuscular Module Version 3.0 Child Report - Hard to Breathe","C138682","Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: It is hard to breathe.","PedsQL Neuromuscular Module Version 3.0 Child Report - Hard to Breathe | PQL05-Hard to Breathe | PQL0501",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526237","PedsQL Neuromuscular Module Version 3.0 Child Report - Get Sick Easily","C138683","Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: I get sick easily.","PedsQL Neuromuscular Module Version 3.0 Child Report - Get Sick Easily | PQL05-Get Sick Easily | PQL0502",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526236","PedsQL Neuromuscular Module Version 3.0 Child Report - Get Sores and/or Rashes","C138684","Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: I get sores and/or rashes.","PedsQL Neuromuscular Module Version 3.0 Child Report - Get Sores and/or Rashes | PQL05-Get Sores and/or Rashes | PQL0503",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526243","PedsQL Neuromuscular Module Version 3.0 Child Report - Legs Hurt","C138685","Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: My legs hurt.","PedsQL Neuromuscular Module Version 3.0 Child Report - Legs Hurt | PQL05-Legs Hurt | PQL0504",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526242","PedsQL Neuromuscular Module Version 3.0 Child Report - Feel Tired","C138686","Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: I feel tired.","PedsQL Neuromuscular Module Version 3.0 Child Report - Feel Tired | PQL05-Feel Tired | PQL0505",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526241","PedsQL Neuromuscular Module Version 3.0 Child Report - Back Feels Stiff","C138687","Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: My back feels stiff.","PedsQL Neuromuscular Module Version 3.0 Child Report - Back Feels Stiff | PQL05-Back Feels Stiff | PQL0506",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526240","PedsQL Neuromuscular Module Version 3.0 Child Report - Wake Up Tired","C138688","Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: I wake up tired.","PedsQL Neuromuscular Module Version 3.0 Child Report - Wake Up Tired | PQL05-Wake Up Tired | PQL0507",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526247","PedsQL Neuromuscular Module Version 3.0 Child Report - Hands Are Weak","C138689","Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: My hands are weak.","PedsQL Neuromuscular Module Version 3.0 Child Report - Hands Are Weak | PQL05-Hands Are Weak | PQL0508",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520552","13q21","C13868","A chromosome band present on 13q","13q21 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526244","PedsQL Neuromuscular Module Version 3.0 Child Report - Hard to Use Hands","C138692","Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: It is hard to use my hands.","PedsQL Neuromuscular Module Version 3.0 Child Report - Hard to Use Hands | PQL05-Hard to Use Hands | PQL0511",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526321","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Wake Up Tired","C138863","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: I wake up tired.","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Wake Up Tired | PQL01-Wake Up Tired | PQL0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526320","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hands Are Weak","C138864","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: My hands are weak.","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hands Are Weak | PQL01-Hands Are Weak | PQL0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525947","FKSI-15 - I Have a Good Appetite","C138453","Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) I have a good appetite.","FKSI-15 - I Have a Good Appetite | FAC039-I Have a Good Appetite | FAC03910",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525946","FKSI-15 - I Have Been Coughing","C138454","Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) I have been coughing.","FKSI-15 - I Have Been Coughing | FAC039-I Have Been Coughing | FAC03911",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525945","FKSI-15 - I Am Bothered by Fevers","C138455","Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) I am bothered by fevers (episodes of high body temperature).","FKSI-15 - I Am Bothered by Fevers | FAC039-I Am Bothered by Fevers | FAC03912",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525944","FKSI-15 - I Am Able to Work","C138456","Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) I am able to work (include work at home).","FKSI-15 - I Am Able to Work | FAC039-I Am Able to Work | FAC03913",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525951","FKSI-15 - I Have Had Blood in My Urine","C138457","Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) I have had blood in my urine.","FKSI-15 - I Have Had Blood in My Urine | FAC039-I Have Had Blood in My Urine | FAC03914",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525950","FKSI-15 - I Am Sleeping Well","C138458","Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) I am sleeping well.","FKSI-15 - I Am Sleeping Well | FAC039-I Am Sleeping Well | FAC03915",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521050","20q11.1","C13845","A chromosome band present on 20q","20q11.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525948","FLSI - I Have a Lack of Energy","C138460","Functional Assessment of Cancer Therapy-Lung Symptom Index (FLSI) I have a lack of energy.","FLSI - I Have a Lack of Energy | FAC043-I Have a Lack of Energy | FAC04302",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525955","FLSI - I Have Pain","C138461","Functional Assessment of Cancer Therapy-Lung Symptom Index (FLSI) I have pain.","FLSI - I Have Pain | FAC043-I Have Pain | FAC04303",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525954","FLSI - I Am Losing Weight","C138462","Functional Assessment of Cancer Therapy-Lung Symptom Index (FLSI) I am losing weight.","FLSI - I Am Losing Weight | FAC043-I Am Losing Weight | FAC04304",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525953","FLSI - I Have Been Coughing","C138463","Functional Assessment of Cancer Therapy-Lung Symptom Index (FLSI) I have been coughing.","FLSI - I Have Been Coughing | FAC043-I Have Been Coughing | FAC04305",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525952","FLSI - Certain Parts of Body Have Pain","C138464","Functional Assessment of Cancer Therapy-Lung Symptom Index (FLSI) I have certain parts of my body where I experience pain.","FLSI - Certain Parts of Body Have Pain | FAC043-Certain Parts of Body Have Pain | FAC04306",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525959","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard to Breathe","C138465","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: It is hard to breathe.","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard to Breathe | PQL14-Hard to Breathe | PQL1401",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525958","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Get Sick Easily","C138466","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: I get sick easily.","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Get Sick Easily | PQL14-Get Sick Easily | PQL1402",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525957","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Get Sores and/or Rashes","C138467","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: I get sores and/or rashes.","PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Get Sores and/or Rashes | PQL14-Get Sores and/or Rashes | PQL1403",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526187","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard Ask Doctors and Nurses Questions","C138725","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: It is hard for my child to ask the doctors and nurses questions.","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard Ask Doctors and Nurses Questions | PQL09-Hard Ask Doctors/Nurses Questions | PQL0919",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526186","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard Explain Illness to People","C138726","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: It is hard for my child to explain his or her illness to other people.","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard Explain Illness to People | PQL09-Hard Explain Illness to People | PQL0920",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525107","CivaSheet Directional Pd103 Brachytherapy Source","C138130","A proprietary brachytherapy source designed to deliver a radiation dose in a single direction. The device incorporates Palladium-103 as a radiation source and utilizes gold shielding to deliver the radiation dose in a unidirectional, planar manner. CivaSheet is flexible, bioabsorbable and features a polymer-encapsulated radiation source.","CivaSheet Directional Pd103 Brachytherapy Source | CivaSheet | Low Dose Rate Planar Directional Brachytherapy Source | Permanently Implantable LDR CivaSheet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521307","3q21-q24","C13813","A chromosome band present on 3q","3q21-q24 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417612","NCKAP1 Gene","C138140","This gene is involved in both lamellipodia formation and endocytosis.","NCKAP1 Gene | NCK Associated Protein 1 Gene | NCKAP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1435989","NCKAP1 protein, human","C138142","Nck-associated protein 1 (1128 aa, ~129 kDa) is encoded by the human NCKAP1 gene. This protein is involved in both cell morphology and endocytosis.","Nck-Associated Protein 1 | Membrane-Associated Protein HEM-2 | NAP 1 | NCKAP1 | p125Nap1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526074","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard Tell Doctors and Nurses How Feel","C138582","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to tell the doctors and nurses how he or she feels.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard Tell Doctors and Nurses How Feel | PQL11-Hard Tell Doctors/Nurses How Feel | PQL1118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526073","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard Ask Doctors and Nurses Questions","C138583","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to ask the doctors and nurses questions.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard Ask Doctors and Nurses Questions | PQL11-Hard Ask Doctors/Nurses Questions | PQL1119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526072","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard Explain Illness to People","C138584","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to explain his or her illness to other people.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard Explain Illness to People | PQL11-Hard Explain Illness to People | PQL1120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526078","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard for Family to Rest","C138586","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: It is hard for our family to get enough rest.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard for Family to Rest | PQL11-Hard for Family to Rest | PQL1122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526077","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Money Problem in Our Family","C138587","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: I think money is a problem in our family.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Money Problem in Our Family | PQL11-Money Problem in Our Family | PQL1123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526076","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Family Has Lot of Problems","C138588","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: I think our family has a lot of problems.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Family Has Lot of Problems | PQL11-Family Has Lot of Problems | PQL1124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526083","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Do Not Have Equipment Need","C138589","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: My child does not have the equipment he or she needs.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Do Not Have Equipment Need | PQL11-Do Not Have Equipment Need | PQL1125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520704","16q23.1","C13858","A chromosome band present on 16q","16q23.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526082","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard to Breathe","C138590","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to breathe.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard to Breathe | PQL17-Hard to Breathe | PQL1701",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526293","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Take Long Time to Eat","C138771","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: My child takes a long time to eat.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Take Long Time to Eat | PQL04-Take Long Time to Eat | PQL0415",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525719","Predominantly Diffuse Follicular Lymphoma with 1p36 Deletion","C138186","A predominantly diffuse, low-grade follicular lymphoma. It often presents as a large localized inguinal mass, lacks BCL2 rearrangement, and is associated with 1p36 deletion.","Predominantly Diffuse Follicular Lymphoma with 1p36 Deletion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525718","Haploidentical Hematopoietic Cell Transplantation","C138187","A clinical treatment in which hematopoietic stem cells are transferred from a HLA half-matched donor to a recipient.","Haploidentical Hematopoietic Cell Transplantation | HLA-Haploidentical Hematopoietic Cell Transplantation | Haploidentical Stem Cell Transplantation | Stem Cell Transplantation, Haploidentical",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525725","Clinical Trials Search-Application Programming Interface Disease Category Terminology","C138188","Terminology subsets used for the purpose of supporting the CTS-API.","Clinical Trials Search-Application Programming Interface Disease Category Terminology | CTS-API Disease Category Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525724","CTS-API Disease Broad Category Terminology","C138189","Terminology subset used for the purpose of supporting the CTS-API disease broad category terminology.","CTS-API Disease Broad Category Terminology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520593","14q24.1","C13818","A chromosome band present on 14q","14q24.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525723","CTS-API Disease Main Type Terminology","C138190","Terminology subset used for the purpose of supporting the CTS-API disease main type terminology.","CTS-API Disease Main Type Terminology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525722","In Situ Mantle Cell Neoplasia","C138191","A neoplastic lymphoid process characterized by the presence of cyclin D1 positive lymphoid cells, typically in the inner mantle zones of lymphoid tissue follicles, in cases that do not suggest the diagnosis of a mantle cell lymphoma. It is often found incidentally and has a low rate of progression.","In Situ Mantle Cell Neoplasia | ISMCN | In Situ Mantle Cell Lymphoma | In Situ Mantle Cell Neoplasm",,,,,,,,,,,,,,,"37206730","In situ mantle cell neoplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL525728","Leukemic Nonnodal Mantle Cell Lymphoma","C138192","Mantle cell lymphoma involving the peripheral blood, bone marrow, and often spleen. It usually has an indolent clinical course.","Leukemic Nonnodal Mantle Cell Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519964","High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements","C138195","High-grade B-cell lymphoma characterized by the abnormal rearrangement of MYC gene, BCL2 gene, and/or BCL6 gene. Patients with this type of lymphoma usually respond poorly to standard treatments and have a poor prognosis.","High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements | HGBL with MYC and BCL2 and/or BCL6 Rearrangements | High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements",,,,,,,,,,,,,,,"37160987","High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526177","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard to Use Bathroom","C138623","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: It is hard to use the bathroom.","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard to Use Bathroom | PQL12-Hard to Use Bathroom | PQL1209",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526176","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard to Gain or Lose Weight","C138624","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: It is hard to gain or lose weight when I want to.","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard to Gain or Lose Weight | PQL12-Hard to Gain/Lose Weight | PQL1210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526183","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard to Use Hands","C138625","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: It is hard to use my hands.","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard to Use Hands | PQL12-Hard to Use Hands | PQL1211",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526182","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard to Swallow Food","C138626","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: It is hard to swallow food.","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard to Swallow Food | PQL12-Hard to Swallow Food | PQL1212",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526181","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Long Time to Bathe or Shower","C138627","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: It takes me a long time to bathe or shower.","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Long Time to Bathe or Shower | PQL12-Long Time to Bathe/Shower | PQL1213",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526180","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Get Hurt Accidentally","C138628","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: I get hurt accidentally.","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Get Hurt Accidentally | PQL12-Get Hurt Accidentally | PQL1214",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526155","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Take Long Time to Eat","C138629","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: I take a long time to eat.","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Take Long Time to Eat | PQL12-Take Long Time to Eat | PQL1215",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520780","17q23","C13862","A chromosome band present on 17q","17q23 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526154","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard to Turn During Night","C138630","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: It is hard to turn myself during the night.","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard to Turn During Night | PQL12-Hard to Turn During Night | PQL1216",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526153","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard to Go Places With Equipment","C138631","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: It is hard for me to go places with my equipment.","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard to Go Places With Equipment | PQL12-Hard to Go Places With Equipment | PQL1217",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526152","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard Tell Doctors and Nurses How Feel","C138632","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: It is hard for me to tell the doctors and nurses how I feel.","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard Tell Doctors and Nurses How Feel | PQL12-Hard Tell Doctors/Nurses How Feel | PQL1218",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521518","Solid Pulmonary Nodule","C138143","A pulmonary nodule with well-defined margins and homogenous soft-tissue attenuation on CT scan examination.","Solid Pulmonary Nodule | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1422186","CYFIP1 Gene","C138145","This gene plays a role in both translational repression and actin filament reorganization.","CYFIP1 Gene | CYFIP1 | Cytoplasmic FMR1 Interacting Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525669","CYFIP1 wt Allele","C138146","Human CYFIP1 wild-type allele is located in the vicinity of 15q11.2 and is approximately 114 kb in length. This allele, which encodes cytoplasmic FMR1-interacting protein 1, is involved in the repression of protein translation and the regulation of cytoskeleton remodeling.","CYFIP1 wt Allele | Cytoplasmic FMR1 Interacting Protein 1 wt Allele | KIAA0068 | P140SRA-1 | SHYC | SRA-1 | SRA1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1431132","CYFIP1 protein, human","C138147","Cytoplasmic FMR1-interacting protein 1 (1253 aa, ~145 kDa) is encoded by the human CYFIP1 gene. This protein plays a role in the regulation of both cytoskeletal dynamics and translation.","Cytoplasmic FMR1-Interacting Protein 1 | CYFIP1 | Cytoplasmic FMRP Interacting Protein 1 | Specifically Rac1-Associated Protein 1 | Sra-1 | p140sra-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526287","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Feel Tired","C138761","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: My child feels tired.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Feel Tired | PQL04-Feel Tired | PQL0405",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526286","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Back Feels Stiff","C138762","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: My child's back feels stiff.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Back Feels Stiff | PQL04-Back Feels Stiff | PQL0406",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526285","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Wake Up Tired","C138763","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: My child wakes up tired.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Wake Up Tired | PQL04-Wake Up Tired | PQL0407",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526284","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hands Are Weak","C138764","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: My child's hands are weak.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hands Are Weak | PQL04-Hands Are Weak | PQL0408",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526291","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard to Use Bathroom","C138765","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: It is hard for my child to use the bathroom.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard to Use Bathroom | PQL04-Hard to Use Bathroom | PQL0409",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526290","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard to Gain or Lose Weight","C138766","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: It is hard for my child to gain or lose weight when he or she wants to.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard to Gain or Lose Weight | PQL04-Hard to Gain/Lose Weight | PQL0410",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526289","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard to Use Hands","C138767","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: It is hard for my child to use his or her hands.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard to Use Hands | PQL04-Hard to Use Hands | PQL0411",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526288","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard to Swallow Food","C138768","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: It is hard for my child to swallow food.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard to Swallow Food | PQL04-Hard to Swallow Food | PQL0412",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526295","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Long Time to Bathe or Shower","C138769","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: It takes my child a long time to bathe or shower.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Long Time to Bathe or Shower | PQL04-Long Time to Bathe/Shower | PQL0413",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520382","11q13.1","C13876","A chromosome band present on 11q","11q13.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526294","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Get Hurt Accidentally","C138770","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: My child gets hurt accidentally.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Get Hurt Accidentally | PQL04-Get Hurt Accidentally | PQL0414",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0682664","Somatosensory Receptor","C13819","Nerve endings encased in connective tissue capsules with myelinated or unmyelinated axons.","Somatosensory Receptor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0125061","Liposomal NDDP","C1383","A synthetic liposomal formulation of bis-neodecanoate diaminocyclohexane platinum (NDDP), a third-generation platinum complex analogue of cisplatin, with potential antineoplastic activity. After displacement of the 2 long-chain aliphatic leaving groups (neodecanoic acid), platinum diaminocyclohexane (DACH) complexes become highly reactive and alkylate macromolecules, forming both inter- and intra-stranded DNA cross-linkings and inhibiting DNA synthesis, which results in tumor cell cytotoxicity. Because DNA mismatch-repair (MMR) complexes do not recognize DACH-platinum adducts, DNA repair mechanisms are inhibited, overcoming limitations observed with other platinum-based agents. In addition, the liposomal encapsulation improves the bioavailability of NDDP and reduces its toxicity profile.","Liposomal NDDP | AROPLATIN | Aroplatin | L-NDDP | Liposomal Neodecanoic Acid Platinum Complex | Liposomal-Cisplatin Analogue | Liposomal-Entrapped Cis-Bis-Neodecanoate-trans-R,R-1,2-Diaminocyclohexane Platinum (II)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525888","PUL 2.0 - Flexion Shoulder Height No Weights","C138400","Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Shoulder flexion to shoulder height (no weights).","PUL 2.0 - Flexion Shoulder Height No Weights | PUL02-Flexion Shoulder Height No Weights | PUL0203",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525895","PUL 2.0 - Flexion to Shoulder Height 500g","C138401","Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Shoulder flexion to shoulder height with 500g weight.","PUL 2.0 - Flexion to Shoulder Height 500g | PUL02-Flexion to Shoulder Height 500g | PUL0204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525894","PUL 2.0 - Flexion Above Shoulder Height 500g","C138402","Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Shoulder flexion above shoulder height with 500g weight.","PUL 2.0 - Flexion Above Shoulder Height 500g | PUL02-Flexion Above Shoulder Height 500g | PUL0205",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525893","PUL 2.0 - Flexion Above Shoulder Height 1kg","C138403","Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Shoulder flexion above shoulder with 1 kg weight.","PUL 2.0 - Flexion Above Shoulder Height 1kg | PUL02-Flexion Above Shoulder Height 1kg | PUL0206",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525892","PUL 2.0 - Hand(s) to Mouth","C138404","Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Hand(s) to mouth.","PUL 2.0 - Hand(s) to Mouth | PUL02-Hand(s) to Mouth | PUL0207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525867","PUL 2.0 - Hands to Table From Lap","C138405","Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Hands to table from lap.","PUL 2.0 - Hands to Table From Lap | PUL02-Hands to Table From Lap | PUL0208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525866","PUL 2.0 - Move Weight On Table 100g","C138406","Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Move weight on table 100g.","PUL 2.0 - Move Weight On Table 100g | PUL02-Move Weight on Table 100g | PUL0209",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525865","PUL 2.0 - Move Weight On Table 500g","C138407","Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Move weight on table 500g.","PUL 2.0 - Move Weight On Table 500g | PUL02-Move Weight on Table 500g | PUL0210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525871","PUL 2.0 - Lift Heavy Can Diagonally","C138409","Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Lift heavy can diagonally.","PUL 2.0 - Lift Heavy Can Diagonally | PUL02-Lift Heavy Can Diagonally | PUL0212",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521704","8p22-p11","C13840","A chromosome band present on 8p","8p22-p11 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526159","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard Ask Doctors and Nurses Questions","C138633","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: It is hard for me to ask the doctors and nurses questions.","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard Ask Doctors and Nurses Questions | PQL12-Hard Ask Doctors/Nurses Questions | PQL1219",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526363","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Family Has Lot of Problems","C138805","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: I think our family has a lot of problems.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Family Has Lot of Problems | PQL02-Family Has Lot of Problems | PQL0224",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526362","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Do Not Have Equipment Need","C138806","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: My child does not have the equipment he or she needs.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Do Not Have Equipment Need | PQL02-Do Not Have Equipment Need | PQL0225",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526360","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Get Sick Easily","C138808","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: My child gets sick easily.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Get Sick Easily | PQL08-Get Sick Easily | PQL0802",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526367","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Get Sores and/or Rashes","C138809","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: My child gets sores and/or rashes.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Get Sores and/or Rashes | PQL08-Get Sores and/or Rashes | PQL0803",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521183","2p21","C13880","A chromosome band present on 2p","2p21 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526366","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Legs Hurt","C138810","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: My child's legs hurt.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Legs Hurt | PQL08-Legs Hurt | PQL0804",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526365","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Feel Tired","C138811","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: My child feels tired.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Feel Tired | PQL08-Feel Tired | PQL0805",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526371","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Wake Up Tired","C138813","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: My child wakes up tired.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Wake Up Tired | PQL08-Wake Up Tired | PQL0807",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520767","17q12-q21.1","C13834","A chromosome band present on 17q","17q12-q21.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526004","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard to Use Bathroom","C138548","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: It is hard for my child to use the bathroom.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard to Use Bathroom | PQL13-Hard to Use Bathroom | PQL1309",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526107","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard to Gain or Lose Weight","C138549","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: It is hard for my child to gain or lose weight when he or she wants to.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard to Gain or Lose Weight | PQL13-Hard to Gain/Lose Weight | PQL1310",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521501","5q35.1-qter","C13854","A chromosome band present on 5q","5q35.1-qter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526106","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard to Use Hands","C138550","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: It is hard for my child to use his or her hands.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard to Use Hands | PQL13-Hard to Use Hands | PQL1311",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526105","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard to Swallow Food","C138551","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: It is hard for my child to swallow food.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard to Swallow Food | PQL13-Hard to Swallow Food | PQL1312",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522284","Stage IA Intrahepatic Cholangiocarcinoma AJCC v8","C134758","Stage IA includes: T1a, N0, M0. T1a: Solitary tumor equal or less than 5 cm without vascular invasion.  N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IA Intrahepatic Cholangiocarcinoma AJCC v8 | IA | Stage IA Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522285","Stage IB Intrahepatic Cholangiocarcinoma AJCC v8","C134759","Stage IB includes: T1b, N0, M0. T1b: Solitary tumor larger than 5 cm without vascular invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IB Intrahepatic Cholangiocarcinoma AJCC v8 | IB | Stage IB Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520803","18q21.3","C13475","A chromosome band present on 18q","18q21.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522996","CDISC Clinical Classification PASI Test Name Terminology","C135677","Test names of clinical classification questions associated with the Psoriasis Area and Severity Index (PASI) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification PASI Test Name Terminology | CC-PASI TEST | PASI01TN | Psoriasis Area and Severity Index Clinical Classification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522998","CDISC Questionnaire BEBQ Concurrent Version Test Name Terminology","C135679","Test names of questionnaire questions associated with the Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire BEBQ Concurrent Version Test Name Terminology | BEBQ01TN | Baby Eating Behaviour Questionnaire Concurrent Version Questionnaire Test Name | QS-BEBQ Concurrent Version TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521552","6p25-p23","C13567","A chromosome band present on 6p","6p25-p23 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522999","CDISC Questionnaire BEBQ Concurrent Version Test Code Terminology","C135680","Test codes of questionnaire questions associated with the Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire BEBQ Concurrent Version Test Code Terminology | BEBQ01TC | Baby Eating Behaviour Questionnaire Concurrent Version Questionnaire Test Code | QS-BEBQ Concurrent Version TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523000","CDISC Questionnaire BEBQ Retrospective Version Test Name Terminology","C135681","Test names of questionnaire questions associated with the Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire BEBQ Retrospective Version Test Name Terminology | BEBQ02TN | Baby Eating Behaviour Questionnaire Retrospective Version Questionnaire Test Name | QS-BEBQ Retrospective Version TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525870","PUL 2.0 - Stack of Three Cans","C138410","Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Stack of three cans.","PUL 2.0 - Stack of Three Cans | PUL02-Stack of Three Cans | PUL0213",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525869","PUL 2.0 - Stack of Five Cans","C138411","Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Stack of five cans.","PUL 2.0 - Stack of Five Cans | PUL02-Stack of Five Cans | PUL0214",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525868","PUL 2.0 - Remove Lid From Container","C138412","Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Remove lid from container.","PUL 2.0 - Remove Lid From Container | PUL02-Remove Lid From Container | PUL0215",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525875","PUL 2.0 - Tearing Paper","C138413","Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Tearing paper.","PUL 2.0 - Tearing Paper | PUL02-Tearing Paper | PUL0216",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525874","PUL 2.0 - Tracing Path","C138414","Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Tracing path.","PUL 2.0 - Tracing Path | PUL02-Tracing Path | PUL0217",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525873","PUL 2.0 - Push on Light","C138415","Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Push on light.","PUL 2.0 - Push on Light | PUL02-Push on Light | PUL0218",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526081","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Get Sick Easily","C138591","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: My child gets sick easily.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Get Sick Easily | PQL17-Get Sick Easily | PQL1702",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526080","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Get Sores and/or Rashes","C138592","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: My child gets sores and/or rashes.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Get Sores and/or Rashes | PQL17-Get Sores and/or Rashes | PQL1703",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526087","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Legs Hurt","C138593","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: My child's legs hurt.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Legs Hurt | PQL17-Legs Hurt | PQL1704",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526086","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Feel Tired","C138594","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: My child feels tired.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Feel Tired | PQL17-Feel Tired | PQL1705",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526085","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Back Feels Stiff","C138595","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: My child's back feels stiff.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Back Feels Stiff | PQL17-Back Feels Stiff | PQL1706",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526084","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Wake Up Tired","C138596","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: My child wakes up tired.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Wake Up Tired | PQL17-Wake Up Tired | PQL1707",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526326","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard to Gain or Lose Weight","C138866","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: It is hard to gain or lose weight when I want to.","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard to Gain or Lose Weight | PQL01-Hard to Gain/Lose Weight | PQL0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526325","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard to Use Hands","C138867","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: It is hard to use my hands.","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard to Use Hands | PQL01-Hard to Use Hands | PQL0111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526324","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard to Swallow Food","C138868","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: It is hard to swallow food.","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard to Swallow Food | PQL01-Hard to Swallow Food | PQL0112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526424","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Long Time to Bathe or Shower","C138869","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: It takes me a long time to bathe or shower.","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Long Time to Bathe or Shower | PQL01-Long Time to Bathe/Shower | PQL0113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521107","22q11.23","C13886","A chromosome band present on 22q","22q11.23 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526423","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Get Hurt Accidentally","C138870","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: I get hurt accidentally.","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Get Hurt Accidentally | PQL01-Get Hurt Accidentally | PQL0114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526422","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Take Long Time to Eat","C138871","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: I take a long time to eat.","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Take Long Time to Eat | PQL01-Take Long Time to Eat | PQL0115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526421","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard to Turn During Night","C138872","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: It is hard to turn myself during the night.","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard to Turn During Night | PQL01-Hard to Turn During Night | PQL0116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526428","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard to Go Places With Equipment","C138873","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: It is hard for me to go places with my equipment.","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard to Go Places With Equipment | PQL01-Hard to Go Places With Equipment | PQL0117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526427","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard Tell Doctors and Nurses How Feel","C138874","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: It is hard for me to tell the doctors and nurses how I feel.","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard Tell Doctors and Nurses How Feel | PQL01-Hard Tell Doctors/Nurses How Feel | PQL0118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526104","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Long Time to Bathe or Shower","C138552","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: It takes my child a long time to bathe or shower.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Long Time to Bathe or Shower | PQL13-Long Time to Bathe/Shower | PQL1313",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526111","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Get Hurt Accidentally","C138553","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: My child gets hurt accidentally.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Get Hurt Accidentally | PQL13-Get Hurt Accidentally | PQL1314",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526110","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Take Long Time to Eat","C138554","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: My child takes a long time to eat.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Take Long Time to Eat | PQL13-Take Long Time to Eat | PQL1315",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526109","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard to Turn During Night","C138555","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: It is hard for my child to turn him or herself during the night.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard to Turn During Night | PQL13-Hard to Turn During Night | PQL1316",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526108","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard to Go Places With Equipment","C138556","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: It is hard for my child to go places with his or her equipment.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard to Go Places With Equipment | PQL13-Hard to Go Places With Equipment | PQL1317",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526115","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard Tell Doctors and Nurses How Feel","C138557","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: It is hard for my child to tell the doctors and nurses how he or she feels.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard Tell Doctors and Nurses How Feel | PQL13-Hard Tell Doctors/Nurses How Feel | PQL1318",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526184","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard for Family to Rest","C138728","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: It is hard for our family to get enough rest.","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard for Family to Rest | PQL09-Hard for Family to Rest | PQL0922",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526191","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Money Problem in Our Family","C138729","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: I think money is a problem in our family.","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Money Problem in Our Family | PQL09-Money Problem in Our Family | PQL0923",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520543","13q13.3","C13872","A chromosome band present on 13q","13q13.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526190","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Family Has Lot of Problems","C138730","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: I think our family has a lot of problems.","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Family Has Lot of Problems | PQL09-Family Has Lot of Problems | PQL0924",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523001","CDISC Questionnaire BEBQ Retrospective Version Test Code Terminology","C135682","Test codes of questionnaire questions associated with the Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire BEBQ Retrospective Version Test Code Terminology | BEBQ02TC | Baby Eating Behaviour Questionnaire Retrospective Version Questionnaire Test Code | QS-BEBQ Retrospective Version TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523002","CDISC Questionnaire CGI Original Version Test Name Terminology","C135683","Test names of questionnaire questions associated with the Clinical Global Impression Original Version (CGI Original Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire CGI Original Version Test Name Terminology | QS-CGI Original Version TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523003","CDISC Questionnaire CGI Original Version Test Code Terminology","C135684","Test codes of questionnaire questions associated with the Clinical Global Impression Original Version (CGI Original Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire CGI Original Version Test Code Terminology | QS-CGI Original Version TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523004","CDISC Questionnaire CGI Generic Modification Version Test Name Terminology","C135685","Test names of questionnaire questions associated with the Clinical Global Impression Generic Modification Version (CGI Generic Modification Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire CGI Generic Modification Version Test Name Terminology | CGI02TN | Clinical Global Impression Generic Modification Version Questionnaire Test Name | QS-CGI Generic Modification Version TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522508","Rattlesnake Fibroma","C134999","A fibroma that occurs in a rattlesnake.","Rattlesnake Fibroma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520508","12q23","C13499","A chromosome band present on 12q","12q23 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0106025","Recombinant Inhibin B","C1349","A recombinant therapeutic agent which is chemically identical to or similar to an endogenous glycoprotein which inhibits pituitary production of follicle-stimulating hormone (FSH).  Produced and secreted by the testis or ovarian follicle, endogenous inhibin B contributes to the control of gametogenesis, embryonic and fetal development, and hematopoiesis. (NCI04)","Recombinant Inhibin B | Inhibin B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522509","Seal Lymphosarcoma","C135000","Lymphosarcoma that occurs in a seal.","Seal Lymphosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522510","Turtle Neoplasm","C135001","A neoplasm that occurs in a turtle.","Turtle Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522511","Walleye Dermal Sarcoma","C135002","Sarcoma arising from the connective tissue of the dermis and occurring in a walleye.","Walleye Dermal Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522512","Budgerigar Testicular Carcinoma","C135003","Carcinoma that arises in the testicle of a budgerigar.","Budgerigar Testicular Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522513","Chicken Lymphoma","C135004","Lymphoma that occurs in a chicken.","Chicken Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522514","Chicken Neoplasm","C135005","A neoplasm that occurs in a chicken.","Chicken Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522515","Fish Melanoma","C135006","Melanoma that occurs in a fish.","Fish Melanoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522516","Feline Reticulum Cell Sarcoma","C135008","Reticulum cell sarcoma that occurs in a cat.","Feline Reticulum Cell Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520470","12p12","C13500","A chromosome band present on 12p","12p12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526059","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hands Are Weak","C138597","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: My child's hands are weak.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hands Are Weak | PQL17-Hands Are Weak | PQL1708",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526058","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard to Use Bathroom","C138598","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to use the bathroom.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard to Use Bathroom | PQL17-Hard to Use Bathroom | PQL1709",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526057","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard to Gain or Lose Weight","C138599","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to gain or lose weight when he or she wants to.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard to Gain or Lose Weight | PQL17-Hard to Gain/Lose Weight | PQL1710",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0125660","Levonantradol","C1385","A synthetic cannabinoid analogue of delta (9)-tetrahydrocannabinol (delta(9)-THC) with antiemetic and anti-analgesic properties. Although its precise mechanism of action is unknown, levonantradol appears to bind and activate the cannabinoid receptors CB1 and/or CB2. (NCI04)","Levonantradol | LEVONANTRADOL | Levonantradol HCl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526056","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard to Use Hands","C138600","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to use his or her hands.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard to Use Hands | PQL17-Hard to Use Hands | PQL1711",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526267","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard to Go Places With Equipment","C138773","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: It is hard for my child to go places with his or her equipment.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard to Go Places With Equipment | PQL04-Hard to Go Places With Equipment | PQL0417",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526266","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard Tell Doctors and Nurses How Feel","C138774","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: It is hard for my child to tell the doctors and nurses how he or she feels.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard Tell Doctors and Nurses How Feel | PQL04-Hard Tell Doctors/Nurses How Feel | PQL0418",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526265","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard Ask Doctors and Nurses Questions","C138775","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: It is hard for my child to ask the doctors and nurses questions.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard Ask Doctors and Nurses Questions | PQL04-Hard Ask Doctors/Nurses Questions | PQL0419",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526264","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard Explain Illness to People","C138776","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: It is hard for my child to explain his or her illness to other people.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard Explain Illness to People | PQL04-Hard Explain Illness to People | PQL0420",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0124355","K 252a","C1382","An indolocarbazole-based alkaloid and staurosporine analog isolated from Nocardiopsis and Actinomadura species, with kinase inhibiting activity. K252a inhibits a wide variety of enzymes, including, but not limited to, protein kinase A (PKA), C (PKC) and G (PKG), calcium (Ca2+)/calmodulin-dependent kinase type II (CaMKII), phosphorylase kinase (PhK), tropomyosin receptor kinase (Trk; neurotrophic tyrosine receptor kinase; NTRK), myosin light-chain kinase (MLCK; MYLK), mixed-lineage protein kinase 3 (MLK3), receptor-type tyrosine-protein kinase FLT3 (CD135; fms-like tyrosine kinase 3; fetal liver kinase-2; FLK2) and actin-regulating kinase PRK1 (PAK1). Inhibition of these kinases prevents the activation of signaling pathways in which these kinases play a key role.","K 252a | 9,1-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9-alpha,10-beta,12-alpha)- | Antibiotic K 252A | Antibiotic SF 2370 | K-252a | K252A | Protein Kinase Inhibitor K252a | SF 2370",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521696","8p11.23","C13830","A chromosome band present on 8p","8p11.23 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526189","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Do Not Have Equipment Need","C138731","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: My child does not have the equipment he or she needs.","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Do Not Have Equipment Need | PQL09-Do Not Have Equipment Need | PQL0925",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526188","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard to Breathe","C138732","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to breathe.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard to Breathe | PQL06-Hard to Breathe | PQL0601",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526195","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Get Sick Easily","C138733","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: My child gets sick easily.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Get Sick Easily | PQL06-Get Sick Easily | PQL0602",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526194","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Get Sores and/or Rashes","C138734","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: My child gets sores and/or rashes.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Get Sores and/or Rashes | PQL06-Get Sores and/or Rashes | PQL0603",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526193","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Legs Hurt","C138735","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: My child's legs hurt.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Legs Hurt | PQL06-Legs Hurt | PQL0604",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526192","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Feel Tired","C138736","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: My child feels tired.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Feel Tired | PQL06-Feel Tired | PQL0605",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526199","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Back Feels Stiff","C138737","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: My child's back feels stiff.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Back Feels Stiff | PQL06-Back Feels Stiff | PQL0606",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526198","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Wake Up Tired","C138738","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: My child wakes up tired.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Wake Up Tired | PQL06-Wake Up Tired | PQL0607",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521520","Pure Ground-Glass Pulmonary Nodule","C138148","A term that refers to a pulmonary nodule in which there are no completely obscured parenchymal areas by the ground-glass opacity on CT scan examination.","Pure Ground-Glass Pulmonary Nodule | GGN | Non-Solid Ground-Glass Pulmonary Nodule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525668","Neoantigen DNA-Based Pancreatic Cancer Vaccine","C138149","A personalized, polyepitope DNA vaccine composed of a DNA plasmid encoding multiple, highly immunogenic tumor associated antigens (TAAs) that are specifically expressed by a patient's pancreatic cancer cells, including personalized epitopes of the TAA mesothelin, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration and electroporation of the neoantigen DNA-based pancreatic cancer vaccine, the expressed TAAs induce a specific cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing the neoantigens.","Neoantigen DNA-Based Pancreatic Cancer Vaccine | Neoantigen DNA Pancreatic Cancer Vaccine | Personalized Neoantigen DNA Pancreatic Cancer Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520944","1p22-p21","C13814","A chromosome band present on 1p","1p22-p21 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522518","CDISC SDTM Pharmacogenomics/Genetics Methods and Supporting Information Test Code Terminology","C135010","Terminology associated with the pharmacogenomics/genetics methods and supporting information test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Pharmacogenomics/Genetics Methods and Supporting Information Test Code Terminology | SDTM-PGTSTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522520","CDISC SDTM AJCC Tumor Grade Response Terminology","C135012","Terminology associated with the AJCC tumor grade response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM AJCC Tumor Grade Response Terminology | AJCC Tumor Grade Response | AJCCGRD | SDTM-AJCCGRD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522521","CDISC SDTM Pharmacogenomics/Genetics Findings Result Category Terminology","C135013","Terminology associated with the pharmacogenomics/genetics findings result category codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Pharmacogenomics/Genetics Findings Result Category Terminology | GENRCAT | Pharmacogenomics/Genetics Findings Result Category | SDTM-GENRCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522522","Dispense Limited Quantity","C135014","The dispenser must dispense only a limited quantity of the drug.","Dispense Limited Quantity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522523","Prescribe Limited Quantity","C135015","The prescriber must prescribe only a limited quantity of the drug.","Prescribe Limited Quantity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522560","CDISC Findings About Class","C135396","This SDTM class is a specialization of the findings general observation class. It is intended, as its name implies, to be used when collected data represent findings about an event or intervention that cannot be represented within an event or intervention record, or as a supplemental qualifier to such a record.","CDISC Findings About Class | FINDINGS ABOUT | Findings About",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526271","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard for Family to Plan Activities","C138777","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: It is hard for our family to plan activities like vacations.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard for Family to Plan Activities | PQL04-Hard for Family to Plan Activities | PQL0421",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526270","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard for Family to Rest","C138778","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: It is hard for our family to get enough rest.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard for Family to Rest | PQL04-Hard for Family to Rest | PQL0422",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526269","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Money Problem in Our Family","C138779","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: I think money is a problem in our family.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Money Problem in Our Family | PQL04-Money Problem in Our Family | PQL0423",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526268","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Family Has Lot of Problems","C138780","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: I think our family has a lot of problems.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Family Has Lot of Problems | PQL04-Family Has Lot of Problems | PQL0424",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526275","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Do Not Have Equipment Need","C138781","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: My child does not have the equipment he or she needs.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Do Not Have Equipment Need | PQL04-Do Not Have Equipment Need | PQL0425",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526274","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard to Breathe","C138782","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: It is hard for my child to breathe.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard to Breathe | PQL02-Hard to Breathe | PQL0201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526039","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Family Has Lot of Problems","C138513","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: I think our family has a lot of problems.","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Family Has Lot of Problems | PQL18-Family Has Lot of Problems | PQL1824",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526038","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Do Not Have Equipment Need","C138514","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: My child does not have the equipment he or she needs.","PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Do Not Have Equipment Need | PQL18-Do Not Have Equipment Need | PQL1825",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526037","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard to Breathe","C138515","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to breathe.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard to Breathe | PQL15-Hard to Breathe | PQL1501",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526036","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Get Sick Easily","C138516","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: My child gets sick easily.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Get Sick Easily | PQL15-Get Sick Easily | PQL1502",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526011","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Get Sores and/or Rashes","C138517","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: My child gets sores and/or rashes.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Get Sores and/or Rashes | PQL15-Get Sores and/or Rashes | PQL1503",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526010","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Legs Hurt","C138518","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: My child's legs hurt.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Legs Hurt | PQL15-Legs Hurt | PQL1504",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526009","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Feel Tired","C138519","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: My child feels tired.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Feel Tired | PQL15-Feel Tired | PQL1505",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521551","6p25","C13851","A chromosome band present on 6p","6p25 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526008","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Back Feels Stiff","C138520","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: My child's back feels stiff.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Back Feels Stiff | PQL15-Back Feels Stiff | PQL1506",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526013","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard to Use Bathroom","C138523","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to use the bathroom.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard to Use Bathroom | PQL15-Hard to Use Bathroom | PQL1509",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1412485","APOL1 Gene","C138151","This gene is involved in the transport of cholesterol and other lipids.","APOL1 Gene | APOL1 | Apolipoprotein L1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525670","APOL1 wt Allele","C138152","Human APOL1 wild-type allele is located in the vicinity of 22q12.3 and is approximately 15 kb in length. This allele, which encodes apolipoprotein L1 protein, plays a role in the metabolism of cholesterol and other lipids. Variation of the gene is associated increased susceptibility to both focal segmental glomerulosclerosis 4 and non-diabetic end-stage renal disease.","APOL1 wt Allele | APO-L | APOL | APOL-I | Apolipoprotein L1 wt Allele | FSGS4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447574","APOL1 protein, human","C138153","Apolipoprotein L1 (398 aa, ~44 kDa) is encoded by the human APOL1 gene. This protein is involved in lipid transport and metabolism.","Apolipoprotein L1 | APOL1 | Apo-L | ApoL | ApoL-I | Apolipoprotein L | Apolipoprotein L 1 | Apolipoprotein L-I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525678","APLNR Gene","C138154","This gene plays a role in peptide hormone-dependent G protein-coupled receptor signaling.","APLNR Gene | APLNR | Apelin Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525672","APLNR wt Allele","C138157","Human APLNR wild-type allele is located in the vicinity of 11q12.1 and is approximately 4 kb in length. This allele, which encodes apelin receptor protein, is involved in the mediation of peptide hormone signaling.","APLNR wt Allele | AGTRL1 | APJ | APJ (Apelin) Receptor Gene | APJ Putative Receptor Protein Related to Angiotensin Receptor Gene | APJR | Apelin Receptor wt Allele | FLJ90771 | HG11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1313689","APLNR protein, human","C138159","Apelin receptor (380 aa, ~43 kDa) is encoded by the human APLNR gene. This protein plays a role in G protein-coupled receptor signaling.","Apelin Receptor | APJ Receptor | APLNR | Angiotensin II Receptor-Like 1 | Angiotensin Receptor-Like 1 | G Protein-Coupled Receptor APJ | G-Protein Coupled Receptor APJ | G-Protein Coupled Receptor HG11 | HG11 Orphan Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521701","8p21-p12","C13815","A chromosome band present on 8p","8p21-p12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526088","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Legs Hurt","C138568","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: My child's legs hurt.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Legs Hurt | PQL11-Legs Hurt | PQL1104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522286","Stage II Intrahepatic Cholangiocarcinoma AJCC v8","C134760","Stage II includes: T2, N0, M0. T2: Solitary tumor with intrahepatic vascular invasion, or multiple tumors, with or without vascular invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Intrahepatic Cholangiocarcinoma AJCC v8 | II | Stage II Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522287","Stage III Intrahepatic Cholangiocarcinoma AJCC v8","C134761","Stage III includes: IIIA: (T3, N0, M0); IIIB: (T4, N0, M0); (Any T, N1, M0). T3: Tumor perforating the visceral peritoneum. T4: Tumor involving local extrahepatic structures by direct invasion. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | III | Stage III Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522288","Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8","C134762","Stage IIIA includes: T3, N0, M0. T3: Tumor perforating the visceral peritoneum. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | IIIA | Stage IIIA Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522289","Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8","C134763","Stage IIIB includes: (T4, N0, M0); (Any T, N1, M0). T4: Tumor involving local extrahepatic structures by direct invasion. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | IIIB | Stage IIIB Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525710","High Grade B-Cell Lymphoma","C138211","A term that refers to high-grade B-cell lymphoma, not otherwise specified or high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.","High Grade B-Cell Lymphoma | HGBL | High-Grade B-Cell Lymphoma",,,,,,,,,,,,,,,"4079692","High grade B-cell lymphoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL525686","CDISC Clinical Classification HAS-BLED Test Name Terminology","C138212","Test names of clinical classification questions associated with the HAS-BLED Bleeding Risk Score (HAS-BLED) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification HAS-BLED Test Name Terminology | CC-HAS-BLED TEST | HAS-BLED Bleeding Risk Score Clinical Classification Test Name | HSB01TN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525685","CDISC Clinical Classification HAS-BLED Test Code Terminology","C138213","Test codes of clinical classification questions associated with the HAS-BLED Bleeding Risk Score (HAS-BLED) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification HAS-BLED Test Code Terminology | CC-HAS-BLED TESTCD | HAS-BLED Bleeding Risk Score Clinical Classification Test Code | HSB01TC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525872","PUL 2.0 - Supination","C138416","Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Supination.","PUL 2.0 - Supination | PUL02-Supination | PUL0219",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525879","PUL 2.0 - Picking Up Coins","C138417","Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Picking up coins.","PUL 2.0 - Picking Up Coins | PUL02-Picking Up Coins | PUL0220",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525878","PUL 2.0 - Placing Finger on Number Diagram","C138418","Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Placing finger on number diagram.","PUL 2.0 - Placing Finger on Number Diagram | PUL02-Placing Finger on Number Diagram | PUL0221",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525877","PUL 2.0 - Pick Up 10g Weight Finger Pinch","C138419","Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Pick up 10g weight finger pinch.","PUL 2.0 - Pick Up 10g Weight Finger Pinch | PUL02-Pick Up 10g Weight Finger Pinch | PUL0222",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515452","8q13.1","C13841","A chromosome band present on 8q","8q13.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526012","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard to Gain or Lose Weight","C138524","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to gain or lose weight when he or she wants to.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard to Gain or Lose Weight | PQL15-Hard to Gain/Lose Weight | PQL1510",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526218","PedsQL Neuromuscular Module Version 3.0 Child Report - Long Time to Bathe or Shower","C138694","Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: It takes me a long time to bathe or shower.","PedsQL Neuromuscular Module Version 3.0 Child Report - Long Time to Bathe or Shower | PQL05-Long Time to Bathe/Shower | PQL0513",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526217","PedsQL Neuromuscular Module Version 3.0 Child Report - Get Hurt Accidentally","C138695","Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: I get hurt accidentally.","PedsQL Neuromuscular Module Version 3.0 Child Report - Get Hurt Accidentally | PQL05-Get Hurt Accidentally | PQL0514",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526216","PedsQL Neuromuscular Module Version 3.0 Child Report - Take Long Time to Eat","C138696","Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: I take a long time to eat.","PedsQL Neuromuscular Module Version 3.0 Child Report - Take Long Time to Eat | PQL05-Take Long Time to Eat | PQL0515",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526223","PedsQL Neuromuscular Module Version 3.0 Child Report - Hard to Turn During Night","C138697","Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: It is hard to turn myself during the night.","PedsQL Neuromuscular Module Version 3.0 Child Report - Hard to Turn During Night | PQL05-Hard to Turn During Night | PQL0516",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526222","PedsQL Neuromuscular Module Version 3.0 Child Report - Hard to Go Places With Equipment","C138698","Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: It is hard for me to go places with my equipment.","PedsQL Neuromuscular Module Version 3.0 Child Report - Hard to Go Places With Equipment | PQL05-Hard to Go Places With Equipment | PQL0517",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526221","PedsQL Neuromuscular Module Version 3.0 Child Report - Hard Tell Doctors and Nurses How Feel","C138699","Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: It is hard for me to tell the doctors and nurses how I feel.","PedsQL Neuromuscular Module Version 3.0 Child Report - Hard Tell Doctors and Nurses How Feel | PQL05-Hard Tell Doctors/Nurses How Feel | PQL0518",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520268","10q11-p12","C13869","A chromosome band present on 10q","10q11-p12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526220","PedsQL Neuromuscular Module Version 3.0 Child Report - Hard Ask Doctors and Nurses Questions","C138700","Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: It is hard for me to ask the doctors and nurses questions.","PedsQL Neuromuscular Module Version 3.0 Child Report - Hard Ask Doctors and Nurses Questions | PQL05-Hard Ask Doctors/Nurses Questions | PQL0519",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525915","HAS-BLED - Hypertension","C138357","HAS-BLED Bleeding Risk Score (HAS-BLED) Hypertension.","HAS-BLED - Hypertension | HSB01-Hypertension | HSB0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525914","HAS-BLED - Abnormal Renal and Liver Function","C138358","HAS-BLED Bleeding Risk Score (HAS-BLED) Abnormal renal and liver function.","HAS-BLED - Abnormal Renal and Liver Function | HSB01-Abnormal Renal and Liver Function | HSB0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525913","HAS-BLED - Stroke","C138359","HAS-BLED Bleeding Risk Score (HAS-BLED) Stroke.","HAS-BLED - Stroke | HSB01-Stroke | HSB0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521570","6q22.33-q24.1","C13835","A chromosome band present on 6q","6q22.33-q24.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525912","HAS-BLED - Bleeding","C138360","HAS-BLED Bleeding Risk Score (HAS-BLED) Bleeding.","HAS-BLED - Bleeding | HSB01-Bleeding | HSB0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525919","HAS-BLED - Labile INRs","C138361","HAS-BLED Bleeding Risk Score (HAS-BLED) Labile INRs.","HAS-BLED - Labile INRs | HSB01-Labile INRs | HSB0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525918","HAS-BLED - Elderly","C138362","HAS-BLED Bleeding Risk Score (HAS-BLED) Elderly.","HAS-BLED - Elderly | HSB01-Elderly | HSB0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522290","Stage IV Intrahepatic Cholangiocarcinoma AJCC v8","C134764","Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | IV | Stage IV Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4077189","alpha-methyl-4-(F-18)fluoro-4-deoxy-D-glucose","C134765","A radioconjugate and sodium-dependent glucose transporter (SGLT)-specific tracer that is composed of a glucose analog labeled with the positron-emitting radioactive isotope fluorine F18, and can be used for tumor cell imaging upon positron emission tomography (PET). Upon administration, alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside (Me4FDG) is specifically taken up by SGLT-expressing tumor cells. The fluorine F 18 moiety can be visualized upon PET imaging and this agent can be used both as a tracer for sugar uptake by and for imaging and staging of certain tumor cell types. Glucose is a major metabolic substrate required for cancer cell survival and growth and is taken up by cancer cells at a much higher rate compared to normal cells. SGLTs, especially SGLT type 2 (SGLT2), are overexpressed on certain tumor cell types and play key roles in glucose transport in these cells. Me4FDG is not transported by glucose uniporter proteins (GLUTs). In contrast, Me4FDG is not transported by glucose transporters (GLUTs).","Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside | Alpha-methyl-4-[F-18]-fluoro-4-deoxy-d-glucopyranoside | Alpha-methyl-4-deoxy-4-(18F)fluoro-D-glucopyranoside | METHYL 4-DEOXY-4-FLUORO-.ALPHA.-D-GLUCOPYRANOSIDE. F-18 | Me-4(18F)DG | Me-4FDG | Me4FDG | a-methyl-4[18F]-4-deoxy-D-glucopyranoside",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522291","Baboon Lymphoma","C134766","Lymphoma that occurs in a baboon.","Baboon Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085919","Bovine Lymphosarcoma","C134767","Lymphosarcoma that occurs in a cow.","Bovine Lymphosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522292","Bovine Rectal Myxoma","C134768","A myxoma that occurs in the rectum of a cow.","Bovine Rectal Myxoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520857","19q13.1-q13.2","C13476","A chromosome band present on 19q","19q13.1-q13.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522294","Feline Erythroleukemia","C134770","Erythroleukemia that occurs in a cat.","Feline Erythroleukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522295","Frog Pronephric Kidney Tumor","C134771","A kidney neoplasm of the pronephric cell type that occurs in a frog.","Frog Pronephric Kidney Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522296","Gerbil Fibrosarcoma","C134772","Fibrosarcoma that occurs in a gerbil.","Gerbil Fibrosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522297","Gerbil Melanoma","C134773","Melanoma that occurs in a gerbil.","Gerbil Melanoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522299","Hamster Kidney Tumor","C134775","A kidney neoplasm that occurs in a hamster.","Hamster Kidney Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522300","Hamster Lymphoma","C134776","Lymphoma that occurs in a hamster.","Hamster Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522301","Hamster Lymphosarcoma","C134777","Lymphosarcoma that occurs in a hamster.","Hamster Lymphosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523005","CDISC Questionnaire CGI Generic Modification Version Test Code Terminology","C135686","Test codes of questionnaire questions associated with the Clinical Global Impression Generic Modification Version (CGI Generic Modification Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire CGI Generic Modification Version Test Code Terminology | CGI02TC | Clinical Global Impression Generic Modification Version Questionnaire Test Code | QS-CGI Generic Modification Version TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523006","CDISC Questionnaire PGI Generic Modification Version Test Name Terminology","C135687","Test names of questionnaire questions associated with the Patient Global Impression Generic Modification Version (PGI Generic Modification Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PGI Generic Modification Version Test Name Terminology | PGI01TN | Patient Global Impression Generic Modification Version Questionnaire Test Name | QS-PGI Generic Modification Version TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525876","PUL 2.0 - Preferred Arm","C138420","Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Preferred arm.","PUL 2.0 - Preferred Arm | PUL02-Preferred Arm | PUL0223",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525979","PUL 2.0 - Right Elbow Extension ROM","C138421","Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Right elbow extension ROM.","PUL 2.0 - Right Elbow Extension ROM | PUL02-Right Elbow Extension ROM | PUL0224",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525978","PUL 2.0 - Left Elbow Extension ROM","C138422","Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Left elbow extension ROM.","PUL 2.0 - Left Elbow Extension ROM | PUL02-Left Elbow Extension ROM | PUL0225",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525977","PUL 2.0 - Right Available Supination ROM","C138423","Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Right available supination ROM.","PUL 2.0 - Right Available Supination ROM | PUL02-Right Available Supination ROM | PUL0226",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525976","PUL 2.0 - Left Available Supination ROM","C138424","Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Left available supination ROM.","PUL 2.0 - Left Available Supination ROM | PUL02-Left Available Supination ROM | PUL0227",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525983","PUL 2.0 - High Level Shoulder Dimension","C138425","Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) High level shoulder dimension score.","PUL 2.0 - High Level Shoulder Dimension | PUL02-High Level Shoulder Dimension | PUL0228",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525982","PUL 2.0 - Mid Level Elbow Dimension","C138426","Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Mid level elbow dimension score.","PUL 2.0 - Mid Level Elbow Dimension | PUL02-Mid Level Elbow Dimension | PUL0229",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525980","PUL 2.0 - Total Score","C138428","Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Total score.","PUL 2.0 - Total Score | PUL02-Total Score | PUL0231",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525987","FBRSI - I Get Headaches","C138429","Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) I get headaches.","FBRSI - I Get Headaches | FAC029-I Get Headaches | FAC02901",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521384","4q12","C13842","A chromosome band present on 4q","4q12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525986","FBRSI - I Have Had Seizures","C138430","Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) I have had seizures (convulsions).","FBRSI - I Have Had Seizures | FAC029-I Have Had Seizures | FAC02902",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525985","FBRSI - Have Weakness in My Arms or Legs","C138431","Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) I have weakness in my arms or legs.","FBRSI - Have Weakness in My Arms or Legs | FAC029-Have Weakness in My Arms or Legs | FAC02903",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525984","FBRSI - I Need Help in Caring for Myself","C138432","Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) I need help in caring for myself (bathing, dressing, eating, etc.).","FBRSI - I Need Help in Caring for Myself | FAC029-I Need Help in Caring for Myself | FAC02904",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525991","FBRSI - I Have a Lack of Energy","C138433","Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) I have a lack of energy.","FBRSI - I Have a Lack of Energy | FAC029-I Have a Lack of Energy | FAC02905",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526063","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard to Swallow Food","C138601","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to swallow food.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard to Swallow Food | PQL17-Hard to Swallow Food | PQL1712",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526227","PedsQL Neuromuscular Module Version 3.0 Child Report - Hard Explain Illness to People","C138701","Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: It is hard for me to explain my illness to other people.","PedsQL Neuromuscular Module Version 3.0 Child Report - Hard Explain Illness to People | PQL05-Hard Explain Illness to People | PQL0520",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526226","PedsQL Neuromuscular Module Version 3.0 Child Report - Hard for Family to Plan Activities","C138702","Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: It is hard for my family to plan activities like vacations.","PedsQL Neuromuscular Module Version 3.0 Child Report - Hard for Family to Plan Activities | PQL05-Hard for Family to Plan Activities | PQL0521",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526225","PedsQL Neuromuscular Module Version 3.0 Child Report - Hard for Family to Rest","C138703","Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: It is hard for my family to get enough rest.","PedsQL Neuromuscular Module Version 3.0 Child Report - Hard for Family to Rest | PQL05-Hard for Family to Rest | PQL0522",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526426","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard Ask Doctors and Nurses Questions","C138875","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: It is hard for me to ask the doctors and nurses questions.","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard Ask Doctors and Nurses Questions | PQL01-Hard Ask Doctors/Nurses Questions | PQL0119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526425","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard Explain Illness to People","C138876","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: It is hard for me to explain my illness to other people.","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard Explain Illness to People | PQL01-Hard Explain Illness to People | PQL0120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526432","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard for Family to Plan Activities","C138877","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: It is hard for my family to plan activities like vacations.","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard for Family to Plan Activities | PQL01-Hard for Family to Plan Activities | PQL0121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526431","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard for Family to Rest","C138878","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: It is hard for my family to get enough rest.","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard for Family to Rest | PQL01-Hard for Family to Rest | PQL0122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526430","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Money Problem in Our Family","C138879","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: I think money is a problem in our family.","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Money Problem in Our Family | PQL01-Money Problem in Our Family | PQL0123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520964","1p35","C13887","A chromosome band present on 1p","1p35 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526429","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Family Has Lot of Problems","C138880","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: I think my family has a lot of problems.","PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Family Has Lot of Problems | PQL01-Family Has Lot of Problems | PQL0124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526113","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard Explain Illness to People","C138559","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: It is hard for my child to explain his or her illness to other people.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard Explain Illness to People | PQL13-Hard Explain Illness to People | PQL1320",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520368","11p15.2-p14.3","C13855","A chromosome band present on 11p","11p15.2-p14.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526112","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard for Family to Plan Activities","C138560","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: It is hard for our family to plan activities like vacations.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard for Family to Plan Activities | PQL13-Hard for Family to Plan Activities | PQL1321",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526119","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard for Family to Rest","C138561","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: It is hard for our family to get enough rest.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard for Family to Rest | PQL13-Hard for Family to Rest | PQL1322",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526118","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Money Problem in Our Family","C138562","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: I think money is a problem in our family.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Money Problem in Our Family | PQL13-Money Problem in Our Family | PQL1323",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526117","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Family Has Lot of Problems","C138563","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: I think our family has a lot of problems.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Family Has Lot of Problems | PQL13-Family Has Lot of Problems | PQL1324",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526116","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Do Not Have Equipment Need","C138564","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: My child does not have the equipment he or she needs.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Do Not Have Equipment Need | PQL13-Do Not Have Equipment Need | PQL1325",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526091","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard to Breathe","C138565","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to breathe.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard to Breathe | PQL11-Hard to Breathe | PQL1101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526090","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Get Sick Easily","C138566","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: My child gets sick easily.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Get Sick Easily | PQL11-Get Sick Easily | PQL1102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526089","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Get Sores and/or Rashes","C138567","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: My child gets sores and/or rashes.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Get Sores and/or Rashes | PQL11-Get Sores and/or Rashes | PQL1103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523008","CDISC Questionnaire LEC-5 Standard Version Test Name Terminology","C135689","Test names of questionnaire questions associated with the Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire LEC-5 Standard Version Test Name Terminology | LEC01TN | Life Events Checklist for DSM-5 Standard Version Questionnaire Test Name | QS-LEC-5 Standard Version TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520952","1p32-p31","C13568","A chromosome band present on 1p","1p32-p31 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523009","CDISC Questionnaire LEC-5 Standard Version Test Code Terminology","C135690","Test codes of questionnaire questions associated with the Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire LEC-5 Standard Version Test Code Terminology | LEC01TC | Life Events Checklist for DSM-5 Standard Version Questionnaire Test Code | QS-LEC-5 Standard Version TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523010","CDISC Questionnaire PCL-5 Test Name Terminology","C135691","Test names of questionnaire questions associated with the PTSD Checklist for DSM-5 (PCL-5) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PCL-5 Test Name Terminology | PCL01TN | QS-PCL-5 TEST | The PTSD Checklist for DSM-5 Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523012","CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology","C135693","Test names of questionnaire questions associated with the Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology | PODCI1TN | Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version Questionnaire Test Name | QS-PODCI Pediatric Parent-Reported Version TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523013","CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology","C135694","Test codes of questionnaire questions associated with the Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology | PODCI1TC | Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version Questionnaire Test Code | QS-PODCI Pediatric Parent-Reported Version TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523014","CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology","C135695","Test names of questionnaire questions associated with the Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology | PODCI2TN | Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version Questionnaire Test Name | QS-PODCI Adolescent Parent-Reported Version TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523015","CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology","C135696","Test codes of questionnaire questions associated with the Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology | PODCI2TC | Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version Questionnaire Test Code | QS-PODCI Adolescent Parent-Reported Version TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526062","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Long Time to Bathe or Shower","C138602","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: It takes my child a long time to bathe or shower.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Long Time to Bathe or Shower | PQL17-Long Time to Bathe/Shower | PQL1713",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526061","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Get Hurt Accidentally","C138603","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: My child gets hurt accidentally.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Get Hurt Accidentally | PQL17-Get Hurt Accidentally | PQL1714",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526060","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Take Long Time to Eat","C138604","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: My child takes a long time to eat.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Take Long Time to Eat | PQL17-Take Long Time to Eat | PQL1715",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526067","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard to Turn During Night","C138605","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to turn him or herself during the night.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard to Turn During Night | PQL17-Hard to Turn During Night | PQL1716",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526065","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard Tell Doctors and Nurses How Feel","C138607","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to tell the doctors and nurses how he or she feels.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard Tell Doctors and Nurses How Feel | PQL17-Hard Tell Doctors/Nurses How Feel | PQL1718",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526064","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard Ask Doctors and Nurses Questions","C138608","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to ask the doctors and nurses questions.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard Ask Doctors and Nurses Questions | PQL17-Hard Ask Doctors/Nurses Questions | PQL1719",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526071","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard Explain Illness to People","C138609","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to explain his or her illness to other people.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard Explain Illness to People | PQL17-Hard Explain Illness to People | PQL1720",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520942","1p21-p13.3","C13860","A chromosome band present on 1p","1p21-p13.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526070","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard for Family to Plan Activities","C138610","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: It is hard for our family to plan activities like vacations.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard for Family to Plan Activities | PQL17-Hard for Family to Plan Activities | PQL1721",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526435","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Hard to Breathe","C138882","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: It is hard to breathe.","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Hard to Breathe | PQL07-Hard to Breathe | PQL0701",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526434","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Get Sick Easily","C138883","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: I get sick easily.","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Get Sick Easily | PQL07-Get Sick Easily | PQL0702",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526433","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Get Sores and/or Rashes","C138884","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: I get sores and/or rashes.","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Get Sores and/or Rashes | PQL07-Get Sores and/or Rashes | PQL0703",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526408","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Legs Hurt","C138885","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: My legs hurt.","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Legs Hurt | PQL07-Legs Hurt | PQL0704",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526095","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Feel Tired","C138569","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: My child feels tired.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Feel Tired | PQL11-Feel Tired | PQL1105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521475","5q13.1","C13873","A chromosome band present on 5q","5q13.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526196","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard to Use Bathroom","C138740","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to use the bathroom.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard to Use Bathroom | PQL06-Hard to Use Bathroom | PQL0609",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526299","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard to Gain or Lose Weight","C138741","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to gain or lose weight when he or she wants to.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard to Gain or Lose Weight | PQL06-Hard to Gain/Lose Weight | PQL0610",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526298","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard to Use Hands","C138742","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to use his or her hands.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard to Use Hands | PQL06-Hard to Use Hands | PQL0611",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526297","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard to Swallow Food","C138743","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to swallow food.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard to Swallow Food | PQL06-Hard to Swallow Food | PQL0612",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526296","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Long Time to Bathe or Shower","C138744","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: It takes my child a long time to bathe or shower.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Long Time to Bathe or Shower | PQL06-Long Time to Bathe/Shower | PQL0613",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526303","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Get Hurt Accidentally","C138745","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: My child gets hurt accidentally.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Get Hurt Accidentally | PQL06-Get Hurt Accidentally | PQL0614",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526302","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Take Long Time to Eat","C138746","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: My child takes a long time to eat.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Take Long Time to Eat | PQL06-Take Long Time to Eat | PQL0615",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526301","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard to Turn During Night","C138747","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to turn him or herself during the night.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard to Turn During Night | PQL06-Hard to Turn During Night | PQL0616",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523816","ASV","C135018","A proprietary, personalized autologous synthetic cancer vaccine composed of patient-specific synthetic cancer neo-epitopes complexed with heat shock protein 70 (HSP 70; HSP70), with potential immunostimulating and antineoplastic activities. Upon administration of the neoantigen-HSP70 peptide cancer vaccine AGEN2017, the HSPs present the neoantigens to antigen presenting cells (APCs) and help elicit a potent neoantigen-specific T-cell-based anti-tumor immune response, thereby killing the neoantigen-expressing cancer cells. HSP70 is able to the transport the neo-epitopes, activate APCs and enhance the T-cell-mediated immune response.","Neoantigen-HSP70 Peptide Cancer Vaccine AGEN2017 | AGEN 2017 | AGEN-2017 | AGEN2017 | ASV | ASV AGEN2017 | AutoSynVax | AutoSynVax AGEN2017 | AutoSynVax Vaccine | Autologous Cancer Vaccine AGEN2017 | Neoantigen Vaccine AGEN2017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522615","Digestive System Neuroendocrine Tumor TNM Finding v8","C135019","A finding about one or more characteristics of a digestive system neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system.","Digestive System Neuroendocrine Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521655","7q32-q36","C13501","A chromosome band present on 7q","7q32-q36 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522616","Gastric Neuroendocrine Tumor TNM Finding v8","C135020","A finding about one or more characteristics of a gastric neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system. This classification system applies to gastric 'carcinoid' tumors (NET G1 and G2, and rare well-differentiated G3). Gastric high-grade neuroendocrine carcinoma and gastric mixed adenoneuroendocrine carcinoma are not included in this classification system. (from AJCC 8th Ed.)","Gastric Neuroendocrine Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522617","Gastric Neuroendocrine Tumor Clinical TNM Finding v8","C135021","A clinical finding about one or more characteristics of a gastric neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system.","Gastric Neuroendocrine Tumor Clinical TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522618","Gastric Neuroendocrine Tumor Clinical Distant Metastasis TNM Finding v8","C135022","A clinical finding about one or more characteristics of a gastric neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Gastric Neuroendocrine Tumor Clinical Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522619","Gastric Neuroendocrine Tumor cM0 TNM Finding v8","C135023","Gastric neuroendocrine tumor without evidence of distant metastasis. (from AJCC 8th Ed.)","Gastric Neuroendocrine Tumor cM0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522620","Gastric Neuroendocrine Tumor cM1 TNM Finding v8","C135024","Gastric neuroendocrine tumor with distant metastasis. (from AJCC 8th Ed.)","Gastric Neuroendocrine Tumor cM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522621","Gastric Neuroendocrine Tumor cM1a TNM Finding v8","C135025","Gastric neuroendocrine tumor with metastasis confined to liver. (from AJCC 8th Ed.)","Gastric Neuroendocrine Tumor cM1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522622","Gastric Neuroendocrine Tumor cM1b TNM Finding v8","C135026","Gastric neuroendocrine tumor with metastasis in at least one extrahepatic site (e.g., lung, ovary, nonregional lymph node, peritoneum, bone). (from AJCC 8th Ed.)","Gastric Neuroendocrine Tumor cM1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522624","Gastric Neuroendocrine Tumor Pathologic TNM Finding v8","C135028","A pathologic finding about one or more characteristics of a gastric neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system.","Gastric Neuroendocrine Tumor Pathologic TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522625","Gastric Neuroendocrine Tumor Pathologic Distant Metastasis TNM Finding v8","C135029","A pathologic finding about one or more characteristics of a gastric neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Gastric Neuroendocrine Tumor Pathologic Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521276","3p11.2","C13502","A chromosome band present on 3p","3p11.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522626","Gastric Neuroendocrine Tumor pM1 TNM Finding v8","C135030","Gastric neuroendocrine tumor with distant metastasis. (from AJCC 8th Ed.)","Gastric Neuroendocrine Tumor pM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522627","Gastric Neuroendocrine Tumor pM1a TNM Finding v8","C135031","Gastric neuroendocrine tumor with metastasis confined to liver. (from AJCC 8th Ed.)","Gastric Neuroendocrine Tumor pM1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526272","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Get Sores and/or Rashes","C138784","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: My child gets sores and/or rashes.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Get Sores and/or Rashes | PQL02-Get Sores and/or Rashes | PQL0203",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526279","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Legs Hurt","C138785","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: My child's legs hurt.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Legs Hurt | PQL02-Legs Hurt | PQL0204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526278","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Feel Tired","C138786","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: My child feels tired.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Feel Tired | PQL02-Feel Tired | PQL0205",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526277","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Back Feels Stiff","C138787","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: My child's back feels stiff.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Back Feels Stiff | PQL02-Back Feels Stiff | PQL0206",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526276","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Wake Up Tired","C138788","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: My child wakes up tired.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Wake Up Tired | PQL02-Wake Up Tired | PQL0207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526251","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hands Are Weak","C138789","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: My child's hands are weak.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hands Are Weak | PQL02-Hands Are Weak | PQL0208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521116","22q13.2-q13.31","C13878","A chromosome band present on 22q","22q13.2-q13.31 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526250","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard to Use Bathroom","C138790","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: It is hard for my child to use the bathroom.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard to Use Bathroom | PQL02-Hard to Use Bathroom | PQL0209",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526249","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard to Gain or Lose Weight","C138791","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: It is hard for my child to gain or lose weight when he or she wants to.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard to Gain or Lose Weight | PQL02-Hard to Gain/Lose Weight | PQL0210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526248","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard to Use Hands","C138792","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: It is hard for my child to use his or her hands.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard to Use Hands | PQL02-Hard to Use Hands | PQL0211",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526019","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard to Use Hands","C138525","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to use his or her hands.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard to Use Hands | PQL15-Hard to Use Hands | PQL1511",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526018","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard to Swallow Food","C138526","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to swallow food.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard to Swallow Food | PQL15-Hard to Swallow Food | PQL1512",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526017","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Long Time to Bathe or Shower","C138527","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: It takes my child a long time to bathe or shower.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Long Time to Bathe or Shower | PQL15-Long Time to Bathe/Shower | PQL1513",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526016","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Get Hurt Accidentally","C138528","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: My child gets hurt accidentally.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Get Hurt Accidentally | PQL15-Get Hurt Accidentally | PQL1514",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526300","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard to Go Places With Equipment","C138748","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to go places with his or her equipment.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard to Go Places With Equipment | PQL06-Hard to Go Places With Equipment | PQL0617",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526307","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard Tell Doctors and Nurses How Feel","C138749","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to tell the doctors and nurses how he or she feels.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard Tell Doctors and Nurses How Feel | PQL06-Hard Tell Doctors/Nurses How Feel | PQL0618",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521468","5q12-q13","C13874","A chromosome band present on 5q","5q12-q13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525677","(13E,14E,22R,6R)-35-fluoro-6-methyl-7-aza-1(5,3)-pyrazolo[1,5-a]pyrimidina-3(3,2)-pyridina-2(1,2)-pyrrolidinacyclooctaphan-8-one","C138160","An orally bioavailable, selective tropomyosin-related-kinase (tyrosine receptor kinase; TRK) inhibitor, with potential antineoplastic activity. Upon oral administration, LOXO-195 specifically targets and binds to TRK, including the fusion proteins containing sequences from neurotrophic tyrosine receptor kinase (NTRK) types 1 (NTRK1), 2 (NTRK2), and 3 (NTRK3).  This prevents neurotrophin-TRK interaction and TRK activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress TRK and/or express NTRK fusion proteins. LOXO-195 targets specific point mutations that occur after treatment with and result in acquired resistance to another TRK inhibitor; therefore, LOXO-195 is able to overcome acquired resistance to other TRK inhibitors. TRK, a family of receptor tyrosine kinases (RTKs) activated by neurotrophins, is encoded by NTRK family genes. The expression of either mutated forms of or fusion proteins involving NTRK family members results in uncontrolled TRK signaling and plays an important role in tumor cell growth and survival.","Selitrectinib | (13E,14E,22R,6R)-35-fluoro-6-methyl-7-aza-1(5,3)-pyrazolo[1,5-a]pyrimidina-3(3,2)-pyridina-2(1,2)-pyrrolidinacyclooctaphan-8-one | BAY 2731954 | LOXO 195 | LOXO-195 | LOXO195 | SELITRECTINIB | TRK Inhibitor LOXO-195",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525676","Therapy-Related Toxicity - Acceptable to Patient","C138161","Indicates that a toxicity adverse effect has been experienced by a patient, but it is not severe enough for the patient to discontinue the treatment.","Therapy-Related Toxicity - Acceptable to Patient | Adverse Event is Acceptable to Patient | Therapy-Related Toxicity is Acceptable to Patient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525675","Therapy-Related Toxicity - Unacceptable to Patient","C138162","Indicates that a toxicity adverse effect has been experienced by a patient, and it is severe enough for the patient to discontinue the treatment.","Therapy-Related Toxicity - Unacceptable to Patient | Adverse Event is Unacceptable to Patient | Therapy-Related Toxicity is Unacceptable to Patient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1328362","Endocrine Therapy Toxicity","C138163","Indicates that a toxicity adverse effect has been experienced during endocrine drug treatment.","Endocrine Therapy Toxicity | Endocrine Toxicity | Hormonal Therapy Toxicity | Hormonal Treatment Toxicity | Hormone Therapy Toxicity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525731","BTK Inhibitor CT-1530","C138164","An inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), with potential antineoplastic activity. Upon administration, CT-1530 binds to and inhibits the activity of BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.","BTK Inhibitor CT-1530 | CT 1530 | CT-1530 | CT1530",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525730","G1T38","C138165","An orally bioavailable inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon administration, lerociclib selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation.","Lerociclib | 7',8'-Dihydro-2'-((5-(4-(1-methylethyl)-1-piperazinyl)-2-pyridinyl)amino)spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one | CDK4/6 Inhibitor G1T38 | G1T38 | G1T38 Free Base | GB 491 | GB-491 | GB491 | LEROCICLIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522628","Gastric Neuroendocrine Tumor pM1b TNM Finding v8","C135032","Gastric neuroendocrine tumor with metastasis in at least one extrahepatic site (e.g., lung, ovary, nonregional lymph node, peritoneum, bone). (from AJCC 8th Ed.)","Gastric Neuroendocrine Tumor pM1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522629","Gastric Neuroendocrine Tumor pM1c TNM Finding v8","C135033","Gastric neuroendocrine tumor with both hepatic and extrahepatic metastases. (from AJCC 8th Ed.)","Gastric Neuroendocrine Tumor pM1c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526255","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard to Swallow Food","C138793","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: It is hard for my child to swallow food.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard to Swallow Food | PQL02-Hard to Swallow Food | PQL0212",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525683","CDISC Clinical Classification LPSS Test Code Terminology","C138215","Test codes of clinical classification questions associated with the Lansky Play-Performance Status Scale (LPSS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification LPSS Test Code Terminology | CC-LPSS TESTCD | LPPSS1TC | Lansky Play-Performance Status Scale Clinical Classification Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525690","CDISC Functional Test PUL 1.2 Test Name Terminology","C138216","Test names of functional test questions associated with the Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Functional Test PUL 1.2 Test Name Terminology | FT-PUL 1.2 TEST | PUL01TN | Performance of the Upper Limb Module for DMD Version 1.2 Functional Test Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525689","CDISC Functional Test PUL 1.2 Test Code Terminology","C138217","Test codes of functional test questions associated with the Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Functional Test PUL 1.2 Test Code Terminology | FT-PUL 1.2 TESTCD | PUL01TC | Performance of the Upper Limb Module for DMD Version 1.2 Functional Test Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525688","CDISC Functional Test PUL 2.0 Test Name Terminology","C138218","Test names of functional test questions associated with the Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Functional Test PUL 2.0 Test Name Terminology | FT-PUL 2.0 TEST | PUL02TN | Performance of the Upper Limb Module for DMD Version 2.0 Functional Test Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525687","CDISC Functional Test PUL 2.0 Test Code Terminology","C138219","Test codes of functional test questions associated with the Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Functional Test PUL 2.0 Test Code Terminology | FT-PUL 2.0 TESTCD | PUL02TC | Performance of the Upper Limb Module for DMD Version 2.0 Functional Test Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525694","CDISC Questionnaire FBRSI Test Name Terminology","C138220","Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FBRSI Test Name Terminology | FAC029TN | Functional Assessment of Cancer Therapy-Brain Symptom Index Questionnaire Test Name | QS-FBRSI TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525693","CDISC Questionnaire FBRSI Test Code Terminology","C138221","Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FBRSI Test Code Terminology | FAC029TC | Functional Assessment of Cancer Therapy-Brain Symptom Index Questionnaire Test Code | QS-FBRSI TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525692","CDISC Questionnaire FKSI-15 Test Name Terminology","C138222","Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FKSI-15 Test Name Terminology | FAC039TN | Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 Questionnaire Test Name | QS-FKSI-15 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525691","CDISC Questionnaire FKSI-15 Test Code Terminology","C138223","Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FKSI-15 Test Code Terminology | FAC039TC | Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 Questionnaire Test Code | QS-FKSI-15 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525698","CDISC Questionnaire FLSI Test Name Terminology","C138224","Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Lung Symptom Index (FLSI) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FLSI Test Name Terminology | FAC043TN | Functional Assessment of Cancer Therapy-Lung Symptom Index Questionnaire Test Name | QS-FLSI TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526023","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Take Long Time to Eat","C138529","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: My child takes a long time to eat.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Take Long Time to Eat | PQL15-Take Long Time to Eat | PQL1515",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520707","16q24.2-q24.3","C13852","A chromosome band present on 16q","16q24.2-q24.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526022","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard to Turn During Night","C138530","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to turn him or herself during the night.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard to Turn During Night | PQL15-Hard to Turn During Night | PQL1516",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526021","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard to Go Places With Equipment","C138531","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to go places with his or her equipment.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard to Go Places With Equipment | PQL15-Hard to Go Places With Equipment | PQL1517",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526020","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard Tell Doctors and Nurses How Feel","C138532","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to tell the doctors and nurses how he or she feels.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard Tell Doctors and Nurses How Feel | PQL15-Hard Tell Doctors/Nurses How Feel | PQL1518",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525994","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard Explain Illness to People","C138534","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to explain his or her illness to other people.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard Explain Illness to People | PQL15-Hard Explain Illness to People | PQL1520",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525993","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard for Family to Plan Activities","C138535","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: It is hard for our family to plan activities like vacations.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard for Family to Plan Activities | PQL15-Hard for Family to Plan Activities | PQL1521",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526224","PedsQL Neuromuscular Module Version 3.0 Child Report - Money Problem in Our Family","C138704","Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: I think money is a problem in our family.","PedsQL Neuromuscular Module Version 3.0 Child Report - Money Problem in Our Family | PQL05-Money Problem in Our Family | PQL0523",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526231","PedsQL Neuromuscular Module Version 3.0 Child Report - Family Has Lot of Problems","C138705","Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: I think my family has a lot of problems.","PedsQL Neuromuscular Module Version 3.0 Child Report - Family Has Lot of Problems | PQL05-Family Has Lot of Problems | PQL0524",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526230","PedsQL Neuromuscular Module Version 3.0 Child Report - Do Not Have Equipment Need","C138706","Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: I do not have the equipment I need.","PedsQL Neuromuscular Module Version 3.0 Child Report - Do Not Have Equipment Need | PQL05-Do Not Have Equipment Need | PQL0525",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525729","Visceral Crisis","C138166","Severe organ dysfunction as assessed by signs, symptoms and laboratory studies, resulting from rapid progression of neoplastic disease. It is indicative of substantial visceral compromise and may serve as an indication for more aggressive therapeutic intervention.","Visceral Crisis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525736","Prostate Carcinoma by Gene Expression Profile","C138167","A header term that includes the following prostate carcinoma subtypes determined by gene expression profiling: luminal A prostate carcinoma, luminal B prostate carcinoma, and basal-like prostate carcinoma.","Prostate Carcinoma by Gene Expression Profile | Prostate Cancer by Gene Expression Profile",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525917","HAS-BLED - Drugs or Alcohol","C138363","HAS-BLED Bleeding Risk Score (HAS-BLED) Drugs or alcohol.","HAS-BLED - Drugs or Alcohol | HSB01-Drugs or Alcohol | HSB0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525923","PUL 1.2 - Preferred Arm","C138365","Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Preferred arm.","PUL 1.2 - Preferred Arm | PUL01-Preferred Arm | PUL0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525922","PUL 1.2 - Elbow Contractures","C138366","Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Elbow contractures of the preferred arm.","PUL 1.2 - Elbow Contractures | PUL01-Elbow Contractures | PUL0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525921","PUL 1.2 - Entry Item","C138367","Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Entry item.","PUL 1.2 - Entry Item | PUL01-Entry Item | PUL01A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525920","PUL 1.2 - Shoulder Abduction to Height","C138368","Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Shoulder abduction to shoulder height.","PUL 1.2 - Shoulder Abduction to Height | PUL01-Shoulder Abduction to Shldr Hgt | PUL01B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520390","11q14","C13836","A chromosome band present on 11q","11q14 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525926","PUL 1.2 - Shoulder Flexion to Height","C138370","Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Shoulder flexion to shoulder height.","PUL 1.2 - Shoulder Flexion to Height | PUL01-Shoulder Flexion to Shldr Height | PUL01D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525924","PUL 1.2 - Hand(s) to Mouth","C138372","Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Hand(s) to mouth.","PUL 1.2 - Hand(s) to Mouth | PUL01-Hand(s) to Mouth | PUL01F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525899","PUL 1.2 - Hand(s) to Table From Lap","C138373","Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Hand(s) to table from lap.","PUL 1.2 - Hand(s) to Table From Lap | PUL01-Hand(s) to Table From Lap | PUL01G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522302","Horse Lymphoma","C134778","Lymphoma that occurs in a horse.","Horse Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522303","Mouse Rectum Carcinoma","C134779","Carcinoma that occurs in the rectum of a mouse.","Mouse Rectum Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0935660","22q11","C13477","A chromosome band present on 22q","22q11 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522304","Mouse Reticulum Cell Sarcoma","C134780","Reticulum cell sarcoma that occurs in a mouse.","Mouse Reticulum Cell Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522305","Ovine Sinus Tumor","C134781","A neoplasm that occurs in the sinus of a sheep.","Ovine Sinus Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522306","Rhesus Monkey Lymphoma","C134783","Lymphoma that occurs in a rhesus monkey.","Rhesus Monkey Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522307","Rhesus Monkey Mammary Tumor","C134784","A mammary neoplasm that occurs in a rhesus monkey.","Rhesus Monkey Mammary Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522308","Zebra Finch Neoplasm","C134785","A neoplasm that occurs in a zebra finch.","Zebra Finch Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522310","Anti-TIGIT Monoclonal Antibody","C134787","Any monoclonal antibody against TIGIT.","Anti-TIGIT Monoclonal Antibody | Anti-TIGIT MoAb | Anti-immunoglobulin (Ig) and Immunoreceptor Tyrosine-based iInhibitory Motif Monoclonal Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522312","Distal Bile Duct Cancer Clinical TNM Finding v8","C134789","A clinical finding about one or more characteristics of distal bile duct cancer, following the rules of the TNM AJCC v8 classification system.","Distal Bile Duct Cancer Clinical TNM Finding v8 | Distal Bile Duct Carcinoma Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520951","1p32","C13478","A chromosome band present on 1p","1p32 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522313","Distal Bile Duct Cancer Clinical Distant Metastasis TNM Finding v8","C134790","A clinical finding about one or more characteristics of distal bile duct cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Distal Bile Duct Cancer Clinical Distant Metastasis TNM Finding v8 | Distal Bile Duct Cancer Clinical Distant Metastasis Status (cM) | Distal Bile Duct Carcinoma Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525697","CDISC Questionnaire FLSI Test Code Terminology","C138225","Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Lung Symptom Index (FLSI) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FLSI Test Code Terminology | FAC043TC | Functional Assessment of Cancer Therapy-Lung Symptom Index Questionnaire Test Code | QS-FLSI TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525696","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Name Terminology","C138226","Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Name Terminology | PQL14TN | Pediatric Quality of Life Neuromuscular Module Acute Version 3 Child Questionnaire Test Name | QS-PedsQL Neuromuscular Module Acute Version 3.0 Child Report TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525990","FBRSI - Difficulty Expressing My Thoughts","C138434","Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) I have difficulty expressing my thoughts.","FBRSI - Difficulty Expressing My Thoughts | FAC029-Difficulty Expressing My Thoughts | FAC02906",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525989","FBRSI - I Have Trouble With Coordination","C138435","Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) I have trouble with coordination.","FBRSI - I Have Trouble With Coordination | FAC029-I Have Trouble With Coordination | FAC02907",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525988","FBRSI - Frustrated I Cannot Do Things","C138436","Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) I get frustrated that I cannot do things I used to.","FBRSI - Frustrated I Cannot Do Things | FAC029-Frustrated I Cannot Do Things | FAC02908",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525963","FBRSI - I Have Nausea","C138437","Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) I have nausea.","FBRSI - I Have Nausea | FAC029-I Have Nausea | FAC02909",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525962","FBRSI - Able to Find the Right Words","C138438","Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) I am able to find the right word(s) to say what I mean.","FBRSI - Able to Find the Right Words | FAC029-Able to Find the Right Words | FAC02910",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525961","FBRSI - Losing Hope Against Illness","C138439","Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) I am losing hope in the fight against my illness.","FBRSI - Losing Hope Against Illness | FAC029-Losing Hope Against Illness | FAC02911",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521055","20q12","C13843","A chromosome band present on 20q","20q12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525960","FBRSI - Trouble Meeting Needs of Family","C138440","Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) Because of my physical condition, I have trouble meeting the needs of my family.","FBRSI - Trouble Meeting Needs of Family | FAC029-Trouble Meeting Needs of Family | FAC02912",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525967","FBRSI - Worry My Condition Will Get Worse","C138441","Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) I worry that my condition will get worse.","FBRSI - Worry My Condition Will Get Worse | FAC029-Worry My Condition Will Get Worse | FAC02913",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525966","FBRSI - I Am Afraid of Having a Seizure","C138442","Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) I am afraid of having a seizure (convulsion).","FBRSI - I Am Afraid of Having a Seizure | FAC029-I Am Afraid of Having a Seizure | FAC02914",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525965","FBRSI - I Am Able to Enjoy Life","C138443","Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) I am able to enjoy life.","FBRSI - I Am Able to Enjoy Life | FAC029-I Am Able to Enjoy Life | FAC02915",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525964","FKSI-15 - I Have a Lack of Energy","C138444","Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) I have a lack of energy.","FKSI-15 - I Have a Lack of Energy | FAC039-I Have a Lack of Energy | FAC03901",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526229","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard to Breathe","C138707","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: It is hard for my child to breathe.","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard to Breathe | PQL09-Hard to Breathe | PQL0901",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526228","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Get Sick Easily","C138708","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: My child gets sick easily.","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Get Sick Easily | PQL09-Get Sick Easily | PQL0902",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526203","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Get Sores and/or Rashes","C138709","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: My child gets sores and/or rashes.","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Get Sores and/or Rashes | PQL09-Get Sores and/or Rashes | PQL0903",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520383","11q13.1-q13.2","C13870","A chromosome band present on 11q","11q13.1-q13.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526202","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Legs Hurt","C138710","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: My child's legs hurt.","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Legs Hurt | PQL09-Legs Hurt | PQL0904",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526201","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Feel Tired","C138711","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: My child feels tired.","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Feel Tired | PQL09-Feel Tired | PQL0905",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526207","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Wake Up Tired","C138713","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: My child wakes up tired.","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Wake Up Tired | PQL09-Wake Up Tired | PQL0907",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526206","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hands Are Weak","C138714","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: My child's hands are weak.","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hands Are Weak | PQL09-Hands Are Weak | PQL0908",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526205","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard to Use Bathroom","C138715","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: It is hard for my child to use the bathroom.","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard to Use Bathroom | PQL09-Hard to Use Bathroom | PQL0909",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525898","PUL 1.2 - Move Weight on Table","C138374","Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Move weight on table.","PUL 1.2 - Move Weight on Table | PUL01-Move Weight on Table | PUL01H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525897","PUL 1.2 - Lifting Light Cans","C138375","Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Lifting light cans.","PUL 1.2 - Lifting Light Cans | PUL01-Lifting Light Cans | PUL01I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525896","PUL 1.2 - Lifting Light Cans Time","C138376","Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Lifting light cans, time.","PUL 1.2 - Lifting Light Cans Time | PUL01-Lifting Light Cans Time | PUL01I1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525903","PUL 1.2 - Lifting Heavy Cans","C138377","Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Lifting heavy cans.","PUL 1.2 - Lifting Heavy Cans | PUL01-Lifting Heavy Cans | PUL01J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525902","PUL 1.2 - Lifting Heavy Cans Time","C138378","Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Lifting heavy cans, time.","PUL 1.2 - Lifting Heavy Cans Time | PUL01-Lifting Heavy Cans Time | PUL01J1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525901","PUL 1.2 - Stacking Light Cans","C138379","Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Stacking light cans.","PUL 1.2 - Stacking Light Cans | PUL01-Stacking Light Cans | PUL01K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520846","19p13.12","C13837","A chromosome band present on 19p","19p13.12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525900","PUL 1.2 - Stacking Light Cans Time","C138380","Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Stacking light cans, time.","PUL 1.2 - Stacking Light Cans Time | PUL01-Stacking Light Cans Time | PUL01K1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526094","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Back Feels Stiff","C138570","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: My child's back feels stiff.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Back Feels Stiff | PQL11-Back Feels Stiff | PQL1106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526093","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Wake Up Tired","C138571","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: My child wakes up tired.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Wake Up Tired | PQL11-Wake Up Tired | PQL1107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526092","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hands Are Weak","C138572","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: My child's hands are weak.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hands Are Weak | PQL11-Hands Are Weak | PQL1108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526099","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard to Use Bathroom","C138573","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to use the bathroom.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard to Use Bathroom | PQL11-Hard to Use Bathroom | PQL1109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526098","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard to Gain or Lose Weight","C138574","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to gain or lose weight when he or she wants to.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard to Gain or Lose Weight | PQL11-Hard to Gain/Lose Weight | PQL1110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522316","Distal Bile Duct Cancer Pathologic TNM Finding v8","C134794","A pathologic finding about one or more characteristics of distal bile duct cancer, following the rules of the TNM AJCC v8 classification system.","Distal Bile Duct Cancer Pathologic TNM Finding v8 | Distal Bile Duct Carcinoma Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522317","Distal Bile Duct Cancer Pathologic Distant Metastasis TNM Finding v8","C134795","A pathologic finding about one or more characteristics of distal bile duct cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Distal Bile Duct Cancer Pathologic Distant Metastasis TNM Finding v8 | Distal Bile Duct Cancer Pathologic Distant Metastasis Status (pM) | Distal Bile Duct Carcinoma Pathologic Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522319","Distal Bile Duct Cancer Pathologic Primary Tumor TNM Finding v8","C134797","A pathologic finding about one or more characteristics of distal bile duct cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Distal Bile Duct Cancer Pathologic Primary Tumor TNM Finding v8 | Distal Bile Duct Cancer Pathologic Primary Tumor Status (pT) | Distal Bile Duct Carcinoma Pathologic Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523016","CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology","C135697","Test names of questionnaire questions associated with the Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology | PODCI3TN | Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version Questionnaire Test Name | QS-PODCI Adolescent Self-Reported Version TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523017","CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology","C135698","Test codes of questionnaire questions associated with the Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology | PODCI3TC | Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version Questionnaire Test Code | QS-PODCI Adolescent Self-Reported Version TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523018","CDISC Questionnaire RAND Social Support Survey Test Name Terminology","C135699","Test names of questionnaire questions associated with the RAND Social Support Survey Instrument (RAND Social Support Survey) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire RAND Social Support Survey Test Name Terminology | QS-RAND Social Support Survey TEST | RAND Social Support Survey Instrument Questionnaire Test Name | RSSS01TN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520847","19p13.2","C13569","A chromosome band present on 19p","19p13.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523019","CDISC Questionnaire RAND Social Support Survey Test Code Terminology","C135700","Test codes of questionnaire questions associated with the RAND Social Support Survey Instrument (RAND Social Support Survey) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire RAND Social Support Survey Test Code Terminology | QS-RAND Social Support Survey TESTCD | RAND Social Support Survey Instrument Questionnaire Test Code | RSSS01TC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523020","PASI Clinical Classification Question","C135701","A question associated with the PASI clinical classification.","PASI Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523021","BEBQ Concurrent Version Questionnaire Question","C135702","A question associated with the BEBQ Concurrent Version questionnaire.","BEBQ Concurrent Version Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523022","BEBQ Retrospective Version Questionnaire Question","C135703","A question associated with the BEBQ Retrospective Version questionnaire.","BEBQ Retrospective Version Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525971","FKSI-15 - Bothered by Treatment Side Effect","C138445","Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) I am bothered by side effects of treatment.","FKSI-15 - Bothered by Treatment Side Effect | FAC039-Bothered by Treatment Side Effect | FAC03902",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525969","FKSI-15 - I Am Losing Weight","C138447","Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) I am losing weight.","FKSI-15 - I Am Losing Weight | FAC039-I Am Losing Weight | FAC03904",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525968","FKSI-15 - I Have Bone Pain","C138448","Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) I have bone pain.","FKSI-15 - I Have Bone Pain | FAC039-I Have Bone Pain | FAC03905",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525975","FKSI-15 - I Feel Fatigued","C138449","Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) I feel fatigued.","FKSI-15 - I Feel Fatigued | FAC039-I Feel Fatigued | FAC03906",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521059","20q12-q13.12","C13844","A chromosome band present on 20q","20q12-q13.12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525974","FKSI-15 - I Am Able to Enjoy Life","C138450","Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) I am able to enjoy life.","FKSI-15 - I Am Able to Enjoy Life | FAC039-I Am Able to Enjoy Life | FAC03907",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526069","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard for Family to Rest","C138611","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: It is hard for our family to get enough rest.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard for Family to Rest | PQL17-Hard for Family to Rest | PQL1722",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526068","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Money Problem in Our Family","C138612","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: I think money is a problem in our family.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Money Problem in Our Family | PQL17-Money Problem in Our Family | PQL1723",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526171","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Family Has Lot of Problems","C138613","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: I think our family has a lot of problems.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Family Has Lot of Problems | PQL17-Family Has Lot of Problems | PQL1724",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526169","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard to Breathe","C138615","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: It is hard to breathe.","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard to Breathe | PQL12-Hard to Breathe | PQL1201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526168","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Get Sick Easily","C138616","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: I get sick easily.","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Get Sick Easily | PQL12-Get Sick Easily | PQL1202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526175","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Get Sores and/or Rashes","C138617","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: I get sores and/or rashes.","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Get Sores and/or Rashes | PQL12-Get Sores and/or Rashes | PQL1203",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518457","Nucleosome Core Particle","C13811","Nucleosome core particle consists of the 146 base pair highly protected DNA segment and its bound histone octamer (two of each histones H2A, H2B, H3 and H4). Nucleosome core particle, linker DNA and histone H1 comprise one structural unit of chromatin, nucleosome. (NCI)","Nucleosome Core Particle | Core Particle | Nucleosome Core | Protein Spool | Spool",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1417523","MYBPC3 Gene","C138123","This gene is involved in cardiac muscle cell contraction.","MYBPC3 Gene | MYBPC3 | Myosin Binding Protein C, Cardiac Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525101","MYBPC3 wt Allele","C138124","Human MYBPC3 wild-type allele is located in the vicinity of 11p11.2 and is approximately 21 kb in length. This allele, which encodes myosin-binding protein C, cardiac-type, plays a role in cardiac muscle cell contraction. Mutation of the gene is associated with hereditary hypertrophic cardiomyopathy.","MYBPC3 wt Allele | CMD1MM | CMH4 | FHC | LVNC10 | MYBP-C | Myosin Binding Protein C, Cardiac wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421481","WASF3 Gene","C138126","This gene plays a role in signaling and cytoskeletal remodeling.","WASF3 Gene | WAS Protein Family Member 3 Gene | WASF3 | WASP Family Member 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525104","WASF3 wt Allele","C138127","Human WASF3 wild-type allele is located in the vicinity of 13q12.13 and is approximately 131 kb in length. This allele, which encodes actin-binding protein WASF3 protein, is involved in cell morphology.","WASF3 wt Allele | Brush-1 | KIAA0900 | SCAR, Dictyostelium, Homolog of, 3 Gene | SCAR3 | WAS Protein Family Member 3 Gene | WAS Protein Family Member 3 wt Allele | WAS Protein Family, Member 3 Gene | WASP Family Member 3 wt Allele | WASP Family Verprolin-Homologous Protein 3 Gene | WASP Family, Member 3 Gene | WASP Family, Verprolin Homology Domain-Containing Protein 3 Gene | WAVE3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1438376","WASF3 protein, human","C138128","Actin-binding protein WASF3 (502 aa, ~55 kDa) is encoded by the human WASF3 gene. This protein plays a role in the mediation of signaling that regulates cell morphology and cytoskeletal remodeling.","Actin-Binding Protein WASF3 | Protein WAVE-3 | Verprolin Homology Domain-Containing Protein 3 | WASF3 | WASP Family Protein Member 3 | WASP Family Verprolin-Homologous Protein 3 | Wiskott-Aldrich Syndrome Protein Family Member 3 | Wiskott-Aldrich Syndrome Protein Family Member 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525681","Radiation Source","C138129","A device designed to emit radiation, either for external use or implantable.","Radiation Source | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519187","Scaffold-Associated Region","C13812","Regions of chromosomal DNA attached to structural components of metaphase (condensed) chromosomes, permitting the partitioning of DNA in the chromosomes into looped domains.  Appear to be related to similar regions denoted matrix-attachment regions that partition the chromosomal DNA in interphase chromosomes.","Scaffold-Associated Region | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515504","9p22.2","C13832","A chromosome band present on 9p","9p22.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526097","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard to Use Hands","C138575","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to use his or her hands.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard to Use Hands | PQL11-Hard to Use Hands | PQL1111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526096","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard to Swallow Food","C138576","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to swallow food.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard to Swallow Food | PQL11-Hard to Swallow Food | PQL1112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526103","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Long Time to Bathe or Shower","C138577","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: It takes my child a long time to bathe or shower.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Long Time to Bathe or Shower | PQL11-Long Time to Bathe/Shower | PQL1113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526102","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Get Hurt Accidentally","C138578","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: My child gets hurt accidentally.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Get Hurt Accidentally | PQL11-Get Hurt Accidentally | PQL1114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526101","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Take Long Time to Eat","C138579","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: My child takes a long time to eat.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Take Long Time to Eat | PQL11-Take Long Time to Eat | PQL1115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520785","17q24","C13857","A chromosome band present on 17q","17q24 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526306","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard Ask Doctors and Nurses Questions","C138750","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to ask the doctors and nurses questions.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard Ask Doctors and Nurses Questions | PQL06-Hard Ask Doctors/Nurses Questions | PQL0619",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526305","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard Explain Illness to People","C138751","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to explain his or her illness to other people.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard Explain Illness to People | PQL06-Hard Explain Illness to People | PQL0620",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526304","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard for Family to Plan Activities","C138752","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: It is hard for our family to plan activities like vacations.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard for Family to Plan Activities | PQL06-Hard for Family to Plan Activities | PQL0621",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526311","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard for Family to Rest","C138753","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: It is hard for our family to get enough rest.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard for Family to Rest | PQL06-Hard for Family to Rest | PQL0622",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523023","CGI Original Version Questionnaire Question","C135704","A question associated with the CGI Original Version questionnaire.","CGI Original Version Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523024","CGI Generic Modification Version Questionnaire Question","C135705","A question associated with the CGI Generic Modification Version questionnaire.","CGI Generic Modification Version Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523025","PGI Generic Modification Version Questionnaire Question","C135706","A question associated with the PGI Generic Modification Version questionnaire.","PGI Generic Modification Version Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523026","LEC-5 Standard Version Questionnaire Question","C135707","A question associated with the LEC-5 Standard Version questionnaire.","LEC-5 Standard Version Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523027","PCL-5 Questionnaire Question","C135708","A question associated with the PCL-5 questionnaire.","PCL-5 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520355","11p11.2","C13570","A chromosome band present on 11p","11p11.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523029","PODCI Adolescent Parent-Reported Version Questionnaire Question","C135710","A question associated with the PODCI Adolescent Parent-Reported Version questionnaire.","PODCI Adolescent Parent-Reported Version Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523030","PODCI Adolescent Self-Reported Version Questionnaire Question","C135711","A question associated with the PODCI Adolescent Self-Reported Version questionnaire.","PODCI Adolescent Self-Reported Version Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522631","Gastric Neuroendocrine Tumor pTX TNM Finding v8","C135035","Gastric neuroendocrine tumor in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Gastric Neuroendocrine Tumor pTX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522632","Gastric Neuroendocrine Tumor pT0 TNM Finding v8","C135036","Gastric neuroendocrine tumor with no evidence of primary tumor. (from AJCC 8th Ed.)","Gastric Neuroendocrine Tumor pT0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522633","Gastric Neuroendocrine Tumor pT1 TNM Finding v8","C135037","Gastric neuroendocrine tumor invading the lamina propria or submucosa and is less than or equal to 1 cm in size. (from AJCC 8th Ed.)","Gastric Neuroendocrine Tumor pT1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522634","Gastric Neuroendocrine Tumor pT2 TNM Finding v8","C135038","Gastric neuroendocrine tumor invading the muscularis propria or is greater than 1 cm in size. (from AJCC 8th Ed.)","Gastric Neuroendocrine Tumor pT2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520841","19p13.1","C13503","A chromosome band present on 19p","19p13.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522636","Gastric Neuroendocrine Tumor pT4 TNM Finding v8","C135040","Gastric neuroendocrine tumor invading visceral peritoneum (serosa) or other organs or adjacent structures. (from AJCC 8th Ed.)","Gastric Neuroendocrine Tumor pT4 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522637","Gastric Neuroendocrine Tumor Pathologic Regional Lymph Nodes TNM Finding v8","C135041","A pathologic finding about one or more characteristics of a gastric neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Gastric Neuroendocrine Tumor Pathologic Regional Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522638","Gastric Neuroendocrine Tumor pNX TNM Finding v8","C135042","Gastric neuroendocrine tumor in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)","Gastric Neuroendocrine Tumor pNX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522639","Gastric Neuroendocrine Tumor pN0 TNM Finding v8","C135043","Gastric neuroendocrine tumor with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","Gastric Neuroendocrine Tumor pN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526174","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Legs Hurt","C138618","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: My legs hurt.","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Legs Hurt | PQL12-Legs Hurt | PQL1204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526173","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Feel Tired","C138619","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: I feel tired.","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Feel Tired | PQL12-Feel Tired | PQL1205",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521636","7q11.1","C13861","A chromosome band present on 7q","7q11.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526172","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Back Feels Stiff","C138620","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: My back feels stiff.","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Back Feels Stiff | PQL12-Back Feels Stiff | PQL1206",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526179","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Wake Up Tired","C138621","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: I wake up tired.","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Wake Up Tired | PQL12-Wake Up Tired | PQL1207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526178","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hands Are Weak","C138622","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: My hands are weak.","PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hands Are Weak | PQL12-Hands Are Weak | PQL1208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526253","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Get Hurt Accidentally","C138795","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: My child gets hurt accidentally.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Get Hurt Accidentally | PQL02-Get Hurt Accidentally | PQL0214",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526252","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Take Long Time to Eat","C138796","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: My child takes a long time to eat.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Take Long Time to Eat | PQL02-Take Long Time to Eat | PQL0215",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526259","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard to Turn During Night","C138797","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: It is hard for my child to turn him or herself during the night.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard to Turn During Night | PQL02-Hard to Turn During Night | PQL0216",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526258","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard to Go Places With Equipment","C138798","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: It is hard for my child to go places with his or her equipment.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard to Go Places With Equipment | PQL02-Hard to Go Places With Equipment | PQL0217",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520765","17q12","C13833","A chromosome band present on 17q","17q12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526310","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Money Problem in Our Family","C138754","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: I think money is a problem in our family.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Money Problem in Our Family | PQL06-Money Problem in Our Family | PQL0623",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526309","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Family Has Lot of Problems","C138755","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: I think our family has a lot of problems.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Family Has Lot of Problems | PQL06-Family Has Lot of Problems | PQL0624",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526283","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard to Breathe","C138757","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: It is hard for my child to breathe.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard to Breathe | PQL04-Hard to Breathe | PQL0401",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526282","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Get Sick Easily","C138758","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: My child gets sick easily.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Get Sick Easily | PQL04-Get Sick Easily | PQL0402",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526281","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Get Sores and/or Rashes","C138759","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: My child gets sores and/or rashes.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Get Sores and/or Rashes | PQL04-Get Sores and/or Rashes | PQL0403",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520171","Xp11.21-p11.22","C13875","A chromosome band present on Xp","Xp11.21-p11.22 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526280","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Legs Hurt","C138760","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: My child's legs hurt.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Legs Hurt | PQL04-Legs Hurt | PQL0404",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0878676","Hyperphenylalaninemia, BH4-deficient A","C138171","An autosomal recessive condition caused by mutation(s) in the PTS gene, encoding 6-pyruvoyl tetrahydrobiopterin synthase. It is characterized by BH4-defecient hyperphenylalanemia, depletion of dopamine and serotonin, and progressive cognitive and motor deficits.","Hyperphenylalaninemia, BH4-deficient A | 6-pyruvoyl Tetrahydropterin Synthase Deficiency | HPABH4A",,,,,,,,,,,,,,,"4035263","6-Pyruvoyl-tetrahydrobiopterin synthase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268465","Hyperphenylalaninemia, BH4-deficient C","C138173","An autosomal recessive condition caused by mutation(s) in the QDPR gene, encoding dihydropteridine reductase. It is characterized by BH4-defecient hyperphenylalanemia, depletion of dopamine and serotonin, and progressive cognitive and motor deficits.","Hyperphenylalaninemia, BH4-deficient C | Dihydropteridine Reductase Deficiency | HPABH4C",,,,,,,,,,,,,,,"4241461","Dihydropteridine reductase deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1855772","Vici Syndrome","C138174","An autosomal recessive condition caused by mutation(s) in the EPG5 gene, encoding ectopic P granules protein 5 homolog. It is characterized by variable immunodeficiency, cleft lip/palate, cataracts, hypopigmentation, and absent corpus callosum.","Vici Syndrome | VICIS",,,,,,,,,,,,,,,"36714540","Vici syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL522640","Gastric Neuroendocrine Tumor pN1 TNM Finding v8","C135044","Gastric neuroendocrine tumor with regional lymph node metastasis. (from AJCC 8th Ed.)","Gastric Neuroendocrine Tumor pN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522525","Gastric Neuroendocrine Tumor by AJCC v8 Stage","C135045","A term that refers to the staging of a gastric neuroendocrine tumor according to the American Joint Committee on Cancer, 8th edition. This staging system applies to gastric 'carcinoid' tumors (NET G1 and G2, and rare well-differentiated G3). Gastric high-grade neuroendocrine carcinoma and gastric mixed adenoneuroendocrine carcinoma are not included in this staging system. (from AJCC 8th Ed.)","Gastric Neuroendocrine Tumor by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522641","Stage I Gastric Neuroendocrine Tumor AJCC v8","C135046","Stage I includes: T1, N0, M0. T1: Tumor invading the lamina propria or submucosa and is less than or equal to 1 cm in size. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Gastric Neuroendocrine Tumor AJCC v8 | Stage I Gastric Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522642","Stage II Gastric Neuroendocrine Tumor AJCC v8","C135047","Stage II includes: (T2, N0, M0); (T3, N0, M0). T2: Tumor invading the muscularis propria or is greater than 1 cm in size. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Gastric Neuroendocrine Tumor AJCC v8 | Stage II Gastric Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522644","Stage IV Gastric Neuroendocrine Tumor AJCC v8","C135049","Stage IV includes: (T1, N0, N1, M1); (T2, N0, N1, M1); (T3, N0, N1, M1); (T4, N0, N1, M1). T1: Tumor invading the lamina propria or submucosa and is less than or equal to 1 cm in size. T2: Tumor invading the muscularis propria or is greater than 1 cm in size. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. T4: Tumor invading visceral peritoneum (serosa) or other organs or adjacent structures. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Gastric Neuroendocrine Tumor AJCC v8 | Stage IV Gastric Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520771","17q21.1","C13504","A chromosome band present on 17q","17q21.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526257","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard Tell Doctors and Nurses How Feel","C138799","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: It is hard for my child to tell the doctors and nurses how he or she feels.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard Tell Doctors and Nurses How Feel | PQL02-Hard Tell Doctors/Nurses How Feel | PQL0218",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520947","1p31-p22","C13879","A chromosome band present on 1p","1p31-p22 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0126758","MAGE-1 Antigen","C1387","A cancer specific antigen expressed by the melanoma antigen gene.","MAGE-1 Antigen | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526256","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard Ask Doctors and Nurses Questions","C138800","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: It is hard for my child to ask the doctors and nurses questions.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard Ask Doctors and Nurses Questions | PQL02-Hard Ask Doctors/Nurses Questions | PQL0219",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526263","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard Explain Illness to People","C138801","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: It is hard for my child to explain his or her illness to other people.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard Explain Illness to People | PQL02-Hard Explain Illness to People | PQL0220",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526262","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard for Family to Plan Activities","C138802","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: It is hard for our family to plan activities like vacations.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard for Family to Plan Activities | PQL02-Hard for Family to Plan Activities | PQL0221",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526260","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Money Problem in Our Family","C138804","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: I think money is a problem in our family.","PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Money Problem in Our Family | PQL02-Money Problem in Our Family | PQL0223",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525695","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Code Terminology","C138227","Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Code Terminology | PQL14TC | Pediatric Quality of Life Neuromuscular Module Acute Version 3 Child Questionnaire Test Code | QS-PedsQL Neuromuscular Module Acute Version 3.0 Child Report TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525791","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Name Terminology","C138228","Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Name Terminology | PQL18TN | Pediatric Quality of Life Neuromuscular Module Acute Version 3 Toddler Parent Report Questionnaire Test Name | QS-PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525992","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard for Family to Rest","C138536","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: It is hard for our family to get enough rest.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard for Family to Rest | PQL15-Hard for Family to Rest | PQL1522",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525999","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Money Problem in Our Family","C138537","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: I think money is a problem in our family.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Money Problem in Our Family | PQL15-Money Problem in Our Family | PQL1523",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525998","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Family Has Lot of Problems","C138538","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: I think our family has a lot of problems.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Family Has Lot of Problems | PQL15-Family Has Lot of Problems | PQL1524",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525997","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Do Not Have Equipment Need","C138539","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: My child does not have the equipment he or she needs.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Do Not Have Equipment Need | PQL15-Do Not Have Equipment Need | PQL1525",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520957","1p33-p31","C13853","A chromosome band present on 1p","1p33-p31 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525996","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard to Breathe","C138540","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: It is hard for my child to breathe.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard to Breathe | PQL13-Hard to Breathe | PQL1301",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526003","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Get Sick Easily","C138541","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: My child gets sick easily.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Get Sick Easily | PQL13-Get Sick Easily | PQL1302",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526002","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Get Sores and/or Rashes","C138542","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: My child gets sores and/or rashes.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Get Sores and/or Rashes | PQL13-Get Sores and/or Rashes | PQL1303",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526001","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Legs Hurt","C138543","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: My child's legs hurt.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Legs Hurt | PQL13-Legs Hurt | PQL1304",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526006","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Wake Up Tired","C138546","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: My child wakes up tired.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Wake Up Tired | PQL13-Wake Up Tired | PQL1307",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520366","11p15.1-p14","C13817","A chromosome band present on 11p","11p15.1-p14 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525717","T-cell Receptor-engineered T-cells","C138180","T-lymphocytes that have been engineered to express a modified antigen-specific T-cell receptor (TCR). In cancer therapy, the TCR-engineered T-cell recognizes a tumor-specific protein fragment complexed with major histocompatibility complex (MHC) molecules on the surface of the tumor cells and kills the tumor cell.","T-cell Receptor-engineered T-cells | T-cell Receptor-engineered T Cells | T-cell Receptor-engineered T-lymphocytes | TCR T Cells | TCR T-cells | TCR-engineered T-cells | TCR-modified T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525716","In Situ Follicular Neoplasia","C138181","A follicular neoplasia confined to the germinal centers of the lymph nodes, without evidence of disseminated disease. It is characterized by the replacement of a germinal center by neoplastic centrocytes with uniformly intense positivity for BCL2. The surrounding mantle cuff and lymphoid architecture are intact. It has a low rate of progression to follicular lymphoma, but is often associated with prior or synchronous overt lymphoma.","In Situ Follicular Neoplasia | FLIS | Follicular Lymphoma In Situ | ISFN | In Situ Follicular B-Cell Neoplasm | In Situ Follicular Lymphoma",,,,,,,,,,,,,,,"37206729","In situ follicular neoplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL525714","Recurrent Abdominal Neuroendocrine Neoplasm","C138183","The reemergence of an abdominal neuroendocrine neoplasm after a period of remission.","Recurrent Abdominal Neuroendocrine Neoplasm | Recurrent Abdominal Neuroendocrine Tumor | Relapsed Abdominal Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525721","Refractory Abdominal Neuroendocrine Neoplasm","C138184","An abdominal neuroendocrine neoplasm that does not respond to treatment.","Refractory Abdominal Neuroendocrine Neoplasm | Refractory Abdominal Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525906","PUL 1.2 - Stacking Heavy Cans Time","C138382","Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Stacking heavy cans, time.","PUL 1.2 - Stacking Heavy Cans Time | PUL01-Stacking Heavy Cans Time | PUL01L1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525905","PUL 1.2 - Remove Lid From Container","C138383","Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Remove lid from container.","PUL 1.2 - Remove Lid From Container | PUL01-Remove Lid From Container | PUL01M",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525904","PUL 1.2 - Tearing Paper","C138384","Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Tearing paper.","PUL 1.2 - Tearing Paper | PUL01-Tearing Paper | PUL01N",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525911","PUL 1.2 - Tracing Path","C138385","Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Tracing path.","PUL 1.2 - Tracing Path | PUL01-Tracing Path | PUL01O",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520263","10p13","C13479","A chromosome band present on 10p","10p13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0104835","Azimexon","C1347","Azimexon (2-cyanaziridinyl-2-carbamoyl-aziridinyl-1-propane) is a derivative of 2-cyanaziridine. Immunostimulant which shows therapeutic effects in tumor models and experimental infections in vitro, enhancing T lymphocyte transformation and phagocytosis. The mode of action of azimexon is unknown. It has been suggested that azimexon may alkylate DNA. In cancer patients it increases leukocytosis, blood active T rosettes, T4/T8 ratio, and is used as an adjuvant to chemotherapy in the treatment of melanoma and myeloma.","Azimexon | 2-Aziridinecarboxamide, 1-[1-(2-cyano-1-aziridinyl)-1-methylethyl] | 2-Cyanaziridinyl-2-carbamoyl-aziridinyl-1-propane | AZ | AZIMEXON | Azimexone | BM 12.531 | BM12531",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525790","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Code Terminology","C138229","Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Code Terminology | PQL18TC | Pediatric Quality of Life Neuromuscular Module Acute Version 3 Toddler Parent Report Questionnaire Test Code | QS-PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039821","Thermoreceptor","C13822","A type of somatosensory receptor located mostly in the skin that detects changes in temperature; there are two classes of thermoreceptors: cold receptors and warm receptors.","Thermoreceptor | Thermoreceptors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525789","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Name Terminology","C138230","Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Name Terminology | PQL15TN | Pediatric Quality of Life Neuromuscular Module Acute Version 3 Child Parent Report Questionnaire Test Name | QS-PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525788","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Code Terminology","C138231","Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Code Terminology | PQL15TC | Pediatric Quality of Life Neuromuscular Module Acute Version 3 Child Parent Report Questionnaire Test Code | QS-PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525795","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Name Terminology","C138232","Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Name Terminology | PQL13TN | Pediatric Quality of Life Neuromuscular Module Acute Version 3 Teen Parent Report Questionnaire Test Name | QS-PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525794","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Code Terminology","C138233","Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Code Terminology | PQL13TC | Pediatric Quality of Life Neuromuscular Module Acute Version 3 Teen Parent Report Questionnaire Test Code | QS-PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525793","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Name Terminology","C138234","Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Name Terminology | PQL11TN | Pediatric Quality of Life Neuromuscular Module Acute Version 3 Young Adult Parent Report Questionnaire Test Name | QS-PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525973","FKSI-15 - I Have Been Short of Breath","C138451","Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) I have been short of breath.","FKSI-15 - I Have Been Short of Breath | FAC039-I Have Been Short of Breath | FAC03908",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525972","FKSI-15 - Worry My Condition Will Get Worse","C138452","Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) I worry that my condition will get worse.","FKSI-15 - Worry My Condition Will Get Worse | FAC039-Worry My Condition Will Get Worse | FAC03909",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526005","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hands Are Weak","C138547","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: My child's hands are weak.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hands Are Weak | PQL13-Hands Are Weak | PQL1308",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526204","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard to Gain or Lose Weight","C138716","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: It is hard for my child to gain or lose weight when he or she wants to.","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard to Gain or Lose Weight | PQL09-Hard to Gain/Lose Weight | PQL0910",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526211","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard to Use Hands","C138717","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: It is hard for my child to use his or her hands.","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard to Use Hands | PQL09-Hard to Use Hands | PQL0911",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526210","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard to Swallow Food","C138718","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: It is hard for my child to swallow food.","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard to Swallow Food | PQL09-Hard to Swallow Food | PQL0912",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526209","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Long Time to Bathe or Shower","C138719","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: It takes my child a long time to bathe or shower.","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Long Time to Bathe or Shower | PQL09-Long Time to Bathe/Shower | PQL0913",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521706","8p22-p21.3","C13871","A chromosome band present on 8p","8p22-p21.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526208","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Get Hurt Accidentally","C138720","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: My child gets hurt accidentally.","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Get Hurt Accidentally | PQL09-Get Hurt Accidentally | PQL0914",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526215","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Take Long Time to Eat","C138721","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: My child takes a long time to eat.","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Take Long Time to Eat | PQL09-Take Long Time to Eat | PQL0915",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526213","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard to Go Places With Equipment","C138723","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: It is hard for my child to go places with his or her equipment.","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard to Go Places With Equipment | PQL09-Hard to Go Places With Equipment | PQL0917",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526212","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard Tell Doctors and Nurses How Feel","C138724","Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: It is hard for my child to tell the doctors and nurses how he or she feels.","PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard Tell Doctors and Nurses How Feel | PQL09-Hard Tell Doctors/Nurses How Feel | PQL0918",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525910","PUL 1.2 - Push on The Light","C138386","Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Push on the light.","PUL 1.2 - Push on The Light | PUL01-Push on The Light | PUL01P",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525909","PUL 1.2 - Supination","C138387","Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Supination.","PUL 1.2 - Supination | PUL01-Supination | PUL01Q",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525908","PUL 1.2 - Picking Up Coins","C138388","Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Picking up coins.","PUL 1.2 - Picking Up Coins | PUL01-Picking Up Coins | PUL01R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525883","PUL 1.2 - Placing Finger on Number Diagram","C138389","Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Placing finger on number diagram.","PUL 1.2 - Placing Finger on Number Diagram | PUL01-Placing Finger on Number Diagram | PUL01S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521494","5q33.2","C13838","A chromosome band present on 5q","5q33.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525882","PUL 1.2 - Finger Pinch Grip","C138390","Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Finger pinch grip.","PUL 1.2 - Finger Pinch Grip | PUL01-Finger Pinch Grip | PUL01T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525881","PUL 1.2 - 3 Point Grip","C138391","Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) 3 point grip.","PUL 1.2 - 3 Point Grip | PUL01-3 Point Grip | PUL01U",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525880","PUL 1.2 - Thumb (Key) Grip","C138392","Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Thumb (key) grip.","PUL 1.2 - Thumb (Key) Grip | PUL01-Thumb (Key) Grip | PUL01V",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525887","PUL 1.2 - High Level Shoulder Dimension","C138393","Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) High level shoulder dimension score.","PUL 1.2 - High Level Shoulder Dimension | PUL01-High Level Shoulder Dimension | PUL0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525886","PUL 1.2 - Mid Level Elbow Dimension","C138394","Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Mid level elbow dimension score.","PUL 1.2 - Mid Level Elbow Dimension | PUL01-Mid Level Elbow Dimension | PUL0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525885","PUL 1.2 - Distal Wrist or Hand Dimension","C138395","Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Distal wrist and hand dimension score.","PUL 1.2 - Distal Wrist or Hand Dimension | PUL01-Distal Wrist/Hand Dimension | PUL0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525891","PUL 2.0 - Entry Item","C138397","Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Entry item.","PUL 2.0 - Entry Item | PUL02-Entry Item | PUL02A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525890","PUL 2.0 - Shoulder Abduction Arms Above Head","C138398","Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Shoulder abduction both arms above head.","PUL 2.0 - Shoulder Abduction Arms Above Head | PUL02-Shoulder Abduction Arms Above Head | PUL0201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525889","PUL 2.0 - Raise Both Arms to Shoulder Height","C138399","Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Raise both arms to shoulder height (elbows at shoulder height).","PUL 2.0 - Raise Both Arms to Shoulder Height | PUL02-Raise Both Arms to Shoulder Height | PUL0202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520406","11q24","C13839","A chromosome band present on 11q","11q24 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526075","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard to Go Places With Equipment","C138581","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to go places with his or her equipment.","PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard to Go Places With Equipment | PQL11-Hard to Go Places With Equipment | PQL1117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522326","Distal Bile Duct Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C134804","A pathologic finding about one or more characteristics of distal bile duct cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Distal Bile Duct Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | Distal Bile Duct Cancer Pathologic Regional Lymph Node Status (pN) | Distal Bile Duct Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL522331","Distal Bile Duct Cancer by AJCC v7 Stage","C134810","A term that refers to the staging of distal bile duct cancer according to the American Joint Committee on Cancer, 7th edition.","Distal Bile Duct Cancer by AJCC v7 Stage | Distal Bile Duct Carcinoma by AJCC v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526232","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Hard to Turn During Night","C138680","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: It is hard to turn myself during the night.","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Hard to Turn During Night | PQL16-Hard to Turn During Night | PQL1616",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526239","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Hard to Go Places With Equipment","C138681","Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: It is hard for me to go places with my equipment.","PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Hard to Go Places With Equipment | PQL16-Hard to Go Places With Equipment | PQL1617",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526981","Tissue Rarefaction","C139136","A morphologic finding indicating reduced tissue density.","Tissue Rarefaction | RAREFACTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526635","Basophilic Hypertrophic Focus","C139137","A central point or locus characterized by hypertrophy and basophilia.","Basophilic Hypertrophic Focus | BASOPHILIC HYPERTROPHIC FOCUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511011","BH2 Domain","C13913","Found in proteins that regulate apoptosis, conserved a-helix BCL-2 Homology (BH1-4) Domains are critical to protein apoptotic function and the protein ability to interact/dimerize with other family members or regulatory proteins. BCL-2 family proteins dimerize among pro- and anti-apoptotic class family members. BCL-2 homodimerization appears to involve head-to-tail interaction of N-terminal BH4 resides with more distal BH1, BH2, and BH3 regions. BCL-2/BAX heterodimerization appears to involve tail-to-tail interaction of the BCL-2 BH1, BH2, and BH3 regions and the BAX BH3 domain region. BCL-2 may suppress cell death partly by binding to BAX via the BH3 domain preventing BAX homodimer formation. (NCI)","BH2 Domain | BCL-2 Homology 2 Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526637","Increased Bone Tissue","C139140","An increase in the amount of bone tissue as compared to a standard or norm.","Increased Bone Tissue | BONE, INCREASED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1849797","Dental Dysplasia","C139141","Chronic degenerative changes of the teeth, mainly the incisors, due to trauma or inflammation. It involves abnormal development of odontogenic tissue and is characterized by abnormal deposits of dentin, cementum, and osteoid.","Dental Dysplasia | DENTAL DYSPLASIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527284","Denticle","C139142","Tooth-like structure formed from displaced odontogenic tissue, which may include dental papilla.","Denticle | DENTICLE",,,,,,,,,,,,,,,"4239161","Pulp stones",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526636","Dentin Matrix Alteration","C139143","A term that refers to alterations in the dentin matrix. Causes include dentinogenesis imperfecta and hypophosphatemic rickets.","Dentin Matrix Alteration | DENTIN MATRIX ALTERATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526618","Dentin Niche Formation","C139144","A finding indicating the formation of a dentin niche due to cellular alterations.","Dentin Niche Formation | DENTIN NICHES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526616","Experimental Organism Fibro-osseous Lesion","C139146","Accumulation of a mixed cell population of non-neoplastic mesenchymal cells along endosteal surfaces which may be associated with focal osteoclastic bone resorption and marrow fibroplasia. (INHAND)","Experimental Organism Fibro-osseous Lesion | FIBRO-OSSEOUS LESION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526615","Fibrous Osteodystrophy","C139147","The replacement of cortical bone by fibrous connective tissue that may be caused by parathyroid hormone-mediated bone resorption with secondary fibroplasia.","Fibrous Osteodystrophy | FIBROUS OSTEODYSTROPHY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526467","HPV Self-Collection","C138957","Any of various methods or devices to allow an individual to collect their own sample for detection of human papillomavirus DNA.","HPV Self-Collection | At-home HPV Self Collection | HPV Self Collection | Human Papillomavirus Self-Collection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537815","Cervical Cancer Clinical Primary Tumor TNM Finding v8","C139687","A clinical finding about one or more characteristics of cervical cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Cervical Cancer Clinical Primary Tumor TNM Finding v8 | Cervical Carcinoma Clinical Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521709","8p23.1","C13968","A chromosome band present on 8p","8p23.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538692","Uveal Melanoma Clinical TNM Finding v8","C140604","A clinical finding about one or more characteristics of uveal melanoma, following the rules of the TNM AJCC v8 classification system.","Uveal Melanoma Clinical TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518794","PKC Phosphorylation Site","C14060","It refers to amino acid residues that can be the target for protein kinase C phosphorylation. (NCI)","PKC Phosphorylation Site | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538669","Uveal Melanoma Pathologic TNM Finding v8","C140611","A pathologic finding about one or more characteristics of uveal melanoma, following the rules of the TNM AJCC v8 classification system.","Uveal Melanoma Pathologic TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510874","Amphipathic Alpha Helix","C14061","The amphipathic helix motif is characterized by a repeating pattern of polar (P) and non-polar (N) side-chains that can be summarized as PxNPPNx. These clusters varied in length from 6 to 15 residues. The conserved non-polar positions are marked by a distinct absence of Asp, Asn and Ser, while other polar side chains are sometimes allowed.","Amphipathic Alpha Helix | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0135981","Peplomycin","C1399","A semisynthetic analog of Bleomycin, a mixture of several basic glycopeptide antineoplastic antibiotics isolated from Streptomyces verticillus.  Peplomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals that cause single- and double-stranded breaks in DNA.  This agent appears to show greater antitumor activity than bleomycin; its use is limited due to pulmonary toxicity. (NCI04)","Peplomycin | (S)-n1-[3-[(1-phenylethyl)amino]propyl]bleomycinamide | PEP | PEPLEOMYCIN | PEPLOMYCIN | Pepleomycin | n1-[3[[(S)-alpha-methylbenzyl]amino]propyl]bleomycinamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538141","PAX9 Gene","C140000","This gene is involved in the development of thymus, parathyroid glands, teeth and other skeletal elements.","PAX9 Gene | PAX9 | Paired Box 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538156","PAX9 wt Allele","C140001","Human PAX9 wild-type allele is located in the vicinity of 14q13.3 and is approximately 22 kb in length. This allele, which encodes paired box protein Pax-9, plays a role in fetal development. Mutation of the gene is associated with selective tooth agenesis type 3 and cleft palate.","PAX9 wt Allele | Paired Box 9 wt Allele | Paired Box Gene 9 | Paired Domain Gene 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1566490","PAX9 protein, human","C140002","Paired box protein Pax-9 (341 aa, ~36 kDa) is encoded by the human PAX9 gene. This protein is involved in transcriptional regulation during fetal development.","Paired Box Protein Pax-9 | PAX9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538154","Primary Peritoneal Cancer by AJCC v7 Stage","C140003","A term that refers to the staging of primary peritoneal cancer according to the American Joint Committee on Cancer, 7th edition.","Primary Peritoneal Cancer by AJCC v7 Stage | Primary Peritoneal Carcinoma by AJCC v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538153","Primary Peritoneal Cancer by AJCC v8 Stage","C140004","A term that refers to the staging of primary peritoneal cancer according to the American Joint Committee on Cancer, 8th edition.","Primary Peritoneal Cancer by AJCC v8 Stage | Primary Peritoneal Carcinoma by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538152","Stage II Primary Peritoneal Cancer AJCC v8","C140005","Stage II includes: T2, N0, M0. T2: Primary peritoneal cancer. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage II Primary Peritoneal Cancer AJCC v8 | Stage II Primary Peritoneal Cancer | Stage II Primary Peritoneal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538151","Stage IIA Primary Peritoneal Cancer AJCC v8","C140006","Stage IIA includes: T2a, N0, M0. T2a: Primary peritoneal cancer with extension and/or implants on the uterus and/or fallopian tube(s) and/or ovaries. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIA Primary Peritoneal Cancer AJCC v8 | Stage IIA Primary Peritoneal Cancer | Stage IIA Primary Peritoneal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538302","Testicular Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C140219","A pathologic finding about one or more characteristics of testicular cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Testicular Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521388","4q13.1","C14021","A chromosome band present on 4q","4q13.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526620","Increased Osteoblastic Surface","C139149","An increase in the amount of osteoblastic surface as compared to a standard or norm.","Increased Osteoblastic Surface | OSTEOBLASTIC SURFACE, INCREASED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526761","Communication/Interviews","C139457","The investigation involved communication/interviews (either interpersonal or through technical means, e.g. phone, e-mail) with persons close to the adverse event, e.g. healthcare professionals (doctors, nurses etc.), the affected patient(s) or other users including, where appropriate, relatives or others engaged in caring for the affected patient.","Communication/Interviews | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526760","Analysis of Information Provided by User/Third Party","C139458","The investigation involved the analysis of relevant information provided by the user (e.g. healthcare professional, patient, clinical engineer) or a third party (e.g. testing facility) in view of supporting the identification of possible causes for the adverse event.","Analysis of Information Provided by User/Third Party | Analysis of Data Provided by User/Third Party",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526759","Device Not Manufactured by Reporting Manufacturer","C139459","Further information was obtained which established that the manufacturer of the device involved was not the one to which it was initially attributed. This includes mistaken identity or falsified device.","Device Not Manufactured by Reporting Manufacturer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517093","FHA Domain","C13945","The FHA (Forkhead-Associated) domain is a phosphopeptide recognition domain found in many regulatory proteins. It displays specificity for phosphothreonine-containing epitopes but will also recognize phosphotyrosine with relatively high affinity. It spans approximately 80-100 amino acid residues folded into an 11-stranded sandwich, which sometimes contain small helical insertions between the loops connecting the strands. To date, genes encoding FHA-containing proteins have been identified in eubacterial and eukaryotic but not aracheal genomes. The domain is present in a diverse range of proteins, such as kinases, phosphatases, kinesins, transcription factors, RNA-binding proteins and metabolic enzymes which partake in many different cellular processes. DNA repair, signal transduction, vesicular transport and protein degradation are just a few examples.","FHA Domain | Forkhead-Associated Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526758","Device Not Returned","C139460","The actual device involved in the adverse event was not returned for testing despite requests by manufacturer.","Device Not Returned | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526765","Device Discarded","C139461","The actual device involved in the adverse event had been already discarded and thus irretrievably lost for testing.","Device Discarded | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526764","Incomplete Device Returned","C139462","The device was returned incompletely, lacking parts, components or accessories that would be required for appropriate testing and analysis of root causes.","Incomplete Device Returned | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526763","Device Not Accessible for Testing","C139463","The actual device involved in the adverse event is not readily accessible for testing (e.g. remains implanted in patient).","Device Not Accessible for Testing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526762","Type of Investigation Not Yet Determined","C139464","Details to determine the type of investigation are not yet available, but are being sought. Do not use this code if the investigation is complete.","Type of Investigation Not Yet Determined | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526864","Insufficient Information Available","C139465","The information available relating to the reported event is not sufficient to identify either the manufacturer, the device, or other essential information.","Insufficient Information Available | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526862","Patient Sample Problem","C139467","Problems that occurred due to endogenous or exogenous interferent in the sample, or unexpected variation in the target analyte/marker.","Patient Sample Problem | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526861","Transport/Storage Problem Identified","C139468","Problems was caused by transport or storage conditions.","Transport/Storage Problem Identified | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526868","Appropriate Term/Code Not Available","C139469","The concluded cause is not adequately described by any other term.","Appropriate Term/Code Not Available Problem | Appropriate Term/Code Not Available",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526867","Cause Traced to Non-Device Related Factors","C139470","The adverse event that occurred is not attributable to a device.","Cause Traced to Non-Device Related Factors  | Cause Cannot be Traced to Device | Cause Traced to Non-Device Related Factors | Caused traced to non-device related factors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515506","9p23","C13969","A chromosome band present on 9p","9p23 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538048","Stage IA Ovarian Cancer AJCC v8","C139965","Stage IA includes: T1a, N0, M0. T1a: Ovarian cancer with tumor limited to one ovary (capsule intact); no malignant cells in ascites or peritoneal washings. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IA Ovarian Cancer AJCC v8 | Stage IA Ovarian Cancer | Stage IA Ovarian Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538047","Stage IB Ovarian Cancer AJCC v8","C139966","Stage IB includes: T1b, N0, M0. T1b: Ovarian cancer with tumor limited to one or both ovaries (capsules intact); no tumor on ovarian surface; no malignant cells in ascites or peritoneal washings. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IB Ovarian Cancer AJCC v8 | Stage IB Ovarian Cancer | Stage IB Ovarian Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538046","Stage IC Ovarian Cancer AJCC v8","C139967","Stage IC includes: T1c, N0, M0. T1c: Ovarian cancer with tumor limited to one or both ovaries, with any of the following: surgical spill, capsule ruptured before surgery or tumor on ovarian surface, or malignant cells in ascites or peritoneal washings. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IC Ovarian Cancer AJCC v8 | Stage IC Ovarian Cancer | Stage IC Ovarian Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538045","Stage II Ovarian Cancer AJCC v8","C139968","Stage II includes: T2, N0, M0. T2: Ovarian cancer with tumor involving one or both ovaries with pelvic extension below pelvic brim. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage II Ovarian Cancer AJCC v8 | Stage II Ovarian Cancer | Stage II Ovarian Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538060","Stage IIA Ovarian Cancer AJCC v8","C139969","Stage IIA includes: T2a, N0, M0. T2a: Ovarian cancer with tumor extension and/or implants on the uterus and/or fallopian tube(s) and/or ovaries. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIA Ovarian Cancer AJCC v8 | Stage IIA Ovarian Cancer | Stage IIA Ovarian Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521647","7q22","C13996","A chromosome band present on 7q","7q22 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538059","Stage IIB Ovarian Cancer AJCC v8","C139970","Stage IIB includes: T2b, N0, M0. T2b: Ovarian cancer with tumor extension to and/or implants on other pelvic tissues. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIB Ovarian Cancer AJCC v8 | Stage IIB Ovarian Cancer | Stage IIB Ovarian Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538058","Stage III Ovarian Cancer AJCC v8","C139971","Stage III includes: IIIA1: T1/2, N1, M0; IIIA2: T3a, N0/N1, M0; IIIB: T3b, N0/N1, M0; IIIC: T3c, N0/N1, M0. T1: Ovarian cancer with tumor limited to ovaries (one or both). T2: Ovarian cancer with tumor involving one or both ovaries with pelvic extension below pelvic brim. T3a: Ovarian cancer with microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. T3b: Ovarian cancer with macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension with or without metastasis to the retroperitoneal lymph nodes. T3c: Ovarian cancer with macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension with or without metastasis to the retroperitoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ). N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)","Stage III Ovarian Cancer AJCC v8 | Stage III Ovarian Cancer | Stage III Ovarian Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538057","Stage IIIA Ovarian Cancer AJCC v8","C139972","Stage IIIA includes: IIIA1: T1/2, N1, M0; IIIA2: T3a, N0/N1, M0. T1: Ovarian cancer with tumor limited to ovaries (one or both). T2: Ovarian cancer with tumor involving one or both ovaries with pelvic extension below pelvic brim. T3a: Ovarian cancer with microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA Ovarian Cancer | Stage IIIA Ovarian Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521109","22q12.1","C14022","A chromosome band present on 22q","22q12.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526866","Cause Not Established","C139471","The investigation findings do not lead to a clear conclusion about the cause of the reported adverse event.","Cause Not Established | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526865","Cause Traced to Component Failure","C139472","Expected or random component failure without any design or manufacturing issue.","Cause Traced to Component Failure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526872","Cause Traced to Environment","C139473","Problems caused by exposure to environmental conditions outside the expected range.","Cause Traced to Environment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526420","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Hard to Turn During Night","C138897","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: It is hard to turn myself during the night.","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Hard to Turn During Night | PQL07-Hard to Turn During Night | PQL0716",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526419","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Hard to Go Places With Equipment","C138898","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: It is hard for me to go places with my equipment.","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Hard to Go Places With Equipment | PQL07-Hard to Go Places With Equipment | PQL0717",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520691","16q12","C13889","A chromosome band present on 16q","16q12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526417","Neoplastic Cells with Double Expression of MYC and BCL2 Proteins Present","C138900","An immunohistochemical finding indicating the presence of double expression of MYC and BCL2 proteins in the neoplastic cells of a tumor sample.","Neoplastic Cells with Double Expression of MYC and BCL2 Proteins Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521207","2q21-q22","C13920","A chromosome band present on 2q","2q21-q22 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538056","Stage IIIA1 Ovarian Cancer AJCC v8","C139973","Stage IIIA1 includes: T1/2, N1, M0. T1: Ovarian cancer with tumor limited to ovaries (one or both). T2: Ovarian cancer with tumor involving one or both ovaries with pelvic extension below pelvic brim. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIIA1 Ovarian Cancer AJCC v8 | Stage IIIA1 Ovarian Cancer | Stage IIIA1 Ovarian Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538055","Stage IIIA2 Ovarian Cancer AJCC v8","C139974","Stage IIIA2 includes: T3a, N0/N1, M0. T3a: Ovarian cancer with microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIIA2 Ovarian Cancer AJCC v8 | Stage IIIA2 Ovarian Cancer | Stage IIIA2 Ovarian Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538344","MSANTD1 Gene","C140176","This gene may be involved in both DNA binding and chromatin remodeling.","MSANTD1 Gene | MSANTD1 | Myb/SANT DNA Binding Domain Containing 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1623044","Subviral Satellite","C140177","A subviral agent composed of nucleic acid that depends on the co-infection of a host cell with a helper virus for its replication.","Subviral Satellite | Satellite",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538358","MSANTD1 wt Allele","C140178","Human MSANTD1 wild-type allele is located in the vicinity of 4p16.3 and is approximately 3 kb in length. This allele, which encodes Myb/SANT-like DNA-binding domain-containing protein 1, may play a role in chromatin remodeling.","MSANTD1 wt Allele | C4orf44 | Chromosome 4 Open Reading Frame 44 Gene | LOC345222 | Myb/SANT DNA Binding Domain Containing 1 wt Allele | Myb/SANT-Like DNA-Binding Domain Containing 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538357","Myb/SANT-Like DNA-Binding Domain-Containing Protein 1","C140179","Myb/SANT-like DNA-binding domain-containing protein 1 (278 aa, ~32 kDa) is encoded by the human MSANTD1 gene. This protein may be involved in binding to both histones and DNA.","Myb/SANT-Like DNA-Binding Domain-Containing Protein 1 | MSANTD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520177","Xp22.2","C14017","A chromosome band present on Xp","Xp22.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538488","Anti-CD38-targeted IgG4-attenuated Interferon Alpha TAK-573","C140427","A proprietary preparation composed of an immunoglobulin G4 (IgG4) directed against the cell surface glycoprotein CD-38 (CD38) that is fused to an attenuated form of human interferon alpha (IFN alpha; IFNa), with potential immunomodulating and antineoplastic activities. Upon administration, modakafusp alfa specifically targets and binds to CD38 on CD38-positive tumor cells. In turn, the IFNa moiety binds to cell-surface IFN receptors, and activates IFN-mediated signal transduction pathways, which results in the transcription and translation of genes whose products may cause antiproliferative effects in CD38-positive tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.","Modakafusp Alfa | Anti-CD38-targeted IgG4-attenuated IFNa TAK-573 | Anti-CD38-targeted IgG4-attenuated Interferon Alpha TAK-573 | CD38-targeted IgG4 Fused with Attenuated IFNa | MODAKAFUSP ALFA | TAK-573 | TEV-48573",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538487","Urethral Cancer TNM Finding v8","C140428","A finding about one or more characteristics of urethral cancer, following the rules of the TNM AJCC v8 classification system. This classification system applies to urothelial (transitional cell), squamous, and glandular carcinomas of the urethra and to urothelial (transitional cell) carcinomas of the prostate and prostatic urethra. It does not apply to squamous cell carcinomas of the penile foreskin (are staged according to the classification for penis), primary urothelial carcinomas of the bladder with transmural involvement of the prostate (are staged according to the classification for urinary bladder), prostatic adenocarcinomas (are staged according to the classification for prostate), mucosal melanomas of the urethra (no AJCC staging system), lymphomas (are staged according to the classification for Hodgkin and non-Hodgkin lymphoma), and sarcomas (are staged according to the classification for soft tissue sarcoma of the abdomen and thoracic visceral organs).  (from AJCC 8th Ed.)","Urethral Cancer TNM Finding v8 | Urethral Carcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538596","Urethral Cancer Clinical TNM Finding v8","C140429","A clinical finding about one or more characteristics of urethral cancer, following the rules of the TNM AJCC v8 classification system.","Urethral Cancer Clinical TNM Finding v8 | Urethral Carcinoma Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511026","BRCT Domain","C14042","BRCT domain was first identified in C-terminal domain of breast cancer associated protein and was found in many proteins that regulate the cellular response to DNA repair, where these domains act as multi-purpose protein-protein interaction modules. Crystallography study reveals that two ~95 amino acid BRCT repeats within the domain adopt similar structures that pack together in a head-to-tail arrangement. (NCI)","BRCT Domain | Breast Cancer Carboxy-Terminal Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538595","Urethral Cancer Clinical Distant Metastasis TNM Finding v8","C140430","A clinical finding about one or more characteristics of urethral cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Urethral Cancer Clinical Distant Metastasis TNM Finding v8 | Urethral Carcinoma Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538594","Urethral Cancer cM0 TNM Finding v8","C140431","Urethral cancer without evidence of distant metastasis. (from AJCC 8th Ed.)","Urethral Cancer cM0 TNM Finding v8 | Urethral Carcinoma cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538593","Urethral Cancer cM1 TNM Finding v8","C140432","Urethral cancer with distant metastasis. (from AJCC 8th Ed.)","Urethral Cancer cM1 TNM Finding v8 | Urethral Carcinoma cM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537772","Vaginal Cancer pT0 TNM Finding v8","C139642","Vaginal cancer with no evidence of primary tumor. (from AJCC 8th Ed.)","Vaginal Cancer pT0 TNM Finding v8 | Vaginal Carcinoma pT0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537771","Vaginal Cancer pT1 TNM Finding v8","C139643","Vaginal cancer with tumor confined to the vagina. (from AJCC 8th Ed.)","Vaginal Cancer pT1 TNM Finding v8 | Vaginal Cancer FIGO Stage I | Vaginal Carcinoma FIGO Stage I | Vaginal Carcinoma pT1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537770","Vaginal Cancer pT1a TNM Finding v8","C139644","Vaginal cancer with tumor confined to the vagina, measuring 2.0 cm or less. (from AJCC 8th Ed.)","Vaginal Cancer pT1a TNM Finding v8 | Vaginal Cancer FIGO Stage I | Vaginal Carcinoma FIGO Stage I | Vaginal Carcinoma pT1a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537769","Vaginal Cancer pT1b TNM Finding v8","C139645","Vaginal cancer with tumor confined to the vagina, measuring more than 2.0 cm. (from AJCC 8th Ed.)","Vaginal Cancer pT1b TNM Finding v8 | Vaginal Cancer FIGO Stage I | Vaginal Carcinoma FIGO Stage I | Vaginal Carcinoma pT1b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537783","Vaginal Cancer pT2 TNM Finding v8","C139646","Vaginal cancer with tumor invading paravaginal tissues but not to pelvic sidewall. (from AJCC 8th Ed.)","Vaginal Cancer pT2 TNM Finding v8 | Vaginal Cancer FIGO Stage II | Vaginal Carcinoma FIGO Stage II | Vaginal Carcinoma pT2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537781","Vaginal Cancer pT2b TNM Finding v8","C139648","Vaginal cancer with tumor invading paravaginal tissues but not to pelvic wall, measuring more than 2.0 cm. (from AJCC 8th Ed.)","Vaginal Cancer pT2b TNM Finding v8 | Vaginal Cancer FIGO Stage II | Vaginal Carcinoma FIGO Stage II | Vaginal Carcinoma pT2b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537780","Vaginal Cancer pT3 TNM Finding v8","C139649","Vaginal cancer with tumor extending to the pelvic sidewall and/or involving the lower third of the vagina and/or causing hydronephrosis or nonfunctioning kidney. Pelvic sidewall is defined as the muscle, fascia, neurovascular structures, or skeletal portions of the bony pelvis. (from AJCC 8th Ed.)","Vaginal Cancer pT3 TNM Finding v8 | Vaginal Cancer FIGO Stage III | Vaginal Carcinoma FIGO Stage III | Vaginal Carcinoma pT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520275","10q21.1","C13964","A chromosome band present on 10q","10q21.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537779","Vaginal Cancer pT4 TNM Finding v8","C139650","Vaginal cancer with tumor invading the mucosa of the bladder or rectum and/or extending beyond the true pelvis (bullous edema is not sufficient evidence to classify a tumor as T4). (from AJCC 8th Ed.)","Vaginal Cancer pT4 TNM Finding v8 | Vaginal Cancer FIGO Stage IVA | Vaginal Carcinoma FIGO Stage IVA | Vaginal Carcinoma pT4 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538616","Botanical Extract DCB-BO1301","C140554","A proprietary botanical, galactolipid-enriched extract derived from the edible plant Crassocephalum crepidioides (Zhaohe Cao), with potential anti-inflammatory and antineoplastic activities. Upon oral administration, DCB-BO1301 may inhibit the growth of certain types of tumor cells, although the exact mechanism of action has yet to be fully elucidated.","Botanical Extract DCB-BO1301 | DCB BO 1301 | DCB BO1301 | DCB-BO1301 | Zhaohe Cao-based Botanical Drug DCB-BO1301",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538615","Carbon C 14-AC0010","C140555","A radioconjugate composed of AC0010, an orally available, third generation, selective inhibitor of mutant forms of the epidermal growth factor receptor (EGFR), including the second-site resistance mutation T790M, that is labeled with the radioisotope carbon C 14, with potential use in evaluating the pharmacokinetic profile of AC0010. Upon administration, the AC0010 moiety specifically and irreversibly binds to and inhibits the activity of mutant forms of EGFR. Labeling of AC0010 with the radioactive tracer carbon C 14 allows for the evaluation of AC0010's pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME).","Carbon C 14-AC0010 | 14C-AC0010 | 14C-labeled AC0010 | [14C] AC0010",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538614","Conjunctival Melanoma TNM Finding v8","C140556","A finding about one or more characteristics of conjunctival melanoma, following the rules of the TNM AJCC v8 classification system. This classification system applies to melanomas arising from the bulbar and palpebral conjunctiva and from the caruncle. Primary eyelid melanomas are staged according to the classification for melanoma of the skin and secondary involvement of the conjunctiva by extraocular uveal melanoma is staged according to the classification for uveal melanoma. There is no proposal for anatomic stage and prognostic groups for conjunctival melanoma. (from AJCC 8th Ed.)","Conjunctival Melanoma TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538613","Conjunctival Melanoma Clinical TNM Finding v8","C140557","A clinical finding about one or more characteristics of conjunctival melanoma, following the rules of the TNM AJCC v8 classification system.","Conjunctival Melanoma Clinical TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538722","Conjunctival Melanoma Clinical Distant Metastasis TNM Finding v8","C140558","A clinical finding about one or more characteristics of conjunctival melanoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Conjunctival Melanoma Clinical Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538721","Conjunctival Melanoma cM0 TNM Finding v8","C140559","Conjunctival melanoma with no distant metastasis. (from AJCC 8th Ed.)","Conjunctival Melanoma cM0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538719","Conjunctival Melanoma Clinical Primary Tumor TNM Finding v8","C140561","A clinical finding about one or more characteristics of conjunctival melanoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Conjunctival Melanoma Clinical Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538718","Conjunctival Melanoma cTX TNM Finding v8","C140562","Conjunctival melanoma in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Conjunctival Melanoma cTX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538717","Conjunctival Melanoma cT0 TNM Finding v8","C140563","Conjunctival melanoma with no evidence of primary tumor. (from AJCC 8th Ed.)","Conjunctival Melanoma cT0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538105","CAGE1 Gene","C139924","This gene may play a role in testes development and carcinogenesis.","CAGE1 Gene | CAGE1 | Cancer Antigen 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538104","CAGE1 wt Allele","C139925","Human CAGE1 wild-type allele is located in the vicinity of 6p24.3 and is approximately 63 kb in length. This allele, which encodes cancer-associated gene 1 protein, may be involved in testes development and carcinogenesis. Aberrant expression is associated with several cancers.","CAGE1 wt Allele | CT3 | CT95 | CTAG3 | Cancer Antigen 1 wt Allele | Cancer/Testis Antigen Gene 1 | bA69L16.7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1175872","CAGE1 protein, human","C139926","Cancer-associated gene 1 protein (777 aa, ~90 kDa) is encoded by the human CAGE1 gene. This protein may play a role in testes development and carcinogenesis.","Cancer-Associated Gene 1 Protein | CAGE-1 | CAGE1 | CT3 | Cancer/Testis Antigen 3 | Cancer/Testis Antigen 95",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538356","Chemotherapy Regimen Used to Treat CNS Neoplasm","C140180","Any regimen that can be used for the treatment of any type of central nervous system (CNS) neoplasm.","Regimen Used to Treat Central Nervous System Neoplasm | Chemotherapy Regimen Used to Treat CNS Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538355","CELSR2 Gene","C140181","This gene plays a role in cell-cell signaling during the development of the nervous system.","CELSR2 Gene | CELSR2 | Cadherin EGF LAG Seven-Pass G-Type Receptor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538354","CELSR2 wt Allele","C140182","Human CELSR2 wild-type allele is located in the vicinity of 1p13.3 and is approximately 26 kb in length. This allele, which encodes cadherin EGF LAG seven-pass G-type receptor 2 protein, is involved in cell-cell signaling.","CELSR2 wt Allele | ADGRC2 | CDHF10 | Cadherin EGF LAG Seven-Pass G-Type Receptor 2 wt Allele | Cadherin, EGF LAG Seven-Pass G-Type Receptor 2 (Flamingo Homolog, Drosophila) Gene | Cadherin, EGF LAG Seven-Pass G-Type Receptor 2 Gene | Cadherin, EGF LAG Seven-Pass G-Type Receptor 2, Flamingo (Drosophila) Homolog Gene | EGF-Like-Domain, Multiple 2 Gene | EGFL2 | Epidermal Growth Factor-Like 2 Gene | Flamingo (Drosophila) Homolog 3 Gene | Flamingo (Drosophila) Homolog Gene | Flamingo1 | KIAA0279 | MEGF3 | Multiple Epidermal Growth Factor-Like Domains 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521014","1q42","C14037","A chromosome band present on 1q","1q42 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538518","Bladder Cancer Clinical TNM Finding v8","C140381","A clinical finding about one or more characteristics of bladder cancer, following the rules of the TNM AJCC v8 classification system.","Bladder Cancer Clinical TNM Finding v8 | Bladder Carcinoma Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538512","Bladder Cancer Pathologic TNM Finding v8","C140387","A pathologic finding about one or more characteristics of bladder cancer, following the rules of the TNM AJCC v8 classification system.","Bladder Cancer Pathologic TNM Finding v8 | Bladder Carcinoma Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520845","19p13.11","C14038","A chromosome band present on 19p","19p13.11 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521643","7q21.2-q22.1","C14066","A chromosome band present on 7q","7q21.2-q22.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538737","Uveal Melanoma by AJCC v7 Stage","C140672","A term that refers to the staging of uveal melanoma, following the rules of the TNM AJCC v7 classification system.","Uveal Melanoma by AJCC v7 Stage | Tumor Stage (Pathologic)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538734","Retinoblastoma TNM Finding v8","C140675","A finding about one or more characteristics of retinoblastoma, following the rules of the TNM AJCC v8 classification system. This classification does not apply to central nervous system component of 'trilateral retinoblastoma' (is staged according to the classification for brain and spinal cord), retinoma (or retinocytoma) (no AJCC staging system), and medulloepithelioma (no AJCC staging system). (from AJCC 8th Ed.)","Retinoblastoma TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538733","Retinoblastoma Clinical TNM Finding v8","C140676","A clinical finding about one or more characteristics of retinoblastoma, following the rules of the TNM AJCC v8 classification system.","Retinoblastoma Clinical TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538732","Retinoblastoma Clinical Distant Metastasis TNM Finding v8","C140677","A clinical finding about one or more characteristics of retinoblastoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Retinoblastoma Clinical Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538731","Retinoblastoma cM0 TNM Finding v8","C140678","Retinoblastoma with no signs or symptoms of intracranial or distant metastasis. (from AJCC 8th Ed.)","Retinoblastoma cM0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538746","Retinoblastoma cM1 TNM Finding v8","C140679","Retinoblastoma with distant metastasis without microscopic confirmation. (from AJCC 8th Ed.)","Retinoblastoma cM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520596","14q31","C14067","A chromosome band present on 14q","14q31 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538745","Retinoblastoma cM1a TNM Finding v8","C140680","Retinoblastoma with tumor(s) involving any distant site (e.g., bone marrow, liver) on clinical or radiologic tests. (from AJCC 8th Ed.)","Retinoblastoma cM1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538744","Retinoblastoma cM1b TNM Finding v8","C140681","Retinoblastoma with tumor involving the CNS on radiologic imaging (not including trilateral retinoblastoma). (from AJCC 8th Ed.)","Retinoblastoma cM1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537778","Vaginal Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C139652","A pathologic finding about one or more characteristics of vaginal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Vaginal Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | Vaginal Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537777","Vaginal Cancer pNX TNM Finding v8","C139653","Vaginal cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Vaginal Cancer pNX TNM Finding v8 | Vaginal Carcinoma pNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537847","Vaginal Cancer pN0 TNM Finding v8","C139654","Vaginal cancer with no regional lymph node metastasis. (from AJCC 8th Ed.)","Vaginal Cancer pN0 TNM Finding v8 | Vaginal Carcinoma pN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537846","Vaginal Cancer pN0(i+) TNM Finding v8","C139655","Vaginal cancer with isolated tumor cells in regional lymph node(s) no greater than 0.2 mm. (from AJCC 8th Ed.)","Vaginal Cancer pN0(i+) TNM Finding v8 | Vaginal Carcinoma pN0(i+) TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537845","Vaginal Cancer pN1 TNM Finding v8","C139656","Vaginal cancer with pelvic or inguinal lymph node metastasis. (from AJCC 8th Ed.)","Vaginal Cancer pN1 TNM Finding v8 | Vaginal Cancer FIGO Stage III | Vaginal Carcinoma FIGO Stage III | Vaginal Carcinoma pN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537843","Stage I Vaginal Cancer AJCC v8","C139658","Stage I includes: IA: T1a, N0, M0; IB: T1b, N0, M0. T1a: Tumor confined to the vagina, measuring 2.0 cm or less. T1b: Tumor confined to the vagina, measuring more than 2.0 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage I Vaginal Cancer AJCC v8 | Stage I Vaginal Cancer | Stage I Vaginal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526619","Increased Osteoid","C139150","An increase in the amount of unmineralized bone matrix as compared to a standard or norm.","Increased Osteoid | OSTEOID, INCREASED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1956089","Osteophyte","C139151","A bony projection that forms on the joints of the body.","Osteophyte | Bone Spur | OSTEOPHYTE",,,,,,,,,,,,,,,"4230331","Osteophyte",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526625","Dental Pulp Concretion","C139152","A mass formed in the dental pulp due to local accumulation of a substance.","Dental Pulp Concretion | PULP CONCRETION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526624","Decreased Physis Thickness","C139153","A decrease in the dimension between the two surfaces, in comparison to a standard or norm.","Decreased Physis Thickness | PHYSIS THICKNESS, DECREASED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526623","Increased Physis Thickness","C139154","An increase in the dimension between the two surfaces, in comparison to a standard or norm.","Increased Physis Thickness | PHYSIS THICKNESS, INCREASED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526622","Infiltrate and Fibrosis","C139155","A morphologic finding indicating the presence of a cellular infiltrate associated with fibrosis in a tissue sample.","Infiltrate and Fibrosis | INFILTRATE/FIBROSIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3495932","Pathologic Intimal Thickening","C139156","A term that refers to a vascular lesion characterized by an extracellular lipid pool with intimal smooth muscle cell loss typically adjacent to the medial wall in addition to varying degrees of macrophage infiltration near the lumen. (Arteriosclerosis, Thrombosis, and Vascular Biology. 2007; 27:986-989)","Pathologic Intimal Thickening | INTIMAL THICKENING | PIT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526626","Necrosis and Infiltrate","C139158","A morphologic finding indicating the presence of necrosis associated with a cellular infiltrate in a tissue sample.","Necrosis and Infiltrate | NECROSIS/INFILTRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1860136","Necrosis and Inflammation","C139159","A morphologic finding indicating the presence of necrosis associated with an inflammatory infiltrate in a tissue sample.","Necrosis and Inflammation | NECROSIS/INFLAMMATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538102","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma TNM Finding v8","C139927","A finding about one or more characteristics of ovarian, fallopian tube, or primary peritoneal carcinoma, following the rules of the TNM AJCC v8 classification system. Nonepithelial primary ovarian cancers may be staged using this classification but should be reported separately. (from AJCC 8th Ed.)","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538101","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Clinical TNM Finding v8","C139928","A clinical finding about one or more characteristics of ovarian, fallopian tube, or primary peritoneal carcinoma, following the rules of the TNM AJCC v8 classification system.","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Clinical TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521221","2q33-q36","C13992","A chromosome band present on 2q","2q33-q36 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538083","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma cM0 TNM Finding v8","C139930","Ovarian, fallopian tube, or primary peritoneal carcinoma without evidence of distant metastasis. (from AJCC 8th Ed.)","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma cM0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538082","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma cM1 TNM Finding v8","C139931","Ovarian, fallopian tube, or primary peritoneal carcinoma with distant metastasis, including pleural effusion with positive cytology; liver or splenic parenchymal metastasis; metastasis to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside the abdominal cavity); and transmural involvement of intestine. (from AJCC 8th Ed.)","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma cM1 TNM Finding v8 | Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538081","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma cM1a TNM Finding v8","C139932","Ovarian, fallopian tube, or primary peritoneal carcinoma with pleural effusion with positive cytology. (from AJCC 8th Ed.)","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma cM1a TNM Finding v8 | Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IVA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538080","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma cM1b TNM Finding v8","C139933","Ovarian, fallopian tube, or primary peritoneal carcinoma with liver or splenic parenchymal metastases; metastases to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside the abdominal cavity); transmural involvement of intestine. (from AJCC 8th Ed.)","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma cM1b TNM Finding v8 | Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IVB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538079","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Pathologic TNM Finding v8","C139934","A pathologic finding about one or more characteristics of ovarian, fallopian tube, or primary peritoneal carcinoma, following the rules of the TNM AJCC v8 classification system.","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Pathologic TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538078","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Pathologic Distant Metastasis TNM Finding v8","C139935","A pathologic finding about one or more characteristics of ovarian, fallopian tube, or primary peritoneal carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Pathologic Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538077","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pM1 TNM Finding v8","C139936","Ovarian, fallopian tube, or primary peritoneal carcinoma with distant metastasis, including pleural effusion with positive cytology; liver or splenic parenchymal metastasis; metastasis to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside the abdominal cavity); and transmural involvement of intestine. (from AJCC 8th Ed.)","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pM1 TNM Finding v8 | Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538092","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pM1a TNM Finding v8","C139937","Ovarian, fallopian tube, or primary peritoneal carcinoma with pleural effusion with positive cytology. (from AJCC 8th Ed.)","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pM1a TNM Finding v8 | Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IVA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538523","Bladder Cancer Pathologic Primary Tumor TNM Finding v8","C140392","A pathologic finding about one or more characteristics of bladder cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Bladder Cancer Pathologic Primary Tumor TNM Finding v8 | Bladder Carcinoma Pathologic Primary Tumor TNM Finding v8 | Pathologic Primary Tumor Status (pT)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538794","Choroidal and Ciliary Body Melanoma Pathologic Primary Tumor TNM Finding v8","C140630","A pathologic finding about one or more characteristics of choroidal and ciliary body melanoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Choroidal and Ciliary Body Melanoma Pathologic Primary Tumor TNM Finding v8 | Pathologic Primary Tumor Status (pT)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538149","Stage III Primary Peritoneal Cancer AJCC v8","C140008","Stage III includes: IIIA: T3a, N0/N1, M0; IIIB: T3b, N0/N1, M0; IIIC: T3c, N0/N1, M0. T3a: Primary peritoneal cancer with microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. T3b: Primary peritoneal cancer with macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension with or without metastasis to the retroperitoneal lymph nodes. T3c: Primary peritoneal cancer with macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension with or without metastasis to the retroperitoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ). N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)","Stage III Primary Peritoneal Cancer AJCC v8 | Stage III Primary Peritoneal Cancer | Stage III Primary Peritoneal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538132","Stage IIIA Primary Peritoneal Cancer AJCC v8","C140009","Stage IIIA includes: T3a, N0/N1, M0. T3a: Primary peritoneal cancer with microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIIA Primary Peritoneal Cancer AJCC v8 | Stage IIIA Primary Peritoneal Cancer | Stage IIIA Primary Peritoneal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520633","15q21.1-q21.2","C14000","A chromosome band present on 15q","15q21.1-q21.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538131","Stage IIIB Primary Peritoneal Cancer AJCC v8","C140010","Stage IIIB includes: T3b, N0/N1, M0. T3b: Primary peritoneal cancer with macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension with or without metastasis to the retroperitoneal lymph nodes. N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIIB Primary Peritoneal Cancer AJCC v8 | Stage IIIB Primary Peritoneal Cancer | Stage IIIB Primary Peritoneal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538130","Stage IIIC Primary Peritoneal Cancer AJCC v8","C140011","Stage IIIC includes: T3c, N0/N1, M0. T3c: Primary peritoneal cancer with macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension with or without metastasis to the retroperitoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ). N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIIC Primary Peritoneal Cancer AJCC v8 | Stage IIIC Primary Peritoneal Cancer | Stage IIIC Primary Peritoneal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538129","Stage IV Primary Peritoneal Cancer AJCC v8","C140012","Stage IV includes: Any T, Any N, M1: M1: Distant metastasis, including pleural effusion with positive cytology; liver or splenic parenchymal metastasis; metastasis to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside the abdominal cavity); and transmural involvement of intestine. (from AJCC 8th Ed.)","Stage IV Primary Peritoneal Cancer AJCC v8 | Stage IV Primary Peritoneal Cancer | Stage IV Primary Peritoneal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538128","Stage IVA Primary Peritoneal Cancer AJCC v8","C140013","Stage IVA includes: Any T, Any N, M1a. M1a: Primary peritoneal cancer with pleural effusion with positive cytology. (from AJCC 8th Ed.)","Stage IVA Primary Peritoneal Cancer AJCC v8 | Stage IVA Primary Peritoneal Cancer | Stage IVA Primary Peritoneal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538126","Gestational Trophoblastic Neoplasm TNM Finding v8","C140015","A finding about one or more characteristics of a gestational trophoblastic neoplasm, following the rules of the TNM AJCC v8 classification system. This classification applies to the following placental neoplasms: invasive hydatidiform mole, choriocarcinoma, placental site trophoblastic tumor, and epithelioid trophoblastic tumor. Complete and partial hydatidiform tumors are not included in this classification. (from AJCC 8th Ed.)","Gestational Trophoblastic Neoplasm TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538125","Gestational Trophoblastic Neoplasm Clinical TNM Finding v8","C140016","A clinical finding about one or more characteristics of a gestational trophoblastic neoplasm, following the rules of the TNM AJCC v8 classification system.","Gestational Trophoblastic Neoplasm Clinical TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538140","Gestational Trophoblastic Neoplasm Clinical Distant Metastasis TNM Finding v8","C140017","A clinical finding about one or more characteristics of a gestational trophoblastic neoplasm, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Gestational Trophoblastic Neoplasm Clinical Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511013","BH4 Domain","C13915","BH4 is present only in the amino-terminal regions of pro-survival family bcl-2 members and is essential for the anti-apoptotic function, although deletion of BH4 does not necessarily impair the ability of BH4-containing proteins to bind to a variety of other bcl-2-related proteins.","BH4 Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3854573","Intimal Hyperplasia","C139160","Thickening of the tunica intima of a blood vessel due to injury.","Intimal Hyperplasia | Intimal Proliferation | PROLIFERATION, INTIMA",,,,,,,,,,,,,,,"4166223","Intimal proliferation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526602","PROLIFERATION, STROMA, VALVE","C139161","A finding indicating proliferation of the stromal valvular cells","Valve-Derived Stromal Cell Proliferation | PROLIFERATION, STROMA, VALVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526601","Ethmoidal Nasal Turbinate","C139162","The nasal turbinates extending from the ethmoidal crest into the nasal cavity.","Ethmoidal Nasal Turbinate | Ethmoturbinate | NASAL TURBINATE, ETHMOIDAL CONCHA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526606","Medial Nasal Turbinate","C139164","The largest of the ethmoidal nasal turbinates, extending from the ethmoidal crest into the middle of the nasal cavity.","Medial Nasal Turbinate | MEDIAL NASAL TURBINATE | Media Nasal Concha | NASAL TURBINATE, MIDDLE CONCHA | Nasal Middle Turbinate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526605","Ventral Nasal Turbinate","C139165","The nasal turbinate originating from the conchal crest on the medial wall of the maxilla and extending into the nasal cavity.","Ventral Nasal Turbinate | Maxilloturbinate | NASAL TURBINATE, VENTRAL CONCHA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526604","Trial Registration Indicator","C139166","An indication as to whether the clinical trial has been registered with a trial registry system.","Trial Registration Indicator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526603","Source of Monetary or Material Support for Study","C139167","The organization(s) providing monetary and/or materials for the conduct of a study or trial.","Source of Monetary or Material Support for Study | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526610","Primary Study Sponsor Name","C139168","The name of the entity that is considered the primary sponsor for the trial or study.","Primary Study Sponsor Name | Primary Sponsor Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526609","Secondary Study Sponsor Name","C139169","The name of the entity that is considered the secondary sponsor for the trial or study.","Secondary Study Sponsor Name | Secondary Sponsor Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526870","Falsified Device","C139475","Devices that deliberately and/or fraudulently misrepresent their identity, composition or source.","Falsified Device | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526869","Design Change Validation Inadequate","C139476","Problems traced to inadequate or lack of validation of design changes of the device leading to malfunction or unintended properties of the device including possible hazards for persons using the device.","Design Change Validation Inadequate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526876","Design Inadequate for Purpose","C139477","Problems traced to design/design features of the device that do not support or interfere with the intended purpose of the device.","Design Inadequate for Purpose | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526875","Human Factors Engineering - Device Difficult to Assemble","C139478","Problems traced to inadequate design of the component parts and/or assembly steps resulting in the device not being able to be assembled correctly.","Human Factors Engineering - Device Difficult to Assemble | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526874","Human Factors Engineering - Device Difficult to Operate","C139479","Problems traced to inappropriate and/or inadequate assessment and engineering design of the device to accommodate how or where the device will be used.","Human Factors Engineering - Device Difficult to Operate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520975","1p36.11","C13947","A chromosome band present on 1p","1p36.11 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526848","Missing or Inadequate Safety Measures","C139481","Problems traced to inadequate design or complete lack of safety measures leading to device malfunction or unintended properties of the device including possible hazards for persons using the device.","Missing or Inadequate Safety Measures Problem | Missing or Inadequate Safety Measures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538275","C5orf67 Gene","C140136","This gene may play a role in longevity.","C5orf67 Gene | C5orf67 | Chromosome 5 Open Reading Frame 67 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520483","12pter-p12","C14013","A chromosome band present on 12p","12pter-p12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538255","C5orf67 wt Allele","C140140","Human C5orf67 wild-type allele is located in the vicinity of 5q11.2 and is approximately 95 kb in length. This allele, which encodes uncharacterized protein C5orf67, may be involved in lifespan.","C5orf67 wt Allele | Chromosome 5 Open Reading Frame 67 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538251","Uncharacterized Protein C5orf67","C140144","Uncharacterized protein C5orf67 (127 aa, ~14 kDa) is encoded by the human C5orf67 gene. This protein may play a role in lifespan.","Uncharacterized Protein C5orf67 | C5orf67",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538250","Prostate Cancer Pathologic TNM Finding v8","C140145","A pathologic finding about one or more characteristics of prostate cancer, following the rules of the TNM AJCC v8 classification system.","Prostate Cancer Pathologic TNM Finding v8 | Pathologic | Prostate Carcinoma Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512198","Globular Region","C14063","A protein region consisting of a hydrophilic surface and a hydrophobic core.","Globular Region | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538054","Stage IIIB Ovarian Cancer AJCC v8","C139975","Stage IIIB includes: T3b, N0/N1, M0. T3b: Ovarian cancer with macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension with or without metastasis to the retroperitoneal lymph nodes. N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIIB Ovarian Cancer AJCC v8 | Stage IIIB Ovarian Cancer | Stage IIIB Ovarian Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538053","Stage IIIC Ovarian Cancer AJCC v8","C139976","Stage IIIC includes: T3c, N0/N1, M0. T3c: Ovarian cancer with macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension with or without metastasis to the retroperitoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ). N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIIC Ovarian Cancer AJCC v8 | Stage IIIC Ovarian Cancer | Stage IIIC Ovarian Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538163","Stage IV Ovarian Cancer AJCC v8","C139977","Stage IV includes: Any T, Any N, M1: M1: Distant metastasis, including pleural effusion with positive cytology; liver or splenic parenchymal metastasis; metastasis to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside the abdominal cavity); and transmural involvement of intestine. (from AJCC 8th Ed.)","Stage IV Ovarian Cancer AJCC v8 | Stage IV Ovarian Cancer | Stage IV Ovarian Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538162","Stage IVA Ovarian Cancer AJCC v8","C139978","Stage IVA includes: Any T, Any N, M1a. M1a: Ovarian cancer with pleural effusion with positive cytology. (from AJCC 8th Ed.)","Stage IVA Ovarian Cancer AJCC v8 | Stage IVA Ovarian Cancer | Stage IVA Ovarian Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538161","Stage IVB Ovarian Cancer AJCC v8","C139979","Stage IVB includes: Any T, Any N, M1b. M1b: Ovarian cancer with liver or splenic parenchymal metastases; metastases to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside the abdominal cavity); transmural involvement of intestine. (from AJCC 8th Ed.)","Stage IVB Ovarian Cancer AJCC v8 | Stage IVB Ovarian Cancer | Stage IVB Ovarian Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521640","7q21-q22","C13997","A chromosome band present on 7q","7q21-q22 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538139","Gestational Trophoblastic Neoplasm cM0 TNM Finding v8","C140018","Gestational trophoblastic neoplasm without evidence of distant metastasis. (from AJCC 8th Ed.)","Gestational Trophoblastic Neoplasm cM0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511077","Bcl-2 Homology Domain","C13911","Proteins that are related to bcl-2 are characterized by the presence of one or more highly conserved stretches of homology with bcl-2, designated BH1, BH2, BH3, BH4. These domains control the ability of these proteins to homo- and heterodimerize with other proteins. Competitive dimerization between family members is thought to regulate their function as regulators of apoptosis.","Bcl-2 Homology Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526846","Cytotoxicity Problem Identified","C139483","The device was found to have an undesirable level of toxicity to living cells.","Cytotoxicity Problem Identified | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526845","Unintended Presence of Allergens","C139484","Unintended or unexpected presence of allergens in the device.","Unintended Presence of Allergens | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526852","Device Incorrectly Assembled During Reprocessing","C139485","Incorrect assembly of the device following reprocessing.","Device Incorrectly Assembled During Reprocessing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526851","Device Incorrectly Cleaned During Reprocessing","C139486","The cleaning procedure is not followed correctly or used inappropriate cleaning materials.","Device Incorrectly Cleaned During Reprocessing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526850","Device Incorrectly Disinfected/Sterilized During Reprocessing","C139487","The disinfection/sterilization process was incorrect and/or the wrong products for disinfection/sterilization were used.","Device Incorrectly Disinfected/Sterilized During Reprocessing | Device Incorrectly Disinfected/Sterilised During Reprocessing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526849","Network Communication Problem","C139488","Communications problems between devices within a network system.","Network Communication Problem | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526856","Electrical/Electronic Component Problem Identified","C139489","The performance of an electrical or electronic component was found to be inadequate.","Electrical/Electronic Component Problem Identified | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526854","Ambient Light Problem Identified","C139491","Device performance was affected by ambient light. This term applies to the direct effects of ambient light on the device, and to the user's ability to operate the device (e.g. to read device output).","Ambient Light Problem Identified | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526853","Contamination of Environment by Device","C139492","Operation of the device results in contamination of the nearby environment e.g. dust, dirt, smoke, heat or biological material.","Contamination of Environment by Device | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526860","Environmental Pressure Problem Identified","C139493","Device performance was affected by the pressure, or changes in pressure, of the environment in which it was used.","Environmental Pressure Problem Identified | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526859","Device Not Compatible With Another Device","C139494","A device that malfunctions due to being used in combination with, or in the presence of, another device.","Device Not Compatible With Another Device | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521303","3q13.3-q21","C14014","A chromosome band present on 3q","3q13.3-q21 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538446","Renal Pelvis and Ureter Cancer pTa TNM Finding v8","C140342","Renal pelvis and ureter cancer with a finding of papillary noninvasive carcinoma. (from AJCC 8th Ed.)","Renal Pelvis and Ureter Cancer pTa TNM Finding v8 | Renal Pelvis and Ureter Urothelial Carcinoma pTa TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538445","Renal Pelvis and Ureter Cancer pTis TNM Finding v8","C140343","Renal pelvis and ureter cancer with a finding of carcinoma in situ. (from AJCC 8th Ed.)","Renal Pelvis and Ureter Cancer pTis TNM Finding v8 | Renal Pelvis and Ureter Urothelial Carcinoma pTis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538444","Renal Pelvis and Ureter Cancer pT1 TNM Finding v8","C140344","Renal pelvis and ureter cancer in which the tumor invades subepithelial connective tissue. (from AJCC 8th Ed.)","Renal Pelvis and Ureter Cancer pT1 TNM Finding v8 | Renal Pelvis and Ureter Urothelial Carcinoma pT1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538443","Renal Pelvis and Ureter Cancer pT2 TNM Finding v8","C140345","Renal pelvis and ureter cancer in which the tumor invades the muscularis. (from AJCC 8th Ed.)","Renal Pelvis and Ureter Cancer pT2 TNM Finding v8 | Renal Pelvis and Ureter Urothelial Carcinoma pT2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538442","Renal Pelvis and Ureter Cancer pT3 TNM Finding v8","C140346","For renal pelvis only: Tumor invades beyond muscularis into peripelvic fat or into the renal parenchyma. For ureter only: Tumor invades beyond muscularis into periureteric fat. (from AJCC 8th Ed.)","Renal Pelvis and Ureter Cancer pT3 TNM Finding v8 | Renal Pelvis and Ureter Urothelial Carcinoma pT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538441","Renal Pelvis and Ureter Cancer pT4 TNM Finding v8","C140347","Renal pelvis and ureter cancer in which the tumor invades adjacent organs, or through the kidney into the perinephric fat. (from AJCC 8th Ed.)","Renal Pelvis and Ureter Cancer pT4 TNM Finding v8 | Renal Pelvis and Ureter Urothelial Carcinoma pT4 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538440","Renal Pelvis and Ureter Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C140348","A pathologic finding about one or more characteristics of renal pelvis and ureter cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Renal Pelvis and Ureter Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | Renal Pelvis and Ureter Urothelial Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538423","Renal Pelvis and Ureter Cancer pNX TNM Finding v8","C140349","Renal pelvis and ureter cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Renal Pelvis and Ureter Cancer pNX TNM Finding v8 | Renal Pelvis and Ureter Urothelial Carcinoma pNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521057","20q12-q13.1","C14034","A chromosome band present on 20q","20q12-q13.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538422","Renal Pelvis and Ureter Cancer pN0 TNM Finding v8","C140350","Renal pelvis and ureter cancer with no regional lymph node metastasis. (from AJCC 8th Ed.)","Renal Pelvis and Ureter Cancer pN0 TNM Finding v8 | Renal Pelvis and Ureter Urothelial Carcinoma pN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538421","Renal Pelvis and Ureter Cancer pN1 TNM Finding v8","C140351","Renal pelvis and ureter cancer with metastasis in a single lymph node, 2 cm or less in greatest dimension. (from AJCC 8th Ed.)","Renal Pelvis and Ureter Cancer pN1 TNM Finding v8 | Renal Pelvis and Ureter Urothelial Carcinoma pN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538420","Renal Pelvis and Ureter Cancer pN2 TNM Finding v8","C140352","Renal pelvis and ureter cancer with metastasis in a single lymph node, more than 2 cm in greatest dimension; or multiple lymph nodes. (from AJCC 8th Ed.)","Renal Pelvis and Ureter Cancer pN2 TNM Finding v8 | Renal Pelvis and Ureter Urothelial Carcinoma pN2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538419","Copper 64 Cu-DOTA-daratumumab","C140353","A radioimmunoconjugate containing daratumumab, a human immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against the cell surface glycoprotein CD38, conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), and labeled with the radioisotope copper Cu 64, with potential diagnostic properties upon positron emission tomography (PET) imaging. The monoclonal antibody moiety of copper Cu 64-DOTA-daratumumab specifically targets and binds to cell surface antigen CD38. Upon binding, the radioisotope moiety may be detected using PET, thereby allowing the imaging and quantification of CD38-expressing tumor cells. CD38, a cell surface glycoprotein, is expressed on various hematopoietic cells and is overexpressed on multiple myeloma (MM) cells.","Copper 64 Cu-DOTA-daratumumab | 64Cu-DOTA-daratumumab | Copper Cu 64 Daratumumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538160","Stage IIIA1","C139980","A stage term that applies to ovarian and fallopian tube carcinoma and indicates that the tumor is limited to ovaries (one or both) or fallopian tube(s) or the tumor involves one or both ovaries or fallopian tubes with pelvic extension below pelvic brim. There are positive retroperitoneal lymph nodes only (histologically confirmed) and no distant metastasis. (adapted from AJCC 8th Ed.)","Stage IIIA1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538159","Stage IIIA2","C139981","A stage term that applies to ovarian and fallopian tube carcinoma and indicates the presence of microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. There is no distant metastasis. (adapted from AJCC 8th Ed.)","Stage IIIA2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1293091","Pre-operative Evaluation","C139982","An examination of an individual to determine their health status prior to a surgical procedure and their suitability for the procedure.","Pre-operative Evaluation | Preoperative Evaluation",,,,,,,,,,,,,,,"4004516","Pre-surgery evaluation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL538158","Fallopian Tube Cancer by AJCC v8 Stage","C139983","A term that refers to the staging of fallopian tube cancer according to the American Joint Committee on Cancer, 8th edition.","Fallopian Tube Cancer by AJCC v8 Stage | Fallopian Tube Carcinoma by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538157","Stage I Fallopian Tube Cancer AJCC v8","C139984","Stage I includes: T1, N0, M0. T1: Fallopian tube cancer with tumor limited to fallopian tube(s). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage I Fallopian Tube Cancer AJCC v8 | Stage I Fallopian Tube Cancer | Stage I Fallopian Tube Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538171","Stage IA Fallopian Tube Cancer AJCC v8","C139985","Stage IA includes: T1a, N0, M0. T1a: Fallopian tube cancer with tumor limited to fallopian tube surface; no malignant cells in ascites or peritoneal washings N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IA Fallopian Tube Cancer AJCC v8 | Stage IA Fallopian Tube Cancer | Stage IA Fallopian Tube Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538170","Stage IB Fallopian Tube Cancer AJCC v8","C139986","Stage IB includes: T1b, N0, M0. T1b: Fallopian tube cancer with tumor limited to fallopian tubes; no tumor on fallopian tube surface; no malignant cells in ascites or peritoneal washings. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IB Fallopian Tube Cancer AJCC v8 | Stage IB Fallopian Tube Cancer | Stage IB Fallopian Tube Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1455125","CELSR2 protein, human","C140183","Cadherin EGF LAG seven-pass G-type receptor 2 (2923 aa, ~317 kDa) is encoded by the human CELSR2 gene. This protein plays a role in Wnt signaling and neural development.","Cadherin EGF LAG Seven-Pass G-Type Receptor 2 | Adhesion G Protein-Coupled Receptor C2 | CELSR2 | Cadherin Family Member 10 | EGF-Like Protein 2 | Epidermal Growth Factor-Like Protein 2 | Flamingo Homolog 3 | Multiple EGF-Like Domains Protein 3 | Multiple Epidermal Growth Factor-Like Domains Protein 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538351","Post-Mastectomy Pain Syndrome","C140185","Chronic pain following mastectomy or lumpectomy that usually affects the anterior thorax, axilla, and/or medial upper arm.","Post-Mastectomy Pain Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538335","Testicular Cancer TNM Finding v8","C140186","A finding about one or more characteristics of testicular cancer, following the rules of the TNM AJCC v8 classification system. This classification system applies to postpubertal germ cell tumors of the testis and malignant sex cord-stromal tumors of the testis. It does not apply to spermatocytic tumors (no AJCC staging system), nonmalignant sex cord-/gonadal -stromal tumors (no AJCC staging system), prepubertal germ cell tumors (no AJCC staging system), hematolymphoid tumors (hematologic malignancies staging system), and paratesticular neoplasms (no AJCC staging system).  (from AJCC 8th Ed.)","Testicular Cancer TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537963","Stage IV Uterine Corpus Cancer AJCC v8","C139812","Stage IV includes: IVA: T4, Any N, M0; IVB: Any T, Any N, M1. T4: Uterine corpus carcinoma or carcinosarcoma with tumor invading the bladder mucosa and/or bowel mucosa (bullous edema is not sufficient to classify a tumor as T4). M0: No distant metastasis. M1: Distant metastasis (includes metastasis to inguinal lymph nodes, intraperitoneal disease, lung, liver, or bone. It excludes metastasis to pelvic or para-aortic lymph nodes, vagina, uterine serosa, or adnexa). (from AJCC 8th Ed.)","Stage IV Uterine Corpus Cancer AJCC v8 | Stage IV | Stage IV Uterine (including Endometrial) Cancer | Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537962","Stage IVA Uterine Corpus Cancer AJCC v8","C139813","Stage IVA includes: T4, Any N, M0. T4: Uterine corpus carcinoma or carcinosarcoma with tumor invading the bladder mucosa and/or bowel mucosa (bullous edema is not sufficient to classify a tumor as T4). M0: No distant metastasis. (from AJCC 8th Ed.)","Stage IVA Uterine Corpus Cancer AJCC v8 | Stage IVA Uterine (including Endometrial) Cancer | Stage IVA Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537961","Stage IVB Uterine Corpus Cancer AJCC v8","C139814","Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis (includes metastasis to inguinal lymph nodes, intraperitoneal disease, lung, liver, or bone. It excludes metastasis to pelvic or para-aortic lymph nodes, vagina, uterine serosa, or adnexa). (from AJCC 8th Ed.)","Stage IVB Uterine Corpus Cancer AJCC v8 | Stage IVB Uterine (including Endometrial) Cancer | Stage IVB Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537960","Uterine Corpus Sarcoma TNM Finding v8","C139815","A finding about one or more characteristics of uterine corpus sarcoma, following the rules of the TNM AJCC v8 classification system. This classification system applies to sarcomas arising in the uterine corpus (leiomyosarcomas, endometrial stromal sarcomas, and adenosarcomas). Carcinosarcomas are staged according to the classification for uterine corpus carcinomas and carcinosarcomas. (from AJCC 8th Ed.)","Uterine Corpus Sarcoma TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537959","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma TNM Finding v8","C139816","A finding about one or more characteristics of uterine corpus leiomyosarcoma or endometrial stromal sarcoma, following the rules of the TNM AJCC v8 classification system.","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537942","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma Clinical TNM Finding v8","C139817","A clinical finding about one or more characteristics of uterine corpus leiomyosarcoma or endometrial stromal sarcoma, following the rules of the TNM AJCC v8 classification system.","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma Clinical TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537941","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma Clinical Distant Metastasis TNM Finding v8","C139818","A clinical finding about one or more characteristics of uterine corpus leiomyosarcoma or endometrial stromal sarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma Clinical Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537940","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma cM0 TNM Finding v8","C139819","Uterine corpus leiomyosarcoma or endometrial stromal sarcoma without evidence of distant metastasis. (from AJCC 8th Ed.)","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma cM0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520756","17q11","C13981","A chromosome band present on 17q","17q11 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537939","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma cM1 TNM Finding v8","C139820","Uterine corpus leiomyosarcoma or endometrial stromal sarcoma with distant metastasis (excluding adnexa, pelvic, and abdominal tissues). (from AJCC 8th Ed.)","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma cM1 TNM Finding v8 | Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma FIGO Stage IVB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537938","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma Pathologic TNM Finding v8","C139821","A pathologic finding about one or more characteristics of uterine corpus leiomyosarcoma or endometrial stromal sarcoma, following the rules of the TNM AJCC v8 classification system.","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma Pathologic TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520777","17q22-q23","C13890","A chromosome band present on 17q","17q22-q23 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526404","EGFR NM_005228.3:c.2310_2311insGGCACA","C138913","An insertion of six nucleotides, guanine-guanine-cytosine-adenine-cytosine-adenine, between position 2310 and 2311 of the coding sequence of the EGFR gene.","EGFR NM_005228.3:c.2310_2311insGGCACA | EGFR c.2305_2310dupGGCACA | EGFR c.2310_2311insGGCACA | ERBB c.2310_2311insGGCACA | ERBB1 c.2310_2311insGGCACA | Epidermal Growth Factor Receptor Gene c.2310_2311insGGCACA | HER1 c.2310_2311insGGCACA | NM_005228.3:c2310_2311insGGCACA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537842","Stage IA Vaginal Cancer AJCC v8","C139659","Stage IA includes: T1a, N0, M0. T1a: Tumor confined to the vagina, measuring 2.0 cm or less. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IA Vaginal Cancer AJCC v8 | Stage IA Vaginal Cancer | Stage IA Vaginal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519640","Trefoil Motif","C13965","Domain found in various secretory polypeptides that has highly conserved cysteine residues that are disulfide bonded in such a way as to generate a trefoil structure (bonded 1-5, 2-4, 3-6). There are also highly conserved A, G and W residues. (The Dictionary of Cell and Molecular Biology - Online)","Trefoil Motif | P Domain | P-Type Domain | TFF Domain | Trefoil | Trefoil Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538417","Renal Pelvis and Ureter Cancer by AJCC v8 Stage","C140355","A term that refers to the staging of renal pelvis and ureter cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to renal pelvis and ureter urothelial (transitional cell) carcinoma, including histologic variants micropapillary and nested subtypes. It does not apply to renal cell carcinomas (are staged according to the classification for kidney), renal medullary carcinomas (are staged according to the classification for kidney), collecting duct carcinomas (are staged according to the classification for kidney),  lymphomas (are staged according to the classification for Hodgkin and non-Hodgkin lymphoma), and mesenchymal tumors (are staged according to the classification for soft tissue sarcoma of the abdomen and thoracic visceral organs). (from AJCC 8th Ed.)","Renal Pelvis and Ureter Cancer by AJCC v8 Stage | Renal Pelvis and Ureter Urothelial Carcinoma by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538716","Conjunctival Melanoma cT1 TNM Finding v8","C140564","Conjunctival melanoma with tumor of the bulbar conjunctiva. (from AJCC 8th Ed.)","Conjunctival Melanoma cT1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538715","Conjunctival Melanoma cT1a TNM Finding v8","C140565","Conjunctival melanoma with tumor of the bulbar conjunctiva, involving less than 1 quadrant. (from AJCC 8th Ed.)","Conjunctival Melanoma cT1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538730","Conjunctival Melanoma cT1b TNM Finding v8","C140566","Conjunctival melanoma with tumor of the bulbar conjunctiva, involving 1 or more to less than 2 quadrants. (from AJCC 8th Ed.)","Conjunctival Melanoma cT1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538728","Conjunctival Melanoma cT1d TNM Finding v8","C140568","Conjunctival melanoma with tumor of the bulbar conjunctiva, involving 3 or more quadrants. (from AJCC 8th Ed.)","Conjunctival Melanoma cT1d TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538727","Conjunctival Melanoma cT2 TNM Finding v8","C140569","Conjunctival melanoma with tumor of the nonbulbar (forniceal, palpebral, tarsal) conjunctiva, and tumor involving the caruncle. (from AJCC 8th Ed.)","Conjunctival Melanoma cT2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519727","Tyrosine Phosphorylation Site","C14056","It refers to amino acid tyrosine residue that was covalently modified by phosphate group (PO4-). (NCI)","Tyrosine Phosphorylation Site | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538726","Conjunctival Melanoma cT2a TNM Finding v8","C140570","Conjunctival melanoma with noncaruncular tumor, and 1 or less quadrant of the nonbulbar conjunctiva involved. (from AJCC 8th Ed.)","Conjunctival Melanoma cT2a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538725","Conjunctival Melanoma cT2b TNM Finding v8","C140571","Conjunctival melanoma with noncaruncular tumor, and more than 1 quadrant of the nonbulbar conjunctiva involved. (from AJCC 8th Ed.)","Conjunctival Melanoma cT2b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538724","Conjunctival Melanoma cT2c TNM Finding v8","C140572","Conjunctival melanoma with caruncular tumor, and 1 or less quadrant of the nonbulbar conjunctiva involved. (from AJCC 8th Ed.)","Conjunctival Melanoma cT2c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538723","Conjunctival Melanoma cT2d TNM Finding v8","C140573","Conjunctival melanoma with caruncular tumor, and more than 1 quadrant of the nonbulbar conjunctiva involved. (from AJCC 8th Ed.)","Conjunctival Melanoma cT2d TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538706","Conjunctival Melanoma cT3 TNM Finding v8","C140574","Conjunctival melanoma with tumor of any size with local invasion. (from AJCC 8th Ed.)","Conjunctival Melanoma cT3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538704","Conjunctival Melanoma cT3b TNM Finding v8","C140576","Conjunctival melanoma with tumor of any size invading the eyelid. (from AJCC 8th Ed.)","Conjunctival Melanoma cT3b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538703","Conjunctival Melanoma cT3c TNM Finding v8","C140577","Conjunctival melanoma with tumor of any size invading the orbit. (from AJCC 8th Ed.)","Conjunctival Melanoma cT3c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538702","Conjunctival Melanoma cT3d TNM Finding v8","C140578","Conjunctival melanoma with tumor of any size invading the nasolacrimal duct and/or lacrimal sac and/or paranasal sinuses. (from AJCC 8th Ed.)","Conjunctival Melanoma cT3d TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538701","Conjunctival Melanoma cT4 TNM Finding v8","C140579","Conjunctival melanoma with tumor of any size invading the central nervous system. (from AJCC 8th Ed.)","Conjunctival Melanoma cT4 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538333","Testicular Cancer Clinical Distant Metastasis TNM Finding v8","C140188","A clinical finding about one or more characteristics of testicular cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Testicular Cancer Clinical Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521699","8p21","C14018","A chromosome band present on 8p","8p21 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538328","Testicular Cancer Clinical Primary Tumor TNM Finding v8","C140193","A clinical finding about one or more characteristics of testicular cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Testicular Cancer Clinical Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521077","21q21.2","C14019","A chromosome band present on 21q","21q21.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0138274","prednisolone sodium succinate","C1403","The sodium succinate salt form of prednisolone, a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisolone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI)","Prednisolone Sodium Succinate | PREDNISOLONE SODIUM SUCCINATE | Precortalon Aquosum | Prednisolone sodium succinate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537937","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma Pathologic Distant Metastasis TNM Finding v8","C139822","A pathologic finding about one or more characteristics of uterine corpus leiomyosarcoma or endometrial stromal sarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma Pathologic Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520750","17p13-p12","C13942","A chromosome band present on 17p","17p13-p12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521650","7q31.1","C13943","A chromosome band present on 7q","7q31.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537841","Stage IB Vaginal Cancer AJCC v8","C139660","Stage IB includes: T1b, N0, M0. T1b: Tumor confined to the vagina, measuring more than 2.0 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IB Vaginal Cancer AJCC v8 | Stage IB Vaginal Cancer | Stage IB Vaginal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537840","Stage II Vaginal Cancer AJCC v8","C139661","Stage II includes: IIA: T2a, N0, M0; IIB: T2b, N0, M0. T2a: Tumor invading paravaginal tissues but not to pelvic wall, measuring 2.0 cm or less. T2b: Tumor invading paravaginal tissues but not to pelvic wall, measuring more than 2.0 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage II Vaginal Cancer AJCC v8 | Stage II Vaginal Cancer | Stage II Vaginal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537855","Stage IIA Vaginal Cancer AJCC v8","C139662","Stage IIA includes: T2a, N0, M0. T2a: Tumor invading paravaginal tissues but not to pelvic wall, measuring 2.0 cm or less. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIA Vaginal Cancer AJCC v8 | Stage IIA Vaginal Cancer | Stage IIA Vaginal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537853","Stage IIB Vaginal Cancer AJCC v8","C139664","Stage IIB includes: T2b, N0, M0. T2b: Tumor invading paravaginal tissues but not to pelvic wall, measuring more than 2.0 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIB Vaginal Cancer AJCC v8 | Stage IIB Vaginal Cancer | Stage IIB Vaginal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537852","Stage III Vaginal Cancer AJCC v8","C139665","Stage III includes: (T1-T3, N1, M0); (T3, N0, M0). T1: Tumor confined to the vagina. T2: Tumor invading paravaginal tissues but not to pelvic sidewall. T3: Tumor extending to the pelvic sidewall and/or involving the lower third of the vagina and/or causing hydronephrosis or nonfunctioning kidney. N0: No regional lymph node metastasis. N1: Pelvic or inguinal lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage III Vaginal Cancer AJCC v8 | Stage III Vaginal Cancer | Stage III Vaginal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537850","Stage IV Vaginal Cancer AJCC v8","C139667","Stage IV includes: IVA: T4, Any N, M0; IVB: Any T, Any N, M1. T4: Tumor invading the mucosa of the bladder or rectum and/or extending beyond the true pelvis (bullous edema is not sufficient evidence to classify a tumor as T4). M0: No distant metastasis. M1: Distant metastasis. (from AJCC 8th Ed.)","Stage IV Vaginal Cancer AJCC v8 | Stage IV Vaginal Cancer | Stage IV Vaginal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537848","Stage IVA Vaginal Cancer AJCC v8","C139669","Stage IVA includes: T4, Any N, M0. T4: Tumor invading the mucosa of the bladder or rectum and/or extending beyond the true pelvis (bullous edema is not sufficient evidence to classify a tumor as T4). M0: No distant metastasis. (from AJCC 8th Ed.)","Stage IVA Vaginal Cancer AJCC v8 | Stage IVA Vaginal Cancer | Stage IVA Vaginal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520798","18p11.32","C13966","A chromosome band present on 18p","18p11.32 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537831","Stage IVB Vaginal Cancer AJCC v8","C139670","Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (from AJCC 8th Ed.)","Stage IVB Vaginal Cancer AJCC v8 | Stage IVB Vaginal Cancer | Stage IVB Vaginal Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537830","CCNB3 Gene","C139671","This gene plays a role in the regulation of mitosis and meiosis.","CCNB3 Gene | CCNB3 | Cyclin B3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526608","Country of Recruitment","C139170","The country in which subjects are located when enrolling in a trial or study.","Country of Recruitment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519254","Serine Phosphorylation Site","C14057","It refers to amino acid serine residue that was covalently modified by phosphate group (PO4-). (NCI)","Serine Phosphorylation Site | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538700","Conjunctival Melanoma Pathologic TNM Finding v8","C140580","A pathologic finding about one or more characteristics of conjunctival melanoma, following the rules of the TNM AJCC v8 classification system.","Conjunctival Melanoma Pathologic TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538699","Conjunctival Melanoma Pathologic Distant Metastasis TNM Finding v8","C140581","A pathologic finding about one or more characteristics of conjunctival melanoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Conjunctival Melanoma Pathologic Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538712","Conjunctival Melanoma pTX TNM Finding v8","C140584","Conjunctival melanoma in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Conjunctival Melanoma pTX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538091","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pM1b TNM Finding v8","C139938","Ovarian, fallopian tube, or primary peritoneal carcinoma with liver or splenic parenchymal metastases; metastases to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside the abdominal cavity); transmural involvement of intestine. (from AJCC 8th Ed.)","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pM1b TNM Finding v8 | Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IVB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538090","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Pathologic Primary Tumor TNM Finding v8","C139939","A pathologic finding about one or more characteristics of ovarian, fallopian tube, or primary peritoneal carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor. The definitions of the T categories correspond to the stages accepted by FIGO. (from AJCC 8th Ed.)","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Pathologic Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520965","1p35-p31.3","C13993","A chromosome band present on 1p","1p35-p31.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538088","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT0 TNM Finding v8","C139941","Ovarian, fallopian tube, or primary peritoneal carcinoma with no evidence of primary tumor. (from AJCC 8th Ed.)","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538087","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT1 TNM Finding v8","C139942","Ovarian, fallopian tube, or primary peritoneal carcinoma with tumor limited to ovaries (one or both) or fallopian tube(s). (from AJCC 8th Ed.)","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT1 TNM Finding v8 | Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538086","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT1a TNM Finding v8","C139943","Ovarian, fallopian tube, or primary peritoneal carcinoma with tumor limited to one ovary (capsule intact) or fallopian tube surface; no malignant cells in ascites or peritoneal washings. (from AJCC 8th Ed.)","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT1a TNM Finding v8 | Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538085","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT1b TNM Finding v8","C139944","Ovarian, fallopian tube, or primary peritoneal carcinoma with tumor limited to one or both ovaries (capsules intact) or fallopian tubes; no tumor on ovarian or fallopian tube surface; no malignant cells in ascites or peritoneal washings. (from AJCC 8th Ed.)","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT1b TNM Finding v8 | Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538068","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT1c TNM Finding v8","C139945","Ovarian, fallopian tube, or primary peritoneal carcinoma with tumor limited to one or both ovaries or fallopian tubes, with any of the following: surgical spill, capsule ruptured before surgery or tumor on ovarian or fallopian tube surface, or malignant cells in ascites or peritoneal washings. (from AJCC 8th Ed.)","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT1c TNM Finding v8 | Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538067","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT1c1 TNM Finding v8","C139946","Ovarian, fallopian tube, or primary peritoneal carcinoma with tumor limited to one or both ovaries or fallopian tubes, with surgical spill. (from AJCC 8th Ed.)","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT1c1 TNM Finding v8 | Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538508","Bladder Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C140407","A pathologic finding about one or more characteristics of bladder cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Bladder Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | Bladder Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8 | Pathologic Regional Lymph Node Status (pN)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521185","2p22.3-p21","C14040","A chromosome band present on 2p","2p22.3-p21 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526781","Breast Cancer Anatomic Stage","C139445","Breast cancer staging used in global regions where biomarker tests are not routinely available.","Breast Cancer Anatomic Stage | Breast Carcinoma Anatomic Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526962","Vulvar Cancer pT3 TNM Finding v8","C139605","Vulvar cancer with tumor of any size with extension to any of the following: upper/proximal two-thirds of the urethra, upper/proximal two-thirds of the vagina, bladder mucosa, or rectal mucosa; or fixed to pelvic bone. (from AJCC 8th Ed.)","Vulvar Cancer pT3 TNM Finding v8 | Vulvar Cancer FIGO Stage IVA | Vulvar Carcinoma FIGO Stage IVA | Vulvar Carcinoma pT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526961","Vulvar Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C139606","A pathologic finding about one or more characteristics of vulvar cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Vulvar Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | Vulvar Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526960","Vulvar Cancer pNX TNM Finding v8","C139607","Vulvar cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Vulvar Cancer pNX TNM Finding v8 | Vulvar Carcinoma pNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526967","Vulvar Cancer pN0 TNM Finding v8","C139608","Vulvar cancer with no regional lymph node metastasis. (from AJCC 8th Ed.)","Vulvar Cancer pN0 TNM Finding v8 | Vulvar Carcinoma pN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526966","Vulvar Cancer pN0(i+) TNM Finding v8","C139609","Vulvar cancer with isolated tumor cells in regional lymph node(s) no greater than 0.2 mm. (from AJCC 8th Ed.)","Vulvar Cancer pN0(i+) TNM Finding v8 | Vulvar Carcinoma pN0(i+) TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526965","Vulvar Cancer pN1 TNM Finding v8","C139610","Vulvar cancer with regional lymph node metastasis with one or two lymph node metastases each less than 5 mm, or one lymph node metastasis equal to 5 mm. (from AJCC 8th Ed.)","Vulvar Cancer pN1 TNM Finding v8 | Vulvar Cancer FIGO Stage III | Vulvar Carcinoma FIGO Stage III | Vulvar Carcinoma pN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526964","Vulvar Cancer pN1a TNM Finding v8","C139611","Vulvar cancer with regional lymph node metastasis with one or two lymph node metastases each less than 5 mm. It includes micrometastasis, N1mi. (from AJCC 8th Ed.)","Vulvar Cancer pN1a TNM Finding v8 | Vulvar Cancer FIGO Stage IIIA | Vulvar Carcinoma FIGO Stage IIIA | Vulvar Carcinoma pN1a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526939","Vulvar Cancer pN1b TNM Finding v8","C139612","Vulvar cancer with one lymph node metastasis equal to 5 mm. (from AJCC 8th Ed.)","Vulvar Cancer pN1b TNM Finding v8 | Vulvar Cancer FIGO Stage IIIA | Vulvar Carcinoma FIGO Stage IIIA | Vulvar Carcinoma pN1b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526938","Vulvar Cancer pN2 TNM Finding v8","C139613","Vulvar cancer with regional lymph node metastasis with three or more lymph node metastases each less than 5 mm, or two or more lymph node metastases equal to 5 mm, or lymph node(s) with extranodal extension. (from AJCC 8th Ed.)","Vulvar Cancer pN2 TNM Finding v8 | Vulvar Carcinoma pN2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526614","Target Sample Size","C139172","The total number of planned participants in a study or trial.","Target Sample Size | Planned Sample Size",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526613","Secondary Endpoint","C139173","An auxiliary endpoint associated with the study or trial.","Secondary Endpoint | secondary endpoint",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526612","Device Feasibility Study","C139174","An intervention of a device product is being evaluated to determine the feasibility of the product or to test a prototype device and not health outcomes. Such studies are conducted to confirm the design and operating specifications of a device before beginning a full clinical trial. (ClinicalTrials.gov)","Device Feasibility Study | DEVICE FEASIBILITY | Device Feasibility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526611","Age at Full-Time Use","C139175","The age at which the full-time use of an entity occurred.","Age at Full-Time Use | AGEFTUSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526591","Extrapolation Imputation Technique","C139176","A method of imputation involving populating an analysis value that is outside the range of observed values and is estimated by a function of those observed values. (CDISC)","Extrapolation Imputation Technique | EXTRAP | Extrapolation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521169","2p11","C13917","A chromosome band present on 2p","2p11 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526595","Rectal Tumor to Anal Verge Distance","C139184","A measurement of the distance between the rectal tumor and the anal margin.","Rectal Tumor to Anal Verge Distance | RTAVDIST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521404","4q28-q31","C13918","A chromosome band present on 4q","4q28-q31 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538066","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT1c2 TNM Finding v8","C139947","Ovarian, fallopian tube, or primary peritoneal carcinoma with tumor limited to one or both ovaries or fallopian tubes, with capsule ruptured before surgery or tumor on ovarian or fallopian tube surface. (from AJCC 8th Ed.)","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT1c2 TNM Finding v8 | Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IC2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538065","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT1c3 TNM Finding v8","C139948","Ovarian, fallopian tube, or primary peritoneal carcinoma with tumor limited to one or both ovaries or fallopian tubes with malignant cells in ascites or peritoneal washings. (from AJCC 8th Ed.)","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT1c3 TNM Finding v8 | Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IC3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538064","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT2 TNM Finding v8","C139949","Ovarian, fallopian tube, or primary peritoneal carcinoma with tumor involving one or both ovaries or fallopian tubes with pelvic extension below pelvic brim or primary peritoneal cancer. (from AJCC 8th Ed.)","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT2 TNM Finding v8 | Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520507","12q22-q23","C13994","A chromosome band present on 12q","12q22-q23 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520279","10q22.3","C14015","A chromosome band present on 10q","10q22.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162808","Tertiary Protein Structure","C14064","Tertiary structure describes the folding of the polypeptide chain to assemble the different secondary structure elements in a particular arrangement.","Tertiary Protein Structure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538772","Uveal Melanoma Pathologic Regional Lymph Nodes TNM Finding v8","C140652","A pathologic finding about one or more characteristics of uveal melanoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Uveal Melanoma Pathologic Regional Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538169","Stage IC Fallopian Tube Cancer AJCC v8","C139987","Stage IC includes: T1c, N0, M0. T1c: Fallopian tube cancer with tumor limited to fallopian tubes, with any of the following: surgical spill, capsule ruptured before surgery or tumor on fallopian tube surface, or malignant cells in ascites or peritoneal washings. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IC Fallopian Tube Cancer AJCC v8 | Stage IC Fallopian Tube Cancer | Stage IC Fallopian Tube Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526937","Vulvar Cancer pN2a TNM Finding v8","C139614","Vulvar cancer with three or more lymph node metastases each less than 5 mm. It includes micrometastasis, N2mi. (from AJCC 8th Ed.)","Vulvar Cancer pN2a TNM Finding v8 | Vulvar Cancer FIGO Stage IIIB | Vulvar Carcinoma FIGO Stage IIIB | Vulvar Carcinoma pN2a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526936","Vulvar Cancer pN2b TNM Finding v8","C139615","Vulvar cancer with two or more lymph node metastases equal to 5 mm. (from AJCC 8th Ed.)","Vulvar Cancer pN2b TNM Finding v8 | Vulvar Cancer FIGO Stage IIIB | Vulvar Carcinoma FIGO Stage IIIB | Vulvar Carcinoma pN2b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526943","Vulvar Cancer pN2c TNM Finding v8","C139616","Vulvar cancer with lymph node(s) metastasis with extranodal extension. (from AJCC 8th Ed.)","Vulvar Cancer pN2c TNM Finding v8 | Vulvar Cancer FIGO Stage IIIC | Vulvar Carcinoma FIGO Stage IIIC | Vulvar Carcinoma pN2c TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526942","Vulvar Cancer pN3 TNM Finding v8","C139617","Vulvar cancer with fixed or ulcerated regional lymph node metastasis. (from AJCC 8th Ed.)","Vulvar Cancer pN3 TNM Finding v8 | Vulvar Cancer FIGO Stage IVA | Vulvar Carcinoma FIGO Stage IVA | Vulvar Carcinoma pN3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526941","Vulvar Cancer by AJCC v8 Stage","C139618","A term that refers to the staging of vulvar cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to all carcinomas of the vulva. Melanoma of the vulva is staged according to the classification for melanoma of the skin. (AJCC 8th Ed.)","Vulvar Cancer by AJCC v8 Stage | Vulvar Carcinoma by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526940","Stage I Vulvar Cancer AJCC v8","C139619","Stage I includes: T1, N0, M0. T1: Tumor confined to the vulva and/or perineum. Multifocal lesions should be designated as such. The largest lesion or the lesion with the greatest depth of invasion will be the target lesion identified to address the highest pT stage. Depth of invasion is defined as the measurement of the tumor from the epithelial-stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage I Vulvar Cancer AJCC v8 | Stage I Vulvar Cancer | Stage I Vulvar Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520638","15q22.1-q22.33","C13961","A chromosome band present on 15q","15q22.1-q22.33 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526947","Stage IA Vulvar Cancer AJCC v8","C139620","Stage IA includes: T1a, N0, M0. T1a: Lesion measuring 2 cm or less, confined to the vulva and/or perineum, and with stromal invasion of 1.0 mm or less. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IA Vulvar Cancer AJCC v8 | Stage IA Vulvar Cancer | Stage IA Vulvar Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526946","Stage IB Vulvar Cancer AJCC v8","C139621","Stage IB includes: T1b, N0, M0. T1b: Lesion measuring more than 2 cm, or any size with stromal invasion of more than 1.0 mm, confined to the vulva and/or perineum. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 8th Ed.)","Stage IB Vulvar Cancer AJCC v8 | Stage IB Vulvar Cancer | Stage IB Vulvar Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526945","Stage II Vulvar Cancer AJCC v8","C139622","Stage II includes: T2, N0, M0. T2: Tumor of any size with extension to adjacent perineal structures (lower/distal third of the urethra, lower/distal third of the vagina, anal involvement). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage II Vulvar Cancer AJCC v8 | Stage II Vulvar Cancer | Stage II Vulvar Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526944","Stage III Vulvar Cancer AJCC v8","C139623","Stage III includes: T1-T2, N1-N2c, M0. T1: Tumor confined to the vulva and/or perineum. Multifocal lesions should be designated as such. The largest lesion or the lesion with the greatest depth of invasion will be the target lesion identified to address the highest pT stage. Depth of invasion is defined as the measurement of the tumor from the epithelial-stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion. T2: Tumor of any size with extension to adjacent perineal structures (lower/distal third of the urethra, lower/distal third of the vagina, anal involvement). N1: Regional lymph node metastasis with one or two lymph node metastases each less than 5 mm, or one lymph node metastasis equal to 5 mm. N2a: Three or more lymph node metastases each less than 5 mm. It includes micrometastasis, N2mi. N2b: Two or more lymph node metastases equal to 5 mm. N2c: Lymph node(s) metastasis with extranodal extension. M0: No distant metastasis. (AJCC 8th Ed.)","Stage III Vulvar Cancer AJCC v8 | Stage III Vulvar Cancer | Stage III Vulvar Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526858","Unintended Compatibility","C139495","The device was confirmed to be compatible with another device with which the device is intended to be incompatible.","Unintended Compatibility | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526857","Inadequate or Incorrect Instructions for Maintenance","C139496","Inadequate or incorrect information in the instructions for maintenance.","Inadequate or Incorrect Instructions for Maintenance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526832","Maintenance of Manufacturing Machinery","C139497","Problems caused by failure to maintain manufacturing equipment used to produce the device.","Maintenance of Manufacturing Machinery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526831","Inadequate Physicochemical Properties","C139498","Problems that occur due to the physicochemical properties.","Inadequate Physicochemical Properties | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526830","Incorrect Dimension","C139499","Problems caused by incorrect physical dimensions of the device or one of its parts.","Incorrect Dimension | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521415","4q32.2","C13949","A chromosome band present on 4q","4q32.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0129341","Mifamurtide","C1394","A liposomal formulation containing a muramyl dipeptide (MDP) analogue with potential immunomodulatory and antineoplastic activities. Muramyl tripeptide phosphatidylethanolamine (MTP-PE), a derivative of the mycobacterial cell wall component MDP, activates both monocytes and macrophages. Activated macrophages secrete cytokines and induce the recruitment and activation of other immune cells, which may result in indirect tumoricidal effects. Liposomal encapsulation of MTP-PE prolongs its half-life and enhances tissue targeting.","Mifamurtide | CGP 19835A Lipid | Junovan | L-Alaninamide, N-(N-acetylmuramoyl)-L-alanyl-D-alpha-glutaminyl-N-((7R)-4-hydroxy-4-oxido-10-oxo-7-((1-oxohexadecyl)oxy)-3,5,9-trioxa-4-phosphapentacos-1-yl)-, Monosodium Salt, Hydrate | L-MTP-PE | MEPACT | MIFAMURTIDE | MTP-PE Liposome | Mepact | Muramyl Tripeptide Phosphatidylethanolamine Liposome | MuramylNAc-Ala-isoGln-Lys-tripeptide-PE | mifamurtide | muramyl tripeptide phosphatidylethanolamine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526829","Leakage/Seal","C139500","Problems caused by inadequate/broken seal within the device.","Leakage/Seal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526836","Incorrect Interpretation of Results/Data","C139501","Problems resulting from the incorrect interpretation by the user of the results or data provided by the device.","Incorrect Interpretation of Results/Data | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526834","Packaging Contains Incorrect or Incomplete Device","C139503","Problems that occurred because the packaging contained an incorrect or incomplete device (missing components).","Packaging Contains Incorrect or Incomplete Device | Packaging Contains Incorrect Device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526833","Packaging Contains Unintended Material","C139504","Problems that occurred because unintended material was packaged with the device.","Packaging Contains Unintended Material | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526840","Packaging Materials Problem","C139505","Problems that occurred because of the composition or type of packaging materials was inappropriate for the device.","Packaging Materials Problem | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526839","Alarm System Problem Identified","C139506","A system intended to warn of a potentially unsafe condition did not operate correctly.","Alarm System Problem Identified | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526838","Fail-safe Problem Identified","C139507","A system intended to prevent unsafe operation of the device did not operate correctly.","Fail-safe Problem Identified | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526837","Missing or Inadequate Safety Measures","C139508","Safety measures are inadequately applied or missing.","Missing or Inadequate Safety Measures Identified | Missing or Inadequate Safety Measures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526844","Premature Indicator Activation","C139509","A system intended to indicate the device status was triggered prematurely.","Premature Indicator Activation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526843","Problem of Device to Self-Test","C139510","Malfunction of the device's self-test system.","Problem of Device to Self-Test | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526842","Problem to Auto Stop","C139511","An auto stop function of a device did not operate correctly.","Problem to Auto Stop | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538234","Whitmore-Jewett Stage","C140161","A prostate cancer stage defined according to the Whitmore-Jewett staging system criteria.","Whitmore-Jewett Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538416","Renal Pelvis Cancer by AJCC v8 Stage","C140356","A term that refers to the staging of renal pelvis cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to renal pelvis urothelial (transitional cell) carcinoma, including histologic variants micropapillary and nested subtypes. It does not apply to renal cell carcinomas (are staged according to the classification for kidney), renal medullary carcinomas (are staged according to the classification for kidney), collecting duct carcinomas (are staged according to the classification for kidney),  lymphomas (are staged according to the classification for Hodgkin and non-Hodgkin lymphoma), and mesenchymal tumors (are staged according to the classification for soft tissue sarcoma of the abdomen and thoracic visceral organs). (from AJCC 8th Ed.)","Renal Pelvis Cancer by AJCC v8 Stage | Renal Pelvis Urothelial Carcinoma by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538431","Ureter Cancer by AJCC v8 Stage","C140357","A term that refers to the staging of ureter cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to ureter urothelial (transitional cell) carcinoma, including histologic variants micropapillary and nested subtypes. (from AJCC 8th Ed.)","Ureter Cancer by AJCC v8 Stage | Ureter Urothelial Carcinoma by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538430","Stage 0a Renal Pelvis and Ureter Cancer AJCC v8","C140358","Stage 0a includes: Ta, N0, M0. Ta: Papillary noninvasive carcinoma. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0a Renal Pelvis and Ureter Cancer AJCC v8 | Stage 0a Renal Pelvis and Ureter Cancer | Stage 0a Renal Pelvis and Ureter Urothelial Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538429","Stage 0a Renal Pelvis Cancer AJCC v8","C140359","Stage 0a includes: Ta, N0, M0. Ta: Papillary noninvasive carcinoma. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0a Renal Pelvis Cancer AJCC v8 | Stage 0a Renal Pelvis Cancer | Stage 0a Renal Pelvis Urothelial Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520172","Xp11.22","C14035","A chromosome band present on Xp","Xp11.22 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538428","Stage 0a Ureter Cancer AJCC v8","C140360","Stage 0a includes: Ta, N0, M0. Ta: Papillary noninvasive carcinoma. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0a Ureter Cancer AJCC v8 | Stage 0a Ureter Cancer | Stage 0a Ureter Urothelial Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538427","Stage 0is Renal Pelvis and Ureter Cancer AJCC v8","C140361","Stage 0is includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0is Renal Pelvis and Ureter Cancer AJCC v8 | Stage 0is Renal Pelvis and Ureter Cancer | Stage 0is Renal Pelvis and Ureter Urothelial Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538168","Stage II Fallopian Tube Cancer AJCC v8","C139988","Stage II includes: T2, N0, M0. T2: Fallopian tube cancer with tumor involving fallopian tubes with pelvic extension below pelvic brim. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage II Fallopian Tube Cancer AJCC v8 | Stage II Fallopian Tube Cancer | Stage II Fallopian Tube Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538167","Stage IIA Fallopian Tube Cancer AJCC v8","C139989","Stage IIA includes: T2a, N0, M0. T2a: Fallopian tube cancer with extension and/or implants on the uterus and/or fallopian tube(s) and/or ovaries. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIA Fallopian Tube Cancer AJCC v8 | Stage IIA Fallopian Tube Cancer | Stage IIA Fallopian Tube Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521573","6q24-q25","C13998","A chromosome band present on 6q","6q24-q25 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538166","Stage IIB Fallopian Tube Cancer AJCC v8","C139990","Stage IIB includes: T2b, N0, M0. T2b: Fallopian tube cancer with tumor extension to and/or implants on other pelvic tissues. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIB Fallopian Tube Cancer AJCC v8 | Stage IIB Fallopian Tube Cancer | Stage IIB Fallopian Tube Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538165","Stage III Fallopian Tube Cancer AJCC v8","C139991","Stage III includes: IIIA1: T1/2, N1, M0; IIIA2: T3a, N0/N1, M0; IIIB: T3b, N0/N1, M0; IIIC: T3c, N0/N1, M0. T1: Fallopian tube cancer with tumor limited to fallopian tube(s). T2: Fallopian tube cancer with tumor involving fallopian tubes with pelvic extension below pelvic brim. T3a: Fallopian tube cancer with microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. T3b: Fallopian tube cancer with macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension with or without metastasis to the retroperitoneal lymph nodes. T3c: Fallopian tube cancer with macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension with or without metastasis to the retroperitoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ). N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)","Stage III Fallopian Tube Cancer AJCC v8 | Stage III Fallopian Tube Cancer | Stage III Fallopian Tube Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538164","Stage IIIA Fallopian Tube Cancer AJCC v8","C139992","Stage IIIA includes: IIIA1: T1/2, N1, M0; IIIA2: T3a, N0/N1, M0. T1: Fallopian tube cancer with tumor limited to fallopian tube(s). T2: Fallopian tube cancer with tumor involving fallopian tubes with pelvic extension below pelvic brim. T3a: Fallopian tube cancer with microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIIA Fallopian Tube Cancer AJCC v8 | Stage IIIA Fallopian Tube Cancer | Stage IIIA Fallopian Tube Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538148","Stage IIIA1 Fallopian Tube Cancer AJCC v8","C139993","Stage IIIA1 includes: T1/2, N1, M0. T1: T1: Fallopian tube cancer with tumor limited to fallopian tube(s). T2: Fallopian tube cancer with tumor involving fallopian tubes with pelvic extension below pelvic brim. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIIA1 Fallopian Tube Cancer AJCC v8 | Stage IIIA1 Fallopian Tube Cancer | Stage IIIA1 Fallopian Tube Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538147","Stage IIIA2 Fallopian Tube Cancer AJCC v8","C139994","Stage IIIA2 includes: T3a, N0/N1, M0. T3a: T3a: Fallopian tube cancer with microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIIA2 Fallopian Tube Cancer AJCC v8 | Stage IIIA2 Fallopian Tube Cancer | Stage IIIA2 Fallopian Tube Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538146","Stage IIIB Fallopian Tube Cancer AJCC v8","C139995","Stage IIIB includes: T3b, N0/N1, M0. T3b: Fallopian tube cancer with macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension with or without metastasis to the retroperitoneal lymph nodes. N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIIB Fallopian Tube Cancer AJCC v8 | Stage IIIB Fallopian Tube Cancer | Stage IIIB Fallopian Tube Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526951","Stage IIIA Vulvar Cancer AJCC v8","C139624","Stage IIIA includes: T1-T2, N1, M0. T1: Tumor confined to the vulva and/or perineum. Multifocal lesions should be designated as such. The largest lesion or the lesion with the greatest depth of invasion will be the target lesion identified to address the highest pT stage. Depth of invasion is defined as the measurement of the tumor from the epithelial-stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion. T2: Tumor of any size with extension to adjacent perineal structures (lower/distal third of the urethra, lower/distal third of the vagina, anal involvement). N1: Regional lymph node metastasis with one or two lymph node metastases each less than 5 mm, or one lymph node metastasis equal to 5 mm. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIIA Vulvar Cancer AJCC v8 | Stage IIIA Vulvar Cancer | Stage IIIA Vulvar Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526950","Stage IIIB Vulvar Cancer AJCC v8","C139625","Stage IIIB includes: T1-T2, N2a, N2b, M0. T1: Tumor confined to the vulva and/or perineum. Multifocal lesions should be designated as such. The largest lesion or the lesion with the greatest depth of invasion will be the target lesion identified to address the highest pT stage. Depth of invasion is defined as the measurement of the tumor from the epithelial-stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion. T2: Tumor of any size with extension to adjacent perineal structures (lower/distal third of the urethra, lower/distal third of the vagina, anal involvement). N2a: Three or more lymph node metastases each less than 5 mm. It includes micrometastasis, N2mi. N2b: Two or more lymph node metastases equal to 5 mm. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIIB Vulvar Cancer AJCC v8 | Stage IIIB Vulvar Cancer | Stage IIIB Vulvar Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526949","Stage IIIC Vulvar Cancer AJCC v8","C139626","Stage IIIC includes: T1-T2, N2c, M0. T1: Tumor confined to the vulva and/or perineum. Multifocal lesions should be designated as such. The largest lesion or the lesion with the greatest depth of invasion will be the target lesion identified to address the highest pT stage. Depth of invasion is defined as the measurement of the tumor from the epithelial-stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion. T2: Tumor of any size with extension to adjacent perineal structures (lower/distal third of the urethra, lower/distal third of the vagina, anal involvement). N2c: Lymph node(s) metastasis with extranodal extension. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIIC Vulvar Cancer AJCC v8 | Stage IIIC Vulvar Cancer | Stage IIIC Vulvar Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537936","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pM1 TNM Finding v8","C139823","Uterine corpus leiomyosarcoma or endometrial stromal sarcoma with distant metastasis (excluding adnexa, pelvic, and abdominal tissues). (from AJCC 8th Ed.)","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pM1 TNM Finding v8 | Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma FIGO Stage IVB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537935","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma Pathologic Primary Tumor TNM Finding v8","C139824","A pathologic finding about one or more characteristics of uterine corpus leiomyosarcoma or endometrial stromal sarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor. The definitions of the T categories correspond to the stages accepted by FIGO. (from AJCC 8th Ed.)","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma Pathologic Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537950","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pTX TNM Finding v8","C139825","Uterine corpus leiomyosarcoma or endometrial stromal sarcoma in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pTX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537949","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pT0 TNM Finding v8","C139826","Uterine corpus leiomyosarcoma or endometrial stromal sarcoma with no evidence of primary tumor. (from AJCC 8th Ed.)","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pT0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537948","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pT1 TNM Finding v8","C139827","Uterine corpus leiomyosarcoma or endometrial stromal sarcoma with tumor limited to the uterus. (from AJCC 8th Ed.)","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pT1 TNM Finding v8 | Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma FIGO Stage I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537947","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pT1a TNM Finding v8","C139828","Uterine corpus leiomyosarcoma or endometrial stromal sarcoma with tumor limited to the uterus, measuring 5 cm or less in greatest dimension. (from AJCC 8th Ed.)","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pT1a TNM Finding v8 | Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma FIGO Stage IA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526841","Reset Problem","C139512","The device does not reset properly.","Reset Problem | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526817","Shielding Problem","C139513","Inadequate shielding of/by the device.","Shielding Problem | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526816","Data Storage or Loss of Data","C139514","Storage of data was unsuccessful in total or in part.","Data Storage or Loss of Data | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526376","EGFR NM_005228.3:c.2320_2321insCCCACG","C138920","An insertion of six nucleotides, cytosine-cytosine-cytosine-adenine-cytosine-guanine, between position 2320 and 2321 of the coding sequence of the EGFR gene.","EGFR NM_005228.3:c.2320_2321insCCCACG | EGFR NM_005228.4:c.2315_2320dupCCCACG | EGFR c.2315_2320dupCCCACG | EGFR c.2315_2320insCCCACG | EGFR c.2320_2321insCCCACG | ERBB c.2315_2320insCCCACG | ERBB c.2320_2321insCCCACG | ERBB1 c.2315_2320insCCCACG | ERBB1 c.2320_2321insCCCACG | Epidermal Growth Factor Receptor Gene c.2315_2320insCCCACG | Epidermal Growth Factor Receptor Gene c.2320_2321insCCCACG | HER1 c.2315_2320insCCCACG | HER1 c.2320_2321insCCCACG | NM_005228.3:c.2315_2320dupCCCACG | NM_005228.3:c.2315_2320insCCCACG | NM_005228.3:c.2320_2321insCCCACG | NM_005228.4(EGFR):c.2315_2320dupCCCACG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520281","10q23.2-q23.3","C13892","A chromosome band present on 10q","10q23.2-q23.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538426","Stage 0is Renal Pelvis Cancer AJCC v8","C140362","Stage 0is includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0is Renal Pelvis Cancer AJCC v8 | Stage 0is Renal Pelvis Cancer | Stage 0is Renal Pelvis Urothelial Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538425","Stage 0is Ureter Cancer AJCC v8","C140363","Stage 0is includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0is Ureter Cancer AJCC v8 | Stage 0is Ureter Cancer | Stage 0is Ureter Urothelial Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538534","Stage I Renal Pelvis Cancer AJCC v8","C140365","Stage I includes: T1, N0, M0. T1: Tumor invades subepithelial connective tissue. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Renal Pelvis Cancer AJCC v8 | Stage I Renal Pelvis Cancer | Stage I Renal Pelvis Urothelial Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538533","Stage I Ureter Cancer AJCC v8","C140366","Stage I includes: T1, N0, M0. T1: Tumor invades subepithelial connective tissue. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Ureter Cancer AJCC v8 | Stage I Ureter Cancer | Stage I Ureter Urothelial Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538532","Stage II Renal Pelvis and Ureter Cancer AJCC v8","C140367","Stage II includes: T2, N0, M0. T2: Tumor invades the muscularis. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Renal Pelvis and Ureter Cancer AJCC v8 | Stage II Renal Pelvis and Ureter Cancer | Stage II Renal Pelvis and Ureter Urothelial Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538531","Stage II Renal Pelvis Cancer AJCC v8","C140368","Stage II includes: T2, N0, M0. T2: Tumor invades the muscularis. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Renal Pelvis Cancer AJCC v8 | Stage II Renal Pelvis Cancer | Stage II Renal Pelvis Urothelial Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538711","Conjunctival Melanoma pT0 TNM Finding v8","C140585","Conjunctival melanoma with no evidence of primary tumor. (from AJCC 8th Ed.)","Conjunctival Melanoma pT0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538710","Conjunctival Melanoma pTis TNM Finding v8","C140586","Conjunctival melanoma confined to the conjunctival epithelium. (from AJCC 8th Ed.)","Conjunctival Melanoma pTis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538709","Conjunctival Melanoma pT1 TNM Finding v8","C140587","Conjunctival melanoma with tumor of the bulbar conjunctiva. (from AJCC 8th Ed.)","Conjunctival Melanoma pT1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538708","Conjunctival Melanoma pT1a TNM Finding v8","C140588","Conjunctival melanoma with tumor of the bulbar conjunctiva invading the substantia propria, not more than 2.0 mm in thickness. (from AJCC 8th Ed.)","Conjunctival Melanoma pT1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538707","Conjunctival Melanoma pT1b TNM Finding v8","C140589","Conjunctival melanoma with tumor of the bulbar conjunctiva invading the substantia propria, more than 2.0 mm in thickness. (from AJCC 8th Ed.)","Conjunctival Melanoma pT1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538690","Conjunctival Melanoma pT2 TNM Finding v8","C140590","Conjunctival melanoma with tumor of the nonbulbar (forniceal, palpebral, tarsal) conjunctiva, and tumor involving the caruncle. (from AJCC 8th Ed.)","Conjunctival Melanoma pT2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538689","Conjunctival Melanoma pT2a TNM Finding v8","C140591","Conjunctival melanoma with tumor of the nonbulbar conjunctiva with invasion of the substantia propria, not more than 2.0 mm in thickness. (from AJCC 8th Ed.)","Conjunctival Melanoma pT2a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538688","Conjunctival Melanoma pT2b TNM Finding v8","C140592","Conjunctival melanoma with tumor of the nonbulbar conjunctiva with invasion of the substantia propria, more than 2.0 mm in thickness. (from AJCC 8th Ed.)","Conjunctival Melanoma pT2b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538687","Conjunctival Melanoma pT3 TNM Finding v8","C140593","Conjunctival melanoma with tumor of any size with local invasion. (from AJCC 8th Ed.)","Conjunctival Melanoma pT3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0888240","Piperazinedione","C1401","A crystalline antibiotic fermentation product isolated from the bacterium Streptomyces griseoluteus with antineoplastic activity. Piperazinedione alkylates DNA at the N-7 position of guanine, inhibiting DNA replication and inducing cell cycle arrest.","Piperazinedione | 2, 5-Piperazinedione, 3,6-bis-(5-chloro-2-piperidyl)-, dihydrochloride | 2, 5-piperazinedione, 3,6-bis-(5-chloro-2-piperidyl)-, dihydrochloride | 2,5-Piperazinedione, 3, 6-bis(5-chloro-2-piperidinyl)-, dihydrochloride, [3S-[3.alpha.(2S*,5R*),6.alpha.(2S*,5R*)]]- (9CI) | 2,5-piperazinedione, 3, 6-bis(5-chloro-2-piperidinyl)-, dihydrochloride, [3S-[3alpha(2S*,5R*),6alpha(2S*,5R*)]]- (9CI) | 593A | Compound 593A | Merck Compound 593A | PZD | PZD dihydrochloride, 3,6-bis(5-chloro-2-piperidinyl)-, dihydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538316","Testicular Cancer Pathologic Distant Metastasis TNM Finding v8","C140205","A pathologic finding about one or more characteristics of testicular cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Testicular Cancer Pathologic Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538312","Testicular Cancer Pathologic Primary Tumor TNM Finding v8","C140209","A pathologic finding about one or more characteristics of testicular cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Testicular Cancer Pathologic Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521280","3p14.3-p14.2","C14020","A chromosome band present on 3p","3p14.3-p14.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537945","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pT2 TNM Finding v8","C139830","Uterine corpus leiomyosarcoma or endometrial stromal sarcoma with tumor extending beyond the uterus, within the pelvis. (from AJCC 8th Ed.)","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pT2 TNM Finding v8 | Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma FIGO Stage II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537944","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pT2a TNM Finding v8","C139831","Uterine corpus leiomyosarcoma or endometrial stromal sarcoma with tumor extending beyond the uterus, within the pelvis and involving adnexa. (from AJCC 8th Ed.)","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pT2a TNM Finding v8 | Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma FIGO Stage IIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537943","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pT2b TNM Finding v8","C139832","Uterine corpus leiomyosarcoma or endometrial stromal sarcoma with tumor involving other pelvic tissues. (from AJCC 8th Ed.)","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pT2b TNM Finding v8 | Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma FIGO Stage IIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537926","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pT3 TNM Finding v8","C139833","Uterine corpus leiomyosarcoma or endometrial stromal sarcoma with tumor infiltrating abdominal tissues. (from AJCC 8th Ed.)","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pT3 TNM Finding v8 | Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma FIGO Stage III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537925","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pT3a TNM Finding v8","C139834","Uterine corpus leiomyosarcoma or endometrial stromal sarcoma with tumor infiltrating abdominal tissues at one site. (from AJCC 8th Ed.)","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pT3a TNM Finding v8 | Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma FIGO Stage IIIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537922","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma Pathologic Regional Lymph Nodes TNM Finding v8","C139837","A pathologic finding about one or more characteristics of uterine corpus leiomyosarcoma or endometrial stromal sarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma Pathologic Regional Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526780","Breast Cancer Prognostic Stage","C139446","Breast cancer staging used in countries in which biomarker tests are routinely performed.","Breast Cancer Prognostic Stage | Breast Carcinoma Prognostic Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526779","Testing of Device from Same Lot/Batch Returned from User","C139447","The investigation employed relevant empirical testing of the device of the same lot or batch than that of the suspected device in the reported adverse event in order to support the identification of possible causes for the adverse event. The device was returned from the user. Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the latest relevant standards.","Testing of Device from Same Lot/Batch Returned from User | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526778","Testing of Device from Other Lot/Batch Retained by Manufacturer","C139448","The investigation employed relevant empirical testing of the device of another lot or batch than that of the suspected device in the reported adverse event in order to support the identification of possible causes for the adverse event. This includes devices without a lot/batch designation. Testing was performed using the device retained by the manufacturer (i.e. was not shipped). Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the latest relevant standards.","Testing of Device from Other Lot/Batch Retained by Manufacturer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526754","Testing of Device from Other Lot/Batch Returned from User","C139449","The investigation employed relevant empirical testing of the device of another lot or batch than that of the suspected device in the reported adverse event in order to support the identification of possible causes for the adverse event. This includes devices without a lot/batch designation. The device was returned from the user. Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the technical file. Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the latest relevant standards.","Testing of Device from Other Lot/Batch Returned from User | Testing of Device from Other Lot/Batch Returned From User",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537829","CCNB3 wt Allele","C139673","Human CCNB3 wild-type allele is located in the vicinity of Xp11.22 and is approximately 149 kb in length. This allele, which encodes G2/mitotic-specific cyclin-B3 protein, is involved in the progression of the cell cycle. A paracentric chromosomal inversion inv(X)(p11.4;p11.22) fuses this gene and the BCOR gene; this fusion is associated with bone sarcomas.","CCNB3 wt Allele | CYCB3 | Cyclin B3 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1121037","CCNB3 protein, human","C139675","G2/mitotic-specific cyclin-B3 (1395 aa, ~158 kDa) is encoded by the human CCNB3 gene. This protein plays a role in cell cycle regulation.","G2/Mitotic-Specific Cyclin-B3 | CCNB3 | Cyclin B3 | Cyclin-B3 | G2/Mitotic-Specific Cyclin B3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537826","CIC/DUX4 Fusion Protein","C139676","A fusion protein encoded by the CIC/DUX4 fusion gene. This protein is comprised of the majority of the protein capicua homolog, including the DNA-binding high-mobility group (HMG)-box and 15 of 16 putative MAPK phosphorylation sites, fused to the C-terminus of double homeobox protein 4, which results in the loss of both of its DNA-binding homeodomains.","CIC/DUX4 Fusion Protein | CIC-DUX4 Fusion Protein | CIC::DUX4 Fusion Protein | Protein Capicua Homolog/Double Homeobox 4 Fusion Protein | Protein Capicua Homolog::Double Homeobox 4 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537825","BCOR/CCNB3 Fusion Protein","C139677","A fusion protein encoded by the BCOR/CCNB3 fusion gene. This protein is comprised of the BCL6 co-repressor protein, which includes its three ankyrin domains, fused to the C-terminal portion of the G2/mitotic-specific cyclin-B3, which includes its two cyclin domains.","BCOR/CCNB3 Fusion Protein | BCL6 Co-Repressor/Cyclin B3 Fusion Protein | BCL6 Co-Repressor/Cyclin-B3 Fusion Protein | BCL6 Co-Repressor/G2/Mitotic-Specific Cyclin-B3 Fusion Protein | BCL6 Co-Repressor::G2/Mitotic-Specific Cyclin-B3 Fusion Protein | BCOR-CCNB3 Fusion Protein | BCOR::CCNB3 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537824","EWSR1/PBX1 Fusion Protein","C139678","A fusion protein encoded by the EWSR1/PBX1 fusion gene. This protein is comprised of the transactivation domain of the RNA-binding protein EWS fused to the C-terminal DNA binding homeodomain of the pre-B-cell leukemia transcription factor 1 protein.","EWSR1/PBX1 Fusion Protein | EWS-PBX1 Fusion Protein | EWS/PBX1 Fusion Protein | EWSR1-PBX1 Fusion Protein | EWSR1::PBX1 Fusion Protein | RNA-Binding Protein EWS/Pre-B-Cell Leukemia Pre-Transcription Factor 1 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538686","Conjunctival Melanoma pT3a TNM Finding v8","C140594","Conjunctival melanoma with tumor of any size invading the globe. (from AJCC 8th Ed.)","Conjunctival Melanoma pT3a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538685","Conjunctival Melanoma pT3b TNM Finding v8","C140595","Conjunctival melanoma with tumor of any size invading the eyelid. (from AJCC 8th Ed.)","Conjunctival Melanoma pT3b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538684","Conjunctival Melanoma pT3c TNM Finding v8","C140596","Conjunctival melanoma with tumor of any size invading the orbit. (from AJCC 8th Ed.)","Conjunctival Melanoma pT3c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538698","Conjunctival Melanoma pT4 TNM Finding v8","C140598","Conjunctival melanoma with tumor of any size invading the central nervous system. (from AJCC 8th Ed.)","Conjunctival Melanoma pT4 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538697","Conjunctival Melanoma Pathologic Regional Lymph Nodes TNM Finding v8","C140599","A pathologic finding about one or more characteristics of conjunctival melanoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Conjunctival Melanoma Pathologic Regional Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520207","YXXP Motif","C14059","YXXP (tyrosine-X-X-Proline), a substrate sequence preferred by Abl tyrosine kinases, is part of the SH2 domain that mediates certain interactions of SH2 containing proteins.  Although both phosphorylated- and unphosphorylated-YXXP can interacts with SH2 containing proteins, the SH2 domain obtain sufficient binding specificity from the recognition of adjacent residues to allow discrimination between different phosphorylated sites. (NCI)","YXXP Motif | YXXP Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538696","Conjunctival Melanoma pNX TNM Finding v8","C140600","Conjunctival melanoma in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Conjunctival Melanoma pNX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538695","Conjunctival Melanoma pN0 TNM Finding v8","C140601","Conjunctival melanoma with no regional lymph node metastasis. (from AJCC 8th Ed.)","Conjunctival Melanoma pN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538062","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT2b TNM Finding v8","C139951","Ovarian, fallopian tube, or primary peritoneal carcinoma with extension to and/or implants on other pelvic tissues. (from AJCC 8th Ed.)","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT2b TNM Finding v8 | Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538061","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT3 TNM Finding v8","C139952","Ovarian, fallopian tube, or primary peritoneal carcinoma with tumor involving one or both ovaries or fallopian tubes, or primary peritoneal cancer, with microscopically confirmed peritoneal metastasis outside the pelvis and/or metastasis to the retroperitoneal (pelvic and/or para-aortic) lymph nodes. (from AJCC 8th Ed.)","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT3 TNM Finding v8 | Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538076","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT3a TNM Finding v8","C139953","Ovarian, fallopian tube, or primary peritoneal carcinoma with microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. (from AJCC 8th Ed.)","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT3a TNM Finding v8 | Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IIIA2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538074","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT3c TNM Finding v8","C139955","Ovarian, fallopian tube, or primary peritoneal carcinoma with macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension with or without metastasis to the retroperitoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ). (from AJCC 8th Ed.)","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT3c TNM Finding v8 | Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IIIC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538484","IDH2 NM_002168.3:c.514A>T","C140415","A nucleotide substitution at position 514 of the coding sequence of the IDH2 gene where adenine has been mutated to thymine.","IDH2 NM_002168.3:c.514A>T | IDH c.514A>T | IDH2 c.514A>T | Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial c.514A>T | Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial c.514A>T | NM_002168.3:c.514A>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520862","19q13.3","C14041","A chromosome band present on 19q","19q13.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515453","8q21","C13944","A chromosome band present on 8q","8q21 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526753","Testing of Model Variant","C139450","The investigation employed relevant empirical testing of a model variant of the device involved in the reported adverse event in order to support the identification of possible causes for the adverse event through plausibility reasoning. A model variant is not identical to the actual device, but shares relevant characteristics with the device involved. Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the latest relevant standards.","Testing of Model Variant | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526752","Testing of Raw/Starting Materials","C139451","The investigation employed relevant empirical testing of the materials used in construction of the device involved in the reported adverse event in order to support the identification of possible causes for the adverse event. Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the latest relevant standards.","Testing of Raw/Starting Materials | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526751","Testing of Patient Sample or Reference Material Using Manufacturer's Device","C139452","The investigation employed relevant empirical testing of a patient sample or reference material using the device (usually an IVD) involved in the reported adverse event in order to support the identification of possible causes for the adverse event. Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the latest relevant standards.","Testing of Patient Sample or Reference Material Using Manufacturer's Device | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526756","Testing of Patient Sample or Reference Material Using Competitor's Device","C139454","The investigation employed relevant empirical testing of a patient sample or reference material using a competitor's device that is comparable to the device (usually an IVD) involved in the reported adverse event in order to support the identification of possible causes for the adverse event. Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the latest relevant standards.","Testing of Patient Sample or Reference Material Using Competitor's Device | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526755","Historical Data Analysis","C139455","The investigation involved the analysis of historical adverse events data of the actual device involved in the adverse event and/or of products from the same and/or different batches/lots.","Historical Data Analysis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526407","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Feel Tired","C138886","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: I feel tired.","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Feel Tired | PQL07-Feel Tired | PQL0705",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526405","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Wake Up Tired","C138888","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: I wake up tired.","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Wake Up Tired | PQL07-Wake Up Tired | PQL0707",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526412","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Hands Are Weak","C138889","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: My hands are weak.","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Hands Are Weak | PQL07-Hands Are Weak | PQL0708",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521397","4q22","C13888","A chromosome band present on 4q","4q22 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537838","Stepped Palliative Care","C139680","A form of palliative care where all patients receive care for their condition, but with a minimum of required contact with specialty trained clinician and more intensive treatment reserved for those who do not benefit sufficiently from the less intensive treatments. A key element of this model is that patients must be monitored systematically and 'stepped up' to more intensive treatment if the minimal level of care does not achieve sufficient health gains.","Stepped Palliative Care | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537837","Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma","C139681","Histologic transformation of a follicular lymphoma to an aggressive diffuse large B-cell lymphoma.","Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515457","8q21.13","C13919","A chromosome band present on 8q","8q21.13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522012","Recombinant Macrophage Inflammatory Protein-1 Alpha","C1391","A recombinant therapeutic agent which is chemically identical to or similar to endogenous macrophage inflammatory protein-1, a member of the CC chemokine family produced by activated macrophages.  Macrophage inflammatory protein-1 alpha activates granulocytes and induces pro-inflammatory cytokine synthesis.  The addition of macrophage inflammatory protein-1 alpha to a vaccine consisting of a DNA immunogen or a pro-inflammatory peptide may enhance vaccine-induced host immune anti-tumor responses. (NCI04)","Recombinant Macrophage Inflammatory Protein-1 Alpha | CCL3 | LD78 | LD78 alpha (e) | MIP-1 Alpha | MIP-1a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538073","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8","C139956","A pathologic finding about one or more characteristics of ovarian, fallopian tube, or primary peritoneal carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538072","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pNX TNM Finding v8","C139957","Ovarian, fallopian tube, or primary peritoneal carcinoma in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pNX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538071","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pN0 TNM Finding v8","C139958","Ovarian, fallopian tube, or primary peritoneal carcinoma with no regional lymph node metastasis. (from AJCC 8th Ed.)","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538070","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pN0(i+) TNM Finding v8","C139959","Ovarian, fallopian tube, or primary peritoneal carcinoma with isolated tumor cells in regional lymph node(s) no greater than 0.2 mm. (from AJCC 8th Ed.)","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pN0(i+) TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515518","9q22.32","C13995","A chromosome band present on 9q","9q22.32 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538069","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pN1 TNM Finding v8","C139960","Ovarian, fallopian tube, or primary peritoneal carcinoma with positive retroperitoneal lymph nodes only (histologically confirmed). (from AJCC 8th Ed.)","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pN1 TNM Finding v8 | Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IIIA1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538052","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pN1a TNM Finding v8","C139961","Ovarian, fallopian tube, or primary peritoneal carcinoma with metastasis up to 10 mm in greatest dimension. (from AJCC 8th Ed.)","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pN1a TNM Finding v8 | Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IIIA1i",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538051","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pN1b TNM Finding v8","C139962","Ovarian, fallopian tube, or primary peritoneal carcinoma with metastasis more than 10 mm in greatest dimension. (from AJCC 8th Ed.)","Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pN1b TNM Finding v8 | Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IIIA1ii",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538050","Ovarian Cancer by AJCC v8 Stage","C139963","A term that refers to the staging of ovarian cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to ovarian carcinomas. Nonepithelial primary ovarian cancers may be staged using this classification but should be reported separately. (from AJCC 8th Ed.)","Ovarian Cancer by AJCC v8 Stage | Ovarian Carcinoma by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538049","Stage I Ovarian Cancer AJCC v8","C139964","Stage I includes: T1, N0, M0. T1: Ovarian cancer with tumor limited to ovaries (one or both). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage I Ovarian Cancer AJCC v8 | Stage I Ovarian Cancer | Stage I Ovarian Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538748","Stage II Choroidal and Ciliary Body Melanoma AJCC v8","C140661","Stage II includes: IIA (T1b-d, N0, M0); (T2a, N0, M0); IIB (T2b, N0, M0); (T3a, N0, M0).  T1b: Tumor size category 1 with ciliary body involvement.  T1c: Tumor size category 1 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in largest diameter.  T1d: Tumor size category 1 with ciliary body involvement and extraocular extension less than or equal to 5 mm in largest diameter. T2a: Tumor size category 2 without ciliary body involvement and extraocular extension. T2b: Tumor size category 2 with ciliary body involvement. T3a: Tumor size category 3 without ciliary body involvement and extraocular extension. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 8th ed.)","Stage II Choroidal and Ciliary Body Melanoma AJCC v8 | Stage II Choroidal and Ciliary Body Melanoma | Stage II Posterior Uveal Melanoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526411","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Hard to Use Bathroom","C138890","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: It is hard to use the bathroom.","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Hard to Use Bathroom | PQL07-Hard to Use Bathroom | PQL0709",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526410","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Hard to Gain or Lose Weight","C138891","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: It is hard to gain or lose weight when I want to.","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Hard to Gain or Lose Weight | PQL07-Hard to Gain/Lose Weight | PQL0710",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526409","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Hard to Use Hands","C138892","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: It is hard to use my hands.","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Hard to Use Hands | PQL07-Hard to Use Hands | PQL0711",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526416","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Hard to Swallow Food","C138893","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: It is hard to swallow food.","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Hard to Swallow Food | PQL07-Hard to Swallow Food | PQL0712",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526415","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Long Time to Bathe or Shower","C138894","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: It takes me a long time to bathe or shower.","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Long Time to Bathe or Shower | PQL07-Long Time to Bathe/Shower | PQL0713",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526414","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Get Hurt Accidentally","C138895","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: I get hurt accidentally.","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Get Hurt Accidentally | PQL07-Get Hurt Accidentally | PQL0714",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526413","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Take Long Time to Eat","C138896","Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: I take a long time to eat.","PedsQL Neuromuscular Module Version 3.0 Young Child Report - Take Long Time to Eat | PQL07-Take Long Time to Eat | PQL0715",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526948","Stage IV Vulvar Cancer AJCC v8","C139627","Stage IV includes: T1-T3, N3, M0-M1. T1: Tumor confined to the vulva and/or perineum. Multifocal lesions should be designated as such. The largest lesion or the lesion with the greatest depth of invasion will be the target lesion identified to address the highest pT stage. Depth of invasion is defined as the measurement of the tumor from the epithelial-stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion. T2: Tumor of any size with extension to adjacent perineal structures (lower/distal third of the urethra, lower/distal third of the vagina, anal involvement). T3: Tumor of any size with extension to any of the following: upper/proximal two-thirds of the urethra, upper/proximal two-thirds of the vagina, bladder mucosa, or rectal mucosa; or fixed to pelvic bone. N3: Fixed or ulcerated regional lymph node metastasis. M0: No distant metastasis. M1: Distant metastasis (including pelvic lymph node metastasis). (from AJCC 8th Ed.)","Stage IV Vulvar Cancer AJCC v8 | Stage IV Vulvar Cancer | Stage IV Vulvar Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526815","Erroneous Data Transfer","C139515","The device software fails to transfer the expected data within a system or to another device.","Erroneous Data Transfer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526814","Software Maintenance Problem Identified","C139516","The device software was not maintained/updated properly.","Software Maintenance Problem Identified | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526821","Excessive Cooling Identified","C139517","The device cooled the patient or another device more than intended or expected during operation.","Excessive Cooling Identified | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526820","Excessive Heating Identified","C139518","The device delivered more heat than intended or expected during operation. This applies to devices which are intended to deliver heat.","Excessive Heating Identified | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526819","Inadequate Cooling Identified","C139519","The device did not sufficiently cool the patient or another device during operation.","Inadequate Cooling Identified | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0598988","Nuclear Pore Complex","C13951","Signal-mediated nuclear import and export proceed through the nuclear pore complex (NPC). NPC is comprised of approximately 50 unique proteins collectively known as nucleoporins. NPC functions in the nuclear transport of protein and RNA. (NCI)","Nuclear Pore Complex | NPC",,,,,,,,,,,,,,,"4302153","Nuclear pore apparatus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526818","Overheating Problem Identified","C139520","The device was found to become hotter than expected during operation. This applies to devices which are not intended to deliver heat.","Overheating Problem Identified | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526825","Change in Target Marker/Variant/Mutant","C139521","Problem due to change in target marker/variant/mutant which is not covered in the labeling.","Change in Target Marker/Variant/Mutant | Change in Target Marker/Variant/ Mutant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526824","Known Interferent","C139522","Known interferent in the sample identified.","Known Interferent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526823","New or Unknown Interferent","C139523","New or unknown endogenous or exogenous interferent (sample) identified.","New or Unknown Interferent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526822","Pre-analytical Handling Problem","C139524","Incorrect pre-analytical handling of patient's sample by the user.","Pre-analytical Handling Problem | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521220","2q33-q34","C14016","A chromosome band present on 2q","2q33-q34 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538530","Stage II Ureter Cancer AJCC v8","C140369","Stage II includes: T2, N0, M0. T2: Tumor invades the muscularis. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Ureter Cancer AJCC v8 | Stage II Ureter Cancer | Stage II Ureter Urothelial Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520389","11q13.5","C14036","A chromosome band present on 11q","11q13.5 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538529","Stage III Renal Pelvis and Ureter Cancer AJCC v8","C140370","Stage III includes: T3, N0, M0. T3: For renal pelvis only: Tumor invades beyond muscularis into peripelvic fat or into the renal parenchyma. For ureter only: Tumor invades beyond muscularis into periureteric fat. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Renal Pelvis and Ureter Cancer AJCC v8 | Stage III Renal Pelvis and Ureter Cancer | Stage III Renal Pelvis and Ureter Urothelial Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538761","Stage III Choroidal and Ciliary Body Melanoma AJCC v8","C140664","Stage III includes: IIIA (T2c-d, N0, M0); (T3b-c, N0, M0); (T4a, N0, M0); IIIB (T3d, N0, M0); (T4b-c, N0, M0); IIIC: (T4d-e, N0, M0). T2c: Tumor size category 2 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in largest diameter. T2d: Tumor size category 2 with ciliary body involvement and extraocular extension less than or equal to 5 mm in largest diameter. T3b: Tumor size category 3 with ciliary body involvement. T3c: Tumor size category 3 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in largest diameter. T4a: Tumor size category 4 without ciliary body involvement and extraocular extension. T3d: Tumor size category 3 with ciliary body involvement and extraocular extension less than or equal to 5 mm in largest diameter.  T4b: Tumor size category 4 with ciliary body involvement. T4c: Tumor size category 4 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in largest diameter. T4d: Tumor size category 4 with ciliary body involvement and extraocular extension less than or equal to 5 mm in largest diameter. T4e: Any tumor size category with extraocular extension more than 5 mm in largest diameter. N0: No regional lymph node metastasis. M0: No distant metastasis.  (AJCC 8th ed.)","Stage III Choroidal and Ciliary Body Melanoma AJCC v8 | Stage III Choroidal and Ciliary Body Melanoma | Stage III Posterior Uveal Melanoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538145","Stage IIIC Fallopian Tube Cancer AJCC v8","C139996","Stage IIIC includes: T3c, N0/N1, M0. T3c: Fallopian tube cancer with macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension with or without metastasis to the retroperitoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ). N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIIC Fallopian Tube Cancer AJCC v8 | Stage IIIC Fallopian Tube Cancer | Stage IIIC Fallopian Tube Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538144","Stage IV Fallopian Tube Cancer AJCC v8","C139997","Stage IV includes: Any T, Any N, M1: M1: Distant metastasis, including pleural effusion with positive cytology; liver or splenic parenchymal metastasis; metastasis to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside the abdominal cavity); and transmural involvement of intestine. (from AJCC 8th Ed.)","Stage IV Fallopian Tube Cancer AJCC v8 | Stage IV Fallopian Tube Cancer | Stage IV Fallopian Tube Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538143","Stage IVA Fallopian Tube Cancer AJCC v8","C139998","Stage IVA includes: Any T, Any N, M1a. M1a: Fallopian tube cancer with pleural effusion with positive cytology. (from AJCC 8th Ed.)","Stage IVA Fallopian Tube Cancer AJCC v8 | Stage IVA Fallopian Tube Cancer | Stage IVA Fallopian Tube Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538142","Stage IVB Fallopian Tube Cancer AJCC v8","C139999","Stage IVB includes: Any T, Any N, M1b. M1b: Fallopian tube cancer with liver or splenic parenchymal metastases; metastases to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside the abdominal cavity); transmural involvement of intestine. (from AJCC 8th Ed.)","Stage IVB Fallopian Tube Cancer AJCC v8 | Stage IVB Fallopian Tube Cancer | Stage IVB Fallopian Tube Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520646","15q24-q25","C13999","A chromosome band present on 15q","15q24-q25 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526935","Stage IVA Vulvar Cancer AJCC v8","C139628","Stage IVA includes: (T1-T2, N3, M0); (T3, Any N, M0). T1: Tumor confined to the vulva and/or perineum. Multifocal lesions should be designated as such. The largest lesion or the lesion with the greatest depth of invasion will be the target lesion identified to address the highest pT stage. Depth of invasion is defined as the measurement of the tumor from the epithelial-stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion. T2: Tumor of any size with extension to adjacent perineal structures (lower/distal third of the urethra, lower/distal third of the vagina, anal involvement). T3: Tumor of any size with extension to any of the following: upper/proximal two-thirds of the urethra, upper/proximal two-thirds of the vagina, bladder mucosa, or rectal mucosa; or fixed to pelvic bone. N3: Fixed or ulcerated regional lymph node metastasis. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage IVA Vulvar Cancer AJCC v8 | Stage IVA Vulvar Cancer | Stage IVA Vulvar Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521550","6p24.3","C13962","A chromosome band present on 6p","6p24.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526934","Stage IVB Vulvar Cancer AJCC v8","C139630","Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis (including pelvic lymph node metastasis). (from AJCC 8th Ed.)","Stage IVB Vulvar Cancer AJCC v8 | Stage IVB Vulvar Cancer | Stage IVB Vulvar Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537789","Vaginal Cancer TNM Finding v8","C139632","A finding about one or more characteristics of vaginal cancer, following the rules of the TNM AJCC v8 classification system. This classification system applies to all carcinomas of the vagina. There is no AJCC staging system for mucosal melanoma of the vagina. (from AJCC 8th Ed.)","Vaginal Cancer TNM Finding v8 | Vaginal Carcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537788","Vaginal Cancer Clinical TNM Finding v8","C139633","A clinical finding about one or more characteristics of vaginal cancer, following the rules of the TNM AJCC v8 classification system.","Vaginal Cancer Clinical TNM Finding v8 | Vaginal Carcinoma Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537787","Vaginal Cancer Clinical Distant Metastasis TNM Finding v8","C139634","A clinical finding about one or more characteristics of vaginal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Vaginal Cancer Clinical Distant Metastasis TNM Finding v8 | Vaginal Carcinoma Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537786","Vaginal Cancer cM0 TNM Finding v8","C139635","Vaginal cancer without evidence of distant metastasis. (from AJCC 8th Ed.)","Vaginal Cancer cM0 TNM Finding v8 | Vaginal Carcinoma cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537784","Vaginal Cancer Pathologic TNM Finding v8","C139637","A pathologic finding about one or more characteristics of vaginal cancer, following the rules of the TNM AJCC v8 classification system.","Vaginal Cancer Pathologic TNM Finding v8 | Vaginal Carcinoma Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537776","Vaginal Cancer Pathologic Distant Metastasis TNM Finding v8","C139638","A pathologic finding about one or more characteristics of vaginal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Vaginal Cancer Pathologic Distant Metastasis TNM Finding v8 | Vaginal Carcinoma Pathologic Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537775","Vaginal Cancer pM1 TNM Finding v8","C139639","Vaginal cancer with distant metastasis. (from AJCC 8th Ed.)","Vaginal Cancer pM1 TNM Finding v8 | Vaginal Carcinoma pM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520682","16p12-p11.2","C13963","A chromosome band present on 16p","16p12-p11.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537774","Vaginal Cancer Pathologic Primary Tumor TNM Finding v8","C139640","A pathologic finding about one or more characteristics of vaginal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor. The definitions of the T categories correspond to the stages accepted by FIGO. (from AJCC 8th Ed.)","Vaginal Cancer Pathologic Primary Tumor TNM Finding v8 | Vaginal Carcinoma Pathologic Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537773","Vaginal Cancer pTX TNM Finding v8","C139641","Vaginal cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Vaginal Cancer pTX TNM Finding v8 | Vaginal Carcinoma pTX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526828","Adverse Event Related to Commutability","C139525","The adverse event occurred because the material being used to calibrate or assess IVD performance did not have similar properties to those of human samples, leading to inappropriate bias and erroneous results. Examples of materials include: reference materials, calibrators, proficiency testing samples.","Adverse Event Related to Commutability | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526827","Adverse Event Related to Procedure","C139526","The adverse event occurred during the procedure and the device had no influence on event.","Adverse Event Related to Procedure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521499","5q35","C13952","A chromosome band present on 5q","5q35 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538528","Stage III Renal Pelvis Cancer AJCC v8","C140371","Stage III includes: T3, N0, M0. T3: Tumor invades beyond muscularis into peripelvic fat or into the renal parenchyma. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Renal Pelvis Cancer AJCC v8 | Stage III Renal Pelvis Cancer | Stage III Renal Pelvis Urothelial Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538527","Stage III Ureter Cancer AJCC v8","C140372","Stage III includes: T3, N0, M0. T3: Tumor invades beyond muscularis into periureteric fat. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Ureter Cancer AJCC v8 | Stage III Ureter Cancer | Stage III Ureter Urothelial Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538542","Stage IV Renal Pelvis and Ureter Cancer AJCC v8","C140373","Stage IV includes: (T4, N0, M0); (Any T, N1, M0); (Any T, N2, M0); (Any T, Any N, M1). T4: Tumor invades adjacent organs, or through the kidney into the perinephric fat. N0: No regional lymph node metastasis. N1: Metastasis in a single lymph node, 2 cm or less in greatest dimension. N2: Metastasis in a single lymph node, more than 2 cm in greatest dimension; or multiple lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Renal Pelvis and Ureter Cancer AJCC v8 | Stage IV Renal Pelvis and Ureter Cancer | Stage IV Renal Pelvis and Ureter Urothelial Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538541","Stage IV Renal Pelvis Cancer AJCC v8","C140374","Stage IV includes: (T4, N0, M0); (Any T, N1, M0); (Any T, N2, M0); (Any T, Any N, M1). T4: Tumor invades adjacent organs, or through the kidney into the perinephric fat. N0: No regional lymph node metastasis. N1: Metastasis in a single lymph node, 2 cm or less in greatest dimension. N2: Metastasis in a single lymph node, more than 2 cm in greatest dimension; or multiple lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Renal Pelvis Cancer AJCC v8 | Stage IV Renal Pelvis Cancer | Stage IV Renal Pelvis Urothelial Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538540","Stage IV Ureter Cancer AJCC v8","C140375","Stage IV includes: (T4, N0, M0); (Any T, N1, M0); (Any T, N2, M0); (Any T, Any N, M1). T4: Tumor invades adjacent organs, or through the kidney into the perinephric fat. N0: No regional lymph node metastasis. N1: Metastasis in a single lymph node, 2 cm or less in greatest dimension. N2: Metastasis in a single lymph node, more than 2 cm in greatest dimension; or multiple lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Ureter Cancer AJCC v8 | Stage IV Ureter Cancer | Stage IV Ureter Urothelial Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538539","Renal Pelvis and Ureter Cancer by AJCC v7 Stage","C140376","A term that refers to the staging of renal pelvis and ureter cancer according to the American Joint Committee on Cancer, 7th edition.","Renal Pelvis and Ureter Cancer by AJCC v7 Stage | Renal Pelvis and Ureter Urothelial Carcinoma by AJCC v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538538","Renal Pelvis Cancer by AJCC v7 Stage","C140377","A term that refers to the staging of renal pelvis cancer according to the American Joint Committee on Cancer, 7th edition.","Renal Pelvis Cancer by AJCC v7 Stage | Renal Pelvis Urothelial Carcinoma by AJCC v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538537","Ureter Cancer by AJCC v7 Stage","C140378","A term that refers to the staging of ureter cancer according to the American Joint Committee on Cancer, 7th edition.","Ureter Cancer by AJCC v7 Stage | Ureter Urothelial Carcinoma by AJCC v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538536","Pan-TRK Inhibitor ONO-7579","C140379","An orally bioavailable, selective pan-tropomyosin-related-kinase (tyrosine receptor kinase; TRK) inhibitor, with potential antineoplastic activity. Upon oral administration, ONO-7579 specifically targets and binds to TRK and fusion proteins containing sequences from neurotrophic tyrosine receptor kinase (NTRK) types 1 (NTRK1; TrkA), 2 (NTRK2; TrkB), and 3 (NTRK3; TrkC).  This inhibits neurotrophin-TRK interaction and TRK activation, thereby preventing the activation of downstream signaling pathways and resulting in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress TRK and/or express NTRK fusion proteins. TRK, a family of receptor tyrosine kinases (RTKs) activated by neurotrophins, is encoded by NTRK family genes.The expression of either mutated forms of, or fusion proteins involving, NTRK family members results in uncontrolled TRK signaling, which plays an important role in tumor cell growth, survival, invasion and treatment resistance.","Pan-TRK Inhibitor ONO-7579 | ONO 7579 | ONO-7579 | ONO7579 | TRK Inhibitor ONO-7579",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538694","Conjunctival Melanoma pN1 TNM Finding v8","C140602","Conjunctival melanoma with regional lymph node metastasis. (from AJCC 8th Ed.)","Conjunctival Melanoma pN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524593","Gastrointestinal Stromal Tumor Pathologic Primary Tumor TNM Finding v8","C136757","A pathologic finding about one or more characteristics of gastrointestinal stromal tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Gastrointestinal Stromal Tumor Pathologic Primary Tumor TNM Finding v8 | GIST Pathologic Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524590","Gastrointestinal Stromal Tumor pTX TNM Finding v8","C136758","Gastrointestinal stromal tumor in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Gastrointestinal Stromal Tumor pTX TNM Finding v8 | GIST pTX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524591","Gastrointestinal Stromal Tumor pT0 TNM Finding v8","C136759","Gastrointestinal stromal tumor with no evidence of primary tumor. (from AJCC 8th Ed.)","Gastrointestinal Stromal Tumor pT0 TNM Finding v8 | GIST pT0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515516","9q22.3","C13675","A chromosome band present on 9q","9q22.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524596","Gastrointestinal Stromal Tumor pT1 TNM Finding v8","C136760","Gastrointestinal stromal tumor measuring 2 cm or less. (from AJCC 8th Ed.)","Gastrointestinal Stromal Tumor pT1 TNM Finding v8 | GIST pT1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524597","Gastrointestinal Stromal Tumor pT2 TNM Finding v8","C136761","Gastrointestinal stromal tumor measuring more than 2 cm but not more than 5 cm. (from AJCC 8th Ed.)","Gastrointestinal Stromal Tumor pT2 TNM Finding v8 | GIST pT2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524594","Gastrointestinal Stromal Tumor pT3 TNM Finding v8","C136762","Gastrointestinal stromal tumor measuring more than 5 cm but not more than 10 cm. (from AJCC 8th Ed.)","Gastrointestinal Stromal Tumor pT3 TNM Finding v8 | GIST pT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524595","Gastrointestinal Stromal Tumor pT4 TNM Finding v8","C136763","Gastrointestinal stromal tumor measuring more than 10 cm in greatest dimension. (from AJCC 8th Ed.)","Gastrointestinal Stromal Tumor pT4 TNM Finding v8 | GIST pT4 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524600","Gastrointestinal Stromal Tumor Pathologic Regional Lymph Nodes TNM Finding v8","C136764","A pathologic finding about one or more characteristics of gastrointestinal stromal tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Gastrointestinal Stromal Tumor Pathologic Regional Lymph Nodes TNM Finding v8 | GIST Pathologic Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524601","Gastrointestinal Stromal Tumor pN0 TNM Finding v8","C136765","Gastrointestinal stromal tumor without regional lymph node metastasis or unknown lymph node status. (from AJCC 8th Ed.)","Gastrointestinal Stromal Tumor pN0 TNM Finding v8 | GIST pN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524598","Gastrointestinal Stromal Tumor pN1 TNM Finding v8","C136766","Gastrointestinal stromal tumor with regional lymph node metastasis. (from AJCC 8th Ed.)","Gastrointestinal Stromal Tumor pN1 TNM Finding v8 | GIST pN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524604","Gastric and Omental Gastrointestinal Stromal Tumor by AJCC v8 Stage","C136768","A term that refers to the staging of gastric and omental gastrointestinal stromal tumor (GIST), following the rules of the TNM AJCC v8 classification system. (from AJCC 8th Ed.)","Gastric and Omental Gastrointestinal Stromal Tumor by AJCC v8 Stage | Gastric and Omental GIST by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515470","8q24.12-q24.13","C13676","A chromosome band present on 8q","8q24.12-q24.13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524602","Stage I Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8","C136770","Stage I includes: IA: (T1 or T2, N0, M0, Low Mitotic Rate); IB: (T3, N0, M0, Low Mitotic Rate). T1: Tumor measuring 2 cm or less. T2: Tumor measuring more than 2 cm but not more than 5 cm. T3: Tumor measuring more than 5 cm but not more than 10 cm. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. Low Mitotic Rate: Five or fewer mitoses per 5 square millimeters, or per 50 HPF. (AJCC 8th ed.)","Stage I Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8 | Stage I Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST) | Stage I Gastric and Omental GIST AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524995","Bevacizumab/Paclitaxel Regimen","C138050","A regimen consisting of paclitaxel and bevacizumab that may be used as a treatment for breast, ovarian, fallopian tube and primary peritoneal cancers.","Bevacizumab/Paclitaxel Regimen | Bevacizumab-Paclitaxel | Bevacizumab-Paclitaxel Regimen | Bevacizumab/Paclitaxel | Paclitaxel and Bevacizumab | Paclitaxel and Bevacizumab-adcd | Paclitaxel and Bevacizumab-awwb | Paclitaxel and Bevacizumab-aybi | Paclitaxel and Bevacizumab-bvzr | Paclitaxel and Bevacizumab-equi | Paclitaxel and Bevacizumab-maly | Paclitaxel and Bevacizumab-onbe | Paclitaxel and Bevacizumab-tnjn",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538095","ESRRB wt Allele","C139918","Human ESRRB wild-type allele is located in the vicinity of 14q24.3 and is approximately 191 kb in length. This allele, which encodes steroid hormone receptor ERR2 protein, is involved in rod cell survival and inner ear development. Mutation of the gene is associated with autosomal recessive deafness type 35.","ESRRB wt Allele | DFNB35 | Deafness, Autosomal Recessive 35 Gene | ERR2 | ERRb | ERRbeta | ESRL2 | Estrogen Related Receptor Beta wt Allele | Estrogen-Related Receptor, Beta Gene | NR3B2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521491","5q32-q34","C13991","A chromosome band present on 5q","5q32-q34 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538093","SLC39A4 Gene","C139920","This gene is involved in zinc homeostasis.","SLC39A4 Gene | SLC39A4 | Solute Carrier Family 39 Member 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538108","SLC39A4 wt Allele","C139921","Human SLC39A4 wild-type allele is located in the vicinity of 8q24.3 and is approximately 8 kb in length. This allele, which encodes zinc transporter ZIP4 protein, plays a role in cellular zinc homeostasis. Mutations in the gene are associated with acrodermatitis enteropathica.","SLC39A4 wt Allele | AEZ | AWMS2 | Acrodermatitis Enteropathica, Zinc-Deficiency Type Gene | Solute Carrier Family 39 (Zinc Transporter), Member 4 Gene | Solute Carrier Family 39 Member 4 wt Allele | ZIP4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1434703","SLC39A4 protein, human","C139922","Zinc transporter ZIP4 (647 aa, ~68 kDa) is encoded by the human SLC39A4 gene. This protein is involved in zinc ion transport.","Zinc Transporter ZIP4 | SLC39A4 | Solute Carrier Family 39 Member 4 | ZIP-4 | Zrt- And Irt-Like Protein 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538106","Breath Carbon Monoxide Monitor","C139923","A device designed to measure carbon monoxide in a smoker's breath as a means toward smoking cessation.","Breath Carbon Monoxide Monitor | Smokerlyzer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1439335","LPA Gene","C140116","This gene is involved in lipid metabolism, proteolysis and the inhibition of tissue-type plasminogen activator.","LPA Gene | LPA | Lipoprotein(a) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538293","LPA wt Allele","C140117","Human LPA wild-type allele is located within 6q25.3-q26 and is approximately 134 kb in length. This allele, which encodes apolipoprotein(a) protein, plays a role in proteolysis, lipid metabolism and the regulation of thrombolysis. Aberrant expression of the gene is associated with atherosclerosis.","LPA wt Allele | AK38 | APOA | Apolipoprotein(a) Gene | LP | Lipoprotein(a) wt Allele | Lipoprotein, Lp(a) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538292","Apolipoprotein(a)","C140118","Apolipoprotein(a) (4548 aa, ~501 kDa) is encoded by the human LPA gene. This protein is involved in the regulation of thrombosis and lipid metabolism.","Apolipoprotein(a) | Antiangiogenic AK38 Protein | Apo(a) | EC 3.4.21.- | LPA | Lp(a)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521548","6p24-p23","C14011","A chromosome band present on 6p","6p24-p23 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524569","Soft Tissue Sarcoma of the Retroperitoneum Pathologic TNM Finding v8","C136797","A pathologic finding about one or more characteristics of soft tissue sarcoma of the retroperitoneum, following the rules of the TNM AJCC v8 classification system.","Soft Tissue Sarcoma of the Retroperitoneum Pathologic TNM Finding v8 | Retroperitoneal Soft Tissue Sarcoma Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524566","Soft Tissue Sarcoma of the Retroperitoneum Pathologic Distant Metastasis TNM Finding v8","C136798","A pathologic finding about one or more characteristics of soft tissue sarcoma of the retroperitoneum, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Soft Tissue Sarcoma of the Retroperitoneum Pathologic Distant Metastasis TNM Finding v8 | Retroperitoneal Soft Tissue Sarcoma Pathologic Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538592","Urethral Cancer Pathologic TNM Finding v8","C140433","A pathologic finding about one or more characteristics of urethral cancer, following the rules of the TNM AJCC v8 classification system.","Urethral Cancer Pathologic TNM Finding v8 | Urethral Carcinoma Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538590","Urethral Cancer pM1 TNM Finding v8","C140435","Urethral cancer with distant metastasis. (from AJCC 8th Ed.)","Urethral Cancer pM1 TNM Finding v8 | Urethral Carcinoma pM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538589","Urethral Cancer Pathologic Primary Tumor TNM Finding v8","C140436","A pathologic finding about one or more characteristics of urethral cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Urethral Cancer Pathologic Primary Tumor TNM Finding v8 | Urethral Carcinoma Pathologic Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538604","Male Penile Urethra and Female Urethra Cancer Pathologic Primary Tumor TNM Finding v8","C140437","A pathologic finding about one or more characteristics of cancer in the male penile urethra and female urethra, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Male Penile Urethra and Female Urethra Cancer Pathologic Primary Tumor TNM Finding v8 | Male Penile Urethra and Female Urethra Carcinoma Pathologic Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538603","Male Penile Urethra and Female Urethra Cancer pTX TNM Finding v8","C140438","Urethral cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Male Penile Urethra and Female Urethra Cancer pTX TNM Finding v8 | Male Penile Urethra and Female Urethra Carcinoma pTX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538602","Male Penile Urethra and Female Urethra Cancer pT0 TNM Finding v8","C140439","Urethral cancer with no evidence of primary tumor. (from AJCC 8th Ed.)","Male Penile Urethra and Female Urethra Cancer pT0 TNM Finding v8 | Male Penile Urethra and Female Urethra Carcinoma pT0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520118","Walker-A Motif","C14043","The ATP binding cassette (ABC) is the largest protein family known and many of its members are membrane proteins (ABC transporters) active in the transport of a wide variety of substances across membranes. ABC proteins are identified by the presence of one or two cytosolically oriented ATP-binding cassettes or nucleotide-binding domains (NBD) of about 200 amino acid residues. Each NBD contains three typical motifs: the Walker A motif, GX4GK(ST), the Walker B motif and the ABC signature or C motif. Walker A and B motifs are found in other nucleotide-binding proteins, including P-, F- and V-ATPases, G proteins, adenylate kinase, myosin, phosphofructokinase and ATP/ADP exchangers. Although the overall similarity between ABC proteins can be very low, their NBDs share an average of 30-40 % similarity.","Walker-A Motif | Walker-A Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538601","Male Penile Urethra and Female Urethra Cancer pTa TNM Finding v8","C140440","Urethral cancer with a finding of non-invasive papillary carcinoma. (from AJCC 8th Ed.)","Male Penile Urethra and Female Urethra Cancer pTa TNM Finding v8 | Male Penile Urethra and Female Urethra Carcinoma pTa TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538600","Male Penile Urethra and Female Urethra Cancer pTis TNM Finding v8","C140441","Urethral cancer with a finding of carcinoma in situ. (from AJCC 8th Ed.)","Male Penile Urethra and Female Urethra Cancer pTis TNM Finding v8 | Male Penile Urethra and Female Urethra Carcinoma pTis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538599","Male Penile Urethra and Female Urethra Cancer pT1 TNM Finding v8","C140442","Urethral cancer with tumor invading subepithelial connective tissue. (from AJCC 8th Ed.)","Male Penile Urethra and Female Urethra Cancer pT1 TNM Finding v8 | Male Penile Urethra and Female Urethra Carcinoma pT1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538598","Male Penile Urethra and Female Urethra Cancer pT2 TNM Finding v8","C140443","Urethral cancer with tumor invading any of the following: corpus spongiosum, periurethral muscle. (from AJCC 8th Ed.)","Male Penile Urethra and Female Urethra Cancer pT2 TNM Finding v8 | Male Penile Urethra and Female Urethra Carcinoma pT2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538190","Stage 0is Penile Cancer AJCC v8","C140077","Stage 0is includes: Tis, N0, M0. Tis: Penile cancer with a finding of carcinoma in situ (penile intraepithelial neoplasia [PeIN]). N0: No lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0is Penile Cancer AJCC v8 | Stage 0is Penile Cancer | Stage 0is Penile Squamous Cell Carcinoma AJCC v8 | Stage 0is Squamous Cell Carcinoma of the Penis AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538189","Stage 0a Penile Cancer AJCC v8","C140078","Stage 0a includes: Ta, N0, M0. Ta: Penile cancer with a finding of noninvasive localized squamous cell carcinoma. N0: No lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0a Penile Cancer AJCC v8 | Stage 0a Penile Cancer | Stage 0a Penile Squamous Cell Carcinoma AJCC v8 | Stage 0a Squamous Cell Carcinoma of the Penis AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538188","Stage I Penile Cancer AJCC v8","C140079","Stage I includes: T1a, N0, M0. T1a: Penile cancer with tumor without lymphovascular invasion or perineural invasion and is not high grade (i.e., grade 3 or sarcomatoid). N0: No lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Penile Cancer AJCC v8 | Stage I Penile Cancer | Stage I Penile Squamous Cell Carcinoma AJCC v8 | Stage I Squamous Cell Carcinoma of the Penis AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521175","2p13.1","C14007","A chromosome band present on 2p","2p13.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538187","Stage II Penile Cancer AJCC v8","C140080","Stage II includes: IIA: (T1b, N0, M0); (T2, N0, M0); IIB: (T3, N0, M0). T1b: Penile cancer with tumor exhibiting lymphovascular invasion and/or perineural invasion or is high grade (i.e., grade 3 or sarcomatoid). T2: Penile cancer with tumor invading into corpus spongiosum (either glans or ventral shaft) with or without urethral invasion. T3: Penile cancer with tumor invading into corpora cavernosum (including tunica albuginea) with or without urethral invasion. N0: No lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Penile Cancer AJCC v8 | Stage II Penile Cancer | Stage II Penile Squamous Cell Carcinoma AJCC v8 | Stage II Squamous Cell Carcinoma of the Penis AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0270749","Hereditary Cerebellar Ataxia","C140268","Cerebellar ataxia that is transmitted from parent to child.","Hereditary Cerebellar Ataxia | Hereditary ataxia, unspecified",,,,,,,,,,,,,,,"4263879","Marie's cerebellar ataxia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1515472","8q24.3","C14026","A chromosome band present on 8q","8q24.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538377","Kidney Cancer TNM Finding v8","C140274","A finding about one or more characteristics of kidney cancer, following the rules of the TNM AJCC v8 classification system. This classification system applies to carcinomas arising in the kidney. It does not apply to urothelial carcinomas (are staged according to the classification for renal pelvis and ureter), lymphomas (are staged according to the classification for Hodgkin and non-Hodgkin lymphoma), sarcomas (are staged according to the classification for soft tissue sarcoma of the abdomen and thoracic visceral organs), and Wilms tumor (no AJCC staging system).  (from AJCC 8th Ed.)","Kidney Cancer TNM Finding v8 | Kidney Carcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538376","Kidney Cancer Clinical TNM Finding v8","C140275","A clinical finding about one or more characteristics of kidney cancer, following the rules of the TNM AJCC v8 classification system.","Kidney Cancer Clinical TNM Finding v8 | Kidney Carcinoma Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538375","Kidney Cancer Clinical Distant Metastasis TNM Finding v8","C140276","A clinical finding about one or more characteristics of kidney cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Kidney Cancer Clinical Distant Metastasis TNM Finding v8 | Clinical Staging: Distant Metastasis (cM) | Kidney Carcinoma Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538652","Eyelid Carcinoma pT3b TNM Finding v8","C140499","Eyelid carcinoma with tumor measuring more than 20 mm but 30 mm or less in greatest dimension with invasion of the tarsal plate or eyelid margin. (from AJCC 8th Ed.)","Eyelid Carcinoma pT3b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512604","ITIM","C14049","ITIM (immunoreceptor Tyr-based inhibition motif) (I/V-X-Y-X-X-L), a protein domain involved in STP, binds to SH2 domain in SHP1 and SHP2, e.g., in KIR family.","ITIM | Immunoreceptor Tyrosine-Based Inhibitor Motif | Immunoreceptor Tyrosine-Based Inhibitory Motif",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538666","Eyelid Carcinoma pT4 TNM Finding v8","C140501","Any eyelid carcinoma invading adjacent ocular, orbital, or facial structures. (from AJCC 8th Ed.)","Eyelid Carcinoma pT4 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538665","Eyelid Carcinoma pT4a TNM Finding v8","C140502","Eyelid carcinoma with tumor invading ocular or intraorbital structures. (from AJCC 8th Ed.)","Eyelid Carcinoma pT4a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538664","Eyelid Carcinoma pT4b TNM Finding v8","C140503","Eyelid carcinoma with tumor invading (or eroding through) the bony walls of the orbit or extending to the paranasal sinuses or invading the lacrimal sac/nasolacrimal duct or brain. (from AJCC 8th Ed.)","Eyelid Carcinoma pT4b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538663","Eyelid Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8","C140504","A pathologic finding about one or more characteristics of eyelid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Eyelid Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538662","Eyelid Carcinoma pNX TNM Finding v8","C140505","Eyelid carcinoma in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Eyelid Carcinoma pNX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538661","Eyelid Carcinoma pN0 TNM Finding v8","C140506","Eyelid carcinoma with no evidence of lymph node involvement. (from AJCC 8th Ed.)","Eyelid Carcinoma pN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538660","Eyelid Carcinoma pN1 TNM Finding v8","C140507","Eyelid carcinoma with metastasis in a single ipsilateral regional lymph node, measuring 3 cm or less in greatest dimension. (from AJCC 8th Ed.)","Eyelid Carcinoma pN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538659","Eyelid Carcinoma pN1b TNM Finding v8","C140508","Eyelid carcinoma with metastasis in a single ipsilateral regional lymph node, measuring 3 cm or less in greatest dimension based on lymph node biopsy. (from AJCC 8th Ed.)","Eyelid Carcinoma pN1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538013","Stage IA Uterine Corpus Leiomyosarcoma AJCC v8","C139872","Stage IA includes: T1a, N0, M0. T1a: Uterine corpus leiomyosarcoma with tumor limited to the uterus, measuring 5 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IA Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IA Uterine Corpus Leiomyosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538028","Stage IB Uterine Corpus Leiomyosarcoma AJCC v8","C139873","Stage IB includes: T1b, N0, M0. T1b: Uterine corpus leiomyosarcoma with tumor limited to the uterus, measuring more than 5 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IB Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IB Uterine Corpus Leiomyosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538027","Stage II Uterine Corpus Leiomyosarcoma AJCC v8","C139874","Stage II includes: T2, N0, M0. T2: Uterine corpus leiomyosarcoma with tumor extending beyond the uterus, within the pelvis. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage II Uterine Corpus Leiomyosarcoma AJCC v8 | Stage II Uterine Corpus Leiomyosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538459","Metastatic Nonfunctional Neuroendocrine Tumor","C140329","A non-functioning, well-differentiated neuroendocrine neoplasm that has spread from the original site of growth to another anatomic site.","Metastatic Non-Functioning Neuroendocrine Tumor | Metastatic Non-Functioning Well Differentiated Neuroendocrine Neoplasm | Metastatic Non-Functioning Well Differentiated Neuroendocrine Neoplasm | Metastatic Nonfunctional Neuroendocrine Tumor | Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm | Metastatic Nonfunctional Well Differentiated Neuroendocrine Tumor | Metastatic Nonfunctioning Well Differentiated Neuroendocrine Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521579","6q26-q27","C14032","A chromosome band present on 6q","6q26-q27 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538457","Renal Pelvis and Ureter Cancer TNM Finding v8","C140331","A finding about one or more characteristics of renal pelvis and ureter cancer, following the rules of the TNM AJCC v8 classification system. This classification system applies to renal pelvis and ureter urothelial (transitional cell) carcinoma, including histologic variants micropapillary and nested subtypes. It does not apply to renal cell carcinomas (are staged according to the classification for kidney), renal medullary carcinomas (are staged according to the classification for kidney), collecting duct carcinomas (are staged according to the classification for kidney),  lymphomas (are staged according to the classification for Hodgkin and non-Hodgkin lymphoma), and mesenchymal tumors (are staged according to the classification for soft tissue sarcoma of the abdomen and thoracic visceral organs). (from AJCC 8th Ed.)","Renal Pelvis and Ureter Cancer TNM Finding v8 | Renal Pelvis and Ureter Urothelial Carcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538456","Renal Pelvis and Ureter Cancer Clinical TNM Finding v8","C140332","A clinical finding about one or more characteristics of renal pelvis and ureter cancer, following the rules of the TNM AJCC v8 classification system.","Renal Pelvis and Ureter Cancer Clinical TNM Finding v8 | Renal Pelvis and Ureter Urothelial Carcinoma Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538597","Male Penile Urethra and Female Urethra Cancer pT3 TNM Finding v8","C140444","Urethral cancer with tumor invading any of the following: corpus cavernosum, anterior vagina. (from AJCC 8th Ed.)","Male Penile Urethra and Female Urethra Cancer pT3 TNM Finding v8 | Male Penile Urethra and Female Urethra Carcinoma pT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538580","Male Penile Urethra and Female Urethra Cancer pT4 TNM Finding v8","C140445","Urethral cancer with tumor invading other adjacent organs (e.g., invasion of the bladder wall). (from AJCC 8th Ed.)","Male Penile Urethra and Female Urethra Cancer pT4 TNM Finding v8 | Male Penile Urethra and Female Urethra Carcinoma pT4 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538578","Prostatic Urethra Cancer pTis TNM Finding v8","C140447","Urethral cancer with a finding of carcinoma in situ involving the prostatic urethra or periurethral or prostatic ducts without stromal invasion. (from AJCC 8th Ed.)","Prostatic Urethra Cancer pTis TNM Finding v8 | Prostatic Urethra Carcinoma pTis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538743","Retinoblastoma Clinical Primary Tumor TNM Finding v8","C140682","A clinical finding about one or more characteristics of retinoblastoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor. Each eye is scored for cT criteria, and the cT category for the patient is based on the most advanced eye. (from AJCC 8th Ed.)","Retinoblastoma Clinical Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538742","Retinoblastoma cTX TNM Finding v8","C140683","Unknown evidence of intraocular tumor. (from AJCC 8th Ed.)","Retinoblastoma cTX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538741","Retinoblastoma cT0 TNM Finding v8","C140684","No evidence of intraocular tumor. (from AJCC 8th Ed.)","Retinoblastoma cT0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538740","Retinoblastoma cT1 TNM Finding v8","C140685","Intraretinal tumor(s) with subretinal fluid 5 mm or less from the base of any tumor. (from AJCC 8th Ed.)","Retinoblastoma cT1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538739","Retinoblastoma cT1a TNM Finding v8","C140686","Tumors 3 mm or less and further than 1.5 mm from disc and fovea. (from AJCC 8th Ed.)","Retinoblastoma cT1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538848","Retinoblastoma cT2 TNM Finding v8","C140688","Intraocular tumor(s) with retinal detachment, vitreous seeding, or subretinal seeding. (from AJCC 8th Ed.)","Retinoblastoma cT2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538847","Retinoblastoma cT2a TNM Finding v8","C140689","Subretinal fluid more than 5 mm from the base of any tumor. (from AJCC 8th Ed.)","Retinoblastoma cT2a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515860","Acidic Region","C14068","Any portion of a protein molecule with a net negative charge.","Acidic Region | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538846","Retinoblastoma cT2b TNM Finding v8","C140690","Vitreous seeding and/or subretinal seeding. (from AJCC 8th Ed.)","Retinoblastoma cT2b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538845","Retinoblastoma cT3 TNM Finding v8","C140691","Advanced intraocular tumor(s). (from AJCC 8th Ed.)","Retinoblastoma cT3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538844","Retinoblastoma cT3a TNM Finding v8","C140692","Phthisis or pre-phthisis bulbi. (from AJCC 8th Ed.)","Retinoblastoma cT3a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538843","Retinoblastoma cT3b TNM Finding v8","C140693","Tumor invasion of choroid, pars plana, ciliary body, lens, zonules, iris, or anterior chamber. (from AJCC 8th Ed.)","Retinoblastoma cT3b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538857","Retinoblastoma cT3d TNM Finding v8","C140695","Hyphema and/or massive vitreous hemorrhage. (from AJCC 8th Ed.)","Retinoblastoma cT3d TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538856","Retinoblastoma cT3e TNM Finding v8","C140696","Aseptic orbital cellulitis. (from AJCC 8th Ed.)","Retinoblastoma cT3e TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538855","Retinoblastoma cT4 TNM Finding v8","C140697","Extraocular tumor(s) involving orbit, including optic nerve. (from AJCC 8th Ed.)","Retinoblastoma cT4 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538854","Retinoblastoma cT4a TNM Finding v8","C140698","Radiologic evidence of retrobulbar optic nerve involvement or thickening of optic nerve or involvement of orbital tissues. (from AJCC 8th Ed.)","Retinoblastoma cT4a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538389","Kidney Cancer cM0 TNM Finding v8","C140277","Kidney cancer without evidence of distant metastasis. (from AJCC 8th Ed.)","Kidney Cancer cM0 TNM Finding v8 | Kidney Carcinoma cM0 TNM Finding v8 | cM0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538388","Kidney Cancer cM1 TNM Finding v8","C140278","Kidney cancer with distant metastasis. (from AJCC 8th Ed.)","Kidney Cancer cM1 TNM Finding v8 | Kidney Carcinoma cM1 TNM Finding v8 | cM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538387","Kidney Cancer Pathologic TNM Finding v8","C140279","A pathologic finding about one or more characteristics of kidney cancer, following the rules of the TNM AJCC v8 classification system.","Kidney Cancer Pathologic TNM Finding v8 | Kidney Carcinoma Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538386","Kidney Cancer Pathologic Distant Metastasis TNM Finding v8","C140280","A pathologic finding about one or more characteristics of kidney cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Kidney Cancer Pathologic Distant Metastasis TNM Finding v8 | Kidney Carcinoma Pathologic Distant Metastasis TNM Finding v8 | Pathologic Staging: Distant Metastasis (pM)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538385","Kidney Cancer pM1 TNM Finding v8","C140281","Kidney cancer with distant metastasis. (from AJCC 8th Ed.)","Kidney Cancer pM1 TNM Finding v8 | Kidney Carcinoma pM1 TNM Finding v8 | pM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538382","Kidney Cancer pT0 TNM Finding v8","C140284","Kidney cancer with no evidence of primary tumor. (from AJCC 8th Ed.)","Kidney Cancer pT0 TNM Finding v8 | Kidney Carcinoma pT0 TNM Finding v8 | pT0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538366","Kidney Cancer pT1 TNM Finding v8","C140285","Kidney cancer in which the tumor measures 7 cm or less in greatest dimension and is limited to the kidney. (from AJCC 8th Ed.)","Kidney Cancer pT1 TNM Finding v8 | Kidney Carcinoma pT1 TNM Finding v8 | pT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538553","Eyelid Carcinoma pT1a TNM Finding v8","C140490","Eyelid carcinoma with tumor measuring 10 mm or less in greatest dimension without invasion of the tarsal plate or eyelid margin. (from AJCC 8th Ed.)","Eyelid Carcinoma pT1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538552","Eyelid Carcinoma pT1b TNM Finding v8","C140491","Eyelid carcinoma with tumor measuring 10 mm or less in greatest dimension with invasion of the tarsal plate or eyelid margin. (from AJCC 8th Ed.)","Eyelid Carcinoma pT1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538551","Eyelid Carcinoma pT1c TNM Finding v8","C140492","Eyelid carcinoma with tumor measuring 10 mm or less in greatest dimension involving the full thickness of the eyelid. (from AJCC 8th Ed.)","Eyelid Carcinoma pT1c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538657","Eyelid Carcinoma pT2a TNM Finding v8","C140494","Eyelid carcinoma with tumor measuring more than 10 mm but 20 mm or less in greatest dimension without invasion of the tarsal plate or eyelid margin. (from AJCC 8th Ed.)","Eyelid Carcinoma pT2a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538656","Eyelid Carcinoma pT2b TNM Finding v8","C140495","Eyelid carcinoma with tumor measuring more than 10 mm but 20 mm or less in greatest dimension with invasion of the tarsal plate or eyelid margin. (from AJCC 8th Ed.)","Eyelid Carcinoma pT2b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538655","Eyelid Carcinoma pT2c TNM Finding v8","C140496","Eyelid carcinoma with tumor measuring more than 10 mm but 20 mm or less in greatest dimension involving the full thickness of the eyelid. (from AJCC 8th Ed.)","Eyelid Carcinoma pT2c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538654","Eyelid Carcinoma pT3 TNM Finding v8","C140497","Eyelid carcinoma with tumor measuring more than 20 mm but 30 mm or less in greatest dimension. (from AJCC 8th Ed.)","Eyelid Carcinoma pT3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538653","Eyelid Carcinoma pT3a TNM Finding v8","C140498","Eyelid carcinoma with tumor measuring more than 20 mm but 30 mm or less in greatest dimension without invasion of the tarsal plate or eyelid margin. (from AJCC 8th Ed.)","Eyelid Carcinoma pT3a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538026","Stage III Uterine Corpus Leiomyosarcoma AJCC v8","C139875","Stage III includes: IIIA: T3a, N0, M0; IIIB: T3b, N0, M0; IIIC: T1-3, N1, M0. T1: Uterine corpus leiomyosarcoma with tumor limited to the uterus. T2: Uterine corpus leiomyosarcoma with tumor extending beyond the uterus, within the pelvis. T3: Uterine corpus leiomyosarcoma with tumor infiltrating abdominal tissues. T3a: Uterine corpus leiomyosarcoma with tumor infiltrating abdominal tissues at one site. T3b: Uterine corpus leiomyosarcoma with tumor infiltrating abdominal tissues at more than one site. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage III Uterine Corpus Leiomyosarcoma AJCC v8 | Stage III Uterine Corpus Leiomyosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538025","Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8","C139876","Stage IIIA includes: T3a, N0, M0. T3a: Uterine corpus leiomyosarcoma with tumor infiltrating abdominal tissues at one site. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IIIA Uterine Corpus Leiomyosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538024","Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8","C139877","Stage IIIB includes: T3b, N0, M0. T3b: Uterine corpus leiomyosarcoma with tumor infiltrating abdominal tissues at more than one site. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IIIB Uterine Corpus Leiomyosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538023","Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8","C139878","Stage IIIC includes: T1-3, N1, M0. T1: Uterine corpus leiomyosarcoma with tumor limited to the uterus. T2: Uterine corpus leiomyosarcoma with tumor extending beyond the uterus, within the pelvis. T3: Uterine corpus leiomyosarcoma with tumor infiltrating abdominal tissues. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IIIC Uterine Corpus Leiomyosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538022","Stage IV Uterine Corpus Leiomyosarcoma AJCC v8","C139879","Stage IV includes: IVA: T4, Any N, M0; IVB: Any T, Any N, M1. T4: Uterine corpus leiomyosarcoma with tumor invading bladder or rectum. M0: No distant metastasis. M1: Distant metastasis (excluding adnexa, pelvic, and abdominal tissues). (from AJCC 8th Ed.)","Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IV Uterine Corpus Leiomyosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521174","2p13-q13","C13987","A chromosome band present on 2p","2p13-q13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538021","Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8","C139880","Stage IVA includes: T4, Any N, M0. T4: Uterine corpus leiomyosarcoma with tumor invading bladder or rectum. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IVA Uterine Corpus Leiomyosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538004","Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8","C139881","Stage IVB includes: Any T, Any N, M1. M1: M1: Distant metastasis (excluding adnexa, pelvic, and abdominal tissues). (from AJCC 8th Ed.)","Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IVB Uterine Corpus Leiomyosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538003","Uterine Corpus Endometrial Stromal Sarcoma by AJCC v8 Stage","C139882","A term that refers to the staging of uterine corpus endometrial stroma sarcoma according to the American Joint Committee on Cancer, 8th edition.","Uterine Corpus Endometrial Stromal Sarcoma by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538002","Stage I Uterine Corpus Endometrial Stromal Sarcoma AJCC v8","C139883","Stage I includes: T1, N0, M0. T1: Uterine corpus endometrial stroma sarcoma with tumor limited to the uterus. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage I Uterine Corpus Endometrial Stromal Sarcoma AJCC v8 | Stage I Uterine Corpus Endometrial Stromal Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538202","Stage IIA Penile Cancer AJCC v8","C140081","Stage IIA includes: (T1b, N0, M0); (T2, N0, M0). T1b: Penile cancer with tumor exhibiting lymphovascular invasion and/or perineural invasion or is high grade (i.e., grade 3 or sarcomatoid). T2: Penile cancer with tumor invading into corpus spongiosum (either glans or ventral shaft) with or without urethral invasion. N0: No lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIA Penile Cancer AJCC v8 | Stage IIA Penile Cancer | Stage IIA Penile Squamous Cell Carcinoma AJCC v8 | Stage IIA Squamous Cell Carcinoma of the Penis AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538439","Renal Pelvis and Ureter Cancer Clinical Distant Metastasis TNM Finding v8","C140333","A clinical finding about one or more characteristics of renal pelvis and ureter cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Renal Pelvis and Ureter Cancer Clinical Distant Metastasis TNM Finding v8 | Renal Pelvis and Ureter Urothelial Carcinoma Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538438","Renal Pelvis and Ureter Cancer cM0 TNM Finding v8","C140334","Renal pelvis and ureter cancer without evidence of distant metastasis. (from AJCC 8th Ed.)","Renal Pelvis and Ureter Cancer cM0 TNM Finding v8 | Renal Pelvis and Ureter Urothelial Carcinoma cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538437","Renal Pelvis and Ureter Cancer cM1 TNM Finding v8","C140335","Renal pelvis and ureter cancer with distant metastasis. (from AJCC 8th Ed.)","Renal Pelvis and Ureter Cancer cM1 TNM Finding v8 | Renal Pelvis and Ureter Urothelial Carcinoma cM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538435","Renal Pelvis and Ureter Cancer Pathologic Distant Metastasis TNM Finding v8","C140337","A pathologic finding about one or more characteristics of renal pelvis and ureter cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Renal Pelvis and Ureter Cancer Pathologic Distant Metastasis TNM Finding v8 | Renal Pelvis and Ureter Urothelial Carcinoma Pathologic Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538434","Renal Pelvis and Ureter Cancer pM1 TNM Finding v8","C140338","Renal pelvis and ureter cancer with distant metastasis. (from AJCC 8th Ed.)","Renal Pelvis and Ureter Cancer pM1 TNM Finding v8 | Renal Pelvis and Ureter Urothelial Carcinoma pM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538433","Renal Pelvis and Ureter Cancer Pathologic Primary Tumor TNM Finding v8","C140339","A pathologic finding about one or more characteristics of renal pelvis and ureter cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Renal Pelvis and Ureter Cancer Pathologic Primary Tumor TNM Finding v8 | Renal Pelvis and Ureter Urothelial Carcinoma Pathologic Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538432","Renal Pelvis and Ureter Cancer pTX TNM Finding v8","C140340","Renal pelvis and ureter cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Renal Pelvis and Ureter Cancer pTX TNM Finding v8 | Renal Pelvis and Ureter Urothelial Carcinoma pTX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538447","Renal Pelvis and Ureter Cancer pT0 TNM Finding v8","C140341","Renal pelvis and ureter cancer with no evidence of primary tumor. (from AJCC 8th Ed.)","Renal Pelvis and Ureter Cancer pT0 TNM Finding v8 | Renal Pelvis and Ureter Urothelial Carcinoma pT0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538618","Anti-PSMA/PBD ADC MEDI3726","C140552","An antibody-drug conjugate (ADC) consisting of an engineered version of anti-human prostate-specific membrane antigen (PSMA) monoclonal antibody J591 conjugated, via a valine-alanine dipeptide linker, to tesirine, a cytotoxic, DNA minor groove crosslinking agent and pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of anti-PSMA/PBD ADC MEDI3726, the antibody moiety targets the cell surface antigen PSMA, which is found on prostate cancer cells. Upon antibody/antigen binding, internalization and lysosome-mediated cleavage of the dipeptide linker, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of PSMA-overexpressing tumor cells. PSMA is overexpressed by prostate cancers; its expression is associated with poor prognosis and metastasis.","Anti-PSMA/PBD ADC MEDI3726 | ADC MEDI3726 | ADCT 401 | ADCT-401 | ADCT401 | MEDI 3726 | MEDI-3726 | MEDI3726",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538617","Simmiparib","C140553","An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) 1 (PARP1) and 2 (PARP2), with potential antineoplastic activity. Upon oral administration, simmiparib selectively binds to PARP and prevents PARP-mediated DNA repair of breaks in single-stranded DNA via the base excision repair pathway. This induces the accumulation of DNA strand breaks, promotes genomic instability, induces G2/M arrest and leads to apoptosis. PARP is activated by single-strand DNA breaks and catalyzes post-translational ADP-ribosylation of nuclear proteins, which signal and recruit other proteins to repair damaged DNA.","Simmiparib | SMOCL-9112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538853","Retinoblastoma cT4b TNM Finding v8","C140699","Extraocular tumor clinically evident with proptosis and/or an orbital mass. (from AJCC 8th Ed.)","Retinoblastoma cT4b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511603","Cysteine-Rich Domain","C14069","The Cysteine-Rich Domain is usually found in two copies per protein. It contains up to four conserved cysteines. The family includes a subunit from heterodisulfide reductase and a subunit from glycolate oxidase and glycerol-3-phosphate dehydrogenase. (Pfam PF02754)","Cysteine-Rich Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0139560","Idoxifene","C1406","No value exists.","Idoxifene | 1-[2-[4-[(1E)-1-(4-Iodophenyl)-2-phenyl-1-butenyl]phenoxy]ethyl]pyrrolidine | IDOXIFENE | Pyrrolidino-4-iodotamoxifen | SB-223030 | idoxifene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538851","Retinoblastoma cNX TNM Finding v8","C140701","Retinoblastoma in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Retinoblastoma cNX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538850","Retinoblastoma cN0 TNM Finding v8","C140702","Retinoblastoma with no regional lymph node involvement. (from AJCC 8th Ed.)","Retinoblastoma cN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538138","Gestational Trophoblastic Neoplasm cM1 TNM Finding v8","C140019","Gestational trophoblastic neoplasm with distant metastasis. (from AJCC 8th Ed.)","Gestational Trophoblastic Neoplasm cM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538137","Gestational Trophoblastic Neoplasm cM1a TNM Finding v8","C140020","Gestational trophoblastic neoplasm with lung metastasis. (from AJCC 8th Ed.)","Gestational Trophoblastic Neoplasm cM1a TNM Finding v8 | Gestational Trophoblastic Neoplasm FIGO Stage III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538136","Gestational Trophoblastic Neoplasm cM1b TNM Finding v8","C140021","Gestational trophoblastic neoplasm with all other distant metastases. (from AJCC 8th Ed.)","Gestational Trophoblastic Neoplasm cM1b TNM Finding v8 | Gestational Trophoblastic Neoplasm FIGO Stage IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538135","Gestational Trophoblastic Neoplasm Pathologic TNM Finding v8","C140022","A pathologic finding about one or more characteristics of a gestational trophoblastic neoplasm, following the rules of the TNM AJCC v8 classification system.","Gestational Trophoblastic Neoplasm Pathologic TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538134","Gestational Trophoblastic Neoplasm Pathologic Distant Metastasis TNM Finding v8","C140023","A pathologic finding about one or more characteristics of a gestational trophoblastic neoplasm, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Gestational Trophoblastic Neoplasm Pathologic Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538133","Gestational Trophoblastic Neoplasm pM1 TNM Finding v8","C140024","Gestational trophoblastic neoplasm with distant metastasis. (from AJCC 8th Ed.)","Gestational Trophoblastic Neoplasm pM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538115","Gestational Trophoblastic Neoplasm pM1b TNM Finding v8","C140026","Gestational trophoblastic neoplasm with all other distant metastases. (from AJCC 8th Ed.)","Gestational Trophoblastic Neoplasm pM1b TNM Finding v8 | Gestational Trophoblastic Neoplasm FIGO Stage IV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538114","Gestational Trophoblastic Neoplasm Pathologic Primary Tumor TNM Finding v8","C140027","A pathologic finding about one or more characteristics of a gestational trophoblastic neoplasm, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Gestational Trophoblastic Neoplasm Pathologic Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538113","Gestational Trophoblastic Neoplasm pTX TNM Finding v8","C140028","Gestational trophoblastic neoplasm in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Gestational Trophoblastic Neoplasm pTX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538112","Gestational Trophoblastic Neoplasm pT0 TNM Finding v8","C140029","Gestational trophoblastic neoplasm with no evidence of primary tumor. (from AJCC 8th Ed.)","Gestational Trophoblastic Neoplasm pT0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515462","8q22.3-q23","C14002","A chromosome band present on 8q","8q22.3-q23 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538111","Gestational Trophoblastic Neoplasm pT1 TNM Finding v8","C140030","Gestational trophoblastic neoplasm in which the tumor is confined to uterus. (from AJCC 8th Ed.)","Gestational Trophoblastic Neoplasm pT1 TNM Finding v8 | Gestational Trophoblastic Neoplasm FIGO Stage I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520197","Xq26.1","C13670","A chromosome band present on Xq","Xq26.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554695","Lung Keratinizing Squamous Cell Carcinoma","C136713","A squamous cell lung carcinoma characterized by the presence of keratinization, pearl formation, and/or intercellular bridges.","Lung Keratinizing Squamous Cell Carcinoma | Keratinizing Squamous Cell Lung Carcinoma | Keratinizing squamous cell carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554694","Lung Non-Keratinizing Squamous Cell Carcinoma","C136714","A squamous cell lung carcinoma characterized by the absence of keratinization, pearl formation, and intercellular bridges.","Lung Non-Keratinizing Squamous Cell Carcinoma | Lung Nonkeratinizing Squamous Cell Carcinoma | Non-Keratinizing Squamous Cell Lung Carcinoma | Non-keratinizing squamous cell carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524519","Intercellular Bridges Present","C136715","A microscopic finding indicating the presence of intercellular bridges connecting adjacent cells in a tissue sample.","Intercellular Bridges Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538201","Stage IIB Penile Cancer AJCC v8","C140083","Stage IIB includes: T3, N0, M0. T3: Penile cancer with tumor invading into corpora cavernosum (including tunica albuginea) with or without urethral invasion. N0: No lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIB Penile Cancer AJCC v8 | Stage IIB Penile Cancer | Stage IIB Penile Squamous Cell Carcinoma AJCC v8 | Stage IIB Squamous Cell Carcinoma of the Penis AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538200","Stage III Penile Cancer AJCC v8","C140084","Stage III includes: IIIA: T1-3, N1, M0; IIIB: T1-3, N2, M0. T1: Glans: Penile cancer with tumor invading lamina propria. Foreskin: Penile cancer with tumor invading dermis, lamina propria, or dartos fascia. Shaft: Penile cancer with tumor invading connective tissue between epidermis and corpora regardless of location. All sites with or without lymphovascular invasion or perineural invasion and is or is not high grade. T2: Penile cancer with tumor invading into corpus spongiosum (either glans or ventral shaft) with or without urethral invasion. T3: Penile cancer with tumor invading into corpora cavernosum (including tunica albuginea) with or without urethral invasion. N1: Penile cancer with two or less unilateral inguinal metastases, no extranodal extension. N2: Penile cancer with three or more unilateral inguinal metastases or bilateral metastases. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Penile Cancer AJCC v8 | Stage III Penile Cancer | Stage III Penile Squamous Cell Carcinoma AJCC v8 | Stage III Squamous Cell Carcinoma of the Penis AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538199","Stage IIIA Penile Cancer AJCC v8","C140085","Stage IIIA includes: T1-3, N1, M0. T1: Glans: Penile cancer with tumor invading lamina propria. Foreskin: Penile cancer with tumor invading dermis, lamina propria, or dartos fascia. Shaft: Penile cancer with tumor invading connective tissue between epidermis and corpora regardless of location. All sites with or without lymphovascular invasion or perineural invasion and is or is not high grade. T2: Penile cancer with tumor invading into corpus spongiosum (either glans or ventral shaft) with or without urethral invasion. T3: Penile cancer with tumor invading into corpora cavernosum (including tunica albuginea) with or without urethral invasion. N1: Penile cancer with two or less unilateral inguinal metastases, no extranodal extension. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIA Penile Cancer AJCC v8 | Stage IIIA Penile Cancer | Stage IIIA Penile Squamous Cell Carcinoma AJCC v8 | Stage IIIA Squamous Cell Carcinoma of the Penis AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538198","Stage IIIB Penile Cancer AJCC v8","C140086","Stage IIIB includes: T1-3, N2, M0. T1: Glans: Penile cancer with tumor invading lamina propria. Foreskin: Penile cancer with tumor invading dermis, lamina propria, or dartos fascia. Shaft: Penile cancer with tumor invading connective tissue between epidermis and corpora regardless of location. All sites with or without lymphovascular invasion or perineural invasion and is or is not high grade. T2: Penile cancer with tumor invading into corpus spongiosum (either glans or ventral shaft) with or without urethral invasion. T3: Penile cancer with tumor invading into corpora cavernosum (including tunica albuginea) with or without urethral invasion. N2: Penile cancer with three or more unilateral inguinal metastases or bilateral metastases. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIB Penile Cancer AJCC v8 | Stage IIIB Penile Cancer | Stage IIIB Penile Squamous Cell Carcinoma AJCC v8 | Stage IIIB Squamous Cell Carcinoma of the Penis AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538197","Stage IV Penile Cancer AJCC v8","C140087","Stage IV includes: (T4, Any N, M0); (Any T, N3, M0); (Any T, Any N, M1). T4: Penile cancer with tumor invading into adjacent structures (i.e., scrotum, prostate, pubic bone). N3: Penile cancer with extranodal extension of lymph node metastases or pelvic lymph node metastases. M1: Distant metastasis present. (AJCC 8th ed.)","Stage IV Penile Cancer AJCC v8 | Stage IV Penile Cancer | Stage IV Penile Squamous Cell Carcinoma AJCC v8 | Stage IV Squamous Cell Carcinoma of the Penis AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538196","CDKN2B-AS1 Gene","C140088","This gene plays a role in the epigenetic silencing of genes in the CDKN2B-CDKN2A gene cluster.","CDKN2B-AS1 Gene | CDKN2B Antisense RNA 1 Gene | CDKN2B-AS1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538195","CDKN2B-AS1 wt Allele","C140089","Human CDKN2B-AS1 wild-type allele is located in the vicinity of 9p21.3 and is approximately 126 kb in length. This allele, which encodes CDKN2B antisense RNA 1, is involved in epigenetic silencing of nearby genes. Loss of expression of the gene may be associated with increased susceptibility for cardiovascular disease, melanoma and several other cancers, intracranial aneurysm, type-2 diabetes, periodontitis, Alzheimer's disease, endometriosis, frailty in the elderly, and glaucoma.","CDKN2B-AS1 wt Allele | ANRIL | CDKN2B Antisense RNA (Non-Protein Coding) Gene | CDKN2B Antisense RNA 1 (Non-Protein Coding) Gene | CDKN2B Antisense RNA 1 wt Allele | CDKN2B Antisense RNA Gene | CDKN2B-AS | CDKN2BAS | NCRNA00089 | Non-Protein Coding RNA 89 Gene | PCAT12 | Prostate Cancer Associated Transcript 12 Gene | RP11-145E5.4 | p15AS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521044","20p12","C14008","A chromosome band present on 20p","20p12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525001","Carboplatin/Paclitaxel/Trastuzumab Regimen","C138052","A regimen consisting of paclitaxel, carboplatin and trastuzumab that may be used as a treatment for breast, esophageal and esophagogastric junction, and gastric cancers and endometrial carcinoma.","Carboplatin/Paclitaxel/Trastuzumab Regimen | Carboplatin and Paclitaxel (CP) and Trastuzumab | Carboplatin and Paclitaxel (CP) and Trastuzumab-anns | Carboplatin and Paclitaxel (CP) and Trastuzumab-dkst | Carboplatin and Paclitaxel (CP) and Trastuzumab-dttb | Carboplatin and Paclitaxel (CP) and Trastuzumab-herw | Carboplatin and Paclitaxel (CP) and Trastuzumab-pkrb | Carboplatin and Paclitaxel (CP) and Trastuzumab-qyyp | Carboplatin and Paclitaxel (CP) and Trastuzumab-strf | Carboplatin and Paclitaxel (CP) and Trastuzumab-zerc | Carboplatin-Paclitaxel-Trastuzumab | Carboplatin-Paclitaxel-Trastuzumab Regimen | Carboplatin/Paclitaxel Plus Trastuzumab Regimen | Carboplatin/Paclitaxel/Trastuzumab | Paclitaxel/Carboplatin Plus Trastuzumab | Paclitaxel/Carboplatin/Trastuzumab | TCH | TPC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525000","Vinorelbine + Trastuzumab","C138053","A regimen consisting of vinorelbine and trastuzumab, used as a treatment for recurrent and metastatic HER-2/neu-positive breast cancer.","VH Regimen | Trastuzumab-Vinorelbine Regimen | Trastuzumab/Vinorelbine Regimen | VH | Vinorelbine + Trastuzumab | Vinorelbine and Trastuzumab (VH) | Vinorelbine and Trastuzumab-anns (VH) | Vinorelbine and Trastuzumab-dkst (VH) | Vinorelbine and Trastuzumab-dttb (VH) | Vinorelbine and Trastuzumab-herw (VH) | Vinorelbine and Trastuzumab-pkrb (VH) | Vinorelbine and Trastuzumab-qyyp (VH) | Vinorelbine and Trastuzumab-strf (VH) | Vinorelbine and Trastuzumab-zerc (VH) | Vinorelbine-Trastuzumab | Vinorelbine/Herceptin | Vinorelbine/Trastuzumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524999","TC Regimen","C138054","A regimen consisting of docetaxel and cyclophosphamide that can be used in the treatment of breast cancer.","TC Regimen | Cyclophosphamide and Docetaxel (TC) | Cyclophosphamide/Docetaxel | Docetaxel + Cyclophosphamide | Docetaxel-Cyclophosphamide | Docetaxel/Cyclophosphamide | Docetaxel/Cyclophosphamide Regimen | TC | Taxotere/Cytoxan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525079","Patient Decision Regarding Continuation of Pregnancy after Cancer Diagnosis","C138059","The patient's decision regarding continuation of pregnancy following a cancer diagnosis.","Patient Decision Regarding Continuation of Pregnancy after Cancer Diagnosis | Patient's Decision Regarding Continuation of Pregnancy after Cancer Diagnosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538110","Gestational Trophoblastic Neoplasm pT2 TNM Finding v8","C140031","Gestational trophoblastic neoplasm in which the tumor extends to other genital structures (ovary, tube, vagina, broad ligaments) by metastasis or direct extension. (from AJCC 8th Ed.)","Gestational Trophoblastic Neoplasm pT2 TNM Finding v8 | Gestational Trophoblastic Neoplasm FIGO Stage II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538109","Gestational Trophoblastic Tumor by AJCC v7 Stage","C140032","A term that refers to the staging of gestational trophoblastic tumor according to the American Joint Committee on Cancer, 7th edition.","Gestational Trophoblastic Tumor by AJCC v7 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538124","Gestational Trophoblastic Neoplasm by AJCC v8 Stage","C140033","A term that refers to the staging of a gestational trophoblastic neoplasm according to the American Joint Committee on Cancer, 8th edition. This classification applies to the following neoplasms: invasive hydatidiform mole, gestational choriocarcinoma, placental site trophoblastic tumor, and epithelioid trophoblastic tumor. Complete and partial hydatidiform moles are not included in this classification. The current FIGO classification includes an anatomic stage designated by Roman numeral I, II, III, or IV, followed by the risk factor score expressed in Arabic numerals (e.g., Stage II: 4, Stage IV: 9).  (from AJCC 8th Ed.)","Gestational Trophoblastic Neoplasm by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538122","Stage II Gestational Trophoblastic Neoplasm AJCC v8","C140035","Stage II includes: T2, M0. T2: Gestational trophoblastic neoplasm in which the tumor extends to other genital structures (ovary, tube, vagina, broad ligaments) by metastasis or direct extension. M0: No distant metastasis. (AJCC 8th Ed.)","Stage II Gestational Trophoblastic Neoplasm AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524522","KISS1 Gene Product","C136718","A protein encoded by the KISS1 gene.","KISS1 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524527","NPY Gene Product","C136720","A protein encoded by the NPY gene.","NPY Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0071934","preproneuropeptide Y","C136721","Pro-neuropeptide Y (97 aa, ~11 kDa) is encoded by the human NPY gene. This protein plays a role in the regulation of feeding behavior.","Pro-Neuropeptide Y | Prepro-Neuropeptide Y",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524526","AGT Gene Product","C136722","A protein encoded by the human AGT gene.","AGT Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2713666","AGT protein, human","C136723","Angiotensinogen (485 aa, ~53 kDa) is encoded by the human AGT gene. This protein plays a role in the regulation of blood pressure, body fluid and electrolyte homeostasis.","Angiotensinogen | AGT | Pre-Angiotensinogen | Serpin A8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525017","Refractory Gray Zone Lymphoma","C138014","Gray-zone lymphoma that is resistant to treatment.","Refractory Gray-Zone Lymphoma | Refractory B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma | Refractory B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma | Refractory B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma | Refractory Gray Zone Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525023","Recurrent Extranodal Diffuse Large B-cell Lymphoma","C138015","The reemergence of extranodal diffuse large B-cell lymphoma after a period of remission.","Recurrent Extranodal Diffuse Large B-cell Lymphoma | Recurrent Extranodal Diffuse Large B-Cell Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525021","Refractory Extranodal Diffuse Large B-cell Lymphoma","C138018","Extranodal diffuse large B-cell lymphoma that is resistant to treatment.","Refractory Extranodal Diffuse Large B-cell Lymphoma | Refractory Extranodal Diffuse Large B-Cell Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538365","Kidney Cancer pT1a TNM Finding v8","C140286","Kidney cancer in which the tumor measures 4 cm or less in greatest dimension and is limited to the kidney. (from AJCC 8th Ed.)","Kidney Cancer pT1a TNM Finding v8 | Kidney Carcinoma pT1a TNM Finding v8 | pT1a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538364","Kidney Cancer pT1b TNM Finding v8","C140287","Kidney cancer in which the tumor measures more than 4 cm but 7 cm or less in greatest dimension and is limited to the kidney. (from AJCC 8th Ed.)","Kidney Cancer pT1b TNM Finding v8 | Kidney Carcinoma pT1b TNM Finding v8 | pT1b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538363","Kidney Cancer pT2 TNM Finding v8","C140288","Kidney cancer in which the tumor measures more than 7 cm in greatest dimension and is limited to the kidney. (from AJCC 8th Ed.)","Kidney Cancer pT2 TNM Finding v8 | Kidney Carcinoma pT2 TNM Finding v8 | pT2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538362","Kidney Cancer pT2a TNM Finding v8","C140289","Kidney cancer in which the tumor measures more than 7 cm but 10 cm or less in greatest dimension and is limited to the kidney. (from AJCC 8th Ed.)","Kidney Cancer pT2a TNM Finding v8 | Kidney Carcinoma pT2a TNM Finding v8 | pT2a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520854","19q12","C14028","A chromosome band present on 19q","19q12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538361","Kidney Cancer pT2b TNM Finding v8","C140290","Kidney cancer in which the tumor measures more than 10 cm in greatest dimension and is limited to the kidney. (from AJCC 8th Ed.)","Kidney Cancer pT2b TNM Finding v8 | Kidney Carcinoma pT2b TNM Finding v8 | pT2b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538360","Kidney Cancer pT3 TNM Finding v8","C140291","Kidney cancer in which the tumor extends into major veins or perinephric tissues, but not into the ipsilateral adrenal gland and not beyond Gerota's fascia. (from AJCC 8th Ed.)","Kidney Cancer pT3 TNM Finding v8 | Kidney Carcinoma pT3 TNM Finding v8 | pT3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538359","Kidney Cancer pT3a TNM Finding v8","C140292","Kidney cancer in which the tumor extends into the renal vein or its segmental branches, or invades the pelvicalyceal system, or invades perirenal and/or renal sinus fat but not beyond Gerota's fascia. (from AJCC 8th Ed.)","Kidney Cancer pT3a TNM Finding v8 | Kidney Carcinoma pT3a TNM Finding v8 | pT3a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538373","Kidney Cancer pT3c TNM Finding v8","C140294","Kidney cancer in which the tumor extends into the vena cava above the diaphragm or invades the wall of the vena cava. (from AJCC 8th Ed.)","Kidney Cancer pT3c TNM Finding v8 | Kidney Carcinoma pT3c TNM Finding v8 | pT3c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538372","Kidney Cancer pT4 TNM Finding v8","C140295","Kidney cancer in which the tumor invades beyond Gerota's fascia (including contiguous extension into the ipsilateral adrenal gland). (from AJCC 8th Ed.)","Kidney Cancer pT4 TNM Finding v8 | Kidney Carcinoma pT4 TNM Finding v8 | pT4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538371","Kidney Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C140296","A pathologic finding about one or more characteristics of kidney cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Kidney Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | Kidney Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8 | Pathologic Staging: Regional Lymph Nodes (pN)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538370","Kidney Cancer pNX TNM Finding v8","C140297","Kidney cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Kidney Cancer pNX TNM Finding v8 | Kidney Carcinoma pNX TNM Finding v8 | pNX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538369","Kidney Cancer pN0 TNM Finding v8","C140298","Kidney cancer with no regional lymph node metastasis. (from AJCC 8th Ed.)","Kidney Cancer pN0 TNM Finding v8 | Kidney Carcinoma pN0 TNM Finding v8 | pN0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538368","Kidney Cancer pN1 TNM Finding v8","C140299","Kidney cancer with metastasis in regional lymph node(s). (from AJCC 8th Ed.)","Kidney Cancer pN1 TNM Finding v8 | Kidney Carcinoma pN1 TNM Finding v8 | pN1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520628","15q15.2","C14029","A chromosome band present on 15q","15q15.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524761","Deleted In Lymphocytic Leukemia 1 Non-Protein Coding RNA","C136969","Deleted in lymphocytic leukemia 1 non-protein coding RNA (~3 kb) is encoded by the human DLEU1 gene. This non-coding RNA may be involved in tumor suppression.","Deleted In Lymphocytic Leukemia 1 Non-Protein Coding RNA | DLEU1 | Deleted In Lymphocytic Leukemia 1 Long Non-Protein Coding RNA | LINCRNA21 | Long Intergenic Non-Protein Coding RNA 21 | Long Non-Coding RNA 21 | NCRNA00021 | Non-Coding RNA 21 | Non-Protein Coding RNA 21",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520547","13q14.1-q14.2","C13696","A chromosome band present on 13q","13q14.1-q14.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524767","Recurrent Lymphocyte-Rich Classic Hodgkin Lymphoma","C136971","The reemergence of lymphocyte-rich classic Hodgkin lymphoma after a period of remission.","Recurrent Lymphocyte-Rich Classic Hodgkin Lymphoma | Recurrent Lymphocyte-Rich Classical Hodgkin Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524765","Long Intergenic Non-Protein Coding RNA 1565","C136973","Long intergenic non-protein coding RNA 1565 (~3 kb) is encoded by the human LINC01565 gene. This non-coding RNA may be involved the suppression of cell growth.","Long Intergenic Non-Protein Coding RNA 1565 | LINC01565",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524770","LMNA Gene Product","C136975","A protein encoded by the LMNA gene.","LMNA Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520188","Xq22-q23","C14023","A chromosome band present on Xq","Xq22-q23 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538577","Prostatic Urethra Cancer pT1 TNM Finding v8","C140448","Urethral cancer with tumor invading urethral subepithelial connective tissue immediately underlying the urothelium. (from AJCC 8th Ed.)","Prostatic Urethra Cancer pT1 TNM Finding v8 | Prostatic Urethra Carcinoma pT1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538576","Prostatic Urethra Cancer pT2 TNM Finding v8","C140449","Urethral cancer with tumor invading the prostatic stroma surrounding ducts either by direct extension from the urothelial surface or by invasion from prostatic ducts. (from AJCC 8th Ed.)","Prostatic Urethra Cancer pT2 TNM Finding v8 | Prostatic Urethra Carcinoma pT2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538575","Prostatic Urethra Cancer pT3 TNM Finding v8","C140450","Urethral cancer with tumor invading the periprostatic fat. (from AJCC 8th Ed.)","Prostatic Urethra Cancer pT3 TNM Finding v8 | Prostatic Urethra Carcinoma pT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538574","Prostatic Urethra Cancer pT4 TNM Finding v8","C140451","Urethral cancer with tumor invading other adjacent organs (e.g., extraprostatic invasion of the bladder wall, rectal wall). (from AJCC 8th Ed.)","Prostatic Urethra Cancer pT4 TNM Finding v8 | Prostatic Urethra Carcinoma pT4 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538573","Urethral Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C140452","A pathologic finding about one or more characteristics of urethral cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Urethral Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | Urethral Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525020","Recurrent Central Nervous System Lymphoma","C138019","The reemergence of central nervous system lymphoma after a period of remission.","Recurrent Central Nervous System Lymphoma | Recurrent Primary Central Nervous System Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520945","1p22.1","C13801","A chromosome band present on 1p","1p22.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525027","Refractory Central Nervous System Lymphoma","C138020","Central nervous system lymphoma that is resistant to treatment.","Refractory Central Nervous System Lymphoma | Refractory Primary Central Nervous System Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525026","Recurrent Testicular Lymphoma","C138021","The reemergence of testicular lymphoma after a period of remission.","Recurrent Testicular Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525025","Refractory Testicular Lymphoma","C138022","Testicular lymphoma that is resistant to treatment.","Refractory Testicular Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525024","Recurrent Breast Lymphoma","C138023","The reemergence of breast lymphoma after a period of remission.","Recurrent Breast Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525005","Refractory Breast Lymphoma","C138024","Breast lymphoma that is resistant to treatment.","Refractory Breast Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525004","Recurrent Intravascular Large B-Cell Lymphoma","C138025","The reemergence of intravascular large B-cell lymphoma after a period of remission.","Recurrent Intravascular Large B-Cell Lymphoma | Recurrent Intravascular B-Cell Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525003","Refractory Intravascular Large B-Cell Lymphoma","C138026","Intravascular large B-cell lymphoma that is resistant to treatment.","Refractory Intravascular Large B-Cell Lymphoma | Refractory Intravascular B-Cell Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525002","Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type","C138027","The reemergence of primary cutaneous diffuse large B-cell lymphoma, leg type after a period of remission.","Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type | Recurrent Primary Cutaneous (Skin) Diffuse Large B-Cell Lymphoma, Leg Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525009","Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type","C138028","Primary cutaneous diffuse large B-cell lymphoma, leg type that is resistant to treatment.","Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type | Refractory Primary Cutaneous (Skin) Diffuse Large B-Cell Lymphoma, Leg Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0138273","Prednisolone Sodium Phosphate","C1402","The sodium phosphate salt form of prednisolone, a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. As a glucocorticoid receptor agonist, prednisolone sodium phosphate binds to specific intracellular glucocorticoid receptors, and causes the ligand- receptor complex to be translocated to the nucleus where it initiates the transcription of glucocorticoid-responsive genes such as various cytokines and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both potent mediators of inflammation. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","Prednisolone Sodium Phosphate | Ak-Pred | Inflamase | Key-Pred SP | Millipred | Orapred | Orapred ODT | PREDNISOLONE SODIUM PHOSPHATE | Pediapred | Polypred | Predmix | Prednabene | Prednesol | Prednisol | Prednisolone Sodium Phosphate ODT | Predsol | Veripred 20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538642","Eyelid Carcinoma pN2 TNM Finding v8","C140509","Eyelid carcinoma with metastasis in a single ipsilateral regional lymph node, measuring more than 3 cm in greatest dimension, or in bilateral or contralateral lymph nodes. (from AJCC 8th Ed.)","Eyelid Carcinoma pN2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538641","Eyelid Carcinoma pN2b TNM Finding v8","C140510","Eyelid carcinoma with metastasis in a single ipsilateral regional lymph node, measuring more than 3 cm in greatest dimension, or in bilateral or contralateral lymph nodes documented based on microscopic findings on lymph node biopsy. (from AJCC 8th Ed.)","Eyelid Carcinoma pN2b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538640","Eyelid Carcinoma by AJCC v7 Stage","C140511","A term that refers to the staging of eyelid carcinoma according to the American Joint Committee on Cancer, 7th edition.","Eyelid Carcinoma by AJCC v7 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538639","Eyelid Carcinoma by AJCC v8 Stage","C140513","A term that refers to the staging of eyelid carcinoma according to the American Joint Committee on Cancer, 8th edition. This staging system applies to all primary carcinomas of the eyelid, including basal cell carcinoma (BCC), squamous cell carcinoma (SCC), sebaceous carcinoma, and other rare carcinomas, such as all varieties of sweat gland carcinoma (e.g., eccrine carcinoma). It does not apply to carcinomas of the head and neck with direct extension to eyelid (are staged according to the cutaneous squamous cell carcinomas of the head and neck), Merkel cell carcinomas of the eyelid (are staged according to the classification for Merkel cell carcinomas), and melanomas of the eyelid (are staged according to the classification for melanomas of the skin).  (from AJCC 8th Ed.)","Eyelid Carcinoma by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538638","Stage 0 Eyelid Carcinoma AJCC v8","C140515","Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No evidence of lymph node involvement. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0 Eyelid Carcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538637","Stage I Eyelid Carcinoma AJCC v8","C140516","Stage I includes: IA: T1, N0, M0; IB: T2a, N0, M0. T1: Tumor measuring 10 mm or less in greatest dimension. T2a: Tumor measuring more than 10 mm but 20 mm or less in greatest dimension without invasion of the tarsal plate or eyelid margin. N0: No evidence of lymph node involvement. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Eyelid Carcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538636","Stage IA Eyelid Carcinoma AJCC v8","C140517","Stage IA includes: T1, N0, M0. T1: Tumor measuring 10 mm or less in greatest dimension. N0: No evidence of lymph node involvement. M0: No distant metastasis. (AJCC 8th ed.)","Stage IA Eyelid Carcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538650","Stage IB Eyelid Carcinoma AJCC v8","C140518","Stage IB includes: T2a, N0, M0. T2a: Tumor measuring more than 10 mm but 20 mm or less in greatest dimension without invasion of the tarsal plate or eyelid margin. N0: No evidence of lymph node involvement. M0: No distant metastasis. (AJCC 8th ed.)","Stage IB Eyelid Carcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0125258","LMNA protein, human","C136976","Lamin-A/C (646 aa, ~72 kDa)  is encoded by the human LMNA gene. This protein plays a role in the formation of the nuclear lamina.","Lamin-A/C | 70 kDa Lamin | Lamin A | Lamin C | Lamin-A | Lamin-C | Renal Carcinoma Antigen NY-REN-32",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524895","Personalized Live-attenuated Double-deleted Listeria monocytogenes","C137823","A proprietary, personalized live, attenuated, double-deleted (pLADD) strain of the Gram-positive bacterium Listeria monocytogenes encoding multiple, patient-specific neoantigens, with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, the tumor-associated antigens (TAAs) expressed in pLADD are taken up by antigen-presenting cells (APCs), including dendritic cells (DCs), and are processed and presented to the immune system by both major histocompatibility complex (MHC) class I and II molecules. This activates the immune system and leads to both an innate immune response and the recruitment and activation of tumor-specific cytotoxic T-lymphocytes (CTLs) against the TAAs specifically expressed by the patient's tumor cells, which eventually results in tumor cell lysis.","Personalized Live-attenuated Double-deleted Listeria monocytogenes | Patient-specific LADD | Personalized LADD | pLADD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3179326","PRO 140","C137824","A humanized immunoglobulin (Ig) G4 monoclonal antibody against CC chemokine receptor 5 (CCR5; CD195), with potential activity as a human immunodeficiency virus (HIV) entry blocker and potential protective activity against graft-versus-host disease (GvHD). Upon administration, leronlimab targets and binds to CCR5 expressed on T-cells. This blocks HIV cell entry, which prevents HIV infection and/or reduces HIV viral load. In addition, blocking CCR5 by PRO 140 decreases CCR5-mediated signaling and the CCR5-induced migration of donor cells into tissues after an allogeneic hematopoietic cell transplantation (HCT). Blocking CCR5 may therefore prevent or reduce GvHD. CCR5, a co-receptor needed for HIV cell entry, plays a key role in immunomodulation. Expressed on monocytes, activated T-cells and dendritic cells (DCs), CCR5 can regulate chemotaxis. Lymphocyte trafficking via chemokine receptors, such as CCR5, and recruitment to target organs, plays a critical role in alloreactive responses.","Leronlimab | LERONLIMAB | PA14 | PRO 140 | PRO-140 | PRO140 | WHO 10751",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0519825","Comprehensive Metabolic Panel","C137828","A broad screening tool that measures glucose, electrolytes and metabolites in blood serum to evaluate organ function and check for conditions such as diabetes, liver disease, and kidney disease.","Comprehensive Metabolic Panel | CMP | Chem 12 | Chemistry Panel | Chemistry Screen | SMA 12",,,,,,,,,,,,,,,"3661905","Comprehensive metabolic panel",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3840133","Fertility Preservation Counseling","C137829","Professional guidance designed to provide information and address the emotional issues which arise in fertility preservation patients.","Fertility Preservation Counseling | Counseling for Fertility Preservation",,,,,,,,,,,,,,,"45765614","Counseling for fertility preservation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1520579","14q11.2","C13782","A chromosome band present on 14q","14q11.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524878","Breast Cancer Risk Reduction Counseling","C137830","Professional guidance designed to present the risks and benefits of various prevention strategies for reducing breast cancer risk, include lifestyle modifications, chemoprevention, surgical approaches, and pharmacotherapy.","Breast Cancer Risk Reduction Counseling | Breast Cancer Risk Reduction and Counseling | Counseling Regarding Breast Cancer Risk Reduction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538588","Urethral Cancer pNX TNM Finding v8","C140453","Urethral cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Urethral Cancer pNX TNM Finding v8 | Urethral Carcinoma pNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538587","Urethral Cancer pN0 TNM Finding v8","C140454","Urethral cancer with no regional lymph node metastasis. (from AJCC 8th Ed.)","Urethral Cancer pN0 TNM Finding v8 | Urethral Carcinoma pN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538586","Urethral Cancer pN1 TNM Finding v8","C140455","Urethral cancer with single regional lymph node metastasis in the inguinal region or true pelvis [perivesical, obturator, internal (hypogastric) and external iliac], or presacral lymph node. (from AJCC 8th Ed.)","Urethral Cancer pN1 TNM Finding v8 | Urethral Carcinoma pN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538585","Urethral Cancer pN2 TNM Finding v8","C140456","Urethral cancer with multiple regional lymph node metastasis in the inguinal region or true pelvis [perivesical, obturator, internal (hypogastric) and external iliac], or presacral lymph node. (from AJCC 8th Ed.)","Urethral Cancer pN2 TNM Finding v8 | Urethral Carcinoma pN2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538584","Urethral Cancer by AJCC v8 Stage","C140457","A term that refers to the staging of urethral cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to urothelial (transitional cell), squamous, and glandular carcinomas of the urethra and to urothelial (transitional cell) carcinomas of the prostate and prostatic urethra. It does not apply to squamous cell carcinomas of the penile foreskin (are staged according to the classification for penis), primary urothelial carcinomas of the bladder with transmural involvement of the prostate (are staged according to the classification for urinary bladder), prostatic adenocarcinomas (are staged according to the classification for prostate), mucosal melanomas of the urethra (no AJCC staging system), lymphomas (are staged according to the classification for Hodgkin and non-Hodgkin lymphoma), and sarcomas (are staged according to the classification for soft tissue sarcoma of the abdomen and thoracic visceral organs).  (from AJCC 8th Ed.)","Urethral Cancer by AJCC v8 Stage | Urethral Carcinoma by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538583","Stage 0a Urethral Cancer AJCC v8","C140458","Stage 0a includes: Ta, N0, M0. Ta: For male penile urethra and female urethra: Non-invasive papillary carcinoma. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0a Urethral Cancer AJCC v8 | Stage 0a Urethral Cancer | Stage 0a Urethral Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538582","Stage 0is Urethral Cancer AJCC v8","C140459","Stage 0is includes: Tis, N0, M0. Tis: For male penile urethra and female urethra: Carcinoma in situ. For prostatic urethra: Carcinoma in situ involving the prostatic urethra or periurethral or prostatic ducts without stromal invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0is Urethral Cancer AJCC v8 | Stage 0is Urethral Cancer | Stage 0is Urethral Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521300","3q13","C14045","A chromosome band present on 3q","3q13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538833","Retinoblastoma cN1 TNM Finding v8","C140703","Retinoblastoma with evidence of preauricular, submandibular, and cervical lymph node involvement. (from AJCC 8th Ed.)","Retinoblastoma cN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538832","Retinoblastoma Pathologic TNM Finding v8","C140704","A pathologic finding about one or more characteristics of retinoblastoma, following the rules of the TNM AJCC v8 classification system.","Retinoblastoma Pathologic TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538831","Retinoblastoma Pathologic Distant Metastasis TNM Finding v8","C140705","A pathologic finding about one or more characteristics of retinoblastoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Retinoblastoma Pathologic Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538830","Retinoblastoma pM1 TNM Finding v8","C140706","Retinoblastoma with distant metastasis with microscopic confirmation. (from AJCC 8th Ed.)","Retinoblastoma pM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538829","Retinoblastoma pM1a TNM Finding v8","C140707","Retinoblastoma with pathological evidence of tumor at any distant site (e.g., bone marrow, liver, or other). (from AJCC 8th Ed.)","Retinoblastoma pM1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538828","Retinoblastoma pM1b TNM Finding v8","C140708","Retinoblastoma with pathological evidence of tumor in the cerebrospinal fluid or CNS parenchyma. (from AJCC 8th Ed.)","Retinoblastoma pM1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520541","13q12-q13","C13691","A chromosome band present on 13q","13q12-q13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524686","Cutaneous Melanoma Pathologic TNM Finding v8","C136921","A pathologic finding about one or more characteristics of cutaneous melanoma, following the rules of the TNM AJCC v8 classification system.","Cutaneous Melanoma Pathologic TNM Finding v8 | Melanoma of the Skin Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538649","Stage II Eyelid Carcinoma AJCC v8","C140519","Stage II includes: IIA: T2b-c, T3, N0, M0; IIB: T4, N0, M0. T2b: Tumor measuring more than 10 mm but 20 mm or less in greatest dimension with invasion of the tarsal plate or eyelid margin. T2c: Tumor measuring more than 10 mm but 20 mm or less in greatest dimension involving the full thickness of the eyelid. T3: Tumor measuring more than 20 mm but 30 mm or less in greatest dimension. T4: Any eyelid carcinoma invading adjacent ocular, orbital, or facial structures. N0: No evidence of lymph node involvement. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Eyelid Carcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538648","Stage IIA Eyelid Carcinoma AJCC v8","C140520","Stage IIA includes: T2b-c, T3, N0, M0: T2b: Tumor measuring more than 10 mm but 20 mm or less in greatest dimension with invasion of the tarsal plate or eyelid margin. T2c: Tumor measuring more than 10 mm but 20 mm or less in greatest dimension involving the full thickness of the eyelid. T3: Tumor measuring more than 20 mm but 30 mm or less in greatest dimension. N0: No evidence of lymph node involvement. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIA Eyelid Carcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538647","Stage IIB Eyelid Carcinoma AJCC v8","C140521","Stage IIB includes: T4, N0, M0. T4: Any eyelid carcinoma invading adjacent ocular, orbital, or facial structures. N0: No evidence of lymph node involvement. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIB Eyelid Carcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538001","Stage IA Uterine Corpus Endometrial Stromal Sarcoma AJCC v8","C139884","Stage IA includes: T1a, N0, M0. T1a: Uterine corpus endometrial stroma sarcoma with tumor limited to the uterus, measuring 5 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IA Uterine Corpus Endometrial Stromal Sarcoma AJCC v8 | Stage IA Uterine Corpus Endometrial Stromal Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538000","Stage IB Uterine Corpus Endometrial Stromal Sarcoma AJCC v8","C139885","Stage IB includes: T1b, N0, M0. T1b: Uterine corpus endometrial stroma sarcoma with tumor limited to the uterus, measuring more than 5 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IB Uterine Corpus Endometrial Stromal Sarcoma AJCC v8 | Stage IB Uterine Corpus Endometrial Stromal Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537999","Stage II Uterine Corpus Endometrial Stromal Sarcoma AJCC v8","C139886","Stage II includes: T2, N0, M0. T2: Uterine corpus endometrial stroma sarcoma with tumor extending beyond the uterus, within the pelvis. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage II Uterine Corpus Endometrial Stromal Sarcoma AJCC v8 | Stage II Uterine Corpus Endometrial Stromal Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537997","Stage IIIA Uterine Corpus Endometrial Stromal Sarcoma AJCC v8","C139888","Stage IIIA includes: T3a, N0, M0. T3a: Uterine corpus endometrial stroma sarcoma with tumor infiltrating abdominal tissues at one site. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIIA Uterine Corpus Endometrial Stromal Sarcoma AJCC v8 | Stage IIIA Uterine Corpus Endometrial Stromal Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538012","Stage IIIB Uterine Corpus Endometrial Stromal Sarcoma AJCC v8","C139889","Stage IIIB includes: T3b, N0, M0. T3b: Uterine corpus endometrial stroma sarcoma with tumor infiltrating abdominal tissues at more than one site. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIIB Uterine Corpus Endometrial Stromal Sarcoma AJCC v8 | Stage IIIB Uterine Corpus Endometrial Stromal Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538011","Stage IIIC Uterine Corpus Endometrial Stromal Sarcoma AJCC v8","C139890","Stage IIIC includes: T1-3, N1, M0. T1: Uterine corpus endometrial stroma sarcoma with tumor limited to the uterus. T2: Uterine corpus endometrial stroma sarcoma with tumor extending beyond the uterus, within the pelvis. T3: Uterine corpus endometrial stroma sarcoma with tumor infiltrating abdominal tissues. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIIC Uterine Corpus Endometrial Stromal Sarcoma AJCC v8 | Stage IIIC Uterine Corpus Endometrial Stromal Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524877","Discussion Regarding the Termination of Pregnancy Due to Cancer Diagnosis","C137831","Discussions between a physician and a pregnant cancer patient regarding the effects of anticancer drugs on the developing fetus or the possibility of long-term complications after the exposure to drugs and radiation, as well as complications to treatment, with the goal toward deciding if the pregnany should be terminated.","Discussion Regarding the Termination of Pregnancy Due to Cancer Diagnosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524876","Sentinel Lymph Node Not Identified","C137832","An indication that sentinel lymph node mapping was attempted but that it did not identify a sentinel lymph node.","Sentinel Lymph Node Not Identified | Unidentified Sentinel Lymph Node",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524603","Stage IA Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8","C136771","Stage IA includes: T1 or T2, N0, M0, Low Mitotic Rate. T1: Tumor measuring 2 cm or less. T2: Tumor measuring more than 2 cm but not more than 5 cm. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. Low Mitotic Rate: Five or fewer mitoses per 5 square millimeters, or per 50 HPF. (AJCC 8th ed.)","Stage IA Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8 | Stage IA Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST) | Stage IA Gastric and Omental GIST AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524576","Stage IB Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8","C136772","Stage IB includes: T3, N0, M0, Low Mitotic Rate. T3: Tumor measuring more than 5 cm but not more than 10 cm. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. Low Mitotic Rate: Five or fewer mitoses per 5 square millimeters, or per 50 HPF. (AJCC 8th ed.)","Stage IB Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8 | Stage IB Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST) | Stage IB Gastric and Omental GIST AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524577","Stage II Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8","C136773","Stage II includes: (T1, N0, M0, High Mitotic Rate); (T2, N0, M0, High Mitotic Rate); (T4, N0, M0, Low Mitotic Rate). T1: Tumor measuring 2 cm or less. T2: Tumor measuring more than 2 cm but not more than 5 cm. T4: Tumor measuring more than 10 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. High Mitotic Rate: Over 5 mitoses per 5 square millimeters, or per 50 HPF. Low Mitotic Rate: Five or fewer mitoses per 5 square millimeters, or per 50 HPF. (AJCC 8th ed.)","Stage II Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8 | Stage II Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST) | Stage II Gastric and Omental GIST AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524574","Stage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8","C136774","Stage III includes: IIIA: (T3, N0, M0, High Mitotic Rate); IIIB: (T4, N0, M0, High Mitotic Rate). T3: Tumor measuring more than 5 cm but not more than 10 cm. T4: Tumor measuring more than 10 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. High Mitotic Rate: Over 5 mitoses per 5 square millimeters, or per 50 HPF. (AJCC 8th ed.)","Stage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8 | Stage III Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST) | Stage III Gastric and Omental GIST AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524575","Stage IIIA Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8","C136775","Stage IIIA includes: T3, N0, M0, High Mitotic Rate. T3: Tumor measuring more than 5 cm but not more than 10 cm. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. High Mitotic Rate: Over 5 mitoses per 5 square millimeters, or per 50 HPF. (AJCC 8th ed.)","Stage IIIA Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8 | Stage IIIA Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST) | Stage IIIA Gastric and Omental GIST AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524580","PSMA-targeting Agent-Technetium Tc99m EC0652","C136776","A radioconjugate composed of 2-[3-(1, 3-dicarboxy propyl)-ureido] pentanedioic acid (DUPA), a prostate-specific membrane antigen (PSMA)-targeting ligand, linked to the radioisotope technetium Tc 99m (Tc99m), that can potentially be used as a radioimaging agent for PSMA-overexpressing tumor cells. Upon administration, the PSMA-targeting moiety of EC0652 targets and binds to PSMA-expressing tumors. Upon uptake and single-photon emission computed tomography (SPECT) imaging, PSMA-expressing tumors can be visualized and identified. In turn, PSMA-overexpression can be used to evaluate both the efficacy of and response to certain PSMA-targeting cytotoxic agents. PSMA, a tumor-associated antigen (TAA), is overexpressed by most prostate cancers.","PSMA-targeting Agent-Technetium Tc99m EC0652 | 99mTc-EC0652 | DUPA-99mTc | DUPA-99mTc EC0652 | EC 0652 | EC-0652 | EC0652 | Radiodiagnostic EC0652",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538826","Retinoblastoma pNX TNM Finding v8","C140710","Retinoblastoma in which regional lymph node involvement cannot be assessed.  (from AJCC 8th Ed.)","Retinoblastoma pNX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538841","Retinoblastoma pN0 TNM Finding v8","C140711","Retinoblastoma with no lymph node involvement. (from AJCC 8th Ed.)","Retinoblastoma pN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538840","Retinoblastoma pN1 TNM Finding v8","C140712","Retinoblastoma with regional lymph node involvement. (from AJCC 8th Ed.)","Retinoblastoma pN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538839","Retinoblastoma Pathologic Primary Tumor TNM Finding v8","C140713","A pathologic finding about one or more characteristics of retinoblastoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Retinoblastoma Pathologic Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538838","Retinoblastoma pTX TNM Finding v8","C140714","Unknown evidence of intraocular tumor. (from AJCC 8th Ed.)","Retinoblastoma pTX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538837","Retinoblastoma pT0 TNM Finding v8","C140715","No evidence of intraocular tumor. (from AJCC 8th Ed.)","Retinoblastoma pT0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538836","Retinoblastoma pT1 TNM Finding v8","C140716","Intraocular tumor(s) without any local invasion, focal choroidal invasion, or pre-or intralaminar involvement of the optic nerve head. (from AJCC 8th Ed.)","Retinoblastoma pT1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538835","Retinoblastoma pT2 TNM Finding v8","C140717","Intraocular tumor(s) with local invasion. (from AJCC 8th Ed.)","Retinoblastoma pT2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538834","Retinoblastoma pT2a TNM Finding v8","C140718","Concomitant focal choroidal invasion and pre-or intralaminar involvement of the optic nerve head. (from AJCC 8th Ed.)","Retinoblastoma pT2a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538817","Retinoblastoma pT2b TNM Finding v8","C140719","Tumor invasion of stroma of iris and/or trabecular meshwork and/or Schlemm's canal. (from AJCC 8th Ed.)","Retinoblastoma pT2b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538816","Retinoblastoma pT3 TNM Finding v8","C140720","Intraocular tumor(s) with significant local invasion. (from AJCC 8th Ed.)","Retinoblastoma pT3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538815","Retinoblastoma pT3a TNM Finding v8","C140721","Massive choroidal invasion (more than 3 mm in largest diameter, or multiple foci of focal choroidal involvement totaling more than 3 mm, or any full-thickness choroidal involvement). (from AJCC 8th Ed.)","Retinoblastoma pT3a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538814","Retinoblastoma pT3b TNM Finding v8","C140722","Retrolaminar invasion of the optic nerve head, not involving the transected end of the optic nerve. (from AJCC 8th Ed.)","Retinoblastoma pT3b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538121","Stage III Gestational Trophoblastic Neoplasm AJCC v8","C140036","Stage III includes: Any T, M1a. M1a: Gestational trophoblastic neoplasm with lung metastasis. (AJCC 8th Ed.)","Stage III Gestational Trophoblastic Neoplasm AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538120","Stage IV Gestational Trophoblastic Neoplasm AJCC v8","C140037","Stage IV includes: Any T, M1b. M1b: Gestational trophoblastic neoplasm with all other distant metastases. (AJCC 8th Ed.)","Stage IV Gestational Trophoblastic Neoplasm AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538119","NPIPB8 Gene","C140038","This gene may be involved in the function of nuclear pores.","NPIPB8 Gene | NPIPB8 | Nuclear Pore Complex Interacting Protein Family Member B8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538118","NPIPB8 wt Allele","C140039","Human NPIPB8 wild-type allele is located in the vicinity of 16p11.2 and is approximately 34 kb in length. This allele, which encodes nuclear pore complex-interacting protein family member B8 protein, may play a role in nuclear transport.","NPIPB8 wt Allele | Nuclear Pore Complex Interacting Protein Family Member B8 wt Allele | Nuclear Pore Complex Interacting Protein Family, Member B8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521403","4q26-q32","C14003","A chromosome band present on 4q","4q26-q32 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521219","2q33","C13770","A chromosome band present on 2q","2q33 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521644","7q21.3","C13771","A chromosome band present on 7q","7q21.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521209","2q22-q23","C13772","A chromosome band present on 2q","2q22-q23 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521648","7q22.1","C13773","A chromosome band present on 7q","7q22.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521698","8p12-p11.2","C13774","A chromosome band present on 8p","8p12-p11.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521481","5q23-q31","C13775","A chromosome band present on 5q","5q23-q31 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521011","1q41","C13776","A chromosome band present on 1q","1q41 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521535","6p21.1","C13777","A chromosome band present on 6p","6p21.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521613","7p12-p11.2","C13778","A chromosome band present on 7p","7p12-p11.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520183","Xq13.1","C13779","A chromosome band present on Xq","Xq13.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0121300","Hematoporphyrin Derivative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524904","Non-Human or Experimental Organism Finding","C137801","An observation based on clinical, laboratory or molecular evidence, as it relates to conditions occurring in a non-human organism; this includes observations of evidence for organisms used in research settings.","Non-Human or Experimental Organism Finding | Experimental Organism Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524903","Non-Human or Experimental Organism Non-Neoplastic Disorder","C137802","A non-neoplastic disorder affecting a non-human organism; this includes disorders occurring in organisms used in research settings.","Non-Human or Experimental Organism Non-Neoplastic Disorder | Experimental Organism Non-Neoplastic Disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538010","Stage IV Uterine Corpus Endometrial Stromal Sarcoma AJCC v8","C139891","Stage IV includes: IVA: T4, Any N, M0; IVB: Any T, Any N, M1. T4: Uterine corpus endometrial stroma sarcoma with tumor invading bladder or rectum. M0: No distant metastasis. M1: Distant metastasis (excluding adnexa, pelvic, and abdominal tissues). (from AJCC 8th Ed.)","Stage IV Uterine Corpus Endometrial Stromal Sarcoma AJCC v8 | Stage IV Uterine Corpus Endometrial Stromal Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538009","Stage IVA Uterine Corpus Endometrial Stromal Sarcoma AJCC v8","C139892","Stage IVA includes: T4, Any N, M0. T4: Uterine corpus endometrial stroma sarcoma with tumor invading bladder or rectum. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage IVA Uterine Corpus Endometrial Stromal Sarcoma AJCC v8 | Stage IVA Uterine Corpus Endometrial Stromal Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538008","Stage IVB Uterine Corpus Endometrial Stromal Sarcoma AJCC v8","C139893","Stage IVB includes: Any T, Any N, M1. M1: M1: Distant metastasis (excluding adnexa, pelvic, and abdominal tissues). (from AJCC 8th Ed.)","Stage IVB Uterine Corpus Endometrial Stromal Sarcoma AJCC v8 | Stage IVB Uterine Corpus Endometrial Stromal Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538007","Uterine Corpus Adenosarcoma by AJCC v8 Stage","C139894","A term that refers to the staging of uterine corpus adenosarcoma according to the American Joint Committee on Cancer, 8th edition.","Uterine Corpus Adenosarcoma by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538006","Stage I Uterine Corpus Adenosarcoma AJCC v8","C139895","Stage I includes: T1, N0, M0. T1: Uterine corpus adenosarcoma with tumor limited to the uterus. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage I Uterine Corpus Adenosarcoma AJCC v8 | Stage I Uterine Corpus Adenosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524578","Stage IV Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8","C136778","Stage IV includes: (Any T, N1, M0, Any Mitotic Rate); (Any T, Any N, M1, Any Mitotic Rate). N1: Regional lymph node metastasis. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8 | Stage IV Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST) | Stage IV Gastric and Omental GIST AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524579","Antibody-drug Conjugate SC-006","C136779","An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) ring finger protein 43 (RNF43), linked to a DNA crosslinking pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of anti-RNF43 ADC SC-006 targets and binds to RNF43 expressed on tumor cells. Upon binding and internalization, the cytotoxic PBD moiety is released and forms highly cytotoxic DNA interstrand cross-links, thereby blocking cell division and killing RNF43-expressing cancer cells. RNF43, a single-span transmembrane E3 ubiquitin ligase, is overexpressed by certain tumor cell types and a negative regulator of the Wnt signaling pathway.","Anti-RNF43 Antibody-drug Conjugate SC-006 | ADC SC-006 | Anti-RNF43 ADC SC-006 | Antibody-drug Conjugate SC-006 | SC 006 | SC-006 | SC006",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525087","ARQ 531","C138066","An orally available reversible inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), with potential antineoplastic activity. Upon administration, nemtabrutinib non-covalently binds to and inhibits the activity of both the wild-type and the C481S mutated form of BTK, a resistance mutation in the BTK active site in which cysteine is substituted for serine at residue 481. This prevents the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B-cells that overexpress BTK. Compared to other BTK inhibitors, nemtabrutinib does not require interaction with the BTK C481 site and inhibits the proliferation of cells harboring the BTK C481S mutation. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.","Nemtabrutinib | ARQ 531 | ARQ-531 | ARQ531 | BTK Inhibitor ARQ 531 | Bruton's Tyrosine Kinase Inhibitor ARQ 531 | MK-1026 | NEMTABRUTINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512665","Immunoglobulin Domains","C13806","The major histocompatibility complex (MHC) molecules are made of 2 chains, alpha and beta. In class I, the alpha chain is composed of 3 extracellular domains, a transmembrane region and a cytoplasmic tail while the beta chain is of a single extracellular domain. In class II, both the alpha and the beta chains are composed of 2 extracellular domains, a transmembrane region and a cytoplasmic tail. The immunoglobulin (Ig) constant chain domains and a single extracellular domain in each type of MHC chains are homologous and approximately one hundred amino acids long, and include a conserved intra-domain disulfide bond. Members of the immunoglobulin superfamily are found in hundreds of proteins of different functions, e.g., antibodies, the giant muscle kinase titin and receptor tyrosine kinases. Immunoglobulin-like domains may be involved in protein-protein and protein-ligand interactions. (InterPro IPR007110)","Immunoglobulin Domain | Immunoglobulin-Like Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538117","Nuclear Pore Complex-Interacting Protein Family Member B8","C140040","Nuclear pore complex-interacting protein family member B8 (432 aa, ~50 kDa) is encoded by the human NPIPB8 gene. This protein may be involved in nuclear pore-dependent transport.","Nuclear Pore Complex-Interacting Protein Family Member B8 | NPIPB8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538225","MK 7684","C140041","An antagonistic agent targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT; T-cell immunoreceptor with Ig and ITIM domains; T-cell immunoglobulin and ITIM domain), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, vibostolimab targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs) and natural killer (NK) cells, thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5), which are expressed on T-cells, NK cells and certain cancer cells. This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as NK cells and CD8+ T-cells, and activates CD226-mediated signaling. This activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family and an immune inhibitory receptor, is overexpressed on tumor antigen-specific CD8+ T-cells and CD8+ TILs and plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","Vibostolimab | MK 7684 | MK-7684 | MK7684 | T-cell Immunoglobulin and Immunoreceptor Tyrosine-based Inhibitory Motif Inhibitor MK-7684 | TIGIT Inhibitor MK-7684 | TIGIT-targeting Agent MK-7684 | VIBOSTOLIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538224","Male Reproductive System Cancer TNM Finding v8","C140043","A finding about one or more characteristics of male reproductive system cancer, following the rules of the TNM AJCC v8 classification system. This classification system applies to penile cancer, prostate cancer, and testicular cancer.","Male Reproductive System Cancer TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538222","Penile Cancer Clinical TNM Finding v8","C140045","A clinical finding about one or more characteristics of penile cancer, following the rules of the TNM AJCC v8 classification system.","Penile Cancer Clinical TNM Finding v8 | Penile Squamous Cell Carcinoma Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538221","Penile Cancer Clinical Distant Metastasis TNM Finding v8","C140046","A clinical finding about one or more characteristics of penile cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Penile Cancer Clinical Distant Metastasis TNM Finding v8 | Penile Squamous Cell Carcinoma Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538220","Penile Cancer cM0 TNM Finding v8","C140047","Penile cancer without evidence of distant metastasis. (from AJCC 8th Ed.)","Penile Cancer cM0 TNM Finding v8 | Penile Squamous Cell Carcinoma cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538219","Penile Cancer cM1 TNM Finding v8","C140048","Penile cancer with distant metastasis present. (from AJCC 8th Ed.)","Penile Cancer cM1 TNM Finding v8 | Penile Squamous Cell Carcinoma cM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538233","Penile Cancer Clinical Regional Lymph Nodes TNM Finding v8","C140049","A clinical finding about one or more characteristics of penile cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Penile Cancer Clinical Regional Lymph Nodes TNM Finding v8 | Penile Squamous Cell Carcinoma Clinical Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524501","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs Clinical TNM Finding v8","C136725","A clinical finding about one or more characteristics of soft tissue sarcoma of the abdomen and thoracic visceral organs, following the rules of the TNM AJCC v8 classification system.","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs Clinical TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524498","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs Clinical Distant Metastasis TNM Finding v8","C136726","A clinical finding about one or more characteristics of soft tissue sarcoma of the abdomen and thoracic visceral organs, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs Clinical Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524505","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs Pathologic TNM Finding v8","C136729","A pathologic finding about one or more characteristics of soft tissue sarcoma of the abdomen and thoracic visceral organs, following the rules of the TNM AJCC v8 classification system.","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs Pathologic TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517692","LIM Domain","C13672","The LIM domain is a zinc binding, cysteine rich motif consisting of two tandemly repeated zinc fingers. Unlike GATA type zinc fingers, LIM domains do not bind DNA but instead mediate protein-protein interactions. Functionally, LIM domain containing proteins have been implicated in cell lineage specification, cytoskeletal organization, and organ development.","LIM Domain | CRR Domain | Cysteine Rich Region",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524502","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs Pathologic Distant Metastasis TNM Finding v8","C136730","A pathologic finding about one or more characteristics of soft tissue sarcoma of the abdomen and thoracic visceral organs, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs Pathologic Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524508","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs Pathologic Primary Tumor TNM Finding v8","C136732","A pathologic finding about one or more characteristics of soft tissue sarcoma of the abdomen and thoracic visceral organs, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs Pathologic Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521374","4p14-q21","C14009","A chromosome band present on 4p","4p14-q21 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0917878","NK-631 (peplomycin sulfate)","C1400","The sulfate salt of the bleomycin analogue peplomycin.  Peplomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals that cause single- and double-stranded breaks in DNA.  This agent appears to show greater antitumor activity than bleomycin; its use is limited due to pulmonary toxicity. (NCI04)","Peplomycin Sulfate | N1-(3-(((S)-(alpha-methylbenzyl))amino)propyl)bleomycinamide Sulfate (1:1) (Salt) | NK-631 | PEPLOMYCIN SULFATE | Pepleo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525065","Sulfur Hexafluoride Lipid Microspheres","C138075","A contrast agent composed of lipid microspheres containing an inorganic fluorinated inert gas comprised of six fluoride atoms bound to one sulfur atom (SF6), with potential contrast enhancing activity for diagnostic imaging during ultrasound procedures. Upon administration of the sulfur hexafluoride lipid microspheres, the microspheres are distributed throughout the bloodstream and into organs. The acoustic impedance of the lipid microspheres is much lower than that of the surrounding tissue and/or fluids. Therefore during ultrasound imaging, this agent reflects the ultrasound waves at the microsphere-tissue interface, which enhances the contrast between the areas where the microspheres are present and the surrounding tissues or fluids.","Sulfur Hexafluoride Lipid Microspheres | Lumason | SF6 Lipid Microspheres | Sulfur Hexafluoride Lipid-type A Microspheres",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524768","Rainbow Trout Mesothelioma","C136977","A neoplasm arising from the mesothelium that occurs in Oncorhynchus mykiss.","Rainbow Trout Mesothelioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524769","Devil Facial Tumor Disease","C136978","A transmissible neoplastic disease that occurs in the Tasmanian devil. It is spread by biting and is characterized by tumors on the face and mouth.","Devil Facial Tumor Disease | DFTD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520796","18p11.3","C13697","A chromosome band present on 18p","18p11.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524774","Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310","C136981","A formulation containing nanoparticles composed of liposomes that are conjugated to scFv antibody fragments directed against the ephrin receptor A2 (EphA2; Ephrin A2) and a proprietary prodrug of docetaxel, a poorly water-soluble, second-generation taxane analog, with potential antineoplastic activity. Upon intravenous administration of the anti-EphA2 antibody-directed liposomal docetaxel prodrug MM-310, the anti-EphA2 moiety selectively targets and binds to cells expressing EphI3:I12A2. Following accumulation of MM-310, docetaxel is slowly released from MM-310 and accumulates at the tumor site due to the unique characteristics of the tumor vasculature. In turn, docetaxel is taken up by tumor cells, where it binds to and stabilizes the beta-subunit of tubulin, thereby stabilizing microtubules and inhibiting microtubule disassembly. This results in cell cycle arrest and the induction of cell death. The cell-surface receptor EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) that are involved in mammalian development, is overexpressed by a variety of cancer cell types and plays an important role in tumor growth; its expression is associated with poor prognosis. Compared to free docetaxel, MM-310 increases docetaxel's half-life, and provides enhanced and specific accumulation in EphA2-expressing tumors, thereby increasing docetaxel's efficacy while lowering its systemic toxicity.","Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310 | Anti-EphA2 Antibody-targeted Nanoliposome MM-310 | Anti-EphA2 Docetaxel-based Nanoliposome MM-310 | EphA2-targeted Docetaxel Nanoliposome MM-310 | MM 310 | MM-310 | MM310",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524771","TCR-specific, alpha Fetoprotein-enhanced Autologous T Lymphocytes","C136982","A preparation of human autologous T-lymphocytes transduced with a viral vector encoding for a T-cell receptor (TCR) specific for human alpha-fetoprotein (AFP), with potential antineoplastic activity. Following administration, the TCR-specific, alpha fetoprotein-enhanced autologous T-lymphocytes recognize and bind to AFP antigen-positive cells, which results in lysis and killing of AFP-positive cancer cells. AFP is overexpressed in a variety of cancers.","TCR-specific, alpha Fetoprotein-enhanced Autologous T Lymphocytes | AFP-C332 CTLs | AFP-C332 T Cells | AFPC332 | Anti-AFP TCR-expressing Autologous CTLs | Autologous Genetically Modified AFPC332 T Cells | Autologous Genetically Modified AFPC332 T-cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538403","Testicular Cancer by AJCC v6 and v7 Stage","C140241","A term that refers to the staging of testicular cancer according to the American Joint Committee on Cancer, 6th and 7th editions.","Testicular Cancer by AJCC v6 and v7 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541321","BSND Gene","C140242","This gene is involved in chloride transport.","BSND Gene | BSND | Barttin CLCNK Type Accessory Beta Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538402","BSND wt Allele","C140243","Human BSND wild-type allele is located in the vicinity of 1p32.3 and is approximately 12 kb in length. This allele, which encodes Barttin protein, plays a role in the modulation of chloride transport. Mutation of the gene is associated with Bartter syndrome with sensorineural deafness.","BSND wt Allele | BART | Bartter Syndrome, Infantile, With Sensorineural Deafness (Barttin) 2 Gene | Barttin CLCNK Type Accessory Beta Subunit wt Allele | DFNB73 | Deafness, Autosomal Recessive 73 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1448189","BSND protein, human","C140244","Barttin (320 aa, ~35 kDa) is encoded by the human BSND gene. This protein is involved in chloride transport.","Barttin | BSND | Barttin CLCNK-Type Chloride Channel Accessory Beta Subunit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538415","GPR15 Gene","C140245","This gene plays a role in T-cell homing.","GPR15 Gene | G Protein-Coupled Receptor 15 Gene | GPR15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538414","GPR15 wt Allele","C140246","Human GPR15 wild-type allele is located in the vicinity of 3q11.2 and is approximately 1 kb in length. This allele, which encodes G-protein coupled receptor 15 protein, is involved in the migration of regulatory T-cells (Tregs).","GPR15 wt Allele | BOB | G Protein-Coupled Receptor 15 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447488","GPR15 protein, human","C140247","G-protein coupled receptor 15 (360 aa, ~41 kDa) is encoded by the human GPR15 gene. This protein plays a role in the modulation of T-cell migration.","G-Protein Coupled Receptor 15 | BoB | Brother of Bonzo | G Protein-Coupled Receptor 15 | GPR15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520992","1q22","C14024","A chromosome band present on 1q","1q22 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538410","HRAS NM_005343.3:c.35G>T","C140250","A nucleotide substitution at position 35 of the coding sequence of the HRAS gene where guanine has been mutated to thymine.","HRAS NM_005343.3:c.35G>T | C-H-RAS c.35G>T | C-HA-RAS1 c.35G>T | H-ras c.35G>T | HRAS c.35G>T | HRAS1 c.35G>T | HRas Proto-Oncogene, GTPase c.35G>T | Ha-ras c.35G>T | Harvey Rat Sarcoma Viral Oncogene Homolog c.35G>T | NM_005343.3:c.35G>T | RASH1 c.35G>T | v-Ha-ras Harvey Rat Sarcoma Viral Oncogene Homolog c.35G>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538409","HRAS Protein Variant","C140251","A variation in the amino acid sequence for the GTPase HRas protein.","HRAS Protein Variant | GTPase HRas Protein Variant | H-Ras Protein Variant | H-Ras-1 Protein Variant | Ha-Ras Protein Variant | Ha-Ras1 Protein Variant | Harvey Rat Sarcoma Viral Oncoprotein Protein Variant | c-H-ras Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538581","Stage I Urethral Cancer AJCC v8","C140460","Stage I includes: T1, N0, M0. T1: For male penile urethra and female urethra: Tumor invades subepithelial connective tissue. For prostatic urethra: Tumor invades urethral subepithelial connective tissue immediately underlying the urothelium. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Urethral Cancer AJCC v8 | Stage I Urethral Cancer | Stage I Urethral Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525008","AC Followed by Docetaxel/Trastuzumab Regimen","C138029","A regimen consisting of cyclophosphamide and doxorubicin followed by docetaxel and trastuzumab, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.","AC Followed by Docetaxel/Trastuzumab Regimen | AC Followed by Docetaxel + Trastuzumab | AC-Docetaxel + Trastuzumab | AC-T Plus Trastuzumab | AC-TH | AC-TH (Docetaxel) | AC-TH (Docetaxel) (trastuzumab-anns) | AC-TH (Docetaxel) (trastuzumab-dkst) | AC-TH (Docetaxel) (trastuzumab-dttb) | AC-TH (Docetaxel) (trastuzumab-herw) | AC-TH (Docetaxel) (trastuzumab-pkrb) | AC-TH (Docetaxel) (trastuzumab-qyyp) | AC-TH (Docetaxel) (trastuzumab-strf) | AC-TH (Docetaxel) (trastuzumab-zerc) | AC-Taxotere/Herceptin | Doxorubicin/Cyclophosphamide Followed by Docetaxel + Trastuzumab | Doxorubicin/Cyclophosphamide Followed by Docetaxel/Trastuzumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162806","Beta Sheet","C13802","In a b-sheet two or more polypeptide chains run alongside each other and are linked in a regular manner by hydrogen bonds between the main chain C=O and N-H groups. The R-groups (side chains) of neighbouring residues in a b-strand point in opposite directions; beta sheets can be parallel, anti-parallel or mixed. (from expasy.org)","Beta Sheet | Beta Pleated Sheet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525006","AC Followed by Pertuzumab/Trastuzumab/Docetaxel Regimen","C138031","A regimen consisting of cyclophosphamide and doxorubicin followed by pertuzumab, trastuzumab, and docetaxel, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.","AC Followed by Pertuzumab/Trastuzumab/Docetaxel Regimen | AC Followed by Docetaxel + Pertuzumab + Trastuzumab | AC Followed by Docetaxel + Trastuzumab + Pertuzumab | AC Followed by Pertuzumab + Trastuzumab + Docetaxel | AC Followed by Pertuzumab-Trastuzumab-Docetaxel Regimen | AC-Pertuzumab + Trastuzumab + Docetaxel | AC-THP (Docetaxel) | AC-THP (Docetaxel) (trastuzumab-anns) | AC-THP (Docetaxel) (trastuzumab-dkst) | AC-THP (Docetaxel) (trastuzumab-dttb) | AC-THP (Docetaxel) (trastuzumab-herw) | AC-THP (Docetaxel) (trastuzumab-pkrb) | AC-THP (Docetaxel) (trastuzumab-qyyp) | AC-THP (Docetaxel) (trastuzumab-strf) | AC-THP (Docetaxel) (trastuzumab-zerc) | Doxorubicin/Cyclophosphamide Followed by Pertuzumab + Trastuzumab + Docetaxel | Doxorubicin/Cyclophosphamide Followed by Pertuzumab/Trastuzumab/Docetaxel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1541534","Capecitabine/Trastuzumab Regimen","C138033","A regimen consisting of capecitabine and trastuzumab that can be used for the treatment of breast, esophageal and esophagogastric junction and gastric cancers.","Capecitabine/Trastuzumab Regimen | Capecitabine + Trastuzumab | Capecitabine Plus Trastuzumab | Capecitabine and Trastuzumab (XH) | Capecitabine and Trastuzumab-anns (XH) | Capecitabine and Trastuzumab-dkst (XH) | Capecitabine and Trastuzumab-dttb (XH) | Capecitabine and Trastuzumab-herw (XH) | Capecitabine and Trastuzumab-pkrb (XH) | Capecitabine and Trastuzumab-qyyp (XH) | Capecitabine and Trastuzumab-strf (XH) | Capecitabine and Trastuzumab-zerc (XH) | Capecitabine-Trastuzumab | Capecitabine-Trastuzumab Regimen | Capecitabine/Trastuzumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525011","Docetaxel + Cyclophosphamide + Trastuzumab","C138034","A regimen consisting of docetaxel, cyclophosphamide and trastuzumab that can be used in the treatment of breast cancer.","Cyclophosphamide/Docetaxel/Trastuzumab Regimen | Docetaxel + Cyclophosphamide + Trastuzumab | Docetaxel-Cyclophosphamide-Trastuzumab | Docetaxel-Cyclophosphamide-Trastuzumab Regimen | Docetaxel/Cyclophosphamide + Trastuzumab | Docetaxel/Cyclophosphamide Plus Trastuzumab | Docetaxel/Cyclophosphamide/Trastuzumab Regimen | TC-H (Docetaxel) | TC-H (Docetaxel) (trastuzumab-anns) | TC-H (Docetaxel) (trastuzumab-dkst) | TC-H (Docetaxel) (trastuzumab-dttb) | TC-H (Docetaxel) (trastuzumab-herw) | TC-H (Docetaxel) (trastuzumab-pkrb) | TC-H (Docetaxel) (trastuzumab-qyyp) | TC-H (Docetaxel) (trastuzumab-strf) | TC-H (Docetaxel) (trastuzumab-zerc) | TCH (Docetaxel) (trastuzumab-anns) | TCH (Docetaxel) (trastuzumab-dkst) | TCH (Docetaxel) (trastuzumab-dttb) | TCH (Docetaxel) (trastuzumab-herw) | TCH (Docetaxel) (trastuzumab-pkrb) | TCH (Docetaxel) (trastuzumab-qyyp) | TCH (Docetaxel) (trastuzumab-zerc) | TCH (Docetaxel, Cyclophosphamide) | TCyH (Docetaxel) (trastuzumab-qyyp) | TCyH (Docetaxel) (trastuzumab-strf)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525010","Dose-dense AC Regimen","C138035","A regimen consisting of doxorubicin and cyclophosphamide, used as a neoadjuvant or adjuvant treatment for breast cancer.","Dose-dense AC Regimen | DD AC | DDAC | Dose-dense AC | Dose-dense Adriamycin/Cytoxan | Dose-dense Cyclophosphamide and Doxorubicin (ddAC) | Dose-dense Doxorubicin-Cyclophosphamide Regimen | Dose-dense Doxorubicin/Cyclophosphamide | ddAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538463","ILF2 wt Allele","C140308","Human ILF2 wild-type allele is located in the vicinity of 1q21.3 and is approximately 9 kb in length. This allele, which encodes interleukin enhancer-binding factor 2 protein, is involved in DNA repair, mRNA localization, the modulation of IL2 gene expression.","ILF2 wt Allele | Interleukin Enhancer Binding Factor 2 wt Allele | Interleukin Enhancer Binding Factor 2, 45kD Gene | Interleukin Enhancer Binding Factor 2, 45kDa Gene | NF45 | Nuclear Factor of Activated T-Cells, 45-kDa Gene | PRO3063",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527442","ILF2 protein, human","C140309","Interleukin enhancer-binding factor 2 (390 aa, ~43 kDa) is encoded by the human ILF2 gene. This protein plays a role in the regulation of IL2 gene transcription, nonhomologous end joining DNA repair and mRNA export.","Interleukin Enhancer-Binding Factor 2 | ILF2 | Nuclear Factor of Activated T-Cells 45 kDa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521066","20q13.2-q13.3","C14030","A chromosome band present on 20q","20q13.2-q13.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538477","Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing Memory T-lymphocytes bb21217","C140310","A preparation of autologous memory T-lymphocytes transduced, ex vivo, with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-B-cell maturation antigen (BCMA) single chain variable fragment (scFv) fused to the signaling domain of 4-1BB (CD137) and a CD3-zeta T-cell activation domain, with potential immunostimulating and antineoplastic activities. Upon intravenous administration back into the patient, the autologous anti-BCMA-CAR-4-1BB-CD3zeta-expressing memory T-lymphocytes bb21217 are directed to, and induce selective toxicity in, BCMA-expressing tumor cells. BCMA, a tumor specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma survival. BCMA is overexpressed on malignant plasma cells.","Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing Memory T-lymphocytes bb21217 | Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing Memory T-Cells bb21217 | BB 21217 | bb-21217 | bb21217",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538475","NELFE wt Allele","C140312","Human NELFE wild-type allele is located in the vicinity of 6p21.33 and is approximately 7 kb in length. This allele, which encodes negative elongation factor E protein, plays a role in transcript elongation and RNA binding.","NELFE wt Allele | D6S45 | Major Histocompatibility Complex Gene RD | NELF-E | Negative Elongation Factor Complex Member E wt Allele | RD | RDBP | RDP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0084297","major histocompatibility complex protein RD, human","C140314","Negative elongation factor E (380 aa, ~43 kDa) is encoded by the human NELFE gene. This protein is involved in RNA binding and the regulation of transcript elongation.","Negative Elongation Factor E | NELF-E | NELFE | Negative Elongation Factor Polypeptide E | RD RNA Binding Protein | RD RNA-Binding Protein | RNA-Binding Protein RD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538646","Stage III Eyelid Carcinoma AJCC v8","C140522","Stage III includes: IIIA: Any T, N1, M0; IIIB: Any T, N2, M0. N1: Metastasis in a single ipsilateral regional lymph node, measuring 3 cm or less in greatest dimension. N2: Metastasis in a single ipsilateral regional lymph node, measuring more than 3 cm in greatest dimension, or in bilateral or contralateral lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Eyelid Carcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538645","Stage IIIA Eyelid Carcinoma AJCC v8","C140523","Stage IIIA includes: Any T, N1, M0. N1: Metastasis in a single ipsilateral regional lymph node, measuring 3 cm or less in greatest dimension. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIA Eyelid Carcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538644","Stage IIIB Eyelid Carcinoma AJCC v8","C140524","Stage IIIB includes: Any T, N2, M0. N2: Metastasis in a single ipsilateral regional lymph node, measuring more than 3 cm in greatest dimension, or in bilateral or contralateral lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","Stage IIIB Eyelid Carcinoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524772","B7-H3 x CD3 DART Protein","C136983","An Fc-bearing humanized bispecific dual-affinity re-targeting (DART) protein composed of Fv regions derived from monoclonal antibodies against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration of obrindatamab, the anti-B7-H3 component targets and binds to the cell surface antigen B7-H3; at the same time, the anti-CD3 component binds to human CD3. This cross-links the T-cells to B7-H3-expressing tumor cells, activates and redirects endogenous T-cells to kill B7-H3-expressing tumor cells, and inhibits proliferation of B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells but is minimally expressed by normal human tissues. B7-H3 is a negative regulator of T-cell activation and its overexpression plays a key role in immuno-evasion, tumor cell invasion and metastasis, and its expression is correlated with poor prognosis.","Obrindatamab | B7-H3 x CD3 DART Protein | B7-H3 x CD3 Dual-affinity Re-targeting Protein MGD009 | DART Protein MGD009 | Dual-affinity B7-H3/CD3-targeted Protein MGD009 | MGD 009 | MGD-009 | MGD009 | OBRINDATAMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524746","Chinese Herbal Medicine YQ1","C136984","A Chinese herbal medicine, with potential immunostimulating and antineoplastic activities. Although the mechanism of action is currently unknown, upon administration, YQ1 may cause an induction of apoptosis and an inhibition of tumor cell proliferation. YQ1 might target cancer stem cells (CSCs).","Chinese Herbal Medicine YQ1 | YQ1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524880","Ultrasound-Guided Fine-Needle Aspiration","C137833","The use of ultrasound imaging to guide needle aspiration.","Ultrasound-Guided Fine-Needle Aspiration | Ultrasound-Guided Fine Needle Aspiration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524879","Ultrasound-Guided Core Biopsy","C137834","The use of ultrasound imaging to guide core biopsy.","Ultrasound-Guided Core Biopsy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524884","PX-478 Free Base","C137838","No value exists.","PX-478 Free Base | PX-478 FREE BASE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521304","3q13.31","C13783","A chromosome band present on 3q","3q13.31 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538564","Stage II Urethral Cancer AJCC v8","C140461","Stage II includes: T2, N0, M0. T2: For male penile urethra and female urethra: Tumor invades any of the following: corpus spongiosum, periurethral muscle. For prostatic urethra: Tumor invades the prostatic stroma surrounding ducts either by direct extension from the urothelial surface or by invasion from prostatic ducts. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Urethral Cancer AJCC v8 | Stage II Urethral Cancer | Stage II Urethral Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538563","Stage III Urethral Cancer AJCC v8","C140462","Stage III includes: (T1, N1, M0); (T2, N1, M0); (T3, N0, M0); (T3, N1, M0). T1: For male penile urethra and female urethra: Tumor invades subepithelial connective tissue. For prostatic urethra: Tumor invades urethral subepithelial connective tissue immediately underlying the urothelium. T2: For male penile urethra and female urethra: Tumor invades any of the following: corpus spongiosum, periurethral muscle. For prostatic urethra: Tumor invades the prostatic stroma surrounding ducts either by direct extension from the urothelial surface or by invasion from prostatic ducts. T3: For male penile urethra and female urethra: Tumor invades any of the following: corpus cavernosum, anterior vagina. For prostatic urethra: Tumor invades the periprostatic fat. N0: No regional lymph node metastasis. N1: Single regional lymph node metastasis in the inguinal region or true pelvis [perivesical, obturator, internal (hypogastric) and external iliac], or presacral lymph node. M0: No distant metastasis. (AJCC 8th ed.)","Stage III Urethral Cancer AJCC v8 | Stage III Urethral Cancer | Stage III Urethral Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538562","Stage IV Urethral Cancer AJCC v8","C140463","Stage IV includes: (T4, N0, M0); (T4, N1, M0); (Any T, N2, M0); (Any T, Any N, M1). T4: For male penile urethra and female urethra: Tumor invades other adjacent organs (e.g., invasion of the bladder wall). For prostatic urethra: Tumor invades other adjacent organs (e.g., extraprostatic invasion of the bladder wall, rectal wall). N0: No regional lymph node metastasis. N1: Single regional lymph node metastasis in the inguinal region or true pelvis [perivesical, obturator, internal (hypogastric) and external iliac], or presacral lymph node. N2: Multiple regional lymph node metastasis in the inguinal region or true pelvis [perivesical, obturator, internal (hypogastric) and external iliac], or presacral lymph node. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Urethral Cancer AJCC v8 | Stage IV Urethral Cancer | Stage IV Urethral Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538561","Urethral Cancer by AJCC v7 Stage","C140464","A term that refers to the staging of urethral cancer according to the American Joint Committee on Cancer, 7th edition.","Urethral Cancer by AJCC v7 Stage | Urethral Carcinoma by AJCC v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538559","Foramen Ovale of the Skull","C140467","An opening in the sphenoid bone at the base of the skull where several nerves, arteries, and veins exit the skull.","Foramen Ovale of the Skull | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0223685","Neck of the Humerus, Surgical","C140468","The constriction on the proximal end of the humerus just below the tuberosities of the humerus.","Neck of the Humerus, Surgical | ",,,,,,,,,,,,,,,"4282328","Structure of surgical neck of humerus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL538572","Ophthalmic Sites Cancer TNM Finding v8","C140469","A finding about one or more characteristics of ophthalmic sites cancer, following the rules of the TNM AJCC v8 classification system.","Ophthalmic Sites Cancer TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521459","5p15.1-p14","C14046","A chromosome band present on 5p","5p15.1-p14 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538570","Eyelid Carcinoma Clinical TNM Finding v8","C140471","A clinical finding about one or more characteristics of eyelid carcinoma, following the rules of the TNM AJCC v8 classification system.","Eyelid Carcinoma Clinical TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537921","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pNX TNM Finding v8","C139838","Uterine corpus leiomyosarcoma or endometrial stromal sarcoma in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pNX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525015","Dose-dense AC Followed by Paclitaxel Regimen","C138037","A regimen consisting of doxorubicin and cyclophosphamide followed by paclitaxel, used as a neoadjuvant or adjuvant treatment for breast cancer.","Dose-dense AC Followed by Paclitaxel Regimen | Dose-dense AC Followed by Paclitaxel | Dose-dense AC Regimen Followed by Paclitaxel | Dose-dense AC-T | Dose-dense AC-Taxol | Dose-dense Adriamycin/Cytoxan Followed by Paclitaxel | Dose-dense Doxorubicin/Cyclophosphamide Followed by Paclitaxel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525014","FEC Followed by Pertuzumab/Trastuzumab/Docetaxel Regimen","C138038","A regimen consisting of fluorouracil, epirubicin and intravenous cyclophosphamide, followed by pertuzumab, trastuzumab and docetaxel, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.","FEC Followed by Pertuzumab/Trastuzumab/Docetaxel Regimen | FEC Followed by Docetaxel/Trastuzumab/Pertuzumab | FEC Followed by Pertuzumab + Trastuzumab + Docetaxel | FEC-THP (Docetaxel) | FEC-THP (Docetaxel) (trastuzumab-anns) | FEC-THP (Docetaxel) (trastuzumab-dkst) | FEC-THP (Docetaxel) (trastuzumab-dttb) | FEC-THP (Docetaxel) (trastuzumab-herw) | FEC-THP (Docetaxel) (trastuzumab-pkrb) | FEC-THP (Docetaxel) (trastuzumab-qyyp) | FEC-THP (Docetaxel) (trastuzumab-strf) | FEC-THP (Docetaxel) (trastuzumab-zerc) | Fluorouracil/Epirubicin/Cyclophosphamide Followed by Pertuzumab + Trastuzumab + Docetaxel | Fluorouracil/Epirubicin/Cyclophosphamide Followed by Pertuzumab/Trastuzumab/Docetaxel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515468","8q24.11-q24.13","C13692","A chromosome band present on 8q","8q24.11-q24.13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524791","Cutaneous Melanoma Pathologic Primary Tumor TNM Finding v8","C136937","A pathologic finding about one or more characteristics of cutaneous melanoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Cutaneous Melanoma Pathologic Primary Tumor TNM Finding v8 | Melanoma of the Skin Pathologic Primary Tumor TNM Finding v8 | Pathologic Staging: Primary Tumor (pT)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520358","11p12-p11","C13693","A chromosome band present on 11p","11p12-p11 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538627","Conjunctival Carcinoma TNM Finding v8","C140527","A finding about one or more characteristics of conjunctival carcinoma, following the rules of the TNM AJCC v8 classification system. This classification system applies only to carcinoma of the conjunctiva. Other tumors of the conjunctiva, including secondary conjunctival tumors (e.g., intraocular tumors extending through the conjunctiva, such as uveal melanoma or uveal non-Hodgkin lymphoma, and orbital tumors extending into the conjunctiva, such as rhabdomyosarcoma), are not classified using this schema. Conjunctival lymphomas are staged according to the classification for ocular adnexal lymphoma and conjunctival melanomas are staged according to the classification for conjunctival melanoma. There is no proposal for anatomic stage and prognostic groups for conjunctival carcinoma. (from AJCC 8th Ed.)","Conjunctival Carcinoma TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538626","Conjunctival Carcinoma Clinical TNM Finding v8","C140528","A clinical finding about one or more characteristics of conjunctival carcinoma, following the rules of the TNM AJCC v8 classification system.","Conjunctival Carcinoma Clinical TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538625","Conjunctival Carcinoma Clinical Distant Metastasis TNM Finding v8","C140529","A clinical finding about one or more characteristics of conjunctival carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Conjunctival Carcinoma Clinical Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513803","Myristic Acylation Site","C14052","It refers to amino acid residue within a peptide that accepts covalent linkage of fatty acid, myristoyl group (C13H27-) as one of the co-translational modifications. N-myristoylation, catalyzed by N-myristoyltransferase, is the amide modification of proteins by the addition of a myristoyl group to an N-terminal glycine residue. (NCI)","Myristic Acylation Site | Myristoylation Site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538624","Conjunctival Carcinoma cM0 TNM Finding v8","C140530","Conjunctival carcinoma with no distant metastasis. (from AJCC 8th Ed.)","Conjunctival Carcinoma cM0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538623","Conjunctival Carcinoma cM1 TNM Finding v8","C140531","Conjunctival carcinoma with distant metastasis. (from AJCC 8th Ed.)","Conjunctival Carcinoma cM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538621","Conjunctival Carcinoma Pathologic Distant Metastasis TNM Finding v8","C140533","A pathologic finding about one or more characteristics of conjunctival carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Conjunctival Carcinoma Pathologic Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538635","Conjunctival Carcinoma pM1 TNM Finding v8","C140534","Conjunctival carcinoma with distant metastasis. (from AJCC 8th Ed.)","Conjunctival Carcinoma pM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538634","Conjunctival Carcinoma Pathologic Primary Tumor TNM Finding v8","C140535","A pathologic finding about one or more characteristics of conjunctival carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Conjunctival Carcinoma Pathologic Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538633","Conjunctival Carcinoma pTX TNM Finding v8","C140536","Conjunctival carcinoma in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Conjunctival Carcinoma pTX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538005","Stage IA Uterine Corpus Adenosarcoma AJCC v8","C139896","Stage IA includes: T1a, N0, M0. T1a: Uterine corpus adenosarcoma with tumor limited to the endometrium/endocervix. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IA Uterine Corpus Adenosarcoma AJCC v8 | Stage IA Uterine Corpus Adenosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524867","Central Lumpectomy with Resection of the Nipple-Areolar Complex","C137848","Breast-sparing surgery that removes diseased tissue from the central part of the breast, including the nipple and areola.","Central Lumpectomy with Resection of the Nipple-Areolar Complex | Central Lumpectomy Including Excision of the Nipple-Areolar Complex | Central Lumpectomy Including NAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524866","Biopsy of Nipple and Areola","C137849","Removal of tissue from the nipple and areola for microscopic examination.","Biopsy of Nipple and Areola | Biopsy of NAC | Biopsy of the Nipple-Areolar Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515469","8q24.12","C13784","A chromosome band present on 8q","8q24.12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524869","Full-thickness Skin Biopsy of Nipple and Areola","C137850","Removal of full-thickness skin tissue from the nipple and areola for microscopic examination.","Full-Thickness Skin Biopsy of Nipple and Areola | Full-Thickness Skin Biopsy of NAC | Full-Thickness Skin Biopsy of Nipple-Areolar Complex | Full-thickness Skin Biopsy of NAC | Full-thickness Skin Biopsy of Nipple and Areola | Full-thickness Skin Biopsy of Nipple-Areolar Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524868","Core Biopsy of Breast","C137851","The removal of breast tissue using a needle with a relatively large diameter, for microscopic examination.","Core Biopsy of Breast | Breast Core Biopsy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521547","6p24","C13677","A chromosome band present on 6p","6p24 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524584","Stage I Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8","C136780","Stage I includes: T1 or T2, N0, M0, Low Mitotic Rate. T1: Tumor measuring 2 cm or less. T2: Tumor measuring more than 2 cm but not more than 5 cm. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. Low Mitotic Rate: Five or fewer mitoses per 5 square millimeters, or per 50 HPF. (AJCC 8th ed.)","Stage I Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8 | Stage I Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal GIST AJCC v8 | Stage I Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor (GIST)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524585","Stage II Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8","C136781","Stage II includes: T3, N0, M0, Low Mitotic Rate. T3: Tumor measuring more than 5 cm but not more than 10 cm. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. Low Mitotic Rate: Five or fewer mitoses per 5 square millimeters, or per 50 HPF. (AJCC 8th ed.)","Stage II Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8 | Stage II Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal GIST AJCC v8 | Stage II Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor (GIST)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537920","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pN0 TNM Finding v8","C139839","Uterine corpus leiomyosarcoma or endometrial stromal sarcoma with no regional lymph node metastasis. (from AJCC 8th Ed.)","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021721","Cell Junction","C13983","Cell junction is the specialized focal contact between cell-cell or cell-matrix in all tissues.  Cell junctions have various functions either communication, anchoring or organization.  There are specific protein associated with subtype of cell junctions and most of the junctions are too small to be resolved by light microscope.","Cell Junction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537919","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pN0(i+) TNM Finding v8","C139840","Uterine corpus leiomyosarcoma or endometrial stromal sarcoma with isolated tumor cells in regional lymph node(s) no greater than 0.2 mm. (from AJCC 8th Ed.)","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pN0(i+) TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537934","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pN1 TNM Finding v8","C139841","Uterine corpus leiomyosarcoma or endometrial stromal sarcoma with regional lymph node metastasis. (from AJCC 8th Ed.)","Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pN1 TNM Finding v8 | Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma FIGO Stage IIIC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537933","Uterine Corpus Adenosarcoma TNM Finding v8","C139842","A finding about one or more characteristics of uterine corpus adenosarcoma, following the rules of the TNM AJCC v8 classification system.","Uterine Corpus Adenosarcoma TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537931","Uterine Corpus Adenosarcoma Clinical Distant Metastasis TNM Finding v8","C139844","A clinical finding about one or more characteristics of uterine corpus  adenosarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Uterine Corpus Adenosarcoma Clinical Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537930","Uterine Corpus Adenosarcoma cM0 TNM Finding v8","C139845","Uterine corpus adenosarcoma without evidence of distant metastasis. (from AJCC 8th Ed.)","Uterine Corpus Adenosarcoma cM0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537928","Uterine Corpus Adenosarcoma Pathologic TNM Finding v8","C139847","A pathologic finding about one or more characteristics of uterine corpus adenosarcoma, following the rules of the TNM AJCC v8 classification system.","Uterine Corpus Adenosarcoma Pathologic TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537927","Uterine Corpus Adenosarcoma Pathologic Distant Metastasis TNM Finding v8","C139848","A pathologic finding about one or more characteristics of uterine corpus adenosarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Uterine Corpus Adenosarcoma Pathologic Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538036","Uterine Corpus Adenosarcoma pM1 TNM Finding v8","C139849","Uterine corpus adenosarcoma with distant metastasis (excluding adnexa, pelvic, and abdominal tissues). (from AJCC 8th Ed.)","Uterine Corpus Adenosarcoma pM1 TNM Finding v8 | Uterine Corpus Adenosarcoma FIGO Stage IVB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0887872","Anchoring Junction","C13984","Anchoring junctions typically are observed as 'spot welds' between cells in many types of epithelia. Detail structures can be seen only with EM.","Anchoring Junction | Adhering Junction | Adhesive Junction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538035","Uterine Corpus Adenosarcoma Pathologic Primary Tumor TNM Finding v8","C139850","A pathologic finding about one or more characteristics of uterine corpus adenosarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor. The definitions of the T categories correspond to the stages accepted by FIGO. (from AJCC 8th Ed.)","Uterine Corpus Adenosarcoma Pathologic Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538034","Uterine Corpus Adenosarcoma pTX TNM Finding v8","C139851","Uterine corpus adenosarcoma in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Uterine Corpus Adenosarcoma pTX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538033","Uterine Corpus Adenosarcoma pT0 TNM Finding v8","C139852","Uterine corpus adenosarcoma with no evidence of primary tumor. (from AJCC 8th Ed.)","Uterine Corpus Adenosarcoma pT0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521580","6q27","C13780","A chromosome band present on 6q","6q27 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537989","Stage IB Uterine Corpus Adenosarcoma AJCC v8","C139897","Stage IB includes: T1b, N0, M0. T1b: Uterine corpus adenosarcoma with tumor invading to less than half of the myometrium. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IB Uterine Corpus Adenosarcoma AJCC v8 | Stage IB Uterine Corpus Adenosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537988","Stage IC Uterine Corpus Adenosarcoma AJCC v8","C139898","Stage IC includes: T1c, N0, M0. T1c: Uterine corpus adenosarcoma with tumor invading more than half of the myometrium. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IC Uterine Corpus Adenosarcoma AJCC v8 | Stage IC Uterine Corpus Adenosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537987","Stage II Uterine Corpus Adenosarcoma AJCC v8","C139899","Stage II includes: T2, N0, M0. T2: Uterine corpus adenosarcoma with tumor extending beyond the uterus, within the pelvis. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage II Uterine Corpus Adenosarcoma AJCC v8 | Stage II Uterine Corpus Adenosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520551","13q14.3","C13989","A chromosome band present on 13q","13q14.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537985","Stage IIIA Uterine Corpus Adenosarcoma AJCC v8","C139901","Stage IIIA includes: T3a, N0, M0. T3a: Uterine corpus adenosarcoma with tumor infiltrating abdominal tissues at one site. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIIA Uterine Corpus Adenosarcoma AJCC v8 | Stage IIIA Uterine Corpus Adenosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537984","Stage IIIB Uterine Corpus Adenosarcoma AJCC v8","C139902","Stage IIIB includes: T3b, N0, M0. T3b: Uterine corpus adenosarcoma with tumor infiltrating abdominal tissues at more than one site. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIIB Uterine Corpus Adenosarcoma AJCC v8 | Stage IIIB Uterine Corpus Adenosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537983","Stage IIIC Uterine Corpus Adenosarcoma AJCC v8","C139903","Stage IIIC includes: T1-3, N1, M0. T1: Uterine corpus adenosarcoma with tumor limited to the uterus. T2: Uterine corpus adenosarcoma with tumor extending beyond the uterus, within the pelvis. T3: Uterine corpus adenosarcoma with tumor infiltrating abdominal tissues. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IIIC Uterine Corpus Adenosarcoma AJCC v8 | Stage IIIC Uterine Corpus Adenosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537982","Stage IV Uterine Corpus Adenosarcoma AJCC v8","C139904","Stage IV includes: IVA: T4, Any N, M0; IVB: Any T, Any N, M1. T4: Uterine corpus adenosarcoma with tumor invading bladder or rectum. M0: No distant metastasis. M1: Distant metastasis (excluding adnexa, pelvic, and abdominal tissues). (from AJCC 8th Ed.)","Stage IV Uterine Corpus Adenosarcoma AJCC v8 | Stage IV Uterine Corpus Adenosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537996","Stage IVA Uterine Corpus Adenosarcoma AJCC v8","C139905","Stage IVA includes: T4, Any N, M0. T4: Uterine corpus adenosarcoma with tumor invading bladder or rectum. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage IVA Uterine Corpus Adenosarcoma AJCC v8 | Stage IVA Uterine Corpus Adenosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537995","Stage IVB Uterine Corpus Adenosarcoma AJCC v8","C139906","Stage IVB includes: Any T, Any N, M1. M1: M1: Distant metastasis (excluding adnexa, pelvic, and abdominal tissues). (from AJCC 8th Ed.)","Stage IVB Uterine Corpus Adenosarcoma AJCC v8 | Stage IVB Uterine Corpus Adenosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537994","NPPA Gene","C139907","This gene is involved in both cardiac homeostasis and pregnancy.","NPPA Gene | NPPA | Natriuretic Peptide A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524582","CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR","C136782","A preparation of CD4+ and CD8+ central memory (CM) T-lymphocytes isolated from the peripheral blood of a transplant donor and transduced with a lentiviral vector (LV) (pRRLSIN) expressing a minor H antigen (HA-1(H); HA1(H)) T-cell receptor (TCR) containing the suicide gene inducible caspase 9 (iCasp9 or iC9)-HA1 TCR2-RQR-CD8 transgene (pRRLSIN iC9-HA1 TCR2-RQR-CD8; HA-1 TCR LV), with potential immunostimulating and antineoplastic activities. Upon intravenous administration and after allogeneic hematopoietic stem cell transplantation (HSCT), the CD8+ and CD4+ donor memory T cells-expressing HA1-specific TCR are directed to and induce selective toxicity in HA1-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If administration of the T-cells lead to unacceptable side effects, a dimerizing agent rimiducid (AP1903), which binds to the FKBP12-F36V drug-binding domain and activates caspase 9, can be administered; caspase-9 activation results in the apoptosis of the administered TCR-modified T-cells. HA1(H) is a tumor-associated antigen (TAA) that is selectively and highly expressed on leukemic stem cells and blasts, but not in normal non-hematopoietic cells. RQR includes a CD20 epitope, and a CD34 epitope that facilitates both purification and cell tracking of the transduced T-cells with an anti-CD34 monoclonal antibody.","CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR | CD8+ and CD4+ Donor Memory T-cells-expressing pRRLSIN iC9-HA1 TCR2-RQR-CD8 | HA-1 TCR CD8+ and CD4+ Tm Cells | HA-1 TCR T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524583","Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8","C136783","Stage III includes: IIIA: (T1, N0, M0, High Mitotic Rate); (T4, N0, M0, Low Mitotic Rate); IIIB: (T2, N0, M0, High Mitotic Rate); (T3, N0, M0, High Mitotic Rate); (T4, N0, M0, High Mitotic Rate). T1: Tumor measuring 2 cm or less. T2: Tumor measuring more than 2 cm but not more than 5 cm. T3: Tumor measuring more than 5 cm but not more than 10 cm. T4: Tumor measuring more than 10 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. High Mitotic Rate: Over 5 mitoses per 5 square millimeters, or per 50 HPF. Low Mitotic Rate: Five or fewer mitoses per 5 square millimeters, or per 50 HPF. (AJCC 8th ed.)","Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8 | Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal GIST AJCC v8 | Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor (GIST)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524588","Stage IIIA Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8","C136784","Stage IIIA includes: (T1, N0, M0, High Mitotic Rate); (T4, N0, M0, Low Mitotic Rate). T1: Tumor measuring 2 cm or less. T4: Tumor measuring more than 10 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. High Mitotic Rate: Over 5 mitoses per 5 square millimeters, or per 50 HPF. Low Mitotic Rate: Five or fewer mitoses per 5 square millimeters, or per 50 HPF. (AJCC 8th ed.)","Stage IIIA Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8 | Stage IIIA Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal GIST AJCC v8 | Stage IIIA Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor (GIST)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525064","ATM Inhibitor M 3541","C138076","An orally bioavailable inhibitor of ataxia telangiectasia mutated kinase (ATM), with potential chemo-/radio-sensitizing and antineoplastic activities. Upon oral administration, M 3541 targets and binds to ATM, thereby inhibiting the kinase activity of ATM and ATM-mediated signaling. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, induces tumor cell apoptosis, and leads to cell death of ATM-overexpressing tumor cells. In addition, M 3541 sensitizes tumor cells to chemo- and radiotherapy. ATM, a serine/threonine protein kinase, is upregulated in a variety of cancer cell types; it is activated in response to DNA damage and plays a key role in DNA-strand repair.","ATM Inhibitor M 3541 | Ataxia Telangiectasia Mutated Kinase Inhibitor M 3541 | M 3541 | M3541",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL521517","Number of Pulmonary Nodules","C138077","The number of observable tumor nodules in the lungs.","Number of Pulmonary Nodules | Pulmonary Nodule Count | Pulmonary Nodule Number",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525070","Size of Persistent and Solid Component of a Sub-Solid Pulmonary Nodule","C138078","The size of the solid component of a solitary part-solid nodules, as observed through CT imaging.","Size of Persistent and Solid Component of a Sub-Solid Pulmonary Nodule | Size of Persistent and Solid Component of a Subsolid Pulmonary Nodule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512942","intraepithelial","C13807","No value exists.","Intraepithelial | intraepithelial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521283","3p21.1","C14004","A chromosome band present on 3p","3p21.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538232","Penile Cancer cNX TNM Finding v8","C140050","Penile cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Penile Cancer cNX TNM Finding v8 | Penile Squamous Cell Carcinoma cNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538231","Penile Cancer cN0 TNM Finding v8","C140051","Penile cancer with no palpable or visibly enlarged inguinal lymph nodes. (from AJCC 8th Ed.)","Penile Cancer cN0 TNM Finding v8 | Penile Squamous Cell Carcinoma cN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538230","Penile Cancer cN1 TNM Finding v8","C140052","Penile cancer with palpable mobile unilateral inguinal lymph node. (from AJCC 8th Ed.)","Penile Cancer cN1 TNM Finding v8 | Penile Squamous Cell Carcinoma cN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538229","Penile Cancer cN2 TNM Finding v8","C140053","Penile cancer with palpable mobile two or more unilateral inguinal nodes or bilateral inguinal lymph nodes. (from AJCC 8th Ed.)","Penile Cancer cN2 TNM Finding v8 | Penile Squamous Cell Carcinoma cN2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538227","Penile Cancer Pathologic TNM Finding v8","C140055","A pathologic finding about one or more characteristics of penile cancer, following the rules of the TNM AJCC v8 classification system.","Penile Cancer Pathologic TNM Finding v8 | Penile Squamous Cell Carcinoma Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538226","Penile Cancer Pathologic Distant Metastasis TNM Finding v8","C140056","A pathologic finding about one or more characteristics of penile cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Penile Cancer Pathologic Distant Metastasis TNM Finding v8 | Penile Squamous Cell Carcinoma Pathologic Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538210","Penile Cancer pM1 TNM Finding v8","C140057","Penile cancer with distant metastasis present. (from AJCC 8th Ed.)","Penile Cancer pM1 TNM Finding v8 | Penile Squamous Cell Carcinoma pM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538209","Penile Cancer Pathologic Primary Tumor TNM Finding v8","C140058","A pathologic finding about one or more characteristics of penile cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Penile Cancer Pathologic Primary Tumor TNM Finding v8 | Penile Squamous Cell Carcinoma Pathologic Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538208","Penile Cancer pTX TNM Finding v8","C140059","Penile cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Penile Cancer pTX TNM Finding v8 | Penile Squamous Cell Carcinoma pTX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521170","2p12","C14005","A chromosome band present on 2p","2p12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538207","Penile Cancer pT0 TNM Finding v8","C140060","Penile cancer with no evidence of primary tumor. (from AJCC 8th Ed.)","Penile Cancer pT0 TNM Finding v8 | Penile Squamous Cell Carcinoma pT0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538206","Penile Cancer pTis TNM Finding v8","C140061","Penile cancer with a finding of carcinoma in situ (penile intraepithelial neoplasia [PeIN]). (from AJCC 8th Ed.)","Penile Cancer pTis TNM Finding v8 | Penile Squamous Cell Carcinoma pTis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538205","Penile Cancer pTa TNM Finding v8","C140062","Penile cancer with a finding of noninvasive localized squamous cell carcinoma. (from AJCC 8th Ed.)","Penile Cancer pTa TNM Finding v8 | Penile Squamous Cell Carcinoma pTa TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538203","Penile Cancer pT1a TNM Finding v8","C140064","Penile cancer with tumor without lymphovascular invasion or perineural invasion and is not high grade (i.e., grade 3 or sarcomatoid). (from AJCC 8th Ed.)","Penile Cancer pT1a TNM Finding v8 | Penile Squamous Cell Carcinoma pT1a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538218","Penile Cancer pT1b TNM Finding v8","C140065","Penile cancer with tumor exhibiting lymphovascular invasion and/or perineural invasion or is high grade (i.e., grade 3 or sarcomatoid). (from AJCC 8th Ed.)","Penile Cancer pT1b TNM Finding v8 | Penile Squamous Cell Carcinoma pT1b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538217","Penile Cancer pT2 TNM Finding v8","C140066","Penile cancer with tumor invading into corpus spongiosum (either glans or ventral shaft) with or without urethral invasion. (from AJCC 8th Ed.)","Penile Cancer pT2 TNM Finding v8 | Penile Squamous Cell Carcinoma pT2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524890","Biopsy Specimen Radiography","C137813","Radiographic examination of a specimen obtained by biopsy or surgical procedure.","Biopsy Specimen Radiography | Biospecimen Radiography | Specimen Radiography",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524889","Core Biopsy with Placement of Image-Detectable Marker","C137814","A core biopsy and simultaneous implantation of an image-detectable marker for the purpose of future localization of the biopsy site.","Core Biopsy with Placement of Image-Detectable Marker | Marker Biopsy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524607","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs Pathologic Regional Lymph Nodes TNM Finding v8","C136743","A pathologic finding about one or more characteristics of soft tissue sarcoma of the abdomen and thoracic visceral organs, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs Pathologic Regional Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521529","6p11.1","C14010","A chromosome band present on 6p","6p11.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1538832","RFWD3 Gene","C138082","This gene is involved in protein ubiquitination and the DNA damage checkpoint in the cell cycle.","RFWD3 Gene | RFWD3 | Ring Finger and WD Repeat Domain 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525056","RFWD3 wt Allele","C138091","Human RFWD3 wild-type allele is located in the vicinity of 16q23.1 and is approximately 45 kb in length. This allele, which encodes E3 ubiquitin-protein ligase RFWD3 protein, plays a role in the modulation of the DNA damage checkpoint of the cell cycle. Biallelic mutations in the gene are associated with Fanconi anemia.","RFWD3 wt Allele | FANCW | FLJ10520 | RNF201 | Ring Finger and WD Repeat Domain 3 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524747","3C23K","C136985","An engineered, humanized, low fucose monoclonal antibody against mullerian hormone receptor II (Müllerian Inhibiting Substance Receptor II; AMHR2; AMHRII), with potential antineoplastic activity. Upon administration, murlentamab targets, binds to and inhibits AMHR2 and its downstream signaling pathways. GM102 primarily induces antibody dependent cellular cytotoxicity (ADCC) directed against AMHR2-expressing tumor cells through binding to CD16 (Fc-gammaRIIIa) that is present on immune effector cells. Decreased antibody fucosylation increases its affinity for binding to CD16 and ultimately enhances ADCC. AMHR2 is expressed in a subset of gynecological cancers.","Murlentamab | 3C23K | Anti-AMHR2 Monoclonal Antibody GM102 | Anti-AMHR2 Monoclonal Antibody GM10II | GM 102 | GM102 | GM102 Antibody | GM10II | MURLENTAMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538216","Penile Cancer pT3 TNM Finding v8","C140067","Penile cancer with tumor invading into corpora cavernosum (including tunica albuginea) with or without urethral invasion. (from AJCC 8th Ed.)","Penile Cancer pT3 TNM Finding v8 | Penile Squamous Cell Carcinoma pT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538396","C-H-RAS c.35_36delGCinsTA","C140252","A complex substitution where the nucleotide sequence at positions 35 and 36 of the coding sequence of the HRAS gene has changed from guanine-cytosine to thymine-adenine.","HRAS NM_005343.3:c.35_36delinsTA | C-H-RAS c.35_36delGCinsTA | C-HA-RAS1 c.35_36delGCinsTA | H-ras c.35_36delGCinsTA | HRAS NM_005343.3:c.35_36GC>TA | HRAS NM_005343.3:c.35_36delGCinsTA | HRAS NM_005343.3:c.35_36delGCinsTA | HRAS c.35_36GC>TA | HRAS c.35_36delGCinsTA | HRAS1 c.35_36delGCinsTA | HRas Proto-Oncogene, GTPase c.35_36delGCinsTA | Ha-ras c.35_36delGCinsTA | Harvey Rat Sarcoma Viral Oncogene Homolog c.35_36delGCinsTA | NM_005343.3:c.35_36GC>TA | NM_005343.3:c.35_36delGCinsTA | NM_005343.3:c.35_36delinsTA | RASH1 c.35_36delGCinsTA | v-Ha-ras Harvey Rat Sarcoma Viral Oncogene Homolog c.35_36delGCinsTA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538394","RREB1 Gene","C140254","This gene is involved in binding to RAS-responsive elements (RREs) in the promoters of target genes.","RREB1 Gene | RREB1 | Ras Responsive Element Binding Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538393","RREB1 wt Allele","C140255","Human RREB1 wild-type allele is located in the vicinity of 6p24.3 and is approximately 144 kb in length. This allele, which encodes Ras-responsive element-binding protein 1, plays a role in Ras signaling-dependent transcriptional regulation.","RREB1 wt Allele | FINB | HNT | Hindsight Homolog (Drosophila) Gene | Hindsight Homolog Gene | LZ321 | RREB-1 | Ras Responsive Element Binding Protein 1 wt Allele | Zep-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0530438","RREB1 protein, human","C140256","Ras-responsive element-binding protein 1 (1687 aa, ~181 kDa) is encoded by the human RREB1 gene. This protein is involved in Ras signaling-dependent gene transcription.","Ras-Responsive Element-Binding Protein 1 | Finger Protein In Nuclear Bodies | RREB-1 | RREB1 | Raf-Responsive Zinc Finger Protein LZ321 | Ras-Responsive Element Binding Protein 1 | Zep-1 | Zinc Finger Motif Enhancer-Binding Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0177666","Percutaneous Breast Biopsy","C140257","The extraction of a sample of breast tissue taken via the insertion of a needle through the skin and into the breast.","Percutaneous Breast Biopsy | Percutaneous Biopsy of Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520536","13p12","C14025","A chromosome band present on 13p","13p12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538399","Enneking Tumor Type","C140262","A description of malignant mesenchymal tumors based on tumor extent.","Enneking Tumor Type | MSTS Tumor Type | enneking msts tumor site | enneking_msts_tumor_site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538398","Genetic Macular Dystrophy","C140264","Macular dystrophy that is related to a change in a gene.","Genetic Macular Dystrophy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0072092","Proglucagon","C136747","Proglucagon  (180 aa, ~21 kDa) is encoded by the human GCG gene. This protein is involved in appetite, digestion, and glucose metabolism and homeostasis.","Proglucagon | Preproglucagon | Pro-Glucagon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524615","GCG Gene Product","C136748","A protein encoded by the GCG gene.","GCG Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524616","Gastrointestinal Stromal Tumor TNM Finding v8","C136749","A finding about one or more characteristics of gastrointestinal stromal tumor (GIST), following the rules of the TNM AJCC v8 classification system. This classification system does not apply to pediatric GIST, familial GIST (germline mutant KIT or PDGFRA), or syndromic GIST (no AJCC staging system available). (from AJCC 8th Ed.)","Gastrointestinal Stromal Tumor TNM Finding v8 | GIST TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520503","12q14.3-q15","C13674","A chromosome band present on 12q","12q14.3-q15 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524613","Gastrointestinal Stromal Tumor Clinical TNM Finding v8","C136750","A clinical finding about one or more characteristics of gastrointestinal stromal tumor, following the rules of the TNM AJCC v8 classification system.","Gastrointestinal Stromal Tumor Clinical TNM Finding v8 | GIST Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524614","Gastrointestinal Stromal Tumor Clinical Distant Metastasis TNM Finding v8","C136751","A clinical finding about one or more characteristics of gastrointestinal stromal tumor, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Gastrointestinal Stromal Tumor Clinical Distant Metastasis TNM Finding v8 | GIST Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524619","Gastrointestinal Stromal Tumor cM0 TNM Finding v8","C136752","Gastrointestinal stromal tumor without distant metastasis. (from AJCC 8th Ed.)","Gastrointestinal Stromal Tumor cM0 TNM Finding v8 | GIST cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524620","Gastrointestinal Stromal Tumor cM1 TNM Finding v8","C136753","Gastrointestinal stromal tumor with distant metastasis. (from AJCC 8th Ed.)","Gastrointestinal Stromal Tumor cM1 TNM Finding v8 | GIST cM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524617","Gastrointestinal Stromal Tumor Pathologic TNM Finding v8","C136754","A pathologic finding about one or more characteristics of gastrointestinal stromal tumor, following the rules of the TNM AJCC v8 classification system.","Gastrointestinal Stromal Tumor Pathologic TNM Finding v8 | GIST Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525013","FEC Followed by Pertuzumab/Trastuzumab/Paclitaxel Regimen","C138039","A regimen consisting of fluorouracil, epirubicin and intravenous cyclophosphamide, followed by pertuzumab, trastuzumab and paclitaxel, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.","FEC Followed by Pertuzumab/Trastuzumab/Paclitaxel Regimen | FEC Followed by Paclitaxel/Trastuzumab/Pertuzumab | FEC Followed by Pertuzumab + Trastuzumab + Paclitaxel | FEC-THP (Paclitaxel) | FEC-THP (Paclitaxel) (trastuzumab-anns) | FEC-THP (Paclitaxel) (trastuzumab-dkst) | FEC-THP (Paclitaxel) (trastuzumab-dttb) | FEC-THP (Paclitaxel) (trastuzumab-herw) | FEC-THP (Paclitaxel) (trastuzumab-pkrb) | FEC-THP (Paclitaxel) (trastuzumab-qyyp) | FEC-THP (Paclitaxel) (trastuzumab-strf) | FEC-THP (Paclitaxel) (trastuzumab-zerc) | Fluorouracil/Epirubicin/Cyclophosphamide Followed by Pertuzumab + Trastuzumab + Paclitaxel | Fluorouracil/Epirubicin/Cyclophosphamide Followed by Pertuzumab/Trastuzumab/Paclitaxel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1541246","Lapatinib/Trastuzumab Regimen","C138040","A regimen consisting of lapatinib and trastuzumab that can be used for the treatment of bone, breast, and colorectal cancers, appendiceal adenocarcinoma, and anaplastic carcinoma.","Lapatinib/Trastuzumab Regimen | Lapatinib + Trastuzumab | Lapatinib + Trastuzumab Regimen | Lapatinib Plus Trastuzumab | Lapatinib and Trastuzumab | Lapatinib and Trastuzumab-anns | Lapatinib and Trastuzumab-dkst | Lapatinib and Trastuzumab-dttb | Lapatinib and Trastuzumab-herw | Lapatinib and Trastuzumab-pkrb | Lapatinib and Trastuzumab-qyyp | Lapatinib and Trastuzumab-strf | Lapatinib and Trastuzumab-zerc | Lapatinib-Trastuzumab Regimen | Lapatinib/Trastuzumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524989","Lapatinib + Capecitabine Regimen","C138041","A regimen consisting of capecitabine and  lapatinib that can be used in the treatment of breast and colon cancers.","Capecitabine/Lapatinib Regimen | Capecitabine and Lapatinib | Lapatinib + Capecitabine Regimen | Lapatinib Plus Capecitabine Regimen | Lapatinib-Capecitabine Regimen | Lapatinib/Capecitabine | Lapatinib/Capecitabine Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524988","Pertuzumab/Trastuzumab Regimen","C138042","A regimen consisting of pertuzumab and trastuzumab that may be used as a treatment for appendiceal adenocarcinoma, salivary gland tumors, breast, hepatobiliary and colorectal cancers.","Pertuzumab/Trastuzumab Regimen | Herceptin-Perjeta | Pertuzumab + Trastuzumab | Pertuzumab Plus Trastuzumab | Pertuzumab and Trastuzumab | Pertuzumab and Trastuzumab-anns | Pertuzumab and Trastuzumab-dkst | Pertuzumab and Trastuzumab-dttb | Pertuzumab and Trastuzumab-herw | Pertuzumab and Trastuzumab-pkrb | Pertuzumab and Trastuzumab-qyyp | Pertuzumab and Trastuzumab-strf | Pertuzumab and Trastuzumab-zerc | Pertuzumab-Trastuzumab Regimen | Pertuzumab/Trastuzumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521418","4q34.1-q34.3","C14031","A chromosome band present on 4q","4q34.1-q34.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538450","Renal Cell Cancer by AJCC v8 Stage","C140322","A term that refers to the staging of kidney cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to carcinomas arising in the kidney. It does not apply to urothelial carcinomas (are staged according to the classification for renal pelvis and ureter), lymphomas (are staged according to the classification for Hodgkin and non-Hodgkin lymphoma), sarcomas (are staged according to the classification for soft tissue sarcoma of the abdomen and thoracic visceral organs), and Wilms tumor (no AJCC staging system). (from AJCC 8th Ed.)","Renal Cell Cancer by AJCC v8 Stage | Renal Cell Carcinoma by AJCC v8 Stage | Tumor Stage (Pathological)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538449","Stage I Renal Cell Cancer AJCC v8","C140323","Stage I includes: T1, N0, M0. T1: Tumor measuring 7 cm or less in greatest dimension, limited to the kidney. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage I Renal Cell Cancer AJCC v8 | Stage I | Stage I Renal Cell Cancer | Stage I Renal Cell Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538448","Stage II Renal Cell Cancer AJCC v8","C140324","Stage II includes: T2, N0, M0. T2: Tumor measuring more than 7 cm in greatest dimension, limited to the kidney. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage II Renal Cell Cancer AJCC v8 | Stage II | Stage II Renal Cell Cancer | Stage II Renal Cell Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538462","Stage III Renal Cell Cancer AJCC v8","C140325","Stage III includes: (T1, N1, M0); (T2, N1, M0); (T3, N0, M0); (T3, N1, M0). T1: Tumor measuring 7 cm or less in greatest dimension, limited to the kidney. T2: Tumor measuring more than 7 cm in greatest dimension, limited to the kidney. T3: Tumor extending into major veins or perinephric tissues, but not into the ipsilateral adrenal gland and not beyond Gerota's fascia. N0: No regional lymph node metastasis. N1: Metastasis in regional lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)","Stage III Renal Cell Cancer AJCC v8 | Stage III | Stage III Renal Cell Cancer | Stage III Renal Cell Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538461","Stage IV Renal Cell Cancer AJCC v8","C140326","Stage IV includes: (T4, Any N, M0); (Any T, Any N, M1). T4: Tumor invading beyond Gerota's fascia (including contiguous extension into the ipsilateral adrenal gland). M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Renal Cell Cancer AJCC v8 | Stage IV | Stage IV Renal Cell Cancer | Stage IV Renal Cell Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524744","LMP1-specific Chimeric Antigen Receptor-expressing T Lymphocytes","C136986","A preparation of cytotoxic T-lymphocytes (CTL) transfected with a chimeric antigen receptor (CAR) specifically recognizing the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1; LMP-1), with potential antineoplastic activity. Upon administration of the LMP1-specific CAR-expressing T lymphocytes to patients with LMP1-positive tumors, the CTLs specifically target and lyse tumor cells expressing LMP1, thereby inhibiting tumor cell proliferation. The tumor-associated antigen (TAA) LMP1 is expressed in various malignancies, including nasopharyngeal cancer and EBV-positive Hodgkin lymphoma.","LMP1-specific Chimeric Antigen Receptor-expressing T Lymphocytes | Anti-LMP1 CAR T Cells | LMP1-CAR-CTLs | LMP1-CAR-T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524745","U3 1402","C136987","An antibody-drug conjugate (ADC) composed of patritumab, a monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3),linked to the topoisomerase I inhibitor DX 8951, a semisynthetic, water-soluble derivative of camptothecin, with potential antineoplastic activity. Upon administration of patritumab deruxtecan, the patritumab moiety targets and binds to HER3. After internalization, DX 8951 inhibits topoisomerase I activity by stabilizing the complex between topoisomerase I and DNA and inhibiting religation of DNA breaks, thereby inhibiting DNA replication and triggering apoptotic cell death. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors.","Patritumab Deruxtecan | Anti-HER3 Antibody-drug Conjugate U3 1402 | PATRITUMAB DERUXTECAN | U3 1402 | U3-1402 | U3-1402a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524750","N-acetylcysteine/Simethicone Solution","C136988","An oral solution composed of N-acetylcysteine, a synthetic N-acetyl derivative of the endogenous amino acid L-cysteine, and simethicone, a mixture of polydimethylsiloxanes and hydrated silica gel, with mucolytic and antifoaming activities. Upon oral administration of the mucolytic solution, N-acetylcysteine breaks down disulfide bonds in mucoproteins, resulting in liquification of mucus in the upper respiratory tract. Simethicone reduces the surface tension of gas bubbles causing them to coalesce into larger bubbles that can be passed more easily. This increases the passage of mucus and gas bubbles from the upper digestive tract. This may also increase visibility of the gastric mucosa during upper endoscopy.","N-acetylcysteine/Simethicone Solution | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521056","20q12-q13","C13698","A chromosome band present on 20q","20q12-q13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520273","10q21","C13699","A chromosome band present on 10q","10q21 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514772","Recombinant Fibroblast Growth Factor 6","C1369","A recombinant therapeutic agent which is chemically identical to or similar to endogenous fibroblast growth factor 6 (FGF-6).  Because of the mitogenic effects of FGF-6 on fibroblasts and endothelial cells and the stimulatory effects of FGF-6 on muscle stem cell migration, therapeutic FGF-6 has a potential role in wound healing and muscle regeneration. (NCI04)","Recombinant Fibroblast Growth Factor 6 | FGF-6 | FGF6 | HBGF-6 | HST-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521641","7q21.1","C13700","A chromosome band present on 7q","7q21.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520863","19q13.3-q13.4","C13701","A chromosome band present on 19q","19q13.3-q13.4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515443","8p23.1-p21.3","C13702","A chromosome band present on 8p","8p23.1-p21.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521495","5q33.2-q33.3","C13703","A chromosome band present on 5q","5q33.2-q33.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520989","1q21-q22","C13704","A chromosome band present on 1q","1q21-q22 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521293","3p24.3","C13705","A chromosome band present on 3p","3p24.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520473","12p12.3","C13706","A chromosome band present on 12p","12p12.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521321","3q26","C13707","A chromosome band present on 3q","3q26 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521281","3p21","C13708","A chromosome band present on 3p","3p21 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521399","4q25","C13709","A chromosome band present on 4q","4q25 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1290912","Palpation Finding","C137852","The results of a palpation examination.","Palpation Finding | Finding by Palpation",,,,,,,,,,,,,,,"4041435","Finding by palpation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL538397","Enneking Metastasis","C140266","A description of malignant mesenchymal tumors based on presence or absence of metastasis.","Enneking Metastasis | MSTS Metastasis | enneking msts metastasis | enneking_msts_metastasis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037773","Hereditary Spastic Paraplegia","C140267","Spastic paraplegia that is transmitted from parent to child.","Hereditary Spastic Paraplegia | Hereditary spastic paraplegia",,,,,,,,,,,,,,,"192901","Hereditary spastic paraplegia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL538569","Eyelid Carcinoma Clinical Distant Metastasis TNM Finding v8","C140472","A clinical finding about one or more characteristics of eyelid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Eyelid Carcinoma Clinical Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538568","Eyelid Carcinoma cM0 TNM Finding v8","C140473","Eyelid carcinoma with no evidence of distant metastasis. (from AJCC 8th Ed.)","Eyelid Carcinoma cM0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538566","Eyelid Carcinoma Clinical Regional Lymph Nodes TNM Finding v8","C140475","A clinical finding about one or more characteristics of eyelid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Eyelid Carcinoma Clinical Regional Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538550","Eyelid Carcinoma cN0 TNM Finding v8","C140477","Eyelid carcinoma with no evidence of lymph node involvement. (from AJCC 8th Ed.)","Eyelid Carcinoma cN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538549","Eyelid Carcinoma cN1 TNM Finding v8","C140478","Eyelid carcinoma with metastasis in a single ipsilateral regional lymph node, measuring 3 cm or less in greatest dimension. (from AJCC 8th Ed.)","Eyelid Carcinoma cN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538548","Eyelid Carcinoma cN1a TNM Finding v8","C140479","Eyelid carcinoma with metastasis in a single ipsilateral regional lymph node, measuring 3 cm or less in greatest dimension based on clinical evaluation or imaging findings. (from AJCC 8th Ed.)","Eyelid Carcinoma cN1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512676","Immunoreceptor Tyrosine-Based Motif","C14047","Short sequences of amino acids that contain tyrosine and are found in immunoglobulin receptor proteins. Phosphorylation of the tyrosine can influence signal transduction.","Immunoreceptor Tyrosine-Based Motif | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538547","Eyelid Carcinoma cN2 TNM Finding v8","C140480","Eyelid carcinoma with metastasis in a single ipsilateral regional lymph node, measuring more than 3 cm in greatest dimension, or in bilateral or contralateral lymph nodes. (from AJCC 8th Ed.)","Eyelid Carcinoma cN2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538546","Eyelid Carcinoma cN2a TNM Finding v8","C140481","Eyelid carcinoma with metastasis in a single ipsilateral regional lymph node, measuring more than 3 cm in greatest dimension, or in bilateral or contralateral lymph nodes documented based on clinical evaluation or imaging findings. (from AJCC 8th Ed.)","Eyelid Carcinoma cN2a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538545","Eyelid Carcinoma Pathologic TNM Finding v8","C140482","A pathologic finding about one or more characteristics of eyelid carcinoma, following the rules of the TNM AJCC v8 classification system.","Eyelid Carcinoma Pathologic TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538543","Eyelid Carcinoma pM1 TNM Finding v8","C140484","Eyelid carcinoma with distant metastasis. (from AJCC 8th Ed.)","Eyelid Carcinoma pM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538558","Eyelid Carcinoma Pathologic Primary Tumor TNM Finding v8","C140485","A pathologic finding about one or more characteristics of eyelid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Eyelid Carcinoma Pathologic Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538557","Eyelid Carcinoma pTX TNM Finding v8","C140486","Eyelid carcinoma in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Eyelid Carcinoma pTX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524987","Pertuzumab + Trastuzumab + Docetaxel","C138043","A regimen consisting of pertuzumab, trastuzumab and docetaxel that can be used in the treatment of breast cancer.","Docetaxel/Pertuzumab/Trastuzumab Regimen | Pertuzumab + Trastuzumab + Docetaxel | Pertuzumab-Trastuzumab-Docetaxel | Pertuzumab-Trastuzumab-Docetaxel Regimen | Pertuzumab/Trastuzumab/Docetaxel | Pertuzumab/Trastuzumab/Docetaxel Regimen | THP | THP (Docetaxel) | THP (Docetaxel) (trastuzumab-anns) | THP (Docetaxel) (trastuzumab-dkst) | THP (Docetaxel) (trastuzumab-dttb) | THP (Docetaxel) (trastuzumab-herw) | THP (Docetaxel) (trastuzumab-pkrb) | THP (Docetaxel) (trastuzumab-qyyp) | THP (Docetaxel) (trastuzumab-strf) | THP (Docetaxel) (trastuzumab-zerc) | THP (Taxotere) Regimen | Taxotere/Herceptin/Pertuzumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524993","Pertuzumab/Trastuzumab/Docetaxel Followed by FEC Regimen","C138044","A regimen consisting of pertuzumab, trastuzumab and docetaxel, followed by fluorouracil, epirubicin and intravenous cyclophosphamide, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.","Pertuzumab/Trastuzumab/Docetaxel Followed by FEC Regimen | Pertuzumab + Trastuzumab + Docetaxel Followed by FEC | Pertuzumab + Trastuzumab + Docetaxel Followed by Fluorouracil/Epirubicin/Cyclophosphamide | Pertuzumab-Trastuzumab-Docetaxel Followed by Fluorouracil-Epirubicin-Cyclophosphamide | Pertuzumab/Trastuzumab/Docetaxel Followed by Fluorouracil/Epirubicin/Cyclophosphamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524991","Pertuzumab/Trastuzumab/Paclitaxel Followed by FEC Regimen","C138046","A regimen consisting of pertuzumab, trastuzumab and paclitaxel, followed by fluorouracil, epirubicin and intravenous cyclophosphamide, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.","Pertuzumab/Trastuzumab/Paclitaxel Followed by FEC Regimen | Pertuzumab + Trastuzumab + Paclitaxel Followed by FEC | Pertuzumab + Trastuzumab + Paclitaxel Followed by Fluorouracil/Epirubicin/Cyclophosphamide | Pertuzumab-Trastuzumab-Paclitaxel Followed by Fluorouracil-Epirubicin-Cyclophosphamide | Pertuzumab/Trastuzumab/Paclitaxel Followed by Fluorouracil/Epirubicin/Cyclophosphamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600477","Short Interspersed Element","C13804","SINEs.  Short, 100-300 bases long, highly repeated sequences which contain RNA polymerase III promoters. The primate Alu and the rodent B1 SINEs are derived from 7SL RNA, the RNA component of the signal recognition particle. Most other SINEs are derived from tRNAs including the MIRs (mammalian-wide interspersed repeats).","Short Interspersed Element | SINE | SINES | Short Interspersed Nuclear Element",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520977","1p36.13-p36.11","C13694","A chromosome band present on 1p","1p36.13-p36.11 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433889","Volumetric Laser Endomicroscopy","C140327","An endoscopic imaging technology that uses optical coherence tomography with near infrared light and balloon-centered imaging probes to produce scans of 6 cm segments of the esophagus, with surface and subsurface image depth greater than 3 mm with 7 micron axial resolution. These high-speed scans allow real-time diagnosis of surface and subsurface abnormalities and can guide endoscopic treatment.","Volumetric Laser Endomicroscopy | NvisionVLE | NvisionVLE Imaging System",,,,,,,,,,,,,,,"37204021","Volumetric laser endomicroscopy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL538460","Advanced Nonfunctional Neuroendocrine Tumor","C140328","A non-functioning neuroendocrine tumor that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Non-Functioning Neuroendocrine Tumor | Advanced Non-Functioning Well Differentiated Neuroendocrine Neoplasm | Advanced Non-Functioning Well Differentiated Neuroendocrine Neoplasm | Advanced Nonfunctional Neuroendocrine Tumor | Advanced Nonfunctional Well Differentiated Neuroendocrine Neoplasm | Advanced Nonfunctioning Well Differentiated Neuroendocrine Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538632","Conjunctival Carcinoma pT0 TNM Finding v8","C140537","Conjunctival carcinoma with no evidence of primary tumor. (from AJCC 8th Ed.)","Conjunctival Carcinoma pT0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538631","Conjunctival Carcinoma pTis TNM Finding v8","C140538","Conjunctival carcinoma with a finding of carcinoma in situ. (from AJCC 8th Ed.)","Conjunctival Carcinoma pTis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538630","Conjunctival Carcinoma pT1 TNM Finding v8","C140539","Conjunctival carcinoma with tumor measuring 5 mm or less in greatest dimension and invading through the conjunctival basement membrane without invasion of adjacent structures. (from AJCC 8th Ed.)","Conjunctival Carcinoma pT1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518862","Palmitic Acylation Site","C14053","It refers to amino acid residue within a peptide that accepts fatty acid, palmitoyl group (C15H31-)as one of the reversible post-translational modifications. Protein palmitoylation is a thioester bond between palmitoyl-CoA and cysteine thiol. (NCI)","Palmitic Acylation Site | Palmitoylation Site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538629","Conjunctival Carcinoma pT2 TNM Finding v8","C140540","Conjunctival carcinoma with tumor measuring more than 5 mm in greatest dimension and invading through the conjunctival basement membrane without invasion of adjacent structures. (from AJCC 8th Ed.)","Conjunctival Carcinoma pT2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538628","Conjunctival Carcinoma pT3 TNM Finding v8","C140541","Conjunctival carcinoma with tumor invading adjacent structures (excluding the orbit). (from AJCC 8th Ed.)","Conjunctival Carcinoma pT3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538612","Conjunctival Carcinoma pT4 TNM Finding v8","C140542","Conjunctival carcinoma with tumor invading the orbit with or without further extension. (from AJCC 8th Ed.)","Conjunctival Carcinoma pT4 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538611","Conjunctival Carcinoma pT4a TNM Finding v8","C140543","Conjunctival carcinoma with tumor invading orbital soft tissues without bone invasion. (from AJCC 8th Ed.)","Conjunctival Carcinoma pT4a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538610","Conjunctival Carcinoma pT4b TNM Finding v8","C140544","Conjunctival carcinoma with tumor invading bone. (from AJCC 8th Ed.)","Conjunctival Carcinoma pT4b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538609","Conjunctival Carcinoma pT4c TNM Finding v8","C140545","Conjunctival carcinoma with tumor invading adjacent paranasal sinuses. (from AJCC 8th Ed.)","Conjunctival Carcinoma pT4c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538608","Conjunctival Carcinoma pT4d TNM Finding v8","C140546","Conjunctival carcinoma with tumor invading brain. (from AJCC 8th Ed.)","Conjunctival Carcinoma pT4d TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538607","Conjunctival Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8","C140547","A pathologic finding about one or more characteristics of conjunctival carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Conjunctival Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538606","Conjunctival Carcinoma pNX TNM Finding v8","C140548","Conjunctival carcinoma in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Conjunctival Carcinoma pNX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538605","Conjunctival Carcinoma pN0 TNM Finding v8","C140549","Conjunctival carcinoma with no regional lymph node metastasis. (from AJCC 8th Ed.)","Conjunctival Carcinoma pN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2919697","Largest Dimension of Residual Neoplasm","C137853","The largest single dimension of the residual tumor after surgical resection.","Largest Dimension of Residual Neoplasm | Greasest Size of Residual Neoplasm | Greatest Dimension of Residual Neoplasm",,,,,,,,,,,,,,,"40492195","Largest dimension of residual neoplasm",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0204452","Psychological Assessment","C137855","The act of determining, usually through interviews and observation, the status of an individual's psychological well being.","Psychological Assessment | Assessment of Psychological Status | Evaluation of Patient's Psychological Status",,,,,,,,,,,,,,,"4226272","Psychological assessment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL524871","Assessment of Distress","C137856","The act of determining, usually through interviews and observation, the status of an individual's distress.","Assessment of Distress | Assessment of Psychological Distress | Evaluation of Patient's Distress",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524870","Refractory Anal Carcinoma","C137857","Anal carcinoma that does not respond to treatment.","Refractory Anal Carcinoma | Refractory Anal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524875","Eligibility for a Procedure","C137858","A question pertaining to patient's eligibility to undergo a certain procedure.","Eligibility for a Procedure | Patient Eligibility for a Procedure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524874","Eligibility for Breast-Conserving Surgery","C137859","A question pertaining to patient's eligibility to undergo a breast conserving surgery.","Eligibility for Breast-Conserving Surgery | Patient Eligibility for Breast-Conserving Surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520943","1p22","C13785","A chromosome band present on 1p","1p22 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524873","Eligibility for Pre-operative Systemic Therapy","C137860","A question pertaining to patient's eligibility to undergo a pre-operative systemic therapy.","Eligibility for Pre-operative Systemic Therapy | Patient's Eligibility for Pre-operative Systemic Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524872","Eligibility Criteria for Breast Conserving Surgery Except for Tumor Size","C137861","An assessment of patient's eligibility for breast conserving surgery showing that all criteria for a breast-conserving surgery are met, except tumor size.","Eligibility Criteria for Breast Conserving Surgery Except for Tumor Size | Fulfills Eligibility Criteria for Breast Conserving Surgery Except for Tumor Size | Patient Fulfills Eligibility Criteria for Breast Conserving Surgery Except for Tumor Size | Patient Meets Eligibility Criteria for Breast Conserving Surgery Except for Tumor Size",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524942","Refractory Pancreatic Neuroendocrine Carcinoma","C137862","Pancreatic neuroendocrine carcinoma that does not respond to treatment.","Refractory Pancreatic Neuroendocrine Carcinoma | Refractory Pancreatic Neuroendocrine Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524941","Allogeneic CD3- CD19- CD57+ NKG2C+ NK Cells FATE-NK100","C137863","A preparation of pharmacologically-enriched, allogeneic natural killer (NK) cells derived from a related but not completely matched human leukocyte antigen (HLA)-haploidentical donor that is seropositive for cytomegalovirus (CMV+), with potential cytolytic and antineoplastic activities. Upon leukapheresis, the donor peripheral blood mononuclear cells (PBMCs) are treated to remove T-lymphocytes (CD3+) and B-lymphocytes (CD19+). The remaining leukocytes are cultured for 7 days with the cytokine interleukin-15 (IL-15) and a small molecule inhibitor of glycogen synthase kinase 3-beta (GSK3beta) to generate the adaptive, CD3- CD19- CD57+ NKG2C+ NK cells FATE-NK100 ex vivo. Upon infusion of the allogeneic CD3- CD19- CD57+ NKG2C+ NK cells FATE-NK100, these cells selectively recognize and bind to tumor cells, and secrete perforins, granzymes, and cytokines, which results in cancer cell lysis. Exposure to CMV induces the expression of the memory-like activating receptor NKG2C and the maturation marker CD57 in the isolated NK cells, making them more potent than those not pre-exposed to CMV. CD57 both enhances the effector function of NK cells and stimulates CD16-dependent signaling. Treatment with IL-15 enhances NK cell proliferation and survival. The GSK3beta inhibitor induces preferential expansion of CD57+ NK cells that exhibit enhanced interferon (IFN)-gamma production.","Allogeneic CD3- CD19- CD57+ NKG2C+ NK Cells FATE-NK100 | Adaptive Memory NKs Cells FATE-NK100 | Adaptive Memory Natural Killer Cells FATE-NK100 | Adaptive NKs Cells FATE-NK100 | FATE NK100 | FATE-NK100",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538556","Eyelid Carcinoma pT0 TNM Finding v8","C140487","Eyelid carcinoma with no evidence of primary tumor. (from AJCC 8th Ed.)","Eyelid Carcinoma pT0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538555","Eyelid Carcinoma pTis TNM Finding v8","C140488","Eyelid carcinoma with a finding of carcinoma in situ. (from AJCC 8th Ed.)","Eyelid Carcinoma pTis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538554","Eyelid Carcinoma pT1 TNM Finding v8","C140489","Eyelid carcinoma with tumor measuring 10 mm or less in greatest dimension. (from AJCC 8th Ed.)","Eyelid Carcinoma pT1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538030","Uterine Corpus Adenosarcoma pT1b TNM Finding v8","C139855","Uterine corpus adenosarcoma with tumor invading to less than half of the myometrium. (from AJCC 8th Ed.)","Uterine Corpus Adenosarcoma pT1b TNM Finding v8 | Uterine Corpus Adenosarcoma FIGO Stage IB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538029","Uterine Corpus Adenosarcoma pT1c TNM Finding v8","C139856","Uterine corpus adenosarcoma with tumor invading more than half of the myometrium. (from AJCC 8th Ed.)","Uterine Corpus Adenosarcoma pT1c TNM Finding v8 | Uterine Corpus Adenosarcoma FIGO Stage IC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538044","Uterine Corpus Adenosarcoma pT2 TNM Finding v8","C139857","Uterine corpus adenosarcoma with tumor extending beyond the uterus, within the pelvis. (from AJCC 8th Ed.)","Uterine Corpus Adenosarcoma pT2 TNM Finding v8 | Uterine Corpus Adenosarcoma FIGO Stage II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538043","Uterine Corpus Adenosarcoma pT2a TNM Finding v8","C139858","Uterine corpus adenosarcoma with tumor extending beyond the uterus, within the pelvis and involving adnexa. (from AJCC 8th Ed.)","Uterine Corpus Adenosarcoma pT2a TNM Finding v8 | Uterine Corpus Adenosarcoma FIGO Stage IIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538042","Uterine Corpus Adenosarcoma pT2b TNM Finding v8","C139859","Uterine corpus adenosarcoma with tumor involving other pelvic tissues. (from AJCC 8th Ed.)","Uterine Corpus Adenosarcoma pT2b TNM Finding v8 | Uterine Corpus Adenosarcoma FIGO Stage IIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1167191","Fascia Adherens","C13985","Fascia adherens, similar to a zonula adherens, is a half Z line found in the cardiac muscle as one of the three intercalated disks.  They anchor actin filaments from terminal sarcomeres and transmit contractile force between myocytes. (NCI)","Fascia Adherens | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538041","Uterine Corpus Adenosarcoma pT3 TNM Finding v8","C139860","Uterine corpus adenosarcoma with tumor infiltrating abdominal tissues. (from AJCC 8th Ed.)","Uterine Corpus Adenosarcoma pT3 TNM Finding v8 | Uterine Corpus Adenosarcoma FIGO Stage III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538040","Uterine Corpus Adenosarcoma pT3a TNM Finding v8","C139861","Uterine corpus adenosarcoma with tumor infiltrating abdominal tissues at one site. (from AJCC 8th Ed.)","Uterine Corpus Adenosarcoma pT3a TNM Finding v8 | Uterine Corpus Adenosarcoma FIGO Stage IIIA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538038","Uterine Corpus Adenosarcoma pT4 TNM Finding v8","C139863","Uterine corpus adenosarcoma with tumor invading bladder or rectum. (from AJCC 8th Ed.)","Uterine Corpus Adenosarcoma pT4 TNM Finding v8 | Uterine Corpus Adenosarcoma FIGO Stage IVA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538037","Uterine Corpus Adenosarcoma Pathologic Regional Lymph Nodes TNM Finding v8","C139864","A pathologic finding about one or more characteristics of uterine corpus adenosarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Uterine Corpus Adenosarcoma Pathologic Regional Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538020","Uterine Corpus Adenosarcoma pNX TNM Finding v8","C139865","Uterine corpus adenosarcoma in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Uterine Corpus Adenosarcoma pNX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538019","Uterine Corpus Adenosarcoma pN0 TNM Finding v8","C139866","Uterine corpus adenosarcoma with no regional lymph node metastasis. (from AJCC 8th Ed.)","Uterine Corpus Adenosarcoma pN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520774","17q21.3","C13695","A chromosome band present on 17q","17q21.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524893","Androgen Receptor Antagonist TAS3681","C137818","An orally bioavailable inhibitor of the androgen receptor (AR), with potential antineoplastic activity. Upon oral administration, AR inhibitor TAS3681 specifically binds to AR. This prevents AR activation, downregulates AR and prevents AR-mediated signaling. This inhibits cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in proliferation, survival and chemoresistance of tumor cells.","Androgen Receptor Antagonist TAS3681 | AR Antagonist TAS3681 | Androgen Receptor Inhibitor TAS3681 | TAS 3681 | TAS3681",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519063","Phosphorylation Site","C14054","Generally refers to amino acids residues that were covalently modified by phosphate group (PO4-). (NCI)","Phosphorylation Site | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538620","Conjunctival Carcinoma pN1 TNM Finding v8","C140550","Conjunctival carcinoma with regional lymph node metastasis. (from AJCC 8th Ed.)","Conjunctival Carcinoma pN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538619","Retinoid X Receptor Agonist IRX4204","C140551","A second generation rexinoid and agonist of retinoid X receptor (RXR), with potential antineoplastic, neuroprotective, immunoregulatory, and disease-modifying activities. Upon administration, IRX4204 specifically binds to and activates RXRs, thereby activating RXR-mediated signaling pathways and inducing changes in gene expression that lead to cell differentiation. In responsive cancer cells, IRX4204 induces cell differentiation, decreases cell proliferation, and induces apoptosis, which leads to cancer regression. IRX4204 enhances the differentiation of CD4-positive T lymphocytes into inducible regulatory T cells (iTreg) and suppresses the development of inflammatory T helper 17 (Th17) cells. In addition, IRX4204 is able to cross the blood-brain barrier (BBB) and induces the differentiation of oligodendrocyte precursor cells (OPCs) into oligodendrocytes, promotes repair of myelin, and enhances the survival of dopaminergic neurons.","Retinoid X Receptor Agonist IRX4204 | AGN194204 | IRX 4204 | IRX-4204 | IRX4204 | RXR Agonist IRX4204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537993","NPPA wt Allele","C139908","Human NPPA wild-type allele is located in the vicinity of 1p36.22 and is approximately 3 kb in length. This allele, which encodes natriuretic peptides A, plays a role in the regulation of natriuresis, diuresis, and vasodilation. Mutation of the gene is associated with atrial fibrillation familial type 6 and atrial standstill type 2.","NPPA wt Allele | ANF | ANP | ATFB6 | ATRST2 | CDD | CDD-ANF | CDP | Natriuretic Peptide A wt Allele | PND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537992","NPPA Gene Product","C139909","A protein encoded by the NPPA gene.","NPPA Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520278","10q22.1-q23","C13990","A chromosome band present on 10q","10q22.1-q23 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1258629","NPPA protein, human","C139910","Natriuretic peptides A (153 aa, ~17 kDa) is encoded by the human NPPA gene. This protein is involved in uterine artery remodeling, trophoblast invasion, natriuresis, diuresis, and vasodilation.","Natriuretic Peptides A | Atrial Natriuretic Polypeptides | CDD | CDP | Cardiodilatin | Cardiodilatin-Related Peptide | NPPA | Natriuretic Peptide Precursor A | Prepronatriodilatin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537991","Atrial Natriuretic Factor","C139911","Atrial natriuretic factor (28 aa, ~3 kDa) is encoded by the human NPPA gene. This protein is involved in both cardiac homeostasis and pregnancy.","Atrial Natriuretic Factor | ANF | ANP | Atrial Natriuretic Peptide | Atrionatriuretic Factor | Atriopeptin | Cardionatrin | NPPA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537990","NMB Gene","C139912","This gene is involved in smooth muscle contraction.","NMB Gene | NMB | Neuromedin B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538100","NMB wt Allele","C139913","Human NMB wild-type allele is located in the vicinity of 15q25.2 and is approximately 3 kb in length. This allele, which encodes neuromedin-B precursor protein, plays a role in the regulation of smooth muscle contraction.","NMB wt Allele | MGC17211 | MGC2277 | MGC3936 | Neuromedin B wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538099","NMB Gene Product","C139914","A protein encoded by the NMB gene.","NMB Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538098","Neuromedin-B Precursor","C139915","Neuromedin-B precursor (121 aa, ~13 kDa) is encoded by the human NMB gene. This protein is involved in smooth muscle contraction.","Neuromedin-B Precursor | NMB | Neuromedin-B | Pro Neuromedin-B | Pro-Neuromedin-B | Proneuromedin B | Proneuromedin-B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538097","Neuromedin-B","C139916","Neuromedin-B (10 aa, ~1 kDa) is encoded by the human NMB gene. This protein plays a role in the stimulation of smooth muscle contraction.","Neuromedin-B | NMB | Neuromedin B | Neuromedin-Beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538096","ESRRB Gene","C139917","This gene plays a role in transcriptional regulation of genes that regulate the maintainance of self-renewal and pluripotency of embryonic and trophoblast stem cells.","ESRRB Gene | ESRRB | Estrogen Related Receptor Beta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524589","Stage IIIB Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8","C136785","Stage IIIB includes: (T2, N0, M0, High Mitotic Rate); (T3, N0, M0, High Mitotic Rate); (T4, N0, M0, High Mitotic Rate). T2: Tumor measuring more than 2 cm but not more than 5 cm. T3: Tumor measuring more than 5 cm but not more than 10 cm. T4: Tumor measuring more than 10 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. High Mitotic Rate: Over 5 mitoses per 5 square millimeters, or per 50 HPF. (AJCC 8th ed.)","Stage IIIB Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8 | Stage IIIB Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal GIST AJCC v8 | Stage IIIB Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor (GIST)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524586","Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8","C136786","Stage IV includes: (Any T, N1, M0, Any Mitotic Rate); (Any T, Any N, M1, Any Mitotic Rate). N1: Regional lymph node metastasis. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)","Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8 | Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal GIST AJCC v8 | Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor (GIST)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524587","GNRH2 Gene Product","C136787","A protein encoded by the GNRH2 gene.","GNRH2 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0064916","Gonadoliberin-2","C136788","Gonadoliberin-2 (10 aa, ~1 kDa) is encoded by the human GNRH2 gene. This protein is involved in the stimulation of luteinizing hormone and follicle-stimulating hormone secretion.","Gonadoliberin-2 | GNRH2 | GnRH II | GnRH-II | Gonadoliberin II | Gonadotropin Releasing Hormone 2 | Gonadotropin-Releasing Hormone 2 | Gonadotropin-Releasing Hormone II | LH-RH II | LH-RHII | Luliberin II | Luteinizing Hormone-Releasing Hormone II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524561","VIP Gene Product","C136789","A protein encoded by the VIP gene.","VIP Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521615","7p12.3-p12.1","C13678","A chromosome band present on 7p","7p12.3-p12.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524560","CHGA Gene Product","C136791","A protein encoded by the CHGA gene.","CHGA Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524565","Soft Tissue Sarcoma of the Retroperitoneum Clinical TNM Finding v8","C136793","A clinical finding about one or more characteristics of soft tissue sarcoma of the retroperitoneum, following the rules of the TNM AJCC v8 classification system.","Soft Tissue Sarcoma of the Retroperitoneum Clinical TNM Finding v8 | Retroperitoneal Soft Tissue Sarcoma Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524562","Soft Tissue Sarcoma of the Retroperitoneum Clinical Distant Metastasis TNM Finding v8","C136794","A clinical finding about one or more characteristics of soft tissue sarcoma of the retroperitoneum, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Soft Tissue Sarcoma of the Retroperitoneum Clinical Distant Metastasis TNM Finding v8 | Retroperitoneal Soft Tissue Sarcoma Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538018","Uterine Corpus Adenosarcoma pN0(i+) TNM Finding v8","C139867","Uterine corpus adenosarcoma with isolated tumor cells in regional lymph node(s) no greater than 0.2 mm. (from AJCC 8th Ed.)","Uterine Corpus Adenosarcoma pN0(i+) TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538017","Uterine Corpus Adenosarcoma pN1 TNM Finding v8","C139868","Uterine corpus adenosarcoma with regional lymph node metastasis. (from AJCC 8th Ed.)","Uterine Corpus Adenosarcoma pN1 TNM Finding v8 | Uterine Corpus Adenosarcoma FIGO Stage IIIC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538016","Uterine Corpus Sarcoma by AJCC v8 Stage","C139869","A term that refers to the staging of uterine corpus sarcoma according to the American Joint Committee on Cancer, 8th edition. This staging system applies to leiomyosarcomas, endometrial stromal sarcomas, and adenosarcomas of the uterine corpus. It does not apply to carcinosarcomas which are staged according to the carcinomas and carcinosarcomas of the uterine corpus. (from AJCC 8th Ed.)","Uterine Corpus Sarcoma by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520287","10q24-q26","C13986","A chromosome band present on 10q","10q24-q26 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538015","Uterine Corpus Leiomyosarcoma by AJCC v8 Stage","C139870","A term that refers to the staging of uterine corpus leiomyosarcoma according to the American Joint Committee on Cancer, 8th edition.","Uterine Corpus Leiomyosarcoma by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538215","Penile Cancer pT4 TNM Finding v8","C140068","Penile cancer with tumor invading into adjacent structures (i.e., scrotum, prostate, pubic bone). (from AJCC 8th Ed.)","Penile Cancer pT4 TNM Finding v8 | Penile Squamous Cell Carcinoma pT4 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538214","Penile Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C140069","A pathologic finding about one or more characteristics of penile cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Penile Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | Penile Squamous Cell Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521372","4p13","C14006","A chromosome band present on 4p","4p13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538213","Penile Cancer pNX TNM Finding v8","C140070","Penile cancer in which lymph node metastasis cannot be established. (from AJCC 8th Ed.)","Penile Cancer pNX TNM Finding v8 | Penile Squamous Cell Carcinoma pNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538212","Penile Cancer pN0 TNM Finding v8","C140071","Penile cancer with no lymph node metastasis. (from AJCC 8th Ed.)","Penile Cancer pN0 TNM Finding v8 | Penile Squamous Cell Carcinoma pN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538211","Penile Cancer pN1 TNM Finding v8","C140072","Penile cancer with two or less unilateral inguinal metastases, no extranodal extension. (from AJCC 8th Ed.)","Penile Cancer pN1 TNM Finding v8 | Penile Squamous Cell Carcinoma pN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538194","Penile Cancer pN2 TNM Finding v8","C140073","Penile cancer with three or more unilateral inguinal metastases or bilateral metastases. (from AJCC 8th Ed.)","Penile Cancer pN2 TNM Finding v8 | Penile Squamous Cell Carcinoma pN2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538193","Penile Cancer pN3 TNM Finding v8","C140074","Penile cancer with extranodal extension of lymph node metastases or pelvic lymph node metastases. (from AJCC 8th Ed.)","Penile Cancer pN3 TNM Finding v8 | Penile Squamous Cell Carcinoma pN3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538192","Penile Cancer by AJCC v8 Stage","C140075","A term that refers to the staging of penile cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to penile squamous cell carcinoma and associated histologic subtypes. It does not apply to urethral carcinomas, sarcomas, and melanomas. (from AJCC 8th Ed.)","Penile Cancer by AJCC v8 Stage | Penile Squamous Cell Carcinoma by AJCC v8 Stage | Squamous Cell Carcinoma of the Penis by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538191","Stage 0 Penile Cancer AJCC v8","C140076","Stage 0 includes: 0is: Tis, N0, M0; 0a: Ta, N0, M0. Tis: Penile cancer with a finding of carcinoma in situ (penile intraepithelial neoplasia [PeIN]). Ta: Penile cancer with a finding of noninvasive localized squamous cell carcinoma. N0: No lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","Stage 0 Penile Cancer AJCC v8 | Stage 0 Penile Cancer | Stage 0 Penile Squamous Cell Carcinoma AJCC v8 | Stage 0 Squamous Cell Carcinoma of the Penis AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524892","Allogeneic CD19-specific Universal CAR19-expressing T-lymphocytes","C137819","A preparation of allogeneic, frozen, 'off-the-shelf', universal transcription activator-like effector nuclease (TALEN)-engineered, gene-edited T-lymphocytes expressing a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19, and containing a RQR8 transgene, with potential immunostimulating and antineoplastic activities. Using TALEN technology, the T-cell receptor (TCR) alpha chain and CD52 genes are deleted from the CAR19 T-cells. Upon infusion, allogeneic universal CD19-specific CAR-modified T cells (UCART19) specifically target and bind to CD19-expressing tumor cells, thereby selectively lysing CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Deletion of the CD52 gene makes the modified donor T-cells resistant to the anti-CD52 monoclonal antibody alemtuzumab, which is used during lymphodepletion. The knockout of the TCR alpha gene eliminates TCR expression and is intended to abrogate the potential induction of graft-versus-host disease (GvHD) by the donor T-cells. The gene-edited allogeneic, frozen UCART19 have reduced production times and provide off-the-shelf CAR-T cells when compared to autologous CAR-T cells, which use the patient's own cells and are produced on an individual basis. The protein expressed by the RQR8 transgene contains epitopes from CD34 and CD20, which allows tracking of the UCART19 cells with a clinically-approved anti-CD34 antibody. Additionally if the UCART19 cells cause unacceptable side effects, the CD20 portion of the protein permits selective depletion of the UCART19 cells when the anti-CD20 monoclonal antibody rituximab is administered.","Allogeneic CD19-specific Universal CAR19-expressing T-lymphocytes | ALLO-501 | S68587 | TCR/CD52-deficient RQR8+ CD19-CAR+ T-cells | UCART 19 | UCART19 Cells | Universal Chimeric Antigen Receptor T-cell 19 | Universal TALEN Gene-edited CART19 Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524891","Anti-TIM3 Monoclonal Antibody LY3321367","C137820","A monoclonal antibody against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, the anti-TIM-3 monoclonal antibody LY3321367 binds to TIM-3 expressed on certain T-cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.","Anti-TIM3 Monoclonal Antibody LY3321367 | LY 3321367 | LY-3321367 | LY3321367",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524897","Antibody-drug Conjugate MEDI7247","C137821","An antibody-drug conjugate (ADC) consisting of a human monoclonal antibody against neutral amino acid transporter B(0) (ASCT2; SLC1A5) that is site-specifically conjugated, via a protease-cleavable linker, to the cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of anti-ASCT2 ADC MEDI7247, the antibody moiety targets and binds to ASCT2 expressed on cancer cells. Upon antibody/antigen binding, internalization and linker cleavage, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of ASCT2-overexpressing tumor cells. ASCT2, a neutral amino acid transporter that mediates the uptake of glutamine, is overexpressed in a variety of cancer cell types.","Anti-ASCT2 Antibody-drug Conjugate MEDI7247 | ADC MEDI7247 | Anti-ASCT2 ADC MEDI7247 | Anti-ASCT2/PBD ADC MEDI7247 | Antibody-drug Conjugate MEDI7247 | MEDI 7247 | MEDI-7247 | MEDI7247",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524896","89Zr-Desferrioxamine-IAB22M2C","C137822","A radioimmunoconjugate comprised of a minibody (Mb), an inert antibody fragment against the human CD8-antigen on CD8-positive T-cells, conjugated to the chelator desferrioxamine (Df) and labeled with the radioisotope zirconium Zr 89, with potential positron emission tomography (PET) imaging activity. Upon administration, zirconium Zr 89 crefmirlimab berdoxam  specifically targets and binds to the CD8 antigen expressed on T-cells. This enables PET detection of the radioisotope moiety, and may allow the imaging, tracking and quantification of CD8-expressing T-cells. This may detect CD8-positive T-cell distribution and activity, and may help determine the patient's response to cancer immunotherapeutic agents. CD8-positive T-cells play a key role in the eradication of cancer cells. Although the Mb has the same antigen specificity and binding affinity as the full-length antibody, the Mb does not activate or induce the proliferation of CD8-positive T-cells.","Zirconium Zr 89 Crefmirlimab Berdoxam | 89Zr-Crefmirlimab Berdoxam | 89Zr-Desferrioxamine-IAB22M2C | 89Zr-Df-Crefmirlimab | 89Zr-Df-IAB22M2C | ZIRCONIUM ZR-89 CREFMIRLIMAB BERDOXAM | ZIRCONIUM ZR-89-DESFERRIOXAMINE-IAB22M2C | Zirconium Zr 89-Df-Crefmirlimab | Zirconium Zr 89-Df-Crefmirlimab | Zirconium Zr 89-Df-IAB22M2C | Zirconium Zr-89 Crefmirlimab Berdoxam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524618","Gastrointestinal Stromal Tumor Pathologic Distant Metastasis TNM Finding v8","C136755","A pathologic finding about one or more characteristics of gastrointestinal stromal tumor, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Gastrointestinal Stromal Tumor Pathologic Distant Metastasis TNM Finding v8 | GIST Pathologic Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524592","Gastrointestinal Stromal Tumor pM1 TNM Finding v8","C136756","Gastrointestinal stromal tumor with distant metastasis. (from AJCC 8th Ed.)","Gastrointestinal Stromal Tumor pM1 TNM Finding v8 | GIST pM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539865","IPAQ Long Last 7 Days Telephone Format Version - Vigorous Leisure Hr and Min per Week","C141833","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing vigorous physical activities in your leisure time?: Hours and minutes per week.","IPAQ Long Last 7 Days Telephone Format Version - Vigorous Leisure Hr and Min per Week | IPA02-Vigorous Leisure Hr & Min per Week | IPA0223B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539864","IPAQ Long Last 7 Days Telephone Format Version - Vigorous Leisure Minutes per Week","C141834","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing vigorous physical activities in your leisure time?: Minutes per week.","IPAQ Long Last 7 Days Telephone Format Version - Vigorous Leisure Minutes per Week | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539863","IPAQ Long Last 7 Days Telephone Format Version - Days Moderate in Your Leisure Time","C141835","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) During the last 7 days, on how many days did you do moderate physical activities in your leisure time?","IPAQ Long Last 7 Days Telephone Format Version - Days Moderate in Your Leisure Time | IPA02-Days Moderate in Your Leisure Time | IPA0224",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539862","IPA0225A","C141836","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days doing moderate physical activities in your leisure time?: Hours and minutes per day.","IPAQ Long Last 7 Days Telephone Format Version - Moderate Leisure Hr and Min per Day | IPA02-Moderate Leisure Hr & Min per Day | IPA0225A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539861","IPAQ Long Last 7 Days Telephone Format Version - Moderate Leisure Minutes per Day","C141837","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days doing moderate physical activities in your leisure time?: Minutes per day.","IPAQ Long Last 7 Days Telephone Format Version - Moderate Leisure Minutes per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539876","IPAQ Long Last 7 Days Telephone Format Version - Moderate Leisure Hr and Min per Week","C141838","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing moderate physical activities in your leisure time?: Hours and minutes per week.","IPAQ Long Last 7 Days Telephone Format Version - Moderate Leisure Hr and Min per Week | IPA02-Moderate Leisure Hr & Min per Week | IPA0225B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539875","IPAQ Long Last 7 Days Telephone Format Version - Moderate Leisure Minutes per Week","C141839","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing moderate physical activities in your leisure time? Minutes per week.","IPAQ Long Last 7 Days Telephone Format Version - Moderate Leisure Minutes per Week | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003064","Laboratory Animal","C14183","A grouping of those animals that are commonly used as subjects in laboratory research.","Laboratory Animal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539874","IPA0226A","C141840","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) During the last 7 days, how much time did you usually spend sitting on a weekday?: Hours and minutes per day.","IPAQ Long Last 7 Days Telephone Format Version - Sitting Weekday Hr and Min per Day | IPA02-Sitting Weekday Hr & Min per Day | IPA0226A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540148","DRRI-2 - O: People Made Me Feel Proud","C142056","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: people made me feel proud to have served my country in the Armed Forces.","DRRI-2 - O: People Made Me Feel Proud | DRRI1-O: People Made Me Feel Proud | DRRI1O02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540147","DRRI-2 - O: Family Make Me Better When Down","C142057","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: my family members and/or friends make me feel better when I am down.","DRRI-2 - O: Family Make Me Better When Down | DRRI1-O: Family Make Me Better When Down | DRRI1O03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539087","Stage I Thyroid Gland Papillary Carcinoma 55 Years and Older AJCC v8","C140979","Stage I includes: (T1, N0/NX, M0); (T2, N0/NX, M0).  T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. N0: No evidence of locoregional lymph node metastasis. NX: Regional lymph nodes cannot be assessed. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage I Thyroid Gland Papillary Carcinoma 55 Years and Older AJCC v8 | II 55 Years and Older | Stage I Thyroid Gland Papillary Cancer 55 Years and Older",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511360","C3H1 Zinc Finger","C14097","Zinc finger domains are thought to be involved in DNA-binding. Different types exist depending on the cysteine residue positions. C-X8-C-X5-C-X3-H type zinc finger proteins often function in cell cycle or growth regulation, e.g. human TIS11B (butyrate response factor 1) and mouse TTP nuclear protein. The splicing factor U2AF 35-kD subunit, which mediates protein-protein and protein-RNA interactions required for 3-prime splice site selection, also contains this domain. Different CCCH zinc finger proteins interact with the 3-prime UTR of various mRNA. This type of zinc finger is often present in two copies. (NCI)","C3H1 Zinc Finger | Zinc Finger C-X8-C-X5-C-X3-H Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539239","Lugano Classification Stage II Bulky Adult Hodgkin Lymphoma AJCC v8","C141195","Stage II Bulky: Stage II with disease bulk. (from AJCC 8th Ed.)","Lugano Classification Stage II Bulky Adult Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539238","Lugano Classification Advanced Stage Adult Hodgkin Lymphoma AJCC v8","C141196","Advanced stage adult Hodgkin lymphoma based on the Lugano classification criteria. It includes stages III and IV. (from AJCC 8th Ed.)","Lugano Classification Advanced Stage Adult Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539237","Lugano Classification Stage III Adult Hodgkin Lymphoma AJCC v8","C141197","Stage III: Involvement of lymph node regions on both sides of the diaphragm; nodes above the diaphragm with spleen involvement. (from AJCC 8th Ed.)","Lugano Classification Stage III Adult Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539249","Lugano Classification Stage IV Adult Hodgkin Lymphoma AJCC v8","C141198","Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or noncontiguous extralymphatic organ involvement in conjunction with nodal stage II disease; or any extralymphatic organ involvement in nodal stage III disease. Stage IV includes any involvement of the CSF, bone marrow, liver, or lungs (other than by direct extension in stage IIE disease). (from AJCC 8th Ed.)","Lugano Classification Stage IV Adult Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3869920","Stage IE","C141199","A stage term referring to Hodgkin or non-Hodgkin lymphoma involving a single extralymphatic site in the absence of nodal involvement. (from AJCC 8th Ed.)","Stage IE | ",,,,,,,,,,,,,,,"37163939","I",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512156","EXO III Motif","C14119","A conserved amino acid sequence (Tyr-(X)3-Asp) in DNA polymerases that is required for 3' > 5' exonuclease activity.","EXO III Motif | EXO III Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3869844","Stage IIE","C141200","A stage term referring to Hodgkin or non-Hodgkin lymphoma with contiguous extralymphatic extension from a nodal site with or without involvement of other lymph node regions on the same side of the diaphragm. (from AJCC 8th Ed.)","Stage IIE | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539993","DRRI-2 - G: Concerned Depleted Uranium","C141961","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was concerned that I might be exposed to depleted uranium in munitions.","DRRI-2 - G: Concerned Depleted Uranium | DRRI1-G: Concerned Depleted Uranium | DRRI1G08",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539992","DRRI-2 - G: Thought I Would Never Survive","C141962","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I thought I would never survive.","DRRI-2 - G: Thought I Would Never Survive | DRRI1-G: Thought I Would Never Survive | DRRI1G09",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539991","DRRI-2 - G: Concerned Taken Hostage","C141963","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was concerned that I might be taken hostage.","DRRI-2 - G: Concerned Taken Hostage | DRRI1-G: Concerned Taken Hostage | DRRI1G10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539990","DRRI-2 - G: Concerned Locals Against Us","C141964","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was concerned that the locals who were supposed to be helping us were actually working against us.","DRRI-2 - G: Concerned Locals Against Us | DRRI1-G: Concerned Locals Against Us | DRRI1G11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539989","DRRI-2 - G: Concerned Trapped in Crossfire","C141965","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was concerned about being trapped in the crossfire of rival factions.","DRRI-2 - G: Concerned Trapped in Crossfire | DRRI1-G: Concerned Trapped in Crossfire | DRRI1G12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540004","DRRI-2 - H: Had All Supplies Needed","C141966","Deployment Risk and Resilience Inventory-2 (DRRI-2) In preparation for deployment: I had all the supplies and equipment needed to get my job done.","DRRI-2 - H: Had All Supplies Needed | DRRI1-H: Had All Supplies Needed | DRRI1H01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540003","DRRI-2 - H: Confident Ability Use Equipment","C141967","Deployment Risk and Resilience Inventory-2 (DRRI-2) In preparation for deployment: the training I received made me feel confident in my ability to use my equipment.","DRRI-2 - H: Confident Ability Use Equipment | DRRI1-H: Confident Ability Use Equipment | DRRI1H02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1312353","MKL-myocardin-like 2 protein, human","C142161","Myocardin-related transcription factor B (1088 aa, ~118 kDa) is encoded by the human MRTFB gene. This protein plays a role in both transcriptional activation and skeletal muscle differentiation.","Myocardin-Related Transcription Factor B | CTA-276F8.1 | MKL/Myocardin-Like Protein 2 | MKL2 | MRTF-B | MRTFB | Megakaryoblastic Leukemia 2 | Myocardin Related Transcription Factor B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810322","C11ORF95/MKL2 FUSION GENE","C142162","A fusion gene that results from a translocation t(11;16)(q13;p13), which fuses exons 1 through 5 of the ZFTA gene to exons 9 through 13 of the MKL2 gene. This rearrangement is associated with chondroid lipoma.","ZFTA/MKL2 Fusion Gene | C11orf95-MKL2 Fusion Gene | C11orf95-MRTFB Fusion Gene | C11orf95/MKL2 Fusion Gene | C11orf95/MRTFB Fusion Gene | MKL2/C11ORF95 Fusion Gene | ZFTA-MRTFB Fusion Gene | ZFTA/MRTFB Fusion Gene | ZFTA::MKL2 Fusion Gene | ZFTA::MRTFB Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540174","C11orf95-MKL2 Fusion Protein","C142163","A fusion protein (1247 aa, ~137 kDa) encoded by the ZFTA/MKL2 fusion gene. This protein is comprised of the glutamic acid-rich and proline-rich regions of zinc finger translocation-associated protein fused to the SAP domain, coiled-coil region, and C-terminal proline-rich region of MKL/myocardin-like protein 2.","ZFTA/MKL2 Fusion Protein | C11orf95-MKL2 Fusion Protein | C11orf95-MRTFB Fusion Protein | C11orf95/MKL2 Fusion Protein | C11orf95/MRTFB Fusion Protein | Uncharacterized Protein C11orf95-MKL/Myocardin-Like Protein 2 Fusion Protein | Uncharacterized Protein C11orf95/MKL/Myocardin-Like Protein 2 Fusion Protein | ZFTA-MRTFB Fusion Protein | ZFTA/MRTFB Fusion Protein | ZFTA::MKL2 Fusion Protein | ZFTA::MRTFB Fusion Protein | Zinc Finger Translocation-Associated Protein-MKL/Myocardin-Like Protein 2 Fusion Protein | Zinc Finger Translocation-Associated Protein/MKL/Myocardin-Like Protein 2 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540173","Hospital Rounds","C142165","The act of seeing patients in the hospital, or another in-patient setting, to evaluate treatment, assess current course, and document the patient's progress.","Hospital Rounds | Rounds",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540252","ZNF608 Gene","C142212","This gene plays a role in transcriptional repression and DNA binding.","ZNF608 Gene | ZNF608 | Zinc Finger Protein 608 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0814857","confirmatory trial","C142460","A type of phase 3 clinical trial in which the previously characterized actions of a therapeutic intervention, in an earlier phase trial, are verified.","Confirmatory Trial | confirmatory trial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540467","Conformity Assessment","C142461","The means by which regulated products are determined to meet the standards of the European Medicine Agency's Essential Requirements.","Conformity Assessment | conformity assessment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540466","Consumer Safety Officer","C142462","An official of the Food and Drug Administration who coordinates the review process of sponsor applications.","Consumer Safety Officer | consumer safety officer (CSO)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540465","Contingent Subject Trial Contact","C142463","Planned response to an anticipated but conditional event in a clinical trial. (CDISC)","Contingent Subject Trial Contact | contingent subject trial contact",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540453","Control of Electronic Records","C142464","The process by which electronic records are created and maintained in a database for regulated clinical investigations such that the data can be considered adequate and accurate.","Control of Electronic Records | Electronic Records Control | control of electronic records",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540452","Coordinating Committee","C142465","A committee that a sponsor may organize to coordinate the conduct of a multicenter trial. (ICH)","Coordinating Committee | coordinating committee",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540451","Cumulative Enrollment","C142466","The number of active and former participants.","Cumulative Enrollment | enrollment (cumulative)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540450","Current Enrollment","C142467","The number of active participants.","Current Enrollment | enrollment (current)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545920","Daily Living","C142468","Ability of a patient or subject to successfully perform tasks required for daily living.","Daily Living | Daily Living Function | functioning | functions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL462065","Data Acquisition","C142469","Information input into a systematic, automated format from another device or automated source.","Data Acquisition | data acquisition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026802","Muridae","C14246","Taxonomic family which includes mice, rats, and gerbils.","Muridae | ",,,,,,,,,,,,,,,"4155791","Muridae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540448","Data Clarification","C142471","The explanation or answer supplied in response to a data query.","Data Clarification | data clarification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540459","Data Collection Instrument","C142472","An electronic or hard copy mechanism used to collect and assemble clinical information.","Data Collection Instrument | data collection instrument | data collection instruments",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545932","Data Discrepancy","C142473","No value exists.","Data Discrepancy | discrepancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540458","Data Element Identifier","C142474","Information associated with a data element that includes the origin of the data element, the date and time of entry, and the identification number of the study subject to whom the data element applies. (FDA)","Data Element Identifier | data element identifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540457","Data Encryption Standard","C142475","A Federal Information Processing Standards (FIPs) approved cryptographic algorithm for enciphering and deciphering binary coded information. The standard specifies both enciphering and deciphering operations, which are based on a 64-bit binary key.","Data Encryption Standard | data encryption standard (DES)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0872340","data integrity","C142476","The overall accuracy and consistency of information and processes for data control and use.","Data Integrity | data integrity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540455","Data Interchange","C142478","Transferring information between two or more individuals or electronic tools while protecting the validity and accuracy of the information.","Data Interchange | data interchange",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540146","DRRI-2 - O: Go to Family When Need Advice","C142058","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I can go to family members or friends when I need good advice.","DRRI-2 - O: Go to Family When Need Advice | DRRI1-O: Go to Family When Need Advice | DRRI1O04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540145","DRRI-2 - O: Family/Friends Understand","C142059","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: my family and friends understand what I have been through in the Armed Forces.","DRRI-2 - O: Family/Friends Understand | DRRI1-O: Family/Friends Understand | DRRI1O05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014662","Equine Infectious Anemia Virus","C14205","A species of lentivirus, subgenus equine lentiviruses, causing acute and chronic infection in horses. It is transmitted mechanically by biting flies, mosquitoes, and midges, and iatrogenically through unsterilized equipment. Chronic infection often consists of acute episodes with remissions.","Equine Infectious Anemia Virus | EIAV",,,,,,,,,,,,,,,"4250639","Equine infectious anemia virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540144","DRRI-2 - O: I Can Talk About My Deployment","C142060","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: there are family and/or friends with whom I can talk about my deployment experiences.","DRRI-2 - O: I Can Talk About My Deployment | DRRI1-O: I Can Talk About My Deployment | DRRI1O06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540143","DRRI-2 - O: Family Would Lend Money","C142061","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: my family members or friends would lend me money if I needed it.","DRRI-2 - O: Family Would Lend Money | DRRI1-O: Family Would Lend Money | DRRI1O07",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540158","DRRI-2 - O: Family Would Help Move","C142062","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: my family members or friends would help me move my belongings if I needed help.","DRRI-2 - O: Family Would Help Move | DRRI1-O: Family Would Help Move | DRRI1O08",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540157","DRRI-2 - O: Someone Would Help With Tasks","C142063","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: if I were unable to attend to daily chores, there is someone who would help me with these tasks.","DRRI-2 - O: Someone Would Help With Tasks | DRRI1-O: Someone Would Help With Tasks | DRRI1O09",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540156","DRRI-2 - O: When Ill Family Will Help Out","C142064","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: when I am ill, family members or friends will help out until I am well.","DRRI-2 - O: When Ill Family Will Help Out | DRRI1-O: When Ill Family Will Help Out | DRRI1O10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540155","DRRI-2 - P: Input Sought Family Decisions","C142065","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: my input is sought on important family decisions.","DRRI-2 - P: Input Sought Family Decisions | DRRI1-P: Input Sought Family Decisions | DRRI1P01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540154","DRRI-2 - P: Feel Like I Fit in With Family","C142066","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I feel like I fit in with my family.","DRRI-2 - P: Feel Like I Fit in With Family | DRRI1-P: Feel Like I Fit in With Family | DRRI1P02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540152","DRRI-2 - P: Contribution Family Appreciated","C142068","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I feel like my contributions to my family are appreciated.","DRRI-2 - P: Contribution Family Appreciated | DRRI1-P: Contribution Family Appreciated | DRRI1P04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540151","DRRI-2 - P: Share Interests With Family","C142069","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I share many common interests and activities with family members.","DRRI-2 - P: Share Interests With Family | DRRI1-P: Share Interests With Family | DRRI1P05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539248","Childhood Lymphoma by AJCC v8 Stage","C141202","Staging systems for Hodgkin and non-Hodgkin lymphomas of childhood. Different systems are used for Hodgkin lymphoma and non-Hodgkin lymphoma of childhood. Staging of childhood Hodgkin lymphoma is the same as for the adult counterpart and is based on the Lugano classification criteria. The Ann Arbor staging system has been found to be inappropriate for staging of the non-Hodgkin lymphomas of childhood. The St. Jude staging system has been widely accepted and remains the recommended staging system for non-Hodgkin lymphomas of childhood. (from AJCC 8th Ed.)","Childhood Lymphoma by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539245","Lymphoma by AJCC v8 Stage","C141205","A term that refers to the staging of Hodgkin lymphoma and non-Hodgkin lymphoma according to the AJCC v8 classification guidelines.","Lymphoma by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539350","Chronic Lymphocytic Leukemia- Modified Rai Staging System","C141206","A term that refers to the staging of chronic lymphocytic leukemia according to modified Rai staging system. This system is mainly used in North America.","Chronic Lymphocytic Leukemia- Modified Rai Staging System | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539348","Chronic Lymphocytic Leukemia- Binet Staging System","C141208","A term that refers to the staging of chronic lymphocytic leukemia according to Binet staging system. This system is in wide use outside the United States.","Chronic Lymphocytic Leukemia- Binet Staging System | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540161","Levoketoconazole","C142167","An orally available levorotary enantiomer of ketoconazole with potential steroidogenesis inhibitory activity. Following oral administration, levoketoconazole inhibits three cytochrome P450 family enzymes involved in glucocorticoid biosynthesis, 11beta-hydroxylase (CYP11B1), 17alpha-hydroxylase/17,20-lyase (CYP17A1) and steroid 21-hydroxylase (CYP21A2), which reduces the circulating levels of glucocorticoids. Therefore, this agent may normalize the high concentration of cortisol in the blood seen in patients with Cushing syndrome. Compared to racemic ketoconazole, the levo form is a more potent inhibitor of glucocorticoid synthesis. Additionally, this enantiomer is less likely to inhibit cholesterol 7alpha-hydroxylase (CYP7A1); therefore, its use may reduce the risk of hepatoxicity. Cushing syndrome is caused by high levels of cortisol in the blood either due to excessive production and secretion of corticosteroids, which is often the result of adrenocorticotropic hormone (ACTH)-secreting pituitary or adrenocortical neoplasms, or the use of synthetic corticosteroids.","Levoketoconazole | (-)-(2S,4R)-Ketoconazole | 2S,4R Ketoconazole | 2S,4R-Ketoconazole | COR-003 | COR003 | Ethanone, 1-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)- | Ketoconazole, (2S,4R)- | LEVOKETOCONAZOLE | NormoCort | Recorlev",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540160","MGA 012","C142168","A proprietary humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, retifanlimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","Retifanlimab | INCMGA 0012 | INCMGA-0012 | INCMGA00012 | INCMGA0012 | MGA 012 | MGA-012 | MGA012 | RETIFANLIMAB | Retifanlimab-dlwr | Zynyz",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545929","On Treatment","C142170","A patient is receiving treatment.","On Treatment | Under Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1855109","Methylmalonic aciduria cblA type","C142171","An autosomal recessive form of methylmalonic aciduria, caused by mutation(s) in the MMAA gene, encoding MMAA protein.","Methylmalonic Aciduria, cblA Type | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1855102","Methylmalonic Aciduria, cblB Type","C142172","An autosomal recessive form of methylmalonic aciduria, caused by mutation(s) in the MMAB gene, encoding cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial.","Methylmalonic Aciduria, cblB Type | ",,,,,,,,,,,,,,,"4290404","Adenosylcobalamin synthesis defect",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540409","Case Report Form Data","C142410","Information collected from a subject and presented on a case report form.","Case Report Form Data | CRF Data | CRF data",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540408","Case Report Tabulation","C142411","Lists of information that are organized in some fashion.","Case Report Tabulation | case report tabulations (CRT)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540407","Categorical Data","C142412","Types of data which may be divided into groups.","Categorical Data | categorical data",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540406","Causality Assessment","C142413","A medical determination about the likely connection between an adverse event and a treatment or product being studied.","Causality Assessment | causality assessment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540405","CDISC Classifier Role","C142414","Classifier for variables that describe observations in the SDTM. Role is a metadata attribute that determines the type of information conveyed by an observation-describing variable and standardizes rules for using the describing variable. (CDISC)","CDISC Classifier Role | role (CDISC classifier)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540404","CDISC SHARE","C142415","A global, accessible electronic library that enables precise and standardized data element definitions to be used within applications and across studies to improve biomedical research and its link with healthcare. (CDISC)","CDISC Library | CDISC SHARE | CDISC Shared Health And Research Electronic Library | CDISC Shared Health And Research Electronic Library",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540454","Data Item","C142479","A named component of a data element, usually the smallest component. (ANSI)","Data Item | Data Element Item | data item",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026979","Avian Myeloblastosis Virus","C14247","A retro-transcribing virus, of the genus Alpharetrovirus and the family Retroviridae, that causes anemia and malignant disease in wild and domestic fowl.","Avian Myeloblastosis Virus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545944","Data Item Query","C142480","A question concerning an error or inconsistency within a data item collected as part of a clinical study; usually a request from a sponsor or representative to the investigator.","Data Item Query | query",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539790","IPA0209A","C141796","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days traveling in a car, bus, train or other kind of motor vehicle?: Hours and minutes per day.","IPAQ Long Last 7 Days Telephone Format Version - Traveling Hr and Min per Day | IPA02-Traveling Hr & Min per Day | IPA0209A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539900","IPAQ Long Last 7 Days Telephone Format Version - Traveling Hr and Min per Week","C141798","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days traveling in a motor vehicle?: Hours and minutes per week.","IPAQ Long Last 7 Days Telephone Format Version - Traveling Hr and Min per Week | IPA02-Traveling Hr & Min per Week | IPA0209B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539899","IPAQ Long Last 7 Days Telephone Format Version - Traveling Minutes per Week","C141799","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days traveling in a motor vehicle?: Minutes per week.","IPAQ Long Last 7 Days Telephone Format Version - Traveling Minutes per Week | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539898","IPAQ Long Last 7 Days Telephone Format Version - Days Bicycle Place to Place","C141800","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) During the last 7 days, on how many days did you bicycle to go from place to place?","IPAQ Long Last 7 Days Telephone Format Version - Days Bicycle Place to Place | IPA02-Days Bicycle Place to Place | IPA0210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539897","IPA0211A","C141801","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days to bicycle from place to place?: Hours and minutes per day.","IPAQ Long Last 7 Days Telephone Format Version - Bicycle Hr and Min per Day | IPA02-Bicycle Hr & Min per Day | IPA0211A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539896","IPAQ Long Last 7 Days Telephone Format Version - Bicycle Minutes per Day","C141802","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days to bicycle from place to place?: Minutes per day.","IPAQ Long Last 7 Days Telephone Format Version - Bicycle Minutes per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539895","IPAQ Long Last 7 Days Telephone Format Version - Bicycling Hr and Min per Week","C141803","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent bicycling over the last 7 days to travel from place to place?: Hours and minutes per week.","IPAQ Long Last 7 Days Telephone Format Version - Bicycling Hr and Min per Week | IPA02-Bicycling Hr & Min per Week | IPA0211B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510701","ATPase Domain","C14074","A protein domain that binds ATP and catalyzes its convertion to ADP and inorganic phosphate.","ATPase Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538804","Retinoblastoma by AJCC v8 Stage","C140750","A term that refers to the staging of retinoblastoma according to the American Joint Committee on Cancer, 8th edition. This staging system does not apply to central nervous system component of 'trilateral retinoblastoma' (is staged according to the classification for brain and spinal cord), retinoma (or retinocytoma) (no AJCC staging system), and medulloepithelioma (no AJCC staging system). (from AJCC 8th Ed.)","Retinoblastoma by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538803","Retinoblastoma by AJCC v8 Clinical Stage","C140751","A term that refers to the clinical staging of retinoblastoma according to the American Joint Committee on Cancer, 8th edition.","Retinoblastoma by AJCC v8 Clinical Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538912","Clinical Stage II Retinoblastoma AJCC v8","C140753","Stage II includes: cT4a, cN0, cM0, Any H. cT4a: Radiologic evidence of retrobulbar optic nerve involvement or thickening of optic nerve or involvement of orbital tissues. cN0: No regional lymph node involvement. cM0: No signs or symptoms of intracranial or distant metastasis. HX: Unknown or insufficient evidence of a constitutional RB1 gene mutation. H0: Normal RB1 alleles in blood tested with demonstrated high-sensitivity assays. H1: Bilateral retinoblastoma, retinoblastoma with an intracranial primitive neuroectodermal tumor (i.e., trilateral retinoblastoma), patient with family history of retinoblastoma, or molecular definition of a constitutional RB1 gene mutation. (AJCC 8th ed.)","Clinical Stage II Retinoblastoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539515","Riviciclib Hydrochloride","C141429","The hydrochloride salt form of riviciclib, a flavone and cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. Riviciclib selectively binds to and inhibits Cdk4/cyclin D1, Cdk1/cyclin B and Cdk9/cyclin T1, serine/threonine kinases that play key roles in the regulation of the cell cycle and cellular proliferation. Inhibition of these kinases leads to cell cycle arrest during the G1/S transition, thereby leading to an induction of apoptosis, and inhibition of tumor cell proliferation.","Riviciclib Hydrochloride | RIVICICLIB HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539514","Voruciclib","C141430","A cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Upon administration, voruciclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6). This inhibits retinoblastoma (Rb) protein phosphorylation early in the G1 phase, which prevents CDK-mediated G1-S phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.","Voruciclib | 2-(2-Chloro-4-(trifluoromethyl)phenyl)-5,7-dihydroxy-8-((2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl)-4H-1-benzopyran-4-one | P1446A-05 | VORUCICLIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539513","Briciclib","C141431","A benzyl styryl sulfone analog, and a phosphate ester prodrug of ON 013100, with potential antineoplastic activity. Upon hydrolysis, briciclib is converted to ON 013100, which blocks cyclin D mRNA translation and decreases protein expression of cyclin D. This may induce cell cycle arrest and apoptosis in cancer cells overexpressing cyclin D and eventually decrease tumor cell proliferation. Cyclin D, a member of the cyclin family of cell cycle regulators, plays a key role in cell cycle division and is often overexpressed in a variety of hematologic and solid tumors and is correlated with poor prognosis. suppresses cyclin D1 accumulation in cancer cells.","Briciclib | 2-Methoxy-5-(((2-(2,4,6-trimethoxyphenyl)ethenyl)sulfonyl)methyl)phenyl Dihydrogen Phosphate | BRICICLIB | ON-014185",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540391","CDISC Standard","C142416","A standard set of data models, controlled vocabularies, and exchange standards developed by the Clinical Data Interchange Standards Consortium (CDISC), and intended to address the life-cycle of clinical trial development and electronic submission of clinical data; including protocol representation, data collection, tabulation, and analysis.","CDISC Standard | CDISC standards",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540390","Certified Copy","C142417","Reproduction of a primary document, in any format, that has on it an endorsement or certificate that it is a true 'copy' of the primary document.","Certified Copy | certified copy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540389","Certified IRB Professional","C142418","An individual certified to administer and oversee the activities of an institutional review board. The individual must satisfy education and employment requirements and pass an examination conducted by the applied research ethics national association, which is the membership division of Public Responsibility in Medicine and Research.","Certified IRB Professional | certified IRB professional (CIP)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540388","Clean Database","C142419","A database in which all errors have been detected and resolved.","Clean Database | clean database",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026398","Moloney Leukemia Virus","C14241","A positive sense, single-stranded RNA (ssRNA) retrovirus species belonging to the Gammaretrovirus genus. It is a causitive agent for lymphoid leukemia in mice and other mammals.","Moloney Leukemia Virus | M-MuLV | MLV | MURINE LEUKEMIA VIRUS SUBTYPE MOLONEY | MoMuLV | Moloney Murine Leukemia Virus | Moloney Murine Leukemia Virus M-MuLV | Moloney Virus | Rat Moloney Murine Leukemia Virus MoMuLV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540387","Clean File","C142420","A single file in which all errors have been detected and resolved.","Clean File | clean file",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540386","Client Computer","C142421","A personal computer or workstation that relies on a server computer for many resources.","Client Computer | client",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540384","Clinical Clarification","C142423","The resolution to a question about the clinical trial, by sponsor staff.","Clinical Clarification | clinical clarification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540397","Clinical Development Plan","C142424","A descriptive record of the clinical investigations to be executed with a particular treatment, substance or device. This is usually done to obtain marketing approval.","Clinical Development Plan | ClinicalDevelopmentPlan | clinical development plan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1828480","Clinical Document","C142425","Any electronic or written record of clinical observations.","Clinical Document | clinical document",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3242442","clinical document architecture","C142426","A Health Level 7 specification containing the structure and semantics that clinical documents should follow in order to facilitate data exchange.","Clinical Document Architecture | clinical document architecture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540396","Clinical Encounter","C142427","Any physical or virtual contact between a patient (or trial subject) and healthcare provider at which an assessment or activity takes place.","Clinical Encounter | Patient Encounter | clinical encounter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540395","Clinical Equipoise","C142428","A state of uncertainty regarding the therapeutic advantages of one treatment over another.","Clinical Equipoise | equipoise",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539824","IPAQ Long Last 7 Days Self-Administered Format Version - Moderate Home Minutes per Day","C141762","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days doing moderate physical activities inside your home?: minutes per day.","IPAQ Long Last 7 Days Self-Administered Format Version - Moderate Home Minutes per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539823","IPAQ Long Last 7 Days Self-Administered Format Version - Days Walk in Leisure Time","C141763","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you walk for at least 10 minutes at a time in your leisure time?: days per week.","IPAQ Long Last 7 Days Self-Administered Format Version - Days Walk in Leisure Time | IPA03-Days Walk in Leisure Time | IPA0320",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539894","IPAQ Long Last 7 Days Telephone Format Version - Bicycling Minutes per Week","C141804","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent bicycling over the last 7 days to travel from place to place?: Minutes per week.","IPAQ Long Last 7 Days Telephone Format Version - Bicycling Minutes per Week | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539893","IPAQ Long Last 7 Days Telephone Format Version - Days Walk Place to Place","C141805","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) During the last 7 days, on how many days did you walk to go from place to place?","IPAQ Long Last 7 Days Telephone Format Version - Days Walk Place to Place | IPA02-Days Walk Place to Place | IPA0212",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539908","IPA0213A","C141806","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days walking from place to place?: Hours and minutes per day.","IPAQ Long Last 7 Days Telephone Format Version - Walking Place Hr and Min per Day | IPA02-Walking Place Hr & Min per Day | IPA0213A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540071","DRRI-2 - K: Physically Forced to Have Sex","C142011","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, the people I worked with: physically forced me to have sex.","DRRI-2 - K: Physically Forced to Have Sex | DRRI1-K: Physically Forced to Have Sex | DRRI1K16",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540070","DRRI-2 - L: Effect Deployment Relationship","C142012","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, I was concerned about: the effect of the deployment on my relationship with my spouse or significant other.","DRRI-2 - L: Effect Deployment Relationship | DRRI1-L: Effect Deployment Relationship | DRRI1L01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540069","DRRI-2 - L: Missing Out on Children Growth","C142013","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, I was concerned about: missing out on my children's growth and development.","DRRI-2 - L: Missing Out on Children Growth | DRRI1-L: Missing Out on Children Growth | DRRI1L02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540084","DRRI-2 - L: Missing Family Events at Home","C142014","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, I was concerned about: missing important family events at home such as birthdays, weddings, funerals, graduations, etc.","DRRI-2 - L: Missing Family Events at Home | DRRI1-L: Missing Family Events at Home | DRRI1L03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540083","DRRI-2 - L: Safety and Well-being of Spouse","C142015","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, I was concerned about: the safety and well-being of my spouse or significant other.","DRRI-2 - L: Safety and Well-being of Spouse | DRRI1-L: Safety and Well-being of Spouse | DRRI1L04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540081","DRRI-2 - L: Unable to Help Family If Crisis","C142017","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, I was concerned about: being unable to help my family if there was some kind of crisis or emergency.","DRRI-2 - L: Unable to Help Family If Crisis | DRRI1-L: Unable to Help Family If Crisis | DRRI1L06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540080","DRRI-2 - L: Inability Manage Family Affairs","C142018","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, I was concerned about: my inability to directly manage or control family affairs.","DRRI-2 - L: Inability Manage Family Affairs | DRRI1-L: Inability Manage Family Affairs | DRRI1L07",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540079","DRRI-2 - L: Damaging Career Because Deploy","C142019","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, I was concerned about: damaging my career because of the deployment.","DRRI-2 - L: Damaging Career Because Deploy | DRRI1-L: Damaging Career Because Deploy | DRRI1L08",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540510","Electronic Source Report Form","C142537","A digital form that is used to capture and manage original data.","Electronic Source Report Form | eSRF | eSRF (electronic source report form)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540509","Electronic System Deployment","C142538","No value exists.","Electronic System Deployment | deployment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540508","Equivalence Trial","C142539","A clinical trial with the objective of demonstrating clinical insignificance between the responses to two or more treatments.","Equivalence Trial | equivalence | equivalence trial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0319132","Papovavirus","C14253","A non-taxonomic group of animal viruses associated with or causing papillomas or polyomas.","Papovavirus | Virus-Papova",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540507","Essential Trial Document","C142540","A document that demonstrates the compliance of the investigator, sponsor, and monitor of a clinical trial with all applicable regulatory requirements and the standards of Good Clinical Practice.","Essential Trial Document | essential documents",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085546","Ethics Committees","C142541","An independent group that comprises medical, scientific, and non-scientific members, and is tasked with the continuing review and approval of a clinical trial's protocol, methods, and informed consent process to ensure the protection of the rights, safety, and wellbeing of participants.","Ethics Committee | ethics committee",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540506","European Harmonized Standard","C142542","A document of guidelines for activities or their results that is established as a European Norm, approved and recognized by all Member States and published in the Official Journal of the European Communities (OJEC).","European Harmonized Standard | harmonized standard",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540505","European Union Competent Authority","C142544","The managing organization, approved by a European Member State government, responsible for ensuring compliance with national regulations.","European Union Competent Authority | Competent Authority (CA) | EU CA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541251","European Union Notified Body","C142545","An organization designated by an EU country to assess the conformity of certain products before being placed on the market. These bodies carry out tasks related to conformity assessment procedures.","European Union Notified Body | EU-NB | NB | Notified Body (NB)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540489","Evaluable for Safety and Efficacy","C142546","Patients who meet a clinical trial's inclusion criteria for safety analysis and efficacy evaluation.","Evaluable for Safety and Efficacy | evaluable (for efficacy and safety)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540488","Exploratory Investigational New Drug Study","C142547","A type of clinical trial that involves low dosage and short duration of drug exposure for a limited number of study participants with the intent of gathering preliminary data on the mechanism of action, pharmacodynamics, pharmacokinetics, or bioavailability of promising therapeutic candidate agents in human subjects.","Exploratory Investigational New Drug Study | Exploratory IND Study | Exploratory Investigational New Drug Trial | exploratory IND study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540487","Extensible Markup Language Data Element","C142548","A component of an extensible markup language (XML) document that is used to encapsulate pieces of data and may be delimited by start and end tags or an empty element tag.","Extensible Markup Language Data Element | XML Data Element | eXtensible markup language (XML) data element",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540486","Extraction Transformation Load","C142549","A data integration process that involves collecting data from source systems, preparing and transforming the data according to business requirements, and loading them into a data warehouse.","Extraction Transformation Load | ETL | extraction transformation load (ETL)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540485","FDA Action Letter","C142550","A letter from the Food and Drug Administration to a study sponsor announcing an agency decision about approval or non-approval. Action letters include Untitled and Warning Letters.","FDA Action Letter | action letter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540484","FDA Approvable Letter","C142551","A letter from the Food and Drug Administration to a study sponsor that lists issues to be resolved before an approval can be issued.","FDA Approvable Letter | approvable letter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024662","Mouse Mammary Tumor Virus","C14235","Type B retrovirus.  Etiologic agent of mouse mammary tumors.  Transmitted horizontally through the lactating mammary gland and vertically through the germline.  Mechanism of tumorigenesis involves the activation of cellular int genes by promoter/enhancer insertion.","Mouse Mammary Tumor Virus | MMTV",,,,,,,,,,,,,,,"4261994","Mouse mammary tumor virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL539822","IPAQ Long Last 7 Days Self-Administered Format Version - No Walking in Leisure Time","C141764","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you walk for at least 10 minutes at a time in your leisure time?: No walking in leisure time.","IPAQ Long Last 7 Days Self-Administered Format Version - No Walking in Leisure Time | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539821","IPAQ Long Last 7 Days Self-Administered Format Version - Walking Leisure Hr and Min per Day","C141765","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days walking in your leisure time?: hours and minutes per day.","IPAQ Long Last 7 Days Self-Administered Format Version - Walking Leisure Hr and Min per Day | IPA03-Walking Leisure Hr & Min per Day | IPA0321",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539804","IPAQ Long Last 7 Days Self-Administered Format Version - Walking Leisure Minutes per Day","C141766","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days walking in your leisure time?: minutes per day.","IPAQ Long Last 7 Days Self-Administered Format Version - Walking Leisure Minutes per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539803","IPAQ Long Last 7 Days Self-Administered Format Version - Days Vigorous in Leisure Time","C141767","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you do vigorous physical activities like aerobics, running, fast bicycling, or fast swimming in your leisure time?: days per week.","IPAQ Long Last 7 Days Self-Administered Format Version - Days Vigorous in Leisure Time | IPA03-Days Vigorous in Leisure Time | IPA0322",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539802","IPAQ Long Last 7 Days Self-Administered Format Version - No Vigorous Activity Leisure Time","C141768","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you do vigorous physical activities like aerobics, running, fast bicycling, or fast swimming in your leisure time?: No vigorous activity in leisure time.","IPAQ Long Last 7 Days Self-Administered Format Version - No Vigorous Activity Leisure Time | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539801","IPAQ Long Last 7 Days Self-Administered Format Version - Vigorous Leisure Hr and Min per Day","C141769","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days doing vigorous physical activities in your leisure time?: hours and minutes per day.","IPAQ Long Last 7 Days Self-Administered Format Version - Vigorous Leisure Hr and Min per Day | IPA03-Vigorous Leisure Hr & Min per Day | IPA0323",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539800","IPAQ Long Last 7 Days Self-Administered Format Version - Vigorous Leisure Minutes per Day","C141770","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days doing vigorous physical activities in your leisure time?: minutes per day.","IPAQ Long Last 7 Days Self-Administered Format Version - Vigorous Leisure Minutes per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539799","IPAQ Long Last 7 Days Self-Administered Format Version - Days Moderate in Leisure Time","C141771","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you do moderate physical activities like bicycling at a regular pace, swimming at a regular pace, and doubles tennis in your leisure time?: days per week.","IPAQ Long Last 7 Days Self-Administered Format Version - Days Moderate in Leisure Time | IPA03-Days Moderate in Leisure Time | IPA0324",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540002","DRRI-2 - H: Prepared to Deal With Climate","C141968","Deployment Risk and Resilience Inventory-2 (DRRI-2) In preparation for deployment: the training I received prepared me to deal with the region's climate.","DRRI-2 - H: Prepared to Deal With Climate | DRRI1-H: Prepared to Deal With Climate | DRRI1H03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540078","DRRI-2 - L: Care Child/Dependents Receiving","C142020","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, I was concerned about: the care that my child(ren) or other dependents were receiving.","DRRI-2 - L: Care Child/Dependents Receiving | DRRI1-L: Care Child/Dependents Receiving | DRRI1L09",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540077","DRRI-2 - L: Being Cheated on by My Spouse","C142021","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, I was concerned about: being cheated on by my spouse or significant other.","DRRI-2 - L: Being Cheated on by My Spouse | DRRI1-L: Being Cheated on by My Spouse | DRRI1L10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540060","DRRI-2 - L: Family Ability Cope With Stress","C142022","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, I was concerned about: my family's ability to cope with the stress of the deployment.","DRRI-2 - L: Family Ability Cope With Stress | DRRI1-L: Family Ability Cope With Stress | DRRI1L11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540059","DRRI-2 - L: Spouse Ability Manage Household","C142023","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, I was concerned about: my spouse or significant other's ability to manage the household (for example, chores, bills, home repairs, etc.).","DRRI-2 - L: Spouse Ability Manage Household | DRRI1-L: Spouse Ability Manage Household | DRRI1L12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540058","DRRI-2 - L: Losing My Civilian Job","C142024","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, I was concerned about: losing my civilian job because of the deployment.","DRRI-2 - L: Losing My Civilian Job | DRRI1-L: Losing My Civilian Job | DRRI1L13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540057","DRRI-2 - L: Effect Relationship My Children","C142025","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, I was concerned about: the effect of the deployment on my relationship with my child(ren).","DRRI-2 - L: Effect Relationship My Children | DRRI1-L: Effect Relationship My Children | DRRI1L14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540251","ZNF608 wt Allele","C142213","Human ZNF608 wild-type allele is located in the vicinity of 5q23.2 and is approximately 112 kb in length. This allele, which encodes zinc finger protein 608, is involved in transcriptional repression.","ZNF608 wt Allele | DKFZp434M098 | KIAA1281 | NY-REN-36",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540250","Zinc Finger Protein 608","C142214","Zinc finger protein 608 (1512 aa, ~162 kDa) is encoded by the human ZNF608 gene. This protein plays a role in the repression of gene transcription.","Zinc Finger Protein 608 | Renal Carcinoma Antigen NY-REN-36 | ZNF608",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540249","RRAGC Gene","C142215","This gene is involved in the localization of the mammalian target of rapamycin complex 1 (mTORC1).","RRAGC Gene | RRAGC | Ras Related GTP Binding C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540248","RRAGC wt Allele","C142216","Human RRAGC wild-type allele is located in the vicinity of 1p34.3 and is approximately 22 kb in length. This allele, which encodes Ras-related GTP-binding protein C, plays a role in regulating the localization of the mammalian target of rapamycin complex 1 (mTORC1).","RRAGC wt Allele | FLJ13311 | GTR2 | RAGC | Ras Related GTP Binding C wt Allele | Ras-Related GTP Binding C Gene | TIB929",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0967698","RRAGC protein, human","C142217","Ras-related GTP-binding protein C (399 aa, ~44 kDa) is encoded by the human RRAGC gene. This protein is involved in the localization of the mammalian target of rapamycin complex 1 (mTORC1).","Ras-Related GTP-Binding Protein C | GTPase-Interacting Protein 2 | RRAGC | Rag C | Rag C Protein | RagC | TIB929",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540230","KLHL14 Gene","C142218","This gene may play a role in the regulation of protein folding.","KLHL14 Gene | KLHL14 | Kelch Like Family Member 14 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540229","KLHL14 wt Allele","C142219","Human KLHL14 wild-type allele is located in the vicinity of 18q12.1 and is approximately 100 kb in length. This allele, which encodes kelch-like protein 14, may be involved in protein folding.","KLHL14 wt Allele | KIAA1384 | Kelch Like Family Member 14 wt Allele | Kelch-Like 14 (Drosophila) Gene | Kelch-Like 14 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540497","FDA Memorandum of Understanding","C142553","A formal document outlining an agreement between the US Food and Drug Administration and another entity.","FDA Memorandum of Understanding | MOU | memorandum of understanding (MOU)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539873","IPAQ Long Last 7 Days Telephone Format Version - Sitting Weekday Minutes per Day","C141841","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) During the last 7 days, how much time did you usually spend sitting on a weekday?: Minutes per day.","IPAQ Long Last 7 Days Telephone Format Version - Sitting Weekday Minutes per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539872","IPAQ Long Last 7 Days Telephone Format Version - Sitting Hr and Min on Wednesday","C141842","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time in total did you spend sitting on Wednesday?: Hours and minutes on Wednesday.","IPAQ Long Last 7 Days Telephone Format Version - Sitting Hr and Min on Wednesday | IPA02-Sitting Hr & Min on Wednesday | IPA0226B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539871","IPAQ Long Last 7 Days Telephone Format Version - Sitting Minutes per Wednesday","C141843","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time in total did you spend sitting on Wednesday?: Minutes per Wednesday.","IPAQ Long Last 7 Days Telephone Format Version - Sitting Minutes per Wednesday | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539870","IPA0227A","C141844","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) During the last 7 days, how much time did you usually spend sitting on a weekend day?: Hours and minutes per day.","IPAQ Long Last 7 Days Telephone Format Version - Sitting Weekend Hr and Min per Day | IPA02-Sitting Weekend Hr & Min per Day | IPA0227A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539869","IPAQ Long Last 7 Days Telephone Format Version - Sitting Weekend Minutes per Day","C141845","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) During the last 7 days, how much time did you usually spend sitting on a weekend day?: Minutes per day.","IPAQ Long Last 7 Days Telephone Format Version - Sitting Weekend Minutes per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539851","IPAQ Long Last 7 Days Telephone Format Version - Sitting Minutes per Saturday","C141847","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time in total did you spend sitting on Saturday?: Minutes per Saturday.","IPAQ Long Last 7 Days Telephone Format Version - Sitting Minutes per Saturday | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539850","IPAQ Short Last 7 Days Telephone Format Version - Days Vigorous Physical Activities","C141848","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) During the last 7 days, on how many days did you do vigorous physical activities?","IPAQ Short Last 7 Days Telephone Format Version - Days Vigorous Physical Activities | IPA01-Days Vigorous Physical Activities | IPA0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539849","IPA0102A","C141849","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) How much time did you usually spend doing vigorous physical activities on one of those days?: Hours and minutes per day.","IPAQ Short Last 7 Days Telephone Format Version - Vigorous Physical Hr and Min per Day | IPA01-Vigorous Physical Hr & Min per Day | IPA0102A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003069","Transgenic Animal","C14184","Experimental organism whose genome has been altered by the transfer of a gene or genes from another species or breed.","Transgenic Animal | Animals, Transgenic | Transgenic | Transgenics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539848","IPAQ Short Last 7 Days Telephone Format Version - Vigorous Physical Minutes per Day","C141850","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) How much time did you usually spend doing vigorous physical activities on one of those days?: Minutes per day.","IPAQ Short Last 7 Days Telephone Format Version - Vigorous Physical Minutes per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540326","Experimental Organism Benign Mesoblastic Nephroma","C142368","A congenital benign neoplasm of the kidney characterized by the presence of interlacing bundles of homogenous spindle cells with small basophilic nuclei and scant eosinophilic cytoplasm.","Experimental Organism Benign Mesoblastic Nephroma | MESOBLASTIC NEPHROMA, BENIGN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024864","Mason-Pfizer Monkey Virus","C14236","Mason-Pfizer Monkey Virus; causes AIDS-like disease (NCI)","Mason-Pfizer Monkey Virus | MPMV",,,,,,,,,,,,,,,"4266854","Mason-Pfizer monkey virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3661441","Chloride, Amprolium","C142371","No value exists.","Amprolium | 2-Picolinium, 1-((4-Amino-2-propyl-5-pyrimidinyl)methyl)-, Chloride | AMPROLIUM CHLORIDE | Pyridinium, 1-((4-Amino-2-propyl-5-pyrimidinyl)methyl)-2-methyl-, Chloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540323","Camiglibose Anhydrous","C142372","No value exists.","Camiglibose Anhydrous | CAMIGLIBOSE ANHYDROUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540322","Cefetecol Anhydrous","C142373","No value exists.","Cefetecol Anhydrous | CEFETECOL ANHYDROUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540321","Adenosine A2A Receptor Antagonist NIR178","C142374","An orally bioavailable immune checkpoint inhibitor and antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, A2AR antagonist NIR178 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This prevents tumor-released adenosine from interacting with the A2A receptors, thereby blocking the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression.","Adenosine A2A Receptor Antagonist NIR178 | A2AR Antagonist NIR178 | NIR 178",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540334","BRINP3 Gene","C142375","This gene plays a role in cell cycle arrest and neuronal differentiation.","BRINP3 Gene | BMP/Retinoic Acid Inducible Neural Specific 3 Gene | BRINP3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540001","DRRI-2 - H: Accurately Informed About Role","C141969","Deployment Risk and Resilience Inventory-2 (DRRI-2) In preparation for deployment: I was accurately informed about the role my unit was expected to play in the deployment.","DRRI-2 - H: Accurately Informed About Role | DRRI1-H: Accurately Informed About Role | DRRI1H04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540000","DRRI-2 - H: Had Enough Gear in Case Attack","C141970","Deployment Risk and Resilience Inventory-2 (DRRI-2) In preparation for deployment: I had enough gear to protect myself in case of an attack.","DRRI-2 - H: Had Enough Gear in Case Attack | DRRI1-H: Had Enough Gear in Case Attack | DRRI1H05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539999","DRRI-2 - H: Training for Deployment","C141971","Deployment Risk and Resilience Inventory-2 (DRRI-2) In preparation for deployment: I received appropriate training for the nature of the deployment I experienced.","DRRI-2 - H: Training for Deployment | DRRI1-H: Training for Deployment | DRRI1H06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539997","DRRI-2 - H: Prepared to Operate as Team","C141973","Deployment Risk and Resilience Inventory-2 (DRRI-2) In preparation for deployment: my unit was well-prepared to operate as a team during deployment.","DRRI-2 - H: Prepared to Operate as Team | DRRI1-H: Prepared to Operate as Team | DRRI1H08",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539980","DRRI-2 - H: Confident to Perform Tasks","C141974","Deployment Risk and Resilience Inventory-2 (DRRI-2) In preparation for deployment: the training I received made me feel confident in my ability to perform tasks assigned to me during deployment.","DRRI-2 - H: Confident to Perform Tasks | DRRI1-H: Confident to Perform Tasks | DRRI1H09",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539979","DRRI-2 - H: Taught Me Everything I Needed","C141975","Deployment Risk and Resilience Inventory-2 (DRRI-2) In preparation for deployment: the training I received taught me everything I needed to know for deployment.","DRRI-2 - H: Taught Me Everything I Needed | DRRI1-H: Taught Me Everything I Needed | DRRI1H10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539978","DRRI-2 - I: Family Sincerely Interested","C141976","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: family members and/or friends at home were sincerely interested in hearing what was going on with me.","DRRI-2 - I: Family Sincerely Interested | DRRI1-I: Family Sincerely Interested | DRRI1I01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539977","DRRI-2 - I: Had Family I Could Talk To","C141977","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I had family members or friends at home I could talk to when I had a problem.","DRRI-2 - I: Had Family I Could Talk To | DRRI1-I: Had Family I Could Talk To | DRRI1I02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539976","DRRI-2 - I: Could Count on Family Advice","C141978","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I could count on my family members or friends at home for good advice.","DRRI-2 - I: Could Count on Family Advice | DRRI1-I: Could Count on Family Advice | DRRI1I03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539975","DRRI-2 - I: Relatives Look Out for Family","C141979","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: relatives or friends at home could be counted on to look out for the well-being of my family or other dependents (including pets).","DRRI-2 - I: Relatives Look Out for Family | DRRI1-I: Relatives Look Out for Family | DRRI1I04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012578","Diptera","C14197","A large order of insects having a single pair of wings and sucking or piercing mouths; includes true flies and mosquitoes and gnats and crane flies.","Diptera | Flies",,,,,,,,,,,,,,,"4279397","Order Diptera",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL539974","DRRI-2 - I: Relatives Take Care of Finances","C141980","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: relatives or friends at home could be counted on to take care of my finances, property, or belongings if needed.","DRRI-2 - I: Relatives Take Care of Finances | DRRI1-I: Relatives Take Care of Finances | DRRI1I05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540228","Kelch-Like Protein 14","C142220","Kelch-like protein 14 (628 aa, ~71 kDa) is encoded by the human KLHL14 gene. This protein may play a role in protein folding.","Kelch-Like Protein 14 | KLHL14 | Printor | Protein Interactor of Torsin A | Protein Interactor of Torsin-1A | Protein Interactor of TorsinA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540227","SETD1B Gene","C142221","This gene is involved in post-translational methylation of the lysine at position 4 in histone H3.","SETD1B Gene | SET Domain Containing 1B Gene | SETD1B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540226","SETD1B wt Allele","C142222","Human SETD1B wild-type allele is located in the vicinity of 12q24.31 and is approximately 29 kb in length. This allele, which encodes histone-lysine N-methyltransferase SETD1B protein, plays a role in methylation of histone H3.","SETD1B wt Allele | KIAA1076 | KMT2G | SET Domain Containing 1B wt Allele | Set1B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540225","Histone-Lysine N-Methyltransferase SETD1B","C142223","Histone-lysine N-methyltransferase SETD1B (1966 aa, ~213 kDa) is encoded by the human SETD1B gene. This protein is involved in catalyzing the methylation of lysine-4 in histone H3.","Histone-Lysine N-Methyltransferase SETD1B | EC 2.1.1.43 | Lysine N-Methyltransferase 2G | Lysine-Specific Methyltransferase 2G | SET1B | SETD1B | hSET1B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540224","ZNF292 Gene","C142224","This gene plays a role in growth hormone signaling-dependent regulation of transcription.","ZNF292 Gene | ZNF292 | Zinc Finger Protein 292 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3490462","ZNF292 protein, human","C142228","Zinc finger protein 292 (2723 aa, ~305 kDa) is encoded by the human ZNF292 gene. This protein plays a role in the regulation of gene expression.","Zinc Finger Protein 292 | 16 Zinc-Finger Domain Protein | ZNF292",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540236","INO80 Gene","C142229","This gene is involved in double-stranded DNA-dependent ATPase activity, UV-damage excision repair, DNA replication and chromosome segregation.","INO80 Gene | INO80 | INO80 Complex Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540442","Data Item Query Management","C142481","The process of conducting, controlling, or supervising data queries. This may include data review, discrepancy generation, and resolution of errors or inconsistencies.","Data Item Query Management | query management",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540441","Data Item Query Resolution","C142482","The satisfactory closure of a data item query.","Data Item Query Resolution | query resolution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540440","Data Listing","C142483","A group of information elements that are arranged by topic.","Data Listing | data listing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540439","Data Management Convention","C142484","Procedures and policies for data management (e.g., documented procedure(s) for resolving self-evident changes). (ICH)","Data Management Convention | data management conventions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540437","Data Model","C142487","Representation of standards recognized to represent information, including official expression and structure of elements as well as the relationship between elements, to retain the expected meaning.","Data Model | Common Data Model | data model",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540447","Data Monitoring","C142488","Review of clinical information to determine veracity, thoroughness, and dependability.","Data Monitoring | data monitoring",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539847","IPAQ Short Last 7 Days Telephone Format Version - Total Vigorous Hr and Min per Week","C141851","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) How much time in total would you spend over the last 7 days doing vigorous physical activities?: Hours and minutes per week.","IPAQ Short Last 7 Days Telephone Format Version - Total Vigorous Hr and Min per Week | IPA01-Total Vigorous Hr & Min per Week | IPA0102B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539846","IPAQ Short Last 7 Days Telephone Format Version - Total Vigorous Minutes per Week","C141852","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) How much time in total would you spend over the last 7 days doing vigorous physical activities?: Minutes per week.","IPAQ Short Last 7 Days Telephone Format Version - Total Vigorous Minutes per Week | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539107","Thyroid Gland Follicular Carcinoma by AJCC v7 Stage","C140958","A term that refers to the staging of follicular thyroid gland carcinoma, following the rules of the TNM AJCC v7 classification system.","Thyroid Gland Follicular Carcinoma by AJCC v7 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539106","Differentiated Thyroid Gland Carcinoma by AJCC v7 Stage","C140959","A term that refers to the staging of differentiated thyroid gland carcinoma, following the rules of the TNM AJCC v7 classification system.","Differentiated Thyroid Gland Carcinoma by AJCC v7 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511029","BTB/POZ Domain","C14095","The BTB/POZ domain is an approximately 120 amino acid long, hydrophobic region found in two distinct classes of transcriptional regulators that contain either a C-terminal basic leucine zipper motif (POK proteins) or a Zn-finger region (Bach proteins).  This domain has been shown to form homo-dimers in a number of BTB/POZ domain containing proteins. (NCI)","BTB/POZ Domain | BTB (POZ) | BTB (POZ) Domain | BTB Domain | POZ Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539105","Thyroid Gland Papillary Carcinoma by AJCC v7 Stage","C140960","A term that refers to the staging of papillary thyroid gland carcinoma, following the rules of the TNM AJCC v7 classification system.","Thyroid Gland Papillary Carcinoma by AJCC v7 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539104","Differentiated Thyroid Gland Carcinoma Under 45 Years AJCC v7 Stage","C140961","A differentiated thyroid gland carcinoma stage for patients under 45 years of age defined according to the AJCC 7th edition criteria.","Differentiated Thyroid Gland Carcinoma Under 45 Years AJCC v7 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539102","Differentiated Thyroid Gland Carcinoma 45 Years and Older AJCC v7 Stage","C140963","A differentiated thyroid gland carcinoma stage for patients 45 years and older defined according to the AJCC 7th edition criteria.","Differentiated Thyroid Gland Carcinoma 45 Years and Older AJCC v7 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539085","Differentiated Thyroid Gland Carcinoma by AJCC v8 Stage","C140965","A term that refers to the staging of differentiated thyroid gland carcinoma, following the rules of the TNM AJCC v8 classification system.","Differentiated Thyroid Gland Carcinoma by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539729","IPAQ Long Last 7 Days Self-Administered Format Version - Vigorous Work Hr and Min per Day","C141729","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days doing vigorous physical activities as part of your work?: hours and minutes per day.","IPAQ Long Last 7 Days Self-Administered Format Version - Vigorous Work Hr and Min per Day | IPA03-Vigorous Work Hr & Min per Day | IPA0303",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539728","IPAQ Long Last 7 Days Self-Administered Format Version - Vigorous Work Minutes per Day","C141730","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days doing vigorous physical activities as part of your work?: minutes per day.","IPAQ Long Last 7 Days Self-Administered Format Version - Vigorous Work Minutes per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539727","IPAQ Long Last 7 Days Self-Administered Format Version - Days Moderate as Part of Work","C141731","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you do moderate physical activities like carrying light loads as part of your work?: days per week.","IPAQ Long Last 7 Days Self-Administered Format Version - Days Moderate as Part of Work | IPA03-Days Moderate as Part of Work | IPA0304",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539726","IPAQ Long Last 7 Days Self-Administered Format Version - No Moderate Job-related Activity","C141732","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you do moderate physical activities like carrying light loads as part of your work?: No moderate job-related physical activity.","IPAQ Long Last 7 Days Self-Administered Format Version - No Moderate Job-related Activity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539725","IPAQ Long Last 7 Days Self-Administered Format Version - Moderate Work Hr and Min per Day","C141733","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days doing moderate physical activities as part of your work?: hours and minutes per day.","IPAQ Long Last 7 Days Self-Administered Format Version - Moderate Work Hr and Min per Day | IPA03-Moderate Work Hr & Min per Day | IPA0305",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539836","IPAQ Long Last 7 Days Self-Administered Format Version - Moderate Work Minutes per Day","C141734","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days doing moderate physical activities as part of your work?: minutes per day.","IPAQ Long Last 7 Days Self-Administered Format Version - Moderate Work Minutes per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539835","IPAQ Long Last 7 Days Self-Administered Format Version - Days Walk as Part of Your Work","C141735","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you walk for at least 10 minutes at a time as part of your work?: days per week.","IPAQ Long Last 7 Days Self-Administered Format Version - Days Walk as Part of Your Work | IPA03-Days Walk as Part of Your Work | IPA0306",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539834","IPAQ Long Last 7 Days Self-Administered Format Version - No Job-related Walking","C141736","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you walk for at least 10 minutes at a time as part of your work?: No job-related walking.","IPAQ Long Last 7 Days Self-Administered Format Version - No Job-related Walking | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539973","DRRI-2 - I: Happy Communication From Home","C141981","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was happy with the amount of communication I received from people at home.","DRRI-2 - I: Happy Communication From Home | DRRI1-I: Happy Communication From Home | DRRI1I06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1856057","Homocystinuria-Megaloblastic Anemia due to Defect in Cobalamin Metabolism, CblE Complementation Type","C142173","An autosomal recessive condition caused by mutation(s) in the MTRR gene, encoding methionine synthase reductase. It is characterized by homocystinuria and megaloblastic anemia.","Homocystinuria-Megaloblastic Anemia, cblE Complementation Type | HMAE | Methylcobalamin Deficiency, cblE Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1848561","Methylmalonic Aciduria and Homocystinuria, cblC Type","C142174","An autosomal recessive form of combined methylmalonic aciduria and homocystinuria, caused by mutation(s) in the MMACHC gene, encoding methylmalonic aciduria and homocystinuria type C protein.","Methylmalonic Aciduria and Homocystinuria, cblC Type | ",,,,,,,,,,,,,,,"4254080","Cobalamin C disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540167","Lutetium Lu 177 Anti-CA19-9 Monoclonal Antibody 5B1","C142176","A radioimmunoconjugate comprised of a human monoclonal antibody (huMAb-5B1) against the carbohydrate antigen sialyl Lewis A (carbohydrate antigen 19-9; CA19-9) that is conjugated to the chelator 2-(p-isothiocyanatobenzyl)-cyclohexyl-diethylenetriaminepentaacetic acid (CHX-A''-DTPA) and labeled with the beta-emitting radioisotope lutetium Lu 177 (Lu 177), with radioisotopic activity and potential use as an antineoplastic radiotherapeutic and an imaging agent in both planar imaging and single-photon emission computed tomography (SPECT). The antibody moiety of Lu 177 anti-CA19-9 monoclonal antibody 5B1 targets and binds to CA19-9-expressing tumor cells. This may promote killing of CA19-9-expressing tumor cells through the local induction of both complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). Additionally, upon binding and internalization, the Lu 177 moiety can deliver a cytotoxic dose of beta radiation to the CA19-9-expressing tumor cells. Furthermore, the radioisotope moiety may be imaged using planar imaging and SPECT, thus allowing evaluation of the pharmacokinetic profile of the agent, and the imaging and quantification of CA19-9-expressing tumor cells, respectively. CA19-9, a Lewis-type carbohydrate antigen overexpressed on a number of different tumor cell types, plays a key role in tumor cell survival and metastasis.","Lutetium Lu 177 Anti-CA19-9 Monoclonal Antibody 5B1 | 177Lu Human Monoclonal Antibody 5B1 | 177Lu-CHX-A''-DTPA-HuMab-5B1 | Lu 177 Anti-CA19-9 Monoclonal Antibody 5B1 | MVT-1075",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540166","EPZ015938","C142177","An orally available, selective small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), with potential antiproliferative and antineoplastic activities. Although the mechanism of action has not been completely determined, pemrametostat binds to the substrate recognition site of PRMT5 following oral administration and inhibits its methyltransferase activity, which decreases the levels of both monomethylated and dimethylated arginine residues in histones H2A, H3 and H4 and modulates the expression of genes involved in several cellular processes, including cell proliferation. Therefore, this agent may increase the expression of antiproliferative genes and/or decrease the expression of genes that promote cell proliferation and may lead to decreased growth of rapidly proliferating cells, including cancer cells. PRTM5, an arginine methyltransferase that can catalyze the formation of both omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA) on histones and a variety of other protein substrates, is overexpressed in several neoplasms.","Pemrametostat | EPZ015938 | GSK-3326595 | GSK3326595 | PEMRAMETOSTAT | PRMT5 Inhibitor GSK3326595 | Protein Arginine Methyltransferase 5 Inhibitor GSK3326595",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540165","Diffuse Proliferation of Pulmonary Neuroendocrine Cells Present","C142178","A morphologic finding indicating the presence of a diffuse proliferation of neuroendocrine cells in the lung parenchyma.","Diffuse Proliferation of Pulmonary Neuroendocrine Cells Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540164","CDISC SDTM Arm Null Reason Response Terminology","C142179","Terminology associated with the arm null reason response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Arm Null Reason Response Terminology | ARMNULRS | Arm Null Reason | SDTM-ARMNULRS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0949757","Clinical Trials Data Monitoring Committees","C142489","A group of experts that periodically assess information from an ongoing clinical study, including participant's safety and trial effectiveness.","Data Monitoring Committee | DMC | DMOC | DSMB | DSMC | Data Monitoring Committee/Data and Safety Monitoring Board (DMC/DSMB) | Data Monitoring and Oversight Committee | Data and Safety Monitoring Board | Data and Safety Monitoring Committee DSMB | IDMC | Independent Data Monitoring Committee | data monitoring committee (DMC)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027581","Nematoda","C14248","The taxonomic class whose members are unsegmented worms with an elongated rounded body pointed at both ends.","Nematoda | NEMATODA | Nematode | Roundworm | Roundworms",,,,,,,,,,,,,,,"4225497","Nematode",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540445","Data Originator","C142490","The creating entity for each information element that identifies the source of the information capture in the electronic case report form for a clinical investigation. The source could be a person, computer system, device or instrument. (FDA)","Data Originator | data originator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242483","Qualities, Data","C142491","The condition of information that describes its credibility, authenticity, and appropriateness for its function. Important aspects include source recognition, accuracy, innovativeness, and information on changes to the data.","Data Quality | data quality",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086100","Security, Data","C142492","The degree to which data are protected from the risk of accidental or malicious alteration or destruction and from unauthorized access or disclosure. (FDA)","Data Security | data security",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540444","Data Selection Criteria","C142493","The guidelines for choosing and moving specific information elements from the time and place of patient care to the patient report and forward from there to a database and eventually broader population analyses.","Data Selection Criteria | data selection criteria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242578","Storage, Data","C142494","To maintain data by placing the data, or a copy of the data, onto an electronically accessible device for preservation (either in plain-text or encrypted format). (HL7)","Data Storage | data storage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540443","Data Subject","C142495","The person to whom data refers.","Data Subject | data subject",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540430","Data Submission Model","C142496","Standards for information provided to authorizing officials for marketing purposes.","Data Submission Model | submission model",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540429","Data Transcription","C142497","The process by which oral source data is transformed into written language.","Data Transcription | transcription",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545943","Data Transmission","C142499","The transfer of information from one source to another.","Data Transmission | transmit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029017","Tumor Virus","C14249","A virus capable of transforming a cell to a malignant phenotype. (BioTech Life Science Dictionary)","Tumor Virus | Oncogenic Virus | Tumor Viruses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539907","IPAQ Long Last 7 Days Telephone Format Version - Walking Place Minutes per Day","C141807","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days walking from place to place?: Minutes per day.","IPAQ Long Last 7 Days Telephone Format Version - Walking Place Minutes per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539906","IPAQ Long Last 7 Days Telephone Format Version - Walking Place Hr and Min per Week","C141808","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days walking from place to place?: Hours and minutes per week.","IPAQ Long Last 7 Days Telephone Format Version - Walking Place Hr and Min per Week | IPA02-Walking Place Hr & Min per Week | IPA0213B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539905","IPAQ Long Last 7 Days Telephone Format Version - Walking Place Minutes per Week","C141809","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days walking from place to place?: Minutes per week.","IPAQ Long Last 7 Days Telephone Format Version - Walking Place Minutes per Week | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539081","Stage II Differentiated Thyroid Gland Carcinoma AJCC v8","C140969","Stage II includes: Under 55 years: Any T, Any N, M1; 55 years and older: (T1, N1, M0); (T2, N1, M0); (T3a/T3b, Any N, M0). T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. T3a: Tumor measuring more than 4 cm in greatest dimension limited to the thyroid. T3b: Gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles) from a tumor of any size. N1: Metastasis to regional nodes. M0: No distant metastasis. M1: Distant metastasis. (from AJCC 8th Ed.)","Stage II Differentiated Thyroid Gland Carcinoma AJCC v8 | Stage II Differentiated Thyroid Gland Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539667","A4STR1TC","C141663","Test codes of questionnaire questions associated with the Four Stair Ascend Test (4 Stair Ascend) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Functional Test 4-Stair Ascend Test Code Terminology | 4-Stair Ascend Functional Test Test Code | A4STR1TC | FT-4 Stair Ascend TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539666","CDISC Questionnaire IPAQ Short Last 7 Days Self-administered Format Version Test Name Terminology","C141664","Test names of questionnaire questions associated with the International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire IPAQ Short Last 7 Days Self-administered Format Version Test Name Terminology | IPAQ04TN | International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format Questionnaire Test Name | QS-IPAQ Short Last 7 Days Self-administered Format Version TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539665","CDISC Questionnaire IPAQ Short Last 7 Days Self-administered Format Version Test Code Terminology","C141665","Test codes of questionnaire questions associated with the International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire IPAQ Short Last 7 Days Self-administered Format Version Test Code Terminology | IPAQ04TC | International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format Questionnaire Test Code | QS-IPAQ Short Last 7 Days Self-administered Format Version TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539664","CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Name Terminology","C141666","Test names of questionnaire questions associated with the International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Name Terminology | IPAQ03TN | International Physical Activity Questionnaire (October 2002) Long Last 7 Days Self-Administered Format Questionnaire Test Name | QS-IPAQ Long Last 7 Days Self-Administered Format Version TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539663","CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Code Terminology","C141667","Test codes of questionnaire questions associated with the International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Code Terminology | IPAQ03TC | International Physical Activity Questionnaire (October 2002) Long Last 7 Days Self-Administered Format Questionnaire Test Code | QS-IPAQ Long Last 7 Days Self-Administered Format Version TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539662","CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology","C141668","Test names of questionnaire questions associated with the International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology | IPAQ02TN | International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format Questionnaire Test Name | QS-IPAQ Long Last 7 Days Telephone Format Version TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539833","IPAQ Long Last 7 Days Self-Administered Format Version - Walking Work Hr and Min per Day","C141737","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days walking as part of your work?: hours and minutes per day.","IPAQ Long Last 7 Days Self-Administered Format Version - Walking Work Hr and Min per Day | IPA03-Walking Work Hr & Min per Day | IPA0307",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539832","IPAQ Long Last 7 Days Self-Administered Format Version - Walking Work Minutes per Day","C141738","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days walking as part of your work?: minutes per day.","IPAQ Long Last 7 Days Self-Administered Format Version - Walking Work Minutes per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539919","DRRI-2 - D: Think I Wounded/Killed Someone","C141923","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I think I wounded or killed someone during combat operations.","DRRI-2 - D: Think I Wounded/Killed Someone | DRRI1-D: Think I Wounded/Killed Someone | DRRI1D13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539918","DRRI-2 - D: Locating Explosive Devices","C141924","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was involved in locating or disarming explosive devices.","DRRI-2 - D: Locating Explosive Devices | DRRI1-D: Locating Explosive Devices | DRRI1D14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539917","DRRI-2 - D: Searching Homes/Buildings","C141925","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was involved in searching or clearing homes, buildings, or other locations.","DRRI-2 - D: Searching Homes/Buildings | DRRI1-D: Searching Homes/Buildings | DRRI1D15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540028","DRRI-2 - D: Participate Hand-to-hand Combat","C141926","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I participated in hand-to-hand combat.","DRRI-2 - D: Participate Hand-to-hand Combat | DRRI1-D: Participate Hand-to-hand Combat | DRRI1D16",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540027","DRRI-2 - D: Search/Disarm Potential Enemy","C141927","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was involved in searching and/or disarming potential enemy combatants.","DRRI-2 - D: Search/Disarm Potential Enemy | DRRI1-D: Search/Disarm Potential Enemy | DRRI1D17",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540026","DRRI-2 - E: Saw People Begging for Food","C141928","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I saw people begging for food.","DRRI-2 - E: Saw People Begging for Food | DRRI1-E: Saw People Begging for Food | DRRI1E01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540025","DRRI-2 - E: Saw Refugees Who Had Lost Homes","C141929","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I saw refugees who had lost their homes or belongings.","DRRI-2 - E: Saw Refugees Who Had Lost Homes | DRRI1-E: Saw Refugees Who Had Lost Homes | DRRI1E02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540023","DRRI-2 - E: Took Care Injured/Dying People","C141931","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I took care of injured or dying people.","DRRI-2 - E: Took Care Injured/Dying People | DRRI1-E: Took Care Injured/Dying People | DRRI1E04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540022","DRRI-2 - E: Saw Civilians After Wounded","C141932","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I saw civilians after they had been severely wounded or disfigured.","DRRI-2 - E: Saw Civilians After Wounded | DRRI1-E: Saw Civilians After Wounded | DRRI1E05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540021","DRRI-2 - E: Saw Combatants Had Been Wounded","C141933","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I saw enemy combatants after they had been severely wounded or disfigured.","DRRI-2 - E: Saw Combatants Had Been Wounded | DRRI1-E: Saw Combatants Had Been Wounded | DRRI1E06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540394","Clinical Generalizability","C142429","The extent to which the findings of a clinical trial can be reliably extrapolated from the subjects who participated in the trial to a broader patient population and a broader range of clinical settings. (ICH)","Clinical Generalizability | generalizability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026399","Moloney Sarcoma Virus","C14242","A positive sense, single-stranded RNA (ssRNA), replication-defective retrovirus species belonging to the Gammaretrovirus genus. It is a causitive agent for sarcomas in mice and other mammals.","Moloney Sarcoma Virus | MMSV | MoMSV | MoMuSV | Moloney Murine Sarcoma Virus",,,,,,,,,,,,,,,"4234374","Moloney murine sarcoma virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540393","Clinical Investigation","C142430","Any experiment that involves a test article and one or more human subjects, and must either meet the requirements for prior submission to the FDA or the results of which are to be submitted to or inspected by the FDA later as part of an application for a research or marketing permit.","Clinical Investigation | clinical investigation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540392","Clinical Item","C142431","A discrete piece of clinical information represented in a way that humans or machines can understand and interpret.","Clinical Item | item",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540375","Clinical Outcomes Assessment Concept of Interest","C142433","The characteristic or variable that is measured in a clinical outcome assessment.","Clinical Outcomes Assessment Concept of Interest | COA COI | concept of interest",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540374","Clinical Outcomes Assessment Context of Use","C142434","A description of the purpose and criteria for use of a clinical outcome assessment.","Clinical Outcomes Assessment Context of Use | context of use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540373","Clinical Research and Development","C142435","The development and testing of a drug, device, or therapy in human subjects to determine safety and efficacy.","Clinical Research and Development | clinical research | clinical research and development",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545916","Clinical Study Anchor","C142436","A planned activity within a clinical study that marks a transition between epochs or elements within the clinical study.","Clinical Study Anchor | Anchor | anchor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540371","Clinical Study Functional Role","C142438","The responsibility assumed by a person administering any activities within a clinical study.","Clinical Study Functional Role | functional roles (in a study)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540370","Clinical Study Report","C142439","A written description of a study of any therapeutic, prophylactic, or diagnostic agent conducted in human subjects, in which the clinical and statistical description, presentations, and analysis are fully integrated into a single report. (ICH E6)","Clinical Study Report | clinical study report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540383","Clinical Trial Authorization","C142440","Authorization from an regulatory agency to undertake a clinical trial.","Clinical Trial Authorization | clinical trial authorization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002668","Amphibia","C14180","A taxonomic class of vertebrates that include frogs, toads, newts, salamanders, and gymnophiona. Amphibians are cold blooded land animals that lay eggs in the water. The juveniles of this class metamorphose from water-breathing organisms to air-breathing organisms upon adult maturation.","Amphibia | Amphibian | Amphibians",,,,,,,,,,,,,,,"4302847","Class Amphibia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL539904","IPAQ Long Last 7 Days Telephone Format Version - Days Vigorous in the Garden/Yard","C141810","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) During the last 7 days, on how many days did you do vigorous physical activities in the garden or yard?","IPAQ Long Last 7 Days Telephone Format Version - Days Vigorous in the Garden/Yard | IPA02-Days Vigorous in the Garden/Yard | IPA0214",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539903","IPA0215A","C141811","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days doing vigorous physical activities in the garden or yard?: Hours and minutes per day.","IPAQ Long Last 7 Days Telephone Format Version - Vigorous Garden Hr and Min per Day | IPA02-Vigorous Garden Hr & Min per Day | IPA0215A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539902","IPAQ Long Last 7 Days Telephone Format Version - Vigorous Garden Minutes per Day","C141812","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days doing vigorous physical activities in the garden or yard?: Minutes per day.","IPAQ Long Last 7 Days Telephone Format Version - Vigorous Garden Minutes per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539901","IPAQ Long Last 7 Days Telephone Format Version - Vigorous Garden Hr and Min per Week","C141813","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing vigorous physical activities in the garden or yard?: Hours and minutes per week.","IPAQ Long Last 7 Days Telephone Format Version - Vigorous Garden Hr and Min per Week | IPA02-Vigorous Garden Hr & Min per Week | IPA0215B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539884","IPAQ Long Last 7 Days Telephone Format Version - Vigorous Garden Minutes per Week","C141814","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing vigorous physical activities in the garden or yard?: Minutes per week.","IPAQ Long Last 7 Days Telephone Format Version - Vigorous Garden Minutes per Week | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539882","IPA0217A","C141816","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days doing moderate physical activities in the garden or yard?: Hours and minutes per day.","IPAQ Long Last 7 Days Telephone Format Version - Moderate Garden Hr and Min per Day | IPA02-Moderate Garden Hr & Min per Day | IPA0217A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539881","IPAQ Long Last 7 Days Telephone Format Version - Moderate Garden Minutes per Day","C141817","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days doing moderate physical activities in the garden or yard?: Minutes per day.","IPAQ Long Last 7 Days Telephone Format Version - Moderate Garden Minutes per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540056","DRRI-2 - L: My Family Financial Situation","C142026","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, I was concerned about: my family's financial situation.","DRRI-2 - L: My Family Financial Situation | DRRI1-L: My Family Financial Situation | DRRI1L15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540055","DRRI-2 - M: Problems Get in Touch Family","C142027","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I had problems getting in touch with a family member or other loved one.","DRRI-2 - M: Problems Get in Touch Family | DRRI1-M: Problems Get in Touch Family | DRRI1M01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540054","DRRI-2 - M: Someone Close Serious Illness","C142028","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: someone close to me experienced a serious illness, injury, or mental health problem (for example, cancer, alcohol/drug problem).","DRRI-2 - M: Someone Close Serious Illness | DRRI1-M: Someone Close Serious Illness | DRRI1M02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539661","CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology","C141669","Test codes of questionnaire questions associated with the International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology | IPAQ02TC | International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format Questionnaire Test Code | QS-IPAQ Long Last 7 Days Telephone Format Version TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539772","CDISC Questionnaire IPAQ Short Last 7 Days Telephone Format Version Test Name Terminology","C141670","Test names of questionnaire questions associated with the International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire IPAQ Short Last 7 Days Telephone Format Version Test Name Terminology | IPAQ01TN | International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format Questionnaire Test Name | QS-IPAQ Short Last 7 Days Telephone Format Version TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539270","Lugano Classification Stage IE Adult Non-Hodgkin Lymphoma AJCC v8","C141161","Stage IE: Single extralymphatic site in the absence of nodal involvement. (from AJCC 8th Ed.)","Lugano Classification Stage IE Adult Non-Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539269","Lugano Classification Stage II Adult Non-Hodgkin Lymphoma AJCC v8","C141162","Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm. (from AJCC 8th Ed.)","Lugano Classification Stage II Adult Non-Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539268","Lugano Classification Stage IIE Adult Non-Hodgkin Lymphoma AJCC v8","C141163","Stage IIE: Contiguous extralymphatic extension from a nodal site with or without involvement of other lymph node regions on the same side of the diaphragm. (from AJCC 8th Ed.)","Lugano Classification Stage IIE Adult Non-Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539267","Lugano Classification Stage II Bulky Adult Non-Hodgkin Lymphoma AJCC v8","C141164","Stage II Bulky: Stage II with disease bulk. (from AJCC 8th Ed.)","Lugano Classification Stage II Bulky Adult Non-Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539266","Lugano Classification Advanced Stage Adult Non-Hodgkin Lymphoma AJCC v8","C141165","Advanced stage adult non-Hodgkin lymphoma based on the Lugano classification criteria. It includes stages III and IV. (from AJCC 8th Ed.)","Lugano Classification Advanced Stage Adult Non-Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539281","Lugano Classification Stage III Adult Non-Hodgkin Lymphoma AJCC v8","C141166","Stage III: Involvement of lymph node regions on both sides of the diaphragm; nodes above the diaphragm with spleen involvement. (from AJCC 8th Ed.)","Lugano Classification Stage III Adult Non-Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539280","Lugano Classification Stage IV Adult Non-Hodgkin Lymphoma AJCC v8","C141167","Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or noncontiguous extralymphatic organ involvement in conjunction with nodal stage II disease; or any extralymphatic organ involvement in nodal stage III disease. Stage IV includes any involvement of the CSF, bone marrow, liver, or lungs (other than by direct extension in stage IIE disease). (from AJCC 8th Ed.)","Lugano Classification Stage IV Adult Non-Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539279","Lugano Classification Hodgkin Lymphoma by AJCC v8 Stage","C141168","A staging system for Hodgkin lymphomas based on the Lugano classification criteria. Staging for childhood Hodgkin lymphoma is the same as for the adult counterpart. (from AJCC 8th Ed.)","Lugano Classification Hodgkin Lymphoma by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539278","Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8","C141169","Limited stage Hodgkin lymphoma based on the Lugano classification criteria. It includes stages I, IE, II, and IIE. (from AJCC 8th Ed.)","Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540035","DRRI-2 - E: Saw Bodies of Dead Enemy","C141935","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I saw the bodies of dead enemy combatants.","DRRI-2 - E: Saw Bodies of Dead Enemy | DRRI1-E: Saw Bodies of Dead Enemy | DRRI1E08",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540034","DRRI-2 - E: Saw Bodies of Dead Americans","C141936","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I saw the bodies of dead Americans or allies.","DRRI-2 - E: Saw Bodies of Dead Americans | DRRI1-E: Saw Bodies of Dead Americans | DRRI1E09",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540033","DRRI-2 - E: Saw Bodies of Dead Civilians","C141937","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I saw the bodies of dead civilians.","DRRI-2 - E: Saw Bodies of Dead Civilians | DRRI1-E: Saw Bodies of Dead Civilians | DRRI1E10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540032","DRRI-2 - E: Interacted With Detainees","C141938","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I interacted with detainees or prisoners of war.","DRRI-2 - E: Interacted With Detainees | DRRI1-E: Interacted With Detainees | DRRI1E11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540181","Lipid Nanoparticle Encapsulated OX40L mRNA-2416","C142137","A proprietary formulation consisting of a lipid nanoparticle encapsulating a synthetic messenger RNA (mRNA) encoding the human co-stimulatory protein tumor necrosis factor ligand superfamily member 4 (TNFSF4; OX40 Ligand; OX40L), with potential immunomodulatory and antitumor activities. Although the mechanism of action has not been completely characterized, following intratumoral injection of lipid nanoparticle encapsulated OX40L mRNA-2416, the lipid nanoparticle moiety presumably binds to the plasma membrane of nearby cells and releases the OX40L mRNA into the cell. The OX40L mRNA is then translated by the cellular protein translation machinery to produce OX40L protein, which is then expressed on the plasma membrane of the cells that internalized the OX40L mRNA. OX40L binds to and activates signaling pathways downstream of its cognate receptor tumor necrosis factor receptor superfamily member 4 (TNFRSF4; OX40), which is expressed on activated T-cells. OX40L/OX40 binding promotes increased cytokine production, which can induce proliferation of memory and effector T-lymphocytes. Altogether, this may enhance an immune response that promotes the killing of nearby tumor cells. OX40L, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) ligand family, provides a co-stimulatory signal for the proliferation and survival of activated T cells.","Lipid Nanoparticle Encapsulated OX40L mRNA-2416 | Lipid Nanoparticle Encapsulated mRNA Encoding Human OX40L | mRNA 2416 | mRNA-2416",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3147319","FTH1P5 Gene","C142138","Human FTH1P5 gene is located in the vicinity of 6p12.3 and is approximately 1 kb in length. The product is a processed pseudogene, which produces an RNA transcript but does not encode a protein product.","FTH1P5 Gene | FTH1P5 | Ferritin Heavy Chain 1 Pseudogene 5 Gene | Ferritin, Heavy Polypeptide 1 Pseudogene 5 Gene | Ferritin, Heavy Polypeptide Pseudogene 1 Gene | Ferritin, Heavy Polypeptide-Like 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540381","Clinical Trial Design Configuration","C142442","No value exists.","Clinical Trial Design Configuration | design configuration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545940","Clinical Trial Development Plan","C142443","No value exists.","Clinical Trial Development Plan | development plan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539798","IPAQ Long Last 7 Days Self-Administered Format Version - No Moderate Activity Leisure Time","C141772","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you do moderate physical activities like bicycling at a regular pace, swimming at a regular pace, and doubles tennis in your leisure time?: No moderate activity in leisure time.","IPAQ Long Last 7 Days Self-Administered Format Version - No Moderate Activity Leisure Time | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539797","IPAQ Long Last 7 Days Self-Administered Format Version - Moderate Leisure Hr and Min per Day","C141773","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days doing moderate physical activities in your leisure time?: hours and minutes per day.","IPAQ Long Last 7 Days Self-Administered Format Version - Moderate Leisure Hr and Min per Day | IPA03-Moderate Leisure Hr & Min per Day | IPA0325",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539812","IPAQ Long Last 7 Days Self-Administered Format Version - Moderate Leisure Minutes per Day","C141774","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days doing moderate physical activities in your leisure time?: minutes per day.","IPAQ Long Last 7 Days Self-Administered Format Version - Moderate Leisure Minutes per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539811","IPAQ Long Last 7 Days Self-Administered Format Version - Sitting Weekday Hr and Min per Day","C141775","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, how much time did you usually spend sitting on a weekday?: hours and minutes per day.","IPAQ Long Last 7 Days Self-Administered Format Version - Sitting Weekday Hr and Min per Day | IPA03-Sitting Weekday Hr & Min per Day | IPA0326",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539810","IPAQ Long Last 7 Days Self-Administered Format Version - Sitting Weekday Minutes per Day","C141776","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, how much time did you usually spend sitting on a weekday?: minutes per day.","IPAQ Long Last 7 Days Self-Administered Format Version - Sitting Weekday Minutes per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539809","IPAQ Long Last 7 Days Self-Administered Format Version - Sitting Weekend Hr and Min per Day","C141777","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, how much time did you usually spend sitting on a weekend day?: hours and minutes per day.","IPAQ Long Last 7 Days Self-Administered Format Version - Sitting Weekend Hr and Min per Day | IPA03-Sitting Weekend Hr & Min per Day | IPA0327",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539808","IPAQ Long Last 7 Days Self-Administered Format Version - Sitting Weekend Minutes per Day","C141778","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, how much time did you usually spend sitting on a weekend day?: minutes per day.","IPAQ Long Last 7 Days Self-Administered Format Version - Sitting Weekend Minutes per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540053","DRRI-2 - M: Family Member Passed Away","C142029","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: a family member or other loved one passed away.","DRRI-2 - M: Family Member Passed Away | DRRI1-M: Family Member Passed Away | DRRI1M03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0013138","Drosophila","C14202","A genus of small, American flies, Diptera. The best known species is D. Melanogaster, often called the fruit fly, but more correctly termed the vinegar fly. First investigated by T.H.Morgan and his group, it has been extensively used in genetic studies. More recently it has been used for studies of embryonic development.","Drosophila | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540068","DRRI-2 - M: My Family Had Money Problems","C142030","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: my family had money problems.","DRRI-2 - M: My Family Had Money Problems | DRRI1-M: My Family Had Money Problems | DRRI1M04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540066","DRRI-2 - M: Spouse Suspected I Cheated","C142032","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: a spouse or significant other suspected that I had cheated on him/her.","DRRI-2 - M: Spouse Suspected I Cheated | DRRI1-M: Spouse Suspected I Cheated | DRRI1M06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540065","DRRI-2 - M: Relationship With Spouse Ended","C142033","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: my relationship with a spouse or significant other ended.","DRRI-2 - M: Relationship With Spouse Ended | DRRI1-M: Relationship With Spouse Ended | DRRI1M07",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540064","DRRI-2 - M: Had Major Conflict With Family","C142034","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I had a major conflict with a family member or other loved one.","DRRI-2 - M: Had Major Conflict With Family | DRRI1-M: Had Major Conflict With Family | DRRI1M08",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540063","DRRI-2 - M: Family Had Difficulty Adjusting","C142035","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: a family member or other loved one had serious difficulty adjusting to my absence.","DRRI-2 - M: Family Had Difficulty Adjusting | DRRI1-M: Family Had Difficulty Adjusting | DRRI1M09",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540062","DRRI-2 - M: My Home Was Robbed","C142036","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: my home was robbed and/or my belongings were stolen.","DRRI-2 - M: My Home Was Robbed | DRRI1-M: My Home Was Robbed | DRRI1M10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540061","DRRI-2 - M: Family Member Wasted Money","C142037","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: a family member or other person I trusted wasted or mismanaged my money.","DRRI-2 - M: Family Member Wasted Money | DRRI1-M: Family Member Wasted Money | DRRI1M11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540044","DRRI-2 - M: Loved One Things I Disapproved","C142038","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I learned that a loved one was doing things I disapproved of.","DRRI-2 - M: Loved One Things I Disapproved | DRRI1-M: Loved One Things I Disapproved | DRRI1M12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540043","DRRI-2 - M: Fam Dangerous Military Duties","C142039","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: a family member or other loved one participated in dangerous military duties.","DRRI-2 - M: Fam Dangerous Military Duties | DRRI1-M: Fam Dangerous Military Duties | DRRI1M13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540042","DRRI-2 - M: Family Got Into Trouble","C142040","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: a family member got into trouble at home, at school, or in the community.","DRRI-2 - M: Family Got Into Trouble | DRRI1-M: Family Got Into Trouble | DRRI1M14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540235","INO80 wt Allele","C142230","Human INO80 wild-type allele is located in the vicinity of 15q15.1 and is approximately 137 kb in length. This allele, which encodes DNA helicase INO80 protein, plays a role in DNA helicase activity.","INO80 wt Allele | Homolog of Yeast INO80 Gene | INO80 Complex Homolog 1 (S. cerevisiae) Gene | INO80 Complex Homolog 1 Gene | INO80 Complex Subunit wt Allele | INO80 Complex, Catalytic Subunit Gene | INO80 Complex, Subunit A Gene | INO80 Homolog (S. cerevisiae) Gene | INO80, S. cerevisae, Homolog of Gene | INO80A | INOC1 | KIAA1259 | hINO80",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539277","Lugano Classification Stage I Hodgkin Lymphoma AJCC v8","C141170","Stage I: Involvement of a single lymphatic site (i.e., nodal region, Waldeyer's ring, thymus, or spleen). (from AJCC 8th Ed.)","Lugano Classification Stage I Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539276","Lugano Classification Stage IE Hodgkin Lymphoma AJCC v8","C141171","Stage IE: Single extralymphatic site in the absence of nodal involvement (rare in Hodgkin lymphoma). (from AJCC 8th Ed.)","Lugano Classification Stage IE Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539275","Lugano Classification Stage II Hodgkin Lymphoma AJCC v8","C141172","Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm. (from AJCC 8th Ed.)","Lugano Classification Stage II Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539274","Lugano Classification Stage IIE Hodgkin Lymphoma AJCC v8","C141173","Stage IIE: Contiguous extralymphatic extension from a nodal site with or without involvement of other lymph node regions on the same side of the diaphragm. (from AJCC 8th Ed.)","Lugano Classification Stage IIE Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539257","Lugano Classification Stage II Bulky Hodgkin Lymphoma AJCC v8","C141174","Stage II Bulky: Stage II with disease bulk. (from AJCC 8th Ed.)","Lugano Classification Stage II Bulky Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539256","Lugano Classification Advanced Stage Hodgkin Lymphoma AJCC v8","C141175","Advanced stage Hodgkin lymphoma based on the Lugano classification criteria. It includes stages III and IV. (from AJCC 8th Ed.)","Lugano Classification Advanced Stage Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540179","INO-1401","C142139","A DNA vaccine consisting of a plasmid encoding a synthetic, full-length sequence of the tumor-associated antigen (TAA) telomerase reverse transcriptase (TERT), which was derived from the consensus sequence from humans and primates and contains two immunogenic mutations (SynCon TERT), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration of INO-1401 in combination with electroporation, TERT protein is expressed and activates the immune system to mount a cytotoxic T-cell (CTL) response against telomerase-expressing tumor cells, which may result in tumor cell death. TERT is the catalytic subunit of telomerase and synthesizes telomeric DNA at the chromosome ends. Telomerase prolongs the functional lifespan of cells via the restoration and maintenance of telomere length. Abnormally activated in tumorigenesis, TERT is expressed by many types of human cancer cells, but its expression is low or non-existent in normal cells.","Synthetic hTERT DNA Vaccine INO-1401 | INO-1401 | SynCon TERT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019092","Hantavirus","C14213","A genus of single-stranded, segmented, negative-sense RNA viruses in the family bunyaviridae. These viruses are transmitted by aerosolized rodent excreta or rodent bites.","Hantavirus | HANTAVIRUS",,,,,,,,,,,,,,,"4174216","Genus Hantavirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540191","SSB Gene","C142143","This gene is involved in binding to both transfer and messenger RNA.","SSB Gene | SSB | Sjogren Syndrome Antigen B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540190","SSB wt Allele","C142144","Human SSB wild-type allele is located in the vicinity of 2q31.1 and is approximately 20 kb in length. This allele, which encodes Lupus La protein, plays a role in metabolism of both tRNA and mRNA.","SSB wt Allele | LARP3 | La | La Ribonucleoprotein Domain Family, Member 3 Gene | La/SSB | SS-B | Sjogren Syndrome Antigen B (Autoantigen La) Gene | Sjogren Syndrome Antigen B wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540189","Lupus La Protein","C142145","Lupus La protein (408 aa, ~47 kDa) is encoded by the human SSB gene. This protein is involved in the modulation of tRNA and mRNA metabolism.","Lupus La Protein | Autoantigen La | La Autoantigen | La Ribonucleoprotein | Lupus La Antigen | SS-B | SS-B/La Protein | SSB | Sjoegren Syndrome Type B Antigen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2353785","DBCCR1-like protein 1, human","C142377","BMP/retinoic acid-inducible neural-specific protein 3 (766 aa, ~88 kDa) is encoded by the human BRINP3 gene. This protein plays a role in promoting cell cycle arrest to induce neuronal differentiation.","BMP/Retinoic Acid-Inducible Neural-Specific Protein 3 | BMP/Retinoic Acid Inducible Neural Specific 3 | BRINP3 | Bone Morphogenetic Protein/Retinoic Acid Inducible Neural-Specific 3 | Bone Morphogenetic Protein/Retinoic Acid-Inducible Neural-Specific Protein 3 | DBCCR1-Like Protein 1 | Protein FAM5C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540330","Hypertext Markup Language","C142380","A standard markup language used to display content on a web page, as specified by the World Wide Web Consortium (W3C).","Hypertext Markup Language | HTML | HyperText Markup Language (HTML)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540329","Interoperability","C142381","The capability of two or more systems or components to use and transfer information reciprocally.","Interoperability | interoperability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539807","IPAQ Long Last 7 Days Telephone Format Version - Currently Have Job or Unpaid Work","C141779","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) Do you currently have a job or do any unpaid work outside your home?","IPAQ Long Last 7 Days Telephone Format Version - Currently Have Job or Unpaid Work | IPA02-Currently Have Job or Unpaid Work | IPA0201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539806","IPAQ Long Last 7 Days Telephone Format Version - Days Vigorous as Part of Work","C141780","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) During the last 7 days, on how many days did you do vigorous physical activities as part of your work?","IPAQ Long Last 7 Days Telephone Format Version - Days Vigorous as Part of Work | IPA02-Days Vigorous as Part of Work | IPA0202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539805","IPA0203A","C141781","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days doing vigorous physical activities as part of your work?: Hours and minutes per day.","IPAQ Long Last 7 Days Telephone Format Version - Vigorous Work Hr and Min per Day | IPA02-Vigorous Work Hr & Min per Day | IPA0203A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539788","IPAQ Long Last 7 Days Telephone Format Version - Vigorous Work Minutes per Day","C141782","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days doing vigorous physical activities as part of your work?: Minutes per day.","IPAQ Long Last 7 Days Telephone Format Version - Vigorous Work Minutes per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539988","DRRI-2 - I: Happy With Support From Home","C141982","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was happy with the amount of support I received from people at home.","DRRI-2 - I: Happy With Support From Home | DRRI1-I: Happy With Support From Home | DRRI1I07",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539987","DRRI-2 - I: People at Home Show They Cared","C141983","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: people at home did things to show they cared about me.","DRRI-2 - I: People at Home Show They Cared | DRRI1-I: People at Home Show They Cared | DRRI1I08",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539986","DRRI-2 - J: My Unit Was Like Family to Me","C141984","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: my unit was like family to me.","DRRI-2 - J: My Unit Was Like Family to Me | DRRI1-J: My Unit Was Like Family to Me | DRRI1J01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539985","DRRI-2 - J: People in Unit Were Trustworthy","C141985","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: people in my unit were trustworthy.","DRRI-2 - J: People in Unit Were Trustworthy | DRRI1-J: People in Unit Were Trustworthy | DRRI1J02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539983","DRRI-2 - J: Felt Valued Fellow Unit Members","C141987","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I felt valued by my fellow unit members.","DRRI-2 - J: Felt Valued Fellow Unit Members | DRRI1-J: Felt Valued Fellow Unit Members | DRRI1J04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539982","DRRI-2 - J: Unit Interested My Well-being","C141988","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: members of my unit were interested in my well-being.","DRRI-2 - J: Unit Interested My Well-being | DRRI1-J: Unit Interested My Well-being | DRRI1J05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539981","DRRI-2 - J: Unit Interested What I Thought","C141989","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: my fellow unit members were interested in what I thought and how I felt about things.","DRRI-2 - J: Unit Interested What I Thought | DRRI1-J: Unit Interested What I Thought | DRRI1J06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012656","Disease Vector","C14198","An invertebrate animal (e.g., tick, mite, mosquito, bloodsucking fly) capable of transmitting an infectious agent among vertebrates.","Disease Vector | Disease Vectors | Vector | Vector (Infectious Agent)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2001250","INO80 protein, human","C142231","DNA helicase INO80 (1556 aa, ~177 kDa) is encoded by the human INO80 gene. This protein is involved in the ATP-depending unwinding of DNA helices.","DNA Helicase INO80 | EC 3.6.4.12 | INO80 | INO80 Complex Homolog 1 | INO80 Complex Subunit A | INO80 Homolog | Putative DNA Helicase INO80 Complex Homolog 1 | hINO80",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540231","Digital Sampling Rate","C142234","The number of digital samples taken or recorded per unit of time.","Digital Sampling Rate | DIGSMPRT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540214","Type of Electrical Current Sensor","C142235","A description of the sensor used to detect electrical current.","Type of Electrical Current Sensor | ECSNRTYP | Electrical Current Sensor Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540213","Continuous Audio Recording Made Indicator","C142236","An indication as to whether a continuous audio recording is made during the assessment.","Continuous Audio Recording Made Indicator | CAUDRIND | Continuous Audio Recording Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540212","Pulse Oximeter Use Indicator","C142237","An indication as to whether a pulse oximeter is used in the assessment.","Pulse Oximeter Use Indicator | PULOXIND | Pulse Oximeter Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540211","Subject Assigned to Arm But Not Treated","C142238","The subject, who met eligibility criteria, was assigned to an arm but was not treated.","Subject Assigned to Arm But Not Treated | ASSIGNED, NOT TREATED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540210","Subject Not Assigned to Arm","C142239","The subject, who met eligibility criteria, was not assigned to an arm and was not treated.","Subject Not Assigned to Arm | NOT ASSIGNED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540209","Subject Received Unplanned Treatment","C142240","The subject, who met eligibility criteria, was assigned to an arm but received treatment not associated with any of the planned arms.","Subject Received Unplanned Treatment | UNPLANNED TREATMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540328","Adequate and Well-controlled Study","C142382","A controlled clinical study with the characteristics specified in Title 21, Section 314.126 of the FDA Code of Federal Regulations, including: a clear statement of the objectives of the investigation and a summary of the proposed methods of analysis in the protocol; a design that permits a valid comparison with a control to provide a quantitative assessment of the effect; a method of subject selection that provides adequate assurance that the subject has the disease or condition that the treatment is directed at; a method of assigning patients to treatment and control groups that minimizes bias and assures comparability of the groups; adequate measures taken to minimize bias, by the subjects, observers and the data analysts; methods of assessment of subjects' response that are well-defined and reliable; and an analysis of the results of the study that is adequate to assess the effect of the drug or device.","Adequate and Well-controlled Study | adequate and well-controlled studies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540418","Administrable Dosage Form","C142383","No value exists.","Administrable Dosage Form | administrable dosage form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540417","Admission Criteria","C142384","The set of qualifications for selecting the target population for a clinical trial. This includes screening for any single qualification that excludes a subject from the trial.","Admission Criteria | admission criteria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041755","Adverse Drug Reaction","C142385","Any detrimental or unintended response associated with the use of a medication in humans.","Adverse Drug Reaction | ADR | Adverse Drug Experience | adverse drug experience | adverse drug reaction (ADR)",,,,,,,,,,,,,,,"441207","Adverse reaction to drug",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540415","American National Standards Institute","C142388","An institution founded in 1918 that facilitates the development of American National Standards by accrediting the procedures of standards developing organizations. ANSI itself does not develop standards.","American National Standards Institute | ANSI | American National Standards Institute (ANSI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540413","Analysis Set of Subjects","C142390","A set of subjects whose data are to be included in the main analyses and defined in the statistical section of the clinical trial protocol. (IHC)","Analysis Set of Subjects | analysis set",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540412","Analysis Variable","C142391","A changeable factor used in the assessment of the statistical hypothesis outlined in the protocol and/or statistical analysis plan.","Analysis Variable | analysis variables",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540424","Anonymization","C142392","The process of removing the association between identifying data and the data subject in order to protect privacy.","Anonymization | anonymization | anonymize",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540423","Applet","C142393","A small application designed to perform a specific function within another application.","Applet | App | applet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539831","IPAQ Long Last 7 Days Self-Administered Format Version - Days Travel in a Motor Vehicle","C141739","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you travel in a motor vehicle like a train, bus, car or tram?: days per week.","IPAQ Long Last 7 Days Self-Administered Format Version - Days Travel in a Motor Vehicle | IPA03-Days Travel in a Motor Vehicle | IPA0308",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539830","IPAQ Long Last 7 Days Self-Administered Format Version - No Traveling in a Motor Vehicle","C141740","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you travel in a motor vehicle like a train, bus, car or tram?: No traveling in a motor vehicle.","IPAQ Long Last 7 Days Self-Administered Format Version - No Traveling in a Motor Vehicle | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540092","DRRI-2 - J: Leader Interested What Thought","C141990","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: my unit leader(s) were interested in what I thought and how I felt about things.","DRRI-2 - J: Leader Interested What Thought | DRRI1-J: Leader Interested What Thought | DRRI1J07",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540091","DRRI-2 - J: Felt Like My Efforts Counted","C141991","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I felt like my efforts really counted to the leaders in my unit.","DRRI-2 - J: Felt Like My Efforts Counted | DRRI1-J: Felt Like My Efforts Counted | DRRI1J08",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540090","DRRI-2 - J: Service Appreciated by Leaders","C141992","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: my service was appreciated by the leaders in my unit.","DRRI-2 - J: Service Appreciated by Leaders | DRRI1-J: Service Appreciated by Leaders | DRRI1J09",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540089","DRRI-2 - J: Could Go to Leaders If Problem","C141993","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I could go to unit leaders for help if I had a problem or concern.","DRRI-2 - J: Could Go to Leaders If Problem | DRRI1-J: Could Go to Leaders If Problem | DRRI1J10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540088","DRRI-2 - J: Leaders Interested in Welfare","C141994","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: the leaders of my unit were interested in my personal welfare.","DRRI-2 - J: Leaders Interested in Welfare | DRRI1-J: Leaders Interested in Welfare | DRRI1J11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540087","DRRI-2 - J: Felt Valued by Leaders of Unit","C141995","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I felt valued by the leaders of my unit.","DRRI-2 - J: Felt Valued by Leaders of Unit | DRRI1-J: Felt Valued by Leaders of Unit | DRRI1J12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540085","DRRI-2 - K: Uncooperative Working With Me","C141997","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, the people I worked with: behaved in way that was uncooperative when working with me.","DRRI-2 - K: Uncooperative Working With Me | DRRI1-K: Uncooperative Working With Me | DRRI1K02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540261","Sextant Core Biopsy","C142183","A prostate biopsy collection protocol in which 6 biopsies are obtained in the parasagittal plane halfway between the lateral border and midline of the prostate on both right and left sides from the base, mid-gland, and apex.","Sextant Core Biopsy | Sextant Biopsy Protocol | Sextant Biopsy Technique",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540257","CDISC SDTM Vaccines Findings About Test Code Terminology","C142187","Terminology associated with the vaccines findings about test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Vaccines Findings About Test Code Terminology | SDTM-VNFATSCD | VNFATSCD | Vaccines Findings About Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540256","CDISC SDTM Vaccines Findings About Test Name Terminology","C142189","Terminology associated with the vaccines findings about test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Vaccines Findings About Test Name Terminology | SDTM-VNFATS | VNFATS | Vaccines Findings About Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0163159","sulforafan","C1424","A naturally-occurring phytochemical belonging to the class of isothiocyanates.  As the aglycone metabolite of glucosinolate glucoraphanin (sulforaphane glucosinolate), sulforaphane acts as an antioxidant and potent stimulator of endogenous detoxifying enzymes.  This agent displays anticarcinogenic properties due to its ability to induce phase II detoxification enzymes, such as glutathione S-transferase and quinone reductase, thereby providing protection against certain carcinogens and toxic, reactive oxygen species.  Broccoli sprouts contain large amounts of sulforaphane, which is also found in other cruciferous vegetables including cabbage and kale. (NCI04)","Sulforaphane | (+/-)-Sulforaphane | 1-Isothiocyanato-4-(methylsulfinyl)butane | 1-isothiocyanato-4-methylsulfinyl-butane | SULFORAPHANE | Sulfaforaphane | Sulforafan | Sulphoraphane",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540428","Data Validation","C142500","Process used to determine if data are inaccurate, incomplete, or unreasonable. The process may include format checks, completeness checks, check key tests, reasonableness checks, limit checks, and checking for compliance with applicable standards, rules, and conventions. (ISO)","Data Validation | data validation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540427","Data Verification","C142501","The checking of information for correctness or compliance with applicable standards, rules, and conventions. (FDA)","Data Verification | Verification of Data | verification of data",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541252","Database Frozen","C142502","A database staus, which usually occurs prior to a database lock, in which the database does not permit any additional changes unless the database is unfrozen.","Database Frozen | frozen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540426","Database Lock","C142503","A database status, that occurs after the final database freeze event, in which the database disallows any additional changes. Database unlocking may occur but requires certain permissions.","Database Lock | database lock",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540425","Decision Rule","C142504","Succinct statement of how a determination will be reached based upon the expected foreseen clinical benefits in terms of outcomes of the primary endpoint. (FDA)","Decision Rule | decision rule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018898","Helsinki Declaration","C142505","A guiding statement, created by the World Medical Association (WMA) in Helsinki, Finland in 1964, that details a set of ethical principles for physicians and other participants in medical research. It has undergone a number of revisions over the years.","Declaration of Helsinki | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545937","Define.xml","C142506","A CDISC standard describing the Extensible Markup Language (XML) data definition file, or metadata describing the format and content of submitted data sets, which is required for submitting clinical trial data to regulatory authorities.","Define.xml | Define-XML",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540436","De-identified Information","C142507","A dataset that has removed or obscured personally identifiable information such that any remaining information cannot be traced to an individual subject.","De-identified Information | de-identified information",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540434","Dependent Variable","C142509","In an experimental modification of independent factors, the factors that are anticipated to alter as a result.","Dependent Variable | dependent variable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540433","Derived Variable","C142510","No value exists.","Derived Variable | derived variable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540432","Direct Access","C142511","No value exists.","Direct Access | direct access",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540517","Direct Identifier","C142513","No value exists.","Direct Identifier | direct identifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540516","Document Legally Authenticated","C142514","A completion status in which a document has been signed manually or electronically by the individual who is legally responsible for that document. (HL7)","Document Legally Authenticated | legal authentication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539509","F-652","C141419","A recombinant fusion protein consisting of human cytokine interleukin 22 (IL-22) fused to a human immunoglobulin G2 (IgG2)-Fc, with potential cell protective activity. Upon intravenous administration of eflepedocokin alfa, IL-22 binds to its cognate receptor IL-22R, which is highly expressed in parenchymal tissues and epithelial cells at mucosal surfaces. This leads to the activation of IL-22/IL-22R-mediated signal transduction pathways, and results in the activation of signal transducer and activator of transcription 3 (STAT3). STAT3 activation may have a protective and regenerative effect and may protect against the development of various inflammatory and immunological diseases. Specifically, recombinant human IL-22 IgG2-Fc may protect intestinal stem cells from dying due to acute graft-versus-host disease (aGvHD). IL-22, produced by various immune cells and upregulated during inflammation, plays a key role in controlling immune responses and bacterial infection, and in the enhancement of intestinal barrier function, gut immunity, and tissue repair.","Eflepedocokin Alfa | EFLEPEDOCOKIN ALFA | F-652 | IL-22 Dimer F-652 | IL-22 IgG2-Fc | Promenakin | Recombinant Human IL-22 IgG2-Fc | Recombinant Human Interleukin-22 IgG2-Fc",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539508","Anti-HER2-vc0101 ADC PF-06804103","C141420","A proprietary antibody-drug conjugate (ADC) composed of a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) site-specifically linked, via a protease cleavable linker, to an analog of dolastatin 10, Auristatin-0101, with potential antineoplastic activity. Upon administration, anti-HER2-vc0101 ADC PF-06804103 targets HER2 expressed on tumor cells. Upon binding, internalization and cleavage, Auristatin-0101 binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and apoptosis of HER2-expressing tumor cells. HER2, a tumor-associated antigen (TAA), is overexpressed on a variety of cancer cells.","Anti-HER2-vc0101 ADC PF-06804103 | Anti-HER2-vcAur0101 ADC PF-06804103 | Anti-NG-HER2 ADC PF-06804103 | Anti-NG-Her2-vc0101 ADC PF-06804103 | Antibody-drug Conjugate PF-06804103 | PF 06804103 | PF-06804103 | PF06804103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539770","CDISC Questionnaire DRRI-2 Test Name Terminology","C141672","Test names of questionnaire questions associated with the Deployment Risk and Resilience Inventory-2 (DRRI-2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire DRRI-2 Test Name Terminology | DRRI1TN | Deployment Risk and Resilience Inventory-2 Questionnaire Test Name | QS-DRRI-2 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539769","CDISC Questionnaire DRRI-2 Test Code Terminology","C141673","Test codes of questionnaire questions associated with the Deployment Risk and Resilience Inventory-2 (DRRI-2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire DRRI-2 Test Code Terminology | DRRI1TC | Deployment Risk and Resilience Inventory-2 Questionnaire Test Code | QS-DRRI-2 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539767","AJCC v7 Clinical Classification Question","C141675","A question associated with the AJCC v7 clinical classification.","AJCC v7 Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539766","10 Meter Walk/Run Functional Test Question","C141676","A question associated with the 10 Meter Walk/Run functional test.","10 Meter Walk/Run Functional Test Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539765","Rising From Floor Functional Test Question","C141677","A question associated with the Rising From Floor functional test.","Rising From Floor Functional Test Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539780","4 Stair Descend Functional Test Question","C141678","A question associated with the 4 Stair Descend functional test.","4 Stair Descend Functional Test Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539779","4 Stair Ascend Functional Test Question","C141679","A question associated with the 4 Stair Ascend functional test.","4 Stair Ascend Functional Test Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539829","IPAQ Long Last 7 Days Self-Administered Format Version - Traveling Hr and Min per Day","C141741","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days traveling in a train, bus, car, tram, or other kind of motor vehicle?: hours and minutes per day.","IPAQ Long Last 7 Days Self-Administered Format Version - Traveling Hr and Min per Day | IPA03-Traveling Hr & Min per Day | IPA0309",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539844","IPAQ Long Last 7 Days Self-Administered Format Version - Traveling Minutes per Day","C141742","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days traveling in a train, bus, car, tram, or other kind of motor vehicle?: minutes per day.","IPAQ Long Last 7 Days Self-Administered Format Version - Traveling Minutes per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539843","IPAQ Long Last 7 Days Self-Administered Format Version - Days Bicycle Place to Place","C141743","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you bicycle for at least 10 minutes at a time to go from place to place?: days per week.","IPAQ Long Last 7 Days Self-Administered Format Version - Days Bicycle Place to Place | IPA03-Days Bicycle Place to Place | IPA0310",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539842","IPAQ Long Last 7 Days Self-Administered Format Version - No Bicycling From Place to Place","C141744","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you bicycle for at least 10 minutes at a time to go from place to place?: No bicycling from place to place.","IPAQ Long Last 7 Days Self-Administered Format Version - No Bicycling From Place to Place | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539840","IPAQ Long Last 7 Days Self-Administered Format Version - Bicycle Minutes per Day","C141746","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days to bicycle from place to place?: minutes per day.","IPAQ Long Last 7 Days Self-Administered Format Version - Bicycle Minutes per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539839","IPAQ Long Last 7 Days Self-Administered Format Version - Days Walk Place to Place","C141747","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you walk for at least 10 minutes at a time to go from place to place?: days per week.","IPAQ Long Last 7 Days Self-Administered Format Version - Days Walk Place to Place | IPA03-Days Walk Place to Place | IPA0312",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539838","IPAQ Long Last 7 Days Self-Administered Format Version - No Walking From Place to Place","C141748","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you walk for at least 10 minutes at a time to go from place to place?: No walking from place to place.","IPAQ Long Last 7 Days Self-Administered Format Version - No Walking From Place to Place | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539837","IPAQ Long Last 7 Days Self-Administered Format Version - Walking Place Hr and Min per Day","C141749","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days walking from place to place?: hours and minutes per day.","IPAQ Long Last 7 Days Self-Administered Format Version - Walking Place Hr and Min per Day | IPA03-Walking Place Hr & Min per Day | IPA0313",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540031","DRRI-2 - E: Sight/Sound/Smell Dead Animals","C141939","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was exposed to the sight, sound, or smell of dead or dying animals.","DRRI-2 - E: Sight/Sound/Smell Dead Animals | DRRI1-E: Sight/Sound/Smell Dead Animals | DRRI1E12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008051","Chicken","C14193","The common domestic fowl, Gallus gallus.","Chicken | CHICKEN | Domestic Chicken | GALLUS GALLUS | Gallus domesticus | Gallus gallus domesticus",,,,,,,,,,,,,,,"4264206","Gallus gallus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540255","CDISC Protocol Entities Clinical Study Attribute Terminology","C142191","Terminology associated with the protocol entity clinical study attribute codelist of the Clinical Data Interchange Standards Consortium (CDISC).","CDISC Protocol Entities Clinical Study Attribute Terminology | Clinical Study Attribute Terminology | PROT-Att Clinical Study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545914","Study Variable","C142192","A variable identified as relevant to a particular clinical study.","Study Variable | Variable | study variable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0759781","ABCD1 protein, human","C142195","ATP-binding cassette sub-family D member (745 aa, ~83 kDa) is encoded by the human ABCD1 gene. This protein plays a role in the peroxisomal import of fatty acids and fatty acyl-coenzyme A (acylCoA) esters.","ATP-Binding Cassette Sub-Family D Member 1 | ABCD1 | ALDP | Adrenoleukodystrophy Protein | EC 7.6.2.4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540265","KPNB1 Gene","C142197","This gene is involved in nuclear import.","KPNB1 Gene | KPNB1 | Karyopherin Subunit Beta 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540264","KPNB1 wt Allele","C142198","Human KPNB1 wild-type allele is located in the vicinity of 17q21.32 and is approximately 36 kb in length. This allele, which encodes importin subunit beta-1 protein, plays a role in nuclear import. Aberrant expression of the gene may be associated with several neoplastic diseases.","KPNB1 wt Allele | IMB1 | IPO1 | IPOB | Impnb | Karyopherin (Importin) Beta 1 Gene | Karyopherin Subunit Beta 1 wt Allele | MGC2155 | MGC2156 | MGC2157 | NTF97",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1448901","KPNB1 protein, human","C142199","Importin subunit beta-1 (876 aa, ~97 kDa) is encoded by the human KPNB1 gene. This protein is involved in nuclear import.","Importin Subunit Beta-1 | Importin 1 | Importin 90 | Importin Beta-1 | Importin Beta-1 Subunit | Importin-90 | KPNB1 | Karyopherin Beta-1 | Karyopherin Subunit Beta-1 | Nuclear Factor p97 | PTAC97",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540379","Clinical Trial Dropout","C142445","A subject who stops participating in a clinical trial before the last visit or observation that is required by the study protocol.","Clinical Trial Dropout | dropout",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540378","Clinical Trial Exemption","C142446","A process that allows sponsors to apply for approval for each clinical study while granting an exemption from the requirement to hold a clinical trial certificate (CTC).","Clinical Trial Exemption | clinical trial exemption (CTX)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540377","Clinical Trial Information","C142447","Any and all information related to a clinical study, including study or trial data, data integrity information, and administration.","Clinical Trial Information | clinical trial information",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545939","Clinical Trial Inspection","C142448","The act by a regulatory authority(ies) of conducting an official review of documents, facilities, records, and any other resources that are deemed by the authority(ies) to be related to the clinical trial and that may be located at the site of the trial, at the sponsor's and/or contract research organization's (CRO's) facilities, or at other establishments deemed appropriate by the regulatory authority(ies). (ICH)","Clinical Trial Inspection | inspection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540464","Clinical Trial Material","C142449","A term of art referring to the entire set of goods and equipment that are given to a researcher by the trial sponsor, in order to carry out the clinical trial.","Clinical Trial Material | clinical trial materials",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541253","Document Type Definition","C142515","No value exists.","Document Type Definition | DTD | document type definition (DTD)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540515","Dosage Regimen","C142516","The specific way a therapeutic drug is to be taken, including formulation, route of administration, dose, dosing interval, and treatment duration.","Dosage Regimen | dosage regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540514","dose strength","C142517","The amount of active drug substance in each dosage unit.","Dose Strength | dose strength | dose strength",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539880","IPAQ Long Last 7 Days Telephone Format Version - Moderate Garden Hr and Min per Week","C141818","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing moderate physical activities in the garden or yard?: Hours and minutes per week.","IPAQ Long Last 7 Days Telephone Format Version - Moderate Garden Hr and Min per Week | IPA02-Moderate Garden Hr & Min per Week | IPA0217B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539879","IPAQ Long Last 7 Days Telephone Format Version - Moderate Garden Minutes per Week","C141819","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing moderate physical activities in the garden or yard?: Minutes per week.","IPAQ Long Last 7 Days Telephone Format Version - Moderate Garden Minutes per Week | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003060","Animal Virus","C14181","An animal pathogen that is a virus.","Animal Virus | Viruses, Animal",,,,,,,,,,,,,,,"4173736","Animal virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL539878","IPAQ Long Last 7 Days Telephone Format Version - Days Moderate Inside Your Home","C141820","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) During the last 7 days, on how many days did you do moderate activities inside your home?","IPAQ Long Last 7 Days Telephone Format Version - Days Moderate Inside Your Home | IPA02-Days Moderate Inside Your Home | IPA0218",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539877","IPA0219A","C141821","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days doing moderate physical activities inside your home?: Hours and minutes per day.","IPAQ Long Last 7 Days Telephone Format Version - Moderate Home Hr and Min per Day | IPA02-Moderate Home Hr & Min per Day | IPA0219A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539892","IPAQ Long Last 7 Days Telephone Format Version - Moderate Home Minutes per Day","C141822","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days doing moderate physical activities inside your home?: Minutes per day.","IPAQ Long Last 7 Days Telephone Format Version - Moderate Home Minutes per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539891","IPAQ Long Last 7 Days Telephone Format Version - Moderate Home Hr and Min per Week","C141823","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing moderate physical activities inside your home?: Hours and minutes per week.","IPAQ Long Last 7 Days Telephone Format Version - Moderate Home Hr and Min per Week | IPA02-Moderate Home Hr & Min per Week | IPA0219B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539890","IPAQ Long Last 7 Days Telephone Format Version - Moderate Home Minutes per Week","C141824","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing moderate physical activities inside your home?: Minutes per week.","IPAQ Long Last 7 Days Telephone Format Version - Moderate Home Minutes per Week | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539889","IPAQ Long Last 7 Days Telephone Format Version - Days Walk in Your Leisure Time","C141825","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) Not counting any walking you have already mentioned, during the last 7 days, on how many days did you walk for at least 10 minutes at a time in your leisure time?","IPAQ Long Last 7 Days Telephone Format Version - Days Walk in Your Leisure Time | IPA02-Days Walk in Your Leisure Time | IPA0220",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539778","IPAQ Short Last 7 Days Self-administered Format Version Questionnaire Question","C141680","A question associated with the IPAQ Short Last 7 Days Self-administered Format Version questionnaire.","IPAQ Short Last 7 Days Self-administered Format Version Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539776","IPAQ Long Last 7 Days Telephone Format Version Questionnaire Question","C141682","A question associated with the IPAQ Long Last 7 Days Telephone Format Version questionnaire.","IPAQ Long Last 7 Days Telephone Format Version Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539775","IPAQ Short Last 7 Days Telephone Format Version Questionnaire Question","C141683","A question associated with the IPAQ Short Last 7 Days Telephone Format Version questionnaire.","IPAQ Short Last 7 Days Telephone Format Version Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539774","DRRI-2 Questionnaire Question","C141684","A question associated with the DRRI-2 questionnaire.","DRRI-2 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539253","Lugano Classification Childhood Hodgkin Lymphoma by AJCC v8 Stage","C141178","A staging system for childhood Hodgkin lymphomas based on the Lugano classification criteria. Staging for childhood Hodgkin lymphoma is the same as for the adult counterpart. (from AJCC 8th Ed.)","Lugano Classification Childhood Hodgkin Lymphoma by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539252","Lugano Classification Limited Stage Childhood Hodgkin Lymphoma AJCC v8","C141179","Limited stage childhood Hodgkin lymphoma based on the Lugano classification criteria. It includes stages I, IE, II, and IIE. (from AJCC 8th Ed.)","Lugano Classification Limited Stage Childhood Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512158","EXO I Motif","C14117","A conserved amino acid sequence (Asp-X-Glu) in DNA polymerases that is required for 3' > 5' exonuclease activity.","EXO I Motif | EXO I Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539251","Lugano Classification Stage I Childhood Hodgkin Lymphoma AJCC v8","C141180","Stage I: Involvement of a single lymphatic site (i.e., nodal region, Waldeyer's ring, thymus, or spleen). (from AJCC 8th Ed.)","Lugano Classification Stage I Childhood Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539250","Lugano Classification Stage IE Childhood Hodgkin Lymphoma AJCC v8","C141181","Stage IE: Single extralymphatic site in the absence of nodal involvement (rare in Hodgkin lymphoma). (from AJCC 8th Ed.)","Lugano Classification Stage IE Childhood Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540030","DRRI-2 - E: Involved Handling Human Remains","C141940","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was involved in handling human remains.","DRRI-2 - E: Involved Handling Human Remains | DRRI1-E: Involved Handling Human Remains | DRRI1E13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540029","DRRI-2 - F: Took Preventative Pills","C141941","Deployment Risk and Resilience Inventory-2 (DRRI-2) Either in preparation for or during my deployment: I took preventative pills (for example, to protect against nerve gas).","DRRI-2 - F: Took Preventative Pills | DRRI1-F: Took Preventative Pills | DRRI1F01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540012","DRRI-2 - F: Received Vaccinations","C141942","Deployment Risk and Resilience Inventory-2 (DRRI-2) Either in preparation for or during my deployment: I received preventative vaccinations by injection (for example, to prevent anthrax or botulism).","DRRI-2 - F: Received Vaccinations | DRRI1-F: Received Vaccinations | DRRI1F02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540011","DRRI-2 - F: Exposed to Nerve Gas Agents","C141943","Deployment Risk and Resilience Inventory-2 (DRRI-2) Either in preparation for or during my deployment: I was exposed to nerve gas agents (for example, sarin).","DRRI-2 - F: Exposed to Nerve Gas Agents | DRRI1-F: Exposed to Nerve Gas Agents | DRRI1F03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540010","DRRI-2 - F: Exposed to Mustard Gas","C141944","Deployment Risk and Resilience Inventory-2 (DRRI-2) Either in preparation for or during my deployment: I was exposed to mustard gas or other blistering agents.","DRRI-2 - F: Exposed to Mustard Gas | DRRI1-F: Exposed to Mustard Gas | DRRI1F04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540009","DRRI-2 - F: Exposed Government-issued DEET","C141945","Deployment Risk and Resilience Inventory-2 (DRRI-2) Either in preparation for or during my deployment: I was exposed to government-issued DEET-containing insect repellents.","DRRI-2 - F: Exposed Government-issued DEET | DRRI1-F: Exposed Government-issued DEET | DRRI1F05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540008","DRRI-2 - F: Exposed to Other Pesticides","C141946","Deployment Risk and Resilience Inventory-2 (DRRI-2) Either in preparation for or during my deployment: I was exposed to other pesticides (for example, in flea collars, uniforms, or the environment).","DRRI-2 - F: Exposed to Other Pesticides | DRRI1-F: Exposed to Other Pesticides | DRRI1F06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540007","DRRI-2 - F: Exposed to Smoke/Air Pollution","C141947","Deployment Risk and Resilience Inventory-2 (DRRI-2) Either in preparation for or during my deployment: I was exposed to smoke or other air pollution.","DRRI-2 - F: Exposed to Smoke/Air Pollution | DRRI1-F: Exposed to Smoke/Air Pollution | DRRI1F07",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540006","DRRI-2 - F: Exposed to Diesel/Fuel on Skin","C141948","Deployment Risk and Resilience Inventory-2 (DRRI-2) Either in preparation for or during my deployment: I was exposed to diesel or other petrochemical fuel on my skin.","DRRI-2 - F: Exposed to Diesel/Fuel on Skin | DRRI1-F: Exposed to Diesel/Fuel on Skin | DRRI1F08",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540005","DRRI-2 - F: Exposed to Fumes From Heaters","C141949","Deployment Risk and Resilience Inventory-2 (DRRI-2) Either in preparation for or during my deployment: I was exposed to fumes or exhaust from heaters or generators, including heaters in tents.","DRRI-2 - F: Exposed to Fumes From Heaters | DRRI1-F: Exposed to Fumes From Heaters | DRRI1F09",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540019","DRRI-2 - F: Exposed to Burning Trash/Feces","C141951","Deployment Risk and Resilience Inventory-2 (DRRI-2) Either in preparation for or during my deployment: I was exposed to burning trash or burning feces.","DRRI-2 - F: Exposed to Burning Trash/Feces | DRRI1-F: Exposed to Burning Trash/Feces | DRRI1F11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540018","DRRI-2 - F: Exposed to Chlorine Gas","C141952","Deployment Risk and Resilience Inventory-2 (DRRI-2) Either in preparation for or during my deployment: I was exposed to chlorine gas.","DRRI-2 - F: Exposed to Chlorine Gas | DRRI1-F: Exposed to Chlorine Gas | DRRI1F12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026626","Mouse Leukemia Virus","C14244","Type C retroviruses that cause leukemia in mice.  Includes the Abelson, AKR, Friend, Moloney, Gross, and other leukemia viruses.","Mouse Leukemia Virus | MURINE LEUKEMIA VIRUS | MuLV | Murine Leukemia Virus | Murine Leukemia Virus MLV | Murine Leukemia Virus MuLV",,,,,,,,,,,,,,,"4035158","Murine leukemia virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL541265","Clinical Trial Objective","C142450","The main purpose of an investigation that can be measured objectively to determine whether the treatment or intervention being studied is beneficial.","Clinical Trial Objective | Study Objective | objective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540463","Clinical Trial Registry","C142452","A publicly available database of clinical trial summary information, which may include purpose of the study, recruiting status, condition and medical product under study, study design, trial phase, participation criteria, contact information, primary outcome measure, and results.","Clinical Trial Registry | clinical trial registry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540462","Clinician-reported Outcome","C142453","An assessment from a qualified medical professional based on examination of a subject's health status.","Clinician-reported Outcome | ClinRO | clinician-reported outcome (ClinRO)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540461","Codelist","C142454","A list of standard terms and meanings that represent the allowable values for a data item.","Codelist | codelist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540460","Cognitive Debriefing","C142455","The process of testing an instrument or patient questionnaire with target populations to see if it is understood as intended by the creators of the tool.","Cognitive Debriefing | cognitive debriefing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540469","Commercially Confidential Information","C142456","Private information from clinical documents that, if allowed to become public, would impair the genuine financial interest of the company who holds the application.","Commercially Confidential Information | commercially confidential information (CCI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545945","Comparative Study","C142457","A type of trial in which the drug of interest is compared against another drug or placebo.","Comparative Study | comparative study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540468","Comparator","C142458","An investigational or marketed product (i.e., active control), or placebo, used as a reference in a clinical trial. (ICH)","Comparator | comparator | comparator (product)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545926","Computer System or Software Supplier","C142459","An individual or entity whose business is to supply computer systems or software to the consumer.","Computer System or Software Supplier | supplier (system)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539786","IPAQ Long Last 7 Days Telephone Format Version - Vigorous Work Minutes per Week","C141784","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing vigorous physical activities as part of your work?: Minutes per week.","IPAQ Long Last 7 Days Telephone Format Version - Vigorous Work Minutes per Week | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539785","IPAQ Long Last 7 Days Telephone Format Version - Days Moderate as Part of Work","C141785","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) During the last 7 days, on how many days did you do moderate physical activities as part of your work?","IPAQ Long Last 7 Days Telephone Format Version - Days Moderate as Part of Work | IPA02-Days Moderate as Part of Work | IPA0204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539784","IPA0205A","C141786","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days doing moderate physical activities as part of your work?: Hours and minutes per day.","IPAQ Long Last 7 Days Telephone Format Version - Moderate Work Hr and Min per Day | IPA02-Moderate Work Hr & Min per Day | IPA0205A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539888","IPA0221A","C141826","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days walking in your leisure time?: Hours and minutes per day.","IPAQ Long Last 7 Days Telephone Format Version - Walking Leisure Hr and Min per Day | IPA02-Walking Leisure Hr & Min per Day | IPA0221A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539887","IPAQ Long Last 7 Days Telephone Format Version - Walking Leisure Minutes Per Day","C141827","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days walking in your leisure time?: Minutes per day.","IPAQ Long Last 7 Days Telephone Format Version - Walking Leisure Minutes Per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539886","IPAQ Long Last 7 Days Telephone Format Version - Walking Leisure Hr and Min per Week","C141828","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days walking in your leisure time?: Hours and minutes per week.","IPAQ Long Last 7 Days Telephone Format Version - Walking Leisure Hr and Min per Week | IPA02-Walking Leisure Hr & Min per Week | IPA0221B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540041","DRRI-2 - N: Robbed/Had My Home Broken Into","C142041","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I was robbed or had my home broken into.","DRRI-2 - N: Robbed/Had My Home Broken Into | DRRI1-N: Robbed/Had My Home Broken Into | DRRI1N01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540040","DRRI-2 - N: Unwanted Sexual Activity","C142042","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I experienced unwanted sexual activity as a result of force, threat or harm, or manipulation.","DRRI-2 - N: Unwanted Sexual Activity | DRRI1-N: Unwanted Sexual Activity | DRRI1N02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540039","DRRI-2 - N: Went Through Divorce/Was Left","C142043","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I went through a divorce or have been left by a partner or significant other.","DRRI-2 - N: Went Through Divorce/Was Left | DRRI1-N: Went Through Divorce/Was Left | DRRI1N03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540038","DRRI-2 - N: Problems Getting Healthcare","C142044","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I had problems getting access to adequate healthcare.","DRRI-2 - N: Problems Getting Healthcare | DRRI1-N: Problems Getting Healthcare | DRRI1N04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540037","DRRI-2 - N: Experienced Natural Disaster","C142045","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I experienced a natural disaster (for example, a hurricane), a fire, or an accident in which I or someone close to me was hurt or had serious property damage.","DRRI-2 - N: Experienced Natural Disaster | DRRI1-N: Experienced Natural Disaster | DRRI1N05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540052","DRRI-2 - N: Someone Close Serious Illness","C142046","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: someone close to me has experienced a serious illness, injury, or mental health problem (for example, cancer, alcohol/drug problem).","DRRI-2 - N: Someone Close Serious Illness | DRRI1-N: Someone Close Serious Illness | DRRI1N06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540050","DRRI-2 - N: Lost My Job/Trouble Finding Job","C142048","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I lost my job or had serious trouble finding a job.","DRRI-2 - N: Lost My Job/Trouble Finding Job | DRRI1-N: Lost My Job/Trouble Finding Job | DRRI1N08",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540049","DRRI-2 - N: Emotionally Mistreated","C142049","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I have been emotionally mistreated (for example, ignored or repeatedly told I was no good).","DRRI-2 - N: Emotionally Mistreated | DRRI1-N: Emotionally Mistreated | DRRI1N09",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539265","Lugano Classification Stage II Childhood Hodgkin Lymphoma AJCC v8","C141182","Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm. (from AJCC 8th Ed.)","Lugano Classification Stage II Childhood Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539264","Lugano Classification Stage IIE Childhood Hodgkin Lymphoma AJCC v8","C141183","Stage IIE: Contiguous extralymphatic extension from a nodal site with or without involvement of other lymph node regions on the same side of the diaphragm. (from AJCC 8th Ed.)","Lugano Classification Stage IIE Childhood Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539262","Lugano Classification Advanced Stage Childhood Hodgkin Lymphoma AJCC v8","C141185","Advanced stage childhood Hodgkin lymphoma based on the Lugano classification criteria. It includes stages III and IV. (from AJCC 8th Ed.)","Lugano Classification Advanced Stage Childhood Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539261","Lugano Classification Stage III Childhood Hodgkin Lymphoma AJCC v8","C141186","Stage III: Involvement of lymph node regions on both sides of the diaphragm; nodes above the diaphragm with spleen involvement. (from AJCC 8th Ed.)","Lugano Classification Stage III Childhood Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539260","Lugano Classification Stage IV Childhood Hodgkin Lymphoma AJCC v8","C141187","Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or noncontiguous extralymphatic organ involvement in conjunction with nodal stage II disease; or any extralymphatic organ involvement in nodal stage III disease. Stage IV includes any involvement of the bone marrow, liver, or lungs (other than by direct extension in stage IIE disease). (from AJCC 8th Ed.)","Lugano Classification Stage IV Childhood Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539258","Lugano Classification Adult Hodgkin Lymphoma by AJCC v8 Stage","C141189","A staging system for adult Hodgkin lymphomas based on the Lugano classification criteria. Staging for adult Hodgkin lymphoma is the same as for the childhood counterpart. (from AJCC 8th Ed.)","Lugano Classification Adult Hodgkin Lymphoma by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512157","EXO II Motif","C14118","A conserved amino acid sequence (Asn-(X)3-Phe-Asp) in DNA polymerases that is required for 3' > 5' exonuclease activity.","EXO II Motif | EXO II Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539244","Lugano Classification Limited Stage Adult Hodgkin Lymphoma AJCC v8","C141190","Limited stage adult Hodgkin lymphoma based on the Lugano classification criteria. It includes stages I, IE, II, and IIE. (from AJCC 8th Ed.)","Lugano Classification Limited Stage Adult Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539243","Lugano Classification Stage I Adult Hodgkin Lymphoma AJCC v8","C141191","Stage I: Involvement of a single lymphatic site (i.e., nodal region, Waldeyer's ring, thymus, or spleen). (from AJCC 8th Ed.)","Lugano Classification Stage I Adult Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539242","Lugano Classification Stage IE Adult Hodgkin Lymphoma AJCC v8","C141192","Stage IE: Single extralymphatic site in the absence of nodal involvement (rare in Hodgkin lymphoma). (from AJCC 8th Ed.)","Lugano Classification Stage IE Adult Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538813","Retinoblastoma pT3c TNM Finding v8","C140723","Any partial-thickness involvement of the sclera within the inner two thirds. (from AJCC 8th Ed.)","Retinoblastoma pT3c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538812","Retinoblastoma pT3d TNM Finding v8","C140724","Full-thickness invasion into the outer third of the sclera and/or invasion into or around emissary channels. (from AJCC 8th Ed.)","Retinoblastoma pT3d TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538811","Retinoblastoma pT4 TNM Finding v8","C140725","Evidence of extraocular tumor: tumor at the transected end of the optic nerve, tumor in the meningeal spaces around the optic nerve, full-thickness invasion of the sclera with invasion of the episclera, adjacent adipose tissue, extraocular muscle, bone, conjunctiva, or eyelids. (from AJCC 8th Ed.)","Retinoblastoma pT4 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538810","Retinoblastoma Heritable Trait (H) Finding v8","C140726","A finding about a heritable trait of retinoblastoma, following the rules of the AJCC v8 classification system.","Retinoblastoma Heritable Trait (H) Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540185","Refractory Waldenstrom Macroglobulinemia","C142149","Waldenstrom macroglobulinemia that does not respond to treatment.","Refractory Waldenstrom Macroglobulinemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019132","Hepadnavirus","C14214","A family of hepatotropic DNA viruses which contains double-stranded DNA genomes and causes hepatitis in humans and animals. Contains two genera: avihepadnavirus and orthohepadnavirus.","Hepadnavirus | ",,,,,,,,,,,,,,,"4308335","Hepadnaviridae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1416969","MAG Gene","C142150","This gene plays a role in myelin sheath maintenance.","MAG Gene | MAG | Myelin Associated Glycoprotein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540172","MAG wt Allele","C142151","Human MAG wild-type allele is located in the vicinity of 19q13.12 and is approximately 22 kb in length. This allele, which encodes myelin-associated glycoprotein, is involved in axon myelination. Mutation of the gene is associated with autosomal recessive spastic paraplegia 75.","MAG wt Allele | GMA | Myelin Associated Glycoprotein wt Allele | S-MAG | SIGLEC-4A | SIGLEC4A | SPG75",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0758772","MAG protein, human","C142152","Myelin-associated glycoprotein (626 aa, ~69 kDa) is encoded by the human MAG gene. This protein plays a role in the maintenance of axon myelination.","Myelin-Associated Glycoprotein | MAG | Sialic Acid Binding Ig-Like Lectin 4A | Sialic Acid-Binding Immunoglobulin-Like Lectin 4A | Siglec-4a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540171","APOH Gene","C142153","This gene is involved in binding to glycosaminoglycans and phospholipids.","APOH Gene | APOH | Apolipoprotein H Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540170","APOH wt Allele","C142154","Human APOH wild-type allele is located in the vicinity of 17q24.2 and is approximately 44 kb in length. This allele, which encodes beta-2-glycoprotein 1, may play a role in lipoprotein metabolism, coagulation, and the production of antiphospholipid autoantibodies.","APOH wt Allele | Apolipoprotein H (Beta-2-Glycoprotein I) Gene | Apolipoprotein H wt Allele | B2G1 | B2GP1 | BG | Glycoprotein 1, Beta-2 Gene | Glycoprotein I, Beta-2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524123","Beta-2-Glycoprotein 1","C142155","Beta-2-glycoprotein 1 (345 aa, ~38 kDa) is encoded by the human APOH gene. This protein is involved in binding to phospholipids, glycosaminoglycans and other negatively charged substances.","Beta-2-Glycoprotein 1 | APC Inhibitor | APOH | Activated Protein C-Binding Protein | Anticardiolipin Cofactor | Apo-H | Apolipoprotein H | B2GPI | BETA-2 GLYCOPROTEIN 1 | Beta(2)GPI | Beta-2 Glycoprotein 1 | Beta-2-Glycoprotein I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537922","MRTFB Gene","C142159","This gene plays a role in the coactivation of transcription.","MRTFB Gene | MKL2 | MRTFB | Myocardin Related Transcription Factor B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539783","IPAQ Long Last 7 Days Telephone Format Version - Moderate Work Minutes per Day","C141787","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days doing moderate physical activities as part of your work?: Minutes per day.","IPAQ Long Last 7 Days Telephone Format Version - Moderate Work Minutes per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539782","IPAQ Long Last 7 Days Telephone Format Version - Moderate Work Hr and Min per Week","C141788","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing moderate physical activities as part of your work?: Hours and minutes per week.","IPAQ Long Last 7 Days Telephone Format Version - Moderate Work Hr and Min per Week | IPA02-Moderate Work Hr & Min per Week | IPA0205B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539781","IPAQ Long Last 7 Days Telephone Format Version - Moderate Work Minutes per Week","C141789","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing moderate physical activities as part of your work?: Minutes per week.","IPAQ Long Last 7 Days Telephone Format Version - Moderate Work Minutes per Week | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539796","IPAQ Long Last 7 Days Telephone Format Version - Days Walk as Part of Your Work","C141790","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) During the last 7 days, on how many days did you walk as part of your work?","IPAQ Long Last 7 Days Telephone Format Version - Days Walk as Part of Your Work | IPA02-Days Walk as Part of Your Work | IPA0206",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539795","IPA0207A","C141791","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days walking as part of your work?: Hours and minutes per day.","IPAQ Long Last 7 Days Telephone Format Version - Walking Work Hr and Min per Day | IPA02-Walking Work Hr & Min per Day | IPA0207A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539793","IPAQ Long Last 7 Days Telephone Format Version - Walking Work Hr and Min per Week","C141793","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent walking over the last 7 days as part of your work?: Hours and minutes per week.","IPAQ Long Last 7 Days Telephone Format Version - Walking Work Hr and Min per Week | IPA02-Walking Work Hr & Min per Week | IPA0207B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539792","IPAQ Long Last 7 Days Telephone Format Version - Walking Work Minutes per Week","C141794","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent walking over the last 7 days as part of your work?: Minutes per week.","IPAQ Long Last 7 Days Telephone Format Version - Walking Work Minutes per Week | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539791","IPAQ Long Last 7 Days Telephone Format Version - Days Travel in a Motor Vehicle","C141795","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) During the last 7 days, on how many days did you travel in a motor vehicle like a train, bus, car or tram?","IPAQ Long Last 7 Days Telephone Format Version - Days Travel in a Motor Vehicle | IPA02-Days Travel in a Motor Vehicle | IPA0208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540100","DRRI-2 - K: Had to Work Harder Prove Myself","C141998","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, the people I worked with: treated me as if I had to work harder than others to prove myself.","DRRI-2 - K: Had to Work Harder Prove Myself | DRRI1-K: Had to Work Harder Prove Myself | DRRI1K03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540099","DRRI-2 - K: Questioned My Abilities Perform","C141999","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, the people I worked with: questioned my abilities or commitment to perform my job effectively.","DRRI-2 - K: Questioned My Abilities Perform | DRRI1-K: Questioned My Abilities Perform | DRRI1K04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0012917","DNA Tumor Virus","C14199","A virus which uses DNA to code its genome and causes tumors in animals.","DNA Tumor Virus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540048","DRRI-2 - N: Serious Financial Problems","C142050","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I have experienced serious financial problems.","DRRI-2 - N: Serious Financial Problems | DRRI1-N: Serious Financial Problems | DRRI1N10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540047","DRRI-2 - N: Serious Physical Health Problem","C142051","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I have experienced serious physical or mental health problems.","DRRI-2 - N: Serious Physical Health Problem | DRRI1-N: Serious Physical Health Problem | DRRI1N11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540046","DRRI-2 - N: Stressful Legal Problems","C142052","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I have experienced stressful legal problems (for example, being sued, suing someone else, or being in a custody battle).","DRRI-2 - N: Stressful Legal Problems | DRRI1-N: Stressful Legal Problems | DRRI1N12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540045","DRRI-2 - N: Injured by Another Person","C142053","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I have been seriously physically injured by another person (for example, hit or beaten up).","DRRI-2 - N: Injured by Another Person | DRRI1-N: Injured by Another Person | DRRI1N13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540150","DRRI-2 - N: Someone Close to Me Has Died","C142054","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: someone close to me has died.","DRRI-2 - N: Someone Close to Me Has Died | DRRI1-N: Someone Close to Me Has Died | DRRI1N14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540149","DRRI-2 - O: People Made Me Feel at Home","C142055","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: the American people made me feel at home.","DRRI-2 - O: People Made Me Feel at Home | DRRI1-O: People Made Me Feel at Home | DRRI1O01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538824","Retinoblastoma H0 Finding v8","C140728","Normal RB1 alleles in blood tested with demonstrated high-sensitivity assays. (from AJCC 8th Ed.)","Retinoblastoma H0 Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538823","Retinoblastoma H1 Finding v8","C140729","Bilateral retinoblastoma, retinoblastoma with an intracranial primitive neuroectodermal tumor (i.e., trilateral retinoblastoma), patient with family history of retinoblastoma, or molecular definition of a constitutional RB1 gene mutation. (from AJCC 8th Ed.)","Retinoblastoma H1 Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517376","GXGXXXG Motif","C14072","The GXGXXXG Motif is often found it the NAD-binding domain (often N-terminal) in metabolic enzymes involved in glycolysis, glyconeogenesis, and the citric acid cycle, such as GAPDH (glyceraldehyde-3-phosphate oxidation and phosphorylation), lactate dehydrogenases (lactate to pyruvate conversion), and malate dehydrogenases (malate to oxaloacetate interconversion). (NCI)","GXGXXXG Motif | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540177","FLJ31823","C142160","Human MRTFB wild-type allele is located in the vicinity of 16p13.12 and is approximately 195 kb in length. This allele, which encodes myocardin-related transcription factor B protein, is involved in skeletal myogenesis. A translocation t(11;16)(q13;p13) that fuses this gene to the C11orf95 gene is associated with chondroid lipoma.","MRTFB wt Allele | FLJ31823 | KIAA1243 | MKL and Myocardin Family Member 2 Gene | MKL/Myocardin Like 2 Gene | MKL1/Myocardin Like 2 Gene | MKL2 | MRTF-B | Myocardin Related Transcription Factor B wt Allele | Myocardin-Related Transcription Factor B, Mouse, Homolog of Gene | NPD001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540422","Applicable Regulatory Requirement","C142394","A law or regulation that addresses the conduct of a clinical trial of investigational products. (ICH)","Applicable Regulatory Requirement | applicable regulatory requirement(s)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540421","Audit Report","C142395","A written evaluation by the auditor of the results of the analysis. (ICH)","Audit Report | audit report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545941","Audit Trail","C142396","Documentation that allows reconstruction of the course of events. (ICH)","Audit Trail | audit trail",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540420","Back Translation","C142397","The process of translating a document back to it originally published language.","Back Translation | back translation (natural language)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540419","Balanced Study","C142398","A study in which there is an equal distribution of individuals across groups or arms.","Balanced Study | balanced study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545923","Bandwidth","C142399","An indicator of the speed of data flow on a transmission path.","Bandwidth | Data Throughput | bandwidth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025932","Mice, Nude","C14239","A hairless mutant mouse with thymic hypoplasia, lacking T-cells.  They are unable to reject transplants.","Nude Mouse | Athymic Mouse | Athymic Nude Mouse | NU | Nude | athymic, nude mouse | nu/nu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540403","Baseline Assessment","C142400","Examination of an individual prior to an event or intervention.","Baseline Assessment | baseline assessment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540401","Baseline Imbalance","C142402","A systematic error in creating intervention groups, such that they differ with respect to prognosis. That is, the groups differ in measured or unmeasured baseline characteristics because of the way participants were selected or assigned. (ICH E9)","Baseline Imbalance | baseline imbalance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242196","Approachs, Bayesian","C142403","Approaches to data analysis that provide a posterior probability distribution for some parameter (e.g., treatment effect), derived from the observed data and a prior probability distribution for the parameter. The posterior distribution is then used as the basis for statistical inference. (ICH E9)","Bayesian Approach | Bayesian approaches",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL025914","Bayesian Statistics","C142404","Statistical method that assigns a probability distribution to some parameter (e.g., treatment effect), based on experience or best guesses before experimentation and data collection and that apply Bayes' theorem to revise the probabilities and distributions after obtaining experimental data.","Bayesian Statistics | Bayesian statistics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540400","Beta Error","C142405","In statistics, beta is the probability of a Type 2 error, when one incorrectly accepts the null hypothesis, creating a false negative.","Beta Error | beta error",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162680","Technetium Tc-99m Sestamibi","C1419","Sestamibi is a large synthetic molecule of the isonitrile family, which can be labeled with Tc99m.  It passes through cells membranes passively, collecting in cells with large numbers of mitochondria.  It is often used for imaging of the thyroid and parathyroid.","Technetium Tc-99m Sestamibi | Cardiolite | Miraluma | TECHNETIUM TC-99M SESTAMIBI | Tc 99m Sestamibi | Tc-99m MIBI | Tc99m Sestamibi | Technetium (99mTc) Sestamibi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540098","DRRI-2 - K: My Mistakes Worse Than Others","C142000","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, the people I worked with: acted as though my mistakes were worse than others'.","DRRI-2 - K: My Mistakes Worse Than Others | DRRI1-K: My Mistakes Worse Than Others | DRRI1K05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540097","DRRI-2 - K: Make My Job More Difficult","C142001","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, the people I worked with: tried to make my job more difficult to do.","DRRI-2 - K: Make My Job More Difficult | DRRI1-K: Make My Job More Difficult | DRRI1K06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540096","DRRI-2 - K: Put Me Down","C142002","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, the people I worked with: 'put me down' or treated me in a condescending way.","DRRI-2 - K: Put Me Down | DRRI1-K: Put Me Down | DRRI1K07",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540095","DRRI-2 - K: Threatened My Physical Safety","C142003","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, the people I worked with: threatened my physical safety.","DRRI-2 - K: Threatened My Physical Safety | DRRI1-K: Threatened My Physical Safety | DRRI1K08",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540093","DRRI-2 - K: Spread Rumors Sexual Activities","C142005","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, the people I worked with: spread negative rumors about my sexual activities.","DRRI-2 - K: Spread Rumors Sexual Activities | DRRI1-K: Spread Rumors Sexual Activities | DRRI1K10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540076","DRRI-2 - K: Tried to Talk into Sexual Acts","C142006","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, the people I worked with: tried to talk me into participating in sexual acts when I didn't want to.","DRRI-2 - K: Tried to Talk into Sexual Acts | DRRI1-K: Tried to Talk into Sexual Acts | DRRI1K11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540075","DRRI-2 - K: Authority Pressure Unwanted Sex","C142007","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, the people I worked with: used a position of authority to pressure me into unwanted sexual activity.","DRRI-2 - K: Authority Pressure Unwanted Sex | DRRI1-K: Authority Pressure Unwanted Sex | DRRI1K12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540074","DRRI-2 - K: Offered Reward Take Part in Sex","C142008","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, the people I worked with: offered me a specific reward or special treatment to take part in sexual behavior.","DRRI-2 - K: Offered Reward Take Part in Sex | DRRI1-K: Offered Reward Take Part in Sex | DRRI1K13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540073","DRRI-2 - K: Threatened Me If Not Sex","C142009","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, the people I worked with: threatened me with some sort of retaliation if I was not sexually cooperative (for example, the threat of negative review or physical violence).","DRRI-2 - K: Threatened Me If Not Sex | DRRI1-K: Threatened Me If Not Sex | DRRI1K14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540072","DRRI-2 - K: Touched Sexual Way Against Will","C142010","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, the people I worked with: touched me in a sexual way against my will.","DRRI-2 - K: Touched Sexual Way Against Will | DRRI1-K: Touched Sexual Way Against Will | DRRI1K15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540513","Double-Dummy","C142518","A technique for retaining the blind in a clinical trial with two treatment groups and two non-identical treatments by administering the active form of the first treatment and a placebo in place of the second treatment to one group, and a placebo in place of the first treatment and the active form of the second treatment to the other group.","Double-Dummy | double-dummy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540512","Drug Development Process","C142519","The process by which an investigational product is brought to the market through a series of preclinical and clinical testing, regulatory review, and approval.","Drug Development Process | drug development process",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540511","Dynamic Hypertext Markup Language","C142520","No value exists.","Dynamic Hypertext Markup Language | Dynamic HTML | dynamic HTML",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540524","Edit Check","C142521","A process, usually automated, that is used to check the validity of the input in a data field.","Edit Check | edit check",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540523","Effectiveness","C142522","The extent to which a diagnostic or therapeutic product achieves its intended effect in the typical clinical setting.","Effectiveness | effectiveness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539507","ASP 8374","C141421","A fully human, immunoglobulin G4 (IgG4) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory and immunostimulating activities. Upon administration, anti-TIGIT monoclonal antibody ASP8374 targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","Anti-TIGIT Monoclonal Antibody ASP8374 | ASP 8374 | ASP-8374 | ASP8374 | PTZ-201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539506","Neoantigen-loaded Autologous Dendritic Cell Vaccine","C141422","A personalized, peptide-based therapeutic dendritic cell (DC) vaccine consisting of autologous DCs loaded with immunogenic peptides derived from autologous cancer cells, with potential immunomodulating and antineoplastic activities. Upon leukapheresis, mature DCs are loaded with immunogenic neoantigens. Vaccination with the neoantigen-loaded autologous DC vaccine stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis.","Neoantigen-loaded Autologous Dendritic Cell Vaccine | Autologous Tumor Peptide-loaded Mature DC Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0268341","Ehlers-Danlos Syndrome, Type V","C141423","An X-linked condition characterized by joint hyperextensibility, mild skin hyperelastisity, and abnormal scarring. The molecular basis for this condition has not been fully elucidated.","Ehlers-Danlos Syndrome, Type V | ",,,,,,,,,,,,,,,"4284819","X-linked Ehlers-Danlos syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1969562","Mental Retardation, Autosomal Dominant 1","C141424","An autosomal dominant condition caused by mutation(s) in the MBD5 gene, encoding methyl-CpG-binding domain protein 5. It is characterized by severe developmental and cognitive delay, short stature, craniofacial dysmorphism, and seizures.","Mental Retardation, Autosomal Dominant 1 | MRD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539505","Spebrutinib Besylate","C141425","The besylate salt form of spebrutinib, an orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity. Upon administration, spebrutinib targets and covalently binds to BTK, thereby preventing its activity. By irreversibly inhibiting BTK, administration of this agent may lead to an inhibition of B cell receptor (BCR) signaling and may inhibit cell proliferation of B-cell malignancies. BTK, a cytoplasmic tyrosine kinase and member of the Tec family of kinases, plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.","Spebrutinib Besylate | 2-Propenamide, N-(3-((5-fluoro-2-((4-(2-methoxyethoxy)phenyl)amino)-4-pyrimidinyl)amino)phenyl)-, Benzenesulfonate (1:1) | CC-292 Besylate | N-(3-((5-fluoro-2-((4-(2-methoxyethoxy)phenyl)amino)pyrimidin-4-yl)amino)phenyl)prop-2-enamide Benzenesulfonate | SPEBRUTINIB BESYLATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539518","Tirabrutinib Hydrochloride","C141426","The hydrochloride salt form of tirabrutinib, an orally available formulation containing an inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity. Upon administration, tirabrutinib covalently binds to BTK within B cells, thereby preventing B cell receptor signaling and impeding B cell development. As a result, this agent may inhibit the proliferation of B cell malignancies. BTK, a cytoplasmic tyrosine kinase and member of the Tec family of kinases, plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.","Tirabrutinib Hydrochloride | GS-4059 Hydrochloride | ONO-4059 Hydrochloride | TIRABRUTINIB HYDROCHLORIDE | Velexbru",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539517","Evobrutinib","C141427","An inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, evobrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival.","Evobrutinib | 1-(4-((6-Amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino)-methyl)-piperidin-1-yl)-propenone | EVOBRUTINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540399","Biometric Signature","C142406","A verified characteristic mark of an individual's identity based on measurement of the individual's unique physical feature(s) or repeatable action(s).","Biometric Signature | biometric signature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540411","Blinded Medication","C142408","Medicinal products, with or without the drug under study, which have the same appearance to ensure that neither the subject nor investigator can determine which medication is being administered.","Blinded Medication | Masked Medication | Masked Medications | blinded (masked) medications",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540410","carry-over effect","C142409","Therapeutic responses that continue beyond cessation of treatment, and sometimes, beyond a pharmaceutical product's established biological action.","Carry-Over Effect | carry-over effect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025936","Transgenic Mouse","C14240","A mouse whose genome has been altered by the inclusion of foreign genetic material. The technique involves microinjection of foreign DNA fragments into the nucleus of a fertilized egg. The inserted gene becomes integrated into every cell and tissue of the mouse.","Transgenic Mouse | Transgenic Mice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539819","IPAQ Long Last 7 Days Self-Administered Format Version - Days Vigorous in the Garden/Yard","C141751","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you do vigorous physical activities like heavy lifting, chopping wood, shoveling snow, or digging in the garden or yard?: days per week.","IPAQ Long Last 7 Days Self-Administered Format Version - Days Vigorous in the Garden/Yard | IPA03-Days Vigorous in the Garden/Yard | IPA0314",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539818","IPAQ Long Last 7 Days Self-Administered Format Version - No Vigorous Activity Garden/Yard","C141752","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you do vigorous physical activities like heavy lifting, chopping wood, shoveling snow, or digging in the garden or yard?: No vigorous activity in garden or yard.","IPAQ Long Last 7 Days Self-Administered Format Version - No Vigorous Activity Garden/Yard | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539817","IPAQ Long Last 7 Days Self-Administered Format Version - Vigorous Garden Hr and Min per Day","C141753","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days doing vigorous physical activities in the garden or yard?: hours and minutes per day.","IPAQ Long Last 7 Days Self-Administered Format Version - Vigorous Garden Hr and Min per Day | IPA03-Vigorous Garden Hr & Min per Day | IPA0315",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539816","IPAQ Long Last 7 Days Self-Administered Format Version - Vigorous Garden Minutes per Day","C141754","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days doing vigorous physical activities in the garden or yard?: minutes per day.","IPAQ Long Last 7 Days Self-Administered Format Version - Vigorous Garden Minutes per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539815","IPAQ Long Last 7 Days Self-Administered Format Version - Days Moderate in the Garden/Yard","C141755","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you do moderate activities like carrying light loads, sweeping, washing windows, and raking in the garden or yard?: days per week.","IPAQ Long Last 7 Days Self-Administered Format Version - Days Moderate in the Garden/Yard | IPA03-Days Moderate in the Garden/Yard | IPA0316",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539814","IPAQ Long Last 7 Days Self-Administered Format Version - No Moderate Activity Garden/Yard","C141756","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you do moderate activities like carrying light loads, sweeping, washing windows, and raking in the garden or yard?: No moderate activity in garden or yard.","IPAQ Long Last 7 Days Self-Administered Format Version - No Moderate Activity Garden/Yard | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539813","IPAQ Long Last 7 Days Self-Administered Format Version - Moderate Garden Hr and Min per Day","C141757","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days doing moderate physical activities in the garden or yard?: hours and minutes per day.","IPAQ Long Last 7 Days Self-Administered Format Version - Moderate Garden Hr and Min per Day | IPA03-Moderate Garden Hr & Min per Day | IPA0317",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1419143","NECTIN2 Gene","C142200","This gene plays a role in T-cell signaling, viral entry and adherens junction organization.","NECTIN2 Gene | NECTIN2 | Nectin Cell Adhesion Molecule 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540245","NECTIN2 wt Allele","C142201","Human NECTIN2 wild-type allele is located in the vicinity of 19q13.32 and is approximately 43 kb in length. This allele, which encodes nectin-2 protein, is involved in viral entry, adherens junction organization and the modulation of receptor-mediated signaling in T-cells. Variation in the gene in subjects with multiple sclerosis may be associated with the severity of the disorder.","NECTIN2 wt Allele | CD112 | HVEB | Nectin 2 Gene | Nectin Cell Adhesion Molecule 2 wt Allele | PRR2 | PVRL2 | PVRR2 | Poliovirus Receptor-Like 2 Gene | Poliovirus Receptor-Related 2 (Herpesvirus Entry Mediator B) Gene | Poliovirus Receptor-Related 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540244","Nectin-2","C142202","Nectin-2 (538 aa, ~58 kDa) is encoded by the human NECTIN2 gene. This protein plays a role in adherens junction organization, the regulation of T-cell signaling, and host cell entry of herpes simplex virus and pseudorabies virus.","Nectin-2 | CD112 | CD112 Antigen | Herpes Virus Entry Mediator B | Herpesvirus Entry Mediator B | Herpesvirus Entry Protein B | HveB | NECTIN2 | Nectin 2 | Nectin Cell Adhesion Molecule 2 | PVRL-2 | PVRL2 | Poliovirus Receptor-Like 2 | Poliovirus Receptor-Related 2 | Poliovirus Receptor-Related Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540243","Autologous CD4 and CD8 Positive Truncated CD19-expressing Antigen Presenting T-cells","C142205","A preparation of ex vivo expanded, autologous CD4 and CD8 positive antigen presenting T-cells (T-APCs), genetically modified with a transgene encoding a truncated form of human cluster of differentiation 19 (CD19t), with potential immunostimulating activity. Upon infusion, autologous CD19t-expressing T-APCs may stimulate the proliferation and activation of preadministered therapeutic CD19-targeted chimeric antigen receptor T-cells (CAR-T). This may both improve the persistence of the therapeutic CAR-T-cells and prevent relapse in patients with CD19 positive leukemia or lymphoma. CD19 is a B-cell specific cell surface antigen that is expressed in all B-cell lineage malignancies.","Autologous CD4 and CD8 Positive Truncated CD19-expressing Antigen Presenting T-cells | Autologous CD19t T-APC | Autologous CD19t T-Antigen Presenting Cells | Autologous T-cell Antigen Presenting Cells Expressing CD19t | Autologous T-cell Antigen Presenting Cells Expressing Truncated CD19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540242","ZNF451 Gene","C142206","This gene is involved in protein sumoylation.","ZNF451 Gene | ZNF451 | Zinc Finger Protein 451 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540241","ZNF451 wt Allele","C142207","Human ZNF451 wild-type allele is located in the vicinity of 6p12.1 and is approximately 83 kb in length. This allele, which encodes E3 SUMO-protein ligase ZNF451 protein, plays a role in post-translational sumoylation.","ZNF451 wt Allele | COASTER | KIAA0576 | KIAA1702 | Zinc Finger Protein 451 wt Allele | dJ417I1.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2604293","ZNF451 protein, human","C142208","E3 SUMO-protein ligase ZNF451 (1061 aa, ~121 kDa) is encoded by the human ZNF451 gene. This protein is involved in the sumoylation of protein substrates.","E3 SUMO-Protein Ligase ZNF451 | Coactivator For Steroid Receptors | E3 SUMO-Protein Transferase ZNF451 | EC 2.3.2.- | ZATT | ZNF451 | Zinc Finger Protein 451",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540239","DENND3 Gene","C142209","This gene is involved in the modulation of Ras-related protein Rab-12 activity.","DENND3 Gene | DENN Domain Containing 3 Gene | DENND3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540254","DENND3 wt Allele","C142210","Human DENND3 wild-type allele is located in the vicinity of 8q24.3 and is approximately 79 kb in length. This allele, which encodes DENN domain-containing protein 3, plays a role in guanine nucleotide exchange.","DENND3 wt Allele | DENN Domain Containing 3 wt Allele | DENN/MADD Domain Containing 3 Gene | KIAA0870",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4277473","DENND3 protein, human","C142211","DENN domain-containing protein 3 (1198 aa, ~136 kDa) is encoded by the human DENND3 gene. This protein is involved in the activation of Ras-related protein Rab-12 through guanine nucleotide exchange.","DENN Domain-Containing Protein 3 | DENN/MADD Domain-Containing Protein 3 | DENND3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540521","Electronic Case Report Tabulation","C142524","The collection of digital data and documentation for a clinical study that is submitted for regulatory review.","Electronic Case Report Tabulation | eCRT | eCRT (electronic case report tabulation)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540520","Electronic Certified Copy","C142525","A copy of original information represented in digital format that has been verified by a dated signature as being an exact copy.","Electronic Certified Copy | eCertified Copy | eCertified copy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540519","Electronic Clinical Trial","C142526","A clinical trial in which computerized systems are used to plan, collect, access, exchange, and archive data.","Electronic Clinical Trial | eClinical Trial | eClinical investigation | eClinical study | eClinical trial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545927","Electronic Data Capture","C142527","The use of a computerized system to collect clinical trial data.","Electronic Data Capture | EDC | EDC (electronic data capture)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540518","Electronic Data Capture Activation","C142528","The act or process of enabling an electronic data capture system to acquire data.","Electronic Data Capture Activation | activation (EDC)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030362","Baboon","C14252","A large terrestrial monkey found in Africa and Arabia, it is the largest non-hominid member of the primate order. This primate has a long dog-like muzzles, close-set eyes, heavy powerful jaws, thick fur, a short tail and often brightly colored ischial callosities.","Baboon | BABOON | Baboons | Papio",,,,,,,,,,,,,,,"4190589","Genus Papio",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540503","Electronic Record","C142531","A collection of digital data that is managed and processed by a computer system.","Electronic Record | electronic record",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540502","Electronic Records Control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540501","Electronic Signature","C142533","An electronic version of an individual's name or personal mark used to sign electronic documents, signifying that the writing which precedes accords with one's wishes and intentions.","Electronic Signature | eSignature | electronic signature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540500","Electronic Source Data","C142534","Digital information in original records, and certified copies of digital information in original records.","Electronic Source Data | eSource Data | eSource data",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540499","Electronic Source Document","C142535","An original record containing digital data.","Electronic Source Document | eSource Document | eSource document",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540498","Electronic Source Record","C142536","A collection of original digital data, and certified copies of collections of original digital data.","Electronic Source Record | eSource | eSource Record",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539867","IPA0223A","C141831","International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days doing vigorous physical activities in your leisure time?: Hours and minutes per day.","IPAQ Long Last 7 Days Telephone Format Version - Vigorous Leisure Hr and Min per Day | IPA02-Vigorous Leisure Hr & Min per Day | IPA0223A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3896894","Zanubrutinib","C141428","An inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, zanubrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival.","Zanubrutinib | (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide | BGB 3111 | BGB-3111 | BGB3111 | BTK-InhB | Brukinsa | ZANUBRUTINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539093","Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8","C140973","Stage IV includes: IVA: 55 years and older: T4b, Any N, M0; IVB: 55 years and older: Any T, Any N, M1. T4b: Gross extrathyroidal extension invading prevertebral fascia or encasing the carotid artery or mediastinal vessels from a tumor of any size. M0: No distant metastasis. M1: Distant metastasis. (from AJCC 8th Ed.)","Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8 | Stage IV Differentiated Thyroid Gland Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539090","Thyroid Gland Papillary Carcinoma by AJCC v8 Stage","C140976","A term that refers to the staging of papillary thyroid gland carcinoma, following the rules of the TNM AJCC v8 classification system.","Thyroid Gland Papillary Carcinoma by AJCC v8 Stage | Tumor Stage (Pathologic)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539089","Stage I Thyroid Gland Papillary Carcinoma AJCC v8","C140977","Stage I includes: Under 55 years: Any T, Any N, M0. 55 years and older: (T1, N0/NX, M0); (T2, N0/NX, M0).  T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. N0: No evidence of locoregional lymph node metastasis. NX: Regional lymph nodes cannot be assessed. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage I Thyroid Gland Papillary Carcinoma AJCC v8 | I | Stage I Thyroid Gland Papillary Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539088","Stage I Thyroid Gland Papillary Carcinoma Under 55 Years AJCC v8","C140978","Stage I includes: Any T, Any N, M0. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage I Thyroid Gland Papillary Carcinoma Under 55 Years AJCC v8 | I Under 55 Years | Stage I Thyroid Gland Papillary Cancer Under 55 Years",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539828","IPAQ Long Last 7 Days Self-Administered Format Version - Moderate Garden Minutes per Day","C141758","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days doing moderate physical activities in the garden or yard?: minutes per day.","IPAQ Long Last 7 Days Self-Administered Format Version - Moderate Garden Minutes per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539827","IPAQ Long Last 7 Days Self-Administered Format Version - Days Moderate Inside Home","C141759","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you do moderate activities like carrying light loads, washing windows, scrubbing floors and sweeping inside your home?: days per week.","IPAQ Long Last 7 Days Self-Administered Format Version - Days Moderate Inside Home | IPA03-Days Moderate Inside Home | IPA0318",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539826","IPAQ Long Last 7 Days Self-Administered Format Version - No Moderate Activity Inside Home","C141760","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you do moderate activities like carrying light loads, washing windows, scrubbing floors and sweeping inside your home?: No moderate activity inside home.","IPAQ Long Last 7 Days Self-Administered Format Version - No Moderate Activity Inside Home | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540017","DRRI-2 - F: Exposed to Nuclear Weapons","C141953","Deployment Risk and Resilience Inventory-2 (DRRI-2) Either in preparation for or during my deployment: I was exposed to nuclear, biological, or chemical weapons.","DRRI-2 - F: Exposed to Nuclear Weapons | DRRI1-F: Exposed to Nuclear Weapons | DRRI1F13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540016","DRRI-2 - G: Concerned Infectious Disease","C141954","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was concerned about getting an infectious disease.","DRRI-2 - G: Concerned Infectious Disease | DRRI1-G: Concerned Infectious Disease | DRRI1G01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540015","DRRI-2 - G: Health Might Suffer NBC Agents","C141955","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was concerned that my health might suffer due to exposure to nuclear, biological, or chemical (NBC) agents.","DRRI-2 - G: Health Might Suffer NBC Agents | DRRI1-G: Health Might Suffer NBC Agents | DRRI1G02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540014","DRRI-2 - G: Felt in Danger of Being Wounded","C141956","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I felt I was in great danger of being wounded (for example, losing a limb).","DRRI-2 - G: Felt in Danger of Being Wounded | DRRI1-G: Felt in Danger of Being Wounded | DRRI1G03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540013","DRRI-2 - G: Concerned Medicine Make Me Sick","C141957","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was concerned that the medicine I was given to protect me from illness would make me sick.","DRRI-2 - G: Concerned Medicine Make Me Sick | DRRI1-G: Concerned Medicine Make Me Sick | DRRI1G04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539995","DRRI-2 - G: Feared Sick From Pesticides","C141959","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I feared that I would become sick from pesticides (for example, bug spray) or other routinely used chemicals.","DRRI-2 - G: Feared Sick From Pesticides | DRRI1-G: Feared Sick From Pesticides | DRRI1G06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539994","DRRI-2 - G: Concern Rocket/Mortar Would Hit","C141960","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was concerned that a rocket or mortar would hit our living quarters.","DRRI-2 - G: Concern Rocket/Mortar Would Hit | DRRI1-G: Concern Rocket/Mortar Would Hit | DRRI1G07",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433720","FGFR inhibitor LY2874455","C139004","An orally bioavailable pan-inhibitor of fibroblast growth factor receptor (FGFR) family proteins, with potential antineoplastic activity. Upon oral administration, FGFR inhibitor LY2874455 binds to and inhibits FGFR subtypes 1 (FGFR1), 2 (FGFR2), 3 (FGFR3) and 4 (FGFR4), which results in the inhibition of FGFR-mediated signal transduction pathways. This inhibits both tumor angiogenesis and proliferation of FGFR-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, plays a key role in cellular proliferation, cell survival and angiogenesis.","Pan-FGFR Inhibitor LY2874455 | LY-2874455 | LY2874455 | Pan FGFR Inhibitor LY2874455 | Pan Fibroblast Growth Factor Receptor Inhibitor LY2874455",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3846373","Durie/Salmon Stage","C139006","A plasma cell myeloma stage defined according to the Durie/Salmon staging system.","Durie/Salmon Stage | DS Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526542","International Staging System Stage","C139007","A plasma cell myeloma stage defined according to the international staging system.","International Staging System Stage | ISS Stage | iss stage | iss_stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526541","Multiple Myeloma Myeloma by DS Stage","C139008","A header term that refers to the staging of multiple myeloma according to the Durie/Salmon staging system.","Multiple Myeloma Myeloma by DS Stage | Plasma Cell Myeloma Myeloma by DS Stage | Plasma Cell Myeloma by DS Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520848","19p13.2-p12","C13900","A chromosome band present on 19p","19p13.2-p12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539742","IPAQ Short Last 7 Days Self-administered Format Version - Moderate Physical Minutes per Day","C141716","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) How much time did you usually spend doing moderate physical activities on one of those days?: minutes per day.","IPAQ Short Last 7 Days Self-administered Format Version - Moderate Physical Minutes per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539741","IPAQ Short Last 7 Days Self-administered Format Version - Time Moderate Don't Know/Not Sure","C141717","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) How much time did you usually spend doing moderate physical activities on one of those days?: Don't know/Not sure.","IPAQ Short Last 7 Days Self-administered Format Version - Time Moderate Don't Know/Not Sure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539724","IPAQ Short Last 7 Days Self-administered Format Version - Days Walk at Least 10 Minutes","C141718","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) During the last 7 days, on how many days did you walk for at least 10 minutes at a time?: days per week.","IPAQ Short Last 7 Days Self-administered Format Version - Days Walk at Least 10 Minutes | IPA04-Days Walk at Least 10 Minutes | IPA0405",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539723","IPAQ Short Last 7 Days Self-administered Format Version - No Walking","C141719","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) During the last 7 days, on how many days did you walk for at least 10 minutes at a time?: No walking.","IPAQ Short Last 7 Days Self-administered Format Version - No Walking | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526877","Prognostic Stage III Breast Cancer AJCC v8","C139582","Stage III includes: IIIA: (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); IIIB: (T2, N1, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status:","Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage III Breast Carcinoma AJCC v8 | Stage III Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526882","Prognostic Stage IIIA Breast Cancer AJCC v8","C139583","Stage IIIA includes: (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); ( T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moder","Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Carcinoma AJCC v8 | Stage IIIA Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520580","14q11.2-q12","C13905","A chromosome band present on 14q","14q11.2-q12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540492","First Subject In Date Time","C142558","The date and time when the first individual is enrolled into a clinical study.","First Subject In Date Time | FPI - date, time | first patient in - date, time | first subject in - date, time (FSI - date, time)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540491","First Subject In Identity","C142559","The name of the first individual who is enrolled into a clinical study.","First Subject In Identity | FPI - identity | first patient in - identity | first subject in - identity (FSI - identity)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030465","Paramyxoviridae","C14255","A family of negative-strand single-strand RNA viruses which includes Mumps and Measles viruses.","Paramyxoviridae | ",,,,,,,,,,,,,,,"4134615","Paramyxoviridae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540490","First Subject Screened Date Time","C142560","The date and time when the first individual is screened for a clinical study.","First Subject Screened Date Time | first patient screened - date, time | first subject screened - date, time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540477","First Subject Screened Identity","C142561","The name of the first individual who is screened for a clinical study.","First Subject Screened Identity | first patient screened - identity | first subject screened - identity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540476","First Subject Treated Date Time","C142562","The date and time when the first individual is administered the test article or placebo in a clinical trial.","First Subject Treated Date Time | first patient treated - date, time | first subject treated - date, time",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540475","First Subject Treated Identity","C142563","The name of the first individual who is administered the test article or placebo in a clinical trial.","First Subject Treated Identity | first patient treated - identity | first subject treated - identity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540474","First-in-Human Study","C142564","A type of phase 1 clinical trial in which the test product is administered to human beings for the first time.","First-in-Human Study | first-in-humans study | first-in-man study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540473","Frequentist Method","C142565","Statistical methods, such as significance tests and confidence intervals, which can be interpreted in terms of the frequency of certain outcomes occurring in hypothetical repeated realizations of the same experimental situation. (ICH)","Frequentist Method | Frequentist Inference | Frequentist Statistics | frequentist methods",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540472","Global Assessment Variable","C142566","A single variable, usually a scale of ordered categorical ratings, which integrates objective variables and the investigator's overall impression about the state or change in state of a subject. (ICH)","Global Assessment Variable | global assessment variable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540471","Granularity","C142567","A data unit, as part of the whole collection of data, that has a high level of detail in distinct parts.","Granularity | granularity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540482","Handwritten Signature","C142569","The scripted name or legal mark of an individual written by that individual and executed or adopted with the present intention to authenticate a writing in a permanent form. (FDA)","Handwritten Signature | handwritten signature",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031886","Picornavirus","C14256","A family of non-enveloped, positive-stranded RNA viruses with an icosahedral capsid.","Picornavirus | Picornaviridae",,,,,,,,,,,,,,,"4251423","Family Picornaviridae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4279947","Health Related Quality Of Life","C142570","A patient's perception of the effect of illness and treatment on their physical and mental health.","Health-related Quality of Life | health-related quality of life (HRQoL)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540481","HL7 Document","C142571","No value exists.","HL7 Document | document (HL7)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539845","IPAQ Short Last 7 Days Telephone Format Version - Days Moderate Physical Activities","C141853","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) During the last 7 days, on how many days did you do moderate physical activities?","IPAQ Short Last 7 Days Telephone Format Version - Days Moderate Physical Activities | IPA01-Days Moderate Physical Activities | IPA0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540140","DRRI-2 - P: Opinions Valued by Family","C142070","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: my opinions are valued by other family members.","DRRI-2 - P: Opinions Valued by Family | DRRI1-P: Opinions Valued by Family | DRRI1P06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540139","DRRI-2 - P: I am Affectionate With Family","C142071","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I am affectionate with family members.","DRRI-2 - P: I am Affectionate With Family | DRRI1-P: I am Affectionate With Family | DRRI1P07",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540138","DRRI-2 - P: Play Important Role in Family","C142072","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I play an important role in my family.","DRRI-2 - P: Play Important Role in Family | DRRI1-P: Play Important Role in Family | DRRI1P08",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540137","DRRI-2 - P: Spend My Free Time With Family","C142073","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I spend as much of my free time with family members as possible.","DRRI-2 - P: Spend My Free Time With Family | DRRI1-P: Spend My Free Time With Family | DRRI1P09",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540136","DRRI-2 - P: Family Tell Me When Problem","C142074","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: family members tell me when they are having a problem.","DRRI-2 - P: Family Tell Me When Problem | DRRI1-P: Family Tell Me When Problem | DRRI1P10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540135","DRRI-2 - P: Can Be Myself Around Family","C142075","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I can be myself around family members.","DRRI-2 - P: Can Be Myself Around Family | DRRI1-P: Can Be Myself Around Family | DRRI1P11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540134","DRRI-2 - P: I Get Along Well With My Family","C142076","Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I get along well with my family members.","DRRI-2 - P: I Get Along Well With My Family | DRRI1-P: I Get Along Well With My Family | DRRI1P12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540133","Anti-LAG-3 Monoclonal Antibody MK-4280","C142077","A humanized, immunoglobulin G4 (IgG4) monoclonal antibody (MAb) directed against the inhibitory receptor lymphocyte activation gene-3 protein (LAG3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, favezelimab binds to LAG3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells, and negatively regulates both proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.","Favezelimab | Anti-LAG-3 Monoclonal Antibody MK-4280 | Anti-LAG3 Monoclonal Antibody MK-4280 | FAVEZELIMAB | MK 4280 | MK-4280 | MK4280",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540142","Adoptive Cell Therapy Agent","C142078","A preparation of allogeneic or autologous cells that is meant to be administered to a patient and may have an immunotherapeutic effect.","Adoptive Cell Therapy Agent | ACT Agent | Adoptive Cell Transfer Agent | Adoptive Cell-based Agent | Adoptive Cellular Therapy Agent | Adoptive Immunotherapy | Cellular Immunotherapy Agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1869123","Limb-Girdle Muscular Dystrophy Type 2A","C142079","An autosomal recessive condition caused by mutation(s) in the CAPN3 gene, encoding calpain-3. It is characterized by muscular dystrophy, primarily affecting the proximal muscles, resulting in difficulty walking.","Limb-Girdle Muscular Dystrophy Type 2A | Autosomal Recessive Muscular Dystrophy Limb-Girdle 1 | LGMD2A | LGMDR1",,,,,,,,,,,,,,,"37395782","Autosomal recessive limb girdle muscular dystrophy type 2A",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1850889","Limb-Girdle Muscular Dystrophy Type 2B","C142080","An autosomal recessive condition caused by mutation(s) in the DYSF gene, encoding dysferlin. It is characterized by progressive muscular dystrophy, primarily affecting the proximal muscles, resulting in difficulty walking.","Limb-Girdle Muscular Dystrophy Type 2B | Autosomal Recessive Muscular Dystrophy Limb-Girdle 2 | LGMD2B | LGMDR2",,,,,,,,,,,,,,,"37397523","Autosomal recessive limb girdle muscular dystrophy type 2B",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2936332","Limb-Girdle Muscular Dystrophy Type 2D","C142081","An autosomal recessive condition caused by mutation(s) in the SGCA gene, encoding alpha-sarcoglycan. It is characterized by progressive muscular dystrophy, primarily affecting the proximal muscles, resulting in difficulty walking.","Limb-Girdle Muscular Dystrophy Type 2D | Autosomal Recessive Muscular Dystrophy Limb-Girdle 3 | LGMD2D | LGMDR3",,,,,,,,,,,,,,,"37395781","Autosomal recessive limb girdle muscular dystrophy type 2D",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL539722","IPAQ Short Last 7 Days Self-administered Format Version - Walking Hr and Min per Day","C141720","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) How much time did you usually spend walking on one of those days?: hours and minutes per day.","IPAQ Short Last 7 Days Self-administered Format Version - Walking Hr and Min per Day | IPA04-Walking Hr & Min per Day | IPA0406",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539721","IPAQ Short Last 7 Days Self-administered Format Version - Walking Minutes per Day","C141721","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) How much time did you usually spend walking on one of those days?: minutes per day.","IPAQ Short Last 7 Days Self-administered Format Version - Walking Minutes per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539720","IPAQ Short Last 7 Days Self-administered Format Version - Time Walking Don't Know/Not Sure","C141722","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) How much time did you usually spend walking on one of those days?: Don't know/Not sure.","IPAQ Short Last 7 Days Self-administered Format Version - Time Walking Don't Know/Not Sure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539719","IPAQ Short Last 7 Days Self-administered Format Version - Sitting Weekday Hr and Min per Day","C141723","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) During the last 7 days, how much time did you spend sitting on a weekday?: hours and minutes per day.","IPAQ Short Last 7 Days Self-administered Format Version - Sitting Weekday Hr and Min per Day | IPA04-Sitting Weekday Hr & Min per Day | IPA0407",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539718","IPAQ Short Last 7 Days Self-administered Format Version - Sitting Weekday Minutes per Day","C141724","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) During the last 7 days, how much time did you spend sitting on a weekday?: minutes per day.","IPAQ Short Last 7 Days Self-administered Format Version - Sitting Weekday Minutes per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539717","IPAQ Short Last 7 Days Self-administered Format Version - Time Sitting Don't Know/Not Sure","C141725","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) During the last 7 days, how much time did you spend sitting on a weekday?: Don't know/Not sure.","IPAQ Short Last 7 Days Self-administered Format Version - Time Sitting Don't Know/Not Sure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539732","IPAQ Long Last 7 Days Self-Administered Format Version - Currently Have Job or Unpaid Work","C141726","International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) Do you currently have a job or do any unpaid work outside your home?","IPAQ Long Last 7 Days Self-Administered Format Version - Currently Have Job or Unpaid Work | IPA03-Currently Have Job or Unpaid Work | IPA0301",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539934","DRRI-2 - C: Hassle With Heavy/Annoying Gear","C141908","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I had to hassle with putting on and taking off heavy or annoying gear.","DRRI-2 - C: Hassle With Heavy/Annoying Gear | DRRI1-C: Hassle With Heavy/Annoying Gear | DRRI1C12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539933","DRRI-2 - C: Not Allowed to Get Job Done","C141909","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was not allowed to do the things I needed to do to get my job done.","DRRI-2 - C: Not Allowed to Get Job Done | DRRI1-C: Not Allowed to Get Job Done | DRRI1C13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006072","Bovine Papillomavirus","C14190","A group of double-stranded DNA viruses that cause warts on the skin and alimentary track of cattle and other mammals.","Bovine Papillomavirus | BPV",,,,,,,,,,,,,,,"4024070","Bovine papillomavirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL539916","DRRI-2 - C: Not Have Adequate Shelter","C141910","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I did not have adequate shelter from uncomfortable living conditions (for example, heat, cold, wet, etc.).","DRRI-2 - C: Not Have Adequate Shelter | DRRI1-C: Not Have Adequate Shelter | DRRI1C14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539915","DRRI-2 - D: Went on Combat Patrols/Missions","C141911","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I went on combat patrols or missions.","DRRI-2 - D: Went on Combat Patrols/Missions | DRRI1-D: Went on Combat Patrols/Missions | DRRI1D01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537867","Uterine Corpus Carcinoma and Carcinosarcoma pN1 TNM Finding v8","C139780","Uterine corpus carcinoma or carcinosarcoma with regional lymph node metastasis to pelvic lymph nodes. (from AJCC 8th Ed.)","Uterine Corpus Carcinoma and Carcinosarcoma pN1 TNM Finding v8 | FIGO Stage IIIC1 Uterine Cancer | Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage IIIC1 | pN1 (FIGO IIIC1)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537866","Uterine Corpus Carcinoma and Carcinosarcoma pN1mi TNM Finding v8","C139781","Uterine corpus carcinoma or carcinosarcoma with regional lymph node metastasis (greater than 0.2 mm but nor greater than 2.0 mm in diameter) to pelvic lymph nodes. (from AJCC 8th Ed.)","Uterine Corpus Carcinoma and Carcinosarcoma pN1mi TNM Finding v8 | Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage IIIC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537865","Uterine Corpus Carcinoma and Carcinosarcoma pN1a TNM Finding v8","C139782","Uterine corpus carcinoma or carcinosarcoma with regional lymph node metastasis (greater than 2.0 mm in diameter) to pelvic lymph nodes. (from AJCC 8th Ed.)","Uterine Corpus Carcinoma and Carcinosarcoma pN1a TNM Finding v8 | Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage IIIC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537864","Uterine Corpus Carcinoma and Carcinosarcoma pN2 TNM Finding v8","C139783","Uterine corpus carcinoma or carcinosarcoma with regional lymph node metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes. (from AJCC 8th Ed.)","Uterine Corpus Carcinoma and Carcinosarcoma pN2 TNM Finding v8 | FIGO Stage IIIC2 Uterine Cancer | Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage IIIC2 | pN2 (FIGO IIIC2)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537973","Uterine Corpus Carcinoma and Carcinosarcoma pN2mi TNM Finding v8","C139784","Uterine corpus carcinoma or carcinosarcoma with regional lymph node metastasis (greater than 0.2 mm but not greater than 2.0 mm in diameter) to para-aortic lymph nodes, with or without positive pelvic lymph nodes. (from AJCC 8th Ed.)","Uterine Corpus Carcinoma and Carcinosarcoma pN2mi TNM Finding v8 | Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage IIIC2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537972","Uterine Corpus Carcinoma and Carcinosarcoma pN2a TNM Finding v8","C139785","Uterine corpus carcinoma or carcinosarcoma with regional lymph node metastasis (greater than 2.0 mm in diameter) to para-aortic lymph nodes, with or without positive pelvic lymph nodes. (from AJCC 8th Ed.)","Uterine Corpus Carcinoma and Carcinosarcoma pN2a TNM Finding v8 | Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage IIIC2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539860","IPA0104A","C141854","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) How much time did you usually spend doing moderate physical activities on one of those days?: Hours and minutes per day.","IPAQ Short Last 7 Days Telephone Format Version - Moderate Physical Hr and Min per Day | IPA01-Moderate Physical Hr & Min per Day | IPA0104A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539859","IPAQ Short Last 7 Days Telephone Format Version - Moderate Physical Minutes per Day","C141855","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) How much time did you usually spend doing moderate physical activities on one of those days?: Minutes per day.","IPAQ Short Last 7 Days Telephone Format Version - Moderate Physical Minutes per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539858","IPAQ Short Last 7 Days Telephone Format Version - Total Moderate Hr and Min per Week","C141856","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing moderate physical activities?: Hours and minutes per week.","IPAQ Short Last 7 Days Telephone Format Version - Total Moderate Hr and Min per Week | IPA01-Total Moderate Hr & Min per Week | IPA0104B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539857","IPAQ Short Last 7 Days Telephone Format Version - Total Moderate Minutes per Week","C141857","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing moderate physical activities?: Minutes per week.","IPAQ Short Last 7 Days Telephone Format Version - Total Moderate Minutes per Week | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539855","IPA0106A","C141859","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) How much time did you usually spend walking on one of those days?: Hours and minutes per day.","IPAQ Short Last 7 Days Telephone Format Version - Walking Hr and Min per Day | IPA01-Walking Hr & Min per Day | IPA0106A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539854","IPAQ Short Last 7 Days Telephone Format Version - Walking Minutes per Day","C141860","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) How much time did you usually spend walking on one of those days?: Minutes per day.","IPAQ Short Last 7 Days Telephone Format Version - Walking Minutes per Day | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539853","IPAQ Short Last 7 Days Telephone Format Version - Total Walking Hr and Min per Week","C141861","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) What is the total amount of time you spent walking over the last 7 days?: Hours and minutes per week.","IPAQ Short Last 7 Days Telephone Format Version - Total Walking Hr and Min per Week | IPA01-Total Walking Hr & Min per Week | IPA0106B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539964","IPAQ Short Last 7 Days Telephone Format Version - Total Walking Minutes per Week","C141862","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) What is the total amount of time you spent walking over the last 7 days?: Minutes per week.","IPAQ Short Last 7 Days Telephone Format Version - Total Walking Minutes per Week | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539963","IPA0107A","C141863","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) During the last 7 days, how much time did you usually spend sitting on a weekday?: Hours and minutes per weekday.","IPAQ Short Last 7 Days Telephone Format Version - Sitting Hr and Min per Weekday | IPA01-Sitting Hr & Min per Weekday | IPA0107A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539962","IPAQ Short Last 7 Days Telephone Format Version - Sitting Minutes per Weekday","C141864","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) During the last 7 days, how much time did you usually spend sitting on a weekday?: Minutes per weekday.","IPAQ Short Last 7 Days Telephone Format Version - Sitting Minutes per Weekday | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540141","Limb-Girdle Muscular Dystrophy Type 2Z","C142082","An autosomal recessive condition caused by mutation(s) in the POGLUT1 gene, encoding protein O-glucosyltransferase 1. It is characterized by progressive muscular dystrophy, primarily affecting the proximal muscles, resulting in difficulty walking.","Limb-Girdle Muscular Dystrophy Type 2Z | Autosomal Recessive Muscular Dystrophy Limb-Girdle 21 | LGMD2Z | LGMDR21",,,,,,,,,,,,,,,"37160986","POGLUT1-related limb girdle muscular dystrophy R21",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162922","Perflubron","C1422","A synthetic radiopaque liquid form of perfluorooctyl bromide.  Used as a contrast agent for magnetic resonance imaging (MRI), perflubron is also used as a liquid ventilation agent to improve pulmonary gas exchange and lung compliance and may be used in surgery to reduce or eliminate the need for donor blood.  Ventilation with perfluorocarbon fluid improves lung function in conditions involving surfactant deficiency and dysfunction, including respiratory distress syndrome and adult respiratory distress syndrome. (NCI04)","Perflubron | Imagent GI | PERFLUBRON | PFOB | Perfluorooctylbromide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539913","DRRI-2 - D: Witnessed Someone Unit Wounded","C141913","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I personally witnessed someone from my unit or an ally unit being seriously wounded or killed.","DRRI-2 - D: Witnessed Someone Unit Wounded | DRRI1-D: Witnessed Someone Unit Wounded | DRRI1D03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539912","DRRI-2 - D: Encountered Land Mines","C141914","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I encountered land or water mines, booby traps, or roadside bombs (for example, IEDs).","DRRI-2 - D: Encountered Land Mines | DRRI1-D: Encountered Land Mines | DRRI1D04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539911","DRRI-2 - D: Exposed Hostile Incoming Fire","C141915","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was exposed to hostile incoming fire.","DRRI-2 - D: Exposed Hostile Incoming Fire | DRRI1-D: Exposed Hostile Incoming Fire | DRRI1D05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539910","DRRI-2 - D: Exposed to Friendly Fire","C141916","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was exposed to 'friendly' fire.","DRRI-2 - D: Exposed to Friendly Fire | DRRI1-D: Exposed to Friendly Fire | DRRI1D06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539909","DRRI-2 - D: Vehicle/Part of Convoy Attacked","C141917","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was in a vehicle (for example, a 'humvee', helicopter, or boat) or part of a convoy that was attacked.","DRRI-2 - D: Vehicle/Part of Convoy Attacked | DRRI1-D: Vehicle/Part of Convoy Attacked | DRRI1D07",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539924","DRRI-2 - D: Part of Unit Fired on Enemy","C141918","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was part of a land or naval artillery unit that fired on enemy combatants.","DRRI-2 - D: Part of Unit Fired on Enemy | DRRI1-D: Part of Unit Fired on Enemy | DRRI1D08",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539923","DRRI-2 - D: Witnessed Enemy Wounded/Killed","C141919","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I personally witnessed enemy combatants being seriously wounded or killed.","DRRI-2 - D: Witnessed Enemy Wounded/Killed | DRRI1-D: Witnessed Enemy Wounded/Killed | DRRI1D09",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539922","DRRI-2 - D: Witnessed Civilians Wounded","C141920","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I personally witnessed civilians (for example, women and children) being seriously wounded or killed.","DRRI-2 - D: Witnessed Civilians Wounded | DRRI1-D: Witnessed Civilians Wounded | DRRI1D10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539921","DRRI-2 - D: Injured Combat-Related Incident","C141921","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was injured in a combat-related incident.","DRRI-2 - D: Injured Combat-Related Incident | DRRI1-D: Injured Combat-Related Incident | DRRI1D11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539920","DRRI-2 - D: Fired My Weapon Enemy Combatant","C141922","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I fired my weapon at enemy combatants.","DRRI-2 - D: Fired My Weapon Enemy Combatant | DRRI1-D: Fired My Weapon Enemy Combatant | DRRI1D12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520585","14q21-q22","C13978","A chromosome band present on 14q","14q21-q22 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526689","Genomic Data Commons","C139307","A project of the The National Cancer Institute, the Genomic Data Commons is an expandable knowledge network supporting the import and standardization of genomic and clinical data from cancer research programs in support of precision medicine in oncology.","Genomic Data Commons | GDC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526688","Genomics of Drug Sensitivity in Cancer","C139308","Part of a Wellcome Trust funded collaboration between The Cancer Genome Project at the Wellcome Trust Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA) designed to to improve cancer treatments by discovering therapeutic biomarkers that can be used to identify patients most likely to respond to an anticancer drug.","Genomics of Drug Sensitivity in Cancer | GDSC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526695","NCI-60 Cell Line","C139309","A panel of 60 different human cancer cell lines grown in culture that were selected to be used in a drug-screening program to identify and characterize novel compounds for growth inhibition or killing of tumor cell lines.","NCI-60 Cell Line | NCI-60 | NCI-60 Cell Panel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515526","9q33","C13931","A chromosome band present on 9q","9q33 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520506","12q22","C13932","A chromosome band present on 12q","12q22 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515522","9q32","C13933","A chromosome band present on 9q","9q32 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520195","Xq26","C13934","A chromosome band present on Xq","Xq26 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520996","1q23","C13935","A chromosome band present on 1q","1q23 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521002","1q25","C13936","A chromosome band present on 1q","1q25 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512115","EGF-Like Domain","C13937","A sequence of about thirty to forty amino-acid residues long found in the sequence of epidermal growth factor (EGF) has been shown to be present, in a conserved form, in a large number of other, mostly animal proteins. The list of proteins currently known to contain one or more copies of an EGF-like pattern is large and varied. The functional significance of EGF domains in what appear to be unrelated proteins is not yet clear. However, a common feature is that these repeats are found in the extracellular domain of membrane-bound proteins or in proteins known to be secreted (exception: prostaglandin G/H synthase). The EGF domain includes six cysteine residues which have been shown (in EGF) to be involved in disulfide bonds. The main structure is a two-stranded beta-sheet followed by a loop to a C-terminal short two-stranded sheet. Subdomains between the conserved cysteines vary in length. (InterPro IPR006209)","EGF-Like Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511990","Disintegrin Domain","C13938","It is an integrin binding domain originally identified in ADAM family proteins. (NCI)","Disintegrin Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521046","20pter-p12","C13953","A chromosome band present on 20p","20pter-p12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0567037","Uterus Present","C138959","An indication that an individual's uterus is present.","Uterus Present | ",,,,,,,,,,,,,,,"4124487","Uterus present",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1521629","7p21.3","C13895","A chromosome band present on 7p","7p21.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4019128","Pregnancy Status at Time of Illness or Condition","C138960","The pregnancy status of an individual at the time of an illness or condition.","Pregnancy Status at Time of Illness or Condition | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526471","PSA Level Finding","C138961","A finding that indicates the amount of prostate specific antigen in a sample.","PSA Level Finding | Biochemical marker (PSA)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540480","Huriet Law","C142572","A French regulation covering the initiation and conduct of all interventional clinical studies, which seeks to protect the participants within interventional trials as well as those individuals and entities that sponsor the trial.","Huriet Law | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376428","hypertext","C142573","Words or phrases in an electronic document or web page, usually displayed as colored, underlined text, that if clicked on, permit individuals to immediately move to another section of the webpage or electronic document.","Hypertext | hypertext",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545931","Hypothesis To Test","C142574","No value exists.","Hypothesis To Test | hypothesis to test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540479","ICH Common Technical Document","C142575","A record format agreed upon by the International Council for Harmonisation to organize applications to regulatory authorities for registration of pharmaceuticals for human use. (ICH)","ICH Common Technical Document | Common Technical Document",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540478","ICH Type Of Comparison","C142576","Within the context of ICH, this data element describes how treatment arms will be compared within the clinical trial, to include trials that show superiority, non-equivalence, or non-inferiority, or dose-response relationships.","ICH Type Of Comparison | type of comparison",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540574","Impartial Witness","C142577","A person who is independent of the trial, who cannot be unfairly influenced by people involved with the trial, who attends the informed consent process if the subject or the subject's legally acceptable representative cannot read, and who reads the informed consent form and any other written information supplied to the subject. (ICH)","Impartial Witness | impartial witness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540573","Independent Data Monitoring Committee","C142578","A committee established by the sponsor to assess at intervals the progress of a clinical trial, safety data, and critical efficacy variables and recommend to the sponsor whether to continue, modify, or terminate the trial. (ICH)","Independent Data Monitoring Committee | IDMC | independent data monitoring committee (IDMC)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540572","Independent Ethics Committee","C142579","A separate body such as an institutional, regional, national or supranational committee, made up of medical/scientific professionals and non-scientific members, whose responsibility it is to ensure the protection of the rights, safety, and well-being of human subjects involved in a clinical trial. It tries to provide public assurance of that protection by reviewing and approving the trial protocol, the suitability of the investigator(s), facilities, methods, and materials to be used in documenting informed consent of the trial subjects. (ICH)","Independent Ethics Committee | IEC | independent ethics committee (IEC)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032092","Plant Virus","C14257","Viruses that replicate in and may produce diseases of higher plants.","Plant Virus | Viruses, Plant",,,,,,,,,,,,,,,"4010600","Plant virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540571","Independent Ethics Committee Opinion","C142580","The judgment and/or the advice provided by an independent ethics committee. (ICH)","Independent Ethics Committee Opinion | opinion (in relation to independent ethics committee)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540570","Indirect Identifier","C142581","Data which, when combined with other information, may enable the identification of a particular individual.","Indirect Identifier | indirect identifier | quasi identifer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540569","Interim Analysis","C142582","A statistical comparison of intervention groups at any timepoint prior to the official end of the clinical trial.","Interim Analysis | interim analysis(es)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540568","Interim Analysis Schedule","C142583","Specification of the intervening time period or stage of information when interim analyses are planned to take place.","Interim Analysis Schedule | interim analysis schedule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526544","Breast Implant-Related Lesion","C139013","A lesion that develops in the breast tissue following breast implant placement.","Breast Implant-Related Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526543","Type D Lymphomatoid Papulosis","C139014","A variant of lymphomatoid papulosis which mimics primary cutaneous aggressive epidermotropic CD8-positive cytotoxic T-cell lymphoma.","Type D Lymphomatoid Papulosis | Type D LyP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526524","Type E Lymphomatoid Papulosis","C139015","A variant of lymphomatoid papulosis characterized by the presence of atypical lymphocytes which exhibited distinct angioinvasion.","Type E Lymphomatoid Papulosis | Angioinvasive Lymphomatoid Papulosis Type E | Type E LyP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526523","Rearrangement of 6p25.3","C139016","A cytogenetic abnormality indicating rearrangement of the DUSP22-IRF4 locus at 6p25.3.","Rearrangement of 6p25.3 | Rearrangement of 6p25",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526522","LyP with Chromosome 6p25 Rearrangement","C139017","A variant of lymphomatoid papulosis associated with chromosomal rearrangements involving the DUSP22-IRF4 locus at 6p25.3.","Lymphomatoid Papulosis with DUSP22-IRF4 Gene Rearrangement | LyP with Chromosome 6p25 Rearrangement | LyP with Chromosome 6p25.3 Rearrangement | LyP with DUSP22-IRF4 Gene Rearrangement | Lymphomatoid Papulosis with Chromosome 6p25.3 Rearrangement | Lymphomatoid Papulosis with DUSP22 Locus Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526521","CDISC SDTM Duchenne Muscular Dystrophy Findings About Test Code Terminology","C139018","Terminology associated with the duchenne muscular dystrophy findings about test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Duchenne Muscular Dystrophy Findings About Test Code Terminology | DMFATSCD | Duchenne Muscular Dystrophy Findings About Test Code | SDTM-DMFATSCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537889","Status of Tumor Eligibility for Definitive Local Therapy","C139742","The status of a tumor based on its characteristics, such as morphology, location, size, presence or absence of carcinoma in situ, vascular invasion, metastasis, and other empirical features with or without biological and molecular basis, that is eligible for definitive local therapy (e.g. surgery, radiation or ablation that is chosen as the primary treatment modality).","Status of Tumor Eligibility for Definitive Local Therapy | Status of Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537899","Biopsy Specimen Size","C139747","The physical dimensions of a biopsy specimen.","Biopsy Specimen Size | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526693","Breast Cancer Clinical TNM Finding v8","C139391","A clinical finding about one or more characteristics of breast cancer, following the rules of the TNM AJCC v8 classification system.","Breast Cancer Clinical TNM Finding v8 | Breast Carcinoma Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526881","Prognostic Stage IIIB Breast Cancer AJCC v8","C139584","Stage IIIB includes: (T2, N1, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)","Prognostic Stage IIIB Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast Carcinoma AJCC v8 | Stage IIIB Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520757","17q11-q12","C13939","A chromosome band present on 17q","17q11-q12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526475","High Risk Myelodysplastic Syndrome","C138962","Myelodysplastic syndrome with more than 4.5 to 6 points, according to the revised International Prognostic Scoring System (IPSS-R).","High Risk Myelodysplastic Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526473","Refractory High Risk Myelodysplastic Syndrome","C138964","High risk myelodysplastic syndrome that does not respond to treatment.","Refractory High Risk Myelodysplastic Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526472","Major Axis Internal Diameter","C138965","No value exists.","Major Axis Internal Diameter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526452","Minor Axis Internal Diameter","C138966","No value exists.","Minor Axis Internal Diameter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526451","Isometric Muscle Strength","C138967","No value exists.","Isometric Muscle Strength | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526450","Basophilic Focus","C138968","A group of cells that exhibit some type of cytologic alteration resulting in basophilia, and that are confined to a specific area of the sample.","Basophilic Focus | BASOPHILIC FOCUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL379115","Dorsal Hand Interosseus Muscle","C138969","No value exists.","Dorsal Hand Interosseus Muscle | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520482","12p13.32","C13896","A chromosome band present on 12p","12p13.32 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526455","Derived Synovial Fluid Cell","C138971","Cells derived from the fluid found in the cavities of synovial joints.","Derived Synovial Fluid Cell | Human Synovial Fluid Derived Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526454","Derived Peripheral Blood Mononuclear Cell","C138972","Mononuclear cells collected from peripheral blood.","Derived Peripheral Blood Mononuclear Cell | Peripheral Blood Mononuclear cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526453","Derived Dental Pulp","C138973","Dental pulp from a tooth.","Derived Dental Pulp | Human Tooth Pulp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526459","Glandular (Acinar)/Tubular Differentiation Score","C138974","A score assigned to a biopsy sample indicating the relative amount of cells with glandular differentiation.","Glandular (Acinar)/Tubular Differentiation Score | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520686","16p13.12","C13897","A chromosome band present on 16p","16p13.12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540567","International Marketing Authorization Birth Date","C142584","The date that marketing authorization is first granted to a company in any country for a new product. (ICH)","International Marketing Authorization Birth Date | International Birth Date | international birth date (IBD)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540579","International Nonproprietary Name","C142585","A unique, internationally consistent and globally recognized name which identifies pharmaceutical substances or active pharmaceutical ingredients and is public property.","International Nonproprietary Name | INN | international nonproprietary name (INN)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540578","Investigational Product","C142587","A pharmaceutical form of an active ingredient or placebo being tested or used as a reference in a clinical trial, including a product with a marketing authorization when used or assembled (formulated or packaged) in a way different from the approved form, or when used for an unapproved indication, or when used to gain further information about an approved use. NOTE: CDISC includes test articles in its definition of investigational products. (ICH)","Investigational Product | Experimental Product | investigational medicine | investigational product",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539961","IPAQ Short Last 7 Days Telephone Format Version - Total Sitting Hr and Min Wednesday","C141865","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) What is the total amount of time you spent sitting last Wednesday?: Hours and minutes on Wednesday.","IPAQ Short Last 7 Days Telephone Format Version - Total Sitting Hr and Min Wednesday | IPA01-Total Sitting Hr & Min Wednesday | IPA0107B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539960","IPAQ Short Last 7 Days Telephone Format Version - Total Sitting Minutes on Wednesday","C141866","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) What is the total amount of time you spent sitting last Wednesday?: Minutes on Wednesday.","IPAQ Short Last 7 Days Telephone Format Version - Total Sitting Minutes on Wednesday | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539959","DRRI-2 - A: Someone Close to Me Died","C141867","Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: someone close to me died.","DRRI-2 - A: Someone Close to Me Died | DRRI1-A: Someone Close to Me Died | DRRI1A01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539958","DRRI-2 - A: Went Through Divorce/Was Left","C141868","Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: I went through a divorce or was left by a significant other.","DRRI-2 - A: Went Through Divorce/Was Left | DRRI1-A: Went Through Divorce/Was Left | DRRI1A02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004423","Alpharetrovirus","C14186","An rna-type retrovirus with a c-type morphology. The viruses have a widespread distribution and include both exogenous (vertical and horizontal transmission) and endogenous viruses of chickens and some other birds. Avian Leukosis virus is the type species. Distantly related endogenous sequences are found in birds and mammals. Virus infections are associated with malignancies and some other diseases such as wasting, and osteopetrosis. Many oncogene-containing members of the genus have been isolated.","Alpharetrovirus | Avian Retrovirus | Retroviruses, Type C, Avian | Type C Avian Retrovirus",,,,,,,,,,,,,,,"4234373","Genus Alpharetrovirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL539972","DRRI-2 - A: Saw/Heard Physical Fight Parent","C141870","Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: I saw or heard physical fighting between my parents or caregivers.","DRRI-2 - A: Saw/Heard Physical Fight Parent | DRRI1-A: Saw/Heard Physical Fight Parent | DRRI1A04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539971","DRRI-2 - A: Physically Punished by Parent","C141871","Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: I was physically punished by a parent or primary caregiver.","DRRI-2 - A: Physically Punished by Parent | DRRI1-A: Physically Punished by Parent | DRRI1A05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539970","DRRI-2 - A: Unwanted Sex Activity Childhood","C141872","Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: I experienced unwanted sexual activity as a result of force, threat of harm, or manipulation during childhood (before age 18).","DRRI-2 - A: Unwanted Sex Activity Childhood | DRRI1-A: Unwanted Sex Activity Childhood | DRRI1A06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539969","DRRI-2 - A: Unwanted Sex Activity Adulthood","C141873","Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: I experienced unwanted sexual activity as a result of force, threat of harm, or manipulation during adulthood (age 18 or later).","DRRI-2 - A: Unwanted Sex Activity Adulthood | DRRI1-A: Unwanted Sex Activity Adulthood | DRRI1A07",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515175","TRIM Motif","C13974","The TRIM motif includes three cysteine-rich zinc-binding domains, a RING finger, a B-box, and a coiled-coil region. The order of the sub-domains is conserved, with the RING finger, B-box and coiled -coil domains arranged from the N to C-terminus. However, the number of B-boxes can vary. (NCI)","TRIM Motif | RBCC/TRIM Motif | TRIM Domain | Tripartite Domain | Tripartite Motif",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0398421","Mediastinal Lymph Node Sampling","C139751","A surgical procedure in which a single or multiple mediastinal lymph nodes are removed for microscopic examination.","Mediastinal Lymph Node Sampling | ",,,,,,,,,,,,,,,"4075134","Mediastinal lymph nodes sampling",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526750","Minimal Risk","C139268","The potential future harm that may arise from some present action or attribute or condition is minimal.","Minimal Risk | MINIMAL RISK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520401","11q23.1","C13926","A chromosome band present on 11q","11q23.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1026647","Citrobacter werkmanii","C139100","A species of facultatively anaerobic, gram negative, rod shaped bacteria assigned to the phylum Proteobacteria; this species is motile by peritrichous flagella, it is negative for ornithine decarboxylase activity, and it is positive for growth on malonate.","Citrobacter werkmanii | CITROBACTER WERKMANII | Citrobacter Genomospecies 7",,,,,,,,,,,,,,,"4016598","Citrobacter werkmanii",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL537798","Cervical Cancer Pathologic Distant Metastasis TNM Finding v8","C139704","A pathologic finding about one or more characteristics of cervical cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Cervical Cancer Pathologic Distant Metastasis TNM Finding v8 | Cervical Carcinoma Pathologic Distant Metastasis TNM Finding v8 | Pathologic Distant Metastasis Status (pM)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537796","Cervical Cancer Pathologic Primary Tumor TNM Finding v8","C139706","A pathologic finding about one or more characteristics of cervical cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Cervical Cancer Pathologic Primary Tumor TNM Finding v8 | Cervical Carcinoma Pathologic Primary Tumor TNM Finding v8 | Pathologic Primary Tumor Status (pT)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539968","DRRI-2 - A: Experienced Natural Disaster","C141874","Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: I experienced a natural disaster (for example, a hurricane), a fire, or an accident in which I or someone close to me was hurt or had serious property damage.","DRRI-2 - A: Experienced Natural Disaster | DRRI1-A: Experienced Natural Disaster | DRRI1A08",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539967","DRRI-2 - A: Someone Close Serious Illness","C141875","Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: someone close to me experienced a serious illness, injury, or mental health problem (for example, cancer, alcohol/drug problem).","DRRI-2 - A: Someone Close Serious Illness | DRRI1-A: Someone Close Serious Illness | DRRI1A09",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539966","DRRI-2 - A: Witnessed Someone Assaulted","C141876","Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: I witnessed someone being seriously assaulted or killed.","DRRI-2 - A: Witnessed Someone Assaulted | DRRI1-A: Witnessed Someone Assaulted | DRRI1A10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539965","DRRI-2 - A: Lost My Job/Trouble Finding Job","C141877","Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: I lost my job or had serious trouble finding a job.","DRRI-2 - A: Lost My Job/Trouble Finding Job | DRRI1-A: Lost My Job/Trouble Finding Job | DRRI1A11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539948","DRRI-2 - A: Emotionally Mistreated","C141878","Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: I was emotionally mistreated (for example, ignored or repeatedly told I was no good).","DRRI-2 - A: Emotionally Mistreated | DRRI1-A: Emotionally Mistreated | DRRI1A12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1861194","Thrombasthenia-Thrombocytopenia, Hereditary","C142084","An autosomal dominant condition caused by mutation(s) in the GFI1B gene, encoding zinc finger protein Gfi-1b. It is characterized by a tendency for increased bleeding due to abnormal platelet function.","Bleeding Disorder, Platelet-Type 17 | BDPLT17",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342686","Aromatic L-Amino-Acid Decarboxylase Deficiency","C142085","An autosomal recessive condition caused by mutation(s) in the DDC gene, encoding aromatic-L-amino-acid decarboxylase. It is characterized by combined serotonin and catecholamine deficiency, resulting in severe neurologic dysfunction usually beginning in infancy or childhood.","Aromatic L-Amino-Acid Decarboxylase Deficiency | AADC Deficiency",,,,,,,,,,,,,,,"4049868","Deficiency of aromatic-L-amino-acid decarboxylase",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540124","Fascin Inhibitor NP-G2-044","C142086","An orally available inhibitor of the protein fascin, with potential antineoplastic activity. Upon oral administration, NP-G2-044 targets and binds to fascin, thereby preventing the interaction of fascin with actin filaments, thereby preventing actin bundling and filopodia formation. By preventing actin cytoskeletal reorganization, the dynamic changes in cell shape that are necessary for tumor cell migration and invasion to occur are impaired, and tumor cell migration and metastasis are inhibited. Fascin, the main actin cross-linker protein in filopodia, is upregulated in many types of metastatic tumor cells while its expression is low or absent in normal adult epithelial cells; its expression is correlated with aggressive phenotypes, poor prognosis, and shorter survival. Filopodia, finger-like plasma membrane protrusions that are formed upon remodeling of the actin cytoskeleton, are found at a high frequency in metastatic tumor cells and their presence is correlated with tumor cell invasiveness.","Fascin Inhibitor NP-G2-044 | 2-Methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-3-furancarboxamide | NP G2 044 | NP-G2-044",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540123","FGFR3 NM_000142.4:c.1948A>G","C142087","A nucleotide substitution at position 1948 of the coding sequence of the FGFR3 gene where adenine has been mutated to guanine.","FGFR3 NM_000142.4:c.1948A>G | CD333 c.1948A>G | FGFR3 c.1948A>G | Fibroblast Growth Factor Receptor 3 c.1948A>G | JKT4 c.1948A>G | JTK4 c.1948A>G | NM_000142.4:c.1948A>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526725","Sample Viability Percent Measurement","C139278","A measurement of the percent of a cell or tissue sample that is viable.","Sample Viability Percent Measurement | Sample Viability Percent | VBLSPCT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526724","Sample Viability Indicator","C139279","An indication as to whether the sample contains viable cells or tissues.","Sample Viability Indicator | VBLSIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520782","17q23-q25","C13927","A chromosome band present on 17q","17q23-q25 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519739","UBC Domain","C13907","The 16-kD UBC domain contains a conserved UBC motif and a conserved cysteine that accepts activated ubiquitin from E1 enzyme to form a thiol ester. Basic residues at the UBC domain N-terminus may be involved in E1 binding. UBC/E2 enzymes catalyze ubiquitination of target proteins with or without E3 'N-end' recognizing proteins. E2s can be classified on the basis of UBC structure. Poor at transferring ubiquitin to proteins on their own, Class I proteins comprise simply the UBC domain and probably require an E3 to ubiquitinate short-lived abnormal proteins prior to degradation. Class II enzymes contain different acidic C-terminal extensions of the UBC domain that appear to involve cellular localization or to mediate interaction with protein substrates for ubiquitination that results in protein modification but not degradation. Class III E2s have N-terminal extensions, but their function is unknown. (NCI)","UBC Domain | Ubiquitin-Conjugating Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540121","FLT3 NM_004119.2:c.2525A>G","C142089","A nucleotide substitution at position 2525 of the coding sequence of the FLT3 gene where adenine has been mutated to guanine.","FLT3 NM_004119.2:c.2525A>G | CD135 c.2525A>G | FLK2 c.2525A>G | FLT3 c.2525A>G | FMS-Related Tyrosine Kinase 3 c.2525A>G | NM_004119.2:c.2525A>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016215","Flavivirus","C14208","A genus of enveloped viruses with a genome consisting of a single molecule of linear positive-sense single-stranded RNA.","Flavivirus | Arboviruses Group B | FLAVIVIRUS",,,,,,,,,,,,,,,"4155355","Flavivirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024267","Lymphocytic Choriomeningitis Virus","C14230","A species of single-stranded, negative-sense RNA viruses in the genus arenavirus and family arenaviridae. It is spread by rodents and causes meningitis and encephalitis.","Lymphocytic Choriomeningitis Virus | LCMV",,,,,,,,,,,,,,,"4221257","Lymphocytic choriomeningitis virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526916","Prognostic Stage IB Breast Cancer AJCC v8","C139558","Stage IB includes: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1-3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N1, M0, G1-3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N1, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1-2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)","Prognostic Stage IB Breast Cancer AJCC v8 | Prognostic Stage IB Breast Carcinoma AJCC v8 | Stage IB Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526915","PTPN11 Inhibitor TNO155","C139559","An inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic activity. Upon oral administration,batoprotafib binds to and inhibits SHP2. This prevents SHP2-mediated signaling, inhibits MAPK signaling and prevents growth of SHP2-expressing tumor cells. SHP2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the RAS-RAF-ERK signaling pathway. SHP2 also regulates programmed cell death 1 (PD-1)-mediated signal transduction and is involved in immune checkpoint modulation.","Batoprotafib | BATOPROTAFIB | PTPN11 Inhibitor TNO155 | SHP2 Inhibitor TNO155 | SHP2 Inhibitor TNO155 | TNO-155 | TNO155",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0011703","Desmosome","C13955","Desmosomes are intercellular anchoring junctions that anchor intermediate filaments at membrane-associated plaques in adjoining cells.  Desmosomes assemble in response to cell-cell contact and raised levels of extracellular calcium. Sensitivity to calcium levels is lost as desmosomes mature.","Desmosome | Desmosomes | Macula Adherens | Spot Desmosome",,,,,,,,,,,,,,,"4165058","Desmosome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526914","SYNT 001","C139561","A monoclonal antibody that targets the neonatal crystallizable fragment receptor (FcRn), with potential immunomodulating activity. Upon administration, orilanolimab targets and binds to FcRn at the immunoglobulin G (IgG) binding site, thereby preventing the interaction between FcRn and the serum protein IgG. By preventing FcRn/IgG binding, SYNT001 blocks the FcRn-mediated rescue of IgG, enables IgG degradation and prevents IgG-mediated inflammation. IgG plays a key role in many autoimmune diseases and is an important factor in inflammatory processes.","Orilanolimab | Anti-FcRn Monoclonal Antibody SYNT001 | Immunoglobulin G4, Anti-(Human FcRn Receptor) (Humanized Monoclonal SYNT001 gamma4-Chain), Disulfide with Humanized Monoclonal SYNT001 kappa-Chain, Dimer | ORILANOLIMAB | SYNT 001 | SYNT-001 | SYNT001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230137","Superior Thoracic Aperture","C139564","The superior opening of the thorax whose margin comprises the upper border of the first thoracic vertebra, the first ribs, and the manubrium.","Superior Thoracic Aperture | Thoracic Inlet",,,,,,,,,,,,,,,"4179960","Structure of thoracic inlet",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1520995","1q22-q25","C13979","A chromosome band present on 1q","1q22-q25 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537974","Trastuzumab/Tesirine Antibody-drug Conjugate ADCT-502","C139800","An antibody-drug conjugate (ADC) consisting of an engineered version of the humanized monoclonal anti-human epidermal growth factor receptor 2 (HER2) immunoglobulin G1 (IgG1) trastuzumab that is site-specifically conjugated, via a cleavable linker, to the cytotoxic, DNA cross-linking pyrrolobenzodiazepine (PBD) dimer-based drug tesirine, which targets DNA minor grooves, with potential antineoplastic activity. Upon administration, the trastuzumab moiety of trastuzumab/tesirine ADC ADCT-502 targets the cell surface antigen HER2, which is expressed on various cancer cells. Upon antibody/antigen binding, internalization of the ADC and cleavage of the linker, the cytotoxic PBD moiety is released. The imine groups of tesirine bind to the N2 positions of guanines on opposite strands of DNA. This induces interstrand cross-links in the minor groove of DNA, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death and inhibits the proliferation of HER2-overexpressing tumor cells. The tumor-associated antigen (TAA) HER2 is expressed by various solid tumors and is associated with a poor prognosis.","Trastuzumab/Tesirine Antibody-drug Conjugate ADCT-502 | ADC ADCT-502 | ADCT 502 | ADCT-502 | ADCT502 | Anti-HER2/PBD ADC ADCT 502",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537958","Uterine Corpus Cancer by AJCC v8 Stage","C139801","A term that refers to the staging of uterine corpus cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to carcinomas and carcinosarcomas. It does not apply to uterine corpus sarcomas: leiomyosarcomas, endometrial stromal sarcomas, and adenosarcomas. These sarcomas are staged according to the classification for uterine corpus sarcomas. (from AJCC 8th Ed.)","Uterine Corpus Cancer by AJCC v8 Stage | Tumor Stage (Pathological) | Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537957","Stage I Uterine Corpus Cancer AJCC v8","C139802","Stage I includes: T1, N0, M0. T1: Uterine corpus carcinoma or carcinosarcoma with tumor confined to the corpus uteri, including endocervical glandular involvement. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage I Uterine Corpus Cancer AJCC v8 | Stage I | Stage I Uterine (including Endometrial) Cancer | Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520108","WAP Domain","C13922","The WAP (Whey Acidic Protein) Domain contains eight characteristically-spaced cysteine residues involved in disulphide bond formation and occurs in so-called 'four-disulphide core' proteins. The spatial pattern of these conserved domain cysteines suggests that the otherwise variable domain sequences may adopt a similar fold. The overall degree of domain sequence similarity is low; a few Pro and Gly residues are reasonably well conserved, as are polar/acidic residues between Cys3 and Cys4. WAP sequences are found in Whey Acidic Protein; Elafin (a human skin elastase-specific inhibitor); rat WDNM1 Protein (involved in metastatic potential); Kallmann Syndrome Protein; and guinea pig Caltrin-Like Protein II (inhibits calcium transport into spermatozoa). (NCI)","WAP Domain | WAP Motif | Whey Acidic Protein Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024398","Macaque","C14231","Any of several species of short-tailed monkeys of the genus Macaca.","Macaque | Macaca | Macacus | Macaques",,,,,,,,,,,,,,,"4308049","Genus Macaca",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526892","Malignant Neoplasm of Lung - Multiple Primary Sites","C139565","Lung cancer comprising malignant neoplasms from two or more sites, as determined by clinicopathological assessment.","Malignant Neoplasm of Lung - Multiple Primary Sites | MPLC | Multiple Primary Lung Cancers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526891","Mediastinal Lymph Node Dissection","C139566","A surgical procedure in which all or most all of the lymph nodes are removed from the mediastinum.","Mediastinal Lymph Node Dissection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526528","CDISC SDTM Duchenne Muscular Dystrophy Findings About Test Name Terminology","C139019","Terminology associated with the duchenne muscular dystrophy findings about test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Duchenne Muscular Dystrophy Findings About Test Name Terminology | DMFATS | Duchenne Muscular Dystrophy Findings About Test Name | SDTM-DMFATS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526527","CDISC Protocol Entities Clinical Trial Attribute Terminology","C139020","Terminology associated with the protocol entity clinical trial attribute codelist of the Clinical Data Interchange Standards Consortium (CDISC).","CDISC Protocol Entities Clinical Trial Attribute Terminology | Clinical Trial Attribute Terminology | PROT-Att Clinical Trial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526530","Acral Lesion","C139024","A lesion that arises in a peripheral site (e.g., limbs, fingers, or ears).","Acral Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3884993","Abrilumab","C139025","No value exists.","Abrilumab | ABRILUMAB | AMG-181 | AMG181 | Immunoglobulin G, Anti-(Human Integrin Alpha4beta7) (Human Monoclonal Heavy Chain), Disulfide with Human Monoclonal Light Chain, Dimer | MEDI-7183",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526529","Odor Detection","C139027","Determining any smells associated with a material.","Odor Detection | Odor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526534","Florid Follicular Hyperplasia","C139029","A morphologic finding indicating the presence of prominent follicular hyperplasia in a lymph node sample.","Florid Follicular Hyperplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520783","17q23.1","C13902","A chromosome band present on 17q","17q23.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526533","THRLBCL-Like Transformation of NLPBL","C139030","Nodular lymphocyte predominant B-cell lymphoma (NLPBL) that has transformed, resembling T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL).","THRLBCL-Like Transformation of NLPBL | NLPBL, THRLBCL-Like | NLPHL, THRLBCL-Like | Nodular Lymphocyte Predominant B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma-Like | Nodular Lymphocyte Predominant Hodgkin Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma-Like | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma-Like Transformation of Nodular Lymphocyte Predominant B-Cell Lymphoma | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma-Like Transformation of Nodular Lymphocyte Predominant Hodgkin Lymphoma | THRLBCL-Like Transformation of NLPHL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526809","Breast Cancer Pathologic Distant Metastasis TNM Finding v8","C139409","A pathologic finding about one or more characteristics of breast cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Breast Cancer Pathologic Distant Metastasis TNM Finding v8 | Breast Carcinoma Pathologic Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515493","9p11.2","C13940","A chromosome band present on 9p","9p11.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526905","Anal Fibroadenoma","C139546","A benign epithelial-stromal neoplasm that arises from the anus and resembles the breast fibroadenoma.","Anal Fibroadenoma | Anal Ectopic Fibroadenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526904","Fibroadenoma of Anogenital Mammary-Type Glands","C139547","A benign epithelial-stromal neoplasm that arises from the perineum and resembles the breast fibroadenoma.","Fibroadenoma of Anogenital Mammary-Type Glands | Fibroadenoma of Anogenital Mammary-Like Glands | Perineal Ectopic Fibroadenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526903","Vulvar Composite Hidradenoma Papilliferum and Fibroadenoma","C139548","A benign composite neoplasm that arises from the vulva and is characterized by mixed histopathologic features of hidradenoma papilliferum and fibroadenoma.","Vulvar Composite Hidradenoma Papilliferum and Fibroadenoma | Vulvar Composite Papillary Hidradenoma and Fibroadenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521060","20q12-q13.2","C13898","A chromosome band present on 20q","20q12-q13.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526446","Product Description/Appearance","C138990","Tests using visual inspection to assess the physical state and color of the drug substance or product.","Product Description/Appearance Assessment | Description | Description/Appearance | Product Description/Appearance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3888332","HH-GV678","C138991","An orally bioavailable tyrosine kinase inhibitor, with potential antineoplastic activity. Upon administration, flumbatinib inhibits the wild-type forms of Bcr-Abl, platelet-derived growth factor receptor (PDGFR) and mast/stem cell growth factor receptor (SCFR; c-Kit) and forms of these proteins with certain point mutations. This results in the inhibition of both Bcr-Abl-, PDGFR- and c-Kit-mediated signal transduction pathways, and the proliferation of tumor cells in which these kinases are overexpressed. Bcr-Abl fusion protein is an abnormal, constitutively active enzyme expressed in Philadelphia chromosome positive chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML). PDGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to cell migration and the development of the microvasculature. c-kit, a receptor tyrosine kinase mutated and constitutively activated in certain tumors, plays a key role in tumor cell survival, proliferation, and differentiation.","Flumbatinib | 4-(4-Methyl-piperazin-1-ylmethyl)-N-[6-methyl-5-(4-pyridin-3-yl-pyrimidin-2-ylamino)-pyridin-3-yl]-3-trifluoromethyl-benzamide | FLUMBATINIB | Flumatinib | HH GV 678 | HH-GV-678 | HH-GV678 | HHGV678",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526445","Homogeneity Assessment","C138992","An assessment of the quality or state of being similar or comparable in kind or nature or of being uniform throughout in composition or structure.","Homogeneity Assessment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539763","VALG - Cancer Stage","C141695","Veterans Administration Lung Study Group (VALG) Cancer stage.","VALG - Cancer Stage | VALG01-Cancer Stage | VALG0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539762","AJCC v7 - Primary Tumor (T)","C141696","AJCC Cancer Staging Manual 7th Edition (AJCC v7) Primary tumor (T).","AJCC v7 - Primary Tumor (T) | AJCC1-Primary Tumor (T) | AJCC101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539761","AJCC v7 - Regional Lymph Nodes (N)","C141697","AJCC Cancer Staging Manual 7th Edition (AJCC v7) Regional lymph nodes (N).","AJCC v7 - Regional Lymph Nodes (N) | AJCC1-Regional Lymph Nodes (N) | AJCC102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539760","AJCC v7 - Distant Metastasis (M)","C141698","AJCC Cancer Staging Manual 7th Edition (AJCC v7) Distant metastasis (M).","AJCC v7 - Distant Metastasis (M) | AJCC1-Distant Metastasis (M) | AJCC103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539759","AJCC v7 - Anatomic Stage","C141699","AJCC Cancer Staging Manual 7th Edition (AJCC v7) Anatomic stage.","AJCC v7 - Anatomic Stage | AJCC1-Anatomic Stage | AJCC104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0149214","yoshi 864","C1416","An alkylsulfonate. Yoshi-864 alkylates and crosslinks DNA, thereby inhibiting DNA replication. (NCI04)","Improsulfan Hydrochloride | 1-Propanol, 3,3'-, Dimethanesulfonate (Ester), Hydrochloride | 1-Propanol, 3,3'-, dimethanesulfonate (ester), hydrochloride | 1-Propanol, 3,3'-Iminobis-, Dimethanesulfonate (Ester), Hydrochloride (9CI) | 1-Propanol, 3,3'-iminobis-, dimethanesulfonate (ester), hydrochloride (9CI) | 1-Propanol, 3,3'-iminodi-, Dimethanesulfonate (Ester), Hydrochloride (8CI) | 1-Propanol, 3,3'-iminodi-, dimethanesulfonate (ester), hydrochloride (8CI) | 1-Propanol-3,3'-iminodidimethanesulfonatehydrochloride | 3, 3'-Dimesyloxydipropylamine HCl | 3, 3'-Dimesyloxydipropylamine Hydrochloride | 3, 3'-Dimesyloxydipropylamine hydrochloride | 3, 3'-Iminodi-1-propanol Di(methanesulfonate) HCl | 3, 3'-Iminodi-1-propanol Di(methanesulfonate) Hydrochloride | 3, 3'-Iminodi-1-propanol Dimethanesulfonate Ester HCl | 3, 3'-Iminodi-1-propanol Dimethanesulfonate Ester Hydrochloride | 3, 3'-Iminodi-1-propanol di(methanesulfonate) hydrochloride | 3, 3'-Iminodi-1-propanol dimethanesulfonate ester hydrochloride | 3,3'-Imidodi-1-propanol, Dimethanesulfonate (Ester) HCl | 3,3'-Imidodi-1-propanol, Dimethanesulfonate (Ester), Hydrochloride | 3,3'-Imidodi-1-propanol, dimethanesulfonate (ester), hydrochloride | Bis(3-mesyloxypropyl)amine HCl | Bis(3-mesyloxypropyl)amine Hydrochloride | Bis(3-mesyloxypropyl)amine hydrochloride | Compound 864 | IMPROSULFAN HYDROCHLORIDE | IPD Hydrochloride | IPD hydrochloride | NCI-C01547 | Yoshi 864 | Yoshi-864",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539758","TENMW1-Time to Walk/Run 10 Meters","C141700","Ten Meter Walk/Run Test (10 Meter Walk/Run) Time to walk or run 10 meters.","10-Meter Walk/Run - Time to Walk/Run 10 Meters | TENMW1-Time to Walk/Run 10 Meters | TENMW102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539757","TENMW1-Test Grade","C141701","Ten Meter Walk/Run Test (10 Meter Walk/Run) Test grade.","10-Meter Walk/Run - Test Grade | TENMW1-Test Grade | TENMW104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539947","DRRI-2 - A: Serious Financial Problems","C141879","Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: I experienced serious financial problems.","DRRI-2 - A: Serious Financial Problems | DRRI1-A: Serious Financial Problems | DRRI1A13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539946","DRRI-2 - A: Serious Physical Health Problem","C141880","Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: I experienced serious physical or mental health problems.","DRRI-2 - A: Serious Physical Health Problem | DRRI1-A: Serious Physical Health Problem | DRRI1A14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4018470","Isavuconazonium Sulfate","C139756","The sulfate ester form of isavuconazonium, a prodrug of the triazole antifungal agent isavuconazole, with broad-spectrum antifungal activity. Upon administration, isavuconazonium sulfate is hydrolyzed by plasma esterases to yield the active moiety isavuconazole. Isavuconazole binds to and inhibits the fungal cytochrome P450 family enzyme lanosterol 14-alpha-demethylase (CYP51), which catalyzes the demethylation of lanosterol to yield ergosterol, an important component of the fungal cell membrane. Inhibition of CYP51 leads to a decrease in fungal ergosterol production and disrupts synthesis of the fungal cell membrane, which decreases membrane integrity, increases cell membrane permeability and promotes the loss of essential intracellular elements. This results in fungal cell lysis and death.","Isavuconazonium Sulfate | 1-((2R,3R)-3-(4-(4-Cyanophenyl)-1,3-thiazol-2-yl)-2-(2,5-difluorophenyl)-2-hydroxybutyl)-4-((1RS)-1-((methyl(3-((((methylamino)acetyl)oxy)methyl)pyridin-2-yl)carbamoyl)oxy)ethyl)-1H-1,2,4-triazol-4-ium Monosulfate | BAL8557-002 | Cresemba | Glycine, N-methyl-, (2-(((1-(1-((2R,3R)-3-(4-(4-cyanophenyl)-2-thiazolyl)-2-(2,5-difluorophenyl)-2-hydroxybutyl)-4H-1,2,4-triazolium-4-yl)ethoxy)carbonyl)methylamino)-3-pyridinyl)methyl Ester, Sulfate (1:1) | ISAVUCONAZONIUM SULFATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537874","Uterine Corpus Carcinoma and Carcinosarcoma TNM Finding v8","C139757","A finding about one or more characteristics of uterine corpus carcinoma or carcinosarcoma, following the rules of the TNM AJCC v8 classification system. This classification system does not apply to uterine corpus sarcomas: leiomyosarcomas, endometrial stromal sarcomas, and adenosarcomas. These sarcomas are staged according to the classification for uterine corpus sarcomas. (from AJCC 8th Ed.)","Uterine Corpus Carcinoma and Carcinosarcoma TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537873","Uterine Corpus Carcinoma and Carcinosarcoma Clinical TNM Finding v8","C139758","A clinical finding about one or more characteristics of uterine corpus carcinoma or carcinosarcoma, following the rules of the TNM AJCC v8 classification system.","Uterine Corpus Carcinoma and Carcinosarcoma Clinical TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514674","RSXpSXP Motif","C13975","The 14-3-3 family of proteins mediates signal transduction by binding to phosphoserine-containing proteins. RSXpSXP Motif is one of two different binding motifs that are present in nearly all known 14-3-3 binding proteins. The14-3-3 dimer binds tightly to single molecules containing tandem repeats of phosphoserine motifs, implicating bidentate association as a signaling mechanism with molecules such as Raf, BAD, and Cbl. (from OMIM)","RSXpSXP Motif | RSXpSXP Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537887","Uterine Corpus Carcinoma and Carcinosarcoma cM0 TNM Finding v8","C139760","Uterine corpus carcinoma or carcinosarcoma without evidence of distant metastasis. (from AJCC 8th Ed.)","Uterine Corpus Carcinoma and Carcinosarcoma cM0 TNM Finding v8 | cM0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537886","Uterine Corpus Carcinoma and Carcinosarcoma cM1 TNM Finding v8","C139761","Uterine corpus carcinoma or carcinosarcoma with distant metastasis (includes metastasis to inguinal lymph nodes, intraperitoneal disease, lung, liver, or bone. It excludes metastasis to pelvic or para-aortic lymph nodes, vagina, uterine serosa, or adnexa). (from AJCC 8th Ed.)","Uterine Corpus Carcinoma and Carcinosarcoma cM1 TNM Finding v8 | Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage IVB | cM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526880","Prognostic Stage IIIC Breast Cancer AJCC v8","C139585","Stage IIIC includes: (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any ); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)","Prognostic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage IIIC Breast Carcinoma AJCC v8 | Stage IIIC Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526885","Female Reproductive System Cancer TNM Finding v8","C139589","A finding about one or more characteristics of female reproductive system cancer, following the rules of the TNM AJCC v8 classification system. The TNM categories have been defined to correspond to the FIGO stages. Some amendments have been made in collaboration with FIGO, and the classifications now published have the approval of FIGO, AJCC, and all other national TNM committees of the Union for International Cancer Control (UICC). (from AJCC 8th Ed.)","Female Reproductive System Cancer TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521324","3q26.3","C13958","A chromosome band present on 3q","3q26.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526982","Material Identification","C138993","Tests that establishes the characteristic and uniqueness of the substance of interest and should be able to discriminate between compounds of closely related structures which are likely to be present.","Material Identification Test | Identification | Material Identification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526449","Copanlisib Hydrochloride","C138994","The dihydrochloride salt form of copanlisib, a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","Copanlisib Hydrochloride | 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2) | Aliqopa | BAY 80-6946 Dihydrochloride | BAY-80-6946 Dihydrochloride | COPANLISIB HYDROCHLORIDE | Copanlisib Dihydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515455","8q21-q24","C13971","A chromosome band present on 8q","8q21-q24 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539945","DRRI-2 - A: Dangerous Military Duties","C141881","Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: I participated in dangerous military duties.","DRRI-2 - A: Dangerous Military Duties | DRRI1-A: Dangerous Military Duties | DRRI1A15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539944","DRRI-2 - A: Injured by Person - Childhood","C141882","Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: I was seriously physically injured by another person (for example, hit or beaten up) during childhood (before age 18).","DRRI-2 - A: Injured by Person - Childhood | DRRI1-A: Injured by Person - Childhood | DRRI1A16",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539942","DRRI-2 - A: Stressful Legal Problems","C141884","Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: I experienced stressful legal problems (for example, being sued, suing someone else, or being in a custody battle).","DRRI-2 - A: Stressful Legal Problems | DRRI1-A: Stressful Legal Problems | DRRI1A18",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539941","DRRI-2 - B: Got Along Well With My Family","C141885","Deployment Risk and Resilience Inventory-2 (DRRI-2) During childhood: I got along well with my family members.","DRRI-2 - B: Got Along Well With My Family | DRRI1-B: Got Along Well With My Family | DRRI1B01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539956","DRRI-2 - B: Felt Like I Fit in With Family","C141886","Deployment Risk and Resilience Inventory-2 (DRRI-2) During childhood: I felt like I fit in with my family.","DRRI-2 - B: Felt Like I Fit in With Family | DRRI1-B: Felt Like I Fit in With Family | DRRI1B02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539955","DRRI-2 - B: Family Knew What I Thought/Felt","C141887","Deployment Risk and Resilience Inventory-2 (DRRI-2) During childhood: family members knew what I thought and how I felt about things.","DRRI-2 - B: Family Knew What I Thought/Felt | DRRI1-B: Family Knew What I Thought/Felt | DRRI1B03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539954","DRRI-2 - B: Contribution Family Appreciated","C141888","Deployment Risk and Resilience Inventory-2 (DRRI-2) During childhood: I felt like my contributions to my family were appreciated.","DRRI-2 - B: Contribution Family Appreciated | DRRI1-B: Contribution Family Appreciated | DRRI1B04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539953","DRRI-2 - B: Shared Interests With Family","C141889","Deployment Risk and Resilience Inventory-2 (DRRI-2) During childhood: I shared many common interests and activities with family members.","DRRI-2 - B: Shared Interests With Family | DRRI1-B: Shared Interests With Family | DRRI1B05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004651","Bacteriophage","C14188","A non-taxonomic grouping of viruses that infect and lyse certain bacteria and archaea.","Bacteriophage | Phage | Viruses, Bacterial",,,,,,,,,,,,,,,"4281834","Bacterial virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL539952","DRRI-2 - B: Opinions Were Valued by Family","C141890","Deployment Risk and Resilience Inventory-2 (DRRI-2) During childhood: my opinions were valued by other family members.","DRRI-2 - B: Opinions Were Valued by Family | DRRI1-B: Opinions Were Valued by Family | DRRI1B06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539951","DRRI-2 - B: I Was Affectionate With Family","C141891","Deployment Risk and Resilience Inventory-2 (DRRI-2) During childhood: I was affectionate with family members.","DRRI-2 - B: I Was Affectionate With Family | DRRI1-B: I Was Affectionate With Family | DRRI1B07",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539950","DRRI-2 - B: Played Important Role in Family","C141892","Deployment Risk and Resilience Inventory-2 (DRRI-2) During childhood: I played an important role in my family.","DRRI-2 - B: Played Important Role in Family | DRRI1-B: Played Important Role in Family | DRRI1B08",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539949","DRRI-2 - B: Spent My Free Time With Family","C141893","Deployment Risk and Resilience Inventory-2 (DRRI-2) During childhood: I spent as much of my free time with family members as possible.","DRRI-2 - B: Spent My Free Time With Family | DRRI1-B: Spent My Free Time With Family | DRRI1B09",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537885","Uterine Corpus Carcinoma and Carcinosarcoma Pathologic TNM Finding v8","C139762","A pathologic finding about one or more characteristics of uterine corpus carcinoma or carcinosarcoma, following the rules of the TNM AJCC v8 classification system.","Uterine Corpus Carcinoma and Carcinosarcoma Pathologic TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537884","Uterine Corpus Carcinoma and Carcinosarcoma Pathologic Distant Metastasis TNM Finding v8","C139763","A pathologic finding about one or more characteristics of uterine corpus carcinoma or carcinosarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Uterine Corpus Carcinoma and Carcinosarcoma Pathologic Distant Metastasis TNM Finding v8 | Pathologic Staging: Distant Metastasis (pM)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537883","Uterine Corpus Carcinoma and Carcinosarcoma pM1 TNM Finding v8","C139764","Uterine corpus carcinoma or carcinosarcoma with distant metastasis (includes metastasis to inguinal lymph nodes, intraperitoneal disease, lung, liver, or bone. It excludes metastasis to pelvic or para-aortic lymph nodes, vagina, uterine serosa, or adnexa). (from AJCC 8th Ed.)","Uterine Corpus Carcinoma and Carcinosarcoma pM1 TNM Finding v8 | Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage IVB | pM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537882","Uterine Corpus Carcinoma and Carcinosarcoma Pathologic Primary Tumor TNM Finding v8","C139765","A pathologic finding about one or more characteristics of uterine corpus carcinoma or carcinosarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor. The definitions of the T categories correspond to the stages accepted by FIGO. (from AJCC 8th Ed.)","Uterine Corpus Carcinoma and Carcinosarcoma Pathologic Primary Tumor TNM Finding v8 | Pathologic Staging: Primary Tumor (pT)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526731","A260 to A280 Ratio","C139280","An assessment of nucleic acid purity that is measured by determining the ratio of light absorbance of the nucleic acid sample at 260nm and 280nm respectively.","A260 to A280 Ratio | A260/A280 Ratio | A260:A280 | A260A280 | a260 a280 ratio | a260_a280_ratio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526730","A260 to A230 Ratio","C139281","An assessment of nucleic acid purity that is measured by determining the ratio of light absorbance of the nucleic acid sample at 260nm and 230nm respectively.","A260 to A230 Ratio | A260/A230 Ratio | A260:A230 | A260A230",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526729","Fluorescent Tag Type","C139282","The type of fluorescent label or dye that is used in a fluorescence-based assay.","Fluorescent Tag Type | FLUORLBL | Fluorescent Label",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526707","Node-Based Epstein-Barr Virus -Positive Peripheral T-Cell Lymphoma","C139288","An EBV-positive peripheral T-cell lymphoma that arises from the lymph nodes. It is characterized by a monomorphic pattern of infiltration and abscence of the angiodestruction and necrosis seen in extranodal NK/T-cell lymphomas. These lymphomas are more common in elderly patient, or in the setting of immune deficiency. For the time being, they are considered a variant of peripheral T-cell lymphoma, not otherwise specified. (WHO 2017)","Primary EBV-Positive Nodal T-Cell or NK-Cell Lymphoma | Node-Based EBV-Positive Peripheral T-Cell Lymphoma | Node-Based Epstein-Barr Virus -Positive Peripheral T-Cell Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526884","Vulvar Cancer TNM Finding v8","C139590","A finding about one or more characteristics of vulvar cancer, following the rules of the TNM AJCC v8 classification system. This classification system applies to all carcinomas of the vulva. Melanoma of the vulva is staged according to the classification for melanoma of the skin.   (from AJCC 8th Ed.)","Vulvar Cancer TNM Finding v8 | Vulvar Carcinoma TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521117","22q13.3","C13908","A chromosome band present on 22q","22q13.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521203","2q12.3","C13909","A chromosome band present on 2q","2q12.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537904","Cervical Cancer Pathologic Regional Lymph Nodes TNM Finding v8","C139725","A pathologic finding about one or more characteristics of cervical cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Cervical Cancer Pathologic Regional Lymph Nodes TNM Finding v8 | Cervical Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8 | Pathologic Regional Lymph Node Status (pN)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521177","2p14-p13","C13972","A chromosome band present on 2p","2p14-p13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526704","Advanced Head and Neck Squamous Cell Carcinoma","C139291","A head and neck squamous cell carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Head and Neck Squamous Cell Carcinoma | Advanced Head and Neck Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526711","TAF12 Gene Product","C139292","A protein encoded by the TAF12 gene.","TAF12 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526710","Patient Navigation","C139294","A healthcare service that is designed to guide a patient through the healthcare system and reduce barriers to timely screening, follow-up, diagnosis, treatment, and supportive care.","Patient Navigation | Patient Navigation Program | Patient Navigator Program",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526896","En Bloc Resection","C139567","A surgical procedure in which organs or tissues are removed as a whole.","En Bloc Resection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526895","Tunneled Pleural Catheter Drainage","C139568","A surgical procedure in which a hollow, flexible tube is placed in the thoracic cavity and exits the body through a tunneled path under the skin.","Tunneled Pleural Catheter Drainage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526894","Prognostic Stage II Breast Cancer AJCC v8","C139569","Stage II includes: IIA: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); IIB: (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larg","Prognostic Stage II Breast Cancer AJCC v8 | Prognostic Stage II Breast Carcinoma AJCC v8 | Stage II Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526893","Endobronchial Stent Placement","C139570","Placement of a stent in a bronchus.","Endobronchial Stent Placement | Endobronchial Stenting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0127565","Merbarone","C1390","A nonsedating derivative of thiobarbituric acid and a novel catalytic topoisomerase II inhibitor with antineoplastic activity. Merbarone interferes with DNA replication via binding directly to topoisomerase II at a domain that maybe shared by other topoisomerase II cleavage-enhancing agents, ex., etoposide. Its mechanism of action appears to be a novel one, since merbarone does not intercalate DNA nor stabilize DNA-topoisomerase II cleavable complexes.","Merbarone | MERBARONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1444098","Extended-spectrum Beta-lactamase Positive Klebsiella pneumoniae","C139101","A subgroup of Klebsiella pneumoniae bacteria that produce beta-lactamase and are therefore resistant to extended-spectrum beta-lactam (penicillin) antibiotics.","Extended-spectrum Beta-lactamase Positive Klebsiella pneumoniae | KLEBSIELLA PNEUMONIAE, ESBL | Klebsiella pneumoniae, Extended-Spectrum Beta-Lactamases",,,,,,,,,,,,,,,"4260332","Extended spectrum beta-lactamase producing Klebsiella pneumoniae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL537956","Stage IA Uterine Corpus Cancer AJCC v8","C139803","Stage IA includes: T1a, N0, M0. T1a: Uterine corpus carcinoma or carcinosarcoma with tumor limited to the endometrium or invading less than half the myometrium. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IA Uterine Corpus Cancer AJCC v8 | Stage IA Uterine (including Endometrial) Cancer | Stage IA Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537955","Stage IB Uterine Corpus Cancer AJCC v8","C139804","Stage IB includes: T1b, N0, M0. T1b: Uterine corpus carcinoma or carcinosarcoma with tumor invading one half or more of the myometrium. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage IB Uterine Corpus Cancer AJCC v8 | Stage IB Uterine (including Endometrial) Cancer | Stage IB Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537954","Stage II Uterine Corpus Cancer AJCC v8","C139805","Stage II includes: T2, N0, M0. T2: Uterine corpus carcinoma or carcinosarcoma with tumor invading the stromal connective tissue of the cervix but not extending beyond the uterus. Does not include endocervical glandular involvement. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage II Uterine Corpus Cancer AJCC v8 | Stage II | Stage II Uterine (including Endometrial) Cancer | Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537953","Stage III Uterine Corpus Cancer AJCC v8","C139806","Stage III includes: T3, N0, M0. T3: Uterine corpus carcinoma or carcinosarcoma with tumor involving serosa, adnexa, vagina, or parametrium. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)","Stage III Uterine Corpus Cancer AJCC v8 | Stage III | Stage III Uterine (including Endometrial) Cancer | Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537952","Stage IIIA Uterine Corpus Cancer AJCC v8","C139807","Stage IIIA includes: T3a, N0, M0. T3a: Uterine corpus carcinoma or carcinosarcoma with tumor involving the serosa and/or adnexa (direct extension or metastasis). N0: No regional lymph node metastasis. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage IIIA Uterine Corpus Cancer AJCC v8 | Stage IIIA Uterine (including Endometrial) Cancer | Stage IIIA Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537951","Stage IIIB Uterine Corpus Cancer AJCC v8","C139808","Stage IIIB includes: T3b, N0, M0. T3b: Uterine corpus carcinoma or carcinosarcoma with vaginal involvement (direct extension or metastasis) or parametrial involvement. N0: No regional lymph node metastasis. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage IIIB Uterine Corpus Cancer AJCC v8 | Stage IIIB Uterine (including Endometrial) Cancer | Stage IIIB Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537966","Stage IIIC Uterine Corpus Cancer AJCC v8","C139809","Stage IIIC includes: IIIC1: T1-T3, N1/N1mi/N1a, M0; IIIC2: T1-T3, N2/N2mi/N2a, M0. T1: Uterine corpus carcinoma or carcinosarcoma with tumor confined to the corpus uteri, including endocervical glandular involvement. T2: Uterine corpus carcinoma or carcinosarcoma with tumor invading the stromal connective tissue of the cervix but not extending beyond the uterus. Does not include endocervical glandular involvement. T3: Uterine corpus carcinoma or carcinosarcoma with tumor involving serosa, adnexa, vagina, or parametrium. N1: Regional lymph node metastasis to pelvic lymph nodes. N1mi: Regional lymph node metastasis (greater than 0.2 mm but nor greater than 2.0 mm in diameter) to pelvic lymph nodes. N1a: Regional lymph node metastasis (greater than 2.0 mm in diameter) to pelvic lymph nodes. N2: Regional lymph node metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes. N2mi: Regional lymph node metastasis (greater than 0.2 mm but not greater than 2.0 mm in diameter) to para-aortic lymph nodes, with or without positive pelvic lymph nodes. N2a: Regional lymph node metastasis (greater than 2.0 mm in diameter) to para-aortic lymph nodes, with or without positive pelvic lymph nodes. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage IIIC Uterine Corpus Cancer AJCC v8 | Stage IIIC Uterine (including Endometrial) Cancer | Stage IIIC Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521289","3p22-p21.3","C13923","A chromosome band present on 3p","3p22-p21.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526909","Anti-FCRH5/CD3 TDB BFCR4350A","C139549","A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) Fc receptor-like protein 5 (FCRH5; CD307; FCRL5; IRTA2; BXMAS1) and one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of cevostamab, the bispecific antibody binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and FCRH5 found on FCRH5-expressing tumor cells. This activates and crosslinks CTLs with FCRH5-expressing tumor cells, which results in the CTL-mediated cell death of FCRH5-expressing tumor cells. FCRH5, an immune receptor translocation-associated protein/Fc receptor homolog (IRTA/FCRH) family member and a B-cell lineage marker, is overexpressed on myeloma cells.","Cevostamab | Anti-FCRH5 x Anti-CD3 Bi-specific T-cell Engager BFCR4350A | Anti-FCRH5/CD3 BiTE Antibody BFCR4350A | Anti-FCRH5/CD3 TDB BFCR4350A | BFCR4350A | CEVOSTAMAB | FCRH5/CD3 T Cell Dependent Bispecific Antibody BFCR4350A | FCRH5/CD3 TDB Antibody BFCR4350A | RO7187797 | Recombinant Anti-FCRH5 x Anti-CD3 Bi-specific T-cell Engager BFCR4350A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521228","2q35-q36","C13954","A chromosome band present on 2q","2q35-q36 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3490973","CCR2/CCR5 Antagonist BMS-813160","C139550","An antagonist of both human C-C chemokine receptor types 2 (CCR2; CD192) and 5 (CCR5; CD195), with potential immunomodulating and antineoplastic activities. Upon administration, CCR2/CCR5 antagonist BMS-813160 specifically binds and prevents the activation of both CCR2 and CCR5. This inhibits the activation of CCR2/CCR5-mediated signal transduction pathways and may inhibit inflammatory processes, angiogenesis, tumor cell migration, tumor cell proliferation and invasion. The G-protein coupled chemokine receptors CCR2 and CCR5 are expressed on the surface of monocytes and macrophages, and stimulate their migration and infiltration; they play key roles in inflammation and autoimmune disease. CCR2 and CCR5 are overexpressed in certain cancer cell types, and are also involved in angiogenesis, and in tumor cell migration, proliferation and metastasis.","CCR2/CCR5 Antagonist BMS-813160 | (S)-1-[(1S,2R,4R)-4-isopropyl(methyl)amino)-2-propylcyclohexyl]-3-(6(trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-2-one | BMS-813160",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024399","Cynomolgus Monkey","C14232","A macaque, Macaca fascicularis (M. cynomolgus), found mostly in southeastern Asia, Borneo, and the Philippines.","Cynomolgus Monkey | CYNOMOLGUS | Crab Eating Macaque | Cynomolgus | Cynomolgus Macaque | MACACA FASCICULARIS | Macaca cynomolgus | Macaca fascicularis | Macaca irus",,,,,,,,,,,,,,,"4023595","Macaca fascicularis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0024400","Rhesus Monkey","C14233","A pale brown macaque (Macaca mulatta) native to India, China, and other parts of Asia; often used in medical research. A medium-sized diurnal primate, the Macaca mulatta has a diet of plant material and insects that it can store in pouches in its mouth. The rhesus monkey has an inquisitive, destructive nature with a tendency to bite and pinch; captive breeds are used almost exclusively for medical research. The rhesus monkey has a long history in biomedical research owing to its relative ease in upkeep, most famously utilized in the study of the rhesus factor in human blood groups, the effects of space travel on humans, as well as being the first cloned and transgenic primate.","Rhesus Monkey | MACACA MULATTA | Macaca mulatta | RHESUS | Rhesus | Rhesus Macaque",,,,,,,,,,,,,,,"4218762","Macaca mulatta",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526900","Prognostic Stage IIA Breast Cancer AJCC v8","C139571","Stage IIA includes: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)","Prognostic Stage IIA Breast Cancer AJCC v8 | Prognostic Stage IIA Breast Carcinoma AJCC v8 | Stage IIA Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515467","8q24.1-q24.3","C13903","A chromosome band present on 8q","8q24.1-q24.3 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520997","1q23-q25","C13980","A chromosome band present on 1q","1q23-q25 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537965","Stage IIIC1 Uterine Corpus Cancer AJCC v8","C139810","Stage IIIC1 includes: T1-T3, N1/N1mi/N1a, M0. T1: Uterine corpus carcinoma or carcinosarcoma with tumor confined to the corpus uteri, including endocervical glandular involvement. T2: Uterine corpus carcinoma or carcinosarcoma with tumor invading the stromal connective tissue of the cervix but not extending beyond the uterus. Does not include endocervical glandular involvement. T3: Uterine corpus carcinoma or carcinosarcoma with tumor involving serosa, adnexa, vagina, or parametrium. N1: Regional lymph node metastasis to pelvic lymph nodes. N1mi: Regional lymph node metastasis (greater than 0.2 mm but nor greater than 2.0 mm in diameter) to pelvic lymph nodes. N1a: Regional lymph node metastasis (greater than 2.0 mm in diameter) to pelvic lymph nodes. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage IIIC1 Uterine Corpus Cancer AJCC v8 | Stage IIIC1 Uterine (including Endometrial) Cancer | Stage IIIC1 Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526908","Oncolytic HSV-1 rQNestin34.5v.2","C139551","A neuroattenuated, replication-competent, recombinant and genetically-engineered herpes simplex virus type 1 (HSV-1), with potential oncolytic and immunostimulating activities. In rQNestin34.5v.2, the UL39 gene encoding for the viral ribonucleotide reductase large subunit infected cell protein 6 (ICP6) and both endogenous copies of the gamma34.5 gene that encodes for the RL1 neurovirulence protein infected cell protein 34.5 (ICP34.5), which is needed for robust viral growth in an infected cell, are deleted, and one copy of the gamma34.5 gene is reinserted under control of a nestin promoter, which is selectively activated in gliomas. Upon intratumoral administration, oncolytic HSV-1 rQNestin34.5v.2 preferentially infects and replicates within the rapidly dividing, glioma cells, thereby directly lysing tumor cells. The released virus particles, in turn, infect and replicate in neighboring tumor cells, thereby further killing tumor cells. rQNestin34.5v.2 also elicits a tumor-specific systemic immune and cytotoxic T-lymphocyte (CTL) response, thereby killing nearby non-infected tumor cells. By inactivating UL39, viral ribonucleotide reductase activity is disrupted, resulting in the inhibition of nucleotide metabolism and viral DNA synthesis in non-dividing, healthy cells but not in dividing cells. Glioma-selective expression of ICP34.5 imparts tumor selectivity by preventing replication in healthy cells.","Oncolytic HSV-1 rQNestin34.5v.2 | Genetically Engineered HSV-1 Virus rQNestin34.5v.2 | Oncolytic rQNestin34.5v.2 | Oncolytic rQNestin34.5v.2 HSV Virus | rQNestin34.5v.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526907","SY-1365","C139552","A selective inhibitor of cyclin-dependent kinase 7 (CDK7), with potential antineoplastic activity. Upon administration, SY-1365 binds to and inhibits CDK7, thereby inhibiting CDK7-mediated signal transduction pathways. This inhibits cell growth of CDK7-overexpressing tumor cells. CDK7, a serine/threonine kinase, plays a key role in cell proliferation; CDK7 is overexpressed in a variety of tumor cell types.","Mevociclib | CDK7 Inhibitor SY-1365 | MEVOCICLIB | SY-1365 | SY1365",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526913","ABBV-927","C139553","An agonistic monoclonal antibody directed against the B-cell surface antigen CD40, with potential antineoplastic activity. Upon administration, giloralimab binds to CD40 on a variety of immune cell types. This induces CD40-dependent signaling pathways, triggers the proliferation and activation of antigen-presenting cells (APCs), and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells and plays a key role in the activation of the immune system.","Giloralimab | ABBV-927 | Agonistic Anti-CD40 Monoclonal Antibody ABBV-927 | Anti-CD40 Agonist Monoclonal Antibody ABBV-927 | Anti-CD40 Monoclonal Antibody ABBV-927 | GILORALIMAB | PR-1614645",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526448","Capmatinib Hydrochloride","C138995","The hydrochloride salt form of capmatinib, an orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Capmatinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","Capmatinib Hydrochloride | CAPMATINIB HYDROCHLORIDE | NVP-INC280-AAA | Tabrecta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL433010","Icotinib","C138996","An orally available quinazoline-based inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Icotinib selectively inhibits the wild-type and several mutated forms of EGFR tyrosine kinase. This may lead to an inhibition of EGFR-mediated signal transduction and may inhibit cancer cell proliferation. EGFR, a receptor tyrosine kinase, has been upregulated in a variety of cancer cell types.","Icotinib | (1,4,7,10)Tetraoxacyclododecino(2,3-g)quinazolin-4-amine, N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro- | BPI-2009 | ICOTINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526447","Anlotinib","C138997","A receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities. Upon administration, catequentinib targets multiple RTKs, including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt tumor cell growth.","Catequentinib | AL 3818 | AL-3818 | AL3818 | Anlotinib | Anlotinib | CATEQUENTINIB | Cyclopropanamine, 1-(((4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539739","Rising From Floor - Test Grade","C141703","Rising From Floor Test (Rising From Floor) Test grade.","Rising From Floor - Test Grade | RISEF1-Test Grade | RISEF104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539738","4-Stair Descend - Time to Do 4-Stair Descend","C141704","Four Stair Descend Test (4 Stair Descend) Time taken to descend 4 stairs.","4-Stair Descend - Time to Do 4-Stair Descend | D4STR1-Time to Do 4-Stair Descend | D4STR102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539737","D4STR1-Test Grade","C141705","Four Stair Descend Test (4 Stair Descend) Test grade.","4-Stair Descend - Test Grade | D4STR1-Test Grade | D4STR104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539735","A4STR1-Test Grade","C141707","Four Stair Ascend Test (4 Stair Ascend) Test grade.","4-Stair Ascend - Test Grade | A4STR1-Test Grade | A4STR104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539734","IPAQ Short Last 7 Days Self-administered Format Version - Days Vigorous Physical Activities","C141708","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) During the last 7 days, on how many days did you do vigorous physical activities like heavy lifting, digging, aerobics, or fast bicycling?: days per week.","IPAQ Short Last 7 Days Self-administered Format Version - Days Vigorous Physical Activities | IPA04-Days Vigorous Physical Activities | IPA0401",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539733","IPAQ Short Last 7 Days Self-administered Format Version - No Vigorous Physical Activities","C141709","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) During the last 7 days, on how many days did you do vigorous physical activities like heavy lifting, digging, aerobics, or fast bicycling?: No vigorous physical activities.","IPAQ Short Last 7 Days Self-administered Format Version - No Vigorous Physical Activities | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539748","IPAQ Short Last 7 Days Self-administered Format Version - Vigorous Physical Hr and Min per Day","C141710","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) How much time did you usually spend doing vigorous physical activities on one of those days?: hours and minutes per day.","IPAQ Short Last 7 Days Self-administered Format Version - Vigorous Physical Hr and Min per Day | IPA04-Vigorous Physical Hr & Min per Day | IPA0402",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539746","IPAQ Short Last 7 Days Self-administered Format Version - Time Vigorous Don't Know/Not Sure","C141712","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) How much time did you usually spend doing vigorous physical activities on one of those days?: Don't know/Not sure.","IPAQ Short Last 7 Days Self-administered Format Version - Time Vigorous Don't Know/Not Sure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539745","IPAQ Short Last 7 Days Self-administered Format Version - Days Moderate Physical Activities","C141713","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) During the last 7 days, on how many days did you do moderate physical activities like carrying light loads, bicycling at a regular pace, or doubles tennis?: days per week.","IPAQ Short Last 7 Days Self-administered Format Version - Days Moderate Physical Activities | IPA04-Days Moderate Physical Activities | IPA0403",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526493","Observed Cardiac Device Type","C139049","A description of the type of cardiac device that is found in a subject.","Observed Cardiac Device Type | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520591","14q24","C13904","A chromosome band present on 14q","14q24 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537881","Uterine Corpus Carcinoma and Carcinosarcoma pTX TNM Finding v8","C139766","Uterine corpus carcinoma or carcinosarcoma in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Uterine Corpus Carcinoma and Carcinosarcoma pTX TNM Finding v8 | pTX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537880","Uterine Corpus Carcinoma and Carcinosarcoma pT0 TNM Finding v8","C139767","Uterine corpus carcinoma or carcinosarcoma with no evidence of primary tumor. (from AJCC 8th Ed.)","Uterine Corpus Carcinoma and Carcinosarcoma pT0 TNM Finding v8 | pT0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537863","Uterine Corpus Carcinoma and Carcinosarcoma pT1 TNM Finding v8","C139768","Uterine corpus carcinoma or carcinosarcoma with tumor confined to the corpus uteri, including endocervical glandular involvement. (from AJCC 8th Ed.)","Uterine Corpus Carcinoma and Carcinosarcoma pT1 TNM Finding v8 | Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage I | pT1 (FIGO I)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537862","Uterine Corpus Carcinoma and Carcinosarcoma pT1a TNM Finding v8","C139769","Uterine corpus carcinoma or carcinosarcoma with tumor limited to the endometrium or invading less than half the myometrium. (from AJCC 8th Ed.)","Uterine Corpus Carcinoma and Carcinosarcoma pT1a TNM Finding v8 | Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage IA | pT1a (FIGO IA)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526883","Vulvar Cancer Clinical TNM Finding v8","C139591","A clinical finding about one or more characteristics of vulvar cancer, following the rules of the TNM AJCC v8 classification system.","Vulvar Cancer Clinical TNM Finding v8 | Vulvar Carcinoma Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526890","Vulvar Cancer Clinical Distant Metastasis TNM Finding v8","C139592","A clinical finding about one or more characteristics of vulvar cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Vulvar Cancer Clinical Distant Metastasis TNM Finding v8 | Vulvar Carcinoma Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526889","Vulvar Cancer cM0 TNM Finding v8","C139593","Vulvar cancer without evidence of distant metastasis (no pathological M0; use clinical M to complete stage group). (from AJCC 8th Ed.)","Vulvar Cancer cM0 TNM Finding v8 | Vulvar Carcinoma cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526888","Vulvar Cancer cM1 TNM Finding v8","C139594","Vulvar cancer with distant metastasis (including pelvic lymph node metastasis). (from AJCC 8th Ed.)","Vulvar Cancer cM1 TNM Finding v8 | Vulvar Carcinoma cM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526887","Vulvar Cancer Pathologic TNM Finding v8","C139595","A pathologic finding about one or more characteristics of vulvar cancer, following the rules of the TNM AJCC v8 classification system.","Vulvar Cancer Pathologic TNM Finding v8 | Vulvar Carcinoma Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526955","Vulvar Cancer Pathologic Distant Metastasis TNM Finding v8","C139596","A pathologic finding about one or more characteristics of vulvar cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Vulvar Cancer Pathologic Distant Metastasis TNM Finding v8 | Vulvar Carcinoma Pathologic Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526954","Vulvar Cancer pM1 TNM Finding v8","C139597","Vulvar cancer with distant metastatis. (from AJCC 8th Ed.)","Vulvar Cancer pM1 TNM Finding v8 | Vulvar Carcinoma pM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526952","Vulvar Cancer pTX TNM Finding v8","C139599","Vulvar cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","Vulvar Cancer pTX TNM Finding v8 | Vulvar Carcinoma pTX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521391","4q13.3-q21.1","C13959","A chromosome band present on 4q","4q13.3-q21.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521010","1q32.2","C13899","A chromosome band present on 1q","1q32.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526538","Glioma Lysate Vaccine GBM6-AD","C139000","An allogeneic cell lysate-based vaccine derived from the glioma stem cell line GBM6-AD, which was isolated from the brain tumor of a patient diagnosed with glioblastoma multiforme (GBM), with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration, the glioma lysate vaccine GBM6-AD exposes the immune system to an undefined amount of glioma-associated antigens (GAAs), and stimulates the immune system to mount a specific anti-tumoral, cytotoxic T-lymphocyte (CTL)-mediated response against the GAA-expressing cells, resulting in glioma cell lysis.","Glioma Lysate Vaccine GBM6-AD | GBM6-AD | GBM6-AD Lysate Protein Vaccine | Glioma Cell Lysate Vaccine GBM6-AD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526537","Refractory Soft Tissue Sarcoma","C139001","A soft tissue sarcoma that does not respond to treatment.","Refractory Soft Tissue Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526536","Recurrent Soft Tissue Sarcoma","C139002","The reemergence of soft tissue sarcoma after a period of remission.","Recurrent Soft Tissue Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2974723","Micellar Nanoparticle-encapsulated Epirubicin","C139003","A nanoparticle-based prodrug formulation consisting of polymeric micelles encapsulating the anthracycline epirubicin, with potential antineoplastic activity. Epirubicin is covalently bound to polyethylene glycol (PEG) polyaspartate block copolymers through an acid-labile hydrazone bond and, upon suspension in an aqueous solution, a micellar structure with an outer hydrophilic PEG shell surrounding the hydrophobic epirubicin is formed. Upon administration of the micellar nanoparticle-encapsulated epirubicin, the nanoparticles are stable in the bloodstream and specifically accumulate in the tumor tissue. Due to the acidic conditions in the tumor and the pH-responsive nature of the micelles, epirubicin is released in the tumor milieu; it then intercalates into DNA and inhibits topoisomerase II, which inhibits DNA replication and interferes with synthesis of both RNA and protein. Compared to the administration of epirubicin alone, this formulation increases the water-solubility of epirubicin and increases its therapeutic effect while decreasing its cardiotoxicity.","Micellar Nanoparticle-encapsulated Epirubicin | Epirubicin-incorporating Micelle | K-912 | NC-6300 | Nanoparticle Epirubicin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537915","Autologous ACTR-CD16-CD28-expressing T-lymphocytes ACTR707","C139730","A preparation of autologous T-lymphocytes that have been genetically modified, using proprietary Antibody-Coupled T-cell Receptor (ACTR) technology, to express a chimeric protein containing, at least, the extracellular Fc receptor domain of CD16, normally found on certain immune cells, such as natural killer (NK) cells, coupled to the co-stimulatory signaling domain of CD28, with potential immunostimulating and antineoplastic activities. Upon reintroduction into the patient with co-administration of a cancer-specific antibody, the co-administered antibody targets and binds to the tumor-associated antigen (TAA) expressed on the tumor cell. In turn, the autologous ACTR-CD16-CD28-expressing T-lymphocytes ACTR707 bind to the antibody, become activated and induce the destruction of the tumor cells by a) releasing cytotoxins that directly kill cancer cells; b) releasing cytokines that trigger an immune response and recruit other immune-mediated killer cells to kill the tumor cells; c) targeting and killing adjacent tumor cells that are not bound to the antibody; d) inducing T-cell proliferation and thereby further enhancing the T-cell mediated tumor cell attack. Compared to other T-cell products, ACTR-based products do not target a specific TAA and can potentially be used in a variety of tumors because targeting is based on the specificity of the co-administered antibody.","Autologous ACTR-CD16-CD28-expressing T-lymphocytes ACTR707 | ACTR707 | ACTR707 Cells | ACTR707 T-cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539744","IPAQ Short Last 7 Days Self-administered Format Version - No Moderate Physical Activities","C141714","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) During the last 7 days, on how many days did you do moderate physical activities like carrying light loads, bicycling at a regular pace, or doubles tennis?: No moderate physical activities.","IPAQ Short Last 7 Days Self-administered Format Version - No Moderate Physical Activities | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539743","IPAQ Short Last 7 Days Self-administered Format Version - Moderate Physical Hr and Min per Day","C141715","International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) How much time did you usually spend doing moderate physical activities on one of those days?: hours and minutes per day.","IPAQ Short Last 7 Days Self-administered Format Version - Moderate Physical Hr and Min per Day | IPA04-Moderate Physical Hr & Min per Day | IPA0404",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539932","DRRI-2 - B: Family Told Me When Problem","C141894","Deployment Risk and Resilience Inventory-2 (DRRI-2) During childhood: family members told me when they were having a problem.","DRRI-2 - B: Family Told Me When Problem | DRRI1-B: Family Told Me When Problem | DRRI1B10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539931","DRRI-2 - B: I Could Be Myself Around Family","C141895","Deployment Risk and Resilience Inventory-2 (DRRI-2) During childhood: I could be myself around family members.","DRRI-2 - B: I Could Be Myself Around Family | DRRI1-B: I Could Be Myself Around Family | DRRI1B11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539930","DRRI-2 - B: Input Sought Family Decisions","C141896","Deployment Risk and Resilience Inventory-2 (DRRI-2) During childhood: my input was sought on important family decisions.","DRRI-2 - B: Input Sought Family Decisions | DRRI1-B: Input Sought Family Decisions | DRRI1B12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539929","DRRI-2 - C: Climate Was Uncomfortable","C141897","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: the climate was uncomfortable.","DRRI-2 - C: Climate Was Uncomfortable | DRRI1-C: Climate Was Uncomfortable | DRRI1C01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539928","DRRI-2 - C: Deal With Annoying Animals","C141898","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I had to deal with annoying animals, insects, or plants.","DRRI-2 - C: Deal With Annoying Animals | DRRI1-C: Deal With Annoying Animals | DRRI1C02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539927","DRRI-2 - C: Food Was of Very Poor Quality","C141899","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: the food I had to eat was of very poor quality (for example, bad or old MREs).","DRRI-2 - C: Food Was of Very Poor Quality | DRRI1-C: Food Was of Very Poor Quality | DRRI1C03",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539926","DRRI-2 - C: Conditions Extremely Unsanitary","C141900","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: the conditions I lived in were extremely unsanitary.","DRRI-2 - C: Conditions Extremely Unsanitary | DRRI1-C: Conditions Extremely Unsanitary | DRRI1C04",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539925","DRRI-2 - C: Didn't Have Bathrooms","C141901","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I didn't have access to bathrooms or showers when I needed them.","DRRI-2 - C: Didn't Have Bathrooms | DRRI1-C: Didn't Have Bathrooms | DRRI1C05",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514675","RXY/FXpSXP Motif","C13976","The 14-3-3 family of proteins mediates signal transduction by binding to phosphoserine-containing proteins. RXY/FXpSXP Motif is one of two different binding motifs that are present in nearly all known 14-3-3 binding proteins. The14-3-3 dimer binds tightly to single molecules containing tandem repeats of phosphoserine motifs, implicating bidentate association as a signaling mechanism with molecules such as Raf, BAD, and Cbl. (from OMIM)","RXY/FXpSXP Motif | RXY/FXpSXP Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537861","Uterine Corpus Carcinoma and Carcinosarcoma pT1b TNM Finding v8","C139770","Uterine corpus carcinoma or carcinosarcoma with tumor invading one half or more of the myometrium. (from AJCC 8th Ed.)","Uterine Corpus Carcinoma and Carcinosarcoma pT1b TNM Finding v8 | Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage IB | pT1b (FIGO IB)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537859","Uterine Corpus Carcinoma and Carcinosarcoma pT3 TNM Finding v8","C139772","Uterine corpus carcinoma or carcinosarcoma with tumor involving serosa, adnexa, vagina, or parametrium. (from AJCC 8th Ed.)","Uterine Corpus Carcinoma and Carcinosarcoma pT3 TNM Finding v8 | Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537858","Uterine Corpus Carcinoma and Carcinosarcoma pT3a TNM Finding v8","C139773","Uterine corpus carcinoma or carcinosarcoma with tumor involving the serosa and/or adnexa (direct extension or metastasis). (from AJCC 8th Ed.)","Uterine Corpus Carcinoma and Carcinosarcoma pT3a TNM Finding v8 | Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage IIIA | pT3a (FIGO IIIA)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537857","Uterine Corpus Carcinoma and Carcinosarcoma pT3b TNM Finding v8","C139774","Uterine corpus carcinoma or carcinosarcoma with vaginal involvement (direct extension or metastasis) or parametrial involvement. (from AJCC 8th Ed.)","Uterine Corpus Carcinoma and Carcinosarcoma pT3b TNM Finding v8 | Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage IIIB | pT3b (FIGO IIIB)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537856","Uterine Corpus Carcinoma and Carcinosarcoma pT4 TNM Finding v8","C139775","Uterine corpus carcinoma or carcinosarcoma with tumor invading the bladder mucosa and/or bowel mucosa (bullous edema is not sufficient to classify a tumor as T4). (from AJCC 8th Ed.)","Uterine Corpus Carcinoma and Carcinosarcoma pT4 TNM Finding v8 | Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage IVA | pT4 (FIGO IVA)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537871","Uterine Corpus Carcinoma and Carcinosarcoma Pathologic Regional Lymph Nodes TNM Finding v8","C139776","A pathologic finding about one or more characteristics of uterine corpus carcinoma or carcinosarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Uterine Corpus Carcinoma and Carcinosarcoma Pathologic Regional Lymph Nodes TNM Finding v8 | Pathologic Staging: Regional Lymph Nodes (pN)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537870","Uterine Corpus Carcinoma and Carcinosarcoma pNX TNM Finding v8","C139777","Uterine corpus carcinoma or carcinosarcoma in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Uterine Corpus Carcinoma and Carcinosarcoma pNX TNM Finding v8 | pNX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537868","Uterine Corpus Carcinoma and Carcinosarcoma pN0(i+) TNM Finding v8","C139779","Uterine corpus carcinoma or carcinosarcoma with isolated tumor cells in regional lymph node(s) no greater than 0.2 mm. (from AJCC 8th Ed.)","Uterine Corpus Carcinoma and Carcinosarcoma pN0(i+) TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519064","Phosphoserine Motif","C13977","A protein motif containing a phosphorylated serine residue. These motifs can influence both protein-protein interactions and cellular signaling.","Phosphoserine Motif | Phosphoserine Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526959","Vulvar Cancer pT0 TNM Finding v8","C139600","Vulvar cancer with no evidence of primary tumor. (from AJCC 8th Ed.)","Vulvar Cancer pT0 TNM Finding v8 | Vulvar Carcinoma pT0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526958","Vulvar Cancer pT1 TNM Finding v8","C139601","Vulvar cancer with tumor confined to the vulva and/or perineum. Multifocal lesions should be designated as such. The largest lesion or the lesion with the greatest depth of invasion will be the target lesion identified to address the highest pT stage. Depth of invasion is defined as the measurement of the tumor from the epithelial-stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion. (from AJCC 8th Ed.)","Vulvar Cancer pT1 TNM Finding v8 | Vulvar Cancer FIGO Stage I | Vulvar Carcinoma FIGO Stage I | Vulvar Carcinoma pT1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526957","Vulvar Cancer pT1a TNM Finding v8","C139602","Vulvar cancer with lesion measuring 2 cm or less, confined to the vulva and/or perineum, and with stromal invasion of 1.0 mm or less. (from AJCC 8th Ed.)","Vulvar Cancer pT1a TNM Finding v8 | Vulvar Cancer FIGO Stage IA | Vulvar Carcinoma FIGO Stage IA | Vulvar Carcinoma pT1a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526956","Vulvar Cancer pT1b TNM Finding v8","C139603","Vulvar cancer with lesion measuring more than 2 cm, or any size with stromal invasion of more than 1.0 mm, confined to the vulva and/or perineum. (from AJCC 8th Ed.)","Vulvar Cancer pT1b TNM Finding v8 | Vulvar Cancer FIGO Stage IB | Vulvar Carcinoma FIGO Stage IB | Vulvar Carcinoma pT1b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526963","Vulvar Cancer pT2 TNM Finding v8","C139604","Vulvar cancer with tumor of any size with extension to adjacent perineal structures (lower/distal third of the urethra, lower/distal third of the vagina, anal involvement). (from AJCC 8th Ed.)","Vulvar Cancer pT2 TNM Finding v8 | Vulvar Cancer FIGO Stage II | Vulvar Carcinoma FIGO Stage II | Vulvar Carcinoma pT2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4075646","Extended-spectrum Beta-lactamase Positive Klebsiella oxytoca","C139102","A subgroup of Klebsiella oxytoca bacteria that produce beta-lactamase and are therefore resistant to extended-spectrum beta-lactam (penicillin) antibiotics.","Extended-spectrum Beta-lactamase Positive Klebsiella oxytoca | KLEBSIELLA OXYTOCA, ESBL | Klebsiella oxytoca, Extended-Spectrum Beta-Lactamases",,,,,,,,,,,,,,,"37017621","Extended spectrum beta-lactamase producing Klebsiella oxytoca",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL537266","Non-Mucoid Pseudomonas aeruginosa","C139103","The wildtype form of Pseudomonas aeruginosa that does not produce an extracellular mucoid alginate.","Non-Mucoid Pseudomonas aeruginosa | PSEUDOMONAS AERUGINOSA, NON-MUCOID",,,,,,,,,,,,,,,"37116715","Non-mucoid Pseudomonas aeruginosa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL537261","Mucoid Pseudomonas aeruginosa","C139104","A substrain of Pseudomonas aeruginosa that produces an exopolysaccharide alginate. Overexpression of alginate in mucoid strains causes formation of micro-colonies that are less susceptible to host defense mechanisms.","Mucoid Pseudomonas aeruginosa | PSEUDOMONAS AERUGINOSA, MUCOID",,,,,,,,,,,,,,,"37116714","Mucoid Pseudomonas aeruginosa",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL526566","Small-Colony Variant Pseudomonas aeruginosa","C139105","A phenotypic variant of Pseudomonas aeruginosa that forms smaller-than-average colonies when cultured; these variants show an increased ability to form a biofilm, and are frequently resistant to multiple antibiotics.","Small-Colony Variant Pseudomonas aeruginosa | PSEUDOMONAS AERUGINOSA, SMALL-COLONY VARIANT | Pseudomonas aeruginosa SCV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0320036","Arthrographis","C139106","A genus of fungi in the phylum Ascomycota with hyaline, septate hyphae. Species in this genus are widely found in compost, decaying plant material, and soil. Some species cause rare infections in humans.","Arthrographis | ARTHROGRAPHIS",,,,,,,,,,,,,,,"4010722","Arthrographis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL537913","EWSR1/ZNF444 Fusion Protein","C139732","A fusion protein encoded by the EWSR1/ZNF444 fusion gene. This protein is comprised of the transactivation domain of the RNA-binding protein EWS fused to the last six C-terminal amino acids of zinc finger protein 444.","EWSR1/ZNF444 Fusion Protein | EWS-ZNF444 Fusion Protein | EWS/ZNF444 Fusion Protein | EWSR1-ZNF444 Fusion Protein | EWSR1::ZNF444 Fusion Protein | RNA-Binding Protein EWS/Zinc Finger Protein 444 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521008","1q32-q41","C13973","A chromosome band present on 1q","1q32-q41 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539940","DRRI-2 - C: Wasn't Able to Get Privacy","C141902","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I wasn't able to get as much privacy as I needed.","DRRI-2 - C: Wasn't Able to Get Privacy | DRRI1-C: Wasn't Able to Get Privacy | DRRI1C06",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539939","DRRI-2 - C: I Was Exposed to Awful Smells","C141903","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was exposed to awful smells.","DRRI-2 - C: I Was Exposed to Awful Smells | DRRI1-C: I Was Exposed to Awful Smells | DRRI1C07",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539937","DRRI-2 - C: Restricted Because Local Custom","C141905","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: my daily activities were restricted because of local religious or ethnic customs.","DRRI-2 - C: Restricted Because Local Custom | DRRI1-C: Restricted Because Local Custom | DRRI1C09",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539936","DRRI-2 - C: Wasn't Able to Rest","C141906","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I wasn't able to get rest when I needed it.","DRRI-2 - C: Wasn't Able to Rest | DRRI1-C: Wasn't Able to Rest | DRRI1C10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539935","DRRI-2 - C: Wasn't Able to Contact Home","C141907","Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I wasn't able to contact home when I needed to.","DRRI-2 - C: Wasn't Able to Contact Home | DRRI1-C: Wasn't Able to Contact Home | DRRI1C11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511474","Cadherin Domain","C13929","Evolutionary related to desmosomal desmogleins, cadherins contain a signal sequence, a propeptide of around 130 residues, an extracellular domain of around 600 residues, a single transmembrane domain, and a well-conserved C-terminal cytoplasmic domain of about 150 residues. The extracellular domain typically consists of four Cadherin Domain repeats of about 110 residues; an adjacent fifth domain contains four conserved cysteines. The domain includes conserved Asp and Arg residues that may be involved in calcium binding. Tissue-specific cadherin glycoproteins are responsible for homophilic calcium-dependent cell-cell adhesion likely involved in cell type sorting during morphogenesis, histogenesis, and regeneration. They may also regulate tight and gap junctions. (NCI)","Cadherin Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0128596","Mitomycin B","C1392","A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus.  Bioreduced mitomycin B generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis. (NCI04)","Mitomycin B | Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 1,1a,2,8,8a,8b-hexahydro-8a-hydroxy-8-(hydroxymethyl)-6-methoxy-1,5-dimethyl-, 8-carbamate | MITOMYCIN B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526691","RAS Protein Family Activation Assay","C139305","An in vitro assay that can indirectly detect the activation of small GTPases in the RAS family through the staining of phosphorylated forms of MEK (MAP2K) family proteins (pMEK). A farnesylated RAS family protein is anchored to an in vitro model of the plasma membrane and, under different conditions, is co-incubated with both a RAF family protein, which binds to and is activated by active RAS proteins, and a MEK family protein, which is phosphorylated by active RAF proteins. pMEK is detected using a donor bead coated with anti-MEK antibodies that is capable of oxidizing an acceptor molecule attached to an anti-pMEK antibody. When the donor and acceptor are in close proximity, the acceptor molecule is oxidized and can be visualized using electron microscopy.","RAS Protein Family Activation Assay | RAS/RAF Activation Assay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526690","Exascale Computer System","C139306","Refers to computer systems capable of a quintillion (10^18) calculations each second. This computing power is expected to facilitate the analysis of data sets that would require too much time with currently available systems. Such analysis would allow more realistic simulations of the complex processes and relationships behind many natural processes. This will have practical applications in everything from precision medicine to regional climate, water use to materials science, nuclear physics to national security.","Exascale Computer System | Exascale Computing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520517","12q24.21","C13910","A chromosome band present on 12q","12q24.21 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540302","HIV-1 and HIV-2 Antibodies and HIV p24 Antigen Measurement","C142278","The determination of the amount of HIV-1 antibody, HIV-2 antibody, and HIV p24 antigen present in a sample.","HIV-1 and HIV-2 Antibodies and HIV p24 Antigen Measurement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521301","3q13.1-q13.2","C13924","A chromosome band present on 3q","3q13.1-q13.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520375","11pter-p13","C13925","A chromosome band present on 11p","11pter-p13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526899","Prognostic Stage IIB Breast Cancer AJCC v8","C139572","Stage IIB includes: (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)","Prognostic Stage IIB Breast Cancer AJCC v8 | Prognostic Stage IIB Breast Carcinoma AJCC v8 | Stage IIB Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526898","Synchronous Nodules with Dominant Lesion(s)","C139573","A finding of multiple pulmonary nodules in which radiologic imaging demonstrates the presence of a dominant lesion.","Synchronous Nodules with Dominant Lesion(s) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526897","Synchronous Nodules without Dominant Lesion(s)","C139574","A finding of multiple pulmonary nodules in which radiologic imaging shows no evidence of a dominant lesion.","Synchronous Nodules without Dominant Lesion(s) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526902","Device Incorrectly Reprocessed","C139575","Problems associated with the failure to properly and adequately reprocess the device.","Device Incorrectly Reprocessed | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526901","Sterilization Problem Identified","C139576","Problems that occurred during terminal sterilization by the manufacturer.","Sterilization Problem Identified | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0475286","Stage R",,,,,,,,,,,,,,,,,,"4077124","Residual tumor stage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1521020","1q43-q44","C13957","A chromosome band present on 1q","1q43-q44 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021948","Invertebrate","C14228","An animal lacking a vertebral column. This group consists of 98% of all animal species.","Invertebrate | Invertebrata | Invertebrates | Invertebrates, General",,,,,,,,,,,,,,,"4165774","Invertebrate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540496","FDA Not Approvable Letter","C142554","A letter from the Food and Drug Administration to a study sponsor indicating deficiencies in an application that preclude approval of a drug, device, or treatment.","FDA Not Approvable Letter | not approvable letter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540495","FDA Regulation Preamble","C142555","A section preceding the text of a final FDA regulation published in the Federal Register. (FDA)","FDA Regulation Preamble | preamble",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540494","FDA Warning Letter","C142556","A written communication from FDA notifying an individual or firm that the agency considers one or more products, practices, processes, or other activities to be in violation of the Federal FD&C Act, or other acts, and that failure of the responsible party to take appropriate and prompt action to correct and prevent any future repeat of the violation may result in administrative and/or regulatory enforcement action without further notice. (FDA)","FDA Warning Letter | Warning Letter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL526910","Prognostic Stage I Breast Cancer AJCC v8","C139556","Stage I includes: IA: (T1, N0, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T1, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (T0-1, N1mi, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T0-1, N1mi, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (MultiGene Panel-Oncotype Dx Recurrence Score Less Than 11, T1-2, N0, M0, G1-3, HER2 Status: Negative, ER Status: Positive, PR Status: Any); IB: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1-3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N1, M0, G1-3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N1, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1-2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)","Prognostic Stage I Breast Cancer AJCC v8 | Prognostic Stage I Breast Carcinoma AJCC v8 | Stage I Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542260","Grade 1 Anorgasmia, CTCAE","C143982","Inability to achieve orgasm not adversely affecting relationship","Grade 1 Anorgasmia, CTCAE | Grade 1 Anorgasmia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542245","Grade 1 Anosmia, CTCAE","C143983","Present","Grade 1 Anosmia, CTCAE | Grade 1 Anosmia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542246","Grade 1 Aortic Valve Disease, CTCAE","C143984","Asymptomatic valvular thickening with or without mild valvular regurgitation or stenosis by imaging","Grade 1 Aortic Valve Disease, CTCAE | Grade 1 Aortic valve disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542247","Grade 1 Arachnoiditis, CTCAE","C143985","Mild symptoms","Grade 1 Arachnoiditis, CTCAE | Grade 1 Arachnoiditis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542248","Grade 1 Arterial Injury, CTCAE","C143986","Asymptomatic diagnostic finding; intervention not indicated","Grade 1 Arterial Injury, CTCAE | Grade 1 Arterial injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542249","Grade 1 Arthralgia, CTCAE","C143987","Mild pain","Grade 1 Arthralgia, CTCAE | Grade 1 Arthralgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542251","Grade 1 Ascites, CTCAE","C143989","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Ascites, CTCAE | Grade 1 Ascites",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511452","CRDH, Rat Strain","C14398","Non-insulin-dependent overt diabetes: blood glucose 384+/- 134 mg/dl (plasma insulin at 60 min following intragastric glucose load 83.3 +/-10.2mU/mL) and hypertension blood pressure 176 +/-8mmHg. There was severe diffuse diabetic glomerulosclerosis and severe hypertensive changes in arteries and arterioles characterised by fibrinoid necrosis and/or onion skin lesions as well as smooth muscle hyperplasia. Myocardial changes were prominent, with foci of ischemic necrosis and hyperplastic vascular changes.","CRDH, Rat Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542252","Grade 1 Aspartate Aminotransferase Increased, CTCAE","C143990",">ULN-3.0 x ULN if baseline was normal; 1.5-3.0 x baseline if baseline was abnormal","Grade 1 Aspartate Aminotransferase Increased, CTCAE | Grade 1 Aspartate aminotransferase increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542237","Grade 1 Atrioventricular Block First Degree, CTCAE","C143991","Asymptomatic, intervention not indicated","Grade 1 Atrioventricular Block First Degree, CTCAE | Grade 1 Atrioventricular block first degree",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542238","Grade 1 Autoimmune Disorder, CTCAE","C143992","Asymptomatic; serologic or other evidence of autoimmune reaction, with normal organ function; intervention not indicated","Grade 1 Autoimmune Disorder, CTCAE | Grade 1 Autoimmune disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542239","Grade 1 Avascular Necrosis, CTCAE","C143993","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Avascular Necrosis, CTCAE | Grade 1 Avascular necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542241","Grade 1 Bile Duct Stenosis, CTCAE","C143995","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Bile Duct Stenosis, CTCAE | Grade 1 Bile duct stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542242","Grade 1 Biliary Anastomotic Leak, CTCAE","C143996","Asymptomatic diagnostic finding; intervention not indicated","Grade 1 Biliary Anastomotic Leak, CTCAE | Grade 1 Biliary anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542243","Grade 1 Bladder Anastomotic Leak, CTCAE","C143997","Asymptomatic diagnostic finding; intervention not indicated","Grade 1 Bladder Anastomotic Leak, CTCAE | Grade 1 Bladder anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542564","Grade 1 Pregnancy, Puerperium and Perinatal Conditions - Other, Specify, CTCAE","C144346","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Pregnancy, Puerperium and Perinatal Conditions - Other, Specify, CTCAE | Grade 1 Pregnancy, puerperium and perinatal conditions - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542549","Grade 1 Premature Delivery, CTCAE","C144347","Delivery of a liveborn infant at >34 to 37 weeks gestation","Grade 1 Premature Delivery, CTCAE | Grade 1 Premature delivery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542550","Grade 1 Productive Cough, CTCAE","C144348","Occasional/minimal production of sputum with cough","Grade 1 Productive Cough, CTCAE | Grade 1 Productive cough",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543001","Grade 2 Lung Infection, CTCAE","C144826","Moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Lung Infection, CTCAE | Grade 2 Lung infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543002","Grade 2 Lymph Gland Infection, CTCAE","C144827","Localized; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Lymph Gland Infection, CTCAE | Grade 2 Lymph gland infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543003","Grade 2 Lymph Leakage, CTCAE","C144828","Symptomatic; medical intervention indicated","Grade 2 Lymph Leakage, CTCAE | Grade 2 Lymph leakage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543004","Grade 2 Lymphedema, CTCAE","C144829","Marked discoloration; leathery skin texture; papillary formation; limiting instrumental ADL","Grade 2 Lymphedema, CTCAE | Grade 2 Lymphedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542989","Grade 2 Lymphocyte Count Decreased, CTCAE","C144830","<800-500/mm3; <0.8-0.5 x 10e9/L","Grade 2 Lymphocyte Count Decreased, CTCAE | Grade 2 Lymphocyte count decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542991","Grade 2 Malaise, CTCAE","C144832","Uneasiness or lack of well being limiting instrumental ADL","Grade 2 Malaise, CTCAE | Grade 2 Malaise",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542992","Grade 2 Mania, CTCAE","C144833","Moderate manic symptoms (e.g., relationship and work difficulties; poor hygiene)","Grade 2 Mania, CTCAE | Grade 2 Mania",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543412","Grade 3 Cytokine Release Syndrome, CTCAE","C145216","Hypotension managed with one pressor; hypoxia requiring >= 40% O2","Grade 3 Cytokine Release Syndrome, CTCAE | Grade 3 Cytokine release syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543397","Grade 3 Cytomegalovirus Infection Reactivation, CTCAE","C145217","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; IV intervention indicated","Grade 3 Cytomegalovirus Infection Reactivation, CTCAE | Grade 3 Cytomegalovirus infection reactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543398","Grade 3 Delirium, CTCAE","C145218","Severe and acute confusional state; limiting self care ADL; urgent intervention indicated; new onset","Grade 3 Delirium, CTCAE | Grade 3 Delirium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543399","Grade 3 Delusions, CTCAE","C145219","Severe delusional symptoms; hospitalization not indicated; new onset","Grade 3 Delusions, CTCAE | Grade 3 Delusions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543400","Grade 3 Dental Caries, CTCAE","C145220","Dental caries resulting in pulpitis or periapical abscess or resulting in tooth loss","Grade 3 Dental Caries, CTCAE | Grade 3 Dental caries",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543402","Grade 3 Dermatitis Radiation, CTCAE","C145222","Moist desquamation in areas other than skin folds and creases; bleeding induced by minor trauma or abrasion","Grade 3 Dermatitis Radiation, CTCAE | Grade 3 Dermatitis radiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543403","Grade 3 Device Related Infection, CTCAE","C145223","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Device Related Infection, CTCAE | Grade 3 Device related infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543389","Grade 3 Dry Mouth, CTCAE","C145225","Inability to adequately aliment orally; tube feeding or TPN indicated; unstimulated saliva <0.1 ml/min","Grade 3 Dry Mouth, CTCAE | Grade 3 Dry mouth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543390","Grade 3 Duodenal Hemorrhage, CTCAE","C145227","Transfusion indicated; invasive intervention indicated; hospitalization","Grade 3 Duodenal Hemorrhage, CTCAE | Grade 3 Duodenal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543391","Grade 3 Duodenal Infection, CTCAE","C145228","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Duodenal Infection, CTCAE | Grade 3 Duodenal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542340","Grade 1 Hyperglycemia, CTCAE","C144161","Abnormal glucose above baseline with no medical intervention","Grade 1 Hyperglycemia, CTCAE | Grade 1 Hyperglycemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542325","Grade 1 Hyperhidrosis, CTCAE","C144162","Limited to one site (palms, soles, or axillae); self care interventions","Grade 1 Hyperhidrosis, CTCAE | Grade 1 Hyperhidrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542327","Grade 1 Hyperkeratosis, CTCAE","C144164","Present","Grade 1 Hyperkeratosis, CTCAE | Grade 1 Hyperkeratosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542328","Grade 1 Hyperlipidemia, CTCAE","C144165","Requiring diet changes","Grade 1 Hyperlipidemia, CTCAE | Grade 1 Hyperlipidemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542329","Grade 1 Hypermagnesemia, CTCAE","C144166",">ULN-3.0 mg/dL; >ULN-1.23 mmol/L","Grade 1 Hypermagnesemia, CTCAE | Grade 1 Hypermagnesemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542330","Grade 1 Hypernatremia, CTCAE","C144167",">ULN-150 mmol/L","Grade 1 Hypernatremia, CTCAE | Grade 1 Hypernatremia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542331","Grade 1 Hyperparathyroidism, CTCAE","C144168","Mild symptoms; intervention not indicated","Grade 1 Hyperparathyroidism, CTCAE | Grade 1 Hyperparathyroidism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542332","Grade 1 Hyperphosphatemia, CTCAE","C144169","Laboratory finding only and intervention not indicated","Grade 1 Hyperphosphatemia, CTCAE | Grade 1 Hyperphosphatemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542445","Grade 1 Hypersomnia, CTCAE","C144170","Mild increased need for sleep","Grade 1 Hypersomnia, CTCAE | Grade 1 Hypersomnia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542446","Grade 1 Hyperthyroidism, CTCAE","C144171","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Hyperthyroidism, CTCAE | Grade 1 Hyperthyroidism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542447","Grade 1 Hypertrichosis, CTCAE","C144172","Increase in length, thickness or density of hair that the patient is either able to camouflage by periodic shaving or removal of hairs or is not concerned enough about the overgrowth to use any form of hair removal","Grade 1 Hypertrichosis, CTCAE | Grade 1 Hypertrichosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542448","Grade 1 Hypertriglyceridemia, CTCAE","C144173","150 mg/dL-300 mg/dL; 1.71 mmol/L-3.42 mmol/L","Grade 1 Hypertriglyceridemia, CTCAE | Grade 1 Hypertriglyceridemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542449","Grade 1 Hyperuricemia, CTCAE","C144174",">ULN without physiologic consequences","Grade 1 Hyperuricemia, CTCAE | Grade 1 Hyperuricemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542450","Grade 1 Hypoalbuminemia, CTCAE","C144175","<LLN-3 g/dL; <LLN-30 g/L","Grade 1 Hypoalbuminemia, CTCAE | Grade 1 Hypoalbuminemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542451","Grade 1 Hypocalcemia, CTCAE","C144176","Corrected serum calcium of <LLN-8.0 mg/dL; <LLN-2.0 mmol/L; Ionized calcium <LLN-1.0 mmol/L","Grade 1 Hypocalcemia, CTCAE | Grade 1 Hypocalcemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542437","Grade 1 Hypoglycemia, CTCAE","C144178","<LLN-55 mg/dL; <LLN-3.0 mmol/L","Grade 1 Hypoglycemia, CTCAE | Grade 1 Hypoglycemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542438","Grade 1 Hypokalemia, CTCAE","C144179","<LLN-3.0 mmol/L","Grade 1 Hypokalemia, CTCAE | Grade 1 Hypokalemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514734","Rat Strains","C14417","Breeds of rats utilized for biological research.","Rat Strains | Common Rat Strains",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542439","Grade 1 Hypomagnesemia, CTCAE","C144180","<LLN-1.2 mg/dL; <LLN-0.5 mmol/L","Grade 1 Hypomagnesemia, CTCAE | Grade 1 Hypomagnesemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542440","Grade 1 Hyponatremia, CTCAE","C144181","<LLN-130 mmol/L","Grade 1 Hyponatremia, CTCAE | Grade 1 Hyponatremia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542441","Grade 1 Hypoparathyroidism, CTCAE","C144182","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Hypoparathyroidism, CTCAE | Grade 1 Hypoparathyroidism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542788","Grade 2 Esophageal Stenosis, CTCAE","C144649","Symptomatic; altered GI function","Grade 2 Esophageal Stenosis, CTCAE | Grade 2 Esophageal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542773","Grade 2 Esophageal Ulcer, CTCAE","C144650","Symptomatic; altered GI function; limiting instrumental ADL","Grade 2 Esophageal Ulcer, CTCAE | Grade 2 Esophageal ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542774","Grade 2 Extraocular Muscle Paresis, CTCAE","C144651","Unilateral paresis without double vision","Grade 2 Extraocular Muscle Paresis, CTCAE | Grade 2 Extraocular muscle paresis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542775","Grade 2 Extrapyramidal Disorder, CTCAE","C144652","Moderate involuntary movements; limiting instrumental ADL","Grade 2 Extrapyramidal Disorder, CTCAE | Grade 2 Extrapyramidal disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542776","Grade 2 Eye Disorders - Other, Specify, CTCAE","C144653","Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL; best corrected visual acuity 20/40 and better or 3 lines or less decreased vision from known baseline","Grade 2 Eye Disorders - Other, Specify, CTCAE | Grade 2 Eye disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542777","Grade 2 Eye Infection, CTCAE","C144654","Localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral)","Grade 2 Eye Infection, CTCAE | Grade 2 Eye infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542780","Grade 2 Facial Nerve Disorder, CTCAE","C144657","Moderate symptoms; limiting instrumental ADL","Grade 2 Facial Nerve Disorder, CTCAE | Grade 2 Facial nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542893","Grade 2 Facial Pain, CTCAE","C144658","Moderate pain; limiting instrumental ADL","Grade 2 Facial Pain, CTCAE | Grade 2 Facial pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543182","Grade 2 Tracheitis, CTCAE","C145046","Moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Tracheitis, CTCAE | Grade 2 Tracheitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543183","Grade 2 Tracheostomy Site Bleeding, CTCAE","C145047","Moderate bleeding; medical intervention indicated","Grade 2 Tracheostomy Site Bleeding, CTCAE | Grade 2 Tracheostomy site bleeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543184","Grade 2 Transient Ischemic Attacks, CTCAE","C145048","Moderate neurologic deficit with or without imaging confirmation","Grade 2 Transient Ischemic Attacks, CTCAE | Grade 2 Transient ischemic attacks",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543186","Grade 2 Trigeminal Nerve Disorder, CTCAE","C145050","Moderate symptoms; limiting instrumental ADL","Grade 2 Trigeminal Nerve Disorder, CTCAE | Grade 2 Trigeminal nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543187","Grade 2 Trochlear Nerve Disorder, CTCAE","C145051","Moderate symptoms; limiting instrumental ADL","Grade 2 Trochlear Nerve Disorder, CTCAE | Grade 2 Trochlear nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543188","Grade 2 Tumor Hemorrhage, CTCAE","C145052","Moderate symptoms; intervention indicated","Grade 2 Tumor Hemorrhage, CTCAE | Grade 2 Tumor hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543173","Grade 2 Unequal Limb Length, CTCAE","C145053","Moderate length discrepancy 2-5 cm; shoe lift indicated; limiting instrumental ADL","Grade 2 Unequal Limb Length, CTCAE | Grade 2 Unequal limb length",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543174","Grade 2 Upper Gastrointestinal Hemorrhage, CTCAE","C145054","Moderate symptoms; intervention indicated","Grade 2 Upper Gastrointestinal Hemorrhage, CTCAE | Grade 2 Upper gastrointestinal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543175","Grade 2 Upper Respiratory Infection, CTCAE","C145055","Moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Upper Respiratory Infection, CTCAE | Grade 2 Upper respiratory infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543176","Grade 2 Ureteric Anastomotic Leak, CTCAE","C145056","Symptomatic; medical intervention indicated","Grade 2 Ureteric Anastomotic Leak, CTCAE | Grade 2 Ureteric anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543178","Grade 2 Urethral Infection, CTCAE","C145058","Localized; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Urethral Infection, CTCAE | Grade 2 Urethral infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542552","Grade 1 Prolapse of Urostomy, CTCAE","C144350","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Prolapse of Urostomy, CTCAE | Grade 1 Prolapse of urostomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542553","Grade 1 Prostatic Obstruction, CTCAE","C144352","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Prostatic Obstruction, CTCAE | Grade 1 Prostatic obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542554","Grade 1 Prostatic Pain, CTCAE","C144353","Mild pain","Grade 1 Prostatic Pain, CTCAE | Grade 1 Prostatic pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542555","Grade 1 Psychiatric Disorders - Other, Specify, CTCAE","C144354","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Psychiatric Disorders - Other, Specify, CTCAE | Grade 1 Psychiatric disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542556","Grade 1 Psychosis, CTCAE","C144355","Mild psychotic symptoms","Grade 1 Psychosis, CTCAE | Grade 1 Psychosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542541","Grade 1 Pulmonary Edema, CTCAE","C144356","Radiologic findings only; minimal dyspnea on exertion","Grade 1 Pulmonary Edema, CTCAE | Grade 1 Pulmonary edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542542","Grade 1 Pulmonary Fibrosis, CTCAE","C144357","Radiologic pulmonary fibrosis <25% of lung volume associated with hypoxia","Grade 1 Pulmonary Fibrosis, CTCAE | Grade 1 Pulmonary fibrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542544","Grade 1 Pulmonary Valve Disease, CTCAE","C144359","Asymptomatic valvular thickening with or without mild valvular regurgitation or stenosis by imaging","Grade 1 Pulmonary Valve Disease, CTCAE | Grade 1 Pulmonary valve disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542545","Grade 1 Purpura, CTCAE","C144360","Combined area of lesions covering <10% BSA","Grade 1 Purpura, CTCAE | Grade 1 Purpura",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542546","Grade 1 Pyramidal Tract Syndrome, CTCAE","C144361","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Pyramidal Tract Syndrome, CTCAE | Grade 1 Pyramidal tract syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542547","Grade 1 Radiation Recall Reaction (Dermatologic), CTCAE","C144362","Faint erythema or dry desquamation","Grade 1 Radiation Recall Reaction (Dermatologic), CTCAE | Grade 1 Radiation recall reaction (dermatologic)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542548","Grade 1 Radiculitis, CTCAE","C144363","Mild symptoms","Grade 1 Radiculitis, CTCAE | Grade 1 Radiculitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542533","Grade 1 Rash Acneiform, CTCAE","C144364","Papules and/or pustules covering <10% BSA, which may or may not be associated with symptoms of pruritus or tenderness","Grade 1 Rash Acneiform, CTCAE | Grade 1 Rash acneiform",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542535","Grade 1 Rectal Anastomotic Leak, CTCAE","C144366","Asymptomatic diagnostic finding; intervention not indicated","Grade 1 Rectal Anastomotic Leak, CTCAE | Grade 1 Rectal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542536","Grade 1 Rectal Fissure, CTCAE","C144367","Asymptomatic","Grade 1 Rectal Fissure, CTCAE | Grade 1 Rectal fissure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542537","Grade 1 Rectal Mucositis, CTCAE","C144370","Asymptomatic or mild symptoms; intervention not indicated","Grade 1 Rectal Mucositis, CTCAE | Grade 1 Rectal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542538","Grade 1 Rectal Pain, CTCAE","C144372","Mild pain","Grade 1 Rectal Pain, CTCAE | Grade 1 Rectal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542539","Grade 1 Rectal Stenosis, CTCAE","C144373","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Rectal Stenosis, CTCAE | Grade 1 Rectal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542540","Grade 1 Recurrent Laryngeal Nerve Palsy, CTCAE","C144375","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Recurrent Laryngeal Nerve Palsy, CTCAE | Grade 1 Recurrent laryngeal nerve palsy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542950","Grade 2 Hypersomnia, CTCAE","C144731","Moderate increased need for sleep","Grade 2 Hypersomnia, CTCAE | Grade 2 Hypersomnia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543392","Grade 3 Duodenal Obstruction, CTCAE","C145229","Hospitalization indicated; invasive intervention indicated","Grade 3 Duodenal Obstruction, CTCAE | Grade 3 Duodenal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543393","Grade 3 Duodenal Perforation, CTCAE","C145230","Invasive intervention indicated","Grade 3 Duodenal Perforation, CTCAE | Grade 3 Duodenal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543394","Grade 3 Duodenal Stenosis, CTCAE","C145231","Severely altered GI function; tube feeding or hospitalization indicated; elective operative intervention indicated","Grade 3 Duodenal Stenosis, CTCAE | Grade 3 Duodenal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543395","Grade 3 Duodenal Ulcer, CTCAE","C145232","Severely altered GI function; TPN indicated; elective invasive intervention indicated; limiting self care ADL","Grade 3 Duodenal Ulcer, CTCAE | Grade 3 Duodenal ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543396","Grade 3 Dysarthria, CTCAE","C145233","Severe impairment of articulation or slurred speech","Grade 3 Dysarthria, CTCAE | Grade 3 Dysarthria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543381","Grade 3 Dysesthesia, CTCAE","C145234","Severe sensory alteration; limiting self care ADL","Grade 3 Dysesthesia, CTCAE | Grade 3 Dysesthesia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543382","Grade 3 Dysmenorrhea, CTCAE","C145235","Severe symptoms; limiting self care ADL","Grade 3 Dysmenorrhea, CTCAE | Grade 3 Dysmenorrhea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543384","Grade 3 Dyspepsia, CTCAE","C145237","Severe symptoms; operative intervention indicated","Grade 3 Dyspepsia, CTCAE | Grade 3 Dyspepsia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512602","IR, Rat Strain","C14405","Vigorous and healthy, but high incidence of physical abnormalities. Skulls of young fragile through weaning. High death rate from hemorrhage due to blood platelet disease (Harrington 1981). Long latency to emerge into familiar environment (12/12 males, 10/12 females) (Harrington 1971a). High open field exploration in females (3/12) (Harrington 1972). Low wheel activity (11/12 males10/12 females) (Harrington 1971b).","IR, Rat Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542304","Grade 1 Dysarthria, CTCAE","C144060","Mild slurred speech","Grade 1 Dysarthria, CTCAE | Grade 1 Dysarthria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542305","Grade 1 Dysesthesia, CTCAE","C144061","Mild sensory alteration","Grade 1 Dysesthesia, CTCAE | Grade 1 Dysesthesia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542306","Grade 1 Dysgeusia, CTCAE","C144062","Altered taste but no change in diet","Grade 1 Dysgeusia, CTCAE | Grade 1 Dysgeusia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542307","Grade 1 Dysmenorrhea, CTCAE","C144063","Mild symptoms; intervention not indicated","Grade 1 Dysmenorrhea, CTCAE | Grade 1 Dysmenorrhea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542308","Grade 1 Dyspareunia, CTCAE","C144064","Mild discomfort or pain associated with vaginal penetration; discomfort relieved with use of vaginal lubricants or estrogen","Grade 1 Dyspareunia, CTCAE | Grade 1 Dyspareunia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542295","Grade 1 Dysuria, CTCAE","C144067","Present","Grade 1 Dysuria, CTCAE | Grade 1 Dysuria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542296","Grade 1 Ear and Labyrinth Disorders - Other, Specify, CTCAE","C144068","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Ear and Labyrinth Disorders - Other, Specify, CTCAE | Grade 1 Ear and labyrinth disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542297","Grade 1 Ear Pain, CTCAE","C144069","Mild pain","Grade 1 Ear Pain, CTCAE | Grade 1 Ear pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542442","Grade 1 Hypophosphatemia, CTCAE","C144183","Laboratory finding only and intervention not indicated","Grade 1 Hypophosphatemia, CTCAE | Grade 1 Hypophosphatemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542443","Grade 1 Hypophysitis, CTCAE","C144184","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Hypophysitis, CTCAE | Grade 1 Hypophysitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542736","Grade 2 Budd-Chiari Syndrome, CTCAE","C144563","Medical management indicated","Grade 2 Budd-Chiari Syndrome, CTCAE | Grade 2 Budd-Chiari syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542737","Grade 2 Bullous Dermatitis, CTCAE","C144564","Blisters covering 10-30% BSA; painful blisters; limiting instrumental ADL","Grade 2 Bullous Dermatitis, CTCAE | Grade 2 Bullous dermatitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542738","Grade 2 Capillary Leak Syndrome, CTCAE","C144565","Symptomatic; medical intervention indicated","Grade 2 Capillary Leak Syndrome, CTCAE | Grade 2 Capillary leak syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542739","Grade 2 Carbon Monoxide Diffusing Capacity Decreased, CTCAE","C144566","6-8 units below LLN; for follow-up, an asymptomatic decrease of >5-8 units (ml/min/mm Hg) below the baseline value; symptomatic and intervention not indicated","Grade 2 Carbon Monoxide Diffusing Capacity Decreased, CTCAE | Grade 2 Carbon monoxide diffusing capacity decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542740","Grade 2 Cardiac Disorders - Other, Specify, CTCAE","C144567","Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL","Grade 2 Cardiac Disorders - Other, Specify, CTCAE | Grade 2 Cardiac disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542725","Grade 2 Catheter Related Infection, CTCAE","C144568","Localized; local intervention indicated; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Catheter Related Infection, CTCAE | Grade 2 Catheter related infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542727","Grade 2 Cecal Hemorrhage, CTCAE","C144570","Moderate symptoms; intervention indicated","Grade 2 Cecal Hemorrhage, CTCAE | Grade 2 Cecal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542728","Grade 2 Cecal Infection, CTCAE","C144571","Localized; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Cecal Infection, CTCAE | Grade 2 Cecal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542729","Grade 2 Central Nervous System Necrosis, CTCAE","C144572","Moderate symptoms; corticosteroids indicated","Grade 2 Central Nervous System Necrosis, CTCAE | Grade 2 Central nervous system necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542730","Grade 2 Cerebrospinal Fluid Leakage, CTCAE","C144573","Post-craniotomy: moderate symptoms; medical intervention indicated; Post-lumbar puncture: persistent moderate symptoms; blood patch indicated","Grade 2 Cerebrospinal Fluid Leakage, CTCAE | Grade 2 Cerebrospinal fluid leakage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542731","Grade 2 Cervicitis Infection, CTCAE","C144574","Localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral)","Grade 2 Cervicitis Infection, CTCAE | Grade 2 Cervicitis infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542732","Grade 2 Chest Pain - Cardiac, CTCAE","C144575","Moderate pain; pain on exertion; limiting instrumental ADL; hemodynamically stable","Grade 2 Chest Pain - Cardiac, CTCAE | Grade 2 Chest pain - cardiac",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542717","Grade 2 Chest Wall Necrosis, CTCAE","C144576","Local wound care; medical intervention indicated (e.g., dressings or topical medications)","Grade 2 Chest Wall Necrosis, CTCAE | Grade 2 Chest wall necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542719","Grade 2 Cholesterol High, CTCAE","C144578",">300-400 mg/dL; >7.75-10.34 mmol/L","Grade 2 Cholesterol High, CTCAE | Grade 2 Cholesterol high",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542720","Grade 2 Chronic Kidney Disease, CTCAE","C144579","eGFR or CrCl 59-30 ml/min/1.73 m2","Grade 2 Chronic Kidney Disease, CTCAE | Grade 2 Chronic kidney disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542721","Grade 2 Chylous Ascites, CTCAE","C144580","Symptomatic; medical intervention indicated (e.g., fat-restricted diet); paracentesis or tube drainage indicated","Grade 2 Chylous Ascites, CTCAE | Grade 2 Chylous ascites",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543179","Grade 2 Urinary Fistula, CTCAE","C145059","Symptomatic, invasive intervention not indicated","Grade 2 Urinary Fistula, CTCAE | Grade 2 Urinary fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543180","Grade 2 Urinary Frequency, CTCAE","C145060","Limiting instrumental ADL; medical management indicated","Grade 2 Urinary Frequency, CTCAE | Grade 2 Urinary frequency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543165","Grade 2 Urinary Tract Infection, CTCAE","C145061","Localized; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Urinary Tract Infection, CTCAE | Grade 2 Urinary tract infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543166","Grade 2 Urinary Tract Obstruction, CTCAE","C145062","Symptomatic but no hydronephrosis, sepsis, or renal dysfunction; urethral dilation, urinary or suprapubic catheter indicated","Grade 2 Urinary Tract Obstruction, CTCAE | Grade 2 Urinary tract obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543167","Grade 2 Urinary Tract Pain, CTCAE","C145063","Moderate pain; limiting instrumental ADL","Grade 2 Urinary Tract Pain, CTCAE | Grade 2 Urinary tract pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543169","Grade 2 Urostomy Leak, CTCAE","C145065","Symptomatic; medical intervention indicated","Grade 2 Urostomy Leak, CTCAE | Grade 2 Urostomy leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543170","Grade 2 Urostomy Obstruction, CTCAE","C145066","Symptomatic; dilation or endoscopic repair or stent placement indicated","Grade 2 Urostomy Obstruction, CTCAE | Grade 2 Urostomy obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543171","Grade 2 Urostomy Site Bleeding, CTCAE","C145067","Moderate bleeding; medical intervention indicated","Grade 2 Urostomy Site Bleeding, CTCAE | Grade 2 Urostomy site bleeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520117","W/Nhg, Rat Strain","C14391","High incidence (97% in females, 36% in males) of spontaneous thymomas starting from about one year of age. They sometimes caused dyspnea, and were occasionally the cause of death, but were not associated with any myopathies or autoimmune disease (Murray et al 1985).","W/Nhg, Rat Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542951","Grade 2 Hyperthyroidism, CTCAE","C144732","Symptomatic; thyroid suppression therapy indicated; limiting instrumental ADL","Grade 2 Hyperthyroidism, CTCAE | Grade 2 Hyperthyroidism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542952","Grade 2 Hypertrichosis, CTCAE","C144733","Increase in length, thickness or density of hair at least on the usual exposed areas of the body [face (not limited to beard/moustache area) plus/minus arms] that requires frequent shaving or use of destructive means of hair removal to camouflage; associated with psychosocial impact","Grade 2 Hypertrichosis, CTCAE | Grade 2 Hypertrichosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542953","Grade 2 Hypertriglyceridemia, CTCAE","C144734",">300 mg/dL-500 mg/dL; >3.42 mmol/L-5.7 mmol/L","Grade 2 Hypertriglyceridemia, CTCAE | Grade 2 Hypertriglyceridemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542954","Grade 2 Hypoalbuminemia, CTCAE","C144735","<3-2 g/dL; <30-20 g/L","Grade 2 Hypoalbuminemia, CTCAE | Grade 2 Hypoalbuminemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542955","Grade 2 Hypocalcemia, CTCAE","C144736","Corrected serum calcium of <8.0-7.0 mg/dL; <2.0-1.75 mmol/L; Ionized calcium <1.0-0.9 mmol/L; symptomatic","Grade 2 Hypocalcemia, CTCAE | Grade 2 Hypocalcemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542956","Grade 2 Hypoglossal Nerve Disorder, CTCAE","C144737","Moderate symptoms; limiting instrumental ADL","Grade 2 Hypoglossal Nerve Disorder, CTCAE | Grade 2 Hypoglossal nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542942","Grade 2 Hypohidrosis, CTCAE","C144739","Symptomatic; limiting instrumental ADL","Grade 2 Hypohidrosis, CTCAE | Grade 2 Hypohidrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542943","Grade 2 Hypokalemia, CTCAE","C144740","Symptomatic with <LLN-3.0 mmol/L; intervention indicated","Grade 2 Hypokalemia, CTCAE | Grade 2 Hypokalemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542944","Grade 2 Hypomagnesemia, CTCAE","C144741","<1.2-0.9 mg/dL; <0.5-0.4 mmol/L","Grade 2 Hypomagnesemia, CTCAE | Grade 2 Hypomagnesemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542945","Grade 2 Hyponatremia, CTCAE","C144742","125-129 mmol/L and asymptomatic","Grade 2 Hyponatremia, CTCAE | Grade 2 Hyponatremia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542946","Grade 2 Hypoparathyroidism, CTCAE","C144743","Moderate symptoms; medical intervention indicated","Grade 2 Hypoparathyroidism, CTCAE | Grade 2 Hypoparathyroidism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542947","Grade 2 Hypophosphatemia, CTCAE","C144744","Oral replacement therapy indicated","Grade 2 Hypophosphatemia, CTCAE | Grade 2 Hypophosphatemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542933","Grade 2 Hypopituitarism, CTCAE","C144746","Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL","Grade 2 Hypopituitarism, CTCAE | Grade 2 Hypopituitarism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542934","Grade 2 Hypothyroidism, CTCAE","C144747","Symptomatic; thyroid replacement indicated; limiting instrumental ADL","Grade 2 Hypothyroidism, CTCAE | Grade 2 Hypothyroidism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542935","Grade 2 Ileal Perforation, CTCAE","C144751","Invasive intervention not indicated","Grade 2 Ileal Perforation, CTCAE | Grade 2 Ileal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542936","Grade 2 Ileal Stenosis, CTCAE","C144752","Symptomatic; altered GI function","Grade 2 Ileal Stenosis, CTCAE | Grade 2 Ileal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542937","Grade 2 Immune System Disorders - Other, Specify, CTCAE","C144755","Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL","Grade 2 Immune System Disorders - Other, Specify, CTCAE | Grade 2 Immune system disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517686","LEC, Rat Strain","C14406","Carries a mutation causing fulminated hepatitis and jaundice at about four months of age. Clinical symptoms include severe jaundice, bleeding, oliguria, loss of body weight and elevation of serum levels of bilirubin and hepatic enzymes. About half the animals die within a week of onset, and in survivors hepatocellular carcinoma spontaneously appears after 1-1.5 years (Kasai et al 1990,Sasaki 1985, Wirth et al 1990).","LEC, Rat Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542298","Grade 1 Eczema, CTCAE","C144070","Asymptomatic or mild symptoms; additional medical intervention over baseline not indicated","Grade 1 Eczema, CTCAE | Grade 1 Eczema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542300","Grade 1 Edema Limbs, CTCAE","C144072","5-10% inter-limb discrepancy in volume or circumference at point of greatest visible difference; swelling or obscuration of anatomic architecture on close inspection","Grade 1 Edema Limbs, CTCAE | Grade 1 Edema limbs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542285","Grade 1 Edema Trunk, CTCAE","C144073","Swelling or obscuration of anatomic architecture on close inspection","Grade 1 Edema Trunk, CTCAE | Grade 1 Edema trunk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542286","Grade 1 Ejaculation Disorder, CTCAE","C144074","Diminished ejaculation","Grade 1 Ejaculation Disorder, CTCAE | Grade 1 Ejaculation disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542287","Grade 1 Electrocardiogram QT Corrected Interval Prolonged, CTCAE","C144075","Average QTc 450-480 ms","Grade 1 Electrocardiogram QT Corrected Interval Prolonged, CTCAE | Grade 1 Electrocardiogram QT corrected interval prolonged",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542288","Grade 1 Electrocardiogram T Wave Abnormal, CTCAE","C144076","T wave flattening","Grade 1 Electrocardiogram T Wave Abnormal, CTCAE | Grade 1 Electrocardiogram T wave abnormal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542290","Grade 1 Endocrine Disorders - Other, Specify, CTCAE","C144078","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Endocrine Disorders - Other, Specify, CTCAE | Grade 1 Endocrine disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542291","Grade 1 Enterocolitis, CTCAE","C144079","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Enterocolitis, CTCAE | Grade 1 Enterocolitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517687","LEW, Rat Strain","C14407","Of the large spectrum of 52 histologically different types of tumors, the highest incidence was observed for adenomas of the pituitary and adenomas/adenocarcinomas of the adrenal cortex in both sexes, mammary gland tumors and endometrial carcinomas (45%) in females, and C-cell adenomas/adenocarcinomas of the thyroid gland and tumors of the hemopoietic system (28%) in males (Baum et al, 1995).","LEW, Rat Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1562010","Pulmonary Langerhans Cell Histiocytosis","C142833","Langerhans cell histiocytosis affecting the lungs. It is characterized by an interstitial proliferation of Langerhans cells in the lung parenchyma. Most patients are current or former smokers. Steroids are the mainstay therapy for this condition.","Pulmonary Langerhans Cell Histiocytosis | PLCH | Pulmonary Eosinophilic Granuloma | Pulmonary Histiocytosis X",,,,,,,,,,,,,,,"4213396","Langerhans cell histiocytosis of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL542722","Grade 2 Colonic Fistula, CTCAE","C144581","Symptomatic, invasive intervention not indicated","Grade 2 Colonic Fistula, CTCAE | Grade 2 Colonic fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542723","Grade 2 Colonic Hemorrhage, CTCAE","C144582","Moderate symptoms; intervention indicated","Grade 2 Colonic Hemorrhage, CTCAE | Grade 2 Colonic hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542724","Grade 2 Colonic Obstruction, CTCAE","C144583","Symptomatic; altered GI function","Grade 2 Colonic Obstruction, CTCAE | Grade 2 Colonic obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542710","Grade 2 Colonic Stenosis, CTCAE","C144585","Symptomatic; altered GI function","Grade 2 Colonic Stenosis, CTCAE | Grade 2 Colonic stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543128","Grade 2 Renal Colic, CTCAE","C144972","Moderate pain; limiting instrumental ADL; prescription medication indicated","Grade 2 Renal Colic, CTCAE | Grade 2 Renal colic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543129","Grade 2 Reproductive System and Breast Disorders - Other, Specify, CTCAE","C144974","Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL","Grade 2 Reproductive System and Breast Disorders - Other, Specify, CTCAE | Grade 2 Reproductive system and breast disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543130","Grade 2 Respiratory, Thoracic and Mediastinal Disorders - Other, Specify, CTCAE","C144975","Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL","Grade 2 Respiratory, Thoracic and Mediastinal Disorders - Other, Specify, CTCAE | Grade 2 Respiratory, thoracic and mediastinal disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543131","Grade 2 Restlessness, CTCAE","C144976","Moderate symptoms; limiting instrumental ADL","Grade 2 Restlessness, CTCAE | Grade 2 Restlessness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543132","Grade 2 Retinal Tear, CTCAE","C144977","No retinal detachment and treatment indicated","Grade 2 Retinal Tear, CTCAE | Grade 2 Retinal tear",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543117","Grade 2 Retinal Vascular Disorder, CTCAE","C144978","Retinal vascular disorder without neovascularization","Grade 2 Retinal Vascular Disorder, CTCAE | Grade 2 Retinal vascular disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543119","Grade 2 Reversible Posterior Leukoencephalopathy Syndrome, CTCAE","C144980","Moderate symptoms; limiting instrumental ADL","Grade 2 Reversible Posterior Leukoencephalopathy Syndrome, CTCAE | Grade 2 Reversible posterior leukoencephalopathy syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543120","Grade 2 Rhabdomyolysis, CTCAE","C144981","Non-urgent intervention indicated","Grade 2 Rhabdomyolysis, CTCAE | Grade 2 Rhabdomyolysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543121","Grade 2 Rhinitis Infective, CTCAE","C144982","Localized; local intervention indicated","Grade 2 Rhinitis Infective, CTCAE | Grade 2 Rhinitis infective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543122","Grade 2 Rotator Cuff Injury, CTCAE","C144983","Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL","Grade 2 Rotator Cuff Injury, CTCAE | Grade 2 Rotator cuff injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543123","Grade 2 Salivary Duct Inflammation, CTCAE","C144984","Thick, ropy, sticky saliva; markedly altered taste; alteration in diet indicated; secretion-induced symptoms; limiting instrumental ADL","Grade 2 Salivary Duct Inflammation, CTCAE | Grade 2 Salivary duct inflammation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543124","Grade 2 Salivary Gland Infection, CTCAE","C144985","Moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Salivary Gland Infection, CTCAE | Grade 2 Salivary gland infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543109","Grade 2 Scleral Disorder, CTCAE","C144986","Symptomatic; moderate decrease in visual acuity (best corrected visual acuity 20/40 and better or 3 lines or less decreased vision from known baseline); limiting instrumental ADL","Grade 2 Scleral Disorder, CTCAE | Grade 2 Scleral disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543111","Grade 2 Scrotal Infection, CTCAE","C144988","Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Scrotal Infection, CTCAE | Grade 2 Scrotal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543112","Grade 2 Scrotal Pain, CTCAE","C144989","Moderate pain; limiting instrumental ADL","Grade 2 Scrotal Pain, CTCAE | Grade 2 Scrotal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510682","ACI, Rat Strain","C14392","Median survival 113 weeks in males, 108 weeks in females. Spontaneous tumors 46% testes, 16% adrenal, 5% pituitary, 6% skin and ear duct and fewer of other types in males; 21% pituitary, 13% uterus, 11% mammary gland, 6% adrenal and fewer of other types in females.  Will grow transplantable Morris hepatomas 3924A which can be used as a model for the treatment of liver cancer (Yang et al 1995).","ACI, Rat Strain | ACI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510676","A28807, Rat Strain","C14393","Very docile. Susceptible to the induction of autoimmune thyroiditis. Low and intermediate antibody responses to 1 and 10 g BSA, respectively. Low antibody response to streptococcal group A carbohydrate; not linked to the MHC. High relative heart weight in 10-week old males (20/23).","A28807, Rat Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542506","Grade 1 Menorrhagia, CTCAE","C144260","Mild; iron supplements indicated","Grade 1 Menorrhagia, CTCAE | Grade 1 Menorrhagia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542507","Grade 1 Metabolism and Nutrition Disorders - Other, Specify, CTCAE","C144261","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Metabolism and Nutrition Disorders - Other, Specify, CTCAE | Grade 1 Metabolism and nutrition disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542493","Grade 1 Mitral Valve Disease, CTCAE","C144263","Asymptomatic valvular thickening with or without mild valvular regurgitation or stenosis by imaging","Grade 1 Mitral Valve Disease, CTCAE | Grade 1 Mitral valve disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542494","Grade 1 Movements Involuntary, CTCAE","C144266","Mild symptoms","Grade 1 Movements Involuntary, CTCAE | Grade 1 Movements involuntary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542495","Grade 1 Mucosal Infection, CTCAE","C144267","Localized, local intervention indicated","Grade 1 Mucosal Infection, CTCAE | Grade 1 Mucosal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542496","Grade 1 Mucositis Oral, CTCAE","C144268","Asymptomatic or mild symptoms; intervention not indicated","Grade 1 Mucositis Oral, CTCAE | Grade 1 Mucositis oral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542497","Grade 1 Muscle Cramp, CTCAE","C144269","Mild pain","Grade 1 Muscle Cramp, CTCAE | Grade 1 Muscle cramp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542498","Grade 1 Muscle Weakness Left-Sided, CTCAE","C144270","Symptomatic; perceived by patient but not evident on physical exam","Grade 1 Muscle Weakness Left-Sided, CTCAE | Grade 1 Muscle weakness left-sided",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542938","Grade 2 Infections and Infestations - Other, Specify, CTCAE","C144756","Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL","Grade 2 Infections and Infestations - Other, Specify, CTCAE | Grade 2 Infections and infestations - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542939","Grade 2 Infective Myositis, CTCAE","C144757","Localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral)","Grade 2 Infective Myositis, CTCAE | Grade 2 Infective myositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543341","Grade 3 Arachnoiditis, CTCAE","C145144","Severe symptoms; limiting self care ADL","Grade 3 Arachnoiditis, CTCAE | Grade 3 Arachnoiditis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543342","Grade 3 Arterial Injury, CTCAE","C145145","Severe symptoms; limiting self care ADL; repair or revision indicated","Grade 3 Arterial Injury, CTCAE | Grade 3 Arterial injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543343","Grade 3 Arterial Thromboembolism, CTCAE","C145146","Urgent intervention indicated","Grade 3 Arterial Thromboembolism, CTCAE | Grade 3 Arterial thromboembolism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543344","Grade 3 Arteritis Infective, CTCAE","C145147","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Arteritis Infective, CTCAE | Grade 3 Arteritis infective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543345","Grade 3 Arthralgia, CTCAE","C145148","Severe pain; limiting self care ADL","Grade 3 Arthralgia, CTCAE | Grade 3 Arthralgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543347","Grade 3 Ascites, CTCAE","C145150","Severe symptoms; invasive intervention indicated","Grade 3 Ascites, CTCAE | Grade 3 Ascites",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543348","Grade 3 Aspartate Aminotransferase Increased, CTCAE","C145151",">5.0-20.0 x ULN if baseline was normal; >5.0-20.0 x baseline if baseline was abnormal","Grade 3 Aspartate Aminotransferase Increased, CTCAE | Grade 3 Aspartate aminotransferase increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543333","Grade 3 Atrioventricular Block Complete, CTCAE","C145152","Symptomatic and incompletely controlled medically, or controlled with device (e.g., pacemaker); new onset","Grade 3 Atrioventricular Block Complete, CTCAE | Grade 3 Atrioventricular block complete",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543334","Grade 3 Autoimmune Disorder, CTCAE","C145153","Autoimmune reactions involving major organ (e.g., colitis, anemia, myocarditis, kidney)","Grade 3 Autoimmune Disorder, CTCAE | Grade 3 Autoimmune disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543335","Grade 3 Avascular Necrosis, CTCAE","C145154","Severe symptoms; limiting self care ADL; elective operative intervention indicated","Grade 3 Avascular Necrosis, CTCAE | Grade 3 Avascular necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543336","Grade 3 Bile Duct Stenosis, CTCAE","C145155","Severely altered GI function; invasive intervention indicated","Grade 3 Bile Duct Stenosis, CTCAE | Grade 3 Bile duct stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543337","Grade 3 Biliary Anastomotic Leak, CTCAE","C145156","Severe symptoms; invasive intervention indicated","Grade 3 Biliary Anastomotic Leak, CTCAE | Grade 3 Biliary anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543338","Grade 3 Biliary Fistula, CTCAE","C145157","Invasive intervention indicated","Grade 3 Biliary Fistula, CTCAE | Grade 3 Biliary fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543340","Grade 3 Bladder Anastomotic Leak, CTCAE","C145159","Severe symptoms; invasive intervention indicated","Grade 3 Bladder Anastomotic Leak, CTCAE | Grade 3 Bladder anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543325","Grade 3 Bladder Infection, CTCAE","C145160","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Bladder Infection, CTCAE | Grade 3 Bladder infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542268","Grade 1 Fibrinogen Decreased, CTCAE","C144105","<1.0-0.75 x LLN; if abnormal, <25% decrease from baseline","Grade 1 Fibrinogen Decreased, CTCAE | Grade 1 Fibrinogen decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542381","Grade 1 Fibrosis Deep Connective Tissue, CTCAE","C144106","Mild induration, able to move skin parallel to plane (sliding) and perpendicular to skin (pinching up)","Grade 1 Fibrosis Deep Connective Tissue, CTCAE | Grade 1 Fibrosis deep connective tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542382","Grade 1 Flank Pain, CTCAE","C144107","Mild pain","Grade 1 Flank Pain, CTCAE | Grade 1 Flank pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542383","Grade 1 Flashing Lights, CTCAE","C144108","Symptomatic but not limiting ADL","Grade 1 Flashing Lights, CTCAE | Grade 1 Flashing lights",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542384","Grade 1 Floaters, CTCAE","C144109","Symptomatic but not limiting ADL","Grade 1 Floaters, CTCAE | Grade 1 Floaters",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513813","NBL, Rat Strain","C14410","Good reproductive performance. Hyperplasia and dysplasia of the dorsolateral prostate caused by implantation of testosterone and estradiol-17-filled silastic capsules. Prolonged implantation leads to prostatic carcinoma (Leav et al 1988, 1989).","NBL, Rat Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542385","Grade 1 Flu Like Symptoms, CTCAE","C144110","Mild flu-like symptoms present","Grade 1 Flu Like Symptoms, CTCAE | Grade 1 Flu like symptoms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542386","Grade 1 Folliculitis, CTCAE","C144111","Covering <10% of the body surface area; no intervention indicated","Grade 1 Folliculitis, CTCAE | Grade 1 Folliculitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542387","Grade 1 Forced Expiratory Volume Decreased, CTCAE","C144112","FEV1% (percentages of observed FEV1 and FVC related to their respective predicted values) 99-70% predicted","Grade 1 Forced Expiratory Volume Decreased, CTCAE | Grade 1 Forced expiratory volume decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542388","Grade 1 Gait Disturbance, CTCAE","C144113","Mild change in gait (e.g., wide-based, limping or hobbling)","Grade 1 Gait Disturbance, CTCAE | Grade 1 Gait disturbance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542373","Grade 1 Gastric Anastomotic Leak, CTCAE","C144114","Asymptomatic diagnostic finding; intervention not indicated","Grade 1 Gastric Anastomotic Leak, CTCAE | Grade 1 Gastric anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542375","Grade 1 Gastric Hemorrhage, CTCAE","C144116","Mild symptoms; intervention not indicated","Grade 1 Gastric Hemorrhage, CTCAE | Grade 1 Gastric hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542376","Grade 1 Gastric Stenosis, CTCAE","C144117","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Gastric Stenosis, CTCAE | Grade 1 Gastric stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542377","Grade 1 Gastric Ulcer, CTCAE","C144118","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Gastric Ulcer, CTCAE | Grade 1 Gastric ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542378","Grade 1 Gastroesophageal Reflux Disease, CTCAE","C144119","Mild symptoms; intervention not indicated","Grade 1 Gastroesophageal Reflux Disease, CTCAE | Grade 1 Gastroesophageal reflux disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542690","Grade 1 Vital Capacity Abnormal, CTCAE","C144484","90-75% of predicted value","Grade 1 Vital Capacity Abnormal, CTCAE | Grade 1 Vital capacity abnormal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542692","Grade 1 Vulval Infection, CTCAE","C144486","Localized, local intervention indicated","Grade 1 Vulval Infection, CTCAE | Grade 1 Vulval infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542677","Grade 1 Watering Eyes, CTCAE","C144487","Intervention not indicated","Grade 1 Watering Eyes, CTCAE | Grade 1 Watering eyes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542678","Grade 1 Wheezing, CTCAE","C144488","Detectable airway noise with minimal symptoms","Grade 1 Wheezing, CTCAE | Grade 1 Wheezing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542679","Grade 1 White Blood Cell Decreased, CTCAE","C144489","<LLN-3000/mm3; <LLN-3.0 x 10e9/L","Grade 1 White Blood Cell Decreased, CTCAE | Grade 1 White blood cell decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543113","Grade 2 Serum Amylase Increased, CTCAE","C144990",">1.5-2.0 x ULN; >2.0-5.0 x ULN and asymptomatic","Grade 2 Serum Amylase Increased, CTCAE | Grade 2 Serum amylase increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543114","Grade 2 Serum Sickness, CTCAE","C144991","Moderate arthralgia; fever, rash, urticaria, antihistamines indicated","Grade 2 Serum Sickness, CTCAE | Grade 2 Serum sickness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543115","Grade 2 Shingles, CTCAE","C144992","Local infection with moderate symptoms; oral intervention indicated; limiting age-appropriate instrumental ADL","Grade 2 Shingles, CTCAE | Grade 2 Shingles",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543116","Grade 2 Sinus Disorder, CTCAE","C144993","Symptomatic stenosis or edema/narrowing interfering with airflow; limiting instrumental ADL","Grade 2 Sinus Disorder, CTCAE | Grade 2 Sinus disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543101","Grade 2 Sinusitis, CTCAE","C144994","Localized; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Sinusitis, CTCAE | Grade 2 Sinusitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511645","DA, Rat Strain","C14385","DA: Urinary bladder tumors 54% in males and 14% in females, with a peak incidence at 25-30 months of age (Deerberg et al 1985). High incidence of hormone-dependent endometrial adenocarcinoma. A transplantable cell line (RUCA-I) derived from such a tumor in DA rats can produce these tumors in ectopic sites. The rate of proliferation is reduced by tamoxifen, and this cell line appears to be a suitable model for the study of molecular aspects of estrogen and tamoxifen-dependent gene expression.","DA, Rat Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516140","BDVI, Rat Strain","C14386","About 4% of spontaneous peripheral nerve tumors, with cystic schwannomas being the most frequent type. 24 spontaneous and 28 ethylnitrosourea-induced tumors has been described by Turusov and Cabral, (1994).","BDVI, Rat Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542499","Grade 1 Muscle Weakness Lower Limb, CTCAE","C144271","Symptomatic; perceived by patient but not evident on physical exam","Grade 1 Muscle Weakness Lower Limb, CTCAE | Grade 1 Muscle weakness lower limb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542485","Grade 1 Muscle Weakness Trunk, CTCAE","C144273","Symptomatic; perceived by patient but not evident on physical exam","Grade 1 Muscle Weakness Trunk, CTCAE | Grade 1 Muscle weakness trunk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542486","Grade 1 Muscle Weakness Upper Limb, CTCAE","C144274","Symptomatic; perceived by patient but not evident on physical exam","Grade 1 Muscle Weakness Upper Limb, CTCAE | Grade 1 Muscle weakness upper limb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542487","Grade 1 Musculoskeletal and Connective Tissue Disorder - Other, Specify, CTCAE","C144275","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Musculoskeletal and Connective Tissue Disorder - Other, Specify, CTCAE | Grade 1 Musculoskeletal and connective tissue disorder - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542488","Grade 1 Musculoskeletal Deformity, CTCAE","C144276","Cosmetically and functionally insignificant hypoplasia","Grade 1 Musculoskeletal Deformity, CTCAE | Grade 1 Musculoskeletal deformity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542489","Grade 1 Myalgia, CTCAE","C144277","Mild pain","Grade 1 Myalgia, CTCAE | Grade 1 Myalgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542490","Grade 1 Myasthenia Gravis, CTCAE","C144278","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Myasthenia Gravis, CTCAE | Grade 1 Myasthenia gravis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542492","Grade 1 Nail Infection, CTCAE","C144281","Localized, local intervention indicated","Grade 1 Nail Infection, CTCAE | Grade 1 Nail infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542477","Grade 1 Nail Loss, CTCAE","C144282","Asymptomatic separation of the nail bed from the nail plate or nail loss","Grade 1 Nail Loss, CTCAE | Grade 1 Nail loss",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542478","Grade 1 Nail Ridging, CTCAE","C144283","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Nail Ridging, CTCAE | Grade 1 Nail ridging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542479","Grade 1 Nasal Congestion, CTCAE","C144284","Mild symptoms; intervention not indicated","Grade 1 Nasal Congestion, CTCAE | Grade 1 Nasal congestion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542481","Grade 1 Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other, Specify, CTCAE","C144286","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other, Specify, CTCAE | Grade 1 Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542894","Grade 2 Fall, CTCAE","C144659","Symptomatic; noninvasive intervention indicated","Grade 2 Fall, CTCAE | Grade 2 Fall",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542895","Grade 2 Fallopian Tube Anastomotic Leak, CTCAE","C144660","Symptomatic; medical intervention indicated","Grade 2 Fallopian Tube Anastomotic Leak, CTCAE | Grade 2 Fallopian tube anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542896","Grade 2 Fat Atrophy, CTCAE","C144661","Covering 10-30% BSA and associated with erythema or tenderness; limiting instrumental ADL","Grade 2 Fat Atrophy, CTCAE | Grade 2 Fat atrophy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542897","Grade 2 Fecal Incontinence, CTCAE","C144662","Daily use of pads required","Grade 2 Fecal Incontinence, CTCAE | Grade 2 Fecal incontinence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542898","Grade 2 Feminization Acquired, CTCAE","C144663","Moderate symptoms; medical intervention indicated","Grade 2 Feminization Acquired, CTCAE | Grade 2 Feminization acquired",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542900","Grade 2 Fever, CTCAE","C144665",">39.0-40.0 degrees C (102.3-104.0 degrees F)","Grade 2 Fever, CTCAE | Grade 2 Fever",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543327","Grade 3 Blood Antidiuretic Hormone Abnormal, CTCAE","C145163","Hospitalization indicated","Grade 3 Blood Antidiuretic Hormone Abnormal, CTCAE | Grade 3 Blood antidiuretic hormone abnormal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543328","Grade 3 Blood Bilirubin Increased, CTCAE","C145164",">3.0-10.0 x ULN if baseline was normal; >3.0-10.0 x baseline if baseline was abnormal","Grade 3 Blood Bilirubin Increased, CTCAE | Grade 3 Blood bilirubin increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543329","Grade 3 Blood Corticotrophin Decreased, CTCAE","C145165","Hospitalization indicated","Grade 3 Blood Corticotrophin Decreased, CTCAE | Grade 3 Blood corticotrophin decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543331","Grade 3 Bone Infection, CTCAE","C145167","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Bone Infection, CTCAE | Grade 3 Bone infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511705","DONRYU, Rat Strain","C14399","DONRYU: Spontaneous tumors 74% in males at 120-weeks, mostly pituitary adenomas, pheochromocytomas and insulinomas. In females incidence 89%, mostly uterine adenocarcinomas, mammary fibroadenomas and pituitary adenomas.","DONRYU, Rat Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542229","Grade 1 Blood and Lymphatic System Disorders - Other, Specify, CTCAE","C144000","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Blood and Lymphatic System Disorders - Other, Specify, CTCAE | Grade 1 Blood and lymphatic system disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542230","Grade 1 Blood Antidiuretic Hormone Abnormal, CTCAE","C144001","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Blood Antidiuretic Hormone Abnormal, CTCAE | Grade 1 Blood antidiuretic hormone abnormal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542231","Grade 1 Blood Bicarbonate Decreased, CTCAE","C144002","<LLN and no intervention initiated","Grade 1 Blood Bicarbonate Decreased, CTCAE | Grade 1 Blood bicarbonate decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542232","Grade 1 Blood Bilirubin Increased, CTCAE","C144003",">ULN-1.5 x ULN if baseline was normal; > 1.0-1.5 x baseline if baseline was abnormal","Grade 1 Blood Bilirubin Increased, CTCAE | Grade 1 Blood bilirubin increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542233","Grade 1 Blood Corticotrophin Decreased, CTCAE","C144004","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Blood Corticotrophin Decreased, CTCAE | Grade 1 Blood corticotrophin decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542234","Grade 1 Blood Gonadotrophin Abnormal, CTCAE","C144005","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Blood Gonadotrophin Abnormal, CTCAE | Grade 1 Blood gonadotrophin abnormal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542235","Grade 1 Blood Lactate Dehydrogenase Increased, CTCAE","C144006",">ULN","Grade 1 Blood Lactate Dehydrogenase Increased, CTCAE | Grade 1 Blood lactate dehydrogenase increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542236","Grade 1 Blood Prolactin Abnormal, CTCAE","C144007","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Blood Prolactin Abnormal, CTCAE | Grade 1 Blood prolactin abnormal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542221","Grade 1 Body Odor, CTCAE","C144008","Mild odor; physician intervention not indicated; self care interventions","Grade 1 Body Odor, CTCAE | Grade 1 Body odor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542222","Grade 1 Bone Marrow Hypocellular, CTCAE","C144009","Mildly hypocellular or <=25% reduction from normal cellularity for age","Grade 1 Bone Marrow Hypocellular, CTCAE | Grade 1 Bone marrow hypocellular",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512112","E3, Rat Strain","C14400","Has platelet storage disease associated with the red-eyed yellow locus, as described by Raymond and Dodds (1975) for the FH strain.","E3, Rat Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542223","Grade 1 Breast Atrophy, CTCAE","C144010","Minimal asymmetry; minimal atrophy","Grade 1 Breast Atrophy, CTCAE | Grade 1 Breast atrophy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542224","Grade 1 Bronchial Fistula, CTCAE","C144011","Asymptomatic","Grade 1 Bronchial Fistula, CTCAE | Grade 1 Bronchial fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542225","Grade 1 Bronchial Obstruction, CTCAE","C144012","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Bronchial Obstruction, CTCAE | Grade 1 Bronchial obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542680","Grade 1 Wound Complication, CTCAE","C144490","Observation only; topical intervention indicated","Grade 1 Wound Complication, CTCAE | Grade 1 Wound complication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542682","Grade 1 Wound Infection, CTCAE","C144492","Localized, local intervention indicated","Grade 1 Wound Infection, CTCAE | Grade 1 Wound infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542683","Grade 1 Wrist Fracture, CTCAE","C144493","Mild; non-operative intervention indicated","Grade 1 Wrist Fracture, CTCAE | Grade 1 Wrist fracture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542684","Grade 2 Abdominal Distension, CTCAE","C144494","Symptomatic; limiting instrumental ADL","Grade 2 Abdominal Distension, CTCAE | Grade 2 Abdominal distension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542669","Grade 2 Abdominal Infection, CTCAE","C144495","Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Abdominal Infection, CTCAE | Grade 2 Abdominal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542670","Grade 2 Abdominal Pain, CTCAE","C144496","Moderate pain; limiting instrumental ADL","Grade 2 Abdominal Pain, CTCAE | Grade 2 Abdominal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542671","Grade 2 Abdominal Soft Tissue Necrosis, CTCAE","C144497","Local wound care; medical intervention indicated (e.g., dressings or topical medications)","Grade 2 Abdominal Soft Tissue Necrosis, CTCAE | Grade 2 Abdominal soft tissue necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542672","Grade 2 Abducens Nerve Disorder, CTCAE","C144498","Moderate symptoms; limiting instrumental ADL","Grade 2 Abducens Nerve Disorder, CTCAE | Grade 2 Abducens nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542674","Grade 2 Acoustic Nerve Disorder NOS, CTCAE","C144500","Moderate symptoms; limiting instrumental ADL","Grade 2 Acoustic Nerve Disorder NOS, CTCAE | Grade 2 Acoustic nerve disorder NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542675","Grade 2 Activated Partial Thromboplastin Time Prolonged, CTCAE","C144501",">1.5-2.5 x ULN","Grade 2 Activated Partial Thromboplastin Time Prolonged, CTCAE | Grade 2 Activated partial thromboplastin time prolonged",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542676","Grade 2 Akathisia, CTCAE","C144502","Moderate restlessness or increased motor activity; limiting instrumental ADL","Grade 2 Akathisia, CTCAE | Grade 2 Akathisia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542661","Grade 2 Alanine Aminotransferase Increased, CTCAE","C144503",">3.0-5.0 x ULN if baseline was normal; >3.0-5.0 x baseline if baseline was abnormal","Grade 2 Alanine Aminotransferase Increased, CTCAE | Grade 2 Alanine aminotransferase increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542662","Grade 2 Alcohol Intolerance, CTCAE","C144504","Present","Grade 2 Alcohol Intolerance, CTCAE | Grade 2 Alcohol intolerance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542663","Grade 2 Alkaline Phosphatase Increased, CTCAE","C144505",">2.5-5.0 x ULN if baseline was normal; >2.5-5.0 x baseline if baseline was abnormal","Grade 2 Alkaline Phosphatase Increased, CTCAE | Grade 2 Alkaline phosphatase increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542665","Grade 2 Allergic Rhinitis, CTCAE","C144507","Moderate symptoms; medical intervention indicated","Grade 2 Allergic Rhinitis, CTCAE | Grade 2 Allergic rhinitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542666","Grade 2 Amenorrhea, CTCAE","C144508","Present","Grade 2 Amenorrhea, CTCAE | Grade 2 Amenorrhea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543074","Grade 2 Pancreatic Anastomotic Leak, CTCAE","C144890","Symptomatic; medical intervention indicated","Grade 2 Pancreatic Anastomotic Leak, CTCAE | Grade 2 Pancreatic anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543076","Grade 2 Pancreatic Enzymes Decreased, CTCAE","C144892","Increase in stool frequency, bulk, or odor; steatorrhea","Grade 2 Pancreatic Enzymes Decreased, CTCAE | Grade 2 Pancreatic enzymes decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543061","Grade 2 Papilledema, CTCAE","C144895","Symptomatic; moderate decrease in visual acuity (best corrected visual acuity 20/40 and better or 3 lines or less decreased vision from known baseline)","Grade 2 Papilledema, CTCAE | Grade 2 Papilledema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542444","Grade 1 Hypopituitarism, CTCAE","C144185","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Hypopituitarism, CTCAE | Grade 1 Hypopituitarism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542429","Grade 1 Hypothyroidism, CTCAE","C144186","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Hypothyroidism, CTCAE | Grade 1 Hypothyroidism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520150","Wild Type Mouse","C14418","No value exists.","Wild Type Mouse | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542431","Grade 1 Immune System Disorders - Other, Specify, CTCAE","C144193","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Immune System Disorders - Other, Specify, CTCAE | Grade 1 Immune system disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542432","Grade 1 Infections and Infestations - Other, Specify, CTCAE","C144194","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Infections and Infestations - Other, Specify, CTCAE | Grade 1 Infections and infestations - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542433","Grade 1 Infusion Related Reaction, CTCAE","C144195","Mild transient reaction; infusion interruption not indicated; intervention not indicated","Grade 1 Infusion Related Reaction, CTCAE | Grade 1 Infusion related reaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542434","Grade 1 Infusion Site Extravasation, CTCAE","C144196","Painless edema","Grade 1 Infusion Site Extravasation, CTCAE | Grade 1 Infusion site extravasation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542435","Grade 1 Injection Site Reaction, CTCAE","C144197","Tenderness with or without associated symptoms (e.g., warmth, erythema, itching)","Grade 1 Injection Site Reaction, CTCAE | Grade 1 Injection site reaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542436","Grade 1 Injury To Superior Vena Cava, CTCAE","C144199","Asymptomatic diagnostic finding; intervention not indicated","Grade 1 Injury To Superior Vena Cava, CTCAE | Grade 1 Injury to superior vena cava",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542421","Grade 1 Injury, Poisoning and Procedural Complications - Other, Specify, CTCAE","C144200","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Injury, Poisoning and Procedural Complications - Other, Specify, CTCAE | Grade 1 Injury, poisoning and procedural complications - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542885","Grade 2 Fibrinogen Decreased, CTCAE","C144666","<0.75-0.5 x LLN; if abnormal, 25-<50% decrease from baseline","Grade 2 Fibrinogen Decreased, CTCAE | Grade 2 Fibrinogen decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542886","Grade 2 Fibrosis Deep Connective Tissue, CTCAE","C144667","Moderate induration, able to slide skin, unable to pinch skin; limiting instrumental ADL","Grade 2 Fibrosis Deep Connective Tissue, CTCAE | Grade 2 Fibrosis deep connective tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542887","Grade 2 Flank Pain, CTCAE","C144668","Moderate pain; limiting instrumental ADL","Grade 2 Flank Pain, CTCAE | Grade 2 Flank pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542888","Grade 2 Flashing Lights, CTCAE","C144669","Limiting instrumental ADL","Grade 2 Flashing Lights, CTCAE | Grade 2 Flashing lights",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542889","Grade 2 Floaters, CTCAE","C144670","Limiting instrumental ADL","Grade 2 Floaters, CTCAE | Grade 2 Floaters",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542890","Grade 2 Flu Like Symptoms, CTCAE","C144671","Moderate symptoms; limiting instrumental ADL","Grade 2 Flu Like Symptoms, CTCAE | Grade 2 Flu like symptoms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542877","Grade 2 Fungemia, CTCAE","C144674","Moderate symptoms; medical intervention indicated","Grade 2 Fungemia, CTCAE | Grade 2 Fungemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542878","Grade 2 Gait Disturbance, CTCAE","C144675","Moderate change in gait (e.g., wide-based, limping or hobbling); assistive device indicated; limiting instrumental ADL","Grade 2 Gait Disturbance, CTCAE | Grade 2 Gait disturbance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542879","Grade 2 Gallbladder Infection, CTCAE","C144676","Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Gallbladder Infection, CTCAE | Grade 2 Gallbladder infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542880","Grade 2 Gastric Anastomotic Leak, CTCAE","C144677","Symptomatic; medical intervention indicated","Grade 2 Gastric Anastomotic Leak, CTCAE | Grade 2 Gastric anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542881","Grade 2 Gastric Fistula, CTCAE","C144678","Symptomatic, invasive intervention not indicated","Grade 2 Gastric Fistula, CTCAE | Grade 2 Gastric fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542883","Grade 2 Gastric Perforation, CTCAE","C144680","Invasive intervention not indicated","Grade 2 Gastric Perforation, CTCAE | Grade 2 Gastric perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542884","Grade 2 Gastric Stenosis, CTCAE","C144681","Symptomatic; altered GI function","Grade 2 Gastric Stenosis, CTCAE | Grade 2 Gastric stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542869","Grade 2 Gastric Ulcer, CTCAE","C144682","Symptomatic; altered GI function; medical intervention indicated; limiting instrumental ADL","Grade 2 Gastric Ulcer, CTCAE | Grade 2 Gastric ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542870","Grade 2 Gastroesophageal Reflux Disease, CTCAE","C144683","Moderate symptoms; medical intervention indicated","Grade 2 Gastroesophageal Reflux Disease, CTCAE | Grade 2 Gastroesophageal reflux disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542871","Grade 2 Gastrointestinal Anastomotic Leak, CTCAE","C144684","Symptomatic; medical intervention indicated","Grade 2 Gastrointestinal Anastomotic Leak, CTCAE | Grade 2 Gastrointestinal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543172","Grade 2 Urostomy Stenosis, CTCAE","C145068","Symptomatic but no hydronephrosis, sepsis, or renal dysfunction; dilation or endoscopic repair or stent placement indicated","Grade 2 Urostomy Stenosis, CTCAE | Grade 2 Urostomy stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543157","Grade 2 Uterine Anastomotic Leak, CTCAE","C145069","Symptomatic; medical intervention indicated","Grade 2 Uterine Anastomotic Leak, CTCAE | Grade 2 Uterine anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543158","Grade 2 Uterine Fistula, CTCAE","C145070","Symptomatic, invasive intervention not indicated","Grade 2 Uterine Fistula, CTCAE | Grade 2 Uterine fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542226","Grade 1 Bronchial Stricture, CTCAE","C144013","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Bronchial Stricture, CTCAE | Grade 1 Bronchial stricture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542227","Grade 1 Bronchopleural Fistula, CTCAE","C144014","Asymptomatic","Grade 1 Bronchopleural Fistula, CTCAE | Grade 1 Bronchopleural fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542228","Grade 1 Bronchopulmonary Hemorrhage, CTCAE","C144015","Mild symptoms; intervention not indicated","Grade 1 Bronchopulmonary Hemorrhage, CTCAE | Grade 1 Bronchopulmonary hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542213","Grade 1 Bronchospasm, CTCAE","C144016","Mild symptoms; intervention not indicated","Grade 1 Bronchospasm, CTCAE | Grade 1 Bronchospasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542214","Grade 1 Bruising, CTCAE","C144017","Localized or in a dependent area","Grade 1 Bruising, CTCAE | Grade 1 Bruising",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542215","Grade 1 Bullous Dermatitis, CTCAE","C144018","Asymptomatic; blisters covering <10% BSA","Grade 1 Bullous Dermatitis, CTCAE | Grade 1 Bullous dermatitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542525","Grade 1 Renal and Urinary Disorders - Other, Specify, CTCAE","C144376","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Renal and Urinary Disorders - Other, Specify, CTCAE | Grade 1 Renal and urinary disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542526","Grade 1 Renal Calculi, CTCAE","C144377","Asymptomatic or mild symptoms; occasional use of nonprescription analgesics indicated","Grade 1 Renal Calculi, CTCAE | Grade 1 Renal calculi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542527","Grade 1 Renal Colic, CTCAE","C144378","Mild pain not interfering with activity; nonprescription medication indicated","Grade 1 Renal Colic, CTCAE | Grade 1 Renal colic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542528","Grade 1 Reproductive System and Breast Disorders - Other, Specify, CTCAE","C144380","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Reproductive System and Breast Disorders - Other, Specify, CTCAE | Grade 1 Reproductive system and breast disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542529","Grade 1 Respiratory, Thoracic and Mediastinal Disorders - Other, Specify, CTCAE","C144381","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Respiratory, Thoracic and Mediastinal Disorders - Other, Specify, CTCAE | Grade 1 Respiratory, thoracic and mediastinal disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542531","Grade 1 Retinal Tear, CTCAE","C144383","No retinal detachment and treatment not indicated","Grade 1 Retinal Tear, CTCAE | Grade 1 Retinal tear",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542532","Grade 1 Rhabdomyolysis, CTCAE","C144384","Asymptomatic, intervention not indicated; laboratory findings only","Grade 1 Rhabdomyolysis, CTCAE | Grade 1 Rhabdomyolysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542517","Grade 1 Rhinorrhea, CTCAE","C144385","Present","Grade 1 Rhinorrhea, CTCAE | Grade 1 Rhinorrhea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542518","Grade 1 Rotator Cuff Injury, CTCAE","C144386","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Rotator Cuff Injury, CTCAE | Grade 1 Rotator cuff injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542519","Grade 1 Salivary Duct Inflammation, CTCAE","C144387","Slightly thickened saliva; slightly altered taste (e.g., metallic)","Grade 1 Salivary Duct Inflammation, CTCAE | Grade 1 Salivary duct inflammation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542520","Grade 1 Scleral Disorder, CTCAE","C144388","No change in vision from baseline","Grade 1 Scleral Disorder, CTCAE | Grade 1 Scleral disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542522","Grade 1 Scrotal Infection, CTCAE","C144390","Localized, local intervention indicated","Grade 1 Scrotal Infection, CTCAE | Grade 1 Scrotal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542523","Grade 1 Scrotal Pain, CTCAE","C144391","Mild pain","Grade 1 Scrotal Pain, CTCAE | Grade 1 Scrotal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543062","Grade 2 Papulopustular Rash, CTCAE","C144896","Papules and/or pustules covering 10-30% BSA, which may or may not be associated with symptoms of pruritus or tenderness; associated with psychosocial impact; limiting instrumental ADL; papules and/or pustules covering > 30% BSA with or without mild symptoms","Grade 2 Papulopustular Rash, CTCAE | Grade 2 Papulopustular rash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543063","Grade 2 Paresthesia, CTCAE","C144897","Moderate symptoms; limiting instrumental ADL","Grade 2 Paresthesia, CTCAE | Grade 2 Paresthesia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543064","Grade 2 Paronychia, CTCAE","C144898","Local intervention indicated; oral intervention indicated (e.g., antibiotic, antifungal, antiviral); nail fold edema or erythema with pain; associated with discharge or nail plate separation; limiting instrumental ADL","Grade 2 Paronychia, CTCAE | Grade 2 Paronychia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543065","Grade 2 Paroxysmal Atrial Tachycardia, CTCAE","C144899","Non-urgent medical intervention indicated","Grade 2 Paroxysmal Atrial Tachycardia, CTCAE | Grade 2 Paroxysmal atrial tachycardia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205850","Nafoxidine Hydrochloride","C1448","The hydrochloride salt of the partial estrogen antagonist nafoxidine.  Nafoxidine competes with endogenous estrogen for binding to specific estrogen receptors.  This agent also inhibits angiogenesis in some tissues by blocking the effects of fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF); paradoxically, it may enhance angiogenesis in uterine tissue.  Nafoxidine also induces oxidative stress, protein kinase C and calcium signaling. (NCI04)","Nafoxidine Hydrochloride | 1-[2-[4-(3,4-Dihydro-6-methoxy-2-phenyl-1-naphthalenyl)phenoxy]ethyl]pyrrolidine Hydrochloride | NAFOXIDINE HYDROCHLORIDE | U 11100A | U-11,000A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543067","Grade 2 Pelvic Infection, CTCAE","C144901","Moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Pelvic Infection, CTCAE | Grade 2 Pelvic infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543068","Grade 2 Pelvic Pain, CTCAE","C144902","Moderate pain; limiting instrumental ADL","Grade 2 Pelvic Pain, CTCAE | Grade 2 Pelvic pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543053","Grade 2 Penile Infection, CTCAE","C144903","Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Penile Infection, CTCAE | Grade 2 Penile infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543054","Grade 2 Pericardial Effusion, CTCAE","C144905","Asymptomatic effusion size small to moderate","Grade 2 Pericardial Effusion, CTCAE | Grade 2 Pericardial effusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543055","Grade 2 Perineal Pain, CTCAE","C144906","Moderate pain; limiting instrumental ADL","Grade 2 Perineal Pain, CTCAE | Grade 2 Perineal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543056","Grade 2 Periorbital Edema, CTCAE","C144907","Indurated or pitting edema; topical intervention indicated","Grade 2 Periorbital Edema, CTCAE | Grade 2 Periorbital edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543057","Grade 2 Periorbital Infection, CTCAE","C144908","Localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral)","Grade 2 Periorbital Infection, CTCAE | Grade 2 Periorbital infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543058","Grade 2 Peripheral Ischemia, CTCAE","C144909","Brief (<24 hrs) episode of ischemia managed medically and without permanent deficit","Grade 2 Peripheral Ischemia, CTCAE | Grade 2 Peripheral ischemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543059","Grade 2 Peripheral Motor Neuropathy, CTCAE","C144910","Moderate symptoms; limiting instrumental ADL","Grade 2 Peripheral Motor Neuropathy, CTCAE | Grade 2 Peripheral motor neuropathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543045","Grade 2 Peripheral Sensory Neuropathy, CTCAE","C144912","Moderate symptoms; limiting instrumental ADL","Grade 2 Peripheral Sensory Neuropathy, CTCAE | Grade 2 Peripheral sensory neuropathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543046","Grade 2 Personality Change, CTCAE","C144913","Moderate personality change","Grade 2 Personality Change, CTCAE | Grade 2 Personality change",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542422","Grade 1 INR Increased, CTCAE","C144201",">1.2-1.5; >1-1.5 x baseline if on anticoagulation; monitoring only indicated","Grade 1 INR Increased, CTCAE | Grade 1 INR increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542423","Grade 1 Intestinal Stoma Leak, CTCAE","C144202","Asymptomatic diagnostic finding; intervention not indicated","Grade 1 Intestinal Stoma Leak, CTCAE | Grade 1 Intestinal stoma leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542424","Grade 1 Intestinal Stoma Site Bleeding, CTCAE","C144203","Minimal bleeding identified on clinical exam; intervention not indicated","Grade 1 Intestinal Stoma Site Bleeding, CTCAE | Grade 1 Intestinal stoma site bleeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542425","Grade 1 Intracranial Hemorrhage, CTCAE","C144204","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Intracranial Hemorrhage, CTCAE | Grade 1 Intracranial hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542426","Grade 1 Intraoperative Arterial Injury, CTCAE","C144205","Primary repair of injured organ/structure indicated","Grade 1 Intraoperative Arterial Injury, CTCAE | Grade 1 Intraoperative arterial injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542427","Grade 1 Intraoperative Breast Injury, CTCAE","C144206","Primary repair of injured organ/structure indicated","Grade 1 Intraoperative Breast Injury, CTCAE | Grade 1 Intraoperative breast injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542428","Grade 1 Intraoperative Ear Injury, CTCAE","C144207","Primary repair of injured organ/structure indicated","Grade 1 Intraoperative Ear Injury, CTCAE | Grade 1 Intraoperative ear injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542413","Grade 1 Intraoperative Endocrine Injury, CTCAE","C144208","Primary repair of injured organ/structure indicated","Grade 1 Intraoperative Endocrine Injury, CTCAE | Grade 1 Intraoperative endocrine injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542414","Grade 1 Intraoperative Gastrointestinal Injury, CTCAE","C144209","Primary repair of injured organ/structure indicated","Grade 1 Intraoperative Gastrointestinal Injury, CTCAE | Grade 1 Intraoperative gastrointestinal injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542711","Grade 2 Colonic Ulcer, CTCAE","C144586","Symptomatic; altered GI function","Grade 2 Colonic Ulcer, CTCAE | Grade 2 Colonic ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542712","Grade 2 Concentration Impairment, CTCAE","C144587","Moderate impairment in attention or decreased level of concentration; limiting instrumental ADL","Grade 2 Concentration Impairment, CTCAE | Grade 2 Concentration impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542713","Grade 2 Conduction Disorder, CTCAE","C144588","Non-urgent medical intervention indicated","Grade 2 Conduction Disorder, CTCAE | Grade 2 Conduction disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542714","Grade 2 Congenital, Familial and Genetic Disorders - Other, Specify, CTCAE","C144589","Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL","Grade 2 Congenital, Familial and Genetic Disorders - Other, Specify, CTCAE | Grade 2 Congenital, familial and genetic disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542715","Grade 2 Conjunctivitis Infective, CTCAE","C144590","Localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral)","Grade 2 Conjunctivitis Infective, CTCAE | Grade 2 Conjunctivitis infective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542716","Grade 2 Conjunctivitis, CTCAE","C144591","Symptomatic; moderate decrease in visual acuity (best corrected visual acuity 20/40 and better or 3 lines or less decreased vision from known baseline)","Grade 2 Conjunctivitis, CTCAE | Grade 2 Conjunctivitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542829","Grade 2 Corneal Infection, CTCAE","C144592","Localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral)","Grade 2 Corneal Infection, CTCAE | Grade 2 Corneal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542830","Grade 2 CPK Increased, CTCAE","C144593",">2.5 x ULN-5 x ULN","Grade 2 CPK Increased, CTCAE | Grade 2 CPK increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542832","Grade 2 Cushingoid, CTCAE","C144595","Moderate symptoms; medical intervention indicated","Grade 2 Cushingoid, CTCAE | Grade 2 Cushingoid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542833","Grade 2 Cyanosis, CTCAE","C144596","Present","Grade 2 Cyanosis, CTCAE | Grade 2 Cyanosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543159","Grade 2 Uterine Infection, CTCAE","C145072","Moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Uterine Infection, CTCAE | Grade 2 Uterine infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543161","Grade 2 Uterine Pain, CTCAE","C145074","Moderate pain; limiting instrumental ADL","Grade 2 Uterine Pain, CTCAE | Grade 2 Uterine pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543162","Grade 2 Uterine Perforation, CTCAE","C145075","Invasive intervention not indicated","Grade 2 Uterine Perforation, CTCAE | Grade 2 Uterine perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543163","Grade 2 Vaccination Complication, CTCAE","C145076","Moderate pain; Erythema 5.1-10 cm; Induration/swelling 5.1-10 cm; lipodystrophy; limiting instrumental ADL","Grade 2 Vaccination Complication, CTCAE | Grade 2 Vaccination complication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543164","Grade 2 Vaccination Site Lymphadenopathy, CTCAE","C145077","Localized ulceration; generalized lymph node enlargement","Grade 2 Vaccination Site Lymphadenopathy, CTCAE | Grade 2 Vaccination site lymphadenopathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543277","Grade 2 Vaginal Anastomotic Leak, CTCAE","C145078","Symptomatic; medical intervention indicated","Grade 2 Vaginal Anastomotic Leak, CTCAE | Grade 2 Vaginal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543278","Grade 2 Vaginal Discharge, CTCAE","C145079","Moderate to heavy vaginal discharge; use of perineal pad or tampon indicated","Grade 2 Vaginal Discharge, CTCAE | Grade 2 Vaginal discharge",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543280","Grade 2 Vaginal Inflammation, CTCAE","C145083","Moderate discomfort or pain, edema, or redness; limiting instrumental ADL","Grade 2 Vaginal Inflammation, CTCAE | Grade 2 Vaginal inflammation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543281","Grade 2 Vaginal Obstruction, CTCAE","C145084","Symptomatic; elective intervention indicated","Grade 2 Vaginal Obstruction, CTCAE | Grade 2 Vaginal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543282","Grade 2 Vaginal Pain, CTCAE","C145085","Moderate pain; limiting instrumental ADL","Grade 2 Vaginal Pain, CTCAE | Grade 2 Vaginal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543283","Grade 2 Vaginal Perforation, CTCAE","C145086","Invasive intervention not indicated","Grade 2 Vaginal Perforation, CTCAE | Grade 2 Vaginal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543284","Grade 2 Vaginal Stricture, CTCAE","C145087","Vaginal narrowing and/or shortening not interfering with physical examination","Grade 2 Vaginal Stricture, CTCAE | Grade 2 Vaginal stricture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543269","Grade 2 Vagus Nerve Disorder, CTCAE","C145088","Moderate symptoms; limiting instrumental ADL","Grade 2 Vagus Nerve Disorder, CTCAE | Grade 2 Vagus nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543270","Grade 2 Vas Deferens Anastomotic Leak, CTCAE","C145089","Symptomatic; medical intervention indicated","Grade 2 Vas Deferens Anastomotic Leak, CTCAE | Grade 2 Vas deferens anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543272","Grade 2 Vascular Disorders - Other, Specify, CTCAE","C145091","Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL","Grade 2 Vascular Disorders - Other, Specify, CTCAE | Grade 2 Vascular disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543273","Grade 2 Venous Injury, CTCAE","C145092","Symptomatic (e.g., claudication); repair or revision not indicated","Grade 2 Venous Injury, CTCAE | Grade 2 Venous injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543274","Grade 2 Ventricular Arrhythmia, CTCAE","C145093","Non-urgent medical intervention indicated","Grade 2 Ventricular Arrhythmia, CTCAE | Grade 2 Ventricular arrhythmia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543275","Grade 2 Vertigo, CTCAE","C145094","Moderate symptoms; limiting instrumental ADL","Grade 2 Vertigo, CTCAE | Grade 2 Vertigo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543276","Grade 2 Vestibular Disorder, CTCAE","C145095","Symptomatic; limiting instrumental ADL","Grade 2 Vestibular Disorder, CTCAE | Grade 2 Vestibular disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542637","Grade 1 Serum Amylase Increased, CTCAE","C144393",">ULN-1.5 x ULN","Grade 1 Serum Amylase Increased, CTCAE | Grade 1 Serum amylase increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542638","Grade 1 Serum Sickness, CTCAE","C144394","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Serum Sickness, CTCAE | Grade 1 Serum sickness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542640","Grade 1 Sinus Disorder, CTCAE","C144396","Asymptomatic mucosal crusting; blood-tinged secretions","Grade 1 Sinus Disorder, CTCAE | Grade 1 Sinus disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542641","Grade 1 Skin and Subcutaneous Tissue Disorders - Other, Specify, CTCAE","C144397","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Skin and Subcutaneous Tissue Disorders - Other, Specify, CTCAE | Grade 1 Skin and subcutaneous tissue disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542642","Grade 1 Skin Hyperpigmentation, CTCAE","C144398","Hyperpigmentation covering <10% BSA; no psychosocial impact","Grade 1 Skin Hyperpigmentation, CTCAE | Grade 1 Skin hyperpigmentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542643","Grade 1 Skin Hypopigmentation, CTCAE","C144399","Hypopigmentation or depigmentation covering <10% BSA; no psychosocial impact","Grade 1 Skin Hypopigmentation, CTCAE | Grade 1 Skin hypopigmentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020247","Organochlorine Compound","C1443","Organochlorines are a group of compounds belonging to the chlorinated hydrocarbon pesticides (as aldrin, DDT, or dieldrin).  These compounds are believed to associated with many cancers, especially with breast cancer.","Organochlorine Compound | Organochlorines",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542940","Grade 2 Infusion Related Reaction, CTCAE","C144758","Therapy or infusion interruption indicated but responds promptly to symptomatic treatment (e.g., antihistamines, NSAIDS, narcotics, IV fluids); prophylactic medications indicated for <=24 hrs","Grade 2 Infusion Related Reaction, CTCAE | Grade 2 Infusion related reaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542926","Grade 2 Injection Site Reaction, CTCAE","C144760","Pain; lipodystrophy; edema; phlebitis","Grade 2 Injection Site Reaction, CTCAE | Grade 2 Injection site reaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542927","Grade 2 Injury To Carotid Artery, CTCAE","C144761","Repair or revision not indicated","Grade 2 Injury To Carotid Artery, CTCAE | Grade 2 Injury to carotid artery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542928","Grade 2 Injury To Jugular Vein, CTCAE","C144763","Repair or revision not indicated","Grade 2 Injury To Jugular Vein, CTCAE | Grade 2 Injury to jugular vein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542929","Grade 2 Injury To Superior Vena Cava, CTCAE","C144764","Symptomatic; repair or revision not indicated","Grade 2 Injury To Superior Vena Cava, CTCAE | Grade 2 Injury to superior vena cava",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542930","Grade 2 Injury, Poisoning and Procedural Complications - Other, Specify, CTCAE","C144765","Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL","Grade 2 Injury, Poisoning and Procedural Complications - Other, Specify, CTCAE | Grade 2 Injury, poisoning and procedural complications - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542932","Grade 2 Intestinal Stoma Leak, CTCAE","C144767","Symptomatic; medical intervention indicated","Grade 2 Intestinal Stoma Leak, CTCAE | Grade 2 Intestinal stoma leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542918","Grade 2 Intestinal Stoma Site Bleeding, CTCAE","C144769","Moderate bleeding; medical intervention indicated","Grade 2 Intestinal Stoma Site Bleeding, CTCAE | Grade 2 Intestinal stoma site bleeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542919","Grade 2 Intra-Abdominal Hemorrhage, CTCAE","C144770","Moderate symptoms; intervention indicated","Grade 2 Intra-Abdominal Hemorrhage, CTCAE | Grade 2 Intra-abdominal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542920","Grade 2 Intracranial Hemorrhage, CTCAE","C144771","Moderate symptoms; intervention indicated","Grade 2 Intracranial Hemorrhage, CTCAE | Grade 2 Intracranial hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0331018","Viscum album","C14379","An evergreen parasitic plant, 'European mistletoe', with waxy white berries and smooth-edged oval leaves in pairs along the woody stem.  The extract is being studied for its potential use in cancer treatment.","Viscum album | European Mistletoe | Mistletoe | VISCUM ALBUM WHOLE | mistletoe",,,,,,,,,,,,,,,"4148447","Viscum album",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1527003","Recombinant CD40-Ligand","C1437","A recombinant therapeutic agent which is chemically identical to or similar to CD40-ligand. CD40-ligand, also known as CD40L/TRAP and CD154, is a type II membrane protein which binds to CD40, a cell surface receptor that belongs to the tumor necrosis factor receptor family; CD40 is expressed on B lymphocytes, monocytes, dendritic cells (DC), hematopoietic progenitors, endothelial cells and epithelial cells. Recombinant CD40-ligand may be used to activate DC ex vivo via CD40 binding; CD40-ligand-activated DC may provide or augment a protective antitumor immunity when administered in dendritic cell cancer vaccines. (NCI04)","Recombinant CD40-Ligand | CD154 antigen | CD40L | T-BAM | T-Cell Antigen gp39 | TNF-Related Activation Protein | TRAP Ligand | gp39 | rhu CD40L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520114","WN, Rat Strain","C14380","Anterior pituitary tumors nearly 100% in females over 18 months of age, pheochromocytomas or preneoplastic nodules in adrenal medulla about 40% in males, granulocytic leukemia 14% in animals over 18 months of age. Rarely show hyperplastic cortical nodules or adrenal cortical adenomas. High incidence of severe chronic nephritis. (Snell 1967). High 10-week body weight in males (19/23), and high relative heart weight in 10-week old males (19/23) (Tanase et al 1982).","WN, Rat Strain | WN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542835","Grade 2 Cytokine Release Syndrome, CTCAE","C144598","Hypotension responding to fluids; hypoxia responding to <40% O2","Grade 2 Cytokine Release Syndrome, CTCAE | Grade 2 Cytokine release syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542836","Grade 2 Cytomegalovirus Infection Reactivation, CTCAE","C144599","Moderate symptoms; medical intervention indicated","Grade 2 Cytomegalovirus Infection Reactivation, CTCAE | Grade 2 Cytomegalovirus infection reactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2828333","Potassium Hyaluronate","C1445","The potassium salt form of hyaluronic acid, a glucosaminoglycan, a component of connective tissue, skin, vitreous humour, umbilical cord, synovial fluid and the capsule of certain microorganisms contributing to adhesion, elasticity, and viscosity of extracellular substances.","Potassium Hyaluronate | Hyaluronate Potassium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542822","Grade 2 Delirium, CTCAE","C144601","Moderate and acute confusional state; limiting instrumental ADL","Grade 2 Delirium, CTCAE | Grade 2 Delirium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542823","Grade 2 Delusions, CTCAE","C144602","Moderate delusional symptoms","Grade 2 Delusions, CTCAE | Grade 2 Delusions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542824","Grade 2 Dental Caries, CTCAE","C144603","Dental caries involving the root","Grade 2 Dental Caries, CTCAE | Grade 2 Dental caries",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542826","Grade 2 Dermatitis Radiation, CTCAE","C144605","Moderate to brisk erythema; patchy moist desquamation, mostly confined to skin folds and creases; moderate edema","Grade 2 Dermatitis Radiation, CTCAE | Grade 2 Dermatitis radiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542827","Grade 2 Device Related Infection, CTCAE","C144606","Oral intervention indicated (e.g., antibiotic, antifungal)","Grade 2 Device Related Infection, CTCAE | Grade 2 Device related infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542828","Grade 2 Dry Eye, CTCAE","C144607","Symptomatic; moderate decrease in visual acuity (best corrected visual acuity 20/40 and better or 3 lines or less decreased vision from known baseline)","Grade 2 Dry Eye, CTCAE | Grade 2 Dry eye",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543103","Grade 2 Skin and Subcutaneous Tissue Disorders - Other, Specify, CTCAE","C144996","Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL","Grade 2 Skin and Subcutaneous Tissue Disorders - Other, Specify, CTCAE | Grade 2 Skin and subcutaneous tissue disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543105","Grade 2 Skin Hypopigmentation, CTCAE","C144998","Hypopigmentation or depigmentation covering >10% BSA; associated psychosocial impact","Grade 2 Skin Hypopigmentation, CTCAE | Grade 2 Skin hypopigmentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543106","Grade 2 Skin Induration, CTCAE","C144999","Moderate induration, able to slide skin, unable to pinch skin; limiting instrumental ADL","Grade 2 Skin Induration, CTCAE | Grade 2 Skin induration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039995","Thorium Dioxide","C1449","A radioactive crystalline solid compound used in a broad range of industrial applications. Thorium dioxide was utilized as a radiographic contrast agent; however, it is no longer considered safe for use in human patients because it was found to be a carcinogen that can cause cholangiocarcinoma.","Thorium Dioxide | THORIUM DIOXIDE | Thoria | Thorium Anhydride | Thorium Oxide | Thorium(IV) Oxide | Thorotrast | Thortrast | Umbrathor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543107","Grade 2 Skin Infection, CTCAE","C145000","Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Skin Infection, CTCAE | Grade 2 Skin infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543108","Grade 2 Skin Papilloma, CTCAE","C145001","Intervention initiated","Grade 2 Skin Papilloma, CTCAE | Grade 2 Skin papilloma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516120","BB, Rat Strain","C14394","BB: The development of lymphocytic thyroiditis is not affected by iodine treatment according to Allen (1992), though Ebner et al (1992) found the opposite. Epitope specificities of collagen-induced arthritis studied by Cremer et al (1992). A lymphopenic, nondiabetic substrain BB-DR has very low T-cell numbers, depressed B-lymphocyte numbers and a complete absence of peripheral CD8+ T cells characteristics of the susceptible BB strain(Joseph et al 1993). Transfusing of BB-DR thymocytes into nude rats transfers the autoimmune insulin-dependent diabetes mellitus (Whalen et al 1995).","BB, Rat Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542155","Ad-RTS-hIL-12","C143953","An inducible adenoviral vector encoding human pro-inflammatory cytokine interleukin-12 (IL-12; IL12), which is under the transcriptional control of the RheoSwitch Therapeutic System (RTS) (Ad-RTS-hIL-12), with potential immunomodulating and antineoplastic activities. RTS consists of two fusion proteins: Gal4-EcR, which contains a modified ecdysone receptor (EcR) fused with the DNA binding domain of the yeast Gal4 transcription factor, and VP16-RXR, which contains a chimeric retinoid X receptor (RXR) fused with the transcription activation domain of the viral protein VP16 of herpes simplex virus type 1 (HSV1). Upon intratumoral administration of Ad-RTS-hIL-12, given in combination with the proprietary, diacylhydrazine-based activator ligand veledimex (INXN-1001), veledimex binds specifically to the EcR part of the RTS and stabilizes heterodimerization between the two fusion proteins, forming an active transcription factor, which induces the transcription of IL-12 under the control of an inducible promoter containing Gal4-binding sites. The expressed IL-12 activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma (IFN-g) and inducing cytotoxic T-lymphocyte (CTL)-mediated responses against tumor cells, which may result in immune-mediated tumor cell lysis and inhibition of tumor cell proliferation. In the presence of veledimex, the protein heterodimer changes to a stable conformation and can bind to the inducible promoter, while without veledimex the two fusion proteins form unstable heterodimers; this allows the controlled, regulated intratumoral expression of the IL-12 gene.","Ad-RTS-hIL-12 | Adenoviral- RheoSwitch Therapeutic System-Human Interleukin 12 | INXN 2001 | INXN-2001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542484","Grade 1 Neutrophil Count Decreased, CTCAE","C144289","<LLN-1500/mm3; <LLN-1.5 x 10e9/L","Grade 1 Neutrophil Count Decreased, CTCAE | Grade 1 Neutrophil count decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542921","Grade 2 Intraoperative Arterial Injury, CTCAE","C144772","Partial resection of injured organ/structure indicated","Grade 2 Intraoperative Arterial Injury, CTCAE | Grade 2 Intraoperative arterial injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542922","Grade 2 Intraoperative Breast Injury, CTCAE","C144773","Partial resection of injured organ/structure indicated","Grade 2 Intraoperative Breast Injury, CTCAE | Grade 2 Intraoperative breast injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542923","Grade 2 Intraoperative Ear Injury, CTCAE","C144774","Partial resection of injured organ/structure indicated","Grade 2 Intraoperative Ear Injury, CTCAE | Grade 2 Intraoperative ear injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542924","Grade 2 Intraoperative Endocrine Injury, CTCAE","C144775","Partial resection of injured organ/structure indicated","Grade 2 Intraoperative Endocrine Injury, CTCAE | Grade 2 Intraoperative endocrine injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542910","Grade 2 Intraoperative Head and Neck Injury, CTCAE","C144777","Partial resection of injured organ/structure indicated","Grade 2 Intraoperative Head and Neck Injury, CTCAE | Grade 2 Intraoperative head and neck injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542911","Grade 2 Intraoperative Hepatobiliary Injury, CTCAE","C144778","Partial resection of injured organ/structure indicated","Grade 2 Intraoperative Hepatobiliary Injury, CTCAE | Grade 2 Intraoperative hepatobiliary injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542912","Grade 2 Intraoperative Musculoskeletal Injury, CTCAE","C144779","Partial resection of injured organ/structure indicated","Grade 2 Intraoperative Musculoskeletal Injury, CTCAE | Grade 2 Intraoperative musculoskeletal injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542913","Grade 2 Intraoperative Neurological Injury, CTCAE","C144780","Partial resection of injured organ/structure indicated","Grade 2 Intraoperative Neurological Injury, CTCAE | Grade 2 Intraoperative neurological injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542914","Grade 2 Intraoperative Ocular Injury, CTCAE","C144781","Partial resection of injured organ/structure indicated","Grade 2 Intraoperative Ocular Injury, CTCAE | Grade 2 Intraoperative ocular injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543317","Grade 3 Breast Atrophy, CTCAE","C145169","Asymmetry >1/3 of breast volume; severe atrophy","Grade 3 Breast Atrophy, CTCAE | Grade 3 Breast atrophy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543318","Grade 3 Breast Infection, CTCAE","C145170","IV antibiotic, antifungal, or antiviral intervention indicated; severe infection; axillary adenitis","Grade 3 Breast Infection, CTCAE | Grade 3 Breast infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543319","Grade 3 Bronchial Fistula, CTCAE","C145171","Invasive intervention indicated","Grade 3 Bronchial Fistula, CTCAE | Grade 3 Bronchial fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543321","Grade 3 Bronchial Obstruction, CTCAE","C145173","Shortness of breath with stridor; endoscopic intervention indicated (e.g., laser, stent placement)","Grade 3 Bronchial Obstruction, CTCAE | Grade 3 Bronchial obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543322","Grade 3 Bronchial Stricture, CTCAE","C145174","Shortness of breath with stridor; endoscopic intervention indicated (e.g., laser, stent placement)","Grade 3 Bronchial Stricture, CTCAE | Grade 3 Bronchial stricture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543323","Grade 3 Bronchopleural Fistula, CTCAE","C145175","Hospitalization; invasive intervention indicated","Grade 3 Bronchopleural Fistula, CTCAE | Grade 3 Bronchopleural fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543324","Grade 3 Bronchopulmonary Hemorrhage, CTCAE","C145176","Transfusion indicated; invasive intervention indicated; hospitalization","Grade 3 Bronchopulmonary Hemorrhage, CTCAE | Grade 3 Bronchopulmonary hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543309","Grade 3 Bronchospasm, CTCAE","C145177","Limiting self care ADL; supplemental oxygen indicated","Grade 3 Bronchospasm, CTCAE | Grade 3 Bronchospasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543310","Grade 3 Budd-Chiari Syndrome, CTCAE","C145178","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; asterixis; mild encephalopathy","Grade 3 Budd-Chiari Syndrome, CTCAE | Grade 3 Budd-Chiari syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543311","Grade 3 Bullous Dermatitis, CTCAE","C145179","Blisters covering >30% BSA; limiting self care ADL","Grade 3 Bullous Dermatitis, CTCAE | Grade 3 Bullous dermatitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513865","NZR, Rat Strain","C14411","Tumors (atriocaval epithelial mesotheliomas) of right atrium or inferior vena cava occur in approximately 12-20% of animals of both sexes over 1 year. These tumors are slow growing, but apparently malignant, and closely resemble similar tumors found in humans (Goodall et al 1975). In a later study, most common neoplasms of animal over one year of age: atrioclaval mesotheliomas 12%, lung adenomas 10% (males), pituitary adenomas 23%, mammary tumors 7%, liver tumors 3%, cervical tumors 3% (in females) (Goodall and Doesburg 1981).","NZR, Rat Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542379","Grade 1 Gastrointestinal Anastomotic Leak, CTCAE","C144120","Asymptomatic diagnostic finding; intervention not indicated","Grade 1 Gastrointestinal Anastomotic Leak, CTCAE | Grade 1 Gastrointestinal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542380","Grade 1 Gastrointestinal Disorders - Other, Specify, CTCAE","C144121","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Gastrointestinal Disorders - Other, Specify, CTCAE | Grade 1 Gastrointestinal disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542365","Grade 1 Gastrointestinal Fistula, CTCAE","C144122","Asymptomatic","Grade 1 Gastrointestinal Fistula, CTCAE | Grade 1 Gastrointestinal fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542366","Grade 1 Gastrointestinal Pain, CTCAE","C144123","Mild pain","Grade 1 Gastrointestinal Pain, CTCAE | Grade 1 Gastrointestinal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542367","Grade 1 Gastroparesis, CTCAE","C144124","Mild nausea, early satiety and bloating, able to maintain caloric intake on regular diet","Grade 1 Gastroparesis, CTCAE | Grade 1 Gastroparesis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542368","Grade 1 General Disorders and Administration Site Conditions - Other, Specify, CTCAE","C144125","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 General Disorders and Administration Site Conditions - Other, Specify, CTCAE | Grade 1 General disorders and administration site conditions - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542369","Grade 1 Generalized Edema, CTCAE","C144126","Noted on exam; 1+ pitting edema","Grade 1 Generalized Edema, CTCAE | Grade 1 Generalized edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542370","Grade 1 Generalized Muscle Weakness, CTCAE","C144127","Symptomatic; perceived by patient but not evident on physical exam","Grade 1 Generalized Muscle Weakness, CTCAE | Grade 1 Generalized muscle weakness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542372","Grade 1 GGT Increased, CTCAE","C144129",">ULN-2.5 x ULN if baseline was normal; 2.0-2.5 x baseline if baseline was abnormal","Grade 1 GGT Increased, CTCAE | Grade 1 GGT increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519142","SHR, Rat Strain","C14412","SHR: rats develop hypertension spontaneously without exception at the age of 7-15 weeks. There is a systolic blood pressure plateau of about 200 mmHg. The genetic basis is polygenic, with at least three major genes involved (Tanase and Suzuki 1971, Yen et al 1974). There is a high incidence of cardiovascular disease (Okamoto et al 1973), but a low incidence of stroke which can be increased to about 30% with chronic stress (Yamori 1984).","SHR, Rat Strain | SHR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542357","Grade 1 Gingival Pain, CTCAE","C144130","Mild pain","Grade 1 Gingival Pain, CTCAE | Grade 1 Gingival pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542358","Grade 1 Glossopharyngeal Nerve Disorder, CTCAE","C144131","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Glossopharyngeal Nerve Disorder, CTCAE | Grade 1 Glossopharyngeal nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542359","Grade 1 Glucose Intolerance, CTCAE","C144132","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Glucose Intolerance, CTCAE | Grade 1 Glucose intolerance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542360","Grade 1 Glucosuria, CTCAE","C144133","Present","Grade 1 Glucosuria, CTCAE | Grade 1 Glucosuria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542361","Grade 1 Growth Hormone Abnormal, CTCAE","C144134","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Growth Hormone Abnormal, CTCAE | Grade 1 Growth hormone abnormal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543093","Grade 2 Skin Ulceration, CTCAE","C145002","Combined area of ulcers 1-2 cm; partial thickness skin loss involving skin or subcutaneous fat","Grade 2 Skin Ulceration, CTCAE | Grade 2 Skin ulceration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543094","Grade 2 Sleep Apnea, CTCAE","C145003","Moderate apnea and oxygen desaturation; excessive daytime sleepiness; medical evaluation indicated; limiting instrumental ADL","Grade 2 Sleep Apnea, CTCAE | Grade 2 Sleep apnea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543096","Grade 2 Small Intestinal Mucositis, CTCAE","C145005","Symptomatic; medical intervention indicated; limiting instrumental ADL","Grade 2 Small Intestinal Mucositis, CTCAE | Grade 2 Small intestinal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543097","Grade 2 Small Intestinal Obstruction, CTCAE","C145006","Symptomatic; altered GI function; limiting instrumental ADL","Grade 2 Small Intestinal Obstruction, CTCAE | Grade 2 Small intestinal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543098","Grade 2 Small Intestinal Perforation, CTCAE","C145007","Invasive intervention not indicated","Grade 2 Small Intestinal Perforation, CTCAE | Grade 2 Small intestinal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543099","Grade 2 Small Intestinal Stenosis, CTCAE","C145008","Symptomatic; altered GI function","Grade 2 Small Intestinal Stenosis, CTCAE | Grade 2 Small intestinal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543100","Grade 2 Small Intestine Infection, CTCAE","C145009","Moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Small Intestine Infection, CTCAE | Grade 2 Small intestine infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543213","Grade 2 Small Intestine Ulcer, CTCAE","C145010","Symptomatic; altered GI function; limiting instrumental ADL","Grade 2 Small Intestine Ulcer, CTCAE | Grade 2 Small intestine ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543214","Grade 2 Sneezing, CTCAE","C145011","Moderate symptoms; medical intervention indicated","Grade 2 Sneezing, CTCAE | Grade 2 Sneezing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543215","Grade 2 Social Circumstances - Other, Specify, CTCAE","C145012","Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL","Grade 2 Social Circumstances - Other, Specify, CTCAE | Grade 2 Social circumstances - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543217","Grade 2 Soft Tissue Necrosis Lower Limb, CTCAE","C145014","Local wound care; medical intervention indicated (e.g., dressings or topical medications)","Grade 2 Soft Tissue Necrosis Lower Limb, CTCAE | Grade 2 Soft tissue necrosis lower limb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543218","Grade 2 Soft Tissue Necrosis Upper Limb, CTCAE","C145015","Local wound care; medical intervention indicated (e.g., dressings or topical medications)","Grade 2 Soft Tissue Necrosis Upper Limb, CTCAE | Grade 2 Soft tissue necrosis upper limb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543219","Grade 2 Somnolence, CTCAE","C145016","Moderate sedation; limiting instrumental ADL","Grade 2 Somnolence, CTCAE | Grade 2 Somnolence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543220","Grade 2 Sore Throat, CTCAE","C145017","Moderate pain; limiting instrumental ADL","Grade 2 Sore Throat, CTCAE | Grade 2 Sore throat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516138","BDIX, Rat Strain","C14387","Strain widely used in carcinogenesis and teratogenesis studies. Highly susceptible to the transplacental induction of malignant tumors of the central nervous system by ethyl nitrosourea (Druckrey et al 1970). A transplantable monocytic-myeloid leukemia L5222 induced by ethyl nitrosourea has been used as a model for chemotherapy (Ivankovic and Zeller 1974). Transplantable colon tumor PROb grows progressively and metastasizes, whereas REGb grows slowly and is then rejected (Blottiere et al 1992a,b).","BDIX, Rat Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542469","Grade 1 Night Blindness, CTCAE","C144290","Symptomatic but not limiting ADL","Grade 1 Night Blindness, CTCAE | Grade 1 Night blindness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542470","Grade 1 Nipple Deformity, CTCAE","C144291","Asymptomatic; asymmetry with slight retraction and/or thickening of the nipple areolar complex","Grade 1 Nipple Deformity, CTCAE | Grade 1 Nipple deformity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542471","Grade 1 Non-Cardiac Chest Pain, CTCAE","C144292","Mild pain","Grade 1 Non-Cardiac Chest Pain, CTCAE | Grade 1 Non-cardiac chest pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542472","Grade 1 Obstruction Gastric, CTCAE","C144293","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Obstruction Gastric, CTCAE | Grade 1 Obstruction gastric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542474","Grade 1 Oligospermia, CTCAE","C144295","Sperm concentration > 0 to < 15 million/ml","Grade 1 Oligospermia, CTCAE | Grade 1 Oligospermia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542475","Grade 1 Optic Nerve Disorder, CTCAE","C144296","Asymptomatic; clinical or diagnostic observations only","Grade 1 Optic Nerve Disorder, CTCAE | Grade 1 Optic nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542476","Grade 1 Oral Cavity Fistula, CTCAE","C144297","Asymptomatic","Grade 1 Oral Cavity Fistula, CTCAE | Grade 1 Oral cavity fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542461","Grade 1 Oral Dysesthesia, CTCAE","C144298","Mild discomfort; not interfering with oral intake","Grade 1 Oral Dysesthesia, CTCAE | Grade 1 Oral dysesthesia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0173377","Morpholinodoxorubicin","C1442","A semisynthetic derivative of the anthracycline antineoplastic antibiotic doxorubicin.  As an antineoplastic agent, morpholinodoxorubicin is more potent than doxorubicin.  Similar to doxorubicin, morpholinodoxorubicin intercalates into DNA and causes single- and double-strand breaks in DNA via inhibition of topoisomerase I and II.  Unlike doxorubicin, this agent is metabolized in vivo to a DNA-alkylating derivative that forms DNA interstrand cross-links, thereby potentiating its doxorubicin-like cytotoxicity. (NCI04)","Morpholinodoxorubicin | 5,12-Naphthacenedione, 7, 8, 9, 10-tetrahydro-6, 8, 11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2, 3, 6-trideoxy-3-(4-morpholinyl)-alpha-L-lyxo-hexopyranosyl] oxy]-, hydrochloride, (8S-cis)- | MORPHOLINODOXORUBICIN | morpholino-ADR | morpholino-adriamycin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542462","Grade 1 Oropharyngeal Pain, CTCAE","C144301","Mild pain","Grade 1 Oropharyngeal Pain, CTCAE | Grade 1 Oropharyngeal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542463","Grade 1 Osteonecrosis of Jaw, CTCAE","C144302","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Osteonecrosis of Jaw, CTCAE | Grade 1 Osteonecrosis of jaw",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542464","Grade 1 Osteonecrosis, CTCAE","C144303","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Osteonecrosis, CTCAE | Grade 1 Osteonecrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542466","Grade 1 Ovarian Rupture, CTCAE","C144306","Asymptomatic clinical or diagnostic observations only; intervention not indicated","Grade 1 Ovarian Rupture, CTCAE | Grade 1 Ovarian rupture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542467","Grade 1 Pain In Extremity, CTCAE","C144307","Mild pain","Grade 1 Pain In Extremity, CTCAE | Grade 1 Pain in extremity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542468","Grade 1 Pain of Skin, CTCAE","C144308","Mild pain","Grade 1 Pain of Skin, CTCAE | Grade 1 Pain of skin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542453","Grade 1 Pain, CTCAE","C144309","Mild pain","Grade 1 Pain, CTCAE | Grade 1 Pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542454","Grade 1 Palmar-Plantar Erythrodysesthesia Syndrome, CTCAE","C144310","Minimal skin changes or dermatitis (e.g., erythema, edema, or hyperkeratosis) without pain","Grade 1 Palmar-Plantar Erythrodysesthesia Syndrome, CTCAE | Grade 1 Palmar-plantar erythrodysesthesia syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542455","Grade 1 Pancreatic Anastomotic Leak, CTCAE","C144311","Asymptomatic diagnostic finding; intervention not indicated","Grade 1 Pancreatic Anastomotic Leak, CTCAE | Grade 1 Pancreatic anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543313","Grade 3 Carbon Monoxide Diffusing Capacity Decreased, CTCAE","C145181","Asymptomatic decrease of >8 units drop; >5 units drop along with the presence of pulmonary symptoms (e.g., >Grade 2 hypoxia or >Grade 2 dyspnea); intervention indicated","Grade 3 Carbon Monoxide Diffusing Capacity Decreased, CTCAE | Grade 3 Carbon monoxide diffusing capacity decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543314","Grade 3 Cardiac Disorders - Other, Specify, CTCAE","C145182","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL","Grade 3 Cardiac Disorders - Other, Specify, CTCAE | Grade 3 Cardiac disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543315","Grade 3 Cardiac Troponin I Increased, CTCAE","C145183","Levels consistent with myocardial infarction as defined by the manufacturer","Grade 3 Cardiac Troponin I Increased, CTCAE | Grade 3 Cardiac troponin I increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543316","Grade 3 Cardiac Troponin T Increased, CTCAE","C145184","Levels consistent with myocardial infarction as defined by the manufacturer","Grade 3 Cardiac Troponin T Increased, CTCAE | Grade 3 Cardiac troponin T increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543301","Grade 3 Catheter Related Infection, CTCAE","C145185","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Catheter Related Infection, CTCAE | Grade 3 Catheter related infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543302","Grade 3 CD4 Lymphocytes Decreased, CTCAE","C145186","<200-50/mm3; <0.2 x 0.05-10e9/L","Grade 3 CD4 Lymphocytes Decreased, CTCAE | Grade 3 CD4 lymphocytes decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543305","Grade 3 Central Nervous System Necrosis, CTCAE","C145189","Severe symptoms; medical intervention indicated","Grade 3 Central Nervous System Necrosis, CTCAE | Grade 3 Central nervous system necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543306","Grade 3 Cerebrospinal Fluid Leakage, CTCAE","C145190","Severe symptoms; medical intervention indicated","Grade 3 Cerebrospinal Fluid Leakage, CTCAE | Grade 3 Cerebrospinal fluid leakage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543307","Grade 3 Cervicitis Infection, CTCAE","C145191","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Cervicitis Infection, CTCAE | Grade 3 Cervicitis infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034703","F344, Rat Strain","C14401","Most animals older than 2 years exhibit small local areas of nephritis; less than 25% show severe nephritis (Snell 1967). Tumors: Mammary tumors 41% in females and 23% in males, pituitary adenomas 36% in females and 24% in males, testicular interstitial cell tumors 85% in males. Other tumor types less common (Sass et al 1975). Thyroid carcinoma 22% (Lindsey et al 1968). Interstitial cell testicular tumors 65%, mononuclear cell leukemia 24%, subcutaneous fibroadenoma 9% in females. Both sexes have a 5% incidence of nodular hyperplasia of the liver.","F344, Rat Strain | F344 | FISCHER 344 | Fischer 344",,,,,,,,,,,,,,,"4218623","Fischer rat",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL542217","Grade 1 Carbon Monoxide Diffusing Capacity Decreased, CTCAE","C144020","3-5 units below LLN; for follow-up, a decrease of 3-5 units (ml/min/mm Hg) below the baseline value; asymptomatic and intervention not indicated","Grade 1 Carbon Monoxide Diffusing Capacity Decreased, CTCAE | Grade 1 Carbon monoxide diffusing capacity decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542218","Grade 1 Cardiac Disorders - Other, Specify, CTCAE","C144021","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Cardiac Disorders - Other, Specify, CTCAE | Grade 1 Cardiac disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542219","Grade 1 Cardiac Troponin I Increased, CTCAE","C144022","Levels above the upper limit of normal and below the level of myocardial infarction as defined by the manufacturer","Grade 1 Cardiac Troponin I Increased, CTCAE | Grade 1 Cardiac troponin I increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542220","Grade 1 Cardiac Troponin T Increased, CTCAE","C144023","Levels above the upper limit of normal and below the level of myocardial infarction as defined by the manufacturer","Grade 1 Cardiac Troponin T Increased, CTCAE | Grade 1 Cardiac troponin T increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542205","Grade 1 CD4 Lymphocytes Decreased, CTCAE","C144024","<LLN-500/mm3; <LLN-0.5 x 10e9/L","Grade 1 CD4 Lymphocytes Decreased, CTCAE | Grade 1 CD4 lymphocytes decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542363","Grade 1 Guillain-Barre Syndrome, CTCAE","C144136","Mild symptoms","Grade 1 Guillain-Barre Syndrome, CTCAE | Grade 1 Guillain-Barre syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542364","Grade 1 Gum Infection, CTCAE","C144137","Local therapy indicated (swish and swallow)","Grade 1 Gum Infection, CTCAE | Grade 1 Gum infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542349","Grade 1 Gynecomastia, CTCAE","C144138","Asymptomatic","Grade 1 Gynecomastia, CTCAE | Grade 1 Gynecomastia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542350","Grade 1 Hair Color Changes, CTCAE","C144139","Present","Grade 1 Hair Color Changes, CTCAE | Grade 1 Hair color changes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542667","Grade 2 Amnesia, CTCAE","C144509","Moderate; short term memory loss; limiting instrumental ADL","Grade 2 Amnesia, CTCAE | Grade 2 Amnesia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542668","Grade 2 Anal Fissure, CTCAE","C144510","Symptomatic","Grade 2 Anal Fissure, CTCAE | Grade 2 Anal fissure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542653","Grade 2 Anal Fistula, CTCAE","C144511","Symptomatic, invasive intervention not indicated","Grade 2 Anal Fistula, CTCAE | Grade 2 Anal fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542654","Grade 2 Anal Hemorrhage, CTCAE","C144512","Moderate symptoms; intervention indicated","Grade 2 Anal Hemorrhage, CTCAE | Grade 2 Anal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542656","Grade 2 Anal Pain, CTCAE","C144514","Moderate pain; limiting instrumental ADL","Grade 2 Anal Pain, CTCAE | Grade 2 Anal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542657","Grade 2 Anal Stenosis, CTCAE","C144515","Symptomatic; altered GI function","Grade 2 Anal Stenosis, CTCAE | Grade 2 Anal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542658","Grade 2 Anal Ulcer, CTCAE","C144516","Symptomatic; altered GI function","Grade 2 Anal Ulcer, CTCAE | Grade 2 Anal ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542659","Grade 2 Anemia, CTCAE","C144517","Hgb <10.0-8.0 g/dL; <6.2-4.9 mmol/L; <100-80g/L","Grade 2 Anemia, CTCAE | Grade 2 Anemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542660","Grade 2 Ankle Fracture, CTCAE","C144518","Limiting instrumental ADL; outpatient operative intervention indicated","Grade 2 Ankle Fracture, CTCAE | Grade 2 Ankle fracture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542645","Grade 2 Anorectal Infection, CTCAE","C144519","Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Anorectal Infection, CTCAE | Grade 2 Anorectal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542646","Grade 2 Anorgasmia, CTCAE","C144520","Inability to achieve orgasm adversely affecting relationship","Grade 2 Anorgasmia, CTCAE | Grade 2 Anorgasmia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542648","Grade 2 Aortic Valve Disease, CTCAE","C144522","Asymptomatic; moderate regurgitation or stenosis by imaging","Grade 2 Aortic Valve Disease, CTCAE | Grade 2 Aortic valve disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542649","Grade 2 Arachnoiditis, CTCAE","C144523","Moderate symptoms; limiting instrumental ADL","Grade 2 Arachnoiditis, CTCAE | Grade 2 Arachnoiditis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542650","Grade 2 Arterial Injury, CTCAE","C144524","Symptomatic; repair or revision not indicated","Grade 2 Arterial Injury, CTCAE | Grade 2 Arterial injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542651","Grade 2 Arthralgia, CTCAE","C144525","Moderate pain; limiting instrumental ADL","Grade 2 Arthralgia, CTCAE | Grade 2 Arthralgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542652","Grade 2 Arthritis, CTCAE","C144526","Moderate pain associated with signs of inflammation, erythema, or joint swelling; limiting instrumental ADL","Grade 2 Arthritis, CTCAE | Grade 2 Arthritis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542765","Grade 2 Ascites, CTCAE","C144527","Symptomatic; medical intervention indicated","Grade 2 Ascites, CTCAE | Grade 2 Ascites",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542767","Grade 2 Atrioventricular Block Complete, CTCAE","C144529","Non-urgent intervention indicated","Grade 2 Atrioventricular Block Complete, CTCAE | Grade 2 Atrioventricular block complete",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516137","BDII, Rat Strain","C14388","Frequent microphthalmia. Genetic markers described for sublines of this strain in the USA differ from those in Europe, suggesting that the US sublines were contaminated at some time in the past with LEW (Czerwinski and Crowell 1986). Mean life-span of BDII/Han 33.6 +/-4.7 months in males and 22.5+/-4.4 months in females, with 91% of females developing endometrial carcinomas, but with a more varied range of tumors in males. These include 26% adrenal pheochromocytomas, 23% histiocytic sarcomas, 18% pituitary tumors and 14% hemangiomas. About 12% of aged male BDII/Han develop diverticula of the stomach (Kaspareit-Rittinghausen and Deerberg 1987). High incidence of hormone-dependent endometrial adenocarcinoma.","BDII, Rat Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513684","Mouse Strains","C14420","Breeds of mice utilized for biological research.","Mouse Strains | Mouse Strain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542415","Grade 1 Intraoperative Head and Neck Injury, CTCAE","C144210","Primary repair of injured organ/structure indicated","Grade 1 Intraoperative Head and Neck Injury, CTCAE | Grade 1 Intraoperative head and neck injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542417","Grade 1 Intraoperative Musculoskeletal Injury, CTCAE","C144212","Primary repair of injured organ/structure indicated","Grade 1 Intraoperative Musculoskeletal Injury, CTCAE | Grade 1 Intraoperative musculoskeletal injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542872","Grade 2 Gastrointestinal Disorders - Other, Specify, CTCAE","C144685","Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL","Grade 2 Gastrointestinal Disorders - Other, Specify, CTCAE | Grade 2 Gastrointestinal disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542873","Grade 2 Gastrointestinal Fistula, CTCAE","C144686","Symptomatic, invasive intervention not indicated","Grade 2 Gastrointestinal Fistula, CTCAE | Grade 2 Gastrointestinal fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542874","Grade 2 Gastrointestinal Pain, CTCAE","C144687","Moderate pain; limiting instrumental ADL","Grade 2 Gastrointestinal Pain, CTCAE | Grade 2 Gastrointestinal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542875","Grade 2 Gastrointestinal Stoma Necrosis, CTCAE","C144688","Superficial necrosis; intervention not indicated","Grade 2 Gastrointestinal Stoma Necrosis, CTCAE | Grade 2 Gastrointestinal stoma necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542861","Grade 2 General Disorders and Administration Site Conditions - Other, Specify, CTCAE","C144690","Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL","Grade 2 General Disorders and Administration Site Conditions - Other, Specify, CTCAE | Grade 2 General disorders and administration site conditions - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542862","Grade 2 Generalized Edema, CTCAE","C144691","Interfering with instrumental ADLs; oral therapy initiated","Grade 2 Generalized Edema, CTCAE | Grade 2 Generalized edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542863","Grade 2 Generalized Muscle Weakness, CTCAE","C144692","Symptomatic; evident on physical exam; limiting instrumental ADL","Grade 2 Generalized Muscle Weakness, CTCAE | Grade 2 Generalized muscle weakness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542864","Grade 2 Genital Edema, CTCAE","C144693","Readily apparent obscuration of anatomic architecture; obliteration of skin folds; readily apparent deviation from normal anatomic contour","Grade 2 Genital Edema, CTCAE | Grade 2 Genital edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542865","Grade 2 GGT Increased, CTCAE","C144694",">2.5-5.0 x ULN if baseline was normal; >2.5-5.0 x baseline if baseline was abnormal","Grade 2 GGT Increased, CTCAE | Grade 2 GGT increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542866","Grade 2 Gingival Pain, CTCAE","C144695","Moderate pain interfering with oral intake","Grade 2 Gingival Pain, CTCAE | Grade 2 Gingival pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542867","Grade 2 Glossopharyngeal Nerve Disorder, CTCAE","C144696","Moderate symptoms; limiting instrumental ADL","Grade 2 Glossopharyngeal Nerve Disorder, CTCAE | Grade 2 Glossopharyngeal nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542868","Grade 2 Glucose Intolerance, CTCAE","C144697","Symptomatic; dietary modification or oral agent indicated","Grade 2 Glucose Intolerance, CTCAE | Grade 2 Glucose intolerance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542854","Grade 2 Growth Hormone Abnormal, CTCAE","C144699","Symptomatic; medical intervention indicated; limiting instrumental ADL","Grade 2 Growth Hormone Abnormal, CTCAE | Grade 2 Growth hormone abnormal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542855","Grade 2 Growth Suppression, CTCAE","C144700","Reduction in growth velocity by 30-49% ideally measured over the period of a year or 0-49% reduction in growth from the baseline growth curve","Grade 2 Growth Suppression, CTCAE | Grade 2 Growth suppression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542856","Grade 2 Guillain-Barre Syndrome, CTCAE","C144701","Moderate symptoms; limiting instrumental ADL","Grade 2 Guillain-Barre Syndrome, CTCAE | Grade 2 Guillain-Barre syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542857","Grade 2 Gum Infection, CTCAE","C144702","Moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Gum Infection, CTCAE | Grade 2 Gum infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542207","Grade 1 Central Nervous System Necrosis, CTCAE","C144026","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Central Nervous System Necrosis, CTCAE | Grade 1 Central nervous system necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542208","Grade 1 Cerebrospinal Fluid Leakage, CTCAE","C144027","Post-craniotomy: asymptomatic; Post-lumbar puncture: transient headache; postural care indicated","Grade 1 Cerebrospinal Fluid Leakage, CTCAE | Grade 1 Cerebrospinal fluid leakage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542209","Grade 1 Chest Pain - Cardiac, CTCAE","C144028","Mild pain","Grade 1 Chest Pain - Cardiac, CTCAE | Grade 1 Chest pain - cardiac",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542210","Grade 1 Chills, CTCAE","C144029","Mild sensation of cold; shivering; chattering of teeth","Grade 1 Chills, CTCAE | Grade 1 Chills",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517096","FH, Rat Strain","C14402","It has been suggested that FH rats represent a genetic model of depression They have altered serotonergic function (Aulka et al, 1994a), they exhibit differential responses to serotonin agonists and antagonists compared with other strains (Meehan and Schechter, 1994), and long-term treatment with imipramine, clomipramine and clorgyline produced significant decreases in plasma corticosterone levels, supporting this suggestion (Aulka et al, 1993).","FH, Rat Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542211","Grade 1 Cholesterol High, CTCAE","C144030",">ULN-300 mg/dL; >ULN-7.75 mmol/L","Grade 1 Cholesterol High, CTCAE | Grade 1 Cholesterol high",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542212","Grade 1 Chronic Kidney Disease, CTCAE","C144031","eGFR (estimated Glomerular Filtration Rate) or CrCl (creatinine clearance) <LLN-60 ml/min/1.73 m2 or proteinuria 2+ present; urine protein/creatinine >0.5","Grade 1 Chronic Kidney Disease, CTCAE | Grade 1 Chronic kidney disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542198","Grade 1 Colonic Fistula, CTCAE","C144033","Asymptomatic","Grade 1 Colonic Fistula, CTCAE | Grade 1 Colonic fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542199","Grade 1 Colonic Hemorrhage, CTCAE","C144034","Mild symptoms; intervention not indicated","Grade 1 Colonic Hemorrhage, CTCAE | Grade 1 Colonic hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542200","Grade 1 Colonic Obstruction, CTCAE","C144035","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Colonic Obstruction, CTCAE | Grade 1 Colonic obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542201","Grade 1 Colonic Stenosis, CTCAE","C144036","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Colonic Stenosis, CTCAE | Grade 1 Colonic stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542202","Grade 1 Colonic Ulcer, CTCAE","C144037","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Colonic Ulcer, CTCAE | Grade 1 Colonic ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542203","Grade 1 Concentration Impairment, CTCAE","C144038","Mild inattention or decreased level of concentration","Grade 1 Concentration Impairment, CTCAE | Grade 1 Concentration impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542629","Grade 1 Skin Infection, CTCAE","C144401","Localized, local intervention indicated","Grade 1 Skin Infection, CTCAE | Grade 1 Skin infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542630","Grade 1 Skin Papilloma, CTCAE","C144402","Asymptomatic; intervention not indicated","Grade 1 Skin Papilloma, CTCAE | Grade 1 Skin papilloma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542631","Grade 1 Skin Ulceration, CTCAE","C144403","Combined area of ulcers <1 cm; nonblanchable erythema of intact skin with associated warmth or edema","Grade 1 Skin Ulceration, CTCAE | Grade 1 Skin ulceration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542632","Grade 1 Sleep Apnea, CTCAE","C144404","Snoring and nocturnal sleep arousal without apneic periods","Grade 1 Sleep Apnea, CTCAE | Grade 1 Sleep apnea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542633","Grade 1 Small Intestinal Anastomotic Leak, CTCAE","C144405","Asymptomatic diagnostic finding; intervention not indicated","Grade 1 Small Intestinal Anastomotic Leak, CTCAE | Grade 1 Small intestinal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542634","Grade 1 Small Intestinal Mucositis, CTCAE","C144406","Asymptomatic or mild symptoms; intervention not indicated","Grade 1 Small Intestinal Mucositis, CTCAE | Grade 1 Small intestinal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542768","Grade 2 Atrioventricular Block First Degree, CTCAE","C144530","Non-urgent intervention indicated","Grade 2 Atrioventricular Block First Degree, CTCAE | Grade 2 Atrioventricular block first degree",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542769","Grade 2 Autoimmune Disorder, CTCAE","C144531","Evidence of autoimmune reaction involving a non-essential organ or function (e.g., hypothyroidism)","Grade 2 Autoimmune Disorder, CTCAE | Grade 2 Autoimmune disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542770","Grade 2 Avascular Necrosis, CTCAE","C144532","Symptomatic; limiting instrumental ADL","Grade 2 Avascular Necrosis, CTCAE | Grade 2 Avascular necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542771","Grade 2 Azoospermia, CTCAE","C144533","Absence of sperm in ejaculate","Grade 2 Azoospermia, CTCAE | Grade 2 Azoospermia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542772","Grade 2 Bacteremia, CTCAE","C144534","Blood culture positive with no signs or symptoms","Grade 2 Bacteremia, CTCAE | Grade 2 Bacteremia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542757","Grade 2 Belching, CTCAE","C144535","Intervention initiated (including over the counter medications)","Grade 2 Belching, CTCAE | Grade 2 Belching",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543047","Grade 2 Phantom Pain, CTCAE","C144914","Moderate pain; limiting instrumental ADL","Grade 2 Phantom Pain, CTCAE | Grade 2 Phantom pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543048","Grade 2 Pharyngeal Anastomotic Leak, CTCAE","C144915","Symptomatic; medical intervention indicated","Grade 2 Pharyngeal Anastomotic Leak, CTCAE | Grade 2 Pharyngeal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543049","Grade 2 Pharyngeal Mucositis, CTCAE","C144918","Moderate pain, analgesics indicated; altered oral intake; limiting instrumental ADL","Grade 2 Pharyngeal Mucositis, CTCAE | Grade 2 Pharyngeal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543051","Grade 2 Pharyngitis, CTCAE","C144920","Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Pharyngitis, CTCAE | Grade 2 Pharyngitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543052","Grade 2 Pharyngolaryngeal Pain, CTCAE","C144921","Moderate pain; limiting instrumental ADL","Grade 2 Pharyngolaryngeal Pain, CTCAE | Grade 2 Pharyngolaryngeal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543037","Grade 2 Phlebitis Infective, CTCAE","C144922","Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Phlebitis Infective, CTCAE | Grade 2 Phlebitis infective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543038","Grade 2 Phlebitis, CTCAE","C144923","Present","Grade 2 Phlebitis, CTCAE | Grade 2 Phlebitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543039","Grade 2 Platelet Count Decreased, CTCAE","C144924","<75,000-50,000/mm3; <75.0-50.0 x 10e9/L","Grade 2 Platelet Count Decreased, CTCAE | Grade 2 Platelet count decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543040","Grade 2 Pleural Effusion, CTCAE","C144925","Symptomatic; intervention indicated (e.g., diuretics or therapeutic thoracentesis)","Grade 2 Pleural Effusion, CTCAE | Grade 2 Pleural effusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543041","Grade 2 Pleural Infection, CTCAE","C144927","Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Pleural Infection, CTCAE | Grade 2 Pleural infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543042","Grade 2 Pleuritic Pain, CTCAE","C144928","Moderate pain; limiting instrumental ADL","Grade 2 Pleuritic Pain, CTCAE | Grade 2 Pleuritic pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543043","Grade 2 Pneumonitis, CTCAE","C144929","Symptomatic; medical intervention indicated; limiting instrumental ADL","Grade 2 Pneumonitis, CTCAE | Grade 2 Pneumonitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543029","Grade 2 Portal Vein Thrombosis, CTCAE","C144931","Intervention not indicated","Grade 2 Portal Vein Thrombosis, CTCAE | Grade 2 Portal vein thrombosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543030","Grade 2 Postnasal Drip, CTCAE","C144932","Moderate symptoms; medical intervention indicated","Grade 2 Postnasal Drip, CTCAE | Grade 2 Postnasal drip",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543031","Grade 2 Postoperative Hemorrhage, CTCAE","C144933","Moderate bleeding requiring transfusion < 2 units (10 cc/kg for pediatrics) of pRBCs","Grade 2 Postoperative Hemorrhage, CTCAE | Grade 2 Postoperative hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542418","Grade 1 Intraoperative Neurological Injury, CTCAE","C144213","Primary repair of injured organ/structure indicated","Grade 1 Intraoperative Neurological Injury, CTCAE | Grade 1 Intraoperative neurological injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542419","Grade 1 Intraoperative Ocular Injury, CTCAE","C144214","Primary repair of injured organ/structure indicated","Grade 1 Intraoperative Ocular Injury, CTCAE | Grade 1 Intraoperative ocular injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542420","Grade 1 Intraoperative Renal Injury, CTCAE","C144215","Primary repair of injured organ/structure indicated","Grade 1 Intraoperative Renal Injury, CTCAE | Grade 1 Intraoperative renal injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542405","Grade 1 Intraoperative Reproductive Tract Injury, CTCAE","C144216","Primary repair of injured organ/structure indicated","Grade 1 Intraoperative Reproductive Tract Injury, CTCAE | Grade 1 Intraoperative reproductive tract injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542406","Grade 1 Intraoperative Respiratory Injury, CTCAE","C144217","Primary repair of injured organ/structure indicated","Grade 1 Intraoperative Respiratory Injury, CTCAE | Grade 1 Intraoperative respiratory injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542407","Grade 1 Intraoperative Urinary Injury, CTCAE","C144218","Primary repair of injured organ/structure indicated","Grade 1 Intraoperative Urinary Injury, CTCAE | Grade 1 Intraoperative urinary injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542408","Grade 1 Intraoperative Venous Injury, CTCAE","C144219","Primary repair of injured organ/structure indicated","Grade 1 Intraoperative Venous Injury, CTCAE | Grade 1 Intraoperative venous injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542409","Grade 1 Investigations - Other, Specify, CTCAE","C144220","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Investigations - Other, Specify, CTCAE | Grade 1 Investigations - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542411","Grade 1 Irritability, CTCAE","C144222","Mild; easily consolable","Grade 1 Irritability, CTCAE | Grade 1 Irritability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542412","Grade 1 Ischemia Cerebrovascular, CTCAE","C144223","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Ischemia Cerebrovascular, CTCAE | Grade 1 Ischemia cerebrovascular",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542397","Grade 1 Jejunal Stenosis, CTCAE","C144227","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Jejunal Stenosis, CTCAE | Grade 1 Jejunal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542398","Grade 1 Joint Range of Motion Decreased Cervical Spine, CTCAE","C144229","Mild restriction of rotation or flexion between 60-70 degrees","Grade 1 Joint Range of Motion Decreased Cervical Spine, CTCAE | Grade 1 Joint range of motion decreased cervical spine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542399","Grade 1 Joint Range of Motion Decreased Lumbar Spine, CTCAE","C144230","Stiffness; difficulty bending to the floor to pick up a very light object but able to do athletic activity","Grade 1 Joint Range of Motion Decreased Lumbar Spine, CTCAE | Grade 1 Joint range of motion decreased lumbar spine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542400","Grade 1 Joint Range of Motion Decreased, CTCAE","C144231","<=25% loss of ROM (range of motion); decreased ROM limiting athletic activity","Grade 1 Joint Range of Motion Decreased, CTCAE | Grade 1 Joint range of motion decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542401","Grade 1 Kidney Anastomotic Leak, CTCAE","C144232","Asymptomatic diagnostic finding; intervention not indicated","Grade 1 Kidney Anastomotic Leak, CTCAE | Grade 1 Kidney anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542402","Grade 1 Kyphosis, CTCAE","C144233","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Kyphosis, CTCAE | Grade 1 Kyphosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542813","Grade 2 Dry Mouth, CTCAE","C144608","Moderate symptoms; oral intake alterations (e.g., copious water, other lubricants, diet limited to purees and/or soft, moist foods); unstimulated saliva 0.1 to 0.2 ml/min","Grade 2 Dry Mouth, CTCAE | Grade 2 Dry mouth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542859","Grade 2 Headache, CTCAE","C144704","Moderate pain; limiting instrumental ADL","Grade 2 Headache, CTCAE | Grade 2 Headache",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542860","Grade 2 Hearing Impaired, CTCAE","C144705","Adults enrolled on a Monitoring Program (on a 1, 2, 3, 4, 6, and 8 kHz audiogram): Threshold shift of >25 dB averaged at 2 contiguous test frequencies in at least one ear; Adults not enrolled on a Monitoring Program: Hearing loss with hearing aid or intervention not indicated; limiting instrumental ADL; Pediatric (on a 1, 2, 3, 4, 6, and 8 kHz audiogram): Threshold shift >20 dB at 4 kHz in at least one ear","Grade 2 Hearing Impaired, CTCAE | Grade 2 Hearing impaired",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543261","Grade 2 Viremia, CTCAE","C145096","Moderate symptoms; medical intervention indicated","Grade 2 Viremia, CTCAE | Grade 2 Viremia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543262","Grade 2 Virilization, CTCAE","C145097","Moderate symptoms; medical intervention indicated","Grade 2 Virilization, CTCAE | Grade 2 Virilization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543264","Grade 2 Vision Decreased, CTCAE","C145099","Moderate decrease in visual acuity (best corrected visual acuity 20/40 and better or 3 lines or less decreased vision from known baseline)","Grade 2 Vision Decreased, CTCAE | Grade 2 Vision decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543265","Grade 2 Vital Capacity Abnormal, CTCAE","C145100","<75-50% of predicted value; limiting instrumental ADL","Grade 2 Vital Capacity Abnormal, CTCAE | Grade 2 Vital capacity abnormal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543266","Grade 2 Voice Alteration, CTCAE","C145101","Moderate or persistent change from normal voice; still understandable","Grade 2 Voice Alteration, CTCAE | Grade 2 Voice alteration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543267","Grade 2 Vulval Infection, CTCAE","C145102","Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Vulval Infection, CTCAE | Grade 2 Vulval infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543268","Grade 2 Watering Eyes, CTCAE","C145103","Symptomatic; moderate decrease in visual acuity (best corrected visual acuity 20/40 and better or 3 lines or less decreased vision from known baseline)","Grade 2 Watering Eyes, CTCAE | Grade 2 Watering eyes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543253","Grade 2 Wheezing, CTCAE","C145104","Moderate symptoms; medical intervention indicated; limiting instrumental ADL","Grade 2 Wheezing, CTCAE | Grade 2 Wheezing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543254","Grade 2 White Blood Cell Decreased, CTCAE","C145105","<3000-2000/mm3; <3.0-2.0 x 10e9/L","Grade 2 White Blood Cell Decreased, CTCAE | Grade 2 White blood cell decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543256","Grade 2 Wound Dehiscence, CTCAE","C145107","Incisional separation, local care (e.g., suturing) or medical intervention indicated (e.g., analgesic)","Grade 2 Wound Dehiscence, CTCAE | Grade 2 Wound dehiscence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543257","Grade 2 Wound Infection, CTCAE","C145108","Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Wound Infection, CTCAE | Grade 2 Wound infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543258","Grade 2 Wrist Fracture, CTCAE","C145109","Limiting instrumental ADL; outpatient operative intervention indicated","Grade 2 Wrist Fracture, CTCAE | Grade 2 Wrist fracture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543259","Grade 3 Abdominal Distension, CTCAE","C145110","Severe discomfort; limiting self care ADL","Grade 3 Abdominal Distension, CTCAE | Grade 3 Abdominal distension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543260","Grade 3 Abdominal Infection, CTCAE","C145111","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Abdominal Infection, CTCAE | Grade 3 Abdominal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542635","Grade 1 Small Intestinal Obstruction, CTCAE","C144407","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Small Intestinal Obstruction, CTCAE | Grade 1 Small intestinal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542636","Grade 1 Small Intestinal Stenosis, CTCAE","C144408","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Small Intestinal Stenosis, CTCAE | Grade 1 Small intestinal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542622","Grade 1 Sneezing, CTCAE","C144410","Mild symptoms; intervention not indicated","Grade 1 Sneezing, CTCAE | Grade 1 Sneezing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542623","Grade 1 Social Circumstances - Other, Specify, CTCAE","C144411","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Social Circumstances - Other, Specify, CTCAE | Grade 1 Social circumstances - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542624","Grade 1 Somnolence, CTCAE","C144412","Mild but more than usual drowsiness or sleepiness","Grade 1 Somnolence, CTCAE | Grade 1 Somnolence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542625","Grade 1 Sore Throat, CTCAE","C144413","Mild pain","Grade 1 Sore Throat, CTCAE | Grade 1 Sore throat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542626","Grade 1 Spasticity, CTCAE","C144414","Mild or slight increase in muscle tone","Grade 1 Spasticity, CTCAE | Grade 1 Spasticity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542627","Grade 1 Spermatic Cord Anastomotic Leak, CTCAE","C144415","Asymptomatic diagnostic finding; intervention not indicated","Grade 1 Spermatic Cord Anastomotic Leak, CTCAE | Grade 1 Spermatic cord anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542628","Grade 1 Spinal Fracture, CTCAE","C144416","Mild back pain; nonprescription analgesics indicated","Grade 1 Spinal Fracture, CTCAE | Grade 1 Spinal fracture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542613","Grade 1 Stoma Site Infection, CTCAE","C144417","Localized, local intervention indicated","Grade 1 Stoma Site Infection, CTCAE | Grade 1 Stoma site infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542615","Grade 1 Stroke, CTCAE","C144419","Incidental radiographic findings only","Grade 1 Stroke, CTCAE | Grade 1 Stroke",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542616","Grade 1 Subcutaneous Emphysema, CTCAE","C144420","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Subcutaneous Emphysema, CTCAE | Grade 1 Subcutaneous emphysema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542617","Grade 1 Suicidal Ideation, CTCAE","C144421","Increased thoughts of death but no wish to kill oneself","Grade 1 Suicidal Ideation, CTCAE | Grade 1 Suicidal ideation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542618","Grade 1 Superficial Soft Tissue Fibrosis, CTCAE","C144422","Mild induration, able to move skin parallel to plane (sliding) and perpendicular to skin (pinching up)","Grade 1 Superficial Soft Tissue Fibrosis, CTCAE | Grade 1 Superficial soft tissue fibrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542619","Grade 1 Superior Vena Cava Syndrome, CTCAE","C144423","Asymptomatic; incidental finding of SVC thrombosis","Grade 1 Superior Vena Cava Syndrome, CTCAE | Grade 1 Superior vena cava syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542620","Grade 1 Surgical and Medical Procedures - Other, Specify, CTCAE","C144424","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Surgical and Medical Procedures - Other, Specify, CTCAE | Grade 1 Surgical and medical procedures - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542915","Grade 2 Intraoperative Renal Injury, CTCAE","C144782","Partial resection of injured organ/structure indicated","Grade 2 Intraoperative Renal Injury, CTCAE | Grade 2 Intraoperative renal injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542916","Grade 2 Intraoperative Reproductive Tract Injury, CTCAE","C144783","Partial resection of injured organ/structure indicated","Grade 2 Intraoperative Reproductive Tract Injury, CTCAE | Grade 2 Intraoperative reproductive tract injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542901","Grade 2 Intraoperative Respiratory Injury, CTCAE","C144784","Partial resection of injured organ/structure indicated","Grade 2 Intraoperative Respiratory Injury, CTCAE | Grade 2 Intraoperative respiratory injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543032","Grade 2 Postoperative Thoracic Procedure Complication, CTCAE","C144934","Extubated within 24-72 hrs postoperatively","Grade 2 Postoperative Thoracic Procedure Complication, CTCAE | Grade 2 Postoperative thoracic procedure complication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543033","Grade 2 Pregnancy, Puerperium and Perinatal Conditions - Other, Specify, CTCAE","C144935","Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL","Grade 2 Pregnancy, Puerperium and Perinatal Conditions - Other, Specify, CTCAE | Grade 2 Pregnancy, puerperium and perinatal conditions - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543034","Grade 2 Premature Delivery, CTCAE","C144936","Delivery of a liveborn infant at >28 to 34 weeks gestation","Grade 2 Premature Delivery, CTCAE | Grade 2 Premature delivery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543036","Grade 2 Presyncope, CTCAE","C144938","Present (e.g., near fainting)","Grade 2 Presyncope, CTCAE | Grade 2 Presyncope",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543149","Grade 2 Productive Cough, CTCAE","C144939","Moderate sputum production; limiting instrumental ADL","Grade 2 Productive Cough, CTCAE | Grade 2 Productive cough",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543150","Grade 2 Prolapse of Intestinal Stoma, CTCAE","C144940","Recurrent after manual reduction; local irritation or stool leakage; difficulty to fit appliance; limiting instrumental ADL","Grade 2 Prolapse of Intestinal Stoma, CTCAE | Grade 2 Prolapse of intestinal stoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543151","Grade 2 Prolapse of Urostomy, CTCAE","C144941","Local care or maintenance; minor revision indicated","Grade 2 Prolapse of Urostomy, CTCAE | Grade 2 Prolapse of urostomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519131","SD/Rij, Rat Strain","C14381","Less sensitive to the induction of mammary tumors by DMBA than two samples of outbred Sprague-Dawley rats; mean life-span 743-22 days.","SD/Rij, Rat Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542815","Grade 2 Duodenal Infection, CTCAE","C144611","Moderate symptoms; medical intervention indicated (e.g., oral antibiotics)","Grade 2 Duodenal Infection, CTCAE | Grade 2 Duodenal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542816","Grade 2 Duodenal Obstruction, CTCAE","C144612","Symptomatic; altered GI function","Grade 2 Duodenal Obstruction, CTCAE | Grade 2 Duodenal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542817","Grade 2 Duodenal Perforation, CTCAE","C144613","Invasive intervention not indicated","Grade 2 Duodenal Perforation, CTCAE | Grade 2 Duodenal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542818","Grade 2 Duodenal Stenosis, CTCAE","C144614","Symptomatic; altered GI function","Grade 2 Duodenal Stenosis, CTCAE | Grade 2 Duodenal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542819","Grade 2 Duodenal Ulcer, CTCAE","C144615","Symptomatic; medical intervention indicated; limiting instrumental ADL","Grade 2 Duodenal Ulcer, CTCAE | Grade 2 Duodenal ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542820","Grade 2 Dysarthria, CTCAE","C144616","Moderate impairment of articulation or slurred speech","Grade 2 Dysarthria, CTCAE | Grade 2 Dysarthria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542806","Grade 2 Dysgeusia, CTCAE","C144618","Altered taste with change in diet (e.g., oral supplements); noxious or unpleasant taste; loss of taste","Grade 2 Dysgeusia, CTCAE | Grade 2 Dysgeusia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542807","Grade 2 Dysmenorrhea, CTCAE","C144619","Moderate symptoms; limiting instrumental ADL","Grade 2 Dysmenorrhea, CTCAE | Grade 2 Dysmenorrhea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542808","Grade 2 Dyspareunia, CTCAE","C144620","Moderate discomfort or pain associated with vaginal penetration; discomfort or pain partially relieved with use of vaginal lubricants or estrogen","Grade 2 Dyspareunia, CTCAE | Grade 2 Dyspareunia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542809","Grade 2 Dyspepsia, CTCAE","C144621","Moderate symptoms; medical intervention indicated","Grade 2 Dyspepsia, CTCAE | Grade 2 Dyspepsia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542811","Grade 2 Ear and Labyrinth Disorders - Other, Specify, CTCAE","C144623","Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL","Grade 2 Ear and Labyrinth Disorders - Other, Specify, CTCAE | Grade 2 Ear and labyrinth disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542812","Grade 2 Ear Pain, CTCAE","C144624","Moderate pain; limiting instrumental ADL","Grade 2 Ear Pain, CTCAE | Grade 2 Ear pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542798","Grade 2 Edema Face, CTCAE","C144626","Moderate localized facial edema; limiting instrumental ADL","Grade 2 Edema Face, CTCAE | Grade 2 Edema face",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542799","Grade 2 Edema Limbs, CTCAE","C144627",">10-30% inter-limb discrepancy in volume or circumference at point of greatest visible difference; readily apparent obscuration of anatomic architecture; obliteration of skin folds; readily apparent deviation from normal anatomic contour; limiting instrumental ADL","Grade 2 Edema Limbs, CTCAE | Grade 2 Edema limbs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542800","Grade 2 Edema Trunk, CTCAE","C144628","Readily apparent obscuration of anatomic architecture; obliteration of skin folds; readily apparent deviation from normal anatomic contour; limiting instrumental ADL","Grade 2 Edema Trunk, CTCAE | Grade 2 Edema trunk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542801","Grade 2 Ejaculation Disorder, CTCAE","C144629","Anejaculation or retrograde ejaculation","Grade 2 Ejaculation Disorder, CTCAE | Grade 2 Ejaculation disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542802","Grade 2 Ejection Fraction Decreased, CTCAE","C144630","Resting ejection fraction (EF) 50-40%; 10-19% drop from baseline","Grade 2 Ejection Fraction Decreased, CTCAE | Grade 2 Ejection fraction decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542803","Grade 2 Electrocardiogram QT Corrected Interval Prolonged, CTCAE","C144631","Average QTc 481-500 ms","Grade 2 Electrocardiogram QT Corrected Interval Prolonged, CTCAE | Grade 2 Electrocardiogram QT corrected interval prolonged",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543246","Grade 3 Abdominal Soft Tissue Necrosis, CTCAE","C145113","Operative debridement or other invasive intervention indicated (e.g., tissue reconstruction, flap, or grafting)","Grade 3 Abdominal Soft Tissue Necrosis, CTCAE | Grade 3 Abdominal soft tissue necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543247","Grade 3 Abducens Nerve Disorder, CTCAE","C145114","Severe symptoms; limiting self care ADL","Grade 3 Abducens Nerve Disorder, CTCAE | Grade 3 Abducens nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543248","Grade 3 Accessory Nerve Disorder, CTCAE","C145115","Severe symptoms; limiting self care ADL","Grade 3 Accessory Nerve Disorder, CTCAE | Grade 3 Accessory nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543249","Grade 3 Acidosis, CTCAE","C145116","pH <7.3","Grade 3 Acidosis, CTCAE | Grade 3 Acidosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543250","Grade 3 Acoustic Nerve Disorder NOS, CTCAE","C145117","Severe symptoms; limiting self care ADL","Grade 3 Acoustic Nerve Disorder NOS, CTCAE | Grade 3 Acoustic nerve disorder NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543251","Grade 3 Activated Partial Thromboplastin Time Prolonged, CTCAE","C145118",">2.5 x ULN; bleeding","Grade 3 Activated Partial Thromboplastin Time Prolonged, CTCAE | Grade 3 Activated partial thromboplastin time prolonged",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542159","Bispecific DART Protein MGD013","C143957","An Fc-bearing, humanized antibody-like protein that specifically recognizes the immune checkpoint molecules programmed cell death 1 (PD-1; PD1; PDCD1; CD279; Programmed Death 1) and lymphocyte activation gene-3 (LAG-3; LAG3; CD223), with potential T-lymphocyte immunomodulatory and antineoplastic activities. Upon administration, tebotelimab specifically binds to both PD-1 and LAG-3, which are both expressed on T-cells. The dual blockade of the PD-1 and LAG-3 pathways enables potent activation of a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. PD-1 and LAG-3 play key roles in suppressing T-cell activation.","Tebotelimab | Anti-PD-1/Anti-LAG-3 DART Protein MGD013 | Bispecific DART Protein MGD013 | Dual-affinity Retargeting Protein MGD013 | MGD 013 | MGD-013 | MGD013 | PD-1 x LAG-3 Bispecific DART Molecule MGD013 | PD-1 x LAG-3 DART Molecule MGD013 | PD-1 x LAG-3 DART Protein MGD013 | TEBOTELIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542160","Grade 1 Abdominal Distension, CTCAE","C143958","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Abdominal Distension, CTCAE | Grade 1 Abdominal distension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542145","Grade 1 Abdominal Pain, CTCAE","C143959","Mild pain","Grade 1 Abdominal Pain, CTCAE | Grade 1 Abdominal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
,,"C14395","An inbred strain of Rattus norvegicus derived from Silvers and Billingham stock (1958), characterized by a non-agouti brown coat color and RT1n MHC haplotype.","BN, Rat Strain | BN | BROWN NORWAY | Brown Norway Rat",,,,,,,,,,,,,,,"4195009","Brown Norway rat",,,,,,,,,,,,,,,,,,,,,,"--"
"CL542146","Grade 1 Abducens Nerve Disorder, CTCAE","C143960","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Abducens Nerve Disorder, CTCAE | Grade 1 Abducens nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542147","Grade 1 Accessory Nerve Disorder, CTCAE","C143961","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Accessory Nerve Disorder, CTCAE | Grade 1 Accessory nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542149","Grade 1 Acoustic Nerve Disorder NOS, CTCAE","C143963","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Acoustic Nerve Disorder NOS, CTCAE | Grade 1 Acoustic nerve disorder NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542150","Grade 1 Activated Partial Thromboplastin Time Prolonged, CTCAE","C143964",">ULN-1.5 x ULN","Grade 1 Activated Partial Thromboplastin Time Prolonged, CTCAE | Grade 1 Activated partial thromboplastin time prolonged",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542151","Grade 1 Akathisia, CTCAE","C143965","Mild restlessness or increased motor activity","Grade 1 Akathisia, CTCAE | Grade 1 Akathisia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542152","Grade 1 Alanine Aminotransferase Increased, CTCAE","C143966",">ULN-3.0 x ULN if baseline was normal; 1.5-3.0 x baseline if baseline was abnormal","Grade 1 Alanine Aminotransferase Increased, CTCAE | Grade 1 Alanine aminotransferase increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542137","Grade 1 Alkaline Phosphatase Increased, CTCAE","C143967",">ULN-2.5 x ULN if baseline was normal; 2.0-2.5 x baseline if baseline was abnormal","Grade 1 Alkaline Phosphatase Increased, CTCAE | Grade 1 Alkaline phosphatase increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542903","Grade 2 Intraoperative Urinary Injury, CTCAE","C144786","Partial resection of injured organ/structure indicated","Grade 2 Intraoperative Urinary Injury, CTCAE | Grade 2 Intraoperative urinary injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542904","Grade 2 Intraoperative Venous Injury, CTCAE","C144787","Partial resection of injured organ/structure indicated","Grade 2 Intraoperative Venous Injury, CTCAE | Grade 2 Intraoperative venous injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542905","Grade 2 Investigations - Other, Specify, CTCAE","C144788","Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL","Grade 2 Investigations - Other, Specify, CTCAE | Grade 2 Investigations - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542906","Grade 2 Irregular Menstruation, CTCAE","C144789","Intermittent/irregular menses for more than 3 consecutive menstrual cycles","Grade 2 Irregular Menstruation, CTCAE | Grade 2 Irregular menstruation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542907","Grade 2 Irritability, CTCAE","C144790","Moderate; limiting instrumental ADL; increased attention indicated","Grade 2 Irritability, CTCAE | Grade 2 Irritability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542908","Grade 2 Ischemia Cerebrovascular, CTCAE","C144791","Moderate symptoms","Grade 2 Ischemia Cerebrovascular, CTCAE | Grade 2 Ischemia cerebrovascular",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543021","Grade 2 Jejunal Perforation, CTCAE","C144795","Invasive intervention not indicated","Grade 2 Jejunal Perforation, CTCAE | Grade 2 Jejunal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543023","Grade 2 Joint Infection, CTCAE","C144798","Localized; local intervention indicated; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral); needle aspiration indicated (single or multiple)","Grade 2 Joint Infection, CTCAE | Grade 2 Joint infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543024","Grade 2 Joint Range of Motion Decreased Cervical Spine, CTCAE","C144799","Rotation <60 degrees to right or left; <60 degrees of flexion","Grade 2 Joint Range of Motion Decreased Cervical Spine, CTCAE | Grade 2 Joint range of motion decreased cervical spine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543025","Grade 2 Joint Range of Motion Decreased Lumbar Spine, CTCAE","C144800","Pain with range of motion (ROM) in lumbar spine; requires a reaching aid to pick up a very light object from the floor","Grade 2 Joint Range of Motion Decreased Lumbar Spine, CTCAE | Grade 2 Joint range of motion decreased lumbar spine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543026","Grade 2 Joint Range of Motion Decreased, CTCAE","C144801",">25-50% decrease in ROM; limiting instrumental ADL","Grade 2 Joint Range of Motion Decreased, CTCAE | Grade 2 Joint range of motion decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543027","Grade 2 Kidney Anastomotic Leak, CTCAE","C144802","Symptomatic; medical intervention indicated","Grade 2 Kidney Anastomotic Leak, CTCAE | Grade 2 Kidney anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543014","Grade 2 Lactation Disorder, CTCAE","C144805","Changes in lactation, significantly affecting breast production or expression of breast milk","Grade 2 Lactation Disorder, CTCAE | Grade 2 Lactation disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543015","Grade 2 Large Intestinal Anastomotic Leak, CTCAE","C144806","Symptomatic; medical intervention indicated","Grade 2 Large Intestinal Anastomotic Leak, CTCAE | Grade 2 Large intestinal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543016","Grade 2 Laryngeal Edema, CTCAE","C144807","Symptomatic; medical intervention indicated (e.g., dexamethasone, epinephrine, antihistamines)","Grade 2 Laryngeal Edema, CTCAE | Grade 2 Laryngeal edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543308","Grade 3 Chest Pain - Cardiac, CTCAE","C145192","Pain at rest; limiting self care ADL; cardiac catheterization; new onset cardiac chest pain; unstable angina","Grade 3 Chest Pain - Cardiac, CTCAE | Grade 3 Chest pain - cardiac",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518519","OM, Rat Strain","C14382","Spontaneous thyroid carcinoma 33% (Lindsey et al 1968). Adrenal cortical tumors 94% and pituitary tumors 8-18% at 18 months (Hansen et al 1973). In animals over 18 months Snell found adenomas or carcinomas of adrenal cortex 73% in males and 95% in females, pituitary tumors 25%, granulosa cell tumors of the ovary 33% in females. High blood pressure (3/23), reaching 154+/-1.0 (SEM) mmHg at 10 weeks of age (Tanase et al 1982). Mammary tumors 26-30%. High incidence of retinal degeneration in animals over 10 months (von Sallman and Grimes 1972, 1974). High systolic blood pressure (2/17) (Hansen et al 1973).","OM, Rat Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518523","OXYS, Rat Strain","C14413","Inherited overproduction of free radicals, high levels of lipid peroxidation, protein oxidation, DNA rearrangements, morbid conditions mimicking human degenerative diseases: cataract, emphysema, cardiomyopathy, carcinogenesis; short life-span and low fecundity. Intensive transport of monosaccharides into the cells (Salganik et al 1994).","OXYS, Rat Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542351","Grade 1 Hair Texture Abnormal, CTCAE","C144140","Present","Grade 1 Hair Texture Abnormal, CTCAE | Grade 1 Hair texture abnormal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542354","Grade 1 Headache, CTCAE","C144143","Mild pain","Grade 1 Headache, CTCAE | Grade 1 Headache",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542355","Grade 1 Hearing Impaired, CTCAE","C144144","Adults enrolled on a Monitoring Program (on a 1, 2, 4, 3, 6, and 8 kHz audiogram): Threshold shift of 15-25 dB averaged at 2 contiguous test frequencies in at least one ear; Adults not enrolled on a Monitoring Program: Subjective change in hearing in the absence of documented hearing loss; Pediatric (on a 1, 2, 3, 4, 6, and 8 kHz audiogram): Threshold shift >20 dB hearing loss (HL) (i.e., 25 dB HL or greater); sensorineural hearing loss (SNHL) above 4 kHz (i.e., 6 or 8 kHz) in at least one ear","Grade 1 Hearing Impaired, CTCAE | Grade 1 Hearing impaired",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542356","Grade 1 Heart Failure, CTCAE","C144145","Asymptomatic with laboratory (e.g., BNP [B-Natriuretic Peptide ]) or cardiac imaging abnormalities","Grade 1 Heart Failure, CTCAE | Grade 1 Heart failure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542341","Grade 1 Hematosalpinx, CTCAE","C144146","Minimal bleeding identified on imaging study or laparoscopy; intervention not indicated","Grade 1 Hematosalpinx, CTCAE | Grade 1 Hematosalpinx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542342","Grade 1 Hematuria, CTCAE","C144147","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Hematuria, CTCAE | Grade 1 Hematuria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542804","Grade 2 Electrocardiogram T Wave Abnormal, CTCAE","C144632","Nonspecific ST segment change","Grade 2 Electrocardiogram T Wave Abnormal, CTCAE | Grade 2 Electrocardiogram T wave abnormal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543205","Grade 2 Spasticity, CTCAE","C145018","Moderate increase in muscle tone and increase in resistance through range of motion","Grade 2 Spasticity, CTCAE | Grade 2 Spasticity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543206","Grade 2 Spermatic Cord Anastomotic Leak, CTCAE","C145019","Symptomatic; medical intervention indicated","Grade 2 Spermatic Cord Anastomotic Leak, CTCAE | Grade 2 Spermatic cord anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543207","Grade 2 Spinal Fracture, CTCAE","C145020","Moderate back pain; prescription analgesics indicated; limiting instrumental ADL","Grade 2 Spinal Fracture, CTCAE | Grade 2 Spinal fracture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543208","Grade 2 Stenosis of Gastrointestinal Stoma, CTCAE","C145021","Symptomatic; IV fluids indicated <24 hrs; manual dilation at bedside","Grade 2 Stenosis of Gastrointestinal Stoma, CTCAE | Grade 2 Stenosis of gastrointestinal stoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543209","Grade 2 Stoma Site Infection, CTCAE","C145022","Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Stoma Site Infection, CTCAE | Grade 2 Stoma site infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543210","Grade 2 Stomal Ulcer, CTCAE","C145023","Symptomatic; medical intervention indicated","Grade 2 Stomal Ulcer, CTCAE | Grade 2 Stomal ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543211","Grade 2 Stroke, CTCAE","C145024","Mild to moderate neurologic deficit; limiting instrumental ADL","Grade 2 Stroke, CTCAE | Grade 2 Stroke",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543197","Grade 2 Suicidal Ideation, CTCAE","C145026","Suicidal ideation with no specific plan or intent","Grade 2 Suicidal Ideation, CTCAE | Grade 2 Suicidal ideation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543198","Grade 2 Superficial Soft Tissue Fibrosis, CTCAE","C145027","Moderate induration, able to slide skin, unable to pinch skin; limiting instrumental ADL","Grade 2 Superficial Soft Tissue Fibrosis, CTCAE | Grade 2 Superficial soft tissue fibrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543199","Grade 2 Superficial Thrombophlebitis, CTCAE","C145028","Present","Grade 2 Superficial Thrombophlebitis, CTCAE | Grade 2 Superficial thrombophlebitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543200","Grade 2 Superior Vena Cava Syndrome, CTCAE","C145029","Symptomatic; medical intervention indicated (e.g., anticoagulation, radiation or chemotherapy)","Grade 2 Superior Vena Cava Syndrome, CTCAE | Grade 2 Superior vena cava syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543201","Grade 2 Surgical and Medical Procedures - Other, Specify, CTCAE","C145030","Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL","Grade 2 Surgical and Medical Procedures - Other, Specify, CTCAE | Grade 2 Surgical and medical procedures - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543202","Grade 2 Tendon Reflex Decreased, CTCAE","C145031","Ankle reflex absent; other reflexes reduced","Grade 2 Tendon Reflex Decreased, CTCAE | Grade 2 Tendon reflex decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543203","Grade 2 Testicular Disorder, CTCAE","C145032","Symptomatic but not interfering with sexual function; intervention not indicated; limiting instrumental ADL","Grade 2 Testicular Disorder, CTCAE | Grade 2 Testicular disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543204","Grade 2 Testicular Pain, CTCAE","C145034","Moderate pain; limiting instrumental ADL","Grade 2 Testicular Pain, CTCAE | Grade 2 Testicular pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543190","Grade 2 Thromboembolic Event, CTCAE","C145036","Medical intervention indicated","Grade 2 Thromboembolic Event, CTCAE | Grade 2 Thromboembolic event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543191","Grade 2 Thrush, CTCAE","C145037","Oral intervention indicated (e.g., antifungal)","Grade 2 Thrush, CTCAE | Grade 2 Thrush",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543192","Grade 2 Tooth Development Disorder, CTCAE","C145038","Impairment correctable with oral surgery","Grade 2 Tooth Development Disorder, CTCAE | Grade 2 Tooth development disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542139","Grade 1 Allergic Reaction, CTCAE","C143969","Systemic intervention not indicated","Grade 1 Allergic Reaction, CTCAE | Grade 1 Allergic reaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324533","BUF, Rat Strain","C14396","Derived from Buffalo stock of H. Morris to the NIH in 1950 and disseminated from Charles River since 1998, the Buffalo is a white albino rat, genotype c. The incidence of spontaneous tumor formation includes anterior pituitary and adrenal cortex in upwards of 30% of aged rats. The Buffalo rat is used most commonly in oncology and carcinogenesis research. Low incidence of dental caries. Spontaneous tumors of anterior pituitary 30%, and of adrenal cortex 25% in older animals. Survival 58% at 2 years of age with thyroid carcinoma in 25% (Lindsey et al 1968). Low incidence of renal neoplasms (Snell 1967). High incidence of tumors of the anterior pituitary, adrenal medulla and adrenal cortex in animals over 18 months old (Snell1965).","BUF, Rat Strain | BUF | BUFFALO | Buffalo Rat",,,,,,,,,,,,,,,"4208108","Buffalo rat",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL542140","Grade 1 Allergic Rhinitis, CTCAE","C143970","Mild symptoms; intervention not indicated","Grade 1 Allergic Rhinitis, CTCAE | Grade 1 Allergic rhinitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542141","Grade 1 Amnesia, CTCAE","C143971","Mild; transient memory loss","Grade 1 Amnesia, CTCAE | Grade 1 Amnesia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542142","Grade 1 Anal Fissure, CTCAE","C143972","Asymptomatic","Grade 1 Anal Fissure, CTCAE | Grade 1 Anal fissure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542143","Grade 1 Anal Fistula, CTCAE","C143973","Asymptomatic","Grade 1 Anal Fistula, CTCAE | Grade 1 Anal fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542253","Grade 1 Anal Mucositis, CTCAE","C143975","Asymptomatic or mild symptoms; intervention not indicated","Grade 1 Anal Mucositis, CTCAE | Grade 1 Anal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542458","Grade 1 Papilledema, CTCAE","C144316","Asymptomatic; no visual field deficit","Grade 1 Papilledema, CTCAE | Grade 1 Papilledema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542459","Grade 1 Papulopustular Rash, CTCAE","C144317","Papules and/or pustules covering <10% BSA, which may or may not be associated with symptoms of pruritus or tenderness","Grade 1 Papulopustular Rash, CTCAE | Grade 1 Papulopustular rash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542460","Grade 1 Paresthesia, CTCAE","C144318","Mild symptoms","Grade 1 Paresthesia, CTCAE | Grade 1 Paresthesia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542573","Grade 1 Paronychia, CTCAE","C144319","Nail fold edema or erythema; disruption of the cuticle","Grade 1 Paronychia, CTCAE | Grade 1 Paronychia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542574","Grade 1 Paroxysmal Atrial Tachycardia, CTCAE","C144320","Asymptomatic, intervention not indicated","Grade 1 Paroxysmal Atrial Tachycardia, CTCAE | Grade 1 Paroxysmal atrial tachycardia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542575","Grade 1 Pelvic Floor Muscle Weakness, CTCAE","C144321","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Pelvic Floor Muscle Weakness, CTCAE | Grade 1 Pelvic floor muscle weakness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542576","Grade 1 Pelvic Pain, CTCAE","C144322","Mild pain","Grade 1 Pelvic Pain, CTCAE | Grade 1 Pelvic pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542578","Grade 1 Perineal Pain, CTCAE","C144325","Mild pain","Grade 1 Perineal Pain, CTCAE | Grade 1 Perineal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542579","Grade 1 Periorbital Edema, CTCAE","C144326","Soft or non-pitting","Grade 1 Periorbital Edema, CTCAE | Grade 1 Periorbital edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542580","Grade 1 Peripheral Motor Neuropathy, CTCAE","C144327","Asymptomatic; clinical or diagnostic observations only","Grade 1 Peripheral Motor Neuropathy, CTCAE | Grade 1 Peripheral motor neuropathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542565","Grade 1 Peripheral Sensory Neuropathy, CTCAE","C144328","Asymptomatic","Grade 1 Peripheral Sensory Neuropathy, CTCAE | Grade 1 Peripheral sensory neuropathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542566","Grade 1 Personality Change, CTCAE","C144329","Mild personality change","Grade 1 Personality Change, CTCAE | Grade 1 Personality change",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542567","Grade 1 Phantom Pain, CTCAE","C144330","Mild pain","Grade 1 Phantom Pain, CTCAE | Grade 1 Phantom pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543294","Grade 3 Chills, CTCAE","C145194","Severe or prolonged, not responsive to narcotics","Grade 3 Chills, CTCAE | Grade 3 Chills",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543295","Grade 3 Cholesterol High, CTCAE","C145195",">400-500 mg/dL; >10.34-12.92 mmol/L","Grade 3 Cholesterol High, CTCAE | Grade 3 Cholesterol high",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543296","Grade 3 Chronic Kidney Disease, CTCAE","C145196","eGFR or CrCl 29-15 ml/min/1.73 m2","Grade 3 Chronic Kidney Disease, CTCAE | Grade 3 Chronic kidney disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543297","Grade 3 Chylous Ascites, CTCAE","C145197","Severe symptoms; elective operative intervention indicated","Grade 3 Chylous Ascites, CTCAE | Grade 3 Chylous ascites",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543298","Grade 3 Colonic Fistula, CTCAE","C145198","Invasive intervention indicated","Grade 3 Colonic Fistula, CTCAE | Grade 3 Colonic fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543299","Grade 3 Colonic Hemorrhage, CTCAE","C145199","Transfusion indicated; invasive intervention indicated; hospitalization","Grade 3 Colonic Hemorrhage, CTCAE | Grade 3 Colonic hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543285","Grade 3 Colonic Perforation, CTCAE","C145201","Invasive intervention indicated","Grade 3 Colonic Perforation, CTCAE | Grade 3 Colonic perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543286","Grade 3 Colonic Stenosis, CTCAE","C145202","Severely altered GI function; tube feeding or hospitalization indicated; elective operative intervention indicated","Grade 3 Colonic Stenosis, CTCAE | Grade 3 Colonic stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543287","Grade 3 Colonic Ulcer, CTCAE","C145203","Severely altered GI function; TPN indicated; elective invasive intervention indicated","Grade 3 Colonic Ulcer, CTCAE | Grade 3 Colonic ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543288","Grade 3 Concentration Impairment, CTCAE","C145204","Severe impairment in attention or decreased level of concentration; limiting self care ADL","Grade 3 Concentration Impairment, CTCAE | Grade 3 Concentration impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543289","Grade 3 Conduction Disorder, CTCAE","C145205","Symptomatic, urgent intervention indicated","Grade 3 Conduction Disorder, CTCAE | Grade 3 Conduction disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543290","Grade 3 Congenital, Familial and Genetic Disorders - Other, Specify, CTCAE","C145206","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL","Grade 3 Congenital, Familial and Genetic Disorders - Other, Specify, CTCAE | Grade 3 Congenital, familial and genetic disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543291","Grade 3 Conjunctivitis Infective, CTCAE","C145207","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Conjunctivitis Infective, CTCAE | Grade 3 Conjunctivitis infective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543405","Grade 3 Corneal Infection, CTCAE","C145209","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Corneal Infection, CTCAE | Grade 3 Corneal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543406","Grade 3 Corneal Ulcer, CTCAE","C145210","Corneal ulcer without perforation in the affected eye","Grade 3 Corneal Ulcer, CTCAE | Grade 3 Corneal ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543407","Grade 3 CPK Increased, CTCAE","C145211",">5 x ULN-10 x ULN","Grade 3 CPK Increased, CTCAE | Grade 3 CPK increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543408","Grade 3 Cranial Nerve Infection, CTCAE","C145212","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Cranial Nerve Infection, CTCAE | Grade 3 Cranial nerve infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543409","Grade 3 Creatinine Increased, CTCAE","C145213",">3.0 x baseline; >3.0-6.0 x ULN","Grade 3 Creatinine Increased, CTCAE | Grade 3 Creatinine increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542343","Grade 1 Hemoglobin Increased, CTCAE","C144148","Increase in >0-2 g/dL","Grade 1 Hemoglobin Increased, CTCAE | Grade 1 Hemoglobin increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520107","WAG, Rat Strain","C14414","Tumors: medullary thyroid carcinoma 27%, chromophobe adenoma of the pituitary 68%, adrenal cortical adenoma 29%, pheochromocytoma 2%, islet cell adenoma 1%. Mean life-span more than 31 months in females and 22 months in males (Boorman et al 1972). Mean life-span 31 months in females with pituitary tumors found in 69% of females. Other common tumors include medullary thyroid carcinoma 40%, adrenal cortical adenoma 29%, fibroadenoma of breast 21% with 19 other types of tumor found in 290 animals (Boorman and Hollander 1973).","WAG, Rat Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542345","Grade 1 Hepatic Hemorrhage, CTCAE","C144150","Mild symptoms; intervention not indicated","Grade 1 Hepatic Hemorrhage, CTCAE | Grade 1 Hepatic hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542346","Grade 1 Hepatic Pain, CTCAE","C144151","Mild pain","Grade 1 Hepatic Pain, CTCAE | Grade 1 Hepatic pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542347","Grade 1 Hepatitis B Reactivation, CTCAE","C144152","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Hepatitis B Reactivation, CTCAE | Grade 1 Hepatitis B reactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542348","Grade 1 Hepatitis Viral, CTCAE","C144153","Asymptomatic, intervention not indicated","Grade 1 Hepatitis Viral, CTCAE | Grade 1 Hepatitis viral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542333","Grade 1 Hepatobiliary Disorders - Other, Specify, CTCAE","C144154","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Hepatobiliary Disorders - Other, Specify, CTCAE | Grade 1 Hepatobiliary disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542334","Grade 1 Herpes Simplex Reactivation, CTCAE","C144155","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Herpes Simplex Reactivation, CTCAE | Grade 1 Herpes simplex reactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542336","Grade 1 Hirsutism, CTCAE","C144157","In women, increase in length, thickness or density of hair in a male distribution that the patient is able to camouflage by periodic shaving, bleaching, or removal of hair","Grade 1 Hirsutism, CTCAE | Grade 1 Hirsutism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542337","Grade 1 Hoarseness, CTCAE","C144158","Mild or intermittent voice change; fully understandable; self-resolves","Grade 1 Hoarseness, CTCAE | Grade 1 Hoarseness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542338","Grade 1 Hot Flashes, CTCAE","C144159","Mild symptoms; intervention not indicated","Grade 1 Hot Flashes, CTCAE | Grade 1 Hot flashes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518518","OM/N, substrain","C14415","No value exists.","OM/N, substrain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542758","Grade 2 Bile Duct Stenosis, CTCAE","C144536","Symptomatic; altered GI function; IV fluids indicated <24 hrs","Grade 2 Bile Duct Stenosis, CTCAE | Grade 2 Bile duct stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542760","Grade 2 Biliary Fistula, CTCAE","C144538","Symptomatic, invasive intervention not indicated","Grade 2 Biliary Fistula, CTCAE | Grade 2 Biliary fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542761","Grade 2 Biliary Tract Infection, CTCAE","C144539","Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Biliary Tract Infection, CTCAE | Grade 2 Biliary tract infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542762","Grade 2 Bladder Anastomotic Leak, CTCAE","C144540","Symptomatic; medical intervention indicated","Grade 2 Bladder Anastomotic Leak, CTCAE | Grade 2 Bladder anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542763","Grade 2 Bladder Infection, CTCAE","C144541","Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Bladder Infection, CTCAE | Grade 2 Bladder infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542764","Grade 2 Bloating, CTCAE","C144543","Symptomatic, decreased oral intake; change in bowel function","Grade 2 Bloating, CTCAE | Grade 2 Bloating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542749","Grade 2 Blood and Lymphatic System Disorders - Other, Specify, CTCAE","C144544","Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL","Grade 2 Blood and Lymphatic System Disorders - Other, Specify, CTCAE | Grade 2 Blood and lymphatic system disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543193","Grade 2 Tooth Infection, CTCAE","C145039","Localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral)","Grade 2 Tooth Infection, CTCAE | Grade 2 Tooth infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543194","Grade 2 Toothache, CTCAE","C145040","Moderate pain; limiting instrumental ADL","Grade 2 Toothache, CTCAE | Grade 2 Toothache",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543195","Grade 2 Tracheal Mucositis, CTCAE","C145043","Moderate symptoms; medical intervention indicated; limiting instrumental ADL","Grade 2 Tracheal Mucositis, CTCAE | Grade 2 Tracheal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510678","A990, Rat Strain","C14389","Resistant to Cysticercus. Susceptible to estrogen-induced mammary and adrenal tumors. Good reproduction. High open-field defecation (2/12, males, 3/12 females) and low ambulation (11/12), Harrington (1972). Low wheel activity (12/12) (Harrington 1971b). Aggressive towards handlers (Harrington 1981).","A990, Rat Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034707","WF, Rat Strain","C14390","A Wistar substrain derived by Furth (1945), this inbred rat strain is a white albino with pink eyes, genotype c. The Wistar Furth rat carries a heteropyenotic Y chromosome that is used as a cellular marker. Leukemia develops in 15-22% of these rats, which is characterized by mononuclear cells with reddish granules. The Wistar Furth rat exhibits good reproductive performance and is docile, with an averages life span of 22 months.","WF, Rat Strain | WF | WISTAR FURTH | Wistar Furth Rat",,,,,,,,,,,,,,,"4071930","Furth Wistar rat",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL542568","Grade 1 Pharyngeal Anastomotic Leak, CTCAE","C144331","Asymptomatic diagnostic finding; intervention not indicated","Grade 1 Pharyngeal Anastomotic Leak, CTCAE | Grade 1 Pharyngeal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542570","Grade 1 Pharyngeal Stenosis, CTCAE","C144335","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Pharyngeal Stenosis, CTCAE | Grade 1 Pharyngeal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542571","Grade 1 Pharyngolaryngeal Pain, CTCAE","C144336","Mild pain","Grade 1 Pharyngolaryngeal Pain, CTCAE | Grade 1 Pharyngolaryngeal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542572","Grade 1 Phlebitis Infective, CTCAE","C144337","Localized, local intervention indicated","Grade 1 Phlebitis Infective, CTCAE | Grade 1 Phlebitis infective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542557","Grade 1 Platelet Count Decreased, CTCAE","C144338","<LLN-75,000/mm3; <LLN-75.0 x 10e9/L","Grade 1 Platelet Count Decreased, CTCAE | Grade 1 Platelet count decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542558","Grade 1 Pleural Effusion, CTCAE","C144339","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Pleural Effusion, CTCAE | Grade 1 Pleural effusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542560","Grade 1 Pneumonitis, CTCAE","C144342","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Pneumonitis, CTCAE | Grade 1 Pneumonitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542561","Grade 1 Postnasal Drip, CTCAE","C144343","Mild symptoms; intervention not indicated","Grade 1 Postnasal Drip, CTCAE | Grade 1 Postnasal drip",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542563","Grade 1 Precocious Puberty, CTCAE","C144345","Physical signs of puberty with no biochemical markers for females <8 years and males <9 years","Grade 1 Precocious Puberty, CTCAE | Grade 1 Precocious puberty",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542845","Grade 2 Heart Failure, CTCAE","C144706","Symptoms with moderate activity or exertion","Grade 2 Heart Failure, CTCAE | Grade 2 Heart failure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542846","Grade 2 Hematosalpinx, CTCAE","C144707","Moderate bleeding; medical intervention indicated","Grade 2 Hematosalpinx, CTCAE | Grade 2 Hematosalpinx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542847","Grade 2 Hematuria, CTCAE","C144708","Symptomatic; urinary catheter or bladder irrigation indicated; limiting instrumental ADL","Grade 2 Hematuria, CTCAE | Grade 2 Hematuria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542848","Grade 2 Hemoglobin Increased, CTCAE","C144709","Increase in >2-4 g/dL","Grade 2 Hemoglobin Increased, CTCAE | Grade 2 Hemoglobin increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542849","Grade 2 Hemorrhoidal Hemorrhage, CTCAE","C144710","Moderate symptoms; intervention indicated","Grade 2 Hemorrhoidal Hemorrhage, CTCAE | Grade 2 Hemorrhoidal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542850","Grade 2 Hepatic Hemorrhage, CTCAE","C144711","Moderate symptoms; intervention indicated","Grade 2 Hepatic Hemorrhage, CTCAE | Grade 2 Hepatic hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542852","Grade 2 Hepatic Pain, CTCAE","C144713","Moderate pain; limiting instrumental ADL","Grade 2 Hepatic Pain, CTCAE | Grade 2 Hepatic pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542837","Grade 2 Hepatitis B Reactivation, CTCAE","C144714","Moderate symptoms; medical intervention indicated","Grade 2 Hepatitis B Reactivation, CTCAE | Grade 2 Hepatitis B reactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542838","Grade 2 Hepatitis Viral, CTCAE","C144715","Moderate symptoms; medical intervention indicated","Grade 2 Hepatitis Viral, CTCAE | Grade 2 Hepatitis viral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542839","Grade 2 Hepatobiliary Disorders - Other, Specify, CTCAE","C144716","Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL","Grade 2 Hepatobiliary Disorders - Other, Specify, CTCAE | Grade 2 Hepatobiliary disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543410","Grade 3 Cushingoid, CTCAE","C145214","Severe symptoms, medical intervention or hospitalization indicated","Grade 3 Cushingoid, CTCAE | Grade 3 Cushingoid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542204","Grade 1 Conduction Disorder, CTCAE","C144039","Mild symptoms; intervention not indicated","Grade 1 Conduction Disorder, CTCAE | Grade 1 Conduction disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517094","FHH, Rat Strain","C14403","Origin: An outbred stock of fawn hooded rats introduced into Europe by Tschopp in the early 1970s. Maintained as an outbred stock until the mid-1980s, then brother x sister mating initiated by A.P. Provoost to produce two strains designated FHH (also known as FHR) and FHL, which differ in hypertension and proteinuria.  FHH develops focal and segmental glomerular sclerosis, systemic hypertension and proteinuria at a young age, but these effects are more marked in FHH than FHL (Simons et al, 1993). The renal disease and hypertension are under independent genetic control, and both appear to be independent of the red-eyed dilution gene which causes platelet storage disease (Brown et al,1996)","FHH, Rat Strain | Fawn Hooded Hypertension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542317","Grade 1 Congenital, Familial and Genetic Disorders - Other, Specify, CTCAE","C144040","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Congenital, Familial and Genetic Disorders - Other, Specify, CTCAE | Grade 1 Congenital, familial and genetic disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542318","Grade 1 Conjunctivitis, CTCAE","C144041","Asymptomatic or mild symptoms; intervention not indicated","Grade 1 Conjunctivitis, CTCAE | Grade 1 Conjunctivitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542319","Grade 1 CPK Increased, CTCAE","C144042",">ULN-2.5 x ULN","Grade 1 CPK Increased, CTCAE | Grade 1 CPK increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542320","Grade 1 Creatinine Increased, CTCAE","C144043",">ULN-1.5 x ULN","Grade 1 Creatinine Increased, CTCAE | Grade 1 Creatinine increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542321","Grade 1 Cushingoid, CTCAE","C144044","Mild symptoms; intervention not indicated","Grade 1 Cushingoid, CTCAE | Grade 1 Cushingoid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542323","Grade 1 Cytokine Release Syndrome, CTCAE","C144046","Fever with or without constitutional symptoms","Grade 1 Cytokine Release Syndrome, CTCAE | Grade 1 Cytokine release syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542309","Grade 1 Delayed Orgasm, CTCAE","C144048","Delay in achieving orgasm not adversely affecting relationship","Grade 1 Delayed Orgasm, CTCAE | Grade 1 Delayed orgasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542310","Grade 1 Delirium, CTCAE","C144049","Mild acute confusional state","Grade 1 Delirium, CTCAE | Grade 1 Delirium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517361","GH, Rat Strain","C14404","GH: Develops hypertension, cardiac hypertrophy and vascular disease (Phelan 1968, Simpson and Phelan 1984, Simpson et al, 1994). Genetic hypertension in GH (but not SHR) may be associated with a defect in renal prostaglandin catabolism (Armstronag et al 1976).","GH, Rat Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542311","Grade 1 Dental Caries, CTCAE","C144050","One or more dental caries, not involving the root","Grade 1 Dental Caries, CTCAE | Grade 1 Dental caries",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542313","Grade 1 Dermatitis Radiation, CTCAE","C144052","Faint erythema or dry desquamation","Grade 1 Dermatitis Radiation, CTCAE | Grade 1 Dermatitis radiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542314","Grade 1 Dry Eye, CTCAE","C144053","Asymptomatic; clinical or diagnostic observations only; symptoms relieved by lubricants","Grade 1 Dry Eye, CTCAE | Grade 1 Dry eye",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542315","Grade 1 Dry Mouth, CTCAE","C144054","Symptomatic (e.g., dry or thick saliva) without significant dietary alteration; unstimulated saliva flow >0.2 ml/min","Grade 1 Dry Mouth, CTCAE | Grade 1 Dry mouth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542750","Grade 2 Blood Antidiuretic Hormone Abnormal, CTCAE","C144545","Symptomatic; medical intervention indicated","Grade 2 Blood Antidiuretic Hormone Abnormal, CTCAE | Grade 2 Blood antidiuretic hormone abnormal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542752","Grade 2 Blood Corticotrophin Decreased, CTCAE","C144547","Symptomatic; medical intervention indicated","Grade 2 Blood Corticotrophin Decreased, CTCAE | Grade 2 Blood corticotrophin decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542753","Grade 2 Blood Gonadotrophin Abnormal, CTCAE","C144548","Symptomatic; medical intervention indicated; limiting instrumental ADL","Grade 2 Blood Gonadotrophin Abnormal, CTCAE | Grade 2 Blood gonadotrophin abnormal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542754","Grade 2 Blood Prolactin Abnormal, CTCAE","C144549","Moderate symptoms; limiting instrumental ADL","Grade 2 Blood Prolactin Abnormal, CTCAE | Grade 2 Blood prolactin abnormal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542755","Grade 2 Body Odor, CTCAE","C144550","Pronounced odor; psychosocial impact; patient seeks medical intervention","Grade 2 Body Odor, CTCAE | Grade 2 Body odor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542756","Grade 2 Bone Infection, CTCAE","C144551","Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Bone Infection, CTCAE | Grade 2 Bone infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542741","Grade 2 Bone Marrow Hypocellular, CTCAE","C144552","Moderately hypocellular or >25-<50% reduction from normal cellularity for age","Grade 2 Bone Marrow Hypocellular, CTCAE | Grade 2 Bone marrow hypocellular",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542742","Grade 2 Breast Atrophy, CTCAE","C144553","Moderate asymmetry; moderate atrophy","Grade 2 Breast Atrophy, CTCAE | Grade 2 Breast atrophy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542743","Grade 2 Breast Infection, CTCAE","C144554","Local infection with moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Breast Infection, CTCAE | Grade 2 Breast infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542745","Grade 2 Bronchial Infection, CTCAE","C144556","Moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Bronchial Infection, CTCAE | Grade 2 Bronchial infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542746","Grade 2 Bronchial Obstruction, CTCAE","C144557","Symptomatic (e.g., mild wheezing); endoscopic evaluation indicated; radiographic evidence of atelectasis/lobar collapse; medical management indicated (e.g., steroids, bronchodilators)","Grade 2 Bronchial Obstruction, CTCAE | Grade 2 Bronchial obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542747","Grade 2 Bronchial Stricture, CTCAE","C144558","Symptomatic (e.g., rhonchi or wheezing) but without respiratory distress; medical intervention indicated (e.g., steroids, bronchodilators)","Grade 2 Bronchial Stricture, CTCAE | Grade 2 Bronchial stricture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542748","Grade 2 Bronchopleural Fistula, CTCAE","C144559","Symptomatic, invasive intervention not indicated","Grade 2 Bronchopleural Fistula, CTCAE | Grade 2 Bronchopleural fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542733","Grade 2 Bronchopulmonary Hemorrhage, CTCAE","C144560","Moderate symptoms; invasive intervention not indicated","Grade 2 Bronchopulmonary Hemorrhage, CTCAE | Grade 2 Bronchopulmonary hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543153","Grade 2 Prostatic Obstruction, CTCAE","C144944","Symptomatic; elective intervention indicated","Grade 2 Prostatic Obstruction, CTCAE | Grade 2 Prostatic obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543154","Grade 2 Prostatic Pain, CTCAE","C144945","Moderate pain; limiting instrumental ADL","Grade 2 Prostatic Pain, CTCAE | Grade 2 Prostatic pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543155","Grade 2 Psychiatric Disorders - Other, Specify, CTCAE","C144946","Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL","Grade 2 Psychiatric Disorders - Other, Specify, CTCAE | Grade 2 Psychiatric disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543156","Grade 2 Psychosis, CTCAE","C144947","Moderate psychotic symptoms (e.g., disorganized speech; impaired reality testing)","Grade 2 Psychosis, CTCAE | Grade 2 Psychosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543141","Grade 2 Pulmonary Edema, CTCAE","C144948","Moderate dyspnea on exertion; medical intervention indicated; limiting instrumental ADL","Grade 2 Pulmonary Edema, CTCAE | Grade 2 Pulmonary edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542404","Grade 1 Large Intestinal Anastomotic Leak, CTCAE","C144235","Asymptomatic diagnostic finding; intervention not indicated","Grade 1 Large Intestinal Anastomotic Leak, CTCAE | Grade 1 Large intestinal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542389","Grade 1 Laryngeal Edema, CTCAE","C144236","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Laryngeal Edema, CTCAE | Grade 1 Laryngeal edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542390","Grade 1 Laryngeal Inflammation, CTCAE","C144239","Mild sore throat; raspy voice","Grade 1 Laryngeal Inflammation, CTCAE | Grade 1 Laryngeal inflammation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542391","Grade 1 Laryngeal Mucositis, CTCAE","C144240","Endoscopic findings only; mild discomfort with normal intake","Grade 1 Laryngeal Mucositis, CTCAE | Grade 1 Laryngeal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542392","Grade 1 Laryngeal Obstruction, CTCAE","C144241","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Laryngeal Obstruction, CTCAE | Grade 1 Laryngeal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542393","Grade 1 Laryngeal Stenosis, CTCAE","C144242","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Laryngeal Stenosis, CTCAE | Grade 1 Laryngeal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542395","Grade 1 Lethargy, CTCAE","C144244","Mild symptoms; reduced alertness and awareness","Grade 1 Lethargy, CTCAE | Grade 1 Lethargy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542396","Grade 1 Leukoencephalopathy, CTCAE","C144245","Asymptomatic; small focal T2/FLAIR hyperintensities; involving periventricular white matter or <1/3 of susceptible areas of cerebrum +/- mild increase in subarachnoid space (SAS) and/or mild ventriculomegaly","Grade 1 Leukoencephalopathy, CTCAE | Grade 1 Leukoencephalopathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542509","Grade 1 Libido Decreased, CTCAE","C144246","Decrease in sexual interest not adversely affecting relationship","Grade 1 Libido Decreased, CTCAE | Grade 1 Libido decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542510","Grade 1 Libido Increased, CTCAE","C144247","Present","Grade 1 Libido Increased, CTCAE | Grade 1 Libido increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542511","Grade 1 Lip Infection, CTCAE","C144248","Localized, local intervention indicated","Grade 1 Lip Infection, CTCAE | Grade 1 Lip infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542512","Grade 1 Lipase Increased, CTCAE","C144249",">ULN-1.5 x ULN","Grade 1 Lipase Increased, CTCAE | Grade 1 Lipase increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542840","Grade 2 Herpes Simplex Reactivation, CTCAE","C144717","Moderate symptoms; medical intervention indicated","Grade 2 Herpes Simplex Reactivation, CTCAE | Grade 2 Herpes simplex reactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542841","Grade 2 Hiccups, CTCAE","C144718","Moderate symptoms; medical intervention indicated; limiting instrumental ADL","Grade 2 Hiccups, CTCAE | Grade 2 Hiccups",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542842","Grade 2 Hip Fracture, CTCAE","C144719","Hairline fracture; mild pain; limiting instrumental ADL; non-operative intervention indicated","Grade 2 Hip Fracture, CTCAE | Grade 2 Hip fracture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542844","Grade 2 Hoarseness, CTCAE","C144721","Moderate or persistent voice changes; may require occasional repetition but understandable on telephone; medical evaluation indicated","Grade 2 Hoarseness, CTCAE | Grade 2 Hoarseness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542957","Grade 2 Hot Flashes, CTCAE","C144722","Moderate symptoms; limiting instrumental ADL","Grade 2 Hot Flashes, CTCAE | Grade 2 Hot flashes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542958","Grade 2 Hypercalcemia, CTCAE","C144723","Corrected serum calcium of >11.5-12.5 mg/dL; >2.9-3.1 mmol/L; Ionized calcium >1.5-1.6 mmol/L; symptomatic","Grade 2 Hypercalcemia, CTCAE | Grade 2 Hypercalcemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542959","Grade 2 Hyperglycemia, CTCAE","C144724","Change in daily management from baseline for a diabetic; oral antiglycemic agent initiated; workup for diabetes","Grade 2 Hyperglycemia, CTCAE | Grade 2 Hyperglycemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542960","Grade 2 Hyperhidrosis, CTCAE","C144725","Involving >1 site; patient seeks medical intervention; associated with psychosocial impact","Grade 2 Hyperhidrosis, CTCAE | Grade 2 Hyperhidrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542961","Grade 2 Hyperkalemia, CTCAE","C144726",">5.5-6.0 mmol/L; intervention initiated","Grade 2 Hyperkalemia, CTCAE | Grade 2 Hyperkalemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542962","Grade 2 Hyperlipidemia, CTCAE","C144727","Requiring pharmaceutical intervention","Grade 2 Hyperlipidemia, CTCAE | Grade 2 Hyperlipidemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542963","Grade 2 Hypernatremia, CTCAE","C144728",">150-155 mmol/L; intervention initiated","Grade 2 Hypernatremia, CTCAE | Grade 2 Hypernatremia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542964","Grade 2 Hyperparathyroidism, CTCAE","C144729","Moderate symptoms; medical intervention indicated","Grade 2 Hyperparathyroidism, CTCAE | Grade 2 Hyperparathyroidism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542949","Grade 2 Hyperphosphatemia, CTCAE","C144730","Noninvasive intervention indicated","Grade 2 Hyperphosphatemia, CTCAE | Grade 2 Hyperphosphatemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543252","Grade 3 Acute Kidney Injury, CTCAE","C145119","Hospitalization indicated","Grade 3 Acute Kidney Injury, CTCAE | Grade 3 Acute kidney injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543237","Grade 3 Akathisia, CTCAE","C145120","Severe restlessness or increased motor activity; limiting self care ADL","Grade 3 Akathisia, CTCAE | Grade 3 Akathisia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543238","Grade 3 Alanine Aminotransferase Increased, CTCAE","C145121",">5.0-20.0 x ULN if baseline was normal; >5.0-20.0 x baseline if baseline was abnormal","Grade 3 Alanine Aminotransferase Increased, CTCAE | Grade 3 Alanine aminotransferase increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543239","Grade 3 Alcohol Intolerance, CTCAE","C145122","Severe symptoms; limiting self care ADL","Grade 3 Alcohol Intolerance, CTCAE | Grade 3 Alcohol intolerance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543240","Grade 3 Alkaline Phosphatase Increased, CTCAE","C145123",">5.0-20.0 x ULN if baseline was normal; >5.0-20.0 x baseline if baseline was abnormal","Grade 3 Alkaline Phosphatase Increased, CTCAE | Grade 3 Alkaline phosphatase increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543242","Grade 3 Allergic Reaction, CTCAE","C145125","Bronchospasm; hospitalization indicated for clinical sequelae; intravenous intervention indicated","Grade 3 Allergic Reaction, CTCAE | Grade 3 Allergic reaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543243","Grade 3 Amnesia, CTCAE","C145126","Severe; long term memory loss; limiting self care ADL","Grade 3 Amnesia, CTCAE | Grade 3 Amnesia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542316","Grade 1 Duodenal Hemorrhage, CTCAE","C144056","Mild symptoms; intervention not indicated","Grade 1 Duodenal Hemorrhage, CTCAE | Grade 1 Duodenal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542302","Grade 1 Duodenal Stenosis, CTCAE","C144058","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Duodenal Stenosis, CTCAE | Grade 1 Duodenal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542303","Grade 1 Duodenal Ulcer, CTCAE","C144059","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Duodenal Ulcer, CTCAE | Grade 1 Duodenal ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542605","Grade 1 Tendon Reflex Decreased, CTCAE","C144425","Ankle reflex reduced","Grade 1 Tendon Reflex Decreased, CTCAE | Grade 1 Tendon reflex decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542606","Grade 1 Testicular Disorder, CTCAE","C144426","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Testicular Disorder, CTCAE | Grade 1 Testicular disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542607","Grade 1 Testicular Pain, CTCAE","C144428","Mild pain","Grade 1 Testicular Pain, CTCAE | Grade 1 Testicular pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542608","Grade 1 Testosterone Deficiency, CTCAE","C144429","Asymptomatic; mild symptoms with no intervention indicated","Grade 1 Testosterone Deficiency, CTCAE | Grade 1 Testosterone deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542609","Grade 1 Thromboembolic Event, CTCAE","C144430","Medical intervention not indicated (e.g., superficial thrombosis)","Grade 1 Thromboembolic Event, CTCAE | Grade 1 Thromboembolic event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542610","Grade 1 Thrush, CTCAE","C144431","Asymptomatic; local symptomatic management","Grade 1 Thrush, CTCAE | Grade 1 Thrush",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542611","Grade 1 Thyroid Stimulating Hormone Increased, CTCAE","C144432","TSH increased and no intervention initiated","Grade 1 Thyroid Stimulating Hormone Increased, CTCAE | Grade 1 Thyroid stimulating hormone increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542597","Grade 1 Tooth Development Disorder, CTCAE","C144434","Asymptomatic; hypoplasia of tooth or enamel","Grade 1 Tooth Development Disorder, CTCAE | Grade 1 Tooth development disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542598","Grade 1 Tooth Discoloration, CTCAE","C144435","Surface stains","Grade 1 Tooth Discoloration, CTCAE | Grade 1 Tooth discoloration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542599","Grade 1 Toothache, CTCAE","C144436","Mild pain","Grade 1 Toothache, CTCAE | Grade 1 Toothache",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542600","Grade 1 Tracheal Mucositis, CTCAE","C144439","Endoscopic findings only; minimal hemoptysis, pain, or respiratory symptoms","Grade 1 Tracheal Mucositis, CTCAE | Grade 1 Tracheal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542601","Grade 1 Tracheal Obstruction, CTCAE","C144440","Partial asymptomatic obstruction on examination (e.g., visual, radiologic or endoscopic)","Grade 1 Tracheal Obstruction, CTCAE | Grade 1 Tracheal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542602","Grade 1 Tracheal Stenosis, CTCAE","C144441","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Tracheal Stenosis, CTCAE | Grade 1 Tracheal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542604","Grade 1 Transient Ischemic Attacks, CTCAE","C144443","Mild neurologic deficit with or without imaging confirmation","Grade 1 Transient Ischemic Attacks, CTCAE | Grade 1 Transient ischemic attacks",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542589","Grade 1 Tricuspid Valve Disease, CTCAE","C144444","Asymptomatic valvular thickening with or without mild valvular regurgitation or stenosis","Grade 1 Tricuspid Valve Disease, CTCAE | Grade 1 Tricuspid valve disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542590","Grade 1 Trigeminal Nerve Disorder, CTCAE","C144445","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Trigeminal Nerve Disorder, CTCAE | Grade 1 Trigeminal nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543142","Grade 2 Pulmonary Fibrosis, CTCAE","C144949","Evidence of pulmonary hypertension; radiographic pulmonary fibrosis 25-50% associated with hypoxia","Grade 2 Pulmonary Fibrosis, CTCAE | Grade 2 Pulmonary fibrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543143","Grade 2 Pulmonary Fistula, CTCAE","C144950","Symptomatic, invasive intervention not indicated","Grade 2 Pulmonary Fistula, CTCAE | Grade 2 Pulmonary fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543144","Grade 2 Pulmonary Valve Disease, CTCAE","C144951","Asymptomatic; moderate regurgitation or stenosis by imaging","Grade 2 Pulmonary Valve Disease, CTCAE | Grade 2 Pulmonary valve disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543146","Grade 2 Pyramidal Tract Syndrome, CTCAE","C144953","Moderate symptoms; limiting instrumental ADL","Grade 2 Pyramidal Tract Syndrome, CTCAE | Grade 2 Pyramidal tract syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543147","Grade 2 Radiation Recall Reaction (Dermatologic), CTCAE","C144954","Moderate to brisk erythema; patchy moist desquamation, mostly confined to skin folds and creases; moderate edema","Grade 2 Radiation Recall Reaction (Dermatologic), CTCAE | Grade 2 Radiation recall reaction (dermatologic)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543148","Grade 2 Radiculitis, CTCAE","C144955","Moderate symptoms; medical intervention indicated; limiting instrumental ADL","Grade 2 Radiculitis, CTCAE | Grade 2 Radiculitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543133","Grade 2 Rash Acneiform, CTCAE","C144956","Papules and/or pustules covering 10-30% BSA, which may or may not be associated with symptoms of pruritus or tenderness; associated with psychosocial impact; limiting instrumental ADL; papules and/or pustules covering > 30% BSA with or without mild symptoms","Grade 2 Rash Acneiform, CTCAE | Grade 2 Rash acneiform",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543134","Grade 2 Rash Maculo-Papular, CTCAE","C144957","Macules/papules covering 10-30% BSA with or without symptoms (e.g., pruritus, burning, tightness); limiting instrumental ADL; rash covering > 30% BSA with or without mild symptoms","Grade 2 Rash Maculo-Papular, CTCAE | Grade 2 Rash maculo-papular",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543135","Grade 2 Rash Pustular, CTCAE","C144958","Localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral)","Grade 2 Rash Pustular, CTCAE | Grade 2 Rash pustular",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543137","Grade 2 Rectal Fissure, CTCAE","C144960","Symptomatic","Grade 2 Rectal Fissure, CTCAE | Grade 2 Rectal fissure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543138","Grade 2 Rectal Mucositis, CTCAE","C144963","Symptomatic; medical intervention indicated; limiting instrumental ADL","Grade 2 Rectal Mucositis, CTCAE | Grade 2 Rectal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543139","Grade 2 Rectal Pain, CTCAE","C144965","Moderate pain; limiting instrumental ADL","Grade 2 Rectal Pain, CTCAE | Grade 2 Rectal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543140","Grade 2 Rectal Stenosis, CTCAE","C144967","Symptomatic; altered GI function","Grade 2 Rectal Stenosis, CTCAE | Grade 2 Rectal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543125","Grade 2 Recurrent Laryngeal Nerve Palsy, CTCAE","C144969","Moderate symptoms","Grade 2 Recurrent Laryngeal Nerve Palsy, CTCAE | Grade 2 Recurrent laryngeal nerve palsy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543126","Grade 2 Renal and Urinary Disorders - Other, Specify, CTCAE","C144970","Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL","Grade 2 Renal and Urinary Disorders - Other, Specify, CTCAE | Grade 2 Renal and urinary disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543127","Grade 2 Renal Calculi, CTCAE","C144971","Symptomatic; oral antiemetics indicated; around the clock nonprescription analgesics or any oral narcotic analgesics indicated","Grade 2 Renal Calculi, CTCAE | Grade 2 Renal calculi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517697","LOU/C, Rat Strain","C14383","Develop spontaneous plasmacytomas after about 8 months of age, with an incidence of about 30% in males and 16% in females. These develop rapidly, and may be detected by palpation. They usually develop in the ileocoecal lymph nodes, and about 60% of them synthesis monoclonal immunoglobulins (Bence-Jones proteins) of IgG1 (35%), IgE (36%) or IgA classes.","LOU/C, Rat Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542514","Grade 1 Localized Edema, CTCAE","C144251","Localized to dependent areas, no disability or functional impairment","Grade 1 Localized Edema, CTCAE | Grade 1 Localized edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542515","Grade 1 Lordosis, CTCAE","C144252","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Lordosis, CTCAE | Grade 1 Lordosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542516","Grade 1 Lower Gastrointestinal Hemorrhage, CTCAE","C144253","Mild symptoms; intervention not indicated","Grade 1 Lower Gastrointestinal Hemorrhage, CTCAE | Grade 1 Lower gastrointestinal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542501","Grade 1 Lymphedema, CTCAE","C144254","Trace thickening or faint discoloration","Grade 1 Lymphedema, CTCAE | Grade 1 Lymphedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542502","Grade 1 Lymphocyte Count Decreased, CTCAE","C144255","<LLN-800/mm3; <LLN-0.8 x 10e9/L","Grade 1 Lymphocyte Count Decreased, CTCAE | Grade 1 Lymphocyte count decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542503","Grade 1 Malaise, CTCAE","C144256","Uneasiness or lack of well being","Grade 1 Malaise, CTCAE | Grade 1 Malaise",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542504","Grade 1 Mania, CTCAE","C144257","Mild manic symptoms (e.g., elevated mood, rapid thoughts, rapid speech, decreased need for sleep)","Grade 1 Mania, CTCAE | Grade 1 Mania",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542789","Grade 2 Endocrine Disorders - Other, Specify, CTCAE","C144633","Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL","Grade 2 Endocrine Disorders - Other, Specify, CTCAE | Grade 2 Endocrine disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542790","Grade 2 Endophthalmitis, CTCAE","C144634","Local intervention indicated","Grade 2 Endophthalmitis, CTCAE | Grade 2 Endophthalmitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542791","Grade 2 Enterocolitis Infectious, CTCAE","C144635","Passage of >3 unformed stools per 24 hrs or duration of illness >48 hrs; moderate abdominal pain; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Enterocolitis Infectious, CTCAE | Grade 2 Enterocolitis infectious",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542792","Grade 2 Enterocolitis, CTCAE","C144636","Abdominal pain; mucus or blood in stool","Grade 2 Enterocolitis, CTCAE | Grade 2 Enterocolitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542793","Grade 2 Enterovesical Fistula, CTCAE","C144637","Symptomatic, invasive intervention not indicated","Grade 2 Enterovesical Fistula, CTCAE | Grade 2 Enterovesical fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542795","Grade 2 Epstein-Barr Virus Infection Reactivation, CTCAE","C144639","Moderate symptoms; medical intervention indicated","Grade 2 Epstein-Barr Virus Infection Reactivation, CTCAE | Grade 2 Epstein-Barr virus infection reactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542796","Grade 2 Erythema Multiforme, CTCAE","C144640","Target lesions covering 10-30% BSA and associated with skin tenderness","Grade 2 Erythema Multiforme, CTCAE | Grade 2 Erythema multiforme",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542781","Grade 2 Erythroderma, CTCAE","C144641","Erythema covering >90% BSA without associated symptoms; limiting instrumental ADL","Grade 2 Erythroderma, CTCAE | Grade 2 Erythroderma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542782","Grade 2 Esophageal Anastomotic Leak, CTCAE","C144642","Symptomatic; medical intervention indicated","Grade 2 Esophageal Anastomotic Leak, CTCAE | Grade 2 Esophageal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542783","Grade 2 Esophageal Hemorrhage, CTCAE","C144644","Moderate symptoms; intervention indicated","Grade 2 Esophageal Hemorrhage, CTCAE | Grade 2 Esophageal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542784","Grade 2 Esophageal Infection, CTCAE","C144645","Local intervention indicated (e.g., oral antibiotic, antifungal, antiviral)","Grade 2 Esophageal Infection, CTCAE | Grade 2 Esophageal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542785","Grade 2 Esophageal Obstruction, CTCAE","C144646","Symptomatic; altered GI function; limiting instrumental ADL","Grade 2 Esophageal Obstruction, CTCAE | Grade 2 Esophageal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542787","Grade 2 Esophageal Perforation, CTCAE","C144648","Invasive intervention not indicated","Grade 2 Esophageal Perforation, CTCAE | Grade 2 Esophageal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543244","Grade 3 Anal Fissure, CTCAE","C145127","Invasive intervention indicated","Grade 3 Anal Fissure, CTCAE | Grade 3 Anal fissure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543229","Grade 3 Anal Fistula, CTCAE","C145128","Invasive intervention indicated","Grade 3 Anal Fistula, CTCAE | Grade 3 Anal fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543230","Grade 3 Anal Hemorrhage, CTCAE","C145129","Transfusion indicated; invasive intervention indicated; hospitalization","Grade 3 Anal Hemorrhage, CTCAE | Grade 3 Anal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543231","Grade 3 Anal Mucositis, CTCAE","C145130","Severe symptoms; limiting self care ADL","Grade 3 Anal Mucositis, CTCAE | Grade 3 Anal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543232","Grade 3 Anal Necrosis, CTCAE","C145131","TPN or hospitalization indicated; invasive intervention indicated","Grade 3 Anal Necrosis, CTCAE | Grade 3 Anal necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543233","Grade 3 Anal Pain, CTCAE","C145132","Severe pain; limiting self care ADL","Grade 3 Anal Pain, CTCAE | Grade 3 Anal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543235","Grade 3 Anal Ulcer, CTCAE","C145134","Severely altered GI function; TPN indicated; elective invasive intervention indicated","Grade 3 Anal Ulcer, CTCAE | Grade 3 Anal ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543236","Grade 3 Anaphylaxis, CTCAE","C145135","Symptomatic bronchospasm, with or without urticaria; parenteral intervention indicated; allergy-related edema/angioedema; hypotension","Grade 3 Anaphylaxis, CTCAE | Grade 3 Anaphylaxis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543221","Grade 3 Anemia, CTCAE","C145136","Hgb <8.0 g/dL; <4.9 mmol/L; <80 g/L; transfusion indicated","Grade 3 Anemia, CTCAE | Grade 3 Anemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543222","Grade 3 Ankle Fracture, CTCAE","C145137","Limiting self care ADL; elective operative intervention indicated requiring hospitalization","Grade 3 Ankle Fracture, CTCAE | Grade 3 Ankle fracture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543223","Grade 3 Anorectal Infection, CTCAE","C145138","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Anorectal Infection, CTCAE | Grade 3 Anorectal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543224","Grade 3 Aortic Injury, CTCAE","C145139","Severe symptoms; limiting self care ADL; repair or revision indicated","Grade 3 Aortic Injury, CTCAE | Grade 3 Aortic injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543225","Grade 3 Aortic Valve Disease, CTCAE","C145140","Symptomatic; severe regurgitation or stenosis by imaging; symptoms controlled with medical intervention","Grade 3 Aortic Valve Disease, CTCAE | Grade 3 Aortic valve disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543226","Grade 3 Aphonia, CTCAE","C145141","Voicelessness; unable to speak","Grade 3 Aphonia, CTCAE | Grade 3 Aphonia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543228","Grade 3 Appendicitis, CTCAE","C145143","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Appendicitis, CTCAE | Grade 3 Appendicitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542254","Grade 1 Anal Pain, CTCAE","C143976","Mild pain","Grade 1 Anal Pain, CTCAE | Grade 1 Anal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542255","Grade 1 Anal Stenosis, CTCAE","C143977","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Anal Stenosis, CTCAE | Grade 1 Anal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542256","Grade 1 Anal Ulcer, CTCAE","C143978","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Anal Ulcer, CTCAE | Grade 1 Anal ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542257","Grade 1 Anemia, CTCAE","C143979","Hemoglobin (Hgb) <LLN-10.0 g/dL; <LLN-6.2 mmol/L; <LLN-100 g/L","Grade 1 Anemia, CTCAE | Grade 1 Anemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511451","COP, Rat Strain","C14397","Spontaneous tumors of the thymus (Dunning and Curtis 1946, Dunning et al 1947)","COP, Rat Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542258","Grade 1 Ankle Fracture, CTCAE","C143980","Mild; non-operative intervention indicated","Grade 1 Ankle Fracture, CTCAE | Grade 1 Ankle fracture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542592","Grade 1 Tumor Hemorrhage, CTCAE","C144447","Mild symptoms; intervention not indicated","Grade 1 Tumor Hemorrhage, CTCAE | Grade 1 Tumor hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542593","Grade 1 Unequal Limb Length, CTCAE","C144448","Mild length discrepancy <2 cm","Grade 1 Unequal Limb Length, CTCAE | Grade 1 Unequal limb length",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542594","Grade 1 Upper Gastrointestinal Hemorrhage, CTCAE","C144449","Mild symptoms; intervention not indicated","Grade 1 Upper Gastrointestinal Hemorrhage, CTCAE | Grade 1 Upper gastrointestinal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542596","Grade 1 Urethral Anastomotic Leak, CTCAE","C144451","Asymptomatic diagnostic finding; intervention not indicated","Grade 1 Urethral Anastomotic Leak, CTCAE | Grade 1 Urethral anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542581","Grade 1 Urinary Frequency, CTCAE","C144452","Present","Grade 1 Urinary Frequency, CTCAE | Grade 1 Urinary frequency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543017","Grade 2 Laryngeal Inflammation, CTCAE","C144810","Moderate sore throat; analgesics indicated","Grade 2 Laryngeal Inflammation, CTCAE | Grade 2 Laryngeal inflammation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543018","Grade 2 Laryngeal Mucositis, CTCAE","C144811","Moderate pain, analgesics indicated; altered oral intake; limiting instrumental ADL","Grade 2 Laryngeal Mucositis, CTCAE | Grade 2 Laryngeal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543019","Grade 2 Laryngeal Obstruction, CTCAE","C144812","Symptomatic (e.g., noisy airway breathing), no respiratory distress; medical intervention indicated (e.g., steroids); limiting instrumental ADL","Grade 2 Laryngeal Obstruction, CTCAE | Grade 2 Laryngeal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543020","Grade 2 Laryngeal Stenosis, CTCAE","C144813","Symptomatic (e.g., noisy airway breathing), no respiratory distress; medical intervention indicated (e.g., steroids); limiting instrumental ADL","Grade 2 Laryngeal Stenosis, CTCAE | Grade 2 Laryngeal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543005","Grade 2 Laryngitis, CTCAE","C144814","Moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Laryngitis, CTCAE | Grade 2 Laryngitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543006","Grade 2 Laryngopharyngeal Dysesthesia, CTCAE","C144815","Moderate symptoms; mild anxiety, but no dyspnea; short duration of observation and/or anxiolytic indicated; limiting instrumental ADL","Grade 2 Laryngopharyngeal Dysesthesia, CTCAE | Grade 2 Laryngopharyngeal dysesthesia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543008","Grade 2 Lethargy, CTCAE","C144817","Moderate symptoms; limiting instrumental ADL","Grade 2 Lethargy, CTCAE | Grade 2 Lethargy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543009","Grade 2 Leukoencephalopathy, CTCAE","C144818","Moderate symptoms; focal T2/FLAIR hyperintensities, involving periventricular white matter extending into centrum semiovale or involving 1/3 to 2/3 of susceptible areas of cerebrum +/- moderate increase in SAS and/or moderate ventriculomegaly","Grade 2 Leukoencephalopathy, CTCAE | Grade 2 Leukoencephalopathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543010","Grade 2 Libido Decreased, CTCAE","C144819","Decrease in sexual interest adversely affecting relationship","Grade 2 Libido Decreased, CTCAE | Grade 2 Libido decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543011","Grade 2 Lip Infection, CTCAE","C144820","Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Lip Infection, CTCAE | Grade 2 Lip infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543012","Grade 2 Lipase Increased, CTCAE","C144821",">1.5-2.0 x ULN; >2.0-5.0 x ULN and asymptomatic","Grade 2 Lipase Increased, CTCAE | Grade 2 Lipase increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542997","Grade 2 Lipohypertrophy, CTCAE","C144822","Covering 10-30% BSA and associated tenderness; limiting instrumental ADL","Grade 2 Lipohypertrophy, CTCAE | Grade 2 Lipohypertrophy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542998","Grade 2 Localized Edema, CTCAE","C144823","Moderate localized edema and intervention indicated; limiting instrumental ADL","Grade 2 Localized Edema, CTCAE | Grade 2 Localized edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543000","Grade 2 Lower Gastrointestinal Hemorrhage, CTCAE","C144825","Moderate symptoms; intervention indicated","Grade 2 Lower Gastrointestinal Hemorrhage, CTCAE | Grade 2 Lower gastrointestinal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542339","Grade 1 Hypercalcemia, CTCAE","C144160","Corrected serum calcium of >ULN-11.5 mg/dL; >ULN-2.9 mmol/L; Ionized calcium >ULN-1.5 mmol/L","Grade 1 Hypercalcemia, CTCAE | Grade 1 Hypercalcemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539160","Medullary Thyroid Carcinoma cN1b TNM Finding v8","C141017","Metastasis to unilateral, bilateral, or contralateral lateral neck lymph node levels I, II, III, IV, or V or retropharyngeal lymph nodes. (from AJCC 8th Ed.)","Medullary Thyroid Carcinoma cN1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539159","Medullary Thyroid Carcinoma Pathologic TNM Finding v8","C141018","A pathologic finding about one or more characteristics of medullary thyroid carcinoma, following the rules of the TNM AJCC v8 classification system.","Medullary Thyroid Carcinoma Pathologic TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539158","Medullary Thyroid Carcinoma Pathologic Distant Metastasis TNM Finding v8","C141019","A pathologic finding about one or more characteristics of medullary thyroid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Medullary Thyroid Carcinoma Pathologic Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510939","Armadillo Repeat","C14101","Identified in over 240 functionally diverse proteins from yeast to man, ARM Repeats are approximately 40-amino acids long and composed of two longer anti-parallel helices (H2 and H3) that follow a perpendicular short helix (H1). Tandem repeats form a right-handed superhelix (3 helixes per unit); tight repeat packing creates a cylindrical hydrophobic core throughout the structure. Lined by highly conserved residues, the positively charged groove of the superhelix appears to mediate interaction with acidic surfaces of target proteins. Despite amino acid variability, ARM repeat structures are highly conserved. Though involved in protein-protein interactions, no common features among target proteins have been identified. ARM repeats have a common phylogenetic origin with the HEAT repeat; both contain seven highly conserved hydrophobic residues.","Armadillo Repeat | ARM Domain | ARM Repeat | Armadillo/Beta-Catenin-Like Repeat | Beta-Catenin Binding Repeat | Beta-Catenin-Binding Domain | Beta-Catenin-Like Repeat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539157","Medullary Thyroid Carcinoma pM1 TNM Finding v8","C141020","Distant metastasis. (from AJCC 8th Ed.)","Medullary Thyroid Carcinoma pM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539172","Medullary Thyroid Carcinoma Pathologic Primary Tumor TNM Finding v8","C141021","A pathologic finding about one or more characteristics of medullary thyroid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Medullary Thyroid Carcinoma Pathologic Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539171","Medullary Thyroid Carcinoma pTX TNM Finding v8","C141022","Primary tumor cannot be assessed. (from AJCC 8th Ed.)","Medullary Thyroid Carcinoma pTX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539170","Medullary Thyroid Carcinoma pT0 TNM Finding v8","C141023","No evidence of primary tumor. (from AJCC 8th Ed.)","Medullary Thyroid Carcinoma pT0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539169","Medullary Thyroid Carcinoma pT1 TNM Finding v8","C141024","Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. (from AJCC 8th Ed.)","Medullary Thyroid Carcinoma pT1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539168","Medullary Thyroid Carcinoma pT1a TNM Finding v8","C141025","Tumor measuring 1 cm or less in greatest dimension limited to the thyroid. (from AJCC 8th Ed.)","Medullary Thyroid Carcinoma pT1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539165","Medullary Thyroid Carcinoma pT3 TNM Finding v8","C141028","Tumor measuring 4 cm or more in greatest dimension or with extrathyroidal extension. (from AJCC 8th Ed.)","Medullary Thyroid Carcinoma pT3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539148","Medullary Thyroid Carcinoma pT3a TNM Finding v8","C141029","Tumor measuring 4 cm or more in greatest dimension limited to the thyroid. (from AJCC 8th Ed.)","Medullary Thyroid Carcinoma pT3a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539312","Centroblastic Lymphoma by Ann Arbor Stage","C141263","An anatomic stage for centroblastic lymphoma based on the Ann Arbor classification criteria.","Centroblastic Lymphoma by Ann Arbor Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542696","Grade 1 Vaginal Pain, CTCAE","C144474","Mild pain","Grade 1 Vaginal Pain, CTCAE | Grade 1 Vaginal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542697","Grade 1 Vaginal Stricture, CTCAE","C144475","Asymptomatic; mild vaginal shortening or narrowing","Grade 1 Vaginal Stricture, CTCAE | Grade 1 Vaginal stricture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542698","Grade 1 Vagus Nerve Disorder, CTCAE","C144476","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Vagus Nerve Disorder, CTCAE | Grade 1 Vagus nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542699","Grade 1 Vas Deferens Anastomotic Leak, CTCAE","C144477","Asymptomatic diagnostic finding; intervention not indicated","Grade 1 Vas Deferens Anastomotic Leak, CTCAE | Grade 1 Vas deferens anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542700","Grade 1 Vascular Access Complication, CTCAE","C144478","TPA administration into line with no intent for systemic therapy indicated","Grade 1 Vascular Access Complication, CTCAE | Grade 1 Vascular access complication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542687","Grade 1 Ventricular Arrhythmia, CTCAE","C144481","Asymptomatic, intervention not indicated","Grade 1 Ventricular Arrhythmia, CTCAE | Grade 1 Ventricular arrhythmia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542688","Grade 1 Vertigo, CTCAE","C144482","Mild symptoms","Grade 1 Vertigo, CTCAE | Grade 1 Vertigo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542689","Grade 1 Virilization, CTCAE","C144483","Mild symptoms; intervention not indicated","Grade 1 Virilization, CTCAE | Grade 1 Virilization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542972","Grade 2 Neuralgia, CTCAE","C144864","Moderate pain; limiting instrumental ADL","Grade 2 Neuralgia, CTCAE | Grade 2 Neuralgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543085","Grade 2 Neutrophil Count Decreased, CTCAE","C144865","<1500-1000/mm3; <1.5-1.0 x 10e9/L","Grade 2 Neutrophil Count Decreased, CTCAE | Grade 2 Neutrophil count decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543086","Grade 2 Night Blindness, CTCAE","C144866","Symptomatic; moderate decrease in visual acuity (best corrected visual acuity 20/40 and better or 3 lines or less decreased vision from known baseline); limiting instrumental ADL","Grade 2 Night Blindness, CTCAE | Grade 2 Night blindness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543087","Grade 2 Nipple Deformity, CTCAE","C144867","Symptomatic; asymmetry of nipple areolar complex with moderate retraction and/or thickening of the nipple areolar complex","Grade 2 Nipple Deformity, CTCAE | Grade 2 Nipple deformity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543088","Grade 2 Non-Cardiac Chest Pain, CTCAE","C144868","Moderate pain; limiting instrumental ADL","Grade 2 Non-Cardiac Chest Pain, CTCAE | Grade 2 Non-cardiac chest pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543089","Grade 2 Obstruction Gastric, CTCAE","C144869","Symptomatic; altered GI function; limiting instrumental ADL","Grade 2 Obstruction Gastric, CTCAE | Grade 2 Obstruction gastric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543090","Grade 2 Oculomotor Nerve Disorder, CTCAE","C144870","Moderate symptoms; limiting instrumental ADL","Grade 2 Oculomotor Nerve Disorder, CTCAE | Grade 2 Oculomotor nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543091","Grade 2 Olfactory Nerve Disorder, CTCAE","C144871","Moderate symptoms; limiting instrumental ADL","Grade 2 Olfactory Nerve Disorder, CTCAE | Grade 2 Olfactory nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543077","Grade 2 Oral Cavity Fistula, CTCAE","C144873","Symptomatic, invasive intervention not indicated","Grade 2 Oral Cavity Fistula, CTCAE | Grade 2 Oral cavity fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539123","Parathyroid Carcinoma pN1 TNM Finding v8","C141071","Regional lymph node metastasis. (from AJCC 8th Ed.)","Parathyroid Carcinoma pN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539122","Parathyroid Carcinoma pN1a TNM Finding v8","C141072","Metastasis to level VI (pretracheal, paratracheal, and prelaryngeal/Delphian lymph nodes), or superior mediastinal lymph nodes (level VII). (from AJCC 8th Ed.)","Parathyroid Carcinoma pN1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539121","Parathyroid Carcinoma pN1b TNM Finding v8","C141073","Metastasis to unilateral, bilateral, or contralateral cervical (levels I, II, III, IV, or V) or retropharyngeal nodes. (from AJCC 8th Ed.)","Parathyroid Carcinoma pN1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521302","3q13.12","C14130","A chromosome band present on 3q","3q13.12 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539189","Pheochromocytoma and Paraganglioma pM1b TNM Finding v8","C141117","Distant metastasis to only distant lymph nodes/liver or lung. (from AJCC 8th Ed.)","Pheochromocytoma and Paraganglioma pM1b TNM Finding v8 | Adrenal-Neuroendocrine Tumor pM1b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539204","Pheochromocytoma and Paraganglioma pM1c TNM Finding v8","C141118","Distant metastasis to bone plus multiple other sites. (from AJCC 8th Ed.)","Pheochromocytoma and Paraganglioma pM1c TNM Finding v8 | Adrenal-Neuroendocrine Tumor pM1c TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539448","Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8","C141356","Stage IV includes: IVA1 (T1-4, N0-2, M0, B2); IVA2 (T1-4, N3, M0, B0-2); IVB (T1-4, N0-3, M1, B0-2). T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. T2: Patches, papules, or plaques covering 10% or more of the skin surface. T3: One or more tumors (equal or greater than 1 cm in diameter). T4: Confluence of erythema covering 80% or more of body surface area. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. N3: Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3-4 or NCI LN4; clone positive or negative. M0: No visceral organ involvement.  M1: Visceral involvement (must have pathology confirmation and organ involved should be specified). B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. B2: High blood tumor burden: 1,000 per microliter or more Sezary cells with positive clone. (AJCC 8th ed.)","Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539447","Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8","C141357","Stage IVA1 includes: T1-4, N0-2, M0, B2. T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. T2: Patches, papules, or plaques covering 10% or more of the skin surface. T3: One or more tumors (equal or greater than 1 cm in diameter). T4: Confluence of erythema covering 80% or more of body surface area. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. M0: No visceral organ involvement. B2: High blood tumor burden: 1,000 per microliter or more Sezary cells with positive clone. (AJCC 8th ed.)","Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539446","Stage IVA2 Mycosis Fungoides and Sezary Syndrome AJCC v8","C141358","Stage IVA2 includes: T1-4, N3, M0, B0-2. T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. T2: Patches, papules, or plaques covering 10% or more of the skin surface. T3: One or more tumors (equal or greater than 1 cm in diameter). T4: Confluence of erythema covering 80% or more of body surface area. N3: Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3-4 or NCI LN4; clone positive or negative. M0: No visceral organ involvement. B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. B2: High blood tumor burden: 1,000 per microliter or more Sezary cells with positive clone. (AJCC 8th ed.)","Stage IVA2 Mycosis Fungoides and Sezary Syndrome AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539461","Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v8","C141359","Stage IVB includes: T1-4, N0-3, M1, B0-2. T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. T2: Patches, papules, or plaques covering 10% or more of the skin surface. T3: One or more tumors (equal or greater than 1 cm in diameter). T4: Confluence of erythema covering 80% or more of body surface area. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. N3: Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3-4 or NCI LN4; clone positive or negative. M1: Visceral involvement (must have pathology confirmation and organ involved should be specified). B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. B2: High blood tumor burden: 1,000 per microliter or more Sezary cells with positive clone. (AJCC 8th ed.)","Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543078","Grade 2 Oral Dysesthesia, CTCAE","C144874","Moderate pain; interfering with oral intake","Grade 2 Oral Dysesthesia, CTCAE | Grade 2 Oral dysesthesia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543079","Grade 2 Oropharyngeal Pain, CTCAE","C144877","Moderate pain; altered oral intake; non-narcotics initiated; topical analgesics initiated","Grade 2 Oropharyngeal Pain, CTCAE | Grade 2 Oropharyngeal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543080","Grade 2 Osteonecrosis of Jaw, CTCAE","C144878","Symptomatic; medical intervention indicated (e.g., topical agents); limiting instrumental ADL","Grade 2 Osteonecrosis of Jaw, CTCAE | Grade 2 Osteonecrosis of jaw",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543081","Grade 2 Osteonecrosis, CTCAE","C144879","Symptomatic; medical intervention indicated (e.g., analgesics or bisphosphonates); limiting instrumental ADL","Grade 2 Osteonecrosis, CTCAE | Grade 2 Osteonecrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543082","Grade 2 Otitis Externa, CTCAE","C144880","Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Otitis Externa, CTCAE | Grade 2 Otitis externa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543083","Grade 2 Otitis Media, CTCAE","C144881","Localized; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Otitis Media, CTCAE | Grade 2 Otitis media",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543084","Grade 2 Ovarian Infection, CTCAE","C144883","Localized; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Ovarian Infection, CTCAE | Grade 2 Ovarian infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543070","Grade 2 Pain In Extremity, CTCAE","C144886","Moderate pain; limiting instrumental ADL","Grade 2 Pain In Extremity, CTCAE | Grade 2 Pain in extremity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543071","Grade 2 Pain of Skin, CTCAE","C144887","Moderate pain; limiting instrumental ADL","Grade 2 Pain of Skin, CTCAE | Grade 2 Pain of skin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543072","Grade 2 Pain, CTCAE","C144888","Moderate pain; limiting instrumental ADL","Grade 2 Pain, CTCAE | Grade 2 Pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543361","Grade 3 Esophageal Hemorrhage, CTCAE","C145263","Transfusion indicated; invasive intervention indicated; hospitalization","Grade 3 Esophageal Hemorrhage, CTCAE | Grade 3 Esophageal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543362","Grade 3 Esophageal Infection, CTCAE","C145264","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Esophageal Infection, CTCAE | Grade 3 Esophageal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543363","Grade 3 Esophageal Necrosis, CTCAE","C145265","Inability to aliment adequately by GI tract; invasive intervention indicated","Grade 3 Esophageal Necrosis, CTCAE | Grade 3 Esophageal necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543349","Grade 3 Esophageal Pain, CTCAE","C145267","Severe pain; limiting self care ADL","Grade 3 Esophageal Pain, CTCAE | Grade 3 Esophageal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543350","Grade 3 Esophageal Perforation, CTCAE","C145268","Invasive intervention indicated","Grade 3 Esophageal Perforation, CTCAE | Grade 3 Esophageal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543351","Grade 3 Esophageal Stenosis, CTCAE","C145269","Severely altered GI function; tube feeding or hospitalization indicated; elective operative intervention indicated","Grade 3 Esophageal Stenosis, CTCAE | Grade 3 Esophageal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543352","Grade 3 Esophageal Ulcer, CTCAE","C145270","Severely altered GI function; TPN indicated; elective invasive intervention indicated; limiting self care ADL","Grade 3 Esophageal Ulcer, CTCAE | Grade 3 Esophageal ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543353","Grade 3 Extraocular Muscle Paresis, CTCAE","C145271","Bilateral paresis or unilateral paresis causing double vision in peripheral gaze, but not in central gaze","Grade 3 Extraocular Muscle Paresis, CTCAE | Grade 3 Extraocular muscle paresis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543354","Grade 3 Extrapyramidal Disorder, CTCAE","C145272","Severe involuntary movements or torticollis; limiting self care ADL","Grade 3 Extrapyramidal Disorder, CTCAE | Grade 3 Extrapyramidal disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519738","UBA Domain","C14131","UBA domains are a commonly occurring sequence motif of approximately 45 amino acid residues that are found in diverse proteins involved in the ubiquitin/proteasome pathway, DNA excision-repair, and cell signaling via protein kinases. The human homologue of yeast Rad23A is one example of a nucleotide excision-repair protein that contains both an internal and a C-terminal UBA domain.","UBA Domain | Ubiquitin-Associated Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538962","Orbital Sarcoma pNX TNM Finding v8","C140848","Orbital sarcoma in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Orbital Sarcoma pNX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538945","Orbital Sarcoma pN0 TNM Finding v8","C140849","Orbital sarcoma with no regional lymph node metastasis. (from AJCC 8th Ed.)","Orbital Sarcoma pN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517644","KDEL Motif","C14084","A motif found at the C termini of several luminal proteins of the ER that serves to mediate the retention of resident proteins of the ER lumen through retrieval from post-ER compartments ER via a transport mechanism involving vesicular and tubular elements.","KDEL Motif | KDEL Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538944","Orbital Sarcoma pN1 TNM Finding v8","C140850","Orbital sarcoma with regional lymph node metastasis. (from AJCC 8th Ed.)","Orbital Sarcoma pN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538943","Ocular Adnexal Lymphoma TNM Finding v8","C140851","A finding about one or more characteristics of ocular adnexal lymphoma, following the rules of the TNM AJCC v8 classification system. The lymphomas staged according to this system are primary lymphomas arising in the ocular adnexa-namely, the conjunctiva, eyelids, lacrimal gland, lacrimal drainage apparatus, and other orbital tissues surrounding the eye. Secondary ocular adnexal lymphomas and intraocular lymphomas are staged according to the classification for Hodgkin and non-Hodgkin lymphoma. There is no prognostic stage grouping for ocular adnexal lymphomas. (from AJCC 8th Ed.)","Ocular Adnexal Lymphoma TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538941","Ocular Adnexal Lymphoma Clinical Distant Metastasis TNM Finding v8","C140853","A clinical finding about one or more characteristics of ocular adnexal lymphoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Ocular Adnexal Lymphoma Clinical Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538940","Ocular Adnexal Lymphoma cM0 TNM Finding v8","C140854","Ocular adnexal lymphoma with no evidence of involvement of other extranodal sites. (from AJCC 8th Ed.)","Ocular Adnexal Lymphoma cM0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538939","Ocular Adnexal Lymphoma cM1a TNM Finding v8","C140855","Ocular adnexal lymphoma with noncontiguous involvement of tissues or organs external to the ocular adnexa (e.g., parotid glands, submandibular gland, lung, liver, spleen, kidney, breast). (from AJCC 8th Ed.)","Ocular Adnexal Lymphoma cM1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538938","Ocular Adnexal Lymphoma cM1b TNM Finding v8","C140856","Ocular adnexal lymphoma with lymphomatous involvement of the bone marrow. (from AJCC 8th Ed.)","Ocular Adnexal Lymphoma cM1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538953","Ocular Adnexal Lymphoma cM1c TNM Finding v8","C140857","Ocular adnexal lymphoma with both M1a and M1b involvement. (from AJCC 8th Ed.)","Ocular Adnexal Lymphoma cM1c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539203","Pheochromocytoma and Paraganglioma Pathologic Primary Tumor TNM Finding v8","C141119","A pathologic finding about one or more characteristics of pheochromocytoma and paraganglioma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Pheochromocytoma and Paraganglioma Pathologic Primary Tumor TNM Finding v8 | Adrenal-Neuroendocrine Tumor Pathologic Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539202","Pheochromocytoma and Paraganglioma pTX TNM Finding v8","C141120","Primary tumor cannot be assessed. (from AJCC 8th Ed.)","Pheochromocytoma and Paraganglioma pTX TNM Finding v8 | Adrenal-Neuroendocrine Tumor pTX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539201","Pheochromocytoma pT1 TNM Finding v8","C141121","Pheochromocytoma measuring less than 5 cm in greatest dimension, with no extra-adrenal invasion. (from AJCC 8th Ed.)","Pheochromocytoma pT1 TNM Finding v8 | Adrenal-Neuroendocrine Tumor pT1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539200","Pheochromocytoma and Paraganglioma pT2 TNM Finding v8","C141122","Pheochromocytoma measuring 5 cm or more in greatest dimension or paraganglioma-sympathetic of any size, with no extra-adrenal invasion. (from AJCC 8th Ed.)","Pheochromocytoma and Paraganglioma pT2 TNM Finding v8 | Adrenal-Neuroendocrine Tumor pT2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539199","Pheochromocytoma and Paraganglioma pT3 TNM Finding v8","C141123","Tumor of any size with invasion into surrounding tissues (e.g., liver, pancreas, spleen, kidneys). (from AJCC 8th Ed.)","Pheochromocytoma and Paraganglioma pT3 TNM Finding v8 | Adrenal-Neuroendocrine Tumor pT3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539198","Pheochromocytoma and Paraganglioma Pathologic Regional Lymph Nodes TNM Finding v8","C141124","A pathologic finding about one or more characteristics of pheochromocytoma and paraganglioma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Pheochromocytoma and Paraganglioma Pathologic Regional Lymph Nodes TNM Finding v8 | Adrenal-Neuroendocrine Tumor Pathologic Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539197","Pheochromocytoma and Paraganglioma pNX TNM Finding v8","C141125","Regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Pheochromocytoma and Paraganglioma pNX TNM Finding v8 | Adrenal-Neuroendocrine Tumor pNX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539180","Pheochromocytoma and Paraganglioma pN0 TNM Finding v8","C141126","No lymph node metastasis. (from AJCC 8th Ed.)","Pheochromocytoma and Paraganglioma pN0 TNM Finding v8 | Adrenal-Neuroendocrine Tumor pN0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539179","Pheochromocytoma and Paraganglioma pN1 TNM Finding v8","C141127","Regional Lymph node metastasis. (from AJCC 8th Ed.)","Pheochromocytoma and Paraganglioma pN1 TNM Finding v8 | Adrenal-Neuroendocrine Tumor pN1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539178","Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma by AJCC v8 Stage","C141128","A term that refers to the staging of adrenal gland pheochromocytoma and sympathetic paraganglioma, following the rules of the TNM AJCC v8 classification system. Parasympathetic paragangliomas are not staged because they are largely benign. This staging system does not apply to neuroendocrine tumors of the pancreas (are staged according to the classification for neuroendocrine tumors of the pancreas) and carotid body tumors (not staged). (from AJCC 8th Ed.)","Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539177","Stage I Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8","C141129","Stage I includes: T1, N0, M0. T1: Pheochromocytoma measuring less than 5 cm in greatest dimension, with no extra-adrenal invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage I Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515525","9q32-q34","C14112","A chromosome band present on 9q","9q32-q34 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539176","Stage II Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8","C141130","Stage II includes: T2, N0, M0. T2: Pheochromocytoma measuring 5 cm or more in greatest dimension or paraganglioma-sympathetic of any size, with no extra-adrenal invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage II Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539025","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma Pathologic Primary Tumor TNM Finding v8","C140912","A pathologic finding about one or more characteristics of papillary, follicular, Hurthle cell, poorly differentiated, and anaplastic thyroid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma Pathologic Primary Tumor TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma Pathologic Primary Tumor TNM Finding v8 | Pathologic Primary Tumor Status (pT)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543355","Grade 3 Eye Disorders - Other, Specify, CTCAE","C145273","Severe or medically significant but not immediately sight-threatening; limiting self care ADL; decrease in visual acuity (best corrected visual acuity worse than 20/40 or more than 3 lines of decreased vision from known baseline, up to 20/200)","Grade 3 Eye Disorders - Other, Specify, CTCAE | Grade 3 Eye disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543356","Grade 3 Eye Infection, CTCAE","C145274","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Eye Infection, CTCAE | Grade 3 Eye infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543470","Grade 3 Facial Muscle Weakness, CTCAE","C145276","Severe symptoms; limiting self care ADL","Grade 3 Facial Muscle Weakness, CTCAE | Grade 3 Facial muscle weakness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543471","Grade 3 Facial Nerve Disorder, CTCAE","C145277","Severe symptoms; limiting self care ADL","Grade 3 Facial Nerve Disorder, CTCAE | Grade 3 Facial nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543472","Grade 3 Facial Pain, CTCAE","C145278","Severe pain; limiting self care ADL","Grade 3 Facial Pain, CTCAE | Grade 3 Facial pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543473","Grade 3 Fall, CTCAE","C145279","Hospitalization indicated; invasive intervention indicated","Grade 3 Fall, CTCAE | Grade 3 Fall",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543474","Grade 3 Fallopian Tube Anastomotic Leak, CTCAE","C145280","Severe symptoms; invasive intervention indicated","Grade 3 Fallopian Tube Anastomotic Leak, CTCAE | Grade 3 Fallopian tube anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543475","Grade 3 Fat Atrophy, CTCAE","C145281","Covering >30% BSA; associated with erythema or tenderness; limiting self-care ADL","Grade 3 Fat Atrophy, CTCAE | Grade 3 Fat atrophy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543476","Grade 3 Fecal Incontinence, CTCAE","C145283","Severe symptoms; elective operative intervention indicated","Grade 3 Fecal Incontinence, CTCAE | Grade 3 Fecal incontinence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543462","Grade 3 Fever, CTCAE","C145285",">40.0 degrees C (>104.0 degrees F) for <=24 hrs","Grade 3 Fever, CTCAE | Grade 3 Fever",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543463","Grade 3 Fibrinogen Decreased, CTCAE","C145286","<0.5-0.25 x LLN; if abnormal, 50-<75% decrease from baseline","Grade 3 Fibrinogen Decreased, CTCAE | Grade 3 Fibrinogen decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543464","Grade 3 Fibrosis Deep Connective Tissue, CTCAE","C145287","Severe induration; unable to slide or pinch skin; limiting joint or orifice movement (e.g., mouth, anus); limiting self care ADL","Grade 3 Fibrosis Deep Connective Tissue, CTCAE | Grade 3 Fibrosis deep connective tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542263","Grade 1 Fallopian Tube Anastomotic Leak, CTCAE","C144100","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Fallopian Tube Anastomotic Leak, CTCAE | Grade 1 Fallopian tube anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542264","Grade 1 Fat Atrophy, CTCAE","C144101","Covering <10% BSA and asymptomatic","Grade 1 Fat Atrophy, CTCAE | Grade 1 Fat atrophy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542265","Grade 1 Fecal Incontinence, CTCAE","C144102","Occasional use of pads required","Grade 1 Fecal Incontinence, CTCAE | Grade 1 Fecal incontinence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542266","Grade 1 Feminization Acquired, CTCAE","C144103","Mild symptoms; intervention not indicated","Grade 1 Feminization Acquired, CTCAE | Grade 1 Feminization acquired",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542267","Grade 1 Fever, CTCAE","C144104","38.0-39.0 degrees C (100.4-102.2 degrees F)","Grade 1 Fever, CTCAE | Grade 1 Fever",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538952","Ocular Adnexal Lymphoma Pathologic TNM Finding v8","C140858","A pathologic finding about one or more characteristics of ocular adnexal lymphoma, following the rules of the TNM AJCC v8 classification system.","Ocular Adnexal Lymphoma Pathologic TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538951","Ocular Adnexal Lymphoma Pathologic Distant Metastasis TNM Finding v8","C140859","A pathologic finding about one or more characteristics of ocular adnexal lymphoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Ocular Adnexal Lymphoma Pathologic Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511656","DIX Domain","C14085","A domain involved in homo- and hetero-oligomerization.","DIX Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538949","Ocular Adnexal Lymphoma pM1b TNM Finding v8","C140861","Ocular adnexal lymphoma with lymphomatous involvement of the bone marrow. (from AJCC 8th Ed.)","Ocular Adnexal Lymphoma pM1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538948","Ocular Adnexal Lymphoma pM1c TNM Finding v8","C140862","Ocular adnexal lymphoma with both M1a and M1b involvement. (from AJCC 8th Ed.)","Ocular Adnexal Lymphoma pM1c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538947","Ocular Adnexal Lymphoma Pathologic Primary Tumor TNM Finding v8","C140863","A pathologic finding about one or more characteristics of ocular adnexal lymphoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Ocular Adnexal Lymphoma Pathologic Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538946","Ocular Adnexal Lymphoma pTX TNM Finding v8","C140864","Lymphoma extent not specified. (from AJCC 8th Ed.)","Ocular Adnexal Lymphoma pTX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538928","Ocular Adnexal Lymphoma pT1 TNM Finding v8","C140866","Ocular adnexal lymphoma involving the conjunctiva alone without eyelid or orbital involvement. (from AJCC 8th Ed.)","Ocular Adnexal Lymphoma pT1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539511","Dose-dense AC Followed by Dose-Dense Paclitaxel Regimen","C141433","A regimen consisting of dose-dense cyclophosphamide and doxorubicin followed by dose-dense paclitaxel that can be used in the treatment of breast cancer.","Dose-dense AC Followed by Dose-Dense Paclitaxel Regimen | ACT Dose Dense | ACT Dose-dense | DD AC Followed by DD Paclitaxel Regimen | DD ACT Regimen | Dose-dense AC Followed by Dose-dense Paclitaxel | Dose-dense AC Regimen Followed by Dose-dense Paclitaxel | Dose-dense ACT Regimen | Dose-dense Adriamycin/Cytoxan Followed by Dose-dense Taxol | Dose-dense Doxorubicin/Cyclophosphamide Followed by Dose-dense Paclitaxel | ddAC-ddT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539497","HER2/Neu Positive by FISH","C141434","A laboratory test result indicating the presence of HER2/Neu in a tissue sample using fluorescence in situ hybridization.","HER2/Neu Positive by FISH | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539495","Roxadustat","C141436","An orally bioavailable, hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), with potential anti-anemic activity. Upon administration, roxadustat binds to and inhibits HIF-PHI, an enzyme responsible for the degradation of transcription factors in the HIF family under normal oxygen conditions. This prevents HIF breakdown and promotes HIF activity. Increased HIF activity leads to an increase in endogenous erythropoietin production, thereby enhancing erythropoiesis. It also reduces the expression of the peptide hormone hepcidin, improves iron availability, and boosts hemoglobin (Hb) levels. HIF regulates the expression of genes in response to reduced oxygen levels, including genes required for erythropoiesis and iron metabolism.","Roxadustat | (((4-Hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl)amino)acetic Acid | ASP 1517 | FG 4592 | FG-4592 | ROXADUSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539494","Early Third Trimester","C141437","The period of gestation generally corresponding to the first half of the third trimester.","Early Third Trimester | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539493","Late Third Trimester","C141438","The period of gestation generally corresponding to the last half of the third trimester.","Late Third Trimester | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539492","NovoTTF-200A Device","C141439","A second generation tumor treatment field (TTF; TTField) device.","NovoTTF-200A Device | NovoTTF-200A | NovoTTF-200A System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539070","Stage II Thyroid Gland Papillary Carcinoma AJCC v8","C140980","Stage II includes: Under 55 years: Any T, Any N, M1; 55 years and older: (T1, N1, M0); (T2, N1, M0); (T3a/T3b, Any N, M0). T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. T3a: Tumor measuring more than 4 cm in greatest dimension limited to the thyroid. T3b: Gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles) from a tumor of any size. N1: Metastasis to regional nodes. M0: No distant metastasis. M1: Distant metastasis. (from AJCC 8th Ed.)","Stage II Thyroid Gland Papillary Carcinoma AJCC v8 | II | Stage II Thyroid Gland Papillary Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539069","Stage II Thyroid Gland Papillary Carcinoma Under 55 Years AJCC v8","C140981","Stage II includes: Any T, Any N, M1. M1: Distant metastasis. (from AJCC 8th Ed.)","Stage II Thyroid Gland Papillary Carcinoma Under 55 Years AJCC v8 | II Under Years | Stage II Thyroid Gland Papillary Cancer Under 55 Years",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539068","Stage II Thyroid Gland Papillary Carcinoma 55 Years and Older AJCC v8","C140982","Stage II includes: (T1, N1, M0); (T2, N1, M0); (T3a/T3b, Any N, M0). T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. T3a: Tumor measuring more than 4 cm in greatest dimension limited to the thyroid. T3b: Gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles) from a tumor of any size. N1: Metastasis to regional nodes. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage II Thyroid Gland Papillary Carcinoma 55 Years and Older AJCC v8 | II 55 Years and Older | Stage II Thyroid Gland Papillary Cancer 55 Years and Older",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539067","Stage III Thyroid Gland Papillary Carcinoma AJCC v8","C140983","Stage III includes: 55 years and older: T4a, Any N, M0. T4a: Gross extrathyroidal extension invading subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve from a tumor of any size. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage III Thyroid Gland Papillary Carcinoma AJCC v8 | III | Stage III Thyroid Gland Papillary Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539012","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8","C140925","A pathologic finding about one or more characteristics of papillary, follicular, Hurthle cell, poorly differentiated, and anaplastic thyroid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8 | Pathologic Regional Lymph Node Status (pN)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539309","KDR Gene Product","C141266","A protein encoded by the KDR gene.","KDR Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521490","5q32","C14126","A chromosome band present on 5q","5q32 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539406","Mature T- and NK-Cell Lymphoma by Ann Arbor Stage","C141272","An anatomic stage for mature T- and NK-cell non-Hodgkin lymphomas based on the Ann Arbor classification criteria.","Mature T- and NK-Cell Lymphoma by Ann Arbor Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539405","Poseltinib","C141273","An inhibitor of Bruton's tyrosine kinase (BTK) with potential anti-inflammatory activity. Upon administration, poseltinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents  the activation of BTK-mediated  inflammatory pathways.","Poseltinib | 2-Propenamide, N-(3-((2-((4-(4-methyl-1-piperazinyl)phenyl)amino)furo(3,2-d)pyrimidin-4-yl)oxy)phenyl)- | HM71224 | LY3337641 | POSELTINIB | PRN1008",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538886","Lacrimal Gland Carcinoma pT4 TNM Finding v8","C140796","Lacrimal gland carcinoma with involvement of adjacent structures, including sinuses, temporal fossa, pterygoid fossa, superior orbital fissure, cavernous sinus, or brain. (from AJCC 8th Ed.)","Lacrimal Gland Carcinoma pT4 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539120","ERK1/2 Inhibitor KO-947","C141074","An inhibitor of the extracellular signal-regulated kinases (ERK) 1 and 2, with potential antineoplastic activity. Upon intravenous administration, KO-947 specifically binds to and inhibits both ERK 1 and 2, thereby preventing the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The MAPK/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in the proliferation, differentiation and survival of tumor cells.","ERK1/2 Inhibitor KO-947 | ERK Inhibitor KO-947 | Extracellular Signal-regulated Kinase 1/2 Inhibitor KO-947 | KO 947 | KO-947 | KO947",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539119","Refractory Lung Carcinoma","C141076","Lung carcinoma that does not respond to treatment.","Refractory Lung Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554791","Recurrent Extensive Stage Lung Small Cell Carcinoma","C141077","The reemergence of extensive stage lung small cell carcinoma after a period of remission.","Recurrent Extensive Stage Lung Small Cell Carcinoma | Recurrent Extensive Stage Small Cell Lung Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554792","Refractory Extensive Stage Lung Small Cell Carcinoma","C141078","Extensive stage small cell lung carcinoma that does not respond to treatment.","Refractory Extensive Stage Lung Small Cell Carcinoma | Refractory Extensive Stage Small Cell Lung Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539227","Adrenal Cortical Carcinoma TNM Finding v8","C141079","A finding about one or more characteristics of adrenal cortical carcinoma, following the rules of the TNM AJCC v8 classification system. Adrenal medullary pheochromocytoma is staged according to the classification for adrenal neuroendocrine tumors. There is no AJCC staging system for neuroblastic tumors of the adrenal gland. (from AJCC 8th Ed.)","Adrenal Cortical Carcinoma TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539066","Stage IV Thyroid Gland Papillary Carcinoma AJCC v8","C140984","Stage IV includes: IVA: 55 years and older: T4b, Any N, M0; IVB: 55 years and older: Any T, Any N, M1. T4b: Gross extrathyroidal extension invading prevertebral fascia or encasing the carotid artery or mediastinal vessels from a tumor of any size. M0: No distant metastasis. M1: Distant metastasis. (from AJCC 8th Ed.)","Stage IV Thyroid Gland Papillary Carcinoma AJCC v8 | IV | Stage IV Thyroid Gland Papillary Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539065","Stage IVA Thyroid Gland Papillary Carcinoma AJCC v8","C140985","Stage IVA includes: 55 years and older: T4b, Any N, M0. T4b: Gross extrathyroidal extension invading prevertebral fascia or encasing the carotid artery or mediastinal vessels from a tumor of any size. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage IVA Thyroid Gland Papillary Carcinoma AJCC v8 | IVA | Stage IVA Thyroid Gland Papillary Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539063","Thyroid Gland Follicular Carcinoma by AJCC v8 Stage","C140987","A term that refers to the staging of follicular thyroid gland carcinoma, following the rules of the TNM AJCC v8 classification system.","Thyroid Gland Follicular Carcinoma by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539078","Stage I Thyroid Gland Follicular Carcinoma AJCC v8","C140988","Stage I includes: Under 55 years: Any T, Any N, M0. 55 years and older: (T1, N0/NX, M0); (T2, N0/NX, M0).  T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. N0: No evidence of locoregional lymph node metastasis. NX: Regional lymph nodes cannot be assessed. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage I Thyroid Gland Follicular Carcinoma AJCC v8 | Stage I Thyroid Gland Follicular Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539077","Stage I Thyroid Gland Follicular Carcinoma Under 55 Years AJCC v8","C140989","Stage I includes: Any T, Any N, M0. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage I Thyroid Gland Follicular Carcinoma Under 55 Years AJCC v8 | Stage I Thyroid Gland Follicular Cancer Under 55 Years",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518791","PHD Finger","C14098","A C4HC3 zinc-finger-like motif, the PHD finger is found in nuclear proteins thought involved in chromatin-mediated transcriptional regulation. Single or multiple fingers are found. A specific function is not yet known, but it could be involved in protein-protein interactions important for assembly/activity of multi-component transcriptional regulatory complexes. In CBP it is an integral part of the acetyltransferase enzymatic core domain and contributes to CBP transcriptional activity. PHD fingers fold into an interleaved Zn-finger chelating two Zn ions in an atypical cross-braced conformation also shared by the FYVE and RING fingers; the zinc sites are located at opposite ends of a beta-sheet. Surrounding loops vary significantly in length and sequence between these three domains. (NCI)","PHD Finger | C4HC3 Zinc Finger | PHD Finger Domain | PHD Finger Motif | PHD-Finger | Plant Homeodomain (PHD) Type Zinc Finger",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539347","Stage A Chronic Lymphocytic Leukemia","C141209","Findings: Lymphocytosis only; Survival (months): more than 120. (from AJCC 8th Ed.)","Stage A Chronic Lymphocytic Leukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520289","10q24.1","C14120","A chromosome band present on 10q","10q24.1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539346","Stage B Chronic Lymphocytic Leukemia","C141210","Findings: Lymphocytosis and adenopathy; Survival (months): 95. (from AJCC 8th Ed.)","Stage B Chronic Lymphocytic Leukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539345","Stage C Chronic Lymphocytic Leukemia","C141211","Findings: Lymphocytosis, adenopathy, and enlarged spleen and/or liver; Survival (months): 72. (from AJCC 8th Ed.)","Stage C Chronic Lymphocytic Leukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539344","Binet Stage","C141212","A stage term that refers to the Binet staging system which is used for the staging of chronic lymphocytic leukemia.","Binet Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539343","65 kDa Phosphoprotein","C141213","65 kDa phosphoprotein (561 aa, ~63 kDa) is encoded by the cytomegalovirus UL83 gene. This protein plays a role in both the inhibition of the host antiviral immune response and the transactivation of viral major immediate-early genes.","65 kDa Phosphoprotein | 65 kDa Matrix Phosphoprotein | CMV UL83 | Human Cytomegalovirus UL83 | Phosphoprotein UL83 | Tegument Protein UL83 | pp65",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539175","Stage III Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8","C141131","Stage III includes: (T1, N1, M0); (T2, N1, M0); (T3, Any N, M0). T1: Pheochromocytoma measuring less than 5 cm in greatest dimension, with no extra-adrenal invasion. T2: Pheochromocytoma measuring 5 cm or more in greatest dimension or paraganglioma-sympathetic of any size, with no extra-adrenal invasion. T3: Tumor of any size with invasion into surrounding tissues (e.g., liver, pancreas, spleen, kidneys). N1: Regional lymph node metastasis. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage III Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539174","Stage IV Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8","C141132","Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (from AJCC 8th Ed.)","Stage IV Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539187","(R)-N-(4-chlorophenyl)-2-((1S,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propenamide","C141135","An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon administration, linrodostat specifically targets and binds to IDO1, a cytosolic enzyme responsible for the oxidation of the amino acid tryptophan into the immunosuppressive metabolite kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, BMS-986205 restores and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes, and causes a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL) response against the IDO1-expressing tumor cells, thereby inhibiting the growth of IDO1-expressing tumor cells. IDO1, overexpressed by multiple tumor cell types, plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system.","Linrodostat | (R)-N-(4-chlorophenyl)-2-((1S,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propenamide | BMS 986205 | BMS-986205 | BMS986205 | IDO-1 Inhibitor BMS-986205 | Indoleamine-pyrrole 2,3-Dioxygenase Inhibitor BMS-986205 | LINRODOSTAT | ONO-7701",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539185","IDO1 Inhibitor","C141137","Any agent that inhibits the activity of the enzyme indoleamine 2,3-dioxygenase 1 (IDO1; IDO).","IDO1 Inhibitor | IDO Inhibitor | IDO Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538884","Lacrimal Gland Carcinoma pT4a TNM Finding v8","C140798","Lacrimal gland carcinoma with involvement of adjacent structures, including sinuses, temporal fossa, pterygoid fossa, superior orbital fissure, cavernous sinus, or brain and measuring 2 cm or less in greatest dimension. (from AJCC 8th Ed.)","Lacrimal Gland Carcinoma pT4a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538883","Lacrimal Gland Carcinoma pT4b TNM Finding v8","C140799","Lacrimal gland carcinoma with involvement of adjacent structures, including sinuses, temporal fossa, pterygoid fossa, superior orbital fissure, cavernous sinus, or brain and measuring more than 2 cm but 4 cm or less in greatest dimension. (from AJCC 8th Ed.)","Lacrimal Gland Carcinoma pT4b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519594","Transcriptional Activation Domain","C14079","A DNA-binding domain binds to a specific DNA sequence and a transcriptional activation domain interacts with the basal transcriptional machinery. An association of a transcriptional activation domain with a DNA-binding domain promotes the assembly of RNA polymerase II complexes at the TATA box and increase transcription. (NCI)","Transcriptional Activation Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0140338","RG 13022","C1407","A tyrosine kinase inhibitor that selectively inhibits epidermal growth factor receptor, epidermal factor-stimulated HER14 cell proliferation, and tumor growth in vivo. (NCI)","RG 13022 | RG-13022 | Tyrphostin RG-13022",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538865","Lacrimal Gland Carcinoma pT4c TNM Finding v8","C140801","Lacrimal gland carcinoma with involvement of adjacent structures, including sinuses, temporal fossa, pterygoid fossa, superior orbital fissure, cavernous sinus, or brain and measuring more than 4 cm in greatest dimension. (from AJCC 8th Ed.)","Lacrimal Gland Carcinoma pT4c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538864","Lacrimal Gland Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8","C140802","A pathologic finding about one or more characteristics of lacrimal gland carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Lacrimal Gland Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538863","Lacrimal Gland Carcinoma pNX TNM Finding v8","C140803","Lacrimal gland carcinoma in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Lacrimal Gland Carcinoma pNX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538861","Lacrimal Gland Carcinoma pN1 TNM Finding v8","C140805","Lacrimal gland carcinoma with regional lymph node metastasis. (from AJCC 8th Ed.)","Lacrimal Gland Carcinoma pN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514648","RGS Domain","C14107","Typically 120 amino acids long, the RGS (Regulator of G protein Signaling) Domain is found in over 20 human proteins, bind activated G-alpha subunits, and are responsible for GAP function. Through other domains (e.g., DEP, PDZ, or PH) RGS proteins link to other signaling molecules. RGS domains contain conserved contiguous, or dispersed, GH subdomains (GH1, 2, and 3). All RGS domains share a tertiary structure of nine alpha helixes that form a right-handed anti-parallel bundle of helixes 4-7 and a terminal bundle of helixes 1-3 and 8-9. The 3-4, 5-6, and 7-8 helix loops form an interaction surface between RGS4 and Ga(i). RGS domains allosterically stabilize the G-alpha GTP binding pocket, accelerating GTPase activity. Thus, RGS Family members rapidly inactivate G protein signal transmission from seven transmembrane receptors in GPCR signaling pathways. (NCI)","RGS Domain | RGS-Signaling Domain | Regulators of G Protein Signaling Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539226","Adrenal Cortical Carcinoma Clinical TNM Finding v8","C141080","A clinical finding about one or more characteristics of adrenal cortical carcinoma, following the rules of the TNM AJCC v8 classification system.","Adrenal Cortical Carcinoma Clinical TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539225","Adrenal Cortical Carcinoma Clinical Distant Metastasis TNM Finding v8","C141081","A clinical finding about one or more characteristics of adrenal cortical carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Adrenal Cortical Carcinoma Clinical Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539224","Adrenal Cortical Carcinoma cM0 TNM Finding v8","C141082","No distant metastasis. (from AJCC 8th Ed.)","Adrenal Cortical Carcinoma cM0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539223","Adrenal Cortical Carcinoma cM1 TNM Finding v8","C141083","Distant metastasis. (from AJCC 8th Ed.)","Adrenal Cortical Carcinoma cM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539222","Adrenal Cortical Carcinoma Pathologic TNM Finding v8","C141084","A pathologic finding about one or more characteristics of adrenal cortical carcinoma, following the rules of the TNM AJCC v8 classification system.","Adrenal Cortical Carcinoma Pathologic TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539221","Adrenal Cortical Carcinoma Pathologic Distant Metastasis TNM Finding v8","C141085","A pathologic finding about one or more characteristics of adrenal cortical carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Adrenal Cortical Carcinoma Pathologic Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539236","Adrenal Cortical Carcinoma pM1 TNM Finding v8","C141086","Distant metastasis. (from AJCC 8th Ed.)","Adrenal Cortical Carcinoma pM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539235","Adrenal Cortical Carcinoma Pathologic Primary Tumor TNM Finding v8","C141087","A pathologic finding about one or more characteristics of adrenal cortical carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Adrenal Cortical Carcinoma Pathologic Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539233","Adrenal Cortical Carcinoma pT0 TNM Finding v8","C141089","No evidence of primary tumor. (from AJCC 8th Ed.)","Adrenal Cortical Carcinoma pT0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539357","Anti-CD20 Monoclonal Antibody","C141215","Any monoclonal antibody that targets CD20.","Anti-CD20 Monoclonal Antibody | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539355","St. Jude Childhood Non-Hodgkin Lymphoma by AJCC v8 Stage","C141217","A staging system for childhood non-Hodgkin Lymphomas based on the St. Jude Children's Research Hospital staging system. The Ann Arbor staging system has been found to be inappropriate for staging of the non-Hodgkin lymphomas of childhood. The St. Jude staging system has been widely accepted for more than three decades and remains the recommended staging system for childhood non-Hodgkin lymphomas. (from AJCC 8th Ed.)","St. Jude Childhood Non-Hodgkin Lymphoma by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539354","St. Jude Stage I Childhood Non-Hodgkin Lymphoma AJCC v8","C141218","Stage I: A single tumor (extranodal) or single anatomic area (nodal), with the exclusion of the mediastinum or abdomen. (from AJCC 8th Ed.)","St. Jude Stage I Childhood Non-Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539353","St. Jude Stage II Childhood Non-Hodgkin Lymphoma AJCC v8","C141219","Stage II: A single tumor (extranodal) with regional node involvement. Two or more nodal areas on the same side of the diaphragm. Two single (extranodal) tumors with or without regional node involvement on the same side of the diaphragm. A primary gastrointestinal tract tumor, usually in the ileocecal area, with or without involvement of associated mesenteric nodes only. (from AJCC 8th Ed.)","St. Jude Stage II Childhood Non-Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521705","8p22-p21","C14121","A chromosome band present on 8p","8p22-p21 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539352","St. Jude Stage III Childhood Non-Hodgkin Lymphoma AJCC v8","C141220","Stage III: Two single tumors (extranodal) on opposite sides of the diaphragm. Two or more nodal areas above and below the diaphragm. All the primary intrathoracic tumors (mediastinal, pleural, and thymic). All extensive primary intra-abdominal disease. All paraspinal or epidural tumors, regardless of other tumor site(s). (from AJCC 8th Ed.)","St. Jude Stage III Childhood Non-Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539351","St. Jude Stage IV Childhood Non-Hodgkin Lymphoma AJCC v8","C141221","Stage IV: Any tumor, with initial CNS and/or bone marrow involvement. (from AJCC 8th Ed.)","St. Jude Stage IV Childhood Non-Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539334","Lymphocyte-Depleted Classic Hodgkin Lymphoma by Ann Arbor Stage","C141222","An anatomic stage for lymphocyte-depleted classic Hodgkin lymphoma based on the Ann Arbor classification criteria.","Lymphocyte-Depleted Classic Hodgkin Lymphoma by Ann Arbor Stage | Lymphocyte-Depleted Classical Hodgkin Lymphoma by Ann Arbor Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539332","Mixed Cellularity Classic Hodgkin Lymphoma by Ann Arbor Stage","C141224","An anatomic stage for mixed cellularity classic Hodgkin lymphoma based on the Ann Arbor classification criteria.","Mixed Cellularity Classic Hodgkin Lymphoma by Ann Arbor Stage | Mixed Cellularity Classical Hodgkin Lymphoma by Ann Arbor Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538911","Clinical Stage III Retinoblastoma AJCC v8","C140754","Stage III includes: (cT4b, cN0, cM0, Any H); (Any cT, cN1, cM0, Any H). cT4b: Extraocular tumor clinically evident with proptosis and/or an orbital mass. cN0: No regional lymph node involvement. cN1: Evidence of preauricular, submandibular, and cervical lymph node involvement. cM0: No signs or symptoms of intracranial or distant metastasis. HX: Unknown or insufficient evidence of a constitutional RB1 gene mutation. H0: Normal RB1 alleles in blood tested with demonstrated high-sensitivity assays. H1: Bilateral retinoblastoma, retinoblastoma with an intracranial primitive neuroectodermal tumor (i.e., trilateral retinoblastoma), patient with family history of retinoblastoma, or molecular definition of a constitutional RB1 gene mutation. (AJCC 8th ed.)","Clinical Stage III Retinoblastoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538910","Clinical Stage IV Retinoblastoma AJCC v8","C140755","Stage IV includes: Any cT, Any N, cM1 or pM1, Any H. cM1: Distant metastasis without microscopic confirmation. pM1: Distant metastasis with microscopic confirmation. HX: Unknown or insufficient evidence of a constitutional RB1 gene mutation. H0: Normal RB1 alleles in blood tested with demonstrated high-sensitivity assays. H1: Bilateral retinoblastoma, retinoblastoma with an intracranial primitive neuroectodermal tumor (i.e., trilateral retinoblastoma), patient with family history of retinoblastoma, or molecular definition of a constitutional RB1 gene mutation. (AJCC 8th ed.)","Clinical Stage IV Retinoblastoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538909","Retinoblastoma by AJCC v8 Pathologic Stage","C140756","A term that refers to the pathologic staging of retinoblastoma according to the American Joint Committee on Cancer, 8th edition.","Retinoblastoma by AJCC v8 Pathologic Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539183","Lymphoma by Ann Arbor Stage","C141139","An anatomic stage for Hodgkin and non-Hodgkin lymphomas  based on the Ann Arbor classification criteria.","Lymphoma by Ann Arbor Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520592","14q24-q31","C14113","A chromosome band present on 14q","14q24-q31 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539181","Hodgkin Lymphoma by Ann Arbor Stage","C141141","An anatomic stage for Hodgkin lymphomas based on the Ann Arbor classification criteria.","Hodgkin Lymphoma by Ann Arbor Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539289","Mycosis Fungoides and Sezary Syndrome by AJCC v7 Stage","C141142","A term that refers to the staging of mycosis fungoides and Sezary syndrome, following the rules of the TNM AJCC v7 classification system.","Mycosis Fungoides and Sezary Syndrome by AJCC v7 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539288","Mycosis Fungoides by AJCC v7 Stage","C141143","A term that refers to the staging of mycosis fungoides, following the rules of the TNM AJCC v7 classification system.","Mycosis Fungoides by AJCC v7 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539287","Immune Checkpoint Modulator","C141144","Any agent that modulates the immune checkpoint pathway, either by blocking any inhibitory immune checkpoint protein or by activating any stimulatory immune checkpoint protein.","Immune Checkpoint Modulator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539286","Anti-ICOS Monoclonal Antibody","C141145","Any monoclonal antibody that is directed against inducible T-cell co-stimulator (ICOS; CD278).","Anti-ICOS Monoclonal Antibody | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539285","Anti-TIM-3 Monoclonal Antibody","C141146","Any monoclonal antibody that targets the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2).","Anti-TIM-3 Monoclonal Antibody | TIM-3 Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539455","Porcine Leukemia","C141365","Leukemia that occurs in a pig.","Porcine Leukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539454","Hemoglobin Lepore Syndrome","C141366","A beta thalassemia resulting from an unequal crossover/recombination event involving portions of the delta and beta globin genes, resulting in underproduction of the abnormal delta-beta globin.","Hemoglobin Lepore Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1848410","Xeroderma pigmentosum, variant type","C141367","A type of xeroderma pigmentosum resulting from mutation(s) in the POLH gene, encoding DNA polymerase eta. This form of the disease is characterized by normal DNA excision repair, but defective post-replication repair of DNA at UV-damaged sites.","Xeroderma Pigmentosum Variant Type | XPV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517053","Extracellular Structure","C14136","Any structures that are not enclosed intracellularly are considered extracellular structure, including structures on the cell surface. (NCI)","Extracellular Structure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511644","DAG/PE-Binding Domain","C14080","The cysteine-rich N-terminal DAG/PE (Diacylglycerol/Phorbol Ester)-Binding (C1) Domain of PKC isoforms interacts with phorbol ester or with the phospholipid-derived second messenger diacylglycerol. C1 contains one or two copies of a Cys-rich domain about 50 amino-acid residues long; the domain binds two zinc ions, probably involving the conserved cysteines and histidines. Bound to DAG, C1 domains are involved in recruitment of proteins to the membrane via basic residues that interact with lipid head groups. Part of the domain contains two beta sheets that form a cavity and a short C-terminal alpha helix; another contains two zinc-binding sites that maintain the domain fold. Binding of diacylglycerol, or phorbol ester, to the domain results in modification of protein function. (NCI)","DAG/PE-Binding Domain | C1 Domain | DAG Binding Domain | Diacylglycerol Binding Domain | Phorbol Ester Binding Domain | Protein Kinase C Conserved Region 1 Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539569","HER2/Neu Positive by Immunohistochemistry 1-10 Percent","C141494","An immunohistochemical staining finding indicating that 1-10 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.","HER2/Neu Positive by Immunohistochemistry 1-10 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539568","HER2/Neu Positive by Immunohistochemistry 11-20 Percent","C141495","An immunohistochemical staining finding indicating that 11-20 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.","HER2/Neu Positive by Immunohistochemistry 11-20 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539567","HER2/Neu Positive by Immunohistochemistry 21-30 Percent","C141496","An immunohistochemical staining finding indicating that 21-30 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.","HER2/Neu Positive by Immunohistochemistry 21-30 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539566","HER2/Neu Positive by Immunohistochemistry 31-40 Percent","C141497","An immunohistochemical staining finding indicating that 31-40 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.","HER2/Neu Positive by Immunohistochemistry 31-40 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539564","HER2/Neu Positive by Immunohistochemistry 51-60 Percent","C141499","An immunohistochemical staining finding indicating that 51-60 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.","HER2/Neu Positive by Immunohistochemistry 51-60 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518633","Osteolytic","C14149","No value exists.","Osteolytic | osteolytic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0146868","Trioxifene Mesylate","C1414","A mesylate salt form of trioxifene, a nonsteroidal selective estrogen receptor modulator (SERM).  Trioxifene competitively inhibits the binding of estradiol to estrogen receptor alpha (ER alpha), resulting in ER alpha-mediated gene expression.  Clinical development of Trioxifene has not proceeded because of lack of superior results over tamoxifen and side effect profile. (NCI)","Trioxifene Mesylate | 3,4-Dihydro-2-(p-methoxyphenyl)-1-naphthyl p-(2-(1-pyrrolidinyl)ethoxy)phenyl Ketone Methanesulfonate | Compound 133314 | LY-133314 | TRIOXIFENE MESYLATE | Trioxifene Mesilate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539563","HER2/Neu Positive by Immunohistochemistry 61-70 Percent","C141500","An immunohistochemical staining finding indicating that 61-70 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.","HER2/Neu Positive by Immunohistochemistry 61-70 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539578","HER2/Neu Positive by Immunohistochemistry 71-80 Percent","C141501","An immunohistochemical staining finding indicating that 71-80 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.","HER2/Neu Positive by Immunohistochemistry 71-80 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539577","HER2/Neu Positive by Immunohistochemistry 81-90 Percent","C141502","An immunohistochemical staining finding indicating that 81-90 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.","HER2/Neu Positive by Immunohistochemistry 81-90 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539576","HER2/Neu Positive by Immunohistochemistry 91-100 Percent","C141503","An immunohistochemical staining finding indicating that 91-100 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.","HER2/Neu Positive by Immunohistochemistry 91-100 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539575","SNX 5422","C141504","No value exists.","SNX 5422 | Glycine, Trans-4-((2-(aminocarbonyl)-5-(4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo-3-(trifluoromethyl)-1H-indazol-1-yl)phenyl)amino)cyclohexyl Ester | PF 04929113 | PF-04929113 | SNX-5422",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538927","Ocular Adnexal Lymphoma pT2 TNM Finding v8","C140867","Ocular adnexal lymphoma with orbital involvement with or without conjunctival involvement. (from AJCC 8th Ed.)","Ocular Adnexal Lymphoma pT2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538926","Ocular Adnexal Lymphoma pT3 TNM Finding v8","C140868","Ocular adnexal lymphoma with preseptal eyelid involvement with or without orbital involvement and with or without conjunctival involvement. (from AJCC 8th Ed.)","Ocular Adnexal Lymphoma pT3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538925","Ocular Adnexal Lymphoma pT4 TNM Finding v8","C140869","Orbital adnexal lymphoma and extraorbital lymphoma extending beyond the orbit to adjacent structures, such as bone, maxillofacial sinuses, and brain. (from AJCC 8th Ed.)","Ocular Adnexal Lymphoma pT4 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538908","Pathologic Stage I Retinoblastoma AJCC v8","C140757","Stage I includes: pT1, pT2, pT3, pN0, cM0, Any H. pT1: Intraocular tumor(s) without any local invasion, focal choroidal invasion, or pre-or intralaminar involvement of the optic nerve head. pT2: Intraocular tumor(s) with local invasion. pT3: Intraocular tumor(s) with significant local invasion. pN0: No lymph node involvement. cM0: No signs or symptoms of intracranial or distant metastasis. HX: Unknown or insufficient evidence of a constitutional RB1 gene mutation. H0: Normal RB1 alleles in blood tested with demonstrated high-sensitivity assays. H1: Bilateral retinoblastoma, retinoblastoma with an intracranial primitive neuroectodermal tumor (i.e., trilateral retinoblastoma), patient with family history of retinoblastoma, or molecular definition of a constitutional RB1 gene mutation. (AJCC 8th ed.)","Pathologic Stage I Retinoblastoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538907","Pathologic Stage II Retinoblastoma AJCC v8","C140758","Stage II includes: pT4, pN0, cM0, Any H. pT4: Evidence of extraocular tumor: tumor at the transected end of the optic nerve, tumor in the meningeal spaces around the optic nerve, full-thickness invasion of the sclera with invasion of the episclera, adjacent adipose tissue, extraocular muscle, bone, conjunctiva, or eyelids. pN0: No lymph node involvement. cM0: No signs or symptoms of intracranial or distant metastasis. HX: Unknown or insufficient evidence of a constitutional RB1 gene mutation. H0: Normal RB1 alleles in blood tested with demonstrated high-sensitivity assays. H1: Bilateral retinoblastoma, retinoblastoma with an intracranial primitive neuroectodermal tumor (i.e., trilateral retinoblastoma), patient with family history of retinoblastoma, or molecular definition of a constitutional RB1 gene mutation. (AJCC 8th ed.)","Pathologic Stage II Retinoblastoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538906","Pathologic Stage III Retinoblastoma AJCC v8","C140759","Stage III includes: Any pT, pN1, cM0, Any H. pN1: Regional lymph node involvement. cM0: No signs or symptoms of intracranial or distant metastasis. HX: Unknown or insufficient evidence of a constitutional RB1 gene mutation. H0: Normal RB1 alleles in blood tested with demonstrated high-sensitivity assays. H1: Bilateral retinoblastoma, retinoblastoma with an intracranial primitive neuroectodermal tumor (i.e., trilateral retinoblastoma), patient with family history of retinoblastoma, or molecular definition of a constitutional RB1 gene mutation. (AJCC 8th ed.)","Pathologic Stage III Retinoblastoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538921","Pathologic Stage IV Retinoblastoma AJCC v8","C140760","Stage IV includes: Any pT, Any N, cM1 or pM1, Any H. cM1: Distant metastasis without microscopic confirmation. pM1: Distant metastasis with microscopic confirmation. HX: Unknown or insufficient evidence of a constitutional RB1 gene mutation. H0: Normal RB1 alleles in blood tested with demonstrated high-sensitivity assays. H1: Bilateral retinoblastoma, retinoblastoma with an intracranial primitive neuroectodermal tumor (i.e., trilateral retinoblastoma), patient with family history of retinoblastoma, or molecular definition of a constitutional RB1 gene mutation. (AJCC 8th ed.)","Pathologic Stage IV Retinoblastoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539491","Uproleselan Sodium","C141440","No value exists.","Uproleselan Sodium | UPROLESELAN SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1838062","Autosomal Dominant Lateral Temporal Lobe Epilepsy","C141441","An autosomal dominant condition caused by mutation(s) in the LGI1 gene, encoding leucine-rich glioma-inactivated protein 1. It is characterized by partial seizures originating in the temporal lobe and often accompanied by auditory sensory manifestations.","Autosomal Dominant Lateral Temporal Lobe Epilepsy | ETL1 | Epilepsy, Familial Temporal Lobe 1",,,,,,,,,,,,,,,"37205088","Autosomal dominant epilepsy with auditory features",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0268467","GTP Cyclohydrolase I Deficiency","C141442","An autosomal recessive condition caused by mutation(s) in the GCH1 gene, encoding GTP cyclohydrolase 1. It is characterized by hyperphenylalaninemia and GTP cyclohydrolase 1-deficient dopa-responsive dystonia.","GTP Cyclohydrolase I Deficiency | GTPCH Deficiency",,,,,,,,,,,,,,,"4052999","GTP cyclohydrolase I deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL539434","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma TNM Finding v8","C141372","A finding about one or more characteristics of primary cutaneous B-cell/T-cell [non-mycosis fungoides/Sezary syndrome (non-MF/SS)] lymphoma, following the rules of the TNM AJCC v8 classification system. There is no stage group system for non-MF/SS primary cutaneous lymphomas- including cutaneous T-cell, B-cell, and NK-cell lymphomas. (from AJCC 8th Ed.)","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma TNM Finding v8 | Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539433","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma Distant Metastasis TNM Finding v8","C141373","A finding about one or more characteristics of primary cutaneous B-cell/T-cell (non-MF/SS) lymphoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases. (from AJCC 8th Ed.)","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma Distant Metastasis TNM Finding v8 | Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539432","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma M0 TNM Finding v8","C141374","No evidence of extracutaneous non-lymph node disease. (from AJCC 8th Ed.)","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma M0 TNM Finding v8 | Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome M0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539445","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma Lymph Nodes TNM Finding v8","C141376","A finding about one or more characteristics of primary cutaneous B-cell/T-cell (non-MF/SS) lymphoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma Lymph Nodes TNM Finding v8 | Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539444","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma NX TNM Finding v8","C141377","Regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma NX TNM Finding v8 | Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome NX TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539443","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma N0 TNM Finding v8","C141378","No clinical or pathological lymph node involvement. (from AJCC 8th Ed.)","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma N0 TNM Finding v8 | Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome N0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517645","KH Domain","C14092","First identified in human hnRNPK protein, the conserved KH Domain of around 45-70 amino acids is present in a variety of nucleic acid-binding proteins. The domain may bind RNA in vivo. KH motifs are found in one or multiple copies, interspersed with RGG repeats, that may function cooperatively or, in single motif proteins, independently. KH domains can be separated into two groups: type-1 (beta-alpha-alpha-beta-beta-alpha) and type-2 (alpha-beta-beta-alpha-alpha-beta). The VIGXXGXXI sequence is preserved in the RNA binding motif between helix 1 and 2 (type-1) and helix 2 and 3 (type-2). The beta sheets are supported by alpha helixes. (NCI)","KH Domain | K Homology Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539147","Medullary Thyroid Carcinoma pT3b TNM Finding v8","C141030","Tumor of any size with gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid or omohyoid muscles). (from AJCC 8th Ed.)","Medullary Thyroid Carcinoma pT3b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539145","Medullary Thyroid Carcinoma pT4a TNM Finding v8","C141032","Moderately advanced disease; tumor of any size with gross extrathyroidal extension into the nearby tissues of the neck, including subcutaneous soft tissue, larynx, trachea, esophagus, or recurrent laryngeal nerve. (from AJCC 8th Ed.)","Medullary Thyroid Carcinoma pT4a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539144","Medullary Thyroid Carcinoma pT4b TNM Finding v8","C141033","Very advanced disease; tumor of any size with extension towards the spine or into nearby large blood vessels, invading the prevertebral fascia, or encasing the carotid artery or mediastinal vessels. (from AJCC 8th Ed.)","Medullary Thyroid Carcinoma pT4b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539143","Medullary Thyroid Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8","C141034","A pathologic finding about one or more characteristics of medullary thyroid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Medullary Thyroid Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539142","Medullary Thyroid Carcinoma pNX TNM Finding v8","C141035","Regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Medullary Thyroid Carcinoma pNX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539141","Medullary Thyroid Carcinoma pN0 TNM Finding v8","C141036","No evidence of locoregional lymph node metastasis. (from AJCC 8th Ed.)","Medullary Thyroid Carcinoma pN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539156","Medullary Thyroid Carcinoma pN0a TNM Finding v8","C141037","One or more cytologically or histologically confirmed benign lymph nodes. (from AJCC 8th Ed.)","Medullary Thyroid Carcinoma pN0a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539155","Medullary Thyroid Carcinoma pN1 TNM Finding v8","C141038","Metastasis to regional nodes. (from AJCC 8th Ed.)","Medullary Thyroid Carcinoma pN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539154","Medullary Thyroid Carcinoma pN1a TNM Finding v8","C141039","Metastasis to level VI or VII (pretracheal, paratracheal, or prelaryngeal/Delphian, or upper mediastinal) lymph nodes. This can be unilateral or bilateral disease. (from AJCC 8th Ed.)","Medullary Thyroid Carcinoma pN1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517104","F-Box Domain","C14103","The F-box consists of three helices. The H1 helix packs orthogonally with the H2-H3 antiparallel pair. The F-box domain is a 42-48 amino acid conserved domain found at the N-terminus of F-box proteins. F-box proteins act as adaptor components of the modular E3 ubiquitin ligase SCF complex that functions in phosphorylation mediated ubiquitination. The F-box domain mediates interaction with Skp1, which links F-box proteins to a core ubiquitin-ligase complex composed of Rbx1, cdc53/Cul1 and the E2 conjugating enzyme cdc34. The C-terminal region of F-box proteins are also composed of various modular domain that interact with target substrates, often in a phosphorylation dependant manner.","F-Box Domain | F Box | F Box Domain | F-Box",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513342","Mitochondrial Import Sequence","C14086","An amino acid sequence that directs the post-translational transport of a protein to the mitochondria. The sequence contains an alternating pattern of hydrophobic and positively charged amino acids.","Mitochondrial Import Sequence | MTS | Mitochondrial Targeting Signal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538924","Ocular Adnexal Lymphoma Pathologic Regional Lymph Nodes TNM Finding v8","C140870","A pathologic finding about one or more characteristics of ocular adnexal lymphoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Ocular Adnexal Lymphoma Pathologic Regional Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538923","Ocular Adnexal Lymphoma pNX TNM Finding v8","C140871","Involvement of lymph nodes not assessed. (from AJCC 8th Ed.)","Ocular Adnexal Lymphoma pNX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538922","Ocular Adnexal Lymphoma pN0 TNM Finding v8","C140872","Ocular adnexal lymphoma with no evidence of lymph node involvement. (from AJCC 8th Ed.)","Ocular Adnexal Lymphoma pN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538937","Ocular Adnexal Lymphoma pN1 TNM Finding v8","C140873","Ocular adnexal lymphoma with involvement of lymph node region or regions draining the ocular adnexal structures and superior to the mediastinum (preauricular, parotid, submandibular, and cervical nodes). (from AJCC 8th Ed.)","Ocular Adnexal Lymphoma pN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538936","Ocular Adnexal Lymphoma pN1a TNM Finding v8","C140874","Ocular adnexal lymphoma with involvement of a single lymph node region superior to the mediastinum. (from AJCC 8th Ed.)","Ocular Adnexal Lymphoma pN1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538935","Ocular Adnexal Lymphoma pN1b TNM Finding v8","C140875","Ocular adnexal lymphoma with involvement of two or more lymph node regions, superior to the mediastinum. (from AJCC 8th Ed.)","Ocular Adnexal Lymphoma pN1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538934","Ocular Adnexal Lymphoma pN2 TNM Finding v8","C140876","Ocular adnexal lymphoma with involvement of lymph node regions of the mediastinum. (from AJCC 8th Ed.)","Ocular Adnexal Lymphoma pN2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513110","Membrane Localization Motif","C14087","An amino acid sequence that directs a protein to become localized in or at the cell membrane. This targeting is determined either by the presence of hydrophobic amino acid residues or by post-translational modification that adds a hydrophobic molecule to the protein at this site.","Membrane Localization Motif | Membrane Localization Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539504","PF-04217903 Monophosphate","C141443","The monophosphate form of PF-04217903, an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity. MET tyrosine kinase inhibitor PF-04217903 selectively binds to and inhibits c-Met, disrupting the c-Met signaling pathway, which may result in the inhibition of tumor cell growth, migration and invasion of tumor cells, and the induction of death in tumor cells expressing c-Met. The receptor tyrosine kinase c-Met, also known as hepatocyte growth factor (HGF) receptor, is overexpressed or mutated in many tumor cell types, playing an important role in tumor cell proliferation, survival, invasion, and metastasis and angiogenesis.","PF-04217903 Monophosphate | 1H-Pyrazole-1-ethanol, 4-(1-(6-Quinolinylmethyl)-1H-1,2,3-triazolo(4,5-b)pyrazin-6-yl)-, Phosphate (1:1) | PF-04217903 MONOPHOSPHATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539502","Recurrent Acute Biphenotypic Leukemia","C141445","The reemergence of acute biphenotypic leukemia after a period of remission.","Recurrent Acute Biphenotypic Leukemia | Acute Biphenotypic Leukemia in Relapse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539501","Recurrent Acute Undifferentiated Leukemia","C141446","The reemergence of acute undifferentiated leukemia after a period of remission.","Recurrent Acute Undifferentiated Leukemia | Acute Undifferentiated Leukemia in Relapse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539500","Progesterone Receptor Positive by Immunohistochemistry Less than 1 Percent","C141447","An immunohistochemical staining finding indicating that less than 1 percent of the cells in a tissue sample are expressing progesterone receptor.","Progesterone Receptor Positive by Immunohistochemistry Less than 1 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539499","Progesterone Receptor Positive by Immunohistochemistry 1-10 Percent","C141448","An immunohistochemical staining finding indicating that 1-10 percent of the cells in a tissue sample are expressing progesterone receptor.","Progesterone Receptor Positive by Immunohistochemistry 1-10 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539498","Progesterone Receptor Positive by Immunohistochemistry 11-20 Percent","C141449","An immunohistochemical staining finding indicating that 11-20 percent of the cells in a tissue sample are expressing progesterone receptor.","Progesterone Receptor Positive by Immunohistochemistry 11-20 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539483","Progesterone Receptor Positive by Immunohistochemistry 21-30 Percent","C141450","An immunohistochemical staining finding indicating that 21-30 percent of the cells in a tissue sample are expressing progesterone receptor.","Progesterone Receptor Positive by Immunohistochemistry 21-30 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539482","Progesterone Receptor Positive by Immunohistochemistry 31-40 Percent","C141451","An immunohistochemical staining finding indicating that 31-40 percent of the cells in a tissue sample are expressing progesterone receptor.","Progesterone Receptor Positive by Immunohistochemistry 31-40 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539481","Progesterone Receptor Positive by Immunohistochemistry 41-50 Percent","C141452","An immunohistochemical staining finding indicating that 41-50 percent of the cells in a tissue sample are expressing progesterone receptor.","Progesterone Receptor Positive by Immunohistochemistry 41-50 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539480","Progesterone Receptor Positive by Immunohistochemistry 51-60 Percent","C141453","An immunohistochemical staining finding indicating that 51-60 percent of the cells in a tissue sample are expressing progesterone receptor.","Progesterone Receptor Positive by Immunohistochemistry 51-60 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539479","Progesterone Receptor Positive by Immunohistochemistry 61-70 Percent","C141454","An immunohistochemical staining finding indicating that 61-70 percent of the cells in a tissue sample are expressing progesterone receptor.","Progesterone Receptor Positive by Immunohistochemistry 61-70 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539076","Stage I Thyroid Gland Follicular Carcinoma 55 Years and Older AJCC v8","C140990","Stage I includes: (T1, N0/NX, M0); (T2, N0/NX, M0).  T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. N0: No evidence of locoregional lymph node metastasis. NX: Regional lymph nodes cannot be assessed. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage I Thyroid Gland Follicular Carcinoma 55 Years and Older AJCC v8 | Stage I Thyroid Gland Follicular Cancer 55 Years and Older",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519134","SET Domain","C14093","SET domains appear to be protein-protein interaction domains. SET domains mediate interactions with a family of proteins that display similarity with dual-specificity phosphatases (dsPTPases). The SET domain genes are widely represented in the eukaryotic genomes. Proteins bearing the widely distributed SET domain (ca. 130 amino acid) contribute to epigenetic mechanisms of gene regulation by methylation of lysine residues in histones and other proteins. The SET domain appears generally as one part of a larger multidomain protein. It appears that the varied domains that occur together with the SET domain are involved in recognizing protein substrates and ''reading'' histone tails in order to dictate which (if any) of their multiple lysine residues should get methylated. (From Pfam PF00856)","SET Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539678","CDISC Clinical Classification VALG Test Name Terminology","C141652","Test names of clinical classification questions associated with the Veterans Administration Lung Study Group (VALG) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification VALG Test Name Terminology | CC-VALG TEST | VALG01TN | Veterans Administration Lung Study Group Clinical Classification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539153","Medullary Thyroid Carcinoma pN1b TNM Finding v8","C141040","Metastasis to unilateral, bilateral, or contralateral lateral neck lymph nodes levels I, II, III, IV, or V or retropharyngeal lymph nodes. (from AJCC 8th Ed.)","Medullary Thyroid Carcinoma pN1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539152","Thyroid Gland Medullary Carcinoma by AJCC v7 Stage","C141041","A term that refers to the staging of thyroid gland medullary carcinoma, following the rules of the TNM AJCC v7 classification system.","Thyroid Gland Medullary Carcinoma by AJCC v7 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539151","Thyroid Gland Medullary Carcinoma by AJCC v8 Stage","C141042","A term that refers to the staging of thyroid gland medullary carcinoma, following the rules of the TNM AJCC v8 classification system. Differentiated and anaplastic thyroid gland carcinomas are staged according to the classification for thyroid-differentiated and anaplastic carcinoma. (from AJCC 8th Ed.)","Thyroid Gland Medullary Carcinoma by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539150","Stage I Thyroid Gland Medullary Carcinoma AJCC v8","C141043","Stage I includes: T1, N0, M0. T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. N0: No evidence of locoregional lymph node metastasis. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage I Thyroid Gland Medullary Carcinoma AJCC v8 | Stage I Thyroid Gland Medullary Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539414","65 kDa Phosphoprotein Antibody","C141279","Any immunoglobulin that recognizes the CMV protein 65 kDa phosphoprotein.","65 kDa Phosphoprotein Antibody | Anti-66 kDa Phosphoprotein Antibody | Anti-CMV 66 kDa Phosphoprotein Antibody | Anti-CMV pp65 Antibody | Anti-Phosphoprotein UL83 Antibody | Anti-pp65 Antibody | CMV 66 kDa Phosphoprotein Antibody | CMV pp65 Antibody | Phosphoprotein UL83 Antibody | pp65 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521383","4q11-q13","C14127","A chromosome band present on 4q","4q11-q13 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539410","Adult T-Cell Leukemia/Lymphoma by Ann Arbor Stage","C141283","An anatomic stage for adult T-cell leukemia/lymphoma based on the Ann Arbor classification criteria.","Adult T-Cell Leukemia/Lymphoma by Ann Arbor Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539409","Noncutaneous Anaplastic Large Cell Lymphoma by Ann Arbor Stage","C141284","An anatomic stage for noncutaneous anaplastic large cell lymphoma based on the Ann Arbor classification criteria.","Noncutaneous Anaplastic Large Cell Lymphoma by Ann Arbor Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539075","Stage II Thyroid Gland Follicular Carcinoma AJCC v8","C140991","Stage II includes: Under 55 years: Any T, Any N, M1; 55 years and older: (T1, N1, M0); (T2, N1, M0); (T3a/T3b, Any N, M0). T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. T3a: Tumor measuring more than 4 cm in greatest dimension limited to the thyroid. T3b: Gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles) from a tumor of any size. N1: Metastasis to regional nodes. M0: No distant metastasis. M1: Distant metastasis. (from AJCC 8th Ed.)","Stage II Thyroid Gland Follicular Carcinoma AJCC v8 | Stage II Thyroid Gland Follicular Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539074","Stage II Thyroid Gland Follicular Carcinoma Under 55 Years AJCC v8","C140992","Stage II includes: Any T, Any N, M1. M1: Distant metastasis. (from AJCC 8th Ed.)","Stage II Thyroid Gland Follicular Carcinoma Under 55 Years AJCC v8 | Stage II Thyroid Gland Follicular Cancer Under 55 Years",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539073","Stage II Thyroid Gland Follicular Carcinoma 55 Years and Older AJCC v8","C140993","Stage II includes: (T1, N1, M0); (T2, N1, M0); (T3a/T3b, Any N, M0). T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. T3a: Tumor measuring more than 4 cm in greatest dimension limited to the thyroid. T3b: Gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles) from a tumor of any size. N1: Metastasis to regional nodes. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage II Thyroid Gland Follicular Carcinoma 55 Years and Older AJCC v8 | Stage II Thyroid Gland Follicular Cancer 55 Years and Older",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539072","NIR Fluorochrome VM110","C140994","A synthetic near infrared fluorescent (NIRF) imaging agent that can potentially be used to detect the presence of certain cancers. Upon intravenous administration, VM110 is specifically cleaved by certain proteases, including cathepsins B, L, and S, and plasmin, which are highly expressed in various types of cancer. Proteolysis liberates a highly fluorescent cleavage product, which can be detected in vivo by NIRF imaging techniques. Thus, tumor cells can be visualized and the presence of micrometastases may be assessed.","NIR Fluorochrome VM110 | NIRF Imaging Agent VM110 | Prosense VM110 | VM110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539071","Stage III Thyroid Gland Follicular Carcinoma AJCC v8","C140995","Stage III includes: 55 years and older: T4a, Any N, M0. T4a: Gross extrathyroidal extension invading subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve from a tumor of any size. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage III Thyroid Gland Follicular Carcinoma AJCC v8 | Stage III Thyroid Gland Follicular Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539054","Stage IV Thyroid Gland Follicular Carcinoma AJCC v8","C140996","Stage IV includes: IVA: 55 years and older: T4b, Any N, M0; IVB: 55 years and older: Any T, Any N, M1. T4b: Gross extrathyroidal extension invading prevertebral fascia or encasing the carotid artery or mediastinal vessels from a tumor of any size. M0: No distant metastasis. M1: Distant metastasis. (from AJCC 8th Ed.)","Stage IV Thyroid Gland Follicular Carcinoma AJCC v8 | Stage IV Thyroid Gland Follicular Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539053","Stage IVA Thyroid Gland Follicular Carcinoma AJCC v8","C140997","Stage IVA includes: 55 years and older: T4b, Any N, M0. T4b: Gross extrathyroidal extension invading prevertebral fascia or encasing the carotid artery or mediastinal vessels from a tumor of any size. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage IVA Thyroid Gland Follicular Carcinoma AJCC v8 | Stage IVA Thyroid Gland Follicular Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539052","Stage IVB Thyroid Gland Follicular Carcinoma AJCC v8","C140998","Stage IVB includes: 55 years and older: Any T, Any N, M1. M1: Distant metastasis. (from AJCC 8th Ed.)","Stage IVB Thyroid Gland Follicular Carcinoma AJCC v8 | Stage IVB Thyroid Gland Follicular Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539051","Thyroid Gland Anaplastic Carcinoma by AJCC v7 Stage","C140999","A term that refers to the staging of thyroid gland anaplastic carcinoma, following the rules of the TNM AJCC v7 classification system.","Thyroid Gland Anaplastic Carcinoma by AJCC v7 Stage | Thyroid Gland Undifferentiated (Anaplastic) Carcinoma by AJCC v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539331","Nodular Lymphocyte Predominant B-Cell Lymphoma by Ann Arbor Stage","C141225","An anatomic stage for nodular lymphocyte predominant B-cell lymphoma based on the Ann Arbor classification criteria.","Nodular Lymphocyte Predominant B-Cell Lymphoma by Ann Arbor Stage | Nodular Lymphocyte Predominant Hodgkin Lymphoma by Ann Arbor Stage | Nodular Lymphocyte Predominant Hodgkin Lymphoma by Ann Arbor Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539677","CDISC Clinical Classification VALG Test Code Terminology","C141653","Test codes of clinical classification questions associated with the Veterans Administration Lung Study Group (VALG) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification VALG Test Code Terminology | CC-VALG TESTCD | VALG01TC | Veterans Administration Lung Study Group Clinical Classification Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539659","CDISC Clinical Classification AJCC v7 Test Code Terminology","C141655","Test codes of clinical classification questions associated with the AJCC Cancer Staging Manual 7th Edition (AJCC v7) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification AJCC v7 Test Code Terminology | AJCC TNM Staging System 7th Edition Clinical Classification Test Code | AJCC1TC | CC-AJCC v7 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539658","FT-10 Meter Walk/Run TEST","C141656","Test names of functional test questions associated with the Ten Meter Walk/Run Test (10 Meter Walk/Run) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Functional Test 10-Meter Walk/Run Test Name Terminology | 10-Meter Walk/Run Functional Test Test Name | FT-10 Meter Walk/Run TEST | TENMW1TN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539657","FT-10 Meter Walk/Run TESTCD","C141657","Test codes of functional test questions associated with the Ten Meter Walk/Run Test (10 Meter Walk/Run) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Functional Test 10-Meter Walk/Run Test Code Terminology | 10-Meter Walk/Run Functional Test Test Code | FT-10 Meter Walk/Run TESTCD | TENMW1TC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539656","CDISC Functional Test Rising From Floor Test Name Terminology","C141658","Test names of functional test questions associated with the Rising From Floor Test (Rising From Floor) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Functional Test Rising From Floor Test Name Terminology | FT-Rising From Floor TEST | RISEF1TN | Rising From Floor Functional Test Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539655","CDISC Functional Test Rising From Floor Test Code Terminology","C141659","Test codes of functional test questions associated with the Rising From Floor Test (Rising From Floor) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Functional Test Rising From Floor Test Code Terminology | FT-Rising From Floor TESTCD | RISEF1TC | Rising From Floor Functional Test Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539654","D4STR1TN","C141660","Test names of questionnaire questions associated with the Four Stair Descend Test (4 Stair Descend) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Functional Test 4-Stair Descend Test Name Terminology | 4-Stair Descend Functional Test Test Name | D4STR1TN | FT-4 Stair Descend TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539653","D4STR1TC","C141661","Test codes of questionnaire questions associated with the Four Stair Descend Test (4 Stair Descend) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Functional Test 4-Stair Descend Test Code Terminology | 4-Stair Descend Functional Test Test Code | D4STR1TC | FT-4 Stair Descend TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539668","A4STR1TN","C141662","Test names of questionnaire questions associated with the Four Stair Ascend Test (4 Stair Ascend) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Functional Test 4-Stair Ascend Test Name Terminology | 4-Stair Ascend Functional Test Test Name | A4STR1TN | FT-4 Stair Ascend TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539284","Lugano Stage","C141147","An adult non-Hodgkin lymphoma and adult and childhood Hodgkin lymphoma stage defined according to the Lugano classification criteria.","Lugano Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539283","Lugano Classification Adult Lymphoma by AJCC v8 Stage","C141148","A staging system for adult Hodgkin and adult non-Hodgkin lymphomas based on the Lugano classification criteria. This staging system does not apply to ocular adnexal lymphomas (are staged according to the classification for ocular adnexal lymphoma), pediatric lymphomas (are staged according to the classification for pediatric lymphoma), primary cutaneous lymphomas (are staged according to the classification for primary cutaneous lymphoma), and multiple myelomas (are staged according to the classification for plasma cell myeloma). (from AJCC 8th Ed.)","Lugano Classification Adult Lymphoma by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539391","Noncutaneous Childhood Anaplastic Large Cell Lymphoma by Ann Arbor Stage","C141292","An anatomic stage for noncutaneous childhood anaplastic large cell lymphoma based on the Ann Arbor classification criteria.","Noncutaneous Childhood Anaplastic Large Cell Lymphoma by Ann Arbor Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539390","Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type by Ann Arbor Stage","C141294","An anatomic stage for follicular helper T-cell lymphoma, angioimmunoblastic-type  based on the Ann Arbor classification criteria.","Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type by Ann Arbor Stage | Angioimmunoblastic T-Cell Lymphoma by Ann Arbor Stage | Angioimmunoblastic T-Cell Lymphoma by Ann Arbor Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539400","Enteropathy-Associated T-Cell Lymphoma by Ann Arbor Stage","C141295","An anatomic stage for enteropathy-associated T-cell lymphoma based on the Ann Arbor classification criteria.","Enteropathy-Associated T-Cell Lymphoma by Ann Arbor Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539399","Nasal Type NK/T-Cell Lymphoma by Ann Arbor Stage","C141296","An anatomic stage for nasal type NK/T-cell lymphoma based on the Ann Arbor classification criteria.","Nasal Type NK/T-Cell Lymphoma by Ann Arbor Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516971","Estrogen Binding Domain","C14081","The Estrogen Binding Domain is an all-helical ligand-binding domain within its nuclear hormone receptor. Steroid hormones, such as estrogen, and their receptors regulate eukaryotic gene expression, affecting target cell proliferation and differentiation. Hormone-receptor complexes recognize discrete DNA sequences upstream of transcription start sites. (NCI)","Estrogen Binding Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519140","SH2-Binding Motif","C14108","Typically found in signaling proteins, the SH2-Binding Motif mediates regulated high-affinity physical interaction (binding) with the target SH2 (SRC Homology 2) domain. SH2 domains of ~100 amino acids bind to specific phosphotyrosine (pY)-containing motifs with dissociation constants of ~50-500 nM. A conserved pocket of SH2 domains recognizes the pY, and a more variable pocket binds residues C-terminal to pY that confer specificity. SH2 domains balance high affinity for pY and recognition of adjacent residues to allow specific discrimination. The SH2 domain, an anti-parallel b-sheet between a-helices, provides a positively charged b-sheet pocket for binding of pY moieties, and an extended b-sheet surface for binding residues C-terminal to pY. B-sheet surface differences have significant effects on ligand-specificity. (NCI)","SH2-Binding Motif | SH2-Binding Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539232","Adrenal Cortical Carcinoma pT1 TNM Finding v8","C141090","Tumor measuring 5 cm or less in greatest dimension, with no extra-adrenal invasion. (from AJCC 8th Ed.)","Adrenal Cortical Carcinoma pT1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539231","Adrenal Cortical Carcinoma pT2 TNM Finding v8","C141091","Tumor measuring more than 5 cm in greatest dimension, with no extra-adrenal invasion. (from AJCC 8th Ed.)","Adrenal Cortical Carcinoma pT2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539230","Adrenal Cortical Carcinoma pT3 TNM Finding v8","C141092","Tumor of any size with local invasion but not invading adjacent organs. (from AJCC 8th Ed.)","Adrenal Cortical Carcinoma pT3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539229","Adrenal Cortical Carcinoma pT4 TNM Finding v8","C141093","Tumor of any size that invades adjacent organs (kidney, diaphragm, pancreas, spleen, or liver) or large blood vessels (renal vein or vena cava). (from AJCC 8th Ed.)","Adrenal Cortical Carcinoma pT4 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539212","Adrenal Cortical Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8","C141094","A pathologic finding about one or more characteristics of adrenal cortical carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Adrenal Cortical Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539211","Adrenal Cortical Carcinoma pNX TNM Finding v8","C141095","Regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Adrenal Cortical Carcinoma pNX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539210","Adrenal Cortical Carcinoma pN0 TNM Finding v8","C141096","No regional lymph node metastasis. (from AJCC 8th Ed.)","Adrenal Cortical Carcinoma pN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539209","Adrenal Cortical Carcinoma pN1 TNM Finding v8","C141097","Metastasis in regional lymph node(s). (from AJCC 8th Ed.)","Adrenal Cortical Carcinoma pN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539208","Adrenal Cortical Carcinoma by AJCC v7 Stage","C141098","A term that refers to the staging of adrenal cortical carcinoma, following the rules of the TNM AJCC v7 classification system.","Adrenal Cortical Carcinoma by AJCC v7 Stage | Adrenal Cortex Carcinoma by AJCC v7 Stage | Adrenal Cortex Carcinoma by AJCC v7 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519141","SH3-Binding Motif","C14109","Typically found in proteins involved in signaling pathways, the SH3-Binding Motif is a peptide sequence that mediates regulated high-affinity physical interaction (binding) with the SH3 (SRC Homology 3) domain in target protein partners. The SH3-binding motif often share proline-rich stretches containing a common PXXP motif. (NCI)","SH3-Binding Motif | SH3-Binding Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1526982","Recombinant Stem Cell Factor","C1410","A therapeutic glycoprotein cytokine chemically identical to or similar to endogenous human stem cell factor with hematopoietic activity. Recombinant human stem cell factor (rhSCF) binds to the receptor tyrosine kinase c-kit, which may stimulate the growth of peripheral blood progenitor cells (PBPCs). This agent works synergistically with other hematopoietic growth factors. rhSCF may promote bone marrow recovery after myeloablative therapies and procedures.","Recombinant Human Stem Cell Factor | Mast Cell Growth Factor | Steel Factor | c-Kit Ligand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539206","Adrenal Cortical Carcinoma by AJCC v8 Stage","C141100","A term that refers to the staging of adrenal cortical carcinoma, following the rules of the TNM AJCC v8 classification system. Adrenal medullary pheochromocytoma is staged according to the classification for adrenal neuroendocrine tumors. There is no AJCC staging system for neuroblastic tumors of the adrenal gland. (from AJCC 8th Ed.)","Adrenal Cortical Carcinoma by AJCC v8 Stage | Adrenal Cortex Carcinoma by AJCC v8 Stage | Adrenal Cortex Carcinoma by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539330","Adult Hodgkin Lymphoma by Ann Arbor Stage","C141226","An anatomic stage for adult Hodgkin lymphoma based on the Ann Arbor classification criteria.","Adult Hodgkin Lymphoma by Ann Arbor Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539329","Childhood Hodgkin Lymphoma by Ann Arbor Stage","C141227","An anatomic stage for childhood Hodgkin lymphoma based on the Ann Arbor classification criteria.","Childhood Hodgkin Lymphoma by Ann Arbor Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520264","10p15-p14","C14122","A chromosome band present on 10p","10p15-p14 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539337","Adult Non-Hodgkin Lymphoma by Ann Arbor Stage","C141235","An anatomic stage for adult non-Hodgkin lymphoma based on the Ann Arbor classification criteria.","Adult Non-Hodgkin Lymphoma by Ann Arbor Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539336","Childhood Non-Hodgkin Lymphoma by Ann Arbor Stage","C141236","An anatomic stage for childhood non-Hodgkin lymphoma based on the Ann Arbor classification criteria.","Childhood Non-Hodgkin Lymphoma by Ann Arbor Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521496","5q33.2-qter","C14123","A chromosome band present on 5q","5q33.2-qter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539314","B-Cell Non-Hodgkin Lymphoma by Ann Arbor Stage","C141243","An anatomic stage for B-cell non-Hodgkin lymphoma based on the Ann Arbor classification criteria.","B-Cell Non-Hodgkin Lymphoma by Ann Arbor Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539297","Lugano Classification Stage I Adult Lymphoma AJCC v8","C141150","Stage I: Involvement of a single lymphatic site (i.e., nodal region, Waldeyer's ring, thymus, or spleen). (from AJCC 8th Ed.)","Lugano Classification Stage I Adult Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539296","Lugano Classification Stage IE Adult Lymphoma AJCC v8","C141151","Stage IE: Single extralymphatic site in the absence of nodal involvement (rare in Hodgkin lymphoma). (from AJCC 8th Ed.)","Lugano Classification Stage IE Adult Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539295","Lugano Classification Stage II Adult Lymphoma AJCC v8","C141152","Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm. (from AJCC 8th Ed.)","Lugano Classification Stage II Adult Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539294","Lugano Classification Stage IIE Adult Lymphoma AJCC v8","C141153","Stage IIE: Contiguous extralymphatic extension from a nodal site with or without involvement of other lymph node regions on the same side of the diaphragm. (from AJCC 8th Ed.)","Lugano Classification Stage IIE Adult Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539293","Lugano Classification Stage II Bulky Adult Lymphoma AJCC v8","C141154","Stage II Bulky: Stage II with disease bulk. (from AJCC 8th Ed.)","Lugano Classification Stage II Bulky Adult Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539292","Lugano Classification Advanced Stage Adult Lymphoma AJCC v8","C141155","Advanced stage adult lymphoma based on the Lugano classification criteria. It includes stages III and IV. (from AJCC 8th Ed.)","Lugano Classification Advanced Stage Adult Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539291","Lugano Classification Stage III Adult Lymphoma AJCC v8","C141156","Stage III: Involvement of lymph node regions on both sides of the diaphragm; nodes above the diaphragm with spleen involvement. (from AJCC 8th Ed.)","Lugano Classification Stage III Adult Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539290","Lugano Classification Stage IV Adult Lymphoma AJCC v8","C141157","Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or noncontiguous extralymphatic organ involvement in conjunction with nodal stage II disease; or any extralymphatic organ involvement in nodal stage III disease. Stage IV includes any involvement of the CSF, bone marrow, liver, or lungs (other than by direct extension in stage IIE disease). (from AJCC 8th Ed.)","Lugano Classification Stage IV Adult Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539272","Lugano Classification Limited Stage Adult Non-Hodgkin Lymphoma AJCC v8","C141159","Limited stage adult non-Hodgkin lymphoma based on the Lugano classification criteria. It includes stages I, IE, II, and IIE. (from AJCC 8th Ed.)","Lugano Classification Limited Stage Adult Non-Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521314","3q22.2","C14115","A chromosome band present on 3q","3q22.2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539271","Lugano Classification Stage I Adult Non-Hodgkin Lymphoma AJCC v8","C141160","Stage I: Involvement of a single lymphatic site (i.e., nodal region, Waldeyer's ring, thymus, or spleen). (from AJCC 8th Ed.)","Lugano Classification Stage I Adult Non-Hodgkin Lymphoma AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539442","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma N1 TNM Finding v8","C141379","Involvement of one peripheral node region that drains an area of current or prior skin involvement. (from AJCC 8th Ed.)","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma N1 TNM Finding v8 | Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome N1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539441","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma N2 TNM Finding v8","C141380","Involvement of two or more peripheral node regions or involvement of any lymph node region that does not drain an area of current or prior skin involvement. (from AJCC 8th Ed.)","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma N2 TNM Finding v8 | Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome N2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519667","Tumor-Derived","C14150","No value exists.","Tumor-Derived | tumor-derived",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539552","Birabresib Dihydrate","C141515","No value exists.","Birabresib Dihydrate | 6H-Thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-6-acetamide, 4-(4-Chlorophenyl)-N-(4-hydroxyphenyl)-2,3,9-trimethyl-, Hydrate (1:2), (6S)- | BIRABRESIB DIHYDRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539205","Stage I Adrenal Cortex Cancer","C141101","Stage I includes: T1, N0, M0. T1: Tumor measuring 5 cm or less in greatest dimension, with no extra-adrenal invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage I Adrenal Cortical Carcinoma AJCC v8 | Stage I Adrenal Cortex Cancer | Stage I Adrenal Cortex Carcinoma AJCC v8 | Stage I Adrenal Cortex Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539220","Stage II Adrenal Cortex Cancer","C141102","Stage II includes: T2, N0, M0. T2: Tumor measuring more than 5 cm in greatest dimension, with no extra-adrenal invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage II Adrenal Cortical Carcinoma AJCC v8 | Stage II Adrenal Cortex Cancer | Stage II Adrenal Cortex Carcinoma AJCC v8 | Stage II Adrenal Cortex Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520372","11p15.4","C14133","A chromosome band present on 11p","11p15.4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539463","Sequential Chemoradiation","C141341","Treatment in which radiation therapy is administered after the completion of chemotherapy.","Sequential Chemoradiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539462","Concurrent Chemoradiation","C141342","Treatment in which radiation therapy is administered at the same time as chemotherapy.","Concurrent Chemoradiation | chemo concurrent to radiation | chemo_concurrent_to_radiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539475","Strontium-90 Beta Radiation","C141343","Beta radiation produced by the decay of strontium-90.","Strontium-90 Beta Radiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539474","Mycosis Fungoides and Sezary Syndrome by AJCC v8 Stage","C141346","A term that refers to the staging of mycosis fungoides and Sezary syndrome, following the rules of the TNM AJCC v8 classification system. This prognostic stage groups system is based on the ISCL/EORTC revision to the staging of mycosis fungoides and Sezary syndrome. There is no prognostic stage groups system for primary cutaneous B-cell/T-cell (non-mycosis fungoides/Sezary syndrome) lymphomas at this time. This staging system does not apply to eyelid skin lymphomas (are staged according to the classification for ocular adnexal lymphoma).  (from AJCC 8th Ed.)","Mycosis Fungoides and Sezary Syndrome by AJCC v8 Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511655","DH Domain","C14076","The Dbl homology (DH) or RhoGEF domain consists of a 150 amino acid region that induces Rho family GTPases to displace GDP. This effectively activates the Rho GTPase by allowing binding to GTP, which is in excess over GDP in the cell. The DH domain is invariably proceeded by a pleckstrin homology (PH) domain. While not absolutely required for catalysis of nucleotide exchange, the PH domain appears to greatly increase catalytic efficiency in many cases. Rho proteins control actin dynamics, gene expression, membrane trafficking, growth factor signaling, and cellular transformation. Proteins encoding DH domains (RhoGEFs) also play a role in these events as they function as the primary activators of Rho GTPases. In fact, many RhoGEFs were identified based on their transforming activity, which was abrogated upon disruption of their DH domain. (Pawson Lab, SLRI, Mount Sinai Hospital, 2003)","DH Domain | DBL-Homology Domain | Dbl Homology Domain | RhoGEF Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538893","Lacrimal Gland Carcinoma TNM Finding v8","C140773","A finding about one or more characteristics of carcinomas of the lacrimal gland, following the rules of the TNM AJCC v8 classification system. There is no AJCC staging system for carcinomas of the nasolacrimal sac. Lymphomas are staged according to the classification for ocular adnexal lymphomas. No stage groupings are currently recommended for lacrimal gland carcinomas. (from AJCC 8th Ed.)","Lacrimal Gland Carcinoma TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538892","Lacrimal Gland Carcinoma Clinical TNM Finding v8","C140774","A clinical finding about one or more characteristics of lacrimal gland carcinoma, following the rules of the TNM AJCC v8 classification system.","Lacrimal Gland Carcinoma Clinical TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538891","Lacrimal Gland Carcinoma Clinical Distant Metastasis TNM Finding v8","C140775","A clinical finding about one or more characteristics of lacrimal gland carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Lacrimal Gland Carcinoma Clinical Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538890","Lacrimal Gland Carcinoma cM0 TNM Finding v8","C140776","Lacrimal gland carcinoma with no distant metastasis. (from AJCC 8th Ed.)","Lacrimal Gland Carcinoma cM0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539439","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma Primary Tumor TNM Finding v8","C141382","A finding about one or more characteristics of primary cutaneous B-cell/T-cell (non-MF/SS) lymphoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor (skin).","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma Primary Tumor TNM Finding v8 | Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome Primary Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539438","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma T1 TNM Finding v8","C141383","Solitary skin involvement. (from AJCC 8th Ed.)","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma T1 TNM Finding v8 | Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome T1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539423","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma T1a TNM Finding v8","C141384","Solitary lesion measuring less than 5 cm. (from AJCC 8th Ed.)","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma T1a TNM Finding v8 | Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome T1a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539422","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma T1b TNM Finding v8","C141385","Solitary lesion measuring 5 cm or more. (from AJCC 8th Ed.)","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma T1b TNM Finding v8 | Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome T1b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539421","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma T2 TNM Finding v8","C141386","Regional skin involvement: multiple lesions limited to one body region or two contiguous body regions.  (from AJCC 8th Ed.)","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma T2 TNM Finding v8 | Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome T2 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539420","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma T2a TNM Finding v8","C141387","All disease encompassing in a less than 15-cm circular area. (from AJCC 8th Ed.)","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma T2a TNM Finding v8 | Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome T2a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539419","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma T2b TNM Finding v8","C141388","All disease encompassing in a 15-cm or more and less than 30-cm circular area. (from AJCC 8th Ed.)","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma T2b TNM Finding v8 | Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome T2b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539418","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma T2c TNM Finding v8","C141390","All disease encompassing in a 30-cm or more circular area. (from AJCC 8th Ed.)","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma T2c TNM Finding v8 | Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome T2c TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539417","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma T3 TNM Finding v8","C141391","Generalized skin involvement. (from AJCC 8th Ed.)","Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma T3 TNM Finding v8 | Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome T3 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539551","Iberdomide Hydrochloride","C141516","The hydrochloride salt form of iberdomide, a modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and pro-apoptotic activities. Upon administration, iberdomide specifically binds to the cereblon (CRBN) part of the ligase complex, thereby affecting the ubiquitin E3 ligase activity, and targeting certain substrate proteins for ubiquitination. This induces the proteasome-mediated degradation of certain transcription factors, including Ikaros (IKZF1) and Aiolos (IKZF3) which are transcriptional repressors in T-cells. This leads to a reduction of their protein levels, and the modulation of the immune system, including activation of T-lymphocytes. In addition, this leads to a downregulation of other proteins, including interferon regulatory factor 4 (IRF4), which plays a key role in the proliferation of certain cancer cell types. CRBN, the substrate recognition component of the E3 ubiquitin ligase complex, plays a key role in the ubiquitination of certain proteins.","Iberdomide Hydrochloride | 2,6-Piperidinedione, 3-(1,3-dihydro-4-((4-(4-morpholinylmethyl)phenyl)methoxy)-1-oxo-2H-isoindol-2-yl)-, Hydrochloride (1:1), (3S)- | CC-220 Hydrochloride | IBERDOMIDE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539132","Stage III Thyroid Gland Medullary Carcinoma AJCC v8","C141045","Stage III includes: T1-3, N1a, M0. T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but less than 4 cm in greatest dimension limited to the thyroid. T3: Tumor measuring 4 cm or more in greatest dimension or with extrathyroidal extension. N1a: Metastasis to level VI or VII (pretracheal, paratracheal, or prelaryngeal/Delphian, or upper mediastinal) lymph nodes. This can be unilateral or bilateral disease. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage III Thyroid Gland Medullary Carcinoma AJCC v8 | Stage III Thyroid Gland Medullary Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539131","Stage IV Thyroid Gland Medullary Carcinoma AJCC v8","C141046","Stage IV includes: IVA: (T4a, Any N, M0); (T1-3, N1b, M0); IVB: (T4b, Any N, M0); IVC: (Any T, Any N, M1). T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but less than 4 cm in greatest dimension limited to the thyroid. T3: Tumor measuring 4 cm or more in greatest dimension or with extrathyroidal extension. T4a: Moderately advanced disease; tumor of any size with gross extrathyroidal extension into the nearby tissues of the neck, including subcutaneous soft tissue, larynx, trachea, esophagus, or recurrent laryngeal nerve. T4b: Very advanced disease; tumor of any size with extension towards the spine or into nearby large blood vessels, invading the prevertebral fascia, or encasing the carotid artery or mediastinal vessels. N1b: Metastasis to unilateral, bilateral, or contralateral lateral neck lymph nodes levels I, II, III, IV, or V or retropharyngeal lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (from AJCC 8th Ed.)","Stage IV Thyroid Gland Medullary Carcinoma AJCC v8 | Stage IV Thyroid Gland Medullary Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539473","Stage I Mycosis Fungoides and Sezary Syndrome AJCC v8","C141347","Stage I includes: IA (T1, N0, M0, B0,1); IB (T2, N0, M0, B0,1). T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. T2: Patches, papules, or plaques covering 10% or more of the skin surface. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. M0: No visceral organ involvement. B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. (AJCC 8th ed.)","Stage I Mycosis Fungoides and Sezary Syndrome AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539471","Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8","C141349","Stage IB includes: T2, N0, M0, B0,1. T2: Patches, papules, or plaques covering 10% or more of the skin surface. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. M0: No visceral organ involvement. B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. (AJCC 8th ed.)","Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513411","Monobasic Proteolytic Cleavage Site","C14088","A site on a protein that is a target for enzymatic cleavage, where the residue on the amino terminal side of the cleavage site is a basic amino acid that is not adjacent to other basic amino acids.","Monobasic Proteolytic Cleavage Site | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539040","Endocrine System Cancer TNM Finding v8","C140895","A finding about one or more characteristics of endocrine system cancer, following the rules of the TNM AJCC v8 classification system.","Endocrine System Cancer TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538905","Lacrimal Gland Carcinoma cM1 TNM Finding v8","C140777","Lacrimal gland carcinoma with distant metastasis. (from AJCC 8th Ed.)","Lacrimal Gland Carcinoma cM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538903","Lacrimal Gland Carcinoma Pathologic Distant Metastasis TNM Finding v8","C140779","A pathologic finding about one or more characteristics of lacrimal gland carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Lacrimal Gland Carcinoma Pathologic Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539478","Progesterone Receptor Positive by Immunohistochemistry 71-80 Percent","C141455","An immunohistochemical staining finding indicating that 71-80 percent of the cells in a tissue sample are expressing progesterone receptor.","Progesterone Receptor Positive by Immunohistochemistry 71-80 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539477","Progesterone Receptor Positive by Immunohistochemistry 81-90 Percent","C141456","An immunohistochemical staining finding indicating that 81-90 percent of the cells in a tissue sample are expressing progesterone receptor.","Progesterone Receptor Positive by Immunohistochemistry 81-90 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539476","Progesterone Receptor Positive by Immunohistochemistry 91-100 Percent","C141457","An immunohistochemical staining finding indicating that 91-100 percent of the cells in a tissue sample are expressing progesterone receptor.","Progesterone Receptor Positive by Immunohistochemistry 91-100 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539490","Progesterone Receptor Positive by Immunohistochemistry","C141458","An immunohistochemical staining finding indicating that cells in a tissue sample are expressing progesterone receptor.","Progesterone Receptor Positive by Immunohistochemistry | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539489","Cergutuzumab Amunaleukin","C141459","A recombinant fusion protein comprised of cergutuzumab, a genetically engineered human immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against carcinoembryonic antigen (CEA, CEACAM5, CD66e), linked to amunaleukin, an engineered, mutated variant form of interleukin-2 (IL-2v), with potential immunostimulating and antineoplastic activities. Upon administration of cergutuzumab amunaleukin, the cergutuzumab moiety recognizes and binds to CEA, thereby specifically targeting IL-2v to CEA-expressing tumor tissue. Subsequently, the IL-2v moiety stimulates a local immune response, which activates both natural killer (NK) cells and cytotoxic T-cells, and eventually leads to tumor cell killing. CEA is a cell surface protein that is expressed on a wide variety of cancer cells. The mutations found in IL-2v inhibit its binding to IL-2 receptor-alpha (CD25, IL2Ra), which prevents the activation of regulatory T-cells (Tregs); however, IL-2v is able to bind to and induce signaling through IL-2Rbetagamma, which allows the preferential expansion of NK cells and CD8-positive T-cells. The Fc domain of cergutuzumab is modified to prevent Fc-gamma binding and downstream effector functions.","Cergutuzumab Amunaleukin | CEA-IL-2variant | CEA-IL2v | CERGUTUZUMAB AMUNALEUKIN | RG-7813 | RG7813 | RO-6895882 | RO6895882",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0234227","Indolent","C14145","Slow growing; causing little or no pain or annoyance.","Indolent | indolent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539488","IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells","C141460","A preparation of ex vivo expanded, genetically modified autologous naïve and memory T-cells (TN/MEM) transduced with a replication incompetent, self-inactivating (SIN) lentiviral vector expressing a hinge-optimized, chimeric antigen receptor (CAR) specific for interleukin-13 receptor alpha 2 (IL13Ra2), and containing the cluster of differentiation 137 (CD137; 4-1BB) co-stimulatory signaling domain fused to the signaling domain of the T-cell antigen receptor complex zeta chain (CD3-zeta), and a truncated form of human cluster of differentiation 19 (CD19t), with potential immunostimulating and antineoplastic activities. Upon intratumoral or intracavitary administration, IL13Ra2-specific hinge-optimized 4-1BB-co-stimulatory CAR/truncated CD19-expressing autologous TN/MEM cells are directed to, and induce selective toxicity and cytolysis in, IL13Ra2-expressing tumor cells. IL13Ra2, overexpressed by a variety of tumor cell types, is associated with increased proliferation, migration and invasiveness of tumor cells. The co-stimulatory signaling domain enhances both proliferation of T-cells and antitumor activity. Hinge optimization prevents the recognition and clearance of the CAR by endogenous Fc receptors (FcRs). CD19t is used as a surface marker to both track and quantify the modified T-cells in vivo.","IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells | IL13 [EQ]BBzeta/truncated CD19[t]+ Naive and Memory T Cells | IL13 [EQ]BBzeta/truncated CD19[t]+ TN/MEM Cells | IL13Ra2-specific-hinge-optimized-4-1BB-CAR/truncated CD19-expressing Autologous TN/MEM Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515859","ARID Domain","C14094","The approximately 100-amino acid ARID (AT-Rich Interaction Domain) DNA-binding domain occurs in some transcriptional regulators (and perhaps modifiers of chromatin structure) involved in embryonic development, cell lineage, and cell cycle control. The domain shows more diversity in structure and function than the highly conserved sequence suggests: at least six alpha helices separated by beta-strands, loops, or turns. Although Bright, dead ringer, and MRF-2 preferentially bind to AT-rich sites, DNA binding of ARID-proteins is not necessarily sequence specific; ARID protein p270 of the SWI-SNF complex exhibits non-specific DNA binding activity. ARID family proteins may be involved in a wide range of DNA interactions. Inappropriate expression of ARID proteins is increasingly implicated in tumorigenesis.","ARID Domain | AT-Rich Interaction Domain | AT-Rich Interactive Domain | BRIGHT Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539130","Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8","C141047","Stage IVA includes: (T4a, Any N, M0); (T1-3, N1b, M0). T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but less than 4 cm in greatest dimension limited to the thyroid. T3: Tumor measuring 4 cm or more in greatest dimension or with extrathyroidal extension. T4a: Moderately advanced disease; tumor of any size with gross extrathyroidal extension into the nearby tissues of the neck, including subcutaneous soft tissue, larynx, trachea, esophagus, or recurrent laryngeal nerve. N1b: Metastasis to unilateral, bilateral, or contralateral lateral neck lymph nodes levels I, II, III, IV, or V or retropharyngeal lymph nodes. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8 | Stage IVA Thyroid Gland Medullary Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539129","Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8","C141048","Stage IVB includes: T4b, Any N, M0. T4b: Very advanced disease; tumor of any size with extension towards the spine or into nearby large blood vessels, invading the prevertebral fascia, or encasing the carotid artery or mediastinal vessels. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8 | Stage IVB Thyroid Gland Medullary Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539128","Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8","C141049","Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (from AJCC 8th Ed.)","Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8 | Stage IVC Thyroid Gland Medullary Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517370","GSK-Binding Domain","C14104","The GSK-Binding Domain of AXIN2 mediates interaction with GSK3-Beta. Involved in regulation of the WNT signaling pathway, AXIN2 organizes an APC/Beta-Catenin/GSK3-Beta/ AXIN2 complex that leads to Beta-Catenin degradation. (NCI)","GSK-Binding Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539127","Autologous Anti-CD19 Chimeric Antigen Receptor T-cells C-CAR011","C141050","A proprietary preparation of autologous T-lymphocytes that have been genetically modified and transduced with a lentiviral vector expressing a second-generation chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed, costimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR T-cells C-CAR011 target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.","Autologous Anti-CD19 Chimeric Antigen Receptor T-cells C-CAR011 | Autologous Anti-CD19 CAR-T Cells C-CAR011 | Autologous Anti-CD19 CART Cells C-CAR011 | Autologous CD19-specific CAR-T Cells C-CAR011 | C-CAR011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539126","Parathyroid Carcinoma TNM Finding v8","C141052","A finding about one or more characteristics of parathyroid carcinoma, following the rules of the TNM AJCC v8 classification system.","Parathyroid Carcinoma TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539140","Parathyroid Carcinoma Clinical TNM Finding v8","C141053","A clinical finding about one or more characteristics of parathyroid carcinoma, following the rules of the TNM AJCC v8 classification system.","Parathyroid Carcinoma Clinical TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539397","FPV Vaccine CV301","C141298","A cancer vaccine consisting of a recombinant fowlpox viral (FPV) vector encoding both the two human tumor-associated antigens (TAAs) carcinoembryonic antigen (CEA) and mucin-1 (MUC-1), and TRICOM, which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration following the administration of a proprietary modified vaccinia Ankara developed by Bavarian Nordic-based prime vaccine MVA-BN-CV301, the FPV vaccine CV301, which is used as a booster vaccine, activates a cytotoxic T-lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells. In addition, the CV301-dependent anti-tumor CTL response upregulates the expression of programmed cell death ligand 1 (PD-L1); therefore, when FPV-CV301 is combined with a programmed cell death 1 (PD-1) immune checkpoint inhibitor, the antitumor effect may be increased. The TAAs CEA and MUC-1 are overexpressed in a variety of cancers.","FPV Vaccine CV301 | Boost Vaccine FPV-CV301 | FPV-CV-301 | FPV-CV301 | Fowlpox-based FPV-CV301",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539022","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma Clinical Distant Metastasis TNM Finding v8","C140899","A clinical finding about one or more characteristics of papillary, follicular, Hurthle cell, poorly differentiated, and anaplastic thyroid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma Clinical Distant Metastasis TNM Finding v8 | Clinical Distant Metastasis Status (cM) | Differentiated and Anaplastic Thyroid Carcinoma Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0148345","Vesnarinone","C1415","A cardiotonic quinolinone derivative, that suppresses cell proliferation and induces apoptosis by inducing the expression of p21, an inhibitor of cyclin dependent kinase activity in p53-mediated cell cycle arrest. (NCI)","Vesnarinone | 1-(3,4-Dimethoxybenzoyl)-4-(1,2,3,4-tetrahydro-2-oxo-6-quinolinyl)piperazine | 3,4-Dihydro-6-(4-(3,4-dimethoxybenzoyl)-1-pip- erazinyl)- 2(1H)-quinolinone | Arkin | Arkin-Z | DRG-0210 | Pieranometazine | Piperazine, 1-(3,4-dimethoxybenzoyl)-4-(1,2,3,4-tetrahydr- o -2-oxo-6-quinolinyl) | VESNARINONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0142817","Carbenicillin Indanyl Sodium","C1409","The sodium salt of indanyl carbenicillin, a broad-spectrum, semi-synthetic carboxypenicillin antibiotic with bactericidal activity. Carbenicillin acylates C-terminal domain of penicillin-sensitive transpeptidase, resulting in opening the lactam ring of the antibiotic. This inactivation prevents the formation of the cross-linkage of peptidoglycan strands, thereby inhibiting the third and last stage of bacterial cell wall synthesis. As a result, cell wall integrity is compromised and cell lysis may follow. This agent is used mainly for gram-negative infections, and has limited gram-positive coverage.","Carbenicillin Indanyl Sodium | CARBENICILLIN INDANYL SODIUM | Geocillin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539050","Thyroid Gland Anaplastic Carcinoma by AJCC v8 Stage","C141000","A term that refers to the staging of thyroid gland anaplastic carcinoma, following the rules of the TNM AJCC v8 classification system.","Thyroid Gland Anaplastic Carcinoma by AJCC v8 Stage | Thyroid Gland Undifferentiated (Anaplastic) Carcinoma by AJCC v8 Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539049","Undifferentiated (Anaplastic) Stage IVA Thyroid Gland Cancer","C141001","Stage IVA includes: T1-T3a, N0/NX, M0. T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. T3a: Tumor measuring more than 4 cm in greatest dimension limited to the thyroid. N0: No evidence of locoregional lymph node metastasis. NX: Regional lymph nodes cannot be assessed. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8 | Stage IVA Thyroid Gland Undifferentiated (Anaplastic) Carcinoma AJCC v8 | Undifferentiated (Anaplastic) Stage IVA Thyroid Gland Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539048","Undifferentiated (Anaplastic) Stage IVB Thyroid Gland Cancer","C141003","Stage IVB includes: (T1-T3a, N1, M0); (T3b, Any N, M0); (T4, Any N, M0). T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. T3a: Tumor measuring more than 4 cm in greatest dimension limited to the thyroid. T3b: Gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles) from a tumor of any size. T4: Tumor of any size with gross extrathyroidal extension. N1: Metastasis to regional nodes. M0: No distant metastasis. (from AJCC 8th Ed.)","Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8 | Stage IVB Thyroid Gland Undifferentiated (Anaplastic) Carcinoma AJCC v8 | Undifferentiated (Anaplastic) Stage IVB Thyroid Gland Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539047","Undifferentiated (Anaplastic) Stage IVC Thyroid Gland Cancer","C141004","Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (from AJCC 8th Ed.)","Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8 | Stage IVC Thyroid Gland Undifferentiated (Anaplastic) Carcinoma AJCC v8 | Undifferentiated (Anaplastic) Stage IVC Thyroid Gland Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539062","Contact Date","C141005","The date on which a direct or indirect interaction between individuals or organizations occurred.","Contact Date | Date of Contact",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539061","Medullary Thyroid Carcinoma TNM Finding v8","C141006","A finding about one or more characteristics of medullary thyroid carcinoma, following the rules of the TNM AJCC v8 classification system. Differentiated and anaplastic thyroid carcinomas are staged according to the classification for thyroid-differentiated and anaplastic carcinoma. (from AJCC 8th Ed.)","Medullary Thyroid Carcinoma TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542993","Grade 2 Meningismus, CTCAE","C144835","Moderate symptoms; limiting instrumental ADL","Grade 2 Meningismus, CTCAE | Grade 2 Meningismus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542994","Grade 2 Menorrhagia, CTCAE","C144836","Moderate symptoms; medical intervention indicated (e.g., hormones)","Grade 2 Menorrhagia, CTCAE | Grade 2 Menorrhagia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542995","Grade 2 Metabolism and Nutrition Disorders - Other, Specify, CTCAE","C144837","Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL","Grade 2 Metabolism and Nutrition Disorders - Other, Specify, CTCAE | Grade 2 Metabolism and nutrition disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542996","Grade 2 Methemoglobinemia, CTCAE","C144838",">ULN","Grade 2 Methemoglobinemia, CTCAE | Grade 2 Methemoglobinemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542981","Grade 2 Middle Ear Inflammation, CTCAE","C144839","Serous otitis, medical intervention indicated","Grade 2 Middle Ear Inflammation, CTCAE | Grade 2 Middle ear inflammation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542983","Grade 2 Movements Involuntary, CTCAE","C144843","Moderate symptoms; limiting instrumental ADL","Grade 2 Movements Involuntary, CTCAE | Grade 2 Movements involuntary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542984","Grade 2 Mucosal Infection, CTCAE","C144844","Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)","Grade 2 Mucosal Infection, CTCAE | Grade 2 Mucosal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542985","Grade 2 Mucositis Oral, CTCAE","C144845","Moderate pain or ulcer that does not interfere with oral intake; modified diet indicated","Grade 2 Mucositis Oral, CTCAE | Grade 2 Mucositis oral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542986","Grade 2 Muscle Cramp, CTCAE","C144846","Moderate pain; limiting instrumental ADL","Grade 2 Muscle Cramp, CTCAE | Grade 2 Muscle cramp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542987","Grade 2 Muscle Weakness Left-Sided, CTCAE","C144847","Symptomatic; evident on physical exam; limiting instrumental ADL","Grade 2 Muscle Weakness Left-Sided, CTCAE | Grade 2 Muscle weakness left-sided",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542988","Grade 2 Muscle Weakness Lower Limb, CTCAE","C144848","Symptomatic; evident on physical exam; limiting instrumental ADL","Grade 2 Muscle Weakness Lower Limb, CTCAE | Grade 2 Muscle weakness lower limb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542973","Grade 2 Muscle Weakness Right-Sided, CTCAE","C144849","Symptomatic; evident on physical exam; limiting instrumental ADL","Grade 2 Muscle Weakness Right-Sided, CTCAE | Grade 2 Muscle weakness right-sided",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542975","Grade 2 Muscle Weakness Upper Limb, CTCAE","C144851","Symptomatic; evident on physical exam; limiting instrumental ADL","Grade 2 Muscle Weakness Upper Limb, CTCAE | Grade 2 Muscle weakness upper limb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542976","Grade 2 Musculoskeletal and Connective Tissue Disorder - Other, Specify, CTCAE","C144852","Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL","Grade 2 Musculoskeletal and Connective Tissue Disorder - Other, Specify, CTCAE | Grade 2 Musculoskeletal and connective tissue disorder - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542977","Grade 2 Musculoskeletal Deformity, CTCAE","C144853","Deformity, hypoplasia, or asymmetry able to be remediated by prosthesis (e.g., shoe insert) or covered by clothing","Grade 2 Musculoskeletal Deformity, CTCAE | Grade 2 Musculoskeletal deformity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542978","Grade 2 Myalgia, CTCAE","C144854","Moderate pain; limiting instrumental ADL","Grade 2 Myalgia, CTCAE | Grade 2 Myalgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542979","Grade 2 Myasthenia Gravis, CTCAE","C144855","Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL","Grade 2 Myasthenia Gravis, CTCAE | Grade 2 Myasthenia gravis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542980","Grade 2 Myocardial Infarction, CTCAE","C144856","Asymptomatic and cardiac enzymes minimally abnormal and no evidence of ischemic ECG changes","Grade 2 Myocardial Infarction, CTCAE | Grade 2 Myocardial infarction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542965","Grade 2 Myocarditis, CTCAE","C144857","Symptoms with moderate activity or exertion","Grade 2 Myocarditis, CTCAE | Grade 2 Myocarditis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521480","5q23","C14129","A chromosome band present on 5q","5q23 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0145106","Teicoplanin","C1412","A glycopeptide antibiotic complex isolated from the bacterium Actinoplanes teichomyceticus. Teicoplanin inhibits peptidoglycan polymerization, resulting in inhibition of bacterial cell wall synthesis and cell death. (NCI04)","Teicoplanin | MDL-507 | TEICOPLANIN | Tagocid | Targocid | Targosid | Teichomycin | Teichomycin A2 | Teicoplanin A2 | teicoplanin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539381","Mycosis Fungoides and Sezary Syndrome TNM Finding v8","C141304","A finding about one or more characteristics of mycosis fungoides and Sezary syndrome, following the rules of the TNM AJCC v8 classification system. This classification is based on the ISCL/EORTC revision to the classification of mycosis fungoides and Sezary syndrome. (from AJCC 8th Ed.)","Mycosis Fungoides and Sezary Syndrome TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538961","Orbital Sarcoma Clinical TNM Finding v8","C140833","A clinical finding about one or more characteristics of orbital sarcoma, following the rules of the TNM AJCC v8 classification system.","Orbital Sarcoma Clinical TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539219","Stage III Adrenal Cortex Cancer","C141103","Stage III includes: (T1, N1, M0); (T2, N1, M0); (T3, Any N, M0); (T4, Any N, M0). T1: Tumor measuring 5 cm or less in greatest dimension, with no extra-adrenal invasion. T2: Tumor measuring more than 5 cm in greatest dimension, with no extra-adrenal invasion. T3: Tumor of any size with local invasion but not invading adjacent organs. T4: Tumor of any size that invades adjacent organs (kidney, diaphragm, pancreas, spleen, or liver) or large blood vessels (renal vein or vena cava). N1: Metastasis in regional lymph node(s). M0: No distant metastasis. (from AJCC 8th Ed.)","Stage III Adrenal Cortical Carcinoma AJCC v8 | Stage III Adrenal Cortex Cancer | Stage III Adrenal Cortex Carcinoma AJCC v8 | Stage III Adrenal Cortex Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539218","Stage IV Adrenal Cortex Cancer","C141104","Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (from AJCC 8th Ed.)","Stage IV Adrenal Cortical Carcinoma AJCC v8 | Stage IV Adrenal Cortex Cancer | Stage IV Adrenal Cortex Carcinoma AJCC v8 | Stage IV Adrenal Cortex Carcinoma AJCC v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539217","Pheochromocytoma and Paraganglioma TNM Finding v8","C141105","A finding about one or more characteristics of pheochromocytoma and paraganglioma, following the rules of the TNM AJCC v8 classification system. This classification system applies to the adrenal medulla pheochromocytomas and sympathetic paragangliomas. Parasympathetic paragangliomas are not staged because they are largely benign. This staging system does not apply to neuroendocrine tumors of the pancreas (are staged according to the classification for neuroendocrine tumors of the pancreas) and carotid body tumors (not staged). (from AJCC 8th Ed.)","Pheochromocytoma and Paraganglioma TNM Finding v8 | Adrenal-Neuroendocrine Tumor TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539216","Pheochromocytoma and Paraganglioma Clinical TNM Finding v8","C141106","A clinical finding about one or more characteristics of pheochromocytoma and paraganglioma, following the rules of the TNM AJCC v8 classification system.","Pheochromocytoma and Paraganglioma Clinical TNM Finding v8 | Adrenal-Neuroendocrine Tumor Clinical TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539215","Pheochromocytoma and Paraganglioma Clinical Distant Metastasis TNM Finding v8","C141107","A clinical finding about one or more characteristics of pheochromocytoma and paraganglioma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Pheochromocytoma and Paraganglioma Clinical Distant Metastasis TNM Finding v8 | Adrenal-Neuroendocrine Tumor Clinical Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539214","Pheochromocytoma and Paraganglioma cM0 TNM Finding v8","C141108","No distant metastasis. (from AJCC 8th Ed.)","Pheochromocytoma and Paraganglioma cM0 TNM Finding v8 | Adrenal-Neuroendocrine Tumor cM0 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539060","Medullary Thyroid Carcinoma Clinical TNM Finding v8","C141007","A clinical finding about one or more characteristics of medullary thyroid carcinoma, following the rules of the TNM AJCC v8 classification system.","Medullary Thyroid Carcinoma Clinical TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539059","Medullary Thyroid Carcinoma Clinical Distant Metastasis TNM Finding v8","C141008","A clinical finding about one or more characteristics of medullary thyroid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Medullary Thyroid Carcinoma Clinical Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539058","Medullary Thyroid Carcinoma cM0 TNM Finding v8","C141009","No distant metastasis. (from AJCC 8th Ed.)","Medullary Thyroid Carcinoma cM0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162527","Ankyrin Repeat","C14100","Ankyrin Repeats are tandem modules of about 33 amino acids. The conserved domain structure has been described as side-by-side anti-parallel alpha helices connected by intervening beta hairpin motifs or as beta, alpha, alpha, beta secondary structures or as an L-shaped beta-hairpin and two alpha-helices. The repeats associate to form a higher order structure. Despite sequence variation, the domain core maintains a stable surface of contact residues to mediate protein-protein interactions. Target protein binding involves contacts by the beta hairpin tips and the helical bundle surface facing the Ankyrin groove. ANK repeats have been identified in over 1700 functionally diverse proteins, primarily from eukaryotes; no common theme among the protein targets has been identified. The Ankyrin cytoskeletal protein is composed almost entirely of these repeats.","Ankyrin Repeat | ANK Domain | ANK Repeat | Ankyrin Repeat Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539057","Medullary Thyroid Carcinoma cM1 TNM Finding v8","C141010","Distant metastasis. (from AJCC 8th Ed.)","Medullary Thyroid Carcinoma cM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520770","17q21-q23","C14124","A chromosome band present on 17q","17q21-q23 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539322","B Lymphoblastic Lymphoma by Ann Arbor Stage","C141250","An anatomic stage for B lymphoblastic lymphoma based on the Ann Arbor classification criteria.","B Lymphoblastic Lymphoma by Ann Arbor Stage | B-Lymphoblastic Lymphoma by Ann Arbor Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539319","Burkitt Lymphoma by Ann Arbor Stage","C141253","An anatomic stage for Burkitt lymphoma based on the Ann Arbor classification criteria.","Burkitt Lymphoma by Ann Arbor Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542968","Grade 2 Nasal Congestion, CTCAE","C144860","Moderate symptoms; medical intervention indicated","Grade 2 Nasal Congestion, CTCAE | Grade 2 Nasal congestion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542969","Grade 2 Neck Edema, CTCAE","C144861","Moderate neck edema; slight obliteration of anatomic landmarks; limiting instrumental ADL","Grade 2 Neck Edema, CTCAE | Grade 2 Neck edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543386","Grade 3 Ear and Labyrinth Disorders - Other, Specify, CTCAE","C145239","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL","Grade 3 Ear and Labyrinth Disorders - Other, Specify, CTCAE | Grade 3 Ear and labyrinth disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543387","Grade 3 Ear Pain, CTCAE","C145240","Severe pain; limiting self care ADL","Grade 3 Ear Pain, CTCAE | Grade 3 Ear pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543374","Grade 3 Edema Face, CTCAE","C145243","Severe swelling; limiting self care ADL","Grade 3 Edema Face, CTCAE | Grade 3 Edema face",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543376","Grade 3 Edema Trunk, CTCAE","C145245","Gross deviation from normal anatomic contour; limiting self care ADL","Grade 3 Edema Trunk, CTCAE | Grade 3 Edema trunk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543377","Grade 3 Ejection Fraction Decreased, CTCAE","C145246","Resting ejection fraction (EF) 39-20%; >=20% drop from baseline","Grade 3 Ejection Fraction Decreased, CTCAE | Grade 3 Ejection fraction decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543378","Grade 3 Electrocardiogram QT Corrected Interval Prolonged, CTCAE","C145247","Average QTc >= 501 ms; >60 ms change from baseline","Grade 3 Electrocardiogram QT Corrected Interval Prolonged, CTCAE | Grade 3 Electrocardiogram QT corrected interval prolonged",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543379","Grade 3 Encephalitis Infection, CTCAE","C145248","IV antibiotic, antifungal, or antiviral intervention indicated; severe changes in mental status; self-limited seizure activity; focal neurologic abnormalities","Grade 3 Encephalitis Infection, CTCAE | Grade 3 Encephalitis infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543365","Grade 3 Endocarditis Infective, CTCAE","C145250","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Endocarditis Infective, CTCAE | Grade 3 Endocarditis infective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543366","Grade 3 Endocrine Disorders - Other, Specify, CTCAE","C145251","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL","Grade 3 Endocrine Disorders - Other, Specify, CTCAE | Grade 3 Endocrine disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543367","Grade 3 Endophthalmitis, CTCAE","C145252","Systemic intervention; hospitalization indicated","Grade 3 Endophthalmitis, CTCAE | Grade 3 Endophthalmitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543368","Grade 3 Enterocolitis Infectious, CTCAE","C145253","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated; profuse watery diarrhea with signs of hypovolemia; bloody diarrhea; fever; severe abdominal pain; hospitalization indicated","Grade 3 Enterocolitis Infectious, CTCAE | Grade 3 Enterocolitis infectious",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543369","Grade 3 Enterocolitis, CTCAE","C145254","Severe or persistent abdominal pain; fever; ileus; peritoneal signs","Grade 3 Enterocolitis, CTCAE | Grade 3 Enterocolitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543370","Grade 3 Enterovesical Fistula, CTCAE","C145255","Invasive intervention indicated","Grade 3 Enterovesical Fistula, CTCAE | Grade 3 Enterovesical fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543371","Grade 3 Eosinophilia, CTCAE","C145256","Steroids initiated","Grade 3 Eosinophilia, CTCAE | Grade 3 Eosinophilia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543372","Grade 3 Epistaxis, CTCAE","C145257","Transfusion; invasive intervention indicated (e.g., hemostasis of bleeding site)","Grade 3 Epistaxis, CTCAE | Grade 3 Epistaxis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538960","Orbital Sarcoma Clinical Distant Metastasis TNM Finding v8","C140834","A clinical finding about one or more characteristics of orbital sarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Orbital Sarcoma Clinical Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538959","Orbital Sarcoma cM0 TNM Finding v8","C140835","Orbital sarcoma with no distant metastasis. (from AJCC 8th Ed.)","Orbital Sarcoma cM0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538958","Orbital Sarcoma cM1 TNM Finding v8","C140836","Orbital sarcoma with distant metastasis. (from AJCC 8th Ed.)","Orbital Sarcoma cM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538957","Orbital Sarcoma Pathologic TNM Finding v8","C140837","A pathologic finding about one or more characteristics of orbital sarcoma, following the rules of the TNM AJCC v8 classification system.","Orbital Sarcoma Pathologic TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538956","Orbital Sarcoma Pathologic Distant Metastasis TNM Finding v8","C140838","A pathologic finding about one or more characteristics of orbital sarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Orbital Sarcoma Pathologic Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538955","Orbital Sarcoma pM1 TNM Finding v8","C140839","Orbital sarcoma with distant metastasis. (from AJCC 8th Ed.)","Orbital Sarcoma pM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522688","Basolateral Sorting Signal","C14083","The polymeric immunoglobulin receptor is a model system to study protein traffic in epithelial cells. This receptor travels first to the basolateral surface where it can bind polymeric IgA or IgM. The receptor is then endocytosed and delivered to endosomes. The receptor is sorted into transcytotic vesicles which are exocytosed at the apical surface. The 103 amino acid cytoplasmic domain of the receptor contains several sorting signals. The 17 residues closest to the membrane are an autonomous signal for basolateral sorting. For endocytosis there are two signals, both of which contain tyrosines. Finally, transcytosis is signaled by serine phosphorylation. (From PubMed PMID1813030 and NCI)","Basolateral Sorting Signal | BASS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538954","Orbital Sarcoma Pathologic Primary Tumor TNM Finding v8","C140840","A pathologic finding about one or more characteristics of orbital sarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Orbital Sarcoma Pathologic Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538969","Orbital Sarcoma pTX TNM Finding v8","C140841","Primary tumor cannot be assessed. (from AJCC 8th Ed.)","Orbital Sarcoma pTX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538968","Orbital Sarcoma pT0 TNM Finding v8","C140842","No evidence of primary tumor. (from AJCC 8th Ed.)","Orbital Sarcoma pT0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538967","Orbital Sarcoma pT1 TNM Finding v8","C140843","Orbital sarcoma with tumor measuring 2 cm or less in greatest dimension. (from AJCC 8th Ed.)","Orbital Sarcoma pT1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538966","Orbital Sarcoma pT2 TNM Finding v8","C140844","Orbital sarcoma with tumor measuring more than 2 cm in greatest diameter without invasion of bony walls or globe. (from AJCC 8th Ed.)","Orbital Sarcoma pT2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538965","Orbital Sarcoma pT3 TNM Finding v8","C140845","Orbital sarcoma with tumor of any size with invasion of bony walls. (from AJCC 8th Ed.)","Orbital Sarcoma pT3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538964","Orbital Sarcoma pT4 TNM Finding v8","C140846","Orbital sarcoma with tumor of any size with invasion of globe or periorbital structures, including eyelid, conjunctiva, temporal fossa, nasal cavity, paranasal sinuses, and/or central nervous system. (from AJCC 8th Ed.)","Orbital Sarcoma pT4 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538963","Orbital Sarcoma Pathologic Regional Lymph Nodes TNM Finding v8","C140847","A pathologic finding about one or more characteristics of orbital sarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Orbital Sarcoma Pathologic Regional Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518834","PXXP Motif","C14110","The SH3 domain, often seen in signaling pathway proteins, frequently binds to a conserved PXXP Motif usually found in proline-rich regions of target proteins. The SH3 domain contains a site located between the RT and n-SRC loops that binds the PXXP motif, which then adopts a poly-proline type II (PPII) conformation. PXXP motifs are often clustered and have residues that contribute to binding specificity. Class I motifs have an amino to carboxy terminal binding orientation and include sites specific for the SRC oncoprotein. More promiscuous in their binding, Class II motifs have a carboxy to amino terminal binding orientation, PXXP can be in either of two positions, and they have basic residues at the C-terminus. (NCI)","PXXP Motif | PXXP Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539196","Pheochromocytoma and Paraganglioma cM1a TNM Finding v8","C141110","Distant metastasis to only bone. (from AJCC 8th Ed.)","Pheochromocytoma and Paraganglioma cM1a TNM Finding v8 | Adrenal-Neuroendocrine Tumor cM1a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539195","Pheochromocytoma and Paraganglioma cM1b TNM Finding v8","C141111","Distant metastasis to only distant lymph nodes/liver or lung. (from AJCC 8th Ed.)","Pheochromocytoma and Paraganglioma cM1b TNM Finding v8 | Adrenal-Neuroendocrine Tumor cM1b TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539194","Pheochromocytoma and Paraganglioma cM1c TNM Finding v8","C141112","Distant metastasis to bone plus multiple other sites. (from AJCC 8th Ed.)","Pheochromocytoma and Paraganglioma cM1c TNM Finding v8 | Adrenal-Neuroendocrine Tumor cM1c TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539193","Pheochromocytoma and Paraganglioma Pathologic TNM Finding v8","C141113","A pathologic finding about one or more characteristics of pheochromocytoma and paraganglioma, following the rules of the TNM AJCC v8 classification system.","Pheochromocytoma and Paraganglioma Pathologic TNM Finding v8 | Adrenal-Neuroendocrine Tumor Pathologic TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539192","Pheochromocytoma and Paraganglioma Pathologic Distant Metastasis TNM Finding v8","C141114","A pathologic finding about one or more characteristics of pheochromocytoma and paraganglioma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Pheochromocytoma and Paraganglioma Pathologic Distant Metastasis TNM Finding v8 | Adrenal-Neuroendocrine Tumor Pathologic Distant Metastasis TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539191","Pheochromocytoma and Paraganglioma pM1 TNM Finding v8","C141115","Distant metastasis. (from AJCC 8th Ed.)","Pheochromocytoma and Paraganglioma pM1 TNM Finding v8 | Adrenal-Neuroendocrine Tumor pM1 TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539190","Pheochromocytoma and Paraganglioma pM1a TNM Finding v8","C141116","Distant metastasis to only bone. (from AJCC 8th Ed.)","Pheochromocytoma and Paraganglioma pM1a TNM Finding v8 | Adrenal-Neuroendocrine Tumor pM1a TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539470","Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8","C141350","Stage II includes: IIA (T1,2, N1,2, M0, B0,1); IIB (T3, N0-2, M0, B0,1). T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. T2: Patches, papules, or plaques covering 10% or more of the skin surface. T3: One or more tumors (equal or greater than 1 cm in diameter). N0: No clinically abnormal peripheral lymph nodes; biopsy not required. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. M0: No visceral organ involvement. B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. (AJCC 8th ed.)","Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539453","Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8","C141351","Stage IIA includes:  T1-2, N1,2, M0, B0,1. T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. T2: Patches, papules, or plaques covering 10% or more of the skin surface. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. M0: No visceral organ involvement. B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. (AJCC 8th ed.)","Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539303","Lymphoplasmacytic Lymphoma by Ann Arbor Stage","C141256","An anatomic stage for lymphoplasmacytic lymphoma based on the Ann Arbor classification criteria.","Lymphoplasmacytic Lymphoma by Ann Arbor Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539302","Mantle Cell Lymphoma by Ann Arbor Stage","C141257","An anatomic stage for mantle cell lymphoma based on the Ann Arbor classification criteria.","Mantle Cell Lymphoma by Ann Arbor Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539301","Marginal Zone Lymphoma by Ann Arbor Stage","C141258","An anatomic stage for marginal zone lymphoma based on the Ann Arbor classification criteria.","Marginal Zone Lymphoma by Ann Arbor Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539300","Small Lymphocytic Lymphoma by Ann Arbor Stage","C141259","An anatomic stage for small lymphocytic lymphoma based on the Ann Arbor classification criteria.","Small Lymphocytic Lymphoma by Ann Arbor Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521412","4q31.23","C14125","A chromosome band present on 4q","4q31.23 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539299","Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue by Ann Arbor Stage","C141260","An anatomic stage for extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue based on the Ann Arbor classification criteria.","Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue by Ann Arbor Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539298","Nodal Marginal Zone Lymphoma by Ann Arbor Stage","C141261","An anatomic stage for nodal marginal zone lymphoma based on the Ann Arbor classification criteria.","Nodal Marginal Zone Lymphoma by Ann Arbor Stage | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550756","Primary Mediastinal Large B-Cell Lymphoma by Ann Arbor Stage","C141262","An anatomic stage for primary mediastinal large B-cell lymphoma based on the Ann Arbor classification criteria.","Primary Mediastinal Large B-Cell Lymphoma by Ann Arbor Stage | Primary Mediastinal (Thymic) Large B-Cell Lymphoma by Ann Arbor Stage | Primary Mediastinal (Thymic) Large B-Cell Lymphoma by Ann Arbor Stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518792","PH Domain","C14077","Pleckstrin-homology (PH) domains are protein modules of approximately 120 amino acids found in a wide variety of signaling proteins in organisms ranging from yeast to humans. Some PH domains bind with high affinity (low mM or nM Kd) to specific phosphoinositides such as phosphatidyl-inositol (PI) -4,5-bisphosphate, PI-3,4-P2 or PI-3,4,5-P3. Binding to phosphoinositides may allow PH proteins to respond to lipid messengers for example by relocation to membranes. The C-termini of some PH domains have also been reported to bind the beta/lambda subunits of heterotrimeric G proteins.","PH Domain | Pleckstrin Homology Domain | Pleckstrin-Homology Domain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538902","Lacrimal Gland Carcinoma pM1 TNM Finding v8","C140780","Lacrimal gland carcinoma with distant metastasis. (from AJCC 8th Ed.)","Lacrimal Gland Carcinoma pM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538901","Lacrimal Gland Carcinoma Pathologic Primary Tumor TNM Finding v8","C140781","A pathologic finding about one or more characteristics of lacrimal gland carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Lacrimal Gland Carcinoma Pathologic Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538899","Lacrimal Gland Carcinoma pT0 TNM Finding v8","C140783","No evidence of primary tumor. (from AJCC 8th Ed.)","Lacrimal Gland Carcinoma pT0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538898","Lacrimal Gland Carcinoma pT1 TNM Finding v8","C140784","Lacrimal gland carcinoma with tumor measuring 2 cm or less in greatest dimension with or without extraglandular extension into the orbital soft tissue. (from AJCC 8th Ed.)","Lacrimal Gland Carcinoma pT1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538881","Lacrimal Gland Carcinoma pT1a TNM Finding v8","C140785","Lacrimal gland carcinoma with tumor measuring 2 cm or less in greatest dimension with or without extraglandular extension into the orbital soft tissue with no periosteal or bone involvement. (from AJCC 8th Ed.)","Lacrimal Gland Carcinoma pT1a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538880","Lacrimal Gland Carcinoma pT1b TNM Finding v8","C140786","Lacrimal gland carcinoma with tumor measuring 2 cm or less in greatest dimension with or without extraglandular extension into the orbital soft tissue with periosteal involvement only. (from AJCC 8th Ed.)","Lacrimal Gland Carcinoma pT1b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543358","Grade 3 Erythema Multiforme, CTCAE","C145259","Target lesions covering >30% BSA and associated with oral or genital erosions","Grade 3 Erythema Multiforme, CTCAE | Grade 3 Erythema multiforme",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543359","Grade 3 Erythroderma, CTCAE","C145260","Erythema covering >90% BSA with associated symptoms (e.g., pruritus or tenderness); limiting self care ADL","Grade 3 Erythroderma, CTCAE | Grade 3 Erythroderma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543360","Grade 3 Esophageal Anastomotic Leak, CTCAE","C145261","Severe symptoms; invasive intervention indicated","Grade 3 Esophageal Anastomotic Leak, CTCAE | Grade 3 Esophageal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542292","Grade 1 Enterovesical Fistula, CTCAE","C144080","Asymptomatic","Grade 1 Enterovesical Fistula, CTCAE | Grade 1 Enterovesical fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542277","Grade 1 Eosinophilia, CTCAE","C144081",">ULN and >Baseline","Grade 1 Eosinophilia, CTCAE | Grade 1 Eosinophilia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542278","Grade 1 Epistaxis, CTCAE","C144082","Mild symptoms; intervention not indicated","Grade 1 Epistaxis, CTCAE | Grade 1 Epistaxis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542279","Grade 1 Epstein-Barr Virus Infection Reactivation, CTCAE","C144083","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated","Grade 1 Epstein-Barr Virus Infection Reactivation, CTCAE | Grade 1 Epstein-Barr virus infection reactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542280","Grade 1 Erythema Multiforme, CTCAE","C144084","Target lesions covering <10% BSA and not associated with skin tenderness","Grade 1 Erythema Multiforme, CTCAE | Grade 1 Erythema multiforme",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542281","Grade 1 Esophageal Anastomotic Leak, CTCAE","C144085","Asymptomatic diagnostic finding; intervention not indicated","Grade 1 Esophageal Anastomotic Leak, CTCAE | Grade 1 Esophageal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542282","Grade 1 Esophageal Hemorrhage, CTCAE","C144087","Mild symptoms; intervention not indicated","Grade 1 Esophageal Hemorrhage, CTCAE | Grade 1 Esophageal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542283","Grade 1 Esophageal Obstruction, CTCAE","C144088","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Esophageal Obstruction, CTCAE | Grade 1 Esophageal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542284","Grade 1 Esophageal Pain, CTCAE","C144089","Mild pain","Grade 1 Esophageal Pain, CTCAE | Grade 1 Esophageal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517691","LH, Rat Strain","C14408","LH: The strain exhibits mild hypertension (approx 165mmHg in males and 140mmHg in females at 14 weeks of age in 1984) with increased body weight and plasma lipids. There is reduced life-span (compared with LN and LL) with histopathological lesions characteristic of hypertensive disease in rats.","LH, Rat Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542269","Grade 1 Esophageal Stenosis, CTCAE","C144090","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Esophageal Stenosis, CTCAE | Grade 1 Esophageal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542270","Grade 1 Esophageal Ulcer, CTCAE","C144091","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Esophageal Ulcer, CTCAE | Grade 1 Esophageal ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542271","Grade 1 Extraocular Muscle Paresis, CTCAE","C144092","Asymptomatic; clinical or diagnostic observations only","Grade 1 Extraocular Muscle Paresis, CTCAE | Grade 1 Extraocular muscle paresis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542272","Grade 1 Extrapyramidal Disorder, CTCAE","C144093","Mild involuntary movements","Grade 1 Extrapyramidal Disorder, CTCAE | Grade 1 Extrapyramidal disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542273","Grade 1 Eye Disorders - Other, Specify, CTCAE","C144094","Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; no change in vision","Grade 1 Eye Disorders - Other, Specify, CTCAE | Grade 1 Eye disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542274","Grade 1 Eyelid Function Disorder, CTCAE","C144095","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Eyelid Function Disorder, CTCAE | Grade 1 Eyelid function disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539452","Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8","C141352","Stage IIB includes: T3, N0-2, M0, B0,1. T3: One or more tumors (equal or greater than 1 cm in diameter). N0: No clinically abnormal peripheral lymph nodes; biopsy not required. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. M0: No visceral organ involvement. B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. (AJCC 8th ed.)","Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539451","Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8","C141353","Stage III includes: (T4, N0-2, M0, B0,1); IIIA (T4, N0-2, M0, B0); IIIB (T4, N0-2, M0, B1). T4: Confluence of erythema covering 80% or more of body surface area. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. M0: No visceral organ involvement. B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. (AJCC 8th ed.)","Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539450","Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8","C141354","Stage IIIA includes: T4, N0-2, M0, B0. T4: Confluence of erythema covering 80% or more of body surface area. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. M0: No visceral organ involvement. B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). (AJCC 8th ed.)","Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539449","Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8","C141355","Stage IIIB includes: T4, N0-2, M0, B1. T4: Confluence of erythema covering 80% or more of body surface area. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. M0: No visceral organ involvement. B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. (AJCC 8th ed.)","Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0525021","Nuclear Localization Signals","C14089","An amino acid sequence that directs the post-translational transport of a protein to the nucleus. The sequence contains positively charged amino acids such as arginine and lysine.","Nuclear Localization Signal | NLS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538879","Lacrimal Gland Carcinoma pT1c TNM Finding v8","C140787","Lacrimal gland carcinoma with tumor measuring 2 cm or less in greatest dimension with or without extraglandular extension into the orbital soft tissue with periosteal and bone involvement. (from AJCC 8th Ed.)","Lacrimal Gland Carcinoma pT1c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538878","Lacrimal Gland Carcinoma pT2 TNM Finding v8","C140788","Lacrimal gland carcinoma with tumor measuring more than 2 cm but 4 cm or less in greatest dimension. (from AJCC 8th Ed.)","Lacrimal Gland Carcinoma pT2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538877","Lacrimal Gland Carcinoma pT2a TNM Finding v8","C140789","Lacrimal gland carcinoma with tumor measuring more than 2 cm but 4 cm or less in greatest dimension with no periosteal or bone involvement. (from AJCC 8th Ed.)","Lacrimal Gland Carcinoma pT2a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538876","Lacrimal Gland Carcinoma pT2b TNM Finding v8","C140790","Lacrimal gland carcinoma with tumor measuring more than 2 cm but 4 cm or less in greatest dimension with periosteal involvement only. (from AJCC 8th Ed.)","Lacrimal Gland Carcinoma pT2b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538875","Lacrimal Gland Carcinoma pT2c TNM Finding v8","C140791","Lacrimal gland carcinoma with tumor measuring more than 2 cm but 4 cm or less in greatest dimension with periosteal and bone involvement. (from AJCC 8th Ed.)","Lacrimal Gland Carcinoma pT2c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538874","Lacrimal Gland Carcinoma pT3 TNM Finding v8","C140792","Lacrimal gland carcinoma with tumor measuring more than 4 cm in greatest dimension. (from AJCC 8th Ed.)","Lacrimal Gland Carcinoma pT3 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538889","Lacrimal Gland Carcinoma pT3a TNM Finding v8","C140793","Lacrimal gland carcinoma with tumor measuring more than 4 cm in greatest dimension with no periosteal or bone involvement. (from AJCC 8th Ed.)","Lacrimal Gland Carcinoma pT3a TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538888","Lacrimal Gland Carcinoma pT3b TNM Finding v8","C140794","Lacrimal gland carcinoma with tumor measuring more than 4 cm in greatest dimension with periosteal involvement only. (from AJCC 8th Ed.)","Lacrimal Gland Carcinoma pT3b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL538887","Lacrimal Gland Carcinoma pT3c TNM Finding v8","C140795","Lacrimal gland carcinoma with tumor measuring more than 4 cm in greatest dimension with periosteal and bone involvement. (from AJCC 8th Ed.)","Lacrimal Gland Carcinoma pT3c TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539484","Estrogen Receptor Positive by Immunohistochemistry","C141465","An immunohistochemical staining finding indicating that cells in a tissue sample are expressing estrogen receptor.","Estrogen Receptor Positive by Immunohistochemistry | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539585","Estrogen Receptor Positive by Immunohistochemistry 1-10 Percent","C141467","An immunohistochemical staining finding indicating that 1-10 percent of the cells in a tissue sample are expressing estrogen receptor.","Estrogen Receptor Positive by Immunohistochemistry 1-10 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539584","Estrogen Receptor Positive by Immunohistochemistry 11-20 Percent","C141468","An immunohistochemical staining finding indicating that 11-20 percent of the cells in a tissue sample are expressing estrogen receptor.","Estrogen Receptor Positive by Immunohistochemistry 11-20 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539583","Estrogen Receptor Positive by Immunohistochemistry 21-30 Percent","C141469","An immunohistochemical staining finding indicating that 21-30 percent of the cells in a tissue sample are expressing estrogen receptor.","Estrogen Receptor Positive by Immunohistochemistry 21-30 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539582","Estrogen Receptor Positive by Immunohistochemistry 31-40 Percent","C141470","An immunohistochemical staining finding indicating that 31-40 percent of the cells in a tissue sample are expressing estrogen receptor.","Estrogen Receptor Positive by Immunohistochemistry 31-40 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539581","Estrogen Receptor Positive by Immunohistochemistry 41-50 Percent","C141471","An immunohistochemical staining finding indicating that 41-50 percent of the cells in a tissue sample are expressing estrogen receptor.","Estrogen Receptor Positive by Immunohistochemistry 41-50 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542275","Grade 1 Facial Muscle Weakness, CTCAE","C144096","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Facial Muscle Weakness, CTCAE | Grade 1 Facial muscle weakness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542261","Grade 1 Facial Pain, CTCAE","C144098","Mild pain","Grade 1 Facial Pain, CTCAE | Grade 1 Facial pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542262","Grade 1 Fall, CTCAE","C144099","Minor with no resultant injuries; intervention not indicated","Grade 1 Fall, CTCAE | Grade 1 Fall",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518097","M520, Rat Strain","C14409","Low frequency of pancreatic exocrine tumors. By 12-15 months of age develop small local areas of nephritis that progress by 22-24 months to moderate to severe nephritis in 75% of animals (Snell 1967). About 33% of females over 18 months develop tumors of the uterus of endometrial origin. Adrenocortical adenomas (about 20% in males and 40% in females over 18 months of age), and phaeochromocytomas or preneoplastic nodules in adrenal medulla (about 67% of males over 21 months of age) (Snell 1965). Low blood pressure (21/23), reaching 121_1.2 (SEM) mmHg at 10 weeks of age. Resistant to development of methylcholanthrene -induced thyroiditis (Glover et al 1969).","M520, Rat Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542583","Grade 1 Urinary Tract Pain, CTCAE","C144454","Mild pain","Grade 1 Urinary Tract Pain, CTCAE | Grade 1 Urinary tract pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542584","Grade 1 Urinary Urgency, CTCAE","C144455","Present","Grade 1 Urinary Urgency, CTCAE | Grade 1 Urinary urgency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542585","Grade 1 Urine Discoloration, CTCAE","C144456","Present","Grade 1 Urine Discoloration, CTCAE | Grade 1 Urine discoloration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542586","Grade 1 Urostomy Leak, CTCAE","C144457","Asymptomatic diagnostic finding; intervention not indicated","Grade 1 Urostomy Leak, CTCAE | Grade 1 Urostomy leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542588","Grade 1 Urostomy Site Bleeding, CTCAE","C144459","Minimal bleeding identified on clinical exam; intervention not indicated","Grade 1 Urostomy Site Bleeding, CTCAE | Grade 1 Urostomy site bleeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542702","Grade 1 Uterine Fistula, CTCAE","C144461","Asymptomatic","Grade 1 Uterine Fistula, CTCAE | Grade 1 Uterine fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542703","Grade 1 Uterine Obstruction, CTCAE","C144463","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Uterine Obstruction, CTCAE | Grade 1 Uterine obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542704","Grade 1 Uterine Pain, CTCAE","C144464","Mild pain","Grade 1 Uterine Pain, CTCAE | Grade 1 Uterine pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542705","Grade 1 Vaccination Complication, CTCAE","C144465","Mild pain; erythema 2.5-5cm; induration/swelling 2.5-5cm; does not interfere with activity","Grade 1 Vaccination Complication, CTCAE | Grade 1 Vaccination complication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542706","Grade 1 Vaccination Site Lymphadenopathy, CTCAE","C144466","Local lymph node enlargement","Grade 1 Vaccination Site Lymphadenopathy, CTCAE | Grade 1 Vaccination site lymphadenopathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542707","Grade 1 Vaginal Anastomotic Leak, CTCAE","C144467","Asymptomatic diagnostic finding; intervention not indicated","Grade 1 Vaginal Anastomotic Leak, CTCAE | Grade 1 Vaginal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542708","Grade 1 Vaginal Discharge, CTCAE","C144468","Mild vaginal discharge (greater than baseline for patient)","Grade 1 Vaginal Discharge, CTCAE | Grade 1 Vaginal discharge",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542694","Grade 1 Vaginal Inflammation, CTCAE","C144472","Mild discomfort or pain, edema, or redness","Grade 1 Vaginal Inflammation, CTCAE | Grade 1 Vaginal inflammation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL542695","Grade 1 Vaginal Obstruction, CTCAE","C144473","Asymptomatic; clinical or diagnostic observations only; intervention not indicated","Grade 1 Vaginal Obstruction, CTCAE | Grade 1 Vaginal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539139","Parathyroid Carcinoma Clinical Distant Metastasis TNM Finding v8","C141054","A clinical finding about one or more characteristics of parathyroid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Parathyroid Carcinoma Clinical Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539138","Parathyroid Carcinoma cM0 TNM Finding v8","C141055","No distant metastasis. (from AJCC 8th Ed.)","Parathyroid Carcinoma cM0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539137","Parathyroid Carcinoma cM1 TNM Finding v8","C141056","Distant metastasis. (from AJCC 8th Ed.)","Parathyroid Carcinoma cM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539135","Parathyroid Carcinoma Pathologic Distant Metastasis TNM Finding v8","C141058","A pathologic finding about one or more characteristics of parathyroid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Parathyroid Carcinoma Pathologic Distant Metastasis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539134","Parathyroid Carcinoma pM1 TNM Finding v8","C141059","Distant metastasis. (from AJCC 8th Ed.)","Parathyroid Carcinoma pM1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518793","PKC Binding Site","C14105","No value exists.","PKC Binding Site | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539133","Parathyroid Carcinoma Pathologic Primary Tumor TNM Finding v8","C141060","A pathologic finding about one or more characteristics of parathyroid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.","Parathyroid Carcinoma Pathologic Primary Tumor TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539117","Parathyroid Carcinoma pTX TNM Finding v8","C141061","Primary tumor cannot be assessed. (from AJCC 8th Ed.)","Parathyroid Carcinoma pTX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539116","Parathyroid Carcinoma pT0 TNM Finding v8","C141062","No evidence of primary tumor. (from AJCC 8th Ed.)","Parathyroid Carcinoma pT0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539115","Parathyroid Carcinoma pTis TNM Finding v8","C141063","Atypical parathyroid neoplasm (neoplasm of uncertain malignant potential). (from AJCC 8th Ed.)","Parathyroid Carcinoma pTis TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539114","Parathyroid Carcinoma pT1 TNM Finding v8","C141064","Tumor localized to the parathyroid gland with extension limited to soft tissue. (from AJCC 8th Ed.)","Parathyroid Carcinoma pT1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539113","Parathyroid Carcinoma pT2 TNM Finding v8","C141065","Tumor with direct invasion into the thyroid gland. (from AJCC 8th Ed.)","Parathyroid Carcinoma pT2 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539111","Parathyroid Carcinoma pT4 TNM Finding v8","C141067","Tumor with direct invasion into major blood vessel or spine. (from AJCC 8th Ed.)","Parathyroid Carcinoma pT4 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539110","Parathyroid Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8","C141068","A pathologic finding about one or more characteristics of parathyroid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Parathyroid Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539125","Parathyroid Carcinoma pNX TNM Finding v8","C141069","Regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Parathyroid Carcinoma pNX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514490","Proline-Rich Domain","C14106","Proline-Rich Domains may be involved in heterotypic protein-protein interactions in signal transduction or other pathways. Found in signaling and structural proteins, WW domains are composed of approximately 40 amino acids folded as a stable, triple stranded beta-sheet that recognize proline-rich sequences. Some WW domains show a remarkable similarity to SH3 domains, which also appear to recognize some proline-rich sequences. Ena/VASP (Drosophila Enabled/Vasodilator-Stimulated Phosphoprotein) Family members regulate actin filament assembly, often through association with binding partners that display a proline-rich FPPPP motif. Ena/VASP proteins interact with these partners via the highly conserved Ena/VASP homology 1 (EVH1) domain. (NCI)","Proline-Rich Domain | Pro-Rich | Proline Rich Domain | Proline Rich Region | Proline-Rich Region",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539019","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma Clinical Regional Lymph Nodes TNM Finding v8","C140902","A clinical finding about one or more characteristics of papillary, follicular, Hurthle cell, poorly differentiated, and anaplastic thyroid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma Clinical Regional Lymph Nodes TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma Clinical Regional Lymph Nodes TNM Finding v8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539027","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma Pathologic Distant Metastasis TNM Finding v8","C140910","A pathologic finding about one or more characteristics of papillary, follicular, Hurthle cell, poorly differentiated, and anaplastic thyroid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.","Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma Pathologic Distant Metastasis TNM Finding v8 | Differentiated and Anaplastic Thyroid Carcinoma Pathologic Distant Metastasis TNM Finding v8 | Pathologic Distant Metastasis Status (pM)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539580","Estrogen Receptor Positive by Immunohistochemistry 51-60 Percent","C141472","An immunohistochemical staining finding indicating that 51-60 percent of the cells in a tissue sample are expressing estrogen receptor.","Estrogen Receptor Positive by Immunohistochemistry 51-60 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539579","Estrogen Receptor Positive by Immunohistochemistry 61-70 Percent","C141473","An immunohistochemical staining finding indicating that 61-70 percent of the cells in a tissue sample are expressing estrogen receptor.","Estrogen Receptor Positive by Immunohistochemistry 61-70 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539593","Estrogen Receptor Positive by Immunohistochemistry 71-80 Percent","C141474","An immunohistochemical staining finding indicating that 71-80 percent of the cells in a tissue sample are expressing estrogen receptor.","Estrogen Receptor Positive by Immunohistochemistry 71-80 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539592","Estrogen Receptor Positive by Immunohistochemistry 81-90 Percent","C141475","An immunohistochemical staining finding indicating that 81-90 percent of the cells in a tissue sample are expressing estrogen receptor.","Estrogen Receptor Positive by Immunohistochemistry 81-90 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539588","HER2/Neu Negative by Immunohistochemistry","C141480","A laboratory test result indicating the absence of HER2/Neu in a tissue sample using immunohistochemical staining.","HER2/Neu Negative by Immunohistochemistry | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539587","HER2/Neu Positive by Immunohistochemistry","C141481","An immunohistochemical staining finding indicating that cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.","HER2/Neu Positive by Immunohistochemistry | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539570","HER2/Neu Positive by Immunohistochemistry Less than 1 Percent","C141493","An immunohistochemical staining finding indicating that less than 1 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.","HER2/Neu Positive by Immunohistochemistry Less than 1 Percent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539056","Medullary Thyroid Carcinoma Clinical Regional Lymph Nodes TNM Finding v8","C141011","A clinical finding about one or more characteristics of medullary thyroid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","Medullary Thyroid Carcinoma Clinical Regional Lymph Nodes TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539055","Medullary Thyroid Carcinoma cNX TNM Finding v8","C141012","Regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","Medullary Thyroid Carcinoma cNX TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539164","Medullary Thyroid Carcinoma cN0 TNM Finding v8","C141013","No evidence of locoregional lymph node metastasis. (from AJCC 8th Ed.)","Medullary Thyroid Carcinoma cN0 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539163","Medullary Thyroid Carcinoma cN0b TNM Finding v8","C141014","No radiologic or clinical evidence of locoregional lymph node metastasis. (from AJCC 8th Ed.)","Medullary Thyroid Carcinoma cN0b TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL539162","Medullary Thyroid Carcinoma cN1 TNM Finding v8","C141015","Metastasis to regional nodes. (from AJCC 8th Ed.)","Medullary Thyroid Carcinoma cN1 TNM Finding v8 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544893","CDKN2A NM_000077.4:c.152T>A","C146929","A nucleotide substitution at position 152 of the coding sequence of the CDKN2A gene where thymine has been mutated to adenine.","CDKN2A NM_000077.4:c.152T>A | CDK4I c.152T>A | CDKN2 c.152T>A | CDKN2A c.152T>A | Cyclin Dependent Kinase Inhibitor 2A c.152T>A | INK4A c.152T>A | MLM c.152T>A | MTS-1 c.152T>A | MTS1 c.152T>A | NM_000077.4:c.152T>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544879","CDKN2A NM_000077.4:c.151G>A","C146931","A nucleotide substitution at position 151 of the coding sequence of the CDKN2A gene where guanine has been mutated to adenine.","CDKN2A NM_000077.4:c.151G>A | CDK4I c.151G>A | CDKN2 c.151G>A | CDKN2A c.151G>A | Cyclin Dependent Kinase Inhibitor 2A c.151G>A | INK4A c.151G>A | MLM c.151G>A | MTS-1 c.151G>A | MTS1 c.151G>A | NM_000077.4:c.151G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544881","CDKN2A NM_000077.4:c.247C>T","C146933","A nucleotide substitution at position 247 of the coding sequence of the CDKN2A gene where cytosine has been mutated to thymine.","CDKN2A NM_000077.4:c.247C>T | CDK4I c.247C>T | CDKN2 c.247C>T | CDKN2A c.247C>T | Cyclin Dependent Kinase Inhibitor 2A c.247C>T | INK4A c.247C>T | MLM c.247C>T | MTS-1 c.247C>T | MTS1 c.247C>T | NM_000077.4:c.247C>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544883","CDKN2A NM_000077.4:c.248A>C","C146935","A nucleotide substitution at position 248 of the coding sequence of the CDKN2A gene where adenine has been mutated to cytosine.","CDKN2A NM_000077.4:c.248A>C | CDK4I c.248A>C | CDKN2 c.248A>C | Cyclin Dependent Kinase Inhibitor 2A c.248A>C | INK4A c.248A>C | MLM c.248A>C | MTS-1 c.248A>C | MTS1 c.248A>C | NM_000077.4:c.248A>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545508","TSCC - Crying","C147712","Trauma Symptom Checklist for Children (TSCC) Crying.","TSCC - Crying | TSCC01-Crying | TSCC0114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545509","TSCC - Getting Scared All of Sudden","C147713","Trauma Symptom Checklist for Children (TSCC) Getting scared all of a sudden and don't know why.","TSCC - Getting Scared All of Sudden | TSCC01-Getting Scared All of Sudden | TSCC0115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545494","TSCC - Getting Mad and Can't Calm Down","C147714","Trauma Symptom Checklist for Children (TSCC) Getting mad and can't calm down.","TSCC - Getting Mad and Can't Calm Down | TSCC01-Getting Mad and Can't Calm Down | TSCC0116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545495","TSCC - Thinking About Having Sex","C147715","Trauma Symptom Checklist for Children (TSCC) Thinking about having sex.","TSCC - Thinking About Having Sex | TSCC01-Thinking About Having Sex | TSCC0117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545496","TSCC - Feeling Dizzy","C147716","Trauma Symptom Checklist for Children (TSCC) Feeling dizzy.","TSCC - Feeling Dizzy | TSCC01-Feeling Dizzy | TSCC0118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545497","TSCC - Wanting to Yell at People","C147717","Trauma Symptom Checklist for Children (TSCC) Wanting to yell at people.","TSCC - Wanting to Yell at People | TSCC01-Wanting to Yell at People | TSCC0119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545498","TSCC - Wanting to Hurt Myself","C147718","Trauma Symptom Checklist for Children (TSCC) Wanting to hurt myself.","TSCC - Wanting to Hurt Myself | TSCC01-Wanting to Hurt Myself | TSCC0120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545499","TSCC - Wanting to Hurt Other People","C147719","Trauma Symptom Checklist for Children (TSCC) Wanting to hurt other people.","TSCC - Wanting to Hurt Other People | TSCC01-Wanting to Hurt Other People | TSCC0121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545500","TSCC - Think Touch People Private Parts","C147720","Trauma Symptom Checklist for Children (TSCC) Thinking about touching other people's private parts.","TSCC - Think Touch People Private Parts | TSCC01-Think Touch People Private Parts | TSCC0122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545027","AMG 701","C147028","A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17), fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of pavurutamab, this bispecific antibody binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA found on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated cell death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.","Pavurutamab | AMG 701 | AMG-701 | AMG701 | Anti-BCMA x Anti-CD3 BiTE AMG 701 | Anti-BCMA/CD3 BiTE Antibody AMG 701 | BCMA/CD3-directed Bispecific T-cell Engager Antibody AMG 701 | BiTE Antibody AMG 701 | Bispecific T-cell Engager Antibody AMG 701 | PAVURUTAMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545028","Antibody-drug Conjugate SC-007","C147029","An antibody-drug conjugate (ADC) composed of a monoclonal antibody against an undisclosed tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of SC-007 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.","Antibody-drug Conjugate SC-007 | ADC SC-007 | SC-007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545029","GDC-49545","C147030","An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, giredestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.","Giredestrant | GDC 9545 | GDC-49545 | GIREDESTRANT | RG6171 | SERD GDC-9545 | Selective Estrogen Receptor Degrader GDC-9545 | Selective Estrogen Receptor Downregulator GDC-9545",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545030","Anti-MUC16/MMAE Antibody-Drug Conjugate DMUC4064A","C147031","An antibody-drug conjugate (ADC) composed of a monoclonal antibody against human mucin 16 (MUC16; cancer antigen 125; CA125; FLJ14303) conjugated to monomethyl auristatin E (MMAE), an auristatin derivative and potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, anti-MUC16/MMAE ADC DMUC4064A binds to MUC16 located on the tumor cell surface. After internalization of the agent, the MMAE moiety is released and binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and apoptosis. MUC16, a member of the mucin family glycoproteins, is overexpressed in a variety of tumor cells and plays a key role in tumor cell proliferation.","Anti-MUC16/MMAE Antibody-Drug Conjugate DMUC4064A | ADC DMUC4064A | DMUC-4064A | DMUC4064A | RG7882 | THIOMAB-drug Conjugate DMUC4064A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545471","FACT-BMT Version 4 - I Worry About Dying","C147611","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I worry about dying.","FACT-BMT Version 4 - I Worry About Dying | FAC061-I Worry About Dying | FAC06119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545472","FACT-BMT Version 4 - Worry My Condition Will Get Worse","C147612","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I worry that my condition will get worse.","FACT-BMT Version 4 - Worry My Condition Will Get Worse | FAC061-Worry My Condition Will Get Worse | FAC06120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545473","FACT-BMT Version 4 - I Am Able to Work","C147613","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am able to work (include work at home).","FACT-BMT Version 4 - I Am Able to Work | FAC061-I Am Able to Work | FAC06121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545474","FACT-BMT Version 4 - My Work Is Fulfilling","C147614","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) My work (include work at home) is fulfilling.","FACT-BMT Version 4 - My Work Is Fulfilling | FAC061-My Work Is Fulfilling | FAC06122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545475","FACT-BMT Version 4 - I Am Able to Enjoy Life","C147615","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am able to enjoy life.","FACT-BMT Version 4 - I Am Able to Enjoy Life | FAC061-I Am Able to Enjoy Life | FAC06123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545476","FACT-BMT Version 4 - I Have Accepted My Illness","C147616","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I have accepted my illness.","FACT-BMT Version 4 - I Have Accepted My Illness | FAC061-I Have Accepted My Illness | FAC06124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544884","CDK4I c.248_249AC>CT","C146936","A complex substitution where the nucleotide sequence at positions 248 and 249 of the coding sequence of the CDKN2A gene has changed from adenine-cytosine to cytosine-thymine.","CDKN2A NM_000077.4:c.248_249delinsCT | CDK4I c.248_249AC>CT | CDKN2 c.248_249AC>CT | CDKN2A NM_000077.4:c.248_249delACinsCT | CDKN2A NM_000077.4:c.248_249delACinsCT | CDKN2A c.248_249AC>CT | CDKN2A c.248_249delACinsCT | INK4A c.248_249AC>CT | MLM c.248_249AC>CT | MTS-1 c.248_249AC>CT | MTS1 c.248_249AC>CT | NM_000077.4:c.248_249AC>CT | NM_000077.4:c.248_249delACinsCT | NM_000077.4:c.248_249delinsCT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545051","Anti-NY-ESO-1 TCR LV-transduced Autologous T-Cells TAEST16001","C147135","A preparation of human autologous T-lymphocytes that are transduced with a lentiviral vector (LV) encoding an affinity-enhanced T-cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1, with potential immunostimulating and antineoplastic activities. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the anti-NY-ESO-1 TCR LV-transduced autologous T-cells TAEST16001 recognize and bind to NY-ESO-1-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of NY-ESO-1-positive tumor cells. NY-ESO-1, a tumor-associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types, and is not, or is minimally, expressed in normal, healthy cells.","Anti-NY-ESO-1 TCR LV-transduced Autologous T-Cells TAEST16001 | Anti-NY-ESO-1 TCR Transduced Autologous T Cells TAEST16001 | NY-ESO-1 Antigen Specific Affinity-enhanced TCR Transduced Autologous T Cells | TAEST 16001 | TAEST16001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545052","Harmonic Ace+7","C147136","A proprietary type of laparoscopic ultrasonic shears designed for secure sealing in vessel sizes up to and including 7mm diameter.","Harmonic Ace+7 | Harmonic Ace 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545053","Planned Number of Cohorts","C147137","The anticipated number of groups or cohorts that are part of the study.","Planned Number of Cohorts | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545054","Observational Study Model","C147138","The study design developed to assess biomedical and/or health outcomes in pre-defined groups of individuals that are not assigned an intervention by the investigator.","Observational Study Model | Observation Model | Observational Study Design",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545055","Study Design Description","C147139","A summary of the components of study design employed for the study including, but not limited to, interventions, study populations, blinding, treatment assignment methods, etc.","Study Design Description | Overall Design | Overall Study Design | Study Design Overview | Summary of Study Design",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545056","Randomization Method","C147140","The type of randomization method used to assign subjects to treatment groups or cohorts.","Randomization Method | Randomization Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545057","Study Primary Purpose","C147141","The principal reason or intention for the execution of an interventional or non-interventional clinical study.","Study Primary Purpose | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545058","Study Secondary Purpose","C147142","The ancillary reason or intention for the execution of an interventional or non-interventional clinical study.","Study Secondary Purpose | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545163","Minimization Randomization","C147143","A type of adaptive randomization schema in which the subject is assigned to the group that has the lowest imbalance score at the time of that particular subject's randomization. If all groups have low imbalance scores, then the subject is randomly assigned to one of the groups.","Minimization Randomization | Covariate Adaptive Randomization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545164","Simple Randomization","C147144","A type of randomization schema in which each subject has the same chance of being randomized into any one group as all other subjects. The assignment of the previous subject has no bearing on how the current subject will be assigned.","Simple Randomization | Unrestricted Randomization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545614","TSCC - Feeling Scared of Men","C147722","Trauma Symptom Checklist for Children (TSCC) Feeling scared of men.","TSCC - Feeling Scared of Men | TSCC01-Feeling Scared of Men | TSCC0124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545615","TSCC - Feeling Scared of Women","C147723","Trauma Symptom Checklist for Children (TSCC) Feeling scared of women.","TSCC - Feeling Scared of Women | TSCC01-Feeling Scared of Women | TSCC0125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545616","TSCC - Washing Myself Because Feel Dirty","C147724","Trauma Symptom Checklist for Children (TSCC) Washing myself because I feel dirty on the inside.","TSCC - Washing Myself Because Feel Dirty | TSCC01-Washing Myself Because Feel Dirty | TSCC0126",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545617","TSCC - Feeling Stupid or Bad","C147725","Trauma Symptom Checklist for Children (TSCC) Feeling stupid or bad.","TSCC - Feeling Stupid or Bad | TSCC01-Feeling Stupid or Bad | TSCC0127",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545618","TSCC - Feeling Like Did Something Wrong","C147726","Trauma Symptom Checklist for Children (TSCC) Feeling like I did something wrong.","TSCC - Feeling Like Did Something Wrong | TSCC01-Feeling Like Did Something Wrong | TSCC0128",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545619","TSCC - Feeling Like Things Aren't Real","C147727","Trauma Symptom Checklist for Children (TSCC) Feeling like things aren't real.","TSCC - Feeling Like Things Aren't Real | TSCC01-Feeling Like Things Aren't Real | TSCC0129",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545620","TSCC - Forgetting Things","C147728","Trauma Symptom Checklist for Children (TSCC) Forgetting things, can't remember things.","TSCC - Forgetting Things | TSCC01-Forgetting Things | TSCC0130",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545621","TSCC - Feeling Like I'm Not in My Body","C147729","Trauma Symptom Checklist for Children (TSCC) Feeling like I'm not in my body.","TSCC - Feeling Like I'm Not in My Body | TSCC01-Feeling Like I'm Not in My Body | TSCC0131",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545606","TSCC - Feeling Nervous or Jumpy Inside","C147730","Trauma Symptom Checklist for Children (TSCC) Feeling nervous or jumpy inside.","TSCC - Feeling Nervous or Jumpy Inside | TSCC01-Feeling Nervous or Jumpy Inside | TSCC0132",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544980","GNAS NM_000516.5:c.601C>A","C146961","A nucleotide substitution at position 601 of the coding sequence of the GNAS gene where cytosine has been mutated to adenine.","GNAS NM_000516.5:c.601C>A | GNAS Complex Locus Gene c.601C>A | GNAS c.601C>A | GNAS1 c.601C>A | GSA c.601C>A | GSP c.601C>A | NM_000516.5:c.601C>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544966","GNAS NM_000516.5:c.680A>G","C146963","A nucleotide substitution at position 680 of the coding sequence of the GNAS gene where adenine has been mutated to guanine.","GNAS NM_000516.5:c.680A>G | GNAS Complex Locus Gene c.680A>G | GNAS c.680A>G | GNAS1 c.680A>G | GSA c.680A>G | GSP c.680A>G | NM_000516.5:c.680A>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544968","GNAS NM_000516.5:c.680A>T","C146965","A nucleotide substitution at position 680 of the coding sequence of the GNAS gene where adenine has been mutated to thymine.","GNAS NM_000516.5:c.680A>T | GNAS Complex Locus Gene c.680A>T | GNAS c.680A>T | GNAS1 c.680A>T | GSA c.680A>T | GSP c.680A>T | NM_000516.5:c.680A>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0209891","Bizelesin","C1472","A synthetic cyclopropylpyrroloindole antineoplastic antibiotic.  Bizelesin binds to the minor groove of DNA and induces interstrand cross-linking of DNA, thereby inhibiting DNA replication and RNA synthesis.  Bizelesin also enhances p53 and p21 induction and triggers G2/M cell-cycle arrest, resulting in cell senescence without apoptosis. (NCI04)","Bizelesin | BIZELESIN | Benzo(1,2-b:4,3-b')dipyrrol-4-ol, 6,6'-(carbonylbis(imino-1H-indole-5,2-diylcarbonyl))bis(8-(chloromethyl)-3,6,7,8-tetrahydro-1-methyl-, (S-(R*,R*)))- | Benzo[1,2-b:4,3-b']dipyrrol-4-ol, 6, 6'-[carbonylbis(imino- 1H-indole-5, 2-diylcarbonyl)]bis[8-(chloromethyl)-3,6,7,8-tetrahydro-1-methyl-, (S-(R*,R*))] | U-77779 | bizelesin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545477","FACT-BMT Version 4 - I Am Sleeping Well","C147617","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am sleeping well.","FACT-BMT Version 4 - I Am Sleeping Well | FAC061-I Am Sleeping Well | FAC06125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545462","FACT-BMT Version 4 - Enjoy Things I Usually Do for Fun","C147618","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am enjoying the things I usually do for fun.","FACT-BMT Version 4 - Enjoy Things I Usually Do for Fun | FAC061-Enjoy Things I Usually Do for Fun | FAC06126",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545463","FACT-BMT Version 4 - Content With Quality of My Life","C147619","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am content with the quality of my life right now.","FACT-BMT Version 4 - Content With Quality of My Life | FAC061-Content With Quality of My Life | FAC06127",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545464","FACT-BMT Version 4 - I Am Concerned About Keeping Job","C147620","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am concerned about keeping my job (include work at home).","FACT-BMT Version 4 - I Am Concerned About Keeping Job | FAC061-I Am Concerned About Keeping Job | FAC06128",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545466","FACT-BMT Version 4 - I Worry Transplant Will Not Work","C147622","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I worry that the transplant will not work.","FACT-BMT Version 4 - I Worry Transplant Will Not Work | FAC061-I Worry Transplant Will Not Work | FAC06130",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545467","FACT-BMT Version 4 - Side Effect of Treatment Worse","C147623","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) The side effects of treatment are worse than I had imagined.","FACT-BMT Version 4 - Side Effect of Treatment Worse | FAC061-Side Effect of Treatment Worse | FAC06131",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545468","FACT-BMT Version 4 - I Have a Good Appetite","C147624","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I have a good appetite.","FACT-BMT Version 4 - I Have a Good Appetite | FAC061-I Have a Good Appetite | FAC06132",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545469","FACT-BMT Version 4 - I Like the Appearance of My Body","C147625","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I like the appearance of my body.","FACT-BMT Version 4 - I Like the Appearance of My Body | FAC061-I Like the Appearance of My Body | FAC06133",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545454","FACT-BMT Version 4 - I Am Able to Get Around by Myself","C147626","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am able to get around by myself.","FACT-BMT Version 4 - I Am Able to Get Around by Myself | FAC061-I Am Able to Get Around by Myself | FAC06134",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1863052","PRESENILE AND SENILE DEMENTIA","C146894","Alzheimer's disease caused by mutation(s) in the APP gene, encoding amyloid-beta A4 protein. The onset of this condition typically occurs before age 65.","Alzheimer's Disease 1 | AD1 | Familial Alzheimer's Disease, Type 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544922","TP53 NM_000546.5:c.733G>A","C146895","A nucleotide substitution at position 733 of the coding sequence of the TP53 gene where guanine has been mutated to adenine.","TP53 NM_000546.5:c.733G>A | LFS1 c.733G>A | Li-Fraumeni Syndrome c.733G>A | NM_000546.5:c.733G>A | P53 c.733G>A | TP53 c.733G>A | Tumor Protein p53 c.733G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544971","GNAS NM_000516.5:c.679C>G","C146968","A nucleotide substitution at position 679 of the coding sequence of the GNAS gene where cytosine has been mutated to guanine.","GNAS NM_000516.5:c.679C>G | GNAS Complex Locus Gene c.679C>G | GNAS c.679C>G | GNAS1 c.679C>G | GSA c.679C>G | GSP c.679C>G | NM_000516.5:c.679C>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545233","Food and Water Consumption Supplemental Qualifiers Dataset","C147214","A dataset containing supplemental information, specifically non-standard variables, to parent records in the food and water consumption domain.","Food and Water Consumption Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545218","Fetal Pathology Findings Supplemental Qualifiers Dataset","C147215","A dataset containing supplemental information, specifically non-standard variables, to parent records in the fetal pathology findings domain.","Fetal Pathology Findings Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545220","Implantation Classification Supplemental Qualifiers Dataset","C147217","A dataset containing supplemental information, specifically non-standard variables, to parent records in the implantation classification domain.","Implantation Classification Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545221","Inclusion/Exclusion Criteria Not Met Supplemental Qualifiers Dataset","C147218","A dataset containing supplemental information, specifically non-standard variables, to parent records in the inclusion/exclusion criteria not met domain.","Inclusion/Exclusion Criteria Not Met Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545222","Immunogenicity Specimen Assessments Supplemental Qualifiers Dataset","C147219","A dataset containing supplemental information, specifically non-standard variables, to parent records in the immunogenicity specimen assessments domain.","Immunogenicity Specimen Assessments Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545223","Laboratory Test Results Supplemental Qualifiers Dataset","C147220","A dataset containing supplemental information, specifically non-standard variables, to parent records in the laboratory test results domain.","Laboratory Test Results Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3711664","ARHGEF10 protein, human","C147568","Rho guanine nucleotide exchange factor 10 (1369 aa, ~152 kDa) is encoded by the human ARHGEF10 gene. This protein plays a role in guanine nucleotide exchange and peripheral nerve myelination.","Rho Guanine Nucleotide Exchange Factor 10 | ARHGEF10 | Gef10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545401","ARHGEF10L Gene","C147569","This gene is involved in guanine nucleotide exchange for Rho family GTPases.","ARHGEF10L Gene | ARHGEF10L | Rho Guanine Nucleotide Exchange Factor 10 Like Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545387","ARHGEF10L wt Allele","C147570","Human ARHGEF10L wild-type allele is located in the vicinity of 1p36.13 and is approximately 178 kb in length. This allele, which encodes Rho guanine nucleotide exchange factor 10-like protein, plays a role in the regulation of Rho family GTPases.","ARHGEF10L wt Allele | FLJ10521 | GRINCHGEF | GrinchGEF | KIAA1626 | Rho Guanine Nucleotide Exchange Factor (GEF) 10-Like Gene | Rho Guanine Nucleotide Exchange Factor 10 Like wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3711663","ARHGEF10L protein, human","C147571","Rho guanine nucleotide exchange factor 10-like protein (1279 aa, ~140 kDa) is encoded by the human ARHGEF10L gene. This protein is involved in the regulation of Rho family-mediated signaling.","Rho Guanine Nucleotide Exchange Factor 10-Like Protein | ARHGEF10L | GrinchGEF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545389","BAZ1A Gene","C147572","This gene plays a role in nucleosome spacing.","BAZ1A Gene | BAZ1A | Bromodomain Adjacent to Zinc Finger Domain 1A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545390","BAZ1A wt Allele","C147573","Human BAZ1A wild-type allele is located within 14q13.1-q13.2 and is approximately 123 kb in length. This allele, which encodes bromodomain adjacent to zinc finger domain protein 1A, is involved in chromatin remodeling.","BAZ1A wt Allele | ACF1 | ACF1, Drosophila, Homolog of Gene | Bromodomain Adjacent to Zinc Finger Domain 1A wt Allele | Bromodomain Adjacent to Zinc Finger Domain, 1A Gene | HSPC317 | WALp1 | WCRF180 | hACF1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1309395","BAZ1A protein, human","C147574","Bromodomain adjacent to zinc finger domain protein 1A (1556 aa, ~179 kDa) is encoded by the human BAZ1A gene. This protein plays a role in ATP-dependent chromatin remodeling.","Bromodomain Adjacent to Zinc Finger Domain Protein 1A | ATP-Dependent Chromatin Remodeling Protein | ATP-Dependent Chromatin-Remodeling Protein | ATP-Utilizing Chromatin Assembly and Remodeling Factor 1 | BAZ1A | CHRAC Subunit ACF1 | WCRF180 | Williams Syndrome Transcription Factor-Related Chromatin-Remodeling Factor 180 | hACF1 | hWALp1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545394","ADC XMT-1536","C147577","A proprietary antibody-drug conjugate (ADC) composed of upinitatug , a proprietary, humanized monoclonal antibody against human sodium-dependent phosphate transport protein 2B (SLC34A2; NaPi2b), site-specifically linked, via a protease cleavable linker, to the proprietary cytotoxic aurastatin derivative auristatin F-HPA (AF-HPA; auristatin F-hydroxypropylamide), with potential antineoplastic activity. Upinitatug rilsodotin is produced via the proprietary dolaflexin ADC conjugation platform, which promotes the conjugation of between 10 and 15 AF-HPA payload molecules to each XMT-1535 antibody. Upon administration of upinitatug rilsodotin, the antibody moiety targets and binds to NaPi2b expressed on tumor cells. Upon binding, internalization by endosomes/lysosomes, and enzymatic cleavage, the AF-HPA binds to tubulin and inhibits microtubule polymerization, which results in G2/M phase arrest and apoptosis of NaPi2b-expressing tumor cells. NaPi2b, a tumor-associated antigen (TAA), is overexpressed on a variety of cancer cells and plays a key role in the transport of inorganic phosphate (Pi) and the maintenance of phosphate homeostasis.","Upinitatug Rilsodotin | ADC XMT-1536 | Anti-NaPi2b ADC XMT-1536 | Anti-NaPi2b/Auristatin F-HPA ADC XMT-1536 | UPIFITAMAB RILSODOTIN | UPINITATUG RILSODOTIN | Upifitamab Rilsodotin | Upifitamab Rilsodotin | XMT 1536 | XMT-1536 | XMT1536",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544909","Chimpanzee Trisomy 22","C146897","A condition resulting from the presence of an extra copy of chromosome 22 in chimpanzees. The condition is in many respects similar to Trisomy 21 in humans.","Chimpanzee Trisomy 22 | Chimpanzee Down Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544910","TP53 NM_000546.5:c.734G>A","C146898","A nucleotide substitution at position 734 of the coding sequence of the TP53 gene where guanine has been mutated to adenine.","TP53 NM_000546.5:c.734G>A | LFS1 c.734G>A | Li-Fraumeni Syndrome c.734G>A | NM_000546.5:c.734G>A | P53 c.734G>A | TP53 c.734G>A | Tumor Protein p53 c.734G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1313961","Trichothiodystrophy 4, Nonphotosensitive","C146899","A subtype of trichothiodystrophy caused by mutation(s) in the MPLKIP gene, encoding M-phase-specific PLK1-interacting protein.","Trichothiodystrophy 4, Nonphotosensitive | ",,,,,,,,,,,,,,,"4032876","Clastothrix",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL544912","TP53 NM_000546.5:c.743G>A","C146901","A nucleotide substitution at position 743 of the coding sequence of the TP53 gene where guanine has been mutated to adenine.","TP53 NM_000546.5:c.743G>A | LFS1 c.743G>A | Li-Fraumeni Syndrome c.743G>A | NM_000546.5:c.743G>A | P53 c.743G>A | TP53 c.743G>A | Tumor Protein p53 c.743G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544913","LFS1 c.743_744GG>AA","C146902","A complex substitution where the nucleotide sequence at positions 743 and 744 of the coding sequence of the TP53 gene has changed from guanine-guanine to adenine-adenine.","TP53 NM_000546.5:c.743_744delinsAA | LFS1 c.743_744GG>AA | LFS1 c.743_744delGGinsAA | Li-Fraumeni Syndrome c.743_744GG>AA | Li-Fraumeni Syndrome c.743_744delGGinsAA | NM_000546.5:c.743_744GG>AA | NM_000546.5:c.743_744delGGinsAA | NM_000546.5:c.743_744delinsAA | P53 c.743_744GG>AA | P53 c.743_744delGGinsAA | TP53 NM_000546.5:c.743_744GG>AA | TP53 NM_000546.5:c.743_744delGGinsAA | TP53 NM_000546.5:c.743_744delGGinsAA | TP53 c.743_744GG>AA | TP53 c.743_744delGGinsAA | Tumor Protein p53 c.743_744GG>AA | Tumor Protein p53 c.743_744delGGinsAA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1432488","TRPM6 protein, human","C147084","Transient receptor potential cation channel subfamily M member 6 (2022 aa, ~232 kDa) is encoded by the human TRPM6 gene. This protein plays a role in serine/threonine phosphorylation and magnesium absorption in the gut and kidney.","Transient Receptor Potential Cation Channel Subfamily M Member 6 | Channel Kinase 2 | EC 2.7.11.1 | Melastatin-Related TRP Cation Channel 6 | TRPM6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545542","FACIT-Dyspnea 10 Item Short Form - Part II: Preparing Meals","C147666","Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part II Functional Limitation. Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Preparing meals.","FACIT-Dyspnea 10 Item Short Form - Part II: Preparing Meals | FAC084-Part II: Preparing Meals | FAC08424",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545543","FACIT-Dyspnea 10 Item Short Form - Part II: Washing Dishes","C147667","Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part II Functional Limitation. Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Washing dishes.","FACIT-Dyspnea 10 Item Short Form - Part II: Washing Dishes | FAC084-Part II: Washing Dishes | FAC08425",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545544","FACIT-Dyspnea 10 Item Short Form - Part II: Sweeping/Mopping","C147668","Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part II Functional Limitation. Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Sweeping or mopping.","FACIT-Dyspnea 10 Item Short Form - Part II: Sweeping/Mopping | FAC084-Part II: Sweeping/Mopping | FAC08426",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545545","FACIT-Dyspnea 10 Item Short Form - Part II: Making a Bed","C147669","Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part II Functional Limitation. Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Making a bed.","FACIT-Dyspnea 10 Item Short Form - Part II: Making a Bed | FAC084-Part II: Making a Bed | FAC08427",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545546","FACIT-Dyspnea 10 Item Short Form - Part II: Lifting 10-20 Lbs","C147670","Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part II Functional Limitation. Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Lifting something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries).","FACIT-Dyspnea 10 Item Short Form - Part II: Lifting 10-20 Lbs | FAC084-Part II: Lifting 10-20 Lbs | FAC08428",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545547","FACIT-Dyspnea 10 Item Short Form - Part II: Carry 10-20 Lbs","C147671","Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part II Functional Limitation. Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Carrying something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries) from one room to another.","FACIT-Dyspnea 10 Item Short Form - Part II: Carry 10-20 Lbs | FAC084-Part II: Carry 10-20 Lbs | FAC08429",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545548","FACIT-Dyspnea 10 Item Short Form - Part II: Walk for 1/2 Mile","C147672","Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part II Functional Limitation. Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Walking (faster than your usual speed) for 1/2 mile (almost 1 km) without stopping.","FACIT-Dyspnea 10 Item Short Form - Part II: Walk for 1/2 Mile | FAC084-Part II: Walk for 1/2 Mile | FAC08430",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0599383","Marine Organism","C14333","Any organism that lives in the sea","Marine Organism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600466","Endogenous Retroviruses","C14334","Genetic elements propagated primarily through the germline, with a proviral structure, i.e. the chromosomally-integrated form of retroviruses and regulated by cellular processes.  Could be involved in development and serve as progenitors to pathogenic retroviruses.  Classified as ecotropic or xenotropic.  Ecotropic viruses can be transmitted to cells of the same species and can produce malignancies. Xenotropic viruses cannot infect cells from their host species but are infectious in heterologous species.  Cycles of transcription and reverse transcription make the elements mobile and mutagenic.","Endogenous Retrovirus | ENDOGENOUS RETROVIRUS | ERV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540706","Refractory B Acute Lymphoblastic Leukemia","C142812","B acute lymphoblastic leukemia that does not respond to treatment.","Refractory B Acute Lymphoblastic Leukemia | Refractory B-Cell Acute Lymphoblastic Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545380","Anti-NaPi2b MoAb XMT-1535","C147578","A proprietary humanized monoclonal antibody against human sodium-dependent phosphate transport protein 2B (SLC34A2; NaPi2b), with potential antineoplastic activity. Upon administration of upinitatug, the antibody targets and binds to NaPi2b expressed on tumor cells. Although the tumor cell killing effects of upinitatug are not established, this binding may induce an antibody-dependent cellular cytotoxicity (ADCC)-mediated immune response against NaPi2b-expressing tumor cells, and/or may inhibit NaPi2b-mediated sodium and phosphate ion cotransport activity and ion-dependent tumor cell signaling. NaPi2b, a tumor-associated antigen (TAA), is overexpressed on a variety of tumor cells. It plays a key role in the transport of inorganic phosphate (Pi) and the maintenance of phosphate homeostasis.","Upinitatug | Anti-NaPi2b MoAb XMT-1535 | Anti-NaPi2b Monoclonal Antibody XMT-1535 | MoAb XMT-1535 | UPIFITAMAB | UPINITATUG | Upifitamab | Upifitamab | XMT 1535 | XMT-1535 | XMT1535",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544823","Locally Advanced Epithelioid Hemangioendothelioma","C146857","An epithelioid hemangioendothelioma that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Epithelioid Hemangioendothelioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544824","Metastatic Epithelioid Hemangioendothelioma","C146858","An epithelioid hemangioendothelioma that has spread from its original site of growth to another anatomic site.","Metastatic Epithelioid Hemangioendothelioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544825","Anti-CD3/Anti-BCMA Bispecific Antibody PF-06863135","C146860","A bispecific monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, with potential antineoplastic activity. Upon administration, elranatamab binds to both CD3 on T-cells and BCMA expressed on malignant plasma cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against BCMA-expressing plasma cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.","Elranatamab | Anti-CD3/Anti-BCMA Bispecific Antibody PF-06863135 | B-cell Maturation Antigen-CD3 Bispecific Antibody PF-06863135 | BCMA x CD3 Bispecific Antibody PF-06863135 | BCMA-CD3 Bispecific Ab PF-06863135 | ELRANATAMAB | Elranatamab-bcmm | Elrexfio | PF 06863135 | PF-06863135 | PF06863135 | RN 613 | RN-613 | RN613",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544826","Mediastinal Mixed Germ Cell Tumor","C146861","A malignant germ cell tumor that arises from the mediastinum. It is characterized by the presence of at least two different germ cell tumor components. The different germ cell tumor components include choriocarcinoma, embryonal carcinoma, yolk sac tumor, teratoma, and seminoma.","Mediastinal Mixed Germ Cell Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544827","Anti-TGF-beta Monoclonal Antibody SAR-439459","C146862","A monoclonal antibody (mAb) directed against human transforming growth factor beta (TGF-beta; TGFb), with potential antineoplastic activity. Upon administration, anti-TGF-beta monoclonal antibody SAR-439459 specifically targets and binds to TGF-beta, thereby preventing the activation of TGF-beta-mediated signaling pathways. This may inhibit the proliferation of tumor cells in which TGF-beta is overactivated. TGF-beta, a pro-inflammatory mediator that is mutated and/or overexpressed in a variety of cancer cell types, is involved in cancer cell proliferation and migration, and in tumor progression.","Anti-TGF-beta Monoclonal Antibody SAR-439459 | Anti-TGFb SAR-439459 | Anti-transforming Growth Factor-beta mAb SAR439459 | SAR 439459 | SAR-439459 | SAR439459",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544829","ALK NM_004304.4:c.3522C>G","C146864","A nucleotide substitution at position 3522 of the coding sequence of the ALK gene where cytosine has been mutated to guanine.","ALK NM_004304.4:c.3522C>G | ALK Receptor Tyrosine Kinase c.3522C>G | ALK c.3522C>G | Anaplastic Lymphoma Kinase (Ki-1) c.3522C>G | Anaplastic Lymphoma Receptor Tyrosine Kinase c.3522C>G | CD246 c.3522C>G | NM_004304.4:c.3522C>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544814","ALK NM_004304.4:c.3522C>A","C146865","A nucleotide substitution at position 3522 of the coding sequence of the ALK gene where cytosine has been mutated to adenine.","ALK NM_004304.4:c.3522C>A | ALK Receptor Tyrosine Kinase c.3522C>A | ALK c.3522C>A | Anaplastic Lymphoma Kinase (Ki-1) c.3522C>A | Anaplastic Lymphoma Receptor Tyrosine Kinase c.3522C>A | CD246 c.3522C>A | NM_004304.4:c.3522C>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545095","Cardiac Angiosarcoma","C147097","An angiosarcoma that arises from the heart. It most often arises in the right atrium near the atrioventricular groove. The prognosis is poor.","Cardiac Angiosarcoma | Heart Angiosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545096","Pericardial Sarcoma","C147098","A rare sarcoma that arises from the pericardium. The two most common types are angiosarcoma and synovial sarcoma. Patients present with symptoms related to pericardial effusion.","Pericardial Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0209660","Loxoribine","C1470","A guanine ribonucleotide derivative with immunostimulatory and immunomodulatory activity. Loxoribine undergoes facilitated transport across the plasma membrane into the cytoplasmic compartment of the cell and acts intracellularly, bypassing the biochemical steps involved in the membrane signal transduction pathway used by Ag or anti-IgM Abs to activate B cells. This agent activates the Toll-like receptor 7 (TLR7), a member of the TLR family of pathogen-associated molecular pattern recognition receptors thereby activating the innate immune system. This activation requires endosomal maturation and recognition is restricted to TLR7. As a result, loxoribine induces cycling B cells to proliferate and differentiate non-specifically and recruit antigen-reactive B cells to undergo differentiation to antibody production, markedly amplifying the underlying response in the process.","Loxoribine | 7-Allyl-8-oxoguanosine | LOXORIBINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545082","Pericardial Synovial Sarcoma","C147102","A rare synovial sarcoma that arises from the pericardium. Patients present with symptoms related to pericardial effusion.","Pericardial Synovial Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545083","Pericardial Teratoma","C147103","A teratoma that arises within the pericardium.","Pericardial Teratoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545549","FAC070-I Feel Fatigued","C147673","Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 (FACIT-Fatigue 13-Item Version 4) I feel fatigued.","FACIT-Fatigue 13-Item Version 4 - I Feel Fatigued | FAC070-I Feel Fatigued | FAC07001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545535","FAC070-I Feel Listless","C147675","Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 (FACIT-Fatigue 13-Item Version 4) I feel listless ('washed out').","FACIT-Fatigue 13-Item Version 4 - I Feel Listless | FAC070-I Feel Listless | FAC07003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545536","FAC070-I Feel Tired","C147676","Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 (FACIT-Fatigue 13-Item Version 4) I feel tired.","FACIT-Fatigue 13-Item Version 4 - I Feel Tired | FAC070-I Feel Tired | FAC07004",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545537","FAC070-Trouble Starting Things","C147677","Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 (FACIT-Fatigue 13-Item Version 4) I have trouble starting things because I am tired.","FACIT-Fatigue 13-Item Version 4 - Trouble Starting Things | FAC070-Trouble Starting Things | FAC07005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545538","FAC070-Trouble Finishing Things","C147678","Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 (FACIT-Fatigue 13-Item Version 4) I have trouble finishing things because I am tired.","FACIT-Fatigue 13-Item Version 4 - Trouble Finishing Things | FAC070-Trouble Finishing Things | FAC07006",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544885","Autologous PBLs Retrovirally-transduced with TCRs Targeting Neoantigens","C146937","Autologous human peripheral blood lymphocytes (PBLs) transduced with a retroviral vector encoding T-cell receptors (TCRs) specific for a patient's individual and unique mutated antigens, with potential immunostimulating and antineoplastic activities. Tumor cells are analyzed to identify and isolate specific mutated tumor-associated antigens (TAAs) that are expressed by the patient's tumor cells; then T-cell receptor coding sequences are engineered to target the patient's TAAs and inserted into retroviral vectors. After transduction, expansion in culture, and reintroduction into the patient, neoantigen-specific TCRs retroviral vector-transduced autologous PBLs recognize and bind to tumor cells expressing the patient's neoantigens, which results in a specific cytotoxic T-lymphocyte (CTL)-mediated immune response against the patient's tumor cells.","Autologous PBLs Retrovirally-transduced with TCRs Targeting Neoantigens | Autologous PBLs Expressing Mutated Neoantigen-specific T-Cell Receptors | Autologous Peripheral Blood Lymphocytes Retrovirally-transduced with TCRs Targeting Neoantigens | Neoantigen-reactive TCRs-transduced Autologous PBLs | Neoantigen-specific TCRs Gene-transduced Autologous PBLs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540705","CD44 Targeted Agent SPL-108","C142813","A proprietary agent that targets the cancer stem cell (CSC) antigen CD44, with potential antineoplastic activity. Although the mechanism of action has not been elucidated, following subcutaneous administration, CD44 targeted agent SPL-108 binds to CD44 and prevents the activation of various CD44-mediated signal transduction pathways, which may lead to reduced proliferation of CD44-expressing tumor stem cells. CD44, a transmembrane glycoprotein and hyaluronic acid receptor, is expressed in healthy tissue and overexpressed in numerous cancer cell types; it plays a key role in the proliferation, migration and survival of tumor cells.","CD44 Targeted Agent SPL-108 | SPL 108 | SPL-108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540718","Autologous Dendritic Cells Pulsed with MART-1 (26-35) Peptide","C142814","A cell-based vaccine consisting of autologous HLA-A2*0201-restricted dendritic cells (DC), which were derived from patient-harvested adherent peripheral blood monocytes cultured in vitro with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4), that were pulsed with a peptide fragment comprised of amino acid residues 26 through 35 of melanoma antigen recognized by T-cells 1 (MART-1 (26-35)), with potential immunostimulatory and antineoplastic activities. Upon intradermal vaccination, autologous DC pulsed with MART-1 (26-35) peptide may stimulate the host immune system to mount a cytotoxic T-lymphocyte immune response against tumor cells expressing MART-1. MART-1, a protein involved in melanosome biogenesis, is overexpressed by melanoma cells. The MART-1 (26-35) peptide is highly immunogenic for the HLA-A2*0201 haplotype.","Autologous Dendritic Cells Pulsed with MART-1 (26-35) Peptide | Autologous MART-1 (26-35) Peptide Pulsed DC Vaccine | Autologous MART-1 (26-35) Peptide Pulsed Dendritic Cell Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540713","Breast Cancer Locator","C142819","A 3D-printed form that matches a patient's breast shape while in the supine MRI and surgical position. The form includes an outline of the breast cancer on the breast surface, at the point where the cancer is closest to the skin, and includes cylinders for precise placement of marker dye and a marker wire.","Breast Cancer Locator | BCL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540712","Anti-TIGIT OMP-313M32","C142821","A monoclonal antibody targeting the human co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, etigilimab binds to TIGIT expressed on various immune cells, including T-cells, and prevents the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8-positive T-cells, and leads to CD226 dimerization and CD226-mediated signaling. This activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion and the inhibition of antiviral immune responses.","Etigilimab | Anti-TIGIT OMP-313M32 | ETIGILIMAB | Immunoglobulin G1, Anti-(Human Receptor TIGIT(T-cell Immunoreceptor with Ig and iTIM Domains)) (Humanized Mouse Monoclonal OMP-313M32 Gamma1-chain), Disulfide with Humanized Mouse Monoclonal OMP-313M32 Kappa-chain, Dimer | OMP 313M32 | OMP-313M32 | WHO 10742",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544815","ALK NM_004304.4:c.3520T>C","C146866","A nucleotide substitution at position 3520 of the coding sequence of the ALK gene where thymine has been mutated to cytosine.","ALK NM_004304.4:c.3520T>C | ALK Receptor Tyrosine Kinase c.3520T>C | ALK c.3520T>C | Anaplastic Lymphoma Kinase (Ki-1) c.3520T>C | Anaplastic Lymphoma Receptor Tyrosine Kinase c.3520T>C | CD246 c.3520T>C | NM_004304.4:c.3520T>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544817","ALK NM_004304.4:c.3521T>G","C146868","A nucleotide substitution at position 3521 of the coding sequence of the ALK gene where thymine has been mutated to guanine.","ALK NM_004304.4:c.3521T>G | ALK Receptor Tyrosine Kinase c.3521T>G | ALK c.3521T>G | Anaplastic Lymphoma Kinase (Ki-1) c.3521T>G | Anaplastic Lymphoma Receptor Tyrosine Kinase c.3521T>G | CD246 c.3521T>G | NM_004304.4:c.3521T>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545012","Refractory Chemotherapy-Induced Nausea and Vomiting","C147045","Chemotherapy-induced nausea and vomiting that does not respond to treatment.","Refractory Chemotherapy-Induced Nausea and Vomiting | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545013","ENPP3 Gene","C147046","This gene plays a role in phosphonucleotide metabolism.","ENPP3 Gene | ENPP3 | Ectonucleotide Pyrophosphatase/Phosphodiesterase 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545014","ENPP3 wt Allele","C147047","Human ENPP3 wild-type allele is located in the vicinity of 6q23.2 and is approximately 119 kb in length. This allele, which encodes ectonucleotide pyrophosphatase/phosphodiesterase family member 3 protein, is involved in the hydrolysis of phosphodiester and phosphosulfate bonds.","ENPP3 wt Allele | B10 | CD203c | DJ1005H11.3 | DJ914N13.3 | Ectonucleotide Pyrophosphatase/Phosphodiesterase 3 wt Allele | NPP3 | PD-IBETA | PDNP3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544873","CDKN2A NM_000077.4:c.322G>C","C146941","A nucleotide substitution at position 322 of the coding sequence of the CDKN2A gene where guanine has been mutated to cytosine.","CDKN2A NM_000077.4:c.322G>C | CDK4I c.322G>C | CDKN2 c.322G>C | CDKN2A c.322G>C | Cyclin Dependent Kinase Inhibitor 2A c.322G>C | INK4A c.322G>C | MLM c.322G>C | MTS-1 c.322G>C | MTS1 c.322G>C | NM_000077.4:c.322G>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511485","Consomic Mouse Strain","C14373","Strains of mice derived by repeated backcrossing while maintaining one whole chromosome genetically different from the background strain. (JAX IMSR glossary)","Consomic Mouse Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514783","Recombinant Inbred Strain","C14374","Recombinant inbred (RI) strains are derived by systematic inbreeding from the cross of two pre-existing progenitor strains. (from JAX Strain Information)","Recombinant Inbred Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447996","ENPP3 protein, human","C147048","Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (875 aa, ~100 kDa) is encoded by the human ENPP3 gene. This protein plays a role in the cleavage of phosphodiester and phosphosulfate bonds.","Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 | CD203c | CD203c Antigen | E-NPP 3 | ENPP3 | PD-Ibeta | Phosphodiesterase I Beta | Phosphodiesterase I/Nucleotide Pyrophosphatase 3 | Phosphodiesterase-I Beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545016","PIK3AP1 Gene","C147049","This gene is involved in signaling from toll-like receptors and the B-cell receptor.","PIK3AP1 Gene | PIK3AP1 | Phosphoinositide-3-Kinase Adaptor Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545017","PIK3AP1 wt Allele","C147050","Human PIK3AP1 wild-type allele is located in the vicinity of 10q24.1 and is approximately 127 kb in length. This allele, which encodes phosphoinositide 3-kinase adapter protein 1, plays a role in B-cell receptor and toll-like receptor signaling.","PIK3AP1 wt Allele | BCAP | FLJ35564 | Phosphoinositide-3-Kinase Adaptor Protein 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1454387","PIK3AP1 protein, human","C147051","Phosphoinositide 3-kinase adapter protein 1 (805 aa, ~90 kDa) is encoded by the human PIK3AP1 gene. This protein is involved in linking the B-cell receptor and toll-like receptors to the phosphoinositide 3-kinase (PI3K)-Akt signaling pathway.","Phosphoinositide 3-Kinase Adapter Protein 1 | B Cell Adaptor Protein | B-Cell Adapter for Phosphoinositide 3-Kinase | B-Cell Adaptor Protein | B-Cell Phosphoinositide 3-Kinase Adapter Protein 1 | PIK3 Adaptor Protein | PIK3AP1 | Phosphoinositide-3-Kinase Adaptor Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545455","FACT-BMT Version 4 - I Get Tired Easily","C147627","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I get tired easily.","FACT-BMT Version 4 - I Get Tired Easily | FAC061-I Get Tired Easily | FAC06135",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545456","FACT-BMT Version 4 - I Am Interested in Sex","C147628","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am interested in sex.","FACT-BMT Version 4 - I Am Interested in Sex | FAC061-I Am Interested in Sex | FAC06136",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545457","FACT-BMT Version 4 - Concerns Ability to Have Children","C147629","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I have concerns about my ability to have children.","FACT-BMT Version 4 - Concerns Ability to Have Children | FAC061-Concerns Ability to Have Children | FAC06137",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545458","FACT-BMT Version 4 - Confidence in My Nurse(s)","C147630","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I have confidence in my nurse(s).","FACT-BMT Version 4 - Confidence in My Nurse(s) | FAC061-Confidence in My Nurse(s) | FAC06138",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545459","FACT-BMT Version 4 - I Regret Bone Marrow Transplant","C147631","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I regret having the bone marrow transplant.","FACT-BMT Version 4 - I Regret Bone Marrow Transplant | FAC061-I Regret Bone Marrow Transplant | FAC06139",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545460","FACT-BMT Version 4 - I Can Remember Things","C147632","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I can remember things.","FACT-BMT Version 4 - I Can Remember Things | FAC061-I Can Remember Things | FAC06140",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545461","FACT-BMT Version 4 - I Am Able to Concentrate","C147633","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am able to concentrate.","FACT-BMT Version 4 - I Am Able to Concentrate | FAC061-I Am Able to Concentrate | FAC06141",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545446","FACT-BMT Version 4 - I Have Frequent Colds/Infections","C147634","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I have frequent colds/infections.","FACT-BMT Version 4 - I Have Frequent Colds/Infections | FAC061-I Have Frequent Colds/Infections | FAC06142",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545447","FACT-BMT Version 4 - My Eyesight Is Blurry","C147635","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) My eyesight is blurry.","FACT-BMT Version 4 - My Eyesight Is Blurry | FAC061-My Eyesight Is Blurry | FAC06143",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545448","FACT-BMT Version 4 - Bothered by Change in Food Tastes","C147636","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am bothered by a change in the way food tastes.","FACT-BMT Version 4 - Bothered by Change in Food Tastes | FAC061-Bothered by Change in Food Tastes | FAC06144",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545449","FACT-BMT Version 4 - I Have Tremors","C147637","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I have tremors.","FACT-BMT Version 4 - I Have Tremors | FAC061-I Have Tremors | FAC06145",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545450","FACT-BMT Version 4 - I Have Been Short of Breath","C147638","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I have been short of breath.","FACT-BMT Version 4 - I Have Been Short of Breath | FAC061-I Have Been Short of Breath | FAC06146",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545452","FACT-BMT Version 4 - I Have Trouble With My Bowels","C147640","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I have trouble with my bowels.","FACT-BMT Version 4 - I Have Trouble With My Bowels | FAC061-I Have Trouble With My Bowels | FAC06148",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545453","FACT-BMT Version 4 - Illness Is Hardship for My Family","C147641","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) My illness is a personal hardship for my close family members.","FACT-BMT Version 4 - Illness Is Hardship for My Family | FAC061-Illness Is Hardship for My Family | FAC06149",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545143","Associated Persons Adverse Events Domain","C147168","A domain utilized for the submission of adverse event records related to persons associated with the study subject.","Associated Persons Adverse Events Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545144","Associated Persons Biospecimen Domain","C147169","A domain utilized for the submission of biospecimen records related to persons associated with the study subject.","Associated Persons Biospecimen Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550639","Associated Persons Exposure Domain","C147171","A domain utilized for the submission of exposure records related to persons associated with the study subject.","Associated Persons Exposure Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545146","Associated Persons Laboratory Test Results Domain","C147172","A domain utilized for the submission of laboratory test records related to persons associated with the study subject.","Associated Persons Laboratory Test Results Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545147","Associated Persons Medical History Domain","C147173","A domain utilized for the submission of medical history records related to persons associated with the study subject.","Associated Persons Medical History Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545148","Associated Persons Questionnaires Domain","C147174","A domain utilized for the submission of questionnaires records related to persons associated with the study subject.","Associated Persons Questionnaires Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545137","Relationship between Associated Persons and Subjects Domain","C147175","A domain utilized for the submission of relationship to subject records related to persons associated with the study subject.","Relationship between Associated Persons and Subjects Domain | APRELSUB | Relationship between Associated Persons and Subjects",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545138","Associated Persons Reproductive System Findings Domain","C147176","A domain utilized for the submission of reproductive system findings records related to persons associated with the study subject.","Associated Persons Reproductive System Findings Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206464","Gammaretrovirus","C14305","A genus of the family Retroviridae. Some species contain oncogenes that may cause leukemias or sarcomas. Some Gammaretrovirus genomes share sequences with endogenous viral elements (ERV) found in mammalian genomes..","Gammaretrovirus | Retroviruses, Type C, Mammalian | Type C Mammalian Retrovirus",,,,,,,,,,,,,,,"4248376","Genus Gammaretrovirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL541456","Autologous Gamma-retroviral MSGV1 139 scFv EGFRvIII CAR Gene-modified T Cells","C143060","A preparation of autologous T-lymphocytes transduced with the gamma retroviral vector MSGV1 expressing a chimeric T-cell antigen receptor (CAR) consisting of a single-chain variable fragment (scFv) from a specific antibody clone (mAb139) that targets a mutant form of epidermal growth factor receptor (EGFR) known as variant III (EGFRvIII; EGFR-vIII), with potential antineoplastic activity. Upon intratumoral administration, the gamma-retroviral MSGV1 139 scFv EGFRvIII CAR gene-modified T-cells specifically target and bind to tumor cells expressing EGFRvIII, leading to selective cytotoxicity in EGFRvIII-expressing tumor cells. EGFRvIII, a tumor-associated antigen (TAA) encoded by an in-frame deletion of exons 2-7 in the EGFR gene, is specifically overexpressed by a subset of tumor cells and is not expressed in normal, healthy cells. It plays a key role in tumor cell proliferation, tumor angiogenesis and radio- and chemoresistance.","Autologous Gamma-retroviral MSGV1 139 scFv EGFRvIII CAR Gene-modified T Cells | Gamma-retroviral MSGV1 139 scFv EGFRvIII CAR Gene-modified Autologous T-lymphocytes | MSGV1-EGFRvIII-specific CAR-transduced Autologous T Lymphocytes | MSGv1-EGFRvIII-CAR Autologous T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541458","CHST11 wt Allele","C143062","Human CHST11 wild-type allele is located in the vicinity of 12q23.3 and is approximately 307 kb in length. This allele, which encodes carbohydrate sulfotransferase 11 protein, is involved in chondroitin sulfate metabolism. A chromosomal translocation involving this gene and the IgH locus, t(12;14)(q23;q32), may be associated with B-cell chronic lymphocytic leukemia.","CHST11 wt Allele | C4ST | C4ST-1 | C4ST1 | Carbohydrate (Chondroitin 4) Sulfotransferase 11 Gene | Carbohydrate Sulfotransferase 11 wt Allele | HSA269537",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1439074","CHST11 protein, human","C143063","Carbohydrate sulfotransferase 11 (352 aa, ~42 kDa) is encoded by the human CHST11 gene. This protein plays a role in the sulfation of chondroitin.","Carbohydrate Sulfotransferase 11 | C4S-1 | C4ST-1 | C4ST1 | CHST11 | Chondroitin 4-O-Sulfotransferase 1 | Chondroitin 4-Sulfotransferase 1 | EC 2.8.2.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541461","LARP4B wt Allele","C143065","Human LARP4B wild-type allele is located in the vicinity of 10p15.3 and is approximately 181 kb in length. This allele, which encodes La-related protein 4B, plays a role in translation. Mutations in the gene may be associated with acute myeloid leukemia, glioma and colorectal cancer.","LARP4B wt Allele | KIAA0217 | LARP5 | La Ribonucleoprotein Domain Family Member 4B wt Allele | La Ribonucleoprotein Domain Family, Member 4B Gene | La Ribonucleoprotein Domain Family, Member 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541446","La ribonucleoprotein domain family, member 5, human","C143066","La-related protein 4B (738 aa, ~81 kDa) is encoded by the human LARP4B gene. This protein is involved in the positive regulation of translation.","La-Related Protein 4B | LARP4B | La Ribonucleoprotein Domain Family Member 4B | La Ribonucleoprotein Domain Family Member 5 | La-Related Protein 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541447","FGFR4 Antagonist INCB062079","C143067","An orally bioavailable, selective inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon oral administration, FGFR4 antagonist INCB062079 specifically and irreversibly binds to the cysteine residue at position 552 (Cys 552) that is within the active site of FGFR4. This blocks FGFR4 autophosphorylation and activation of receptor tyrosine kinase activity that would normally occur after binding to its ligand fibroblast growth factor 19 (FGF19), which both inhibits FGFR4-mediated signaling and leads to an inhibition of tumor cell proliferation in FGF19- and FGFR4-overexpressing cells. FGFR4, a receptor tyrosine kinase, is involved in angiogenesis and in the proliferation, differentiation, and survival of tumor cells. FGFR4 expression is associated with poor prognosis. FGF19 is overexpressed by certain tumor cell types.","FGFR4 Antagonist INCB062079 | FGFR4 Inhibitor INCB062079 | Fibroblast Growth Factor Receptor 4 Antagonist INCB062079 | INCB 062079 | INCB-062079 | INCB062079 | INCB62079",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545381","Tablet with Sensor Dosage Form","C147579","A solid dosage form containing medicinal substances, with or without suitable diluents, plus an ingestible sensor that communicates with medical devices that are usually located outside of the body.","Tablet with Sensor Dosage Form | Tablet with Sensor | Tablet with sensor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545382","CPEB3 Gene","C147580","This gene is involved in RNA binding and translation regulation.","CPEB3 Gene | CPEB3 | Cytoplasmic Polyadenylation Element Binding Protein 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545383","CPEB3 wt Allele","C147581","Human CPEB3 wild-type allele is located in the vicinity of 10q23.32 and is approximately 244 kb in length. This allele, which encodes cytoplasmic polyadenylation element-binding protein 3, plays a role in the modulation of translation.","CPEB3 wt Allele | Cytoplasmic Polyadenylation Element Binding Protein 3 wt Allele | KIAA0940",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1738215","CPEB3 protein, human","C147582","Cytoplasmic polyadenylation element-binding protein 3 (698 aa, ~76 kDa) is encoded by the human CPEB3 gene. This protein is involved in the regulation of mRNA synthesis.","Cytoplasmic Polyadenylation Element-Binding Protein 3 | CPE-BP3 | CPE-Binding Protein 3 | CPEB3 | hCPEB-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545438","FACT-BMT Version 4 - Cost of Treatment Is Burden on Me","C147642","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) The cost of my treatment is a burden on me or my family.","FACT-BMT Version 4 - Cost of Treatment Is Burden on Me | FAC061-Cost of Treatment Is Burden on Me | FAC06150",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544901","LFS1 c.741_742CC>TT","C146905","A complex substitution where the nucleotide sequence at positions 741 and 742 of the coding sequence of the TP53 gene has changed from cytosine-cytosine to thymine-thymine.","TP53 NM_000546.5:c.741_742delinsTT | LFS1 c.741_742CC>TT | LFS1 c.741_742delCCinsTT | Li-Fraumeni Syndrome c.741_742CC>TT | Li-Fraumeni Syndrome c.741_742delCCinsTT | NM_000546.5:c.741_742CC>TT | NM_000546.5:c.741_742delCCinsTT | NM_000546.5:c.741_742delinsTT | P53 c.741_742CC>TT | P53 c.741_742delCCinsTT | TP53 NM_000546.5:c.741_742CC>TT | TP53 NM_000546.5:c.741_742delCCinsTT | TP53 NM_000546.5:c.741_742delCCinsTT | TP53 c.741_742CC>TT | TP53 c.741_742delCCinsTT | Tumor Protein p53 c.741_742CC>TT | Tumor Protein p53 c.741_742delCCinsTT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544903","TP53 NM_000546.5:c.797G>T","C146907","A nucleotide substitution at position 797 of the coding sequence of the TP53 gene where guanine has been mutated to thymine.","TP53 NM_000546.5:c.797G>T | LFS1 c.797G>T | Li-Fraumeni Syndrome c.797G>T | NM_000546.5:c.797G>T | P53 c.797G>T | TP53 c.797G>T | Tumor Protein p53 c.797G>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544905","TP53 NM_000546.5:c.797G>A","C146909","A nucleotide substitution at position 797 of the coding sequence of the TP53 gene where guanine has been mutated to adenine.","TP53 NM_000546.5:c.797G>A | LFS1 c.797G>A | Li-Fraumeni Syndrome c.797G>A | NM_000546.5:c.797G>A | P53 c.797G>A | TP53 c.797G>A | Tumor Protein p53 c.797G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544907","TP53 NM_000546.5:c.814G>A","C146912","A nucleotide substitution at position 814 of the coding sequence of the TP53 gene where guanine has been mutated to adenine.","TP53 NM_000546.5:c.814G>A | LFS1 c.814G>A | Li-Fraumeni Syndrome c.814G>A | NM_000546.5:c.814G>A | P53 c.814G>A | TP53 c.814G>A | Tumor Protein p53 c.814G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545539","FAC070-I Have Energy","C147679","Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 (FACIT-Fatigue 13-Item Version 4) I have energy.","FACIT-Fatigue 13-Item Version 4 - I Have Energy | FAC070-I Have Energy | FAC07007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545540","FAC070-Able to Do My Usual Activities","C147680","Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 (FACIT-Fatigue 13-Item Version 4) I am able to do my usual activities.","FACIT-Fatigue 13-Item Version 4 - Able to Do My Usual Activities | FAC070-Able to Do My Usual Activities | FAC07008",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545541","FAC070-I Need to Sleep During the Day","C147681","Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 (FACIT-Fatigue 13-Item Version 4) I need to sleep during the day.","FACIT-Fatigue 13-Item Version 4 - I Need to Sleep During the Day | FAC070-I Need to Sleep During the Day | FAC07009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545526","FAC070-I Am Too Tired to Eat","C147682","Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 (FACIT-Fatigue 13-Item Version 4) I am too tired to eat.","FACIT-Fatigue 13-Item Version 4 - I Am Too Tired to Eat | FAC070-I Am Too Tired to Eat | FAC07010",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545376","A4STR1-Wear Orthoses","C147590","Four Stair Ascend Test (4 Stair Ascend) Did subject wear orthoses?","4-Stair Ascend - Wear Orthoses | A4STR1-Wear Orthoses | A4STR103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545377","D4STR1-Wear Orthoses","C147591","Four Stair Descend Test (4 Stair Descend) Did subject wear orthoses?","4-Stair Descend - Wear Orthoses | D4STR1-Wear Orthoses | D4STR103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545379","FACT-BMT Version 4 - I Have a Lack of Energy","C147593","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I have a lack of energy.","FACT-BMT Version 4 - I Have a Lack of Energy | FAC061-I Have a Lack of Energy | FAC06101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545486","FACT-BMT Version 4 - I Have Nausea","C147594","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I have nausea.","FACT-BMT Version 4 - I Have Nausea | FAC061-I Have Nausea | FAC06102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544819","ALK NM_004304.4:c.3520T>G","C146870","A nucleotide substitution at position 3520 of the coding sequence of the ALK gene where thymine has been mutated to guanine.","ALK NM_004304.4:c.3520T>G | ALK Receptor Tyrosine Kinase c.3520T>G | ALK c.3520T>G | Anaplastic Lymphoma Kinase (Ki-1) c.3520T>G | Anaplastic Lymphoma Receptor Tyrosine Kinase c.3520T>G | CD246 c.3520T>G | NM_004304.4:c.3520T>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544820","ALK NM_004304.4:c.3185A>T","C146871","A nucleotide substitution at position 3185 of the coding sequence of the ALK gene where adenine has been mutated to thymine.","ALK NM_004304.4:c.3185A>T | ALK Receptor Tyrosine Kinase c.3185A>T | ALK c.3185A>T | Anaplastic Lymphoma Kinase (Ki-1) c.3185A>T | Anaplastic Lymphoma Receptor Tyrosine Kinase c.3185A>T | CD246 c.3185A>T | NM_004304.4:c.3185A>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544894","TP53 NM_000546.5:c.818G>A","C146914","A nucleotide substitution at position 818 of the coding sequence of the TP53 gene where guanine has been mutated to adenine.","TP53 NM_000546.5:c.818G>A | LFS1 c.818G>A | Li-Fraumeni Syndrome c.818G>A | NM_000546.5:c.818G>A | P53 c.818G>A | TP53 c.818G>A | Tumor Protein p53 c.818G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545084","Malignant Pericardial Germ Cell Tumor","C147104","A malignant germ cell tumor that arises within the pericardium.","Malignant Pericardial Germ Cell Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545085","Pericardial Yolk Sac Tumor","C147105","A yolk sac tumor that arises within the pericardium.","Pericardial Yolk Sac Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545086","Benign Pericardial Germ Cell Tumor","C147106","A germ cell tumor that arises from the pericardium. There is no evidence of atypia or metastases.","Benign Pericardial Germ Cell Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545087","Refractory Glioma","C147107","Glioma that does not respond to treatment.","Refractory Glioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545527","FAC070-Need Help Doing Usual Activities","C147683","Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 (FACIT-Fatigue 13-Item Version 4) I need help doing my usual activities.","FACIT-Fatigue 13-Item Version 4 - Need Help Doing Usual Activities | FAC070-Need Help Doing Usual Activities | FAC07011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545528","FAC070-Frustrated by Being Too Tired","C147684","Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 (FACIT-Fatigue 13-Item Version 4) I am frustrated by being too tired to do the things I want to do.","FACIT-Fatigue 13-Item Version 4 - Frustrated by Being Too Tired | FAC070-Frustrated by Being Too Tired | FAC07012",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545529","FAC070-Limit Social Activity, I am Tired","C147685","Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 (FACIT-Fatigue 13-Item Version 4) I have to limit my social activity because I am tired.","FACIT-Fatigue 13-Item Version 4 - Limit Social Activity, I am Tired | FAC070-Limit Social Activity, I am Tired | FAC07013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545530","Peds-FACIT-F - I Feel Tired","C147686","Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (Peds-FACIT-F) I feel tired.","Peds-FACIT-F - I Feel Tired | FAC099-I Feel Tired | FAC09901",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545532","Peds-FACIT-F - Could Do My Usual Things at Home","C147688","Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (Peds-FACIT-F) I could do my usual things at home.","Peds-FACIT-F - Could Do My Usual Things at Home | FAC099-Could Do My Usual Things at Home | FAC09903",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545533","Peds-FACIT-F - Trouble Starting Things","C147689","Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (Peds-FACIT-F) I had trouble starting things because I was too tired.","Peds-FACIT-F - Trouble Starting Things | FAC099-Trouble Starting Things | FAC09904",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545518","Peds-FACIT-F - Trouble Finishing Things","C147690","Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (Peds-FACIT-F) I had trouble finishing things because I was too tired.","Peds-FACIT-F - Trouble Finishing Things | FAC099-Trouble Finishing Things | FAC09905",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545519","Peds-FACIT-F - I Needed to Sleep During the Day","C147691","Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (Peds-FACIT-F) I needed to sleep during the day.","Peds-FACIT-F - I Needed to Sleep During the Day | FAC099-I Needed to Sleep During the Day | FAC09906",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545520","Peds-FACIT-F - Upset by Being Too Tired","C147692","Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (Peds-FACIT-F) I got upset by being too tired to do things I wanted to do.","Peds-FACIT-F - Upset by Being Too Tired | FAC099-Upset by Being Too Tired | FAC09907",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545521","Peds-FACIT-F - Hard for Me to Play With Friends","C147693","Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (Peds-FACIT-F) Being tired made it hard for me to play or go out with my friends as much as I'd like.","Peds-FACIT-F - Hard for Me to Play With Friends | FAC099-Hard for Me to Play With Friends | FAC09908",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545522","Peds-FACIT-F - Needed Help Doing Usual Things","C147694","Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (Peds-FACIT-F) I needed help doing my usual things at home.","Peds-FACIT-F - Needed Help Doing Usual Things | FAC099-Needed Help Doing Usual Things | FAC09909",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540711","Anti-A PRoliferation-Inducing Ligand Monoclonal Antibody BION-1301","C142822","A humanized monoclonal antibody targeting a proliferation-inducing ligand (APRIL; tumor necrosis factor ligand superfamily member 13; TNFSF13), with potential antineoplastic and immune checkpoint inhibitory activities. Upon administration, zigakibart binds to APRIL and inhibits its binding to both of its receptors, B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and transmembrane activator and CAML Interactor (TACI; tumor necrosis factor receptor superfamily member 13B; TNFRSF13B). This inhibits the activation of both BCMA and TACI, and their downstream signaling pathways, which prevents tumor growth, tumor cell adhesion to bone marrow cells and immune suppression. Additionally, zigakibart may reduce APRIL-induced drug resistance which occurs in some tumors. APRIL, an extracellular protein and member of the tumor necrosis factor ligand superfamily (TNFSF), is expressed by bone marrow plasma cells and myeloid cells, and overexpressed in multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and colorectal carcinoma. APRIL induces immune suppression and tumor progression through the activation of BCMA- and TACI-dependent signaling pathways.","Zigakibart | Anti-A PRoliferation-Inducing Ligand Monoclonal Antibody BION-1301 | Anti-APRIL Monoclonal Antibody BION-1301 | Anti-APRIL Monoclonal Antibody BION-1301 | Anti-TNFSF13 Monoclonal Antibody BION-1301 | BION-1301 | ZIGAKIBART",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1266124","Congenital Peribronchial Myofibroblastic Tumor","C142823","A rare lung neoplasm that occurs in the intrauterine and perinatal period. It is characterized by the proliferation of spindle cells in an interstitial, peribronchial pattern. Surgical resection of the involved lung parenchyma is the treatment of choice.","Congenital Peribronchial Myofibroblastic Tumor | Congenital Bronchopulmonary Leiomyosarcoma | Congenital Fibrosarcoma | Congenital Mesenchymal Malformation of Lung | Congenital Pulmonary Myofibroblastic Tumor | Congenital peribronchial myofibroblastic tumor | Neonatal Pulmonary Hamartoma",,,,,,,,,,,,,,,"4029524","Myofibroblastic tumor, peribronchial",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540698","Peribronchial Proliferation of Neoplastic Cells Present","C142824","A morphologic finding indicating the proliferation of neoplastic cells around bronchi in the lung parenchyma.","Peribronchial Proliferation of Neoplastic Cells Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540697","Pulmonary Artery Intimal Sarcoma","C142825","A sarcoma arising from the arterial intima of pulmonary arteries.","Pulmonary Artery Intimal Sarcoma | Intimal Sarcoma of the Pulmonary Artery | PAIS | PAS | PIS | Pulmonary Artery Sarcoma | Pulmonary Intimal Sarcoma | Pulmonary artery intimal sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540696","Monoclonal Antibody TRK-950","C142826","A humanized monoclonal antibody directed against cell cycle associated protein 1 (cytoplasmic activation- and proliferation-associated protein 1; Caprin-1; CAPRIN1; RNA granule protein 105; RNG105), with potential antineoplastic activity. Upon administration, anti-Caprin-1 monoclonal antibody TRK-950 targets and binds to Caprin-1 expressed on tumor cells. This may induce antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), thereby killing Caprin-1-expressing tumor cells. Caprin-1 is overexpressed on certain tumor cell types and plays a key role in tumor cell proliferation and metastasis.","Anti-Caprin-1 Monoclonal Antibody TRK-950 | Monoclonal Antibody TRK-950 | TRK 950 | TRK-950 | TRK950",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL536391","Primary Pulmonary Myxoid Sarcoma with EWSR1-CREB1 Fusion","C142827","A sarcoma that arises from the lung. It is related to a bronchus and is often predominantly endobronchial. It is characterized by the proliferation of round and spindle cells within a myxoid stroma. It is associated with the presence of an EWSR1::CREB1 fusion gene.","Primary Pulmonary Myxoid Sarcoma with EWSR1-CREB1 Fusion | Low-Grade Malignant Myxoid Endobronchial Tumor | PPMS | Primary Pulmonary Myxoid Sarcoma | Primary Pulmonary Myxoid Sarcoma with EWSR1-CREB1 Fusion | Primary Pulmonary Myxoid Sarcoma with EWSR1-CREB1 Fusion | Primary Pulmonary Myxoid Sarcoma with EWSR1::CREB1 Fusion | Primary Pulmonary Myxoid Sarcoma with EWSR1::CREB1 Fusion | Pulmonary Myxoid Sarcoma with EWSR1-CREB1 Translocation | Pulmonary myxoid sarcoma with EWSR1-CREB1 translocation",,,,,,,,,,,,,,,"37116988","Pulmonary myxoid sarcoma with EWSR1-CREB1 translocation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540695","Lung Myoepithelial Tumor","C142828","A very rare, benign or malignant lung tumor with myoepithelial differentiation.","Lung Myoepithelial Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540694","Lung Myoepithelioma","C142829","A very rare benign lung tumor with myoepithelial differentiation.","Lung Myoepithelioma | Benign Lung Myoepithelioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545984","Lung Myoepithelial Carcinoma","C142830","A very rare malignant lung tumor with myoepithelial differentiation.","Lung Myoepithelial Carcinoma | ",,,,,,,,,,,,,,,"37165775","Myoepithelial carcinoma of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL544806","ALK NM_004304.4:c.3824G>A","C146873","A nucleotide substitution at position 3824 of the coding sequence of the ALK gene where guanine has been mutated to adenine.","ALK NM_004304.4:c.3824G>A | ALK Receptor Tyrosine Kinase c.3824G>A | ALK c.3824G>A | Anaplastic Lymphoma Kinase (Ki-1) c.3824G>A | Anaplastic Lymphoma Receptor Tyrosine Kinase c.3824G>A | CD246 c.3824G>A | NM_004304.4:c.3824G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544810","ALK NM_004304.4:c.3735C>G","C146877","A nucleotide substitution at position 3735 of the coding sequence of the ALK gene where cytosine has been mutated to guanine.","ALK NM_004304.4:c.3735C>G | ALK Receptor Tyrosine Kinase c.3735C>G | ALK c.3735C>G | Anaplastic Lymphoma Kinase (Ki-1) c.3735C>G | Anaplastic Lymphoma Receptor Tyrosine Kinase c.3735C>G | CD246 c.3735C>G | NM_004304.4:c.3735C>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544811","ALK NM_004304.4:c.3735C>A","C146878","A nucleotide substitution at position 3735 of the coding sequence of the ALK gene where cytosine has been mutated to adenine.","ALK NM_004304.4:c.3735C>A | ALK Receptor Tyrosine Kinase c.3735C>A | ALK c.3735C>A | Anaplastic Lymphoma Kinase (Ki-1) c.3735C>A | Anaplastic Lymphoma Receptor Tyrosine Kinase c.3735C>A | CD246 c.3735C>A | NM_004304.4:c.3735C>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544812","ALK NM_004304.4:c.3733T>C","C146879","A nucleotide substitution at position 3733 of the coding sequence of the ALK gene where thymine has been mutated to cytosine.","ALK NM_004304.4:c.3733T>C | ALK Receptor Tyrosine Kinase c.3733T>C | ALK c.3733T>C | Anaplastic Lymphoma Kinase (Ki-1) c.3733T>C | Anaplastic Lymphoma Receptor Tyrosine Kinase c.3733T>C | CD246 c.3733T>C | NM_004304.4:c.3733T>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544813","BRAF NM_004333.4:c.1801A>G","C146880","A nucleotide substitution at position 1801 of the coding sequence of the BRAF gene where adenine has been mutated to guanine.","BRAF NM_004333.4:c.1801A>G | B-RAF1 c.1801A>G | BRAF c.1801A>G | NM_004333.4:c.1801A>G | v-raf Murine Sarcoma Viral Oncogene Homolog B1 c.1801A>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545067","MET Intron 13 Mutation","C147120","A molecular genetic abnormality indicating the presence of a mutation in intron 13 of the MET gene.","MET Intron 13 Mutation | HGFR Intron 13 Mutation | MET Proto-Oncogene, Receptor Tyrosine Kinase Intron 13 Mutation | Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Intron 13 Mutation | c-Met Intron 13 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544875","CDKN2A NM_000077.4:c.322G>T","C146943","A nucleotide substitution at position 322 of the coding sequence of the CDKN2A gene where guanine has been mutated to thymine.","CDKN2A NM_000077.4:c.322G>T | CDK4I c.322G>T | CDKN2 c.322G>T | CDKN2A c.322G>T | Cyclin Dependent Kinase Inhibitor 2A c.322G>T | INK4A c.322G>T | MLM c.322G>T | MTS-1 c.322G>T | MTS1 c.322G>T | NM_000077.4:c.322G>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544877","CDKN2A NM_000077.4:c.389T>A","C146945","A nucleotide substitution at position 389 of the coding sequence of the CDKN2A gene where thymine has been mutated to adenine.","CDKN2A NM_000077.4:c.389T>A | CDK4I c.389T>A | CDKN2 c.389T>A | CDKN2A c.389T>A | Cyclin Dependent Kinase Inhibitor 2A c.389T>A | INK4A c.389T>A | MLM c.389T>A | MTS-1 c.389T>A | MTS1 c.389T>A | NM_000077.4:c.389T>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544982","CDKN2A NM_000077.4:c.439G>A","C146947","A nucleotide substitution at position 439 of the coding sequence of the CDKN2A gene where guanine has been mutated to adenine.","CDKN2A NM_000077.4:c.439G>A | CDK4I c.439G>A | CDKN2 c.439G>A | CDKN2A c.439G>A | Cyclin Dependent Kinase Inhibitor 2A c.439G>A | INK4A c.439G>A | MLM c.439G>A | MTS-1 c.439G>A | MTS1 c.439G>A | NM_000077.4:c.439G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544984","CDKN2A NM_000077.4:c.442G>A","C146949","A nucleotide substitution at position 442 of the coding sequence of the CDKN2A gene where guanine has been mutated to adenine.","CDKN2A NM_000077.4:c.442G>A | CDK4I c.442G>A | CDKN2 c.442G>A | CDKN2A c.442G>A | Cyclin Dependent Kinase Inhibitor 2A c.442G>A | INK4A c.442G>A | MLM c.442G>A | MTS-1 c.442G>A | MTS1 c.442G>A | NM_000077.4:c.442G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545139","Associated Persons Subject Characteristics Domain","C147177","A domain utilized for the submission of subject characteristics records related to persons associated with the study subject.","Associated Persons Subject Characteristics Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545988","Associated Persons Subject Status Domain","C147178","A domain utilized for the submission of subject status records related to persons associated with the study subject.","Associated Persons Subject Status Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545140","Associated Persons Substance Use Domain","C147179","A domain utilized for the submission of substance use records related to persons associated with the study subject.","Associated Persons Substance Use Domain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540704","Methionine Aminopeptidase 2 Inhibitor M8891","C142831","A proprietary orally available inhibitor of methionine aminopeptidase 2 (MetAP2), which cleaves the amino-terminal methionine residue from nascent proteins, with potential antiangiogenic and antineoplastic activities. Upon administration, MetAP2 inhibitor M8891 inhibits MetAP2 aminopeptidase activity and impairs protein synthesis, which may lead to a decrease in endothelial cell proliferation. Decreased proliferation of endothelial cells results in reductions of both angiogenesis and the growth and spread of solid tumors that are dependent on new blood vessel formation. MetAP2, a metallopeptidase, is involved in promoting protein synthesis and endothelial cell proliferation.","Methionine Aminopeptidase 2 Inhibitor M8891 | M8891 | MetAP2 Inhibitor M8891",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545420","CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology","C147540","Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology | FAC061TC | Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 Questionnaire Test Code | QS-FACT-BMT Version 4 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545421","CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology","C147541","Test names of questionnaire questions associated with the Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology | FAC084TN | Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form Questionnaire Test Name | QS-FACIT-Dyspnea 10 Item Short Form TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545422","CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology","C147542","Test codes of questionnaire questions associated with the Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology | FAC084TC | Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form Questionnaire Test Code | QS-FACIT-Dyspnea 10 Item Short Form TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545423","FAC070TN","C147543","Test names of questionnaire questions associated with the Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 (FACIT-Fatigue 13-Item Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Name Terminology | FAC070TN | Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 Questionnaire Test Name | QS-FACIT-Fatigue Version 4 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545409","FAC070TC","C147544","Test codes of questionnaire questions associated with the Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 (FACIT-Fatigue 13-Item Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Code Terminology | FAC070TC | Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 Questionnaire Test Code | QS-FACIT-Fatigue Version 4 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545410","CDISC Questionnaire Peds-FACIT-F Test Name Terminology","C147545","Test names of questionnaire questions associated with the Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (Peds-FACIT-F) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire Peds-FACIT-F Test Name Terminology | FAC099TN | Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue Questionnaire Test Name | QS-Peds-FACIT-F TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545411","CDISC Questionnaire Peds-FACIT-F Test Code Terminology","C147546","Test codes of questionnaire questions associated with the Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (Peds-FACIT-F) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire Peds-FACIT-F Test Code Terminology | FAC099TC | Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue Questionnaire Test Code | QS-Peds-FACIT-F TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545413","CDISC Questionnaire TSCC Test Code Terminology","C147548","Test codes of questionnaire questions associated with the Trauma Symptom Checklist for Children (TSCC) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire TSCC Test Code Terminology | QS-TSCC TESTCD | TSCC01TC | Trauma Symptom Checklist for Children Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545001","CDISC Protocol Entities Study Design Attribute Terminology","C147066","Terminology associated with the protocol entity study design attribute codelist of the Clinical Data Interchange Standards Consortium (CDISC).","CDISC Protocol Entities Study Design Attribute Terminology | PROT-Att Study Design | Study Design Attribute Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545002","CDISC Protocol Study Purpose Response Terminology","C147067","Terminology associated with the study purpose response codelist of the Clinical Data Interchange Standards Consortium (CDISC) protocol entities.","CDISC Protocol Study Purpose Response Terminology | PROT-SPURPRS | Study Purpose Value Set",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545439","FACIT-Dyspnea 10 Item Short Form - Part I: Dressing Without Help","C147643","Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Dressing yourself without help.","FACIT-Dyspnea 10 Item Short Form - Part I: Dressing Without Help | FAC084-Part I: Dressing Without Help | FAC08401",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545440","FACIT-Dyspnea 10 Item Short Form - Part I: Dressing Why Not","C147644","Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Dressing yourself without help. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea 10 Item Short Form - Part I: Dressing Why Not | FAC084-Part I: Dressing Why Not | FAC08402",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545441","FACIT-Dyspnea 10 Item Short Form - Part I: Walk 50 Steps","C147645","Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Walking 50 steps/paces on flat ground at a normal speed without stopping.","FACIT-Dyspnea 10 Item Short Form - Part I: Walk 50 Steps | FAC084-Part I: Walk 50 Steps | FAC08403",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545442","FACIT-Dyspnea 10 Item Short Form - Part I: Walk 50 Steps Why Not","C147646","Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Walking 50 steps/paces on flat ground at a normal speed without stopping. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea 10 Item Short Form - Part I: Walk 50 Steps Why Not | FAC084-Part I: Walk 50 Steps Why Not | FAC08404",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545443","FACIT-Dyspnea 10 Item Short Form - Part I: Walk Up 20 Stairs","C147647","Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Walking up 20 stairs (2 flights) without stopping.","FACIT-Dyspnea 10 Item Short Form - Part I: Walk Up 20 Stairs | FAC084-Part I: Walk Up 20 Stairs | FAC08405",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545141","Pool Definition Dataset","C147181","A dataset that identifies individual subjects included in a pool of subjects for which a single observation record (pool level) is captured. (CDISC)","Pool Definition Dataset | POOLDEF | Pool Definition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545132","Procedure Agents Supplemental Qualifiers Dataset","C147186","A dataset containing supplemental information, specifically non-standard variables, to parent records in the procedure agents domain.","Procedure Agents Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545133","Biospecimen Events Supplemental Qualifiers Dataset","C147187","A dataset containing supplemental information, specifically non-standard variables, to parent records in the biospecimen events domain.","Biospecimen Events Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545134","Body Weight Gain Supplemental Qualifiers Dataset","C147188","A dataset containing supplemental information, specifically non-standard variables, to parent records in the body weight gain domain.","Body Weight Gain Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545136","Body Weight Supplemental Qualifiers Dataset","C147190","A dataset containing supplemental information, specifically non-standard variables, to parent records in the body weight domain.","Body Weight Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545122","Clinical Events Supplemental Qualifiers Dataset","C147191","A dataset containing supplemental information, specifically non-standard variables, to parent records in the clinical events domain.","Clinical Events Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545124","Concomitant and Prior Medications Supplemental Qualifiers Dataset","C147193","A dataset containing supplemental information, specifically non-standard variables, to parent records in the concomitant and prior medications domain.","Concomitant and Prior Medications Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545125","Comments Supplemental Qualifiers Dataset","C147194","A dataset containing supplemental information, specifically non-standard variables, to parent records in the comments domain.","Comments Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545126","Cardiovascular System Findings Supplemental Qualifiers Dataset","C147195","A dataset containing supplemental information, specifically non-standard variables, to parent records in the cardiovascular system findings domain.","Cardiovascular System Findings Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545127","Drug Accountability Supplemental Qualifiers Dataset","C147196","A dataset containing supplemental information, specifically non-standard variables, to parent records in the drug accountability domain.","Drug Accountability Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545414","CDISC Questionnaire TSCYC Test Name Terminology","C147549","Test names of questionnaire questions associated with the Trauma Symptom Checklist for Young Children (TSCYC) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire TSCYC Test Name Terminology | QS-TSCYC TEST | TSCYC1TN | Trauma Symptom Checklist for Young Children Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545415","CDISC Questionnaire TSCYC Test Code Terminology","C147550","Test codes of questionnaire questions associated with the Trauma Symptom Checklist for Young Children (TSCYC) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire TSCYC Test Code Terminology | QS-TSCYC TESTCD | TSCYC1TC | Trauma Symptom Checklist for Young Children Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545416","ATLAS Clinical Classification Question","C147551","A question associated with the ATLAS clinical classification.","ATLAS Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545402","FACT-BMT Version 4 Questionnaire Question","C147552","A question associated with the FACT-BMT Version 4 questionnaire.","FACT-BMT Version 4 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545560","TSCYC - Seeming to Be in a Daze","C147780","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Seeming to be in a daze.","TSCYC - Seeming to Be in a Daze | TSCYC1-Seeming to Be in a Daze | TSCYC128",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545561","TSCYC - Trouble Remember Upsetting Thing","C147781","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Having trouble remembering an upsetting thing that happened in the past.","TSCYC - Trouble Remember Upsetting Thing | TSCYC1-Trouble Remember Upsetting Thing | TSCYC129",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545562","TSCYC - Using Drugs","C147782","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Using drugs.","TSCYC - Using Drugs | TSCYC1-Using Drugs | TSCYC130",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545563","TSCYC - Fear of the Dark","C147783","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Fear of the dark.","TSCYC - Fear of the Dark | TSCYC1-Fear of the Dark | TSCYC131",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545564","TSCYC - Being Afraid to Be Alone","C147784","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Being afraid to be alone.","TSCYC - Being Afraid to Be Alone | TSCYC1-Being Afraid to Be Alone | TSCYC132",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545565","TSCYC - Spacing Out","C147785","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Spacing out.","TSCYC - Spacing Out | TSCYC1-Spacing Out | TSCYC133",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545678","TSCYC - Being Too Aggressive","C147786","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Being too aggressive.","TSCYC - Being Too Aggressive | TSCYC1-Being Too Aggressive | TSCYC134",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545679","TSCYC - Touching Other Private Parts","C147787","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Touching other children's or adults' private parts (under or over clothes).","TSCYC - Touching Other Private Parts | TSCYC1-Touching Other Private Parts | TSCYC135",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545680","TSCYC - Seeing Bad Happened in the Past","C147788","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Suddenly seeing, feeling, or hearing something bad that happened in the past.","TSCYC - Seeing Bad Happened in the Past | TSCYC1-Seeing Bad Happened in the Past | TSCYC136",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545444","FACIT-Dyspnea 10 Item Short Form - Part I: Walk Up 20 Stairs Why Not","C147648","Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Walking up 20 stairs (2 flights) without stopping. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea 10 Item Short Form - Part I: Walk Up 20 Stairs Why Not | FAC084-Part I: Walk Up 20 Stairs Why Not | FAC08406",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545445","FACIT-Dyspnea 10 Item Short Form - Part I: Preparing Meals","C147649","Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Preparing Meals.","FACIT-Dyspnea 10 Item Short Form - Part I: Preparing Meals | FAC084-Part I: Preparing Meals | FAC08407",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545431","FACIT-Dyspnea 10 Item Short Form - Part I: Washing Dishes","C147651","Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Washing dishes.","FACIT-Dyspnea 10 Item Short Form - Part I: Washing Dishes | FAC084-Part I: Washing Dishes | FAC08409",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545432","FACIT-Dyspnea 10 Item Short Form - Part I: Washing Dishes Why Not","C147652","Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Washing dishes. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea 10 Item Short Form - Part I: Washing Dishes Why Not | FAC084-Part I: Washing Dishes Why Not | FAC08410",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545433","FACIT-Dyspnea 10 Item Short Form - Part I: Sweeping/Mopping","C147653","Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Sweeping or mopping.","FACIT-Dyspnea 10 Item Short Form - Part I: Sweeping/Mopping | FAC084-Part I: Sweeping/Mopping | FAC08411",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545434","FACIT-Dyspnea 10 Item Short Form - Part I: Sweeping/Mopping Why Not","C147654","Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Sweeping or mopping. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea 10 Item Short Form - Part I: Sweeping/Mopping Why Not | FAC084-Part I: Sweeping/Mopping Why Not | FAC08412",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544896","TP53 NM_000546.5:c.817C>T","C146916","A nucleotide substitution at position 817 of the coding sequence of the TP53 gene where cytosine has been mutated to thymine.","TP53 NM_000546.5:c.817C>T | LFS1 c.817C>T | Li-Fraumeni Syndrome c.817C>T | NM_000546.5:c.817C>T | P53 c.817C>T | TP53 c.817C>T | Tumor Protein p53 c.817C>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0025084","Medical History Taking","C146918","The process of gathering information regarding a person's medical history.","Medical History Taking | Medical History Collection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545681","TSCYC - Hearing Voices to Hurt Someone","C147789","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Hearing voices telling him or her to hurt someone.","TSCYC - Hearing Voices to Hurt Someone | TSCYC1-Hearing Voices to Hurt Someone | TSCYC137",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545682","TSCYC - Staring Off Into Space","C147790","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Staring off into space.","TSCYC - Staring Off Into Space | TSCYC1-Staring Off Into Space | TSCYC138",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545683","TSCYC - Changing Subject About Bad Thing","C147791","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Changing the subject or not answering when he or she was asked about a bad thing that happened to him or her.","TSCYC - Changing Subject About Bad Thing | TSCYC1-Changing Subject About Bad Thing | TSCYC139",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545684","TSCYC - Having a Nervous Breakdown","C147792","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Having a nervous breakdown.","TSCYC - Having a Nervous Breakdown | TSCYC1-Having a Nervous Breakdown | TSCYC140",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545685","TSCYC - Not Happy Like Other Children","C147793","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Not laughing or being happy like other children.","TSCYC - Not Happy Like Other Children | TSCYC1-Not Happy Like Other Children | TSCYC141",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545047","EGFR NM_005228.3:c.2375T>A","C147015","A nucleotide substitution at position 2375 of the coding sequence of the EGFR gene where thymine has been mutated to adenine.","EGFR NM_005228.3:c.2375T>A | EGFR c.2375T>A | ERBB c.2375T>A | ERBB1 c.2375T>A | Epidermal Growth Factor Receptor Gene c.2375T>A | HER1 c.2375T>A | NM_005228.3:c.2375T>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545035","EGFR NM_005228.3:c.2153T>A","C147019","A nucleotide substitution at position 2153 of the coding sequence of the EGFR gene where thymine has been mutated to adenine.","EGFR NM_005228.3:c.2153T>A | EGFR c.2153T>A | ERBB c.2153T>A | ERBB1 c.2153T>A | Epidermal Growth Factor Receptor Gene c.2153T>A | HER1 c.2153T>A | NM_005228.3:c.2153T>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545487","FACT-BMT Version 4 - Trouble Meeting Needs of Family","C147595","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) Because of my physical condition, I have trouble meeting the needs of my family.","FACT-BMT Version 4 - Trouble Meeting Needs of Family | FAC061-Trouble Meeting Needs of Family | FAC06103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545488","FACT-BMT Version 4 - I Have Pain","C147596","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I have pain.","FACT-BMT Version 4 - I Have Pain | FAC061-I Have Pain | FAC06104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545489","FACT-BMT Version 4 - Bothered by Treatment Side Effect","C147597","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am bothered by side effects of treatment.","FACT-BMT Version 4 - Bothered by Treatment Side Effect | FAC061-Bothered by Treatment Side Effect | FAC06105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545490","FACT-BMT Version 4 - I Feel Ill","C147598","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I feel ill.","FACT-BMT Version 4 - I Feel Ill | FAC061-I Feel Ill | FAC06106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545491","FACT-BMT Version 4 - I Am Forced to Spend Time in Bed","C147599","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am forced to spend time in bed.","FACT-BMT Version 4 - I Am Forced to Spend Time in Bed | FAC061-I Am Forced to Spend Time in Bed | FAC06107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0211011","Ziconotide","C1475","A synthetic, nonopiod, twenty-five amino acid polybasic peptide analogue of an omega-conotoxin derived from the marine snail Conus magus with analgesic activity. Ziconotide appears to block neuronal N-type voltage-sensitive calcium channels (NCCB), inhibiting transmission from pain-sensing primary nociceptors. This agent may exhibit significant analgesic activity in refractory pain.","Ziconotide | Prialt | SNX 111 | SNX-111 | ZICONOTIDE | ziconotide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545492","FACT-BMT Version 4 - I Feel Close to My Friends","C147600","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I feel close to my friends.","FACT-BMT Version 4 - I Feel Close to My Friends | FAC061-I Feel Close to My Friends | FAC06108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545478","FACT-BMT Version 4 - I Get Support From My Friends","C147602","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I get support from my friends.","FACT-BMT Version 4 - I Get Support From My Friends | FAC061-I Get Support From My Friends | FAC06110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545479","FACT-BMT Version 4 - My Family Has Accepted My Illness","C147603","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) My family has accepted my illness.","FACT-BMT Version 4 - My Family Has Accepted My Illness | FAC061-My Family Has Accepted My Illness | FAC06111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545480","FACT-BMT Version 4 - Satisfied Communication Illness","C147604","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am satisfied with family communication about my illness.","FACT-BMT Version 4 - Satisfied Communication Illness | FAC061-Satisfied Communication Illness | FAC06112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545481","FACT-BMT Version 4 - I Feel Close to My Partner","C147605","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I feel close to my partner (or the person who is my main support).","FACT-BMT Version 4 - I Feel Close to My Partner | FAC061-I Feel Close to My Partner | FAC06113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545482","FACT-BMT Version 4 - I Am Satisfied With My Sex Life","C147606","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am satisfied with my sex life.","FACT-BMT Version 4 - I Am Satisfied With My Sex Life | FAC061-I Am Satisfied With My Sex Life | FAC06114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544900","TP53 NM_000546.5:c.844C>T","C146921","A nucleotide substitution at position 844 of the coding sequence of the TP53 gene where cytosine has been mutated to thymine.","TP53 NM_000546.5:c.844C>T | LFS1 c.844C>T | Li-Fraumeni Syndrome c.844C>T | NM_000546.5:c.844C>T | P53 c.844C>T | TP53 c.844C>T | Tumor Protein p53 c.844C>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544886","LFS1 c.843_844CC>TT","C146922","A complex substitution where the nucleotide sequence at positions 843 and 844 of the coding sequence of the TP53 gene has changed from cytosine-cytosine to thymine-thymine.","TP53 NM_000546.5:c.843_844delinsTT | LFS1 c.843_844CC>TT | LFS1 c.843_844delCCinsTT | Li-Fraumeni Syndrome c.843_844CC>TT | Li-Fraumeni Syndrome c.843_844delCCinsTT | NM_000546.5:c.843_844CC>TT | NM_000546.5:c.843_844delCCinsTT | NM_000546.5:c.843_844delinsTT | P53 c.843_844CC>TT | P53 c.843_844delCCinsTT | TP53 NM_000546.5:c.843_844CC>TT | TP53 NM_000546.5:c.843_844delCCinsTT | TP53 NM_000546.5:c.843_844delCCinsTT | TP53 c.843_844CC>TT | TP53 c.843_844delCCinsTT | Tumor Protein p53 c.843_844CC>TT | Tumor Protein p53 c.843_844delCCinsTT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544888","TP53 NM_000546.5:c.844C>G","C146924","A nucleotide substitution at position 844 of the coding sequence of the TP53 gene where cytosine has been mutated to guanine.","TP53 NM_000546.5:c.844C>G | LFS1 c.844C>G | Li-Fraumeni Syndrome c.844C>G | NM_000546.5:c.844C>G | P53 c.844C>G | TP53 c.844C>G | Tumor Protein p53 c.844C>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544891","CDKN2A NM_000077.4:c.89C>T","C146927","A nucleotide substitution at position 89 of the coding sequence of the CDKN2A gene where cytosine has been mutated to thymine.","CDKN2A NM_000077.4:c.89C>T | CDK4I c.89C>T | CDKN2 c.89C>T | CDKN2A c.89C>T | Cyclin Dependent Kinase Inhibitor 2A c.89C>T | INK4A c.89C>T | MLM c.89C>T | MTS-1 c.89C>T | MTS1 c.89C>T | NM_000077.4:c.89C>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545073","Adaptive Randomization","C147126","A type of randomization schema in which a subject's group assignment probability is adjusted based on the group assignments of those subjects already randomized in the trial.","Adaptive Randomization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545059","Block Randomization","C147127","A type of adaptive randomization schema in which a pre-specified number of subjects is assigned to a block containing the same pre-specified number of balanced group assignments in random order. This block is normally determined prior to the start of the study.","Block Randomization | Constrained Randomization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545523","Peds-FACIT-F - I Feel Weak","C147695","Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (Peds-FACIT-F) I feel weak.","Peds-FACIT-F - I Feel Weak | FAC099-I Feel Weak | FAC09910",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545524","Peds-FACIT-F - I Was Too Tired to Eat","C147696","Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (Peds-FACIT-F) I was too tired to eat.","Peds-FACIT-F - I Was Too Tired to Eat | FAC099-I Was Too Tired to Eat | FAC09911",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545525","Peds-FACIT-F - Being Tired Made Me Sad","C147697","Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (Peds-FACIT-F) Being tired made me sad.","Peds-FACIT-F - Being Tired Made Me Sad | FAC099-Being Tired Made Me Sad | FAC09912",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545510","Peds-FACIT-F - Being Tired Made Me Mad","C147698","Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (Peds-FACIT-F) Being tired made me mad (angry).","Peds-FACIT-F - Being Tired Made Me Mad | FAC099-Being Tired Made Me Mad | FAC09913",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545511","TSCC - Bad Dreams or Nightmares","C147699","Trauma Symptom Checklist for Children (TSCC) Bad dreams or nightmares.","TSCC - Bad Dreams or Nightmares | TSCC01-Bad Dreams or Nightmares | TSCC0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545512","TSCC - Afraid Something Bad Might Happen","C147700","Trauma Symptom Checklist for Children (TSCC) Feeling afraid something bad might happen.","TSCC - Afraid Something Bad Might Happen | TSCC01-Afraid Something Bad Might Happen | TSCC0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545513","TSCC - Scary Ideas Just Pop Into My Head","C147701","Trauma Symptom Checklist for Children (TSCC) Scary ideas or pictures just pop into my head.","TSCC - Scary Ideas Just Pop Into My Head | TSCC01-Scary Ideas Just Pop Into My Head | TSCC0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545514","TSCC - Wanting to Say Dirty Words","C147702","Trauma Symptom Checklist for Children (TSCC) Wanting to say dirty words.","TSCC - Wanting to Say Dirty Words | TSCC01-Wanting to Say Dirty Words | TSCC0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545515","TSCC - Pretending I am Someone Else","C147703","Trauma Symptom Checklist for Children (TSCC) Pretending I am someone else.","TSCC - Pretending I am Someone Else | TSCC01-Pretending I am Someone Else | TSCC0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545516","TSCC - Arguing Too Much","C147704","Trauma Symptom Checklist for Children (TSCC) Arguing too much.","TSCC - Arguing Too Much | TSCC01-Arguing Too Much | TSCC0106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545517","TSCC - Feeling Lonely","C147705","Trauma Symptom Checklist for Children (TSCC) Feeling lonely.","TSCC - Feeling Lonely | TSCC01-Feeling Lonely | TSCC0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545502","TSCC - Touching Private Parts Too Much","C147706","Trauma Symptom Checklist for Children (TSCC) Touching my private parts too much.","TSCC - Touching Private Parts Too Much | TSCC01-Touching Private Parts Too Much | TSCC0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545503","TSCC - Feeling Sad or Unhappy","C147707","Trauma Symptom Checklist for Children (TSCC) Feeling sad or unhappy.","TSCC - Feeling Sad or Unhappy | TSCC01-Feeling Sad or Unhappy | TSCC0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545504","TSCC - Remembering Things I Didn't Like","C147708","Trauma Symptom Checklist for Children (TSCC) Remembering things that happened that I didn't like.","TSCC - Remembering Things I Didn't Like | TSCC01-Remembering Things I Didn't Like | TSCC0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545505","TSCC - Going Away in My Mind","C147709","Trauma Symptom Checklist for Children (TSCC) Going away in my mind, trying not to think.","TSCC - Going Away in My Mind | TSCC01-Going Away in My Mind | TSCC0111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545037","EGFR NM_005228.3:c.2386G>A","C147022","A nucleotide substitution at position 2386 of the coding sequence of the EGFR gene where guanine has been mutated to adenine.","EGFR NM_005228.3:c.2386G>A | EGFR c.2386G>A | ERBB c.2386G>A | ERBB1 c.2386G>A | Epidermal Growth Factor Receptor Gene c.2386G>A | HER1 c.2386G>A | NM_005228.3:c.2386G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545039","EGFR NM_005228.3:c.2386G>C","C147024","A nucleotide substitution at position 2386 of the coding sequence of the EGFR gene where guanine has been mutated to cytosine.","EGFR NM_005228.3:c.2386G>C | EGFR c.2386G>C | ERBB c.2386G>C | ERBB1 c.2386G>C | Epidermal Growth Factor Receptor Gene c.2386G>C | HER1 c.2386G>C | NM_005228.3:c.2386G>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545483","FACT-BMT Version 4 - I Feel Sad","C147607","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I feel sad.","FACT-BMT Version 4 - I Feel Sad | FAC061-I Feel Sad | FAC06115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545484","FACT-BMT Version 4 - Satisfied With How I Am Coping","C147608","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am satisfied with how I am coping with my illness.","FACT-BMT Version 4 - Satisfied With How I Am Coping | FAC061-Satisfied With How I Am Coping | FAC06116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545485","FACT-BMT Version 4 - Losing Hope Against Illness","C147609","Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am losing hope in the fight against my illness.","FACT-BMT Version 4 - Losing Hope Against Illness | FAC061-Losing Hope Against Illness | FAC06117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087167","Tumor Treating Fields Therapy","C146882","A type of electromagnetic field therapy that uses low-intensity, intermediate-frequency alternating electrical fields to a target area to induce selective toxicity to proliferating cells.","Tumor Treating Fields Therapy | Alternating Electric Field Therapy | TTF | TTFields",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544925","Mediastinal Granulocytic Sarcoma","C146883","A malignant tumor that arises from the mediastinum and is composed of myeloblasts, neutrophils and neutrophil precursors. It is the most common type of myeloid sarcoma affecting the mediastinum.","Mediastinal Granulocytic Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544927","TP53 NM_000546.5:c.524G>A","C146885","A nucleotide substitution at position 524 of the coding sequence of the TP53 gene where guanine has been mutated to adenine.","TP53 NM_000546.5:c.524G>A | LFS1 c.524G>A | Li-Fraumeni Syndrome c.524G>A | NM_000546.5:c.524G>A | P53 c.524G>A | TP53 c.524G>A | Tumor Protein p53 c.524G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544929","TP53 NM_000546.5:c.638G>T","C146887","A nucleotide substitution at position 638 of the coding sequence of the TP53 gene where guanine has been mutated to thymine.","TP53 NM_000546.5:c.638G>T | LFS1 c.638G>T | Li-Fraumeni Syndrome c.638G>T | NM_000546.5:c.638G>T | P53 c.638G>T | TP53 c.638G>T | Tumor Protein p53 c.638G>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544916","TP53 NM_000546.5:c.659A>G","C146889","A nucleotide substitution at position 659 of the coding sequence of the TP53 gene where adenine has been mutated to guanine.","TP53 NM_000546.5:c.659A>G | LFS1 c.659A>G | Li-Fraumeni Syndrome c.659A>G | NM_000546.5:c.659A>G | P53 c.659A>G | TP53 c.659A>G | Tumor Protein p53 c.659A>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545065","Allogeneic Double Negative T Cells","C147134","A population of healthy, donor-derived CD4 and CD8 double-negative T-lymphocytes (DNTs), with potential immunomodulating and anti-leukemic activities. The DNTs are expanded ex vivo in order to enhance their tumor destroying potential. Upon administration of the allogeneic DNTs (DNT-UHN-1), the receptors NKG2-D type II integral membrane protein (KLRK1; NKG2D) and  DNAX accessory molecule 1 (cluster of differentiation 226; CD226; DNAM-1) expressed on the DNTs recognize and bind to their cognate ligands expressed on leukemia cells. Upon binding, the DNTs release interferon-gamma (IFN-g), thereby destroying the tumor cells. DNTs derived from peripheral blood of healthy donors appear to be effective against certain types of tumor cells, including leukemia cells, and do not attack normal hematopoietic cells. NKG2D, a member of the CD94/NKG2 family of C-type lectin-like receptors, and DNAM-1, a member of the immunoglobulin superfamily containing 2 Ig-like domains of the V-set, play a key role in natural killer cell (NK)-mediated tumor cell killing. Certain tumor cells express higher levels of NKG2D and DNAM-1 ligands on their surfaces, thereby increasing their susceptibility to DNT-mediated cell lysis.","Allogeneic Double Negative T Cells | Allogeneic DNT Cells | DNT-UHN-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545506","TSCC - Remembering Scary Things","C147710","Trauma Symptom Checklist for Children (TSCC) Remembering scary things.","TSCC - Remembering Scary Things | TSCC01-Remembering Scary Things | TSCC0112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545507","TSCC - Wanting to Yell and Break Things","C147711","Trauma Symptom Checklist for Children (TSCC) Wanting to yell and break things.","TSCC - Wanting to Yell and Break Things | TSCC01-Wanting to Yell and Break Things | TSCC0113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544988","GNAS NM_000516.5:c.374A>G","C146953","A nucleotide substitution at position 374 of the coding sequence of the GNAS gene where adenine has been mutated to guanine.","GNAS NM_000516.5:c.374A>G | GNAS Complex Locus Gene c.374A>G | GNAS c.374A>G | GNAS1 c.374A>G | GSA c.374A>G | GSP c.374A>G | NM_000516.5:c.374A>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544974","GNAS NM_000516.5:c.478C>T","C146955","A nucleotide substitution at position 478 of the coding sequence of the GNAS gene where cytosine has been mutated to thymine.","GNAS NM_000516.5:c.478C>T | GNAS Complex Locus Gene c.478C>T | GNAS c.478C>T | GNAS1 c.478C>T | GSA c.478C>T | GSP c.478C>T | NM_000516.5:c.478C>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544976","GNAS NM_000516.5:c.602G>A","C146957","A nucleotide substitution at position 602 of the coding sequence of the GNAS gene where guanine has been mutated to adenine.","GNAS NM_000516.5:c.602G>A | GNAS Complex Locus Gene c.602G>A | GNAS c.602G>A | GNAS1 c.602G>A | GSA c.602G>A | GSP c.602G>A | NM_000516.5:c.602G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545403","FACIT-Dyspnea 10 Item Short Form Questionnaire Question","C147553","A question associated with the FACIT-Dyspnea 10 Item Short Form questionnaire.","FACIT-Dyspnea 10 Item Short Form Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545404","FACIT-Fatigue 13-Item Version 4 Questionnaire Question","C147554","A question associated with the FACIT-Fatigue 13-Item Version 4 questionnaire.","FACIT-Fatigue 13-Item Version 4 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545405","Peds-FACIT-F Questionnaire Question","C147555","A question associated with the Peds-FACIT-F questionnaire.","Peds-FACIT-F Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545406","TSCC Questionnaire Question","C147556","A question associated with the TSCC questionnaire.","TSCC Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545407","TSCYC Questionnaire Question","C147557","A question associated with the TSCYC questionnaire.","TSCYC Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545408","Platinum-Resistant Disease","C147558","A finding indicating that a cancer is resistant to platinum therapy. For non-gynecologic cancers, the terms 'platinum-resistant' and 'platinum-refractory' are used interchangeably. For gynecologic cancers, it refers to cancer progression between one and six months of completing the last platinum therapy.","Platinum-Resistant Disease | Platinum-Resistant | Platinum-resistant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3156590","Interleukin-23 Receptor Complex","C147560","A heterodimeric complex composed of interleukin-12 receptor subunit beta-1 and interleukin-23 receptor. This receptor complex binds to interleukin-23, which activates the JAK-STAT signaling pathway and modulates the activation of T-lymphocytes, natural killer cells and some myeloid lineage cells.","Interleukin-23 Receptor Complex | IL-23 Receptor | IL-23R | IL23R | IL23R/IL12RB1 Complex | Interleukin 23 Receptor | Interleukin-23 Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544918","TP53 NM_000546.5:c.713G>A","C146891","A nucleotide substitution at position 713 of the coding sequence of the TP53 gene where guanine has been mutated to adenine.","TP53 NM_000546.5:c.713G>A | LFS1 c.713G>A | Li-Fraumeni Syndrome c.713G>A | NM_000546.5:c.713G>A | P53 c.713G>A | TP53 c.713G>A | Tumor Protein p53 c.713G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544989","CDISC Protocol Subject Allocation Response Terminology","C147068","Terminology associated with the subject allocation response codelist of the Clinical Data Interchange Standards Consortium (CDISC) protocol entities.","CDISC Protocol Subject Allocation Response Terminology | PROT-SUBALLRS | Participant Allocation Value Set",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544990","CDISC Protocol Randomization Type Response Terminology","C147069","Terminology associated with the randomization type response codelist of the Clinical Data Interchange Standards Consortium (CDISC) protocol entities.","CDISC Protocol Randomization Type Response Terminology | PROT-RANDTYP | Randomization Type Value Set",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1839333","Developmental and Epileptic Encephalopathy 2","C147070","An X-linked dominant form of early infantile epileptic encephalopathy, caused by mutation(s) in the CDKL5 gene, encoding cyclin-dependent kinase-like 5.","Developmental and Epileptic Encephalopathy 2 | CDKL5 Deficiency Disorder | Cyclin-Dependent Kinase-Like 5 Deficiency Disorder | DEE2 | EIEE2 | Early Infantile Epileptic Encephalopathy 2",,,,,,,,,,,,,,,"36676367","Cyclin-dependent kinase-like 5 deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL544991","EIEE6","C147071","An autosomal dominant form of early infantile epileptic encephalopathy, caused by mutation(s) in the SCN1A gene, encoding sodium channel protein type 1 subunit alpha.","Developmental and Epileptic Encephalopathy 6A | DEE6 | Dravet Syndrome | EIEE6 | Early Infantile Epileptic Encephalopathy 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0751208","Juvenile Huntington Disease","C147072","An early-onset form of Huntington disease (before age 20) caused by trinucleotide repeat expansion in the HTT gene, encoding huntingtin.","Juvenile Huntington Disease | ",,,,,,,,,,,,,,,"4043381","Juvenile onset Huntington's disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL544992","Canine Mammary Adenoma","C147073","An adenoma arising from the mammary gland of a dog.","Canine Mammary Adenoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0210233","recombinant soluble CD4","C1473","A recombinant form of CD4 antigen with anti-HIV application. Recombinant soluble T4 antigen (rsT4) is derived from cell surface antigen CD4 lacking its transmembrane and cytoplasmic domains, thereby the agent is mobile within tissues. rsT4 binds to the envelope glycoprotein gp110 of HIV and prevents the binding of virus to CD4 positive lymphocytes, resulting in an inhibition of virus infectivity.","Recombinant Soluble T4 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545435","FACIT-Dyspnea 10 Item Short Form - Part I: Making a Bed","C147655","Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Making a bed.","FACIT-Dyspnea 10 Item Short Form - Part I: Making a Bed | FAC084-Part I: Making a Bed | FAC08413",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545436","FACIT-Dyspnea 10 Item Short Form - Part I: Making a Bed Why Not","C147656","Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Making a bed. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea 10 Item Short Form - Part I: Making a Bed Why Not | FAC084-Part I: Making a Bed Why Not | FAC08414",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544978","GNAS NM_000516.5:c.601C>T","C146959","A nucleotide substitution at position 601 of the coding sequence of the GNAS gene where cytosine has been mutated to thymine.","GNAS NM_000516.5:c.601C>T | GNAS Complex Locus Gene c.601C>T | GNAS c.601C>T | GNAS1 c.601C>T | GSA c.601C>T | GSP c.601C>T | NM_000516.5:c.601C>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545128","Death Details (human clinical trials) Supplemental Qualifiers Dataset","C147197","A dataset containing supplemental information, specifically non-standard variables, to parent records in the death details (human clinical trials) domain.","Death Details (human clinical trials) Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545129","Device Events Supplemental Qualifiers Dataset","C147198","A dataset containing supplemental information, specifically non-standard variables, to parent records in the device events domain.","Device Events Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545115","Demographics Supplemental Qualifiers Dataset","C147200","A dataset containing supplemental information, specifically non-standard variables, to parent records in the demographics domain.","Demographics Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545116","Device Properties Supplemental Qualifiers Dataset","C147201","A dataset containing supplemental information, specifically non-standard variables, to parent records in the device properties domain.","Device Properties Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545117","Device Subject Relationships Supplemental Qualifiers Dataset","C147202","A dataset containing supplemental information, specifically non-standard variables, to parent records in the device subject relationships domain.","Device Subject Relationships Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545119","Device Tracking and Disposition Supplemental Qualifiers Dataset","C147204","A dataset containing supplemental information, specifically non-standard variables, to parent records in the device tracking and disposition domain.","Device Tracking and Disposition Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545120","Device In-Use Supplemental Qualifiers Dataset","C147205","A dataset containing supplemental information, specifically non-standard variables, to parent records in the device in-use domain.","Device In-Use Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545226","Device Exposure Supplemental Qualifiers Dataset","C147207","A dataset containing supplemental information, specifically non-standard variables, to parent records in the device exposure domain.","Device Exposure Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545395","Platinum-Resistant Ovarian Carcinoma","C147561","Ovarian carcinoma that progresses between one and six months of completing platinum therapy.","Platinum-Resistant Ovarian Carcinoma | Platinum-Resistant Ovarian Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545397","Anti-CD38/CD3 Bispecific Monoclonal Antibody GBR 1342","C147563","A humanized, bispecific monoclonal antibody (BsAb) against human CD3, a T-cell surface antigen, and the human cell surface glycoprotein CD38, a tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, anti-CD38/anti-CD3 bispecific monoclonal antibody GBR 1342 binds to both CD3 on T-cells and CD38 expressed on certain tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis. GBR 1342 uses the proprietary bispecific engagement by antibodies based on the T-cell receptor (BEAT) platform.","Anti-CD38/CD3 Bispecific Monoclonal Antibody GBR 1342 | Anti-CD38 x Anti-CD3 Bispecific Monoclonal Antibody GBR 1342 | Anti-CD38/Anti-CD3 Bispecific Monoclonal Antibody GBR 1342 | BEAT GBR 1342 | CD38xCD3 BsAb GBR 1342 | GBR 1342 | GBR-1342 | GBR1342",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0520983","Hormone Resistance","C147564","A finding indicating decreased tissue sensitivity to a hormone.","Hormone Resistance | Hormone Therapy Resistance",,,,,,,,,,,,,,,"4177861","Hormonal resistance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545399","ARHGEF10 wt Allele","C147566","Human ARHGEF10 wild-type allele is located in the vicinity of 8p23.3 and is approximately 135 kb in length. This allele, which encodes Rho guanine nucleotide exchange factor 10 protein, is involved in the regulation of GTPase-mediated signaling. Mutations in the gene are associated with autosomal dominant slowed nerve conduction velocity.","ARHGEF10 wt Allele | GEF10 | KIAA0294 | Rho Guanine Nucleotide Exchange Factor (GEF) 10 Gene | Rho Guanine Nucleotide Exchange Factor 10 wt Allele | SNCV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545670","TSCYC - Crying at Night Frightened","C147794","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Crying at night because he or she was frightened.","TSCYC - Crying at Night Frightened | TSCYC1-Crying at Night Frightened | TSCYC142",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545671","TSCYC - Hitting Adults","C147795","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Hitting adults (including parents).","TSCYC - Hitting Adults | TSCYC1-Hitting Adults | TSCYC143",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545672","TSCYC - Being Frightened of Men","C147796","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Being frightened of men.","TSCYC - Being Frightened of Men | TSCYC1-Being Frightened of Men | TSCYC144",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545673","TSCYC - Not Being Able to Pay Attention","C147797","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Not being able to pay attention.","TSCYC - Not Being Able to Pay Attention | TSCYC1-Not Being Able to Pay Attention | TSCYC145",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545113","TRPM6 wt Allele","C147083","Human TRPM6 wild-type allele is located in the vicinity of 9q21.13 and is approximately 166 kb in length. This allele, which encodes transient receptor potential cation channel subfamily M member 6 protein, is involved in both magnesium homeostasis and protein phosphorylation. Mutation of the gene is associated with hypomagnesemia.","TRPM6 wt Allele | CHAK2 | FLJ22628 | HMGX | HOMG | HOMG1 | HSH | Hypomagnesemia, Secondary Hypocalcemia Gene | Transient Receptor Potential Cation Channel Subfamily M Member 6 wt Allele | Transient Receptor Potential Cation Channel, Subfamily M, Member 6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545437","FACIT-Dyspnea 10 Item Short Form - Part I: Lifting 10-20 Lbs","C147657","Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Lifting something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries).","FACIT-Dyspnea 10 Item Short Form - Part I: Lifting 10-20 Lbs | FAC084-Part I: Lifting 10-20 Lbs | FAC08415",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545550","FACIT-Dyspnea 10 Item Short Form - Part I: Lifting 10-20 Lbs Why Not","C147658","Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Lifting something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries). Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea 10 Item Short Form - Part I: Lifting 10-20 Lbs Why Not | FAC084-Part I: Lifting 10-20 Lbs Why Not | FAC08416",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545551","FACIT-Dyspnea 10 Item Short Form - Part I: Carry 10-20 Lbs","C147659","Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Carrying something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries) from one room to another.","FACIT-Dyspnea 10 Item Short Form - Part I: Carry 10-20 Lbs | FAC084-Part I: Carry 10-20 Lbs | FAC08417",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545552","FACIT-Dyspnea 10 Item Short Form - Part I: Carry 10-20 Lbs Why Not","C147660","Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Carrying something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries) from one room to another. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea 10 Item Short Form - Part I: Carry 10-20 Lbs Why Not | FAC084-Part I: Carry 10-20 Lbs Why Not | FAC08418",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545553","FACIT-Dyspnea 10 Item Short Form - Part I: Walk for 1/2 Mile","C147661","Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Walking (faster than your usual speed) for 1/2 mile (almost 1 km) without stopping.","FACIT-Dyspnea 10 Item Short Form - Part I: Walk for 1/2 Mile | FAC084-Part I: Walk for 1/2 Mile | FAC08419",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545554","FACIT-Dyspnea 10 Item Short Form - Part I: Walk for 1/2 Mile Why Not","C147662","Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Walking (faster than your usual speed) for 1/2 mile (almost 1 km) without stopping. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea 10 Item Short Form - Part I: Walk for 1/2 Mile Why Not | FAC084-Part I: Walk for 1/2 Mile Why Not | FAC08420",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545555","FACIT-Dyspnea 10 Item Short Form - Part II: Dressing Without Help","C147663","Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part II Functional Limitation. Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Dressing yourself without help.","FACIT-Dyspnea 10 Item Short Form - Part II: Dressing Without Help | FAC084-Part II: Dressing Without Help | FAC08421",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545556","FACIT-Dyspnea 10 Item Short Form - Part II: Walk 50 Steps","C147664","Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part II Functional Limitation. Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Walking 50 steps/paces on flat ground at a normal speed without stopping.","FACIT-Dyspnea 10 Item Short Form - Part II: Walk 50 Steps | FAC084-Part II: Walk 50 Steps | FAC08422",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545228","ECG Test Results Supplemental Qualifiers Dataset","C147209","A dataset containing supplemental information, specifically non-standard variables, to parent records in the ECG test results domain.","ECG Test Results Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545229","Environmental and Social Factors Supplemental Qualifiers Dataset","C147210","A dataset containing supplemental information, specifically non-standard variables, to parent records in the environmental and social factors domain.","Environmental and Social Factors Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545230","Exposure Supplemental Qualifiers Dataset","C147211","A dataset containing supplemental information, specifically non-standard variables, to parent records in the exposure domain.","Exposure Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545232","Fetal Measurements Supplemental Qualifiers Dataset","C147213","A dataset containing supplemental information, specifically non-standard variables, to parent records in the fetal measurements domain.","Fetal Measurements Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546050","Oxacillin Resistant Staphylococcus aureus","C147469","A species of Gram-positive coccus-shaped bacterium in the family Micrococcaceae that is resistant to oxacillin.","Oxacillin Resistant Staphylococcus aureus | ORSA | OXACILLIN RESISTANT STAPHYLOCOCCUS AUREUS | Oxacillin-resistant Staphylococcus aureus | STAPHYLOCOCCUS AUREUS, OXACILLIN-RESISTANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545674","TSCYC - Seeming to Be Million Miles Away","C147798","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Seeming to be a million miles away.","TSCYC - Seeming to Be Million Miles Away | TSCYC1-Seeming to Be Million Miles Away | TSCYC146",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545675","TSCYC - Being Easily Startled","C147799","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Being easily startled.","TSCYC - Being Easily Startled | TSCYC1-Being Easily Startled | TSCYC147",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545676","TSCYC - Watching Out for Possible Danger","C147800","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Watching out everywhere for possible danger.","TSCYC - Watching Out for Possible Danger | TSCYC1-Watching Out for Possible Danger | TSCYC148",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545677","TSCYC - No Longer Doing Things Enjoy","C147801","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: No longer doing things that he or she used to enjoy.","TSCYC - No Longer Doing Things Enjoy | TSCYC1-No Longer Doing Things Enjoy | TSCYC149",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545662","TSCYC - Frightened Something Sexual Seen","C147802","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Becoming frightened or disturbed when something sexual was mentioned or seen.","TSCYC - Frightened Something Sexual Seen | TSCYC1-Frightened Something Sexual Seen | TSCYC150",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545663","TSCYC - Not Sleeping for Two or More Days","C147803","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Not sleeping for two or more days.","TSCYC - Not Sleeping for Two or More Days | TSCYC1-Not Sleeping for Two or More Days | TSCYC151",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545664","TSCYC - Not Paying Attention in Own World","C147804","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Not paying attention because he or she was in his or her own world.","TSCYC - Not Paying Attention in Own World | TSCYC1-Not Paying Attention in Own World | TSCYC152",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540755","Autologous Anti-BCMA-CAR Expressing Stem Memory T-cells P-BCMA-101","C142864","A preparation consisting of autologous T-cells that are enriched to be primarily stem memory T-cells (Tscm) and are transfected by electroporation with a proprietary transposon-based DNA plasmid vector (PiggyBac) containing an undisclosed selection gene and encoding both an unidentified human-derived safety switch and a chimeric antigen receptor (CAR) based on a proprietary non-immunoglobulin scaffold molecule Centyrin (CARTyrin), which specifically recognizes human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-BCMA-CAR-expressing Tscm P-BCMA-101 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. Use of CARTyrin may elicit less immunotoxicity than agents based on antibody-derived single chain variable fragments (scFv), and this agent may exhibit increased persistence and decreased exhaustion for the administered T-cells. If significant side effects occur, the safety switch mechanism can induce the rapid attenuation or elimination of P-BCMA-101. BCMA, a tumor-specific antigen and a member of the tumor necrosis factor receptor superfamily (TNFRSF) that binds to both a proliferation-inducing ligand (APRIL; TNFSF13) and B-cell activating factor (BAFF; TNFSF13B), plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and is overexpressed on malignant plasma cells.","Autologous Anti-BCMA-CAR Expressing Stem Memory T-cells P-BCMA-101 | Autologous Anti-BCMA Centyrin-based Chimeric Antigen Receptor-expressing Tscm | Autologous P-BCMA-101 CAR-T Cells | Autologous P-BCMA-101 CAR-T-cells | Autologous P-BCMA-101 CARTyrin-T cells | P-BCMA-101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540710","Autologous Anti-BCMA-CAR CD4+/CD8+ Cells","C142807","A preparation of ex vivo expanded autologous CD8+ and CD4+ T-cells that have been genetically modified to express a chimeric antigen receptor (CAR) specific for human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.","Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143 | Autologous Anti-BCMA-CAR CD4+/CD8+ Cells | Autologous Anti-BCMA-CAR-expressing CD8+ and CD4+ T-lymphocytes | BCMA CAR-CD4+/CD8+ T-cells | BCMA-specific CAR-expressing CD4+/CD8+ T-lymphocytes | FCARH143",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540709","Refractory Pancreatic Carcinoma","C142808","Pancreatic carcinoma that does not respond to treatment.","Refractory Pancreatic Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540707","Recurrent B Acute Lymphoblastic Leukemia","C142811","The reemergence of B acute lymphoblastic leukemia after a period of remission.","Recurrent B Acute Lymphoblastic Leukemia | Recurrent B-Cell Acute Lymphoblastic Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519280","Sexually Transmitted Agents","C14370","No value exists.","Sexually Transmitted Agents | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541357","Alisertib Sodium","C142912","The sodium salt form of alisertib, a second-generation, orally bioavailable,  selective inhibitor of the serine/threonine protein kinase Aurora A kinase, with potential antineoplastic activity. Upon oral administration, alisertib targets, binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation in susceptible cancer cells. Aurora A kinase localizes to the spindle poles and to spindle microtubules during mitosis, and is thought to regulate spindle assembly. Aberrant expression of Aurora kinases occurs in a wide variety of cancers and plays a key role in cancer cell proliferation.","Alisertib Sodium | ALISERTIB SODIUM | MLN8237 Sodium | MLN8237-004",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541358","Alniditan Dihydrochloride","C142913","No value exists.","Alniditan Dihydrochloride | ALNIDITAN DIHYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0051511","Aluminum Chlorohydrate","C142916","No value exists.","Aluminum Chlorohydrate | ALUMINUM CHLOROHYDRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541361","ALUMINUM CHLOROHYDREX PROPYLENE GLYCOL","C142917","No value exists.","Aluminum Chlorohydrex Propylene Glycol | ALUMINUM CHLOROHYDREX PROPYLENE GLYCOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541362","aluminum sesquichlorohydrate","C142918","No value exists.","Aluminum Sesquichlorohydrate | ALUMINUM SESQUICHLOROHYDRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541347","Amfenac Sodium","C142919","No value exists.","Amfenac Sodium | AMFENAC SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541604","Trimeric GITRL-Fc OMP-336B11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541605","Anti-CD19-CD20-CAR-CD3zeta-4-1BB-expressing Autologous T-lymphocytes","C143156","Autologous T-lymphocytes that have been transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) of anti-CD19 in tandem with an anti-CD20 scFv, and coupled to the cytoplasmic portion of the zeta chain of the human T-cell receptor (CD3zeta), and the co-stimulatory molecule 4-1BB (CD137), with potential immunostimulating and antineoplastic activities. Upon transfusion, anti-CD19-CD20-CAR-CD3zeta-4-1BB-expressing autologous T-lymphocytes recognize and direct T-cells to CD19- or CD20-expressing tumor B-cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19- or CD20-expressing tumor cells, and causes tumor cell lysis. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies.","Anti-CD19-CD20-CAR-CD3zeta-4-1BB-expressing Autologous T-lymphocytes | Anti-CD19/CD20 CAR Autologous T-lymphocytes | Autologous CAR-20/19-T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541606","Allogeneic Nicotinamide-expanded Natural Killer Cells","C143157","Allogeneic, nicotinamide (NAM)-expanded natural killer (NK) cells, with potential cytolytic and antineoplastic activities. Upon administration, the allogeneic NAM-expanded NK cells may lyse cancer cells. These cells also secrete pro-inflammatory cytokines, which further stimulate an anti-tumor immune response. Ex-vivo treatment with the vitamin B3 derivative NAM increases the in-vivo homing, retention and proliferation potential of the NK cells.","Allogeneic Nicotinamide-expanded Natural Killer Cells | Allogeneic NAM NK Cells | Allogeneic NAM NKs | Donor Nicotinamide expanded-Natural Killer Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541607","Microtubule Inhibitor SCB01A","C143158","An aroylindole derivative and tubulin polymerization inhibitor, with potential tubulin-inhibiting, vascular-disrupting and antineoplastic activities. Upon administration, tubulin polymerization inhibitor SCB01A binds at the colchicine binding site of tubulin and prevents its polymerization in tumor blood vessel endothelial cells and in tumor cells. This blocks the formation of the mitotic spindle and leads to both cell cycle arrest at the G2/M phase and tumor cell apoptosis. Also, this agent's effect on the tumor blood vessel endothelial cells leads to a disruption of the tumor vasculature and tumor blood flow, which deprives tumor cells of nutrients and induces tumor cell apoptosis.","Microtubule Inhibitor SCB01A | 6-Methoxy-3-(3',4',5'-trimethoxybenzoyl) Indole | BPR 0L075 | DBPR104 | SB 01 | SCB 01A | SCB-01A | SCB01A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541608","Hou Gu Mi Xi","C143159","An orally bioavailable dietary supplement and a formulation derived from the traditional Chinese medicine (TCM) Shen Ling Bai Zhu San, that can potentially be used to ameliorate spleen deficiency and improve symptoms of digestive disorders. Shen Ling Bai Zhu San is composed of ginseng, tuckahoe, atractylodes, baked licorice, coixenolide, Chinese yam, lotus seed, shrinkage fructus amomi, platycodon grandiflorum, white hyacinth bean, and dried orange peel. In Hou Gu Mi Xi, atractylodes and platycodon grandiflorum are removed from Shen Ling Bai Zhu San and perilla leaf is added. Upon oral administration, Hou Gu Mi Xi replenishes qi, and may improve spleen qi deficiency, gastrointestinal (GI) symptoms and GI function.","Hou Gu Mi Xi | TCM Hou Gu Mi Xi | Traditional Chinese Medicine Hou Gu Mi Xi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016720","Friend Murine Leukemia Virus","C14362","A murine leukemia virus producing leukemia of the reticulum-cell type with massive infiltration of liver, spleen, and bone marrow. It infects DBA/2 and Swiss mice.","Friend Murine Leukemia Virus | CFV | Friend Leukemia Virus | Friend Leukemia Virus, Conventional",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449798","Number of Metastases","C142987","An indication of the number of metastatic tumors detected.","Number of Metastases | ",,,,,,,,,,,,,,,"4091275","Number of metastases",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1265545","Bovidae","C14323","Taxonomic family which includes domestic cattle, goats, and sheep.","Bovidae | Bovid | Bovids",,,,,,,,,,,,,,,"4305278","Family Bovidae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1325725","Virus-like Particle","C14324","Non-infectious particle(s) derived from viral structural proteins. These particles are used as vaccines to stimulate a host immune response against the virus that the particles were derived from.","Virus-like Particle | VLP",,,,,,,,,,,,,,,"4283067","Virus-like particles",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0079936","Oncornavirus","C14371","An informal grouping of rna-containing viruses that are capable of inducing tumors.","Oncornavirus | RNA Tumor Virus",,,,,,,,,,,,,,,"4300298","Family Retroviridae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512691","Inbred Recombinant Congenic Mouse Strains","C14372","No value exists.","Inbred Recombinant Congenic Mouse Strains | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541475","ARQ-087 Dihydrochloride","C143047","No value exists.","Derazantinib Hydrochloride | AQ14741087 | ARQ 087.2HCl | ARQ-087 Dihydrochloride | Benzo(H)quinazolin-2-amine, 6-(2-Fluorophenyl)-5,6-dihydro-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-, Hydrochloride (1:2), (6R)- | DERAZANTINIB HYDROCHLORIDE | Derazantinib Dihydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541476","National Cancer Institute Terminology","C143048","Terminology sets that are designed to fulfill the need to have consistent coding, analysis, and data sharing across a broad range of National Cancer Institute (NCI) resources.","National Cancer Institute Terminology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006752","Caliciviridae","C14304","A family of single-stranded, non-segmented, positive-sense RNA viruses with a hexagonal/spherical capsid and no envelope. These viruses can be spread by the fecal-oral or respiratory route and infection typically leads to acute gastroenteritis.","Caliciviridae | CALICIVIRIDAE",,,,,,,,,,,,,,,"4085605","Family Caliciviridae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL541462","CRNKL1 wt Allele","C143050","Human CRNKL1 wild-type allele is located in the vicinity of 20p11.23 and is approximately 22 kb in length. This allele, which encodes crooked neck-like protein 1, plays a role in pre-mRNA splicing. Mutations in the gene may be associated with basal cell cancer.","CRNKL1 wt Allele | CGI-201 | CLF | CRN | Clf1 | Crn, Crooked Neck-Like 1 (Drosophila) Gene | Crooked Neck (Drosophila Crn Homolog)-Like 1 Gene | Crooked Neck Pre-mRNA Splicing Factor 1 wt Allele | Crooked Neck Pre-mRNA Splicing Factor-Like 1 (Drosophila) Gene | Crooked Neck, Drosophila, Homolog of Gene | Crooked Neck-Like 1 Gene | HCRN | MSTP021 | SYF3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282472","Canarypox Virus","C14315","A poxvirus of the genus Avipoxvirus.  Has been adapted as a cloning vector (canarypox vector) for use as a mammalian expression vector.","Canarypox Virus | Canarypox",,,,,,,,,,,,,,,"4197543","Canarypox virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL541609","Life Expectancy Greater than Six Months","C143160","A response indicating that an individual expects to, or is expected to, live longer than six months.","Life Expectancy Greater than Six Months | Life Expectancy More than 6 Months",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541611","PCM 075","C143162","An orally bioavailable, adenosine triphosphate (ATP) competitive inhibitor of polo-like kinase 1 (PLK1; PLK-1; STPK13), with potential antineoplastic activity. Upon administration, onvansertib selectively binds to and inhibits PLK1, which disrupts mitosis and induces selective G2/M cell-cycle arrest followed by apoptosis in PLK1-overexpressing tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase that is crucial for the regulation of mitosis, and plays a key role in tumor cell proliferation. PLK1 expression is upregulated in a variety of tumor cell types and high expression is associated with increased aggressiveness and poor prognosis.","Onvansertib | 'PLK1 Inhibitor PCM-075 | NMS-1286937 | ONVANSERTIB | PCM 075 | PCM-075 | PLK-1 Inhibitor PCM-075 | PLK1 Inhibitor PCM-075 | Polo-like Kinase 1 Inhibitor NMS-1286937 | Polo-like Kinase 1 Inhibitor PCM-075",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540593","Secondary Outcome Variable","C142680","A factor or condition subject to change in a clinical trial that is used to evaluate additional effects of the intervention not included in the primary outcome measure.","Secondary Outcome Variable | secondary outcome variable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540606","Self-Evident Change","C142681","An information error that can be quickly and accurately fixed based on existing data on the form.","Self-Evident Change | self-evident change",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540605","Semantic Interoperability","C142682","The ability of computer systems to share data with unambiguous meaning.","Semantic Interoperability | semantic interoperability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540604","Sensitive Data","C142683","Any information that, in the event of re-identification, would harm a patient in terms of employability, reputation, insurability, or self-esteem or results in loss of income. (HIPAA)","Sensitive Data | sensitive data",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL340767","Arm of","C142684","An outlined set of steps that correspond to a therapeutic intervention for a clinical trial.","Sequence Arm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540603","Serious Adverse Drug Reaction","C142685","A noxious and unintended response to a medicinal product occurring at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in a persistent or significant disability/incapacity, or results in a congenital anomaly/birth defect.","Serious Adverse Drug Reaction | Serious ADR | serious adverse drug reaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545905","Serious Adverse Experience","C142686","A situation referring to a severe reaction, risk or indication against use of a treatment or device.","Serious Adverse Experience | SAE | serious adverse experience (SAE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540602","Serious Risk","C142687","No value exists.","Serious Risk | serious risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540601","Signal of a Serious Risk","C142688","Information related to a serious adverse drug experience associated with use of a drug and derived from-(a) a clinical trial; (b) adverse event reports; (c) a post-approval study; (d) peer-reviewed biomedical literature; (e) data derived from the post-market REMs. [505-1(b) of FD&C Act (21 USC. 355-1(b)]","Signal of a Serious Risk | signal of a serious risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540586","Site Screening","C142689","The process by which a location is monitored and assessed to ensure that the venue and staff are appropriate for clinical study work.","Site Screening | screening (of sites)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541405","SPA17 Gene","C142990","This gene plays a role in binding to carbohydrates in the zona pellucida.","SPA17 Gene | SPA17 | Sperm Autoantigenic Protein 17 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541406","SPA17 wt Allele","C142991","Human SPA17 wild-type allele is located in the vicinity of 11q24.2 and is approximately 24 kb in length. This allele, which encodes sperm surface protein Sp17, is involved in the binding of spermatozoa to oocytes. Aberrant expression may be associated with neoplastic disease.","SPA17 wt Allele | CT22 | SP17 | SP17-1 | Sperm Autoantigenic Protein 17 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1433301","SPA17 protein, human","C142992","Sperm surface protein Sp17 (151 aa, ~17 kDa) is encoded by the human SPA17 gene. This protein plays a role in the binding of spermatozoa to the carbohydrates in the zona pellucida.","Sperm Surface Protein Sp17 | CT22 | Cancer/Testis Antigen 22 | SPA17 | Sp17 | Sp17-1 | Sperm Autoantigenic Protein 17 | Sperm Protein 17",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541397","Vabicaserin Hydrochloride","C142993","No value exists.","Vabicaserin Hydrochloride | VABICASERIN HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541398","AKAP4 Gene","C142994","This gene is involved in both sperm motility and protein kinase A binding.","AKAP4 Gene | A-Kinase Anchoring Protein 4 Gene | AKAP4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541399","AKAP4 wt Allele","C142995","Human AKAP4 wild-type allele is located in the vicinity of Xp11.22 and is approximately 10 kb in length. This allele, which encodes A-kinase anchor protein 4, plays a role in both protein kinase A localization and sperm motility. Aberrant expression may be associated with neoplastic disease.","AKAP4 wt Allele | A Kinase (PRKA) Anchor Protein 4 Gene | A-Kinase Anchor Protein, 82-kD Gene | A-Kinase Anchoring Protein 4 wt Allele | AKAP 82 | AKAP-4 | AKAP82 | CT99 | FSC1 | FSC1, Mouse, Homolog of Gene | HI | Testis-Specific Gene HI | hAKAP82 | p82",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1431594","AKAP4 protein, human","C142996","A-kinase anchor protein 4 (854 aa, ~94 kDa) is encoded by the human AKAP4 gene. This protein is involved in the localization of protein kinase A in sperm.","A-Kinase Anchor Protein 4 | A-Kinase Anchor Protein 82 kDa | A-Kinase Anchoring Protein 4 | AKAP 82 | AKAP-4 | AKAP4 | HI | Major Sperm Fibrous Sheath Protein | PRKA4 | Protein Kinase A Anchoring Protein 4 | Protein Kinase A-Anchoring Protein 4 | hAKAP82",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541400","Tubocurarine Chloride Anhydrous","C142997","No value exists.","Tubocurarine Chloride Anhydrous | TUBOCURARINE CHLORIDE ANHYDROUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541401","Pentaazacentopthylene","C142998","No value exists.","Triciribine | 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-Dihydro-5-methyl-1-beta-D-ribofuranosyl- | Pentaazacentopthylene | TRICIRIBINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541402","Tasidotin Hydrochloride","C142999","No value exists.","Tasidotin Hydrochloride | TASIDOTIN HYDROCHLORIDE | Tasidotin HCl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0164678","Vapreotide","C1429","A synthetic cyclic octapeptide analogue of somatostatin with direct and indirect antitumor effects. Vapreotide binds to somatostatin receptors (SSTR), specifically SSTR-2 and to SSTR-5 with a lesser affinity, in the similar behaviors as other octapeptide somatostatin analogues. Like octreotide, this agent has direct and indirect antitumor effects via inhibiting the release of growth hormone and other peptides that regulate release of insulin, gastrointestinal hormones. Furthermore, vapreotide may also be useful for inducing hemostasis in cases of acute hemorrhage of the upper gastrointestinal tract.","Vapreotide | BMY-41606 | Docrised | RC-160 | VAPREOTIDE | vapreotide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541403","Semuloparin Sodium","C143000","No value exists.","Semuloparin Sodium | SEMULOPARIN SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541390","Sibopirdine Anhydrous","C143001","No value exists.","Sibopirdine Anhydrous | 5H-Cyclopenta(2,1-b-3,4-b')dipyridine, 5,5-Bis(4-pyridinylmethyl)- | SIBOPIRDINE ANHYDROUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541391","Lifastuzumab","C143002","No value exists.","Lifastuzumab | LIFASTUZUMAB | MNIB2126A | NaPi3b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540662","RAB12 Gene","C142754","This gene is involved in intracellular membrane and protein trafficking.","RAB12 Gene | RAB12 | RAB12, Member RAS Oncogene Family Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540661","RAB12 wt Allele","C142755","Human RAB12 wild-type allele is located in the vicinity of 18p11.22 and is approximately 30 kb in length. This allele, which encodes Ras-related protein Rab-12, plays a role in vesicle transport.","RAB12 wt Allele | RAB12, Member RAS Oncogene Family wt Allele | Rab-12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4045245","Rab12 protein, human","C142756","Ras-related protein Rab-12 (244 aa, ~27 kDa) is encoded by the human RAB12 gene. This protein is involved in the regulation of trafficking of intracellular vesicles.","Ras-Related Protein Rab-12 | RAB12 | Ras-Associated Protein Rab12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540643","TOR1A Gene","C142757","This gene plays a role in post-translational processing of proteins.","TOR1A Gene | TOR1A | Torsin Family 1 Member A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540642","TOR1A wt Allele","C142758","Human TOR1A wild-type allele is located in the vicinity of 9q34.11 and is approximately 11 kb in length. This allele, which encodes torsin-1A protein, is involved in chaperone activity. Mutation of the gene is associated with autosomal dominant torsion dystonia 1.","TOR1A wt Allele | DQ2 | DYT1 | Dystonia 1, Torsion (Autosomal Dominant; Torsin A) Gene | TA | TORA | Torsin A Gene | Torsin Family 1 Member A wt Allele | Torsin Family 1, Member A (Torsin A) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0665823","TOR1A protein, human","C142759","Torsin-1A (332 aa, ~38 kDa) is encoded by the human TOR1A gene. This protein plays a role in protein folding, maturation and localization.","Torsin-1A | Dystonia 1 Protein | EC 3.6.4.- | TOR1A | Torsin 1A | Torsin A | Torsin ATPase 1 | Torsin ATPase-1A | Torsin Family 1 Member A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037788","Specific Pathogen Free Organism","C14275","An organism that is born and reared in an environment that is lacking a select individual disease-causing organism or a whole class of pathogens.","Specific Pathogen Free Organism | SPF Organism | Specific-Pathogen-Free Organism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540640","SLC38A9 Gene","C142760","This gene is involved in signaling and lysosomal amino acid transport.","SLC38A9 Gene | SLC38A9 | Solute Carrier Family 38 Member 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540639","SLC38A9 wt Allele","C142761","Human SLC38A9 wild-type allele is located in the vicinity of 5q11.2 and is approximately 147 kb in length. This allele, which encodes sodium-coupled neutral amino acid transporter 9 protein, plays a role in both amino acid sensing and the regulation of mammalian target of rapamycin complex 1 (mTORC1) activity.","SLC38A9 wt Allele | FLJ90709 | Solute Carrier Family 38 Member 9 wt Allele | Solute Carrier Family 38, Member 9 Gene | URLC11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3884687","SLC38A9 protein, human","C142762","Sodium-coupled neutral amino acid transporter 9 (561 aa, ~64 kDa) is encoded by the human SLC38A9 gene. This protein is involved in amino acid sensing, amino acid transport and activation of the mammalian target of rapamycin complex 1 (mTORC1).","Sodium-Coupled Neutral Amino Acid Transporter 9 | SLC38A9 | Solute Carrier Family 38 Member 9 | Up-Regulated In Lung Cancer 11 | Upregulated In Lung Cancer 11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540637","MIR509-1 Gene","C142763","This gene is involved in silencing gene transcription.","MIR509-1 Gene | MIR509-1 | MicroRNA 509-1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540652","MIR509-2 Gene","C142764","This gene is involved in the silencing of transcription.","MIR509-2 Gene | MIR509-2 | MicroRNA 509-2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540651","MIR509-1 wt Allele","C142765","Human MIR509-1 wild-type allele is located in the vicinity of Xq27.3 and is approximately 94 bases in length. This allele, which encodes MIR509-1 pre-miRNA, plays a role in the modulation of target gene expression.","MIR509-1 wt Allele | MIRN509 | MIRN509-1 | Micro RNA 509 Gene | Micro RNA 509-1 Gene | MicroRNA 509 Gene | MicroRNA 509-1 wt Allele | hsa-mir-509 | hsa-mir-509-1 | miRNA509-1 | mir-509-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540650","MIR509-2 wt Allele","C142766","Human MIR509-2 wild-type allele is located in the vicinity Xq27.3 and is approximately 91 bases in length. This allele, which encodes MIR509-2 pre-miRNA, plays a role in gene silencing.","MIR509-2 wt Allele | MIRN509-2 | Micro RNA 509-2 Gene | MicroRNA 509-2 wt Allele | hsa-mir-509-2 | mir-509-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0966214","CRNKL1 protein, human","C143051","Crooked neck-like protein 1 (848 aa, ~100 kDa) is encoded by the human CRNKL1 gene. This protein is involved in splicing of pre-mRNA.","Crooked Neck-Like Protein 1 | CRNKL1 | Crooked Neck Homolog | Crooked Neck Pre-mRNA Splicing Factor 1 | SYF3 Pre-mRNA-Splicing Factor | hCrn",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541465","COL3A1 wt Allele","C143053","Human COL3A1 wild-type allele is located in the vicinity of 2q32.2 and is approximately 38 kb in length. This allele, which encodes collagen alpha-1(III) chain protein, is involved in collagen formation. Mutations in this gene are associated with Ehlers-Danlos syndrome type IV, aortic and arterial aneurysms and lipoblastoma.","COL3A1 wt Allele | Collagen Type III Alpha 1 Chain wt Allele | Collagen, Blood Vessel Gene | Collagen, Fetal Gene | Collagen, Type III, Alpha 1 Gene | Collagen, Type III, Alpha-1 Gene | EDS4A | Ehlers-Danlos Syndrome Type IV, Autosomal Dominant Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541466","COL3A1 Gene Product","C143054","A protein encoded by the COL3A1 gene.","COL3A1 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1448187","COL3A1 protein, human","C143055","Collagen alpha-1(III) chain (1466 aa, ~139 kDa) is encoded by the human COL3A1 gene. This protein plays a role in connective tissue organization.","Collagen Alpha-1(III) Chain | Alpha-1 Type 3 Collagen | Alpha-1 Type III Collagen | Alpha1 (III) Collagen | COL3A1 | Collagen Type 3 Alpha 1 Chain | Collagen Type III Alpha 1 Chain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541469","CNBD1 wt Allele","C143057","Human CNBD1 wild-type allele is located in the vicinity of 8q21.3 and is approximately 749 kb in length. This allele, which encodes cyclic nucleotide-binding domain-containing protein 1, plays a role in cyclic nucleotide binding. Mutations in the gene may be associated with gastric cancer and colorectal cancer.","CNBD1 wt Allele | Cyclic Nucleotide Binding Domain Containing 1 wt Allele | FLJ35802",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541454","Cyclic Nucleotide-Binding Domain-Containing Protein 1","C143058","Cyclic nucleotide-binding domain-containing protein 1 (436 aa, ~50 kDa) is encoded by the human CNBD1 gene. This protein is involved in cyclic nucleotide binding.","Cyclic Nucleotide-Binding Domain-Containing Protein 1 | CNBD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541455","Prime Cancer Vaccine MVA-BN-CV301","C143059","A cancer priming vaccine consisting of a proprietary version of the recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN), encoding both the two human tumor-associated antigens (TAAs) carcinoembryonic antigen (CEA) and mucin-1 (MUC-1), and TRICOM, which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration of MVA-BN-CV301, followed by multiple boosting doses of the fowlpox virus (FPV) vaccine CV301, a cytotoxic T-lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells is activated. In addition, the CV301-dependent anti-tumor CTL response upregulates the expression of programmed cell death ligand 1 (PD-L1); therefore, when CV301 is combined with a programmed cell death 1 (PD-1) immune checkpoint inhibitor, the antitumor effect may be increased. CEA and MUC-1 are overexpressed in a variety of cancers.","Prime Cancer Vaccine MVA-BN-CV301 | MVA-BN Vaccine CV301 | MVA-BN-CV301 | Modified Vaccinia Ankara-Bavarian Nordic Vaccine CV301 | Prime Vaccine CV301",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510995","Avian Leukemia Sarcoma Virus","C14332","A type C avian retrovirus","Avian Leukemia Sarcoma Virus | ALSV-A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545906","Software Validation","C142690","A process of confirmation by examination and provision of objective evidence that software specifications conform to user needs and intended uses and that the particular requirements implemented through software can be consistently fulfilled.","Software Validation | software validation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540585","Source Document","C142692","The original information in a variety of media, which may substantiate information contained in an electronic record of the study.","Source Document | source documents",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540584","Source Document Verification","C142693","Confirming the accuracy, authenticity, and thoroughness of a primary record by comparing it to original evidence and reports.","Source Document Verification | source document verification (SDV)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540583","Specified Substance","C142694","Substance defined by groups of elements that describes multi-substance materials or specifies further information on substances relevant to the description of Medicinal Products. (IDMP)","Specified Substance | specified substance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540582","Sponsor-Investigator","C142695","An individual person who both initiates and conducts, alone or with others, a clinical trial and under whose immediate direction the investigational product is administered to, dispensed to, or used by a subject. (FDA)","Sponsor-Investigator | sponsor-investigator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540592","Stopping Rules","C142698","A set of circumstances in which the study should be stopped early, keeping in mind the statistical reliability of the circumstances.","Stopping Rules | stopping rules",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517710","Laboratory Organism","C14354","A grouping of those organisms that are commonly used in laboratory research.","Laboratory Organism | Experimental Organism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0752124","Spinocerebellar Ataxia Type 6","C142838","An autosomal recessive spinocerebellar ataxia caused by an expanded CAG repeat in the CACNA1A gene, encoding voltage-dependent P/Q-type calcium channel subunit alpha-1A. It is an almost pure cerebellar syndrome, with onset typically between the ages of 20 to 60.","Spinocerebellar Ataxia Type 6 | SCA6",,,,,,,,,,,,,,,"37396075","Spinocerebellar ataxia type 6",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540649","MIR509-1 Pre-miRNA","C142767","MIR509-1 pre-miRNA is an oligonucleotide (94 bases) that is encoded by the human MIR509-1 gene and is involved in the regulation of gene expression.","MIR509-1 Pre-miRNA | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540648","MIR509-2 Pre-miRNA","C142768","MIR509-2 pre-miRNA is an oligonucleotide (91 bases) that is encoded by the human MIR509-2 gene and may play a role in the regulation of gene expression.","MIR509-2 Pre-miRNA | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540647","MicroRNA 509-5p","C142769","A 21 ribonucleotide sequence that is a final product of the processing of either MIR509-1 pre-miRNA or MIR509-2 pre-miRNA. This oligonucleotide may be involved in the negative regulation of gene expression.","MicroRNA 509-5p | hsa-mir-509-5p | miR-509-5p | miRNA 509-5p",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541535","FAM47C wt Allele","C143110","Human FAM47C wild-type allele is located in the vicinity of Xp21.1 and is approximately 3 kb in length. This allele, which encodes putative protein FAM47C, has no known function.","FAM47C wt Allele | Family with Sequence Similarity 47 Member C wt Allele | Family with Sequence Similarity 47, Member C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541536","Putative Protein FAM47C","C143111","Putative protein FAM47C (1035 aa, ~115 kDa) is encoded by the human FAM47C gene. This protein has no known function.","Putative Protein FAM47C | Family with Sequence Similarity 47 Member C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541538","FAM135B wt Allele","C143113","Human FAM135B wild-type allele is located in the vicinity of 8q24.23 and is approximately 367 kb in length. This allele, which encodes protein FAM135B, may be involved in cholesterol metabolism.","FAM135B wt Allele | C8ORFK32 | Family with Sequence Similarity 135 Member B wt Allele | Family with Sequence Similarity 135, Member B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541523","Protein FAM135B","C143114","Protein FAM135B (1406 aa, ~156 kDa) is encoded by the human FAM135B gene. This protein may play a role in lipid metabolism.","Protein FAM135B | Family with Sequence Similarity 135 Member B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541525","CTNNA2 wt Allele","C143116","Human CTNNA2 wild-type allele is located in the vicinity of 2p12 and is approximately 1464 kb in length. This allele, which encodes catenin alpha-2 protein, plays a role in neuronal differentiation.","CTNNA2 wt Allele | CAP-R | CAPR | CT114 | CTNR | Cadherin-Associated Protein, Related Gene | Catenin (Cadherin-Associated Protein), Alpha 2 Gene | Catenin Alpha 2 wt Allele | Catenin, Alpha-2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0657307","CTNNA2 protein, human","C143117","Catenin alpha-2 (953 aa, ~105 kDa) is encoded by the human CTNNA2 gene. This protein is involved in neuronal differentiation and neural development.","Catenin Alpha-2 | Alpha N-Catenin | Alpha-Catenin-Related Protein | Alpha-N-Catenin | CTNNA2 | Cancer/Testis Antigen 114 | Catenin Alpha 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541528","RGS7 wt Allele","C143119","Human RGS7 wild-type allele is located in the vicinity of 1q43 and is approximately 582 kb in length. This allele, which encodes regulator of G-protein signaling 7 protein, is involved in the stimulation of G alpha activation.","RGS7 wt Allele | Regulator of G Protein Signaling 7 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1505333","RGS7 protein, human","C143120","Regulator of G-protein signaling 7 (495 aa, ~58 kDa) is encoded by the human RGS7 gene. This protein plays a role in the promotion of G alpha protein GTPase activity.","Regulator of G-Protein Signaling 7 | RGS7 | Regulator of G Protein Signaling 7 | Regulator of G-Protein Signalling 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0297511","PRDM2 protein, human","C143123","PR domain zinc finger protein 2 (1718 aa, ~189 kDa) is encoded by the human PRDM2 gene. This protein is involved in both transcriptional regulation and the methylation of histone H3.","PR Domain Zinc Finger Protein 2 | EC 2.1.1.43 | GATA-3 Binding Protein G3B | GATA-3-Binding Protein G3B | Lysine N-Methyltransferase 8 | MTB-ZF | MTE-Binding Protein | PR Domain-Containing Protein 2 | PRDM2 | Retinoblastoma Protein-Binding Zinc Finger Protein | Retinoblastoma Protein-Binding Zinc Finger Protein RIZ | Retinoblastoma Protein-Interacting Zinc Finger Protein | Zinc Finger Protein RIZ | Zinc-Finger DNA-Binding Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510832","Agents of Opportunistic Infection","C14355","Infectious agents, which while normally present but remaining benign under the control of the immune system, become virulent and pathogenic in immune-compromised hosts (i.e when they get the opportunity to become infectious).","Agents of Opportunistic Infection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0950105","Betaretrovirus","C14291","A genus of single-stranded, reverse-transcribing RNA retroviruses with type B or type C morphology. It is the genus to which the mouse mammary tumor virus (MMTV) belongs.","Betaretrovirus | Retroviruses, Type B, Mammalian | Type B Mammalian Retrovirus | Type B Virus | Type D Retrovirus",,,,,,,,,,,,,,,"4248379","Genus Betaretrovirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL541348","Amicloral","C142920","No value exists.","Amicloral | AMICLORAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541349","Amifampridine Phosphate","C142921","No value exists.","Amifampridine Phosphate | AMIFAMPRIDINE PHOSPHATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541350","Amiselimod Hydrochloride","C142922","No value exists.","Amiselimod Hydrochloride | AMISELIMOD HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541351","Amitifadine Hydrochloride","C142923","No value exists.","Amitifadine Hydrochloride | AMITIFADINE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541352","Angiotensin II Acetate","C142924","The acetate salt form of therapeutic angiotensin II, a synthetic form of the endogenous angiotensin II, a peptide hormone of the renin-angiotensin-aldosterone system (RAAS) that causes vasoconstriction and an increase in blood pressure, that may be used for the treatment of septic or other distributive shock. Upon administration, therapeutic angiotensin II binds to angiotensin II type 1 receptor on vascular smooth muscle cells which leads to Ca2+/calmodulin-dependent phosphorylation of myosin. This causes smooth muscle contraction and results in vasoconstriction and an increase in blood pressure. Therapeutic angiotensin II also increases blood pressure by stimulating the release of the steroid hormone aldosterone, which regulates the renal absorption of water and sodium.","Angiotensin II Acetate | ANGIOTENSIN II ACETATE | Giapreza",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541353","Anivamersen Sodium","C142925","No value exists.","Anivamersen Sodium | ANIVAMERSEN SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541354","Anoxomer","C142926","No value exists.","Anoxomer | ANOXOMER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541339","antimony trisulfide","C142927","No value exists.","Antimony Trisulfide | ANTIMONY TRISULFIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541341","Aptiganel Hydrochloride","C142929","No value exists.","Aptiganel Hydrochloride | APTIGANEL HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518665","Other Organism Groupings","C14376","A non-taxonomic grouping of organisms based on a shared characteristic.","Other Organism Groupings | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541448","IDO-1 Inhibitor LY3381916","C143068","An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1; IDO-1), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1 inhibitor LY3381916 specifically targets and binds to IDO1, a cytosolic enzyme responsible for the oxidation of the amino acid tryptophan into the immunosuppressive metabolite kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, LY3381916 restores and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes, and causes a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL) response against the IDO1-expressing tumor cells, thereby inhibiting the growth of IDO1-expressing tumor cells. IDO1, overexpressed by multiple tumor cell types, plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system.","IDO-1 Inhibitor LY3381916 | IDO1 Inhibitor LY3381916 | LY-3381916 | LY3381916",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541392","SPIROGERMANIUM HYDROCHLORIDE","C143003","No value exists.","Spirogermanium Hydrochloride | 2-(3-(Dimethylamino)propyl)-8,8-diethyl-2-aza-8-germaspiro(4.5)decane Dihydrochloride | 2-Aza-8-germaspiro(4.5)decane-2-propanamine, 8,8-Diethyl-N,N-dimethyl-, Dihydrochloride | 2-Aza-8-germaspiro[4.5]decane-2-propanamine, 8, 8-diethyl-N,N-dimethyl-, dihydrochloride | 8,8-Diethyl-N,N-dimethyl-2-aza-8-germaspiro(4.5)decane-2-propanamine Dihydrochloride | SPIROGERMANIUM HYDROCHLORIDE | Spirogermanium HCl | Spirogermanium hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541393","Squalamine","C143004","No value exists.","Squalamine | 3-((3-(4-(Aminobutyl)amino)propyl)amio)cholestane-7,24-diol 24-(Hydrogen Sulfate), (3beta,5alpha,7alpha,24R)- | Cholestane-7,24-diol, 3-((3-(4-(Aminobutyl)amino)propyl)amio)-, 24-(Hydrogen sulfate), (3beta,5alpha,7alpha,24R)- | SQUALAMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541394","Sodium Picosulfate Anhydrous","C143005","No value exists.","Sodium Picosulfate Anhydrous | 4,4'-(2-Pyridylmethylene)diphenol Bis(hydrogen Sulfate) Disodium Salt | SODIUM PICOSULFATE ANHYDROUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541396","ROPN1 Gene","C143008","This gene plays a role in spermatozoa capacitation.","ROPN1 Gene | ROPN1 | Rhophilin Associated Tail Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541500","ROPN1 wt Allele","C143009","Human ROPN1 wild-type allele is located in the vicinity of 3q21.1 and is approximately 23 kb in length. This allele, which encodes ropporin-1A protein, is involved in sperm capacitation. Aberrant expression may be associated with neoplastic disease.","ROPN1 wt Allele | CT91 | ODF6 | RHPNAP1 | ROPN1A | Rhophilin Associated Tail Protein 1 wt Allele | Ropporin Gene | Ropporin, Rhophilin Associated Protein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086943","Rous Sarcoma Virus","C14300","A species of single-stranded, reverse-transcribing RNA retrovirus of the genus alpharetrovirus and the family retroviridae. It is the first oncovirus described in the literature and was found to cause sarcoma in chickens.","Rous Sarcoma Virus | RSV",,,,,,,,,,,,,,,"4231254","Rous sarcoma virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1438785","ROPN1 protein, human","C143010","Ropporin-1A (212 aa, ~24 kDa) is encoded by the human ROPN1 gene. This protein plays a role in sperm motility and capacitation.","Ropporin-1A | CT91 | Cancer/Testis Antigen 91 | Outer Dense Fiber of Sperm Tails 6 | ROPN1 | Rhophilin Associated Tail Protein 1 | Rhophilin-Associated Protein 1A | Ropporin | Testis Secretory Sperm-Binding Protein Li 239w",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540545","Operational Model","C142622","A design model that lays out how a study will be carried out in order to fulfill its objectives.","Operational Model | operational model",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540544","Original Data","C142623","The values reported in the initial documents used to record study data.","Original Data | original data",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0150103","MATCHING","C142624","A subject selection method whereby subjects with similar characteristics are assigned as a pair, with the intention that each will receive different treatment within the course of the clinical trial.","Pairing | matching | pairing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540530","Paper Case Report Form","C142625","A case report form that is printed on paper.","Paper Case Report Form | CRF (paper)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540529","Password Aging","C142626","A system for computer access control that requires a user to create a new password at set intervals.","Password Aging | Password Expiration | password aging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540528","Patient File","C142627","A file containing demographic, medical, and treatment information pertaining to an individual patient.","Patient File | patient file",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541259","Patient Reported Outcome Stem","C142628","The prompt, question or instruction in a patient-reported outcome item. (CDISC Glossary)","Patient Reported Outcome Stem | PRO Stem | stem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540527","Patient-reported Outcome Item","C142629","A question, statement, or task and its pre-specified response values within a patient-reported outcome instrument.","Patient-reported Outcome Item | PRO Item | PRO Question | item (PRO)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033147","Primate","C14262","The taxonomic order of mammals that includes man, monkeys, and lemurs.","Primate | Mammals, Primates | Primates",,,,,,,,,,,,,,,"4310496","Order Primates",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540526","Patient-Reported Outcome Item Generation","C142630","The process for identifying the individual questions, statements, or tasks within a patient reported outcome (PRO) instrument.","Patient-Reported Outcome Item Generation | PRO Item Generation | item generation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540525","Performance Outcome","C142632","A clinical outcome assessment in which a task is performed by a subject under the administration of a healthcare professional.","Performance Outcome | PerfO | performance outcome (PerfO)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540536","Period Effect","C142633","A change which occurs at a particular time, affecting all age groups and cohorts uniformly.","Period Effect | period effect",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540535","Permanent Data","C142634","Data that is not, under normal circumstances, subject to change.","Permanent Data | permanent data",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540534","Per-Protocol Analysis Set","C142635","The set of data generated by the subset of subjects who complied with the protocol sufficiently to ensure that these data would be likely to exhibit the effects of treatment according to the underlying scientific model. (ICH)","Per-Protocol Analysis Set | per-protocol analysis set",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206335","Economics, Pharmaceutical","C142636","A scientific discipline, and subdivision of Health Economics, that compares one pharmaceutical product or treatment to another with respect to various cost comparison measures.","Pharmacoeconomics | pharmacoeconomics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3178990","Pharmacovigilance","C142637","Surveillance of drug performance, including detection, monitoring, and prevention of adverse effects by substances with pharmacological activity.","Pharmacovigilance | pharmacovigilance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540533","Planned Trial Subject Contact","C142638","Any intended, protocol-defined activity involving data collection from a study subject.","Planned Trial Subject Contact | subject trial contact",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540532","Postmarketing Commitment","C142639","A candidate's agreement to carry out investigations or trials that are not required by any legal provision.","Postmarketing Commitment | postmarketing commitment (PMC)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541342","Aripiprazole Cavoxil","C142930","No value exists.","Aripiprazole Cavoxil | ARIPIPRAZOLE CAVOXIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541343","Aripiprazole Lauroxil","C142931","No value exists.","Aripiprazole Lauroxil | ARIPIPRAZOLE LAUROXIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541344","Artilide Fumarate","C142932","No value exists.","Artilide Fumarate | ARTILIDE FUMARATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541346","Asalhydromorphone Hydrochloride","C142934","No value exists.","Asalhydromorphone Hydrochloride | ASALHYDROMORPHONE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541331","Asvasiran Sodium","C142935","No value exists.","Asvasiran Sodium | ASVASIRAN SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541332","Atesidorsen Sodium","C142936","No value exists.","Atesidorsen Sodium | ATESIDORSEN SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541333","Atopaxar Hydrobromide","C142937","No value exists.","Atopaxar Hydrobromide | ATOPAXAR HYDROBROMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541335","Atropine Oxide Hydrochloride","C142939","No value exists.","Atropine Oxide Hydrochloride | ATROPINE OXIDE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0080180","Spumavirus","C14293","Genus of retroviruses which establish persistent, but non pathogenic infections in mammals and primates, including humans, chimpanzees, cattle, and cats. It is unique among retroviruses in having infectious particles that carry DNA rather than RNA. Similar to hepadnaviruses, spumaviruses bud from the endoplasmic reticulum instead of the plasma membrane. Infected cells accumulate vacuoles, giving them a foamy appearance and are often involved in syncytium formation.","Spumavirus | Foamy Retrovirus | Foamy Virus",,,,,,,,,,,,,,,"4234491","Genus Spumavirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL541336","Avacincaptad Pegol Sodium","C142940","No value exists.","Avacincaptad Pegol Sodium | AVACINCAPTAD PEGOL SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541337","Avatrombopag Maleate","C142941","The maleate salt form of avatrombopag, an orally available platelet thrombopoietin receptor (TPOR; MPL) agonist, with potential megakaryopoiesis stimulating activity. Upon administration, avatrombopag binds to and stimulates TPOR, which may lead to the proliferation and differentiation of megakaryocytes from bone marrow progenitor cells. This increases the production of platelets and may prevent chemotherapy-induced thrombocytopenia (CIT). TPOR is a cytokine receptor and member of the hematopoietin receptor superfamily.","Avatrombopag Maleate | 1-(3-Chloro-5-((4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2- yl)carbamoyl)pyridin-2-yl)piperidine-4-carboxylic acid mono-(2Z)-but-2-enedioate | 4-Piperidinecarboxylic Acid, 1-(3-Chloro-5-(((4-(4-chloro-2-thienyl)-5-(4-cyclohexyl-1- piperazinyl)-2-thiazolyl)amino)carbonyl)-2-pyridinyl)-, (2Z)-2-butenedioate (1:1) | AVATROMBOPAG MALEATE | E5501 Maleate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3892871","Avibactam Sodium","C142942","No value exists.","Avibactam Sodium | AVIBACTAM SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541596","CTCAE by Body System","C143163","No value exists.","CTCAE by Body System | Common Terminology Criteria for Adverse Events by Body System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541597","Blood and Lymphatic System Disorders, CTCAE","C143164","No value exists.","Blood and Lymphatic System Disorders, CTCAE | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541598","Cardiac Disorders, CTCAE","C143165","No value exists.","Cardiac Disorders, CTCAE | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541599","Endocrine Disorders, CTCAE","C143166","No value exists.","Endocrine Disorders, CTCAE | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541601","General Disorders and Administration Site Conditions, CTCAE","C143169","No value exists.","General Disorders and Administration Site Conditions, CTCAE | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541602","Hepatobiliary Disorders, CTCAE","C143170","No value exists.","Hepatobiliary Disorders, CTCAE | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541603","Infections and Infestations, CTCAE","C143171","No value exists.","Infections and Infestations, CTCAE | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541589","Investigations, CTCAE","C143173","No value exists.","Investigations, CTCAE | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541590","Metabolism and Nutrition Disorders, CTCAE","C143174","No value exists.","Metabolism and Nutrition Disorders, CTCAE | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541591","Musculoskeletal and Connective Tissue Disorders, CTCAE","C143175","No value exists.","Musculoskeletal and Connective Tissue Disorders, CTCAE | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206497","Arenavirus","C14306","A genus of negative-sense, single-stranded, RNA viruses of the family Arenaviridae that are spherical in shape and enveloped in a lipid membrane. The mechanism of replication is unknown, however new virions containing host ribosomes bud off of the surface of host cells. These zoonotic viruses are found mostly in rodent reservoirs, although the Tacaribe virus was isolated from a bat.","Arenavirus | ARENAVIRUS",,,,,,,,,,,,,,,"4240948","Arenavirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL541450","POLG wt Allele","C143070","Human POLG wild-type allele is located in the vicinity of 15q26.1 and is approximately 30 kb in length. This allele, which encodes DNA polymerase subunit gamma-1 protein, is involved in mitochondrial DNA replication. Mutations in the gene are associated with colorectal cancer, progressive external ophthalmoplegia with mitochondrial DNA deletions 1 (PEOA1), sensory ataxic neuropathy dysarthria and ophthalmoparesis (SANDO), Alpers-Huttenlocher syndrome (AHS), and mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE).","POLG wt Allele | DNA Polymerase Gamma, Catalytic Subunit wt Allele | MDP1 | MIRAS | MTDPS4A | MTDPS4B | PEO | POLG1 | POLGA | Polymerase (DNA Directed), Gamma Gene | Polymerase (DNA) Gamma, Catalytic Subunit Gene | Polymerase, DNA, Gamma Gene | Polymerase, DNA, Gamma-1 Gene | SANDO | SCAE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447764","POLG protein, human","C143071","DNA polymerase subunit gamma-1 (1239 aa, ~140 kDa) is encoded by the human POLG gene. This protein plays a role in mitochondrial DNA replication.","DNA Polymerase Subunit Gamma-1 | EC 2.7.7.7 | Mitochondrial DNA Polymerase Catalytic Subunit | POLG | PolG-Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541453","PABPC1 wt Allele","C143073","Human PABPC1 wild-type allele is located in the vicinity of 8q22.3 and is approximately 37 kb in length. This allele, which encodes polyadenylate-binding protein 1, plays a role in mRNA binding. Mutations in the gene may be associated with head and neck squamous cell carcinoma and biliary tract carcinoma.","PABPC1 wt Allele | PAB1 | PABP | PABP1 | PABPC2 | PABPL1 | Poly(A) Binding Protein Cytoplasmic 1 wt Allele | Poly(A) Binding Protein, Cytoplasmic 2 Gene | Poly(A)-Binding Protein, Cytoplasmic 2 Gene | Polyadenylate-Binding Protein, Cytoplasmic, 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541562","Polyadenylate-Binding Protein 1","C143074","Polyadenylate-binding protein 1 (636 aa, ~71 kDa) is encoded by the human PABPC1 gene. This protein is involved in binding to the poly(A) tail of mRNA.","Polyadenylate-Binding Protein 1 | PABP-1 | PABPC1 | Poly(A)-Binding Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541564","NBEA wt Allele","C143076","Human NBEA wild-type allele is located in the vicinity of 13q13.3 and is approximately 731 kb in length. This allele, which encodes neurobeachin protein, is involved the localization of protein kinase A. Mutations in or aberrant expression of the gene may be associated with autism, multiple myeloma and colorectal carcinoma.","NBEA wt Allele | BCL8B | FLJ10197 | KIAA1544 | LYST2 | Neurobeachin wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1435475","NBEA protein, human","C143077","Neurobeachin (2946 aa, ~328 kDa) is encoded by the human NBEA gene. This protein plays a role in protein kinase A localization.","Neurobeachin | Lysosomal-Trafficking Regulator 2 | NBEA | Protein BCL8B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0319145","Bovine Papillomavirus-1","C14337","A type of Bovine Papillomavirus.","Bovine Papillomavirus-1 | BPV-1",,,,,,,,,,,,,,,"4172356","Bovine papillomavirus type 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL541504","Inoperable Disease","C143015","Disease state in which the surgical removal of a tumor is not feasible or useful.","Inoperable Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541505","WDR26 Gene","C143016","This gene is involved in the regulation of heterotrimeric G protein localization and activity.","WDR26 Gene | WD Repeat Domain 26 Gene | WDR26",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541506","WDR26 wt Allele","C143017","Human WDR26 wild-type allele is located within 1q42.11-q42.12 and is approximately 52 kb in length. This allele, which encodes WD repeat-containing protein 26, plays a role in the regulation of G protein activity. Mutation of the gene is associated with Skraban-Deardorff syndrome.","WDR26 wt Allele | CDW2 | FLJ21016 | GID Complex Subunit 7 Homolog (S. cerevisiae) Gene | GID Complex, Subunit 7 Gene | GID7 | Glucose-Induced Degradation-Deficient Protein 7, S. cerevisiae, Homolog of Gene | MIP2 | PRO0852 | SKDEAS | WD Repeat Domain 26 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2744063","WDR26 protein, human","C143018","WD repeat-containing protein 26 (661 aa, ~72 kDa) is encoded by the human WDR26 gene. This protein is involved in the localization of G beta-gamma complexes.","WD Repeat-Containing Protein 26 | CUL4- and DDB1-Associated WDR Protein 2 | GID Complex Subunit 7 Homolog | Myocardial Ischemic Preconditioning Up-Regulated Protein 2 | Myocardial Ischemic Preconditioning Upregulated Protein 2 | WDR26",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540531","Postmarketing Surveillance","C142640","Programs to identify adverse events that did not appear during the drug approval process.","Postmarketing Surveillance | post-market surveillance | postmarketing surveillance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206452","Deltaretrovirus","C14347","A genus in the family retroviridae consisting of exogenous horizontally transmitted viruses found in mammals; associated with B or T cell leukemia/lymphoma with a long latency. Bovine Leukemia Virus is the type species. (from CRISP)","Deltaretrovirus | BLV-HTLV Retrovirus | DELTARETROVIRUS",,,,,,,,,,,,,,,"4231255","Genus Deltaretrovirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512048","Double Stranded DNA Virus","C14348","A virus that has double stranded DNA as its genetic material.","Double Stranded DNA Virus | dsDNA Virus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541592","Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps), CTCAE","C143176","No value exists.","Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps), CTCAE | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541593","Nervous System Disorders, CTCAE","C143177","No value exists.","Nervous System Disorders, CTCAE | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541595","Renal and Urinary Disorders, CTCAE","C143179","No value exists.","Renal and Urinary Disorders, CTCAE | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0318356","Human Virus","C14317","Viruses which routinely infect humans","Human Virus | Viruses, Human",,,,,,,,,,,,,,,"4173455","Human virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL541580","Reproductive System and Breast Disorders, CTCAE","C143180","No value exists.","Reproductive System and Breast Disorders, CTCAE | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541581","Respiratory, Thoracic and Mediastinal Disorders, CTCAE","C143181","No value exists.","Respiratory, Thoracic and Mediastinal Disorders, CTCAE | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541582","Skin and Subcutaneous Tissue Disorders, CTCAE","C143182","No value exists.","Skin and Subcutaneous Tissue Disorders, CTCAE | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541584","Congenital, Familial and Genetic Disorders, CTCAE","C143184","No value exists.","Congenital, Familial and Genetic Disorders, CTCAE | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541585","Ear and Labyrinth Disorders, CTCAE","C143185","No value exists.","Ear and Labyrinth Disorders, CTCAE | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541587","Psychiatric Disorders, CTCAE","C143187","No value exists.","Psychiatric Disorders, CTCAE | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541574","Social Circumstances, CTCAE","C143188","No value exists.","Social Circumstances, CTCAE | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0887881","Ovine Jaagziekte Virus","C14318","A betaretrovirus of sheep associated with transmissible ovine pulmonary adenocarcinoma.","Ovine Jaagziekte Virus | JSRV | Jaagsiekte Sheep Retrovirus | Sheep Pulmonary Adenomatosis Virus",,,,,,,,,,,,,,,"4205866","Ovine pulmonary adenocarcinoma virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540591","Structured Data","C142699","Structured health record information is divided into discrete fields, and may be enumerated, numeric, or codified. examples of structured health information include: patient address (non-codified, but discrete field); diastolic blood pressure (numeric); coded result observation; coded diagnosis; patient risk assessment questionnaire with multiple-choice answers. Context may determine whether or not data are unstructured, e.g., a progress note might be standardized and structured in some eHR-s (e.g., subjective/objective/ assessment/Plan) but unstructured in others. (HL7)","Structured Data | structured data",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522638","Recombinant Heregulin","C1426","A growth factor of the EGF family that induces growth and differentiation of epithelial, glial and muscle cells in culture.  It binds the receptor erbB3 which will heterodimerize with HER-2/erbB2.","Recombinant Heregulin | Heregulin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540590","Structured Product Labeling","C142700","A Health Level 7 (HL7) ANSI-approved document markup standard that specifies the structure and semantics for the exchange of product information. (HL7)","Structured Product Labeling | SPL | structured product label (SPL)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376479","Rubulavirus","C14326","A genus of Paramyxovirinae which includes Mumps Virus","Rubulavirus | RUBULAVIRUS",,,,,,,,,,,,,,,"4027704","Genus Rubulavirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037994","Spleen Focus-Forming Virus","C14276","Defective virus found in certain strains of Friend virus, detected by its ability to form foci in spleens of mice and believed to be responsible in those strains for the production of a leukemia associated with polycythaemia rather than anemia. (DictionaryBarn.com)","Spleen Focus-Forming Virus | Friend Spleen Focus-Forming Virus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540646","MIR1243 Gene","C142770","This gene is involved in epigenetics.","MIR1243 Gene | MIR1243 | MicroRNA 1243 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540645","MIR1243 wt Allele","C142771","Human MIR1243 wild-type allele is located in the vicinity of 4q25 and is approximately 93 kb in length. This allele, which encodes MIR1243 pre-miRNA, is involved in the regulation of target mRNA translation.","MIR1243 wt Allele | MIRN1243 | MicroRNA 1243 wt Allele | hsa-mir-1243 | mir-1243",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540731","MIR1243 Pre-miRNA","C142772","MIR1243 pre-miRNA is an oligonucleotide (93 bases) that is encoded by the human MIR1243 gene and may play a role in the regulation of gene expression.","MIR1243 Pre-miRNA | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540730","MicroRNA 1243","C142773","A 22 ribonucleotide sequence that is a final product of the processing of MIR1243 pre-miRNA. This oligonucleotide may be involved in the regulation of gene expression.","MicroRNA 1243 | hsa-miR-1243 | mir-1243",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518674","Other Virus Grouping","C14349","A non-taxonomic grouping of viruses based on a shared characteristic.","Other Virus Grouping | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541384","Recurrent Primary Cutaneous Lymphoma","C142876","The reemergence of primary cutaneous lymphoma after a period of remission.","Recurrent Primary Cutaneous Lymphoma | Recurrent Primary Cutaneous (Skin) Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541385","Refractory Primary Cutaneous Lymphoma","C142877","Primary cutaneous lymphoma that does not respond to treatment.","Refractory Primary Cutaneous Lymphoma | Refractory Primary Cutaneous (Skin) Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541388","Refractory Alveolar Rhabdomyosarcoma","C142880","Alveolar rhabdomyosarcoma that does not respond to treatment.","Refractory Alveolar Rhabdomyosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541389","Recurrent Alveolar Rhabdomyosarcoma","C142881","The reemergence of alveolar rhabdomyosarcoma after a period of remission.","Recurrent Alveolar Rhabdomyosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541313","Study Branch","C142701","A planned point in time within the study design in which there is a subdivision of subjects to particular procedures or treatment groups.","Study Branch | arm | branch",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540589","Study Completion Date","C142702","The date on which the concluding information for a clinical investigation is completed. Usually, this is when the last subject has a final visit or any other protocol-defined completion date.","Study Completion Date | Study End Date | study completion date",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541309","Study Control","C142703","A comparator treatment in a clinical trial against which the treatment under study is evaluated. (ICH)","Study Control | Control Product | control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540588","Study Description","C142704","Specific, essential aspects of an investigation that are detailed, including structure,  blinding, dosage, and participant demographics.","Study Description | clinical study description | clinical_study_description | study description",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540587","Study Design Rationale","C142705","Justification for the type investigation method employed by the study.","Study Design Rationale | study design rationale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541320","Study Monitoring","C142707","The act of overseeing the progress of a clinical trial and of ensuring that it is conducted, recorded, and reported in accordance with the protocol, standard operating procedures (SOPs), good clinical practice (GCP), and the applicable regulatory requirement(s). (ICH)","Study Monitoring | Trial Monitoring | study monitoring",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540685","Study Monitoring Report","C142708","A written report from the monitor to the sponsor after each site visit and/or other trial-related communication according to the sponsor's SOPs. (ICH)","Study Monitoring Report | monitoring report",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540684","Study Monitoring Visit","C142709","A visit to a study site to review the progress of a clinical study and to ensure protocol adherence, accuracy of data, safety of subjects, and compliance with regulatory requirements and good clinical practice guidelines. (ICH)","Study Monitoring Visit | monitoring visit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035804","Rodentia","C14270","The taxonomic order of mammals that includes mice, rats, guinea pigs, squirrels, beavers, and many others.","Rodentia | Mammals, Rodents | Rodent | Rodents",,,,,,,,,,,,,,,"4302993","Order Rodentia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540682","Study Publication Date","C142711","The date of publication of an abstract or article pertaining to a particular clinical study.","Study Publication Date | Publication Date | study publication date",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540681","Study Reconstruction","C142712","The process for eClinical trials where the FDA expects archival trial records that support review of the data as well as the processes used for obtaining and managing the data so that the trustworthiness of results can be evaluated. (FDA)","Study Reconstruction | reconstruction (of a study)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0331705","Non-Vascular Plant","C14340","A plant that does not have vascular tubes/tissues to transport food and water.  It belongs to the division Bryophyta, which includes liverwort, and moss.","Non-Vascular Plant | Bryophyte | Non-tracheophytes | Plants, Non-Vascular",,,,,,,,,,,,,,,"4218857","Lower plant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1514432","Primate Retrovirus","C14341","An RNA containing virus infecting primates (SIV, STLV, SFV).","Primate Retrovirus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540726","Wnt Signaling Pathway Inhibitor SM08502","C142777","An orally bioavailable, small molecule inhibitor of the Wnt signaling pathway, with potential antineoplastic activity. Upon oral administration, SM08502 inhibits the expression of genes involved in the Wnt signaling pathway through an as of yet not fully elucidated mechanism. This decreased expression of Wnt pathway-related genes prevents Wnt signaling and may inhibit proliferation of cancer cells in which the Wnt signaling pathway is overactivated. The Wnt signaling pathway is dysregulated in many cancer cell types and plays a crucial role in tumor cell proliferation.","Wnt Signaling Pathway Inhibitor SM08502 | SM 08502 | SM-08502 | SM08502",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038344","Simian T-Lymphotropic Virus Type I","C14277","A single-stranded reverse-transcribing RNA retrovirus of the genus deltaretrovirus that infects a wide range of non-human primates.","Simian T-Lymphotropic Virus Type I | STLV | Simian T-Lymphotropic Virus I",,,,,,,,,,,,,,,"4251444","Simian T-lymphotropic virus 1",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540736","Lung PEComa","C142783","A lung tumor that arises from perivascular epithelioid cells (PECs).","Lung PEComa | Lung PEComatous Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540735","Benign Lung PEComa","C142784","A benign lung tumor that arises from perivascular epithelioid cells (PECs).","Benign Lung PEComa | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540734","Lung Malignant PEComa","C142785","A malignant lung tumor that arises from perivascular epithelioid cells (PECs).","Lung Malignant PEComa | Malignant Lung PEComa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3864922","Orexin Receptor Antagonist","C142786","Any agent that inhibits the activity of the orexin receptor.","Orexin Receptor Antagonist | Orexin Antagonist",,,,,,,,,,,,,,,"3661490","Orexin receptor antagonist",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516786","Congenic Strain","C14365","Congenic strains are produced by transferring a mutation from one genetic background to a specific inbred strain through repeated backcrossing. The congenic strain and the inbred partner are expected to be identical at all loci except for the transferred locus and a linked segment of chromosome. The size of the segment and the possibility of transferred alleles on other chromosomes depend on the number of backcross generations. A strain is considered fully congenic after ten generations of backcrossing (N10). (from JAX Strain Information)","Congenic Strain | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2854100","Recurrent Hairy Cell Leukemia","C142882","The reemergence of hairy cell leukemia after a period of remission.","Recurrent Hairy Cell Leukemia | Hairy cell leukemia, in relapse | Relapsed Hairy Cell Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541378","Autologous Anti-CD19 Chimeric Antigen Receptor T-cells SJCAR19","C142887","A proprietary preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed, costimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR T-cells SJCAR19 target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.","Autologous Anti-CD19 Chimeric Antigen Receptor T-cells SJCAR19 | Autologous Anti-CD19 CAR-T Cells SJCAR19 | Autologous Anti-CD19 CART Cells SJCAR19 | Autologous CD19-specific CAR-T Cells SJCAR19 | SJCAR19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541518","FOXR1 wt Allele","C143125","Human FOXR1 wild-type allele is located in the vicinity of 11q23.3 and is approximately 10 kb in length. This allele, which encodes forkhead box protein R1, is involved in the modulation of gene transcription.","FOXR1 wt Allele | DLNB13 | FOXN5 | Forkhead Box R1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541519","Forkhead Box Protein R1","C143126","Forkhead box protein R1 (292 aa, ~33 kDa) is encoded by the human FOXR1 gene. This protein plays a role in the regulation of gene expression.","Forkhead Box Protein R1 | FOXR1 | Forkhead Box Protein N5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541521","FKBP9 wt Allele","C143128","Human FKBP9 wild-type allele is located in the vicinity of 7p14.3 and is approximately 50 kb in length. This allele, which encodes peptidyl-prolyl cis-trans isomerase FKBP9 protein, plays a role in protein folding.","FKBP9 wt Allele | FK506 Binding Protein 9 wt Allele | FK506 Binding Protein 9, 63 kDa Gene | FK506-Binding Protein 9 (63 kD) Gene | FK506-Binding Protein, 60-kD Gene | FK506-Binding Protein, 63-kD Gene | FKBP60 | FKBP63 | PPIase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1438508","FKBP9 protein, human","C143129","Peptidyl-prolyl cis-trans isomerase FKBP9 (570 aa, ~63 kDa) is encoded by the human FKBP9 gene. This protein is involved in chaperone-mediated protein folding.","Peptidyl-Prolyl Cis-Trans Isomerase FKBP9 | 63 kDa FK506-Binding Protein | 63 kDa FKBP | EC 5.2.1.8 | FK506 Binding Protein 9 | FK506-Binding Protein 9 | FKBP-63 | FKBP-9 | FKBP9 | PPIase FKBP9 | Rotamase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541508","FBLN2 wt Allele","C143131","Human FBLN2 wild-type allele is located in the vicinity of 3p25.1 and is approximately 89 kb in length. This allele, which encodes fibulin-2 protein, is involved in the structure of the extracellular matrix.","FBLN2 wt Allele | Fibulin 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1619942","fibulin 2 protein, human","C143132","Fibulin-2 (1184 aa, ~127 kDa) is encoded by the human FBLN2 gene. This protein plays a role in matrix protein interactions.","Fibulin-2 | FBLN2 | FIBL-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512715","Infectious Agent, Bacteria","C14356","No value exists.","Infectious Agent, Bacteria | Bacterial Infectious Agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512716","Infectious Agent, Virus","C14357","No value exists.","Infectious Agent, Virus | Viral Infectious Agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0999629","Leporidae","C14358","Taxonomic family which includes rabbits and hares.","Leporidae | Rabbits and Hares",,,,,,,,,,,,,,,"4026486","Leporidae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0619980","azarole","C142944","No value exists.","Azarole | AZAROLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541440","azficel-T","C142945","No value exists.","Azficel-T | AZFICEL-T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541441","Batefenterol Succinate","C142946","No value exists.","Batefenterol Succinate | BATEFENTEROL SUCCINATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541442","Bavisant Dihydrochloride","C142947","No value exists.","Bavisant Dihydrochloride | BAVISANT DIHYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517745","Latent Virus","C14367","Virus integrated within host genome but inactive; may be reactivated by stress such as ultraviolet irradiation.","Latent Virus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541493","METAP2 Gene","C143019","This gene plays a role in the removal of the amino-terminal methionine from nascent proteins.","METAP2 Gene | METAP2 | Methionyl Aminopeptidase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541494","METAP2 wt Allele","C143020","Human METAP2 wild-type allele is located in the vicinity of 12q22 and is approximately 42 kb in length. This allele, which encodes methionine aminopeptidase 2 protein, is involved in nascent protein processing and the regulation of angiogenesis.","METAP2 wt Allele | MAP2 | MNPEP | Methionyl Aminopeptidase 2 wt Allele | p67 | p67eIF2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541511","FAT3 wt Allele","C143134","Human FAT3 wild-type allele is located in the vicinity of 11q14.3 and is approximately 582 kb in length. This allele, which encodes protocadherin Fat 3 protein, plays a role in neurite development.","FAT3 wt Allele | CDHF15 | CDHR10 | FAT Atypical Cadherin 3 wt Allele | FAT Tumor Suppressor Homolog 3 (Drosophila) Gene | FAT Tumor Suppressor, Drosophila, Homolog of, 3 Gene | KIAA1989 | hFat3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1143303","FAT3 protein, human","C143135","Protocadherin Fat 3 (4589 aa, ~506 kDa) is encoded by the human FAT3 gene. This protein is involved in cell-cell adhesion.","Protocadherin Fat 3 | Cadherin Family Member 15 | Cadherin-Related Family Member 10 | FAT Tumor Suppressor Homolog 3 | hFat3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541514","ARFRP1 wt Allele","C143138","Human ARFRP1 wild-type allele is located in the vicinity of 20q13.33 and is approximately 9 kb in length. This allele, which encodes ADP-ribosylation factor-related protein 1, is involved in GTPase activity and trans-Golgi protein localization.","ARFRP1 wt Allele | ADP Ribosylation Factor Related Protein 1 wt Allele | ARL18 | ARP | Arp1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2716447","ARFRP1 protein, human","C143139","ADP-ribosylation factor-related protein 1 (201 aa, ~23 kDa) is encoded by the human ARFRP1 gene. This protein plays a role in protein localization.","ADP-Ribosylation Factor-Related Protein 1 | ARF-Related Protein 1 | ARFRP1 | ARP | Helicase-Like Protein NHL | SCG10 Like-Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242616","Equidae","C14313","Taxonomic family which includes horses, zebras, and asses.","Equidae | ",,,,,,,,,,,,,,,"4304615","Equidae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540628","Preclinical Study","C142642","An investigation that tests a drug, procedure or medical treatment in animals to determine any toxic effects before trials can be carried out in humans.","Preclinical Study | Preclinical Trial | preclinical studies | preclinical study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540627","Primary Completion Date","C142643","The date on which the last clinical study subject was given the final intervention or examination in order to obtain information to support the primary outcome.","Primary Completion Date | primary completion date",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540626","Primary Outcome Variable","C142644","The study outcome factor of greatest priority that contributes to the main objective of the trial.","Primary Outcome Variable | primary outcome variable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540625","Prognostic Covariate","C142645","A variable that directly or indirectly impacts the outcome of a clinical trial.","Prognostic Covariate | covariate (prognostic)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540624","Prospective Study","C142646","A type of study in which participants are enrolled into the study before they develop the disease or outcome in question.","Prospective Study | prospective study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541269","Protected Personal Data","C142647","Any representation of information that permits the identity of an individual to whom the information applies to be reasonably inferred by either direct or indirect means.","Protected Personal Data | PII | PPD | Personally Identifiable Information | protected personal data (PPD)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540623","Protocol Approval by Sponsor","C142648","An indication that the sponsor, including all reviewers, have approved the protocol.","Protocol Approval by Sponsor | protocol approval (Sponsor)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540636","Protocol Background Material","C142649","Any documentation that pertains to the further understanding of a study protocol.","Protocol Background Material | background material",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540635","Protocol Referenced Documents","C142650","A citation to a publication that is significantly related to a study protocol.","Protocol Referenced Documents | protocol referenced documents",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540634","Proxy Data Origin","C142651","An indication that the source of clinical trial data comes from a person other than the subject.","Proxy Data Origin | proxy (as an origin of outcome measures)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540633","Proxy Respondent","C142652","A person in a clinical trial other than the subject who provides responses about the subject on their behalf, but not as an observer.","Proxy Respondent | proxy respondent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541443","Beclabuvir Hydrochloride","C142948","No value exists.","Beclabuvir Hydrochloride | BECLABUVIR HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3530515","Bedaquiline Fumarate","C142949","The fumarate salt form of bedaquiline, an orally bioavailable diarylquinoline antimycobacterial agent, that can be used in the treatment of pulmonary multi-drug resistant tuberculosis (MDR-TB). Upon oral administration, bedaquiline specifically binds to subunit c of Mycobacterium tuberculosis (M. tuberculosis) adenosine 5'-triphosphate (ATP) synthase, thereby preventing ATP synthase activity. This inhibits ATP synthesis in M. tuberculosis, thereby blocking its energy metabolism and killing M. tuberculosis.","Bedaquiline Fumarate | BDQ Fumarate | BEDAQUILINE FUMARATE | R403323 | Sirturo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085112","SCID Mice","C14294","Severe combined immunodeficient (SCID) mice like their human counterparts with immunodeficiency diseases are helpless not only to fight infection but also to reject transplanted tissue. These animals lack both T and B-cells and are used extensively in researches of immune disease or tissue transplantation.","SCID Mouse | SCID | severe combined immune deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0525133","Bentoquatam","C142950","No value exists.","Bentoquatam | BENTOQUATAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541431","Benzhydrocodone Hydrochloride","C142951","No value exists.","Benzhydrocodone Hydrochloride | BENZHYDROCODONE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541432","Bevantolol Hydrochloride","C142952","No value exists.","Bevantolol Hydrochloride | BEVANTOLOL HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541433","Bevasiranib Sodium","C142953","No value exists.","Bevasiranib Sodium | BEVASIRANIB SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541434","Biclodil Hydrochloride","C142954","No value exists.","Biclodil Hydrochloride | BICLODIL HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541435","Bictegravir Sodium","C142955","No value exists.","Bictegravir Sodium | BICTEGRAVIR SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541437","Bipenamol Hydrochloride","C142957","No value exists.","Bipenamol Hydrochloride | BIPENAMOL HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541438","Birtamimab","C142958","A monoclonal antibody against amyloid with potential use in the treatment of amyloid light chain (AL) and AA amyloidosis. Upon intravenous administration, birtamimab specifically binds to amyloid fibrils. This prevents the formation of amyloid deposits in certain organs and facilitates their clearance. It also reduces the level of amyloid deposits in organs and prevents organ dysfunction.","Birtamimab | Anti-amyloid Monoclonal Antibody NEOD001 | BIRTAMIMAB | NEOD 001 | NEOD-001 | NEOD001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541423","Bisacodyl Tannex","C142959","No value exists.","Bisacodyl Tannex | BISACODYL TANNEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541425","Bisoxatin Acetate","C142961","No value exists.","Bisoxatin Acetate | BISOXATIN ACETATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541426","Bispyrithione Magsulfex","C142962","No value exists.","Bispyrithione Magsulfex | BISPYRITHIONE MAGSULFEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541427","Bivalirudin Trifluoroacetate","C142963","The trifluoroacetate salt form of bivalirudin, a 20 amino acid long synthetic peptide, with thrombin-specific anticoagulant activity. Upon intravenous administration, bivalirudin reversibly binds thrombin, free as well as clot bound, at the catalytic site and the anion-binding exosite, thereby preventing the formation and activation of fibrin, factor XIIIa, and other coagulation factors. Bivalirudin is primarily used during coronary angioplasty procedures, in combination with aspirin, in patients with unstable angina.","Bivalirudin Trifluoroacetate | Angiomax | Angiox | BIVALIRUDIN TRIFLUOROACETATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541428","bornyl acetate","C142964","No value exists.","Bornyl Acetate | BORNYL ACETATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL601802","Brilacidin Tetrahydrochloride","C142966","No value exists.","Brilacidin Tetrahydrochloride | BRILACIDIN TETRAHYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541415","Brivoligide Sodium","C142967","No value exists.","Brivoligide Sodium | BRIVOLIGIDE SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005647","Bromhexine Hydrochloride","C142968","The hydrochloride salt form of bromhexine, a secretolytic, with mucolytic activity. Upon administration, bromhexine increases lysosomal activity and enhances hydrolysis of acid mucopolysaccharide polymers in the respiratory tract. This increases the production of serous mucus in the respiratory tract, which makes the phlegm thinner and decreases mucus viscosity. This contributes to its secretomotoric effect, and allows the cilia to more easily transport the phlegm out of the lungs. This clears mucus from the respiratory tract and may aid in the treatment of respiratory disorders associated with abnormal viscid mucus, excessive mucus secretion and impaired mucus transport.","Bromhexine Hydrochloride | BROMHEXINE HYDROCHLORIDE | Benzenemethanamine, 2-Amino-3,5-dibromo-N-cyclohexyl-N-methyl-, Monohydrochloride | Viscolyt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541417","Bromperidol Decanoate","C142969","No value exists.","Bromperidol Decanoate | BROMPERIDOL DECANOATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541567","S100A7 wt Allele","C143079","Human S100A7 wild-type allele is located in the vicinity of 1q21.3 and is approximately 3 kb in length. This allele, which encodes protein S100-A7, plays a role in calcium binding, epidermal development and antimicrobial activity. Aberrant overexpression is associated with hyperproliferative skin diseases and mutations in the gene may be associated with melanoma and T-cell lymphoma.","S100A7 wt Allele | PSOR1 | S100 Calcium Binding Protein A7 (Psoriasin 1) Gene | S100 Calcium Binding Protein A7 wt Allele | S100 Calcium-Binding Protein A7 (Psoriasin 1) Gene | S100A7c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206533","Paramyxovirinae","C14307","The subfamily of Paramyxoviridae which includes Mumps and Measles viruses.","Paramyxovirinae | ",,,,,,,,,,,,,,,"4027703","Paramyxovirinae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1611561","S100A7 protein, human","C143080","Protein S100-A7 (101 aa, ~11 kDa) is encoded by the human S100A7 gene. This protein is involved in antimicrobial activity, calcium binding and epidermal development.","Protein S100-A7 | Psoriasin | Psoriasin 1 | S100 Calcium-Binding Protein A7 | S100A7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541556","RGPD3 wt Allele","C143083","Human RGPD3 wild-type allele is located in the vicinity of 2q12.2 and is approximately 77 kb in length. This allele, which encodes RanBP2-like and GRIP domain-containing protein 3, may involved in GTP-binding nuclear protein Ran localization. Mutations in the gene may be associated with endometrioid adenocarcinoma.","RGPD3 wt Allele | RANBP2-Like and GRIP Domain Containing 3 wt Allele | RGP3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541557","RanBP2-Like and GRIP Domain-Containing Protein 3","C143084","RanBP2-like and GRIP domain-containing protein 3 (1758 aa, ~197 kDa) is encoded by the human RGPD3 gene. This protein may play a role in the localization of GTP-binding nuclear protein Ran.","RanBP2-Like and GRIP Domain-Containing Protein 3 | RGPD3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087393","Refractory Marginal Zone Lymphoma","C143085","Marginal zone lymphoma which does not respond to treatment.","Refractory Marginal Zone Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032901","Bitartrate, Prajmalium","C143086","No value exists.","Prajmalium Bitartrate | 17R,21-alpha-Dihydroxy-4-propylajmalanium Hydrogen Tartrate | Ajmalanium, 17,21-Dihydroxy-4-propyl-, (17R,21alpha)-, Salt with (2R,3R)-2,3-dihydroxybutanedioic Acid (1:1) | PRAJMALIUM BITARTRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541559","maxacalcitol","C143087","No value exists.","Maxacalcitol | (+)-(5Z,7E,20S)-20-(3-Hydroxy-3-methylbutoxy)-9,10-secopregna-5,7,10(19)-triene-1alpha,3beta-diol | 1,3-Cyclohexanediol, 4-Methylene-5-((2E)-((1S,3aS,7aS)-octahydro-1-((1S)-1-(3-hydroxy-3-methylbutoxy)ethyl)-7a-methyl-4H-inden-4-ylidene)ethylidene)-, (1R,3S,5Z)- | 22-Oxa-1,25-dihydroxyvitamin D3 | 22-Oxa-calcitriol | MAXACALCITOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541560","Nolatrexed","C143088","A water-soluble lipophilic quinazoline folate analog, with antineoplastic activity. Upon administration, nolatrexed occupies the folate binding site of thymidylate synthase, resulting in inhibition of thymidylate synthase activity and thymine nucleotide synthesis with subsequent inhibition of DNA replication, DNA damage, S-phase cell cycle arrest, and caspase-dependent apoptosis. Nolatrexed also exhibits radiosensitizing activity.","Nolatrexed | 2-Amino-6-methyl-5-(4-pyridylthio)-4(3H)-quinazolinone | NOLATREXED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541561","Naflocort Anhydrous","C143089","No value exists.","Naflocort Anhydrous | 2'H-Naphtho(2',3':16,17)pregna-1,4-diene-3,20-dione, 9-Fluoro-1',4'-dihydro-11,21-dihydroxy-, (11beta,16beta)- | NAFLOCORT ANHYDROUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1433609","METAP2 protein, human","C143021","Methionine aminopeptidase 2 (478 aa, ~53 kDa) is encoded by the human METAP2 gene. This protein plays a role in both the steric hindrance of phosphorylation of the alpha subunit of eukaryotic initiation factor 2 (EIF2S1) and the removal of the amino-terminal methionine from nascent proteins.","Methionine Aminopeptidase 2 | EC 3.4.11.18 | EIF-2-Associated p67 Homolog | Eukaryotic Initiation Factor 2-Associated Protein, 67-kD | Initiation Factor 2 Associated 67 kDa Glycoprotein | Initiation Factor 2-Associated 67 kDa Glycoprotein | MAP 2 | METAP2 | MetAP 2 | Methionyl Aminopeptidase 2 | Peptidase M | Testicular Tissue Protein Li 17 | p67 | p67eIF2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426574","RHPN1 Gene","C143022","This gene is involved in GTP binding.","RHPN1 Gene | RHPN1 | Rhophilin Rho GTPase Binding Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541497","RHPN1 wt Allele","C143023","Human RHPN1 wild-type allele is located in the vicinity of 8q24.3 and is approximately 15 kb in length. This allele, which encodes rhophilin-1 protein, plays a role in GTP binding, cytoskeletal modeling and signal transduction.","RHPN1 wt Allele | KIAA1929 | ODF5 | RHOPHILIN | RHPN | Rhophilin Rho GTPase Binding Protein 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2000361","rhophilin, Rho GTPase binding protein 1, human","C143024","Rhophilin-1 (695 aa, ~76 kDa) is encoded by the human RHPN1 gene. This protein is involved in cytoskeletal modeling and signal transduction.","Rhophilin-1 | GTP-Rho-Binding Protein 1 | Outer Dense Fiber of Sperm Tails 5 | PKN-Related Rho-Binding Protein | RHPN1 | Rho GTPase-Binding Protein 1 | Rhophilin 1 | Rhophilin Rho GTPase Binding Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420818","TNFSF18 Gene","C143026","This gene plays a role in the modulation of T-cell activation and proliferation.","TNFSF18 Gene | TNFSF18 | Tumor Necrosis Factor Superfamily Member 18 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541487","TNFSF18 wt Allele","C143027","Human TNFSF18 wild-type allele is located in the vicinity of 1q25.1 and is approximately 11 kb in length. This allele, which encodes tumor necrosis factor ligand superfamily member 18 protein, is involved in the positive regulation of T-cell survival.","TNFSF18 wt Allele | AITRL | GITRL | TL6 | TNF Superfamily Member 18 wt Allele | TNLG2A | Tumor Necrosis Factor (Ligand) Superfamily, Member 18 Gene | Tumor Necrosis Factor Superfamily, Member 18 Gene | UNQ149/PRO175 | hGITRL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162570","Bacteriophage T4","C14302","A double-stranded DNA virus that infects bacteria such as E. coli.","Bacteriophage T4 | Coliphage T4 | Enterobacteria Phage T4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541490","A1CF wt Allele","C143032","Human A1CF wild-type allele is located in the vicinity of 10q11.23 and is approximately 86 kb in length. This allele, which encodes APOBEC1 complementation factor, plays a role in RNA binding and mRNA metabolism.","A1CF wt Allele | ACF | ACF64 | ACF65 | APOBEC1 Complementation Factor wt Allele | APOBEC1CF | ASP | Apobec-1 Complementation Factor (ACF) (ASP) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0104364","A1CF protein, human","C143033","APOBEC1 complementation factor (594 aa, ~65 kDa) is encoded by the human A1CF gene. This protein is involved in binding to and metabolism of APOB mRNA. Missense mutations in the gene may be associated with melanoma and other neoplastic diseases.","APOBEC1 Complementation Factor | A1CF | APOBEC-1 Stimulating Protein | APOBEC1-Stimulating Protein | Apo-B RNA Editing Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540632","Proxy-reported Outcome","C142653","A clinical outcome assessment that is reported by someone other than the patient as if he or she is the patient.","Proxy-reported Outcome | proxy-reported outcome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540631","Pseudonymization","C142654","A form of encryption where identifiable parts of personal data are replaced with unique artificial identifiers in order to de-identify the data within a specific context.","Pseudonymization | pseudonymization | pseudonymize",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540630","Psychometric Instrument Reliability","C142655","The extent to which the administration of a psychometric instrument and the data collected from that administration is accurate, repeatable, and sensitive.","Psychometric Instrument Reliability | psychometric reliability | reliability, psychometric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540614","Qualitative Variable","C142657","Variables that cannot be represent by a number, used to describe data that fits into categories.","Qualitative Variable | qualitative variable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540613","Quantitative Variable","C142658","A variable that can be expressed with numeric values.","Quantitative Variable | quantitative variable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540612","Radiopharmaceutical Medicinal Product","C142659","A radioactive compound that is administered to patients for diagnostic or therapeutic purposes.","Radiopharmaceutical Medicinal Product | radiopharmaceutical medicinal product",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003459","Frog","C14265","An amphibian in the order Anura, which includes the toads. The commonest frog genera are Rana (grass frogs) and Hyla (tree frogs).","Frog | FROG | Frogs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540611","Random Allocation","C142660","The process of resource distribution that is done by chance.","Random Allocation | random allocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540610","Random Number Table","C142661","A chart containing numbers, with or without duplication and arranged with no discernable pattern. This table may be used as a statistical tool for selection assignment.","Random Number Table | random number table",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0165747","Lobaplatin","C1434","A third-generation, water-soluble platinum compound with potential antineoplastic activity. Lobaplatin forms highly reactive, charged, platinum complexes that bind to nucleophilic groups such as GC- and AG-rich sites in DNA, inducing intrastrand DNA cross-links. These cross-links will ultimately result in induction of apoptosis and cell growth inhibition. Compared to first and second generation platinum compounds, lobaplatin appears to be more stable, less toxic, have a better therapeutic index and may overcome tumor resistance.","Lobaplatin | 1,2-diammino-methy lcyclobutane-platinum (II) lactate | D 19466 | D-19466 | D19466 | LOBAPLATIN | lobaplatin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0324044","Poikilotherms","C14320","Animals which have a body temperature which is largely controlled by external factors of the environment.","Poikilotherms | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541548","PRPF40B wt Allele","C143091","Human PRPF40B wild-type allele is located in the vicinity of 12q13.12 and is approximately 76 kb in length. This allele, which encodes pre-mRNA-processing factor 40 homolog B protein, may play a role in mRNA splicing. Mutations in the gene may be associated with myelodysplastic syndrome, melanoma and colon carcinoma.","PRPF40B wt Allele | HYPC | PRP40 Homolog, Pre-mRNA Processing Factor B Gene | PRP40 Pre-mRNA Processing Factor 40 Homolog B (S. cerevisiae) Gene | PRP40 Pre-mRNA Processing Factor 40 Homolog B (Yeast) Gene | Pre-mRNA Processing Factor 40 Homolog B wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4042328","PRPF40B protein, human","C143092","Pre-mRNA-processing factor 40 homolog B (871 aa, ~99 kDa) is encoded by the human PRPF40B gene. This protein may be involved in splicing of pre-mRNA.","Pre-mRNA-Processing Factor 40 Homolog B | Huntingtin Interacting Protein C | Huntingtin Yeast Partner C | Huntingtin-Interacting Protein C | PRPF40B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541551","CDH10 wt Allele","C143094","Human CDH10 wild-type allele is located within 5p14.2-p14.1 and is approximately 158 kb in length. This allele, which encodes cadherin-10 protein, is involved in cell-cell adhesion. Mutations in the gene may be associated with melanoma, pancreatic ductal adenocarcinoma, lung squamous cell carcinoma and colorectal cancer.","CDH10 wt Allele | Cadherin 10 Type 2 Gene | Cadherin 10 wt Allele | Cadherin 10, Type 2 (T2-Cadherin) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545946","Investigational Subject Case History","C142588","The detailed documentation about an individual in a clinical trial that is compiled and managed by the investigator. This includes information on informed consent, medical records and other observations.","Investigational Subject Case History | case history",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540577","Investigator Recruitment Process","C142590","A set of actions used by sponsors to identify and select clinical assessors to serve in a clinical study.","Investigator Recruitment Process | recruitment (investigators)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540576","Investigator/Institution","C142591","An expression meaning the study leader and/or organization, as required by the applicable regulatory requirements. (ICH)","Investigator/Institution | investigator/institution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540575","Item Definition","C142592","The formal specification of the properties of an element or field of data in study or trial. (CDISC)","Item Definition | item definition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540558","Item Group Definition","C142593","The formal specification of the properties of a group of related items.","Item Group Definition | item group definition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540556","Janus Study Data Repository","C142595","An electronic repository within the US Food and Drug Administration containing subject-level clinical and nonclinical study data submitted to the FDA as part of a regulatory submission.","Janus Study Data Repository | Janus study data repository",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540555","Last Subject In Date Time","C142596","The date and/or date and time when the final participant in a clinical trial is enrolled.","Last Subject In Date Time | LPI - date, time | last patient in - date, time | last subject in - date, time (LSI - date, time)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540554","Last Subject In Identity","C142597","The identity of the final subject to enroll in a clinical trial.","Last Subject In Identity | LPI - identity | last patient in - identity | last subject in - identity (LSI - identity)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540553","Last Subject Last Visit Date Time","C142598","The date and or date and time when the final participant has reached a planned or achieved milestone representing the completion of the trial.","Last Subject Last Visit Date Time | last subject last visit - date, time (LSLV - date, time) | last subject out/complete (LSC/LPC or LSO/LPO) - date, time)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376574","GB virus C","C14328","A species of enveloped viruses in the Flaviviridae family and Pegivirus genus. The genome is composed of linear, single-stranded, positive-sense RNA. GB Virus C has been shown to infect human cells in vitro and in vivo but has not yet been shown to be the causative agent of disease.","GB virus C | GB Virus C/ Hepatitis G Virus | GB virus C/HGV | GBV-C | GBV-C/G | GBV-HGV | HEPATITIS G VIRUS | HGV | HGV-1 | Hepatitis G Virus | Hepatitis GB virus C | Hepatitis GB virus C/G | hepatitis G virus",,,,,,,,,,,,,,,"4265444","Hepatitis G virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1002566","Single Stranded DNA Virus","C14350","A virus that has single stranded DNA as its genetic material.","Single Stranded DNA Virus | ssDNA Virus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1005564","Positive Sense ssRNA Virus","C14351","A single stranded RNA virus where the RNA strand has the same polarity as a mRNA.","Positive Sense ssRNA Virus | + Strand ssRNA Virus | Positive Strand ssRNA Virus | ssRNA Virus, (+) Strand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540692","Subject Data Event","C142717","Information produced, compiled, or examined during a visit with a clinical trial subject.","Subject Data Event | subject data event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540690","Subject Termination","C142719","Premature discontinuation of an individual's participation in a clinical trial.","Subject Termination | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540689","Subject Well-Being","C142720","The physical and mental integrity of the individuals participating in a clinical study. (ICH)","Subject Well-Being | well-being (of the trial subjects)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540688","Substance Screening","C142721","Random or targeted evaluation of material using biochemical tests or assays constructed to identify a particular biological aspect or action.","Substance Screening | screen/screening (of substances)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540687","Superiority Trial","C142722","A trial with the primary objective of showing that the response to the investigational product is superior to a comparative agent (active or placebo control). (ICH)","Superiority Trial | superiority trial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540686","Supporting Variable","C142723","A factor or condition subject to change that is not a primary or secondary variable but may provide additional information to enhance the assessment of clinical effect.","Supporting Variable | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0086589","Surrogate Markers","C142724","In a clinical trial, an assessment of an intervention's effects that takes the place of a patient-based conclusion.","Surrogate Marker | surrogate marker",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600210","population migration","C142726","The act of moving a computer system and its data from one operational environment to another.","System Migration | migration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540670","Tabulation Dataset","C142727","Standardized clinical trial information arranged in a table.","Tabulation Dataset | tabulation dataset",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039309","Target Populations","C142728","The population within the general population for which the study results can be generalized. For interventional trials, a group of patients to which the indication of an investigational or authorized medicinal product applies. (ISO)","Target Study Population | Target Population | target population",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540669","Technology Provider","C142729","An individual or organization that sells software applications or computer hardware.","Technology Provider | technology provider | technology vendor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540668","Terminology","C142730","A standardized, finite set of concepts, designations, and relationships for a specialized subject area.","Terminology | terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540667","Treatment Benefit","C142731","The direct or indirect impact of treatment as measured by outcome assessments of a patient's feelings, level of functioning, or survival.","Treatment Benefit | treatment benefit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540552","Last Subject Last Visit Identity","C142599","The identity of the final subject to reach the final scheduled visit, which is a planned or achieved milestone representing the completion of the trial.","Last Subject Last Visit Identity | LPC-dentity | LPO - identity | LSC - identity | LSO - identity | last subject complete - identity | last subject last visit - identity (LSLV - identity) | last subject out - identity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540566","Low-interventional Clinical Trial","C142601","A clinical trial that is non-interventional by design but includes diagnostic or monitoring procedures that carry minimal risk or impact on patients.","Low-interventional Clinical Trial | low-interventional clinical trial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540565","Marketing Authorization Procedure","C142602","A formal procedure by which a regulatory agency grants an applicant authorization for the marketing or free distribution of a product after evaluation for safety, efficacy and quality.","Marketing Authorization Procedure | marketing authorization procedure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518831","PVC-211 MuLV","C14342","A murine leukemia virus (MuLV) variant cloned from rats infected with the Friend leukemia virus.  Neuropathogenic, causes hind limb paralysis in rats and mice, unlike the parent Friend virus which causes erythroleukemia.","PVC-211 MuLV | Friend murine leukemia virus (ISOLATE PVC-211)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540733","Diethyl Dihydroxyhomospermine","C142788","The hydrochloride salt form of ivospemin, an analogue of naturally occurring polyamine (PA), with potential antineoplastic activity. Upon subcutaneous administration,  ivospemin displaces endogenous PAs from PA-binding sites on the cell surface, which prevents internalization of PA. This inhibits PA-dependent cell cycle processes and results in cell cycle arrest, the induction of apoptosis, and inhibition of tumor cell proliferation. PA uptake is upregulated in various tumor types and increased levels of PA leads to enhanced tumor cell growth.","Ivospemin Hydrochloride | Diethyl Dihydroxyhomospermine | HO2-DEHSPM | IVOSPEMIN HYDROCHLORIDE | Polyamine Analogue SBP-101 | Polyamine Analogue SBP-101 | SBP 101 | SBP 101 Tetrahydrochloride | SBP-101 | SBP-101 Tetrahydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540732","Neurokinin-3 Receptor Antagonist","C142789","Any agent that inhibits the activity of the neurokinin type 3 receptor.","Neurokinin-3 Receptor Antagonist | NK3 Antagonist | NK3 Receptor Antagonist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541380","Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody GBR 1302","C142889","An anti-human epidermal growth factor receptor 2 (HER2)/anti-CD3 bispecific monoclonal antibody with potential immunostimulatory and antineoplastic activities. Anti-HER2/Anti-CD3 bispecific monoclonal antibody GBR 1302 possesses two antigen recognition sites, one for HER2, a tyrosine kinase receptor overexpressed by many cancer cell types, and one for the CD3 complex, a group of T-cell surface glycoproteins that interact with the T-cell receptor (TCR). Upon administration of GBR 1302, this bispecific monoclonal antibody simultaneously binds to both CD3-expressing T-cells and HER2-expressing cancer cells, thereby crosslinking HER2-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated lysis of HER2-expressing tumor cells. HER2 plays a key role in tumor cell proliferation and tumor vascularization.","Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody GBR 1302 | Anti-HER2 x Anti-CD3 Bispecific Monoclonal Antibody GBR 1302 | GBR 1302 | GBR-1302",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0079337","Feline Immunodeficiency Virus","C14288","A lentivirus causing acquired immunodeficiency in cats. The FIV virus is transmitted in the saliva or blood, commonly through the bite wound from an infected cat. Strictly a feline disease, FIV cannot be transmitted to humans.","Feline Immunodeficiency Virus | FIV",,,,,,,,,,,,,,,"4185676","Feline immunodeficiency virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL541381","PRS-343","C142890","A bivalent, bispecific fusion protein comprised of an anti-human epidermal growth factor receptor (HER2) monoclonal antibody linked to a CD137-targeting anticalin with potential immunostimulatory and antineoplastic activities. Upon administration of cinrebafusp alfa, CD137 clustering is promoted by bridging CD137-positive T-cells with HER2-positive tumor cells, leading to the recruitment of tumor antigen-specific cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated lysis of HER2-expressing tumor cells. HER2 plays a key role in tumor cell proliferation and tumor vascularization. CD137 is a costimulatory immunoreceptor and a member of the tumor necrosis factor receptor superfamily (TNFRSF). Anticalins are synthetic antigen-binding proteins derived from lipocalins. Structurally dissimilar to antibodies, anticalins are able to bind to smaller antigens and exhibit improved tissue penetration.","Cinrebafusp Alfa | Anti-HER2 Monoclonal Antibody/Anti-CD137 Anticalin Bispecific Fusion Protein PRS-343 | Anti-HER2 Monoclonal Antibody/Anti-CD137Anticalin Bispecific Fusion Protein PRS-343 | CINREBAFUSP ALFA | PRS-343",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541382","Brugada Syndrome","C142891","A genetically heterogeneous condition characterized by complete or incomplete right bundle branch block accompanied by ST elevation in leads V1-V3. There is a high incidence of ventricular arrhythmia that may result in sudden death.","Brugada Syndrome | Right Bundle Branch Block, ST Segment Elevation, and Sudden Death Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541383","Familial Hypertrophic Cardiomyopathy Type 2","C142892","An autosomal dominant subtype of familial hypertrophic cardiomyopathy caused by mutation(s) in the TNNT2 gene, encoding troponin T, cardiac muscle.","Familial Hypertrophic Cardiomyopathy Type 2 | CMH2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2931355","Spastic Paraplegia 3A","C142893","An autosomal dominant subtype of hereditary spastic paraplegia caused by mutation(s) in the ATL1 gene, encoding atlastin-1.","Spastic Paraplegia 3A | Strumpell Disease",,,,,,,,,,,,,,,"37204171","Autosomal dominant spastic paraplegia type 3",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1832916","Long QT Syndrome 8","C142894","An autosomal dominant condition caused by mutation(s) in the CACNA1C gene, encoding voltage-dependent L-type calcium channel subunit alpha-1C. It is characterized by a prolonged QT interval that may result in torsade de pointes, ventricular fibrillation and/or sudden cardiac death.","Long QT Syndrome 8 | LQT8 | Timothy Syndrome",,,,,,,,,,,,,,,"37155430|44783199","Timothy syndrome|Timothy syndrome type 1",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL541371","Abafilcon A","C142895","No value exists.","Abafilcon A | ABAFILCON A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541372","Abediterol Napadisylate","C142896","No value exists.","Abediterol Napadisylate | ABEDITEROL NAPADISYLATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541621","Tabelecleucel","C143140","Allogeneic cytotoxic T-lymphocytes (CTLs) selective for the tumor-associated antigens (TAAs) expressed by the Epstein-Barr virus (EBV), with potential immunostimulating and antineoplastic activities. Upon administration, and after hematopoietic cell transplants (HCT) or solid organ transplants (SOT), or during certain other immunocompromised states, tabelecleucel targets and binds to EBV-associated antigens expressed on EBV-infected cells. This results in lysis of EBV-infected cells and prevents growth of EBV-associated cancer cells. EBV is associated with a variety of cancers and post-transplant lymphoproliferative disorders (EBV+ PTLD).","Tabelecleucel | ATA 129 | ATA-129 | ATA129 | Allogeneic EBV-specific CTLs ATA129 | Allogeneic EBV-specific Cytotoxic T-lymphocytes | CTLs ATA129 | EBV-CTLs | Ebvallo | TABELECLEUCEL | Tab-cel | Teb-cel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541622","Topical VBP-926 Solution","C143141","A topical solution with potential anti-inflammatory activity. Upon topical application to the affected area, VBP-926 may help reduce paronychia. Iatrogenic paronychia is associated with chemotherapy treatment.","Topical VBP-926 Solution | VBP 926 | VBP-926 | VBP-926 Solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540678","Treatment Contrast Interaction","C142732","The situation in which a treatment contrast (e.g., difference between investigational product and control) is dependent on another factor (e.g., center). A quantitative interaction refers to the case where the magnitude of the contrast differs at the different levels of the factor, whereas for a qualitative interaction, the direction of the contrast differs for at least one level of the factor. (ICH)","Treatment Contrast Interaction | interaction (qualitative and quantitative) | treatment contrast interaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540675","Trial Design Element","C142735","No value exists.","Trial Design Element | Study Design Element | trial design element",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517583","Invertebrates, Land","C14359","Terrestrial animals without back bones","Invertebrates, Land | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540756","BHV 4157","C142847","A formulation comprised of a prodrug form of the benzothiazole derivative riluzole, with potential anti-depressant, anxiolytic and antineoplastic activities. Following oral administration, troriluzole is converted into the active form riluzole. While the mechanism of action of riluzole is unknown, its pharmacological activities, some of which may be related to its effect, include the following: 1) an inhibitory effect on glutamate release, 2) inactivation of voltage-dependent sodium channels, and 3) interference with intracellular events that follow transmitter binding at excitatory amino acid receptors. These activities may result in myorelaxation and sedation due to the blockade of glutamatergic neurotransmission. Additionally, these activities may result in the inhibition of enzymes that are necessary for cell growth, which may decrease tumor cell growth and metastasis.","Troriluzole | BHV 4157 | BHV-4157 | Glycinamide, Glycylglycyl-N2-methyl-N-(6-(trifluoromethoxy)-2-benzothiazolyl)- | TRORILUZOLE | Trigriluzole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540771","Recurrent Malignant Glioma","C142848","The reemergence of malignant glioma after a period of remission.","Recurrent Malignant Glioma | Recurrent High Grade Glioma | Recurrent High-Grade Glioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540770","Recurrent Rhabdoid Tumor","C142849","The reemergence of rhabdoid tumor after a period of remission.","Recurrent Rhabdoid Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540769","Refractory Peripheral Primitive Neuroectodermal Tumor","C142850","Peripheral primitive neuroectodermal tumor that does not respond to treatment.","Refractory Peripheral Primitive Neuroectodermal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540768","Refractory Rhabdomyosarcoma","C142851","Rhabdomyosarcoma that does not respond to treatment.","Refractory Rhabdomyosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540725","CTRP Biomarker Terminology","C142799","A set of terms that is comprised of the biomarkers referenced in NCI-sponsored clinical trials.","CTRP Biomarker Terminology | Clinical Trials Reporting Program Biomarker Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518095","Lytic Virus","C14368","A virus which, as part of its life cycle, causes its host cells plasma membrane to rupture (to lyse).","Lytic Virus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518032","Lower Organism","C14369","A subjective term that might be applied to any non-human organism.","Lower Organism | Lower Organisms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0166939","Baccatin III","C1436","A compound obtained from the needles of the Taxus baccata tree that is used as a precursor of paclitaxel.","Baccatin III | BACCATIN III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541623","ARF1 Gene","C143142","This gene is involved in protein trafficking through the endoplasmic reticulum and Golgi apparatus.","ARF1 Gene | ADP Ribosylation Factor 1 Gene | ARF1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541624","ARF1 wt Allele","C143143","Human ARF1 wild-type allele is located in the vicinity of 1q42.13 and is approximately 17 kb in length. This allele, which encodes ADP-ribosylation factor 1 protein, plays a role in intracellular protein trafficking.","ARF1 wt Allele | ADP Ribosylation Factor 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541625","ADP-Ribosylation Factor 1","C143144","ADP-ribosylation factor 1 (181 aa, ~21 kDa) is encoded by the human ARF1 gene. This protein is involved in both activation of the cholera toxin catalytic subunit and protein localization.","ADP-Ribosylation Factor 1 | ARF1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1742415","ADP-Ribosylation Factor 6","C143145","ADP-ribosylation factor 6 (175 aa, ~20 kDa) is encoded by the human ARF6 gene. This protein plays a role in protein localization and the remodeling of both lipid membranes and the cytoskeleton.","ADP-Ribosylation Factor 6 | ARF6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541627","ARF6 Gene","C143146","This gene plays a role in vesicle trafficking, membrane lipid remodeling and cytoskeleton reorganization.","ARF6 Gene | ADP Ribosylation Factor 6 Gene | ARF6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541612","ARF6 wt Allele","C143147","Human ARF6 wild-type allele is located in the vicinity of 14q21.3 and is approximately 4 kb in length. This allele, which encodes ADP-ribosylation factor 6, is involved in both membrane and protein trafficking.","ARF6 wt Allele | ADP Ribosylation Factor 6 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541613","Transrectal Ultrasonography Guided Biopsy","C143148","A procedure that uses transrectal ultrasound to image the prostate and guide the placement of a biopsy needles to obtain a tissue sample.","Transrectal Ultrasonography Guided Biopsy | TRUS Biopsy | TRUS-Guided Biopsy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242854","SENCAR Mouse","C14314","A mouse strain that was selectively bred to be highly susceptible to agents and procedures that induce carcinogenesis, primarily skin carcinogenesis; these mice have a low incidence of spontaneous tumor formation.","SENCAR Mouse | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541615","Restriction Spectrum Imaging","C143150","A diffusion-weighted MRI technique that utilizes data obtained from multiple b-values and diffusion directions to measure diffusion orientation and length scale; it has been used to identify distinct microscopic tissues based on water diffusion behavior.","Restriction Spectrum Imaging | RSI | RSI-MRI | Restriction Spectrum MRI | Restriction Spectrum Magnetic Resonance Imaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541616","Masaoka-Koga Stage","C143151","A thymoma stage defined according to the Masaoka-Koga staging criteria.","Masaoka-Koga Stage | masaoka stage | masaoka_stage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540609","Random Sample Population","C142662","The target group that is chosen via a sampling methodology created to provide an equal probability of being chosen.","Random Sample Population | random sample",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517584","Invertebrates, Marine","C14360","Animals without a backbone that live in the ocean","Invertebrates, Marine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085508","Helicobacter","C14296","A genus of gram-negative helical, curved, or straight microaerophilic bacteria with rounded ends and multiple sheathed flagella (unipolar or bipolar and lateral) with terminal bulbs. Form nonpigmented, translucent colonies, 1-2 mm in diameter. Catalase and oxidase positive. Found in gastric mucosa of primates, including human beings and ferrets. Some species are associated with gastric and peptic ulcers and gastric cancer. The type species is Helicobacter pylori.","Helicobacter | HELICOBACTER",,,,,,,,,,,,,,,"4024285","Helicobacter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL541418","Bucainide Maleate","C142970","No value exists.","Bucainide Maleate | BUCAINIDE MALEATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541419","Bucindolol Hydrochloride","C142971","No value exists.","Bucindolol Hydrochloride | BUCINDOLOL HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541420","Bunolol Hydrochloride","C142972","No value exists.","Bunolol Hydrochloride | BUNOLOL HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541421","Buparlisib Hydrochloride","C142973","No value exists.","Buparlisib Hydrochloride | BUPARLISIB HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541422","Butacetin","C142974","No value exists.","Butacetin | BUTACETIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0724541","Butamben Picrate","C142975","No value exists.","Butamben Picrate | BUTAMBEN PICRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541408","Butamirate Citrate","C142976","No value exists.","Butamirate Citrate | BUTAMIRATE CITRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541409","Butirosin Sulfate","C142977","No value exists.","Butirosin Sulfate | BUTIROSIN SULFATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540766","Refractory Ewing Sarcoma","C142853","Ewing sarcoma that does not respond to treatment.","Refractory Ewing Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540765","Refractory Hepatoblastoma","C142854","Hepatoblastoma that does not respond to treatment.","Refractory Hepatoblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540747","Refractory Medulloblastoma","C142856","Medulloblastoma that does not respond to treatment.","Refractory Medulloblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540746","Refractory Osteosarcoma","C142857","Osteosarcoma that does not respond to treatment.","Refractory Osteosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540745","Refractory Rhabdoid Tumor","C142858","Rhabdoid tumor that does not respond to treatment.","Refractory Rhabdoid Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043342","Xenopus","C14285","Any of various aquatic, tongueless, clawed frogs of the genus Xenopus, native to southern Africa, especially X. laevis, widely used in the study of vertebrate development.","Xenopus | ",,,,,,,,,,,,,,,"4253518","Xenopus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL448598","Lapatinib-Letrozole Regimen","C142860","A regimen consisting of lapatinib and letrozole that is used as a treatment for breast cancer.","Lapatinib/Letrozole Regimen | Lapatinib + Letrozole | Lapatinib Plus Letrozole | Lapatinib and Letrozole | Lapatinib-Letrozole | Lapatinib-Letrozole Regimen | Tykerb/Femara",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540743","Recurrent Anaplastic Oligoastrocytoma","C142861","The reemergence of anaplastic oligoastrocytoma after a period of remission.","Recurrent Anaplastic Oligoastrocytoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1611857","CDH10 protein, human","C143095","Cadherin-10 (788 aa, ~88 kDa) is encoded by the human CDH10 gene. This protein plays a role in cell-cell adhesion.","Cadherin-10 | CDH10 | Cadherin 10 | T2-Cadherin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541554","CDH17 wt Allele","C143097","Human CDH17 wild-type allele is located in the vicinity of 8q22.1 and is approximately 90 kb in length. This allele, which encodes cadherin-17 protein, plays a role in cell-cell adhesion and peptide transport. Mutations in the gene may be associated with melanoma.","CDH17 wt Allele | CDH16 | Cadherin 16, Formerly Gene | Cadherin 17 wt Allele | Cadherin, Liver-Intestine Gene | Cadherin-16 Gene | HPT-1 | HPT1 | LI Cadherin (Liver-Intestine) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0246443","CDH17 protein, human","C143098","Cadherin-17 (832 aa, ~92 kDa) is encoded by the human CDH17 gene. This protein is involved in cell-cell adhesion and intestinal proton-dependent peptide absorption.","Cadherin-17 | CDH17 | Cadherin 17 | HPT-1 Cadherin | Human Intestinal Peptide-Associated Transporter HPT-1 | Human Peptide Transporter 1 | Intestinal Peptide-Associated Transporter HPT-1 | LI Cadherin | LI-Cadherin | Liver-Intestine Cadherin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206536","Morbillivirus","C14309","A genus of Paramyxovirinae which includes Measles Virus","Morbillivirus | MORBILLIVIRUS",,,,,,,,,,,,,,,"4306484","Genus Morbillivirus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL541481","DCAF12L2 wt Allele","C143037","Human DCAF12L2  wild-type allele is located in the vicinity of Xq25 and is approximately 3 kb in length. This allele, which encodes DDB1- and CUL4-associated factor 12-like protein 2, is involved in protein-protein interactions. Mutations in the gene may be associated with colorectal cancer.","DCAF12L2 wt Allele | DDB1 and CUL4 Associated Factor 12 Like 2 wt Allele | WD Repeat Domain 40C Gene | WDR40C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541482","DDB1- and CUL4-Associated Factor 12-Like Protein 2","C143038","DDB1- and CUL4-associated factor 12-like protein 2 (463 aa, ~51 kDa) is encoded by the human DCAF12L2 gene. This protein plays a role in the modulation of protein-protein interactions.","DDB1- and CUL4-Associated Factor 12-Like Protein 2 | DCAF12L2 | WD Repeat-Containing Protein 40C | WDR40C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541484","CYSLTR2 wt Allele","C143040","Human CYSLTR2 wild-type allele is located in the vicinity of 13q14.2 and is approximately 58 kb in length. This allele, which encodes cysteinyl leukotriene receptor 2, plays a role in leukotriene-dependent signaling. Mutations in the gene may be associated with uveal melanoma.","CYSLTR2 wt Allele | CYSLT2 | CYSLT2R | Cysteinyl Leukotriene Receptor 2 wt Allele | GPCR21 | HG57 | HPN321 | KPG_011 | PSEC0146 | hGPCR21",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1432903","cysteinyl leukotriene receptor 2 protein, human","C143041","Cysteinyl leukotriene receptor 2 (346 aa, ~40 kDa) is encoded by the human CYSLTR2 gene. This protein is involved in the mediation of cysteinyl leukotriene-dependent signal transdution.","Cysteinyl Leukotriene Receptor 2 | CYSLTR2 | CysLT(2) | Cysteinyl Leukotriene CysLT2 Receptor | G-Protein Coupled Receptor GPCR21 | G-Protein Coupled Receptor HG57 | HPN321 | hGPCR21",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540607","Recruitment Period","C142664","The interval of time during which subjects are to be enrolled in a clinical study.","Recruitment Period | recruitment period",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540622","Recruitment Target","C142665","The total number of study subjects to be collected for entry into the study to fulfill the protocol conditions.","Recruitment Target | recruitment target",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540621","Regulated Clinical Research and Information Management","C142666","A technical committee within Health Level 7 (HL7) that deals with regulated clinical research and information.","Regulated Clinical Research and Information Management | RCRIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540620","Repeat Activity Until Rule","C142667","A rule that sets the conditions under which a repeating activity will stop.","Repeat Activity Until Rule | repeat rule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540619","Research Hypothesis","C142668","The proposed assertion about which the study will determine to prove or disprove.","Research Hypothesis | Study Hypothesis | hypothesis | research hypothesis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540618","Residual Risk","C142669","Risk that remains after risk control measures have been taken.","Residual Risk | residual risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540617","Response Option","C142670","Choices for replies to questions or instructions on patient-reported outcomes.","Response Option | response option",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540616","Results Posting","C142671","The process of submitting and updating summary information about the conclusions of a clinical study to a structured, publicly accessible, Web-based results database, such as the ClinicalTrials.gov results database. (clinicaltrials.gov)","Results Posting | Results Submission | results posting (results submission)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540615","Results Posting Date","C142672","The date and time that the summary information about the conclusions of the clinical study are submitted to a structured, publicly accessible, Web-based results database, such as the ClinicalTrials.gov results database. (clinicaltrials.gov)","Results Posting Date | Results Submission Date | results posting date (results submission date)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540600","Retrospective Data Capture","C142673","Data that is collected after the fact, originating from subject recall or memory.","Retrospective Data Capture | retrospective data capture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540599","Risk Based Monitoring","C142674","An approach to clinical trial monitoring that involves identifying, assessing, monitoring and mitigating the risks that could affect the quality or safety of a study.","Risk Based Monitoring | Risk Monitoring | Risk-Based Monitoring | Risk-based Monitoring | risk based monitoring | risk-based monitoring",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540598","SAFE-Biopharma Standard","C142675","A standard established by the biopharmaceutical industry to digitally identify subscribers, mitigating legal, regulatory, and other business risks associated with electronic transactions.","SAFE-Biopharma Standard | BioPharma Digital Identity and Signature Standard | SAFE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540597","Safety and Tolerability","C142676","The aspects of medical product evaluation associated with risk to the subject/patient and the degree to which overt adverse effects can be tolerated.","Safety and Tolerability | safety and tolerability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540596","Sample Size Adjustment","C142677","A change to a previously determined sample population size for a study, following a review of blinded information during an intermediate point in the study.","Sample Size Adjustment | sample size adjustment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540594","Secondary Sponsor","C142679","Additional individuals, organizations or other legal persons, if any, that have agreed with the primary sponsor to take on sponsorship responsibilities. (WHO)","Secondary Sponsor | secondary sponsor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541413","Zoptarelin Doxorubicin Acetate","C142981","No value exists.","Zoptarelin Doxorubicin Acetate | ZOPTARELIN DOXORUBICIN ACETATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541414","Refractory Lymphocyte-Rich Classic Hodgkin Lymphoma","C142982","Lymphocyte-rich classic Hodgkin lymphoma that does not respond to treatment.","Refractory Lymphocyte-Rich Classic Hodgkin Lymphoma | Refractory Lymphocyte-Rich Classical Hodgkin Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541404","Refractory Thyroid Gland Carcinoma","C142983","Thyroid gland carcinoma that does not respond to treatment.","Refractory Thyroid Gland Carcinoma | Refractory Thyroid Cancer | Refractory Thyroid Gland Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0325089","Felidae","C14321","Taxonomic family which includes domestic and wild cats such as lions and tigers.","Felidae | Felid | Felids",,,,,,,,,,,,,,,"4303579","Cats",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0165023","Cephalomannine","C1430","A diterpene taxane obtained from the bark and leaves of the yew tree (Taxus brevifolia) and can convert to taxol. (NCI)","Cephalomannine | CEPHALOMANNINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541542","ZNF429 wt Allele","C143101","Human ZNF429 wild-type allele is located in the vicinity of 19p12 and is approximately 60 kb in length. This allele, which encodes zinc finger protein 429, may be involved in transcriptional regulation.","ZNF429 wt Allele | Zinc Finger Protein 429 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541543","Zinc Finger Protein 429","C143102","Zinc finger protein 429 (674 aa, ~78 kDa) is encoded by the human ZNF429 gene. This protein may play a role in the regulation of transcription.","Zinc Finger Protein 429 | ZNF429",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541545","ZNF479 wt Allele","C143104","Human ZNF479 wild-type allele is located in the vicinity of 7p11.2 and is approximately 22 kb in length. This allele, which encodes zinc finger protein 479, may play a role in the regulation of gene transcription.","ZNF479 wt Allele | HKr19 | KR19 | Zinc Finger Protein 479 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541546","Zinc Finger Protein 479","C143105","Zinc finger protein 479 (524 aa, ~61 kDa) is encoded by the human ZNF479 gene. This protein may be involved in transcriptional repression.","Zinc Finger Protein 479 | HKr19 | KRAB Zinc Finger Protein KR19 | ZNF479 | Zinc Finger Protein Kr19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541532","WNK2 wt Allele","C143107","Human WNK2 wild-type allele is located in the vicinity of 9q22.31 and is approximately 136 kb in length. This allele, which encodes serine/threonine-protein kinase WNK2 protein, is involved in serine/threonine phosphorylation of substrates that regulate electrolyte homeostasis and signal transduction.","WNK2 wt Allele | KIAA1760 | NY-CO-43 | P/OKcl.13 | PRKWNK2 | Protein Kinase, Lysine-Deficient 2 Gene | SDCCAG43 | WNK Lysine Deficient Protein Kinase 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541533","WNK2 protein, human","C143108","Serine/threonine-protein kinase WNK2 (2297 aa, ~243 kDa) is encoded by the human WNK2 gene. This protein plays a role in the regulation of cell signaling and ion transport.","Serine/Threonine-Protein Kinase WNK2 | Antigen NY-CO-43 | EC 2.7.11.1 | Protein Kinase Lysine-Deficient 2 | Protein Kinase with No Lysine 2 | Serologically Defined Colon Cancer Antigen 43",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540563","Matched-Pair Design","C142604","A type of parallel trial in which investigators identify pairs of subjects who are identical with respect to relevant factors, then randomize them so that one receives Treatment A and the other Treatment B. (CDISC Glossary)","Matched-Pair Design | matched-pair design",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540562","Medicinal Product","C142605","Any substance or combination of substances that may be administered to human beings (or animals) for treating or preventing disease, or with the intent to make a medical diagnosis or to restore, correct or modify physiological functions. (IDMP)","Medicinal Product | medicinal product",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540561","Medicinal Product Identifier","C142606","A worldwide unique identifier allocated to a medicinal product that is supplementary to any existing identifier approved by a regulatory authority in the country of authorization.","Medicinal Product Identifier | medicinal product identifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540560","Medicinal Product Name","C142607","The name assigned to a medicinal product as approved by a regulatory authority of the country of authorization.","Medicinal Product Name | medicinal product name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541471","CSMD3 wt Allele","C143043","Human CSMD3 wild-type allele is located in the vicinity of 8q23.3 and is approximately 1215 kb in length. This allele, which encodes CUB and sushi domain-containing protein 3, is involved in dendrite development.","CSMD3 wt Allele | CUB and Sushi Multiple Domains 3 wt Allele | KIAA1894",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541473","Quinuclium Bromide Anhydrous","C143045","No value exists.","Quinuclium Bromide Anhydrous | 1-Azoniabicyclo(2.2.2)octane, 1-methyl-3-oxo-4-phenyl-, Bromide | 1-Methyl-3-oxo-4-phenyl-1-azoniabicyclo(2.2.2)octane, Bromide | QUINUCLIUM BROMIDE ANHYDROUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541474","Ralimetinib","C143046","No value exists.","Ralimetinib | 3H-Imidazo(4,5-b)pyridin-2-amine, 5-(2-(1,1-Dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-(2,2-dimethylpropyl)- | LY2228820 Free Base | RALIMETINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0445868","Helicobacter felis","C14330","A species of helix-shaped, Gram-negative Helicobacter in the phylum Proteobacteria that has been shown to be a human pathogen. H. felis infection induces chronic gastric inflammation.","Helicobacter felis | H. felis | HELICOBACTER FELIS",,,,,,,,,,,,,,,"4287560","Helicobacter felis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1511486","Consomic Strain","C14352","Strains derived by repeated backcrossing while maintaining one whole chromosome genetically different from the background strain. (JAX IMSR glossary)","Consomic Strain | Chromosome Substitution Strain | Consomic Strain/Chromosome Substitution Strain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514798","Recombinants","C14353","An individual cell or organisms which carries recombinant DNA","Recombinants | recombinant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039005","Suidae","C14322","Taxonomic family which includes the domestic pig.","Suidae | Suid | Suids",,,,,,,,,,,,,,,"4028569","Pigs and hogs",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540674","Trial Design Model","C142736","A standard structure for representing the planned sequence of events and the treatment plan of a clinical trial. (CDISC)","Trial Design Model | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540673","Trial Statistician","C142737","A statistician who has a combination of education, training and experience to be responsible for the statistical aspects of the trial. (ICH)","Trial Statistician | study statistician | trial statistician",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541304","Trial Subject Replacement","C142738","The process of enrolling a trial subject to compensate for another participant that has left the clinical trial.","Trial Subject Replacement | Study Subject Replacement | Subject Replacement | replacement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540660","Trustworthy Electronic Record","C142740","A characteristic of an electronic record, specifically data quality and integrity, that indicates fitness for safety and efficacy recommendations.","Trustworthy Electronic Record | trustworthy (electronic records)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540659","Type 3 Error","C142741","In statistics, the probability of a Type 3 error, when one correctly rejects the null hypothesis, but the reason for rejecting it is incorrect. In the context of study interventions, this means that one incorrectly determines that the less useful treatment is more useful.","Type 3 Error | Type III Error | type 3 (or type III) error",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540559","Medicines And Healthcare Products Regulatory Agency","C142608","A government agency of the United Kingdom responsible for ensuring that medicines and medical devices work, and are acceptably safe. (MHRA)","Medicines And Healthcare Products Regulatory Agency | MHRA | Medicines and Healthcare products Regulatory agency (MHRA)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540543","Mega-Trial","C142609","A type of clinical trial in which 10,000 or more subjects are enrolled.","Mega-Trial | large sample trial | mega-trials",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540542","Missing Data","C142610","Required or expected data that is not present, which may be due to non-completion or corruption.","Missing Data | missing data",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545942","Multi-Institutional Clinical Study","C142611","A clinical study that is being conducted at multiple locations.","Multi-Institutional Clinical Study | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540540","New Safety Information","C142613","Pharmaceutical data received from factual, observational sources such as adverse event reports, clinical or post-approval studies or other scientific studies about a severe or unexpected severe hazard related to the pharmaceutical after approval or following the most recent assessment of the drug.","New Safety Information | new safety information",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540539","N-of-1 Study","C142614","A clinical trial that uses a single individual as the entire study population. This subject receives different treatments and control treatments with the goal of determining the best intervention for an individual patient using objective data-driven criteria.","N-of-1 Study | n-of-1 study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540538","Non-Interventional Study","C142615","No value exists.","Non-Interventional Study | non-interventional study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540550","Nuremberg Code","C142617","A set of ten ethical principles for human experimentation established as a result of the Nuremberg trials at the end of the Second World War.","Nuremberg Code | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540549","Objective Measurement","C142618","Any measurement that is not subject to observer assessment, such as those registered by an instrument.","Objective Measurement | objective measurement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540548","Observer Assessment","C142619","Any assessment made by an observer, as opposed to a device.","Observer Assessment | observer assessment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032868","Poxvirus","C14261","A family of enveloped, double-stranded DNA viruses that infect mammals, birds, and insects. It is divided into two subfamilies: chordopoxvirinae, poxviruses of vertebrates, and entomopoxvirinae, poxviruses of insects.","Poxvirus | Poxviridae",,,,,,,,,,,,,,,"4312771","Poxviridae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540547","Observer-reported Outcome","C142620","A clinical outcome assessment that is reported by someone other than the patient or a healthcare professional.","Observer-reported Outcome | ObsRO | observer-reported outcome (ObsRO)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540546","Open To Enrollment","C142621","An indication that a study is able to add subjects.","Open To Enrollment | Study Open to Enrollment | open to enrollment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519356","Sloan Kettering Virus","C14344","The Sloan-Kettering viruses (SKVs) are a group of transforming retroviruses that were isolated from chicken embryo cells which had been infected with the avian leukosis virus transformation-defective Bratislava 77 (tdB77). (from Li et al.  J Virol 1986;57:1065-72)","Sloan Kettering Virus | Avian erythroblastosis virus (strain Sloan-Kettering) | SKVS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0524515","Canidae","C14331","Taxonomic family which includes the domestic dog, wolves and foxes.","Canidae | Canid | Canids",,,,,,,,,,,,,,,"4027938","Canidae",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0164550","Rogletimide","C1427","An orally active aminoglutethimide derivative with potential antineoplastic activity. Rogletimide reversibly inhibits the activity of aromatase, a cytochrome P450 family enzyme found in many tissues and the key enzyme in the oxidative aromatization process of androgens to estrogens. In estrogen-dependent cancers, the inhibition of aromatase by this agent leads to a reduction in the synthesis of estrogen, thereby inhibiting estrogen-mediated signal transduction and consequently reducing tumor cell growth. In addition, rogletimide also inhibits enzymes that catalyzing conversion of cholesterol to corticosteroids.","Rogletimide | Pyridoglutethimide | ROGLETIMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540724","CTRP Molecular Genetic Biomarker Terminology","C142800","A set of terms that is comprised of any biomarkers related to genes (i.e. genes, alleles, proteins, molecular abnormalities, or any related findings or assays) referenced in NCI-sponsored clinical trials.","CTRP Molecular Genetic Biomarker Terminology | Clinical Trials Reporting Program Molecular Genetic Biomarker Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540723","CTRP Reference Gene Terminology","C142801","A set of terms that is comprised of all the genes referenced in NCI-sponsored clinical trials.","CTRP Reference Gene Terminology | Clinical Trials Reporting Program Reference Gene Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3810400","EIEE19","C142802","An autosomal dominant form of early infantile epileptic encephalopathy, caused by mutation(s) in the GABRA1 gene, encoding gamma-aminobutyric acid receptor subunit alpha-1.","Developmental and Epileptic Encephalopathy 19 | DEE19 | EIEE19 | Early Infantile Epileptic Encephalopathy 19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3550904","Developmental and Epileptic Encephalopathy 36","C142803","An X-linked dominant form of early infantile epileptic encephalopathy, caused by mutation(s) in the ALG13 gene, encoding putative bifunctional UDP-N-acetylglucosamine transferase and deubiquitinase ALG13.","Developmental and Epileptic Encephalopathy 36 | DEE36 | EIEE36 | Early Infantile Epileptic Encephalopathy 36",,,,,,,,,,,,,,,"37118676","Congenital disorder of glycosylation type 1s",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4015420","EPILEPSY, PROGRESSIVE MYOCLONIC 7","C142804","An autosomal dominant form of early progressive myoclonic epilepsy, caused by mutation(s) in the KCNC1 gene, encoding potassium voltage-gated channel subfamily C member 1.","Epilepsy, Progressive Myoclonic 7 | EPM7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0339273","Gelatinous Drop-Like Corneal Dystrophy","C142805","An autosomal recessive corneal dystrophy caused by mutation(s) in the TACSTD2 gene, encoding tumor-associated calcium signal transducer 2. It is characterized by severe corneal amyloidosis that may result in blindness.","Gelatinous Drop-Like Corneal Dystrophy | CDGDL",,,,,,,,,,,,,,,"4171866","Gelatinous droplike corneal dystrophy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0342701","Transcobalamin II Deficiency","C142806","An autosomal recessive condition caused by mutation(s) in the TCN2 gene, encoding transcobalamin-2. it is characterized by failure to thrive, megaloblastic anemia, and pancytopenia.","Transcobalamin II Deficiency | Transcobalamin II deficiency",,,,,,,,,,,,,,,"4029726","Transcobalamin II deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL541373","Abexinostat Hydrochloride","C142897","The hydrochloride salt form of abexinostat, an orally bioavailable hydroxamate-based pan-inhibitor of histone deacetylase (HDAC), with potential antineoplastic and radiosensitizing activities. Upon administration, abexinostat inhibits HDAC, resulting in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling; the selective transcription of tumor suppressor genes; and the tumor suppressor protein-mediated inhibition of tumor cell division and induction of tumor cell apoptosis. In addition, abexinostat decreases the expression of the DNA-repair protein RAD51, thereby reducing the RAD51 protein, preventing repair of DNA double-strand breaks and increasing sensitivity of tumor cells to DNA damaging agents. HDAC, upregulated in many tumor types, is an enzyme that is responsible for the deacetylation of chromatin histone proteins.","Abexinostat Hydrochloride | ABEXINOSTAT HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541374","Acorafloxacin Hydrochloride","C142898","No value exists.","Acorafloxacin Hydrochloride | ACORAFLOXACIN HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541375","Adomiparin","C142899","No value exists.","Adomiparin | ADOMIPARIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541376","Afovirsen Sodium","C142900","No value exists.","Afovirsen Sodium | AFOVIRSEN SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541363","Aftobetin Hydrochloride","C142901","No value exists.","Aftobetin Hydrochloride | AFTOBETIN HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541364","Afuresertib Hydrochloride","C142902","No value exists.","Afuresertib Hydrochloride | AFURESERTIB HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541366","Aganepag Isopropyl","C142904","No value exists.","Aganepag Isopropyl | AGANEPAG ISOPROPYL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541367","Aladorian Sodium","C142906","No value exists.","Aladorian Sodium | ALADORIAN SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541368","Alamecin","C142907","No value exists.","Alamecin | ALAMECIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541369","Albumin, Aggregated Iodinated I-131 Serum","C142908","No value exists.","Albumin, Aggregated Iodinated I-131 Serum | ALBUMIN, AGGREGATED IODINATED I-131 SERUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541355","Alexomycin","C142910","No value exists.","Alexomycin | ALEXOMYCIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL541356","Alicaforsen Sodium","C142911","No value exists.","Alicaforsen Sodium | ALICAFORSEN SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540658","Unblinding","C142742","The process by which identifying information for a patient or group of outcomes from a clinical trial is revealed to the subject and/or investigators conducting the clinical study.","Unblinding | Study Unblinding | TREATMENT UNBLINDED | Unblinded | Unmasking | unblinding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540657","Unequal Randomization","C142743","A type of sorting to allocate subjects/patients in a clinical trial into groups at different rates.","Unequal Randomization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540656","Unexpected Adverse Drug Reaction","C142744","An adverse drug reaction, whose nature, severity, specificity, or outcome is not consistent with the term or description used in the applicable product information (e.g., IB for an unapproved investigational product or PI/summary of product characteristics for an approved product, and/or scientific literature). (ICH)","Unexpected Adverse Drug Reaction | unexpected adverse drug reaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540655","Unexpected Serious Risk","C142745","A serious adverse drug experience that is not listed in the labeling of a drug, or that may be symptomatically or pathophysiologically related to an adverse drug experience identified in the labeling, but differs because of greater severity, specificity, or prevalence. [505-1(b) of FD&C Act (21 USC. 355-1(b)","Unexpected Serious Risk | unexpected serious risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540654","User Site Testing","C142746","Any examination of software/hardware functionality that takes place outside of the developer's controlled environment.","User Site Testing | UST | user site testing (UST)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3658317","Web Browser","C142748","A software tool that enables Internet navigation to Web sites and other online resources using Hypertext Transfer Protocol (HTTP).","Web Browser | web browser",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540666","Web Page","C142749","A hypertext document on the World Wide Web that may incorporate text, graphics, sound, and/or other features.","Web Page | web page",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037224","Simian Immunodeficiency Virus","C14274","An HIV-like virus that infects monkeys, chimpanzees, and other non-human primates. (AIDS Info HIV Glossary)","Simian Immunodeficiency Virus | SIV",,,,,,,,,,,,,,,"4195559","Simian immunodeficiency virus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL540664","XML Document Root","C142751","No value exists.","XML Document Root | document root",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540663","Source Data Verification","C142752","Confirming the accuracy, authenticity, and thoroughness of information by comparing it to original information and records.","Source Data Verification | source data verification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545975","System Alert","C142753","A high-priority signal that is sent to a specific person by way of a system, according to an established set of rules.","System Alert | Warning | alert",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1093214","Negative Sense ssRNA Virus","C14346","A single stranded RNA virus where the RNA strand is the complement of a mRNA.","Negative Sense ssRNA Virus | (-) Strand ssRNA Virus | Negative Strand ssRNA Virus | ssRNA Virus, (-) Strand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL540741","Everolimus/Exemestane Regimen","C142863","A regimen consisting of everolimus and exemestane that is used as a treatment for breast cancer.","Everolimus/Exemestane Regimen | Afinitor/Aromasin | Everolimus + Exemestane | Everolimus and Exemestane | Everolimus-Exemestane | Everolimus-Exemestane Regimen | Everolimus/Exemestane",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551912","Partial Brain Radiation Therapy","C150141","Radiation therapy that limits external beam radiation to a portion of the brain in order to reduce the total radiation exposure and decrease side effects.","Partial Brain Radiation Therapy | PBRT | Partial Brain Irradiation | Partial Brain Radiotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551911","Balloon Catheter Shaft Length","C150142","The length of the balloon catheter tube that extends from the catheter handle to the distal end of the catheter.","Balloon Catheter Shaft Length | Shaft length",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551907","Balloon Catheter Characteristics","C150143","No value exists.","Balloon Catheter Characteristics | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449964","Introducer Sheath Compatibility","C150144","The size of the device that would fit through an introducer sheath.","Introducer Sheath Compatibility | Introducer Size | Sheath Compatibility | Sheath Size",,,,,,,,,,,,,,,"4126841","Size of introducer",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL551908","Catheter Balloon Diameter","C150145","The nominal diameter of the balloon per manufacturer specification.","Catheter Balloon Diameter | Balloon Diameter | Nominal Diameter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL462152","Catheter Balloon Length","C150146","The nominal length of the balloon per manufacturer specification.","Catheter Balloon Length | Balloon Length | Nominal Diameter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551904","Balloon Catheter Nominal Inflation Pressure","C150147","Balloon pressure at balloon nominal diameter condition.","Balloon Catheter Nominal Inflation Pressure | Nominal (Inflation) Pressure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551235","Oral Cachet Dosage Form","C149365","Solid discoid preparation consisting of a wafer enclosing a unit dose intended for oral use.","Oral Cachet Dosage Form | Cachet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551234","Hard Capsule plus Tablet Dosage Form","C149366","Combination package consisting of a hard capsule and a tablet.","Hard Capsule plus Tablet Dosage Form | Capsule, hard + tablet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551604","Oral Drops, Liquid Dosage Form","C149709","Liquid, usually multidose preparation consisting of a liquid active substance per se, intended for oral use. The preparation is administered in small volumes as drops by means of a suitable device such as a dropper. The measured dose may be diluted in water or another suitable liquid before swallowing.","Oral Drops, Liquid Dosage Form | Oral drops, liquid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551603","Oral Drops, Powder for Suspension Dosage Form","C149710","Solid preparation consisting of one or more powders intended to be dispersed in the specified liquid to obtain an oral drops suspension.","Oral Drops, Powder for Suspension Dosage Form | Oral drops, powder for suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551598","Oral Drops, Solution Dosage Form","C149711","Liquid, usually multidose preparation consisting of a solution intended for oral use. The preparation is administered in small volumes as drops by means of a suitable device such as a dropper. The measured dose may be diluted in water or another suitable liquid before swallowing.","Oral Drops, Solution Dosage Form | Oral drops, solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551597","Oral Drops, Suspension Dosage Form","C149712","Liquid, usually multidose preparation consisting of a suspension intended for oral use. The preparation is administered in small volumes as drops by means of a suitable device such as a dropper. The measured dose may be diluted in water or another suitable liquid before swallowing.","Oral Drops, Suspension Dosage Form | Oral drops, suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551734","Actuation Spray Valve Device","C149949","A valve device on a container that delivers a precise spray dose of contents by actuation.","Actuation Spray Valve Device | Spray valve",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL512080","Spray - dosing instruction imperative","C149950","The technique of administration of a pharmaceutical product by atomizing or otherwise dissipating it into a fine dispersion of particles in air, directing it such that it comes into contact with the affected area.","Spraying Method of Administration | Spraying",,,,,,,,,,,,,,,"764106","Spray - dosing instruction imperative",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL551731","Stab Vaccinator","C149951","Device for administering a product by stabbing the bird.","Stab Vaccinator | Stab vaccinator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552438","Stomach Irrigation Dosage Form","C149952","Liquid sterile preparation consisting of an aqueous solution intended for irrigation of the stomach.","Stomach Irrigation Dosage Form | Stomach irrigation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551728","Straw Dosing Unit","C149954","A unit of presentation used to represent the quantity of product that is found in a single straw container.","Straw Dosing Unit | Straw",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551727","Sublingual Film Dosage Form","C149955","Solid preparation consisting of a single- or multilayer sheet of suitable material(s) intended for sublingual use to obtain a systemic effect.","Sublingual Film Dosage Form | Sublingual film",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551730","Sublingual Powder Dosage Form","C149956","Solid preparation consisting of a powder intended for sublingual use.","Sublingual Powder Dosage Form | Sublingual powder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551729","Sublingual Spray, Emulsion Dosage Form","C149957","Liquid, usually multidose preparation consisting of an emulsion intended for sublingual use. Sublingual sprays are usually presented in pressurized containers with a metering valve.","Sublingual Spray, Emulsion Dosage Form | Sublingual spray, emulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551725","Sublingual Spray, Solution Dosage Form","C149958","Liquid, usually multidose preparation consisting of a solution intended for sublingual use. Sublingual sprays are usually presented in pressurized containers with a metering valve.","Sublingual Spray, Solution Dosage Form | Sublingual spray, solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551724","Sublingual Spray, Suspension Dosage Form","C149959","Liquid, usually multidose preparation consisting of a suspension intended for sublingual use. Sublingual sprays are usually presented in pressurized containers with a metering valve.","Sublingual Spray, Suspension Dosage Form | Sublingual spray, suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552474","Sucking Method of Administration","C149961","The technique of administration of a pharmaceutical product by placing it in the mouth and encouraging it to dissolve in the saliva, usually by moving the tongue.","Sucking Method of Administration | Sucking",,,,,,,,,,,,,,,"35608013","Suck",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL544080","Grade 4 Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other, Specify, CTCAE","C146009","Life-threatening consequences; urgent intervention indicated","Grade 4 Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other, Specify, CTCAE | Grade 4 Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544081","Grade 4 Nephrotic Syndrome, CTCAE","C146010","Life-threatening consequences; urgent intervention indicated","Grade 4 Nephrotic Syndrome, CTCAE | Grade 4 Nephrotic syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544083","Grade 4 Neutrophil Count Decreased, CTCAE","C146012","<500/mm3; <0.5 x 10e9/L","Grade 4 Neutrophil Count Decreased, CTCAE | Grade 4 Neutrophil count decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544084","Grade 4 Night Blindness, CTCAE","C146013","Best corrected visual acuity of 20/200 or worse in the affected eye","Grade 4 Night Blindness, CTCAE | Grade 4 Night blindness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544070","Grade 4 Optic Nerve Disorder, CTCAE","C146015","Best corrected visual acuity of 20/200 or worse in the affected eye","Grade 4 Optic Nerve Disorder, CTCAE | Grade 4 Optic nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544437","Grade 5 Oral Cavity Fistula, CTCAE","C146457","Death","Grade 5 Oral Cavity Fistula, CTCAE | Grade 5 Oral cavity fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544438","Grade 5 Osteonecrosis of Jaw, CTCAE","C146459","Death","Grade 5 Osteonecrosis of Jaw, CTCAE | Grade 5 Osteonecrosis of jaw",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544439","Grade 5 Osteonecrosis, CTCAE","C146460","Death","Grade 5 Osteonecrosis, CTCAE | Grade 5 Osteonecrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544441","Grade 5 Otitis Media, CTCAE","C146462","Death","Grade 5 Otitis Media, CTCAE | Grade 5 Otitis media",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544442","Grade 5 Ovarian Infection, CTCAE","C146464","Death","Grade 5 Ovarian Infection, CTCAE | Grade 5 Ovarian infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544443","Grade 5 Ovarian Rupture, CTCAE","C146465","Death","Grade 5 Ovarian Rupture, CTCAE | Grade 5 Ovarian rupture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544444","Grade 5 Pancreas Infection, CTCAE","C146466","Death","Grade 5 Pancreas Infection, CTCAE | Grade 5 Pancreas infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544557","Grade 5 Pancreatic Anastomotic Leak, CTCAE","C146467","Death","Grade 5 Pancreatic Anastomotic Leak, CTCAE | Grade 5 Pancreatic anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544559","Grade 5 Pancreatic Necrosis, CTCAE","C146471","Death","Grade 5 Pancreatic Necrosis, CTCAE | Grade 5 Pancreatic necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544560","Grade 5 Papulopustular Rash, CTCAE","C146472","Death","Grade 5 Papulopustular Rash, CTCAE | Grade 5 Papulopustular rash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544561","Grade 5 Paroxysmal Atrial Tachycardia, CTCAE","C146473","Death","Grade 5 Paroxysmal Atrial Tachycardia, CTCAE | Grade 5 Paroxysmal atrial tachycardia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544562","Grade 5 Pelvic Infection, CTCAE","C146474","Death","Grade 5 Pelvic Infection, CTCAE | Grade 5 Pelvic infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544563","Grade 5 Penile Infection, CTCAE","C146475","Death","Grade 5 Penile Infection, CTCAE | Grade 5 Penile infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544564","Grade 5 Perforation Bile Duct, CTCAE","C146476","Death","Grade 5 Perforation Bile Duct, CTCAE | Grade 5 Perforation bile duct",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544549","Grade 5 Pericardial Effusion, CTCAE","C146477","Death","Grade 5 Pericardial Effusion, CTCAE | Grade 5 Pericardial effusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544551","Grade 5 Periorbital Infection, CTCAE","C146479","Death","Grade 5 Periorbital Infection, CTCAE | Grade 5 Periorbital infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551607","Powder for Nebulizer Solution Dosage Form","C149835","Solid preparation consisting of one or more powders, intended to be dissolved in the specified liquid to obtain a nebulizer solution.","Powder for Nebulizer Solution Dosage Form | Powder for nebuliser solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551717","Powder for Nebulizer Suspension Dosage Form","C149836","Solid preparation consisting of one or more powders, intended to be dispersed in the specified liquid to obtain a nebulizer suspension.","Powder for Nebulizer Suspension Dosage Form | Powder for nebuliser suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551716","Powder for oral solution in sachet","C149838","Medicinal product consisting of a powder for oral solution presented in a sachet.","Powder for Oral Solution in Sachet Dosage Form | Powder for Oral Solution in Sachet | Powder for oral solution in sachet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551719","Powder for Oral/Rectal Suspension Dosage Form","C149840","Solid preparation consisting of one or more powders, intended to be dissolved in the specified liquid to obtain an oral/rectal solution.","Powder for Oral/Rectal Suspension Dosage Form | Powder for oral/rectal suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551718","Powder for oral/rectal suspension in sachet","C149841","Medicinal product consisting of a powder for oral/rectal suspension presented in a sachet.","Powder for Oral/Rectal Suspension in Sachet Dosage Form | Powder for Oral/Rectal Suspension in Sachet | Powder for oral/rectal suspension in sachet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551712","Powder for Rectal Solution Dosage Form","C149843","Solid preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain a rectal solution.","Powder for Rectal Solution Dosage Form | Powder for rectal solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551715","Powder for Rectal Suspension Dosage Form","C149844","Solid preparation consisting of one or more powders intended to be dispersed in the specified liquid to obtain a rectal suspension.","Powder for Rectal Suspension Dosage Form | Powder for rectal suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551714","Powder for Sealant Dosage Form","C149845","Solid sterile preparation consisting of one or more powder intended to be dissolved in the specified liquid to obtain a sealant.","Powder for Sealant Dosage Form | Powder for sealant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551709","Powder for Solution for Fish Treatment Dosage Form","C149846","Powder to be used to produce a solution intended for the treatment of fish by immersion.","Powder for Solution for Fish Treatment Dosage Form | Powder for solution for fish treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272895","Powder for Solution for Infusion Dosage Form","C149847","Solid sterile preparation consisting of one or more powders intended to be dissolved in the specified aqueous liquid to obtain a solution for infusion.","Powder for Solution for Infusion Dosage Form | Powder for solution for infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551711","Powder for Solution for Injection/Infusion Dosage Form","C149848","Solid sterile preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain a solution for injection/infusion.","Powder for Solution for Injection/Infusion Dosage Form | Powder for solution for injection/infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551710","Powder for Solution for Injection/Skin-Prick Test Dosage Form","C149849","Solid sterile preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain a solution for injection/skin-prick test.","Powder for Solution for Injection/Skin-Prick Test Dosage Form | Powder for solution for injection/skin-prick test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551706","Powder for Solution for Intraocular Irrigation Dosage Form","C149850","Solid sterile preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain a solution for intraocular irrigation.","Powder for Solution for Intraocular Irrigation Dosage Form | Powder for solution for intraocular irrigation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551705","Powder for Solution for Iontophoresis Dosage Form","C149851","Solid preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain a solution for iontophoresis.","Powder for Solution for Iontophoresis Dosage Form | Powder for solution for iontophoresis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551232","Soft Capsule plus Tablet Dosage Form","C149367","Combination package consisting of a soft capsule and a tablet.","Soft Capsule plus Tablet Dosage Form | Capsule, soft + tablet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551231","Chewable Soft Capsule Dosage Form","C149368","A soft tablet that must be chewed to release the active and/or inert ingredient(s).","Chewable Soft Capsule Dosage Form | Chewable capsule, soft",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551233","Chewable-Dispersible Tablet Dosage Form","C149369","An uncoated tablet intended either to be chewed before being swallowed, or to be dispersed in the specified liquid before being swallowed.","Chewable-Dispersible Tablet Dosage Form | Chewable/dispersible tablet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524116","Chewing Method of Administration","C149370","The technique of administration of a pharmaceutical product by crushing or grinding it with the teeth; after chewing, some products are intended to be swallowed, some are intended to be spat out.","Chewing Method of Administration | Chewing",,,,,,,,,,,,,,,"42538099|4303254","Chew|Chew",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL551228","Child-Resistant Closure","C149371","A closure which is difficult for young children to open but which is not difficult for adults to open properly.","Child-Resistant Closure | Child-resistant closure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551227","Coated granules in sachet","C149372","Medicinal product consisting of coated granules presented in a sachet.","Coated Granules in Sachet Dosage Form | Coated Granules in Sachet | Coated granules in sachet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551230","Collodion Dosage Form","C149373","Liquid preparation usually containing pyroxylin in a mixture of ether and ethanol. When applied to the skin, the preparation forms a flexible film on the site of application.","Collodion Dosage Form | Collodion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551224","Concentrate and Solvent for Concentrate for Oral Spray, Suspension Dosage Form","C149375","A concentrate and a solvent intended for the preparation of a concentrate for oral spray, suspension by diluting the concentrate with the solvent; the resulting concentrate for oral spray, suspension must subsequently be diluted again before administration as an oral spray, suspension.","Concentrate and Solvent for Concentrate for Oral Spray, Suspension Dosage Form | Concentrate and solvent for concentrate for oral spray, suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551223","Concentrate and Solvent for Concentrate for Solution for Infusion Dosage Form","C149376","Sterile concentrate and sterile solvent intended for the preparation of a concentrate for solution for infusion by diluting the concentrate with the solvent; the resulting concentrate for solution for infusion must subsequently be diluted again before administration as a solution for infusion.","Concentrate and Solvent for Concentrate for Solution for Infusion Dosage Form | Concentrate and solvent for concentrate for solution for infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551226","Concentrate and Solvent for Cutaneous Solution Dosage Form","C149377","Concentrate and solvent intended for the preparation of a cutaneous solution by diluting the concentrate with the solvent.","Concentrate and Solvent for Cutaneous Solution Dosage Form | Concentrate and solvent for cutaneous solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551225","Concentrate and Solvent for Solution for Infusion Dosage Form","C149378","Sterile concentrate and sterile solvent intended for the preparation of a solution for infusion by diluting the concentrate with the solvent.","Concentrate and Solvent for Solution for Infusion Dosage Form | Concentrate and solvent for solution for infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551220","Concentrate and Solvent for Solution for Injection Dosage Form","C149379","Sterile concentrate and sterile solvent intended for the preparation of a solution for injection by diluting the concentrate with the solvent.","Concentrate and Solvent for Solution for Injection Dosage Form | Concentrate and solvent for solution for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551219","Concentrate and Solvent for Solution for Injection/Infusion Dosage Form","C149380","Sterile concentrate and sterile solvent intended for the preparation of a solution for injection/infusion by diluting the concentrate with the solvent.","Concentrate and Solvent for Solution for Injection/Infusion Dosage Form | Concentrate and solvent for solution for injection/infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551222","Concentrate and Solvent for Suspension for Injection Dosage Form","C149381","Sterile concentrate and sterile solvent intended for the preparation of a suspension for injection by diluting the concentrate with the solvent.","Concentrate and Solvent for Suspension for Injection Dosage Form | Concentrate and solvent for suspension for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551721","Suspension and Solution for Spray Dosage Form","C149963","Suspension and solution intended for use as a spray by mixing the suspension into the solution.","Suspension and Solution for Spray Dosage Form | Suspension and solution for spray",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551720","Injectable Suspension for Emulsion Dosage Form","C149964","Liquid sterile preparation consisting of a suspension intended for use in the preparation of an emulsion for injection.","Injectable Suspension for Emulsion Dosage Form | Suspension for emulsion for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551723","Suspension for injection in cartridge","C149966","Medicinal product consisting of a suspension for injection presented in a cartridge.","Suspension for Injection in Cartridge Dosage Form | Suspension for Injection in Cartridge | Suspension for injection in cartridge",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551722","Suspension for injection in pre-filled injector","C149967","Medicinal product consisting of a suspension for injection presented in a pre-filled injector.","Suspension for Injection in Pre-filled Injector Dosage Form | Suspension for Injection in Pre-filled Injector | Suspension for injection in pre-filled injector",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551830","Suspension for injection in pre-filled pen","C149968","Medicinal product consisting of a suspension for injection presented in a pre-filled pen.","Suspension for Injection in Pre-filled Pen Dosage Form | Suspension for Injection in Pre-filled Pen | Suspension for injection in pre-filled pen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551829","Suspension for injection in pre-filled syringe","C149969","Medicinal product consisting of a suspension for injection presented in a pre-filled syringe.","Suspension for Injection in Pre-filled Syringe Dosage Form | Suspension for Injection in Pre-filled Syringe | Suspension for injection in pre-filled syringe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551832","Suspension for Oral Suspension Dosage Form","C149970","Liquid preparation consisting of a suspension intended for use in the preparation of an oral suspension.","Suspension for Oral Suspension Dosage Form | Suspension for oral suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551971","Atherectomy Device Tip Length","C150200","The length of the tip of the atherectomy device, if present.","Atherectomy Device Tip Length | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551966","Advanced Oropharyngeal Throat Squamous Cell Cancer","C150201","A squamous cell carcinoma of the oropharynx that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Oropharyngeal Squamous Cell Carcinoma | Advanced Oropharyngeal Throat Squamous Cell Cancer | Advanced Squamous Cell Carcinoma of the Oropharynx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551965","Metastatic Squamous Cell Carcinoma of the Oropharynx","C150202","A squamous cell carcinoma of the oropharynx which has spread from the original site of growth to another anatomic site.","Metastatic Oropharyngeal Squamous Cell Carcinoma | Metastatic Oropharyngeal Throat Squamous Cell Cancer | Metastatic Squamous Cell Carcinoma of the Oropharynx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551967","Advanced Oral Cavity Squamous Cell Cancer","C150204","A squamous cell carcinoma of the oral cavity that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Oral Cavity Squamous Cell Carcinoma | Advanced Oral Cavity Squamous Cell Cancer | Advanced Squamous Cell Carcinoma of the Oral Cavity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551962","CDH20 wt Allele","C150205","Human CDH20 wild-type allele is located in the vicinity of 18q21.33 and is approximately 222 kb in length. This allele, which encodes cadherin-20 protein, plays a role in cell-cell adhesion.","CDH20 wt Allele | CDH7L3 | Cadherin 20 wt Allele | Cadherin 20, Type 2 Gene | Cdh7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544552","Grade 5 Peripheral Ischemia, CTCAE","C146480","Death","Grade 5 Peripheral Ischemia, CTCAE | Grade 5 Peripheral ischemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544553","Grade 5 Peripheral Motor Neuropathy, CTCAE","C146481","Death","Grade 5 Peripheral Motor Neuropathy, CTCAE | Grade 5 Peripheral motor neuropathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544554","Grade 5 Peripheral Nerve Infection, CTCAE","C146482","Death","Grade 5 Peripheral Nerve Infection, CTCAE | Grade 5 Peripheral nerve infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544556","Grade 5 Pharyngeal Anastomotic Leak, CTCAE","C146485","Death","Grade 5 Pharyngeal Anastomotic Leak, CTCAE | Grade 5 Pharyngeal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544541","Grade 5 Pharyngeal Mucositis, CTCAE","C146488","Death","Grade 5 Pharyngeal Mucositis, CTCAE | Grade 5 Pharyngeal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544542","Grade 5 Pharyngeal Stenosis, CTCAE","C146490","Death","Grade 5 Pharyngeal Stenosis, CTCAE | Grade 5 Pharyngeal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544543","Grade 5 Pharyngitis, CTCAE","C146491","Death","Grade 5 Pharyngitis, CTCAE | Grade 5 Pharyngitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544545","Grade 5 Pleural Effusion, CTCAE","C146493","Death","Grade 5 Pleural Effusion, CTCAE | Grade 5 Pleural effusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544546","Grade 5 Pleural Infection, CTCAE","C146495","Death","Grade 5 Pleural Infection, CTCAE | Grade 5 Pleural infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543682","Grade 3 Skin Induration, CTCAE","C145619","Severe induration; unable to slide or pinch skin; limiting joint or orifice movement (e.g., mouth, anus); limiting self care ADL","Grade 3 Skin Induration, CTCAE | Grade 3 Skin induration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543683","Grade 3 Skin Infection, CTCAE","C145620","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Skin Infection, CTCAE | Grade 3 Skin infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543684","Grade 3 Skin Ulceration, CTCAE","C145621","Combined area of ulcers >2 cm; full-thickness skin loss involving damage to or necrosis of subcutaneous tissue that may extend down to fascia","Grade 3 Skin Ulceration, CTCAE | Grade 3 Skin ulceration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543670","Grade 3 Small Intestinal Anastomotic Leak, CTCAE","C145623","Severe symptoms; invasive intervention indicated","Grade 3 Small Intestinal Anastomotic Leak, CTCAE | Grade 3 Small intestinal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543671","Grade 3 Small Intestinal Mucositis, CTCAE","C145624","Severe pain; interfering with oral intake; tube feeding, TPN or hospitalization indicated; limiting self care ADL","Grade 3 Small Intestinal Mucositis, CTCAE | Grade 3 Small intestinal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543673","Grade 3 Small Intestinal Perforation, CTCAE","C145626","Invasive intervention indicated","Grade 3 Small Intestinal Perforation, CTCAE | Grade 3 Small intestinal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543674","Grade 3 Small Intestinal Stenosis, CTCAE","C145627","Symptomatic and severely altered GI function; tube feeding, TPN or hospitalization indicated; non-emergent operative intervention indicated","Grade 3 Small Intestinal Stenosis, CTCAE | Grade 3 Small intestinal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543675","Grade 3 Small Intestine Infection, CTCAE","C145628","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Small Intestine Infection, CTCAE | Grade 3 Small intestine infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543676","Grade 3 Small Intestine Ulcer, CTCAE","C145629","Severely altered GI function; TPN indicated; elective invasive intervention indicated; limiting self care ADL","Grade 3 Small Intestine Ulcer, CTCAE | Grade 3 Small intestine ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551937","EDQM-HC Combined Pharmaceutical Dose Form Terminology","C150104","Terminology subset about single terms to describe two or more manufactured items that are intended to be combined in a specific way to produce a single pharmaceutical product, and which includes information on the manufactured dose form of each manufactured item and the administrable dose form of the pharmaceutical product. Note: in the example 'Powder and solvent for solution for injection', the medicinal product contains two manufactured items: (i) a powder for solution for injection, and (ii) a solvent; the pharmaceutical product that is prepared form the two manufactured items is a solution for injection; the combined pharmaceutical dose form for the medicinal product is therefore 'powder and solvent for solution for injection'.","EDQM-HC Combined Pharmaceutical Dose Form Terminology | CDF | Combined Pharmaceutical Dose Form | European Directorate for the Quality of Medicines and HealthCare Combined Pharmaceutical Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552435","EDQM-HC Combined Term Terminology","C150105","Terminology subset about single terms to describe a pharmaceutical dose form (or combined pharmaceutical dose for) and an item of packaging, either for the purpose of distinguishing between marketed products that differ only in the container or administration device, or where the item of packaging has special characteristics that are relevant to the use of the medicinal product.","EDQM-HC Combined Term Terminology | CMT | Combined Term | European Directorate for the Quality of Medicines and HealthCare Combined Term",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551939","EDQM-HC Combined Pack Terminology","C150106","Terminology subset about single terms to describe two or more medicinal products that are packaged together and marketed under a single license, and which are intended to be administered independently, as separate pharmaceutical products.","EDQM-HC Combined Pack Terminology | CMP | Combined Pack | European Directorate for the Quality of Medicines and HealthCare Combined Pack",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552476","EDQM-HC Routes and Methods of Administration Terminology","C150107","Terminology subset about the paths by which the pharmaceutical product is taken into or makes contact with the body.","EDQM-HC Routes and Methods of Administration Terminology | European Directorate for the Quality of Medicines and HealthCare Routes and Methods of Administration | ROA | Routes and Methods of Administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552458","EDQM-HC Closure Terminology","C150108","Terminology subset about items used to close a container for the purpose of the correct storage and (where appropriate) use of the product.","EDQM-HC Closure Terminology | CLO | Closure | European Directorate for the Quality of Medicines and HealthCare Closures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551936","EDQM-HC Container Terminology","C150109","Terminology subset about items of packaging that is part of a medicinal product and is used for storage, identification and/or transport of the components of the medicinal product. Note: 'Container' is a general concept that groups together the concepts of immediate container, intermediate packaging and outer packaging.","EDQM-HC Container Terminology | CON | Container | European Directorate for the Quality of Medicines and HealthCare Containers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551935","EDQM-HC Administration Device Terminology","C150110","Terminology subset about devices that are used to administer a pharmaceutical product.","EDQM-HC Administration Device Terminology | Administration Device | DEV | European Directorate for the Quality of Medicines and HealthCare Administration Device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552440","EDQM-HC Units of Presentation Terminology","C150111","Terminology subset about qualitative terms describing the discrete countable entity in which a pharmaceutical product or manufactured item is presented, in cases where strength or quantity is expressed referring to one instance of this countable entity. Note: A unit of presentation will often have the same name as a concept in another controlled vocabulary list, such as a basic dose form or a container, but the two concepts are not equivalent, and each has its own definition and identifier.","EDQM-HC Units of Presentation Terminology | European Directorate for the Quality of Medicines and HealthCare Units of Presentation | UOP | Units of Presentation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551933","EDQM-HC Administration Method Terminology","C150112","Terminology subset about general methods by which a pharmaceutical product is intended to be administered to the patient.","EDQM-HC Administration Method Terminology | AME | Administration Method | European Directorate for the Quality of Medicines and HealthCare Administration Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551934","EDQM-HC Basic Dose Form Terminology","C150113","Terminology subset about generalized versions of the pharmaceutical dose form, used to group together related pharmaceutical dose forms.","EDQM-HC Basic Dose Form Terminology | BDF | Basic Dose Form | European Directorate for the Quality of Medicines and HealthCare Basic Dose Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551551","Lyophilisate for use in drinking water","C149644","Solid preparation for veterinary use consisting of a freeze-dried powder intended to be dissolved in the animal drinking water. If alternative methods of administration to individual animals are also authorized, the method of administration is clearly described in the product information.","Lyophilisate for Use in Drinking Water Dosage Form | Lyophilisate for use in drinking water",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552464","Matrix Dosing Unit","C149645","A unit of presentation used to represent the quantity of product that is found in a single discrete entity where the pharmaceutical dose form is a type of matrix.","Matrix Dosing Unit | Matrix",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551553","Matrix for Implantation Matrix Dosage Form","C149646","Solid sterile preparation consisting of a usually pliable, absorbent piece of material (e.g. collagen) intended to be used in the preparation of an implantation matrix.","Matrix for Implantation Matrix Dosage Form | Matrix for implantation matrix",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551548","Measuring Spoon","C149647","Spoon for the administration of liquid and multidose solid pharmaceutical forms.","Measuring Spoon | Measuring spoon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551547","Oral Gum Dosage Form","C149648","Solid single-dose preparation with a gum-like consistency, intended to be sucked or chewed before being swallowed. Medicated chewing gum is excluded.","Oral Gum Dosage Form | Oral gum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551550","Medicated Collar Dosage Form","C149649","Solid preparation for veterinary use consisting of a matrix impregnated with active substance(s), which is worn around the animal's neck. The active substance(s) are released by diffusion, by mechanical means or by vaporization over a period of time.","Medicated Collar Dosage Form | Medicated collar",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551549","Medicated Nail Lacquer Dosage Form","C149650","Liquid preparation to be applied to the nails to form a lacquer by evaporation of the volatile solvent.","Medicated Nail Lacquer Dosage Form | Medicated nail lacquer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551544","Medicated Pellets Dosage Form","C149651","Solid single-dose or multidose preparation intended for veterinary use, consisting of large granules, usually formed by extrusion, intended for oral use.","Medicated Pellets Dosage Form | Medicated pellets",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551543","Medicated Pendant Dosage Form","C149652","Solid preparation for veterinary use consisting of a matrix impregnated with active substance(s), which is fixed to a device to be worn around the animal's neck. The active substance(s) are released by diffusion, by mechanical means or by vaporization over a period of time.","Medicated Pendant Dosage Form | Medicated pendant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551546","Medicated Plaster Dosage Form","C149653","Flexible single-dose preparation intended to be applied to the skin to obtain, usually, a local effect. Medicated plasters consist of an adhesive basis containing the active substance and spread as a uniform layer on an appropriate support made of natural or synthetic material. The adhesive layer is covered by a suitable protective liner, which is removed before applying the plaster to the skin. Medicated plasters are presented in a range of sizes or as larger sheets to be cut before use.","Medicated Plaster Dosage Form | Medicated plaster",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551545","Medicated Thread Dosage Form","C149654","Solid preparation consisting of a biodegradable or non-degradable thread impregnated with active substance(s).","Medicated Thread Dosage Form | Medicated thread",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551540","Medicated Vaginal Tampon Dosage Form","C149655","Solid single-dose preparation consisting of a suitable material impregnated with active substance(s) intended to be inserted in the vagina for a limited period of time.","Medicated Vaginal Tampon Dosage Form | Medicated vaginal tampon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551542","Cryogenic Medicinal Gas Dosage Form","C149657","A gas which liquefies at 1.013 bar at a temperature below -150 degrees C.","Cryogenic Medicinal Gas Dosage Form | Medicinal gas, cryogenic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551541","Liquefied Medicinal Gas Dosage Form","C149658","A gas packaged under pressure, which is partially liquid (gas over liquid) at -50 degrees C.","Liquefied Medicinal Gas Dosage Form | LIQUEFIED GAS | Medicinal gas, liquefied",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551537","Metered Actuation Pump Device","C149659","Closure whereby a measured quantity of the contents is released by mechanical actuation of the pump.","Metered Actuation Pump Device | Metering pump",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551961","Metastatic Oral Cavity Squamous Cell Cancer","C150206","A squamous cell carcinoma of the oral cavity which has spread from the original site of growth to another anatomic site.","Metastatic Oral Cavity Squamous Cell Carcinoma | Metastatic Oral Cavity Squamous Cell Cancer | Metastatic Squamous Cell Carcinoma of the Oral Cavity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551964","Advanced Nasopharyngeal Throat Squamous Cell Cancer","C150207","A squamous cell carcinoma of the nasopharynx that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Nasopharyngeal Squamous Cell Carcinoma | Advanced Nasopharyngeal Throat Squamous Cell Cancer | Advanced Squamous Cell Carcinoma of the Nasopharynx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551963","Cadherin-20","C150208","Cadherin-20 (801 aa, ~89 kDa) is encoded by the human CDH20 gene. This protein is involved in the mediation of cell-cell adhesion.","Cadherin-20 | CDH20 | Cadherin 20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551957","Advanced Hypopharyngeal Throat Squamous Cell Cancer","C150210","A squamous cell carcinoma of the hypopharynx that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Hypopharyngeal Squamous Cell Carcinoma | Advanced Hypopharyngeal Throat Squamous Cell Cancer | Advanced Squamous Cell Carcinoma of the Hypopharynx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551960","Advanced Laryngeal Throat Squamous Cell Cancer","C150211","A squamous cell carcinoma of the larynx that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Laryngeal Squamous Cell Carcinoma | Advanced Laryngeal Throat Squamous Cell Cancer | Advanced Squamous Cell Carcinoma of the Larynx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551959","Metastatic Hypopharyngeal Throat Squamous Cell Cancer","C150212","A squamous cell carcinoma of the hypopharynx that has spread from the original site of growth to another anatomic site.","Metastatic Hypopharyngeal Squamous Cell Carcinoma | Metastatic Hypopharyngeal Throat Squamous Cell Cancer | Metastatic Squamous Cell Carcinoma of the Hypopharynx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551954","Metastatic Laryngeal Throat Squamous Cell Cancer","C150213","A squamous cell carcinoma of the larynx that has spread from the original site of growth to another anatomic site.","Metastatic Laryngeal Squamous Cell Carcinoma | Metastatic Laryngeal Throat Squamous Cell Cancer | Metastatic Squamous Cell Carcinoma of the Larynx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551280","Dip Suspension Dosage Form","C149436","Liquid preparation consisting of a suspension intended for veterinary use by dipping.","Dip Suspension Dosage Form | Dip suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337426","Dipping - Abdominal percussion note finding","C149437","Administration of a veterinary medicinal product by immersing the animal into a bath or plunge pool containing the medicinal product.","Dipping Route of Administration | Dipping",,,,,,,,,,,,,,,"4093330","Dipping",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL551282","Dispersible tablets for dose dispenser","C149438","Solid preparation consisting of small, dispersible tablets that are designed to be used in a dose dispenser, each tablet usually consisting of a small fraction of a dose, with multiple tablets being automatically counted and administered as a single dose.","Dispersible Tablet for Dose Dispenser Dosage Form | Dispersible Tablet for Dose Dispenser | Dispersible tablets for dose dispenser",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551277","Dispersion for Concentrate for Dispersion for Infusion Dosage Form","C149439","Liquid sterile preparation consisting of a dispersion intended for use in the preparation of a concentrate for dispersion for infusion, which in turn is intended to be diluted in the specified liquid to obtain a dispersion for infusion.","Dispersion for Concentrate for Dispersion for Infusion Dosage Form | Dispersion for concentrate for dispersion for infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551276","Dispersion for Infusion Dosage Form","C149440","Liquid sterile preparation consisting of two or more phases of which at least one is dispersed in the liquid phase, intended to be introduced, usually in large volumes, usually into the circulating blood stream.","Dispersion for Infusion Dosage Form | Dispersion for infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551278","Dispersion for Injection/Infusion Dosage Form","C149442","Sterile liquid preparation consisting of two or more phases of which at least one is dispersed in the liquid phase, intended for administration by injection or infusion.","Dispersion for Injection/Infusion Dosage Form | Dispersion for injection/infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543789","Grade 3 Social Circumstances - Other, Specify, CTCAE","C145630","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL","Grade 3 Social Circumstances - Other, Specify, CTCAE | Grade 3 Social circumstances - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543790","Grade 3 Soft Tissue Infection, CTCAE","C145631","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Soft Tissue Infection, CTCAE | Grade 3 Soft tissue infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543791","Grade 3 Soft Tissue Necrosis Lower Limb, CTCAE","C145632","Operative debridement or other invasive intervention indicated (e.g., tissue reconstruction, flap, or grafting)","Grade 3 Soft Tissue Necrosis Lower Limb, CTCAE | Grade 3 Soft tissue necrosis lower limb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543792","Grade 3 Soft Tissue Necrosis Upper Limb, CTCAE","C145633","Operative debridement or other invasive intervention indicated (e.g., tissue reconstruction, flap, or grafting)","Grade 3 Soft Tissue Necrosis Upper Limb, CTCAE | Grade 3 Soft tissue necrosis upper limb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543794","Grade 3 Sore Throat, CTCAE","C145635","Severe pain; limiting self care ADL; limiting ability to swallow","Grade 3 Sore Throat, CTCAE | Grade 3 Sore throat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543795","Grade 3 Spasticity, CTCAE","C145636","Severe increase in muscle tone and increase in resistance through range of motion","Grade 3 Spasticity, CTCAE | Grade 3 Spasticity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543796","Grade 3 Spermatic Cord Anastomotic Leak, CTCAE","C145637","Severe symptoms; invasive intervention indicated","Grade 3 Spermatic Cord Anastomotic Leak, CTCAE | Grade 3 Spermatic cord anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543781","Grade 3 Spinal Cord Compression, CTCAE","C145638","Severe symptoms; limiting self care ADL","Grade 3 Spinal Cord Compression, CTCAE | Grade 3 Spinal cord compression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543782","Grade 3 Spinal Fracture, CTCAE","C145639","Severe back pain; hospitalization or intervention indicated for pain control (e.g., vertebroplasty); limiting self care ADL; disability","Grade 3 Spinal Fracture, CTCAE | Grade 3 Spinal fracture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544866","SMRT Sequencing","C146819","A proprietary third-generation DNA sequencing system from Pacific Biosciences that uses zero-mode waveguides (ZMWs) and phospholinked nucleotides. A single DNA polymerase enzyme is affixed at the bottom of a ZMW structure with a single molecule of DNA as a template. A fluorescent tag is cleaved off with each base addition and is detected to create the sequence.","SMRT Sequencing | PacBio | PacBio SMRT | SMRT Sequencing Technology | Single Molecule, Real-Time Sequencing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544867","Anti-SSTR2 x Anti-CD3 Monoclonal Antibody XmAb18087","C146820","A humanized, Fc domain-containing, bispecific monoclonal antibody targeting human CD3, a T-cell surface antigen, and somatostatin receptor 2 (SSTR2), a tumor-associated antigen (TAA) expressed on certain cancer cells, with potential antineoplastic activity. Upon administration, tidutamab binds to both T-cells and SSTR2-expressing cancer cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the SSTR2-expressing cancer cells. The inclusion of an Fc domain on the antibody prolongs the half-life of the bispecific antibody.","Tidutamab | Anti-SSTR2 x Anti-CD3 Monoclonal Antibody XmAb18087 | TIDUTAMAB | XmAb 18087 | XmAb-18087 | XmAb18087",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544868","Nanoparticle Paclitaxel Ointment SOR007","C146821","A topical ointment composed of the water-insoluble taxane paclitaxel that has been processed to form uncoated nanoparticles, with potential antineoplastic activity. Upon topical administration of nanoparticle paclitaxel ointment SOR007 to the affected area, and following epithelial and dermal penetration, paclitaxel binds to tubulin and inhibits the disassembly of microtubules, which leads to the inhibition of cell division, thereby halting the proliferation of rapidly-dividing tumor cells. The nanoparticles in the nanoparticle paclitaxel ointment are produced through a specific proprietary submicron particle production.","Nanoparticle Paclitaxel Ointment SOR007 | NanoPac Ointment | Nanopartcle Paclitaxel SOR007 | SOR007 | SOR007 Ointment | Topical Nanoparticle Paclitaxel Ointment | Uncoated Nanoparticle Paclitaxel Ointment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552460","EDQM-HC Intended Site of Administration Terminology","C150114","Terminology subset about general body sites at which a pharmaceutical product is intended to be administered.","EDQM-HC Intended Site of Administration Terminology | European Directorate for the Quality of Medicines and HealthCare Intended Site of Administration | ISI | Intended Site of Administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551931","EDQM-HC Release Characteristics Terminology","C150115","Terminology subset about descriptions of the timing by which an active ingredient is made available in the body after administration of the pharmaceutical product, in comparison with a conventional, direct release of the active ingredient.","EDQM-HC Release Characteristics Terminology | European Directorate for the Quality of Medicines and HealthCare Release Characteristics | RCA | Release Characteristics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552437","EDQM Health Care Terminology","C148636","A terminology developed by the European Directorate for the Quality of Medicines and HealthCare to provide the basis for global harmonization of pharmaceutical products in marketing authorization applications, labelling, and electronic communications in pharmacovigilance and adverse reporting. For more information, please visit: https://standardterms.edqm.eu","EDQM Health Care Terminology | EDQM HC | EDQM HealthCare Controlled Vocabularies | European Directorate for the Quality of Medicines and HealthCare Controlled Vocabularies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551154","TAFIa Inhibitor DS-1040b","C148637","An inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa; carboxypeptidase B2; CPB2), with potential fibrinolytic activity. Upon DS-1040 infusion, this agent binds to and inhibits TAFIa. This abrogates TAFIa-mediated inhibition of fibrinolysis. This induces fibrinolysis, degrades fibrin clots and prevents thrombus formation. TAFIa, a carboxypeptidase that is activated by thrombin, cleaves C-terminal amino acid residues from fibrin, which prevents binding and activation of plasminogen and inhibits plasmin-mediated fibrinolysis.","TAFIa Inhibitor DS-1040b | (2S)-5-amino-2-[[1-(4-methylcyclohexyl)imidazol-4-yl]methyl]pentanoic Acid | CPB2 Inhibitor DS-1040b | Carboxypeptidase B2 Inhibitor DS-1040b | Carboxypeptidase U Inhibitor DS-1040b | DS 1040 | DS-1040 | DS-1040b | DS1040 | Inhibitor of Activated Thrombin Activatable Fibrinolysis Inhibitor DS-1040b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551536","Metered Actuation Valve Device","C149660","Closure whereby a measured quantity of the contents is released by actuation of the valve.","Metered Actuation Valve Device | Metering valve",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551538","Mobile Cryogenic Vessel","C149661","A mobile thermally insulated container designed to maintain the contents in a liquid state.","Mobile Cryogenic Vessel | Mobile cryogenic vessel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551672","Solution for Beehive Solution Dosage Form","C149900","Liquid preparation consisting of a solution intended for use in the preparation of a bee-hive solution.","Solution for Beehive Solution Dosage Form | Solution for bee-hive solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551671","Solution for Beehive Strip Dosage Form","C149901","Liquid preparation consisting of a solution intended for use in the preparation of a bee-hive strip by application to an absorbent matrix; the bee-hive strip is usually used immediately after preparation.","Solution for Beehive Strip Dosage Form | Solution for bee-hive strip",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551773","Solution for blood fraction modification","C149902","Liquid sterile preparation consisting of a solution intended for use in extracorporeal modification of a blood fraction that is returned to the patient following modification.","Solution for Blood Fraction Modification Dosage Form | Solution for Blood Fraction Modification | Solution for blood fraction modification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551772","Solution for Cardioplegia Dosage Form","C149903","Liquid sterile preparation consisting of an aqueous solution intended for use in inducing cardiac arrest during heart surgery. Some preparations may require mixing with other preparations prior to administration, for example to adjust the pH.","Solution for Cardioplegia Dosage Form | Solution for cardioplegia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551775","Solution for Cardioplegia/Organ Preservation Dosage Form","C149904","Liquid sterile preparation consisting of an aqueous solution of electrolytes typically at a concentration close to the intracellular electrolyte composition, intended for inducing cardiac arrest during heart surgery, and for storage, protection and/or perfusion of mammalian body organs that are in particular destined for transplantation.","Solution for Cardioplegia/Organ Preservation Dosage Form | Solution for cardioplegia/organ preservation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551774","Solution for Dental Cement Dosage Form","C149905","Liquid preparation consisting of a solution intended for use in the preparation of a dental cement.","Solution for Dental Cement Dosage Form | Solution for dental cement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551769","Solution for Hemodiafiltration Dosage Form","C149906","Liquid sterile preparation consisting of an aqueous solution containing electrolytes with a concentration close to the electrolytic composition of plasma, intended for parenteral use in hemodiafiltration. Glucose may be included.","Solution for Hemodiafiltration Dosage Form | Solution for haemodiafiltration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019006","Solution for Hemodialysis Dosage Form","C149907","Liquid preparation consisting of an aqueous solution containing electrolytes with a concentration close to the electrolytic composition of plasma, intended for use in hemodialysis. Glucose may be included.","Solution for Hemodialysis Dosage Form | Solution for haemodialysis",,,,,,,,,,,,,,,"45758026","Hemodialysis dialysate",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL551771","Solution for Hemodialysis/Hemofiltration Dosage Form","C149908","Liquid sterile preparation consisting of a solution intended for use as a solution for hemodialysis or a solution for hemofiltration.","Solution for Hemodialysis/Hemofiltration Dosage Form | Solution for haemodialysis/haemofiltration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544017","Grade 4 Intestinal Stoma Leak, CTCAE","C145937","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Intestinal Stoma Leak, CTCAE | Grade 4 Intestinal stoma leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544018","Grade 4 Intestinal Stoma Obstruction, CTCAE","C145938","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Intestinal Stoma Obstruction, CTCAE | Grade 4 Intestinal stoma obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544412","Grade 5 Hypertriglyceridemia, CTCAE","C146352","Death","Grade 5 Hypertriglyceridemia, CTCAE | Grade 5 Hypertriglyceridemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544397","Grade 5 Hyperuricemia, CTCAE","C146353","Death","Grade 5 Hyperuricemia, CTCAE | Grade 5 Hyperuricemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544399","Grade 5 Hypocalcemia, CTCAE","C146355","Death","Grade 5 Hypocalcemia, CTCAE | Grade 5 Hypocalcemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544400","Grade 5 Hypoglycemia, CTCAE","C146356","Death","Grade 5 Hypoglycemia, CTCAE | Grade 5 Hypoglycemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544401","Grade 5 Hypohidrosis, CTCAE","C146357","Death","Grade 5 Hypohidrosis, CTCAE | Grade 5 Hypohidrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544402","Grade 5 Hypokalemia, CTCAE","C146358","Death","Grade 5 Hypokalemia, CTCAE | Grade 5 Hypokalemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544403","Grade 5 Hypomagnesemia, CTCAE","C146359","Death","Grade 5 Hypomagnesemia, CTCAE | Grade 5 Hypomagnesemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544389","Grade 5 Hypoparathyroidism, CTCAE","C146361","Death","Grade 5 Hypoparathyroidism, CTCAE | Grade 5 Hypoparathyroidism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544390","Grade 5 Hypophosphatemia, CTCAE","C146362","Death","Grade 5 Hypophosphatemia, CTCAE | Grade 5 Hypophosphatemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544391","Grade 5 Hypophysitis, CTCAE","C146363","Death","Grade 5 Hypophysitis, CTCAE | Grade 5 Hypophysitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544392","Grade 5 Hypopituitarism, CTCAE","C146364","Death","Grade 5 Hypopituitarism, CTCAE | Grade 5 Hypopituitarism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544393","Grade 5 Hypothyroidism, CTCAE","C146365","Death","Grade 5 Hypothyroidism, CTCAE | Grade 5 Hypothyroidism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544394","Grade 5 Ileal Perforation, CTCAE","C146369","Death","Grade 5 Ileal Perforation, CTCAE | Grade 5 Ileal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544396","Grade 5 Immune System Disorders - Other, Specify, CTCAE","C146373","Death","Grade 5 Immune System Disorders - Other, Specify, CTCAE | Grade 5 Immune system disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544381","Grade 5 Infections and Infestations - Other, Specify, CTCAE","C146374","Death","Grade 5 Infections and Infestations - Other, Specify, CTCAE | Grade 5 Infections and infestations - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544382","Grade 5 Infective Myositis, CTCAE","C146375","Death","Grade 5 Infective Myositis, CTCAE | Grade 5 Infective myositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544383","Grade 5 Infusion Related Reaction, CTCAE","C146376","Death","Grade 5 Infusion Related Reaction, CTCAE | Grade 5 Infusion related reaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544384","Grade 5 Infusion Site Extravasation, CTCAE","C146377","Death","Grade 5 Infusion Site Extravasation, CTCAE | Grade 5 Infusion site extravasation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544386","Grade 5 Injury To Carotid Artery, CTCAE","C146379","Death","Grade 5 Injury To Carotid Artery, CTCAE | Grade 5 Injury to carotid artery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544387","Grade 5 Injury To Jugular Vein, CTCAE","C146381","Death","Grade 5 Injury To Jugular Vein, CTCAE | Grade 5 Injury to jugular vein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544388","Grade 5 Injury To Superior Vena Cava, CTCAE","C146382","Death","Grade 5 Injury To Superior Vena Cava, CTCAE | Grade 5 Injury to superior vena cava",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544869","Autologous iCASP9-CD19-expressing T-Lymphocytes","C146823","A preparation of autologous T-lymphocytes that are transduced with a retroviral vector encoding a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19 and the inducible suicide gene human caspase 9 (iCASP9 or iC9), that is linked to a drug binding domain, with potential immunomodulating and antineoplastic activities. The iCASP9 construct consists of the entire coding sequence for the human FK506-drug binding protein (FKBP12) with an F36V mutation (FKBP12-F36V) that is linked to the gene encoding iC9, which is a modified form of the CASP9 gene where the sequences encoding the endogenous caspase activation and recruitment domains have been deleted. Upon intravenous administration, autologous iCASP9-CD19-expressing T-lymphocytes (iC9-CAR19 T-cells) target and bind to CD19-expressing tumor cells, thereby selectively lysing these tumor cells. If the administered T-cells cause unacceptable side effects, the chemical homodimerizer AP1903, which binds to the FKBP12-F36V drug-binding domain, can be administered; this induces caspase 9 expression, and results in apoptosis of the administered iC9-CAR19 T-cells. The CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.","Autologous iCASP9-CD19-expressing T-Lymphocytes | ATLCAR.CD19 | Autologous  iC9-CAR19 Cells | Autologous ATL-iC9-CAR-CD19 | Autologous iC9-CAR19 Cells | Autologous iC9-CAR19 T-cells | Autologous iC9-CARCD19 T Cells | Autologous iC9-CART19 Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544854","AMG 596","C146824","A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one that is directed against a tumor-associated antigen (TAA), the epidermal growth factor receptor (EGFR) deletion-mutant form, EGFR variant III (EGFRvIII), and one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of etevritamab, the bispecific antibody binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and EGFRvIII found on EGFRvIII-expressing tumor cells. This activates and crosslinks CTLs with EGFRvIII-expressing tumor cells, which results in the CTL-mediated cell death of EGFRvIII-expressing tumor cells. EGFRvIII, a mutation in the EGFR gene where exons 2-7 have been deleted, is overexpressed by a variety of cancers, but is absent in normal, healthy cells. It plays a key role in tumor cell proliferation, tumor angiogenesis and resistance to both radio- and chemotherapy.","Etevritamab | AMG 596 | AMG-596 | AMG596 | Anti-EGFRvIII x Anti-CD3 Bi-specific T-cell Engager AMG 596 | Anti-EGFRvIII/CD3 BiTE Antibody AMG 596 | BiTE Antibody AMG 596 | Bispecific BITE Antibody AMG 596 | EGFRvIII specific BiTE Antibody AMG 596 | ETEVRITAMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544855","BRD4 Inhibitor PLX2853","C146825","An orally bioavailable inhibitor of the bromodomain-containing protein 4 (BRD4), with potential antineoplastic activity. Upon oral administration, the BRD4 inhibitor PLX2853 binds to the acetylated lysine recognition motifs in the bromodomains of the BRD4 protein, thereby preventing the binding of BRD4 to acetylated lysines on histones. This disrupts chromatin remodeling and dyregulates gene expression. This may lead to the downregulation of the expression of certain growth-promoting genes, which may induce apoptosis and inhibit the proliferation of BRD4-overexpressing tumor cells. BRD4, a member of the human bromodomain and extra-terminal (BET) family of proteins, is a transcriptional regulator that is overexpressed in certain tumor cells and plays an important role in cellular proliferation.","BRD4 Inhibitor PLX2853 | PLX 2853 | PLX-2853 | PLX2853",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544856","Mediastinal Germ Cell Tumor TNM Finding","C146826","A TNM finding about one or more characteristics of a mediastinal germ cell tumor. This is not an official UICC TNM classification. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)","Mediastinal Germ Cell Tumor TNM Finding | Thymic Germ Cell Tumor TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544071","Grade 4 Oral Cavity Fistula, CTCAE","C146016","Life-threatening consequences; urgent intervention indicated","Grade 4 Oral Cavity Fistula, CTCAE | Grade 4 Oral cavity fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544074","Grade 4 Otitis Externa, CTCAE","C146020","Life-threatening consequences; urgent intervention indicated","Grade 4 Otitis Externa, CTCAE | Grade 4 Otitis externa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544075","Grade 4 Otitis Media, CTCAE","C146021","Life-threatening consequences; urgent intervention indicated","Grade 4 Otitis Media, CTCAE | Grade 4 Otitis media",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544076","Grade 4 Ovarian Infection, CTCAE","C146023","Life-threatening consequences; urgent intervention indicated","Grade 4 Ovarian Infection, CTCAE | Grade 4 Ovarian infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544061","Grade 4 Ovarian Rupture, CTCAE","C146024","Life-threatening consequences; urgent intervention indicated","Grade 4 Ovarian Rupture, CTCAE | Grade 4 Ovarian rupture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551487","In-ovo Injection Device","C149593","Device for automatic injection into embryonated eggs.","In-ovo Injection Device | In-ovo injection device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551486","Insertion Method of Administration","C149594","The technique of administration of a pharmaceutical product by placing it into a body cavity, lesion, wound etc.","Insertion Method of Administration | Insertion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551483","Instant Herbal Tea Dosage Form","C149595","Solid preparation consisting of a lyophilized herbal drug extract intended to be dissolved in water before oral use. Instant herbal teas are supplied in bulk form (multidose) or in sachets (single-dose).","Instant Herbal Tea Dosage Form | Instant herbal tea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0184959","Drop Instillation Method of Administration","C149596","The technique of administration of a pharmaceutical product drop by drop onto or into the affected area.","Drop Instillation Method of Administration | Instillation",,,,,,,,,,,,,,,"4045058|4185533","Instillation - action|Instillation",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL551485","Internal Graduated Calibration Chamber","C149597","Graduated device for connection to a container for administering a cutaneous liquid to an animal.","Internal Graduated Calibration Chamber | Internal graduated calibration chamber",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551484","Intestinal Gel Dosage Form","C149598","Semi-solid preparation consisting of a gel intended for intestinal use.","Intestinal Gel Dosage Form | Intestinal gel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551480","Intestinal Route of Administration","C149599","Administration of a medicinal product to the intestine (duodenum, jejunum, ileum and colon) by means of an appropriate device.","Intestinal Route of Administration | Intestinal use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0217476","Intoplicine","C1495","A benzopyridoindole derivative with antineoplastic property. Intoplicine inhibits activities of both topoisomerase I and II via intercalating DNA helix, thereby hindering the movements of enzymes along DNA molecules during DNA transcription and replication, respectively. Furthermore, this agent stabilizes DNA-enzyme complexes during unwinding processes by both topoisomerases, leading to double- and single-stranded DNA breaks. Consequently, these effects bring about cell growth inhibition and apoptosis of tumor cells.","Intoplicine | 7H-benzo(e)pyrido(4,3-b)indol-3-ol, 11-((3-(dimethylamino)propyl)amino)-8-methyl | INTOPLICINE | intoplicine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551482","Intracholangiopancreatic Route of Administration","C149601","Injection of a medicinal product into the bile duct and the pancreatic duct, for example via a cannula introduced into the ampulla of Vater, usually for the administration of a contrast medium for techniques such as endoscopic retrograde cholangiopancreatography (ERCP).","Intracholangiopancreatic Route of Administration | Intracholangiopancreatic use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551481","Intraglandular Route of Administration","C149602","Administration of a medicinal product directly into a gland, usually by injection.","Intraglandular Route of Administration | Intraglandular use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0358508","Solution for Hemofiltration Dosage Form","C149909","Liquid sterile preparation consisting of an aqueous solution containing electrolytes with a concentration close to the electrolytic composition of plasma, intended for parenteral use in hemofiltration. Glucose may be included.","Solution for Hemofiltration Dosage Form | Solution for haemofiltration",,,,,,,,,,,,,,,"4227037|4303965","Hemofiltration solution|Hemofiltration solution",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C1272893","Solution for Infusion Dosage Form","C149910","Liquid sterile preparation consisting of an aqueous solution intended to be introduced, usually in large volumes, usually into the circulating blood stream.","Solution for Infusion Dosage Form | Solution for infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551765","Solution for infusion in administration system","C149911","Medicinal product consisting of a solution for infusion presented in an administration system.","Solution for Infusion in Administration System Dosage Form | Solution for Infusion in Administration System | Solution for infusion in administration system",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551892","ACTG1 wt Allele","C150160","Human ACTG1 wild-type allele is located in the vicinity of 17q25.3 and is approximately 44 kb in length. This allele, which encodes actin, cytoplasmic 2 protein, is involved in cell motility. Mutation of the gene is associated with autosomal dominant non-syndromic sensorineural progressive hearing loss and Baraitser-Winter syndrome.","ACTG1 wt Allele | ACT | ACTG | Actin Gamma 1 wt Allele | Actin, Cytoplasmic, 2 Gene | Actin, Gamma Gene | DFNA20 | DFNA26 | Deafness, Autosomal Dominant 20 Gene | Deafness, Autosomal Dominant 20/26 Gene | Deafness, Autosomal Dominant 26 Gene | HEL-176",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551891","Balloon Catheter Nominal Outer Diameter","C150161","The nominal measure of the outer diameter of the the balloon.","Balloon Catheter Nominal Outer Diameter | Crossing Profile | Distal Outer Diameter (OD) | Outer Diameter (OD) | Proximal Outer Diameter (OD)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3884655","ACTG1 protein, human","C150162","Actin, cytoplasmic 2 (375 aa, ~42 kDa) is encoded by the human ACTG1 gene. This protein plays a role in cytoskeletal structure.","Actin, Cytoplasmic 2 | ACTG1 | Cytoskeletal Gamma-Actin | Epididymis Luminal Protein 176 | Gamma-Actin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551893","Balloon Catheter Tip Length","C150163","The length of the distal end of the catheter to the distal end of the balloon.","Balloon Catheter Tip Length | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544373","Grade 5 Injury, Poisoning and Procedural Complications - Other, Specify, CTCAE","C146383","Death","Grade 5 Injury, Poisoning and Procedural Complications - Other, Specify, CTCAE | Grade 5 Injury, poisoning and procedural complications - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544374","Grade 5 Intestinal Stoma Leak, CTCAE","C146384","Death","Grade 5 Intestinal Stoma Leak, CTCAE | Grade 5 Intestinal stoma leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544376","Grade 5 Intestinal Stoma Site Bleeding, CTCAE","C146386","Death","Grade 5 Intestinal Stoma Site Bleeding, CTCAE | Grade 5 Intestinal stoma site bleeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544378","Grade 5 Intracranial Hemorrhage, CTCAE","C146388","Death","Grade 5 Intracranial Hemorrhage, CTCAE | Grade 5 Intracranial hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543614","Grade 3 Phantom Pain, CTCAE","C145539","Severe pain; limiting self care ADL","Grade 3 Phantom Pain, CTCAE | Grade 3 Phantom pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543616","Grade 3 Pharyngeal Mucositis, CTCAE","C145543","Severe pain; unable to adequately aliment or hydrate orally; limiting self care ADL","Grade 3 Pharyngeal Mucositis, CTCAE | Grade 3 Pharyngeal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543617","Grade 3 Pharyngeal Stenosis, CTCAE","C145545","Limiting self care ADL; stridor; endoscopic intervention indicated (e.g., stent, laser)","Grade 3 Pharyngeal Stenosis, CTCAE | Grade 3 Pharyngeal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543618","Grade 3 Pharyngitis, CTCAE","C145546","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Pharyngitis, CTCAE | Grade 3 Pharyngitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543619","Grade 3 Pharyngolaryngeal Pain, CTCAE","C145547","Severe pain; limiting self care ADL","Grade 3 Pharyngolaryngeal Pain, CTCAE | Grade 3 Pharyngolaryngeal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543620","Grade 3 Phlebitis Infective, CTCAE","C145548","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Phlebitis Infective, CTCAE | Grade 3 Phlebitis infective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543605","Grade 3 Platelet Count Decreased, CTCAE","C145549","<50,000-25,000/mm3; <50.0-25.0 x 10e9/L","Grade 3 Platelet Count Decreased, CTCAE | Grade 3 Platelet count decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543606","Grade 3 Pleural Effusion, CTCAE","C145550","Symptomatic with respiratory distress and hypoxia; operative intervention including chest tube or pleurodesis indicated","Grade 3 Pleural Effusion, CTCAE | Grade 3 Pleural effusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543608","Grade 3 Pleuritic Pain, CTCAE","C145553","Severe pain; limiting self care ADL","Grade 3 Pleuritic Pain, CTCAE | Grade 3 Pleuritic pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543609","Grade 3 Pneumonitis, CTCAE","C145554","Severe symptoms; limiting self care ADL; oxygen indicated","Grade 3 Pneumonitis, CTCAE | Grade 3 Pneumonitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543610","Grade 3 Portal Hypertension, CTCAE","C145555","Reversal/retrograde portal vein flow; associated with varices and/or ascites","Grade 3 Portal Hypertension, CTCAE | Grade 3 Portal hypertension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543611","Grade 3 Portal Vein Thrombosis, CTCAE","C145556","Medical intervention indicated","Grade 3 Portal Vein Thrombosis, CTCAE | Grade 3 Portal vein thrombosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543612","Grade 3 Postoperative Hemorrhage, CTCAE","C145557","Transfusion indicated of >=2 units (10 cc/kg for pediatrics) pRBCs; invasive intervention indicated; hospitalization","Grade 3 Postoperative Hemorrhage, CTCAE | Grade 3 Postoperative hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543725","Grade 3 Postoperative Thoracic Procedure Complication, CTCAE","C145558","Extubated >72 hrs postoperatively, but before tracheostomy indicated","Grade 3 Postoperative Thoracic Procedure Complication, CTCAE | Grade 3 Postoperative thoracic procedure complication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543726","Grade 3 Pregnancy, Puerperium and Perinatal Conditions - Other, Specify, CTCAE","C145559","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL","Grade 3 Pregnancy, Puerperium and Perinatal Conditions - Other, Specify, CTCAE | Grade 3 Pregnancy, puerperium and perinatal conditions - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544062","Grade 4 Pancreas Infection, CTCAE","C146025","Life-threatening consequences; urgent intervention indicated","Grade 4 Pancreas Infection, CTCAE | Grade 4 Pancreas infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544063","Grade 4 Pancreatic Anastomotic Leak, CTCAE","C146026","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Pancreatic Anastomotic Leak, CTCAE | Grade 4 Pancreatic anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544064","Grade 4 Pancreatic Duct Stenosis, CTCAE","C146027","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Pancreatic Duct Stenosis, CTCAE | Grade 4 Pancreatic duct stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544066","Grade 4 Papilledema, CTCAE","C146031","Best corrected visual acuity of 20/200 or worse in the affected eye","Grade 4 Papilledema, CTCAE | Grade 4 Papilledema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544067","Grade 4 Papulopustular Rash, CTCAE","C146032","Life-threatening consequences","Grade 4 Papulopustular Rash, CTCAE | Grade 4 Papulopustular rash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544068","Grade 4 Paroxysmal Atrial Tachycardia, CTCAE","C146033","Life-threatening consequences; incompletely controlled medically; cardioversion indicated","Grade 4 Paroxysmal Atrial Tachycardia, CTCAE | Grade 4 Paroxysmal atrial tachycardia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544053","Grade 4 Pelvic Infection, CTCAE","C146034","Life-threatening consequences; urgent intervention indicated","Grade 4 Pelvic Infection, CTCAE | Grade 4 Pelvic infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544054","Grade 4 Penile Infection, CTCAE","C146035","Life-threatening consequences; urgent intervention indicated","Grade 4 Penile Infection, CTCAE | Grade 4 Penile infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544055","Grade 4 Perforation Bile Duct, CTCAE","C146036","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Perforation Bile Duct, CTCAE | Grade 4 Perforation bile duct",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544056","Grade 4 Pericardial Effusion, CTCAE","C146037","Life-threatening consequences; urgent intervention indicated","Grade 4 Pericardial Effusion, CTCAE | Grade 4 Pericardial effusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544058","Grade 4 Periorbital Infection, CTCAE","C146039","Life-threatening consequences; urgent intervention indicated","Grade 4 Periorbital Infection, CTCAE | Grade 4 Periorbital infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544059","Grade 4 Peripheral Ischemia, CTCAE","C146040","Life-threatening consequences; evidence of end organ damage; urgent operative intervention indicated","Grade 4 Peripheral Ischemia, CTCAE | Grade 4 Peripheral ischemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544060","Grade 4 Peripheral Motor Neuropathy, CTCAE","C146041","Life-threatening consequences; urgent intervention indicated","Grade 4 Peripheral Motor Neuropathy, CTCAE | Grade 4 Peripheral motor neuropathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544173","Grade 4 Peripheral Nerve Infection, CTCAE","C146042","Life-threatening consequences; urgent intervention indicated","Grade 4 Peripheral Nerve Infection, CTCAE | Grade 4 Peripheral nerve infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544174","Grade 4 Peripheral Sensory Neuropathy, CTCAE","C146043","Life-threatening consequences; urgent intervention indicated","Grade 4 Peripheral Sensory Neuropathy, CTCAE | Grade 4 Peripheral sensory neuropathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544175","Grade 4 Peritoneal Infection, CTCAE","C146044","Life-threatening consequences; urgent intervention indicated","Grade 4 Peritoneal Infection, CTCAE | Grade 4 Peritoneal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544548","Grade 5 Portal Hypertension, CTCAE","C146497","Death","Grade 5 Portal Hypertension, CTCAE | Grade 5 Portal hypertension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544534","Grade 5 Postoperative Hemorrhage, CTCAE","C146499","Death","Grade 5 Postoperative Hemorrhage, CTCAE | Grade 5 Postoperative hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0442116","Intramammary","C149603","Relating to the milk-producing organs (mammae) of a female mammal as the intended site of administration, to describe veterinary-only pharmaceutical products that are administered via the teat canal.","Intramammary | ",,,,,,,,,,,,,,,"4136279","Intramammary",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL551477","Intramammary Emulsion Dosage Form","C149604","Liquid sterile preparation for veterinary use consisting of an emulsion intended for intramammary use. Intramammary emulsions are presented in intramammary syringes for use on one occasion only to introduce the emulsion into a single teat canal.","Intramammary Emulsion Dosage Form | Intramammary emulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551479","Intramammary Gel Dosage Form","C149605","Semi-solid preparation for veterinary use consisting of a gel containing dissolved or dispersed active substance(s) intended for intramammary use. Intramammary gels are presented in intramammary syringes for use on one occasion only to introduce the gel into a single teat canal.","Intramammary Gel Dosage Form | Intramammary gel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551478","Intramammary Ointment Dosage Form","C149606","Semi-solid sterile preparation for veterinary use consisting of an ointment containing dissolved or dispersed active substance(s) intended for intramammary use. Intramammary ointments are presented in intramammary syringes for use on one occasion only to introduce the ointment into a single teat canal.","Intramammary Ointment Dosage Form | Intramammary ointment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551474","Intramammary Solution Dosage Form","C149607","Liquid sterile preparation for veterinary use consisting of a solution intended for intramammary use. Intramammary solutions are presented in intramammary syringes for use on one occasion only to introduce the solution into a single teat canal.","Intramammary Solution Dosage Form | Intramammary solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551473","Intramammary Suspension Dosage Form","C149608","Liquid sterile preparation for veterinary use consisting of a suspension intended for intramammary use. Intramammary suspensions are presented in intramammary syringes for use on one occasion only to introduce the suspension into a single teat canal.","Intramammary Suspension Dosage Form | Intramammary suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551708","Powder for Solution for Skin-Prick Test Dosage Form","C149852","Solid sterile preparation consisting of one or more powder intended to be dissolved in the specified liquid to obtain a solution for skin-prick test.","Powder for Solution for Skin-Prick Test Dosage Form | Powder for solution for skin-prick test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551707","Powder for Suspension for Fish Treatment Dosage Form","C149853","Solid preparation for veterinary use consisting of one or more powders intended to be dispersed in the specified liquid to obtain a suspension for fish treatment by immersion.","Powder for Suspension for Fish Treatment Dosage Form | Powder for suspension for fish treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551702","Powder for Syrup Dosage Form","C149854","Solid preparation consisting of one or more powders that may include excipients to facilitate dissolution in water and to obtain the characteristics of a syrup, intended to be dissolved in water to obtain a syrup.","Powder for Syrup Dosage Form | Powder for syrup",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551701","Powder for Use in Drinking Water Dosage Form","C149855","Solid preparation for veterinary use consisting of one or more powder intended to be dissolved in the animal drinking water.","Powder for Use in Drinking Water Dosage Form | Powder for use in drinking water",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551704","Powder for Use in Drinking Water/Milk Dosage Form","C149856","Solid preparation for veterinary use consisting of one or more powders intended to be dissolved in the animal drinking water, milk or milk replacer.","Powder for Use in Drinking Water/Milk Dosage Form | Powder for use in drinking water/milk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551703","Powder, Dispersion and Solvent for Concentrate for Dispersion for Infusion Dosage Form","C149857","Sterile powder and sterile dispersion, both of which contain active substance(s), and sterile solvent intended for the preparation of a concentrate for dispersion for infusion; it is prepared as specified in the packaging information; the resulting concentrate for dispersion for infusion must subsequently be diluted before administration as a dispersion for infusion.","Powder, Dispersion and Solvent for Concentrate for Dispersion for Infusion Dosage Form | Powder, dispersion and solvent for concentrate for dispersion for infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552000","Balloon Catheter Rated Burst Pressure","C150164","Calculated pressure at which a balloon would not be expected to burst. Based on an appropriate confidence and reliability from measured burst pressures.","Balloon Catheter Rated Burst Pressure | RBP | Rated Burst Pressure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552002","ADAMTS20 wt Allele","C150166","Human ADAMTS20 wild-type allele is located in the vicinity of 12q12 and is approximately 199 kb in length. This allele, which encodes a disintegrin and metalloproteinase with thrombospondin motifs 20 protein, plays a role in extracellular proteolysis.","ADAMTS20 wt Allele | A Disintegrin-Like and Metalloprotease (Reprolysin Type) with Thrombospondin Type 1 Motif, 20 Gene | A Disintegrin-Like and Metalloproteinase with Thrombospondin Type 1 Motif, 20 Gene | ADAM Metallopeptidase with Thrombospondin Type 1 Motif 20 wt Allele | ADAM-TS20 | ADAMTS-20 | GON-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551221","Concentrate for Concentrate for Oral Spray, Suspension Dosage Form","C149382","Liquid preparation for veterinary use intended to be diluted in the specified liquid to obtain a concentrate for oral spray, suspension, which in turn is intended to be diluted in the specified liquid to obtain an oral spray, suspension.","Concentrate for Concentrate for Oral Spray, Suspension Dosage Form | Concentrate for concentrate for oral spray, suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551216","Concentrate for Concentrate for Solution for Infusion Dosage Form","C149383","Liquid sterile preparation intended to be diluted in the specified liquid to obtain a concentrate for solution for infusion, which in turn is intended to be diluted in the specified liquid to obtain a solution for infusion.","Concentrate for Concentrate for Solution for Infusion Dosage Form | Concentrate for concentrate for solution for infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551215","Concentrate for Cutaneous Solution Dosage Form","C149384","Liquid preparation intended to be diluted in the specified liquid to obtain a cutaneous solution.","Concentrate for Cutaneous Solution Dosage Form | Concentrate for cutaneous solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551218","Concentrate for Cutaneous Spray, Emulsion Dosage Form","C149385","Liquid preparation intended to be diluted in the specified liquid to obtain a cutaneous spray emulsion.","Concentrate for Cutaneous Spray, Emulsion Dosage Form | Concentrate for cutaneous spray, emulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551217","Concentrate for Dip Emulsion Dosage Form","C149386","Liquid preparation intended to be diluted in the specified liquid to obtain a dip emulsion.","Concentrate for Dip Emulsion Dosage Form | Concentrate for dip emulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551324","Concentrate for Dip Solution Dosage Form","C149387","Liquid preparation intended to be diluted in the specified liquid to obtain a dip solution.","Concentrate for Dip Solution Dosage Form | Concentrate for dip solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551323","Concentrate for Dip Suspension Dosage Form","C149388","Liquid preparation intended to be diluted in the specified liquid to obtain a dip suspension.","Concentrate for Dip Suspension Dosage Form | Concentrate for dip suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551326","Concentrate for Dispersion for Infusion Dosage Form","C149389","Liquid sterile preparation intended to be diluted in the specified liquid to obtain a dispersion for infusion.","Concentrate for Dispersion for Infusion Dosage Form | Concentrate for dispersion for infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551325","Concentrate for Emulsion for Infusion Dosage Form","C149390","Liquid sterile preparation intended to be diluted in the specified liquid to obtain an emulsion for infusion.","Concentrate for Emulsion for Infusion Dosage Form | Concentrate for emulsion for infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551320","Concentrate for Gargle Dosage Form","C149391","Liquid preparation consisting of an aqueous solution intended to be diluted in water to obtain a gargle.","Concentrate for Gargle Dosage Form | Concentrate for gargle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551322","Concentrate for Nebulizer Solution Dosage Form","C149393","Liquid preparation intended to be diluted in the specified liquid to obtain a nebulizer solution.","Concentrate for Nebulizer Solution Dosage Form | Concentrate for nebuliser solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543727","Grade 3 Premature Delivery, CTCAE","C145560","Delivery of a liveborn infant at 24 to 28 weeks gestation","Grade 3 Premature Delivery, CTCAE | Grade 3 Premature delivery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543729","Grade 3 Prolapse of Intestinal Stoma, CTCAE","C145562","Severe symptoms; elective operative intervention indicated; limiting self care ADL","Grade 3 Prolapse of Intestinal Stoma, CTCAE | Grade 3 Prolapse of intestinal stoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543730","Grade 3 Prolapse of Urostomy, CTCAE","C145563","Dysfunctional stoma; elective operative intervention or major stomal revision indicated","Grade 3 Prolapse of Urostomy, CTCAE | Grade 3 Prolapse of urostomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543731","Grade 3 Prostate Infection, CTCAE","C145564","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Prostate Infection, CTCAE | Grade 3 Prostate infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543732","Grade 3 Prostatic Obstruction, CTCAE","C145566","Severe symptoms; invasive intervention indicated","Grade 3 Prostatic Obstruction, CTCAE | Grade 3 Prostatic obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543717","Grade 3 Prostatic Pain, CTCAE","C145567","Severe pain; limiting self care ADL","Grade 3 Prostatic Pain, CTCAE | Grade 3 Prostatic pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544535","Grade 5 Postoperative Thoracic Procedure Complication, CTCAE","C146500","Death","Grade 5 Postoperative Thoracic Procedure Complication, CTCAE | Grade 5 Postoperative thoracic procedure complication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544536","Grade 5 Pregnancy, Puerperium and Perinatal Conditions - Other, Specify, CTCAE","C146501","Death","Grade 5 Pregnancy, Puerperium and Perinatal Conditions - Other, Specify, CTCAE | Grade 5 Pregnancy, puerperium and perinatal conditions - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544537","Grade 5 Prolapse of Intestinal Stoma, CTCAE","C146502","Death","Grade 5 Prolapse of Intestinal Stoma, CTCAE | Grade 5 Prolapse of intestinal stoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544538","Grade 5 Prolapse of Urostomy, CTCAE","C146503","Death","Grade 5 Prolapse of Urostomy, CTCAE | Grade 5 Prolapse of urostomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544540","Grade 5 Psychiatric Disorders - Other, Specify, CTCAE","C146506","Death","Grade 5 Psychiatric Disorders - Other, Specify, CTCAE | Grade 5 Psychiatric disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544525","Grade 5 Psychosis, CTCAE","C146507","Death","Grade 5 Psychosis, CTCAE | Grade 5 Psychosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544526","Grade 5 Pulmonary Edema, CTCAE","C146508","Death","Grade 5 Pulmonary Edema, CTCAE | Grade 5 Pulmonary edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544527","Grade 5 Pulmonary Fibrosis, CTCAE","C146509","Death","Grade 5 Pulmonary Fibrosis, CTCAE | Grade 5 Pulmonary fibrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544529","Grade 5 Pulmonary Valve Disease, CTCAE","C146511","Death","Grade 5 Pulmonary Valve Disease, CTCAE | Grade 5 Pulmonary valve disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544530","Grade 5 Pyramidal Tract Syndrome, CTCAE","C146512","Death","Grade 5 Pyramidal Tract Syndrome, CTCAE | Grade 5 Pyramidal tract syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544532","Grade 5 Radiculitis, CTCAE","C146514","Death","Grade 5 Radiculitis, CTCAE | Grade 5 Radiculitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544517","Grade 5 Rash Acneiform, CTCAE","C146515","Death","Grade 5 Rash Acneiform, CTCAE | Grade 5 Rash acneiform",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544518","Grade 5 Rectal Anastomotic Leak, CTCAE","C146516","Death","Grade 5 Rectal Anastomotic Leak, CTCAE | Grade 5 Rectal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544520","Grade 5 Rectal Stenosis, CTCAE","C146523","Death","Grade 5 Rectal Stenosis, CTCAE | Grade 5 Rectal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544521","Grade 5 Recurrent Laryngeal Nerve Palsy, CTCAE","C146525","Death","Grade 5 Recurrent Laryngeal Nerve Palsy, CTCAE | Grade 5 Recurrent laryngeal nerve palsy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544522","Grade 5 Renal and Urinary Disorders - Other, Specify, CTCAE","C146526","Death","Grade 5 Renal and Urinary Disorders - Other, Specify, CTCAE | Grade 5 Renal and urinary disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551698","Powder, Solvent and Matrix for Implantation Matrix Dosage Form","C149858","Sterile powder (including freeze-dried powder), sterile solvent and sterile matrix intended for the preparation of an implantation matrix, for example by dissolving the powder in the solvent and using the resulting solution to impregnate the matrix. The powder contains active ingredient(s); the matrix does not contain active ingredient(s).","Powder, Solvent and Matrix for Implantation Matrix Dosage Form | Powder, solvent and matrix for implantation matrix",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551697","Pre-filled Gastroenteral Tube","C149859","Pre-filled tube for the administration of a medicinal product to the gastroenteral tract.","Pre-filled Gastroenteral Tube | Pre-filled gastroenteral tube",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551700","Pre-filled Injector","C149860","Filled container, usually fitted with an injection needle, containing a sterile, single-dose parenteral preparation.","Pre-filled Injector | Pre-filled injector",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551699","Pre-filled Oral Applicator","C149861","Filled container for administering a liquid or semi-solid pharmaceutical form to the oral cavity, containing the final preparation in one compartment, or the components necessary for its preparation in different compartments.","Pre-filled Oral Applicator | Pre-filled oral applicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551694","Pre-filled Oral Syringe","C149862","Filled container for administering a liquid or semi-solid pharmaceutical form to the oral cavity, containing the final preparation in one compartment, or the components necessary for its preparation in different compartments.","Pre-filled Oral Syringe | Pre-filled oral syringe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554824","Unspecified Premix Dosage Form Category","C149863","A type of specialized pharmaceutical dose form that is used in the preparation of products such as medicated feeding stuffs.","Unspecified Premix Dosage Form Category | Premix (unspecified)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551696","Premix for Medicated Feeding Stuff Dosage Form","C149864","Liquid, semi-solid or solid preparation intended to facilitate oral administration of active substances to animals. Premixes for medicated feeding stuff are used exclusively in the preparation of medicated feeding stuffs. Used as powders or granules, they are free-flowing and homogeneous. Used in liquid form, they are homogeneous suspensions or solutions which may be obtained from thixotropic gels or structured liquids. The particle size and other properties are such as to ensure uniform distribution of the active substance(s) in the final feeding stuff.","Premix for Medicated Feeding Stuff Dosage Form | Premix for medicated feeding stuff",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272874","Pressurized Inhalation Emulsion Dosage Form","C149866","Liquid, usually multidose preparation consisting of an emulsion intended for inhalation use. The preparation is presented in a pressurized container fitted with a metering dose valve.","Pressurized Inhalation Emulsion Dosage Form | Pressurised inhalation, emulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551930","EDQM-HC State of Matter Terminology","C150116","Terminology subset about physical conditions describing the molecular form of a product. Note: State of matter is used to group basic dose forms according to their physical properties.","EDQM-HC State of Matter Terminology | European Directorate for the Quality of Medicines and HealthCare State of Matter | SOM | State of Matter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552439","EDQM-HC Transformation Terminology","C150117","Terminology subset about procedures that are carried out in order to convert a manufactured item that requires such a procedure into a pharmaceutical product, i.e., from its manufactured dose form to its administrable dose form. Note: A transformation is not required when the manufactured item is equal to the pharmaceutical product.","EDQM-HC Transformation Terminology | European Directorate for the Quality of Medicines and HealthCare Transformation | TRA | Transformation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551928","PRKCD wt Allele","C150119","Human PRKCD wild-type allele is located in the vicinity of 3p21.1 and is approximately 37 kb in length. This allele, which encodes protein kinase C delta type protein, is involved in both cell death and cell survival. Mutation of the gene is associated with autoimmune lymphoproliferative syndrome 3.","PRKCD wt Allele | ALPS3 | CVID9 | MAY1 | PKCD | Protein Kinase C Delta wt Allele | Protein Kinase C, Delta Gene | SDK1 | Sphingosine-Dependent Protein Kinase-1 Gene | nPKC-delta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1566443","PRKCD protein, human","C150120","Protein kinase C delta type (676 aa, ~78 kDa) is encoded by the human PRKCD gene. This protein plays a role in the regulation of apoptosis.","Protein Kinase C Delta Type | EC 2.7.10.2 | EC 2.7.11.13 | PRKCD | Tyrosine-Protein Kinase PRKCD | nPKC-Delta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551321","Concentrate for Oral Solution Dosage Form","C149394","Liquid preparation intended to be diluted in the specified liquid to obtain an oral solution.","Concentrate for Oral Solution Dosage Form | Concentrate for oral solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551316","Concentrate for Oral Suspension Dosage Form","C149395","Liquid preparation intended to be diluted in the specified liquid to obtain an oral suspension.","Concentrate for Oral Suspension Dosage Form | Concentrate for oral suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551315","Concentrate for Oral/Rectal Solution Dosage Form","C149396","Liquid preparation intended to be diluted in the specified liquid to obtain an oral/rectal solution.","Concentrate for Oral/Rectal Solution Dosage Form | Concentrate for oral/rectal solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551318","Concentrate for Oromucosal Solution Dosage Form","C149397","Liquid preparation intended to be diluted in the specified liquid to obtain an oromucosal solution.","Concentrate for Oromucosal Solution Dosage Form | Concentrate for oromucosal solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551317","Concentrate for Rectal Solution Dosage Form","C149398","Liquid preparation intended to be diluted in the specified liquid to obtain a rectal solution.","Concentrate for Rectal Solution Dosage Form | Concentrate for rectal solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551312","Concentrate for Solution for Fish Treatment Dosage Form","C149399","Liquid preparation intended to be diluted in the specified liquid to obtain a solution for fish treatment by immersion.","Concentrate for Solution for Fish Treatment Dosage Form | Concentrate for solution for fish treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552432","Modified-release Mechanism of Action","C149662","Release of the substance(s) in a way that differs from that which would be achieved with a conventional-release product, which is achieved by a special formulation design and/or manufacturing method, but which is not classified as delayed-release or prolonged-release; pulsatile-release products are included.","Modified-release Mechanism of Action | Modified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551533","Modified-release capsule, hard","C149663","Solid single-dose preparation consisting of a hard shell containing a solid or semi-solid formulation, showing a rate, a place and/or a time of release different from that of a conventional-release capsule. This deliberate modification is achieved by a special formulation design and/or manufacturing method.","Modified-release Hard Capsule Dosage Form | Modified-release Hard Capsule Form | Modified-release capsule, hard",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551532","Modified-release capsule, soft","C149664","Solid single-dose preparation consisting of a soft shell containing a semi-solid or liquid formulation, showing a rate, a place and/or a time of release different from that of a conventional-release capsule. This deliberate modification is achieved by a special formulation design and/or manufacturing method.","Modified-release Soft Capsule Dosage Form | Modified-release Soft Capsule Form | Modified-release capsule, soft",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551535","Modified-release Granule Dosage Form","C149665","Solid preparation consisting of granules showing a rate and/or place of release different from that of conventional-release granules. This deliberate modification is achieved by a special formulation design and/or manufacturing method. Modified-release granules are usually single-dose preparations intended for oral use, and include prolonged-release, delayed release and pulsatile-release granules.","Modified-release Granule Dosage Form | Modified-release granules",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551534","Modified-release Granule for Oral Suspension Dosage Form","C149666","Solid preparation consisting of modified-release granules intended to be dispersed in the specified liquid to obtain an oral suspension.","Modified-release Granule for Oral Suspension Dosage Form | Modified-release Granule for Oral Suspension | Modified-release granules for oral suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551530","Mouthpiece","C149667","Aid used for the administration or inhalation of a medicinal product by mouth.","Mouthpiece | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551529","Mouthwash, Powder for Solution Dosage Form","C149668","Solid preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain a mouthwash.","Mouthwash, Powder for Solution Dosage Form | Mouthwash, powder for solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551531","Mouthwash, Tablet for Solution Dosage Form","C149669","Solid preparation consisting of an uncoated tablet intended to be dissolved in water to obtain a mouthwash.","Mouthwash, Tablet for Solution Dosage Form | Mouthwash, tablet for solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3887559","Recombinant Human Macrophage Inflammatory Protein-1 Beta","C1467","The recombinant form of endogenous MIP-1 beta chemokine that chemoattracts both neutrophils and monocytes, stimulates macrophages, and stimulates myelopoietic cell growth.","Recombinant Human Macrophage Inflammatory Protein-1 Beta | ACT-2 | CCL4 | H400is SIS gamma | HuMIP-1-Beta | HuMIP-1b | Human Macrophage Inflammatory Protein-1 Beta | MIP-1 Beta | MIP-1-b | MIP-1Beta | PAT 744 | rHuMIP-1-Beta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544019","Grade 4 Intestinal Stoma Site Bleeding, CTCAE","C145939","Life-threatening consequences; urgent intervention indicated","Grade 4 Intestinal Stoma Site Bleeding, CTCAE | Grade 4 Intestinal stoma site bleeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544020","Grade 4 Intra-Abdominal Hemorrhage, CTCAE","C145940","Life-threatening consequences; urgent intervention indicated","Grade 4 Intra-Abdominal Hemorrhage, CTCAE | Grade 4 Intra-abdominal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544006","Grade 4 Intraoperative Arterial Injury, CTCAE","C145942","Life-threatening consequences; urgent intervention indicated","Grade 4 Intraoperative Arterial Injury, CTCAE | Grade 4 Intraoperative arterial injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544007","Grade 4 Intraoperative Breast Injury, CTCAE","C145943","Life-threatening consequences; urgent intervention indicated","Grade 4 Intraoperative Breast Injury, CTCAE | Grade 4 Intraoperative breast injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544008","Grade 4 Intraoperative Cardiac Injury, CTCAE","C145944","Life-threatening consequences; urgent intervention indicated","Grade 4 Intraoperative Cardiac Injury, CTCAE | Grade 4 Intraoperative cardiac injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544009","Grade 4 Intraoperative Ear Injury, CTCAE","C145945","Life-threatening consequences; urgent intervention indicated","Grade 4 Intraoperative Ear Injury, CTCAE | Grade 4 Intraoperative ear injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544010","Grade 4 Intraoperative Endocrine Injury, CTCAE","C145946","Life-threatening consequences; urgent intervention indicated","Grade 4 Intraoperative Endocrine Injury, CTCAE | Grade 4 Intraoperative endocrine injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544011","Grade 4 Intraoperative Gastrointestinal Injury, CTCAE","C145947","Life-threatening consequences; urgent intervention indicated","Grade 4 Intraoperative Gastrointestinal Injury, CTCAE | Grade 4 Intraoperative gastrointestinal injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544012","Grade 4 Intraoperative Head and Neck Injury, CTCAE","C145948","Life-threatening consequences; urgent intervention indicated","Grade 4 Intraoperative Head and Neck Injury, CTCAE | Grade 4 Intraoperative head and neck injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543998","Grade 4 Intraoperative Hepatobiliary Injury, CTCAE","C145950","Life-threatening consequences; urgent intervention indicated","Grade 4 Intraoperative Hepatobiliary Injury, CTCAE | Grade 4 Intraoperative hepatobiliary injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544523","Grade 5 Renal Calculi, CTCAE","C146527","Death","Grade 5 Renal Calculi, CTCAE | Grade 5 Renal calculi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543784","Grade 3 Stenosis of Gastrointestinal Stoma, CTCAE","C145641","Severely altered GI function; tube feeding, TPN or hospitalization indicated; elective operative intervention indicated","Grade 3 Stenosis of Gastrointestinal Stoma, CTCAE | Grade 3 Stenosis of gastrointestinal stoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543785","Grade 3 Stevens-Johnson Syndrome, CTCAE","C145642","Skin sloughing covering <10% BSA with associated signs (e.g., erythema, purpura, epidermal detachment, and mucous membrane detachment)","Grade 3 Stevens-Johnson Syndrome, CTCAE | Grade 3 Stevens-Johnson syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543786","Grade 3 Stoma Site Infection, CTCAE","C145643","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Stoma Site Infection, CTCAE | Grade 3 Stoma site infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543788","Grade 3 Stridor, CTCAE","C145645","Respiratory distress limiting self care ADL; medical intervention indicated","Grade 3 Stridor, CTCAE | Grade 3 Stridor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543773","Grade 3 Stroke, CTCAE","C145646","Severe neurologic deficit; limiting self care ADL; hospitalization","Grade 3 Stroke, CTCAE | Grade 3 Stroke",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543774","Grade 3 Subcutaneous Emphysema, CTCAE","C145647","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL","Grade 3 Subcutaneous Emphysema, CTCAE | Grade 3 Subcutaneous emphysema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543775","Grade 3 Suicidal Ideation, CTCAE","C145648","Specific plan to commit suicide without serious intent to die which may not require hospitalization","Grade 3 Suicidal Ideation, CTCAE | Grade 3 Suicidal ideation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543776","Grade 3 Suicide Attempt, CTCAE","C145649","Suicide attempt or gesture without intent to die","Grade 3 Suicide Attempt, CTCAE | Grade 3 Suicide attempt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543777","Grade 3 Superficial Soft Tissue Fibrosis, CTCAE","C145650","Severe induration; unable to slide or pinch skin; limiting joint or orifice movement (e.g., mouth, anus); limiting self care ADL","Grade 3 Superficial Soft Tissue Fibrosis, CTCAE | Grade 3 Superficial soft tissue fibrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543779","Grade 3 Surgical and Medical Procedures - Other, Specify, CTCAE","C145652","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL","Grade 3 Surgical and Medical Procedures - Other, Specify, CTCAE | Grade 3 Surgical and medical procedures - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543780","Grade 3 Tendon Reflex Decreased, CTCAE","C145653","Absence of all reflexes","Grade 3 Tendon Reflex Decreased, CTCAE | Grade 3 Tendon reflex decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543765","Grade 3 Testicular Disorder, CTCAE","C145654","Severe symptoms; interfering with sexual function; limiting self care ADL; intervention indicated","Grade 3 Testicular Disorder, CTCAE | Grade 3 Testicular disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543766","Grade 3 Testicular Pain, CTCAE","C145656","Severe pain; limiting self care ADL","Grade 3 Testicular Pain, CTCAE | Grade 3 Testicular pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543767","Grade 3 Thromboembolic Event, CTCAE","C145657","Urgent medical intervention indicated (e.g., pulmonary embolism or intracardiac thrombus)","Grade 3 Thromboembolic Event, CTCAE | Grade 3 Thromboembolic event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543768","Grade 3 Thrombotic Thrombocytopenic Purpura, CTCAE","C145658","Laboratory findings with clinical consequences (e.g., renal insufficiency, petechiae)","Grade 3 Thrombotic Thrombocytopenic Purpura, CTCAE | Grade 3 Thrombotic thrombocytopenic purpura",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543769","Grade 3 Thrush, CTCAE","C145659","IV antifungal intervention indicated","Grade 3 Thrush, CTCAE | Grade 3 Thrush",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543770","Grade 3 Tooth Development Disorder, CTCAE","C145660","Maldevelopment with impairment not surgically correctable; limiting self care ADL","Grade 3 Tooth Development Disorder, CTCAE | Grade 3 Tooth development disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0180488","Radiation Dosimeter Device","C150121","A device that is used to measure the amount of ionizing radiation exposure or absorption.","Radiation Dosimeter Device | Dosimeter",,,,,,,,,,,,,,,"4049902","Dosimeter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL551929","High-Grade Myeloid Neoplasm","C150122","A finding indicating that a myeloproliferative process has high-grade pathologic and/or clinical features.","High Grade Myeloid Neoplasm | High-Grade Myeloid Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551924","EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma","C150124","A finding indicating the presence of the epidermal growth factor receptor T790M amino acid substitution mutation in a tumor sample from a patient with non-small cell lung carcinoma.","EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma | EGFR NP_005219.2:p.T790M Positive NSCLC | EGFR NP_005219.2:p.Thr790Met Positive NSCLC | EGFR T790M Mutation Positive NSCLC | EGFR T790M Mutation Positive Non-Small Cell Lung Cancer | EGFR Thr790Met Mutation Positive NSCLC | EGFR Thr790Met Mutation Positive Non-Small Cell Lung Cancer | EGFR Thr790Met Mutation Positive Non-Small Cell Lung Carcinoma | NSCLC with EGFR T790M Mutation | NSCLC with EGFR Thr790Met Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3853880","Telotristat Ethyl","C150126","The ethyl ester form of telotristat, a tryptophan hydroxylase (TPH) inhibitor, with potential anti-serotonergic activity. Upon administration, telotristat binds to and inhibits the activity of TPH. This may result in a reduction in peripheral serotonin (5-HT) production and improvement of serotonin-mediated gastrointestinal effects such as severe diarrhea. TPH, the rate-limiting enzyme in serotonin biosynthesis, is overexpressed in carcinoid tumor cells.","Telotristat Ethyl | LX 1032 | LX 1606 | LX-1032 | LX-1606 | LX1032 | LX1606 | TELOTRISTAT ETHYL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551653","Powder and Solvent for Intraocular Instillation Solution Dosage Form","C149785","Sterile powder and sterile solvent intended for the preparation of an intraocular instillation solution by dissolving the powder in the solvent.","Powder and Solvent for Intraocular Instillation Solution Dosage Form | Powder and solvent for intraocular instillation solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972798","Known History of Rheumatic Fever","C168305","An indication that the patient has a history of rheumatic fever.","Known History of Rheumatic Fever | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL972662","No History of Myopathy","C168347","An indication that the patient does not have a history of myopathy.","No History of Myopathy | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551526","Multidose Container with Airless Pump","C149671","Multidose container with an integral pump designed to protect the contents against in use-contamination.","Multidose Container with Airless Pump | Multidose container with airless pump",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551525","Multidose Container with Metering Pump","C149672","Multidose container with integral metering pump.","Multidose Container with Metering Pump | Multidose container with metering pump",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551528","Multidose Container with Pump","C149673","Multidose container with an integral pump. Metering pump, spray pump, and multidose container with airless pump are excluded.","Multidose Container with Pump | Multidose container with pump",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551527","Multipuncturer","C149674","Device for puncturing the skin, normally used for immunological products, especially diagnostics.","Multipuncturer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551522","Nasal Applicator Device","C149675","Aid used for the administration of a drug by nose.","Nasal Applicator Device | Nasal applicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551521","Emulsion Nasal Drops Dosage Form","C149676","Liquid single-dose or multidose preparation consisting of an emulsion intended for nasal use by means of a suitable applicator.","Emulsion Nasal Drops Dosage Form | Nasal drops, emulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551524","Nasal drops, lyophilisate and solvent for suspension","C149677","Lyophilisate and solvent intended for the preparation of nasal drops, suspension, for veterinary use, by dispersing the lyophilisate in the solvent.","Nasal Drops, Lyophilisate and Solvent for Suspension Dosage Form | Nasal drops, lyophilisate and solvent for suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551523","Nasal drops, lyophilisate for suspension","C149678","Solid preparation for veterinary use consisting of a freeze-dried powder intended to be dispersed in the specified liquid to obtain a suspension for use as nasal drops.","Nasal Drops, Lyophilisate for Suspension Dosage Form | Nasal drops, lyophilisate for suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551766","Solution for injection in administration system","C149913","Medicinal product consisting of a solution for injection presented in an administration system.","Solution for Injection in Administration System Dosage Form | Solution for Injection in Administration System | Solution for injection in administration system",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551762","Solution for injection in cartridge","C149914","Medicinal product consisting of a solution for injection presented in a cartridge.","Solution for Injection in Cartridge Dosage Form | Solution for Injection in Cartridge | Solution for injection in cartridge",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551761","Solution for injection in dose-dispenser cartridge","C149915","Medicinal product consisting of a solution for injection presented in a dose-dispenser cartridge.","Solution for Injection in Dose-Dispenser Cartridge Dosage Form | Solution for Injection in Dose-Dispenser Cartridge | Solution for injection in dose-dispenser cartridge",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551763","Solution for injection in pre-filled injector","C149917","Medicinal product consisting of a solution for injection presented in a pre-filled injector.","Solution for Injection in Pre-filled Injector Dosage Form | Solution for Injection in Pre-filled Injector | Solution for injection in pre-filled injector",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551758","Solution for injection in pre-filled pen","C149918","Medicinal product consisting of a solution for injection presented in a pre-filled pen.","Solution for Injection in Pre-filled Pen Dosage Form | Solution for Injection in Pre-filled Pen | Solution for injection in pre-filled pen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551757","Solution for injection in pre-filled syringe","C149919","Medicinal product consisting of a solution for injection presented in a pre-filled syringe.","Solution for Injection in Pre-filled Syringe Dosage Form | Solution for Injection in Pre-filled Syringe | Solution for injection in pre-filled syringe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551760","Solution for Injection/Infusion Dosage Form","C149920","Liquid sterile single-dose or multidose preparation consisting of a solution intended for administration by injection or infusion.","Solution for Injection/Infusion Dosage Form | Solution for injection/infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551759","Solution for injection/infusion in pre-filled syringe","C149921","Medicinal product consisting of a solution for injection/infusion presented in a pre-filled syringe.","Solution for Injection/Infusion in Pre-filled Syringe Dosage Form | Solution for Injection/Infusion in Pre-filled Syringe | Solution for injection/infusion in pre-filled syringe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543999","Grade 4 Intraoperative Musculoskeletal Injury, CTCAE","C145951","Life-threatening consequences; urgent intervention indicated","Grade 4 Intraoperative Musculoskeletal Injury, CTCAE | Grade 4 Intraoperative musculoskeletal injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544000","Grade 4 Intraoperative Neurological Injury, CTCAE","C145952","Life-threatening consequences; urgent intervention indicated","Grade 4 Intraoperative Neurological Injury, CTCAE | Grade 4 Intraoperative neurological injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544001","Grade 4 Intraoperative Ocular Injury, CTCAE","C145953","Life-threatening consequences; urgent intervention indicated","Grade 4 Intraoperative Ocular Injury, CTCAE | Grade 4 Intraoperative ocular injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544002","Grade 4 Intraoperative Renal Injury, CTCAE","C145954","Life-threatening consequences; urgent intervention indicated","Grade 4 Intraoperative Renal Injury, CTCAE | Grade 4 Intraoperative renal injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544003","Grade 4 Intraoperative Reproductive Tract Injury, CTCAE","C145955","Life-threatening consequences; urgent intervention indicated","Grade 4 Intraoperative Reproductive Tract Injury, CTCAE | Grade 4 Intraoperative reproductive tract injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544004","Grade 4 Intraoperative Respiratory Injury, CTCAE","C145956","Life-threatening consequences; urgent intervention indicated","Grade 4 Intraoperative Respiratory Injury, CTCAE | Grade 4 Intraoperative respiratory injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543991","Grade 4 Intraoperative Venous Injury, CTCAE","C145959","Life-threatening consequences; urgent intervention indicated","Grade 4 Intraoperative Venous Injury, CTCAE | Grade 4 Intraoperative venous injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543992","Grade 4 Investigations - Other, Specify, CTCAE","C145960","Life-threatening consequences; urgent intervention indicated","Grade 4 Investigations - Other, Specify, CTCAE | Grade 4 Investigations - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543993","Grade 4 Jejunal Perforation, CTCAE","C145964","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Jejunal Perforation, CTCAE | Grade 4 Jejunal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544379","Grade 5 Intraoperative Arterial Injury, CTCAE","C146389","Death","Grade 5 Intraoperative Arterial Injury, CTCAE | Grade 5 Intraoperative arterial injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544380","Grade 5 Intraoperative Breast Injury, CTCAE","C146390","Death","Grade 5 Intraoperative Breast Injury, CTCAE | Grade 5 Intraoperative breast injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544493","Grade 5 Intraoperative Cardiac Injury, CTCAE","C146391","Death","Grade 5 Intraoperative Cardiac Injury, CTCAE | Grade 5 Intraoperative cardiac injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544494","Grade 5 Intraoperative Ear Injury, CTCAE","C146392","Death","Grade 5 Intraoperative Ear Injury, CTCAE | Grade 5 Intraoperative ear injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544495","Grade 5 Intraoperative Endocrine Injury, CTCAE","C146393","Death","Grade 5 Intraoperative Endocrine Injury, CTCAE | Grade 5 Intraoperative endocrine injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544497","Grade 5 Intraoperative Head and Neck Injury, CTCAE","C146395","Death","Grade 5 Intraoperative Head and Neck Injury, CTCAE | Grade 5 Intraoperative head and neck injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544499","Grade 5 Intraoperative Hepatobiliary Injury, CTCAE","C146397","Death","Grade 5 Intraoperative Hepatobiliary Injury, CTCAE | Grade 5 Intraoperative hepatobiliary injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544500","Grade 5 Intraoperative Musculoskeletal Injury, CTCAE","C146398","Death","Grade 5 Intraoperative Musculoskeletal Injury, CTCAE | Grade 5 Intraoperative musculoskeletal injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544485","Grade 5 Intraoperative Neurological Injury, CTCAE","C146399","Death","Grade 5 Intraoperative Neurological Injury, CTCAE | Grade 5 Intraoperative neurological injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543771","Grade 3 Tooth Infection, CTCAE","C145661","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Tooth Infection, CTCAE | Grade 3 Tooth infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543757","Grade 3 Tracheal Mucositis, CTCAE","C145665","Severe pain; hemorrhage or respiratory symptoms; limiting self care ADL","Grade 3 Tracheal Mucositis, CTCAE | Grade 3 Tracheal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543758","Grade 3 Tracheal Obstruction, CTCAE","C145666","Stridor or respiratory distress limiting self care ADL; invasive intervention indicated (e.g., stent, laser)","Grade 3 Tracheal Obstruction, CTCAE | Grade 3 Tracheal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551860","HLA Class II Histocompatibility Antigen, DM Alpha Chain","C150073","HLA class II histocompatibility antigen, DM alpha chain (261 aa, ~29 kDa) is encoded by the human HLA-DMA gene. This protein plays a role in facilitating the presentation of antigenic peptides.","HLA Class II Histocompatibility Antigen, DM Alpha Chain | Class II Histocompatibility Antigen, M Alpha Chain | HLA-DM Histocompatibility Type, Alpha Chain | HLA-DMA | MHC Class II Antigen DMA | MHC Class II Antigen HLA-DM Alpha Chain | MHC Class II HLA-DMA | Really Interesting New Gene 6 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551859","Powder and Solvent for Dispersion for Injection Dosage Form","C150074","Sterile powder and sterile solvent intended for the preparation of a dispersion for injection by dispersing the powder in the solvent.","Powder and Solvent for Dispersion for Injection Dosage Form | Powder and solvent for dispersion for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551854","SLA Gene","C150075","This gene is involved in the regulation of T-cell receptor and B-cell receptor signaling.","SLA Gene | SLA | Src Like Adaptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551853","SLA wt Allele","C150076","Human SLA wild-type allele is located in the vicinity of 8q24.22 and is approximately 66 kb in length. This allele, which encodes Src-like-adapter protein, plays a role in the modulation of signaling from both the B-cell receptor and the T-cell receptor.","SLA wt Allele | SLA1 | SLAP | SLAP1 | Src Like Adaptor wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1453415","SLA protein, human","C150077","Src-like-adapter (276 aa, ~31 kDa) is encoded by the human SLA gene. This protein is involved in the regulation of B-cell receptor and T-cell receptor signaling.","Src-Like-Adapter | SLA | SLAP-1 | Src-Like Adaptor | Src-Like-Adapter Protein 1 | Src-Like-Adaptor | hSLAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551855","MAP4K1 Gene","C150078","This gene plays a role in hematopoiesis.","MAP4K1 Gene | MAP4K1 | Mitogen-Activated Protein Kinase Kinase Kinase Kinase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551850","MAP4K1 wt Allele","C150079","Human MAP4K1 wild-type allele is located in the vicinity of 19q13.2 and is approximately 31 kb in length. This allele, which encodes mitogen-activated protein kinase kinase kinase kinase 1 protein, is involved in protein kinase-dependent signaling.","MAP4K1 wt Allele | HPK1 | MEKKK1 | Mitogen-Activated Protein Kinase Kinase Kinase Kinase 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0531165","human HPK1","C150080","Mitogen-activated protein kinase kinase kinase kinase 1 (833 aa, ~91 kDa) is encoded by the human MAP4K1 gene. This protein plays a role in the modulation of serine/threonine kinase-dependent signaling pathways.","Mitogen-Activated Protein Kinase Kinase Kinase Kinase 1 | EC 2.7.11.1 | Hematopoietic Progenitor Kinase | Hematopoietic Progenitor Kinase 1 | MAP4K1 | MAPK/ERK Kinase Kinase Kinase 1 | MEK Kinase Kinase 1 | MEKKK 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551851","LAPTM5 wt Allele","C150082","Human LAPTM5 wild-type allele is located in the vicinity of 1p35.2 and is approximately 25 kb in length. This allele, which encodes lysosomal-associated transmembrane protein 5, plays a role in the modulation of both embryogenesis and hematopoietic cell differentiation.","LAPTM5 wt Allele | CD40-Ligand-Activated Specific Transcripts Gene | CLAST6 | E3 | KIAA0085 | Lysosomal Protein Transmembrane 5 wt Allele | Lysosome-Associated Protein, Transmembrane 5 Gene | Retinoic Acid-Inducible Gene E3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0528585","LAPTM5 protein, human","C150083","Lysosomal-associated transmembrane protein 5 (262 aa, ~30 kDa) is encoded by the human LAPTM5 gene. This protein is involved in the regulation of both hematopoietic cell differentiation and embryogenesis.","Lysosomal-Associated Transmembrane Protein 5 | E3 Protein | Human Retinoic Acid-Inducible E3 Protein | LAPTM5 | Lysosomal Associated Multispanning Membrane Protein 5 | Lysosomal Multispanning Membrane Protein 5 | Lysosomal-Associated Multitransmembrane Protein 5 | Lysosome-Associated Multispanning Transmembrane Protein 5 | Retinoic Acid-Inducible E3 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0213960","Trecovirsen","C1486","A 25-mer antisense oligodeoxynucleotide phosphorothioate.  GEM-91 is complementary to the gag mRNA of human immunodeficiency virus type 1 (HIV-1), resulting in HIV-1 replication inhibition. (NCI)","Trecovirsen | Deoxyribonucleic acid d(P-thio)(T-C-T-T-C-C-T-C-T-C-T-C-T-A-C-C-C-A-C-G-C-T-C-T-C) | GEM 91 | GEM91 | Gene Expression Modulator 91 | TRECOVIRSEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522557","Recombinant Interleukin-13","C1489","The recombinant analogue of an endogenous cytokine interleukin 13 with potential antineoplastic activity. Produced by lymphocytes and exhibiting a variety of functions, interleukin-13 (therapeutic) inhibits DNA synthesis and regulates inflammatory and immune responses. In animal models, this agent has been shown to kill tumor cells both directly and indirectly by activating the host immune system at the tumor site. (NCI04)","Recombinant Interleukin-13 | IL-13 | Interleukin 13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0215862","Tyrphostin AG 879","C1491","A compound that selectively inhibits protein tyrosine kinase and nerve growth factor-dependent tyrosine phosphorylation. (NCI)","Tyrphostin AG 879 | AG 879 | a-Cyano-(3,5-Di-T-Butyl-4-Hydroxy) Thiocinnamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551247","HIVEP1 Gene","C149344","This gene plays a role in the transcriptional regulation of both viral and cellular genes.","HIVEP1 Gene | HIVEP1 | Human Immunodeficiency Virus Type I Enhancer Binding Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551476","Intramammary Syringe","C149609","Device for introducing a pharmaceutical form through the teat canal.","Intramammary Syringe | Intramammary syringe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551475","Intraocular Instillation Solution Dosage Form","C149610","Liquid sterile preparation consisting of a solution intended to be instilled as drops into an internal part of the eye.","Intraocular Instillation Solution Dosage Form | Intraocular instillation solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551470","Intraportal Route of Administration","C149611","Injection/infusion of a medicinal product into the hepatic portal vein for local delivery to the liver.","Intraportal Route of Administration | Intraportal use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551755","Solution for Injection/Skin-prick Test Dosage Form","C149922","Liquid sterile preparation consisting of a solution containing an allergen product intended for diagnostic use in a skin-prick test or as an injection (usually intraepidermal); it may also be licensed for immunotherapy treatment by injection (usually subcutaneous).","Solution for Injection/Skin-prick Test Dosage Form | Solution for injection/skin-prick test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551754","Solution for Intraocular Irrigation Dosage Form","C149923","Liquid sterile preparation consisting of a solution intended for irrigation of one or more internal structures of the eye, for example during surgical procedures.","Solution for Intraocular Irrigation Dosage Form | Solution for intraocular irrigation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272970","Solution for Iontophoresis Dosage Form","C149924","Liquid preparation consisting of an aqueous solution intended for transdermal delivery by means of iontophoresis.","Solution for Iontophoresis Dosage Form | Solution for iontophoresis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0182061","Organ Preservation Solutions","C149925","Liquid sterile preparation consisting of an aqueous solution of electrolytes typically at a concentration close to the intracellular electrolyte composition, intended for storage, protection and/or perfusion of mammalian body organs that are in particular destined for transplantation.","Solution for Organ Preservation Dosage Form | Solution for organ preservation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551750","Solution for Provocation Test Dosage Form","C149927","Liquid preparation consisting of a solution containing an allergen intended for provocation testing by the nasal, ocular or bronchial routes.","Solution for Provocation Test Dosage Form | Solution for provocation test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551753","Solution for Sealant Dosage Form","C149928","Liquid sterile preparation consisting of a solution intended for the preparation of a sealant.","Solution for Sealant Dosage Form | Solution for sealant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551752","Solution for Skin-prick Test Dosage Form","C149929","Liquid sterile preparation consisting of a solution containing an allergen product intended for diagnostic use in a skin-prick test.","Solution for Skin-prick Test Dosage Form | Solution for skin-prick test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551747","Solution for Skin-scratch Test Dosage Form","C149930","Liquid sterile preparation consisting of a solution containing an allergen product intended for diagnostic use in a skin-scratch test.","Solution for Skin-scratch Test Dosage Form | Solution for skin-scratch test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552001","ATM Kinase Inhibitor AZD1390","C150167","An orally bioavailable inhibitor of ataxia telangiectasia mutated (ATM) kinase, with potential antineoplastic activity. Upon oral administration, AZD1390 targets and binds to ATM, thereby inhibiting the kinase activity of ATM and ATM-mediated signaling. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, induces tumor cell apoptosis, and leads to cell death in ATM-overexpressing tumor cells. AZD1390 hypersensitizes tumors to chemo/radiotherapy. In addition, AZD1390 is able to cross the blood-brain barrier (BBB). ATM, a serine/threonine protein kinase belonging to the phosphatidylinositol 3-kinase-related kinase (PIKK) family of protein kinases, is upregulated in a variety of cancer cell types. It is activated in response to DNA double-strand breaks (DSB) and plays a key role in DNA repair.","ATM Kinase Inhibitor AZD1390 | 7-Fluoro-1-isopropyl-3-methyl-8-(6-(3-(piperidin-1-yl)propoxy)pyridin-3-yl)-1H-imidazo[4,5-c]quinolin-2(3H)-one | AZD-1390 | AZD1390",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551996","ADAMTS20 protein, human","C150168","A disintegrin and metalloproteinase with thrombospondin motifs 20 (1910 aa, ~215 kDa) is encoded by the human ADAMTS20 gene. This protein is involved in remodeling of tissues and the extracellular matrix.","A Disintegrin and Metalloproteinase with Thrombospondin Motifs 20 | A Disintegrin and Metalloprotease with Thrombospondin Motifs 20 | A Disintegrin and Metalloprotease with Thrombospondin Motifs-20 | ADAM-TS 20 | ADAM-TS20 | ADAMTS-20 | ADAMTS20 | EC 3.4.24.-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551998","ANKRD24 wt Allele","C150170","Human ANKRD24 wild-type allele is located in the vicinity of 19p13.3 and is approximately 42 kb in length. This allele, which encodes ankyrin repeat domain-containing protein 24, is involved in protein-protein interactions.","ANKRD24 wt Allele | Ankyrin Repeat Domain 24 wt Allele | KIAA1981",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551997","Ankyrin Repeat Domain-Containing Protein 24","C150171","Ankyrin repeat domain-containing protein 24 (1146 aa, ~124 kDa) is encoded by the human ANKRD24 gene. This protein plays a role in protein-protein interactions.","Ankyrin Repeat Domain-Containing Protein 24 | ANKRD24",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0208317","Dihydrolenperone","C1463","A butyrophenone that has been investigated for antineoplastic activity. (NCI04)","Dihydrolenperone | 1-Butanone, 1-(4-fluorophenyl)-4-[4-[(4-fluorophenyl)hydroxymethyl]-1-piperidi nyl]- | 1-Butanone, 1-(4-fluorophenyl)-4-[4-[(4-fluorophenyl)hydroxymethyl]-1-piperidinyl]- | DIHYDROLENPERONE | Dihydro-lenperone | RMI 11974",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544487","Grade 5 Intraoperative Renal Injury, CTCAE","C146401","Death","Grade 5 Intraoperative Renal Injury, CTCAE | Grade 5 Intraoperative renal injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544488","Grade 5 Intraoperative Reproductive Tract Injury, CTCAE","C146402","Death","Grade 5 Intraoperative Reproductive Tract Injury, CTCAE | Grade 5 Intraoperative reproductive tract injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544489","Grade 5 Intraoperative Respiratory Injury, CTCAE","C146403","Death","Grade 5 Intraoperative Respiratory Injury, CTCAE | Grade 5 Intraoperative respiratory injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544490","Grade 5 Intraoperative Splenic Injury, CTCAE","C146404","Death","Grade 5 Intraoperative Splenic Injury, CTCAE | Grade 5 Intraoperative splenic injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544491","Grade 5 Intraoperative Urinary Injury, CTCAE","C146405","Death","Grade 5 Intraoperative Urinary Injury, CTCAE | Grade 5 Intraoperative urinary injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544492","Grade 5 Intraoperative Venous Injury, CTCAE","C146406","Death","Grade 5 Intraoperative Venous Injury, CTCAE | Grade 5 Intraoperative venous injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544479","Grade 5 Jejunal Stenosis, CTCAE","C146412","Death","Grade 5 Jejunal Stenosis, CTCAE | Grade 5 Jejunal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544480","Grade 5 Joint Infection, CTCAE","C146414","Death","Grade 5 Joint Infection, CTCAE | Grade 5 Joint infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544481","Grade 5 Kidney Anastomotic Leak, CTCAE","C146415","Death","Grade 5 Kidney Anastomotic Leak, CTCAE | Grade 5 Kidney anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544482","Grade 5 Kidney Infection, CTCAE","C146416","Death","Grade 5 Kidney Infection, CTCAE | Grade 5 Kidney infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544483","Grade 5 Large Intestinal Anastomotic Leak, CTCAE","C146417","Death","Grade 5 Large Intestinal Anastomotic Leak, CTCAE | Grade 5 Large intestinal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544484","Grade 5 Laryngeal Edema, CTCAE","C146418","Death","Grade 5 Laryngeal Edema, CTCAE | Grade 5 Laryngeal edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543718","Grade 3 Psychiatric Disorders - Other, Specify, CTCAE","C145568","Severe or medically significant but not immediately life-threatening; limiting self care ADL","Grade 3 Psychiatric Disorders - Other, Specify, CTCAE | Grade 3 Psychiatric disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543719","Grade 3 Psychosis, CTCAE","C145569","Severe psychotic symptoms (e.g., paranoid, extreme disorganization); hospitalization not indicated; new onset","Grade 3 Psychosis, CTCAE | Grade 3 Psychosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543720","Grade 3 Pulmonary Edema, CTCAE","C145570","Severe dyspnea or dyspnea at rest; oxygen indicated; limiting self care ADL","Grade 3 Pulmonary Edema, CTCAE | Grade 3 Pulmonary edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543722","Grade 3 Pulmonary Fistula, CTCAE","C145572","Invasive intervention indicated","Grade 3 Pulmonary Fistula, CTCAE | Grade 3 Pulmonary fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543723","Grade 3 Pulmonary Valve Disease, CTCAE","C145573","Symptomatic; severe regurgitation or stenosis by imaging; symptoms controlled with medical intervention","Grade 3 Pulmonary Valve Disease, CTCAE | Grade 3 Pulmonary valve disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543724","Grade 3 Purpura, CTCAE","C145574","Combined area of lesions covering >30% BSA; spontaneous bleeding","Grade 3 Purpura, CTCAE | Grade 3 Purpura",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543709","Grade 3 Pyramidal Tract Syndrome, CTCAE","C145575","Severe symptoms; limiting self care ADL","Grade 3 Pyramidal Tract Syndrome, CTCAE | Grade 3 Pyramidal tract syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1455461","RNF2 protein, human","C150306","E3 ubiquitin-protein ligase RING2 (336 aa, ~38 kDa) is encoded by the human RNF2 gene. This protein is involved in both transcriptional repression and the monoubiquitination of lysine-119 of histone H2A.","E3 Ubiquitin-Protein Ligase RING2 | EC 2.3.2.27 | HIP2-Interacting Protein 3 | Huntingtin-Interacting Protein 2-Interacting Protein 3 | Protein DinG | RING Finger Protein 1B | RING Finger Protein 2 | RING Finger Protein BAP-1 | RING-Type E3 Ubiquitin Transferase RING2 | RING1b | RNF2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552118","RPS6KA2 wt Allele","C150308","Human RPS6KA2 wild-type allele is located in the vicinity of 6q27 and is approximately 497 kb in length. This allele, which encodes ribosomal protein S6 kinase alpha-2 protein, is involved in mitogen activated protein kinase (MAPK) signaling.","RPS6KA2 wt Allele | HU-2 | MAPKAPK1C | RSK | RSK3 | Ribosomal Protein S6 Kinase A2 wt Allele | Ribosomal Protein S6 Kinase, 90-kD, 2 Gene | Ribosomal Protein S6 Kinase, 90kD, Polypeptide 2 Gene | Ribosomal Protein S6 Kinase, 90kDa, Polypeptide 2 Gene | S6K-alpha | S6K-alpha2 | p90-RSK3 | p90RSK2 | pp90RSK3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2002840","ribosomal protein S6 kinase, 90kDa, polypeptide 2, human","C150309","Ribosomal protein S6 kinase alpha-2 (733 aa, ~83 kDa) is encoded by the human RPS6KA2 gene. This protein plays a role in the modulation of transcription, cellular proliferation, differentiation, and survival.","Ribosomal Protein S6 Kinase Alpha-2 | EC 2.7.11.1 | MAP Kinase-Activated Protein Kinase 1c | MAPK-Activated Protein Kinase 1c | MAPKAP Kinase 1c | MAPKAPK-1c | Mitogen-Activated Protein Kinase-Activated Protein Kinase 1c | RPS6KA2 | RSK-3 | Ribosomal S6 Kinase 3 | S6K-Alpha-2 | p90-RSK 2 | p90RSK2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552114","RYR1 wt Allele","C150312","Human RYR1 wild-type allele is located in the vicinity of 19q13.2 and is approximately 154 kb in length. This allele, which encodes ryanodine receptor 1 protein, plays a role in skeletal muscle contraction and neuronal signaling. Mutation of the gene is associated with central core disease, King-Denborough syndrome, minicore myopathy with external ophthalmoplegia, congenital neuromuscular disease with uniform type 1 fiber and susceptibility to malignant hyperthermia type 1.","RYR1 wt Allele | CCO | Central Core Disease of Muscle Gene | MHS | MHS1 | PPP1R137 | Protein Phosphatase 1, Regulatory Subunit 137 Gene | RYDR | RYR | RYR-1 | Ryanodine Receptor 1 (Skeletal) Gene | SKRR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552109","Ryanodine Receptor 1","C150313","Ryanodine receptor 1 (5038 aa, ~565 kDa) is encoded by the human RYR1 gene. This protein is involved in the transport of calcium ions from the sarcoplasmic reticulum and neurons.","Ryanodine Receptor 1 | RYR-1 | RYR1 | RyR1 | Sarcoplasmic Reticulum Calcium Release Channel | Skeletal Muscle Calcium Release Channel | Skeletal Muscle Ryanodine Receptor | Skeletal Muscle-Type Ryanodine Receptor | Type 1 Ryanodine Receptor | Type 1-Like Ryanodine Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554819","Intraruminal Device Dosage Form Category","C149612","A type of solid pharmaceutical dose form intended for administration to ruminant animals where it is retained in the rumen for release of the active substance(s), usually over an extended period of time.","Intraruminal Device Dosage Form Category | Intraruminal device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551472","Intrauterine Capsule Dosage Form","C149613","Solid single-dose preparation for veterinary use consisting of a soft capsule containing a liquid or semi-solid preparation intended for intrauterine use, including preparations releasing their contents over an extended period of time.","Intrauterine Capsule Dosage Form | Intrauterine capsule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551466","Intrauterine Emulsion Dosage Form","C149615","Liquid preparation for veterinary use consisting of an emulsion intended for intrauterine use.","Intrauterine Emulsion Dosage Form | Intrauterine emulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551465","Intrauterine Foam Dosage Form","C149616","Liquid preparation for veterinary use, usually presented in a pressurized container provided with an applicator suitable for delivery to the uterus of foam containing large volumes of gas dispersed in a liquid containing the active substance(s).","Intrauterine Foam Dosage Form | Intrauterine foam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551468","Intrauterine Solution Dosage Form","C149617","Liquid preparation for veterinary use consisting of a solution intended for intrauterine use.","Intrauterine Solution Dosage Form | Intrauterine solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551467","Intrauterine Suspension Dosage Form","C149618","Liquid preparation for veterinary use consisting of a suspension intended for intrauterine use.","Intrauterine Suspension Dosage Form | Intrauterine suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272901","Intravesical Solution Dosage Form","C149620","Liquid preparation consisting of an aqueous solution intended for intravesical use by means of a suitable applicator.","Intravesical Solution Dosage Form | Intravesical solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551464","Intravesical Solution/Solution for Injection Dosage Form","C149621","Liquid sterile preparation consisting of a solution intended for intravesical use or for administration by injection.","Intravesical Solution/Solution for Injection Dosage Form | Intravesical solution/solution for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551463","Intravesical Suspension Dosage Form","C149622","Liquid preparation consisting of a small-volume suspension intended for intravesical use by means of a suitable applicator.","Intravesical Suspension Dosage Form | Intravesical suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551459","Intravesical/Urethral","C149623","Relating to the urinary bladder or the urethra as the intended site of administration.","Intravesical/Urethral | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551458","Intravitreal implant in applicator","C149624","Medicinal product consisting of an intravitreal implant presented in an applicator.","Intravitreal Implant in Applicator Dosage Form | Intravitreal Implant in Applicator | Intravitreal implant in applicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551460","Radiopharmaceutical Preparation Kit Dosage Form","C149625","A preparation to be reconstituted or combined with radionuclides in the final radiopharmaceutical, usually prior to its administration.","Radiopharmaceutical Preparation Kit Dosage Form | Kit for radiopharmaceutical preparation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556865","Lacquer Dosage Form Category","C149626","A type of liquid pharmaceutical dose form consisting of one or more substances dissolved or suspended in a volatile solvent that evaporates to leave a hard coating.","Lacquer Dosage Form Category | Lacquer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551455","Laryngopharyngeal Solution Dosage Form","C149627","Liquid preparation consisting of a solution intended for administration to the laryngopharynx for a local effect, other than by spraying.","Laryngopharyngeal Solution Dosage Form | Laryngopharyngeal solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272872","Pressurized Inhalation, Solution Dosage Form","C149867","Liquid, usually multidose preparation consisting of a solution intended for inhalation use. The preparation is presented in a pressurized container usually fitted with a metering dose valve.","Pressurized Inhalation, Solution Dosage Form | Pressurised inhalation, solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551991","ARFGAP3 wt Allele","C150173","Human ARFGAP3 wild-type allele is located in the vicinity of 22q13.2 and is approximately 62 kb in length. This allele, which encodes ADP-ribosylation factor GTPase-activating protein 3, plays a role in the modulation of ADP-ribosylation factor 1-dependent secretory pathways.","ARFGAP3 wt Allele | ADP Ribosylation Factor GTPase Activating Protein 3 wt Allele | ADP-Ribosylation Factor GTPase Activating Protein 1 Gene | ARFGAP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551994","ADP-Ribosylation Factor GTPase-Activating Protein 3","C150174","ADP-ribosylation factor GTPase-activating protein 3 (516 aa, ~57 kDa) is encoded by the human ARFGAP3 gene. This protein is involved in the promotion of ADP-ribosylation factor 1 GTPase activity.","ADP-Ribosylation Factor GTPase-Activating Protein 3 | ARF GAP 3 | ARFGAP3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551987","BOD1L1 wt Allele","C150177","Human BOD1L1 wild-type allele is located in the vicinity of 4p15.33 and is approximately 59 kb in length. This allele, which encodes biorientation of chromosomes in cell division protein 1-like 1 protein, is involved in replication fork maintenance.","BOD1L1 wt Allele | BOD1L | Biorientation of Chromosomes in Cell Division 1 Like 1 wt Allele | Biorientation of Chromosomes in Cell Division 1-Like Gene | FAM44A | FLJ33215 | Family with Sequence Similarity 44, Member A Gene | KIAA1327",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551990","Biorientation of Chromosomes in Cell Division Protein 1-Like 1","C150178","Biorientation of chromosomes in cell division protein 1-like 1 (3051 aa, ~330 kDa) is encoded by the human BOD1L1 gene. This protein plays a role in promoting the repair of damaged replication forks.","Biorientation of Chromosomes in Cell Division Protein 1-Like 1 | BOD1-Like Protein 1 | BOD1L1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551989","Non-Neoplastic Optic Nerve Disorder","C150179","A non-neoplastic disorder that affects the optic nerve.","Non-Neoplastic Optic Nerve Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551311","Concentrate for Solution for Hemodialysis Dosage Form","C149400","Liquid preparation consisting of an aqueous solution of electrolytes intended to be diluted with water of a suitable quality to obtain a solution for hemodialysis.C80","Concentrate for Solution for Hemodialysis Dosage Form | Concentrate for solution for haemodialysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551314","Concentrate for Solution for Infusion Dosage Form","C149401","Liquid sterile preparation consisting of an aqueous solution intended to be diluted in the specified aqueous liquid to obtain a solution for infusion. It may be added to a solution for infusion during the administration.","Concentrate for Solution for Infusion Dosage Form | Concentrate for solution for infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551313","Concentrate for Solution for Injection Dosage Form","C149402","Liquid sterile preparation intended to be diluted in the specified liquid to obtain a solution for injection.","Concentrate for Solution for Injection Dosage Form | Concentrate for solution for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543710","Grade 3 Radiation Recall Reaction (Dermatologic), CTCAE","C145576","Moist desquamation in areas other than skin folds and creases; bleeding induced by minor trauma or abrasion","Grade 3 Radiation Recall Reaction (Dermatologic), CTCAE | Grade 3 Radiation recall reaction (dermatologic)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543711","Grade 3 Radiculitis, CTCAE","C145577","Severe symptoms; limiting self care ADL","Grade 3 Radiculitis, CTCAE | Grade 3 Radiculitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543712","Grade 3 Rash Acneiform, CTCAE","C145578","Papules and/or pustules covering >30% BSA with moderate or severe symptoms; limiting self-care ADL; associated with local superinfection with oral antibiotics indicated","Grade 3 Rash Acneiform, CTCAE | Grade 3 Rash acneiform",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543713","Grade 3 Rash Maculo-Papular, CTCAE","C145579","Macules/papules covering >30% BSA with moderate or severe symptoms; limiting self care ADL","Grade 3 Rash Maculo-Papular, CTCAE | Grade 3 Rash maculo-papular",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543715","Grade 3 Rectal Anastomotic Leak, CTCAE","C145581","Severe symptoms; invasive intervention indicated","Grade 3 Rectal Anastomotic Leak, CTCAE | Grade 3 Rectal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543716","Grade 3 Rectal Fissure, CTCAE","C145582","Invasive intervention indicated","Grade 3 Rectal Fissure, CTCAE | Grade 3 Rectal fissure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543701","Grade 3 Rectal Mucositis, CTCAE","C145585","Severe symptoms; limiting self care ADL","Grade 3 Rectal Mucositis, CTCAE | Grade 3 Rectal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543702","Grade 3 Rectal Pain, CTCAE","C145588","Severe pain; limiting self care ADL","Grade 3 Rectal Pain, CTCAE | Grade 3 Rectal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543703","Grade 3 Rectal Stenosis, CTCAE","C145590","Severely altered GI function; tube feeding or hospitalization indicated; elective operative intervention indicated","Grade 3 Rectal Stenosis, CTCAE | Grade 3 Rectal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543704","Grade 3 Recurrent Laryngeal Nerve Palsy, CTCAE","C145592","Severe symptoms; medical intervention indicated (e.g., thyroplasty, vocal cord injection)","Grade 3 Recurrent Laryngeal Nerve Palsy, CTCAE | Grade 3 Recurrent laryngeal nerve palsy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543705","Grade 3 Renal and Urinary Disorders - Other, Specify, CTCAE","C145593","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL","Grade 3 Renal and Urinary Disorders - Other, Specify, CTCAE | Grade 3 Renal and urinary disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543707","Grade 3 Renal Colic, CTCAE","C145595","Hospitalization indicated; limiting self care ADL","Grade 3 Renal Colic, CTCAE | Grade 3 Renal colic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543708","Grade 3 Reproductive System and Breast Disorders - Other, Specify, CTCAE","C145597","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL","Grade 3 Reproductive System and Breast Disorders - Other, Specify, CTCAE | Grade 3 Reproductive system and breast disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552111","SAMD9 wt Allele","C150315","Human SAMD9 wild-type allele is located in the vicinity of 7q21.2 and is approximately 19 kb in length. This allele, which encodes sterile alpha motif domain-containing protein 9, may be involved in extra-osseous calcification, inflammatory responses and endosomal vesicle fusion. Mutation of the gene is associated with normophosphatemic familial tumoral calcinosis and MIRAGE syndrome.","SAMD9 wt Allele | C7orf5 | Chromosome 7 Open Reading Frame 5 Gene | DRIF1 | Expressed in Aggressive Fibromatosis Gene | FLJ20073 | KIAA2004 | MIRAGE | NFTC | OEF1 | OEF2 | Sterile Alpha Motif Domain Containing 9 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552110","Refractory Bladder Carcinoma","C150316","Bladder carcinoma that does not respond to treatment.","Refractory Bladder Carcinoma | Refractory Bladder Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552104","SMUG1 protein, human","C150318","Single-strand selective monofunctional uracil DNA glycosylase (270 aa, ~30 kDa) is encoded by the human SMUG1 gene. This protein is involved in DNA repair.","Single-Strand Selective Monofunctional Uracil DNA Glycosylase | EC 3.2.2.- | SMUG1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1692876","Implantation","C149562","The technique of administration of a pharmaceutical product by placing it within a tissue of the body, usually as part of a surgical procedure.","Implantation Method of Administration | Implantation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272900","Implantation Chain Dosage Form","C149563","Solid sterile preparation consisting of small spheres mounted on a non-degradable thread to form a chain that allows withdrawal of the remainder of the chain after a certain period of action. Each implantation chain is presented in a sterile container. The implantation chain is intended for release over an extended period of time in order to obtain local or systemic effect.","Implantation Chain Dosage Form | Implantation chain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551394","Implantation Matrix Dosage Form","C149564","Solid sterile preparation consisting of a usually pliable, absorbent piece of material (e.g. collagen), usually impregnated with a liquid preparation, intended for implantation in the body. The material may be cut into smaller pieces before implantation, and may be shaped around a tissue (e.g. a bone) or inserted into a medical device that is then implanted. Implantation matrices are intended for release over an extended period of time, usually in order to obtain a local effect. Usually the matrix disappears with time.","Implantation Matrix Dosage Form | Implantation matrix",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551396","Implantation Paste Dosage Form","C149565","Semi-solid sterile preparation containing large proportions of solids finely dispersed in the basis, intended to be implanted in the body for release of the active substance(s) over an extended period of time, usually to obtain a systemic effect.","Implantation Paste Dosage Form | Implantation paste",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551395","Implantation Suspension Dosage Form","C149566","Liquid sterile preparation consisting of a suspension intended for implantation in the body; the active substance(s) are released over an extended period of time to obtain a local or systemic effect.","Implantation Suspension Dosage Form | Implantation suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272899","Implantation Tablet Dosage Form","C149567","Solid sterile preparation prepared by compression of a solid active substance as such or of a formulation thereof into an implant of a size and shape suitable for implantation, usually subcutaneously. Each implantation tablet is presented in a sterile container. Implantation tablets are intended for release over an extended period of time in order to obtain local or systemic effect.","Implantation Tablet Dosage Form | Implantation tablet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551392","Implanter Device","C149568","Device for administering implants.","Implanter Device | Implanter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272873","Pressurized Inhalation, Suspension Dosage Form","C149868","Liquid, usually multidose preparation consisting of a suspension intended for inhalation use. The preparation is presented in a pressurized container fitted with a metering dose valve.","Pressurized Inhalation, Suspension Dosage Form | Pressurised inhalation, suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551692","Prick Test Applicator","C149869","Device for prick testing of allergen products.","Prick Test Applicator | Prick test applicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551689","Prolonged-Release Capsule, Hard Dosage Form","C149871","Solid single-dose preparation consisting of a hard shell containing a solid or semi-solid formulation, showing a slower release of the active substance(s) than that of a conventional-release capsule. Prolonged release is achieved by a special formulation design and/or manufacturing method. Hard prolonged-release capsules are intended for oral use.","Prolonged-Release Capsule, Hard Dosage Form | Prolonged-release capsule, hard",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551691","Prolonged-Release Capsule, Soft Dosage Form","C149872","Solid single-dose preparation consisting of a soft shell containing a semi-solid or liquid formulation, showing a slower release of the active substance(s) than that of a conventional-release capsule. Prolonged release is achieved by a special formulation design and/or manufacturing method. Soft prolonged-release capsules are intended for oral use.","Prolonged-Release Capsule, Soft Dosage Form | Prolonged-release capsule, soft",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551690","Extended Release Granule for Oral Suspension Dosage Form","C149873","Solid preparation consisting of prolonged-release granules intended to be dispersed in the specified liquid to obtain an oral suspension.","Extended Release Granule for Oral Suspension Dosage Form | Extended Release Granule for Oral Suspension | Prolonged-release granules for oral suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551686","Prolonged-Release Granules for Oral Suspension in Sachet Dosage Form","C149874","Medicinal product consisting of prolonged-release granules for oral suspension presented in a sachet.","Prolonged-Release Granules for Oral Suspension in Sachet Dosage Form | Prolonged-Release Granules for Oral Suspension in Sachet | Prolonged-release granules for oral suspension in sachet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551685","Prolonged-release granules in sachet","C149875","Medicinal product consisting of prolonged-release granules presented in a sachet.","Prolonged-Release Granules in Sachet Dosage Form | Prolonged-Release Granules in Sachet | Prolonged-release granules in sachet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551688","Prolonged-Release Solution for Injection Dosage Form","C149876","Liquid sterile preparation consisting of a solution intended for administration by injection; the active substance(s) are released over an extended period of time.","Prolonged-Release Solution for Injection Dosage Form | Prolonged-release solution for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551687","Prolonged-Release Suspension for Injection Dosage Form","C149877","Liquid sterile preparation consisting of a suspension intended for administration by injection; the active substance(s) are released over an extended period of time.","Prolonged-Release Suspension for Injection Dosage Form | Prolonged-release suspension for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551683","Prolonged-release suspension for injection in pre-filled syringe","C149878","Medicinal product consisting of a prolonged-release suspension for injection presented in a pre-filled syringe.","Prolonged-Release Suspension for Injection in Pre-filled Syringe Dosage Form | Prolonged-Release Suspension for Injection in Pre-filled Syringe | Prolonged-release suspension for injection in pre-filled syringe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551682","Pulsatile-release intraruminal device","C149879","Solid single-dose preparation intended for oral use in ruminant animals. It is designed to be retained in the rumen to deliver the active substance(s) in a pulsatile manner by the release of a specific quantity of active substance(s) at one or several defined intermediate intervals. This may be achieved by corrosion by ruminal fluids of the metallic elements of the intraruminal device which leads to sequential release of the constituent units which are usually in the form of tablets.","Pulsatile Release Intraruminal Device Dosage Form | Pulsatile-release intraruminal device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272909","Precursor Radiopharmaceutical Dosage Form","C149880","A radionuclide produced for the radio-labelling of another substance prior to administration.","Precursor Radiopharmaceutical Dosage Form | Radiopharmaceutical precursor",,,,,,,,,,,,,,,"4299187","Radiopharmaceutical precursor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL551684","Precursor Radiopharmaceutical Solution Dosage Form","C149881","Liquid preparation consisting of a solution containing a radionuclide produced for the radio-labelling of another substance prior to administration.","Precursor Radiopharmaceutical Solution Dosage Form | Radiopharmaceutical precursor, solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551308","Concentrate for Solution for Injection/Infusion Dosage Form","C149403","Sterile liquid preparation intended to be diluted in the specified liquid to obtain a solution for injection/infusion.","Concentrate for Solution for Injection/Infusion Dosage Form | Concentrate for solution for injection/infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551307","Concentrate for Solution for Intraocular Irrigation Dosage Form","C149404","Liquid sterile preparation intended to be diluted in the specified liquid to obtain a solution for intraocular irrigation.","Concentrate for Solution for Intraocular Irrigation Dosage Form | Concentrate for solution for intraocular irrigation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551310","Concentrate for Solution for Peritoneal Dialysis Dosage Form","C149405","Liquid sterile preparation intended to be diluted in the specified liquid to obtain a solution for peritoneal dialysis.","Concentrate for Solution for Peritoneal Dialysis Dosage Form | Concentrate for solution for peritoneal dialysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551305","Concentrate for Suspension for Injection Dosage Form","C149407","Liquid sterile preparation intended to be diluted in the specified liquid to obtain a suspension for injection.","Concentrate for Suspension for Injection Dosage Form | Concentrate for suspension for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551304","Continuous Release Intraruminal Device Dosage Form","C149408","Solid single-dose preparation intended for oral use in ruminant animals. It is designed to be retained in the rumen to deliver the active substance(s) in a continuous manner at a defined rate over a defined period of time. This may be achieved by erosion, corrosion, diffusion, osmotic pressure or any other suitable chemical, physical or physico-chemical means.","Continuous Release Intraruminal Device Dosage Form | Continuous-release intraruminal device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552463","Conventional Release Mechanism of Action","C149409","Release of the substance(s) in a way that is not deliberately modified by a special formulation design and/or manufacturing method.","Conventional Release Mechanism of Action | Conventional",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551306","Cream plus Pessary Dosage Form","C149410","Combination package consisting of a cream and a pessary.","Cream plus Pessary Dosage Form | Cream + pessary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551301","Cream plus Soft Vaginal Capsule Dosage Form","C149411","Combination package consisting of a cream and a soft vaginal capsule.","Cream plus Soft Vaginal Capsule Dosage Form | Cream + vaginal capsule, soft",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551300","Cream plus Vaginal Tablet Dosage Form","C149412","Combination package consisting of a cream and a vaginal tablet.","Cream plus Vaginal Tablet Dosage Form | Cream + vaginal tablet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551303","Cutaneous Emulsion Dosage Form","C149413","Liquid, usually multidose preparation consisting of an emulsion intended for cutaneous use.","Cutaneous Emulsion Dosage Form | Cutaneous emulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551302","Topical Paste Dosage Form","C149414","Semi-solid single-dose or multidose preparation containing a large proportion of finely divided solids dispersed in the basis, intended for cutaneous use.","Topical Paste Dosage Form | Cutaneous paste",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551297","Cutaneous Solution plus Medicated Sponge Dosage Form","C149415","Combination package consisting of a cutaneous solution and a medicated sponge.","Cutaneous Solution plus Medicated Sponge Dosage Form | Cutaneous solution + medicated sponge",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551518","Nasal Drops, Powder and Solvent for Solution Dosage Form","C149679","Powder and solvent intended for the preparation of nasal drops, solution, by dissolving the powder in the solvent.","Nasal Drops, Powder and Solvent for Solution Dosage Form | Nasal drops, powder and solvent for solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551517","Nasal Drops, Powder for Solution Dosage Form","C149680","Solid preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain a nasal drops solution.","Nasal Drops, Powder for Solution Dosage Form | Nasal drops, powder for solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551520","Nasal drops, solution in single-dose container","C149681","Medicinal product consisting of a nasal drops solution presented in a single-dose container.","Nasal Drops, Solution in Single-dose Container Dosage Form | Nasal Drops, Solution in Single-dose Container | Nasal drops, solution in single-dose container",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544762","Givosiran","C146805","A proprietary enhanced stabilization chemistry (ESC)-stabilized conjugate composed of the liver-targeted ligand N-acetylgalactosamine (GalNAc) conjugated to small-interfering RNAs (siRNAs) directed against the liver-expressed enzyme aminolevulinic acid synthase 1 (delta-aminolevulinate synthase 1; ALAS1; ALAS-1) that can potentially be used in the treatment of acute hepatic porphyrias (AHPs). Upon subcutaneous administration of givosiran, the GalNAc moiety targets and binds with high affinity to asialoglycoprotein receptors (ASGPRs) expressed on hepatocytes. Once inside the cell, the siRNAs bind to and silence ALAS1 mRNA and inhibit both the translation and expression of the ALAS1 protein. This prevents delta-aminolevulinic acid (ALA) formation, decreases 5-ALA levels and prevents the production of porphyrins and hemes, such as porphobilinogen (PBG). AHPs are a group of metabolic disorders caused by deficiencies of specific enzymes that are responsible for hemoglobulin biosynthesis within the liver, which leads to the accumulation of toxic intermediates, such as ALA and PBG. ALAS1, a liver-expressed, rate-limiting enzyme in the heme biosynthesis pathway, is responsible for the formation of ALA from succinyl-CoA and glycine. ESC enables the subcutaneous dosing of givosiran with increased efficacy, durability and a wide therapeutic index as compared to non-ESC GalNAc-siRNA conjugates.","Givosiran | ALN AS1 | ALN-AS1 | ESC-GalNAc-siRNA Conjugate ALN-AS1 | GIVOSIRAN | RNA Interference Therapeutic ALN-AS1 | RNAi ALN-AS1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544763","Allogeneic CD123-specific Universal CAR123-expressing T-lymphocytes","C146806","Allogeneic, off-the-shelf, universal transcription activator-like effector nuclease (TALEN)-engineered T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) human interleukin-3 receptor alpha chain (IL3RA; cluster of differentiation 123; CD123), with potential immunomodulating and antineoplastic activities.  Upon transfusion of allogeneic CD123-specific universal CAR123-expressing T-lymphocytes (UCART123), these cells target and bind to cancer cells expressing CD123. This induces selective toxicity in and causes lysis of CD123-expressing tumor cells. CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with both increased leukemic cell proliferation and aggressiveness. Using TALEN technology, the UCART123 cells no longer express the endogenous T-cell receptor (TCR) thereby abrogating the potential induction of graft-versus-host disease (GvHD) by the donor T-cells.","Allogeneic CD123-specific Universal CAR123-expressing T-lymphocytes | Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor | UCART123 | UCART123 T Cells | Universal Chimeric Antigen Receptor T-cell 123 | Universal Chimeric Antigen Receptor T-cells targeting CD123 | Universal TALEN Gene-edited CART123 Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544748","ATR Inhibitor BAY1895344","C146807","An orally available ataxia telangiectasia and Rad3-related (ATR)-specific kinase inhibitor, with potential antineoplastic activity. Upon oral administration, elimusertib selectively binds to and inhibits the activity of ATR, which prevents ATR-mediated signaling. This inhibits DNA damage checkpoint activation, disrupts DNA damage repair and induces apoptosis in ATR-overexpressing tumor cells. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression and cell survival.","Elimusertib | ATR Inhibitor BAY1895344 | ATR Kinase Inhibitor BAY1895344 | BAY 1895344 | BAY-1895344 | BAY1895344 | ELIMUSERTIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544749","Anti-IL17A Monoclonal Antibody CJM112","C146808","A human immunoglobulin G1 (IgG1) monoclonal antibody against the pro-inflammatory cytokine interleukin 17A (IL-17A; IL-17), with potential anti-inflammatory activity. Upon subcutaneous administration, anti-IL17A monoclonal antibody CJM112 selectively targets and binds to IL-17A, thereby neutralizing the IL-17A protein. This prevents binding of IL-17A to the IL-17 receptor (IL-17R), and inhibits IL-17A/IL-17R-mediated signaling and inflammation mediated by this pathway. IL-17A is mainly produced by inflammatory T helper 17 cells (Th17), and certain lymphocytes. IL-17A production is upregulated in many immune-mediated inflammatory diseases, such as psoriasis and multiple sclerosis (MS), and plays a key role in the development of inflammation and the immune response.","Anti-IL17A Monoclonal Antibody CJM112 | CJM 112 | CJM-112 | CJM112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543994","Grade 4 Jejunal Stenosis, CTCAE","C145965","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Jejunal Stenosis, CTCAE | Grade 4 Jejunal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543995","Grade 4 Joint Infection, CTCAE","C145967","Life-threatening consequences; urgent intervention indicated","Grade 4 Joint Infection, CTCAE | Grade 4 Joint infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544109","Grade 4 Kidney Infection, CTCAE","C145969","Life-threatening consequences; urgent intervention indicated","Grade 4 Kidney Infection, CTCAE | Grade 4 Kidney infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554821","Impregnated Material Dosage Form Category","C149570","A type of solid pharmaceutical dose form consisting of a material onto or into which active substance(s) are absorbed for subsequent release after administration, often over an extended period of time.","Impregnated Material Dosage Form Category | Impregnated material",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272918","Impregnated Pad Dosage Form","C149571","Solid preparation consisting of a piece of absorbent material impregnated with a liquid preparation.","Impregnated Pad Dosage Form | Impregnated pad",,,,,,,,,,,,,,,"4300031","Impregnated pad",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL551389","Impregnated Plug Dosage Form","C149572","Solid preparation consisting of a piece of material (e.g. polyethylene), usually porous, in which a liquid, semi-solid or solid preparation is impregnated.","Impregnated Plug Dosage Form | Impregnated plug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551391","In Drinking Water Use Route of Administration","C149573","Administration of a veterinary medicinal product by incorporation into the animal drinking water.","In Drinking Water Use Route of Administration | In drinking water use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551390","In Drinking Water/Milk Use Route of Administration","C149574","Administration of a veterinary medicinal product by incorporation into the animal drinking water, milk or milk replacer.C238","In Drinking Water/Milk Use Route of Administration | In drinking water/milk use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2827729","In-Ovo Route of Administration","C149575","Administration of a veterinary medicinal product through the shell into an embryonated egg.","In Ovo Route of Administration | In Ovo | In ovo | In-Ovo | In-Ovo Route of Administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551387","In-feed Use Route of Administration","C149576","Administration of a veterinary medicinal product by incorporation into the animal feed.","In-feed Use Route of Administration | In-feed use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551627","Powder for Topical Solution Dosage Form","C149815","Solid preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain a cutaneous solution.","Powder for Topical Solution Dosage Form | Powder for cutaneous solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551622","Powder for Dental Cement Dosage Form","C149816","Solid preparation consisting of one or more powders intended for use in the preparation of a dental cement.","Powder for Dental Cement Dosage Form | Powder for dental cement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551621","Powder for dental gel","C149817","Solid preparation consisting of one or more powders intended to be mixed with the specified liquid or gel to obtain a dental gel.","Powder for Dental Gel Dosage Form | Powder for dental gel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551624","Powder for Dental Solution Dosage Form","C149818","Solid preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain a dental solution.","Powder for Dental Solution Dosage Form | Powder for dental solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551623","Powder for Dip Solution Dosage Form","C149819","Solid preparation for veterinary use consisting of one or more powders intended to be dissolved in the specified liquid to obtain a dip solution.","Powder for Dip Solution Dosage Form | Powder for dip solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551618","Powder for Dispersion for Infusion Dosage Form","C149820","Solid sterile preparation consisting of one or more powders intended to be dispersed in the specified liquid to obtain a dispersion for infusion.","Powder for Dispersion for Infusion Dosage Form | Powder for dispersion for infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551620","Powder for Emulsion for Injection Dosage Form","C149822","Solid sterile preparation consisting of one or more powders intended to be mixed with the specified liquid to obtain an emulsion for injection.","Powder for Emulsion for Injection Dosage Form | Powder for emulsion for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272869","Rectal Capsule Dosage Form","C149882","Solid single-dose preparation consisting of a soft capsule of elongated shape suitable for rectal use, containing a liquid or semi-solid formulation, and which may have a lubricating coating.","Rectal Capsule Dosage Form | Rectal capsule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551921","Anti-BCMA/PBD ADC MEDI2228","C150127","An antibody-drug conjugate (ADC) consisting of a fully human monoclonal antibody against the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA, TNFRSF17) that is site-specifically conjugated, via a protease-cleavable linker, to a cytotoxic, DNA minor groove crosslinking agent and pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of anti-BCMA/PBD ADC MEDI2228, the antibody moiety targets the cell surface antigen BCMA expressed on certain cancer cells. Upon antibody/antigen binding, internalization and lysosome-mediated cleavage, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of BCMA-overexpressing tumor cells. BCMA, a receptor for a proliferation-inducing ligand (APRIL; tumor necrosis factor ligand superfamily member 13; TNFSF13), and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in plasma survival; it is found on the surfaces of plasma cells and is overexpressed on malignant plasma cells.","Anti-BCMA/PBD ADC MEDI2228 | ADC MEDI2228 | Anti-BCMA ADC MEDI2228 | Anti-BCMA/PBD MEDI2228 | Antibody-drug Conjugate MEDI2228 | MEDI 2228 | MEDI-2228 | MEDI2228",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551922","Uveal Melanoma Metastatic in the Liver","C150130","A melanoma that originates from melanocytes of the uveal tract and has spread to the liver.","Uveal Melanoma Metastatic in the Liver | Metastatic Uveal Melanoma in the Liver",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551918","Recurrent T Acute Lymphoblastic Leukemia","C150131","The reemergence of T acute lymphoblastic leukemia after a period of remission.","Recurrent T Acute Lymphoblastic Leukemia | Recurrent T-Acute Lymphoblastic Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551917","Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma","C150132","The reemergence of monomorphic epitheliotropic intestinal T-cell lymphoma after a period of remission.","Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551919","Recurrent T-Cell Prolymphocytic Leukemia","C150133","The reemergence of T-cell prolymphocytic leukemia after a period of remission.","Recurrent T-Cell Prolymphocytic Leukemia | Prolymphocytic leukemia of T-cell type, in relapse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4022560","Splanchnic Vein Thrombosis","C150134","Thrombosis within the hepatic portal system.","Splanchnic Vein Thrombosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551519","Emulsion Nasal Spray Dosage Form","C149682","Liquid single-dose or multidose preparation consisting of an emulsion in a container with or without a metering dose valve or in a container with a spray pump or equivalent device to create a spray, intended for nasal use.","Emulsion Nasal Spray Dosage Form | Nasal spray, emulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551514","Nasal spray, lyophilisate and solvent for suspension","C149683","Lyophilisate and solvent intended for the preparation of a nasal spray, suspension, for veterinary use, by dispersing the lyophilisate in the solvent.","Nasal Spray, Lyophilisate and Solvent for Suspension Dosage Form | Nasal spray, lyophilisate and solvent for suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551513","Nasal spray, lyophilisate for suspension","C149684","Solid preparation consisting of a freeze-dried powder intended to be dispersed in the specified liquid to obtain a nasal spray, suspension.","Nasal Spray, Lyophilisate for Suspension Dosage Form | Nasal spray, lyophilisate for suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551516","Nasal Spray, Powder for Solution Dosage Form","C149685","Solid preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain a nasal spray solution.","Nasal Spray, Powder for Solution Dosage Form | Nasal spray, powder for solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551515","Nasal Spray, Solution Dosage Form","C149686","Liquid single-dose or multidose preparation consisting of a solution in a container with or without a metering dose valve or in a container with a spray pump or equivalent device to create a spray, intended for nasal use.","Nasal Spray, Solution Dosage Form | Nasal spray, solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551510","Nasal Spray, Solution/Oromucosal Solution Dosage Form","C149688","Liquid preparation consisting of a solution intended for use as a nasal spray or an oromucosal solution.","Nasal Spray, Solution/Oromucosal Solution Dosage Form | Nasal spray, solution/oromucosal solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551512","Nasal Spray, Suspension Dosage Form","C149689","Liquid single-dose or multidose preparation consisting of a suspension in a container with or without a metering dose valve or in a container with a spray pump or equivalent device to create a spray, intended for nasal use.","Nasal Spray, Suspension Dosage Form | Nasal spray, suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1273003","Nasal Stick Dosage Form","C149690","Solid single-dose preparation, usually rod-shaped or conical, intended for nasal use to obtain a local effect.","Nasal Stick Dosage Form | Nasal stick",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552470","Nasal Wash Dosage Form","C149691","Liquid single-dose or multidose preparation consisting of usually an aqueous isotonic solution intended for cleansing the nasal cavities.","Nasal Wash Dosage Form | Nasal wash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551507","Nasal/Oromucosal Solution Dosage Form","C149692","Liquid preparation consisting of a solution intended for nasal or oromucosal application.","Nasal/Oromucosal Solution Dosage Form | Nasal/oromucosal solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551509","Nasal/Oromucosal Spray Solution Dosage Form","C149693","Liquid preparation consisting of a solution in a container with or without a metering dose valve or in a container with a spray pump, intended for nasal or oromucosal use.","Nasal/Oromucosal Spray Solution Dosage Form | Nasal/oromucosal spray, solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551508","Nebulization Solution Dosage Form","C149694","Liquid preparation consisting of a solution intended for conversion by nebulizers into an aerosol.","Nebulization Solution Dosage Form | Nebulisation solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551504","Nebulizer Route of Administration","C149695","Administration of medicinal product converted into an aerosol.","Nebulizer Route of Administration | Nebulisation use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551503","Nebulizer Emulsion Dosage Form","C149696","Liquid preparation consisting of an emulsion intended for inhalation to obtain local effect or systemic delivery. The emulsion is converted into an aerosol by a continuously operating nebulizer or a metered-dose nebulizer.","Nebulizer Emulsion Dosage Form | Nebuliser emulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551746","Solution for Solution for Infusion Dosage Form","C149931","Liquid sterile preparation consisting of a solution intended for use in the preparation of a solution for infusion.","Solution for Solution for Infusion Dosage Form | Solution for solution for infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544110","Grade 4 Large Intestinal Anastomotic Leak, CTCAE","C145970","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Large Intestinal Anastomotic Leak, CTCAE | Grade 4 Large intestinal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544111","Grade 4 Laryngeal Edema, CTCAE","C145971","Life-threatening airway compromise; urgent intervention indicated (e.g., tracheotomy or intubation)","Grade 4 Laryngeal Edema, CTCAE | Grade 4 Laryngeal edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544112","Grade 4 Laryngeal Mucositis, CTCAE","C145974","Life-threatening airway compromise; urgent intervention indicated (e.g., tracheotomy or intubation)","Grade 4 Laryngeal Mucositis, CTCAE | Grade 4 Laryngeal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544113","Grade 4 Laryngeal Obstruction, CTCAE","C145975","Life-threatening consequences; urgent intervention indicated","Grade 4 Laryngeal Obstruction, CTCAE | Grade 4 Laryngeal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544114","Grade 4 Laryngeal Stenosis, CTCAE","C145976","Life-threatening consequences; urgent intervention indicated","Grade 4 Laryngeal Stenosis, CTCAE | Grade 4 Laryngeal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544115","Grade 4 Laryngitis, CTCAE","C145977","Life-threatening consequences; urgent intervention indicated","Grade 4 Laryngitis, CTCAE | Grade 4 Laryngitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544116","Grade 4 Laryngopharyngeal Dysesthesia, CTCAE","C145978","Life-threatening consequences","Grade 4 Laryngopharyngeal Dysesthesia, CTCAE | Grade 4 Laryngopharyngeal dysesthesia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544102","Grade 4 Leukemia Secondary To Oncology Chemotherapy, CTCAE","C145980","Present","Grade 4 Leukemia Secondary To Oncology Chemotherapy, CTCAE | Grade 4 Leukemia secondary to oncology chemotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544103","Grade 4 Leukocytosis, CTCAE","C145981","Clinical manifestations of leucostasis; urgent intervention indicated","Grade 4 Leukocytosis, CTCAE | Grade 4 Leukocytosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544104","Grade 4 Leukoencephalopathy, CTCAE","C145982","Life-threatening consequences; extensive T2/FLAIR hyperintensities, involving periventricular white matter involving most of susceptible areas of cerebrum +/- moderate to severe increase in SAS and/or moderate to severe ventriculomegaly","Grade 4 Leukoencephalopathy, CTCAE | Grade 4 Leukoencephalopathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544105","Grade 4 Lipase Increased, CTCAE","C145983",">5.0 x ULN and with signs or symptoms","Grade 4 Lipase Increased, CTCAE | Grade 4 Lipase increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544106","Grade 4 Lower Gastrointestinal Hemorrhage, CTCAE","C145984","Life-threatening consequences; urgent intervention indicated","Grade 4 Lower Gastrointestinal Hemorrhage, CTCAE | Grade 4 Lower gastrointestinal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544107","Grade 4 Lung Infection, CTCAE","C145985","Life-threatening consequences; urgent intervention indicated","Grade 4 Lung Infection, CTCAE | Grade 4 Lung infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544108","Grade 4 Lymph Gland Infection, CTCAE","C145986","Life-threatening consequences; urgent intervention indicated","Grade 4 Lymph Gland Infection, CTCAE | Grade 4 Lymph gland infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544093","Grade 4 Lymph Leakage, CTCAE","C145987","Life-threatening consequences; urgent intervention indicated","Grade 4 Lymph Leakage, CTCAE | Grade 4 Lymph leakage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544095","Grade 4 Mania, CTCAE","C145989","Life-threatening consequences, threats of harm to self or others; hospitalization indicated","Grade 4 Mania, CTCAE | Grade 4 Mania",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544096","Grade 4 Mediastinal Infection, CTCAE","C145991","Life-threatening consequences; urgent intervention indicated","Grade 4 Mediastinal Infection, CTCAE | Grade 4 Mediastinal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544097","Grade 4 Meningismus, CTCAE","C145992","Life-threatening consequences; urgent intervention indicated","Grade 4 Meningismus, CTCAE | Grade 4 Meningismus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544471","Grade 5 Laryngeal Stenosis, CTCAE","C146423","Death","Grade 5 Laryngeal Stenosis, CTCAE | Grade 5 Laryngeal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551619","Powder for Endocervical Gel Dosage Form","C149823","Solid preparation consisting of one or more powders intended to be mixed with the specified liquid or gel to obtain an endocervical gel.","Powder for Endocervical Gel Dosage Form | Powder for endocervical gel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551614","Powder for Endosinusial Solution Dosage Form","C149824","Solid preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain an endosinusial solution.","Powder for Endosinusial Solution Dosage Form | Powder for endosinusial solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551616","Powder for Gel Dosage Form","C149826","Solid preparation consisting of one or more powders intended to be mixed with the specified liquid or gel to obtain a gel (for cutaneous use).","Powder for Gel Dosage Form | Powder for gel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551615","Powder for Gingival Gel Dosage Form","C149827","Solid preparation consisting of one or more powders intended to be mixed with the specified liquid or gel to obtain a gingival gel.","Powder for Gingival Gel Dosage Form | Powder for gingival gel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551610","Powder for Implantation Matrix Dosage Form","C149828","Solid sterile preparation consisting of one or more powders intended to be used in the preparation of an implantation matrix, e.g. by dissolving in the specified liquid to prepare the solution used to impregnate the matrix.","Powder for Implantation Matrix Dosage Form | Powder for implantation matrix",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551609","Powder for Implantation Paste Dosage Form","C149829","Solid sterile preparation consisting of one or more powders intended to be mixed with the specified liquid or paste to obtain an implantation paste.","Powder for Implantation Paste Dosage Form | Powder for implantation paste",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551612","Powder for Implantation Suspension Dosage Form","C149830","Solid sterile preparation consisting of one or more powder intended to be dispersed in the specified liquid to obtain an implantation suspension.","Powder for Implantation Suspension Dosage Form | Powder for implantation suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551611","Powder for Intraocular Instillation Solution Dosage Form","C149831","Solid sterile preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain an intraocular instillation solution.","Powder for Intraocular Instillation Solution Dosage Form | Powder for intraocular instillation solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551838","Refractory Ovarian Carcinoma","C150091","Ovarian carcinoma that is resistant to treatment.","Refractory Ovarian Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551837","Refractory Uterine Corpus Cancer","C150092","Uterine corpus cancer that is resistant to treatment.","Refractory Uterine Corpus Cancer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551840","Refractory Endometrial Carcinoma","C150093","Endometrial carcinoma that is resistant to treatment","Refractory Endometrial Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551839","Recurrent Endometrial Carcinoma","C150094","The reemergence of endometrial carcinoma after a period of remission.","Recurrent Endometrial Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551834","Recurrent Ovarian Endometrioid Adenocarcinoma","C150095","The reemergence of ovarian endometrioid adenocarcinoma after a period of remission.","Recurrent Ovarian Endometrioid Adenocarcinoma | Recurrent Ovarian Endometrioid Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551914","Expanded Cord Blood Stem Cells Mixed with Engineered Human Endothelial Cells AB-110","C150135","A population of ex vivo expanded, CD34-positive-enriched hematopoietic progenitor cells (HPCs), which are derived from allogeneic human umbilical cord blood (UCB), and are co-cultured and expanded with a proprietary preparation of human endothelial cells (ECs), which are genetically modified with an adenovirus (Ad) vector that includes the Ad E4 region that encodes the ORF1 (E4ORF1) gene, that can be used for transplantation. Upon transplantation of the expanded cord blood stem cells mixed with engineered human ECs AB-110, the UCB-derived cells can differentiate into a variety of cell types and promote blood cell recovery. Compared to bone marrow transplants, these HPCs demonstrate a decreased risk of causing graft-versus-host disease (GvHD), increase survival and enhance the potential for transplant and engraftment in any given patient as there is no need for a matched donor. Compared to HPCs alone, inclusion of the ECs increases blood stem cell count, enhances engraftment potential and increases the chances for blood cell recovery, thereby further increasing the potential for a successful cord blood transplantation. Insertion of the Ad E4ORF1 gene enhances survival and replication of the ECs ex vivo, preserves the ECs' vascular functions and improves the ability of the ECs to secrete angiocrines, which promotes stem cell proliferation and increases engraftment.","Expanded Cord Blood Stem Cells Mixed with Engineered Human Endothelial Cells AB-110 | AB 110 | AB-110 | AB-110 Cell Product | CD34+ Cord-Blood Derived Hematopoietic Stem Cells Co-Cultured and Co-Infused with Genetically Modified Endothelial Cells AB-110 | CD34-positive Enriched HPCs Mixed with Engineered Human ECs AB-110 | Cord Blood-derived HPCs Co-cultured and Expanded with E-CEL UVEC Cells AB-110 | Genetically-modified Endothelial Cells Plus Expanded Cord Blood Hematopoietic Stem Cells AB-110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551913","Intracervical Route of Administration","C150136","Injection of a medicinal product into the cervix uteri.","Intracervical Route of Administration | Intracervical use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551916","Abbreviated Breast MRI Protocol","C150137","Protocols aimed at reducing the cost of breast MRI to improve access to it as a supplemental screening method. Shorter protocols and shorter acquisition times can be achieved with maintenance of diagnostic accuracy comparable to that obtained with conventional MRI protocols. Use of these abbreviated MRI protocols could result in lower cost and faster throughput, thus increasing availability.","Abbreviated Breast MRI Protocol | AB-MRI | Abbreviated Breast MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551250","HIVEP1 wt Allele","C149345","Human HIVEP1 wild-type allele is located in the vicinity of 6p24.1 and is approximately 157 kb in length. This allele, which encodes zinc finger protein 40, is involved in the modulation of viral and cellular gene expression.","HIVEP1 wt Allele | CIRIP | CRYBP1 | GAAP | Human Immunodeficiency Virus Type I Enhancer Binding Protein 1 wt Allele | MBP-1 | PRDII-BF1 | Schnurri-1 | ZAS Family, Member 1 Gene | ZAS1 | ZNF40 | ZNF40A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554820","Additive Dosage Form Category","C149346","A type of pharmaceutical dose form that may be liquid, semi-solid or solid, to be added to a large volume of diluent, such as in a bath.","Additive Dosage Form Category | Additive (unspecified)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551245","Anticoagulant and Preservative Solution for Blood Dosage Form","C149347","Sterile aqueous liquid preparation intended to be mixed with extracorporeal blood to preserve the blood and prevent coagulation.","Anticoagulant and Preservative Solution for Blood Dosage Form | Anticoagulant and preservative solution for blood",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552427","Application Method of Administration","C149348","The technique of administration of a pharmaceutical product by placing or spreading it onto the affected area.","Application Method of Administration | Application",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551246","Balling Gun Delivery Device","C149349","Device for delivery of a solid dose into the throat of the animal.","Balling Gun Delivery Device | Balling gun",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2700485","Barrel Dosing Unit","C149350","A unit of presentation used to represent the quantity of product that is found in a single barrel container.","Barrel Dosing Unit | Barrel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551242","Bath Additive Dosage Form","C149351","A pharmaceutical dose form that is added to a bath.","Bath Additive Dosage Form | Bath additive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551244","Beak Dipping Route of Administration","C149353","Administration of a veterinary medicinal product by dipping the beak of birds into an aqueous solution of the medicinal product.","Beak Dipping Route of Administration | Beak dipping",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551243","Bee Smoke Paper Dosage Form","C149354","Pharmaceutical impregnated strips that deliver the active substance(s) when lit. This is used to treat bee hives and nests.","Bee Smoke Paper Dosage Form | Bee smoke paper",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551749","Solution for Solution for Injection Dosage Form","C149932","Liquid sterile preparation consisting of a solution intended for use in the preparation of a solution for injection.","Solution for Solution for Injection Dosage Form | Solution for solution for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551748","Solution for Spray Dosage Form","C149933","Liquid preparation consisting of a solution intended for use in the preparation of a spray.","Solution for Spray Dosage Form | Solution for Spray",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551743","Solution for Suspension for Injection Dosage Form","C149934","Liquid sterile preparation consisting of a solution intended for use in the preparation of a suspension for injection.","Solution for Suspension for Injection Dosage Form | Solution for suspension for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551745","Solution for Use in Drinking Water/Milk Dosage Form","C149936","Solution for veterinary use, intended for administration by incorporation into the animal drinking water, milk or milk replacer. If direct oral administration to individual animals is also authorized, the method of administration, including any necessary dilution, is clearly described in the product information.","Solution for Use in Drinking Water/Milk Dosage Form | Solution for use in drinking water/milk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551744","Solvent for Parenteral Use Dosage Form","C149937","Liquid sterile preparation consisting of a solvent containing no active substances, intended for use in the preparation of a product for parenteral use.","Solvent for Parenteral Use Dosage Form | Solvent for parenteral use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551740","Solvent for Solution for Infusion Dosage Form","C149938","Liquid sterile preparation consisting of a solvent containing no active substances, intended for use in the preparation of a solution for infusion.","Solvent for Solution for Infusion Dosage Form | Solvent for solution for infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551739","Solvent for Solution for Intraocular Irrigation Dosage Form","C149939","Liquid sterile preparation consisting of a solvent containing no active substances, intended for use in the preparation of a solution for intraocular irrigation.","Solvent for Solution for Intraocular Irrigation Dosage Form | Solvent for solution for intraocular irrigation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551741","Solvent for [Product Name] Dosage Form","C149940","Liquid preparation consisting of an excipient that contains no active substances itself but is intended to be used in the preparation of a pharmaceutical product, e.g. for diluting/dissolving/dispersing the item(s) containing the active substance(s).","Solvent for [Product Name] Dosage Form | Solvent for...",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552480","Spatula Device","C149941","Administration device with a flattened side used for the application of semi-solid pharmaceutical forms.","Spatula Device | Spatula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552441","Spoonful Dosing Unit","C149942","A unit of presentation used to represent the quantity of product that is administered by filling a single spoon administration device.","Spoonful Dosing Unit | Spoonful",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551736","Spot-on Applicator","C149943","Device for administration by spot-on use.","Spot-on Applicator | Spot-on applicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551738","Spot-on Emulsion Dosage Form","C149944","Liquid preparation consisting of an emulsion intended for spot-on use for the prevention and treatment of ectoparasitic and/or endoparasitic infestations of animals. Spot-on-emulsions are applied in volumes that are usually less than 10 mL.","Spot-on Emulsion Dosage Form | Spot-on emulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551737","Spot-on Solution Dosage Form","C149945","Liquid preparation consisting of a solution intended for spot-on use for the prevention and treatment of ectoparasitic and/or endoparasitic infestations of animals. Spot-on-solutions are applied in volumes that are usually less than 10 mL.","Spot-on Solution Dosage Form | Spot-on solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551733","Spot-on Suspension Dosage Form","C149946","Liquid preparation consisting of a suspension intended for spot-on use for the prevention and treatment of ectoparasitic and/or endoparasitic infestations of animals. Spot-on-suspensions are applied in volumes that are usually less than 10 mL.","Spot-on Suspension Dosage Form | Spot-on suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551732","Spot-on Route of Administration","C149947","Administration of a veterinary medicinal product to a single site on the back of the animal or the base of the poll of the head.","Spot-on Route of Administration | Spot-on use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544472","Grade 5 Laryngitis, CTCAE","C146424","Death","Grade 5 Laryngitis, CTCAE | Grade 5 Laryngitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544473","Grade 5 Laryngopharyngeal Dysesthesia, CTCAE","C146425","Death","Grade 5 Laryngopharyngeal Dysesthesia, CTCAE | Grade 5 Laryngopharyngeal dysesthesia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544474","Grade 5 Laryngospasm, CTCAE","C146426","Death","Grade 5 Laryngospasm, CTCAE | Grade 5 Laryngospasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544475","Grade 5 Leukemia Secondary To Oncology Chemotherapy, CTCAE","C146427","Death","Grade 5 Leukemia Secondary To Oncology Chemotherapy, CTCAE | Grade 5 Leukemia secondary to oncology chemotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544476","Grade 5 Leukocytosis, CTCAE","C146428","Death","Grade 5 Leukocytosis, CTCAE | Grade 5 Leukocytosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544462","Grade 5 Lower Gastrointestinal Hemorrhage, CTCAE","C146430","Death","Grade 5 Lower Gastrointestinal Hemorrhage, CTCAE | Grade 5 Lower gastrointestinal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544463","Grade 5 Lung Infection, CTCAE","C146431","Death","Grade 5 Lung Infection, CTCAE | Grade 5 Lung infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544464","Grade 5 Lymph Gland Infection, CTCAE","C146432","Death","Grade 5 Lymph Gland Infection, CTCAE | Grade 5 Lymph gland infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544465","Grade 5 Lymph Leakage, CTCAE","C146433","Death","Grade 5 Lymph Leakage, CTCAE | Grade 5 Lymph leakage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544466","Grade 5 Mania, CTCAE","C146434","Death","Grade 5 Mania, CTCAE | Grade 5 Mania",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544467","Grade 5 Mediastinal Infection, CTCAE","C146436","Death","Grade 5 Mediastinal Infection, CTCAE | Grade 5 Mediastinal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544453","Grade 5 Meningitis, CTCAE","C146438","Death","Grade 5 Meningitis, CTCAE | Grade 5 Meningitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544454","Grade 5 Menorrhagia, CTCAE","C146439","Death","Grade 5 Menorrhagia, CTCAE | Grade 5 Menorrhagia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544455","Grade 5 Metabolism and Nutrition Disorders - Other, Specify, CTCAE","C146440","Death","Grade 5 Metabolism and Nutrition Disorders - Other, Specify, CTCAE | Grade 5 Metabolism and nutrition disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544456","Grade 5 Methemoglobinemia, CTCAE","C146441","Death","Grade 5 Methemoglobinemia, CTCAE | Grade 5 Methemoglobinemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544457","Grade 5 Middle Ear Inflammation, CTCAE","C146442","Death","Grade 5 Middle Ear Inflammation, CTCAE | Grade 5 Middle ear inflammation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544459","Grade 5 Mucosal Infection, CTCAE","C146446","Death","Grade 5 Mucosal Infection, CTCAE | Grade 5 Mucosal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544460","Grade 5 Mucositis Oral, CTCAE","C146447","Death","Grade 5 Mucositis Oral, CTCAE | Grade 5 Mucositis oral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544446","Grade 5 Myasthenia Gravis, CTCAE","C146450","Death","Grade 5 Myasthenia Gravis, CTCAE | Grade 5 Myasthenia gravis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544447","Grade 5 Myelodysplastic Syndrome, CTCAE","C146451","Death","Grade 5 Myelodysplastic Syndrome, CTCAE | Grade 5 Myelodysplastic syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544448","Grade 5 Myocardial Infarction, CTCAE","C146452","Death","Grade 5 Myocardial Infarction, CTCAE | Grade 5 Myocardial infarction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544449","Grade 5 Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other, Specify, CTCAE","C146453","Death","Grade 5 Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other, Specify, CTCAE | Grade 5 Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551833","Refractory Ovarian Endometrioid Adenocarcinoma","C150096","Ovarian endometrioid adenocarcinoma that is resistant to treatment.","Refractory Ovarian Endometrioid Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551836","Recurrent Endometrial Endometrioid Adenocarcinoma","C150097","The reemergence of endometrial endometrioid adenocarcinoma after a period of remission.","Recurrent Endometrial Endometrioid Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551835","Refractory Endometrial Endometrioid Adenocarcinoma","C150098","Endometrial endometrioid adenocarcinoma that is resistant to treatment.","Refractory Endometrial Endometrioid Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551940","DGKZ Gene","C150100","This gene is involved in the phosphorylation of diacylglycerols.","DGKZ Gene | DGKZ | Diacylglycerol Kinase Zeta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551943","DGKZ wt Allele","C150101","Human DGKZ wild-type allele is located in the vicinity of 11p11.2 and is approximately 48 kb in length. This allele, which encodes diacylglycerol kinase zeta protein, plays a role in the modulation of second messenger signaling.","DGKZ wt Allele | DAGK5 | DAGK6 | DGK-ZETA | Diacylglycerol Kinase Zeta wt Allele | Diacylglycerol Kinase, Zeta 104kDa Gene | Diacylglycerol Kinase, Zeta, 104-kD Gene | hDGKzeta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551942","Diacylglycerol Kinase Zeta","C150102","Diacylglycerol kinase zeta (1117 aa, ~124 kDa) is encoded by the human DGKZ gene. This protein is involved in the phosphorylation of the second messenger molecule diacylglycerol.","Diacylglycerol Kinase Zeta | DAG Kinase Zeta | DGK-Zeta | Diglyceride Kinase Zeta | EC 2.7.1.107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551938","EDQM-HC Pharmaceutical Dosage Form Terminology","C150103","Terminology subset about the physical manifestation of a product that contains the active ingredient(s) and/or inactive ingredient(s) that are intended to be delivered to the patient. Note: 'Pharmaceutical dose form' and 'Dosage form' are synonyms. 'Pharmaceutical dose form' can refer to the administrable dose form or the manufactured dose form, depending on the product that it is describing.","EDQM-HC Pharmaceutical Dosage Form Terminology | Dosage Form | European Directorate for the Quality of Medicines and HealthCare Pharmaceutical Dosage Form | PDF | Pharmaceutical Dosage Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552106","SMUG1 wt Allele","C150320","Human SMUG1 wild-type allele is located in the vicinity of 12q13.13 and is approximately 68 kb in length. This allele, which encodes single-strand selective monofunctional uracil DNA glycosylase protein, plays a role in base excision repair of DNA.","SMUG1 wt Allele | FDG | HMUDG | Single-Strand-Selective Monofunctional Uracil-DNA Glycosylase 1 wt Allele | UNG3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552100","SP140 wt Allele","C150322","Human SP140 wild-type allele is located in the vicinity of 2q37.1 and is approximately 114 kb in length. This allele, which encodes nuclear body protein SP140, may be involved in the promotion of gene expression in leukocytes. Variation of this gene is associated with multiple sclerosis, Crohn disease, and chronic lymphocytic leukemia.","SP140 wt Allele | LYSP100 | LYSP100-A | LYSP100-B | SP140 Nuclear Body Protein wt Allele | Speckled, 140-kD Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0531920","SP140 protein, human","C150323","Nuclear body protein SP140 (867 aa, ~98 kDa) is encoded by the human SP140 gene. This protein may play a role in the activation of gene expression in leukocytes.","Nuclear Body Protein SP140 | LYSp100 | Lymphoid-Restricted Homolog of Sp100 | Lymphoid-Restricted SP100 Homolog | Nuclear Autoantigen Sp-140 | SP140 | Speckled 140 kDa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551239","Bee Smoke Stick Dosage Form","C149355","Pharmaceutical impregnated sticks that deliver the active substance(s) when lit. This is used to treat bee hives and nests.","Bee Smoke Stick Dosage Form | Bee smoke stick",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551238","Bee-hive dispersion in sachet","C149356","Medicinal product consisting of a bee-hive dispersion presented in a sachet.","Beehive Dispersion in Sachet Dosage Form | Bee-hive dispersion in sachet | Beehive Dispersion in Sachet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551241","Beehive Gel Dosage Form","C149357","Semi-solid multidose preparation intended for veterinary use, consisting of a gel from which the active substance(s) are released by vaporization or physical contact over an extended period of time.","Beehive Gel Dosage Form | Bee-hive gel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551240","Beehive Solution Dosage Form","C149358","Liquid preparation intended for in-hive use, consisting of a solution from which the active substance(s) are released by vaporization or physical contact usually over an extended period of time. The precise method of administration of the solution is described in the product information.","Beehive Solution Dosage Form | Bee-hive solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551236","Beehive Strip Dosage Form","C149359","Solid preparation for veterinary use consisting of a matrix impregnated with active substance(s) that are released by vaporization or physical contact over an extended period of time. Any specific requirements for the placing of the bee-hive strip are described in the product information.","Beehive Strip Dosage Form | Bee-hive strip",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272902","Bladder irrigation (product)","C149360","Sterile liquid preparation intended for irrigation of the urinary bladder.","Bladder Irrigation Solution Dosage Form | Bladder irrigation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552473","Pharmaceutical Brush Device","C149361","Administration device fitted with a fine brush used for the application of liquid pharmaceutical forms.","Pharmaceutical Brush Device | Brush",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552443","Smoking Method of Administration","C149363","The technique of administration of a pharmaceutical product by lighting it in order to evolve smoke that is taken in by the subject.","Smoking Method of Administration | Burning",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552406","Cachet Dosing Unit","C149364","A unit of presentation used to represent the quantity of product that is found in a single discrete entity where the pharmaceutical dose form is a type of cachet.","Cachet Dosing Unit | Cachet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551454","Laryngopharyngeal Spray, Solution Dosage Form","C149628","Liquid preparation consisting of a solution intended for spraying onto the laryngopharynx for a local effect.","Laryngopharyngeal Spray, Solution Dosage Form | Laryngopharyngeal spray, solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551457","Lick Block Dosage Form","C149629","Solid block containing active substance(s) intended for veterinary use. It is formed by pressing. Administration takes place when the animal is licking the block.","Lick Block Dosage Form | Lick block",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551456","Living Tissue Equivalent Dosage Form","C149630","Cultured, living tissue used for the reconstruction of parts of the body. The tissue may consist of ex vivo expanded cells with an extracellular matrix.","Living Tissue Equivalent Dosage Form | Living tissue equivalent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551451","Lyophilisate","C149631","A unit of presentation used to represent the quantity of product that is found in a single discrete entity where the pharmaceutical dose form is a type of lyophilisate.","Lyophilisate Dosing Unit | Lyophilisate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551450","Lyophilisate and solvent for oculonasal suspension","C149632","Lyophilisate and solvent intended for the preparation of an oculonasal suspension, for veterinary use, by dispersing the lyophilisate in the solvent.","Lyophilisate and Solvent for Oculonasal Suspension Dosage Form | Lyophilisate and solvent for oculonasal suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551453","Lyophilisate and solvent for oral suspension","C149633","Lyophilisate and solvent intended for the preparation of an oral suspension, for veterinary use, by dispersing the lyophilisate in the solvent.","Lyophilisate and Solvent for Oral Suspension Dosage Form | Lyophilisate and solvent for oral suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551735","Spray Container","C149948","Container for a liquid pharmaceutical form to be converted into a spray by mechanical means.","Spray Container | Spray container",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551983","CACNA1E wt Allele","C150181","Human CACNA1E wild-type allele is located in the vicinity of 1q25.3 and is approximately 395 kb in length. This allele, which encodes voltage-dependent R-type calcium channel subunit alpha-1E protein, plays a role in membrane depolarization.","CACNA1E wt Allele | BII | CACH6 | CACNL1A6 | Calcium Channel, L Type, Alpha-1 Polypeptide Gene | Calcium Channel, L Type, Alpha-1 Polypeptide, Isoform 6 Gene | Calcium Channel, R Type, Alpha-1 Polypeptide Gene | Calcium Channel, Voltage-Dependent, Alpha-1E Subunit Gene | Calcium Channel, Voltage-Dependent, R Type, Alpha 1E Subunit Gene | Calcium Voltage-Gated Channel Subunit Alpha1 E wt Allele | Cav2.3 | gm139",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551986","CACNA1E protein, human","C150182","Voltage-dependent R-type calcium channel subunit alpha-1E (2313 aa, ~262 kDa) is encoded by the human CACNA1E gene. This protein is involved in voltage-dependent calcium transport.","Voltage-Dependent R-Type Calcium Channel Subunit Alpha-1E | BII | Brain Calcium Channel II | CACNA1E | Calcium Channel, L Type, Alpha-1 Polypeptide, Isoform 6 | Calcium Channel, Voltage-Dependent, R Type, Alpha 1E Subunit | Calcium Voltage-Gated Channel Subunit Alpha1 Subunit E | Voltage-Dependent Calcium Channel Alpha 1E Subunit | Voltage-Gated Calcium Channel Alpha Subunit Cav2.3 | Voltage-Gated Calcium Channel Subunit Alpha Cav2.3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551985","Catheter Characteristics","C150183","No value exists.","Catheter Characteristics | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449463","Catheter Length","C150184","The length of the catheter.","Catheter Length | ",,,,,,,,,,,,,,,"4077566","Length of catheter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL551980","Guidewire Compatibility","C150185","The size of the guidewires that will fit through the inner lumen of the device.","Guidewire Compatibility | Inner Lumen Dimension | Maximum Guidewire Size",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551982","Catheter Working Length","C150186","The length of the catheter that can be inserted into the body or the working/functional measurement from the beginning to the end of delivery system.","Catheter Working Length | Effective Length | Working Length",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551981","Tip Bend Radius","C150187","The radius of an imaginary circle drawn inside of a curve of a curved catheter or guidewire.","Tip Bend Radius | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551978","Stent Characteristics","C150188","No value exists.","Stent Characteristics | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551977","Nominal Stent Diameter","C150189","Deployed stent diameter, as marked on packaging.","Nominal Stent Diameter | Stent Diameter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449462","Nominal Stent Length","C150190","Deployed stent length, as marked on the packaging.","Nominal Stent Length | Stent Length",,,,,,,,,,,,,,,"4078488","Length of stent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL551979","Tapered Stent Smaller Diameter","C150192","The diameter of the portion of the tapered end of the stent that is the smaller of the two tapered ends.","Tapered Stent Smaller Diameter | Distal Stent | Tapered Stent Smallest Diameter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551973","Tapered Stent Larger Diameter","C150194","The diameter of the portion of the tapered end of the stent that is the larger of the two tapered ends.","Tapered Stent Larger Diameter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551975","Tapered Stent Length","C150196","The length of the tapered portion of the stent.","Tapered Stent Length | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1439118","CACNA1S protein, human","C150198","Voltage-dependent L-type calcium channel subunit alpha-1S (1873 aa, ~212 kDa) is encoded by the human CACNA1S gene. This protein plays a role in voltage-dependent calcium transport in muscle cells.","Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1S | CACNA1S | Calcium Channel, L Type, Alpha-1 Polypeptide, Isoform 3, Skeletal Muscle | Dihydropyridine Receptor Alpha 1 Subunit | Dihydropyridine-Sensitive L-Type Calcium Channel Alpha-1 Subunit | Voltage-Gated Calcium Channel Alpha 1 Subunit | Voltage-Gated Calcium Channel Subunit Alpha Cav1.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544452","Grade 5 Obstruction Gastric, CTCAE","C146456","Death","Grade 5 Obstruction Gastric, CTCAE | Grade 5 Obstruction gastric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543693","Grade 3 Respiratory, Thoracic and Mediastinal Disorders - Other, Specify, CTCAE","C145598","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL","Grade 3 Respiratory, Thoracic and Mediastinal Disorders - Other, Specify, CTCAE | Grade 3 Respiratory, thoracic and mediastinal disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206515","Conjugate Vaccine","C1455","A category of vaccines created by covalently attaching an antigen from an organism to a carrier protein from the same organism to aid in the delivery of the immunogen.","Conjugate Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543695","Grade 3 Retinal Vascular Disorder, CTCAE","C145600","Retinal vascular disorder with neovascularization","Grade 3 Retinal Vascular Disorder, CTCAE | Grade 3 Retinal vascular disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543696","Grade 3 Retroperitoneal Hemorrhage, CTCAE","C145601","Transfusion indicated; invasive intervention indicated; hospitalization","Grade 3 Retroperitoneal Hemorrhage, CTCAE | Grade 3 Retroperitoneal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543697","Grade 3 Reversible Posterior Leukoencephalopathy Syndrome, CTCAE","C145602","Severe symptoms; limiting self care ADL; hospitalization","Grade 3 Reversible Posterior Leukoencephalopathy Syndrome, CTCAE | Grade 3 Reversible posterior leukoencephalopathy syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543698","Grade 3 Rhabdomyolysis, CTCAE","C145603","Symptomatic, urgent intervention indicated","Grade 3 Rhabdomyolysis, CTCAE | Grade 3 Rhabdomyolysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543699","Grade 3 Rotator Cuff Injury, CTCAE","C145604","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL","Grade 3 Rotator Cuff Injury, CTCAE | Grade 3 Rotator cuff injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543685","Grade 3 Salivary Gland Infection, CTCAE","C145606","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Salivary Gland Infection, CTCAE | Grade 3 Salivary gland infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543686","Grade 3 Scleral Disorder, CTCAE","C145607","Symptomatic with marked decrease in visual acuity (best corrected visual acuity worse than 20/40 or more than 3 lines of decreased vision from known baseline, up to 20/200); limiting self care ADL","Grade 3 Scleral Disorder, CTCAE | Grade 3 Scleral disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543687","Grade 3 Scoliosis, CTCAE","C145608",">45 degrees; scapular prominence in forward flexion; operative intervention indicated; limiting self care ADL","Grade 3 Scoliosis, CTCAE | Grade 3 Scoliosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543688","Grade 3 Scrotal Infection, CTCAE","C145609","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Scrotal Infection, CTCAE | Grade 3 Scrotal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543689","Grade 3 Scrotal Pain, CTCAE","C145610","Severe pain; limiting self care ADL","Grade 3 Scrotal Pain, CTCAE | Grade 3 Scrotal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543690","Grade 3 Sepsis, CTCAE","C145611","Blood culture positive with signs or symptoms; treatment indicated","Grade 3 Sepsis, CTCAE | Grade 3 Sepsis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543691","Grade 3 Serum Amylase Increased, CTCAE","C145612",">2.0-5.0 x ULN with signs or symptoms; >5.0 x ULN and asymptomatic","Grade 3 Serum Amylase Increased, CTCAE | Grade 3 Serum amylase increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543692","Grade 3 Shingles, CTCAE","C145613","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; IV intervention indicated; limiting self-care ADL","Grade 3 Shingles, CTCAE | Grade 3 Shingles",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543677","Grade 3 Sinus Disorder, CTCAE","C145614","Stenosis with significant nasal obstruction; limiting self care ADL","Grade 3 Sinus Disorder, CTCAE | Grade 3 Sinus disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543678","Grade 3 Sinusitis, CTCAE","C145615","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Sinusitis, CTCAE | Grade 3 Sinusitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552097","STK36 wt Allele","C150325","Human STK36 wild-type allele is located in the vicinity of 2q35 and is approximately 31 kb in length. This allele, which encodes serine/threonine-protein kinase 36 protein plays a role in the modulation of GLI family transcription factor activity.","STK36 wt Allele | FU | Fused Homolog (Drosophila) Gene | Fused, Drosophila, Homolog of Gene | KIAA1278 | Serine/Threonine Kinase 36 (Fused Homolog, Drosophila) Gene | Serine/Threonine Kinase 36 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1565882","STK36 protein, human","C150326","Serine/threonine-protein kinase 36 (1315 aa, ~144 kDa) is encoded by the human STK36 gene. This protein is involved in the induction of GLI zinc-finger family transcription factor activity.","Serine/Threonine-Protein Kinase 36 | EC 2.7.11.1 | Fused Homolog | STK36 | Serine/Threonine Kinase 36 | Testicular Tissue Protein Li 188",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552098","SYNE1 wt Allele","C150328","Human SYNE1 wild-type allele is located in the vicinity of 6q25.2 and is approximately 516 kb in length. This allele, which encodes nesprin-1 protein, is involved in the subcellular position of the nucleus. Mutation of the gene is associated with autosomal recessive spinocerebellar ataxia 8.","SYNE1 wt Allele | 8B | ARCA1 | C6orf98 | CPG2 | CPG2 Full Length Gene | Chromosome 6 Open Reading Frame 98 Gene | EDMD4 | KASH1 | KIAA0796 | KIAA1262 | KIAA1756 | MYNE1 | Nesp1 | Nuclear Envelope Spectrin Repeat-1 Gene | SCAR8 | Spectrin Repeat Containing Nuclear Envelope Protein 1 wt Allele | Spectrin Repeat Containing, Nuclear Envelope 1 Gene | Synaptic Nuclei Expressed Gene 1 | dJ45H2.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552093","Nesprin-1","C150329","Nesprin-1 (8797 aa, ~1011 kDa) is encoded by the human SYNE1 gene. This protein plays a role in linking the nuclear lamina and the cytoskeleton.","Nesprin-1 | Enaptin | KASH Domain-Containing Protein 1 | KASH1 | Myne-1 | Myocyte Nuclear Envelope Protein 1 | Nesprin 1 | Nuclear Envelope Spectrin Repeat Protein 1 | SYNE1 | Spectrin Repeat Containing Nuclear Envelope Protein 1 | Spectrin Repeat-Containing Nuclear Envelope Protein 1 | Synaptic Nuclear Envelope Protein 1 | Syne-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552095","SYT1 wt Allele","C150331","Human SYT1 wild-type allele is located in the vicinity of 12q21.2 and is approximately 588 kb in length. This allele, which encodes synaptotagmin-1 protein, plays a role in localization and exocytosis of synaptic vesicles.","SYT1 wt Allele | P65 | SVP65 | SYT | Synaptotagmin 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1530318","SYT1 protein, human","C150332","Synaptotagmin-1 (422 aa, ~48 kDa) is encoded by the human SYT1 gene. This protein is involved in trafficking and exocytosis of synaptic vesicles.","Synaptotagmin-1 | SYT1 | Synaptotagmin 1 | Synaptotagmin I | SytI | p65",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551388","Inhalation Method of Administration","C149578","The technique of administration of a pharmaceutical product by breathing it into the lungs, usually via the mouth.","Inhalation Method of Administration | Inhalation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272875","Inhalation Powder, Hard Capsule Dosage Form","C149579","Solid single-dose preparation intended for inhalation use, consisting of one or more powders of solid active substance(s) enclosed in a hard capsule. The capsule is loaded into a dry-powder inhaler to generate an aerosol.","Inhalation Powder, Hard Capsule Dosage Form | Inhalation powder, hard capsule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551494","Pre-dispensed Inhalation Powder Dosage Form","C149580","Solid preparation intended for inhalation use, consisting of one or more powders of solid active substance(s) presented in a suitable pharmaceutical form other than a hard capsule, either in the form of a single dose or divided into multiple single doses. The preparation is loaded into a dry-powder inhaler to generate an aerosol.","Pre-dispensed Inhalation Powder Dosage Form | Inhalation powder, pre-dispensed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551452","Lyophilisate and solvent for solution for injection","C149634","Sterile lyophilisate and sterile solvent intended for the preparation of a solution for injection, for veterinary use, by dissolving the lyophilisate in the solvent.","Lyophilisate and Solvent for Solution for Injection Dosage Form | Lyophilisate and solvent for solution for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551447","Lyophilisate and solvent for suspension for injection","C149635","Sterile lyophilisate and sterile solvent intended for the preparation of a suspension for injection, for veterinary use, by dispersing the lyophilisate in the solvent.","Lyophilisate and Solvent for Suspension for Injection Dosage Form | Lyophilisate and solvent for suspension for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551449","Lyophilisate for oculonasal suspension","C149637","Solid preparation for veterinary use consisting of a freeze-dried powder intended to be dispersed in the specified liquid to create a suspension for oculonasal use.","Lyophilisate for Oculonasal Suspension Dosage Form | Lyophilisate for oculonasal suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551448","Lyophilisate for oculonasal suspension/use in drinking water","C149638","Solid preparation for veterinary use consisting of a freeze-dried powder intended to be dispersed in the specified liquid to create a suspension for oculonasal use, or to be dispersed in the animal drinking water.","Lyophilisate for Oculonasal Suspension/Use in Drinking Water Dosage Form | Lyophilisate for oculonasal suspension/use in drinking water",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551443","Lyophilisate for oral spray, suspension","C149639","Solid preparation for veterinary use consisting of a freeze-dried powder intended to be dispersed in the specified liquid to obtain an oral spray, suspension.","Lyophilisate for Oral Spray, Suspension Dosage Form | Lyophilisate for oral spray, suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551442","Lyophilisate for oral suspension","C149640","Solid preparation for veterinary use consisting of a freeze-dried powder intended to be dispersed in the specified liquid to create an oral suspension.","Lyophilisate for Oral Suspension Dosage Form | Lyophilisate for oral suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551445","Lyophilisate for solution for infusion","C149641","Solid sterile preparation for veterinary use consisting of a freeze-dried powder intended to be dissolved in the specified liquid to obtain a solution for infusion.","Lyophilisate for Solution for Infusion Dosage Form | Lyophilisate for solution for infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551444","Lyophilisate for solution for injection","C149642","Solid sterile preparation for veterinary use consisting of a freeze-dried powder intended to be dissolved in the specified liquid to obtain a solution for injection.","Lyophilisate for Solution for Injection Dosage Form | Lyophilisate for solution for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551552","Lyophilisate for suspension for injection","C149643","Solid sterile preparation for veterinary use consisting of a freeze-dried powder intended to be dispersed in the specified liquid to obtain a suspension for injection.","Lyophilisate for Suspension for Injection Dosage Form | Lyophilisate for suspension for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551679","Rectal Emulsion Dosage Form","C149883","Liquid preparation consisting of an emulsion intended for rectal use or for diagnostic purposes. Rectal emulsions are usually presented in containers with a volume in the range of 2.5 mL to 2000 mL. The container is fitted with an applicator or an applicator is provided separately.","Rectal Emulsion Dosage Form | Rectal emulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551681","Rectal Solution Dosage Form","C149884","Liquid preparation consisting of a solution intended for rectal use or for diagnostic purposes. Rectal solutions are usually presented in containers with a volume in the range of 2.5 mL to 2000 mL. The container is fitted with an applicator or an applicator is provided separately.","Rectal Solution Dosage Form | Rectal solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551680","Rectal Suspension Dosage Form","C149885","Liquid preparation consisting of a suspension intended for rectal use or for diagnostic purposes. Rectal suspension are usually presented in containers with a volume in the range of 2.5 mL to 2000 mL. The container is fitted with an applicator or an applicator is provided separately.","Rectal Suspension Dosage Form | Rectal suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272870","Rectal Tampon Dosage Form","C149886","Solid single-dose preparation consisting of a suitable material impregnated with active substance(s) intended to be inserted in the rectum for a limited period of time usually for a local effect.","Rectal Tampon Dosage Form | Rectal tampon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551972","Atherectomy Device Characteristics","C150199","No value exists.","Atherectomy Device Characteristics | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551296","Cutaneous solution in single-dose container","C149416","Medicinal product consisting of a cutaneous solution presented in a single-dose container.","Cutaneous Solution in Single-dose Container Dosage Form | Cutaneous Solution in Single-dose Container | Cutaneous solution in single-dose container",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551299","Topical Solution/Concentrate for Oromucosal Solution Dosage Form","C149417","Liquid preparation consisting of a solution intended for cutaneous use or intended to be diluted in the specified liquid to obtain an oromucosal solution.","Topical Solution/Concentrate for Oromucosal Solution Dosage Form | Cutaneous solution/concentrate for oromucosal solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551298","Topical Emulsion Spray Dosage Form","C149418","Liquid preparation, usually multidose, consisting of an emulsion in a pressurized container with a spray valve or in a container equipped with a spray pump, intended for cutaneous use.","Topical Emulsion Spray Dosage Form | Cutaneous spray, emulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551293","Topical Ointment Spray Dosage Form","C149419","Ointment formed at the time of administration from a liquid preparation in a pressurized container with a spray valve or in a container equipped with a spray pump.","Topical Ointment Spray Dosage Form | Cutaneous spray, ointment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272928","Topical Suspension Spray Dosage Form","C149420","Liquid, usually multidose preparation consisting of a suspension in a pressurized container with a spray valve or in a container equipped with a spray pump, intended for cutaneous use.","Topical Suspension Spray Dosage Form | Cutaneous spray, suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551295","Topical Stick Dosage Form","C149421","Solid preparation, usually rod-shaped or conical, intended for application to the skin to obtain a local effect. Cutaneous sticks may consist of the active substance(s) alone or dissolved or dispersed in a suitable basis.","Topical Stick Dosage Form | Cutaneous stick",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551294","Cutaneous/Nasal Ointment Dosage Form","C149422","Semi-solid preparation consisting of an ointment intended for cutaneous or nasal use.","Cutaneous/Nasal Ointment Dosage Form | Cutaneous/nasal ointment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551291","Cutaneous/Transdermal","C149423","Relating to the skin or its appendages (e.g. hair, nails) as the intended site of administration, including where the pharmaceutical product is intended for action on the surface of the skin, within the skin, or systemically after passing through the skin.","Cutaneous/Transdermal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552466","Dart Device","C149425","A pointed missile which on contact with an animal delivers its medicinal content.","Dart Device | Dart",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551292","Dart Dosing Unit","C149426","A unit of presentation used to represent the quantity of product that is found in a single dart device.","Dart Dosing Unit | Dart",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551287","Delayed Release Mechanism of Action","C149427","Release of the substance(s) at a later time than would be achieved with a conventional-release product, achieved by a special formulation design and/or manufacturing method; enteric-coated and other gastro-resistant products are included.","Delayed Release Mechanism of Action | Delayed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551286","Dental Emulsion Dosage Form","C149428","Liquid, usually multidose preparation consisting of an emulsion intended for administration on to the teeth and the gums.","Dental Emulsion Dosage Form | Dental emulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551289","Dental Solution Dosage Form","C149429","Liquid, usually multidose preparation consisting of a solution intended for administration on teeth and gums.","Dental Solution Dosage Form | Dental solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551288","Dental Stick Dosage Form","C149430","Solid single-dose preparation, rod-shaped and usually prepared by compression or molding, intended for dental use.","Dental Stick Dosage Form | Dental stick",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551283","Denture Lacquer Dosage Form","C149432","Liquid preparation to be applied to dentures to form a lacquer by evaporation of the volatile solvent.","Denture Lacquer Dosage Form | Denture lacquer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543680","Grade 3 Skin and Subcutaneous Tissue Disorders - Other, Specify, CTCAE","C145617","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL","Grade 3 Skin and Subcutaneous Tissue Disorders - Other, Specify, CTCAE | Grade 3 Skin and subcutaneous tissue disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543681","Grade 3 Skin Atrophy, CTCAE","C145618","Covering >30% BSA; associated with ulceration","Grade 3 Skin Atrophy, CTCAE | Grade 3 Skin atrophy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544751","HER2 Inhibitor TAS0728","C146810","An orally available covalent inhibitor of human epidermal growth factor receptor 2 (HER2; ERBB2), with potential antineoplastic activity. Upon oral administration, HER2 inhibitor TAS0728 specifically and irreversibly binds to and inhibits the activity of HER2. This prevents HER2-mediated signaling and leads to cell death in HER2- and HER3 (ErbB3)-expressing tumor cells. HER2, a receptor tyrosine kinase mutated or overexpressed in many tumor cell types, play key roles in tumor cell proliferation and tumor vascularization. HER3 has no active kinase domain but is activated through heterodimerization with other members of the EGFR receptor family, such as HER2.","HER2 Inhibitor TAS0728 | TAS 0728 | TAS-0728 | TAS0728 | TPC-107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544753","BGISEQ-500 Sequencing","C146812","A proprietary next-generation DNA sequencing system from BGI Genomics using combinatorial Probe-Anchor Synthesis (cPAS) and improved DNA Nanoballs (DNB) technology. The cPAS chemistry works by incorporating a fluorescent probe to a DNA anchor on the DNB, followed by high-resolution digital imaging.","BGISEQ-500 Sequencing | BGISEQ | BGISEQ-500 Sequencing Technology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544754","mRNA-based Personalized Cancer Vaccine mRNA-4157","C146813","An mRNA-based individualized, therapeutic personalized cancer vaccine (PCV) targeting twenty tumor-associated antigens (TAAs) that are specifically expressed by the patient's cancer cells, with potential immunostimulatory and antineoplastic activities. The cells from the patient's tumor are analyzed, and genetic sequencing is used to identify twenty neoantigen epitopes that may elicit the strongest immune response in the patient. The sequences encoding the twenty patient-specific epitopes are transcribed and loaded onto a single mRNA molecule. Upon administration, intismeran autogene is taken up and translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy the patient's cancer cells that express these neoantigens.","Intismeran Autogene | INTISMERAN AUTOGENE | PCV mRNA-4157 | V 940 | V-940 | V940 | mRNA 4157 | mRNA-4157 | mRNA-based PCV mRNA-4157 | mRNA-based Personalized Cancer Vaccine mRNA-4157 | mRNA-based Personalized Cancer Vaccine mRNA-4157",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544755","Capillary Sequencing","C146814","A DNA sequencing technology that uses a long, thin, acrylic-fiber capillary to size-separate fluorescence-labelled DNA fragments.","Capillary Sequencing | Capillary Sequencing Technology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544862","Complete Genomics Sequencing","C146815","A next-generation DNA sequencing service offered by Complete Genomics. Unamplified human genomic DNA is sheared into 500bp fragments and then amplified to create DNA nano-balls (DNBs). The DNBs are arrayed on a substrate and their sequence is determined by Combinatorial Probe-Anchor Ligation (cPAL) sequencing.","Complete Genomics Sequencing | Complete Genomics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544863","Helicos Sequencing","C146816","A proprietary next-generation DNA sequencing system from Helicos BioSciences based on zero wave guide technology and using unamplified DNA templates that are anchored to the surface of a glass slide. For each nucleotide cycle, polymerases are bound to the immobilized templates, and both fluorescently labeled nucleotides and proprietary terminators, which kinetically inhibit the polymerase from incorporating more than a single base, are added. The slide surface is then imaged with a high-intensity laser and where the fluorescent signal detected indicates a base incorporation at that position in the fluorescing template sequence.","Helicos Sequencing | HeliScope | Helicos | Helicos Sequencing Technology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551495","Inhalation Powder, Tablet Dosage Form","C149581","Solid multidose preparation intended for inhalation use. The dose of inhalation powder is generated from the tablet by a metering mechanism within the inhaler, for example by scraping off a small amount of powder from the tablet.","Inhalation Powder, Tablet Dosage Form | Inhalation powder, tablet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551491","Inhalation vapour, effervescent tablet","C149583","Solid preparation consisting of a tablet usually containing acid substances and carbonates or hydrogen carbonates that react rapidly in the presence of aqueous liquid to release carbon dioxide, intended for generation of vapor to be inhaled to obtain a local effect. The vapor may be generated by adding the tablet to hot water.","Effervescent Tablet Inhalation Vapor Dosage Form | Effervescent Tablet Inhalation Vapor | Inhalation vapour, effervescent tablet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551490","Emulsion Inhalation Vapor Dosage Form","C149584","Liquid preparation consisting of an emulsion intended for generation of vapor to be inhaled to obtain a local effect. The vapor may be generated by adding the emulsion to hot water.","Emulsion Inhalation Vapor Dosage Form | Inhalation vapour, emulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551493","Inhalation Vapor from Impregnated Pad Dosage Form","C149585","Solid preparation consisting of a piece of absorbent material impregnated usually with a liquid or semi-solid preparation, intended for generation of vapor to be inhaled to obtain a local effect.","Inhalation Vapor from Impregnated Pad Dosage Form | Inhalation vapour, impregnated pad",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551492","Inhalation Vapor from Impregnated Plug Dosage Form","C149586","Solid preparation consisting of an impregnated plug that generates a vapor to be inhaled, for example by the patient inhaling through a device containing the plug, thereby drawing air through or over it and vaporizing the active ingredient(s) impregnated therein.","Inhalation Vapor from Impregnated Plug Dosage Form | Inhalation vapour, impregnated plug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272881","Inhalation Vapor, Ointment Dosage Form","C149588","Semi-solid preparation consisting of an ointment intended for generation of vapor to be inhaled to obtain a local effect. The vapor may be generated by adding the ointment to hot water.","Inhalation Vapor, Ointment Dosage Form | Inhalation vapour, ointment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272877","Inhalation Vapor, Powder Dosage Form","C149589","Solid preparation consisting of one or more powders of solid active substance(s) intended for generation of vapor to be inhaled to obtain a local effect. The vapor is usually generated by adding the powder to hot water.","Inhalation Vapor, Powder Dosage Form | Inhalation vapour, powder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272879","Inhalation Vapor, Solution Dosage Form","C149590","Liquid preparation consisting of a solution intended for generation of vapor to be inhaled to obtain a local effect. The vapor is usually generated by adding the solution to hot water.","Inhalation Vapor, Solution Dosage Form | Inhalation vapour, solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272880","Inhalation Vapor, Tablet Dosage Form","C149591","Solid preparation consisting of a tablet intended for generation of vapor to be inhaled to obtain a local effect. The vapor is usually generated by adding the tablet to hot water.","Inhalation Vapor, Tablet Dosage Form | Inhalation vapour, tablet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551605","Powder for Intravesical Solution/Solution for Injection Dosage Form","C149833","Solid sterile preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain an intravesical solution/solution for injection.","Powder for Intravesical Solution/Solution for Injection Dosage Form | Powder for intravesical solution/solution for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551608","Powder for Intravesical Suspension Dosage Form","C149834","Solid preparation consisting of one or more powders intended to be dispersed in the specified liquid to obtain an intravesical suspension.","Powder for Intravesical Suspension Dosage Form | Powder for intravesical suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551677","Rinsing/Washing Method of Administration","C149887","The technique of administration of a pharmaceutical product by bringing it into contact with the affected area for a short period of time, e.g. by pouring it over the area and allowing it to drain away, or swilling it around the area and then removing it.","Rinsing/Washing Method of Administration | Rinsing/washing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551678","Roll-on Container","C149888","A container, usually a bottle, fitted with a roll-on applicator","Roll-on Container | Roll-on container",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1319685","Sachet","C149889","Container consisting of two surfaces made of flexible material to be closed only by sealing or folding over. The contents are intended for single use.","Sachet Container | Sachet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0183142","Scarifier Device","C149890","Device for scratching the skin.","Scarifier Device | Scarifier",,,,,,,,,,,,,,,"45759165","Scarifier",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1551383","Screw Cap","C149891","Hollow cylindrical object with screw thread, meant to close a container.","Screw Cap Device | Screw cap",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552444","Sealant Dosage Form","C149892","Liquid, more or less viscous, sterile preparation intended for use as tissue glue.","Sealant Dosage Form | Sealant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551676","Sealant Matrix Dosage Form","C149893","Solid sterile preparation consisting of a pliable piece of material impregnated or coated with a sealant or with a powder that forms a sealant after contact with an appropriate fluid (e.g. blood). It may act as a hemostatic agent and/or tissue glue. The matrix may itself form part of the seal, and is usually absorbed by the body over time.","Sealant Matrix Dosage Form | Sealant matrix",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551673","Sealant Powder Dosage Form","C149894","Solid sterile preparation consisting of one or more powders intended to be applied directly onto the intended site (e.g. a lesion) to form a hemostatic agent and/or tissue glue after contact with an appropriate fluid (e.g. blood).","Sealant Powder Dosage Form | Sealant powder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL463872","Semi-solid","C149895","A state of matter consisting of molecules in a non-rigid structure that can retain its shape and volume but that is not resistant to such change.","Semi-solid | ",,,,,,,,,,,,,,,"42537332","Semi-solid",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL551675","Single-dose Container","C149896","A container that holds a quantity of the preparation intended for total or partial use on one occasion only.","Single-dose Container | Single-dose container",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551674","Skin Scarification Route of Administration","C149897","Administration of a medicinal product by scratching the skin.","Skin Scarification Route of Administration | Skin scarification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551670","Solution and suspension for suspension for injection in pre-filled syringe","C149898","Medicinal product consisting of a solution and suspension for suspension for injection presented in a pre-filled syringe. The solution and suspension are contained in different compartments of the pre-filled syringe, which contains all of the components necessary to prepare the suspension for injection.","Solution and Suspension for Suspension for Injection in Pre-filled Syringe Dosage Form | Solution and Suspension for Suspension for Injection in Pre-filled Syringe | Solution and suspension for suspension for injection in pre-filled syringe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551669","Solution for Beehive Dispersion Dosage Form","C149899","Liquid preparation consisting of a solution intended for use in the preparation of a bee-hive dispersion.","Solution for Beehive Dispersion Dosage Form | Solution for bee-hive dispersion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551915","Unit-dose Blister","C150138","Container consisting of two layers of which one is shaped to contain the individual unit, usually provided with perforations, the intention being to allow each individual unit to be separated for single unit administration. All the information required for blister packs must appear on each unit dose presentation.","Unit-dose Blister | Unit-dose blister",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552477","Dialysis Method of Administration","C149433","The technique of administration of a pharmaceutical product by inclusion in a dialysis system as a dialysis or substitution product.","Dialysis Method of Administration | Dialysis",,,,,,,,,,,,,,,"37157673","Dialysis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL551285","Dip Emulsion Dosage Form","C149434","Liquid preparation consisting of an emulsion intended for veterinary use by dipping.","Dip Emulsion Dosage Form | Dip emulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551281","Dip Solution Dosage Form","C149435","Liquid preparation consisting of a solution intended for veterinary use by dipping.","Dip Solution Dosage Form | Dip solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551506","Nebulizer Solution Dosage Form","C149697","Liquid preparation consisting of a solution intended for inhalation use. The solution is converted into an aerosol by a continuously operating nebulizer or a metered-dose nebulizer.","Nebulizer Solution Dosage Form  | Neb | Nebs | Nebuliser solution | Nebulizer Solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551505","Nebulizer Suspension Dosage Form","C149698","Liquid preparation consisting of a suspension intended for inhalation use. The suspension is converted into an aerosol by a continuously operating nebulizer or a metered-dose nebulizer.","Nebulizer Suspension Dosage Form | Nebuliser suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551500","Needle-free Injector","C149699","Device for injecting a medicinal product, usually a liquid, by means of high pressure without a needle, through the skin barrier.","Needle-free Injector | Needle-free injector",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0217981","DOTMP","C1496","A bone-seeking chelating agent.  Has been used as a radiopharmaceutical in complexes with radioactive metals for bone marrow ablation.","DOTMP | (1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrayltetrakis(methylene))tetrakisphosphonic Acid | 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetramethylene-Phosphonic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552461","No Transformation","C149700","No transformation of the product takes place.","No Transformation | No transformation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551502","Unspecified Method of Administration","C149701","The technique of administration of a pharmaceutical product by an unspecified method.","Unspecified Method of Administration | Not specified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551496","Ophthalmic Insert Dosage Form","C149704","Solid sterile preparation of suitable size and shape, designed to be inserted in the conjunctival sac to produce a local or ocular effect by the release of active substance(s) over a determined period of time. Ophthalmic inserts generally consist of a reservoir of active substance(s) embedded in a matrix or bounded by a rate-controlling membrane. They are presented individually in sterile containers.","Ophthalmic Insert Dosage Form | Ophthalmic insert",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551499","Ophthalmic Strip Dosage Form","C149705","Solid sterile single-dose preparation consisting of a strip made of a suitable material usually impregnated with active substance(s) intended for use on the eyeball.","Ophthalmic Strip Dosage Form | Ophthalmic strip",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551498","Oral Applicator Device","C149706","Administration device for administering a liquid or semi-solid pharmaceutical form to the oral cavity.","Oral Applicator Device | Oral applicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551602","Oral Drops, Emulsion Dosage Form","C149707","Liquid, usually multidose preparation consisting of an emulsion intended for oral use. The preparation is administered in small volumes as drops by means of a suitable device such as a dropper. The measured dose may be diluted in water or another suitable liquid before swallowing.","Oral Drops, Emulsion Dosage Form | Oral drops, emulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551601","Oral Drops, Granules for Solution Dosage Form","C149708","Solid preparation consisting of granules intended to be dissolved in the specified liquid to obtain an oral drops solution.","Oral Drops, Granules for Solution Dosage Form | Oral drops, granules for solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544864","Illumina Sequencing","C146817","A proprietary next-generation DNA sequencing system from Solexa that uses reversible terminator nucleotides. The genomic DNA to be sequenced is fragmented and ligated to adapter molecules on both ends to construct an Illumina-specific adapter library. PCR amplification of the DNA fragments is then performed using the adapter sequence as primer. Sequencing is carried out by repeated cycles of adding reversible fluorescent-labelled nucleotide and incorporation of the nucleotides to the complementary strand. The fluorescence of the incorporated nucleotides is detected.","Illumina Sequencing | Illumina | Illumina Sequencing Technology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544865","Oxford Nanopore Sequencing Technology","C146818","A proprietary next-generation DNA sequencing technology from Oxford Nanopore Technologies that can directly identify and sequence a DNA molecule as it passes through a nanopore, driven by electrophoresis.","Nanopore Sequencing | Oxford Nanopore | Oxford Nanopore Sequencing | Oxford Nanopore Sequencing | Oxford Nanopore Sequencing Technology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544098","Grade 4 Meningitis, CTCAE","C145993","Life-threatening consequences; urgent intervention indicated","Grade 4 Meningitis, CTCAE | Grade 4 Meningitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544099","Grade 4 Menorrhagia, CTCAE","C145994","Life-threatening consequences; urgent intervention indicated","Grade 4 Menorrhagia, CTCAE | Grade 4 Menorrhagia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544085","Grade 4 Methemoglobinemia, CTCAE","C145996","Life-threatening consequences","Grade 4 Methemoglobinemia, CTCAE | Grade 4 Methemoglobinemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544086","Grade 4 Middle Ear Inflammation, CTCAE","C145997","Life-threatening consequences; urgent intervention indicated","Grade 4 Middle Ear Inflammation, CTCAE | Grade 4 Middle ear inflammation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544087","Grade 4 Mitral Valve Disease, CTCAE","C145998","Life-threatening consequences; urgent intervention indicated (e.g., valve replacement, valvuloplasty)","Grade 4 Mitral Valve Disease, CTCAE | Grade 4 Mitral valve disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527004","Recombinant Glial Cell-Line Derived Neurotrophic Factor","C1459","A recombinant therapeutic agent which is chemically identical to or similar to endogenous glial cell line-derived neurotrophic factor (GDNF).  GDNF is a glycosylated, disulfide-bonded homodimer distantly related member of the transforming growth factor-beta superfamily.  This agent is important in the development and maintenance of dopamine neurons, has restorative effects in a wide variety of rodent and primate models of Parkinson disease, and may have utility in the treatment of Parkinson's disease, which is marked by progressive degeneration of midbrain dopaminergic neurons. (NCI04)","Liatermin | GDNF | Glial Cell-Line Derived Neurotrophic Factor | LIATERMIN | Recombinant Glial Cell-Line Derived Neurotrophic Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544088","Grade 4 Mucosal Infection, CTCAE","C146001","Life-threatening consequences; urgent intervention indicated","Grade 4 Mucosal Infection, CTCAE | Grade 4 Mucosal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544089","Grade 4 Mucositis Oral, CTCAE","C146002","Life-threatening consequences; urgent intervention indicated","Grade 4 Mucositis Oral, CTCAE | Grade 4 Mucositis oral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544090","Grade 4 Multi-Organ Failure, CTCAE","C146003","Life-threatening consequences (e.g., vasopressor dependent and oliguric or anuric or ischemic colitis or lactic acidosis)","Grade 4 Multi-Organ Failure, CTCAE | Grade 4 Multi-organ failure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544091","Grade 4 Musculoskeletal and Connective Tissue Disorder - Other, Specify, CTCAE","C146004","Life-threatening consequences; urgent intervention indicated","Grade 4 Musculoskeletal and Connective Tissue Disorder - Other, Specify, CTCAE | Grade 4 Musculoskeletal and connective tissue disorder - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544092","Grade 4 Myasthenia Gravis, CTCAE","C146005","Life-threatening consequences; urgent intervention indicated","Grade 4 Myasthenia Gravis, CTCAE | Grade 4 Myasthenia gravis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544078","Grade 4 Myocardial Infarction, CTCAE","C146007","Life-threatening consequences; hemodynamically unstable","Grade 4 Myocardial Infarction, CTCAE | Grade 4 Myocardial infarction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544079","Grade 4 Neck Edema, CTCAE","C146008","Vascular or respiratory impairment requiring urgent intervention","Grade 4 Neck Edema, CTCAE | Grade 4 Neck edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544857","Mediastinal Germ Cell Tumor Distant Metastasis TNM Finding","C146827","A TNM finding about one or more characteristics of a mediastinal germ cell tumor as they pertain to distant metastases. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)","Mediastinal Germ Cell Tumor Distant Metastasis TNM Finding | Thymic Germ Cell Tumor Distant Metastasis TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544858","Mediastinal Germ Cell Tumor M0 TNM Finding","C146828","Mediastinal germ cell tumor without evidence of distant metastasis. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)","Mediastinal Germ Cell Tumor M0 TNM Finding | Thymic Germ Cell Tumor M0 TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544859","Mediastinal Germ Cell Tumor M1 TNM Finding","C146829","Mediastinal germ cell tumor with distant metastasis. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)","Mediastinal Germ Cell Tumor M1 TNM Finding | Thymic Germ Cell Tumor M1 TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544860","Mediastinal Germ Cell Tumor Primary Tumor TNM Finding","C146830","A TNM finding about one or more characteristics of a mediastinal germ cell tumor as they pertain to staging of the primary tumor. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)","Mediastinal Germ Cell Tumor Primary Tumor TNM Finding | Thymic Germ Cell Tumor Primary Tumor TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544846","Mediastinal Germ Cell Tumor T0 TNM Finding","C146832","No evidence of primary tumor. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)","Mediastinal Germ Cell Tumor T0 TNM Finding | Thymic Germ Cell Tumor T0 TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544847","Mediastinal Germ Cell Tumor T1 TNM Finding","C146833","Mediastinal germ cell tumor confined to the organ of origin (thymus and mediastinal fat). (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)","Mediastinal Germ Cell Tumor T1 TNM Finding | Thymic Germ Cell Tumor T1 TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544848","Mediastinal Germ Cell Tumor T1a TNM Finding","C146834","Mediastinal germ cell tumor confined to the organ of origin (thymus and mediastinal fat) and measuring 5 cm or less. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)","Mediastinal Germ Cell Tumor T1a TNM Finding | Thymic Germ Cell Tumor T1a TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544849","Mediastinal Germ Cell Tumor T1b TNM Finding","C146835","Mediastinal germ cell tumor confined to the organ of origin (thymus and mediastinal fat) and measuring more than 5 cm. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)","Mediastinal Germ Cell Tumor T1b TNM Finding | Thymic Germ Cell Tumor T1b TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544850","Mediastinal Germ Cell Tumor T2 TNM Finding","C146836","Mediastinal germ cell tumor infiltrating contiguous organs or accompanied by malignant effusion. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)","Mediastinal Germ Cell Tumor T2 TNM Finding | Thymic Germ Cell Tumor T2 TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544851","Mediastinal Germ Cell Tumor T2a TNM Finding","C146837","Mediastinal germ cell tumor infiltrating contiguous organs or accompanied by malignant effusion and measuring 5 cm or less. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)","Mediastinal Germ Cell Tumor T2a TNM Finding | Thymic Germ Cell Tumor T2a TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544852","Mediastinal Germ Cell Tumor T2b TNM Finding","C146838","Mediastinal germ cell tumor infiltrating contiguous organs or accompanied by malignant effusion and measuring more than 5 cm. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)","Mediastinal Germ Cell Tumor T2b TNM Finding | Thymic Germ Cell Tumor T2b TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544853","Mediastinal Germ Cell Tumor T3 TNM Finding","C146839","Mediastinal germ cell tumor invading into neighboring structures, such as pericardium, mediastinal pleura, thoracic wall, great vessels and lung. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)","Mediastinal Germ Cell Tumor T3 TNM Finding | Thymic Germ Cell Tumor T3 TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544839","Mediastinal Germ Cell Tumor Regional Lymph Nodes TNM Finding","C146841","A TNM finding about one or more characteristics of a mediastinal germ cell tumor as they pertain to staging of regional lymph nodes. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)","Mediastinal Germ Cell Tumor Regional Lymph Nodes TNM Finding | Thymic Germ Cell Tumor Regional Lymph Nodes TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543643","Grade 3 Papulopustular Rash, CTCAE","C145518","Papules and/or pustules covering >30% BSA with moderate or severe symptoms; limiting self-care ADL; IV antibiotics indicated","Grade 3 Papulopustular Rash, CTCAE | Grade 3 Papulopustular rash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543644","Grade 3 Paresthesia, CTCAE","C145519","Severe symptoms; limiting self care ADL","Grade 3 Paresthesia, CTCAE | Grade 3 Paresthesia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543629","Grade 3 Paronychia, CTCAE","C145520","Operative intervention indicated; IV antibiotics indicated; limiting self care ADL","Grade 3 Paronychia, CTCAE | Grade 3 Paronychia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543630","Grade 3 Paroxysmal Atrial Tachycardia, CTCAE","C145521","Symptomatic, urgent intervention indicated; ablation","Grade 3 Paroxysmal Atrial Tachycardia, CTCAE | Grade 3 Paroxysmal atrial tachycardia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543631","Grade 3 Pelvic Floor Muscle Weakness, CTCAE","C145522","Severe symptoms; limiting self care ADL","Grade 3 Pelvic Floor Muscle Weakness, CTCAE | Grade 3 Pelvic floor muscle weakness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543632","Grade 3 Pelvic Infection, CTCAE","C145523","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Pelvic Infection, CTCAE | Grade 3 Pelvic infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543634","Grade 3 Penile Infection, CTCAE","C145525","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Penile Infection, CTCAE | Grade 3 Penile infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543635","Grade 3 Perforation Bile Duct, CTCAE","C145527","Invasive intervention indicated","Grade 3 Perforation Bile Duct, CTCAE | Grade 3 Perforation bile duct",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543636","Grade 3 Pericardial Effusion, CTCAE","C145528","Effusion with physiologic consequences","Grade 3 Pericardial Effusion, CTCAE | Grade 3 Pericardial effusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543621","Grade 3 Perineal Pain, CTCAE","C145529","Severe pain; limiting self care ADL","Grade 3 Perineal Pain, CTCAE | Grade 3 Perineal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543622","Grade 3 Periorbital Edema, CTCAE","C145530","Edema associated with visual disturbance; increased intraocular pressure, glaucoma or retinal hemorrhage; optic neuritis; diuretics indicated; operative intervention indicated","Grade 3 Periorbital Edema, CTCAE | Grade 3 Periorbital edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543623","Grade 3 Periorbital Infection, CTCAE","C145531","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Periorbital Infection, CTCAE | Grade 3 Periorbital infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543625","Grade 3 Peripheral Motor Neuropathy, CTCAE","C145533","Severe symptoms; limiting self care ADL","Grade 3 Peripheral Motor Neuropathy, CTCAE | Grade 3 Peripheral motor neuropathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543626","Grade 3 Peripheral Nerve Infection, CTCAE","C145534","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Peripheral Nerve Infection, CTCAE | Grade 3 Peripheral nerve infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543627","Grade 3 Peripheral Sensory Neuropathy, CTCAE","C145535","Severe symptoms; limiting self care ADL","Grade 3 Peripheral Sensory Neuropathy, CTCAE | Grade 3 Peripheral sensory neuropathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543628","Grade 3 Peritoneal Infection, CTCAE","C145536","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Peritoneal Infection, CTCAE | Grade 3 Peritoneal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543613","Grade 3 Personality Change, CTCAE","C145538","Severe personality change; hospitalization not indicated","Grade 3 Personality Change, CTCAE | Grade 3 Personality change",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543834","Grade 3 Wrist Fracture, CTCAE","C145729","Limiting self care ADL; elective operative intervention indicated requiring hospitalization","Grade 3 Wrist Fracture, CTCAE | Grade 3 Wrist fracture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543835","Grade 4 Abdominal Infection, CTCAE","C145730","Life-threatening consequences; urgent intervention indicated","Grade 4 Abdominal Infection, CTCAE | Grade 4 Abdominal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543836","Grade 4 Abdominal Soft Tissue Necrosis, CTCAE","C145731","Life-threatening consequences; urgent intervention indicated","Grade 4 Abdominal Soft Tissue Necrosis, CTCAE | Grade 4 Abdominal soft tissue necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543821","Grade 4 Acidosis, CTCAE","C145732","Life-threatening consequences","Grade 4 Acidosis, CTCAE | Grade 4 Acidosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543822","Grade 4 Acute Kidney Injury, CTCAE","C145733","Life-threatening consequences; dialysis indicated","Grade 4 Acute Kidney Injury, CTCAE | Grade 4 Acute kidney injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543823","Grade 4 Alanine Aminotransferase Increased, CTCAE","C145734",">20.0 x ULN if baseline was normal; >20.0 x baseline if baseline was abnormal","Grade 4 Alanine Aminotransferase Increased, CTCAE | Grade 4 Alanine aminotransferase increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543824","Grade 4 Alcohol Intolerance, CTCAE","C145735","Life-threatening consequences; urgent intervention indicated","Grade 4 Alcohol Intolerance, CTCAE | Grade 4 Alcohol intolerance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543826","Grade 4 Alkalosis, CTCAE","C145737","Life-threatening consequences","Grade 4 Alkalosis, CTCAE | Grade 4 Alkalosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543827","Grade 4 Allergic Reaction, CTCAE","C145738","Life-threatening consequences; urgent intervention indicated","Grade 4 Allergic Reaction, CTCAE | Grade 4 Allergic reaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544239","Grade 4 Small Intestine Infection, CTCAE","C146121","Life-threatening consequences; urgent intervention indicated","Grade 4 Small Intestine Infection, CTCAE | Grade 4 Small intestine infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544240","Grade 4 Small Intestine Ulcer, CTCAE","C146122","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Small Intestine Ulcer, CTCAE | Grade 4 Small intestine ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544241","Grade 4 Social Circumstances - Other, Specify, CTCAE","C146123","Life-threatening consequences; urgent intervention indicated","Grade 4 Social Circumstances - Other, Specify, CTCAE | Grade 4 Social circumstances - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544242","Grade 4 Soft Tissue Infection, CTCAE","C146124","Life-threatening consequences; urgent intervention indicated","Grade 4 Soft Tissue Infection, CTCAE | Grade 4 Soft tissue infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544244","Grade 4 Soft Tissue Necrosis Upper Limb, CTCAE","C146126","Life-threatening consequences; urgent intervention indicated","Grade 4 Soft Tissue Necrosis Upper Limb, CTCAE | Grade 4 Soft tissue necrosis upper limb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544229","Grade 4 Somnolence, CTCAE","C146127","Life-threatening consequences; urgent intervention indicated","Grade 4 Somnolence, CTCAE | Grade 4 Somnolence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544230","Grade 4 Spasticity, CTCAE","C146128","Life-threatening consequences; unable to move active or passive range of motion","Grade 4 Spasticity, CTCAE | Grade 4 Spasticity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544231","Grade 4 Spermatic Cord Anastomotic Leak, CTCAE","C146129","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Spermatic Cord Anastomotic Leak, CTCAE | Grade 4 Spermatic cord anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544232","Grade 4 Spinal Cord Compression, CTCAE","C146130","Life-threatening consequences; urgent intervention indicated","Grade 4 Spinal Cord Compression, CTCAE | Grade 4 Spinal cord compression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544233","Grade 4 Spinal Fracture, CTCAE","C146131","Life-threatening consequences; symptoms associated with neurovascular compromise","Grade 4 Spinal Fracture, CTCAE | Grade 4 Spinal fracture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543596","Grade 3 Laryngeal Inflammation, CTCAE","C145431","Severe throat pain; endoscopic intervention indicated","Grade 3 Laryngeal Inflammation, CTCAE | Grade 3 Laryngeal inflammation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543581","Grade 3 Laryngeal Mucositis, CTCAE","C145432","Severe pain; severely altered eating/swallowing; medical intervention indicated","Grade 3 Laryngeal Mucositis, CTCAE | Grade 3 Laryngeal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543582","Grade 3 Laryngeal Obstruction, CTCAE","C145433","Limiting self care ADL; stridor; endoscopic intervention indicated (e.g., stent, laser)","Grade 3 Laryngeal Obstruction, CTCAE | Grade 3 Laryngeal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544735","Fluorine F 18 Tetrafluoroborate","C146693","A radioconjugate composed of the sodium-iodide symporter (NIS; SLC5A5) ligand tetrafluoroborate (TFB) labeled with the radionuclide fluorine F 18, with potential use as an imaging agent for NIS-expressing cells upon positron emission tomography (PET). Upon administration, fluorine F 18 tetrafluoroborate targets, binds to, and is taken up by NIS, which is expressed on the surface of cells in the normal thyroid gland, lactating mammary gland and various tumors. Then, NIS-expressing cells can be visualized and NIS expression levels can be assessed using PET. Since iodides are taken up by NIS, this agent may predict the uptake of radioactive iodine by thyroid cancer cells.","Fluorine F 18 Tetrafluoroborate | 18F-TFB | 18F-Tetrafluoroborate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527007","Recombinant Fibroblast Growth Factor 3","C1466","A recombinant agent which is chemically identical to or similar to endogenous fibroblast growth factor 3 (FGF-3). FGF-3 is a growth factor for epithelial cells, and is involved in the differentiation of mesodermal structures during embryonic development. (NCI04)","Recombinant Fibroblast Growth Factor 3 | FGF3 | Fibroblast Growth Factor 3 | HBGF-3 | Proto-Oncogene Protein Int-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543868","Grade 4 Ejection Fraction Decreased, CTCAE","C145828","Resting ejection fraction (EF) <20%","Grade 4 Ejection Fraction Decreased, CTCAE | Grade 4 Ejection fraction decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543981","Grade 4 Electrocardiogram QT Corrected Interval Prolonged, CTCAE","C145829","Torsade de pointes; polymorphic ventricular tachycardia; signs/symptoms of serious arrhythmia","Grade 4 Electrocardiogram QT Corrected Interval Prolonged, CTCAE | Grade 4 Electrocardiogram QT corrected interval prolonged",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543982","Grade 4 Encephalitis Infection, CTCAE","C145830","Life-threatening consequences; urgent intervention indicated","Grade 4 Encephalitis Infection, CTCAE | Grade 4 Encephalitis infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543984","Grade 4 Endocarditis Infective, CTCAE","C145832","Life-threatening consequences; urgent intervention indicated","Grade 4 Endocarditis Infective, CTCAE | Grade 4 Endocarditis infective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543985","Grade 4 Endocrine Disorders - Other, Specify, CTCAE","C145833","Life-threatening consequences; urgent intervention indicated","Grade 4 Endocrine Disorders - Other, Specify, CTCAE | Grade 4 Endocrine disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543986","Grade 4 Endophthalmitis, CTCAE","C145834","Best corrected visual acuity of 20/200 or worse in the affected eye","Grade 4 Endophthalmitis, CTCAE | Grade 4 Endophthalmitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543987","Grade 4 Enterocolitis Infectious, CTCAE","C145835","Life-threatening consequences; urgent intervention indicated","Grade 4 Enterocolitis Infectious, CTCAE | Grade 4 Enterocolitis infectious",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544274","Grade 5 Atrioventricular Block Complete, CTCAE","C146226","Death","Grade 5 Atrioventricular Block Complete, CTCAE | Grade 5 Atrioventricular block complete",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544276","Grade 5 Avascular Necrosis, CTCAE","C146228","Death","Grade 5 Avascular Necrosis, CTCAE | Grade 5 Avascular necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544261","Grade 5 Bile Duct Stenosis, CTCAE","C146229","Death","Grade 5 Bile Duct Stenosis, CTCAE | Grade 5 Bile duct stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544262","Grade 5 Biliary Anastomotic Leak, CTCAE","C146230","Death","Grade 5 Biliary Anastomotic Leak, CTCAE | Grade 5 Biliary anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544263","Grade 5 Biliary Fistula, CTCAE","C146231","Death","Grade 5 Biliary Fistula, CTCAE | Grade 5 Biliary fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544264","Grade 5 Biliary Tract Infection, CTCAE","C146232","Death","Grade 5 Biliary Tract Infection, CTCAE | Grade 5 Biliary tract infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544265","Grade 5 Bladder Anastomotic Leak, CTCAE","C146233","Death","Grade 5 Bladder Anastomotic Leak, CTCAE | Grade 5 Bladder anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544267","Grade 5 Blood and Lymphatic System Disorders - Other, Specify, CTCAE","C146235","Death","Grade 5 Blood and Lymphatic System Disorders - Other, Specify, CTCAE | Grade 5 Blood and lymphatic system disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544268","Grade 5 Bone Infection, CTCAE","C146236","Death","Grade 5 Bone Infection, CTCAE | Grade 5 Bone infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544253","Grade 5 Bone Marrow Hypocellular, CTCAE","C146237","Death","Grade 5 Bone Marrow Hypocellular, CTCAE | Grade 5 Bone marrow hypocellular",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544254","Grade 5 Breast Infection, CTCAE","C146238","Death","Grade 5 Breast Infection, CTCAE | Grade 5 Breast infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544255","Grade 5 Bronchial Fistula, CTCAE","C146239","Death","Grade 5 Bronchial Fistula, CTCAE | Grade 5 Bronchial fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544256","Grade 5 Bronchial Infection, CTCAE","C146240","Death","Grade 5 Bronchial Infection, CTCAE | Grade 5 Bronchial infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544258","Grade 5 Bronchial Stricture, CTCAE","C146242","Death","Grade 5 Bronchial Stricture, CTCAE | Grade 5 Bronchial stricture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544788","BMS 986249","C146765","A probody composed of ipilimumab, a recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), linked to a proprietary masking peptide that covers the active antigen-binding site of the antibody through a protease-cleavable linker, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of sovipostobart, the masking peptide is cleaved by tumor-associated proteases upon extravasation into the tumor microenvironment (TME). Protease-mediated removal of the linker enables binding of the unmasked monoclonal antibody moiety to CTLA-4, which is expressed on certain T-cells. This inhibits the CTLA4-mediated downregulation of T-cell activation, and leads to both activation of tumor infiltrating T-effector cells and a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily expressed on activated effector T-cells (Teffs) and regulatory T-cells (Tregs), plays a key role in the inhibition of T-cell activity and downregulation of the immune system. The peptide masking of BMS-986249 minimizes binding to CTLA-4 in normal tissues and may reduce systemic toxicity, when compared to ipilimumab. Tumor-associated proteases are present in high concentrations and aberrantly activated in the TME.","Sovipostobart | BMS 986249 | BMS-986249 | BMS986249 | CTLA-4 Probody BMS-986249 | CTLA-4-directed Probody BMS-986249 | CTLA-4-directed Probody BMS-986249 | Protease-activated Anti-CTLA-4 Antibody Prodrug BMS-986249 | SOVIPOSTOBART",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544786","Autologous TCR-engineered T-cells IMA201","C146779","A preparation of autologous T-lymphocytes that are genetically modified with a lentiviral vector encoding a T-cell receptor (TCR) specific for an as of yet not identified tumor-associated antigen (TAA), with potential antineoplastic activity. Upon intravenous administration back into the patient, the autologous TCR-engineered T-cells IMA201 specifically recognize and bind to the TAA on cancer cells, which induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against the TAA-positive cancer cells.","Autologous TCR-engineered T-cells IMA201 | ACTengine IMA201 | Autologous T-cell Receptor-engineered T-cells IMA201 | IMA 201 | IMA-201 | IMA201 | IMA201 Autologous T-lymphocytes | IMA201 T-cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544235","Grade 4 Stenosis of Gastrointestinal Stoma, CTCAE","C146133","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Stenosis of Gastrointestinal Stoma, CTCAE | Grade 4 Stenosis of gastrointestinal stoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544236","Grade 4 Stevens-Johnson Syndrome, CTCAE","C146134","Skin sloughing covering 10-30% BSA with associated signs (e.g., erythema, purpura, epidermal detachment and mucous membrane detachment)","Grade 4 Stevens-Johnson Syndrome, CTCAE | Grade 4 Stevens-Johnson syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544222","Grade 4 Stridor, CTCAE","C146136","Life-threatening airway compromise; urgent intervention indicated (e.g., tracheotomy or intubation)","Grade 4 Stridor, CTCAE | Grade 4 Stridor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544223","Grade 4 Stroke, CTCAE","C146137","Life-threatening consequences; urgent intervention indicated","Grade 4 Stroke, CTCAE | Grade 4 Stroke",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544224","Grade 4 Suicidal Ideation, CTCAE","C146138","Specific plan to commit suicide with serious intent to die which requires hospitalization","Grade 4 Suicidal Ideation, CTCAE | Grade 4 Suicidal ideation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544225","Grade 4 Suicide Attempt, CTCAE","C146139","Suicide attempt with intent to die which requires hospitalization","Grade 4 Suicide Attempt, CTCAE | Grade 4 Suicide attempt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544227","Grade 4 Superior Vena Cava Syndrome, CTCAE","C146141","Life-threatening consequences; urgent multi-modality intervention indicated (e.g., lysis, thrombectomy, surgery)","Grade 4 Superior Vena Cava Syndrome, CTCAE | Grade 4 Superior vena cava syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544228","Grade 4 Surgical and Medical Procedures - Other, Specify, CTCAE","C146142","Life-threatening consequences; urgent intervention indicated","Grade 4 Surgical and Medical Procedures - Other, Specify, CTCAE | Grade 4 Surgical and medical procedures - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544213","Grade 4 Testicular Disorder, CTCAE","C146143","Life-threatening consequences; urgent intervention indicated","Grade 4 Testicular Disorder, CTCAE | Grade 4 Testicular disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543415","Grade 3 Hepatic Infection, CTCAE","C145334","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Hepatic Infection, CTCAE | Grade 3 Hepatic infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543416","Grade 3 Hepatic Pain, CTCAE","C145335","Severe pain; limiting self care ADL","Grade 3 Hepatic Pain, CTCAE | Grade 3 Hepatic pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543418","Grade 3 Hepatitis Viral, CTCAE","C145337","Symptomatic liver dysfunction; fibrosis by biopsy; compensated cirrhosis; hospitalization or prolongation of existing hospitalization indicated","Grade 3 Hepatitis Viral, CTCAE | Grade 3 Hepatitis viral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543419","Grade 3 Hepatobiliary Disorders - Other, Specify, CTCAE","C145338","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL","Grade 3 Hepatobiliary Disorders - Other, Specify, CTCAE | Grade 3 Hepatobiliary disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543420","Grade 3 Herpes Simplex Reactivation, CTCAE","C145339","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; IV intervention indicated","Grade 3 Herpes Simplex Reactivation, CTCAE | Grade 3 Herpes simplex reactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543533","Grade 3 Hiccups, CTCAE","C145340","Severe symptoms; interfering with sleep; limiting self care ADL","Grade 3 Hiccups, CTCAE | Grade 3 Hiccups",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543534","Grade 3 Hip Fracture, CTCAE","C145341","Severe pain; hospitalization or intervention indicated for pain control (e.g., traction); operative intervention indicated","Grade 3 Hip Fracture, CTCAE | Grade 3 Hip fracture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543535","Grade 3 Hoarseness, CTCAE","C145342","Severe voice changes including predominantly whispered speech","Grade 3 Hoarseness, CTCAE | Grade 3 Hoarseness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544717","Mediastinal/Thymic NUT Carcinoma","C146706","A highly aggressive, poorly differentiated carcinoma that arises from the mediastinum/thymus. It is characterized by mutations and rearrangement of the NUT gene.","Mediastinal/Thymus NUT Carcinoma | Mediastinal/Thymic NMC | Mediastinal/Thymic NUT Carcinoma | Mediastinal/Thymic NUT Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543884","Grade 4 Cytokine Release Syndrome, CTCAE","C145811","Life-threatening consequences; urgent intervention indicated","Grade 4 Cytokine Release Syndrome, CTCAE | Grade 4 Cytokine release syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543870","Grade 4 Death Neonatal, CTCAE","C145813","Neonatal loss of life","Grade 4 Death Neonatal, CTCAE | Grade 4 Death neonatal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543871","Grade 4 Delirium, CTCAE","C145814","Life-threatening consequences, threats of harm to self or others; urgent intervention indicated","Grade 4 Delirium, CTCAE | Grade 4 Delirium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543872","Grade 4 Delusions, CTCAE","C145815","Life-threatening consequences, threats of harm to self or others; hospitalization indicated","Grade 4 Delusions, CTCAE | Grade 4 Delusions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543874","Grade 4 Dermatitis Radiation, CTCAE","C145817","Life-threatening consequences; skin necrosis or ulceration of full thickness dermis; spontaneous bleeding from involved site; skin graft indicated","Grade 4 Dermatitis Radiation, CTCAE | Grade 4 Dermatitis radiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543875","Grade 4 Device Related Infection, CTCAE","C145818","Life-threatening consequences; urgent intervention indicated","Grade 4 Device Related Infection, CTCAE | Grade 4 Device related infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543876","Grade 4 Duodenal Hemorrhage, CTCAE","C145820","Life-threatening consequences; urgent intervention indicated","Grade 4 Duodenal Hemorrhage, CTCAE | Grade 4 Duodenal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543861","Grade 4 Duodenal Infection, CTCAE","C145821","Life-threatening consequences; urgent intervention indicated","Grade 4 Duodenal Infection, CTCAE | Grade 4 Duodenal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543862","Grade 4 Duodenal Obstruction, CTCAE","C145822","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Duodenal Obstruction, CTCAE | Grade 4 Duodenal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543864","Grade 4 Duodenal Stenosis, CTCAE","C145824","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Duodenal Stenosis, CTCAE | Grade 4 Duodenal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543865","Grade 4 Duodenal Ulcer, CTCAE","C145825","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Duodenal Ulcer, CTCAE | Grade 4 Duodenal ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543866","Grade 4 Ear and Labyrinth Disorders - Other, Specify, CTCAE","C145826","Life-threatening consequences; urgent intervention indicated","Grade 4 Ear and Labyrinth Disorders - Other, Specify, CTCAE | Grade 4 Ear and labyrinth disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544259","Grade 5 Bronchopleural Fistula, CTCAE","C146243","Death","Grade 5 Bronchopleural Fistula, CTCAE | Grade 5 Bronchopleural fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544260","Grade 5 Bronchopulmonary Hemorrhage, CTCAE","C146244","Death","Grade 5 Bronchopulmonary Hemorrhage, CTCAE | Grade 5 Bronchopulmonary hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544245","Grade 5 Bronchospasm, CTCAE","C146245","Death","Grade 5 Bronchospasm, CTCAE | Grade 5 Bronchospasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544246","Grade 5 Budd-Chiari Syndrome, CTCAE","C146246","Death","Grade 5 Budd-Chiari Syndrome, CTCAE | Grade 5 Budd-Chiari syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544247","Grade 5 Bullous Dermatitis, CTCAE","C146247","Death","Grade 5 Bullous Dermatitis, CTCAE | Grade 5 Bullous dermatitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544249","Grade 5 Cardiac Arrest, CTCAE","C146249","Death","Grade 5 Cardiac Arrest, CTCAE | Grade 5 Cardiac arrest",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544250","Grade 5 Cardiac Disorders - Other, Specify, CTCAE","C146250","Death","Grade 5 Cardiac Disorders - Other, Specify, CTCAE | Grade 5 Cardiac disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544252","Grade 5 Cecal Hemorrhage, CTCAE","C146252","Death","Grade 5 Cecal Hemorrhage, CTCAE | Grade 5 Cecal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544365","Grade 5 Cecal Infection, CTCAE","C146253","Death","Grade 5 Cecal Infection, CTCAE | Grade 5 Cecal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544366","Grade 5 Central Nervous System Necrosis, CTCAE","C146254","Death","Grade 5 Central Nervous System Necrosis, CTCAE | Grade 5 Central nervous system necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544367","Grade 5 Cerebrospinal Fluid Leakage, CTCAE","C146255","Death","Grade 5 Cerebrospinal Fluid Leakage, CTCAE | Grade 5 Cerebrospinal fluid leakage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543584","Grade 3 Laryngitis, CTCAE","C145435","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Laryngitis, CTCAE | Grade 3 Laryngitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543585","Grade 3 Laryngopharyngeal Dysesthesia, CTCAE","C145436","Severe symptoms; dyspnea and swallowing difficulty; limiting self care ADL","Grade 3 Laryngopharyngeal Dysesthesia, CTCAE | Grade 3 Laryngopharyngeal dysesthesia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543587","Grade 3 Leukocytosis, CTCAE","C145438",">100,000/mm3","Grade 3 Leukocytosis, CTCAE | Grade 3 Leukocytosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543588","Grade 3 Leukoencephalopathy, CTCAE","C145439","Severe symptoms; extensive T2/FLAIR hyperintensities, involving periventricular white matter involving 2/3 or more of susceptible areas of cerebrum +/- moderate to severe increase in SAS and/or moderate to severe ventriculomegaly","Grade 3 Leukoencephalopathy, CTCAE | Grade 3 Leukoencephalopathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543573","Grade 3 Lip Infection, CTCAE","C145440","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Lip Infection, CTCAE | Grade 3 Lip infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543574","Grade 3 Lipase Increased, CTCAE","C145441",">2.0-5.0 x ULN with signs or symptoms; >5.0 x ULN and asymptomatic","Grade 3 Lipase Increased, CTCAE | Grade 3 Lipase increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543575","Grade 3 Lipohypertrophy, CTCAE","C145442","Covering >30% BSA and associated tenderness and narcotics or NSAIDs indicated; lipohypertrophy; limiting self care ADL","Grade 3 Lipohypertrophy, CTCAE | Grade 3 Lipohypertrophy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543576","Grade 3 Localized Edema, CTCAE","C145443","Severe localized edema and intervention indicated; limiting self care ADL","Grade 3 Localized Edema, CTCAE | Grade 3 Localized edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543577","Grade 3 Lordosis, CTCAE","C145444","Severe accentuation; operative intervention indicated; limiting self care ADL","Grade 3 Lordosis, CTCAE | Grade 3 Lordosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543578","Grade 3 Lower Gastrointestinal Hemorrhage, CTCAE","C145445","Transfusion indicated; invasive intervention indicated; hospitalization","Grade 3 Lower Gastrointestinal Hemorrhage, CTCAE | Grade 3 Lower gastrointestinal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544042","Grade 4 Hypocalcemia, CTCAE","C145908","Corrected serum calcium of <6.0 mg/dL; <1.5 mmol/L; Ionized calcium <0.8 mmol/L; life-threatening consequences","Grade 4 Hypocalcemia, CTCAE | Grade 4 Hypocalcemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544044","Grade 4 Hypohidrosis, CTCAE","C145910","Heat stroke","Grade 4 Hypohidrosis, CTCAE | Grade 4 Hypohidrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544029","Grade 4 Hypokalemia, CTCAE","C145911","<2.5 mmol/L; life-threatening consequences","Grade 4 Hypokalemia, CTCAE | Grade 4 Hypokalemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544030","Grade 4 Hypomagnesemia, CTCAE","C145912","<0.7 mg/dL; <0.3 mmol/L; life-threatening consequences","Grade 4 Hypomagnesemia, CTCAE | Grade 4 Hypomagnesemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544031","Grade 4 Hyponatremia, CTCAE","C145913","<120 mmol/L; life-threatening consequences","Grade 4 Hyponatremia, CTCAE | Grade 4 Hyponatremia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544032","Grade 4 Hypoparathyroidism, CTCAE","C145914","Life-threatening consequences; urgent intervention indicated","Grade 4 Hypoparathyroidism, CTCAE | Grade 4 Hypoparathyroidism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544033","Grade 4 Hypophosphatemia, CTCAE","C145915","Life-threatening consequences","Grade 4 Hypophosphatemia, CTCAE | Grade 4 Hypophosphatemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544034","Grade 4 Hypophysitis, CTCAE","C145916","Life-threatening consequences; urgent intervention indicated","Grade 4 Hypophysitis, CTCAE | Grade 4 Hypophysitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544036","Grade 4 Hypothyroidism, CTCAE","C145918","Life-threatening consequences; urgent intervention indicated","Grade 4 Hypothyroidism, CTCAE | Grade 4 Hypothyroidism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544021","Grade 4 Ileal Perforation, CTCAE","C145922","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Ileal Perforation, CTCAE | Grade 4 Ileal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544022","Grade 4 Ileal Stenosis, CTCAE","C145923","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Ileal Stenosis, CTCAE | Grade 4 Ileal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544023","Grade 4 Immune System Disorders - Other, Specify, CTCAE","C145926","Life-threatening consequences; urgent intervention indicated","Grade 4 Immune System Disorders - Other, Specify, CTCAE | Grade 4 Immune system disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544024","Grade 4 Infections and Infestations - Other, Specify, CTCAE","C145927","Life-threatening consequences; urgent intervention indicated","Grade 4 Infections and Infestations - Other, Specify, CTCAE | Grade 4 Infections and infestations - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544025","Grade 4 Infective Myositis, CTCAE","C145928","Life-threatening consequences; urgent intervention indicated","Grade 4 Infective Myositis, CTCAE | Grade 4 Infective myositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544026","Grade 4 Infusion Related Reaction, CTCAE","C145929","Life-threatening consequences; urgent intervention indicated","Grade 4 Infusion Related Reaction, CTCAE | Grade 4 Infusion related reaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544028","Grade 4 Injection Site Reaction, CTCAE","C145931","Life-threatening consequences; urgent intervention indicated","Grade 4 Injection Site Reaction, CTCAE | Grade 4 Injection site reaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544013","Grade 4 Injury To Carotid Artery, CTCAE","C145932","Life-threatening consequences; urgent intervention indicated","Grade 4 Injury To Carotid Artery, CTCAE | Grade 4 Injury to carotid artery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544014","Grade 4 Injury To Jugular Vein, CTCAE","C145934","Life-threatening consequences; urgent intervention indicated","Grade 4 Injury To Jugular Vein, CTCAE | Grade 4 Injury to jugular vein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544015","Grade 4 Injury To Superior Vena Cava, CTCAE","C145935","Life-threatening consequences; urgent intervention indicated","Grade 4 Injury To Superior Vena Cava, CTCAE | Grade 4 Injury to superior vena cava",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544016","Grade 4 Injury, Poisoning and Procedural Complications - Other, Specify, CTCAE","C145936","Life-threatening consequences; urgent intervention indicated","Grade 4 Injury, Poisoning and Procedural Complications - Other, Specify, CTCAE | Grade 4 Injury, poisoning and procedural complications - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543536","Grade 3 Hot Flashes, CTCAE","C145343","Severe symptoms; limiting self care ADL","Grade 3 Hot Flashes, CTCAE | Grade 3 Hot flashes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543537","Grade 3 Hypercalcemia, CTCAE","C145344","Corrected serum calcium of >12.5-13.5 mg/dL; >3.1-3.4 mmol/L; Ionized calcium >1.6-1.8 mmol/L; hospitalization indicated","Grade 3 Hypercalcemia, CTCAE | Grade 3 Hypercalcemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543538","Grade 3 Hyperglycemia, CTCAE","C145345","Insulin therapy initiated; hospitalization indicated","Grade 3 Hyperglycemia, CTCAE | Grade 3 Hyperglycemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543539","Grade 3 Hyperhidrosis, CTCAE","C145346","Associated with electrolyte/hemodynamic imbalance","Grade 3 Hyperhidrosis, CTCAE | Grade 3 Hyperhidrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543525","Grade 3 Hyperkeratosis, CTCAE","C145348","Limiting self-care ADLs","Grade 3 Hyperkeratosis, CTCAE | Grade 3 Hyperkeratosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543526","Grade 3 Hyperlipidemia, CTCAE","C145349","Hospitalization; pancreatitis","Grade 3 Hyperlipidemia, CTCAE | Grade 3 Hyperlipidemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543527","Grade 3 Hypermagnesemia, CTCAE","C145350",">3.0-8.0 mg/dL; >1.23-3.30 mmol/L","Grade 3 Hypermagnesemia, CTCAE | Grade 3 Hypermagnesemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543528","Grade 3 Hypernatremia, CTCAE","C145351",">155-160 mmol/L; hospitalization indicated","Grade 3 Hypernatremia, CTCAE | Grade 3 Hypernatremia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543529","Grade 3 Hyperphosphatemia, CTCAE","C145352","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated","Grade 3 Hyperphosphatemia, CTCAE | Grade 3 Hyperphosphatemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543530","Grade 3 Hypersomnia, CTCAE","C145353","Severe increased need for sleep","Grade 3 Hypersomnia, CTCAE | Grade 3 Hypersomnia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543532","Grade 3 Hypertriglyceridemia, CTCAE","C145355",">500 mg/dL-1000 mg/dL; >5.7 mmol/L-11.4 mmol/L","Grade 3 Hypertriglyceridemia, CTCAE | Grade 3 Hypertriglyceridemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543517","Grade 3 Hyperuricemia, CTCAE","C145356",">ULN with physiologic consequences","Grade 3 Hyperuricemia, CTCAE | Grade 3 Hyperuricemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543518","Grade 3 Hypoalbuminemia, CTCAE","C145357","<2 g/dL; <20 g/L","Grade 3 Hypoalbuminemia, CTCAE | Grade 3 Hypoalbuminemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543519","Grade 3 Hypocalcemia, CTCAE","C145358","Corrected serum calcium of <7.0-6.0 mg/dL; <1.75-1.5 mmol/L; Ionized calcium <0.9-0.8 mmol/L; hospitalization indicated","Grade 3 Hypocalcemia, CTCAE | Grade 3 Hypocalcemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545224","Macroscopic Findings Supplemental Qualifiers Dataset","C147221","A dataset containing supplemental information, specifically non-standard variables, to parent records in the macroscopic findings domain.","Macroscopic Findings Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545225","Microbiology Specimen Supplemental Qualifiers Dataset","C147222","A dataset containing supplemental information, specifically non-standard variables, to parent records in the microbiology specimen domain.","Microbiology Specimen Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545210","Medical History Supplemental Qualifiers Dataset","C147223","A dataset containing supplemental information, specifically non-standard variables, to parent records in the medical history domain.","Medical History Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545211","Microscopic Findings Supplemental Qualifiers Dataset","C147224","A dataset containing supplemental information, specifically non-standard variables, to parent records in the microscopic findings domain.","Microscopic Findings Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545212","Musculoskeletal System Findings Supplemental Qualifiers Dataset","C147225","A dataset containing supplemental information, specifically non-standard variables, to parent records in the musculoskeletal system findings domain.","Musculoskeletal System Findings Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545214","Microbiology Susceptibility Supplemental Qualifiers Dataset","C147227","A dataset containing supplemental information, specifically non-standard variables, to parent records in the microbiology susceptibility domain.","Microbiology Susceptibility Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545215","Nervous System Findings Supplemental Qualifiers Dataset","C147228","A dataset containing supplemental information, specifically non-standard variables, to parent records in the nervous system findings domain.","Nervous System Findings Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545216","Ophthalmic Examinations Supplemental Qualifiers Dataset","C147229","A dataset containing supplemental information, specifically non-standard variables, to parent records in the ophthalmic examinations domain.","Ophthalmic Examinations Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545217","Non-Host Organism Identifiers Supplemental Qualifiers Dataset","C147230","A dataset containing supplemental information, specifically non-standard variables, to parent records in the non-host organism identifiers domain.","Non-Host Organism Identifiers Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545202","Organ Measurements Supplemental Qualifiers Dataset","C147231","A dataset containing supplemental information, specifically non-standard variables, to parent records in the organ measurements domain.","Organ Measurements Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545203","Pharmacogenomics/Genetics Biomarker Supplemental Qualifiers Dataset","C147232","A dataset containing supplemental information, specifically non-standard variables, to parent records in the pharmacogenomics/genetics biomarker domain.","Pharmacogenomics/Genetics Biomarker Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543580","Grade 3 Lymph Gland Infection, CTCAE","C145447","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Lymph Gland Infection, CTCAE | Grade 3 Lymph gland infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543565","Grade 3 Lymph Leakage, CTCAE","C145448","Severe symptoms; invasive intervention indicated","Grade 3 Lymph Leakage, CTCAE | Grade 3 Lymph leakage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543566","Grade 3 Lymphedema, CTCAE","C145449","Severe symptoms; limiting self care ADL","Grade 3 Lymphedema, CTCAE | Grade 3 Lymphedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543567","Grade 3 Lymphocyte Count Decreased, CTCAE","C145450","<500-200/mm3; <0.5-0.2 x 10e9/L","Grade 3 Lymphocyte Count Decreased, CTCAE | Grade 3 Lymphocyte count decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543568","Grade 3 Lymphocyte Count Increased, CTCAE","C145451",">20,000/mm3","Grade 3 Lymphocyte Count Increased, CTCAE | Grade 3 Lymphocyte count increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543570","Grade 3 Mania, CTCAE","C145453","Severe manic symptoms (e.g., hypomania; major sexual or financial indiscretions); hospitalization not indicated; new onset","Grade 3 Mania, CTCAE | Grade 3 Mania",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543571","Grade 3 Mediastinal Infection, CTCAE","C145455","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Mediastinal Infection, CTCAE | Grade 3 Mediastinal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543557","Grade 3 Meningitis, CTCAE","C145457","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated; focal neurologic deficit","Grade 3 Meningitis, CTCAE | Grade 3 Meningitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543558","Grade 3 Menorrhagia, CTCAE","C145458","Severe; transfusion indicated; operative intervention indicated (e.g., hysterectomy)","Grade 3 Menorrhagia, CTCAE | Grade 3 Menorrhagia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543559","Grade 3 Metabolism and Nutrition Disorders - Other, Specify, CTCAE","C145459","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL","Grade 3 Metabolism and Nutrition Disorders - Other, Specify, CTCAE | Grade 3 Metabolism and nutrition disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544722","Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM","C146711","A vaccine consisting of irradiated allogeneic breast cancer cells, derived from the breast cancer cell line SV-BR-1 that are transfected with the immunostimulant granulocyte-macrophage colony-stimulating factor (GM-CSF; CSF2) gene, with potential immunostimulating and antineoplastic activities. Upon intradermal administration of the allogeneic GM-CSF-secreting breast cancer vaccine SV-BR-1-GM, the genetically-modified cells secrete GM-CSF. This potentiates a tumor-specific cytotoxic T-lymphocyte (CTL) immune response against breast cancer cells.","Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM | Breast Cancer Vaccine SV-BR-1-GM | Bria-IMT | GM-CSF Gene-transfected Breast Cancer Vaccine SV-BR-1-GM | SV-BR-1 Breast Cancer Cell Line Vaccine | SV-BR-1-GM | SV-BR-1-GM Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544840","Mediastinal Germ Cell Tumor NX TNM Finding","C146842","Regional lymph nodes cannot be assessed. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)","Mediastinal Germ Cell Tumor NX TNM Finding | Thymic Germ Cell Tumor NX TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544841","Mediastinal Germ Cell Tumor N0 TNM Finding","C146843","Mediastinal germ cell tumor with no regional lymph node metastasis. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)","Mediastinal Germ Cell Tumor N0 TNM Finding | Thymic Germ Cell Tumor N0 TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544176","Grade 4 Personality Change, CTCAE","C146046","Life-threatening consequences, threats of harm to self or others; hospitalization indicated","Grade 4 Personality Change, CTCAE | Grade 4 Personality change",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544177","Grade 4 Pharyngeal Anastomotic Leak, CTCAE","C146047","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Pharyngeal Anastomotic Leak, CTCAE | Grade 4 Pharyngeal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544178","Grade 4 Pharyngeal Mucositis, CTCAE","C146050","Life-threatening consequences; urgent intervention indicated","Grade 4 Pharyngeal Mucositis, CTCAE | Grade 4 Pharyngeal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544179","Grade 4 Pharyngeal Stenosis, CTCAE","C146052","Life-threatening airway compromise; urgent intervention indicated (e.g., tracheotomy or intubation)","Grade 4 Pharyngeal Stenosis, CTCAE | Grade 4 Pharyngeal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544180","Grade 4 Pharyngitis, CTCAE","C146053","Life-threatening consequences; urgent intervention indicated","Grade 4 Pharyngitis, CTCAE | Grade 4 Pharyngitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544165","Grade 4 Phlebitis Infective, CTCAE","C146054","Life-threatening consequences; urgent intervention indicated","Grade 4 Phlebitis Infective, CTCAE | Grade 4 Phlebitis infective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544166","Grade 4 Platelet Count Decreased, CTCAE","C146055","<25,000/mm3; <25.0 x 10e9/L","Grade 4 Platelet Count Decreased, CTCAE | Grade 4 Platelet count decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544167","Grade 4 Pleural Effusion, CTCAE","C146056","Life-threatening respiratory or hemodynamic compromise; intubation or urgent intervention indicated","Grade 4 Pleural Effusion, CTCAE | Grade 4 Pleural effusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544168","Grade 4 Pleural Infection, CTCAE","C146058","Life-threatening consequences; urgent intervention indicated","Grade 4 Pleural Infection, CTCAE | Grade 4 Pleural infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544169","Grade 4 Pneumonitis, CTCAE","C146059","Life-threatening respiratory compromise; urgent intervention indicated (e.g., tracheotomy or intubation)","Grade 4 Pneumonitis, CTCAE | Grade 4 Pneumonitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544170","Grade 4 Portal Hypertension, CTCAE","C146060","Life-threatening consequences; urgent intervention indicated","Grade 4 Portal Hypertension, CTCAE | Grade 4 Portal hypertension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544171","Grade 4 Portal Vein Thrombosis, CTCAE","C146061","Life-threatening consequences; urgent intervention indicated","Grade 4 Portal Vein Thrombosis, CTCAE | Grade 4 Portal vein thrombosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544172","Grade 4 Postoperative Hemorrhage, CTCAE","C146062","Life-threatening consequences; urgent intervention indicated","Grade 4 Postoperative Hemorrhage, CTCAE | Grade 4 Postoperative hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544157","Grade 4 Postoperative Thoracic Procedure Complication, CTCAE","C146063","Life-threatening airway compromise; urgent intervention indicated (e.g., tracheotomy or intubation)","Grade 4 Postoperative Thoracic Procedure Complication, CTCAE | Grade 4 Postoperative thoracic procedure complication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544158","Grade 4 Pregnancy Loss, CTCAE","C146064","Fetal loss at any gestational age","Grade 4 Pregnancy Loss, CTCAE | Grade 4 Pregnancy loss",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544159","Grade 4 Pregnancy, Puerperium and Perinatal Conditions - Other, Specify, CTCAE","C146065","Life-threatening consequences; urgent intervention indicated","Grade 4 Pregnancy, Puerperium and Perinatal Conditions - Other, Specify, CTCAE | Grade 4 Pregnancy, puerperium and perinatal conditions - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543828","Grade 4 Anal Fistula, CTCAE","C145739","Life-threatening consequences; urgent intervention indicated","Grade 4 Anal Fistula, CTCAE | Grade 4 Anal fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543813","Grade 4 Anal Hemorrhage, CTCAE","C145740","Life-threatening consequences; urgent intervention indicated","Grade 4 Anal Hemorrhage, CTCAE | Grade 4 Anal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543814","Grade 4 Anal Necrosis, CTCAE","C145741","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Anal Necrosis, CTCAE | Grade 4 Anal necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543816","Grade 4 Anal Ulcer, CTCAE","C145743","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Anal Ulcer, CTCAE | Grade 4 Anal ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545355","Qualitative Histopathologic Examination","C147493","A general histopathologic examination, without a prespecified visual target, focused on qualitative or semi-quantitative findings.","Qualitative Histopathologic Examination | GHISTXQL | General Histopathologic Exam, Qual | General Histopathologic Examination, Qualitative | General Histopathological Exam, Qual",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545356","Decreased Corpora Lutea","C147494","A decrease in the number of corpora lutea within the ovary.","Decreased Corpora Lutea | CORPORA LUTEA, DECREASED NUMBER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545345","Increased Eroded Surface","C147496","An increase in the amount of surface erosion.","Increased Eroded Surface | ERODED SURFACE, INCREASED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545346","Intrahepatocellular Erythrocytes","C147497","The presence of red blood cells within hepatocytes of the liver parenchyma.","Intrahepatocellular Erythrocytes | INTRAHEPATOCELLULAR ERYTHROCYTES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545347","Increased Osteoclasts","C147498","An increase in the amount of osteoclasts.","Increased Osteoclasts | OSTEOCLASTS, INCREASED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL535097","Severity One Out of Three","C147499","A severity result of one, on a three level scale.","Severity One Out of Three | 1 OF 3 | Severity 1 of 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550647","Severity One Out of Four","C147500","A severity result of one, on a four level scale.","Severity One Out of Four | 1 OF 4 | Severity 1 of 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550649","Severity One Out of Five","C147501","A severity result of one, on a five level scale.","Severity One Out of Five | 1 OF 5 | Severity 1 of 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550653","Severity Two Out of Four","C147503","A severity result of two, on a four level scale.","Severity Two Out of Four | 2 OF 4 | Severity 2 of 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550654","Severity Two Out of Five","C147504","A severity result of two, on a five level scale.","Severity Two Out of Five | 2 OF 5 | Severity 2 of 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550646","Severity Three Out of Three","C147505","A severity result of three, on a three level scale.","Severity Three Out of Three | 3 OF 3 | Severity 3 of 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545608","TSCC - Not Trusting People Because Sex","C147732","Trauma Symptom Checklist for Children (TSCC) Not trusting people because they might want sex.","TSCC - Not Trusting People Because Sex | TSCC01-Not Trusting People Because Sex | TSCC0134",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545609","TSCC - Can't Stop Thinking Something Bad","C147733","Trauma Symptom Checklist for Children (TSCC) Can't stop thinking about something bad that happened to me.","TSCC - Can't Stop Thinking Something Bad | TSCC01-Can't Stop Thinking Something Bad | TSCC0135",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544711","Thymic Hepatoid Adenocarcinoma","C146717","A very rare adenocarcinoma that arises from the thymus. It is characterized by the presence of malignant polygonal cells resembling hepatocytes.","Thymus Hepatoid Adenocarcinoma | Thymic Hepatoid Adenocarcinoma | Thymic Hepatoid Adenocarcinoma | Thymic Hepatoid Carcinoma | Thymus Hepatoid Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544714","Fosnetupitant/Palonosetron Hydrochloride","C146720","A combination formulation containing the prodrug of netupitant, fosnetupitant, a selective neurokinin 1 receptor (NK1R; TACR1) antagonist, and the hydrochloride salt form of palonosetron, a selective serotonin (5-hydroxytrytamine; 5-HT) receptor subtype 3 (5-HT3R) antagonist, with potential antiemetic activity. Upon intravenous administration, fosnetupitant is converted by phosphatases to its active form netupitant. Netupitant competitively binds to and blocks the activity of NK1Rs in the central nervous system (CNS), by inhibiting binding of the endogenous tachykinin-derived neuropeptide substance P (SP) to NK1R. This prevents delayed emesis, which is associated with SP secretion. Palonosetron competitively blocks the interaction of 5-HT with 5-HT3Rs located on vagal afferent nerves in the chemoreceptor trigger zone (CTZ). This inhibits acute emesis associated with 5-HT secretion and subsequent 5-HT3R activation. Altogether, this results in inhibition of acute and delayed nausea and vomiting, and may prevent chemotherapy-induced nausea and vomiting (CINV).","Fosnetupitant/Palonosetron Hydrochloride | Fosnetupitant-Palonosetron HCl | Fosnetupitant/Palonosetron HCl Combination | IV NEPA FDC | Pro-netupitant/Palonosetron | Pronetupitant/Palonosetron",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543988","Grade 4 Enterocolitis, CTCAE","C145836","Life-threatening consequences; urgent intervention indicated","Grade 4 Enterocolitis, CTCAE | Grade 4 Enterocolitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543973","Grade 4 Enterovesical Fistula, CTCAE","C145837","Life-threatening consequences; urgent intervention indicated","Grade 4 Enterovesical Fistula, CTCAE | Grade 4 Enterovesical fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543975","Grade 4 Epstein-Barr Virus Infection Reactivation, CTCAE","C145839","Life-threatening consequences; urgent intervention indicated","Grade 4 Epstein-Barr Virus Infection Reactivation, CTCAE | Grade 4 Epstein-Barr virus infection reactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543976","Grade 4 Erythema Multiforme, CTCAE","C145840","Target lesions covering >30% BSA; associated with fluid or electrolyte abnormalities; ICU care or burn unit indicated","Grade 4 Erythema Multiforme, CTCAE | Grade 4 Erythema multiforme",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543977","Grade 4 Erythroderma, CTCAE","C145841","Erythema covering >90% BSA with associated fluid or electrolyte abnormalities; ICU care or burn unit indicated","Grade 4 Erythroderma, CTCAE | Grade 4 Erythroderma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543978","Grade 4 Esophageal Anastomotic Leak, CTCAE","C145842","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Esophageal Anastomotic Leak, CTCAE | Grade 4 Esophageal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543979","Grade 4 Esophageal Hemorrhage, CTCAE","C145844","Life-threatening consequences; urgent intervention indicated","Grade 4 Esophageal Hemorrhage, CTCAE | Grade 4 Esophageal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544160","Grade 4 Premature Delivery, CTCAE","C146066","Delivery of a liveborn infant at 24 weeks of gestation or less","Grade 4 Premature Delivery, CTCAE | Grade 4 Premature delivery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544161","Grade 4 Prolapse of Intestinal Stoma, CTCAE","C146067","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Prolapse of Intestinal Stoma, CTCAE | Grade 4 Prolapse of intestinal stoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544163","Grade 4 Prostate Infection, CTCAE","C146069","Life-threatening consequences; urgent intervention indicated","Grade 4 Prostate Infection, CTCAE | Grade 4 Prostate infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544524","Grade 5 Reproductive System and Breast Disorders - Other, Specify, CTCAE","C146529","Death","Grade 5 Reproductive System and Breast Disorders - Other, Specify, CTCAE | Grade 5 Reproductive system and breast disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544510","Grade 5 Respiratory, Thoracic and Mediastinal Disorders - Other, Specify, CTCAE","C146531","Death","Grade 5 Respiratory, Thoracic and Mediastinal Disorders - Other, Specify, CTCAE | Grade 5 Respiratory, thoracic and mediastinal disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544511","Grade 5 Retroperitoneal Hemorrhage, CTCAE","C146532","Death","Grade 5 Retroperitoneal Hemorrhage, CTCAE | Grade 5 Retroperitoneal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544512","Grade 5 Reversible Posterior Leukoencephalopathy Syndrome, CTCAE","C146533","Death","Grade 5 Reversible Posterior Leukoencephalopathy Syndrome, CTCAE | Grade 5 Reversible posterior leukoencephalopathy syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544513","Grade 5 Rhabdomyolysis, CTCAE","C146534","Death","Grade 5 Rhabdomyolysis, CTCAE | Grade 5 Rhabdomyolysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544514","Grade 5 Salivary Duct Inflammation, CTCAE","C146535","Death","Grade 5 Salivary Duct Inflammation, CTCAE | Grade 5 Salivary duct inflammation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544516","Grade 5 Scrotal Infection, CTCAE","C146537","Death","Grade 5 Scrotal Infection, CTCAE | Grade 5 Scrotal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544501","Grade 5 Sepsis, CTCAE","C146538","Death","Grade 5 Sepsis, CTCAE | Grade 5 Sepsis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544502","Grade 5 Shingles, CTCAE","C146539","Death","Grade 5 Shingles, CTCAE | Grade 5 Shingles",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544503","Grade 5 Sinus Disorder, CTCAE","C146540","Death","Grade 5 Sinus Disorder, CTCAE | Grade 5 Sinus disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544504","Grade 5 Sinusitis, CTCAE","C146541","Death","Grade 5 Sinusitis, CTCAE | Grade 5 Sinusitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544505","Grade 5 Sinusoidal Obstruction Syndrome, CTCAE","C146542","Death","Grade 5 Sinusoidal Obstruction Syndrome, CTCAE | Grade 5 Sinusoidal obstruction syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544507","Grade 5 Skin Induration, CTCAE","C146544","Death","Grade 5 Skin Induration, CTCAE | Grade 5 Skin induration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544508","Grade 5 Skin Infection, CTCAE","C146545","Death","Grade 5 Skin Infection, CTCAE | Grade 5 Skin infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544621","Grade 5 Skin Ulceration, CTCAE","C146546","Death","Grade 5 Skin Ulceration, CTCAE | Grade 5 Skin ulceration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544622","Grade 5 Sleep Apnea, CTCAE","C146547","Death","Grade 5 Sleep Apnea, CTCAE | Grade 5 Sleep apnea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543817","Grade 4 Anaphylaxis, CTCAE","C145744","Life-threatening consequences; urgent intervention indicated","Grade 4 Anaphylaxis, CTCAE | Grade 4 Anaphylaxis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543818","Grade 4 Anemia, CTCAE","C145745","Life-threatening consequences; urgent intervention indicated","Grade 4 Anemia, CTCAE | Grade 4 Anemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543819","Grade 4 Anorectal Infection, CTCAE","C145746","Life-threatening consequences; urgent intervention indicated","Grade 4 Anorectal Infection, CTCAE | Grade 4 Anorectal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543820","Grade 4 Aortic Injury, CTCAE","C145747","Life-threatening consequences; evidence of end organ damage; urgent operative intervention indicated","Grade 4 Aortic Injury, CTCAE | Grade 4 Aortic injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543805","Grade 4 Aortic Valve Disease, CTCAE","C145748","Life-threatening consequences; urgent intervention indicated (e.g., valve replacement, valvuloplasty)","Grade 4 Aortic Valve Disease, CTCAE | Grade 4 Aortic valve disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543806","Grade 4 Appendicitis Perforated, CTCAE","C145749","Life-threatening consequences; urgent intervention indicated","Grade 4 Appendicitis Perforated, CTCAE | Grade 4 Appendicitis perforated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543808","Grade 4 Arachnoiditis, CTCAE","C145751","Life-threatening consequences; urgent intervention indicated","Grade 4 Arachnoiditis, CTCAE | Grade 4 Arachnoiditis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543809","Grade 4 Arterial Injury, CTCAE","C145752","Life-threatening consequences; evidence of end organ damage; urgent operative intervention indicated","Grade 4 Arterial Injury, CTCAE | Grade 4 Arterial injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543810","Grade 4 Arterial Thromboembolism, CTCAE","C145753","Life-threatening consequences; hemodynamic or neurologic instability; organ damage; loss of extremity(ies)","Grade 4 Arterial Thromboembolism, CTCAE | Grade 4 Arterial thromboembolism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543811","Grade 4 Arteritis Infective, CTCAE","C145754","Life-threatening consequences; urgent intervention indicated","Grade 4 Arteritis Infective, CTCAE | Grade 4 Arteritis infective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543812","Grade 4 Ascites, CTCAE","C145755","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Ascites, CTCAE | Grade 4 Ascites",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543797","Grade 4 Aspartate Aminotransferase Increased, CTCAE","C145756",">20.0 x ULN if baseline was normal; >20.0 x baseline if baseline was abnormal","Grade 4 Aspartate Aminotransferase Increased, CTCAE | Grade 4 Aspartate aminotransferase increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543799","Grade 4 Autoimmune Disorder, CTCAE","C145758","Life-threatening consequences; urgent intervention indicated","Grade 4 Autoimmune Disorder, CTCAE | Grade 4 Autoimmune disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543800","Grade 4 Avascular Necrosis, CTCAE","C145759","Life-threatening consequences; urgent intervention indicated","Grade 4 Avascular Necrosis, CTCAE | Grade 4 Avascular necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543801","Grade 4 Bile Duct Stenosis, CTCAE","C145760","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Bile Duct Stenosis, CTCAE | Grade 4 Bile duct stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543802","Grade 4 Biliary Anastomotic Leak, CTCAE","C145761","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Biliary Anastomotic Leak, CTCAE | Grade 4 Biliary anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543803","Grade 4 Biliary Fistula, CTCAE","C145762","Life-threatening consequences; urgent intervention indicated","Grade 4 Biliary Fistula, CTCAE | Grade 4 Biliary fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543804","Grade 4 Biliary Tract Infection, CTCAE","C145763","Life-threatening consequences; urgent intervention indicated","Grade 4 Biliary Tract Infection, CTCAE | Grade 4 Biliary tract infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544215","Grade 4 Thrombotic Thrombocytopenic Purpura, CTCAE","C146146","Life-threatening consequences, (e.g., CNS hemorrhage or thrombosis/embolism or renal failure)","Grade 4 Thrombotic Thrombocytopenic Purpura, CTCAE | Grade 4 Thrombotic thrombocytopenic purpura",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545610","TSCC - Getting Into Fights","C147734","Trauma Symptom Checklist for Children (TSCC) Getting into fights.","TSCC - Getting Into Fights | TSCC01-Getting Into Fights | TSCC0136",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545611","TSCC - Feeling Mean","C147735","Trauma Symptom Checklist for Children (TSCC) Feeling mean.","TSCC - Feeling Mean | TSCC01-Feeling Mean | TSCC0137",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545612","TSCC - Pretending I'm Somewhere Else","C147736","Trauma Symptom Checklist for Children (TSCC) Pretending I'm somewhere else.","TSCC - Pretending I'm Somewhere Else | TSCC01-Pretending I'm Somewhere Else | TSCC0138",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545613","TSCC - Being Afraid of the Dark","C147737","Trauma Symptom Checklist for Children (TSCC) Being afraid of the dark.","TSCC - Being Afraid of the Dark | TSCC01-Being Afraid of the Dark | TSCC0139",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545598","TSCC - Scared When Think About Sex","C147738","Trauma Symptom Checklist for Children (TSCC) Getting scared or upset when I think about sex.","TSCC - Scared When Think About Sex | TSCC01-Scared When Think About Sex | TSCC0140",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516108","BALB/c-Hfh11nu X DD/1","C14773","No value exists.","BALB/c-Hfh11nu X DD/1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545600","TSCC - Feeling Like Nobody Likes Me","C147740","Trauma Symptom Checklist for Children (TSCC) Feeling like nobody likes me.","TSCC - Feeling Like Nobody Likes Me | TSCC01-Feeling Like Nobody Likes Me | TSCC0142",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545601","TSCC - Remembering Things Don't Want To","C147741","Trauma Symptom Checklist for Children (TSCC) Remembering things I don't want to remember.","TSCC - Remembering Things Don't Want To | TSCC01-Remembering Things Don't Want To | TSCC0143",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545602","TSCC - Having Sex Feelings in My Body","C147742","Trauma Symptom Checklist for Children (TSCC) Having sex feelings in my body.","TSCC - Having Sex Feelings in My Body | TSCC01-Having Sex Feelings in My Body | TSCC0144",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545603","TSCC - My Mind Going Empty or Blank","C147743","Trauma Symptom Checklist for Children (TSCC) My mind going empty or blank.","TSCC - My Mind Going Empty or Blank | TSCC01-My Mind Going Empty or Blank | TSCC0145",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545604","TSCC - Feeling Like I Hate People","C147744","Trauma Symptom Checklist for Children (TSCC) Feeling like I hate people.","TSCC - Feeling Like I Hate People | TSCC01-Feeling Like I Hate People | TSCC0146",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545590","TSCC - Trying Not to Have Any Feelings","C147746","Trauma Symptom Checklist for Children (TSCC) Trying not to have any feelings.","TSCC - Trying Not to Have Any Feelings | TSCC01-Trying Not to Have Any Feelings | TSCC0148",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545592","TSCC - Feeling Afraid Somebody Kill Me","C147748","Trauma Symptom Checklist for Children (TSCC) Feeling afraid somebody will kill me.","TSCC - Feeling Afraid Somebody Kill Me | TSCC01-Feeling Afraid Somebody Kill Me | TSCC0150",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545593","TSCC - Wishing Bad Things Never Happened","C147749","Trauma Symptom Checklist for Children (TSCC) Wishing bad things had never happened.","TSCC - Wishing Bad Things Never Happened | TSCC01-Wishing Bad Things Never Happened | TSCC0151",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517650","KSN Mouse","C14774","No value exists.","KSN Mouse | KSN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545594","TSCC - Wanting to Kill Myself","C147750","Trauma Symptom Checklist for Children (TSCC) Wanting to kill myself.","TSCC - Wanting to Kill Myself | TSCC01-Wanting to Kill Myself | TSCC0152",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543980","Grade 4 Esophageal Infection, CTCAE","C145845","Life-threatening consequences; urgent intervention indicated","Grade 4 Esophageal Infection, CTCAE | Grade 4 Esophageal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543965","Grade 4 Esophageal Necrosis, CTCAE","C145846","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Esophageal Necrosis, CTCAE | Grade 4 Esophageal necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543967","Grade 4 Esophageal Perforation, CTCAE","C145848","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Esophageal Perforation, CTCAE | Grade 4 Esophageal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543968","Grade 4 Esophageal Stenosis, CTCAE","C145849","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Esophageal Stenosis, CTCAE | Grade 4 Esophageal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543969","Grade 4 Esophageal Ulcer, CTCAE","C145850","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Esophageal Ulcer, CTCAE | Grade 4 Esophageal ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543970","Grade 4 Extraocular Muscle Paresis, CTCAE","C145851","Bilateral paresis requiring head turning to see beyond central 60 degrees or double vision in central gaze","Grade 4 Extraocular Muscle Paresis, CTCAE | Grade 4 Extraocular muscle paresis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543971","Grade 4 Extrapyramidal Disorder, CTCAE","C145852","Life-threatening consequences; urgent intervention indicated","Grade 4 Extrapyramidal Disorder, CTCAE | Grade 4 Extrapyramidal disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543972","Grade 4 Eye Disorders - Other, Specify, CTCAE","C145853","Sight-threatening consequences; urgent intervention indicated; best corrected visual acuity of 20/200 or worse in the affected eye","Grade 4 Eye Disorders - Other, Specify, CTCAE | Grade 4 Eye disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543957","Grade 4 Eye Infection, CTCAE","C145854","Life-threatening consequences; urgent intervention indicated; enucleation","Grade 4 Eye Infection, CTCAE | Grade 4 Eye infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543959","Grade 4 Fetal Growth Retardation, CTCAE","C145857","<1% percentile of weight for gestational age","Grade 4 Fetal Growth Retardation, CTCAE | Grade 4 Fetal growth retardation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543960","Grade 4 Fever, CTCAE","C145858",">40.0 degrees C (>104.0 degrees F) for >24 hrs","Grade 4 Fever, CTCAE | Grade 4 Fever",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543961","Grade 4 Fibrinogen Decreased, CTCAE","C145859","<0.25 x LLN; if abnormal, 75% decrease from baseline; absolute value <50 mg/dL","Grade 4 Fibrinogen Decreased, CTCAE | Grade 4 Fibrinogen decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543962","Grade 4 Fibrosis Deep Connective Tissue, CTCAE","C145860","Generalized; associated with signs or symptoms of impaired breathing or feeding","Grade 4 Fibrosis Deep Connective Tissue, CTCAE | Grade 4 Fibrosis deep connective tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543963","Grade 4 Forced Expiratory Volume Decreased, CTCAE","C145861","<=49%","Grade 4 Forced Expiratory Volume Decreased, CTCAE | Grade 4 Forced expiratory volume decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544369","Grade 5 Chest Wall Necrosis, CTCAE","C146257","Death","Grade 5 Chest Wall Necrosis, CTCAE | Grade 5 Chest wall necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544370","Grade 5 Chronic Kidney Disease, CTCAE","C146258","Death","Grade 5 Chronic Kidney Disease, CTCAE | Grade 5 Chronic kidney disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544372","Grade 5 Colonic Fistula, CTCAE","C146260","Death","Grade 5 Colonic Fistula, CTCAE | Grade 5 Colonic fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544357","Grade 5 Colonic Hemorrhage, CTCAE","C146261","Death","Grade 5 Colonic Hemorrhage, CTCAE | Grade 5 Colonic hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544358","Grade 5 Colonic Obstruction, CTCAE","C146262","Death","Grade 5 Colonic Obstruction, CTCAE | Grade 5 Colonic obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544359","Grade 5 Colonic Perforation, CTCAE","C146263","Death","Grade 5 Colonic Perforation, CTCAE | Grade 5 Colonic perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544623","Grade 5 Small Intestinal Anastomotic Leak, CTCAE","C146548","Death","Grade 5 Small Intestinal Anastomotic Leak, CTCAE | Grade 5 Small intestinal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544624","Grade 5 Small Intestinal Mucositis, CTCAE","C146549","Death","Grade 5 Small Intestinal Mucositis, CTCAE | Grade 5 Small intestinal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544625","Grade 5 Small Intestinal Obstruction, CTCAE","C146550","Death","Grade 5 Small Intestinal Obstruction, CTCAE | Grade 5 Small intestinal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544626","Grade 5 Small Intestinal Perforation, CTCAE","C146551","Death","Grade 5 Small Intestinal Perforation, CTCAE | Grade 5 Small intestinal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544627","Grade 5 Small Intestinal Stenosis, CTCAE","C146552","Death","Grade 5 Small Intestinal Stenosis, CTCAE | Grade 5 Small intestinal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544614","Grade 5 Social Circumstances - Other, Specify, CTCAE","C146555","Death","Grade 5 Social Circumstances - Other, Specify, CTCAE | Grade 5 Social circumstances - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544615","Grade 5 Soft Tissue Infection, CTCAE","C146556","Death","Grade 5 Soft Tissue Infection, CTCAE | Grade 5 Soft tissue infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544616","Grade 5 Soft Tissue Necrosis Lower Limb, CTCAE","C146557","Death","Grade 5 Soft Tissue Necrosis Lower Limb, CTCAE | Grade 5 Soft tissue necrosis lower limb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544617","Grade 5 Soft Tissue Necrosis Upper Limb, CTCAE","C146558","Death","Grade 5 Soft Tissue Necrosis Upper Limb, CTCAE | Grade 5 Soft tissue necrosis upper limb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544618","Grade 5 Somnolence, CTCAE","C146559","Death","Grade 5 Somnolence, CTCAE | Grade 5 Somnolence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544619","Grade 5 Spasticity, CTCAE","C146560","Death","Grade 5 Spasticity, CTCAE | Grade 5 Spasticity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544605","Grade 5 Spinal Cord Compression, CTCAE","C146562","Death","Grade 5 Spinal Cord Compression, CTCAE | Grade 5 Spinal cord compression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544606","Grade 5 Spinal Fracture, CTCAE","C146563","Death","Grade 5 Spinal Fracture, CTCAE | Grade 5 Spinal fracture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544607","Grade 5 Splenic Infection, CTCAE","C146564","Death","Grade 5 Splenic Infection, CTCAE | Grade 5 Splenic infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544608","Grade 5 Stenosis of Gastrointestinal Stoma, CTCAE","C146565","Death","Grade 5 Stenosis of Gastrointestinal Stoma, CTCAE | Grade 5 Stenosis of gastrointestinal stoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544609","Grade 5 Stevens-Johnson Syndrome, CTCAE","C146566","Death","Grade 5 Stevens-Johnson Syndrome, CTCAE | Grade 5 Stevens-Johnson syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544610","Grade 5 Stoma Site Infection, CTCAE","C146567","Death","Grade 5 Stoma Site Infection, CTCAE | Grade 5 Stoma site infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544612","Grade 5 Stroke, CTCAE","C146569","Death","Grade 5 Stroke, CTCAE | Grade 5 Stroke",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544597","Grade 5 Sudden Death NOS, CTCAE","C146570","Death","Grade 5 Sudden Death NOS, CTCAE | Grade 5 Sudden death NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544598","Grade 5 Suicide Attempt, CTCAE","C146571","Death","Grade 5 Suicide Attempt, CTCAE | Grade 5 Suicide attempt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544599","Grade 5 Superficial Soft Tissue Fibrosis, CTCAE","C146572","Death","Grade 5 Superficial Soft Tissue Fibrosis, CTCAE | Grade 5 Superficial soft tissue fibrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544600","Grade 5 Superior Vena Cava Syndrome, CTCAE","C146573","Death","Grade 5 Superior Vena Cava Syndrome, CTCAE | Grade 5 Superior vena cava syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544602","Grade 5 Thromboembolic Event, CTCAE","C146576","Death","Grade 5 Thromboembolic Event, CTCAE | Grade 5 Thromboembolic event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544216","Grade 4 Tooth Infection, CTCAE","C146147","Life-threatening consequences; urgent intervention indicated","Grade 4 Tooth Infection, CTCAE | Grade 4 Tooth infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544217","Grade 4 Toxic Epidermal Necrolysis, CTCAE","C146148","Skin sloughing covering >=30% BSA with associated symptoms (e.g., erythema, purpura, or epidermal detachment)","Grade 4 Toxic Epidermal Necrolysis, CTCAE | Grade 4 Toxic epidermal necrolysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544218","Grade 4 Tracheal Mucositis, CTCAE","C146151","Life-threatening consequences; urgent intervention indicated","Grade 4 Tracheal Mucositis, CTCAE | Grade 4 Tracheal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544219","Grade 4 Tracheal Obstruction, CTCAE","C146152","Life-threatening airway compromise; urgent intervention indicated (e.g., tracheotomy or intubation)","Grade 4 Tracheal Obstruction, CTCAE | Grade 4 Tracheal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544220","Grade 4 Tracheal Stenosis, CTCAE","C146153","Life-threatening airway compromise; urgent intervention indicated (e.g., tracheotomy or intubation)","Grade 4 Tracheal Stenosis, CTCAE | Grade 4 Tracheal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544205","Grade 4 Tracheitis, CTCAE","C146154","Life-threatening consequences; urgent intervention indicated","Grade 4 Tracheitis, CTCAE | Grade 4 Tracheitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544206","Grade 4 Tracheostomy Site Bleeding, CTCAE","C146155","Life-threatening consequences; urgent intervention indicated","Grade 4 Tracheostomy Site Bleeding, CTCAE | Grade 4 Tracheostomy site bleeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544208","Grade 4 Tricuspid Valve Disease, CTCAE","C146157","Life-threatening consequences; urgent intervention indicated (e.g., valve replacement, valvuloplasty)","Grade 4 Tricuspid Valve Disease, CTCAE | Grade 4 Tricuspid valve disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544209","Grade 4 Tumor Hemorrhage, CTCAE","C146158","Life-threatening consequences; urgent intervention indicated","Grade 4 Tumor Hemorrhage, CTCAE | Grade 4 Tumor hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544211","Grade 4 Upper Gastrointestinal Hemorrhage, CTCAE","C146160","Life-threatening consequences; urgent intervention indicated","Grade 4 Upper Gastrointestinal Hemorrhage, CTCAE | Grade 4 Upper gastrointestinal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544212","Grade 4 Upper Respiratory Infection, CTCAE","C146161","Life-threatening consequences; urgent intervention indicated","Grade 4 Upper Respiratory Infection, CTCAE | Grade 4 Upper respiratory infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544197","Grade 4 Ureteric Anastomotic Leak, CTCAE","C146162","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Ureteric Anastomotic Leak, CTCAE | Grade 4 Ureteric anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544198","Grade 4 Urethral Anastomotic Leak, CTCAE","C146163","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Urethral Anastomotic Leak, CTCAE | Grade 4 Urethral anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544199","Grade 4 Urethral Infection, CTCAE","C146164","Life-threatening consequences; urgent intervention indicated","Grade 4 Urethral Infection, CTCAE | Grade 4 Urethral infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544201","Grade 4 Urinary Tract Infection, CTCAE","C146166","Life-threatening consequences; urgent intervention indicated","Grade 4 Urinary Tract Infection, CTCAE | Grade 4 Urinary tract infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544202","Grade 4 Urinary Tract Obstruction, CTCAE","C146167","Life-threatening consequences; urgent intervention indicated","Grade 4 Urinary Tract Obstruction, CTCAE | Grade 4 Urinary tract obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544203","Grade 4 Urine Output Decreased, CTCAE","C146168","Adult: Anuria (<240 ml in 24 hr); Pediatric: No urine output over 12 hours","Grade 4 Urine Output Decreased, CTCAE | Grade 4 Urine output decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544204","Grade 4 Urostomy Leak, CTCAE","C146169","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Urostomy Leak, CTCAE | Grade 4 Urostomy leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544960","RNF43 NM_017763.5:c.420C>G","C146974","A nucleotide substitution at position 420 of the coding sequence of the RNF453 gene where cytosine has been mutated to guanine.","RNF43 NM_017763.5:c.420C>G | NM_017763.5:c.420C>G | RNF124 c.420C>G | RNF43 c.420C>G | Ring Finger Protein 43 Gene c.420C>G | URCC c.420C>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544962","RNF43 NM_017763.5:c.461C>T","C146976","A nucleotide substitution at position 461 of the coding sequence of the RNF453 gene where cytosine has been mutated to thymine.","RNF43 NM_017763.5:c.461C>T | NM_017763.5:c.461C>T | RNF124 c.461C>T | RNF43 c.461C>T | Ring Finger Protein 43 Gene c.461C>T | URCC c.461C>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544964","RNF43 NM_017763.5:c.505G>A","C146978","A nucleotide substitution at position 505 of the coding sequence of the RNF453 gene where guanine has been mutated to adenine.","RNF43 NM_017763.5:c.505G>A | NM_017763.5:c.505G>A | RNF124 c.505G>A | RNF43 c.505G>A | Ring Finger Protein 43 Gene c.505G>A | URCC c.505G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544950","RNF43 NM_017763.5:c.954G>T","C146980","A nucleotide substitution at position 954 of the coding sequence of the RNF453 gene where guanine has been mutated to thymine.","RNF43 NM_017763.5:c.954G>T | NM_017763.5:c.954G>T | RNF124 c.954G>T | RNF43 c.954G>T | Ring Finger Protein 43 Gene c.954G>T | URCC c.954G>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544360","Grade 5 Colonic Stenosis, CTCAE","C146264","Death","Grade 5 Colonic Stenosis, CTCAE | Grade 5 Colonic stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544362","Grade 5 Conduction Disorder, CTCAE","C146266","Death","Grade 5 Conduction Disorder, CTCAE | Grade 5 Conduction disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544363","Grade 5 Congenital, Familial and Genetic Disorders - Other, Specify, CTCAE","C146267","Death","Grade 5 Congenital, Familial and Genetic Disorders - Other, Specify, CTCAE | Grade 5 Congenital, familial and genetic disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544364","Grade 5 Corneal Infection, CTCAE","C146268","Death","Grade 5 Corneal Infection, CTCAE | Grade 5 Corneal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544349","Grade 5 Cranial Nerve Infection, CTCAE","C146269","Death","Grade 5 Cranial Nerve Infection, CTCAE | Grade 5 Cranial nerve infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544351","Grade 5 Cytokine Release Syndrome, CTCAE","C146271","Death","Grade 5 Cytokine Release Syndrome, CTCAE | Grade 5 Cytokine release syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544353","Grade 5 Delirium, CTCAE","C146274","Death","Grade 5 Delirium, CTCAE | Grade 5 Delirium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544354","Grade 5 Delusions, CTCAE","C146275","Death","Grade 5 Delusions, CTCAE | Grade 5 Delusions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544356","Grade 5 Dermatitis Radiation, CTCAE","C146277","Death","Grade 5 Dermatitis Radiation, CTCAE | Grade 5 Dermatitis radiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544341","Grade 5 Device Related Infection, CTCAE","C146278","Death","Grade 5 Device Related Infection, CTCAE | Grade 5 Device related infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544342","Grade 5 Disease Progression, CTCAE","C146279","Death","Grade 5 Disease Progression, CTCAE | Grade 5 Disease progression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544343","Grade 5 Duodenal Hemorrhage, CTCAE","C146281","Death","Grade 5 Duodenal Hemorrhage, CTCAE | Grade 5 Duodenal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544345","Grade 5 Duodenal Obstruction, CTCAE","C146283","Death","Grade 5 Duodenal Obstruction, CTCAE | Grade 5 Duodenal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544346","Grade 5 Duodenal Perforation, CTCAE","C146284","Death","Grade 5 Duodenal Perforation, CTCAE | Grade 5 Duodenal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544347","Grade 5 Duodenal Stenosis, CTCAE","C146285","Death","Grade 5 Duodenal Stenosis, CTCAE | Grade 5 Duodenal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544333","Grade 5 Ear and Labyrinth Disorders - Other, Specify, CTCAE","C146287","Death","Grade 5 Ear and Labyrinth Disorders - Other, Specify, CTCAE | Grade 5 Ear and labyrinth disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543561","Grade 3 Middle Ear Inflammation, CTCAE","C145461","Mastoiditis; necrosis of canal soft tissue or bone","Grade 3 Middle Ear Inflammation, CTCAE | Grade 3 Middle ear inflammation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543562","Grade 3 Mitral Valve Disease, CTCAE","C145462","Symptomatic; severe regurgitation or stenosis by imaging; symptoms controlled with medical intervention","Grade 3 Mitral Valve Disease, CTCAE | Grade 3 Mitral valve disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543563","Grade 3 Movements Involuntary, CTCAE","C145465","Severe symptoms; limiting self care ADL","Grade 3 Movements Involuntary, CTCAE | Grade 3 Movements involuntary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544603","Grade 5 Thrombotic Thrombocytopenic Purpura, CTCAE","C146577","Death","Grade 5 Thrombotic Thrombocytopenic Purpura, CTCAE | Grade 5 Thrombotic thrombocytopenic purpura",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544604","Grade 5 Tooth Infection, CTCAE","C146578","Death","Grade 5 Tooth Infection, CTCAE | Grade 5 Tooth infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544589","Grade 5 Toxic Epidermal Necrolysis, CTCAE","C146579","Death","Grade 5 Toxic Epidermal Necrolysis, CTCAE | Grade 5 Toxic epidermal necrolysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544590","Grade 5 Tracheal Mucositis, CTCAE","C146582","Death","Grade 5 Tracheal Mucositis, CTCAE | Grade 5 Tracheal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544591","Grade 5 Tracheal Obstruction, CTCAE","C146583","Death","Grade 5 Tracheal Obstruction, CTCAE | Grade 5 Tracheal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544592","Grade 5 Tracheal Stenosis, CTCAE","C146584","Death","Grade 5 Tracheal Stenosis, CTCAE | Grade 5 Tracheal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544594","Grade 5 Tracheostomy Site Bleeding, CTCAE","C146586","Death","Grade 5 Tracheostomy Site Bleeding, CTCAE | Grade 5 Tracheostomy site bleeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544595","Grade 5 Treatment Related Secondary Malignancy, CTCAE","C146587","Death","Grade 5 Treatment Related Secondary Malignancy, CTCAE | Grade 5 Treatment related secondary malignancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544581","Grade 5 Tumor Hemorrhage, CTCAE","C146589","Death","Grade 5 Tumor Hemorrhage, CTCAE | Grade 5 Tumor hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544582","Grade 5 Upper Gastrointestinal Hemorrhage, CTCAE","C146590","Death","Grade 5 Upper Gastrointestinal Hemorrhage, CTCAE | Grade 5 Upper gastrointestinal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544843","Mediastinal Germ Cell Tumor N2 TNM Finding","C146845","Mediastinal germ cell tumor with metastasis in other intrathoracic lymph nodes excluding anterior mediastinal lymph nodes. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)","Mediastinal Germ Cell Tumor N2 TNM Finding | Thymic Germ Cell Tumor N2 TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544844","Mediastinal Germ Cell Tumor N3 TNM Finding","C146846","Mediastinal germ cell tumor with metastasis in scalene and/or supraclavicular lymph nodes. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)","Mediastinal Germ Cell Tumor N3 TNM Finding | Thymic Germ Cell Tumor N3 TNM Finding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544845","Mediastinal Malignant Germ Cell Tumor Stage","C146847","A mediastinal malignant germ cell tumor stage defined according to the Pediatric Study Group classification criteria.","Mediastinal Malignant Germ Cell Tumor Stage | Mediastinal Malignant Germ Cell Tumor Stage of the Pediatric Study Group | Thymic Malignant Germ Cell Tumor Stage | Thymic Malignant Germ Cell Tumor Stage of the Pediatric Study Group",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544830","Malignant Mediastinal Germ Cell Tumor Stage Grouping of the Pediatric Study Group","C146848","A term that refers to the staging of mediastinal malignant germ cell tumors according to the Pediatric Study Group staging criteria. This staging system is not an official UICC TNM classification. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)","Malignant Mediastinal Germ Cell Tumor Stage Grouping of the Pediatric Study Group | Malignant Thymic Germ Cell Tumor Stage Grouping of the Pediatric Study Group",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544831","Stage I Malignant Mediastinal Germ Cell Tumor","C146849","Locoregional tumor, non-metastatic, complete resection. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)","Stage I Malignant Mediastinal Germ Cell Tumor | Stage I Malignant Thymic Germ Cell Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544832","Stage II Malignant Mediastinal Germ Cell Tumor","C146850","Locoregional tumor, non-metastatic, macroscopic complete resection but microscopic residual tumor. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)","Stage II Malignant Mediastinal Germ Cell Tumor | Stage II Malignant Thymic Germ Cell Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544189","Grade 4 Urostomy Obstruction, CTCAE","C146170","Life-threatening consequences; organ failure; urgent operative intervention indicated","Grade 4 Urostomy Obstruction, CTCAE | Grade 4 Urostomy obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543520","Grade 3 Hypoglossal Nerve Disorder, CTCAE","C145359","Severe symptoms; limiting self care ADL","Grade 3 Hypoglossal Nerve Disorder, CTCAE | Grade 3 Hypoglossal nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543521","Grade 3 Hypoglycemia, CTCAE","C145360","<40-30 mg/dL; <2.2-1.7 mmol/L","Grade 3 Hypoglycemia, CTCAE | Grade 3 Hypoglycemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543522","Grade 3 Hypohidrosis, CTCAE","C145361","Increase in body temperature; limiting self care ADL","Grade 3 Hypohidrosis, CTCAE | Grade 3 Hypohidrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543523","Grade 3 Hypokalemia, CTCAE","C145362","<3.0-2.5 mmol/L; hospitalization indicated","Grade 3 Hypokalemia, CTCAE | Grade 3 Hypokalemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543524","Grade 3 Hypomagnesemia, CTCAE","C145363","<0.9-0.7 mg/dL; <0.4-0.3 mmol/L","Grade 3 Hypomagnesemia, CTCAE | Grade 3 Hypomagnesemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543509","Grade 3 Hyponatremia, CTCAE","C145364","125-129 mmol/L symptomatic; 120-124 mmol/L regardless of symptoms","Grade 3 Hyponatremia, CTCAE | Grade 3 Hyponatremia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543510","Grade 3 Hypoparathyroidism, CTCAE","C145365","Severe symptoms; medical intervention or hospitalization indicated","Grade 3 Hypoparathyroidism, CTCAE | Grade 3 Hypoparathyroidism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543511","Grade 3 Hypophosphatemia, CTCAE","C145366","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated","Grade 3 Hypophosphatemia, CTCAE | Grade 3 Hypophosphatemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543512","Grade 3 Hypophysitis, CTCAE","C145367","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL","Grade 3 Hypophysitis, CTCAE | Grade 3 Hypophysitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543514","Grade 3 Hypothyroidism, CTCAE","C145369","Severe symptoms; limiting self care ADL; hospitalization indicated","Grade 3 Hypothyroidism, CTCAE | Grade 3 Hypothyroidism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543515","Grade 3 Ileal Perforation, CTCAE","C145373","Invasive intervention indicated","Grade 3 Ileal Perforation, CTCAE | Grade 3 Ileal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543516","Grade 3 Ileal Stenosis, CTCAE","C145374","Severely altered GI function; tube feeding or hospitalization indicated; elective operative intervention indicated","Grade 3 Ileal Stenosis, CTCAE | Grade 3 Ileal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543501","Grade 3 Immune System Disorders - Other, Specify, CTCAE","C145377","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL","Grade 3 Immune System Disorders - Other, Specify, CTCAE | Grade 3 Immune system disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543502","Grade 3 Infections and Infestations - Other, Specify, CTCAE","C145378","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL","Grade 3 Infections and Infestations - Other, Specify, CTCAE | Grade 3 Infections and infestations - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543503","Grade 3 Infective Myositis, CTCAE","C145379","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Infective Myositis, CTCAE | Grade 3 Infective myositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543504","Grade 3 Infusion Related Reaction, CTCAE","C145380","Prolonged (e.g., not rapidly responsive to symptomatic medication and/or brief interruption of infusion); recurrence of symptoms following initial improvement; hospitalization indicated for clinical sequelae","Grade 3 Infusion Related Reaction, CTCAE | Grade 3 Infusion related reaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543505","Grade 3 Infusion Site Extravasation, CTCAE","C145381","Ulceration or necrosis; severe tissue damage; operative intervention indicated","Grade 3 Infusion Site Extravasation, CTCAE | Grade 3 Infusion site extravasation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545204","Pharmacokinetics Concentrations Supplemental Qualifiers Dataset","C147233","A dataset containing supplemental information, specifically non-standard variables, to parent records in the pharmacokinetics concentrations domain.","Pharmacokinetics Concentrations Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545205","Physical Examination Supplemental Qualifiers Dataset","C147234","A dataset containing supplemental information, specifically non-standard variables, to parent records in the physical examination domain.","Physical Examination Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545206","Pharmacogenomics/Genetics Findings Supplemental Qualifiers Dataset","C147235","A dataset containing supplemental information, specifically non-standard variables, to parent records in the pharmacogenomics/genetics findings domain.","Pharmacogenomics/Genetics Findings Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545207","Pharmacogenomics/Genetics Methods and Supporting Information Supplemental Qualifiers Dataset","C147236","A dataset containing supplemental information, specifically non-standard variables, to parent records in the pharmacogenomics/genetics methods and supporting information domain.","Pharmacogenomics/Genetics Methods and Supporting Information Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545208","Palpable Masses Supplemental Qualifiers Dataset","C147237","A dataset containing supplemental information, specifically non-standard variables, to parent records in the palpable masses domain.","Palpable Masses Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545194","Procedures Supplemental Qualifiers Dataset","C147239","A dataset containing supplemental information, specifically non-standard variables, to parent records in the procedures domain.","Procedures Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545195","Questionnaires Supplemental Qualifiers Dataset","C147240","A dataset containing supplemental information, specifically non-standard variables, to parent records in the questionnaires domain.","Questionnaires Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545196","ECG QT Correction Model Data Supplemental Qualifiers Dataset","C147241","A dataset containing supplemental information, specifically non-standard variables, to parent records in the ECG QT correction model data domain.","ECG QT Correction Model Data Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545197","Respiratory Test Results Supplemental Qualifiers Dataset","C147242","A dataset containing supplemental information, specifically non-standard variables, to parent records in the respiratory test results domain.","Respiratory Test Results Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545198","Reproductive System Findings Supplemental Qualifiers Dataset","C147243","A dataset containing supplemental information, specifically non-standard variables, to parent records in the reproductive system findings domain.","Reproductive System Findings Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545199","Disease Response Supplemental Qualifiers Dataset","C147244","A dataset containing supplemental information, specifically non-standard variables, to parent records in the disease response domain.","Disease Response Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545200","Subject Biomarker Supplemental Qualifiers Dataset","C147245","A dataset containing supplemental information, specifically non-standard variables, to parent records in the subject biomarker domain.","Subject Biomarker Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545201","Subject Characteristics Supplemental Qualifiers Dataset","C147246","A dataset containing supplemental information, specifically non-standard variables, to parent records in the subject characteristics domain.","Subject Characteristics Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543564","Grade 3 Mucosal Infection, CTCAE","C145466","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Mucosal Infection, CTCAE | Grade 3 Mucosal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543549","Grade 3 Mucositis Oral, CTCAE","C145467","Severe pain; interfering with oral intake","Grade 3 Mucositis Oral, CTCAE | Grade 3 Mucositis oral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543550","Grade 3 Multi-Organ Failure, CTCAE","C145468","Shock with azotemia and acid-base disturbances; significant coagulation abnormalities","Grade 3 Multi-Organ Failure, CTCAE | Grade 3 Multi-organ failure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543552","Grade 3 Muscle Weakness Left-Sided, CTCAE","C145470","Limiting self care ADL","Grade 3 Muscle Weakness Left-Sided, CTCAE | Grade 3 Muscle weakness left-sided",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543553","Grade 3 Muscle Weakness Lower Limb, CTCAE","C145471","Limiting self care ADL","Grade 3 Muscle Weakness Lower Limb, CTCAE | Grade 3 Muscle weakness lower limb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543554","Grade 3 Muscle Weakness Right-Sided, CTCAE","C145472","Limiting self care ADL","Grade 3 Muscle Weakness Right-Sided, CTCAE | Grade 3 Muscle weakness right-sided",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543555","Grade 3 Muscle Weakness Trunk, CTCAE","C145473","Limiting self care ADL","Grade 3 Muscle Weakness Trunk, CTCAE | Grade 3 Muscle weakness trunk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543556","Grade 3 Muscle Weakness Upper Limb, CTCAE","C145474","Limiting self care ADL","Grade 3 Muscle Weakness Upper Limb, CTCAE | Grade 3 Muscle weakness upper limb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543541","Grade 3 Musculoskeletal and Connective Tissue Disorder - Other, Specify, CTCAE","C145475","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL","Grade 3 Musculoskeletal and Connective Tissue Disorder - Other, Specify, CTCAE | Grade 3 Musculoskeletal and connective tissue disorder - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543543","Grade 3 Myalgia, CTCAE","C145477","Severe pain; limiting self care ADL","Grade 3 Myalgia, CTCAE | Grade 3 Myalgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543544","Grade 3 Myasthenia Gravis, CTCAE","C145478","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL","Grade 3 Myasthenia Gravis, CTCAE | Grade 3 Myasthenia gravis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543545","Grade 3 Myocardial Infarction, CTCAE","C145479","Severe symptoms; cardiac enzymes abnormal; hemodynamically stable; ECG changes consistent with infarction","Grade 3 Myocardial Infarction, CTCAE | Grade 3 Myocardial infarction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543546","Grade 3 Nail Infection, CTCAE","C145480","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Nail Infection, CTCAE | Grade 3 Nail infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543547","Grade 3 Nasal Congestion, CTCAE","C145481","Associated with bloody nasal discharge or epistaxis","Grade 3 Nasal Congestion, CTCAE | Grade 3 Nasal congestion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543548","Grade 3 Neck Edema, CTCAE","C145482","Generalized neck edema (e.g., difficulty in turning neck); limiting self care ADL","Grade 3 Neck Edema, CTCAE | Grade 3 Neck edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543661","Grade 3 Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other, Specify, CTCAE","C145483","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL","Grade 3 Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other, Specify, CTCAE | Grade 3 Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543662","Grade 3 Nephrotic Syndrome, CTCAE","C145484","Not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL","Grade 3 Nephrotic Syndrome, CTCAE | Grade 3 Nephrotic syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544833","Stage III Malignant Mediastinal Germ Cell Tumor","C146851","Locoregional tumor, regional lymph nodes negative or positive; no distant metastasis; biopsy only or gross residual tumor after primary resection. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)","Stage III Malignant Mediastinal Germ Cell Tumor | Stage III Malignant Thymic Germ Cell Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544835","Porcupine Inhibitor CGX1321","C146853","An orally bioavailable inhibitor of the membrane-bound O-acyltransferase (MBOAT) porcupine (PORCN), with potential antineoplastic, protective and regenerative activities. Upon oral administration, PORCN inhibitor CGX1321 specifically targets and binds to PORCN in the endoplasmic reticulum (ER), thereby inhibiting the post-translational palmitoylation and secretion of Wnt ligands, thus preventing the activation of Wnt-mediated signaling, and inhibiting cell growth in Wnt-driven tumors. In addition, by inhibiting the secretion of Wnt ligands and preventing Wnt-mediated signaling, CGX1321 may also limit fibrosis and promote regeneration of certain tissues upon cell injury. PORCN catalyzes the palmitoylation of Wnt ligands, and plays a key role in Wnt ligand secretion. Wnt signaling is dysregulated in a variety of cancers and plays a key role in tumor cell proliferation. It also plays a key role in tissue regeneration.","Porcupine Inhibitor CGX1321 | CGX 1321 | CGX-1321 | CGX1321 | PORCN Inhibitor CGX1321 | WNT Signaling Inhibitor CGX1321 | WTN Inhibitor CGX1321",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544836","ABBV 621","C146854","A fusion protein composed of a tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor agonist consisting of six receptor binding domains (RBDs) of TRAIL fused to the Fc-domain of a human immunoglobulin G1 (IgG1) antibody, with potential pro-apoptotic and antineoplastic activities. Upon administration of eftozanermin alfa, this fusion protein binds to TRAIL-receptors, pro-apoptotic death receptors (DRs) TRAIL-R1 (death receptor 4; DR4) and TRAIL-R2 (death receptor 5; DR5), expressed on tumor cells, thereby inducing tumor cell apoptosis.  ABBV-621 is designed to maximize receptor clustering for optimal efficacy. TRAIL, a member of the TNF superfamily of cytokines, plays a key role in the induction of apoptosis through TRAIL-mediated death receptor pathways.","Eftozanermin Alfa | ABBV 621 | ABBV-621 | ABBV621 | APG880 | EFTOZANERMIN ALFA | HERA Ligand ABBV-621 | Hexavalent TRAIL Receptor Agonist ABBV-621 | TRAIL Receptor Agonist ABBV-621 | TRAIL-Fc Protein ABBV-621 | TRAIL-receptor Agonist Fusion Protein ABBV-621",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544822","Locally Advanced Angiosarcoma","C146856","An angiosarcoma that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Angiosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544164","Grade 4 Psychiatric Disorders - Other, Specify, CTCAE","C146071","Life-threatening consequences; hospitalization or urgent intervention indicated","Grade 4 Psychiatric Disorders - Other, Specify, CTCAE | Grade 4 Psychiatric disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544149","Grade 4 Psychosis, CTCAE","C146072","Life-threatening consequences, threats of harm to self or others; hospitalization indicated","Grade 4 Psychosis, CTCAE | Grade 4 Psychosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544150","Grade 4 Pulmonary Edema, CTCAE","C146073","Life-threatening respiratory compromise; urgent intervention or intubation with ventilatory support indicated","Grade 4 Pulmonary Edema, CTCAE | Grade 4 Pulmonary edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544152","Grade 4 Pulmonary Fistula, CTCAE","C146075","Life-threatening consequences; urgent intervention indicated","Grade 4 Pulmonary Fistula, CTCAE | Grade 4 Pulmonary fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544153","Grade 4 Pulmonary Valve Disease, CTCAE","C146076","Life-threatening consequences; urgent intervention indicated (e.g., valve replacement, valvuloplasty)","Grade 4 Pulmonary Valve Disease, CTCAE | Grade 4 Pulmonary valve disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544154","Grade 4 Pyramidal Tract Syndrome, CTCAE","C146077","Life-threatening consequences; urgent intervention indicated","Grade 4 Pyramidal Tract Syndrome, CTCAE | Grade 4 Pyramidal tract syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544155","Grade 4 Radiation Recall Reaction (Dermatologic), CTCAE","C146078","Life-threatening consequences; skin necrosis or ulceration of full thickness dermis; spontaneous bleeding from involved site; skin graft indicated","Grade 4 Radiation Recall Reaction (Dermatologic), CTCAE | Grade 4 Radiation recall reaction (dermatologic)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544156","Grade 4 Radiculitis, CTCAE","C146079","Life-threatening consequences; urgent intervention indicated","Grade 4 Radiculitis, CTCAE | Grade 4 Radiculitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543506","Grade 3 Injection Site Reaction, CTCAE","C145382","Ulceration or necrosis; severe tissue damage; operative intervention indicated","Grade 3 Injection Site Reaction, CTCAE | Grade 3 Injection site reaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543508","Grade 3 Injury To Jugular Vein, CTCAE","C145385","Symptomatic limiting self care ADL; repair or revision indicated","Grade 3 Injury To Jugular Vein, CTCAE | Grade 3 Injury to jugular vein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543493","Grade 3 Injury To Superior Vena Cava, CTCAE","C145386","Severe symptoms; limiting self care ADL; repair or revision indicated","Grade 3 Injury To Superior Vena Cava, CTCAE | Grade 3 Injury to superior vena cava",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544644","CC 92480","C146660","A modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and antineoplastic activities. Upon administration, mezigdomide specifically binds to cereblon (CRBN), thereby affecting the ubiquitin E3 ligase activity, and targeting certain substrate proteins for ubiquitination. This induces proteasome-mediated degradation of certain transcription factors, some of which are transcriptional repressors in T-cells. This leads to modulation of the immune system, including activation of T-lymphocytes, and downregulation of the activity of other proteins, some of which play key roles in the proliferation of certain cancer cell types. CRBN, the substrate recognition component of the CRL4-CRBN E3 ubiquitin ligase complex, plays a key role in the ubiquitination of certain proteins.","Mezigdomide | BMS 986348 | BMS-986348 | BMS986348 | CC 92480 | CC-92480 | CC92480 | CELMoD CC-92480 | Cereblon E3 Ligase Modulation Drug CC-92480 | Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480 | Cereblon Modulator CC-92480 | MEZIGDOMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545186","Subject Elements Supplemental Qualifiers Dataset","C147247","A dataset containing supplemental information, specifically non-standard variables, to parent records in the subject elements domain.","Subject Elements Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545187","Subject Stages Supplemental Qualifiers Dataset","C147248","A dataset containing supplemental information, specifically non-standard variables, to parent records in the subject stages domain.","Subject Stages Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545190","Subject Status Supplemental Qualifiers Dataset","C147251","A dataset containing supplemental information, specifically non-standard variables, to parent records in the subject status domain.","Subject Status Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545191","Substance Use Supplemental Qualifiers Dataset","C147252","A dataset containing supplemental information, specifically non-standard variables, to parent records in the substance use domain.","Substance Use Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550660","Severity Three Out of Four","C147506","A severity result of three, on a four level scale.","Severity Three Out of Four | 3 OF 4 | Severity 3 of 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0442758","Severity Three Out of Five","C147507","A severity result of three, on a five level scale.","Severity Three Out of Five | 3 OF 5 | Severity 3 of 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL535299","Severity Four Out of Four","C147508","A severity result of four, on a four level scale.","Severity Four Out of Four | 4 OF 4 | Severity 4 of 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550655","Severity Four Out of Five","C147509","A severity result of four, on a five level scale.","Severity Four Out of Five | 4 OF 5 | Severity 4 of 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL535359","Severity Five Out of Five","C147510","A severity result of five, on a five level scale.","Severity Five Out of Five | 5 OF 5 | Severity 5 of 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0228919","Saphenous Nerve","C147511","A branch of the femoral nerve traveling the length of the leg/hindlimb, which innervates the sartorius and the skin of the medial aspect of the leg/hindlimb from the knee/stifle joint to the metatarsus.","Saphenous Nerve | NERVE, SAPHENOUS",,,,,,,,,,,,,,,"4268023","Structure of saphenous nerve",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545337","Subcutaneous Port Site","C147512","The anatomic site at which a subcutaneous port is implanted under the skin, allowing access to the vascular system or a body cavity.","Subcutaneous Port Site | SITE, SUBCUTANEOUS PORT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545338","Planned Dose Frequency","C147513","The intended number of times a substance is administered within a specific time period.","Planned Dose Frequency | PDOSFRQ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545339","Planned Pharmacologic Target Common Name","C147514","The common name of disease, gene, or protein that is the target of the pharmaceutical intervention.","Planned Pharmacologic Target Common Name | PPTCNAM | Planned Pharm Target Common Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545340","Planned Pharmacologic Target Entrez Gene Identifier","C147515","The accession number maintained within the Entrez Gene database for the assumed gene target of the pharmacologic intervention.","Planned Pharmacologic Target Entrez Gene Identifier | PPTEGID | Planned Pharm Target Entrez Gene ID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545341","Planned Pharmacologic Target Entrez Gene Symbol","C147516","The official alpha-numeric name maintained within the Entrez Gene database for the assumed gene target of the pharmacologic intervention.","Planned Pharmacologic Target Entrez Gene Symbol | PPTEGSYM | Planned Pharm Target Entrez Gene Symbol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545342","Planned Pharmacologic Target Mode of Action","C147517","A description of the cellular functional or anatomic change for the assumed target of the pharmacologic intervention.","Planned Pharmacologic Target Mode of Action | PPTMDA | Planned Pharm Target Mode of Action",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545974","Antibiotic Lock Therapy","C147519","The use of a highly concentrated antibiotic solution for the to treatment of catheter-related bloodstream infections.","Antibiotic Lock Therapy | ALT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544697","Refractory Glioblastoma","C146734","A glioblastoma that is resistant to treatment.","Refractory Glioblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544141","Grade 4 Rash Acneiform, CTCAE","C146080","Life-threatening consequences; papules and/or pustules covering any % BSA, which may or may not be associated with symptoms of pruritus or tenderness and are associated with extensive superinfection with IV antibiotics indicated","Grade 4 Rash Acneiform, CTCAE | Grade 4 Rash acneiform",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544142","Grade 4 Rectal Anastomotic Leak, CTCAE","C146081","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Rectal Anastomotic Leak, CTCAE | Grade 4 Rectal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544143","Grade 4 Rectal Mucositis, CTCAE","C146084","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Rectal Mucositis, CTCAE | Grade 4 Rectal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544144","Grade 4 Rectal Stenosis, CTCAE","C146088","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Rectal Stenosis, CTCAE | Grade 4 Rectal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544145","Grade 4 Recurrent Laryngeal Nerve Palsy, CTCAE","C146090","Life-threatening consequences; urgent intervention indicated","Grade 4 Recurrent Laryngeal Nerve Palsy, CTCAE | Grade 4 Recurrent laryngeal nerve palsy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544147","Grade 4 Renal Calculi, CTCAE","C146092","Life-threatening consequences; urgent invasive intervention indicated","Grade 4 Renal Calculi, CTCAE | Grade 4 Renal calculi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544148","Grade 4 Reproductive System and Breast Disorders - Other, Specify, CTCAE","C146094","Life-threatening consequences; urgent intervention indicated","Grade 4 Reproductive System and Breast Disorders - Other, Specify, CTCAE | Grade 4 Reproductive system and breast disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544133","Grade 4 Respiratory Failure, CTCAE","C146095","Life-threatening consequences; urgent intervention, intubation, or ventilatory support indicated","Grade 4 Respiratory Failure, CTCAE | Grade 4 Respiratory failure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544134","Grade 4 Respiratory, Thoracic and Mediastinal Disorders - Other, Specify, CTCAE","C146096","Life-threatening consequences; urgent intervention indicated","Grade 4 Respiratory, Thoracic and Mediastinal Disorders - Other, Specify, CTCAE | Grade 4 Respiratory, thoracic and mediastinal disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544135","Grade 4 Retroperitoneal Hemorrhage, CTCAE","C146097","Life-threatening consequences; urgent intervention indicated","Grade 4 Retroperitoneal Hemorrhage, CTCAE | Grade 4 Retroperitoneal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544136","Grade 4 Reversible Posterior Leukoencephalopathy Syndrome, CTCAE","C146098","Life-threatening consequences","Grade 4 Reversible Posterior Leukoencephalopathy Syndrome, CTCAE | Grade 4 Reversible posterior leukoencephalopathy syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543466","Grade 3 Flashing Lights, CTCAE","C145289","Limiting self care ADL","Grade 3 Flashing Lights, CTCAE | Grade 3 Flashing lights",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543467","Grade 3 Floaters, CTCAE","C145290","Limiting self care ADL","Grade 3 Floaters, CTCAE | Grade 3 Floaters",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543468","Grade 3 Flu Like Symptoms, CTCAE","C145291","Severe symptoms; limiting self care ADL","Grade 3 Flu Like Symptoms, CTCAE | Grade 3 Flu like symptoms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543453","Grade 3 Flushing, CTCAE","C145292","Symptomatic, associated with hypotension and/or tachycardia; limiting self care ADL","Grade 3 Flushing, CTCAE | Grade 3 Flushing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543454","Grade 3 Folliculitis, CTCAE","C145293",">30% BSA; systemic intervention indicated","Grade 3 Folliculitis, CTCAE | Grade 3 Folliculitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543455","Grade 3 Forced Expiratory Volume Decreased, CTCAE","C145294","50-59%","Grade 3 Forced Expiratory Volume Decreased, CTCAE | Grade 3 Forced expiratory volume decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543457","Grade 3 Gait Disturbance, CTCAE","C145296","Limiting self care ADL","Grade 3 Gait Disturbance, CTCAE | Grade 3 Gait disturbance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544636","Anti-c-Met Antibody-drug Conjugate HTI-1066","C146667","An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the tumor-associated antigen (TAA) the proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of HTI-1066 targets and binds to c-Met expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the c-Met-expressing cancer cells, through an as of yet unknown mechanism of action. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis.","Anti-c-Met Antibody-drug Conjugate HTI-1066 | ADC HTI-1066 | HTI 1066 | HTI-1066",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543917","Grade 4 Bladder Anastomotic Leak, CTCAE","C145764","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Bladder Anastomotic Leak, CTCAE | Grade 4 Bladder anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543918","Grade 4 Bladder Infection, CTCAE","C145765","Life-threatening consequences; urgent intervention indicated","Grade 4 Bladder Infection, CTCAE | Grade 4 Bladder infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543919","Grade 4 Blood and Lymphatic System Disorders - Other, Specify, CTCAE","C145766","Life-threatening consequences; urgent intervention indicated","Grade 4 Blood and Lymphatic System Disorders - Other, Specify, CTCAE | Grade 4 Blood and lymphatic system disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543920","Grade 4 Blood Bilirubin Increased, CTCAE","C145767",">10.0 x ULN if baseline was normal; >10.0 x baseline if baseline was abnormal","Grade 4 Blood Bilirubin Increased, CTCAE | Grade 4 Blood bilirubin increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543921","Grade 4 Bone Infection, CTCAE","C145768","Life-threatening consequences; urgent intervention indicated","Grade 4 Bone Infection, CTCAE | Grade 4 Bone infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543923","Grade 4 Breast Infection, CTCAE","C145770","Life-threatening consequences; urgent intervention indicated","Grade 4 Breast Infection, CTCAE | Grade 4 Breast infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543924","Grade 4 Bronchial Fistula, CTCAE","C145771","Life-threatening consequences; urgent intervention indicated","Grade 4 Bronchial Fistula, CTCAE | Grade 4 Bronchial fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543909","Grade 4 Bronchial Infection, CTCAE","C145772","Life-threatening consequences; urgent intervention indicated","Grade 4 Bronchial Infection, CTCAE | Grade 4 Bronchial infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543910","Grade 4 Bronchial Obstruction, CTCAE","C145773","Life-threatening respiratory or hemodynamic compromise; intubation or urgent intervention indicated","Grade 4 Bronchial Obstruction, CTCAE | Grade 4 Bronchial obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543911","Grade 4 Bronchial Stricture, CTCAE","C145774","Life-threatening respiratory or hemodynamic compromise; intubation or urgent intervention indicated","Grade 4 Bronchial Stricture, CTCAE | Grade 4 Bronchial stricture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543912","Grade 4 Bronchopleural Fistula, CTCAE","C145775","Life-threatening consequences; urgent intervention indicated","Grade 4 Bronchopleural Fistula, CTCAE | Grade 4 Bronchopleural fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546017","Mino-Lok Therapy","C147520","Administration of a proprietary solution of minocycline, disodium EDTA, and ethyl alcohol to a patient as a treatment for catheter-related bloodstream infections.","Mino-Lok Therapy | MLT | Mino-Lok",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545331","cEt KRAS Antisense Oligonucleotide AZD4785","C147521","A proprietary formulation composed of a high affinity antisense oligonucleotide (ASO) that contains 2'-4' constrained ethyl residues (cEt) and targets KRAS (K-RAS) transcripts, with potential antineoplastic activity. Upon intravenous administration, cEt KRAS antisense oligonucleotide AZD4785 targets and binds, with high affinity, to a unique genetic sequence within KRAS messenger RNA (mRNA), thereby inhibiting translation of KRAS protein, including forms containing activating mutations. Inhibition of KRAS protein synthesis prevents KRAS-dependent signaling and inhibits the proliferation of KRAS-driven tumor cells. KRAS, a tumor-associated antigen (TAA), is mutated in a variety of tumor cell types. It plays a key role in tumor cell proliferation and survival and is associated with tumor initiation, metastasis and poor prognosis.","cEt KRAS Antisense Oligonucleotide AZD4785 | ASO AZD4785 | AZD 4785 | AZD-4785 | AZD4785 | Generation 2.5 Drug AZD4785 | IONIS-KRAS-2.5Rx | cEt KRAS ASO AZD4785",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545595","TSCC - Daydreaming","C147751","Trauma Symptom Checklist for Children (TSCC) Daydreaming.","TSCC - Daydreaming | TSCC01-Daydreaming | TSCC0153",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545596","TSCC - Getting Upset People Talk Sex","C147752","Trauma Symptom Checklist for Children (TSCC) Getting upset when people talk about sex.","TSCC - Getting Upset People Talk Sex | TSCC01-Getting Upset People Talk Sex | TSCC0154",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545597","TSCYC - Temper Tantrums","C147753","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Temper tantrums.","TSCYC - Temper Tantrums | TSCYC1-Temper Tantrums | TSCYC101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545582","TSCYC - Looking Sad","C147754","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Looking sad.","TSCYC - Looking Sad | TSCYC1-Looking Sad | TSCYC102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545583","TSCYC - Telling a Lie","C147755","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Telling a lie.","TSCYC - Telling a Lie | TSCYC1-Telling a Lie | TSCYC103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545584","TSCYC - Bad Dreams or Nightmares","C147756","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Bad dreams or nightmares.","TSCYC - Bad Dreams or Nightmares | TSCYC1-Bad Dreams or Nightmares | TSCYC104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545585","TSCYC - Living in a Fantasy World","C147757","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Living in a fantasy world.","TSCYC - Living in a Fantasy World | TSCYC1-Living in a Fantasy World | TSCYC105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545586","TSCYC - Seeming to Know More About Sex","C147758","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Seeming to know more about sex than he or she should.","TSCYC - Seeming to Know More About Sex | TSCYC1-Seeming to Know More About Sex | TSCYC106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545587","TSCYC - Being Easily Scared","C147759","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Being easily scared.","TSCYC - Being Easily Scared | TSCYC1-Being Easily Scared | TSCYC107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545588","TSCYC - Not Wanting to Go Somewhere","C147760","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Not wanting to go somewhere that reminded him or her of a bad thing from the past.","TSCYC - Not Wanting to Go Somewhere | TSCYC1-Not Wanting to Go Somewhere | TSCYC108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543964","Grade 4 Gallbladder Infection, CTCAE","C145862","Life-threatening consequences; urgent intervention indicated","Grade 4 Gallbladder Infection, CTCAE | Grade 4 Gallbladder infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543949","Grade 4 Gastric Anastomotic Leak, CTCAE","C145863","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Gastric Anastomotic Leak, CTCAE | Grade 4 Gastric anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543950","Grade 4 Gastric Fistula, CTCAE","C145864","Life-threatening consequences; urgent intervention indicated","Grade 4 Gastric Fistula, CTCAE | Grade 4 Gastric fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543951","Grade 4 Gastric Hemorrhage, CTCAE","C145865","Life-threatening consequences; urgent intervention indicated","Grade 4 Gastric Hemorrhage, CTCAE | Grade 4 Gastric hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543952","Grade 4 Gastric Necrosis, CTCAE","C145866","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Gastric Necrosis, CTCAE | Grade 4 Gastric necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543953","Grade 4 Gastric Perforation, CTCAE","C145867","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Gastric Perforation, CTCAE | Grade 4 Gastric perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543955","Grade 4 Gastric Ulcer, CTCAE","C145869","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Gastric Ulcer, CTCAE | Grade 4 Gastric ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543956","Grade 4 Gastrointestinal Anastomotic Leak, CTCAE","C145870","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Gastrointestinal Anastomotic Leak, CTCAE | Grade 4 Gastrointestinal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543941","Grade 4 Gastrointestinal Disorders - Other, Specify, CTCAE","C145871","Life-threatening consequences; urgent intervention indicated","Grade 4 Gastrointestinal Disorders - Other, Specify, CTCAE | Grade 4 Gastrointestinal disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543942","Grade 4 Gastrointestinal Fistula, CTCAE","C145872","Life-threatening consequences; urgent intervention indicated","Grade 4 Gastrointestinal Fistula, CTCAE | Grade 4 Gastrointestinal fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543943","Grade 4 Gastrointestinal Stoma Necrosis, CTCAE","C145873","Life-threatening consequences; urgent intervention indicated","Grade 4 Gastrointestinal Stoma Necrosis, CTCAE | Grade 4 Gastrointestinal stoma necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543944","Grade 4 Gastroparesis, CTCAE","C145874","Life-threatening consequences; urgent intervention indicated","Grade 4 Gastroparesis, CTCAE | Grade 4 Gastroparesis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543945","Grade 4 General Disorders and Administration Site Conditions - Other, Specify, CTCAE","C145875","Life-threatening consequences; urgent intervention indicated","Grade 4 General Disorders and Administration Site Conditions - Other, Specify, CTCAE | Grade 4 General disorders and administration site conditions - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543947","Grade 4 GGT Increased, CTCAE","C145877",">20.0 x ULN if baseline was normal; >20.0 x baseline if baseline was abnormal","Grade 4 GGT Increased, CTCAE | Grade 4 GGT increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543948","Grade 4 Glossopharyngeal Nerve Disorder, CTCAE","C145878","Life-threatening consequences; urgent intervention indicated","Grade 4 Glossopharyngeal Nerve Disorder, CTCAE | Grade 4 Glossopharyngeal nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543933","Grade 4 Glucose Intolerance, CTCAE","C145879","Life-threatening consequences; urgent intervention indicated","Grade 4 Glucose Intolerance, CTCAE | Grade 4 Glucose intolerance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543458","Grade 3 Gallbladder Infection, CTCAE","C145297","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Gallbladder Infection, CTCAE | Grade 3 Gallbladder infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543459","Grade 3 Gastric Anastomotic Leak, CTCAE","C145298","Severe symptoms; invasive intervention indicated","Grade 3 Gastric Anastomotic Leak, CTCAE | Grade 3 Gastric anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543460","Grade 3 Gastric Fistula, CTCAE","C145299","Invasive intervention indicated","Grade 3 Gastric Fistula, CTCAE | Grade 3 Gastric fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543445","Grade 3 Gastric Hemorrhage, CTCAE","C145300","Transfusion indicated; invasive intervention indicated; hospitalization","Grade 3 Gastric Hemorrhage, CTCAE | Grade 3 Gastric hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543446","Grade 3 Gastric Necrosis, CTCAE","C145301","Inability to aliment adequately by GI tract; invasive intervention indicated","Grade 3 Gastric Necrosis, CTCAE | Grade 3 Gastric necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543447","Grade 3 Gastric Perforation, CTCAE","C145302","Invasive intervention indicated","Grade 3 Gastric Perforation, CTCAE | Grade 3 Gastric perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543449","Grade 3 Gastric Ulcer, CTCAE","C145304","Severely altered GI function; TPN indicated; elective invasive intervention indicated; limiting self care ADL","Grade 3 Gastric Ulcer, CTCAE | Grade 3 Gastric ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543450","Grade 3 Gastroesophageal Reflux Disease, CTCAE","C145305","Severe symptoms; operative intervention indicated","Grade 3 Gastroesophageal Reflux Disease, CTCAE | Grade 3 Gastroesophageal reflux disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543451","Grade 3 Gastrointestinal Anastomotic Leak, CTCAE","C145306","Severe symptoms; invasive intervention indicated","Grade 3 Gastrointestinal Anastomotic Leak, CTCAE | Grade 3 Gastrointestinal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543452","Grade 3 Gastrointestinal Disorders - Other, Specify, CTCAE","C145307","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL","Grade 3 Gastrointestinal Disorders - Other, Specify, CTCAE | Grade 3 Gastrointestinal disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543437","Grade 3 Gastrointestinal Fistula, CTCAE","C145308","Invasive intervention indicated","Grade 3 Gastrointestinal Fistula, CTCAE | Grade 3 Gastrointestinal fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543438","Grade 3 Gastrointestinal Pain, CTCAE","C145309","Severe pain; limiting self care ADL","Grade 3 Gastrointestinal Pain, CTCAE | Grade 3 Gastrointestinal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543439","Grade 3 Gastrointestinal Stoma Necrosis, CTCAE","C145310","Severe symptoms; hospitalization indicated; elective operative intervention indicated","Grade 3 Gastrointestinal Stoma Necrosis, CTCAE | Grade 3 Gastrointestinal stoma necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544583","Grade 5 Upper Respiratory Infection, CTCAE","C146591","Death","Grade 5 Upper Respiratory Infection, CTCAE | Grade 5 Upper respiratory infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544584","Grade 5 Ureteric Anastomotic Leak, CTCAE","C146592","Death","Grade 5 Ureteric Anastomotic Leak, CTCAE | Grade 5 Ureteric anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544585","Grade 5 Urethral Anastomotic Leak, CTCAE","C146593","Death","Grade 5 Urethral Anastomotic Leak, CTCAE | Grade 5 Urethral anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544586","Grade 5 Urethral Infection, CTCAE","C146594","Death","Grade 5 Urethral Infection, CTCAE | Grade 5 Urethral infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543913","Grade 4 Bronchopulmonary Hemorrhage, CTCAE","C145776","Life-threatening consequences; intubation or urgent intervention indicated","Grade 4 Bronchopulmonary Hemorrhage, CTCAE | Grade 4 Bronchopulmonary hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543915","Grade 4 Budd-Chiari Syndrome, CTCAE","C145778","Life-threatening consequences; moderate to severe encephalopathy; coma","Grade 4 Budd-Chiari Syndrome, CTCAE | Grade 4 Budd-Chiari syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543916","Grade 4 Bullous Dermatitis, CTCAE","C145779","Blisters covering >30% BSA; associated with fluid or electrolyte abnormalities; ICU care or burn unit indicated","Grade 4 Bullous Dermatitis, CTCAE | Grade 4 Bullous dermatitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543901","Grade 4 Capillary Leak Syndrome, CTCAE","C145780","Life-threatening consequences; urgent intervention indicated","Grade 4 Capillary Leak Syndrome, CTCAE | Grade 4 Capillary leak syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543902","Grade 4 Cardiac Arrest, CTCAE","C145781","Life-threatening consequences; urgent intervention indicated","Grade 4 Cardiac Arrest, CTCAE | Grade 4 Cardiac arrest",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543903","Grade 4 Cardiac Disorders - Other, Specify, CTCAE","C145782","Life-threatening consequences; urgent intervention indicated","Grade 4 Cardiac Disorders - Other, Specify, CTCAE | Grade 4 Cardiac disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543904","Grade 4 Cataract, CTCAE","C145783","Best corrected visual acuity of 20/200 or worse in the affected eye","Grade 4 Cataract, CTCAE | Grade 4 Cataract",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543905","Grade 4 Catheter Related Infection, CTCAE","C145784","Life-threatening consequences; urgent intervention indicated","Grade 4 Catheter Related Infection, CTCAE | Grade 4 Catheter related infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543907","Grade 4 Cecal Hemorrhage, CTCAE","C145786","Life-threatening consequences; urgent intervention indicated","Grade 4 Cecal Hemorrhage, CTCAE | Grade 4 Cecal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543908","Grade 4 Cecal Infection, CTCAE","C145787","Life-threatening consequences; urgent intervention indicated","Grade 4 Cecal Infection, CTCAE | Grade 4 Cecal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544191","Grade 4 Urostomy Stenosis, CTCAE","C146172","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Urostomy Stenosis, CTCAE | Grade 4 Urostomy stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544192","Grade 4 Uterine Anastomotic Leak, CTCAE","C146173","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Uterine Anastomotic Leak, CTCAE | Grade 4 Uterine anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544193","Grade 4 Uterine Fistula, CTCAE","C146174","Life-threatening consequences; urgent intervention indicated","Grade 4 Uterine Fistula, CTCAE | Grade 4 Uterine fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544194","Grade 4 Uterine Infection, CTCAE","C146176","Life-threatening consequences; urgent intervention indicated","Grade 4 Uterine Infection, CTCAE | Grade 4 Uterine infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544195","Grade 4 Uterine Perforation, CTCAE","C146177","Life-threatening consequences; urgent intervention indicated","Grade 4 Uterine Perforation, CTCAE | Grade 4 Uterine perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544196","Grade 4 Vaccination Complication, CTCAE","C146178","Life-threatening consequences; urgent intervention indicated","Grade 4 Vaccination Complication, CTCAE | Grade 4 Vaccination complication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544181","Grade 4 Vaginal Anastomotic Leak, CTCAE","C146179","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Vaginal Anastomotic Leak, CTCAE | Grade 4 Vaginal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544183","Grade 4 Vaginal Inflammation, CTCAE","C146183","Life-threatening consequences; widespread areas of mucosal ulceration; urgent intervention indicated","Grade 4 Vaginal Inflammation, CTCAE | Grade 4 Vaginal inflammation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544184","Grade 4 Vaginal Perforation, CTCAE","C146184","Life-threatening consequences; urgent intervention indicated","Grade 4 Vaginal Perforation, CTCAE | Grade 4 Vaginal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545589","TSCYC - Worrying Food Was Poisoned","C147761","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Worrying that his or her food was poisoned.","TSCYC - Worrying Food Was Poisoned | TSCYC1-Worrying Food Was Poisoned | TSCYC109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545574","TSCYC - Flinching When Someone Moved","C147762","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Flinching or jumping when someone moved quickly or there was a loud noise.","TSCYC - Flinching When Someone Moved | TSCYC1-Flinching When Someone Moved | TSCYC110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545575","TSCYC - Being Bothered by Memories","C147763","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Being bothered by memories of something that happened to him or her.","TSCYC - Being Bothered by Memories | TSCYC1-Being Bothered by Memories | TSCYC111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545576","TSCYC - Worrying Someone Might Be Sexual","C147764","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Worrying that someone might be sexual with him or her.","TSCYC - Worrying Someone Might Be Sexual | TSCYC1-Worrying Someone Might Be Sexual | TSCYC112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545577","TSCYC - Not Wanting to Talk","C147765","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Not wanting to talk about something that happened to him or her.","TSCYC - Not Wanting to Talk | TSCYC1-Not Wanting to Talk | TSCYC113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0886855","Imipenem Anhydrous","C146984","No value exists.","Imipenem Anhydrous | (5R,6S)-3-((2-(Formimidoylamino)ethyl)thio)-6-((R)-1-hydroxyethyl)-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic Acid | IMIPENEM ANHYDROUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544943","Mediastinal Hemangioma","C146987","A hemangioma that arises from the mediastinum. It can be of the capillary or the cavernous type.","Mediastinal Hemangioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544944","Mediastinal Epithelioid Hemangioendothelioma","C146988","An epithelioid hemangioendothelioma that arises from the mediastinum.","Mediastinal Epithelioid Hemangioendothelioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544945","Refractory Central Nervous System Non-Hodgkin Lymphoma","C146989","A central nervous system non-Hodgkin lymphoma which does not respond to treatment.","Refractory Central Nervous System Non-Hodgkin Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544946","Recurrent Central Nervous System Non-Hodgkin Lymphoma","C146990","The reemergence of central nervous system non-Hodgkin lymphoma after a period of remission.","Recurrent Central Nervous System Non-Hodgkin Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543934","Grade 4 Guillain-Barre Syndrome, CTCAE","C145880","Life-threatening consequences; urgent intervention indicated; intubation","Grade 4 Guillain-Barre Syndrome, CTCAE | Grade 4 Guillain-Barre syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543935","Grade 4 Gum Infection, CTCAE","C145881","Life-threatening consequences; urgent intervention indicated","Grade 4 Gum Infection, CTCAE | Grade 4 Gum infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543937","Grade 4 Hearing Impaired, CTCAE","C145883","Adults: Decrease in hearing to profound bilateral loss (absolute threshold >80 dB HL at 2 kHz and above); nonservicable hearingPediatric: Audiologic indication for cochlear implant; > 40 dB HL (i.e., 45 dB HL or more); SNHL at 2 kHz and above","Grade 4 Hearing Impaired, CTCAE | Grade 4 Hearing impaired",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544336","Grade 5 Encephalomyelitis Infection, CTCAE","C146290","Death","Grade 5 Encephalomyelitis Infection, CTCAE | Grade 5 Encephalomyelitis infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544338","Grade 5 Endocrine Disorders - Other, Specify, CTCAE","C146292","Death","Grade 5 Endocrine Disorders - Other, Specify, CTCAE | Grade 5 Endocrine disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544339","Grade 5 Enterocolitis Infectious, CTCAE","C146293","Death","Grade 5 Enterocolitis Infectious, CTCAE | Grade 5 Enterocolitis infectious",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544325","Grade 5 Enterovesical Fistula, CTCAE","C146295","Death","Grade 5 Enterovesical Fistula, CTCAE | Grade 5 Enterovesical fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544326","Grade 5 Epistaxis, CTCAE","C146296","Death","Grade 5 Epistaxis, CTCAE | Grade 5 Epistaxis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544327","Grade 5 Epstein-Barr Virus Infection Reactivation, CTCAE","C146297","Death","Grade 5 Epstein-Barr Virus Infection Reactivation, CTCAE | Grade 5 Epstein-Barr virus infection reactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544329","Grade 5 Erythroderma, CTCAE","C146299","Death","Grade 5 Erythroderma, CTCAE | Grade 5 Erythroderma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0207800","monorden","C1462","A macrocyclic antifungal antibiotic that inhibits signal-dependent transcriptional activation and induces differentiation in leukemia. (NCI)","Radicicol | (1aR,2Z,4E,14R,15aR)-8-Chloro-1a,14,15,15a-Tetrahydro-9,11-dihydroxy-14-methyl-6H-oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione | MONORDEN | Monorden | RDC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544330","Grade 5 Esophageal Anastomotic Leak, CTCAE","C146300","Death","Grade 5 Esophageal Anastomotic Leak, CTCAE | Grade 5 Esophageal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544331","Grade 5 Esophageal Hemorrhage, CTCAE","C146302","Death","Grade 5 Esophageal Hemorrhage, CTCAE | Grade 5 Esophageal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544332","Grade 5 Esophageal Infection, CTCAE","C146303","Death","Grade 5 Esophageal Infection, CTCAE | Grade 5 Esophageal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544317","Grade 5 Esophageal Necrosis, CTCAE","C146304","Death","Grade 5 Esophageal Necrosis, CTCAE | Grade 5 Esophageal necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544319","Grade 5 Esophageal Perforation, CTCAE","C146306","Death","Grade 5 Esophageal Perforation, CTCAE | Grade 5 Esophageal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544320","Grade 5 Esophageal Stenosis, CTCAE","C146307","Death","Grade 5 Esophageal Stenosis, CTCAE | Grade 5 Esophageal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544321","Grade 5 Esophageal Ulcer, CTCAE","C146308","Death","Grade 5 Esophageal Ulcer, CTCAE | Grade 5 Esophageal ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544322","Grade 5 Extrapyramidal Disorder, CTCAE","C146309","Death","Grade 5 Extrapyramidal Disorder, CTCAE | Grade 5 Extrapyramidal disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544587","Grade 5 Urinary Fistula, CTCAE","C146595","Death","Grade 5 Urinary Fistula, CTCAE | Grade 5 Urinary fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544573","Grade 5 Urinary Tract Obstruction, CTCAE","C146597","Death","Grade 5 Urinary Tract Obstruction, CTCAE | Grade 5 Urinary tract obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544574","Grade 5 Urostomy Leak, CTCAE","C146598","Death","Grade 5 Urostomy Leak, CTCAE | Grade 5 Urostomy leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544575","Grade 5 Urostomy Obstruction, CTCAE","C146599","Death","Grade 5 Urostomy Obstruction, CTCAE | Grade 5 Urostomy obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0208704","Dexniguldipine","C1465","Dexniguldipine is the (+)-enantiomer of the dihydropyridine derivate niguldipine. Dexniguldipine showed a binding affinity to the P-glycoprotein and therefore it is to be assumed to block the P-glycoprotein pumping mechanism and to modulate multidrug resistance. (NCI)","Dexniguldipine | ((-)-3-Methyl-5- 3-(4,4-diphenyl-l-piperidinyl)-propyl-l,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-pyridine-3,5-dicarboxylate-hydrochloride) | (R)-Nigaldipine Hydrochloride | (S)-(+)-Watanidipine Hydrochloride | 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic Acid, 3-(4,4-Diphenyl-1-piperidinyl)propyl Methyl Ester, Monohydrochloride (R)- | B 859-35 | B8509-035 | B859 35 | DEXNIGULDIPINE | DNIG | Dexniguldipine Hydrochloride | Dexniguldipine.HCl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544576","Grade 5 Urostomy Site Bleeding, CTCAE","C146600","Death","Grade 5 Urostomy Site Bleeding, CTCAE | Grade 5 Urostomy site bleeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544577","Grade 5 Urostomy Stenosis, CTCAE","C146601","Death","Grade 5 Urostomy Stenosis, CTCAE | Grade 5 Urostomy stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544579","Grade 5 Uterine Fistula, CTCAE","C146603","Death","Grade 5 Uterine Fistula, CTCAE | Grade 5 Uterine fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544580","Grade 5 Uterine Infection, CTCAE","C146605","Death","Grade 5 Uterine Infection, CTCAE | Grade 5 Uterine infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544565","Grade 5 Uterine Perforation, CTCAE","C146606","Death","Grade 5 Uterine Perforation, CTCAE | Grade 5 Uterine perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544566","Grade 5 Vaginal Anastomotic Leak, CTCAE","C146607","Death","Grade 5 Vaginal Anastomotic Leak, CTCAE | Grade 5 Vaginal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544567","Grade 5 Vaginal Infection, CTCAE","C146610","Death","Grade 5 Vaginal Infection, CTCAE | Grade 5 Vaginal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544568","Grade 5 Vaginal Perforation, CTCAE","C146611","Death","Grade 5 Vaginal Perforation, CTCAE | Grade 5 Vaginal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544569","Grade 5 Vaginal Stricture, CTCAE","C146612","Death","Grade 5 Vaginal Stricture, CTCAE | Grade 5 Vaginal stricture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544571","Grade 5 Vas Deferens Anastomotic Leak, CTCAE","C146614","Death","Grade 5 Vas Deferens Anastomotic Leak, CTCAE | Grade 5 Vas deferens anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544572","Grade 5 Vascular Access Complication, CTCAE","C146615","Death","Grade 5 Vascular Access Complication, CTCAE | Grade 5 Vascular access complication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544679","Grade 5 Vascular Disorders - Other, Specify, CTCAE","C146616","Death","Grade 5 Vascular Disorders - Other, Specify, CTCAE | Grade 5 Vascular disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544680","Grade 5 Vasovagal Reaction, CTCAE","C146617","Death","Grade 5 Vasovagal Reaction, CTCAE | Grade 5 Vasovagal reaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544681","Grade 5 Venous Injury, CTCAE","C146618","Death","Grade 5 Venous Injury, CTCAE | Grade 5 Venous injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543734","Grade 3 Uterine Anastomotic Leak, CTCAE","C145690","Severe symptoms; invasive intervention indicated","Grade 3 Uterine Anastomotic Leak, CTCAE | Grade 3 Uterine anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543735","Grade 3 Uterine Fistula, CTCAE","C145691","Invasive intervention indicated","Grade 3 Uterine Fistula, CTCAE | Grade 3 Uterine fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544185","Grade 4 Vagus Nerve Disorder, CTCAE","C146185","Life-threatening consequences; urgent intervention indicated","Grade 4 Vagus Nerve Disorder, CTCAE | Grade 4 Vagus nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544186","Grade 4 Vas Deferens Anastomotic Leak, CTCAE","C146186","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Vas Deferens Anastomotic Leak, CTCAE | Grade 4 Vas deferens anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544187","Grade 4 Vascular Access Complication, CTCAE","C146187","Life-threatening consequences with hemodynamic or neurologic instability","Grade 4 Vascular Access Complication, CTCAE | Grade 4 Vascular access complication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544188","Grade 4 Vascular Disorders - Other, Specify, CTCAE","C146188","Life-threatening consequences; urgent intervention indicated","Grade 4 Vascular Disorders - Other, Specify, CTCAE | Grade 4 Vascular disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544301","Grade 4 Vasovagal Reaction, CTCAE","C146189","Life-threatening consequences; urgent intervention indicated","Grade 4 Vasovagal Reaction, CTCAE | Grade 4 Vasovagal reaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544303","Grade 4 Ventricular Arrhythmia, CTCAE","C146191","Life-threatening consequences; hemodynamic compromise","Grade 4 Ventricular Arrhythmia, CTCAE | Grade 4 Ventricular arrhythmia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544304","Grade 4 Visceral Arterial Ischemia, CTCAE","C146192","Life-threatening consequences; evidence of end organ damage; urgent operative intervention indicated","Grade 4 Visceral Arterial Ischemia, CTCAE | Grade 4 Visceral arterial ischemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544305","Grade 4 Vision Decreased, CTCAE","C146193","Best corrected visual acuity of 20/200 or worse in the affected eye","Grade 4 Vision Decreased, CTCAE | Grade 4 Vision decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544306","Grade 4 Vitreous Hemorrhage, CTCAE","C146194","Best corrected visual acuity of 20/200 or worse in the affected eye","Grade 4 Vitreous Hemorrhage, CTCAE | Grade 4 Vitreous hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544307","Grade 4 Vulval Infection, CTCAE","C146195","Life-threatening consequences; urgent intervention indicated","Grade 4 Vulval Infection, CTCAE | Grade 4 Vulval infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544308","Grade 4 Watering Eyes, CTCAE","C146196","Best corrected visual acuity of 20/200 or worse in the affected eye","Grade 4 Watering Eyes, CTCAE | Grade 4 Watering eyes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544293","Grade 4 Wheezing, CTCAE","C146197","Life-threatening consequences; urgent intervention indicated","Grade 4 Wheezing, CTCAE | Grade 4 Wheezing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543494","Grade 3 Injury, Poisoning and Procedural Complications - Other, Specify, CTCAE","C145387","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL","Grade 3 Injury, Poisoning and Procedural Complications - Other, Specify, CTCAE | Grade 3 Injury, poisoning and procedural complications - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543495","Grade 3 INR Increased, CTCAE","C145388",">2.5; >2.5 x baseline if on anticoagulation; bleeding","Grade 3 INR Increased, CTCAE | Grade 3 INR increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543496","Grade 3 Intestinal Stoma Leak, CTCAE","C145389","Severe symptoms; invasive intervention indicated","Grade 3 Intestinal Stoma Leak, CTCAE | Grade 3 Intestinal stoma leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543497","Grade 3 Intestinal Stoma Obstruction, CTCAE","C145390","Severe symptoms; IV fluids, tube feeding, or TPN indicated >=24 hrs; elective operative intervention indicated","Grade 3 Intestinal Stoma Obstruction, CTCAE | Grade 3 Intestinal stoma obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543498","Grade 3 Intestinal Stoma Site Bleeding, CTCAE","C145391","Transfusion indicated; invasive intervention indicated","Grade 3 Intestinal Stoma Site Bleeding, CTCAE | Grade 3 Intestinal stoma site bleeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543499","Grade 3 Intra-Abdominal Hemorrhage, CTCAE","C145392","Transfusion indicated; invasive intervention indicated; hospitalization","Grade 3 Intra-Abdominal Hemorrhage, CTCAE | Grade 3 Intra-abdominal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544947","Allogeneic UCB-derived Hematopoietic Stem and Progenitor Cells NLA101","C146992","A preparation of universal, off-the-shelf, ex vivo expanded, allogeneic umbilical cord blood (UCB)-derived hematopoietic stem and progenitor cells (HSPCs) that can potentially be used to improve hematopoietic recovery after chemotherapy or hematopoietic cell transplantation (HCT).  Upon administration of dilanubicel, these cells increase and restore the number of HSPCs, which may prevent or decrease infection and other complications of chemotherapy-induced neutropenia (CIN) or cord blood transplantation.","Dilanubicel | Allogeneic UCB-derived Hematopoietic Stem and Progenitor Cells NLA101 | Allogeneic Umbilical Cord Blood-derived HSPCs NLA101 | DILANUBICEL | NLA101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0002842","Androgen Receptor Inhibitor","C146993","Any agent that inhibits the activity of the androgen receptor (AR).","Androgen Receptor Inhibitor | AR Antagonist | AR Inhibitor | Androgen Receptor Antagonist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544939","Supplemental Qualifiers Tabulation Dataset","C146996","A dataset containing supplemental information, specifically non-standard variables, to parent records in a domain.","Supplemental Qualifiers Tabulation Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0681832","purpose of study","C146997","The overall rationale, reason, or intention of the clinical study.","Study Purpose | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0392889","Protoporphyrin Measurement","C146998","The determination of the amount of protoporphyrin present in a sample.","Protoporphyrin Measurement | ",,,,,,,,,,,,,,,"4140240","Protoporphyrin measurement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL550739","Mode of Action","C146999","The mechanism by which a pharmacologically active substance produces an effect on the cellular level of a living organism or in a biochemical system.","Mode of Action | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545192","Subject Visits Supplemental Qualifiers Dataset","C147253","A dataset containing supplemental information, specifically non-standard variables, to parent records in the subject visits domain.","Subject Visits Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545193","Trial Arms Supplemental Qualifiers Dataset","C147254","A dataset containing supplemental information, specifically non-standard variables, to parent records in the trial arms domain.","Trial Arms Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545179","Trial Elements Supplemental Qualifiers Dataset","C147256","A dataset containing supplemental information, specifically non-standard variables, to parent records in the trial elements domain.","Trial Elements Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545180","Tumor Findings Supplemental Qualifiers Dataset","C147257","A dataset containing supplemental information, specifically non-standard variables, to parent records in the tumor findings domain.","Tumor Findings Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545181","Trial Inclusion and Exclusion Criteria Supplemental Qualifiers Dataset","C147258","A dataset containing supplemental information, specifically non-standard variables, to parent records in the trial inclusion/exclusion criteria domain.","Trial Inclusion and Exclusion Criteria Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545182","Trial Disease Milestones Supplemental Qualifiers Dataset","C147259","A dataset containing supplemental information, specifically non-standard variables, to parent records in the trial disease milestones domain.","Trial Disease Milestones Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545183","Trial Paths Supplemental Qualifiers Dataset","C147260","A dataset containing supplemental information, specifically non-standard variables, to parent records in the trial paths domain.","Trial Paths Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544323","Grade 5 Eye Infection, CTCAE","C146310","Death","Grade 5 Eye Infection, CTCAE | Grade 5 Eye infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544324","Grade 5 Fallopian Tube Anastomotic Leak, CTCAE","C146311","Death","Grade 5 Fallopian Tube Anastomotic Leak, CTCAE | Grade 5 Fallopian tube anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544311","Grade 5 Gallbladder Infection, CTCAE","C146315","Death","Grade 5 Gallbladder Infection, CTCAE | Grade 5 Gallbladder infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544312","Grade 5 Gastric Anastomotic Leak, CTCAE","C146316","Death","Grade 5 Gastric Anastomotic Leak, CTCAE | Grade 5 Gastric anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544313","Grade 5 Gastric Fistula, CTCAE","C146317","Death","Grade 5 Gastric Fistula, CTCAE | Grade 5 Gastric fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544314","Grade 5 Gastric Hemorrhage, CTCAE","C146318","Death","Grade 5 Gastric Hemorrhage, CTCAE | Grade 5 Gastric hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544315","Grade 5 Gastric Necrosis, CTCAE","C146319","Death","Grade 5 Gastric Necrosis, CTCAE | Grade 5 Gastric necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543664","Grade 3 Neuralgia, CTCAE","C145486","Severe pain; limiting self care ADL","Grade 3 Neuralgia, CTCAE | Grade 3 Neuralgia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543665","Grade 3 Neutrophil Count Decreased, CTCAE","C145487","<1000-500/mm3; <1.0-0.5 x 10e9/L","Grade 3 Neutrophil Count Decreased, CTCAE | Grade 3 Neutrophil count decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543666","Grade 3 Night Blindness, CTCAE","C145488","Symptomatic with marked decrease in visual acuity (best corrected visual acuity worse than 20/40 or more than 3 lines of decreased vision from known baseline, up to 20/200); limiting self care ADL","Grade 3 Night Blindness, CTCAE | Grade 3 Night blindness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543667","Grade 3 Non-Cardiac Chest Pain, CTCAE","C145489","Severe pain; limiting self care ADL","Grade 3 Non-Cardiac Chest Pain, CTCAE | Grade 3 Non-cardiac chest pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543653","Grade 3 Oculomotor Nerve Disorder, CTCAE","C145491","Severe symptoms; limiting self care ADL","Grade 3 Oculomotor Nerve Disorder, CTCAE | Grade 3 Oculomotor nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543654","Grade 3 Olfactory Nerve Disorder, CTCAE","C145492","Severe symptoms; limiting self care ADL","Grade 3 Olfactory Nerve Disorder, CTCAE | Grade 3 Olfactory nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543655","Grade 3 Optic Nerve Disorder, CTCAE","C145493","Marked decrease in visual acuity (best corrected visual acuity worse than 20/40 or more than 3 lines of decreased vision from known baseline, up to 20/200)","Grade 3 Optic Nerve Disorder, CTCAE | Grade 3 Optic nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543656","Grade 3 Oral Cavity Fistula, CTCAE","C145494","Invasive intervention indicated","Grade 3 Oral Cavity Fistula, CTCAE | Grade 3 Oral cavity fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543657","Grade 3 Oral Dysesthesia, CTCAE","C145495","Disabling pain; tube feeding or TPN indicated","Grade 3 Oral Dysesthesia, CTCAE | Grade 3 Oral dysesthesia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543658","Grade 3 Oropharyngeal Pain, CTCAE","C145498","Severe pain; severely altered eating/swallowing; narcotics initiated; requires parenteral nutrition","Grade 3 Oropharyngeal Pain, CTCAE | Grade 3 Oropharyngeal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543659","Grade 3 Osteonecrosis of Jaw, CTCAE","C145499","Severe symptoms; limiting self care ADL; elective operative intervention indicated","Grade 3 Osteonecrosis of Jaw, CTCAE | Grade 3 Osteonecrosis of jaw",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543660","Grade 3 Osteonecrosis, CTCAE","C145500","Severe symptoms; limiting self care ADL; elective operative intervention indicated","Grade 3 Osteonecrosis, CTCAE | Grade 3 Osteonecrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543737","Grade 3 Uterine Obstruction, CTCAE","C145694","Severe symptoms; invasive intervention indicated","Grade 3 Uterine Obstruction, CTCAE | Grade 3 Uterine obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543738","Grade 3 Uterine Pain, CTCAE","C145695","Severe pain; limiting self care ADL","Grade 3 Uterine Pain, CTCAE | Grade 3 Uterine pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543739","Grade 3 Uterine Perforation, CTCAE","C145696","Invasive intervention indicated","Grade 3 Uterine Perforation, CTCAE | Grade 3 Uterine perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543740","Grade 3 Vaccination Complication, CTCAE","C145697","Severe pain; Erythema > 10 cm; Induration/swelling > 10 cm; necrosis; limiting self care ADL","Grade 3 Vaccination Complication, CTCAE | Grade 3 Vaccination complication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543853","Grade 3 Vaginal Anastomotic Leak, CTCAE","C145698","Severe symptoms; invasive intervention indicated","Grade 3 Vaginal Anastomotic Leak, CTCAE | Grade 3 Vaginal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543854","Grade 3 Vaginal Dryness, CTCAE","C145699","Severe vaginal dryness resulting in dyspareunia or severe discomfort","Grade 3 Vaginal Dryness, CTCAE | Grade 3 Vaginal dryness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206527","Superantigen","C1456","An antigen produced by bacteria or viruses that cause non-specific activation of T-lymphocytes. Superantigens form crosslinks between either two major histocompatibility class (MHC) II molecules, which increases both cytokine expression and costimulatory receptor expression in antigen presenting cells, or one MHC class II molecule and the variable region of the T-cell receptor beta chain, which results in increased proliferation of and cytokine expression by T-lymphocytes. This non-specific release of cytokines and upregulation of immune cell activation can lead to rashes, fever, vomiting, anergy, and damage to tissues and organs. These symptoms can progress to autoimmunity, multi-organ failure, coma and death.","Superantigen | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543855","Grade 3 Vaginal Infection, CTCAE","C145702","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Vaginal Infection, CTCAE | Grade 3 Vaginal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543857","Grade 3 Vaginal Obstruction, CTCAE","C145704","Severe symptoms; invasive intervention indicated","Grade 3 Vaginal Obstruction, CTCAE | Grade 3 Vaginal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543858","Grade 3 Vaginal Pain, CTCAE","C145705","Severe pain; limiting self care ADL","Grade 3 Vaginal Pain, CTCAE | Grade 3 Vaginal pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543859","Grade 3 Vaginal Perforation, CTCAE","C145706","Invasive intervention indicated","Grade 3 Vaginal Perforation, CTCAE | Grade 3 Vaginal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543860","Grade 3 Vaginal Stricture, CTCAE","C145707","Vaginal narrowing and/or shortening interfering with the use of tampons, sexual activity or physical examination","Grade 3 Vaginal Stricture, CTCAE | Grade 3 Vaginal stricture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543845","Grade 3 Vagus Nerve Disorder, CTCAE","C145708","Severe symptoms; limiting self care ADL","Grade 3 Vagus Nerve Disorder, CTCAE | Grade 3 Vagus nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543846","Grade 3 Vas Deferens Anastomotic Leak, CTCAE","C145709","Severe symptoms; invasive intervention indicated","Grade 3 Vas Deferens Anastomotic Leak, CTCAE | Grade 3 Vas deferens anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543847","Grade 3 Vascular Access Complication, CTCAE","C145710","Pulmonary embolism, deep vein or cardiac thrombosis; intervention indicated (e.g., anticoagulation, lysis, filter, invasive procedure)","Grade 3 Vascular Access Complication, CTCAE | Grade 3 Vascular access complication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543850","Grade 3 Venous Injury, CTCAE","C145713","Severe symptoms; limiting self care ADL; repair or revision indicated","Grade 3 Venous Injury, CTCAE | Grade 3 Venous injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543851","Grade 3 Ventricular Arrhythmia, CTCAE","C145714","Urgent intervention indicated","Grade 3 Ventricular Arrhythmia, CTCAE | Grade 3 Ventricular arrhythmia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543500","Grade 3 Intracranial Hemorrhage, CTCAE","C145393","Ventriculostomy, ICP monitoring, intraventricular thrombolysis, or invasive intervention indicated; hospitalization","Grade 3 Intracranial Hemorrhage, CTCAE | Grade 3 Intracranial hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543486","Grade 3 Intraoperative Breast Injury, CTCAE","C145395","Complete resection or reconstruction of injured organ/structure indicated; limiting self care ADL","Grade 3 Intraoperative Breast Injury, CTCAE | Grade 3 Intraoperative breast injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543487","Grade 3 Intraoperative Cardiac Injury, CTCAE","C145396","Primary repair of injured organ/structure indicated","Grade 3 Intraoperative Cardiac Injury, CTCAE | Grade 3 Intraoperative cardiac injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543488","Grade 3 Intraoperative Ear Injury, CTCAE","C145397","Complete resection or reconstruction of injured organ/structure indicated; limiting self care ADL (e.g., impaired hearing; impaired balance)","Grade 3 Intraoperative Ear Injury, CTCAE | Grade 3 Intraoperative ear injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543489","Grade 3 Intraoperative Endocrine Injury, CTCAE","C145398","Complete resection or reconstruction of injured organ/structure indicated; limiting self care ADL","Grade 3 Intraoperative Endocrine Injury, CTCAE | Grade 3 Intraoperative endocrine injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543490","Grade 3 Intraoperative Gastrointestinal Injury, CTCAE","C145399","Complete resection or reconstruction of injured organ/structure indicated; limiting self care ADL","Grade 3 Intraoperative Gastrointestinal Injury, CTCAE | Grade 3 Intraoperative gastrointestinal injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543491","Grade 3 Intraoperative Head and Neck Injury, CTCAE","C145400","Complete resection or reconstruction of injured organ/structure indicated; limiting self care ADL","Grade 3 Intraoperative Head and Neck Injury, CTCAE | Grade 3 Intraoperative head and neck injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543492","Grade 3 Intraoperative Hemorrhage, CTCAE","C145401","Postoperative invasive intervention indicated; hospitalization","Grade 3 Intraoperative Hemorrhage, CTCAE | Grade 3 Intraoperative hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543478","Grade 3 Intraoperative Musculoskeletal Injury, CTCAE","C145403","Complete resection or reconstruction of injured organ/structure indicated; limiting self care ADL","Grade 3 Intraoperative Musculoskeletal Injury, CTCAE | Grade 3 Intraoperative musculoskeletal injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543479","Grade 3 Intraoperative Neurological Injury, CTCAE","C145404","Complete resection or reconstruction of injured organ/structure indicated; limiting self care ADL","Grade 3 Intraoperative Neurological Injury, CTCAE | Grade 3 Intraoperative neurological injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543481","Grade 3 Intraoperative Renal Injury, CTCAE","C145406","Complete resection or reconstruction of injured organ/structure indicated; limiting self care ADL","Grade 3 Intraoperative Renal Injury, CTCAE | Grade 3 Intraoperative renal injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545184","Tumor Response Supplemental Qualifiers Dataset","C147261","A dataset containing supplemental information, specifically non-standard variables, to parent records in the tumor response domain.","Tumor Response Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545185","Trial Summary Supplemental Qualifiers Dataset","C147262","A dataset containing supplemental information, specifically non-standard variables, to parent records in the trial summary domain.","Trial Summary Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545171","Trial Stages Supplemental Qualifiers Dataset","C147263","A dataset containing supplemental information, specifically non-standard variables, to parent records in the trial stages domain.","Trial Stages Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545172","Tumor/Lesion Identification Supplemental Qualifiers Dataset","C147264","A dataset containing supplemental information, specifically non-standard variables, to parent records in the tumor/lesion identification domain.","Tumor/Lesion Identification Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545173","Trial Visits Supplemental Qualifiers Dataset","C147265","A dataset containing supplemental information, specifically non-standard variables, to parent records in the trial visits domain.","Trial Visits Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545175","Urinary System Findings Supplemental Qualifiers Dataset","C147267","A dataset containing supplemental information, specifically non-standard variables, to parent records in the urinary system findings domain.","Urinary System Findings Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545176","Vital Signs Supplemental Qualifiers Dataset","C147268","A dataset containing supplemental information, specifically non-standard variables, to parent records in the vital signs domain.","Vital Signs Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545177","Whole Body Findings Supplemental Qualifiers Dataset","C147269","A dataset containing supplemental information, specifically non-standard variables, to parent records in the whole body findings domain.","Whole Body Findings Supplemental Qualifiers Dataset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550427","Trial Disease Milestones Domain","C147270","A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to trial disease milestones.","Trial Disease Milestones Domain | TM | Trial Disease Milestones",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545269","CDISC Study Reference Class","C147271","This special purpose SDTM class contains further descriptions of study-specific identifiers that will be used in subject based domains. (CDISC)","CDISC Study Reference Class | STUDY REFERENCE | Study Reference",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545332","PSIP1 Gene Product","C147522","A protein encoded by the PSIP1 gene.","PSIP1 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543645","Grade 3 Otitis Externa, CTCAE","C145501","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Otitis Externa, CTCAE | Grade 3 Otitis externa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543646","Grade 3 Otitis Media, CTCAE","C145502","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Otitis Media, CTCAE | Grade 3 Otitis media",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543647","Grade 3 Ovarian Infection, CTCAE","C145504","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Ovarian Infection, CTCAE | Grade 3 Ovarian infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543648","Grade 3 Ovarian Rupture, CTCAE","C145505","Transfusion; invasive intervention indicated","Grade 3 Ovarian Rupture, CTCAE | Grade 3 Ovarian rupture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543649","Grade 3 Pain In Extremity, CTCAE","C145506","Severe pain; limiting self care ADL","Grade 3 Pain In Extremity, CTCAE | Grade 3 Pain in extremity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543651","Grade 3 Pain, CTCAE","C145508","Severe pain; limiting self care ADL","Grade 3 Pain, CTCAE | Grade 3 Pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543652","Grade 3 Palmar-Plantar Erythrodysesthesia Syndrome, CTCAE","C145509","Severe skin changes (e.g., peeling, blisters, bleeding, fissures, edema, or hyperkeratosis) with pain; limiting self care ADL","Grade 3 Palmar-Plantar Erythrodysesthesia Syndrome, CTCAE | Grade 3 Palmar-plantar erythrodysesthesia syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543637","Grade 3 Pancreas Infection, CTCAE","C145510","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Pancreas Infection, CTCAE | Grade 3 Pancreas infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0207628","Sorivudine","C1460","A synthetic thymidine analogue with potent antiviral activity against herpes simplex and varicella zoster viruses. Sorivudine is phosphorylated into triphosphate form within the cells; this metabolite interferes with viral DNA replication by inhibiting DNA polymerase activity without been incorporated into elongating viral DNA. Due to the dangerous effects of drug-drug interactions via its metabolite, sorivudine has been removed from the market.","Sorivudine | (+)-1-Beta-D-arabinofuranosyl-5-[(E)-2-bromovi- ny1] uracil | (E)-1-beta-D-arabinofuranosyl-5-(2-bromoethenyl)-2,4(1H,3H)-pyrimidinedione | 1-Beta-D-arabinofuranosyl-(E)-5-(2-bromovinyl)uracil | 2,4(1H,3H)-pyrimidinedione, 1-beta-D-arabinofuranosyl-5-(2-bromoethenyl) | 5-(2-bromovinyl)-1-beta-D- arabinofuranosyluracil | 5-Bromovinyl-araU | BV-araU | Bravavir | SORIVUDINE | SQ 32756 | Usevir | YN-72 | sorivudine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544139","Grade 4 Salivary Gland Infection, CTCAE","C146101","Life-threatening consequences; urgent intervention indicated","Grade 4 Salivary Gland Infection, CTCAE | Grade 4 Salivary gland infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544140","Grade 4 Scleral Disorder, CTCAE","C146102","Best corrected visual acuity of 20/200 or worse in the affected eye","Grade 4 Scleral Disorder, CTCAE | Grade 4 Scleral disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544125","Grade 4 Scrotal Infection, CTCAE","C146103","Life-threatening consequences; urgent intervention indicated","Grade 4 Scrotal Infection, CTCAE | Grade 4 Scrotal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544126","Grade 4 Sepsis, CTCAE","C146104","Life-threatening consequences; urgent intervention indicated","Grade 4 Sepsis, CTCAE | Grade 4 Sepsis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544127","Grade 4 Serum Amylase Increased, CTCAE","C146105",">5.0 x ULN and with signs or symptoms","Grade 4 Serum Amylase Increased, CTCAE | Grade 4 Serum amylase increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544128","Grade 4 Serum Sickness, CTCAE","C146106","Life-threatening consequences; pressor or ventilatory support indicated","Grade 4 Serum Sickness, CTCAE | Grade 4 Serum sickness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544129","Grade 4 Shingles, CTCAE","C146107","Life-threatening consequences; urgent intervention indicated","Grade 4 Shingles, CTCAE | Grade 4 Shingles",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544130","Grade 4 Sinus Disorder, CTCAE","C146108","Necrosis of soft tissue or bone; urgent operative intervention indicated","Grade 4 Sinus Disorder, CTCAE | Grade 4 Sinus disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544132","Grade 4 Sinusoidal Obstruction Syndrome, CTCAE","C146110","Life-threatening consequences (e.g., ventilatory support, dialysis, plasmapheresis, peritoneal drainage)","Grade 4 Sinusoidal Obstruction Syndrome, CTCAE | Grade 4 Sinusoidal obstruction syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544117","Grade 4 Skin and Subcutaneous Tissue Disorders - Other, Specify, CTCAE","C146111","Life-threatening consequences; urgent intervention indicated","Grade 4 Skin and Subcutaneous Tissue Disorders - Other, Specify, CTCAE | Grade 4 Skin and subcutaneous tissue disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544118","Grade 4 Skin Induration, CTCAE","C146112","Generalized; associated with signs or symptoms of impaired breathing or feeding","Grade 4 Skin Induration, CTCAE | Grade 4 Skin induration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544119","Grade 4 Skin Infection, CTCAE","C146113","Life-threatening consequences; urgent intervention indicated","Grade 4 Skin Infection, CTCAE | Grade 4 Skin infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544120","Grade 4 Skin Ulceration, CTCAE","C146114","Any size ulcer with extensive destruction, tissue necrosis, or damage to muscle, bone, or supporting structures with or without full thickness skin loss","Grade 4 Skin Ulceration, CTCAE | Grade 4 Skin ulceration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544121","Grade 4 Sleep Apnea, CTCAE","C146115","Cardiovascular or neuropsychiatric symptoms; urgent operative intervention indicated","Grade 4 Sleep Apnea, CTCAE | Grade 4 Sleep apnea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544123","Grade 4 Small Intestinal Mucositis, CTCAE","C146117","Life-threatening consequences; urgent intervention indicated","Grade 4 Small Intestinal Mucositis, CTCAE | Grade 4 Small intestinal mucositis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544124","Grade 4 Small Intestinal Obstruction, CTCAE","C146118","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Small Intestinal Obstruction, CTCAE | Grade 4 Small intestinal obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543893","Grade 4 Central Nervous System Necrosis, CTCAE","C145788","Life-threatening consequences; urgent intervention indicated","Grade 4 Central Nervous System Necrosis, CTCAE | Grade 4 Central nervous system necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543894","Grade 4 Cerebrospinal Fluid Leakage, CTCAE","C145789","Life-threatening consequences; urgent intervention indicated","Grade 4 Cerebrospinal Fluid Leakage, CTCAE | Grade 4 Cerebrospinal fluid leakage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545426","MIRAGE Syndrome","C147530","An autosomal dominant condition caused by mutation(s) in the SAMD9 gene, encoding sterile alpha motif domain-containing protein 9A. It is a syndromic condition comprising myelodysplasia, infection, restriction of growth, adrenal hypoplasia, genital abnormalities, and enteropathy.","MIRAGE Syndrome | Myelodysplasia, Infection, Restriction of Growth, Adrenal Hypoplasia, Genital Phenotypes, and Enteropathy",,,,,,,,,,,,,,,"37164811","MIRAGE syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545427","Sheep Lung Adenocarcinoma","C147532","Adenocarcinoma arising from the lung of a sheep.","Sheep Lung Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546020","Interleukin-23","C147535","A heterodimeric cytokine composed of interleukin-12 subunit beta and interleukin-23 subunit alpha. This complex binds to the interleukin-23 receptor complex, which activates the JAK-STAT signaling pathway and modulates the proliferation, differentiation and effector functions of T-lymphocytes, natural killer cells and some myeloid lineage cells.","Interleukin-23 | IL-23 | IL23 | Interleukin 23",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545417","CDISC Clinical Classification ATLAS Test Name Terminology","C147537","Test names of clinical classification questions associated with the ATLAS Score (ATLAS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification ATLAS Test Name Terminology | ATLAS Clinical Classification Test Name | ATLAS1TN | CC-ATLAS TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545418","CDISC Clinical Classification ATLAS Test Code Terminology","C147538","Test codes of clinical classification questions associated with the ATLAS Score (ATLAS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification ATLAS Test Code Terminology | ATLAS Clinical Classification Test Code | ATLAS1TC | CC-ATLAS TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545419","CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology","C147539","Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology | FAC061TN | Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 Questionnaire Test Name | QS-FACT-BMT Version 4 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545578","TSCYC - Not Do Something Supposed to Do","C147766","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Not doing something he or she was supposed to do.","TSCYC - Not Do Something Supposed to Do | TSCYC1-Not Do Something Supposed to Do | TSCYC114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545579","TSCYC - Breaking Things on Purpose","C147767","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Breaking things on purpose.","TSCYC - Breaking Things on Purpose | TSCYC1-Breaking Things on Purpose | TSCYC115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545580","TSCYC - Talking About Sexual Things","C147768","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Talking about sexual things.","TSCYC - Talking About Sexual Things | TSCYC1-Talking About Sexual Things | TSCYC116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544800","Anti-ICOS Agonist Monoclonal Antibody BMS-986226","C146762","An agonistic monoclonal antibody that recognizes inducible T-cell co-stimulator (ICOS; CD278), with potential immunomodulating and antineoplastic activities. Upon administration, anti-ICOS agonist monoclonal antibody BMS-986226 targets and binds to ICOS expressed on certain T-cells. This stimulates ICOS-mediated signaling, induces proliferation of ICOS-positive T-cells, enhances cytotoxic T-lymphocyte (CTL) survival and augments the CTL-mediated immune response against tumor cells. ICOS, a T-cell specific, CD28-superfamily co-stimulatory molecule and immune checkpoint protein, is normally expressed on certain activated T-cells and plays a key role in the proliferation and activation of T-cells.","Anti-ICOS Agonist Monoclonal Antibody BMS-986226 | Anti-ICOS BMS-986226 | Anti-inducible T-cell Co-stimulator BMS-986226 | BMS 986226 | BMS-986226 | BMS986226",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543940","Grade 4 Hematuria, CTCAE","C145886","Life-threatening consequences; urgent invasive intervention indicated","Grade 4 Hematuria, CTCAE | Grade 4 Hematuria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543925","Grade 4 Hemolytic Uremic Syndrome, CTCAE","C145887","Life-threatening consequences, (e.g., CNS hemorrhage or thrombosis/embolism or renal failure)","Grade 4 Hemolytic Uremic Syndrome, CTCAE | Grade 4 Hemolytic uremic syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543926","Grade 4 Hemorrhoidal Hemorrhage, CTCAE","C145888","Life-threatening consequences; urgent intervention indicated","Grade 4 Hemorrhoidal Hemorrhage, CTCAE | Grade 4 Hemorrhoidal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543927","Grade 4 Hepatic Failure, CTCAE","C145889","Life-threatening consequences; moderate to severe encephalopathy; coma","Grade 4 Hepatic Failure, CTCAE | Grade 4 Hepatic failure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543928","Grade 4 Hepatic Hemorrhage, CTCAE","C145890","Life-threatening consequences; urgent intervention indicated","Grade 4 Hepatic Hemorrhage, CTCAE | Grade 4 Hepatic hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543929","Grade 4 Hepatic Infection, CTCAE","C145891","Life-threatening consequences; urgent intervention indicated","Grade 4 Hepatic Infection, CTCAE | Grade 4 Hepatic infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543931","Grade 4 Hepatitis Viral, CTCAE","C145893","Life-threatening consequences; severe decompensated liver function (e.g., coagulopathy, encephalopathy, coma)","Grade 4 Hepatitis Viral, CTCAE | Grade 4 Hepatitis viral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543932","Grade 4 Hepatobiliary Disorders - Other, Specify, CTCAE","C145894","Life-threatening consequences; urgent intervention indicated","Grade 4 Hepatobiliary Disorders - Other, Specify, CTCAE | Grade 4 Hepatobiliary disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544045","Grade 4 Herpes Simplex Reactivation, CTCAE","C145895","Life-threatening consequences; urgent intervention indicated","Grade 4 Herpes Simplex Reactivation, CTCAE | Grade 4 Herpes simplex reactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544237","Grade 4 Small Intestinal Perforation, CTCAE","C146119","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Small Intestinal Perforation, CTCAE | Grade 4 Small intestinal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544238","Grade 4 Small Intestinal Stenosis, CTCAE","C146120","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Small Intestinal Stenosis, CTCAE | Grade 4 Small intestinal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543440","Grade 3 Gastroparesis, CTCAE","C145311","Weight loss >=20% from baseline; tube feeding or TPN indicated; elective operative intervention indicated","Grade 3 Gastroparesis, CTCAE | Grade 3 Gastroparesis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543441","Grade 3 General Disorders and Administration Site Conditions - Other, Specify, CTCAE","C145312","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL","Grade 3 General Disorders and Administration Site Conditions - Other, Specify, CTCAE | Grade 3 General disorders and administration site conditions - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543442","Grade 3 Generalized Edema, CTCAE","C145313","Interferes with self care ADL; intravenous therapy indicated; skin breakdown","Grade 3 Generalized Edema, CTCAE | Grade 3 Generalized edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543444","Grade 3 Genital Edema, CTCAE","C145315","Lymphorrhea; gross deviation from normal anatomic contour; limiting self care ADL","Grade 3 Genital Edema, CTCAE | Grade 3 Genital edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543429","Grade 3 GGT Increased, CTCAE","C145316",">5.0-20.0 x ULN if baseline was normal; >5.0-20.0 x baseline if baseline was abnormal","Grade 3 GGT Increased, CTCAE | Grade 3 GGT increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543430","Grade 3 Gingival Pain, CTCAE","C145317","Severe pain; inability to aliment orally","Grade 3 Gingival Pain, CTCAE | Grade 3 Gingival pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543431","Grade 3 Glossopharyngeal Nerve Disorder, CTCAE","C145318","Severe symptoms; limiting self care ADL","Grade 3 Glossopharyngeal Nerve Disorder, CTCAE | Grade 3 Glossopharyngeal nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543432","Grade 3 Glucose Intolerance, CTCAE","C145319","Severe symptoms; insulin indicated","Grade 3 Glucose Intolerance, CTCAE | Grade 3 Glucose intolerance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543433","Grade 3 Growth Suppression, CTCAE","C145320","Reduction in growth velocity of >=50% ideally measured over the period of a year","Grade 3 Growth Suppression, CTCAE | Grade 3 Growth suppression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543435","Grade 3 Gum Infection, CTCAE","C145322","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Gum Infection, CTCAE | Grade 3 Gum infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543421","Grade 3 Headache, CTCAE","C145324","Severe pain; limiting self care ADL","Grade 3 Headache, CTCAE | Grade 3 Headache",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543422","Grade 3 Hearing Impaired, CTCAE","C145325","Adults enrolled on a Monitoring Program (on a 1, 2, 3, 4, 6, and 8 kHz audiogram): Threshold shift of >25 dB averaged at 3 contiguous test frequencies in at least one ear; therapeutic intervention indicated; Adults not enrolled on a Monitoring Program: Hearing loss with hearing aid or intervention indicated; limiting self care ADL; Pediatric (on a 1, 2, 3, 4, 6, and 8 kHz audiogram): Hearing loss sufficient to indicate therapeutic intervention, including hearing aids; threshold shift >20 dB at 2 to < 4 kHz in at least one ear","Grade 3 Hearing Impaired, CTCAE | Grade 3 Hearing impaired",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543423","Grade 3 Heart Failure, CTCAE","C145326","Symptoms at rest or with minimal activity or exertion; hospitalization; new onset of symptoms","Grade 3 Heart Failure, CTCAE | Grade 3 Heart failure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543424","Grade 3 Hematosalpinx, CTCAE","C145327","Transfusion indicated; invasive intervention indicated","Grade 3 Hematosalpinx, CTCAE | Grade 3 Hematosalpinx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543425","Grade 3 Hematuria, CTCAE","C145328","Gross hematuria; transfusion, IV medications, or hospitalization indicated; elective invasive intervention indicated; limiting self care ADL","Grade 3 Hematuria, CTCAE | Grade 3 Hematuria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543895","Grade 4 Cervicitis Infection, CTCAE","C145790","Life-threatening consequences; urgent intervention indicated","Grade 4 Cervicitis Infection, CTCAE | Grade 4 Cervicitis infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543896","Grade 4 Chest Wall Necrosis, CTCAE","C145791","Life-threatening consequences; urgent intervention indicated","Grade 4 Chest Wall Necrosis, CTCAE | Grade 4 Chest wall necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543897","Grade 4 Cholesterol High, CTCAE","C145792",">500 mg/dL; >12.92 mmol/L","Grade 4 Cholesterol High, CTCAE | Grade 4 Cholesterol high",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543898","Grade 4 Chronic Kidney Disease, CTCAE","C145793","eGFR or CrCl <15 ml/min/1.73 m2; dialysis or renal transplant indicated","Grade 4 Chronic Kidney Disease, CTCAE | Grade 4 Chronic kidney disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543899","Grade 4 Chylous Ascites, CTCAE","C145794","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Chylous Ascites, CTCAE | Grade 4 Chylous ascites",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543885","Grade 4 Colonic Hemorrhage, CTCAE","C145796","Life-threatening consequences; urgent intervention indicated","Grade 4 Colonic Hemorrhage, CTCAE | Grade 4 Colonic hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543886","Grade 4 Colonic Obstruction, CTCAE","C145797","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Colonic Obstruction, CTCAE | Grade 4 Colonic obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543887","Grade 4 Colonic Perforation, CTCAE","C145798","Life-threatening consequences; urgent intervention indicated","Grade 4 Colonic Perforation, CTCAE | Grade 4 Colonic perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543888","Grade 4 Colonic Stenosis, CTCAE","C145799","Life-threatening consequences; urgent operative intervention indicated","Grade 4 Colonic Stenosis, CTCAE | Grade 4 Colonic stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0206665","Yeast Artificial Chromosome","C1457","A cloning vector based upon elements of yeast chromosomes.  At a minimum these include: yeast telomeres, a yeast centromere, and a yeast autonomously replicating sequence (ARS).  Such vectors are propagated in yeast and then transferred into a target eukaryotic cell where the yeast sequences can be recognized and will maintain the molecule through cell division.  These vectors can maintain extremely large amounts of foreign DNA.  YACs are maintained as linear molecules","Yeast Artificial Chromosome | YAC | YAC Vector",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543890","Grade 4 Conduction Disorder, CTCAE","C145801","Life-threatening consequences","Grade 4 Conduction Disorder, CTCAE | Grade 4 Conduction disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543891","Grade 4 Congenital, Familial and Genetic Disorders - Other, Specify, CTCAE","C145802","Life-threatening consequences; urgent intervention indicated","Grade 4 Congenital, Familial and Genetic Disorders - Other, Specify, CTCAE | Grade 4 Congenital, familial and genetic disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543877","Grade 4 Conjunctivitis, CTCAE","C145804","Best corrected visual acuity of 20/200 or worse in the affected eye","Grade 4 Conjunctivitis, CTCAE | Grade 4 Conjunctivitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543878","Grade 4 Corneal Infection, CTCAE","C145805","Life-threatening consequences; urgent intervention indicated","Grade 4 Corneal Infection, CTCAE | Grade 4 Corneal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543879","Grade 4 Corneal Ulcer, CTCAE","C145806","Perforation in the affected eye","Grade 4 Corneal Ulcer, CTCAE | Grade 4 Corneal ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543880","Grade 4 CPK Increased, CTCAE","C145807",">10 x ULN","Grade 4 CPK Increased, CTCAE | Grade 4 CPK increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543882","Grade 4 Creatinine Increased, CTCAE","C145809",">6.0 x ULN","Grade 4 Creatinine Increased, CTCAE | Grade 4 Creatinine increased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545581","TSCYC - Having Trouble Concentrating","C147769","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Having trouble concentrating.","TSCYC - Having Trouble Concentrating | TSCYC1-Having Trouble Concentrating | TSCYC117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545566","TSCYC - Blaming for Things Weren't Fault","C147770","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Blaming himself or herself for things that weren't his or her fault.","TSCYC - Blaming for Things Weren't Fault | TSCYC1-Blaming for Things Weren't Fault | TSCYC118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545567","TSCYC - Acting Frightened Reminded Past","C147771","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Acting frightened when he or she was reminded of something that happened in the past.","TSCYC - Acting Frightened Reminded Past | TSCYC1-Acting Frightened Reminded Past | TSCYC119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545568","TSCYC - Pretending to Have Sex","C147772","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Pretending to have sex.","TSCYC - Pretending to Have Sex | TSCYC1-Pretending to Have Sex | TSCYC120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545569","TSCYC - Worrying Bad Things in Future","C147773","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Worrying that bad things would happen in the future.","TSCYC - Worrying Bad Things in Future | TSCYC1-Worrying Bad Things in Future | TSCYC121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545570","TSCYC - Arguing","C147774","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Arguing.","TSCYC - Arguing | TSCYC1-Arguing | TSCYC122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545571","TSCYC - Getting Into Physical Fights","C147775","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Getting into physical fights.","TSCYC - Getting Into Physical Fights | TSCYC1-Getting Into Physical Fights | TSCYC123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545573","TSCYC - Not Noticing What He or She Doing","C147777","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Not noticing what he or she was doing.","TSCYC - Not Noticing What He or She Doing | TSCYC1-Not Noticing What He or She Doing | TSCYC125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545558","TSCYC - Having Trouble Sitting Still","C147778","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Having trouble sitting still.","TSCYC - Having Trouble Sitting Still | TSCYC1-Having Trouble Sitting Still | TSCYC126",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545559","TSCYC - Playing Games Something Bad Past","C147779","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Playing games about something bad that actually happened to him or her in the past.","TSCYC - Playing Games Something Bad Past | TSCYC1-Playing Games Something Bad Past | TSCYC127",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0209389","In 111 Satumomab Pendetide","C1469","An radioimmunoconjugate of the murine monoclonal antibody, Satumomab (MoAb B72.3), conjugated to the linker-chelator, glycyl-tyrosyl-(N,-diethylenetriaminepentaacetic acid)-lysine hydrochloride (GYK-DTPA-HCl; pendetide) labeled with indium 111 (In-111). Satumomab recognizes TAG-72, an antigen expressed by the majority of adenocarcinomas. In-111 Satumomab pendetide emits gamma radiation and X-Ray photons that can be captured by gamma camera allowing imaging of TAG-72 expressing tissues.","In 111 Satumomab Pendetide | INDIUM IN-111 SATUMOMAB PENDETIDE | Indium In 111 Satumomab Pendetide | Indium In-11 CYT-103 | OncoScint CR/OV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544046","Grade 4 Hip Fracture, CTCAE","C145896","Life-threatening consequences; symptoms associated with neurovascular compromise","Grade 4 Hip Fracture, CTCAE | Grade 4 Hip fracture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544047","Grade 4 Hypercalcemia, CTCAE","C145897","Corrected serum calcium of >13.5 mg/dL; >3.4 mmol/L; Ionized calcium >1.8 mmol/L; life-threatening consequences","Grade 4 Hypercalcemia, CTCAE | Grade 4 Hypercalcemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544048","Grade 4 Hyperglycemia, CTCAE","C145898","Life-threatening consequences; urgent intervention indicated","Grade 4 Hyperglycemia, CTCAE | Grade 4 Hyperglycemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544049","Grade 4 Hyperkalemia, CTCAE","C145899",">7.0 mmol/L; life-threatening consequences","Grade 4 Hyperkalemia, CTCAE | Grade 4 Hyperkalemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544050","Grade 4 Hyperlipidemia, CTCAE","C145900","Life-threatening consequences","Grade 4 Hyperlipidemia, CTCAE | Grade 4 Hyperlipidemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544052","Grade 4 Hypernatremia, CTCAE","C145902",">160 mmol/L; life-threatening consequences","Grade 4 Hypernatremia, CTCAE | Grade 4 Hypernatremia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544037","Grade 4 Hyperphosphatemia, CTCAE","C145903","Life-threatening consequences; urgent intervention indicated (e.g., dialysis)","Grade 4 Hyperphosphatemia, CTCAE | Grade 4 Hyperphosphatemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544038","Grade 4 Hyperthyroidism, CTCAE","C145904","Life-threatening consequences; urgent intervention indicated","Grade 4 Hyperthyroidism, CTCAE | Grade 4 Hyperthyroidism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544039","Grade 4 Hypertriglyceridemia, CTCAE","C145905",">1000 mg/dL; >11.4 mmol/L; life-threatening consequences","Grade 4 Hypertriglyceridemia, CTCAE | Grade 4 Hypertriglyceridemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544040","Grade 4 Hyperuricemia, CTCAE","C145906","Life-threatening consequences","Grade 4 Hyperuricemia, CTCAE | Grade 4 Hyperuricemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544041","Grade 4 Hypoalbuminemia, CTCAE","C145907","Life-threatening consequences; urgent intervention indicated","Grade 4 Hypoalbuminemia, CTCAE | Grade 4 Hypoalbuminemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544429","Grade 5 Gastric Stenosis, CTCAE","C146321","Death","Grade 5 Gastric Stenosis, CTCAE | Grade 5 Gastric stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544431","Grade 5 Gastrointestinal Anastomotic Leak, CTCAE","C146323","Death","Grade 5 Gastrointestinal Anastomotic Leak, CTCAE | Grade 5 Gastrointestinal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544432","Grade 5 Gastrointestinal Disorders - Other, Specify, CTCAE","C146324","Death","Grade 5 Gastrointestinal Disorders - Other, Specify, CTCAE | Grade 5 Gastrointestinal disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544433","Grade 5 Gastrointestinal Fistula, CTCAE","C146325","Death","Grade 5 Gastrointestinal Fistula, CTCAE | Grade 5 Gastrointestinal fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544434","Grade 5 Gastrointestinal Stoma Necrosis, CTCAE","C146326","Death","Grade 5 Gastrointestinal Stoma Necrosis, CTCAE | Grade 5 Gastrointestinal stoma necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544435","Grade 5 General Disorders and Administration Site Conditions - Other, Specify, CTCAE","C146327","Death","Grade 5 General Disorders and Administration Site Conditions - Other, Specify, CTCAE | Grade 5 General disorders and administration site conditions - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544436","Grade 5 Glossopharyngeal Nerve Disorder, CTCAE","C146328","Death","Grade 5 Glossopharyngeal Nerve Disorder, CTCAE | Grade 5 Glossopharyngeal nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543427","Grade 3 Hemolytic Uremic Syndrome, CTCAE","C145330","Laboratory findings with clinical consequences (e.g., renal insufficiency, petechiae)","Grade 3 Hemolytic Uremic Syndrome, CTCAE | Grade 3 Hemolytic uremic syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543428","Grade 3 Hemorrhoidal Hemorrhage, CTCAE","C145331","Transfusion indicated; invasive intervention indicated; hospitalization","Grade 3 Hemorrhoidal Hemorrhage, CTCAE | Grade 3 Hemorrhoidal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543413","Grade 3 Hepatic Failure, CTCAE","C145332","Asterixis; mild encephalopathy; drug-induced liver injury (DILI); limiting self care ADL","Grade 3 Hepatic Failure, CTCAE | Grade 3 Hepatic failure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543414","Grade 3 Hepatic Hemorrhage, CTCAE","C145333","Transfusion indicated; invasive intervention indicated; hospitalization","Grade 3 Hepatic Hemorrhage, CTCAE | Grade 3 Hepatic hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544684","Grade 5 Vulval Infection, CTCAE","C146621","Death","Grade 5 Vulval Infection, CTCAE | Grade 5 Vulval infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544685","Grade 5 Wheezing, CTCAE","C146622","Death","Grade 5 Wheezing, CTCAE | Grade 5 Wheezing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544686","Grade 5 Wound Complication, CTCAE","C146623","Death","Grade 5 Wound Complication, CTCAE | Grade 5 Wound complication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544671","Grade 5 Wound Dehiscence, CTCAE","C146624","Death","Grade 5 Wound Dehiscence, CTCAE | Grade 5 Wound dehiscence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544672","Grade 5 Wound Infection, CTCAE","C146625","Death","Grade 5 Wound Infection, CTCAE | Grade 5 Wound infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544676","Gastrointestinal Disorders, CTCAE","C146630","No value exists.","Gastrointestinal Disorders, CTCAE | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544668","IL-2/9/15 Gamma Chain Receptor Inhibitor BNZ-1","C146636","A pegylated peptide antagonist that binds to the common gamma chain (gc; IL2RG; CD132) of the signaling receptor for the pro-inflammatory cytokines interleukin (IL)-2, IL-9, and IL-15, with potential immunomodulating and antineoplastic activities. Upon administration, IL-2/9/15 gc receptor inhibitor BNZ-1 specifically targets and binds to the IL binding site on the gc receptor and blocks IL-2, IL-9 and IL-15 binding, thereby inhibiting IL-2-, IL-9-, and IL-15-mediated signaling and downstream pathways. This may inhibit proliferation of tumor cells that are dependent on IL-2/9/15 signaling for their growth. IL-2/9/15 are upregulated in certain tumor cell types and play a key role in tumor progression and survival.","IL-2/9/15 Gamma Chain Receptor Inhibitor BNZ-1 | BNZ-1 | BNZ132-1-40",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544295","Grade 4 Wound Complication, CTCAE","C146199","Life-threatening consequences","Grade 4 Wound Complication, CTCAE | Grade 4 Wound complication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544296","Grade 4 Wound Dehiscence, CTCAE","C146200","Life-threatening consequences; symptomatic hernia with evidence of strangulation; fascial disruption with evisceration; major reconstruction flap, grafting, resection, or amputation indicated","Grade 4 Wound Dehiscence, CTCAE | Grade 4 Wound dehiscence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544297","Grade 4 Wound Infection, CTCAE","C146201","Life-threatening consequences; urgent intervention indicated","Grade 4 Wound Infection, CTCAE | Grade 4 Wound infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544298","Grade 5 Abdominal Infection, CTCAE","C146202","Death","Grade 5 Abdominal Infection, CTCAE | Grade 5 Abdominal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544299","Grade 5 Abdominal Soft Tissue Necrosis, CTCAE","C146203","Death","Grade 5 Abdominal Soft Tissue Necrosis, CTCAE | Grade 5 Abdominal soft tissue necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544300","Grade 5 Acidosis, CTCAE","C146204","Death","Grade 5 Acidosis, CTCAE | Grade 5 Acidosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544285","Grade 5 Acute Kidney Injury, CTCAE","C146205","Death","Grade 5 Acute Kidney Injury, CTCAE | Grade 5 Acute kidney injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544286","Grade 5 Alcohol Intolerance, CTCAE","C146206","Death","Grade 5 Alcohol Intolerance, CTCAE | Grade 5 Alcohol intolerance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544287","Grade 5 Alkalosis, CTCAE","C146207","Death","Grade 5 Alkalosis, CTCAE | Grade 5 Alkalosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544288","Grade 5 Allergic Reaction, CTCAE","C146208","Death","Grade 5 Allergic Reaction, CTCAE | Grade 5 Allergic reaction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544289","Grade 5 Anal Fistula, CTCAE","C146209","Death","Grade 5 Anal Fistula, CTCAE | Grade 5 Anal fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544290","Grade 5 Anal Hemorrhage, CTCAE","C146210","Death","Grade 5 Anal Hemorrhage, CTCAE | Grade 5 Anal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544291","Grade 5 Anal Necrosis, CTCAE","C146211","Death","Grade 5 Anal Necrosis, CTCAE | Grade 5 Anal necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544292","Grade 5 Anal Stenosis, CTCAE","C146212","Death","Grade 5 Anal Stenosis, CTCAE | Grade 5 Anal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544277","Grade 5 Anal Ulcer, CTCAE","C146213","Death","Grade 5 Anal Ulcer, CTCAE | Grade 5 Anal ulcer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544278","Grade 5 Anaphylaxis, CTCAE","C146214","Death","Grade 5 Anaphylaxis, CTCAE | Grade 5 Anaphylaxis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544279","Grade 5 Anemia, CTCAE","C146215","Death","Grade 5 Anemia, CTCAE | Grade 5 Anemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544280","Grade 5 Anorectal Infection, CTCAE","C146216","Death","Grade 5 Anorectal Infection, CTCAE | Grade 5 Anorectal infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544281","Grade 5 Aortic Injury, CTCAE","C146217","Death","Grade 5 Aortic Injury, CTCAE | Grade 5 Aortic injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544282","Grade 5 Aortic Valve Disease, CTCAE","C146218","Death","Grade 5 Aortic Valve Disease, CTCAE | Grade 5 Aortic valve disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544283","Grade 5 Appendicitis Perforated, CTCAE","C146219","Death","Grade 5 Appendicitis Perforated, CTCAE | Grade 5 Appendicitis perforated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544284","Grade 5 Appendicitis, CTCAE","C146220","Death","Grade 5 Appendicitis, CTCAE | Grade 5 Appendicitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544269","Grade 5 Arachnoiditis, CTCAE","C146221","Death","Grade 5 Arachnoiditis, CTCAE | Grade 5 Arachnoiditis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544270","Grade 5 Arterial Injury, CTCAE","C146222","Death","Grade 5 Arterial Injury, CTCAE | Grade 5 Arterial injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544931","Cardiac Extraskeletal Osteosarcoma","C147003","An extraskeletal osteosarcoma that arises from the heart. It produces osteoid and bone, and occasionally shows chondroblastic differentiation.","Cardiac Extraskeletal Osteosarcoma | Cardiac Osteogenic Sarcoma | Cardiac Osteosarcoma | Heart Extraskeletal Osteosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544932","Cardiac Myxofibrosarcoma","C147004","A low-grade sarcoma that arises from the heart. It is composed of spindle or rounded cells in a myxoid stroma. The most common location is the left atrium.","Cardiac Myxofibrosarcoma | Cardiac Myxoid Malignant Fibrous Histiocytoma | Heart Myxofibrosarcoma | Heart Myxoid Malignant Fibrous Histiocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544933","Cardiac Germ Cell Tumor","C147005","A germ cell tumor that arises within the myocardium or cardiac chambers. The reported cases have been teratomas and yolk sac tumors.","Cardiac Germ Cell Tumor | Heart Germ Cell Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544934","Cardiac Yolk Sac Tumor","C147006","A yolk sac tumor that arises within the myocardium or cardiac chambers.","Cardiac Yolk Sac Tumor | Heart Yolk Sac Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1112387","Cardiac Teratoma","C147007","A teratoma that arises within the myocardium or cardiac chambers.","Cardiac Teratoma | Heart Teratoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544935","TNFRSF1A Gene Product","C147008","A protein encoded by the TNFRSF1A gene.","TNFRSF1A Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544936","EGFR NM_005228.3:c.2389T>A","C147009","A nucleotide substitution at position 2389 of the coding sequence of the EGFR gene where thymine has been mutated to adenine.","EGFR NM_005228.3:c.2389T>A | EGFR c.2389T>A | ERBB c.2389T>A | ERBB1 c.2389T>A | Epidermal Growth Factor Receptor Gene c.2389T>A | HER1 c.2389T>A | NM_005228.3:c.2389T>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544937","EGFR NM_005228.3:c.2390G>C","C147010","A nucleotide substitution at position 2390 of the coding sequence of the EGFR gene where guanine has been mutated to cytosine.","EGFR NM_005228.3:c.2390G>C | EGFR c.2390G>C | ERBB c.2390G>C | ERBB1 c.2390G>C | Epidermal Growth Factor Receptor Gene c.2390G>C | HER1 c.2390G>C | NM_005228.3:c.2390G>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545045","EGFR NM_005228.3:c.2374C>T","C147013","A nucleotide substitution at position 2374 of the coding sequence of the EGFR gene where cytosine has been mutated to thymine.","EGFR NM_005228.3:c.2374C>T | EGFR c.2374C>T | ERBB c.2374C>T | ERBB1 c.2374C>T | Epidermal Growth Factor Receptor Gene c.2374C>T | HER1 c.2374C>T | NM_005228.3:c.2374C>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543759","Grade 3 Tracheal Stenosis, CTCAE","C145667","Stridor or respiratory distress limiting self care ADL; invasive intervention indicated (e.g., stent, laser)","Grade 3 Tracheal Stenosis, CTCAE | Grade 3 Tracheal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543760","Grade 3 Tracheitis, CTCAE","C145668","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Tracheitis, CTCAE | Grade 3 Tracheitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544422","Grade 5 Guillain-Barre Syndrome, CTCAE","C146330","Death","Grade 5 Guillain-Barre Syndrome, CTCAE | Grade 5 Guillain-Barre syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544423","Grade 5 Gum Infection, CTCAE","C146331","Death","Grade 5 Gum Infection, CTCAE | Grade 5 Gum infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544425","Grade 5 Heart Failure, CTCAE","C146333","Death","Grade 5 Heart Failure, CTCAE | Grade 5 Heart failure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544426","Grade 5 Hematosalpinx, CTCAE","C146334","Death","Grade 5 Hematosalpinx, CTCAE | Grade 5 Hematosalpinx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544428","Grade 5 Hemolytic Uremic Syndrome, CTCAE","C146336","Death","Grade 5 Hemolytic Uremic Syndrome, CTCAE | Grade 5 Hemolytic uremic syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544413","Grade 5 Hemorrhoidal Hemorrhage, CTCAE","C146337","Death","Grade 5 Hemorrhoidal Hemorrhage, CTCAE | Grade 5 Hemorrhoidal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544414","Grade 5 Hepatic Failure, CTCAE","C146338","Death","Grade 5 Hepatic Failure, CTCAE | Grade 5 Hepatic failure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544415","Grade 5 Hepatic Hemorrhage, CTCAE","C146339","Death","Grade 5 Hepatic Hemorrhage, CTCAE | Grade 5 Hepatic hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544416","Grade 5 Hepatic Infection, CTCAE","C146340","Death","Grade 5 Hepatic Infection, CTCAE | Grade 5 Hepatic infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544418","Grade 5 Hepatitis Viral, CTCAE","C146342","Death","Grade 5 Hepatitis Viral, CTCAE | Grade 5 Hepatitis viral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544419","Grade 5 Hepatobiliary Disorders - Other, Specify, CTCAE","C146343","Death","Grade 5 Hepatobiliary Disorders - Other, Specify, CTCAE | Grade 5 Hepatobiliary disorders - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544420","Grade 5 Herpes Simplex Reactivation, CTCAE","C146344","Death","Grade 5 Herpes Simplex Reactivation, CTCAE | Grade 5 Herpes simplex reactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544405","Grade 5 Hypercalcemia, CTCAE","C146345","Death","Grade 5 Hypercalcemia, CTCAE | Grade 5 Hypercalcemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544407","Grade 5 Hyperkalemia, CTCAE","C146347","Death","Grade 5 Hyperkalemia, CTCAE | Grade 5 Hyperkalemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544408","Grade 5 Hypermagnesemia, CTCAE","C146348","Death","Grade 5 Hypermagnesemia, CTCAE | Grade 5 Hypermagnesemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544410","Grade 5 Hyperphosphatemia, CTCAE","C146350","Death","Grade 5 Hyperphosphatemia, CTCAE | Grade 5 Hyperphosphatemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544411","Grade 5 Hyperthyroidism, CTCAE","C146351","Death","Grade 5 Hyperthyroidism, CTCAE | Grade 5 Hyperthyroidism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543638","Grade 3 Pancreatic Anastomotic Leak, CTCAE","C145511","Severe symptoms; invasive intervention indicated","Grade 3 Pancreatic Anastomotic Leak, CTCAE | Grade 3 Pancreatic anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543639","Grade 3 Pancreatic Duct Stenosis, CTCAE","C145512","Severely altered GI function; tube feeding or hospitalization indicated; elective operative intervention indicated","Grade 3 Pancreatic Duct Stenosis, CTCAE | Grade 3 Pancreatic duct stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543642","Grade 3 Papilledema, CTCAE","C145517","Symptomatic with marked decrease in visual acuity (best corrected visual acuity worse than 20/40 or more than 3 lines of decreased vision from known baseline, up to 20/200)","Grade 3 Papilledema, CTCAE | Grade 3 Papilledema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3658299","Spectrum, Zellweger","C146639","A group of conditions with overlapping signs and symptoms. It includes Zellweger syndrome, neonatal adrenoleukodystrophy, and infantile Refsum disease.","Peroxisome Biogenesis Disorders in the Zellweger Spectrum | PBD-ZSD | Zellweger Spectrum Disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544670","Atypical Type A Thymoma","C146640","A rare type A thymoma displaying atypical features (hypercellularity, increased mitotic activity, and focal necrosis).","Atypical Type A Thymoma | Atypical Type A Thymoma Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543852","Grade 3 Vertigo, CTCAE","C145715","Severe symptoms; limiting self care ADL","Grade 3 Vertigo, CTCAE | Grade 3 Vertigo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543837","Grade 3 Vestibular Disorder, CTCAE","C145716","Severe symptoms; limiting self care ADL","Grade 3 Vestibular Disorder, CTCAE | Grade 3 Vestibular disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543838","Grade 3 Viremia, CTCAE","C145717","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated","Grade 3 Viremia, CTCAE | Grade 3 Viremia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543839","Grade 3 Visceral Arterial Ischemia, CTCAE","C145718","Prolonged (>=24 hrs) or recurring symptoms and/or invasive intervention indicated","Grade 3 Visceral Arterial Ischemia, CTCAE | Grade 3 Visceral arterial ischemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543840","Grade 3 Vision Decreased, CTCAE","C145719","Marked decrease in visual acuity (best corrected visual acuity worse than 20/40 or more than 3 lines of decreased vision from known baseline, up to 20/200)","Grade 3 Vision Decreased, CTCAE | Grade 3 Vision decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543842","Grade 3 Voice Alteration, CTCAE","C145721","Severe voice changes including predominantly whispered speech; may require frequent repetition or face-to-face contact for understandability; may require assistive technology","Grade 3 Voice Alteration, CTCAE | Grade 3 Voice alteration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543843","Grade 3 Vulval Infection, CTCAE","C145722","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Vulval Infection, CTCAE | Grade 3 Vulval infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543844","Grade 3 Watering Eyes, CTCAE","C145723","Marked decrease in visual acuity (best corrected visual acuity worse than 20/40 or more than 3 lines of decreased vision from known baseline, up to 20/200)","Grade 3 Watering Eyes, CTCAE | Grade 3 Watering eyes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543829","Grade 3 Wheezing, CTCAE","C145724","Severe respiratory symptoms limiting self care ADL; oxygen therapy or hospitalization indicated","Grade 3 Wheezing, CTCAE | Grade 3 Wheezing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543830","Grade 3 White Blood Cell Decreased, CTCAE","C145725","<2000-1000/mm3; <2.0-1.0 x 10e9/L","Grade 3 White Blood Cell Decreased, CTCAE | Grade 3 White blood cell decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543831","Grade 3 Wound Complication, CTCAE","C145726","Operative intervention indicated","Grade 3 Wound Complication, CTCAE | Grade 3 Wound complication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543832","Grade 3 Wound Dehiscence, CTCAE","C145727","Fascial disruption or dehiscence without evisceration; revision by operative intervention indicated","Grade 3 Wound Dehiscence, CTCAE | Grade 3 Wound dehiscence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544271","Grade 5 Arterial Thromboembolism, CTCAE","C146223","Death","Grade 5 Arterial Thromboembolism, CTCAE | Grade 5 Arterial thromboembolism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL544272","Grade 5 Arteritis Infective, CTCAE","C146224","Death","Grade 5 Arteritis Infective, CTCAE | Grade 5 Arteritis infective",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543482","Grade 3 Intraoperative Reproductive Tract Injury, CTCAE","C145407","Complete resection or reconstruction of injured organ/structure indicated; limiting self care ADL","Grade 3 Intraoperative Reproductive Tract Injury, CTCAE | Grade 3 Intraoperative reproductive tract injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543483","Grade 3 Intraoperative Respiratory Injury, CTCAE","C145408","Complete resection or reconstruction of injured organ/structure indicated; limiting self care ADL","Grade 3 Intraoperative Respiratory Injury, CTCAE | Grade 3 Intraoperative respiratory injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543484","Grade 3 Intraoperative Splenic Injury, CTCAE","C145409","Resection or reconstruction of injured organ/structure indicated; limiting self care ADL","Grade 3 Intraoperative Splenic Injury, CTCAE | Grade 3 Intraoperative splenic injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543597","Grade 3 Intraoperative Urinary Injury, CTCAE","C145410","Complete resection or reconstruction of injured organ/structure indicated; limiting self care ADL","Grade 3 Intraoperative Urinary Injury, CTCAE | Grade 3 Intraoperative urinary injury",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543599","Grade 3 Investigations - Other, Specify, CTCAE","C145412","Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL","Grade 3 Investigations - Other, Specify, CTCAE | Grade 3 Investigations - Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543600","Grade 3 Irritability, CTCAE","C145413","Severe abnormal or excessive response; limiting self care ADL; inconsolable; medical or psychiatric intervention indicated","Grade 3 Irritability, CTCAE | Grade 3 Irritability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543601","Grade 3 Jejunal Perforation, CTCAE","C145417","Invasive intervention indicated","Grade 3 Jejunal Perforation, CTCAE | Grade 3 Jejunal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543602","Grade 3 Jejunal Stenosis, CTCAE","C145418","Severely altered GI function; tube feeding or hospitalization indicated; elective operative intervention indicated","Grade 3 Jejunal Stenosis, CTCAE | Grade 3 Jejunal stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543603","Grade 3 Joint Infection, CTCAE","C145420","Arthroscopic intervention indicated (e.g., drainage) or arthrotomy (e.g., open surgical drainage)","Grade 3 Joint Infection, CTCAE | Grade 3 Joint infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543604","Grade 3 Joint Range of Motion Decreased Cervical Spine, CTCAE","C145421","Ankylosed/fused over multiple segments with no C-spine rotation","Grade 3 Joint Range of Motion Decreased Cervical Spine, CTCAE | Grade 3 Joint range of motion decreased cervical spine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543589","Grade 3 Joint Range of Motion Decreased Lumbar Spine, CTCAE","C145422","<50% lumbar spine flexion; associated with symptoms of ankylosis or fused over multiple segments with no L-spine flexion (e.g., unable to reach to floor to pick up a very light object)","Grade 3 Joint Range of Motion Decreased Lumbar Spine, CTCAE | Grade 3 Joint range of motion decreased lumbar spine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543590","Grade 3 Joint Range of Motion Decreased, CTCAE","C145423",">50% decrease in ROM; limiting self care ADL","Grade 3 Joint Range of Motion Decreased, CTCAE | Grade 3 Joint range of motion decreased",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543592","Grade 3 Kidney Infection, CTCAE","C145425","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Kidney Infection, CTCAE | Grade 3 Kidney infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543593","Grade 3 Kyphosis, CTCAE","C145426","Severe accentuation; operative intervention indicated; limiting self care ADL","Grade 3 Kyphosis, CTCAE | Grade 3 Kyphosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543594","Grade 3 Large Intestinal Anastomotic Leak, CTCAE","C145427","Severe symptoms; invasive intervention indicated","Grade 3 Large Intestinal Anastomotic Leak, CTCAE | Grade 3 Large intestinal anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543595","Grade 3 Laryngeal Edema, CTCAE","C145428","Stridor; respiratory distress; hospitalization indicated","Grade 3 Laryngeal Edema, CTCAE | Grade 3 Laryngeal edema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543762","Grade 3 Treatment Related Secondary Malignancy, CTCAE","C145670","Non life-threatening secondary malignancy","Grade 3 Treatment Related Secondary Malignancy, CTCAE | Grade 3 Treatment related secondary malignancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543763","Grade 3 Tricuspid Valve Disease, CTCAE","C145671","Symptomatic; severe regurgitation or stenosis; symptoms controlled with medical intervention","Grade 3 Tricuspid Valve Disease, CTCAE | Grade 3 Tricuspid valve disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543764","Grade 3 Trigeminal Nerve Disorder, CTCAE","C145672","Severe symptoms; limiting self care ADL","Grade 3 Trigeminal Nerve Disorder, CTCAE | Grade 3 Trigeminal nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543749","Grade 3 Trochlear Nerve Disorder, CTCAE","C145673","Severe symptoms; limiting self care ADL","Grade 3 Trochlear Nerve Disorder, CTCAE | Grade 3 Trochlear nerve disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543750","Grade 3 Tumor Hemorrhage, CTCAE","C145674","Transfusion indicated; invasive intervention indicated; hospitalization","Grade 3 Tumor Hemorrhage, CTCAE | Grade 3 Tumor hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543751","Grade 3 Unequal Limb Length, CTCAE","C145675","Severe length discrepancy >5 cm; limiting self care ADL; operative intervention indicated","Grade 3 Unequal Limb Length, CTCAE | Grade 3 Unequal limb length",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543752","Grade 3 Upper Gastrointestinal Hemorrhage, CTCAE","C145676","Transfusion indicated; invasive intervention indicated; hospitalization","Grade 3 Upper Gastrointestinal Hemorrhage, CTCAE | Grade 3 Upper gastrointestinal hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543753","Grade 3 Upper Respiratory Infection, CTCAE","C145677","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Upper Respiratory Infection, CTCAE | Grade 3 Upper respiratory infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543755","Grade 3 Urethral Anastomotic Leak, CTCAE","C145679","Severe symptoms; invasive intervention indicated","Grade 3 Urethral Anastomotic Leak, CTCAE | Grade 3 Urethral anastomotic leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543756","Grade 3 Urethral Infection, CTCAE","C145680","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Urethral Infection, CTCAE | Grade 3 Urethral infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543741","Grade 3 Urinary Fistula, CTCAE","C145681","Invasive intervention indicated","Grade 3 Urinary Fistula, CTCAE | Grade 3 Urinary fistula",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543742","Grade 3 Urinary Tract Infection, CTCAE","C145682","IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated","Grade 3 Urinary Tract Infection, CTCAE | Grade 3 Urinary tract infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543743","Grade 3 Urinary Tract Obstruction, CTCAE","C145683","Altered organ function (e.g., hydronephrosis or renal dysfunction); invasive intervention indicated","Grade 3 Urinary Tract Obstruction, CTCAE | Grade 3 Urinary tract obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543744","Grade 3 Urinary Tract Pain, CTCAE","C145684","Severe pain; limiting self care ADL","Grade 3 Urinary Tract Pain, CTCAE | Grade 3 Urinary tract pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543746","Grade 3 Urostomy Leak, CTCAE","C145686","Severe symptoms; invasive intervention indicated","Grade 3 Urostomy Leak, CTCAE | Grade 3 Urostomy leak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543747","Grade 3 Urostomy Obstruction, CTCAE","C145687","Altered organ function (e.g., sepsis or hydronephrosis, or renal dysfunction); elective operative intervention indicated","Grade 3 Urostomy Obstruction, CTCAE | Grade 3 Urostomy obstruction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543748","Grade 3 Urostomy Site Bleeding, CTCAE","C145688","Transfusion indicated; invasive intervention indicated","Grade 3 Urostomy Site Bleeding, CTCAE | Grade 3 Urostomy site bleeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL543733","Grade 3 Urostomy Stenosis, CTCAE","C145689","Symptomatic (e.g., hydronephrosis, or renal dysfunction); elective operative intervention indicated","Grade 3 Urostomy Stenosis, CTCAE | Grade 3 Urostomy stenosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2830214","HDAC inhibitor CHR-2845","C152539","A hydroxamic acid-derived histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Tefinostat inhibits HDAC leading to an accumulation of highly acetylated histones, which may result in chromatin remodeling, inhibition of tumor oncogene transcription, inhibition of tumor cell division, and the induction of tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins; this agent may specifically target HDACs in cells of the monocyte-macrophage lineage.","Tefinostat | CHR 2845 | CHR-2845 | CHR2845 | TEFINOSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019948","Hospital Administration","C15253","General management of a hospital, or the more specific processes involved in the management of an individual department.","Hospital Administration | Hospital Administration / HMO | Hospital Management",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0076042","teflurane","C152540","No value exists.","Teflurane | TEFLURANE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553873","tegobuvir","C152541","No value exists.","Tegobuvir | TEGOBUVIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553874","Tegoprazan","C152542","No value exists.","Tegoprazan | TEGOPRAZAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553875","Telacebec","C152543","No value exists.","Telacebec | TELACEBEC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553877","Telcagepant","C152545","No value exists.","Telcagepant | TELCAGEPANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553878","Telcagepant Potassium","C152546","No value exists.","Telcagepant Potassium | TELCAGEPANT POTASSIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553880","Telmapitant","C152548","No value exists.","Telmapitant | TELMAPITANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553881","Telotristat","C152549","A tryptophan hydroxylase (TPH) inhibitor, with potential anti-serotonergic activity. Upon administration, telotristat binds to and inhibits the activity of TPH. This may result in a reduction in peripheral serotonin (5-HT) production and improvement of serotonin-mediated gastrointestinal effects such as severe diarrhea. TPH, the rate-limiting enzyme in serotonin biosynthesis, is overexpressed in carcinoid tumor cells.","Telotristat | TELOTRISTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553882","Tematropium Methylsulfate","C152550","No value exists.","Tematropium Methylsulfate | TEMATROPIUM METHYLSULFATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553883","Temavirsen","C152551","No value exists.","Temavirsen | TEMAVIRSEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553884","Temavirsen Sodium","C152552","No value exists.","Temavirsen Sodium | TEMAVIRSEN SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553885","Temsavir","C152553","No value exists.","Temsavir | TEMSAVIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553886","Temurtide","C152554","No value exists.","Temurtide | TEMURTIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553887","Tenapanor","C152555","No value exists.","Tenapanor | TENAPANOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553888","Tenapanor Hydrochloride","C152556","No value exists.","Tenapanor Hydrochloride | TENAPANOR HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553889","Tendamistat","C152557","No value exists.","Tendamistat | TENDAMISTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553890","Tenidap","C152558","No value exists.","Tenidap | TENIDAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020632","Hypophysectomy","C15255","Surgical removal of part or all of the pituitary gland.","Hypophysectomy | Excision of the Hypophysis | Excision of the Pituitary Gland | Excision of the Pituitary Gland+B3297 | Hypophysis Cerebri Excision | Hypophysis Excision | Pituitary Gland Excision | Pituitectomy",,,,,,,,,,,,,,,"4201001","Hypophysectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL553892","Tenofovir Exalidex","C152560","No value exists.","Tenofovir Exalidex | TENOFOVIR EXALIDEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553893","Tenonitrozole","C152561","No value exists.","Tenonitrozole | TENONITROZOLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553894","Tenylidone","C152562","No value exists.","Tenylidone | TENYLIDONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553895","Teoprolol","C152563","No value exists.","Teoprolol | TEOPROLOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553896","Tepilamide Fumarate","C152564","No value exists.","Tepilamide Fumarate | TEPILAMIDE FUMARATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553898","Teprotide","C152566","No value exists.","Teprotide | TEPROTIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553899","dironyl","C152567","No value exists.","Terguride | TERGURIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553190","ADC DS-1062a","C151967","An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against tumor-associated antigen (TAA) trophoblast cell surface protein 2 (calcium signal transducer 2; TROP2; TROP-2; TACSTD2) conjugated, via an enzymatically cleavable tetrapeptide-based  linker, to the cytotoxic DNA topoisomerase I inhibitor and exatecan (DX-8951) derivative DXd (MAAA-1181a; MAAA-1181), with potential antineoplastic activity. Upon administration of the datopotamab deruxtecan, the anti-TROP2 antibody targets and binds to TROP2 expressed on tumor cells. Upon cellular uptake and lysosomal degradation of the linker, DXd targets and binds to DNA topoisomerase I, thereby stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication and apoptosis. This inhibits tumor cell proliferation of TROP2-expressing tumor cells. TROP2 is a transmembrane protein overexpressed in various tumors while its expression is low and/or restricted in normal, healthy tissues. Its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival. The ADC allows for reduced systemic exposure and enhanced delivery of the cytotoxic agent DXd.","Datopotamab Deruxtecan | ADC DS-1062a | Anti-TROP2/DXd Antibody-drug Conjugate DS-1062a | DATOPOTAMAB DERUXTECAN | DS-1062 | DS-1062a | Dato-DXd",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553191","Donor-derived CD34+ HPCs/CD3+ T-cells MDR-101","C151968","A preparation of allogeneic, organ donor-derived CD34-positive hematopoietic stem and progenitor cells (HPCs) and CD3-positive T-cells that can be used after organ transplantation to potentially prevent organ rejection. Upon infusion of sizavaleucel after organ transplantation, these cells mix and co-exist with the recipient's blood and immune cells, thereby inducing hematologic mixed chimerism and enabling the recipient's immune system to become immune tolerant to the donor cells. This increases acceptance of the transplanted organ, decreases the risk of organ transplant rejection, increases organ survival and may decrease the need for additional immunosuppressive agents. Sizavaleucel is ex vivo processed in a specific and unique way which has yet to be fully elucidated. Cell doses are dependent on the degree of human leukocyte antigen (HLA)-match/HLA-mismatch between the recipient and donor.","Sizavaleucel | Donor-derived CD34+ HPCs/CD3+ T-cells MDR-101 | Donor-derived CD34+ Hematopoietic Stem and Progenitor Cells Plus CD3+ T-cells MDR-101 | MDR 101 | MDR-101 | SIZAVALEUCEL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553414","Ribociclib Succinate","C152210","The succinate salt form of ribociclib, an orally available inhibitor of the cyclin-dependent kinases (CDKs) 4 and 6, with antineoplastic activity. Upon oral administration, ribociclib specifically targets, binds to and inhibits CDK4 and CDK6. This inhibits the cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, which inhibits phosphorylation of the retinoblastoma (Rb) protein. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle dysregulation.","Ribociclib Succinate | Kisqali | RIBOCICLIB SUCCINATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553415","Ribuvaptan","C152211","No value exists.","Ribuvaptan | RIBUVAPTAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553416","Ridinilazole","C152212","A narrow-spectrum antibiotic with potential activity against Clostridioides difficile infection (CDI). Upon oral administration, ridinilazole exerts its bactericidal activity against C. difficile through inhibition of cell division. This suppresses bacterial toxin production and inhibits the associated inflammatory response. Compared to other antibiotics that treat C. difficile, ridinilazole does not deplete intestinal bacteria and preserves the intestinal bacterial activity and the associated bile acid metabolome.","Ridinilazole | 5,5'-Bi-1H-benzimidazole, 2,2'-Di-4-pyridinyl- | RIDINILAZOLE | SMT-19969 | SMT19969 | WHO 10075",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553417","benzoxazinorifamycin","C152213","No value exists.","Rifalazil | RIFALAZIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553418","Rifamexil","C152214","No value exists.","Rifamexil | RIFAMEXIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553419","Rifamide","C152215","No value exists.","Rifamide | RIFAMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553420","Rigosertib","C152216","A synthetic benzyl styryl sulfone analogue and Ras mimetic, with potential antineoplastic activity. Upon administration, rigosertib targets and binds to Ras-binding domain (RBD) found in many Ras effector proteins, including Raf kinase and phosphatidylinositol 3-kinase (PI3K). This prevents Ras from binding to its targets and inhibits Ras-mediated signaling pathways, including Ras/Raf/Erk, Ras/CRAF/polo-like kinase1 (Plk1), and Ras/ PI3K/Akt signaling pathways. This induces cell cycle arrest and apoptosis and inhibits proliferation in a variety of susceptible tumor cells.","Rigosertib | Glycine, N-(2-methoxy-5-((((1E)-2-(2,4,6-trimethoxyphenyl)ethenyl)sulfonyl) methyl)phenyl)- | N-(2-Methoxy-5-((((1E)-2-(2,4,6-trimethoxyphenyl)ethenyl)sulfonyl)methyl) phenyl)glycine | ON 01910 | RIGOSERTIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3154850","Rilpivirine Hydrochloride","C152217","No value exists.","Rilpivirine Hydrochloride | RILPIVIRINE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553422","rimcazole","C152218","No value exists.","Rimcazole | RIMCAZOLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550783","Trastuzumab Conjugate BI-CON-02","C148165","A conjugated form of trastuzumab, a humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2; ERBB2), with potential immunomodulating and antineoplastic activities. Upon administration, the trastuzumab conjugate BI-CON-02 targets and binds to HER2 on the tumor cell surface, thereby inducing both cytotoxic T-lymphocyte (CTL) and antibody-dependent cell-mediated cytotoxicity (ADCC) responses against tumor cells that overexpress HER2. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","Trastuzumab Conjugate BI-CON-02 | BI-CON-02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550778","Cyclin-dependent Kinase 8/19 Inhibitor BCD 115","C148166","An orally bioavailable inhibitor of cyclin dependent kinases 8 and 19 (CDK8/19), with potential antineoplastic and chemoprotective activities. Upon oral administration, CDK8/19 inhibitor BCD 115 binds to and inhibits the activity of CDK8/19, which prevents activation of CDK8/19-mediated oncogenic signaling pathways, blocks selective transcription of certain tumor promoting genes, and inhibits proliferation of CDK8/19-overexpressing tumor cells. CDKs are serine/threonine kinases involved in the regulation of the cell cycle and may be overexpressed in certain cancer cell types. CDK8 plays a key role in transcription regulation and is an important oncogenic driver in a variety of cancer cell types.","Cyclin-dependent Kinase 8/19 Inhibitor BCD 115 | BCD 115 | BCD-115 | BCD115 | CDK 8/19 Inhibitor BCD 115 | SENEXIN B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550777","Zirconium Zr 89 Pembrolizumab","C148167","A radioimmunoconjugate composed of pembrolizumab, a humanized monoclonal antibody immunoglobulin (Ig) G4 antibody directed against the human cell surface receptor programmed cell death 1 (PD-1; PDCD1; CD279; programmed cell death-1), labeled with the radioisotope zirconium Zr 89, with potential use as an imaging agent upon positron emission tomography (PET). Upon administration of zirconium Zr 89 pembrolizumab, the antibody moiety binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T-cells, and blocks the binding to and activation of PD-1 by its ligands. Upon PET imaging, PD-1-expressing T-cells, as well as pembrolizumab biodistribution, can be visualized and the expected response to treatment with pembrolizumab, as well as selection of patients that would respond to pembrolizumab, can be assessed. The ligands for PD-1 include programmed cell death-1 ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death-1 ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","Zirconium Zr 89 Pembrolizumab | 89Zr-labeled Pembrolizumab | 89Zr-pembrolizumab | PEMBROLIZUMAB DESFERRIOXAMINE ZIRCONIUM ZR-89",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551030","Refractory Laryngeal Squamous Cell Carcinoma","C148383","Laryngeal squamous cell carcinoma that does not respond to treatment.","Refractory Laryngeal Squamous Cell Carcinoma | Refractory Laryngeal Throat Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3151136","CILIARY DYSKINESIA, PRIMARY, 14","C148370","An autosomal recessive primary ciliary motility defect caused by mutation(s) in the CCDC39 gene, encoding coiled-coil domain-containing protein 39.","Primary Ciliary Dyskinesia 14 | CILD14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1857512","Temtamy Syndrome","C148371","An extremely rare autosomal recessive condition caused by mutation(s) in the C12orf57 gene, encoding protein C10. It is characterized by agenesis/hypoplasia of the corpus callosum, associated with developmental delay, and variable craniofacial and skeletal abnormalities.","Temtamy Syndrome | TEMTYS",,,,,,,,,,,,,,,"36714637","Temtamy syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL550939","DNMT3L Gene","C148372","This gene is involved in the regulation of DNA methyltransferase activity.","DNMT3L Gene | DNA Methyltransferase 3 Like Gene | DNMT3L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550938","DNMT3L wt Allele","C148373","Human DNMT3L wild-type allele is located in the vicinity of 21q22.3 and is approximately 21 kb in length. This allele, which encodes DNA (cytosine-5)-methyltransferase 3-like protein, plays a role in the regulation of DNA methylation and gene transcription.","DNMT3L wt Allele | DNA Methyltransferase 3 Like wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550941","DNA (Cytosine-5)-Methyltransferase 3-Like","C148374","DNA (cytosine-5)-methyltransferase 3-like (386 aa, ~44 kDa) is encoded by the human DNMT3L gene. This protein is involved in the modulation of DNA methyltransferase activity.","DNA (Cytosine-5)-Methyltransferase 3-Like | Cytosine-5-Methyltransferase 3-Like Protein | DNA (Cytosine-5-)-Methyltransferase 3-Like | DNA Cytosine-5-Methyltransferase 3-Like Protein | DNA Methyltransferase 3-Like Protein | DNMT3L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550940","DEPDC5 Gene","C148375","This gene plays a role in the regulation of Ras-related GTP-binding protein-mediated signaling.","DEPDC5 Gene | DEP Domain Containing 5 Gene | DEPDC5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545818","Childhood Recurrent Malignant Solid Tumor","C148026","The reemergence of a childhood malignant solid neoplasm after a period of remission.","Recurrent Childhood Malignant Solid Neoplasm | Childhood Recurrent Malignant Solid Neoplasm | Childhood Recurrent Malignant Solid Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545819","Childhood Refractory Malignant Solid Tumor","C148027","A childhood malignant solid neoplasm that does not respond to treatment.","Refractory Childhood Malignant Solid Neoplasm | Childhood Refractory Malignant Solid Neoplasm | Childhood Refractory Malignant Solid Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545821","Childhood Malignant Solid Neoplasm","C148029","A malignant solid neoplasm that occurs during childhood.","Childhood Malignant Solid Neoplasm | Childhood Malignant Solid Tumor | Malignant Solid Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553900","Terlakiren","C152568","No value exists.","Terlakiren | TERLAKIREN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552964","FACT-L Version 4 - I Am Satisfied With My Sex Life","C151247","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Social/Family Well-Being: I am satisfied with my sex life.","FACT-L Version 4 - I Am Satisfied With My Sex Life | FAC016-I Am Satisfied With My Sex Life | FAC01614",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552965","FACT-L Version 4 - I Feel Sad","C151248","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Emotional Well-Being: I feel sad.","FACT-L Version 4 - I Feel Sad | FAC016-I Feel Sad | FAC01615",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552966","FACT-L Version 4 - Satisfied With How I Am Coping","C151249","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Emotional Well-Being: I am satisfied with how I am coping with my illness.","FACT-L Version 4 - Satisfied With How I Am Coping | FAC016-Satisfied With How I Am Coping | FAC01616",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552967","FACT-L Version 4 - Losing Hope Against Illness","C151250","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Emotional Well-Being: I am losing hope in the fight against my illness.","FACT-L Version 4 - Losing Hope Against Illness | FAC016-Losing Hope Against Illness | FAC01617",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552968","FACT-L Version 4 - I Feel Nervous","C151251","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Emotional Well-Being: I feel nervous.","FACT-L Version 4 - I Feel Nervous | FAC016-I Feel Nervous | FAC01618",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552969","FACT-L Version 4 - I Worry About Dying","C151252","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Emotional Well-Being: I worry about dying.","FACT-L Version 4 - I Worry About Dying | FAC016-I Worry About Dying | FAC01619",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552970","FACT-L Version 4 - Worry My Condition Will Get Worse","C151253","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Emotional Well-Being: I worry that my condition will get worse.","FACT-L Version 4 - Worry My Condition Will Get Worse | FAC016-Worry My Condition Will Get Worse | FAC01620",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552972","FACT-L Version 4 - My Work Is Fulfilling","C151255","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Functional Well-Being: My work (include work at home) is fulfilling.","FACT-L Version 4 - My Work Is Fulfilling | FAC016-My Work Is Fulfilling | FAC01622",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552973","FACT-L Version 4 - I Am Able to Enjoy Life","C151256","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Functional Well-Being: I am able to enjoy life.","FACT-L Version 4 - I Am Able to Enjoy Life | FAC016-I Am Able to Enjoy Life | FAC01623",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552974","FACT-L Version 4 - I Have Accepted My Illness","C151257","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Functional Well-Being: I have accepted my illness.","FACT-L Version 4 - I Have Accepted My Illness | FAC016-I Have Accepted My Illness | FAC01624",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553103","FACT-L Version 4 - I Am Sleeping Well","C151258","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Functional Well-Being: I am sleeping well.","FACT-L Version 4 - I Am Sleeping Well | FAC016-I Am Sleeping Well | FAC01625",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553104","FACT-L Version 4 - Enjoy Things I Usually Do for Fun","C151259","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Functional Well-Being: I am enjoying the things I usually do for fun.","FACT-L Version 4 - Enjoy Things I Usually Do for Fun | FAC016-Enjoy Things I Usually Do for Fun | FAC01626",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553105","FACT-L Version 4 - Content With Quality of My Life","C151260","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Functional Well-Being: I am content with the quality of my life right now.","FACT-L Version 4 - Content With Quality of My Life | FAC016-Content With Quality of My Life | FAC01627",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553106","FACT-L Version 4 - I Have Been Short of Breath","C151261","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Additional Concerns: I have been short of breath.","FACT-L Version 4 - I Have Been Short of Breath | FAC016-I Have Been Short of Breath | FAC01628",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553423","Rimcazole Hydrochloride","C152219","No value exists.","Rimcazole Hydrochloride | RIMCAZOLE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553424","Rimegepant","C152220","No value exists.","Rimegepant | RIMEGEPANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553425","Rimegepant Sulfate","C152221","No value exists.","Rimegepant Sulfate | RIMEGEPANT SULFATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553426","Rimigorsen","C152222","No value exists.","Rimigorsen | RIMIGORSEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553427","RINFABATE","C152223","No value exists.","Rinfabate | RINFABATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553428","Rinucumab","C152224","No value exists.","Rinucumab | RINUCUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553429","Riociguat","C152225","No value exists.","Riociguat | RIOCIGUAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553430","Ripasudil","C152226","No value exists.","Ripasudil | RIPASUDIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553432","Rislenemdaz","C152228","No value exists.","Rislenemdaz | RISLENEMDAZ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553433","Rismorelin","C152229","No value exists.","Rismorelin | RISMORELIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553985","Tiprinast","C152653","No value exists.","Tiprinast | TIPRINAST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553986","Tiprostanide","C152654","No value exists.","Tiprostanide | TIPROSTANIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553987","Tiqueside","C152655","No value exists.","Tiqueside | TIQUESIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553989","Tirasemtiv","C152657","No value exists.","Tirasemtiv | TIRASEMTIV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0245179","tirilazad","C152658","No value exists.","Tirilazad | TIRILAZAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553991","Tirilazad Mesylate","C152659","No value exists.","Tirilazad Mesylate | TIRILAZAD MESYLATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553992","Tiropramide","C152660","No value exists.","Tiropramide | TIROPRAMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553995","Tisoquone","C152663","No value exists.","Tisoquone | TISOQUONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553996","Tisotumab","C152664","No value exists.","Tisotumab | TISOTUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553997","Tivanisiran","C152665","No value exists.","Tivanisiran | TIVANISIRAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550935","DEPDC5 wt Allele","C148376","Human DEPDC5 wild-type allele is located within 22q12.2-q12.3 and is approximately 153 kb in length. This allele, which encodes GATOR complex protein DEPDC5, is involved in the modulation of signaling by Ras-related GTP-binding proteins. Mutations in this gene are associated with autosomal dominant familial focal epilepsy with variable foci and with an increased risk of hepatocellular carcinoma in individuals with chronic hepatitis C virus infection.","DEPDC5 wt Allele | DEP Domain Containing 5 wt Allele | DEP.5 | FFEVF | FFEVF1 | KIAA0645",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3849647","DEPDC5 protein, human","C148377","GATOR complex protein DEPDC5 (1603 aa, ~181 kDa) is encoded by the human DEPDC5 gene. This protein plays a role in the inhibition of Ras-related GTP-binding protein-mediated signaling.","GATOR Complex Protein DEPDC5 | DEP Domain-Containing Protein 5 | DEPDC5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550937","Endocervical Dosage Form","C148378","No value exists.","Endocervical Dosage Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551029","Lm-tLLO-neoantigens Vaccine ADXS-NEO","C148380","A proprietary, personalized plasmid DNA-based cancer vaccine composed of a live-attenuated strain of the Gram-positive bacterium Listeria monocytogenes (Lm) carrying a proprietary plasmid vector encoding multiple, patient-specific, immunogenic neoepitopes fused to a truncated form of the immunostimulant listeriolysin O (tLLO), with potential immunostimulatory and antineoplastic activities. Upon administration of the Lm-tLLO-neoantigens vaccine ADXS-NEO, the ADXS-NEO is taken up by antigen presenting cells (APCs), such as dendritic cells (DCs), and the expressed tLLO-neoantigens fusion protein is processed and presented to the immune system by both major histocompatibility complex (MHC) I and II molecules. This activates the immune system to exert both innate and adaptive immune responses involving the recruitment and activation of T-lymphocytes against the tumor-associated antigens (TAAs) specifically expressed by the patient's tumor cells, and inhibits the immunosuppressive tumor-infiltrating T-regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSCs) within the tumor microenvironment (TME). This results in tumor cell lysis. The various unique mutation-derived TAAs that are used in ADXS-NEO are identified from a biopsy of the patient's tumor.","Lm-tLLO-neoantigens Vaccine ADXS-NEO | ADXS NEO | ADXS-NEO | Neoepitope-based Immunotherapeutic ADXS-NEO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551031","Refractory Hypopharyngeal Squamous Cell Carcinoma","C148382","Hypopharyngeal squamous cell carcinoma that does not respond to treatment.","Refractory Hypopharyngeal Squamous Cell Carcinoma | Refractory Hypopharyngeal Throat Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1869988","PTPRO protein, human","C147977","Receptor-type tyrosine-protein phosphatase O (1216 aa, ~138 kDa) is encoded by the human PTPRO gene. This protein is involved in tyrosine phosphatase activity and glomerular epithelium development.","Receptor-Type Tyrosine-Protein Phosphatase O | EC 3.1.3.48 | Osteoclastic Transmembrane Protein-Tyrosine Phosphatase | PTPRO | Phosphotyrosine Phosphatase U2 | Protein Tyrosine Phosphatase PTP-U2 | Protein Tyrosine Phosphatase U2 | R-PTP-O",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545748","PARP3 Gene","C147978","This gene plays a role in the ADP-ribosylation of proteins involved in base excision repair.","PARP3 Gene | PARP3 | Poly(ADP-Ribose) Polymerase Family Member 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545749","PARP3 wt Allele","C147979","Human PARP3 wild-type allele is located in the vicinity of 3p21.2 and is approximately 7 kb in length. This allele, which encodes protein mono-ADP-ribosyltransferase PARP3 protein, is involved in the regulation of DNA base excision repair.","PARP3 wt Allele | ADP-Ribosyltransferase (NAD+; Poly (ADP-Ribose) Polymerase)-Like 2 Gene | ADP-Ribosyltransferase (NAD+; Poly (ADP-Ribose) Polymerase)-Like 3 Gene | ADPRT3 | ADPRTL2 | ADPRTL3 | ARTD3 | IRT1 | PADPRT-3 | Poly(ADP-Ribose) Polymerase Family Member 3 wt Allele | Poly(ADP-Ribose) Polymerase Family, Member 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1434346","PARP3 protein, human","C147980","Protein mono-ADP-ribosyltransferase PARP3 (533 aa, ~60 kDa) is encoded by the human PARP3 gene. This protein plays a role in DNA repair and mono-ADP-ribosylation of target proteins.","Protein Mono-ADP-Ribosyltransferase PARP3 | ADP-Ribosyltransferase 3 | ADP-Ribosyltransferase Diphtheria Toxin-Like 3 | ADP-Ribosyltransferase-Like 3 | ADPRT-3 | ARTD3 | DNA ADP-Ribosyltransferase PARP3 | EC 2.4.2.- | EC 2.4.2.30 | IRT1 | NAD(+) ADP-Ribosyltransferase 3 | NAD+ ADP-Ribosyltransferase 3 | PARP-3 | PARP3 | Poly (ADP-Ribose) Polymerase 3 | Poly (ADP-Ribosyl) Transferase-Like 3 | Poly [ADP-Ribose] Polymerase 3 | Poly [ADP-Ribose] Polymerase 3 | Poly(ADP-Ribose) Polymerase 3 | Poly(ADP-Ribose) Synthase 3 | Poly(ADP-Ribose) Synthetase-3 | Poly[ADP-Ribose] Synthase 3 | Poly[ADP-Ribose] Synthetase 3 | hPARP-3 | pADPRT-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545822","Autologous Anti-CD19 T-cell Receptor T cells ET190L1","C148030","Autologous human peripheral blood T-lymphocytes transduced with a lentivirus encoding a proprietary expression construct composed of a T-cell receptor (TCR)-like human antibody, which is synthesized by a proprietary phage display platform, targeting peptides derived from the tumor-associated antigen (TAA) CD19 that are presented in the context of major histocompatibility complex (MHC) molecules, with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and re-introduction into the patient, the autologous anti-CD19 TCR T-cells ET190L1 target and bind to tumor cells expressing CD19 peptide/MHC complexes. This results in cytotoxic T-lymphocyte (CTL)-mediated elimination of CD19-positive tumor cells. CD19, cluster of differentiation antigen 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage malignancies. ET190L1 is able to match the anticancer activity of chimeric antigen receptor (CAR) T-cells; however, ET190L1 is less likely to stimulate cytokine release syndrome (CRS) and does not cause CAR T-cell-triggered neurotoxicity.","Autologous Anti-CD19 T-cell Receptor T cells ET190L1 | ET 190 | ET190 | ET190L1 | ET190L1-ARTEMIS (TM) | ET190L1-ARTEMIS (TM) T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545811","Unresectable Malignant Solid Neoplasm","C148036","A malignant solid neoplasm that is not amenable to surgical resection.","Unresectable Malignant Solid Neoplasm | Unresectable Malignant Solid Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545812","Recurrent Grade II Glioma","C148037","The reemergence of WHO grade 2 glioma after a period of remission.","Recurrent WHO Grade 2 Glioma | Recurrent Grade 2 Glioma | Recurrent Grade II Glioma | Recurrent WHO Grade II Glioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545813","Recurrent Grade III Glioma","C148038","The reemergence of a WHO grade III glioma after a period of remission.","Recurrent WHO Grade 3 Glioma | Recurrent Grade III Glioma | Recurrent WHO Grade III Glioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553107","FACT-L Version 4 - I Am Losing Weight","C151262","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Additional Concerns: I am losing weight.","FACT-L Version 4 - I Am Losing Weight | FAC016-I Am Losing Weight | FAC01629",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553108","FACT-L Version 4 - My Thinking Is Clear","C151263","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Additional Concerns: My thinking is clear.","FACT-L Version 4 - My Thinking Is Clear | FAC016-My Thinking Is Clear | FAC01630",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553168","Extracranial Solid Neoplasm","C151940","A solid neoplasm involving any anatomic site other than the brain.","Extracranial Solid Neoplasm | Extracranial Solid Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553169","Acyclic Nucleoside Phosphonate Prodrug ABI-1968","C151941","A prodrug of an acyclic nucleoside phosphonate, with potential anti-viral and antineoplastic activities. Upon administration, acyclic nucleoside phosphonate prodrug ABI-1968 is taken up by viral-infected cells and converted to its active metabolite. The metabolite is incorporated into DNA chains by DNA polymerases, which results in the termination of DNA synthesis, inhibits viral replication and induces apoptosis and inhibits the proliferation of susceptible virally-infected tumor cells.","Acyclic Nucleoside Phosphonate Prodrug ABI-1968 | ABI-1968 | ABI1968 | HTI 1968",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553170","Therapeutic Liver Cancer Peptide Vaccine IMA970A","C151942","An off-the-shelf hepatocellular cancer (HCC) multi-peptide-based therapeutic vaccine composed of sixteen peptides derived from tumor-associated antigens (TAAs) expressed by hepatic tumor cells, of which seven are restricted to human leukocyte antigen (HLA)-A2 (HLA-A*02), five to HLA-A*24 and four to HLA class II, with potential immunomodulating and antineoplastic activities. Upon intradermal administration of the therapeutic liver cancer peptide vaccine IMA970A, the liver-specific peptides in the vaccine activate the immune system to exert both CD4+ T-helper and CD8+ cytotoxic T-lymphocyte (CTL)-mediated immune responses against liver cancer cells.","Therapeutic Liver Cancer Peptide Vaccine IMA970A | HCC Vaccine  IMA970A | HCC Vaccine IMA970A | IMA970A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553171","Bivalent BRD4 Inhibitor AZD5153","C151943","An orally bioavailable bivalent inhibitor of  bromodomain-containing protein 4 (BRD4), with potential antineoplastic activity. Upon oral administration, the BRD4 inhibitor AZD5153 selectively binds to the acetylated lysine recognition motifs in two bromodomains in the BRD4 protein, thereby preventing the binding of BRD4 to acetylated lysines on histones. This disrupts chromatin remodeling and dysregulates expression of target genes, which leads to the downregulation of the expression of certain growth-promoting genes, induces apoptosis and inhibits the proliferation of BRD4-overexpressing tumor cells. BRD4, a member of the human bromodomain and extra-terminal (BET) family of proteins, is a transcriptional regulator that is overexpressed in certain tumor cells and plays an important role in cellular proliferation.","Bivalent BRD4 Inhibitor AZD5153 | (R)-4-(2-(4-(1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl)phenoxy)ethyl)-1,3-dimethylpiperazin-2-one | AZD 5153 | AZD-5153 | AZD5153 | BET Inhibitor AZD5153 | BRD4/BET Bromodomain Antagonist AZD5153 | Bivalent BET Bromodomain Inhibitor AZD5153",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553172","Autologous PD1-inhibiting Anti-CD19 4-1BB CAR T Cells","C151944","A preparation of autologous T-lymphocytes that are transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19) linked to the intracellular signaling domain of 4-1BB (CD137) that also encodes a cell-intrinsic programmed cell death 1 (PD1; PDCD1; CD279; programmed death-1) short/small hairpin RNA (shRNA)-expressing cassette, with potential immunomodulating and antineoplastic activities. Upon administration of the autologous PD1-inhibiting anti-CD19 4-1BB CAR T-cells, these cells target, bind to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. The shRNA silences expression of PD1, abrogates T-cell exhaustion, increases CAR T-cell activity and enhances tumor cytotoxicity. Expression of PD-1, an inhibitory receptor expressed on activated T-cells, plays a key role in CTL suppression, T-cell exhaustion and CTL apoptosis.","Autologous PD1-inhibiting Anti-CD19 4-1BB CAR T Cells | Autologous iPD1 CD19 eCAR T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553998","Tivozanib Hydrochloride","C152666","The hydrochloride salt of tivozanib, an orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death. VEGFR tyrosine kinases, frequently overexpressed by a variety of tumor cell types, play a key role in angiogenesis.","Tivozanib Hydrochloride | Fotivda | TIVOZANIB HYDROCHLORIDE | Tivozanib Hydrochloride Hydrate | Tivozanib Monohydrochloride Monohydrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554000","Tixocortol Pivalate","C152668","No value exists.","Tixocortol Pivalate | TIXOCORTOL PIVALATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554001","Tizabrin","C152669","No value exists.","Tizabrin | TIZABRIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554002","Toborinone","C152670","No value exists.","Toborinone | TOBORINONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554004","Tocofenoxate","C152672","No value exists.","Tocofenoxate | TOCOFENOXATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554005","Tocofibrate","C152673","No value exists.","Tocofibrate | TOCOFIBRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554006","Tofetridine","C152674","No value exists.","Tofetridine | TOFETRIDINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554008","Tofogliflozin Anhydrous","C152676","No value exists.","Tofogliflozin Anhydrous | TOFOGLIFLOZIN ANHYDROUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554009","Tolafentrine","C152677","No value exists.","Tolafentrine | TOLAFENTRINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554010","Tolamolol","C152678","No value exists.","Tolamolol | TOLAMOLOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554011","Tolciclate","C152679","No value exists.","Tolciclate | TOLCICLATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554012","Toldimfos","C152680","No value exists.","Toldimfos | TOLDIMFOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554013","Tolevamer","C152681","No value exists.","Tolevamer | TOLEVAMER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554014","Tolevamer Potassium Sodium","C152682","No value exists.","Tolevamer Potassium Sodium | TOLEVAMER POTASSIUM SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554015","Tolimidone","C152683","No value exists.","Tolimidone | TOLIMIDONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554016","Tolmesoxide","C152684","No value exists.","Tolmesoxide | TOLMESOXIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554017","Tolnapersine","C152685","No value exists.","Tolnapersine | TOLNAPERSINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554019","Toloxychlorinol","C152687","No value exists.","Toloxychlorinol | TOLOXYCHLORINOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553154","NCCN-FACT FHNSI-22 Version 2 - Trouble Meeting Needs of Family","C151309","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) Because of my physical condition, I have trouble meeting the needs of my family.","NCCN-FACT FHNSI-22 Version 2 - Trouble Meeting Needs of Family | FAC036-Trouble Meeting Needs of Family | FAC03606",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553155","NCCN-FACT FHNSI-22 Version 2 - Can Swallow Naturally and Easily","C151310","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I can swallow naturally and easily.","NCCN-FACT FHNSI-22 Version 2 - Can Swallow Naturally and Easily | FAC036-Can Swallow Naturally and Easily | FAC03607",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553156","NCCN-FACT FHNSI-22 Version 2 - Able to Eat the Foods That I Like","C151311","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I am able to eat the foods that I like.","NCCN-FACT FHNSI-22 Version 2 - Able to Eat the Foods That I Like | FAC036-Able to Eat the Foods That I Like | FAC03608",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545751","Verbal Support","C147981","Therapy in which a therapist, or other personnel, provides nondirective, supportive care by offering supportive, validating statements and reflective listening. Verbal support sessions are aimed at providing an empathic, therapeutic environment to facilitate emotional expression and sharing of worries and fears.","Verbal Support | Verbal Support Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545853","Refractory Colorectal Carcinoma","C147982","Colorectal carcinoma that does not respond to treatment.","Refractory Colorectal Carcinoma | Refractory Colorectal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545855","KEL wt Allele","C147985","Human KEL wild-type allele is located in the vicinity of 7q34 and is approximately 22 kb in length. This allele, which encodes Kell blood group glycoprotein, plays a role in peptide hormone-converting enzyme activity. Point mutations in the gene determine an individual's Kell blood group antigen profile.","KEL wt Allele | CD238 | ECE3 | Kell Blood Group Gene | Kell Blood Group, Metallo-Endopeptidase wt Allele | Kell Blood Group, Metalloendopeptidase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3710659","KEL protein, human","C147986","Kell blood group glycoprotein (732 aa, ~83 kDa) is encoded by the human KEL gene. This protein is involved in cleavage of endothelin-3.","Kell Blood Group Glycoprotein | CD238 | CD238 Antigen | EC 3.4.24.- | KEL | Kell Blood Group Antigen | Kell Glycoprotein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545857","IKBKE wt Allele","C147988","Human IKBKE wild-type allele is located in the vicinity of 1q32.1 and is approximately 27 kb in length. This allele, which encodes inhibitor of nuclear factor kappa-B kinase subunit epsilon, is involved in the modulation of both interferon expression and the nuclear factor kappa-B signaling pathway. Amplification and overexpression of the gene is associated with breast carcinoma.","IKBKE wt Allele | IKK-E | IKK-I | IKKE | IKKI | Inhibitor of Kappa Light Polypeptide Gene Enhancer in B Cells, Kinase of, Epsilon Gene | Inhibitor of Kappa Light Polypeptide Gene Enhancer in B-Cells, Kinase Epsilon Gene | Inhibitor of Nuclear Factor Kappa B Kinase Subunit Epsilon wt Allele | KIAA0151",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545846","FGF12 Gene","C147991","This gene plays a role in both nervous system development and neuronal excitation.","FGF12 Gene | FGF12 | Fibroblast Growth Factor 12 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551124","Triclosan/Copolymer/Fluoride Toothpaste","C148541","A fluoride-based toothpaste containing the anti-inflammatory and broad-spectrum antibacterial agent triclosan and polyvinylmethyl ether maleic acid copolymer (PVM/MA), with potential antibacterial, anti-inflammatory, and protective activities. Upon application of the triclosan/copolymer/fluoride toothpaste to the teeth, the toothpaste helps remove plaque accumulation. The fluoride protects the teeth against cavities while the triclosan prevents inflammation and may protect against gingivitis and mucositis. The copolymer in the toothpaste enhances the uptake of triclosan by enamel and buccal epithelial cells, thereby prolonging its protective effect and enhancing its activity.","Triclosan/Copolymer/Fluoride Toothpaste | Triclosan/Copolymer/Fluoride Dentifrice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551123","Magnesium-rich Mineral Water","C148542","Carbonated, iron-depleted mineral water from the French springs of Beauregard-Vendon (Rouzat) containing very high amounts of the mineral magnesium as well as sodium, calcium, potassium, bicarbonate, sulfate, chloride and nitrate, that can be used for supplemental purposes and can potentially be used to treat hypomagnesemia. Magnesium, an electrolyte, plays a key role as a cofactor in multiple enzymatic reactions and for muscle and nervous system functioning. Hypomagnesemia may manifest as asthenia, cramps, muscle weakness, fatigue, and mood disorders.","Magnesium-rich Mineral Water | Rozana",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551198","ZC3H12A Gene","C148595","This gene is involved in ribonuclease activity and transcriptional regulation.","ZC3H12A Gene | ZC3H12A | Zinc Finger CCCH-Type Containing 12A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553173","IDO/TDO Inhibitor HTI-1090","C151945","An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1; IDO-1) and the kynurenine-producing hepatic enzyme tryptophan 2,3-dioxygenase (TDO), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1/TDO inhibitor HTI-1090 specifically targets and binds to both IDO1, a cytosolic enzyme responsible for the oxidation of the amino acid tryptophan into the immunosuppressive metabolite kynurenine, and TDO, a hepatic enzyme catalyzing the first step of tryptophan degradation. By inhibiting IDO1 and TDO, HTI-1090 decreases kynurenine levels in tumor cells, restores tryptophan and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells and T-lymphocytes. This reduces the number of tumor-associated regulatory T-cells (Tregs) and activates the immune system to induce a cytotoxic T-lymphocyte (CTL) response against the IDO1/TDO-expressing tumor cells, thereby inhibiting the growth of the tumor cells. IDO1 and TDO, both overexpressed by multiple tumor cell types, play important roles in immunosuppression and the promotion of tumor cell survival and proliferation. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system.","IDO/TDO Inhibitor HTI-1090 | HTI 1090 | HTI-1090 | SHR9146",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553467","Rabacfosadine Succinate","C152135","The succinate form of rabacfosadine, an acyclic nucleotide phosphonate prodrug and polymerase inhibitor that can potentially be used for its antineoplastic activity in the treatment of lymphoma in dogs. Upon administration, rabacfosadine is hydrolyzed intracellularly to 9-(2-phosphonylmethoxyethyl)-N6-cyclopropyl-2, 6-diaminopurine (cPrPMEDAP) and subsequently deaminated to 9-(2-phosphonylmethoxyethyl) guanine (PMEG) and phosphorylated to PMEG diphosphate (PMEGpp). PMEGpp binds to and inhibits DNA polymerases. This inhibits DNA synthesis, resulting in S phase arrest and induction of apoptosis.","Rabacfosadine Succinate | RABACFOSADINE SUCCINATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553468","Rabeximod","C152136","No value exists.","Rabeximod | RABEXIMOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553469","Racemethorphan","C152137","No value exists.","Racemethorphan | RACEMETHORPHAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553470","Racemorphan","C152138","No value exists.","Racemorphan | RACEMORPHAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0072953","Raclopride","C152139","No value exists.","Raclopride | RACLOPRIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0009472","Community Health Service","C15213","Diagnostic, therapeutic and preventive health service provided for individuals in the community.","Community Health Service | ",,,,,,,,,,,,,,,"4134829","Community health services",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL553472","Raclopride C-11","C152140","No value exists.","Raclopride C-11 | RACLOPRIDE C-11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553473","Radalbuvir","C152141","No value exists.","Radalbuvir | RADALBUVIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553474","Radavirsen","C152142","No value exists.","Radavirsen | RADAVIRSEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553475","Radiprodil","C152143","No value exists.","Radiprodil | RADIPRODIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553478","Rafoxanide","C152146","No value exists.","Rafoxanide | RAFOXANIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553479","Ralaniten","C152147","No value exists.","Ralaniten | RALANITEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553480","Ralinepag","C152148","No value exists.","Ralinepag | RALINEPAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553481","Ralpancizumab","C152149","No value exists.","Ralpancizumab | RALPANCIZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553482","Raluridine","C152150","No value exists.","Raluridine | RALURIDINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553483","Ramatercept","C152151","No value exists.","Ramatercept | RAMATERCEPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553484","Ramoplanin","C152152","No value exists.","Ramoplanin | RAMOPLANIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553485","Ramorelix","C152153","No value exists.","Ramorelix | RAMORELIX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553486","Ranevetmab","C152154","No value exists.","Ranevetmab | RANEVETMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553487","Ranimycin","C152155","No value exists.","Ranimycin | RANIMYCIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550798","PD-L1 Peptide Vaccine","C148146","A vaccine composed of a peptide derived from the tumor-associated antigen (TAA) and immune checkpoint molecule programmed cell death-1 ligand 1 (PD-L1) combined with the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Vaccination with PD-L1 peptide vaccine may activate the immune system to induce an immune response against PD-L1-expressing cells. This may increase and restore the proliferation and activation of various immune cells, including cytotoxic T-lymphocytes (CTLs), and may eradicate PD-L1-expressing tumor cells. PD-L1 is overexpressed on many human cancer cell types as well as on antigen presenting cells (APCs) and immunosuppressive cells in the tumor micro-environment (TME), such as regulatory T-cells (Tregs). PD-L1 binding to its cognate receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) on T-cells suppresses the immune system and results in increased immune evasion and decreased CTL activation. Montanide ISA-51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens.","PD-L1 Peptide Vaccine | PD-L1 Peptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550797","Lazertinib","C148147","An orally available third-generation, selective inhibitor of certain forms of the epidermal growth factor receptor (EGFR) with activating mutations, including the resistance mutation T790M, exon 19 deletions (Del19), and the L858R mutation, with potential antineoplastic activity. Upon administration, lazertinib specifically and irreversibly binds to and inhibits selective EGFR mutants, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Lazertinib may inhibit programmed cell death-1 ligand 1 (PD-L1) and inflammatory cytokines in specific cancer cells harboring certain EGFR mutations. Compared to some other EGFR inhibitors, lazertinib may have therapeutic benefits in tumors with T790M- or L858R-mediated drug resistance. In addition, lazertinib penetrates the blood-brain barrier (BBB). This agent shows minimal activity against wild-type EGFR (wtEGFR), and does not cause dose-limiting toxicities, which occur during the use of non-selective EGFR inhibitors and inhibit wtEGFR. EGFR, a receptor tyrosine kinase (RTK) mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","Lazertinib | GNS 1480 | GNS-1480 | GNS1480 | LAZERTINIB | Leclaza | N-{5-[(4-{4-[(dimethylamino)methyl]-3-phenyl-1H-pyrazol-1-yl}pyrimidin-2-yl)amino]-4-methoxy-2-(morpholin-4-yl)phenyl}prop-2-enamide | YH 25448 | YH-25448 | YH25448",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550800","Lactobacillus reuteri Probiotic Tablet","C148148","A tablet containing a strain of the probiotic Gram-positive, naturally-occurring bacterium Lactobacillus reuteri (L. reuteri), with potential antimicrobial, immunomodulatory and protective activities. Upon oral administration of the L. reuteri probiotic tablet, the Lactobacillus strain may improve digestion and help maintain adequate colonization of the gastrointestinal (GI) tract by modulating the composition of the normal microflora. During colonization of the GI tract, this bacterium adheres to human intestinal epithelial cells, and activates intestinal epithelial proliferation; both of these processes promote the formation and maintenance of a protective barrier, thereby preventing the attachment of harmful pathogens. L. reuteri produces lactic acid and other substances during fermentation, and creates an acidic environment that is unfavorable for pathogens, thereby further protecting the intestinal mucosa against pathogen-induced damage and loss of integrity of the intestinal mucosal barrier. Dietary supplementation with this bacterium has been shown to decrease intestinal inflammation and enhance innate and acquired immunity. Lactobacillus reuteri is naturally found in the GI tract.","Lactobacillus reuteri Probiotic Tablet | L. reuteri Probiotic | Lactobacillus reuteri Probiotic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550973","SERPINB3 wt Allele","C148320","Human SERPINB3 wild-type allele is located in the vicinity of 18q21.33 and is approximately 7 kb in length. This allele, which encodes serpin B3 protein, plays a role in proteinase inhibition.","SERPINB3 wt Allele | HsT1196 | SCC | SCCA | SCCA-1 | SCCA-PD | SCCA1 | SSCA1 | Serine (Or Cysteine) Proteinase Inhibitor, Clade B (Ovalbumin), Member 3 Gene | Serpin Family B Member 3 wt Allele | Serpin Peptidase Inhibitor, Clade B (Ovalbumin), Member 3 Gene | T4-A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550972","Mitochondrially Inherited Nonsyndromic Sensorineural Deafness","C148321","A maternally inherited form of nonsyndromic sensorineural deafness that is caused by a mutation in any of several mitochondrial genes.","Mitochondrially Inherited Nonsyndromic Sensorineural Deafness | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1451614","serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 3, human","C148322","Serpin B3 (390 aa, ~45 kDa) is encoded by the human SERPINB3 gene. This protein is involved in the inhibition of serine- and cysteine-type proteinases.","Serpin B3 | Protein T4-A | SCCA-1 | SERPINB3 | Squamous Cell Carcinoma Antigen 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550974","SERPINB4 Gene","C148323","This gene plays a role in the inhibition of protease activity.","SERPINB4 Gene | SERPINB4 | Serpin Family B Member 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551126","Anti-CD3/MUC1 Antibody-armed PD-1 Inhibitor-induced Cytokine-induced Killer Cells","C148543","A preparation of cytokine-induced killer cells (CIKs), which have been exposed, ex vivo, to a specific set of cytokines and a programmed cell death protein 1 (PD-1) inhibitor, mixed with a bispecific anti-cluster of differentiation 3 (CD3)/anti-mucin-1 (MUC1) antibody, with potential anti-tumor cytotoxic activity. Upon administration of the anti-CD3/MUC1 antibody-armed PD-1 inhibitor-induced CIKs, the antibody moiety binds to both CD3 on the CIKs and MUC1 on cancer cells. This crosslinks the CIKs and tumor cells, which allows the CIKs to target and lyse MUC1-expressing cancer cells. PD-1 blockade activates the CIKs. The cytokines used, usually interferon-gamma (IFNg), interleukin 1 (IL-1), and IL-2, stimulate the proliferation and maturation of peripheral blood mononuclear cells (PBMCs) into CIK cells. Anti-CD3 stimulation allows for the CIKs' improved lytic activity.","Anti-CD3/MUC1 Antibody-armed PD-1 Inhibitor-induced Cytokine-induced Killer Cells | Anti-CD3/MUC1-armed PD-1 Inhibitor-induced CIK Cells | PD-1 Activated CIK Armed With Anti-CD3/Anti-MUC1 Bispecific Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551119","Ivabradine Hydrochloride","C148546","The hydrochloride salt form of ivabradine, an orally bioavailable, hyperpolarization-activated, cyclic nucleotide-gated (HCN) channel blocker, with negative chronotropic activity. Upon administration, ivabradine selectively binds to the intracellular portion of the HCN channel pore and blocks HCN channels in the pacemaker cells within the sinoatrial (SA) node. This inhibits the If (funny) pacemaker ion current, prevents the inward flow and intracellular accumulation of positively charged ions, reduces pacemaker activity and slows diastolic depolarization. This decreases heart rate, reduces myocardial oxygen demand and allows more time for blood to flow to the myocardium without affecting cardiac contractility. HCN channels, mixed sodium (Na+) and potassium (K+) channels that carry the inward If current, play a key role in the regulation of pacemaker firing rate in the SA node. The If pacemaker current, the inward flow of positively charged Na+-K+ ions, initiates the spontaneous diastolic depolarization phase and modulating heart rate.","Ivabradine Hydrochloride | (7,8-Dimethoxy 3-(3-(((1S)-(4,5-dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-2H-benzazepin-2-one Hydrochloride | 2H-3-Benzazepin-2-one, 3-(3-((((7S)-3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-, Monohydrochloride | Corlanor | IVABRADINE HYDROCHLORIDE | Ivabradine HCl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551122","Ophthalmic Powder Dosage Form","C148547","No value exists.","Ophthalmic Powder Dosage Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554817","Radiopharmaceutical Dosage Form Category","C148548","A type of specialized pharmaceutical dose form that is used in the preparation of radiopharmaceuticals.","Radiopharmaceutical Dosage Form Category | Radiopharmaceutical",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556516","Solvent Dosage Form Category","C148549","A type of liquid pharmaceutical dose form consisting of a vehicle that contains no active ingredient itself, and is used to dissolve, disperse or dilute another product.","Solvent Dosage Form Category | Solvent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551117","Beehive Dispersion Dosage Form","C148550","Liquid preparation intended for in-hive use, consisting of two or more phases, at least one of which is dispersed in the liquid phase, from which the active substance(s) are released by vaporization or physical contact usually over an extended period of time. The precise method of administration of the dispersion is described in the product information.","Beehive Dispersion Dosage Form | Bee-hive dispersion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL414314","Amoxicillin-Clavulanic Acid","C1481","A fixed combination of Amoxicillin and Clavulanic Acid, which inhibits beta-lactamase, a bacterial enzyme that inactivates amoxicillin.","Amoxicillin-Clavulanic Acid | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553488","Rapastinel","C152156","No value exists.","Rapastinel | RAPASTINEL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553490","Ravidasvir","C152158","No value exists.","Ravidasvir | RAVIDASVIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553491","Ravidasvir Hydrochloride","C152159","No value exists.","Ravidasvir Hydrochloride | RAVIDASVIR HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553492","Raxibacumab","C152160","No value exists.","Raxibacumab | RAXIBACUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553901","Terodiline","C152569","No value exists.","Terodiline | TERODILINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553902","Terodiline Hydrochloride","C152570","No value exists.","Terodiline Hydrochloride | TERODILINE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553903","Teroxalene","C152571","No value exists.","Teroxalene | TEROXALENE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553904","Teroxalene Hydrochloride","C152572","No value exists.","Teroxalene Hydrochloride | TEROXALENE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553905","Tesevatinib Tosylate","C152573","No value exists.","Tesevatinib Tosylate | TESEVATINIB TOSYLATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553906","Tesicam","C152574","No value exists.","Tesicam | TESICAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553907","Teslexivir","C152575","No value exists.","Teslexivir | TESLEXIVIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553908","Testosterone Ketolaurate","C152576","No value exists.","Testosterone Ketolaurate | TESTOSTERONE KETOLAURATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553909","Tetraethylammonium Bromide","C152577","No value exists.","Tetraethylammonium Bromide | TETRAETHYLAMMONIUM BROMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553910","Tetramisole Hydrochloride","C152578","No value exists.","Tetramisole Hydrochloride | TETRAMISOLE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553911","Tetroquinone","C152579","No value exists.","Tetroquinone | TETROQUINONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553784","Tetrydamine","C152580","No value exists.","Tetrydamine | TETRYDAMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553786","Tezepelumab","C152582","No value exists.","Tezepelumab | TEZEPELUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553787","theofibrate","C152583","No value exists.","Theofibrate | THEOFIBRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1302010","Theophylline Ephedrine","C152584","No value exists.","Theophylline Ephedrine | THEOPHYLLINE EPHEDRINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553789","Thiazesim","C152585","No value exists.","Thiazesim | THIAZESIM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553791","Thiazosulfone","C152587","No value exists.","Thiazosulfone | THIAZOSULFONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553792","Thimerfonate Sodium","C152588","No value exists.","Thimerfonate Sodium | THIMERFONATE SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553793","Thiocolchicoside","C152589","No value exists.","Thiocolchicoside | THIOCOLCHICOSIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550969","SERPINB4 wt Allele","C148324","Human SERPINB4 wild-type allele is located in the vicinity of 18q21.33 and is approximately 7 kb in length. This allele, which encodes serpin B4 protein, is involved in the inhibition of serine proteinases.","SERPINB4 wt Allele | LEUPIN | PI11 | Protease Inhibitor (Leucine-Serpin) Gene | SCCA-2 | SCCA1 | SCCA2 | Serine (Or Cysteine) Proteinase Inhibitor, Clade B (Ovalbumin), Member 4 Gene | Serpin Family B Member 4 wt Allele | Serpin Peptidase Inhibitor, Clade B (Ovalbumin), Member 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1832560","RIPPLING MUSCLE DISEASE 2 (disorder)","C148325","An autosomal dominant condition caused by mutation(s) in the CAV3 gene, encoding caveolin-3. It is characterized by mechanically triggered contractions of skeletal muscles. Limb-girdle muscular dystrophy type 1C is an allelic disorder with an overlapping phenotype.","Rippling Muscle Disease 2 | RMD2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1451613","squamous cell carcinoma antigen 2, human","C148326","Serpin B4 (390 aa, ~45 kDa) is encoded by the human SERPINB4 gene. This protein plays a role in the inhibition of protease activity for enzymes such as granzyme M.","Serpin B4 | Leupin | PI-11 | Peptidase Inhibitor 11 | SCCA-2 | SERPINB4 | Squamous Cell Carcinoma Antigen 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550970","HyperCKmia","C148327","A condition characterized by elevated concentrations of creatine kinase in the blood. It is one of a group of conditions caused by mutation(s) in the CAV3 gene, encoding caveolin-3. Isolated hyperCKmia has no other associated manifestations.","HyperCKmia | Isolated HyperCKemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550966","GZMM Gene","C148328","This gene is involved in peptide cleavage.","GZMM Gene | GZMM | Granzyme M Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550965","GZMM wt Allele","C148329","Human GZMM wild-type allele is located in the vicinity of 19p13.3 and is approximately 6 kb in length. This allele, which encodes granzyme M protein, plays a role in the cleavage of peptide substrates.","GZMM wt Allele | Granzyme M (Lymphocyte Met-Ase 1) Gene | Granzyme M wt Allele | LMET1 | MET1 | Protease, Serine, Natural Killer Cell, Met-Ase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1700559","GZMM protein, human","C148330","Granzyme M (257 aa, ~28 kDa) is encoded by the human GZMM gene. This protein is involved in the cleavage of protein and peptide substrates.","Granzyme M | EC 3.4.21.- | GZMM | Hu-Met-1 | Lymphocyte Met-Ase 1 | Met-1 Serine Protease | Met-Ase | Natural Killer Cell Granular Protease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550963","GALT Gene","C148332","This gene plays a role in galactose metabolism.","GALT Gene | GALT | Galactose-1-Phosphate Uridylyltransferase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550962","GALT wt Allele","C148333","Human GALT wild-type allele is located in the vicinity of 9p13.3 and is approximately 13 kb in length. This allele, which encodes galactose-1-phosphate uridylyltransferase protein, is involved in carbohydrate metabolism. Mutation of the gene is associated with galactosemia.","GALT wt Allele | Galactose-1-Phosphate Uridylyltransferase wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550964","Galactose-1-Phosphate Uridylyltransferase","C148334","Galactose-1-phosphate uridylyltransferase (379 aa, ~43 kDa) is encoded by the human GALT gene. This protein plays a role in the metabolism of galactose.","Galactose-1-Phosphate Uridylyltransferase | EC 2.7.7.12 | GALT | Gal-1-P Uridylyltransferase | UDP-Glucose--Hexose-1-Phosphate Uridylyltransferase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL018612","Other and Ill-Defined Sites ICD-O-3","C148336","Other anatomic sites that are referenced in topographic category C76 of ICD-O-3.","Other and Ill-Defined Sites ICD-O-3 | Other and Ill-Defined Sites | Other and ill-defined sites | Other ill-defined sites",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545793","DUX4L2 Gene","C147931","This gene may be involved in the regulation of gene expression.","DUX4L2 Gene | DUX4L2 | Double Homeobox 4 Like 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545794","DUX4L2 wt Allele","C147932","Human DUX4L2 gene is located in the vicinity of 4q35.2 and is approximately 1 kb in length. This allele, which encodes double homeobox protein 4-like protein 2, may play a role in transcription. This gene is within a D4Z4 repeat array; contraction of this macrosatellite repeat is associated with facioscapulohumeral muscular dystrophy (FSHD).","DUX4L2 wt Allele | DUX4 | Double Homeobox 4 Like 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545781","Double Homeobox Protein 4-Like Protein 2","C147933","Double homeobox protein 4-like protein 2 (424 aa, ~45 kDa) is encoded by the human DUX4L2 gene. This protein may be involved in transcriptional regulation.","Double Homeobox Protein 4-Like Protein 2 | DUX4L2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550780","Autologous EGFRt/BCMA-41BBz-targeted CAR T Cells","C148168","A preparation of autologous T-lymphocytes transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) fused to the co-stimulatory domain of 4-1BB (CD137) and the CD3-zeta (CD3z) T-cell signaling domain, and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous EGFRt/BCMA-41BBz-targeted CAR T cells are directed to, and induce selective toxicity in, BCMA-expressing tumor cells. Devoid of both ligand-binding domains and tyrosine kinase activity, the expressed EGFRt facilitates in vivo detection of the administered, transduced T-cells and, if the administered T-cells cause unacceptable side effects, can promote elimination of those cells through a cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) response. The 4-1BB costimulatory signaling domain enhances both proliferation of T-cells and antitumor activity. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and is overexpressed on malignant plasma cells.","Autologous EGFRt/BCMA-41BBz-targeted CAR T Cells | Autologous EGFRt/BCMA-41BBz CAR T Cell | B-cell Maturation Antigen-Targeted EGFRt/BCMA-41BBz CAR-modified T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550779","Fluorescein-conjugated Wisteria floribunda Lectin","C148169","A fluorescein conjugated to a preparation of lectin(s) extracted from the seeds of Wisteria floribunda (Japanese wisteria), with potential use as a diagnostic agent. Upon administration of fluorescein-conjugated Wisteria floribunda lectin, the lectin moiety preferentially targets and binds to carbohydrate structures containing N-acetylgalactosamine and galactose residues overexpressed on certain tumor cell surfaces. Using white and fluorescent light,  tumor cells with increased lectin-binding affinity can be visualized or imaged.","Fluorescein-conjugated Wisteria floribunda Lectin | Fluorescein-labeled WFA | Fluorescein-labeled WFL | Fluorescein-labeled Wisteria floribunda Lectin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550774","Raltitrexed Disodium","C148170","The disodium salt form of raltitrexed, a quinazoline folate analogue, with potential antineoplastic activity.  Upon administration of raltitrexed, this agent is taken up by cells via the reduced folate carrier, undergoes intracellular polyglutamation, and blocks the folate-binding site of thymidylate synthase (TS). This inhibits the conversion of deoxyuridine monophosphate (dUMP) into deoxythymidine monophosphate (dTMP) and thus increases dUMP levels and decreases the amount of deoxythymidine triphosphate (dTTP) available for DNA synthesis. This prevents DNA replication and repair, and leads to DNA fragmentation and cell death, and results in reduced tumor cell 'proliferation.","Raltitrexed Disodium | L-glutamic Acid, N-((5-(((3,4-Dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl)methylamino)-2-thienyl)carbonyl)-, Disodium Salt | RALTITREXED DISODIUM | Tomudex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550775","Refractory Thymic Carcinoma","C148173","A thymus carcinoma that does not respond to treatment.","Refractory Thymus Carcinoma | Refractory Thymic Carcinoma | Refractory Thymic Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550770","Histone Gene","C148174","A gene encoding a histone protein.","Histone Gene | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550769","Refractory Indolent Adult Non-Hodgkin Lymphoma","C148175","Indolent adult non-Hodgkin lymphoma that is resistant to treatment.","Refractory Indolent Adult Non-Hodgkin Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550994","PKC-beta Inhibitor MS-553","C148422","An orally available inhibitor of the beta-isoform of protein kinase C (PKC), with potential immunosuppressive and antineoplastic activities. Upon oral administration, PKC-beta inhibitor MS-553 selectively binds to and inhibits PKC-beta, which prevents the activation of PKC-beta-mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells. PKC-beta, a serine/threonine protein kinase overexpressed in certain types of cancer cells, is involved in tumor cell differentiation, proliferation, invasion and survival.","PKC-beta Inhibitor MS-553 | MS 553 | MS-553 | MS553 | PKC-b Inhibitor MS-553",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550993","Recurrent Mixed Phenotype Acute Leukemia","C148423","The reemergence of mixed phenotype acute leukemia after a period of remission.","Recurrent Mixed Phenotype Acute Leukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550986","Refractory Mixed Phenotype Acute Leukemia","C148430","Mixed phenotype acute leukemia that does not respond to treatment.","Refractory Mixed Phenotype Acute Leukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550985","Refractory Acute Leukemia","C148431","Acute leukemia that does not respond to treatment.","Refractory Acute Leukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550988","Unresectable Intrahepatic Cholangiocarcinoma","C148432","Intrahepatic cholangiocarcinoma that is not amenable to surgical removal.","Unresectable Intrahepatic Cholangiocarcinoma | Unresectable Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550987","Percutaneous Hepatic Perfusion","C148433","A minimally invasive procedure in which high dose chemotherapy is delivered directly to the liver via a catheter placed in the hepatic artery, and the effluent blood returning through the hepatic veins is filtered via an extracorporeal system before being returned through a sheath in the internal jugular vein.","Percutaneous Hepatic Perfusion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550983","Refractory Nasopharyngeal Carcinoma","C148434","Nasopharyngeal carcinoma that is resistant to treatment.","Refractory Nasopharyngeal Carcinoma | Refractory Nasopharyngeal Throat Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553794","Thiopropazate","C152590","No value exists.","Thiopropazate | THIOPROPAZATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553796","Thozalinone","C152592","No value exists.","Thozalinone | THOZALINONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553797","Thymoctonan","C152593","No value exists.","Thymoctonan | THYMOCTONAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553798","Thyropropic Acid","C152594","No value exists.","Thyropropic Acid | THYROPROPIC ACID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553799","Thyroxine I-125","C152595","No value exists.","Thyroxine I-125 | THYROXINE I-125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553801","Tiadenol","C152597","No value exists.","Tiadenol | TIADENOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553802","Tiafibrate","C152598","No value exists.","Tiafibrate | TIAFIBRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553803","Tianeptine","C152599","No value exists.","Tianeptine | TIANEPTINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020974","Passive Immunization","C15259","The conference of active humoral immunity from one individual to another via the transfer of formed antibodies.","Passive Immunization | Adoptive Transfer",,,,,,,,,,,,,,,"4199458","Passive immunization",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL553109","FACT-L Version 4 - I Have Been Coughing","C151264","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Additional Concerns: I have been coughing.","FACT-L Version 4 - I Have Been Coughing | FAC016-I Have Been Coughing | FAC01631",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553110","FACT-L Version 4 - I Am Bothered by Hair Loss","C151265","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Additional Concerns: I am bothered by hair loss.","FACT-L Version 4 - I Am Bothered by Hair Loss | FAC016-I Am Bothered by Hair Loss | FAC01632",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553111","FACT-L Version 4 - I Have a Good Appetite","C151266","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Additional Concerns: I have a good appetite.","FACT-L Version 4 - I Have a Good Appetite | FAC016-I Have a Good Appetite | FAC01633",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553112","FACT-L Version 4 - I Feel Tightness in My Chest","C151267","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Additional Concerns: I feel tightness in my chest.","FACT-L Version 4 - I Feel Tightness in My Chest | FAC016-I Feel Tightness in My Chest | FAC01634",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553113","FACT-L Version 4 - Breathing Is Easy for Me","C151268","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Additional Concerns: Breathing is easy for me.","FACT-L Version 4 - Breathing Is Easy for Me | FAC016-Breathing Is Easy for Me | FAC01635",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553114","FACT-L Version 4 - Have You Ever Smoked","C151269","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Additional Concerns: Have you ever smoked?","FACT-L Version 4 - Have You Ever Smoked | FAC016-Have You Ever Smoked | FAC01636",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553115","FACT-L Version 4 - I Regret My Smoking","C151270","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Additional Concerns: I regret my smoking.","FACT-L Version 4 - I Regret My Smoking | FAC016-I Regret My Smoking | FAC01637",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553116","FKSI-DRS Version 4 - I Have a Lack of Energy","C151271","Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms Version 4 (FKSI-DRS Version 4) I have a lack of energy.","FKSI-DRS Version 4 - I Have a Lack of Energy | FAC041-I Have a Lack of Energy | FAC04101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553118","FKSI-DRS Version 4 - I Am Losing Weight","C151273","Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms Version 4 (FKSI-DRS Version 4) I am losing weight.","FKSI-DRS Version 4 - I Am Losing Weight | FAC041-I Am Losing Weight | FAC04103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545783","GPRC5D wt Allele","C147935","Human GPRC5D wild-type allele is located in the vicinity of 12p13.1 and is approximately 39 kb in length. This allele, which encodes G-protein coupled receptor family C group 5 member D, is involved in G protein-coupled receptor signaling.","GPRC5D wt Allele | G Protein-Coupled Receptor Class C Group 5 Member D wt Allele | G Protein-Coupled Receptor, Class C, Group 5, Member D Gene | G Protein-Coupled Receptor, Family C, Group 5, Member D Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3529805","GPRC5D protein, human","C147936","G-protein coupled receptor family C group 5 member D (39 aa, ~39 kDa) is encoded by the human GPRC5D gene. This protein plays a role in G protein-coupled receptor signaling.","G-Protein Coupled Receptor Family C Group 5 Member D | G Protein-Coupled Receptor Class C Group 5 Member D | G Protein-Coupled Receptor Family C Group 5 Member D | G-Protein Coupled Receptor Class C Group 5 Member D | GPRC5D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545786","SHANK2 Gene","C147939","This gene is involved in linking the postsynaptic membrane to glutamate receptors.","SHANK2 Gene | SH3 and Multiple Ankyrin Repeat Domains 2 Gene | SHANK2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0683805","Outreach","C147940","Education or intervention aimed at individuals outside of a medical care system, especially those who might not otherwise have access to medical services.","Outreach | Outreach Strategy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545774","SHANK2 wt Allele","C147941","Human SHANK2 wild-type allele is located within 11q13.3-q13.4 and is approximately 785 kb in length. This allele, which encodes SH3 and multiple ankyrin repeat domains protein 2, plays a role in postsynaptic signal transduction. Deletions and nonsense mutation of the gene may be associated with autism.","SHANK2 wt Allele | AUTS17 | CORTBP1 | CTTNBP1 | KIAA1022 | PROSAP1 | ProSAP1 | SH3 and Multiple Ankyrin Repeat Domains 2 wt Allele | SHANK | SPANK-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545775","Inreach","C147942","Education or intervention aimed at individuals within a medical care system.","Inreach | Inreach Strategy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545776","Outreach and Inreach","C147943","Education or intervention aimed at individuals both outside of, and within a medical care system.","Outreach and Inreach | Both Outreach and Inreach Strategies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545778","TOX wt Allele","C147947","Human TOX wild-type allele is located in the vicinity of 8q12.1 and is approximately 314 kb in length. This allele, which encodes thymocyte selection-associated high mobility group box protein TOX, is involved in DNA binding and T-cell development.","TOX wt Allele | KIAA0808 | TOX Transcription Factor Gene | TOX1 | Thymocyte Selection Associated High Mobility Group Box wt Allele | Thymus High Mobility Group Box Protein, Mouse, Homolog of Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550772","Anti-BCMA Antibody SEA-BCMA","C148176","A humanized, afucosylated monoclonal antibody created using the proprietary, sugar-engineered antibody (SEA) platform and directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17), with potential immunoadjuvant activity. Upon administration, the anti-BCMA antibody SEA-BCMA targets and binds to BCMA expressed on tumor cells.  When administered with antibody-coupled T-cell receptor (ACTR)-expressing T-cells, the ACTR-expressing T-cells bind, with high affinity, to the anti-BCMA antibody SEA-BCMA. This activates the ACTR T-cells and the T-cells induce specific cytotoxic T-lymphocyte (CTL)-mediated cytotoxicity toward BCMA-expressing tumor cells. BCMA, a cell surface protein and member of the tumor necrosis factor (TNF) receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.","Anti-BCMA Antibody SEA-BCMA | Anti-BCMA Afucosylated Monoclonal Antibody SEA-BCMA | SEA-BCMA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551025","Refractory Oral Cavity Squamous Cell Carcinoma","C148384","Oral cavity squamous cell carcinoma that does not respond to treatment.","Refractory Oral Cavity Squamous Cell Carcinoma | Refractory Oral Cavity Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551024","Refractory Oropharyngeal Squamous Cell Carcinoma","C148385","Oropharyngeal squamous cell carcinoma that does not respond to treatment.","Refractory Oropharyngeal Squamous Cell Carcinoma | Refractory Oropharyngeal Throat Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551027","Refractory Paranasal Sinus Squamous Cell Carcinoma","C148386","Paranasal sinus squamous cell carcinoma that does not respond to treatment.","Refractory Paranasal Sinus Squamous Cell Carcinoma | Refractory Paranasal Sinus Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551026","Recurrent Paranasal Sinus Squamous Cell Carcinoma","C148387","The reemergence of paranasal sinus squamous cell carcinoma after a period of remission.","Recurrent Paranasal Sinus Squamous Cell Carcinoma | Recurrent Paranasal Sinus Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551021","BCL6 Gene Fusion","C148388","A molecular genetic abnormality indicating the presence of a fusion gene involving sequences derived from the BCL6 gene.","BCL6 Gene Fusion | B-Cell CLL/Lymphoma 6 Gene Fusion | BCL5 Gene Fusion | Bcl-6 Gene Fusion | LAZ3 Gene Fusion | ZBTB27 Gene Fusion | ZNF51 Gene Fusion | Zinc Finger Protein 51 Gene Fusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551022","Inhalation Vapor Dosage Form","C148391","No value exists.","Inhalation Vapor Dosage Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551017","Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Molecular Subtypes","C148392","Molecular subtyping of diffuse large B-cell lymphomas (DLBCL) based on structural genomic abnormalities and gene expression data obtained from biopsy samples. The molecular analysis revealed four subtypes of DLBCL (MCD, BN2, N1, and EZB) which have distinct genotypic, epigenetic, and clinical characteristics. (NEJM 2018; 378: 1396-407)","Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Molecular Subtypes | DLBCL, NOS Genetic Subtypes | DLBCL, NOS Molecular Subtypes | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Genetic Subtypes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551016","MDS Neoantigen-specific Autologous T-lymphocytes","C148393","A preparation of autologous T-lymphocytes that are exposed, ex vivo, to multiple, patient-specific myelodysplastic syndrome (MDS) stem cell neoantigens, with potential immunostimulating and antineoplastic activities. Upon infusion of the MDS neoantigen-specific autologous T-lymphocytes, the immunized T-cells specifically target and lyse cells expressing the MDS neoantigens.","MDS Neoantigen-specific Autologous T-lymphocytes | Autologous T-lymphocytes Targeting Patient-specific MDS Stem Cell Neoantigens | MDS Neoantigen-specific Autologous T-cells | MDS Neoantigen-specific Immunized Autologous T-cells | MDS-specific PACTN Agent | Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens Agent | Personalized MDS Neoantigen-specific Autologous T-lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551019","MCD Diffuse Large B-Cell Lymphoma","C148394","A diffuse large B-cell lymphoma molecular subtype characterized by the co-occurrence of MYD88 and CD79B gene mutations. Patients who belong in this subtype have an inferior outcome. (NEJM 2018; 378: 1396-407)","MCD Diffuse Large B-Cell Lymphoma | MCD DLBCL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545803","Anti-TIM-3 Antibody BMS-986258","C148042","An antibody against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Following administration, anti-TIM-3 antibody BMS-986258 binds to TIM-3 that is expressed on certain T-cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which together result in decreased tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.","Anti-TIM-3 Antibody BMS-986258 | Anti-TIM3 Antibody BMS-986258 | BMS 986258 | BMS-986258",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1139841","Skin Staple","C148064","A type of surgical staple designed to close skin wounds.","Skin Staple | ",,,,,,,,,,,,,,,"45760270","Skin staple",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545805","Advanced B-Cell Neoplasm","C148065","A B-cell malignant neoplasm that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced B-Cell Malignant Neoplasm | Advanced B-Cell Malignancy | Advanced B-Cell Neoplasm | Advanced B-Cell Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545806","Anti-CD74 Antibody-drug Conjugate STRO-001","C148066","An antibody-drug conjugate (ADC) comprised of an aglycosylated human anti-CD74 IgG1 antibody (SP7219) that has been genetically modified to incorporate the non-natural amino acid (nnAA) para-azidomethyl-L-phenylalanine (pAMF), which is site-specifically conjugated to a non-cleavable dibenzocyclooctyne (DBCO)-maytansinoid linker-warhead, with potential antineoplastic activity. The antibody moiety of anti-CD74 ADC STRO-001 targets and binds to the CD74 expressed on tumor cells; upon internalization, the maytansinoid linker-warhead moiety binds to tubulin and disrupts microtubule assembly/disassembly dynamics, which results in the inhibition of both cell division and cell growth of CD74-expressing tumor cells. CD74, a transmembrane glycoprotein and tumor-associated antigen (TAA) involved in major histocompatibility complex (MHC) class II protein formation and localization, is a receptor for macrophage migration inhibitory factor (MIF; MMIF). MIF binding induces intramembrane cleavage of CD74, which liberates the cytosolic intracellular domain (ICD) of CD74 and regulates the expression of genes involved in promoting cell survival. CD74 is overexpressed on cells from hematologic B-lineage malignancies.","Anti-CD74 Antibody-drug Conjugate STRO-001 | ADC STRO-001 | Anti-CD74 ADC STRO-001 | Anti-CD74 Antibody-drug Conjugate BN301 | BEZETABART DEBOTANSINE | BN 301 | BN-301 | BN301 | SP7675 | STRO-001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545889","HSATII DNA","C148069","Human HSATII is comprised of an approximately 26 bp tandem repeat sequence that is the main component of pericentromeric heterochromatin located on chromosomes 2, 5, 7, 10, 13, 14, 15, 17, 21, 22, and Y; additionally large (5-6 Mb) blocks of this repeat are located at 1q12 and on chromosome 16. This satellite DNA is not expressed in normal cells. Aberrant expression and translation of HSATII RNA, which occurs when the sequence is demethylated, is associated with various cancers and may result in sequestration of transcription regulation proteins.","HSATII DNA | HSAT-II DNA | Human Satellite II Repeat DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553693","Tafenoquine Succinate","C152489","The succinate salt form of tafenoquine, an orally bioavailable 8-aminoquinoline derivative, with antimalarial activity. Although the mechanism is not completely understood, upon administration, tafenoquine inhibits the parasitic enzyme heme polymerase in the blood stages of the parasites. This inhibits the conversion of the toxic heme into non-toxic hemazoin, thereby resulting in the accumulation of toxic heme within the parasite. Tafenoquine is active against all the stages of Plasmodium species and is also active against the pre-erythrocytic liver stages of the parasites. This prevents the development of the erythrocytic forms of the parasite which are responsible for relapses in P. vivax malaria.","Tafenoquine Succinate | Arakoda | Krintafel | TAFENOQUINE SUCCINATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553119","FKSI-DRS Version 4 - I Have Bone Pain","C151274","Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms Version 4 (FKSI-DRS Version 4) I have bone pain.","FKSI-DRS Version 4 - I Have Bone Pain | FAC041-I Have Bone Pain | FAC04104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553120","FKSI-DRS Version 4 - I Feel Fatigued","C151275","Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms Version 4 (FKSI-DRS Version 4) I feel fatigued.","FKSI-DRS Version 4 - I Feel Fatigued | FAC041-I Feel Fatigued | FAC04105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553121","FKSI-DRS Version 4 - I Have Been Short of Breath","C151276","Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms Version 4 (FKSI-DRS Version 4) I have been short of breath.","FKSI-DRS Version 4 - I Have Been Short of Breath | FAC041-I Have Been Short of Breath | FAC04106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553122","FKSI-DRS Version 4 - I Have Been Coughing","C151277","Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms Version 4 (FKSI-DRS Version 4) I have been coughing.","FKSI-DRS Version 4 - I Have Been Coughing | FAC041-I Have Been Coughing | FAC04107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553123","FKSI-DRS Version 4 - I Am Bothered by Fevers","C151278","Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms Version 4 (FKSI-DRS Version 4) I am bothered by fevers (episodes of high body temperature).","FKSI-DRS Version 4 - I Am Bothered by Fevers | FAC041-I Am Bothered by Fevers | FAC04108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553124","FKSI-DRS Version 4 - I Have Had Blood in My Urine","C151279","Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms Version 4 (FKSI-DRS Version 4) I have had blood in my urine.","FKSI-DRS Version 4 - I Have Had Blood in My Urine | FAC041-I Have Had Blood in My Urine | FAC04109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553125","NCCN-FACT FBRSI-24 Version 2 - I Get Headaches","C151280","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I get headaches.","NCCN-FACT FBRSI-24 Version 2 - I Get Headaches | FAC030-I Get Headaches | FAC03001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553174","Topical Potassium Dobesilate","C151946","A topical formulation composed of an inhibitor of fibroblast growth factor (FGF), with potential antineoplastic activity. Upon topical administration potassium dobesilate selectively binds to and blocks the activity of FGF, interferes with the binding of FGF to FGFR and prevents FGFR-mediated signaling. This inhibits angiogenesis and tumor cell proliferation, and induces cell death in FGFR-overexpressing tumor cells. FGF plays a key role in angiogenesis, tumor cell proliferation, survival and invasiveness, and is upregulated in many tumor cell types.","Topical Potassium Dobesilate | AM-001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937684","CK 301","C151947","An immunoglobulin G1 (IgG1), human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, cosibelimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death protein 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.","Cosibelimab | Anti-PD-L1 Monoclonal Antibody TG-1501 | Anti-PDL1 Monoclonal Antibody TG-1501 | CK 301 | CK-301 | COSIBELIMAB | TG 1501 | TG-1501 | TG1501",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553176","161533","C151948","A trispecific killer engager (TriKE) molecule containing an anti-cluster of differentiation 16 (CD16; FcgammaRIII) single-chain variable fragment (scFv) to engage natural killer (NK) cells, an anti-CD33 scFv to engage myeloid cells and a human modified interleukin-15 (IL-15) linker, that links the two scFv, with potential immunomodulating and antineoplastic activities against CD33-expressing tumor cells. Upon administration of the CD16/IL15/CD33 TriKE OXS-3550, the simultaneous binding to CD16 on NK cells and CD33 on tumor cells will induce NK cell cytotoxicity specifically against CD33-expressing tumor cells. The cytokine  IL-15 linker promotes NK cell proliferation, activity, survival and expansion. CD33 is expressed on normal non-pluripotent hematopoietic stem cells and is overexpressed on myeloid leukemia cells.","CD16/IL15/CD33 Trispecific Killer Cell Engager OXS-3550 | 161533 | 161533 TRIKE | CD16/IL-15/CD33 161533 Tri-Specific Killer Engagers | CD16/IL15/CD33 TriKE OXS-3550 | OXIS3550 | OXS 3550 | OXS-3550 | OXS3550",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551144","Autologous CD22-4SCAR-expressing T-cells 4SCAR22","C148524","A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a  fourth generation chimeric antigen receptor (4SCAR) consisting of an anti-CD22 single chain variable fragment (scFv) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (TCR), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous CD22-4SCAR-expressing T-cells 4SCAR22 are directed to and induce selective toxicity in CD22-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. CD22, a B-lineage-restricted, transmembrane phosphoglycoprotein, is expressed on malignant B cells. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.","Autologous CD22-4SCAR-expressing T-cells 4SCAR22 | 4S-CD22-CAR-T Cell | 4SCAR22 | 4SCAR22 T-cells | Anti-CD22 CAR-T Cells 4SCAR22 | Anti-CD22-CD28-CD137-CD27-CD3z-iCasp9 CAR T-cells 4SCAR22 | CD22-4SCAR-expressing T Lymphocytes | CD22-scFv/CD28/CD137/CD27/CD3z-iCasp9 T-cells | CD22-specific 4th Generation Chimeric Antigen Receptor-modified T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551140","Autologous CD20-4SCAR-expressing T-cells 4SCAR20","C148525","A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a  fourth generation chimeric antigen receptor (4SCAR) consisting of an anti-CD20 single chain variable fragment (scFv) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (TCR), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous CD20-4SCAR-expressing T-cells 4SCAR20 are directed to and induce selective toxicity in CD20-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.","Autologous CD20-4SCAR-expressing T-cells 4SCAR20 | 4S-CD20-CAR-T Cell | 4SCAR20 | 4SCAR20 T-cells | Anti-CD20 CAR-T Cells 4SCAR20 | Anti-CD20-CD28-CD137-CD27-CD3z-iCasp9 CAR T-cells 4SCAR20 | CD20-4SCAR-expressing T Lymphocytes | CD20-scFv/CD28/CD137/CD27/CD3z-iCasp9 T-cells | CD20-specific 4th Generation Chimeric Antigen Receptor-modified T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551139","Autologous CD123-4SCAR-expressing T-cells 4SCAR123","C148526","A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a  fourth generation chimeric antigen receptor (4SCAR) consisting of an anti-CD123 (interleukin-3 receptor alpha chain or IL3RA) single chain variable fragment (scFv) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (TCR), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon administration, autologous CD123-4SCAR-expressing T-cells 4SCAR123 are directed to and induce selective toxicity in CD123-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with increased leukemic cell proliferation and aggressiveness. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.","Autologous CD123-4SCAR-expressing T-cells 4SCAR123 | 4S-CD123-CAR-T Cell | 4SCAR123 | 4SCAR123 T-cells | Anti-CD123 CAR-T Cells 4SCAR123 | Anti-CD123-CD28-CD137-CD27-CD3z-iCasp9 CAR T-cells 4SCAR123 | CD123-4SCAR-expressing T Lymphocytes | CD123-scFv/CD28/CD137/CD27/CD3z-iCasp9 T-cells | CD123-specific 4th Generation Chimeric Antigen Receptor-modified T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551018","BN2 Diffuse Large B-Cell Lymphoma","C148395","A diffuse large B-cell lymphoma molecular subtype characterized by the presence of BCL6 gene fusions and NOTCH2 gene mutations. Patients who belong in this subtype have a favorable outcome. (NEJM 2018; 378: 1396-407)","BN2 Diffuse Large B-Cell Lymphoma | BN2 DLBCL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551013","N1 Diffuse Large B-Cell Lymphoma","C148396","A diffuse large B-cell lymphoma molecular subtype characterized by the presence of NOTCH1 gene mutations. Patients who belong in this subtype have an inferior outcome. (NEJM 2018; 378: 1396-407)","N1 Diffuse Large B-Cell Lymphoma | N1 DLBCL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551012","Intramammary Dosage Form","C148397","No value exists.","Intramammary Dosage Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551015","EZB Diffuse Large B-Cell Lymphoma","C148398","A diffuse large B-cell lymphoma molecular subtype characterized by the presence of EZH2 gene mutations and BCL2 gene translocations. Patients who belong in this subtype have a favorable outcome. (NEJM 2018; 378: 1396-407)","EZB Diffuse Large B-Cell Lymphoma | EZB DLBCL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551014","Beehive Dosage Form","C148399","No value exists.","Beehive Dosage Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545847","FGF14 wt Allele","C147992","Human FGF14 wild-type allele is located in the vicinity of 13q33.1 and is approximately 692 kb in length. This allele, which encodes fibroblast growth factor 14 protein, plays a role in nervous system development. Mutation of the gene is associated with spinocerebellar ataxia 27.","FGF14 wt Allele | BA397O8.2 | FGF-14 | FHF-4 | FHF4 | Fibroblast Growth Factor 14 wt Allele | SCA27",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545848","FGF12 wt Allele","C147993","Human FGF12 wild-type allele is located within 3q28-q29 and is approximately 329 kb in length. This allele, which encodes fibroblast growth factor 12 protein, is involved in the development and function of the nervous system. Mutation of the gene is associated with early infantile epileptic encephalopathy.","FGF12 wt Allele | EIEE47 | FGF-12 | FGF12B | FHF-1 | FHF1 | Fibroblast Growth Factor 12 wt Allele | Fibroblast Growth Factor 12B Gene | Fibroblast Growth Factor FGF-12b Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1451205","fibroblast growth factor 14, human","C147995","Fibroblast growth factor 14 (247 aa, ~28 kDa) is encoded by the human FGF14 gene. This protein is involved in signal transduction in central nervous system development.","Fibroblast Growth Factor 14 | FGF-14 | FGF14 | FHF-4 | Fibroblast Growth Factor Homologous Factor 4 | Fibroblast Growth Factor-14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545850","Refractory Gastric Carcinoma","C147996","Gastric carcinoma that does not respond to treatment.","Refractory Gastric Carcinoma | Refractory Gastric (Stomach) Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1436266","FGF12 protein, human","C147997","Fibroblast growth factor 12 (243 aa, ~27 kDa) is encoded by the human FGF12 gene. This protein plays a role in both nervous system development and the promotion of voltage-gated sodium channel activity in neurons.","Fibroblast Growth Factor 12 | FGF-12 | FGF12 | FHF-1 | Fibroblast Growth Factor Homologous Factor 1 | Fibroblast Growth Factor-12 | Myocyte-Activating Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545852","EDN3 Gene","C147998","This gene is involved in vasoconstriction.","EDN3 Gene | EDN3 | Endothelin 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545837","EDN3 wt Allele","C147999","Human EDN3 wild-type allele is located in the vicinity of 20q13.32 and is approximately 26 kb in length. This allele, which encodes endothelin-3 protein, plays a role in vasoconstriction. Mutation of the gene is associated with congenital central hyperventilation syndrome, Waardenburg syndrome type 4B and increased susceptibility to Hirschsprung disease (aganglionic megacolon).","EDN3 wt Allele | ET-3 | ET3 | Endothelin 3 wt Allele | HSCR4 | PPET3 | WS4B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0211671","ALVAC Vaccine","C1479","A derivative of the Canarypox Virus, ALVAC can infect mammalian cells but it can't replicate.  Thus, it produces a self-limiting infection which does not produce symptoms or harm the host.  When carrying foreign genes it will cause transient expression of protein.","ALVAC Vaccine | ALVAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3852391","EDN3 protein, human","C148000","Endothelin-3 (238 aa, ~26 kDa) is encoded by the human EDN3 gene. This protein is involved in vasoconstriction.","Endothelin-3 | EDN3 | ET-3 | Endothelin 3 | PPET3 | Preproendothelin 3 | Preproendothelin-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545839","XK Gene","C148001","This gene may play a role in sodium-dependent transport of neutral amino acids or peptides.","XK Gene | X-Linked Kx Blood Group Gene | XK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553694","Tafluposide","C152490","No value exists.","Tafluposide | TAFLUPOSIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553695","Taglutimide","C152491","No value exists.","Taglutimide | TAGLUTIMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039266","Talampicillin","C152492","No value exists.","Talampicillin | TALAMPICILLIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553697","Talampicillin Hydrochloride","C152493","No value exists.","Talampicillin Hydrochloride | TALAMPICILLIN HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553698","Talazoparib Tosylate","C152494","The tosylate salt form of talazoparib, an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. Upon administration, talazoparib selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.","Talazoparib Tosylate | TALAZOPARIB TOSYLATE | Talzenna",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553699","Talinexomer","C152495","No value exists.","Talinexomer | TALINEXOMER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553700","Talipexole","C152496","No value exists.","Talipexole | TALIPEXOLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553701","Talisomycin","C152497","No value exists.","Talisomycin | BU 2231A | BU-2231A | BU2231A | TALISOMYCIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553702","Talnetant Hydrochloride","C152498","No value exists.","Talnetant Hydrochloride | TALNETANT HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553703","Taloximine","C152499","No value exists.","Taloximine | TALOXIMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0245820","Liarozole Fumarate","C1524","The orally active fumarate salt of the benzimidazole derivative liarozole with potential antineoplastic activity. As a retinoic acid metabolism blocking agent (RAMBA), liarozole inhibits cytochrome P450-dependent all-trans-retinoic acid (ATRA)-4-hydroxylase, resulting in an increase in endogenous ATRA production, inhibition of cell proliferation, and induction of cell differentiation. This agent also inhibits aromatase, the enzyme that catalyzes the final, rate-limiting step in estrogen biosynthesis.","Liarozole Fumarate | (+-)-5-(m-Chloro-alpha-imidazol-1-ylbenzyl)benzimidazole Fumarate (2:3) | 1H-Benzimidazole, 5-((3-chlorophenyl)-1H-imidazol-1-ylmethyl)-, (+-)-, (E)-2-butenedioate (2:3) | LIAROZOLE FUMARATE | R85246",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553704","Talsaclidine Fumarate","C152500","No value exists.","Talsaclidine Fumarate | TALSACLIDINE FUMARATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553705","Tametraline","C152501","No value exists.","Tametraline | TAMETRALINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553707","Tampramine","C152503","No value exists.","Tampramine | TAMPRAMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553708","Tampramine Fumarate","C152504","No value exists.","Tampramine Fumarate | TAMPRAMINE FUMARATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553709","Tamtuvetmab","C152505","No value exists.","Tamtuvetmab | TAMTUVETMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553710","Tandamine","C152506","No value exists.","Tandamine | TANDAMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553711","Tandamine Hydrochloride","C152507","No value exists.","Tandamine Hydrochloride | TANDAMINE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553713","Tanurmotide","C152509","No value exists.","Tanurmotide | TANURMOTIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553177","Vonoprazan Fumarate","C151949","The fumarate salt form of vonoprazan, a pyrrole derivative and reversible potassium-competitive acid blocker (P-CAB), with potential antacid activity. Upon administration, vonoprazan specifically and competitively binds to the gastric hydrogen-potassium ATPase (H+/K+ ATPase) proton pump at or, more likely, near its potassium ion (K+) binding site and sterically inhibits K+ binding. This blocks the activation of the H+/K+ ATPase by K+, inhibits the proton pump and prevents gastric acid secretion, thereby lowering gastric acid levels.","Vonoprazan Fumarate | 1H-Pyrrole-3-methanamine, 5-(2-Fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl)-, (2E)-2-Butenedioate (1:1) | TAK-438 | Takecab | VONOPRAZAN FUMARATE | Voquezna",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553179","CC 90010","C151951","An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, trotabresib preferentially binds to the second bromodomain (BD2) of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of proliferation in BET-overexpressing tumor cells. BET proteins (BRD2, BRD3, BRD4 and BRDT) are transcriptional regulators that contain two homologous bromodomains, the BD1 and BD2 domains. They play an important role during development and cellular growth.","Trotabresib | 4-(2-(Cyclopropylmethoxy)-5-methylsulfonylphenyl)-2-methylisoquinolin-1-one | BET Inhibitor CC-90010 | CC 90010 | CC-90010 | CC90010 | TROTABRESIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553494","Rebastinib","C152162","An orally bioavailable small-molecule inhibitor of multiple tyrosine kinases with potential antineoplastic activity. Upon oral administration, rebastinib binds to and inhibits the Bcr-Abl fusion oncoprotein by changing the conformation of the folded protein to disallow ligand-dependent and ligand-independent activation; in addition, this agent binds to and inhibits Src family kinases LYN, HCK and FGR and the receptor tyrosine kinases TIE-2 and VEGFR-2. Rebastinib may exhibit more potent activity against T315I Bcr-Abl gatekeeper mutant kinases than other Bcr-Abl kinase inhibitors. The TIE-2 and VEGFR-2 receptor tyrosine kinases regulate angiogenesis, respectively, while the Src family kinases Abl, LYN, and HCK Src regulate a variety of cellular responses including differentiation, division, adhesion, and the stress response.","Rebastinib | DCC-2036 | REBASTINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0168387","Reboxetine Mesylate","C152163","No value exists.","Reboxetine Mesylate | REBOXETINE MESYLATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553496","Recainam","C152164","No value exists.","Recainam | RECAINAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553497","Recainam Hydrochloride","C152165","No value exists.","Recainam Hydrochloride | RECAINAM HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553498","Recainam Tosylate","C152166","No value exists.","Recainam Tosylate | RECAINAM TOSYLATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553499","Recanaclotide","C152167","No value exists.","Recanaclotide | RECANACLOTIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553500","Recilisib","C152168","No value exists.","Recilisib | RECILISIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553501","Recilisib Sodium","C152169","No value exists.","Recilisib Sodium | RECILISIB SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553502","Recoflavone","C152170","No value exists.","Recoflavone | RECOFLAVONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553503","Redasemtide","C152171","No value exists.","Redasemtide | REDASEMTIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553505","Regenerated Cellulose","C152173","No value exists.","Regenerated Cellulose | REGENERATED CELLULOSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553506","Relamorelin","C152174","No value exists.","Relamorelin | RELAMORELIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553507","Relebactam Anhydrous","C152175","No value exists.","Relebactam Anhydrous | RELEBACTAM ANHYDROUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550799","Allogeneic TCR alpha/beta-positive T-lymphocyte-depleted Peripheral Blood Stem Cells","C148149","A preparation of allogeneic T-cell receptor (TCR) alpha/beta-positive T cell-depleted peripheral blood stem cells (PBSCs), that can potentially be used for hematopoietic stem cell transplantation (HSCT). Allogeneic PBMCs are processed, using the proprietary CliniMACS device, to remove TCRalpha/beta T-cells, while retaining other cells, such as donor-derived natural killer (NK) cells and gamma/delta T-cells. As TCR alpha/beta-positive T-cells appear to be related to the development of graft versus host disease (GvHD), depletion of these cells may lower the risk of the recipient developing GvHD. Upon infusion of the TCR alpha/beta-positive T-cell-depleted PBSCs for allogeneic stem cell transplantation (allo SCT), the alpha/beta-positive T-cell depletion as well as the presence of allogeneic NK cells, and other cells, may facilitate engraftment, exert graft-versus-leukemia effects, enhance post-transplant immune recovery, and reduce the risk of infections and GvHD.","Allogeneic TCR alpha/beta-positive T-lymphocyte-depleted Peripheral Blood Stem Cells | Allogeneic TCR a/b T cell-depleted PBSCs | Allogeneic TCR alpha/beta T Cell-depleted PBSCs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550794","Autologous NY-ESO-1 TCR-targeted T Lymphocytes","C148150","A preparation of human autologous T-lymphocytes that are transduced with a gene encoding a T-cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1, with potential immunostimulating and antineoplastic activities. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the anti-NY-ESO-1 TCR-transduced autologous T-cells recognize and bind to NY-ESO-1-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of NY-ESO-1-positive tumor cells. NY-ESO-1, a tumor-associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types, and is not, or is minimally, expressed in normal, healthy cells.","Autologous NY-ESO-1 TCR-targeted T Lymphocytes | NY-ESO-1 T Cell Receptor Genetically Modified Autologous T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550793","Child-Pugh A-B7 Cirrhosis","C148151","An indication that Child-Pugh scores ranging from A (scores 5 or 6) to B7 (score 7) for liver cirrhosis will be considered for trial inclusion.","Child-Pugh A-B7 Cirrhosis | Child-Pugh A-B7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550796","Refractory Head and Neck Squamous Cell Carcinoma","C148152","A head and neck squamous cell carcinoma that does not respond to treatment.","Refractory Head and Neck Squamous Cell Carcinoma | Refractory Head and Neck Squamous Cell Cancer | Refractory Squamous Cell Carcinoma of the Head and Neck",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550795","Metastatic Head and Neck Squamous Cell Carcinoma","C148153","A head and neck squamous cell carcinoma which has spread from the original site of growth to another anatomic site.","Metastatic Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550790","PD-L1/IDO Peptide Vaccine","C148154","A peptide vaccine composed of IO103, a peptide vaccine derived from the tumor-associated antigen (TAA) programmed cell death-1 ligand 1 (PD-L1), IO102, the 21-mer peptide vaccine derived from the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO), and the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Vaccination with the PD-L1/IDO peptide vaccine IO102-103 may activate the immune system to induce an immune response against PD-L1 and IDO-expressing cells. This may increase and restore the proliferation and activation of various immune cells, including cytotoxic T-lymphocytes (CTLs), and may eradicate PD-L1 and IDO-expressing tumor cells through a CTL-mediated immune response. PD-L1 is overexpressed on many human cancer cell types. PD-L1 binding to its cognate receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) on T-cells suppresses the immune system and results in increased immune evasion and decreased CTL activation. IDO, a cytosolic enzyme responsible for tryptophan catabolism and conversion of tryptophan into kynurenine, is overexpressed by a variety of tumor cell types and antigen presenting cells (APCs) and plays an important role in immunosuppression mainly through suppression of CTL activation; tryptophan depletion inhibits T-lymphocyte proliferation and activation, and suppresses the immune system. Montanide ISA-51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens.","PD-L1/IDO Peptide Vaccine IO102-103 | IDO/PD-L1 Peptide Vaccine IO 102 IO 103 | IO102 and IO103 | IO102-103 | IO102-IO103 | IO102-IO103 Peptide Vaccine | IO102/IO103 | IO103/IO102 Peptide Vaccine | PD-L1/IDO Peptide | PD-L1/IDO Peptide Vaccine | Peptide Vaccine IO102-IO103 | Peptide Vaccine IO103/IO102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1382578","BCD 100","C148155","A monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, prolgolimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","Prolgolimab | BCD 100 | BCD-100 | BCD100 | PROLGOLIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545840","XK wt Allele","C148002","Human XK wild-type allele is located in the vicinity of Xp21.1 and is approximately 46 kb in length. This allele, which encodes membrane transport protein XK, may be involved in transmembrane transport of amino acids or peptides. Mutation or deletion of the gene is associated with the McLeod phenotype of the Kell blood group system.","XK wt Allele | KX | Kell Blood Group Precursor (McLeod Phenotype) Gene | Kell Blood Group Precursor Gene | McLeod Syndrome Gene | NA | NAC | Neuroacanthocytosis Gene | Neurocanthocytosis Gene | Precursor Substance, Kell Blood Group Gene | X-Linked Kx Blood Group wt Allele | X1k | XK Locus Gene | XK, Kell Blood Group Complex Subunit (McLeod Syndrome) Gene | XKR1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0256075","XK protein, human","C148003","Membrane transport protein XK (444 aa, ~51 kDa) is encoded by the human XK gene. This protein may play a role in amino acid transport.","Membrane Transport Protein XK | Kell Complex 37 kDa Component | Kell Complex, 37-kD Component | Kx Antigen | Kx Blood Group Antigen | XK | XK-Related Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545843","GUSB wt Allele","C148005","Human GUSB wild-type allele is located in the vicinity of 7q11.21 and is approximately 22 kb in length. This allele, which encodes beta-glucuronidase protein, plays a role in the metabolism of glycosaminoglycans. Mutation of the gene is associated with mucopolysaccharidosis VII.","GUSB wt Allele | BG | GUS | Glucuronidase Beta wt Allele | Glucuronidase, Beta Gene | MPS7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545844","Beta-Glucuronidase","C148006","Beta-glucuronidase (651 aa, ~75 kDa) is encoded by the human GUSB gene. This protein is involved in the catabolism of glycosaminoglycans.","Beta-Glucuronidase | Beta-D-Glucuronidase | Beta-G1 | EC 3.2.1.31 | GUSB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551118","Coated Granules Dosage Form","C148551","A granule whose outer shell is covered with a substance.","Coated Granules Dosage Form | Coated Granule Dosage Form | Coated granules | GRANULE, COATED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556879","Lyophilized Dosage Form Category","C148552","A type of solid pharmaceutical dose form consisting of a powder or disc formed by freeze-drying of a liquid or semi-solid preparation. When referring to a powder, the use of this term is restricted to veterinary medicines.","Lyophilized Dosage Form Category | Lyophilisate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551113","OSBPL10 Gene","C148554","This gene plays a role in binding to cholesterol and acidic phospholipids.","OSBPL10 Gene | OSBPL10 | Oxysterol Binding Protein Like 10 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551116","OSBPL10 wt Allele","C148555","Human OSBPL10 wild-type allele is located in the vicinity of 3p23 and is approximately 420 kb in length. This allele, which encodes oxysterol-binding protein-related protein 10, is involved in sterol binding and phospholipid transport.","OSBPL10 wt Allele | ORP10 | OSBP9 | Oxysterol Binding Protein Like 10 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551115","Oxysterol-Binding Protein-Related Protein 10","C148556","Oxysterol-binding protein-related protein 10 (764 aa, ~84 kDa) is encoded by the human OSBPL10 gene. This protein plays a role in subcellular phospholipid localization and cholesterol binding.","Oxysterol-Binding Protein-Related Protein 10 | ORP-10 | OSBP-Related Protein 10 | OSBPL10 | Oxysterol Binding Protein-Like 10 | Oxysterol-Binding Protein-Like Protein 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551110","Therapeutic Invariant Natural Killer T-cells","C148557","A preparation of natural killer T-cells (NKTs) expressing an invariant (alpha, beta) T-cell receptor (iNKTs), with potential immunomodulating and antineoplastic activities. Upon infusion of the therapeutic iNKTs, these cells recognize CD1d-restricted lipid ligands, which are expressed on certain tumor cells, and secrete large amounts of various cytokines. This may activate the immune system against tumor cells. Additionally, iNKTs directly target and lyse tumor cells.","Therapeutic Invariant Natural Killer T-cells | Therapeutic Invariant NK T-cells | Therapeutic iNK T-cells | Therapeutic iNKT Cells | Therapeutic iNKTs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4053681","pan IDH mutant inhibitor AG-881","C152914","An orally available inhibitor of mutated forms of both isocitrate dehydrogenase type 1 (IDH1, IDH1 [NADP+] soluble) in the cytoplasm and type 2 (IDH2, isocitrate dehydrogenase [NADP+], mitochondrial) in the mitochondria, with potential antineoplastic activity. Upon administration, vorasidenib specifically inhibits mutant forms of IDH1 and IDH2, thereby inhibiting the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing IDH mutations. In addition, vorasidenib is able to penetrate the blood-brain barrier (BBB). IDH1 and 2, metabolic enzymes that catalyze the conversion of isocitrate into a-KG, play key roles in energy production and are mutated in a variety of cancer cell types. In addition, mutant forms of IDH1 and 2 catalyze the formation of 2HG and drive cancer growth by blocking cellular differentiation and inducing cellular proliferation.","Vorasidenib | AG 881 | AG-881 | AG881 | VORASIDENIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL787800","Voretigene Neparvovec","C152915","No value exists.","Voretigene Neparvovec | VORETIGENE NEPARVOVEC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554248","Vorsetuzumab","C152916","No value exists.","Vorsetuzumab | VORSETUZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554250","Vosoritide","C152918","No value exists.","Vosoritide | VOSORITIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554251","Vutrisiran","C152919","No value exists.","Vutrisiran | ALN-TTRSC02 | VUTRISIRAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554252","Votucalis","C152920","No value exists.","Votucalis | VOTUCALIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554253","Voxilaprevir","C152922","An orally bioavailable inhibitor of the hepatitis C virus (HCV) non-structural protein 3/non-structural protein 4A (NS3/NS4A) serine protease, with antiviral activity. Upon administration, voxilaprevir binds to the HCV NS3/NS4A serine protease and prevents NS3/NS4A protease-mediated polyprotein maturation. This disrupts both the processing of viral proteins and the formation of the viral replication complex, thereby preventing viral replication and function. NS3, a serine protease, is essential for the proteolytic cleavage of multiple sites within the HCV polyprotein and plays a key role during HCV ribonucleic acid (RNA) replication. NS4A is an activating factor for NS3. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family; HCV infection is associated with the development of hepatocellular carcinoma (HCC).","Voxilaprevir | GS 9857 | GS-9857 | GS9857 | VOXILAPREVIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554254","Vunakizumab","C152923","No value exists.","Vunakizumab | VUNAKIZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554255","Xaliproden","C152924","No value exists.","Xaliproden | XALIPRODEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554256","Fumarate, Xamoterol","C152925","No value exists.","Xamoterol Fumarate | XAMOTEROL FUMARATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554258","Xanomeline Tartrate","C152927","No value exists.","Xanomeline Tartrate | XANOMELINE TARTRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043319","Xanthinol Niacinate","C152928","No value exists.","Xanthinol Niacinate | XANTHINOL NIACINATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554260","Xanthiol","C152929","No value exists.","Xanthiol | XANTHIOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554262","Xenalipin","C152931","No value exists.","Xenalipin | XENALIPIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554263","Xibornol","C152932","No value exists.","Xibornol | XIBORNOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553508","Relebactam Monohydrate","C152176","The monohydrate form of relebactam, a beta-lactamase inhibitor, that can be used to inhibit the breakdown of certain drugs, such as the broad spectrum beta-lactam carbapenem antibiotic imipenem. Upon administration of relebactam monohydrate, relebactam targets, binds to and inhibits beta-lactamase. This reduces the breakdown  of drugs, such as imipenem, and thereby increases the activity and therapeutic effect of such drugs that would otherwise be inactivated by beta-lactamase.","Relebactam Monohydrate | RELEBACTAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553510","Relenopride Hydrochloride","C152178","No value exists.","Relenopride Hydrochloride | RELENOPRIDE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553511","Relmapirazin","C152179","No value exists.","Relmapirazin | APC-2 | Lumtrace | MB-102 | N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine) | RELMAPIRAZIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553512","Reloxaliase","C152180","No value exists.","Reloxaliase | RELOXALIASE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553514","Reltecimod Sodium","C152182","No value exists.","Reltecimod Sodium | RELTECIMOD SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553515","remacemide","C152183","No value exists.","Remacemide | REMACEMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553516","Remacemide Hydrochloride","C152184","No value exists.","Remacemide Hydrochloride | REMACEMIDE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0246228","RG 12915","C1525","A 5-hydroxytryptamine-3 (5-HT3) receptor antagonist with antiemetic activity. RG 12915 binds to and antagonizes the action of serotonin on the 5-HT-3 receptor located on vagal afferents in the chemoreceptor trigger zone (CTZ), resulting in suppression of chemotherapy-induced nausea and vomiting.","RG 12915 | RG-12915 | RG12915",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553804","Tiapamil","C152600","No value exists.","Tiapamil | TIAPAMIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553805","Tiapamil Hydrochloride","C152601","No value exists.","Tiapamil Hydrochloride | TIAPAMIL HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553806","Tiapride","C152602","No value exists.","Tiapride | TIAPRIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553807","Tiaramide","C152603","No value exists.","Tiaramide | TIARAMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553808","Tiaramide Hydrochloride","C152604","No value exists.","Tiaramide Hydrochloride | TIARAMIDE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553809","Tiazotic Acid","C152605","No value exists.","Tiazotic Acid | TIAZOTIC ACID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553810","tibric acid","C152606","No value exists.","Tibric Acid | TIBRIC ACID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553811","Tibrofan","C152607","No value exists.","Tibrofan | TIBROFAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553812","Tibulizumab","C152608","No value exists.","Tibulizumab | TIBULIZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553813","Ticabesone","C152609","No value exists.","Ticabesone | TICABESONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021052","Immunodiagnostic Procedure","C15260","No value exists.","Immunodiagnostic Procedure | Immunodiagnosis | Immunodiagnostics",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553814","Ticabesone Propionate","C152610","No value exists.","Ticabesone Propionate | TICABESONE PROPIONATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL018317","Other and Unspecified Major Salivary Glands ICD-O-3","C148340","Major salivary glands that are referenced in topographic category C08 of ICD-O-3.","Other and Unspecified Major Salivary Glands ICD-O-3 | Other and Unspecified Major Salivary Glands | Other and unspecified major salivary glands",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL018343","Other and Unspecified Parts of Biliary Tract ICD-O-3","C148342","Components of the biliary tract that are referenced in topographic category C24 of ICD-O-3.","Other and Unspecified Parts of Biliary Tract ICD-O-3 | Other and Unspecified Parts of Biliary Tract | Other and unspecified parts of biliary tract",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL018300","Other and Unspecified Parts of Tongue ICD-O-3","C148344","Components of the tongue that are referenced in topographic category C02 of ICD-O-3.","Other and Unspecified Parts of Tongue ICD-O-3 | Other and Unspecified Parts of Tongue | Other and unspecified parts of tongue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414945","GAL Gene","C148347","This gene is involved in neuropeptide activity.","GAL Gene | GAL | Galanin and GMAP Prepropeptide Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550958","GAL wt Allele","C148348","Human GAL wild-type allele is located in the vicinity of 11q13.2 and is approximately 7 kb in length. This allele, which encodes galanin peptides protein, plays a role in neuropeptide signaling. Mutation of the gene may be associated with familial temporal lobe epilepsy 8.","GAL wt Allele | ETL8 | GAL-GMAP | GALN | GLNN | GMAP | Galanin and GMAP Prepropeptide wt Allele | Galanin-Related Peptide Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550957","GAL Gene Product","C148349","A protein encoded by the GAL gene.","GAL Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550959","Galanin","C148351","Galanin (30 aa, ~3 kDa) is encoded by the human GAL gene. This protein is involved in nociception, secretion of cortisol, growth hormone and insulin, hair follicle development and contraction of smooth muscle cells of the gastrointestinal and genitourinary tracts.","Galanin | GAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550771","Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes","C148177","A preparation of an approximately equal ratio of autologous CD4- and CD8-positive T-lymphocytes that have been ex vivo transduced with a genetically-engineered self-inactivating (SIN) lentiviral vector (LV) expressing a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) specific for the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) fused to the co-stimulatory domain of 4-1BB (CD137), the CD3-zeta (CD3z) T-cell signaling domain, and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-BCMA-CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes specifically recognize and induce selective toxicity against BCMA-expressing tumor cells. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt facilitates both in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) response. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and is overexpressed on malignant plasma cells.","Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes | Anti-BCMA-CAR-4-1BB-CD3zeta-EGFRt SIN Lentiviral Vector-transduced Autologous CD4+/CD8+ T-lymphocytes | Autologous BCMA-specific CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554264","Xilobam","C152933","No value exists.","Xilobam | XILOBAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554265","Ximoprofen","C152934","No value exists.","Ximoprofen | XIMOPROFEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554267","Xorphanol Mesylate","C152936","No value exists.","Xorphanol Mesylate | XORPHANOL MESYLATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553265","Autologous CISH-inactivated TILs","C151926","A preparation of autologous tumor-infiltrating lymphocytes (TILs) where the cytokine-inducible SH2-containing protein gene (CISH) has been inactivated using the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR associated protein 9 (Cas9) editing system, containing guide RNA (gRNA) coupled to a recombinant form of the DNA endonuclease Cas9, with potential immunomodulating and antineoplastic activities. Using the CRISPR/Cas9 system, the autologous TILs are transfected, ex vivo, with a plasmid encoding for a gRNA that site-specifically targets and binds to the human CISH gene. Cas9 cleaves these specific DNA sites, which causes double strand breaks, disrupts the gene encoding CISH and prevents transcription. Upon intravenous administration, the autologous CISH-inactivated TILs are able to induce a T-cell-mediated immune response against tumor cells. CISH, a member of the suppressor of cytokine signaling family (SOCS; cytokine-induced STAT inhibitor; STAT-induced STAT inhibitor; SSI), is induced by T-cell receptor (TCR) stimulation. CISH plays a key role in the negative regulation of both T-cell signaling and CTL-mediated tumor cell eradication. The knockout of the CISH gene enhances the expansion and anti-tumor activities of effector T-cells.","Autologous CISH-inactivated TILs | Autologous CISH-inactivated T-lymphocytes | Autologous CISH-inactivated TIL | Autologous CISH-inactivated Tumor-infiltrating Lymphocytes | Autologous CRISPR/Cas 9-CISH Knockout TILs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553266","GX-I7","C151927","A long-acting immunoglobulin (Ig) fusion protein composed of a recombinant form of the endogenous human protein interleukin-7 (rhIL-7) and fused to a hybrid Fc (hyFc) region of a human antibody, with hematopoietic and immunopotentiating activities. Upon administration of efineptakin alfa, IL-7 stimulates the proliferation, differentiation, trafficking and survival of a variety of T-cell subsets, including naive, central memory (CM), effector memory (EM), terminally differentiated effector memory (TEMRA) and natural killer (NK) T-cells, and enhances T-cell-mediated anti-tumor immune responses. Compared to rhIL-7 alone, fusion to the hyFc region enhances the half-life of IL-7. The hyFc region is composed of the hinge and N-terminal portion of heavy chain constant (CH) region 2 (hinge-CH2) of human IgD, which is fused to the C-terminal region of CH2 and the entire CH3 region of human IgG4.","Efineptakin alfa | EFINEPTAKIN ALFA | GX-I7 | Hyleukin-7 (TM) | IL-7-hyFc | Il-7 Hybrid Fc | NT-I7 | NT-I7 Recombinant Human Interleukin-7-hyFc | TJ 107 | TJ-107 | TJ107 | rhIL-7-hyFc",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3710774","ANKRD26 protein, human","C151928","Ankyrin repeat domain-containing protein 26 (1709 aa, ~196 kDa) is encoded by the human ANKRD26 gene. This protein plays a role in appetite, platelet functions and adipogenesis.","Ankyrin Repeat Domain-Containing Protein 26 | ANKRD26 | Ankyrin Repeat Domain 26",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553268","cinobufotalin","C151929","A bufadienolide isolated from toad venom and utilized in traditional Chinese medicine (TCM) for its cardiotonic, diuretic and hemostatic effects, with potential cytotoxic and antineoplastic activities. Upon administration and although the exact mechanism of action(s) (MoAs) through which this agent exerts its effects have yet to be fully discovered, cinobufotalin causes DNA fragmentation, decreases mitochondrial membrane potential (MMP), increases intracellular calcium (Ca2+) ion concentrations and reactive oxygen species (ROS) production, upregulates Fas protein and activates cytochrome C, various caspases, Bid and Bax. This causes cell cycle arrest, induces apoptosis and inhibits tumor cell growth and survival. In addition, cinobufotalin inhibits the activity of sphingosine kinase 1 (SphK1) and induces pro-apoptotic ceramide production, which further promotes tumor cell apoptosis. Cinobufotalin also induces mitochondrial protein cyclophilin D (Cyp-D)-dependent opening of the mitochondrial permeability transition pore (mPTP), which may contribute to cinobufotalin-induced non-apoptotic death of certain tumor cells.","Cinobufotalin | 14,15b-Epoxy-3b,5a,16b-trihydroxy-5b,20(22)-bufadienolide 16-Acetate | 5-Beta-bufa-20,22-dienolide, 14,15-beta-epoxy-3-beta,5,16-beta-trihydroxy-, 16-Acetate | 5b,20(22)-Bufadienolide-14,15b-epoxy-3b,5a,16b-triol 16-Acetate | CB | CINOBUFOTALIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553815","Ticarcillin Cresyl Sodium","C152611","No value exists.","Ticarcillin Cresyl Sodium | TICARCILLIN CRESYL SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553816","Ticlatone","C152612","No value exists.","Ticlatone | TICLATONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040209","Ticrynafen","C152613","No value exists.","Ticrynafen | TICRYNAFEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553818","Tifacogin","C152614","No value exists.","Tifacogin | TIFACOGIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553819","Tiflamizole","C152615","No value exists.","Tiflamizole | TIFLAMIZOLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553820","Tiformin","C152616","No value exists.","Tiformin | TIFORMIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553821","Tifuvirtide","C152617","No value exists.","Tifuvirtide | TIFUVIRTIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553822","Tigapotide Triflutate","C152618","No value exists.","Tigapotide Triflutate | TIGAPOTIDE TRIFLUTATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553823","Tigemonam","C152619","No value exists.","Tigemonam | TIGEMONAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553824","Tigemonam Dicholine","C152620","No value exists.","Tigemonam Dicholine | TIGEMONAM DICHOLINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553825","Tigestol","C152621","No value exists.","Tigestol | 19-Nor-17alpha-pregn-5(10)-en-20-yn-17-ol | 19-Norpregn-5(10)-en-20-yn-17-ol, (17alpha)- | TIGESTOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553826","Tigilanol Tiglate","C152622","A short-chain diterpene ester isolated from the seed of Fontainea picrosperma, with potential antineoplastic activity. Upon intratumoral administration, tigilanol tiglate disrupts mitochondrial functioning and induces mitochondrial swelling, which leads to oncolysis of tumor cells that are in direct contact of the agent. In addition, tigilanol tiglate activates protein kinase C (PKC) signaling cascade, which leads to an acute inflammatory response. This results in hypoxia and activates innate immune cells including neutrophils and macrophages, thereby further killing tumor cells. The activation of the beta-II isoform of PKC (PKC beta II ) also increases tumor vasculature permeability, which leads to the destruction of tumor vasculature.","Tigilanol Tiglate | EBC-46 | EBI-46 | TIGILANOL TIGLATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553828","Tigolaner","C152624","No value exists.","Tigolaner | TIGOLANER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553829","Tilapertin","C152625","No value exists.","Tilapertin | TILAPERTIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553830","Tildipirosin","C152626","No value exists.","Tildipirosin | TILDIPIROSIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553126","NCCN-FACT FBRSI-24 Version 2 - I Have Trouble With Coordination","C151281","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I have trouble with coordination.","NCCN-FACT FBRSI-24 Version 2 - I Have Trouble With Coordination | FAC030-I Have Trouble With Coordination | FAC03002",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553127","NCCN-FACT FBRSI-24 Version 2 - I Have Had Seizures","C151282","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I have had seizures (convulsions).","NCCN-FACT FBRSI-24 Version 2 - I Have Had Seizures | FAC030-I Have Had Seizures | FAC03003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553128","NCCN-FACT FBRSI-24 Version 2 - I Need Help in Caring for Myself","C151283","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I need help in caring for myself (bathing, dressing, eating, etc.).","NCCN-FACT FBRSI-24 Version 2 - I Need Help in Caring for Myself | FAC030-I Need Help in Caring for Myself | FAC03004",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553129","NCCN-FACT FBRSI-24 Version 2 - Have Weakness in My Arms or Legs","C151284","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I have weakness in my arms or legs.","NCCN-FACT FBRSI-24 Version 2 - Have Weakness in My Arms or Legs | FAC030-Have Weakness in My Arms or Legs | FAC03005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550954","Galanin Message-Associated Peptide","C148352","Galanin message-associated peptide (59 aa, ~7 kDa) is encoded by the human GAL gene. This protein may play a role in innate immunity.","Galanin Message-Associated Peptide | GAL | GMAP | Galanin-Message-Associated Peptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550953","GDF11 Gene","C148353","This gene plays a role in anterior/posterior axis development.","GDF11 Gene | GDF11 | Growth Differentiation Factor 11 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545779","Central Nervous System B-Cell Non-Hodgkin Lymphoma","C147948","A B-cell non-Hodgkin lymphoma that arises from the brain, meninges, or spinal cord.","Central Nervous System B-Cell Non-Hodgkin Lymphoma | B-Cell Primary Central Nervous System Non-Hodgkin Lymphoma | Primary Central Nervous System B-Cell Non-Hodgkin's Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3177193","TOX protein, human","C147950","Thymocyte selection-associated high mobility group box protein TOX (526 aa, ~58 kDa) is encoded by the human TOX gene. This protein plays a role in thymocyte development.","Thymocyte Selection-Associated High Mobility Group Box Protein TOX | TOX | Thymus High Mobility Group Box Protein TOX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545768","LEMD3 Gene","C147952","This gene is involved in inhibition of nuclear import of receptor-regulated SMADs (R-SMADs).","LEMD3 Gene | LEM Domain Containing 3 Gene | LEMD3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545769","LEMD3 wt Allele","C147953","Human LEMD3 wild-type allele is located in the vicinity of 12q14.3 and is approximately 79 kb in length. This allele, which encodes inner nuclear membrane protein Man1, plays a role in the downregulation of transforming growth factor beta (TGF-B) receptor signaling. Mutations in the gene have been associated with osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis.","LEMD3 wt Allele | LEM Domain Containing 3 wt Allele | MAN1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1438822","integral inner nuclear membrane protein, human","C147954","Inner nuclear membrane protein Man1 (911 aa, ~100 kDa) is encoded by the human LEMD3 gene. This protein is involved in the negative regulation of transforming growth factor beta (TGF-B) receptor signaling.","Inner Nuclear Membrane Protein Man1 | Integral Inner Nuclear Membrane Protein | LEM Domain-Containing Protein 3 | LEMD3 | MAN Antigen 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1435745","MAP3K4 protein, human","C147957","Mitogen-activated protein kinase kinase kinase 4 (1608 aa, ~182 kDa) is encoded by the human MAP3K4 gene. This protein plays a role in stress induced signaling pathways.","Mitogen-Activated Protein Kinase Kinase Kinase 4 | EC 2.7.11.25 | MAP Three Kinase 1 | MAP/ERK Kinase Kinase 4 | MAP3K4 | MAPK/ERK Kinase Kinase 4 | MEK Kinase 4 | MEKK 4 | Predicted Protein of HQ0412",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550766","Oncolytic Vaccinia Virus TG6002","C148178","A modified, replicative oncolytic vaccinia virus (VV), deleted of the genes for tyrosine kinase (TK) and ribonucleotide reductase (RR), and expressing the yeast-originated, bifunctional cytosine deaminase/uracil phosphoribosyltransferase gene (FCU1), with potential immunomodulating and antineoplastic activities. Upon intravenous administration of the oncolytic vaccinia virus TG6002, the virus preferentially targets and infects tumor cells, causing oncolysis. In turn, the lysed tumor cells release various tumor-associated antigens (TAAs), which induce an immune response against the tumor cells. Upon concomitant administration of the non-cytotoxic prodrug flucytosine (5-fluorocytosine; 5-FC), the FCU1 expressed in the infected cancer cells produce the enzymes cytosine deaminase and uracil phosphoribosyltransferase which catalyze the conversion of 5-FC into the cytotoxic forms 5-fluorouracil (5-FU) and 5-fluoro-uridilyl monophosphate (5-FUMP); 5-FU and 5-FUMP exert a cytotoxic effect in the infected tumor cells. Double gene deletion (TK-RR-) restricts the propagation of TG6002 to the tumor cells, thereby reducing toxicity to normal cells.","Oncolytic Vaccinia Virus TG6002 | Oncolytic FCU1-expressing TK-RR-deleted Vaccinia Virus TG6002 | T 601 | T-601 | T601 | TG 6002 | TG-6002 | TG6002 | Vaccinia Virus TG6002",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550765","Licochalcone A","C148179","A derivative of the phenol chalconoid, found in and extracted from the roots of Glycyrrhiza species G. glabra and inflata, with potential anti-inflammatory, antibacterial, and anticancer activities. Upon administration, licochalcone A inhibits the phosphatidylinositol-3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway and inhibits the activity of c-Jun N-terminal kinase 1 (JNK-1), a member of the mitogen-activated protein kinase (MAPK) family that plays a role in the MAPK-mediated signaling pathway. Inhibition of the PI3K/Akt/mTOR- and MAPK-signaling pathways induces cell cycle arrest and apoptosis, decreases migration and invasion of cancer cells, and inhibits tumor cell proliferation. Licochalcone A also prevents the production of reactive oxygen species (ROS), and reduces oxidative stress through the nuclear factor-erythroid 2-related factor 2 (Nrf2) pathway.","Licochalcone A | 2-Propen-1-one, 3-(5-(1,1-Dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl)-1-(4-hydroxyphenyl)-, (E)- | 3-Dimethylallyl-4,4'-dihydroxy-6-methoxychalcone | LICOCHALCONE A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550768","PD-1 knockout EBV-specific Cytotoxic T Lymphocytes","C148180","A preparation of Epstein-Barr virus (EBV) reactive cytotoxic T-lymphocytes (CTLs) in which the programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1) gene is deleted, with potential immunomodulating activity. Upon administration of the PD-1 knockout EBV-specific CTLs, these CTLs target and induce selective toxicity in EBV-positive cancer cells. This results in cell lysis and inhibition of cancer cell proliferation. Expression of PD-1, an inhibitory receptor expressed on activated T-cells, plays a key role in CTL suppression, T-cell exhaustion and CTL apoptosis. PD-1 knockout abrogates T-cell exhaustion and increases T-cell activity and cytotoxicity. EBV, a ubiquitous human herpesvirus, is associated with various cancer cell types.","PD-1 knockout EBV-specific Cytotoxic T Lymphocytes | PD-1 knockout EBV-CTLs | PD-1 knockout EBV-reactive CTLs | PD-1 knockout Epstein-Barr Virus-Cytotoxic T-lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550767","ACH 4471","C148181","An orally bioavailable inhibitor of complement factor D (FD; CFD), a serine protease that cleaves complement factor B, with potential complement system inhibiting activity. Upon administration, danicopan targets, binds to and blocks the activity of FD, and thereby inhibits cleavage of complement factor B into Ba and Bb in the alternative pathway of the complement cascade. This inhibits FD-mediated signaling and activation of the alternative complement pathway (ACP), blocks complement-mediated hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and prevents ACP-induced tissue damage. FD plays a key role in the activation of the ACP.","Danicopan | ACH 4471 | ACH-0144471 | ACH-4471 | ACH4471 | ALXN 2040 | ALXN-2040 | ALXN2040 | DANICOPAN | Factor D Inhibitor ACH-4471",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551008","Refractory Sinonasal Squamous Cell Carcinoma","C148401","Nasal cavity and paranasal sinus squamous cell carcinoma that does not respond to treatment.","Refractory Sinonasal Squamous Cell Carcinoma | Refractory Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553269","Bushen-Jianpi Decoction","C151930","A traditional Chinese medicine (TCM) that is used for Yin deficiency of the liver, kidney and spleen, with potential immunomodulating and antineoplastic activities. Bushen-Jianpi decoction (BSJPD; BJD) consists of various herbs, including, but not limited to, Radix Codonopsis (Dang Shen), Fructus Lycii (the fruit of Chinese wolfberry), Rhizoma Atractylodis Macrocephalae (Baishu; Bai Zhu), Fructus Ligustri Lucidi, Cuscuta chinensis (Chinese dodder) seed, and Psoralea corylifolia Linn. As a TCM, Bushen-Jianpi is used as an antineoplastic agent as it is thought to invigorate the spleen and tonify the kidney, which presumably prevents or treats a variety of cancers. Upon administration of Bushen-Jianpi decoction, the ingredients in the decoction may affect signaling pathways involved in carcinogenesis and enhance the immune system by increasing the levels of numerous cytokines and a variety of immune cells, such as cytotoxic T-lymphocytes (CTLs), natural killer cells (NKs) and macrophages. It may also reduce the expression of various proteins involved in tumorigenesis.","Bushen-Jianpi Decoction | BJD | BJHD | BSJPD | JPBS | Jianpi Bushen | Jianpi Bushen Decoction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553303","NHP2 wt Allele","C152095","Human NHP2 wild-type allele is located in the vicinity of 5q35.3 and is approximately 5 kb in length. This allele, which encodes H/ACA ribonucleoprotein complex subunit 2 protein, plays a role in both ribosome biogenesis and telomere maintenance. Mutation of the gene is associated with autosomal recessive dyskeratosis congenita type 2.","NHP2 wt Allele | DKCB2 | FLJ20479 | HSPC286 | NHP2 Ribonucleoprotein Homolog (Yeast) Gene | NHP2 Ribonucleoprotein wt Allele | NHP2, S. cerevisiae, Homolog of Gene | NHP2P | NOLA2 | Nucleolar Protein Family A, Member 2 (H/ACA Small Nucleolar RNPs) Gene | Nucleolar Protein Family A, Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553304","NHP2 protein, human","C152096","H/ACA ribonucleoprotein complex subunit 2 (153 aa, ~17 kDa) is encoded by the human NHP2 gene. This protein is involved in both ribosome stability and telomere maintenance.","H/ACA Ribonucleoprotein Complex Subunit 2 | NHP2 | NHP2 Ribonucleoprotein Homolog | NHP2-Like Protein | Nucleolar Protein Family A Member 2 | SnoRNP Protein NHP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553306","CTC1 Gene","C152098","This gene plays a role in telomere replication.","CTC1 Gene | CST Telomere Replication Complex Component 1 Gene | CTC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553307","CTC1 wt Allele","C152099","Human CTC1 wild-type allele is located in the vicinity of 17p13.1 and is approximately 23 kb in length. This allele, which encodes CST complex subunit CTC1 protein, is involved in the replication of telomeric DNA. Mutation of the gene is associated with cerebroretinal microangiopathy with calcifications and cysts.","CTC1 wt Allele | AAF-132 | AAF132 | C17orf68 | CRMCC | CST Telomere Replication Complex Component 1 wt Allele | Chromosome 17 Open Reading Frame 68 Gene | FLJ22170 | tmp494178",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0244823","Teloxantrone","C1520","An anthrapyrazole antineoplastic antibiotic. Teloxantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair, as well as RNA and protein synthesis.","Teloxantrone | Anthra(1,9-cd)pyrazol-6(2H)-one,7,10-dihydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)-5-((2-(methylamino)ethyl)amino)- | CI-937 | Moxantrazole | TELOXANTRONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553308","Ctc1 protein, human","C152100","CST complex subunit CTC1 (1217 aa, ~135 kDa) is encoded by the human CTC1 gene. This protein plays a role in the regulation of telomeric DNA replication.","CST Complex Subunit CTC1 | Alpha Accessory Factor 132 | Alpha Accessory Factor, 132-kD Subunit | CST Telomere Maintenance Complex Component 1 | CST Telomere Replication Complex Component 1 | CTC1 | CTS Telomere Maintenance Complex Component 1 | Conserved Telomere Capping Protein 1 | Conserved Telomere Maintenance Component 1 | HBV DNAPTP1-Transactivated Protein B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553309","PARN Gene","C152101","This gene is involved in exonucleolytic degradation of mRNA poly(A) tails and maturation of the telomerase RNA component (TERC).","PARN Gene | PARN | Poly(A)-Specific Ribonuclease Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553130","NCCN-FACT FBRSI-24 Version 2 - I Am Losing Weight","C151285","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I am losing weight.","NCCN-FACT FBRSI-24 Version 2 - I Am Losing Weight | FAC030-I Am Losing Weight | FAC03006",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553131","NCCN-FACT FBRSI-24 Version 2 - Trouble Meeting Needs of Family","C151286","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) Because of my physical condition, I have trouble meeting the needs of my family.","NCCN-FACT FBRSI-24 Version 2 - Trouble Meeting Needs of Family | FAC030-Trouble Meeting Needs of Family | FAC03007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553132","NCCN-FACT FBRSI-24 Version 2 - Difficulty Expressing My Thoughts","C151287","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I have difficulty expressing my thoughts.","NCCN-FACT FBRSI-24 Version 2 - Difficulty Expressing My Thoughts | FAC030-Difficulty Expressing My Thoughts | FAC03008",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553133","NCCN-FACT FBRSI-24 Version 2 - I Am Sleeping Well","C151288","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I am sleeping well.","NCCN-FACT FBRSI-24 Version 2 - I Am Sleeping Well | FAC030-I Am Sleeping Well | FAC03009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553135","NCCN-FACT FBRSI-24 Version 2 - I Can Remember New Things","C151290","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I can remember new things.","NCCN-FACT FBRSI-24 Version 2 - I Can Remember New Things | FAC030-I Can Remember New Things | FAC03011",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553136","NCCN-FACT FBRSI-24 Version 2 - Able to Find the Right Words","C151291","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I am able to find the right word(s) to say what I mean.","NCCN-FACT FBRSI-24 Version 2 - Able to Find the Right Words | FAC030-Able to Find the Right Words | FAC03012",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553137","NCCN-FACT FBRSI-24 Version 2 - Bothered by Change in Personality","C151292","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I am bothered by the change in my personality.","NCCN-FACT FBRSI-24 Version 2 - Bothered by Change in Personality | FAC030-Bothered by Change in Personality | FAC03013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553138","NCCN-FACT FBRSI-24 Version 2 - Worry My Condition Will Get Worse","C151293","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I worry that my condition will get worse.","NCCN-FACT FBRSI-24 Version 2 - Worry My Condition Will Get Worse | FAC030-Worry My Condition Will Get Worse | FAC03014",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553139","NCCN-FACT FBRSI-24 Version 2 - I Am Afraid of Having a Seizure","C151294","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I am afraid of having a seizure (convulsion).","NCCN-FACT FBRSI-24 Version 2 - I Am Afraid of Having a Seizure | FAC030-I Am Afraid of Having a Seizure | FAC03015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553180","Glyco-engineered Anti-CD20 Monoclonal Antibody CHO H01","C151952","A glyco-engineered monoclonal antibody directed against the human B-cell-specific cell surface antigen CD20, with potential antineoplastic and immunomodulating activities. Upon administration of glyco-engineered anti-CD20 monoclonal antibody CHO H01, the antibody specifically targets and binds to CD20. This induces antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B-cells, which leads to B-cell apoptosis and the inhibition of tumor cell proliferation. In addition, CHO H01 inhibits CD20-mediated signaling which further induces apoptosis in and inhibits proliferation of CD20-expressing tumor cells. CD20, a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B-cells during most stages of B-cell development, is often overexpressed in B-cell malignancies. The Fc-glycans are homogenously engineered onto the antibody and increase ADCC, anti-tumor activity and the half-life of the antibody.","Glyco-engineered Anti-CD20 Monoclonal Antibody CHO H01 | CHO H01 | CHO-H01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1421307","UBTF Gene","C147961","This gene is involved in the transcription of ribosomal RNA genes.","UBTF Gene | UBTF | Upstream Binding Transcription Factor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545764","UBTF wt Allele","C147962","Human UBTF wild-type allele is located in the vicinity of 17q21.31 and is approximately 17 kb in length. This allele, which encodes nucleolar transcription factor 1 protein, plays a role in ribosomal RNA synthesis. Mutation of the gene is associated with childhood-onset neurodegeneration with brain atrophy (CONDBA).","UBTF wt Allele | CONDBA | NOR-90 | UBF | UBF-1 | UBF1 | UBF2 | Upstream Binding Factor Gene | Upstream Binding Transcription Factor (RNA Polymerase I) Gene | Upstream Binding Transcription Factor wt Allele | Upstream Binding Transcription Factor, RNA Polymerase I Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551136","Ningetinib Tosylate","C148529","The tosylate salt form of ningetinib, an orally available inhibitor of the receptor tyrosine kinases c-MET/hepatocyte growth factor receptor (HGFR), vascular endothelial growth factor receptor 2 (VEGFR2 KDR), Axl (UFO), Mer, and Fms-like tyrosine kinase 3 (Flt3; CD135; STK1; FLK2), with antineoplastic activity. Upon administration, ningetinib binds to a variety of kinases, including c-Met, VEGFR2, Axl, Mer and Flt3, thereby inhibiting their signaling pathways. This inhibits growth, angiogenesis and metastasis of tumor cells that overexpress these kinases. c-Met, VEGFR2, Axl, Mer and Flt3 are overexpressed by many tumor cell types and play key roles in tumor cell proliferation, survival, invasion and metastasis.","Ningetinib Tosylate | CT-053 Tosylate | CT-053-PTSA | CT-053PTSA | NINGETINIB TOSYLATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551135","CD33-specific CAR Lentiviral Vector-transduced Autologous T-lymphocytes","C148530","Autologous T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) specific for the CD33 antigen, with potential immunomodulating and antineoplastic activities. Upon transfusion, CD33-specific CAR lentiviral vector-transduced autologous T-lymphocytes target and induce selective toxicity in CD33-expressing tumor cells. CD33 is expressed on normal non-pluripotent hematopoietic stem cells and on myeloid leukemia cells.","CD33-specific CAR Lentiviral Vector-transduced Autologous T-lymphocytes | Autologous Anti-CD33 CAR-T Cells | Autologous Anti-CD33 Chimeric Antigen Receptor T Cells | Autologous CD33-CAR-T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551138","Paclitaxel Polymeric Micelle Formulation NANT-008","C148531","A nanoparticle-based formulation consisting of polymeric micelles encapsulating the taxane paclitaxel, with potential antineoplastic activity. Paclitaxel is covalently bound to polyethylene glycol (PEG)-based block copolymers which forms a micellar structure with an outer hydrophilic PEG shell surrounding the hydrophobic paclitaxel. Upon administration of the paclitaxel polymeric micelle formulation NANT-008, the nanoparticles are stable in the bloodstream and specifically accumulate in the tumor tissue. Due to the acidic conditions in the tumor and the pH-responsive nature of the micelles, paclitaxel is released in the tumor environment. Paclitaxel binds to microtubules, promotes microtubule assembly, and prevents depolymerization, thus interfering with normal mitosis. Compared to the administration of paclitaxel alone, this formulation increases the solubility of paclitaxel, enhances its specific retention in cancer tissue, and increases its therapeutic effect, while decreasing its toxicity. In addition, the micellar formulation allows the delivery of higher doses of paclitaxel to target tissues while minimizing systemic toxicity.","Paclitaxel Polymeric Micelle Formulation NANT-008 | Cynviloq | Genexol-PM | IG-001 | Micellar Nanoparticle-encapsulated NANT-008 | NANT 008 | NANT-008 | NANT008 | Nant-paclitaxel | Paclitaxel-loaded Micellar Diblock Copolymer NANT-008 | Paclitaxel-loaded Polymeric Micelle NANT-008",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551001","Nebulizer Dosage Form","C148409","No value exists.","Nebulizer Dosage Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545832","RPLP0 wt Allele","C148008","Human RPLP0 wild-type allele is located in the vicinity of 12q24.23 and is approximately 5 kb in length. This allele, which encodes 60S acidic ribosomal protein P0, is involved in the structure of the ribosome.","RPLP0 wt Allele | L10E | LP0 | P0 | PRLP0 | RPP0 | Ribosomal Phosphoprotein, Acidic, P0 Gene | Ribosomal Phosphoprotein, Large, P0 Gene | Ribosomal Protein Lateral Stalk Subunit P0 wt Allele | Ribosomal Protein, Large, P0 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545833","60S Acidic Ribosomal Protein P0","C148009","60S acidic ribosomal protein P0 (317 aa, ~34 kDa) is encoded by the human RPLP0 gene. This protein plays a role in ribosome structure.","60S Acidic Ribosomal Protein P0 | 60S Ribosomal Protein L10E | Acidic Ribosomal Phosphoprotein P0 | Large Ribosomal Subunit Protein uL10 | Neutral Ribosomal Phosphoprotein P0 | RPLP0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553310","PARN wt Allele","C152102","Human PARN wild-type allele is located in the vicinity of 16p13.12 and is approximately 197 kb in length. This allele, which encodes poly(A)-specific ribonuclease PARN protein, plays a role in the positive regulation of mRNA decay and telomere synthesis. Mutation of the gene is associated with telomere-related pulmonary fibrosis and/or bone marrow failure type 4 and autosomal recessive dyskeratosis congenita type 6.","PARN wt Allele | DAN | DKCB6 | Deadenylation Nuclease Gene | PFBMFT4 | Poly(A)-Specific Ribonuclease (Deadenylation Nuclease) Gene | Poly(A)-Specific Ribonuclease wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553313","Antihemophilic Factor, Pegylated (MW 20000) Human Sequence Recombinant","C152106","No value exists.","Antihemophilic Factor, Pegylated (MW 20000) Human Sequence Recombinant | ANTIHEMOPHILIC FACTOR, PEGYLATED (MW 20000) HUMAN SEQUENCE RECOMBINANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553714","Tanzisertib","C152510","No value exists.","Tanzisertib | TANZISERTIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3491918","benvitimod","C152511","No value exists.","Tapinarof | TAPINAROF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553716","Taprenepag","C152512","No value exists.","Taprenepag | TAPRENEPAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553717","Taprenepag Isopropyl","C152513","No value exists.","Taprenepag Isopropyl | TAPRENEPAG ISOPROPYL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553718","Tarloxotinib Bromide","C152514","No value exists.","Tarloxotinib Bromide | TARLOXOTINIB BROMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1313052","Tasimelteon","C152515","No value exists.","Tasimelteon | TASIMELTEON",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553848","Tasipimidine","C152516","No value exists.","Tasipimidine | TASIPIMIDINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553850","taspoglutide","C152518","No value exists.","Taspoglutide | TASPOGLUTIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553851","Tauroselcholic Acid","C152519","No value exists.","Tauroselcholic Acid | TAUROSELCHOLIC ACID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019930","Postmenopausal Hormone Replacement Therapy","C15251","No value exists.","Postmenopausal Hormone Replacement Therapy | ",,,,,,,,,,,,,,,"37110086","Postmenopausal hormone replacement therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL553852","Tazadolene","C152520","No value exists.","Tazadolene | TAZADOLENE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553854","Tebufelone","C152522","No value exists.","Tebufelone | TEBUFELONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553855","tecarfarin","C152523","No value exists.","Tecarfarin | TECARFARIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553856","Tecarfarin Sodium","C152524","No value exists.","Tecarfarin Sodium | TECARFARIN SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553857","Technetium Tc-99M Etarfolatide","C152525","No value exists.","Technetium Tc-99M Etarfolatide | TECHNETIUM TC-99M ETARFOLATIDE | Technetium (99MTc) Etarfolatide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553859","Technetium Tc-99M Furifosmin","C152527","No value exists.","Technetium Tc-99M Furifosmin | TECHNETIUM TC-99M FURIFOSMIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553860","Technetium Tc-99M Medronate Disodium","C152528","No value exists.","Technetium Tc-99M Medronate Disodium | TECHNETIUM TC-99M MEDRONATE DISODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL601355","HDC SN-38","C151953","A miniature drug conjugate composed of the irinotecan metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) conjugated, through a cleavable linker, to a ligand of chaperone protein heat shock protein 90 (Hsp90), with potential antineoplastic activity. Upon administration of locnartecan, the HSP90 ligand moiety targets HSP90, which allows the conjugate to penetrate, accumulate and be retained in the tumor cell. Once the linker is cleaved, the SN-38 moiety is released in a sustained manner. SN-38 then binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, which results in DNA breaks, inhibition of DNA replication and apoptosis. Compared to SN-38 alone, locnartecan preferentially targets, accumulates  and is retained in the tumor cells due to its binding to Hsp90, which results in increased concentrations of SN-38 at the tumor site. This allows sustained release of SN-38 and leads to increased and prolonged efficacy while reducing toxicity to normal, healthy tissues. Hsp90, a chaperone protein upregulated and activated in a variety of tumor cells compared to normal healthy tissue, regulates the folding, stability and degradation of many oncogenic signaling proteins.","Locnartecan | HDC SN-38 | HSP90-targeted SN-38 Conjugate PEN-866 | LOCNARTECAN | PEN 866 | PEN-866 | PEN866 | STA-12-8666 | STA-8666",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553182","Autologous Anti-Muc1/CD33/CD38/CD56/CD123 Gene-engineered CAR-T Cells","C151954","A preparation of genetically modified autologous T-cells transduced with lentiviral vectors expressing chimeric antigen receptors (CARs) specific for the tumor-associated antigens (TAAs) mucin 1 (Muc1; MUC1), cluster of differentiation 33 (CD33), CD38, CD56 and CD123 (interleukin-3 receptor alpha chain or IL3RA), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous anti-Muc1/CD33/CD38/CD56/CD123 gene-engineered CAR-T cells are directed to and induce selective toxicity in Muc1/CD33/CD38/CD56/CD123-expressing tumor cells. Muc1/CD33/CD38/CD56/CD123 are present on certain tumor cell types and are minimally expressed on normal, healthy cells. Expression of these TAAs are correlated with poor prognosis. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules included in the CARs, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.","Autologous Anti-Muc1/CD33/CD38/CD56/CD123 Gene-engineered CAR-T Cells | Autologous Muc1/CD33/CD38/CD56/CD123-specific Gene-engineered CAR-T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553183","AJT-240","C151955","The sodium hydrate form of upacicalcet, an agonist of calcium-sensing receptors (CaSR), with potential use in the treatment of secondary hyperparathyroidism (SHPT). Upon administration, upacicalcet targets and binds to CaSRs expressed on the membranes of cells in the parathyroid glands, which suppresses osteoclast activity and reduces the excessive secretion of parathyroid hormone (PTH). This prevents the excessive PTH-mediated efflux of phosphorus and calcium from bone into the blood and normalizes serum calcium and phosphorus levels. Upacicalcet may decrease the risk of bone fracture, may lower depositions of phosphorus and calcium salts in non-bone tissues, may reduce bone and joint pain and may slow the progression of other diseases related to increased levels of PTH. CaSR controls calcium homeostasis and regulates the release of PTH.","Upacicalcet Sodium Hydrate | AJT-240 | AJT240 | CaSR Agonist SK 1403 | Calcium-sensing Receptor Agonist SK 1403 | Calcium-sensing Receptor Agonist SK 1403 | PLS 240 | PLS-240 | PLS240 | SK1403 | UPACICALCET SODIUM HYDRATE | UPASITA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553184","HPV16-E6-T27","C151956","A transcription activator-like effector nucleases (TALEN)-edited plasmid targeting the human papillomavirus (HPV) type 16 (HPV16) epitope E6, with potential antineoplastic activity. Upon administration of TALEN-edited HPV16 E6 T27, the TALEN targets and binds to a specific site on genomic HPV16 E6 and cleaves the DNA sequences encoding E6. This causes double-strand DNA (dsDNA) breaks within the viral DNA, which prevents the transcription and translation of E6. Inhibition of E6 expression restores and increases the expression of tumor suppressor genes, such as p53, and proapoptotic protein BAK, and promotes downstream signaling. Altogether, TALEN-based HPV editing increases apoptosis, reduces viral replication and viral load, eliminates HPV and inhibits tumor cell proliferation of HPV-driven cancer cells. HPV16 E6 is an oncogene vital to viral function and HPV infection, and promotes carcinogenesis.","HPV16-E6-T27 | HPV16-targeting TALEN T27 | T27",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553185","Transformed Non-Hodgkin Lymphoma","C151957","Histologic transformation of a usually indolent non-Hodgkin lymphoma to an aggressive non-Hodgkin lymphoma.","Transformed Non-Hodgkin Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553519","Remimazolam","C152187","A short-acting benzodiazepine derivative that is structurally related to midazolam, with sedative-hypnotic activity. Upon administration, remimazolam targets and binds to a specific site on the gamma-aminobutyric acid (GABA)-A-chloride ionophore receptor complex located on the neuronal membrane. Binding causes an allosteric modification of the receptor thereby enhancing the affinity of GABA to the receptor leading to an increase in the frequency of chloride-channel opening events, which leads to an increase in chloride ion conductance, neuronal hyperpolarization, inhibition of the action potential, and a decrease in neuronal excitability.","Remimazolam | CNS 7056 | CNS-7056 | CNS7056 | REMIMAZOLAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553520","Remiprostol","C152188","No value exists.","Remiprostol | REMIPROSTOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553521","Remtolumab","C152189","No value exists.","Remtolumab | REMTOLUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551137","HMPL 689","C148532","An orally bioavailable selective inhibitor of the delta isoform of phosphatidylinositide 3-kinase (phosphoinositide 3'-kinase delta; PI3Kd; PI3K-d), with potential antineoplastic activity. Upon oral administration, amdizalisib selectively binds to and inhibits PI3Kd, and prevents the activation of the PI3Kd/AKT signaling pathway, and B-cell activation. This both decreases proliferation and induces cell death in PI3Kd-overexpressing tumor cells. PI3Kd plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of hematologic cancer cells. The targeted inhibition of PI3Kd is designed to preserve PI3K signaling in normal, non-neoplastic cells and thereby to minimize serious side effects. PI3Kd, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.","Amdizalisib | AMDIZALISIB | HMPL 689 | HMPL-689 | HMPL689 | PI3K-d Inhibitor HMPL 689 | PI3K-delta Inhibitor HMPL 689",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551132","ALK Inhibitor PLB 1003","C148533","An orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon oral administration, PLB1003 selectively binds to and inhibits wild-type ALK, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to the disruption of ALK-mediated signaling and inhibits tumor cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors. ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors.","ALK Inhibitor PLB 1003 | PLB 1003 | PLB-1003 | PLB1003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550792","Autologous CD19CAR-CD28-CD137/CD27/CD3zeta-iCasp9-expressing T-lymphocytes","C148156","Autologous T-lymphocytes that have been transduced with a fourth generation-lentiviral vector to express the 4SCAR19 gene composed of a chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) of anti-CD19 coupled to the co-stimulatory molecules CD28, 4-1BB (CD137), and CD27, and to the cytoplasmic portion of the zeta chain of the human T-cell receptor (CD3zeta), and containing the apoptosis-inducible suicide gene human caspase 9 (iCASP9 or iC9), that is linked to a drug binding domain, with potential immunostimulating and antineoplastic activities. The iCASP9 construct consists of the entire coding sequence for the human FK506-drug binding protein (FKBP12) with an F36V mutation (FKBP12-F36V) that is linked to the gene encoding iC9, which is a modified form of the CASP9 gene where the sequences encoding the endogenous caspase activation and recruitment domains have been deleted. Upon transfusion, anti-CD19-CAR-CD28/CD137/CD27/CD3zeta-iCasp9-expressing autologous T-lymphocytes target and bind to CD19-expressing neoplastic B-cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells, and causes tumor cell lysis. If the administered T-cells cause unacceptable side effects, the chemical homodimerizer AP1903, which binds to the FKBP12-F36V drug-binding domain, can be administered; this induces caspase 9 expression, and results in apoptosis of the administered 4SCAR19 T-cells. CD19, cluster of differentiation 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. Incorporation of the costimulatory signaling domains increases human T-cell function, expansion, and survival.","Autologous CD19CAR-CD28-CD137/CD27/CD3zeta-iCasp9-expressing T-lymphocytes | 4S-CAR-T19 | 4SCAR19 | 4SCAR19 Cells | Autologous Anti-CD19 CAR-T cells 4SCAR19 | Autologous CD19- scFv/CD28/CD137/CD27/CD3z-iCasp9 4SCAR-19 T-cells | Autologous CD19-scFv/CD28/CD137/CD27/CD3z-iCasp9 CAR-T-cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550791","HDAC Inhibitor CKD-581",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550785","CBT 501","C148159","An immunoglobulin G4 (IgG4) humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PD1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, geptanolimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","Geptanolimab | APL-501 | CBT 501 | CBT-501 | CBT501 | GB-226 | GEPTANOLIMAB | Genolimzumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545815","Sleep-Disordered Breathing","C148023","A group of breathing disorders characterized by abnormal respiratory patterns or insufficient ventilation during sleep.","Sleep-Disordered Breathing | Breathing-related sleep disorder | SDB | Sleep Disordered Breathing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545816","BRCA-Associated Ovarian Carcinoma","C148024","Hereditary ovarian carcinoma caused by deleterious germline mutation in a gene of the BRCA family.","BRCA Hereditary Ovarian Carcinoma | BRCA Familial Ovarian Cancer | BRCA Familial Ovarian Carcinoma | BRCA Hereditary Ovarian Cancer | BRCA-Associated Ovarian Carcinoma | BRCA-Associated Ovarian Carcinoma | BRCA-Mutated Ovarian Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545817","Recurrent BRCA-Mutated Ovarian Cancer","C148025","The reemergence of BRCA hereditary ovarian carcinoma after a period of remission.","Recurrent BRCA Hereditary Ovarian Carcinoma | Recurrent BRCA Familial Ovarian Cancer | Recurrent BRCA Familial Ovarian Carcinoma | Recurrent BRCA Hereditary Ovarian Cancer | Recurrent BRCA- Associated Ovarian Carcinoma | Recurrent BRCA- Associated Ovarian Carcinoma | Recurrent BRCA-Mutated Ovarian Cancer | Recurrent BRCA-Mutated Ovarian Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553861","Technetium Tc-99M Nitridocade","C152529","No value exists.","Technetium Tc-99M Nitridocade | TECHNETIUM TC-99M NITRIDOCADE | Technetium (99mTc) Nitridocade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553862","Technetium Tc-99M Pentetate Calcium Trisodium","C152530","No value exists.","Technetium Tc-99M Pentetate Calcium Trisodium | TECHNETIUM TC-99M PENTETATE CALCIUM TRISODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553863","Technetium Tc-99M Siboroxime","C152531","No value exists.","Technetium Tc-99M Siboroxime | TECHNETIUM TC-99M SIBOROXIME | Technetium (99mTc) Siboroxime",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553864","Technetium Tc-99M Trofolastat Chloride","C152532","No value exists.","Technetium Tc-99M Trofolastat Chloride | TECHNETIUM TC-99M TROFOLASTAT CHLORIDE | Technetium (99mTc) Trofolastat Chloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553866","Tedalinab","C152534","No value exists.","Tedalinab | TEDALINAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553867","Tedatioxetine","C152535","No value exists.","Tedatioxetine | TEDATIOXETINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553868","Tedatioxetine Hydrobromide","C152536","No value exists.","Tedatioxetine Hydrobromide | TEDATIOXETINE HYDROBROMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554268","Xylamidine Tosylate Anhydrous","C152937","No value exists.","Xylamidine Tosylate Anhydrous | XYLAMIDINE TOSYLATE ANHYDROUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554269","Yttrium Y-90 Epratuzumab","C152938","No value exists.","Yttrium Y-90 Epratuzumab | YTTRIUM Y-90 EPRATUZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554270","Yttrium Y-90 Labetuzumab","C152939","No value exists.","Yttrium Y-90 Labetuzumab | YTTRIUM Y-90 LABETUZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554271","Yttrium Y-90 Labetuzumab Tetraxetan","C152940","No value exists.","Yttrium Y-90 Labetuzumab Tetraxetan | YTTRIUM Y-90 LABETUZUMAB TETRAXETAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554272","Yttrium Y-90 Tacatuzumab","C152941","No value exists.","Yttrium Y-90 Tacatuzumab | YTTRIUM Y-90 TACATUZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554273","Zacopride","C152942","No value exists.","Zacopride | ZACOPRIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554274","Zacopride Hydrochloride","C152943","No value exists.","Zacopride Hydrochloride | ZACOPRIDE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554275","Zalospirone","C152944","No value exists.","Zalospirone | ZALOSPIRONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554277","Zaltidine Hydrochloride","C152946","No value exists.","Zaltidine Hydrochloride | ZALTIDINE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554278","Zamicastat","C152947","No value exists.","Zamicastat | ZAMICASTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0010705","Cystostomy","C15218","Surgical creation of an external opening into the anterior bladder wall.","Cystostomy | Vesicostomy",,,,,,,,,,,,,,,"4221381","Incision of bladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL553522","Renapersen","C152190","No value exists.","Renapersen | RENADIRSEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553523","Renzapride","C152191","No value exists.","Renzapride | RENZAPRIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553524","Repifermin","C152192","No value exists.","Repifermin | REPIFERMIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553525","Repromicin","C152193","No value exists.","Repromicin | REPROMICIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553526","Reproterol","C152194","No value exists.","Reproterol | REPROTEROL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0771023","reproterol hydrochloride","C152195","No value exists.","Reproterol Hydrochloride | REPROTEROL HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553400","Reproxalap","C152196","No value exists.","Reproxalap | REPROXALAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553401","Reslizumab","C152197","No value exists.","Reslizumab | RESLIZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553402","Resocortol","C152198","No value exists.","Resocortol | RESOCORTOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553403","Resocortol Butyrate","C152199","No value exists.","Resocortol Butyrate | RESOCORTOL BUTYRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553404","Revefenacin","C152200","No value exists.","Revefenacin | REVEFENACIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553405","Reveglucosidase Alfa","C152201","No value exists.","Reveglucosidase Alfa | REVEGLUCOSIDASE ALFA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553406","Revexepride","C152202","No value exists.","Revexepride | REVEXEPRIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553407","Reviparin Sodium","C152203","No value exists.","Reviparin Sodium | REVIPARIN SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553408","Revusiran","C152204","No value exists.","Revusiran | REVUSIRAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553409","Rezafungin","C152205","A next-generation, semi-synthetic, cyclic lipopeptide and echinocandin derivative, with potential antifungal activity. Upon administration, rezafungin inhibits the fungal specific enzyme 1,3-beta-D-glucan synthase, which is essential for fungal cell wall synthesis, and results in decreased synthesis of beta(1,3)-D-glucan. This weakens the fungal cell wall thereby causing osmotic lysis, fungal cell wall rupture and fungal cell death.","Rezafungin | REZAFUNGIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553410","Rezafungin Acetate","C152206","The acetate form of rezafungin, a next-generation, semi-synthetic, cyclic lipopeptide and echinocandin derivative, with potential antifungal activity. Upon administration, rezafungin inhibits the fungal specific enzyme 1,3-beta-D-glucan synthase, which is essential for fungal cell wall synthesis, and results in decreased synthesis of beta(1,3)-D-glucan. This weakens the fungal cell wall thereby causing osmotic lysis, fungal cell wall rupture and fungal cell death.","Rezafungin Acetate | REZAFUNGIN ACETATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553411","Rezatomidine","C152207","No value exists.","Rezatomidine | REZATOMIDINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553412","Riamilovir","C152208","A synthetic guanine derivative, with potential broad-spectrum antiviral activity. Upon administration, riamilovir inhibits viral RNA synthesis, thereby preventing viral transcription and replication. Riamilovir may also bind to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and human angiotensin-converting enzyme 2 (ACE2). This may block the entry of SARS-CoV-2 into human host cells.","Riamilovir | RIAMILOVIR | TZV | Triazavirin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553413","Ribaxamase","C152209","An orally administered recombinant beta-lactamase that can be used to protect the gut microbiome from disruption caused by intravenous (IV) administered beta-lactam antibiotics. Upon administration, ribaxamase hydrolyzes the beta-lactam ring of susceptible antibiotics that were administered intravenously and are excreted into the intestines. This degrades the beta-lactam antibiotic, may prevent antibiotic-mediated damage in the gastrointestinal (GI) tract and may protect the gut microbiome. This may also prevent the overgrowth and associated infection with Clostridioides difficile and antibiotic-associated diarrhea. Ribaxamase is not systemically absorbed and does not interfere with the efficacy of IV beta-lactam antibiotics.","Ribaxamase | RIBAXAMASE | SYN 004 | SYN-004 | SYN004",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550788","Autologous Mesothelin-specific CAR-T Cells","C148160","Genetically modified, autologous T-lymphocytes transduced with a gene encoding a chimeric antigen receptor (CAR) specific for the human tumor-associated antigen (TAA) mesothelin, with potential immunomodulating and antineoplastic activities. After isolation, transduction, expansion in culture, and reintroduction into the patient, the autologous mesothelin-specific CAR-T cells specifically target and kill mesothelin-expressing tumor cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types.","Autologous Mesothelin-specific CAR-T Cells | Autologous CART-meso | Hu-CART Meso Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550787","Carbon C 14 Pevonedistat","C148161","An orally bioavailable radioconjugate composed of pevonedistat, a small molecule inhibitor of NEDD8-activating enzyme (NAE), radiolabeled with the radioisotope carbon C 14, with potential use for evaluating the pharmacokinetic profile of pevonedistat. Pevonedistat binds to and inhibits NAE, which results in the inhibition of tumor cell proliferation and survival. Labeling of pevonedistat with the radioactive tracer carbon C 14 allows for the evaluation of pevonedistat's pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME).","Carbon C 14 Pevonedistat | Carbon C 14-pevonedistat | [14 C]-pevonedistat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550782","Rituximab Conjugate CON-4619","C148162","A proprietary conjugate of rituximab, a recombinant chimeric murine/human antibody directed against the CD20 antigen, with potential antineoplastic activity. Upon administration of the rituximab conjugate CON-4619, the rituximab moiety targets and binds to CD20, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells.","Rituximab Conjugate CON-4619 | Aurixim | Aurixim Antibody Conjugate | CON-4619",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550956","GDF11 wt Allele","C148354","Human GDF11 wild-type allele is located in the vicinity of 12q13.2 and is approximately 14 kb in length. This allele, which encodes growth/differentiation factor 11 protein, is involved in embryological pattern formation during development.","GDF11 wt Allele | BMP-11 | BMP11 | Bone Morphogenetic Protein 11 Gene | Growth Differentiation Factor 11 wt Allele | VHO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1453137","GDF11 protein, human","C148355","Growth/differentiation factor 11 (407 aa, ~45 kDa) is encoded by the human GDF11 gene. This protein plays a role in patterning of mesodermal, neural and skeletal tissues during development.","Growth/Differentiation Factor 11 | BMP-11 | Bone Morphogenetic Protein 11 | Bone Morphogenetic Protein-11 | GDF-11 | GDF11 | Growth/Differentiation Factor-11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550950","KDM4C Gene","C148356","This gene is involved in histone H3 demethylation.","KDM4C Gene | KDM4C | Lysine Demethylase 4C Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550952","KDM4C protein, human","C148358","Lysine-specific demethylase 4C (1056 aa, ~120 kDa) is encoded by the human KDM4C gene. This protein is involved in the demethylation of trimethylated lysine-9 and -36 in histone H3.","Lysine-Specific Demethylase 4C | EC 1.14.11.- | GASC-1 Protein | Gene Amplified In Squamous Cell Carcinoma 1 Protein | JmjC Domain-Containing Histone Demethylation Protein 3C | Jumonji Domain Containing 2C | Jumonji Domain-Containing Protein 2C | KDM4C | Lysine (K)-Specific Demethylase 4C | Lysine Demethylase 4C | Tudor Domain Containing 14C | [Histone H3]-Trimethyl-L-Lysine(9) Demethylase 4C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550951","PFKFB4 Gene","C148359","This gene plays a role in the metabolism of fructose-2,6-bisphosphate and ATP.","PFKFB4 Gene | 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 4 Gene | PFKFB4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550946","PFKFB4 wt Allele","C148360","Human PFKFB4 wild-type allele is located in the vicinity of 3p21.31 and is approximately 45 kb in length. This allele, which encodes 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 protein, is involved in the regulation of glycolysis. Expression of the gene by hypoxic cancer cells is essential to their survival.","PFKFB4 wt Allele | 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 4 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550945","6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 4","C148361","6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (469 aa, ~54 kDa) is encoded by the human PFKFB4 gene. This protein plays a role in the biosynthesis and catabolism of fructose-2,6-bisphosphate and ATP.","6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 4 | 6PF-2-K/Fru-2,6-P2ase 4 | 6PF-2-K/Fru-2,6-P2ase Testis-Type Isozyme | PFK/FBPase 4 | PFKFB4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551099","MPEG1 Gene","C148572","This gene may be involved in antimicrobial activity.","MPEG1 Gene | MPEG1 | Macrophage Expressed 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551094","MPEG1 wt Allele","C148573","Human MPEG1 wild-type allele is located in the vicinity of 11q12.1 and is approximately 5 kb in length. This allele, which encodes macrophage-expressed gene 1 protein, may play a role in perforin-like activity.","MPEG1 wt Allele | MPG1 | MPS1 | Macrophage Expressed 1 wt Allele | Macrophage Expressed Gene 1 | Mpg-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0295305","MPEG1 protein, human","C148574","Macrophage-expressed gene 1 protein (716 aa, ~79 kDa) is encoded by the human MPEG1 gene. This protein may be involved in host defense.","Macrophage-Expressed Gene 1 Protein | MPEG1 | Macrophage Gene 1 Protein | Mpg-1 | Perforin 2 | Perforin-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551207","ITPKB wt Allele","C148582","Human ITPKB wild-type allele is located in the vicinity of 1q42.12 and is approximately 108 kb in length. This allele, which encodes inositol-trisphosphate 3-kinase B protein, is involved in second messenger metabolism.","ITPKB wt Allele | IP3-3KB | IP3K | IP3K-B | IP3KB | Inositol-Trisphosphate 3-Kinase B wt Allele | PIG37",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554279","Zenocutuzumab","C152948","A full-length IgG1 bispecific antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) directed against human epidermal growth factor receptor 2 (HER2; EGFR2, ERBB2) and human epidermal growth factor receptor 3 (HER3; ErbB3), with potential antineoplastic activity. Upon intravenous administration of zenocutuzumab, the bispecific antibody docks on HER2, and subsequently blocks heregulin-stimulated proliferation of tumor cells by binding HER3. In addition to inhibiting HER3-dependent signaling, simultaneous targeting of HER2 and HER3 by zenocutuzumab may overcome a common resistance mechanism driven by heregulin-mediated dimerization of HER2 and HER3. Zenocutuzumab is expected to eliminate tumor cells by recruiting natural killer (NK) cells to tumor cells coated with the bispecific antibody.","Zenocutuzumab | Anti-HER2 x Anti-HER3 Bispecific Monoclonal Antibody MCLA-128 | Anti-HER2/Anti-HER3 Bispecific Monoclonal Antibody MCLA-128 | MCLA 128 | MCLA-128 | MCLA128 | ZENOCUTUZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554280","Zibrofusidic Acid","C152949","No value exists.","Zibrofusidic Acid | ZIBROFUSIDIC ACID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554281","Zicronapine","C152950","No value exists.","Zicronapine | ZICRONAPINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554282","Zicronapine Succinate","C152951","No value exists.","Zicronapine Succinate | ZICRONAPINE SUCCINATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554283","Zidebactam","C152952","No value exists.","Zidebactam | ZIDEBACTAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554284","Zilascorb (2H)","C152953","No value exists.","Zilascorb (2H) | ZILASCORB (2H)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554286","Zimeldine Hydrochloride","C152955","No value exists.","Zimeldine Hydrochloride | ZIMELDINE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554287","Zinc Acetate, Basic","C152956","No value exists.","Zinc Acetate, Basic | ZINC ACETATE, BASIC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554289","Zinterol","C152958","No value exists.","Zinterol | ZINTEROL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554290","Zinterol Hydrochloride","C152959","No value exists.","Zinterol Hydrochloride | ZINTEROL HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554292","Zoleprodolol","C152961","No value exists.","Zoleprodolol | ZOLEPRODOLOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554293","Zoliflodacin","C152962","No value exists.","Zoliflodacin | ZOLIFLODACIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553270","Anti-PRL-3 Monoclonal Antibody PRL3-zumab","C151931","A humanized monoclonal antibody against  phosphatase of regenerating liver 3 (PRL-3; PTP4A3), with potential immunomodulating and antineoplastic activities. Upon administration, anti-PRL-3 monoclonal antibody PRL3-zumab targets, binds to and blocks PRL-3 expressed on tumor cells. Although the exact mechanism of action through which this antibody kills tumor cells has yet to be fully elucidated, PRL3-zumab binds to PRL-3. This prevents PRL-3-mediated signaling in, inhibits the proliferation of and induces apoptosis in PRL-3-expressing tumor cells. PRL-3, a member of the PRL family of protein tyrosine kinases, is upregulated in a variety of tumor cells. Its expression is associated with increased invasiveness, higher metastatic potential, increased tumor cell survival and poor prognosis.","Anti-PRL-3 Monoclonal Antibody PRL3-zumab | PRL3 Zumab | PRL3-zumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553831","Tildrakizumab","C152627","A humanized monoclonal antibody directed against the p19 protein subunit of interleukin-23 (IL-23), with immunomodulating activity. Upon subcutaneous administration, tildrakizumab targets and binds to the p19 subunit of IL-23, thereby neutralizing IL-23 and preventing the binding of IL-23 to its receptor. This inhibits IL-23-mediated signaling and inhibits differentiation of CD4 positive T-cells into Th1 and Th17 cells. This prevents Th1- and Th17-mediated responses and cytokine production. This may prevent or reduce symptoms and severity of graft versus host disease (GVHD). IL-23, a pro-inflammatory cytokine that play a key role in the regulation of the immune system, is upregulated in immune-mediated inflammatory disorders. Both Th1 and Th17 cells play a crucial role in GVHD.","Tildrakizumab | Immunoglobulin G1, Anti-(Human Interleukin 23) (Human-Mus Musculus Monoclonal Heavy Chain), Disulfide with Human-Mus Musculus Monoclonal Light Chain, Dimer | Immunoglobulin G1, Anti-(Human Interleukin-23); Humanized Mouse Monoclonal Gamma1 Heavy Chain (219-214')-Disulfide with Humanized Mouse Monoclonal Kappa Light Chain Dimer (225-225'':228-228'')-Bisdisulfide | MK-3222 | TILDRAKIZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0040219","Tilidine","C152628","No value exists.","Tilidine | TILIDINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282365","Tilidine Hydrochloride","C152629","No value exists.","Tilidine Hydrochloride | TILIDINE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553834","Tilivapram","C152630","No value exists.","Tilivapram | TILIVAPRAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553835","Tilomisole","C152631","No value exists.","Tilomisole | TILOMISOLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553836","Tilsotolimod","C152632","A proprietary synthetic oligonucleotide-based agonist of toll-like receptor 9 (TLR9), with potential immunostimulating activity. Upon administration, tilsotolimod binds to and activates TLR9 expressed by plasmacytoid dendritic cells (pDCs) and B-cells. This initiates immune signaling pathways, activates B-cells and pDCs, and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.","Tilsotolimod | TILSOTOLIMOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553837","Timapiprant","C152633","No value exists.","Timapiprant | TIMAPIPRANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553838","Timefurone","C152634","No value exists.","Timefurone | TIMEFURONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553839","Timigutuzumab","C152635","No value exists.","Timigutuzumab | TIMIGUTUZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553840","Timobesone","C152636","No value exists.","Timobesone | TIMOBESONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553842","Tiodonium Chloride","C152638","No value exists.","Tiodonium Chloride | TIODONIUM CHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553843","Tiomergine","C152639","No value exists.","Tiomergine | TIOMERGINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553845","Tioperidone Hydrochloride","C152641","No value exists.","Tioperidone Hydrochloride | TIOPERIDONE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553846","Tiopinac","C152642","No value exists.","Tiopinac | TIOPINAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553847","Tiotidine","C152643","No value exists.","Tiotidine | TIOTIDINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553976","Tipentosin","C152644","No value exists.","Tipentosin | TIPENTOSIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4056441","Tipiracil","C152646","No value exists.","Tipiracil | TIPIRACIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553979","Tipiracil Hydrochloride","C152647","No value exists.","Tipiracil Hydrochloride | TIPIRACIL HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553980","Tiplimotide","C152648","No value exists.","Tiplimotide | TIPLIMOTIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553981","Tipredane","C152649","No value exists.","Tipredane | TIPREDANE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550948","Refractory Myelodysplastic Syndrome","C148362","Myelodysplastic syndrome that does not respond to treatment.","Refractory Myelodysplastic Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550947","Recurrent Myelodysplastic Syndrome","C148363","The reemergence of myelodysplastic syndrome after a period of remission.","Recurrent Myelodysplastic Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550944","Percutaneous Local Ablation","C148364","Any ablation procedure where a needle or probe is passed through the skin.","Percutaneous Local Ablation | PLA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550943","Ophthalmic/Otic Dosage Form","C148365","No value exists.","Ophthalmic/Otic Dosage Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1855114","Methylmalonic Aciduria due to Methylmalonyl-CoA Mutase Deficiency","C148366","An autosomal recessive form of methylmalonic aciduria caused by mutation(s) in the MUT gene, encoding methylmalonyl-CoA mutase, mitochondrial.","Methylmalonic Aciduria Due to Methylmalonyl-CoA Mutase Deficiency | Methylmalonic Aciduria, Mut Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1847352","Bilateral Frontoparietal Polymicrogyria","C148367","An autosomal recessive condition caused by mutation(s) in the ADGRG1 gene, encoding adhesion G-protein coupled receptor G1. It is characterized by motor and cognitive developmental delay, pyramidal signs, and seizures.","Bilateral Frontoparietal Polymicrogyria |  BFPP | BFPP",,,,,,,,,,,,,,,"604379","Bilateral frontoparietal polymicrogyria",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2750785","Muscular Dystrophy Congenital, LMNA-Related","C148369","An autosomal recessive muscular dystrophy caused by mutation(s) in the LMNA gene, encoding prelamin-A/C. Limb-girdle muscular dystrophy type 1B and Emery-Dreifuss muscular dystrophy-2 are allelic disorders with overlapping phenotypes.","Muscular Dystrophy Congenital, LMNA-Related | MDCL",,,,,,,,,,,,,,,"36674283","Congenital muscular dystrophy due to LMNA mutation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL545765","Nucleolar Transcription Factor 1","C147963","Nucleolar transcription factor 1 (764 aa, ~89 kDa) is encoded by the human UBTF gene. This protein is involved in the positive regulation of ribosomal RNA gene transcription.","Nucleolar Transcription Factor 1 | 90-kDa Nucleolus Organizer Region Autoantigen | Autoantigen NOR-90 | UBF-1 | UBTF | Upstream Binding Factor 1 | Upstream-Binding Factor 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545766","Refractory Breast Carcinoma","C147965","Breast carcinoma that does not respond to treatment.","Refractory Breast Carcinoma | Refractory Breast Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545752","TUSC7 Gene","C147966","This gene plays a role in the negative regulation of cell proliferation.","TUSC7 Gene | TUSC7 | Tumor Suppressor Candidate 7 (Non-Protein Coding) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545753","TUSC7 wt Allele","C147967","Human TUSC7 wild-type allele is located in the vicinity of 3q13.31 and is approximately 14 kb in length. This allele, which encodes tumor suppressor candidate 7 long non-coding RNA, is involved in the modulation of cell proliferation.","TUSC7 wt Allele | LINC00902 | LOC285194 | LSAMP Antisense RNA 3 (Non-Protein Coding) Gene | LSAMP Antisense RNA 3 Gene | LSAMP-AS1 | LSAMP-AS3 | LSAMPAS3 | NCRNA00295 | Non-Protein Coding RNA 295 Gene | Tumor Suppressor Candidate 7 (Non-Protein Coding) wt Allele | Tumor Suppressor Candidate 7 (Noncoding) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3657192","loc285194 LncRNA, human","C147968","Tumor suppressor candidate 7 (~2 kb) is encoded by the human TUSC7 gene. This long non-coding RNA plays a role in the downregulation of cell proliferation.","Tumor Suppressor Candidate 7 | LINC00902 | LSAMP Antisense RNA 3 | LSAMP-AS3 | LSAMPAS3 | LncRNA LOC285194 | Long Noncoding RNA LOC285194 | NCRNA00295 | Non-Protein Coding RNA 295 | TUSC7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550762","Ruthenium-based Photosensitizer TLD1411","C148182","A ruthenium-based photosensitizer (PS), that can potentially be used for photodynamic therapy (PDT). Upon intratumoral administration, the ruthenium-based PS TLD1411 targets mitochondria in tumor cells. Upon PDT, TLD1411 produces singlet molecular oxygen (O2), and induces a reactive oxygen species (ROS)-mediated tumor cell apoptosis.","Ruthenium-based Photosensitizer TLD1411 | PS TLD1411 | TLD 1411 | TLD-1411 | TLD1411",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550761","Amorphous Calcium Carbonate","C148184","A nutritional supplement composed of a proprietary synthetic and amorphous form of calcium carbonate, that can potentially be used to replenish calcium. Upon administration of amorphous calcium carbonate (ACC), the mineral calcium may give calcium supplementary support, improve bone, muscle and heart strength, improve performance and decrease bone-associated pain.","Amorphous Calcium Carbonate | ACC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550764","CRISPR/Cas9-edited HPV16/18 E6/E7 Plasmid","C148185","A plasmid encoding for clustered regularly interspaced short palindromic repeats (CRISPR) targeting the promoters for the human papillomavirus (HPV) type 16 (HPV16) and 18 (HPV18) epitopes E6 and E7, and coupled to the endonuclease cas9, with potential antineoplastic activities. Upon administration and transfection of the CRISPR/Cas9-edited HPV16/18 E6/E7 plasmid, the guide RNA (gRNA) of the CRISPR moiety specifically targets and binds to complementary sites on the HPV 16/18 promoter regions for E6 and E7. Cas9 cleaves these specific DNA sites, thereby disrupting HPV16/18 E6/E7 transcription. Decreased expression of E6 and E7 induces apoptosis and decreases tumor cell proliferation in HPV-driven tumor cells. This induces the expression of certain tumor suppressor genes, such as p53 and retinoblastoma 1 (RB1), which induces tumor cell apoptosis and inhibits tumor cell proliferation.","CRISPR/Cas9-edited HPV16/18 E6/E7 Plasmid | CRISPR/Cas9 targeting HPV16/18 E6 and E7 Genes | CRISPR/Cas9-HPV16 E6/E7T1 Plus CRISPR/Cas9-HPV18 E6/ E7T2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550763","TALEN-edited HPV16/18 E6/E7 Plasmid","C148186","A transcription activator-like effector nuclease (TALEN)-edited plasmid targeting human papillomavirus (HPV) types 16 (HPV16) and 18 (HPV18) epitopes E6 and E7, with potential antineoplastic activity. Upon administration of TALEN-edited HPV16/18 E6/E7, the TALEN targets and binds to specific sites on genomic HPV16 and 18 E6 and E7, and cleaves the DNA sequences encoding E6 and E7. This causes double-strand DNA (dsDNA) breaks, which prevents the transcription and translation of E6 and E7. In addition, inhibition of HPV16/18 E6/E7 increases the expression of tumor suppressor genes, such as p53 and retinoblastoma 1 (RB1). Altogether, TALEN-based HPV editing increases apoptosis and inhibits tumor cell proliferation of HPV-driven cancer cells. HPV16/18 E6 and E7 are oncogenes vital to viral function and carcinogenesis.","TALEN-edited HPV16/18 E6/E7 Plasmid | Plasmid HPV16/18 E6E7-targeting TALEN | TALEN-HPV16 E6/E7/TALEN-HPV18 E6/E7 | TALEN-HPV16 E6/E7/TALEN-HPV18 E6/E7 Plasmid | TALEN-mediated HPV16/18 E6/7 Editing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550880","RIG-I selective Ligand RGT100","C148187","A synthetic RNA oligonucleotide and agonist of the retinoic acid-inducible gene I protein (RIG-I; DDX58), with potential antineoplastic activity. Upon intratumoral/intralesional administration, the RIG-I selective ligand RGT100 targets and binds to the cytosolic RNA receptor RIG-I. This induces RIG-I-mediated signaling, upregulates interferon (IFN)-alfa (IFN-a) and beta (IFN-b), and induces a potent IFN-mediated innate immune response against the tumor cells. This induces the activation of natural killer (NK) cells and cytotoxic T-lymphocytes (CTL) and induces apoptosis in cancer cells.","RIG-I selective Ligand RGT100 | RGT 100 | RGT-100 | RGT100",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550879","Neo-multiple TAA-loaded Dendritic Cell Vaccine","C148188","An autologous dendritic cell (DC) vaccine composed of DCs loaded with multiple distinct neoantigens, with potential immunomodulating and antineoplastic activities. Upon administration, the neo-multiple tumor-associated antigens (TAA)-loaded DC vaccine may stimulate a cytotoxic T-lymphocyte (CTL)-mediated immune response against the tumor cells expressing these neoantigens.","Neo-multiple TAA-loaded Dendritic Cell Vaccine | Neo-multiple TAA-loaded DC Vaccine | Neoantigen-loaded Dendritic Cell Vaccine | neo-MASCT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550881","Autologous Mesenchymal Stem Cells-Poly Lactic-co-glycolic Acid","C148189","A preparation of autologous bone marrow derived mesenchymal stem cells (MSC) that are seeded on biodegradable poly lactic-co-glycolic acid (PLGA)-containing polymer scaffolds, that can potentially be used for bone marrow engraftment. When administered into the bone lesion of the patient, the autologous MSC-PLGA can be used for bone marrow engraftment.","Autologous Mesenchymal Stem Cells-Poly Lactic-co-glycolic Acid | Autologous Bone Marrow-derived MSCs-PLGA | Autologous MSC-PLGA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553271","C188-9","C151932","An orally bioavailable, binaphthol-sulfonamide-based inhibitor of signal transducer and activator of transcription 3 (STAT3), with potential antineoplastic activity. Upon oral administration, the STAT3 inhibitor C-188-9 specifically targets and binds to the phosphotyrosyl peptide binding site within the Src homology 2 (SH2) domain of STAT3. This inhibits the Janus kinase (JAK)-mediated tyrosine phosphorylation and activation of STAT3. This impedes nuclear translocation of STAT3, prevents STAT3 binding to responsive gene promoters and blocks STAT3-mediated regulation of gene expression. STAT3 regulates the transcription of genes involved in several cellular functions. STAT3 is constitutively activated in a variety of human cancers and plays a key role in neoplastic transformation, uncontrolled tumor cell proliferation, resistance to apoptosis, metastasis, immune evasion, tumor angiogenesis, epithelial-mesenchymal transition (EMT) and the Warburg effect.","STAT3 Inhibitor C-188-9 | C-188-9 | C188-9 | STAT3 Inhibitor TTI-101 | STAT3 Inhibitor XIII | TTI 101 | TTI-101 | TTI101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553272","T 1101 Tosylate","C151933","The tosylate salt form of T-1101, an orally bioavailable inhibitor of highly expressed in cancer 1 (Hec1) and NIMA-related kinase 2 (Nek2), with potential antineoplastic activity. Upon oral administration, T-1101 specifically targets, binds to and inhibits the interaction of Hec1 with Nek2. This prevents Hec1/Nek2-mediated signal transduction pathways, inhibits mitosis, induces apoptosis and tumor cell proliferation. Hec1, overexpressed in some cancers, is located at the centromere during cell mitosis and plays an essential role in the pathway of spindle checkpoint. It is correlated with cancer formation, progression, and survival. Phosphorylation of Hec1 by Nek2 kinase is essential for its mitotic function.","Hec1/Nek2 Inhibitor T-1101 Tosylate | T 1101 Tosylate | T1101 Tosylate | TAI-95",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553273","Serial Liquid Biopsy","C151934","Multiple liquid biopsies made over time.","Serial Liquid Biopsy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553274","Anti-CD19/CD20/CD22/CD30 CAR-T Cells","C151935","A preparation of human T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19), CD20, CD22 and CD30, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD19/CD20/CD22/CD30 CAR-T cells target and bind to CD19, CD20, CD22 and CD30 expressed on the surface of certain tumor cells. This induces selective toxicity in tumor cells expressing these TAAs. The TAAs are overexpressed in certain hematologic malignancies.","Anti-CD19/CD20/CD22/CD30 CAR-T Cells | Anti-CD19/CD20/CD22/CD30 Chimeric Antigen Receptor-T Cells | CAR-T CD19/CD20/CD22/CD30",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553275","Autologous E6 T Cell Receptor Genetically-modified T Cells","C151936","A preparation of human autologous peripheral blood lymphocytes (PBLs) that have been genetically engineered to express a T-cell receptor (TCR) that specifically targets the viral oncoprotein human papillomavirus type 16 (HPV-16) E6, with potential antineoplastic activity. Upon administration, the HPV E6 TCR genetically-modified T-cells target and bind to HPV-16 E6-expressing tumor cells, which leads to specific cytotoxic T-lymphocyte (CTL)-mediated killing of HPV-16 E6-positive tumor cells. HPV-16 E6, a cell surface glycoprotein, plays a key role in the tumorigenesis of various HPV-associated tumors and is absent from healthy human tissues.","Autologous E6 T Cell Receptor Genetically-modified T Cells | Autologous Anti-HPV-16 E6 TCR T Cells | Autologous E6 TCR T Cells | Autologous E6 TCR T-cells | Autologous HPV-16 E6 TCR T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553276","RV 001","C151937","A cancer vaccine composed of an immunogenic peptide derived from the Ras homolog family member C (RhoC; Rho-related GTP-binding protein RhoC) that is emulsified in the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, onilcamotide may stimulate the host immune system to mount a humoral and cytotoxic T-lymphocyte (CTL) response against tumor cells expressing RhoC, which results in tumor cell lysis. RhoC, a tumor-associated antigen (TAA) that is overexpressed in a variety of tumor cell types, is associated with increased metastatic potential.","Onilcamotide | ONILCAMOTIDE | RV 001 | RV 001V | RV001 Vaccine | RV001V | RhoC Peptide Vaccine RV001V",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0347944","Pelvic Mass","C151938","A benign or malignant tumor-like pathologic process involving the organs and structures in the pelvis.","Pelvic Mass | ",,,,,,,,,,,,,,,"201131","Pelvic mass",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL553167","Fluorescence Imaging Agent IC2000","C151939","A fluorescent imaging agent that can potentially be used as a diagnostic imaging agent.","Fluorescence Imaging Agent IC2000 | IC 2000 | IC2000",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553314","CHLORAMINE-T ANHYDROUS","C152107","No value exists.","Chloramine-T Anhydrous | CHLORAMINE-T ANHYDROUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037512","Sodium Aurotiosulfate","C152109","No value exists.","Sodium Aurotiosulfate | Gold Sodium Thiosulfate | Gold Sodium Thiosulfate Dihydrate | SODIUM AUROTIOSULFATE | Sodium Aurotiosulfate Dihydrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0021279","infant nutrition","C15264","Nutritional studies with a focus on the specific nutritional needs of children under the age of 2.","Infant Nutrition | Lactation / Infant Nutrition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553983","Tiprenolol","C152651","No value exists.","Tiprenolol | TIPRENOLOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553984","Tiprenolol Hydrochloride","C152652","No value exists.","Tiprenolol Hydrochloride | TIPRENOLOL HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553140","NCCN-FACT FBRSI-24 Version 2 - Frustrated I Cannot Do Things","C151295","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I get frustrated that I cannot do things I used to.","NCCN-FACT FBRSI-24 Version 2 - Frustrated I Cannot Do Things | FAC030-Frustrated I Cannot Do Things | FAC03016",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553141","NCCN-FACT FBRSI-24 Version 2 - Losing Hope Against Illness","C151296","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I am losing hope in the fight against my illness.","NCCN-FACT FBRSI-24 Version 2 - Losing Hope Against Illness | FAC030-Losing Hope Against Illness | FAC03017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553142","NCCN-FACT FBRSI-24 Version 2 - I Have a Lack of Energy","C151297","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I have a lack of energy.","NCCN-FACT FBRSI-24 Version 2 - I Have a Lack of Energy | FAC030-I Have a Lack of Energy | FAC03018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553143","NCCN-FACT FBRSI-24 Version 2 - I Have Nausea","C151298","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I have nausea.","NCCN-FACT FBRSI-24 Version 2 - I Have Nausea | FAC030-I Have Nausea | FAC03019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553144","NCCN-FACT FBRSI-24 Version 2 - Bothered by Treatment Side Effect","C151299","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I am bothered by side effects of treatment.","NCCN-FACT FBRSI-24 Version 2 - Bothered by Treatment Side Effect | FAC030-Bothered by Treatment Side Effect | FAC03020",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553145","NCCN-FACT FBRSI-24 Version 2 - I Feel Fatigued","C151300","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I feel fatigued.","NCCN-FACT FBRSI-24 Version 2 - I Feel Fatigued | FAC030-I Feel Fatigued | FAC03021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553146","NCCN-FACT FBRSI-24 Version 2 - I Have a Good Appetite","C151301","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I have a good appetite.","NCCN-FACT FBRSI-24 Version 2 - I Have a Good Appetite | FAC030-I Have a Good Appetite | FAC03022",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553147","NCCN-FACT FBRSI-24 Version 2 - I Am Able to Enjoy Life","C151302","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I am able to enjoy life.","NCCN-FACT FBRSI-24 Version 2 - I Am Able to Enjoy Life | FAC030-I Am Able to Enjoy Life | FAC03023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553148","NCCN-FACT FBRSI-24 Version 2 - Content With Quality of My Life","C151303","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I am content with the quality of my life right now.","NCCN-FACT FBRSI-24 Version 2 - Content With Quality of My Life | FAC030-Content With Quality of My Life | FAC03024",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553149","NCCN-FACT FHNSI-22 Version 2 - I Have Pain","C151304","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I have pain.","NCCN-FACT FHNSI-22 Version 2 - I Have Pain | FAC036-I Have Pain | FAC03601",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553150","NCCN-FACT FHNSI-22 Version 2 - I Am Losing Weight","C151305","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I am losing weight.","NCCN-FACT FHNSI-22 Version 2 - I Am Losing Weight | FAC036-I Am Losing Weight | FAC03602",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545756","GABRA6 wt Allele","C147970","Human GABRA6 wild-type allele is located in the vicinity of 5q34 and is approximately 156 kb in length. This allele, which encodes gamma-aminobutyric acid receptor subunit alpha-6 protein, plays a role in chloride conductance.","GABRA6 wt Allele | GABA(A) Receptor, Alpha 6 Gene | GABA-A Receptor, Alpha-6 Polypeptide Gene | Gamma-Aminobutyric Acid (GABA) A Receptor, Alpha 6 Gene | Gamma-Aminobutyric Acid Receptor, Alpha-6 Gene | Gamma-Aminobutyric Acid Type A Receptor Alpha6 Subunit wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1741671","GABRA6 protein, human","C147971","Gamma-aminobutyric acid receptor subunit alpha-6 (453 aa, ~51 kDa) is encoded by the human GABRA6 gene. This protein is involved in ligand-gated chloride transport.","Gamma-Aminobutyric Acid Receptor Subunit Alpha-6 | GABA(A) Receptor Subunit Alpha-6 | GABRA6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545759","GID4 wt Allele","C147973","Human GID4 wild-type allele is located in the vicinity of 17p11.2 and is approximately 29 kb in length. This allele, which encodes glucose-induced degradation protein 4 homolog, is involved in the degradation of gluconeogenic enzymes.","GID4 wt Allele | C17orf39 | Chromosome 17 Open Reading Frame 39 Gene | GID Complex Subunit 4 Homolog wt Allele | GID Complex Subunit 4, VID24 Homolog (S. cerevisiae) Gene | GID Complex Subunit 4, VID24 Homolog Gene | Glucose-Induced Defradation-Deficient Protein 4, S cerevisiae, Homolog of Gene | VID2 | VID24 | Vacuolar Import and Degradation 24 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545744","Glucose-Induced Degradation Protein 4 Homolog","C147974","Glucose-induced degradation protein 4 homolog (300 aa, ~34 kDa) is encoded by the human GID4 gene. This protein plays a role in the ubiquitination and proteasomal targeting of gluconeogenic enzymes.","Glucose-Induced Degradation Protein 4 Homolog | GID Complex Subunit 4 | GID4 | Vacuolar Import and Degradation Protein 24 | Vacuolar Import and Degradation Protein 24 Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545745","PTPRO Gene","C147975","This gene is involved in glomerulus development.","PTPRO Gene | PTPRO | Protein Tyrosine Phosphatase, Receptor Type O Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545746","PTPRO wt Allele","C147976","Human PTPRO wild-type allele is located in the vicinity of 12p12.3 and is approximately 276 kb in length. This allele, which encodes receptor-type tyrosine-protein phosphatase O protein, plays a role in both glomerulus development and protein tyrosine phosphatase activity. Mutation of the gene may be associated with nephrotic syndrome.","PTPRO wt Allele | GLEPP1 | NPHS6 | PTP Phi | PTP-OC | PTP-U2 | PTPROT | PTPU2 | Protein Tyrosine Phosphatase, Receptor Type O wt Allele | Protein Tyrosine Phosphatase, Receptor Type, O Gene | R-PTP-O",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551131","Polyinosinic-polycytidylic Acid/Inactivated Rabies Virus Vaccine YS-ON-001","C148534","A cancer vaccine composed of inactivated rabies vaccine (RV-V) and polyinosinic-polycytidylic acid (poly IC; poly I-C), an immunostimulant and Toll-like receptor 3 (TLR3) agonist, with potential immunostimulating and antineoplastic activities. Upon administration of the poly IC/inactivated RV-V YS-ON-001, the RV-V stimulates the immune system in various ways, such as promoting the activation and proliferation of T helper type 1 (Th1) cells, dendritic cells (DCs), B cells and natural killer cells (NKs), promoting macrophage M1 polarization, downregulating regulatory T-cells (Tregs), and inducing the production of anti-tumor cytokines. This re-activates immune responses in the suppressed tumor microenvironment (TME), leading to an induction of cytotoxic T-lymphocyte (CTL)-mediated immune response against the tumor cells, which cause tumor cell apoptosis and a reduction of tumor cell proliferation. Poly IC, a synthetic double-stranded RNA with one strand composed of a inosinic acid polymer and the other strand a cytidylic acid polymer, binds to TLR3 and stimulates the release of cytotoxic cytokines, such as interferon-gamma (IFNg). This may boost the immune response against the tumor cells.","Polyinosinic-polycytidylic Acid/Inactivated Rabies Virus Vaccine YS-ON-001 | Poly IC/Inactivated RV-V YS-ON-001 | YS ON 001 | YS-ON-001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551134","HTI-1088","C148535","An immunoglobulin G4 (IgG4), humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, adebrelimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.","Adebrelimab | ADEBRELIMAB | HTI 1088 | HTI-1088 | HTI1088 | SHR 1316 | SHR-1316 | SHR1316",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038917","Surgical Clip","C148190","A type of surgical staple designed to close wounds and control bleeding from blood vessels.","Surgical Clip | Clip Closure | Clip Closure Device",,,,,,,,,,,,,,,"4300940","Surgical clip",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL550876","F-18 Fluciclovine Positron Emission Tomography and Magnetic Resonance Imaging","C148191","An imaging procedure that combines fluciclovine F18 PET with an MRI scan to overlay activity data onto detailed anatomic images.","F-18 Fluciclovine Positron Emission Tomography and Magnetic Resonance Imaging | F-18 Fluciclovine PET/MRI | F-18 Fluciclovine PET/MRI Scan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551003","Milciclib","C148410","An orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and tropomyosin receptor kinase A (TRKA), with potential antineoplastic activity. CDK2/TRKA inhibitor PHA-848125 AC potently inhibits cyclin-dependent kinase 2 (CDK2) and exhibits activity against other CDKs including CDK1 and CDK4, in addition to TRKA. Inhibition of these kinases may result in cell cycle arrest and apoptosis of tumor cells that express these kinases. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some cancer cell types. The neurotrophin receptor TRKA is mutated in a variety of cancer cell types.","Milciclib | 1H-Pyrazolo(4,3-h)quinazoline-3-carboxamide, 4,5-dihydro-N,1,4,4-tetramethyl-8-((4-(4-methyl-1-piperazinyl)phenyl)amino)- | MILCICLIB | N,1,4,4-Tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide | PHA 848125 | PHA-848125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3854130","T2d Stage Finding","C148411","A TNM stage finding term that refers to choroidal and ciliary body melanoma or conjunctival melanoma TNM staging. For choroidal and ciliary body melanoma it means tumor size category 2 with ciliary body involvement and extraocular extension 5 mm or less in largest diameter. For conjunctival melanoma it means caruncular tumor, and more than 1 quadrant of the nonbulbar conjunctiva involved. (from AJCC 8th Ed.)","T2d TNM Finding | T2d | T2d Cancer Stage Finding | T2d Primary Tumor Finding | T2d Primary Tumor Stage Finding | T2d Stage | T2d Stage Finding | T2d TNM Finding | T2d Tumor Finding | T2d Tumor Stage | Tumor Stage T2d",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3854131","T3d TNM Finding","C148412","A TNM finding term that refers to choroidal and ciliary body melanoma, conjunctival melanoma, or retinoblastoma TNM staging. For choroidal and ciliary body melanoma it means tumor size category 3 with ciliary body involvement and extraocular extension 5 mm or less in largest diameter. For conjunctival melanoma it means tumor of any size invading the nasolacrimal duct and/or lacrimal sac and/or paranasal sinuses. For retinoblastoma it means hyphema and/or massive vitreous hemorrhage (clinical) or full-thickness invasion into the outer third of the sclera and/or invasion into or around emissary channels (pathologic). (from AJCC 8th Ed.)","T3d TNM Finding | T3d | T3d Cancer Stage Finding | T3d Primary Tumor Finding | T3d Primary Tumor Stage Finding | T3d Stage | T3d Stage Finding | T3d TNM Finding | T3d Tumor Finding | T3d Tumor Stage | Tumor Stage T3d",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550998","Oral Solid Dosage Form","C148413","No value exists.","Oral Solid Dosage Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551000","Oromucosal Dosage Form","C148414","No value exists.","Oromucosal Dosage Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037530","Morrhuate Sodium","C152110","No value exists.","Morrhuate Sodium | MORRHUATE SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553318","Proxazole Citrate","C152111","No value exists.","Proxazole Citrate | PROXAZOLE CITRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553319","Prucalopride Succinate","C152112","The succinate salt form of prucalopride, an orally bioavailable dihydro-benzofuran-carboxamide and selective serotonin (5-HT4) receptor agonist, with gastrointestinal (GI) prokinetic activity. Upon oral administration, prucalopride specifically targets, binds to and stimulates the 5-HT4 receptor. This alters colonic motility patterns and stimulates colonic mass movements. This may normalize bowel movements and may relief chronic constipation. In addition, by increasing esophageal and gastric motility, prucalopride may also provide relief for aspiration-associated symptoms.","Prucalopride Succinate | Motegrity | PRUCALOPRIDE SUCCINATE | Resolor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553320","Psyllium Hemicellulose","C152113","No value exists.","Psyllium Hemicellulose | PSYLLIUM HEMICELLULOSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034257","Pyridinolcarbamate","C152114","No value exists.","Pyricarbate | PYRICARBATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553322","Pyroxylin","C152115","No value exists.","Pyroxylin | PYROXYLIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553323","Quilizumab","C152116","No value exists.","Quilizumab | QUILIZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553324","Quilseconazole","C152117","No value exists.","Quilseconazole | QUILSECONAZOLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553325","Quindecamine","C152118","No value exists.","Quindecamine | QUINDECAMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553327","Quindonium Bromide","C152120","No value exists.","Quindonium Bromide | QUINDONIUM BROMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553328","Quinelorane","C152121","No value exists.","Quinelorane | QUINELORANE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553329","Quinelorane Hydrochloride","C152122","No value exists.","Quinelorane Hydrochloride | QUINELORANE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553330","Quinetolate","C152123","No value exists.","Quinetolate | QUINETOLATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553332","Quingestanol Acetate","C152125","No value exists.","Quingestanol Acetate | 19-Nor-17-alpha-pregna-3,5-dien-20-yn-17-ol, 3-(Cyclopentyloxy)-, Acetate | 19-Nor-17-alpha-pregna-3,5-dien-20-yn-17-ol, 3-(Cyclopentyloxy)-, Acetate (Ester) | 3-Cyclopentyl Enol Ether of Norethindrone Acetate | BRN 2186975 | QUINGESTANOL ACETATE | W 4540 | W-4540 | W4540",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553334","quinine ascorbate","C152127","No value exists.","Quinine Ascorbate | QUININE ASCORBATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553335","Quinpirole","C152128","No value exists.","Quinpirole | QUINPIROLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553337","Quinterenol","C152130","No value exists.","Quinterenol | QUINTERENOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553338","Quinterenol Sulfate","C152131","No value exists.","Quinterenol Sulfate | QUINTERENOL SULFATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553464","quinupramine","C152132","No value exists.","Quinupramine | QUINUPRAMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553465","Quisinostat Hydrochloride","C152133","No value exists.","Quisinostat Hydrochloride | QUISINOSTAT HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2930762","Tedizolid Phosphate","C152537","The phosphate salt form of tedizolid, an antibacterial agent of the oxazolidinone class, that is used for the treatment of acute bacterial skin and skin structure infections caused by certain Gram-positive microorganisms. Upon intravenous administration, tedizolid targets and binds to the 50S subunit of the bacterial ribosome. This inhibits bacterial protein synthesis.","Tedizolid Phosphate | Sivextro | TEDIZOLID PHOSPHATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553870","Tefibazumab","C152538","No value exists.","Tefibazumab | TEFIBAZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553151","NCCN-FACT FHNSI-22 Version 2 - I Have Trouble Breathing","C151306","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I have trouble breathing.","NCCN-FACT FHNSI-22 Version 2 - I Have Trouble Breathing | FAC036-I Have Trouble Breathing | FAC03603",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553152","NCCN-FACT FHNSI-22 Version 2 - I Feel Ill","C151307","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I feel ill.","NCCN-FACT FHNSI-22 Version 2 - I Feel Ill | FAC036-I Feel Ill | FAC03604",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553153","NCCN-FACT FHNSI-22 Version 2 - Pain in My Mouth, Throat or Neck","C151308","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I have pain in my mouth, throat or neck.","NCCN-FACT FHNSI-22 Version 2 - Pain in My Mouth, Throat or Neck | FAC036-Pain in My Mouth, Throat or Neck | FAC03605",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553186","HPV16-E7-T512","C151958","A transcription activator-like effector nucleases (TALEN)-edited plasmid targeting human papillomavirus (HPV) type 16 (HPV16) epitope E7, with potential antineoplastic activity. Upon administration of TALEN-edited HPV16 E7 T512, the TALEN targets and binds to a specific site on genomic HPV16 E7, and cleaves the DNA sequences encoding E7. This causes double-strand DNA (dsDNA) breaks within the viral DNA, which prevents the transcription and translation of E7. Inhibition of E7 expression restores and increases the expression of tumor suppressor genes, such as retinoblastoma 1 (RB1), and promotes downstream signaling. Altogether, TALEN-based HPV editing increases cell cycle arrest, induces apoptosis, reduces viral replication and load, eliminates HPV and inhibits tumor cell proliferation of HPV-driven cancer cells. HPV16 E7 is an oncogene that is vital to viral function and HPV infection, and promotes carcinogenesis.","HPV16-E7-T512 | HPV16-targeting TALEN T512 | T512",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553187","Less than Partial Clinical Response","C151961","A change towards improvement from the pretreatment baseline, but not meeting the criteria for complete response or partial response.","Less than Partial Clinical Response | Less than Partial Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0563533","Magnetic Field","C151962","The region around a magnetic material or a moving electric charge within which the force of magnetism acts.","Magnetic Field | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553188","Atomic Nucleus","C151963","The region of an atom that contains the protons and neutrons.","Atomic Nucleus | Nucleus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554562","Saturation Recovery Pulse Sequence","C151964","A sequence of multiple 90 degree radio frequency pulses spaced at repetition times that allow the recovery of all the longitudinal magnetization before the next pulse.","Saturation Recovery Pulse Sequence | SR | Saturation Recovery Sequence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553189","Tissue Suppression","C151965","Any of various techniques that allow the imaging of a body part while suppressing signals coming from a selected tissue.","Tissue Suppression | Signal Suppression | Tissue Signal Suppression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551133","Castration-Naive Prostate Carcinoma","C148536","Advanced prostatic carcinoma which was not previously treated with androgen-deprivation therapy.","Castration-Naive Prostate Carcinoma | CNPC | Castration-Naive Prostate Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551128","MET Kinase Inhibitor OMO-1","C148537","An inhibitor of the proto-oncogene and receptor tyrosine kinase (RTK) hepatocyte growth factor receptor (c-Met; HGFR; MET) with potential antineoplastic activity. Upon administration, OMO-1 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","MET Kinase Inhibitor OMO-1 | JNJ 38877618 | JNJ-38877618 | JNJ38877618 | OMO-1 | OMO1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551127","ABX-1431","C148538","An orally bioavailable inhibitor of the serine hydrolase monoacylglycerol lipase (MGLL), with potential use for the treatment of various central nervous system (CNS) diseases and with potential analgesic and anti-neuroinflammatory activities. Upon oral administration, elcubragistat targets and binds to MGLL, thereby inhibiting MGLL activity and preventing the breakdown and inactivation of endogenous 2-arachidonoylglycerol (2-AG). Increased 2-AG levels results in enhanced activation of the cannabinoid receptor 1 (CB1) in the CNS and enhanced CB1 endocannabinoid signaling in active neural circuits. Activation of CB1 helps modulate the endocannabinoid system and reduce neurotransmitter release, thereby decreasing overactive neural signaling. This induces analgesic, anti-inflammatory and various neurological effects that are caused by dysregulation of the endocannabinoid system and overactive neural signaling, including anxiolytic effects, reduced spasticity and decreased neurodegenerative effects. In addition, MGLL inhibition by elcubragistat depletes the supply of the inflammatory signaling molecule arachidonic acid, thereby further alleviating pain and inflammation. CB1 plays a key role in the regulation of neurotransmission; increased CB1 activation decreases overactive neural signaling. MGLL, an enzyme that catalyzes the breakdown of 2-AG, regulates the activation of CB1 and CB2 to modulate neurotransmission and inflammatory signaling, respectively.","Elcubragistat | ABX-1431 | ABX1431 | ELCUBRAGISTAT | MGLL Inhibitor ABX-1431 | Serine Hydrolase Monoacylglycerol Lipase Inhibitor ABX-1431 | Serine Hydrolase Monoacylglycerol Lipase Inhibitor ABX-1431",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551130","HPV E6/E7-encoding Semliki Forest Virus Vaccine Vvax001","C148539","A vaccine consisting of a recombinant, attenuated, replication-incompetent form of the Semliki Forest Virus (SFV) vector encoding the viral oncoproteins E6 and E7 derived from the human papillomavirus (HPV), with potential immunomodulating and antineoplastic activities. Upon intramuscular administration, HPV E6/E7-encoding SFV vaccine Vvax001 induces expression of the E6/E7 proteins and stimulates both the innate and the adaptive immune system, resulting in a potent cytotoxic T-lymphocyte (CTL) response against and lysis of tumor cells expressing HPV E6 and E7. Oncoproteins E6 and E7 play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.","HPV E6/E7-encoding Semliki Forest Virus Vaccine Vvax001 | HPV E6/7 Semliki Forest Virus Based Cancer Vaccine | SFVeE6,7 | Vvax-001 | Vvax001 | Vvax001 Therapeutic Cancer Vaccine | rSFVeE6,7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551129","Castration-Naive","C148540","A finding indicating that an advanced prostate carcinoma was not previously treated with androgen-deprivation therapy.","Castration-Naive | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550781","Zirconium Zr 89 Anti-EGFR Monoclonal Antibody ABT-806","C148163","A radioimmunoconjugate composed of ABT-806, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the epidermal growth factor receptor (EGFR), labeled with the radioisotope zirconium Zr 89, with potential use as an imaging agent upon positron emission tomography (PET). Upon administration of zirconium Zr 89 anti-EGFR monoclonal antibody ABT-806, the antibody moiety binds to a specific EGFR epitope of either the wild-type or the variant III mutant (EGFRvIII; de2-7 EGFR; DEGFR) on tumor cells. Upon PET imaging, EGFR-expressing tumor cells can be visualized and assessed. This may result in the quantification of EGFR-expressing tumor cells, an assessment of the expected response to treatment with ABT-806 and the selection of patients that would respond to ABT-806. ABT-806 is the humanized version of chimeric monoclonal antibody 806. EGFR, a receptor tyrosine kinase overexpressed on the cell surfaces of many tumor cell types, plays a key role in tumor cell proliferation.","Zirconium Zr 89 Anti-EGFR Monoclonal Antibody ABT-806 | 89Zr-ABT806 | 89Zr-labeled ABT-806",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550784","Autologous mRNA-modified Anti-cMET CAR-T Cells","C148164","A preparation of autologous, genetically-engineered T-lymphocytes that have been electroporated with an mRNA encoding a chimeric antigen receptor (CAR) consisting of an anti-human hepatocyte growth factor receptor (HGFR or cMET) single chain variable fragment (scFv), with potential antineoplastic activities. Upon administration, autologous mRNA-modified anti-cMET CAR-T cells direct T-cells to cMET-expressing tumor cells, which induces selective toxicity against cMET-expressing tumor cells and causes tumor cell lysis. cMET, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.","Autologous mRNA-modified Anti-cMET CAR-T Cells | Autologous cMET Redirected CAR-T Cells | Autologous mRNA CART-cMET | cMET CAR-mRNA-electroporated Autologous T lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551336","Eye Drops, Powder for Suspension Dosage Form","C149503","Solid preparation consisting of one or more powders intended to be dispersed in the specified liquid to obtain an eye drops suspension.","Eye Drops, Powder for Suspension Dosage Form | Eye drops, powder for suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551335","Eye Drops, Prolonged Release Dosage Form","C149504","Liquid sterile single-dose or multidose preparation intended for ocular use. The active substance is released over an extended period of time.","Eye Drops, Prolonged Release Dosage Form | Eye drops, prolonged-release",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551338","Eye drops, prolonged-release solution in single-dose container","C149505","Medicinal product consisting of a prolonged-release eye drops solution presented in a single-dose container.","Eye Drops, Prolonged-Release Solution in Single-dose Container Dosage Form | Eye Drops, Prolonged-Release Solution in Single-dose Container | Eye drops, prolonged-release solution in single-dose container",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551337","Eye drops, solution in single-dose container","C149506","Medicinal product consisting of an eye drops solution presented in a single-dose container.","Eye Drops, Solution in Single-dose Container Dosage Form | Eye Drops, Solution in Single-dose Container | Eye drops, solution in single-dose container",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551554","Pour-on Suspension Dosage Form","C149769","Liquid preparation consisting of a suspension intended for pour-on use for the prevention and treatment of ectoparasitic and/or endoparasitic infestations of animals. Pour-on suspensions are applied in volumes that are usually greater than 5 mL.","Pour-on Suspension Dosage Form | Pour-on suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551557","Pour-on Route of Administration","C149770","Administration of a veterinary medicinal product by pouring onto the dorsal midline of the animal or to the top of the head and around the base of the horns.","Pour-on Route of Administration | Pour-on use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551556","Powder and Gel for Gel Dosage Form","C149771","Powder and gel intended for the preparation of a gel (for cutaneous use) by mixing the powder in the gel. The powder contains active ingredient(s); the gel does not contain active ingredient(s).","Powder and Gel for Gel Dosage Form | Powder and gel for gel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551666","Powder and Solution for Beehive Dispersion Dosage Form","C149772","Powder and solution, both of which contain active ingredient(s), intended for the preparation of a bee-hive dispersion by mixing the powder with the solution.","Powder and Solution for Beehive Dispersion Dosage Form | Powder and solution for bee-hive dispersion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551665","Powder and Solution for Beehive Solution Dosage Form","C149773","Powder and solution, both of which contain active ingredient(s), intended for the preparation of a bee-hive solution by dissolving the powder in the solution.","Powder and Solution for Beehive Solution Dosage Form | Powder and solution for bee-hive solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551668","Powder and Solution for Dental Cement Dosage Form","C149774","Powder and solution, both containing active substance(s), intended for the preparation of a dental cement by mixing the powder and the solution.","Powder and Solution for Dental Cement Dosage Form | Powder and solution for dental cement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551667","Powder and Solution for Solution for Injection Dosage Form","C149775","Sterile powder and sterile solution, both containing active substance(s), intended for the preparation of a solution for injection by dissolving the powder in the solution.","Powder and Solution for Solution for Injection Dosage Form | Powder and solution for solution for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551662","Powder and Solvent for Concentrate for Solution for Infusion Dosage Form","C149776","Sterile powder and sterile solvent intended for the preparation of a concentrate for solution for infusion by dissolving the powder in the solvent; the resulting concentrate for solution for infusion must subsequently be diluted before administration as a solution for infusion.","Powder and Solvent for Concentrate for Solution for Infusion Dosage Form | Powder and solvent for concentrate for solution for infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551661","Powder and Solvent for Topical Solution Dosage Form","C149777","Powder and solvent intended for the preparation of a cutaneous solution by dissolving the powder in the solvent.","Powder and Solvent for Topical Solution Dosage Form | Powder and solvent for cutaneous solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551664","Powder and Solvent for Dental Gel Dosage Form","C149778","Powder and solvent intended for the preparation of a dental gel by mixing the powder and the solvent.","Powder and Solvent for Dental Gel Dosage Form | Powder and solvent for dental gel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552431","Prepro-Secretin","C148313","Prepro-secretin (121 aa, ~13 kDa) is encoded by the human SCT gene. This protein plays a role in the production of bicarbonate-rich digestive juices.","Prepro-Secretin | PreproSCT | Preprosecretin | SCT | Secretin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2752584","Secretin","C148314","Secretin (27 aa, ~3 kDa) is encoded by the human SCT gene. This protein is involved in the secretion of bile and bicarbonate in the duodenum and in the pancreatic and biliary ducts.","Secretin | SCT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3472711","Spinocerebellar Ataxia Type 36","C148316","An autosomal dominant condition caused by mutation(s) in the NOP56 gene, encoding nucleolar protein 56. It is characterized by slowly progressive adult-onset gait ataxia, associated with eye movement abnormalities, tongue fasciculations and variable upper motor neuron signs.","Spinocerebellar Ataxia Type 36 | SCA36",,,,,,,,,,,,,,,"46273590","Spinocerebellar ataxia type 36",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1858479","Spastic paraplegia 11, autosomal recessive","C148317","An autosomal recessive condition caused by mutation(s) in the SPG11 gene, encoding spatacsin. It is a complicated sub-type of hereditary spastic paraplegia that has varying neurologic manifestations in addition to spasticity.","Spastic Paraplegia 11 | HSP-TCC | Spastic Paraplegia, Autosomal Recessive, Complicated, with Thin Corpus Callosum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1832567","MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1C","C148318","A sub-type of limb-girdle muscular dystrophy caused by mutation(s) in the CAV3 gene, encoding caveolin-3.","Limb-Girdle Muscular Dystrophy Type 1C |  LGMD1C | LGMD1C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550976","SERPINB3 Gene","C148319","This gene is involved in the inhibition of protease activity.","SERPINB3 Gene | SERPINB3 | Serpin Family B Member 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545799","Selective Androgen Receptor Modulator","C147920","No value exists.","Selective Androgen Receptor Modulator | SARM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL546041","CYP17A1 Inhibitor","C147923","Any agent that inhibits the activity of the enzyme CYP17A1.","CYP17A1 Inhibitor | 17,20-lyase Inhibitor | CYP17 Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545882","Anti-CD38 MAb TAK-079","C148078","A human, non-agonistic immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface glycoprotein ADP-ribosyl cyclase 1 (CD38) with potential immunomodulating and antineoplastic activities. Mezagitamab specifically binds to CD38 that is expressed on human plasmablasts, plasma cells, NK cells and activated T- and B-cells. This may trigger antibody-dependent cellular cytotoxicity (ADCC), cell lysis and depletion of CD38-expressing cells. Additionally, TAK-079 does not induce CD38-dependent signaling and does not promote cytokine activation in peripheral blood mononuclear cells (PMBCs). CD38, a type II transmembrane glycoprotein, is overexpressed on cells associated with autoimmune diseases and hematologic malignancies.","Mezagitamab | Anti-CD38 MAb TAK-079 | MEZAGITAMAB | TAK 079 | TAK-079 | TAK079",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545884","C-11 Choline Positron Emission Tomography and Magnetic Resonance Imaging","C148080","An imaging procedure that combines C-11 choline PET with an MRI scan to overlay activity data onto detailed anatomic images.","C-11 Choline Positron Emission Tomography and Magnetic Resonance Imaging | C-11 Choline PET/MRI | C-11 Choline PET/MRI Scan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551190","ZC3H12A protein, human","C148603","Endoribonuclease ZC3H12A (599 aa, ~66 kDa) is encoded by the human ZC3H12A gene. This protein is involved in the modulation of both RNA metabolism and transcription.","Endoribonuclease ZC3H12A | Bifunctional Endoribonuclease and Deubiquitinase ZC3H12A | EC 3.1.-.- | MCP Induced Protein 1 | MCP-1 Treatment-Induced Protein | MCP-Induced Protein 1 | MCP1-Induced Protein | MCPIP-1 | Monocyte Chemotactic Protein-Induced Protein 1 | Reg1 | Reginase 1 | Regnase 1 | Regnase-1 | Ribonuclease ZC3H12A | ZC3H12A | Zinc Finger CCCH Domain-Containing Protein 12A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550926","JOUBERT SYNDROME 3","C148259","An autosomal recessive subtype of Joubert syndrome caused by mutation(s) in the AHI1 gene, encoding Jouberin.","Joubert Syndrome 3 | JBTS3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545630","TSCYC - Acting Jumpy","C147834","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Acting jumpy.","TSCYC - Acting Jumpy | TSCYC1-Acting Jumpy | TSCYC182",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545631","TSCYC - Making a Mess","C147835","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Making a mess.","TSCYC - Making a Mess | TSCYC1-Making a Mess | TSCYC183",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545632","TSCYC - Acting Sad or Depressed","C147836","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Acting sad or depressed.","TSCYC - Acting Sad or Depressed | TSCYC1-Acting Sad or Depressed | TSCYC184",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545633","TSCYC - Being Absent-minded","C147837","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Being so absent-minded that he or she didn't notice what was going on around him or her.","TSCYC - Being Absent-minded | TSCYC1-Being Absent-minded | TSCYC185",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545634","TSCYC - Not Wanting to Eat Certain Foods","C147838","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Not wanting to eat certain foods.","TSCYC - Not Wanting to Eat Certain Foods | TSCYC1-Not Wanting to Eat Certain Foods | TSCYC186",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545635","TSCYC - Yelling at Family, Friends or Teachers","C147839","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Yelling at family, friends, or teachers.","TSCYC - Yelling at Family, Friends or Teachers | TSCYC1-Yelling at Family/Friend/Teachers | TSCYC187",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545636","TSCYC - Not Playing Because Depressed","C147840","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Not playing because he or she was depressed.","TSCYC - Not Playing Because Depressed | TSCYC1-Not Playing Because Depressed | TSCYC188",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545637","TSCYC - Being Disobedient","C147841","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Being disobedient.","TSCYC - Being Disobedient | TSCYC1-Being Disobedient | TSCYC189",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545622","TSCYC - Intentionally Hurt Other Children","C147842","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Intentionally hurting other children or family members.","TSCYC - Intentionally Hurt Other Children | TSCYC1-Intentionally Hurt Other Children | TSCYC190",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545623","ATLAS - Age","C147843","ATLAS Score (ATLAS) Age.","ATLAS - Age | ATLAS1-Age | ATLAS101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545624","ATLAS - Treatment With Antibiotics","C147844","ATLAS Score (ATLAS) Treatment with systemic antibiotics during CDI therapy (>= 1 day).","ATLAS - Treatment With Antibiotics | ATLAS1-Treatment With Antibiotics | ATLAS102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545625","ATLAS - Leukocyte Count","C147845","ATLAS Score (ATLAS) Leukocyte count (total).","ATLAS - Leukocyte Count | ATLAS1-Leukocyte Count | ATLAS103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551050","Hepatitis B Virus Antigen Peptides/Hepatitis G2 Cell Protein Lysate-activated Dendritic Cells","C148495","A cell-based cancer vaccine composed of autologous dendritic cells (DCs) ex vivo activated with the hepatitis B virus (HBV)-specific tumor-associated antigen (TAA) peptides derived from the patient's tumor and cell lysate proteins harvested from the immortalized human liver cancer cell line HepG2, with potential immunostimulatory and antineoplastic activities. Upon administration, the HBV peptides/HepG2 cell protein lysate-activated DCs expose the immune system to the HBV epitopes and an undefined amount of other TAAs from the HepG2 cell lysate, which may result in the induction of a specific anti-tumor cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing the HBV/HepG2 TAAs. HBV TAAs are found on HBV-positive cells and on HBV-induced hepatocellular carcinoma (HBV-HCC).","Hepatitis B Virus Antigen Peptides/Hepatitis G2 Cell Protein Lysate-activated Dendritic Cells | HBV Antigen Peptides/HepG2 Cell Protein Lysate-activated DCs | HBV Antigen Peptides/HepG2 Cell Protein Lysate-activated Dendritic Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554802","Advanced Lung Non-Squamous Non-Small Cell Carcinoma","C147924","Non-squamous non-small cell lung carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Advanced Non-Squamous Non-Small Cell Lung Cancer | Advanced Non-Squamous Non-Small Cell Lung Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545787","Allogeneic Hematopoietic Stem Cell Transplantation Recipient","C147925","A person receiving an allogeneic hematopoietic stem cell transplant.","Allogeneic Hematopoietic Stem Cell Transplant Recipient | Allogeneic Hematopoietic Stem Cell Transplantation Recipient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545788","AMHR2 Gene Product","C147926","A protein encoded by the AMHR2 gene.","AMHR2 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545789","Anti-Muellerian Hormone Type-2 Receptor Extracellular Domain","C147927","Anti-Muellerian hormone type-2 receptor extracellular domain is encoded by the human AMHR2 gene. This protein may play a role in ovarian carcinogenesis.","Anti-Muellerian Hormone Type-2 Receptor Extracellular Domain | AMHR2-ED | Anti-Mullerian Hormone Receptor II Extracellular Domain | Anti-Müllerian Hormone Receptor II Extracellular Domain | Extracellular Domain of Anti-Mullerian Hormone Receptor II | Extracellular Domain of Anti-Müllerian Hormone Receptor II",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1824528","CARTPT Gene","C147928","This gene plays a role in the negative regulation of appetite.","CARTPT Gene | CART Prepropeptide Gene | CARTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545791","CARTPT wt Allele","C147929","Human CARTPT wild-type allele is located in the vicinity of 5q13.2 and is approximately 2 kb in length. This allele, which encodes cocaine- and amphetamine-regulated transcript protein, is involved in the regulation of appetite.","CARTPT wt Allele | CART | CART Prepropeptide wt Allele | Cocaine and Amphetamine Regulated Transcript Gene | Cocaine- and Amphetamine-Regulated Transcript Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1738809","cocaine- and amphetamine-regulated transcript protein, human","C147930","Cocaine- and amphetamine-regulated transcript protein (116 aa, ~13 kDa) is encoded by the human CARTPT gene. This protein plays a role in the inhibition of appetite.","Cocaine- and Amphetamine-Regulated Transcript Protein | CART | CART Prepropeptide | CARTPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551149","Topical Celecoxib","C148519","A topical cream formulation containing celecoxib, a nonsteroidal anti-inflammatory drug (NSAID), with anti-inflammatory and potential keratolytic, chemopreventive and antineoplastic activities. Upon topical application to the affected area, celecoxib selectively binds to and inhibits cyclooxygenase-2 activity (COX-2), which may result in localized keratinocyte apoptosis. The breakdown of keratinocytes prevents their proliferation locally and may reduce tumor cell proliferation.","Topical Celecoxib | Celecoxib Cream | Celecoxib Topical | DFD-07 | DFD07",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551148","Androgen Receptor Antagonist BAY 1161116","C148520","An orally bioavailable antagonist of the androgen receptor (AR), with potential antineoplastic activity. Upon oral administration, AR antagonist BAY 1161116 specifically binds to AR, inhibits AR activation, and prevents AR-mediated signaling. This inhibits cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in proliferation, survival and chemoresistance of tumor cells.","Androgen Receptor Antagonist BAY 1161116 | AR Antagonist BAY 1161116 | BAY 1161116 | BAY-1161116 | BAY1161116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551143","Amblyomin-X","C148521","A recombinant form of a toxic protein derived from the salivary glands of the Amblyomma cajennense tick that inhibits Factor Xa and induces apoptosis, with potential antithrombotic and antineoplastic activities.  Upon administration, amblyomin-X promotes endoplasmic reticulum (ER) stress, mitochondrial dysfunction, cytochrome-c release, poly(ADP-ribose) polymerase (PARP) cleavage, and activation of caspase. Additionally, this agent selectively induces apoptosis in tumor cells. It also affects endothelial cell functions, such as adhesion, and may inhibit angiogenesis. Amblyomin-X targets and binds to factor Xa, inhibits its activity and interrupts the blood coagulation cascade, thereby preventing thrombin formation and thrombus development. As cancer is associated with thrombosis, amblyomin-X could potentially exert its antineoplastic and antithrombotic effects in the cancer patient at the same time.","Amblyomin-X | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418381","PCNX2 Gene","C148617","This gene may play a role in Notch signaling, cell cycle regulation and tumorigenesis.","PCNX2 Gene | PCNX2 | Pecanex Homolog 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545626","ATLAS - Albumin","C147846","ATLAS Score (ATLAS) Albumin (serum).","ATLAS - Albumin | ATLAS1-Albumin | ATLAS104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545627","ATLAS - Serum Creatinine","C147847","ATLAS Score (ATLAS) Serum creatinine (as a measure of renal function).","ATLAS - Serum Creatinine | ATLAS1-Serum Creatinine | ATLAS105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545628","ATLAS - Score","C147848","ATLAS Score (ATLAS) Score.","ATLAS - Score | ATLAS1-Score | ATLAS106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545629","IGF2BP2 Gene","C147849","This gene plays a role in RNA transport and mRNA stability.","IGF2BP2 Gene | IGF2BP2 | Insulin-Like Growth Factor 2 mRNA Binding Protein 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551052","Astragalus membranaceus/Angelica gigas/Trichosanthes kirilowii Maximowicz Mixed Herbal Extract SH003","C148489","A traditional Chinese medicine (TCM)-based herbal extract composed of Astragalus membranaceus (Am), Angelica gigas (Ag) and Trichosanthes kirilowii Maximowicz (Tk), with potential anti-angiogenic and antineoplastic activities. Upon administration, the active ingredients in Am/Ag/Tk mixed herbal extract SH003 work synergistically to exert a number of activities through various mechanisms of action (MOA); although, not all of the MOAs are fully elucidated. SH003 blocks the binding of vascular endothelial growth factor (VEGF) to its receptor VEGF receptor 2 (VEGFR2; KDR), thereby inhibiting VEGF/VEGFR2-mediated signaling and VEGF-induced tumor endothelial cell migration, invasion and tube formation. This inhibits tumor angiogenesis. In addition, SH003 inhibits signal transducer and activator of transcription 3 (STAT3) activation and STAT3-mediated signaling, decreases the production of the pro-inflammatory cytokine interleukin-6 (IL-6), and the expression of STAT3 target genes. This induces apoptosis in, and reduces proliferation and metastasis of, cancer cells in which STAT3 signaling is overactivated. STAT3 activation contributes to inflammation in the cancer environment and tumor cell proliferation.","Astragalus membranaceus/Angelica gigas/Trichosanthes kirilowii Maximowicz Mixed Herbal Extract SH003 | Am/Ag/Tk Herbal Extract SH003 | SH003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551051","Autologous CD5-specific CAR-28 zeta CAR T-cells","C148490","Autologous T-lymphocytes transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD5 single chain variable fragment (scFv) coupled to the costimulatory signaling domain CD28 and the zeta chain of the T-cell receptor (TCR), with potential immunomodulating and antineoplastic activities. Upon transfusion, the autologous CD5-specific CAR-28 zeta CAR T-cells are directed to and induce selective toxicity in CD5-expressing tumor cells. The tumor-associated antigen (TAA) CD5 is a T-cell surface glycoprotein expressed on the surface of normal T-cells, and is overexpressed on various B- and T-cell malignancies; its expression is associated with poor prognosis.","Autologous CD5-specific CAR-28 zeta CAR T-cells | Autologous CD5-specific CAR-28 zeta CAR T-lymphocytes | Autologous CD5.CAR/28zeta CAR T Cells | CD5.CAR/28zeta CAR T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551054","HER2-targeted DARPin MP0274","C148491","A proprietary, designed ankyrin repeat proteins (DARPin)-based agent targeting the tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2), with potential antineoplastic activity. Compared to antibodies, DARPins are small in size, have favorable pharmacokinetics and allow for both high affinity binding and efficacy. Upon administration, the HER2-targeted DARPin MP0274 binds to two distinct non-overlapping epitopes on HER2, thereby inhibiting the activity of HER2 and promoting HER2 internalization. This prevents HER2-mediated signaling, induces apoptosis and inhibits the growth of HER2-overexpressing tumor cells. DARPin also binds to human serum albumin, which extends the half-life of MP0274. HER2 is overexpressed in a variety of cancer cell types and is associated with increased tumor cell proliferation.","HER2-targeted DARPin MP0274 | DARPin MP0274 | HER-2-targeting DARPin MP0274 | HER2-targeting DARPin Drug MP0274 | MP 0274 | MP0274",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551048","Advanced Urothelial Carcinoma","C148493","Urothelial carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Urothelial Carcinoma | Advanced Urothelial Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551047","Locally Advanced Melanoma","C148494","Melanoma that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Melanoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550925","GLAUCOMA 3, PRIMARY CONGENITAL, A","C148260","An autosomal recessive form of congenital glaucoma caused by mutation(s) in the CYP1B1 gene, encoding cytochrome P450 1B1.","Primary Congenital Glaucoma 3A | GLC3A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0406704","Ectrodactyly-Ectodermal Dysplasia-Cleft Syndrome","C148261","A rare form of ectodermal dysplasia, inherited in an autosomal dominant fashion, manifesting with varying degrees of severity, ectrodactyly and cleft lip/palate.","Ectrodactyly-Ectodermal Dysplasia-Cleft Syndrome | EEC Syndrome",,,,,,,,,,,,,,,"4219588","Ectrodactyly-ectodermal dysplasia-clefting syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL550927","Administration via Dialysis","C148262","No value exists.","Administration via Dialysis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552454","System Support Mapping","C148263","A method by which trained facilitators guide participants to create a visual diagram of their self-management activities within their broader life context. MAP helps participants tangibly see complex self-management activities on paper, facilitating self-awareness and patient-driven engagement which makes them more actionable.","System Support Mapping | MAP | MAP Intervention | System Support Mapping Intervention",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550922","CliniMACS CD34 Reagent System","C148264","A proprietary flow cytometry system that uses anti-CD34 antibodies to isolate CD34+ cells from apheresis specimens.","CliniMACS CD34 Reagent System | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550919","Combined Dosage Form","C148268","No value exists.","Combined Dosage Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551142","PAN 301-1","C148522","A nanoparticle-based cancer vaccine composed of a neutralized bacteriophage Lambda construct that is genetically engineered to contain peptide fragments of human aspartyl/asparaginyl beta-hydroxylase (HAAH; ASPH) on its surface and are fused to the C-terminus of the head protein of phage lambda gpD, with potential immunostimulating and antineoplastic activities. HAAH lambda phage vaccine SNS-301 also contains DNA fragments representing the phage CpG motif that activate the MHC class II pathway. Upon intradermal administration of the HAAH lambda phage vaccine SNS-301, the bacteriophage exposes the immune system to HAAH, producing a HAAH-specific antibody response, and may activate the immune system to induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against HAAH-expressing tumor cells. HAAH is a transmembrane protein and highly conserved enzyme that catalyzes the hydroxylation of aspartyl and asparaginyl residues in epidermal growth factor-like domains of substrate proteins. HAAH is normally expressed in fetal development and is upregulated in a variety of cancer cell types, while its expression is nearly absent in healthy, normal cells. HAAH plays a key role in cancer cell growth, cell motility and invasiveness. Its expression is associated with a poor prognosis.","HAAH Lambda phage Vaccine SNS-301 | Bacteriophage Cancer Vaccine SNS-301 | HAAH-1/2/3 Lambda Phage Vaccine SNS-301 | Nanoparticle HAAH Vaccine SNS-301 | PAN 301-1 | PAN-301-1 | SNS 301 | SNS-301 | SNS301",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551145","Autologous CD38-4SCAR-expressing T-cells 4SCAR38","C148523","A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a fourth generation chimeric antigen receptor (4SCAR) consisting of an anti-CD38 single chain variable fragment (scFv) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (TCR), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous CD38-4SCAR-expressing T-cells 4SCAR38 are directed to and induce selective toxicity in CD38-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.","Autologous CD38-4SCAR-expressing T-cells 4SCAR38 | 4S-CD38-CAR-T Cell | 4SCAR38 | 4SCAR38 T-cells | Anti-CD38 CAR-T Cells 4SCAR38 | Anti-CD38-CD28-CD137-CD27-CD3z-iCasp9 CAR T-cells 4SCAR38 | CD38-4SCAR-expressing T Lymphocytes | CD38-scFv/CD28/CD137/CD27/CD3z-iCasp9 T-cells | CD38-specific 4th Generation Chimeric Antigen Receptor-modified T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550804","Oral Therapeutic Vaccine V3-X","C148144","An orally bioavailable therapeutic vaccine consisting of the tumor-associated antigen (TAA) oligosaccharide antigen sialyl Lewis A (CA19-9; sialylated Lewis A antigen; carbohydrate antigen 19-9; cancer antigen 19-9), with potential immunostimulating and antineoplastic activities. Upon oral administration, oral therapeutic vaccine V3-X induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing CA19-9. CA19-9 is an antigen that is overexpressed in a variety of cancer cell types, and plays a key role in tumor cell survival and metastasis.","Oral Therapeutic Vaccine V3-X | CA19-9 Oral Vaccine V3-X | V3 X | V3-X | V3-X Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550803","Lutetium Lu 177 Vipivotide Tetraxetan","C148145","A radioconjugate composed of PSMA-617, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of lutetium Lu 177  vipivotide tetraxetan, vipivotide tetraxetan targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.","Lutetium Lu 177 Vipivotide Tetraxetan | 177Lu-PSMA-617 | 177Lu-labeled PSMA-617 | AAA 617 | AAA-617 | AAA617 | LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN | Lu177-PSMA-617 | Lutetium Lu 177  Vipivotide Tetraxetan | Lutetium Lu 177 vipivotide tetraxetan | Lutetium Lu 177-PSMA-617 | Lutetium-177-PSMA-617 | Pluvicto",,,,,,,,,,,,,,,"37167158","Lutetium (Lu-177) vipivotide tetraxetan",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL550859","Donor-derived Cytokine-induced Memory-like Natural Killer Cells","C148213","A population of donor-derived cytokine-induced, memory-like, cytotoxic natural killer (NK) cells (CIML NKs), with potential antitumor activity. Allogeneic NK cells are pre-activated ex vivo with various cytokines, which induces the differentiation of the NK cells into CIML NK cells. The pretreated NK cells exhibit enhanced activation and interferon-gamma (IFN-g) responses, and may exert enhanced cytotoxicity against tumor cells. Upon administration, the CIML NKs may induce an anti-tumor immune response and kill tumor cells.","Donor-derived Cytokine-induced Memory-like Natural Killer Cells | Allogeneic CIML NK Cells | Allogeneic CIML NKs | Allogeneic Cytokine-induced Memory-like NK Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550858","Autologous AML/Dendritic Cell Fusion Vaccine","C148214","A therapeutic cell-based cancer vaccine consisting of autologous dendritic cells (DCs) fused with autologous acute myeloid leukemia (AML) cells, with potential immunostimulatory and antineoplastic activities. The autologous AML/DC fusion vaccine is generated in vitro by mixing DCs and irradiated AML cells harvested from individual patients, in the presence of polyethylene glycol (PEG), to produce hybrid DC-leukemia fusion cells. Upon re-administration, the autologous AML/DC fusion vaccine may elicit a cytotoxic T-lymphocyte (CTL)-mediated antitumor immune response against a broad array of AML-associated antigens, which may lead to AML cell lysis.","Autologous AML/Dendritic Cell Fusion Vaccine | Autologous AML/DC Fusion Vaccine | Autologous DC/AML Fusion Vaccine | Autologous Dendritic Cell/AML Fusion Vaccine | DC/AML Fusion Cell Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550854","Allogeneic iC9/CAR19/IL15-transduced CB-NK Cells","C148215","A preparation of allogeneic, umbilical cord blood (CB)-derived natural killer cells (NKs) transduced with a retroviral vector expressing interleukin-15 (IL-15) and encoding a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19 that is coupled to the co-stimulatory domains of CD28 and to the zeta chain of the TCR/CD3 complex (CD3-zeta), and is linked to the suicide gene inducible caspase 9 (iCasp9; iC9), with potential immunomodulating and antineoplastic activities. Upon transfusion, the allogeneic iC9/CD19-CAR-CD28-zeta-2A-IL15-transduced CB-NKs TAK-007 recognize, bind to and induce selective cytotoxicity in CD19-expressing tumor cells. The iCasp9 safety switch consists of a full-length caspase 9, including its caspase recruitment domain, linked to a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V). If the administered NK cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered; AP1903 binds to the FKBP12-F36V drug-binding domain, activates caspase 9, and results in apoptosis of the administered NK cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. IL-15 enhances the cytotoxic effect of the NK cells.","Allogeneic iC9/CD19-CAR-CD28-zeta-2A-IL15-transduced Cord Blood-derived Natural Killer Cells TAK-007 | Allogeneic iC9/CAR19/IL15-transduced CB-NK Cells | CAR-CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK Cells | TAK 007 | TAK-007 | TAK007 | UCB-derived CAR-CD19-CD28-zeta-2A-iCasp9-IL15 Engineered NK Cells | iC9/CAR-CD19-CD28-zeta-2A/IL-15 CB-NK Cells | iC9/CAR.19/IL15-transduced CB-NK Cells | iC9/CAR19/IL15-transduced CB-NKs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550853","Autologous PD-L1/CD80/CD86-targeted CAR-T Cells","C148216","A preparation of autologous human T-lymphocytes engineered to express a chimeric antigen receptor (CAR) composed of a modified from of the human inhibitory receptor programmed cell death protein 1 (PD-1; PDCD1), in which the intracellular signal domain of PD-1 is transformed to allow for stimulatory signaling but with an intact extracellular ligand binding domain that specifically binds the tumor-associated antigen (TAA) programmed cell death-1 ligand 1 (PD-L1), and a modified form of the T-cell inhibitory receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with a transformed intracellular signal domain to allow for stimulatory signaling, which specifically binds the B7 proteins CD80 (B7-1) and CD86 (B7-2), with potential immunostimulating and antineoplastic activities. Usually, ligand binding to PD-1 and CTLA-4 inhibits T-cell activity; however, these modified forms of PD-1 and CTLA-4 promote T-cell stimulatory signaling. Upon administration, the autologous PD-L1/CD80/CD86-targeted CAR-T cells target and bind to PD-L1 expressed on certain tumor cells and to CD80/CD86 expressed on antigen-presenting cells (APCs). This stimulates T-cell activation, T-cell proliferation and enhanced cytokine production, which induces selective toxicity in tumor cells expressing PD-L1. PD-1, found on activated T-cells, negatively regulates T-cell activity; it plays a key role in immune evasion and prevents tumor cell lysis. PD-L1 is often overexpressed on tumor cell types and plays a key role in immune evasion. The co-stimulatory molecules CD80 and CD86 play a key role in T-lymphocyte activation upon binding to CD28 upon antigen recognition; however, binding of CD80 and CD86 to wild-type CTLA-4 inhibits T-cell activity and results in T-cell exhaustion.","Autologous PD-L1/CD80/CD86-targeted CAR-T Cells | Autologous CAR-T Cells Targeting PD-L1 and CD80/CD86 | Z-CTLs | Zeushield CTLs | Zeushield Cytotoxic T Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551273","Dose Dispenser Cartridge","C149443","Container intended for use in a dose dispenser, usually pre-filled with a medicinal product.","Dose Dispenser Cartridge | Dose-dispenser cartridge",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551272","Dredging Applicator Device","C149444","Closure with dredging device.","Dredging Applicator Device | Dredging applicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551274","Drench Gun","C149446","Device for administering an oral liquid to an animal.","Drench Gun | Drench gun",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552446","Dressing Dosing Unit","C149447","A unit of presentation used to represent the quantity of product that is found in a single discrete entity where the pharmaceutical dose form is a type of dressing.","Dressing Dosing Unit | Dressing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551269","Dropper with Screw Cap Device","C149448","Screw cap with dropper.","Dropper with Screw Cap Device | Dropper applicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551271","Dropper Container","C149449","A container, usually a bottle, fitted with a dropper applicator.","Dropper Container | Dropper container",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551270","Ear Drops Emulsion Dosage Form","C149450","Liquid single-dose or multidose preparation consisting of an emulsion intended for application to the external auditory meatus. Multidose containers may be dropper containers or containers provided with a dropper applicator, or the dropper may be supplied separately. Drops are not necessarily administered dropwise, but may also be administered as a small volume.","Ear Drops Emulsion Dosage Form | Ear drops, emulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551384","Ear drops, Powder for Suspension Dosage Form","C149451","Powder and solvent intended for the preparation of ear drops, suspension, by dispersing the powder in the solvent.","Ear drops, Powder for Suspension Dosage Form | Ear drops, powder and solvent for suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551386","Ear Drops Solution Dosage Form","C149453","Liquid single-dose or multidose preparation consisting of an aqueous or oily solution intended for application to the external auditory meatus. Multidose containers may be dropper containers or containers provided with a dropper applicator, or the dropper may be supplied separately. Drops are not necessarily administered dropwise, but may also be administered as a small volume.","Ear Drops Solution Dosage Form | Ear drops, solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551385","Ear Gel Dosage Form","C149454","Semi-solid single-dose or multidose preparation consisting of a gel intended for application to the external auditory meatus, if necessary by means of a tampon impregnated with the preparation.","Ear Gel Dosage Form | Ear gel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551600","Oral Emulsion Dosage Form","C149713","Liquid, single-dose or multidose preparation consisting of an emulsion intended for oral use. Each dose from a multidose container is administered by means of a device suitable for measuring the prescribed volume. The device is usually a spoon or a cup for volumes of 5 mL or multiples thereof or an oral syringe for other volumes.","Oral Emulsion Dosage Form | Oral emulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551599","Oral emulsion in sachet","C149714","Medicinal product consisting of an oral emulsion presented in a sachet.","Oral Emulsion in Sachet Dosage Form | Oral Emulsion in Sachet | Oral emulsion in sachet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551594","Oral Herbal Material Dosage Form","C149715","Solid preparation consisting of whole, broken or fragmented plants or parts of plants in an unprocessed state (herbal drug), intended for oral use without requiring transformation (e.g. dissolution or dispersion in water); the material may be dried or fresh, and may be chewed before being swallowed. The word 'plant' is used in the broader sense to include also algae, fungi and lichens.","Oral Herbal Material Dosage Form | Oral herbal material",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551593","Oral Liquid Dosage Form","C149716","Liquid, single-dose or multidose preparation consisting of a liquid active substance per se, intended for oral use. Each dose from a multidose container is administered by means of a device suitable for measuring the prescribed volume. The device is usually a spoon or a cup for volumes of 5 mL or multiples thereof or an oral syringe for other volumes.","Oral Liquid Dosage Form | Oral liquid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550916","Dosage Form and Package Type","C148275","No value exists.","Dosage Form and Package Type | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447796","IGF2BP2 protein, human","C147851","Insulin-like growth factor 2 mRNA-binding protein 2 (599 aa, ~66 kDa) is encoded by the human IGF2BP2 gene. This protein plays a role in the translation, localization and stability of mRNA.","Insulin-Like Growth Factor 2 mRNA Binding Protein 2 | Hepatocellular Carcinoma Autoantigen p62 | IGF II mRNA Binding Protein 2 | IGF-II mRNA-Binding Protein 2 | IGF2 mRNA-Binding Protein 2 | IGF2BP2 | IMP-2 | VICKZ Family Member 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545731","Recurrent Lymphoproliferative Disorder","C147861","The reemergence of a lymphoproliferative disorder after a period of remission.","Recurrent Lymphoproliferative Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551663","Powder and Solvent for Emulsion for Injection Dosage Form","C149779","Sterile powder and sterile solvent intended for the preparation of an emulsion for injection by mixing the powder and the solvent.","Powder and Solvent for Emulsion for Injection Dosage Form | Powder and solvent for emulsion for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551657","Powder and Solvent for Endosinusial Solution Dosage Form","C149781","Powder and solvent intended for the preparation of an endosinusial solution by dissolving the powder in the solvent.","Powder and Solvent for Endosinusial Solution Dosage Form | Powder and solvent for endosinusial solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551660","Powder and Solvent for Epilesional Solution Dosage Form","C149782","Sterile powder and sterile solvent intended for the preparation of an epilesional solution by dissolving the powder in the solvent.","Powder and Solvent for Epilesional Solution Dosage Form | Powder and solvent for epilesional solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551659","Powder and Solvent for Gingival Gel Dosage Form","C149783","Powder and solvent intended for the preparation of a gingival gel by mixing the powder and the solvent.","Powder and Solvent for Gingival Gel Dosage Form | Powder and solvent for gingival gel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551654","Powder and Solvent for Implantation Paste Dosage Form","C149784","Sterile powder and sterile solvent intended for the preparation of an implantation paste by dispersing the powder in the solvent.","Powder and Solvent for Implantation Paste Dosage Form | Powder and solvent for implantation paste",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3851786","UBE2O protein, human","C150023","(E3-independent) E2 ubiquitin-conjugating enzyme (1292 aa, ~141 kDa) is encoded by the human UBE2O gene. This protein is involved in the monoubiquitination of target proteins.","(E3-Independent) E2 Ubiquitin-Conjugating Enzyme | E2/E3 Hybrid Ubiquitin-Protein Ligase UBE2O | EC 2.3.2.24 | UBE2O | Ubiquitin Carrier Protein O | Ubiquitin Conjugating Enzyme E2O | Ubiquitin-Conjugating Enzyme E2 O | Ubiquitin-Conjugating Enzyme E2 of 230 kDa | Ubiquitin-Conjugating Enzyme E2-230K | Ubiquitin-Conjugating Enzyme E2O | Ubiquitin-Protein Ligase O",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551786","Ceftolozane","C150024","A semi-synthetic, broad-spectrum, fifth-generation cephalosporin antibiotic with bactericidal activity against certain Gram-negative and Gram-positive bacteria. Upon administration, ceftolozane binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. This interferes with the final transpeptidation step required to form peptidoglycan chain cross-links, which are a key component of and provide strength and rigidity to the bacterial cell wall. This inhibits bacterial cell wall synthesis and reduces cell wall stability, which weakens the bacterial cell wall and causes bacterial cell lysis.","Ceftolozane | (6R,7R)-3-((5-Amino-4-(((2-aminoethyl)carbamoyl)amino)-1-methyl-1H-pyrazol-2-ium-2- yl)methyl)-7-(((2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-((1-carboxy-1- methylethoxy)imino)acetyl)amino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- Carboxylate | 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic Acid, 3-((4-((((2- Aminoethyl)amino)carbonyl)amino)-2,3-dihydro-3-imino-2-methyl-1H-pyrazol-1- yl)methyl)-7-(((2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-((1-carboxy-1- methylethoxy)imino)acetyl)amino)-8-oxo-, (6R,7R)- | CEFTOLOZANE | CXA-101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551781","NFKBIZ Gene","C150025","This gene plays a role in the regulation of nuclear factor kappa-B-mediated gene transcription.","NFKBIZ Gene | NFKB Inhibitor Zeta Gene | NFKBIZ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551780","NFKBIZ wt Allele","C150026","Human NFKBIZ wild-type allele is located in the vicinity of 3q12.3 and is approximately 33 kb in length. This allele, which encodes NF-kappa-B inhibitor zeta protein, is involved in the modulation of nuclear factor kappa-B-mediated gene transcription.","NFKBIZ wt Allele | FLJ34463 | IKBZ | INAP | MAIL | NFKB Inhibitor Zeta wt Allele | Nuclear Factor of Kappa Light Polypeptide Gene Enhancer in B-Cells Inhibitor, Zeta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551783","Thoracic Esophagus Adenocarcinoma","C150027","An adenocarcinoma that arises from the thoracic esophagus.","Thoracic Esophagus Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551782","Barrel Container","C150028","A large, cylindrical container, suited for liquid, solid and semi-solid pharmaceutical forms.","Barrel Container | Barrel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551777","Thoracic Esophagus Squamous Cell Carcinoma","C150029","A squamous cell carcinoma that arises from the thoracic esophagus.","Thoracic Esophagus Squamous Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551776","Cervical Esophagus Adenocarcinoma","C150031","An adenocarcinoma that arises from the cervical esophagus.","Cervical Esophagus Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550980","Impregnated Dosage Form","C148439","No value exists.","Impregnated Dosage Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556367","Dispersion Dosage Form Category","C148443","A type of liquid pharmaceutical dose form consisting of one or more substances, excluding solid particles and large liquid droplets, that are dispersed in an appropriate liquid vehicle.","Dispersion Dosage Form Category | Dispersion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550979","Gastrointestinal Dosage Form","C148444","No value exists.","Gastrointestinal Dosage Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550978","Gingival Dosage Form","C148445","No value exists.","Gingival Dosage Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551092","Herbal Dosage Form","C148448","No value exists.","Herbal Dosage Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551091","Uterine Dosage Form","C148449","No value exists.","Uterine Dosage Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551085","Laryngopharyngeal Dosage Form","C148451","No value exists.","Laryngopharyngeal Dosage Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554818","Medicinal Gas Dosage Form Category","C148452","A type of gaseous pharmaceutical dose form consisting of a pure substance or mixture of substances that exist in the form of a gas at normal atmospheric pressure and room temperature.","Medicinal Gas Dosage Form Category | Medicinal gas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551087","Multi-dose Container","C148453","A container holding a quantity of the preparation suitable for 2 or more doses.","Multi-dose Container | Multidose container",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551082","Nasal Powder Dosage Form","C148454","Solid, usually multidose preparation consisting of one or more powders of solid active substance(s) intended for nasal use by insufflation into the nasal cavity.","Nasal Powder Dosage Form | Nasal powder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551596","Oral Lyophilisate Dosage Form","C149717","Solid single-dose preparation made by freeze-drying of a liquid or semi-solid preparation. This fast-releasing preparation is intended to be placed in the mouth where its contents are released in saliva and swallowed or, alternatively, to be dissolved in water before oral administration.","Oral Lyophilisate Dosage Form | Oral lyophilisate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551595","Oral paste in sachet","C149718","Medicinal product consisting of an oral paste presented in a sachet.","Oral Paste in Sachet Dosage Form | Oral Paste in Sachet | Oral paste in sachet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551590","Oral powder in sachet","C149719","Medicinal product consisting of an oral powder presented in a sachet.","Oral Powder in Sachet Dosage Form | Oral Powder in Sachet | Oral powder in sachet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551592","Oral solution in single-dose container","C149721","Medicinal product consisting of an oral solution presented in a single-dose container.","Oral Solution in Single-dose Container Dosage Form | Oral Solution in Single-dose Container | Oral solution in single-dose container",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551591","Oral solution/concentrate for nebuliser solution","C149722","Liquid preparation consisting of a solution intended for oral use or intended to be diluted in the specified liquid to obtain a nebulizer solution.","Oral Solution/Concentrate for Nebulizer Solution Dosage Form | Oral Solution/Concentrate for Nebulizer Solution | Oral solution/concentrate for nebuliser solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551587","Oral Spray, Suspension Dosage Form","C149723","Liquid, usually multidose preparation for veterinary use consisting of a suspension intended for oral use. It is administered by spraying, including by spraying as coarse droplets over the animal(s), which then consume the product, for example during preening.","Oral Spray, Suspension Dosage Form | Oral spray, suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551586","Oral suspension in pre-filled oral applicator","C149724","Medicinal product consisting of an oral suspension presented in a pre-filled oral applicator.","Oral Suspension in Pre-filled Oral Applicator Dosage Form | Oral Suspension in Pre-filled Oral Applicator | Oral suspension in pre-filled oral applicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551588","Oral suspension in sachet","C149725","Medicinal product consisting of an oral suspension presented in a sachet.","Oral Suspension in Sachet Dosage Form | Oral Suspension in Sachet | Oral suspension in sachet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0302620","Oral Syringe","C149726","Administration device for administering a liquid or semi-solid pharmaceutical form to the oral cavity.","Oral Syringe | Oral syringe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551583","Oral/Rectal Solution Dosage Form","C149727","Liquid preparation consisting of a solution intended for oral or rectal use.","Oral/Rectal Solution Dosage Form | Oral/rectal solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551585","Orally Disintegrating Film Dosage Form","C149729","Solid preparation consisting of a single- or multilayer sheet of suitable material(s) intended to be placed in the mouth where it disperses rapidly before being swallowed.","Orally Disintegrating Film Dosage Form | Orodispersible film",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551584","Oral Disintegration Method of Administration","C149730","The technique of administration of a pharmaceutical product by placing it in the mouth and allowing it to dissipate; the product is usually then swallowed.","Oral Disintegration Method of Administration | Orodispersion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550447","Oromucosal","C149731","Relating to the mouth as the intended site of administration, where the pharmaceutical product is administered with the intention of acting on the mucosa of the mouth, whether for local or systemic use.","Oromucosal | ",,,,,,,,,,,,,,,"42538091","Oromucosal",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL551831","Suspension for Suspension for Injection Dosage Form","C149971","Liquid sterile preparation consisting of a suspension intended for use in the preparation of a suspension for injection.","Suspension for Suspension for Injection Dosage Form | Suspension for suspension for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551827","Suspension for Use in Drinking Water Dosage Form","C149972","Liquid preparation for veterinary use consisting of a suspension intended for administration by incorporation into the animal drinking water. If direct oral administration to individual animals is also authorized, the method of administration, including any necessary dilution, is clearly described in the product information.","Suspension for Use in Drinking Water Dosage Form | Suspension for use in drinking water",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545732","Recurrent EBV-Related Lymphoma","C147863","The reemergence of EBV-related lymphoma after a period of remission.","Recurrent EBV-Related Lymphoma | Recurrent EBV-Associated Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416826","LEPROTL1 Gene","C147864","This gene is involved in the downregulation of growth hormone receptor (GHR) signaling.","LEPROTL1 Gene | LEPROTL1 | Leptin Receptor Overlapping Transcript Like 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545734","LEPROTL1 wt Allele","C147865","Human LEPROTL1 wild-type allele is located in the vicinity of 8p12 and is approximately 82 kb in length. This allele, which encodes leptin receptor overlapping transcript-like 1 protein, plays a role in the negative regulation of growth hormone receptor (GHR) signaling.","LEPROTL1 wt Allele | HSPC112 | Leptin Receptor Overlapping Transcript Like 1 wt Allele | UNQ577/PRO1139 | Vps55 | my047",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545735","Leptin Receptor Overlapping Transcript-Like 1","C147866","Leptin receptor overlapping transcript-like 1 (131 aa, ~14 kDa) is encoded by the human LEPROTL1 gene. This protein is involved in the modulation of growth hormone receptor (GHR) localization to the cell surface.","Leptin Receptor Overlapping Transcript-Like 1 | Endospanin-2 | LEPROTL1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545720","N4BP2 Gene","C147867","This gene plays a role in 5'-polydeoxyribonucleotide kinase and nicking endonuclease activity.","N4BP2 Gene | N4BP2 | NEDD4 Binding Protein 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545721","N4BP2 wt Allele","C147868","Human N4BP2 wild-type allele is located in the vicinity of 4p14 and is approximately 130 kb in length. This allele, which encodes NEDD4-binding protein 2, is involved in DNA processing.","N4BP2 wt Allele | B3BP | KIAA1413 | NEDD4 Binding Protein 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1310699","N4BP2 protein, human","C147869","NEDD4-binding protein 2 (1770 aa, ~199 kDa) is encoded by the human N4BP2 gene. This protein plays a role in DNA modification.","NEDD4-Binding Protein 2 | BCL-3 Binding Protein | BCL-3-Binding Protein | N4BP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545723","SOX21 Gene","C147870","This gene is involved in the promotion of cellular differentiation.","SOX21 Gene | SOX21 | SRY-Box 21 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551049","Autologous PSMA-specific TGFb-resistant CAR T Cells","C148496","Autologous T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-prostate specific membrane antigen (PSMA) single chain variable fragment (scFv) and expressing a dominant negative (DN) form of transforming growth factor-beta (TGF-beta; TGFb) receptor, with potential immunomodulating and antineoplastic activities. Upon transfusion, the autologous PSMA-specific TGFb-resistant CAR T cells are directed to and induce selective toxicity in PSMA-expressing tumor cells. The tumor-associated antigen (TAA) PSMA is overexpressed by prostate cancers; its expression is associated with poor prognosis and metastasis. The inclusion of the DN TGFb receptor blocks signaling of the immunosuppressive cytokine TGFb in the tumor microenvironment (TME) and makes the CAR T cells resistant to TGFb. TGFb negatively regulates T-cell proliferation and activation and plays a key role in tumor immune suppression.","Autologous PSMA-specific TGFb-resistant CAR T Cells | Autologous CART-PSMA-TGFbRDN Cells | Autologous CART-PSMA-TGFbRDN T-cells | PSMA-specific/TGFb-resistant CAR-modified Autologous T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551045","Carbon C 11-JNJ-63779586","C148497","A radioconjugate composed of JNJ-63779586 labeled with the positron-emitting isotope carbon C 11, with potential use in imaging via positron emission tomography (PET).  Upon administration of carbon C 11-JNJ-63779586, the JNJ-63779586 moiety acts as a substrate for the efflux transporter P-glycoprotein (P-gp) and the breast cancer resistance protein (BCRP). Upon PET imaging, this radioligand may allow for the assessment of P-gp and BCRP function and expression in tumors. As P-gp and BCRP activity may influence response to therapy, measuring P-gp and BCRP activity may be beneficial when choosing chemotherapy. P-gp and BCRP, efflux transporters, are overexpressed by certain tumor cells and may contribute to multidrug resistance to chemotherapy.","Carbon C 11-JNJ-63779586 | 11C-JNJ-63779586",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551779","Cervical Esophagus Squamous Cell Carcinoma","C150032","A squamous cell carcinoma that arises from the cervical esophagus.","Cervical Esophagus Squamous Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551778","Gastric Cardia Squamous Cell Carcinoma","C150034","A squamous cell carcinoma that arises from the gastric cardia.","Gastric Cardia Squamous Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552425","Dispersion Activity","C150035","Transformation of a solid or gas into a dispersion or suspension by mixing it with a specified liquid.","Dispersion Activity | Dispersion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447823","NFKBIZ protein, human","C150036","NF-kappa-B inhibitor zeta (718 aa, ~78 kDa) is encoded by the human NFKBIZ gene. This protein plays a role in the inhibition of nuclear factor kappa-B-mediated gene transcription.","NF-Kappa-B Inhibitor Zeta | I-Kappa-B-Zeta | IL-1 Inducible Nuclear Ankyrin-Repeat Protein | IL1-Induced Nuclear Ankyrin Repeat Protein | INAP | IkB-Zeta | IkappaB-Zeta | IkappaBzeta | Interleukin 1-Induced Nuclear Ankyrin Repeat Protein | MAIL | Molecule Possessing Ankyrin Repeats Induced by Lipopolysaccharide | NFKBIZ | Nuclear Factor of Kappa Light Polypeptide Gene Enhancer in B-Cells Inhibitor Zeta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551890","Distal Esophagus Squamous Cell Carcinoma","C150037","A squamous cell carcinoma that arises from the distal esophagus.","Distal Esophagus Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Distal Esophagus | Squamous Cell Carcinoma of the Lower Third of the Esophagus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551889","KLHL42 Gene","C150038","This gene is involved in the regulation of both ubiquitination and microtubule dynamics.","KLHL42 Gene | KLHL42 | Kelch Like Family Member 42 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551887","Oromucosal/Laryngopharyngeal Solution/Spray, Solution Dosage Form","C150039","Liquid preparation consisting of a solution intended for oromucosal or laryngopharyngeal use, presented in a container with an optional spray device to allow administration as a spray.","Oromucosal/Laryngopharyngeal Solution/Spray, Solution Dosage Form | Oromucosal/laryngopharyngeal solution/spray, solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552038","ECO","C150262","Human CILK1 wild-type allele is located in the vicinity of 6p12.1 and is approximately 61 kb in length. This allele, which encodes serine/threonine-protein kinase ICK protein, is involved in intraflagellar transport and ciliogenesis. Mutation of the gene is associated with endocrine-cerebroosteodysplasia and susceptibility to juvenile myoclonic epilepsy.","CILK1 wt Allele | Ciliogenesis Associated Kinase 1 wt Allele | ECO | EJM10 | ICK | Iciliogenesis Associated Kinase 1 Gene | Intestinal Cell (MAK-Like) Kinase Gene | Intestinal Cell Kinase Gene | KIAA0936 | LCK2 | MGC46090 | MRK | hICK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1433158","intestinal cell (MAK-like) kinase protein, human","C150263","Serine/threonine-protein kinase ICK (632 aa, ~71 kDa) is encoded by the human CILK1 gene. This protein plays a role in serine/threonine-protein kinase activity, ciliogenesis and intraflagellar transport.","Serine/Threonine-Protein Kinase ICK | CILK1 | Ciliogenesis Associated Kinase 1 | EC 2.7.11.1 | ICK | Intestinal Cell Kinase | LCK2 | Laryngeal Cancer Kinase 2 | MAK-Related Kinase | MRK | Serine/Threonine Protein Kinase ICK | hICK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552031","ING4 wt Allele","C150265","Human ING4 wild-type allele is located in the vicinity of 12p13.31 and is approximately 13 kb in length. This allele, which encodes inhibitor of growth protein 4, plays a role in chromatin remodeling.","ING4 wt Allele | Candidate Tumor Suppressor p33 ING1 Homolog Gene | Inhibitor of Growth 4 Gene | Inhibitor of Growth Family Member 4 wt Allele | my036 | p29ING4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1436661","ING4 protein, human","C150266","Inhibitor of growth protein 4 (249 aa, ~29 kDa) is encoded by the human ING4 gene. This protein is involved in chromatin acetylation.","Inhibitor of Growth Protein 4 | Brain My036 Protein | ING4 | p29ING4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552028","ITGA10 wt Allele","C150268","Human ITGA10 wild-type allele is located in the vicinity of 1q21.1 and is approximately 19 kb in length. This allele, which encodes integrin alpha-10 protein, is involved in cell-matrix adhesion.","ITGA10 wt Allele | Integrin Subunit Alpha 10 wt Allele | Integrin, Alpha 10 Gene | Integrin, Alpha-10 Gene | PRO827 | UNQ468/PRO827",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551081","AU 4948","C148455","An orally bioavailable, reversible inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), with potential antineoplastic, immunomodulating and anti-inflammatory activities. Upon oral administration, emavusertib targets, binds to, and blocks the kinase activity of IRAK4. This inhibits IRAK4-mediated signaling, prevents the activation of IRAK4-mediated nuclear factor-kappa B (NF-kB) signaling and decreases the expression of inflammatory cytokines and certain pro-survival factors. This inhibits proliferation of IRAK4-overactivated tumor cells, which are found in cells harboring MYD88 activating mutations or those with overactivated toll-like receptor (TLR) pathways. In addition, CA-4948 may inhibit inflammation and immune-mediated cell destruction in inflammatory and auto-immune diseases where TLR or interleukin 1 receptor (IL-1R) signaling is overactivated and MYD88 is dysregulated. IRAK4, a serine/threonine-protein kinase that plays a key role in both the TLR and IL-1R signaling pathways, is activated though the adaptor protein MYD88 and links the TLR and IL-1R signaling pathway to the NF-kB pathway.","Emavusertib | AU 4948 | AU-4948 | CA 4948 | CA-4948 | CA4948 | EMAVUSERTIB | IRAK4 Inhibitor CA-4948 | Interleukin-1 Receptor-associated Kinase 4 Inhibitor CA-4948",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551084","Sublingual Dosage Form","C148456","No value exists.","Sublingual Dosage Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551083","Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma","C148457","A finding indicating the presence of a sarcoma arising from the soft tissue, other than rhabdomyosarcoma.","Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551079","Recurrent Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma","C148458","A finding indicating the reemergence of a sarcoma arising from the soft tissue, other than rhabdomyosarcoma, after a period of remission.","Recurrent Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551078","Refractory Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma","C148459","A finding indicating the presence of a sarcoma arising from the soft tissue, other than rhabdomyosarcoma, that is resistant to treatment.","Refractory Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1969029","Lissencephaly 3","C148461","An autosomal dominant sub-type of lissencephaly caused by mutation(s) in the TUBA1A gene, encoding adhesion tubulin alpha-1A chain.","Lissencephaly 3 | LIS3",,,,,,,,,,,,,,,"604649","Type 3 lissencephaly",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL551080","LOAd703","C148462","A double-armed oncolytic adenovirus composed of a recombinant genetically modified E1/E3-deleted, adenoviral serotype 5 (Ad5) vector, with the L5 segment of the Ad5 fiber replaced by the shaft and knob from the Ad35 serotype (Ad5/35), which expresses a trimerized (TMZ) form of the membrane-bound immunostimulator CD40 ligand (CD40L; TNFSF5) and the ligand for the signaling domain 4-1BB (4-1BBL; CD137L; TNFSF9), under the control of a CMV promoter, with potential immunostimulating and antineoplastic activities. Upon intratumoral administration of delolimogene mupadenorepvec, the virus infects and selectively replicates in tumor cells. This causes direct oncolysis and the release of a plethora of tumor-associated antigens (TAAs) from the tumor cells. The released TAAs stimulate the immune system and activate anti-tumor cytotoxic T-lymphocytes (CTLs), thereby further killing tumor cells. In addition, infected tumor cells and tumor stroma cells, including stellate cells and infiltrating immune cells, express the immunostimulants CD40L and 4-1BBL. The expressed CD40L and 4-1BBL proteins activate the CD40L- and 4-1BBL-mediated signaling pathways, respectively. This activates antigen-presenting cells (APCs), such as dendritic cells (DCs) and M1 macrophages. The DCs produce various cytokines, including interleukin-12 (IL12), IL21, tumor necrosis factor-alpha (TNFa), and interferon-gamma (IFNg), which leads to the activation and expansion of both T-cells and natural killer (NK) cells. Altogether, this modulates immune suppression in the tumor microenvironment (TME), disrupts tumor stroma, and causes additional immune stimulation against tumor cells, thereby inducing further tumor cell lysis. In addition, CD40L reduces myeloid suppressor cells in the TME. Inclusion of the chimeric Ad5/35 fiber targets CD46 and increases viral uptake in cells. Transgene expression is driven by a separate promoter to allow for efficient expression in both tumor cells and tumor stroma. Replication is restricted to tumor cells by the presence of the delta24 mutation in the E1A gene, which deletes the retinoplastoma protein (pRb)-binding domain and forces viral replication to be conditional on hyperphosphorylated pRb and a dysfunctional Rb pathway.","Delolimogene Mupadenorepvec | DELOLIMOGENE MUPADENOREPVEC | LOAd 703 | LOAd-703 | LOAd703 | Oncolytic Adenovirus LOAd703",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550591","Swallowing Method of Administration","C149973","The technique of administration of a pharmaceutical product by introducing it into the stomach via the mouth and esophagus with a voluntary muscular action.","Swallowing Method of Administration | Swallowing",,,,,,,,,,,,,,,"42538101","Swallow",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL551828","Syrup in sachet","C149974","Medicinal product consisting of a syrup in a sachet.","Syrup in Sachet Dosage Form | Syrup in Sachet | Syrup in sachet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552467","System Dosing Unit","C149975","A unit of presentation used to represent the quantity of product that is found in a single discrete entity where the pharmaceutical dose form is a type of system.","System Dosing Unit | System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551824","Tablet plus Vaginal Tablet Dosage Form","C149976","Combination package consisting of a tablet and a vaginal tablet.","Tablet plus Vaginal Tablet Dosage Form | Tablet + vaginal tablet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551823","Tablet and Powder for Oral Solution Dosage Form","C149977","Tablet and powder intended for the preparation of an oral solution by dissolving the tablet and the powder in the specified liquid. The tablet contains active ingredient(s); the powder does not contain active ingredient(s).","Tablet and Powder for Oral Solution Dosage Form | Tablet and powder for oral solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551826","Tablet and Solvent for Rectal Suspension Dosage Form","C149978","Tablet and solvent intended for the preparation of a rectal suspension by dispersing the tablet in the solvent.","Tablet and Solvent for Rectal Suspension Dosage Form | Tablet and solvent for rectal suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551825","Tablet Container","C149979","Container without neck and with a flat bottom, suited for tablets, capsules, etc., can be re-closed well.","Tablet Container | Tablet container",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551819","Tablet for Rectal Solution Dosage Form","C149981","Solid, usually single-dose preparation consisting of a tablet, usually uncoated, intended to be dissolved in the specified liquid to obtain a rectal solution.","Tablet for Rectal Solution Dosage Form | Tablet for rectal solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551822","Tablet for Rectal Suspension Dosage Form","C149982","Solid, usually single-dose preparation consisting of a tablet, usually uncoated, intended to be dispersed in the specified liquid to obtain a rectal suspension.","Tablet for Rectal Suspension Dosage Form | Tablet for rectal suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551821","Tablet for Vaginal Solution Dosage Form","C149983","Solid, usually single-dose preparation consisting of a tablet, usually uncoated, intended to be dissolved in the specified liquid to obtain a vaginal solution.","Tablet for Vaginal Solution Dosage Form | Tablet for vaginal solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554823","Tea Dosage Form Category","C149984","A type of solid pharmaceutical dose form consisting of one or more herbal drugs intended for preparation of a solution by decoction or maceration, or a lyophilized preparation of such a solution.","Tea Dosage Form Category | Tea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551815","Teat Dip Emulsion Dosage Form","C149985","Liquid preparation consisting of an emulsion intended for teat use. The teats of an animal are dipped pre- and, where necessary, post-milking to reduce the population of pathogenic micro-organisms on the surfaces.","Teat Dip Emulsion Dosage Form | Teat dip emulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551818","Teat Dip Solution Dosage Form","C149986","Liquid preparation consisting of a solution intended for teat use. The teats of an animal are dipped pre- and, where necessary, post-milking to reduce the population of pathogenic micro-organisms on the surfaces.","Teat Dip Solution Dosage Form | Teat dip solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551817","Teat Dip Suspension Dosage Form","C149987","Liquid preparation consisting of a suspension intended for teat use. The teats of an animal are dipped pre- and, where necessary, post-milking to reduce the population of pathogenic micro-organisms on the surfaces.","Teat Dip Suspension Dosage Form | Teat dip suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551812","Teat Dip/Spray Solution Dosage Form","C149988","Liquid preparation intended for use as a teat dip solution or as a teat spray solution.","Teat Dip/Spray Solution Dosage Form | Teat dip/spray solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551046","Allogeneic interleukin-17-producing CD8-positive T-cells","C148499","A preparation of allogeneic human cytotoxic T-lymphocytes that express the pro-inflammatory cytokine interleukin-17 (IL-17; IL17), with potential immunomodulating and anti-tumor activities. Upon ex vivo stimulation, the IL-17-producing CD8-positive T-cells (Tc17) convert to interferon-gamma (IFNg; IFN-g)-producing CD8-positive T-cells (Tc1). Tc1 cells exert enhanced anti-tumor cytotoxicity. Human Tc17 cells may contribute to a number of human inflammatory and malignant diseases.","Allogeneic interleukin-17-producing CD8-positive T-cells | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0213654","Tyrphostin A25","C1484","A member of the tyrphostin family of tyrosine kinase inhibitors that competitively binds and inhibits epidermal growth factor receptor and GTPase activity of transducin and induces apoptosis in human leukemic cell lines. (NCI)","Tyrphostin A25 | 4,5-Trihydroxybenzylidene malononitrile | AG 82",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1135757","ITGA10, human","C150269","Integrin alpha-10 (1167 aa, ~128 kDa) is encoded by the human ITGA10 gene. This protein plays a role in cell adhesion to collagen in the extracellular matrix.","Integrin Alpha-10 | ITGA10 | Integrin Subunit Alpha 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552029","ITGA9 wt Allele","C150271","Human ITGA9 wild-type allele is located in the vicinity of 3p22.2 and is approximately 371 kb in length. This allele, which encodes integrin alpha-9 protein, plays a role in cell adhesion-regulated signaling. Aberrant expression is associated with small cell lung cancers.","ITGA9 wt Allele | ALPHA-RLC | Alpha Related to the Development of Lung Cancer Gene | ITGA4L | Integrin Subunit Alpha 9 wt Allele | Integrin, Alpha 4-Like Gene | Integrin, Alpha 9 Gene | Integrin, Alpha-9 Gene | RLC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2717020","integrin alpha 9, human","C150272","Integrin alpha-9 (1035 aa, ~114 kDa) is encoded by the human ITGA9 gene. This protein is involved in cell-matrix binding and cell adhesion-dependent signaling.","Integrin Alpha-9 | ITGA9 | Integrin Alpha-RLC | Integrin Subunit Alpha 9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552026","ADGRL3 wt Allele","C150274","Human ADGRL3 wild-type allele is located in the vicinity of 4q13.1 and is approximately 877 kb in length. This allele, which encodes adhesion G protein-coupled receptor L3 protein, is involved in neuronal migration, cell-cell adhesion and G protein-coupled receptor signaling.","ADGRL3 wt Allele | Adhesion G Protein-Coupled Receptor L3 wt Allele | CIRL3 | CL3 | KIAA0768 | LEC3 | LPHN3 | Latrophilin Homolog 3 (Cow) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552019","LYZ wt Allele","C150277","Human LYZ wild-type allele is located in the vicinity of 12q15 and is approximately 6 kb in length. This allele, which encodes lysozyme C protein, plays a role in antimicrobial activity. Missense mutations in this gene are associated with hereditary renal amyloidosis.","LYZ wt Allele | LYZF1 | LZM | Lysozyme (Renal Amyloidosis) Gene | Lysozyme wt Allele | Renal Amyloidosis Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551332","Eye Drops Solvent for Reconstitution Dosage Form","C149507","Liquid preparation consisting of a sterile solvent containing no active substances, intended for reconstitution of a usually freeze-dried powder for eye drops.","Eye Drops Solvent for Reconstitution Dosage Form | Eye drops, solvent for reconstitution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551331","Ophthalmic Suspension Drops Dosage Form","C149508","Liquid sterile single-dose or multidose preparation consisting of an aqueous or oily suspension intended for ocular use. Multidose preparations are presented in containers that allow successive drops to be administered. The containers contain usually at most 10 mL of the preparation.","Ophthalmic Suspension Drops Dosage Form | Eye drops, suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551334","Eye drops, suspension in single-dose container","C149509","Medicinal product consisting of an eye drops suspension presented in a single-dose container.","Eye Drops, Suspension in Single-dose Container Dosage Form | Eye Drops, Suspension in Single-dose Container | Eye drops, suspension in single-dose container",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551333","Eye gel in single-dose container","C149510","Medicinal product consisting of an eye gel presented in a single-dose container.","Eye Gel in Single-dose Container Dosage Form | Eye Gel in Single-dose Container | Eye gel in single-dose container",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551327","Eye Lotion Solvent for Reconstitution Dosage Form","C149512","Liquid preparation consisting of a sterile solvent containing no active substances, intended for reconstitution of a usually freeze-dried powder for eye lotion.","Eye Lotion Solvent for Reconstitution Dosage Form | Eye lotion, solvent for reconstitution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551330","Eye ointment in single-dose container","C149513","Medicinal product consisting of an eye ointment presented in a single-dose container.","Eye Ointment in Single-dose Container Dosage Form | Eye Ointment in Single-dose Container | Eye ointment in single-dose container",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551329","Film-Coated Tablet plus Pessary Dosage Form","C149514","Combination package consisting of a film-coated tablet and a pessary.","Film-Coated Tablet plus Pessary Dosage Form | Film-coated tablet + pessary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551174","PCNX2 wt Allele","C148619","Human PCNX2 wild-type allele is located in the vicinity of 1q42.2 and is approximately 312 kb in length. This allele, which encodes pecanex-like protein 2, may be involved in cell cycle regulation and tumorigenesis. Mutation of the gene is associated with colorectal carcinomas.","PCNX2 wt Allele | FLJ11383 | KIAA0435 | PCNXL2 | Pecanex Homolog 2 (Drosophila) Gene | Pecanex Homolog 2 wt Allele | Pecanex, Drosophila, Homolog of, 2 Gene | Pecanex-Like 2 (Drosophila) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551167","Pecanex-Like Protein 2","C148622","Pecanex-like protein 2 (2137 aa, ~237 kDa) is encoded by the human PCNX2 gene. This protein may play a role in tumorigenesis, Notch signaling and cell cycle regulation.","Pecanex-Like Protein 2 | PCNX2 | Pecanex Homolog Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551163","GRHPR Gene","C148626","This gene is involved in the metabolism of glyoxylate and hydroxypyruvate.","GRHPR Gene | GRHPR | Glyoxylate and Hydroxypyruvate Reductase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551160","GRHPR wt Allele","C148629","Human GRHPR wild-type allele is located in the vicinity of 9p13.2 and is approximately 14 kb in length. This allele, which encodes glyoxylate reductase/hydroxypyruvate reductase protein, plays a role in hydroxypyruvate and glyoxylate metabolism. Mutation of the gene is associated with type II primary hyperoxaluria.","GRHPR wt Allele | GLXR | GLYD | Glycerate-2-Dehydrogenase Gene | Glyoxylate and Hydroxypyruvate Reductase wt Allele | MSTP035 | PH2 | Primary Hyperoxaluria Type 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551956","CMPK1 wt Allele","C150215","Human CMPK1 wild-type allele is located in the vicinity of 1p33 and is approximately 45 kb in length. This allele, which encodes UMP-CMP kinase protein, is involved in pyrimidine nucleoside monophosphate metabolism.","CMPK1 wt Allele | CK | CMK | CMPK | Cytidine Monophosphate (UMP-CMP) Kinase 1, Cytosolic Gene | Cytidine/Uridine Monophosphate Kinase 1 wt Allele | UCK | UMK | UMP-CMPK | UMPK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551955","APE1/Ref-1 Redox Inhibitor APX3330","C150216","An orally bioavailable inhibitor of apurinic/apyrimidinic endonuclease 1/reduction-oxidation (redox) effector factor-1 (APE1/Ref-1; APEX1), with potential anti-angiogenic and antineoplastic activities. Upon administration, the APE1/Ref-1 Inhibitor APX3330 selectively targets and binds to APE1/Ref-1. This inhibits the redox-dependent signaling activity of APE1/Ref-1, by preventing the reduction and activation of numerous APE1/Ref-1-dependent oncogenic transcription factors (TFs), such as nuclear factor kappa B (NF-kB), AP-1, STAT3, p53, NRF2 and HIF-1alpha, that are involved in signaling, cell proliferation, tumor progression and survival of cancer cells. Therefore, this agent inhibits the activation of multiple TF-mediated signaling pathways and inhibits tumor cell proliferation and survival.  APE1/Ref-1, a multifunctional protein overexpressed in many cancer cell types, plays a key role as a redox regulator of transcription factor activation and in base excision repair upon DNA damage. It drives cancer cell proliferation, migration, drug resistance, angiogenesis and inflammation and its expression level correlates with increased tumor aggressiveness and decreased patient survival. APX3330 specifically blocks the redox activity of APE1/Ref-1 and does not affect its ability to act as a DNA repair endonuclease.","APE1/Ref-1 Redox Inhibitor APX3330 | APE1/Ref-1 Inhibitor APX3330 | APX 3330 | APX-3330 | APX3330 | E 3330 | E3330 | [(2E)-2-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methylene]-undecanoic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552426","UMP-CMP Kinase","C150217","UMP-CMP kinase (196 aa, ~22 kDa) is encoded by the human CMPK1 gene. This protein plays a role in catalyzing the synthesis of cytidine and uridine diphosphate.","UMP-CMP Kinase | CK | CMPK1 | Cytidine Monophosphate Kinase | Cytidine/Uridine Monophosphate Kinase 1 | Cytidylate Kinase | Deoxycytidylate Kinase | EC 2.7.4.14 | EC 2.7.4.6 | Nucleoside-Diphosphate Kinase | UMP/CMP Kinase | UMP/CMPK | Uridine Monophosphate Kinase | Uridine Monophosphate/Cytidine Monophosphate Kinase | dCMP Kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551952","DNAH9 wt Allele","C150220","Human DNAH9 wild-type allele is located in the vicinity of 17p12 and is approximately 372 kb in length. This allele, which encodes dynein heavy chain 9, axonemal protein, plays a role in the regulation of the movement of cilia and flagella.","DNAH9 wt Allele | DNAH17L | DNEL1 | DYH9 | Dnahc9 | Dynein Axonemal Heavy Chain 9 wt Allele | Dynein, Axonemal, Heavy Chain 17-Like Gene | Dynein, Axonemal, Heavy Chain 9 Gene | Dynein, Axonemal, Heavy Polypeptide 17-Like Gene | Dynein, Axonemal, Heavy Polypeptide 9 Gene | Dynein, Axonemal, Light Intermediate Chain 1 Gene | HL-20 | HL20 | KIAA0357",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0967708","DNAH9 protein, human","C150221","Dynein heavy chain 9, axonemal (4486 aa, ~512 kDa) is encoded by the human DNAH9 gene. This protein is involved in the mediation of ciliary and flagellar movement.","Dynein Heavy Chain 9, Axonemal | Axonemal Beta Dynein Heavy Chain 9 | Ciliary Dynein Heavy Chain 9 | DNAH9",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551947","EPHB6 wt Allele","C150224","Human EPHB6 wild-type allele is located in the vicinity of 7q34 and is approximately 16 kb in length. This allele, which encodes ephrin type-B receptor 6, is involved in the modulation of ephrin-B signaling.","EPHB6 wt Allele | EPH Receptor B6 wt Allele | HEP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0540659","EPHB6 protein, human","C150225","Ephrin type-B receptor 6 (1021 aa, ~111 kDa) is encoded by the human EPHB6 gene. This protein plays a role in the regulation of ephrin-B signaling pathways.","Ephrin Type-B Receptor 6 | EPHB6 | Ephrin Receptor EphB6 | HEP | Human Kinase-Defective Eph-Family Receptor Protein | Tyrosine-Protein Kinase-Defective Receptor EPH-6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551949","Catheter Inner Diameter","C150226","The measurement of the diameter of the inner catheter tubing which goes over the guidewire.","Catheter Inner Diameter | Inner Diameter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550821","Unresectable Thymic Carcinoma","C148125","A thymus carcinoma that is not amenable to surgical resection.","Unresectable Thymus Carcinoma | Unresectable Thymic Carcinoma | Unresectable Thymic Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550818","Locally Advanced Thymic Carcinoma","C148126","A thymus carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Thymus Carcinoma | Locally Advanced Thymic Carcinoma | Locally Advanced Thymic Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550817","Recurrent Thymic Carcinoma","C148127","A thymus carcinoma that has recurred after a period of remission.","Recurrent Thymus Carcinoma | Recurrent Thymic Carcinoma | Recurrent Thymic Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4038952","Metastatic Thymic Carcinoma","C148128","A carcinoma that arises from the thymus and has spread from its original site of growth to another anatomic site.","Metastatic Thymus Carcinoma | Metastatic Thymic Carcinoma | Metastatic Thymic Carcinoma",,,,,,,,,,,,,,,"46271143","Metastatic thymic carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0862206","Refractory Mycosis Fungoides and Sezary Syndrome","C148129","Mycosis fungoides and Sezary syndrome that is resistant to treatment.","Refractory Mycosis Fungoides and Sezary Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550814","Locally Advanced Carcinoma","C148130","A carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550816","MR-Compatible Sectioning and Localization Device","C148132","A device designed to facilitate lesion detection and improve direct comparison of histopathologic specimens with prior in vivo imaging, consisting of an MRI compatible localization device, with MR-visible fiducial marks for ex vivo imaging to facilitate radiographic-pathologic correlation.","MR-Compatible Sectioning and Localization Device | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550910","Total Number of Prostate Tissue Cores","C148277","An indication of the total number of prostate core specimens collected during a biopsy procedure.","Total Number of Prostate Tissue Cores | Number Of Cores | Total Number of Prostate Cores",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550913","Number of Prostate Tissue Cores Positive for Carcinoma","C148278","An indication of the number of prostate core specimens that are identified as positive for carcinoma.","Number of Prostate Tissue Cores Positive for Carcinoma | Number Of Positive Cores | Number of Prostate Cores Positive for Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551439","Film-Coated Tablet plus Tablet Dosage Form","C149515","Combination package consisting of a film-coated tablet and a tablet.","Film-Coated Tablet plus Tablet Dosage Form | Film-coated tablet + tablet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551438","Film-coated tablet and gastro-resistant granules in sachet","C149516","Medicinal product consisting of a film-coated tablet and gastro-resistant granules presented together in a sachet and intended to be swallowed together as a single dose.","Film-Coated Tablet and Gastro-Resistant Granules in Sachet Dosage Form | Film-Coated Tablet and Gastro-Resistant Granules in Sachet | Film-coated tablet and gastro-resistant granules in sachet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551441","Fixed Cryogenic Vessel","C149517","A static thermally insulated container designed to maintain the contents in the liquid state.","Fixed Cryogenic Vessel | Fixed cryogenic vessel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551440","Foot-stab Route of Administration","C149518","Administration of a veterinary medicinal product into the foot of birds.","Foot-stab Route of Administration | Foot-stab use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551435","Gargle, Powder for Solution Dosage Form","C149519","Solid preparation consisting of one or more powders intended to be dissolved in water to obtain a gargle.","Gargle, Powder for Solution Dosage Form | Gargle, powder for solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551437","Gargle/Mouthwash Dosage Form","C149521","Liquid preparation consisting of a solution intended for use as a gargle or a mouthwash.","Gargle/Mouthwash Dosage Form | Gargle/mouthwash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551436","Gargle/Nasal Wash Dosage Form","C149522","Liquid preparation consisting of a solution intended for use as a gargle or a nasal wash.","Gargle/Nasal Wash Dosage Form | Gargle/nasal wash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2825047","Gargling Method of Administration","C149523","The technique of administration of a pharmaceutical product by rinsing the throat and/or mouth with it, holding it in the throat and keeping it in motion by releasing a stream of air from the lungs; after gargling, the product is usually intended to be spat out.","Gargling Method of Administration | Gargling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551431","Gas and Solvent for dispersion for Injection/Infusion Dosage Form","C149524","Sterile gas and sterile solvent, either in the same compartment or in different compartments, intended for the preparation of a dispersion for injection/infusion by dispersing the gas in the solvent.","Gas and Solvent for dispersion for Injection/Infusion Dosage Form | Gas and solvent for dispersion for injection/infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551433","Gas for Dispersion for Infusion Dosage Form","C149525","Sterile preparation consisting of a gas that is intended to be mixed with the specified liquid to obtain a dispersion of the gas in the liquid, which is intended for administration by infusion.","Gas for Dispersion for Infusion Dosage Form | Gas for dispersion for infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551656","Powder and Solvent for Intravesical Solution Dosage Form","C149786","Powder and solvent intended for the preparation of an intravesical solution by dissolving the powder in the solvent.","Powder and Solvent for Intravesical Solution Dosage Form | Powder and solvent for intravesical solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551655","Powder and Solvent for Intravesical Suspension Dosage Form","C149787","Powder and solvent intended for the preparation of an intravesical suspension by dispersing the powder in the solvent.","Powder and Solvent for Intravesical Suspension Dosage Form | Powder and solvent for intravesical suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551650","Powder and Solvent for Nebulizer Solution Dosage Form","C149788","Powder and solvent intended for the preparation of a nebulizer solution by dissolving the powder in the solvent.","Powder and Solvent for Nebulizer Solution Dosage Form | Powder and solvent for nebuliser solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551652","Powder and Solvent for Oral Suspension Dosage Form","C149790","Powder and solvent intended for the preparation of an oral suspension by dispersing the powder in the solvent.","Powder and Solvent for Oral Suspension Dosage Form | Powder and solvent for oral suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551651","Powder and Solvent for Prolonged-Release Suspension for Injection Dosage Form","C149791","Sterile powder and sterile solvent intended for the preparation of a prolonged-release suspension for injection by dispersing the powder in the solvent.","Powder and Solvent for Prolonged-Release Suspension for Injection Dosage Form | Powder and solvent for prolonged-release suspension for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551161","Glyoxylate Reductase/Hydroxypyruvate Reductase","C148632","Glyoxylate reductase/hydroxypyruvate reductase (328 aa, ~36 kDa) is encoded by the human GRHPR gene. This protein is involved in the metabolism of hydroxypyruvate and glyoxylate.","Glyoxylate Reductase/Hydroxypyruvate Reductase | EC 1.1.1.79 | EC 1.1.1.81 | GRHPR | Glyoxylate Reductase and Hydroxypyruvate Reductase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2882221","Acute Pulmonary Embolism","C148633","An acute embolism to the pulmonary vasculature.","Acute Pulmonary Embolism | ",,,,,,,,,,,,,,,"45768439","Acute pulmonary embolism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL551157","Acute Submassive Pulmonary Embolism","C148634","Acute pulmonary embolism with evidence of right ventricular dysfunction, but not associated with systemic hypotension.","Acute Submassive Pulmonary Embolism | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551158","PEOX-based Polymer Encapsulated Paclitaxel FID-007","C148635","A nanoparticle-based formulation composed of the poorly water-soluble paclitaxel encapsulated within branched polymers composed of polyethyloxazoline (PEOX), with potential antineoplastic activity. Upon injection of the PEOX-based polymer encapsulated paclitaxel FID-007, the nanoparticles accumulate at the tumor site, due to the unique characteristics of the tumor vasculature, while avoiding normal, healthy tissue. Once the paclitaxel is released, it binds to tubulin inside tumor cells and inhibits the disassembly-assembly dynamics of microtubules, resulting in cell cycle arrest and cell death. Compared to the administration of paclitaxel alone, this formulation increases paclitaxel's solubility and enhances its tumor tissue penetration and efficacy, while avoiding systemic exposure, which minimizes its toxicity.","PEOX-based Polymer Encapsulated Paclitaxel FID-007 | FID 007 | FID-007 | FID007 | Nanoencapsulated Paclitaxel FID-007 | Paclitaxel in Polyethyloxazoline Polymer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551944","FGA wt Allele","C150228","Human FGA wild-type allele is located in the vicinity of 4q31.3 and is approximately 8 kb in length. This allele, which encodes fibrinogen alpha chain protein, plays a role in blood clotting. Mutation of the gene is associated with congenital afibrinogenemia, familial visceral amyloidosis, congenital dysfibrinogenemia and congenital hypodysfibrinogenemia.","FGA wt Allele | Fib2 | Fibrinogen Alpha Chain wt Allele | Fibrinogen, A Alpha Polypeptide Gene | Fibrinogen--Alpha Polypeptide Chain Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551380","Ear Drops Suspension Dosage Form","C149455","Liquid single-dose or multidose preparation consisting of an aqueous or oily suspension intended for application to the external auditory meatus. Multidose containers may be dropper containers or containers provided with a dropper applicator, or the dropper may be supplied separately. Drops are not necessarily administered dropwise, but may also be administered as a small volume.","Ear Drops Suspension Dosage Form | Ear drops, suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551379","Ear drops, suspension in single-dose container","C149456","Medicinal product consisting of an ear drops suspension presented in a single-dose container.","Ear Drops, Suspension in Single-dose Container Dosage Form | Ear Drops, Suspension in Single-dose Container | Ear drops, suspension in single-dose container",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551382","Ear Ointment Dosage Form","C149457","Semi-solid single-dose or multidose preparation consisting of an ointment intended for application to the external auditory meatus, if necessary by means of a tampon impregnated with the preparation.","Ear Ointment Dosage Form | Ear ointment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551381","Ear Powder Dosage Form","C149458","Solid, usually multidose preparation consisting of one or more powders consisting of (a) solid active substance(s) intended for application to the external auditory meatus. Ear powders are presented in containers fitted with a suitable applicator or device for insufflation.","Ear Powder Dosage Form | Ear powder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551376","Ear Spray Emulsion Dosage Form","C149459","Liquid, usually multidose preparation consisting of an emulsion intended for application to the external auditory meatus by spraying to obtain local effect. Ear sprays are presented in containers with a spray pump or in pressurized containers fitted with a spray valve.","Ear Spray Emulsion Dosage Form | Ear spray, emulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551375","Ear Spray Solution Dosage Form","C149460","Liquid, usually multidose preparation consisting of a solution intended for application to the external auditory meatus by spraying to obtain a local effect. Ear sprays are presented in containers with a spray pump or in pressurized containers fitted with a spray valve.","Ear Spray Solution Dosage Form | Ear spray, solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551378","Ear Spray Suspension Dosage Form","C149461","Liquid, usually multidose preparation consisting of a suspension intended for application to the external auditory meatus by spraying to obtain a local effect. Ear sprays are presented in containers with a spray pump or in pressurized containers fitted with a spray valve.","Ear Spray Suspension Dosage Form | Ear spray, suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551377","Ear Stick Dosage Form","C149462","Solid single-dose preparation of usually conical shape intended to be inserted in the external auditory meatus where it melts or dissolves.","Ear Stick Dosage Form | Ear stick",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272994","Ear Tampon Dosage Form","C149464","Solid single-dose preparation intended to be inserted into the external auditory meatus for a limited period of time, consisting of a suitable material impregnated with active substance(s).","Ear Tampon Dosage Form | Ear tampon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551374","Ear Wash Emulsion Dosage Form","C149465","Liquid single-dose or multidose preparation consisting usually of an oil-in-water emulsion with a pH within physiological limits. Ear washes are intended to clean the external auditory meatus.","Ear Wash Emulsion Dosage Form | Ear wash, emulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551373","Ear Wash Solution Dosage Form","C149466","Liquid single-dose or multidose preparation consisting usually of an aqueous solution with a pH within physiological limits. Ear washes are intended to clean the external auditory meatus.","Ear Wash Solution Dosage Form | Ear wash, solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551369","Ear/Eye Drops, Solution Dosage Form","C149467","Liquid sterile preparation consisting of a solution intended for use as ear drops or eye drops.","Ear/Eye Drops, Solution Dosage Form | Ear/eye drops, solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550912","Greatest Percentage of Core Involvement by Cancer in Any Core","C148279","An indication of the percentage of cancerous cells present in the tissue core with the greatest amount of tumor involvement.","Greatest Percentage of Core Involvement by Cancer in Any Core | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550908","MOF Compound RiMO-301","C148280","A nanoparticle-based metal-organic framework (MOF) compound composed of proprietary X-ray-absorbing metals, with potential radiosensitizing properties. Upon intratumoral administration and subsequent irradiation of the tumor site, RiMO-301 absorbs the X-ray photons and produces reactive oxygen species (ROS), such as hydroxyl radicals and singlet oxygen, which induces ROS-mediated DNA damage in the irradiated cancer cells leading to tumor cell lysis. In addition, RiMO-301 may also contain an as of yet unidentified immunomodulating agent loaded into the channels/pores of the construct that may induce an immune response against the tumor-associated antigens (TAAs) released by the lysed tumor cells, thereby locally killing additional tumor and non-tumor cells. MOFs, porous crystalline materials composed of metal clusters and organic linkers, generate ROS at much lower X-ray dosages than used in standard radiotherapy, which results in reduced radiation exposure and X-ray damage to normal, healthy cells.","MOF Compound RiMO-301 | RiMO-301",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550907","Contrast-Enhanced Ultrasound","C148281","Ultrasound imaging following the administration of a microbubble contrast agent.","Contrast-Enhanced Ultrasound | CEUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550906","Refractory Stage 0 Bladder Cancer AJCC v6 and v7","C148286","Stage 0 bladder cancer defined according to the AJCC v6 and v7 criteria that is resistant to treatment.","Refractory Stage 0 Bladder Cancer AJCC v6 and v7 | Refractory Bladder Carcinoma In Situ AJCC v6 and v7 | Refractory Stage 0 Bladder Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551646","Powder and solvent for prolonged-release suspension for injection in pre-filled pen","C149792","Medicinal product consisting of a powder and solvent for prolonged-release suspension for injection presented in a pre-filled pen. The powder and solvent are contained in different compartments of the pre-filled pen, which contains all of the components necessary to prepare the prolonged-release suspension for injection.","Powder and Solvent for Prolonged-Release Suspension for Injection in Pre-filled Pen Dosage Form | Powder and Solvent for Prolonged-Release Suspension for Injection in Pre-filled Pen | Powder and solvent for prolonged-release suspension for injection in pre-filled pen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551645","Powder and solvent for prolonged-release suspension for injection in pre-filled syringe","C149793","Medicinal product consisting of a powder and solvent for prolonged-release suspension for injection presented in a pre-filled syringe. The powder and solvent are contained in different compartments of the pre-filled syringe, which contains all of the components necessary to prepare the prolonged-release suspension for injection.","Powder and Solvent for Prolonged-Release Suspension for Injection in Pre-filled Syringe Dosage Form | Powder and Solvent for Prolonged-Release Suspension for Injection in Pre-filled Syringe | Powder and solvent for prolonged-release suspension for injection in pre-filled syringe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551648","Powder and Solvent for Sealant Dosage Form","C149794","Sterile powder and sterile solvent intended for the preparation of a sealant by dissolving the powder in the solvent.","Powder and Solvent for Sealant Dosage Form | Powder and solvent for sealant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551647","Powder and Solvent for Solution for Infusion Dosage Form","C149795","Sterile powder and sterile solvent intended for the preparation of a solution for infusion by dissolving the powder in the solvent.","Powder and Solvent for Solution for Infusion Dosage Form | Powder and solvent for solution for infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551642","Powder and Solvent for Solution for Injection Dosage Form","C149796","Sterile powder and sterile solvent intended for the preparation of a solution for injection by dissolving the powder in the solvent.","Powder and Solvent for Solution for Injection Dosage Form | Powder and solvent for solution for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551641","Powder and solvent for solution for injection in cartridge","C149797","Medicinal product consisting of a powder and solvent for solution for injection presented in a cartridge. The powder and solvent are contained in different compartments of the cartridge, which contains all of the components necessary to prepare the solution for injection.","Powder and Solvent for Solution for Injection in Cartridge Dosage Form | Powder and Solvent for Solution for Injection in Cartridge | Powder and solvent for solution for injection in cartridge",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551644","Powder and solvent for solution for injection in pre-filled pen","C149798","Medicinal product consisting of a powder and solvent for solution for injection presented in a pre-filled pen. The powder and solvent are contained in different compartments of the pre-filled pen, which contains all of the components necessary to prepare the solution for injection.","Powder and Solvent for Solution for Injection in Pre-filled Pen Dosage Form | Powder and Solvent for Solution for Injection in Pre-filled Pen | Powder and solvent for solution for injection in pre-filled pen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551886","KLHL42 wt Allele","C150040","Human KLHL42 wild-type allele is located in the vicinity of 12p11.22 and is approximately 23 kb in length. This allele, which encodes kelch-like protein 42, plays a role in the modulation of microtubule dynamics and the regulation of protein ubiquitination.","KLHL42 wt Allele | Ctb9 | KIAA1340 | KLHDC5 | Kelch Domain Containing 5 Gene | Kelch Like Family 42 Gene | Kelch Like Family Member 42 wt Allele | Kelch Like Family, Member 42 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL574424","Kelch-Like Protein 42","C150042","Kelch-like protein 42 (505 aa, ~57 kDa) is encoded by the human KLHL42 gene. This protein is involved in microtubule dynamics and protein ubiquitination.","Kelch-Like Protein 42 | Ctb9 | Cullin 3-Binding Protein 9 | Cullin-3-Binding Protein 9 | KLHL42 | Kelch Domain-Containing Protein 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551884","Recurrent Chronic Leukemia","C150043","The reemergence of chronic leukemia after a period of remission.","Recurrent Chronic Leukemia | Chronic leukemia of unspecified cell type, in relapse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551883","Refractory Chronic Leukemia","C150044","Chronic leukemia that is resistant to treatment.","Refractory Chronic Leukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550843","F-18 Fluciclovine Positron Emission Tomography and Computed Tomography","C148230","An imaging procedure that combines fluciclovine F18 PET with an computed tomography to overlay activity data onto detailed anatomic images.","F-18 Fluciclovine Positron Emission Tomography and Computed Tomography | F-18 Fluciclovine PET/CT | F-18 Fluciclovine PET/CT Scan | PET-CT (F-18 fluciclovine)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4018912","Patient Preference for Care Action","C148231","The patient's decision about an intervention or a procedure offered.","Patient Preference for Care Action | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545666","TSCYC - Crying for No Obvious Reason","C147806","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Crying for no obvious reason.","TSCYC - Crying for No Obvious Reason | TSCYC1-Crying for No Obvious Reason | TSCYC154",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545667","TSCYC - Not Wanting to Be Around Someone","C147807","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Not wanting to be around someone who did something bad to him or her or reminded him or her of something bad.","TSCYC - Not Wanting to Be Around Someone | TSCYC1-Not Wanting to Be Around Someone | TSCYC155",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545668","TSCYC - Being Tense","C147808","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Being tense.","TSCYC - Being Tense | TSCYC1-Being Tense | TSCYC156",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545669","TSCYC - Worrying About People's Safety","C147809","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Worrying about other people's safety.","TSCYC - Worrying About People's Safety | TSCYC1-Worrying About People's Safety | TSCYC157",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545654","TSCYC - Very Angry Over a Little Thing","C147810","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Becoming very angry over a little thing.","TSCYC - Very Angry Over a Little Thing | TSCYC1-Very Angry Over a Little Thing | TSCYC158",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545655","TSCYC - Drawing Pictures About Sex Things","C147811","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Drawing pictures about sexual things.","TSCYC - Drawing Pictures About Sex Things | TSCYC1-Drawing Pictures About Sex Things | TSCYC159",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545656","TSCYC - Pulling His or Her Hair Out","C147812","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Pulling his or her hair out.","TSCYC - Pulling His or Her Hair Out | TSCYC1-Pulling His or Her Hair Out | TSCYC160",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545657","TSCYC - Calling Himself or Herself Bad","C147813","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Calling himself or herself bad, stupid, or ugly.","TSCYC - Calling Himself or Herself Bad | TSCYC1-Calling Himself or Herself Bad | TSCYC161",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545658","TSCYC - Throwing Things at Friends/Family","C147814","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Throwing things at friends or family members.","TSCYC - Throwing Things at Friends/Family | TSCYC1-Throwing Things at Friends/Family | TSCYC162",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551368","Ear/Eye Drops, Suspension Dosage Form","C149468","Liquid sterile preparation consisting of a suspension intended for use as ear drops or eye drops.","Ear/Eye Drops, Suspension Dosage Form | Ear/eye drops, suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551370","Ear/Eye/Nasal Drops, Solution Dosage Form","C149470","Liquid sterile preparation consisting of a solution intended for use as ear drops, eye drops or nasal drops.","Ear/Eye/Nasal Drops, Solution Dosage Form | Ear/eye/nasal drops, solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551365","Ear/Nasal Drops, Suspension Dosage Form","C149471","Liquid preparation consisting of a suspension intended for use as ear drops or nasal drops.","Ear/Nasal Drops, Suspension Dosage Form | Ear/nasal drops, suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551364","Effervescent Granules plus Film-Coated Tablet Dosage Form","C149472","Combination package consisting of effervescent granules and a film-coated tablet.","Effervescent Granules plus Film-Coated Tablet Dosage Form | Effervescent granules + film-coated tablet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272950","Oromucosal Capsule Dosage Form","C149732","Solid single-dose preparation contained in a soft shell to be chewed or sucked to obtain a local effect in the oral cavity.","Oromucosal Capsule Dosage Form | Oromucosal capsule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551581","Oromucosal Cream Dosage Form","C149733","Semi-solid, usually multidose preparation consisting of an oil-in-water emulsion intended for oromucosal use. Oromucosal creams are applied to the oral cavity or onto a specific part of the oral cavity, other than the gingivae, to obtain a local effect.","Oromucosal Cream Dosage Form | Oromucosal cream",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1273656","Oromucosal Drops Dosage Form","C149734","Liquid, usually multidose preparation consisting of a solution, suspension or emulsion intended for oromucosal use. Oromucosal drops are administered by instillation into the oral cavity or onto a specific part of the oral cavity.","Oromucosal Drops Dosage Form | Oromucosal drops",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551578","Oromucosal Gel Dosage Form","C149735","Semi-solid single-dose or multidose preparation consisting of a hydrophilic gel intended for oromucosal use. It is applied to the oral cavity or onto a specific part of the oral cavity, to obtain a local effect.","Oromucosal Gel Dosage Form | Oromucosal gel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551580","Oromucosal Paste Dosage Form","C149737","Semi-solid single-dose or multidose preparation consisting of a paste of solid particles finely dispersed in a hydrophilic basis intended for oromucosal use. Oromucosal pastes are applied to the oral cavity or onto a specific part of the oral cavity, to obtain a local effect.","Oromucosal Paste Dosage Form | Oromucosal paste",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551579","Oromucosal Patch Dosage Form","C149738","Flexible single-dose preparation intended to be applied to the oral cavity to obtain either a systemic or a local effect by delivering the active substance(s) over a certain period of time, after which it is then removed.","Oromucosal Patch Dosage Form | Oromucosal patch",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551574","Oromucosal Powder in Pouch Dosage Form","C149739","Medicinal product consisting of an oromucosal powder presented in a pouch.","Oromucosal Powder in Pouch Dosage Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551573","Oromucosal Solution Dosage Form","C149740","Liquid single-dose or multidose preparation consisting of a solution intended for oromucosal use.","Oromucosal Solution Dosage Form | Oromucosal solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551576","Oromucosal Spray, Emulsion Dosage Form","C149741","Liquid, usually multidose preparation consisting of an emulsion intended for oromucosal use. It is administered by spraying into the oral cavity or onto a specific part of the oral cavity or the throat. It is presented in a container with a spray pump or in a pressurized container with or without a metering valve.","Oromucosal Spray, Emulsion Dosage Form | Oromucosal spray, emulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545715","SOX21 wt Allele","C147878","Human SOX21 wild-type allele is located in the vicinity of 13q32.1 and is approximately 3 kb in length. This allele, which encodes transcription factor SOX-21 protein, plays a role in transcriptional regulation and cellular differentiation.","SOX21 wt Allele | SOX25 | SOXA | SRY (Sex Determining Region Y)-Box 21 Gene | SRY Box 21 Gene | SRY-Box 21 wt Allele | SRY-Related HMG-Box Gene 21",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1436201","SOX21 protein, human","C147884","Transcription factor SOX-21 (276 aa, ~29 kDa) is encoded by the human SOX21 gene. This protein is involved in cellular differentiation and transcriptional regulation.","Transcription Factor SOX-21 | SOX-A | SOX21",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551041","AK 01","C148501","An orally bioavailable inhibitor of the serine/threonine protein kinase aurora A, with potential antimitotic and antineoplastic activities. Upon administration, aurora A kinase inhibitor LY3295668 targets, binds to and inhibits the activity of aurora A kinase. This may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, inhibition of cell division and the induction of apoptosis in cells overexpressing aurora A kinase. Aurora A kinase, overexpressed in a wide variety of cancers, plays an essential role in the regulation of spindle assembly and mitosis.","Aurora A Kinase Inhibitor LY3295668 | AK 01 | AK-01 | LY 3295668 | LY-3295668 | LY3295668",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551040","MBD1 Gene","C148502","This gene plays a role in transcriptional repression through binding to methylated CpG islands.","MBD1 Gene | MBD1 | Methyl-CpG Binding Domain Protein 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551880","Recurrent Chronic Myelomonocytic Leukemia","C150048","The reemergence of chronic myelomonocytic leukemia after a period of remission.","Recurrent Chronic Myelomonocytic Leukemia | Chronic myelomonocytic leukemia, in relapse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551882","Refractory Chronic Myelomonocytic Leukemia","C150049","Chronic myelomonocytic leukemia that is resistant to treatment.","Refractory Chronic Myelomonocytic Leukemia | Refractory Chronic Myelomonocytic Leukemia (CMML)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551877","UGGT2 Gene","C150051","This gene plays a role in protein folding and glycosylation.","UGGT2 Gene | UDP-Glucose Glycoprotein Glucosyltransferase 2 Gene | UGGT2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551876","UGGT2 wt Allele","C150052","Human UGGT2 wild-type allele is located in the vicinity of 13q32.1 and is approximately 252 kb in length. This allele, which encodes UDP-glucose:glycoprotein glucosyltransferase 2 protein, is involved in protein folding quality control.","UGGT2 wt Allele | FLJ10873 | FLJ11485 | HUGT2 | MGC117360 | MGC150689 | MGC87276 | UDP-Glucose Glycoprotein Glucosyltransferase 2 wt Allele | UGCGL2 | UGT2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551878","HLA-DMB Gene","C150054","This gene is involved in the post-translational modification of class II major histocompatibility protein complexes.","HLA-DMB Gene | HLA-DMB | Major Histocompatibility Complex, Class II, DM Beta Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551873","HLA-DMB wt Allele","C150055","Human HLA-DMB wild-type allele is located in the vicinity of 6p21.32 and is approximately 6 kb in length. This allele, which encodes HLA class II histocompatibility antigen, DM beta chain protein, plays a role in facilitating the presentation of antigenic peptides.","HLA-DMB wt Allele | D6S221E | DMB | HLADMB | Major Histocompatibility Complex, Class II, DM Beta wt Allele | RING7 | Really Interesting New Gene 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551872","HLA Class II Histocompatibility Antigen, DM Beta Chain","C150056","HLA class II histocompatibility antigen, DM beta chain (263 aa, ~29 kDa) is encoded by the human HLA-DMB gene. This protein is involved in removing the class II-associated invariant chain peptide (CLIP) from newly synthesized class II major histocompatibility protein complexes.","HLA Class II Histocompatibility Antigen, DM Beta Chain | Class II Histocompatibility Antigen, M Beta Chain | HLA-DM Histocompatibility Type, Beta Chain | HLA-DMB | MHC Class II Antigen DMB | MHC Class II Antigen HLA-DM Beta Chain | MHC Class II HLA-DMB | Really Interesting New Gene 7 Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551875","SEL1L3 Gene","C150057","This gene may play a role in calcium binding and signal transduction.","SEL1L3 Gene | SEL1L Family Member 3 Gene | SEL1L3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1743795","lysozyme C, human","C150278","Lysozyme C (148 aa, ~17 kDa) is encoded by the human LYZ gene. This protein is involved in the proteolytic degradation of bacterial peptidoglycans.","Lysozyme C | 1,4-Beta-N-Acetylmuramidase C | C-Type Lysozyme | EC 3.2.1.17 | LYZ | Lysozyme F1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552016","MARK1 wt Allele","C150280","Human MARK1 wild-type allele is located in the vicinity of 1q41 and is approximately 136 kb in length. This allele, which encodes serine/threonine-protein kinase MARK1 protein, is involved in both microtubule dynamics and protein phosphorylation.","MARK1 wt Allele | KIAA1477 | MARK | Microtubule Affinity Regulating Kinase 1 wt Allele | Par-1c | Par1c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552015","High-Risk Neuroblastoma","C150281","Neuroblastoma usually presenting with metastatic disease and MYCN gene amplifications.","High Risk Neuroblastoma | High-Risk Neuroblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545659","TSCYC - Getting Upset About the Past","C147815","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Getting upset about something in the past.","TSCYC - Getting Upset About the Past | TSCYC1-Getting Upset About the Past | TSCYC163",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545660","TSCYC - Temporary Blindness or Paralysis","C147816","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Temporary blindness or paralysis.","TSCYC - Temporary Blindness or Paralysis | TSCYC1-Temporary Blindness or Paralysis | TSCYC164",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545661","TSCYC - Getting Upset Something Sexual","C147817","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Getting upset about something sexual.","TSCYC - Getting Upset Something Sexual | TSCYC1-Getting Upset Something Sexual | TSCYC165",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545647","TSCYC - Fear He or She Killed by Someone","C147819","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Fear that he or she would be killed by someone.","TSCYC - Fear He or She Killed by Someone | TSCYC1-Fear He or She Killed by Someone | TSCYC167",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551571","Oromucosal Spray, Suspension Dosage Form","C149743","Liquid, usually multidose preparation consisting of a suspension intended for oromucosal use. It is administered by spraying into the oral cavity or onto a specific part of the oral cavity or the throat. It is presented in a container with a spray pump or in a pressurized container with or without a metering valve.","Oromucosal Spray, Suspension Dosage Form | Oromucosal spray, suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551570","Oromucosal Suspension Dosage Form","C149744","Liquid single-dose or multidose preparation consisting of a suspension intended for oromucosal use.","Oromucosal Suspension Dosage Form | Oromucosal suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551572","Oromucosal/Laryngopharyngeal Solution Dosage Form","C149745","Liquid preparation consisting of a solution intended for oromucosal or laryngopharyngeal use.","Oromucosal/Laryngopharyngeal Solution Dosage Form | Oromucosal/laryngopharyngeal solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552465","Pastille Dosing Unit","C149747","A unit of presentation used to represent the quantity of product that is found in a single discrete entity where the pharmaceutical dose form is a type of pastille.","Pastille Dosing Unit | Pastille",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552455","Pen Dosing Unit","C149748","A unit of presentation used to represent the quantity of product that is found in a single pen container.","Pen Dosing Unit | Pen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551567","Pendant Dosing Unit","C149749","A unit of presentation used to represent the quantity of product that is found in a single discrete entity where the pharmaceutical dose form is a type of pendant.","Pendant Dosing Unit | Pendant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551811","Teat Spray Solution Dosage Form","C149989","Liquid preparation consisting of a solution intended to be sprayed onto the teats of an animal pre-, and where necessary, post-milking to reduce the population of pathogenic micro-organisms on the surfaces.","Teat Spray Solution Dosage Form | Teat spray solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551814","Teat Stick Dosage Form","C149990","Solid single-dose preparation for veterinary use, usually rod shaped, intended to be inserted into the teat canal of an animal where it melts or dissolves.","Teat Stick Dosage Form | Teat stick",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551813","Teat Route of Administration","C149991","Administration of a veterinary medicinal product to the surface of teat(s).","Teat Route of Administration | Teat use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552468","Thread Dosing Unit","C149992","A unit of presentation used to represent the quantity of product that is found in a single discrete entity where the pharmaceutical dose form is a type of thread.","Thread Dosing Unit | Thread",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551808","Top-dressing Route of Administration","C149993","Administration of a veterinary medicinal product by application onto the surface of the feed immediately prior to feeding.","Top-dressing Route of Administration | Top-dressing use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551810","Transdermal Gel Dosage Form","C149994","Semi-solid single-dose or multidose preparation consisting of a single-phase basis of liquids gelled by a suitable gelling agent. Active substance(s) is (are) dissolved or dispersed in the basis, which may be hydrophilic or hydrophobic. Transdermal gels are intended for transdermal use.","Transdermal Gel Dosage Form | Transdermal gel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551809","Transdermal Ointment Dosage Form","C149995","Semi-solid single-dose or multidose preparation consisting of a single-phase basis in which solids or liquids may be dispersed. Active substance(s) are dissolved or dispersed in the basis, which may be hydrophilic, hydrophobic or water-emulsifying. Transdermal ointments are intended for transdermal use.","Transdermal Ointment Dosage Form | Transdermal ointment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0911529","MBD1 protein, human","C148504","Methyl-CpG-binding domain protein 1 (605 aa, ~67 kDa) is encoded by the human MBD1 gene. This protein plays a role in the repression of gene expression.","Methyl-CpG-Binding Domain Protein 1 | CXXC Finger Protein 3 | CXXC-Type Zinc Finger Protein 3 | MBD1 | Methyl-CpG Binding Domain Protein 1 | Methyl-CpG-Binding Protein MBD1 | Protein Containing Methyl-CpG-Binding Domain 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551037","Vilaprisan","C148505","An orally available progestin and selective progesterone receptor modulator (SPRM), with potential anti-progesterone and antineoplastic activities. Upon oral administration, vilaprisan competitively binds to the progesterone receptor (PR) in progesterone-responsive tissue and inhibits PR-mediated gene expression. This interferes with progesterone activity in the reproductive system and may inhibit PR-mediated proliferative effects in cells overexpressing PRs. As a result, this agent may suppress ovulation and inhibit proliferation of endometrial tissue or uterine fibroid formation.","Vilaprisan | (8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-11-(4-methylsulfonylphenyl)-17-(1,1,2,2,2-pentafluoroethyl)-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one | BAY 1002670 | BAY-1002670 | BAY1002670 | VILAPRISAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551036","Autologous BCMA-4-1BBz-targeted CAR T-cells","C148506","A preparation of autologous T-lymphocytes that have been ex vivo transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) specific for the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) fused to the co-stimulatory domain of 4-1BB (CD137), and the CD3-zeta (CD3z) T-cell signaling domain (4-1BBz), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous BCMA-4-1BBz-targeted CAR T-cells specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells; it is overexpressed on malignant plasma cells, and plays a key role in plasma cell survival.","Autologous BCMA-4-1BBz-targeted CAR T-cells | Autologous Anti-BCMA CAR4-1BBz T Cells | Autologous Anti-BCMA:TCRz-4-1-BB CAR-T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551039","Anti-EGFR/DM1 Antibody-drug Conjugate AVID100","C148507","A targeted antibody drug conjugate (ADC) consisting of a human monoclonal antibody directed against the epidermal growth factor receptor (EGFR) conjugated to the cytotoxic agent maytansinoid mertansine (DM1), with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of AVID100 binds to  EGFR on tumor cell surfaces. Following receptor internalization, the mertansine moiety binds to tubulin and interferes with microtubule assembly/disassembly dynamics. This inhibits both cell division and proliferation of cancer cells that express EGFR. EGFR, overexpressed by a variety of cancers, plays a key role in tumor cell proliferation and survival.","Anti-EGFR/DM1 Antibody-drug Conjugate AVID100 | ADC AVID100 | AVID-100 | AVID100 | Antibody-drug Conjugate AVID100",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551038","Fluorine F 18-Al-NOTA-MATBBN","C148508","A radioconjugate containing a bombesin (BBN) peptide analog, derived from an unspecified GRPR antagonist (MATBBN) that targets the gastrin-releasing peptide receptor (GRPR), and is linked to the radionuclide fluorine F 18 (18F), by the macrocyclic chelating agent, 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA), through a method that first couples 18F to aluminum (Al), with potential use in diagnostic imaging using positron emission tomography/computed tomography (PET/CT). Upon administration of fluorine F 18-Al-NOTA-MATBBN, the peptide moiety targets and binds to GRPR. Upon PET/CT, GRPR-expressing tumor cells can then be visualized. GRPR, also called bombesin receptor 2 (BB2), is a seven-transmembrane G protein-coupled receptor belonging to the bombesin receptor family. It is overexpressed in certain types of cancers. Bombesin is a peptide exhibiting high affinity for the gastrin-releasing peptide receptor (GRPR).","Fluorine F 18-Al-NOTA-MATBBN | 18F-Al-NOTA-MATBBN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1430753","MARK1 protein, human","C150283","Serine/threonine-protein kinase MARK1 (795 aa, ~89 kDa) is encoded by the human MARK1 gene. This protein plays a role in the phosphorylation of microtubule-associated proteins (MAPs), which results in microtubule disassembly.","Serine/Threonine-Protein Kinase MARK1 | EC 2.7.11.1 | EC 2.7.11.26 | MAP/Microtubule Affinity-Regulating Kinase 1 | MARK1 | MRK | PAR1 Homolog C | Par-1c | Par1c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552012","NUP93 wt Allele","C150285","Human NUP93 wild-type allele is located in the vicinity of 16q13 and is approximately 120 kb in length. This allele, which encodes nuclear pore complex protein Nup93, plays a role in nuclear import.","NUP93 wt Allele | KIAA0095 | NIC96 | NIC96. S cerevisiae, Homolog of Gene | Nucleoporin 93 wt Allele | Nucleoporin, 93-kD Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1701389","Nup93 protein, human","C150286","Nuclear pore complex protein Nup93 (819 aa, ~93 kDa) is encoded by the human NUP93 gene. This protein is involved in nuclear pore functions.","Nuclear Pore Complex Protein Nup93 | 93 kDa Nucleoporin | NUP93 | Nucleoporin 93kDa | Nucleoporin Nup93",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552014","Refractory Osteomedullary Disease","C150287","A finding indicating that a disease has affected the medullary bone and is resistant to treatment.","Refractory Osteomedullary Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552008","PCDHAC2 wt Allele","C150289","Human PCDHAC2 wild-type allele is located in the vicinity of 5q31.3 and is approximately 46 kb in length. This allele, which encodes protocadherin alpha-C2 protein, is involved in cell-cell adhesion.","PCDHAC2 wt Allele | PCDH-ALPHA-C2 | Protocadherin Alpha Subfamily C, 2 wt Allele | Protocadherin-Alpha, Subfamily C, Member 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552007","Protocadherin Alpha-C2","C150290","Protocadherin alpha-C2 (1007 aa, ~109 kDa) is encoded by the human PCDHAC2 gene. This protein plays a role in calcium-dependent cell-cell adhesion.","Protocadherin Alpha-C2 | PCDH-Alpha-C2 | PCDHAC2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551432","Gas for Dispersion for Injection Dosage Form","C149526","Sterile preparation consisting of a gas that is intended to be mixed with the specified liquid to obtain a dispersion of the gas in the liquid, which is intended for administration by injection.","Gas for Dispersion for Injection Dosage Form | Gas for dispersion for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551428","Gas for Dispersion for Injection/Infusion Dosage Form","C149527","Sterile preparation consisting of a gas that is intended to be mixed with the specified liquid to obtain a dispersion of the gas in the liquid, which is intended for administration by injection or infusion.","Gas for Dispersion for Injection/Infusion Dosage Form | Gas for dispersion for injection/infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551427","Gastrointestinal Emulsion Dosage Form","C149528","Liquid preparation consisting of an emulsion intended for administration to the stomach or duodenum by means of a suitable applicator.","Gastrointestinal Emulsion Dosage Form | Gastroenteral emulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551060","OBE2109","C148479","An orally bioavailable gonadotropin-releasing hormone (GnRH or LHRH) receptor antagonist, with potential hormone production inhibitory activity. Upon oral administration of linzagolix, this agent competes with GnRH for receptor binding and inhibits GnRH receptor signaling in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. As a result, this may relieve symptoms associated with hormonally dependent disease states such as hormone-dependent prostate cancer. In women, this prevents the production of estrogen by the ovaries and may relieve symptoms from sex-hormone dependent diseases, such as pain associated with endometriosis, heavy menstrual bleeding or uterine fibroids.","Linzagolix | KLH 2109 | KLH-2109 | KLH2109 | LINZAGOLIX | OBE2109 | Thieno(3,4-d)pyrimidine-5-carboxylic acid, 3-(5-((2,3-Difluoro-6-methoxyphenyl)methoxy)-2-fluoro-4-methoxyphenyl)-1,2,3,4-tetrahydro-2,4-dioxo-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551059","WT1/PSMA/hTERT-encoding Plasmid DNA INO-5401","C148480","A preparation composed of three separate DNA plasmids encoding the tumor-associated antigens (TAAs) Wilms tumor gene-1 (WT1), prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT), with potential immunostimulating and antineoplastic activites. Upon intramuscular delivery and electroporation of the WT1/PSMA/hTERT-encoding plasmid DNA INO-5401, the genes are translated into their respective proteins inside the cell. The expressed proteins activate the immune system and induce a cytotoxic T-lymphocyte (CTL)-mediated response against cells expressing the WT1, PSMA and hTERT antigens, causing tumor cell lysis. hTERT, WT1 and PSMA are upregulated in many cancer cell types.","WT1/PSMA/hTERT-encoding Plasmid DNA INO-5401 | INO 5401 | INO-5401 | INO5401",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551805","Transdermal Patch Dosage Form","C149996","Flexible single-dose preparation intended to be applied to the unbroken skin to obtain a systemic delivery over an extended period of time. Transdermal patches consist of a backing sheet supporting a reservoir or a matrix containing the active substance(s) and on the top a pressure-sensitive adhesive, which assures the adhesion of the preparation to the skin. The backing sheet is impermeable to the active substance(s) and normally impermeable to water. In reservoir systems the active substance may be dissolved or dispersed in a semi-solid basis or in a solid polymer matrix, which is separated from the skin by a rate-controlling membrane. The pressure-sensitive adhesive may, in this case, be applied to some or all parts of the membrane, or only around the border of the membrane and the backing sheet. Matrix systems contain the active substance in a solid or semi-solid matrix, the properties of which control the diffusion pattern to the skin. The matrix system may also be a solution or dispersion of the active substance in the pressure-sensitive adhesive. The releasing surface of the patch is covered by a protective liner to be removed before applying the patch to the skin.","Transdermal Patch Dosage Form | Transdermal patch",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551804","Transdermal Solution Dosage Form","C149997","Liquid single-dose or multidose preparation consisting of a solution intended for transdermal use.","Transdermal Solution Dosage Form | Transdermal solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551807","Transdermal Spray, Solution Dosage Form","C149998","Liquid, usually multidose preparation consisting of a solution in a pressurized container with a spray valve or a container equipped with a spray pump, intended for transdermal use.","Transdermal Spray, Solution Dosage Form | Transdermal spray, solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551806","Transdermal System Dosage Form","C149999","Assembly of components intended for transdermal delivery driven by external forces (e.g., electrical current, chemical reaction).","Transdermal System Dosage Form | Transdermal system",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938108","Unknown Dosage Form Category","C150001","The type of pharmaceutical dose form is unknown, or has unspecified or variable physical characteristics.","Unknown Dosage Form Category | UNKNOWN | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552421","Unknown","C150002","Release of the substance(s) in a way that is unknown or not specified.","Unknown Release Mechanism of Action | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4086145","Crossing Profile","C150229","A linear measure of the maximum breadth of the stent/delivery system over the distal most region of the delivery system.","Crossing Profile | Catheter Gauge | Catheter Size",,,,,,,,,,,,,,,"4126840","Size of catheter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL551946","Atherectomy Cutter Length","C150230","The length of the cutter component for atherectomy devices that are used to cut plaque/thrombus.","Atherectomy Cutter Length | Cutter Length",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552478","Fibrinogen Alpha Chain","C150231","Fibrinogen alpha chain (866 aa, ~95 kDa) is encoded by the human FGA gene. This protein is involved in blood clot formation.","Fibrinogen Alpha Chain | FGA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552063","Atherectomy Cutter Diameter","C150233","The diameter of the cutter component for atherectomy devices that is used to cut the plaque/thrombus.","Atherectomy Cutter Diameter | Cutter Diameter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552062","FOXP4 wt Allele","C150234","Human FOXP4 wild-type allele is located in the vicinity of 6p21.1 and is approximately 56 kb in length. This allele, which encodes forkhead box protein P4, is involved in transcriptional repression.","FOXP4 wt Allele | FKHLA | Forkhead Box P4 wt Allele | hFKHLA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550815","Autologous PD-1 Antibody-expressing Mesothelin-specific CAR-T Cells","C148133","Genetically modified, autologous T-lymphocytes that express an antibody that targets the negative immunoregulatory human cell surface receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and are transduced with a gene encoding a chimeric antigen receptor (CAR) specific for the human tumor-associated antigen (TAA) mesothelin, with potential immunomodulating and antineoplastic activities. After isolation, transduction, expansion in culture, and reintroduction into the patient, the autologous PD-1 antibody expressing mesothelin specific CAR-T cells specifically target and kill mesothelin-expressing tumor cells. The anti-PD-1 expressed on the CAR-T cells binds to PD-1 expressed on T-cells and prevents the interaction of PD-1 with its ligand programmed cell death 1 ligand 1 (PD-L1, PD-1L1; CD274) expressed on cancer cells, which prevents PD-1-mediated signaling and T-cell exhaustion, enhances T-cell activation, and results in enhanced toxicity in mesothelin-expressing tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation and overexpression within the tumor microenvironment and inhibits T-cell function. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types.","Autologous PD-1 Antibody-expressing Mesothelin-specific CAR-T Cells | Autologous PD-1 Antibody expressing Mesothelin Specific CAR-T Cells | Autologous PD-1 Antibody-expressing Mesothelin-specific CAR T-cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550810","DS 1001","C148134","An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1; IDH-1; IDH1 [NADP+] soluble) mutant forms, including substitution mutations at the arginine in position 132, IDH1(R132) (IDH1-R132), with potential antineoplastic activity. Upon oral administration, safusidenib specifically binds to and inhibits certain mutant forms of IDH1, thereby inhibiting the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing IDH1 mutations. IDH1(R132) mutations are highly expressed in certain malignancies, including gliomas; they initiate and drive cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG. Safusidenib minimally targets and affects wild-type IDH1, which is expressed in normal, healthy cells.","Safusidenib | AB 218 | AB-218 | AB218 | DS 1001 | DS-1001 | DS-1001b | Mutant IDH1 Inhibitor DS-1001 | Mutant Isocitrate Dehydrogenase Type 1 Inhibitor DS-1001 | SAFUSIDENIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550809","iC9-GD2-CAR-CD28-OX40-expressing Autologous NKT Cells","C148135","A preparation of autologous interleukin-15 (IL-15)-expressing natural killer T-cells (NKT) transduced with a retroviral vector encoding a chimeric antigen receptor (CAR) derived from the antibody 14G2a that recognizes disialoganglioside GD2 (GD2-CAR) that is coupled to the co-stimulatory domains of CD28 and OX40 (CD134), and to the zeta chain of the TCR/CD3 complex (CD3-zeta), and linked to the suicide gene inducible caspase 9 (iCasp9 or iC9), with potential immunomodulating and antineoplastic activities. Upon transfusion, the iC9-GD2-CAR-CD28-OX40-expressing autologous NKT cells recognize, bind to and induce selective cytotoxicity in GD2-expressing tumor cells. The tumor-associated antigen (TAA) GD2 is overexpressed on the surface of neuroblastoma cells and by other neuroectoderm-derived neoplasms, while it is minimally expressed on normal, healthy cells. The iCasp9 safety switch consists of a full-length caspase 9, including its caspase recruitment domain, linked to a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V). If the administered NKT cells lead to unacceptable side effects, the chemical homodimerizer AP1903, which binds to the FKBP12-F36V drug-binding domain, activates caspase 9, and results in apoptosis of the administered NKT cells, can be administered.","iC9-GD2-CAR-CD28-OX40-expressing Autologous NKT Cells | GD2-CAR NKT Cells | GD2-CAR-expressing Autologous Natural Killer T-Cells | GINAKIT Cells | GINAKIT-cells | iC9-GD2.CD28.OX40.zeta Natural Killer T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550812","Nutritious Semisolid Food Gel","C148136","A proprietary, flavored, semisolid food gel-based nutritional supplement containing a variety of vitamins, iron, calcium, protein, fat and carbohydrates, that can be consumed for nutritional support. Upon oral intake, the nutritious semisolid food gel may prevent malnutrition and weight loss. The food gel has a semisolid texture and is specifically formulated for patients who have difficulty chewing and swallowing.","Nutritious Semisolid Food Gel | Nutri-jelly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550811","Nutritious Semisolid Food Gel with Phenethyl Isothiocyanate","C148137","A proprietary, flavored, semisolid food gel-based nutritional supplement containing a variety of vitamins, iron, calcium, protein, fat and carbohydrates, in combination with the phytochemical phenethyl isothiocyanate (PEITC), that can be consumed for nutritional support, and with chemopreventive and anti-cancer activities. Upon oral intake, the nutritious semisolid food gel may aid in the prevention of malnutrition and weight loss. The food gel has a semisolid texture and is specifically formulated for patients who have difficulty chewing and swallowing. PEITC may delay cancer growth, and inhibit cancer cell migration and invasion.","Nutritious Semisolid Food Gel with Phenethyl Isothiocyanate | Nutri-jelly with PEITC | Semisolid Food Gel with PEITC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551430","Gastroenteral Solution Dosage Form","C149529","Liquid preparation consisting of a solution intended for administration to the stomach or duodenum by means of a suitable applicator.","Gastroenteral Solution Dosage Form | Gastroenteral solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551429","Gastroenteral Suspension Dosage Form","C149530","Liquid preparation consisting of a suspension intended for administration to the stomach or duodenum by means of a suitable applicator.","Gastroenteral Suspension Dosage Form | Gastroenteral suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551424","Gastro-resistant Capsule, Hard Dosage Form","C149531","Solid single-dose, delayed-release preparation contained in a hard shell. The preparation is intended to resist the gastric fluid and to release the active substance(s) in the intestinal fluid. Hard gastro-resistant capsules are usually made by filling hard capsules with gastro-resistant granules or solid particles made gastro-resistant by coating or, in certain cases, by providing hard capsules with a gastro-resistant shell. They are intended for oral use.","Gastro-resistant Capsule, Hard Dosage Form | Gastro-resistant capsule, hard",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551426","Delayed Release Granule for Oral Suspension Dosage Form","C149533","Solid preparation consisting of gastro-resistant granules intended to be dispersed in the specified liquid to obtain an oral suspension.","Delayed Release Granule for Oral Suspension Dosage Form | Gastro-resistant granules for oral suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551425","Gastro-Resistant Granules for Oral Suspension in Sachet Dosage Form","C149534","Medicinal product consisting of gastro-resistant granules for oral suspension presented in a sachet.","Gastro-Resistant Granules for Oral Suspension in Sachet Dosage Form | Gastro-Resistant Granules for Oral Suspension in Sachet | Gastro-resistant granules for oral suspension in sachet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551420","Gastro-Resistant Tablet plus Rectal Suspension Dosage Form","C149535","Combination package consisting of a gastro-resistant tablet and a rectal suspension.","Gastro-Resistant Tablet plus Rectal Suspension Dosage Form | Gastro-resistant tablet + rectal suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551419","Gel for Gel Dosage Form","C149536","Semi-solid preparation consisting of a gel intended for use in the preparation of a gel for cutaneous use.","Gel for Gel Dosage Form | Gel for gel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551422","Gel for Injection Dosage Form","C149537","Sterile single-dose preparation consisting of a hydrophilic gel intended for injection into a specific tissue or organ.","Gel for Injection Dosage Form | Gel for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551421","Gel in pressurised container","C149538","Medicinal product consisting of a gel presented in a pressurized container.","Gel in Pressurized Container Dosage Form | Gel in Pressurized Container | Gel in pressurised container",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551416","Gel in sachet","C149539","Medicinal product consisting of a gel presented in a sachet.","Gel in Sachet Dosage Form | Gel in Sachet | Gel in sachet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551415","Gingival Gel Dosage Form","C149540","Semi-solid single-dose or multidose preparation consisting of a gel intended for gingival use to obtain a local effect.","Gingival Gel Dosage Form | Gingival gel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551418","Gingival Paste Dosage Form","C149541","Semi-solid single-dose or multidose preparation consisting of a paste of solid particles finely dispersed in a hydrophilic basis intended for gingival use to obtain a local effect.","Gingival Paste Dosage Form | Gingival paste",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551417","Gingival Solution Dosage Form","C149542","Liquid, usually multidose preparation consisting of a solution intended for gingival use.","Gingival Solution Dosage Form | Gingival solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1298996","Gingival Route of Administration","C149543","Administration of a medicinal product to the gingivae.","Gingival Route of Administration | Gingival use",,,,,,,,,,,,,,,"4156704","Gingival",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL551638","Powder and Solvent for Solution for Injection/Infusion Dosage Form","C149800","Sterile powder and sterile solvent intended for the preparation of a solution for injection/infusion by dissolving the powder in the solvent.","Powder and Solvent for Solution for Injection/Infusion Dosage Form | Powder and solvent for solution for injection/infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550836","IDO1 Inhibitor MK-7162","C148235","An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1 inhibitor MK-7162 specifically targets and binds to IDO1, a cytosolic enzyme responsible for the oxidation of the amino acid tryptophan into the immunosuppressive metabolite kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, MK-7162 restores and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells and T-lymphocytes. This agent may also induce increased interferon (IFN) production, which may lead to a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL) response against and inhibit the growth of the IDO1-expressing tumor cells. IDO1, an enzyme overexpressed by multiple tumor cell types, plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and suppresses the immune system.","IDO1 Inhibitor MK-7162 | Indoleamine-2,3-dioxygenase-1 Inhibitor MK-7162 | MK 7162 | MK-7162 | MK7162",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3529965","FOXP4 protein, human","C150235","Forkhead box protein P4 (680 aa, ~73 kDa) is encoded by the human FOXP4 gene. This protein plays a role in the tissue-specific regulation of transcription.","Forkhead Box Protein P4 | FOXP4 | Fork Head-Related Protein Like A | Fork Head-Related Protein-Like A | Winged-Helix Repressor FOXP4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552060","FZR1 wt Allele","C150237","Human FZR1 wild-type allele is located in the vicinity of 19p13.3 and is approximately 32 kb in length. This allele, which encodes fizzy-related protein homolog protein, plays a role in cell cycle-specific ubiquitination.","FZR1 wt Allele | CDC20 Homolog 1 Gene | CDC20-Like 1b Gene | CDC20C | CDH1 | CDH1/HCT1, S. cerevisiae, Homolog of Gene | FZR | FZR, Drosophila, Homolog of, 1 Gene | FZR2 | Fizzy and Cell Division Cycle 20 Related 1 wt Allele | Fizzy-Related Protein, Drosophila, Homolog of, 1 Gene | Fizzy/Cell Division Cycle 20 Related 1 (Drosophila) Gene | Fizzy/Cell Division Cycle 20 Related 1 Gene | HCDH | HCDH1 | KIAA1242",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3711541","FZR1 protein, human","C150238","Fizzy-related protein homolog (496 aa, ~55 kDa) is encoded by the human FZR1 gene. This protein is involved in the positive regulation of protein ubiquitination during anaphase.","Fizzy-Related Protein Homolog | CDC20-Like Protein 1 | Cdh1/Hct1 Homolog | FZR1 | Fzr | hCDH1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552053","ADGRA2 wt Allele","C150240","Human ADGRA2 wild-type allele is located in the vicinity of 8p11.23 and is approximately 61 kb in length. This allele, which encodes adhesion G protein-coupled receptor A2 protein, is involved in endothelial cell migration and central nervous system development.","ADGRA2 wt Allele | Adhesion G Protein-Coupled Receptor A2 wt Allele | DKFZp434C211 | DKFZp434J0911 | FLJ14390 | GPR124 | KIAA1531 | TEM5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552056","Adhesion G Protein-Coupled Receptor A2","C150241","Adhesion G protein-coupled receptor A2 (1338 aa, ~143 kDa) is encoded by the human ADGRA2 gene. This protein plays a role in central nervous system development and endothelial cell migration.","Adhesion G Protein-Coupled Receptor A2 | ADGRA2 | G Protein-Coupled Receptor 124 | G-Protein Coupled Receptor 124 | Tumor Endothelial Marker 5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552055","Atherectomy Rotating Component Length","C150243","The length of the rotating component of an atherectomy device.","Atherectomy Rotating Component Length | Rotating Component Length",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552050","Atherectomy Rotating Component Diameter","C150244","The diameter of the rotating component of an atherectomy device.","Atherectomy Rotating Component Diameter | Rotating Component Diameter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551366","Effervescent Tablet plus Film-Coated Tablet Dosage Form","C149474","Combination package consisting of an effervescent tablet and a film-coated tablet.","Effervescent Tablet plus Film-Coated Tablet Dosage Form | Effervescent tablet + film-coated tablet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551361","Effervescent Vaginal Tablet Dosage Form","C149475","Solid single-dose preparation consisting of a vaginal tablet usually containing acid substances and carbonates or hydrogen carbonates that react rapidly in the presence of aqueous liquid to release carbon dioxide.","Effervescent Vaginal Tablet Dosage Form | Effervescent vaginal tablet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551360","Emulsion and lyophilisate for suspension for injection","C149476","Sterile emulsion and sterile lyophilisate (freeze-dried powder) intended for the preparation of a suspension for injection, for veterinary use, by dispersing the lyophilisate in the emulsion. The emulsion contains active ingredient(s); the lyophilisate may or may not contain active ingredient(s).","Emulsion and Lyophilisate for Suspension for Injection Dosage Form | Emulsion and lyophilisate for suspension for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550902","Online Mindfulness Meditation","C148288","Online, guided sessions designed to improve psychological well-being through reduced anxiety, depressive symptoms, and distress, and improved mood.","Online Mindfulness Meditation | Online MBSR | Online Mindful Meditation | Online Mindfullness Meditation | Online Mindfulness Relaxation | Online Mindfulness-Based Stress Reduction | Web-Based Mindfulness Meditation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550901","PEG-conjugated TLR7/8 Agonist NKTR-262",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550903","Otic Emulsion Dosage Form","C148290","No value exists.","Otic Emulsion Dosage Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019843","Holidays","C148291","A day set aside by custom or by law on which normal activities, especially business, work, or school, are suspended or reduced.","Holiday | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550899","Refractory Undifferentiated Pleomorphic Sarcoma","C148295","Undifferentiated pleomorphic sarcoma that does not respond to treatment.","Refractory Undifferentiated Pleomorphic Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550895","Refractory Synovial Sarcoma","C148296","Synovial sarcoma that does not respond to treatment.","Refractory Synovial Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550894","Refractory Myxoid Liposarcoma","C148297","Myxoid liposarcoma that does not respond to treatment.","Refractory Myxoid Liposarcoma | Refractory Myxoid/Round Cell Liposarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087469","Metastatic Myxoid Liposarcoma","C148298","Myxoid liposarcoma that has spread to other anatomic sites.","Metastatic Myxoid Liposarcoma | Metastatic Myxoid/Round Cell Liposarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550896","Refractory Round Cell Liposarcoma","C148299","Round cell liposarcoma that does not respond to treatment.","Refractory Round Cell Liposarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550891","Metastatic Round Cell Liposarcoma","C148300","Round cell liposarcoma that has spread to other anatomic sites.","Metastatic Round Cell Liposarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551640","Powder and Solvent for Suspension for Injection Dosage Form","C149802","Sterile powder and sterile solvent intended for the preparation of a suspension for injection by dispersing the powder in the solvent.","Powder and Solvent for Suspension for Injection Dosage Form | Powder and solvent for suspension for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551639","Powder and solvent for suspension for injection in pre-filled syringe","C149803","Medicinal product consisting of a powder and solvent for suspension for injection presented in a pre-filled syringe. The powder and solvent are contained in different compartments of the pre-filled syringe, which contains all of the components necessary to prepare the suspension for injection.","Powder and Solvent for Suspension for Injection in Pre-filled Syringe Dosage Form | Powder and Solvent for Suspension for Injection in Pre-filled Syringe | Powder and solvent for suspension for injection in pre-filled syringe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551634","Powder and Solvent for Syrup Dosage Form","C149804","Powder and solvent intended for the preparation of a syrup by dissolving the powder in the solvent.","Powder and Solvent for Syrup Dosage Form | Powder and solvent for syrup",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551633","Powder and Suspension for Suspension for Injection Dosage Form","C149805","Sterile powder and sterile suspension, both of which contain active substance(s), intended for the preparation of a suspension for injection by dispersing the powder in the suspension.","Powder and Suspension for Suspension for Injection Dosage Form | Powder and suspension for suspension for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551636","Powder for Beehive Dispersion Dosage Form","C149806","Solid preparation consisting of one or more powders intended to be mixed with the specified liquid to obtain a bee-hive dispersion.","Powder for Beehive Dispersion Dosage Form | Powder for bee-hive dispersion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551635","Powder for Beehive Solution Dosage Form","C149807","Solid preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain a bee-hive solution.","Powder for Beehive Solution Dosage Form | Powder for bee-hive solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551630","Powder for Bladder Irrigation Dosage Form","C149808","Solid sterile preparation consisting of one or more powders intended to be dissolved in sterile water to obtain a bladder irrigation.","Powder for Bladder Irrigation Dosage Form | Powder for bladder irrigation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551629","Powder for Concentrate and Solution for Solution for Infusion Dosage Form","C149809","Medicinal product consisting of a powder for concentrate for solution for infusion and a solution for solution for infusion, intended for the preparation of a solution for infusion.","Powder for Concentrate and Solution for Solution for Infusion Dosage Form | Powder for concentrate and solution for solution for infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551632","Powder for Concentrate for Dispersion for Infusion Dosage Form","C149810","Solid sterile preparation consisting of one or more powders intended to be dispersed in the specified liquid to obtain a concentrate for dispersion for infusion, which must subsequently be diluted before administration as a dispersion for infusion.","Powder for Concentrate for Dispersion for Infusion Dosage Form | Powder for concentrate for dispersion for infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551631","Powder for Concentrate for Intravesical Suspension Dosage Form","C149811","Solid sterile preparation consisting of one or more powders intended to be dispersed in the specified liquid to obtain a concentrate for intravesical suspension, which must subsequently be diluted before administration as an intravesical suspension.","Powder for Concentrate for Intravesical Suspension Dosage Form | Powder for concentrate for intravesical suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551626","Powder for Concentrate for Solution for Hemodialysis Dosage Form","C149812","Solid sterile preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain a concentrate for solution for hemodialysis, which must subsequently be diluted before use as a solution for hemodialysis.","Powder for Concentrate for Solution for Hemodialysis Dosage Form | Powder for concentrate for solution for haemodialysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551625","Powder for Concentrate for Solution for Infusion Dosage Form","C149813","Solid sterile preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain a concentrate for solution for infusion, which must subsequently be diluted before administration as a solution for infusion.","Powder for Concentrate for Solution for Infusion Dosage Form | Powder for concentrate for solution for infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550832","mRNA-based Personalized Cancer Vaccine NCI-4650","C148239","An mRNA-based therapeutic personalized cancer vaccine (PCV) targeting up to fifteen tumor-associated antigens (TAAs) that are specifically expressed by a patient's cancer cells, with potential immunostimulatory and antineoplastic activities. The cells from the patient's tumor are analyzed and subjected to RNA sequencing to identify mutant and immunogenic epitopes. The neoantigen epitopes are screened to select those that induce a strong immune response in tumor- infiltrating lymphocytes (TILs) isolated from the patient. The selected mRNA sequences encoding up to fifteen neoantigen epitopes are incorporated in a proprietary formulation designed to maximize mRNA delivery and minimize mRNA-triggered immune responses. Upon administration, the mRNA-based PCV NCI-4650 is taken up and the mRNAs are translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This induces both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy the patient's cancer cells that express these neoantigens.","mRNA-based Personalized Cancer Vaccine NCI-4650 | NCI 4650 | NCI-4650 | mRNA-based PCV NCI-4650",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550831","Autologous CD34-positive BCL11A-disrupted Hematopoietic Progenitor Cells ST-400","C148240","A population of autologous CD34-positive, B-cell lymphoma/leukemia 11A (BCL11A)-disrupted hematopoietic progenitor cells (HPCs) that may be used for bone marrow autotransplantation. CD34-positive HPCs are isolated from human blood upon apheresis and are genetically modified in vitro using a proprietary zinc finger nuclease (ZFN) technology to specifically disrupt the transcriptional enhancer sequence for the BCL11A gene. Upon infusion into the patient following conditioning chemotherapy, the autologous CD34-positive BCL11A-disrupted HPCs ST-400 can populate the bone marrow and differentiate into a variety of blood cell types including lymphoid cells, myeloid cells and erythroblasts. BCL11A is a suppressor of fetal hemoglobin (HbF) expression. Therefore, disruption of the BCL11A enhancer decreases the expression of BCL11A and stimulates the expression of HbF in erythrocytes that differentiate from ST-400. HbF may compensate for reduced or absent expression of adult hemoglobin in patients, including those with transfusion-dependent beta-thalassemia.","Autologous CD34-positive BCL11A-disrupted Hematopoietic Progenitor Cells ST-400 | Autologous BCL11A-disrupted HPCs ST-400 | Autologous BCL11A-disrupted Hematopoietic Progenitor Cells ST-400 | Autologous CD34-positive BCL11A-disrupted HPCs ST-400 | ST 400 | ST-400",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545648","TSCYC - Saying Nobody Liked Him or Her","C147820","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Saying that nobody liked him or her.","TSCYC - Saying Nobody Liked Him or Her | TSCYC1-Saying Nobody Liked Him or Her | TSCYC168",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545649","TSCYC - Crying When Reminded From Past","C147821","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Crying when he or she was reminded of something from the past.","TSCYC - Crying When Reminded From Past | TSCYC1-Crying When Reminded From Past | TSCYC169",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545650","TSCYC - Saying Bad Didn't Happen","C147822","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Saying that something bad didn't happen to him or her even though it did happen.","TSCYC - Saying Bad Didn't Happen | TSCYC1-Saying Bad Didn't Happen | TSCYC170",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545651","TSCYC - Saying He or She Wanted to Die","C147823","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Saying he or she wanted to die or be killed.","TSCYC - Saying He or She Wanted to Die | TSCYC1-Saying He or She Wanted to Die | TSCYC171",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551363","Emulsion and Suspension for Emulsion for Injection Dosage Form","C149477","Sterile emulsion and sterile suspension, both of which contain active substance(s), intended for the preparation of an emulsion for injection by mixing the emulsion and the suspension.","Emulsion and Suspension for Emulsion for Injection Dosage Form | Emulsion and suspension for emulsion for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551362","Emulsion for Emulsion for Injection Dosage Form","C149478","Liquid sterile preparation consisting of an emulsion intended for use in the preparation of an emulsion for injection.","Emulsion for Emulsion for Injection Dosage Form | Emulsion for emulsion for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551357","Emulsion for Infusion Dosage Form","C149479","Liquid sterile preparation consisting of an oil-in-water emulsion intended to be introduced, usually in large volumes, usually into the circulating blood stream.","Emulsion for Infusion Dosage Form | Emulsion for infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551356","Emulsion for infusion in administration system","C149480","Medicinal product consisting of an emulsion for infusion presented in an administration system.","Emulsion for Infusion in Administration System Dosage Form | Emulsion for Infusion in Administration System | Emulsion for infusion in administration system",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551359","Emulsion for Injection/Infusion Dosage Form","C149481","Liquid sterile single-dose or multidose preparation consisting of an emulsion intended for administration by injection or infusion.","Emulsion for Injection/Infusion Dosage Form | Emulsion for injection/infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551358","Emulsion for injection/infusion in pre-filled syringe","C149482","Medicinal product consisting of an emulsion for injection/infusion presented in a pre-filled syringe.","Emulsion for Injection/Infusion in Pre-filled Syringe Dosage Form | Emulsion for Injection/Infusion in Pre-filled Syringe | Emulsion for injection/infusion in pre-filled syringe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551353","Emulsion for Suspension for Injection Dosage Form","C149483","Liquid sterile preparation consisting of an emulsion intended for use in the preparation of a suspension for injection.","Emulsion for Suspension for Injection Dosage Form | Emulsion for suspension for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551354","Endosinusial Solution Dosage Form","C149486","Liquid preparation consisting of a solution intended to be administered to the sinuses to obtain a local effect.","Endosinusial Solution Dosage Form | Endosinusial solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551350","Endosinusial Suspension Wash Dosage Form","C149487","Liquid preparation consisting of a suspension intended for cleaning the sinuses.","Endosinusial Suspension Wash Dosage Form | Endosinusial wash, suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551349","Endotracheopulmonary Instillation, Powder and Solvent for Solution Dosage Form","C149488","Powder and aqueous solvent intended for the preparation of an endotracheopulmonary instillation solution by dissolving the powder in the solvent.","Endotracheopulmonary Instillation, Powder and Solvent for Solution Dosage Form | Endotracheopulmonary instillation, powder and solvent for solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551352","Endotracheopulmonary Instillation, Powder and Solvent for Suspension Dosage Form","C149489","Powder and aqueous solvent intended for the preparation of an endotracheopulmonary instillation suspension by dispersing the powder in the solvent.","Endotracheopulmonary Instillation, Powder and Solvent for Suspension Dosage Form | Endotracheopulmonary instillation, powder and solvent for suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1272905","Endotracheopulmonary Instillation, Powder for Solution Dosage Form","C149490","Solid preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain an endotracheopulmonary instillation solution.","Endotracheopulmonary Instillation, Powder for Solution Dosage Form | Endotracheopulmonary instillation, powder for solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551569","Periodontal Gel Dosage Form","C149750","Semi-solid preparation consisting of a gel intended to be placed in the pouch between the tooth and the gingiva.","Periodontal Gel Dosage Form | Periodontal gel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551568","Periodontal Insert Dosage Form","C149751","Solid single-dose preparation consisting of a medicated insert to be placed within the tooth socket/periodontal membrane. The biodegradable insert is a sheet which slowly releases active substance(s).","Periodontal Insert Dosage Form | Periodontal insert",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545698","IL23R Gene","C147893","This gene plays a role in interleukin signaling, immunity and inflammation.","IL23R Gene | IL23R | Interleukin 23 Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545703","IL23R wt Allele","C147898","Human IL23R wild-type allele is located in the vicinity of 1p31.3 and is approximately 121 kb in length. This allele, which encodes interleukin-23 receptor, is involved in immune cell activation.","IL23R wt Allele | Interleukin 23 Receptor wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0211668","QS21","C1478","A purified, natural saponin isolated from the soapbark tree Quillaja saponaria Molina with potential immunoadjuvant activity. When co-administered with vaccine peptides, QS21 may increase total antitumoral vaccine-specific antibody responses and cytotoxic T-cell responses.","QS21 | NIAID VEU 016 | Purified Quillaja Saponin | QS-21 | QS-21 Adjuvant | QUILLAJA SAPONIN (QS-21) | Stimulon QS-21 Adjuvant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1872104","IL23R protein, human","C147900","Interleukin-23 receptor (629 aa, ~72 kDa) is encoded by the human IL23R gene. This protein plays a role in JAK-STAT signaling and immune cell activation.","Interleukin-23 Receptor | IL-23 Receptor | IL-23R | IL23 Receptor | IL23R | Interleukin 23 Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545693","Childhood Brain Glioblastoma","C147901","A brain glioblastoma that occurs during childhood.","Childhood Brain Glioblastoma | Brain Glioblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2733510","Number of Lymph Nodes with Micrometastases","C147903","The number of examined lymph nodes that were positive for micrometastases.","Number of Lymph Nodes with Micrometastases | ",,,,,,,,,,,,,,,"40479814","Number of lymph nodes containing micrometastases in excised specimen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2733106","Number of Lymph Nodes with Macrometastases","C147904","The number of examined lymph nodes that were positive for macrometastases.","Number of Lymph Nodes with Macrometastases | ",,,,,,,,,,,,,,,"40479400","Number of lymph nodes containing macrometastases in excised specimen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL551874","SEL1L3 wt Allele","C150058","Human SEL1L3 wild-type allele is located in the vicinity of 4p15.2 and is approximately 142 kb in length. This allele, which encodes protein sel-1 homolog 3 protein, may be involved in signal transduction and calcium binding.","SEL1L3 wt Allele | KIAA0746 | SEL1L Family Member 3 wt Allele | Sel-1 Suppressor of Lin-12-Like 3 (C. elegans) Gene | Sel-1 Suppressor of Lin-12-Like 3 Gene | Sel-1L3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551869","Protein Sel-1 Homolog 3","C150059","Protein sel-1 homolog 3 (1132 aa, ~129 kDa) is encoded by the human SEL1L3 gene. This protein may play a role in calcium binding and signal transduction.","Protein Sel-1 Homolog 3 | KIAA0746 Protein | SEL1L3 | Sel-1L3 | Suppressor of Lin-12-Like Protein 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551868","NFKBID Gene","C150060","This gene may be involved in the regulation of nuclear factor-kappa-B activity and cytokine gene expression.","NFKBID Gene | NFKB Inhibitor Delta Gene | NFKBID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551871","NFKBID wt Allele","C150061","Human NFKBID wild-type allele is located in the vicinity of 19q13.12 and is approximately 15 kb in length. This allele, which encodes NF-kappa-B inhibitor delta protein, may play a role in the regulation of cytokine gene expression.","NFKBID wt Allele | IKBNS | IkappaBNS | NF-Kappa-B Inhibitor, Delta Gene | NFKB Inhibitor Delta wt Allele | NFKB Inhibitor, Delta Gene | Nuclear Factor of Kappa Light Polypeptide Gene Enhancer in B-Cells Inhibitor, Delta Gene | TA-NFKBH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551870","NF-Kappa-B Inhibitor Delta","C150062","NF-kappa-B inhibitor delta (313 aa, ~33 kDa) is encoded by the human NFKBID gene. This protein may be involved in the regulation of nuclear factor-kappa-B signaling-dependent cytokine gene expression.","NF-Kappa-B Inhibitor Delta | I-Kappa-B-Delta | IkB-Delta | IkappaBNS | IkappaBdelta | NFKBID | Nuclear Factor of Kappa Light Polypeptide Gene Enhancer in B-Cells Inhibitor Delta | T-Cell Activation NFKB-Like Protein | TA-NFKBH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551865","SPATA2 Gene","C150063","This gene plays a role in sperm formation.","SPATA2 Gene | SPATA2 | Spermatogenesis Associated 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551864","SPATA2 wt Allele","C150064","Human SPATA2 wild-type allele is located in the vicinity of 20q13.13 and is approximately 12 kb in length. This allele, which encodes spermatogenesis-associated protein 2, is involved in spermatogenesis.","SPATA2 wt Allele | KIAA0757 | PD1 | PPP1R145 | Protein Phosphatase 1, Regulatory Subunit 145 Gene | Spermatogenesis Associated 2 wt Allele | tamo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551867","Spermatogenesis-Associated Protein 2","C150065","Spermatogenesis-associated protein 2 (520 aa, ~58 kDa) is encoded by the human SPATA2 gene. This protein plays a role in spermatogenesis.","Spermatogenesis-Associated Protein 2 | SPATA2 | Spermatogenesis Associated PD1 | Spermatogenesis-Associated Protein PD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551866","Ear drops, solution in single-dose container","C150066","Medicinal product consisting of an ear drops solution presented in a single-dose container.","Ear Drops, Solution in Single-dose Container Dosage Form | Ear Drops, Solution in Single-dose Container | Ear drops, solution in single-dose container",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551861","Nasal Drops, Solution Dosage Form","C150068","Liquid single-dose or multidose preparation consisting of a solution intended for nasal use by means of a suitable applicator.","Nasal Drops, Solution Dosage Form | Nasal drops, solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551863","TNIP1 wt Allele","C150069","Human TNIP1 wild-type allele is located in the vicinity of 5q33.1 and is approximately 64 kb in length. This allele, which encodes TNFAIP3-interacting protein 1, plays a role in the modulation of tumor necrosis factor alpha-induced protein 3 (TNFAIP3)-mediated deubiquitination activity.","TNIP1 wt Allele | ABIN-1 | KIAA0113 | NAF1 | Nef-Associated Factor 1 SNP Gene | TNFAIP3 Interacting Protein 1 wt Allele | VAN | nip40-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552448","TNFAIP3-Interacting Protein 1","C150070","TNFAIP3-interacting protein 1 (636 aa, ~72 kDa) is encoded by the human TNIP1 gene. This protein is involved in the regulation of tumor necrosis factor alpha-induced protein 3 (TNFAIP3)-mediated deubiquitination activity.","TNFAIP3-Interacting Protein 1 | A20-Binding Inhibitor of NFKB 1 | ABIN-1 | HIV-1 Nef-Interacting Protein | Naf1 | Nef-Associated Factor 1 | Nip40-1 | TNIP1 | VAN | Virion-Associated Nuclear Shuttling Protein | Virion-Associated Nuclear-Shuttling Protein | hVAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545652","TSCYC - Acting as If Didn't Have Feelings","C147824","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Acting as if he or she didn't have any feelings about something bad that happened to him or her.","TSCYC - Acting as If Didn't Have Feelings | TSCYC1-Acting as If Didn't Have Feelings | TSCYC172",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545653","TSCYC - Whining","C147825","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Whining.","TSCYC - Whining | TSCYC1-Whining | TSCYC173",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545638","TSCYC - Not Sleeping Well","C147826","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Not sleeping well.","TSCYC - Not Sleeping Well | TSCYC1-Not Sleeping Well | TSCYC174",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545639","TSCYC - Worrying About Sexual Things","C147827","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Worrying about sexual things.","TSCYC - Worrying About Sexual Things | TSCYC1-Worrying About Sexual Things | TSCYC175",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545640","TSCYC - Being Frightened by Things","C147828","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Being frightened by things that didn't used to scare him or her.","TSCYC - Being Frightened by Things | TSCYC1-Being Frightened by Things | TSCYC176",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545641","TSCYC - Hallucinating","C147829","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Hallucinating.","TSCYC - Hallucinating | TSCYC1-Hallucinating | TSCYC177",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545642","TSCYC - Acting Like He or She Was in Trance","C147830","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Acting like he or she was in a trance.","TSCYC - Acting Like He or She Was in Trance | TSCYC1-Acting Like He/She Was in Trance | TSCYC178",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545643","TSCYC - Forgetting His or Her Own Name","C147831","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Forgetting his or her own name.","TSCYC - Forgetting His or Her Own Name | TSCYC1-Forgetting His or Her Own Name | TSCYC179",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545644","TSCYC - Upset When Reminded Bad Happened","C147832","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Getting upset when he or she was reminded of something bad that happened.","TSCYC - Upset When Reminded Bad Happened | TSCYC1-Upset When Reminded Bad Happened | TSCYC180",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545645","TSCYC - Avoiding Bad Happened in Past","C147833","Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Avoiding things that reminded him or her of a bad thing that had happened in the past.","TSCYC - Avoiding Bad Happened in Past | TSCYC1-Avoiding Bad Happened in Past | TSCYC181",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551565","Periodontal Powder Dosage Form","C149752","Solid preparation consisting of one or more powders intended for administration within the tooth socket/periodontal membrane.","Periodontal Powder Dosage Form | Periodontal powder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551564","Periosseous Route of Administration","C149753","Administration of a medicinal product on or around the bone","Periosseous Route of Administration | Periosseous use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551566","Peritumoral Route of Administration","C149754","Administration of a medicinal product directly into the region surrounding a tumor.","Peritumoral Route of Administration | Peritumoral use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552451","Pessary Dosage Form","C149755","Solid, single-dose preparation usually prepared by molding, of various shapes, usually ovoid, with a volume and consistency suitable for insertion into the vagina to obtain a local effect. It contains one or more active substances dispersed or dissolved in a suitable basis that may be soluble or dispersible in water or may melt at body temperature.","Pessary Dosage Form | Pessary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551562","Pessary Dosage Unit","C149756","A unit of presentation used to represent the quantity of product that is found in a single discrete entity where the pharmaceutical dose form is a type of pessary.","Pessary Dosage Unit | Pessary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524075","Pillule Dosage Unit","C149757","A unit of presentation used to represent the quantity of product that is found in a single discrete entity where the pharmaceutical dose form is a type of pillule.","Pillule Dosage Unit | Pillule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1273649","Pillule Dosage Form","C149758","Solid preparation for homeopathic use, obtained from sucrose, lactose or other suitable excipients. Pillules may be prepared by impregnation of preformed pillules with a dilution or dilutions of homeopathic stocks or by progressive addition of these excipients and the addition of a dilution or dilutions of homeopathic stocks. Pillules are intended for oral or sublingual use.","Pillule Dosage Form | Pillules",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551563","Pillules in single-dose container","C149759","Medicinal product consisting of pillules presented in a single-dose container.","Pillules in Single-dose Container Dosage Form | Pillules in Single-dose Container | Pillules in single-dose container",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552423","Pipette Dosage Unit","C149760","A unit of presentation used to represent the quantity of product that is found in a single pipette administration device.","Pipette Dosage Unit | Pipette",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL537766","Plaster Dosing Unit","C149761","A unit of presentation used to represent the quantity of product that is found in a single discrete entity where the pharmaceutical dose form is a type of plaster.","Plaster Dosing Unit | Plaster",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551561","Plaster for Provocation Test Dosage Form","C149762","Solid flexible preparation containing an allergen product intended for provocation testing by application to the skin.","Plaster for Provocation Test Dosage Form | Plaster for provocation test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551558","Posterior Juxtascleral Route of Administration","C149764","Administration of a medicinal product beneath the sub-tenon membrane of the sclera (i.e. in the episcleral space), adjacent to the macula.","Posterior Juxtascleral Route of Administration | Posterior juxtascleral use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552442","Pouch Dosage Form","C149765","No value exists.","Pouch Dosage Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551560","Pour-on Container","C149766","Container with built-in applicator for pouring-on use.","Pour-on Container | Pour-on container",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551559","Pour-on Emulsion Dosage Form","C149767","Liquid preparation consisting of an emulsion intended for pour-on use for the prevention and treatment of ectoparasitic and/or endoparasitic infestations of animals. Pour-on emulsions are applied in volumes that are usually greater than 5 mL.","Pour-on Emulsion Dosage Form | Pour-on emulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551555","Pour-on Solution Dosage Form","C149768","Liquid preparation consisting of a solution intended for pour-on use for the prevention and treatment of ectoparasitic and/or endoparasitic infestations of animals. Pour-on solutions are applied in volumes that are usually greater than 5 mL.","Pour-on Solution Dosage Form | Pour-on solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551033","CDC7 Kinase Inhibitor LY3143921 Hydrate","C148509","The hydrated form of an orally bioavailable inhibitor of cell division cycle 7 (CDC7) kinase, with potential antineoplastic activity. Upon administration of CDC7 kinase inhibitor LY3143921 hydrate, LY3143921 targets, binds to and inhibits the activity of CDC7, which may result in the inhibition of DNA replication and mitosis, the induction of tumor cell apoptosis, and the inhibition of tumor cell proliferation in CDC7-overexpressing tumor cells. The serine-threonine kinase CDC7 plays a key role in DNA replication by binding to and  phosphorylating serine (Ser)-40 and 53 of MCM2 (minichromosome maintenance complex component 2), which is required for the initiation of DNA replication. Although expressed at low levels in healthy, normal cells, CDC7 is expressed at much higher levels in cancer cells.","CDC7 Kinase Inhibitor LY3143921 Hydrate | LY-3143921 Hydrate | LY3143921 Hydrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551032","Recurrent Human Papillomavirus-Related Malignant Neoplasm","C148510","The reemergence of human papillomavirus-related malignant neoplasm after a period of remission.","Recurrent Human Papillomavirus-Related Malignant Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551035","Nanoparticle SN-38-encapsulated Micelle Formulation IT-141","C148511","A nanoparticle-based formulation consisting of polymeric micelles, composed of triblock copolymers, loaded with the bioactive hydrophobic irinotecan metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38), with potential antineoplastic activity. Upon administration, nanoparticle SN-38-encapsulated micelle formulation IT141 diffuses into the tumor site and the SN-38 moiety binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, which results in DNA breaks, inhibition of DNA replication, and apoptosis. Compared to SN-38 alone, this formulation increases the water solubility of SN-38 and allows the delivery of higher doses of SN-38. IT-141 also has a much longer circulation time and reduces toxicity to normal, healthy tissues.","Nanoparticle SN-38-encapsulated Micelle Formulation IT-141 | IT-141 | IT141 | Nanoparticle SN-38 Formulation IT141",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551034","Refractory Human Papillomavirus-Related Malignant Neoplasm","C148512","Human papillomavirus-related malignant neoplasm that does not respond to treatment.","Refractory Human Papillomavirus-Related Malignant Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551150","ALK/c-Met Inhibitor TQ-B3139","C148513","An orally available, small molecule inhibitor of the receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and hepatocyte growth factor receptor (c-Met; HGFR), with potential antineoplastic activity. Upon oral administration, TQ-B3139 binds to and inhibits the activity of ALK and c-Met, which leads to the disruption of ALK- and c-Met-mediated signaling and the inhibition of cell growth in ALK- and c-Met-expressing tumor cells. ALK and c-Met, overexpressed or mutated in many tumor cell types, play key roles in tumor cell proliferation, survival, invasion and metastasis.","ALK/c-Met Inhibitor TQ-B3139 | ALK/c-Met Inhibitor  TQ-B3139 | TQ B3139 | TQ-B3139",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL376191","metastatic intraocular melanoma","C148514","Uveal melanoma that has spread from its primary site to another anatomic site.","Metastatic Uveal Melanoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551152","Advanced Uveal Melanoma","C148515","Uveal melanoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Uveal Melanoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3501337","AZD4017","C148516","A selective, orally bioavailable inhibitor of the enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11b-HSD1; 11bHSD1; HSD11B1), with potential protective activity. Upon administration, AZD4017 selectively binds to and inhibits the activity of 11b-HSD1. This prevents the conversion of cortisone to the active hormone cortisol that activates glucocorticoid receptors. By blocking cortisol production in metabolic tissues, AZD4017 may inhibit the adverse metabolic effects, such as glucose intolerance, hyperinsulinemia, systolic hypertension, increased adiposity, myoatrophy and dermal atrophy, caused by exogenous administration of glucocorticoids in these tissues. 11bHSD1 is highly expressed in metabolic tissues, such as liver, skeletal muscle, and adipose tissue. It plays a crucial role in regenerating active glucocorticoid from circulating glucocorticoids and regulates the production of cortisol to activate the glucocorticoid receptors. AZD4017 does not inhibit the anti-inflammatory activity of the administered glucocorticoids.","11beta-hydroxysteroid Dehydrogenase Type 1 Inhibitor AZD4017 | 11-beta-hydroxysteroid Dehydrogenase Type 1 Inhibitor AZD4017 | 11b-HSD1 inhibitor AZD4017 | 11bHSD1 Inhibitor AZD4017 | AZD 4017 | AZD-4017 | AZD4017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551858","HLA-DMA Gene","C150071","This gene plays a role in removing the class II-associated invariant chain peptide (CLIP) from newly synthesized class II major histocompatibility protein complexes.","HLA-DMA Gene | HLA-DMA | Major Histocompatibility Complex, Class II, DM Alpha Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551857","HLA-DMA wt Allele","C150072","Human HLA-DMA wild-type allele is located in the vicinity of 6p21.32 and is approximately 20 kb in length. This allele, which encodes HLA class II histocompatibility antigen, DM alpha chain protein, is involved in the post-translational modification of class II major histocompatibility protein complexes.","HLA-DMA wt Allele | D6S222E | DMA | HLADM | HLADMA | Major Histocompatibility Complex, Class II, DM Alpha wt Allele | RING6 | Really Interesting New Gene 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552003","Methylene Blue Oral Rinse","C150294","An oral rinse composed of the diaminophenothiazine dye methylene blue (MB), an inhibitor of nitric oxide (NO) synthase (NOS) and soluble guanylate cyclase (sGC), with potential local analgesic and antioxidant activities. Although the exact mechanism by which MB exerts its analgesic effect has yet to be fully elucidated, upon rinsing with the MB oral rinse, the MB preferentially targets and binds to nerve cells and blocks the electrical conductivity of nerve fibers, thereby blocking neuronal excitability. This inhibits pain signaling and produces an anti-nociceptive effect. In addition, MB inhibits the production of oxygen, NO, oxygen free radicals and superoxides by NOS, and prevents the accumulation of cyclic guanosine monophosphate (cGMP) by directly inhibiting sGC and by constraining NO-dependent sGC activity. This prevents the activation of the NO-cGMP signal pathway, which plays a role in neuropathic pain, and promotes an analgesic effect. Administration of the MB oral rinse may improve the intractable pain of oral mucositis.","Methylene Blue Oral Rinse | MB Oral Rinse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552005","PKD1L2 wt Allele","C150296","Human PKD1L2 wild-type allele is located in the vicinity of 16q23.2 and is approximately 119 kb in length. This allele, which encodes polycystic kidney disease protein 1-like 2, may be involved in G protein-coupled receptor signaling and the regulation of calcium transport.","PKD1L2 wt Allele | KIAA1879 | PC1L2 | Polycystin 1 Like 2 (Gene/Pseudogene) wt Allele | Polycystin 1-Like 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1565760","PKD1L2 protein, human","C150297","Polycystic kidney disease protein 1-like 2 (2459 aa, ~273 kDa) is encoded by the human PKD1L2 gene. This protein may play a role in calcium transport and receptor signaling.","Polycystic Kidney Disease Protein 1-Like 2 | PC1-Like 2 Protein | PKD1L2 | Polycystic Kidney Disease 1-Like 2 | Polycystin-1L2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552127","PKHD1 wt Allele","C150299","Human PKHD1 wild-type allele is located within 6p12.3-p12.2 and is approximately 473 kb in length. This allele, which encodes fibrocystin protein, may play a role in kidney and biliary development and in receptor signaling. Mutations in this gene are associated with autosomal recessive polycystic kidney disease (polycystic kidney and hepatic disease 1; polycystic kidney disease 4).","PKHD1 wt Allele | ARPKD | FCYT | FPC | Fibrocystin/Polyductin Complex Gene | PKD4 | PKHD1, Fibrocystin/Polyductin wt Allele | Polycystic Kidney and Hepatic Disease 1 (Autosomal Recessive) Gene | Polycystic Kidney and Hepatic Disease 1 Gene | TIG Multiple Domains 1 Gene | TIGM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552126","Fibrocystin","C150300","Fibrocystin (4074 aa, ~447 kDa) is encoded by the human PKHD1 gene. This protein may be involved in receptor signaling that promotes differentiation of the kidney and biliary system.","Fibrocystin | PKHD1 | Polycystic Kidney and Hepatic Disease 1 Protein | Polyductin | Tigmin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551062","Bifidobacterium lactis/Lactobacillus acidophilus/Inulin Probiotic Supplement","C148481","A tablet probiotic supplement containing the polysaccharide inulin and the non-pathogenic microorganisms Bifidobacterium lactis and Lactobacillus acidophilus, with potential anti-inflammatory, immunomodulating and protective activities. Upon oral administration of B. lactis/L. acidophilus/inulin probiotic supplement, the bacterial components in this dietary supplement may improve digestion and promote adequate colonization of the gastrointestinal (GI) tract by modulating the composition of the normal microflora. During colonization in the GI tract, the bacteria may form a protective intestinal barrier that may prevent both damage to the mucosal epithelia caused by toxins and attachment of potential pathogens, which protects against bacterial translocation and infection. In addition, this agent may both reduce the secretion of pro-inflammatory cytokines, including interleukin-10, and potentiate natural and acquired immunity. In colon cancer patients, these probiotic bacteria may favorably modulate the composition of the colon cancer-associated microbiota and may increase expression of tumor-suppressing genes. Inulin promotes growth and activity of beneficial GI bacteria, thereby altering the endogenous flora further.","Bifidobacterium lactis/Lactobacillus acidophilus/Inulin Probiotic Supplement | B. lactis/L. acidophilus/Inulin Probiotic Supplement | ProBion Clinica",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551056","Androgen Receptor Antagonist ONC1-0013B","C148485","An orally bioavailable antagonist of the androgen receptor (AR), with potential antineoplastic activity. Upon oral administration, AR antagonist ONC1-13B specifically binds to AR, prevents AR activation, downregulates AR expression and prevents AR-mediated signaling. This inhibits cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in proliferation, survival and chemoresistance of tumor cells.","Androgen Receptor Antagonist ONC1-0013B | (R)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-4-oxo-2-thioxo-7-oxa-1,3-diazaspiro[4.4]nonan-1-yl)-2-fluoro-N-methylbenzamide | AR Antagonist ONC1-0013B | ONC 10013B | ONC 113B | ONC-10013B | ONC1-0013B | ONC1-13B | ONC10013B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551055","Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody RO7082859","C148486","A bispecific monoclonal antibody, with potential antineoplastic activity. Glofitamab contains two antigen-recognition sites: one for human CD3, a T cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, glofitamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells.","Glofitamab | Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody RO7082859 | Columvi | GLOFITAMAB | Glofitamab-gxbm | RO 7082859 | RO-7082859 | RO7082859",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551058","Polyamine Transport Inhibitor AMXT-1501 Dicaprate","C148487","The dicaprate salt form of AMXT-1501, an orally bioavailable polyamine transport inhibitor, with immunostimulating and antineoplastic activities.  Upon administration, AMXT-1501 targets, binds to and blocks polyamine transport from the bloodstream into the tumor microenvironment (TME), thereby preventing cancer cell uptake. This decreases polyamine concentrations inside the TME and tumor cell, inhibits tumor cell proliferation and induces apoptosis. In addition, AMXT-1501 may abrogate polyamine-mediated immune suppression in the TME. Polyamines, naturally found in normal, heathy cells, are required for normal cell growth and division. In cancer cells, polyamines play key roles in tumor cell proliferation and tumor-induced suppression of the patient's immune system.","Polyamine Transport Inhibitor AMXT-1501 Dicaprate | AMX 513 Dicaprate | AMX513 Dicaprate | AMXT 1501 Dicaprate | AMXT-1501 Dicaprate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551057","APG 1252","C148488","A Bcl-2 homology (BH)-3 mimetic and selective inhibitor of the anti-apoptotic proteins B-cell lymphoma 2 (Bcl-2) and Bcl-XL, with potential pro-apoptotic and antineoplastic activities. Upon administration, pelcitoclax specifically binds to and inhibits the activity of the pro-survival proteins Bcl-2 and Bcl-XL. This restores apoptotic processes and inhibits cell proliferation in Bcl-2/Bcl-XL-dependent tumor cells. Bcl-2 and Bcl-XL, proteins belonging to the Bcl-2 family that are overexpressed in many cancers, play an important role in the negative regulation of apoptosis; tumor expression is associated with increased drug resistance and cancer cell survival.","Pelcitoclax | APG 1252 | APG-1252 | APG1252 | Bcl-2/Bcl-XL Inhibitor APG-1252 | PELCITOCLAX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552420","Unknown Transformation","C150003","It is unknown whether any transformation of the product takes place.","Unknown Transformation | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551800","Unknown/Miscellaneous Anatomical Location","C150004","Relating to various unspecified parts of the body as the intended site of administration, or where the intended site of administration is unknown or not specified.","Unknown/Miscellaneous Anatomical Location | Unknown/Miscellaneous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551799","Urethral Emulsion Dosage Form","C150005","Liquid preparation consisting of an emulsion intended for urethral use by means of a suitable applicator.","Urethral Emulsion Dosage Form | Urethral emulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551802","Urethral Stick Dosage Form","C150006","Solid sterile single-dose preparation, usually rod-shaped and of a size adapted to the dimensions of the urethra, intended for insertion into the urethra. They may be prepared by compression or molding.","Urethral Stick Dosage Form | Urethral stick",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551801","Hard Vaginal Capsule Dosage Form","C150007","Solid single-dose preparation consisting of a hard capsule of a size and shape suited for vaginal use, containing a liquid or semi-solid formulation, intended for a local effect.","Hard Vaginal Capsule Dosage Form | Vaginal capsule, hard",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551796","Soft Vaginal Capsule Dosage Form","C150008","Solid single-dose preparation consisting of a soft capsule of a size and shape suited for vaginal use, containing a liquid or semi-solid formulation, intended for a local effect.","Soft Vaginal Capsule Dosage Form | Vaginal capsule, soft",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551798","Vaginal Cream plus Vaginal Tablet Dosage Form","C150010","Combination package consisting of a vaginal cream and a vaginal tablet.","Vaginal Cream plus Vaginal Tablet Dosage Form | Vaginal cream + vaginal tablet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551797","Vaginal Delivery System Dosage Form","C150011","Drug delivery system intended to be inserted in the vagina where it releases its contents over an extended period of time.","Vaginal Delivery System Dosage Form | SYSTEM | Vaginal delivery system",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551792","Vaginal Emulsion Dosage Form","C150012","Liquid preparation consisting of an emulsion intended for vaginal use by means of a suitable applicator in order to obtain a local effect.","Vaginal Emulsion Dosage Form | Vaginal emulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1273007","Vaginal Solution Dosage Form","C150014","Liquid preparation consisting of a solution intended for vaginal use by means of a suitable applicator in order to obtain a local effect.","Vaginal Solution Dosage Form | Vaginal solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551794","Vaginal Sponge Applicator","C150015","Device for introducing a sponge into the vagina of an animal.","Vaginal Sponge Applicator | Vaginal sponge applicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551793","Vaginal Suspension Dosage Form","C150016","Liquid preparation consisting of a suspension intended for vaginal use by means of a suitable applicator in order to obtain a local effect.","Vaginal Suspension Dosage Form | Vaginal suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552453","Vessel Dosing Unit","C150017","A unit of presentation used to represent the quantity of product that is found in a single vessel-type container.","Vessel Dosing Unit | Vessel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551788","Water-borne Use Route of Administration","C150018","Administration of a veterinary medicinal product to aquatic (marine or fresh water) species by medication of the water environment.","Water-borne Use Route of Administration | Water-borne use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551790","Wing-web-stab Use Route of Administration","C150019","Administration of a veterinary medicinal product into the wing-web of a bird.","Wing-web-stab Use Route of Administration | Wing-web-stab use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551785","UBE2O Gene","C150021","This gene is involved in the monoubiquitination of substrate proteins.","UBE2O Gene | UBE2O | Ubiquitin Conjugating Enzyme E2 O Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551146","EPS8 Peptide-specific Dendritic Cells","C148518","A preparation of dendritic cells (DCs) pulsed with peptides derived from epidermal growth factor receptor (EGFR) pathway substrate 8 (EPS8), with potential immunostimulating and antineoplastic activities. Upon administration of the EPS8 peptide-specific DCs, the immune system is exposed to the EPS8 antigens. This results in the induction of a specific cytotoxic T-lymphocyte (CTL) response against EPS8-expressing tumor cells and tumor cell lysis. EPS8, a tumor-associated antigen (TAA), is overexpressed in a variety of tumor cell types but rarely in normal tissues. As a substrate for the EGFR kinase, it plays a key role in tumor progression through the EGFR-dependent pathway. Its expression is correlated with a poor prognosis.","EPS8 Peptide-specific Dendritic Cells | EPS8 Peptide-specific DCs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550806","BET-bromodomain Inhibitor ODM-207","C148138","An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, the BET inhibitor ODM-207 binds to the acetylated lysine recognition motifs in the bromodomains of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression of oncogenic drivers that are important for cell proliferation and survival. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of proliferation in BET-overexpressing tumor cells. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that bind to acetylated lysine residues in histones and play an important role during development and cellular growth. In tumor cells, BET proteins play a key role in the regulation of oncogene transcription and tumor cell proliferation.","BET-bromodomain Inhibitor ODM-207 | BET Inhibitor ODM-207 | Bromodomain and Extraterminal Domain Protein Inhibitor ODM-207 | ODM 207 | ODM-207 | ODM207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550805","Oral Moisturizing Jelly","C148139","An edible, gel-based formulation containing an artificial saliva substitute, composed of water, electrolytes and buffering agents, with potential anti-xerostomia and protective activities. Upon application of the oral moisturizing jelly (OMJ), the natural electrolyte and pH balance of human saliva is restored, which increases moisture of mucosal tissues of the mouth, tongue and oropharynx. This relieves dryness, enhances lubrication, and increases salivary flow. OMJ makes it easier to chew, swallow and talk, and also prevents xerostomia-induced infections, as well as tooth decay.","Oral Moisturizing Jelly | Gel-based Artificial Saliva | OMJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550808","Karonudib","C148140","An orally available inhibitor of Karolinska nudt1 (MTH1; MutT homologue 1; NUDT1), with potential antineoplastic activity. Upon administration, karonudib targets and binds to the active site of MTH1, thereby preventing the activity of MTH1. This leads to the incorporation of oxidized deoxynucleoside triphosphates (dNTPs) into the DNA of cancer cells, which causes DNA damage, introduces double strand breaks (DSBs), and induces apoptosis in cancer cells. MTH1, a member of the Nudix phosphohydrolase superfamily hydrolyzes oxidized purine nucleoside triphosphates, including 8-oxo-dGTP and 2-OH-dATP, converts them into their corresponding monophosphate forms, and prevents their incorporation into DNA, which allows MTH1-expressing cells to evade cell death. Compared to normal, healthy cells, cancer cells overexpress MTH1, which leads to dysregulation of the cellular redox system and increased reactive oxygen species (ROS) production, which together prevents the incorporation of damaged and oxidized nucleotides into DNA.","Karonudib | Karolinska MTH1 Inhibitor TH1579 | Karolinska NUDT1 Inhibitor TH1579 | TH1579",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550807","Anti-CLEC12A x CD3 Bispecific Antibody MCLA117","C148141","An immunoglobulin G1 (IgG1) bispecific human monoclonal antibody against human CD3, a T-cell surface antigen, and human C-type lectin domain family 12 member A (CLEC12A), a tumor-associated antigen (TAA) overexpressed on certain tumor cells, with potential antineoplastic activity. Upon administration, tepoditamab binds to both CD3 on T-cells and CLEC12A expressed on malignant cells, such as myeloid blasts, atypical progenitor cells and leukemic stem cells (LSCs). This results in the cross-linking of T-cells with tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against CLEC12A-expressing tumor cells. CLEC12A, a myeloid differentiation antigen and member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily, is overexpressed on myeloid leukemia cells, but not on normal early hematopoietic progenitors, including hematopoietic stem cells (HSCs).","Tepoditamab | Anti-CLEC12A x CD3 Bispecific Antibody MCLA117 | Anti-CLEC12A/Anti-CD3 Bispecific Antibody MCLA117 | Bispecific Antibody MCLA-117 | Immunoglobulin G1, Bispecific, Anti-(C-type lectin CLEC12A and CD3 Antigen) (Human Monoclonal MCLA-117 Gamma1-chain), Disulfide with Human Monoclonal MCLA-117 Kappa-chain, Dimer | MCLA 117 | MCLA-117 | MCLA117 | TEPODITAMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552120","PLEKHG5 wt Allele","C150302","Human PLEKHG5 wild-type allele is located in the vicinity of 1p36.31 and is approximately 54 kb in length. This allele, which encodes pleckstrin homology domain-containing family G member 5 protein, is involved in the regulation of nuclear factor kappa B and transforming protein RhoA signaling pathways. Mutation of the gene is associated with recessive intermediate Charcot-Marie-Tooth disease type C and autosomal recessive distal spinal muscular atrophy.","PLEKHG5 wt Allele | CMTRIC | DSMA4 | GEF720 | KIAA0720 | Pleckstrin Homology Domain Containing, Family G (with RhoGef Domain) Member 5 Gene | Pleckstrin Homology Domain-Containing Protein, Family G. Member 5 Gene | Pleckstrin Homology and RhoGEF Domain Containing G5 wt Allele | Syx | Tech",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2001300","PLEKHG5 protein, human","C150303","Pleckstrin homology domain-containing family G member 5 (1062 aa, ~117 kDa) is encoded by the human PLEKHG5 gene. This protein plays a role in the activation of transforming protein RhoA and nuclear factor kappa B signaling pathways.","Pleckstrin Homology Domain-Containing Family G Member 5 | GEF720 | Guanine Nucleotide Exchange Factor 720 | PH Domain-Containing Family G Member 5 | PLEKHG5 | Pleckstrin Homology Domain- and RhoGEF Domain-Containing Protein G5 | Pleckstrin Homology Domain-Containing Protein, Family G. Member 5 | Synectin-Binding Guanine Exchange Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552117","RNF2 wt Allele","C150305","Human RNF2 wild-type allele is located in the vicinity of 1q25.3 and is approximately 57 kb in length. This allele, which encodes E3 ubiquitin-protein ligase RING2 protein, plays a role in histone ubiquitination and the repression of gene transcription.","RNF2 wt Allele | BAP-1 | BAP1 | DING | HIPI3 | RING1B | RING2 | Ring Finger Protein 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551412","Granule and Solvent for Oral Suspension Dosage Form","C149544","Granules and solvent intended for the preparation of an oral suspension by dispersing the granules in the solvent.","Granule and Solvent for Oral Suspension Dosage Form | Granule and Solvent for Oral Suspension  Dosage Form | Granules and solvent for oral suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551414","Granule and Solvent for Suspension for Injection Dosage Form","C149545","Sterile granules and sterile solvent intended for the preparation of a suspension for injection by dispersing the granules in the solvent.","Granule and Solvent for Suspension for Injection Dosage Form | Granules and solvent for suspension for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551413","Granules for Oral Solution Dosage Form","C149546","Solid preparation consisting of aggregated particles that may include excipients to facilitate wetting and dissolution, intended to be dissolved in the specified liquid to obtain an oral solution, which is usually prepared just before administration to the patient.","Granules for Oral Solution Dosage Form | Granules for oral solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551409","Granules for oral solution in sachet","C149547","Medicinal product consisting of granules for oral solution presented in a sachet.","Granules for Oral Solution in Sachet Dosage Form | Granules for Oral Solution in Sachet | Granules for oral solution in sachet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551408","Granules for oral suspension","C149548","Solid preparation consisting of aggregated particles that may include excipients to facilitate wetting and dispersion, intended to be dispersed in the specified liquid to obtain an oral suspension, which is usually prepared just before administration to the patient.","Granules for Oral Suspension Dosage Form | Granule for Oral Suspension Dosage Form | Granules for oral suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551410","Granules for oral/rectal suspension","C149550","Solid preparation consisting of granules intended to be dispersed in the specified liquid to obtain an oral/rectal suspension.","Granules for Oral/Rectal Suspension Dosage Form | Granule for Oral/Rectal Suspension Dosage Form | Granules for oral/rectal suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551405","Granules for rectal suspension","C149551","Solid preparation consisting of aggregated particles that may include excipients to facilitate wetting and dispersion, intended to be dispersed in the specified liquid to obtain a rectal suspension, which is usually prepared just before administration to the patient.","Granules for Rectal Suspension Dosage Form | Granule for Rectal Suspension Dosage Form | Granules for rectal suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551404","Granules for suspension for injection","C149552","Solid sterile preparation consisting of granules intended to be dispersed in the specified liquid to obtain a suspension for injection.","Granules for Suspension for Injection Dosage Form | Granule for Suspension for Injection Dosage Form | Granules for suspension for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545872","NOURISH-T","C148098","A program for behavior modification that focusing on caregivers as agents for change. In NOURISH-T, caregivers are educated about the importance of modeling healthy eating and physical activity behaviors to promote positive health behavior change and healthy weight management in pediatric cancer survivors.","NOURISH-T | NOURISH for Healthy Transitions | Nourishing Our Understanding of Role Modeling to Improve Support and Health for Healthy Transitions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545873","Refractory Malignant Thymoma","C148099","Malignant thymoma that does not respond to treatment.","Refractory Malignant Thymoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0212399","Damnacanthal","C1480","An alkaloid phytochemical found in the Morinda Citrifolia (Noni) that inhibits the growth of RAS cancer cells. The exact mechanism is unknown but may involve the inhibition of tyrosine kinase. (NCI)","Damnacanthal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545860","Hedgehog Pathway Mutation","C148101","A change in the sequence of one or more genes that are involved in the hedgehog signaling pathway.","Hedgehog Pathway Mutation | Hedgehog Pathway Gene Mutation | Hedgehog Signaling Mutation | Hedgehog Signaling Pathway Gene Mutation | Hedgehog Signaling Pathway Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545861","Dextromethorphan/Bupropion Tablet AXS-05","C148102","A tablet composed of the non-opioid derivative of morphine dextromethorphan (DM) and the aminoketone bupropion, with potential analgesic, antidepressant and anti-agitation activities. Upon oral administration, the DM component may act as a weak N-methyl-D-aspartate (NMDA) receptor antagonist, a sigma-1 receptor agonist and an inhibitor of the serotonin and norepinephrine transporters, which together may alleviate pain, agitation, anxiety and depression. While the bupropion component acts as a norepinephrine and dopamine reuptake inhibitor and a central nicotinic acetylcholine receptor antagonist, which is beneficial in the treatment of depression. Additionally, bupropion may increase the bioavailability of DM, thus prolonging the therapeutic effects of DM.","Dextromethorphan/Bupropion Tablet AXS-05 | AXS 05 | AXS-05 | DM + BUP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545862","Anti-CD48/MMAE Antibody-drug Conjugate SGN-CD48A","C148103","An antibody-drug conjugate (ADC) composed of an antibody targeting the cell surface antigen CD48 that is conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), via a proprietary next-generation PEGylated glucuronide linker, with potential antineoplastic activity. Following intravenous administration, the antibody moiety of anti-CD48 ADC SGN-CD48A binds to CD48 on the surface of tumor cells. Following internalization of the ADC, the MMAE binds to tubulin and inhibits microtubule polymerization, which may result in G2/M phase cell cycle arrest and apoptosis in CD48-expressing tumor cells. CD48, a member of the signaling lymphocyte activation molecule (SLAM) family of immune cell receptors, is involved in T-cell activation and leukocyte trafficking. Additionally, CD48 is expressed on the surface of multiple myeloma cells at significantly higher levels than it is expressed on normal lymphocytes and monocytes. The linkage system in SGN-CD48A improves stability, reduces off-target uptake, and enables conjugation of larger numbers of MMAE/antibody than other systems, resulting in increased specificity against CD48-positive cells.","Anti-CD48/MMAE Antibody-drug Conjugate SGN-CD48A | Anti-CD48 ADC SGN-CD48A | SGN CD48A | SGN-CD48A | SGNCD48A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545863","DDR2 Gene Mutation","C148104","A change in the nucleotide sequence of the DDR2 gene.","DDR2 Gene Mutation | DDR2 Mutation | Discoidin Domain Receptor Family Member 2 Gene Mutation | Discoidin Domain Receptor Family, Member 2 Gene Mutation | MIG20a Gene Mutation | NTRKR3 Gene Mutation | TKT Gene Mutation | TYRO10 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545864","G Protein Subunit Alpha I Gene Mutation","C148105","A change in the nucleotide sequence of a GNAI family gene.","GNAI Family Gene Mutation | G Protein Subunit Alpha I Gene Mutation | G(i) Alpha Gene Mutation | GNAI Gene Mutation | Guanine Nucleotide Binding Protein (G Protein), Alpha Inhibiting Activity Gene Mutation | Guanine Nucleotide Binding Protein Alpha Inhibiting Activity Gene Mutation | Guanine Nucleotide-Binding Protein G(i), Alpha Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545865","Inactivating ERBB2 Gene Mutation","C148106","A change in the nucleotide sequence of the ERBB2 gene that either inhibits expression of the receptor tyrosine-protein kinase erbB-2 protein or results in the translation of an inactive receptor tyrosine-protein kinase erbB-2 protein.","Inactivating ERBB2 Gene Mutation | CD340 Inactivating Mutation | HER-2 Inactivating Mutation | HER2 Inactivating Mutation | HER2/Neu Inactivating Mutation | Inactivating HER2 Mutation | Loss of Function ERBB2 Mutation | Loss of Function HER2 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551784","UBE2O wt Allele","C150022","Human UBE2O wild-type allele is located in the vicinity of 17q25.1 and is approximately 64 kb in length. This allele, which encodes (E3-independent) E2 ubiquitin-conjugating enzyme protein, plays a role in protein monoubiquitination.","UBE2O wt Allele | E2-230K | KIAA1734 | Ubiquitin Conjugating Enzyme E2 O wt Allele | Ubiquitin-Conjugating Enzyme E2, 230-kD Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552048","ASN007","C150248","An orally bioavailable inhibitor of the extracellular signal-regulated kinases 1 (ERK1) and 2 (ERK2), with potential antineoplastic activity. Upon oral administration, ERAS-007 specifically binds to and inhibits the serine/threonine-protein kinase activities of both ERK1 and ERK2, thereby preventing the phosphorylation of ERK1/2 substrates and the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent proliferation and survival of tumor cells. The MAPK/ERK pathway, also known as the RAS/RAF/MEK/ERK pathway, is hyperactivated in a variety of tumor cell types due to mutations in upstream targets. It plays a key role in the proliferation, differentiation and survival of tumor cells.","ERK1/2 Inhibitor ERAS-007 | ASN 007 | ASN-007 | ASN007 | ERAS 007 | ERAS-007 | ERAS007 | ERK Inhibitor ASN007 | ERK Inhibitor ERAS-007 | ERK1/2 Inhibitor ASN007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4014261","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 16","C150250","An autosomal recessive form of spinocerebellar ataxia caused by mutation(s) in the STUB1 gene, encoding E3 ubiquitin-protein ligase CHIP.","Spinocerebellar Ataxia Type 16 | SCAR16",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1533041","Primary Congenital Glaucoma","C150251","Congenital glaucoma that arises independent of another pathologic process, disease, or injury.","Primary Congenital Glaucoma | ",,,,,,,,,,,,,,,"4190744","Primary congenital glaucoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552044","GSN wt Allele","C150252","Human GSN wild-type allele is located in the vicinity of 9q33.2 and is approximately 125 kb in length. This allele, which encodes gelsolin protein, plays a role in both assembly and disassembly of actin filaments. Mutation of the gene is associated with Finnish type familial amyloidosis (amyloidosis V).","GSN wt Allele | ADF | AGEL | Amyloidosis, Finnish Type Gene | DKFZp313L0718 | Gelsolin (Amyloidosis, Finnish Type) Gene | Gelsolin wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552043","Gelsolin","C150253","Gelsolin (782 aa, ~86 kDa) is encoded by the human GSN gene. This protein is involved in the modulation of actin filament polymerization.","Gelsolin | ADF | AGEL | Actin-Depolymerizing Factor | Brevin | GSN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552040","HCAR1 wt Allele","C150256","Human HCAR1 wild-type allele is located in the vicinity of 12q24.31 and is approximately 5 kb in length. This allele, which encodes hydroxycarboxylic acid receptor 1 protein, is involved in lactate-mediated signaling.","HCAR1 wt Allele | FKSG80 | GPR104 | GPR81 | HCA1 | Hydroxycarboxylic Acid Receptor 1 wt Allele | LACR1 | TA-GPCR | TAGPCR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552039","Hydroxycarboxylic Acid Receptor 1","C150257","Hydroxycarboxylic acid receptor 1 (346 aa, ~39 kDa) is encoded by the human HCAR1 gene. This protein plays a role in lactate-dependent G protein-coupled receptor signaling.","Hydroxycarboxylic Acid Receptor 1 | G Protein-Coupled Receptor 104 | G Protein-Coupled Receptor 81 | G-Protein Coupled Receptor 104 | G-Protein Coupled Receptor 81 | HCAR1 | Hydroxy-Carboxylic Acid Receptor 1 | Lactate Receptor 1 | T-Cell Activation G Protein-Coupled Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552041","HNRNPK wt Allele","C150259","Human HNRNPK wild-type allele is located in the vicinity of 9q21.32 and is approximately 13 kb in length. This allele, which encodes Heterogeneous nuclear ribonucleoprotein K, plays a role in pre-mRNA binding, single-stranded DNA binding and transcriptional regulation. Mutation of the gene is associated with Au-Kline syndrome.","HNRNPK wt Allele | AUKS | CSBP | HNRPK | Heterogeneous Nuclear Ribonucleoprotein K wt Allele | TUNP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550801","Resiquimod Gel CD11301","C148143","A topical gel containing the Toll-like receptor (TLR) agonist resiquimod, an imidazoquinolinamine, with potential immunomodulating activity. Upon topical application, the resiquimod gel CD11301 binds to TLR7 and 8, which are found mainly on dendritic cells (DCs), macrophages, and B-lymphocytes, and activates the TLR signaling pathway, which results in the induction of the nuclear translocation of transcription activator nuclear factor kappa-B (NF-kB) and activation of other transcription factors. Subsequently, NF-kB-dependent gene expression is induced and cytokine production increases, especially interferon-alpha (INF-a), which results in the enhancement of T-helper 1 (Th1) immune responses. In addition, topical application of resiquimod appears to activate epidermal Langerhans cells, leading to enhanced activation of T-lymphocytes.","Resiquimod Gel CD11301 | CD 11301 | CD11301 | CD11301 Topical Gel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550892","INSM2 Gene","C148303","This gene may play a role in the repression of genes involved in cell growth.","INSM2 Gene | INSM Transcriptional Repressor 2 Gene | INSM2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550887","INSM2 wt Allele","C148304","Human INSM2 wild-type allele is located in the vicinity of 14q13.2 and is approximately 3 kb in length. This allele, which encodes insulinoma-associated protein 2, is involved in transcriptional repression, cell growth regulation and tumor suppression.","INSM2 wt Allele | IA-6 | IA6 | INSM Transcriptional Repressor 2 wt Allele | Insulinoma-Associated 2 Gene | Insulinoma-Associated Gene 6 | Nbla106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550886","Insulinoma-Associated Protein 2","C148305","Insulinoma-associated protein 2 (566 aa, ~59 kDa) is encoded by the human INSM2 gene. This protein plays a role in cell growth regulation and tumor suppression.","Insulinoma-Associated Protein 2 | IA-2 | INSM2 | INSULINOMA-ASSOCIATED PROTEIN 2 | Insulinoma-Associated Protein IA-6 | Zinc Finger Protein IA-6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550889","PTPRN Gene","C148306","This gene is involved in the regulation of neurotransmitter, pituitary hormone and insulin secretion.","PTPRN Gene | PTPRN | Protein Tyrosine Phosphatase Receptor Type N Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550888","PTPRN wt Allele","C148307","Human PTPRN wild-type allele is located in the vicinity of 2q35 and is approximately 20 kb in length. This allele, which encodes receptor-type tyrosine-protein phosphatase-like N protein, plays a role in processes that regulate secretory vesicle functions.","PTPRN wt Allele | IA-2 | IA-2/PTP | IA2 | ICA3 | ICA512 | Protein Tyrosine Phosphatase Receptor Type N wt Allele | Protein Tyrosine Phosphatase, Receptor Type N Gene | Protein-Tyrosine Phosphatase, Receptor-Type, N Gene | R-PTP-N",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1568433","PTPRN protein, human","C148308","Receptor-Type Tyrosine-Protein Phosphatase-Like N (979 aa, ~106 kDa) is encoded by the human PTPRN gene. This protein is involved in neurotransmitter and hormone secretion.","Receptor-Type Tyrosine-Protein Phosphatase-Like N | IA-2 | ICA 512 | ICA512 | ISLET CELL ANTIGEN 512 | Insulinoma-Associated Protein 2 | Insulinoma-Associated Tyrosine-Phosphatase-Like Protein | Islet Antigen 2 | Islet Cell Antigen 2 | Islet Cell Antigen 512 | Islet Cell Autoantigen 3 | PTP IA-2 | PTP-IA2 | PTPRN | Protein Tyrosine Phosphatase Receptor Type-N | Protein Tyrosine Phosphatase-Like N | R-PTP-N | Receptor Type Protein Tyrosine Phosphatase N | Receptor-type Tyrosine-protein Phosphatase-like N",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550883","Unresectable Metastasis","C148309","A finding indicating that a metastatic tumor is not amenable to surgical resection.","Unresectable Metastasis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552430","SCT Gene","C148310","This gene plays a role in the formation of pancreatic juice and bile.","SCT Gene | SCT | Secretin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550885","SCT wt Allele","C148311","Human SCT wild-type allele is located in the vicinity of 11p15.5 and is approximately 2 kb in length. This allele, which encodes prepro-secretin, is involved in the production of digestive juices.","SCT wt Allele | Secretin wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550882","SCT Gene Product","C148312","A protein encoded by the SCT gene.","SCT Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551407","Granules for syrup","C149553","Solid preparation consisting of aggregated particles that may include excipients to facilitate wetting and dissolution and to obtain the characteristics of a syrup, intended to be dissolved in water to obtain a syrup.","Granules for Syrup Dosage Form | Granule for Syrup Dosage Form | Granules for syrup",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551406","Granules for use in drinking water","C149554","Solid preparation for veterinary use consisting of granules intended to be dissolved in the animal drinking water.","Granules for Use in Drinking Water Dosage Form | Granule for Use in Drinking Water Dosage Form | Granules for use in drinking water",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551401","Granules for Vaginal Solution Dosage Form","C149555","Solid preparation consisting of aggregated particles that may include excipients to facilitate wetting and dissolution, intended to be dissolved in the specified liquid to obtain a vaginal solution, which is usually prepared just before administration to the patient.","Granules for Vaginal Solution Dosage Form | Granules for vaginal solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551400","Granules in sachet","C149556","Medicinal product consisting of granules presented in a sachet, the entire contents of which are intended for oral administration as a single dose.","Granules in Sachet Dosage Form | Granules in Sachet | Granules in sachet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551403","Granules in single-dose container","C149557","Medicinal product consisting of granules presented in a single-dose container.","Granules in Single-dose Container Dosage Form | Granules in Single-dose Container | Granules in single-dose container",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554822","Herbal Material (Unprocessed) Dosage Form Category","C149558","A type of solid pharmaceutical dose form consisting of whole, broken or fragmented plants or parts of plants (including algae, fungi, lichen) in an unprocessed state, and which may be dried or fresh.","Herbal Material (Unprocessed) Dosage Form Category | Herbal material (unprocessed)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551397","Herbal tea in bag","C149560","Medicinal product consisting of a herbal tea enclosed in a porous bag (a tea bag) intended to be placed in water for the preparation of an oral aqueous preparation on one occasion only.","Herbal Tea in Bag Dosage Form | Herbal Tea in Bag | Herbal tea in bag",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545880","Unresectable Craniopharyngioma","C148076","A craniopharyngioma that is not amenable to surgical resection.","Unresectable Craniopharyngioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL545866","Somatic KIT Gene Mutation","C148107","A change in the nucleotide sequence of the KIT gene that originated in non-germline cells.","Somatic KIT Gene Mutation | C-KIT Somatic Mutation | CD117 Somatic Mutation | KIT Proto-Oncogene Tyrosine Protein Kinase Gene Somatic Mutation | KIT Somatic Mutation | Somatic c-KIT Gene Mutation | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Gene Somatic Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550834","Autologous Dendritic Cells Transduced with Wild-type p53 Adenovirus Vaccine","C148241","A cancer vaccine consisting of autologous dendritic cells (DCs) transduced with a recombinant replication-defective adenoviral (Ad) vector encoding the full-length wild-type (wt) cancer tumor antigen p53 protein (TP53; p53), with potential immunomodulating activity. Intradermal vaccination with the autologous DCs transduced with wt p53 Ad vaccine may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells overexpressing wt and mutant forms of p53, resulting in tumor cell lysis. p53, a tumor suppressor gene, is overexpressed and/or mutated in many tumor cells, resulting in the loss of apoptosis regulation and abnormal cell proliferation.","Autologous Dendritic Cells Transduced with Wild-type p53 Adenovirus Vaccine | Ad.p53-DC | Autologous DCs Transduced with Ad.p53 Vaccine | Autologous DCs Transduced with wt p53 Ad Vaccine | Dendritic Cell Based p53 Vaccine | Dendritic Cell-based p53 Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550833","Veterinary Route of Administration","C148242","Methods of administraion of pharmaceutical preparations that are used in the veterinary setting.","Veterinary Route of Administration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550828","Veterinary Dosage Form","C148243","Pharmaceutical preparations intended for veterinary use.","Veterinary Dosage Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550827","Recurrent Grade 3a Follicular Lymphoma","C148244","The reemergence of grade 3a follicular lymphoma after a period of remission.","Recurrent Grade 3a Follicular Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL550830","Unresectable Cutaneous Melanoma","C148245","A skin melanoma that is not amenable to surgical resection.","Unresectable Cutaneous Melanoma | Unresectable Cutaneous (Skin) Melanoma | Unresectable Melanoma of Skin | Unresectable Skin Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1447150","HNRNPK protein, human","C150260","Heterogeneous nuclear ribonucleoprotein K (463 aa, ~51 kDa) is encoded by the human HNRNPK gene. This protein is involved in the regulation of transcription and binding to poly-cytidine sequences in mRNA and single-stranded DNA.","Heterogeneous Nuclear Ribonucleoprotein K | HNRNPK | HnRNP K | TUNP | Transformation Up-Regulated Nuclear Protein | Transformation Upregulated Nuclear Protein | dC-Stretch Binding Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL561957","Endotracheopulmonary Instillation, Powder for Suspension Dosage Form","C149491","Solid preparation consisting of one or more powders intended to be dispersed in the specified liquid to obtain an endotracheopulmonary instillation suspension.","Endotracheopulmonary Instillation, Powder for Suspension Dosage Form | Endotracheopulmonary instillation, powder for suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551346","Endotracheopulmonary Instillation, Solution Dosage Form","C149492","Liquid preparation consisting of an aqueous solution intended for instillation to the trachea and/or bronchi.","Endotracheopulmonary Instillation, Solution Dosage Form | Endotracheopulmonary instillation, solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1276320","Endotracheopulmonary Instillation, Suspension Dosage Form","C149493","Liquid preparation consisting of an aqueous suspension intended for instillation to the trachea and/or bronchi. Preparations for inhalation use are excluded.","Endotracheopulmonary Instillation, Suspension Dosage Form | Endotracheopulmonary instillation, suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551348","Environmental","C149494","Relating to the surroundings in which the target of the pharmaceutical product is found, as the intended site of administration, e.g. an enclosed volume of water or air; usually the product disperses in the area and is subsequently taken up by the subject.","Environmental | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551344","Epilesional Solution Dosage Form","C149495","Liquid sterile preparation consisting of a solution intended to be administered onto a lesion.","Epilesional Solution Dosage Form | Epilesional solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551343","Epilesional Route of Administration","C149496","Administration of a medicinal product onto a lesion.","Epilesional Route of Administration | Epilesional use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0442087","Extracorporeal","C149497","Relating to a body substance or tissue as the intended site of administration, after being removed from the body in order to be treated with the pharmaceutical product and then subsequently returned to the body.","Extracorporeal | ",,,,,,,,,,,,,,,"37157672|4125575","Extracorporeal|Extracorporeal",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL551340","Eye drops, emulsion in single-dose container","C149499","Medicinal product consisting of an eye drops emulsion presented in a single-dose container.","Eye Drops, Emulsion in Single-dose Container Dosage Form | Eye Drops, Emulsion in Single-dose Container | Eye drops, emulsion in single-dose container",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938206","Arcitumomab","C1494","A murine IgG monoclonal Fab' fragment antibody directed against carcinoembryonic antigen (CEA), a protein that is overexpressed by many tumor cell types. For tumors that overexpress CEA, technetium-99m labeled arcitumomab may be used as an adjunct diagnostic imaging tool to obtain prognostic information following resection and to monitor for recurrent disease. (NCI04)","Arcitumomab | ARCITUMOMAB | CEA-Scan | IMMU-4 | Immunoglobulin G 1 (mouse monoclonal IMMU-4 Fab' fragment gamma-chain anti-human antigen CEA), disulfide with mouse Monoclonal IMMU-4 Light Chain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551339","Eye Drops, Powder and Solvent for Solution Dosage Form","C149500","Sterile powder and sterile solvent intended for the preparation of eye drops, solution, by dissolving the powder in the solvent.","Eye Drops, Powder and Solvent for Solution Dosage Form | Eye drops, powder and solvent for solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551342","Eye Drops, Powder and Solvent for Suspension Dosage Form","C149501","Sterile powder and sterile solvent intended for the preparation of eye drops, suspension, by dispersing the powder in the solvent.","Eye Drops, Powder and Solvent for Suspension Dosage Form | Eye drops, powder and solvent for suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL551341","Eye Drops, Powder for Solution Dosage Form","C149502","Solid sterile preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain an eye drops solution.","Eye Drops, Powder for Solution Dosage Form | Eye drops, powder for solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0678583","sourness","C150482","Having a sharp, acidic taste.","Sour | Sour Taste | Sourness",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552189","Cord Blood-derived Expanded Allogeneic Natural Killer Cells","C150483","A preparation of human umbilical cord blood (UCB)-derived and ex vivo-expanded allogeneic natural killer (NK) cells, with immunomodulating and cytotoxic activities. Upon infusion of the cord blood-derived expanded allogeneic NK cells, these cells recognize and bind to tumor cells, and secrete perforins, granzymes, and cytokines, which cause cancer cell lysis.","Cord Blood-derived Expanded Allogeneic Natural Killer Cells | Allogeneic CB-derived Ex vivo-expanded NK Cells | CB-derived Expanded Allogeneic NK Cells | UCB-derived Expanded Allogeneic NK Cells | Umbilical Cord Blood-derived Expanded Allogeneic Natural Killer Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552188","Umami","C150484","Having a meaty, broth-like taste.","Umami | Savoriness | Savory Taste | Umami Taste",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552918","FACT/GOG-NTX Version 4 - I Feel Ill","C151201","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Physical Well-Being: I feel ill.","FACT/GOG-NTX Version 4 - I Feel Ill | FAC057-I Feel Ill | FAC05706",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552919","FACT/GOG-NTX Version 4 - I Am Forced to Spend Time in Bed","C151202","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Physical Well-Being: I am forced to spend time in bed.","FACT/GOG-NTX Version 4 - I Am Forced to Spend Time in Bed | FAC057-I Am Forced to Spend Time in Bed | FAC05707",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552920","FACT/GOG-NTX Version 4 - I Feel Close to My Friends","C151203","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Social/Family Well-Being: I feel close to my friends.","FACT/GOG-NTX Version 4 - I Feel Close to My Friends | FAC057-I Feel Close to My Friends | FAC05708",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552921","FACT/GOG-NTX Version 4 - Get Emotional Support From Family","C151204","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Social/Family Well-Being: I get emotional support from my family.","FACT/GOG-NTX Version 4 - Get Emotional Support From Family | FAC057-Get Emotional Support From Family | FAC05709",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552924","FACT/GOG-NTX Version 4 - Satisfied Communication Illness","C151207","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Social/Family Well-Being: I am satisfied with family communication about my illness.","FACT/GOG-NTX Version 4 - Satisfied Communication Illness | FAC057-Satisfied Communication Illness | FAC05712",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555377","CDISC Questionnaire FACT-BL Version 4 Test Name Terminology","C154452","Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACT-BL Version 4 Test Name Terminology | FAC006TN | Functional Assessment of Cancer Therapy-Bladder Version 4 Questionnaire Test Name | QS-FACT-BL Version 4 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555378","CDISC Questionnaire FACT-BL Version 4 Test Code Terminology","C154453","Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACT-BL Version 4 Test Code Terminology | FAC006TC | Functional Assessment of Cancer Therapy-Bladder Version 4 Questionnaire Test Code | QS-FACT-BL Version 4 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555383","CDISC Questionnaire NSCLC-SAQ Version 1.0 Test Name Terminology","C154454","Test names of questionnaire questions associated with the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire v1.0 (NSCLC-SAQ Version 1.0) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire NSCLC-SAQ Version 1.0 Test Name Terminology | NSCLC1TN | Non-Small Cell Lung Cancer Symptom Assessment Questionnaire v1.0 Questionnaire Test Name | QS-NSCLC-SAQ Version 1.0 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555384","CDISC Questionnaire NSCLC-SAQ Version 1.0 Test Code Terminology","C154455","Test codes of questionnaire questions associated with the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire v1.0 (NSCLC-SAQ Version 1.0) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire NSCLC-SAQ Version 1.0 Test Code Terminology | NSCLC1TC | Non-Small Cell Lung Cancer Symptom Assessment Questionnaire v1.0 Questionnaire Test Code | QS-NSCLC-SAQ Version 1.0 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555381","CDISC Questionnaire SMDDS Version 1.0 Test Name Terminology","C154456","Test names of questionnaire questions associated with the Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire SMDDS Version 1.0 Test Name Terminology | QS-SMDDS Version 1.0 TEST | SMDDS1TN | Symptoms of Major Depressive Disorder Scale v1.0 Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555382","CDISC Questionnaire SMDDS Version 1.0 Test Code Terminology","C154457","Test codes of questionnaire questions associated with the Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire SMDDS Version 1.0 Test Code Terminology | QS-SMDDS Version 1.0 TESTCD | SMDDS1TC | Symptoms of Major Depressive Disorder Scale v1.0 Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555387","CDRS-R Clinical Classification Question","C154458","A question associated with the CDRS-R clinical classification.","CDRS-R Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555388","UHDRS 1999 Version Clinical Classification Question","C154459","A question associated with the UHDRS 1999 Version clinical classification.","UHDRS 1999 Version Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555385","FACIT-Dyspnea Scale 33 Item Bank Version Questionnaire Question","C154460","A question associated with the FACIT-Dyspnea Scale 33 Item Bank Version questionnaire.","FACIT-Dyspnea Scale 33 Item Bank Version Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555386","FACT-BL Version 4 Questionnaire Question","C154461","A question associated with the FACT-BL Version 4 questionnaire.","FACT-BL Version 4 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555390","NSCLC-SAQ Version 1.0 Questionnaire Question","C154462","A question associated with the NSCLC-SAQ Version 1.0 questionnaire.","NSCLC-SAQ Version 1.0 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555391","SMDDS Version 1.0 Questionnaire Question","C154463","A question associated with the SMDDS Version 1.0 questionnaire.","SMDDS Version 1.0 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555389","Drop Dosage Form Category","C154464","A type of liquid pharmaceutical dose form that may be a dispersion, an emulsion, a solution or a suspension, and that is administered in small volumes by instillation; to be used only when further details of the specific form (e.g. dispersion, emulsion, solution, suspension) are unknown.","Drop Dosage Form Category | Drops (unspecified)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552814","FACT-C Version 4 - My Work Is Fulfilling","C151097","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Functional Well-Being: My work (include work at home) is fulfilling.","FACT-C Version 4 - My Work Is Fulfilling | FAC008-My Work Is Fulfilling | FAC00822",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552815","FACT-C Version 4 - I Am Able to Enjoy Life","C151098","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Functional Well-Being: I am able to enjoy life.","FACT-C Version 4 - I Am Able to Enjoy Life | FAC008-I Am Able to Enjoy Life | FAC00823",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552816","FACT-C Version 4 - I Have Accepted My Illness","C151099","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Functional Well-Being: I have accepted my illness.","FACT-C Version 4 - I Have Accepted My Illness | FAC008-I Have Accepted My Illness | FAC00824",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552817","FACT-C Version 4 - I Am Sleeping Well","C151100","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Functional Well-Being: I am sleeping well.","FACT-C Version 4 - I Am Sleeping Well | FAC008-I Am Sleeping Well | FAC00825",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552818","FACT-C Version 4 - Enjoy Things I Usually Do for Fun","C151101","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Functional Well-Being: I am enjoying the things I usually do for fun.","FACT-C Version 4 - Enjoy Things I Usually Do for Fun | FAC008-Enjoy Things I Usually Do for Fun | FAC00826",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552819","FACT-C Version 4 - Content With Quality of My Life","C151102","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Functional Well-Being: I am content with the quality of my life right now.","FACT-C Version 4 - Content With Quality of My Life | FAC008-Content With Quality of My Life | FAC00827",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552821","FACT-C Version 4 - I Am Losing Weight","C151104","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Additional Concerns: I am losing weight.","FACT-C Version 4 - I Am Losing Weight | FAC008-I Am Losing Weight | FAC00829",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552822","FACT-C Version 4 - I Have Control of My Bowels","C151105","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Additional Concerns: I have control of my bowels.","FACT-C Version 4 - I Have Control of My Bowels | FAC008-I Have Control of My Bowels | FAC00830",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552326","Metastatic Malignant Neoplasm in the Viscera","C150597","A malignant neoplasm which has spread from its original site of growth to any visceral site.","Metastatic Malignant Neoplasm in the Viscera | Secondary Malignant Neoplasm of Viscera | Visceral Metastases",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552325","Unresectable Dedifferentiated Liposarcoma","C150598","Dedifferentiated liposarcoma that is not amenable to surgical resection.","Unresectable Dedifferentiated Liposarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0319931","Aspergillus niveus","C150877","A species of mold fungus in the phylum Ascomycota that is commonly found in soil. This species is a rare opportunistic pathogen in humans.","Aspergillus niveus | ASPERGILLUS NIVEUS",,,,,,,,,,,,,,,"4088370","Aspergillus niveus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL564785","Staphylococcus capitis Subspecies urealyticus","C150878","A subspecies of Staphylococcus capitis that is positive for urease activity and is able to produce acid from maltose aerobically.","Staphylococcus capitis Subspecies urealyticus | STAPHYLOCOCCUS CAPITIS SUBSP. UREALYTICUS | Staphylococcus capitis Subspecies ureolyticus",,,,,,,,,,,,,,,"4011498","Staphylococcus capitis subspecies urealyticus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2960746","Carbapenem Resistant Acinetobacter","C150879","Any species, subspecies, or strain of Acinetobacter that is able to grow in the presence of carbapenem.","Carbapenem Resistant Acinetobacter | ACINETOBACTER, CARBAPENEM-RESISTANT | CARBAPENEM RESISTANT ACINETOBACTER | Carbapenem-resistant Acinetobacter",,,,,,,,,,,,,,,"40492250","Carbapenem resistant Acinetobacter",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0317767","Mycobacterium malmoense","C150880","A species of slow-growing non-photochromogenic bacteria in the genus Mycobacterium. This species is a frequent cause of nontuberculous lung infections in norther Europe.","Mycobacterium malmoense | MYCOBACTERIUM MALMOENSE",,,,,,,,,,,,,,,"4250651","Mycobacterium malmoense",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0317758","Mycobacterium xenopi","C150881","A species of slow-growing, nontuberculous bacteria in the genus Mycobacterium. This species is able to cause opportunistic lung infections and extrapulmonary or disseminated disease in immunocompromised individuals.","Mycobacterium xenopi | MYCOBACTERIUM XENOPI",,,,,,,,,,,,,,,"4239461","Mycobacterium xenopi",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552736","Mycobacterium abscessus Subspecies bolletii","C150883","A subspecies of Mycobacterium abscessus. M. abscessus subsp. bolletii is recognized as a rare pathogen with a functional inducible erythromycin ribosome methyltransferase (erm) (41) gene and macrolide resistance.","Mycobacterium abscessus Subspecies bolletii | MYCOBACTERIUM ABSCESSUS SUBSP. BOLLETII | Mycobacterium bolletii",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552925","FACT/GOG-NTX Version 4 - I Feel Close to My Partner","C151208","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Social/Family Well-Being: I feel close to my partner (or the person who is my main support).","FACT/GOG-NTX Version 4 - I Feel Close to My Partner | FAC057-I Feel Close to My Partner | FAC05713",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552926","FACT/GOG-NTX Version 4 - I Am Satisfied With My Sex Life","C151209","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Social/Family Well-Being: I am satisfied with my sex life.","FACT/GOG-NTX Version 4 - I Am Satisfied With My Sex Life | FAC057-I Am Satisfied With My Sex Life | FAC05714",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552927","FACT/GOG-NTX Version 4 - I Feel Sad","C151210","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Emotional Well-Being: I feel sad.","FACT/GOG-NTX Version 4 - I Feel Sad | FAC057-I Feel Sad | FAC05715",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552928","FACT/GOG-NTX Version 4 - Satisfied With How I Am Coping","C151211","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Emotional Well-Being: I am satisfied with how I am coping with my illness.","FACT/GOG-NTX Version 4 - Satisfied With How I Am Coping | FAC057-Satisfied With How I Am Coping | FAC05716",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552929","FACT/GOG-NTX Version 4 - Losing Hope Against Illness","C151212","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Emotional Well-Being: I am losing hope in the fight against my illness.","FACT/GOG-NTX Version 4 - Losing Hope Against Illness | FAC057-Losing Hope Against Illness | FAC05717",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552930","FACT/GOG-NTX Version 4 - I Feel Nervous","C151213","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Emotional Well-Being: I feel nervous.","FACT/GOG-NTX Version 4 - I Feel Nervous | FAC057-I Feel Nervous | FAC05718",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552931","FACT/GOG-NTX Version 4 - I Worry About Dying","C151214","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Emotional Well-Being: I worry about dying.","FACT/GOG-NTX Version 4 - I Worry About Dying | FAC057-I Worry About Dying | FAC05719",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552932","FACT/GOG-NTX Version 4 - Worry My Condition Will Get Worse","C151215","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Emotional Well-Being: I worry that my condition will get worse.","FACT/GOG-NTX Version 4 - Worry My Condition Will Get Worse | FAC057-Worry My Condition Will Get Worse | FAC05720",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552498","Autologous Ovarian Cancer Immunogene-modified T Lymphocytes","C150696","A preparation of autologous immunogene modified T-lymphocytes (IgT) that have been genetically engineered to be specifically reactive to ovarian cancer (OC) cells, with potential antineoplastic and immunostimulating activities. Upon administration of the autologous OC-IgT cells, the T-cells recognize and induce specific toxicity in the OC cells.","Autologous Ovarian Cancer Immunogene-modified T Lymphocytes | Autologous Human OC-IgT Cells | OC-IgT Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552499","Autologous Tumor-specific Antigen-loaded Dendritic Cells","C150697","A cell-based cancer vaccine composed of autologous dendritic cells (DCs) loaded with tumor-specific antigen(s) (TSAs), with potential immunostimulatory and antineoplastic activities. Upon administration of the autologous TSA-loaded DCs, the DCs stimulate a specific cytotoxic T-lymphocyte (CTL)-mediated immune response against the tumor cells expressing the TSA(s), resulting in tumor cell lysis.","Autologous Tumor-specific Antigen-loaded Dendritic Cells | Autologous TSA-DC | Autologous TSA-DC Vaccine | Autologous TSA-DCs | Autologous TSA-loaded Dendritic Cells | Tumor Specific Antigen-loaded Autologous Dendritic Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0872259","repetitive transcranial magnetic stimulation","C154664","A form of brain stimulation therapy that has been studied as a treatment for depression, psychosis, anxiety, and other disorders.","Repetitive Transcranial Magnetic Stimulation | rTMS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555443","H3 Histone, Family 3C Gene","C154667","Human H3-5 wild-type allele is located in the vicinity of 12p11.21 and is approximately 1 kb in length. This allele, which encodes histone H3.3C protein, plays a role in the regulation of gene transcription.","H3-5 wt Allele | H3 Histone Family Member 3C Gene | H3 Histone, Family 3C Gene | H3.3C | H3.5 | H3.5 Histone wt Allele | H3F3C | Histone Variant H3.5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555444","Histone H3.3C","C154668","Histone H3.3C (135 aa, ~15 kDa) is encoded by the human H3-5 gene. This protein is involved in the modulation of DNA accessibility to the transcriptional machinery.","Histone H3.3C | H3-5 | H3.3C | H3.5 | H3F3C | Histone H3.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555450","H3 Histone Family, Member T Gene","C154670","Human H3-4 wild-type allele is located in the vicinity of 1q42.13 and is approximately 1 kb in length. This allele, which encodes histone H3.1t protein, plays a role in DNA sequestration.","H3-4 wt Allele | H3 Histone Family, Member T Gene | H3.4 | H3.4 Histone wt Allele | H3/g | H3FT | H3t | HIST3 Cluster, H3 Gene | HIST3H3 | Histone 3, H3 Gene | Histone Cluster 3 H3 Gene | Histone Cluster 3, H3 Gene | Histone Gene Cluster 3, H3 Gene | Histone Gene Cluster 3, H3 Histone Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555447","Histone H3.1t","C154671","Histone H3.1t (136 aa, ~16 kDa) is encoded by the human H3-4 gene. This protein is involved in formation of higher order chromatin structures.","Histone H3.1t | H3-4 | H3.4 | H3/g | H3/t | H3t | H3t (H3.4) | HIST3H3 | Histone H3.4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555452","BrainCheck Cognitive Assessment","C154673","A proprietary set of cognitive assessments designed to aid in diagnosing mild cognitive impairment, dementia, traumatic brain injuries, and sports-related head injuries. The tests are designed to be taken through an app on a mobile device.","BrainCheck Cognitive Assessment | BrainCheck",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552528","Citrullinemia Type I","C150601","An autosomal recessive sub-type of citrullinemia caused by mutation(s) in the ASS1 gene, encoding argininosuccinate synthetase.","Citrullinemia Type I | Argininosuccinate Synthetase Deficiency | CTLN1",,,,,,,,,,,,,,,"600653","Citrullinemia type I",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3844612","Citrullinemia Type II","C150603","An autosomal recessive sub-type of citrullinemia caused by mutation(s) in the SLC25A13 gene, encoding calcium-binding mitochondrial carrier protein Aralar2.","Citrullinemia Type II | CTLN2",,,,,,,,,,,,,,,"37396888","Citrullinemia type II",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552318","Resectable Sarcoma","C150605","Sarcoma that is amenable to surgical resection.","Resectable Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552321","Resectable Liposarcoma","C150606","Liposarcoma that is amenable to surgical resection.","Resectable Liposarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552320","Resectable Dedifferentiated Liposarcoma","C150607","Dedifferentiated liposarcoma that is amenable to surgical resection.","Resectable Dedifferentiated Liposarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552315","Charcot-Marie-Tooth Disease Type 2A1","C150609","An autosomal dominant sub-type of Charcot-Marie-Tooth disease caused by mutation(s) in the KIF1B gene, encoding kinesin-like protein KIF1B.","Charcot-Marie-Tooth Disease Type 2A1 | CMT2A1",,,,,,,,,,,,,,,"36717089|37397007","Autosomal dominant Charcot-Marie-Tooth disease type 2L|Autosomal dominant Charcot-Marie-Tooth disease type 2A1",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL552317","Unresectable Undifferentiated Pleomorphic Sarcoma","C150610","Undifferentiated pleomorphic sarcoma that is not amenable to surgical resection.","Unresectable Undifferentiated Pleomorphic Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552316","Resectable Undifferentiated Pleomorphic Sarcoma","C150611","Undifferentiated pleomorphic sarcoma that is amenable to surgical resection.","Resectable Undifferentiated Pleomorphic Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552225","ALKATI Allele","C150443","Human ALKATI allele is located within 2p23 and is approximately 3 kb in length. This allele, which encodes ALKATI protein, plays a role in tumor formation.","ALKATI Allele | ALK ATI | ALK Alternative Transcription Initiation Allele | ALK Intron 19 ATI Isoform Gene | ALK(ATI) | ALK-ATI | ALKATI | ALKATI Alteration | Anaplastic Lymphoma Kinase (Ki-1) Alternative Transcription Initiation Gene | Anaplastic Lymphoma Receptor Tyrosine Kinase Alternative Transcription Initiation Gene | CD246 Alternative Transcription Initiation Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552224","ALK Gene Product","C150444","A protein encoded by the ALK gene.","ALK Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552227","ALKATI Protein","C150445","ALKATI protein (~60 kDa) is encoded by the ALKATI allele of the human ALK gene. This protein is involved in tyrosine phosphorylation, signal transduction and tumorigenesis.","ALKATI Protein | ALK ATI | ALK Alternative Transcription Initiation Protein | ALK Intron 19 ATI Isoform Protein | ALK(ATI) | ALK-ATI | ALKATI | Anaplastic Lymphoma Kinase Alternative Transcription Initiation Protein | Anaplastic Lymphoma Receptor Tyrosine Kinase Alternative Transcription Initiation Protein | CD246 Alternative Transcription Initiation Protein | CD246 Antigen Alternative Transcription Initiation Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552500","Autologous FRa-4SCAR-expressing T-cells 4SCAR-FRa","C150698","A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a fourth generation chimeric antigen receptor (4SCAR) consisting of an anti-folate receptor alpha (FRa; folate receptor 1; FOLR1) single chain variable fragment (scFv) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (CD3zeta; CD3z), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon administration, autologous FRa-4SCAR-expressing T-cells 4SCAR-FRa are directed to and induce selective toxicity in FRa-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. FRa is overexpressed in various tumor cell types, and is associated with increased leukemic cell proliferation and aggressiveness. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.","Autologous FRa-4SCAR-expressing T-cells 4SCAR-FRa | 4SCAR-FRa | Autologous 4S-FRa-CAR-T Cells | Autologous Anti-FRa-CD28-CD137-CD27-CD3z-iCasp9 CAR T-cells 4SCAR-FRa | Chimeric Antigen Receptor T Cells 4SCAR-FRa | FRa-specific 4th Generation CART Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552501","Autologous PSMA-4SCAR-expressing T-cells 4SCAR-PSMA","C150699","A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a fourth generation chimeric antigen receptor (4SCAR) consisting of an anti-prostate-specific membrane antigen (PSMA) single chain variable fragment (scFv) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (CD3zeta; CD3z), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon administration, autologous PSMA-4SCAR-expressing T-cells 4SCAR-PSMA are directed to and induce selective toxicity in PSMA-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.","Autologous PSMA-4SCAR-expressing T-cells 4SCAR-PSMA | 4SCAR-PSMA | Autologous 4S-PSMA-CAR-T Cells | Autologous Anti-PSMA-CD28-CD137-CD27-CD3z-iCasp9 CAR T-cells 4SCAR-PSMA | Chimeric Antigen Receptor T Cells 4SCAR-PSMA | PSMA-specific 4th Generation CART Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552671","ERT - Anger Responded as Disgust","C150940","Emotion Recognition Test (ERT) Number of anger stimuli responded to as disgust.","ERT - Anger Responded as Disgust | EMO1-Anger Responded as Disgust | EMO107B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0496685","Encounter due to Problem Related to Social Environment, Unspecified","C183436","An ICD encounter due to problem related to social environment, unspecified.","Encounter due to Problem Related to Social Environment, Unspecified | Problem related to social environment, unspecified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552773","ERT - Total Stimuli Completed","C150928","Emotion Recognition Test (ERT) Total number of stimuli (face images) actually completed in the task.","ERT - Total Stimuli Completed | EMO1-Total Stimuli Completed | EMO103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552774","ERT - Total Stimuli Response Correct","C150929","Emotion Recognition Test (ERT) Total number of stimuli (face images) for which the participant's response was correct.","ERT - Total Stimuli Response Correct | EMO1-Total Stimuli Response Correct | EMO103A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552775","ERT - Total Stimuli Response Incorrect","C150930","Emotion Recognition Test (ERT) Total number of stimuli (face images) for which the participant's response was incorrect.","ERT - Total Stimuli Response Incorrect | EMO1-Total Stimuli Response Incorrect | EMO103B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555453","Clostridium butyricum CBM 588 Probiotic Strain","C154674","A probiotic containing a specific strain of the anaerobic, butyric acid-forming Gram-positive bacterium Clostridium butyricum (C. butyricum), with potential immunomodulatory, anti-inflammatory and antineoplastic activities. Clostridium butyricum MIYAIRI (CBM) 588 is the 588th MIYAIRI strain, isolated from a soil sample in Japan in 1963. Upon oral administration of C. butyricum CBM 588 probiotic strain, C. butyricum modulates the composition of the normal gastrointestinal (GI) microflora, by increasing the beneficial bacteria and decreasing the harmful bacteria, and helps maintain adequate colonization of the GI tract, thereby improving digestion and preventing GI disturbances. These bacteria and the butyric acid produced by them create an environment unfavorable to pathogens by adhering to human epithelial cells and forming a protective mucosal barrier. This prevents attachment of pathogens and reduces the risk of infection. By restoring gut microbiota, these bacteria may restore or enhance intestinal immune responses. C. butyricum induces interleukin-10-producing macrophages in inflamed mucosa via the Toll-like receptor 2 (TLR2)/myeloid differentiation primary response gene 88 (MyD88) pathway, thereby decreasing inflammatory responses. In addition, CBM588 may exert antineoplastic activity by inducing the release of the endogenous cytokine tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) from intracellular stores in polymorphonuclear neutrophils (PMNs), most likely involving matrix metalloproteinase 8 (MMP-8) and the Toll-like receptors (TLR)2/4 signaling pathways. This results in TRAIL-mediated induction of apoptosis in susceptible tumor cells.","Clostridium butyricum CBM 588 Probiotic Strain | C. butyricum CBM 588 Probiotic Strain | C. butyricum MIYAIRI Strain | C. butyricum Strain MIYAIRI 588 | CBM 588 | CBM588 | CLOSTRIDIUM BUTYRICUM MIYAIRI 588 STRAIN | Clostridium butyricum MIYAIRI 588 | Clostridium butyricum MIYAIRI 588 Probiotic Strain | MIYAIRI 588 | MIYAIRI 588 Strain of C. butyricum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555640","Neonatal Convulsion, AE","C154952","An adverse event in a newborn characterized by sudden, involuntary, rapid rhythmic or stereotyped skeletal muscular contraction.","Neonatal Convulsion, AE | Neonatal Convulsion | Neonatal Convulsion, Adverse Event | Neonatal convulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556880","Neonatal Diarrhea, AE","C154953","An adverse event in a newborn characterized by watery bowel movements.","Neonatal Diarrhea, AE | Diarrhea Neonatal | Diarrhea neonatal | Neonatal Diarrhea, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279758","Estrogen Receptor Status Unknown","C15495","Indicates that the test result for estrogen receptor alpha is unknown or the test has not been performed.","Estrogen Receptor Status Unknown | Unknown Status, Estrogen Receptor | Unknown: Could not be determined or unsure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279768","Progesterone Receptor Status Unknown","C15498","No value exists.","Progesterone Receptor Status Unknown | PGR Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279787","Prior Oophorectomy","C15499","No value exists.","Prior Oophorectomy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0259637","BR96 sFv-PE40","C1549","A single-chain immunotoxin consisting of Fv fragments of the BR96 monoclonal antibody (MoAb) and a truncated Pseudomonas exotoxin (PE40) that lacking the binding domain. MoAb BR96 specifically binds to Lewis Y-related carbohydrate antigen, a cell surface antigen overexpressed in many carcinomas.  After internalization, PE40 causes ADP-ribosylation of transcription elongation factor 2, thereby inactivating elongation factor 2 and inhibiting protein synthesis in the cancer cells.","BR96 sFv-PE40 | SGN-10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279788","Prior Estrogen Therapy","C15500","No value exists.","Prior Estrogen Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279797","Prior Antiestrogen Therapy","C15501","No value exists.","Prior Antiestrogen Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279798","Prior Progestin Therapy","C15502","No value exists.","Prior Progestin Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449789","Number of Occurrences","C150827","The number of times something happened.","Number of Occurrences | ",,,,,,,,,,,,,,,"4078188","Number of occurrences",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552588","Cycloserine-Cefoxitin Fructose Agar","C150828","A solid growth medium mainly consisting of proteose peptone, fructose, cycloserine, cefoxitin, fructose, and egg yolk, which is used primarily for the isolation and cultivation of Clostridium difficile.","Cycloserine-Cefoxitin Fructose Agar | CCFA | CYCLOSERINE-CEFOXITIN FRUCTOSE AGAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552589","Chromogenic Selective Medium","C150829","A solid growth medium mainly consisting of various peptones, taurocholate and a chromogenic substrate which is used primarily for the isolation and cultivation of Clostridium difficile.","Chromogenic Selective Medium | CHROMOGENIC SELECTIVE MEDIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552590","Mononucleotide Marker Name","C150830","The literal identifier of the mononucleotide marker of interest.","Mononucleotide Marker Name | MONTMKNM | Mononucleotide Marker Names",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552591","Pentanucleotide Marker Name","C150831","The literal identifier of the pentanucleotide marker of interest.","Pentanucleotide Marker Name | PENTMKNM | Pentanucleotide Marker Names",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552592","Software Name","C150832","The literal identifier of the software program.","Software Name | SFTWRNAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552144","Body Cavity Primary Effusion Lymphoma","C150407","A large B-cell lymphoma presenting as a serous effusion without detectable tumor masses. It is universally associated with human herpes virus 8 (HHV8), also called Kaposi sarcoma-associated herpesvirus.  It mostly occurs in the setting of immunodeficiency. The most common sites of involvement are the pleural, pericardial, and peritoneal cavities. (WHO 2017)","Body Cavity Primary Effusion Lymphoma | Body Cavity PEL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552143","CLDN18 Gene","C150408","This gene plays a role in tight junction assembly.","CLDN18 Gene | CLDN18 | Claudin 18 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553000","FACT-Taxane Version 4 - Bothered by My Hands/Nails Look","C151155","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: I am bothered by the way my hands or nails look.","FACT-Taxane Version 4 - Bothered by My Hands/Nails Look | FAC063-Bothered by My Hands/Nails Look | FAC06343",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553001","FACT-BRM Version 4 - I Have a Lack of Energy","C151156","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Physical Well-Being: I have a lack of energy.","FACT-BRM Version 4 - I Have a Lack of Energy | FAC062-I Have a Lack of Energy | FAC06201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553002","FACT-BRM Version 4 - I Have Nausea","C151157","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Physical Well-Being: I have nausea.","FACT-BRM Version 4 - I Have Nausea | FAC062-I Have Nausea | FAC06202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553004","FACT-BRM Version 4 - I Have Pain","C151159","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Physical Well-Being: I have pain.","FACT-BRM Version 4 - I Have Pain | FAC062-I Have Pain | FAC06204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553005","FACT-BRM Version 4 - Bothered by Treatment Side Effect","C151160","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Physical Well-Being: I am bothered by side effects of treatment.","FACT-BRM Version 4 - Bothered by Treatment Side Effect | FAC062-Bothered by Treatment Side Effect | FAC06205",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553006","FACT-BRM Version 4 - I Feel Ill","C151161","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Physical Well-Being: I feel ill.","FACT-BRM Version 4 - I Feel Ill | FAC062-I Feel Ill | FAC06206",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553007","FACT-BRM Version 4 - I Am Forced to Spend Time in Bed","C151162","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Physical Well-Being: I am forced to spend time in bed.","FACT-BRM Version 4 - I Am Forced to Spend Time in Bed | FAC062-I Am Forced to Spend Time in Bed | FAC06207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553008","FACT-BRM Version 4 - I Feel Close to My Friends","C151163","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Social/Family Well-Being: I feel close to my friends.","FACT-BRM Version 4 - I Feel Close to My Friends | FAC062-I Feel Close to My Friends | FAC06208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553009","FACT-BRM Version 4 - Get Emotional Support From Family","C151164","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Social/Family Well-Being: I get emotional support from my family.","FACT-BRM Version 4 - Get Emotional Support From Family | FAC062-Get Emotional Support From Family | FAC06209",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553010","FACT-BRM Version 4 - I Get Support From My Friends","C151165","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Social/Family Well-Being: I get support from my friends.","FACT-BRM Version 4 - I Get Support From My Friends | FAC062-I Get Support From My Friends | FAC06210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552776","ERT - Total Stimuli Not Responded","C150931","Emotion Recognition Test (ERT) Total number of stimuli (face images) for which the participant has not responded.","ERT - Total Stimuli Not Responded | EMO1-Total Stimuli Not Responded | EMO103C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552777","ERT - Total Negative Stimuli Expected","C150932","Emotion Recognition Test (ERT) Total number of negative emotion stimuli (face images) expected to be administered in the task.","ERT - Total Negative Stimuli Expected | EMO1-Total Negative Stimuli Expected | EMO104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552778","ERT - Total Negative Stimuli Administered","C150933","Emotion Recognition Test (ERT) Total number of negative emotion stimuli (face images) actually administered in the task.","ERT - Total Negative Stimuli Administered | EMO1-Total Negative Stimuli Administered | EMO105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552779","ERT - Total Negative Stimuli Completed","C150934","Emotion Recognition Test (ERT) Total number of negative emotion stimuli (face images) actually completed in the task.","ERT - Total Negative Stimuli Completed | EMO1-Total Negative Stimuli Completed | EMO106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552780","ERT - Total Negative Stimuli Correct","C150935","Emotion Recognition Test (ERT) Total number of negative emotion stimuli (face images) for which the participant's response was correct.","ERT - Total Negative Stimuli Correct | EMO1-Total Negative Stimuli Correct | EMO106A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552781","ERT - Total Negative Stimuli Incorrect","C150936","Emotion Recognition Test (ERT) Total number of negative emotion stimuli (face images) for which the participant's response was incorrect.","ERT - Total Negative Stimuli Incorrect | EMO1-Total Negative Stimuli Incorrect | EMO106B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552782","ERT - Total Negative Stimuli Not Respond","C150937","Emotion Recognition Test (ERT) Total number of negative emotion stimuli (face images) for which the participant has not responded.","ERT - Total Negative Stimuli Not Respond | EMO1-Total Negative Stimuli Not Respond | EMO106C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552670","ERT - Anger Responded as Anger","C150939","Emotion Recognition Test (ERT) Number of anger stimuli responded to as anger.","ERT - Anger Responded as Anger | EMO1-Anger Responded as Anger | EMO107A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552672","ERT - Anger Responded as Fear","C150941","Emotion Recognition Test (ERT) Number of anger stimuli responded to as fear.","ERT - Anger Responded as Fear | EMO1-Anger Responded as Fear | EMO107C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552673","ERT - Anger Responded as Happiness","C150942","Emotion Recognition Test (ERT) Number of anger stimuli responded to as happiness.","ERT - Anger Responded as Happiness | EMO1-Anger Responded as Happiness | EMO107D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552674","ERT - Anger Responded as Neutral","C150943","Emotion Recognition Test (ERT) Number of anger stimuli responded to as neutral.","ERT - Anger Responded as Neutral | EMO1-Anger Responded as Neutral | EMO107E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552675","ERT - Anger Responded as Sadness","C150944","Emotion Recognition Test (ERT) Number of anger stimuli responded to as sadness.","ERT - Anger Responded as Sadness | EMO1-Anger Responded as Sadness | EMO107F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552676","ERT - Anger Responded as Surprise","C150945","Emotion Recognition Test (ERT) Number of anger stimuli responded to as surprise.","ERT - Anger Responded as Surprise | EMO1-Anger Responded as Surprise | EMO107G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552897","Paced Tapping - Trials Completed in Trial","C151052","Paced Tapping Test (Paced Tapping) Number of trials actually completed in Trial n.","Paced Tapping - Trials Completed in Trial | PTAP1-Trials Completed in Trial | PTAP110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552898","Paced Tapping - Num Intervals Expected Tone Trial","C151053","Paced Tapping Test (Paced Tapping) Total number of intertap intervals expected for the tone-tapping phase of Trial n.","Paced Tapping - Num Intervals Expected Tone Trial | PTAP1-Num Intervals Expected Tone Trial | PTAP111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552899","Paced Tapping - Num Intervals Trim Tone Trial","C151054","Paced Tapping Test (Paced Tapping) Total number of intertap intervals within the tone-tapping phase of Trial n, that were trimmed before analysis.","Paced Tapping - Num Intervals Trim Tone Trial | PTAP1-Num Intervals Trim Tone Trial | PTAP112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552359","Anti-CD40 Agonist Monoclonal Antibody CDX-1140","C150558","A fully human immunoglobulin G2 (IgG2) agonistic monoclonal antibody targeting the B-cell surface antigen CD40, with potential immunostimulatory and antineoplastic activities. Upon administration, CDX-1140 targets and binds to CD40 on a variety of immune cell types. This induces CD40-dependent signaling pathways, triggers the proliferation and activation of antigen-presenting cells (APCs) and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells, such as dendritic cells (DCs), macrophages and B-cells, and plays a key role in the activation of the immune system.","Anti-CD40 Agonist Monoclonal Antibody CDX-1140 | Agonist CD40 Antibody CDX-1140 | Anti-CD40 Agonistic Monoclonal Antibody CDX-1140 | CDX 1140 | CDX-1140",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552362","Avatrombopag","C150559","An orally available platelet thrombopoietin receptor (TPOR; MPL) agonist, with potential megakaryopoiesis stimulating activity. Upon administration, avatrombopag binds to and stimulates TPOR, which may lead to the proliferation and differentiation of megakaryocytes from bone marrow progenitor cells. This increases the production of platelets and may prevent chemotherapy-induced thrombocytopenia (CIT). TPOR is a cytokine receptor and member of the hematopoietin receptor superfamily.","Avatrombopag | 4-Piperidinecarboxylic Acid, 1-(3-Chloro-5-(((4-(4-chloro-2-thienyl)-5-(4-cyclohexyl-1-piperazinyl)-2-thiazolyl)amino)carbonyl)-2-pyridinyl)- | AKR 501 | AKR-501 | AKR501 | AS 1670542 | AVATROMBOPAG | Doptelet | E 5501 | E-5501 | E5501 | YM 477 | YM-477 | YM477",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552361","Anti-TIM-3 Monoclonal Antibody Sym023","C150560","A recombinant, fully human monoclonal antibody against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, the anti-TIM-3 monoclonal antibody Sym023 binds to TIM-3 expressed on certain T-cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor cell proliferation. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.","Anti-TIM-3 Monoclonal Antibody Sym023 | Anti-TIM3 Monoclonal Antibody Sym023 | SYM-023 | Sym 023 | Sym-023 | Sym023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552355","CD2-Positive Neoplastic Cells Present","C150563","An indication that expression of CD2 has been detected in a sample of neoplastic cells.","CD2-Positive Neoplastic Cells Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552358","B-Cell Markers Negative","C150564","A finding indicating that expression of B-lymphocyte lineage markers have not been detected in a sample.","B-Cell Markers Negative | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552357","Myeloid Markers Negative","C150565","A finding indicating that expression of myeloid lineage markers have not been detected in a sample.","Myeloid Markers Negative | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552146","CLDN18 wt Allele","C150409","Human CLDN18 wild-type allele is located in the vicinity of 3q22.3 and is approximately 35 kb in length. This allele, which encodes claudin-18 protein, is involved in tight junction assembly. Aberrant expression may be associated with gastric, pancreatic, esophageal, ovarian and lung neoplasms.","CLDN18 wt Allele | Claudin 18 wt Allele | SFTA5 | SFTPJ | Surfactant Associated 5 Gene | Surfactant, Pulmonary Associated Protein J Gene | UNQ778/PRO1572",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552145","CLDN18 Gene Product","C150410","A protein encoded by the CLDN18 gene.","CLDN18 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552141","CLDN18 protein, human","C150411","Claudin-18 (261 aa, ~28 kDa) is encoded by the human CLDN18 gene. This protein plays a role in tight junction formation in the epithelium of the lung.","Claudin-18 | CLDN-18 | CLDN-18.1 | CLDN18 | CLDN18.1 | Claudin 18 | Claudin 18 Isoform 1 | Claudin 18 Isoform A1 | Claudin 18.1 | Claudin-18 Isoform 1 | Claudin-18 Isoform A1 | Surfactant Associated Protein J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552140","Claudin-18 Isoform A2","C150412","Claudin-18 isoform A2 (261 aa, ~28 kDa) is encoded by the human CLDN18 gene. This protein is involved in tight junction formation in the epithelium of the gastric mucosa.","Claudin-18 Isoform A2 | CLDN-18.2 | CLDN18.2 | Claudin 18 Isoform 2 | Claudin 18 Isoform A2 | Claudin 18.2 | Claudin-18 Isoform 2 | Claudin-18.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552142","2-Pyridineacetamide, N-(5-(4-(6-((2-(3-(trifluoromethoxy)phenyl)acetyl)amino)-3-pyridazinyl)butyl)-1,3,4-thiadiazol-2-yl)-, Hydrochloride (1:1)","C150413","The hydrochloride salt form of CB-839, an orally bioavailable inhibitor of glutaminase, with potential antineoplastic and immunostimulating activities. Upon oral administration, CB-839 selectively and reversibly binds to and inhibits human glutaminase, an enzyme that is essential for the conversion of the amino acid glutamine into glutamate. Blocking glutamine metabolism inhibits proliferation in rapidly growing tumor cells and leads to an induction of cell death. Unlike normal healthy cells, glutamine-dependent tumors heavily rely on the intracellular conversion of exogenous glutamine into glutamate and glutamate metabolites to both provide energy and generate building blocks for the production of macromolecules, which are needed for cellular growth and survival. In addition, CB-839 causes accumulation of glutamine in tumor cells and increases glutamine concentration in the tumor microenvironment (TME) upon cell death. As glutamine is essential for T-cell generation, CB-839 may also enhance T-cell proliferation and activation in the TME, which may lead to further killing of tumor cells.","Telaglenastat Hydrochloride | 2-Pyridineacetamide, N-(5-(4-(6-((2-(3-(trifluoromethoxy)phenyl)acetyl)amino)-3-pyridazinyl)butyl)-1,3,4-thiadiazol-2-yl)-, Hydrochloride (1:1) | CB-839 HCl | Glutaminase Inhibitor CB-839 Hydrochloride | TELAGLENASTAT HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552434","Parenteral","C150414","Relating to the internal body as the intended site of administration, other than the natural openings and cavities such as the gastrointestinal tract, auditory canal, nasal cavity, lungs, etc.; the pharmaceutical product is usually administered by breaking the skin, such as by injection, infusion, and implantation.","Parenteral | ",,,,,,,,,,,,,,,"42538093","Parenteral",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552824","FACT-C Version 4 - I Have Diarrhea","C151107","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Additional Concerns: I have diarrhea (diarrhoea).","FACT-C Version 4 - I Have Diarrhea | FAC008-I Have Diarrhea | FAC00832",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552825","FACT-C Version 4 - I Have a Good Appetite","C151108","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Additional Concerns: I have a good appetite.","FACT-C Version 4 - I Have a Good Appetite | FAC008-I Have a Good Appetite | FAC00833",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553011","FACT-BRM Version 4 - My Family Has Accepted My Illness","C151166","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Social/Family Well-Being: My family has accepted my illness.","FACT-BRM Version 4 - My Family Has Accepted My Illness | FAC062-My Family Has Accepted My Illness | FAC06211",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553012","FACT-BRM Version 4 - Satisfied Communication Illness","C151167","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Social/Family Well-Being: I am satisfied with family communication about my illness.","FACT-BRM Version 4 - Satisfied Communication Illness | FAC062-Satisfied Communication Illness | FAC06212",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553013","FACT-BRM Version 4 - I Feel Close to My Partner","C151168","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Social/Family Well-Being: I feel close to my partner (or the person who is my main support).","FACT-BRM Version 4 - I Feel Close to My Partner | FAC062-I Feel Close to My Partner | FAC06213",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553014","FACT-BRM Version 4 - I Am Satisfied With My Sex Life","C151169","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Social/Family Well-Being: I am satisfied with my sex life.","FACT-BRM Version 4 - I Am Satisfied With My Sex Life | FAC062-I Am Satisfied With My Sex Life | FAC06214",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553015","FACT-BRM Version 4 - I Feel Sad","C151170","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Emotional Well-Being: I feel sad.","FACT-BRM Version 4 - I Feel Sad | FAC062-I Feel Sad | FAC06215",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0199404","Alcoholism Counseling","C150658","Counseling designed to guide and support an individual to overcome alcohol dependence.","Alcoholism Counseling | Alcohol Counseling",,,,,,,,,,,,,,,"4083236","Alcoholism counseling",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0198826","Preanesthetic Evaluation","C150659","A medical examination by an anesthesiologist before an operation, to assess the patient's physical condition and identify medical conditions or diseases that could significantly increase the risk of complications.","Preanesthetic Evaluation | Preanesthesia Assessment | Preanesthesia Evaluation | Preanesthesia Study | Preanesthetic Assessment",,,,,,,,,,,,,,,"4057399","Pre-anesthetic assessment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552371","Total Laryngopharyngectomy","C150661","Surgical removal of the entire larynx and pharynx.","Total Laryngopharyngectomy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552370","Partial Laryngopharyngectomy","C150662","Laryngopharyngectomy in which one side of the larynx is spared from surgery.","Partial Laryngopharyngectomy | PLP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034579","Orthopantomogram","C150663","A panoramic or wide-view x-ray of the upper and lower jaw and teeth.","Orthopantomogram | OPG | Orthopantogram | PX | Panoramic Dental X-ray | Panoramic Radiograph | Panoramic X-Ray | Panorex",,,,,,,,,,,,,,,"4233227","Orthopantogram",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552372","Videostroboscopy","C150664","An imaging technique used to assess the function of the larynx. It uses a strobe light to illuminate the larynx and records the results, allowing the function of the larynx to be viewed in slow motion.","Videostroboscopy | Videostrobe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552367","COL6A3 Gene","C150665","This gene plays a role in both cell-matrix adhesion and the organization of the extracellular matrix in connective tissues.","COL6A3 Gene | COL6A3 | Collagen Type VI Alpha 3 Chain Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552366","COL6A3 wt Allele","C150666","Human COL6A3 wild-type allele is located in the vicinity of 2q37.3 and is approximately 90 kb in length. This allele, which encodes collagen alpha-3(VI) chain protein, is involved in beaded filament collagen formation. Mutation of the gene is associated with Bethlem myopathy, type 27 dystonia and Ullrich congenital muscular dystrophy.","COL6A3 wt Allele | BTHLM1 | Collagen Type VI Alpha 3 Chain wt Allele | Collagen, Type VI, Alpha 3 Gene | Collagen, Type VI, Alpha-3 Gene | DYT27 | UCMD1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552301","Intestinal T-Cell Lymphoma","C150495","A group of mature T-cell and NK-cell non-Hodgkin lymphomas that includes enteropathy-associated T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, and intestinal T-cell lymphoma, not otherwise specified. Most of these lymphomas arise from the small intestine and a minority from the large intestine or stomach.","Intestinal T-Cell Lymphoma | ","9717/3","Intestinal T-cell lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"C1515368","Recombinant Epidermal Growth Factor","C1504","A recombinant therapeutic agent which is chemically identical to or similar to endogenous epidermal growth factor (EGF).  As a mitogen, EGF stimulates the proliferation of epidermal, epithelial, and embryonic cells.  This agent is also a strong chemoattractant for fibroblasts and epithelial cells and is an important factor mediating angiogenesis and wound healing.  EGF and EGF-like factors have been shown to promote regeneration of the epidermis and the generation of granulation tissues following severe burns and, when locally administered, may improve healing of injured corneal tissues. (NCI04)","Recombinant Epidermal Growth Factor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552352","IgM Monoclonal Gammopathy of Undetermined Significance","C150566","Monoclonal gammopathy of undetermined significance defined by a serum IgM paraprotein concentration less than 30g/L; bone marrow lymphoplasmacytic infiltration of less than 10%; and no evidence of anemia, constitutional symptoms, hyperviscocity, lymphadenopathy, hepatosplenomegaly, or other end-organ damage that can be attributed to the underlying lymphoproliferative disorder. It is a precursor condition that may progress to lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia, other B-cell neoplasms, or primary amyloidosis. Progression to plasma cell myeloma occurs rarely, if at all. (WHO 2017)","IgM Monoclonal Gammopathy of Undetermined Significance | IgM MGUS",,,,,,,,,,,,,,,"37312312","IgM monoclonal gammopathy of undetermined significance",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552351","Serum IgM Monoclonal Gammopathy of Less than 30g/L","C150567","An abnormal laboratory test result indicating that a serum IgM paraprotein concentration is less than 30g/L.","Serum IgM Monoclonal Gammopathy of Less than 30g/L | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552354","Bone Marrow Lymphoplasmacytic Infiltration of Less than 10%","C150568","A morphologic finding indicating the presence of a lymphoplasmacytic infiltrate in the bone marrow, comprising less than 10% of the cellular population.","Bone Marrow Lymphoplasmacytic Infiltration of Less than 10% | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552353","Radial Probe Endobronchial Ultrasound","C150569","Endobronchial ultrasound that employs a flexible catheter housing a rotating ultrasound transducer to produces a 360 degree (radial) ultrasound image.","Radial Probe Endobronchial Ultrasound | RP-EBUS | Radial EBUS | Radial Endobronchial Ultrasound | Radial Probe EBUS | Radial-Probe Endobronchial Ultrasound",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552348","Infiltrating Bladder Cancer","C150570","A carcinoma that arises from the bladder mucosa and invades the bladder wall.","Invasive Bladder Carcinoma | Infiltrating Bladder Cancer | Infiltrating Bladder Carcinoma | Infiltrating Bladder Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552637","CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology","C150778","Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology | FAC062TC | Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 Questionnaire Test Code | QS-FACT-BRM Version 4 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552638","CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology","C150779","Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology | FAC057TN | Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 Questionnaire Test Name | QS-FACT/GOG-NTX Version 4 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552639","CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology","C150780","Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology | FAC057TC | Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 Questionnaire Test Code | QS-FACT/GOG-NTX Version 4 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552640","CDISC Questionnaire FACT-L Version 4 Test Name Terminology","C150781","Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACT-L Version 4 Test Name Terminology | FAC016TN | Functional Assessment of Cancer Therapy-Lung Version 4 Questionnaire Test Name | QS-FACT-L Version 4 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552641","CDISC Questionnaire FACT-L Version 4 Test Code Terminology","C150782","Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACT-L Version 4 Test Code Terminology | FAC016TC | Functional Assessment of Cancer Therapy-Lung Version 4 Questionnaire Test Code | QS-FACT-L Version 4 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552826","FACT-C Version 4 - I Like the Appearance of My Body","C151109","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Additional Concerns: I like the appearance of my body.","FACT-C Version 4 - I Like the Appearance of My Body | FAC008-I Like the Appearance of My Body | FAC00834",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552827","FACT-C Version 4 - Do You Have an Ostomy Appliance","C151110","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Additional Concerns: Do you have an ostomy appliance?","FACT-C Version 4 - Do You Have an Ostomy Appliance | FAC008-Do You Have an Ostomy Appliance | FAC00835",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552828","FACT-C Version 4 - Embarrassed by Ostomy Appliance","C151111","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Additional Concerns: I am embarrassed by my ostomy appliance.","FACT-C Version 4 - Embarrassed by Ostomy Appliance | FAC008-Embarrassed by Ostomy Appliance | FAC00836",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552829","FACT-C Version 4 - Caring for Ostomy Is Difficult","C151112","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Additional Concerns: Caring for my ostomy appliance is difficult.","FACT-C Version 4 - Caring for Ostomy Is Difficult | FAC008-Caring for Ostomy Is Difficult | FAC00837",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552830","FACT-Taxane Version 4 - I Have a Lack of Energy","C151113","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Physical Well-Being: I have a lack of energy.","FACT-Taxane Version 4 - I Have a Lack of Energy | FAC063-I Have a Lack of Energy | FAC06301",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552831","FACT-Taxane Version 4 - I Have Nausea","C151114","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Physical Well-Being: I have nausea.","FACT-Taxane Version 4 - I Have Nausea | FAC063-I Have Nausea | FAC06302",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552832","FACT-Taxane Version 4 - Trouble Meeting Needs of Family","C151115","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Physical Well-Being: Because of my physical condition, I have trouble meeting the needs of my family.","FACT-Taxane Version 4 - Trouble Meeting Needs of Family | FAC063-Trouble Meeting Needs of Family | FAC06303",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552833","FACT-Taxane Version 4 - I Have Pain","C151116","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Physical Well-Being: I have pain.","FACT-Taxane Version 4 - I Have Pain | FAC063-I Have Pain | FAC06304",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552835","FACT-Taxane Version 4 - I Feel Ill","C151118","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Physical Well-Being: I feel ill.","FACT-Taxane Version 4 - I Feel Ill | FAC063-I Feel Ill | FAC06306",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552836","FACT-Taxane Version 4 - I Am Forced to Spend Time in Bed","C151119","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Physical Well-Being: I am forced to spend time in bed.","FACT-Taxane Version 4 - I Am Forced to Spend Time in Bed | FAC063-I Am Forced to Spend Time in Bed | FAC06307",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552837","FACT-Taxane Version 4 - I Feel Close to My Friends","C151120","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Social/Family Well-Being: I feel close to my friends.","FACT-Taxane Version 4 - I Feel Close to My Friends | FAC063-I Feel Close to My Friends | FAC06308",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552838","FACT-Taxane Version 4 - Get Emotional Support From Family","C151121","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Social/Family Well-Being: I get emotional support from my family.","FACT-Taxane Version 4 - Get Emotional Support From Family | FAC063-Get Emotional Support From Family | FAC06309",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552839","FACT-Taxane Version 4 - I Get Support From My Friends","C151122","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Social/Family Well-Being: I get support from my friends.","FACT-Taxane Version 4 - I Get Support From My Friends | FAC063-I Get Support From My Friends | FAC06310",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552369","Collagen Alpha-3(VI) Chain","C150667","Collagen alpha-3(VI) chain (3177 aa, ~344 kDa) is encoded by the human COL6A3 gene. This protein plays a role in extracellular matrix formation and cell-matrix adhesion in connective tissues.","Collagen Alpha-3(VI) Chain | COL6A3 | Collagen Type VI Alpha 3 Chain | Collagen Type VI Alpha 3 Polypeptide | Collagen VI, Alpha-3 Polypeptide | Type VI Collagen Alpha 3 Chain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552563","Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells","C150671","A preparation of autologous T-lymphocytes that are engineered to express a chimeric antigen receptor (CAR) composed of an anti-cluster of differentiation 19 (CD19) single chain variable fragment (scFv) linked to the intracellular signaling domains of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), with potential immunomodulating and antineoplastic activities. Upon administration of the autologous anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells, these cells target, bind to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.","Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells | Autologous CD19CAR-CD3zeta-4-1BB-expressing T-lymphocytes | Autologous CD3zeta-4-1BB-expressing CART-19 Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552564","Immunodeficiency-Related Lymphoproliferative Disorder","C150672","A lymphoproliferative disorder that occurs in a patient with immunodeficiency.","Immunodeficiency-Related Lymphoproliferative Disorder | Immunodeficiency-Associated Lymphoproliferative Disorder | Immunodeficiency-Associated Lymphoproliferative Disorder | Lymphoid Hyperplasia Arising in Setting of Immune Deficiency/Dysregulation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552565","Lymphoproliferative Disease Associated with Primary Immune Disorder","C150673","A lymphoid proliferation that arises in the setting of immune deficiency due to a primary immunodeficiency or immunoregulatory disorder. The primary immune disorders most frequently associated with lymphoproliferative disorders are ataxia-telangiectasia, Wiskott-Aldrich syndrome, common variable immunodeficiency, severe combined immunodeficiency, X-linked lymphoproliferative disease, Nijmegen breakage syndrome, hyper-IgM syndrome, and autoimmune lymphoproliferative syndrome. (WHO 2017)","Lymphoproliferative Disease Associated with Primary Immune Disorder | Lymphoproliferative Disease Associated with PID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555706","Allosteric Modulator","C154904","A class of substances that binds to a target allosterically and induces a conformational change in the target. This leads to an altered binding affinity of the target to its substrate.","Allosteric Modulator | ALLOSTERIC MODULATOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555707","RNA-based Molecule","C154905","Any compound that contains a polymeric ribonucleic acid molecule.","RNA-based Molecule | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555606","Number of Electrocardiogram Electrodes","C154906","The number of electrocardiogram electrodes used in the assessment.","Number of Electrocardiogram Electrodes | ECGELCTN | Number of ECG Electrodes | Number of EKG Electrodes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555607","Number of Electrooculogram Electrodes","C154907","The number of electrooculogram electrodes used in the assessment.","Number of Electrooculogram Electrodes | EOGELCTN | Number of EOG Electrodes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555604","Number of Electromyogram Electrodes","C154908","The number of electromyogram electrodes used in the assessment.","Number of Electromyogram Electrodes | EMGELCTN | Number of EMG Electrodes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555611","Neonatal Adverse Event","C154913","Findings suggesting an adverse event in a neonate or newborn.","Neonatal Adverse Event | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555608","INC-MedDRA Neonatal Adverse Events Terminology","C154914","A neonatal adverse event severity scale developed by NCIt EVS and the Clinical Pharmacology workgroup of INC to help researchers use a common approach when reporting adverse events (AEs).  This work will enhance regulatory science for neonates by providing standardized terminology for adverse event reporting.","INC-MedDRA Neonatal Adverse Events Terminology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555615","Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation","C154917","The removal of naive T-cells from the donor's hematopoietic stem cell specimen prior to its transfusion into the recipient.","Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555613","Bronchopulmonary Dysplasia, AE","C154919","An adverse event in a newborn characterized by a lung disorder associated with pulmonary maldevelopment, scarring, and/or inflammation that develops in preterm neonates. The condition is defined based on treatment with supplemental oxygen for at least 28 days adjusted for the degree of prematurity.","Bronchopulmonary Dysplasia, AE | BPD, AE | Bronchopulmonary Dysplasia | Bronchopulmonary Dysplasia, Adverse Event | Bronchopulmonary dysplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937345","Neonatal Pneumothorax, AE","C154920","An adverse event in a newborn characterized by a collection of air or other gas between the visceral and parietal pleura.","Neonatal Pneumothorax, AE | Neonatal Pneumothorax | Neonatal Pneumothorax, Adverse Event | Neonatal pneumothorax",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552642","CDISC Questionnaire FKSI-DRS Version 4 Test Name Terminology","C150783","Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms Version 4 (FKSI-DRS Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FKSI-DRS Version 4 Test Name Terminology | FAC041TN | Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms Version 4 Questionnaire Test Name | QS-FKSI-DRS Version 4 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552643","CDISC Questionnaire FKSI-DRS Version 4 Test Code Terminology","C150784","Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms Version 4 (FKSI-DRS Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FKSI-DRS Version 4 Test Code Terminology | FAC041TC | Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms Version 4 Questionnaire Test Code | QS-FKSI-DRS Version 4 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552644","CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Name Terminology","C150785","Test names of questionnaire questions associated with the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Name Terminology | FAC030TN | National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 Questionnaire Test Name | QS-NCCN-FACT FBRSI-24 Version 2 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552645","CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Code Terminology","C150786","Test codes of questionnaire questions associated with the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Code Terminology | FAC030TC | National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 Questionnaire Test Code | QS-NCCN-FACT FBRSI-24 Version 2 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552646","CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Name Terminology","C150787","Test names of questionnaire questions associated with the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Name Terminology | FAC036TN | National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 Questionnaire Test Name | QS-NCCN-FACT FHNSI-22 Version 2 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552166","Autologous Anti-Claudin18.2 CAR-T Cells","C150382","A preparation of autologous T-lymphocytes ex vivo transduced with a lentiviral vector encoding for a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, satricabtagene autoleucel specifically recognize and induce selective toxicity in CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein, is expressed on a variety of tumor cells, but its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.","Satricabtagene Autoleucel | Autologous Anti-Claudin18.2 CAR-T Cells | Autologous Anti-Claudin18.2-transduced T Lymphocytes CT041 | Autologous Anti-Claudin18.2-transduced T Lymphocytes CT041 | Autologous CAR-CLD18 T Cells | Autologous CAR-CLD18.2 T Cells | CT 041 | CT-041 | CT041 | Claudin18.2-redirected Autologous Cells | SATRICABTAGENE AUTOLEUCEL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552165","FGFR1/2/3 Inhibitor HMPL-453","C150383","An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), with potential antineoplastic activity. Upon administration, fanregratinib binds to and inhibits FGFR1/2/3, which may result in the inhibition of FGFR1/2/3-related signal transduction pathways. This inhibits proliferation in FGFR1/2/3-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases (RTKs) upregulated in many tumor cell types, plays a key role in cellular proliferation, migration and survival.","Fanregratinib | FANREGRATINIB | FGFR Inhibitor HMPL-453 | FGFR1/2/3 Inhibitor HMPL-453 | FGFR1/2/3 Inhibitor HMPL-453 | HMPL 453 | HMPL-453 | HMPL453",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552304","Resectable Neuroblastoma","C150620","Neuroblastoma that is amenable to surgical resection.","Resectable Neuroblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552306","Unresectable Neuroblastoma","C150622","Neuroblastoma which is not amenable to surgical resection.","Unresectable Neuroblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600401","Retrotransposon","C1508","Retrotransposons are transposable DNA elements (transposons) that employ retroviral-like reverse transcription during the process of transposition: retrotransposon DNA is first transcribed into an RNA template, then reverse transcribed into DNA, and then inserted into a new genomic site.","Retrotransposon | Transposon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552750","Unencoded Data","C150902","The source or original information exists but has not yet been translated by an encoding system.","Unencoded Data | UNC | UNENCODED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1549057","No information - temporarily unavailable","C150903","Information is not available currently but expected to be made available in the near future.","Temporarily Unavailable | NAV | TEMPORARILY UNAVAILABLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4046073","Masking, Data","C150904","Information exists but is not provided due to security or privacy concerns.","Masked Data | MASKED | MSK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552751","Draining Lymph Node","C150905","The lymph node or group of lymph nodes that drain a particular anatomic site or organ.","Draining Lymph Node | LYMPH NODE, DRAINING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556868","Neonatal Coagulation Disorder, AE","C154921","An adverse event in a newborn characterized by abnormal blood clotting or bleeding.","Neonatal Coagulation Disorder, AE | Coagulation Disorder Neonatal | Coagulation disorder neonatal | Neonatal Coagulation Disorder, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555926","Autologous CCR4-CD30CAR-CD28-CD3zeta-expressing T-Lymphocytes","C155293","A preparation of autologous T-lymphocytes (ATL) that have been transduced with the retroviral vector SFG, a Moloney murine leukemia (Mo-MuLV) virus-based vector, encoding human C-C chemokine receptor 4 (CCR4), linked via an internal ribosome entry site (IRES), to a chimeric antigen receptor (CAR) composed of a single chain single-chain variable fragment (scFv) directed against the CD30 antigen (CAR.CD30) and linked, via the spacer human IgG1 immunoglobulin heavy constant region (hinge-CH2CH3 region), to the co-stimulatory domains of CD28 and the zeta chain of the TCR/CD3 complex (CD3-zeta) (CD28zeta), with potential immunostimulating and antineoplastic activities. Upon administration of the autologous CCR4-CD30CAR-CD28-CD3zeta-expressing T-lymphocytes, the expressed CCR4 on the T-cells allows for enhanced migration of the cells to chemokine-secreting tumor cells. The expressed CAR.CD30 moiety specifically recognizes and binds to CD30-expressing tumor cells, resulting in specific T-cell-mediated tumor cell lysis. CD30, a cell surface receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is transiently expressed on activated lymphocytes and is constitutively expressed in hematologic malignancies. CCR4, a G-coupled-protein receptor for C-C chemokines normally expressed on regulatory T-cells (Tregs) but not on cytotoxic T-lymphocytes (CTLs), is involved in chemokine-mediated cellular migration. The co-expression of CCR4 on these CTLs may enhance their anti-tumor activity compared to T-lymphocytes expressing the same CAR-CD30 receptor but without CCR4 expression.","Autologous CCR4-CD30CAR-CD28-CD3zeta-expressing T-Lymphocytes | ATLCAR.CD30-CD28zeta-CCR4 Cells | ATLCAR.CD30.CCR4 Cells | ATLs Co-expressing CD30-CARCD28zeta and CCR4 | Anti-CD30-CAR/CD28z-CCR4 Retroviral Vector-transduced Autologous T-Cells | Autologous CCR4-CAR-CD19-CD28-zeta-transduced T-lymphocytes | CCR4-CAR-CD30-28zeta-specific Autologous T-cells | SFG.CCR4-CAR.CD30 Autologous T-lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555929","Autologous CD30CAR-CD28-CD3zeta-expressing T-Lymphocytes","C155294","A preparation of autologous T-lymphocytes (ATL) that have been transduced with the retroviral vector SFG, a Moloney murine leukemia (Mo-MuLV) virus-based vector, encoding a chimeric antigen receptor (CAR) composed of a single chain single-chain variable fragment (scFv) directed against the CD30 antigen (CAR.CD30) and linked, via the spacer human IgG1 immunoglobulin heavy constant region (hinge-CH2CH3 region), to the co-stimulatory domains of CD28 and the zeta chain of the TCR/CD3 complex (CD3-zeta) (CD28zeta), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous CD30CAR-CD28-CD3zeta-expressing T-lymphocytes specifically recognize and bind to CD30-expressing tumor cells, resulting in specific T-cell-mediated tumor cell lysis. CD30, a cell surface receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is transiently expressed on activated lymphocytes and is constitutively expressed in hematologic malignancies.","Autologous CD30CAR-CD28-CD3zeta-expressing T-Lymphocytes | ATL-expressing CD30-CAR-CD28zeta | ATLCAR.CD30 Cells | ATLCAR.CD30-CD28zeta Cells | Anti-CD30-CAR/CD28z Retroviral Vector-transduced Autologous T-Cells | Autologous CAR-CD19-CD28-zeta-transduced T-lymphocytes | CAR-CD30-28zeta-specific Autologous T-cells | SFG.CAR.CD30 Autologous T-lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555934","ERBB2 NM_004448.3:c.2305G>T","C155299","A nucleotide substitution at position 2305 of the coding sequence of the ERBB2 gene where guanine has been mutated to thymine.","ERBB2 NM_004448.3:c.2305G>T | ERBB2 c.2305G>T | HER-2 c.2305G>T | HER-2/neu c.2305G>T | HER2 c.2305G>T | NEU c.2305G>T | NM_004448.3:c.2305G>T | v-erb-b2 Erythroblastic Leukemia Viral Oncogene Homolog 2, Neuro/Glioblastoma Derived Oncogene Homolog (Avian) c.2305G>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280855","Bone Metastases Prevention","C15529","Methods used to prevent the spread of cancer from a primary tumor site to the bone.","Bone Metastases Prevention | Prevention of Bone Metastases",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552167","Vandetanib-eluting Radiopaque Bead BTG-002814","C150384","Radiopaque drug-eluting beads (DEBs) that are loaded with vandetanib, a dual inhibitor of both vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR), with potential antineoplastic, anti-angiogenic and imaging activities. Upon intra-arterial hepatic artery administration of vandetanib (VTB)-eluting Radiopaque beads (VERBs) BTG-002814, the DEBs occlude the tumor blood vessels and deprive tumor cells of oxygen and nutrients, thereby causing hepatic arterial embolization and direct tumor cell death. The VERBs release vandetanib from the beads in a sustained manner. Vandetanib selectively inhibits the tyrosine kinase activity of both VEGFR and EGFR, thereby blocking both VEGF/VEGFR- and EGF/EGFR-stimulated signaling and inhibiting cell proliferation, migration and angiogenesis in VEGFR/EGFR-expressing hepatic tumor cells. The DEBs, controlled release microspherical devices, cause low systemic exposure and prevent systemic toxicity of vandetanib. DEBs also deliver high concentrations of vandetanib in the tumor for a controlled and extended period of time. Use of radiopaque DEBs allows for visualization of both the bead location and the degree of embolization upon imaging.","Vandetanib-eluting Radiopaque Bead BTG-002814 | BTG-002814 | VERB | VERB BTG-002814 | VTB-loaded Beads | Vandetanib-eluting Radiopaque Embolic Beads",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4277684","Ecological Momentary Assessment","C150385","A method for assessment in clinical psychology that involves repeated sampling of subjects' current behaviors and experiences in real time, in a subjects' natural environments. EMA aims to minimize recall bias, maximize ecological validity, and allow study of microprocesses that influence behavior in real-world contexts.","Ecological Momentary Assessment | EMA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554825","Basic Dosage Form Category","C150386","A category of terms used to group together pharmaceutical dose forms.","Basic Dosage Form Category | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4039858","Robot-assisted Laparoscopic Partial Nephrectomy","C150387","A surgical procedure where a partial nephrectomy is done using a laparoscopic robot.","Robot-assisted Laparoscopic Partial Nephrectomy | RPN | Robot-assisted Partial Nephrectomy | Robotic-assisted Partial Nephrectomy",,,,,,,,,,,,,,,"46270931","Robot assisted laparoscopic partial nephrectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552164","IRDye800CW-labeled Heptapeptide KSP-910638G","C150388","An imaging agent composed of a heptapeptide targeting human epithelial growth factor receptor type 2 (EGFR2; HER2; ErbB2) conjugated, via a five-amino acid linker, to the near-infrared (NIR) fluorescent dye IRDye800CW, that can potentially be used for the imaging of HER2-expressing tumors. Upon oral administration of the IRDye800CW-labeled heptapeptide KSP-910638G, the peptide moiety targets and binds to HER2 expressed on tumor cells in the gastrointestinal (GI) tract. Upon fluorescence imaging of the fluorophore IRDye800CW, the tumor cells can be detected.","IRDye800CW-labeled Heptapeptide KSP-910638G | KSP Heptapeptide | KSP-910638G | KSP-910638G Heptapeptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552903","Paced Tapping - Median Interval Tone Trial","C151058","Paced Tapping Test (Paced Tapping) The median intertap interval within the tone-tapping phase of Trial n (in milliseconds).","Paced Tapping - Median Interval Tone Trial | PTAP1-Median Interval Tone Trial | PTAP112D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552904","Paced Tapping - Variance Interval Tone Trial","C151059","Paced Tapping Test (Paced Tapping) The variance of the intertap interval within the tone-tapping phase of Trial n (in milliseconds).","Paced Tapping - Variance Interval Tone Trial | PTAP1-Variance Interval Tone Trial | PTAP112E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553016","FACT-BRM Version 4 - Satisfied With How I Am Coping","C151171","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Emotional Well-Being: I am satisfied with how I am coping with my illness.","FACT-BRM Version 4 - Satisfied With How I Am Coping | FAC062-Satisfied With How I Am Coping | FAC06216",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553017","FACT-BRM Version 4 - Losing Hope Against Illness","C151172","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Emotional Well-Being: I am losing hope in the fight against my illness.","FACT-BRM Version 4 - Losing Hope Against Illness | FAC062-Losing Hope Against Illness | FAC06217",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553018","FACT-BRM Version 4 - I Feel Nervous","C151173","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Emotional Well-Being: I feel nervous.","FACT-BRM Version 4 - I Feel Nervous | FAC062-I Feel Nervous | FAC06218",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553019","FACT-BRM Version 4 - I Worry About Dying","C151174","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Emotional Well-Being: I worry about dying.","FACT-BRM Version 4 - I Worry About Dying | FAC062-I Worry About Dying | FAC06219",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553020","FACT-BRM Version 4 - Worry My Condition Will Get Worse","C151175","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Emotional Well-Being: I worry that my condition will get worse.","FACT-BRM Version 4 - Worry My Condition Will Get Worse | FAC062-Worry My Condition Will Get Worse | FAC06220",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279172","Vasopressin Tannate in Oil","C1552","An oil based formulation of Vasopressin, which could be administered intramuscularly. (NCI)","Vasopressin Tannate in Oil | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555247","Nonfunctional Corticotroph Adenoma","C154429","Corticotroph pituitary neuroendocrine tumor not associated with a hormonal syndrome.","Non-Functioning Corticotroph Pituitary Neuroendocrine Tumor | Non-Functioning Corticotroph Adenoma | Nonfunctional Corticotroph Adenoma | Nonfunctioning Corticotroph Adenoma | Silent Corticotroph Adenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555245","Definitive Surgical Resection","C154430","Surgical resection that has been chosen as the best alternative for treatment, considering all available therapeutic options.","Definitive Surgical Resection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555246","Densely Granulated Nonfunctional Corticotroph Adenoma","C154431","A densely granulated corticotroph pituitary neuroendocrine tumor not associated with a hormonal syndrome.","Non-Functioning Densely Granulated Corticotroph Pituitary Neuroendocrine Tumor | Densely Granulated Non-Functioning Corticotroph Adenoma | Densely Granulated Nonfunctional Corticotroph Adenoma | Densely Granulated Nonfunctioning Corticotroph Adenoma | Densely Granulated Silent Corticotroph Adenoma | Non-Functioning Densely Granulated  Corticotroph Adenoma | Non-Functioning Densely Granulated Corticotroph Adenoma | Nonfunctional Corticotroph Adenoma Type 1 | Silent Corticotroph Adenoma Type 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555249","Nonfunctional Corticotroph Adenoma Type 2","C154432","A sparsely granulated corticotroph pituitary neuroendocrine tumor not associated with a hormonal syndrome.","Non-Functioning Sparsely Granulated Corticotroph Pituitary Neuroendocrine Tumor | Non-Functioning Sparsely Granulated Corticotroph Adenoma | Nonfunctional Corticotroph Adenoma Type 2 | Silent Corticotroph Adenoma Type 2 | Sparsely Granulated Non-Functioning Corticotroph Adenoma | Sparsely Granulated Nonfunctional Corticotroph Adenoma | Sparsely Granulated Nonfunctioning Corticotroph Adenoma | Sparsely Granulated Silent Corticotroph Adenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552905","Paced Tapping - Deviation Interval Tone Trial","C151060","Paced Tapping Test (Paced Tapping) The standard deviation of the intertap intervals within the tone-tapping phase of Trial n.","Paced Tapping - Deviation Interval Tone Trial | PTAP1-Deviation Interval Tone Trial | PTAP112F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552906","Paced Tapping - Reciprocal Interval ToneTrial","C151061","Paced Tapping Test (Paced Tapping) The reciprocal of the standard deviation of the intertap intervals within the tone-tapping phase of Trial n.","Paced Tapping - Reciprocal Interval ToneTrial | PTAP1-Reciprocal Interval ToneTrial | PTAP112G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552907","Paced Tapping - Avg Sign Dev Interval Tone Trial","C151062","Paced Tapping Test (Paced Tapping) The average signed deviation of the intertap intervals within the tone-tapping phase of Trial n.","Paced Tapping - Avg Sign Dev Interval Tone Trial | PTAP1-Avg Sign Dev Interval Tone Trial | PTAP112H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552908","Paced Tapping - Num Intervals Expected Self Trial","C151063","Paced Tapping Test (Paced Tapping) Total number of intertap intervals expected for the self-paced tapping phase of Trial n.","Paced Tapping - Num Intervals Expected Self Trial | PTAP1-Num Intervals Expected Self Trial | PTAP113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552909","Paced Tapping - Num Intervals Trim Self Trial","C151064","Paced Tapping Test (Paced Tapping) Total number of intertap intervals within the self-paced tapping phase of Trial n, that were trimmed before analysis.","Paced Tapping - Num Intervals Trim Self Trial | PTAP1-Num Intervals Trim Self Trial | PTAP114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552910","Paced Tapping - Minimum Interval Self Trial","C151065","Paced Tapping Test (Paced Tapping) The minimum intertap interval within the self-paced tapping phase of Trial n (in milliseconds).","Paced Tapping - Minimum Interval Self Trial | PTAP1-Minimum Interval Self Trial | PTAP114A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552783","Paced Tapping - Maximum Interval Self Trial","C151066","Paced Tapping Test (Paced Tapping) The maximum intertap interval within the self-paced tapping phase of Trial n (in milliseconds).","Paced Tapping - Maximum Interval Self Trial | PTAP1-Maximum Interval Self Trial | PTAP114B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552784","Paced Tapping - Mean Interval Self Trial","C151067","Paced Tapping Test (Paced Tapping) The mean intertap interval within the self-paced tapping phase of Trial n (in milliseconds).","Paced Tapping - Mean Interval Self Trial | PTAP1-Mean Interval Self Trial | PTAP114C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552786","Paced Tapping - Variance Interval Self Trial","C151069","Paced Tapping Test (Paced Tapping) The variance of the intertap interval within the self-paced tapping phase of Trial n (in milliseconds).","Paced Tapping - Variance Interval Self Trial | PTAP1-Variance Interval Self Trial | PTAP114E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552787","Paced Tapping - Deviation Interval Self Trial","C151070","Paced Tapping Test (Paced Tapping) The standard deviation of the intertap intervals within the self-paced tapping phase of Trial n.","Paced Tapping - Deviation Interval Self Trial | PTAP1-Deviation Interval Self Trial | PTAP114F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552788","Paced Tapping - Reciprocal Interval Self Trial","C151071","Paced Tapping Test (Paced Tapping) The reciprocal of the standard deviation of the intertap intervals within the self-paced tapping phase of Trial n.","Paced Tapping - Reciprocal Interval Self Trial | PTAP1-Reciprocal Interval Self Trial | PTAP114G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552789","Paced Tapping - Avg Sign Dev Interval Self Trial","C151072","Paced Tapping Test (Paced Tapping) The average signed deviation of the intertap intervals within the self-paced tapping phase of Trial n.","Paced Tapping - Avg Sign Dev Interval Self Trial | PTAP1-Avg Sign Dev Interval Self Trial | PTAP114H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552350","Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall","C150572","A carcinoma that arises from the bladder mucosa and invades the muscle of the bladder wall.","Muscle Invasive Bladder Carcinoma | Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall | Muscle-Invasive Bladder Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552349","Localized Cerebral Neoplasm","C150573","A cerebral neoplasm that is confined to a specific site without evidence of spread to other anatomic sites.","Localized Cerebral Neoplasm | Non-Metastatic Cerebral Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552138","Fluorine F 18 DASA-23","C150418","A radiotracer composed of DASA-23, a pyruvate kinase isoform M2 (PKM2) ligand, conjugated to the radioisotope fluorine F 18, with potential use for imaging of PKM2-expressing tumor cells upon positron emission tomography (PET). Upon administration of fluorine F 18 DASA-23, the DASA-23 moiety selectively targets and is taken up by tumor cells that express PKM2. Upon binding to PKM2 and following PET, PKM2-expressing tumor cells can be visualized and the metabolic activity of the tumor cells can be assessed through the quantitation of PKM2 expression levels. PKM2, an enzyme that plays a key role in the glycolytic reprogramming, metabolic activity and rapid proliferation of tumor cells, is selectively overexpressed in various tumor cell types. Tumor uptake of fluorine F 18 DASA-23 is positively correlated with PKM2 expression.","Fluorine F 18 DASA-23 | 1-((2-Fluoro-6-[18F]fluorophenyl)sulfonyl)-4-((4-methoxyphenyl)sulfonyl)piperazine | 18F-DASA-23 | F18-labeled PKM2 Inhibitor DASA-23 | F18-labeled Pyruvate Kinase M2 Inhibitor DASA-23 | [18F]DASA-23 | [18F]DASA23",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552133","Bluetooth-enabled Activity Monitor","C150419","A consumer, wearable device that is designed to collect and display information about an individual's activities and is able to transfer that information to another device or system over a Bluetooth connection. Information collected may include steps, stairs climbed, distance traveled, calories used, heart rate, sleep quality, or other metrics.","Bluetooth-enabled Activity Monitor | Bluetooth-enabled Activity Tracker | Bluetooth-enabled Activity Tracking Device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552132","Robotic Uterine Manipulator","C150420","A robotic device designed to assist a surgeon in moving the uterus into an optimal position during laparoscopic procedures.","Robotic Uterine Manipulator | BAUM | Barakat Automated Uterine Manipulator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552134","Deep Inspiration Breath Hold","C150422","A type of active breathing control where a breath is held during a procedure while the lungs are fully expanded. It is typically used during radiation therapy to help limit radiation to underlying organs.","Deep Inspiration Breath Hold | DIBH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552128","Non-myeloablative TCR alpha/beta-depleted Haploidentical Hematopoietic Stem Cell Transplantation","C150424","An allogeneic hematopoietic stem cell transplantation (HSCT) in a recipient that was not pre-treated with a conditioning regimen of high doses of chemotherapy or radiation, using cells depleted of T-cell receptors (TCR) alpha and beta as Graft-versus-Host Disease (GvHD) prophylaxis, from a related donor who is a partial human leukocyte antigen (HLA) tissue type match.","Non-myeloablative TCR alpha/beta-depleted Haploidentical Hematopoietic Stem Cell Transplantation | Non-myeloablative TCR alpha/beta-depleted Haploidentical HSCT | Nonmyeloablative T-cell Receptor-alpha-beta-depleted Haploidentical Hematopoietic Cell Transplantation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553021","FACT-BRM Version 4 - I Am Able to Work","C151176","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Functional Well-Being: I am able to work (include work at home).","FACT-BRM Version 4 - I Am Able to Work | FAC062-I Am Able to Work | FAC06221",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553023","FACT-BRM Version 4 - I Am Able to Enjoy Life","C151178","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Functional Well-Being: I am able to enjoy life.","FACT-BRM Version 4 - I Am Able to Enjoy Life | FAC062-I Am Able to Enjoy Life | FAC06223",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553024","FACT-BRM Version 4 - I Have Accepted My Illness","C151179","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Functional Well-Being: I have accepted my illness.","FACT-BRM Version 4 - I Have Accepted My Illness | FAC062-I Have Accepted My Illness | FAC06224",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553025","FACT-BRM Version 4 - I Am Sleeping Well","C151180","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Functional Well-Being: I am sleeping well.","FACT-BRM Version 4 - I Am Sleeping Well | FAC062-I Am Sleeping Well | FAC06225",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553026","FACT-BRM Version 4 - Enjoy Things I Usually Do for Fun","C151181","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Functional Well-Being: I am enjoying the things I usually do for fun.","FACT-BRM Version 4 - Enjoy Things I Usually Do for Fun | FAC062-Enjoy Things I Usually Do for Fun | FAC06226",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553027","FACT-BRM Version 4 - Content With Quality of My Life","C151182","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Functional Well-Being: I am content with the quality of my life right now.","FACT-BRM Version 4 - Content With Quality of My Life | FAC062-Content With Quality of My Life | FAC06227",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553028","FACT-BRM Version 4 - I Get Tired Easily","C151183","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Additional Concerns-Physical: I get tired easily.","FACT-BRM Version 4 - I Get Tired Easily | FAC062-I Get Tired Easily | FAC06228",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553029","FACT-BRM Version 4 - I Feel Weak All Over","C151184","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Additional Concerns-Physical: I feel weak all over.","FACT-BRM Version 4 - I Feel Weak All Over | FAC062-I Feel Weak All Over | FAC06229",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553030","FACT-BRM Version 4 - I Have a Good Appetite","C151185","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Additional Concerns-Physical: I have a good appetite.","FACT-BRM Version 4 - I Have a Good Appetite | FAC062-I Have a Good Appetite | FAC06230",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553031","FACT-BRM Version 4 - I Have Pain in My Joints","C151186","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Additional Concerns-Physical: I have pain in my joints.","FACT-BRM Version 4 - I Have Pain in My Joints | FAC062-I Have Pain in My Joints | FAC06231",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552567","Autologous GPC3/NY-ESO-1/AFP specific CD8-positive T-lymphocytes","C150676","A preparation of autologous CD8-positive T-lymphocytes that are exposed, ex vivo, to multiple specific hepatocellular carcinoma (HCC) antigens, including glypican (GPC)-3, New York esophageal squamous cell carcinoma-1 (NY-ESO-1) and alpha-fetoprotein (AFP), with potential immunostimulating and antineoplastic activities. Upon infusion of the GPC3/NY-ESO-1/AFP-specific CD8-positive T lymphocytes, the T-cells specifically target and lyse cells expressing the targeted HCC neoantigens.","Autologous GPC3/NY-ESO-1/AFP specific CD8-positive T-lymphocytes | Autologous HCC Antigens-specific CD8+ T lymphocytes | Autologous HCC Antigens-specific CD8-positive T-lymphocytes | Autologous Specific HCC Antigens CD8+ T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556389","Capsule Dose Form Category","C154433","A type of solid pharmaceutical dose form consisting of a shell inside which a single dose of the active substance(s) is enclosed. Cachet is excluded.","Capsule Dose Form Category | Capsule",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562653","Cement Dosage Form Category","C154434","A type of semi-solid pharmaceutical dose form that hardens after application to form a seal or bond.","Cement Dosage Form Category | Cement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555248","Collodion Dosage Form Category","C154435","A type of liquid pharmaceutical dose form usually consisting of a solution of pyroxylin in ether and ethanol.","Collodion Dosage Form Category | Collodion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279023","Chemosensitization","C15463","The synergistic action of two drugs, being greater than the sum of the effects of each used alone.","Chemosensitization | Chemosensitization/Potentiation | Potentiation | potentiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555423","Gastrointestinal System Small Cell Neuroendocrine Carcinoma","C154641","An aggressive high-grade carcinoma with neuroendocrine differentiation that arises from the digestive system and is composed of malignant small cells. The mitotic count is more than 20 per 2 mm2 and/or the Ki-67 index is more than 20% (often more than 70%).","Digestive System Small Cell Neuroendocrine Carcinoma | Digestive System Small Cell Carcinoma | Gastrointestinal System Small Cell Neuroendocrine Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555424","Pipette Closure Device","C154642","Closure with pipette.","Pipette Closure Device | Pipette applicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552344","Thoracic Epidural Analgesia","C150574","Epidural analgesia administered to the thoracic spine to treat pain in the thoracic and upper abdominal areas during surgery.","Thoracic Epidural Analgesia | TEA | Thoracic Epidural",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552343","Advanced Magnetic Resonance Imaging","C150575","Any of various magnetic resonance (MR) imaging techniques with predictive power beyond that achievable with conventional contrast-enhanced MR, such as diffusion MRI, perfusion MRI, functional MRI, dynamic susceptibility contrast MRI, dynamic contrast enhancement MRI, higher order diffusion techniques such as diffusion tensor imaging, and MR spectroscopy.","Advanced Magnetic Resonance Imaging | AMRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552346","Four Quadrants Transverse Abdominis Plane Block","C150576","A peripheral nerve block that involves performing bilateral subcostal as well as posterior transverse abdominis plane blocks.","Four Quadrants Transverse Abdominis Plane Block | 4 Quadrant TAP Block | 4Q-TAP Block",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552345","Metastatic Gastroesophageal Junction Adenocarcinoma","C150577","Gastroesophageal junction adenocarcinoma which has spread from its original site of growth to another anatomic site.","Metastatic Gastroesophageal Junction Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552340","Unresectable Gastroesophageal Junction Adenocarcinoma","C150578","Gastroesophageal junction adenocarcinoma that is not amenable to surgical resection.","Unresectable Gastroesophageal Junction Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552339","Recurrent Myxoid Liposarcoma","C150579","The reemergence of myxoid liposarcoma after a period of remission.","Recurrent Myxoid Liposarcoma | Recurrent Myxoid/Round Cell Liposarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552342","Unresectable Adrenal Cortical Carcinoma","C150580","Adrenal cortical carcinoma that is not amenable to surgical resection.","Unresectable Adrenal Cortical Carcinoma | Unresectable Adrenal Cortex Carcinoma | Unresectable Adrenal Cortex Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554813","Refractory Lung Small Cell Carcinoma","C150581","Small cell lung carcinoma that does not respond to treatment.","Refractory Lung Small Cell Carcinoma | Refractory Small Cell Lung Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552648","CDISC Questionnaire SIQ Test Name Terminology","C150789","Test names of questionnaire questions associated with the Suicidal Ideation Questionnaire (SIQ) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire SIQ Test Name Terminology | QS-SIQ TEST | SIQ01TN | Suicidal Ideation Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552840","FACT-Taxane Version 4 - My Family Has Accepted My Illness","C151123","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Social/Family Well-Being: My family has accepted my illness.","FACT-Taxane Version 4 - My Family Has Accepted My Illness | FAC063-My Family Has Accepted My Illness | FAC06311",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552841","FACT-Taxane Version 4 - Satisfied Communication Illness","C151124","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Social/Family Well-Being: I am satisfied with family communication about my illness.","FACT-Taxane Version 4 - Satisfied Communication Illness | FAC063-Satisfied Communication Illness | FAC06312",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552842","FACT-Taxane Version 4 - I Feel Close to My Partner","C151125","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Social/Family Well-Being: I feel close to my partner (or the person who is my main support).","FACT-Taxane Version 4 - I Feel Close to My Partner | FAC063-I Feel Close to My Partner | FAC06313",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552843","FACT-Taxane Version 4 - I Am Satisfied With My Sex Life","C151126","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Social/Family Well-Being: I am satisfied with my sex life.","FACT-Taxane Version 4 - I Am Satisfied With My Sex Life | FAC063-I Am Satisfied With My Sex Life | FAC06314",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552844","FACT-Taxane Version 4 - I Feel Sad","C151127","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Emotional Well-Being: I feel sad.","FACT-Taxane Version 4 - I Feel Sad | FAC063-I Feel Sad | FAC06315",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552845","FACT-Taxane Version 4 - Satisfied With How I Am Coping","C151128","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Emotional Well-Being: I am satisfied with how I am coping with my illness.","FACT-Taxane Version 4 - Satisfied With How I Am Coping | FAC063-Satisfied With How I Am Coping | FAC06316",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552846","FACT-Taxane Version 4 - Losing Hope Against Illness","C151129","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Emotional Well-Being: I am losing hope in the fight against my illness.","FACT-Taxane Version 4 - Losing Hope Against Illness | FAC063-Losing Hope Against Illness | FAC06317",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552975","FACT-Taxane Version 4 - I Feel Nervous","C151130","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Emotional Well-Being: I feel nervous.","FACT-Taxane Version 4 - I Feel Nervous | FAC063-I Feel Nervous | FAC06318",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552977","FACT-Taxane Version 4 - Worry My Condition Will Get Worse","C151132","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Emotional Well-Being: I worry that my condition will get worse.","FACT-Taxane Version 4 - Worry My Condition Will Get Worse | FAC063-Worry My Condition Will Get Worse | FAC06320",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552568","Anti-CD26 Monoclonal Antibody YS110","C150677","A humanized, immunoglobulin G1 (IgG1) monoclonal antibody directed against the extracellular domain of dipeptidyl peptidase 4 (CD26; DPP4; DPP IV), with potential antineoplastic activity. Upon administration of anti-CD26 monoclonal antibody YS110, this antibody targets and binds to CD26 expressed on tumor cells. This inhibits CD26 activity and causes internalization of CD26-YS110. This leads to cell cycle arrest, lysis and inhibition of growth in CD26-positive tumor cells. YS110 also induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against CD26-expressing tumor cells. CD26, a 110-kDa, type II transmembrane glycoprotein, is overexpressed in a variety of cancer cell types while absent in normal, healthy cells and plays a key role in tumor cell growth, migration, invasion and survival. It also plays a major role in the regulation of T-cell activity.","Anti-CD26 Monoclonal Antibody YS110 | YS110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552570","MK 1308","C150679","A monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, quavonlimab targets and binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.","Quavonlimab | Anti-CTLA-4 Monoclonal Antibody MK-1308 | MK 1308 | MK-1308 | MK1308 | QUAVONLIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552486","MEK Inhibitor SHR 7390","C150680","An orally available small molecule inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK), with potential antineoplastic activity. Upon administration, MEK inhibitor SHR 7390 selectively binds to and inhibits the activity of MEK. This prevents the activation of MEK-dependent effector proteins, which results in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a dual-specificity threonine/tyrosine kinase family that plays a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway, is frequently upregulated in a variety of tumor cell types.","MEK Inhibitor SHR 7390 | MAP2K Inhibitor SHR 7390 | MAPK Kinase Inhibitor SHR 7390 | MEKi SHR 7390 | SHR 7390 | SHR-7390 | SHR7390",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552488","Autologous Mesothelin-specific CAR-T-Cells Expressing Anti-PD-1/CTLA-4 Antibodies","C150682","A preparation of autologous, engineered T-lymphocytes that express both a second-generation chimeric antigen receptor (CAR) specific for the human gastric carcinoma-associated antigen MG7, and the co-stimulatory molecule 4-1BB (CD137), with potential antineoplastic activity. Upon intratumoral injection, the autologous anti-MG7-CAR T-lymphocytes target and attach to cancer cells expressing MG7. This induces selective toxicity in and causes lysis of MG7-expressing tumor cells. MG7, a glycosylated protein sequence from the tumor-associated antigen (TAA) carcinoembryonic antigen (CEA), plays a key role in the development of certain tumor cell types. 4-1BB enhances T-cell activation and signaling after recognition of MG7.","Autologous Mesothelin-specific CAR-T-Cells Expressing Anti-PD-1/CTLA-4 Antibodies | Autologous Anti-MG7 CAR-T Cells | Autologous Anti-MG7-CAR T Lymphocytes | Autologous MG7-CART | Autologous MG7-CART Cells | MG7-targeted Chimeric Antigen Receptor T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552490","Other Iatrogenic Immunodeficiency-Related Lymphoproliferative Disorders","C150684","Lymphoid proliferations or lymphomas that arise in patients treated with immunosuppressive drugs for autoimmune diseases or conditions other than in the post-transplant setting. (WHO 2017)","Other Iatrogenic Immunodeficiency-Related Lymphoproliferative Disorders | Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders | Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555422","H3 Histone Family, Member N Gene","C154644","Human H3C15 wild-type allele is located in the vicinity of 1q21.2 and is approximately 2 kb in length. This allele, which encodes histone H3.2 protein, plays a role in chromatin structure.","H3C15 wt Allele | H3 Clustered Histone 15 wt Allele | H3 Histone Family, Member N Gene | H3 Histone Family, Member O Gene | H3/n | H3/o | H3FN | HIST2H3A | Histone 2, H3a Gene | Histone Cluster 2 H3 Family Member A Gene | Histone Cluster 2, H3a Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555428","H3 Histone Family, Member M Gene","C154646","Human H3C14 wild-type allele is located in the vicinity of 1q21.2 and is approximately 2 kb in length. This allele, which encodes histone H3.2 protein, is involved in the formation of complex DNA-containing structures.","H3C14 wt Allele | H3 Clustered Histone 14 Gene | H3 Clustered Histone 14 wt Allele | H3 Histone Family, Member M Gene | H3 Histone Family, Member N Gene | H3 Histone, Family 2 Gene | H3/M | H3/m | H3F2 | H3FM | HIST2 Cluster, H3C Gene | HIST2H3C | Histone 2, H3c Gene | Histone Cluster 2 H3 Family Member C Gene | Histone Cluster 2, H3c Gene | Histone Gene Cluster 2, H3 Family, Member C Gene | Histone Gene Cluster 2, H3c Gene | MGC9629",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555616","Necrotizing Enterocolitis, AE","C154922","An adverse event in newborns characterized by extensive mucosal ulceration, pseudomembrane formation, submucosal hemorrhage, and necrosis in the intestines .","Necrotizing Enterocolitis, AE | Necrotizing Enterocolitis | Necrotizing Enterocolitis, Adverse Event | Necrotizing enterocolitis neonatal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555617","Periventricular Leukomalacia, AE","C154923","An adverse event in a newborn characterized by a form of cerebral white matter injury usually seen in preterm infants that is characterized by necrotic degeneration or gliosis of white matter adjacent to the cerebral ventricles that may evolve into focal cysts.","Periventricular Leukomalacia, AE | Periventricular Leukomalacia | Periventricular Leukomalacia, Adverse Event | Periventricular leukomalacia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555620","Neonatal Spontaneous Intestinal Perforation, AE","C154924","An adverse event in a newborn characterized by a perforation in the gastrointestinal tract of a newborn with no demonstrable cause.","Neonatal Spontaneous Intestinal Perforation, AE | Neonatal SIP, AE | Neonatal Spontaneous Intestinal Perforation | Neonatal Spontaneous Intestinal Perforation, Adverse Event | Neonatal spontaneous intestinal perforation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555621","Retinopathy of Prematurity, AE","C154925","An adverse event characterized by a retinal condition of very immature infants that may be characterized by non-vascularized retinae that may lead to neovascularization, scarring, retinal detachment, and blindness.","Retinopathy of Prematurity, AE | Retinopathy of Prematurity | Retinopathy of Prematurity, Adverse Event | Retinopathy of prematurity | RoP, AE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555618","Infant Sedation, AE","C154926","An adverse event in a newborn characterized by a state of a lowered level of consciousness.","Infant Sedation, AE | Infant Sedation | Infant Sedation, Adverse Event | Infant sedation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555619","Neonatal Culture Positive Sepsis, AE","C154927","An adverse event in a newborn characterized by a systemic inflammatory response to an infection with an identifiable cause.","Neonatal Culture Positive Sepsis, AE | Culture Positive Neonatal Sepsis | Culture positive neonatal sepsis | Neonatal Culture Positive Sepsis, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555622","Neonatal Culture Negative Sepsis, AE","C154928","An adverse event in a newborn characterized by a systemic inflammatory response without identifiable cause.","Neonatal Culture Negative Sepsis, AE | Culture Negative Neonatal Sepsis | Culture negative neonatal sepsis | Neonatal Culture Negative Sepsis, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556891","Neonatal Hypotension, AE","C154930","An adverse event in a newborn characterized by abnormally low blood pressure, which is usually symptomatic.","Neonatal Hypotension, AE | Neonatal Hypotension | Neonatal Hypotension, Adverse Event | Neonatal hypotension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556508","Neonatal Edema, AE","C154931","An adverse event in a newborn characterized by accumulation of an excessive amount of fluid in cells or intercellular tissues.","Neonatal Edema, AE | Edema Neonatal | Edema neonatal | Neonatal Edema, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552649","CDISC Questionnaire SIQ Test Code Terminology","C150790","Test codes of questionnaire questions associated with the Suicidal Ideation Questionnaire (SIQ) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire SIQ Test Code Terminology | QS-SIQ TESTCD | SIQ01TC | Suicidal Ideation Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552650","CDISC Questionnaire SIQ-JR Test Name Terminology","C150791","Test names of questionnaire questions associated with the Suicidal Ideation Questionnaire-Junior (SIQ-JR) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire SIQ-JR Test Name Terminology | QS-SIQ-JR TEST | SIQ02TN | Suicidal Ideation Questionnaire-JR Questionnaire Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552651","CDISC Questionnaire SIQ-JR Test Code Terminology","C150792","Test codes of questionnaire questions associated with the Suicidal Ideation Questionnaire-Junior (SIQ-JR) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire SIQ-JR Test Code Terminology | QS-SIQ-JR TESTCD | SIQ02TC | Suicidal Ideation Questionnaire-JR Questionnaire Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552652","COWAT Functional Test Question","C150793","A question associated with the COWAT functional test.","COWAT Functional Test Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552653","MMSE-2 Standard Version Functional Test Question","C150794","A question associated with the MMSE-2 functional test.","MMSE-2 Standard Version Functional Test Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552654","ERT Functional Test Question","C150795","A question associated with the ERT functional test.","ERT Functional Test Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552655","Paced Tapping Functional Test Question","C150796","A question associated with the Paced Tapping functional test.","Paced Tapping Functional Test Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552656","FACT-C Version 4 Questionnaire Question","C150797","A question associated with the FACT-C Version 4 questionnaire.","FACT-C Version 4 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552657","FACT-Taxane Version 4 Questionnaire Question","C150798","A question associated with the FACT-Taxane Version 4 questionnaire.","FACT-Taxane Version 4 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552658","FACT-BRM Version 4 Questionnaire Question","C150799","A question associated with the FACT-BRM Version 4 questionnaire.","FACT-BRM Version 4 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552659","FACT/GOG-NTX Version 4 Questionnaire Question","C150800","A question associated with the FACT/GOG-NTX Version 4 questionnaire.","FACT/GOG-NTX Version 4 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552660","FACT-L Version 4 Questionnaire Question","C150801","A question associated with the FACT-L Version 4 questionnaire.","FACT-L Version 4 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552661","FKSI-DRS Version 4 Questionnaire Question","C150802","A question associated with the FKSI-DRS Version 4 questionnaire.","FKSI-DRS Version 4 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552662","NCCN-FACT FBRSI-24 Version 2 Questionnaire Question","C150803","A question associated with the NCCN-FACT FBRSI-24 Version 2 questionnaire.","NCCN-FACT FBRSI-24 Version 2 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552663","NCCN-FACT FHNSI-22 Version 2 Questionnaire Question","C150804","A question associated with the NCCN-FACT FHNSI-22 Version 2 questionnaire.","NCCN-FACT FHNSI-22 Version 2 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552664","SIQ Questionnaire Question","C150805","A question associated with the SIQ questionnaire.","SIQ Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552978","FACT-Taxane Version 4 - I Am Able to Work","C151133","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Functional Well-Being: I am able to work (include work at home).","FACT-Taxane Version 4 - I Am Able to Work | FAC063-I Am Able to Work | FAC06321",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552980","FACT-Taxane Version 4 - I Am Able to Enjoy Life","C151135","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Functional Well-Being: I am able to enjoy life.","FACT-Taxane Version 4 - I Am Able to Enjoy Life | FAC063-I Am Able to Enjoy Life | FAC06323",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552981","FACT-Taxane Version 4 - I Have Accepted My Illness","C151136","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Functional Well-Being: I have accepted my illness.","FACT-Taxane Version 4 - I Have Accepted My Illness | FAC063-I Have Accepted My Illness | FAC06324",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552982","FACT-Taxane Version 4 - I Am Sleeping Well","C151137","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Functional Well-Being: I am sleeping well.","FACT-Taxane Version 4 - I Am Sleeping Well | FAC063-I Am Sleeping Well | FAC06325",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552983","FACT-Taxane Version 4 - Enjoy Things I Usually Do for Fun","C151138","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Functional Well-Being: I am enjoying the things I usually do for fun.","FACT-Taxane Version 4 - Enjoy Things I Usually Do for Fun | FAC063-Enjoy Things I Usually Do for Fun | FAC06326",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552395","ERBB2 Exon 20 Mutation","C150632","A molecular genetic abnormality indicating the presence of a mutation in exon 20 of the ERBB2 gene.","ERBB2 Exon 20 Mutation | CD340 Exon 20 Mutation | Erb-B2 Receptor Tyrosine Kinase 2 Exon 20 Mutation | Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation | HER-2 Exon 20 Mutation | HER2 Exon 20 Mutation | HER2/Neu Exon 20 Mutation | Neu Exon 20 Mutation | Other ERBB2 exon 20 mutation, specify | c-erbB2 Exon 20 Mutation | v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 Exon 20 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552752","Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells","C150906","A preparation of autologous, genetically modified T-lymphocytes, that have been electroporated ex vivo with sleeping beauty (SB)-derived DNA plasmids, expressing a second-generation chimeric antigen receptor (CAR) composed of a mouse single-chain variable fragment (scFv) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19) that is linked to the co-stimulatory molecules T-cell surface glycoproteins CD8 and CD28 and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3-zeta) and co-expressed with a chimeric membrane-bound fusion protein comprised of interleukin-15 (IL-15) fused to IL-15 receptor (mbIL15) and a safety/kill switch composed of a truncated form of the human epidermal growth factor receptor (ErbB1t; EGFR) (HER1t), with potential immunostimulating and antineoplastic activities. Upon reintroduction of the autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells into the patient, the T-cells target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.  HER1t can promote selective elimination of the CAR-T cells through cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). IL-15 is a pro-survival cytokine that is required for the maintenance of long-lived CD8+ memory T-cells and use of mbIL15 preserves T stem-cell memory (TSCM) through sustained IL-15 signaling, improves T-cell persistence and potentiates the immune response against tumor cells. The SB system permits electroporation of the CAR, the IL-15 fusion variant and safety switch transgenes into T-cells without the need for viral vectors and accelerates the manufacturing process.","Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells | Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-EGFRt T Cells | CD19-CD8CD28zCAR-specific-mbIL15-HER1t T-lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555625","Neonatal Sinus Tachycardia, AE","C154932","An adverse event in a newborn characterized by an abnormally high heart rate for age.","Neonatal Sinus Tachycardia, AE | Neonatal Sinus Tachycardia | Neonatal Sinus Tachycardia, Adverse Event | Neonatal sinus tachycardia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555626","Neonatal Sinus Bradycardia, AE","C154933","An adverse event in a newborn characterized by an abnormally low heart rate for age.","Neonatal Sinus Bradycardia, AE | Neonatal Sinus Bradycardia | Neonatal Sinus Bradycardia, Adverse Event | Neonatal sinus bradycardia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555624","Neonatal Epileptic Seizure, AE","C154934","An adverse event in a newborn characterized by an electroencephalogram (EEG) confirmed paroxysmal surge of electrical activity in the brain that may result in physical or behavioral changes.","Neonatal Epileptic Seizure, AE | Neonatal Epileptic Seizure | Neonatal Epileptic Seizure, Adverse Event | Neonatal epileptic seizure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556885","Neonatal Rash, AE","C154935","An adverse event in a newborn characterized by an eruption in the skin which affects its appearance and/or texture.","Neonatal Rash, AE | Neonatal Rash, Adverse Event | Rash Neonatal | Rash neonatal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936827","Neonatal Pulmonary Hemorrhage, AE","C154936","An adverse event in a newborn characterized by bleeding in the respiratory tract of a neonate.","Neonatal Pulmonary Hemorrhage, AE | Neonatal Pulmonary Hemorrhage | Neonatal Pulmonary Hemorrhage, Adverse Event | Neonatal pulmonary hemorrhage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555932","ERBB2 NM_004448.3:c.2305G>C","C155301","A nucleotide substitution at position 2305 of the coding sequence of the ERBB2 gene where guanine has been mutated to cytosine.","ERBB2 NM_004448.3:c.2305G>C | ERBB2 c.2305G>C | HER-2 c.2305G>C | HER-2/neu c.2305G>C | HER2 c.2305G>C | NEU c.2305G>C | NM_004448.3:c.2305G>C | v-erb-b2 Erythroblastic Leukemia Viral Oncogene Homolog 2, Neuro/Glioblastoma Derived Oncogene Homolog (Avian) c.2305G>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555938","Gain of Chromosome 14q","C155303","A cytogenetic abnormality that refers to allelic gain within the chromosomal region 14q.","Gain of Chromosome 14q | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555935","Pituitary Gland Blastoma","C155304","A rare developmental early childhood neoplasm, arising within the fetal anterior pituitary. It is associated with DICER1 mutations. Patients present with features of Cushing disease, with elevated blood ACTH levels and hypercortisolism. Ophthalmoplegia is a frequent symptom. The overall prognosis is poor. (WHO)","Pituitary Gland Blastoma | Pituitary Blastoma | Pituitary Embryoma | Pituitary Gland Embryoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555936","Cutaneous Melanoma of the Extremity","C155305","A cutaneous melanoma that arises from the upper or lower extremity.","Cutaneous Melanoma of the Extremity | Primary Cutaneous Melanoma of the Extremity | Primary Extremity Melanoma | Primary Melanoma of the Extremity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555941","Recurrent Cutaneous Melanoma of the Extremity","C155306","Cutaneous melanoma of the upper or lower extremity that has recurred after a period of remission.","Recurrent Cutaneous Melanoma of the Extremity | Recurrent Extremity Melanoma | Recurrent Melanoma of the Extremity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552665","SIQ-JR Questionnaire Question","C150806","A question associated with the SIQ-JR questionnaire.","SIQ-JR Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3852217","Guselkumab","C150390","An orally available, human, immunoglobulin G1 (IgG1) kappa, monoclonal antibody directed against the p19 protein subunit of interleukin-23 (IL-23), with immunomodulating activity. Upon administration, guselkumab binds to the p19 subunit of IL-23, thereby blocking the binding of IL-23 to the IL-23 receptor. This inhibits IL-23-mediated signaling and the differentiation of CD4-positive T-cells into Th1 and Th17 cells. This prevents Th1- and Th17-mediated immune responses and inhibits the production of pro-inflammatory cytokines. This may prevent or reduce symptoms and severity of immune-mediated inflammatory disorders. IL-23 plays a key role in the regulation of inflammation and the immune system, and modulates the release of various pro-inflammatory cytokines and chemokines. It is upregulated in various immune-mediated inflammatory disorders.","Guselkumab | CNTO 1959 | GUSELKUMAB | Tremfya",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552159","Fluorine F 18 Integrin Alpha v Beta 6-targeted Peptide","C150392","A radiotracer composed of an integrin alphaVbeta6 (aVb6) binding peptide (BP) radiolabeled with the radionuclide fluorine F 18, with potential integrin aVb6 imaging activity using positron emission tomography (PET). Upon administration, the fluorine F 18 integrin aVb6-targeted peptide selectively binds to integrin aVb6-positive cancer cells. During PET, aVb6-expressing tumor cells can be visualized and the degree of tumor growth can be determined. Integrin aVb6, a cell adhesion and signaling receptor, is upregulated in certain cancer cell types and has been associated with increased proliferation, migration and invasion of tumor cells.","Fluorine F 18 Integrin Alpha v Beta 6-targeted Peptide | 18F-aVb6-BP | 18F-aVb6-Binding-Peptide | 18F-alphavbeta6-binding Peptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552162","Indoximod Prodrug NLG802","C150393","An orally bioavailable prodrug of indoximod, a methylated tryptophan, with immune checkpoint inhibitory and antineoplastic activities. Upon oral administration, the indoximod prodrug NLG802 is converted to indoximod. Indoximod targets, binds to and inhibits the enzyme indoleamine 2,3-dioxygenase (IDO; IDO1), which converts the essential amino acid tryptophan into the immunosuppressive metabolite kynurenine. By increasing tryptophan levels and decreasing kynurenine levels, indoximod restores and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes, and causes a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL) response against IDO1-expressing tumor cells, thereby inhibiting their growth. IDO1, overexpressed by multiple tumor cell types, plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system. NLG802 elicits increased plasma concentrations of indoximod and improves its efficacy, compared to the direct administration of indoximod.","Indoximod Prodrug NLG802 | ETHYL LEUCYL-1-METHYL-D-TRYPTOPHANATE | IDO1 Inhibitor NLG802 | Indoleamine 2,3-Dioxygenase (IDO) Inhibitor | NLG 802 | NLG-1564 | NLG-802 | NLG802",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552161","Fibrinous Material Present","C150394","A finding indicating the presence of fibrinous material in a surgical pathology specimen.","Fibrinous Material Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552156","Small Aggregates of Tumor Cells Present","C150395","A morphologic finding indicating the presence of small aggregates of tumor cells in a tissue sample.","Small Aggregates of Tumor Cells Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552155","Fibrin-Associated Diffuse Large B-Cell Lymphoma","C150396","An unusual form of diffuse large B-cell lymphoma. It is not mass-forming and does not directly produce symptoms, but it is discovered incidentally on histological examination of surgical pathology specimens, excised for various pathologies other than lymphoma. The specimens typically contain fibrinous materials. Single and small aggregates of large lymphoma cells are found in only small foci within the fibrinous or amorphous material. EBV is positive, with type III latency. The clinical outcome is highly favorable, even with surgical excision alone. (WHO 2017)","Fibrin-Associated Diffuse Large B-Cell Lymphoma | FA-DLBCL | Fibrin-Associated EBV-Positive Large B-Cell Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552158","Gallium Ga 68-NOTA-RM26","C150397","A radioconjugate containing RM26, a synthetic bombesin analogue and antagonist of the gastrin-releasing peptide receptor (GRPR), that is linked, through the macrocyclic chelating agent 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA) to the radionuclide gallium (Ga) 68, with potential use in diagnostic imaging using positron emission tomography/computed tomography (PET/CT). Upon administration of gallium Ga 68-NOTA-RM26, the peptide moiety targets and binds to GRPR. Upon PET/CT, GRPR-expressing tumor cells can then be visualized. GRPR, also called bombesin receptor subtype 2 (BB2), is a G protein-coupled seven-transmembrane receptor belonging to the bombesin receptor family. It is overexpressed in certain types of cancers.","Gallium Ga 68-NOTA-RM26 | 68Ga-NOTA-RM26",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552206","Anti-PD-1/Anti-CTLA-4 XmAb20717","C150463","A Fc-engineered bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, vudalimab targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T-lymphocytes (TILs) and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD1 and CTLA4 with XmAb20717 may enhance T cell activation and proliferation more than the blockade of either immune checkpoint receptor alone. The engineered Fc domain increases the stability and half-life of the antibody.","Vudalimab | Anti-PD-1/Anti-CTLA-4 XmAb20717 | Anti-PD1/CTLA4 Bispecific Antibody XmAb20717 | PD-1 x CTLA-4 Bispecific Antibody XmAb20717 | PD-1 x CTLA-4 Dual Checkpoint Inhibitor XmAb20717 | VUDALIMAB | XmAb 20717 | XmAb20717",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552202","Lutetium Lu-177 PSMA-R2","C150467","A radioconjugate composed of PSMA-R2, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of 177Lu-PSMA-R2, the PSMA-R2 moiety targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on the majority of prostate tumor cells.","Lutetium Lu-177 PSMA-R2 | 177Lu-PSMA-R2 | 177LuPSMA-R2 | Lu177-PSMA-R2 | Lutetium-177 PSMA-R2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1112747","Sickle cell-hemoglobin E disease","C155307","A variant of sickle cell disease due to heterozygosity for hemoglobin S and hemoglobin E mutations. Patients present with the symptoms of sickle cell disease but the symptoms are less frequent and severe compared to patients with hemoglobin SS disease.","Sickle Cell-Hemoglobin E Disease | Hemoglobin SE Disease",,,,,,,,,,,,,,,"4264046","Sickle cell-hemoglobin E disease",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555939","ERBB2 NM_004448.3:c.962A>G","C155308","A nucleotide substitution at position 962 of the coding sequence of the ERBB2 gene where adenine has been mutated to guanine.","ERBB2 NM_004448.3:c.962A>G | ERBB2 c.962A>G | HER-2 c.962A>G | HER-2/neu c.962A>G | HER2 c.962A>G | NEU c.962A>G | NM_004448.3:c.962A>G | v-erb-b2 Erythroblastic Leukemia Viral Oncogene Homolog 2, Neuro/Glioblastoma Derived Oncogene Homolog (Avian) c.962A>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555940","ERBB2 NP_004439.2:p.E321G","C155309","A change in the amino acid residue at position 321 in the receptor tyrosine-protein kinase erbB-2 protein where glutamic acid has been replaced by glycine.","ERBB2 NP_004439.2:p.E321G | ERBB2 E321G | ERBB2 Glu321Gly | ERBB2 NP_004439.2:p.Glu321Gly | ERBB2 p.E321G | ERBB2 p.Glu321Gly | NP_004439.2:p.E321G | NP_004439.2:p.Glu321Gly | Proto-Oncogene Neu E321G | Proto-Oncogene Neu Glu321Gly | Receptor Tyrosine-Protein Kinase erbB-2 E321G | Receptor Tyrosine-Protein Kinase erbB-2 Glu321Gly | Tyrosine Kinase-Type Cell Surface Receptor HER2 E321G | Tyrosine Kinase-Type Cell Surface Receptor HER2 Glu321Gly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555943","Advanced Cutaneous Melanoma of the Extremity","C155311","Cutaneous melanoma of the upper or lower extremity that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Cutaneous Melanoma of the Extremity | Advanced Extremity Melanoma | Advanced Melanoma of the Extremity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555367","Concentrated Solution Dosage Form Category","C154437","A type of liquid pharmaceutical dose form consisting of a concentrated preparation that must be diluted before administration.","Concentrated Solution Dosage Form Category | Concentrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555368","Cream Dosage Form Category","C154438","A type of semi-solid pharmaceutical dose form consisting of an oil-in-water or water-in-oil emulsion.","Cream Dosage Form Category | Cream",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278777","Low-LET Cobalt-60 Gamma Ray Therapy","C15443","No value exists.","Low-LET Cobalt-60 Gamma Ray Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555365","Bosutinib Monohydrate","C154440","The monohydrate form of bosutinib, a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype.","Bosutinib Monohydrate | 3-Quinolinecarbonitrile, 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-, Hydrate (1:1) | BOSUTINIB MONOHYDRATE | Bosulif | SKI-606 Monohydrate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555366","Resectable Pleural Malignant Mesothelioma","C154441","Malignant mesothelioma of the pleura that is amenable to surgical resection.","Resectable Pleural Malignant Mesothelioma | Resectable Malignant Pleural Mesothelioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555371","Resectable Malignant Mesothelioma","C154442","Malignant mesothelioma that is amenable to surgical resection.","Resectable Malignant Mesothelioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555372","Unresectable Malignant Mesothelioma","C154443","Malignant mesothelioma that is not amenable to surgical resection.","Unresectable Malignant Mesothelioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555369","Unresectable Pleural Malignant Mesothelioma","C154444","Malignant mesothelioma of the pleura that is not amenable to surgical resection.","Unresectable Pleural Malignant Mesothelioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552157","Hydrocortisone Sodium Succinate/Aluminum Phosphate Gel","C150398","A gel composed of the sodium succinate form of the glucocorticoid hydrocortisone mixed with aluminum phosphate, with potential protective activity. Upon oral administration of the hydrocortisone sodium succinate/aluminum phosphate gel, the gel forms a layer over the esophageal mucosa, which may restore and protect the esophageal membrane against damage. Hydrocortisone exerts anti-inflammatory effects locally, may reduce or prevent infection, may reduce the formation of connective tissue in order to prevent postoperative esophageal stenosis and stricture, and may reduce symptoms of dysphagia or choking, after endoscopic submucosal dissection (ESD). The aluminum phosphate acts as a buffer and may protect the local mucosal membrane from the acidic environment.","Hydrocortisone Sodium Succinate/Aluminum Phosphate Gel | Hydrocortisone Sodium Succinate Mixed with Aluminum Phosphate Gel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552790","Rising From Floor - Wear Orthoses","C151073","Rising From Floor Test (Rising From Floor) Did subject wear orthoses?","Rising From Floor - Wear Orthoses | RISEF1-Wear Orthoses | RISEF103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552791","T25FW - Did Patient Wear AFO","C151074","Timed 25-Foot Walk (T25FW) Did patient wear an AFO?","T25FW - Did Patient Wear AFO | T25FW1-Did Patient Wear AFO | T25FW103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552792","T25FW - Was Assistive Device Used","C151075","Timed 25-Foot Walk (T25FW) Was assistive device used?","T25FW - Was Assistive Device Used | T25FW1-Was Assistive Device Used | T25FW104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552793","FACT-C Version 4 - I Have a Lack of Energy","C151076","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Physical Well-Being: I have a lack of energy.","FACT-C Version 4 - I Have a Lack of Energy | FAC008-I Have a Lack of Energy | FAC00801",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552794","FACT-C Version 4 - I Have Nausea","C151077","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Physical Well-Being: I have nausea.","FACT-C Version 4 - I Have Nausea | FAC008-I Have Nausea | FAC00802",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552795","FACT-C Version 4 - Trouble Meeting Needs of Family","C151078","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Physical Well-Being: Because of my physical condition, I have trouble meeting the needs of my family.","FACT-C Version 4 - Trouble Meeting Needs of Family | FAC008-Trouble Meeting Needs of Family | FAC00803",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552796","FACT-C Version 4 - I Have Pain","C151079","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Physical Well-Being: I have pain.","FACT-C Version 4 - I Have Pain | FAC008-I Have Pain | FAC00804",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552797","FACT-C Version 4 - Bothered by Treatment Side Effect","C151080","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Physical Well-Being: I am bothered by side effects of treatment.","FACT-C Version 4 - Bothered by Treatment Side Effect | FAC008-Bothered by Treatment Side Effect | FAC00805",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552799","FACT-C Version 4 - I Am Forced to Spend Time in Bed","C151082","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Physical Well-Being: I am forced to spend time in bed.","FACT-C Version 4 - I Am Forced to Spend Time in Bed | FAC008-I Am Forced to Spend Time in Bed | FAC00807",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552800","FACT-C Version 4 - I Feel Close to My Friends","C151083","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Social/Family Well-Being: I feel close to my friends.","FACT-C Version 4 - I Feel Close to My Friends | FAC008-I Feel Close to My Friends | FAC00808",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552801","FACT-C Version 4 - Get Emotional Support From Family","C151084","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Social/Family Well-Being: I get emotional support from my family.","FACT-C Version 4 - Get Emotional Support From Family | FAC008-Get Emotional Support From Family | FAC00809",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552802","FACT-C Version 4 - I Get Support From My Friends","C151085","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Social/Family Well-Being: I get support from my friends.","FACT-C Version 4 - I Get Support From My Friends | FAC008-I Get Support From My Friends | FAC00810",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552243","Copper Cu-64-DOTA-alendronate","C150429","A radioconjugate containing the biphosphonate alendronate conjugated with the bifunctional, macrocyclic chelating agent 1,4,7,10-tetra-azacyclododecane-1,4,7,10-tetra-acetic acid (DOTA) and labeled with the radioisotope copper Cu 64, with potential use as an imaging agent for microcalcifications in mammary tumors using positron emission tomography (PET). Upon administration of the copper Cu-64 alendronate, the alendronate moiety targets and binds to hydroxyapatite crystals found in malignant tumors. Upon binding and PET imaging, the radioisotope moiety is detected, thereby allowing differentiation between malignant tumors, benign tumors and normal tissue, as the highest uptake of 64Cu-DOTA-alendronate occurs in malignant tumors while the lowest uptake occurs in benign tumors and normal mammary tissue.","Copper Cu-64-DOTA-alendronate | 64Cu-DOTA-alendronate | [64Cu]-DOTA-alendronate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552242","Radgocitabine Hydrochloride","C150430","The hydrochloride salt form of radgocitabine, an analogue of the nucleoside deoxycytidine with potential antineoplastic activity. Upon administration, radgocitabine is incorporated into DNA and directly inhibits the activity of DNA polymerase, which may result in inhibition of DNA replication and cell cycle arrest in the S and G2/M phases, DNA fragmentation, and tumor cell apoptosis.","Radgocitabine Hydrochloride | 2'-Cyano-2'-deoxy-1-(beta-D-arabinofuranosyl)cytosine Monohydrochloride | CNDAC Hydrochloride | Deoxycytidine Analogue TAS-109 Hydrochloride | RADGOCITABINE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552198","Personalized Synthetic Long Peptide Vaccine","C150471","A personalized peptide vaccine consisting of synthetic long peptides (SLPs), ranging from 20-35 amino acids in size, that are derived from two or more of the patient's tumor-specific mutant antigens (TSMAs), with potential immunostimulatory and antitumor activities. A patient's tumor is isolated, TSMAs are identified, assessed and prioritized, and two or more TSMAs are selected to be further processed into SLPs. Upon administration, personalized SLP vaccine may stimulate the host immune system to mount a cytotoxic T-cell lymphocyte (CTL)-mediated immune response against the TSMAs expressed by the tumor cells.","Personalized Synthetic Long Peptide Vaccine | Personalized SLP Vaccine | TSMA-based SLP Vaccine | TSMA-based Synthetic Long Peptide Vaccine | Tumor Specific Mutant Antigen-based Synthetic Long Peptide Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553032","FACT-BRM Version 4 - I Am Bothered by the Chills","C151187","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Additional Concerns-Physical: I am bothered by the chills.","FACT-BRM Version 4 - I Am Bothered by the Chills | FAC062-I Am Bothered by the Chills | FAC06232",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553033","FACT-BRM Version 4 - I Am Bothered by Fevers","C151188","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Additional Concerns-Physical: I am bothered by fevers (episodes of high body temperature).","FACT-BRM Version 4 - I Am Bothered by Fevers | FAC062-I Am Bothered by Fevers | FAC06233",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553034","FACT-BRM Version 4 - I Am Bothered by Sweating","C151189","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Additional Concerns-Physical: I am bothered by sweating.","FACT-BRM Version 4 - I Am Bothered by Sweating | FAC062-I Am Bothered by Sweating | FAC06234",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553035","FACT-BRM Version 4 - I Have Trouble Concentrating","C151190","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Additional Concerns-Mental: I have trouble concentrating.","FACT-BRM Version 4 - I Have Trouble Concentrating | FAC062-I Have Trouble Concentrating | FAC06235",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553036","FACT-BRM Version 4 - I Have Trouble Remembering Things","C151191","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Additional Concerns-Mental: I have trouble remembering things.","FACT-BRM Version 4 - I Have Trouble Remembering Things | FAC062-I Have Trouble Remembering Things | FAC06236",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553037","FACT-BRM Version 4 - I Get Depressed Easily","C151192","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Additional Concerns-Mental: I get depressed easily.","FACT-BRM Version 4 - I Get Depressed Easily | FAC062-I Get Depressed Easily | FAC06237",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553038","FACT-BRM Version 4 - I Get Annoyed Easily","C151193","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Additional Concerns-Mental: I get annoyed easily.","FACT-BRM Version 4 - I Get Annoyed Easily | FAC062-I Get Annoyed Easily | FAC06238",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552911","FACT-BRM Version 4 - I Have Emotional Ups and Downs","C151194","Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Additional Concerns-Mental: I have emotional ups and downs.","FACT-BRM Version 4 - I Have Emotional Ups and Downs | FAC062-I Have Emotional Ups and Downs | FAC06239",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552913","FACT/GOG-NTX Version 4 - I Have a Lack of Energy","C151196","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Physical Well-Being: I have a lack of energy.","FACT/GOG-NTX Version 4 - I Have a Lack of Energy | FAC057-I Have a Lack of Energy | FAC05701",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552914","FACT/GOG-NTX Version 4 - I Have Nausea","C151197","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Physical Well-Being: I have nausea.","FACT/GOG-NTX Version 4 - I Have Nausea | FAC057-I Have Nausea | FAC05702",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555370","Rivipansel Sodium","C154445","No value exists.","Rivipansel Sodium | PF-06460031-02 | RIVIPANSEL SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555375","CDISC Clinical Classification CDRS-R Test Name Terminology","C154446","Test names of clinical classification questions associated with the Children's Depression Rating Scale, Revised (CDRS-R) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification CDRS-R Test Name Terminology | CC-CDRS-R TEST | CDRS1TN | Children's Depression Rating Scale, Revised Clinical Classification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555376","CDISC Clinical Classification CDRS-R Test Code Terminology","C154447","Test codes of clinical classification questions associated with the Children's Depression Rating Scale, Revised (CDRS-R) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification CDRS-R Test Code Terminology | CC-CDRS-R TESTCD | CDRS1TC | Children's Depression Rating Scale, Revised Clinical Classification Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555373","CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology","C154448","Test names of clinical classification questions associated with the Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology | CC-UHDRS 1999 Version TEST | UHDR1TN | Unified Huntington's Disease Rating Scale '99 Clinical Classification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555374","CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology","C154449","Test codes of clinical classification questions associated with the Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology | CC-UHDRS 1999 Version TESTCD | UHDR1TC | Unified Huntington's Disease Rating Scale '99 Clinical Classification Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278778","Low-LET Photon Therapy","C15444","No value exists.","Low-LET Photon Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555379","CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology","C154450","Test names of questionnaire questions associated with the Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology | FAC100TN | Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank Questionnaire Test Name | QS-FACIT-Dyspnea Scale 33 Item Bank Version TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555426","Histone 2, H3d Gene","C154648","Human H3C13 wild-type allele is located in the vicinity of 1q21.2 and is approximately 1 kb in length. This allele, which encodes histone H3.2 protein, plays a role in the incorporation of DNA into nucleosomes.","H3C13 wt Allele | H3 Clustered Histone 13 wt Allele | HIST2H3D | Histone 2, H3d Gene | Histone Cluster 2 H3 Family Member D Gene | Histone Cluster 2, H3d Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555431","H2AB1 Gene","C154649","This gene plays a role in DNA compaction, gene transcription and mRNA processing.","H2AB1 Gene | H2A.B Variant Histone 1 Gene | H2AB1 | H2AFB1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555432","H2A Histone Family, Member B1 Gene","C154650","Human H2AB1 wild-type allele is located in the vicinity of Xq28 and is approximately 1 kb in length. This allele, which encodes histone H2A-Bbd type 1 protein, is involved in the modulation of DNA compaction, which regulates gene transcription and mRNA processing.","H2AB1 wt Allele | H2A Histone Family Member B1 Gene | H2A Histone Family, Member B1 Gene | H2A.B | H2A.B Variant Histone 1 wt Allele | H2A.Bbd | H2AFB1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555429","Histone H2A-Bbd Type 1","C154651","Histone H2A-Bbd type 1 (115 aa, ~13 kDa) is encoded by the human H2AB1 gene. This protein plays a role in chromatin structures that are associated with active gene expression.","Histone H2A-Bbd Type 1 | H2A Barr Body-Deficient | H2A.B | H2A.Bbd | H2AB1 | H2AFB1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555430","H2AB2 Gene","C154652","This gene plays a role in chromatin compaction, transcriptional activation and mRNA processing.","H2AB2 Gene | H2A.B Variant Histone 2 Gene | H2AB2 | H2AFB2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552803","FACT-C Version 4 - My Family Has Accepted My Illness","C151086","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Social/Family Well-Being: My family has accepted my illness.","FACT-C Version 4 - My Family Has Accepted My Illness | FAC008-My Family Has Accepted My Illness | FAC00811",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552804","FACT-C Version 4 - Satisfied Communication Illness","C151087","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Social/Family Well-Being: I am satisfied with family communication about my illness.","FACT-C Version 4 - Satisfied Communication Illness | FAC008-Satisfied Communication Illness | FAC00812",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552805","FACT-C Version 4 - I Feel Close to My Partner","C151088","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Social/Family Well-Being: I feel close to my partner (or the person who is my main support).","FACT-C Version 4 - I Feel Close to My Partner | FAC008-I Feel Close to My Partner | FAC00813",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552806","FACT-C Version 4 - I Am Satisfied With My Sex Life","C151089","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Social/Family Well-Being: I am satisfied with my sex life.","FACT-C Version 4 - I Am Satisfied With My Sex Life | FAC008-I Am Satisfied With My Sex Life | FAC00814",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552337","TAM/c-Met Inhibitor RXDX-106","C150585","An orally available and selective inhibitor of the receptor tyrosine kinase (RTK) activity of both hepatocyte growth factor receptor (c-Met; HGFR) and receptors in the TYRO3, AXL, and MER (TAM) family, with potential immunomodulating and antineoplastic activities. Upon oral administration of TAM/c-Met inhibitor RXDX-106, this agent selectively targets and binds to TYRO3, AXL, MER and c-Met, and prevents their RTK activity. This blocks TYRO3/AXL/MER/c-Met-mediated signal transduction pathways, and inhibits the proliferation and migration of TYRO3-, AXL-, MER- and c-Met-overexpressing tumor cells. Inhibition of the TAM family in the tumor microenvironment (TME) activates the immune system in the TME, reverses TAM mediated immunosuppression and enhances the anti-tumor immune response, which lead to immune-mediated tumor cell killing. TYRO3, AXL and MER, members of the TAM family of RTKs, are overexpressed in many tumor cell types. TAMs play key roles in tumor cell proliferation, survival, invasion, angiogenesis and metastasis, and their expression is associated with drug resistance and poor prognosis. c-Met, also overexpressed in many tumor cell types, plays a critical role in tumor formation, proliferation, invasion and metastasis, and contributes to tumor resistance. In the TME, TAM expression on immune cells contributes to tumor cell evasion of immune surveillance and to the negative regulation of immune responses.","TAM/c-Met Inhibitor RXDX-106 | CEP 40783 | CEP-40783 | CEP40783 | N-[4-(6,7-Dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-3-(4-fluorophenyl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide | RXDX 106 | RXDX-106 | RXDX106 | TYRO3/AXL/MER/c-Met Inhibitor RXDX-106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552332","CAR T-Cells AMG 119","C150586","A preparation of T-lymphocytes that are genetically engineered to express a chimeric antigen receptor (CAR) that targets an as of yet unidentified tumor-associated antigen (TAA), with potential immunomodulatory and antineoplastic activities. Upon administration of the CAR T-cells AMG 119, the T-cells target, bind to and induce selective cytotoxicity in tumor cells expressing the TAA.","CAR T-Cells AMG 119 | AMG 119 | AMG 119 CAR-T Cells | AMG-119 | AMG119 | CAR-T Cells AMG 119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552334","Non-IgM Monoclonal Gammopathy of Undetermined Significance","C150588","Monoclonal gammopathy of undetermined significance defined by the presence in the serum of an IgG, IgA, or (rarely) IgD paraprotein at a concentration of less than 30g/L; clonal bone marrow plasma cells less than 10%; and absence of end-organ damage such as hypercalcemia, renal insufficiency, anemia, bone marrow lesions, and amyloidosis attributable to the plasma cell proliferative disorder. The risk of progression to plasma cell myeloma, light-chain amyloidosis, or a related disorder is 1% per year. (WHO 2017)","Non-IgM Monoclonal Gammopathy of Undetermined Significance | Non-IgM MGUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552333","Testicular Follicular Lymphoma","C150589","A distinctive variant of follicular lymphoma arising from the testis. It has been reported with higher frequency in children, but is also seen rarely in adults. It differs biologically from nodal follicular lymphoma because it lacks evidence of the BCL2 translocation. It is usually of high cytological grade, usually grade 3A, but has a good prognosis, even without additional therapy beyond surgical excision. (WHO 2017)","Testicular Follicular Lymphoma | PFLT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552239","CD79A Gene Mutation","C150433","A change in the nucleotide sequence of the CD79A gene.","CD79A Gene Mutation | CD79a Molecule Gene Mutation | CD79a Molecule, Immunoglobulin-Associated Alpha Gene Mutation | IGA Gene Mutation | MB-1 Gene Mutation | MB1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552984","FACT-Taxane Version 4 - Content With Quality of My Life","C151139","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Functional Well-Being: I am content with the quality of my life right now.","FACT-Taxane Version 4 - Content With Quality of My Life | FAC063-Content With Quality of My Life | FAC06327",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552985","FACT-Taxane Version 4 - Numbness or Tingling in My Hands","C151140","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: I have numbness or tingling in my hands.","FACT-Taxane Version 4 - Numbness or Tingling in My Hands | FAC063-Numbness or Tingling in My Hands | FAC06328",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552986","FACT-Taxane Version 4 - Numbness or Tingling in My Feet","C151141","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: I have numbness or tingling in my feet.","FACT-Taxane Version 4 - Numbness or Tingling in My Feet | FAC063-Numbness or Tingling in My Feet | FAC06329",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552915","FACT/GOG-NTX Version 4 - Trouble Meeting Needs of Family","C151198","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Physical Well-Being: Because of my physical condition, I have trouble meeting the needs of my family.","FACT/GOG-NTX Version 4 - Trouble Meeting Needs of Family | FAC057-Trouble Meeting Needs of Family | FAC05703",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552916","FACT/GOG-NTX Version 4 - I Have Pain","C151199","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Physical Well-Being: I have pain.","FACT/GOG-NTX Version 4 - I Have Pain | FAC057-I Have Pain | FAC05704",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0243019","Radioimmunoconjugate","C1511","Monoclonal antibodies (MoAb) conjugated with radioisotopes, i.e., I-131, Y-90, T-99, or In-111. Using radioimmunoconjugates in radiotherapy or radioimaging has the advantage of targeting cells carrying specific antigens, thereby limiting toxic effects on normal cells. Tumor eradication can be achieved by either the antibody-mediated immune response or by only the cytotoxic activity of the radiation.","Radioimmunoconjugate | Radiolabeled Antibodies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552917","FACT/GOG-NTX Version 4 - Bothered by Treatment Side Effect","C151200","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Physical Well-Being: I am bothered by side effects of treatment.","FACT/GOG-NTX Version 4 - Bothered by Treatment Side Effect | FAC057-Bothered by Treatment Side Effect | FAC05705",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1541294","carboplatin/cetuximab","C150687","A regimen consisting of carboplatin and cetuximab that can be used for the treatment of head and neck cancer.","Carboplatin/Cetuximab Regimen | Carboplatin-Cetuximab | Carboplatin-Cetuximab Regimen | Carboplatin/Cetuximab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0200262","Medical Evaluation of Speech, Language, and Hearing Problems","C150688","A medical evaluation of speech, language, and hearing problems.","Medical Evaluation of Speech, Language, and Hearing Problems | ",,,,,,,,,,,,,,,"4299235","Medical evaluation of speech, language and hearing problem",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552493","Carboplatin-Docetaxel-Cetuximab","C150690","A regimen consisting of carboplatin, docetaxel and cetuximab that can be used for the treatment of head and neck cancer and non-small cell lung cancer (NSCLC).","Carboplatin/Cetuximab/Docetaxel Regimen | Carboplatin and Docetaxel (DCb) and Cetuximab | Carboplatin-Docetaxel-Cetuximab | Carboplatin-Docetaxel-Cetuximab Regimen | Carboplatin/Docetaxel/Cetuximab | Carboplatin/Docetaxel/Cetuximab Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552494","Tumors Derived from Langerhans Cells","C150692","This category includes two main sub-groups, according to the degree of cytological atypia and clinical aggressiveness: Langerhans cell histiocytosis and Langerhans cell sarcoma. (WHO 2017)","Tumors Derived from Langerhans Cells | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555435","H2A Histone Family, Member B2 Gene","C154653","Human H2AB2 wild-type allele is located in the vicinity of Xq28 and is approximately 1 kb in length. This allele, which encodes histone H2A-Bbd type 2/3 protein, plays a role in the modulation of both gene transcription and mRNA processing.","H2AB2 wt Allele | H2A Histone Family Member B2 Gene | H2A Histone Family, Member B2 Gene | H2A.B Variant Histone 2 wt Allele | H2A.Bbd | H2AFB2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555436","H2AB3 Gene","C154654","This gene plays a role in the modulation of chromatin structure.","H2AB3 Gene | H2A.B Variant Histone 3 Gene | H2AB3 | H2AFB3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555433","H2A Histone Family Member B3 wt Allele","C154655","Human H2AB3 wild-type allele is located in the vicinity of Xq28 and is approximately 1 kb in length. This allele, which encodes histone H2A-Bbd type 2/3 protein, is involved in the modulation of DNA compaction, which regulates gene transcription and mRNA processing.","H2AB3 wt Allele | H2A Histone Family Member B3 Gene | H2A Histone Family Member B3 wt Allele | H2A Histone Family, Member B3 Gene | H2A.B Variant Histone 3 Gene | H2A.B Variant Histone 3 wt Allele | H2ABBD | H2AFB | H2AFB3 | Histone Variant H2A, Barr-Body Deficient Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555438","MACROH2A2 Gene","C154657","This gene plays a role in the formation of chromatin structures that repress gene transcription.","MACROH2A2 Gene | H2AFY2 | MACROH2A2 | MacroH2A.1 Histone Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555439","H2A Histone Family, Member Y2 Gene","C154658","Human MACROH2A2 wild-type allele is located in the vicinity of 10q22.1 and is approximately 60 kb in length. This allele, which encodes core histone macro-H2A.2 protein, is involved in transcriptional repression.","MACROH2A2 wt Allele | H2A Histone Family Member Y2 Gene | H2A Histone Family, Member Y2 Gene | H2AFY2 | Macro H2A2 Gene | MacroH2A.1 Histone wt Allele | macroH2A2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555437","Core Histone Macro-H2A.2","C154659","Core histone macro-H2A.2 (372 aa, ~40 kDa) is encoded by the human MACROH2A2 gene. This protein plays a role in nucleosome formation and transcriptional repression.","Core Histone Macro-H2A.2 | Core Histone MacroH2A2.2 | H2A2.2 | H2AFY2 | Histone MacroH2A2 | MACROH2A2 | mH2A.2 | mH2A2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555440","Powder for Vaginal Solution Dosage Form","C154663","Solid preparation consisting of one or more powders, including freeze-dried powders, intended to be dissolved in the specified liquid to obtain a vaginal solution.","Powder for Vaginal Solution Dosage Form | Powder for vaginal solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556884","Infantile Apnea, AE","C154938","An adverse event in a newborn characterized by cessation of air flow.","Infantile Apnea, AE | Infantile Apnea | Infantile Apnea, Adverse Event | Infantile apnea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555627","Infant Irritability, AE","C154939","An adverse event in a newborn characterized by crying easily and difficulty consoling.","Infant Irritability, AE | Infant Irritability | Infant Irritability, Adverse Event | Infant irritability",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552328","ABBV 321","C150590","A antibody drug conjugate (ADC) consisting of serclutamab, an affinity-matured humanized monoclonal antibody directed against the epidermal growth factor receptor (EGFR) conjugated to a talirine, a cytotoxic, DNA minor groove crosslinking agent and pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon intravenous administration of serclutamab talirine, the serclutamab moiety targets and binds to EGFR on tumor cell surfaces. Following receptor internalization and lysosome-mediated cleavage, talirine is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase (RTK) that is overexpressed by a variety of cancers, plays a key role in tumor cell proliferation and survival.","Serclutamab Talirine | ABBV 321 | ABBV-321 | ABBV321 | ADC ABBV-321 | Anti-EGFR/PBD ADC ABBV-321 | SERCLUTAMAB TALIRINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552327","Recurrent Dedifferentiated Liposarcoma","C150592","The reemergence of dedifferentiated liposarcoma after a period of remission.","Recurrent Dedifferentiated Liposarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552330","Refractory Dedifferentiated Liposarcoma","C150593","Dedifferentiated liposarcoma that does not respond to treatment.","Refractory Dedifferentiated Liposarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552329","Refractory Liposarcoma","C150594","Liposarcoma that does not respond to treatment.","Refractory Liposarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552324","Metastatic Renal Cell Carcinoma","C150595","Renal cell carcinoma that has spread from the kidney to other anatomic sites.","Metastatic Renal Cell Carcinoma | Metastatic Renal Cell Cancer",,,,,,,,,,,,,,,"3661467","Metastatic renal cell carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552666","Gemcitabine-Releasing Intravesical System","C150807","A controlled-release intravesical system consisting of a small flexible tube-like device with a solid core composed of gemcitabine, a broad-spectrum antimetabolite and deoxycytidine analogue, with antineoplastic activity. Upon placement of the gemcitabine-releasing intravesical system (GemRIS) into the bladder, gemcitabine is gradually and continuously released from the system over an extended period of time before being removed from the bladder. Upon release, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA, resulting in premature termination of DNA replication and the induction of apoptosis of bladder tumor cells. In addition, dFdCDP inhibits ribonucleotide reductase (RNR) and reduces the deoxynucleotide pool available for DNA synthesis.","Gemcitabine-Releasing Intravesical System | GemRIS | TAR 200 | TAR-200",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552667","Magnetic Resonance-Guided Radiotherapy","C150808","A therapeutic procedure that utilizes magnetic resonance imaging for detailed anatomic visualization immediately before or during radiation treatment.","Magnetic Resonance-Guided Radiotherapy | MRGRT | MRgRT | Magnetic-Resonance Guided Radiotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552668","Synthetic Long HPV16 E6/E7 Peptides Vaccine ISA101b","C150809","A therapeutic peptide vaccine consisting of nine overlapping synthetic long peptides (SLPs), 25 to 32 amino acids in size, derived from the human papillomavirus (HPV) type 16 (HPV16) oncoprotein E6 and three SLPs, each 35 amino acids in size, derived from HPV16 E7, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the synthetic long HPV16 E6/E7 peptides vaccine ISA101b is taken up and the long peptides are proteolytically degraded to form shorter peptide epitopes by dendritic cells (DCs). The processed viral epitopes are presented by DCs, which stimulate the host immune system to mount helper T-cell and cytotoxic T-lymphocyte (CTL) responses against HPV16 E6/E7-expressing tumor cells. This results in the destruction of tumor cells and leads to decreased tumor growth. The HPV16 E6 and E7 oncoproteins are implicated in the tumorigenesis of a variety of cancers. The SLPs allow optimal presentation by antigen-presenting cells (APCs). Compared to ISA101, the E6 SLPs in ISA101b are identical, overlap by ten to eighteen residues and cover the complete sequence of HPV16 E6. However, ISA101 has four overlapping SLPs E7 peptides while ISA101b has three E7 SLPs, which leaves seven amino acids of the E7 SLPs uncovered in ISA101b but this modification is not likely to alter the immunogenicity of ISA101b.","Synthetic Long HPV16 E6/E7 Peptides Vaccine ISA101b | HPV16 E6/E7-SLP ISA101b | ISA 101b | ISA-101b | ISA101b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552571","CDISC SEND Null Flavor Reason Terminology","C150810","The terminology that includes concepts relevant to the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND) null flavor.","CDISC SEND Null Flavor Reason Terminology | NULLFLAV | Null Flavor Reason | SEND-NULLFLAV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552987","FACT-Taxane Version 4 - I Feel Discomfort in My Hands","C151142","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: I feel discomfort in my hands.","FACT-Taxane Version 4 - I Feel Discomfort in My Hands | FAC063-I Feel Discomfort in My Hands | FAC06330",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552988","FACT-Taxane Version 4 - I Feel Discomfort in My Feet","C151143","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: I feel discomfort in my feet.","FACT-Taxane Version 4 - I Feel Discomfort in My Feet | FAC063-I Feel Discomfort in My Feet | FAC06331",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552989","FACT-Taxane Version 4 - Have Joint Pain or Muscle Cramps","C151144","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: I have joint pain or muscle cramps.","FACT-Taxane Version 4 - Have Joint Pain or Muscle Cramps | FAC063-Have Joint Pain or Muscle Cramps | FAC06332",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552991","FACT-Taxane Version 4 - I Have Trouble Hearing","C151146","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: I have trouble hearing.","FACT-Taxane Version 4 - I Have Trouble Hearing | FAC063-I Have Trouble Hearing | FAC06334",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552992","FACT-Taxane Version 4 - Get Ringing or Buzzing in My Ears","C151147","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: I get a ringing or buzzing in my ears.","FACT-Taxane Version 4 - Get Ringing or Buzzing in My Ears | FAC063-Get Ringing or Buzzing in My Ears | FAC06335",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552993","FACT-Taxane Version 4 - I Have Trouble Buttoning Buttons","C151148","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: I have trouble buttoning buttons.","FACT-Taxane Version 4 - I Have Trouble Buttoning Buttons | FAC063-I Have Trouble Buttoning Buttons | FAC06336",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552994","FACT-Taxane Version 4 - Trouble Feeling Shape of Objects","C151149","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: I have trouble feeling the shape of small objects when they are in my hand.","FACT-Taxane Version 4 - Trouble Feeling Shape of Objects | FAC063-Trouble Feeling Shape of Objects | FAC06337",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552995","FACT-Taxane Version 4 - I Have Trouble Walking","C151150","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: I have trouble walking.","FACT-Taxane Version 4 - I Have Trouble Walking | FAC063-I Have Trouble Walking | FAC06338",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552996","FACT-Taxane Version 4 - I Feel Bloated","C151151","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: I feel bloated.","FACT-Taxane Version 4 - I Feel Bloated | FAC063-I Feel Bloated | FAC06339",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552997","FACT-Taxane Version 4 - My Hands Are Swollen","C151152","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: My hands are swollen.","FACT-Taxane Version 4 - My Hands Are Swollen | FAC063-My Hands Are Swollen | FAC06340",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552998","FACT-Taxane Version 4 - My Legs or Feet Are Swollen","C151153","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: My legs or feet are swollen.","FACT-Taxane Version 4 - My Legs or Feet Are Swollen | FAC063-My Legs or Feet Are Swollen | FAC06341",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552999","FACT-Taxane Version 4 - I Have Pain in My Fingertips","C151154","Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: I have pain in my fingertips.","FACT-Taxane Version 4 - I Have Pain in My Fingertips | FAC063-I Have Pain in My Fingertips | FAC06342",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552497","Autologous EGFR-specific CAR-T-Cells Expressing Anti-PD-1/CTLA-4 Antibodies","C150695","A preparation of autologous T-lymphocytes that have been activated and genetically modified to express immune checkpoint antibodies against the negative immunoregulatory receptors human cell surface receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), and are transduced with a gene encoding a chimeric antigen receptor (CAR) specific for the human tumor-associated antigen (TAA) epidermal growth factor receptor (EGFR), with potential immunomodulating and antineoplastic activities. After isolation, activation, transduction, expansion in culture and reintroduction into the patient, the T-cells in the autologous EGFR specific CAR-T-cells expressing anti-PD-1/CTLA4 antibodies  specifically target and kill EGFR-expressing tumor cells. The anti-PD-1 antibody secreted from the CAR-T cells binds to PD-1 expressed on T-cells and prevents the interaction of PD-1 with its ligand programmed cell death 1 ligand 1 (PD-L1, PD-1L1; CD274) expressed on cancer cells, which prevents PD-1-mediated signaling and T-cell exhaustion. The anti-CTLA4 expressed by the CAR-T cells targets and binds to CTLA4 expressed on T-cells, and inhibits the CTLA4-mediated downregulation of T-cell activation. Both antibodies enhance T-cell activation, improve immunosuppression in the tumor microenvironment (TME) and improve the T-cell mediated immune response against and toxicity in EGFR-expressing tumor cells. Both PD-1 and CTLA-4 negatively regulate T-cell activation and proliferation, and play a key role in immunosuppression within the TME. EGFR, a receptor tyrosine kinase that is overexpressed in a variety of cancer cell types, plays a key role in tumor cell proliferation.","Autologous EGFR-specific CAR-T-Cells Expressing Anti-PD-1/CTLA-4 Antibodies | Autologous Anti-CTLA-4/PD-1 Expressing EGFR-CAR-T Cells | Autologous Anti-CTLA-4/PD-1-expressing EGFR-CAR-T | Autologous Anti-PD-1/CTLA4-targeting Antibodies-expressing EGFR-specific CAR-T Cells | Autologous CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555630","Persistent Pulmonary Hypertension of the Newborn, AE","C154940","An adverse event in a newborn characterized by elevated pulmonary vascular pressure in a neonate.","Persistent Pulmonary Hypertension of the Newborn, AE | Persistent Pulmonary Hypertension of the Newborn | Persistent Pulmonary Hypertension of the Newborn, Adverse Event | Persistent pulmonary hypertension of the newborn",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556882","Neonatal Fever, AE","C154941","An adverse event in a newborn characterized by elevation of body temperature above normal due to the production of more heat than the body is able to dissipate.","Neonatal Fever, AE | Fever Neonatal | Fever neonatal | Neonatal Fever, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556872","Infantile Vomiting, AE","C154942","An adverse event in a newborn characterized by expulsion of the contents of the stomach through the mouth.","Infantile Vomiting, AE | Infantile Vomiting | Infantile Vomiting, Adverse Event | Infantile vomiting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555629","Neonatal Gastrointestinal Bleeding, AE","C154943","An adverse event in a newborn characterized by hemorrhage originating at any site located within the gastrointestinal tract.","Neonatal Gastrointestinal Bleeding, AE | Gastro-intestinal Bleeding Neonatal | Gastrointestinal bleeding neonatal | Neonatal Gastrointestinal Bleeding, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555633","Feeding Intolerance, AE","C154944","An adverse event in a newborn characterized by inability to achieve a full feeding volume.","Feeding Intolerance, AE | Feeding Intolerance | Feeding Intolerance, Adverse Event | Feeding intolerance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555634","Hypoxic Ischemic Encephalopathy, AE","C154945","An adverse event in a newborn characterized by injury to the central nervous system that occurs when there is insufficient delivery of oxygen to all or part of the brain.","Hypoxic Ischemic Encephalopathy, AE | HIE, AE | Hypoxic Ischemic Encephalopathy | Hypoxic Ischemic Encephalopathy, Adverse Event | Hypoxic-ischemic encephalopathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555631","Neonatal Constipation, AE","C154946","An adverse event in a newborn characterized by irregular and infrequent or difficult evacuation of the bowels.","Neonatal Constipation, AE | Constipation Neonatal | Constipation neonatal | Neonatal Constipation, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555632","Neonatal Administration Site Complication, AE","C154947","An adverse event in a newborn characterized by local irritation or a complication at the administration site of a drug.","Neonatal Administration Site Complication, AE | Administration Site Complication Neonatal | Administration site reaction neonatal | Neonatal Administration Site Complication, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555636","Neonatal Tachyarrhythmia, AE","C154948","An adverse event in a newborn characterized by non-sinus rhythm with an abnormally high heart rate for age.","Neonatal Tachyarrhythmia, AE | Neonatal Tachyarrhythmia | Neonatal Tachyarrhythmia, Adverse Event | Neonatal tachyarrhythmia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555637","Neonatal Bradyarrhythmia, AE","C154949","An adverse event in a newborn characterized by non-sinus rhythm with an abnormally low heart rate for age.","Neonatal Bradyarrhythmia, AE | Neonatal Bradyarrhythmia | Neonatal Bradyarrhythmia, Adverse Event | Neonatal bradyarrhythmia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279757","Fatigue Assessment and Management","C15494","No value exists.","Fatigue Assessment and Management | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555635","Neonatal Respiratory Distress Syndrome, AE","C154950","An adverse event in a newborn characterized by progressive alveolar atelectasis from birth due to an abnormality of synthesis, function or metabolism of surfactant, characterized by respiratory failure and an abnormal chest radiograph showing diffuse reticulogranular densities and air bronchograms.","Neonatal Respiratory Distress Syndrome, AE | Neonatal Respiratory Distress Syndrome | Neonatal Respiratory Distress Syndrome, Adverse Event | Neonatal respiratory distress syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556519","Tokelau Language","C154169","A Polynesian language spoken in Tokelau and on Swains Island in American Samoa.","Tokelau Language | TKL | Tokelau",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0205991","Active Immunization","C15416","Deliberate stimulation of a host's immune response via administration of antigens or immunologic adjuvants.","Active Immunization | ",,,,,,,,,,,,,,,"4144375","Active immunization",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574602","Tlingit Language","C154170","A Na-Dene language spoken by the Tlingit people of Southeast Alaska and Western Canada.","Tlingit Language | TLI | Tlingit",,,,,,,,,,,,,,,"4177449","Tlingit language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555209","Tamasheq Language","C154171","An Afro-Asiatic language spoken by the Tuareg people, principally in the Timbuktu area of Mali.","Tamasheq Language | TMH | Tamashek | Tamasheq",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552572","CDISC SDTM Other Disposition Event Response Terminology","C150811","Terminology associated with the other event codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Other Disposition Event Response Terminology | OTHEVENT | Other Disposition Event Response | SDTM-OTHEVENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552573","CDISC SDTM CDAD Findings About Test Code Terminology","C150812","Terminology associated with the Clostridium difficile-associated diarrhea findings about test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM CDAD Findings About Test Code Terminology | CDAD Findings About Test Code | CDFATSCD | SDTM-CDFATSCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552574","CDISC SDTM CDAD Findings About Test Name Terminology","C150813","Terminology associated with the Clostridium difficile-associated diarrhea findings about test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM CDAD Findings About Test Name Terminology | CDAD Findings About Test Name | CDFATS | SDTM-CDFATS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552152","HHV8-Associated Lymphoproliferative Disorder","C150399","A lymphoproliferative disorder caused by the human herpesvirus 8 (HHV8). This category includes the following: HHV8-positive multicentric Castleman disease; HHV8-positive diffuse large B-cell lymphoma, not otherwise specified; primary effusion lymphoma; and germinotropic lymphoproliferative disorders.","HHV8-Related Lymphoproliferative Disorder | HHV8-Associated Lymphoproliferative Disorder | KSHV/HHV8-Related Lymphoproliferative Disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552151","Oral Pancreatic Cancer Vaccine V3-P","C150400","An orally bioavailable, therapeutic cancer vaccine composed of the carbohydrate antigen sialyl-Lewis A (carbohydrate antigen 19-9; CA19.9; CA19-9) that is derived from pooled blood of pancreatic cancer patients, with potential immunomodulating activity. Upon oral administration of the oral pancreatic cancer vaccine V3-P, the CA19.9 antigens may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL)-mediated immune response against pancreatic cancer cells expressing the CA19.9 antigen. CA19.9 is overexpressed on a number of different tumor cell types and plays a key role in tumor cell survival and metastasis.","Oral Pancreatic Cancer Vaccine V3-P | Cancer Vaccine V3-P | Oral Tableted Therapeutic Vaccine V3-P | V3 P | V3-P | V3-P Cancer Vaccine | V3P",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552154","ssRNA-based Immunomodulator CV8102","C150401","A 547 nucleotide (nt), noncoding, uncapped single-stranded RNA (ssRNA) containing several polyU-repeats complexed with a polymeric carrier formed by disulfide-crosslinked cationic peptides, with potential immunostimulating activity. Upon intratumoral injection, the ssRNA in CV8102 activates toll-like receptors (TLRs) and retinoic acid-inducible gene I (RIG I; RIG-I; DDX58). This stimulates a T-helper type 1 cell (Th1) response, the production of a variety of pro-inflammatory cytokines and chemokines, and activates a systemic cytotoxic-T-lymphocyte (CTL)-mediated immune response against the tumor cells when simultaneously exposed to tumor-associated antigens (TAAs). The cationic carrier peptides protect the ssRNA from RNase degradation.","ssRNA-based Immunomodulator CV8102 | CV 8102 | CV-8102 | CV8102 | RNA-based Adjuvant CV8102 | RNAdjuvant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1836485","CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2A2 (disorder)","C150646","No value exists.","Charcot-Marie-Tooth Disease Type 2A2A | CMT2A2 | CMT2A2A | Charcot-Marie-Tooth Disease Type 2A2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552385","Charcot-Marie-Tooth Disease Type 2A2B","C150647","An autosomal recessive sub-type of Charcot-Marie-Tooth disease caused by compound heterozygous or homozygous mutation(s) in the MFN2 gene, encoding mitofusin-2. This condition is more severe and has an earlier onset as compared to Charcot-Marie-Tooth disease type 2A2A.","Charcot-Marie-Tooth Disease Type 2A2B | CMT2A2B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552373","Endoscopy Under Anesthesia","C150657","Any endoscopic procedure done while the patient is sedated.","Endoscopy Under Anesthesia | Examination Under Anesthesia with Endoscopy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552767","COWAT - Another Word That Begins With R","C150922","Controlled Oral Word Association Test (COWAT) Can you tell me another word that begins with R?","COWAT - Another Word That Begins With R | COWAT1-Another Word That Begins With R | COWAT101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552768","COWAT - Number Correct Words: C","C150923","Controlled Oral Word Association Test (COWAT) Number correct words: Now I'm going to give you another letter, and again, say all words beginning with that letter that you can think of. You will have a minute for each one. The first letter is C.","COWAT - Number Correct Words: C | COWAT1-Number Correct Words: C | COWAT102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552769","COWAT - Number Correct Words: F","C150924","Controlled Oral Word Association Test (COWAT) Number correct words: Now I am going to give another letter. Tell me as many words as you can that begin with F. Tell me as many words as quickly as you can that begin with F.","COWAT - Number Correct Words: F | COWAT1-Number Correct Words: F | COWAT103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552770","COWAT - Number Correct Words: L","C150925","Controlled Oral Word Association Test (COWAT) Number correct words: Now I am going to give another letter. Tell me as many words as you can that begin with L. Tell me as many words as quickly as you can that begin with L.","COWAT - Number Correct Words: L | COWAT1-Number Correct Words: L | COWAT104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552771","ERT - Total Stimuli Expected","C150926","Emotion Recognition Test (ERT) Total number of stimuli (face images) expected to be administered in the task.","ERT - Total Stimuli Expected | EMO1-Total Stimuli Expected | EMO101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552772","ERT - Total Stimuli Administered","C150927","Emotion Recognition Test (ERT) Total number of stimuli (face images) actually administered in the task.","ERT - Total Stimuli Administered | EMO1-Total Stimuli Administered | EMO102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1063137","Tonga Language (Nyasa)","C154172","A Niger-Congo Bantu language spoken mainly in the Nkhata Bay District of Malawi.","Tonga Language (Nyasa) | TOG | Tonga | Tonga (Nyasa)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555207","Tonga Language (Tonga Islands)","C154173","An Austronesian language of the Polynesian branch spoken as a national language in Tonga.","Tonga Language (Tonga Islands) | TON | Tonga | Tonga (Tonga Islands)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555208","Tok Pisin Language","C154174","An English Creole language spoken as an official language in Papua New Guinea.","Tok Pisin Language | TPI | Tok Pisin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551944","Tsimshian Language","C154175","A dialect of the Tsimshian language spoken in northwestern British Columbia and southeastern Alaska.","Tsimshian Language | Coast Tsimshian | Sm'algyax | TSI | Tsimshian",,,,,,,,,,,,,,,"4182822","Tsimshian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574475","Tswana Language","C154176","A Niger-Congo Bantu language spoken in Southern Africa and as an official language of Botswana.","Tswana Language | TSN | Tswana",,,,,,,,,,,,,,,"4183789","Tswana language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574474","Tsonga Language","C154177","A Niger-Congo Bantu language spoken by the Tsonga people of southern Africa and native to Mozambique, South Africa, Swaziland, and Zimbabwe.","Tsonga Language | TSO | Tsonga | Xitsonga",,,,,,,,,,,,,,,"4177292","Tsonga language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574210","Turkmen Language","C154178","A Turkic language spoken as an official language of Turkmenistan.","Turkmen Language | TUK | Turkmen",,,,,,,,,,,,,,,"4182476","Turkmen language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574476","Tumbuka Language","C154179","A Niger-Congo Bantu language spoken in the Northern Region of Malawi and also in the Lundazi district of Zambia.","Tumbuka Language | TUM",,,,,,,,,,,,,,,"4177293","Tumbuka language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555210","Tuvalua Language","C154181","A Polynesian language spoken as the official language of Tuvalu.","Tuvalua Language | TVL | Tuvalua",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574507","Twi Language","C154182","A dialect of the Niger-Congo Akan language spoken by the Ashanti people in southern and central Ghana.","Twi Language | Akan Kasa | TWI | Twi",,,,,,,,,,,,,,,"4183796","Twi language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574694","Udmurt Language","C154184","A Uralic language spoken by the Udmurt people of the Russian constituent republic of Udmurtia.","Udmurt Language | UDM | Udmurt",,,,,,,,,,,,,,,"4183944","Udmurt language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555147","Uyghur Language","C154185","A Turkic language spoken primarily by the Uyghur people in the Xinjiang Uyghur Autonomous Region of Western China.","Uyghur Language | UIG | Uighur | Uyghur",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041581","Ukrainian Language","C154186","An Indo-European East Slavic language that is the official state language of the Ukraine.","Ukrainian Language | UKR | Ukrainian",,,,,,,,,,,,,,,"4175904","Ukrainian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555148","Umbundu Language","C154187","A Niger-Congo Bantu language spoken by the Ovimbundu people of Angola.","Umbundu Language | South Mbundu | UMB | Umbundu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574208","Uzbek Language","C154189","A Turkic language that is the sole official language of Uzbekistan.","Uzbek Language | UZB | Uzbek",,,,,,,,,,,,,,,"4175743","Uzbek language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555380","CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology","C154451","Test codes of questionnaire questions associated with the Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology | FAC100TC | Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank Questionnaire Test Code | QS-FACIT-Dyspnea Scale 33 Item Bank Version TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552153","Lactobacillus rhamnosus/Lactobacillus reuteri Probiotic Supplement","C150402","A probiotic supplement containing the bacteria Lactobacillus (L.) rhamnosus and L. reuteri, with potential restorative and protective activities. Upon oral administration of the L. rhamnosus and L. reuteri probiotic supplement, the bacteria may restore and provide balance to the microbiota in the breast tissue. This may reduce or prevent inflammation, and may protect against the invasion of harmful bacteria and infection in the breast. In addition, the bacteria may restore the natural balance of the vaginal flora. This may prevent the invasion of harmful bacteria and yeast, and may prevent bacterial and yeast infections. This supplement may also relieve symptoms such as vaginal itching, odor and discharge, and may improve vaginal discomfort.","Lactobacillus rhamnosus/Lactobacillus reuteri Probiotic Supplement | L. rhamnosus and L. reuteri Probiotic Supplement | RepHresh Pro-B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552148","Anti-Lymphocyte Activation Gene 3 Protein Monoclonal Antibody BI 754111","C150403","A monoclonal antibody directed against the inhibitory receptor lymphocyte activation gene 3 protein (LAG3; LAG-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration,miptenalimab binds to LAG3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells, and negatively regulates both proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.","Miptenalimab | Anti-LAG3 Monoclonal Antibody BI 754111 | Anti-Lymphocyte Activation Gene 3 Protein Monoclonal Antibody BI 754111 | BI 754111 | BI-754111 | BI754111 | MIPTENALIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552147","HHV8-Positive Multicentric Castleman Disease","C150404","Multicentric Castleman disease associated with HHV8 infection.","HHV8-Positive Multicentric Castleman Disease | KSHV-Associated Multicentric Castleman Disease | KSHV/HHV8-Associated Multicentric Castleman Disease | KSHV/HHV8-MCD | KSHV/HHV8-Positive Multicentric Castleman Disease | Kaposi Sarcoma HHV-Associated Multicentric Castleman Disease | Kaposi Sarcoma Virus-Associated Multicentric Castleman Disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552150","HHV8-Positive Germinotropic Lymphoproliferative Disorder","C150405","A monotypic HHV8-positive lymphoproliferative disorder that usually occurs in HIV-negative individuals. It is characterized by the presence of HHV8-positive plasmablasts partially or completely replacing germinal centers. Coinfection with EBV is characteristic. In most cases, there is a favorable response to chemotherapy or radiation. (WHO 2017)","HHV8-Positive Germinotropic Lymphoproliferative Disorder | GLPD | HHV8+ GLPD | KSHV/HHV8-Positive Germinotropic Lymphoproliferative Disorder | KSVH/HHV8+ GLPD",,,,,,,,,,,,,,,"37204028","Germinotropic lymphoproliferative disorder caused by Human herpesvirus 8",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL552149","Extracavitary Primary Effusion Lymphoma","C150406","A rare HHV8-positive B-cell lymphoma indistinguishable from primary effusion lymphoma presenting as solid tumor mass. (WHO 2017)","Extracavitary Primary Effusion Lymphoma | Extracavitary PEL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552807","FACT-C Version 4 - I Feel Sad","C151090","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Emotional Well-Being: I feel sad.","FACT-C Version 4 - I Feel Sad | FAC008-I Feel Sad | FAC00815",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552808","FACT-C Version 4 - Satisfied With How I Am Coping","C151091","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Emotional Well-Being: I am satisfied with how I am coping with my illness.","FACT-C Version 4 - Satisfied With How I Am Coping | FAC008-Satisfied With How I Am Coping | FAC00816",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552809","FACT-C Version 4 - Losing Hope Against Illness","C151092","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Emotional Well-Being: I am losing hope in the fight against my illness.","FACT-C Version 4 - Losing Hope Against Illness | FAC008-Losing Hope Against Illness | FAC00817",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552810","FACT-C Version 4 - I Feel Nervous","C151093","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Emotional Well-Being: I feel nervous.","FACT-C Version 4 - I Feel Nervous | FAC008-I Feel Nervous | FAC00818",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552812","FACT-C Version 4 - Worry My Condition Will Get Worse","C151095","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Emotional Well-Being: I worry that my condition will get worse.","FACT-C Version 4 - Worry My Condition Will Get Worse | FAC008-Worry My Condition Will Get Worse | FAC00820",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552813","FACT-C Version 4 - I Am Able to Work","C151096","Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Functional Well-Being: I am able to work (include work at home).","FACT-C Version 4 - I Am Able to Work | FAC008-I Am Able to Work | FAC00821",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553094","SIQ-JR - Tell People I Plan to Kill Myself","C151377","Suicidal Ideation Questionnaire-Junior (SIQ-JR) I thought about telling people I plan to kill myself.","SIQ-JR - Tell People I Plan to Kill Myself | SIQ02-Tell People I Plan to Kill Myself | SIQ0209",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553095","SIQ-JR - How People Feel If I Killed Myself","C151378","Suicidal Ideation Questionnaire-Junior (SIQ-JR) I thought about how people would feel if I killed myself.","SIQ-JR - How People Feel If I Killed Myself | SIQ02-How People Feel If I Killed Myself | SIQ0210",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553096","SIQ-JR - I Wished I Were Dead","C151379","Suicidal Ideation Questionnaire-Junior (SIQ-JR) I wished I were dead.","SIQ-JR - I Wished I Were Dead | SIQ02-I Wished I Were Dead | SIQ0211",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007530","Cecostomy","C15200","Surgical creation of an opening in the cecum.","Cecostomy | ",,,,,,,,,,,,,,,"4160163","Creation of cecostomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL553346","Transmembrane Protein 45B","C152010","Transmembrane protein 45B (275 aa, ~32 kDa) is encoded by the human TMEM45B gene. This protein may play a role in the modulation of cell proliferation and cell migration.","Transmembrane Protein 45B | TMEM45B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553347","MLPH Gene","C152011","This gene is involved in melanosome transport.","MLPH Gene | MLPH | Melanophilin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553348","MLPH wt Allele","C152012","Human MLPH wild-type allele is located in the vicinity of 2q37.3 and is approximately 70 kb in length. This allele, which encodes melanophilin protein, plays a role in melanosome transport. Mutation of the gene is associated with hypopigmentation in type 3 Griscelli syndrome.","MLPH wt Allele | Melanophilin wt Allele | SLAC2-A | SLAC2A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553349","Melanophilin","C152013","Melanophilin (600 aa, ~66 kDa) is encoded by the human MLPH gene. This protein is involved in melanin transport.","Melanophilin | Exophilin 3 | Exophilin-3 | MLPH | SlaC2-a | Slp Homolog Lacking C2 Domains A | Synaptotagmin-Like Protein 2a | Synaptotagmin-Like Protein Lacking C2 Domains A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553350","NDC80 Gene","C152014","This gene plays a role in kinetochore assembly and microtubule organization.","NDC80 Gene | NDC80 | NDC80 Kinetochore Complex Component Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553351","NDC80 wt Allele","C152015","Human NDC80 wild-type allele is located in the vicinity of 18p11.32 and is approximately 45 kb in length. This allele, which encodes kinetochore protein NDC80 homolog protein, is involved in chromosome segregation and mitotic spindle checkpoint activity.","NDC80 wt Allele | HEC | HEC1 | Highly Expressed In Cancer, Rich In Leucine Heptad Repeats Gene | Highly Expressed in Cancer Gene | Highly Expressed in Cancer, Rich in Leucine Heptad Repeats (Yeast) Gene | HsHec1 | KNTC2 | Kinetochore Associated 2 Gene | NDC80 Homolog, Kinetochore Complex Component Gene | NDC80 Kinetochore Complex Component Homolog (S. cerevisiae) Gene | NDC80 Kinetochore Complex Component wt Allele | NDC80, Kinetochore Complex Component Gene | NDC80, S. cerevisiae, Homolog of Gene | TID3 | hsNDC80",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1438393","NDC80 protein, human","C152016","Kinetochore protein NDC80 homolog (642 aa, ~74 kDa) is encoded by the human NDC80 gene. This protein plays a role in the attachment of mitotic spindle microtubules to the kinetochore.","Kinetochore Protein NDC80 Homolog | Hec1 | Highly Expressed in Cancer Protein | HsHec1 | Kinetochore Protein Hec1 | Kinetochore-Associated Protein 2 | NDC80 | NDC80 Kinetochore Complex Component Homolog | Retinoblastoma-Associated Protein HEC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553353","GPR160 Gene","C152017","This gene may be involved in G protein-coupled receptor signaling.","GPR160 Gene | G Protein-Coupled Receptor 160 Gene | GPR160",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553354","GPR160 wt Allele","C152018","Human GPR160 wild-type allele is located in the vicinity of 3q26.2 and is approximately 48 kb in length. This allele, which encodes probable G-protein coupled receptor 160 protein, may play a role in G protein-coupled receptor signaling.","GPR160 wt Allele | G Protein-Coupled Receptor 160 wt Allele | GPCR1 | GPCR150",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552626","CDISC Functional Test ERT Test Name Terminology","C150767","Test names of functional test questions associated with the Emotion Recognition Test (ERT) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Functional Test ERT Test Name Terminology | EMO1TN | Emotion Recognition Functional Test Test Name | FT-ERT TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552627","CDISC Functional Test ERT Test Code Terminology","C150768","Test codes of functional test questions associated with the Emotion Recognition Test (ERT) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Functional Test ERT Test Code Terminology | EMO1TC | Emotion Recognition Functional Test Test Code | FT-ERT TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552628","CDISC Functional Test MMSE-2 Standard Version Test Name Terminology","C150769","Test names of functional test questions associated with the Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Functional Test MMSE-2 Standard Version Test Name Terminology | FT-MMSE-2 Standard Version TEST | MMS2TN | Mini-Mental State Examination 2 Standard Version Functional Test Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552630","CDISC Functional Test Paced Tapping Test Name Terminology","C150771","Test names of functional test questions associated with the Paced Tapping Test (Paced Tapping) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Functional Test Paced Tapping Test Name Terminology | FT-Paced Tapping TEST | PTAP1TN | Paced Tapping Functional Test Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552631","CDISC Functional Test Paced Tapping Test Code Terminology","C150772","Test codes of functional test questions associated with the Paced Tapping Test (Paced Tapping) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Functional Test Paced Tapping Test Code Terminology | FT-Paced Tapping TESTCD | PTAP1TC | Paced Tapping Functional Test Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552632","CDISC Questionnaire FACT-C Version 4 Test Name Terminology","C150773","Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACT-C Version 4 Test Name Terminology | FAC008TN | Functional Assessment of Cancer Therapy-Colorectal Version 4 Questionnaire Test Name | QS-FACT-C Version 4 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552633","CDISC Questionnaire FACT-C Version 4 Test Code Terminology","C150774","Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACT-C Version 4 Test Code Terminology | FAC008TC | Functional Assessment of Cancer Therapy-Colorectal Version 4 Questionnaire Test Code | QS-FACT-C Version 4 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552634","CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology","C150775","Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology | FAC063TN | Functional Assessment of Cancer Therapy-Taxane Version 4 Questionnaire Test Name | QS-FACT-Taxane Version 4 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552635","CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology","C150776","Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology | FAC063TC | Functional Assessment of Cancer Therapy-Taxane Version 4 Questionnaire Test Code | QS-FACT-Taxane Version 4 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552636","CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology","C150777","Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology | FAC062TN | Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 Questionnaire Test Name | QS-FACT-BRM Version 4 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553396","CDC42BPA wt Allele","C152062","Human CDC42BPA wild-type allele is located in the vicinity of 1q42.13 and is approximately 329 kb in length. This allele, which encodes serine/threonine-protein kinase MRCK alpha protein, is involved in signal transduction downstream of CDC42.","CDC42BPA wt Allele | CDC42 Binding Protein Kinase Alpha (DMPK-Like) Gene | CDC42 Binding Protein Kinase Alpha wt Allele | CDC42-Binding Protein Kinase Alpha (DMPK-Like) Gene | FLJ23347 | KIAA0451 | MRCK | MRCKA | PK428 | Protein Kinase, Serine/Threonine, Related to the Myotonic Dystrophy Protein Kinase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1308056","CDC42BPA protein, human","C152063","Serine/threonine-protein kinase MRCK alpha (1732 aa, ~197 kDa) is encoded by the human CDC42BPA gene. This protein plays a role in cytoskeleton reorganization and cell migration.","Serine/Threonine-Protein Kinase MRCK Alpha | CDC42-Binding Protein Kinase Alpha | CDC42BPA | DMPK-Like Alpha | EC 2.7.11.1 | MRCK Alpha | Myotonic Dystrophy Kinase-Related CDC42-Binding Kinase Alpha | Myotonic Dystrophy Kinase-Related CDC42-Binding Protein Kinase Alpha | Myotonic Dystrophy Kinase-Related Cdc42-Binding Kinase | Myotonic Dystrophy Protein Kinase-Like Alpha | Ser-Thr Protein Kinase PK428 | Ser-Thr Protein Kinase Related To The Myotonic Dystrophy Protein Kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1327916","Revesz Syndrome","C152064","An autosomal dominant form of dyskeratosis congenita, caused by mutation(s) in the TINF2 gene, encoding TERF1-interacting nuclear factor 2. It is a fatal disease associated with exudative retinopathy and bone marrow failure.","Revesz Syndrome | DKCA5 | Dyskeratosis Congenita, Autosomal Dominant, 5 | Exudative Retinopathy with Bone Marrow Failure",,,,,,,,,,,,,,,"37117164","Revesz syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0203762","Hepatobiliary Iminodiacetic Acid Scan","C152066","Radionuclide imaging of the liver, gallbladder, and bile ducts using the radioactive tracer 99mTc-hepatic iminodiacetic acid.","Hepatobiliary Iminodiacetic Acid Scan | HIDA Scan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553728","Somatrogon","C152396","No value exists.","Somatrogon | SOMATROGON",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553729","Somatropin Pegol","C152397","No value exists.","Somatropin Pegol | SOMATROPIN PEGOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553730","Somavaratan","C152398","No value exists.","Somavaratan | SOMAVARATAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553731","Somavubove","C152399","No value exists.","Somavubove | SOMAVUBOVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552677","ERT - Number Stimuli Portraying Disgust","C150946","Emotion Recognition Test (ERT) Number of stimuli defined as portraying disgust.","ERT - Number Stimuli Portraying Disgust | EMO1-Number Stimuli Portraying Disgust | EMO108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552678","ERT - Disgust Responded as Anger","C150947","Emotion Recognition Test (ERT) Number of disgust stimuli responded to as anger.","ERT - Disgust Responded as Anger | EMO1-Disgust Responded as Anger | EMO108A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552679","ERT - Disgust Responded as Disgust","C150948","Emotion Recognition Test (ERT) Number of disgust stimuli responded to as disgust.","ERT - Disgust Responded as Disgust | EMO1-Disgust Responded as Disgust | EMO108B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552680","ERT - Disgust Responded as Fear","C150949","Emotion Recognition Test (ERT) Number of disgust stimuli responded to as fear.","ERT - Disgust Responded as Fear | EMO1-Disgust Responded as Fear | EMO108C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552681","ERT - Disgust Responded as Happiness","C150950","Emotion Recognition Test (ERT) Number of disgust stimuli responded to as happiness.","ERT - Disgust Responded as Happiness | EMO1-Disgust Responded as Happiness | EMO108D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552683","ERT - Disgust Responded as Sadness","C150952","Emotion Recognition Test (ERT) Number of disgust stimuli responded to as sadness.","ERT - Disgust Responded as Sadness | EMO1-Disgust Responded as Sadness | EMO108F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552684","ERT - Disgust Responded as Surprise","C150953","Emotion Recognition Test (ERT) Number of disgust stimuli responded to as surprise.","ERT - Disgust Responded as Surprise | EMO1-Disgust Responded as Surprise | EMO108G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552685","ERT - Number Stimuli Portraying Fear","C150954","Emotion Recognition Test (ERT) Number of stimuli defined as portraying fear.","ERT - Number Stimuli Portraying Fear | EMO1-Number Stimuli Portraying Fear | EMO109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552686","ERT - Fear Responded as Anger","C150955","Emotion Recognition Test (ERT) Number of fear stimuli responded to as anger.","ERT - Fear Responded as Anger | EMO1-Fear Responded as Anger | EMO109A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552687","ERT - Fear Responded as Disgust","C150956","Emotion Recognition Test (ERT) Number of fear stimuli responded to as disgust.","ERT - Fear Responded as Disgust | EMO1-Fear Responded as Disgust | EMO109B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552688","ERT - Fear Responded as Fear","C150957","Emotion Recognition Test (ERT) Number of fear stimuli responded to as fear.","ERT - Fear Responded as Fear | EMO1-Fear Responded as Fear | EMO109C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552689","ERT - Fear Responded as Happiness","C150958","Emotion Recognition Test (ERT) Number of fear stimuli responded to as happiness.","ERT - Fear Responded as Happiness | EMO1-Fear Responded as Happiness | EMO109D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552690","ERT - Fear Responded as Neutral","C150959","Emotion Recognition Test (ERT) Number of fear stimuli responded to as neutral.","ERT - Fear Responded as Neutral | EMO1-Fear Responded as Neutral | EMO109E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552709","ERT - Number Stimuli Portraying Sadness","C150978","Emotion Recognition Test (ERT) Number of stimuli defined as portraying sadness.","ERT - Number Stimuli Portraying Sadness | EMO1-Number Stimuli Portraying Sadness | EMO112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552710","ERT - Sadness Responded as Anger","C150979","Emotion Recognition Test (ERT) Number of sadness stimuli responded to as anger.","ERT - Sadness Responded as Anger | EMO1-Sadness Responded as Anger | EMO112A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552711","ERT - Sadness Responded as Disgust","C150980","Emotion Recognition Test (ERT) Number of sadness stimuli responded to as disgust.","ERT - Sadness Responded as Disgust | EMO1-Sadness Responded as Disgust | EMO112B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552712","ERT - Sadness Responded as Fear","C150981","Emotion Recognition Test (ERT) Number of sadness stimuli responded to as fear.","ERT - Sadness Responded as Fear | EMO1-Sadness Responded as Fear | EMO112C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552713","ERT - Sadness Responded as Happiness","C150982","Emotion Recognition Test (ERT) Number of sadness stimuli responded to as happiness.","ERT - Sadness Responded as Happiness | EMO1-Sadness Responded as Happiness | EMO112D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552714","ERT - Sadness Responded as Neutral","C150983","Emotion Recognition Test (ERT) Number of sadness stimuli responded to as neutral.","ERT - Sadness Responded as Neutral | EMO1-Sadness Responded as Neutral | EMO112E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552715","ERT - Sadness Responded as Sadness","C150984","Emotion Recognition Test (ERT) Number of sadness stimuli responded to as sadness.","ERT - Sadness Responded as Sadness | EMO1-Sadness Responded as Sadness | EMO112F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552948","FACT/GOG-NTX Version 4 - I Have Trouble Buttoning Buttons","C151231","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Additional Concerns: I have trouble buttoning buttons.","FACT/GOG-NTX Version 4 - I Have Trouble Buttoning Buttons | FAC057-I Have Trouble Buttoning Buttons | FAC05736",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552949","FACT/GOG-NTX Version 4 - Trouble Feeling Shape of Objects","C151232","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Additional Concerns: I have trouble feeling the shape of small objects when they are in my hand.","FACT/GOG-NTX Version 4 - Trouble Feeling Shape of Objects | FAC057-Trouble Feeling Shape of Objects | FAC05737",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552950","FACT/GOG-NTX Version 4 - I Have Trouble Walking","C151233","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Additional Concerns: I have trouble walking.","FACT/GOG-NTX Version 4 - I Have Trouble Walking | FAC057-I Have Trouble Walking | FAC05738",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552951","FACT-L Version 4 - I Have a Lack of Energy","C151234","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Physical Well-Being: I have a lack of energy.","FACT-L Version 4 - I Have a Lack of Energy | FAC016-I Have a Lack of Energy | FAC01601",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552952","FACT-L Version 4 - I Have Nausea","C151235","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Physical Well-Being: I have nausea.","FACT-L Version 4 - I Have Nausea | FAC016-I Have Nausea | FAC01602",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552953","FACT-L Version 4 - Trouble Meeting Needs of Family","C151236","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Physical Well-Being: Because of my physical condition, I have trouble meeting the needs of my family.","FACT-L Version 4 - Trouble Meeting Needs of Family | FAC016-Trouble Meeting Needs of Family | FAC01603",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552954","FACT-L Version 4 - I Have Pain","C151237","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Physical Well-Being: I have pain.","FACT-L Version 4 - I Have Pain | FAC016-I Have Pain | FAC01604",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552175","EP4 Antagonist ONO-4578","C150376","An orally bioavailable antagonist of the prostaglandin E2 receptor subtype 4 (PTGER4; EP4), with potential analgesic, immunomodulating and antineoplastic activities. Upon administration, the EP4 antagonist ONO-4578 selectively targets and binds to EP4, inhibiting the binding of the immunosuppressive prostaglandin E2 (PGE2) to EP4. This prevents the activation of EP4 and inhibits PGE2-EP4-mediated signaling, thereby inhibiting proliferation of tumor cells in which the PGE2-EP4 signaling pathway is over-activated. In addition, EP4 inhibition prevents the activity of tumor-associated myeloid cells (TAMCs) in the tumor microenvironment (TME) by inhibiting interleukin-23 (IL-23) production and the IL-23-mediated expansion of Th17 cells. EP4, a prostanoid receptor, is a G protein-coupled receptor that is expressed in certain types of cancers; it promotes tumor cell proliferation and invasion.","EP4 Antagonist ONO-4578 | BMS 986310 | BMS-986310 | BMS986310 | ONO 4578 | ONO-4578 | ONO4578 | PGE2 Receptor Antagonist ONO-4578 | Prostaglandin E2 Receptor Antagonist ONO-4578 | Selective PGE2 Receptor 4 Antagonist ONO-4578",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552174","Anti-CD19-CAR T-cells TBI-1501","C150377","Autologous T-lymphocytes that have been transduced, via a proprietary technology involving a recombinant human fibronectin fragment to enhance transduction efficiency, with a retroviral vector to express a chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) of anti-CD19 coupled to co-stimulatory molecules, with potential immunostimulating and antineoplastic activities. Upon transfusion, anti-CD19-CAR-expressing autologous T-lymphocytes TBI-1501 target and bind to CD19-expressing neoplastic B-cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells, the release of cytotoxic molecules and the induction of tumor cell lysis. CD19, cluster of differentiation 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. Incorporation of the costimulatory signaling domains increase proliferation and activation of T-cells.","Autologous Anti-CD19 CAR-T Cells TBI-1501 | Anti-CD19-CAR T-cells TBI-1501 | Autologous Anti-CD19 Chimeric Antigen Receptor T Cells TBI-1501 | CAR19 T-lymphocytes TBI-1501 | TBI-1501",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552169","Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T Lymphocytes BinD19","C150378","Autologous T-lymphocytes that have been transduced with a lentiviral vector to express a T-cell receptor (TCR) consisting of a single chain variable fragment (scFv) of anti-CD19 coupled to the co-stimulatory molecule 4-1BB (CD137) and to the cytoplasmic portion of the zeta chain of the human T-cell receptor (CD3zeta), with potential immunostimulating and antineoplastic activities. Upon transfusion, the autologous anti-CD19 CAR TCR-zeta/4-1BB-transduced T-lymphocytes BinD19 target and bind to CD19-expressing neoplastic B-cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells, the release of cytotoxic molecules and tumor cell lysis. CD19, cluster of differentiation 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. Incorporation of the costimulatory signaling domains increases human T-cell function, expansion, and survival.","Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T Lymphocytes BinD19 | Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T-cells BinD19 | BinD 19 | BinD19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552168","Candida albicans Antigen Injection","C150379","An injectable formulation composed of antigens derived from the culture filtrate and cells of two different strains of Candida albicans (C. albicans), with immunomodulatory activity. Upon intralesional administration into the cutaneous human papilloma virus (HPV)-infected warts, the C. albicans antigens stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL)-mediated immune response against the injected antigens and cause a delayed type hypersensitivity response against other local antigens, including antigens within the wart tissue. This leads to the production of Th1 cytokines, and the activation of natural killer (NK) cell- and CTL- mediated killing of HPV-infected cells. This causes clearing of both local and distant warts, and prevents both HPV infection and wart formation that results from HPV infection.","Candida albicans Antigen Injection | Candida albicans Skin Test Antigen | Candida albicans Test Antigen Injection | Candin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552171","East Indian Sandalwood Oil Cream","C150380","A cream containing an essential oil derived from the East Indian sandalwood tree (Santalum album), containing alpha- and beta-santalols, with potential anti-inflammatory, anti-proliferative, anti-bacterial, anti-viral and immunomodulating activities. Upon topical application of the East Indian sandalwood oil (EISO) cream to an affected area of skin, the active ingredients in the cream may suppress various enzymes, such as cyclooxygenase (COX) and cyclic adenosine monophosphate (cAMP) phosphodiesterases (PDEs), prevent the production of pro-inflammatory cytokines and chemokines and directly cause apoptosis in susceptible cell types, including certain cancer cells and virally-infected cells.","East Indian Sandalwood Oil Cream | EISO Cream | SAN 007 | Santalum album Oil Cream | VIR 003 | VIR 007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553732","Somenopor","C152400","No value exists.","Somenopor | SOMENOPOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553733","Sometripor","C152401","No value exists.","Sometripor | SOMETRIPOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553734","Somfasepor","C152402","No value exists.","Somfasepor | SOMFASEPOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553735","Somidobove","C152403","No value exists.","Somidobove | SOMIDOBOVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553736","Soneclosan","C152404","No value exists.","Soneclosan | SONECLOSAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553737","Sonidegib Phosphate","C152405","No value exists.","Sonidegib Phosphate | SONIDEGIB PHOSPHATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553739","Sorbitan Sesquioleate","C152407","No value exists.","Sorbitan Sesquioleate | SORBITAN SESQUIOLEATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553740","Soretolide","C152408","No value exists.","Soretolide | SORETOLIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553741","Soterenol","C152409","No value exists.","Soterenol | SOTERENOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553742","Soterenol Hydrochloride","C152410","No value exists.","Soterenol Hydrochloride | SOTERENOL HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553744","Sparsentan","C152412","No value exists.","Sparsentan | SPARSENTAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553745","Sparsomycin","C152413","No value exists.","Sparsomycin | SPARSOMYCIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037760","Sparteine","C152414","No value exists.","Sparteine | SPARTEINE",,,,,,,,,,,,,,,"4294769","Sparteine",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL553748","Spiclamine","C152416","No value exists.","Spiclamine | SPICLAMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553749","spiradoline","C152417","No value exists.","Spiradoline | SPIRADOLINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553750","Spiradoline Mesylate","C152418","No value exists.","Spiradoline Mesylate | SPIRADOLINE MESYLATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553751","Spiraprilat","C152419","No value exists.","Spiraprilat | SPIRAPRILAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017430","Genomic Library","C15241","A collection of DNA molecules, derived from restriction fragments that have been cloned in vectors, that includes all or part of the genetic material of an organism.","Genomic Library | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553753","Spiroxasone","C152421","No value exists.","Spiroxasone | SPIROXASONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553754","Sprifermin","C152422","No value exists.","Sprifermin | SPRIFERMIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553755","Stallimycin Hydrochloride","C152423","No value exists.","Stallimycin Hydrochloride | STALLIMYCIN HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0027495","Naturopathy Therapy","C15283","A system of therapy based on preventative care, and on the use of heat, water, light, air, and massage as primary therapies for disease. Some naturopaths use no medications, either pharmaceutical or herbal. Some recommend herbal remedies only. A few who are licensed to prescribe may recommend pharmaceuticals in those cases where they feel their use is warranted. (MedicineNet.com)","Naturopathy Therapy | Naturopathic | Naturopathic Therapy | Naturopathy | naturopathy",,,,,,,,,,,,,,,"4259556","Naturopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554044","Vatiquinone","C152840","No value exists.","Vatiquinone | VATIQUINONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554045","Vatreptacog Alfa","C152841","No value exists.","Vatreptacog Alfa | VATREPTACOG ALFA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554046","Vedotin Fragment","C152842","No value exists.","Vedotin Fragment | VEDOTIN FRAGMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552691","ERT - Fear Responded as Sadness","C150960","Emotion Recognition Test (ERT) Number of fear stimuli responded to as sadness.","ERT - Fear Responded as Sadness | EMO1-Fear Responded as Sadness | EMO109F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552693","ERT - Number Stimuli Portraying Happiness","C150962","Emotion Recognition Test (ERT) Number of stimuli defined as portraying happiness.","ERT - Number Stimuli Portraying Happiness | EMO1-Number Stimuli Portraying Happiness | EMO110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552694","ERT - Happiness Responded as Anger","C150963","Emotion Recognition Test (ERT) Number of happiness stimuli responded to as anger.","ERT - Happiness Responded as Anger | EMO1-Happiness Responded as Anger | EMO110A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552695","ERT - Happiness Responded as Disgust","C150964","Emotion Recognition Test (ERT) Number of happiness stimuli responded to as disgust.","ERT - Happiness Responded as Disgust | EMO1-Happiness Responded as Disgust | EMO110B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552696","ERT - Happiness Responded as Fear","C150965","Emotion Recognition Test (ERT) Number of happiness stimuli responded to as fear.","ERT - Happiness Responded as Fear | EMO1-Happiness Responded as Fear | EMO110C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552697","ERT - Happiness Responded as Happiness","C150966","Emotion Recognition Test (ERT) Number of happiness stimuli responded to as happiness.","ERT - Happiness Responded as Happiness | EMO1-Happiness Responded as Happiness | EMO110D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552698","ERT - Happiness Responded as Neutral","C150967","Emotion Recognition Test (ERT) Number of happiness stimuli responded to as neutral.","ERT - Happiness Responded as Neutral | EMO1-Happiness Responded as Neutral | EMO110E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552699","ERT - Happiness Responded as Sadness","C150968","Emotion Recognition Test (ERT) Number of happiness stimuli responded to as sadness.","ERT - Happiness Responded as Sadness | EMO1-Happiness Responded as Sadness | EMO110F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552700","ERT - Happiness Responded as Surprise","C150969","Emotion Recognition Test (ERT) Number of happiness stimuli responded to as surprise.","ERT - Happiness Responded as Surprise | EMO1-Happiness Responded as Surprise | EMO110G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552701","ERT - Number Stimuli Portraying Neutral","C150970","Emotion Recognition Test (ERT) Number of stimuli defined as portraying a neutral expression.","ERT - Number Stimuli Portraying Neutral | EMO1-Number Stimuli Portraying Neutral | EMO111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552702","ERT - Neutral Responded as Anger","C150971","Emotion Recognition Test (ERT) Number of neutral stimuli responded to as anger.","ERT - Neutral Responded as Anger | EMO1-Neutral Responded as Anger | EMO111A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552703","ERT - Neutral Responded as Disgust","C150972","Emotion Recognition Test (ERT) Number of neutral stimuli responded to as disgust.","ERT - Neutral Responded as Disgust | EMO1-Neutral Responded as Disgust | EMO111B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552704","ERT - Neutral Responded as Fear","C150973","Emotion Recognition Test (ERT) Number of neutral stimuli responded to as fear.","ERT - Neutral Responded as Fear | EMO1-Neutral Responded as Fear | EMO111C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552705","ERT - Neutral Responded as Happiness","C150974","Emotion Recognition Test (ERT) Number of neutral stimuli responded to as happiness.","ERT - Neutral Responded as Happiness | EMO1-Neutral Responded as Happiness | EMO111D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552706","ERT - Neutral Responded as Neutral","C150975","Emotion Recognition Test (ERT) Number of neutral stimuli responded to as neutral.","ERT - Neutral Responded as Neutral | EMO1-Neutral Responded as Neutral | EMO111E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552707","ERT - Neutral Responded as Sadness","C150976","Emotion Recognition Test (ERT) Number of neutral stimuli responded to as sadness.","ERT - Neutral Responded as Sadness | EMO1-Neutral Responded as Sadness | EMO111F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552955","FACT-L Version 4 - Bothered by Treatment Side Effect","C151238","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Physical Well-Being: I am bothered by side effects of treatment.","FACT-L Version 4 - Bothered by Treatment Side Effect | FAC016-Bothered by Treatment Side Effect | FAC01605",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552957","FACT-L Version 4 - I am Forced to Spend Time in Bed","C151240","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Physical Well-Being: I am forced to spend time in bed.","FACT-L Version 4 - I am Forced to Spend Time in Bed | FAC016-I am Forced to Spend Time in Bed | FAC01607",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552958","FACT-L Version 4 - I Feel Close to My Friends","C151241","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Social/Family Well-Being: I feel close to my friends.","FACT-L Version 4 - I Feel Close to My Friends | FAC016-I Feel Close to My Friends | FAC01608",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552959","FACT-L Version 4 - Get Emotional Support From Family","C151242","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Social/Family Well-Being: I get emotional support from my family.","FACT-L Version 4 - Get Emotional Support From Family | FAC016-Get Emotional Support From Family | FAC01609",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552960","FACT-L Version 4 - I Get Support From My Friends","C151243","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Social/Family Well-Being: I get support from my friends.","FACT-L Version 4 - I Get Support From My Friends | FAC016-I Get Support From My Friends | FAC01610",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552961","FACT-L Version 4 - My Family Has Accepted My Illness","C151244","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Social/Family Well-Being: My family has accepted my illness.","FACT-L Version 4 - My Family Has Accepted My Illness | FAC016-My Family Has Accepted My Illness | FAC01611",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552962","FACT-L Version 4 - Satisfied Communication Illness","C151245","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Social/Family Well-Being: I am satisfied with family communication about my illness.","FACT-L Version 4 - Satisfied Communication Illness | FAC016-Satisfied Communication Illness | FAC01612",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552963","FACT-L Version 4 - I Feel Close to My Partner","C151246","Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Social/Family Well-Being: I feel close to my partner (or the person who is my main support).","FACT-L Version 4 - I Feel Close to My Partner | FAC016-I Feel Close to My Partner | FAC01613",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552170","CMV/EBV/ADV/BKV-specific Cytotoxic T Lymphocytes","C150381","A population of cytotoxic T-lymphocytes (CTLs) specifically reactive to cytomegalovirus (CMV), Epstein-Barr virus (EBV), adenovirus (ADV) and BK virus (BKV), with potential antiviral and protective activities. T-cells derived from peripheral blood mononuclear cells (PBMCs) are exposed to and activated by dendritic cells (DCs) that are loaded with specific peptides from CMV, EBV, ADV and BKV. Upon infusion of the CMV/EBV/ADV/BKV-specific CTLs, these lymphocytes target and cause lysis of CMV-, EBV-, ADV- and/or BKV-infected cells and may prevent infection and complications from CMV-, EBV-, ADV- and BKV-driven viral diseases. Opportunistic infections caused by these viruses are often seen in immunosuppressed patients.","CMV/EBV/ADV/BKV-specific Cytotoxic T Lymphocytes | CMV/EBV/ADV/BKV specific Cytotoxic T-lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552884","Paced Tapping - Avg Sign Dev Interval Tone All","C151039","Paced Tapping Test (Paced Tapping) The average signed deviation of the intertap intervals within the tone-paced tapping phase across all trials.","Paced Tapping - Avg Sign Dev Interval Tone All | PTAP1-Avg Sign Dev Interval Tone All | PTAP105H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552885","Paced Tapping - Total Interval Self Admin All","C151040","Paced Tapping Test (Paced Tapping) Total number of interlap intervals across all 4 trials administered (self-paced tapping phases).","Paced Tapping - Total Interval Self Admin All | PTAP1-Total Interval Self Admin All | PTAP106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552886","Paced Tapping - Total Interval Self Trim All","C151041","Paced Tapping Test (Paced Tapping) Total number of intertap intervals across all 4 trials that were trimmed before analysis (self-paced tapping phases).","Paced Tapping - Total Interval Self Trim All | PTAP1-Total Interval Self Trim All | PTAP107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552887","Paced Tapping - Minimum Interval Self All","C151042","Paced Tapping Test (Paced Tapping) The minimum intertap interval within the self-paced tapping phase across all trials (in milliseconds).","Paced Tapping - Minimum Interval Self All | PTAP1-Minimum Interval Self All | PTAP107A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552889","Paced Tapping - Mean Interval Self All","C151044","Paced Tapping Test (Paced Tapping) The mean intertap interval within the self-paced tapping phase across all trials (in milliseconds).","Paced Tapping - Mean Interval Self All | PTAP1-Mean Interval Self All | PTAP107C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552890","Paced Tapping - Median Interval Self All","C151045","Paced Tapping Test (Paced Tapping) The median intertap interval within the self-paced tapping phase across all trials (in milliseconds).","Paced Tapping - Median Interval Self All | PTAP1-Median Interval Self All | PTAP107D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552891","Paced Tapping - Variance Interval Self All","C151046","Paced Tapping Test (Paced Tapping) The variance of the intertap interval within the self-paced tapping phase across all trials (in milliseconds).","Paced Tapping - Variance Interval Self All | PTAP1-Variance Interval Self All | PTAP107E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552892","Paced Tapping - Deviation Interval Self All","C151047","Paced Tapping Test (Paced Tapping) The standard deviation of the intertap intervals within the self-paced tapping phase across all trials.","Paced Tapping - Deviation Interval Self All | PTAP1-Deviation Interval Self All | PTAP107F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552893","Paced Tapping - Reciprocal Interval Self All","C151048","Paced Tapping Test (Paced Tapping) The reciprocal of the standard deviation of the intertap intervals within the self-paced tapping phase across all trials.","Paced Tapping - Reciprocal Interval Self All | PTAP1-Reciprocal Interval Self All | PTAP107G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552894","Paced Tapping - Avg Sign Dev Interval Self All","C151049","Paced Tapping Test (Paced Tapping) The average signed deviation of the intertap intervals within the self-paced tapping phase across all trials.","Paced Tapping - Avg Sign Dev Interval Self All | PTAP1-Avg Sign Dev Interval Self All | PTAP107H",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552895","Paced Tapping - Trials Expected in Trial","C151050","Paced Tapping Test (Paced Tapping) Number of trials expected to be administered in Trial n.","Paced Tapping - Trials Expected in Trial | PTAP1-Trials Expected in Trial | PTAP108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552896","Paced Tapping - Trials Administered in Trial","C151051","Paced Tapping Test (Paced Tapping) Number of trials actually administered in Trial n.","Paced Tapping - Trials Administered in Trial | PTAP1-Trials Administered in Trial | PTAP109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554047","Vedroprevir","C152843","No value exists.","Vedroprevir | VEDROPREVIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554048","Velagliflozin","C152844","No value exists.","Velagliflozin | VELAGLIFLOZIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554049","Velaresol","C152845","No value exists.","Velaresol | VELARESOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554050","Veldoreotide","C152846","No value exists.","Veldoreotide | VELDOREOTIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554051","Veledimex","C152847","An orally bioavailable, small molecule diacylhydrazine-based activator ligand, that can be used to activate certain genes using the ecdysone receptor (EcR)-based inducible gene regulation system, the RheoSwitch Therapeutic System (RTS). Upon administration of veledimex, this agent specifically binds to the EcR located on the separately administered RTS, which includes two fusions proteins: Gal4-EcR, which contains a modified ecdysone receptor (EcR) fused with the DNA binding domain of the yeast Gal4 transcription factor, and VP16-RXR, which contains a chimeric retinoid X receptor (RXR) fused with the transcription activation domain of the viral protein VP16 of herpes simplex virus type 1 (HSV1). The fusion proteins form inactive, unstable and unproductive heterodimers in the absence of veledimex. In the presence of veledimex, the protein heterodimer changes to a stable conformation, forming an active transcription factor complex, which can bind to the inducible promoter, thereby allowing the induction of controlled transcription of the target gene.","Veledimex | Benzoic Acid, 2-Ethyl-3-methoxy-, 2-(3,5-Dimethylbenzoyl)-2-((1R)-1-(1,1-dimethylethyl)butyl)hydrazide | INXN-1001 | RG-115932 | VELEDIMEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554052","Veliflapon","C152848","No value exists.","Veliflapon | VELIFLAPON",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554053","Velmanase Alfa","C152849","No value exists.","Velmanase Alfa | VELMANASE ALFA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554054","Velneperit","C152850","No value exists.","Velneperit | VELNEPERIT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4079582","Velpatasvir","C152851","An orally available inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex, with potential activity against HCV genotypes 1-6. Although the exact mechanism of action of velpatasvir has not yet been completely determined, upon oral administration and intracellular uptake, it appears to bind to domain I of the NS5A protein. This inhibits the activity of the NS5A protein and results in the disruption of the viral RNA replication complex, blockage of viral HCV RNA production, and inhibition of viral replication. NS5A, a zinc-binding and proline-rich hydrophilic phosphoprotein, plays a crucial role in HCV RNA replication. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family.","Velpatasvir | GS 5816 | GS-5816 | GS5816 | VELPATASVIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554056","Venglustat","C152852","No value exists.","Venglustat | VENGLUSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554057","Venritidine","C152853","No value exists.","Venritidine | VENRITIDINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554058","Vepalimomab","C152854","No value exists.","Vepalimomab | VEPALIMOMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554059","Veradoline","C152855","No value exists.","Veradoline | VERADOLINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554060","Veradoline Hydrochloride","C152856","No value exists.","Veradoline Hydrochloride | VERADOLINE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554061","Veralipride","C152857","No value exists.","Veralipride | VERALIPRIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554062","vercirnon","C152858","No value exists.","Vercirnon | VERCIRNON",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554063","Vercirnon Sodium","C152859","No value exists.","Vercirnon Sodium | VERCIRNON SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028695","Nursing Research","C15285","Clinical research carried out by nurses.","Nursing Research | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554064","verdinexor","C152860","No value exists.","Verdinexor | VERDINEXOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554065","Verdiperstat","C152861","No value exists.","Verdiperstat | VERDIPERSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553157","NCCN-FACT FHNSI-22 Version 2 - Able to Communicate With Others","C151312","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I am able to communicate with others.","NCCN-FACT FHNSI-22 Version 2 - Able to Communicate With Others | FAC036-Able to Communicate With Others | FAC03609",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553158","NCCN-FACT FHNSI-22 Version 2 - I Can Eat Solid Foods","C151313","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I can eat solid foods.","NCCN-FACT FHNSI-22 Version 2 - I Can Eat Solid Foods | FAC036-I Can Eat Solid Foods | FAC03610",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553159","NCCN-FACT FHNSI-22 Version 2 - I Am Sleeping Well","C151314","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I am sleeping well.","NCCN-FACT FHNSI-22 Version 2 - I Am Sleeping Well | FAC036-I Am Sleeping Well | FAC03611",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553160","NCCN-FACT FHNSI-22 Version 2 - Worry My Condition Will Get Worse","C151315","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I worry that my condition will get worse.","NCCN-FACT FHNSI-22 Version 2 - Worry My Condition Will Get Worse | FAC036-Worry My Condition Will Get Worse | FAC03612",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553161","NCCN-FACT FHNSI-22 Version 2 - I Have a Lack of Energy","C151316","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I have a lack of energy.","NCCN-FACT FHNSI-22 Version 2 - I Have a Lack of Energy | FAC036-I Have a Lack of Energy | FAC03613",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553162","NCCN-FACT FHNSI-22 Version 2 - I Have Nausea","C151317","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I have nausea.","NCCN-FACT FHNSI-22 Version 2 - I Have Nausea | FAC036-I Have Nausea | FAC03614",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553163","NCCN-FACT FHNSI-22 Version 2 - Had Change in the Way Food Tastes","C151318","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I have had a change in the way food tastes.","NCCN-FACT FHNSI-22 Version 2 - Had Change in the Way Food Tastes | FAC036-Had Change in the Way Food Tastes | FAC03615",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553165","NCCN-FACT FHNSI-22 Version 2 - I Am Bothered by Hair Loss","C151320","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I am bothered by hair loss.","NCCN-FACT FHNSI-22 Version 2 - I Am Bothered by Hair Loss | FAC036-I Am Bothered by Hair Loss | FAC03617",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553166","NCCN-FACT FHNSI-22 Version 2 - Bothered by Treatment Side Effect","C151321","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I am bothered by side effects of treatment.","NCCN-FACT FHNSI-22 Version 2 - Bothered by Treatment Side Effect | FAC036-Bothered by Treatment Side Effect | FAC03618",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553039","NCCN-FACT FHNSI-22 Version 2 - I Have a Good Appetite","C151322","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I have a good appetite.","NCCN-FACT FHNSI-22 Version 2 - I Have a Good Appetite | FAC036-I Have a Good Appetite | FAC03619",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553192","Indium In 111 Monoclonal Antibody HuJ591","C151969","A radioimmunoconjugate containing the recombinant humanized monoclonal antibody rosopatamab directed against the extracellular domain of prostate-specific membrane antigen (PSMA) and labeled with the gamma-emitting isotope indium 111 (In 111; 111In), with potential radioimaging application. Upon administration, indium In 111 rosopatamab tetraxetan targets and binds to PSMA expressed on tumor cells. The use of gamma scintigraphy allows for the detection and imaging of the radioactive In 111, which can be used to determine the distribution and tumor localization of PSMA. PSMA is a transmembrane peptidase that is highly expressed on prostate tumor cells.","Indium In 111 Rosopatamab Tetraxetan | 111In-J591 | In111-HuJ591 | In111-J591 | Indium In 111 Monoclonal Antibody HuJ591 | Indium In 111 Monoclonal Antibody HuJ591",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007089","Carcinogenicity Test","C15196","An assay, usually performed on in vitro systems, in which the propensity of an agent to cause tumors is measured.","Carcinogenicity Test | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552517","Mutation-Negative Lynch Syndrome","C150716","A finding of Lynch syndrome in which one is identified as having a 'non-sporadic' DNA mismatch repair (MMR) deficient premalignant lesion or 'non-sporadic' MMR deficient malignant tumor, but germline MMR genetic testing did not demonstrate a recognized pathogenic mutation in the genes responsible for DNA mismatch repair.","Mutation-Negative Lynch Syndrome | Lynch-Like Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552518","Panobinostat Nanoparticle Formulation MTX110","C150717","A gold nanoparticle (GNP)-based formulation containing panobinostat, a pan histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon intra-tumoral injection of MTX110, panobinostat is released from the formulation and selectively targets, binds to and inhibits histone deacetylase (HDAC), which induces hyperacetylation of core histone proteins. The accumulation of highly acetylated histones leads to chromatin remodeling, an altered pattern of gene expression, inhibition of tumor oncogene transcription and the selective transcription of tumor suppressor genes. This results in the inhibition of tumor cell division and the induction of tumor cell apoptosis. HDAC, upregulated in many tumor cell types, is an enzyme family that deacetylates histone proteins. Panobinostat is water insoluble and does not cross the blood-brain barrier (BBB) when administered orally or intravenously. MTX110 solubilizes panobinostat and can be directly injected into the brain, which bypasses the BBB and delivers high concentrations of panobinostat to the tumor, while minimizing systemic toxicity.","Panobinostat Nanoparticle Formulation MTX110 | MTX 110 | MTX-110 | MTX110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552088","TAF1L wt Allele","C150334","Human TAF1L wild-type allele is located in the vicinity of 9p21.1 and is approximately 6 kb in length. This allele, which encodes transcription initiation factor TFIID subunit 1-like protein, is involved in the modulation of transcription during male meiosis.","TAF1L wt Allele | TAF(II)210 | TAF1 RNA Polymerase II, TATA Box Binding Protein (TBP)-Associated Factor, 210kDa-Like Gene | TAF1 RNA Polymerase II-Like Gene | TAF1-Like RNA Polymerase II, TATA Box Binding Protein (TBP)-Associated Factor, 210kDa Gene | TAF2A2 | TATA-Box Binding Protein Associated Factor 1 Like wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552091","Transcription Initiation Factor TFIID Subunit 1-Like","C150335","Transcription initiation factor TFIID subunit 1-like (1826 aa, ~207 kDa) is encoded by the human TAF1L gene. This protein plays a role in the initiation of transcription and the regulation of gene expression during male meiosis.","Transcription Initiation Factor TFIID Subunit 1-Like | TAF(II)210 | TAF1L | TATA Box-Binding Protein-Associated Factor 1-Like | TBP-Associated Factor 1-Like | TBP-Associated Factor 210 kDa | TBP-Associated Factor RNA Polymerase 1-Like | Transcription Initiation Factor TFIID 210 kDa Subunit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553646","Secalciferol","C152314","No value exists.","Secalciferol | SECALCIFEROL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553647","Secukinumab","C152315","A recombinant human immunoglobulin G1 (IgG1) monoclonal antibody against the pro-inflammatory cytokine interleukin 17A (IL-17A; IL-17), with potential anti-inflammatory activity. Upon subcutaneous administration, secukinumab selectively targets and binds to IL-17A, thereby neutralizing the IL-17A protein. This prevents binding of IL-17A to the IL-17 receptor (IL-17R), and inhibits IL-17A/IL-17R-mediated signaling and inflammation mediated by this pathway. IL-17A is mainly produced by inflammatory T helper 17 cells (Th17), and certain lymphocytes. IL-17A production is upregulated in many immune-mediated inflammatory diseases and plays a key role in the development of inflammation and the immune response.","Secukinumab | AIN457 | Cosentyx | SECUKINUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553648","Segesterone Acetate","C152316","No value exists.","Segesterone Acetate | SEGESTERONE ACETATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553649","Seglitide","C152317","No value exists.","Seglitide | SEGLITIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553650","Seglitide Acetate","C152318","No value exists.","Seglitide Acetate | SEGLITIDE ACETATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553651","Selepressin","C152319","No value exists.","Selepressin | SELEPRESSIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553652","Seletalisib","C152320","No value exists.","Seletalisib | SELETALISIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553653","Selexipag","C152321","No value exists.","Selexipag | SELEXIPAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553528","Seliforant","C152324","No value exists.","Seliforant | SELIFORANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553529","Selisistat","C152325","No value exists.","Selisistat | SELISISTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553530","Seltorexant","C152326","No value exists.","Seltorexant | SELTOREXANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553532","Semaglutide","C152328","A glucagon-like peptide-1 (GLP-1) receptor agonist that is 94% homologous to human GLP-1 (7-37), with antihyperglycemic and appetite regulating activities. Upon administration, semaglutide binds to and activates GLP-1 receptor. In pancreatic beta cells, this increases glucose-dependent insulin release. Semaglutide also reduces the elevated glucagon secretion by inhibiting alpha cells of the pancreas and slows gastric emptying. Altogether this lowers the postprandial glucose level. In the brain, the binding to and activation of GLP-1 receptor suppresses appetite, which decreases caloric intake and lowers body weight. GLP-1 is normally secreted by L cells of the gastrointestinal (GI) mucosa in response to a meal to normalize blood glucose levels. It also plays an important role in the regulation of appetite and caloric intake.","Semaglutide | Ozempic | Rybelsus | SEMAGLUTIDE | Wegovy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553533","Sematilide","C152329","No value exists.","Sematilide | SEMATILIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553534","Sematilide Hydrochloride","C152330","No value exists.","Sematilide Hydrochloride | SEMATILIDE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0244119","Stallimycin","C1517","An oligopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces distallicus.  Distamycin preferentially binds to adenine-thymine (A-T) rich sequences in the minor groove of DNA, thereby inhibiting DNA replication and RNA transcription.  In addition to antitumor effects, distamycin also possesses antiviral and antiprotozoal activities and is used as a chromosome dye. (NCI04)","Stallimycin | DISTAMYCIN A | Distamycin 3 | Distamycin A | Herperetin | STALLIMYCIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0003059","Animal Testing Alternative","C15182","Any method or technique that eliminates the use of animals in experiments, research, and testing.","Animal Testing Alternative | Animal Alternative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL523879","Chemotherapy, Cancer, Antimetabolites","C15183","Treatment of cancer that utilizes antimetabolite substances to disrupt DNA, RNA, or protein synthesis.","Antimetabolite Chemotherapy | Chemotherapy, Antimetabolites | Chemotherapy, Cancer, Antimetabolites",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0004939","Behavioral Research","C15185","Studies of the motivating factors that influence health practices as well as efforts to modify these practices.","Behavioral Research | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0005491","Biofeedback","C15186","A training technique in which various bodily functions, such as heart rate, skin temperature, muscle tension, and brain activity are monitored so that people can learn to control them voluntarily so as to improve their health and physical performance.","Biofeedback | biofeedback",,,,,,,,,,,,,,,"4151220","Biofeedback procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0005540","Biomedical Research","C15188","Research concerned with the application of biological and physiological principles to clinical medicine.","Biomedical Research | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553193","Locally Advanced Bile Duct Carcinoma","C151971","A bile duct carcinoma that has spread to nearby tissues or lymph nodes.","Locally Advanced Bile Duct Carcinoma | Locally Advanced Bile Duct Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553195","Cardiac Synchronization","C151973","Techniques to coordinate imaging data to the movement of the heart during the cardiac cycle.","Cardiac Synchronization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553197","Acute Leukemia of Ambiguous Lineage, Not Otherwise Specified","C151975","Acute leukemia of ambiguous lineage, expressing combinations of markers that do not allow for its classification as either acute undifferentiated leukemia or mixed phenotype acute leukemia, and definitive classification along a single lineage is difficult. (WHO 2017)","Acute Leukemia of Ambiguous Lineage, Not Otherwise Specified | Acute Leukemia of Ambiguous Lineage, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553198","Recurrent Burkitt Leukemia","C151976","The reemergence of Burkitt leukemia after a period of remission.","Recurrent Burkitt Leukemia | Mature B-cell leukemia Burkitt-type, in relapse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553199","Refractory Burkitt Leukemia","C151977","Burkitt leukemia resistant to treatment.","Refractory Burkitt Leukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553200","Refractory Lymphoblastic Lymphoma","C151978","Lymphoblastic lymphoma that is resistant to treatment.","Refractory Lymphoblastic Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0007328","Case-Control Study","C15197","A study that compares two groups of people: those with the disease or condition under study (cases) and a very similar group of people who do not have the disease or condition (controls). Researchers study the medical and lifestyle histories of the people in each group to learn what factors may be associated with the disease or condition. For example, one group may have been exposed to a particular substance that the other was not. Also called retrospective study.","Case-Control Study | CASE CONTROL | case-control study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553202","Recurrent High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements","C151980","The reemergence of high-grade B-cell lymphoma with MYC and BCL2 or BCL6 rearrangements after a period of remission.","Recurrent High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements | Recurrent Double-Hit Lymphoma | Recurrent High-Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553203","Pelvic Rhabdomyosarcoma","C151981","Rhabdomyosarcoma involving the organs and structures in the pelvis.","Pelvic Rhabdomyosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553204","Abdominal Rhabdomyosarcoma","C151982","Rhabdomyosarcoma involving the organs and structures in the abdomen.","Abdominal Rhabdomyosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553205","Unresectable Rhabdomyosarcoma","C151983","Rhabdomyosarcoma which is not amenable to surgical resection.","Unresectable Rhabdomyosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553206","Pelvic Undifferentiated High Grade Pleomorphic Sarcoma","C151984","Undifferentiated high grade pleomorphic sarcoma  involving the bones of the pelvis.","Pelvic Undifferentiated High Grade Pleomorphic Sarcoma | Undifferentiated High Grade Pleomorphic Sarcoma of the Pelvis | Undifferentiated Pelvic Pleomorphic Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553434","Risotilide","C152230","No value exists.","Risotilide | RISOTILIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552085","TBX22 wt Allele","C150337","Human TBX22 wild-type allele is located in the vicinity of Xq21.1 and is approximately 21 kb in length. This allele, which encodes T-box transcription factor TBX22 protein, plays a role in palate development. Mutation of the gene is associated with X-linked cleft palate and ankyloglossia.","TBX22 wt Allele | ABERS | CLPA | CPX | Cleft Palate and/or Ankyloglossia Gene | T-Box 22 wt Allele | TBXX | dJ795G23.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552084","T-Box Transcription Factor TBX22","C150338","T-box transcription factor TBX22 (520 aa, ~58 kDa) is encoded by the human TBX22 gene. This protein is involved in palate development and transcriptional regulation.","T-Box Transcription Factor TBX22 | T-Box Protein 22 | TBOX22 | TBX22",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552086","TCF7L1 wt Allele","C150340","Human TCF7L1 wild-type allele is located in the vicinity of 2p11.2 and is approximately 177 kb in length. This allele, which encodes transcription factor 7-like 1 protein, is involved in Wnt pathway-dependent transcriptional regulation.","TCF7L1 wt Allele | TCF-3 | TCF3 | Transcription Factor 3, Formerly Gene | Transcription Factor 7 Like 1 wt Allele | Transcription Factor 7-Like 1 (T-Cell Specific, HMG-Box) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1570012","TCF7L1 protein, human","C150341","Transcription factor 7-like 1 (588 aa, ~63 kDa) is encoded by the human TCF7L1 gene. This protein plays a role in transcriptional regulation that is modulated by the Wnt signaling pathway.","Transcription Factor 7-Like 1 | HMG Box Transcription Factor 3 | TCF-3 | TCF7L1 | Transcription Factor 7 Like 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552083","Local Skin Heating","C150343","The application of heat to a limited portion of the body.","Local Skin Heating | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552082","TGM7 wt Allele","C150344","Human TGM7 wild-type allele is located 15q15.2 and is approximately 26 kb in length. This allele, which encodes protein-glutamine gamma-glutamyltransferase Z protein, plays a role in post-translational protein modification.","TGM7 wt Allele | TGMZ | Transglutaminase 7 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552077","Protein-Glutamine Gamma-Glutamyltransferase Z","C150345","Protein-glutamine gamma-glutamyltransferase Z (710 aa, ~80 kDa) is encoded by the human TGM7 gene. This protein is involved in protein cross-linking and conjugation of polyamines to proteins.","Protein-Glutamine Gamma-Glutamyltransferase Z | EC 2.3.2.13 | TG(Z) | TGM7 | TGZ | TGase Z | TGase-7 | Transglutaminase 7 | Transglutaminase Z | Transglutaminase-7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552079","UMODL1 wt Allele","C150347","Human UMODL1 wild-type allele is located in the vicinity of 21q22.3 and is approximately 112 kb in length. This allele, which encodes uromodulin-like 1 protein, is involved in calcium binding.","UMODL1 wt Allele | Uromodulin Like 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1454784","UMODL1 protein, human","C150348","Uromodulin-like 1 (1318 aa, ~144 kDa) is encoded by the human UMODL1 gene. This protein plays a role in calcium binding.","Uromodulin-Like 1 | Olfactorin | UMODL1 | Uromodulin Like 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552716","ERT - Sadness Responded as Surprise","C150985","Emotion Recognition Test (ERT) Number of sadness stimuli responded to as surprise.","ERT - Sadness Responded as Surprise | EMO1-Sadness Responded as Surprise | EMO112G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553536","Semparatide","C152332","No value exists.","Semparatide | SEMPARATIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553537","Semparatide Acetate","C152333","No value exists.","Semparatide Acetate | SEMPARATIDE ACETATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553538","Senrebotase","C152334","No value exists.","Senrebotase | SENREBOTASE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3179475","Sepantronium","C152335","No value exists.","Sepantronium | SEPANTRONIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553541","Sepetaprost","C152337","No value exists.","Sepetaprost | SEPETAPROST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376202","3beta Hydroxy 5alpha pregnan 20 one","C152338","No value exists.","Sepranolone | SEPRANOLONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553543","Seprilose","C152339","No value exists.","Seprilose | SEPRILOSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553544","Serazapine","C152340","No value exists.","Serazapine | SERAZAPINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553546","Serelaxin","C152342","No value exists.","Serelaxin | SERELAXIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553547","Sergolexole","C152343","No value exists.","Sergolexole | SERGOLEXOLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553548","Sergolexole Maleate","C152344","No value exists.","Sergolexole Maleate | SERGOLEXOLE MALEATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553549","Seridopidine","C152345","No value exists.","Seridopidine | SERIDOPIDINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553964","Tropabazate","C152760","No value exists.","Tropabazate | TROPABAZATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553965","Tropapride","C152761","No value exists.","Tropapride | TROPAPRIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553966","Tropatepine","C152762","No value exists.","Tropatepine | TROPATEPINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553967","Tropenziline Bromide","C152763","No value exists.","Tropenziline Bromide | TROPENZILINE BROMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553968","Tropifexor","C152764","No value exists.","Tropifexor | TROPIFEXOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553969","Tropigline","C152765","No value exists.","Tropigline | TROPIGLINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553970","Tropirine","C152766","No value exists.","Tropirine | TROPIRINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553971","Troplasminogen Alfa","C152767","No value exists.","Troplasminogen Alfa | TROPLASMINOGEN ALFA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553972","Tropodifene","C152768","No value exists.","Tropodifene | TROPODIFENE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553974","Trospectomycin Sulfate","C152770","No value exists.","Trospectomycin Sulfate | TROSPECTOMYCIN SULFATE | Trospectinomycin | U-63366",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553975","Troxipide","C152771","No value exists.","Troxipide | TROXIPIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554104","Troxolamide","C152772","No value exists.","Troxolamide | TROXOLAMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554106","Troxypyrrolium Tosilate","C152774","No value exists.","Troxypyrrolium Tosilate | TROXYPYRROLIUM TOSILATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446641","Cerenkov luminescence imaging","C151895","An imaging modality to study charged particles in tissue by detecting the Cerenkov luminescence produced, allowing the imaging of beta-emitting nuclear medicine probes by optical methods.","Cerenkov Luminescence Imaging | CLI | Cerenkov Imaging | Cherenkov Imaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553283","Metastatic Unresectable Sarcoma","C152074","A metastatic sarcoma that is not amenable to surgical resection.","Metastatic Unresectable Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553284","Modotuximab","C152075","A recombinant immunoglobulin G1 (IgG1) monoclonal antibody directed against the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, modotuximab targets and binds to an epitope located in the extracellular domain (ECD) of EGFR, which causes internalization and degradation of EGFR, including the mutated EGFR variant III (EGFRvIII). This prevents EGFR-mediated signaling, thereby inhibiting EGFR-dependent tumor cell proliferation. EGFR, a receptor tyrosine kinase, is often overexpressed on the cell surfaces of various solid tumor cell types.","Modotuximab | 1024 DS | 1024-DS | Immunoglobulin G1, Anti-(human epidermal growth factor receptor extracellular domain III) (human-mus musculus monoclonal 1024 DS heavy chain), Disulfide with human-mus musculus monoclonal 1024 DS light chain, Dimer | MODOTUXIMAB | Zatuximab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553435","Risotilide Hydrochloride","C152231","No value exists.","Risotilide Hydrochloride | RISOTILIDE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553436","Ristianol","C152232","No value exists.","Ristianol | RISTIANOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553437","Ristianol Phosphate","C152233","No value exists.","Ristianol Phosphate | RISTIANOL PHOSPHATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553438","Ristocetin","C152234","No value exists.","Ristocetin | RISTOCETIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553439","Rivabazumab","C152235","No value exists.","Rivabazumab | RIVABAZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553440","KB001 antibody","C152236","No value exists.","Rivabazumab Pegol | RIVABAZUMAB PEGOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553441","Rivoceranib","C152237","An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Upon administration, rivoceranib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.","Rivoceranib | -Pyridinecarboxamide, N-(4-(1-cyanocyclopentyl)phenyl)-2-((4-pyridinylmethyl)amino)- | Apatinib | Apatinib Free Base | RIVOCERANIB | YN968D1 Free Base",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553443","Roflurane","C152239","No value exists.","Roflurane | ROFLURANE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518483","Nutrition, Carbohydrates","C15223","Role of carbohydrates in cancer causation or prevention and in general health.","Nutrition, Carbohydrates | Carbohydrate Nutrition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553444","Rokitamycin","C152240","No value exists.","Rokitamycin | ROKITAMYCIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553445","Roledumab","C152241","No value exists.","Roledumab | ROLEDUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553447","Rolipoltide","C152243","No value exists.","Rolipoltide | ROLIPOLTIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553448","Rolitetracycline Nitrate","C152244","No value exists.","Rolitetracycline Nitrate | ROLITETRACYCLINE NITRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553449","Rolodine","C152245","No value exists.","Rolodine | ROLODINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3661283","Romosozumab","C152246","A recombinant humanized immunoglobulin G2 (IgG2) monoclonal antibody directed against sclerostin, with anti-osteoporotic activity. Upon administration, romosozumab targets, binds to and inhibits the activity of sclerostin, a regulatory factor in bone metabolism. This stimulates osteoblastic activity, increases bone formation and, to a lesser extent, decreases bone resorption This may increase trabecular and cortical bone mass and improve bone structure and strength. Altogether, this may decrease the risk of fractures. Sclerostin, a negative regulator of bone formation secreted by osteocytes, inhibits Wnt signaling and suppresses osteoblast development and function.","Romosozumab | Evenity | ROMOSOZUMAB | Romosozumab-aqqg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035839","Ronidazole","C152248","No value exists.","Ronidazole | RONIDAZOLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553453","4-amino-tetrahydrobiopterin","C152249","No value exists.","Ronopterin | 4-AMINOTETRAHYDROBIOPTERIN | 4-Aminotetrahydrobiopterin | RONOPTERIN | VAS 203 | VAS-203 | VAS203",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527016","Study of Nutrition, Fats","C15224","Role of dietary fats in cancer causation or prevention and in general health.","Nutrition, Fats | Dietary Fat | Lipid Nutrition, Fats",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553456","Ropitoin Hydrochloride","C152252","No value exists.","Ropitoin Hydrochloride | ROPITOIN HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553457","Rosaprostol","C152253","No value exists.","Rosaprostol | ROSAPROSTOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553458","Rosaramicin","C152254","No value exists.","Rosaramicin | ROSARAMICIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553459","Rosaramicin Propionate","C152255","No value exists.","Rosaramicin Propionate | ROSARAMICIN PROPIONATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553461","Rosaramicin Stearate","C152257","No value exists.","Rosaramicin Stearate | ROSARAMICIN STEARATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553462","Rosiptor","C152258","No value exists.","Rosiptor | ROSIPTOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553463","Rosiptor Acetate","C152259","No value exists.","Rosiptor Acetate | ROSIPTOR ACETATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518490","Nutrition, Fiber","C15225","Role of dietary fiber in cancer causation or prevention and in general health.","Nutrition, Fiber | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554020","Tolpadol","C152688","No value exists.","Tolpadol | TOLPADOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552717","ERT - Number Stimuli Portraying Surprise","C150986","Emotion Recognition Test (ERT) Number of stimuli defined as portraying surprise.","ERT - Number Stimuli Portraying Surprise | EMO1-Number Stimuli Portraying Surprise | EMO113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552718","ERT - Surprise Responded as Anger","C150987","Emotion Recognition Test (ERT) Number of surprise stimuli responded to as anger.","ERT - Surprise Responded as Anger | EMO1-Surprise Responded as Anger | EMO113A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552719","ERT - Surprise Responded as Disgust","C150988","Emotion Recognition Test (ERT) Number of surprise stimuli responded to as disgust.","ERT - Surprise Responded as Disgust | EMO1-Surprise Responded as Disgust | EMO113B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552720","ERT - Surprise Responded as Fear","C150989","Emotion Recognition Test (ERT) Number of surprise stimuli responded to as fear.","ERT - Surprise Responded as Fear | EMO1-Surprise Responded as Fear | EMO113C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552721","ERT - Surprise Responded as Happiness","C150990","Emotion Recognition Test (ERT) Number of surprise stimuli responded to as happiness.","ERT - Surprise Responded as Happiness | EMO1-Surprise Responded as Happiness | EMO113D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552722","ERT - Surprise Responded as Neutral","C150991","Emotion Recognition Test (ERT) Number of surprise stimuli responded to as neutral.","ERT - Surprise Responded as Neutral | EMO1-Surprise Responded as Neutral | EMO113E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552724","ERT - Surprise Responded as Surprise","C150993","Emotion Recognition Test (ERT) Number of surprise stimuli responded to as surprise.","ERT - Surprise Responded as Surprise | EMO1-Surprise Responded as Surprise | EMO113G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552725","MMSE-2 Standard Version - Repeat Word 1","C150994","Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Now repeat those words back to me: Word 1.","MMSE-2 Standard Version - Repeat Word 1 | MMS2-Repeat Word 1 | MMS201A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552726","MMSE-2 Standard Version - Repeat Word 2","C150995","Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Now repeat those words back to me: Word 2.","MMSE-2 Standard Version - Repeat Word 2 | MMS2-Repeat Word 2 | MMS201B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552727","MMSE-2 Standard Version - Repeat Word 3","C150996","Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Now repeat those words back to me: Word 3.","MMSE-2 Standard Version - Repeat Word 3 | MMS2-Repeat Word 3 | MMS201C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552728","MMSE-2 Standard Version - What Is the Year","C150997","Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) What is the year?","MMSE-2 Standard Version - What Is the Year | MMS2-What Is the Year | MMS202A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552729","MMSE-2 Standard Version - What Is the Season","C150998","Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) What is the season?","MMSE-2 Standard Version - What Is the Season | MMS2-What Is the Season | MMS202B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552730","MMSE-2 Standard Version - What Is the Month of Year","C150999","Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) What is the month of the year?","MMSE-2 Standard Version - What Is the Month of Year | MMS2-What Is the Month of Year | MMS202C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242912","Neuroprotective Agent","C1509","A pharmacological agent that protects the central nervous system from damage caused by acute ischemia or chronic neurodegenerative diseases.","Neuroprotective Agent | Neuroprotectants | Neuroprotective Drugs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552731","MMSE-2 Standard Version - What Is the Day of Week","C151000","Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) What is the day of the week?","MMSE-2 Standard Version - What Is the Day of Week | MMS2-What Is the Day of Week | MMS202D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552847","MMSE-2 Standard Version - What Is the State","C151002","Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Where are we now? What is the state (or province)?","MMSE-2 Standard Version - What Is the State | MMS2-What Is the State | MMS203A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554107","Truxicurium Iodide","C152775","No value exists.","Truxicurium Iodide | TRUXICURIUM IODIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554108","Truxipicurium Iodide","C152776","No value exists.","Truxipicurium Iodide | TRUXIPICURIUM IODIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554109","Tuaminoheptane","C152777","No value exists.","Tuaminoheptane | TUAMINOHEPTANE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554111","Tubulozole Hydrochloride","C152779","No value exists.","Tubulozole Hydrochloride | TUBULOZOLE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554112","Tucaresol","C152780","No value exists.","Tucaresol | TUCARESOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554113","Tulathromycin","C152781","No value exists.","Tulathromycin | TULATHROMYCIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554115","Tulobuterol","C152783","No value exists.","Tulobuterol | TULOBUTEROL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554116","Tulrampator","C152784","No value exists.","Tulrampator | TULRAMPATOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554117","Turoctocog Alfa","C152785","No value exists.","Turoctocog Alfa | TUROCTOCOG ALFA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554118","Turoctocog Alfa Pegol","C152786","No value exists.","Turoctocog Alfa Pegol | TUROCTOCOG ALFA PEGOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554120","Tylvalosin tartrate","C152788","No value exists.","Tylvalosin Tartrate | TYLVALOSIN TARTRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041499","Tyrothricin","C152789","No value exists.","Tyrothricin | TYROTHRICIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554122","Ubrogepant","C152790","An orally bioavailable calcitonin gene-related peptide (CGRP) receptor antagonist that can be used in the acute treatment of migraines. Upon oral administration, ubrogepant targets, binds to and blocks the activity of CGRP receptor. This prevents CGRP-mediated signaling. By blocking the CGRP-mediated pathways, ubrogepant is able to ease migraine symptoms, especially migraine headache pain. CGRP-mediated signaling plays a key role in migraine pathogenesis.","Ubrogepant | MK-1602 | UBROGEPANT | Ubrelvy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553097","SIQ-JR - Killing Myself Would Solve Problem","C151380","Suicidal Ideation Questionnaire-Junior (SIQ-JR) I thought that killing myself would solve my problems.","SIQ-JR - Killing Myself Would Solve Problem | SIQ02-Killing Myself Would Solve Problem | SIQ0212",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553098","SIQ-JR - Others Be Happier If I Was Dead","C151381","Suicidal Ideation Questionnaire-Junior (SIQ-JR) I thought that others would be happier if I was dead.","SIQ-JR - Others Be Happier If I Was Dead | SIQ02-Others Be Happier If I Was Dead | SIQ0213",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553099","SIQ-JR - Wished I Had Never Been Born","C151382","Suicidal Ideation Questionnaire-Junior (SIQ-JR) I wished that I had never been born.","SIQ-JR - Wished I Had Never Been Born | SIQ02-Wished I Had Never Been Born | SIQ0214",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553100","SIQ-JR - No One Cared If I Lived or Died","C151383","Suicidal Ideation Questionnaire-Junior (SIQ-JR) I thought that no one cared if I lived or died.","SIQ-JR - No One Cared If I Lived or Died | SIQ02-No One Cared If I Lived or Died | SIQ0215",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553101","SIQ-JR - TS","C151384","Suicidal Ideation Questionnaire-Junior (SIQ-JR) TS (total raw score).","SIQ-JR - TS | SIQ02-TS | SIQ0216",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553102","SIQ-JR - Total %","C151385","Suicidal Ideation Questionnaire-Junior (SIQ-JR) Total standardization sample %.","SIQ-JR - Total % | SIQ02-Total % | SIQ0217",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553224","SIQ-JR - Specific %: Standard Sample 1","C151386","Suicidal Ideation Questionnaire-Junior (SIQ-JR) Specific standardization %: Sample 1.","SIQ-JR - Specific %: Standard Sample 1 | SIQ02-Specific %: Standard Sample 1 | SIQ0218",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553285","Recurrent Malignant Head and Neck Neoplasm","C152077","The reemergence of a malignant head and neck neoplasm after a period of remission.","Recurrent Malignant Head and Neck Neoplasm | Recurrent Head and Neck Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553286","Refractory Malignant Head and Neck Neoplasm","C152078","A malignant head and neck neoplasm that is resistant to treatment.","Refractory Malignant Head and Neck Neoplasm | Refractory Head and Neck Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0076693","tin mesoporphyrin","C152424","No value exists.","Stannsoporfin | STANNSOPORFIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553757","Statolon","C152425","No value exists.","Statolon | STATOLON",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553758","Steffimycin","C152426","No value exists.","Steffimycin | STEFFIMYCIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553759","Stenbolone","C152427","No value exists.","Stenbolone | STENBOLONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553760","Stenbolone Acetate","C152428","No value exists.","Stenbolone Acetate | STENBOLONE ACETATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553761","Stibamine Glucoside","C152429","No value exists.","Stibamine Glucoside | STIBAMINE GLUCOSIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553762","Stibosamine","C152430","No value exists.","Stibosamine | STIBOSAMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553764","Stilbazium Iodide","C152432","No value exists.","Stilbazium Iodide | STILBAZIUM IODIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL777680","Stiripentol","C152433","No value exists.","Stiripentol | STIRIPENTOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL977046","Stirofos","C152434","A synthetic alkenyl phosphate, dialkyl phosphate, trichlorobenzene compound, and organophosphate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a colorless or off-white crystalline solid, and exposure occurs by inhalation, ingestion, or contact.","Stirofos | STIROFOS | TCVP | TETRACHLORVINPHOS | Tetrachlorvinphos",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038415","Streptodornase","C152435","No value exists.","Streptodornase | STREPTODORNASE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038418","Streptokinase","C152436","No value exists.","Streptokinase | STREPTOKINASE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553770","Streptonicozid","C152438","No value exists.","Streptonicozid | STREPTONICOZID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL388709","Health Promotion","C15243","The realization that individual behavior plays a key role in health and disease prevention. Health promotion encourages individuals to adopt and maintain healthy behaviors (e.g., good eating habits and regular physical exercise) and modify unhealthy behaviors (e.g., quitting smoking) to foster healing and reduce the risks of major chronic diseases.","Health Promotion | Health Promotion (Salutogenesis) | Health Promotion and Wellness | Mindfulness Health Promotion | Salutogenesis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553773","Strontium Nitrate Sr-85","C152441","No value exists.","Strontium Nitrate Sr-85 | STRONTIUM NITRATE SR-85",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0301418","Styramate","C152442","No value exists.","Styramate | STYRAMATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553775","Succinylsulfathiazole","C152443","No value exists.","Succinylsulfathiazole | SUCCINYLSULFATHIAZOLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553776","Sucrosofate","C152444","No value exists.","Sucrosofate | SUCROSOFATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553777","Sucrosofate Potassium","C152445","No value exists.","Sucrosofate Potassium | SUCROSOFATE POTASSIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554021","Tolquinzole","C152689","No value exists.","Tolquinzole | TOLQUINZOLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554022","Tomeglovir","C152690","No value exists.","Tomeglovir | TOMEGLOVIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554023","Tomicorat","C152691","No value exists.","Tomicorat | TOMICORAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554024","Tomuzotuximab","C152692","A glycoengineered second-generation antibody of cetuximab with potential antineoplastic activities. Upon intravenous administration, tomuzotuximab selectively binds to the extracellular domain of the epidermal growth factor receptor (EGFR), thereby preventing the activation and subsequent dimerization of the receptor. This may prevent EGFR-mediated signaling and inhibit EGFR-dependent tumor cell proliferation.  Further, tomuzotuximab has a fully human glycosylation pattern and is glyco-optimized at its Fc domain to promote antibody-dependent cell-mediated cytotoxicity (ADCC). EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surfaces of certain tumor types.","Tomuzotuximab | TOMUZOTUXIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554025","Tonabacase","C152693","No value exists.","Tonabacase | TONABACASE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554026","Tonogenchoncel-L","C152694","No value exists.","Tonogenchoncel-L | TONOGENCHONCEL-L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554027","Toquizine","C152695","No value exists.","Toquizine | TOQUIZINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554028","Toralizumab","C152696","No value exists.","Toralizumab | TORALIZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554029","Torapsel","C152697","No value exists.","Torapsel | TORAPSEL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554030","Toreforant","C152698","No value exists.","Toreforant | TOREFORANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554031","Toreforant Tartrate","C152699","No value exists.","Toreforant Tartrate | TOREFORANT TARTRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554032","Tosactide","C152700","No value exists.","Tosactide | TOSACTIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554033","Tosatoxumab","C152701","No value exists.","Tosatoxumab | TOSATOXUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554034","tosifen","C152702","No value exists.","Tosifen | TOSIFEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552282","Metastatic Renal Pelvis Urothelial Carcinoma","C150514","Renal pelvis urothelial carcinoma that has spread to another anatomical site.","Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0862458","Metastatic Ureter Urothelial Carcinoma","C150515","Ureter urothelial carcinoma that has spread to another anatomical site.","Metastatic Ureter Urothelial Carcinoma | Metastatic Ureter Urothelial Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0862460","Recurrent Ureter Urothelial Carcinoma","C150516","The reemergence of ureter urothelial carcinoma after a period of remission.","Recurrent Ureter Urothelial Carcinoma | Recurrent Ureter Urothelial Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552279","Ad5 [E1-, E2b-]-HER2/Neu Vaccine ETBX-021","C150517","A cancer vaccine composed of a genetically engineered, replication-defective oncolytic adenovirus serotype 5 (Ad5) vector, in which the E1, E2b and E3 genes are deleted, that encodes a modified version of the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (HER2/neu; ErbB-2; ERBB2), with potential antineoplastic activity. Upon administration of Ad5 [E1-, E2b-]-HER2/neu ETBX-021, the vector expresses HER2/neu and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing the HER2/neu antigen. This results in the immune-mediated induction of death in and inhibition of proliferation of HER2/neu-expressing tumor cells. HER2/neu, a member of the epidermal growth factor receptor (EGFR) family of tyrosine kinases, is overexpressed in various tumor cell types while expression is restricted and minimal in certain normal healthy cells. It plays a key role in cancer cell proliferation and survival. The gene deletions in Ad5 may circumvent pre-existing anti-adenovirus immunity, allow HER2 gene insertion and expression and induce a strong immune response.","Ad5 [E1-, E2b-]-HER2/Neu Vaccine ETBX-021 | Ad5 [E1-, E2b-]-HER2/neu Vaccine | Adenovirus Type 5 E1/E2b-deleted HER2/neu Vaccine ETBX-021 | ETBX-021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552278","Autologous Anti-EGFRvIII 4SCAR-IgT Cells","C150518","A preparation of autologous T-cells that are genetically modified to express immunoglobulins (Igs) that target the negative immunoregulatory human cell surface receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and programmed death-ligand 1 (PD-L1; CD274) and are transduced with a replication incompetent, self-inactivating lentiviral vector expressing a fourth generation chimeric antigen receptor (4SCAR) consisting of a single chain variable fragment (scFv) targeting anti-epidermal growth factor receptor variant III (EGFRvIII) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (TCR), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-EGFRvIII 4SCAR-IgT cells are directed to and induce selective toxicity in EGFRvIII-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. EGFRvIII, a tumor-associated antigen (TAA) encoded by an in-frame deletion of exons 2-7 in the EGFR gene, is overexpressed by a variety of cancer cell types and is not expressed by normal, healthy cells. It plays a key role in tumor cell proliferation, tumor angiogenesis and resistance to both radio- and chemotherapy. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity. The anti-PD-1 and anti-PD-L1 antibodies produced by the T-cells (IgT) bind to PD-1, expressed on T-cells, and its ligand PD-L1 expressed on cancer cells, respectively. This inhibits PD-1/PD-L1-mediated signaling, prevents T-cell inhibition and exhaustion, enhances T-cell activation within the tumor microenvironment (TME) and results in an enhanced T-cell-mediated immune response against and toxicity in the EGFRvIII-expressing tumor cells.","Autologous Anti-EGFRvIII 4SCAR-IgT Cells | Anti-PD-1/PD-L1-Antibodies-expressing Autologous GBM-specific CAR-T Cells | Autologous Anti-PD-1/Anti-PD-L1 Antibodies-expressing Anti-EGFRvIII CAR T Cells | Autologous EGFRvIII-4SCAR-IgT | EGFRvIII-4SCAR-IgT Cells-producing PD1 and PD-L1 Antibodies | PD-1/PD-L1 Antibody-producing T cells (IgT)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552281","Recurrent Renal Pelvis Urothelial Carcinoma","C150519","The reemergence of renal pelvis urothelial carcinoma after a period of remission.","Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552276","Unresectable Urothelial Carcinoma","C150521","Urothelial carcinoma that is not amenable to surgical resection.","Unresectable Urothelial Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553225","SIQ-JR - Specific %: Standard Sample 2","C151387","Suicidal Ideation Questionnaire-Junior (SIQ-JR) Specific standardization %: Sample 2.","SIQ-JR - Specific %: Standard Sample 2 | SIQ02-Specific %: Standard Sample 2 | SIQ0219",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553226","SIQ-JR - Specific %: Standard Sample 3","C151388","Suicidal Ideation Questionnaire-Junior (SIQ-JR) Specific standardization %: Sample 3.","SIQ-JR - Specific %: Standard Sample 3 | SIQ02-Specific %: Standard Sample 3 | SIQ0220",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553227","SIQ-JR - Critical Item 1","C151389","Suicidal Ideation Questionnaire-Junior (SIQ-JR) Critical item 1.","SIQ-JR - Critical Item 1 | SIQ02-Critical Item 1 | SIQ0221",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553229","SIQ-JR - Critical Item 3","C151391","Suicidal Ideation Questionnaire-Junior (SIQ-JR) Critical item 3.","SIQ-JR - Critical Item 3 | SIQ02-Critical Item 3 | SIQ0223",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553230","SIQ-JR - Critical Item 4","C151392","Suicidal Ideation Questionnaire-Junior (SIQ-JR) Critical item 4.","SIQ-JR - Critical Item 4 | SIQ02-Critical Item 4 | SIQ0224",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553231","SIQ-JR - Critical Item 5","C151393","Suicidal Ideation Questionnaire-Junior (SIQ-JR) Critical item 5.","SIQ-JR - Critical Item 5 | SIQ02-Critical Item 5 | SIQ0225",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553232","SIQ-JR - Critical Item 6","C151394","Suicidal Ideation Questionnaire-Junior (SIQ-JR) Critical item 6.","SIQ-JR - Critical Item 6 | SIQ02-Critical Item 6 | SIQ0226",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553233","Aqueous Volumeter","C151395","A device that measures the volume of an object or body part by capturing the equivalent water displaced from a vessel.","Aqueous Volumeter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553234","Transanal Total Mesorectal Excision","C151396","A surgical procedure for rectal cancer that involves the removal of the rectum by combining abdominal and transanal endoscopic approaches to overcome limitations of standard laparoscopic total mesorectal excision.","Transanal Total Mesorectal Excision | TaTME",,,,,,,,,,,,,,,"37165984","Transanal total mesorectal excision",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0230180","Left Lower Quadrant of Abdomen","C151399","The region of the abdomen that extends from the median plane to the left of the patient, and below the umbilicus.","Left Lower Quadrant of Abdomen | ABDOMINAL QUADRANT, LEFT LOWER | LLQ | Left Lower Quadrant",,,,,,,,,,,,,,,"4285903","Structure of left lower quadrant of abdomen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1707378","Child Development Study","C15202","No value exists.","Child Development Study | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553365","CXXC5 Gene","C152030","This gene plays a role in the regulation of apoptosis, signaling pathways and gene expression.","CXXC5 Gene | CXXC Finger Protein 5 Gene | CXXC5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553366","CXXC5 wt Allele","C152031","Human CXXC5 wild-type allele is located in the vicinity of 5q31.2 and is approximately 7 kb in length. This allele, which encodes CXXC-type zinc finger protein 5, is involved in the modulation of signaling, the regulation of apoptosis and transcriptional regulation.","CXXC5 wt Allele | CF5 | CXXC Finger Protein 5 wt Allele | HSPC195 | RINF | WID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553779","Sudoxicam","C152447","No value exists.","Sudoxicam | SUDOXICAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553780","Sulamserod","C152448","No value exists.","Sulamserod | SULAMSEROD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553781","Sulamserod Hydrochloride","C152449","No value exists.","Sulamserod Hydrochloride | SULAMSEROD HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553783","Sulesomab","C152451","No value exists.","Sulesomab | SULESOMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553656","Sulfabenz","C152452","No value exists.","Sulfabenz | SULFABENZ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553657","Sulfacarbamide","C152453","No value exists.","Sulfacarbamide | SULFACARBAMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553658","Sulfadicramide","C152454","No value exists.","Sulfadicramide | SULFADICRAMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554066","Vericiguat","C152862","An orally bioavailable stimulator of soluble guanylate cyclase (sGC), with vasodilating activity.  Upon oral administration, vericiguat directly stimulates the catalytic activity of sGC and increases the formation of the intracellular second messenger cyclic guanosine monophosphate (cGMP), which is derived from guanosine triphosphate (GTP). This results in smooth muscle relaxation and vasodilation. sGC, a heme-containing cytoplasmic signaling enzyme, catalyzes the formation of cGMP from GTP in response to nitric oxide (NO) binding to heme. Vericiguat stimulates sGC independently of and synergistically with NO.","Vericiguat | BAY-1021189 | MK-1242 | VERICIGUAT | Verquvo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554067","Verinurad","C152863","No value exists.","Verinurad | VERINURAD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554068","Vernakalant","C152864","No value exists.","Vernakalant | VERNAKALANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554069","Vernakalant Hydrochloride","C152865","No value exists.","Vernakalant Hydrochloride | VERNAKALANT HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554070","Verosudil","C152866","No value exists.","Verosudil | VEROSUDIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554071","Verosudil Hydrochloride","C152867","No value exists.","Verosudil Hydrochloride | VEROSUDIL HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554072","Verubecestat","C152868","No value exists.","Verubecestat | VERUBECESTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554073","Verucerfont","C152869","No value exists.","Verucerfont | VERUCERFONT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554074","Vesatolimod","C152870","No value exists.","Vesatolimod | VESATOLIMOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL777929","Vestronidase Alfa","C152871","No value exists.","Vestronidase Alfa | VESTRONIDASE ALFA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554076","Vibegron","C152872","An orally bioavailable agonist of the human beta-3 adrenergic receptor (ADRB3), with muscle relaxing activity. Upon oral administration, vibegron targets, binds to and activates ADRB3, which leads to relaxation of the detrusor smooth muscle during bladder filling. This increases bladder capacity and provides symptomatic relief, including urge urinary incontinence, urgency, and urinary frequency, for overactive bladder.","Vibegron | Gemtesa | VIBEGRON",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554078","Vidupiprant","C152874","No value exists.","Vidupiprant | VIDUPIPRANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2935023","Vilanterol","C152875","A long-acting beta-2 adrenergic agonist, with bronchodilator activity. Upon administration, vilanterol stimulates beta-2 adrenergic receptors in the lungs, thereby activating the enzyme adenylate cyclase that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increased cAMP concentrations relax bronchial smooth muscle, relieve bronchospasms, and reduce inflammatory cell mediator release, especially from mast cells.","Vilanterol | GW 642444 | GW-642444 | GW642444 | VILANTEROL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554080","Vilanterol Trifenatate","C152876","No value exists.","Vilanterol Trifenatate | VILANTEROL TRIFENATATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042665","Viloxazine","C152877","No value exists.","Viloxazine | VILOXAZINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554082","Viloxazine Hydrochloride","C152878","No value exists.","Viloxazine Hydrochloride | VILOXAZINE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554083","Viminol","C152879","No value exists.","Viminol | VIMINOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554035","Totrombopag","C152703","An orally available small molecule agonist of the platelet thrombopoietin (TPO) receptor (TPOR; MPL), with potential megakaryopoiesis stimulating activity. Upon administration, totrombopag mimics TPO and binds to TPOR. This stimulates TPOR and leads to the proliferation and differentiation of megakaryocytes in the bone marrow. This increases the production of blood platelets and decreases bleeding in thrombocytopenic patients. TPOR is a cytokine receptor and member of the hematopoietin receptor superfamily.","Totrombopag | LGD-4665 | TOTROMBOPAG | TPO Mimetic LGD-4665 | Thrombopoietin Receptor Agonist LGD-4665",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554037","Trabodenoson","C152705","No value exists.","Trabodenoson | TRABODENOSON",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554038","Tracazolate","C152706","No value exists.","Tracazolate | TRACAZOLATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553040","NCCN-FACT FHNSI-22 Version 2 - I Am Able to Work","C151323","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I am able to work (include work at home).","NCCN-FACT FHNSI-22 Version 2 - I Am Able to Work | FAC036-I Am Able to Work | FAC03620",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553041","NCCN-FACT FHNSI-22 Version 2 - I Am Able to Enjoy Life","C151324","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I am able to enjoy life.","NCCN-FACT FHNSI-22 Version 2 - I Am Able to Enjoy Life | FAC036-I Am Able to Enjoy Life | FAC03621",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553042","NCCN-FACT FHNSI-22 Version 2 - Content With Quality of My Life","C151325","National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I am content with the quality of my life right now.","NCCN-FACT FHNSI-22 Version 2 - Content With Quality of My Life | FAC036-Content With Quality of My Life | FAC03622",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553043","SIQ - Would Be Better If I Was Not Alive","C151326","Suicidal Ideation Questionnaire (SIQ) I thought it would be better if I was not alive.","SIQ - Would Be Better If I Was Not Alive | SIQ01-Would Be Better If I Was Not Alive | SIQ0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553044","SIQ - I Thought About Killing Myself","C151327","Suicidal Ideation Questionnaire (SIQ) I thought about killing myself.","SIQ - I Thought About Killing Myself | SIQ01-I Thought About Killing Myself | SIQ0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553045","SIQ - I Thought How I Would Kill Myself","C151328","Suicidal Ideation Questionnaire (SIQ) I thought about how I would kill myself.","SIQ - I Thought How I Would Kill Myself | SIQ01-I Thought How I Would Kill Myself | SIQ0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553046","SIQ - I Thought When I Would Kill Myself","C151329","Suicidal Ideation Questionnaire (SIQ) I thought about when I would kill myself.","SIQ - I Thought When I Would Kill Myself | SIQ01-I Thought When I Would Kill Myself | SIQ0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553047","SIQ - I Thought About People Dying","C151330","Suicidal Ideation Questionnaire (SIQ) I thought about people dying.","SIQ - I Thought About People Dying | SIQ01-I Thought About People Dying | SIQ0105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553049","SIQ - What to Write in a Suicide Note","C151332","Suicidal Ideation Questionnaire (SIQ) I thought about what to write in a suicide note.","SIQ - What to Write in a Suicide Note | SIQ01-What to Write in a Suicide Note | SIQ0107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553050","SIQ - I Thought About Writing a Will","C151333","Suicidal Ideation Questionnaire (SIQ) I thought about writing a will.","SIQ - I Thought About Writing a Will | SIQ01-I Thought About Writing a Will | SIQ0108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553051","SIQ - Tell People I Plan to Kill Myself","C151334","Suicidal Ideation Questionnaire (SIQ) I thought about telling people I plan to kill myself.","SIQ - Tell People I Plan to Kill Myself | SIQ01-Tell People I Plan to Kill Myself | SIQ0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553052","SIQ - People Happier If Not Around","C151335","Suicidal Ideation Questionnaire (SIQ) I thought that people would be happier if I were not around.","SIQ - People Happier If Not Around | SIQ01-People Happier If Not Around | SIQ0110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552275","Proton Beam Craniospinal Irradiation","C150522","The use of proton beam radiation therapy to treat central nervous system malignancies of the cerebrospinal space.","Proton Beam Craniospinal Irradiation | Craniospinal Proton Beam Radiation Therapy | Proton Craniospinal Irradiation | Proton Craniospinal Radiation Therapy | p-CSI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552521","Anti-LAG-3/PD-L1 Bispecific Antibody FS118","C150734","A bispecific antibody directed against two immune checkpoint proteins, the inhibitory receptor lymphocyte activation gene 3 protein (LAG3; LAG-3) and the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. FS118 is generated by incorporating an anti-LAG-3 Fc-region with antigen binding (Fcab) into a PD-L1-specific antibody. Upon administration, FS118 simultaneously targets and binds to LAG3 expressed on T-cells in the tumor microenvironment (TME) and PD-L1 expressed on tumor cells. This prevents LAG3- and PD-L1-mediated signaling, reverses T-cell inactivation, activates the immune system and enhances cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses against PD-L1-expressing tumor cells, which together lead to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF) negatively regulates both proliferation and activation of T-cells. Its expression is associated with tumor-mediated immune suppression. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to its receptor programmed death 1 (PD-1; PDCD1; CD279) on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.","Anti-LAG-3/PD-L1 Bispecific Antibody FS118 | FS118 | LAG-3/PD-L1 Bispecific Antibody FS118 | LAG-3/PD-L1 Mab2 FS118 | Mab2 FS118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552523","Metastatic Gastrointestinal Stromal Tumor","C150738","Gastrointestinal stromal tumor which has spread from its original site of growth to another anatomic site.","Metastatic Gastrointestinal Stromal Tumor | Metastatic Gastrointestinal Stromal Tumor (GIST)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552524","Locally Advanced Gastrointestinal Stromal Tumor","C150739","Gastrointestinal stromal tumor that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Gastrointestinal Stromal Tumor | Locally Advanced Gastrointestinal Stromal Tumor (GIST)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552525","Unresectable Gastrointestinal Stromal Tumor (GIST)","C150741","Malignant gastrointestinal stromal tumor that is not amenable to surgical resection.","Unresectable Malignant Gastrointestinal Stromal Tumor | Unresectable Gastrointestinal Stromal Tumor | Unresectable Gastrointestinal Stromal Tumor (GIST)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2715638","CXXC5 protein, human","C152032","CXXC-type zinc finger protein 5 (322 aa, ~33 kDa) is encoded by the human CXXC5 gene. This protein plays a role in transcriptional regulation.","CXXC-Type Zinc Finger Protein 5 | CF5 | CXXC Finger 5 Protein | CXXC Finger Protein 5 | CXXC5 | Putative MAPK-Activating Protein PM08 | Putative NF-Kappa-B-Activating Protein 102 | RINF | Retinoid-Inducible Nuclear Factor | WT1-Induced Inhibitor of Dishevelled",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553371","Distal Esophagus Adenocarcinoma","C152036","An adenocarcinoma arising from the lower third of the esophagus. The vast majority of esophageal adenocarcinomas involve the lower third of the esophagus.","Distal Esophagus Adenocarcinoma | Adenocarcinoma of the Lower Third of the Esophagus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553372","BLVRA Gene","C152037","This gene is involved in the conversion of biliverdin to bilirubin.","BLVRA Gene | BLVRA | Biliverdin Reductase A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553373","BLVRA wt Allele","C152038","Human BLVRA wild-type allele is located in the vicinity of 7p13 and is approximately 49 kb in length. This allele, which encodes biliverdin reductase A protein, plays a role in protoheme degradation. Truncation mutations in the gene are associated with hyperbiliverdinemia.","BLVRA wt Allele | BLVR | BVR | BVRA | Biliverdin Reductase A wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553374","Biliverdin Reductase A","C152039","Biliverdin reductase A (296 aa, ~33 kDa) is encoded by the human BLVRA gene. This protein is involved in the reduction of biliverdin IX alpha.","Biliverdin Reductase A | BLVRA | BVR A | Biliverdin-IX Alpha-Reductase | EC 1.3.1.24 | Testis Tissue Sperm-Binding Protein Li 61n",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1707379","Child Health Study","C15203","No value exists.","Child Health Study | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553375","ACTR3B Gene","C152040","This gene may play a role in actin binding and organization of the cytoskeleton.","ACTR3B Gene | ACTR3B | ARP3 Actin Related Protein 3 Homolog B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553376","ACTR3B wt Allele","C152041","Human ACTR3B wild-type allele is located within 7q36.1-q36.2 and is approximately 128 kb in length. This allele, which encodes actin-related protein 3B, is involved in cytoskeletal organization.","ACTR3B wt Allele | ARP11 | ARP3 Actin Related Protein 3 Homolog B wt Allele | ARP3 Actin-Related Protein 3 Homolog B (Yeast) Gene | ARP3BETA | ARP4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0964846","ACTR3B protein, human","C152042","Actin-related protein 3B (418 aa, ~48 kDa) is encoded by the human ACTR3B gene. This protein plays a role in actin binding and organization of the cytoskeleton.","Actin-Related Protein 3B | ACTR3B | ARP3 Actin Related Protein 3 Homolog B | ARP3-Beta | Actin-Like Protein 3B | Actin-Related Protein 3-Beta | Actin-Related Protein ARP4 | Actin-Related Protein Arp11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0074389","Serrapeptase","C152346","No value exists.","Serrapeptase | SERRAPEPTASE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553551","Setileuton","C152347","No value exists.","Setileuton | SETILEUTON",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553552","Setipiprant","C152348","No value exists.","Setipiprant | SETIPIPRANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553553","Setmelanotide","C152349","No value exists.","Setmelanotide | SETMELANOTIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553554","Setoxaximab","C152350","No value exists.","Setoxaximab | SETOXAXIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553555","Setrobuvir","C152351","No value exists.","Setrobuvir | SETROBUVIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554084","Vinburnine","C152880","No value exists.","Vinburnine | VINBURNINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554085","Vincofos","C152881","No value exists.","Vincofos | VINCOFOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554086","Vinepidine Sulfate","C152882","No value exists.","Vinepidine Sulfate | (4'S)-4'-Deoxyleurocristine Sulfate (1:1) | LY 119863 | LY-119863 | LY119863 | VINEPIDINE SULFATE | Vincaleukoblastine, 4'-Deoxy-22-oxo-, (4'alpha)-, Sulfate (1:1) (Salt)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554087","Vinformide","C152883","No value exists.","Vinformide | VINFORMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554088","Vinleurosine","C152884","No value exists.","Vinleurosine | VINLEUROSINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554089","Vinleurosine Sulfate","C152885","No value exists.","Vinleurosine Sulfate | VINLEUROSINE SULFATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554090","Vinmegallate","C152886","No value exists.","Vinmegallate | VINMEGALLATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554091","Vinpocetine","C152887","No value exists.","Vinpocetine | VINPOCETINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3711382","Familial Acute Myeloid Leukemia with Mutated Cebpa","C151898","Familial acute myeloid leukemia (AML) syndrome associated with biallelic CEBPA mutations. Patients typically present with AML as children or young adults. The familial form of AML with germline CEBPA mutation has morphological and immunophenotypic features similar to those of sporadic AML with CEBPA mutations. Overall, it has a favorable prognosis. (WHO 2017)","Acute Myeloid Leukemia with Germline CEBPA Mutation | Acute Myeloid Leukemia with Germline Biallelic CEBPA Mutations | Familial Acute Myeloid Leukemia with Mutated CEBPA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553243","DDX41 Gene Mutation","C151900","A change in the nucleotide sequence of the DDX41 gene.","DDX41 Gene Mutation | ABS Gene Mutation | DEAD-Box Helicase 41 Gene Mutation | DEAD/H Box 41 Gene Mutation | Drosophila Abstrakt Homolog Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553245","Hematologic Neoplasm with Germline Predisposition Associated with a Constitutional Platelet Disorder","C151902","Hematologic neoplasms associated with germline mutations and familial platelet disorders.","Hematologic Neoplasm with Germline Predisposition Associated with a Constitutional Platelet Disorder | Hematologic Neoplasm with Germline Predisposition and Preexisting Platelet Disorder | Myeloid Neoplasm with Germline Predisposition and Preexisting Platelet Disorder | Myeloid Neoplasms with Germline Predisposition and Preexisting Platelet Disorders",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553053","SIQ - How People Feel If I Killed Myself","C151336","Suicidal Ideation Questionnaire (SIQ) I thought about how people would feel if I killed myself.","SIQ - How People Feel If I Killed Myself | SIQ01-How People Feel If I Killed Myself | SIQ0111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553054","SIQ - I Wished I Were Dead","C151337","Suicidal Ideation Questionnaire (SIQ) I wished I were dead.","SIQ - I Wished I Were Dead | SIQ01-I Wished I Were Dead | SIQ0112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553055","SIQ - How Easy It Would Be to End It All","C151338","Suicidal Ideation Questionnaire (SIQ) I thought about how easy it would be to end it all.","SIQ - How Easy It Would Be to End It All | SIQ01-How Easy It Would Be to End It All | SIQ0113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553056","SIQ - Killing Myself Would Solve Problem","C151339","Suicidal Ideation Questionnaire (SIQ) I thought that killing myself would solve my problems.","SIQ - Killing Myself Would Solve Problem | SIQ01-Killing Myself Would Solve Problem | SIQ0114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553207","Abdominal Undifferentiated Pleomorphic Sarcoma","C151985","Undifferentiated pleomorphic sarcoma involving the organs and structures in the abdomen.","Abdominal Undifferentiated Pleomorphic Sarcoma | Undifferentiated Abdominal Pleomorphic Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553209","Blasts Expressing B-Lymphoid and T-Lymphoid Markers Present","C151987","A finding indicating the presence of blasts with evidence of both B-cell and T-cell lineage assignment.","Blasts Expressing B-Lymphoid and T-Lymphoid Markers Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553210","CDK Inhibitor PF-06873600","C151988","An orally bioavailable, cyclin dependent kinase (CDK) inhibitor, with potential antineoplastic activity. Upon administration, ebvaciclib selectively targets, binds to and inhibits the activity of CDKs. Inhibition of these kinases leads to cell cycle arrest, an induction of apoptosis, and inhibition of tumor cell proliferation. CDKs are ATP-dependent serine/threonine kinases that are important regulators of cell cycle progression and proliferation and are frequently overexpressed in tumor cells.","Ebvaciclib | CDK Inhibitor PF-06873600 | EBVACICLIB | PF 06873600 | PF-06873600",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552072","VIPR2 wt Allele","C150350","Human VIPR2 wild-type allele is located in the vicinity of 7q36.3 and is approximately 117 kb in length. This allele, which encodes vasoactive intestinal polypeptide receptor 2 protein, plays a role in G protein-coupled receptor signaling.","VIPR2 wt Allele | C16DUPq36.3 | DUP7q36.3 | PACAP-R-3 | PACAP-R3 | VIP-R-2 | VPAC2 | VPAC2R | VPCAP2R | Vasoactive Intestinal Peptide Receptor 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552075","VIPR2 protein, human","C150351","Vasoactive intestinal polypeptide receptor 2 (438 aa, ~49 kDa) is encoded by the human VIPR2 gene. This protein is involved in neuroendocrine hormone-dependent G protein-coupled receptor signaling.","Vasoactive Intestinal Polypeptide Receptor 2 | Helodermin-Preferring VIP Receptor | PACAP Type III Receptor | PACAP-R-3 | PACAP-R3 | Pituitary Adenylate Cyclase Activating Polypeptide Type III Receptor | Pituitary Adenylate Cyclase-Activating Polypeptide Type III Receptor | VIP and PACAP Receptor 2 | VIP-R-2 | VIPR2 | VPAC2 | Vasoactive Intestinal Peptide Receptor 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552069","ZBTB7B wt Allele","C150353","Human ZBTB7B wild-type allele is located in the vicinity of 1q21.3 and is approximately 16 kb in length. This allele, which encodes zinc finger and BTB domain-containing protein 7B, is involved in the repression of type I collagen gene expression and the promotion of CD4-positive T-cell differentiation.","ZBTB7B wt Allele | CKROX | THPOK | ZBTB15 | ZFP-67 | ZFP67 | ZNF857B | Zinc Finger Protein 67 Homolog (Mouse) Gene | Zinc Finger Protein 67, Mouse, Homolog of Gene | Zinc Finger and BTB Domain Containing 7B wt Allele | c-KROX | hcKROX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552068","ZBTB7B protein, human","C150354","Zinc finger and BTB domain-containing protein 7B (539 aa, ~58 kDa) is encoded by the human ZBTB7B gene. This protein plays a role in the regulation of both T-cell differentiation and collagen gene expression.","Zinc Finger and BTB Domain-Containing Protein 7B | Collagen Krox Protein | Krueppel-Related Zinc Finger Protein cKrox | T Helper-Inducing POZ/Kruppel-Like Factor | T-Helper-Inducing POZ/Krueppel-Like Factor | ZBTB7B | Zfp-67 | Zinc Finger Protein 67 Homolog | Zinc Finger Protein 857A | Zinc Finger Protein 857B | Zinc Finger Protein Th-POK | Zinc Finger and BTB Domain Containing 15 | Zinc Finger and BTB Domain-Containing Protein 15 | hcKrox",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552070","ZSWIM4 wt Allele","C150356","Human ZSWIM4 wild-type allele is located in the vicinity of 19p13.13 and is approximately 37 kb in length. This allele, which encodes zinc finger SWIM domain-containing protein 4, plays a role in zinc binding.","ZSWIM4 wt Allele | FLJ00044 | FLJ12221 | Zinc Finger SWIM-Type Containing 4 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552065","Zinc Finger SWIM Domain-Containing Protein 4","C150357","Zinc finger SWIM domain-containing protein 4 (989 aa, ~110 kDa) is encoded by the human ZSWIM4 gene. This protein may be involved in zinc-dependent protein-protein or protein-DNA interactions.","Zinc Finger SWIM Domain-Containing Protein 4 | ZSWIM4 | Zinc Finger SWIM-Type Containing 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552064","Oculus Rift Headset","C150358","A proprietary virtual reality headset.","Oculus Rift Headset | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553556","Setrusumab","C152352","No value exists.","Setrusumab | SETRUSUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553557","Seviprotimut-L","C152353","No value exists.","Seviprotimut-L | SEVIPROTIMUT-L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553558","Sevitropium Mesilate","C152354","No value exists.","Sevitropium Mesilate | SEVITROPIUM MESILATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553559","Sevuparin Sodium","C152355","No value exists.","Sevuparin Sodium | SEVUPARIN SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553560","Sfericase","C152356","No value exists.","Sfericase | SFERICASE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553561","siagoside","C152357","No value exists.","Siagoside | SIAGOSIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553562","Sibrafiban","C152358","No value exists.","Sibrafiban | SIBRAFIBAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600334","Silibinin","C152359","No value exists.","Silibinin | SILIBININ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518491","Nutrition, Food Additives","C15235","Role of food additives in cancer causation or prevention and in general health.","Nutrition, Food Additives | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553564","Silidianin","C152360","No value exists.","Silidianin | SILIDIANIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3555540","SILODRATE","C152361","No value exists.","Silodrate | SILODRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553566","Simenepag","C152362","No value exists.","Simenepag | SIMENEPAG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553567","Simenepag Isopropyl","C152363","No value exists.","Simenepag Isopropyl | SIMENEPAG ISOPROPYL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4064080","Simoctocog Alfa","C152364","No value exists.","Simoctocog Alfa | SIMOCTOCOG ALFA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553569","sinapultide","C152365","No value exists.","Sinapultide | SINAPULTIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553570","syntropium bromide","C152366","No value exists.","Sintropium Bromide | SINTROPIUM BROMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553571","Sipatrigine","C152367","No value exists.","Sipatrigine | SIPATRIGINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3657824","Siponimod","C152368","An orally bioavailable sphingosine 1-phosphate (S1P) receptor modulator, with potential anti-inflammatory and immunomodulating activities. Upon oral administration, siponimod targets and binds to S1P receptors 1 and 5 on lymphocytes. This prevents the egress of lymphocytes from lymph nodes, thereby reducing both the number of circulating peripheral lymphocytes and the infiltration of lymphocytes into target tissues, such as the central nervous system (CNS). This prevents lymphocyte-mediated immune response and may reduce inflammation. S1P plays a key role in lymphocyte migration from lymphoid tissues. Siponimod does not target S1P receptor 3, the activation of which may be responsible for adverse effects such as bradycardia associated with other S1P receptor modulators.","Siponimod | 1-((4-((1E)-1-(((4-Cyclohexyl-3-(trifluoromethyl)phenyl)methoxy)imino)ethyl)- 2-ethylphenyl)methyl)azetidine-3-carboxylic Acid | 3-Azetidinecarboxylic Acid, 1-((4-((1E)-1-(((4-Cyclohexyl-3-(trifluoromethyl)phenyl)methoxy)imino)ethyl)-2-ethylphenyl)methyl)- | BAF 312 | BAF-312 | BAF312 | SIPONIMOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553573","Sirtratumab","C152369","No value exists.","Sirtratumab | SIRTRATUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554124","Ulimorelin","C152792","No value exists.","Ulimorelin | ULIMORELIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554125","Ulodesine","C152793","No value exists.","Ulodesine | ULODESINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554126","Ulodesine Succinate","C152794","No value exists.","Ulodesine Succinate | ULODESINE SUCCINATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553246","Hematologic Neoplasm with Germline RUNX1 Mutation","C151903","An autosomal dominant syndrome characterized by abnormalities in platelet number and function and enhanced risk of developing myelodysplastic syndrome/acute myeloid leukemia at a young age. Patients have germline monoallelic mutations in RUNX1 gene. The clinical presentation is variable, even within the same family. Most affected individuals have a mild to moderate bleeding tendency. Platelet counts are normal or mildly reduced, with normal platelet morphology and variable degrees of platelet dysfunction. Distinct families with germline RUNX1 mutations exhibit varying risks of development of myeloid neoplasms with 11-100% (median: 44%) of family members affected. (WHO 2017)","Hematologic Neoplasm with Germline RUNX1 Mutation | Myeloid Neoplasms with Germline RUNX1 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553247","Refractory Metastatic Digestive System Carcinoma","C151904","A digestive system carcinoma that has metastasized to another anatomic site and is resistant to treatment.","Refractory Metastatic Digestive System Carcinoma | Refractory Metastatic Gastrointestinal System Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553248","Recurrent Metastatic Digestive System Carcinoma","C151905","The reemergence of a metastatic digestive system carcinoma after a period of remission.","Recurrent Metastatic Digestive System Carcinoma | Recurrent Metastatic Gastrointestinal System Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553249","Refractory Digestive System Carcinoma","C151906","A carcinoma hat arises from any part of the digestive system and is resistant to treatment.","Refractory Digestive System Carcinoma | Refractory Gastrointestinal System Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553250","Refractory Head and Neck Carcinoma","C151907","A head and neck carcinoma that does not respond to treatment.","Refractory Head and Neck Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553251","Hematologic Neoplasm with Germline ANKRD26 Mutation","C151908","An autosomal dominant disorder characterized by moderate thrombocytopenia and increased risk of developing myelodysplastic syndrome/acute myeloid leukemia. This disorder is characterized by germline mutations in ANKRD26, located on chromosome band 10p12.1. (WHO 2017)","Hematologic Neoplasm with Germline ANKRD26 Mutation | Myeloid Neoplasm with Germline ANKRD26 Mutation | Myeloid Neoplasms with Germline ANKRD26 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553214","Locally Advanced Pancreatic Ductal Adenocarcinoma","C151993","A pancreatic ductal adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Pancreatic Ductal Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553215","STAT3 Inhibitor DSP-0337","C151994","An orally administered prodrug of napabucasin, a small molecule cancer stemness inhibitor with potential antineoplastic activity. Upon administration, DSP-0337 is converted to its active form, napabucasin. Napabucasin targets and inhibits signal transducer and activator of transcription 3 (STAT3), thereby preventing STAT-3-mediated signaling. The STAT3 pathway is overly active in many cancer types and is implicated in cancer stem cell-mediated growth, recurrence and resistance to conventional chemotherapies.","STAT3 Inhibitor DSP-0337 | Cancer Stemness Inhibitor DSP-0337 | DSP 0337 | DSP-0337 | Napabucasin Prodrug DSP-0337",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553216","Resectable Pancreatic Ductal Adenocarcinoma","C151995","Pancreatic ductal adenocarcinoma amenable to surgical resection.","Resectable Pancreatic Ductal Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553217","GALNT12 Gene","C151996","This gene plays a role in O-linked protein glycosylation.","GALNT12 Gene | GALNT12 | Polypeptide N-Acetylgalactosaminyltransferase 12 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553218","GALNT12 wt Allele","C151997","Human GALNT12 wild-type allele is located in the vicinity of 9q22.33 and is approximately 42 kb in length. This allele, which encodes polypeptide N-acetylgalactosaminyltransferase 12 protein, is involved in O-linked glycosylation of protein substrates. Mutation of the gene is associated with an increased risk of colorectal cancer.","GALNT12 wt Allele | CRCS1 | Colorectal Cancer, Susceptibility To 1 Gene | GalNAc-T12 | Polypeptide N-Acetylgalactosaminyltransferase 12 wt Allele | UDP-N-Acetyl-Alpha-D-Galactosamine:Polypeptide N-Acetylgalactosaminyltransferase 12 (GalNAc-T12) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553592","Rotigaptide","C152260","No value exists.","Rotigaptide | ROTIGAPTIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553593","Rovalpituzumab","C152261","No value exists.","Rovalpituzumab | ROVALPITUZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553594","rovatirelin","C152262","No value exists.","Rovatirelin | ROVATIRELIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553595","Rovazolac","C152263","No value exists.","Rovazolac | ROVAZOLAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553596","Rovelizumab","C152264","No value exists.","Rovelizumab | ROVELIZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553597","Roxatidine","C152265","No value exists.","Roxatidine | ROXATIDINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553598","Roxatidine Acetate Hydrochloride","C152266","No value exists.","Roxatidine Acetate Hydrochloride | ROXATIDINE ACETATE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553599","Roxifiban","C152267","No value exists.","Roxifiban | ROXIFIBAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553600","Roxifiban Acetate","C152268","No value exists.","Roxifiban Acetate | ROXIFIBAN ACETATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553601","Roxolonium Metilsulfate","C152269","No value exists.","Roxolonium Metilsulfate | ROXOLONIUM METILSULFATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553602","Rozanolixizumab","C152270","No value exists.","Rozanolixizumab | ROZANOLIXIZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3181260","rozrolimupab","C152271","No value exists.","Rozrolimupab | ROZROLIMUPAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553604","Ruclosporin","C152272","No value exists.","Ruclosporin | RUCLOSPORIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553606","Rusalatide","C152274","No value exists.","Rusalatide | RUSALATIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553607","Rusalatide Acetate","C152275","No value exists.","Rusalatide Acetate | RUSALATIDE ACETATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553608","Rutamycin","C152276","No value exists.","Rutamycin | RUTAMYCIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552066","Pre-existing Chronic Kidney Disease, Stage 3","C150360","Stage 3 chronic kidney disease that was diagnosed or treated before a specific date.","Pre-existing Chronic Kidney Disease, Stage 3 | Preexisting Chronic Kidney Disease, Stage 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552181","Selective Human Estrogen-receptor Alpha Partial Agonist TTC-352","C150363","A benzothiophene and orally bioavailable selective human estrogen receptor alpha (ERalpha; ESR1; ERa) partial agonist (ShERPA), with potential antineoplastic activity. Upon administration, TTC-352 mimics the naturally-occurring 17beta-estradiol (E2) and targets and binds to ERa located in the nucleus. This causes translocation of ERa to extranuclear sites. Nuclear export of ERa prevents normal ER-mediated signaling and inhibits proliferation of ER-positive tumor cells. TTC-352 causes tumor regression of tamoxifen (TAM)-resistant (TR) tumor cells which often overexpress protein kinase C alpha (PKCalpha; PKCa). PKCa expression is associated with poor patient survival and breast cancer aggressiveness and may predict tumor responses to E2, E2-like compounds and ShERPAs. Unlike E2 and E2-like compounds, TTC-352 does not cause endometrial proliferation.","Selective Human Estrogen-receptor Alpha Partial Agonist TTC-352 | 3-(4-Fluorophenyl)-2-(4-hydroxyphenoxy)benzo[b]thiophen-6-ol | ERa Partial Agonist TTC-352 | SEM TTC-352 | Selective Estrogen Mimic TTC-352 | Selective Estrogen Modulator TTC-352 | ShERPA TTC-352 | TTC 352 | TTC-352",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552848","MMSE-2 Standard Version - What Is the County","C151003","Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Where are we now? What is the county (or city/town)?","MMSE-2 Standard Version - What Is the County | MMS2-What Is the County | MMS203B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552849","MMSE-2 Standard Version - What Is the City/Town","C151004","Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Where are we now? What is the city/town (or part of city/neighborhood)?","MMSE-2 Standard Version - What Is the City/Town | MMS2-What Is the City/Town | MMS203C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552850","MMSE-2 Standard Version - What Is the Building","C151005","Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Where are we now? What is the building (name or type)?","MMSE-2 Standard Version - What Is the Building | MMS2-What Is the Building | MMS203D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552851","MMSE-2 Standard Version - What Is the Floor","C151006","Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Where are we now? What is the floor of the building (room number or address)?","MMSE-2 Standard Version - What Is the Floor | MMS2-What Is the Floor | MMS203E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552853","MMSE-2 Standard Version - Recall Word 2","C151008","Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) What were those three words I asked you to remember: Word 2?","MMSE-2 Standard Version - Recall Word 2 | MMS2-Recall Word 2 | MMS204B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552854","MMSE-2 Standard Version - Recall Word 3","C151009","Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) What were those three words I asked you to remember: Word 3?","MMSE-2 Standard Version - Recall Word 3 | MMS2-Recall Word 3 | MMS204C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552855","MMSE-2 Standard Version - What is 100 Take Away 7","C151010","Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) What is 100 take away 7 [93]?","MMSE-2 Standard Version - What is 100 Take Away 7 | MMS2-What is 100 Take Away 7 | MMS205A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552856","MMSE-2 Standard Version - Keep Subtracting 7 Step 2","C151011","Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Keep going [86].","MMSE-2 Standard Version - Keep Subtracting 7 Step 2 | MMS2-Keep Subtracting 7 Step 2 | MMS205B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552857","MMSE-2 Standard Version - Keep Subtracting 7 Step 3","C151012","Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Keep going [79].","MMSE-2 Standard Version - Keep Subtracting 7 Step 3 | MMS2-Keep Subtracting 7 Step 3 | MMS205C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552858","MMSE-2 Standard Version - Keep Subtracting 7 Step 4","C151013","Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Keep going [72].","MMSE-2 Standard Version - Keep Subtracting 7 Step 4 | MMS2-Keep Subtracting 7 Step 4 | MMS205D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554127","Umbralisib Tosylate","C152795","The tosylate form of umbralisib, an orally bioavailable, selective inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinases (PI3K) with potential antineoplastic activity.  umbralisib inhibits PI3K and prevents the activation of the PI3K/AKT kinase signaling pathway. This decreases proliferation and induces cell death in susceptible tumor cells.  Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in tumor cells and cells of the hematopoietic lineage. The targeted inhibition of PI3K-delta allows for PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.","Umbralisib Tosylate | UMBRALISIB TOSYLATE | Ukoniq",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3709474","Umeclidinium Bromide","C152797","The bromide salt form of umeclidinium, a muscarinic receptor antagonist, with bronchodilator activity. Although it does not display selectivity for specific muscarinic receptors, on topical application, umeclidinium acts mainly on M3 muscarinic receptors located on smooth muscle cells, thereby preventing smooth muscle contraction and resulting in bronchodilatory effect.","Umeclidinium Bromide | GSK 573719A | GSK-573719A | GSK573719A | Incruse | UMECLIDINIUM BROMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554130","Umespirone","C152798","No value exists.","Umespirone | UMESPIRONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0254211","Umifenovir","C152799","An orally bioavailable indole derivative, with broad-spectrum antiviral and potential anti-inflammatory activities. Upon oral administration, umifenovir inhibits the fusion of the viral envelope with host cell membrane, thereby blocking the entry of virus into host cells and preventing viral infection and replication. Umifenovir may also suppress the expression of the cytokines interleukin-1beta (IL-1b), IL-6, IL-12 and tumor necrosis factor-alpha (TNF-a) and promote the expression of IL-10. This may reduce inflammation.","Umifenovir | Arbidol | UMIFENOVIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554132","Umirolimus","C152800","No value exists.","Umirolimus | UMIROLIMUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554133","undecanoic acid","C152801","No value exists.","Undecanoic Acid | UNDECANOIC ACID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554134","Upadacitinib","C152802","No value exists.","Upadacitinib | UPADACITINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554135","Upadacitinib Tartrate","C152803","No value exists.","Upadacitinib Tartrate | UPADACITINIB TARTRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554137","Uprifosbuvir","C152805","No value exists.","Uprifosbuvir | UPRIFOSBUVIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554138","Urapidil","C152806","No value exists.","Urapidil | URAPIDIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554139","Ursulcholic Acid","C152807","No value exists.","Ursulcholic Acid | URSULCHOLIC ACID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554140","monoclonal antibody TMA-15","C152808","No value exists.","Urtoxazumab | URTOXAZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL777522","Vaborbactam","C152810","No value exists.","Vaborbactam | VABORBACTAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553300","NOP10 protein, human","C152092","H/ACA ribonucleoprotein complex subunit 3 (64 aa, ~8 kDa) is encoded by the human NOP10 gene. This protein plays a role in ribosomal RNA (rRNA) stability and telomere maintenance.","H/ACA Ribonucleoprotein Complex Subunit 3 | NOP10 | NOP10 Ribonucleoprotein Homolog | Nucleolar Protein 10 | Nucleolar Protein Family A Member 3 | SnoRNP Protein NOP10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553301","NHP2 Gene","C152093","This gene is involved in both telomere maintenance and ribosomal RNA (rRNA) stability.","NHP2 Gene | NHP2 | NHP2 Ribonucleoprotein Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038700","Sulfamoxole","C152456","No value exists.","Sulfamoxole | SULFAMOXOLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553661","Sulfanilate Zinc","C152457","No value exists.","Sulfanilate Zinc | SULFANILATE ZINC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553662","Sulfasymazine","C152458","No value exists.","Sulfasymazine | SULFASYMAZINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553663","Sulfatroxazole","C152459","No value exists.","Sulfatroxazole | SULFATROXAZOLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553664","Sulfazamet","C152460","No value exists.","Sulfazamet | SULFAZAMET",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553665","Sulfinalol","C152461","No value exists.","Sulfinalol | SULFINALOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553666","sulfinalol hydrochloride","C152462","No value exists.","Sulfinalol Hydrochloride | SULFINALOL HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038744","Sulfisomidine","C152463","No value exists.","Sulfisomidine | SULFISOMIDINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553668","Sulfomyxin","C152464","No value exists.","Sulfomyxin | SULFOMYXIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553669","Sulglicotide","C152465","No value exists.","Sulglicotide | SULGLICOTIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553670","Suloctidil","C152466","No value exists.","Suloctidil | SULOCTIDIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0061450","Sulodexide","C152467","No value exists.","Sulodexide | SULODEXIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553673","Sulthiame","C152469","No value exists.","Sulthiame | SULTHIAME",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553609","Ruzasvir","C152277","No value exists.","Ruzasvir | RUZASVIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553610","Sabcomeline","C152278","No value exists.","Sabcomeline | SABCOMELINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553613","Sacubitril","C152281","A neprilysn (NEP) inhibitor prodrug with natriuretic activity. Upon administration, sacubitril is metabolized by esterases to its active metabolite, sacubitrilat, which inhibits NEP, a neutral endopeptidase that cleaves natriuretic peptides such as atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and c-type natriuretic peptide (CNP), as well as certain vasoconstricting peptides including as angiotensin I and II, and endothelin-1. Additionally, sacubitrilat may inhibit NEP-mediated catabolism of certain peptide-based agents, thereby improving their in vivo stability and increasing tumor cell exposure.","Sacubitril | (2R,4S)-5-(biphenyl-4-yl)-4-((3-carboxypropionyl)amino)-2-methylpentanoic acid ethyl ester | AHU 377 | AHU-377 | AHU377 | SACUBITRIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553614","Sacubitrilat","C152282","No value exists.","Sacubitrilat | SACUBITRILAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553616","Salcolex","C152284","No value exists.","Salcolex | SALCOLEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553617","Salethamide","C152285","No value exists.","Salethamide | SALETHAMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553618","Salethamide Maleate","C152286","No value exists.","Salethamide Maleate | SALETHAMIDE MALEATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553619","Salicylate Meglumine","C152287","No value exists.","Salicylate Meglumine | SALICYLATE MEGLUMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553621","Salnacedin","C152289","No value exists.","Salnacedin | SALNACEDIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554039","Tradipitant","C152707","An orally bioavailable, centrally-acting, selective, neurokinin 1 receptor (NK1-receptor; NK1R; NK-1R) antagonist with potential anti-emetic, anti-pruritic and anti-inflammatory activities. Upon oral administration, tradipitant competitively binds to and blocks the activity of the NK1R in the central nervous system (CNS), thereby inhibiting the binding of the endogenous ligand and neuropeptide, substance P (SP; neurokinin-1; NK1). This inhibits SP/NK1-mediated signal transduction and may prevent both SP-induced emesis and pruritis. In addition, inhibition of SP/NK1R signaling also reduces neurogenic inflammation which is triggered by the release of neuropeptides, such as substance P, from nerve cells. NK1R is a G protein-coupled receptor (GPCR) that preferentially binds to SP, a neuropeptide secreted by neuronal cells and inflammatory cells.","Tradipitant | LY-686017 | LY686017 | TRADIPITANT | VLY-686",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0757422","trafermin","C152708","No value exists.","Trafermin | TRAFERMIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553913","Tralesinidase Alfa","C152709","No value exists.","Tralesinidase Alfa | TRALESINIDASE ALFA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3658667","Tralokinumab","C152710","No value exists.","Tralokinumab | TRALOKINUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553915","Trametinib Dimethyl Sulfoxide","C152711","A dimethyl sulfoxide (DMSO) solvated form of trametinib, an orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration, trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity serine/threonine and tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.","Trametinib Dimethyl Sulfoxide | Mekinist | Meqsel | Spexotras | TRAMETINIB DIMETHYL SULFOXIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0146337","tranilast","C152712","No value exists.","Tranilast | TRANILAST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553917","Transcrocetin","C152713","No value exists.","Transcrocetin | TRANSCROCETIN | Transcrocetinate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552859","MMSE-2 Standard Version - Keep Subtracting 7 Step 5","C151014","Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Keep going [65].","MMSE-2 Standard Version - Keep Subtracting 7 Step 5 | MMS2-Keep Subtracting 7 Step 5 | MMS205E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552860","MMSE-2 Standard Version - Naming Object 1","C151015","Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) What is this: Object 1?","MMSE-2 Standard Version - Naming Object 1 | MMS2-Naming Object 1 | MMS206A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552861","MMSE-2 Standard Version - Naming Object 2","C151016","Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) What is this: Object 2?","MMSE-2 Standard Version - Naming Object 2 | MMS2-Naming Object 2 | MMS206B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552862","MMSE-2 Standard Version - Repeat What I Say","C151017","Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Now I am going to ask you to repeat what I say. Ready? 'It is a lovely, sunny day but too warm.' Now you say that.","MMSE-2 Standard Version - Repeat What I Say | MMS2-Repeat What I Say | MMS207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552864","MMSE-2 Standard Version - Point to the Square","C151019","Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Then point to the square.","MMSE-2 Standard Version - Point to the Square | MMS2-Point to the Square | MMS208B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552865","MMSE-2 Standard Version - Point to the Triangle","C151020","Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Then point to the triangle.","MMSE-2 Standard Version - Point to the Triangle | MMS2-Point to the Triangle | MMS208C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4279961","physical performance testing","C150523","Any of various activities and tests designed to assess an individual's physical fitness.","Physical Performance Testing | Physical Fitness Testing | Physical Function Testing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552272","Refractory Malignant Bone Neoplasm","C150525","Malignant bone neoplasm that is resistant to treatment.","Refractory Malignant Bone Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552271","Recurrent Malignant Female Reproductive System Neoplasm","C150526","The reemergence of a malignant female reproductive system neoplasm after a period of remission.","Recurrent Malignant Female Reproductive System Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552274","Refractory Malignant Female Reproductive System Neoplasm","C150527","Malignant female reproductive system neoplasm that is resistant to treatment.","Refractory Malignant Female Reproductive System Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552273","Recurrent Malignant Neoplasm of Multiple Primary Sites","C150528","Reemergence of a malignant neoplasm of multiple primary sites after a period of remission.","Recurrent Malignant Neoplasm of Multiple Primary Sites | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552268","Refractory Malignant Neoplasm of Multiple Primary Sites","C150529","Malignant neoplasm of multiple primary sites that is resistant to treatment.","Refractory Malignant Neoplasm of Multiple Primary Sites | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552267","Refractory Malignant Oral Neoplasm","C150530","Lip or oral cavity malignant neoplasm that is resistant to treatment.","Refractory Malignant Oral Neoplasm | Refractory Malignant Lip and Oral Cavity Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552270","Recurrent Malignant Pharyngeal Neoplasm","C150531","Reemergence of a malignant pharyngeal neoplasm after a period of remission.","Recurrent Malignant Pharyngeal Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552269","Refractory Malignant Pharyngeal Neoplasm","C150532","Malignant pharyngeal neoplasm that is resistant to treatment.","Refractory Malignant Pharyngeal Neoplasm | Refractory Malignant Pharyngeal Throat Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552263","Refractory Malignant Male Reproductive System Neoplasm","C150534","Malignant male reproductive system neoplasm that is resistant to treatment.","Refractory Malignant Male Reproductive System Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230178","Right Lower Quadrant of Abdomen","C151400","The region of the abdomen that extends from the median plane to the right of the patient, and from the umbilical plane to the right inguinal ligament.","Right Lower Quadrant of Abdomen | ABDOMINAL QUADRANT, RIGHT LOWER | RLQ | Right Lower Quadrant",,,,,,,,,,,,,,,"4174976","Structure of right lower quadrant of abdomen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL553237","PTP4A3 wt Allele","C151405","Human PTP4A3 wild-type allele is located in the vicinity of 8q24.3 and is approximately 40 kb in length. This allele, which encodes protein tyrosine phosphatase type IVA 3 protein, is involved in protein phosphatase activity, progression of the cell cycle and promotion of cell proliferation and cell motility. Aberrant expression of the gene is associated with tumor metastasis.","PTP4A3 wt Allele | PRL-3 | PRL-R | PRL3 | Protein Tyrosine Phosphatase Type IVA, Member 3 wt Allele | Protein Tyrosine Phosphatase, Type 4A, 3 Gene | Protein-Tyrosine Phosphatase, Type 4A, 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553238","PTP4A3 protein, human","C151406","Protein tyrosine phosphatase type IVA 3 (173 aa, ~20 kDa) is encoded by the human PTP4A3 gene. This protein plays a role in tyrosine phosphatase activity that promotes cell cycle progression.","Protein Tyrosine Phosphatase Type IVA 3 | EC 3.1.3.48 | PRL-3 | PRL-R | PTP4A3 | Phosphatase of Regenerating Liver 3 | Potentially Prenylated Protein Tyrosine Phosphatase | Protein-Tyrosine Phosphatase 4a3 | Protein-Tyrosine Phosphatase of Regenerating Liver 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553239","Flt3/MerTK Inhibitor MRX-2843","C151407","An orally bioavailable inhibitor of two receptor tyrosine kinases (RTKs), FMS-like tyrosine kinase-3 (Flt3; CD135; fetal liver kinase-2; Flk2) and tyrosine-protein kinase Mer (MerTK; proto-oncogene c-Mer; Mer), with potential antineoplastic activity. Upon administration, MRX-2843 targets and binds to both Flt3 and MerTK. This prevents ligand-dependent phosphorylation and activation of Flt3 and MerTK, which inhibits the activation of their downstream signaling pathways. This induces apoptosis and inhibits proliferation of Flt3- and/or MerTK-overexpressing tumor cells. Flt3 and MerTK, are overexpressed in certain tumor cell types and play key roles in tumor cell proliferation and survival.","Flt3/MerTK Inhibitor MRX-2843 | MRX 2843 | MRX-2843 | MRX2843 | UNC-2371A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511417","CD-1 Nude Mouse","C15152","An inbred strain of athymic, nude mouse developed by transferring the Foxn1nu gene to a CD1 mouse.","CD-1 Nude Mouse | CD-1 Nude | CD1 NU | Cr1:CD-1 -nuBR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516116","BALB/c Nude Mouse","C15153","No value exists.","BALB/c Nude Mouse | BALB/c Nude | BALB/cAnNCr1-nuBR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513840","NIH-III Mouse","C15154","No value exists.","NIH-III Mouse | N:NIH-bg-nu-xidBR | NIH-III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513861","NU/NU Mouse","C15155","No value exists.","NU/NU Mouse | Crl:NU/NU-nuBR | NU/NU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553674","Sultimotide Alfa","C152470","No value exists.","Sultimotide Alfa | SULTIMOTIDE ALFA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553675","Suncillin","C152471","No value exists.","Suncillin | SUNCILLIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553676","Suncillin Sodium","C152472","No value exists.","Suncillin Sodium | SUNCILLIN SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553678","Sunepitron Hydrochloride","C152474","No value exists.","Sunepitron Hydrochloride | SUNEPITRON HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553679","Suplatast Tosilate","C152475","No value exists.","Suplatast Tosilate | SUPLATAST TOSILATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553680","Suptavumab","C152476","No value exists.","Suptavumab | SUPTAVUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553681","Suricainide","C152477","No value exists.","Suricainide | SURICAINIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553683","Suritozole","C152479","No value exists.","Suritozole | SURITOZOLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553684","Surotomycin","C152480","No value exists.","Surotomycin | SUROTOMYCIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553685","antihemophilic factor, porcine B-domain truncated recombinant","C152481","No value exists.","Susoctocog Alfa | SUSOCTOCOG ALFA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553687","Suvizumab","C152483","No value exists.","Suvizumab | SUVIZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553688","Suvratoxumab","C152484","No value exists.","Suvratoxumab | SUVRATOXUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553689","Syrosingopine","C152485","No value exists.","Syrosingopine | SYROSINGOPINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553690","Taclamine","C152486","No value exists.","Taclamine | TACLAMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553692","Tadekinig Alfa","C152488","No value exists.","Tadekinig Alfa | TADEKINIG ALFA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554092","Vinrosidine","C152888","No value exists.","Vinrosidine | VINROSIDINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554093","Vinrosidine Sulfate","C152889","No value exists.","Vinrosidine Sulfate | (4'-alpha)Vincaleukoblastine Sulfate | VINROSIDINE SULFATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554094","Vintiamol","C152890","No value exists.","Vintiamol | VINTIAMOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554095","Vintriptol","C152891","No value exists.","Vintriptol | VINTRIPTOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554096","Vipadenant","C152892","No value exists.","Vipadenant | VIPADENANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554097","Viprostol","C152893","No value exists.","Viprostol | VIPROSTOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554098","Viqualine","C152894","No value exists.","Viqualine | VIQUALINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554099","Viquidacin","C152895","No value exists.","Viquidacin | VIQUIDACIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554100","Viquidil","C152896","No value exists.","Viquidil | VIQUIDIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554101","Viridofulvin","C152897","No value exists.","Viridofulvin | VIRIDOFULVIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553918","Transferrin Aldifitox","C152714","No value exists.","Transferrin Aldifitox | TRANSFERRIN ALDIFITOX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553919","Trantelinium Bromide","C152715","No value exists.","Trantelinium Bromide | TRANTELINIUM BROMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553921","Trebenzomine","C152717","No value exists.","Trebenzomine | TREBENZOMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553922","Trebenzomine Hydrochloride","C152718","No value exists.","Trebenzomine Hydrochloride | TREBENZOMINE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553924","Trefentanil","C152720","No value exists.","Trefentanil | TREFENTANIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553925","Trefentanil Hydrochloride","C152721","No value exists.","Trefentanil Hydrochloride | TREFENTANIL HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553926","Tregalizumab","C152722","No value exists.","Tregalizumab | TREGALIZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553927","trelagliptin","C152723","No value exists.","Trelagliptin | TRELAGLIPTIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553928","Trelagliptin Succinate","C152724","No value exists.","Trelagliptin Succinate | TRELAGLIPTIN SUCCINATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553930","Trempamotide","C152726","No value exists.","Trempamotide | TREMPAMOTIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553931","Trenonacog Alfa","C152727","No value exists.","Trenonacog Alfa | TRENONACOG ALFA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553932","Trepipam","C152728","No value exists.","Trepipam | TREPIPAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553933","Trepipam Maleate","C152729","No value exists.","Trepipam Maleate | TREPIPAM MALEATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553934","Treprostinil Diolamine","C152730","No value exists.","Treprostinil Diolamine | TREPROSTINIL DIOLAMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553935","Trequinsin","C152731","No value exists.","Trequinsin | TREQUINSIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553936","Trethocanoic Acid","C152732","No value exists.","Trethocanoic Acid | TRETHOCANOIC ACID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553058","SIQ - Wished I Had the Nerve Kill Myself","C151341","Suicidal Ideation Questionnaire (SIQ) I wished I had the nerve to kill myself.","SIQ - Wished I Had the Nerve Kill Myself | SIQ01-Wished I Had the Nerve Kill Myself | SIQ0116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553059","SIQ - Wished I Had Never Been Born","C151342","Suicidal Ideation Questionnaire (SIQ) I wished that I had never been born.","SIQ - Wished I Had Never Been Born | SIQ01-Wished I Had Never Been Born | SIQ0117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553060","SIQ - If Had Chance I Would Kill Myself","C151343","Suicidal Ideation Questionnaire (SIQ) I thought if I had the chance I would kill myself.","SIQ - If Had Chance I Would Kill Myself | SIQ01-If Had Chance I Would Kill Myself | SIQ0118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553062","SIQ - Thought Killing Myself Not Do It","C151345","Suicidal Ideation Questionnaire (SIQ) I thought about killing myself, but would not do it.","SIQ - Thought Killing Myself Not Do It | SIQ01-Thought Killing Myself Not Do It | SIQ0120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553063","SIQ - Thought About Having Bad Accident","C151346","Suicidal Ideation Questionnaire (SIQ) I thought about having a bad accident.","SIQ - Thought About Having Bad Accident | SIQ01-Thought About Having Bad Accident | SIQ0121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552266","Refractory Malignant Mesothelioma","C150535","Malignant mesothelioma that is resistant to treatment.","Refractory Malignant Mesothelioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552265","Recurrent Malignant Soft Tissue Neoplasm","C150536","Reemergence of a malignant soft tissue neoplasm after a period of remission.","Recurrent Malignant Soft Tissue Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552260","Refractory Malignant Soft Tissue Neoplasm","C150537","Malignant soft tissue neoplasm that is resistant to treatment.","Refractory Malignant Soft Tissue Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552259","Recurrent Malignant Thyroid Gland Neoplasm","C150538","The reemergence of malignant thyroid gland neoplasm after a period of remission.","Recurrent Malignant Thyroid Gland Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552262","Refractory Malignant Thyroid Gland Neoplasm","C150539","Malignant thyroid gland neoplasm that is resistant to treatment.","Refractory Malignant Thyroid Gland Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552261","Recurrent Malignant Endocrine Neoplasm","C150540","Reemergence of a malignant endocrine neoplasm after a period of remission.","Recurrent Malignant Endocrine Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552256","Refractory Malignant Endocrine Neoplasm","C150541","Malignant endocrine neoplasm that is resistant to treatment.","Refractory Malignant Endocrine Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552255","Recurrent Malignant Urinary System Neoplasm","C150542","Reemergence of a malignant urinary system neoplasm after a period of remission.","Recurrent Malignant Urinary System Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552620","Venlafaxine Hydrochloride Extended Release","C150751","An extended-release (ER) formulation composed of the hydrochloride salt form of venlafaxine, a synthetic phenethylamine bicyclic derivative and serotonin (5-hydroxytryptamine; 5-HT) and norepinephrine (NE) reuptake inhibitor (SNRI), with antidepressant and anti-anxiety activities and with potential use in the treatment of neuropathic pain. Upon administration, venlafaxine is released from the formulation in a controlled manner for an extended period of time. Venlafaxine, and its main active metabolite, O-desmethylvenlafaxine (ODV), selectively bind to the pre-synaptic 5-HT and NE transporters in the synaptic cleft and inhibit the re-uptake of 5-HT and NE, and to a lesser extent dopamine, thereby prolonging and potentiating the activities and signaling mediated by these neurotransmitters in the central nervous system (CNS). This relieves depressive and anxious states. Additionally, venlafaxine may exert analgesic effects through blockade of neuronal NE reuptake and inhibition of nociceptive pathways, or through its potential to regulate monoaminergic and opioidergic systems.","Venlafaxine Hydrochloride Extended Release | Effexor XR | Venlafaxine HCl ER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512658","Immunodeficient Mouse","C15156","Any mouse strain with a faulty immune system such that its ability to fight infectious disease is compromised or ablated. Immunodeficient mice may be derived by inbreeding or genetic engineering. Immunodeficiency may also be induced by some chemicals, heavy metals, alkylating agents, radiation, and thymectomy.","Immunodeficient Mouse | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514714","Rag1-Deficient Mouse","C15157","No value exists.","Rag1 Mouse | Rag1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553378","ALDH4A1 Gene","C152043","This gene is involved in the conversion of proline and ornithine to glutamate.","ALDH4A1 Gene | ALDH4A1 | Aldehyde Dehydrogenase 4 Family Member A1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553379","ALDH4A1 wt Allele","C152044","Human ALDH4A1 wild-type allele is located in the vicinity of 1p36.13 and is approximately 31 kb in length. This allele, which encodes delta-1-pyrroline-5-carboxylate dehydrogenase protein, mitochondrial, plays a role in glutamate synthesis. Mutation of the gene is associated with type II hyperprolinemia.","ALDH4A1 wt Allele | ALDH4 | Aldehyde Dehydrogenase 4 Family Member A1 wt Allele | Aldehyde Dehydrogenase 4 Family, Member A1 Gene | P5CD | P5CDH | P5CDh",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553380","Delta-1-Pyrroline-5-Carboxylate Dehydrogenase, Mitochondrial","C152045","Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial (563 aa, ~62 kDa) is encoded by the human ALDH4A1 gene. This protein is involved in the conversion of proline pyrroline-5-carboxylate to glutamate.","Delta-1-Pyrroline-5-Carboxylate Dehydrogenase, Mitochondrial | ALDH4A1 | Aldehyde Dehydrogenase 4 | Aldehyde Dehydrogenase 4 Family Member A1 | Aldehyde Dehydrogenase Family 4 Member A1 | EC 1.2.1.88 | Epididymis Secretory Sperm Binding Protein | L-Glutamate Gamma-Semialdehyde Dehydrogenase | Mitochondrial Delta-1-Pyrroline 5-Carboxylate Dehydrogenase | P5C Dehydrogenase | Pyrroline-5-Carboxylate Dehydrogenase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553381","Refractory Primary Peritoneal Carcinoma","C152046","Primary peritoneal carcinoma that is resistant to treatment.","Refractory Primary Peritoneal Carcinoma | Refractory Primary Peritoneal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553382","Refractory Fallopian Tube Carcinoma","C152047","Fallopian tube carcinoma that is resistant to treatment.","Refractory Fallopian Tube Carcinoma | Refractory Fallopian Tube Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553383","Refractory Female Reproductive System Carcinoma","C152048","Female reproductive system carcinoma that is resistant to treatment.","Refractory Female Reproductive System Carcinoma | Refractory Female Reproductive System Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553384","AP2B1 Gene","C152049","This gene plays a role in protein transport via clathrin-coated vesicles.","AP2B1 Gene | AP2B1 | Adaptor Related Protein Complex 2 Beta 1 Subunit Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0008138","Chiropractic (field)","C15204","An alternative medical system that focuses on the relationship between bodily structure (primarily that of the spine) and function, and how that relationship affects the preservation and restoration of health. Chiropractors use manipulative therapy as an integral treatment tool.","Chiropractic Therapy | Chiropractic | Chiropractic Medicine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553385","AP2B1 wt Allele","C152050","Human AP2B1 wild-type allele is located in the vicinity of 17q12 and is approximately 148 kb in length. This allele, which encodes AP-2 complex subunit beta protein, is involved in endocytosis mediated by clathrin-coated vesicles.","AP2B1 wt Allele | ADTB2 | AP105B | AP2-BETA | Adaptin, Beta 2 (Beta) Gene | Adaptin, Beta 2 Gene | Adaptin, Beta-2 Gene | Adaptor Related Protein Complex 2 Beta 1 Subunit wt Allele | Adaptor-Related Protein Complex 2, Beta 1 Subunit Gene | CLAPB1 | Clathrin Adaptor Complex AP2, Beta Subunit Gene | Clathrin-Associated/Assembly/Adaptor Protein, Large, Beta 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3659156","AP2B1 protein, human","C152051","AP-2 complex subunit beta (937 aa, ~105 kDa) is encoded by the human AP2B1 gene. This protein plays a role in formation of and cargo selection for clathrin-coated vesicles.","AP-2 Complex Subunit Beta | AP105B | AP2B1 | Adapter-Related Protein Complex 2 Beta Subunit | Adapter-Related Protein Complex 2 Subunit Beta | Adaptor Protein Complex AP-2 Subunit Beta | Adaptor-Related Protein Complex 2 Subunit Beta | Beta-2-Adaptin | Beta-Adaptin | Clathrin Assembly Protein Complex 2 Beta Large Chain | Plasma Membrane Adaptor HA2/AP2 Adaptin Beta Subunit | Testicular Tissue Protein Li 22",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554102","Viroxime","C152898","No value exists.","Viroxime | VIROXIME",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL773298","Vixotrigine","C152899","No value exists.","Vixotrigine | VIXOTRIGINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554232","Vixotrigine Hydrochloride","C152900","No value exists.","Vixotrigine Hydrochloride | VIXOTRIGINE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554233","Vobarilizumab","C152901","No value exists.","Vobarilizumab | VOBARILIZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554234","Voclosporin","C152902","No value exists.","Voclosporin | VOCLOSPORIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554235","Vofopitant Dihydrochloride","C152903","No value exists.","Vofopitant Dihydrochloride | VOFOPITANT DIHYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554236","ISIS 304801","C152904","No value exists.","Volanesorsen | VOLANESORSEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554237","Volanesorsen Sodium","C152905","No value exists.","Volanesorsen Sodium | VOLANESORSEN SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554238","Volasertib Trihydrochloride","C152906","No value exists.","Volasertib Trihydrochloride | VOLASERTIB TRIHYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554239","Volixibat","C152907","No value exists.","Volixibat | VOLIXIBAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554240","Volixibat Potassium","C152908","No value exists.","Volixibat Potassium | VOLIXIBAT POTASSIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554241","Vonapanitase","C152909","No value exists.","Vonapanitase | VONAPANITASE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL592127","Vonicog Alfa","C152910","No value exists.","Vonicog Alfa | VONICOG ALFA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554243","1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine","C152911","A potassium-competitive acid blocker (P-CAB), with acid suppressing activity. Upon oral administration, vonoprazan concentrates in the gastric parietal cells and competitively and reversibly binds to the potassium binding site of the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase), thereby inhibiting the pump's activity and the parietal cell secretion of H+ ions into the gastric lumen, the final step in gastric acid production. By inhibiting gastric acid secretion, vonoprazan provides relief and healing in the treatment of various conditions, such as gastroduodenal ulcers and reflux esophagitis.","Vonoprazan | VONOPRAZAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3818693","vorapaxar sulfate","C152913","The sulfate salt form of vorapaxar, an orally bioavailable protease-activated receptor-1 (PAR-1) antagonist, with antiplatelet activity. Upon oral administration, vorapaxar binds to PAR-1 expressed on platelets, and inhibits PAR-1-mediated platelet aggregation. Vorapaxar inhibits thrombin-induced and thrombin receptor agonist peptide (TRAP)-induced platelet aggregation, and does not inhibit platelet aggregation induced by adenosine diphosphate (ADP), collagen or a thromboxane mimetic.","Vorapaxar Sulfate | SCH 530348 | VORAPAXAR SULFATE | Zontivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553253","Hematologic Neoplasm with Germline Predisposition Associated with a Constitutional Disorder Affecting Multiple Organ Systems","C151910","Familial hematologic neoplasms associated with germline mutations and a preexisting disorder or organ dysfunction other than a platelet disorder.","Hematologic Neoplasm with Germline Predisposition Associated with a Constitutional Disorder Affecting Multiple Organ Systems | Hematologic Neoplasm with Germline Predisposition Associated with Other Organ Dysfunction | Myeloid Neoplasm with Germline Predisposition Associated with Other Organ Dysfunction | Myeloid Neoplasms with Germline Predisposition Associated with Other Organ Dysfunction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553254","Hematologic Neoplasm with Germline ETV6 Mutation","C151911","Autosomal dominant familial thrombocytopenia associated with germline ETV6 mutation and hematologic malignancies. The hematologic malignancies reported are diverse, including myelodysplastic syndrome, acute myeloid leukemia, chronic myelomonocytic leukemia, B lymphoblastic leukemia, and plasma cell myeloma. Non-hematological neoplasms, including colorectal adenocarcinoma, have been also reported in affected families. (WHO 2017)","Hematologic Neoplasm with Germline ETV6 Mutation | Myeloid Neoplasms with Germline ETV6 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553255","Hematologic Neoplasm with Germline GATA2 Mutation","C151912","Myelodysplastic syndromes/acute myeloid leukemias associated with germline GATA2 mutation.","Hematologic Neoplasm with Germline GATA2 Mutation | Myeloid Neoplasm with Germline GATA2 Mutation | Myeloid Neoplasms with Germline GATA2 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553064","SIQ - Thought Life Was Not Worth Living","C151347","Suicidal Ideation Questionnaire (SIQ) I thought that life was not worth living.","SIQ - Thought Life Was Not Worth Living | SIQ01-Thought Life Was Not Worth Living | SIQ0122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553065","SIQ - My Life Was Too Rotten to Continue","C151348","Suicidal Ideation Questionnaire (SIQ) I thought that my life was too rotten to continue.","SIQ - My Life Was Too Rotten to Continue | SIQ01-My Life Was Too Rotten to Continue | SIQ0123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553067","SIQ - People Realize Worth Caring About","C151350","Suicidal Ideation Questionnaire (SIQ) I thought that if I killed myself people would realize I was worth caring about.","SIQ - People Realize Worth Caring About | SIQ01-People Realize Worth Caring About | SIQ0125",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553068","SIQ - No One Cared If I Lived or Died","C151351","Suicidal Ideation Questionnaire (SIQ) I thought that no one cared if I lived or died.","SIQ - No One Cared If I Lived or Died | SIQ01-No One Cared If I Lived or Died | SIQ0126",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553069","SIQ - Hurting Myself but Not Kill Myself","C151352","Suicidal Ideation Questionnaire (SIQ) I thought about hurting myself but not really killing myself.","SIQ - Hurting Myself but Not Kill Myself | SIQ01-Hurting Myself but Not Kill Myself | SIQ0127",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553070","SIQ - Wondered If Had Nerve Kill Myself","C151353","Suicidal Ideation Questionnaire (SIQ) I wondered if I had the nerve to kill myself.","SIQ - Wondered If Had Nerve Kill Myself | SIQ01-Wondered If Had Nerve Kill Myself | SIQ0128",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553071","SIQ - If Things Not Better I Kill Myself","C151354","Suicidal Ideation Questionnaire (SIQ) I thought that if things did not get better I would kill myself.","SIQ - If Things Not Better I Kill Myself | SIQ01-If Things Not Better I Kill Myself | SIQ0129",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553072","SIQ - Wished I Had Right to Kill Myself","C151355","Suicidal Ideation Questionnaire (SIQ) I wished that I had the right to kill myself.","SIQ - Wished I Had Right to Kill Myself | SIQ01-Wished I Had Right to Kill Myself | SIQ0130",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553073","SIQ - TS","C151356","Suicidal Ideation Questionnaire (SIQ) TS (total raw score).","SIQ - TS | SIQ01-TS | SIQ0131",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553074","SIQ - Total %","C151357","Suicidal Ideation Questionnaire (SIQ) Total standardization sample %.","SIQ - Total % | SIQ01-Total % | SIQ0132",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553075","SIQ - Specific %: Standard Sample 1","C151358","Suicidal Ideation Questionnaire (SIQ) Specific standardization %: Sample 1.","SIQ - Specific %: Standard Sample 1 | SIQ01-Specific %: Standard Sample 1 | SIQ0133",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553076","SIQ - Specific %: Standard Sample 2","C151359","Suicidal Ideation Questionnaire (SIQ) Specific standardization %: Sample 2.","SIQ - Specific %: Standard Sample 2 | SIQ01-Specific %: Standard Sample 2 | SIQ0134",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553219","Polypeptide N-Acetylgalactosaminyltransferase 12","C151998","Polypeptide N-acetylgalactosaminyltransferase 12 (581 aa, ~67 kDa) is encoded by the human GALNT12 gene. This protein plays a role in catalyzing the transfer of an N-acetyl-D-galactosamine (GalNAc) residue to a serine or threonine residue on a protein substrate.","Polypeptide N-Acetylgalactosaminyltransferase 12 | EC 2.4.1.41 | GALNT12 | GalNAc-T12 | Polypeptide GalNAc Transferase 12 | Protein-UDP Acetylgalactosaminyltransferase 12 | UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase 12 | UDP-N-Acetyl-Alpha-D-Galactosamine:Polypeptide N-Acetylgalactosaminyltransferase 12 | pp-GaNTase 12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552183","Refractory Urothelial Carcinoma","C150364","Urothelial carcinoma that does not respond to treatment.","Refractory Urothelial Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552182","Platinum-Resistant Urothelial Carcinoma","C150365","Urothelial carcinoma that is resistant to platinum therapy.","Platinum-Resistant Urothelial Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552180","Percent of Prostate Cores Positive for Carcinoma","C150366","The number of prostate core biopsy samples positive for carcinoma divided by the total number of prostate core samples.","Percent of Prostate Cores Positive for Carcinoma | Number of Prostate Cores Positive for Carcinoma/Total Number of Prostate Cores",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2931875","Hermansky-Pudlak Syndrome 1","C150367","An autosomal recessive sub-type of Hermansky-Pudlak syndrome caused by mutation(s) in the HPS1 gene, encoding Hermansky-Pudlak syndrome 1 protein. This sub-type is associated with pulmonary fibrosis.","Hermansky-Pudlak Syndrome 1 | HPS1",,,,,,,,,,,,,,,"4246348","Platelet dense granule deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1842362","HERMANSKY-PUDLAK SYNDROME 2","C150368","An autosomal recessive sub-type of Hermansky-Pudlak syndrome caused by mutation(s) in the AP3B1 gene, encoding AP-3 complex subunit beta-1. Immunodeficiency due to neutropenia is a characteristic of this sub-type.","Hermansky-Pudlak Syndrome 2 | HPS2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553574","Sirtratumab Vedotin","C152370","An antibody-drug conjugate (ADC) composed of sirtratumab, a monoclonal antibody directed against SLIT and NTRK-like protein 6 (SLITRK6), covalently linked to the cytotoxic agent monomethyl auristatin E (MMAE), an auristatin derivative and a potent inhibitor of microtubule polymerization, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of sirtratumab vedotin binds to SLITRK6 expressed on tumor cells, which facilitates both the internalization of the ADC and the intracellular delivery of MMAE. Upon cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and tumor cell apoptosis.  SLITRK6, a member of the Slitrk family of leucine-rich repeat (LRR) neuronal transmembrane proteins, is minimally expressed in normal tissue but overexpressed in a variety of cancers, including bladder cancer, some forms of lung cancer, breast cancer and glioblastoma.","Sirtratumab Vedotin | AGS-15E | AGS15E | ASG-15ME | Anti-SLITRK6 ADC AGS15E | Anti-SLITRK6 Antibody-drug Conjugate AGS15E | Anti-SLITRK6 Monoclonal Antibody-MMAE Conjugate AGS15E | SIRTRATUMAB VEDOTIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553575","Sirukumab","C152371","A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the pro-inflammatory cytokine interleukin-6 (IL-6), with potential immunomodulating and anti-inflammatory activities. Upon administration, sirukumab targets, binds to and blocks the activity of IL-6, which may inhibit the binding of IL-6 to its receptor interleukin-6 receptor (IL-6R). This may inhibit the IL-6/IL-6R-mediated signal transduction pathway and the associated inflammatory response.","Sirukumab | CNTO 136 | CNTO-136 | Plivensia (TM) | SIRUKUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553576","Sisapronil","C152372","No value exists.","Sisapronil | SISAPRONIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553577","Sitaxentan Sodium","C152373","No value exists.","Sitaxentan Sodium | SITAXENTAN SODIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553578","smilagenin","C152374","No value exists.","Smilagenin | SMILAGENIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553579","Sodium Amylosulfate","C152375","No value exists.","Sodium Amylosulfate | SODIUM AMYLOSULFATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553580","Sodium Arsenate As-74","C152376","No value exists.","Sodium Arsenate As-74 | SODIUM ARSENATE AS-74",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553581","Sodium Ethasulfate","C152377","No value exists.","Sodium Ethasulfate | SODIUM ETHASULFATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553582","Sodium Glucaspaldrate","C152378","No value exists.","Sodium Glucaspaldrate | SODIUM GLUCASPALDRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553583","Sodium Stibocaptate","C152379","No value exists.","Sodium Stibocaptate | SODIUM STIBOCAPTATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0017272","Gene Bank","C15237","A stored copy of genetic information of a species in a preferred environment for conservation purposes. (biology-online.org)","Gene Bank | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553584","Sodium Sulfate S-35","C152380","No value exists.","Sodium Sulfate S-35 | SODIUM SULFATE S-35",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553586","Sofigatran","C152382","No value exists.","Sofigatran | SOFIGATRAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553587","Sofituzumab","C152383","No value exists.","Sofituzumab | SOFITUZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553257","DDX41 wt Allele","C151914","Human DDX41 wild-type allele is located in the vicinity of 5q35.3 and is approximately 6 kb in length. This allele, which encodes probable ATP-dependent RNA helicase DDX41 protein, may be involved in the functionality of the spliceosome. Heterozygous mutation of the gene may be associated with susceptibility to multiple types of familial myeloproliferative and lymphoproliferative neoplasms.","DDX41 wt Allele | ABS | Abstrakt, Drosophila, Homolog of Gene | DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 41 Gene | DEAD-Box Helicase 41 wt Allele | DEAD/H Box 41 Gene | Drosophila Abstrakt Homolog Gene | MGC8828 | MPLPF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553258","DDX41 protein, human","C151915","Probable ATP-dependent RNA helicase DDX41 (622 aa, ~70 kDa) is encoded by the human DDX41 gene. This protein may play a role in gene splicing.","Probable ATP-Dependent RNA Helicase DDX41 | DDX41 | DEAD Box Protein 41 | DEAD Box Protein Abstrakt Homolog | DEAD-Box Protein Abstrakt | EC 3.6.4.13",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553259","Non-Research Project","C151918","A project that does not have a specific hypothesis or discovery objective and typically supports research projects. Supporting projects can be one-time or ongoing operations.","Non-Research Project | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553260","Telomere Maintenance Gene Mutation","C151919","A change in the nucleotide sequence of a gene involved in telomere synthesis and maintenance.","Telomere Maintenance Gene Mutation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1443933","Biosafety Level","C151920","A set of biocontainment precautions, consisting of combinations of laboratory practices and techniques, safety equipment, and specialized laboratory facilities, required to isolate potentially dangerous biological agents in an enclosed laboratory facility. They include individual safeguards designed to protect laboratory personnel, as well as safeguards designed to protect the surrounding environment and community.","Biosafety Level | BSL | Biosafety Containment Level | Laboratory Biosafety Level",,,,,,,,,,,,,,,"4256221","Laboratory biosafety level",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL553261","Hematologic Neoplasm with Germline Predisposition Associated with Telomerase Biology Disorder","C151921","Familial myelodysplastic syndromes/ acute myeloid leukemias associated with telomerase biology disorders.","Hematologic Neoplasm with Germline Predisposition Associated with Telomerase Biology Disorder | Myeloid Neoplasm with Germline Predisposition Associated with Telomerase Biology Disorder | Myeloid Neoplasms with Germline Predisposition Associated with Telomerase Biology Disorders",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553262","Hematologic Neoplasm with Germline Predisposition Associated with Inherited Bone Marrow Failure Syndrome","C151922","Familial myelodysplastic syndromes/ acute myeloid leukemias associated with inherited bone marrow failure syndromes.","Hematologic Neoplasm with Germline Predisposition Associated with Inherited Bone Marrow Failure Syndrome | Hematologic Neoplasm Associated with Inherited Bone Marrow Failure Syndrome | Myeloid Neoplasm Associated with Inherited Bone Marrow Failure Syndrome | Myeloid Neoplasm with Germline Predisposition Associated with Inherited Bone Marrow Failure Syndrome | Myeloid Neoplasms with Germline Predisposition Associated with Inherited Bone Marrow Failure Syndromes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553264","ANKRD26 wt Allele","C151925","Human ANKRD26 wild-type allele is located in the vicinity of 10p12.1 and is approximately 134 kb in length. This allele, which encodes ankyrin repeat domain-containing protein 26, is involved in adipogenesis, appetite and platelet functions. Mutations in the 5' promoter region of this gene that result in increased expression are associated with autosomal dominant thrombocytopenia 2.","ANKRD26 wt Allele | Ankyrin Repeat Domain 26 wt Allele | KIAA1074 | THC2 | Thrombocytopenia 2 (Autosomal Dominant) Gene | bA145E8.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552289","Small Intestinal Monomorphic Epitheliotropic T-Cell Lymphoma","C150504","A monomorphic epitheliotropic intestinal T-cell lymphoma arising from the small intestine. It is characterized by the presence of a monomorphic cellular infiltrate of small to medium-sized T-lymphocytes that are cytotoxic and express CD56. It is not associated with celiac disease.","Small Intestinal Monomorphic Epitheliotropic T-Cell Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0244748","Roquinimex","C1519","A quinoline-3-carboxamide with potential antineoplastic activity.  Roquinimex inhibits endothelial cell proliferation, migration, and basement membrane invasion; reduces the secretion of the angiogenic factor tumor necrosis factor alpha by tumor-associated macrophages (TAMs); and inhibits angiogenesis.  This agent is also an immune modulator that appears to alter cytokine profiles and enhance the activity of T cells, natural killer cells, and macrophages. (NCI04)","Roquinimex | 1,2-Dihydro-4-hydroxy-N,1-dimethyl-2-oxo-3-quinolinecarboxanilide | 1,2-Dihydro-4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide | FCF 89 | LS 2616 | Linomide | N-Phenyl-N-methyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxamide | ROQUINIMEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553221","GREM1 wt Allele","C152000","Human GREM1 wild-type allele is located in the vicinity of 15q13.3 and is approximately 27 kb in length. This allele, which encodes gremlin-1 protein, plays a role in antagonizing bone morphogenetic protein signaling pathways. Mutation of the gene is associated with hereditary mixed polyposis syndrome 1.","GREM1 wt Allele | C15DUPq | CKTSF1B1 | CRAC1 | CRCS4 | Cell Proliferation-Inducing Gene 2 | Colorectal Adenoma and Carcinoma 1 Gene | Cystine Knot Superfamily 1, BMP Antagonist 1 Gene | DAND2 | DRM | DUP15q | GREMLIN | Gremlin 1 Homolog, Cysteine Knot Superfamily Gene | Gremlin 1, Cysteine Knot Superfamily, Homolog (Xenopus laevis) Gene | Gremlin 1, Cysteine Knot Superfamily, Homolog Gene | Gremlin 1, DAN Family BMP Antagonist wt Allele | HMPS | HMPS1 | IHG-2 | MPSH | PIG2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1438932","GREM1 protein, human","C152001","Gremlin-1 (184 aa, ~21 kDa) is encoded by the human GREM1 gene. This protein is involved in the modulation of signaling by bone morphogenetic proteins.","Gremlin-1 | Cell Proliferation-Inducing Gene 2 Protein | Cysteine Knot Superfamily 1, BMP Antagonist 1 | DAN Domain Family Member 2 | Down-Regulated in Mos-Transformed Cells Protein | GREM1 | Gremlin 1 | IHG-2 | Increased In High Glucose Protein 2 | Increased In High Glucose-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553223","KIF1B Gene","C152002","This gene plays a role in localization of mitochondria and transport of synaptic vesicles.","KIF1B Gene | KIF1B | Kinesin Family Member 1B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553339","KIF1B wt Allele","C152003","Human KIF1B wild-type allele is located in the vicinity of 1p36.22 and is approximately 171 kb in length. This allele, which encodes kinesin-like protein KIF1B, is involved in the transport of synaptic vesicles and mitochondria. Mutation of the gene is associated with pheochromocytoma, increased susceptibility to neuroblastoma and Charcot-Marie-Tooth disease type 2A1.","KIF1B wt Allele | CMT2 | CMT2A | CMT2A1 | HMSNII | KIAA0591 | KIAA1448 | KLP | Kinesin Family Member 1B wt Allele | NBLST1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1309478","KIF1B protein, human","C152004","Kinesin-like protein KIF1B (1816 aa, ~204 kDa) is encoded by the human KIF1B gene. This protein plays a role in intercellular transport of organelles and vesicles.","Kinesin-Like Protein KIF1B | KIF1B | Kinesin Family Member 1B | Kinesin Superfamily Protein KIF1B | Klp",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553341","RPS20 Gene","C152005","This gene is involved in both translation and nonsense-mediated mRNA decay.","RPS20 Gene | RPS20 | Ribosomal Protein S20 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553342","RPS20 wt Allele","C152006","Human RPS20 wild-type allele is located in the vicinity of 8q12.1 and is approximately 7 kb in length. This allele, which encodes 40S ribosomal protein S20, plays a role in mRNA decay and translation.","RPS20 wt Allele | Ribosomal Protein S20 wt Allele | S20 | uS10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1615592","40S ribosomal protein S20, human","C152007","40S ribosomal protein S20 (119 aa, ~13 kDa) is encoded by the human RPS20 gene. This protein is involved in mRNA catabolism and protein synthesis.","40S Ribosomal Protein S20 | RPS20 | Small Ribosomal Subunit Protein uS10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553344","TMEM45B Gene","C152008","This gene may play a role in cell proliferation and migration.","TMEM45B Gene | TMEM45B | Transmembrane Protein 45B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553345","TMEM45B wt Allele","C152009","Human TMEM45B wild-type allele is located in the vicinity of 11q24.3 and is approximately 44 kb in length. This allele, which encodes transmembrane protein 45B, may be involved in cell migration and cellular proliferation.","TMEM45B wt Allele | BC016153 | FLJ40787 | Transmembrane Protein 45B wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553622","Salprotoside","C152290","No value exists.","Salprotoside | SALPROTOSIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3888007","HERMANSKY-PUDLAK SYNDROME 6","C150369","An autosomal recessive sub-type of Hermansky-Pudlak syndrome caused by mutation(s) in the HPS6 gene, encoding Hermansky-Pudlak syndrome 6 protein. Individuals with this type of syndrome, as well as with types 3 or 5, have the mildest symptoms.","Hermansky-Pudlak Syndrome 6 | HPS6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552177","Cavernous Nerve Electrical Stimulation","C150370","Stimulation of the cavernous nerve with an electrical current for the purpose of treating neurogenic cases of erectile dysfunction.","Cavernous Nerve Electrical Stimulation | Cavernosal Nerve Electrical Stimulation | Cavernosal Nerve Stimulation | Cavernous Nerve Stimulation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552176","Guidewire Length","C150371","The length of the guidewire.","Guidewire Length | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552179","Guidewire Diameter","C150372","The diameter of the guidewire.","Guidewire Diameter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552178","Imaging Agent QRH-882260 Heptapeptide","C150373","An orally bioavailable fluorescent imaging agent composed of the near-infrared (NIR) fluorophore cyanine 5 (Cy5) linked to a seven-amino acid long peptide that specifically binds to the tumor-associated antigen (TAA) epithelial growth factor receptor (epidermal growth factor receptor; EGFR), that can potentially be used for the imaging of EGFR-expressing tumor cells. Upon oral administration of the fluorescent imaging agent QRH-882260 heptapeptide, the peptide moiety selectively binds to EGFR expressed on tumor cells in the gastrointestinal (GI) tract. Upon fluorescence imaging, EGFR-expressing tumor cells can be visualized. EGFR, a member of the epidermal growth factor receptor family, is overexpressed on the surfaces of various tumors cells.","Imaging Agent QRH-882260 Heptapeptide | Fluorescence Peptide QRH-882260 | Fluorescently-labeled Peptide QRH-882260 | Gln-Arg-His-Lys-Pro-Arg-Glu-Gly-Gly-Gly-Ser-Lys(Cy5)-NH2 | QRH-882260 | QRH-882260 Cy-5-labeled Heptapeptide | QRHKPRE-GGGSK-(Cy5)-NH2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552172","Licogliflozin","C150375","An inhibitor of the sodium-dependent glucose co-transporter (sodium-glucose transporter; sodium-glucose transport protein; sodium-glucose linked transporter; SGLT) family members 1 and 2 (SGLT1/2) with antihyperglycemic activity. By binding to and blocking SGLT1/2, licogliflozin suppresses the reabsorption of glucose in the proximal tubule within the kidneys and enhances urinary excretion of glucose. This normalizes blood glucose levels. SGLT1/2, parts of a transport system expressed in the proximal renal tubules, mediate the majority of renal glucose reabsorption from tubular fluid.","Licogliflozin | D-Glucitol, 1,5-Anhydro-1-C-(3-((2,3-dihydro-1,4-benzodioxin-6-yl)methyl)-4-ethylphenyl)-, (1S)- | LICOGLIFLOZIN | LIK 066 | LIK-066 | LIK066",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552866","MMSE-2 Standard Version - Do What This Says to Do","C151021","Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Please do what this says to do.","MMSE-2 Standard Version - Do What This Says to Do | MMS2-Do What This Says to Do | MMS209",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552868","MMSE-2 Standard Version - Copy This Design","C151023","Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Please copy this design.","MMSE-2 Standard Version - Copy This Design | MMS2-Copy This Design | MMS211",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552869","MMSE-2 Standard Version - BV Total Raw Score","C151024","Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) BV (Brief Version) total raw score.","MMSE-2 Standard Version - BV Total Raw Score | MMS2-BV Total Raw Score | MMS212",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552870","MMSE-2 Standard Version - SV Total Raw Score","C151025","Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) SV (Standard Version) total raw score.","MMSE-2 Standard Version - SV Total Raw Score | MMS2-SV Total Raw Score | MMS213",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552871","MMSE-2 Standard Version - Level of Consciousness","C151026","Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Assessment of level of consciousness.","MMSE-2 Standard Version - Level of Consciousness | MMS2-Level of Consciousness | MMS214",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553588","Sofpironium Bromide","C152384","No value exists.","Sofpironium Bromide | SOFPIRONIUM BROMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553589","Solcitinib","C152385","No value exists.","Solcitinib | SOLCITINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553590","Solithromycin","C152386","No value exists.","Solithromycin | SOLITHROMYCIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553720","Solpecainol","C152388","No value exists.","Solpecainol | SOLPECAINOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553721","Solriamfetol","C152389","No value exists.","Solriamfetol | SOLRIAMFETOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553722","Solypertine","C152390","No value exists.","Solypertine | SOLYPERTINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553724","Somagrebove","C152392","No value exists.","Somagrebove | SOMAGREBOVE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553725","Somalapor","C152393","No value exists.","Somalapor | SOMALAPOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553726","Somapacitan","C152394","No value exists.","Somapacitan | SOMAPACITAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553727","Somatosalm","C152395","No value exists.","Somatosalm | SOMATOSALM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554143","Vadadustat","C152811","An orally bioavailable, hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor (HIF-PHI), with potential anti-anemic and anti-inflammatory activities. Upon administration, vadadustat binds to and inhibits HIF-PH, an enzyme responsible for the degradation of transcription factors in the HIF family under normal oxygen conditions. This prevents HIF breakdown and promotes HIF activity. Increased HIF activity leads to an increase in endogenous erythropoietin production, thereby enhancing erythropoiesis. It also reduces the expression of the peptide hormone hepcidin, improves iron availability, and boosts hemoglobin (Hb) levels. HIF regulates the expression of genes in response to reduced oxygen levels, including genes required for erythropoiesis and iron metabolism. In addition, HIF 1-alpha (HIF1A) may play a role in reducing inflammation during acute lung injury (ALI) through HIF-dependent control of glucose metabolism in the alveolar epithelium.","Vadadustat | AKB 6548 | AKB-6548 | AKB6548 | VADADUSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554144","Vadastuximab","C152812","No value exists.","Vadastuximab | VADASTUXIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554145","Valactate","C152813","No value exists.","Valactate | VALACTATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554146","Valategrast","C152814","No value exists.","Valategrast | VALATEGRAST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4078701","Valbenazine","C152815","No value exists.","Valbenazine | VALBENAZINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554148","Valbenazine Ditosylate","C152816","No value exists.","Valbenazine Ditosylate | VALBENAZINE TOSYLATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554149","Valnivudine","C152817","No value exists.","Valnivudine | VALNIVUDINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554150","Valnoctamide","C152818","No value exists.","Valnoctamide | VALNOCTAMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554151","Valoctocogene Roxaparvovec","C152819","No value exists.","Valoctocogene Roxaparvovec | VALOCTOCOGENE ROXAPARVOVEC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554152","Valomaciclovir Stearate","C152820","No value exists.","Valomaciclovir Stearate | VALOMACICLOVIR STEARATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554153","Valperinol","C152821","No value exists.","Valperinol | VALPERINOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554154","Valpromide","C152822","No value exists.","Valpromide | VALPROMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552288","Intestinal T-Cell Lymphoma, Not Otherwise Specified","C150505","A T-cell lymphoma arising in the intestines, or sometimes other sites in the gastrointestinal tract, that does not conform to either classic enteropathy-associated T-cell lymphoma or monomorphic epitheliotropic intestinal T-cell lymphoma. (WHO 2017)","Intestinal T-Cell Lymphoma, Not Otherwise Specified | Intestinal T-Cell Lymphoma, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552291","SMAC Mimetic BI 891065","C150507","A mimetic of second mitochondrial-derived activator of caspases (Smac/DIABLO) and inhibitor of IAPs (Inhibitor of Apoptosis Proteins), with potential antineoplastic activity. Upon administration, Smac mimetic BI 891065 targets and binds to the Smac binding groove on IAPs, including the caspase inhibitor X chromosome-linked IAP (XIAP) and the cellular IAPs 1 and 2. This inhibits the activities of these IAPs and promotes the induction of apoptosis through apoptotic signaling pathways. IAPs are overexpressed by many cancer cell types and suppress apoptosis by binding to and inhibiting certain caspases.","SMAC Mimetic BI 891065 | BI 891065 | PROPANAMIDE, N-(5-(2-(2-METHOXY-3-PYRIDINYL)-7-METHYLIMIDAZO(1,2-A)PYRIDIN-3-YL)-6-(2-(1-METHYL-6-ISOQUINOLINYL)ETHYNYL)-2-PYRIDINYL)-2-(METHYLAMINO)-, (2S)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552290","Polymer-encapsulated Luteolin Nanoparticle","C150508","A nanoparticle formulation containing the poorly water-soluble naturally-occurring flavonoid luteolin encapsulated within a water-soluble polymer, with potential anti-oxidant, anti-inflammatory, apoptosis-inducing and chemopreventive activities. Upon administration of the polymer-encapsulated luteolin nanoparticle, luteolin scavenges free radicals, protects cells from reactive oxygen species (ROS)-induced damage and induces direct tumor cell cycle arrest and apoptosis in tumor cells. This inhibits tumor cell proliferation and suppresses metastasis. Compared to luteolin alone, encapsulation increases the delivery of luteolin to the tumor cells by protecting the drug against clearance and degradation, increases blood circulation time and enhances delivery into the tumor through the leaky vasculature.","Polymer-encapsulated Luteolin Nanoparticle | 3',4',5,7-Tetrahydroxyflavone-encapsulated Polymer Nanoparticles | Nano-luteolin | Nanoluteolin | Nanoparticle-based Luteolin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552285","Autologous BCMA/TACI-targeted CAR T Cells AUTO2","C150509","A preparation of autologous T-lymphocytes that are genetically engineered to contain a dual-targeted chimeric antigen receptor (CAR), which includes the natural protein a proliferation-inducing ligand (APRIL; TNFSF13), that targets the tumor-associated antigens (TAAs) B-cell maturation antigen (BCMA; TNFRSF17) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI; TNFRSF13B), with potential immunomodulating and antineoplastic activities. Upon administration, the autologous BCMA/TACI-targeted CAR T-cells AUTO2 bind to BCMA and TACI expressed on tumor cells and induce selective cytotoxicity in those cells. In addition, AUTO2 carries the universal RQR8 safety 'off' switch, which allows selective removal of the T-cells through both complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) following administration of rituximab if unacceptable side-effects occur.","Autologous BCMA/TACI-targeted CAR T Cells AUTO2 | APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI | APRIL CAR T Cells Targeting BCMA and TACI | AUTO 2 | AUTO2 | Autologous APRIL CAR T Cells | Autologous CAR T Product AUTO2 | SUB-96123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552284","Refractory T Acute Lymphoblastic Leukemia","C150510","T acute lymphoblastic leukemia that does not respond to treatment.","Refractory T Acute Lymphoblastic Leukemia | Refractory T-Acute Lymphoblastic Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552287","Allogeneic NY-ESO-1-C259 T-cells","C150511","Genetically engineered human allogeneic T-lymphocytes that are transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the cancer/testis antigen NY-ESO-1, with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo and introduction into the patient, the allogeneic T-lymphocytes expressing NY-ESO-1-C259-specific TCR specifically target and bind to NY-ESO-1-overexpressing tumor cells. This may result in the specific cytotoxic T-lymphocyte (CTL) killing of NY-ESO-1-positive cancer cells. NY-ESO-1, a tumor-associated antigen (TAA), is expressed in normal testis and on the surface of various tumor cell types.","Allogeneic T-lymphocytes Expressing NY-ESO-1-C259-specific TCR | Allogeneic NY-ESO-1-C259 T-cells | NY-ESO-1 c259 T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552286","Metastatic Urethral Urothelial Carcinoma","C150512","A urethral urothelial carcinoma that has spread to another anatomical site.","Metastatic Urethral Urothelial Carcinoma | Metastatic Urethral Urothelial Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552283","Metastatic Bladder Urothelial Carcinoma","C150513","Bladder urothelial carcinoma that has spread to another anatomical site.","Metastatic Bladder Urothelial Carcinoma | Metastatic Bladder Urothelial Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552933","FACT/GOG-NTX Version 4 - I Am Able to Work","C151216","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Functional Well-Being: I am able to work (include work at home).","FACT/GOG-NTX Version 4 - I Am Able to Work | FAC057-I Am Able to Work | FAC05721",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553623","Samarium Sm-153 Lexidronam","C152291","No value exists.","Samarium Sm-153 Lexidronam | 153Sm-EDTMP | SAMARIUM SM-153 LEXIDRONAM | Samarium (153SM) Lexidronam | Samarium SM 153 Lexidronam | Samarium Sm-153 EDTMP | Samarium, SM-153 Lexidronam | Samarium-153 EDTMP | Samarium-153 Ethylenediaminetetramethylenephosphonate | Samarium-153 Ethylenediaminetetramethylenephosphonic Acid | Sm-153 EDTMP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553624","Samatasvir","C152292","No value exists.","Samatasvir | SAMATASVIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553625","3-carboxamido-4-hydroxynaltrexone","C152293","No value exists.","Samidorphan | SAMIDORPHAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553626","Samidorphan L-Malate","C152294","No value exists.","Samidorphan L-Malate | SAMIDORPHAN L-MALATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553627","Sampeginterferon Beta-1A","C152295","No value exists.","Sampeginterferon Beta-1A | SAMPEGINTERFERON BETA-1A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553628","Sanfetrinem Cilexetil","C152296","No value exists.","Sanfetrinem Cilexetil | SANFETRINEM CILEXETIL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553629","Saprisartan","C152297","No value exists.","Saprisartan | SAPRISARTAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553630","Saprisartan Potassium","C152298","No value exists.","Saprisartan Potassium | SAPRISARTAN POTASSIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553631","Sarecycline","C152299","No value exists.","Sarecycline | SARECYCLINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0245514","Troglitazone","C1522","An orally-active thiazolidinedione with antidiabetic and hepatotoxic properties and potential antineoplastic activity.  Troglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis.  This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation. (NCI04)","Troglitazone | 5-((4-((3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy)phenyl)methyl)-2,4-Thiazolidinedione | 5-[4-[(6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione | CI-991 | CS-045 | Prelay | Rezulin | Romozin | TROGLITAZONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553632","Sarecycline Hydrochloride","C152300","No value exists.","Sarecycline Hydrochloride | SARECYCLINE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553633","saredutant","C152301","No value exists.","Saredutant | SAREDUTANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3885145","Sarilumab","C152302","A recombinant, human immunoglobulin (IgG) monoclonal antibody targeting the interleukin 6 receptor (IL-6R), with potential anti-inflammatory activity. Upon intravenous administration of sarilumab, this agent targets and binds to both soluble IL-6 receptor (sIL-6R) and membrane-bound IL-6 receptor (mIL-6R). This inhibits the binding of the pro-inﬂammatory cytokine IL-6 to the IL-6 receptor (IL-6R), which results in the blockade of the IL-6/IL-6R-mediated signal transduction pathway. This may inhibit IL-6/IL-6R-mediated inflammation.","Sarilumab | IL-6 receptor monoclonal antibodies: sarilumab | Immunoglobulin G1, Anti-Human Interleukin 6 Receptor alpha) (Human REGN88 Heavy Chain), Disulfide with Human REGN88 Light Chain, Dimer | Kevzara | REGN88 | SAR153191 | SARILUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553635","Saroglitazar","C152303","No value exists.","Saroglitazar | SAROGLITAZAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553636","Sarolaner","C152304","No value exists.","Sarolaner | SAROLANER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553637","Sarsagenin","C152305","No value exists.","Sarsagenin | SARSAGENIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553638","Saruplase","C152306","No value exists.","Saruplase | SARUPLASE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553639","Satralizumab","C152307","No value exists.","Satralizumab | SATRALIZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553641","2-(4-(2,2,3,3,4,4,4-heptafluorobutyloxy)-2-pyridyl)methylsulfinylthieno(3,4-d)imidazole","C152309","No value exists.","Saviprazole | SAVIPRAZOLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553642","Savoxepin","C152310","No value exists.","Savoxepin | SAVOXEPIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553643","Scopafungin","C152311","No value exists.","Scopafungin | SCOPAFUNGIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553644","Sebelipase Alfa","C152312","No value exists.","Sebelipase Alfa | SEBELIPASE ALFA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552872","Paced Tapping - Total Trials Expected","C151027","Paced Tapping Test (Paced Tapping) Total number of trials expected to be administered in the task.","Paced Tapping - Total Trials Expected | PTAP1-Total Trials Expected | PTAP101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552873","Paced Tapping - Total Trials Administered","C151028","Paced Tapping Test (Paced Tapping) Total number of trials actually administered in the task.","Paced Tapping - Total Trials Administered | PTAP1-Total Trials Administered | PTAP102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552874","Paced Tapping - Total Trials Completed","C151029","Paced Tapping Test (Paced Tapping) Total number of trials actually completed in the task.","Paced Tapping - Total Trials Completed | PTAP1-Total Trials Completed | PTAP103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552875","Paced Tapping - Total Interval Tone Admin All","C151030","Paced Tapping Test (Paced Tapping) Total number of intertap intervals across all 4 toned tapping phases of each trial administered.","Paced Tapping - Total Interval Tone Admin All | PTAP1-Total Interval Tone Admin All | PTAP104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552876","Paced Tapping - Total Interval Tone Trim All","C151031","Paced Tapping Test (Paced Tapping) Total number of intertap intervals across the 4 toned tapping phases of each trial, that were trimmed before analysis.","Paced Tapping - Total Interval Tone Trim All | PTAP1-Total Interval Tone Trim All | PTAP105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552877","Paced Tapping - Minimum Interval Tone All","C151032","Paced Tapping Test (Paced Tapping) The minimum intertap interval within the tone-paced tapping phase across all trials (in milliseconds).","Paced Tapping - Minimum Interval Tone All | PTAP1-Minimum Interval Tone All | PTAP105A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552879","Paced Tapping - Mean Interval Tone All","C151034","Paced Tapping Test (Paced Tapping) The mean intertap interval within the tone-paced tapping phase across all trials (in milliseconds).","Paced Tapping - Mean Interval Tone All | PTAP1-Mean Interval Tone All | PTAP105C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552880","Paced Tapping - Median Interval Tone All","C151035","Paced Tapping Test (Paced Tapping) The median intertap interval within the tone-paced tapping phase across all trials (in milliseconds).","Paced Tapping - Median Interval Tone All | PTAP1-Median Interval Tone All | PTAP105D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552881","Paced Tapping - Variance Interval Tone All","C151036","Paced Tapping Test (Paced Tapping) The variance of the intertap interval within the tone-paced tapping phase across all trials (in milliseconds).","Paced Tapping - Variance Interval Tone All | PTAP1-Variance Interval Tone All | PTAP105E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552882","Paced Tapping - Deviation Interval Tone All","C151037","Paced Tapping Test (Paced Tapping) The standard deviation of the intertap intervals within the tone-paced tapping phase across all trials.","Paced Tapping - Deviation Interval Tone All | PTAP1-Deviation Interval Tone All | PTAP105F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552883","Paced Tapping - Reciprocal Interval Tone All","C151038","Paced Tapping Test (Paced Tapping) The reciprocal of the standard deviation of the intertap intervals within the tone-paced tapping phase across all trials.","Paced Tapping - Reciprocal Interval Tone All | PTAP1-Reciprocal Interval Tone All | PTAP105G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554812","Refractory Cutaneous Melanoma","C150544","Melanoma of the skin that is resistant to treatment.","Refractory Cutaneous Melanoma | Refractory Cutaneous (Skin) Melanoma | Refractory Melanoma of the Skin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552252","Recurrent Malignant Skin Neoplasm","C150545","Reemergence of a malignant skin neoplasm after a period of remission.","Recurrent Malignant Skin Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552251","Refractory Malignant Skin Neoplasm","C150546","Malignant skin neoplasm that is resistant to treatment.","Refractory Malignant Skin Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554155","Valtrate","C152823","No value exists.","Valtrate | VALTRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554156","Valziflocept","C152824","No value exists.","Valziflocept | VALZIFLOCEPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554157","Vamorolone","C152825","No value exists.","Vamorolone | VAMOROLONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554158","Vandortuzumab","C152826","No value exists.","Vandortuzumab | VANDORTUZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554159","Vangatalcite","C152827","No value exists.","Vangatalcite | VANGATALCITE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554160","Vaniprevir","C152828","No value exists.","Vaniprevir | VANIPREVIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554161","Vanutide Cridificar","C152829","No value exists.","Vanutide Cridificar | VANUTIDE CRIDIFICAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554162","Vapaliximab","C152830","No value exists.","Vapaliximab | VAPALIXIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554163","Vapendavir","C152831","No value exists.","Vapendavir | VAPENDAVIR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554164","varespladib","C152832","No value exists.","Varespladib | VARESPLADIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554166","Varfollitropin Alfa","C152834","No value exists.","Varfollitropin Alfa | VARFOLLITROPIN ALFA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554167","Varisacumab","C152835","No value exists.","Varisacumab | VARISACUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554040","Varodarsen","C152836","No value exists.","Varodarsen | VARODARSEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554041","Vatanidipine","C152837","No value exists.","Vatanidipine | VATANIDIPINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554043","Vatinoxan","C152839","No value exists.","Vatinoxan | VATINOXAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517307","Fox Chase SCID Mouse","C15158","Discovered by Bosma (1980) at Fox Chase Cancer Center, the CB17 SCID mouse has an autosomal recessive mutation in the Prkdc gene which causes a severe combined immunodeficiency affecting B and T lymphocytes.","Fox Chase SCID Mouse | C.B-17/IcrCrl-scid-BR | CB17 SCID | CB17 SCID Mouse | Fox Chase SCID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519130","SCID Beige Mouse","C15159","No value exists.","SCID Beige Mouse | C.B-17/IcrCrl-scid-bgBR | CB-17/IcrCrl-scid-bgBR | SCID Beige",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0243666","ranimustine","C1515","A chloroethylnitrosourea derivative that inhibits proliferation and growth of tumor cells by alkylation and cross-linkage of DNA strands of tumor cells. (NCI)","Ranimustine | Cymer | Cymerin | MCNU | RANIMUSTINE | Ranomustine | alpha-D-glucopyranoside, methyl 6-((((2-chloroethyl)nitrosoamino)carbonyl)amino)-6-deoxy- | methyl 6-((((2-chloroethyl)nitrosoamino)carbonyl) amino)-6-deoxy-alpha-D-glucopyranoside | methyl 6-(3-(2-chloroethyl)-3-nitrosoiureido)-6-deoxy-alpha-D-glucopyranoside | methyl 6-(3-(2-chloroethyl)-3-nitrosoureido)-6-deoxy-alpha-D-glucopyranoside",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516105","B6.Cg-Foxn1-nu Mouse","C15160","No value exists.","B6.Cg-Foxn1-nu Mouse | B6.Cg-Foxn1-nu | C57BL/6J-Hfh1l-nu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511411","CBy.Cg-Foxn1-nu","C15161","No value exists.","CBy.Cg-Foxn1-nu | BALB/cByJ-Hfh1l-nu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511409","CByB6F1/J-Foxn1-nu Mouse","C15162","No value exists.","CByB6F1/J-Foxn1-nu Mouse | CByB6F1/J-Foxn1-nu | CByB6F1/J-Hfh1l-nu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513860","NU/J Foxn1-nu Mouse","C15163","No value exists.","NU/J Foxn1-nu Mouse | NU/J Foxn1-nu | NU/J Hfh1l-nu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511410","CBySmn.CB17-Prkdc-scid/J Mouse","C15164","No value exists.","CBySmn.CB17-Prkdc-scid/J Mouse | BALB/cBySmn-Prkdc-scid/J | CBySmn.CB17-Prkdc-scid/J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511369","C3Smn.CB17-Prkdc-scid/J Mouse","C15165","No value exists.","C3Smn.CB17-Prkdc-scid/J Mouse | C3Smn.C-Prkdc-scid/J | C3Smn.CB17-Prkdc-scid/J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516104","B6.CB17-Prkdc-scid/SzJ Mouse","C15166","No value exists.","B6.CB17-Prkdc-scid/SzJ Mouse | C57BL/6J-Prkdc-scid/SzJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552934","FACT/GOG-NTX Version 4 - My Work Is Fulfilling","C151217","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Functional Well-Being: My work (include work at home) is fulfilling.","FACT/GOG-NTX Version 4 - My Work Is Fulfilling | FAC057-My Work Is Fulfilling | FAC05722",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552936","FACT/GOG-NTX Version 4 - I Have Accepted My Illness","C151219","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Functional Well-Being: I have accepted my illness.","FACT/GOG-NTX Version 4 - I Have Accepted My Illness | FAC057-I Have Accepted My Illness | FAC05724",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552937","FACT/GOG-NTX Version 4 - I Am Sleeping Well","C151220","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Functional Well-Being: I am sleeping well.","FACT/GOG-NTX Version 4 - I Am Sleeping Well | FAC057-I Am Sleeping Well | FAC05725",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552939","FACT/GOG-NTX Version 4 - Content With Quality of My Life","C151222","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Functional Well-Being: I am content with the quality of my life right now.","FACT/GOG-NTX Version 4 - Content With Quality of My Life | FAC057-Content With Quality of My Life | FAC05727",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552940","FACT/GOG-NTX Version 4 - Numbness or Tingling in My Hands","C151223","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Additional Concerns: I have numbness or tingling in my hands.","FACT/GOG-NTX Version 4 - Numbness or Tingling in My Hands | FAC057-Numbness or Tingling in My Hands | FAC05728",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552941","FACT/GOG-NTX Version 4 - Numbness or Tingling in My Feet","C151224","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Additional Concerns: I have numbness or tingling in my feet.","FACT/GOG-NTX Version 4 - Numbness or Tingling in My Feet | FAC057-Numbness or Tingling in My Feet | FAC05729",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552942","FACT/GOG-NTX Version 4 - I Feel Discomfort in My Hands","C151225","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Additional Concerns: I feel discomfort in my hands.","FACT/GOG-NTX Version 4 - I Feel Discomfort in My Hands | FAC057-I Feel Discomfort in My Hands | FAC05730",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552943","FACT/GOG-NTX Version 4 - I Feel Discomfort in My Feet","C151226","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Additional Concerns: I feel discomfort in my feet.","FACT/GOG-NTX Version 4 - I Feel Discomfort in My Feet | FAC057-I Feel Discomfort in My Feet | FAC05731",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552944","FACT/GOG-NTX Version 4 - Have Joint Pain or Muscle Cramps","C151227","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Additional Concerns: I have joint pain or muscle cramps.","FACT/GOG-NTX Version 4 - Have Joint Pain or Muscle Cramps | FAC057-Have Joint Pain or Muscle Cramps | FAC05732",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552945","FACT/GOG-NTX Version 4 - I Feel Weak All Over","C151228","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Additional Concerns: I feel weak all over.","FACT/GOG-NTX Version 4 - I Feel Weak All Over | FAC057-I Feel Weak All Over | FAC05733",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552946","FACT/GOG-NTX Version 4 - I Have Trouble Hearing","C151229","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Additional Concerns: I have trouble hearing.","FACT/GOG-NTX Version 4 - I Have Trouble Hearing | FAC057-I Have Trouble Hearing | FAC05734",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553937","Trevogrumab","C152733","No value exists.","Trevogrumab | TREVOGRUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553938","Triamcinolone Acetonide Sodium Phosphate","C152734","No value exists.","Triamcinolone Acetonide Sodium Phosphate | CL-106359 | CL-61965 | Pregna-1,4-diene-3,20-dione, 9-Fluoro-11-hydroxy-16,17-((1-methylethylidene)bis(oxy))-21-(phosphonooxy)-, Disodium Salt, (11beta,16alpha)- | TRIAMCINOLONE ACETONIDE SODIUM PHOSPHATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553939","Tribenoside","C152735","No value exists.","Tribenoside | TRIBENOSIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553940","Triclobisonium Chloride","C152736","No value exists.","Triclobisonium Chloride | TRICLOBISONIUM CHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553941","Triclofenol Piperazine","C152737","No value exists.","Triclofenol Piperazine | TRICLOFENOL PIPERAZINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553942","Tricosactide","C152738","No value exists.","Tricosactide | TRICOSACTIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553943","Tricyclamol Chloride","C152739","No value exists.","Tricyclamol Chloride | TRICYCLAMOL CHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553944","Tridecactide","C152740","A synthetic 13-amino acid peptide analogue of the naturally occurring alpha-melanocyte stimulating hormone (a-MSH) and derived from proteolytic cleavage of adrenocorticotropic hormone (ACTH), with potential analgesia, antipyretic, antioxidative, cytoprotective, anti-inflammatory and immunomodulating activities. Upon administration, tridecactide mimics the action of a-MSH, binds to melanocortin receptors (MC-Rs) and stimulates melanocytes to increase the production and release of melanin. In addition, tridecactide's anti-inflammatory effects are through the activation of MC-Rs that are expressed in a number of tissues, such as peripheral immune cells and hypothalamic neurons, and affects various pathways regulating inflammatory responses. Specifically, tridecactide inhibits the activation of nuclear factor-kappa B (NF-κB), inhibits the expression of pro-inflammatory cytokines and adhesion molecule expression, prevents T-cell proliferation and inflammatory cell migration. This agent may also suppress pro-inflammatory non-cytokine regulators such as nitric oxide (NO), prostaglandin E (PGE), and reactive oxygen species (ROS), and induces the expression of interleukin (IL) 10.","Tridecactide | ACTH (1-13) | EK-12 | TRIDECACTIDE | alpha-1-13-Corticotropin, HumanL-seryl-L-tyrosyl-L-seryl-L-methionyl-L-glutamyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophylglycyl-L-lysyl-L-prolyl-L-valine | alpha-Corticotropin 1-13 | alpha1-13-Corticotropin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553945","Tridihexethyl Iodide","C152741","No value exists.","Tridihexethyl Iodide | TRIDIHEXETHYL IODIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553947","Triflubazam","C152743","No value exists.","Triflubazam | TRIFLUBAZAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553948","Triletide","C152744","No value exists.","Triletide | TRILETIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553949","Trimedoxime Bromide","C152745","No value exists.","Trimedoxime Bromide | TRIMEDOXIME BROMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553950","Trimegestone","C152746","No value exists.","Trimegestone | TRIMEGESTONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553951","Trimethidinium Methosulfate","C152747","No value exists.","Trimethidinium Methosulfate | TRIMETHIDINIUM METHOSULFATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553953","Trimoxamine","C152749","No value exists.","Trimoxamine | TRIMOXAMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553954","Trimoxamine Hydrochloride","C152750","No value exists.","Trimoxamine Hydrochloride | TRIMOXAMINE HYDROCHLORIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553955","Tripamide","C152751","No value exists.","Tripamide | TRIPAMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553957","Trixolane","C152753","No value exists.","Trixolane | TRIXOLANE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553958","Trizoxime","C152754","No value exists.","Trizoxime | TRIZOXIME",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553959","Trocimine","C152755","No value exists.","Trocimine | TROCIMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552245","Allogeneic Most Closely HLA-matched Adenovirus-specific Cytotoxic T Lymphocytes","C150553","A population of off the shelf, closely human leukocyte antigen (HLA)-matched allogeneic, ex vivo-expanded cytotoxic T-lymphocytes (CTLs) specifically reactive to human adenovirus (Ad), with potential immunomodulating and anti-adenoviral activities. Upon administration, the allogeneic most closely HLA-matched Ad-specific CTLs may reconstitute Ad-specific CTL responses in patients at risk of developing Ad infections either following allogeneic stem cell transplantation or in Ad-infected immunocompromised hosts. The anti-adenoviral CTLs are provided by a third party donor and not by the allogeneic stem cell transplant donor.","Allogeneic Most Closely HLA-matched Adenovirus-specific Cytotoxic T Lymphocytes | Most Closely HLA Matched Third-Party Donor Adenovirus Specific CTLs | Most Closely HLA Matched Third-Party Donor Adenovirus Specific T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552246","Schuurs-Hoeijmakers Syndrome","C150555","An autosomal dominant condition caused by mutation(s) in the PACS1 gene, encoding phosphofurin acidic cluster sorting protein 1. It is characterized by intellectual developmental delay, craniofacial abnormalities, as well as other variable congenital abnormalities.","Schuurs-Hoeijmakers Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3554478","OSTEOPETROSIS, AUTOSOMAL RECESSIVE 8","C150556","A sub-type of autosomal recessive osteopetrosis caused by mutation(s) in the SNX10 gene, encoding sorting nexin-10.","Autosomal Recessive Osteopetrosis 8 | OPTB8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552360","Prostate Adenocarcinoma without Neuroendocrine Differentiation","C150557","A prostate adenocarcinoma characterized by the absence of focal or diffuse neuroendocrine differentiation.","Prostate Adenocarcinoma without Neuroendocrine Differentiation | Prostate Adenocarcinoma without Evidence of Neuroendocrine Differentiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552624","CDISC Functional Test COWAT Test Name Terminology","C150765","Test names of functional test questions associated with the Controlled Oral Word Association Test (COWAT) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Functional Test COWAT Test Name Terminology | COWAT1TN | Controlled Oral Word Association Test Functional Test Test Name | FT-COWAT TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552625","CDISC Functional Test COWAT Test Code Terminology","C150766","Test codes of functional test questions associated with the Controlled Oral Word Association Test (COWAT) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Functional Test COWAT Test Code Terminology | COWAT1TC | Controlled Oral Word Association Test Functional Test Test Code | FT-COWAT TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513849","NOD.CB17-Prkdc-scid/J Mouse","C15167","No value exists.","NOD.CB17-Prkdc-scid/J Mouse | NOD SCID | NOD.CB17-Prkdc-scid/J | NOD.SCID | NOD/LtSz-Prkdc-scid/J",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513848","NOD.129S7(B6)-Rag1-tm1Mom Mouse","C15168","No value exists.","NOD.129S7(B6)-Rag1-tm1Mom Mouse | NOD.129S7(B6)-Rag1-tm1Mom | NOD/LtSz-Rag1-tm1Mom",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511472","C.129S7-Rag1-tm1Mom Mouse","C15169","No value exists.","C.129S7-Rag1-tm1Mom Mouse | BALB/c-Rag1-tm1Mom | C.129S7-Rag1-tm1Mom",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0243902","Lisofylline","C1516","No value exists.","Lisofylline | CT 1501R | CT-1501R | LISOFYLLINE | Lisofenicol | lisofylline",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516102","B6;129-Rag1-tm1Mom Mouse","C15170","No value exists.","B6;129-Rag1-tm1Mom Mouse | B6,129-Rag1-tm1Mom | B6;129-Rag1-tm1Mom",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516725","Common Rattus Norvegicus Strains","C15172","Rat breeds, belonging to the species Rattus norvegicus, that are commonly used as experimental organisms.","Common Rattus Norvegicus Strains | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553392","LPCAT1 Gene","C152058","This gene is involved in the conversion of lysophosphatidylcholine to phosphatidylcholine.","LPCAT1 Gene | LPCAT1 | Lysophosphatidylcholine Acyltransferase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553393","LPCAT1 wt Allele","C152059","Human LPCAT1 wild-type allele is located in the vicinity of 5p15.33 and is approximately 69 kb in length. This allele, which encodes lysophosphatidylcholine acyltransferase 1 protein, plays a role in phosphatidylcholine biosynthesis.","LPCAT1 wt Allele | AGPAT10 | AGPAT9 | AYTL2 | Acyltransferase Like 2 Gene | FLJ12443 | LPCAT | LPCAT-1 | Lysophosphatidylcholine Acyltransferase 1 wt Allele | PFAAP3 | lpcat | lysoPAFAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1663192","Nutrition, Cholesterol","C15205","Role of cholesterol in cancer causation or prevention and in general health.","Nutrition, Cholesterol | Lipid Nutrition, Cholesterol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553394","Lpcat1 protein, human","C152060","Lysophosphatidylcholine acyltransferase 1 (534 aa, ~59 kDa) is encoded by the human LPCAT1 gene. This protein is involved in the synthesis of phosphatidylcholine from lysophosphatidylcholine.","Lysophosphatidylcholine Acyltransferase 1 | 1-Acylglycerophosphocholine O-Acyltransferase | 1-Alkylglycerophosphocholine O-Acetyltransferase | Acetyl-CoA:Lyso-PAF Acetyltransferase | Acetyl-CoA:Lyso-Platelet-Activating Factor Acetyltransferase | Acyltransferase-Like 2 | EC 2.3.1.23 | EC 2.3.1.67 | LPC Acyltransferase 1 | LPCAT-1 | LPCAT1 | Lyso-PAF Acetyltransferase | LysoPAFAT | LysoPC Acyltransferase 1 | Lysophosphatidylcholine Acyltransferase | Phosphonoformate Immuno-Associated Protein 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553395","CDC42BPA Gene","C152061","This gene plays a role in protein phosphorylation, cytoskeleton reorganization and cell migration.","CDC42BPA Gene | CDC42 Binding Protein Kinase Alpha Gene | CDC42BPA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552947","FACT/GOG-NTX Version 4 - Get Ringing or Buzzing in My Ears","C151230","Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Additional Concerns: I get a ringing or buzzing in my ears.","FACT/GOG-NTX Version 4 - Get Ringing or Buzzing in My Ears | FAC057-Get Ringing or Buzzing in My Ears | FAC05735",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552502","Encochleated Amphotericin B","C150700","A proprietary, orally bioavailable, nanoparticle-based encochleated formulation composed of amphotericin B, a polyene antifungal antibiotic produced by Streptomyces nodosus, encochleated within lipid-based crystals, which are composed of multi-layered, rolled-up sheets of soy-derived phosphatidylserine (PS) bilayers and calcium, with broad-spectrum antifungal activity. Upon oral administration, the cochleate crystal structure protects amphotericin B from degradation within the gastrointestinal (GI) tract. The lipid structure facilitates uptake into the bloodstream where the nanoparticles are taken up by macrophages and fungal cells though phagocytosis. Amphotericin B is released from the cochleate due to the calcium differential between the inside of the cell, which has low calcium levels, and the outside of the cell, which has high calcium levels. This delivers amphotericin B directly to the fungal-infected site and to its target cells. In turn, amphotericin B binds to ergosterol, an essential component of the fungal cell membrane. This results in depolarization of the cell membrane, alterations in cell membrane permeability, leakage of important intracellular components, and cell rupture. This causes fungal cell death and prevents fungal infections. Compared to amphotericin B alone, which can only be administered intravenously (IV), this formulation permits oral administration and reduces treatment-limiting side effects that are seen with IV amphotericin B, particularly nephro- and hepato-toxicity.","Encochleated Amphotericin B | CAMB | Cochleate Lipid-crystal Nano-particles-containing Amphotericin B | Cochleate-Amphotericin B | Lipid-crystal Nano-particle Formulation of Amphotericin B | Lipid-crystal Nanoparticle-based Amphotericin B Formulation | MAT2203 | Nano-cochleated-particles containing Amphotericin B | Oral Encochleated Amphotericin B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552503","Langerhans Cell Histiocytosis, Monostotic","C150701","Langerhans cell histiocytosis presenting as a solitary lesion.","Langerhans Cell Histiocytosis, Monostotic | Langerhans cell histiocytosis, mono-ostotic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552504","Langerhans Cell Histiocytosis, Polyostotic","C150702","Langerhans cell histiocytosis presenting with multiple sites of involvement.","Langerhans Cell Histiocytosis, Polyostotic | Langerhans cell histiocytosis, poly-ostotic",,,,,,,,,,,,,,,"37152517","Polyostotic Langerhans cell histiocytosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL480899","Langerhans Cell Histiocytosis, Disseminated","C150703","Langerhans cell histiocytosis presenting with disseminated disease.","Langerhans Cell Histiocytosis, Disseminated | Langerhans cell histiocytosis, disseminated",,,,,,,,,,,,,,,"4028708|4038846","Langerhans cell histiocytosis, disseminated|Langerhans cell histiocytosis, disseminated (clinical)",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL552505","Epstein-Barr Virus Positive Inflammatory Follicular Dendritic Cell Sarcoma of the Digestive System","C150704","EBV-positive inflammatory follicular dendritic cell/fibroblastic reticular cell tumor that arises from the digestive system.","EBV-Positive Inflammatory Follicular Dendritic Cell/Fibroblastic Reticular Cell Tumor of the Digestive System | EBV-Positive Inflammatory Follicular Dendritic Cell Sarcoma of the Digestive System | EBV-Positive Inflammatory Follicular Dendritic Cell Sarcoma of the Digestive System | EBV-Positive Inflammatory Follicular Dendritic Cell Tumor of the Digestive System | Epstein-Barr Virus Positive Inflammatory Follicular Dendritic Cell Sarcoma of the Digestive System | Epstein-Barr Virus-Positive Inflammatory Follicular Dendritic Cell Sarcoma of the Digestive System | Inflammatory Pseudotumor-Like Follicular/Fibroblastic Dendritic Cell Sarcoma of the Digestive System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL552508","Cisplatin-Docetaxel-Cetuximab","C150707","A regimen consisting of cisplatin, docetaxel and cetuximab that can be used for the treatment of head and neck cancer and non-small cell lung cancer (NSCLC).","Cetuximab/Cisplatin/Docetaxel Regimen | Cisplatin and Docetaxel (DC) and Cetuximab | Cisplatin-Docetaxel-Cetuximab | Cisplatin-Docetaxel-Cetuximab Regimen | Cisplatin/Docetaxel/Cetuximab | Cisplatin/Docetaxel/Cetuximab Regimen | Docetaxel/Cisplatin/Cetuximab | TPE | TPEx | Taxotere/Platinol/Erbitux",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553960","Troclosene Potassium","C152756","No value exists.","Troclosene Potassium | TROCLOSENE POTASSIUM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553962","Trofolastat","C152758","No value exists.","Trofolastat | TROFOLASTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553963","Trolnitrate","C152759","No value exists.","Trolnitrate | TROLNITRATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553077","SIQ - Specific %: Standard Sample 3","C151360","Suicidal Ideation Questionnaire (SIQ) Specific standardization %: Sample 3.","SIQ - Specific %: Standard Sample 3 | SIQ01-Specific %: Standard Sample 3 | SIQ0135",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553078","SIQ - Critical Item 1","C151361","Suicidal Ideation Questionnaire (SIQ) Critical item 1.","SIQ - Critical Item 1 | SIQ01-Critical Item 1 | SIQ0136",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553079","SIQ - Critical Item 2","C151362","Suicidal Ideation Questionnaire (SIQ) Critical item 2.","SIQ - Critical Item 2 | SIQ01-Critical Item 2 | SIQ0137",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553080","SIQ - Critical Item 3","C151363","Suicidal Ideation Questionnaire (SIQ) Critical item 3.","SIQ - Critical Item 3 | SIQ01-Critical Item 3 | SIQ0138",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553081","SIQ - Critical Item 4","C151364","Suicidal Ideation Questionnaire (SIQ) Critical item 4.","SIQ - Critical Item 4 | SIQ01-Critical Item 4 | SIQ0139",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553082","SIQ - Critical Item 5","C151365","Suicidal Ideation Questionnaire (SIQ) Critical item 5.","SIQ - Critical Item 5 | SIQ01-Critical Item 5 | SIQ0140",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553083","SIQ - Critical Item 6","C151366","Suicidal Ideation Questionnaire (SIQ) Critical item 6.","SIQ - Critical Item 6 | SIQ01-Critical Item 6 | SIQ0141",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553084","SIQ - Critical Item 7","C151367","Suicidal Ideation Questionnaire (SIQ) Critical item 7.","SIQ - Critical Item 7 | SIQ01-Critical Item 7 | SIQ0142",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553085","SIQ - Critical Item 8","C151368","Suicidal Ideation Questionnaire (SIQ) Critical item 8.","SIQ - Critical Item 8 | SIQ01-Critical Item 8 | SIQ0143",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553086","SIQ-JR - Would Be Better If I Was Not Alive","C151369","Suicidal Ideation Questionnaire-Junior (SIQ-JR) I thought it would be better if I was not live.","SIQ-JR - Would Be Better If I Was Not Alive | SIQ02-Would Be Better If I Was Not Alive | SIQ0201",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553087","SIQ-JR - I Thought About Killing Myself","C151370","Suicidal Ideation Questionnaire-Junior (SIQ-JR) I thought about killing myself.","SIQ-JR - I Thought About Killing Myself | SIQ02-I Thought About Killing Myself | SIQ0202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553088","SIQ-JR - I Thought How I Would Kill Myself","C151371","Suicidal Ideation Questionnaire-Junior (SIQ-JR) I thought about how I would kill myself.","SIQ-JR - I Thought How I Would Kill Myself | SIQ02-I Thought How I Would Kill Myself | SIQ0203",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553089","SIQ-JR - I Thought When I Would Kill Myself","C151372","Suicidal Ideation Questionnaire-Junior (SIQ-JR) I thought about when I would kill myself.","SIQ-JR - I Thought When I Would Kill Myself | SIQ02-I Thought When I Would Kill Myself | SIQ0204",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553091","SIQ-JR - I Thought About Death","C151374","Suicidal Ideation Questionnaire-Junior (SIQ-JR) I thought about death.","SIQ-JR - I Thought About Death | SIQ02-I Thought About Death | SIQ0206",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553092","SIQ-JR - What to Write in a Suicide Note","C151375","Suicidal Ideation Questionnaire-Junior (SIQ-JR) I thought about what to write in a suicide note.","SIQ-JR - What to Write in a Suicide Note | SIQ02-What to Write in a Suicide Note | SIQ0207",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL553093","SIQ-JR - I Thought About Writing a Will","C151376","Suicidal Ideation Questionnaire-Junior (SIQ-JR) I thought about writing a will.","SIQ-JR - I Thought About Writing a Will | SIQ02-I Thought About Writing a Will | SIQ0208",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555023","Androgen-sensitive","C153559","Describes cells, tissues, conditions, or diseases that are responsive to or dependent on any of the androgen hormones.","Androgen-sensitive | Androgen-sensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0085101","Radioimmunotherapy","C15355","Treatment with a radioactive substance that is linked to an antibody so that it will attach to a tumor when injected into the body.","Radioimmunotherapy | Immunoradiotherapy | Immunotherapy, Cancer, Radioisotope | radioimmunotherapeutics | radioimmunotherapy",,,,,,,,,,,,,,,"4043010","Radioimmunotherapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555025","Magnesium-based Bone Void Filler","C153566","An injectable magnesium oxide-based bone void filler (BVF) with potential osteoconductive properties. Upon injection into bony voids or defects, the magnesium-based BVF mimics cancellous bone and provides a supportive scaffold to facilitate the bone healing process. Magnesium contributes to the structural development of bone and may potentially increase proliferation of bone marrow stromal cells and improve attachment and growth of osteoblasts.","Magnesium-based Bone Void Filler | Magnesium-based BVF | Osteocrete",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555026","Recurrent Breast Acinic Cell Carcinoma","C153568","The reemergence of acinic cell breast carcinoma after a period of remission.","Recurrent Breast Acinic Cell Carcinoma | Recurrent Acinic Cell Breast Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555030","Recurrent Pancreatic Acinar Cell Carcinoma","C153569","The reemergence of pancreatic acinar cell carcinoma after a period of remission.","Recurrent Pancreatic Acinar Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555188","Inari Sami Language","C154121","A Uralic Sami language spoken by the Inari Sami people of Finland.","Inari Sami Language | Inari Sami | SMN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574401","Samoan Language","C154122","An Austronesian language spoken mainly in the Samoan islands.","Samoan Language | SMO | Samoan",,,,,,,,,,,,,,,"4181558","Samoan language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556416","Skolt Sami Language","C154123","A Uralic Sami language that is spoken by the Skolts people in Finland.","Skolt Sami Language | SMS | Skolt Sami",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0376252","Shona Language","C154124","A Niger-Congo Bantu language spoken by the Shona people of Zimbabwe.","Shona Language | SNA | Shona",,,,,,,,,,,,,,,"4175936","Shona language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574347","Sindhi Language","C154125","An Indo-Aryan language spoken by the Sindhi people of the Pakistani province of Sindh.","Sindhi Language | SND | Sindhi",,,,,,,,,,,,,,,"4181545","Sindhi language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2585592","Sesotho Language","C154127","A Niger-Congo Bantu language spoken in South Africa and in Lesotho, where it is the national language.","Sesotho Language | SOT | Sesotho | Sotho | Southern Sotho",,,,,,,,,,,,,,,"4234468","Southern Sotho language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0001910","Albanian Language","C154128","An Indo-European language that is an official language in Albania and Kosovo.","Albanian Language | Albanian | SQI",,,,,,,,,,,,,,,"4182497","Albanian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574322","Sardinian Language","C154129","An Indo-European Romance language spoken mainly on the island of Sardinia, Italy.","Sardinian Language | SRD | Sardinian",,,,,,,,,,,,,,,"4180193","Sardinian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0199976","Lymphokine-Activated Killer Cell Therapy","C15412","The use of lymphokine-activated killer cells in the treatment of any disease or disorder.","Lymphokine-Activated Killer Cell Therapy | LAK cell therapy",,,,,,,,,,,,,,,"4246611","Lymphokine activated killer cell therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555190","Sranan Tongo Language","C154130","An English-based creole spoken in Suriname.","Sranan Tongo Language | SRN | Sranan | Sranan Tongo | Sranantongo | Surinaams | Surinamese | Surinamese Creole | Taki Taki",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2919513","Serbian Language","C154131","An Indo-European Slavic language spoken mainly by the Serbs as the official language of Serbia.","Serbian Language | SRP | Serbian",,,,,,,,,,,,,,,"40483799","Serbian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574471","Swati Language","C154133","A Niger-Congo Bantu language spoken by the Swazi people in Swaziland and South Africa.","Swati Language | SSW | Swati",,,,,,,,,,,,,,,"4183788","Swazi language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555191","BST2 Gene","C154134","This gene is involved in interferon-dependent antiviral responses.","BST2 Gene | BST2 | Bone Marrow Stromal Cell Antigen 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554840","In Vitro Kinase Inhibitor Assay","C153397","Any of various laboratory assay methods designed to measure the kinase inhibition activity of a test compound.","In Vitro Kinase Inhibitor Assay | In Vitro Kinase Inhibition Assay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554211","Polyspecific Direct Antiglobulin Test","C153063","A nonspecific screening test to detect the presence of antibody and complement-coated erythrocytes in a blood specimen in vivo.","Polyspecific Direct Antiglobulin Test | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554212","Chronic Hemolysis","C153064","Persisting and longstanding disruption of erythrocyte membrane integrity and the resulting release of hemoglobin.","Chronic Hemolysis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554213","Locally Advanced Soft Tissue Sarcoma","C153066","Soft tissue sarcoma that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Soft Tissue Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554214","Antifungal Agent VL-2397","C153067","A cyclic hexapeptide and natural compound isolated from the Malaysian leaf litter fungus, Acremonium persicinium MF-347833, with potential antifungal activity against various invasive fungal infections including invasive aspergillosis (IA). Upon administration, VL-2397, by resembling the siderophore ferrichrome, is specifically taken up by fungal cells through the membrane-bound transporter siderophore iron transporter 1 (Sit; Sit1). Upon fungal cell entry, VL-2397 targets and binds to an as of yet undisclosed intracellular site, thereby killing fungal cells. Since mammalian cells lack the Sit1 transporter, VL-2397 is not taken up by human cells.","Antifungal Agent VL-2397 | ASP 2397 | ASP-2397 | ASP2397 | VL 2397 | VL-2397 | VL2397",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554215","Unresectable Soft Tissue Sarcoma","C153068","Soft tissue sarcoma that is not amenable to surgical resection.","Unresectable Soft Tissue Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555101","Lower Sorbian Language","C153903","A Slavic minority language spoken in eastern Germany in the historical province of Lower Lusatia.","Lower Sorbian Language | DSB | Lower Sorbian",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574512","Dyula Language","C153905","A Mande language spoken in Burkina Faso, Ivory Coast and Mali.","Dyula Language | DYU | Dioula | Dyula | Jula",,,,,,,,,,,,,,,"4180360","Dyula language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574674","Dzongkha Language","C153906","A Sino-Tibetan language that is the official and national language of Bhutan.","Dzongkha Language | Bhutanese | DZO | Dzongkha",,,,,,,,,,,,,,,"4183937","Jonkha language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574480","Efik Language","C153907","A Niger-Congo language that is the native language of the Efik people of Nigeria.","Efik Language | EFI | Efik",,,,,,,,,,,,,,,"4177295","Efik language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555103","Ekajuk Language","C153908","An Ekoid language of the Niger-Congo family spoken in the Cross River State and some surrounding regions of Nigeria.","Ekajuk Language | Akajo | Akajuk | EKA | Ekajuk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574690","Komi Language","C153983","A Uralic macrolanguage spoken by the Komi peoples in the northeastern European part of Russia.","Komi Language | KOM | Komi",,,,,,,,,,,,,,,"4181731","Komi language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574447","Kongo Language","C153984","A Niger-Congo Bantu language spoken by the Kongo and Ndundu people living in the tropical forests of the Democratic Republic of the Congo, the Republic of the Congo, and Angola.","Kongo Language | KON | Kongo",,,,,,,,,,,,,,,"4183782","Kongo language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556395","Kosraean Language","C153985","An Austroasiatic language spoken on the Kosrae and Caroline Islands of Micronesia, and Nauru.","Kosraean Language | KOS | Kosraean | Kusaiean",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574513","Kpelle Language","C153986","A Mande language spoken by the Kpelle people of Liberia and Guinea.","Kpelle Language | KPE | Kpelle",,,,,,,,,,,,,,,"4180361","Kpelle language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555091","Karachay-Balkar Language","C153987","A Turkic language spoken by the Karachay and Balkar people in the Kabardino-Balkaria and Karachay-Cherkessia republics of Russia.","Karachay-Balkar Language | KRC | Karachay-Balkar",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554423","CORT 125281","C153309","An orally available, selective glucocorticoid receptor (GR) antagonist, with potential antineoplastic activity. Upon oral administration, exicorilant competitively and selectively binds to GRs, inhibiting the activation of GR-mediated proliferative and anti-apoptotic gene expression pathways. The GR, a member of the nuclear receptor superfamily of ligand-dependent transcription factors, is overexpressed in certain tumor types and may be associated with tumor cell proliferation and treatment resistance. Inhibition of GR activity may potentially slow tumor cell growth and disease progression in certain cancers.","Exicorilant | CORT 125281 | CORT-1252 | CORT125281 | EXICORILANT | Glucocorticoid Receptor Antagonist CORT125281 | Methanone, ((4aR,8aS)-1-(4-Fluorophenyl)-1,4,5,6,7,8,8a,9-octahydro-6-((2-methyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4ah-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)-2-pyridinyl)- | WHO 10854",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL507840","involved-site radiation therapy","C153310","A type of conformal radiation therapy in which the prechemotherapy gross tumor volume determines the clinical target volume, resulting in an irradiated volume that is significantly smaller than with involved-field radiation therapy.","Involved-site Radiation Therapy | ISRT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554425","Autologous Tumor Infiltrating Lymphocytes MDA-TIL","C153312","A preparation of autologous tumor infiltrating lymphocytes (TILs) with potential antineoplastic activity. TILs are isolated from a patient's tumor tissue, then cultured and expanded in vitro in the presence of interleukin-2 (IL-2) and an agonistic anti-4-1BB (CD137) antibody. Upon infusion of the autologous expanded TILs back into the patient, the cells specifically recognize, target, and kill the patient's tumor cells.","Autologous Tumor Infiltrating Lymphocytes MDA-TIL | MDA Autologous TILs | MDA Autologous Tumor Infiltrating Lymphocytes | MDA-TILs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555031","Recurrent Prostate Acinar Adenocarcinoma","C153570","The reemergence of prostate acinar adenocarcinoma after a period of remission.","Recurrent Prostate Acinar Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555028","Recurrent Parotid Gland Acinic Cell Carcinoma","C153571","The reemergence of parotid gland acinic cell carcinoma after a period of remission.","Recurrent Parotid Gland Acinic Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554394","BAY 2402234","C153137","An orally available inhibitor of dihydroorotate dehydrogenase (DHODH), with potential antineoplastic activity. Upon administration, orludodstat specifically targets, binds to and prevents the activation of DHODH, thereby preventing the fourth enzymatic step in de novo pyrimidine synthesis. This prevents uridine monophosphate (UMP) formation, DNA synthesis, cell division and cellular proliferation, causes reactive oxygen species (ROS) production, enables differentiation and induces apoptosis in susceptible tumor cells. DHODH, a mitochondrial enzyme, catalyzes the conversion of dihydroorotate (DHO) to orotate in the endogenous synthesis of UMP.","Orludodstat | BAY 2402234 | BAY-2402234 | BAY2402234 | DHODH Inhibitor BAY2402234 | Dihydroorotate Dehydrogenase Inhibitor BAY2402234 | ORLUDODSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554395","Information Source Type Code","C153138","A coded value specifying the kind of system or data collection from which the record of the activity was derived.","Information Source Type Code | InformationSourceTypeCode | informationSourceTypeCode",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0260787","Bone Marrow Donor","C153141","Someone from whom bone marrow is removed for transplantation or other purpose.","Bone Marrow Donor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554570","Cornea Donor","C153142","Someone from whom a cornea is removed for transplantation or other purpose.","Cornea Donor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554398","Study Conduct","C153144","An ongoing and/or past performance of a formal investigation as specified in a study protocol.","Study Conduct | StudyConduct | conduct",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554399","Enrolled Study Subject Number","C153145","An integer specifying the quantity of study subjects enrolled in the study at the current time.","Enrolled Study Subject Number | enrolledStudySubjectNumber",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020588","Hypnosis, Anesthetic","C153146","A sedation technique that combines hypnosis, local anesthesia, and conscious sedation.","Hypnosedation | Hypnoanesthesia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554400","Anti-CD3/CD38 Bispecific Monoclonal Antibody AMG 424","C153147","A humanized, bispecific monoclonal antibody (BsAb) targeting CD3, a T-cell surface antigen, and CD38, a human cell surface glycoprotein and tumor-associated antigen (TAA), with potential antineoplastic activity. Upon intravenous administration, anti-CD3/CD38 bispecific monoclonal antibody AMG 424 binds to both CD3 on T-cells and CD38 expressed on tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis.","Anti-CD3/CD38 Bispecific Monoclonal Antibody AMG 424 | AMG 424 | AMG-424 | AMG424 | Anti-CD3 x Anti-CD38 Bispecific Monoclonal Antibody AMG 424 | Anti-CD3/Anti-CD38 Bispecific Monoclonal Antibody AMG 424 | CD3xCD38 BsAb AMG 424",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0179834","Centrifuge","C153402","A machine that uses centrifugal force to separate heavier substances from lighter ones, for removing moisture, or for simulating gravitational effects.","Centrifuge | ",,,,,,,,,,,,,,,"45767727","Centrifuge",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554843","Subfacial","C153403","Situated, occurring, or performed below a fascia.","Subfacial | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554844","Spread of Lymphoma","C153404","A finding indicating the spread of a lymphoma from a nodal or extranodal primary site.","Spread of Lymphoma | Lymphoma Spread",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574498","Ewe Language","C153912","A Niger-Congo language spoken in southeastern Ghana, part of a cluster of related languages commonly called Gbe.","Ewe Language | EWE | Ewe",,,,,,,,,,,,,,,"4177302","Ewe language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555104","Ewondo Language","C153913","A Niger-Congo language spoken by the Ewondo people of Cameroon.","Ewondo Language | EWO | Ewondo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574439","Fang Language","C153914","A Niger-Congo, Bantu language spoken in Cameroon, Gabon, Equatorial Guinea, Sao Tome and Principe, and the Congo Republic.","Fang Language | FAN | Fang",,,,,,,,,,,,,,,"4181568","Fang language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574310","Faroese Language","C153915","An Indo-European, North Germanic language spoken mainly on the Faroe Islands and parts of Denmark.","Faroese Language | FAO | Faroese",,,,,,,,,,,,,,,"4180184","Faroese language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556402","Fantse Language","C153917","One of the three formal literary dialects of the Akan language. It is the major local dialect in the Central Region of Ghana, as well as in other regions from mid to southern Ghana.","Fantse Language | FAT | Fante | Fanti | Fantse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0185056","Electrodesiccation","C15391","A procedure in which tissue desiccation is achieved via employment of a moderately damped alternating electrical current.","Electrodesiccation | electrodesiccation",,,,,,,,,,,,,,,"4221867","Electrodesiccation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574500","Fon Language","C153920","A Niger-Congo language, part of the Eastern Gbe language cluster, spoken mainly in Benin.","Fon Language | FON | Fon",,,,,,,,,,,,,,,"4181704","Fon language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555105","Northern Frisian Language","C153921","A part of the larger group of the West Germanic Frisian languages, spoken in the North Frisia area of Germany.","Northern Frisian Language | FRR | Northern Frisian",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556898","East Frisian Low Saxon Language","C153922","A West Low German, Friso-Saxon dialect spoken in the East Frisian peninsula of northwestern Lower Saxony state of Germany.","East Frisian Low Saxon Language | East Frisian Low German | East Frisian Low Saxon | Eastern Frisian | FRS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2919859","Western Frisian Language","C153923","A West Germanic language spoken mostly in the province of Friesland in the north of the Netherlands.","Western Frisian Language | FRY | Western Frisian",,,,,,,,,,,,,,,"40481130","Western Frisian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554426","RIVAC Regimen","C153313","A regimen consisting of rituximab, ifosfamide, high-dose cytarabine and etoposide that can be used in the treatment of non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL).","RIVAC Regimen | R-IVAC Regimen | RIVAC | Rituximab + Ifosfamide + Cytarabine + Etoposide | Rituximab-Ifosfamide-Cytarabine-Etoposide | Rituximab/Ifosfamide/Cytarabine/Etoposide | Rituximab/Ifosfamide/VP-16/ARA-C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554427","DSP 0509","C153314","A synthetic, small molecule, toll-like receptor (TLR) 7 agonist, with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, guretolimod activates TLR7, resulting in type I interferon secretion and activation of  cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses. TLR7 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.","Guretolimod | (((4-((2-Amino-4-(((3s)-1-hydroxyhexan-3-yl)amino)-6-methylpyrimidin-5-yl)methyl)-3- methoxyphenyl)methyl)(2,2,2-trifluoroethyl)amino)acetic Acid | DSP 0509 | DSP-0509 | DSP0509 | GURETOLIMOD | TLR7 Agonist DSP-0509 | Toll-like Receptor 7 Agonist DSP-0509",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554428","Metastatic Unresectable Carcinoma","C153315","A carcinoma that has spread from its original site of growth to another anatomic site and is not amenable to surgical resection.","Metastatic Unresectable Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554429","Metastatic Unresectable Gastric Adenocarcinoma","C153316","A gastric adenocarcinoma that has spread from its original site of growth to another anatomic site and is not amenable to surgical resection.","Metastatic Unresectable Gastric Adenocarcinoma | Metastatic Unresectable Gastric (Stomach) Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971298","Advanced Unresectable Gastric Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554401","IW 1701","C153148","An orally bioavailable stimulator of soluble guanylate cyclase (sGC), with potential anti-inflammatory and vasodilating activities.  Upon oral administration, olinciguat targets, allosterically binds to and enhances the nitric oxide (NO)-dependent catalytic activity of sGC. This enhances NO-sGC signaling and increases the formation of the intracellular second messenger cyclic guanosine monophosphate (cGMP), which is derived from guanosine triphosphate (GTP). This enhances NO/cGMP-mediated muscle relaxation, suppresses leukocyte-endothelial interactions and promotes vascular anti-inflammatory effects. The NO/sGC/cGMP signaling pathway plays an important role in vasodilation, blood flow and inflammatory processes. sGC, a heme-containing cytoplasmic signaling enzyme, catalyzes the formation of cGMP from GTP in response to NO binding to heme.","Olinciguat | IW 1701 | IW-1701 | IW1701 | OLINCIGUAT | Soluble Guanylate Cyclase Stimulator IW-1701 | Stimulator of Soluble Guanylate Cyclase IW-1701 | sGC Stimulator IW-1701",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0198402","Mediastinotomy","C15404","A surgical procedure in which an opening is made into the mediastinum.","Mediastinotomy | incision of the mediastinum",,,,,,,,,,,,,,,"4078220","Incision of mediastinum",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555146","Low German Language","C154050","A West Germanic language spoken mainly in northern Germany and the eastern part of the Netherlands.","Low German Language | Low German | Low Saxon | NDS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556392","Newar Language","C154052","A Sino-Tibetan language spoken by the Newar people of Nepal.","Newar Language | NEW | Nepal Bhasa | Newari",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556511","Nias Language","C154053","An Austronesian language spoken on Nias Island and the Batu Islands of Indonesia.","Nias Language | NIA | Nias",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574399","Niuean Language","C154054","An Austronesian language native to Niue Island.","Niuean Language | NIU | Niuean",,,,,,,,,,,,,,,"4180224","Niuean language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0376242","Flemish Language","C154055","A West Germanic language native to Netherlands and Flanders.","Flemish Language | Dutch | Flemish | NLD",,,,,,,,,,,,,,,"4180187","Flemish language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555108","Nynorsk Language","C154056","One of the two written standards of the Norwegian language.","Nynorsk Language | NNO | Norwegian Nynorsk | Nynorsk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555107","Bokmal Language","C154057","The preferred written standard for the Norwegian language.","Bokmal Language | Bokmal | NOB | Norwegian Bokmal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574203","Nogai Language","C154058","A Turkic language spoken in southwestern European Russia.","Nogai Language | NOG | Nogai",,,,,,,,,,,,,,,"4178571","Nogai language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555110","N'Ko Language","C154060","A script devised as a writing system for the Manding languages of West Africa, and the name of the literary language written in that script.","N'Ko Language | N'Ko | NKo Language | NQO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555109","Northern Sotho Language","C154061","A Niger-Congo Bantu language spoken primarily in South Africa.","Northern Sotho Language | NSO | Northern Sotho | Pedi | Sepedi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574464","Chewa Language","C154062","A Niger-Congo Bantu language native to Zambia, Malawi, Mozambique, and Zimbabwe.","Chewa Language | Chewa | Chichewa | NYA | Nyanja",,,,,,,,,,,,,,,"4180353","Nyanja language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574463","Nyamwezi Language","C154063","A Niger-Congo Bantu language spoken in central Tanzania.","Nyamwezi Language | NYM | Nyamwezi",,,,,,,,,,,,,,,"4181694","Nyamwezi language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555112","Nkore Language","C154064","A Niger-Congo Bantu language spoken by the Nkore and Hima peoples of south-western Uganda.","Nkore Language | NYN | Nkole | Nkore | Nyankole | Nyankore | Orunyankole | Orunyankore | Runyankole | Runyankore",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574465","Nyoro Language","C154065","A Niger-Congo Bantu language spoken by the Nyoro people of Uganda.","Nyoro Language | NYO | Nyoro",,,,,,,,,,,,,,,"4181695","Nyoro language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0684043","Occitan Language","C154067","A Romance language spoken in southern France, Italy's Occitan Valleys, Monaco, and Spain's Val d'Aran.","Occitan Language | OCI | Occitan | Occitan (post 1500)",,,,,,,,,,,,,,,"4229842","Occitan language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574538","Ojibwe Language","C154068","An indigenous language in the Algonquian language family spoken by the Ojubwe people in Canada and the United States.","Ojibwe Language | Chippewa | OJI | Ojibwa | Ojibwe | Otchipwe",,,,,,,,,,,,,,,"4181716","Ojibwa language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0252925","Bruceanol E","C1536","A quassinoid phytochemical isolated from the plant Brucea antidysenterica with potential antineoplastic activity. (NCI04)","Bruceanol E | Picrasan-21-oic Acid, 15-((3,4-dimethyl-1-oxo-2-pentenyl)oxy)-13,20-epoxy-1,11,12-trihydroxy-2,16-dioxo-, Methyl Ester, (1beta,11beta,12alpha,15beta(E))-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0150165","Cerebral Edema Management","C15371","Any activity related to the care and/or treatment of cerebral edema.","Cerebral Edema Management | management of cerebral edema",,,,,,,,,,,,,,,"4296243","Cerebral edema control",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1621885","Smoking Cessation Intervention","C15372","Any intervention designed to reduce and eliminate an individual's smoking.","Smoking Cessation Intervention | Smoking and Tobacco Use Cessation Interventions",,,,,,,,,,,,,,,"4021160","Smoking cessation education",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0152054","Therapeutic Touch","C15373","An energy (biofield) therapy that encompasses a group of non-invasive techniques that utilize the hands to clear, energize, and balance the human and environmental energy fields.  Healing Touch interventions may be used to restore, energize, and balance an energy field disturbance. (HTA)","Therapeutic Touch | Healing Touch | healing touch | therapeutic touch",,,,,,,,,,,,,,,"4302397","Therapeutic touch",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0150627","Imagery Therapy","C15375","A therapeutic exercise used in treatment of pain, hyperventilation, panic, and other conditions.  The practitioner guides the patient into a semi-hypnotic state by verbally introducing positive and soothing images.  It is as a form of distraction and attention therapy.","Imagery Therapy | Guided Imagery | Imagery | imagery",,,,,,,,,,,,,,,"4210287","Imagery therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0150814","Transcendental Meditation Therapy","C15376","No value exists.","Transcendental Meditation Therapy | TM | Transcendental Meditation | transcendental meditation",,,,,,,,,,,,,,,"4084640","Transcendental meditation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162352","Immunologic Desensitization","C15377","Treatment or therapy to reduce or eliminate a patient's allergic response to an allergen (NCI/OSP)","Immunologic Desensitization | Desensitization | Desensitization, Immunologic | Hyposensitization Therapy",,,,,,,,,,,,,,,"4057262","Allergen immunotherapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162505","Boron Neutron Capture Therapy","C15378","A type of radiation therapy in which the patient is given an intravenous boron infusion that is absorbed by tumor cells. Radiation is then directed at the boron, killing the tumor cells but not the surrounding normal tissue.","Boron Neutron Capture Therapy | BNCT | Neutron capture therapy (procedure) | boron neutron capture therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554992","Ochsner Medical Center","C153798","A medical center located in New Orleans, LA. It includes acute and sub-acute facilities and centers of excellence: Ochsner Cancer Institute, Ochsner Multi-Organ Transplant Center, and Ochsner Heart and Vascular Institute.","Ochsner Medical Center | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554324","Lipidome","C153197","The complete set of lipids produced in a given cell or organism under specific conditions.","Lipidome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554542","Morisky Medication Adherence Scale","C153198","A structured, self-reported measure designed to estimate the risk of medication non-adherence. It was originally developed with 4 questions (MMAS-4), but was later expanded to 8 questions (MMAS-8).","Morisky Medication Adherence Scale | MMAS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554504","TDGF1 wt Allele","C153276","Human CRIPTO wild-type allele is located in the vicinity of 3p21.31 and is approximately 8 kb in length. This allele, which encodes protein Cripto, is involved in regulation of signaling by Nodal homolog. Mutation of the gene is associated with defects in forebrain development.","CRIPTO wt Allele | CR | CR-1 | CRGF | CRIPTO | Cripto, EGF-CFC Family Member wt Allele | Cripto-1 | TDGF1 | TDGF1 wt Allele | TDGF1 wt Allele | Teratocarcinoma-Derived Growth Factor 1 Gene | Teratocarcinoma-Derived Growth Factor 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554505","Teratocarcinoma-Derived Growth Factor 1","C153277","Protein Cripto (188 aa, ~21 kDa) is encoded by the human CRIPTO gene. This protein plays a role in growth factor signaling pathways mediated by Nodal homolog.","Protein Cripto | CR-1 | CRGF | CRIPTO | CRIPTO-1 | Cripto Growth Factor | Cripto, EGF-CFC Family Member | Cripto-1 | Cripto-1 Growth Factor | Epidermal Growth Factor-Like Cripto Protein CR1 | TDGF-1 | TDGF1 | Teratocarcinoma-Derived Growth Factor 1 | Teratocarcinoma-Derived Growth Factor 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554507","Metastatic Unresectable Malignant Neoplasm","C153279","A malignant neoplasm that has spread from its original site of growth to another anatomic site and is not amenable to surgical resection.","Metastatic Unresectable Malignant Neoplasm | Metastatic Unresectable Malignant Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554363","Evocalcet","C153105","An orally available calcium receptor (CaR) modulator, with potential calcimimetic activity. Upon administration, evocalcet allosterically binds to and inhibits the activity of CaR, thereby suppressing the production of serum parathyroid hormone (PTH) and prevents the PTH-mediated efflux of calcium from bone and normalizes calcium levels.","Evocalcet | EVOCALCET | KHK7580 | MT-4580 | Orkedia | benzeneacetic Acid, 4-((3S)-3-(((1R)-1-(1-naphthalenyl)ethyl)amino)-1-pyrrolidinyl)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554364","Integrated Statistical Analysis Plan","C153106","A type of statistical analysis plan that is intended to draw conclusions across multiple studies.","Integrated Statistical Analysis Plan | IntegratedStatisticalAnalysisPlan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554366","Performed Composition Relationship","C153108","A relationship between a composite activity and a component activity that comprises it, i.e. parent and child activities where all activities have occurred in the context of a particular study or experiment.","Performed Composition Relationship | PerformedCompositionRelationship",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556401","Odia Language","C154069","An Indo-Aryan language that is spoken mostly in eastern India.","Odia Language | ORI | Odia | Oriya",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574158","Oromo Language","C154070","An Afroasiatic language spoken in the Horn of Africa.","Oromo Language | ORM | Oromo",,,,,,,,,,,,,,,"4182349","Oromo language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574594","Osage Language","C154071","A Siouan language spoken by the Osage people of Oklahoma.","Osage Language | OSA | Osage",,,,,,,,,,,,,,,"4177447","Osage language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574354","Ossetian Language","C154072","An Eastern Iranian language spoken in the Ossetia region of Russia.","Ossetian Language | OSS | Ossete | Ossetian | Ossetic",,,,,,,,,,,,,,,"4180206","Ossetian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554524","Body Mass Index Greater Than 25","C153368","Indicates a body mass index measurement greater than 25.","Body Mass Index Greater Than 25 | BMI Greater than 25",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554526","Metastatic Soft Tissue Sarcoma, Excluding Liposarcoma","C153370","A finding indicating that a soft tissue sarcoma other than liposarcoma has spread from its original site of growth to another anatomic site.","Metastatic Soft Tissue Sarcoma, Excluding Liposarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554527","Locally Advanced Soft Tissue Sarcoma, Excluding Liposarcoma","C153371","A finding indicating that a soft tissue sarcoma other than liposarcoma has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Soft Tissue Sarcoma, Excluding Liposarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554528","Oxidative Phosphorylation Inhibitor IM156","C153372","The acetate salt form of lixumistat, an orally bioavailable biguanide compound and mitochondrial oxidative phosphorylation (OxPhos) inhibitor, with potential antineoplastic activity. Upon administration, lixumistat inhibits oxidative phosphorylation, decreases mitochondrial function, prevents tumor cell metabolism and deprives tumor cells of energy, thereby preventing tumor cell proliferation. Mitochondrial OxPhos is overactivated in cancer cells and plays a key role in tumor cell proliferation. Drug resistant tumor cells are very susceptible to decreased mitochondrial OxPhos as they cannot easily compensate for the decrease in mitochondrial function by increasing glycolysis.","Lixumistat Acetate | HL271 Acetate | IM 156 | IM-156 | IM156 | LIXUMISTAT ACETATE | Mitochondrial Oxidative Phosphorylation Inhibitor IM156 | OxPhos Inhibitor IM156 | Oxidative Phosphorylation Inhibitor IM156 | Oxidative Phosphorylation Inhibitor IM156",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554179","AXL Inhibitor DS-1205c","C152976","An orally available and selective inhibitor of the receptor tyrosine kinase AXL (UFO), with potential antineoplastic activity. Upon administration, DS-1205c targets, binds to and prevents the activation of AXL. This blocks AXL-mediated signal transduction pathways and inhibits tumor cell proliferation and migration. AXL, a member of the Tyro3, AXL and Mer (TAM) family of receptor tyrosine kinases, is overexpressed by many tumor cell types. It plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance and poor prognosis.","AXL Inhibitor DS-1205c | DS 1205c | DS-1205c | DS1205c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554180","CMC2 wt Allele","C152977","Human CMC2 wild-type allele is located in the vicinity of 16q23.2 and is approximately 54 kb in length. This allele, which encodes COX assembly mitochondrial protein 2 homolog, may play a role in cytochrome c oxidase localization.","CMC2 wt Allele | 2310061C15Rik | C-X(9)-C Motif Containing 2 Gene | C-X9-C Motif Containing 2 wt Allele | C16orf61 | COX Assembly Mitochondrial Protein 2 Homolog (S. cerevisiae) Gene | Chromosome 16 Open Reading Frame 61 Gene | DC13 | MGC45036",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554181","COX Assembly Mitochondrial Protein 2 Homolog","C152978","COX assembly mitochondrial protein 2 homolog (79 aa, ~9 kDa) is encoded by the human CMC2 gene. This protein may be involved in localization and assembly of complex IV of the mitochondrial electron transport chain.","COX Assembly Mitochondrial Protein 2 Homolog | C-X(9)-C Motif Containing 2 | C-X9-C Motif Containing Protein 2 | CMC2 | Cx9C Motif-Containing Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556418","Asturian Language","C153841","A West Iberian Romance language spoken in the Principality of Asturias, Spain.","Asturian Language | AST | Asturian | Asturleonese | Bable | Leonese",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574219","Avar Language","C153843","A language that belongs to the Avar-Andic group of the Northeast Caucasian family. It is spoken mainly in the western and southern parts of the Russian Caucasus republic of Dagestan, and the Balaken, Zaqatala regions of north-western Azerbaijan.","Avar Language | AVA | Avar | Avaric",,,,,,,,,,,,,,,"4175748","Avar language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555020","Awadhi Language","C153844","An Indo-Aryan language spoken primarily in the Awadh region of Uttar Pradesh and Terai belt of Nepal.","Awadhi Language | AWA | Awadhi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555019","Refractory Malignant Brain Neoplasm","C153845","A malignant brain neoplasm that is resistant to treatment.","Refractory Malignant Brain Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574238","Aymara Language","C153846","An Aymaran language spoken by the Aymara people of the Andes and by some communities in northern Chile.","Aymara Language | AYM | Aymara",,,,,,,,,,,,,,,"4181391","Aymara language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004487","Azerbaijani Language","C153847","A Turkic language spoken primarily by the Azerbaijanis, mainly in Transcaucasia and Iranian Azerbaijan.","Azerbaijani Language | AZE | Azerbaijani | Azeri | Azeri Turkic | Azeri Turkish",,,,,,,,,,,,,,,"4181383","Azerbaijani language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574198","Bashkir Language","C153848","A Turkic language belonging to the Kipchak branch, mostly spoken in the Republic of Bashkortostan, Russia.","Bashkir Language | BAK | Bashkir",,,,,,,,,,,,,,,"4182473","Bashkir language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556415","Balochi Language","C153849","An Indo-European language that is the principal language of the Baloch people, spoken primarily in Iran, Pakistan and Afghanistan.","Balochi Language | BAL | Balochi | Baluchi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574364","Balinese Language","C153851","A Malayo-Polynesian language spoken on the Indonesian island of Bali as well as northern Nusa Penida, western Lombok and eastern Java.","Balinese Language | BAN | Balinese",,,,,,,,,,,,,,,"4180211","Balinese language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556376","Basa Language","C153852","A cluster of Kainji languages spoken in scattered areas across Nigeria.","Basa Language | BAS | Basa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554973","Dolcanatide","C153478","An orally administered analog of the human endogenous natriuretic hormone uroguanylin and guanylate cyclase C (GC-C) agonist, with potential laxative, anti-nociceptive and anti-inflammatory activities. Upon administration, dolcanatide, by mimicking uroguanylin, binds to and activates GC-C locally on endothelial cells in the gastrointestinal (GI) tract, without entering the systemic circulation. Activation of GC-C results in an increase in cyclic guanosine monophosphate (cGMP). Increased concentrations of cGMP lead to the activation of the anion channel cystic fibrosis transmembrane conductance regulator (CFTR). CFTR activation increases the secretion of negatively charged ions, particularly chloride and bicarbonate, into the GI tract lumen, which further drives sodium ions and then water into the lumen. This leads to increased fluid secretion in the GI tract, accelerated transit and changes in stool consistency. In addition, ion channel modulation may decrease muscle contractions and the activity of pain-sensing nerves, thereby decreasing intestinal pain. Also, GC-C may inhibit the secretion of pro-inflammatory cytokines, which may ameliorate GI inflammation. Uroguanylin, a naturally occurring human GI peptide, is a ligand for GC-C and plays a key role in anti-inflammatory processes in the GI tract.","Dolcanatide | D-Leucine, D-asparaginyl-L-alpha-aspartyl-L-alpha-glutamyl-L-cysteinyl-L-alpha-glutamyl-L-leucyl-L-cysteinyl-L-valyl-L-asparaginyl-L-valyl-L-alanyl-L-cysteinyl-L-threonylglycyl-L-cysteinyl-, Cyclic (4->12),(7->15)-bis(disulfide) | DOLCANATIDE | SP 333 | SP-333 | SP333",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554978","5-Aza-4'-thio-2'-deoxycytidine","C153479","An orally bioavailable, nucleoside analog and DNA methyltransferase I (DNMT1) inhibitor, with potential DNA hypomethylating and antineoplastic activities. Upon administration, 5-aza-4'-thio-2'-deoxycytidine (Aza-TdC) gets incorporated into DNA, where it binds to the active site of DNMT1, a maintenance methyltransferase that contributes to the hypermethylation and silencing of tumor suppressor genes. The formation of covalent DNMT1-DNA complexes inhibits DNMT1, prevents DNA methylation of CpG sites, causes CpG demethylation, and results in the re-expression and re-activation of silenced tumor suppressor genes. This inhibits tumor cell proliferation. DNMT1, overactivated in tumor cells, plays a key role in tumor cell proliferation.","5-Aza-4'-thio-2'-deoxycytidine | 5-AZA-4'-THIO-2'-DEOXYCYTIDINE | 5-Aza-4-thio-2-deoxycytidine | 5-Aza-TdCyd | Aza-TdC | Aza-TdCyd",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554979","Cetuximab/Irinotecan/Vemurafenib Regimen","C153480","A regimen consisting of cetuximab, irinotecan and vemurafenib that can be used for the treatment of colon cancer.","Cetuximab/Irinotecan/Vemurafenib Regimen | Cetuximab-Irinotecan-Vemurafenib | Cetuximab-Irinotecan-Vemurafenib Regimen | Cetuximab/Irinotecan/Vemurafenib | Irinotecan + Cetuximab + Vemurafenib | Irinotecan + Cetuximab + Vemurafenib Regimen | Irinotecan, Vemurafenib, Cetuximab | Irinotecan/Cetuximab/Vemurafenib | Irinotecan/Cetuximab/Vemurafenib Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1541404","bevacizumab/irinotecan/oxaliplatin","C153483","A regimen consisting of bevacizumab, irinotecan and oxaliplatin that can be used for the treatment of appendiceal adenocarcinoma and colorectal cancer.","IROX-Bevacizumab Regimen | Bevacizumab-Irinotecan-Oxaliplatin Regimen | Bevacizumab/Irinotecan/Oxaliplatin Regimen | Bevacizumab/Irinotecan/Oxaliplatin Regimen | IROX (Irinotecan/Oxaliplatin) + Bevacizumab | IROX + Bevacizumab | IROX + Bevacizumab Regimen | IROX Plus Bevacizumab | IROX/Bev | Oxaliplatin/Irinotecan + Bevacizumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554368","Assessed Activity Relationship","C153110","Specifies the link between an assessment (performed observation) and the performed activity that the assessment is based on.","Assessed Activity Relationship | AssessedActivityRelationship",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554370","Target Anatomic Site Directionality Code","C153112","A coded value specifying the directional portion of the anatomic site that is a target site for a procedure.","Target Anatomic Site Directionality Code | TargetAnatomicSite.directionalityCode | TargetAnatomicSiteDirectionalityCode | targetAnatomicSiteDirectionalityCode",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555092","Karelian Language","C153988","A Uralic language spoken mainly in the Russian Republic of Karelia.","Karelian Language | KRL | Karelian",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574289","Kurukh Language","C153989","A Dravidian language spoken by the Oraon and Kisan tribespeople of  India, Bangladesh, Nepal, and Bhutan.","Kurukh Language | KRU | Kurukh | Kurux | Oraon | Uranw",,,,,,,,,,,,,,,"4175766","Kurukh language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0194560","Urethrostomy","C15398","No value exists.","Urethrostomy | ",,,,,,,,,,,,,,,"4206331","Urethrostomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555090","Kwanyama Language","C153990","A Niger-Congo language that is the national language of Angola and Namibia.","Kwanyama Language | KUA | Kuanyama | Kwanyama | Oshikwanyama",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574202","Kumyk Language","C153991","A Turkic language spoken by the Kumyk people of the Dagestan, North Ossetia, and Chechen republics of the Russian Federation.","Kumyk Language | KUM | Kumyk",,,,,,,,,,,,,,,"4182475","Kumyk language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574352","Kurdish Language","C153992","A continuum of Northwestern Iranian languages spoken by the Kurdish people in Western Asia.","Kurdish Language | KUR | Kurdish",,,,,,,,,,,,,,,"4175909","Kurdish language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1551893","Kootenai language","C153993","A language isolate that is the native language of the Kutenai people of Montana and Idaho in the United States and British Columbia in Canada.","Kutenai Language | KUT | Kootenai | Kootenay | Ksanka | Ktunaxa | Kutenai",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556413","Ladino Language","C153994","A Romance language derived from Old Spanish, originally spoken in the former territories of the Ottoman Empire.","Ladino Language | Judeo-Spanish | LAD | Ladino",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554529","Elagolix","C153373","An orally bioavailable, second-generation, non-peptide based, small molecule compound and selective gonadotropin-releasing hormone (GnRH; LHRH) receptor antagonist, with potential hormone production inhibitory activity. Upon oral administration, elagolix competes with GnRH for receptor binding and inhibits GnRH receptor signaling in the anterior pituitary gland. This inhibits the secretion of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. In women, inhibition of FSH and LH prevents the production of estrogen by the ovaries. Inhibition of GnRH signaling may treat or prevent symptoms of sex hormone-dependent disease states.","Elagolix | ABT-620 | Butanoic Acid, 4-(((1R)-2-(5-(2-fluoro-3-methoxyphenyl)-3-((2-fluoro-6-(trifluoromethyl)phenyl)methyl)-3,6-dihydro-4-methyl-2,6-dioxo-1(2H)-pyrimidinyl)-1-phenylethyl)amino)- | ELAGOLIX | NBI 56418 | NBI-56418 | Orilissa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554530","Helicobacter pylori Therapeutic Vaccine IMX101","C153374","A Helicobacter pylori (H. pylori) therapeutic vaccine comprised of three components: two antigens, the immunosuppressive antigen, gamma-glutamyl transpeptidase (GGT), and an as of yet not disclosed H. pylori outer membrane protein and mucosal adjuvant, which consists of a fusion protein containing two domains, with potential immunostimulating and H. pylori-eradicating activities. Upon administration of the H. pylori therapeutic vaccine IMX101, the GGT antigen, which is an immune evasion factor, elicits a strong B-cell-mediated immune response against the GGT antigen, thereby generating neutralizing antibodies that bind to and inhibit GGT. This inhibits H. pylori's central immune evasion mechanism and enables the immune system to elicit a strong cytotoxic T-lymphocyte (CTL)-mediated immune response against the second outer membrane protein antigen, thereby killing H. pylori. The third component contains a domain that targets immune cells present near the site of H. pylori infection in the stomach. Once taken up by immune cells, the second domain is able to activate and enhance the immune response against H. pylori antigens. H. pylori infections may lead to gastritis and in some cases gastric cancer. GGT plays a key role in H. pylori's immune evasion mechanisms.","Helicobacter pylori Therapeutic Vaccine IMX101 | H. pylori Therapeutic Vaccine IMX101 | IMX 101 | IMX-101 | IMX101 | IMX101 Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555029","Recurrent Submandibular Gland Acinic Cell Carcinoma","C153572","The reemergence of submandibular gland acinic cell carcinoma after a period of remission.","Recurrent Submandibular Gland Acinic Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555034","Recurrent Endocervical Adenocarcinoma, Usual-Type","C153573","The reemergence of endocervical adenocarcinoma, usual-type after a period of remission.","Recurrent Endocervical Adenocarcinoma, Usual-Type | Recurrent Cervical Adenocarcinoma, Usual Type | Recurrent Cervical Adenocarcinoma, Usual-Type | Recurrent Endocervical Adenocarcinoma, Usual Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555035","Recurrent Ampulla of Vater Adenocarcinoma","C153574","The reemergence of ampulla of Vater adenocarcinoma after a period of remission.","Recurrent Ampulla of Vater Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555032","Recurrent Anal Adenocarcinoma","C153575","The reemergence of anal adenocarcinoma after a period of remission.","Recurrent Anal Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555033","Recurrent Anal Mucinous Adenocarcinoma","C153576","The reemergence of anal mucinous adenocarcinoma after a period of remission.","Recurrent Anal Mucinous Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555038","Recurrent Paget Disease of the Anal Canal","C153577","The reemergence of Paget disease of the anal canal after a period of remission.","Recurrent Paget Disease of the Anal Canal | Recurrent Paget's Disease of the Anal Canal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555039","Powder and solvent for suspension for injection in multidose container","C153578","Medicinal product consisting of a powder and solvent for suspension for injection presented in a multidose container; usually the powder is presented in the multidose container while the solvent is presented in a separate container, and is added to the powder in order to prepare the suspension for injection in the multidose container.","Powder and Solvent for Suspension for Injection in Multidose Container Dosage Form | Powder and Solvent for Suspension for Injection in Multidose Container | Powder and solvent for suspension for injection in multidose container",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555036","Recurrent Appendix Mucinous Adenocarcinoma","C153579","The reemergence of appendix mucinous adenocarcinoma after a period of remission.","Recurrent Appendix Mucinous Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574157","Beja Language","C153853","An Afroasiatic language of the Cushitic branch spoken on the western coast of the Red Sea by the Beja people.","Beja Language | BEJ | Bedawiyet | Beja",,,,,,,,,,,,,,,"4178558","Beja language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004958","Belarusian Language","C153854","An East Slavic language spoken as the official language of Belarus.","Belarusian Language | BEL | Belarusian",,,,,,,,,,,,,,,"4180194","Belorussian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574432","Bemba Language","C153855","A Niger-Congo Bantu language spoken primarily in north-eastern Zambia by the Bemba people.","Bemba Language | BEM | Bemba",,,,,,,,,,,,,,,"4180229","Bemba language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556897","Bhojpuri Language","C153857","An Indo-Aryan language spoken in the Northern-Eastern part of India and the Terai region of Nepal.","Bhojpuri Language | BHO | Bhojpuri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574497","Edo Language","C153859","A Volta-Niger language spoken primarily in the Edo State of Nigeria by the Edo people.","Edo Language | BIN | Bini | Edo",,,,,,,,,,,,,,,"4183795","Edo language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2585476","Bislama Language","C153860","A creole language, one of the official languages of Vanuatu.","Bislama Language | BIS | Bislama",,,,,,,,,,,,,,,"4233570","Bislama language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1555604","Blackfoot Language","C153861","An Algonquian language spoken by the Niitsitapi people, who currently live in the northwestern plains of North America.","Blackfoot Language | BLA | Blackfoot | Siksika",,,,,,,,,,,,,,,"4180366","Blackfoot language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554464","ACKR1 Gene Mutation","C153229","A change in the nucleotide sequence of the ACKR1 gene.","ACKR1 Gene Mutation | Atypical Chemokine Receptor 1 (Duffy Blood Group) Gene Mutation | CCBP1 Gene Mutation | CD234 Gene Mutation | DARC Gene Mutation | DARC/ACKR1 Gene Mutation | Dfy Gene Mutation | Duffy Blood Group, Chemokine Receptor Gene Mutation | FY Gene Mutation | GPD Gene Mutation | GpFy Gene Mutation | WBCQ1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554465","ACKR1 NM_002036.3:c.-67T>C","C153230","A nucleotide substitution at position -67 in the upstream promoter region of the ACKR1 gene where thymine has been mutated to cytosine.","ACKR1 NM_002036.3:c.-67T>C | ACKR1 c.-67T>C | Atypical Chemokine Receptor 1 (Duffy Blood Group) Gene c.-67T>C | CCBP1 c.-67T>C | CD234 c.-67T>C | DARC -46T>C | DARC c.-46T>C | DARC c.-67T>C | DARC/ACKR1 c.-67T>C | Dfy c.-67T>C | Duffy Blood Group, Chemokine Receptor Gene c.-67T>C | FY c.-67T>C | FYB-ES Allele | FYB-Erythroid Silent Allele | GPD c.-67T>C | GpFy c.-67T>C | WBCQ1 c.-67T>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554216","Metastatic Soft Tissue Sarcoma","C153069","Soft tissue sarcoma that has spread from the original site of growth to another anatomic site.","Metastatic Soft Tissue Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0033144","Primary Prevention","C15306","Prevention of disease or mental disorders in susceptible individuals or populations through promotion of health, including mental health, and specific protection, as in immunization, as distinguished from the prevention of complications or after-effects of existing disease.","Primary Prevention | PRIMARY PREVENTION | Prevention, Primary",,,,,,,,,,,,,,,"4201926","Primary prevention",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554217","Locally Advanced Bone Sarcoma","C153070","Bone sarcoma that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Bone Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554218","Locally Advanced Sarcoma","C153071","Sarcoma that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554219","Unresectable Bone Sarcoma","C153072","Bone sarcoma that is not amenable to surgical resection.","Unresectable Bone Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554220","Metastatic Bone Sarcoma","C153073","Bone sarcoma that has spread from the original site of growth to another anatomic site.","Metastatic Bone Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554221","Unresectable Synovial Sarcoma","C153074","Synovial sarcoma that is not amenable to surgical resection.","Unresectable Synovial Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554222","Metastatic Pancreatic Neuroendocrine Carcinoma","C153075","Pancreatic neuroendocrine carcinoma that has spread from the original site of growth to another anatomic site.","Metastatic Pancreatic Neuroendocrine Carcinoma | Metastatic Pancreatic Neuroendocrine Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554223","IGHV4-34 Gene","C153076","This gene plays a role in the specificity of antigen recognition by immunoglobulins.","IGHV4-34 Gene | IGHV4-34 | IGKV4-34 | Immunoglobulin Heavy Variable 4-34 Gene | Immunoglobulin Kappa Variable 4-34 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554224","IGHV4-34 wt Allele","C153077","Human IGHV4-34 wild-type allele is located in the vicinity of 14q32.33 and is approximately 1 kb in length. This allele, which encodes immunoglobulin heavy variable 4-34, is involved in antigen recognition.","IGHV4-34 wt Allele | Homo sapiens Immunoglobulin Heavy Variable 4-34 Gene | IGHV434 | Ig Heavy Chain V-II Region ARH-77 Gene | Immunogloblin Heavy Chain Variable Region 4-34 Gene | Immunoglobulin Heavy Variable 4-34 wt Allele | VH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554225","Immunoglobulin Heavy Variable 4-34","C153078","Immunoglobulin heavy variable 4-34 (123 aa, ~14 kDa) is encoded by the human IGHV4-34 gene. This protein plays a role in antigen recognition variability.","Immunoglobulin Heavy Variable 4-34 | IGHV4-34 | Ig Heavy Chain V-II Region ARH-77 | Immunogloblin Heavy Chain Variable Region 4-34 | Protein IGHV3-21 | Protein IGHV4-34",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554226","Unresectable Pancreatic Neuroendocrine Carcinoma","C153079","Pancreatic neuroendocrine carcinoma that is not amenable to surgical resection.","Unresectable Pancreatic Neuroendocrine Carcinoma | Unresectable Pancreatic Neuroendocrine Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554227","Unresectable Carcinoid Tumor","C153080","Neuroendocrine tumor grade 1 that is not amenable to surgical resection.","Unresectable Neuroendocrine Tumor G1 | Unresectable Carcinoid Tumor | Unresectable Carcinoid Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554814","Refractory Lung Non-Small Cell Carcinoma","C153081","Non-small cell lung carcinoma that does not respond to treatment.","Refractory Lung Non-Small Cell Carcinoma | Refractory Non-Small Cell Lung Cancer | Refractory Non-Small Cell Lung Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555132","Lamba Language","C153996","A Niger-Congo Bantu language spoken in Zambia and the Democratic Republic of the Congo.","Lamba Language | LAM | Lamba",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0023033","Lao Language","C153997","A Kra-Dai language that is the official language of Laos.","Lao Language | LAO | Lao | Laotian",,,,,,,,,,,,,,,"4182952","Lao language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023129","Latvian Language","C153998","An Indo-European Baltic language that is the official language of Latvia.","Latvian Language | LAV | Latvian",,,,,,,,,,,,,,,"4180064","Latvian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555134","Lezghian Language","C153999","A Northeast Caucasian language that is spoken mainly by the Lezgin people of Russia.","Lezghian Language | LEZ | Lezghian | Lezgi | Lezgin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556877","Limburgish Language","C154000","A group of East Low Franconian language varieties spoken in the Belgian and Dutch provinces both named Limburg and some neighboring areas of Germany.","Limburgish Language | LIM | Limburgan | Limburger | Limburgish",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555133","Surefire Antireflux Microcatheter","C154001","A proprietary catheter with an expandable tip designed to increase infusion pressure while maintaining antegrade blood flow in order to deliver a higher concentration of agents to a target.","Surefire Antireflux Microcatheter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574448","Lingala Language","C154002","A Niger-Congo Bantu language spoken throughout the northwestern part of the Democratic Republic of the Congo and a large part of the Republic of the Congo.","Lingala Language | LIN | Lingala",,,,,,,,,,,,,,,"4181690","Lingala language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0023880","Lithuanian Language","C154003","An Indo-European Baltic language that is the official language of Lithuania.","Lithuanian Language | LIT | Lithuanian",,,,,,,,,,,,,,,"4175772","Lithuanian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574459","Mongo Language","C154004","A Niger-Congo Bantu language spoken by several of the Mongo peoples in the Democratic Republic of the Congo.","Mongo Language | LOL | Mongo | Mongo-Nkundu | Nkundo",,,,,,,,,,,,,,,"4175934","Mongo language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574450","Lozi Language","C154005","A Niger-Congo Bantu language spoken by the Lozi people, primarily in southwestern Zambia and in surrounding countries.","Lozi Language | LOZ | Lozi | Rozi | siLozi",,,,,,,,,,,,,,,"4181691","Lozi language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3160888","Metastatic Gastric Adenocarcinoma","C153319","A gastric adenocarcinoma that has spread from its original site of growth to another anatomic site.","Metastatic Gastric Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554431","Metastatic Gastric Carcinoma","C153320","A gastric carcinoma that has spread from its original site of growth to another anatomic site.","Metastatic Gastric Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0454525","Manual Therapy","C153321","A physical treatment primarily used to treat musculoskeletal pain and disability through physical manipulation of the body.","Manual Therapy | MT",,,,,,,,,,,,,,,"4039926","Manual therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554432","Metastatic Chordoma","C153323","A chordoma that has spread from its original site of growth to other anatomic sites.","Metastatic Chordoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554433","Locally Advanced Chordoma","C153324","A chordoma that has spread from its original site of growth to nearby tissues.","Locally Advanced Chordoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554434","Unresectable Chordoma","C153325","A chordoma which is not amenable to surgical resection.","Unresectable Chordoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555037","Incomplete, Incorrect or Alternative Diagnosis Code Assigned","C153580","A diagnosis code was assigned based on incomplete, incorrect or non-ideal (an alternative diagnosis may be more appropriate) supporting information.","Incomplete, Incorrect or Alternative Diagnosis Code Assigned | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555044","Recurrent Invasive Ductal Carcinoma of the Breast","C153587","The reemergence of invasive breast carcinoma of no special type after a period of remission.","Recurrent Invasive Breast Carcinoma of No Special Type | Recurrent Invasive Breast Ductal Carcinoma | Recurrent Invasive Ductal Breast Carcinoma | Recurrent Invasive Ductal Carcinoma of the Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555045","Recurrent Paget's Disease of the Breast","C153588","The reemergence of Paget disease of the breast after a period of remission.","Recurrent Breast Paget Disease | Recurrent Paget Disease of the Breast | Recurrent Paget's Disease of the Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554402","LZM 009","C153149","A recombinant, humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor, programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, lipustobart binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands, programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways, leading to the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1 is a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells that negatively regulates T-cell activation and effector function when activated by its ligands. PD-1 plays an important role in tumor evasion from host immunity.","Lipustobart | ANTI-PD-1 MONOCLONAL ANTIBODY LZM009 | Anti-PD-1 Monoclonal Antibody LZM009 | Anti-PD-1 Monoclonal Antibody LZM009 | LIPUSTOBART | LZM 009 | LZM-009 | LZM009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034758","Reagent Kits, Diagnostic","C15314","A diagnostic test kit that includes the necessary reagents.","Diagnostic Reagents and Test Kits | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554404","CXCR2 Antagonist QBM076","C153151","An orally available small molecule antagonist of the G protein-coupled receptor, C-X-C motif chemokine receptor 2 (CXCR2), with potential immunomodulating and antineoplastic activities. Upon administration, QBM076 binds to and inhibits the activation of CXCR2, resulting in reduced neutrophil recruitment, myeloid-derived suppressor cell (MDSC) accumulation, and may potentially slow tumorigenesis and metastatic processes. CXCR2 is upregulated in a variety of cancer types, predominately in neutrophils/MDSCs rather than tumor cells, and is thought to contribute to tumor cell proliferation, invasion, and metastasis.","CXCR2 Antagonist QBM076 | QBM 076 | QBM-076 | QBM076",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554933","SLC6A8 protein, human","C153432","Sodium- and chloride-dependent creatine transporter 1 (635 aa, ~71 kDa) is encoded by the human SLC6A8 gene. This protein plays a role in sodium and chloride ion-dependent transmembrane transport of creatine and phosphocreatine.","Sodium- and Chloride-Dependent Creatine Transporter 1 | CT1 | Creatine Transporter | Creatine Transporter 1 | Creatine Transporter SLC6A8 | SLC6A8 | Solute Carrier Family 6 Member 8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554229","Autologous CD8+ SLC45A2-specific T Lymphocytes","C153083","A preparation of autologous CD8+ T lymphocytes targeting SLC45A2, a melanoma-associated antigen, with potential immunomodulating and antineoplastic activities. Following peripheral blood mononuclear cell (PBMC) collection and ex vivo expansion of SLC45A2-specific cytotoxic T-lymphocytes (CTLs), the autologous CD8+ SLC45A2-specific CTLs are re-infused into the patient, where they target and lyse SLC45A2-expressing tumor cells. While SLC45A2 is expressed by approximately 80% of cutaneous melanomas, its expression is limited in mature normal melanocytes, allowing high tumor selectivity and reduced potential for autoimmune toxicity.","Autologous CD8+ SLC45A2-specific T Lymphocytes | Autologous SLC45A2-specific CTLs | Autologous SLC45A2-specific Cytotoxic T Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556894","Fula Language","C153924","A Niger-Congo language spoken as a set of various dialects in a continuum that stretches across 20 countries in West and Central Africa.","Fula Language | FUL | Fula | Fulah | Fulani",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555106","Friulian Language","C153925","An Indo-European Romance language spoken in the Friuli region of northeastern Italy.","Friulian Language | FUR | Friulian",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574501","Ga Language","C153926","A Niger-Congo Kwa language spoken in the capital area of Ghana.","Ga Language | GAA | Ga",,,,,,,,,,,,,,,"4177304","Ga language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556398","Gayo Language","C153927","An Austronesian language spoken in the mountainous region of Aceh, Central Aceh, Bener Meriah, and Gayo Lues regencies of Indonesia.","Gayo Language | GAY | Gayo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574426","Gbaya Language","C153928","A family of languages spoken mainly in the Central African Republic, Cameroon, the Democratic Republic of the Congo, and the Republic of the Congo.","Gbaya Language | GBA | Gbaya | Gbaya-Manza-Ngbaka",,,,,,,,,,,,,,,"4181565","Gbaya language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574385","Gilbertese Language","C153929","A Micronesian language of the Austronesian language family native to the island of Kiribati.","Gilbertese Language | GIL | Gilbertese | Kiribati | Taetae ni Kiribati",,,,,,,,,,,,,,,"4180218","Gilbertese language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2919372","Manx Language","C153933","An Indo-European Celtic language spoken as a first language by the Manx people on the Isle of Man.","Manx Language | GLV | Manx | Manx Gaelic",,,,,,,,,,,,,,,"40481069","Manx language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574286","Gondi Language","C153934","A South-Central Dravidian language, spoken chiefly in the Indian states of Madhya Pradesh, Gujarat, Telangana, Maharashtra, Chhattisgarh, and Andhra Pradesh.","Gondi Language | GON | Gondi",,,,,,,,,,,,,,,"4180056","Gondi language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556510","Gorontalo Language","C153935","An Austronesian language spoken in the Gorontalo Province of Indonesia by the Gorontaloan people.","Gorontalo Language | GOR | Gorontalo | Hulontalo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574502","Grebo Language","C153936","A Niger-Congo Kru language spoken in Liberia.","Grebo Language | GRB | Grebo",,,,,,,,,,,,,,,"4181706","Grebo language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574239","Guarani Language","C153937","A language in the Tupí-Guarani branch of the Tupi linguistic family that is an indigenous language in Latin America.","Guarani Language | GRN | Guarani",,,,,,,,,,,,,,,"4182484","Guarani language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555081","Swiss German Language","C153938","Any of the Alemannic dialects spoken in the German-speaking part of Switzerland and in some Alpine communities in Northern Italy bordering Switzerland.","Swiss German Language | Alemannic | Alsatian | GSW | Swiss German",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0018388","Gujarati Language","C153939","An Indo-Aryan language native to the Indian state of Gujarat.","Gujarati Language | GUJ | Gujarati",,,,,,,,,,,,,,,"4059174","Gujarati language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554435","Ara-C Asparagine Conjugate","C153327","A small molecule pro-drug consisting of cytarabine, an antimetabolite analog of cytidine with a modified arabinose sugar moiety, covalently bonded to asparagine, with potential antineoplastic activity. Upon intravenous administration, aspacytarabine targets cancer cells, which often lack asparagine synthetase and are dependent on an external source of amino acids due to their high metabolic rate. Once the prodrug is inside target cells, the cytarabine component is cleaved and competes with cytidine for incorporation into DNA. The arabinose sugar moiety of cytarabine sterically hinders the rotation of the molecule within DNA, resulting in cell cycle arrest, specifically during the S phase of replication. Cytarabine also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Because BST-236 specifically targets cancer cells, it may spare normal tissues from cytarabine-related toxicities.","Aspacytarabine | ASPACYTARABINE | Ara-C Asparagine Conjugate | Asparagine Ara-C Conjugate | Asparagine Cytarabine Conjugate | Astarabine | BST 236 | BST-236 | BST236 | Cytarabine Asparagine Conjugate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574348","Sinhalese Language","C153328","An Indo-European language of the Indo-Aryan branch that is the native language of the Sinhalese people, who make up the largest ethnic group in Sri Lanka.","Sinhalese Language | SIN | Sinhala | Sinhalese",,,,,,,,,,,,,,,"4183657","Sinhalese language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038902","Gynecological Surgical Procedure","C15332","Surgery performed on the female reproductive system.","Gynecological Surgical Procedure | Gynecologic Surgical Procedure | gynecologic surgery | gynecologic surgical procedures | gynecological surgery",,,,,,,,,,,,,,,"4129747","Operation on female genital organs",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554438","Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","C153332","EBV-positive diffuse large B-cell lymphoma, not otherwise specified that is resistant to treatment.","Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, NOS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3151426","Reticulocytosis","C153333","A laboratory test result indicating an increased number of reticulocytes in the peripheral blood.","Reticulocytosis | ",,,,,,,,,,,,,,,"4261785","Reticulocytosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554439","Allogeneic GM-CSF-secreting Lethally Irradiated Pancreatic Tumor Cell Vaccine","C153334","An allogeneic tumor vaccine composed of lethally irradiated allogeneic pancreatic tumor cells that are genetically modified to secrete the immunostimulatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Upon intradermal injection, allogeneic GM-CSF-secreting lethally irradiated pancreatic tumor cell vaccine secretes GM-CSF at the injection site. In turn, GM-CSF may stimulate the body's immune system against tumor cells by attracting and enhancing the activation of antigen-presenting cells (APCs), such as dendritic cells (DCs). This promotes antigen presentation to T-lymphocytes and induces a cytotoxic T-lymphocyte (CTL) response against the pancreatic tumor cells expressing the pancreatic tumor-associated antigens (TAAs).","Allogeneic GM-CSF-secreting Lethally Irradiated Pancreatic Tumor Cell Vaccine | GVAX Allogeneic Irradiated Pancreatic Tumor Cell Vaccine | Irradiated Allogeneic GM-CSF-secreting Pancreatic Tumor Cell Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554298","Actinium Ac-225 Anti-PSMA Monoclonal Antibody J591","C153159","A radioimmunoconjugate consisting of a humanized monoclonal antibody directed against prostate specific membrane antigen (PSMA) labeled with the alpha particle-emitting radioisotope actinium Ac-225, with potential antineoplastic activity. Upon administration, actinium Ac 225 rosopatamab tetraxetan binds to the extracellular domain of PSMA with high affinity, thereby delivering alpha radiation to PSMA expressing cells. PSMA, a type II membrane protein expressed in all types of prostatic tissues, is often overexpressed in tumor cells.","Actinium Ac 225 Rosopatamab Tetraxetan | 225Ac-J591 | Ac 225 MOAB J591 | Ac 225 Monoclonal Antibody J591 | Actinium Ac-225 Anti-PSMA Monoclonal Antibody J591 | Actinium Ac-225 Anti-PSMA Monoclonal Antibody J591 | Actinium Ac-225 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554299","Recurrent Hepatosplenic T-Cell Lymphoma","C153160","The reemergence of hepatosplenic T-cell lymphoma after a period of remission.","Recurrent Hepatosplenic T-Cell Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554300","Refractory Hepatosplenic T-Cell Lymphoma","C153161","Hepatosplenic T-cell lymphoma that is resistant to treatment.","Refractory Hepatosplenic T-Cell Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556378","Pampanga Language","C154074","An Austronesian language of the Phillipines spoken in the provinces of Pampanga, Tarlac, and Bataan.","Pampanga Language | Kapampangan | PAM | Pampanga",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574647","Papiamento Language","C154076","A Portuguese-based creole language spoken in the Dutch West Indies.","Papiamento Language | PAP | Papiamento",,,,,,,,,,,,,,,"4177462","Papiamento language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555113","Palauan Language","C154077","An Austronesian language that is an official language of the Republic of Palau.","Palauan Language | PAU | Palauan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555114","Metastatic Fibrolamellar Carcinoma","C154078","A fibrolamellar carcinoma that has spread from the liver to another anatomic site.","Metastatic Fibrolamellar Carcinoma | Metastatic FLC | Metastatic Fibrolamellar Hepatocellular Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554182","LAM 003","C152979","An L-alanine ester prodrug of LAM-003A, an orally bioavailable, synthetic, second-generation small-molecule inhibitor of heat shock protein 90 (Hsp90), with potential antineoplastic activity. Upon oral administration, LAM-003 is converted to LAM-003A. LAM-003A selectively targets and binds to Hsp90, thereby inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. This may inhibit the growth and survival of a wide variety of cancer cell types. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability, and degradation of many oncogenic signaling proteins.","Hsp90 Inhibitor LAM-003 | LAM 003 | LAM-003 | LAM-003A Prodrug LAM-003 | LAM003 | Prodrug LAM-003",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554183","Related Donor Adenovirus-specific Cytotoxic T Cells","C152980","A population of allogeneic related donor cytotoxic T-lymphocytes (CTLs) specifically reactive to human adenovirus (Ad) with potential immunomodulating and anti-adenoviral activities. Upon infusion of related donor Ad-specific CTLs, these cells help reconstitute Ad-specific CTL responses in patients at risk of developing Ad infections after allogeneic stem cell transplant or in Ad-infected immunocompromised hosts. These related donor Ad-specific CTLs are manufactured with the CliniMACS Prodigy Cytokine Capture System which facilitates production of the Ad-specific CTLs.","Related Donor Adenovirus-specific Cytotoxic T Cells | Related Donor Ad-specific CTLs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551909","Kutchin language","C153940","An Athabaskan language spoken by the Gwich'in First Nation in Canada and the Alaska Native People of the United States.","Gwich'in Language | GWI | Gwich'in | Gwichin Language",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574549","Haida Language","C153941","A language isolate that is the language of the Haida people, spoken in the Haida Gwaii archipelago off the northern Pacific coast of Canada and on Prince of Wales Island in Alaska.","Haida Language | HAI | Haida",,,,,,,,,,,,,,,"4177435","Haida language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554509","FCN2 wt Allele","C153281","Human FCN2 wild-type allele is located in the vicinity of 9q34.3 and is approximately 25 kb in length. This allele, which encodes ficolin-2 protein, plays a role in lectin activity.","FCN2 wt Allele | EBP-37 | FCNL | Ficolin (Collagen/Fibrinogen Domain Containing Lectin) 2 (Hucolin) Gene | Ficolin (Collagen/Fibrinogen Domain Containing Lectin) 2 Gene | Ficolin (Collagen/Fibrinogen Domain-Containing Lectin) 2 (Hucolin) Gene | Ficolin 2 wt Allele | Ficolin-2 Gene | P35",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554512","TRPA1 wt Allele","C153284","Human TRPA1 wild-type allele is located in the vicinity of 8q21.11 and is approximately 70 kb in length. This allele, which encodes transient receptor potential cation channel subfamily A member 1 protein, is involved in cation transport and pain responses. Mutation of the gene is associated with familial episodic pain syndrome type 1.","TRPA1 wt Allele | ANKTM1 | Ankyrin-Like with Transmembrane Domains 1 Gene | FEPS | FEPS1 | Transient Receptor Potential Cation Channel Subfamily A Member 1 wt Allele | Transient Receptor Potential Cation Channel, Subfamily A, Member 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554513","Transient Receptor Potential Cation Channel Subfamily A Member 1","C153285","Transient receptor potential cation channel subfamily A member 1 (1119 aa, ~128 kDa) is encoded by the human TRPA1 gene. This protein plays a role in ion transport and the detection of pain.","Transient Receptor Potential Cation Channel Subfamily A Member 1 | Ankyrin-Like Protein with Transmembrane Domains 1 | Ankyrin-Like with Transmembrane Domains 1 | Ankyrin-Like with Transmembrane Domains Protein 1 | TRPA1 | Transformation-Sensitive Protein p120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554514","Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor","C153286","A malignant small round cell tumor with or without neural differentiation that is resistant to treatment.","Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554374","TrkA Inhibitor VMD-928","C153116","An orally bioavailable, selective inhibitor of tropomyosin receptor kinase A (TrkA; neurotrophic tyrosine receptor kinase (NTRK) type 1; NTRK1; TRK1-transforming tyrosine kinase protein), with potential antineoplastic activity. Upon oral administration, VMD-928 specifically targets and binds to TrkA, inhibits neurotrophin-TrkA interaction and prevents TrkA activation. This prevents the activation of downstream signaling pathways and inhibits cell growth in tumors that overexpress TrkA. Uncontrolled TrkA signaling plays an important role in tumor cell growth, survival, invasion and treatment resistance.","TrkA Inhibitor VMD-928 | NTRK1 Inhibitor VMD-928 | VMD 928 | VMD-928 | VMD928",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555116","Pohnpeian Language","C154080","An Austronesian Micronesian language spoken as the indigenous language of the island of Pohnpei in the Caroline Islands.","Pohnpeian Language | PON | Pohnpeian",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0424924","Pashto Language","C154081","An Indo-European language spoken by the Pashtun people of Afghanistan and Pakistan.","Pashto Language | PUS | Pashto | Pushto",,,,,,,,,,,,,,,"4052347","Pashtu language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555115","Recurrent Fibrolamellar Carcinoma","C154082","The reemergence of fibrolamellar carcinoma after a period of remission.","Recurrent Fibrolamellar Carcinoma | Recurrent FLC | Recurrent Fibrolamellar Hepatocellular Carcinoma | Relapsed FLC | Relapsed Fibrolamellar Carcinoma | Relapsed Fibrolamellar Hepatocellular Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0682386","Quechuan language","C154083","An indigenous, primary language family spoken by the Quechua peoples, primarily living in the Andes and highlands of South America.","Quechuan Language | QUE | Quechua | Quechuan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574344","Rajasthani Language","C154084","A group of Indo-Aryan languages spoken primarily in the state of Rajasthan and adjacent areas of Haryana, Punjab, Gujarat, and Madhya Pradesh in India.","Rajasthani Language | RAJ | Rajasthani",,,,,,,,,,,,,,,"4181543","Rajasthani language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555117","Rapa Nui Language","C154085","An Eastern Polynesian language spoken on the island of Rapa Nui (Easter Island).","Rapa Nui Language | Pascuan | RAP | Rapa Nui | Rapanui",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0438965","Cook Islands Maori Language","C154086","An Eastern Polynesian language spoken as the official language of the Cook Islands.","Cook Islands Maori Language | Cook Islands Maori | RAR | Rarotongan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2585590","Romansh Language","C154087","A Romance language spoken predominantly in the southeastern Swiss canton of Grisons.","Romansh Language | ROH | Romansh",,,,,,,,,,,,,,,"4259983","Romansh language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556403","Romani Language","C154089","Any of several languages of the Romani people belonging to the Indo-Aryan branch of the Indo-European language family.","Romani Language | ROM | Romani | Romany",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0035827","Romanian Language","C154090","An Eastern Romance language spoken as a native language, primarily in Romania and Moldova.","Romanian Language | Moldavian | Moldovan | RON | Romanian",,,,,,,,,,,,,,,"4181537","Rumanian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0744869","Metastatic Hepatocellular Carcinoma","C154091","A hepatocellular carcinoma that has spread to another anatomic site.","Metastatic Hepatocellular Carcinoma | ",,,,,,,,,,,,,,,"37162050|46270968","Metastatic hepatocellular carcinoma|Metastatic hepatocellular carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL554531","Nidanilimab","C153375","A low fucose, fully humanized monoclonal immunoglobulin G1 (IgG1) antibody (hmAb) against the interleukin 1 receptor accessory protein (interleukin-1 receptor associated protein; IL1RAP), with potential immunomodulating, anti-inflammatory and antineoplastic activities. Upon intravenous administration, nidanilimab targets and binds to IL1RAP, thereby preventing IL1RAP-mediated signaling, and disrupting IL-1 and IL-33 mediated nuclear factor kappa beta (NFkB) activation. This prevents the secretion of tumor stimulating cytokines, decreases tumor inflammation and inhibits tumor cell proliferation. In addition, nidanilimab induces antibody-dependent cellular cytotoxicity (ADCC), and stimulates natural killer (NK) cells to attack tumor cells, thereby killing the IL1RAP-poisitive tumor cells. IL1RAP, a co-receptor of the IL-1 receptor (IL1R1) and the IL-33 receptor (ST2), is upregulated in certain tumor cells, and plays a key role in tumor cell proliferation.","Nidanilimab | CAN 04 | CAN-04 | CAN04 | NIDANILIMAB | Nadunolimab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554184","COL4A2 Gene","C152981","This gene plays a role in the formation of basement membrane collagen structures.","COL4A2 Gene | COL4A2 | Collagen Type IV Alpha 2 Chain Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554185","COL4A2 wt Allele","C152982","Human COL4A2 wild-type allele is located in the vicinity of 13q34 and is approximately 207 kb in length. This allele, which encodes collagen alpha-2(IV) chain protein, is involved in basement membrane collagen structures. Mutation of the gene is associated with porencephaly 2 and increased susceptibility for intracerebral hemorrhage.","COL4A2 wt Allele | COL4A2 | Collagen Type IV Alpha 2 Chain wt Allele | Collagen of Basement Membrane, Alpha-2 Gene | Collagen, Type IV, Alpha-2 Gene | DKFZp686I14213 | FLJ22259 | ICH | POREN2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554186","COL4A2 Gene Product","C152983","A protein encoded by the COL4A2 gene.","COL4A2 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1689848","COL4A2 protein, human","C152984","Collagen alpha-2(IV) chain (1712 aa, ~168 kDa) is encoded by the human COL4A2 gene. This protein is involved in basement membrane formation.","Collagen Alpha-2(IV) Chain | COL4A2 | Collagen Type 4 Alpha-2 Chain | Collagen Type IV Alpha 2 | Collagen Type IV Alpha 2 Chain | Collagen Type IV Alpha-2 Chain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554188","Canstatin","C152985","Canstatin (227 aa, ~25 kDa) is encoded by the human COL4A2 gene. This protein plays a role in the inhibition of angiogenesis.","Canstatin | COL4A2 C-Terminal NC1 Peptide | Collagen Alpha-2(IV) Chain C-Terminal NC1 Peptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554189","EBF4 Gene","C152986","This gene is involved in neural development and B-cell maturation.","EBF4 Gene | EBF4 | Early B-Cell Factor 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554190","EBF4 wt Allele","C152987","Human EBF4 wild-type allele is located in the vicinity of 20p13 and is approximately 67 kb in length. This allele, which encodes transcription factor COE4 protein, plays a role in transcriptional regulation.","EBF4 wt Allele | COE4 | Early B Cell Factor 4 wt Allele | KIAA1442 | O/E-4 | RP5-860F19.3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554191","Transcription Factor COE4","C152988","Transcription factor COE4 (602 aa, ~64 kDa) is encoded by the human EBF4 gene. This protein is involved in transcriptional regulation, B-cell maturation and neural development.","Transcription Factor COE4 | EBF4 | Early B-Cell Factor 4 | O/E-4 | OE-4 | Olf-1/EBF-Like 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0215791","Batimastat","C1529","A synthetic hydroxamate with potential antineoplastic activity.  Batimastat binds covalently to the zinc ion in the active site of matrix metalloproteinases (MMPs), thereby inhibiting the action of MMPs, inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. (NCI04)","Batimastat | (2R,3S)-N{4}-Hydroxy-N{1}-[(1S)-2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-2-(2-methylpropyl)-3-[(2-thienylthio)methyl]butanediamide | BATIMASTAT | BB-94 | BB94 | Butanediamide, N4-hydroxy-N1-(2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl)-2-(2-methylpropyl)-3-((2-thienylthio)methyl)-, (2R-(1(S*),2R*,3S*))- | [4-(N-Hydroxyamino)-2R-isobutyl-3S-(2-thienylthiomethyl)-succinyl]-L-phenylalanine-N-methylamide | [4-(N-Hydroxyamino)-2R-isobutyl-3S-(thiophen-2-ylthiomethyl)-succinyl]-L-phenylalanine-N-methylamide | batimastat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556384","Braj Language","C153864","A Western Hindi language mostly spoken in the Indian Braj region.","Braj Language | BRA | Braj | Braj Bhasha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555093","Refractory WHO Grade III Glioma","C153865","A WHO grade 3 glioma that is resistant to treatment.","Refractory WHO Grade 3 Glioma | Refractory WHO Grade III Glioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574305","Breton Language","C153866","A Southwestern Brittonic Celtic language spoken in the Brittany area of France.","Breton Language | BRE | Breton",,,,,,,,,,,,,,,"4175773","Breton language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554515","Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029","C153287","A probody-drug conjugate (PDC) composed of a monoclonal antibody directed against the transferrin receptor 1 (TFR1;TRP1; CD71), linked to a proprietary masking peptide that covers the active antigen-binding site of the antibody through a protease-cleavable linker, and conjugated, via a valine-citrulline (VC) peptide linker, to the potent cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of the anti-CD71/vcMMAE PDC CX-2029, the anti-CD71 moiety is unable to bind to CD71 antigen, which is highly expressed on both tumor and healthy dividing cells, until the masking peptide that is attached to the anti-CD71 probody is cleaved by tumor-associated proteases upon extravasation into the tumor microenvironment (TME). Local protease-mediated removal of the linker and masking peptide enables specific binding of the unmasked anti-CD71 moiety to CD71 expressed on tumor cells. Upon internalization and proteolytic cleavage, MMAE is released into the cytosol of CD71-expressing tumor cells, binds to tubulin, and inhibits microtubule polymerization, which induces both G2/M phase arrest and tumor cell apoptosis. CD71, a transmembrane glycoprotein, is a highly expressed protein present in a number of solid and hematologic cancers, but is also expressed on normal, healthy tissues. The peptide masking of CX-2029 minimizes binding of the anti-CD71 antibody moiety to normal, healthy cells and may minimize systemic toxicity, when compared to other anti-CD71 antibody-drug conjugates (ADCs). Tumor-associated proteases are present in high concentrations and aberrantly activated in the TME.","Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029 | Anti-CD71 Probody/vcMMAE Drug Conjugate CX-2029 | Antibody Prodrug-drug Conjugate CX-2029 | CD71-Directed Probody Therapeutic CX-2029 | CD71-directed PDC CX-2029 | CX 2029 | CX-2029 | CX2029 | PBC CX-2029 | PDC-targeting CD71 CX-2029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554516","Extended-release Microsphere Capsule-based Oxycodone","C153288","A wax microsphere capsule formulation of oxycodone, a semi-synthetic, morphine-like opioid alkaloid, with analgesic activity. Upon administration, oxycodone exerts its analgesic activity by binding to the mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids. Due to the unique formulation, extended-release microsphere capsule-based oxycodone may provide an identical pharmacokinetic profile regardless of whether the capsule is intact when ingested or if ingested via enteral feeding tube, leading to a predictable level of analgesia in patients that must be transitioned from oral to enteral administration.","Extended-release Microsphere Capsule-based Oxycodone | Oxycodone ER Microsphere Capsule | Xtampza ER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554376","Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells PZ01","C153118","A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) of anti-CD19, coupled to the costimulatory domains of 4-1BB (CD137) and the zeta chain of the human T-cell receptor (CD3zeta), with potential immunostimulating and antineoplastic activities. Upon transfusion, the autologous anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells PZ01 target, bind to, and induce selective toxicity in CD19-expressing B cells. The CD19 antigen is a B-cell-specific cell surface antigen expressed in all B-cell lineage malignancies.","Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells PZ01 | Autologous CD19-specific CAR-T cells PZ01 | Autologous PZ01 CAR-T Cells | PZ01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554380","Axl/Mer Inhibitor INCB081776","C153122","An orally available and selective inhibitor of the receptor tyrosine kinases (RTKs) Axl (UFO) and Mer, with potential antineoplastic activity. Upon administration, INCB081776 targets and binds to both Axl and Mer, and prevents their activity. This blocks Axl- and Mer-mediated signal transduction pathways, and inhibits proliferation and migration of Axl- and Mer-overexpressing tumor cells. Axl and Mer, both members of the TAM (Tyro3, Axl and Mer) family of RTKs, are overexpressed by many tumor cell types. They play key roles in tumor cell proliferation, survival, invasion, angiogenesis and metastasis, and their expression is associated with enhanced immunosuppression, drug resistance and poor prognosis.","Axl/Mer Inhibitor INCB081776 | 5-PYRIMIDINECARBOXAMIDE, N-(4-(4-AMINO-7-(1-(2-METHYL-1-OXOPROPYL)-4-PIPERIDINYL)PYRROLO(2,1-F)(1,2,4)TRIAZIN-5-YL)PHENYL)-1,2,3,4-TETRAHYDRO-1-(1-METHYLETHYL)-2,4-DIOXO-3-(2-PYRIDINYL)- | INCB 081776 | INCB 81776 | INCB-081776 | INCB-81776 | INCB081776 | INCB81776",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554381","CTAG2 Gene Product","C153123","A protein encoded by the CTAG2 gene.","CTAG2 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554382","Study Research Coordinator","C153124","A person who handles the administrative responsibilities of a study on behalf of the study investigator, acts as a liaison between study site and study sponsor, and reviews all data and records before a monitor's visit.","Study Research Coordinator | StudyResearchCoordinator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554383","Cancer/Testis Antigen 2 Isoform LAGE-1A","C153125","Cancer/testis antigen 2 (180 aa, ~18 kDa) is encoded by the human CTAG2 gene. This protein may play a role in tumorigenesis of several tissues.","Cancer/Testis Antigen 2 Isoform LAGE-1A | CT6.2a | Cancer/Testis Antigen 6.2a | Isoform LAGE-1A | L Antigen Family Member 1 Isoform A | LAGE-1A | LAGE-1S | LAGE-1a Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555135","Luxembourgish Language","C154006","A West Germanic language that is the national language of Luxembourg.","Luxembourgish Language | LTZ | Letzeburgesch | Luxembourgish | Luxemburgish",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554532","CBP/beta-catenin Modulator E7386","C153376","An orally bioavailable, specific inhibitor of the canonical Wnt/beta-catenin signaling pathway, with potential antineoplastic activity. Upon oral administration, CBP/beta-catenin modulator E7386 inhibits beta-catenin and prevents the interaction of beta-catenin with its transcriptional coactivator, CREB (cAMP response element-binding) binding protein (CBP). This prevents binding of beta-catenin/CBP to WRE (Wnt-responsive element), and inhibits the activation of transcription of a wide range of target genes of Wnt/beta-catenin signaling, thereby preventing gene expression of many Wnt-related, pro-survival proteins and suppressing tumor cell growth. The Wnt/beta-catenin signaling pathway regulates cell morphology, motility, and proliferation; aberrant regulation of this pathway leads to neoplastic proliferation. Beta-catenin is frequently mutated in various tumors.","CBP/beta-catenin Modulator E7386 | E 7386 | E-7386 | E7386",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554533","CDK9 Inhibitor AZD4573","C153377","A selective, short-acting inhibitor of the serine/threonine cyclin-dependent kinase 9 (CDK9), the catalytic subunit of the RNA polymerase II (RNA Pol II) elongation factor positive transcription elongation factor b (PTEF-b; PTEFb), with potential antineoplastic activity. Upon intravenous administration, zemirciclib binds to and blocks the phosphorylation and kinase activity of CDK9, thereby preventing PTEFb-mediated activation of RNA Pol II, leading to the inhibition of gene transcription of various anti-apoptotic proteins. This induces cell cycle arrest and apoptosis, and leads to a reduction in tumor cell proliferation. CDK9 regulates elongation of transcription through phosphorylation of RNA polymerase II at serine 2 (p-Ser2-RNAPII). It is upregulated in various tumor cell types and plays a key role in the regulation of Pol II-mediated transcription of anti-apoptotic proteins. Tumor cells are dependent on anti-apoptotic proteins for their survival.","Zemirciclib | AZD 4573 | AZD-4573 | AZD4573 | CDK9 Inhibitor AZD4573 | CDK9 Inhibitor AZD4573 | ZEMIRCICLIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3858051","Ledipasvir/Sofosbuvir","C153378","A tablet containing a fixed dose combination of ledipasvir, an inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex, and the prodrug sofosbuvir, an inhibitor of HCV NS5B polymerase, with activity against HCV. Upon oral administration of ledipasvir/sofosbuvir and intracellular uptake, ledipasvir binds to and blocks the activity of the NS5A protein. This results in the disruption of the viral RNA replication complex, blockage of HCV RNA production, and inhibition of viral replication. Sofosbuvir is converted to its active triphosphate form, and competes with uridine triphosphate for incorporation into RNA, thereby inhibiting NS5B polymerase and preventing viral replication. This may eradicate HCV and prevent HCV-mediated tumorigenesis. NS5A, a zinc-binding and proline-rich hydrophilic phosphoprotein, plays a crucial role in HCV RNA replication. The HCV NS5B protein, an RNA-dependent RNA polymerase, is essential for the replication of the viral HCV RNA genome. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family; HCV infection is associated with the development of certain tumors.","Ledipasvir/Sofosbuvir | Harvoni | Ledipasvir Mixture with Sofosbuvir | Ledipasvir and Sofosbuvir | Ledipasvir-Sofosbuvir | Ledipasvir/Sofosbuvir Tablet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554535","AK 104","C153379","A bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, cadonilimab targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T lymphocytes (TILs), and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a sustained cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD1 and CTLA4 with cadonilimab may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.","Cadonilimab | AK 104 | AK-104 | AK104 | Anti-PD-1 x CTLA-4 Bispecific Antibody AK104 | Anti-PD-1/CTLA-4 Bispecific Antibody AK104 | Anti-PD1/Anti-CTLA4 Bispecific Antibody AK104 | CADONILIMAB | PD-1 x CTLA-4 Dual Checkpoint Inhibitor AK104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555051","Recurrent Clear Cell Renal Cell Carcinoma","C153590","The reemergence of clear cell renal cell carcinoma after a period of remission.","Recurrent Clear Cell Renal Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574180","Buriat Language","C153867","A variety of Mongolic spoken by the Buryats people of Russia and Mongolia.","Buriat Language | BUA | Buriat | Buryat",,,,,,,,,,,,,,,"4175736","Buryat language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574367","Buginese Language","C153868","A Malayo-Polynesian language spoken by the Austronesian people of the island nations of Southeast Asia and the Pacific Ocean.","Buginese Language | BUG | Buginese",,,,,,,,,,,,,,,"4183664","Buginese language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0006369","Bulgarian Language","C153869","An Indo-European language, a member of the Southern branch of the Slavic language family.","Bulgarian Language | BUL | Bulgarian",,,,,,,,,,,,,,,"4182512","Bulgarian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555094","Bilen Language","C153870","An Afro-Asiatic language spoken by the Bilen people in Eritrea and eastern Sudan.","Bilen Language | BYN | Bilen | Bilin | Blin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574547","Caddo Language","C153871","A Native American language which is the traditional language of the Caddo Nation in Oklahoma.","Caddo Language | CAD | Caddo",,,,,,,,,,,,,,,"4177434","Caddo language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574244","Carib Language","C153872","A Cariban language spoken by the Kalina people of South America.","Carib Language | CAR | Galibi Carib | Kari'nja",,,,,,,,,,,,,,,"4181392","Carib language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0007366","Catalan Language","C153873","A Western Romance language native to parts of Andorra, France, Italy, and Spain.","Catalan Language | CAT | Catalan | Valencian | Valencian Language",,,,,,,,,,,,,,,"4181535","Catalan language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574369","Chamorro Language","C153876","An Austronesian language spoken by the Chamorro people of Guam and the Northern Mariana Islands.","Chamorro Language | CHA | Chamorran | Chamorran Language | Chamorro",,,,,,,,,,,,,,,"4180212","Chamorro language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574225","Chechen Language","C153877","A Northeast Caucasian language spoken mostly in the Chechen Republic.","Chechen Language | CHE | Chechen",,,,,,,,,,,,,,,"4178687","Chechen language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554631","Chuukese Language","C153878","A Trukic language of the Austronesian language family spoken primarily on the islands of Chuuk in the Caroline Islands in Micronesia.","Chuukese Language | CHK | Chuukese | Trukese",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574692","Mari Language","C153879","A language in the Uralic language family spoken primarily in the Mari Republic of the Russian Federation.","Mari Language | CHM | Mari",,,,,,,,,,,,,,,"4181732","Mari language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1551945","Chinook Jargon language","C153880","An American indigenous language originating as a pidgin trade language in the Pacific Northwest.","Chinook Jargon Language | CHN | Chinook Jargon | Chinook Wawa | Chinuk Wawa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574569","Choctaw Language","C153881","A Native American language, traditionally spoken by the Native American Choctaw people of the southeastern United States.","Choctaw Language | CHO | Choctaw",,,,,,,,,,,,,,,"4183808","Choctaw language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574551","Cherokee Language","C153883","An Iroquoian language spoken by the Cherokee people.","Cherokee Language | CHR | Cherokee",,,,,,,,,,,,,,,"4180373","Cherokee language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554473","FGFR Gene Rearrangement","C153240","A molecular abnormality indicating rearrangement of an FGFR family gene.","FGFR Gene Rearrangement | FGF Receptor Gene Family Rearrangement | FGF Receptor Gene Rearrangement | FGFR Family Gene Rearrangement | FGFR Family Rearrangement | Fibroblast Growth Factor Receptor Family Gene Rearrangement | Fibroblast Growth Factor Receptor Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518511","Nutrition, Water","C15349","Role of water in cancer causation or prevention and in general health.","Nutrition, Water | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554876","TNFRSF9 Gene Product","C153500","A protein encoded by the TNFRSF9 gene.","TNFRSF9 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL592045","Bezlotoxumab","C153084","A human monoclonal antibody directed against Clostridium difficile Toxin B (TcdB), with anti-toxin activity. Upon intravenous infusion, the two Fab regions of bezlotoxumab bind to two distinct epitopes within the N-terminal half of the TcdB combined repetitive oligopeptide (CROP) domain, blocking the carbohydrate binding pockets of the toxin and preventing binding of the toxin to target host cells. TcdB is one of two exotoxins responsible for the symptoms of Clostridium difficile infections.","Bezlotoxumab | BEZLOTOXUMAB | MK 6072 | MK-6072 | MK6072 | Zinplava",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554231","Resectable Soft Tissue Sarcoma","C153086","Soft tissue sarcoma that is amenable to surgical resection.","Resectable Soft Tissue Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554348","MUC20 wt Allele","C153088","Human MUC20 wild-type allele is located in the vicinity of 3q29 and is approximately 20 kb in length. This allele, which encodes mucin-20 protein, plays a role in modulation of the hepatocyte growth factor (HGF)/HGF receptor (c-Met) signaling pathway.","MUC20 wt Allele | FLJ14408 | KIAA1359 | MUC-20 | Mucin 20, Cell Surface Associated wt Allele | Mucin 20, Cell Surface-Associated Gene | UNQ2782/PRO7170",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555136","Luba-Kasai Language","C154007","A Niger-Congo Bantu language that is spoken in Central Africa and is an official language of the Democratic Republic of the Congo.","Luba-Kasai Language | LUA | Luba-Kasai | Luba-Lulua | Western Luba",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555137","Luba-Katanga Language","C154008","A Niger-Congo Bantu language spoken by the Luba people in the Democratic Republic of the Congo.","Luba-Katanga Language | Kiluba | LUB | Luba-Katanga | Luba-Shaba",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574440","Ganda Language","C154009","A Niger-Congo Bantu language spoken mainly by the Baganda people in central Uganda.","Ganda Language | Ganda | LUG",,,,,,,,,,,,,,,"4180232","Ganda language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0194818","Perineal Prostatectomy","C15400","No value exists.","Perineal Prostatectomy | perineal prostatectomy",,,,,,,,,,,,,,,"4211496","Perineal prostatectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1551980","Luiseno Language","C154010","A Uto-Aztecan language spoken by the Luiseno Native American people of California.","Luiseno Language | LUI | Luiseno",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574453","Lunda Language","C154011","A Niger-Congo Bantu language spoken in Zambia and the Democratic Republic of the Congo.","Lunda Language | Chilunda | LUN | Lunda",,,,,,,,,,,,,,,"4180350","Lunda language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574279","Luo Language","C154012","A Nilotic language spoken by the Luo people of Kenya and Tanzania.","Luo Language | LUO | Luo | Luo (Kenya and Tanzania)",,,,,,,,,,,,,,,"4175760","Luo language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556408","Lushai Language","C154013","A Sino-Tibetan language spoken by the Mizo people in the Mizoram state of India and Chin State in Burma.","Lushai Language | LUS | Lushai | Mizo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574374","Madurese Language","C154014","An Austronesian language spoken by the Madurese people of Madura Island, eastern Java, and surrounding islands of Indonesia.","Madurese Language | MAD | Madurese",,,,,,,,,,,,,,,"4180214","Madurese language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556887","Magahi Language","C154015","An Indo-European language spoken in the Bihar, Jharkhand, and West Bengal states of eastern India.","Magahi Language | MAG | Magadhi | Magahi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574386","Marshallese Language","C154016","A Micronesian language spoken in the Marshall Islands.","Marshallese Language | Ebon | MAH | Marshallese",,,,,,,,,,,,,,,"4175916","Marshallese language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556375","Maithili Language","C154017","An Indo-Aryan language spoken in the Bihar and Jharkhand states of India.","Maithili Language | MAI | Maithili",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0024551","Malayalam Language","C154019","A Dravidian language spoken across the Indian state of Kerala by the Malayali people.","Malayalam Language | MAL | Malayalam",,,,,,,,,,,,,,,"4180058","Malayalam language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0194823","Retropubic Prostatectomy","C15401","The surgical removal of all or part of the prostate gland through a lower abdominal (retropubic) incision.","Retropubic Prostatectomy | retropubic prostatectomy",,,,,,,,,,,,,,,"4194172","Retropubic prostatectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556370","Mandinka Language","C154020","A Niger-Congo Mande language spoken by the Mandinka people of the Casamance region of Senegal, the Gambia, and northern Guinea-Bissau.","Mandinka Language | MAN | MNK | Mandingo | Mandinka",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556371","Maasai Language","C154022","An Eastern Nilotic language spoken in Southern Kenya and Northern Tanzania by the Maasai people.","Maasai Language | MAS | Maa | Maasai | Masai",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555139","Moksha Language","C154023","A member of the Mordvinic branch of the Uralic languages spoken mainly in the western part of the Mordovia Republic of Russia.","Moksha Language | MDF | Moksha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556380","Mandar Language","C154024","An Austronesian language spoken by the Mandar people of the West Sulawesi province of Indonesia,","Mandar Language | Andian | MDR | Mandar | Mandharsche | Manjar",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574516","Mende Language","C154025","A Niger-Congo Mande language spoken mainly by the Mende people of Sierra Leone.","Mende Language | MEN | Mende",,,,,,,,,,,,,,,"4177307","Mende language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL936838","Recurrent Chromophobe Renal Cell Carcinoma","C153595","The reemergence of chromophobe renal cell carcinoma after a period of remission.","Recurrent Chromophobe Renal Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0252924","Bruceanol D","C1535","A quassinoid phytochemical isolated form the plant Brucea antidysenterica with potential antineoplastic activity. (NCI04)","Bruceanol D | Picras-3-en-21-oic Acid, 15-((3,4-dimethyl-1-oxo-2-pentenyl)oxy)-13,20-epoxy-1,11,12-trihydroxy-2,16-dioxo-, Methyl Ester, (1beta,11beta,12alpha,15beta(E))-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554349","MUC20 protein, human","C153089","Mucin-20 (709 aa, ~72 kDa) is encoded by the human MUC20 gene. This protein is involved in suppression of hepatocyte growth factor (HGF)/HGF receptor (c-Met) signaling.","Mucin-20 | MUC-20 | MUC20 | Mucin 20 | Transmembrane Mucin MUC20S",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554350","Guardant360","C153090","A proprietary epigenomic and genomic profiling system for the identification of disease and treatment response biomarkers in cell-free circulating tumor DNA (ctDNA) found in liquid biopsy (blood) samples. This system uses next-generation digital sequencing technology to assist in the diagnosis of multiple solid tumor types, facilitate the selection of diagnosis-specific targeted therapeutics based on markers for treatment sensitivity or resistance and identification of new markers of disease progression, minimal residual disease and recurrence.","Guardant360 Profiling System | Guardant360 | Guardant360 | Guardant360 Diagnostic Test | Guardant360 Genomic Profiling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554352","Sutimlimab","C153093","A humanized monoclonal immunoglobulin G4 (IgG4) antibody directed against human compliment factor C1s, with potential immunomodulatory activity. Upon intravenous administration, sutimlimab targets, binds to and blocks the activity of C1s, a portion of the C1 complex, preventing enzymatic action on its substrates, C4 and C2, and inhibiting the formation of C3 convertase. By selectively targeting the classical complement pathway (CP), the function of both the alternative and lectin pathways are preserved. C1s, a serine protease, is responsible for the propagation of the classical complement pathway of the immune system; dysregulation of the classical compliment cascade plays a key role in a variety of complement-mediated disorders.","Sutimlimab | BIVV 009 | BIVV-009 | BIVV009 | Enjaymo | IPN 009 | IPN-009 | IPN009 | Immunoglobulin G4, Anti-(Human Complement C1S) (Humanized Mouse Monoclonal TNT009 Gamma4-chain), Disulfide with Humanized Mouse Monoclonal TNT009 Kappa-chain, Dimer | SUTIMLIMAB | Sutimlimab-jome | TNT009 | WHO 10757",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554353","TetMYB DNA Vaccine","C153094","A therapeutic engineered DNA vaccine composed of DNA sequences encoding for one or more tetanus toxoid peptides and the oncoprotein MYB, with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, TetMYB is taken up and processed by dendritic cells (DCs), which present the processed antigen to the immune system. This activates cytotoxic T-lymphocytes (CTLs) and causes a CTL-mediated immune response against MYB-expressing tumor cells. MYB, an oncoprotein and transcription factor, is overexpressed in a variety of cancer types and is essential for tumor cell growth, inhibition of differentiation, and protection from apoptosis. Its expression is correlated with lower T-cell infiltration and poorer prognosis. As MYB is only weakly immunogenic, the tetanus toxoid peptides enhance the T-cell mediated immune responses against the MYB-expressing tumor cells.","TetMYB DNA Vaccine | DNA Vaccine TetMYB | DNA-based TetMYB Vaccine | TetMYB | TetMYB Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554354","Epitinib Succinate","C153095","The succinate salt form of epitinib, an orally available epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon administration, epitinib inhibits the activity of EGFR, thereby preventing EGFR-mediated signaling. This may lead to induction of cell death and inhibition of tumor growth in EGFR-overexpressing tumor cells. EGFR is a receptor tyrosine kinase (RTK) that is overexpressed in certain tumor types and plays a key role in tumor cell proliferation and vascularization.","Epitinib Succinate | EPITINIB SUCCINATE | HMPL 813 | HMPL-813 | HMPL813",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574443","Herero Language","C153946","A Niger-Congo Bantu language spoken by the Herero and Mbanderu peoples in Namibia and Botswana.","Herero Language | HER | Herero",,,,,,,,,,,,,,,"4183781","Herero language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555082","Hiligaynon Language","C153947","An Austronesian regional language spoken in the Philippines.","Hiligaynon Language | HIL | Hiligaynon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556369","Hiri Motu Language","C153949","A simplified version of Motu that is an official language of Papua New Guinea.","Hiri Motu Language | HMO | Hiri | Hiri Motu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574377","Minangkabau Language","C154027","An Austronesian language spoken by the Minangkabau people of the Indonesian province of West Sumatra, the western part of Riau Province, South Aceh Regency, and the northern part of Bengkulu and Jambi Provinces.","Minangkabau Language | MIN | Minangkabau",,,,,,,,,,,,,,,"4183667","Minangkabau language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554440","Castration-Sensitive","C153335","A finding indicating that a metastatic prostate carcinoma is sensitive to androgen-deprivation therapy.","Castration-Sensitive | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554442","Cytokine-treated Veto Cells","C153337","A preparation of activated veto cells, with potential immunostimulating and antineoplastic activities. White blood cells (WBCs), taken from either the patient or a healthy third-party donor, are processed and ex-vivo treated with an as of yet not disclosed mix of cytokines to activate specific cytotoxic veto cells. Upon administration, the veto cells specifically target and bind to tumor or foreign cells, thereby inducing apoptosis. Veto cells are able to selectively activate the immune system to only attack and kill tumor or foreign cells upon transplantation to prevent graft-versus-host disease (GvHD).","Cytokine-treated Veto Cells | Activated Veto Cells | Activated Veto T-cells | Veto CD8-positive T-cells | Veto Cell | Veto Cells | Veto-enhanced CTL | Veto-enhanced Cytotoxic T-cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554443","ClariCore Optical Biopsy System","C153338","A proprietary system for prostate cancer biopsy collection. The system uses an optical fiber 'needle', spectral analysis, and a proprietary algorithm to distinguish normal tissue from suspicious tissue. It then guides the collection of biopsy samples when suspicious tissue is identified.","ClariCore Optical Biopsy System | ClariCore",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038912","Urogenital Surgical Procedure","C15333","Any surgery to the reproductive or urinary system or its parts.","Urogenital Surgical Procedure | Genitourinary System Surgical Procedure | Surgery, Genitourinary | Urogenital Surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554444","Recurrent Cushing Disease","C153340","The reemergence of Cushing disease after a period of remission.","Recurrent Cushing Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554445","Transabdominal Resection","C153341","Surgery comprising either abdominoperineal resection, low anterior resection, or coloanal anastomosis with total mesorectal excision.","Transabdominal Resection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554449","Recurrent Ovarian Carcinosarcoma","C153347","The reemergence of ovarian carcinosarcoma after a period of remission.","Recurrent Ovarian Carcinosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554450","Metastatic Triple-Negative Breast Carcinoma","C153348","A triple-negative breast carcinoma that has spread from its original site of growth to another anatomic site.","Metastatic Triple-Negative Breast Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554304","Advanced Melanoma","C153169","Melanoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Melanoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282333","Relaxation Therapy","C15316","A therapeutic regimen in which the patient is guided by the therapist into alternate relaxation and flexing of muscles throughout the body as a method of pain control.  It is related to guided imagery and distraction and attention therapies.","Relaxation Therapy | ",,,,,,,,,,,,,,,"4275895","Relaxation training therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554305","Advanced Renal Cell Carcinoma","C153170","Renal cell carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Renal Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554308","EGFR Mutant-specific Inhibitor ZN-e4","C153173","An orally available selective inhibitor of certain epidermal growth factor receptor (EGFR) activating mutations, including the resistance mutation T790M, with potential antineoplastic activity. Upon administration, the EGFR mutant-specific inhibitor ZN-e4 specifically binds to and inhibits selective EGFR mutations, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Compared to other EGFR inhibitors, ZN-e4 may offer therapeutic benefits in tumors with T790M-mediated drug resistance and may limit toxicities associated with non-selective EGFR inhibitors. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","EGFR Mutant-specific Inhibitor ZN-e4 | KP-673 | ZN e4 | ZN-e4 | ZNe4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2931213","USH2B, FORMERLY","C153174","An autosomal recessive sub-type of Usher syndrome caused by homozygous or compound heterozygous mutation(s) in the ADGRV1 gene, encoding adhesion G protein-coupled receptor V1. It may also result from biallelic digenic mutation(s) in ADGRV1 and PDZD7, which encodes PDZ domain-containing protein 7.","Usher Syndrome Type 2C | USH2C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0041626","UV Light Therapy","C15344","A form of treatment, mainly used for skin disorders, in which the skin is irradiated with ultraviolet light.","UV Light Therapy | Light Therapy, UV | Therapy, UV Light | UV Phototherapy | Ultraviolet Radiation Therapy | ultraviolet radiation therapy",,,,,,,,,,,,,,,"4180942|4273547","Ultraviolet light therapy|General actinotherapy",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0041963","Ureterostomy","C15345","A surgically created connection between the ureter and the skin, which drains urine from the ureter in individuals with urinary obstruction or other issues that prevent normal urination.","Ureterostomy | ",,,,,,,,,,,,,,,"4264011","Ureterostomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555083","Upper Sorbian Language","C153951","An Indo-European language spoken by Sorbs in the province of Upper Lusatia in Germany.","Upper Sorbian Language | HSB | Upper Sorbian",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551913","Hoopa language","C153952","An Athabaskan language spoken along the lower course of the Trinity River in Northwestern California by the Hupa people.","Hupa Language | HUP | Hupa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2585053","Iban Language","C153954","An Austronesian language spoken by the Iban people of the Malaysian state of Sarawak, the Indonesian province of West Kalimantan, and in Brunei.","Iban Language | IBA | Iban",,,,,,,,,,,,,,,"4234319","Iban language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556902","Nuosu Language","C153956","A Sino-Tibetan language of the Yi people of Southern Sichuan and northern Yunnan provinces of China.","Nuosu Language | III | Liangshan Yi | Northern Yi | Nosu | Nuosu | Sichuan Yi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555084","Inuvialuktun Language","C153957","An Eskimo-Aleut language spoken in the northern Northwest Territories and Nunavut Territory of Canada.","Inuvialuktun Language | IKU | Inuktitut | Inuvialuktun | Western Canadian Inuit | Western Canadian Inuktitut | Western Canadian Inuktun",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555085","Ilocano Language","C153958","An Austronesian language spoken in the Phillipines in northwest Luzon, the Babuyan Islands, Cordillera Administrative Region, Cagayan Valley, parts of Central Luzon, and scattered areas in Mindanao.","Ilocano Language | ILO | Ilocano | Ilokano | Iloko",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574226","Ingush Language","C153960","A Northeast Caucasian language spoken by the Ingush people in the the Russian republics of Ingushetia and Chechnya.","Ingush Language | INH | Ingush",,,,,,,,,,,,,,,"4182480","Ingush language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555086","Judeo-Persian Language","C153963","A group of Jewish dialects spoken by the Jews living in Iran.","Judeo-Persian Language | JPR | Jidi | Judeo-Persian",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555087","Judeo-Arabic Language","C153964","A continuum of specifically Jewish varieties of Arabic formerly spoken by Arab Jews.","Judeo-Arabic Language | JRB | Judeo-Arabic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574199","Kara-Kalpak Language","C153965","A Turkic language spoken by the Karakalpak people in the Karakalpakstan republic of Uzbekistan.","Kara-Kalpak Language | KAA | Kara-Kalpak",,,,,,,,,,,,,,,"4178570","Kara-Kalpak language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574147","Kabyle Language","C153966","An Afro-Asiatic Berber language spoken by the Kabyle people in the north and northeast of Algeria.","Kabyle Language | KAB | Kabyle",,,,,,,,,,,,,,,"4180042","Kabyle language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554407","Rubinstein-Taybi Syndrome Type 1","C153290","The most common form of Rubinstein-Taybi syndrome, caused by a mutation in the CREB binding protein (CREBBP) gene.","Rubinstein-Taybi Syndrome Type 1 | RSTS1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554451","Autologous Hematopoietic Stem Cell Transplantation Recipient","C153350","A person receiving an autologous hematopoietic stem cell transplant.","Autologous Hematopoietic Stem Cell Transplant Recipient | Autologous Hematopoietic Stem Cell Transplantation Recipient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554309","Recurrent Mediastinal Lymphoma","C153175","The reemergence of a mediastinal lymphoma after a period of remission.","Recurrent Mediastinal Lymphoma | Recurrent Primary Mediastinal Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554311","Refractory Mediastinal Lymphoma","C153177","Mediastinal lymphoma that is resistant to treatment.","Refractory Mediastinal Lymphoma | Refractory Primary Mediastinal Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555122","C3 Gene Product","C154098","A protein encoded by the C3 gene.","C3 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556514","Complement C3d","C154099","Complement C3d (302 aa, ~34 kDa) is encoded by the human C3 gene. This protein is involved in the promotion of B-cell and complement activation.","Complement C3d | C3d | COMPLEMENT C3D | Complement C3d Fragment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0253468","Tyrphostin A46","C1540","A protein tyrosine kinase inhibitor that selectively inhibits EGFR kinase, involved in signaling pathways. (NCI)","Tyrphostin A46 | AG 99 | TYRPHOSTIN A46",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555126","Squamous Dysplasia","C154100","A morphologic finding indicating the presence of dysplasia in the squamous epithelium of a tissue sample.","Squamous Dysplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574467","Kirundi Language","C154101","A Niger-Congo Bantu language spoken in Burundi, adjacent parts of Tanzania, and the Democratic Republic of the Congo.","Kirundi Language | Kirundi | RUN | Rundi",,,,,,,,,,,,,,,"4181697","Rundi language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555125","Aromanian Language","C154102","An Eastern Romance language spoken in Southeastern Europe.","Aromanian Language | Aromanian | Arumanian | Macedo-Romanian | RUP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574359","Sandawe Language","C154103","A click language spoken by the Sandawe people in the Dodoma region of Tanzania.","Sandawe Language | SAD | Sandawe",,,,,,,,,,,,,,,"4181549","Sandawe language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574427","Sango Language","C154104","A creole language spoken as an official language of the Central African Republic.","Sango Language | SAG | Sango",,,,,,,,,,,,,,,"4180228","Sango language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574211","Yakut Language","C154105","A Turkic language spoken by the Yakut people in the Sakha Republic in the Russian Federation.","Yakut Language | SAH",,,,,,,,,,,,,,,"4178685","Yakut language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554192","FBXO31 Gene","C153044","This gene plays a role in protein ubiquitination and cell cycle arrest.","FBXO31 Gene | F-Box Protein 31 Gene | FBXO31",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554193","FBXO31 wt Allele","C153045","Human FBXO31 wild-type allele is located in the vicinity of 16q24.2 and is approximately 65 kb in length. This allele, which encodes F-box only protein 31, is involved in G1 arrest and protein ubiquitination. Mutation of the gene is associated with autosomal recessive mental retardation type 45.","FBXO31 wt Allele | F-Box Protein 31 wt Allele | FBX14 | FBXO14 | Fbx31 | MGC15419 | MRT45 | Putative Breast Cancer Tumor-Suppressor Gene | pp2386",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1702147","FBXO31 protein, human","C153046","F-box only protein 31 (539 aa, ~61 kDa) is encoded by the human FBXO31 gene. This protein plays a role in ubiquitination of phosphorylated cyclin-D1.","F-Box Only Protein 31 | F-Box Protein 31 | FBXO31 | SCF Ubiquitin Ligase Specificity Factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554195","FGF18 Gene","C153047","This gene is involved in bone development and cell proliferation in the liver and small intestine.","FGF18 Gene | FGF18 | Fibroblast Growth Factor 18 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554196","FGF18 wt Allele","C153048","Human FGF18 wild-type allele is located in the vicinity of 5q35.1 and is approximately 38 kb in length. This allele, which encodes fibroblast growth factor 18 protein, plays a role in promoting cell proliferation in the small intestine and liver.","FGF18 wt Allele | FGF-18 | Fibroblast Growth Factor 18 wt Allele | UNQ420/PRO856 | ZFGF5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1432638","FGF18 protein, human","C153049","Fibroblast growth factor 18 (207 aa, ~24 kDa) is encoded by the human FGF18 gene. This protein is involved in ossification and the positive regulation of cell proliferation.","Fibroblast Growth Factor 18 | FGF-18 | FGF18 | Fibroblast Growth Factor-18 | zFGF5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554198","ADGRG6 Gene","C153050","This gene plays a role in development of the heart and nervous system and in stature.","ADGRG6 Gene | ADGRG6 | Adhesion G Protein-Coupled Receptor G6 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554199","ADGRG6 wt Allele","C153051","Human ADGRG6 wild-type allele is located in the vicinity of 6q24.2 and is approximately 144 kb in length. This allele, which encodes adhesion G-protein coupled receptor G6 protein, is involved in axon myelination, heart development and stature. Mutation of the gene is associated with lethal congenital contracture syndrome type 9.","ADGRG6 wt Allele | APG1 | DREG | FLJ14937 | GPR126 | LCCS9 | PR126 | PS1TP2 | VIGR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554408","Rubinstein-Taybi Syndrome Type 2","C153291","Rubinstein-Taybi syndrome caused by a mutation in the EP300 gene on chromosome 22q13, which presents with a mild phenotype associated with less severe facial dysmorphism and better cognitive function.","Rubinstein-Taybi Syndrome Type 2 | RSTS2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554409","Caris Molecular Intelligence Tumor Profiling","C153292","A proprietary genomic profiling system that assesses DNA, RNA and proteins to establish a molecular profile for use, along with any relevant pathology data, in guiding individualized treatment decisions.","Caris Molecular Intelligence Tumor Profiling | Caris Molecular Intelligence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554410","Recurrent Aplastic Anemia","C153293","The reemergence of aplastic anemia after a period of remission.","Recurrent Aplastic Anemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554411","Recurrent Severe Aplastic Anemia","C153294","The reemergence of severe aplastic anemia after a period of remission.","Recurrent Severe Aplastic Anemia | Relapsed Severe Aplastic Anemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554412","Refractory Severe Aplastic Anemia","C153295","Severe aplastic anemia that is resistant to treatment.","Refractory Severe Aplastic Anemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554413","Recurrent Hemophagocytic Lymphohistiocytosis","C153296","The reemergence of hemophagocytic lymphohistiocytosis after a period of remission.","Recurrent Hemophagocytic Lymphohistiocytosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554414","Refractory Hemophagocytic Lymphohistiocytosis","C153297","Hemophagocytic lymphohistiocytosis that is resistant to treatment.","Refractory Hemophagocytic Lymphohistiocytosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0250977","Gutolactone","C1532","A quassinoid phytochemical isolated from the plant Simaba guianensis with potential antineoplastic and antimalarial activities. (NCI04)","Gutolactone | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556892","Promoting Resilience in Stress Management","C153554","A resilience-building intervention program for adolescents and young adults with serious illness. It focuses of 4 disease-non-specific skills: stress management, goal-setting and problem-solving, positive re-appraisals of stressors, and meaning-making or benefit-finding.","Promoting Resilience in Stress Management | PRISM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554385","Last Follow-up Source Type Code","C153127","A coded value specifying the kind of medical record that provided the latest vital status information about this person.","Last Follow-up Source Type Code | LastFollowUpSourceTypeCode | lastFollowUpSourceTypeCode",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554386","REGN 4018","C153129","A bispecific, human monoclonal antibody with potential antineoplastic activity. REGN4018 contains two antigen-recognition sites: one for human CD3, a T cell surface antigen that is part of the T cell receptor complex, and one for human mucin 16 (MUC16, cancer antigen 125; CA125; FLJ14303), a member of the mucin family of glycoproteins that is overexpressed by several epithelial cancers, including ovarian cancer. Upon administration, ubamatamab binds to both T-cells and MUC16-expressing tumor cells, which cross-links the T-cells to the tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against the MUC16-expressing tumor cells.","Ubamatamab | Anti-MUC16 x Anti-CD3 REGN4018 | Anti-MUC16/CD3 Bispecific Antibody REGN4018 | REGN 4018 | REGN-4018 | REGN4018 | UBAMATAMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556866","Sasak Language","C154107","An Austronesian language spoken by the Sasak people on the island of Lombok, Indonesia.","Sasak Language | SAS | Sasak",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574418","Santali Language","C154108","An Austroasiatic language spoken mainly in the Indian states of Jharkhand, West Bengal, and Chhattisgarh.","Santali Language | SAT | Santali",,,,,,,,,,,,,,,"4183774","Santali language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555128","Sicilian Language","C154109","A Romance language spoken on the island of Sicily and its satellite islands.","Sicilian Language | SCN | Sicilian",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555129","Scots Language","C154110","A Germanic language variety spoken in Lowland Scotland and parts of Ulster, Ireland","Scots Language | SCO | Scots",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574702","Selkup Language","C154111","A Uralic language spoken by the Selkup people of Russia.","Selkup Language | SEL | Selkup",,,,,,,,,,,,,,,"4183946","Selkup language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554536","Milled Seed Mix","C153380","A nutritional supplement composed of a milled seed mixture, including milled flax, sesame and pumpkin seeds, in sour milk, with potential anti-inflammatory and lipid regulating activities. The seeds contain high levels of fatty acids, including omega-3 and omega-6 polyunsaturated fatty acids (PUFAs), such as dihomo-gamma-linolenic acid (DGLA), alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA). Upon administration of the milled seed mix, the intake of PUFAs improves PUFA levels and may favorably change the n-6/n-3 PUFA ratio, decrease triglyceride (TG) levels, and improve body weight. In addition, the active ingredients in the milled seed mix may change the expression of inflammatory markers, such as C-reactive protein (CRP) and pro-inflammatory cytokines, including interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-a), thereby decreasing inflammation. The milled seed mix may also prevent oxidative stress and affect glycemic control. Tumors cause inflammatory states and unfavorably affect lipid and fatty acid metabolism.","Milled Seed Mix | Milled Flax/Sesame/Pumpkin Seed Mix | Milled Mix of Flax/Sesame/Pumpkin Seeds in Sour Milk | Milled Sesame/Pumpkin/Flax Seed Mixture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554833","Metastatic Cervical Carcinoma","C153387","A carcinoma of the cervix that has spread to another anatomic site.","Metastatic Cervical Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554830","Metastatic Cervical Squamous Cell Carcinoma","C153388","Cervical squamous cell carcinoma that has spread to another anatomic site.","Metastatic Cervical Squamous Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554200","Adhesion G-Protein Coupled Receptor G6","C153052","Adhesion G-protein coupled receptor G6 (1221 aa, ~137 kDa) is encoded by the human ADGRG6 gene. This protein plays a role in heart development, stature and myelin sheath formation.","Adhesion G-Protein Coupled Receptor G6 | ADGRG6 | Adhesion G Protein-Coupled Receptor G6 | Developmentally Regulated G-Protein-Coupled Receptor | G Protein-Coupled Receptor 126 | G-Protein Coupled Receptor 126 | HBV PreS1-Transactivated Protein | Vascular Inducible G Protein-Coupled Receptor | Vascular-Inducible G Protein-Coupled Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554201","GPR180 Gene","C153053","This gene may be involved in signaling and vascular remodeling.","GPR180 Gene | G Protein-Coupled Receptor 180 Gene | GPR180",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554202","GPR180 wt Allele","C153054","Human GPR180 wild-type allele is located in the vicinity of 13q32.1 and is approximately 33 kb in length. This allele, which encodes integral membrane protein GPR180, may play a role in vascular remodeling and receptor signaling.","GPR180 wt Allele | G Protein-Coupled Receptor 180 wt Allele | ITR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574191","Chuvash Language","C153884","A Turkic language spoken in European Russia, primarily in the Chuvash Republic and adjacent areas.","Chuvash Language | CHV | Chuvash",,,,,,,,,,,,,,,"4175738","Chuvash language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555096","Allogeneic CD34-positive E-rosetted T-cell Depleted Peripheral Blood Stem Cells","C153885","A preparation of CD34+ selected peripheral blood stem cells (PBSCs) that are depleted of T-cells via erythrocyte rosetting (E-rosetting) and intended for allogeneic stem cell transplant. Administration of this particular preparation of CD34+E- T-cell depleted PBSCs may potentially reduce the occurrence of graft-versus-host disease (GvHD) without increasing the risk of graft failure or poor graft function","Allogeneic CD34-positive E-rosetted T-cell Depleted Peripheral Blood Stem Cells | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574532","Cheyenne Language","C153886","A Native American language of the Algonquian language family spoken by the Cheyenne people.","Cheyenne Language | CHY | Cheyenne",,,,,,,,,,,,,,,"4177314","Cheyenne language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0682388","Cornish Language","C153887","A Southwestern Brittonic Celtic language that is native to Cornwall in south-west England.","Cornish Language | COR | Cornish",,,,,,,,,,,,,,,"40483377","Cornish language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2584754","Corsican Language","C153888","A Romance language within the Italo-Dalmatian subfamily spoken mainly in Corsica and northern Sardinia.","Corsican Language | COS | Corsican",,,,,,,,,,,,,,,"4232095","Corsican language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574533","Cree Language","C153889","A dialect continuum of Algonquian languages native to areas of Canada and the United States.","Cree Language | CRE | Cree",,,,,,,,,,,,,,,"4180367","Cree language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555097","Crimean Tatar Language","C153890","A Kipchak Turkic language spoken mainly in Crimea, as well as small communities in the United States and Canada.","Crimean Tatar Language | CRH | Crimean | Crimean Tatar | Crimean Turkish",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556373","Kashubian Language","C153891","A West Slavic language belonging to the Lechitic subgroup that is native to Poland.","Kashubian Language | CSB | Cassubian | Kashubian",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574595","Dakota Language","C153893","A Siouan language spoken by the Dakota people of the Sioux tribes.","Dakota Language | DAK | Dakhota | Dakota",,,,,,,,,,,,,,,"4180383","Sioux language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555098","Dargwa Language","C153895","A Northeast Caucasian language spoken by the Dargin people in the Russian republic of Dagestan.","Dargwa Language | DAR | Dargin | Dargwa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574534","Delaware Language","C153896","An Eastern Algonquian language spoken by the native Lenape people of the New York City area.","Delaware Language | DEL | Delaware | Lenape",,,,,,,,,,,,,,,"4180368","Delaware language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556405","Athabascan Language","C153897","A large family of indigenous languages of western North America.","Athabascan Language | ATH | Athabaskan | Dene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554387","Anti-NY-ESO1/LAGE-1A TCR/scFv Anti-CD3 IMCnyeso","C153130","A bispecific molecule composed of a soluble, affinity-enhanced T-cell receptor (TCR) specific for human leukocyte antigen A2 (HLA-A2)-restricted cancer-testis antigens (CTAs) NY-ESO-1 and L antigen family member 1 isoform A (LAGE-1A; LAGE-A1; CT6.2a), fused to a single-chain variable fragment (scFv) specific for the T-cell surface antigen CD3, with potential immunomodulating and antineoplastic activities. Upon infusion, anti-NY-ESO1/LAGE-1A TCR/scFv anti-CD3 IMCnyeso specifically targets and binds with its TCR moiety to NY-ESO-1 and/or LAGE-1A expressed on tumor cells and with its scFv moiety to CD3 expressed on T-cells. This crosslinks tumor cells and T-cells, re-directs and activates T-cells, and results in a cytotoxic T-lymphocyte (CTL)-mediated destruction of NY-ESO-1 and/or LAGE-1A-positive tumor cells. NY-ESO-1 and LAGE-1A, members of the cancer-testis antigen (CTA) family, are overexpressed on the surface of various tumor cell types; they share a specific HLA-A*0201 epitope, 157-165, which is expressed on certain tumor cell types while its expression is not found on normal, healthy cells.","Anti-NY-ESO1/LAGE-1A TCR/scFv Anti-CD3 IMCnyeso | Bispecific NY-ESO-1- and LAGE-1A-specific TCR/Anti-CD3 | HLA- A*0201-Restricted NY-ESO-1- and LAGE-1A-specific Soluble TCR/Anti-CD3 Bispecific Molecule | IMCNYESO | IMCnyeso",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554388","Performed Experiment Unit Allocation","C153131","The completed action that is the assignment of an experimental unit to a portion of the study, such as an arm or a portion of an arm (when secondary allocations may occur).","Performed Experiment Unit Allocation | PerformedExperimentUnitAllocation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554389","Occurrence Study Day Range","C153132","The relative timing for a medical condition expressed as the number of days offset from the study-defined reference activity (e.g., date of registration, start of treatment) for this particular experimental unit.","Occurrence Study Day Range | OccurrenceStudyDayRange | occurrenceStudyDayRange",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554390","Aerosol Gemcitabine","C153133","An aerosol inhalation formulation containing gemcitabine (GCB), a broad-spectrum antimetabolite and deoxycytidine analogue, with potential antineoplastic activity. Upon inhalation via a nebulizer, GCB is converted intracellularly by deoxycytidine kinase to its active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP). dFdCDP inhibits ribonucleotide reductase (RNR), thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA, resulting in DNA strand termination and the induction of apoptosis of lung tumor cells. GCB administration directly into the lungs via aerosol yields higher concentrations of GCB locally than can be achieved by systemic GCB administration, potentially reducing systemic toxicity.","Aerosol Gemcitabine | Aerosolized GCB | Aerosolized Gemcitabine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554391","Study Country","C153134","A country in which a study takes or took place.","Study Country | StudyCountry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554392","Study Subject Experience Document Version","C153135","A document capturing the actual end-to-end (or beginning to point-in-time) experience of a single study subject within the context of a particular study.","Study Subject Experience Document Version | StudySubjectExperienceDocumentVersion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574375","Malagasy Language","C154029","An Austronesian language that is the national language of Madagascar.","Malagasy Language | MLG | Malagasy",,,,,,,,,,,,,,,"4180215","Malagasy language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574178","Maltese Language","C154030","An Afro-Asiatic Semitic language that is the national language of Malta.","Maltese Language | MLT | Maltese",,,,,,,,,,,,,,,"4175735","Maltese language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574187","Manchu Language","C154031","A Tungusic language spoken in Manchuria, China.","Manchu Language | MNC | Manchu",,,,,,,,,,,,,,,"4178565","Manchu language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555140","Meitei Language","C154032","A Sino-Tibetan language that is the predominant language in the southeastern Himalayan state of Manipur, in northeastern India.","Meitei Language | MNI | Manipuri | Meetei | Meitei | Meithei",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555645","Mohawk Language","C154033","An Iroquoian language spoken by people of the Mohawk Nation of Canada and the United States.","Mohawk Language | MOH | Mohawk",,,,,,,,,,,,,,,"4183805","Mohawk language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554831","Metastatic Cervical Adenocarcinoma","C153389","A cervical adenocarcinoma that has spread to another anatomic site.","Metastatic Cervical Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554836","Metastatic Cervical Adenosquamous Carcinoma","C153390","A cervical adenosquamous carcinoma that has spread to another anatomic site.","Metastatic Cervical Adenosquamous Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555066","Recurrent Salivary Duct Carcinoma","C153611","The reemergence of salivary duct carcinoma after a period of remission.","Recurrent Salivary Duct Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555067","Recurrent Minor Salivary Gland Adenocarcinoma","C153612","The reemergence of minor salivary gland adenocarcinoma after a period of remission.","Recurrent Minor Salivary Gland Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555072","Recurrent Ovarian Adenocarcinoma","C153614","The reemergence of ovarian adenocarcinoma after a period of remission.","Recurrent Ovarian Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555069","Recurrent Ovarian Serous Adenocarcinoma","C153615","The reemergence of ovarian serous adenocarcinoma after a period of remission.","Recurrent Ovarian Serous Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555070","Recurrent Ovarian Mucinous Adenocarcinoma","C153616","The reemergence of ovarian mucinous adenocarcinoma after a period of remission.","Recurrent Ovarian Mucinous Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555075","Recurrent Ovarian Cystadenocarcinoma","C153617","The reemergence of ovarian cystadenocarcinoma after a period of remission.","Recurrent Ovarian Cystadenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555076","Recurrent Ovarian Clear Cell Adenocarcinoma","C153618","The reemergence of ovarian clear cell adenocarcinoma after a period of remission.","Recurrent Ovarian Clear Cell Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555074","Recurrent Pancreatic Cystadenocarcinoma","C153620","The reemergence of pancreatic cystadenocarcinoma after a period of remission.","Recurrent Pancreatic Cystadenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556368","Slavey Language","C153898","An Athabaskan language spoken among the Slavey and Sahtu people of Canada in the Northwest Territories","Slavey Language | DEN | Dene K'e | Slave",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555100","Dogrib Language","C153899","A Northern Athabaskan language spoken by the Dogrib people of the Canadian Northwest Territories.","Dogrib Language | DGR | Dogrib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515370","Recombinant Fas Ligand","C1538","A recombinant agent, which is chemically identical to or similar to the endogenous protein Fas ligand, a protein related to tumor necrosis factor (TNF) with potential antineoplastic activity.  Fas ligand binds to the Fas receptor, thereby activating caspases and inducing apoptosis. (NCI04)","Recombinant Fas Ligand | FAS-Ligand | Fas Ligand | Fas-L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574339","Maldivian Language","C153901","An Indo-Aryan language spoken in the South Asian island country of Maldives.","Maldivian Language | DIV | Dhivehi | Divehi | Maldivian",,,,,,,,,,,,,,,"4180202","Maldivian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555099","Dogri Language","C153902","An Indo-Aryan language spoken in India and Pakistan, chiefly in the Jammu region.","Dogri Language | DOI | Dogri",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554487","GEN 1029","C153259","An agonistic hexamer formation-enhanced mixture of two antibodies (HexaBody) that target two separate epitopes on death receptor type 5 (DR5; TNFRSF10B; tumor necrosis factor-related apoptosis-inducing ligand receptor 2; TRAILR2), with potential antineoplastic activity. Upon administration, tilogotamab specifically binds to and activates DR5. This results in the activation of caspase cascades and the induction of apoptosis in DR5-expressing tumor cells. DR5, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is involved in the promotion of caspase-dependent apoptosis. Compared to other DR5 antibody-based agonists, the antibodies in GEN1029 (DR5-01 and DR5-05) elicit increased receptor activation because they exhibit enhanced formation of antibody hexamers and receptor clusters at the cell surface due to E430G mutations in the Fc domains of both antibodies.","Tilogotamab | DR5 HexaBody Agonist GEN1029 | GEN 1029 | GEN1029 | HexaBody-DR5-01/DR5-05 | HexaBody-DR5/DR5 | Hx-DR5-01/05 | TILOGOTAMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0353697","Carbidopa/Levodopa","C153096","An orally available combination of carbidopa, an inhibitor of aromatic amino acid decarboxylation, and levodopa, an inert, metabolic precursor to dopamine, with dopaminergic and antiparkinsonian properties. Upon oral administration, levodopa crosses the blood-brain barrier (BBB) and is decarboxylated to dopamine via dopa decarboxylase in the brain, promoting increased activation of dopamine receptors. Carbidopa inhibits dopa decarboxylase in the periphery, thereby preventing decarboxylation of levodopa in extracerebral tissues and increasing the delivery of dopamine to the central nervous system (CNS). As carbidopa does not cross the BBB, it does not interfere with CNS levodopa metabolism.","Carbidopa/Levodopa | Carbidopa Levodopa | Carbidopa-Levodopa | Sinemet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554356","CD137L/Epstein-Barr Virus-Targeting Autologous Dendritic Cell Vaccine","C153097","A cell-based cancer vaccine composed of in vitro generated, highly potent, CD137 ligand (CD137L)-dendritic cells (CD137L-DCs), pulsed with Epstein-Bar Virus (EBV) antigen peptides, with potential antineoplastic and immunostimulatory activities. Upon administration, CD137L-DCs induce potent CD8+ T-cell responses against EBV+ target cells. DCs stimulated with CD137L enhance cytotoxic T-lymphocyte proliferation and activation to a greater extent compared to non-CD137L-stimulated DCs.","CD137L/Epstein-Barr Virus-Targeting Autologous Dendritic Cell Vaccine | CD137L-DC-EBV-VAX | CD137L/Epstein-Barr Virus-Targeting Autologous DC Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0034020","Public Health Administration","C15309","A health profession that focusses on community-wide disease prevention and health promotion. Public health administrators run the organizations that promote health and disseminate information about health.","Public Health Administration | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554360","HM2/MMAE Antibody-Drug Conjugate ALT-P7","C153102","An antibody-drug conjugate (ADC) composed of the trastuzumab biobetter HM2 conjugated, in a site-specific manner, to monomethyl auristatin E (MMAE), an auristatin derivative and potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration of ALT-P7, the antibody moiety targets and binds to human epidermal growth factor receptor 2 (HER2) on tumor cells. Upon antibody/antigen binding and internalization, the MMAE moiety is released, binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and apoptosis. HER2 is a receptor tyrosine kinase (RTK) that is overexpressed by many cancer cell types.","HM2/MMAE Antibody-Drug Conjugate ALT-P7 | ADC ALT-P7 | ALT-P7 | HER2ALT-P7 | HM2-MMAE | HM2/MMAE ADC ALT-P7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0026409","Mongolian Language","C154034","A Mongolic language that is the official language of Mongolia.","Mongolian Language | MON | Mongolian",,,,,,,,,,,,,,,"4182357","Mongolian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574490","Mossi Language","C154035","A Niger-Congo Gur language that is an official regional language of Burkina Faso.","Mossi Language | MOS | Mossi",,,,,,,,,,,,,,,"4177299","Mossi language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0376248","Maori Language","C154036","An Eastern Polynesian language spoken by the Maori people of New Zealand.","Maori Language | MRI | Maori",,,,,,,,,,,,,,,"4180223","Māori language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1551897","Muskogee language","C154038","A Muskogean language spoken by Muscogee (Creek) and Seminole people, primarily in the U.S. states of Oklahoma and Florida.","Muscogee Language | Creek | Creek Language | MUS | Muscogee",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555142","Mirandese Language","C154039","An Indo-European language spoken in the northeastern municipalities of Miranda do Douro, Mogadouro, and Vimioso in Portugal.","Mirandese Language | MWL | Mirandese",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555143","Marwari Language","C154040","An Indo-European language spoken in the Indian state of Rajasthan.","Marwari Language | MWR | Marwari",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006417","Burmese Language","C154041","A Sino-Tibetan language spoken in Myanmar where it is an official language and the language of the Bamar people.","Burmese Language | Burmese | MYA",,,,,,,,,,,,,,,"4181727","Burmese language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555141","Erzya Language","C154042","A Uralic language spoken in the northern, eastern, and north-western parts of the Republic of Mordovia and adjacent regions of Nizhny Novgorod, Chuvashia, Penza, Samara, Saratov, Orenburg, Ulyanovsk, Tatarstan, and Bashkortostan in Russia.","Erzya Language | Erzya | MYV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555144","Neapolitan Language","C154043","A Romance language of the Italo-Dalmatian group spoken across much of southern Italy.","Neapolitan Language | NAP | Neapolitan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574387","Nauru Language","C154044","An Austronesian language spoken in the country of Nauru.","Nauru Language | NAU | Nauru | Nauruan",,,,,,,,,,,,,,,"4181555","Nauruan language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574545","Navajo Language","C154045","A Southern Athabaskan language of the Na-Dene family spoken primarily in the Southwestern United States, especially in the Navajo Nation.","Navajo Language | NAV | Navaho | Navajo",,,,,,,,,,,,,,,"4182808","Navajo language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2919374","South Ndebele Language","C154046","A Niger-Congo Bantu language spoken by the Ndebele people of South Africa.","South Ndebele Language | NBL | South Ndebele",,,,,,,,,,,,,,,"40481151","South Ndebele language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2919911","Ndonga Language","C154048","A Niger-Congo Bantu language spoken in Namibia and parts of Angola.","Ndonga Language | NDO | Ndonga | Oshindonga",,,,,,,,,,,,,,,"40483759","Ndonga language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554452","Refractory Colon Carcinoma","C153351","Colon carcinoma that is resistant to treatment.","Refractory Colon Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554453","Refractory Liver Carcinoma","C153352","Liver carcinoma that is resistant to treatment.","Refractory Liver Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555079","Recurrent Thyroid Gland Papillary Carcinoma","C153621","The reemergence of thyroid gland papillary carcinoma after a period of remission.","Recurrent Thyroid Gland Papillary Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555080","Recurrent Thyroid Gland Follicular Carcinoma","C153622","The reemergence of thyroid gland follicular carcinoma after a period of remission.","Recurrent Thyroid Gland Follicular Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555077","Recurrent Thyroid Gland Medullary Carcinoma","C153623","The reemergence of thyroid gland medullary carcinoma after a period of remission.","Recurrent Thyroid Gland Medullary Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555078","Recurrent Thyroid Gland Anaplastic Carcinoma","C153624","The reemergence of thyroid gland anaplastic carcinoma after a period of remission.","Recurrent Thyroid Gland Anaplastic Carcinoma | Recurrent Thyroid Gland Undifferentiated (Anaplastic) Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554993","Solution for injection in multidose container","C153625","Medicinal product consisting of a solution for injection presented in a multidose container.","Solution for Injection in Multidose Container Dosage Form | Solution for Injection in Multidose Container | Solution for injection in multidose container",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554991","Suspension for injection in multidose container","C153627","Medicinal product consisting of a suspension for injection presented in a multidose container.","Suspension for Injection in Multidose Container Dosage Form | Suspension for Injection in Multidose Container | Suspension for injection in multidose container",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2751318","Nijmegen Breakage Syndrome-Like Disorder","C153178","A condition caused by mutation(s) in the RAD50 gene, encoding DNA repair protein RAD50. It is characterized by microcephaly and chromosomal instability.","Nijmegen Breakage Syndrome-Like Disorder | NBSLD | RAD50 Deficiency",,,,,,,,,,,,,,,"35624153","Nijmegen breakage syndrome-like disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C3281044","MRT34","C153179","An autosomal recessive condition caused by mutation(s) in the CRADD gene, encoding death domain-containing protein CRADD. It is characterized by mild to moderate intellectual disability and lissencephaly with anterior-predominant pachygyria.","Mental Retardation, Autosomal Recessive 34 | MRT34 | Mental Retardation, Autosomal Recessive 34, with Variant Lissencephaly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554312","MAT2A Inhibitor AG-270","C153180","An orally available small molecule inhibitor of methionine adenosyltransferase II alpha (MAT2A) with potential antineoplastic activity. Upon administration, AG-270 inhibits the activity of MAT2A, a metabolic enzyme responsible for the production of S-Adenosyl-L-methionine (SAM), a primary donor of methyl groups in cellular transmethylation reactions that regulate gene expression, cell growth, and differentiation. MAT2A activity is selectively essential in cancer cells deficient in methylthioadenosine phosphorylase (MTAP), a critical enzyme in the methionine salvage pathway, that is deleted in some human cancers. Inhibition of MAT2A may potentially inhibit tumor cell growth in MTAP-deleted cancers that rely heavily on SAM synthesis.","MAT2A Inhibitor AG-270 | 3-(CYCLOHEX-1-EN-1-YL)-6-(4-METHOXYPHENYL)-2-PHENYL-5-(PYRIDIN-2-YLAMINO)PYRAZOLO(1,5-A)PYRIMIDIN-7(4H)-ONE | AG 270 | AG-270 | AG270",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554313","Contrast-Enhanced Mammography","C153181","A mammography technique that incorporates the administration of an iodinated contrast agent to enhance lesions that are not visible on standard mammograms. CEM provides low-energy 2D mammographic images analogous to digital mammography and contrast-enhanced recombined images that allow assessment of neovascularity similar to that offered by MRI.","Contrast-Enhanced Mammography | CEM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554314","Locally Advanced Skin Squamous Cell Carcinoma","C153182","A squamous cell carcinoma of the skin that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Skin Squamous Cell Carcinoma | Locally Advanced Cutaneous Squamous Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554315","Advanced Synovial Sarcoma","C153184","A synovial sarcoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Synovial Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554316","Advanced Sarcoma","C153185","A sarcoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554489","Anti-Globo H Monoclonal Antibody OBI-888","C153261","A monoclonal antibody targeting the hexasaccharide glycosphingolipid antigen Globo H with potential immunostimulating, anti-angiogenic and antineoplastic activities. Upon infusion, anti-Globo H monoclonal antibody OBI-888 may induce tumor cell destruction via the activation of antibody dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC), and may reduce immunosuppression. Globo H is a tumor-associated antigen (TAA) expressed on the surface of various types of cancer cells.","Anti-Globo H Monoclonal Antibody OBI-888 | OBI 888 | OBI-888 | OBI888",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554490","ETC 1907206","C153262","A selective mitogen-activated protein kinase (MAPK)-interacting protein kinase (MNK) types 1/2 inhibitor with potential antineoplastic activity. Upon administration, tinodasertib may inhibit MNK1/2-dependent phosphorylation of eukaryotic initiation factor 4E (eIF4E) and interfere with its role in mRNA translation. eIF4E is an oncoprotein that must be phosphorylated before it can promote the proliferation and progression of tumor cells. MNKs are a family of serine/threonine kinases that have been implicated in oncogenic transformation and tumor progression.","Tinodasertib | AUM-001 | AUM001 | ETC 1907206 | ETC 206 | ETC-1907206 | ETC-206 | ETC1907206 | ETC206 | MNK1/2 Inhibitor ETC-1907206 | MNK1/2 Inhibitor ETC-1907206 | TINODASERTIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556518","Jingpho Language","C153967","A Tibeto-Burman language of the Sal branch mainly spoken in the Kachin State of Myanmar and the Yunnan Province of China.","Jingpho Language | Jingpho | KAC | Kachin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555088","Greenlandic Language","C153968","An Eskimo-Aleut language spoken by Greenlandic Inuit in Greenland.","Greenlandic Language | Greenlandic | KAL | Kalaallisut",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574444","Kamba Language","C153969","A Niger-Congo Bantu language spoken by the Kamba people of Kenya.","Kamba Language | KAM | Kamba",,,,,,,,,,,,,,,"4180233","Kamba language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574287","Kannada Language","C153970","A Dravidian language spoken predominantly by the Kannada people in India, mainly in the state of Karnataka.","Kannada Language | KAN | Kannada",,,,,,,,,,,,,,,"4182495","Kanarese language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574337","Kashmiri Language","C153971","A language from the Dardic subgroup of Indo-Aryan languages spoken primarily in the Kashmir Valley and Chenab Valley of the Jammu and Kashmir state in India.","Kashmiri Language | KAS | Kashmiri",,,,,,,,,,,,,,,"4182518","Kashmiri language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0017453","Georgian Language","C153972","A Kartvelian language spoken by the Georgian people in Georgia.","Georgian Language | Georgian | KAT",,,,,,,,,,,,,,,"4182481","Georgian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574653","Kanuri Language","C153973","A dialect continuum of the Saharan language spoken mainly in Nigeria, Niger, Chad and Cameroon.","Kanuri Language | KAU | Kanuri",,,,,,,,,,,,,,,"4181721","Kanuri language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0022536","Kazakh Language","C153974","A Turkic language that is the official language of the Republic of Kazakhstan.","Kazakh Language | KAZ | Kazakh",,,,,,,,,,,,,,,"4182474","Kazakh language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574233","Kabardian Language","C153975","A Northwest Caucasian language spoken mainly in parts of the North Caucasus republics of Kabardino-Balkaria and Karachay-Cherkessia and in Turkey, Jordan and Syria.","Kabardian Language | East Circassian | KBD | Kabardian | Kabardino-Cherkess",,,,,,,,,,,,,,,"4181389","Kabardian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574408","Khasi Language","C153976","An Austroasiatic language spoken primarily in the Meghalaya state of India by the Khasi people.","Khasi Language | KHA | Khasi",,,,,,,,,,,,,,,"4175922","Khasi language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2584864","Central Khmer Language","C153977","An Austroasiatic language that is spoken by the the Khmer people and is the official language of Cambodia.","Central Khmer Language | Cambodian | Central Khmer | KHM",,,,,,,,,,,,,,,"4232100","Central Khmer language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574445","Kikuyu Language","C153978","A Niger-Congo Bantu language spoken primarily by the Kikuyu people of Kenya.","Kikuyu Language | Gikuyu | KIK | Kikuyu",,,,,,,,,,,,,,,"4181688","Kikuyu language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0682416","Kinyarwanda Language","C153979","A Niger-Congo language that is the official language of Rwanda.","Kinyarwanda Language | KIN | Kinyarwanda",,,,,,,,,,,,,,,"4175935","Ruanda language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556899","Kyrgyz Language","C153980","A Turkic language spoken in Kyrgyzstan, as well as China, Afghanistan, Kazakhstan, Tajikistan, Turkey, Uzbekistan, Pakistan, and Russia.","Kyrgyz Language | KIR | Kirghiz | Kyrgyz",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555089","Kimbundu Language","C153981","A Niger-Congo Bantu language spoken by the Ambundu people of Angola.","Kimbundu Language | KMB | Kimbundu | North Mbundu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574338","Konkani Language","C153982","An Indo-Aryan language belonging to the Indo-European family of languages that is spoken along the western coast of India.","Konkani Language | KOK | Konkani",,,,,,,,,,,,,,,"4175907","Konkani language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0664965","pterostilbene","C153353","A naturally-derived stilbenoid structurally related to resveratrol, with potential antioxidant, anti-inflammatory, pro-apoptotic, antineoplastic and cytoprotective activities. Upon administration, pterostilbene exerts its anti-oxidant activity by scavenging reactive oxygen species (ROS), thereby preventing oxidative stress and ROS-induced cell damage. It may also activate the nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated pathway and increase the expression of various antioxidant enzymes, such as superoxide dismutase (SOD).  In addition, pterostilbene is able to inhibit inflammation by reducing the expression of various inflammatory mediators, such as interleukin (IL) 1beta, tumor necrosis factor alpha (TNF-a), inducible nitric oxide synthase (iNOS), cyclooxygenases (COX), and nuclear factor kappa B (NF-kB). It also inhibits or prevents the activation of many signaling pathways involved in carcinogenesis, and increases expression of various tumor suppressor genes while decreasing expression of certain tumor promoting genes. It also directly induces apoptosis in tumor cells.","Pterostilbene | 3',5'-Dimethoxy-4-stilbenol | 3,5-Dimethoxy-4'-hydroxystilbene | PTEROSTILBENE | Phenol, 4-(2-(3,5-Dimethoxyphenyl)ethenyl)-, (E)- | Trans-3,5-dimethoxy-4-hydroxystilbene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554455","RGX 202","C153354","An orally available, small molecule inhibitor of the creatine transporter, solute carrier family 6, member 8 (SLC6a8), with potential antineoplastic activity. Upon oral administration, ompenaclid inhibits phosphocreatine uptake by SLC6a8, thereby reducing intracellular levels of phosphocreatine available for ATP synthesis in tumor cells. SLC6a8 is overexpressed in some cancer types and inhibition of its activity may potentially limit tumor cell growth and metastasis.","Ompenaclid | OMPENACLID | RGX 202 | RGX-202 | RGX-202-01 | RGX202 | SLC6A8 Inhibitor RGX-202 | SLC6A8 Inhibitor RGX-202",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554456","Refractory Bile Duct Carcinoma","C153355","Bile duct carcinoma that is resistant to treatment.","Refractory Bile Duct Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554457","Refractory Small Intestinal Carcinoma","C153356","Small intestinal carcinoma that is resistant to treatment.","Refractory Small Intestinal Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554458","Locally Advanced Small Intestinal Carcinoma","C153357","Small intestinal carcinoma that has spread to nearby tissues or lymph nodes.","Locally Advanced Small Intestinal Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554459","Locally Advanced Digestive System Carcinoma","C153358","Digestive system carcinoma that has spread to nearby tissues or lymph nodes.","Locally Advanced Digestive System Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554517","Recurrent Gastroesophageal Junction Adenocarcinoma","C153359","The reemergence of gastroesophageal junction adenocarcinoma after a period of remission.","Recurrent Gastroesophageal Junction Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0039422","Technology Assessment","C15335","Technology assessment (TA) arose in the mid-1960s from an appreciation of the critical role of technology in modern society and its potential for unintended, and sometimes harmful, consequences. TA was conceived as a way to identify the desirable first-order, intended effects of technologies as well as the higher-order, unintended social, economic and environmental effects.  TA methodology draws upon a variety of analytical, evaluative and planning techniques. Among these are systems analysis, cost-benefit analysis, consensus methods (e.g., Delphi method), engineering feasibility studies, clinical trials, market research, technological forecasting, and others. TA practitioners and policy makers recognized that TA is evolving, flexible, and should be tailored to the task (Brooks and Bowers 1970 and U.S. Congress, Office of Technology Assessment 1977).","Technology Assessment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0854791","Recurrent Bile Duct Carcinoma","C153360","The reemergence of bile duct carcinoma after a period of remission.","Recurrent Bile Duct Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554518","Soft Tissue Sarcoma, Excluding Liposarcoma","C153361","A finding indicating the presence of a sarcoma arising from the soft tissue, other than liposarcoma.","Soft Tissue Sarcoma, Excluding Liposarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554317","Systematic Light Exposure","C153187","A type of light therapy that uses exposure to bright white light (BWL) from a proprietary LED light source for treatment of cancer-related fatigue.","Systematic Light Exposure | sLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554318","Litebook","C153188","A proprietary light source that uses white light emitting diodes (LED) to mimic the visible spectrum of sunlight (full spectrum white light), with minimum glare and maximum eye comfort.","Litebook | Litebook 1.2 | Litebook Edge",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2936263","Epigenomics","C153190","A study of the complete set of epigenetic modifications on the genetic material of a cell.","Epigenomics | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2717799","Metagenomics","C153191","The direct study of genetic material recovered from environmental samples, largely dominated by microbial organisms.","Metagenomics | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512223","Glycobiology","C153192","A study of the complete set of glycans produced in a given cell or organism under specific conditions.","Glycomics | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554320","Lipidomics","C153193","A study of the complete set of lipids produced in a given cell or organism under specific conditions.","Lipidomics | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554321","Transcriptome","C153194","The complete set of RNA transcripts that are produced by the genome, under specific circumstances or in a specific cell.","Transcriptome | Transcriptome Profiling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554322","Epigenome","C153195","The complete set of epigenetic modifications on the genome of a cell.","Epigenome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554323","Metagenome","C153196","The total genetic material recovered from an environmental sample.","Metagenome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574668","Shan Language","C154114","A Kra-Dai language that is spoken by the Shan people, mostly in the Shan State of Myanmar.","Shan Language | SHN | Shan",,,,,,,,,,,,,,,"4177467","Shan language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574160","Sidamo Language","C154115","An Afro-Asiatic language, belonging to the Highland East Cushitic branch of the Cushitic family spoken in parts of southern Ethiopia by the Sidama people.","Sidamo Language | SID | Sidaama | Sidaamu Afoo | Sidamo",,,,,,,,,,,,,,,"4178560","Sidamo language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574327","Slovenian Language","C154117","An Indo-European Western South Slavic language that is spoken in Slovenia.","Slovenian Language | SLV | Slovenian",,,,,,,,,,,,,,,"4182513","Slovenian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556382","Southern Sami Language","C154118","A Uralic Sami language spoken mostly in Snasa, Royrvik, Roros, and Hattfjelldal in Norway.","Southern Sami Language | SMA | Southern Sami",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2919920","Northern Sami Language","C154119","A Uralic Sami language spoken in the northern parts of Norway, Sweden, and Finland.","Northern Sami Language | North Sami | Northern Sami | SME",,,,,,,,,,,,,,,"40482032","Northern Sami language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555189","Lule Sami Language","C154120","A Uralic Sami language spoken in Lule Lappmark, Sweden and in the northern parts of Nordland county in Norway.","Lule Sami Language | Lule Sami | SMJ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0180053","Compresses (device)","C153473","Cloth or another material applied to an area of the skin for application of pressure or medication to a restricted area, or for local applications of heat or cold, and held in place for a period of time.","Compress | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0812453","Cold Compress","C153474","A chilled cloth or similar dressing applied to the skin.","Cold Compress | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554974","Locally Advanced Unresectable Bone Sarcoma","C153475","A bone sarcoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.","Locally Advanced Unresectable Bone Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554975","Locally Advanced Unresectable Soft Tissue Sarcoma","C153476","A soft tissue sarcoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.","Locally Advanced Unresectable Soft Tissue Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554972","Locally Advanced Unresectable Sarcoma","C153477","A sarcoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.","Locally Advanced Unresectable Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554203","Integral Membrane Protein GPR180","C153055","Integral membrane protein GPR180 (440 aa, ~49 kDa) is encoded by the human GPR180 gene. This protein may be involved in G protein-receptor-mediated signaling and remodeling of the vasculature.","Integral Membrane Protein GPR180 | G Protein-Coupled Receptor 180 | G-Protein Coupled Receptor 180 | GPR180 | Intimal Thickness Related Receptor | Intimal Thickness-Related Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554204","PLAAT1 Gene","C153056","This gene plays a role in lipid acetylation and phospholipase activity.","PLAAT1 Gene | HRASLS | PLAAT1 | Phospholipase A and Acyltransferase 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554205","A-C1","C153057","Human PLAAT1 wild-type allele is located in the vicinity of 3q29 and is approximately 60 kb in length. This allele, which encodes phospholipid A and acyltransferase 1 protein, is involved in lipid metabolism.","PLAAT1 wt Allele | A-C1 | H-REV107 | HRAS Like Suppressor Gene | HRAS-Like Suppressor Gene | HRASLS | HRASLS1 | HRSL1 | HSD28 | PLA/AT1 | PLAAT-1 | Phospholipase A and Acyltransferase 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554206","HRAS-like suppressor protein, human","C153058","Phospholipid A and acyltransferase 1 (168 aa, ~19 kDa) is encoded by the human PLAAT1 gene. This protein plays a role in phosphate removal from and acetylation of lipids.","Phospholipase A and Acyltransferase 1 | EC 2.3.1.- | EC 3.1.1.- | H-REV107 Protein-Related Protein | HRAS-Like Suppressor | HRAS-Like Suppressor 1 | HRASLS | HRSL1 | PLAAT1 | Phospholipase A-C1 | Phospholipid-Metabolizing Enzyme A-C1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242239","Record Linkage Study","C15424","A study in which data from different sources are 'linked'.  Usually used to compile epidemiological data.  The logic of record linkage is that two or more items of information about a person recorded at different times, and perhaps in different places, may be of greater value when considered together than when either is considered alone.","Record Linkage Study | Data Linkage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556379","Timne Language","C154160","A Niger-Congo language spoken in Sierra Leone.","Timne Language | TEM | Timne",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556881","Terena Language","C154161","An Arawakan language spoken by the Terena people of Brazil.","Terena Language | Etelena | TER | Terena | Tereno",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2959953","Tetum Language","C154162","An Austronesian language spoken on the island of Timor.","Tetum Language | TET | Tetum | Tetun",,,,,,,,,,,,,,,"40486431","Tetum language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0162882","Tajik Language","C154163","An Indo-European language variety of Persian spoken in Tajikistan and Uzbekistan.","Tajik Language | TGK | Tajik",,,,,,,,,,,,,,,"4181547","Tajik language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0039724","Thai Language","C154165","A Kra-Dai language that is spoken as the official and national language of Thailand.","Thai Language | Central Thai | Siamese | THA | Thai",,,,,,,,,,,,,,,"4183934","Thai language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574173","Tigrinya Language","C154167","An Afroasiatic language of the Semitic branch mainly spoken by the Tigrayan people in the highlands of Eritrea and in the Tigray Region of northern Ethiopia.","Tigrinya Language | TIR | Tigrinya",,,,,,,,,,,,,,,"4182356","Tigrinya language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574482","Tiv Language","C154168","A Niger-Congo Southern Bantoid language spoken in Nigeria, mainly in the Benue State.","Tiv Language | TIV | Tiv",,,,,,,,,,,,,,,"4177296","Tiv language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555285","Allogeneic CD19CAR-transfected Cytokine-induced Killer Cells","C154284","A preparation of allogeneic cytokine-induced killer (CIK) cells derived from peripheral blood mononuclear cells (PBMCs) transfected with the Sleeping Beauty (SB) transposon, CD19CAR (CARCIK-CD19), with potential immunomodulatory and antineoplastic activities. CIK cells are CD3- and CD56-positive, non-major histocompatibility complex (MHC)-restricted, natural killer (NK)-like T-lymphocytes. Upon infusion following an allogeneic stem cell transplantation, the CARCIK-CD19 cells bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CIK cells may have enhanced cytotoxic activity compared to lymphokine-activated killer (LAK) cells. CD19 is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.","Allogeneic CD19CAR-transfected Cytokine-induced Killer Cells | Allogeneic CARCIK-CD19 (SY) | Allogeneic CARCIK-CD19 Cells | Transposon-manipulated Allogeneic CARCIK-CD19 Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555286","Autologous TAAs-loaded Autologous Dendritic Cells AV-GBM-1","C154285","A preparation of autologous dendritic cells (DCs) loaded with immunogenic tumor-associated antigens (TAAs) derived from cultured autologous glioblastoma multiforme (GBM) tumor cells, with potential immunostimulatory and antineoplastic activities. Upon administration, the autologous TAA-loaded DCs AV-GBM-1 expose the immune system to the GBM neoantigens, which results in a cytotoxic T-lymphocyte (CTL)-mediated immune response against the autologous GBM cells leading to GBM cell lysis.","Autologous TAAs-loaded Autologous Dendritic Cells AV-GBM-1 | AV GBM 1 | AV-GBM-1 | Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens | Autologous TAAs-loaded Autologous DCs AV-GBM-1 | Neoantigen-loaded Autologous Dendritic Cells AV-GBM-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556400","Lozenge Dosage Form Category","C154554","A type of solid pharmaceutical dose form consisting of a hard mass formed by moulding or compression, intended to dissolve or disintegrate slowly in the oral cavity when sucked.","Lozenge Dosage Form Category | Lozenge",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555351","Methionine-Restricted Diet","C154555","A diet which is limited in the amino acid methionine. Methionine depletion inhibits cell cycle progression and induces apoptosis in many transformed cells, but not normal cells. Dietary methionine restriction inhibits tumor growth in diverse cancer models and is in trial as part of clinical cancer treatments.","Methionine-Restricted Diet | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555352","Ointment Dosage Form Category","C154557","A type of semi-solid pharmaceutical dose form consisting of a single-phase basis in which solids or liquids may be dispersed; ointments may be composed of a variety of bases including hydrocarbons, emulsifiers, vegetable oils and animal fats; they may be hydrophobic (bases made from substances such as hard, liquid, or light liquid paraffins, vegetable oils, animal fats, synthetic glycerides, waxes and liquid polyalkylsiloxanes, and which are only able to absorb a small amount of water), hydrophilic (with a water-miscible basis, usually a mixture of liquid and solid macrogols) or water-emulsifying (capable of absorbing larger amounts of water and forming emulsions, with bases containing water-in-oil emulsifiers such as wool alcohols, sorbitan esters, monoglycerides and fatty alcohols, or oil-in-water emulsifiers such as sulfated fatty alcohols, polysorbates, macrogol cetostearyl ether, esters of fatty acids with macrogols).","Ointment Dosage Form Category | Ointment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555356","Paste Dosage Form Category","C154559","A type of semi-solid pharmaceutical dose form consisting of a large proportion of solid particles dispersed in a hydrophobic or hydrophilic basis.","Paste Dosage Form Category | Paste",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279005","Evaluation of Cancer Risk Factors","C15455","No value exists.","Evaluation of Cancer Risk Factors | cancer risk factors evaluation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280661","Tumor Infiltrating Lymphocyte Therapy","C15524","A form of adoptive cell transfer in which lymphocytes are isolated from a patient's tumor, grown in vitro, and then infused into the patient in combination with interleukin 2.","Tumor Infiltrating Lymphocyte Therapy | ",,,,,,,,,,,,,,,"37154488","Tumor infiltrating lymphocyte therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555760","Grade 1 Neonatal Gastrointestinal Bleeding, AE","C155250","A gastrointestinal bleeding adverse event in a newborn characterized by mild, self-limiting, bleeding; no change in care required.","Grade 1 Neonatal Gastrointestinal Bleeding, AE | Grade 1 Gastro-intestinal Bleeding Neonatal | Grade 1 Neonatal Gastrointestinal Bleeding, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555758","Grade 3 Neonatal Gastrointestinal Bleeding, AE","C155252","A gastrointestinal bleeding adverse event in a newborn characterized by severe bleeding; non-life threatening hemodynamic consequences; major care change required (e.g. invasive intervention, transfusion, long term medical treatment).","Grade 3 Neonatal Gastrointestinal Bleeding, AE | Grade 3 Gastro-intestinal Bleeding Neonatal | Grade 3 Neonatal Gastrointestinal Bleeding, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555759","Grade 4 Neonatal Gastrointestinal Bleeding, AE","C155253","A gastrointestinal bleeding adverse event in a newborn characterized by life-threatening consequences (e.g. hemorrhagic shock); urgent major care change required.","Grade 4 Neonatal Gastrointestinal Bleeding, AE | Grade 4 Gastro-intestinal Bleeding Neonatal | Grade 4 Neonatal Gastrointestinal Bleeding, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555764","Grade 5 Neonatal Gastrointestinal Bleeding, AE","C155254","A gastrointestinal bleeding adverse event in a newborn which results in death.","Grade 5 Neonatal Gastrointestinal Bleeding, AE | Grade 5 Gastro-intestinal Bleeding Neonatal | Grade 5 Neonatal Gastrointestinal Bleeding, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555765","Grade 3 Neonatal Spontaneous Intestinal Perforation, AE","C155255","An adverse event in a newborn characterized by presence of spontaneous intestinal perforation (SIP), non-urgent medical stabilization and surgical intervention indicated.","Grade 3 Neonatal Spontaneous Intestinal Perforation, AE | Grade 3 Neonatal SIP, AE | Grade 3 Neonatal Spontaneous Intestinal Perforation | Grade 3 Neonatal Spontaneous Intestinal Perforation, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555762","Grade 4 Neonatal Spontaneous Intestinal Perforation, AE","C155256","A spontaneous intestinal perforation (SIP) adverse event in a newborn characterized by life-threatening consequences (e.g. shock, organ failure); urgent intervention indicated.","Grade 4 Neonatal Spontaneous Intestinal Perforation, AE | Grade 4 Neonatal SIP, AE | Grade 4 Neonatal Spontaneous Intestinal Perforation | Grade 4 Neonatal Spontaneous Intestinal Perforation, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555763","Grade 5 Neonatal Spontaneous Intestinal Perforation, AE","C155257","A spontaneous intestinal perforation (SIP) adverse event in a newborn which results in death.","Grade 5 Neonatal Spontaneous Intestinal Perforation, AE | Grade 5 Neonatal SIP, AE | Grade 5 Neonatal Spontaneous Intestinal Perforation | Grade 5 Neonatal Spontaneous Intestinal Perforation, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555768","Grade 1 Neonatal Constipation, AE","C155258","An adverse event in a newborn characterized by reduced number of stools or hard stools; no apparent discomfort.","Grade 1 Neonatal Constipation, AE | Grade 1 Constipation Neonatal | Grade 1 Neonatal Constipation, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555769","Grade 2 Neonatal Constipation, AE","C155259","An adverse event in a newborn characterized by reduced number of stools or hard stools; apparent discomfort; minor care changes indicated.","Grade 2 Neonatal Constipation, AE | Grade 2 Constipation Neonatal | Grade 2 Neonatal Constipation, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280674","Aromatase Inhibition Therapy","C15525","Drug treatment to block the action of aromatases, thereby reducing estrogen biosynthesis.","Aromatase Inhibition Therapy | Aromatase Inhibition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555766","Grade 3 Neonatal Constipation, AE","C155260","An adverse event in a newborn characterized by reduced number of stools or hard stools; signs of obstruction; apparent discomfort or affecting feeding; major care changes indicated (e.g. long term medical treatment, enema).","Grade 3 Neonatal Constipation, AE | Grade 3 Constipation Neonatal | Grade 3 Neonatal Constipation, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555767","Grade 4 Neonatal Constipation, AE","C155261","A constipation adverse event in a newborn characterized by life-threatening consequences.","Grade 4 Neonatal Constipation, AE | Grade 4 Constipation Neonatal | Grade 4 Neonatal Constipation, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555496","Spray Dosage Form Category","C154599","A type of pharmaceutical dose form that may be liquid, semi-solid or solid, administered as a dispersion in air; to be used only when further details of the specific form (e.g. solution, suspension, powder) are unknown.","Spray Dosage Form Category | Spray (unspecified)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279018","High-LET Pion Therapy","C15459","No value exists.","High-LET Pion Therapy | therapy, high-LET pion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556410","Stick Dosage Form Category","C154600","A type of solid pharmaceutical dose form consisting of a preparation usually in a cylindrical or conical shape, usually prepared by compression or moulding, intended for insertion in or application to a specific area of the body.","Stick Dosage Form Category | Stick",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556414","Suppository Dosage Form Category","C154601","A type of solid pharmaceutical dose form consisting of a material that is usually formed by moulding, of a suitable shape, volume and consistency for insertion into the rectum where it dissolves, disperses or melts.","Suppository Dosage Form Category | Suppository",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555495","Suspension Dosage Form Category","C154602","A type of liquid pharmaceutical dose form consisting of one or more substances dispersed in a liquid vehicle; the dispersed substance(s) are solid particles that are practically insoluble in the vehicle.","Suspension Dosage Form Category | Suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555499","Syrup Dosage Form Category","C154604","A type of liquid pharmaceutical dose form consisting of a viscous liquid usually with a high concentration of sugar or other sweetening agent.","Syrup Dosage Form Category | Syrup",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556385","Tablet Dosage Form Category","C154605","A type of solid pharmaceutical dose form consisting of a mass that is formed by compression of uniform volumes of particulate solids, or by other means such as extrusion or moulding.","Tablet Dosage Form Category | Tablet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555497","Endoesophageal Brachytherapy","C154606","The use of localized, internal radiation therapy for the treatment of esophageal cancer.","Endoesophageal Brachytherapy | Esophageal Brachytherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555498","6-Channel Balloon Repositioning, Multichannel Applicator","C154607","A five-balloon self-centering applicator with one treatment catheter. The five balloons center and anchor the catheter within the esophagus and the catheter is used to deliver localized therapy.","6-Channel Balloon Repositioning, Multichannel Applicator | E-App | Esophageal Applicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555502","Recurrent Metastatic Malignant Neoplasm","C154608","The reemergence of a metastatic malignant neoplasm after a period of remission.","Recurrent Metastatic Malignant Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279019","Mixed High-Low LET Therapy","C15460","No value exists.","Mixed High-Low LET Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554864","tridecanoin","C153424","An orally available precursor of decanoic acid (DA), a 10-carbon fatty acid and major component of medium chain triglyceride oils, with potential antiandrogen and antihyperglycemic properties. Upon oral administration, tricaprin is hydrolyzed to DA, which binds to and partially activates peroxisome proliferator-activated receptor (PPAR)-gamma, as well as PPAR-alpha and PPAR-beta/delta, without inducing adipogenesis. Additionally, tricaprin may improve insulin sensitivity and decrease androgen production.","Tricaprin | Capric Acid Triglyceride | Glycerol Tricaprin | Glycerol Tridecanoate | TRICAPRIN | Tricapric Glyceride | Tridecanoin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554861","Platinum Acetylacetonate-Titanium Dioxide Nanoparticles","C153425","A preparation of platinum acetylacetonate supported by sol-gel technology functionalized titania, with potential antineoplastic activity. Upon intravenous administration, the platinum moiety forms complexes with nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links, resulting in apoptosis and cell growth inhibition. Compared to platinum alone, the nanoparticle formulation allows increased delivery of platinum to the tumor site, thereby increasing efficacy while reducing systemic toxicity.","Platinum Acetylacetonate-Titanium Dioxide Nanoparticles | NPt | NPt Nanomaterial | NPt Nanoparticles | NPt-Ca | Sol-gel NPt Nanomaterial | Sol-gel NPt Nanoparticles",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554862","Triamcinolone Acetonide Transdermal System SUN-131","C153426","A transdermal system (TDS) containing triamcinolone acetonide, a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. Upon application of the TDS to the eyelid, triamcinolone acetonide binds to intracellular glucocorticoid receptors, ultimately inducing the expression of glucocorticoid-responsive genes and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both mediators of inflammation. In addition, pro-inflammatory cytokine production, including interleukin (IL)-1and IL-6, and the activation of cytotoxic T-lymphocytes is also inhibited. Triamcinolone acetonide also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis through increasing Ikappa-B expression and curtailing activation of nuclear factor (NF)kappa-B.","Triamcinolone Acetonide Transdermal System SUN-131 | SUN 131 | SUN-131 | SUN-131 TDS | SUN131 | Triamcinolone Acetonide Transdermal Patch SUN-131",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554867","DBPR 112","C153427","An orally bioavailable dual kinase inhibitor of epidermal growth factor receptor (EGFR; ErbB1) and human epidermal growth factor receptor 2 (HER2; EGFR2; ErbB2), including EGFR L858R, EGFR T790M and HER2 exon 20 insertion (Ex20ins) mutations, with potential antineoplastic activity. Upon oral administration, EGFR/HER2 inhibitor ABT-101 targets, binds to and inhibits the activity of EGFR or HER2 insertions or mutations. This prevents EGFR/HER2-mediated signaling, which may induce cell death and inhibit tumor growth in EGFR/HER2-overexpressing tumor cells. The ErbB receptor tyrosine kinase family is involved in key cellular functions, including cell growth and survival. EGFR and HER2 alterations constitutively upregulate kinase activity.","EGFR/HER2 Inhibitor ABT-101 | ABT 101 | ABT-101 | ABT101 | DBPR 112 | DBPR-112 | DBPR112 | EGFR Inhibitor DBPR112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554868","Indium In 111 Minigastrin Analog CP04","C153428","A radioconjugate consisting of the minigastrin analog, CP04, labeled with the gamma-emitting radioisotope indium-111, with radioimaging potential. Upon intravenous administration, 111In-CP04 binds to and is subsequently internalized by cells expressing cholecystokinin receptor subtype 2 (CCK2R), which is overexpressed in certain tumor types. 111In-CP04 emits gamma radiation and X-ray photons that allow detection of tumor localization and distribution using gamma scintigraphy.","Indium In 111 Minigastrin Analog CP04 | 111-Indium CP04 | 111In-CP04 | Indium In 111 CP04 | PPF11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554865","Colloidal Modified Fluid Gelatin Plasma Substitute","C153429","A colloidal, isotonic, physiologically balanced, plasma volume substitute containing succinylated gelatine and electrolytes, with potential nephroprotective properties. Upon intravenous administration, colloidal modified fluid gelatin plasma substitute expands the blood volume, restores intravascular volume and increases blood flow, thereby preventing hypovolemia, hypotension and shock and may decrease the accumulation of nephrotoxic agents in the kidneys.","Colloidal Modified Fluid Gelatin Plasma Substitute | Colloidal Succinylated Gelatine Plasma Substitute | Gelaspan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554866","SLC6A8 Gene","C153430","This gene plays a role in the transmembrane transport of creatine and phosphocreatine.","SLC6A8 Gene | SLC6A8 | Solute Carrier Family 6 Member 8 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555354","PARP 1/2 Inhibitor NOV1401","C154560","An orally available small molecule inhibitor of the nuclear enzymes poly (ADP-ribose) polymerase (PARP) 1 and 2, with potential antineoplastic activity. Upon administration, NOV1401 selectively binds to PARP-1 and -2, thereby preventing PARP-1 and -2-mediated DNA repair. This promotes genetic instability and enhances the accumulation of single and double strand DNA breaks, ultimately leading to apoptosis. The PARP family of proteins catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks.","PARP 1/2 Inhibitor NOV1401 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556870","Pastille Dosage Form Category","C154562","A type of solid pharmaceutical dose form consisting of a soft, flexible mass formed by moulding, intended to dissolve or disintegrate slowly in the oral cavity when sucked.","Pastille Dosage Form Category | Pastille",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555359","PD-L2 Peptide-Montanide Vaccine","C154563","A vaccine composed of a peptide derived from the immune checkpoint molecule programmed death ligand 2 (PD-L2) combined with the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Vaccination with PD-L2 peptide-montanide vaccine may mount an immune response against PD-L2 expressing cells. This may enhance T-cell proliferation, cytokine production, and T-cell mediated cytolysis. PD-L2 binding to its cognate receptor, programmed cell death protein 1 (PD-1; PDCD1; CD279), downregulates T-cell responses and enhances immune evasion. Montanide ISA-51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens.","PD-L2 Peptide-Montanide Vaccine | PD-L2 Peptide Plus Montanide ISA-51 Vaccine | PD-L2 Peptide Plus Montanide Vaccine | Programmed Death Ligand 2 Peptide Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555212","H3 Histone Family Member 3A c.83A>T","C154320","A nucleotide substitution at position 83 of the coding sequence of the H3-3A gene where adenine has been mutated to thymine.","H3-3A NM_002107.4:c.83A>T | H3 Histone Family Member 3A c.83A>T | H3-3A c.83A>T | H3.3 Histone A c.83A>T | H3.3A c.83A>T | H3F3 c.83A>T | H3F3A NM_002107.4:c.83A>T | H3F3A c.83A>T | NM_002107.4:c.83A>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555213","Locally Advanced Squamous Cell Carcinoma","C154321","A squamous cell carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Squamous Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555218","Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","C154322","A squamous cell carcinoma that arises from the nasal cavity and/or paranasal sinuses and has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Sinonasal Squamous Cell Carcinoma | Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma | Locally Advanced Squamous Cell Carcinoma of the Nasal Cavity and Paranasal Sinus | Locally Advanced Squamous Cell Carcinoma of the Nasal Cavity and/or Paranasal Sinuses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555219","Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma","C154324","A poorly differentiated carcinoma that arises from the nasal cavity and/or paranasal sinuses.","Sinonasal Poorly Differentiated Carcinoma | Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma | Poorly Differentiated Carcinoma of the Nasal Cavity and/or Paranasal Sinuses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555222","Seclidemstat","C154328","An orally available, reversible, noncompetitive inhibitor of lysine-specific demethylase 1 (LSD1, or KDM1A), with potential antineoplastic activity. Upon oral administration, seclidemstat reversibly inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone 3 (H3K4) to mono- and unmethylated H3K4, respectively. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. In addition, LSD1 demethylates mono- or di-methylated H3K9 which increases gene expression of tumor promoting genes; inhibition of LSD1 promotes H3K9 methylation and decreases transcription of these genes.","Seclidemstat | LSD1 Inhibitor SP-2577 | SECLIDEMSTAT | SP 2577 | SP-2577 | SP2577",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555220","Biochemotherapy","C154330","A drug treatment regime that combines chemotherapy drugs with biological or immunological agents.","Biochemotherapy | Biotherapy and Chemotherapy | Combined Biotherapy and Chemotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555506","Histone H2A-Bbd","C154613","A variant form of histone H2A found in chromatin structures that are transcriptionally active.","Histone H2A-Bbd | H2A Barr Body Deficient | H2A Barr Body-Deficient | H2A-Bbd | H2A.B | H2A.Bbd",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555675","Heterosexual Contact","C154862","Sexual contact with someone of the opposite sex.","Heterosexual Contact | OPPOSITE-SEX SEXUAL CONTACT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555676","Homosexual Contact","C154863","Sexual contact with someone of the same sex.","Homosexual Contact | SAME-SEX SEXUAL CONTACT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555674","Intrauterine Exposure","C154864","The exposure to agents that occurs during in utero development.","Intrauterine Exposure | INTRAUTERINE EXPOSURE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279497","Prostaglandin Inhibition","C15486","No value exists.","Prostaglandin Inhibition | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1955752","Thoracoscopic wedge resection","C154873","A minimally invasive surgical procedure in which video-assisted thoracoscopy is used to remove of a portion of the lung.","Thorascopic Wedge Resection of the Lung | THORACOSCOPIC WEDGE RESECTION | TWR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554932","SLC6A8 wt Allele","C153431","Human SLC6A8 wild-type allele is located in the vicinity of Xq28 and is approximately 8 kb in length. This allele, which encodes sodium- and chloride-dependent creatine transporter 1 protein, is involved in muscle cell physiology and creatine/phosphocreatine transport. Alterations of the gene are associated with X-linked creatine deficiency syndrome.","SLC6A8 wt Allele | CCDS1 | CRT | CRTR | CT1 | CTR5 | Solute Carrier Family 6 (Neurotransmitter Transporter), Member 8 Gene | Solute Carrier Family 6 (Neurotransmitter Transporter, Creatine), Member 8 Gene | Solute Carrier Family 6 Member 8 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554295","Zonampanel Anhydrous","C152964","No value exists.","Zonampanel Anhydrous | ZONAMPANEL ANHYDROUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554168","Zorbamycin","C152965","No value exists.","Zorbamycin | ZORBAMYCIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554169","Zoxazolamine","C152966","No value exists.","Zoxazolamine | ZOXAZOLAMINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554170","Zuretinol Acetate","C152967","No value exists.","Zuretinol Acetate | ZURETINOL ACETATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554171","CDCA7 Gene","C152968","This gene is involved in MYC-dependent cell proliferation.","CDCA7 Gene | CDCA7 | Cell Division Cycle Associated 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554172","CDCA7 wt Allele","C152969","Human CDCA7 wild-type allele is located in the vicinity of 2q31.1 and is approximately 15 kb in length. This allele, which encodes cell division cycle-associated protein 7, plays a role in the regulation of cell proliferation. Mutation of the gene is associated with immunodeficiency-centromeric instability-facial anomalies syndrome 3.","CDCA7 wt Allele | Cell Division Cycle Associated 7 wt Allele | FLJ14736 | ICF3 | JPO1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0031006","Isolated Chemotherapeutic Perfusion","C15296","The delivery of chemotherapy to a specific tissue area that is excluded from the general circulation during the period of infusion, which allows for a high concentration of the drug in the tumour area as well as sparing of the rest of the body from the side effects of the drug.","Isolated Chemotherapeutic Perfusion | perfusion, isolated",,,,,,,,,,,,,,,"4243600","In situ perfusion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1310364","CDCA7 protein, human","C152970","Cell division cycle-associated protein 7 (371 aa, ~43 kDa) is encoded by the human CDCA7 gene. This protein is involved in the modulation of cell proliferation.","Cell Division Cycle-Associated Protein 7 | CDCA7 | Protein JPO1 | c-Myc Target JPO1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554174","Futuximab","C152971","A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor receptor (EGFR; ErbB1; HER1), with potential antineoplastic activity. Upon administration, futuximab targets and binds to an epitope located in the extracellular domain (ECD) of EGFR, which causes internalization and degradation of EGFR, including the mutated EGFR variant III (EGFRvIII). This prevents EGFR-mediated signaling, thereby inhibiting EGFR-dependent tumor cell proliferation. EGFR, a receptor tyrosine kinase, is overexpressed on the cell surfaces of various solid tumor cell types.","Futuximab | 992 DS | 992-DS | 992DS | FUTUXIMAB | Immunoglobulin G1, Anti-(Human Epidermal Growth Factor Receptor Extracellular Domain III) (Human-Mus Musculus Monoclonal 992 DS Heavy Chain), Disulfide with Human-Mus Musculus Monoclonal 992 DS Light Chain, Dimer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554176","CENPA wt Allele","C152973","Human CENPA wild-type allele is located in the vicinity of 2p23.3 and is approximately 40 kb in length. This allele, which encodes histone H3-like centromeric protein A, is involved in cell division and centromeric nucleosome structure.","CENPA wt Allele | CENP-A | CenH3 | Centromere Protein A (17kD) Gene | Centromere Protein A wt Allele | Centromere Protein A, 17kDa Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554177","Histone H3-Like Centromeric Protein A","C152974","Histone H3-like centromeric protein A (140 aa, ~16 kDa) is encoded by the human CENPA gene. This protein plays a role in cell cycle progression, cell division and centromeric nucleosome assembly.","Histone H3-Like Centromeric Protein A | CENP-A | CENPA | CENTROMERE A | Centromere Autoantigen A | Centromere Protein A | Centromere-Specific Histone | Centromeric Protein A | Histone cenH3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0540034","Compound 32","C1547","A protein tyrosine kinase inhibitor that has specific activity for the epidermal growth factor receptor. (NCI)","Compound 32 | 4-(3'-bromoanilino)-6,7-dimethoxyquinazoline | PD 153035 | ZM 252868",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555717","Grade 1 Neonatal Respiratory Distress Syndrome, AE","C155207","An adverse event in a newborn characterized by radiological evidence without clinical signs; clinical evidence of mildly increased respiratory distress (e.g. increased work of breathing) without significant deterioration in gas exchange (increase in partial pressure of carbon dioxide (pCO2) or decrease in oxygenation); no supportive care required.","Grade 1 Neonatal Respiratory Distress Syndrome, AE | Grade 1 Neonatal Respiratory Distress Syndrome | Grade 1 Neonatal Respiratory Distress Syndrome, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555714","Grade 2 Neonatal Respiratory Distress Syndrome, AE","C155208","An adverse event in a newborn characterized by clinical evidence of increased respiratory distress without significant deterioration in gas exchange (increase in partial pressure of carbon dioxide (pCO2) or decrease in oxygenation); corrected by minor adjustments in current ventilatory support, supplemental oxygen or non-invasive support.","Grade 2 Neonatal Respiratory Distress Syndrome, AE | Grade 2 Neonatal Respiratory Distress Syndrome | Grade 2 Neonatal Respiratory Distress Syndrome, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555715","Grade 3 Neonatal Respiratory Distress Syndrome, AE","C155209","An adverse event in a newborn characterized by clinical evidence of increased respiratory distress with relevant deterioration in gas exchange (increase in partial pressure of carbon dioxide (pCO2) or decrease in oxygenation); requiring major care change (e.g. starting invasive support).","Grade 3 Neonatal Respiratory Distress Syndrome, AE | Grade 3 Neonatal Respiratory Distress Syndrome | Grade 3 Neonatal Respiratory Distress Syndrome, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555720","Grade 4 Neonatal Respiratory Distress Syndrome, AE","C155210","A respiratory distress adverse event in a newborn characterized by life-threatening respiratory and/or hemodynamic compromise; requiring urgent care change (e.g. urgent intubation).","Grade 4 Neonatal Respiratory Distress Syndrome, AE | Grade 4 Neonatal Respiratory Distress Syndrome | Grade 4 Neonatal Respiratory Distress Syndrome, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555721","Grade 5 Neonatal Respiratory Distress Syndrome, AE","C155211","A respiratory distress adverse event in a newborn which results in death.","Grade 5 Neonatal Respiratory Distress Syndrome, AE | Grade 5 Neonatal Respiratory Distress Syndrome | Grade 5 Neonatal Respiratory Distress Syndrome, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279804","Prior LHRH Agonist Therapy","C15503","No value exists.","Prior LHRH Agonist Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279813","Prior Androgen Therapy","C15504","No value exists.","Prior Androgen Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279823","Peripheral Blood Lymphocyte Therapy","C15505","No value exists.","Peripheral Blood Lymphocyte Therapy | peripheral blood lymphocyte therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279840","Anticachectic Therapy","C15506","Treatment to manage or alleviate the fatigue and weight loss often associated with cancer.","Anticachectic Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL375167","Antibody-Drug Conjugate Therapy","C15508","Treatment with injections of therapeutic substances linked with specific antibodies in order to directly destroy specific, usually cancerous, cells or to stimulate the immune system to destroy those cells.","Antibody-Drug Conjugate Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0076943","Amino Acid Injection","C15509","A concentrated dietary supplement for injection containing the essential amino acids leucine, isoleucine, lysine, valine, phenylalanine, histidine, threonine, methionine and tryptophan as well as the non-essential amino acids alanine, arginine, glycine, proline, serine and tyrosine, with potential anabolic and anti-catabolic activities. Upon dilution and intravenous infusion of the amino acid nutritional supplement, the amino acids serve as protein building blocks, promote protein synthesis in muscle cells and prevent protein breakdown.","Amino Acid Injection | RenAmin | Travasol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574477","Venda Language","C154191","A Niger-Congo Bantu language mainly spoken by the Venda people in the northern part of South Africa's Limpopo Province, as well as by some Lemba people in Zimbabwe.","Venda Language | Tshivenda | VEN | Venda",,,,,,,,,,,,,,,"4180354","Venda language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555150","Votic Language","C154193","A Uralic language spoken by the Vote people of the Ingria area of Finland.","Votic Language | VOT | Votian | Votic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555149","Wolaytta Language","C154194","An Afro-Asiatic language spoken in the Wolayita Zone and some other parts of the Southern Nations, Nationalities, and People's Region of Ethiopia.","Wolaytta Language | WAL | Wolaitta | Wolaytta",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556893","Waray Language","C154195","An Austronesian language native to Eastern Visayas of the Philippines.","Waray Language | WAR | Waray",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555640","Washoe language","C154196","A Native American language isolate spoken by the Washo people in the area of the California-Nevada border, especially around Lake Tahoe.","Washo Language | WAS | Washo | Washoe",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2919244","Walloon Language","C154197","A Romance language that is spoken in the Wallonia region in Belgium and some villages of Northern France.","Walloon Language | WLN | Walloon",,,,,,,,,,,,,,,"40481577","Walloon language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555151","Oirat Language","C154199","A Mongolic language that is regarded as either a dialect of Mongolian or a distinct language.","Oirat Language | Kalmyk | Oirat | XAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279531","Hypercalcemia Therapy","C15487","Any care or treatment provided for the resolution of an abnormally high blood calcium concentration.","Hypercalcemia Therapy | bone resorption/hypercalcemia control | hypercalcemia control/bone resorption",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555773","Grade 2 Neonatal Culture Negative Sepsis, AE","C155263","An adverse event in a newborn characterized by suspected sepsis with mild or ambiguous signs; anti-infectives initiated.","Grade 2 Neonatal Culture Negative Sepsis, AE | Grade 2 Culture Negative Neonatal Sepsis | Grade 2 Neonatal Culture Negative Sepsis, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555770","Grade 3 Neonatal Culture Negative Sepsis, AE","C155264","An adverse event in a newborn characterized by suspected sepsis with severe signs (e.g. fever, grunting); supportive treatment escalated or initiated.","Grade 3 Neonatal Culture Negative Sepsis, AE | Grade 3 Culture Negative Neonatal Sepsis | Grade 3 Neonatal Culture Negative Sepsis, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555771","Grade 4 Neonatal Culture Negative Sepsis, AE","C155265","A culture negative neonatal sepsis adverse event in a newborn characterized by life-threatening consequences (e.g. shock, disseminated intravascular coagulation (DIC)); urgent major care change required.","Grade 4 Neonatal Culture Negative Sepsis, AE | Grade 4 Culture Negative Neonatal Sepsis | Grade 4 Neonatal Culture Negative Sepsis, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555904","Grade 5 Neonatal Culture Negative Sepsis, AE","C155266","A culture negative neonatal sepsis adverse event in a newborn which results in death.","Grade 5 Neonatal Culture Negative Sepsis, AE | Grade 5 Culture Negative Neonatal Sepsis | Grade 5 Neonatal Culture Negative Sepsis, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555905","Grade 1 Neonatal Culture Positive Sepsis, AE","C155267","An adverse event in a newborn characterized by a positive blood culture positive; no care change indicated (e.g. contamination suspected).","Grade 1 Neonatal Culture Positive Sepsis, AE | Grade 1 Culture Positive Neonatal Sepsis | Grade 1 Neonatal Culture Positive Sepsis, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555902","Grade 2 Neonatal Culture Positive Sepsis, AE","C155268","An adverse event in a newborn characterized by a positive blood culture positive with mild or ambiguous signs; anti-infectives initiated.","Grade 2 Neonatal Culture Positive Sepsis, AE | Grade 2 Culture Positive Neonatal Sepsis | Grade 2 Neonatal Culture Positive Sepsis, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555903","Grade 3 Neonatal Culture Positive Sepsis, AE","C155269","An adverse event in a newborn characterized by a positive blood culture positive with severe signs; supportive treatment escalated or initiated.","Grade 3 Neonatal Culture Positive Sepsis, AE | Grade 3 Culture Positive Neonatal Sepsis | Grade 3 Neonatal Culture Positive Sepsis, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280703","5a-Reductase Inhibition","C15526","Treatment with a 5a-reductase inhibitor with the goal of suppressing the conversion of testosterone to dihydrotestosterone.","5a-Reductase Inhibition | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555908","Grade 4 Neonatal Culture Positive Sepsis, AE","C155270","A culture positive sepsis adverse event in a newborn characterized by life-threatening consequences (e. g. shock, disseminated intravascular coagulation (DIC)); urgent major care change required.","Grade 4 Neonatal Culture Positive Sepsis, AE | Grade 4 Culture Positive Neonatal Sepsis | Grade 4 Neonatal Culture Positive Sepsis, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555318","H3 Histone Family, Member D Gene","C154516","Human H3C6 wild-type allele is located in the vicinity of 6p22.2 and is approximately 3 kb in length. This allele, which encodes histone H3.1 protein, plays a role in chromosome dynamics.","H3C6 wt Allele | H3 Clustered Histone 6 wt Allele | H3 Histone Family, Member D Gene | H3 Histone Family, Member E Gene | H3/d | H3FD | H3e | HIST1 Cluster, H3e Gene | HIST1H3E | HIST1H3E wt Allele | Histone 1, H3e Gene | Histone Cluster 1 H3 Family Member E Gene | Histone Cluster 1, H3e Gene | Histone Gene Cluster 1, H3 Histone Family, Member E Gene | Histone Gene Cluster 1, H3e Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556391","Insert Dosage Form Category","C154518","A type of solid pharmaceutical dose form consisting of a material of an appropriate shape and size to be placed inside an orifice of the body, and which dissolves or disintegrates over time. Pessaries and suppositories are excluded.","Insert Dosage Form Category | Insert",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555321","Double Pituitary Neuroendocrine Tumors of Distinct Lineages","C154519","Pituitary neuroendocrine tumors composed of adenohypopheseal cells of two lineages or a null cell tumor in combination with a lineage-specific pituitary neuroendocrine tumor in the same gland.","Double Pituitary Neuroendocrine Tumors of Distinct Lineages | Double PitNET/Adenomas of Distinct Lineages | Double Pituitary Neuroendocrine Tumors/Adenomas of Distinct Lineages | Pituitary Gland Double Adenomas | Pituitary Gland Double Adenomas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278941","prior anthracycline therapy","C15451","No value exists.","Prior Anthracycline Therapy | Prior Anthracycline | Prior Anthracycline Usage",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555322","Multiple Synchronous Pituitary Neuroendocrine Tumors of Distinct Lineages","C154520","Multiple pituitary neuroendocrine tumors composed of adenohypopheseal cells of two or more lineages or a null cell tumor in combination with a lineage-specific pituitary neuroendocrine tumor in the same gland.","Multiple Synchronous Pituitary Neuroendocrine Tumors of Distinct Lineages | Multiple Synchronous PitNET/Adenomas of Distinct Lineages | Multiple Synchronous Pituitary Neuroendocrine Tumors/Adenomas of Distinct Lineages | Pituitary Gland Multiple Adenomas | Pituitary Gland Multiple Adenomas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555325","Two Separate Tumor Masses Present in the Same Organ","C154521","A finding indicating the presence of two separate tumor masses in the same organ.","Two Separate Tumor Masses Present in the Same Organ | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555326","More Than Two Separate Tumor Masses Present in the Same Organ","C154522","A finding indicating the presence of more than two separate tumor masses in the same organ.","More Than Two Separate Tumor Masses Present in the Same Organ | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555718","Grade 1 Neonatal Pulmonary Hemorrhage, AE","C155212","An adverse event in a newborn characterized by limited hemorrhagic secretion in an endotracheal (ET) tube.","Grade 1 Neonatal Pulmonary Hemorrhage, AE | Grade 1 Neonatal Pulmonary Hemorrhage | Grade 1 Neonatal Pulmonary Hemorrhage, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555719","Grade 2 Neonatal Pulmonary Hemorrhage, AE","C155213","An adverse event in a newborn characterized by hemorrhagic secretion in an endotracheal (ET) tube; without relevant increase in partial pressure of carbon dioxide (pCO2) or decrease in oxygenation; requiring minor changes in care (e.g. increase in positive end-expiration pressure (PEEP)).","Grade 2 Neonatal Pulmonary Hemorrhage, AE | Grade 2 Neonatal Pulmonary Hemorrhage | Grade 2 Neonatal Pulmonary Hemorrhage, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555724","Grade 3 Neonatal Pulmonary Hemorrhage, AE","C155214","An adverse event in a newborn characterized by hemorrhagic secretion in an endotracheal (ET) tube; with relevant increase in partial pressure of carbon dioxide (pCO2) or decrease in oxygenation; requiring major change in ventilatory support or transfusion.","Grade 3 Neonatal Pulmonary Hemorrhage, AE | Grade 3 Neonatal Pulmonary Hemorrhage | Grade 3 Neonatal Pulmonary Hemorrhage, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555722","Grade 5 Neonatal Pulmonary Hemorrhage, AE","C155216","A pulmonary hemorrhage adverse event in a newborn which results in death.","Grade 5 Neonatal Pulmonary Hemorrhage, AE | Grade 5 Neonatal Pulmonary Hemorrhage | Grade 5 Neonatal Pulmonary Hemorrhage, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555728","Grade 2 Persistent Pulmonary Hypertension of the Newborn, AE","C155218","An adverse event in a newborn characterized by increased estimated right ventricular pressures; with moderate clinical symptoms; oxygenation index less than 25; minor care changes required.","Grade 2 Persistent Pulmonary Hypertension of the Newborn, AE | Grade 2 PPHN, AE | Grade 2 Persistent Pulmonary Hypertension of the Newborn | Grade 2 Persistent Pulmonary Hypertension of the Newborn, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555729","Grade 3 Persistent Pulmonary Hypertension of the Newborn, AE","C155219","An adverse event in a newborn characterized by Increased estimated right ventricular pressures; with severe clinical symptoms; oxygenation index greater than 25; major care changes required (e.g. inhaled nitric oxide (iNO)).","Grade 3 Persistent Pulmonary Hypertension of the Newborn, AE | Grade 3 PPHN, AE | Grade 3 Persistent Pulmonary Hypertension of the Newborn | Grade 3 Persistent Pulmonary Hypertension of the Newborn, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555283","BPI 7711","C154286","An orally available third-generation and selective inhibitor of certain epidermal growth factor receptor (EGFR) activating mutations, including the resistance mutations T790M and L858R, as well as exon 19 deletion, with potential antineoplastic activity. Upon administration, rezivertinib specifically and covalently binds to and inhibits selective EGFR mutations, with particularly high selectivity against the T790M mutation, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Compared to some other EGFR inhibitors, BPI-7711 may have therapeutic benefits in tumors with T790M-mediated drug resistance. This agent shows minimal activity against wild-type EGFR (wt EGFR), and does not cause dose-limiting toxicities that occur during the use of non-selective EGFR inhibitors, which also inhibit wt EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.","Rezivertinib | BPI 7711 | BPI-7711 | BPI7711 | EGFR Mutant-specific Inhibitor BPI-7711 | REZIVERTINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0253788","C-myb Antisense Oligonucleotide G4460","C1541","A 24-base phosphorothiolate antisense oligodeoxynucleotide (ODN) for the proto-oncogene c-myb with potential antineoplastic activity. C-myb antisense oligonucleotide G4460 binds to codon sequences 2 to 9 of c-myb mRNA, inhibiting translation of the transcript. Suppression of c-myb expression with this agent may result in the restoration of normal differentiation pathways, increased antiproliferative effects, and the induction of apoptosis in early progenitor hematopoietic cells and in tumor cells that overexpress c-myb. Tumor-cell overexpression of c-myb blocks differentiation, promotes proliferation, and inhibits apoptosis.","C-myb Antisense Oligonucleotide G4460 | G4460 | INX-3001 | LR-3001 | OL(1)p53 | c-MYB Antisense | c-MYB Antisense Oligodeoxynucleotide | c-Myb Antisense OND | c-Myb LR-3001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0043354","Xhosa Language","C154200","A Niger-Congo Bantu language spoken as an official language in South Africa and Zimbabwe.","Xhosa Language | XHO | Xhosa",,,,,,,,,,,,,,,"4180355","Xhosa language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555152","Yao Language","C154201","A Niger-Congo Bantu language spoken mainly in Malawi, Tanzania, and Mozambique.","Yao Language | YAO | Yao",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574390","Yapese Language","C154202","An Austronesian language spoken by the people on the island of Yap, Federated States of Micronesia.","Yapese Language | YAP | Yapese",,,,,,,,,,,,,,,"4180220","Yapese language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043412","Yiddish Language","C154203","A High German-based vernacular fused with elements taken from Hebrew and Aramaic as well as from Slavic languages and traces of Romance languages.","Yiddish Language | YID | Yiddish",,,,,,,,,,,,,,,"4181531","Yiddish language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574509","Yoruba Language","C154204","A Niger-Congo language spoken in West Africa.","Yoruba Language | YOR | Yoruba",,,,,,,,,,,,,,,"4183798","Yoruba language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574578","Zapotec Language","C154205","A group of around 50 closely related indigenous Mesoamerican languages spoken by the Zapotec people from the southwestern-central highlands of Mexico.","Zapotec Language | ZAP | Zapotec",,,,,,,,,,,,,,,"4182821","Zapotec language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555154","Standard Moroccan Berber Language","C154207","The standardized national variety of Berber spoken in Morocco.","Standard Moroccan Berber Language | Standard Moroccan Berber | Standard Moroccan Tamazight | ZGH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574665","Zhuang Language","C154208","Any of more than a dozen Tai languages spoken by the Zhuang people of southern China in the province of Guangxi and adjacent parts of Yunnan and Guangdong.","Zhuang Language | Chuang | ZHA | Zhuang",,,,,,,,,,,,,,,"4177466","Chuang language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0376254","Zulu Language","C154209","A Niger-Congo Bantu language spoken by the Zulu people of South Africa.","Zulu Language | ZUL | Zulu",,,,,,,,,,,,,,,"4181699","Zulu language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556417","Drug Delivery System Category","C154465","A type of pharmaceutical dose form consisting of one or more components that are used to deliver active substance(s) in a specified manner, usually with a modified release mechanism, after administration to a specified location on or in the body; to be used only where more specific terms are not applicable.","Drug Delivery System Category | System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555393","Emulsion Dosage Form Category","C154466","A type of liquid pharmaceutical dose form consisting of a stable dispersion of non-miscible liquids; it consists either of oil droplets in an aqueous continuous phase (oil-in-water emulsion) or aqueous droplets in an oily continuous phase (water-in-oil emulsion); for colloidal dispersions (droplets with a nominal diameter less than approximately 1 micrometre in size), see 'Dispersion'.","Emulsion Dosage Form Category | Emulsion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562649","Film Dosage Form Category","C154467","A type of solid pharmaceutical dose form consisting of a thin, single- or multilayer sheet of material, which usually dissolves or otherwise dissipates in an aqueous environment.","Film Dosage Form Category | Film",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556513","Gel Dosage Form Category","C154468","A type of semi-solid pharmaceutical dose form consisting of a colloidal dispersion of a liquid in a solid; lipophilic gels (oleogels) usually consist of liquid paraffin with polyethylene or fatty oils gelled with colloidal silica or aluminium or zinc soaps; hydrophilic gels (hydrogels) usually consists of water, glycerol or propylene glycol gelled with suitable gelling agents such as poloxamers, starch, cellulose derivatives, carbomers and magnesium-aluminium silicates.","Gel Dosage Form Category | Gel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555909","Grade 5 Neonatal Culture Positive Sepsis, AE","C155271","A culture positive sepsis adverse event in a newborn which results in death.","Grade 5 Neonatal Culture Positive Sepsis, AE | Grade 5 Culture Positive Neonatal Sepsis | Grade 5 Neonatal Culture Positive Sepsis, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555907","Grade 2 Neonatal Rash, AE","C155273","An adverse event in a newborn characterized by diffuse rash or target lesions.","Grade 2 Neonatal Rash, AE | Grade 2 Neonatal Rash, Adverse Event | Grade 2 Rash Neonatal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555912","Grade 3 Neonatal Rash, AE","C155274","An adverse event in a newborn characterized by diffuse rash and vesicles or limited number of bullae or superficial ulcerations of mucous membranes limited to one site.","Grade 3 Neonatal Rash, AE | Grade 3 Neonatal Rash, Adverse Event | Grade 3 Rash Neonatal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555913","Grade 4 Neonatal Rash, AE","C155275","An adverse event in a newborn characterized by extensive or generalized bullous lesions or ulceration of mucous membranes involving two or more distinct mucosal sites or Stevens-Johnson syndrome or toxic epidermal necrosis.","Grade 4 Neonatal Rash, AE | Grade 4 Neonatal Rash, Adverse Event | Grade 4 Rash Neonatal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555910","Grade 5 Neonatal Rash, AE","C155276","A rash adverse event in a newborn which results in death.","Grade 5 Neonatal Rash, AE | Grade 5 Neonatal Rash, Adverse Event | Grade 5 Rash Neonatal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555911","Grade 1 Neonatal Administration Site Complication, AE","C155277","An administration site complication adverse event in a newborn characterized by painless edema.","Grade 1 Neonatal Administration Site Complication, AE | Grade 1 Administration Site Complication Neonatal | Grade 1 Neonatal Administration Site Complication, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555916","Grade 2 Neonatal Administration Site Complication, AE","C155278","An administration site complication adverse event in a newborn characterized by erythema with associated symptoms (e.g., edema, pain, induration, phlebitis).","Grade 2 Neonatal Administration Site Complication, AE | Grade 2 Administration Site Complication Neonatal | Grade 2 Neonatal Administration Site Complication, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555224","Near Infrared Imaging Agent HS-196","C154332","An imaging agent containing a human heat shock protein 90 (Hsp90) inhibitor connected by a linker to a near infrared (NIR) fluorescent dye. Upon intravenous administration, HS-196 selectively and competitively binds to Hsp90 in cells. As Hsp90 is upregulated in a variety of tumor cells, the accumulation of the NIR-tethered imaging agent allows for in vivo detection due to enhanced uptake of HS-196. Hsp90 is a molecular chaperone that plays a key role in the conformational maturation, stability and function of oncogenic signaling proteins, such as HER2/ERBB2, AKT, RAF1, BCR-ABL and mutated p53, as well as many other molecules that are important in cell cycle regulation and/or immune responses.","Near Infrared Imaging Agent HS-196 | HS 196 | HS-196 | HS196 | HSP90 Inhibitor-linked NIR Probe HS-196 | NIR-tethered Hsp90 Inhibitor HS-196",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555223","Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified","C154333","The reemergence of peripheral T-cell lymphoma, not otherwise specified after a period of remission.","Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555227","MGMT-Methylated Glioblastoma","C154335","A glioblastoma characterized by the presence of DNA methylation in the promoter region of the MGMT gene. It is associated with improved survival.","MGMT-Methylated Glioblastoma | Methylated MGMT Glioblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555225","Neoplastic Corticotroph Cell with Abundant Secretory Granules","C154337","A neoplastic basophilic PAS-positive and ACTH-positive cell with an abundance of secretory granules seen at the ultrastructural level.","Neoplastic Corticotroph Cell with Abundant Secretory Granules | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555226","Neoplastic Corticotroph Cell with Scarce Secretory Granules","C154338","A neoplastic faintly basophilic or chromophobic PAS-positive and weakly ACTH-positive cell with scant and small secretory granules seen at the ultrastructural level.","Neoplastic Corticotroph Cell with Scarce Secretory Granules | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555230","Densely Granulated Corticotroph Pituitary Neuroendocrine Tumor","C154339","A corticotroph pituitary neuroendocrine tumor composed of basophilic PAS-positive cells that are diffusely and strongly positive for ACTH, consistent with the abundance of secretory granules seen at the ultrastructural level. (WHO)","Densely Granulated Corticotroph Pituitary Neuroendocrine Tumor | Densely Granulated Corticotroph Adenoma | Densely Granulated Corticotroph PitNET/Adenoma | Densely Granulated Corticotroph Pituitary Neuroendocrine Tumor/Adenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279035","Nausea and Vomiting Therapy","C15473","No value exists.","Nausea and Vomiting Therapy | antiemetic support | management of nausea and vomiting | nausea and vomiting management | vomiting and nausea management",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555289","Autologous NY-ESO-1-redirected CRISPR-edited T Cells","C154288","A preparation of human autologous T-lymphocytes that are transduced with a lentiviral vector (LV) encoding a T-cell receptor (TCR) specific for the tumor-associated antigen (TAA) cancer-testis antigen NY-ESO-1 and gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to eliminate endogenous TCR and programmed cell death 1 (PD-1) expression, with potential immunostimulating and antineoplastic activities. The CRISPR guide RNA (gRNA) specifically targets and binds to complementary sites on TCRalpha, TCRbeta and PD-1. In turn, Cas9 cleaves these specific DNA sites, thereby disrupting transcription. Upon isolation, transduction, electroporation with TCRalpha, TCRbeta and PD-1 gRNAs which are complexed to Cas9 RNA to disrupt expression of endogenous TCRalpha, TCRbeta and PD-1, expansion ex vivo, and reintroduction into the patient, the anti-NY-ESO-1 TCR LV-transduced CRISPR-edited autologous T-cells recognize and bind to NY-ESO-1-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of NY-ESO-1-positive tumor cells. NY-ESO-1, a tumor-associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types, and is not, or is minimally, expressed in normal, healthy cells. PD-1, an immune checkpoint receptor expressed on T-cells, plays a key role in tumor immune evasion by binding to its ligand programmed cell death ligand 1 (PD-L1) expressed on tumor cells. By removing PD-1 from T-cells, PD-1-mediated signaling is halted which may decrease T-cell exhaustion and may enhance T-cell activity against the NY-ESO-1-expressing tumor cells. Removal of endogenous TCR reduces TCR competition for expression, increases the persistence and function of the expressed transgenic TCR, enhances resistance to T-cell exhaustion and increases T-cell activity.","Autologous NY-ESO-1-redirected CRISPR-edited T Cells | Autologous NY-ESO-1 TCR-expressing CRISPR-edited (TCR and PD-1) T Cells | Autologous NY-ESO-1 Transgenic TCR-expressing Endogenous TCR-PD-1 Gene-edited T-cells | Autologous NYCE Cells | Autologous NYCE T Cells | Autologous NYCE T-cells | NY-ESO-1 TCR-PD-1-CRISPR-gene-edited Autologous T-lymphocytes | NY-ESO-1-redirected Autologous T Cells with CRISPR Edited Endogenous TCR and PD-1 | NY-ESO-1-redirected Autologous T-cells with CRISPR-edited Endogenous TCR and PD-1 | NY-ESO-1-redirected CRISPR Edited T Cells | NY-ESO-1-redirected CRISPR-TCRendo/PD1-edited T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555290","Coffea arabica Extract","C154289","An orally bioavailable dietary supplement composed of an extract from the beans of green coffee (Coffea arabica), which are unprocessed and unroasted, with potential anti-inflammatory, antioxidant and chemopreventive activities. Coffea arabica extract contain high amounts of phenolic compounds and their derivatives, such as chlorogenic acid (CGA), and alkaloids, such as caffeine. As many of the active components in the Coffea arabica are antioxidant compounds, upon administration, they scavenge free radicals, protect against oxidation of low-density lipoprotein (LDL), and inhibit cell damage due to reactive oxygen species (ROS). This inhibits oxidative stress and protects against DNA damage. The components in the extract also inhibit enzymes involved in inflammation, cell replication and DNA synthesis, and induce the expression of antioxidant enzymes. They also induce anti-inflammatory-mediated pathways, decrease nuclear factor Kappa-B (NF-kB) activation and decrease the expression of pro-inflammatory cytokines. This may inhibit growth and induce apoptosis of cancer cells. In addition, Coffea arabica extract upregulates the expression of anti-inflammatory adipokines (adipocytokines), such as adiponectin, and reduces the expression of pro-inflammatory adipokines, such as tumor necrosis factor-alpha (TNF-a), leptin and interleukin 6 (IL-6), thereby further preventing inflammation and inflammation-induced cancer. Adipokines are normally secreted by adipose tissue and play a key role in the regulation of glucose and fat metabolism, insulin sensitivity and inflammation.","Coffea arabica Extract | Coffee Bean Extract | Green Coffee Bean Extract | Green Coffee Beans Extract",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242479","Interdisciplinary Research","C15428","Studies that bring together multiple scientific disciplines to address specific issues.","Interdisciplinary Research | Interdisciplinary Studies | Multidisciplinary Collaboration | Multidisciplinary Research",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555287","Somatostatin Antagonist","C154290","Any agent that binds to and antagonizes somatostatin receptors.","Somatostatin Antagonist | Somatostatin Receptor Antagonist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555360","PD-L1/PD-L2 Peptide-Montanide Vaccine","C154564","A vaccine composed of peptides derived from the immune checkpoint molecules, programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2), combined with the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Vaccination with PD-L1/PD-L2 peptide-montanide vaccine may stimulate an immune response against PD-L1 and PD-L2 expressing cells. This may enhance T-cell proliferation, cytokine production, and T-cell mediated cytolysis. Binding of programmed cell death protein 1 (PD-1; PDCD1; CD279) by its ligands, PD-L1 and PD-L2, results in downregulation of T-cell responses and enhanced immune evasion. Montanide ISA-51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens.","PD-L1/PD-L2 Peptide-Montanide Vaccine | PD-L1/PD-L2 Peptide Plus Montanide ISA-51 Vaccine | PD-L1/PD-L2 Peptide Plus Montanide Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510810","Adjuvant Study","C15446","A study performed secondary to and in support of a primary or base study in order to support, enhance, or expand upon its results or findings.","Adjuvant Study | Adjuvant Protocol | Adjuvant Trial | Adjuvant Trials",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555392","Vascular-Targeted Photodynamic Therapy","C154471","A type of photodynamic therapy for localized treatment of tumors. It makes use of photosensitizers that are limited to the vascular bed and are rapidly cleared from the circulation.","Vascular-Targeted Photodynamic Therapy | VTP | Vascular Targeted Photodynamic Therapy | Vascular Targeted Phototherapy | Vascular-Targeted Phototherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555394","ExoDx Prostate Intelliscore","C154472","A proprietary non-invasive, urine-based, liquid biopsy for high-grade prostate cancer. It uses an exosomal RNA (exoRNA)-based assay.","ExoDx Prostate Intelliscore | ExoDx Prostate (IntelliScore) | Intelliscore | Prostate Intelliscore",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555395","Melanoma of Unknown Primary","C154473","A melanoma which has metastasized from an unknown primary anatomic site.","Melanoma of Unknown Primary | Melanoma of Unknown Primary Origin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556867","Granule Dosage Form Category","C154480","A type of solid pharmaceutical dose form consisting of dry aggregates of powder particles that are sufficiently resistant to withstand handling.","Granule Dosage Form Category | Granules",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL759918","Ribociclib/Letrozole","C154675","An orally available co-packaged agent combination of the succinate salt form of ribociclib, a cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6, and letrozole, a nonsteroidal inhibitor of estrogen synthesis, with antineoplastic activity. Upon oral administration, ribociclib specifically inhibits CDK4 and CDK6, thereby inhibiting retinoblastoma (Rb) phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Letrozole selectively and reversibly inhibits aromatase, which may result in growth inhibition of estrogen-dependent cancer cells.","Ribociclib/Letrozole | Kisqali Femara Co-pack | Kisqali and Femara Co-pack | Kisqali/Femara | Ribociclib + Letrozole | Ribociclib Plus Letrozole | Ribociclib Succinate/Letrozole | Ribociclib and Letrozole Co-pack | Ribociclib-Letrozole | Ribociclib-Letrozole Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555231","Sparsely Granulated Corticotroph Pituitary Neuroendocrine Tumor","C154340","A corticotroph pituitary neuroendocrine tumor composed of faintly basophilic or chromophobic PAS-positive cells with weak or patchy positivity for ACTH, consistent with the scant, small secretory granules seen ultrastructurally. (WHO)","Sparsely Granulated Corticotroph Pituitary Neuroendocrine Tumor | Sparsely Granulated Corticotroph Adenoma | Sparsely Granulated Corticotroph PitNET/Adenoma | Sparsely Granulated Corticotroph Pituitary Neuroendocrine Tumor/Adenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555228","Crooke Hyaline Change","C154341","Intracytoplasmic accumulation of cytokeratin.","Crooke Hyaline Change | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555229","Crooke Cell Tumor","C154342","A corticotroph pituitary tumor composed of cells with Crooke hyaline change. Ring-like cytokeratin expression is typical of these neoplasms. ACTH expression is dislocated to the cell periphery and juxtanuclear region. Ultrastructurally, intermediate filaments are arranged in a ring-like pattern. (WHO)","Crooke Cell Tumor | Crooke Cell Adenoma | Crooke Cell Adenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0242804","Technology Transfer","C15434","The process of converting scientific findings from research laboratories into useful products by the commercial sector.","Technology Transfer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0259788","Transfer Factor Therapy","C15435","No value exists.","Transfer Factor Therapy | therapy, transfer factor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513305","Mind-Body Intervention Procedure","C15436","No value exists.","Mind-Body Intervention Procedure | Mind-Body Interventions | Mind-Body Medicine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518492","Nutrition, Food and Water Contaminants","C15437","Role of food and water contaminants in cancer causation or prevention and in general health.","Nutrition, Food and Water Contaminants | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555235","Gallium Ga 68-NeoB","C154381","A radioconjugate consisting of the gastrin-releasing peptide receptor (GRPR) antagonist, NeoBOMB1, linked via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope gallium Ga 68, with potential imaging activity during positron emission topography/computed tomography (PET/CT). Upon administration, gallium Ga 68-DOTA-NeoBOMB1 binds to GRPRs present on cancer cells. Upon binding, this radioconjugate can be used to quantify tumor uptake of NeoBOMB1 using PET/CT. GRPR, also known as bombesin receptor subtype 2, is a G-protein-coupled receptor that is overexpressed in some cancer types.","Gallium Ga 68-NeoB | 68Ga-NeoB | Gallium Ga 68 DOTA-NeoBOMB1 | Gallium Ga 68 NeoBOMB1 | [68Ga]-NeoB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1849140","Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay","C154614","An autosomal recessive condition caused by mutation(s) in the SACS gene, encoding sacsin. It is characterized by  early onset cerebellar ataxia, pyramidal tract signs and peripheral neuropathy.","Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay | ARSACS | SPAX6 | Spastic Ataxia 6",,,,,,,,,,,,,,,"45765494","Autosomal recessive spastic ataxia of Charlevoix-Saguenay",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555504","Leukocyte Adhesion Deficiency Type 3","C154615","An autosomal recessive condition caused by mutation(s) in the FERMT3 gene, encoding fermitin family homolog 3. It is characterized by a defect in activation of all beta integrins. It manifests clinically as severe infections with marked leukocytosis, accompanied by life-threatening bleeding episodes.","Leukocyte Adhesion Deficiency Type 3 | LAD-3 | LAD-III",,,,,,,,,,,,,,,"37167986","Leukocyte adhesion deficiency type III",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555509","Digestive System Large Cell Neuroendocrine Carcinoma","C154617","An aggressive high-grade carcinoma with neuroendocrine differentiation that arises from the digestive system and is composed of malignant large cells. The mitotic count is more than 20 per 2 mm2 and/or the Ki-67 index is more than 20% (often more than 70%).","Digestive System Large Cell Neuroendocrine Carcinoma | Gastrointestinal System Large Cell Neuroendocrine Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3281029","Lethal Neonatal Rigidity and Multifocal Seizure Syndrome","C154618","No value exists.","Lethal Neonatal Rigidity and Multifocal Seizure Syndrome | RMFSL",,,,,,,,,,,,,,,"37162794","Lethal neonatal spasticity, epileptic encephalopathy syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555507","Prior Invasive Malignancy","C154619","A finding indicating the presence of a previously diagnosed invasive malignant neoplasm.","Prior Invasive Malignancy | Prior Invasive Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555508","Prior Invasive Malignancy of Other Sites","C154620","A finding indicating the presence of a previously diagnosed malignant neoplasm infiltrating other, non-specified anatomic sites.","Prior Invasive Malignancy of Other Sites | Prior Invasive Cancer of Other Sites",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555795","Grade 5 Neonatal Hypotension, AE","C155161","A hypotensive adverse event in a newborn which results in death.","Grade 5 Neonatal Hypotension, AE | Grade 5 Neonatal Hypotension | Grade 5 Neonatal Hypotension, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555800","Grade 1 Neonatal Hypertension","C155162","An adverse event in a newborn characterized by systolic or diastolic blood pressure above the 90th percentile but below the 95th percentile; self-limiting.","Grade 1 Neonatal Hypertension, AE | Grade 1 Neonatal Hypertension | Grade 1 Neonatal Hypertension, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555801","Grade 2 Neonatal Hypertension, AE","C155163","An adverse event in a newborn characterized by persistent or recurrent hypertension, with systolic or diastolic blood pressure between the 95th percentile and the 99th percentile.","Grade 2 Neonatal Hypertension, AE | Grade 2 Neonatal Hypertension | Grade 2 Neonatal Hypertension, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555798","Grade 3 Neonatal Hypertension, AE","C155164","An adverse event in a newborn characterized by persistent or recurrent hypertension, with systolic or diastolic blood pressure above the 99th percentile; need for antihypertensive medication.","Grade 3 Neonatal Hypertension, AE | Grade 3 Neonatal Hypertension | Grade 3 Neonatal Hypertension, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555799","Grade 4 Neonatal Hypertension, AE","C155165","A hypertensive adverse event in a newborn characterized by life-threatening consequences (e.g. malignant hypertension: shock, cardiac failure or neonatal encephalopathy).","Grade 4 Neonatal Hypertension, AE | Grade 4 Neonatal Hypertension | Grade 4 Neonatal Hypertension, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555804","Grade 5 Neonatal Hypertension, AE","C155166","A hypertensive adverse event in a newborn which results in death.","Grade 5 Neonatal Hypertension, AE | Grade 5 Neonatal Hypertension | Grade 5 Neonatal Hypertension, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555805","Grade 1 Neonatal Sinus Tachycardia, AE","C155167","An adverse event in a newborn characterized by brief, self-limiting, episodes of sinus tachycardia; no care changes.","Grade 1 Neonatal Sinus Tachycardia, AE | Grade 1 Neonatal Sinus Tachycardia | Grade 1 Neonatal Sinus Tachycardia, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555802","Grade 2 Neonatal Sinus Tachycardia, AE","C155168","An adverse event in a newborn characterized by persistent sinus tachycardia; no change in age appropriate behavior; requiring minor care changes (e.g. concomitant medication changed).","Grade 2 Neonatal Sinus Tachycardia, AE | Grade 2 Neonatal Sinus Tachycardia | Grade 2 Neonatal Sinus Tachycardia, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555803","Grade 3 Neonatal Sinus Tachycardia, AE","C155169","An adverse event in a newborn characterized by persistent sinus tachycardia; resulting in non-life threatening hemodynamic compromise; requiring major care changes (e.g. new medication or intervention).","Grade 3 Neonatal Sinus Tachycardia, AE | Grade 3 Neonatal Sinus Tachycardia | Grade 3 Neonatal Sinus Tachycardia, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280429","Fertility Assessment and Management","C15516","Evaluations used to determine reproductive status and potential, and the treatments that will be required to maintain a pregnancy.","Fertility Assessment and Management | fertility management/assessment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555808","Grade 4 Neonatal Sinus Tachycardia, AE","C155170","A sinus tachycardia adverse event in a newborn characterized by life-threatening consequences; requiring urgent major care changes.","Grade 4 Neonatal Sinus Tachycardia, AE | Grade 4 Neonatal Sinus Tachycardia | Grade 4 Neonatal Sinus Tachycardia, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555357","Autologous TBX-4000-treated Peripheral Blood Mononuclear Cells TBX-3400","C154565","An autologous cell preparation in which the autologous peripheral blood mononuclear cells (PBMCs) are treated ex vivo with TBX-4000, a recombinant TAT-MYC fusion protein, with potential antineoplastic and immunomodulating activities. Upon reintroduction of the TBX-3400 cells into the patient, the generated T-cells may activate the immune system and exert a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. The TBX-4000 recombinant fusion protein consists of the N-terminal 9 amino acid segment of the HIV TAT protein transduction domain (PTD) fused to the MYC protein. TBX-4000 TAT-MYC rapidly localizes to the nucleus and transiently provides signals to drive proliferation and survival of T-cells.","Autologous TBX-4000-treated Peripheral Blood Mononuclear Cells TBX-3400 | Autologous PBMCs TBX-3400 | Autologous TBX-4000-treated Human PBMCs | TBX 3400 | TBX-3400 | TBX-3400 Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555358","Gallium Ga 68-NOTA-Sgc8","C154566","A radioconjugate containing a derivative of the androgen testosterone, 16-beta-fluoro-5-alpha-dihydrotestosterone (FDHT), labeled with the radioisotope fluorine F18 (18F-FDHT), with potential use as an imaging agent for positron emission tomography (PET). Upon administration, 18F-FDHT binds to the androgen receptor (AR). Upon PET imaging, AR-expressing prostate tumor cells can be imaged and assessed.","Gallium Ga 68-NOTA-Sgc8 | 68Ga Labeled ssDNA Aptamer Sgc8 | 68Ga-Sgc8 | [68Ga]-Sgc8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555363","maimendongtang","C154567","A traditional East Asian herbal medicine composed of six herbs, including Ophiopogonis tuber, Pinelliae tuber, Glycyrrhizae radix, Zizyphi fructus, Ginseng radix, and Oryzae semen, with potential anti-tussive activity. Maekmoondong-tang is traditionally prescribed for respiratory symptoms to direct the qi downwards and compensate for lung-yin deficiency or dry lung by tonifying yin and moistening the lung. Although the exact mechanisms through which Maekmoondong-tang exerts its effects have yet to be fully elucidated, this agent may, upon administration, improve the severity of chronic cough, reduce airway hyper-responsiveness possibly by reducing the cough reflex and bronchodilation, and airway inflammation possibly through anti-inflammatory and immunomodulatory effects.","Maekmoondong-tang | Bakumondo-to | MMDT | Maekgeuron Granules | Mai-men-dong-tang | Ophiopogonis tuber/Pinelliae tuber/Glycyrrhizae radix/Zizyphi fructus/Ginseng radix/Oryzae semen Herbal Formulation | TJ-29",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555364","Genetically-modified Anti-HER2-CAR-CD28zeta-expressing Allogeneic NK-92/5.28.z Cells","C154568","A preparation of genetically-modified natural killer (NK) cells derived from the allogeneic NK-92 cell line that are transduced with a lentiviral vector expressing a codon-optimized chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) of the anti-human epidermal growth factor 2 (HER2; ErbB2) monoclonal antibody FRP5, and fused, via hinge and transmembrane regions, to the intracellular domain of the costimulatory molecule CD28, and the intracellular signaling domain of the T-cell antigen receptor complex zeta chain (CD3-zeta), with potential cytolytic, immunomodulating and antineoplastic activities. Upon infusion of the genetically modified anti-HER2-CAR-CD28zeta-expressing allogeneic NK-92/5.28.z cells, the NK cells recognize and bind to HER2 expressed on tumor cells. This leads to the secretion and release of perforins, granzymes, cytokines and chemokines, which results in selective tumor cell lysis in HER2-expressing tumor cells. HER2, a receptor tyrosine kinase (RTK) mutated or overexpressed in many tumor cell types, plays a significant role in tumor cell proliferation and tumor vascularization. The NK-92 cells are derived from a human cytotoxic cell line composed of allogeneic, activated, interleukin-2-(IL-2) dependent-NK cells from a 50-year old male patient with rapidly progressive non-Hodgkin's lymphoma. As NK-92 cells are devoid of killer inhibitory receptors (KIRs; also called killer cell immunoglobulin-like receptors), which are negative regulators of NK cell activity, cancer cells are unable to suppress the cancer cell killing ability of the NK-92 cells.","Genetically-modified Anti-HER2-CAR-CD28zeta-expressing Allogeneic NK-92/5.28.z Cells | Anti-HER2-CAR-CD28zeta NK-92 Cells | Anti-HER2-CAR-engineered NK-92/5.28.z Cells | HER2.taNK | HER2.taNK Cells | NK-92/5.28.z | NK-92/5.28.z Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0717752","Esterified Estrogens","C154677","A mixture of the sodium salts of the sulfate esters of estrogen including sodium estrone sulfate, sodium equilin sulfate and the concomitant component, 17 alpha-estradiol, that is used for estrogen replacement. Estrogens bind to nuclear receptors in estrogen-responsive tissues and modulate the secretion of the gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), stimulate skeletal growth, and have a widespread effect on metabolic processes including protein transport and electrolyte balance.","Esterified Estrogens | ESTROGENS, ESTERIFIED | Estrogens, Esterified | Menest (BR)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279028","Ablative Endocrine Surgery","C15467","Destructive or removal of any part of the endocrine system by surgical means, including the use of lasers or electrical current.","Ablative Endocrine Surgery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555455","CDISC Protocol Entities Protocol Contact Role Response Terminology","C154681","Terminology associated with the protocol contact role response codelist of the Clinical Data Interchange Standards Consortium (CDISC) protocol entities.","CDISC Protocol Entities Protocol Contact Role Response Terminology | PROT-PROTCRRS | Protocol Contact Role Value Set",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555460","CDISC Protocol Entities Study Contact Information Attribute Terminology","C154682","Terminology associated with the protocol entity study contact information attribute codelist of the Clinical Data Interchange Standards Consortium (CDISC).","CDISC Protocol Entities Study Contact Information Attribute Terminology | PROT-Att Study Contact Information | Study Contact Information Attribute Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555458","CDISC SEND Planned Pharmacologic Target Mode of Action Response Terminology","C154684","Terminology associated with the planned pharmacologic target mode of action response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).","CDISC SEND Planned Pharmacologic Target Mode of Action Response Terminology | PPTMDARS | Planned Pharmacologic Target Mode of Action Response | SEND-PPTMDARS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555459","CDISC SDTM Nutrition Findings About Test Code Terminology","C154685","Terminology associated with the nutrition findings about test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Nutrition Findings About Test Code Terminology | NTFATSCD | Nutrition Findings About Test Code | SDTM-NTFATSCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555464","CDISC SDTM Nutrition Findings About Test Name Terminology","C154686","Terminology associated with the nutrition findings about test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Nutrition Findings About Test Name Terminology | NTFATS | Nutrition Findings About Test Name | SDTM-NTFATS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555465","CDISC SDTM Lung Cancer Findings About Test Code Terminology","C154687","Terminology associated with the lung cancer findings about test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Lung Cancer Findings About Test Code Terminology | LUFATSCD | Lung Cancer Findings About Test Code | SDTM-LUFATSCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555462","CDISC SDTM Lung Cancer Findings About Test Name Terminology","C154688","Terminology associated with the lung cancer findings about test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Lung Cancer Findings About Test Name Terminology | LUFATS | Lung Cancer Findings About Test Name | SDTM-LUFATS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555463","Sexual Contact","C154689","Sexual interaction between individuals.","Sexual Contact | SEXUAL CONTACT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279029","Depigmentation Therapy","C15468","No value exists.","Depigmentation Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555468","Main Pancreatic and Accessory Ducts","C154699","Any of the ducts that conveys pancreatic secretions from the pancreas to the duodenum.","Main Pancreatic and Accessory Ducts | DUCT, PANCREATIC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555511","Advanced Well Differentiated Neuroendocrine Neoplasm","C154621","A neuroendocrine tumor that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Neuroendocrine Tumor | Advanced Carcinoid Tumor | Advanced Well Differentiated Neuroendocrine Neoplasm | Advanced Well Differentiated Neuroendocrine Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0863168","Recurrent Gastric Adenocarcinoma","C154622","The reemergence of gastric adenocarcinoma after a period of remission.","Recurrent Gastric Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555512","Daromun","C154627","A combination of darleukin (L19-IL2), an immunocytokine consisting of the recombinant form of interleukin-2 (IL-2), fused to a human single-chain variable fragment (scFv) directed against the extra-domain B (ED-B) of fibronectin (L19), and fibromun (L19-TNFalpha), an immunocytokine consisting of human tumor necrosis factor alpha (TNFalpha) fused to a human scFv antibody fragment directed against the ED-B of L19, with potential antineoplastic and immunostimulating activities. Upon administration, the L-19 moieties of each immunocytokine bind to the ED-B domain of fibronectin on tumor cells in the tumor neovasculature. In turn, the IL-2 and TNF-alpha moieties of darleukin and fibromun, respectively, may locally induce an immune response against ED-B fibronectin-expressing tumor cells. ED-B is predominantly expressed during angiogenesis and tumor growth.","Daromun | Darleukin and Fibromun | Darleukin/Fibromun | L19-IL2 and L19-TNF-alpha | L19-IL2/L19-TNF-alpha | L19IL2/L19TNF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279022","In Vitro-Treated Bone Marrow Transplantation","C15462","No value exists.","In Vitro-Treated Bone Marrow Transplantation | antibody treated bone marrow transplant | antibody treated bone marrow transplantation | in vitro-treated bone marrow transplant | monoclonal antibody treated bone marrow transplant | monoclonal antibody treated bone marrow transplantation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279532","Drug Modulation","C15488","No value exists.","Drug Modulation | modulation, drug",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555806","Grade 1 Neonatal Sinus Bradycardia, AE","C155172","An adverse event in a newborn characterized by brief, self-limiting, episodes of sinus bradycardia; no care changes.","Grade 1 Neonatal Sinus Bradycardia, AE | Grade 1 Neonatal Sinus Bradycardia | Grade 1 Neonatal Sinus Bradycardia, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555807","Grade 2 Neonatal Sinus Bradycardia, AE","C155173","An adverse event in a newborn characterized by persistent sinus bradycardia; no change in age-appropriate behavior; requiring minor care changes (e.g. concomitant medication adapted, intermittent increase of fraction of inspired oxygen (FiO2)).","Grade 2 Neonatal Sinus Bradycardia, AE | Grade 2 Neonatal Sinus Bradycardia | Grade 2 Neonatal Sinus Bradycardia, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555812","Grade 3 Neonatal Sinus Bradycardia, AE","C155174","An adverse event in a newborn characterized by persistent sinus bradycardia; resulting in non-life threatening hemodynamic compromise; requiring major care changes (e.g. new medication or intervention).","Grade 3 Neonatal Sinus Bradycardia, AE | Grade 3 Neonatal Sinus Bradycardia | Grade 3 Neonatal Sinus Bradycardia, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555813","Grade 4 Neonatal Sinus Bradycardia, AE","C155175","A sinus bradycardia adverse event in a newborn characterized by life-threatening consequences (e.g. shock); requiring urgent major care changes.","Grade 4 Neonatal Sinus Bradycardia, AE | Grade 4 Neonatal Sinus Bradycardia | Grade 4 Neonatal Sinus Bradycardia, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555810","Grade 5 Neonatal Sinus Bradycardia, AE","C155176","A sinus bradycardia adverse event in a newborn which results in death.","Grade 5 Neonatal Sinus Bradycardia, AE | Grade 5 Neonatal Sinus Bradycardia | Grade 5 Neonatal Sinus Bradycardia, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555263","External Qigong Therapy","C154263","A form of traditional Chinese energy therapy that involves the use of hand movements, acupressure, focused attention, and other mind healing techniques to direct the therapist's emitted Qi into a patient to regulate the patient's Qi activity.","External Qigong Therapy | EQT | External Qi Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555268","Carbon Dioxide Fractional Laser","C154265","A carbon dioxide gas laser device that uses continuous or short-pulsed light beams to target and remove thin layers of skin in precise areas without damaging the surrounding skin.","Carbon Dioxide Fractional Laser | CO2 Fractional Laser | CO2RE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280531","Antiprogesterone Therapy","C15521","Drug treatment to block the action of the female hormone progesterone.","Antiprogesterone Therapy | Antiprogestational Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0259753","Fat-Soluble Vitamin","C1550","A vitamin that is soluble in fat solvents and oils (lipo-soluble). Fat-soluble vitamins include vitamins A, D, E, K, F. Absorbed with ingested dietary fat, fat-soluble vitamins are stored in moderate amounts from the gastrointestinal tract. Present in minute amounts in various foods, these vitamins are essential to maintaining normal metabolism and biochemical functions; fat malabsorption may result in fat-soluble vitamin deficiencies. Fat-soluble vitamins are found in many types of foods and may be supplemented with pharmaceutical formulations. (NCI04)","Fat-Soluble Vitamin | Fat Soluble Vitamin | fat-soluble vitamin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280112","Growth Factor Antagonist Therapy","C15510","No value exists.","Growth Factor Antagonist Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555639","Grade 1 Neonatal Convulsion, AE","C155121","An adverse event in a newborn characterized by a single, self-limited suspected seizure requiring no treatment.","Grade 1 Neonatal Convulsion, AE | Grade 1 Neonatal Convulsion | Grade 1 Neonatal Convulsion, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555643","Grade 2 Neonatal Convulsion, AE","C155122","An adverse event in a newborn characterized by suspected seizures controlled with one anti-seizure drug (no recurrence within three days after treatment).","Grade 2 Neonatal Convulsion, AE | Grade 2 Neonatal Convulsion | Grade 2 Neonatal Convulsion, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555644","Grade 3 Neonatal Convulsion, AE","C155123","An adverse event in a newborn characterized by suspected seizures uncontrolled with one anti-seizure drug (recurrence within three days after treatment or requiring two or more anti-seizure drugs).","Grade 3 Neonatal Convulsion, AE | Grade 3 Neonatal Convulsion | Grade 3 Neonatal Convulsion, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555641","Grade 4 Neonatal Convulsion, AE","C155124","An adverse event in a newborn characterized by suspected seizures with life-threatening consequences (e.g. need for ventilation); suspected status epilepticus (greater than 30 minutes of convulsions within any 60 minute period) despite multiple anti-seizure drugs.","Grade 4 Neonatal Convulsion, AE | Grade 4 Neonatal Convulsion | Grade 4 Neonatal Convulsion, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555642","Grade 5 Neonatal Convulsion, AE","C155125","An adverse event in a newborn characterized by death related to suspected seizures.","Grade 5 Neonatal Convulsion, AE | Grade 5 Neonatal Convulsion | Grade 5 Neonatal Convulsion, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555647","Grade 1 Neonatal Epileptic Seizure, AE","C155126","An adverse event in a newborn characterized by a single, self-limited electroencephalogram (EEG)-proven seizure requiring no treatment.","Grade 1 Neonatal Epileptic Seizure, AE | Grade 1 Neonatal Epileptic Seizure | Grade 1 Neonatal Epileptic Seizure, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555648","Grade 2 Neonatal Epileptic Seizure, AE","C155127","An adverse event in a newborn characterized by electroencephalogram (EEG)-proven seizures that are controlled with one anti-seizure drug (no recurrence within three days after treatment).","Grade 2 Neonatal Epileptic Seizure, AE | Grade 2 Neonatal Epileptic Seizure | Grade 2 Neonatal Epileptic Seizure, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555645","Grade 3 Neonatal Epileptic Seizure, AE","C155128","An adverse event in a newborn characterized by electroencephalogram (EEG)-proven seizures uncontrolled with one anti-seizure drug (recurrence within three days after treatment or requiring two or more anti-seizure drugs).","Grade 3 Neonatal Epileptic Seizure, AE | Grade 3 Neonatal Epileptic Seizure | Grade 3 Neonatal Epileptic Seizure, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280229","Prior Endocrine Therapy for Advanced Disease","C15512","No value exists.","Prior Endocrine Therapy for Advanced Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555651","Grade 5 Neonatal Epileptic Seizure, AE","C155130","An adverse event in a newborn characterized by death related to electroencephalogram (EEG)-proven seizures.","Grade 5 Neonatal Epileptic Seizure, AE | Grade 5 Neonatal Epileptic Seizure | Grade 5 Neonatal Epileptic Seizure, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555652","Grade 1 Neonatal Intraventricular Hemorrhage, AE","C155131","An adverse event in a newborn characterized by asymptomatic hemorrhage confined to the germinal matrix; minimal hemorrhage within the ventricle (less than 10% on parasagittal view).","Grade 1 Neonatal Intraventricular Hemorrhage, AE | Grade 1 Intraventricular Hemorrhage neonatal | Grade 1 Neonatal Intraventricular Hemorrhage, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555698","Experimental Organism Adenocarcinoma Arising in Fibroadenoma","C154892","A malignant glandular neoplasm that arises from a pre-existing benign fibroadenoma.","Experimental Organism Adenocarcinoma Arising in Fibroadenoma | ADENOCARCINOMA ARISING IN FIBROADENOMA, MALIGNANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555702","Squamous Plaque/Cyst","C154894","A focus of squamous epithelium in or near the surface of the heart, generally believed to be an embryonic rest.","Squamous Plaque/Cyst | SQUAMOUS PLAQUE/CYST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0544919","Cytoplasmic Alteration","C154895","A microscopic finding indicating the presence of intracytoplasmic changes in reactive, atypical, dysplastic, or neoplastic cells.","Cytoplasmic Alteration | CYTOPLASMIC ALTERATION",,,,,,,,,,,,,,,"4053750","Cytoplasmic alteration",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555701","Test Article Physical Class","C154896","The physicochemical category that a test article belongs to based on the composition and properties of that article.","Test Article Physical Class | TAPHSCLS | Test Article Physical Substance Class | Test Article Physical Substance Classification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556886","Activator","C154897","A class of substances that binds to, activates and increases the activity of a target.","Activator | ACTIVATOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555705","Full Receptor Agonist","C154899","A class of substances that binds to and activates a receptor and induces the maximal biological response.","Full Receptor Agonist | FULL RECEPTOR AGONIST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527028","Recombinant OX40 Ligand","C1548","A recombinant agent, which is chemically identical to or similar to the endogenous protein Fas ligand OX40, a member of the tumor necrosis factor (TNF) family.  Expressed by antigen presenting cells (APC), OX40 ligand binds to the OX40 receptor on CD4 T-cells, thereby priming antigen-specific activation of CD4 T-cells and inducing CD4 T-cell secretion of interleukin 4 (IL-4). (NCI04)","Recombinant OX40 Ligand | OX40 ligand | OX40L",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555703","Partial Receptor Agonist","C154900","A class of substances that binds to and activates a receptor with less efficacy, and produces submaximal receptor activation relative to a full agonist.","Partial Receptor Agonist | PARTIAL RECEPTOR AGONIST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555704","Inverse Receptor Agonist","C154901","A class of substances that binds to a receptor at the same binding site as an agonist, but induces a biological response opposite to that agonist.","Inverse Receptor Agonist | INVERSE RECEPTOR AGONIST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555708","Mixed Agonist/Antagonist","C154902","A class of substances that binds to and acts as a full agonist or partial agonist at one receptor and an antagonist at another.","Mixed Agonist/Antagonist | AGONIST-ANTAGONIST | Mixed Agonist-Antagonist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555709","Allosteric Potentiator","C154903","A class of substances that binds to a target allosterically and induces a conformational change in the target. This leads to an enhanced binding affinity of the target to its substrate, and thereby amplifies the effect of the substrate on that target.","Allosteric Potentiator | ALLOSTERIC POTENTIATOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555917","Grade 3 Neonatal Administration Site Complication, AE","C155279","An administration site complication adverse event in a newborn characterized by ulceration or necrosis; severe tissue damage; operative intervention indicated.","Grade 3 Neonatal Administration Site Complication, AE | Grade 3 Administration Site Complication Neonatal | Grade 3 Neonatal Administration Site Complication, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555914","Grade 4 Neonatal Administration Site Complication, AE","C155280","An administration site complication adverse event in a newborn characterized by life-threatening consequences; urgent intervention indicated.","Grade 4 Neonatal Administration Site Complication, AE | Grade 4 Administration Site Complication Neonatal | Grade 4 Neonatal Administration Site Complication, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555266","Electronic Patient Visit Assessment","C154266","A web-based instrument that is used capture a patient's self-assessments prior to a healthcare encounter.","Electronic Patient Visit Assessment | ePVA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555267","Histone H1 Gene","C154267","A gene encoding the linker histone protein histone H1.","Histone H1 Gene | H1 Gene | H1 Histone Family Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0195775","Brain Surgery","C154268","Surgery performed on any part of the brain.","Brain Surgery | ",,,,,,,,,,,,,,,"4323283","Operation on brain",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555270","Bevacizumab/Everolimus Regimen","C154269","A regimen consisting of bevacizumab and everolimus that can be used for the treatment of kidney cancer and meningioma.","Bevacizumab/Everolimus Regimen | Bevacizumab + Everolimus | Bevacizumab Plus Everolimus | Bevacizumab-Everolimus | Bevacizumab-Everolimus Regimen | Bevacizumab/Everolimus | Everolimus/Bevacizumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL412798","Endobronchial Ultrasound Bronchoscopy","C154271","A minimally invasive technique that uses endoscopic ultrasound to produce an image of the endobronchial passages.","Endobronchial Ultrasound Bronchoscopy | EBUS | Endobronchial Ultrasound",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555330","Topical Fibrinogen-depleted Human Standardized Platelet Lysate CAM-101","C154531","A topical ophthalmic drop formulation containing fibrinogen-depleted, standardized human platelet lysate which is derived from pooled human platelet lysates (phPL) collected from healthy human donors, that can potentially be used to treat dry eye disease (DED). Upon ophthalmic administration of the topical fibrinogen-depleted human platelet lysate CAM-101, CAM-101 serves as artificial tears to relieve ocular dryness. In addition, as CAM-101 is rich in various growth factors and contains numerous nutritive, anti-inflammatory and pro-regenerative components, the components in CAM-101 may abrogate the underlying processes, such as inflammation, that contribute to DED. Compared to autologous serum drops that are used as artificial tears, CAM-101 is a more shelf-stable, convenient and standardized formulation.","Topical Fibrinogen-depleted Human Standardized Platelet Lysate CAM-101 | AXS-05 | CAM 101 | CAM-101 | FD hPL CAM-101 | Ophthalmic Fibrinogen Depleted Allogeneic Standardized Human Platelet Lysate | Topical Fibrinogen Depleted Human Platelet Lysate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555726","Grade 4 Persistent Pulmonary Hypertension of the Newborn, AE","C155220","A persistent pulmonary hypertension adverse event in a newborn characterized by life-threatening respiratory and/or hemodynamic compromise; extracorporeal membrane oxygenation (ECMO) required; oxygenation index greater than 40.","Grade 4 Persistent Pulmonary Hypertension of the Newborn, AE | Grade 4 PPHN, AE | Grade 4 Persistent Pulmonary Hypertension of the Newborn | Grade 4 Persistent Pulmonary Hypertension of the Newborn, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555727","Grade 5 Persistent Pulmonary Hypertension of the Newborn, AE","C155221","A persistent pulmonary hypertension adverse event in a newborn which results in death.","Grade 5 Persistent Pulmonary Hypertension of the Newborn, AE | Grade 5 PPHN, AE | Grade 5 Persistent Pulmonary Hypertension of the Newborn | Grade 5 Persistent Pulmonary Hypertension of the Newborn, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555732","Grade 1 Neonatal Pneumothorax, AE","C155222","An adverse event in a newborn characterized by radiological evidence of pneumothorax; no clinical signs; no care change required.","Grade 1 Neonatal Pneumothorax, AE | Grade 1 Neonatal Pneumothorax | Grade 1 Neonatal Pneumothorax, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555733","Grade 2 Neonatal Pneumothorax, AE","C155223","An adverse event in a newborn characterized by radiological evidence of pneumothorax; minor clinical signs; minor care change required (e.g. oxygen, increased monitoring).","Grade 2 Neonatal Pneumothorax, AE | Grade 2 Neonatal Pneumothorax | Grade 2 Neonatal Pneumothorax, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555730","Grade 3 Neonatal Pneumothorax, AE","C155224","An adverse event in a newborn characterized by radiological evidence of pneumothorax; with clinical signs; major care change required (e.g. chest drainage).","Grade 3 Neonatal Pneumothorax, AE | Grade 3 Neonatal Pneumothorax | Grade 3 Neonatal Pneumothorax, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555731","Grade 4 Neonatal Pneumothorax, AE","C155225","A pneumothorax adverse event in a newborn characterized by life-threatening respiratory and/or hemodynamic compromise (e.g. tension pneumothorax); urgent major care change required.","Grade 4 Neonatal Pneumothorax, AE | Grade 4 Neonatal Pneumothorax | Grade 4 Neonatal Pneumothorax, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555736","Grade 5 Neonatal Pneumothorax, AE","C155226","A pneumothorax adverse event in a newborn which results in death.","Grade 5 Neonatal Pneumothorax, AE | Grade 5 Neonatal Pneumothorax | Grade 5 Neonatal Pneumothorax, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555737","Grade 1 Bronchopulmonary Dysplasia, AE","C155227","An adverse event in a newborn characterized by the need for supplemental oxygen at 28 days AND breathing room air at 36 weeks postmenstrual age (PMA) in infants born less than 32 weeks' gestation; breathing room air by 56 days postnatal age in infants born greater than 32 weeks' gestation; breathing room air at discharge. Note: For conversion of oxygen administered by different modalities to fraction of inspired oxygen (FiO2): see http://nicutools.org/MediCalcs/ActualO2.php3.","Grade 1 Bronchopulmonary Dysplasia, AE | Grade 1 BPD, AE | Grade 1 Bronchopulmonary Dysplasia | Grade 1 Bronchopulmonary Dysplasia, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555734","Grade 2 Bronchopulmonary Dysplasia, AE","C155228","An adverse event in a newborn characterized by the need for supplemental oxygen at 28 days AND need for 22-30% oxygen at 36 weeks postmenstrual age (PMA) in infants born less than 32 weeks' gestation; need for 22-30% oxygen by 56 days postnatal age in infants born greater than 32 weeks' gestation; need for 22-30% oxygen at discharge. Note: For conversion of oxygen administered by different modalities to fraction of inspired oxygen (FiO2): see http://nicutools.org/MediCalcs/ActualO2.php3.","Grade 2 Bronchopulmonary Dysplasia, AE | Grade 2 BPD, AE | Grade 2 Bronchopulmonary Dysplasia | Grade 2 Bronchopulmonary Dysplasia, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555735","Grade 3 Bronchopulmonary Dysplasia, AE","C155229","An adverse event in a newborn characterized by the need for supplemental oxygen at 28 days AND need for greater than 30% oxygen or positive pressure at 36 weeks postmenstrual age (PMA) in infants born less than 32 weeks' gestation; need for greater than 30% oxygen or positive pressure by 56 days postnatal age in infants born greater than 32 weeks' gestation; need for greater than 30% oxygen and/or positive pressure at discharge. Note: For conversion of oxygen administered by different modalities to fraction of inspired oxygen (FiO2): see http://nicutools.org/MediCalcs/ActualO2.php3.","Grade 3 Bronchopulmonary Dysplasia, AE | Grade 3 BPD, AE | Grade 3 Bronchopulmonary Dysplasia | Grade 3 Bronchopulmonary Dysplasia, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555649","Grade 2 Neonatal Intraventricular Hemorrhage, AE","C155132","An adverse event in a newborn characterized by hemorrhage occupying less than 50% of ventricular volume without ventricular dilatation greater than 4mm above the 97th percentile.","Grade 2 Neonatal Intraventricular Hemorrhage, AE | Grade 2 Intraventricular Hemorrhage neonatal | Grade 2 Neonatal Intraventricular Hemorrhage, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574626","Zuni Language","C154210","A language of the Zuni people, indigenous to western New Mexico and eastern Arizona in the United States.","Zuni Language | ZUN | Zuni",,,,,,,,,,,,,,,"4177456","Zuni language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555155","Zaza Language","C154211","An Indo-European language spoken primarily in eastern Turkey by the Zaza people.","Zaza Language | Dimili | Dimli | Kirdki | Kirmanjki | ZZA | Zaza | Zazaki",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555158","Bendamustine/Obinutuzumab Regimen","C154212","A regimen consisting of bendamustine and obinutuzumab that can be used in the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).","Bendamustine/Obinutuzumab Regimen | Bendamustine + Obinutuzumab | Bendamustine and Obinutuzumab | Bendamustine-Obinutuzumab | Bendamustine-Obinutuzumab Regimen | Bendamustine/Obinutuzumab | Obinutuzumab Plus Bendamustine | Obinutuzumab-Bendamustine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555159","CHOP + Obinutuzumab","C154213","A regimen consisting of cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and obinutuzumab that can be used in the treatment of some forms of non-Hodgkin lymphoma (NHL), including follicular lymphoma, gastric and nongastric MALT lymphomas, nodal marginal zone lymphoma (NMZL) and splenic marginal zone lymphoma (SMZL).","G-CHOP Regimen | CHOP + Obinutuzumab | CHOP + Obinutuzumab Regimen | CHOP Plus Obinutuzumab | CHOP Plus Obinutuzumab Regimen | CHOP-Obinutuzumab Regimen | G-CHOP | GCHOP | Gazyva Plus CHOP | Obinutuzumab Plus Cyclophosphamide/Doxorubicin/Vincristine/Prednisone | Obinutuzumab-Cyclophosphamide-Doxorubicin-Prednisone-Vincristine | Obinutuzumab-Cyclophosphamide-Doxorubicin-Prednisone-Vincristine Regimen | Obinutuzumab-Cyclophosphamide-Hydroxydaunorubicin-Oncovin-Prednisone | Obinutuzumab-Cyclophosphamide-Hydroxydaunorubicin-Oncovin-Prednisone Regimen | Obinutuzumab/Cyclophosphamide/Doxorubicin/Prednisone/Vincristine | Obinutuzumab/Cyclophosphamide/Doxorubicin/Prednisone/Vincristine Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555156","R-CEPP Regimen","C154214","A regimen consisting of cyclophosphamide, etoposide, prednisone, procarbazine (CEPP) and rituximab that can be used in the treatment of some forms of non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), and post-transplant lymphoproliferative disorders.","R-CEPP Regimen | CEPP + Rituximab Regimen | CEPP Plus Rituximab Regimen | CEPP-Rituximab Regimen | Cyclophosphamide/Etoposide/Prednisone/Procarbazine + Rituximab | Cyclophosphamide/Etoposide/Prednisone/Procarbazine Plus Rituximab | Cyclophosphamide/Etoposide/Prednisone/Procarbazine Plus Rituximab Regimen | R-CEPP | RCEPP | Rituximab-Cyclophosphamide-Etoposide-Prednisone-Procarbazine | Rituximab-Cyclophosphamide-Etoposide-Prednisone-Procarbazine Regimen | Rituximab/Cyclophosphamide/Etoposide/Prednisone/Procarbazine | Rituximab/Cyclophosphamide/Etoposide/Prednisone/Procarbazine Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555157","R-CDOP Regimen","C154215","A regimen consisting of rituximab, cyclophosphamide, liposomal doxorubicin, vincristine and prednisone (R-CDOP) that can be used in the treatment of some forms of non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL).","R-CDOP Regimen | R-CDOP | R-CDOP (rituximab-abbs) | R-CDOP (rituximab-arrx) | R-CDOP (rituximab-blit) | R-CDOP (rituximab-pvvr) | R-CDOP (rituximab-rite) | R-CDOP (rituximab-rixa) | R-CDOP (rituximab-rixi) | RCDOP | Rituximab-Cyclophosphamide-Doxil-Oncovin-Prednisone Regimen | Rituximab-Cyclophosphamide-Liposomal Doxorubicin-Vincristine-Prednisone | Rituximab-Cyclophosphamide-Liposomal Doxorubicin-Vincristine-Prednisone Regimen | Rituximab/Cyclophosphamide/Doxil/Oncovin/Prednisone Regimen | Rituximab/Cyclophosphamide/Liposomal Doxorubicin/Vincristine/Prednisone | Rituximab/Cyclophosphamide/Liposomal Doxorubicin/Vincristine/Prednisone Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555161","Immunohistochemical Panel for Burkitt Lymphoma","C154216","An immunohistochemical screening panel for Burkitt lymphoma consisting of reagents that identify the cell-surface presence of: CD3, CD10, CD20, CD45, Ki-67, BCL2, BCL6, and TdT (terminal deoxynucleotide transferase).","Immunohistochemical Panel for Burkitt Lymphoma | IHC Panel for Burkitt Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555162","Flow Cytometry Panel for Burkitt Lymphoma","C154217","A flow cytometry screening panel for Burkitt lymphoma consisting of reagents that identify the cell-surface presence of: CD3, CD5, CD10, CD19, CD20, CD45, TdT (terminal deoxynucleotide transferase), and kappa or lambda light chains.","Flow Cytometry Panel for Burkitt Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555160","Chlorambucil/Rituximab Regimen","C154218","A regimen consisting of chlorambucil and rituximab that can be used in the treatment of some forms of non-Hodgkin lymphoma (NHL), including follicular lymphoma, gastric and nongastric mucosa-associated lymphoid tissue (MALT) lymphoma, nodal and splenic marginal zone lymphoma, and chronic lymphocytic leukemia (CLL).","Chlorambucil/Rituximab Regimen | Chlorambucil + Rituximab | Chlorambucil Plus Rituximab | Chlorambucil and Rituximab (RClb) | Chlorambucil and Rituximab-abbs (RClb) | Chlorambucil and Rituximab-arrx (RClb) | Chlorambucil and Rituximab-blit (RClb) | Chlorambucil and Rituximab-pvvr (RClb) | Chlorambucil and Rituximab-rite (RClb) | Chlorambucil and Rituximab-rixa (RClb) | Chlorambucil and Rituximab-rixi (RClb) | Chlorambucil-Rituximab | Chlorambucil-Rituximab Regimen | Chlorambucil/Rituximab | Rituximab + Chlorambucil | Rituximab/Chlorambucil Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0872279","Resistance Training","C154219","Physical exercise that uses weight, or other forms of resistance, to induce muscle contraction and build strength, anaerobic endurance, and size of skeletal muscles. Typical exercises include leg and chest press, knee extension, leg curl, row, abdominal crunch, and bicep curl.","Resistance Training | Strength Training",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555915","Grade 5 Neonatal Administration Site Complication, AE","C155281","An administration site complication adverse event in a newborn which results in death.","Grade 5 Neonatal Administration Site Complication, AE | Grade 5 Administration Site Complication Neonatal | Grade 5 Neonatal Administration Site Complication, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555920","Grade 1 Neonatal Fever, AE","C155282","An adverse event in a newborn characterized by isolated, not sustained fever, no change in baseline age-appropriate behavior.","Grade 1 Neonatal Fever, AE | Grade 1 Fever Neonatal | Grade 1 Neonatal Fever, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555921","Grade 2 Neonatal Fever, AE","C155283","An adverse event in a newborn characterized by fever, minor change in baseline age-appropriate behavior; minor changes in care (e.g. environmental settings, symptomatic treatment).","Grade 2 Neonatal Fever, AE | Grade 2 Fever Neonatal | Grade 2 Neonatal Fever, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555918","Grade 3 Neonatal Fever, AE","C155284","An adverse event in a newborn characterized by fever, major change in baseline age-appropriate behavior and without resolution to symptomatic treatment.","Grade 3 Neonatal Fever, AE | Grade 3 Fever Neonatal | Grade 3 Neonatal Fever, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555919","Grade 4 Neonatal Fever, AE","C155285","A febrile adverse event in a newborn characterized by life-threatening consequences.","Grade 4 Neonatal Fever, AE | Grade 4 Fever Neonatal | Grade 4 Neonatal Fever, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555923","Grade 5 Neonatal Fever, AE","C155286","A febrile adverse event in a newborn which results in death.","Grade 5 Neonatal Fever, AE | Grade 5 Fever Neonatal | Grade 5 Neonatal Fever, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555925","Fluorine F 18 PARP Inhibitor","C155292","A radiotracer consisting of a 1(2H)phthalazinone-based poly(ADP-ribose) polymerase 1 (PARP1) inhibitor (PARPi) radiolabeled with the positron emitting isotope fluorine F 18, which can potentially be used for the imaging of PARP1 expression using positron emission tomography (PET). Upon administration, fluorine F 18 PARPi targets and binds to PARP1. Upon PET, PARP1-expressing tumor cells can be visualized. PARP1, which is overexpressed in many cancer cell types, catalyzes post-translational ADP-ribosylation of nuclear proteins and plays a key role in the repair of DNA strand breaks.","Fluorine F 18 PARP Inhibitor | 18F Fluorinated PARP1-targeted Probe | 18F-1(2H)phthalazinone-based PARPi Imaging Agent | 18F-radiolabeled 1(2H)phthalazinone PARPi | Fluorine F 18 PARPi | Fluorine F 18 Poly(ADP-ribose) Polymerase Inhibitor | [18F]PARP1-targeted Probe | [18F]PARPi | [18F]PARPi Imaging Agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555338","H3 Histone Family, Member F Gene","C154537","Human H3C7 wild-type allele is located in the vicinity of 6p22.2 and is approximately 1 kb in length. This allele, which encodes histone H3.1 protein, is involved in DNA compartmentalization.","H3C7 wt Allele | H3 Clustered Histone 7 wt Allele | H3 Histone Family, Member F Gene | H3 Histone Family, Member I Gene | H3/i | H3FI | H3f | HIST1 Cluster, H3f Gene | HIST1H3F | HIST1H3F wt Allele | Histone 1, H3f Gene | Histone Cluster 1 H3 Family Member F Gene | Histone Cluster 1, H3f Gene | Histone Gene Cluster 1, H3 Histone Family, Member F Gene | Histone Gene Cluster 1, H3f Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555336","H3 Histone Family, Member G Gene","C154539","Human H3C8 wild-type allele is located in the vicinity of 6p22.2 and is approximately 2 kb in length. This allele, which encodes histone H3.1 protein, plays a role in the formation of higher order chromosome structures.","H3C8 wt Allele | H3 Clustered Histone 8 wt Allele | H3 Histone Family, Member G Gene | H3 Histone Family, Member H Gene | H3/h | H3FH | H3g | HIST1 Cluster, H3g Gene | HIST1H3G | HIST1H3G wt Allele | Histone 1, H3g Gene | Histone Cluster 1 H3 Family Member G Gene | Histone Cluster 1, H3g Gene | Histone Gene Cluster 1, H3 Histone Family, Member G Gene | Histone Gene Cluster 1, H3g Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278953","Prior Interferon Therapy","C15453","No value exists.","Prior Interferon Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555342","H3 Histone Family, Member H Gene","C154541","Human H3C10 wild-type allele is located in the vicinity of 6p22.1 and is approximately 1 kb in length. This allele, which encodes histone H3.1 protein, is involved in the formation of higher order nucleosome structures.","H3C10 wt Allele | H3 Clustered Histone 10 wt Allele | H3 Histone Family, Member H Gene | H3 Histone Family, Member K Gene | H3/k | H3FK | H3h | HIST1 Cluster, H3h Gene | HIST1H3H | HIST1H3H wt Allele | Histone 1, H3h Gene | Histone Cluster 1 H3 Family Member H Gene | Histone Cluster 1, H3h Gene | Histone Gene Cluster 1, H3 Histone Family, Member H Gene | Histone Gene Cluster 1, H3h Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555343","Gradient Echo MRI","C154542","An application of magnetic resonance imaging that uses spin refocusing and spin echo generation, resulting in shorter repetition times and faster imaging.","Gradient Echo MRI | GRE | GRE MRI | Gradient Echo Magnetic Resonance Imaging | Gradient Recalled Echo Imaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279038","Radioprotection","C15475","No value exists.","Radioprotection | Radiation Protection | Radiological Protection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555740","Grade 4 Bronchopulmonary Dysplasia, AE","C155230","An adverse event in a newborn characterized by the need for supplemental oxygen at 28 days AND need for greater than 30% oxygen AND positive pressure at 36 weeks postmenstrual age (PMA) in infants born less than 32 weeks' gestation; need for greater than 30% oxygen AND positive pressure by 56 days postnatal age in infants born greater than 32 weeks' gestation; need for greater than 30% oxygen AND positive pressure at discharge. Note: For conversion of oxygen administered by different modalities to fraction of inspired oxygen (FiO2): see http://nicutools.org/MediCalcs/ActualO2.php3.","Grade 4 Bronchopulmonary Dysplasia, AE | Grade 4 BPD, AE | Grade 4 Bronchopulmonary Dysplasia | Grade 4 Bronchopulmonary Dysplasia, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555288","Peroxisome Proliferator-Activated Receptor Agonist","C154291","Any agent that binds to and activates the peroxisome proliferator-activated (PPAR) receptor.","Peroxisome Proliferator-Activated Receptor Agonist | PPAR Agonist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555293","Nerve Growth Factor Mimetic","C154292","Any agent that mimics nerve growth factor (NGF).","Nerve Growth Factor Mimetic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555294","Ga-68 NeoBOMB1 PET/MRI Positron Emission Tomography and Magnetic Resonance Imaging","C154293","An imaging procedure that combines gallium-68-labelled NeoBomb1 PET with an MRI scan to overlay activity data onto detailed anatomic images.","Ga-68 NeoBOMB1 PET/MRI Positron Emission Tomography and Magnetic Resonance Imaging | 68Ga NeoBOMB1 PET/MRI | Ga-68 NeoBOMB1 PET/MRI | Gallium Ga 68-NeoB PET/MRI | Gallium Ga-68 NeoBOMB1 PET/MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555291","Ga-68 PSMA-R2 Positron Emission Tomography and Magnetic Resonance Imaging","C154294","An imaging procedure that combines gallium-68-labelled PSMA-R2 with an MRI scan to overlay activity data onto detailed anatomic images.","Ga-68 PSMA-R2 Positron Emission Tomography and Magnetic Resonance Imaging | 68Ga PSMA-R2 PET/MRI | Ga-68 PSMA-R2 PET/MRI | Gallium Ga-68 PMSA-R2 PET/MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555292","Abrineurin","C154295","No value exists.","Abrineurin | ABRINEURIN | N-L-Methionylneurotrophic Factor (Human Brain-derived)Dimer | Neurotrophic Factor (Human Brain-derived), N-L-methionyl-, Dimer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555297","Dapagliflozin Propanediol","C154296","The propanediol form of dapagliflozin, a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. Upon administration, dapagliflozin selectively targets and inhibits SGLT2, thereby preventing the reabsorption of glucose by the kidneys.","Dapagliflozin Propanediol | D-Glucitol, 1,5-Anhydro-1-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-, (1S)-, Compd. with (2S)-1,2-propanediol, Hydrate (1:1:1) | DAPAGLIFLOZIN PROPANEDIOL | Dapagliflozin Propylene Glycol Hydrate | Dapagliflozin S-propylene Glycol Monohydrate | Farxiga",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555298","Histone H2 Gene","C154298","A gene encoding the core histone protein histone H2.","Histone H2 Gene | H2 Gene | H2 Histone Family Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555295","Histone H2A Gene","C154299","A gene encoding the core histone protein histone H2A.","Histone H2A Gene | H2A Gene | H2A Histone Family Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0254093","Pibrozelesin","C1542","A semisynthetic water-soluble derivative of the antineoplastic antibiotic duocarmycin B2.  Activated by carboxyl esterase, pibrozelesin alkylates DNA by binding to adenine-thymine (A-T)-rich sequences in the minor groove of DNA, thereby inhibiting DNA replication and inducing apoptosis.","Pibrozelesin | Benzo(1,2-b:4,3-b')dipyrrole-1-carboxylic Acid, 8-(bromomethyl)-3,6,7,8-tetrahydro-2-methy-4-(((4-methyl-1-piperazinyl)carbonyl)oxy)-6-((5,6,7,-trimethoxy-1H-indol-2-yl)carbonyl)-, Methyl Ester (S) | Duocamycin B2 Analog | KW 2189 | KW-2189 | KW2189 | PIBROZELESIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555296","Histone H2B Gene","C154300","A gene encoding the core histone protein histone H2B.","Histone H2B Gene | H2B Gene | H2B Histone Family Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555301","Clopenthixol","C154301","No value exists.","Clopenthixol | 1-Piperazineethanol, 4-(3-(2-Chloro-9H-thioxanthen-9-ylidene)propyl)- | 4-(3-(2-Chlorothioxanthen-9-ylidene)propyl)-1-piperazineethanol | CLOPENTHIXOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555302","Histone H3 Gene","C154302","A gene encoding the core histone protein histone H3.","Histone H3 Gene | H3 Gene | H3 Histone Family Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555164","Cognitively-Based Compassion Training","C154220","Classes consisting of didactics, class discussion, and guided meditation practice designed to challenge unexamined assumptions regarding feelings and actions toward others with a focus on generating spontaneous empathy and compassion for self and others.","Cognitively-Based Compassion Training | CBCT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555165","Unresectable Gastric Adenocarcinoma","C154221","A gastric adenocarcinoma that is not amenable to surgical resection.","Unresectable Gastric Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555405","H3 Histone Family, Member A Gene","C154488","Human H3C1 wild-type allele is located in the vicinity of 6p22.2 and is approximately 1 kb in length. This allele, which encodes histone H3.1 protein, is involved in the formation of complex DNA structures.","H3C1 wt Allele | H3 Clustered Histone 1 wt Allele | H3 Histone Family, Member A Gene | H3/A | H3FA | H3a | HIST1 Cluster, H3A Gene | HIST1H3A | HIST1H3A wt Allele | Histone 1, H3a Gene | Histone Cluster 1 H3 Family Member A Gene | Histone Cluster 1, H3a Gene | Histone Gene Cluster 1, H3 Histone Family, Member A Gene | Histone Gene Cluster 1, H3a Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556363","Gum Dosage Form Category","C154491","A type of solid pharmaceutical dose form consisting of a basis composed of gum(s) or with a gum-like consistency.","Gum Dosage Form Category | Gum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555409","TFEB Protein Overexpression","C154492","Overexpression of TFEB protein that results from a t(6;11)(p21;q12) translocation, which involves the human genes MALAT1 and TFEB and is associated with renal cell carcinoma with t(6;11)(p21;q12); MALAT1-TFEB.","TFEB Protein Overexpression | Class E Basic Helix-Loop-Helix Protein 35 Overexpression | T-Cell Transcription Factor EB Overexpression | Transcription Factor EB Overexpression | bHLHe35 Protein Overexpression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555407","MiT Family Translocation","C154495","Translocations/gene fusions in the MiT family transcription factors TFE3 or TFEB.","MiT Family Translocation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555232","Gallium Ga 68 PSMA-R2","C154382","A radioconjugate composed of PSMA-R2, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope gallium Ga 68, with potential imaging activity during positron emission topography/computed tomography (PET/CT). Upon administration of gallium Ga 68 PSMA-R2, the PSMA-R2 moiety targets and binds to PSMA-expressing tumor cells. This allows for visualization of PSMA-expressing cells upon imaging. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on the majority of prostate tumor cells.","Gallium Ga 68 PSMA-R2 | 68Ga-PSMA-R2 | 68GaPSMA-R2 | Gallium-68 PSMA-R2 | PSMA-R2 GALLIUM GA-68",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555233","Aerosol Foam Dosage Form Category","C154383","A type of semi-solid pharmaceutical dose form consisting of a large volume of gas dispersed in a liquid or sometimes a solid phase.","Aerosol Foam Dosage Form Category | Foam",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555237","Block Dosage Form Category","C154384","A type of solid pharmaceutical dose form consisting of a large, compact mass, usually formed by compression of the component material into a cuboid or similar shape.","Block Dosage Form Category | Block",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0254201","Peptide 946","C1543","No value exists.","Peptide 946 | peptide 946",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556889","Cachet Dosage Form Category","C154406","A type of solid pharmaceutical dose form consisting of a disc inside which a single dose of the active substance(s) is enclosed. Capsule is excluded.","Cachet Dosage Form Category | Cachet",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278623","High-LET Neutron Therapy","C15440","A type of radiation therapy that utilizes cyclotron-generated neutrons to destroy tumor cells via direct interaction.","High-LET Neutron Therapy | NEUTRON Therapy | fast-neutron beam radiation | neutron therapy | therapy, high-LET neutron | therapy, neutron",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL033463","Management of Therapy Complications","C15476","No value exists.","Management of Therapy Complications | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555811","Grade 1 Neonatal Tachyarrhythmia, AE","C155177","An adverse event in a newborn characterized by brief, self-limiting, episodes of asymptomatic tachyarrhythmia (e.g. extra-systolic beats); no care changes.","Grade 1 Neonatal Tachyarrhythmia, AE | Grade 1 Neonatal Tachyarrhythmia | Grade 1 Neonatal Tachyarrhythmia, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555816","Grade 2 Neonatal Tachyarrhythmia, AE","C155178","A tachyarrhythmia adverse event in a newborn characterized by no change in age-appropriate behavior; requiring minor care changes (e.g. increased monitoring).","Grade 2 Neonatal Tachyarrhythmia, AE | Grade 2 Neonatal Tachyarrhythmia | Grade 2 Neonatal Tachyarrhythmia, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555817","Grade 3 Neonatal Tachyarrhythmia, AE","C155179","A tachyarrhythmia adverse event in a newborn resulting in non-life threatening hemodynamic compromise or changes in age-appropriate behavior; requiring major care changes (e.g. new medication or intervention).","Grade 3 Neonatal Tachyarrhythmia, AE | Grade 3 Neonatal Tachyarrhythmia | Grade 3 Neonatal Tachyarrhythmia, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280440","Catheter Management","C15517","Any activity related to the care and supervision of any type of catheter.","Catheter Management | management of catheter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555299","Histone H4 Gene","C154303","A gene encoding the core histone protein histone H4.","Histone H4 Gene | H4 Gene | H4 Histone Family Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555300","Histone Gene Mutation","C154305","A change in the sequence of a histone family gene.","Histone Gene Mutation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555305","Histone H3 Gene Mutation","C154306","A change in the sequence of a histone H3 family gene.","Histone H3 Gene Mutation | H3 Gene Mutation | H3 Histone Family Gene Mutation | H3 Mutation | Histone H3 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555361","Curcumin/Doxorubicin-encapsulating Nanoparticle IMX-110","C154569","A water-soluble, nano-sized formulation composed of nanoparticles encapsulating the poorly water-soluble curcumin, a signal transducer and activator of transcription 3 (Stat3), nuclear factor Kappa B (NF-kB) and poly-tyrosine kinase inhibitor (TKI), and the antineoplastic anthracycline antibiotic doxorubicin, with potential antineoplastic activity. Upon administration of the curcumin/doxorubicin-encapsulating nanoparticle IMX-110, the curcumin moiety targets and inhibits the activation of STAT3 and NF-kB and prevents STAT3- and NF-kB-mediated signaling pathways, both of which are activated in a variety of human cancers and plays a key role in neoplastic transformation, uncontrolled tumor cell proliferation, tumor resistance to apoptosis, metastasis and immune evasion. The doxorubicin moiety intercalates into DNA and interferes with topoisomerase II activity. This inhibits DNA replication and RNA synthesis, leading to tumor cell growth inhibition and apoptosis. This agent also interacts with cell membrane lipids causing lipid peroxidation. Delivery of doxorubicin in nanoparticles may improve drug penetration into tumors and curcumin, by inhibiting NFkB and STAT3 activity, may circumvent the tumor cells multidrug resistance mechanisms and may therefore be effective in chemoresistant tumor cells. Chemotherapeutic agents, such as doxorubicin, upregulate the expression of NF-kB in tumor cells which generates chemotherapy-resistant tumor cells.","Curcumin/Doxorubicin-encapsulating Nanoparticle IMX-110 | IMX 110 | IMX-110 | IMX110 | Stat3/NF-kB/poly-tyrosine Kinase Inhibitor/Doxorubicin-encapsulating Nanoparticle IMX-110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279015","Low-LET Implant Therapy","C15456","No value exists.","Low-LET Implant Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555408","Anaplastic Sarcoma of the Kidney","C154496","A rare tumor, usually occurring in young adults (mean age 12 years) with slight female predominance. It is characterized by a proliferation of anaplastic spindle cells with bizarre, pleomorphic nuclei and atypical mitotic figures. Most cases show chondroid differentiation.","Anaplastic Sarcoma of the Kidney | ASK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556399","Implant Dosage Form Category","C154497","A type of solid pharmaceutical dose form consisting of a mass with a size and shape suitable for implantation, allowing release of active substance(s) over an extended period of time.","Implant Dosage Form Category | Implant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279030","Interferon Therapy","C15469","The use of any form of interferon in the treatment of any disease or disorder.","Interferon Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0257217","Cryptophycin","C1546","The cryptophycins are a family of 16-membered macrolide antimitotic agents isolated from the cyanobacteria Nostoc sp. The mechanism of anticancer activity of the cryptophycins has been associated with their destabilization of microtubules and induction of bcl-2 phosphorylation leading to apoptosis. Cryptophycins demonstrated activity against the wide spectrum of solid tumors including those that overexpress the multidrug resistance efflux pump P-glycoprotein. (NCI)","Cryptophycin | 10-((3-Chloro-4-methoxyphenyl)methyl)-6-methyl-3-(2-methylpropyl)-16-(1-(3-phenyloxiranyl)ethyl)-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone | CRYPTOPHYCIN 1 | Cryptophycin 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555469","Transplant-Related Squamous Cell Carcinoma","C154700","A squamous cell carcinoma that arises in a patient with a history of organ transplantation.","Transplant-Related Squamous Cell Carcinoma | Transplant-Associated Squamous Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555466","Apparent Total Body Clearance Rate","C154701","The apparent total body clearance for intravascular administration.","Apparent Total Body Clearance Rate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555467","SAE Battery","C154702","A series of evaluations designed to learn whether cancer treatment changes emotions, attention span, or behavior, or the way the brain processes and filters information.","SAE Battery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555470","Study Contact Information","C154705","Information regarding the means of contacting a person or group associated with the clinical study.","Study Contact Information | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555471","National Coordinating Investigator","C154706","In the case of a multinational study, a person who has the responsibilities of the sponsor of the study in his/her country and will be responsible for the coordination of the principal investigators at different sites within that member state. (EMA)","National Coordinating Investigator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555474","Technical Lead","C154707","An individual who is responsible for the delivery of technical aspects of a project.","Technical Lead | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555475","Clinical Informaticist","C154708","An individual that designs, implements, evaluates and/or analyzes information technology in a healthcare or research setting.","Clinical Informaticist | Clinical Informatician",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1551211","Biostatistician - Specialist/Technologist","C154709","A person who is responsible for the statistical aspects of the clinical or pre-clinical study.","Biostatistician | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554337","Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA","C153214","Exosomes derived from mesenchymal stromal cells (MSCs) that have been engineered to carry short interfering RNA (siRNA) specific to the KRAS G12D mutation subtype. Upon administration, the KRAS G12D siRNA-loaded exosomes deliver siRNA to tumor cells expressing the mutant form of KRAS, potentially silencing its activity. The KRAS G12D mutation is thought to drive tumorigenesis and progression in some cancers.","Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA | KrasG12D siRNA-loaded Mesenchymal Stromal Cells-derived Exosomes | MSC-derived Exosomes with KrasG12D siRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554338","Anti-CD19/CD3 BiTE Antibody AMG 562","C153215","A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the B-cell-specific membrane protein CD19, and another that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19/CD3 BiTE antibody AMG 562 binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD19 antigen expressed on malignant B-cells. This activates and redirects CTLs to CD19-expressing tumor cells, resulting in CTL-mediated killing of tumor cells. CD19 is a membrane antigen that is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.","Anti-CD19/CD3 BiTE Antibody AMG 562 | AMG 562 | AMG-562 | AMG562 | BiTE Antibody AMG 562 | Bispecific T-cell Engager Antibody AMG 562 | CD19/CD3-directed Bispecific T-cell Engager Antibody AMG 562",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0264737","Cardiac Amyloidosis","C153217","The accumulation of amyloid protein in the heart. Cardiac amyloidosis is irreversible and may lead to conductive dysfunction as well as heart failure secondary to restrictive cardiomyopathy.","Cardiac Amyloidosis | ",,,,,,,,,,,,,,,"4040994","Senile cardiac amyloidosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL554340","Autologous TCR-engineered T-cells IMA202","C153218","A preparation of autologous T-lymphocytes that are genetically modified with a lentiviral vector encoding a T-cell receptor (TCR) targeting patient-specific tumor associated antigens (TAAs), with potential antineoplastic activity. Upon intravenous administration back into the patient, the autologous TCR-engineered T-cells IMA202 specifically recognize and bind to the TAA on cancer cells, which induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against the TAA-positive cancer cells.","Autologous TCR-engineered T-cells IMA202 | ACTengine IMA202 | IMA 202 | IMA-202 | IMA202 | IMA202 T-cell Product | IMA202 T-cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555814","Grade 4 Neonatal Tachyarrhythmia, AE","C155180","A tachyarrhythmia adverse event in a newborn characterized by life-threatening consequences (e.g. shock); requiring urgent major care changes.","Grade 4 Neonatal Tachyarrhythmia, AE | Grade 4 Neonatal Tachyarrhythmia | Grade 4 Neonatal Tachyarrhythmia, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555815","Grade 5 Neonatal Tachyarrhythmia, AE","C155181","A tachyarrhythmia adverse event in a newborn which results in death.","Grade 5 Neonatal Tachyarrhythmia, AE | Grade 5 Neonatal Tachyarrhythmia | Grade 5 Neonatal Tachyarrhythmia, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555820","Grade 1 Neonatal Bradyarrhythmia, AE","C155182","An adverse event in a newborn characterized by brief, self-limiting, episodes of asymptomatic bradyarrhythmia; no care changes.","Grade 1 Neonatal Bradyarrhythmia, AE | Grade 1 Neonatal Bradyarrhythmia | Grade 1 Neonatal Bradyarrhythmia, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555821","Grade 2 Neonatal Bradyarrhythmia, AE","C155183","A bradyarrhythmia adverse event in a newborn characterized by no change in age-appropriate behavior; requiring minor care changes (e.g. increased monitoring).","Grade 2 Neonatal Bradyarrhythmia, AE | Grade 2 Neonatal Bradyarrhythmia | Grade 2 Neonatal Bradyarrhythmia, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555818","Grade 3 Neonatal Bradyarrhythmia, AE","C155184","A bradyarrhythmia adverse event in a newborn resulting in non-life threatening hemodynamic compromise; requiring major care changes (e.g. new medication or intervention).","Grade 3 Neonatal Bradyarrhythmia, AE | Grade 3 Neonatal Bradyarrhythmia | Grade 3 Neonatal Bradyarrhythmia, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555819","Grade 4 Neonatal Bradyarrhythmia, AE","C155185","A bradyarrhythmia adverse event in a newborn characterized by life-threatening consequences (e.g. shock); requiring urgent major care changes.","Grade 4 Neonatal Bradyarrhythmia, AE | Grade 4 Neonatal Bradyarrhythmia | Grade 4 Neonatal Bradyarrhythmia, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555824","Grade 5 Neonatal Bradyarrhythmia, AE","C155186","A bradyarrhythmia adverse event in a newborn which results in death.","Grade 5 Neonatal Bradyarrhythmia, AE | Grade 5 Neonatal Bradyarrhythmia | Grade 5 Neonatal Bradyarrhythmia, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555825","Grade 1 Neonatal Edema, AE","C155187","An adverse event in a newborn characterized by mild edema; no change in age appropriate behavior; no care changes indicated.","Grade 1 Neonatal Edema, AE | Grade 1 Edema Neonatal | Grade 1 Neonatal Edema, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555823","Grade 3 Neonatal Edema, AE","C155189","An adverse event in a newborn characterized by severe edema; limiting age appropriate behavior; requiring major care changes (e.g. diuretics).","Grade 3 Neonatal Edema, AE | Grade 3 Edema Neonatal | Grade 3 Neonatal Edema, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516645","Clinical Trials Information for Patients","C15518","No value exists.","Clinical Trials Information for Patients | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555828","Grade 4 Neonatal Edema, AE","C155190","An edema adverse event in a newborn characterized by life threatening consequences (e.g. respiratory failure, shock); requiring urgent major care changes (e.g. intubation, dialysis).","Grade 4 Neonatal Edema, AE | Grade 4 Edema Neonatal | Grade 4 Neonatal Edema, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555829","Grade 5 Neonatal Edema, AE","C155191","An edema adverse event in a newborn which results in death.","Grade 5 Neonatal Edema, AE | Grade 5 Edema Neonatal | Grade 5 Neonatal Edema, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555826","Grade 1 Neonatal Coagulation Disorder, AE","C155192","An adverse event in a newborn characterized by minor biochemical coagulation abnormalities without clinical signs; no care changes indicated.","Grade 1 Neonatal Coagulation Disorder, AE | Grade 1 Coagulation Disorder Neonatal | Grade 1 Neonatal Coagulation Disorder, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555274","Non-Malignant Nodule","C154273","A usually circumscribed and non-metastasizing nodular mass.","Non-Malignant Nodule | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279016","Low-LET Electron Therapy","C15457","No value exists.","Low-LET Electron Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555473","Archive Sample Retrieval","C154710","The act of removing a biological specimen from a biobank or other biorepository for further use.","Archive Sample Retrieval | ARCHIVE RETRIEVING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555563","Internal Orifice Area","C154711","The extent of a 2-dimensional surface enclosed within the boundary of an internal orifice.","Internal Orifice Area | IORFAREA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555561","Number of Electroencephalogram Electrodes","C154713","The number of electroencephalogram electrodes used in the assessment.","Number of Electroencephalogram Electrodes | EEGELCTN | Number of EEG Electrodes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555562","Reference Equation","C154716","A calculation based upon a set of normalized data or values that are derived from a specified population.","Reference Equation | REFEQU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555567","Continuous Surface ECG Recording for Non-human Species","C154717","A continuous electrocardiographic (ECG) recording utilizing one or more surface leads in a non-human species. (CDISC)","Continuous Surface ECG Recording for Non-human Species | CONTINUOUS SURFACE ECG RECORDING FOR NON-HUMAN SPECIES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555568","Continuous ECG Recording for Non-human Species Using Implanted Leads","C154718","A continuous electrocardiographic (ECG) recording utilizing one or more implanted leads in a non-human species. (CDISC)","Continuous ECG Recording for Non-human Species Using Implanted Leads | CONTINUOUS ECG RECORDING FOR NON-HUMAN SPECIES USING IMPLANTED LEADS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555650","Grade 3 Neonatal Intraventricular Hemorrhage, AE","C155133","An adverse event in a newborn characterized by hemorrhage occupying greater than 50% of the ventricle volume; ventricular dilatation greater than 4mm above the 97th percentile; parenchymal venous infarction; requiring temporizing neurosurgical procedure (drain, shunt or reservoir).","Grade 3 Neonatal Intraventricular Hemorrhage, AE | Grade 3 Intraventricular Hemorrhage neonatal | Grade 3 Neonatal Intraventricular Hemorrhage, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555655","Grade 4 Neonatal Intraventricular Hemorrhage, AE","C155134","An adverse event in a newborn characterized by intraventricular hemorrhage with parenchymal venous infarction; resulting in life threatening consequences (e.g. refractory seizures, hypotension, respiratory depression); requiring urgent stabilization or surgical decompression.","Grade 4 Neonatal Intraventricular Hemorrhage, AE | Grade 4 Intraventricular Hemorrhage neonatal | Grade 4 Neonatal Intraventricular Hemorrhage, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555656","Grade 5 Neonatal Intraventricular Hemorrhage, AE","C155135","An intraventricular hemorrhage adverse event in a newborn which results in death.","Grade 5 Neonatal Intraventricular Hemorrhage, AE | Grade 5 Intraventricular Hemorrhage neonatal | Grade 5 Neonatal Intraventricular Hemorrhage, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555653","Grade 1 Retinopathy of Prematurity, AE","C155136","An adverse event in a newborn characterized by zone 2 International Classification of Retinopathy of Prematurity (ICROP) stage 1 with or without plus disease; zone 2 ICROP stage 2 without plus disease; zone 3 any ICROP stage; no care changes indicated.","Grade 1 Retinopathy of Prematurity, AE | Grade 1 Retinopathy of Prematurity | Grade 1 Retinopathy of Prematurity, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555654","Grade 2 Retinopathy of Prematurity, AE","C155137","An adverse event in a newborn characterized by type 2 prethreshold retinopathy of prematurity (ROP) (zone 1 International Classification of Retinopathy of Prematurity (ICROP) stage 1 or 2 without plus disease; zone 2 ICROP stage 3 without plus disease); requiring more frequent ophthalmic monitoring.","Grade 2 Retinopathy of Prematurity, AE | Grade 2 Retinopathy of Prematurity | Grade 2 Retinopathy of Prematurity, Adverse Event | Grade 2 RoP, AE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555776","Grade 3 Retinopathy of Prematurity, AE","C155138","An adverse event in a newborn characterized by type 1 prethreshold retinopathy of prematurity (ROP) (zone 1 any stage with plus disease; zone 1 International Classification of Retinopathy of Prematurity (ICROP) stage 3 without plus disease; zone 2 ICROP stage 2 or 3 with plus disease); threshold ROP; requiring major care changes (e.g. laser intervention, intravitreal anti-VEGF therapy or operative management).","Grade 3 Retinopathy of Prematurity, AE | Grade 3 Retinopathy of Prematurity | Grade 3 Retinopathy of Prematurity, Adverse Event | Grade 3 RoP, AE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555777","Grade 4 Retinopathy of Prematurity, AE","C155139","An adverse event in a newborn characterized by unilateral retinal detachment.","Grade 4 Retinopathy of Prematurity, AE | Grade 4 Retinopathy of Prematurity | Grade 4 Retinopathy of Prematurity, Adverse Event | Grade 4 RoP, AE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280283","Drug Extravasation Therapy","C15513","No value exists.","Drug Extravasation Therapy | drug extravasation management",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554346","Colorectal Carcinoma Metastatic in the Lung","C153224","A carcinoma that originates from the wall of the colon or rectum and has spread to the lungs.","Colorectal Carcinoma Metastatic in the Lung | Metastatic Colorectal Cancer in the Lung",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554461","Breast Carcinoma Metastatic in the Spine","C153226","A carcinoma that arises from the breast and has spread to the spine.","Breast Carcinoma Metastatic in the Spine | Metastatic Breast Cancer in the Spine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555194","BST2 wt Allele","C154135","Human BST2 wild-type allele is located in the vicinity of 19p13.11 and is approximately 3 kb in length. This allele, which encodes bone marrow stromal antigen 2, plays a role in the negative regulation of viral infectivity.","BST2 wt Allele | Bone Marrow Stromal Cell Antigen 2 wt Allele | CD317 | NPC-A-7 | PDCA-1 | TETHERIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555195","BST2 protein, human","C154136","Bone marrow stromal antigen 2 (180 aa, ~20 kDa) is encoded by the human BST2 gene. This protein is involved in preventing the release of virions from infected cells.","Bone Marrow Stromal Antigen 2 | BST2 | Bone Marrow Stromal Cell Antigen 2 | CD317 | CD317 Antigen | HM1.24 Antigen | NPC-A-7 | PDCA-1 | Tetherin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0200069","Fertility Study","C15413","Research to investigate issues regarding reproductive processes.","Fertility Study | ",,,,,,,,,,,,,,,"4227745","Infertility study",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574470","Sukuma Language","C154141","A Niger-Congo Bantu language spoken in Tanzania.","Sukuma Language | SUK | Sukuma",,,,,,,,,,,,,,,"4175937","Sukuma language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574382","Sundanese Language","C154142","An Austronesian language spoken by the Sudanese people of Indonesia.","Sundanese Language | SUN | Sundanese",,,,,,,,,,,,,,,"4181554","Sundanese language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574518","Susu Language","C154143","A Niger-Congo Mande language spoken by the Susu people of Guinea and Sierra Leone, West Africa.","Susu Language | SUS | Susu",,,,,,,,,,,,,,,"4181713","Susu language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555271","mRNA-based TriMix Melanoma Vaccine ECI-006","C154274","A melanoma vaccine consisting of mRNAs encoding five different melanoma tumor-associated antigens (TAAs) and a TriMix platform comprised of three mRNAs encoding for constitutively activated toll-like receptor 4 (caTLR4), CD40 ligand (CD40L), and CD70, with potential immunomodulatory and antineoplastic activities. Upon intranodal injection, mRNA based TriMix vaccine ECI-006 may stimulate the immune system to mount both humoral and cellular responses against tumor cells expressing the five TAAs specific to the vaccine, potentially decreasing cellular proliferation of cells expressing these antigens. The TriMix adjuvants CD40L and caTLR4 promote the generation of mature and active dendritic cells (DCs), and CD70 provides a costimulatory signal to CD27+ naive T-cells, thereby supporting T-cell proliferation and inhibiting T-cell apoptosis.","mRNA-based TriMix Melanoma Vaccine ECI-006 | ECI 006 | ECI-006 | ECI006",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555272","Recombinant HSA/Filgrastim Fusion Protein","C154275","A long-acting recombinant fusion protein composed of human serum albumin (HSA) fused to granulocyte colony stimulating factor (G-CSF), with potential granulopoietic activity. Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, thereby stimulating the proliferation, differentiation, function, and survival of neutrophil precursors and mature neutrophils. This may prevent granulocytopenia. HSA fusion increases the molecular weight of G-CSF, prolongs its half-life and masks G-CSF, thereby preventing G-CSF degradation which further increases the half-life and bioavailability of G-CSF.","Recombinant HSA/Filgrastim Fusion Protein | Fusion Protein rHSA/GCSF | Human Serum Albumin GCSF | rHSA/G-CSF | rHSA/GCSF Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555277","Autologous AXL-targeted CAR T-cells CCT301-38","C154276","A preparation of genetically modified autologous T-lymphocytes transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) targeting the receptor tyrosine kinase (RTK) AXL, with potential immunomodulatory and antineoplastic activities. After isolation, transduction, and expansion in culture, the CCT301-38 cells are reintroduced into the patient and are activated within the tumor microenvironment (TME) using proprietary Conditionally Active Biologic (CAB) technology. Upon activation, CAB antibodies bind to a proprietary T-cell signaling domain, promoting T-cell recognition and killing of AXL-expressing tumor cells. AXL is a RTK and oncogene that is overexpressed in many cancer types and is involved in the stimulation of tumor cell proliferation.","Autologous AXL-targeted CAR T-cells CCT301-38 | Autologous Anti-AXL CAR T Cells CCT30138 | Autologous CAR T-cells Targeting AXL CCT301-38 | CCT301 38 | CCT301-38 | CCT30138 CAR T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555278","Autologous ROR2-targeted CAR T-cells CCT301-59","C154277","A preparation of genetically modified autologous T-lymphocytes transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) targeting the receptor tyrosine kinase-like orphan receptor 2 (ROR2), with potential immunomodulatory and antineoplastic activities. After isolation, transduction, and expansion in culture, CCT301-59 cells are reintroduced into the patient and are activated within the tumor microenvironment (TME) using proprietary Conditionally Active Biologic (CAB) technology. Upon activation, CAB antibodies bind to a proprietary T-cell signaling domain, promoting T-cell recognition and killing of ROR2-expressing tumor cells. ROR2 is involved in Wnt signal transduction and is involved in tumorigenesis and progression. ROR2 expression is upregulated in certain tumor types and high levels of ROR2 expression often correlates with poor prognosis.","Autologous ROR2-targeted CAR T-cells CCT301-59 | Autologous Anti-ROR2 CAR T Cells CCT301-59 | Autologous CAR T-cells Targeting ROR2 CCT301-59 | Autologous CCT301-59 CAR T Cells | CCT301 59 | CCT301-59",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555276","FL 006","C154279","An orally available, small molecule inhibitor of the receptor tyrosine kinase (RTK) anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon oral administration, iruplinalkib binds to and inhibits ALK tyrosine kinase, ALK fusion proteins, ALK point mutation variants ALK L1196M, ALK C1156Y, and EGFR L858R/T790M. Inhibition of ALK leads to the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors. Additionally, ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors.","Iruplinalkib | ALK Inhibitor WX-0593 | ALK Inhibitor WX-0593 | FL 006 | FL-006 | FL006 | IRUPLINALKIB | WX 0593 | WX-0593 | WX0593",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279494","Estrogen Therapy","C15483","The use of estrogen in the treatment of any disease or disorder.","Estrogen Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555741","Grade 5 Bronchopulmonary Dysplasia, AE","C155231","A bronchopulmonary dysplasia adverse event in a newborn which results in death.","Grade 5 Bronchopulmonary Dysplasia, AE | Grade 5 BPD, AE | Grade 5 Bronchopulmonary Dysplasia | Grade 5 Bronchopulmonary Dysplasia, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555738","Grade 3 Necrotizing Enterocolitis, AE","C155232","An adverse event in a newborn characterized by confirmed necrotizing enterocolitis; major care change indicated (e.g. NPO, antibiotics, non-urgent surgery).","Grade 3 Necrotizing Enterocolitis, AE | Grade 3 Necrotizing Enterocolitis | Grade 3 Necrotizing Enterocolitis, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555739","Grade 4 Necrotizing Enterocolitis, AE","C155233","A necrotizing enterocolitis adverse event in a newborn characterized by bowel perforation (pneumoperitoneum)(modified Bell stage IIIB); shock, disseminated intravascular coagulation (DIC), combined respiratory and metabolic acidosis (modified Bell stage IIIA); urgent major care change indicated.","Grade 4 Necrotizing Enterocolitis, AE | Grade 4 Necrotizing Enterocolitis | Grade 4 Necrotizing Enterocolitis, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555744","Grade 5 Necrotizing Enterocolitis, AE","C155234","A necrotizing enterocolitis adverse event in a newborn which results in death.","Grade 5 Necrotizing Enterocolitis, AE | Grade 5 Necrotizing Enterocolitis | Grade 5 Necrotizing Enterocolitis, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555745","Grade 1 Neonatal Diarrhea, AE","C155235","An adverse event in a newborn characterized by an increase of 2-4 stools per day over baseline; mild increase in ostomy output compared to baseline.","Grade 1 Neonatal Diarrhea, AE | Grade 1 Diarrhea Neonatal | Grade 1 Neonatal Diarrhea, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555742","Grade 2 Neonatal Diarrhea, AE","C155236","An adverse event in a newborn characterized by an increase of 4 - 6 stools per day over baseline; moderate increase in ostomy output compared to baseline.","Grade 2 Neonatal Diarrhea, AE | Grade 2 Diarrhea Neonatal | Grade 2 Neonatal Diarrhea, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555743","Grade 3 Neonatal Diarrhea, AE","C155237","An adverse event in a newborn characterized by an increase of 7 stools or more per day over baseline; severe increase in ostomy output compared to baseline; signs of dehydration.","Grade 3 Neonatal Diarrhea, AE | Grade 3 Diarrhea Neonatal | Grade 3 Neonatal Diarrhea, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555749","Grade 5 Neonatal Diarrhea, AE","C155239","A diarrhea adverse event in a newborn which results in death.","Grade 5 Neonatal Diarrhea, AE | Grade 5 Diarrhea Neonatal | Grade 5 Neonatal Diarrhea, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555774","Grade 5 Retinopathy of Prematurity, AE","C155140","An adverse event in a newborn characterized by bilateral retinal detachment and blindness.","Grade 5 Retinopathy of Prematurity, AE | Grade 5 Retinopathy of Prematurity | Grade 5 Retinopathy of Prematurity, Adverse Event | Grade 5 RoP, AE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555775","Grade 1 Hypoxic Ischemic Encephalopathy, AE","C155141","An adverse event in a newborn clinically classified as perinatal asphyxia, but not resulting in encephalopathy.","Grade 1 Hypoxic Ischemic Encephalopathy, AE | Grade 1 HIE, AE | Grade 1 Hypoxic Ischemic Encephalopathy | Grade 1 Hypoxic Ischemic Encephalopathy, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555781","Grade 3 Hypoxic Ischemic Encephalopathy, AE","C155143","An adverse event in a newborn characterized by moderate clinical signs (see Sarnat stages for further guidance on mild, moderate and severe clinical signs of encephalopathy) of encephalopathy resulting from a perinatal asphyxia event; meeting criteria for therapeutic hypothermia.","Grade 3 Hypoxic Ischemic Encephalopathy, AE | Grade 3 HIE, AE | Grade 3 Hypoxic Ischemic Encephalopathy | Grade 3 Hypoxic Ischemic Encephalopathy, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555778","Grade 4 Hypoxic Ischemic Encephalopathy, AE","C155144","An adverse event in a newborn characterized by severe clinical signs (see Sarnat stages for further guidance on mild, moderate and severe clinical signs of encephalopathy) of encephalopathy resulting from a perinatal asphyxia event with life-threatening consequences (e.g. respiratory depression, refractory seizures).","Grade 4 Hypoxic Ischemic Encephalopathy, AE | Grade 4 HIE, AE | Grade 4 Hypoxic Ischemic Encephalopathy | Grade 4 Hypoxic Ischemic Encephalopathy, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555779","Grade 5 Hypoxic Ischemic Encephalopathy, AE","C155145","An hypoxic ischemic encephalopathy adverse event in a newborn which results in death.","Grade 5 Hypoxic Ischemic Encephalopathy, AE | Grade 5 HIE, AE | Grade 5 Hypoxic Ischemic Encephalopathy | Grade 5 Hypoxic Ischemic Encephalopathy, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3544195","Pituitary Hyperplasia","C154222","A rare condition characterized by hyperplasia and hypertrophy of the pituitary gland. It is caused by hypersecretion of hypothalamic stimulating hormones.","Pituitary Hyperplasia | Pituitary Gland Hyperplasia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555163","Cord Blood Transplant Recipient","C154223","An individual receiving a cord blood transplant.","Cord Blood Transplant Recipient | CBT Recipient | Cord Blood Transplantation Recipient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555167","Pectoral Nerve Block","C154224","A peripheral neural block of the medial and lateral pectoral nerves.","Pectoral Nerve Block | PECS 1 | PECS-1 | Pectoralis Nerve Block",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0600080","Stretching","C154225","A physical exercise in which a specific muscle or tendon is deliberately flexed or stretched in order to improve the muscle's elasticity.","Stretching | ",,,,,,,,,,,,,,,"4047493","Stretching",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0043010","Waiting Lists (patient)","C154226","A list of people waiting for inclusion in some activity, vacancy, or service.","Waiting List | Waitlist",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0237731","Human Migration","C15422","Movement of residence from one place to another. Includes nomadism; labor or seasonal migration; patterns of rural, urban, or suburban migration; or voluntary or forced relocation. (PSY94)","Human Migration | Human Migration / Distribution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0038996","Swedish Language","C154146","A North Germanic language spoken as the official language of Sweden.","Swedish Language | SWE | Swedish",,,,,,,,,,,,,,,"4175777","Swedish language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574166","Syriac Language","C154147","An Afro-Asiatic language dialect of Middle Aramaic.","Syriac Language | SYR | Syriac | Syriac Aramaic",,,,,,,,,,,,,,,"4175732","Syriac language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574402","Tahitian Language","C154149","A Polynesian language, spoken mainly on the Society Islands in French Polynesia.","Tahitian Language | TAH | Tahitian",,,,,,,,,,,,,,,"4175921","Tahitian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
,,,,,,,,,,,,,,,,,,,"4148553","Antibody dependent cellular cytotoxicity assay",,,,,,,,,,,,,,,,,,,,,,"--"
"CL555341","H3 Histone Family, Member F Gene","C154544","Human H3C11 wild-type allele is located in the vicinity of 6p22.1 and is approximately 1 kb in length. This allele, which encodes histone H3.1 protein, plays a role in nucleosome formation.","H3C11 wt Allele | H3 Clustered Histone 11 Gene | H3 Histone Family, Member F Gene | H3 Histone Family, Member I Gene | H3/f | H3FF | H3i | HIST1 Cluster, H3i Gene | HIST1H3I | HIST1H3I wt Allele | Histone 1, H3i Gene | Histone Cluster 1 H3 Family Member I Gene | Histone Cluster 1, H3i Gene | Histone Gene Cluster 1, H3 Histone Family, Member I Gene | Histone Gene Cluster 1, H3i Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555346","Unresectable Renal Cell Carcinoma","C154545","A renal cell carcinoma that is not amenable to surgical resection.","Unresectable Renal Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555344","Resectable Renal Cell Carcinoma","C154547","Renal cell carcinoma that is amenable to surgical resection.","Resectable Renal Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555345","H3 Histone Family, Member J Gene","C154548","Human H3C12 wild-type allele is located in the vicinity of 6p22.1 and is approximately 3 kb in length. This allele, which encodes histone H3.1 protein, is involved in the structure of nucleosomes.","H3C12 wt Allele | H3 Clustered Histone 12 wt Allele | H3 Histone Family, Member J Gene | H3/j | H3FJ | H3j | HIST1 Cluster, H3j Gene | HIST1H3J | HIST1H3J wt Allele | Histone 1, H3j Gene | Histone Cluster 1 H3 Family Member J Gene | Histone Cluster 1, H3j Gene | Histone Gene Cluster 1, H3 Histone Family, Member J Gene | Histone Gene Cluster 1, H3j Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555349","Lutetium Lu 177-DOTA-EB-TATE","C154549","A radioconjugate consisting of Evans blue (EB) modified, tyrosine-containing somatostatin analog, Tyr3-octreotate (TATE), conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecane tetraacetic acid (DOTA), and radiolabeled with the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon intravenous administration, lutetium Lu 177-DOTA-EB-TATE binds to somatostatin receptors (SSTRs), specifically with high affinity to type 2 SSTRs (SSTR2s), present on the cell membranes of many neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR2-positive cells. The incorporation of an albumin-binding moiety through EB modification allows lutetium Lu 177-DOTA-EB-TATE to reversibly bind to endogenous albumin, potentially extending half-life and increasing targeted accumulation of the drug in tumors. SSTRs, especially SSTR2s, are expressed at relatively higher levels in many tumor cell types and tumor blood vessels, compared to normal tissues.","Lutetium Lu 177-DOTA-EB-TATE | (177)Lu-DOTA-EB-TATE | 177 Lu-DOTA-EB-TATE | 177Lu-DOTA-EB-TATE | 177Lu-DOTA0-EB-Tyr3-Octreotate | Lutetium Lu 177 DOTA(0)-EB-Tyr(3)-Octreotate | Lutetium Lu 177-DOTA-EB-Tyr3-Octreotate | Lutetium Lu 177-DTPA-omburtamab | Lutetium-177-1, 4, 7, 10-tetra-azacyclododecane-1, 4, 7, 10-tetraacetic acid-Evans blue-octreotate | Lutetium-177-DOTA-EB-TATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555350","Anti-PD-L1 Monoclonal Antibody WBP 3155","C154550","A fully human monoclonal antibody directed against the immunosuppressive ligand, programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sugemalimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor, programmed cell death 1 (PD-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells. Anti-PD-L1 monoclonal antibody CS1001 mirrors natural immunoglobulin G4 (IgG4), potentially reducing immunogenicity and other toxicities.","Sugemalimab | Anti-PD-L1 Monoclonal Antibody CS1001 | Anti-PD-L1 Monoclonal Antibody WBP 3155 | CS 1001 | CS-1001 | CS1001 | Cejemly | SUGEMALIMAB | WBP 315 | WBP-315 | WBP315",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556365","Liquid Dose Form Category","C154551","A type of liquid pharmaceutical dose form consisting of a pure substance in a liquid state.","Liquid Dose Form Category | Liquid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555746","Grade 1 Infantile Vomiting, AE","C155240","An adverse event in a newborn characterized by an increase in vomiting over baseline, self limiting.","Grade 1 Infantile Vomiting, AE | Grade 1 Infantile Vomiting | Grade 1 Infantile Vomiting, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555747","Grade 2 Infantile Vomiting, AE","C155241","An adverse event in a newborn characterized by a persistent increase in vomiting over baseline; no dehydration; minor changes in feeding support indicated.","Grade 2 Infantile Vomiting, AE | Grade 2 Infantile Vomiting | Grade 2 Infantile Vomiting, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555752","Grade 3 Infantile Vomiting, AE","C155242","An adverse event in a newborn characterized by a persistent increase in vomiting over baseline; signs of dehydration; major changes in feeding support indicated (e.g. change to total parenteral nutrition (TPN) or gavage).","Grade 3 Infantile Vomiting, AE | Grade 3 Infantile Vomiting | Grade 3 Infantile Vomiting, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555753","Grade 4 Infantile Vomiting, AE","C155243","A vomiting adverse event in a newborn characterized by life-threatening consequences (e. g. severe dehydration).","Grade 4 Infantile Vomiting, AE | Grade 4 Infantile Vomiting | Grade 4 Infantile Vomiting, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555750","Grade 5 Infantile Vomiting, AE","C155244","A vomiting adverse event in a newborn which results in death.","Grade 5 Infantile Vomiting, AE | Grade 5 Infantile Vomiting | Grade 5 Infantile Vomiting, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555751","Grade 1 Feeding Intolerance, AE","C155245","An adverse event in a newborn characterized by mild feeding intolerance (e.g. increased gastric residual volume or abdominal distension); without discomfort; no change in care indicated.","Grade 1 Feeding Intolerance, AE | Grade 1 Feeding Intolerance | Grade 1 Feeding Intolerance, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555756","Grade 2 Feeding Intolerance, AE","C155246","An adverse event in a newborn characterized by moderate feeding intolerance; resulting in minor discomfort or alteration of drinking behavior; minor care changes indicated (e.g. feeds withheld).","Grade 2 Feeding Intolerance, AE | Grade 2 Feeding Intolerance | Grade 2 Feeding Intolerance, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555757","Grade 3 Feeding Intolerance, AE","C155247","An adverse event in a newborn characterized by severe feeding intolerance; requiring major changes in feeding support indicated (e.g. change to total parenteral nutrition (TPN) or gavage).","Grade 3 Feeding Intolerance, AE | Grade 3 Feeding Intolerance | Grade 3 Feeding Intolerance, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555309","H3/l Gene Mutation","C154310","A change in the sequence of the HIST1H3B gene.","H3C2 Gene Mutation | H3 Clustered Histone 2 Gene Mutation | H3/l Gene Mutation | H3FL Gene Mutation | H3b Gene Mutation | HIST1H3B Gene Mutation | Histone Cluster 1 H3 Family Member B Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555310","H3/l c.83A>T","C154311","A nucleotide substitution at position 83 of the coding sequence of the HIST1H3B gene where adenine has been mutated to thymine.","H3C2 NM_003537.3:c.83A>T | H3 Clustered Histone 2 c.83A>T | H3/l c.83A>T | H3C2 c.83A>T | H3FL c.83A>T | H3b c.83A>T | HIST1H3B NM_003537.3:c.83A>T | HIST1H3B c.83A>T | Histone Cluster 1 H3 Family Member B Gene c.83A>T | NM_003537.3:c.83A>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555169","Genetically-engineered Immune Cell","C154231","Autologous or allogeneic cells that have been genetically modified.","Genetically-engineered Cell | Cell-based Gene Therapy Agent | Genetically-altered Cell | Genetically-altered Immune Cell | Genetically-engineered Immune Cell | Genetically-modified ICell | Genetically-modified Immune Cell",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555416","H3 Histone Family, Member B Gene","C154501","Human H3C4 wild-type allele is located in the vicinity of 6p22.2 and is approximately 2 kb in length. This allele, which encodes histone H3.1 protein, is involved in DNA compaction.","H3C4 wt Allele | H3 Clustered Histone 4 wt Allele | H3 Histone Family, Member B Gene | H3 Histone Family, Member D Gene | H3/b | H3FB | H3d | HIST1 Cluster, H3D Gene | HIST1H3D | HIST1H3D wt Allele | Histone 1, H3d Gene | Histone Cluster 1 H3 Family Member D Gene | Histone Cluster 1, H3d Gene | Histone Gene Cluster 1, H3 Histone Family, Member D Gene | Histone Gene Cluster 1, H3d Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555417","Multihormonal Immunoreactivity Present in a Single Cell Type","C154502","A finding indicating that neoplastic cells of a single cell type have detectable immunoreactivity for two or more hormones in a tissue sample.","Multihormonal Immunoreactivity Present in a Single Cell Type | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554853","Furosemide Topical Gel CLS006","C153417","A sulfamoylanthranilic acid derivative and loop diuretic, with potential antiviral activity. Upon topical administration, furosemide gel inhibits potassium influx by interacting with cell membrane ion co-transporter,  Na+-K+-2Cl-co-transporter-1(NKCC1; SLC12A2). This may inhibit potassium influx and prevent the replication of DNA viruses, such as human papillomavirus (HPV), that rely on potassium for replication.","Furosemide Topical Gel CLS006 | CLS 006 | CLS-006 | CLS006 | Furosemide Topical Gel CLS 006 | Furosemide Topical Gel CLS-006",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554859","Botanical Agent BEL-X-HG","C153419","An orally available botanically-based agent with potential antineoplastic activity. Upon oral administration, the components in BEL-X-HG may exert cytotoxic effects against cancer cells.","Botanical Agent BEL-X-HG | BEL X HG | BEL-X-HG | BELXHG | Botanical Agent BEL X HG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162647","Teleradiology","C15379","The transmission of radiology images by electronic means to facilitate collaborative interpretation.","Teleradiology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0252926","Bruceanol F","C1537","A quassinoid phytochemical isolated from the plant Brucea antidysenterica with potential antineoplastic activity. (NCI04)","Bruceanol F | Picras-2-en-21-oic Acid, 15-((3,4-dimethyl-1-oxo-2-pentenyl)oxy)-13,20-epoxy-2,11,12-trihydroxy-1,16-dioxo-, Methyl Ester, (11beta,12alpha,15beta(E))-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554998","Recurrent Submandibular Gland Carcinoma","C153801","The reemergence of submandibular gland carcinoma after a period of remission.","Recurrent Submandibular Gland Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554995","Recurrent Appendix Carcinoma","C153802","The reemergence of appendix carcinoma after a period of remission.","Recurrent Appendix Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554996","Recurrent Parotid Gland Adenoid Cystic Carcinoma","C153804","The reemergence of parotid gland adenoid cystic carcinoma after a period of remission.","Recurrent Parotid Gland Adenoid Cystic Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555001","Recurrent Parotid Gland Carcinoma ex Pleomorphic Adenoma","C153805","The reemergence of parotid gland carcinoma ex pleomorphic adenoma after a period of remission.","Recurrent Parotid Gland Carcinoma ex Pleomorphic Adenoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555002","Recurrent Parotid Gland Mucoepidermoid Carcinoma","C153806","The reemergence of parotid gland mucoepidermoid carcinoma after a period of remission.","Recurrent Parotid Gland Mucoepidermoid Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554999","Recurrent Submandibular Gland Mucoepidermoid Carcinoma","C153807","The reemergence of submandibular gland mucoepidermoid carcinoma after a period of remission.","Recurrent Submandibular Gland Mucoepidermoid Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555000","Recurrent Submandibular Gland Carcinoma ex Pleomorphic Adenoma","C153808","The reemergence of submandibular gland carcinoma ex pleomorphic adenoma after a period of remission.","Recurrent Submandibular Gland Carcinoma ex Pleomorphic Adenoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555348","Gentuximab","C154552","A recombinant, humanized monoclonal antibody directed against the vascular endothelial growth factor receptor 2 (VEGFR-2), with potential anti-angiogenic and antineoplastic activities. Upon intravenous injection, gentuximab specifically binds to VEGFR-2, preventing the binding of its ligand, vascular endothelial growth factor (VEGF). Inhibition of VEGFR-2 signaling may potentially inhibit tumor angiogenesis and decrease nutrient supply to tumor cells, resulting in tumor cell death. VEGFR-2 is a type V receptor tyrosine kinase (RTK) expressed on endothelial cells and some tumor cells that regulates endothelial migration and proliferation.","Gentuximab | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555308","H3/c c.83A>T","C154313","A nucleotide substitution at position 83 of the coding sequence of the HIST1H3C gene where adenine has been mutated to thymine.","H3C3 NM_003531.2:c.83A>T | H3 Clustered Histone 3 c.83A>T | H3/c c.83A>T | H3C3 c.83A>T | H3FC c.83A>T | H3c c.83A>T | HIST1H3C NM_003531.2:c.83A>T | HIST1H3C c.83A>T | Histone Cluster 1 H3 Family Member C Gene c.83A>T | NM_003531.2:c.83A>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1856251","Granulomatous Disease, Chronic, Autosomal Recessive, Cytochrome B-Positive, Type I","C154314","An autosomal recessive form of chronic granulomatous disease caused by mutation(s) in the NCF1 gene, encoding neutrophil cytosol factor 1.","Autosomal Recessive Cytochrome B-Positive Chronic Granulomatous Disease Type I | CDG1 | Chronic Granulomatous Disease due to Deficiency of NCF-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1844376","Granulomatous Disease, Chronic, X-Linked","C154315","An X-linked recessive form of chronic granulomatous disease caused by mutation(s) in the CYBB gene, encoding cytochrome b-245 beta chain.","X-linked Chronic Granulomatous Disease | CDGX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1858501","Spinocerebellar Ataxia Type 12","C154316","An autosomal dominant sub-type of spinocerebellar ataxia caused by mutation(s) in the PPP2R2B gene, encoding serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B beta isoform. It presents with characteristic action tremors in the upper limbs, followed by other movement abnormalities.","Spinocerebellar Ataxia Type 12 | SCA12",,,,,,,,,,,,,,,"36714108","Spinocerebellar ataxia type 12",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555211","H3/b Gene Mutation","C154317","A change in the sequence of the HIST1H3D gene.","H3C4 Gene Mutation | H3 Clustered Histone 4 Gene Mutation | H3/b Gene Mutation | H3FB Gene Mutation | H3d Gene Mutation | HIST1H3D Gene Mutation | Histone Cluster 1 H3 Family Member D Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555214","H3/b c.83A>T","C154318","A nucleotide substitution at position 83 of the coding sequence of the HIST1H3D gene where adenine has been mutated to thymine.","H2C4 NM_003530.4:c.83A>T | H3 Clustered Histone 4 c.83A>T | H3/b c.83A>T | H3C4 c.83A>T | H3FB c.83A>T | H3d c.83A>T | HIST1H3D NM_003530.4:c.83A>T | HIST1H3D c.83A>T | Histone Cluster 1 H3 Family Member D Gene c.83A>T | NM_003530.4:c.83A>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555215","H3 Histone Family Member 3A Gene Mutation","C154319","A change in the sequence of the H3-3A gene.","H3-3A Gene Mutation | H3 Histone Family Member 3A Gene Mutation | H3.3 Histone A Gene Mutation | H3.3A Gene Mutation | H3F3 Gene Mutation | H3F3A | H3F3A Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555414","Multihormonal Immunoreactivity Present in Two or More Cell Types","C154503","A finding indicating that neoplastic cells of two or more cell types have detectable immunoreactivity for different hormones in a tissue sample.","Multihormonal Immunoreactivity Present in Two or More Cell Types | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555415","Monomorphous Plurihormonal Pituitary Neuroendocrine Tumor","C154504","A plurihormonal pituitary neuroendocrine tumor consisting of a single cell type producing two (or rarely more) hormones. (WHO)","Monomorphous Plurihormonal Pituitary Neuroendocrine Tumor | Monomorphous Plurihormonal Pituitary Gland Adenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555313","Plurimorphous Plurihormonal Pituitary Neuroendocrine Tumor","C154505","A plurihormonal pituitary neuroendocrine tumor consisting of two or more different cell lineages. (WHO)","Plurimorphous Plurihormonal Pituitary Neuroendocrine Tumor | Plurimorphous Plurihormonal Pituitary Gland Adenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0278940","Prior Chemotherapy for Advanced Disease","C15450","No value exists.","Prior Chemotherapy for Advanced Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555006","Recurrent Parotid Gland Squamous Cell Carcinoma","C153810","The reemergence of parotid gland squamous cell carcinoma after a period of remission.","Recurrent Parotid Gland Squamous Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555003","Recurrent Submandibular Gland Squamous Cell Carcinoma","C153811","The reemergence of submandibular gland squamous cell carcinoma after a period of remission.","Recurrent Submandibular Gland Squamous Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555004","Recurrent Submandibular Gland Undifferentiated Carcinoma","C153812","The reemergence of submandibular gland undifferentiated carcinoma after a period of remission.","Recurrent Submandibular Gland Undifferentiated Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555009","Recurrent Parotid Gland Undifferentiated Carcinoma","C153813","The reemergence of parotid gland undifferentiated carcinoma after a period of remission.","Recurrent Parotid Gland Undifferentiated Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555008","Recurrent Malignant Ovarian Brenner Tumor","C153818","The reemergence of malignant ovarian Brenner tumor after a period of remission.","Recurrent Malignant Ovarian Brenner Tumor | Recurrent Malignant Ovarian Transitional Cell Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555010","Recurrent Ovarian Transitional Cell Carcinoma","C153819","The reemergence of ovarian transitional cell carcinoma after a period of remission.","Recurrent Ovarian Transitional Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574156","Afar Language","C153821","An Afroasiatic language belonging to the Cushitic branch, spoken by the Afar people inhabiting Djibouti, Eritrea and Ethiopia.","Afar Language | AAR",,,,,,,,,,,,,,,"4180043","Afar language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574230","Abkhazian Language","C153822","A Northwest Caucasian language spoken mostly by the Abkhaz people. It is one of the official languages of Abkhazia.","Abkhazian Language | ABK | Abkhaz | Abkhazian | Abxaz",,,,,,,,,,,,,,,"4178691","Abkhazian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574363","Achinese Language","C153824","A Malayo-Polynesian language spoken by the Acehnese people natively in Aceh, Sumatra, Indonesia.","Achinese Language | ACE | Acehnese | Achinese",,,,,,,,,,,,,,,"4180210","Achinese language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556388","Acoli Language","C153825","A Southern Luo dialect spoken by the Acoli people in the districts of Gulu, Kitgum and Pader in northern Uganda. It is also spoken in southern Sudan in Magwi County of Eastern Equatoria state.","Acoli Language | ACH | Acholi | Acoli | Acooli | Akoli | Atscholi | Dok Acoli | Gang | Lok Acoli | Lwo | Lwoo | Shuli",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574493","Adangme Language","C153826","A Ghana-Togo Mountain language of the Kwa family, spoken by the Adan and Agotime people of Ghana and Togo.","Adangme Language | ADA | Adan | Adangme | Adantonwi | Agotime | Dangbe",,,,,,,,,,,,,,,"4177301","Adangme language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555013","Adyghe Language","C153827","A Northwest Caucasian language that is the official language of the Republic of Adygea in the Russian Federation, spoken by various tribes of the Adyghe people.","Adyghe Language | ADY | Adygei | Adyghe | West Circassian",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512278","Group C/Treatment IND Protocol","C15478","A means for providing compassionate use of investigational agents between the time that an agent has been shown to have anti-tumor activity and the time that drug becomes available on the market.  Investigational agents that have been given Group C/Treatment IND designation by the FDA have reproducible efficacy in one or more specific tumor types. Such an agent is likely to alter the pattern of treatment of the disease and can be safely administered by properly trained physicians without specialized supportive care facilities. If a drug meets these criteria CTEP may initiate a formal application to the FDA to authorize Group C distribution for a specific indication. Such approval is not equivalent to formal FDA approval of effectiveness for this indication. Any registered investigator may receive a Group C agent.","Group C/Treatment IND Protocol | Treatment IND Protocol, Group C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555827","Grade 2 Neonatal Coagulation Disorder, AE","C155193","An adverse event in a newborn characterized by biochemical coagulation abnormalities with clinical signs; requiring increased monitoring.","Grade 2 Neonatal Coagulation Disorder, AE | Grade 2 Coagulation Disorder Neonatal | Grade 2 Neonatal Coagulation Disorder, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555832","Grade 3 Neonatal Coagulation Disorder, AE","C155194","An adverse event in a newborn characterized by biochemical or clinical coagulation abnormalities; requiring intervention.","Grade 3 Neonatal Coagulation Disorder, AE | Grade 3 Coagulation Disorder Neonatal | Grade 3 Neonatal Coagulation Disorder, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555833","Grade 4 Neonatal Coagulation Disorder, AE","C155195","A coagulation disorder adverse event in a newborn characterized by life threatening consequences (e.g. severe pulmonary embolism, limb ischemia, hemorrhagic shock, disseminated intravascular coagulation (DIC)); requiring urgent major care changes.","Grade 4 Neonatal Coagulation Disorder, AE | Grade 4 Coagulation Disorder Neonatal | Grade 4 Neonatal Coagulation Disorder, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555830","Grade 5 Neonatal Coagulation Disorder, AE","C155196","A coagulation disorder adverse event in a newborn which results in death.","Grade 5 Neonatal Coagulation Disorder, AE | Grade 5 Coagulation Disorder Neonatal | Grade 5 Neonatal Coagulation Disorder, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555831","Grade 1 Infantile Apnea, AE","C155197","An adverse event in a newborn characterized by self-limiting apnea.","Grade 1 Infantile Apnea, AE | Grade 1 Infantile Apnea | Grade 1 Infantile Apnea, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555836","Grade 2 Infantile Apnea, AE","C155198","An adverse event in a newborn characterized by apnea responsive to stimulation or intermittent fraction of inspired oxygen (FiO2) increase.","Grade 2 Infantile Apnea, AE | Grade 2 Infantile Apnea | Grade 2 Infantile Apnea, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555837","Grade 3 Infantile Apnea, AE","C155199","An adverse event in a newborn characterized by apnea requiring stimulation and sustained fraction of inspired oxygen (FiO2) increase; requiring non-invasive ventilation; reoccurrences requiring start of or relevant increase in dose of respiratory stimulants or other major care changes.","Grade 3 Infantile Apnea, AE | Grade 3 Infantile Apnea | Grade 3 Infantile Apnea, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516646","Clinical Trials Information for Physicians","C15519","No value exists.","Clinical Trials Information for Physicians | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0259754","Water-Soluble Vitamin","C1551","Vitamins that are freely soluble in water.","Water-Soluble Vitamin | Water Soluble Vitamin | water-soluble vitamin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555834","Grade 4 Infantile Apnea, AE","C155200","An apneic adverse event in a newborn characterized by life-threatening respiratory and/or hemodynamic compromise; (semi-)urgent intubation required.","Grade 4 Infantile Apnea, AE | Grade 4 Infantile Apnea | Grade 4 Infantile Apnea, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555835","Grade 5 Infantile Apnea, AE","C155201","An apneic adverse event in a newborn which results in death.","Grade 5 Infantile Apnea, AE | Grade 5 Infantile Apnea | Grade 5 Infantile Apnea, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0180384","Dermatoscope","C154586","An instrument that employs light and magnification to evaluate skin lesions.","Dermatoscope | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556407","Patch Dosage Form Category","C154587","A type of solid pharmaceutical dose form consisting of a flexible preparation, with an adhesive layer and a reservoir of active substance(s) that is usually behind a semi-permeable membrane. Plasters are excluded.","Patch Dosage Form Category | Patch",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555490","Melanoma Advanced Imaging Dermatoscope","C154588","A dermatoscope designed to use hyperspectral imaging and software algorithms to identify early-stage skin melanomas with high specificity.","Melanoma Advanced Imaging Dermatoscope | mAID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0016400","Focus Groups","C154589","A small, usually diverse group of people whose response to something is studied to determine the response that can be expected from a larger population. It is used especially in market research and political analysis.","Focus Group | focus group",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556372","Pellet Dosage Form Category","C154590","A type of solid pharmaceutical dose form consisting of usually cylindrical masses, usually formed by extrusion.","Pellet Dosage Form Category | Pellets",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556412","Pessary Dosage Form Category","C154591","A type of solid pharmaceutical dose form consisting of a material that is usually ovoid and formed by moulding, of a suitable volume and consistency for insertion into the vagina where it dissolves, disperses or melts.","Pessary Dosage Form Category | Pessary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556520","Pillule Dosage Form Category","C154592","A type of solid pharmaceutical dose form consisting of small spheroids that are sufficiently resistant to withstand handling, used for homeopathic medicine.","Pillule Dosage Form Category | Pillules",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556397","Plaster Dosage Form Category","C154593","A type of solid pharmaceutical dose form consisting of a flexible preparation with an adhesive layer containing active substance(s). Patches are excluded.","Plaster Dosage Form Category | Plaster",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556515","Pouch Dosage Form Category","C154594","A type of solid pharmaceutical dose form that consists of a small bag that is intended to be placed in a body cavity for release of the active substance(s) contained within.","Pouch Dosage Form Category | Pouch",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555493","Poultice Dosage Form Category","C154595","A type of semi-solid pharmaceutical dose form consisting of a moist mass, such as meal, herbs, seeds, etc., usually held within or spread upon an appropriate permeable material or dressing.","Poultice Dosage Form Category | Poultice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555491","Shampoo Dosage Form Category","C154597","A type of liquid (or occasionally semi-solid) pharmaceutical dose form that contains surface-active agents and usually forms a foam after rubbing on the scalp with water.","Shampoo Dosage Form Category | Shampoo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555492","Solution Dosage Form Category","C154598","A type of liquid pharmaceutical dose form consisting of one or more substances dissolved in, or miscible with, an appropriate solvent, forming a single-phase liquid.","Solution Dosage Form Category | Solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279034","Adrenal Blockade","C15472","Treatment to block production of adrenal hormones.","Adrenal Blockade | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555784","Grade 1 Periventricular Leukomalacia, AE","C155146","An adverse event in a newborn characterized by transient periventricular echodensities persisting greater than seven days and resolving completely.","Grade 1 Periventricular Leukomalacia, AE | Grade 1 Periventricular Leukomalacia | Grade 1 Periventricular Leukomalacia, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555785","Grade 2 Periventricular Leukomalacia, AE","C155147","An adverse event in a newborn characterized by transient periventricular echodensities evolving in to small localized fronto-parietal cysts or persistent diffuse echodensities.","Grade 2 Periventricular Leukomalacia, AE | Grade 2 Periventricular Leukomalacia | Grade 2 Periventricular Leukomalacia, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555782","Grade 3 Periventricular Leukomalacia, AE","C155148","An adverse event in a newborn characterized by periventricular echodensities, evolving in to extensive cystic periventricular lesions; or densities extending in to the deep white matter.","Grade 3 Periventricular Leukomalacia, AE | Grade 3 Periventricular Leukomalacia | Grade 3 Periventricular Leukomalacia, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574295","Ainu Language","C153829","A language spoken by members of the Ainu ethnic group on the northern Japanese island of Hokkaido. It has no generally accepted genealogical relationship to any other language family.","Ainu Language | AIN | Ainu",,,,,,,,,,,,,,,"4182496","Ainu language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C2919582","Akan Language","C153830","A Central Tano language that is the principal native language of the Akan people of Ghana, spoken over much of the southern half of that country and among some of the population of Ivory Coast.","Akan Language | AKA | Akan",,,,,,,,,,,,,,,"40482419","Akan language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556390","Southern Altai Language","C153832","A Turkic language, spoken officially in the Altai Republic of Russia.","Southern Altai Language | ALT | Gorno-Altai | Gorno-Altay | Southern Altai",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162874","Amharic Language","C153833","A Semitic language spoken as a first language by the Amharas ethnic group and which serves as the official working language of Ethiopia.","Amharic Language | AMH | Amharic",,,,,,,,,,,,,,,"4182354","Amharic language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555014","Angika Language","C153834","An Eastern Indo-Aryan language spoken primarily in the Bihar and Jharkhand states of India and the Terai region of Nepal.","Angika Language | ANP | Angika | Chhika-Chhiki",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555016","Mapuche Language","C153836","A language isolate spoken in south-central Chile and west central Argentina by the Mapuche people.","Mapuche Language | ARN | Mapudungun | Mapuzugun",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555015","Recurrent Malignant Brain Neoplasm","C153837","The reemergence of a malignant brain neoplasm after a period of remission.","Recurrent Malignant Brain Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1555607","Arapaho Language","C153838","A Plains Algonquian language spoken by the Arapaho of Wyoming and Oklahoma.","Arapaho Language | ARP | Arapaho",,,,,,,,,,,,,,,"4180365","Arapaho language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555018","Lokono Language","C153839","An Arawak language spoken by the Lokono people of South America in eastern Venezuela, Guyana, Suriname, and French Guiana.","Lokono Language | ARW | Arawak | Lokono",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574332","Assamese Language","C153840","An Eastern Indo-Aryan language spoken mainly in the Indian state of Assam.","Assamese Language | ASM | Asamiya | Assamese",,,,,,,,,,,,,,,"4182517","Assamese language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0574204","Tatar Language","C154151","A Turkic language spoken by Tatar people in the Russian republics of Tartarstan and  ashkortostan, as well as Siberia.","Tatar Language | TAT | Tatar",,,,,,,,,,,,,,,"4178572","Tatar language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555712","Grade 1 Neonatal Respiratory Insufficiency, AE","C155202","An adverse event in a newborn characterized by clinical evidence of mildly increased respiratory distress (e.g. increased work of breathing) without significant deterioration in gas exchange (increase in partial pressure of carbon dioxide (pCO2) or decrease in oxygenation); no change in baseline functioning; no care changes required.","Grade 1 Neonatal Respiratory Insufficiency, AE | Grade 1 Neonatal Respiratory Insufficiency | Grade 1 Neonatal Respiratory Insufficiency, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555713","Grade 2 Neonatal Respiratory Insufficiency, AE","C155203","An adverse event in a newborn characterized by clinical evidence of increased respiratory distress without significant deterioration in gas exchange (increase in partial pressure of carbon dioxide (pCO2) or decrease in oxygenation); corrected by minor adjustments in current ventilatory support, supplemental oxygen or non-invasive support.","Grade 2 Neonatal Respiratory Insufficiency, AE | Grade 2 Neonatal Respiratory Insufficiency | Grade 2 Neonatal Respiratory Insufficiency, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555711","Grade 4 Neonatal Respiratory Insufficiency, AE","C155205","A respiratory insufficiency adverse event in a newborn characterized by life-threatening respiratory and/or hemodynamic compromise; requiring urgent care change (e.g. urgent intubation).","Grade 4 Neonatal Respiratory Insufficiency, AE | Grade 4 Neonatal Respiratory Insufficiency | Grade 4 Neonatal Respiratory Insufficiency, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555716","Grade 5 Neonatal Respiratory Insufficiency, AE","C155206","A respiratory insufficiency adverse event in a newborn which results in death.","Grade 5 Neonatal Respiratory Insufficiency, AE | Grade 5 Neonatal Respiratory Insufficiency | Grade 5 Neonatal Respiratory Insufficiency, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555281","Therapeutic Ex-vivo-treated Autologous Central Memory T Cells","C154280","A preparation of autologous ex-vivo treated central memory T (Tcm) cells with potential immunostimulatory activity. Upon isolation and ex-vivo treatment through as an of yet not elucidated method, the therapeutic ex-vivo-treated autologous Tcm cells, upon reintroduction into the patient, can activate an antitumor immune response which may eradicate tumor cells.","Therapeutic Ex-vivo-treated Autologous Central Memory T Cells | Autologous Tcm Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555282","Autologous Anti-HER2-CAR-4-1BB-CD3zeta-CD19t+-expressing Tcm-enriched T-lymphocytes","C154281","A preparation of genetically modified autologous central memory (Tcm) enriched T-cells transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-human epidermal growth factor receptor 2 (HER2) single chain variable fragment (scFv) derived from trastuzumab, with a 4-1BB (CD137) costimulatory domain that is linked to the signaling domain of the T-cell antigen receptor complex zeta chain (CD3-zeta) (BBz), and truncated CD19 (CD19t), with potential immunostimulatory and antineoplastic activities. Upon intravenous infusion, Anti-HER2-CAR-4-1BB-CD19t+-expressing Tcm-enriched T-lymphocytes are directed against HER2-expressing cells, thereby inducing selective toxicity in HER2-expressing tumor cells. HER2, a receptor tyrosine kinase, is mutated or overexpressed in many tumor cell types, plays a significant role in tumor cell proliferation and tumor vascularization. The BBz costimulatory signaling domain enhances proliferation of T-cells and antitumor activity, while CD19t, a marker for transduction, is utilized to calculate CAR T-cell dosing and for CAR-expressing cell tracking. Tcm cells have the capacity for long-lived persistence and retain their ability to proliferate upon antigen re-encounter. The immunoglobulin G4 (IgG4) extracellular spacer contains a double mutation, (L235E;N297Q) (EQ) within the CH2 region to reduce Fc receptor recognition.","Autologous Anti-HER2-CAR-4-1BB-CD3zeta-CD19t+-expressing Tcm-enriched T-lymphocytes | Autologous HER2(EQ) BBz/CD19t+ Tcm Cells | Autologous Memory Enriched HER2(EQ)BBzeta/CD19t+-expressing T-cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555279","Fluorine F 18 Azafol","C154282","A radioconjugate containing a folic acid receptor (FR; folate receptor) tracer labeled with fluorine F 18, with potential use for FR-expressing tumor imaging using positron emission tomography (PET). Upon administration of fluorine F 18 azafol, the azafol moiety selectively targets and binds to FR. This allows the visualization of tumor cells expressing FR using PET. FR is overexpressed on certain tumor cell types.","Fluorine F 18 Azafol | 3'-Aza-2'-[(18)F]fluorofolic Acid | [18F]-azafol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555280","Topical Ammonia-oxidizing Bacteria-based Probiotic Solution","C154283","A probiotic spray containing a live-cultured strain of ammonia-oxidizing bacteria (AOB), with potential skin restorative activity. Upon topical application of the AOB-based probiotic solution, the AOBs within the solution oxidize ammonia, thereby converting ammonia on your skin into nitric oxide and nitrite. AOB may potentially protect and restore the skin by preventing ammonia-mediated skin damage. AOB are a naturally-occurring bacteria found in ammonia-rich soil and water.","Topical Ammonia-oxidizing Bacteria-based Probiotic Solution | AO Bacteria-containing Mist | AO+ Mist | AOB-based Probiotic Spray | Ammonia Oxidizing Bacteria-containing Probiotic Mist | Topical Probiotic Solution | Topical Probiotic Spray",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279495","Progestin Therapy","C15484","The use of progestogens in the treatment of any disease or disorder.","Progestin Therapy | ",,,,,,,,,,,,,,,"4072512","Progestogen hormone therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0279496","Neurotoxicity Attenuation","C15485","No value exists.","Neurotoxicity Attenuation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555671","Cancer Primary Site Known Indicator","C154860","An indication as to whether the primary site of cancer is known.","Cancer Primary Site Known Indicator | ORCANIND | Origin of Cancer Known Ind | Origin of Cancer Known Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555672","Tumor Resected Indicator","C154861","An indication as to whether the tumor has been resected.","Tumor Resected Indicator | RESCTIND | Resected Tumor Ind | Resected Tumor Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555754","Grade 4 Feeding Intolerance, AE","C155248","A feeding intolerance adverse event in a newborn characterized by life-threatening consequences.","Grade 4 Feeding Intolerance, AE | Grade 4 Feeding Intolerance | Grade 4 Feeding Intolerance, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555755","Grade 5 Feeding Intolerance, AE","C155249","A feeding intolerance adverse event in a newborn which results in death.","Grade 5 Feeding Intolerance, AE | Grade 5 Feeding Intolerance | Grade 5 Feeding Intolerance, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555783","Grade 1 Infant Irritability, AE","C155149","An adverse event in a newborn characterized by mild, self-limiting, irritability, not affecting feeding and sleeping.","Grade 1 Infant Irritability, AE | Grade 1 Infant Irritability | Grade 1 Infant Irritability, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1455743","Psychosocial Assessment and Care","C15514","The act of determining, usually through interviews and observation, the state of an individual's psychological state and social environment, and subsequently providing assistance to the individual based on their needs.","Psychosocial Assessment and Care | Psychosocial Care/Assessment",,,,,,,,,,,,,,,"4161194|4248977|4248978","Psychosocial assessment|Psychosocial care|Psychosocial analysis assessment",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--"
"CL555788","Grade 2 Infant Irritability, AE","C155150","An adverse event in a newborn characterized by moderate irritability, minor changes in feeding and sleeping behavior, requiring minor additional care (e.g. occasional analgesics).","Grade 2 Infant Irritability, AE | Grade 2 Infant Irritability | Grade 2 Infant Irritability, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555789","Grade 3 Infant Irritability, AE","C155151","An adverse event in a newborn characterized by severe irritability, major changes in feeding behavior, requiring support other than oral feeding; requiring long term medical treatment (e.g. sedatives).","Grade 3 Infant Irritability, AE | Grade 3 Infant Irritability | Grade 3 Infant Irritability, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555786","Grade 4 Infant Irritability, AE","C155152","An adverse event in a newborn characterized by life threatening irritability, with loss of autonomic control of temperature or heart rate; requiring urgent care change.","Grade 4 Infant Irritability, AE | Grade 4 Infant Irritability | Grade 4 Infant Irritability, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555792","Grade 2 Infant Sedation, AE","C155154","An adverse event in a newborn characterized by moderate sedation; limiting interactions and minor changes in feeding behavior; requiring increased monitoring.","Grade 2 Infant Sedation, AE | Grade 2 Infant Sedation | Grade 2 Infant Sedation, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555793","Grade 3 Infant Sedation, AE","C155155","An adverse event in a newborn characterized by severe sedation, major changes in feeding behavior; requiring support other than oral feeding (e.g. tube feeding).","Grade 3 Infant Sedation, AE | Grade 3 Infant Sedation | Grade 3 Infant Sedation, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555790","Grade 4 Infant Sedation, AE","C155156","An adverse event in a newborn characterized by life-threatening sedation with cardiorespiratory instability; requiring urgent care change.","Grade 4 Infant Sedation, AE | Grade 4 Infant Sedation | Grade 4 Infant Sedation, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555796","Grade 2 Neonatal Hypotension, AE","C155158","An adverse event in a newborn characterized by persistent (greater than 60 minutes) hypotension; not affecting perfusion; requiring minor care changes (e.g. additional fluids).","Grade 2 Neonatal Hypotension, AE | Grade 2 Neonatal Hypotension | Grade 2 Neonatal Hypotension, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555797","Grade 3 Neonatal Hypotension, AE","C155159","An adverse event in a newborn characterized by persistent hypotension affecting perfusion; requiring major care change (e.g. vaso-active drugs or hydrocortisone).","Grade 3 Neonatal Hypotension, AE | Grade 3 Neonatal Hypotension | Grade 3 Neonatal Hypotension, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280342","Colony-Stimulating Factor Therapy","C15515","The use of colony-stimulating factor to increase leukocyte production in the treatment of any disease or disorder.","Colony-Stimulating Factor Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555794","Grade 4 Neonatal Hypotension, AE","C155160","A hypotensive adverse event in a newborn characterized by life-threatening consequences (e.g. shock, organ failure).","Grade 4 Neonatal Hypotension, AE | Grade 4 Neonatal Hypotension | Grade 4 Neonatal Hypotension, Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0204512","Psychosocial Rehabilitation","C15423","Programs, techniques, or processes of treatment by which individuals acquire psychological and social skills and attitudes which facilitate community interaction.  (from PSY94)","Psychosocial Rehabilitation | ",,,,,,,,,,,,,,,"4097523","Psychiatric rehabilitation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556109","FACT-BL Version 4 - Content With Quality of My Life","C155607","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Functional Well-Being: I am content with the quality of my life right now.","FACT-BL Version 4 - Content With Quality of My Life | FAC006-Content With Quality of My Life | FAC00627",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556106","FACT-BL Version 4 - Trouble Controlling My Urine","C155608","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Additional Concerns: I have trouble controlling my urine.","FACT-BL Version 4 - Trouble Controlling My Urine | FAC006-Trouble Controlling My Urine | FAC00628",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556107","FACT-BL Version 4 - I Am Losing Weight","C155609","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Additional Concerns: I am losing weight.","FACT-BL Version 4 - I Am Losing Weight | FAC006-I Am Losing Weight | FAC00629",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556112","FACT-BL Version 4 - I Have Control of My Bowels","C155610","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Additional Concerns: I have control of my bowels.","FACT-BL Version 4 - I Have Control of My Bowels | FAC006-I Have Control of My Bowels | FAC00630",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556113","FACT-BL Version 4 - I Urinate More Frequently","C155611","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Additional Concerns: I urinate more frequently than usual.","FACT-BL Version 4 - I Urinate More Frequently | FAC006-I Urinate More Frequently | FAC00631",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556110","FACT-BL Version 4 - I Have Diarrhea","C155612","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Additional Concerns: I have diarrhea (diarrhoea).","FACT-BL Version 4 - I Have Diarrhea | FAC006-I Have Diarrhea | FAC00632",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556111","FACT-BL Version 4 - I Have a Good Appetite","C155613","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Additional Concerns: I have a good appetite.","FACT-BL Version 4 - I Have a Good Appetite | FAC006-I Have a Good Appetite | FAC00633",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556116","FACT-BL Version 4 - I Like the Appearance of My Body","C155614","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Additional Concerns: I like the appearance of my body.","FACT-BL Version 4 - I Like the Appearance of My Body | FAC006-I Like the Appearance of My Body | FAC00634",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556117","FACT-BL Version 4 - It Burns When I Urinate","C155615","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Additional Concerns: It burns when I urinate.","FACT-BL Version 4 - It Burns When I Urinate | FAC006-It Burns When I Urinate | FAC00635",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556114","FACT-BL Version 4 - I Am Interested in Sex","C155616","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Additional Concerns: I am interested in sex.","FACT-BL Version 4 - I Am Interested in Sex | FAC006-I Am Interested in Sex | FAC00636",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556115","FACT-BL Version 4 - Able to Have/Maintain Erection","C155617","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Additional Concerns: (For men only) I am able to have and maintain an erection.","FACT-BL Version 4 - Able to Have/Maintain Erection | FAC006-Able to Have/Maintain Erection | FAC00637",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555973","UHDRS 1999 Version - Permanently Institutionalized","C155471","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Since the last visit, has the subject been permanently institutionalized?","UHDRS 1999 Version - Permanently Institutionalized | UHDR1-Permanently Institutionalized | UHDR183A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555970","UHDRS 1999 Version - Continue to Be Assessed for Study","C155472","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) If the subject was institutionalized will the subject continue to be assessed for this study?","UHDRS 1999 Version - Continue to Be Assessed for Study | UHDR1-Continue to Be Assessed for Study | UHDR183B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555971","UHDRS 1999 Version - Total Motor Score","C155473","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Total Motor score.","UHDRS 1999 Version - Total Motor Score | UHDR1-Total Motor Score | UHDR184",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555977","UHDRS 1999 Version - Mood Subscale Score","C155475","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Mood subscale score of the total behavior score.","UHDRS 1999 Version - Mood Subscale Score | UHDR1-Mood Subscale Score | UHDR186",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555974","UHDRS 1999 Version - Behavior Subscale Score","C155476","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Behavior subscale score of the total behavior score.","UHDRS 1999 Version - Behavior Subscale Score | UHDR1-Behavior Subscale Score | UHDR187",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555975","UHDRS 1999 Version - Psychosis Subscale Score","C155477","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Psychosis subscale score of the total behavior score.","UHDRS 1999 Version - Psychosis Subscale Score | UHDR1-Psychosis Subscale Score | UHDR188",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555980","UHDRS 1999 Version - Obsessive Subscale Score","C155478","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Obsessive subscale score of the total behavior score.","UHDRS 1999 Version - Obsessive Subscale Score | UHDR1-Obsessive Subscale Score | UHDR189",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555981","UHDRS 1999 Version - Total Functional Capacity Score","C155479","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Total functional capacity score.","UHDRS 1999 Version - Total Functional Capacity Score | UHDR1-Total Functional Capacity Score | UHDR190",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2919584","Screening for Skin Cancer","C15547","No value exists.","Screening for Skin Cancer | early detection of skin cancer | skin cancer early detection | skin cancer screening",,,,,,,,,,,,,,,"40480252","Screening for malignant neoplasm of skin",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555978","UHDRS 1999 Version - Independence Scale Score","C155480","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Independence scale score.","UHDRS 1999 Version - Independence Scale Score | UHDR1-Independence Scale Score | UHDR191",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555979","UHDRS 1999 Version - Functional Checklist Score","C155481","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Functional checklist score.","UHDRS 1999 Version - Functional Checklist Score | UHDR1-Functional Checklist Score | UHDR192",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555984","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Dressing Without Help","C155482","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Dressing yourself without help.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Dressing Without Help | FAC100-Sev: Dressing Without Help | FAC10001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555985","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Dressing Why Not","C155483","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Dressing yourself without help. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Dressing Why Not | FAC100-Sev: Dressing Why Not | FAC10002",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562924","Metastatic Oral Cavity Adenoid Cystic Carcinoma","C156089","An adenoid cystic carcinoma that arises from the oral cavity and has metastasized to another anatomic site.","Metastatic Oral Cavity Adenoid Cystic Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4275058","Smoothened Antagonist","C155725","Any agent that is an antagonist at the Smoothened (SMO) receptor.","Smoothened Antagonist | SMO Antagonist | Smoothened Receptor Antagonist",,,,,,,,,,,,,,,"37396019","Smoothened receptor antagonist",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0235656","Lesion of the Cervix Uteri","C155726","A localized pathological or traumatic structural change, damage, deformity, or discontinuity of the cervix uteri.","Lesion of the Cervix Uteri | Cervical Lesion",,,,,,,,,,,,,,,"443285","Lesion of cervix",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556219","ZBTB33 Gene","C155729","This gene plays a role in the regulation of both gene transcription and signal transduction.","ZBTB33 Gene | ZBTB33 | Zinc Finger And BTB Domain Containing 33 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281413","Prevention of Prostate Cancer","C15572","No value exists.","Prevention of Prostate Cancer | Prostate Cancer Prevention",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556216","ZBTB33 wt Allele","C155730","Human ZBTB33 wild-type allele is located in the vicinity of Xq24 and is approximately 8 kb in length. This allele, which encodes transcriptional regulator Kaiso protein, is involved in transcriptional regulation, signaling and DNA binding.","ZBTB33 wt Allele | KAISO | WUGSC:H_DJ525N14.1 | ZNF-kaiso | ZNF348 | Zinc Finger And BTB Domain Containing 33 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556217","Transcriptional Regulator Kaiso","C155731","Transcriptional regulator Kaiso (672 aa, ~74 kDa) is encoded by the human ZBTB33 gene. This protein plays a role in DNA binding, transcriptional regulation, chromatin modification and signal pathway regulation.","Transcriptional Regulator Kaiso | Kaiso Transcription Factor | ZBTB33 | Zinc Finger and BTB Domain-Containing Protein 33 | Zinc Finger- and BTB Domain-Containing Protein 33",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556222","LINC00598 Gene","C155732","This gene may be involved in breast cancer and leukemia.","LINC00598 Gene | LINC00598 | Long Intergenic Non-Protein Coding RNA 598 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556223","LINC00598 wt Allele","C155733","Human LINC00598 wild-type allele is located in the vicinity of 13q14.11 and is approximately 457 kb in length. This allele, which encodes long intergenic non-protein coding RNA 598, may play a role in tumorigenesis. A translocation t(12;13)(p13;q14) involving this gene and the ETV6 gene is associated with B-cell acute lymphoblastic leukemia.","LINC00598 wt Allele | FLJ21437 | LIN00598 | LOC646982 | LncFOXO1 | Long Intergenic Non-Protein Coding RNA 598 wt Allele | TTL | TTL-B1 | TTL-B2 | TTL-T | Twelve-Thirteen Translocation Leukemia Transcript (Non-Protein Coding) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556220","Long Intergenic Non-Protein Coding RNA 598","C155734","Long intergenic non-protein coding RNA 598 (~2-4 kb) is encoded by the human LINC00598 gene. This non-coding RNA may be involved in tumorigenesis.","Long Intergenic Non-Protein Coding RNA 598 | LINC00598 | LncFOXO1 | TTL | Twelve-Thirteen Translocation Leukemia Transcript",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556221","H3Y2 Gene","C155735","This gene may play a role in chromatin structure and transcriptional regulation.","H3Y2 Gene | H3 Histone, Family 3B Pseudogene Gene | H3.3B Gene | H3.X | H3.X Gene | H3.Y Histone 2 Gene | H3.Y.2 | H3Y2 | Histone Cluster 2, H3d Pseudogene Gene | LOC340096",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555884","UHDRS 1999 Version - Saccade Velocity: Horizontal","C155374","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Saccade velocity, horizontal.","UHDRS 1999 Version - Saccade Velocity: Horizontal | UHDR1-Saccade Velocity: Horizontal | UHDR103A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555885","UHDRS 1999 Version - Saccade Velocity: Vertical","C155375","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Saccade velocity, vertical.","UHDRS 1999 Version - Saccade Velocity: Vertical | UHDR1-Saccade Velocity: Vertical | UHDR103B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555883","UHDRS 1999 Version - Tongue Protrusion","C155377","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Tongue protrusion.","UHDRS 1999 Version - Tongue Protrusion | UHDR1-Tongue Protrusion | UHDR105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555888","UHDRS 1999 Version - Finger Taps: Right","C155378","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Finger taps, right.","UHDRS 1999 Version - Finger Taps: Right | UHDR1-Finger Taps: Right | UHDR106A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555889","UHDRS 1999 Version - Finger Taps: Left","C155379","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Finger taps, left.","UHDRS 1999 Version - Finger Taps: Left | UHDR1-Finger Taps: Left | UHDR106B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555886","UHDRS 1999 Version - Pronate/Supinate: Hands: Right","C155380","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Pronate/supinate-hands, right.","UHDRS 1999 Version - Pronate/Supinate: Hands: Right | UHDR1-Pronate/Supinate: Hands: Right | UHDR107A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555887","UHDRS 1999 Version - Pronate/Supinate: Hands: Left","C155381","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Pronate/supinate-hands, left.","UHDRS 1999 Version - Pronate/Supinate: Hands: Left | UHDR1-Pronate/Supinate: Hands: Left | UHDR107B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555892","UHDRS 1999 Version - Luria","C155382","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Luria (fist-hand palm test).","UHDRS 1999 Version - Luria | UHDR1-Luria | UHDR108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4225350","EIEE32","C155998","An autosomal dominant form of early infantile epileptic encephalopathy, caused by mutation(s) in the KCNA2 gene, encoding potassium voltage-gated channel subfamily A member 2.","Developmental and Epileptic Encephalopathy 32 | DEE32 | EIEE32 | Early Infantile Epileptic Encephalopathy 32",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3151137","CILIARY DYSKINESIA, PRIMARY, 15","C155999","An autosomal recessive primary ciliary motility defect caused by mutation(s) in the CCDC40 gene, encoding coiled-coil domain-containing protein 40.","Primary Ciliary Dyskinesia 15 | CILD15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556121","FACT-BL Version 4 - Embarrassed by Ostomy Appliance","C155619","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Additional Concerns: I am embarrassed by my ostomy appliance.","FACT-BL Version 4 - Embarrassed by Ostomy Appliance | FAC006-Embarrassed by Ostomy Appliance | FAC00639",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281207","Cancer Prevention Intervention","C15561","No value exists.","Cancer Prevention Intervention | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556118","FACT-BL Version 4 - Caring for Ostomy Appliance Is Difficult","C155620","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Additional Concerns: Caring for my ostomy appliance is difficult.","FACT-BL Version 4 - Caring for Ostomy Appliance Is Difficult | FAC006-Caring for Ostomy Is Difficult | FAC00640",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556119","NSCLC-SAQ Version 1.0 - Rate Coughing at Worst","C155621","Non-Small Cell Lung Cancer Symptom Assessment Questionnaire v1.0 (NSCLC-SAQ Version 1.0) How would you rate your coughing at its worst over the last 7 days?","NSCLC-SAQ Version 1.0 - Rate Coughing at Worst | NSCLC1-Rate Coughing at Worst | NSCLC101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556359","Unresectable Low Grade Glioma","C155829","Low grade glioma that is not amenable to surgical removal.","Unresectable Low Grade Glioma | Unresectable Low-Grade Glioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281551","Prevention of Aerodigestive Tract Cancer","C15582","No value exists.","Prevention of Aerodigestive Tract Cancer | aerodigestive tract cancer prevention",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562670","National Drug Code Unit of Measure","C155837","A unit of measure that is required when submitting a national drug code for billing purposes.","National Drug Code Unit of Measure | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563210","NDC ME (Milligram)","C155838","A recognized billing qualifier that may be used to identify milligrams as the NDC unit of measure.","NDC ME (Milligram) | ME | National Drug Code Milligram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563214","NDC UN (Unit)","C155839","A recognized billing qualifier that may be used to identify a unit as the NDC unit of measure. This is often used when describing a powder for injection (needs to be reconstituted), pellet, kit, patch, tablet or device.","NDC UN (Unit) | National Drug Code Unit | UN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563209","NDC ML (Milliliter)","C155840","A recognized billing qualifier that may be used to identify a milliliter as the NDC unit of measure. This is often used when describing a liquid, solution, or suspension.","NDC ML (Milliliter) | ML | National Drug Code Milliliter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562926","Metastatic Lip Squamous Cell Carcinoma","C156091","A squamous cell carcinoma that arises from the lip and has metastasized to another anatomic site.","Metastatic Lip Squamous Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562927","Metastatic Lung Squamous Cell Carcinoma","C156092","A squamous cell carcinoma that arises from the lung and has metastasized to another anatomic site.","Metastatic Lung Squamous Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562832","Metastatic Lung Adenosquamous Carcinoma","C156093","An adenosquamous carcinoma that arises from the lung and has metastasized to another anatomic site.","Metastatic Lung Adenosquamous Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562833","Metastatic Lung Non-Small Cell Carcinoma","C156094","A non-small cell carcinoma that arises from the lung and has metastasized to another anatomic site.","Metastatic Lung Non-Small Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562834","Metastatic Lung Small Cell Carcinoma","C156095","A small cell carcinoma that arises from the lung and has metastasized to another anatomic site.","Metastatic Lung Small Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562835","Metastatic Colorectal Carcinoma","C156096","A carcinoma that arises from the colon or rectum and has metastasized to another anatomic site.","Metastatic Colorectal Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562828","Metastatic Colon Carcinoma","C156097","A carcinoma that arises from the colon and has metastasized to another anatomic site.","Metastatic Colon Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562829","Metastatic Rectal Carcinoma","C156098","A carcinoma that arises from the rectum and has metastasized to another anatomic site.","Metastatic Rectal Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562830","Metastatic Thyroid Gland Follicular Carcinoma","C156099","A follicular carcinoma that arises from the thyroid gland and has metastasized to another anatomic site.","Metastatic Thyroid Gland Follicular Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280509","Brequinar","C1560","A synthetic quinolinecarboxylic acid analogue with antineoplastic properties.  Brequinar inhibits the enzyme dihydroorotate dehydrogenase, thereby blocking de novo pyrimidine biosynthesis.  This agent may also enhance the in vivo antitumor effect of antineoplastic agents such as 5-FU. (NCI04)","Brequinar | 6-Fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-4-quinolinecarboxylic Acid | BREQUINAR | Bipenquinate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562831","Metastatic Thyroid Gland Papillary Carcinoma","C156100","A papillary carcinoma that arises from the thyroid gland and has metastasized to another anatomic site.","Metastatic Thyroid Gland Papillary Carcinoma | Metastatic Papillary Thyroid Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493285","Metastatic Neuroblastoma","C156101","A neuroblastoma that has metastasized from its original site of growth to another anatomic site.","Metastatic Neuroblastoma | ",,,,,,,,,,,,,,,"45766888","Neuroblastoma, metastatic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL562825","Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","C156103","The reemergence of a blastic plasmacytoid dendritic cell neoplasm after a period of remission.","Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562826","Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm","C156104","Blastic plasmacytoid dendritic cell neoplasm that is resistant to treatment.","Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556227","H3.Y.1","C155737","Human H3Y1 wild-type allele is located in the vicinity of 5p15.1 and is approximately 0.9 kb in length. This allele, which encodes histone H3.Y protein, may play a role in the chromatin structure and transcriptional regulation.","H3Y1 wt Allele | H3 Histone, Family 3B (H3.3B) Pseudogene Gene | H3.X | H3.Y | H3.Y Histone 1 wt Allele | H3.Y wt Allele | H3.Y.1 | Histone Cluster 2, H3c Pseudogene Gene | Histone Cluster 2, H3c Pseudogene wt Allele | LOC391769",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555942","Sickle Cell Chronic Lung Disease","C155312","A pulmonary complication of sickle cell disease characterized by radiographic interstitial abnormalities and impaired pulmonary function. In severe cases, pulmonary hypertension is present.","Sickle Cell Chronic Lung Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0339467","Proliferative Retinopathy","C155313","Retinopathy characterized by the formation of new vessels in the retina. The new vessels are abnormal and fragile. If hemorrhage occurs due to the vascular fragility, there is increased risk of vision loss or blindness.","Proliferative Retinopathy | ",,,,,,,,,,,,,,,"45757798","Proliferative retinopathy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555944","Bilateral Proliferative Retinopathy","C155316","Proliferative retinopathy occurring in both eyes.","Bilateral Proliferative Retinopathy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555945","PDHX Gene","C155317","This gene plays a role in the localization of the pyruvate dehydrogenase complex.","PDHX Gene | PDHX | Pyruvate Dehydrogenase Complex Component X Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555949","PDHX wt Allele","C155318","Human PDHX wild-type allele is located in the vicinity of 11p13 and is approximately 105 kb in length. This allele, which encodes pyruvate dehydrogenase protein X component, mitochondrial protein, is involved in the regulation of pyruvate dehydrogenase activity. Mutation of the gene is associated with lactic acidosis due to pyruvate dehydrogenase E3-binding protein deficiency.","PDHX wt Allele | DLDBP | E3BP | OPDX | PDHXD | PDX1 | Pyruvate Dehydrogenase Complex Component X wt Allele | Pyruvate Dehydrogenase Complex, Component X Gene | proX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555950","Pyruvate Dehydrogenase Protein X Component, Mitochondrial","C155319","Pyruvate dehydrogenase protein X component, mitochondrial (501 aa, ~54 kDa) is encoded by the human PDHX gene. This protein plays a role in anchoring dihydrolipoamide dehydrogenase (E3) to the dihydrolipoamide transacetylase (E2) core of the pyruvate dehydrogenase complex.","Pyruvate Dehydrogenase Protein X Component, Mitochondrial | Dihydrolipoamide Dehydrogenase-Binding Protein of Pyruvate Dehydrogenase Complex | E3-Binding Protein | E3BP | Lipoyl-Containing Pyruvate Dehydrogenase Complex Component X | PDHX | Pyruvate Dehydrogenase Complex, E3-Binding Protein Subunit | Pyruvate Dehydrogenase Complex, Lipoyl-Containing Component X | proX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562749","IL6R Gene Product","C156001","A protein encoded by the IL6R gene.","IL6R Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556195","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Lifting 5-10 Lbs","C155569","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Lifting something weighing 5-10 lbs (about 2-4.5 kg, like a basket of clothes).","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Lifting 5-10 Lbs | FAC100-Limit: Lifting 5-10 Lbs | FAC10088",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281192","Prevention of Skin Cancer","C15556","No value exists.","Prevention of Skin Cancer | Skin Cancer Prevention",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556200","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Lifting More Than 20 Lbs","C155570","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Lifting something weighing more than 20 lbs (about 9 kg, like a medium-sized suitcase).","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Lifting More Than 20 Lbs | FAC100-Limit: Lifting More Than 20 Lbs | FAC10089",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562666","NDC GR (Gram)","C155841","A recognized billing qualifier that may be used to identify a unit as the NDC unit of measure. This is often used when describing ointments, creams, inhalers or bulk powder in a jar.","NDC GR (Gram) | GR | National Drug Code Gram",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556056","UHDRS 1999 Version - UDHR1-Examiner Believe Subject Confused","C155426","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Confusion is defined as intermittent or persistent disorganized thinking, perceptual disturbances or disorientation to time, place, or person. Does the examiner believe the subject is confused?","UHDRS 1999 Version - UDHR1-Examiner Believe Subject Confused | UDHR1-Examiner Believe Subject Confused | UHDR136",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556057","UHDRS 1999 Version - UDHR1-Confusion Altered Performance","C155427","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) If yes: Does the examiner believe that this has altered the performance on the UHDRS?","UHDRS 1999 Version - UDHR1-Confusion Altered Performance | UDHR1-Confusion Altered Performance | UHDR136A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556054","UHDRS 1999 Version - UDHR1-Examiner Believe Signs of Dementia","C155428","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Unified Huntington's Disease Rating Scale '99 - Dementia is defined as progressive impairment in memory, abstract thinking or judgment that interferes with work or usual social activities and relationships. Does the examiner believe that the participant is showing signs of dementia?","UHDRS 1999 Version - UDHR1-Examiner Believe Signs of Dementia | UDHR1-Examiner Believe Signs of Dementia | UHDR137",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556055","UHDRS 1999 Version - UDHR1-Dementia Altered Performance","C155429","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) If yes: Does the examiner believe that this has altered the performance on the UHDRS?","UHDRS 1999 Version - UDHR1-Dementia Altered Performance | UDHR1-Dementia Altered Performance | UHDR137A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556060","UHDRS 1999 Version - UDHR1-Examiner Believe Signs Depression","C155430","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Unified Huntington's Disease Rating Scale '99 - Depression is defined as persistent depressed mood, anhedonia, or vegetative signs sufficient to interfere with daily functioning. Does the examiner believe that the participant is showing signs of depression?","UHDRS 1999 Version - UDHR1-Examiner Believe Signs Depression | UDHR1-Examiner Believe Signs Depression | UHDR138",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556061","UHDRS 1999 Version - Pharmacotherapy of Depression","C155431","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) In the opinion of the examiner, is a clinical evaluation or follow up warranted for possible pharmacotherapy of depression?","UHDRS 1999 Version - Pharmacotherapy of Depression | UHDR1-Pharmacotherapy of Depression | UHDR139",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513920","Neoadjuvant Study","C15566","No value exists.","Neoadjuvant Study | study, neoadjuvant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556282","NRAS NM_002524.4:c.38G>T","C155676","A nucleotide substitution at position 38 of the coding sequence of the NRAS gene where guanine has been mutated to thymine.","NRAS NM_002524.4:c.38G>T | N-ras c.38G>T | NM_002524.4:c.38G>T | NRAS c.38G>T | NRAS1 c.38G>T | Neuroblastoma RAS Viral (v-ras) Oncogene Homolog c.38G>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281305","Screening for Gastric Cancer","C15567","No value exists.","Screening for Gastric Cancer | early detection of gastric cancer | early detection of stomach cancer | gastric cancer early detection | gastric cancer screening | screening for stomach cancer | stomach cancer early detection | stomach cancer screening",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562720","FPA 150","C155967","A fully human, glycoengineered monoclonal antibody targeting B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1) with potential antineoplastic and immune checkpoint inhibitory activities. Upon intravenous administration, alsevalimab binds to B7-H4 on the surface of tumor cells, thereby preventing B7-H4 binding to T-cells and abrogating the B7-H4-mediated negative regulation of T-cell activation. This increases a cytotoxic T-lymphocyte (CTL)-mediated immune response against B7-H4-expressing tumor cells. In addition, the afucosylated Fc region of the anti-B7-H4 monoclonal antibody FPA150 enhances its binding affinity for human FcgammaRIIIa receptors (CD16) on natural killer (NK) cells, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) against B7-H4-expressing tumor cells. B7-H4, a member of the B7 family of immune modulators, is upregulated in a variety of tumor cell types and negatively regulates T-cell immune responses.","Alsevalimab | ALSEVALIMAB | Anti-B7-H4 Monoclonal Antibody FPA150 | FPA 150 | FPA-150 | FPA150",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562721","Carbon C 14-TAK-659","C155968","A radioconjugate composed of the citrate form of mivavotinib, an orally bioavailable selective inhibitor of the non-receptor tyrosine kinase (RTK) spleen tyrosine kinase (Syk), labeled with the radioisotope carbon C 14, with potential use for evaluating the pharmacokinetic profile of mivavotinin. Upon administration of carbon C 14 mivavotinib citrate, mivavotinib targets, binds to and inhibits Syk. Labeling of mivavotinib with the radioactive tracer carbon C 14 permits the evaluation of this agent's pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME). Syk, a B-cell receptor (BCR)-associated non-receptor tyrosine kinase that mediates B-cell activation, chemotaxis, adhesion and proliferation, is expressed in hematopoietic tissues and is often overexpressed in hematopoietic malignancies.","Carbon C 14 Mivavotinib Citrate | 14C-labeled Anlotinib Hydrochloride | 14C-labeled Mivavotinib Citrate | Carbon C 14-TAK-659 | [14 C]-TAK-659 | [14C]TAK 659 | [14C]TAK-659",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562714","Total Tumor mRNA-pulsed Tumor-specific Ex vivo-expanded Autologous Lymphocyte Transfer Cells","C155969","A preparation of ex vivo expanded, autologous lymphocyte transfer cells (xALTs) that are loaded with total tumor RNA (TTRNA) derived from autologous tumor cells, with potential immunostimulatory and antineoplastic activities. Upon re-infusion of the TTRNA-loaded ALTs into the patient, these ALTs may elicit a highly specific cytotoxic T-lymphocyte (CTL) response against the tumor-associated antigens (TAAs) encoded by the TTRNA.","Total Tumor mRNA-pulsed Tumor-specific Ex vivo-expanded Autologous Lymphocyte Transfer Cells | Autologous TTRNA mRNA-loaded Lymphocyte Transfer Cells | TTRNA-xALT | TTRNA-xALT Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562715","Anti-CD33/CD3 Bispecific Antibody GEM 333","C155970","A bispecific antibody possessing two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for the tumor-associated antigen (TAA) CD33, with potential immunostimulating and antineoplastic activities. Upon administration of anti-CD33/CD3 bispecific antibody GEM 333, this bispecific antibody binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD33 antigen found on CD33-expressing tumor cells, thereby crosslinking tumor cells and CTLs. This activates and redirects CTLs to CD33-expressing tumor cells, which results in the CTL-mediated cell death of CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem and progenitor cells (HSPCs) and is overexpressed on a variety of cancer cell types, including acute myeloid leukemia (AML). It plays a key role in tumor initiation, proliferation and progression.","Anti-CD33/CD3 Bispecific Antibody GEM 333 | Anti-CD33 Bispecific Antibody GEM 333 | Anti-CD33/Anti-CD3 Bispecific Antibody GEM 333 | Anti-CD33/CD3 Antibody GEM 333 | GEM 333 | GEM-333 | GEM333",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556198","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Carrying 5-10 Lbs","C155572","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Carrying something weighing 5-10 lbs (about 2-4.5 kg, like a basket of clothes) from one room to another.","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Carrying 5-10 Lbs | FAC100-Limit: Carrying 5-10 Lbs | FAC10091",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556199","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Get In/Out of a Car","C155573","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Getting in or out of a car.","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Get In/Out of a Car | FAC100-Limit: Get In/Out of a Car | FAC10092",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556204","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Dining Out","C155574","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Dining out.","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Dining Out | FAC100-Limit: Dining Out | FAC10093",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556205","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Low-intensity Activity","C155575","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Low-intensity leisure activity (gardening, etc.).","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Low-intensity Activity | FAC100-Limit: Low-intensity Activity | FAC10094",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556202","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Moderate Activity","C155576","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Moderate-intensity leisure activity (bicycling on level terrain, etc.).","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Moderate Activity | FAC100-Limit: Moderate Activity | FAC10095",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556203","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Walk Fast 50 Steps","C155577","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Walking (faster than your usual speed) for 50 steps without stopping.","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Walk Fast 50 Steps | FAC100-Limit: Walk Fast 50 Steps | FAC10096",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556208","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Walking Fast 1 Mile","C155578","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Walking (faster than your usual speed) for at least 1 mile (a little more than 1.5 km) without stopping.","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Walking Fast 1 Mile | FAC100-Limit: Walking Fast 1 Mile | FAC10097",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556263","ERK 1/2 Inhibitor ASTX029","C155785","The anhydrous form of beroterkib, an orally bioavailable inhibitor of the extracellular signal-regulated kinases (ERK) 1 and 2, with potential antineoplastic activity. Upon administration, beroterkib specifically binds to and inhibits both ERK 1 and 2, thereby preventing the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The MAPK/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in the proliferation, differentiation and survival of tumor cells.","Beroterkib Anhydrous | ASTX 029 | ASTX-029 | ASTX029 | AT-35029 | AT35029 | BEROTERKIB ANHYDROUS | ERK 1/2 Inhibitor ASTX029 | ERK 1/2 Inhibitor ASTX029 | ERK Inhibitor ASTX029 | Extracellular Signal-regulated Kinase 1/2 Inhibitor ASTX029 | Extracellular Signal-regulated Kinase Inhibitor ASTX029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556058","UHDRS 1999 Version - Pharmacotherapy of Irritability","C155432","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) In the opinion of the examiner, is a clinical evaluation or follow up warranted for possible pharmacotherapy of irritability?","UHDRS 1999 Version - Pharmacotherapy of Irritability | UHDR1-Pharmacotherapy of Irritability | UHDR140",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556059","UHDRS 1999 Version - Behavior Assessment Obtained From","C155433","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Was the Behavioral Assessment information obtained from.","UHDRS 1999 Version - Behavior Assessment Obtained From | UHDR1-Behavior Assessment Obtained From | UHDR141",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556064","UHDRS 1999 Version - Gainful Employment Accustomed Work","C155434","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject engage in gainful employment in his/her accustomed work?","UHDRS 1999 Version - Gainful Employment Accustomed Work | UHDR1-Gainful Employment Accustomed Work | UHDR143",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556062","UHDRS 1999 Version - Volunteer or Non Gainful Work","C155436","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject engage in any kind of volunteer or non gainful work?","UHDRS 1999 Version - Volunteer or Non Gainful Work | UHDR1-Volunteer or Non Gainful Work | UHDR145",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556063","UHDRS 1999 Version - Manage Finances Without Help","C155437","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject manage his/her finances (monthly) without any help?","UHDRS 1999 Version - Manage Finances Without Help | UHDR1-Manage Finances Without Help | UHDR146",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556068","UHDRS 1999 Version - Shop for Groceries Without Help","C155438","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject shop for groceries without help?","UHDRS 1999 Version - Shop for Groceries Without Help | UHDR1-Shop for Groceries Without Help | UHDR147",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562902","Hobnail Variant Thyroid Gland Papillary Carcinoma","C156050","A rare variant of papillary thyroid gland carcinoma in which more than 30% of cells have hobnail features. (WHO)","Hobnail Variant Thyroid Gland Papillary Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936080","Coke Oven Emission Exposure","C157008","Occupational exposure to gases and particulates produced when coal is processed in a coke oven.","Coke Oven Emission Exposure | Coke Oven Emission | Coke ovens",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0020075","Neuropathy, Hereditary Sensory and Autonomic, Type V","C156360","An autosomal recessive condition caused by mutation(S) in the NGF gene, encoding beta-nerve growth factor. It is characterized by loss of pain sensation, particularly in the extremities.","Neuropathy, Hereditary Sensory and Autonomic, Type V | HSAN5 | Hereditary Sensory and Autonomic Neuropathy Type V",,,,,,,,,,,,,,,"4028086","Congenital sensory neuropathy with selective loss of small myelinated fibers",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1414216","Torsion Dystonia 6","C156361","An autosomal dominant condition caused by mutation(s) in the THAP1 gene, encoding THAP domain-containing protein 1. It is characterized by dystonic craniofacial movements, dysarthria, and dysphagia. Limb involvement is common.","Torsion Dystonia 6 | DYT6",,,,,,,,,,,,,,,"45765497","Dystonia 6",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL562716","MEK inhibitor CS3006","C155971","An orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPKK; MEK), with potential antineoplastic activity. Upon oral administration, MEK inhibitor CS3006 specifically targets, binds to and inhibits the catalytic activity of MEK, thereby inhibiting the activation of MEK-dependent effector proteins including extracellular signal-regulated kinase (ERK) and inhibits the proliferation of tumor cells in which the RAS/RAF/MEK/ERK signaling pathway is overactivated. The threonine/tyrosine protein kinase MEK plays a key role in the  RAS/RAF/MEK/ERK signaling pathway, which is frequently upregulated in a variety of tumor cell types. The RAS/RAF/MEK/ERK pathway regulates key cellular activities including cell growth, proliferation, survival, differentiation and apoptosis.","MEK inhibitor CS3006 | CS 3006 | CS-3006 | CS3006 | MAPK Kinase Inhibitor CS3006",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562717","Fluorine F 18-AIF-NOTA-neurotensin","C155972","A radioconjugate containing neurotensin (NT) linked to the radionuclide fluorine F 18 (18F), by the macrocyclic chelating agent, 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA), through a method that first couples 18F to aluminum (Al), with potential use in diagnostic imaging using positron emission tomography/computed tomography (PET/CT). Upon administration of fluorine F 18-Al-NOTA-neurotensin, the ligand moiety targets and binds to the neurotensin receptor (NTR). Upon PET/CT, NTR-expressing tumor cells can then be visualized and NTR tumor cell expression can be assessed, as well as the diagnosis and stage of cancer. The neuropeptide NT is overexpressed in certain types of cancers and plays a key role in tumor cell proliferation.","Fluorine F 18-AIF-NOTA-neurotensin | 18F-AlF-NOTA-NT | 18F-AlF-NOTA-neurotensin | 18F-aluminum Fluoride-1,4,7-triazacyclononane-1,4,7-triacetic Acid-neurotensin | Fluorine F 18-Al-NOTA-neurotensin | [18F]AlF-NOTA-neurotensin | [18F]Aluminum Fluoride-1,4,7-triazacyclononane-1,4,7-triacetic Acid-neurotensin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556163","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Moderate Activity Why Not","C155537","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Moderate-intensity leisure activity (bicycling on level terrain, etc.). Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Moderate Activity Why Not | FAC100-Sev: Moderate Activity Why Not | FAC10056",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556168","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walk Fast 50 Steps","C155538","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking (faster than your usual speed) for 50 steps without stopping.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walk Fast 50 Steps | FAC100-Sev: Walk Fast 50 Steps | FAC10057",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556169","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walk Fast 50 Steps Why Not","C155539","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking (faster than your usual speed) for 50 steps without stopping. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walk Fast 50 Steps Why Not | FAC100-Sev: Walk Fast 50 Steps Why Not | FAC10058",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556166","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking Fast 1 Mile","C155540","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking (faster than your usual speed) for at least 1 mile ( a little more than 1.5 km) without stopping.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking Fast 1 Mile | FAC100-Sev: Walking Fast 1 Mile | FAC10059",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556167","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking Fast 1 Mile Why Not","C155541","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking (faster than your usual speed) for at least 1 mile ( a little more than 1.5 km) without stopping. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking Fast 1 Mile Why Not | FAC100-Sev: Walking Fast 1 Mile Why Not | FAC10060",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556264","Metastatic Malignant Neoplasm in the Sellar Region","C155786","A malignant neoplasm that has metastasized to the sellar region from another anatomic site.","Metastatic Malignant Neoplasm in the Sellar Region | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281488","In Vitro Sensitivity-Directed Chemotherapy","C15578","Uses the results of a chemosensitivity testing assay to tailor the treatment to the individual.","In Vitro Sensitivity-Directed Chemotherapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556325","Malignant Skull Neoplasm","C155790","A primary or metastatic malignant neoplasm that affects the bones and structures of the skull.","Malignant Skull Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556323","Malignant Skull Base Neoplasm","C155791","A primary or metastatic malignant neoplasm that affects the skull base.","Malignant Skull Base Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556324","Benign Skull Neoplasm","C155792","A neoplasm that arises from the bones and structures of skull and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Skull Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556328","Benign Skull Base Neoplasm","C155793","A neoplasm that arises the skull base and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Skull Base Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556329","Epratuzumab-cys-tesirine","C155794","An antibody-drug conjugate (ADC) composed of a cysteine-engineered version of epratuzumab (hLL2), a humanized anti-CD22 monoclonal antibody derived from the murine immunoglobulin (Ig) G2a monoclonal antibody LL2 (EPB-2), site-specifically conjugated to the cross-linking cytotoxic agent tesirine (SG3249), a cathepsin B-cleavable valine-alanine pyrrolobenzodiazepine dimer (PBD), with potential antineoplastic activity. Upon administration of epratuzumab-cys-tesirine, the epratuzumab moiety targets and binds to the B cell-specific CD22 receptor and is rapidly internalized. Upon cleavage, the imine groups of tesirine target and bind to the N2 positions of guanines on opposite strands of DNA. This induces interstrand cross-links in the minor groove of DNA and inhibits DNA replication, which inhibits the proliferation of CD22-overexpressing tumor cells. CD22, a cell surface glycoprotein, is expressed on mature B-cells and on most malignant B-cells.","Epratuzumab-cys-tesirine | ADC ADCT-602 | ADCT-602 | ADCT602 | Anti-CD22/PBD ADC ADCT-602 | Antibody-drug Conjugate ADCT-602 | EPRATUZUMAB-CYS-TESIRINE | Epratuzumab-cys-SG3249 | hLL2-cys-PBD | hLL2-cys-SG3249",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556327","Pituitary Gland Non-Hodgkin Lymphoma","C155796","A rare non-Hodgkin lymphoma that arises from the pituitary gland. The majority are diffuse large B-cell lymphomas.","Pituitary Gland Non-Hodgkin Lymphoma | Primary Pituitary Gland Non-Hodgkin Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556332","Pituitary Gland Diffuse Large B-Cell Lymphoma","C155797","A rare diffuse large B-cell lymphoma that arises from the pituitary gland.","Pituitary Gland Diffuse Large B-Cell Lymphoma | Pituitary Gland Diffuse Large B-Cell Lymphoma | Pituitary Gland Diffuse Large B-Cell Lymphoma | Primary Pituitary Gland Diffuse Large B-Cell Lymphoma | Primary Pituitary Gland Diffuse Large B-Cell Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562897","BCMA x CD3 T-cell Engaging Antibody CC-93269",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562898","Cabazitaxel-Prednisone","C156053","A regimen consisting of cabazitaxel and prednisone that can be used for the treatment of prostate cancer.","Cabazitaxel/Prednisone Regimen | Cabazitaxel and Prednisone | Cabazitaxel-Prednisone | Cabazitaxel-Prednisone Regimen | Cabazitaxel/Prednisone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1628029","Human Papillomavirus-63","C156054","A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-63 may be associated with a risk for cervical cancer.","Human Papillomavirus-63 | 63 | HPV-63 | HPV63 | Human Papilloma Virus 63 | Human Papilloma Virus-63 | Human Papillomavirus 63",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562893","ATAC-Seq","C156056","A molecular genetic technique that isolates and sequences chromosomal regions that are rich in open chromatin. First, nuclei are harvested from a cellular sample. Then a hyperactive Tn5 transposase is added to the nuclei where it excises non-nucleosomal DNA strands and ligates co-administered high-throughput sequencing adapters (tagmentation).  The tagged DNA fragments are isolated, amplified by PCR and sequenced. The number of reads for specific region of DNA correlate with increased chromatin accessibility and this method can identify regions of transcription factor and nucleosome binding.","ATAC-Seq | ATAC-seq (assay for Transposase-Accessible Chromatin (ATAC) strategy is used to study genome-wide chromatin accessibility) | Assay for Transposase Accessible Chromatin with High-Throughput Sequencing | Assay for Transposase-Accessible Chromatin Sequencing | Assay for Transposase-Accessible Chromatin Using Sequencing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556124","NSCLC-SAQ Version 1.0 - Rate Worst Pain in Chest","C155622","Non-Small Cell Lung Cancer Symptom Assessment Questionnaire v1.0 (NSCLC-SAQ Version 1.0) How would you rate the worst pain in your chest over the last 7 days?","NSCLC-SAQ Version 1.0 - Rate Worst Pain in Chest | NSCLC1-Rate Worst Pain in Chest | NSCLC102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556125","NSCLC-SAQ Version 1.0 - Rate Worst Pain Other Than Chest","C155623","Non-Small Cell Lung Cancer Symptom Assessment Questionnaire v1.0 (NSCLC-SAQ Version 1.0) How would you rate the worst pain in areas other than your chest over the last 7 days?","NSCLC-SAQ Version 1.0 - Rate Worst Pain Other Than Chest | NSCLC1-Rate Worst Pain Other Than Chest | NSCLC103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556122","NSCLC-SAQ Version 1.0 - Short of Breath Usual Activities","C155624","Non-Small Cell Lung Cancer Symptom Assessment Questionnaire v1.0 (NSCLC-SAQ Version 1.0) How often did you feel short of breath during usual activities over the last 7 days?","NSCLC-SAQ Version 1.0 - Short of Breath Usual Activities | NSCLC1-Short of Breath Usual Activities | NSCLC104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556123","NSCLC-SAQ Version 1.0 - How Often Low Energy","C155625","Non-Small Cell Lung Cancer Symptom Assessment Questionnaire v1.0 (NSCLC-SAQ Version 1.0) How often did you have low energy over the last 7 days?","NSCLC-SAQ Version 1.0 - How Often Low Energy | NSCLC1-How Often Low Energy | NSCLC105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556128","NSCLC-SAQ Version 1.0 - How Often Tire Easily","C155626","Non-Small Cell Lung Cancer Symptom Assessment Questionnaire v1.0 (NSCLC-SAQ Version 1.0) How often did you tire easily over the last 7 days?","NSCLC-SAQ Version 1.0 - How Often Tire Easily | NSCLC1-How Often Tire Easily | NSCLC106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563070","Feline Melanoma","C156362","A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes that occurs in a cat.","Feline Melanoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563071","Tavokinogene Telseplasmid","C156363","A DNA plasmid that encodes genes for both the p35 and p40 subunits of the heterodimeric human interleukin 12 (hIL-12) protein that are separated by an internal ribosome entry site (IRES) and under the control of a single cytomegalovirus (CMV) promoter, with potential immunomodulatory and antineoplastic activities. Upon administration via intratumoral injection and electroporation, the plasmid is introduced into human cells resulting in expression and highly-localized secretion of a functional IL-12 p70 protein into the tumor microenvironment (TME). IL-12 is a pro-inflammatory cytokine that plays a significant role in priming and maintaining T-helper (Th) cells, activating natural killer (NK) cells, and regulating the reactivation and survival of memory T-cells (Tm). Increased levels of IL-12 in the TME may augment host immune response against tumor cells by inhibiting regulatory T-cells (Tregs), T-helper 2 (Th2) responses, and myeloid-derived suppressor cells (MDSCs).","Tavokinogene Telseplasmid | IT-Tavo-EP | Plasmid IL-12 pUMVC3-hIL-12-NGVL3 | TAVOKINOGENE TELSEPLASMID | Tavo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563072","Eribulin/Trastuzumab Regimen","C156364","A regimen consisting of eribulin and trastuzumab that may be used in the treatment of breast cancer.","Eribulin/Trastuzumab Regimen | Eribulin and Trastuzumab | Eribulin and Trastuzumab-anns | Eribulin and Trastuzumab-dkst | Eribulin and Trastuzumab-dttb | Eribulin and Trastuzumab-herw | Eribulin and Trastuzumab-pkrb | Eribulin and Trastuzumab-qyyp | Eribulin and Trastuzumab-zerc | Eribulin-Trastuzumab | Eribulin-Trastuzumab Regimen | Eribulin/Trastuzumab | Halaven/Herceptin | Trastuzumab-Eribulin | Trastuzumab/Eribulin | Trastuzumab/Eribulin Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563066","Cyclophosphamide/Trastuzumab Regimen","C156365","A regimen consisting of cyclophosphamide and trastuzumab that may be used in the treatment of HER-2 (EGFR2; ErbB2)-positive breast cancer.","Cyclophosphamide/Trastuzumab Regimen | Cyclophosphamide-Trastuzumab | Cyclophosphamide-Trastuzumab Regimen | Cyclophosphamide/Herceptin | Cyclophosphamide/Trastuzumab | Trastuzumab-Cyclophosphamide | Trastuzumab/Cyclophosphamide | Trastuzumab/Cyclophosphamide Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563067","Cisplatin/Trastuzumab Regimen","C156366","A regimen consisting of cisplatin and trastuzumab that may be used in the treatment of recurrent and metastatic HER-2 (EGFR2; ErbB2)-positive breast cancer.","Cisplatin/Trastuzumab Regimen | Cisplatin-Trastuzumab | Cisplatin/Herceptin | Cisplatin/Trastuzumab | Trastuzumab-Cisplatin | Trastuzumab/Cisplatin | Trastuzumab/Cisplatin Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563069","Exemestane/Palbociclib Regimen","C156368","A regimen consisting of exemestane and palbociclib that may be used in the treatment of breast cancer.","Exemestane/Palbociclib Regimen | Aromasin/Ibrance | Exemestane and Palbociclib | Exemestane-Palbociclib | Exemestane-Palbociclib Regimen | Exemestane/Palbociclib | Palbociclib-Exemestane | Palbociclib/Exemestane | Palbociclib/Exemestane Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563062","Fulvestrant/Palbociclib Regimen","C156369","A regimen consisting of fulvestrant and palbociclib that may be used in the treatment of breast cancer.","Fulvestrant/Palbociclib Regimen | Faslodex/Ibrance | Fulvestrant and Palbociclib | Fulvestrant-Palbociclib | Fulvestrant-Palbociclib Regimen | Fulvestrant/Palbociclib | Palbociclib-Fulvestrant | Palbociclib/Fulvestrant | Palbociclib/Fulvestrant Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516239","Cancer and Nutrition","C15658","Systematic investigation into the role that nutrition plays in cancer.","Cancer and Nutrition | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556172","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Singing or Humming","C155542","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Singing or humming.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Singing or Humming | FAC100-Sev: Singing or Humming | FAC10061",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556173","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Singing or Humming Why Not","C155543","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Singing or humming. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Singing or Humming Why Not | FAC100-Sev: Singing or Humming Why Not | FAC10062",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556170","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Talking While Walking","C155544","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Talking while walking.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Talking While Walking | FAC100-Sev: Talking While Walking | FAC10063",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556171","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Talking While Walk Why Not","C155545","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Talking while walking. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Talking While Walk Why Not | FAC100-Sev: Talking While Walk Why Not | FAC10064",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556176","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Scrubbing the Floor","C155546","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Scrubbing the floor or counter.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Scrubbing the Floor | FAC100-Sev: Scrubbing the Floor | FAC10065",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556224","Histone H3.Y","C155738","Histone H3.Y (136 aa, ~15 kDa) is encoded by the human H3Y1 gene. This protein may be involved in both the positive regulation of transcription and the formation of higher order chromatin structures.","Histone H3.Y | H3.Y | H3.Y.1 | H3Y1 | Histone H3.Y.1 | Histone H3.Y1 | Histone H3.y",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281444","Tumor-Draining Lymph Node Lymphocyte Therapy","C15573","No value exists.","Tumor-Draining Lymph Node Lymphocyte Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0861741","Recurrent Pancreatic Adenocarcinoma","C155742","The reemergence of pancreatic adenocarcinoma after a period of remission.","Recurrent Pancreatic Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556228","Locally Advanced Unresectable Pancreatic Adenocarcinoma","C155743","A pancreatic adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.","Locally Advanced Unresectable Pancreatic Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555893","UHDRS 1999 Version - Rigidity: Arms: Right","C155383","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Rigidity-arms, right.","UHDRS 1999 Version - Rigidity: Arms: Right | UHDR1-Rigidity: Arms: Right | UHDR109A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555890","UHDRS 1999 Version - Rigidity: Arms: Left","C155384","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Rigidity-arms, left.","UHDRS 1999 Version - Rigidity: Arms: Left | UHDR1-Rigidity: Arms: Left | UHDR109B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555896","UHDRS 1999 Version - Maximal Dystonia: Trunk","C155386","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Maximal dystonia-Trunk.","UHDRS 1999 Version - Maximal Dystonia: Trunk | UHDR1-Maximal Dystonia: Trunk | UHDR111A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555897","UHDRS 1999 Version - Maximal Dystonia: RUE","C155387","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Maximal dystonia-RUE.","UHDRS 1999 Version - Maximal Dystonia: RUE | UHDR1-Maximal Dystonia: RUE | UHDR111B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555894","UHDRS 1999 Version - Maximal Dystonia: LUE","C155388","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Maximal dystonia-LUE.","UHDRS 1999 Version - Maximal Dystonia: LUE | UHDR1-Maximal Dystonia: LUE | UHDR111C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555895","UHDRS 1999 Version - Maximal Dystonia: RLE","C155389","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Maximal dystonia-RLE.","UHDRS 1999 Version - Maximal Dystonia: RLE | UHDR1-Maximal Dystonia: RLE | UHDR111D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555900","UHDRS 1999 Version - Maximal Dystonia: LLE","C155390","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Maximal dystonia-LLE.","UHDRS 1999 Version - Maximal Dystonia: LLE | UHDR1-Maximal Dystonia: LLE | UHDR111E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555901","UHDRS 1999 Version - Maximal Chorea: Face","C155391","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Maximal chorea-Face.","UHDRS 1999 Version - Maximal Chorea: Face | UHDR1-Maximal Chorea: Face | UHDR112A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555898","UHDRS 1999 Version - Maximal Chorea: BOL","C155392","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Maximal chorea-BOL.","UHDRS 1999 Version - Maximal Chorea: BOL | UHDR1-Maximal Chorea: BOL | UHDR112B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555899","UHDRS 1999 Version - Maximal Chorea: Trunk","C155393","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Maximal chorea-Trunk.","UHDRS 1999 Version - Maximal Chorea: Trunk | UHDR1-Maximal Chorea: Trunk | UHDR112C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556025","UHDRS 1999 Version - Maximal Chorea: LUE","C155395","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Maximal chorea-LUE.","UHDRS 1999 Version - Maximal Chorea: LUE | UHDR1-Maximal Chorea: LUE | UHDR112E",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556022","UHDRS 1999 Version - Maximal Chorea: RLE","C155396","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Maximal chorea-RLE.","UHDRS 1999 Version - Maximal Chorea: RLE | UHDR1-Maximal Chorea: RLE | UHDR112F",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556023","UHDRS 1999 Version - Maximal Chorea: LLE","C155397","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Maximal chorea-LLE.","UHDRS 1999 Version - Maximal Chorea: LLE | UHDR1-Maximal Chorea: LLE | UHDR112G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556028","UHDRS 1999 Version - Gait","C155398","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Gait.","UHDRS 1999 Version - Gait | UHDR1-Gait | UHDR113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556126","NSCLC-SAQ Version 1.0 - Total Score","C155628","Non-Small Cell Lung Cancer Symptom Assessment Questionnaire v1.0 (NSCLC-SAQ Version 1.0) Total score.","NSCLC-SAQ Version 1.0 - Total Score | NSCLC1-Total Score | NSCLC113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556127","SMDDS Version 1.0 - How Sad Have You Felt","C155629","Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how sad have you felt?","SMDDS Version 1.0 - How Sad Have You Felt | SMDDS1-How Sad Have You Felt | SMDDS101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556132","SMDDS Version 1.0 - How Hopeless Have You Felt","C155630","Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how hopeless have you felt?","SMDDS Version 1.0 - How Hopeless Have You Felt | SMDDS1-How Hopeless Have You Felt | SMDDS102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556133","SMDDS Version 1.0 - How Irritable Have You Felt","C155631","Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how irritable have you felt?","SMDDS Version 1.0 - How Irritable Have You Felt | SMDDS1-How Irritable Have You Felt | SMDDS103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556130","SMDDS Version 1.0 - How Overwhelmed Have You Felt","C155632","Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how overwhelmed have you felt?","SMDDS Version 1.0 - How Overwhelmed Have You Felt | SMDDS1-How Overwhelmed Have You Felt | SMDDS104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556131","SMDDS Version 1.0 - How Worried Have You Felt","C155633","Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how worried have you felt?","SMDDS Version 1.0 - How Worried Have You Felt | SMDDS1-How Worried Have You Felt | SMDDS105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556136","SMDDS Version 1.0 - How Tired Have You Felt","C155634","Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how tired have you felt?","SMDDS Version 1.0 - How Tired Have You Felt | SMDDS1-How Tired Have You Felt | SMDDS106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556137","SMDDS Version 1.0 - How Difficult Stop Think Problems","C155635","Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how difficult was it for you to stop thinking about your problems?","SMDDS Version 1.0 - How Difficult Stop Think Problems | SMDDS1-How Difficult Stop Think Problems | SMDDS107",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556134","SMDDS Version 1.0 - How Difficult to Concentrate","C155636","Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how difficult was it for you to concentrate?","SMDDS Version 1.0 - How Difficult to Concentrate | SMDDS1-How Difficult to Concentrate | SMDDS108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556135","SMDDS Version 1.0 - How Difficult to Enjoy Daily Life","C155637","Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how difficult was it for you to enjoy your daily life?","SMDDS Version 1.0 - How Difficult to Enjoy Daily Life | SMDDS1-How Difficult to Enjoy Daily Life | SMDDS109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0262718","Kegel Exercise","C155847","An exercise to strengthen the pelvic floor muscles, in which the levator muscles are squeezed and held, then released, for a number of repetitions.","Kegel Exercise | Kegel",,,,,,,,,,,,,,,"4083020","Pelvic floor exercises",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL562680","Circadian Biometric Recorder","C155848","A proprietary device that uses a thermal differential detection system to detect and record abnormal circadian cellular temperature changes, including those associated with breast cancer tumor infusion.","Circadian Biometric Recorder | CBR System | Cyrcadia Health Circadian Biometric Recorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935742","Open Label for Treatment And Double Blind to Dose","C156592","A study in which the therapeutic treatment is open label but the dosing information of the investigational medicinal product (IMP) is double-blinded.","Open Label for Treatment And Double Blind to Dose | OPEN LABEL TO TREATMENT AND DOUBLE BLIND TO IMP DOSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936109","Mobilization Clinical Trial Setting","C156596","A clinical trial or treatment setting in which the therapy of interest is considered mobilization therapy.","Mobilization Clinical Trial Setting | MOBILIZATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937373","Conditioning Clinical Trial Setting","C156597","A clinical trial or treatment setting in which the therapy of interest is considered conditioning therapy.","Conditioning Clinical Trial Setting | CONDITIONING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936115","Salvage Clinical Trial Setting","C156600","A clinical trial or treatment setting in which the therapy of interest is considered salvage therapy.","Salvage Clinical Trial Setting | SALVAGE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556233","Anti-CD137 Monoclonal Antibody","C155745","Any monoclonal antibody directed against the co-stimulatory immune checkpoint molecule CD137 (tumor necrosis factor receptor superfamily member 9; TNFRSF9; 4-1BB; induced by lymphocyte activation; ILA).","Anti-CD137 Monoclonal Antibody | Anti-4-1BB Monoclonal Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1832200","Peroxisome Biogenesis Disorder","C155747","A group of conditions characterized by impairment of peroxisome assembly and metabolic pathways confined to this organelle, caused by mutation(s) in the peroxin (PEX) gene family. Phenotypically, they manifest as Zellweger syndrome (ZS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and rhizomelic chondrodysplasia punctata (RCDP1), the latter a distinct peroxisome biogenesis disorder phenotype. ZS, NALD, and IRD have multiple complementation groups and form a spectrum of diseases with overlapping features.","Peroxisome Biogenesis Disorder | PBD",,,,,,,,,,,,,,,"42538228","Peroxisome biogenesis disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556235","Peroxisome Biogenesis Disorder 1A","C155748","An autosomal recessive condition caused by mutation(s) in the PEX1 gene, encoding peroxisome biogenesis factor 1. Peroxisome biogenesis disorder 1A manifests phenotypically as Zellweger syndrome.","Peroxisome Biogenesis Disorder 1A | PBD1A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556236","Peroxisome Biogenesis Disorder 1B","C155749","An autosomal recessive condition caused by mutation(s) in the PEX1 gene, encoding peroxisome biogenesis factor 1. Peroxisome biogenesis disorder 1B is characterized by overlapping phenotypes of neonatal adrenoleukodystrophy and infantile Refsum disease.","Peroxisome Biogenesis Disorder 1B |  PBD1B | PBD1B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556234","PEROXISOME BIOGENESIS DISORDER 2A (ZELLWEGER)","C155750","An autosomal recessive condition caused by mutation(s) in the PEX5 gene, encoding peroxisomal targeting signal 1 receptor. Peroxisome biogenesis disorder 2A manifests phenotypically as Zellweger syndrome.","Peroxisome Biogenesis Disorder 2A |  PBD2A | PBD2A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556238","PEROXISOME BIOGENESIS DISORDER 3A (ZELLWEGER)","C155752","An autosomal recessive condition caused by mutation(s) in the PEX12 gene, encoding peroxisome assembly protein 12. Peroxisome biogenesis disorder 3A manifests phenotypically as Zellweger syndrome.","Peroxisome Biogenesis Disorder 3A |  PBD3A | PBD3A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555955","CDRS-R - Impaired Schoolwork","C155329","Children's Depression Rating Scale, Revised (CDRS-R) Impaired schoolwork.","CDRS-R - Impaired Schoolwork | CDRS1-Impaired Schoolwork | CDRS101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280914","In Vitro-Treated Peripheral Blood Stem Cell Transplantation","C15532","No value exists.","In Vitro-Treated Peripheral Blood Stem Cell Transplantation | in vitro-treated PBPC transplantation | in vitro-treated peripheral blood progenitor cell transplantation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555840","CDRS-R - Impaired Schoolwork Comment","C155330","Children's Depression Rating Scale, Revised (CDRS-R) Impaired schoolwork comment.","CDRS-R - Impaired Schoolwork Comment | CDRS1-Impaired Schoolwork Comment | CDRS101A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556029","UHDRS 1999 Version - Tandem Walking","C155399","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Tandem walking.","UHDRS 1999 Version - Tandem Walking | UHDR1-Tandem Walking | UHDR114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519638","Treatment Referral Center Protocol","C15539","No value exists.","Treatment Referral Center Protocol | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0279175","Thyroid Agent","C1553","Compounds that influence the function of the thyroid hormone through replacement, inhibition or stimulation. (NCI)","Thyroid Agent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562758","Adenoviral Cancer Vaccine PF-06936308","C156015","A cancer vaccine composed of a replication-defective E1-deleted adenovirus vector based on chimpanzee adenovirus serotype 68 (AdC68) expressing three not yet disclosed tumor-associated antigens (TAAs), with potential immunostimulating and antineoplastic activities. Upon vaccination with the adenoviral cancer vaccine PF-06936308, the adenovirus infects cells and expresses the TAAs. In turn, the TAAs activate the immune system to produce a cytotoxic T-lymphocyte (CTL) response against cells expressing the TAAs.","Adenoviral Cancer Vaccine PF-06936308 | PF 06936308 | PF-06936308 | PF06936308",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562677","mySmartCheck","C155849","An online program for skin self-examination (SSE) designed to introduce users to melanoma risk factors and the importance of SSE behaviors; review past experiences doing skin self-checks, teach how to identify potentially suspicious moles, enhance confidence, address skin self-check barriers, and help users to create a monthly skin self-check action plan; take the user through the process of conducting a thorough skin self-check and record moles and other growths using an online body mole map.","mySmartCheck | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562678","PTPN11 Inhibitor RMC-4630","C155850","An orally bioavailable inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; Src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic activity. Upon oral administration, vociprotafib targets, binds to and inhibits the activity of SHP2. This prevents SHP2-mediated signaling, inhibits MAPK signaling and prevents growth of SHP2-expressing tumor cells. SHP2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the RAS-RAF-MEK-ERK signaling pathway. The RAS-MAPK pathway is often hyperactivated in cancer cells due to specific mutations and rearrangements and are dependent on SHP2 for their oncogenic signaling. SHP2 also regulates programmed cell death 1 (PD-1)-mediated signal transduction and is involved in immune checkpoint modulation.","Vociprotafib | (6-((2-Amino-3-chloropyridin-4-yl)sulfanyl)-3-((3S,4S)-4-amino- 3-methyl-2-oxa-8-azaspiro(4.5)decan-8-yl)- 5-methylpyrazin-2-yl)methanol | 2-Pyrazinemethanol, 6-((2-amino-3-chloro-4-pyridinyl)thio)-3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro(4.5)dec-8-yl)-5-methyl- | PTPN11 Inhibitor RMC-4630 | RMC 4630 | RMC-4630 | RMC4630 | SAR 442720 | SAR-442720 | SAR442720 | SHP2 Inhibitor RMC-4630 | SHP2 Inhibitor RMC-4630 | VOCIPROTAFIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562679","Metastatic Malignant Pancreatic Neoplasm","C155852","A malignant neoplasm that arises from the pancreas and has metastasized to another anatomic site.","Metastatic Malignant Pancreatic Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562676","MyPatientPal","C155856","A smartphone-based application designed to track of cancer symptoms, manage medications, develop charts to share with a doctor, and receive alerts about when to call the doctor's office or when to seek immediate medical attention. Features include a daily symptom log and a daily medication log.","MyPatientPal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562671","Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy","C155857","Photodynamic treatment of deep-seated solid tumors using a light source that is placed by a transbronchial needle, using ultrasound guidance.","Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy | EBUS-TBN IPDT | EBUS-TBN Interstitial Photodynamic Therapy | Endobronchial Ultrasound Transbronchial Needle-Guided Interstitial Photodynamic Therapy | Endobronchial Ultrasound with Transbronchial Needle (EBUS-TBN) Guided Interstitial PDT (IPDT) | Ultrasound-Guided Transbronchial Needle-Guided Interstitial Photodynamic Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562672","Gardasil Immunogenicity with Needle-Free Injection","C155858","A study to determine if immunogenicity to human papillomavirus will develop following needle-free vaccine delivery of Gardasil.","Gardasil Immunogenicity with Needle-Free Injection | GINI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562673","Diode Laser Fiber Type Selective Stimulator","C155859","A device designed to use a diode laser to stimulate peripheral nerves. It is being tested to help predict whether a patient will develop peripheral neuropathy.","Diode Laser Fiber Type Selective Stimulator | DLss",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556069","UHDRS 1999 Version - Handle Money as Purchaser","C155439","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject handle money as a purchaser in a simple cash (store) transaction?","UHDRS 1999 Version - Handle Money as Purchaser | UHDR1-Handle Money as Purchaser | UHDR148",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935819","Copper Cu 64-CB-TE1A1P-PEG4-LLP2A","C156772","A radioconjugate containing LLP2A, a high-affinity peptidomimetic ligand for the tumor-associated antigen (TAA) very-late-antigen-4 (VLA-4; VLA 4; alpha4beta1 integrin; CD49d/CD29), conjugated, via the chelator 1,4,8,11-tetraazacyclotetradecane-1-(methane phosphonic acid)-8-(methane carboxylic acid) (CB-TE1A1P), to the radioisotope copper Cu 64, and conjugated to polyethylene glycol (PEG) chains that can potentially be used as a diagnostic imaging agent of VLA-4-expressing tumor cells using positron-emitting tomography (PET). Upon administration, copper Cu 64-CB-TE1A1P-PEG4-LLP2A targets, binds to and is taken up by VLA-4-expressing tumor cells. Upon PET, the VLA-4-expressing tumor cells can be visualized, and the tumor can be assessed. VLA-4, a transmembrane adhesion receptor overexpressed and activated on various tumor cell types and surrounding stroma, plays an important role in tumor growth, angiogenesis, metastasis, drug resistance and immune responses. Pegylation optimizes the pharmacokinetic profile of 64Cu-LLP2A.","Copper Cu 64-CB-TE1A1P-PEG4-LLP2A | (64)Cu-CB-TE1A1P-PEG4-LLP2A | (64)Cu-labeled CB-TE1A1P-PEG4 LLP2A | (64)Cu-labeled CB-TE1A1P-PEG4-LLP2A | 64Cu-CB-TE1A1P-PEG4-LLP2A | 64Cu-LLP2A | 64Cu-PEG4-LLP2A | Copper Cu 64-LLP2A | Cu[64]-CB-TE1A1P-PEG4-LLP2A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935810","AZD 4205","C156774","An orally available inhibitor of Janus-associated kinase 1 (JAK1), with potential antineoplastic activity. Upon oral administration, golidocitinib inhibits JAK-dependent signaling and may lead to an inhibition of cellular proliferation in JAK1-overexpressing tumor cells. The JAK-STAT (signal transducer and activator of transcription) signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types. Additionally, JAK1 may be a primary driver of STAT3 phosphorylation and signaling, which plays a role in neoplastic transformation, resistance to apoptosis, tumor angiogenesis, metastasis, immune evasion, and treatment resistance.","Golidocitinib | AZD 4205 | AZD-4205 | AZD4205 | GOLIDOCITINIB | JAK1 Inhibitor AZD4205",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935808","Cognitive Electrophysiology Assessment","C156776","Assessments of cognition that focus on intracranial recordings of brain activity.","Cognitive Electrophysiology Assessment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935809","ASLAN 003","C156777","An orally available inhibitor of dihydroorotate dehydrogenase (DHODH), with potential antineoplastic activity. Upon administration, farudodstat specifically targets, binds to and prevents the activation of DHODH, thereby preventing the fourth enzymatic step in de novo pyrimidine synthesis. This prevents uridine monophosphate (UMP) formation, DNA synthesis, cell division and cellular proliferation, causes reactive oxygen species (ROS) formation, enables differentiation and induces apoptosis in susceptible tumor cells. DHODH, a mitochondrial enzyme, catalyzes the conversion of dihydroorotate (DHO) to orotate in the endogenous synthesis of UMP.","Farudodstat | ASLAN 003 | ASLAN-003 | ASLAN003 | DHODH Inhibitor ASLAN003 | Dihydroorotate Dehydrogenase Inhibitor ASLAN003 | FARUDODSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935814","Vision Assessment","C156778","Tests to assess the ability to focus on and discern objects, colors, depth, etc.","Vision Assessment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935815","Entity With Role in Clinical Study","C156779","Any person or entity that has a role or participates in a clinical research study, including both study personnel and study subjects.","Entity With Role in Clinical Study | participant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935812","Biliary Tract Carcinoma","C156781","A carcinoma arising from the intrahepatic bile ducts, hepatic ducts, common bile duct, cystic duct, or gallbladder.","Biliary Tract Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935813","Recurrent Biliary Tract Carcinoma","C156782","The reemergence of a carcinoma arising from any part of the biliary tract after a period of remission.","Recurrent Biliary Tract Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162645","Laryngeal Mask Airway","C156783","A supraglottic airway device that is composed of an airway tube that connects to an inflatable elliptical mask on the distal end which is inserted through the patient's mouth, down the trachea, and inflated to form an airtight seal on top the glottis.","Laryngeal Mask Airway | LMA | Laryngeal Mask",,,,,,,,,,,,,,,"4106029","Laryngeal mask",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL555839","CDRS-R - Social Withdrawal","C155333","Children's Depression Rating Scale, Revised (CDRS-R) Social withdrawal.","CDRS-R - Social Withdrawal | CDRS1-Social Withdrawal | CDRS103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555844","CDRS-R - Social Withdrawal Comment","C155334","Children's Depression Rating Scale, Revised (CDRS-R) Social withdrawal comment.","CDRS-R - Social Withdrawal Comment | CDRS1-Social Withdrawal Comment | CDRS103A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555845","CDRS-R - Sleep Disturbance","C155335","Children's Depression Rating Scale, Revised (CDRS-R) Sleep disturbance.","CDRS-R - Sleep Disturbance | CDRS1-Sleep Disturbance | CDRS104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555842","CDRS-R - Sleep Disturbance Comment","C155336","Children's Depression Rating Scale, Revised (CDRS-R) Sleep disturbance comment.","CDRS-R - Sleep Disturbance Comment | CDRS1-Sleep Disturbance Comment | CDRS104A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555843","CDRS-R - Appetite Disturbance","C155337","Children's Depression Rating Scale, Revised (CDRS-R) Appetite disturbance.","CDRS-R - Appetite Disturbance | CDRS1-Appetite Disturbance | CDRS105",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555848","CDRS-R - Appetite Disturbance Comment","C155338","Children's Depression Rating Scale, Revised (CDRS-R) Appetite disturbance comment.","CDRS-R - Appetite Disturbance Comment | CDRS1-Appetite Disturbance Comment | CDRS105A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555849","CDRS-R - Excessive Fatigue","C155339","Children's Depression Rating Scale, Revised (CDRS-R) Excessive fatigue.","CDRS-R - Excessive Fatigue | CDRS1-Excessive Fatigue | CDRS106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280959","Chemoprotection","C15533","The use of drugs to protect normal tissue from damage by cancer therapy agents.","Chemoprotection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555846","CDRS-R - Excessive Fatigue Comment","C155340","Children's Depression Rating Scale, Revised (CDRS-R) Excessive fatigue comment.","CDRS-R - Excessive Fatigue Comment | CDRS1-Excessive Fatigue Comment | CDRS106A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555852","CDRS-R - Physical Complaints Comment","C155342","Children's Depression Rating Scale, Revised (CDRS-R) Physical complaints comment.","CDRS-R - Physical Complaints Comment | CDRS1-Physical Complaints Comment | CDRS107A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555853","CDRS-R - Irritability","C155343","Children's Depression Rating Scale, Revised (CDRS-R) Irritability.","CDRS-R - Irritability | CDRS1-Irritability | CDRS108",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555850","CDRS-R - Irritability Comment","C155344","Children's Depression Rating Scale, Revised (CDRS-R) Irritability comment.","CDRS-R - Irritability Comment | CDRS1-Irritability Comment | CDRS108A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562710","Recurrent Chordoma","C155973","The reemergence of chordoma after a period of remission.","Recurrent Chordoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562711","Babaodan Capsule","C155974","An orally available mixed powder of traditional Chinese medicine containing eight constituents including natural calculus bovis, snake gall, antelope horn, pearl, musk, radix notoginseng, and other as of yet not disclosed ingredients, with potential antifibrotic, immunomodulatory, and antineoplastic activities. Upon oral administration, babaodan may ameliorate substance-induced liver injury and fibrosis, and inhibit lipopolysaccharide (LPS)-induced hepatic stellate cell (HSC) activation and proliferation through toll-like receptor 4 (TLR4)/nuclear factor-kappa B and TLR4/extracellular-signal-regulated kinase (ERK) pathways. Babaodan may, through an as of yet not elucidated mechanism, enhance the efficacy of chemotherapeutic drugs and may inhibit the occurrence and development of certain tumor types.","Babaodan Capsule | BBD | BD | Babao Dan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562760","AVB S6 500","C156017","A soluble fusion protein comprised of the extracellular domain of the receptor tyrosine kinase (RTK) AXL (UFO) fused to a human immunoglobulin G1 (IgG1) Fc domain, with potential antineoplastic activity. Upon administration, batiraxcept selectively binds to growth arrest-specific protein 6 (GAS6), the endogenous ligand for AXL. This may inhibit GAS6/AXL-mediated signaling, which plays a key role in tumor cell proliferation, survival, invasion and metastasis, as well as immune evasion and resistance to other anticancer agents. AXL, a member of the Tyro3, AXL and Mer (TAM) family of RTKs, is overexpressed by many tumor cell types and its expression is associated with drug resistance and poor prognosis.","Batiraxcept | AVB S6 500 | AVB-500 | AVB-S6-500 | AVBS6500 | AXL Fc Fusion Protein AVB-S6-500 | Anti-AXL Fusion Protein AVB-S6-500 | BATIRAXCEPT | RUGA-S6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556209","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Singing or Humming","C155579","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Singing or humming.","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Singing or Humming | FAC100-Limit: Singing or Humming | FAC10098",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556206","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Talking While Walking","C155580","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Talking while walking.","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Talking While Walking | FAC100-Limit: Talking While Walking | FAC10099",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556207","FACT-BL Version 4 - I Have a Lack of Energy","C155581","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Physical Well-Being: I have a lack of energy.","FACT-BL Version 4 - I Have a Lack of Energy | FAC006-I Have a Lack of Energy | FAC00601",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556212","FACT-BL Version 4 - I Have Nausea","C155582","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Physical Well-Being: I have nausea.","FACT-BL Version 4 - I Have Nausea | FAC006-I Have Nausea | FAC00602",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556213","FACT-BL Version 4 - Trouble Meeting Needs of Family","C155583","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Physical Well-Being: Because of my physical condition, I have trouble meeting the needs of my family.","FACT-BL Version 4 - Trouble Meeting Needs of Family | FAC006-Trouble Meeting Needs of Family | FAC00603",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556210","FACT-BL Version 4 - I Have Pain","C155584","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Physical Well-Being: I have pain.","FACT-BL Version 4 - I Have Pain | FAC006-I Have Pain | FAC00604",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556088","FACT-BL Version 4 - I Feel Ill","C155586","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Physical Well-Being: I feel ill.","FACT-BL Version 4 - I Feel Ill | FAC006-I Feel Ill | FAC00606",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556089","FACT-BL Version 4 - I Am Forced to Spend Time in Bed","C155587","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Physical Well-Being: I am forced to spend time in bed.","FACT-BL Version 4 - I Am Forced to Spend Time in Bed | FAC006-I Am Forced to Spend Time in Bed | FAC00607",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556086","FACT-BL Version 4 - I Feel Close to My Friends","C155588","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Social/Family Well-Being: I feel close to my friends.","FACT-BL Version 4 - I Feel Close to My Friends | FAC006-I Feel Close to My Friends | FAC00608",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556087","FACT-BL Version 4 - Get Emotional Support From Family","C155589","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Social/Family Well-Being: I get emotional support from my family.","FACT-BL Version 4 - Get Emotional Support From Family | FAC006-Get Emotional Support From Family | FAC00609",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281177","Interleukin Therapy","C15543","The use of interleukin in the treatment of any disease or disorder.","Interleukin Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556066","UHDRS 1999 Version - Supervise Children Without Help","C155440","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject supervise children without help?","UHDRS 1999 Version - Supervise Children Without Help | UHDR1-Supervise Children Without Help | UHDR149",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556067","UHDRS 1999 Version - Operate Automobile Safely","C155441","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject operate an automobile safely and independently?","UHDRS 1999 Version - Operate Automobile Safely | UHDR1-Operate Automobile Safely | UHDR150",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556072","UHDRS 1999 Version - Do Housework Without Help","C155442","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject do his/her own housework without help?","UHDRS 1999 Version - Do Housework Without Help | UHDR1-Do Housework Without Help | UHDR151",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556070","UHDRS 1999 Version - Prepare Own Meals Without Help","C155444","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject prepare his/her own meals without help?","UHDRS 1999 Version - Prepare Own Meals Without Help | UHDR1-Prepare Own Meals Without Help | UHDR153",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556071","UHDRS 1999 Version - Use Telephone Without Help","C155445","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject use the telephone without help?","UHDRS 1999 Version - Use Telephone Without Help | UHDR1-Use Telephone Without Help | UHDR154",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556076","UHDRS 1999 Version - Take Medications Without Help","C155446","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject take his/her own medications without help?","UHDRS 1999 Version - Take Medications Without Help | UHDR1-Take Medications Without Help | UHDR155",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556077","UHDRS 1999 Version - Feed Himself/Herself Without Help","C155447","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject feed himself/herself without help?","UHDRS 1999 Version - Feed Himself/Herself Without Help | UHDR1-Feed Himself/Herself Without Help | UHDR156",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556074","UHDRS 1999 Version - Dress Himself/Herself Without Help","C155448","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject dress himself/herself without help?","UHDRS 1999 Version - Dress Himself/Herself Without Help | UHDR1-Dress Himself/Herself Without Help | UHDR157",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556075","UHDRS 1999 Version - Bathe Himself/Herself Without Help","C155449","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject bathe himself/herself without help?","UHDRS 1999 Version - Bathe Himself/Herself Without Help | UHDR1-Bathe Himself/Herself Without Help | UHDR158",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281178","Anti-Cytokine Therapy","C15544","Drug treatment to reduce the activity of cytokines, particulary to control inflammation in disease modalities.","Anti-Cytokine Therapy | Anticytokine Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556080","UHDRS 1999 Version - Public Transportation Without Help","C155450","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject use public transportation to get places without help?","UHDRS 1999 Version - Public Transportation Without Help | UHDR1-Public Transportation Without Help | UHDR159",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556081","UHDRS 1999 Version - Walk Own Neighborhood Without Help","C155451","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject walk to places in his/her own neighborhood without help?","UHDRS 1999 Version - Walk Own Neighborhood Without Help | UHDR1-Walk Own Neighborhood Without Help | UHDR160",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556078","UHDRS 1999 Version - Walk Without Falling","C155452","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject walk without falling?","UHDRS 1999 Version - Walk Without Falling | UHDR1-Walk Without Falling | UHDR161",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519559","Total Estrogen Blockade","C15700","No value exists.","Total Estrogen Blockade | total estrogen blockade",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0030206","Paint","C157010","A pigmented liquid or mastic substance that is applied to an object and dries to form a solid thin film, which may color, protect or impart texture to the object's surface. Paints or dry painted surfaces may be toxic if they contain lead or volatile organic compounds (or VOCs).","Paint | Paints",,,,,,,,,,,,,,,"4277019","Paint",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL562713","BAY 2287411","C155977","A radioimmunoconjugate consisting of anetumab, a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface glycoprotein mesothelin, conjugated to the chelating agent corixetan, and labeled with the alpha-emitting radioisotope thorium Th 227, with potential antineoplastic activity. Upon administration of thorium Th 227 anetumab corixetan, the anetumab moiety binds to the tumor-associated antigen (TAA) mesothelin, delivering a cytotoxic dose of alpha radiation to cells expressing mesothelin.","Thorium Th 227 Anetumab Corixetan | 227Th Anetumab Corixetan | ANETUMAB CORIXETAN THORIUM TH-227 | BAY 2287411 | BAY2287411 | Thorium Th 227 Monoclonal Antibody BAY2287411 | Thorium-227 Labeled Anetumab | Thorium-227 Labeled Antibody-chelator Conjugate BAY2287411",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562736","Thyroid Gland Follicular Tumor of Uncertain Malignant Potential","C155978","An encapsulated or well-circumscribed thyroid gland tumor composed of well-differentiated follicular cells with no nuclear features of papillary thyroid carcinoma and with questionable capsular or vascular invasion. This is a tumor indeterminate between follicular adenoma and follicular carcinoma. (WHO)","Thyroid Gland Follicular Tumor of Uncertain Malignant Potential | FT-UMP | Thyroid Gland Follicular Neoplasm of Uncertain Malignant Potential",,,,,,,,,,,,,,,"37311479","Follicular neoplasm of uncertain malignant potential",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL562737","Questionable Invasive Lesion","C155979","A neoplastic lesion in which the adjacent tissues, surrounding capsule, or vessels may or may not be invaded by neoplastic cells.","Questionable Invasive Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562739","Defibrotide","C155981","A mixture of single-stranded oligodeoxyribonucleotides derived from the intestinal mucosa of pigs, with anti-thrombotic, thrombolytic, and fibrinolytic activities. Upon administration, and although the exact mechanism of action has yet to be fully elucidated, defibrotide induces the release of prostaglandin I2 (PGI2), E2 (PGE2), and prostacyclin and reduces the expression of adhesion molecules on endothelial cells. This relaxes the smooth muscle of blood vessels and prevents platelets from adhering to each other and to the endothelium. This protects the endothelium lining bloods vessels. Defibrotide increases tissue plasminogen activator (t-PA) and decreases plasminogen activator inhibitor-1 activity. This increases the activity of plasmin, prevents blood clot formation and dissolves blood clots.","Defibrotide | DEFIBROTIDE FREE ACID",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556177","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Scrubbing the Floor Why Not","C155547","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Scrubbing the floor or counter. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Scrubbing the Floor Why Not | FAC100-Sev: Scrubbing the Floor Why Not | FAC10066",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556174","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Dressing Without Help","C155548","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Dressing yourself without help.","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Dressing Without Help | FAC100-Limit: Dressing Without Help | FAC10067",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281194","Prevention of Lung Cancer","C15558","No value exists.","Prevention of Lung Cancer | Lung Cancer Prevention",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556092","FACT-BL Version 4 - I Get Support From My Friends","C155590","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Social/Family Well-Being: I get support from my friends.","FACT-BL Version 4 - I Get Support From My Friends | FAC006-I Get Support From My Friends | FAC00610",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556093","FACT-BL Version 4 - My Family Has Accepted My Illness","C155591","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Social/Family Well-Being: My family has accepted my illness.","FACT-BL Version 4 - My Family Has Accepted My Illness | FAC006-My Family Has Accepted My Illness | FAC00611",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556090","FACT-BL Version 4 - Satisfied Communication Illness","C155592","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Social/Family Well-Being: I am satisfied with family communication about my illness.","FACT-BL Version 4 - Satisfied Communication Illness | FAC006-Satisfied Communication Illness | FAC00612",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556091","FACT-BL Version 4 - I Feel Close to My Partner","C155593","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Social/Family Well-Being: I feel close to my partner (or the person who is my main support).","FACT-BL Version 4 - I Feel Close to My Partner | FAC006-I Feel Close to My Partner | FAC00613",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280039","Pyrimidine Antagonist","C1557","An antimetabolite that affects the metabolism and utilization of pyrimidines.","Pyrimidine Antagonist | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556331","CS1-CAR T Therapy","C155800","Treatment with CAR T cells that are directed against the CS1 surface glycoprotein on multiple myeloma cells.","CS1-CAR T Therapy | CS1-CAR T Infusion | CS1-CAR T-cell Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556335","Sellar Germ Cell Tumor","C155801","A germ cell tumor that arises from or adjacent to the sellar region.","Sellar Germ Cell Tumor | Germ Cell Tumor of the Sellar Region",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556336","Sellar Germinoma","C155802","A germinoma that arises from or adjacent to the sellar region.","Sellar Germinoma | Germinoma of the Sellar Region",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556333","Suprasellar Germinoma","C155803","A germinoma that arises from the suprasellar region.","Suprasellar Germinoma | Germinoma of the Suprasellar Region",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556334","Sellar Yolk Sac Tumor","C155804","A yolk sac tumor that arises from or adjacent to the sellar region.","Sellar Yolk Sac Tumor | Yolk Sac Tumor of the Sellar Region",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556339","Sellar Embryonal Carcinoma","C155805","An embryonal carcinoma that arises from or adjacent to the sellar region.","Sellar Embryonal Carcinoma | Embryonal Carcinoma of the Sellar Region",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556340","Sellar Choriocarcinoma","C155806","A choriocarcinoma that arises from or adjacent to the sellar region.","Sellar Choriocarcinoma | Choriocarcinoma of the Sellar Region",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556337","Sellar Teratoma","C155807","A teratoma that arises from or adjacent to the sellar region.","Sellar Teratoma | Teratoma of the Sellar Region",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556338","Sellar Mature Teratoma","C155808","A mature teratoma that arises from or adjacent to the sellar region.","Sellar Mature Teratoma | Mature Teratoma of the Sellar Region",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556343","Sellar Immature Teratoma","C155809","An immature teratoma that arises from or adjacent to the sellar region.","Sellar Immature Teratoma | Immature Teratoma of the Sellar Region",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0200591","Intra-Operative Blood Salvage Autotransfusion","C15580","No value exists.","Intra-Operative Blood Salvage Autotransfusion | Intra-Operative Blood Salvage | intraoperative blood salvage",,,,,,,,,,,,,,,"4051322","Intraoperative blood salvage",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556079","UHDRS 1999 Version - Walk Without Help","C155453","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject walk without help?","UHDRS 1999 Version - Walk Without Help | UHDR1-Walk Without Help | UHDR162",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562894","MicroRNA Sequencing","C156057","A next-generation or massively parallel high-throughput DNA sequencing-based procedure that can identify and quantify the microRNA sequences present in a biological sample.","MicroRNA Sequencing | MicroRNA-Seq | miRNA Sequencing | miRNA-Seq | miRNA-Seq (microRNA sequencing) | microRNA Sequencing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562895","ALX 0171","C156058","A trivalent nanobody composed of three monovalent Nb017 moieties linked with glycine-serine (GS) linkers, directed against the fusion protein (F protein) of human respiratory syncytial virus (RSV), with potential activity against RSV infections. Upon administration via nebulization and inhalation, gontivimab targets and binds to RSV F protein, neutralizing the virus, and preventing viral entry into host cells. RSV F protein is a small envelope glycoprotein required for cytopathic syncytia formation that results from cell-to-cell fusion.","Gontivimab | ALX 0171 | ALX-0171 | ALX0171 | Anti-RSV F Nanobody ALX-0171 | Anti-RSV Protein F Nanobody ALX-0171 | GONTIVIMAB | RSV-specific Nanobody ALX-0171",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522501","Nutrition, Trace Elements Research Activity","C15605","Role of trace elements in cancer causation or prevention and in general health.","Nutrition, Trace Elements | Micronutrients | Trace Element Nutrition | Trace Nutrients",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562920","CPI 006","C156061","A type II humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, mupadolimab targets and binds to CD73 on tumor cells, leading to internalization of CD73. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine, thereby preventing adenosine-mediated suppression of lymphocyte activity and increasing the activity of cytotoxic T-lymphocytes (CTLs). This also activates macrophages, and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes. By abrogating the inhibitory effect on the immune system and enhancing the CTL-mediated immune response against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, is upregulated on a number of cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment.","Mupadolimab | Anti-CD73 Monoclonal Antibody CPI-006 | CPI 006 | CPI-006 | CPI006 | CPX-006 | MUPADOLIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562921","Metastatic Bladder Carcinoma","C156062","A carcinoma that arises from the bladder and has metastasized to another anatomic site.","Metastatic Bladder Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562922","Metastatic Fallopian Tube Carcinoma","C156063","A carcinoma that arises from the fallopian tube and has metastasized to another anatomic site.","Metastatic Fallopian Tube Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562923","Metastatic Ovarian Carcinoma","C156064","A carcinoma that arises from the ovary and has metastasized to another anatomic site.","Metastatic Ovarian Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562916","Metastatic Vaginal Carcinoma","C156065","A carcinoma that arises from the vagina and has metastasized to another anatomic site.","Metastatic Vaginal Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562917","Metastatic Vulvar Carcinoma","C156066","A carcinoma that arises from the vulva and has metastasized to another anatomic site.","Metastatic Vulvar Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936065","L-lysine/L-arginine-containing Amino Acid","C157025","An intravenous (IV) amino acid (AA) solution containing the cationic amino acids L-lysine and L-arginine, with radioprotective activity. Upon IV administration of the AA solution, L-lysine and L-arginine are specifically taken up by the kidneys. This protects the kidneys from toxicity by certain co-administered radio-labeled peptides as they compete with radio-labeled peptides for renal uptake. This reduces uptake of the radio-labeled peptides by the kidneys and decreases their renal retention. It also increases the target-to-kidney ratio of the radio-labeled peptides, thereby reducing radiation exposure to the kidneys and preventing nephrotoxicity.","L-lysine/L-arginine-containing Amino Acid | Amino Acid Renal Protectant Solution | Amino Acid Solution-containing L-lysine and L-arginine | Intravenous L-lysine/L-arginine-containing Amino Acid Solution | L-lysine/L-arginine AA Solution | Lysine-Arginine Amino Acid Solution | Lysine/Arginine Amino Acid Solution | Radioprotective Amino Acid Solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563063","Anastrozole/Ribociclib Regimen","C156370","A regimen consisting of anastrozole and ribociclib that may be used as a treatment for hormone receptor (HR)-positive advanced or metastatic breast cancer.","Anastrozole/Ribociclib Regimen | Anastrozole and Ribociclib | Anastrozole-Ribociclib | Anastrozole-Ribociclib Regimen | Anastrozole/Ribociclib | Arimidex/Kisqali | Ribociclib-Anastrozole | Ribociclib/Anastrozole | Ribociclib/Anastrozole Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563064","Exemestane/Ribociclib Regimen","C156371","A regimen consisting of exemestane and ribociclib that may be used in the treatment of breast cancer.","Exemestane/Ribociclib Regimen | Aromasin/Kisqali | Exemestane-Ribociclib | Exemestane-Ribociclib Regimen | Exemestane/Ribociclib | Ribociclib-Exemestane | Ribociclib/Exemestane | Ribociclib/Exemestane Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563065","Trastuzumab/Nab-paclitaxel Regimen","C156372","A regimen consisting of trastuzumab and nab-paclitaxel, an albumin-bound formulation of paclitaxel, that may be used for the treatment of HER-2 (EGFR2; ErbB2)-positive breast cancer.","Trastuzumab/Nab-paclitaxel Regimen | Albumin-bound Paclitaxel/Trastuzumab | Nab-paclitaxel-Trastuzumab | Nab-paclitaxel/Trastuzumab | Trastuzumab-Albumin-bound Paclitaxel | Trastuzumab-Albumin-bound Paclitaxel Regimen | Trastuzumab-Nab-paclitaxel | Trastuzumab/Albumin-bound Paclitaxel | Trastuzumab/Albumin-bound Paclitaxel Regimen | Trastuzumab/Nab-paclitaxel | nab-Paclitaxel and Trastuzumab | nab-Paclitaxel and Trastuzumab-anns | nab-Paclitaxel and Trastuzumab-dkst | nab-Paclitaxel and Trastuzumab-dttb | nab-Paclitaxel and Trastuzumab-herw | nab-Paclitaxel and Trastuzumab-pkrb | nab-Paclitaxel and Trastuzumab-qyyp | nab-Paclitaxel and Trastuzumab-strf | nab-Paclitaxel and Trastuzumab-zerc",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563086","Tamoxifen/Trastuzumab Regimen","C156374","A regimen consisting of tamoxifen and trastuzumab that may be used for the treatment of hormone receptor (HR)-positive/HER-2 (EGFR2; ErbB2)-positive breast cancer.","Tamoxifen/Trastuzumab Regimen | Tamoxifen and Trastuzumab | Tamoxifen and Trastuzumab-anns | Tamoxifen and Trastuzumab-dkst | Tamoxifen and Trastuzumab-dttb | Tamoxifen and Trastuzumab-herw | Tamoxifen and Trastuzumab-pkrb | Tamoxifen and Trastuzumab-qyyp | Tamoxifen and Trastuzumab-strf | Tamoxifen and Trastuzumab-zerc | Tamoxifen-Trastuzumab | Tamoxifen-Trastuzumab Regimen | Tamoxifen/Trastuzumab | Trastuzumab-Tamoxifen | Trastuzumab/Tamoxifen | Trastuzumab/Tamoxifen Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563087","Ribociclib-Tamoxifen","C156375","A regimen consisting of tamoxifen and ribociclib that may be used in the treatment of hormone receptor (HR)-positive advanced or metastatic breast cancer.","Ribociclib/Tamoxifen Regimen | Ribociclib-Tamoxifen | Ribociclib/Tamoxifen | Tamoxifen-Ribociclib | Tamoxifen-Ribociclib Regimen | Tamoxifen/Kisqali | Tamoxifen/Ribociclib | Tamoxifen/Ribociclib Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563088","Fulvestrant/Ribociclib Regimen","C156376","A regimen consisting of fulvestrant and ribociclib that may be used in the treatment of breast cancer.","Fulvestrant/Ribociclib Regimen | Faslodex/Kisqali | Fulvestrant and Ribociclib | Fulvestrant-Ribociclib | Fulvestrant-Ribociclib Regimen | Fulvestrant/Ribociclib | Ribociclib-Fulvestrant | Ribociclib/Fulvestrant | Ribociclib/Fulvestrant Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563081","Abemaciclib/Letrozole Regimen","C156377","A regimen consisting of abemaciclib and letrozole that can be used in the treatment of breast cancer.","Abemaciclib/Letrozole Regimen | Abemaciclib and Letrozole | Abemaciclib-Letrozole | Abemaciclib-Letrozole Regimen | Abemaciclib/Letrozole | Letrozole-Abemaciclib | Letrozole/Abemaciclib | Letrozole/Abemaciclib Regimen | Verzenio/Femara",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281190","Prevention of Colorectal Cancer","C15554","No value exists.","Prevention of Colorectal Cancer | Colorectal Cancer Prevention",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556180","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Walk Up 20 Stairs","C155550","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Walking up 20 stairs (2 flights) without stopping.","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Walk Up 20 Stairs | FAC100-Limit: Walk Up 20 Stairs | FAC10069",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556181","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Preparing Meals","C155551","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Preparing meals.","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Preparing Meals | FAC100-Limit: Preparing Meals | FAC10070",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556178","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Washing Dishes","C155552","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Washing dishes.","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Washing Dishes | FAC100-Limit: Washing Dishes | FAC10071",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556179","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Sweeping/Mopping","C155553","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Sweeping or mopping.","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Sweeping/Mopping | FAC100-Limit: Sweeping/Mopping | FAC10072",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556184","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Making a Bed","C155554","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Making a bed.","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Making a Bed | FAC100-Limit: Making a Bed | FAC10073",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556185","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Lifting 10-20 Lbs","C155555","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Lifting something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries).","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Lifting 10-20 Lbs | FAC100-Limit: Lifting 10-20 Lbs | FAC10074",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556182","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Carry 10-20 Lbs","C155556","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Carrying something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries) from one room to another.","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Carry 10-20 Lbs | FAC100-Limit: Carry 10-20 Lbs | FAC10075",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556183","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Walk for 1/2 Mile","C155557","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Walking (faster than your usual speed) for 1/2 mile (almost 1 km) without stopping.","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Walk for 1/2 Mile | FAC100-Limit: Walk for 1/2 Mile | FAC10076",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3550693","PEROXISOME BIOGENESIS DISORDER 3B","C155753","An autosomal recessive condition caused by mutation(s) in the PEX12 gene, encoding peroxisome assembly protein 12. Peroxisome biogenesis disorder 3B is characterized by overlapping phenotypes of neonatal adrenoleukodystrophy and infantile Refsum disease.","Peroxisome Biogenesis Disorder 3B |  PBD3B | PBD3B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556237","PEROXISOME BIOGENESIS DISORDER 4A (ZELLWEGER)","C155754","An autosomal recessive condition caused by mutation(s) in the PEX6 gene, peroxisome assembly factor 2. Peroxisome biogenesis disorder 4A manifests phenotypically as Zellweger syndrome.","Peroxisome Biogenesis Disorder 4A |  PBD4A | PBD4A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556344","Sellar Teratoma with Malignant Transformation","C155810","A teratoma with malignant transformation that arises from or adjacent to the sellar region.","Sellar Teratoma with Malignant Transformation | Teratoma with Malignant Transformation of the Sellar Region",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556341","Sellar Mixed Germ Cell Tumor","C155811","A mixed germ cell tumor that arises from or adjacent to the sellar region.","Sellar Mixed Germ Cell Tumor | Mixed Germ Cell Tumor of the Sellar Region",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556342","ADC BA3021","C155812","An antibody-drug conjugate (ADC) composed of ozuriftamab, a conditionally active biologic (CAB) antibody against receptor tyrosine kinase-like orphan receptor 2 (ROR2) conjugated to monomethyl auristatin E, with potential antineoplastic activity. Upon administration of ozuriftamab vedotin, the anti-ROR2 antibody becomes activated through an as of yet not fully elucidated process, only under the unique microphysical conditions that are present in the tumor microenvironment (TME) as a result of the glycolytic metabolism of cancer cells and not in the microenvironment of normal, healthy tissues. Upon binding to ROR2-expressing cancer cells and internalization, the cytotoxic agent kills the cancer cells. ROR2, highly expressed during embryonic development while only minimally expressed on certain normal, healthy cells, is involved in Wnt signal transduction and is overexpressed on certain cancer cells. It plays a key role in cancer cell proliferation, migration and invasion. High levels of ROR2 expression often correlates with poor prognosis. The CAB antibody allows for efficient binding to ROR2-expressing cancer cells only, thereby maximizing efficacy while minimizing toxicity by avoiding activation and thus binding of the antibody to normal, healthy ROR2-expressing cells under normal conditions.","Ozuriftamab Vedotin | ADC BA3021 | Anti-ROR2 CAB ADC | Antibody-drug Conjugate BA3021 | BA 3021 | BA3021 | CAB Anti-ROR2 ADC BA3021 | CAB-ROR2-ADC | CAB-ROR2-ADC BA3021 | Conditionally Active Biologic Anti-ROR2 Antibody-drug Conjugate | OZURIFTAMAB VEDOTIN | ROR2-targeted ADC BA3021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556026","UHDRS 1999 Version - Retropulsion Pull Test","C155400","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Retropulsion pull test.","UHDRS 1999 Version - Retropulsion Pull Test | UHDR1-Retropulsion Pull Test | UHDR115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556027","UHDRS 1999 Version - Diagnosis Confidence Level","C155401","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Diagnosis confidence level: To what degree are you confident that this person meets the operational definition of the unequivocal presence of an otherwise unexplained extrapyramidal movement disorder (e.g., chorea, dystonia, bradykinesia, rigidity) in a subject at risk of HD?","UHDRS 1999 Version - Diagnosis Confidence Level | UHDR1-Diagnosis Confidence Level | UHDR117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556032","UHDRS 1999 Version - Verbal Fluency Test","C155402","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Verbal fluency test (raw score).","UHDRS 1999 Version - Verbal Fluency Test | UHDR1-Verbal Fluency Test | UHDR119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556033","UHDRS 1999 Version - Symbol Digit Modalities Test","C155403","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Symbol digit modalities test (raw score).","UHDRS 1999 Version - Symbol Digit Modalities Test | UHDR1-Symbol Digit Modalities Test | UHDR120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556030","UHDRS 1999 Version - Depressed Mood: Frequency","C155404","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Depressed mood: Frequency: Within the past month, how often have you been feeling sad, down or 'blue'?","UHDRS 1999 Version - Depressed Mood: Frequency | UHDR1-Depressed Mood: Frequency | UHDR125A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556031","UHDRS 1999 Version - Depressed Mood: Severity","C155405","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Depressed mood: Severity: How has your mood affected your daily activities? [Evidence of sad mood from behavioral observation includes sad voice or expression, tearfulness.].","UHDRS 1999 Version - Depressed Mood: Severity | UHDR1-Depressed Mood: Severity | UHDR125B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556036","UHDRS 1999 Version - Apathy: Frequency","C155406","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Apathy: Frequency: Within the past month, how often have you found that you have lost interest in things that used to be important to you?","UHDRS 1999 Version - Apathy: Frequency | UHDR1-Apathy: Frequency | UHDR126A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556037","UHDRS 1999 Version - Apathy: Severity","C155407","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Apathy: Severity: How has apathy impacted your ability to carry out daily activities?","UHDRS 1999 Version - Apathy: Severity | UHDR1-Apathy: Severity | UHDR126B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562918","Autologous CMV-pp65-flLAMP mRNA Loaded Dendritic Cell Vaccine","C156067","A cancer cell vaccine consisting of autologous dendritic cells (DCs) loaded with mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) as a fusion protein with the full-length lysosome-associated membrane protein (flLAMP), with potential immunostimulatory and antineoplastic activities. Upon vaccination, the autologous CMV-pp65-flLAMP mRNA loaded DC vaccine exposes the immune system to the CMV pp65 peptide, which may elicit a cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells. The incorporation of flLAMP may route CMV pp-65 antigens into the lysosomal compartment, resulting in enhanced MHC class II antigen presentation, thereby promoting CD4-positive T-cell responses. The CMV pp65 protein is the primary component of the enveloped subviral particle of CMV and is expressed in certain tumor types.","Autologous CMV-pp65-flLAMP mRNA Loaded Dendritic Cell Vaccine | Autologous CMV pp65-LAMP mRNA-loaded DC Vaccine | Autologous CMV-pp65-flLamp DCs | Autologous flLAMP-pp65 mRNA-pulsed DC Vaccine | Autologous flLAMP-pp65-DC Vaccine | Autologous flLAMP-pp65-DCs | Autologous pp65-flLAMP DC Vaccine | Autologous pp65-flLAMP DCs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562919","Metastatic Endometrial Carcinoma","C156068","A carcinoma that arises from the endometrium and has metastasized to another anatomic site.","Metastatic Endometrial Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556140","SMDDS Version 1.0 - How Often Problem With Sleep","C155638","Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how often did you have a problem with your sleep (falling asleep, staying asleep, or sleeping too much)?","SMDDS Version 1.0 - How Often Problem With Sleep | SMDDS1-How Often Problem With Sleep | SMDDS110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556141","SMDDS Version 1.0 - How Often Have Poor Appetite","C155639","Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how often did you have a poor appetite?","SMDDS Version 1.0 - How Often Have Poor Appetite | SMDDS1-How Often Have Poor Appetite | SMDDS111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556138","SMDDS Version 1.0 - How Often Did You Over Eat","C155640","Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how often did you over eat?","SMDDS Version 1.0 - How Often Did You Over Eat | SMDDS1-How Often Did You Over Eat | SMDDS112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556139","SMDDS Version 1.0 - How Much Push Yourself Do Things","C155641","Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how much of the time did you have to push yourself to do things?","SMDDS Version 1.0 - How Much Push Yourself Do Things | SMDDS1-How Much Push Yourself Do Things | SMDDS113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556144","SMDDS Version 1.0 - How Much Feel Like Doing Nothing","C155642","Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how much of the time did you feel like doing nothing?","SMDDS Version 1.0 - How Much Feel Like Doing Nothing | SMDDS1-How Much Feel Like Doing Nothing | SMDDS114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556145","SMDDS Version 1.0 - How Much Blame Yourself Bad Thing","C155643","Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how much of the time did you blame yourself when bad things happened?","SMDDS Version 1.0 - How Much Blame Yourself Bad Thing | SMDDS1-How Much Blame Yourself Bad Thing | SMDDS115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556142","SMDDS Version 1.0 - How Much Feel Not Worth Living","C155644","Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how much of the time did you feel that life is not worth living?","SMDDS Version 1.0 - How Much Feel Not Worth Living | SMDDS1-How Much Feel Not Worth Living | SMDDS116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556143","SMDDS Version 1.0 - Total Score","C155645","Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Total score.","SMDDS Version 1.0 - Total Score | SMDDS1-Total Score | SMDDS126",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556148","HAMA - Total Score","C155646","Hamilton Anxiety Rating Scale (HAMA) Total score.","HAMA - Total Score | HAMA1-Total Score | HAMA115",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563082","Abemaciclib/Exemestane Regimen","C156378","A regimen consisting of abemaciclib and exemestane that may be used in the treatment of breast cancer.","Abemaciclib/Exemestane Regimen | Abemaciclib-Exemestane | Abemaciclib-Exemestane Regimen | Abemaciclib/Exemestane | Aromasin/Verzenio | Exemestane-Abemaciclib | Exemestane/Abemaciclib | Exemestane/Abemaciclib Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563084","Trastuzumab/Pertuzumab/Vinorelbine Regimen","C156380","A regimen consisting of trastuzumab, pertuzumab, and vinorelbine that may be used as a treatment for recurrent and metastatic HER-2 (EGFR2; ErbB2)-positive advanced or metastatic breast cancer.","Trastuzumab/Pertuzumab/Vinorelbine Regimen | Pertuzumab/Trastuzumab/Vinorelbine | Trastuzumab-Pertuzumab-Vinorelbine | Trastuzumab-Pertuzumab-Vinorelbine Regimen | Trastuzumab/Pertuzumab/Vinorelbine | VHP | VHP (trastuzumab-anns) | VHP (trastuzumab-dkst) | VHP (trastuzumab-dttb) | VHP (trastuzumab-herw) | VHP (trastuzumab-pkrb) | VHP (trastuzumab-qyyp) | VHP (trastuzumab-zerc)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1328219","ixabepilone/trastuzumab","C156381","A regimen consisting of ixabepilone and trastuzumab that may be used for the treatment of HER-2 (EGFR2; ErbB2)-positive metastatic breast cancer.","Ixabepilone/Trastuzumab Regimen | Ixabepilone-Trastuzumab Regimen | Ixabepilone/Trastuzumab | Ixempra/Herceptin | Tamoxifen and Trastuzumab | Tamoxifen-Trastuzumab | Trastuzumab-Ixabepilone | Trastuzumab/Ixabepilone | Trastuzumab/Ixabepilone Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556156","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Carrying Less Than 5 Lbs","C155526","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Carrying something weighing less than 5 lbs (about 2 kg, like a houseplant) from one room to another.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Carrying Less Than 5 Lbs | FAC100-Sev: Carrying Less Than 5 Lbs | FAC10045",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556157","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Carrying Less Than 5 Why Not","C155527","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Carrying something weighing less than 5 lbs (about 2 kg, like a houseplant) from one room to another. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Carrying Less Than 5 Why Not | FAC100-Sev: Carrying Less Than 5 Why Not | FAC10046",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556154","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Carrying 5-10 Lbs","C155528","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Carrying something weighing 5-10 lbs (about 2-4.5 kg, like a basket of clothes) from one room to another.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Carrying 5-10 Lbs | FAC100-Sev: Carrying 5-10 Lbs | FAC10047",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556155","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Carrying 5-10 Lbs Why Not","C155529","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Carrying something weighing 5-10 lbs (about 2-4.5 kg, like a basket of clothes) from one room to another. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Carrying 5-10 Lbs Why Not | FAC100-Sev: Carrying 5-10 Lbs Why Not | FAC10048",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281188","Screening for Testicular Cancer","C15552","No value exists.","Screening for Testicular Cancer | early detection of testicular cancer | testicular cancer early detection | testicular cancer screening",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556160","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Get In/Out of a Car","C155530","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Getting in or out of a car.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Get In/Out of a Car | FAC100-Sev: Get In/Out of a Car | FAC10049",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556161","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Get In/Out of a Car Why Not","C155531","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Getting in or out of a car. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Get In/Out of a Car Why Not | FAC100-Sev: Get In/Out of a Car Why Not | FAC10050",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3553937","PEROXISOME BIOGENESIS DISORDER 4B","C155755","An autosomal recessive condition caused by mutation(s) in the PEX6 gene, peroxisome assembly factor 2, Peroxisome biogenesis disorder 4B is characterized by overlapping phenotypes of neonatal adrenoleukodystrophy and infantile Refsum disease.","Peroxisome Biogenesis Disorder 4B |  PBD4B | PBD4B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556240","PEROXISOME BIOGENESIS DISORDER 5A (ZELLWEGER)","C155756","An autosomal recessive condition caused by mutation(s) in the PEX2 gene, encoding peroxisome biogenesis factor 2. Peroxisome biogenesis disorder 5A manifests phenotypically as Zellweger syndrome.","Peroxisome Biogenesis Disorder 5A |  PBD5A | PBD5A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3542026","PEROXISOME BIOGENESIS DISORDER 5B","C155757","An autosomal recessive condition caused by mutation(s) in the PEX2 gene, encoding peroxisome biogenesis factor 2. Peroxisome biogenesis disorder 5B is characterized by overlapping phenotypes of neonatal adrenoleukodystrophy and infantile Refsum disease.","Peroxisome Biogenesis Disorder 5B |  PBD5B | PBD5B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556239","PEROXISOME BIOGENESIS DISORDER 6A (ZELLWEGER)","C155758","An autosomal recessive condition caused by mutation(s) in the PEX10 gene, encoding peroxisome biogenesis factor 10. Peroxisome biogenesis disorder 6A manifests phenotypically as Zellweger syndrome.","Peroxisome Biogenesis Disorder 6A |  PBD6A | PBD6A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3553948","PEROXISOME BIOGENESIS DISORDER 6B","C155759","An autosomal recessive condition caused by mutation(s) in the PEX10 gene, encoding peroxisome biogenesis factor 10. Peroxisome biogenesis disorder 6B is characterized by overlapping phenotypes of neonatal adrenoleukodystrophy and infantile Refsum disease.","Peroxisome Biogenesis Disorder 6B | PBD6B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281477","Screening for Lung Cancer","C15575","No value exists.","Screening for Lung Cancer | early detection of lung cancer | lung cancer early detection | lung cancer screening",,,,,,,,,,,,,,,"4171431","Screening for malignant neoplasm of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556242","Peroxisome Biogenesis Disorder 7A","C155760","An autosomal recessive condition caused by mutation(s) in the PEX26 gene, encoding peroxisome assembly protein 26. Peroxisome biogenesis disorder 7A manifests phenotypically as Zellweger syndrome.","Peroxisome Biogenesis Disorder 7A |  PBD7A | PBD7A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3553951","PEROXISOME BIOGENESIS DISORDER 7B","C155761","An autosomal recessive condition caused by mutation(s) in the PEX26 gene, encoding peroxisome assembly protein 26. Peroxisome biogenesis disorder 7B is characterized by overlapping phenotypes of neonatal adrenoleukodystrophy and infantile Refsum disease.","Peroxisome Biogenesis Disorder 7B |  PBD7B | PBD7B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556241","PEROXISOME BIOGENESIS DISORDER 8A (ZELLWEGER)","C155762","An autosomal recessive condition caused by mutation(s) in the PEX16 gene, encoding peroxisomal membrane protein PEX16. Peroxisome biogenesis disorder 8A manifests phenotypically as Zellweger syndrome.","Peroxisome Biogenesis Disorder 8A |  PBD8A | PBD8A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3553960","PEROXISOME BIOGENESIS DISORDER 8B","C155763","An autosomal recessive condition caused by mutation(s) in the PEX16 gene, encoding peroxisomal membrane protein PEX16. Peroxisome biogenesis disorder 8B is characterized by overlapping phenotypes of neonatal adrenoleukodystrophy and infantile Refsum disease.","Peroxisome Biogenesis Disorder 8B |  PBD8B | PBD8B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556244","AKT Inhibitor","C155764","Any agent that inhibits protein kinase B (AKT).","AKT Inhibitor | Akt Inhibitor | Protein Kinase B Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556245","TRK Inhibitor","C155765","Any agent that inhibits tropomyosin-related-kinase (TRK;  tropomyosin receptor kinase).","TRK Inhibitor | Tropomyosin-related-kinase Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556243","Pituitary Gland Adenoma with Gangliocytic Component","C155767","A pituitary neoplasm composed of mature ganglionic cells admixed with pituitary neoplastic neuroendocrine cells.","Mixed Gangliocytoma-Pituitary Neuroendocrine Tumor | Mixed Gangliocytoma-PitNET | Mixed Gangliocytoma-PitNET/Adenoma | Mixed Gangliocytoma-Pituitary Neuroendocrine Tumor/Adenoma | Pituitary Gland Adenoma with Gangliocytic Component | Pituitary Gland Adenoma-Neuronal Choristoma | Pituitary Gland Mixed Gangliocytoma-Adenoma | Pituitary Gland Mixed Gangliocytoma-Adenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556034","UHDRS 1999 Version - Self-esteem/Guilt: Frequency","C155408","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Self-esteem/guilt: Frequency: Within the past month, how often have you been feeling badly about yourself?","UHDRS 1999 Version - Self-esteem/Guilt: Frequency | UHDR1-Self-esteem/Guilt: Frequency | UHDR127A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556035","UHDRS 1999 Version - Self-esteem/Guilt: Severity","C155409","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Self-esteem/guilt: Severity: How have these feelings affected your daily activities?","UHDRS 1999 Version - Self-esteem/Guilt: Severity | UHDR1-Self-esteem/Guilt: Severity | UHDR127B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281149","Antiprolactin Therapy","C15540","Drug treatment to block the action of the female hormone prolactin.","Antiprolactin Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556040","UHDRS 1999 Version - Suicidal Thoughts: Frequency","C155410","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Suicidal thoughts: Frequency: Within the past month, how often have you thought about hurting yourself or ending it all?","UHDRS 1999 Version - Suicidal Thoughts: Frequency | UHDR1-Suicidal Thoughts: Frequency | UHDR128A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556041","UHDRS 1999 Version - Suicidal Thoughts: Severity","C155411","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Suicidal thoughts: Severity: Do you have a plan in mind to end it all? Have you taken any steps toward carrying out your plan?","UHDRS 1999 Version - Suicidal Thoughts: Severity | UHDR1-Suicidal Thoughts: Severity | UHDR128B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556038","UHDRS 1999 Version - Anxiety: Frequency","C155412","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Anxiety: Frequency: Within the past month, how often have you found yourself worrying about things?","UHDRS 1999 Version - Anxiety: Frequency | UHDR1-Anxiety: Frequency | UHDR129A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556039","UHDRS 1999 Version - Anxiety: Severity","C155413","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Anxiety: Severity: How much has nervousness or worry affected your daily activities?","UHDRS 1999 Version - Anxiety: Severity | UHDR1-Anxiety: Severity | UHDR129B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562756","Zirconium Zr 89 DFO-Daratumumab","C156021","A radioimmunoconjugate containing daratumumab, a human immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against the cell surface glycoprotein CD38, and linked, via the chelator desferrioxamine (DFO), to the radioisotope zirconium Zr 89 (Zr89), with potential diagnostic properties upon positron emission tomography (PET) imaging. Upon administration, the monoclonal antibody moiety of zirconium Zr 89-DFO-daratumumab specifically targets and binds to cell surface antigen CD38. Upon binding, the radioisotope moiety may be detected using PET, thereby allowing the imaging and quantification of CD38-expressing tumor cells. CD38, a cell surface glycoprotein, is expressed on various hematopoietic cells and is overexpressed on multiple myeloma (MM) cells.","Zirconium Zr 89 DFO-Daratumumab | (89)Zr-Daratumumab | 89Zr-DFO-Daratumumab | DARATUMUMAB-DFO ZR-89 | Zr 89-DFO-Daratumumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556146","Recurrent Sarcoma of the Extremity","C155648","A sarcoma of the soft tissues or bones of the upper or lower extremity that has recurred after a period of remission.","Recurrent Sarcoma of the Extremity | Recurrent Extremity Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556147","Advanced Sarcoma of the Extremity","C155649","A sarcoma of the soft tissues or bones of the upper or lower extremity that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Sarcoma of the Extremity | Advanced Extremity Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556268","CT 7001","C155652","An orally available, selective inhibitor of cyclin-dependent kinase 7 (CDK7) with potential antineoplastic activity. Upon oral administration, samuraciclib selectively and competitively binds to the CDK7 ATP binding site, thereby inhibiting CDK7-mediated signaling. CDK7, a serine/threonine kinase, plays a role in controlling cell cycle progression, transcriptional regulation, and promotes the expression of key oncogenes such as c-Myc through the phosphorylation of RNA polymerase II. Inhibition of CDK7 may inhibit tumor cell proliferation in certain cancers that are dependent on CDK7-mediated transcriptional regulation and signaling.","Samuraciclib | CDK7 Inhibitor CT7001 | CT 7001 | CT-7001 | CT7001 | SAMURACICLIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281589","Targeted Fusion Protein Therapy","C15585","Drug therapy in which the drug is a fusion protein generated by molecular biology procedures.  The fusion protein combines a cell targeting moiety, such as an antibody fragment, with an effector moiety, like a bacterial toxin.","Targeted Fusion Protein Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0430838","Quantitative Sensory Testing","C155860","A non-invasive method for diagnosing peripheral nervous system disorders. It determines an individual's sensation and pain thresholds for cold and warm temperatures, and vibration sensation threshold by stimulating the skin and comparing the results to standard values.","Quantitative Sensory Testing | QST",,,,,,,,,,,,,,,"4098793","Quantitative sensory test",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL562688","Intermediate Grade Neuroendocrine Lesion","C155862","A neoplastic lesion with neuroendocrine differentiation and histological features of intermediate grade.","Intermediate Grade Neuroendocrine Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562689","Poorly Differentiated Neuroendocrine Lesion","C155863","A neoplastic lesion with neuroendocrine differentiation and poorly differentiated histological features.","Poorly Differentiated Neuroendocrine Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562690","Low Grade Neuroendocrine Lesion","C155864","A neoplastic lesion with neuroendocrine differentiation and histological features of low grade.","Low Grade Neuroendocrine Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1425512","MIA2 Gene","C155865","This gene is involved in intracellular lipoprotein transport.","MIA2 Gene | MIA SH3 Domain ER Export Factor 2 Gene | MIA2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562686","MIA2 wt Allele","C155866","Human MIA2 wild-type allele is located in the vicinity of 14q21.1 and is approximately 158 kb in length. This allele, which encodes melanoma inhibitory activity protein 2, plays a role in lipoprotein transport.","MIA2 wt Allele | CTAGE5 | FLJ22404 | MEA11 | MEA6 | MGEA | MGEA11 | MGEA6 | MIA SH3 Domain ER Export Factor 2 wt Allele | Melanoma Inhibitory Activity 2 Gene | Meningioma Expressed Antigen 11 Gene | Meningioma Expressed Antigen 6 (Coiled-Coil Proline-Rich) Gene | Meningioma Expressed Antigen Gene | Meningioma-Expressed Antigen 6/11 Gene | TALI | TANGO1-Like Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2351264","Melanoma Inhibitory Activity Protein 2","C155867","Melanoma inhibitory activity protein 2 (1412 aa, ~160 kDa) is encoded by the human MIA2 gene. This protein is involved in ER-to-Golgi transport of lipoproteins.","Melanoma Inhibitory Activity Protein 2 | MIA SH3 Domain ER Export Factor 2 | MIA2 | TALI | TANGO-Like Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3833473","Device Unique Identifier","C155868","A globally-unique identifier for a device.","Device Unique Identifier | UDI | Unique Device Identifier | Universal Device Identifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556158","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Dining Out","C155532","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Dining out.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Dining Out | FAC100-Sev: Dining Out | FAC10051",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556159","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Dining Out Why Not","C155533","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Dining out. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Dining Out Why Not | FAC100-Sev: Dining Out Why Not | FAC10052",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556164","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Low-intensity Activity","C155534","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Low-intensity leisure activity (gardening, etc.).","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Low-intensity Activity | FAC100-Sev: Low-intensity Activ | FAC10053",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556165","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Low-intensity Activity Why Not","C155535","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Low-intensity leisure activity (gardening, etc.). Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Low-intensity Activity Why Not | FAC100-Sev: Low-intensity Activ Why Not | FAC10054",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562872","Autologous B-cell/Monocyte-presenting HER2/neu Antigen Vaccine BVAC-B","C156153","An autologous vaccine composed of the antigen presenting cells (APCs) B-lymphocytes and monocytes presenting the tumor-associated antigen (TAA) human epidermal growth factor receptor type 2 (HER2/neu; HER-2; EGFR2; ErbB2). Upon administration of the autologous B-cell- and monocyte-presenting HER2/neu antigen vaccine BVAC-B, the APCs may stimulate the immune system to mount a HER2/neu-specific cytotoxic T-lymphocyte (CTL) immune response as well as a natural killer (NK) cell, and antibody-mediated immune response against HER-2/neu-positive tumor cells, which may result in tumor cell death and decreased tumor growth. HER-2, a tyrosine kinase receptor for epidermal growth factor (EGF), is overexpressed by a variety of tumors.","Autologous B-cell/Monocyte-presenting HER2/neu Antigen Vaccine BVAC-B | BVAC B | BVAC-B | BVACB | HER2/neu-specific Autologous B-cell/Monocyte Vaccine BVAC-B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562866","Cisplatin Transmucosal Patch","C156155","A transmucosal patch containing cisplatin, an inorganic platinum agent, with potential antineoplastic activity. Upon mucosal application to the tumor site in the oral cavity, and upon subsequent release from the patch, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and growth inhibition of tumor cells.","Cisplatin Transmucosal Patch | Cisplatin Drug-loaded Patch | Cisplatin Transmucosal System | PRV 111 | PRV-111 | PRV111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562867","Autologous HER2-specific/EGFRt-expressing CD4/CD8-positive CAR T-cells","C156156","A preparation of CD4+ and CD8+ autologous T-lymphocytes transduced with a lentiviral vector expressing a human epidermal growth factor receptor type 2 (HER2; EGFR2; ErbB2)-specific chimeric antigen receptor (CAR) coupled to a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, the autologous HER2-specific/EGFRt-expressing CD4/CD8-positive CAR T-cells are directed to and induce selective toxicity in HER2-expressing tumor cells. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of these cells through an anti-EGFR antibody-induced antibody-dependent cellular cytotoxicity (ADCC) response. HER2, a receptor tyrosine kinase (RTK) overexpressed by a variety of tumor cell types, belongs to the EGFR superfamily and plays a key role in tumor cell proliferation.","Autologous HER2-specific/EGFRt-expressing CD4/CD8-positive CAR T-cells | Autologous HER2 CAR/EGFRt-expressing CD4+ and CD8+ T-cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555851","CDRS-R - Excessive Guilt","C155345","Children's Depression Rating Scale, Revised (CDRS-R) Excessive guilt.","CDRS-R - Excessive Guilt | CDRS1-Excessive Guilt | CDRS109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555856","CDRS-R - Excessive Guilt Comment","C155346","Children's Depression Rating Scale, Revised (CDRS-R) Excessive guilt comment.","CDRS-R - Excessive Guilt Comment | CDRS1-Excessive Guilt Comment | CDRS109A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555857","CDRS-R - Low Self-esteem","C155347","Children's Depression Rating Scale, Revised (CDRS-R) Low self-esteem.","CDRS-R - Low Self-esteem | CDRS1-Low Self-esteem | CDRS110",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555854","CDRS-R - Low Self-esteem Comment","C155348","Children's Depression Rating Scale, Revised (CDRS-R) Low self-esteem comment.","CDRS-R - Low Self-esteem Comment | CDRS1-Low Self-esteem Comment | CDRS110A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555855","CDRS-R - Depressed Feelings","C155349","Children's Depression Rating Scale, Revised (CDRS-R) Depressed feelings.","CDRS-R - Depressed Feelings | CDRS1-Depressed Feelings | CDRS111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280960","Cardiotoxicity Attenuation","C15534","No value exists.","Cardiotoxicity Attenuation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555860","CDRS-R - Depressed Feelings Comment","C155350","Children's Depression Rating Scale, Revised (CDRS-R) Depressed feelings comment.","CDRS-R - Depressed Feelings Comment | CDRS1-Depressed Feelings Comment | CDRS111A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555861","CDRS-R - Morbid Ideation","C155351","Children's Depression Rating Scale, Revised (CDRS-R) Morbid ideation.","CDRS-R - Morbid Ideation | CDRS1-Morbid Ideation | CDRS112",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555859","CDRS-R - Suicidal Ideation","C155353","Children's Depression Rating Scale, Revised (CDRS-R) Suicidal ideation.","CDRS-R - Suicidal Ideation | CDRS1-Suicidal Ideation | CDRS113",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555864","CDRS-R - Suicidal Ideation Comment","C155354","Children's Depression Rating Scale, Revised (CDRS-R) Suicidal ideation comment.","CDRS-R - Suicidal Ideation Comment | CDRS1-Suicidal Ideation Comment | CDRS113A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555865","CDRS-R - Excessive Weeping","C155355","Children's Depression Rating Scale, Revised (CDRS-R) Excessive weeping.","CDRS-R - Excessive Weeping | CDRS1-Excessive Weeping | CDRS114",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555862","CDRS-R - Excessive Weeping Comment","C155356","Children's Depression Rating Scale, Revised (CDRS-R) Excessive weeping comment.","CDRS-R - Excessive Weeping Comment | CDRS1-Excessive Weeping Comment | CDRS114A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555868","CDRS-R - Depressed Facial Affect Comment","C155358","Children's Depression Rating Scale, Revised (CDRS-R) Depressed facial affect comment.","CDRS-R - Depressed Facial Affect Comment | CDRS1-Depressed Facial Affect Comment | CDRS115A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555869","CDRS-R - Listless Speech","C155359","Children's Depression Rating Scale, Revised (CDRS-R) Listless speech.","CDRS-R - Listless Speech | CDRS1-Listless Speech | CDRS116",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280961","Urothelial Toxicity Attenuation","C15535","No value exists.","Urothelial Toxicity Attenuation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555866","CDRS-R - Listless Speech Comment","C155360","Children's Depression Rating Scale, Revised (CDRS-R) Listless speech comment.","CDRS-R - Listless Speech Comment | CDRS1-Listless Speech Comment | CDRS116A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555872","CDRS-R - Hypoactivity Comment","C155362","Children's Depression Rating Scale, Revised (CDRS-R) Hypoactivity comment.","CDRS-R - Hypoactivity Comment | CDRS1-Hypoactivity Comment | CDRS117A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556096","FACT-BL Version 4 - I Am Satisfied With My Sex Life","C155594","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Social/Family Well-Being: I am satisfied with my sex life.","FACT-BL Version 4 - I Am Satisfied With My Sex Life | FAC006-I Am Satisfied With My Sex Life | FAC00614",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556097","FACT-BL Version 4 - I Feel Sad","C155595","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Emotional Well-Being: I feel sad.","FACT-BL Version 4 - I Feel Sad | FAC006-I Feel Sad | FAC00615",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556094","FACT-BL Version 4 - Satisfied With How I Am Coping","C155596","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Emotional Well-Being: I am satisfied with how I am coping with my illness.","FACT-BL Version 4 - Satisfied With How I Am Coping | FAC006-Satisfied With How I Am Coping | FAC00616",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556095","FACT-BL Version 4 - Losing Hope Against Illness","C155597","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Emotional Well-Being: I am losing hope in the fight against my illness.","FACT-BL Version 4 - Losing Hope Against Illness | FAC006-Losing Hope Against Illness | FAC00617",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556100","FACT-BL Version 4 - I Feel Nervous","C155598","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Emotional Well-Being: I feel nervous.","FACT-BL Version 4 - I Feel Nervous | FAC006-I Feel Nervous | FAC00618",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3203639","Metastatic Neuroendocrine Carcinoma","C155869","A neuroendocrine carcinoma that has spread from its original site of growth to another anatomic site.","Metastatic Neuroendocrine Carcinoma | ",,,,,,,,,,,,,,,"763049","Neuroendocrine carcinoma, metastatic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL562685","Advanced Neuroendocrine Carcinoma","C155870","A neuroendocrine carcinoma that has metastasized from its original site of growth to distal anatomic sites or is no longer responding to treatment.","Advanced Neuroendocrine Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0019340","Herpes Simplex Virus Infection","C155871","An infection that is caused by herpes simplex virus.","Herpes Simplex Virus Infection | HSV Infection | Herpes | Herpes Simplex Virus",,,,,,,,,,,,,,,"444429","Herpes simplex",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0026393","Molluscum Contagiosum Virus Infection","C155872","An infection that is caused by molluscum contagiosum virus.","Molluscum Contagiosum Virus Infection | ",,,,,,,,,,,,,,,"141216","Molluscum contagiosum infection",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL562682","Locally Advanced Unresectable Gastric Adenocarcinoma","C155874","A gastric adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.","Locally Advanced Unresectable Gastric Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562683","Recurrent Desmoid Tumor","C155875","Desmoid fibromatosis that has recurred after a period of remission.","Recurrent Desmoid Fibromatosis | Recurrent Desmoid Tumor | Recurrent Desmoid-Type Fibromatosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556084","UHDRS 1999 Version - Comb Hair Without Help","C155454","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject comb hair without help?","UHDRS 1999 Version - Comb Hair Without Help | UHDR1-Comb Hair Without Help | UHDR163",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556085","UHDRS 1999 Version - Transfer Chair Without Help","C155455","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject transfer between chairs without help?","UHDRS 1999 Version - Transfer Chair Without Help | UHDR1-Transfer Chair Without Help | UHDR164",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556082","UHDRS 1999 Version - Get in and Out of Bed Without Help","C155456","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject get in and out of bed without help?","UHDRS 1999 Version - Get in and Out of Bed Without Help | UHDR1-Get in and Out of Bed Without Help | UHDR165",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556083","UHDRS 1999 Version - Use Toilet/Commode Without Help","C155457","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject use the toilet/commode without help?","UHDRS 1999 Version - Use Toilet/Commode Without Help | UHDR1-Use Toilet/Commode Without Help | UHDR166",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555960","UHDRS 1999 Version - Care Provided at Home","C155458","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject's care still be provided at home?","UHDRS 1999 Version - Care Provided at Home | UHDR1-Care Provided at Home | UHDR167",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555961","UHDRS 1999 Version - Functional Assess Obtained From","C155459","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Was the Functional Assessment information obtained from.","UHDRS 1999 Version - Functional Assess Obtained From | UHDR1-Functional Assess Obtained From | UHDR168",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281179","Leukocyte Therapy","C15545","No value exists.","Leukocyte Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563003","Localized Gastroesophageal Junction Adenocarcinoma","C156166","An adenocarcinoma that arises from the gastroesophageal junction and has not spread to other anatomic sites.","Localized Gastroesophageal Junction Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563004","Localized Gastric Carcinoma","C156167","A carcinoma that arises from the stomach and has not spread to other anatomic sites.","Localized Gastric Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556315","KIT NM_000222.2:c.2537A>G","C155717","A nucleotide substitution at position 2537 of the coding sequence of the KIT gene where adenine has been mutated to guanine.","KIT NM_000222.2:c.2537A>G | CD117 c.2537A>G | KIT Proto-Oncogene Tyrosine Protein Kinase c.2537A>G | KIT c.2537A>G | NM_000222.2:c.2537A>G | c-KIT c.2537A>G | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.2537A>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555873","CDRS-R - Subtotal 1","C155363","Children's Depression Rating Scale, Revised (CDRS-R) Subtotal 1 - sum of questions 1 to 6.","CDRS-R - Subtotal 1 | CDRS1-Subtotal 1 | CDRS118",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555870","CDRS-R - Subtotal 2","C155364","Children's Depression Rating Scale, Revised (CDRS-R) Subtotal 2 - sum of questions 7 to 14.","CDRS-R - Subtotal 2 | CDRS1-Subtotal 2 | CDRS119",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562732","Defibrotide (Bovine)","C155982","A mixture of single-stranded oligodeoxyribonucleotides derived from bovine pulmonary tissue, with anti-thrombotic, thrombolytic, and fibrinolytic activities. Upon administration, and although the exact mechanism of action has yet to be fully elucidated, defibrotide induces the release of prostaglandin I2 (PGI2), E2 (PGE2), and prostacyclin and reduces the expression of adhesion molecules on endothelial cells. This relaxes the smooth muscle of blood vessels and prevents platelets from adhering to each other and to the endothelium. This protects the endothelium lining bloods vessels. Defibrotide increases tissue plasminogen activator (t-PA) and decreases plasminogen activator inhibitor-1 activity. This increases the activity of plasmin, prevents blood clot formation and dissolves blood clots.","Defibrotide (Bovine) | DEFIBROTIDE (BOVINE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562733","Recurrent Visual Pathway Glioma","C155983","The reemergence of visual pathway glioma after a period of remission.","Recurrent Visual Pathway Glioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562734","Refractory Visual Pathway Glioma","C155984","Visual pathway glioma that is resistant to treatment.","Refractory Visual Pathway Glioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562735","Recurrent Neurofibromatosis Type 1","C155985","The reemergence of neurofibromatosis type 1 after a period of remission.","Recurrent Neurofibromatosis Type 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562729","Refractory Neurofibromatosis Type 1","C155986","Neurofibromatosis type 1 that is resistant to treatment.","Refractory Neurofibromatosis Type 1 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562730","Refractory Malignant Peripheral Nerve Sheath Tumor","C155987","Malignant peripheral nerve sheath tumor that is resistant to treatment.","Refractory Malignant Peripheral Nerve Sheath Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL474088","quadratus lumborum block","C155988","A technique for regional anesthesia that uses ultrasound-guided injection of an anesthetic agent into the posterior abdominal wall.","Quadratus Lumborum Block | QL Block",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562725","Staged Resection","C155990","A surgical procedure for the removal a tumor or multiple tumors during multiple operative procedures.","Staged Resection | Staged Excision | Staged Tumor Resection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556101","FACT-BL Version 4 - I Worry About Dying","C155599","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Emotional Well-Being: I worry about dying.","FACT-BL Version 4 - I Worry About Dying | FAC006-I Worry About Dying | FAC00619",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281195","Prevention of Esophageal Cancer","C15559","No value exists.","Prevention of Esophageal Cancer | Esophageal Cancer Prevention",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556098","FACT-BL Version 4 - Worry My Condition Will Get Worse","C155600","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Emotional Well-Being: I worry that my condition will get worse.","FACT-BL Version 4 - Worry My Condition Will Get Worse | FAC006-Worry My Condition Will Get Worse | FAC00620",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556099","FACT-BL Version 4 - I Am Able to Work","C155601","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Functional Well-Being: I am able to work (include work at home).","FACT-BL Version 4 - I Am Able to Work | FAC006-I Am Able to Work | FAC00621",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556104","FACT-BL Version 4 - My Work Is Fulfilling","C155602","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Functional Well-Being: My work (include work at home) is fulfilling.","FACT-BL Version 4 - My Work Is Fulfilling | FAC006-My Work Is Fulfilling | FAC00622",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556102","FACT-BL Version 4 - I Have Accepted My Illness","C155604","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Functional Well-Being: I have accepted my illness.","FACT-BL Version 4 - I Have Accepted My Illness | FAC006-I Have Accepted My Illness | FAC00624",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556103","FACT-BL Version 4 - I Am Sleeping Well","C155605","Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Functional Well-Being: I am sleeping well.","FACT-BL Version 4 - I Am Sleeping Well | FAC006-I Am Sleeping Well | FAC00625",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556346","Anti-M-CSFR Monoclonal Antibody SNDX-6352","C155813","A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against colony-stimulating factor 1 receptor (CSF-1R), with potential antineoplastic activity. Upon intravenous administration, axatilimab binds to the ligand binding domain of CSF-1R, preventing binding and consequent activation by its natural ligands, IL-34 and colony-stimulating factor 1 (CSF-1). Inhibition of CSF-1R activation may disrupt the activity of tumor-associated macrophages (TAMs), which promote initiation and metastasis of tumor cells, inhibit T-cell responses, and stimulate tumor angiogenesis and disease progression. CSF-1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and cluster of differentiation 115 (CD115), is a tyrosine-protein kinase that plays an essential role in the regulation, proliferation, survival and differentiation of tissue macrophages as well as TAMs.","Axatilimab | AXATILIMAB | Anti-M-CSFR Monoclonal Antibody SNDX-6352 | Axatilimab-csfr | Niktimvo | SNDX 6352 | SNDX-6352 | SNDX6352 | UCB6352",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555958","UHDRS 1999 Version - Current Level Subject Independence","C155460","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Please indicate the most accurate current level of subject's independence (only increments of 5 are acceptable).","UHDRS 1999 Version - Current Level Subject Independence | UHDR1-Current Level Subject Independence | UHDR169",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555959","UHDRS 1999 Version - Occupation","C155461","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Occupation.","UHDRS 1999 Version - Occupation | UHDR1-Occupation | UHDR170",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555965","UHDRS 1999 Version - Domestic Chores","C155463","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Domestic Chores.","UHDRS 1999 Version - Domestic Chores | UHDR1-Domestic Chores | UHDR172",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555962","UHDRS 1999 Version - ADL","C155464","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) ADL.","UHDRS 1999 Version - ADL | UHDR1-ADL | UHDR173",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555963","UHDRS 1999 Version - Care Level","C155465","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Care Level.","UHDRS 1999 Version - Care Level | UHDR1-Care Level | UHDR174",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555968","UHDRS 1999 Version - Functional Capacity Obtained From","C155466","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Was the Functional Capacity information obtained from.","UHDRS 1999 Version - Functional Capacity Obtained From | UHDR1-Functional Capacity Obtained From | UHDR175",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555969","UHDRS 1999 Version - Purpose of This Visit","C155467","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) What was the purpose of this visit?","UHDRS 1999 Version - Purpose of This Visit | UHDR1-Purpose of This Visit | UHDR177",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555966","UHDRS 1999 Version - Since Last Assessment Opinion","C155468","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Since your last assessment of the subject, in your opinion, has the subject.","UHDRS 1999 Version - Since Last Assessment Opinion | UHDR1-Since Last Assessment Opinion | UHDR178",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555967","UHDRS 1999 Version - Since Last Assessment Feel","C155469","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Since your last assessment does the subject feel.","UHDRS 1999 Version - Since Last Assessment Feel | UHDR1-Since Last Assessment Feel | UHDR179",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562912","Metastatic Pancreatic Carcinoma","C156069","A carcinoma that arises from the pancreas and has metastasized to another anatomic site.","Metastatic Pancreatic Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282614","Acupressure Therapy","C15606","The application of non-invasive finger pressure along energy points throughout the body in order to relieve pain and induce a feeling of well-being.","Acupressure Therapy | Acupressure | Ischemic Compression | acupressure",,,,,,,,,,,,,,,"4333835","Acupressure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL562913","Metastatic Adrenal Cortical Carcinoma","C156070","A carcinoma that arises from the adrenal cortex and has metastasized to another anatomic site.","Metastatic Adrenal Cortical Carcinoma | Metastatic Adrenal Cortex Carcinoma | Metastatic Adrenal Cortex Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562915","Metastatic Cutaneous Melanoma","C156072","A melanoma that arises from the skin and has metastasized to another anatomic site.","Metastatic Cutaneous Melanoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562908","Metastatic Esophageal Carcinoma","C156073","A carcinoma that arises from the esophagus and has metastasized to another anatomic site.","Metastatic Esophageal Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562909","Metastatic Esophageal Adenocarcinoma","C156074","An adenocarcinoma that arises from the esophagus and has metastasized to another anatomic site.","Metastatic Esophageal Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281375","Differentiation Therapy","C15571","Drug therapy aimed at forcing cancer cells to resume the process of maturation and therefore to induce tumor to a more differentiated, less aggressive state. Differentiation therapy restrains cancer cells growth and facilitates the application of more conventional therapies.","Differentiation Therapy | therapy, differentiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556322","KIT NM_000222.2:c.2554G>A","C155720","A nucleotide substitution at position 2554 of the coding sequence of the KIT gene where guanine has been mutated to adenine.","KIT NM_000222.2:c.2554G>A | CD117 c.2554G>A | KIT Proto-Oncogene Tyrosine Protein Kinase c.2554G>A | KIT c.2554G>A | NM_000222.2:c.2554G>A | c-KIT c.2554G>A | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.2554G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556320","KIT NM_000222.2:c.2576T>C","C155722","A nucleotide substitution at position 2576 of the coding sequence of the KIT gene where thymine has been mutated to cytosine.","KIT NM_000222.2:c.2576T>C | CD117 c.2576T>C | KIT Proto-Oncogene Tyrosine Protein Kinase c.2576T>C | KIT c.2576T>C | NM_000222.2:c.2576T>C | c-KIT c.2576T>C | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.2576T>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562796","Metastatic Digestive System Neuroendocrine Carcinoma","C155936","A neuroendocrine carcinoma that arises from any part of the digestive system and has metastasized to another anatomic site.","Metastatic Digestive System Neuroendocrine Carcinoma | Metastatic Gastrointestinal System Neuroendocrine Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562797","Refractory Digestive System Neuroendocrine Carcinoma","C155937","A neuroendocrine carcinoma that arises from any part of the digestive system and does not respond to treatment.","Refractory Digestive System Neuroendocrine Carcinoma | Refractory Gastrointestinal System Neuroendocrine Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562798","Recurrent Digestive System Neuroendocrine Carcinoma","C155938","The reemergence of a neuroendocrine carcinoma in any part of the digestive system after a period of remission.","Recurrent Digestive System Neuroendocrine Carcinoma | Recurrent Gastrointestinal System Neuroendocrine Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281723","gp100 Antigen/Interleukin-2","C15593","No value exists.","gp100 Antigen/Interleukin-2 | gp100/IL-2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1848533","Ataxia with Isolated Vitamin E Deficiency","C155996","An autosomal recessive condition caused by mutation(s) in the TTPA gene, encoding alpha-tocopherol transfer protein. It is characterized by spinocerebellar ataxia and extremely low concentrations of vitamin E.","Ataxia with Isolated Vitamin E Deficiency | AVED",,,,,,,,,,,,,,,"45765491","Ataxia with vitamin E deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL562751","MR Sialography","C155997","The use of magnetic resonance imaging to evaluate the salivary glands and ducts.","MR Sialography | MRI Sialography | Magnetic Resonance Sialography",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556189","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Taking a Shower","C155559","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Taking a shower.","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Taking a Shower | FAC100-Limit: Taking a Shower | FAC10078",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281191","Prevention of Head and Neck Cancer","C15555","No value exists.","Prevention of Head and Neck Cancer | Head and Neck Cancer Prevention",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556186","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Putting on Socks","C155560","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Putting on socks or stockings.","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Putting on Socks | FAC100-Limit: Putting on Socks | FAC10079",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556187","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Standing 5 Minutes","C155561","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Standing for at least 5 minutes.","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Standing 5 Minutes | FAC100-Limit: Standing 5 Minutes | FAC10080",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556192","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Walking 10 Steps","C155562","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Walking 10 steps/paces on flat ground at a normal speed without stopping.","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Walking 10 Steps | FAC100-Limit: Walking 10 Steps | FAC10081",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556193","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Walking 1/2 Mile","C155563","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Walking 1/2 mile (almost 1 km) on flat ground at a normal speed without stopping.","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Walking 1/2 Mile | FAC100-Limit: Walking 1/2 Mile | FAC10082",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556190","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Walking Up 5 Stairs","C155564","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Walking up 5 stairs without stopping.","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Walking Up 5 Stairs | FAC100-Limit: Walking Up 5 Stairs | FAC10083",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556191","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Walking Up 10 Stairs","C155565","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Walking up 10 stairs (1 flight) without stopping.","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Walking Up 10 Stairs | FAC100-Limit: Walking Up 10 Stairs | FAC10084",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556345","Recurrent Endometrial Clear Cell Adenocarcinoma","C155816","The reemergence of endometrial clear cell adenocarcinoma after a period of remission.","Recurrent Endometrial Clear Cell Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556350","Recurrent Endometrial Undifferentiated Carcinoma","C155817","The reemergence of endometrial undifferentiated carcinoma after a period of remission.","Recurrent Endometrial Undifferentiated Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556351","Recurrent Uterine Corpus Carcinosarcoma","C155818","The reemergence of uterine corpus carcinosarcoma after a period of remission.","Recurrent Uterine Corpus Carcinosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556348","Recurrent Endometrial Mixed Cell Adenocarcinoma","C155819","The reemergence of endometrial mixed cell adenocarcinoma after a period of remission.","Recurrent Endometrial Mixed Cell Adenocarcinoma | Recurrent Endometrial Mixed Epithelial Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556349","Aerodigestive Invasive Malignancy","C155820","A finding indicating the presence of an invasive malignant neoplasm involving the respiratory tract and the upper digestive tract.","Aerodigestive Invasive Malignancy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556355","Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy","C155822","Techniques for maximizing LET in target volumes and minimizing LET in critical structures and normal tissues during proton beam radiation therapy.","Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy | LET-Optimized IMPT | LET-Optimized Intensity Modulated Proton Therapy | Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556352","Kegel Nation App","C155823","A smartphone-based application designed to help monitor the frequency, progress and quality of a Kegel exercise regimen in both men and women. It allows patients to measure the duration of the pelvic muscle contraction and relaxation by touching the phone's screen during each exercise phase. The app then archives and charts the measured times with a time and date stamp. Patients can also use the app to track other indicators of bladder function recovery, such as urinary urgency and incontinence episodes, pad use, and voiding events.","Kegel Nation App | Kegel Nation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556044","UHDRS 1999 Version - Irritable Behavior: Frequency","C155414","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Irritable behavior: Frequency: In the past month, how often have you felt impatient, irritable, or 'cranky'?","UHDRS 1999 Version - Irritable Behavior: Frequency | UHDR1-Irritable Behavior: Frequency | UHDR130A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556045","UHDRS 1999 Version - Irritable Behavior: Severity","C155415","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Irritable behavior: Severity: How has irritability impacted your ability to get along with others?","UHDRS 1999 Version - Irritable Behavior: Severity | UHDR1-Irritable Behavior: Severity | UHDR130B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562910","Metastatic Esophageal Squamous Cell Carcinoma","C156075","A squamous cell carcinoma that arises from the esophagus and has metastasized to another anatomic site.","Metastatic Esophageal Squamous Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562936","Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma","C156077","A keratinizing squamous cell carcinoma that arises from the nasopharynx and has metastasized to another anatomic site.","Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562937","Metastatic Nasopharyngeal Undifferentiated Carcinoma","C156078","An undifferentiated carcinoma that arises from the nasopharynx and has metastasized to another anatomic site.","Metastatic Nasopharyngeal Undifferentiated Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562938","Metastatic Nasopharyngeal Carcinoma","C156079","A carcinoma that arises from the nasopharynx and has metastasized to another anatomic site.","Metastatic Nasopharyngeal Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562932","Metastatic Hypopharyngeal Carcinoma","C156081","A carcinoma that arises from the hypopharynx and has metastasized to another anatomic site.","Metastatic Hypopharyngeal Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562933","Metastatic Oropharyngeal Carcinoma","C156082","A carcinoma that arises from the oropharynx and has metastasized to another anatomic site.","Metastatic Oropharyngeal Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562928","Metastatic Laryngeal Carcinoma","C156085","A carcinoma that arises from the larynx and has metastasized to another anatomic site.","Metastatic Laryngeal Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562929","Metastatic Lip and Oral Cavity Carcinoma","C156086","A carcinoma that arises from the lip and/or oral cavity and has metastasized to another anatomic site.","Metastatic Lip and Oral Cavity Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562930","Metastatic Oral Cavity Carcinoma","C156087","A carcinoma that arises from the oral cavity and has metastasized to another anatomic site.","Metastatic Oral Cavity Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556266","BGB A333","C155654","A humanized immunoglobulin G1 (IgG1)-variant monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, garivulimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. In addition, BGB-A333 blocks the interaction between PD-L1 and its other receptor, the immunostimulatory molecule cluster of differentiation 80 (CD80; B7-1). This prevents PD-L1/CD80 signaling and inhibits the induction of PD-L1-induced apoptosis of activated CD8+ T-cells and increases T-cell proliferation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on activated T-cells suppresses the immune system and results in immune evasion. PD-1 negatively regulates T-cell activation.","Garivulimab | Anti-PD-L1 Monoclonal Antibody BGB-A333 | BGB A333 | BGB-A333 | BGBA333 | GARIVULIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562792","Anti-HER2/PBD-MA Antibody-drug Conjugate DHES0815A","C155940","An antibody-drug conjugate (ADC) consisting of a monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2) linked to a DNA minor groove crosslinking agent pyrrolo[2,1- c][1,4]benzodiazepine monoamide (PBD-MA), with potential antineoplastic activity. Upon intravenous administration of ADC DHES0815A, the monoclonal antibody moiety targets and binds to HER2 expressed on tumor cells. Following receptor internalization and lysosome-mediated cleavage, the cytotoxic PBD-MA moiety is released. In turn, the imine groups of the PBD-MA moiety bind to and crosslink specific sites of DNA, resulting in DNA strand breaks, cell cycle arrest, and cell death in HER2 expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","Anti-HER2/PBD-MA Antibody-drug Conjugate DHES0815A | ADC DHES0815A | Anti-HER2/PBD-MA ADC DHES0815A | Anti-HER2/PBD-Monoamide ADC DHES0815A | DHES-0815A | DHES0815A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562818","NLRP3 Agonist BMS-986299","C155945","A nucleotide-binding domain and leucine-rich repeat (NLR) family pyrin domain containing 3 (NLRP3; NACHT, LRR and PYD Containing Protein 3; NALP3) agonist with potential immunomodulatory and antineoplastic activities. Upon administration, NLRP3 agonist BMS-986299 binds to and activates NLRP3, potentially promoting NLRP3 inflammasome-mediated secretion of interleukin-8 (IL-8), which may induce tumoricidal activity of natural killer (NK) cells against tumor cells. NLRP3, a sensor component of the NLRP3 inflammasome plays a significant role in immunity and inflammation, and may protect against tumorigenesis in some cancers.","NLRP3 Agonist BMS-986299 | BMS 986299 | BMS-986299 | BMS986299 | NLR Family Pyrin Domain Containing 3 Agonist BMS-986299",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562819","INC Terminology","C155946","Terminology developed by NCIt EVS and the International Neonatal Consortium (INC), a C-Path consortium formed to forge a predictable regulatory path for evaluating the safety and effectiveness of therapies for neonates.  Operating in the pre-competitive space, INC addresses the need for measurement and assessment of clinical outcomes in neonates through teams that share data and expertise to advance regulatory science.","INC Terminology | International Neonatal Consortium Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562820","Cerebral Hemangioblastoma","C155947","A hemangioblastoma that arises from the cerebrum.","Cerebral Hemangioblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562814","Medullary Hemangioblastoma","C155949","A hemangioblastoma that arises from the medulla oblongata.","Medullary Hemangioblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562815","Hereditary Malignant Urinary System Neoplasm","C155950","A malignant urinary system neoplasm that has developed in relatives of patients with a history of malignant urinary system neoplasm.","Hereditary Malignant Urinary System Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562816","Chromophobe Renal Cell Carcinoma Associated with Birt-Hogg-Dube Syndrome","C155951","Chromophobe renal cell carcinoma that develops in a patient with Birt-Hogg-Dube syndrome.","Chromophobe Renal Cell Carcinoma Associated with Birt-Hogg-Dube Syndrome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556196","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Walking Up 30 Stairs","C155566","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Walking up 30 stairs (3 flights) without stopping.","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Walking Up 30 Stairs | FAC100-Limit: Walking Up 30 Stairs | FAC10085",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556197","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Scrubbing the Floor","C155567","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Scrubbing the floor or counter.","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Scrubbing the Floor | FAC100-Limit: Scrubbing the Floor | FAC10086",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556194","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Lifting Less Than 5 Lbs","C155568","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Lifting something weighing less than 5 lbs (about 2 kg, like a houseplant).","FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Lifting Less Than 5 Lbs | FAC100-Limit: Lifting Less Than 5 Lbs | FAC10087",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556248","Sellar Neurocytoma","C155768","A rare extraventricular neurocytoma (WHO grade 2) of the hypothalamic-pituitary area. (WHO 2017)","Sellar Neurocytoma | Extraventricular Neurocytoma of the Sellar Region | Extraventricular Neurocytoma of the Sellar Region (WHO Grade 2) | Extraventricular Neurocytoma of the Sellar Region (WHO Grade II) | Sellar Neurocytoma (WHO Grade 2) | Sellar Neurocytoma (WHO Grade II)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556249","Sellar Paraganglioma","C155769","An extremely rare paraganglioma arising from chief cells of the dispersed paraganglia of the sellar region. (WHO)","Sellar Paraganglioma | Pituitary Gland Paraganglioma | Sellar Paraganglioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281478","Screening for Ovarian Cancer","C15576","No value exists.","Screening for Ovarian Cancer | early detection of ovarian cancer | ovarian cancer early detection | ovarian cancer screening",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556247","Sellar Neuroblastoma","C155772","An extremely rare ectopic olfactory neuroblastoma that arises from the sellar region.","Sellar Neuroblastoma | Primary Sellar Neuroblastoma | Sellar Esthesioneuroblastoma | Sellar Olfactory Neuroblastoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556252","FLT3 Kinase Inhibitor SKI-G-801","C155773","The hydrochloride salt form of denfivontinib, an orally bioavailable inhibitor of both wild type and mutant forms of FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon administration, denfivontinib binds to and inhibits the activity of FLT3, including FLT3-ITD (internal tandem duplications), FLT3-D835Y as well as other mutants. This inhibits uncontrolled FLT3 signaling and results in the inhibition of proliferation in tumor cells overexpressing FLT3. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B lineage neoplasms and in acute myeloid leukemias, and plays a key role in tumor cell proliferation. In addition, denfivontinib also inhibits, to a lesser degree, the receptor tyrosine kinases AXL (UFO), Mer, Ret, vascular endothelial growth factor receptor 1 (VEGFR1), Fms, fibroblast growth factor receptors (FGFR) 1 and 3, and the serine/threonine kinases Aurora B and C.","Denfivontinib Hydrochloride | DENFIVONTINIB HYDROCHLORIDE | FLT3 Inhibitor SKI-G-801 | FLT3 Inhibitor SKI-G-801 | FLT3 Kinase Inhibitor SKI-G-801 | FLT3 Tyrosine Kinase Inhibitor SKI-G-801 | G-749 HCl Salt | G-749 HYDROCHLORIDE | G-749 Hydrochloride | G-801 | SKI-G-801",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556253","Ependymal Pituicytoma","C155774","A very rare, low-grade neoplasm that arises from the posterior pituitary. It is composed of epithelioid and oncocytic cells forming sheets and fascicles. It shows histopathological features reminiscent of ependymomas, including perivascular pseudorosettes and true rosettes. There is no evidence of necrosis or increased mitotic activity. Despite the presence of ependymal histopathological features, these neoplasms probably are not related to ependymomas. Their prognosis is unknown.","Ependymal Pituicytoma | Sellar Ependymoma | Sellar Ependymoma",,,,,,,,,,,,,,,"37312305","Sellar ependymoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL556250","Autologous Mesothelin-specific Human mRNA CAR-transfected PBMCs MCY-M11","C155775","Autologous peripheral blood mononuclear cells (PBMCs) transfected with anti-mesothelin chimeric antigen receptor (CAR) mRNA, with potential antineoplastic activity. Upon intraperitoneal (IP) administration, the autologous mesothelin-specific human mRNA CAR-transfected PBMCs MCY-M11 recognize, bind to, phagocytose and directly kill cancer cells expressing mesothelin. In addition, MCY-M11 stimulates the immune system to induce a cytotoxic T-lymphocyte response against the mesothelin-expressing cancer cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in many epithelial-derived cancers.","Autologous Mesothelin-specific Human mRNA CAR-transfected PBMCs MCY-M11 | Anti-mesothelin mRNA-transfected Autologous PBMCs MCY-M11 | MCY-M11",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556042","UHDRS 1999 Version - Disruptive Behavior: Frequency","C155416","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Disruptive or aggressive behavior: Frequency: Within the past month, how often have you had emotional or temper outbursts? How often have you had times when you lost control of yourself?","UHDRS 1999 Version - Disruptive Behavior: Frequency | UHDR1-Disruptive Behavior: Frequency | UHDR131A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556043","UHDRS 1999 Version - UDHR1-Disruptive Behavior: Severity","C155417","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Disruptive or aggressive behavior: Severity: Have you used threats or hostile words? Have you hit or shoved or thrown things or expressed your temper in a physical way?","UHDRS 1999 Version - UDHR1-Disruptive Behavior: Severity | UDHR1-Disruptive Behavior: Severity | UHDR131B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556048","UHDRS 1999 Version - Perseverative Thinking: Frequency","C155418","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Perseverative/obsessional thinking: Frequency: Within the past month, how often have you found yourself getting stuck on certain ideas? How often have you been bothered by thoughts, images, or fears that keep coming back even if you try not to have them?","UHDRS 1999 Version - Perseverative Thinking: Frequency | UHDR1-Perseverative Thinking: Frequency | UHDR132A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556049","UHDRS 1999 Version - UDHR1-Perseverative Thinking: Severity","C155419","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Perseverative/obsessional thinking: Severity: Have do repeated thoughts impact your daily life?","UHDRS 1999 Version - UDHR1-Perseverative Thinking: Severity | UDHR1-Perseverative Thinking: Severity | UHDR132B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281168","Sleep Disorder Therapy","C15541","Any treatment that is undertaken with the purpose of alleviating any form of sleep disorder.","Sleep Disorder Therapy | Sleep Disorders",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556046","UHDRS 1999 Version - Compulsive Behavior: Frequency","C155420","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Compulsive behavior: Frequency: Within the past month, how often have you found yourself doing certain things over and over again (counting, washing, checking)?","UHDRS 1999 Version - Compulsive Behavior: Frequency | UHDR1-Compulsive Behavior: Frequency | UHDR133A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556047","UHDRS 1999 Version - UDHR1-Compulsive Behavior: Severity","C155421","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Compulsive behavior: Severity: Are you unable to resist doing some of these things?","UHDRS 1999 Version - UDHR1-Compulsive Behavior: Severity | UDHR1-Compulsive Behavior: Severity | UHDR133B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556052","UHDRS 1999 Version - Delusions: Frequency","C155422","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Delusions: Frequency: How often does it seem like people are out to get you, people are controlling you, or you are very suspicious of others? Do you have special powers or importance?","UHDRS 1999 Version - Delusions: Frequency | UHDR1-Delusions: Frequency | UHDR134A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556053","UHDRS 1999 Version - UDHR1-Delusions: Severity","C155423","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Delusions: Severity: When you feel suspicious (insert delusion here), are you able to convince yourself that it is not rational? [Severity should reflect the behavior's impact on the individual's ability to carry out daily activities as indicated by response choices.].","UHDRS 1999 Version - UDHR1-Delusions: Severity | UDHR1-Delusions: Severity | UHDR134B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556050","UHDRS 1999 Version - Hallucinations: Frequency","C155424","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Hallucinations: Frequency: How often have you heard things that other people couldn't hear, or seen things that other people couldn't see?","UHDRS 1999 Version - Hallucinations: Frequency | UHDR1-Hallucinations: Frequency | UHDR135A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556051","UHDRS 1999 Version - UDHR1-Hallucinations: Severity","C155425","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Hallucinations: Severity: When you see or hear things (insert hallucination here), are you able to convince yourself that it is not rational? [Severity should reflect the behavior's impact on the individual's ability to carry out daily activities as indicated by response choices.].","UHDRS 1999 Version - UDHR1-Hallucinations: Severity | UDHR1-Hallucinations: Severity | UHDR135B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556271","Plasmodium vivax-infected Red Blood Cell","C155655","A preparation of red blood cells (RBCs) that have been infected with the malaria parasite Plasmodium vivax (P. vivax), with potential immunomodulating and antineoplastic activities. Upon administration of the P. vivax-infected RBCs, the P. vivax infection stimulates host immune responses against the P. vivax-infected RBCs. This also stimulates both innate and adaptive anti-tumor immune responses. This leads to the production of cytokines, including interferon-gamma (IFN-g) and tumor-necrosis factor alpha (TNF-a), the proliferation and activation of natural killer (NK) cells, dendritic cells (DCs), CD4-positive T-lymphocytes, and cytotoxic T-lymphocytes (CTLs). This results in the inhibition of tumor cell proliferation, induction of tumor cell apoptosis, and prevents angiogenesis.","Plasmodium vivax-infected Red Blood Cell | P. vivax-infected RBCs | P. vivax-infected Red Blood Cells | Plasmodium vivax RBC Immunotherapy Agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556269","Autologous Cervical Cancer-specific Engineered Immune Effector Cells","C155657","A preparation of autologous immune effector cells genetically modified to target a not yet disclosed cervical cancer-specific tumor-associated antigen (TAA), with potential immunomodulating and antineoplastic activities. After isolation, transduction, expansion in culture, and reintroduction into the patient, the autologous cervical cancer-specific engineered immune effector (CC-EIE) cells bind to and induce selective toxicity in tumor cells expressing the TAA.","Autologous Cervical Cancer-specific Engineered Immune Effector Cells | Autologous CC-EIE Cells | Autologous CC-EIEs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281266","Prior Adjuvant Endocrine Therapy","C15565","An indication that an individual has been previously treated with endocrine/hormonal therapy following surgery.","Prior Adjuvant Endocrine Therapy | Prior Adjuvant Endocrine/Hormonal Therapy | Prior Adjuvant Hormonal Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556270","Autologous Ovarian Cancer-specific Cytotoxic T-Lymphocytes","C155664","A preparation of autologous cytotoxic T-lymphocytes (CTLs) genetically modified to target a not yet disclosed ovarian cancer-specific tumor-associated antigen (TAA), with potential immunomodulating and antineoplastic activities. After isolation, transduction, expansion in culture, and reintroduction into the patient, the autologous ovarian cancer-specific cytotoxic T-lymphocytes (OC-CTLs) bind to and induce selective toxicity in tumor cells expressing the TAA.","Autologous Ovarian Cancer-specific Cytotoxic T-Lymphocytes | Autologous OC-CTLs | Autologous Ovarian Cancer-specific CTLs | OC-CTLs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556275","MIR27B Gene","C155665","This gene may be involved in the negative regulation of CYP1B1 gene expression.","MIR27B Gene | MIR27B | MicroRNA 27b Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556276","MIR27B wt Allele","C155666","Human MIR27B wild-type allele is located in the vicinity of 9q22.32 and is approximately 97 bases in length. This allele, which encodes MIR27B pre-miRNA, plays a role in the regulation of target gene expression. Downregulation of this gene may be associated with breast cancer and chronic lymphocytic leukemia.","MIR27B wt Allele | MIR-27b | MIRN27B | Micro RNA 27B Gene | MicroRNA 27b wt Allele | hsa-miR-27b | miRNA27B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556273","MIR27B Pre-miRNA","C155667","MIR27B pre-miRNA (97 bases) is encoded by the human MIR27B gene. This ribonucleotide may be involved in the regulation of CYP1B1 gene transcription.","MIR27B Pre-miRNA | Pre-MIR27B | Pre-MicroRNA 27B | Pre-miRNA 27B | Pre-miRNA MIR27B | Pre-miRNA27B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556274","NRAS NM_002524.4:c.34G>T","C155668","A nucleotide substitution at position 34 of the coding sequence of the NRAS gene where guanine has been mutated to thymine.","NRAS NM_002524.4:c.34G>T | N-ras c.34G>T | NM_002524.4:c.34G>T | NRAS c.34G>T | NRAS1 c.34G>T | Neuroblastoma RAS Viral (v-ras) Oncogene Homolog c.34G>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562684","Anti-EGFR Monoclonal Antibody CPGJ 602","C155876","A recombinant, human-mouse chimeric monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Upon intravenous administration, anti-EGFR monoclonal antibody CPGJ 602 targets and binds to EGFR, which prevents receptor dimerization and activation. This leads to an inhibition of EGFR-dependent downstream pathways and EGFR-dependent tumor cell proliferation and metastasis. EGFR, a receptor tyrosine kinase, may be overexpressed on the surfaces of various tumor cell types.","Anti-EGFR Monoclonal Antibody CPGJ 602 | CPGJ 602 | CPGJ-602 | CPGJ602",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562703","Unresectable Desmoid Tumor","C155877","Desmoid fibromatosis that is not amenable to surgical resection.","Unresectable Desmoid Fibromatosis | Unresectable Desmoid Tumor | Unresectable Desmoid-Type Fibromatosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562811","Uterine Ligament Papillary Cystadenoma","C155952","A cystadenoma that arises from the broad or other uterine ligaments. It is characterized by the presence of small papillary projections in the inner surface of the cysts. It may be sporadic or associated with von Hippel-Lindau disease.","Uterine Ligament Papillary Cystadenoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562812","Epididymal Papillary Cystadenoma","C155953","A cystadenoma that arises from the epididymis. It is characterized by the presence of small papillary projections in the inner surface of the cysts. It may be sporadic or associated with von Hippel-Lindau disease.","Epididymal Papillary Cystadenoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0345891","Intestinal Polyposis Syndrome","C155954","A syndrome associated with the development of multiple polyps throughout the intestine. It includes familial adenomatous polyposis , hamartomatous polyposis syndromes, and other rare polyposis syndromes.","Intestinal Polyposis Syndrome | ",,,,,,,,,,,,,,,"4112732","Intestinal polyposis syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL562813","CDK2/4/6/FLT3 Inhibitor FN-1501","C155956","A small molecule multi-kinase inhibitor of cyclin-dependent kinase (CDK) subtypes 2 (CDK2), 4 (CDK4), and 6 (CDK6) and FMS-related tyrosine kinase 3 (FLT3, FLK2, STK1), with potential antineoplastic activity. Upon intravenous administration, CDK2/4/6/FLT3 inhibitor FN-1501 binds to and inhibits CDK2, CDK4, and CDK6, as well as FLT3. This may induce apoptosis and inhibit tumor cell proliferation in cancer cells that overexpress these kinases. CDKs are serine/threonine kinases that assist in cell cycle regulation and cellular proliferation. FLT3, a class III tyrosine kinase receptor, is overexpressed or mutated in many cancer types.","CDK2/4/6/FLT3 Inhibitor FN-1501 | 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide | CDK/FLT3 Inhibitor FN-1501 | FN 1501 | FN-1501 | FN1501",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562807","Thyroid Gland Spindle Cell Follicular Adenoma","C155957","A rare thyroid gland follicular adenoma composed predominantly of spindle cells.","Thyroid Gland Spindle Cell Follicular Adenoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562808","Thyroid Gland Black Follicular Adenoma","C155958","A thyroid gland follicular adenoma seen in patients treated with minocycline. The tumors have black discoloration visible on macroscopic examination and cytoplasmic accumulation of black pigment. (WHO 2017)","Thyroid Gland Black Follicular Adenoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562809","Black Discoloration","C155959","Color change of a tissue to black.","Tissue Black Discoloration | Black Discoloration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281735","Transitional Care Planning","C15595","No value exists.","Transitional Care Planning | transitional care",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562810","Cytoplasmic Accumulation of Black Pigment","C155960","A morphologic finding indicating the presence of black pigment within the cytoplasm of cells in a tissue sample.","Cytoplasmic Accumulation of Black Pigment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562722","Submucosal Invasion Depth","C155962","A morphological finding indicating the depth of tumor invasion into the submucosal tissue.","Submucosal Invasion Depth | tumor depth | tumor_depth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562723","Submucosal 1 Invasion","C155963","Submucosal tumor invasion into the upper third of the submucosal tissue.","Submucosal 1 Invasion | Submucosal Invasion Depth Class 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562724","Submucosal 2 Invasion","C155964","Submucosal tumor invasion into the middle third of the submucosal tissue.","Submucosal 2 Invasion | Submucosal Invasion Depth Class 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562718","Submucosal 3 Invasion","C155965","Submucosal tumor invasion into the lower third of the submucosal tissue.","Submucosal 3 Invasion | Submucosal Invasion Depth Class 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556251","Sellar Meningioma","C155776","A rare meningioma that arises from the sellar region.","Sellar Meningioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556256","Sellar Region","C155777","The area inside or around the sella turcica.","Sellar Region | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556257","Intrasellar Meningioma","C155778","A rare meningioma arising from the intrasellar region.","Intrasellar Meningioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556254","Intrasellar Region","C155779","The area inside the sella turcica.","Intrasellar Region | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556260","Sellar Chordoma","C155781","A chordoma that arises from the sellar region.","Sellar Chordoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556261","Sellar Chondroid Chordoma","C155782","A chondroid chordoma that arises from the sellar region.","Sellar Chondroid Chordoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556258","Sellar Dedifferentiated Chordoma","C155783","A dedifferentiated chordoma that arises from the sellar region.","Sellar Dedifferentiated Chordoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556259","Sellar Hemangiopericytoma/ Solitary Fibrous Tumor","C155784","An extremely rare meningeal solitary fibrous tumor that arises from the sellar region.","Sellar Solitary Fibrous Tumor | Sellar Hemangiopericytoma/ Solitary Fibrous Tumor | Sellar Solitary Fibrous Tumor/Hemangiopericytoma | Sellar Solitary Fibrous Tumor/Hemangiopericytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555871","CDRS-R - Subtotal 3","C155365","Children's Depression Rating Scale, Revised (CDRS-R) Subtotal 3 - sum of questions 15 to 17.","CDRS-R - Subtotal 3 | CDRS1-Subtotal 3 | CDRS120",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555876","CDRS-R - CDRS-R Raw Summary Score","C155366","Children's Depression Rating Scale, Revised (CDRS-R) CDRS-R raw summary score.","CDRS-R - CDRS-R Raw Summary Score | CDRS1-CDRS-R Raw Summary Score | CDRS121",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555877","CDRS-R - CDRS-R T-Score","C155367","Children's Depression Rating Scale, Revised (CDRS-R) CDRS-R T-score.","CDRS-R - CDRS-R T-Score | CDRS1-CDRS-R T-Score | CDRS122",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555875","CDRS-R - CDRS-R T-Score Range","C155369","Children's Depression Rating Scale, Revised (CDRS-R) CDRS-R T-score range.","CDRS-R - CDRS-R T-Score Range | CDRS1-CDRS-R T-Score Range | CDRS124",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2698538","Therapeutic Bone Marrow Suppression","C15536","Induction of bone marrow suppression for the treatment of disease, especially myeloproliferative disease.","Therapeutic Bone Marrow Suppression | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555880","UHDRS 1999 Version - Ocular Pursuit: Horizontal","C155370","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Ocular pursuit, horizontal.","UHDRS 1999 Version - Ocular Pursuit: Horizontal | UHDR1-Ocular Pursuit: Horizontal | UHDR101A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555881","UHDRS 1999 Version - Ocular Pursuit: Vertical","C155371","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Ocular pursuit, vertical.","UHDRS 1999 Version - Ocular Pursuit: Vertical | UHDR1-Ocular Pursuit: Vertical | UHDR101B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555878","UHDRS 1999 Version - Saccade Initiation: Horizontal","C155372","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Saccade initiation, horizontal.","UHDRS 1999 Version - Saccade Initiation: Horizontal | UHDR1-Saccade Initiation: Horizontal | UHDR102A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555879","UHDRS 1999 Version - Saccade Initiation: Vertical","C155373","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Saccade initiation, vertical.","UHDRS 1999 Version - Saccade Initiation: Vertical | UHDR1-Saccade Initiation: Vertical | UHDR102B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL516453","Xeroderma Pigmentosum-Cockayne Syndrome Complex","C156031","A condition characterized by the cutaneous features of xeroderma pigmentosum and the systemic and neurological features of Cockayne syndrome.","Xeroderma Pigmentosum-Cockayne Syndrome Complex | XP-CS | XP/CS | Xeroderma Pigmentosum/Cockayne Syndrome",,,,,,,,,,,,,,,"36714536","Xeroderma pigmentosum and Cockayne syndrome complex",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0037277","Genodermatosis","C156032","A group of inherited skin disorders that present with multisystem involvement. It includes ichthyosis, epidermolysis bullosa, ectodermal dysplasia, cutis laxa, progeroid conditions, xeroderma pigmentosum, Rothmund Thomson syndrome, and dyskeratosis congenita.","Genodermatosis | ",,,,,,,,,,,,,,,"4033514","Genodermatosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL562888","Encapsulated Variant Thyroid Gland Papillary Carcinoma","C156034","A typical papillary thyroid gland carcinoma that is totally surrounded by a fibrous capsule, which may be intact or only focally infiltrated by tumor growth. It accounts for about 10% of all cases of papillary thyroid gland carcinoma and has an excellent prognosis. Regional nodal metastases may be present, but bloodborne metastases are rare. The survival rate is nearly 100%. (WHO 2017)","Encapsulated Variant Thyroid Gland Papillary Carcinoma | ","8343/3","Papillary carcinoma, encapsulated, of thyroid",,,,,,,,,,,,,,,,,,,,,,,,,,,"--","--"
"CL562889","Frontal Lobe Anaplastic Astrocytoma","C156035","An anaplastic astrocytoma occurring in the frontal lobe.","Frontal Lobe Anaplastic Astrocytoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562884","Temporal Lobe Anaplastic Astrocytoma","C156036","An anaplastic astrocytoma occurring in the temporal lobe.","Temporal Lobe Anaplastic Astrocytoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562886","Hypothalamic-Chiasmatic Pilomyxoid Astrocytoma","C156038","A pilomyxoid astrocytoma occurring in the hypothalamic-chiasmatic region.","Hypothalamic-Chiasmatic Pilomyxoid Astrocytoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562887","Fourth Ventricle Medulloblastoma","C156039","A medulloblastoma occurring in the fourth ventricle.","Fourth Ventricle Medulloblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562880","Third Ventricle Germinoma","C156040","A germinoma that arises from the third ventricle.","Third Ventricle Germinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562881","Supratentorial Pleomorphic Xanthoastrocytoma","C156041","A pleomorphic xanthoastrocytoma that arises from the supratentorial region of the brain.","Supratentorial Pleomorphic Xanthoastrocytoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562882","Temporal Lobe Pleomorphic Xanthoastrocytoma","C156042","A pleomorphic xanthoastrocytoma that arises from the temporal lobe of the brain.","Temporal Lobe Pleomorphic Xanthoastrocytoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562883","Zirconium Zr 89 Panitumumab","C156043","A radioimmunoconjugate composed of panitumumab, a human immunoglobulin G2 (IgG2) monoclonal antibody directed against the epidermal growth factor receptor (EGFR; HER1; ErbB1), labeled with the radioisotope zirconium Zr 89, with potential use as an imaging agent upon positron emission tomography (PET). Upon administration of zirconium Zr 89 panitumumab, the antibody moiety targets and binds to the extracellular domain of EGFR on tumor cells. Upon PET imaging, EGFR-expressing tumor cells can be visualized and assessed. This allows quantification of EGFR-expressing tumor cells and may allow selection of patients that would respond to panitumumab therapy. EGFR, a receptor tyrosine kinase overexpressed on the cell surfaces of many tumor cell types, plays a key role in tumor cell proliferation.","Zirconium Zr 89 Panitumumab | 89Zr-labeled Panitumumab | 89Zr-panitumumab | ZIRCONIUM PANITUMUMAB ZR-89 | Zr 89-Panitumumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562905","Spindle Cell Variant Thyroid Gland Papillary Carcinoma","C156045","Papillary carcinoma of the thyroid gland with focal areas of spindle cell metaplasia.","Spindle Cell Variant Thyroid Gland Papillary Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562704","Autologous Anti-CD19 CAR T-cells JWCAR029","C155878","A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed, costimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, relmacabtagene autoleucel target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.","Relmacabtagene Autoleucel | Autologous Anti-CD19 CAR T-cells JWCAR029 | Autologous CD19-targeted CAR T Cells JWCAR029 | JWCAR 029 | JWCAR-029 | JWCAR029 | RELMACABTAGENE AUTOLEUCEL | Relma-cel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562705","AK 105","C155879","A monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, penpulimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","Penpulimab | AK 105 | AK-105 | AK105 | Anti-PD-1 Monoclonal Antibody AK105 | PENPULIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281605","Bone Marrow Ablation with Stem Cell Support","C15587","Bone marrow ablation followed by replacement of stem cells in the circulating blood to help the bone marrow recover and continue producing healthy blood cells.","Bone Marrow Ablation with Stem Cell Support | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562706","Autologous HPV-specific Cytotoxic T Lymphocytes","C155880","A population of autologous cytotoxic T-lymphocytes (CTLs) that are specifically reactive to human papillomavirus (HPV), with potential antiviral and antineoplastic activities activities. Upon infusion of the autologous HPV-specific CTLs, these CTLs induce selective toxicity in HPV-positive cancer cells and other HPV-infected cells. HPV is associated with various cancer cell types.","Autologous HPV-specific Cytotoxic T Lymphocytes | Autologous HPV Specific Immune Lymphocytes | Autologous HPV-CTLs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562699","Allogeneic HPV-specific Cytotoxic T Lymphocytes","C155881","A population of allogeneic cytotoxic T-lymphocytes (CTLs) that are specifically reactive to human papillomavirus (HPV), with potential antiviral and antineoplastic activities. Upon infusion of the allogeneic HPV-specific CTLs, these CTLs induce selective toxicity in HPV-positive cancer cells and other HPV-infected cells. HPV is associated with various cancer cell types.","Allogeneic HPV-specific Cytotoxic T Lymphocytes | Allogeneic HPV Specific Immune Lymphocytes | Allogeneic HPV-CTLs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562700","Qilisheng Immunoregulatory Oral Solution","C155882","An oral solution containing Spondias axillaris, Panax ginseng, schisandra berry, hawthorn, soybean and an as of yet not elucidated bacterium, with potential immunomodulating activity. Upon oral administration of the qilisheng immunoregulatory oral solution, the ingredients in qilisheng may modulate the immune system.","Qilisheng Immunoregulatory Oral Solution | Qilisheng | Qilisheng Solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562701","Autologous Anti-BCMA CAR-transduced T-cells KITE-585","C155883","A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) derived from a human monoclonal antibody specific for the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) fused, via an as of yet unknown linker, to the co-stimulatory domain of CD28, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-BCMA CAR transduced T-cells KITE-585 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma cells and plays a key role in plasma cell proliferation and survival. The CD28 co-stimulatory domain optimizes T-cell expansion and function.","Autologous Anti-BCMA CAR-transduced T-cells KITE-585 | Autologous Genetically Modified Anti-BCMA CAR-T Cells KITE-585 | Autologous Genetically-modified Anti-BCMA CAR-transduced T-cells KITE-585 | Autologous T-cells KITE-585 | KITE 585 | KITE-585 | KITE585",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555972","UHDRS 1999 Version - Believe Subject Has Manifest HD","C155470","Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Based on the entire UHDRS (Motor, Cognitive, Behavioral and Functional components) do you believe with a confidence level >= 99% that this subject has manifest HD?","UHDRS 1999 Version - Believe Subject Has Manifest HD | UHDR1-Believe Subject Has Manifest HD | UHDR180",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563005","Autologous Natural Killer Cell-like CTLs","C156168","A preparation of cytotoxic T-lymphocytes (CTLs) that express natural killer (NK)-like features (nCTLs), with potential immunomodulating and antineoplastic activities. The nCTLs are derived from autologous lymphocytes that have been in vitro exposed to autologous alpha-type-1 polarized dendritic cells that are pulsed with specific autologous tumor-associated antigens (TAAs); the nCTLs are subsequently expanded in the presence of the cytokine human interleukin-2 (IL-2). The generated nCTLs are potent CTLs that produce high amounts of granzyme B and perforin, and interferon-gamma (IFNg) with high killer activity and tumor-homing potential. Upon infusion of the autologous nCTLs, these cells specifically recognize the TAAs on the tumor cells, then bind to and directly lyse tumor cells.","Autologous Natural Killer Cell-like CTLs | Autologous CTLs Sensitized Ex-vivo with Autologous TAA-loaded alphaDC1 | Autologous NK-like CTLs | Autologous Natural Killer-like Cytotoxic Lymphocytes | Autologous aDC1-induced CTLs | Autologous nCTLs | In Vitro DC-sensitized CTLs | In-vitro DC-sensitized Autologous CTLs | Therapeutic iNKT Cells | Therapeutic nCTLs | Tumor Neo-antigen-specific nCTLs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563006","Autologous Anti-CD19CAR-CD3zeta-4-1BB-IL-15-PD1-expressing Tri-functional T-lymphocytes","C156169","A preparation of autologous T-lymphocytes engineered to express a tri-functional chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19), and an extracellular domain consisting of interleukin 15 (IL-15) and programmed cell death 1 (PD1; PDCD1; CD279; programmed death-1), linked to the intracellular signaling domains of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), with potential antineoplastic activity. Upon intravenous administration, autologous anti-CD19CAR-CD3zeta-4-1BB-IL-15-PD1-expressing tri-functional T-lymphocytes target, bind to, and induce selective toxicity in CD19-expressing tumor cells. IL-15 is a pro-survival cytokine that promotes T-cell persistence and potentiates the immune response against tumor cells. The PD1 moiety binds to programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) on tumor cells, reversing T-cell inactivation caused by endogenous PD1/PD-L1 signaling and enhancing the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. CD19 is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. Incorporation of the costimulatory signaling domains increases human T-cell function, expansion, and survival.","Autologous Anti-CD19CAR-CD3zeta-4-1BB-IL-15-PD1-expressing Tri-functional T-lymphocytes | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562999","Autologous Anti-CD38 A2 CAR2-expressing T-cells","C156170","A preparation of genetically modified autologous T-cells expressing a chimeric antigen receptor recognizing the tumor-associated antigen (TAA) cluster of differentiation 38 (CD38), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous anti-CD38 A2 CAR2-expressing T-cells are directed to and induce selective toxicity in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.","Autologous Anti-CD38 A2 CAR2-expressing T-cells | Autologous Anti-CD38 A2 CAR2 T-cells | Autologous CAR2 Anti-CD38 A2 CAR T-cells | Autologous CAR2 Anti-CD38 A2 T-lymphocytes | Autologous CD38-A2 CAR2-expressing T-lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0070286","pentaglobulin","C156171","An immunoglobulin preparation consisting of immunoglobulin G (IgG) and immunoglobulin A (IgA), supplemented with immunoglobulin M (IgM), with potential antibacterial and immunomodulatory properties. Upon intravenous administration, IgM-enriched immunoglobulins may increase the elimination of infectious pathogens in comparison to immunoglobulin regimens lacking IgM. IgM is the major immunoglobulin secreted during the primary immune response and plays a significant role in compliment activation and in the neutralization of bacterial endo- and exotoxins.","IgM-enriched Immunoglobulins | IgM-enriched Immunoglobulin | Immunoglobulin GMA | Immunoglobulin M-enriched Immunoglobulins | Pentaglobin | ivIgGMA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563001","HLX 06","C156172","A fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with potential anti-angiogenesis and antineoplastic activities. Upon administration, vulinacimab specifically binds to and inhibits VEGFR-2, which may inhibit tumor angiogenesis and tumor cell proliferation. VEGFR-2, a tyrosine-protein kinase that plays an essential role in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells, is overexpressed in certain tumor types.","Vulinacimab | Anti-VEGFR2 Monoclonal Antibody HLX06 | HLX 06 | HLX-06 | HLX06 | VULINACIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563002","ICP 022","C156173","A small molecule inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase) with potential antineoplastic activity. Upon administration, orelabrutinib binds to and inhibits the activity of BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.","Orelabrutinib | BTK Inhibitor ICP-022 | ICP 022 | ICP-022 | ICP022 | ORELABRUTINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935686","Development International Birth Date","C156648","The date of a sponsor's first authorization to conduct a clinical trial in any country worldwide.","Development International Birth Date | DIBD | DIBD (development international birth date)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935687","Electronic Document Room","C156649","The online repository for electronic FDA CDER submissions; it is an extension of the Central Document Room.","Electronic Document Room | EDR | EDR (electronic document room)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0599834","Technology Development","C15664","No value exists.","Technology Development | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3849995","Health Information Exchange","C156650","The process of sharing patient-level health information through electronic networks among disparate health information systems, primarily to permit immediate access at the point of care.","Health Information Exchange | HIE | HIE (Health Information Exchange)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935692","No Observable Effect Level","C156651","The greatest amount, or highest dose or exposure level, of a substance that produces no noticeable toxicity.","No Observable Effect Level | NOEL | NOEL (no observable effect level)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935690","Regional Health Information Organization","C156652","A group of stakeholders in a given geographic region that govern and share healthcare-related information among them, often electronically, according to accepted healthcare information technology standards.","Regional Health Information Organization | RHIO | RHIO (Regional Health Information Organization)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935691","Standard for the Exchange of Nonclinical Data","C156653","An implementation of the CDISC SDTM standard for the collection and storage of nonclinical study data.","Standard for the Exchange of Nonclinical Data | SEND | SEND (standard for the exchange of nonclinical data)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0449406","Organ of Origin","C156840","The organ identified as the original site of the tumor.","Organ of Origin | Primary Organ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563142","Cisplatin/Fluorouracil Regimen","C156353","A regimen consisting of cisplatin and fluorouracil that can be used in the treatment of head and neck, gastric, anal, esophageal and esophagogastric junction, hepatobiliary, occult primary, penile, vulvar, bladder and squamous cell skin cancer,and cancer of the nasopharynx.","Cisplatin/Fluorouracil Regimen | CF | CF Regimen | Cisplatin and Fluorouracil (CF) | Cisplatin-Fluorouracil | Cisplatin-Fluorouracil Regimen | Cisplatin/Fluorouracil | FUP | FUP Regimen | Fluorouracil/Cisplatin | Fluorouracil/Cisplatin Regimen | PF | PF Regimen | Wayne State Protocol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935996","C-H-RAS c.35_36GC>AT","C156887","A complex substitution where the nucleotide sequence at positions 35 and 36 of the coding sequence of the HRAS gene has changed from guanine-cytosine to adenine-thymine.","HRAS NM_005343.3:c.35_36delinsAT | C-H-RAS c.35_36GC>AT | C-H-RAS c.35_36delGCinsAT | C-HA-RAS1 c.35_36GC>AT | C-HA-RAS1 c.35_36delGCinsAT | H-ras c.35_36GC>AT | H-ras c.35_36delGCinsAT | HRAS NM_005343.3:c.35_36GC>AT | HRAS NM_005343.3:c.35_36delGCinsAT | HRAS NM_005343.3:c.35_36delGCinsAT | HRAS c.35_36GC>AT | HRAS c.35_36delGCinsAT | HRAS1 c.35_36GC>AT | HRAS1 c.35_36delGCinsAT | HRas Proto-Oncogene, GTPase c.35_36GC>AT | HRas Proto-Oncogene, GTPase c.35_36delGCinsAT | Ha-ras c.35_36GC>AT | Ha-ras c.35_36delGCinsAT | Harvey Rat Sarcoma Viral Oncogene Homolog c.35_36GC>AT | Harvey Rat Sarcoma Viral Oncogene Homolog c.35_36delGCinsAT | NM_005343.3:c.35_36GC>AT | NM_005343.3:c.35_36delGCinsAT | NM_005343.3:c.35_36delinsAT | RASH1 c.35_36GC>AT | RASH1 c.35_36delGCinsAT | v-Ha-ras Harvey Rat Sarcoma Viral Oncogene Homolog c.35_36GC>AT | v-Ha-ras Harvey Rat Sarcoma Viral Oncogene Homolog c.35_36delGCinsAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935987","HER2/Neu Expression by Validated Immunohistochemistry","C156890","An immunohistochemistry assay for HER2/Neu expression in a tissue sample that uses a validated antibody in a validated testing lab.. A validated testing lab must have only 5% or less of samples classified as either positive or negative disagree with a 'validated' assay.","HER2/Neu Expression by Validated Immunohistochemistry | HER2 Testing by Validated IHC Assay | HER2/Neu Expression by Validated IHC | HER2/Neu Testing by Validated IHC | HER2/Neu Testing by Validated Immunohistochemistry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935984","HER2/Neu Status by Validated Single-probe in Situ Hybridization","C156891","An in situ hybridization assay for HER2/Neu that uses a validated assay for HER2 in a validated testing lab.","HER2/Neu Status by Validated Single-probe in Situ Hybridization | HER2 Testing by Validated Single-probe ISH Assay | HER2/Neu Status by Validated Single-probe ISH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935985","HER2/Neu Status by Validated Dual-probe in Situ Hybridization","C156892","An in situ hybridization assay for HER2/Neu that combines a validated assay for HER2 with a probe for chromosome 17, with the assay performed in a validated testing lab.","HER2/Neu Status by Validated Dual-probe in Situ Hybridization | HER2 Testing by Validated Dual-probe ISH Assay | HER2/Neu Status by Validated Dual-probe ISH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562949","Prolonged-release suspension for injection in pre-filled pen","C156229","Medicinal product consisting of a prolonged-release suspension for injection presented in a pre-filled pen.","Prolonged-Release Suspension for Injection in Pre-filled Pen Dosage Form | Prolonged-Release Suspension for Injection in Pre-filled Pen | Prolonged-release suspension for injection in pre-filled pen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935853","Sodium-Potassium Adenosine Triphosphatase Inhibitor RX108","C156728","A small-molecule, inhibitor of sodium-potassium adenosine triphosphatase (Na+/K+-ATPase) with potential antineoplastic activity. Upon administration, RX108 inhibits the activity of the Na+/K+-ATPase, which prevents the activation of various signal transduction pathways that play a key role in tumor proliferation. This may lead to cell-cycle arrest, apoptosis, and autophagic cell death. Na+/K+-ATPase is overexpressed in certain tumor types and may serve as a scaffold for the assembly of multiple-protein signaling complexes that regulate cell proliferation and motility. In normal, healthy cells, the Na+/K+-ATPase controls transportation of Na+ and K+ across the cell membrane and is essential for electrochemical gradient maintenance, osmotic balance, and cellular pH.","Sodium-Potassium Adenosine Triphosphatase Inhibitor RX108 | Na+/K+-ATPase Inhibitor RX108 | RX 108 | RX-108 | RX108 | Sodium-Potassium Pump Inhibitor RX10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537454","METTL13 Gene","C156930","This gene is involved in both the methylation of translation elongation factor 1a and anti-apoptotic activity.","METTL13 Gene | EEF1AKNMT | METTL13 | Methyltransferase 13, eEF1A Lysine and N-Terminal Methyltransferase Gene | Methyltransferase 13, eEF1A N-Terminus and K55 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935950","5630401D24Rik","C156931","Human METTL13 wild-type allele is located in the vicinity of 1q24.3 and is approximately 32 kb in length. This allele, which encodes eEF1A lysine and N-terminal methyltransferase protein, plays a role in the modulation of both apoptosis and protein translation. Mutation of the gene is associated with type 26 autosomal recessive deafness.","METTL13 wt Allele | 5630401D24Rik | CGI-01 | DFNB26 | DFNB26M | DFNM1 | Deafness (Autosomal Recessive, Nonsyndromic) Modifier 1 Gene | Deafness (Recessive, Non-Syndromic) Modifier 1 Gene | Deafness (Recessive, Nonsyndromic) Modifier 1 Gene | Deafness, Autosomal Recessive 26 Gene | FEAT | Faint Expression in Normal Tissues, Aberrant Overexpression in Tumors Gene | KIAA0859 | METTL13 | Methyltransferase 13, eEF1A Lysine and N-Terminal Methyltransferase Gene | Methyltransferase 13, eEF1A Lysine and N-Terminal Methyltransferase wt Allele | Methyltransferase 13, eEF1A N-Terminus and K55 wt Allele | Methyltransferase Like 13 Gene | Methyltransferase-Like 13 Gene | eEF1A Lysine and N-Terminal Methyltransferase Gene | feat",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935947","Antiapoptotic Protein FEAT","C156932","eEF1A lysine and N-terminal methyltransferase (699 aa, ~79 kDa) is encoded by the human METTL13 gene. This protein is involved in the inhibition of apoptosis and the methylation of translation elongation factor 1a.","eEF1A Lysine and N-Terminal Methyltransferase | Antiapoptotic Protein FEAT | EC 2.1.1.- | EEF1AKNMT | METTL13 | Methyltransferase-Like Protein 13 | eEF1A Lysine Methyltransferase | eEF1A N-Terminal Methyltransferase | eEF1A-KNMT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935948","Human Anti-CD30 CAR-expressing Autologous T-lymphocytes","C156933","A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) derived from a human anti-CD30 monoclonal antibody, with potential immunostimulating and antineoplastic activities. Upon administration, the human anti-CD30 CAR-expressing autologous T-lymphocytes specifically recognize and bind to CD30-expressing tumor cells, resulting in tumor cell lysis. CD30, a cell surface receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is transiently expressed on activated lymphocytes and is constitutively expressed in hematologic malignancies. Compared to CAR-T cells that use murine scFv-based CARs, CAR-T cells containing CARs with human scFv regions reduces the immunogenicity of the CAR-T cells and may improve their longevity.","Human Anti-CD30 CAR-expressing Autologous T-lymphocytes | Human Anti-CD30 CAR-expressing Autologous T-cells | Human Anti-CD30scFv CAR-expressing Autologous T-lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935953","KCNJ5 Gene Mutation","C156934","A change in the nucleotide sequence of the KCNJ5 gene.","KCNJ5 Gene Mutation | CIR Gene Mutation | GIRK4 Gene Mutation | KATP1 Gene Mutation | KIR3.4 Gene Mutation | LQT13 Gene Mutation | Potassium Channel, Inwardly Rectifying Subfamily J Member 5 Gene Mutation | Potassium Channel, Inwardly Rectifying Subfamily J, Member 5 Gene Mutation | Potassium Voltage-Gated Channel Subfamily J Member 5 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935954","ATP1A1 Gene Mutation","C156935","A change in the nucleotide sequence of the ATP1A1 gene.","ATP1A1 Gene Mutation | ATPase Na+/K+ Transporting Subunit Alpha 1 Gene Mutation | ATPase, Na+/K+ Transporting, Alpha 1 Polypeptide Gene Mutation | ATPase, Na+/K+ Transporting, Alpha-1 Polypeptide Gene Mutation | CMT2DD Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935951","ATP2B3 Gene Mutation","C156936","A change in the nucleotide sequence of the ATP2B3 gene.","ATP2B3 Gene Mutation | ATPase Plasma Membrane Ca2+ Transporting 3 Gene Mutation | ATPase, Ca(2+)-Transporting, Plasma Membrane, 3 Gene Mutation | ATPase, Ca++ Transporting, Plasma Membrane 3 Gene Mutation | CFAP39 Gene Mutation | CLA2 Gene Mutation | OPCA Gene Mutation | PMCA3 Gene Mutation | SCAX1 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935952","CACNA1D Gene Mutation","C156937","A change in the nucleotide sequence of the CACNA1D gene.","CACNA1D Gene Mutation | CACH3 Gene Mutation | CACN4 Gene Mutation | CACNL1A2 Gene Mutation | CCHL1A2 Gene Mutation | Calcium Channel, Voltage-Dependent, L Type, Alpha 1D Subunit Gene Mutation | Calcium Channel, Voltage-Dependent, L Type, Alpha-1D Subunit Gene Mutation | Calcium Voltage-Gated Channel Subunit Alpha1 D Gene Mutation | Cav1.3 Gene Mutation | PASNA Gene Mutation | SANDD Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0596197","Blood Treatment","C15657","General term for hemodialysis, plasmapheresis, blood transfusions, and related procedures involving autologous removal, alteration, and replacement of patients' blood or blood components.","Blood Treatment | Hematologic Procedure | Therapeutic Procedures Hematopoietic System",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935749","Local Immunotherapy Procedure","C156582","Any immunotherapy that targets, or is restricted to, a specific anatomical location.","Local Immunotherapy Procedure | LOCAL IMMUNOTHERAPY | Local Immunotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562943","Proactive Therapy","C156230","Therapy that is received or administered before a condition or symptom begins.","Proactive Therapy | Proactive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563205","Reactive Therapy","C156231","Therapy that is received or administered after a condition or symptom begins.","Reactive Therapy | Reactive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562944","Recurrent Aggressive Non-Hodgkin Lymphoma","C156232","An aggressive non-Hodgkin lymphoma that has recurred after a period of remission.","Recurrent Aggressive Non-Hodgkin Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562945","Refractory Aggressive Non-Hodgkin Lymphoma","C156233","An aggressive non-Hodgkin lymphoma that is resistant to treatment.","Refractory Aggressive Non-Hodgkin Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0589274","Swallowing Therapy","C156237","Any treatment designed to lessen the effects of dysphagia. Treatment may include restoration of normal swallow function (rehabilitative), modifications to diet consistency and patient behavior (compensatory), or a combination of these approaches.","Swallowing Therapy | Swallowing Intervention",,,,,,,,,,,,,,,"4206734","Swallowing promotion therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL562968","Fluorouracil-Oxaliplatin Regimen","C156240","A regimen consisting of 5-fluorouracil and oxaliplatin that may be used for the treatment of colorectal, esophageal and esophagogastric junction, gastric and hepatobiliary cancers.","FUOX Regimen | FUOX | Fluorouracil-Oxaliplatin | Fluorouracil-Oxaliplatin Regimen | Fluorouracil/Oxaliplatin | Fluorouracil/Oxaliplatin Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935854","ACVR1 Inhibitor TP-0184","C156729","An orally bioavailable inhibitor of activin A receptor type 1 (activin receptor-like kinase 2; ALK2; ALK-2; ACRV1), with potential antineoplastic activity. Upon oral administration,itacnosertib targets, binds to and inhibits the activity of ALK-2. This prevents ALK-2-mediated signaling and inhibits cell growth in ALK-2-overexpressing tumor cells. In addition, in cancer and inflammatory conditions, ALK-2 is upregulated in response to increased signaling of pro-inflammatory cytokines, especially interleukin-6 (IL-6), and enhances the secretion of hepcidin, a peptide liver hormone and a key modulator of iron homeostasis. Blocking ALK-2-mediated pathways in inflammation and cancer leads to a decrease of hepcidin expression and restores plasma iron levels, thereby preventing low serum iron levels and anemia of chronic disease (ACD). ALK-2, a serine/threonine receptor kinase, is constitutively activated due to activating mutations or upregulated upstream signaling pathways in inflammatory conditions and certain types of cancer.","Itacnosertib | ACVR1 Inhibitor TP-0184 | ALK-2 Inhibitor TP-0184 | ALK2 Inhibitor TP-0184 | ITACNOSERTIB | TP 0184 | TP-0184 | TP0184",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677830","Hot Flashes Attenuation","C15672","No value exists.","Hot Flashes Attenuation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935858","Navarixin","C156730","An orally available small molecule antagonist of the C-X-C motif chemokine receptor 1 (CXCR1; interleukin-8 receptor alpha; IL8RA) and 2 (CXCR2; interleukin-8 receptor beta; IL8RB), with potential immunomodulating and antineoplastic activities. Upon administration, navarixin binds to and inhibits the activation of CXCR 1 and 2. This inhibits CXCR1/2-mediated signaling, reduces both recruitment and migration of immunosuppressive myeloid-derived suppressor cells (MDSCs) and neutrophils in the tumor microenvironment (TME), inhibits inflammatory processes and abrogates the immunosuppressive nature of the TME. This allows effector cells, such as natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs), to kill and eliminate cancer cells. This inhibits tumor cell migration, metastasis, angiogenesis and tumor cell proliferation. CXCR 1 and 2, G protein-coupled receptor proteins located on myeloid cells and certain tumor cells, play key roles in the immunosuppressive nature of the TME, tumor metastasis, therapy-resistance, myeloid cell suppression, and inflammation.","Navarixin | 2-Hydroxy-N,N-dimethyl-3-((2-((1R)-1-(5-methylfuran-2-yl)propyl)amine)-3,4- dioxocyclobut-1-enyl)amino)benzamide Monohydrate | MK-7123 | NAVARIXIN | PS291822 | SCH 527123",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935856","EGFR Antisense DNA BB-401","C156732","A recombinant, plasmid DNA expression vector encoding a 39 nucleotide (nt) short hairpin RNA (shRNA) specific for the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon intratumoral administration, the EGFR antisense DNA BB-401 is taken up by tumor cells and shRNA is transcribed. The shRNA is converted into small interfering RNA (siRNA) via the RNA interference (RNAi) pathway. The siRNA targets and binds to EGFR RNA expressed by tumor cells. This blocks EGFR mRNA translation and prevents EGFR protein expression.","EGFR Antisense DNA BB-401 | Anti-EGFR ddRNAi BB-401 | BB 401 | BB-401 | BB401 | ddRNAi BB-401",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935857","MARCKS Protein Inhibitor BIO-11006","C156733","An aerosolized 10-amino acid peptide that inhibits the myristoylated alanine rich protein kinase C substrate (MARCKS) protein, with potential immunomodulating and antineoplastic activities. Upon inhalation, the MARCKS protein inhibitor BIO-11006 targets, binds to and inhibits the phosphorylation of MARCKS (P-MARCKS). This prevents MARCKS-mediated signaling, thereby preventing the release of phosphatidylinositol 4,5-bisphosphate (PIP2) from the cell membrane upon MARCKS binding. This prevents the PIP2-mediated activation of focal adhesion kinase (FAK) and the FAK-mediated activation of the PI3K/AKT pathway and the activation of integrins, talin, vinculin and paxillin. This leads to an inhibition of tumor cell proliferation, migration, metastasis and survival. In addition, inhibition of MARCKS prevents mucin granule release and reduces the overproduction of mucus in the lungs. This may abrogate airway obstruction, impaired lung function, airway inflammation and bacterial infections associated with overproduction of mucus in the lungs. The MARCKS protein, a filamentous actin crosslinking protein and substrate for protein kinase C (PKC) is localized on the plasma membrane. Upon phosphorylation by PKC or binding to the calcium-calmodulin complex, the association of MARCKS with actin and with the plasma membrane is blocked, leading to its presence in the cytoplasm. The MARCKS protein plays a key role in the exocytosis of a number of vesicles and granules, cell movement, mitogenesis and membrane trafficking.","MARCKS Protein Inhibitor BIO-11006 | Aerosolized BIO-11006 | BIO 11006 | BIO-11006 | BIO-11006 Peptide | BIO11006 | Myristoylated Alanine Rich C Kinase Substrate Inhibitor BIO-11006",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935910","Peptidyl-Prolyl Cis-Trans Isomerase A","C156929","Peptidyl-prolyl cis-trans isomerase A (165 aa, ~18 kDa) is encoded by the human PPIA gene. This protein plays a role in cyclosporin-mediated immunosuppression, HIV virion assembly and protein folding.","Peptidyl-Prolyl Cis-Trans Isomerase A | Cyclophilin A | Cyclosporin A-Binding Protein | EC 5.2.1.8 | Epididymis Secretory Sperm Binding Protein Li 69p | PPIA | PPIase A | Peptidyl-Prolyl Isomerase A | Peptidylprolyl Isomerase A | Rotamase A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935941","PRKACA Gene Mutation","C156938","A change in the nucleotide sequence of the PRKACA gene.","PRKACA Gene Mutation | PKACA Gene Mutation | PPNAD4 Gene Mutation | Protein Kinase A, C-Alpha Subunit Gene Mutation | Protein Kinase cAMP-Activated Catalytic Subunit Alpha Gene Mutation | Protein Kinase, cAMP-Dependent, Alpha Catalytic Subunit Gene Mutation | Protein Kinase, cAMP-Dependent, Catalytic, Alpha Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562989","Parotid Gland Sarcoma","C156280","A sarcoma that arises from the parotid gland.","Parotid Gland Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562990","Parotid Gland Liposarcoma","C156281","A liposarcoma that arises from the parotid gland.","Parotid Gland Liposarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562991","Scrotal Liposarcoma","C156282","A liposarcoma involving the scrotum.","Scrotal Liposarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562984","Scrotal Sarcoma","C156283","A sarcoma involving the scrotum.","Scrotal Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562985","Advanced Prostate Carcinoma","C156284","A prostatic carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Prostate Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562986","Locally Advanced Prostate Carcinoma","C156285","A prostatic carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Prostate Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562987","Advanced Prostate Adenocarcinoma","C156286","A prostatic adenocarcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Prostate Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563132","Locally Advanced Unresectable Prostate Carcinoma","C156288","A prostatic carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.","Locally Advanced Unresectable Prostate Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563133","Locally Advanced Unresectable Prostate Adenocarcinoma","C156289","A prostatic adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.","Locally Advanced Unresectable Prostate Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563134","Chemotherapy Regimen Used to Treat Malignant Neuroendocrine and Adrenal Carcinoma","C156290","Any regimen that can be used for the treatment of malignant neuroendocrine and adrenal neoplasm.","Regimen Used to Treat Malignant Neuroendocrine and Adrenal Neoplasm | Chemotherapy Regimen Used to Treat Malignant Neuroendocrine and Adrenal Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563128","High Risk Acute Myeloid Leukemia","C156292","Acute myeloid leukemia characterized by poor response to induction chemotherapy and poor long-term survival following treatment with consolidation chemotherapy.","High Risk Acute Myeloid Leukemia | High-Risk Acute Myeloid Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563129","High Risk Chronic Myelomonocytic Leukemia","C156293","Chronic myelomonocytic leukemia with cytogenetic abnormalities including trisomy 8, complex karyotypes, monosomy 7, and del17q. Mutations in RUNX1, NRAS, SETBP1, and ASXL1 are independently associated with inferior overall survival time. (Oncology Letters 15:7132-7138, 2018)","High Risk Chronic Myelomonocytic Leukemia | High-Risk Chronic Myelomonocytic Leukemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563130","Advanced Cervical Carcinoma","C156294","A cervical carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Cervical Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563123","Locally Advanced Cervical Carcinoma","C156295","A cervical carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Cervical Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935817","2-((1-(7-chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)pyrazol-3-yl)carbonylamino)tricyclo(3.3.1.1.(3.7))decan-2-carboxylic acid","C156766","No value exists.","Meclinertant | 2-((1-(7-Chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)pyrazol-3-yl)carbonylamino)tricyclo(3.3.1.1.(3.7))decan-2-carboxylic Acid | MECLINERTANT | SR 48692 | SR-48692 | SR48692 | Tricyclo(3.3.1.13,7)decane-2-carboxylic Acid, 2-(((1-(7-Chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl)carbonyl)amino)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935816","Malignant Basal Cell","C156768","No value exists.","Malignant Basal Cell | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1304306","Metastatic Basal Cell Carcinoma","C156769","A carcinoma that arises from the basal cells and has metastasized to another anatomic site.","Metastatic Basal Cell Carcinoma | ",,,,,,,,,,,,,,,"37155308","Metastatic basal cell carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL935821","Locally Advanced Basal Cell Carcinoma","C156770","A basal cell carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Basal Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935822","Biochemically Recurrent Prostate Carcinoma","C156771","Increasing prostate-specific antigen (PSA) following prostatectomy or radiation therapy in a patient with a history of localized prostate carcinoma. Signs of metastasis are absent using the currently available scanning technology.","Biochemically Recurrent Prostate Carcinoma | BCR Prostate Carcinoma | Micro-Metastatic Prostate Carcinoma | PSA-Only (Biochemically) Recurrent Prostate Carcinoma | PSA-Only Recurrent Prostate Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563195","Anti-CD32B Monoclonal Antibody BI-1206","C156458","A fully human monoclonal antibody targeting the Fc gamma receptor IIB (FcgRIIB; CD32B) with potential immunomodulatory and antineoplastic activities. Upon intravenous administration, anti-CD32B monoclonal antibody BI-1206 selectively binds to CD32B, a receptor expressed on the surface of B-cells. This prevents CD32B-mediated internalization of anti-CD20 monoclonal antibodies, such as rituximab, which abrogates tumor cell resistance caused by CD32B-mediated monoclonal antibody internalization and degradation of CD32B-expressing B-cells. By blocking CD32B, BI-1206 may recover and enhance the activity of rituximab and other anti CD20 monoclonal antibodies. In addition, BI-1206 itself activates the immune system to exert an immune-mediated tumor cell death of B-cells. CD32B, an inhibitory member of the FcgammaR family, is implicated in immune cell desensitization and tumor cell resistance.","Anti-CD32B Monoclonal Antibody BI-1206 | Anti-hFcgRIIB Monoclonal Antibody BI-1206 | Anti-hFcgammaRIIB mAb BI-1206 | BI 1206 | BI-1206 | BI1206",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563188","Malignant Primitive Cellular Infiltrate","C156460","A morphologic finding indicating the presence of a malignant primitive cellular infiltrate in a tissue sample.","Malignant Primitive Cellular Infiltrate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563189","Pharmacological Ascorbate","C156461","A high dose (HD) of ascorbic acid, a pro-oxidant agent, with potential antineoplastic and radio-chemo-sensitizing activities. Upon intravenous (IV) administration, pharmacological ascorbate is able to generate reactive oxygen species (ROS) by donating an electron to oxygen (O2) and forming hydrogen peroxide (H2O2), thereby causing oxidative stress and overwhelming the cell's anti-oxidant defense mechanisms. This induces DNA double-stranded breaks (DSBs) and cell death. Tumor cells are highly susceptible to ascorbate-mediated oxidative stress and cytotoxicity while normal, healthy cells are mostly unaffected. This induces the cell death of susceptible tumor cells and decreases tumor cell growth. Higher plasma ascorbate concentrations are achieved upon higher intravenous doses of ascorbate; oral administration of ascorbate is limited and uptake does not increase after a certain amount is administered. Only IV ascorbate produces plasma concentrations high enough to induce ascorbate-mediated cytotoxicity to susceptible tumor cells. In addition, HD parenteral ascorbate enhances radio- and chemo-sensitivity of susceptible cancer cells.","Pharmacological Ascorbate | Ascorbate Injection | Ascorbic Acid Injection | HD Ascorbate | HD P-AscH- | HD Vitamin C | High Dose Ascorbic Acid | High-Dose Parenteral Ascorbate | High-Dose Vitamin C | High-dose Ascorbate | High-dose Ascorbic Acid | IV Ascorbate | Intravenous Ascorbate | Intravenous High Dose Ascorbate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563190","Brain Ependymoma","C156462","An ependymoma that arises from the brain.","Brain Ependymoma | Intracranial Ependymoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563191","Loss of Immunohistochemical Expression of Succinate Dehydrogenase (SDH) B","C156463","An immunohistochemical test result indicating the loss of expression of succinate dehydrogenase (SDH) B in the neoplastic cells of a tumor sample.","Loss of Immunohistochemical Expression of Succinate Dehydrogenase (SDH) B | Loss of Immunohistochemical Expression of SDHB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563185","Low Intensity Vibration Therapy","C156465","The use of a low magnitude (<1 g), high frequency (30 Hz) signal to mitigate deleterious effects of estrogen deprivation on both bone health and muscle function. A low intensity vibration can be delivered synchronously to the lower extremities by a platform, transmitting the signal throughout the skeleton, recapitulating some of the mechanical stimulation experienced during exercise.","Low Intensity Vibration Therapy | LIV | Low Intensity Vibration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563186","Endobronchial Obstruction","C156466","Partial or complete blockage of the bronchial lumen by a pathological process that occurs within the bronchus.","Endobronchial Obstruction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527022","Recombinant Eotaxin","C1531","A recombinant therapeutic agent which is chemically identical to or similar to the endogenous chemokine eotaxin, a member of the C-C cytokine family which is chemotactic for eosinophils.  The early increase in eotaxin paralleled eosinophil infiltration in the asthmatic lung tissue in animal models hinted a potential role for eotaxin in immunotherapy.","Recombinant Eotaxin | Eotaxin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554815","Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma","C153200","Non-squamous non-small cell lung carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Locally Advanced Non-Squamous Non-Small Cell Lung Cancer | Locally Advanced Non-Squamous Non-Small Cell Lung Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554816","Advanced Lung Non-Small Cell Squamous Carcinoma","C153201","Non-small cell squamous lung carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Lung Non-Small Cell Squamous Carcinoma | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Squamous Lung Carcinoma | Advanced Squamous Non-Small Cell Lung Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554328","Metastatic Lung Carcinoma","C153202","A carcinoma that arises from the lung and has metastasized to another anatomic site.","Metastatic Lung Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554329","Advanced Lung Carcinoma","C153203","A lung carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Lung Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554330","Chemokine Modulation Therapy","C153205","Therapy used to modulate the activity of chemokine receptors or their ligands, potentially modifying immune response and tumor-related processes, including tumor cell growth, angiogenesis, and metastasis.","Chemokine Modulation Therapy | Chemokine Targeted Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554331","Locally Advanced Lung Carcinoma","C153206","A lung carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Lung Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554333","Miridesap","C153209","A small molecule compound that depletes serum amyloid P component (SAP), with potential anti-amyloid activity. Upon injection, miridesap binds to circulating SAP, forming complexes that are rapidly cleared in the liver. SAP bound to amyloid deposits is in equilibrium with plasma SAP, and depletion of the latter should lead to the eventual removal of SAP from amyloid deposits as well. SAP is a universal component of amyloid deposits and contributes to the pathogenesis of amyloidosis.","Miridesap | (2R)-1-[6-[(2R)-2-carboxypyrrolidin-1-yl]-6-oxohexanoyl]pyrrolidine-2-carboxylic acid | CPHPC | GSK 2315698 | GSK-2315698 | GSK2315698 | MIRIDESAP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554334","Dezamizumab","C153210","A fully humanized monoclonal IgG1 anti-serum amyloid P component (SAP) antibody, with potential anti-amyloid activity. Upon intravenous administration, dezamizumab binds to SAP in amyloid deposits, thereby activating compliment and triggering the rapid clearance of amyloid by macrophage-derived multinucleated giant cells. SAP is a universal component of amyloid deposits and contributes to the pathogenesis of amyloidosis.","Dezamizumab | Anti-SAP Monoclonal Antibody | Anti-SAP mAb | DEZAMIZUMAB | GSK-2398852 | GSK2398852",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL554336","Locally Advanced Head and Neck Carcinoma","C153213","A head and neck carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Head and Neck Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0429620","Bone Age","C156787","An indication of skeletal growth potential based on skeletal maturity indicators, such as radiologic imaging of growth plates.","Bone Age | Skeletal Age | Skeletal Maturity",,,,,,,,,,,,,,,"4047792","Bone age",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL563125","Locally Advanced Cervical Adenocarcinoma","C156297","A cervical adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Cervical Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563126","Locally Advanced Unresectable Cervical Adenocarcinoma","C156299","A cervical adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.","Locally Advanced Unresectable Cervical Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512558","Chemotherapeutic Hyperthermic Perfusion","C15684","No value exists.","Chemotherapeutic Hyperthermic Perfusion | hyperthermic perfusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935964","New Tumor Event After Initial Treatment Present","C156850","There is evidence of a new tumor after the initial treatment.","New Tumor Event After Initial Treatment Present | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935969","New Tumor Event","C156851","A section header about new tumor activity.","New Tumor Event Header | New Tumor Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935968","Specify Site of New Tumor Event","C156854","A directive to specify the anatomic site of a new tumor event.","Specify Site of New Tumor Event | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935710","SHP-1 Agonist SC-43","C156695","An orally available, small molecule agonist of Src homology region 2 domain-containing phosphatase-1 (SHP-1; tyrosine-protein phosphatase non-receptor type 6; PTPN6) with potential antineoplastic activity. Upon administration, SHP-1 agonist SC-43 enhances SHP-1 activity by impairing the association between the N-terminal Src homology 2 (N-SH2) domain and the protein tyrosine phosphatase (PTP) domain of SHP-1, triggering a conformational change of SHP-1 and relieving its autoinhibition. Activation of SHP-1 represses signal transducer and activator of transcription 3 (STAT3) signaling by inhibiting constitutive and interleukin-6 (IL-6)-induced STAT3 phosphorylation. The STAT3 pathway is overly active in many cancer types and is implicated in cancer stem cell-mediated growth, recurrence, stemness, and resistance to conventional chemotherapies.","SHP-1 Agonist SC-43 | 1-[4-Chloro-3(trifluoromethyl)phenyl-3-[3-(4-cyanophenoxy)] Urea | SC 43 | SC-43 | SC-43 Oral Solution | SC43",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935715","Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma","C156696","The reemergence of T-cell/histiocyte-rich large B-cell lymphoma after a period of remission.","Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935716","Halichondrin Analogue E7130","C156697","A halichondrin analogue derived from a marine sponge with potential antineoplastic activity. Upon intravenous infusion, halichondrin analogue E7130 may bind to the vinca domain of tubulin and inhibit the polymerization of tubulin and the assembly of microtubules, thereby inhibiting mitotic spindle assembly and inducing cell cycle arrest at the G2/M phase.","Halichondrin Analogue E7130 | E 7130 | E-7130 | E7130",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935713","Rhenium Re-188 Etidronate","C156698","A synthetic compound containing the bisphosphonate etidronate (hydroxyethylidene diphosphonate, HEDP) labeled with rhenium Re188, a beta-emitting radioisotope with potential antineoplastic activity. Upon administration, Re-188 etidronate binds to hydroxyapatite in bone, delivering a cytotoxic dose of beta radiation to primary and metastatic bone tumors. The beta-radiation may provide localized anti-tumor radiotoxicity while sparing extramedullary bone marrow tissues.","Rhenium Re-188 Etidronate | 188Re-HEDP | 88Re-Etidronate | RHENIUM RE-188 ETIDRONATE | Re 188 Etidronic Acid | Re 188 Hydroxyethylidene Diphosphonate | Re-188 Etidronate | Re-188 HEDP | Re-188 Hydroxyethylidene Diphosphonate | Re-188Etidronate | Rhenium Re-188 Hydroxyethylidene Diphosphonate (SY) | Rhenium-188 Etidronate | Rhenium-188 HEDP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935714","Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma","C156699","Histologic transformation of a marginal zone lymphoma to an aggressive diffuse large B-cell lymphoma.","Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma Transformed from Underlying Marginal Zone Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935869","SCC 244","C156700","An orally bioavailable, small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration, gumarontinib targets and binds to the c-Met protein, thereby disrupting c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","Gumarontinib | GLUMETINIB | GUMARONTINIB | Glumetinib | Glumetinib | SCC 244 | SCC-244 | SCC244",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935807","Metastatic Unresectable Basal Cell Carcinoma","C156788","A basal cell carcinoma that has spread from its original site of growth to another anatomic site and is not amenable to surgical resection.","Metastatic Unresectable Basal Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935805","Locally Advanced Unresectable Basal Cell Carcinoma","C156789","A basal cell carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.","Locally Advanced Unresectable Basal Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935797","Anti-PVRIG Monoclonal Antibody COM701","C156791","A humanized, hybridoma monoclonal antibody against the poliovirus receptor-related immunoglobulin (PVRIG; PVR Related Immunoglobulin Domain Containing Protein; CD112R), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PVRIG monoclonal antibody COM701 targets and binds to PVRIG expressed on cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells within the tumor microenvironment (TME). This blocks the interaction of PVRIG with its ligand nectin cell adhesion molecule 2 (poliovirus receptor-related 2; PVRL2; CD112), which is overexpressed on a variety of tumor cell types. Inhibiting the activation of PVRIG, abrogates the PVRIG-induced inhibition of T-lymphocyte and NK cell activation. This activates CTLs and NK cells, enhances anti-tumor responses and immune-mediated tumor cell killing, and inhibits tumor cell proliferation. PVRIG, a member of the B7/CD28 family and immune checkpoint receptor that, upon activation, negatively regulates the activation of various immune cells. It plays a key role in immunosuppression.","Anti-PVRIG Monoclonal Antibody COM701 | Anti-poliovirus Receptor-related Immunoglobulin COM701 | COM 701 | COM-701 | COM701 | PVRIG Inhibitor COM701",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935798","9 ING 41","C156792","A maleimide-based, small molecule inhibitor of glycogen synthase kinase-3 (GSK-3; serine/threonine-protein kinase GSK3) with potential antineoplastic activity. Upon intravenous administration, elraglusib binds to and competitively inhibits GSK-3, which may lead to downregulation of nuclear factor kappa B (NF-kappaB) and decreased expression of NF-kappaB target genes including cyclin D1, B-cell lymphoma 2 (Bcl-2), anti-apoptotic protein XIAP, and B-cell lymphoma extra-large (Bcl-XL). This may inhibit NF-kappaB-mediated survival and chemoresistance in certain tumor types. GSK-3, a constitutively active serine/threonine kinase that plays a role in numerous pathways involved in protein synthesis, cellular proliferation, differentiation, and metabolism, is aberrantly overexpressed in certain tumor types and may promote tumor cell survival and resistance to chemotherapy and radiotherapy.","Elraglusib | 9 ING 41 | 9-ING-41 | ELRAGLUSIB | GSK-3 Inhibitor 9-ING-41 | Glycogen Synthase Kinase-3 Inhibitor 9-ING-41",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935795","Metastatic Human Papillomavirus-Related Malignant Neoplasm","C156793","A malignant neoplasm that is associated with human papillomavirus infection and has spread from its original site of growth to another anatomic site.","Metastatic Human Papillomavirus-Related Malignant Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935796","ITK Inhibitor","C156794","Any agent that inhibits interleukin-2-inducible kinase (ITK).","ITK Inhibitor | Interleukin-2-inducible Kinase Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935801","Prior Radiation Therapy of Affected Breast","C156795","An indication that an individual has previously received radiation treatment of their currently affected breast.","Prior Radiation Therapy of Affected Breast | Prior Ipsilateral Breast Radiation Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935802","Prior Systemic Chemotherapy for Current Cancer","C156796","An indication that an individual has previously received systemic chemotherapy for their current malignancy.","Prior Systemic Chemotherapy for Current Cancer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935799","Prior Systemic Therapy for Current Cancer","C156797","An indication that an individual has previously received systemic therapy for their current malignancy.","Prior Systemic Therapy for Current Cancer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935901","BCD 145","C156734","A monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, nurulimab targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.","Nurulimab | Anti-CTLA-4 Monoclonal Antibody BCD-145 | BCD 145 | BCD-145 | BCD145 | NURULIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935902","D 0502","C156735","An orally available, nonsteroidal selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, taragarestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.","Taragarestrant | (2E)-3-(3,5-Dichloro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1hpyrido(3,4-b)indol-1-yl)phenyl)prop-2-enoic acid | 2-Propenoic acid, 3-(3,5-dichloro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-2,3,4,9-tetrahydro-3-methyl-1H-pyrido(3,4-b)indol-1-yl)phenyl)-, (2E)- | D 0502 | D-0502 | D0502 | SERD D-0502 | SERD D-0502 | Selective Estrogen Receptor Degrader G1T48 | Selective Estrogen Receptor Downregulator D-0502 | TARAGARESTRANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935899","Fermented Prebiotic Dietary Supplement AferBio","C156736","A powder-based nutritional supplement composed of Brazilian fermented non-digestible food composed of soy, wheat, and organic wheat germ, and containing a mixture of non-soluble and fermentable fibers rich in oligosaccharides, with potential immunomodulating and prebiotic activities. Upon oral administration of the fermented prebiotic dietary supplement, the high concentrations of beta-glucans are able to stimulate the proliferation of beneficial bacteria in the gastrointestinal (GI) tract. This modulates the GI flora ecosystem, improves the functions of the intestinal barrier and protects against harmful viruses and bacteria. In addition, this prebiotic modulates the immune system and may inhibit inflammation.","Fermented Prebiotic Dietary Supplement AferBio | AferBio | AferBio Nutritional Supplement | Fermented Food Powder AferBio",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935900","RIPK1 Inhibitor GSK3145095","C156737","An orally available, small-molecule inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1; receptor-interacting protein 1; RIP1) with potential antineoplastic and immunomodulatory activities.  Upon administration, GSK3145095 disrupts RIPK1-mediated signaling, which may reduce C-X-C motif chemokine ligand 1 (CXCL1)-driven recruitment and migration of immunosuppressive myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TME). This allows effector cells, such as natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs), to kill and eliminate cancer cells. RIPK1, a serine-threonine kinase that normally plays a key role in inflammation and cell death in response to tissue damage and pathogen recognition, is overexpressed in certain cancer types and may be associated with oncogenesis and promotion of the immunosuppressive nature of the TME.","RIPK1 Inhibitor GSK3145095 | GSK 3145095 | GSK-3145095 | GSK3145095 | Receptor-interacting Serine/Threonine-protein Kinase 1 Inhibitor GSK3145095",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935905","HLX 10","C156738","A humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, serplulimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","Serplulimab | HLX 10 | HLX-10 | HLX10 | SERPLULIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563017","Pressure Specified Sensory Device","C156189","A computer-based quantitative sensory testing device that detects cutaneous pressure perception and two-point discrimination. It is designed to quantify and record both specific peripheral nerve threshold levels and peripheral nerve innervation density.","Pressure Specified Sensory Device | PSSD | Pronged Sensation Device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563113","Grade 1 Teratoma","C156411","A teratoma that contains mature tissue elements and a limited amount of immature tissue elements.","Grade 1 Teratoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563114","AKR1C3-activated Prodrug TH-3424","C156414","A small-molecule nitro-benzene, aldo-keto reductase 1C3 (AKR1C3)-activated prodrug of N,N'-bisethylenephosphoramidate, a DNA bis-alkylating agent, with potential antineoplastic activity. Upon intravenous administration, AKR1C3-activated prodrug AST-3424 is converted to its active form by AKR1C3, which is upregulated in certain tumor cell types while not expressed in normal healthy cells. The active metabolite selectively binds to and alkylates DNA in AKR1C3-overexpressing tumor cells, resulting in DNA base pair mismatching, interstrand crosslinking and inhibition of DNA repair and synthesis, cell-cycle arrest, and apoptosis. As the expression of AKR1C3 is restricted to tumors, AST-3424 is selectively converted to its active metabolite in tumor cells only while its conversion in normal, healthy tissue is absent; this allows for an increased cytotoxic effect of the alkylating agent in tumor cells while decreasing its toxicity.","AKR1C3-activated Prodrug AST-3424 | AKR1C3-activated Prodrug OBI-3424 | AKR1C3-activated Prodrug OBI-3424 | AKR1C3-activated Prodrug TH-3424 | AST-3424 | Aldo-keto Reductase 1c3-activated Prodrug OBI-3424 | OBI 3424 | OBI-3424 | OBI3424 | TH 3424 | TH-3424 | TH3424",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563108","Anti-CD46 Antibody-drug Conjugate FOR46","C156416","An antibody-drug conjugate (ADC) composed of a human monoclonal antibody directed against the cluster of differentiation 46 (CD46; membrane cofactor protein; MCP) and conjugated to an as of yet undisclosed cytotoxic payload, with potential antineoplastic activity. Upon administration, anti-CD46 ADC FOR46 specifically targets and binds to a specific conformational epitope on the immune modulatory receptor CD46 expressed on certain tumor cells. Upon binding and internalization, the cytotoxic payload kills the CD46-expressing tumor cells. The conformational epitope of CD46 is highly expressed in multiple tumor cell types while minimally expressed or absent in normal, healthy tissues.  FOR46 does not interfere with other CD46-mediated pathways that naturally occur in normal, healthy tissues.","Anti-CD46 Antibody-drug Conjugate FOR46 | ADC FOR46 | Anti-CD46 ADC FOR46 | Antibody-drug Conjugate FOR46 | CD46-ADC FOR46 | FOR 46 | FOR-46 | FOR46",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935870","Porcupine Inhibitor RXC004","C156701","An orally available inhibitor of porcupine (PORCN), with potential antineoplastic activity. Upon oral administration, zamaporvint binds to and inhibits PORCN in the endoplasmic reticulum (ER), which blocks post-translational acylation of Wnt ligands and inhibits their secretion. This prevents the activation of Wnt ligands, interferes with Wnt-mediated signaling, and inhibits cell growth in Wnt-driven tumors. Porcupine, a membrane-bound O-acyltransferase (MBOAT), is required for the palmitoylation of Wnt ligands, and plays a key role in Wnt ligand secretion and activity. Wnt signaling is dysregulated in a variety of cancers.","Zamaporvint | Porcupine Inhibitor RXC004 | Porcupine Inhibitor RXC004 | RXC 004 | RXC-004 | RXC004 | ZAMAPORVINT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935868","4-toluenesulfonamide","C156702","A low-molecular-weight organic compound with potential antineoplastic activity. Upon intra-tumoral injection, para-toluenesulfonamide increases lysosomal membrane permeabilization (LMP) and the release of cathepsin B. Cytosolic cathepsin B released from lysosomes cleaves and activates proapoptotic B-cell lymphoma 2 (Bcl-2) family member BH3 interacting-domain death agonist (Bid) and poly [ADP-ribose] polymerase 1 (PARP-1), which may induce tumor cell death.","Para-toluenesulfonamide | P-TOLUENESULFONAMIDE | PTS | PTS 100 | PTS-100 | PTS100",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935990","PD-1 Ligand Inhibitor","C156893","Any agent that binds to any of the ligands for the receptor programmed cell death protein 1 (PD-1; PD1); programmed death ligand 1 (PD-L1; CD274) and 2 (PD-L2; CD273).","PD-1 Ligand Inhibitor | PD-1 Ligand-targeting Agent | PD-1 Ligands Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935988","Larotrectinib Sulfate","C156895","The sulfate salt form of larotrectinib, an orally available, tropomyosin receptor kinase (Trk) inhibitor, with potential antineoplastic activity. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Trk, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.","Larotrectinib Sulfate | (3S)-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide;sulfuric acid | 1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-Difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-, Sulfate (1:1) | ARRY 470 Sulfate | LAROTRECTINIB SULFATE | LOXO 101 Sulfate | LOXO-101 Sulfate | Vitrakvi",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935989","APPSPIRE","C156896","A smartphone application for smoking cessation specifically targeted to 18-24 year olds.","APPSPIRE | APPSPIRE App | APPSPIRE Application | APPSPIRE Smartphone App | APPSPIRE Smartphone Application",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL106505","Activity Monitor","C156897","A consumer, wearable device that is designed to collect and display information about an individual's activities. Information collected may include steps, stairs climbed, distance traveled, calories used, heart rate, sleep quality, or other metrics.","Activity Monitor | Activity Tracker | Activity Tracker Device | Physical Activity Measuring Device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935925","Exercise Log","C156898","A paper or electronic record of an individual's fitness, exercise, or other physical activities. This usually includes a description of the type of activity and a entry for time at the activity. Other information might include specific details of the activity and subjective feelings about the activity and the individual's perceived effort and fitness.","Exercise Log | Activity Log | Workout Log",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935800","PVRIG Gene","C156798","This gene plays a role in the inhibition of T-cell activation and proliferation.","PVRIG Gene | PVR Related Immunoglobulin Domain Containing Gene | PVRIG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936034","AG 348","C157039","An orally available, small-molecule, allosteric activator of the red cell isoform of pyruvate kinase (PK-R), with potential to improve hemolytic anemia in patients with pyruvate kinase deficiency (PKD). Upon oral administration, mitapivat binds to and activates PK-R, thereby enhancing glycolytic pathway activity, improving adenosine triphosphate (ATP) levels and reducing 2,3-diphosphoglycerate (2,3-DPG) levels. Mutations in PK-R cause deficiency in PK-R which prevents adequate red blood cell (RBC) glycolysis, leading to a buildup of the upstream glycolytic intermediate 2,3-DPG and deficiency in the PK-R product ATP.","Mitapivat | AG 348 | AG-348 | AG348 | MITAPIVAT | PK-R Activator AG-348 | PKR-IN-1 | Red Cell Pyruvate Kinase Activator AG-348",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935906","Zirconium Zr 89-DFO-cRGDY PEG-Cy5-C' Dots","C156739","A radioconjugate composed of a tumor-selective fluorescent imaging agent containing silica-based nanoparticles labeled with a near-infrared (NIR) fluorophore, cyanine 5 (Cy5), and surrounded by polyethylene glycol (PEG) chains attached to cyclic arginine-glycine-aspartic acid-tyrosine) (cyclo-(Arg-Gly-Asp-Tyr; cRGDY) peptides (C' dots; Cornell prime dots; cRGDY-PEG-C' dots), and linked, via the chelator desferrioxamine (DFO), to the radioisotope zirconium Zr 89 (Zr89), with potential diagnostic properties upon positron emission tomography (PET) imaging. Upon intradermal administration of the zirconium Zr 89 cRGDY PEG-Cy5-C' dots, the cRGDY moiety selectively binds to alphaVbeta3 integrin expressed on tumor cells. Upon binding, the radioisotope moiety may be detected using PET, thereby allowing the imaging and quantification of integrin-expressing tumor cells as well as the visualization of the distribution, uptake and removal within tumor tissues. The fluorescence imaging agent is used to visualize alphaVbeta3-expressing tumor cells and assess the degree of both tumor metastasis and sentinel lymph node (SLN) trafficking. Integrins are transmembrane glycoproteins upregulated on proliferating tumor vessel endothelial cells and various cancer cells; their overexpression has been associated with neovascularization, differentiation, proliferation of tumor cells, metastasis and an overall poor prognosis.","Zirconium Zr 89-DFO-cRGDY PEG-Cy5-C' Dots | 89Zr-DFO-cRGDY-PEG-Cy5-C' Dot Nanoparticles | 89Zr-DFO-cRGDY-PEG-Cy5-C' Dot Particles | 89Zr-DFO-cRGDY-PEG-Cy5-C' Dots | Zr 89-DFO-cRGDY PEG-Cy5-C' Dots",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677833","Keratinocyte Growth Factor Therapy","C15673","No value exists.","Keratinocyte Growth Factor Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935939","USP18 Gene","C156940","This gene plays a role in the cleavage of ubiquitin-like protein ISG15 conjugates and the regulation of interferon-mediated signaling.","USP18 Gene | USP18 | Ubiquitin Specific Peptidase 18 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935940","USP18 wt Allele","C156941","Human USP18 wild-type allele is located in the vicinity of 22q11.2 and is approximately 27 kb in length. This allele, which encodes Ubl carboxyl-terminal hydrolase 18 protein, is involved in the cleavage of proteins conjugated with ubiquitin-like protein ISG15. Mutation of the gene is associated with pseudo-TORCH syndrome 2.","USP18 wt Allele | ISG43 | Interferon-Stimulated Gene, 43-kD Gene | PTORCH2 | UBP43 | Ubiquitin Specific Peptidase 18 wt Allele | Ubiquitin-Specific Protease, 43-kD Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1436576","USP18 protein, human","C156942","Ubl carboxyl-terminal hydrolase 18 (372 aa, ~43 kDa) is encoded by the human USP18 gene. This protein plays a role in the modulation of type I interferon-dependent signaling through the cleavage of ubiquitin-like protein ISG15 conjugated-proteins.","Ubl Carboxyl-Terminal Hydrolase 18 | 43 kDa ISG15-Specific Protease | EC 3.4.19.- | ISG15-Specific-Processing Protease | USP18 | Ubiquitin Specific Peptidase 18 | Ubiquitin Specific Protease 18 | Ubiquitin Thioesterase 18 | Ubiquitin-Specific Peptidase 18 | Ubiquitin-Specific Protease 18 | Ubl Thiolesterase 18 | hUBP43",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935946","Adrenal Cortical Sex Cord-Stromal Tumor","C156943","An extremely rare sex cord-stromal tumor that arises from the adrenal cortex. The reported cases were solitary and unilateral.","Adrenal Cortical Sex Cord-Stromal Tumor | Adrenal Cortex Sex Cord-Stromal Tumor | Adrenal Cortex Sex Cord-Stromal Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935943","Adrenal Gland Schwannoma","C156944","A rare schwannoma that arises from the adrenal medulla.","Adrenal Gland Schwannoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935944","Adrenal Gland Lymphoma","C156945","A rare lymphoma that arises from the adrenal gland.","Adrenal Gland Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563109","Days Between Diagnosis and Treatment","C156417","The number of days from the date of initial pathologic diagnosis to when treatment began.","Days Between Diagnosis and Treatment | Days to Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563110","Days Between Birth and Diagnosis","C156418","The time interval from a person's date of birth to the date of initial pathologic diagnosis, represented as a calculated number of days.","Days Between Birth and Diagnosis | Days from Birth | Days to birth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563104","Days between Diagnosis and Death","C156419","The time interval from a person's date of death to the date of initial pathologic diagnosis, represented as a calculated number of days.","Days between Diagnosis and Death | Days to death | Time from diagnosis to decease (if known)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1828181","Age at Diagnosis","C156420","The age of an individual at the time of initial pathologic diagnosis.","Age at Diagnosis | AGE_AT_TUMOR_ASSESSMENT | Age at diagnosis",,,,,,,,,,,,,,,"4307859","Age at diagnosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL563105","Site of Resection or Biopsy","C156421","The anatomic site from which a biopsy sample, or other tissue, was removed.","Site of Resection or Biopsy | Site of resection or biopsy | site of resection or biopsy | site_of_resection_or_biopsy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563106","Tissue or Organ of Origin","C156422","The anatomic site of a tumor or pathological process.","Tissue or Organ of Origin | Tissue or Organ Origin | Tissue or organ of origin | tissue or organ of origin | tissue_or_organ_of_origin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563163","Smoking Onset Year","C156423","The year in which an individual began smoking.","Smoking Onset Year | Tobacco smoking onset year | tobacco smoking onset year | tobacco_smoking_onset_year",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0342705","Hereditary Folate Malabsorption","C156424","An autosomal recessive condition caused by mutation(s) in the SCL46A1 gene, encoding proton-coupled folate transporter. It is characterized by low concentrations of folate resulting in megaloblastic anemia, immune deficiency, and neurologic deficits.","Hereditary Folate Malabsorption | ",,,,,,,,,,,,,,,"4267433","Congenital defect of folate absorption",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL563164","Smoking Cessation Year","C156425","The year in which an individual quit smoking.","Smoking Cessation Year | Smoking Quit Year | Tobacco smoking quit year | tobacco smoking quit year | tobacco_smoking_quit_year",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563165","Year of Death","C156426","The year in which an individual died.","Year of Death | Death Year | Year of death | year of death | year_of_death",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563161","Cancer-Related Death","C156427","A death attributed to the progression of a cancer-related pathologic condition.","Cancer-Related Death | Cancer Death | Cancer Related | Cancer Related Death",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935681","Water Signal Suppression Method","C156661","The technique used to suppress the signal that is generated from body water during imaging.","Water Signal Suppression Method | H2OSUPPR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935684","Non-Neoplastic Genitourinary System Disorder","C156664","A non-neoplastic disorder that affects the genitourinary system.","Non-Neoplastic Genitourinary System Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677911","multidrug resistance inhibition therapy","C15689","No value exists.","Drug Resistance Inhibition Treatment | Multidrug Resistance Inhibition | multi-drug resistance inhibition | multidrug resistance inhibition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281466","Safingol","C1568","A saturated derivative of sphingosine. As an inhibitor of protein kinase C (PKC), safingol competitively binds to the regulatory phorbol-binding domain of PKC, a kinase involved in tumorigenesis. This agent has been shown to act synergistically with other chemotherapeutic agents and may potentiate chemotherapy drug-induced apoptosis in vitro and in vivo.","Safingol | (2S,3S)-2-Amino-1,3-Octadecanediol | Kynacyte | L-(-)-threo-Sphingnine | L-Threo-Dihydrosphingosine | L-threo-2-Amino-1,3-octadecanediol | L-threo-dihydrosphingosine | SAFINGOL | SPC-100270 | Sphinganine | safingol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935924","HBB Gene Mutation","C156900","A change in the nucleotide sequence of the HBB gene.","HBB Gene Mutation | Beta-Globin Gene Mutation | Hemoglobin Beta Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935928","HBB NM_000518.4:c.364G>A","C156901","A nucleotide substitution at position 364 of the coding sequence of the HBB gene where guanine has been mutated to adenine.","HBB NM_000518.4:c.364G>A | Beta-Globin c.364G>A | HBB c.364G>A | Hemoglobin Beta c.364G>A | NM_000518.4:c.364G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562958","CHOP-R Plus Methotrexate","C156246","A regimen consisting of rituximab, cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine (Oncovin), prednisone (R-CHOP), and methotrexate used to treat certain types of lymphomas.","R-CHOP-Methotrexate Regimen | CHOP-R Plus Methotrexate | Cyclophosphamide/Doxorubicin/Methotrexate/Prednisone/Rituximab/Vincristine Regimen | Methotrexate Plus R-CHOP | R-CHOP Plus MTX | R-CHOP Plus Methotrexate Regimen | R-M-CHOP | R-M-CHOP (rituximab-abbs) | R-M-CHOP (rituximab-arrx) | R-M-CHOP (rituximab-blit) | R-M-CHOP (rituximab-pvvr) | R-M-CHOP (rituximab-rite) | R-M-CHOP (rituximab-rixa) | R-M-CHOP (rituximab-rixi) | Rituximab-Cyclophosphamide-Hydroxydaunorubicin-Oncovin-Prednisone-Methotrexate Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562959","Megestrol/Tamoxifen Regimen","C156247","A regimen consisting of alternating megestrol acetate and tamoxifen with potential use in the treatment of endometrial carcinoma.","Megestrol/Tamoxifen Regimen | Megace/Tamoxifen Regimen | Megestrol Acetate/Tamoxifen Regimen | Megestrol Alternating with Tamoxifen | Megestrol and Tamoxifen | Tamoxifen-Megace | Tamoxifen-Megestrol Acetate | Tamoxifen/Megace Regimen | Tamoxifen/Megestrol Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562960","Arimidex-Tamoxifen Regimen","C156248","A regimen consisting of tamoxifen and anastrozole that may be used in the treatment of breast cancer.","Anastrozole/Tamoxifen Regimen | Anastrozole and Tamoxifen | Arimidex-Tamoxifen Regimen | Tamoxifen-Anastrozole | Tamoxifen-Anastrozole Regimen | Tamoxifen/Anastrozole Regimen | Tamoxifen/Arimidex Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936033","GSR wt Allele","C157041","Human GSR wild-type allele is located in the vicinity of 8p12 and is approximately 50 kb in length. This allele, which encodes glutathione reductase, mitochondrial protein, is involved in cellular glutathione homeostasis. Mutation of the gene is associated with hemolytic anemia due to hereditary glutathione reductase deficiency.","GSR wt Allele | GLUR | GR | GRD1 | Glutathione Reductase Gene | Glutathione S-Reductase Gene | Glutathione-Disulfide Reductase wt Allele | HEL-75 | HEL-S-122m",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936314","Glutathione Reductase, Mitochondrial","C157042","Glutathione reductase, mitochondrial (522 aa, ~56 kDa) is encoded by the human GSR gene. This protein plays a role in the synthesis of the sulfhydryl form of glutathione.","Glutathione Reductase, Mitochondrial | EC 1.8.1.7 | Epididymis Luminal Protein 75 | Epididymis Secretory Sperm Binding Protein Li 122m | GR | GRase | GSR | Glutathione Reductase | Glutathione S-Reductase | Glutathione-Disulfide Reductase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563078","Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR","C156382","A preparation of autologous CD4+ and CD62L-expressing CD8+ T-cells transduced with a third generation lentiviral vector (LV) to express the high affinity T-cell receptor (TCR) A2 -MCC1, specific for the human leukocyte antigen (HLA)-A02-restricted Merkel cell polyomavirus (MCPyV; MCV) viral oncoprotein, with potential immunomodulating and antineoplastic activities. Upon reintroduction into the patient, the autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD8+ and CD4+ T-cells FH-MCVA2TCR selectively bind to the KLLEIAPNC epitope (KLL epitope) within the MCPyV viral oncoprotein. This results in cytotoxic T-lymphocyte (CTL)-mediated elimination of tumor cells expressing the MCPyV viral oncoprotein. Additionally, tumor-specific HLA-A02-restricted CD4+ cells promote class I-restricted CD8+ proliferation, survival and effector functions by producing interleukin (IL)-2 and facilitating the activation of dendritic cells (DCs). MCPyV viral oncoprotein is highly expressed in Merkel cell carcinoma (MCC) caused by MCPyV.","Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR | Autologous CD8+ and CD4+ T-cells transduced with TCR A2-MCC1 | FH-MCVA2TCR | FH-MCVA2TCR Autologous CD8+ and CD4+ T-cells Transduced with TCR A2-MCC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563080","Combination Product Report Indicator","C156384","An indication as to whether the Individual Case Safety Report (ICSR) contains at least one suspected medical product that is a combination product.","Combination Product Report Indicator | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563074","Malfunction Only (No AE) Report","C156385","A report of a device malfunction that does not include an adverse event.","Malfunction Only (No AE) Report | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935936","CPTAC Terminology","C156952","Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC).","CPTAC Terminology | Clinical Proteomic Tumor Analysis Consortium Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935937","CPTAC Baseline Medical Forms Terminology","C156953","Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on obtaining data for baseline medical forms.","CPTAC Baseline Medical Forms Terminology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936834","CPTAC Medical History Form","C156954","Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on Medical History Form data.","CPTAC Medical History Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935932","CPTAC Follow-Up Form","C156955","Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on Follow-Up Form data.","CPTAC Follow-Up Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280809","Rhenium Re 186 Etidronate","C1562","An synthetic compound containing the organic phosphonate hydroxyethylidene diphosphonate (HEDP) labeled with the radioisotope rhenium Re 186. Re-186 etidronate binds to hydroxyapatite in bone, delivering a cytotoxic dose of beta radiation to primary and metastatic bone tumors. Re-186 is a beta emitter with a short half-life, a radioisotope profile that provides localized antitumor radiocytotoxicity while sparing extramedullary bone marrow tissues.","Rhenium Re 186 Etidronate | 186Re-Etidronate | RHENIUM RE-186 ETIDRONATE | Re 186 Hydroxyethylidene Diphosphonate | Re-186 HEDP | Re-186 Hydroxyethylidene Diphosphonate | Rhenium Re-186 Hydroxyethylidene Diphosphonate | Rhenium-186 HEDP",,,,,,,,,,,,,,,"4216956|4217753","Rhenium (186-Re) hydroxyethylidene diphosphonate|Rhenium (186-Re) etidronate",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL563119","Locally Advanced Unresectable Cervical Carcinoma","C156300","A cervical carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.","Locally Advanced Unresectable Cervical Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563120","Everolimus/Tamoxifen Regimen","C156302","A regimen consisting of everolimus and tamoxifen that may be used in the treatment of breast cancer.","Everolimus/Tamoxifen Regimen | Everolimus and Tamoxifen | Everolimus-Tamoxifen | Everolimus-Tamoxifen Regimen | Everolimus/Tamoxifen | Tamoxifen and Everolimus | Tamoxifen/Everolimus | Tamoxifen/Everolimus Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563121","Exemestane/Lapatinib/Trastuzumab Regimen","C156303","A regimen consisting of exemestane, lapatinib, and trastuzumab that may be used in the treatment of breast cancer.","Exemestane/Lapatinib/Trastuzumab Regimen | Exemestane, Lapatinib, Trastuzumab | Exemestane, Lapatinib, Trastuzumab-anns | Exemestane, Lapatinib, Trastuzumab-dkst | Exemestane, Lapatinib, Trastuzumab-dttb | Exemestane, Lapatinib, Trastuzumab-herw | Exemestane, Lapatinib, Trastuzumab-pkrb | Exemestane, Lapatinib, Trastuzumab-qyyp | Exemestane, Lapatinib, Trastuzumab-strf | Exemestane, Lapatinib, Trastuzumab-zerc | Exemestane-Lapatinib-Trastuzumab | Exemestane-Lapatinib-Trastuzumab Regimen | Exemestane-Trastuzumab-Lapatinib | Exemestane/Lapatinib/Herceptin | Exemestane/Lapatinib/Trastuzumab | Exemestane/Trastuzumab/Lapatinib | Exemestane/Trastuzumab/Lapatinib Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563122","Advanced Cervical Adenocarcinoma","C156304","A cervical adenocarcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Cervical Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563136","Exemestane/Lapatinib Regimen","C156305","A regimen consisting of exemestane and lapatinib that may be used in the treatment of breast cancer.","Exemestane/Lapatinib Regimen | Exemestane and Lapatinib | Exemestane-Lapatinib | Exemestane-Lapatinib Regimen | Exemestane/Lapatinib | Lapatinib/Exemestane | Lapatinib/Exemestane Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935685","Micro Needle Array-Doxorubicin","C156665","A formulation composed of dissolvable small, adhesive-like patches composed of a biocompatible material which is coated with the anthracycline antibiotic doxorubicin, with potential antineoplastic and immunomodulating activities. Upon cutaneous administration of the microneedle-array-doxorubicin, the microneedles degrade once inserted into the skin and doxorubicin is released from the dissolvable microneedle array delivery device directly into the tumor microenvironment (TME). Doxorubicin is taken up by tumor cells and intercalates into DNA and interferes with topoisomerase II activity. This inhibits DNA replication and RNA synthesis, leading to tumor cell growth inhibition and apoptosis. This agent also interacts with cell membrane lipids causing lipid peroxidation. In addition, doxorubicin induces innate, adaptive, and tumor-specific effector and memory immune responses, thereby further killing the tumor cells. Delivery of doxorubicin using the microneedle array delivery system allows direct and specific administration of doxorubicin to the TME which may improve drug concentration into tumor cells and may reduce systemic toxicity, compared to the administration of systemic doxorubicin alone.","Micro Needle Array-Doxorubicin | D-MNA | Dissolvable Microneedles-containing Doxorubicin | Doxorubicin-coated Patches | Doxorubicin-loaded Patches | MNA-D | MNA-D Patches | MNA-Doxorubicin | Micro-needle Array Doxorubicin | Microneedle Applicator-Doxorubicin | Microneedle Array Doxorubicin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935682","Microneedle Drug Delivery System","C156666","A drug delivery device consisting of an adhesive-like patch covered with solid or hollow projections (microneedles), usually ranging in length from 50 to 900 micrometers, designed to deliver therapeutic agents through the skin.","Microneedle Drug Delivery System | Dissolvable Microneedle Array | MNA | Micro Needle Array | Micro-Needle Applicator | Microneedle Applicator | Microneedle Array | Microneedle Patch",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935683","ILDR2 Gene","C156667","This gene may play a role in Notch signaling, insulin homeostasis, inflammation and the unfolded protein response pathway.","ILDR2 Gene | ILDR2 | Immunoglobulin Like Domain Containing Receptor 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935735","ILDR2 wt Allele","C156668","Human ILDR2 wild-type allele is located in the vicinity of 1q24.1 and is approximately 93 kb in length. This allele, which encodes immunoglobulin-like domain-containing receptor 2 protein, may be involved in immunomodulation, Notch signaling, the response to glucose and cellular homeostasis. Overexpression of the gene may be associated with increased susceptibility for type 2 diabetes.","ILDR2 wt Allele | C1orf32 | Chromosome 1 Open Reading Frame 32 Gene | Immunoglobulin Like Domain Containing Receptor 2 wt Allele | LISCH-Like Gene | dJ782G3.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935734","Steroid-Refractory Pneumonitis","C156671","Pneumonitis that does not respond to corticosteroid therapy.","Steroid-Refractory Pneumonitis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562961","APG 2575","C156249","An orally bioavailable and selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon oral administration, lisaftoclax targets, binds to and inhibits the activity of Bcl-2. This restores apoptotic processes in tumor cells. Bcl-2 is overexpressed in many cancers and plays an important role in the negative regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival.","Lisaftoclax | APG 2575 | APG-2575 | APG2575 | Bcl-2 Inhibitor APG 2575 | LISAFTOCLAX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562954","Carboplatin/Topotecan Regimen","C156250","A regimen consisting of carboplatin and topotecan with potential use in the treatment of some cancers, including small cell lung, ovarian and cervical cancer.","Carboplatin/Topotecan Regimen | Carboplatin and Topotecan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562955","Autologous Anti-CD22 CAR-4-1BB-TCRz-transduced T-lymphocytes CART22-65s","C156251","Autologous human T-lymphocytes transduced with a recombinant lentiviral vector encoding a chimeric antigen receptor (CAR) consisting of an anti-CD22 human single chain variable fragment (scFv) and linked to the co-stimulatory domain 4-1BB (CD137) coupled to the zeta chain of the TCR/CD3 complex (CD3-zeta), with potential immunostimulating and antineoplastic activities. Upon reintroduction into the patient, the autologous anti-CD22 CAR-4-1BB-TCRz -transduced T-lymphocytes CART22-65s express anti-CD22-CAR on their cell surfaces and bind to the CD22 antigen on tumor cell surfaces, resulting in lysis of CD22-expressing tumor cells. CD22, a B-lineage-restricted, transmembrane phosphoglycoprotein, is expressed on malignant B-cells.","Autologous Anti-CD22 CAR-4-1BB-TCRz-transduced T-lymphocytes CART22-65s | Autologous Anti-CD22 CAR T-Cells CART22-65s | Autologous Anti-CD22 scFv CAR 4-1BB-TCRz-expressing T-lymphocytes CART22-65s | Autologous CART22-65s Cells | Autologous CART22-65s T-cells | Autologous CART22-65s-expressing T-cells | CART22-65s",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562957","Recurrent Cytomegalovirus Infection","C156253","A cytomegalovirus infection that has recurred after a period of remission.","Recurrent Cytomegalovirus Infection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562981","Recurrent Adenovirus Infection","C156254","An adenovirus infection that has recurred after a period of remission.","Recurrent Adenovirus Infection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1740834","Recurrent EBV Infection","C156255","An Epstein-Barr virus infection that has recurred after a period of remission.","Recurrent EBV Infection | Recurrent Epstein-Barr Virus Infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563200","Name and Version","C156472","An identifier that includes the words or language units by which a thing is known and the form or variant of the original.","Name and Version | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563201","Auxiliary Medicinal Product","C156473","A medicinal product that is used in a clinical trial for purposes other than as an investigational agent","Auxiliary Medicinal Product | NIMP (AxMP) | auxiliary medicinal product",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563202","Refractory Kaposi Sarcoma","C156474","Kaposi sarcoma that is resistant to treatment.","Refractory Kaposi Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1299260","Metastatic Kaposi Sarcoma","C156475","Kaposi sarcoma that has spread from its original site of growth to another anatomic site.","Metastatic Kaposi Sarcoma | ",,,,,,,,,,,,,,,"4162254","Kaposi's sarcoma, metastatic",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL563198","Advanced Kaposi Sarcoma","C156476","Kaposi sarcoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Kaposi Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935783","Experimental Organism Endocardial Schwannoma","C156607","A malignant schwannoma of the heart arising from subendocardial schwann cells that appear as an expansile spindle cell mass, which may infiltrate the myocardium and protrude into the ventricular lumen. (INHAND)","Experimental Organism Endocardial Schwannoma | SCHWANNOMA, ENDOCARDIAL, MALIGNANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935784","Experimental Organism Intramural Schwannoma","C156608","A malignant schwannoma of the heart of the heart arising from intramural swan cells that appears as a poorly circumscribed spindle cell mass within the ventricular myocardium with a more discrete boundary, that is generally more infiltrative than expansile. (INHAND)","Experimental Organism Intramural Schwannoma | SCHWANNOMA, INTRAMURAL, MALIGNANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935788","Experimental Organism Ductal Cell Adenocarcinoma","C156609","An experimental organism carcinoma that arises from a ductal structure.","Experimental Organism Ductal Cell Adenocarcinoma | ADENOCARCINOMA, DUCTAL CELL, MALIGNANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935789","Experimental Organism Ductal Cell Adenoma","C156610","An experimental organism adenoma that arises from a ductal structure.","Experimental Organism Ductal Cell Adenoma | ADENOMA, DUCTAL CELL, BENIGN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935786","Experimental Organism Brunner's Gland Carcinoma","C156611","A malignant epithelial neoplasm arising from the cells of the Brunner's gland with desmoplasia being the most dominant feature along with a diminished or lost glandular structure. (INHAND)","Experimental Organism Brunner's Gland Carcinoma | CARCINOMA, BRUNNER'S GLAND, MALIGNANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935787","Experimental Organism Benign Thecoma","C156612","A benign sex cord/stromal neoplasm characterized by densely packed fusiform theca cells arranged in interlacing bundles and whorls giving a nodular appearance. (INHAND)","Experimental Organism Benign Thecoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935777","Experimental Organism Malignant Thecoma","C156613","A malignant sex cord/stromal neoplasm characterized by densely packed fusiform theca cells arranged in interlacing bundles and whorls giving a nodular appearance. (INHAND)","Experimental Organism Malignant Thecoma | THECOMA, MALIGNANT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831720","fulvestrant/trastuzumab","C156306","A regimen consisting of fulvestrant and trastuzumab that may be used in the treatment of breast cancer.","Fulvestrant/Trastuzumab Regimen | Fulvestrant-Trastuzumab | Fulvestrant-Trastuzumab Regimen | Fulvestrant/Herceptin | Fulvestrant/Trastuzumab | Trastuzumab/Fulvestrant | Trastuzumab/Fulvestrant Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563137","Lapatinib/Letrozole/Trastuzumab Regimen","C156307","A regimen consisting of lapatinib, letrozole, and trastuzumab that can be used in the treatment of breast cancer.","Lapatinib/Letrozole/Trastuzumab Regimen | Lapatinib, Letrozole, Trastuzumab | Lapatinib, Letrozole, Trastuzumab-anns | Lapatinib, Letrozole, Trastuzumab-dkst | Lapatinib, Letrozole, Trastuzumab-dttb | Lapatinib, Letrozole, Trastuzumab-herw | Lapatinib, Letrozole, Trastuzumab-pkrb | Lapatinib, Letrozole, Trastuzumab-qyyp | Lapatinib, Letrozole, Trastuzumab-strf | Lapatinib, Letrozole, Trastuzumab-zerc | Lapatinib-Letrozole-Trastuzumab | Lapatinib-Letrozole-Trastuzumab Regimen | Lapatinib/Letrozole/Herceptin | Lapatinib/Letrozole/Trastuzumab | Letrozole/Lapatinib/Trastuzumab | Letrozole/Lapatinib/Trastuzumab Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563138","Letrozole/Trastuzumab Regimen","C156308","A regimen consisting of letrozole and trastuzumab that can be used in the treatment of  breast cancer.","Letrozole/Trastuzumab Regimen | Letrozole and Trastuzumab | Letrozole and Trastuzumab-anns | Letrozole and Trastuzumab-dkst | Letrozole and Trastuzumab-dttb | Letrozole and Trastuzumab-herw | Letrozole and Trastuzumab-pkrb | Letrozole and Trastuzumab-qyyp | Letrozole and Trastuzumab-strf | Letrozole and Trastuzumab-zerc | Letrozole-Trastuzumab | Letrozole-Trastuzumab Regimen | Letrozole/Herceptin | Letrozole/Trastuzumab | Trastuzumab/Letrozole | Trastuzumab/Letrozole Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4225296","MRD39","C156309","An autosomal dominant condition caused by mutation(s) in the MYT1L gene, encoding myelin transcription factor 1-like protein. It is characterized by intellectual disability and mild dysmorphic facial features.","Mental Retardation, Autosomal Dominant 39 | MRD39",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0393538","Spinal Muscular Atrophy Type 2","C156310","An autosomal recessive condition caused by mutation(s) in the SMN1 gene, encoding survival motor neuron protein. It is characterized by onset between 3 and 15 months of age, and is intermediate in terms of severity between spinal muscular atrophy (SMA) type I and SMA type III.","Spinal Muscular Atrophy Type 2 | SMA2",,,,,,,,,,,,,,,"4027536","Spinal muscular atrophy, type II",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL935649","Separated","C156541","A person who is separated from their spouse, whether or not there is a legal arrangement.","Separated | SEPARATED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935962","Number of Days from Date of Initial Cancer Diagnosis to Date of Additional Surgery for New Tumor Event","C156860","The number of days from the date of the initial cancer diagnosis to the date of additional surgery for the new tumor event.","Number of Days from Date of Initial Cancer Diagnosis to Date of Additional Surgery for New Tumor Event | Number of Days from Date of Initial Pathologic Diagnosis to Date of Additional Surgery for New Tumor Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936008","Aluminum Milling","C156863","An occupation involving the processing or shaping of aluminum using a rotating cutter.","Aluminum Milling | Aluminum Miller | Aluminum milling",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936007","Hard Rock Mining","C156866","A process and occupation involving the excavation of hard minerals or their ores from the ground.","Hard Rock Mining | Hard Rick Miner | Underground Hard Rock Mining",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936013","Mineral Cutting","C156868","An occupation or process involving the shaping of hard minerals or metals using hammers, saws, or abrasives.","Mineral Cutting | Lapidary | Mineral Cutter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936010","Sand Blasting","C156869","An occupation involving forcibly propelling a stream of abrasive material against a surface under high pressure to smooth a rough surface, roughen a smooth surface, shape a surface, or remove surface contaminants.","Sand Blasting | Sand Blaster | Sand blasting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517606","Isolated Chemotherapeutic Hepatic Perfusion","C15686","No value exists.","Isolated Chemotherapeutic Hepatic Perfusion | isolated hepatic perfusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936011","Solder Fume Exposure","C156871","Environmental, occupational, or consumer-based exposure to vaporized materials during the soldering process.","Solder Fume Exposure | Solder Fumes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936001","Cotton or Jute Dust Exposure","C156872","Environmental, occupational, or consumer-based exposure to airborne cotton or jute fibers created during the manufacture, processing, or handling of these materials.","Cotton or Jute Dust Exposure | Cotton or Jute Dust | Cotton or Jute Fibers | Cotton or Jute processing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563199","Intrauterine Gel Dosage Form","C156477","Semi-solid preparation consisting of a gel intended for intrauterine use.","Intrauterine Gel Dosage Form | Intrauterine gel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935677","A 166","C156480","An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), conjugated, via a cleavable linker, to the microtubule inhibitor and auristatin derivative duostatin-5 (Duo-5), with potential antineoplastic activity. Upon administration of trastuzumab botidotin, the trastuzumab moiety targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, duo-5 binds to tubulin and inhibits its polymerization, which results in cell cycle arrest and induces tumor cell apoptosis. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.","Trastuzumab Botidotin | A 166 | A-166 | A166 | ADC A166 | Anti-HER2 ADC A166 | Anti-HER2 Antibody-drug Conjugate A166 | Anti-HER2 Antibody-drug Conjugate A166 | TRASTUZUMAB BOTIDOTIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935678","Young Autologous Tumor-infiltrating Lymphocytes","C156481","A preparation of autologous young tumor infiltrating lymphocytes (TILs), that are isolated from the patient's tumor tissue and minimally cultured ex vivo, with potential antineoplastic and immunomodulating activities. Upon re-administration of the young TILs, the TILs re-infiltrate the tumor, recognize the tumor cells and initiate tumor cell lysis. This inhibits tumor cell growth.","Young Autologous Tumor-infiltrating Lymphocytes | Therapeutic Young Autologous TILs | Young Autologous TIL | Young Autologous TILs | Young Autologous Tumor Infiltrating Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935675","Genitourinary System Neoplasm","C156482","A benign or malignant neoplasm that affects the genitourinary system.","Genitourinary System Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935676","Benign Genitourinary System Neoplasm","C156483","A neoplasm that arises from the genitourinary system and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Genitourinary System Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935873","Anti-HER2 x Anti-CD3 Bispecific Monoclonal Antibody BTRC 4017A","C156705","An anti-human epidermal growth factor receptor 2 (HER2)/anti-CD3 T-cell-dependent bispecific (TDB) monoclonal antibody with potential immunostimulatory and antineoplastic activities. Upon administration, runimotamab possesses two antigen recognition sites, one for HER2, a tyrosine kinase receptor overexpressed by many cancer cell types, and one for the CD3 complex, a group of T-cell surface glycoproteins that interact with the T-cell receptor (TCR). Upon administration of runimotamab, this bispecific monoclonal antibody simultaneously binds to both CD3-expressing T-cells and HER2-expressing cancer cells, thereby crosslinking HER2-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated lysis of HER2-expressing tumor cells. HER2 plays a key role in tumor cell proliferation and tumor vascularization.","Runimotamab | Anti-HER2 x Anti-CD3 Bispecific Monoclonal Antibody BTRC 4017A | Anti-HER2 x Anti-CD3 Bispecific Monoclonal Antibody RG 6194 | Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody 4017A | Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody BTRC 4017A | BTRC 4017A | BTRC-4017A | BTRC4017A | RG 6194 | RG-6194 | RG6194 | RUNIMOTAMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935874","Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes","C156706","A preparation of autologous CD8-positive T-lymphocytes that have been genetically modified via transient mRNA transfection to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and containing, as of yet undisclosed co-stimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-BCMA-CAR-mRNA transfected CD8+ T-lymphocytes specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.","Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes | Anti-BCMA-CAR-mRNA-transfected Autologous CD8+ T-cells | Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-cells | Autologous Anti-BCMA-CAR-mRNA-transfected CD8-positive T-cells | Descartes-08",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935778","Irreversible Inhibitor","C156614","A class of substances that irreversibly and permanently binds to and decreases the activity of, and/or deactivates a target.","Irreversible Inhibitor | IRREVERSIBLE INHIBITOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935775","Physiologic Antagonist","C156615","A substance that binds to and activates a receptor and produces a biological effect which inhibits or negates the biological response produced by an agonist at a different receptor.","Physiologic Antagonist | PHYSIOLOGIC ANTAGONIST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935776","SEND Developmental and Reproductive Toxicology Implementation Guide Version 1.1","C156616","The 1.1 version of the standard for exchange of nonclinical data (SEND) developmental and reproductive toxicology (DART) implementation guide.","SEND Developmental and Reproductive Toxicology Implementation Guide Version 1.1 | SEND DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY IMPLEMENTATION GUIDE VERSION 1.1 | SEND IG DART Version 1.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935781","Authorized Investigational Medicinal Product","C156617","A medicinal product with marketing authorization that is being tested or used as a reference in a clinical trial.","Authorized Investigational Medicinal Product | authorised investigational medicinal product",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935782","Authorized Auxiliary Medicinal Product","C156618","A medicinal product with marketing authorization that is used in a clinical trial for purposes other than as the investigational agent.","Authorized Auxiliary Medicinal Product | authorised auxiliary medicinal product",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935779","Clinical Trial Results Registry","C156620","A clinical trial registry that serves as a publicly available database of clinical trial results.","Clinical Trial Results Registry | clinical trial results registry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281385","Strontium Sr-89","C1567","A radioisotope of strontium, a heavy metal found naturally as a non-radioactive element.  With a half-life of 50 days, strontium-89 is a beta emitter that is metabolized much like calcium.  This agent is preferentially absorbed by osteoblastic bone metastases. (NCI04)","Strontium Sr-89 | STRONTIUM SR-89 | Strontium-89 | strontium-89",,,,,,,,,,,,,,,"4298430","Strontium-89",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL935848","Prior Treatment of Current Cancer","C156800","An indication that an individual has previously received therapy for their current malignancy.","Prior Treatment of Current Cancer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935845","Treatment-sensitive HIV Infection","C156801","An infection with human immunodeficiency virus that responds to therapy.","Treatment-sensitive HIV Infection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935846","Radiation to Greater than 25 Percent of Bone Marrow","C156802","Bone marrow irradiation targeting greater than 25 percent of the total bone marrow.","Radiation to Greater than 25 Percent of Bone Marrow | Radiation to More than 25 Percent of Bone Marrow",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935642","Injection Needle Reuse","C156549","The use of injection needles that have been previously used.","Injection Needle Reuse | INJECTION NEEDLE REUSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935903","AMG 397","C156740","An inhibitor of induced myeloid leukemia cell differentiation protein (myeloid cell leukemia-1; Mcl-1; Bcl2-L-3), with potential pro-apoptotic and antineoplastic activities. Upon administration, MCL-1 inhibitor AMG 397 targets and binds to Mcl-1, thereby preventing the binding of Mcl-1 to and inactivation of certain pro-apoptotic proteins. This promotes apoptosis of cells overexpressing Mcl-1. Mcl-1, an anti-apoptotic protein belonging to the B-cell lymphoma 2 (Bcl-2) family of proteins, is upregulated in cancer cells and promotes tumor cell survival.","Murizatoclax | AMG 397 | AMG-397 | AMG397 | MCL-1 inhibitor AMG 397 | MURIZATOCLAX | Myeloid Cell Leukemia 1 Inhibitor AMG 397",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935904","BCD 135","C156741","A monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, manelimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.","Manelimab | BCD 135 | BCD-135 | BCD135 | MANELIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280726","Monoclonal Antibody Lym-1","C1561","A murine IgG2a monoclonal antibody directed against the HLA-Dr10 protein, a cell surface marker present on over eighty percent of lymphoma cells.  When conjugated with a radioactive isotope, Lym-1 monoclonal antibody selectively transports the cytotoxic radioisotope to HLA-Dr10-expressing tumor cells, thereby sparing healthy B-cells and normal tissues.  This agent also mediates antibody-dependent cytotoxicity thereby promoting Raji B-lymphoid cell lysis by human neutrophils. (NCI04)","Monoclonal Antibody Lym-1 | IgG2a murine monoclonal antibody Lym-1 | Lym-1 | MoAb Lym-1 | Monoclonal Antibody Lym-1, IgG2a Murine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563055","Carboplatin/Paclitaxel/Nivolumab Regimen","C156211","A regimen consisting of carboplatin, paclitaxel and nivolumab that may be used for the treatment of head and neck squamous cell carcinoma, ovarian cancer, and non-small cell lung cancer (NSCLC).","Carboplatin/Paclitaxel/Nivolumab Regimen | Carboplatin and Paclitaxel (CP) and Nivolumab | Carboplatin-Paclitaxel-Nivolumab | Carboplatin-Paclitaxel-Nivolumab Regimen | Carboplatin/Nivolumab/Paclitaxel | Carboplatin/Paclitaxel Plus Nivolumab | Carboplatin/Paclitaxel/Nivolumab | Carboplatin/Paclitaxel/Opdivo",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935871","Anti-GCC Antibody-Drug Conjugate TAK-164","C156707","An antibody-drug conjugate (ADC) comprised of a full-length, fully-human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) directed against the extracellular domain of guanylyl cyclase C (GCC; GUCY2C), conjugated using the peptide-linked indolino-benzodiazepine DNA alkylator DGN549 (IGN-P1), with potential antineoplastic activity. Upon intravenous administration of TAK-164, the antibody moiety selectively binds to GCC-expressing cells. Upon antibody/antigen binding and internalization, the cytotoxic DGN549 payload is released and binds to guanine residues on opposing strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of GCC-expressing cells. GCC, a transmembrane receptor normally found on intestinal cells and dopamine neurons in the brain, is overexpressed on the surface of certain tumor cells.","Anti-GCC Antibody-Drug Conjugate TAK-164 | Anti-GCC ADC TAK-164 | TAK 164 | TAK-164 | TAK164",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935872","eHealth for Sedentary Behavior","C156708","The use of websites, applications, or other electronic means to induce individuals to partake in spontaneous movement and reduce their sedentary behavior.","eHealth for Sedentary Behavior | eHealth Interventions for Sedentary Behavior",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935863","BI 907828","C156709","An orally available inhibitor of murine double minute 2 (MDM2), with potential antineoplastic activity. Upon oral administration, brigimadlin binds to MDM2 protein and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. By preventing MDM2-p53 interaction, the transcriptional activity of p53 is restored. This leads to p53-mediated induction of tumor cell apoptosis. Compared to currently available MDM2 inhibitors, the pharmacokinetic properties of BI 907828 allow for more optimal dosing and dose schedules that may reduce myelosuppression, an on-target, dose-limiting toxicity for this class of inhibitors.","Brigimadlin | BI 907828 | BI-907828 | BI907828 | BRIGIMADLIN | MDM2 Inhibitor BI 907828 | MDM2 Inhibitor BI 907828",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935864","Goserelin Acetate Extended-release Microspheres LY01005","C156710","A long-acting, extended-release microsphere formulation of the acetate form of goserelin, a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH), with potential antineoplastic activity. Upon administration, goserelin binds to and activates pituitary gonadotropin-releasing hormone (GnRH) receptors. Prolonged administration of goserelin inhibits the secretion of pituitary gonadotropin, thereby decreasing levels of testosterone (in males) and estradiol (in females).  Administration of this agent in an extended-release formulation may result in the regression of sex hormone-sensitive tumors and a reduction in sex organ size and function.","Goserelin Acetate Extended-release Microspheres LY01005 | Goserelin Acetate Extended-release Microspheres | LY 01005 | LY-01005 | LY01005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935929","HBB NM_000518.4:c.20A>T","C156902","A nucleotide substitution at position 20 of the coding sequence of the HBB gene where adenine has been mutated to thymine.","HBB NM_000518.4:c.20A>T | Beta-Globin c.20A>T | HBB c.20A>T | Hemoglobin Beta c.20A>T | NM_000518.4:c.20A>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935926","HBB Protein Variant","C156903","A variation in the amino acid sequence for the hemoglobin subunit beta protein.","HBB Protein Variant | Beta-Globin Protein Variant | Hemoglobin Beta Chain Protein Variant | Hemoglobin Subunit Beta Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935927","HBB NP_000509.1:p.E122K","C156904","A change in the amino acid residue at position 122 in the hemoglobin subunit beta protein where glutamic acid has been replaced by lysine.","HBB NP_000509.1:p.E122K | Beta-Globin E122K | Beta-Globin Glu122Lys | HBB E121K | HBB E122K | HBB Glu121Lys | HBB Glu122Lys | HBB Hemoglobin O (Arab) | HBB Hemoglobin O-Arab | HBB NP_000509.1:p.Glu122Lys | HBB p.E122K | HBB p.Glu122Lys | Hemoglobin Beta Chain E122K | Hemoglobin Beta Chain Glu122Lys | Hemoglobin O (Arab) Variant | Hemoglobin O-Arab Variant | Hemoglobin Subunit Beta E121K | Hemoglobin Subunit Beta E122K | Hemoglobin Subunit Beta Glu121Lys | Hemoglobin Subunit Beta Glu122Lys | NP_000509.1:p.E122K | NP_000509.1:p.Glu122Lys",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935920","HBB NP_000509.1:p.E7V","C156905","A change in the amino acid residue at position 7 in the hemoglobin subunit beta protein where glutamic acid has been replaced by valine.","HBB NP_000509.1:p.E7V | Beta-Globin E7V | Beta-Globin Glu7Val | HBB E6V | HBB E7V | HBB Glu6Val | HBB Glu7Val | HBB Hemoglobin S | HBB NP_000509.1:p.Glu7Val | HBB p.E7V | HBB p.Glu7Val | Hemoglobin Beta Chain E7V | Hemoglobin Beta Chain Glu7Val | Hemoglobin Beta S Variant | Hemoglobin S Variant | Hemoglobin Subunit Beta E6V | Hemoglobin Subunit Beta E7V | Hemoglobin Subunit Beta Glu6Val | Hemoglobin Subunit Beta Glu7Val | NP_000509.1:p.E7V | NP_000509.1:p.Glu7Val",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935851","Transmembrane Protein PVRIG","C156803","Transmembrane protein PVRIG (326 aa, ~34 kDa) is encoded by the human PVRIG gene. This protein plays a role in the inhibition of T-cell-mediated immunity.","Transmembrane Protein PVRIG | CD 112R | CD112 Receptor | CD112R | Nectin-2 Receptor | Poliovirus Receptor Related Immunoglobulin Domain Containing Protein | Poliovirus Receptor-Related Immunoglobulin Domain-Containing Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935852","EZH2 Inhibitor","C156804","Any agent that inhibits the histone lysine methyltransferase EZH2.","EZH2 Inhibitor | Enhancer of Zeste Homolog 2 Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935849","Tumor Event Information","C156805","No value exists.","Tumor Event Information | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935832","Date of Last Chemotherapy Treatment","C156815","The date of the last administration of chemotherapy.","Date of Last Chemotherapy Treatment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936025","SRXN1 wt Allele","C157044","Human SRXN1 wild-type allele is located in the vicinity of 20p13 and is approximately 7 kb in length. This allele, which encodes sulfiredoxin-1 protein, is involved in resistance to oxidative stress.","SRXN1 wt Allele | C20orf139 | Chromosome 20 Open Reading Frame 139 Gene | Npn3 | SRX | SRX1 | Sulfiredoxin 1 Homolog (S. cerevisiae) Gene | Sulfiredoxin 1 wt Allele | YKL086W | dJ850E9.2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936022","Sulfiredoxin-1","C157045","Sulfiredoxin-1 (137 aa, ~14 kDa) is encoded by the human SRXN1 gene. This protein plays a role in the reduction of cysteine-sulfinic acid residues in peroxiredoxins.","Sulfiredoxin-1 | EC 1.8.98.2 | SRXN1 | Sulfiredoxin 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936023","GPAT3 Gene","C157046","This gene is involved in triacylglycerol synthesis.","GPAT3 Gene | GPAT3 | Glycerol-3-Phosphate Acyltransferase 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936027","GPAT3 wt Allele","C157047","Human GPAT3 wild-type allele is located in the vicinity of 4q21.23 and is approximately 70 kb in length. This allele, which encodes glycerol-3-phosphate acyltransferase 3 protein, plays a role in glycerolipid biosynthesis.","GPAT3 wt Allele | 1-Acylglycerol-3-Phosphate O-Acyltransferase 9 (Lysophosphatidic Acid Acyltransferase, Theta) Gene | AGPAT 10 | AGPAT10 | AGPAT8 | AGPAT9 | GPAT, Endoplasmic Reticulum-Associated Gene | Glycerol-3-Phosphate Acyltransferase 3 wt Allele | HMFN0839 | LPAAT-Theta | Lung Cancer Metastasis-Associated Gene 1 | Lysophosphatidic Acid Acyltransferase, Theta Gene | MAG1 | UNQ2753/PRO6492",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935893","Carbon C 11-osimertinib","C156742","A radioconjugate composed of osimertinib, a third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, labeled with the positron-emitting isotope carbon C 11, with potential use in imaging via positron emission tomography (PET).  Upon intravenous administration of carbon C 11 osimertinib, the osimertinib targets and binds to mutant forms of EGFR on tumor cells. Upon PET imaging, this radioligand may allow for the assessment of EGFR mutant-expressing tumor cells. This also allows assessment of osimetinib's pharmacokinetic profile and affinity of EGFR mutant-positive cancer cells and may identify patients who may respond well to osimertinib.","Carbon C 11-osimertinib | 11C-osimertinib | [11C] Osimertinib | [11C]AZD9291",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935894","EZH2 Inhibitor PF-06821497","C156743","An orally available selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2), with potential antineoplastic activity. Upon oral administration, mevrometostat selectively targets, binds to and inhibits the activity of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 on lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased proliferation of EZH2-expressing cancer cells. EZH2, an HMT class enzyme and the catalytic subunit of the polycomb repressive complex 2 (PRC2), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation; its expression is correlated with tumor initiation, progression, stem cell self-renewal, migration and angiogenesis.","Mevrometostat | 1(2H)-Isoquinolinone, 5,8-Dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)- | EZH2 Inhibitor PF-06821497 | EZH2 Inhibitor PF-06821497 | MEVROMETOSTAT | PF 06821497 | PF-06821497 | PF06821497",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935891","CYP11A1 inhibitor ODM-208","C156744","An orally bioavailable, non-steroidal, selective inhibitor of the enzyme cytochrome 450 side-chain cleavage (scc) (CYP11A1), with potential antineoplastic activity. Upon oral administration, opevesostat targets, binds to and inhibits the activity of CYP11A1. This prevents the synthesis of all steroid hormones and their precursors. This may inhibit proliferation of hormone-positive tumor cells. CYP11A1, a mitochondrial enzyme, catalyzes the conversion of cholesterol to pregnenolone (Preg), which is the first rate-liming step in steroid hormone biosynthesis.","Opevesostat | CYP11A1 inhibitor ODM-208 | CYP11A1 inhibitor ODM-208 | MK 5684 | MK-5684 | MK5684 | ODM 208 | ODM-208 | ODM208 | OPEVESOSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935892","Locally Advanced Microsatellite Stable Colorectal Carcinoma","C156745","A microsatellite stable colorectal carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Microsatellite Stable Colorectal Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935897","Advanced Digestive System Carcinoma","C156746","Digestive system carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Digestive System Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935898","AssureMDx","C156747","A proprietary non-invasive, urine-based test that uses methylation and mutation biomarkers to assess the risk of bladder cancer for patients diagnosed with hematuria.","AssureMDx | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935895","Millimeter-Wave Holographic Imaging","C156748","An imaging technology that uses non-ionizing, millimeter-length electromagnetic waves (30GHz to 300GHz) to scan the surface of an object or body. Millimeter-wave imaging (MMW) can image through non-polar and non-metallic materials such as clothing, plastic, and cardboard with relatively little energy loss. Compared to microwaves and radio-frequency waves, MMW can achieve better spatial resolution due to its shorter wavelength. MMW is harmless to humans.","Millimeter-Wave Holographic Imaging | Holographic Millimeter-wave Imaging | Holographic mm-Wave Imaging | MMW | MMW Holographic Imaging | MMW Imaging | Millimeter-wave Imaging",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337676","Social Drinker","C156429","An individual who generally only drinks at social events.","Social Drinker | ",,,,,,,,,,,,,,,"4102142","Social drinker",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0002913","Epidural Block","C15642","An anesthetic procedure that involves administering pharmaceutical agents into the epidural space of the spinal canal. Frequently administered agents include local anesthetics and analgesics.","Epidural Block | Epidural Analgesia | epidural block",,,,,,,,,,,,,,,"4078199","Epidural anesthesia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0398788","Immunodeficiency-Centromeric Instability-Facial Anomalies Syndrome 1","C156430","An autosomal recessive condition caused by mutation(s) in the DNMT3B gene, encoding DNA (cytosine-5)-methyltransferase 3B. It is characterized by immunoglobulin deficiency, centromeric instability of chromosomes 1,9, and 19 (rarely chromosome 2), and facial dysmorphism.","Immunodeficiency-Centromeric Instability-Facial Anomalies Syndrome 1 | ",,,,,,,,,,,,,,,"4120781","Centromeric instability of chromosomes 1,9 and 16 and immunodeficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL563158","Anterior Endometrium","C156431","The part of the endometrium that is located in the anterior uterine wall.","Anterior Endometrium | Anterior endometrium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563159","Posterior Endometrium","C156432","The part of the endometrium that is located in the posterior uterine wall.","Posterior Endometrium | Posterior endometrium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1866504","Photosensitive Trichothiodystrophy","C156433","An autosomal recessive subtype of trichothiodystrophy caused by mutation(s) in the ERCC2 gene, encoding general transcription and DNA repair factor IIH helicase subunit XPD.","Trichothiodystrophy 1, Photosensitive | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563160","Analyte Type","C156434","The type of biospecimen subjected to analysis.","Analyte Type | analyte type | analyte_type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563157","sibrotuzumab","C156438","A humanized monoclonal antibody (MoAb) against human fibroblast activation protein (FAP). FAP is a 95 kDa cell surface glycoprotein and an inducible tumor stromal antigen of epithelial cancers and of a subset of soft tissue sarcomas. FAP shows a very limited distribution pattern in normal tissues, thereby sibrotuzumab has possible diagnostic and therapeutic applications in epithelial cancers.","Sibrotuzumab | HuMoAb F19 | Humanized F19 Monoclonal Antibody | SIBROTUZUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563177","REPLI-g X DNA","C156439","A genomic DNA sample that has been produced by two rounds of REPLI-g amplification.","REPLI-g X DNA | Repli-G X (Qiagen) DNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563178","Metastatic Tumor Sample","C156440","A biospecimen derived from a metastatic tumor.","Metastatic Tumor Sample | Additional Metastatic | Metastatic | Metastatic Sample",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563180","Control Analyte","C156442","A biospecimen that is used as a comparator for an experimental sample.","Control Analyte | Input Control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563174","Cell Line-Derived Xenograft","C156443","A biospecimen derived from the culturing of a derived cell line in a non-human organism.","Cell Line-Derived Xenograft | CDX | Cell Line Derived Xenograft Tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0861748","Resectable Pancreatic Adenocarcinoma","C156906","Pancreatic adenocarcinoma that is amenable to surgical resection.","Resectable Pancreatic Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935918","Resectable Pancreatic Acinar Cell Carcinoma","C156907","Pancreatic acinar cell carcinoma that is amenable to surgical resection.","Resectable Pancreatic Acinar Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935919","Resectable Intrahepatic Cholangiocarcinoma","C156908","Intrahepatic cholangiocarcinoma that is amenable to surgical resection.","Resectable Intrahepatic Cholangiocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935923","Resectable Digestive System Carcinoma","C156909","A digestive system carcinoma that is amenable to surgical resection.","Resectable Digestive System Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0862970","Resectable Bile Duct Adenocarcinoma","C156910","Bile duct adenocarcinoma that is amenable to surgical resection.","Resectable Bile Duct Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935921","Resectable Extrahepatic Bile Duct Adenocarcinoma","C156911","Extrahepatic bile duct adenocarcinoma that is amenable to surgical resection.","Resectable Extrahepatic Bile Duct Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935916","Month Follow-Up","C156917","A form header for month follow-up.","Month Follow-Up | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562982","Partially HLA-matched AdV/CMV/EBV-specific Allogeneic T-Lymphocytes","C156256","Partially or closely human leukocyte antigen (HLA)-matched allogeneic cytotoxic T-lymphocytes (CTLs), derived from cell lines, specifically reactive to the three human viruses adenovirus (AdV), cytomegalovirus (CMV) and Epstein-Barr virus (EBV), with potential antiviral activity. Upon infusion of the partially HLA-matched AdV/CMV/EBV-specific allogeneic T-lymphocytes in immunocompromised patients or upon allogeneic hematopoietic stem cell transplantation (HSCT) in an immunodeficient recipient, these CTLs may kill AdV, CMV, and/or EBV-infected cells, and may prevent or reduce the severity of viral infections by these pathogens.","Partially HLA-matched AdV/CMV/EBV-specific Allogeneic T-Lymphocytes | Allogeneic HLA-matched VSTs | Allogeneic HLA-matched Virus-specific T-cell Lines | Allogeneic Partially HLA-matched AdV/CMV/EBV-specific T-cells | Partially HLA-matched AdV/CMV/EBV-specific Allogeneic T-cells | Partially HLA-matched Adenovirus/Cytomegalovirus/Epstein-Barr Virus-specific Allogeneic Cytotoxic T-Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936094","Pen Device","C157049","Administration device intended to house a cartridge that contains a sterile, single-dose or multidose, parenteral preparation. It is usually supplied without a fixed needle, and may or may not be fitted with a needle safety device. The cartridge is usually replaceable when it is empty. The pre-defined dose, which may or may not be adjustable, is administered via an actuation, such as the pressing of a button. Dose dispenser is excluded.","Pen Device | Pen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0678026","Antifungal Therapy","C15704","Drug treatment to destroy or inhibit the growth or multiplication of fungi.","Antifungal Therapy | Treatment of Fungal Infectious Disease",,,,,,,,,,,,,,,"36713613","Antifungal therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL936026","Ipilimumab/Talimogene Laherparepvec Regimen","C157051","A regimen consisting of intralesional talimogene laherparepvec followed by intravenous ipilimumab that may be used in the treatment of melanoma.","Ipilimumab/Talimogene Laherparepvec Regimen | Intralesional T-VEC/Ipilimumab | Intralesional Talimogene Laherparepvec/Ipilimumab | Ipilimumab-Talimogene Laherparepvec Regimen | Ipilimumab/Talimogene Laherparepvec | Talimogene Laherparepvec/ Ipilimumab | Talimogene Laherparepvec/Ipilimumab | Yervoy/Imlygic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936016","LUM Imaging System","C157052","A proprietary imaging system designed to detect residual tumor tissue in breast cancer patients by identifying microscopic residual cancer in the tumor bed. The LUM Imaging System consists of the cancer imaging agent LUM015 and a hand-held fluorescence-based imager that detects the emission of activated LUM015 in and around a tumor. The LUM Imaging System is designed to detect microscopic residual cancer cells in real-time.","LUM Imaging System | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936017","LUM Imaging Device","C157053","A proprietary hand-held fluorescence-based imager that detects the emission of activated LUM015 in and around a tumor. The LUM Imaging System is designed to detect microscopic residual cancer cells in a tumor bed in real-time.","LUM Imaging Device | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936014","Incisional Vacuum-Assisted Closure Therapy","C157054","A type of postoperative wound therapy that uses a dressing composed of a non-adhesive dressing, sponge, and vacuum tubing, all covered with an adhesive, non-permeable material. Suction is applied through the tube. This system results in a decreased need for dressing changes during the immediate postoperative period and a cleaner wound environment.","Incisional Vacuum-Assisted Closure Therapy | Incisional VAC | Incisional Vacuum-Assisted Closure | Incisional Vacuum-Assisted Dressing | iVAC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936020","Hormone Receptor Positive Breast Carcinoma","C157056","Breast adenocarcinoma that is positive for hormone receptors.","Hormone Receptor-Positive Breast Carcinoma | Hormone Receptor Positive Breast Adenocarcinoma | Hormone Receptor Positive Breast Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936021","Refractory Hormone Receptor Positive Breast Carcinoma","C157057","Hormone receptor-positive breast adenocarcinoma that does not respond to treatment.","Refractory Hormone Receptor-Positive Breast Carcinoma | Refractory Hormone Receptor Positive Breast Adenocarcinoma | Refractory Hormone Receptor Positive Breast Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563096","HHLA2 wt Allele","C156393","Human HHLA2 wild-type allele is located in the vicinity of 3q13.13 and is approximately 92 kb in length. This allele, which encodes HERV-H LTR-associating protein 2, is involved in costimulatory signaling through the T-cell receptor complex.","HHLA2 wt Allele | B7 Homolog 7 Gene | B7-H5 | B7-H7 | B7H7 | B7y | HERV-H LTR-Associating 2 wt Allele | HHLA-2 | Human Endogenous Retrovirus-H Long Terminal Repeat-Associating 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563097","HERV-H LTR-Associating Protein 2","C156394","HERV-H LTR-associating protein 2 (414 aa, ~47 kDa) is encoded by the human HHLA2 gene. This protein plays a role in the regulation of T-cell receptor-mediated T-cell activation.","HERV-H LTR-Associating Protein 2 | B7 Homolog 7 | B7-H7 | HHLA-2 | HHLA2 | Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936060","GFUS Gene","C156967","This gene is involved in mannose metabolism.","GFUS Gene | GDP-L-Fucose Synthase Gene | GFUS | TSTA3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936058","FX","C156968","Human GFUS wild-type allele is located in the vicinity of 8q24.3 and is approximately 5 kb in length. This allele, which encodes GDP-L-fucose synthase protein, plays a role in GDP-L-fucose synthesis.","GFUS wt Allele | FX | GDP-Keto-6-Deoxymannose 3,5-Epimerase, 4-Reductase Gene | GDP-L-Fucose Synthase wt Allele | P35B | SDR4E1 | Short Chain Dehydrogenase/Reductase Family 4E, Member 1 Gene | Tissue Specific Transplantation Antigen 3 Gene | Tissue Specific Transplantation Antigen P35B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936052","CLN3 Gene","C156970","This gene plays a role in endosome and lysosome transport.","CLN3 Gene | CLN3 | CLN3, Battenin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936053","CLN3 wt Allele","C156971","Human CLN3 wild-type allele is located in the vicinity of 16p12.1 and is approximately 29 kb in length. This allele, which encodes battenin protein, is involved in microtubule-dependent transport of organelles. Deletions within the gene are associated with neuronal ceroid lipofuscinosis type 3 (Batten disease).","CLN3 wt Allele | BTN1 | BTS | Batten, Spielmeyer-Vogt Disease Gene | CLN3, Battenin wt Allele | Ceroid-Lipofuscinosis, Neuronal 3 Gene | JNCL | Juvenile Neuronal Ceroid Lipofuscinosis Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936050","CLN3 protein, human","C156972","Battenin (438 aa, ~48 kDa) is encoded by the human CLN3 gene. This protein plays a role in anterograde transport of late endosomes and lysosomes.","Battenin | Batten Disease Protein | CLN3 | Protein CLN3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0220726","Diastrophic Dysplasia","C156311","An autosomal recessive condition caused by mutation(s) in the SLC26A2 gene, encoding sulfate transporter. It is characterized by  cartilaginous and bony abnormalities, in particular very short arms and legs and the 'hitchhiker' thumb, resulting from deformity of the first metacarpal.","Diastrophic Dysplasia | DTD",,,,,,,,,,,,,,,"4238810","Diastrophic dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL563176","Derived Cell Line","C156445","A biospecimen generated by in vitro culturing of a single cell isolated from a tissue of interest.","Derived Cell Line | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935739","CDISC Clinical Classification COVI Test Name Terminology","C156672","Test names of clinical classification questions associated with the Covi Anxiety Scale (COVI) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification COVI Test Name Terminology | CC-COVI TEST | COVI01TN | Covi Anxiety Scale Clinical Classification Test Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935740","CDISC Clinical Classification COVI Test Code Terminology","C156673","Test codes of clinical classification questions associated with the Covi Anxiety Scale (COVI) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Clinical Classification COVI Test Code Terminology | CC-COVI TESTCD | COVI01TC | Covi Anxiety Scale Clinical Classification Test Code",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935737","COVI Clinical Classification Question","C156674","A question associated with the COVI clinical classification.","COVI Clinical Classification Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935727","COVI - Verbal Report","C156676","Covi Anxiety Scale (COVI) Verbal report.","COVI - Verbal Report | COVI01-Verbal Report | COVI0101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935728","COVI - Behavior","C156677","Covi Anxiety Scale (COVI) Behavior.","COVI - Behavior | COVI01-Behavior | COVI0102",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935725","COVI - Somatic Symptoms of Anxiety","C156678","Covi Anxiety Scale (COVI) Somatic symptoms of anxiety.","COVI - Somatic Symptoms of Anxiety | COVI01-Somatic Symptoms of Anxiety | COVI0103",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935726","COVI - Total Score","C156679","Covi Anxiety Scale (COVI) Total score.","COVI - Total Score | COVI01-Total Score | COVI0104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935731","5-FU Analog Prodrug NUC-3373","C156680","A phosphoramidate-based prodrug of the monophosphate (MP) form of 5-fluoro-2'-deoxyuridine (FUdR; FUDR), the active metabolite of fluorouracil (5-FU), an antimetabolite fluoropyrimidine analog of the pyrimidine nucleoside, with potential antineoplastic activity. Upon administration of the nucleotide analog prodrug fosifloxuridine nafalbenamide, fosifloxuridine nafalbenamide is readily taken up by tumor cells. In the tumor cell, the phosphoramidate moiety is removed and fosifloxuridine nafalbenamide is converted to its active form FUDR-MP. In turn, FUDR-MP binds to and inhibits thymidylate synthase (TS), resulting in the depletion of thymidine triphosphate (TTP) and thus DNA synthesis. With the phosphoramidate moiety attached to FUDR-MP, fosifloxuridine nafalbenamide, compared to 5-FU, is more lipophilic and accumulates in cancer cells by passive diffusion and does not require a nucleoside transporter, thereby generating higher intracellular concentrations. In addition, compared to 5-FU, once inside the cell FUDR-MP does not need to be phosphorylated and is already in its active form. Unlike 5-FU, fosifloxuridine nafalbenamide does not get deactivated or converted into toxic metabolites by dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (TP), which leads to both a longer half-life and less toxicity.","Fosifloxuridine Nafalbenamide | 5-FU Analog Prodrug NUC-3373 | FOSIFLOXURIDINE NAFALBENAMIDE | L-Alanine, N-(-2'-Deoxy-2',2'-difluoro-p-1-naphthalenyl-5'-cytidylyl)-, Phenylmethyl Ester | NUC 3373 | NUC-3373 | NUC3373 | Nucleotide Analog NUC-3373 | Phosphoramidate-FUDR-MP Prodrug NUC-3373",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562983","Anastrozole/Lapatinib Regimen","C156257","A regimen consisting of anastrozole and lapatinib that may be used in the treatment of breast cancer.","Anastrozole/Lapatinib Regimen | Anastrozole and Lapatinib | Anastrozole-Lapatinib | Anastrozole-Lapatinib Regimen | Anastrozole/Lapatinib | Lapatinib/Anastrozole Regimen | Tykerb/Anastrozole",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562977","Abemaciclib/Fulvestrant Regimen","C156258","A regimen consisting of abemaciclib and fulvestrant that may be used in the treatment of breast cancer.","Abemaciclib/Fulvestrant Regimen | Abemaciclib and Fulvestrant | Abemaciclib-Fulvestrant | Abemaciclib-Fulvestrant Regimen | Abemaciclib/Fulvestrant | Fulvestrant/Abemaciclib Regimen | Verzenio/Faslodex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562978","Anastrozole/Lapatinib/Trastuzumab Regimen","C156259","A regimen consisting of anastrozole, lapatinib, and trastuzumab that may be used in the treatment of breast cancer.","Anastrozole/Lapatinib/Trastuzumab Regimen | Anastrozole, Lapatinib, Trastuzumab | Anastrozole, Lapatinib, Trastuzumab-anns | Anastrozole, Lapatinib, Trastuzumab-dkst | Anastrozole, Lapatinib, Trastuzumab-dttb | Anastrozole, Lapatinib, Trastuzumab-herw | Anastrozole, Lapatinib, Trastuzumab-pkrb | Anastrozole, Lapatinib, Trastuzumab-qyyp | Anastrozole, Lapatinib, Trastuzumab-strf | Anastrozole, Lapatinib, Trastuzumab-zerc | Anastrozole-Lapatinib-Trastuzumab | Anastrozole-Lapatinib-Trastuzumab Regimen | Anastrozole/Lapatinib/Trastuzumab | Anastrozole/Tykerb/Herceptin | Tykerb/Anastrozole/Herceptin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562979","Temozolomide/Veliparib Regimen","C156260","A regimen consisting of temozolomide and veliparib that can potentially be used for the treatment of various cancers, such as non-small cell lung cancer (NSCLC) and acute myeloid leukemia (AML).","Temozolomide/Veliparib Regimen | ABT-888 and Temozolomide | Temozolomide Plus Veliparib | Temozolomide and Veliparib | Temozolomide-Veliparib | Temozolomide/ABT-888 | Temozolomide/Veliparib | Veliparib/Temozolomide | Veliparib/Temozolomide Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562980","CVD","C156261","A regimen consisting of cyclophosphamide, vincristine and dacarbazine that can be used for the treatment of malignant paraganglioma and pheochromocytoma.","Cyclophosphamide/Dacarbazine/Vincristine Regimen | CVD | Cyclophosphamide, Dacarbazine, Vincristine | Cyclophosphamide-Vincristine-Dacarbazine | Cyclophosphamide/Vincristine/Dacarbazine | Cyclophosphamide/Vincristine/Dacarbazine Regimen | Cytoxan/Vincristine/Dacarbazine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562973","Carboplatin-Doxil","C156262","A regimen consisting of carboplatin and liposomal doxorubicin that can be used for the treatment of ovarian, fallopian tube and primary peritoneal cancer.","Carboplatin/Liposomal Doxorubicin Regimen | Carboplatin and Pegylated liposomal doxorubicin | Carboplatin-Doxil | Carboplatin-Doxil Regimen | Doxil-Carboplatin | Doxil/Carboplatin | Doxil/Carboplatin Regimen | Liposomal Doxorubicin/Carboplatin Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562974","Adriamycin/Cyclophosphamide/Tamoxifen","C156263","A regimen consisting of doxorubicin, cyclophosphamide and tamoxifen that can potentially be used for the treatment of breast cancer.","AC-TAM Regimen | AC-TAM | Adriamycin/Cyclophosphamide/Tamoxifen | Doxorubicin-Cyclophosphamide-Tamoxifen | Doxorubicin/Cyclophosphamide/Tamoxifen | Doxorubicin/Cyclophosphamide/Tamoxifen Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562976","Fluorouracil/Mitomycin Regimen","C156265","A regimen consisting of fluorouracil and mitomycin that may be used for the treatment of a variety of cancers, such as anal, vulvar, bladder and penile cancer.","Fluorouracil/Mitomycin Regimen | Fluorouracil and Mitomycin | Fluorouracil-Mitomycin | Fluorouracil/Mitomycin | Mitomycin-5-FU | Mitomycin-Fluorouracil | Mitomycin/5-FU",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562969","Gemcitabine/Cisplatin/Everolimus Regimen","C156266","A regimen consisting of gemcitabine, cisplatin and everolimus that may be used for the treatment of a variety of cancers, such as urothelial, bladder and breast cancer.","Gemcitabine/Cisplatin/Everolimus Regimen | Everolimus/Gemcitabine/Cisplatin | GPE | Gemcitabine and Cisplatin with Everolimus | Gemcitabine-Cisplatin-Everolimus | Gemcitabine/Cisplatin/Everolimus | Gemcitabine/Platinol/Everolimus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562970","Thyroid Gland Mucinous Carcinoma","C156267","A rare primary carcinoma of the thyroid gland characterized by the presence of clusters of malignant epithelial cells associated with abundant extracellular mucin deposition.","Thyroid Gland Mucinous Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562971","Intrathyroidal Thymoma","C156268","A rare thymoma arising within or is attached to the thyroid gland.","Intrathyroidal Thymoma | Ectopic Thyroid Gland Thymoma | Ectopic Thyroid Gland Thymoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935670","Metastatic Neuroendocrine Neoplasm","C156485","A neuroendocrine neoplasm that has spread from its original site of growth to another anatomic site.","Metastatic Neuroendocrine Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935668","Advanced Neuroendocrine Neoplasm","C156486","A neuroendocrine neoplasm that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Neuroendocrine Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563098","TLR Agonist BDB001","C156395","A toll-like receptor type 7 and 8 (TLR7/8) agonist, with potential immunostimulating and antineoplastic activities. Upon administration, TLR7/8 agonist EIK1001 targets, binds to and activates TLR7 and 8, thereby activating TLR7/8-mediated pathways. This stimulates the maturation and activation of antigen-presenting cells (APCs), including dendritic cells (DCs). Activation of DCs results in the production of pro-inflammatory cytokines, and the activation of cytotoxic T-lymphocyte (CTL)- and B-lymphocyte-mediated immune responses. This may lead to tumor cell lysis. TLR7 and 8, members of the TLR family, play fundamental roles in the activation of the innate immune system, myeloid cell responses and tumor antigen presentation.","Toll-like Receptor 7/8 Agonist EIK1001 | BDB 001 | BDB-001 | BDB001 | EIK 1001 | EIK-1001 | EIK1001 | TLR Agonist BDB001 | TLR Agonist BDB001 | TLR7/8 Agonist EIK1001 | Toll-like Receptor Agonist BDB001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3656593","Ceftolozane-Tazobactam","C156396","A combination preparation containing ceftolozane, a semi-synthetic, broad-spectrum, fifth-generation cephalosporin and tazobactam, a beta-lactamase inhibitor, with activity against Gram-negative and Gram-positive bacteria. Upon intravenous administration, ceftolozane binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. This interferes with the final transpeptidation step required to form peptidoglycan chain cross-links, which are a key component of and provide strength and rigidity to the bacterial cell wall. This inhibits bacterial cell wall synthesis and reduces cell wall stability, which weakens the bacterial cell wall and causes bacterial cell lysis. Tazobactam irreversibly inhibits certain penicillinases and cephalosporinases and covalently binds to some chromosomal and plasmid-mediated bacterial beta-lactamases, thereby protecting ceftolozane from degradation and improving ceftolozane's activity.","Ceftolozane-Tazobactam | CXA 201 | CXA-201 | CXA201 | Ceftolozane/Tazobactam | Zerbaxa",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563092","Ginseng/Lingzhi Mushroom/Cordyceps sinensis/Rose Oral Liquid","C156397","An orally available supplement containing ginseng, lingzhi mushroom, Cordyceps sinensis, and rose with potential immunostimulating activities. Upon oral administration, ginseng/lingzhi mushroom/Cordyceps sinensis/rose oral liquid may, through a not yet elucidated mechanism, enhance immune responses and relieve fatigue.","Ginseng/Lingzhi Mushroom/Cordyceps sinensis/Rose Oral Liquid | Ginseng/Lingzhi Mushroom/Cordyceps sinensis/Rose Supplement | Shen-Ling-Cao | Shenlingcao Oral Liquid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563093","Monoclonal Antibody NEO-201","C156398","A humanized immunoglobulin G1 (IgG1) monoclonal antibody derived from an immunogenic preparation of tumor-associated antigens (TAAs) from pooled allogeneic colon cancer tissue extracts, with potential antineoplastic and immunomodulatory activities. Upon intravenous administration, monoclonal antibody NEO-201 targets and binds to malignant tissues with tumor-specific mutations in the membrane-anchored proteins, carcinoembryonic antigen-related cell adhesion molecules 5 and 6 (CEACAM5 and CEACAM6). This prevents the interaction between tumor cell CEACAM 5 and natural killer (NK) cell CEACAM1, and reverses CEACAM1-dependent inhibition of NK cytotoxicity. This may result in the activation of NKs and results in NK-mediated tumor cell killing. Additionally, monoclonal antibody NEO-201 may activate innate immune responses against tumor cells such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). CEACAM 5, and 6 are members of the CEA family of proteins. These membrane proteins are over expressed in a variety of cancer cell types and play a key role in cell migration, invasion, and adhesion.","Monoclonal Antibody NEO-201 | NEO 201 | NEO-201 | NEO201 | Neoantigen-targeting Antibody NEO-201 | h16C3 | h16C3 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563094","AMG 427","C156399","A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) FLT3 tyrosine kinase receptor (Fms-like tyrosine kinase 3; FLT3; FLT-3; CD135; fetal liver kinase-2; FLK2), fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, emirodatamab binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and FLT3 found on FLT3-expressing tumor cells. This activates and redirects CTLs to FLT3-expressing tumor cells, which results in the CTL-mediated cell death of FLT3-expressing tumor cells. FLT3, a cytokine receptor belonging to the class III tyrosine kinase receptors, is overexpressed or mutated in most B-lineage and acute myeloid leukemias (AMLs).","Emirodatamab | AMG 427 | AMG-427 | AMG427 | Anti-FLT3 x Anti-CD3 BiTE AMG 427 | Anti-FLT3/CD3 BiTE Antibody AMG 427 | Anti-FLT3/CD3 BiTE Antibody AMG 427 | BiTE Antibody AMG 427 | Bispecific T-cell Engager Antibody AMG 427 | EMIRODATAMAB | FLT3/CD3-directed Bispecific T-cell Engager Antibody AMG 427",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0393009","Level of Evidence","C15639","A formal ranking system of the strength of evidence linked to a reported result.","Level of Evidence | levels of evidence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935780","Attributable, Legible, Contemporaneous, Original, Accurate","C156621","Fundamental elements of data integrity as described by the US Food and Drug Administration; this acronym stands for attributable, legible, contemporaneous, original, and accurate.","Attributable, Legible, Contemporaneous, Original, Accurate | ALCOA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935732","PSMA/CD3 Tri-specific T-cell Activating Construct HPN424","C156681","A recombinant antibody derivative composed of tri-specific T-cell activating construct (TriTAC) directed against the human tumor-associated antigen (TAA) prostate-specific membrane antigen (PSMA; FOLH1) and the CD3 antigen found on T-lymphocytes and an albumin-binding domain, with potential immunostimulating and antineoplastic activities.  Upon administration, PSMA/CD3 tri-specific T-cell antibody construct HPN424 targets and binds PSMA on tumor cells and CD3 on cytotoxic T-lymphocytes (CTLs), thereby bringing PSMA-expressing tumor cells and CTLs together, which results in the CTL-mediated cell death of PSMA-expressing tumor cells. The albumin-binding domain targets and binds to serum albumin, thereby extending the serum half-life of HPN424. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate tumor cells.","PSMA/CD3 Tri-specific T-cell Activating Construct HPN424 | Anti-PSMA/CD3 TriTAC HPN424 | HPN 424 | HPN-424 | HPN424 | PSMA/CD3 TriTAC HPN424 | PSMA/CD3-specific TriTAC HPN424 | TriTAC HPN424",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935729","Metastatic Gastric Neuroendocrine Carcinoma","C156682","A gastric neuroendocrine carcinoma that has spread from its original site of growth to another anatomic site.","Metastatic Gastric Neuroendocrine Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936000","Other Investigational Agent","C156875","An investigational agent that is not the lead agent being investigated in a clinical trial.","Other Investigational Agent | Other Clinical Trial Agent | Other Study Agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936003","Quit2Heal","C156878","A smartphone-based application for smoking cessation specifically tailored to cancer patients. Quit2Heal is designed for the specific needs of the cancer patient, which include high prevalence of comorbid mental disorders, distress from cancer diagnosis, and lack of awareness of smoking's effects on treatments and outcomes.","Quit2Heal | Quit2Heal App | Quit2Heal Smartphone App | Quit2Heal Smartphone Application",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936004","QuitGuide","C156879","A smartphone-based application designed to help an individual to understand their smoking patterns and build the skills needed to become and stay smokefree. The app can be used to track cravings by time of day and location, and get motivational messages for each tracked craving.","QuitGuide | QuitGuide App | QuitGuide Smartphone App | QuitGuide Smartphone Application",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935994","HSP90 Inhibitor","C156880","Any agent that inhibits heat shock protein (Hsp) 90.","HSP90 Inhibitor | Heat Shock Protein 90 Inhibitor | Hsp 90 Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935995","Anti-CD22 ADC TRPH-222","C156882","An antibody-drug conjugate (ADC) composed of an anti-CD22 humanized monoclonal antibody site-specifically conjugated to, via formylglycine (FG) residues and a protease insensitive 4AP linker, a cytotoxic microtubule-targeting maytansinoid payload, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of TRPH-222 binds to B-cell-specific CD22 receptors and is rapidly internalized, thereby delivering the payload intracellularly. Upon proteolytic cleavage, the maytansinoid payload binds to tubulin, disrupting microtubule assembly/disassembly dynamics, inhibiting both cell division and tumor cell proliferation. CD22, a cell surface sialoglycoprotein, is expressed on mature B-cells and on most malignant B-cells. The site specific and stable conjugation to the payload allows for a higher drug-to-antibody ratio (DAR) and an enhanced therapeutic index.","Anti-CD22 ADC TRPH-222 | Anti-CD22 Antibody-drug Conjugate TRPH-222 | Anti-CD22-4AP ADC TRPH-222 | CAT-02-106 | TRPH 222 | TRPH-222 | TRPH222",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935669","Advanced Carcinoid Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2609093","Metastatic Pancreatic Neuroendocrine Tumor","C156488","A neuroendocrine tumor that arises from the islet cells of the pancreas and has spread to another anatomic site.","Metastatic Pancreatic Neuroendocrine Tumor | Metastatic Pancreatic Islet Cell Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935673","Advanced Pancreatic Neuroendocrine Tumor","C156489","A pancreatic neuroendocrine tumor that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Pancreatic Neuroendocrine Tumor | Advanced Pancreatic Islet Cell Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0444889","Continuous Infusion Procedure","C15648","No value exists.","Continuous Infusion Procedure | Continuous Infusion | continuous infusion",,,,,,,,,,,,,,,"4129275","Continuous infusion",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL935671","Anti-ILDR2 Inhibitor BAY1905254","C156490","A mouse/human cross-reactive immunoglobulin G2 (IgG2) monoclonal antibody against the immune checkpoint immunoglobulin-like domain containing receptor 2 (ILDR2; Chromosome 1 Open Reading Frame 32; C1orf32), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, bapotulimab targets, binds to and inhibits ILDR2, thereby blocking the immunosuppressive activity of ILDR2. This prevents ILDR2-mediated inhibition of T-cell activities and induces a cytotoxic T-lymphocyte (CTL) response against tumor cells. ILDR2, a type I transmembrane protein belonging to the B7 family of immunomodulatory receptors, negatively regulates T-cell responses.","Bapotulimab | Anti-ILDR2 Inhibitor BAY1905254 | Anti-ILDR2 Monoclonal Antibody BAY 1905254 | Anti-immunoglobulin-like Domain Containing Receptor 2 MoAb BAY1905254 | BAPOTULIMAB | BAY 1905254 | BAY-1905254 | BAY1905254 | ILDR2 Function-blocking Antibody BAY1905254 | Immune Checkpoint Inhibitor BAY1905254",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935672","Metastatic Digestive System Neuroendocrine Neoplasm","C156492","A neuroendocrine neoplasm that arises from any part of the digestive system and has metastasized to another anatomic site.","Metastatic Digestive System Neuroendocrine Neoplasm | Metastatic Gastroenteropancreatic Neuroendocrine Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935662","Metastatic Breast Neuroendocrine Neoplasm","C156493","A neuroendocrine neoplasm that arises from the breast and has metastasized to another anatomic site.","Metastatic Breast Neuroendocrine Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935660","Number of Unsuppressed Water Averages","C156495","The integer that describes that number of averages that are captured of the unsuppressed water spectrum signal during imaging.","Number of Unsuppressed Water Averages | USH2OAVN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935661","Spectral Width","C156496","The width of the wavelength interval at half maximum amplitude.","Spectral Width | SPECTWD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935666","X-Axis Voxel Dimension","C156497","The linear measurement of a voxel along the X-axis.","X-Axis Voxel Dimension | VOXDIMX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935667","Y-Axis Voxel Dimension","C156498","The linear measurement of a voxel along the Y-axis.","Y-Axis Voxel Dimension | VOXDIMY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935664","Z-Axis Voxel Dimension","C156499","The linear measurement of a voxel along the Z-axis.","Z-Axis Voxel Dimension | VOXDIMZ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448789","Diet Research","C15649","No value exists.","Diet Research | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280970","Pyrazoloacridine","C1564","A 9-methoxy acridine compound containing a reducible 5-nitro substituent.  Pyrazoloacridine appears to intercalate into DNA and inhibit RNA synthesis, DNA synthesis, and the activities of topoisomerases I and II, thereby causing cytotoxicity. (NCI04)","Pyrazoloacridine | PYRAZOLOACRIDINE | pyrazoloacridine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935665","Voxel Orientation","C156500","The orientation of the voxel relative to the coordinate system of the scanner. May be measured in degrees or radians depending on the scanner make and model.","Voxel Orientation | VOXORIEN | Voxel Angle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935771","Attributable, Legible, Contemporaneous, Original, Accurate Plus","C156622","A modified guide to the fundamental elements of data integrity originally described by the US Food and Drug Administration; this acronym stands for attributable, legible, contemporaneous, original, and accurate, as well as the additional elements of complete, consistent, enduring, and available.","Attributable, Legible, Contemporaneous, Original, Accurate Plus | ALCOA + | ALCOA Plus | ALCOA+",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935772","Individual Exposure","C156623","An exposure measured in direct proximity to an individual.","Individual Exposure | exposure (individual)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935769","Extent of Exposure","C156624","An assessment of the amount, duration, and number of individuals affected by an exposure.","Extent of Exposure | extent of exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935770","Device Manufacture","C156625","A person or entity that designs, manufactures, fabricates, assembles, or processes a finished device.","Device Manufacture | manufacturer (device)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935774","Drug Manufacturer","C156626","A person or entity that is engaged in the manufacturing, preparing, propagating, compounding, processing, packaging, repackaging, or labeling of a prescription drug.","Drug Manufacturer | manufacturer (drug)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3544346","Device Use Error","C156628","An error associated with the use of a medical device, due to problems with the design of the device or the manner in which the device is used, that causes or leads to inappropriate device use or patient harm.","Device Use Error | use error (device)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935773","Anticipated Adverse Event",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1643975","Neuroprotection","C15662","The use of drugs to protect nerve cells from damage by cancer therapy agents.","Neuroprotection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935703","Clinical Trial Temporary Halt","C156630","An interruption in clinical trial activity by the sponsor that is not in the clinical protocol, with an intention to resume the study.","Clinical Trial Temporary Halt | temporary halt (of a clinical trial)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935704","Clinical Trial Suspension","C156631","An interruption in some or all clinical trial activities.","Clinical Trial Suspension | suspension (of a clinical trial)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935701","Clinical Outcome Assessment Content Validation","C156632","A performance outcome measure that assesses the degree of correspondence between clinical outcome assessment measures and how patients feel or function in everyday life.","Clinical Outcome Assessment Content Validation | content validation (COA) | content validation (re COA)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935707","Clinical Outcome Assessment Criterion Validation","C156634","A performance outcome measure that assesses the degree to which the scores of a clinical outcome assessment instrument are related to a known gold standard measure of the same concept.","Clinical Outcome Assessment Criterion Validation | criterion validation (COA) | criterion validation (re COA)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935708","Mutual Recognition Procedure","C156635","A European authorization process in which a marketing authorization holder for a product that is already authorized in at least one Member State, known as the Reference Member State, seeks to obtain marketing authorization for the same product in at least one other Member State, known as the Concerned Member State(s).","Mutual Recognition Procedure | MRP | mutual recognition procedure (MRP)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935705","Serious Breach","C156636","A deviation from clinical trial protocol that is likely to affect, to a significant degree, the safety, physical, or mental integrity of the subjects of the trial, or the scientific value of the trial.","Serious Breach | serious breach",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935706","Privacy Breach","C156637","Unauthorized access to, or disclosure of, an individual's personal information.","Privacy Breach | privacy breach",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935992","Autologous CD4+/CD8+ EGFR806 Specific 4-1BB-CD3zeta-EGFRt-expressing CAR T Cells","C156883","A preparation of CD4+ and CD8+ autologous T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) composed of a short chain variable fragment (scFv) binding domain derived from depatuxizumab, a human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MAb806; ABT-806), coupled to the zeta chain of the TCR/CD3 complex (CD3-zeta) and the signaling domain of 4-1BB (CD137),  and linked to a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Depatuxizumab specifically targets abnormal conformational states of EGFR, including the EGFR deletion mutation variant III (EGFRvIII), and activating mutations, with very low affinity for wild-type EGFR. Upon intravenous administration, the autologous CD4+/CD8+ EGFR806 specific 4-1BB-CD3zeta-EGFRt-expressing CAR T-cells are directed to and induce selective toxicity in EGFRvIII-expressing tumor cells. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of these cells through an anti-EGFR antibody-dependent cellular cytotoxicity (ADCC) response. EGFRvIII, an in-frame deletion of exons 2-7 in the EGFR gene, is overexpressed by a variety of cancer cell types but absent in normal, healthy cells. It plays a key role in tumor cell proliferation, tumor angiogenesis and resistance to both radio- and chemotherapy.","Autologous CD4+/CD8+ EGFR806 Specific 4-1BB-CD3zeta-EGFRt-expressing CAR T Cells | Autologous CD4+/CD8+ T Cells Expressing EGFR806-specific CAR/EGFRt | Autologous EGFR806 Specific CAR T Cells | Autologous EGFR806-specific CAR T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0338238","H2 Receptor Antagonist Therapy","C15621","A type of treatment that uses histamine H2-receptor antagonists.","H2 Receptor Antagonist Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935866","Benign Peritoneal and Retroperitoneal Neoplasm","C156713","A neoplasm that arises from the peritoneum and/or retroperitoneum and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","Benign Peritoneal and Retroperitoneal Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935865","Recurrent Acute Myeloid Leukemia Not Otherwise Specified","C156716","The reemergence of acute myeloid leukemia not otherwise specified after a period of remission.","Recurrent Acute Myeloid Leukemia Not Otherwise Specified | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935860","Recurrent Acute Myeloid Leukemia with Recurrent Genetic Abnormalities","C156718","The reemergence of acute myeloid leukemia with recurrent genetic abnormalities after a period of remission.","Recurrent Acute Myeloid Leukemia with Recurrent Genetic Abnormalities | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677799","Screening for Endometrial Cancer","C15671","No value exists.","Screening for Endometrial Cancer | early detection of endometrial cancer | endometrial cancer early detection | endometrial cancer screening",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935861","Total Lymphoid Irradiation","C156721","The use of extensive lymphatic irradiation to achieve immunosuppression. The irradiated areas includ the cervical, supraclavicular, and axillary lymph nodes, and the mediastinal region, as well as the the porta hepatis, celiac nodes, splenic pedicle and spleen, and para-aortic, iliac, inguinal, and femoral nodes.","Total Lymphoid Irradiation | TLI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2861609","Acute Myeloid Leukemia with Multilineage Dysplasia in Remission","C156724","A finding of acute myeloid leukemia with multilineage dysplasia that is not growing and responds to treatment.","Acute Myeloid Leukemia with Multilineage Dysplasia in Remission | Acute myeloid leukemia with multilineage dysplasia, in remission",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2861617","Acute Monoblastic and Monocytic Leukemia in Remission","C156725","A finding of acute monoblastic and monocytic leukemia that is not growing and responds to treatment.","Acute Monoblastic and Monocytic Leukemia in Remission | Acute monoblastic/monocytic leukemia, in remission",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936124","Month-Day-Year","C156816","A format of a date in time, with the month followed by the date followed by the year.","Month-Day-Year | MM/DD/YYYY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512044","Dose Rate","C15682","The amount of any substance administered over a specific period of time.","Dose-Rate | DOSFRQ | dose-rate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935896","Melanoma Risk Factor","C156749","Any factor, such as age, ethnicity, genetic factor, family history, or environmental factor, that increases a person's chance of developing melanoma.","Melanoma Risk Factor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677841","Prevention of Endometrial Cancer","C15674","No value exists.","Prevention of Endometrial Cancer | Endometrial Cancer Prevention",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935889","Proximity Ligation Assay","C156754","A technique that leverages immunoassay and DNA amplification technology to detect protein-protein interactions with high specificity and sensitivity. A sample is prepared and then exposed to primary antibodies raised in different species recognizing the target epitopes on the proteins of interest. Then, secondary antibodies that are tagged with short oligonucleotides and that target each primary antibody are added. Next, a mixture comprised of a ligase, PCR components and a connector oligonucleotide, which hybridizes to both oligonucleotide tags and can prime rolling DNA circle synthesis, are added and the sample is subjected to real-time PCR to amplify the DNA circles. Rolling circle synthesis and amplification is only possible if the protein epitopes are in close proximity (i.e. in a protein complex). Finally, a labeled complementary nucleotide probe is added to detect and/or visualize the amplified DNA.","Proximity Ligation Assay | PLA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935888","ADENOMA, PARATHYROID GLAND, BENIGN","C156757","A benign ovoid parathyroid gland neoplasm surrounded by a pseudocapsule. It is composed of chief cells, clear cells, oncocytic cells, or a mixture of cell types. It lacks the morphological characteristics of parathyroid gland carcinoma and there is no evidence of capsular invasion, vascular invasion, and perineural invasion.","Parathyroid Gland Adenoma | ADENOMA, PARATHYROID GLAND, BENIGN | Benign Parathyroid Gland Adenoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935855","CS 1003","C156726","A humanized, immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, nofazinlimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","Nofazinlimab | Anti-PD-1 Monoclonal Antibody CS1003 | CS 1003 | CS-1003 | CS1003 | NOFAZINLIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936132","Canonical BAF Complex","C156919","A SWI/SNF family chromatin-remodeling complex comprised of at least ACTB, ARID1A/BAF250A or ARID1B/BAF250B, SMARCA2/BRM and/or SMARCA4/BRG1/BAF190A, ACTL6A/BAF53 or ACTL6B/BAF53B, DPF1/BAF45B, DPF2/BAF45D or DPF3/BAF45C, SMARCE1/BAF57, SMARCC1/BAF155, SMARCC2/BAF170, SMARCB1/SNF5/INI1, BCL7A, BCL7B or BCL7C, and SMARCD1/BAF60A, SMARCD2/BAF60B or SMARCD3/BAF60C.","Canonical BAF Complex | BAF | BAF Complex | BRG1- or hBRM-Associated Factor | BRG1-Associated Factor | BRM/BRG1 Associated Factor | BRM/BRG1-Associated Factor | Brg/Brahma-Associated Factor | Canonical BAF | SWI/SNF-A | cBAF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936117","Neuron-Specific BAF Complex","C156920","A SWI/SNF family chromatin-remodeling complex expressed in postmitotic neurons and comprised of at least ACTB, ARID1A/BAF250A, ARID1B/BAF250B or ARID2/BAF200, BCL11A or BCL11B, SMARCA2/BRM/BAF190B or SMARCA4/BRG1/BAF190A, ACTL6B/BAF53B, SMARCB1/BAF47, SMARCC1/BAF155, SMARCE1/BAF57, SMARCC2/BAF170, SS18L1/CREST, PBRM1/BAF180, DPF1/BAF45B or DPF3/BAF45C, BCL7A, BCL7B or BCL7C, and SMARCD1/BAF60A, SMARCD2/BAF60B or SMARCD3/BAF60C.","Neuron-Specific BAF Complex | Neuron-Specific BAF | Neuronal BAF | nBAF | nBAF Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936118","Neural Progenitors-Specific BAF","C156921","A SWI/SNF family chromatin-remodeling complex expressed in neural progenitor cells and comprised of at least ACTB, ARID1A/BAF250A or ARID1B/BAF250B, SMARCD1/BAF60A, BCL11A or BCL11B, SMARCA2/BRM/BAF190B or SMARCA4/BRG1/BAF190A, ACTL6A/BAF53A, SMARCB1/BAF47, SMARCC1/BAF155, SMARCE1/BAF57, SMARCC2/BAF170, SS18, PBRM1/BAF180, PHF10/BAF45A or DPF2/BAF45D, and BCL7A, BCL7B or BCL7C.","Neural Progenitor-Specific BAF Complex | Neural Progenitors-Specific BAF | npBAF | npBAF Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL567678","PBAF Complex","C156922","A SWI/SNF family chromatin-remodeling complex comprised of at least ACTB, BRD7, PHF10/BAF45A, SMARCA4/BRG1 and/or SMARCB1/BAF47/SNF5, ACTL6A/BAF53A or ACTL6B/BAF53B, SMARCE1/BAF57, SMARCC1/BAF155, SMARCC2/BAF170, PBRM1/BAF180, ARID2/BAF200, and SMARCD1/BAF60A, SMARCD2/BAF60B or SMARCD3/BAF60C.","PBAF Complex | PBAF | Polybromo- and BAF Containing Complex | Polybromo-Associated BAF | Polybromo-Associated BAF Complex | Polybromo-Associated BRM/BRG1-Associated Factor | Polybromo-BAF | SWI/SNF-B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935907","Non-Canonical BAF Complex","C156923","A SWI/SNF family chromatin-remodeling complex comprised of least ACTB, BICRA (GLTSCR1) or BICRAL (GLTSCR1L), BRD9, SS18 or SS18L1/CREST, SMARCA2/BRM or SMARCA4/BRG1/BAF190A, ACTL6A/BAF53A or ACTL6B/BAF53B, SMARCC1/BAF155, and SMARCD1/BAF60A, SMARCD2/BAF60B or SMARCD3/BAF60C.","Non-Canonical BAF Complex | BRD9/GLTSCR1-Specific BAF | GBAF | GBAF Complex | Glioma Tumor Suppressor Candidate Region-Associated BAF | Non-Canonical BAF | Noncanonical BAF | Noncanonical BRM/BRG1-Associated Factor | ncBAF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935908","Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901","C156925","A personalized cancer vaccine comprised of a chimpanzee adenovirus vector (ChAdV) encoding twenty tumor-specific neoantigens (TSNAs) that have been identified through genetic sequencing of a patient's tumor cells, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration of lutadenovec autogene, the adenovirus infects cells and expresses the TSNAs. This stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the TSNAs, leading to tumor cell lysis. Adenoviral-TSNA vaccine GRT-C901 is followed by monthly boosting with a self-amplifying mRNA (SAM) boosting vaccine that encodes the same 20 target TSNAs. The combined immunotherapy product, consisting of priming and boosting vaccines, is referred to as GRANITE-001.","Lutadenovec Autogene | Adenoviral TSNA Priming Vaccine GRT-C901 | Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901 | Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901 | GRT C901 | GRT-C901 | GRTC901 | LUTADENOVEC AUTOGENE | Priming Cancer Vaccine GRT-C901",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563026","Curcumin/Chondroitin Sulfate/Hyaluronic Acid/Quercetin Soft Gels","C156174","An orally available preparation containing curcumin, quercetin, hyaluronic acid, and chondroitin sulfate with potential radioprotective activity. Upon administration, the glycosaminoglycans may improve barrier function and reduce inflammation and irritation in the genitourinary tract caused by radiotherapy.","Curcumin/Chondroitin Sulfate/Hyaluronic Acid/Quercetin Soft Gels | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563027","Alkylglycerol/Rosemary Capsules","C156175","An orally available capsule containing alkylglycerols and Rosmarinus officinalis extracts standardized to diterpenes, including carnosic acid and carnosol, with potential antineoplastic and anti-inflammatory activities. Upon administration, carnosic acid and carnosol may induce apoptosis by decreasing apoptosis regulator B-cell lymphoma 2 (Bcl-2) expression, decrease tumor cell growth through inhibition of mammalian target of rapamycin (mTOR) phosphorylation, and inhibit metastatic activity by preventing the adhesion of tumor cells to type I collagen and fibronectin. Additionally, these diterpenes may decrease inflammation by downregulating cyclooxygenase (COX) type 2 (COX-2) protein synthesis. Alkylglycerols (alkyl-Gro) are bioactive ether lipids that may, through a not yet fully elucidated mechanism, inhibit tumor cell growth and metastases.","Alkylglycerol/Rosemary Capsules | Alkylglycerol and Rosemary Capsules | Rosemary/Alkylglycerol Dietary Supplement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563028","MSC 1","C156176","A humanized immunoglobulin G1 (IgG1) monoclonal antibody against leukemia inhibitory factor (LIF), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, falbikitug binds to LIF and inhibits LIF signaling by blocking the recruitment of glycoprotein 130 (gp130) to the LIF-LIF receptor (LIFR)-gp130 signaling complex. This inhibits signal transducer and activator of transcription 3 (STAT3) signaling and inhibits tumor cell growth. In addition, the inhibition of LIF signaling abrogates the immunosuppressive tumor microenvironment (TME) by decreasing immunosuppressive M2 macrophages and allows for the activation of natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs) against tumor cells. LIF, a member of the interleukin-6 (IL-6) family of cytokines, is involved in many physiological and pathological processes and plays an important role in both creating the TME and promoting the activity of cancer-initiating cells (CICs). LIF is overexpressed in many tumor cell types and its expression correlates with poor prognosis.","Falbikitug | AZD 0171 | AZD-0171 | AZD0171 | Anti-LIF Monoclonal Antibody MSC-1 | Anti-LIF Monoclonal Antibody MSC-1 | FALBIKITUG | MSC 1 | MSC-1 | MSC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563029","Anti-LAG-3 Monoclonal Antibody Sym022","C156177","A recombinant, human Fc-inert monoclonal antibody targeting lymphocyte-activation gene 3 protein (LAG-3; LAG3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, monoclonal antibody Sym022 binds to human LAG-3 and blocks the interaction between LAG-3 and major histocompatibility complex class II (MHCII) molecules on the surface of antigen-presenting cells (APCs) and tumor cells. This prevents the negative regulation of T-cell activity that occurs via LAG-3-MHCII binding and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Additionally, Sym022 decreases LAG-3 surface levels through internalization and shredding. LAG-3 plays a key role in the activation of T-cells and natural killer (NK) cells.","Anti-LAG-3 Monoclonal Antibody Sym022 | SYM-022 | Sym 022 | Sym-022 | Sym022",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935878","PRMT1 Inhibitor GSK3368715","C156759","An orally available inhibitor of protein arginine N-methyltransferase 1 (PRMT1; Histone-arginine N-methyltransferase PRMT1; Interferon receptor 1-bound protein 4) with potential antineoplastic activity. Upon administration, GSK3368715 inhibits monomethylation and asymmetric dimethylation of arginine-bearing substrates, including histones, estrogen receptors, RNA-binding proteins, and numerous non-histone substrates catalyzed by PRMT1. This may inhibit tumor cell proliferation, migration, and invasion that is potentially driven by PRMT1 overexpression or dysregulation. PRMT1-mediated methylation plays a key role in the modulation of protein function, gene expression and cellular signaling. Dysregulation and overexpression of PRMT1 has been associated with a number of solid and hematopoietic cancers.","PRMT1 Inhibitor GSK3368715 | GSK 3368715 | GSK-3368715 | GSK3368715 | Protein Arginine Methyltransferase 1 Inhibitor GSK3368715",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563167","Dexverapamil Hydrochloride","C156452","The R-enantiomer of the calcium channel blocker verapamil. Dexverapamil competitively inhibits the multidrug resistance efflux pump P-glycoprotein (MDR-1), thereby potentially increasing the effectiveness of a wide range of antineoplastic drugs which are inactivated by MDR-1 mechanisms.  This agent exhibits decreased calcium antagonistic activity and toxicity compared to racemic verapamil. (NCI04)","Dexverapamil Hydrochloride | DEXVERAPAMIL HYDROCHLORIDE | R Verapamil Hydrochloride | R-Verapamil Hydrochloride | Verapamil (R)-form Hydrochloride | Verapamil Hydrochloride, (+)-",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563168","Recurrent Primary Peritoneal Serous Adenocarcinoma","C156453","The reemergence of primary peritoneal serous adenocarcinoma after a period of remission.","Recurrent Primary Peritoneal Serous Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563169","Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma","C156454","The reemergence of primary peritoneal low grade serous adenocarcinoma after a period of remission.","Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563192","Recurrent Low Grade Ovarian Serous Adenocarcinoma","C156455","The reemergence of ovarian low-grade serous adenocarcinoma after a period of remission.","Recurrent Ovarian Low Grade Serous Adenocarcinoma | Recurrent Low Grade Ovarian Serous Adenocarcinoma | Recurrent Ovarian Low-Grade Serous Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563193","Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma","C156456","The reemergence of low grade fallopian tube serous adenocarcinoma after a period of remission.","Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563194","ESCC","C156457","A small cell neuroendocrine carcinoma that arises from an anatomic site other than the lung.","Extrapulmonary Small Cell Neuroendocrine Carcinoma | ESCC | Extrapulmonary SCC | Extrapulmonary Small Cell Carcinoma | Small cell car. (extrapulmonary) | Small cell carcinoma (extrapulmonary)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556162","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Moderate Activity","C155536","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Moderate-intensity leisure activity (bicycling on level terrain, etc.).","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Moderate Activity | FAC100-Sev: Moderate Activity | FAC10055",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935730","Advanced Gastric Neuroendocrine Carcinoma","C156683","A gastric neuroendocrine carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Gastric Neuroendocrine Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935719","Advanced Gastric Large Cell Neuroendocrine Carcinoma","C156684","A gastric large cell neuroendocrine carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Gastric Large Cell Neuroendocrine Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935720","Advanced Gastric Small Cell Neuroendocrine Carcinoma","C156685","A gastric small cell neuroendocrine carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Gastric Small Cell Neuroendocrine Carcinoma | Advanced Gastric Small Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935717","Metastatic Small Intestinal Neuroendocrine Carcinoma","C156686","A small intestinal neuroendocrine carcinoma that has spread from its original site of growth to another anatomic site.","Metastatic Small Intestinal Neuroendocrine Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935718","Advanced Small Intestinal Neuroendocrine Carcinoma","C156687","A small intestinal neuroendocrine carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Small Intestinal Neuroendocrine Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935723","Advanced Small Intestinal Small Cell Neuroendocrine Carcinoma","C156688","A small intestinal small cell neuroendocrine carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Small Intestinal Small Cell Neuroendocrine Carcinoma | Advanced Small Intestinal Small Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935911","mRNA-based Tumor-specific Neoantigen Boosting Vaccine GRT-R902","C156926","An mRNA-based, personalized cancer vaccine consisting of a self-amplifying mRNA (SAM), formulated in a lipid nanoparticle (LNP), targeting twenty tumor-specific neoantigens (TSNAs) that have been identified through genetic sequencing of a patient's tumor cells, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration of sapecmeran autogene, the mRNA is taken up and translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of APCs. This leads to an induction of both cytotoxic T-lymphocyte and memory T-cell dependent immune responses that specifically target and destroy the patient's cancer cells that express these neoantigens. mRNA-based TSNA boosting vaccine is administered after a single dose of the adenoviral tumor-specific neoantigen priming vaccine GRT-C901.  The combined immunotherapy product, consisting of priming and boosting vaccines, is referred to as GRANITE-001.","Sapecmeran Autogene | Boosting Cancer Vaccine GRT-R902 | GRT R902 | GRT-R902 | GRTR902 | SAPECMERAN AUTOGENE | mRNA-based TSNA Boosting Vaccine GRT-R902 | mRNA-based Tumor-specific Neoantigen Boosting Vaccine GRT-R902 | mRNA-based Tumor-specific Neoantigen Boosting Vaccine GRT-R902",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935912","PPIA Gene","C156927","This gene plays a role in protein folding, cyclosporin binding and HIV virion assembly.","PPIA Gene | PPIA | Peptidylprolyl Isomerase A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935909","PPIA wt Allele","C156928","Human PPIA wild-type allele is located in the vicinity of 7p13 and is approximately 28 kb in length. This allele, which encodes peptidyl-prolyl cis-trans isomerase A protein, is involved in viral replication, protein folding and immunosuppression.","PPIA wt Allele | CYPA | CYPH | HEL-S-69p | Peptidylprolyl Isomerase A (Cyclophilin A) Gene | Peptidylprolyl Isomerase A wt Allele | T Cell Cyclophilin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562972","Locally Advanced Pancreatic Adenocarcinoma","C156269","A pancreatic adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Pancreatic Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0338268","Neuroendocrine Therapy","C15626","No value exists.","Neuroendocrine Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562995","TAK 981","C156270","A small molecule inhibitor of sumoylation, with potential immune-activating and antineoplastic activities. Upon intravenous administration, subasumstat targets and covalently binds to the small ubiquitin-like modifier (SUMO; small ubiquitin-related modifier) protein, forming an adduct with SUMO protein (subasumstat-SUMO adduct). This prevents the transfer of SUMO from the SUMO-activating enzyme (SAE) to SUMO-conjugating enzyme UBC9. This prevents SUMO conjugation to lysine residues on target proteins and abrogates many sumoylated protein-mediated cellular processes that play key roles in tumor cells, including proliferation, DNA repair, metastasis and survival. In addition, by preventing sumoylation, subasumstat is able to increase the production of type 1 interferon (IFN), thereby increasing type 1 IFN-mediated signaling, activating innate effector cells and enhancing the antitumor innate immune responses. This may further increase tumor cell killing. Sumoylation, a post-translational modification that attaches the SUMO protein to target proteins, plays a key role in regulating their activity, function, subcellular localization and stability.  Sumoylation also plays a key role in inhibiting innate immune responses, specifically by inhibiting the pattern recognition receptor (PRR) pathway and preventing type 1 IFN expression. Abnormal sumoylation of target proteins is associated with many cancers.","Subasumstat | SUBASUMSTAT | TAK 981 | TAK-981 | TAK981",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562996","Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T-lymphocytes huCART19","C156271","Autologous T-lymphocytes that have been transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) consisting of a humanized single chain variable fragment (scFv) of anti-CD19 coupled to the cytoplasmic portion of the zeta chain of the human T-cell receptor (CD3zeta) and the co-stimulatory molecule 4-1BB (CD137), with potential immunostimulating and antineoplastic activities. Upon re-introduction into the patient, the autologous anti-CD19 CAR TCR-zeta/4-1BB-transduced T-lymphocytes huCART19 target and bind to CD19-expressing neoplastic B-cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells, resulting in tumor cell lysis. CD19 (cluster of differentiation 19) is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. Incorporation of the co-stimulatory signaling domains increases human T-cell function, expansion, and survival.","Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T-lymphocytes huCART19 | Anti-CD19 CAR-T Cells huCART19 | Anti-CD19 Humanized scFv TCRz-41BB-CAR Lentiviral Vector-transduced Autologous T-lymphocytes | Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells huCART19 | CTL119 | CTL119 Cells | huCART19 Cells | huCART19 T-lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280858","Dexverapamil","C1563","The R-enantiomer of the calcium channel blocker verapamil. Dexverapamil competitively inhibits the multidrug resistance efflux pump P-glycoprotein (MDR-1), thereby potentially increasing the effectiveness of a wide range of antineoplastic drugs which are inactivated by MDR-1 mechanisms.  This agent exhibits decreased calcium antagonistic activity and toxicity compared to racemic verapamil. (NCI04)","Dexverapamil | DEXVERAPAMIL | R Verapamil | R-Verapamil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563095","Anetumab","C156400","A monoclonal antibody directed against the tumor-associated antigen (TAA) mesothelin.","Anetumab | ANETUMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563089","DARA Co-formulated with rHuPH20","C156401","A co-formulation composed of daratumumab, a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against the cell surface glycoprotein cluster of differentiation 38 (CD-38; CD38), and a recombinant form of human hyaluronidase (rHuPH20), with potential antineoplastic activity. Upon subcutaneous administration of daratumumab and hyaluronidase-fihj, daratumumab targets and binds to CD38 on certain CD38-expressing tumors, such as multiple myeloma (MM) and plasma cell leukemia. This binding induces direct apoptosis through Fc-mediated cross-linking and triggers immune-mediated tumor cell lysis through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP) immune responses. CD38, a transmembrane glycoprotein, is expressed in both hematopoietic and non-hematopoietic lineage cells. Hyaluronidase-fihj hydrolyzes and degrades the glycosaminoglycan hyaluronic acid (HA), thereby decreasing interstitial viscosity and enhancing penetration of daratumumab through the interstitial space. This facilitates the delivery of daratumumab to CD38-expressing tumor cells.","Daratumumab and Recombinant Human Hyaluronidase | DARA Co-formulated with rHuPH20 | DARA/rHuPH20 | Daratumumab + rHuPH20 | Daratumumab and Hyaluronidase | Daratumumab and Hyaluronidase-fihj | Daratumumab and Hyaluronidase-fihj | Daratumumab and Vorhyaluronidase Alfa | Daratumumab and hyaluronidase | Daratumumab and vorhyaluronidase | Daratumumab with rHuPH20 | Daratumumab-rHuPH20 | Daratumumab/Hyaluronidase-fihj | Daratumumab/rHuPH20 Co-formulation | Darzalex Faspro | Darzalex/rHuPH20 | Darzquro | HuMax-CD38-rHuPH20 | Recombinant Human Hyaluronidase Mixed with Daratumumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563090","ASP 1948","C156402","A human immunoglobulin G4 (IgG4) monoclonal antibody directed against neuropilin-1 (NRP1; CD304; BDCA-4), with potential immunomodulatory and antineoplastic activities. Upon administration, anti-NRP1 antibody ASP1948 specifically targets and binds to NRP1. This prevents the binding of NRP1 to its ligand and may block the immune inhibitory actions of regulatory T-cells (Tregs) mediated by the interaction of NRP1 with its ligand. This may enhance the immune response against tumor cells. NRP1 is a transmembrane co-receptor protein expressed in Tregs; it plays an important role in maintaining the stability and function of Tregs.","Anti-NRP1 Antibody ASP1948 | ASP 1948 | ASP-1948 | ASP1948 | Anti-neuropilin-1 Antibody ASP1948 | PTZ 329 | PTZ-329 | PTZ329",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563091","Radiation Therapy Recipient","C156403","An individual receiving radiation therapy.","Radiation Therapy Recipient | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563204","STEPS to Enhance Physical Activity","C156404","A free-living physical activity intervention that uses pedometers, or other physical activity tracking, to reduce sitting time and other sedentary behaviors to improve fatigue, functional ability, muscle strength, physical activity, and quality of life, and promote positive health outcomes.","STEPS to Enhance Physical Activity | STEPS | STEPS Intervention | STEPS to Enhance Physical Activity (STEPS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563115","Airway Tumor Mass","C156405","A tumor mass that is located in the airways.","Airway Tumor Mass | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563116","Thyroid Gland Histiocytic and Dendritic Cell Neoplasm","C156406","A rare histiocytic and dendritic cell neoplasm that affects the thyroid gland.","Thyroid Gland Histiocytic and Dendritic Cell Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0392921","Cancer Pain Management","C15633","Therapy directed toward reduction and control of cancer pain.","Cancer Pain Management | management of cancer pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563150","Thyroid Gland Schwannoma","C156340","A rare schwannoma that arises from the thyroid gland.","Thyroid Gland Schwannoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563146","Thyroid Gland Malignant Peripheral Nerve Sheath Tumor","C156341","A rare malignant peripheral nerve sheath tumor that arises from the thyroid gland.","Thyroid Gland Malignant Peripheral Nerve Sheath Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563147","Benign Thyroid Gland Vascular Neoplasm","C156342","A rare benign vascular neoplasm that arises from the thyroid gland. This category includes hemangiomas, cavernous hemangiomas, and lymphangiomas.","Benign Thyroid Gland Vascular Neoplasm | Thyroid Gland Benign Vascular Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563148","Thyroid Gland Hemangioma","C156343","A rare hemangioma that arises from the thyroid gland.","Thyroid Gland Hemangioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563149","Thyroid Gland Cavernous Hemangioma","C156344","A rare cavernous hemangioma that arises from the thyroid gland.","Thyroid Gland Cavernous Hemangioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563143","Thyroid Gland Lymphangioma","C156345","An extremely rare lymphangioma that arises from the thyroid gland.","Thyroid Gland Lymphangioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563144","Thyroid Gland Leiomyoma","C156346","A leiomyoma that arises from the thyroid gland.","Thyroid Gland Leiomyoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563145","Thyroid Gland Leiomyosarcoma","C156347","A leiomyosarcoma that arises from the thyroid gland.","Thyroid Gland Leiomyosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935724","Advanced Small Intestinal Large Cell Neuroendocrine Carcinoma","C156689","A small intestinal large cell neuroendocrine carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Small Intestinal Large Cell Neuroendocrine Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0677769","Prevention of Liver Cancer","C15668","No value exists.","Prevention of Liver Cancer | Liver Cancer Prevention",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935722","LNP 023","C156691","An orally available, small-molecule inhibitor of complement factor B (FB) with potential immunomodulatory activity. Upon administration, iptacopan binds to FB and prevents the formation of the alternative pathway (AP) C3-convertase (C3bBb). This limits the cleavage of C3 to the active fragment C3b and may prevent C3b-mediated extravascular hemolysis in certain complement-driven disorders such as paroxysmal nocturnal hemoglobinuria (PNH).","Iptacopan | Factor B Inhibitor LNP023 | IPTACOPAN | LNP 023 | LNP-023 | LNP023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935711","Anti-PD-L1 Monoclonal Antibody TQB2450","C156692","A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, benmelstobart specifically targets and binds to PD-L1, preventing the binding and subsequent activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1, a transmembrane protein expressed on activated T-cells, is overexpressed in some cancer types and plays a significant role in immune evasion by tumor cells.","Benmelstobart | APL502 | Anti-PD-L1 Monoclonal Antibody CBT-502 | Anti-PD-L1 Monoclonal Antibody CBT-502 | Anti-PD-L1 Monoclonal Antibody TQB2450 | BENMELSTOBART | CBT 502 | CBT-502 | CBT502 | TQB 2450 | TQB-2450 | TQB2450",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935712","ECT-001 Expanded Cord Blood","C156693","A preparation of umbilical cord blood (UCB) co-cultured and expanded in an optimized culture system with a small molecule agonist of hematopoietic stem cell (HSC) renewal, with potential use in hematopoietic cell transplantation (HCT). Upon administration, the ECT-001 expanded cord blood cells increase and restore the number of hematopoietic stem and progenitor cells (HSPCs) that can differentiate into a variety of cell types and promote blood cell recovery. Compared to untreated UBCs, ECT-001 expanded UCB cells may exhibit enhanced stem cell proliferation and engraftment.","ECT-001 Expanded Cord Blood | ECT-001 Expanded UCB | ECT-001 Expanded Umbilical Cord Blood | UM171 Expanded Cord Blood",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935709","Antitumor B Key Active Component-alpha","C156694","An orally available concentrated preparation of antitumor B (ATB, Zeng Sheng Ping), a Chinese herbal formula comprised of Sophora tonkinensis, Polygonum bistorta, Prunella vulgaris, Sonchus brachyotus, Dictamnus dasycarpus, and Dioscorea bulbifera, with potential antineoplastic activity. Upon administration, antitumor B key active component-alpha (ATB-KAC-alpha) may, through a not yet fully elucidated mechanism, inhibit tumorigenesis and prevent the development of certain cancers.","Antitumor B Key Active Component-alpha | Antitumor B KAC-a | C156694 | Chinese Herbal Mixture Antitumor B KAC-a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935993","HRAS NP_005334.1:p.G12X","C156884","A change in the amino acid residue at position 12 in the GTPase HRas protein where glycine has been replaced by another amino acid.","HRAS NP_005334.1:p.G12X | GTPase HRas G12X | GTPase HRas Gly12Xxx | H-Ras G12X | H-Ras Gly12Xxx | H-Ras-1 G12X | H-Ras-1 Gly12Xxx | HRAS G12X | HRAS Gly12Xxx | HRAS NP_005334.1:p.Gly12Xxx | HRAS p.G12X | HRAS p.Gly12Xxx | Ha-Ras G12X | Ha-Ras Gly12Xxx | Ha-Ras1 G12X | Ha-Ras1 Gly12Xxx | Harvey Rat Sarcoma Viral Oncoprotein G12X | Harvey Rat Sarcoma Viral Oncoprotein Gly12Xxx | NP_005334.1:p.G12X | NP_005334.1:p.Gly12Xxx | c-H-ras G12X | c-H-ras Gly12Xxx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1322284","Malignant Bronchial Neoplasm","C156885","A malignant neoplasm that affects the bronchial tree.","Malignant Bronchial Neoplasm | Malignant Neoplasm of Bronchus | Malignant neoplasm of unspecified main bronchus",,,,,,,,,,,,,,,"443399","Malignant tumor of bronchus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL935998","HRAS NM_005343.3:c.35G>A","C156886","A nucleotide substitution at position 35 of the coding sequence of the HRAS gene where guanine has been mutated to adenine.","HRAS NM_005343.3:c.35G>A | C-H-RAS c.35G>A | C-HA-RAS1 c.35G>A | H-ras c.35G>A | HRAS c.35G>A | HRAS1 c.35G>A | HRas Proto-Oncogene, GTPase c.35G>A | Ha-ras c.35G>A | Harvey Rat Sarcoma Viral Oncogene Homolog c.35G>A | NM_005343.3:c.35G>A | RASH1 c.35G>A | v-Ha-ras Harvey Rat Sarcoma Viral Oncogene Homolog c.35G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562997","Autologous Anti-BCMA-CAR-TCRz/4-1BB-expressing T-lymphocytes CART-BCMA","C156272","A preparation of autologous T-lymphocytes that have been ex vivo transduced with a genetically-engineered lentiviral vector (LV) expressing a chimeric antigen receptor (CAR) containing an extracellular human single chain variable fragment (scFv) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) fused to an intracellular tandem signaling domain comprised of the co-stimulatory domain of 4-1BB (CD137) and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3z), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-lymphocytes specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.","Autologous Anti-BCMA-CAR-TCRz/4-1BB-expressing T-lymphocytes CART-BCMA | Autologous BCMA 4-1BBz CAR T-Cells CART-BCMA | Autologous BCMA-specific CAR-TCRz/4-1BB-expressing T-Lymphocytes CART-BCMA | CART-BCMA | CART-BCMA Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562998","Tongue Alveolar Soft Part Sarcoma'","C156273","An alveolar soft part sarcoma involving the tongue. It usually occurs in children.","Tongue Alveolar Soft Part Sarcoma' | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562992","Tongue Sarcoma","C156274","A sarcoma that arises from the tongue.","Tongue Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562993","Orbital Alveolar Soft Part Sarcoma","C156276","An alveolar soft part sarcoma involving the orbit. It usually occurs in children.","Orbital Alveolar Soft Part Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562994","Bladder Alveolar Soft Part Sarcoma","C156277","An alveolar soft part sarcoma involving the bladder.","Bladder Alveolar Soft Part Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1275959","Cellular Nerve Sheath Myxoma","C156278","A benign cutaneous neoplasm of uncertain differentiation that usually affects children and young adults and presents as a usually solitary well-circumscribed dermal nodule, predominantly in the face. It is a multilobulated neoplasm composed of nests of epithelioid cells with pale eosinophilic cytoplasm and vesicular nucleus. The nests of neoplastic cells are usually separated by collagenous or myxoid stroma.","Cellular Neurothekeoma | Cellular Nerve Sheath Myxoma | Cellular Neurothekeoma | Neurothekeoma",,,,,,,,,,,,,,,"4266174","Cellular neurothekeoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL562988","Colon Liposarcoma","C156279","A liposarcoma that arises from the colon.","Colon Liposarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935626","Bowel Obstruction Indicator","C156503","An indication as to whether bowel obstruction has occurred.","Bowel Obstruction Indicator | BWOBIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935627","Bowel Perforation Indicator","C156504","An indication as to whether bowel perforation has occurred.","Bowel Perforation Indicator | BWPFIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935631","Lymphovascular Invasion Indicator","C156505","An indication as to whether lymphovascular invasion by tumor cells has occurred.","Lymphovascular Invasion Indicator | LVINVIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563117","Thyroid Gland Langerhans Cell Histiocytosis","C156407","Langerhans cell histiocytosis involving the thyroid gland focally or diffusely. It is exceedingly rare and usually occurs in patients with multifocal disease.","Thyroid Gland Langerhans Cell Histiocytosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563118","Thyroid Gland Follicular Dendritic Cell Sarcoma","C156408","A rare follicular dendritic cell sarcoma involving the thyroid gland. It may be associated with chronic lymphocytic thyroiditis.","Thyroid Gland Follicular Dendritic Cell Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563111","Thyroid Gland Sinus Histiocytosis with Massive Lymphadenopathy","C156409","Rosai-Dorfman-Destombes disease affecting the thyroid gland. It is rare and is usually accompanied by involvement of cervical lymph nodes.","Thyroid Gland Rosai-Dorfman-Destombes Disease | Thyroid Gland Rosai-Dorfman Disease | Thyroid Gland Rosai-Dorfman Disease | Thyroid Gland Sinus Histiocytosis with Massive Lymphadenopathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563112","Thyroid Gland Follicular Lymphoma","C156410","A rare follicular lymphoma primarily involving the thyroid gland.","Thyroid Gland Follicular Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935695","Accelerated Approval","C156638","A regulatory process that allows for shortened time to approval of drugs that treat serious conditions and/or fill an unmet medical need based on surrogate or intermediate clinical endpoints.","Accelerated Approval | accelerated approval | fast track designation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935696","Subject Monitoring","C156639","The act of observing, recording, and reporting the status, safety, and performance of clinical trial participants as specified in the study protocol.","Subject Monitoring | subject monitoring",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935693","Concerned Member State","C156640","A European Economic Area country that is seeking to obtain marketing authorization, through Mutual Recognition or Decentralized procedures, for a medicinal product that has already been authorized in at least one other European Economic Area country.","Concerned Member State | CMS | concerned member state (CMS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935694","Reference Member State","C156641","A European Economic Area country with marketing authorization for a medicinal product that evaluates the marketing authorization application dossier and prepares the assessment report on behalf of another European Economic Area country that is seeking to obtain marketing authorization for the same product through Mutual Recognition or Decentralized procedures.","Reference Member State | RMS | reference member state (RMS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935699","Marketing Authorization","C156642","A license issued by a regulatory authority that allows a medicinal product to be put on the market.","Marketing Authorization | marketing approval | marketing authorization",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935700","Medicinal Product Classification","C156643","The categorization of medicinal products based on chemical, pharmacological, or therapeutic properties or regulatory status.","Medicinal Product Classification | medicinal product classification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935698","ADROIT Electronically Generated Information Service","C156645","An online subscription service that provides access to anonymized adverse drug reaction data on the ADROIT database.","ADROIT Electronically Generated Information Service | AEGIS | AEGIS (ADROIT Electronically Generated Information Service)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL935688","American Health Information Community","C156646","A US federal government advisory committee that was established by the Secretary of Health and Human Services in 2005 to make recommendations for accelerating the development and adoption of health information technology.","American Health Information Community | AHIC | AHIC (American Health Information Community)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936772","Form Completed by (signature)","C157097","A directive to provide the signature of the individual completing the form.","Form Completed by (Signature) | Form Completed by (signature)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936824","If yes, specify (type and results)","C157105","A directive to specify the type and results if the response is yes.","Specify Type of Testing and Results if Yes | If yes, specify (type and result) | If yes, specify (type and results)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936825","Print this form, then sign and date the section below","C157107","A directive to print the form, sign and date the section indicated.","Print, Sign, Date Form | Print this form, then sign and date the section below",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936820","Select One","C157109","A directive to choose one of the options provided.","Select One | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937394","Bladder Neuroendocrine Neoplasm","C157758","An epithelial neoplasm with neuroendocrine differentiation that arises from the bladder. This category includes neuroendocrine tumors, neuroendocrine carcinomas, and paragangliomas.","Bladder Neuroendocrine Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL508346","Bladder Neuroendocrine Carcinoma","C157759","An aggressive high-grade carcinoma with neuroendocrine differentiation that arises from the bladder. This category includes small cell and large cell neuroendocrine carcinoma.","Bladder Neuroendocrine Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511288","Breast Cancer Detection Research","C15775","Research project involving detection of breast tumors (screening, diagnosis clinical trials), development or refinement of diagnostic techniques or devices, education or promotion of breast cancer detection.","Breast Cancer Detection Research | Breast Cancer Detection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937392","Bladder Large Cell Neuroendocrine Carcinoma","C157760","An aggressive high-grade carcinoma with neuroendocrine differentiation that arises from the bladder. It is characterized by the presence of malignant large cells.","Bladder Large Cell Neuroendocrine Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936992","Testosterone Level Finding","C157377","A finding that indicates the amount of testosterone in a sample.","Testosterone Level Finding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937234","Magnesium Transporter Protein 1","C157563","Magnesium transporter protein 1 (335 aa, ~38 kDa) is encoded by the human MAGT1 gene. This protein is involved in magnesium ion transport an N-glycosylation of proteins.","Magnesium Transporter Protein 1 | Dolichyl-Diphosphooligosaccharide--Protein Glycosyltransferase Subunit MAGT1 | Dolichyl-Diphosphooligosaccharide-Protein Glycosyltransferase Subunit MAGT1 | IAP | Implantation-Associated Protein | MagT1 | Oligosaccharyl Transferase Subunit MAGT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938077","Autologous Anti-CD19 CAR-expressing T-lymphocytes CLIC-1901","C158604","A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) that targets the human tumor associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR-expressing T-lymphocytes CLIC-1901 bind to and induce selective toxicity against CD19-expressing tumor cells. The CD19 antigen is a B-cell-specific cell surface antigen expressed in all B-cell lineage malignancies.","Autologous Anti-CD19 CAR-expressing T-lymphocytes CLIC-1901 | Autologous CLIC-1901 CAR-T Cells | CLIC 1901 | CLIC-1901 | CLIC1901",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938074","Whey Protein Isolate-based Nutritional Supplement","C158605","A nutritional supplement composed of a lactose- and gluten-free whey-based protein isolate and containing various vitamins and minerals, with potential immunomodulating activity. In addition to whey protein isolate, this supplement contains phosphoric acid, L-cysteine, ascorbic acid, vitamin E, zinc, ferrous sulfate, niacinamide, vitamin A, calcium pantothenate, copper, manganese, vitamin D3, pyridoxine, thiamine, riboflavin, folic acid, biotin, iodine, phytonadione, and vitamin B12. Upon administration, whey protein isolate is broken down in the body into cysteine and glutamylcysteine. The available cysteine allows cells to synthesize glutathione (GSH), a tripeptide containing amino acids glycine, glutamate and cysteine, thereby maintaining and increasing intracellular GSH concentrations. GSH plays a major role as an antioxidant, thereby protecting cells from oxidative damage due to harmful substances such as free radicals and reactive oxygen compounds. In addition, the supplement provides necessary vitamins and minerals to the body, which may stimulate the immune system, help with wound healing and  regulate metabolic dysregulation.","Whey Protein Isolate-based Nutritional Supplement | Boost Breeze | Whey Protein Isolate-based  Nutritional Supplement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938075","CRISPR-Cas9-mediated PD-1 and TCR Gene-deleted Anti-mesothelin CAR T-cells","C158606","A preparation of human T-lymphocytes transduced with a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) mesothelin and gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to eliminate endogenous TCR and programmed death 1 (PD-1; PDCD1; CD279; programmed cell death-1) expression, with potential immunostimulating and antineoplastic activities. The CRISPR guide RNA (gRNA) specifically targets and binds to complementary sites on TCRalpha, TCRbeta and PD-1. In turn, Cas9 cleaves these specific DNA sites, thereby disrupting transcription. Upon isolation, transduction, electroporation with TCRalpha, TCRbeta and PD-1 gRNAs, which are complexed to Cas9 RNA to disrupt expression of endogenous TCRalpha, TCRbeta and PD-1, expansion ex vivo, and introduction into the patient, the CRISPR-Cas9-mediated PD-1 and TCR gene-deleted anti-mesothelin CAR T-cells recognize and bind to mesothelin-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of mesothelin-positive tumor cells. PD-1, an immune checkpoint receptor expressed on T-cells, plays a key role in tumor immune evasion by binding to its ligand programmed death ligand 1 (PD-L1; cluster of differentiation 274; CD274; programmed cell death-1 ligand 1) expressed on tumor cells. By removing PD-1 from T-cells, PD-1-mediated signaling is halted which may decrease T-cell exhaustion and may enhance T-cell activity against the mesothelin-expressing tumor cells. Removal of endogenous TCR reduces TCR competition for expression, increases the persistence and function of the expressed transgenic TCR, enhances resistance to T-cell exhaustion and increases T-cell activity. Mesothelin is upregulated on a variety of tumor cell types.","CRISPR-Cas9-mediated PD-1 and TCR Gene-deleted Anti-mesothelin CAR T-cells | Anti-mesothelin CAR-transduced CRISPR-Cas9-edited T-cells | CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells | CRISPR-Cas9-mediated Anti-mesothelin CAR T-cells | CRISPR-Cas9-mediated Gene-edited Anti-mesothelin CAR-T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938073","Survivin-expressing CVD908ssb-TXSVN Vaccine","C158607","An orally bioavailable Salmonella-based survivin vaccine composed of a weakened form of a live strain of  Salmonella bacteria (CVD908ssb strain) that has been genetically modified to produce the tumor-associated antigen (TAA) survivin, with potential immunopotentiating and antineoplastic activities. Upon administration of the CVD908ssb-TXSVN vaccine, the expressed survivin stimulates the immune response to elicit a cytotoxic T-lymphocyte (CTL)-mediated immune response against survivin-expressing cancer cells, resulting in a decrease in tumor cell proliferation and an induction of tumor cell death. Survivin, a member of the inhibitor of apoptosis (IAP) family expressed during embryonic development, is upregulated in a variety of human cancers while absent in most normal adult cells; its expression in tumors is associated with a more aggressive phenotype, decreased survival, and increased resistance to chemotherapy.","Survivin-expressing CVD908ssb-TXSVN Vaccine | CVD908ssb-TXSVN | Salmonella-based Survivin Vaccine CVD908ssb-TXSVN | TXSVN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937073","EBV LMP-2A-specific Autologous CD8+ T-cells","C157488","A preparation of autologous cytotoxic T-lymphocytes (CTLs) that are specifically reactive to Epstein-Barr virus (EBV) latent membrane protein-2A (LMP-2A) and expressing the co-stimulatory domain 4-1BB (CD137), with potential antineoplastic activity. Upon administration of the EBV/LMP-2A-specific autologous CD8+ T-cells to patients with EBV-positive tumors, these cells bind to and cause cell death in EBV-infected cells. This inhibits proliferation of EBV LMP-2A-expressing tumor cells. EBV LMP-2A is expressed in various malignancies and plays a key role in tumor cell proliferation and survival. 4-1BB, an inducible costimulatory member of the tumor-necrosis factor receptor (TNFR) family, is expressed on activated T-cells. It activates additional CD8+ T-cells, prevents activation-induced cell death of CD8+ T-cells, and selectively induces T-helper 1 (Th1)-type cytokines such as interferon (IFN)-gamma and tumor-necrosis factor-alpha (TNF-alpha).","EBV LMP-2A-specific Autologous CD8+ T-cells | EBV Latent Membrane Protein-2a Specific Eutil Autologous Blood-derived T-Lymphocytes | EBV-induced Natural T-cells | EBV-induced T-lymphocytes | EBV/LMP-2A-specific CD8 T-Cells | EBViNT | EBViNT Cell | Epstein-Barr Virus Induced Natural T-cells | Eutil Autologous T-lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937074","Adenosine A2A Receptor Antagonist/Phosphodiesterase 10A PBF-999","C157489","An orally bioavailable inhibitor of both the adenosine A2A receptor (A2AR; ADORA2A) and phosphodiesterase 10A (PDE-10A), with potential immunomodulating and antineoplastic activities. Upon administration, A2A/PDE-10A inhibitor PBF-999 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This blocks tumor-released adenosine from interacting with A2AR and prevents the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits T-cell proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression. In addition, PBF-999 binds to and inhibits the activity of PDE-10A, thereby preventing the degradation of cyclic guanosine monophosphate (cGMP) and activates cGMP/cGMP-dependent protein kinase G (PKG) signaling. This induces beta-catenin degradation and thereby prevents the translocation of beta-catenin into the nucleus, and the beta-catenin-mediated induction of transcription of survival proteins, such as cyclin D1 and survivin. It also suppresses RAS/RAF/mitogen-activated protein kinase (MAPK) signaling. This induces apoptosis and inhibits the growth of tumor cells in which PDE-10A is overexpressed. PDE-10A is a cGMP-degrading PDE isozyme that is highly expressed in the brain and overexpressed in certain types of tumor cells. Elevation of intracellular cGMP is known to inhibit tumor proliferation and induce apoptosis. cGMP levels are low in cancer cells resulting from the overexpression PDE-10A.","Adenosine A2A Receptor Antagonist/Phosphodiesterase 10A PBF-999 | A2A/PDE-10A Inhibitor PBF-999 | PBF 999 | PBF-999 | PBF999",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937075","Lactobacillus rhamnosus/L. acidophilus/L. plantarum/ Enterococcus faecium Aqueous Probiotic Supplement","C157490","A water-based multi-strain probiotic composed of an extract of germinated barley containing the four live, activated lactic acid bacteria strains Lactobacillus rhamnosus, L. acidophilus, L. plantarum, and Enterococcus faecium, with potential immunomodulatory and anti-inflammatory activities. Upon oral administration of Lactobacillus rhamnosus/L. acidophilus/L. plantarum/ Enterococcus faecium aqueous probiotic supplement, these four live bacteria modulate the composition of the normal gastrointestinal (GI) microflora, by increasing the beneficial bacteria and decreasing the harmful bacteria, and helps maintain adequate colonization of the GI tract, thereby improving digestion and preventing GI disturbances. These bacteria and the butyric acid produced by them create an environment unfavorable to pathogens by adhering to human epithelial cells, protecting epithelium by maintaining the tight junction integrity and forming a protective mucosal barrier. This prevents attachment of pathogens and reduces the risk of infection, and potentially reduces the severity of mucositis. By restoring gut microbiota, these bacteria may restore or enhance intestinal immune responses.","Lactobacillus rhamnosus/L. acidophilus/L. plantarum/ Enterococcus faecium Aqueous Probiotic Supplement | Lactobacillus acidophilus/Lactobacillus plantarum/Lactobacillus rhamnosus/Enterococcus faecium Aqueous Probiotic Supplement | PROBIO-FIX INUM | Symprove | Symprove Liquid Probiotic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937068","xinmailong","C157492","A Chinese medicine composed of bioactive composite extracted from Periplaneta americana consisting of adenosine, inosine, protocatechuic acid, and pyroglutamate dipeptides, with potential cardioprotective activity. Upon administration, xinmailong may inhibit the phosphorylation of mitogen-activated protein kinase 3/extracellular signal-regulated kinase 1 (MAPK3/ERK1), mitogen-activated protein kinase 1 (MAPK1)/ERK2, AKT, and glycogen synthase kinase-3 beta (GSK3-beta), thereby decreasing the expression of transcription factor GATA-4. GATA-4 is a key regulator of cardiac hypertrophy, mediating gene expressions in response to heart failure (HF) stimuli by activating a variety of HF-associated genes, such as atrial natriuretic factor (ANF), B-type natriuretic peptide (BNP), and beta-myosin heavy chain (beta-MHC). Decreased expression of GATA-4 may limit the transcription of these genes and offer protection against certain types of HF.","Xinmailong | XML",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937390","Metastatic Bladder Large Cell Neuroendocrine Carcinoma","C157762","Bladder large cell neuroendocrine carcinoma that has spread to another anatomical site.","Metastatic Bladder Large Cell Neuroendocrine Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937391","Metastatic Bladder Small Cell Neuroendocrine Carcinoma","C157763","Bladder small cell neuroendocrine carcinoma that has spread to another anatomic site.","Metastatic Bladder Small Cell Neuroendocrine Carcinoma | Metastatic Bladder Small Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937389","Metastatic Prostate Small Cell Neuroendocrine Carcinoma","C157764","Prostate small cell neuroendocrine carcinoma that has spread to another anatomic site.","Metastatic Prostate Small Cell Neuroendocrine Carcinoma | Metastatic Prostate Small Cell Carcinoma | Metastatic Small Cell Neuroendocrine Prostate Cancer | Metastatic Small Cell Prostate Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0683474","Motivational Interviewing","C157765","A directive, client-centered counseling style that helps people resolve ambivalent feelings and insecurities  in order to find internal motivation and elicit behavior changes.","Motivational Interviewing | MI | Motivational Interviewing Intervention",,,,,,,,,,,,,,,"763462","Motivational interviewing",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937387","Metastatic Sarcomatoid Bladder Urothelial Carcinoma","C157766","Bladder sarcomatoid urothelial carcinoma that has spread to another anatomical site.","Metastatic Bladder Sarcomatoid Urothelial Carcinoma | Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant | Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant | Metastatic Invasive Bladder Urothelial Carcinoma, Sarcomatoid Variant | Metastatic Sarcomatoid Bladder Urothelial Carcinoma | Metastatic Sarcomatoid Urothelial Carcinoma | Metastatic Sarcomatoid Urothelial Carcinoma of the Bladder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937388","Metastatic Micropapillary Bladder Urothelial Carcinoma","C157767","Bladder micropapillary urothelial carcinoma that has spread to another anatomic site.","Metastatic Bladder Micropapillary Urothelial Carcinoma | Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant | Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant | Metastatic Invasive Bladder Urothelial Carcinoma, Micropapillary Variant | Metastatic Micropapillary Bladder Urothelial Carcinoma | Metastatic Micropapillary Urothelial Carcinoma | Metastatic Micropapillary Urothelial Carcinoma of the Bladder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937385","Metastatic Clear Cell Bladder Urothelial Carcinoma","C157768","Bladder clear cell (glycogen-rich) urothelial carcinoma that has spread to another anatomic site.","Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma | Metastatic Clear Cell Bladder Urothelial Carcinoma | Metastatic Clear Cell Urothelial Carcinoma | Metastatic Clear Cell Urothelial Carcinoma of the Bladder | Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant | Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant | Metastatic Invasive Bladder Urothelial Carcinoma, Clear Cell (Glycogen-Rich) Variant | Metastatic Invasive Bladder Urothelial Carcinoma, Clear Cell Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937386","Metastatic Giant Cell Bladder Urothelial Carcinoma","C157769","Bladder giant cell urothelial carcinoma that has spread to another anatomic site.","Metastatic Bladder Giant Cell Urothelial Carcinoma | Metastatic Giant Cell  Bladder Urothelial Carcinoma | Metastatic Giant Cell Bladder Urothelial Carcinoma | Metastatic Giant Cell Urothelial Carcinoma | Metastatic Giant Cell Urothelial Carcinoma of the Bladder | Metastatic Infiltrating Bladder Urothelial Carcinoma with Giant Cells | Metastatic Infiltrating Bladder Urothelial Carcinoma with Giant Cells | Metastatic Invasive Bladder Urothelial Carcinoma with Giant Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937383","Metastatic Nested Bladder Urothelial Carcinoma","C157770","Bladder nested urothelial carcinoma that has spread to another anatomic site.","Metastatic Bladder Nested Urothelial Carcinoma | Metastatic Infiltrating Bladder Urothelial Carcinoma, Nested Variant | Metastatic Infiltrating Bladder Urothelial Carcinoma, Nested Variant | Metastatic Invasive Bladder Urothelial Carcinoma, Nested Variant | Metastatic Nested Bladder Urothelial Carcinoma | Metastatic Nested Urothelial Carcinoma | Metastatic Nested Urothelial Carcinoma of the Bladder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL497895","Low Grade Anal Intraepithelial Neoplasia","C157573","Anal canal or perianal skin intraepithelial neoplasia with mild dysplasia.","Low Grade Anal Intraepithelial Neoplasia | AIN1 | Anal Intraepithelial Neoplasia 1 | LG-AIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937282","Anal Intraepithelial Neoplasia 2","C157574","Anal canal or perianal skin intraepithelial neoplasia with moderate dysplasia.","Anal Intraepithelial Neoplasia 2 | AIN2 | Anal Squamous Intraepithelial Neoplasia 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0154778","Pathological Myopia","C157149","A sub-type of myopia characterized by high myopia with any posterior myopia-specific pathology resulting from axial elongation.","Pathological Myopia | ",,,,,,,,,,,,,,,"381281","Degenerative progressive high myopia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL936904","Spastic Paraplegia 76","C157150","An autosomal recessive subtype of hereditary spastic paraplegia caused by mutation(s) in the CAPN1 gene, encoding calpain-1 catalytic subunit.","Spastic Paraplegia 76 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2673535","Tyrosine Hydroxylase Deficiency","C157158","An autosomal recessive condition caused by mutation(s) in the TH gene, encoding tyrosine 3-monooxygenase. It is characterized by onset in infancy of dopa-responsive dystonia.","Tyrosine Hydroxylase Deficiency | Dystonia, Dopa-Responsive, Autosomal Recessive | Parkinsonism, Infantile, Autosomal Recessive | Segawa Syndrome, Autosomal Recessive",,,,,,,,,,,,,,,"37396129","Autosomal recessive dopa responsive dystonia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0681834","Applied Research","C15715","Research directed toward solving a specific problem.","Applied Research | Applied Science",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936898","AFP Level Finding","C157163","A finding that indicates the amount of alpha-fetoprotein tumor marker in a sample.","AFP Level Finding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0428519","Albumin Level Finding","C157164","A finding that indicates the amount of albumin in a sample.","Albumin Level Finding | ",,,,,,,,,,,,,,,"4275213","Albumin level - finding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519572","Trace Element Nutrition, Mercury","C15860","Studies of the role of the trace element mercury, obtained through diet, on general health","Trace Element Nutrition, Mercury | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950644","Endometrioid Adenocarcinoma, Variant with Squamous Differentiation","C158610","An endometrioid adenocarcinoma exhibiting squamous differentiation.","Endometrioid Adenocarcinoma, Variant with Squamous Differentiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1420682","TEAD4 Gene","C158838","This gene plays a role in hippo pathway-mediated regulation of gene transcription.","TEAD4 Gene | TEA Domain Transcription Factor 4 Gene | TEAD4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950851","TEAD4 wt Allele","C158839","Human TEAD4 wild-type allele is located in the vicinity of 12p13.33 and is approximately 81 kb in length. This allele, which encodes transcriptional enhancer factor TEF-3 protein, is involved in both the regulation of organ size and tumor suppression.","TEAD4 wt Allele | EFTR-2 | RTEF1 | Related Transcription Enhancer Factor 1B Gene | TCF13L1 | TEA Domain Transcription Factor 4 wt Allele | TEF-3 | TEF3 | TEFR-1 | Transcriptional Enhancer Factor 1-Related Gene | hRTEF-1B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518319","New Avenues for the Development of Therapeutics","C15883","NIH Emphasis Area -- The result of efforts in chemistry, structural biology, genetics, and cellular and molecular biology are providing new means to design therapies for a variety of diseases.  Efforts to discover and develop drugs to combat cancer and drug and alcohol addiction and methods of bioengineering to repair tissues are ripe for discovery.","New Avenues for the Development of Therapeutics | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950852","Transcriptional Enhancer Factor TEF-3","C158840","Transcriptional enhancer factor TEF-3 (434 aa, ~48 kDa) is encoded by the human TEAD4 gene. This protein plays a role in transcriptional regulation in the hippo signaling pathway.","Transcriptional Enhancer Factor TEF-3 | Other Mutational Analysis Performed | TEA Domain Family Member 4 | TEA Domain Transcription Factor 4 | TEAD-4 | TEAD4 | Transcription Factor 13-Like 1 | Transcription Factor RTEF-1 | Transcriptional Enhancer Factor 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950853","PEG4000/Simethicone/Sodium Sulphate/Sodium Bicarbonate/Electrolytes Oral Solution","C158841","A powder for oral solution containing polyethylene glycol (PEG) 4000 (Macrogol 4000), simethicone, sodium sulphate, sodium bicarbonate, and electrolytes, with laxative and bowel cleansing activities. Upon oral administration, macrogol 4000-based oral osmotic laxative promotes the retention of water in the bowel, thereby increasing the water content of stool, which results in increased gastrointestinal (GI) motility, accelerated stool transit time and evacuation of colonic contents.","PEG4000/Simethicone/Sodium Sulphate/Sodium Bicarbonate/Electrolytes Oral Solution | Macrogol 4000-based Oral Osmotic Laxative | PEG4000/Simethicone/Sodium Sulphate/Sodium Bicarbonate/Electrolytes | Powder-for-oral-solution containing PEG4000/Simethicone/Sodium Sulphate/Sodium Bicarbonate/Electrolyte | SELG-ESSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950854","AKNA wt Allele","C158843","Human AKNA wild-type allele is located in the vicinity of 9q32 and is approximately 64 kb in length. This allele, which encodes AT-hook-containing transcription factor protein, plays a role in the transcriptional activation of the CD40 and CD40LG genes.","AKNA wt Allele | AT-Hook Transcription Factor wt Allele | KIAA1968",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950855","AKNA protein, human","C158844","AT-hook-containing transcription factor (1439 aa, ~155 kDa) is encoded by the human AKNA gene. This protein is involved in the positive regulation of expression of tumor necrosis factor receptor superfamily member 5 (CD40; TNFRSF5) and CD40 ligand.","AT-Hook-Containing Transcription Factor | AKNA | AT-Hook Transcription Factor AKNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936018","Anti-PD-L1/TIM-3 Bispecific Antibody LY3415244","C157058","A bispecific antibody directed against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2) and the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, LY3415244 simultaneously targets and binds to TIM-3 expressed on certain T-cells, including tumor-infiltrating lymphocytes (TILs), and PD-L1 expressed on tumor cells. This blocks the interaction of TIM-3 with some of its physiologic ligands and prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is often co-expressed with PD-1 on tumor-antigen-specific T-cells. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.","Anti-PD-L1/TIM-3 Bispecific Antibody LY3415244 | LY 3415244 | LY-3415244 | LY3415244",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936042","Suspicion of Metastasis","C157060","An impression that a tumor has possibly spread from its original site of growth to another anatomic site.","Suspicion of Metastasis | Suspicion of Metastases",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936043","Anti-S15 Monoclonal Antibody NC318","C157061","A humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting sialic acid binding Ig-like lectin 15 (Siglec-15; SIGLEC15; S15), a member of the sialic acid-binding immunoglobulin type lectins, with potential antineoplastic and immunomodulatory activities. Upon administration, anti-S15 monoclonal antibody NC318 targets and binds to S15 on the surface of tumor-associated macrophages (TAMs) and certain tumor cells. Binding to S15 may disrupt TAM-mediated activities such as promotion of tumor initiation and metastasis of tumor cells, inhibition of T-cell responses, and stimulation of tumor angiogenesis and disease progression. S15, a highly conserved type 1 cell surface protein, normally involved in osteoclast differentiation and bone remodeling, may play a role in the survival and differentiation of TAMs.","Anti-S15 Monoclonal Antibody NC318 | Anti-S15 mAb NC318 | Anti-Siglec-15 Monoclonal Antibody NC318 | NC 318 | NC-318 | NC318",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936041","Anti-DR5 Agonistic Monoclonal Antibody INBRX-109","C157062","A recombinant, humanized, agonistic, tetravalent monoclonal antibody directed against human death receptor type 5 (DR5), also called tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 (TRAILR2), with potential pro-apoptotic and antineoplastic activities. Upon administration, ozekibart specifically binds to exactly four DR5 receptors per molecule, which mimics the interaction of DR5 with its natural ligand TRAIL. This activates DR5 and the death receptor signaling pathway, which results in the activation of caspase cascades, the induction of tumor cell apoptosis and a reduction in proliferation of DR5-expressing tumor cells. Utilizing a tetravalent monoclonal antibody may overcome the challenge of generating effective DR5 clustering while avoiding toxicities associated with anti-drug antibody (ADA) hyper-clustering. DR5, a member of the TNF receptor superfamily (TNFRSF), is expressed on the surfaces of a variety of tumor cells and plays a key role in the induction of tumor cell apoptosis.","Ozekibart | Anti-DR5 Agonistic Monoclonal Antibody INBRX-109 | Anti-DR5 Agonistic Monoclonal Antibody INBRX-109 | INBRX 109 | INBRX-109 | INBRX109 | OZEKIBART",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936835","Primary Vitreoretinal Non-Hodgkin Lymphoma","C157065","An uncommon and potentially fatal intraocular non-Hodgkin lymphoma that involves the uvea, retina, vitreous body, and optic nerve. It is a subset of primary central nervous system non-Hodgkin lymphoma. The majority of cases are diffuse large B-cell lymphomas.","Primary Vitreoretinal Non-Hodgkin Lymphoma | PVRL | Primary Vitreoretinal Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936836","Vitreoretinal Area","C157066","The intraocular area that refers to the uvea, retina, vitreous body, and optic nerve.","Vitreoretinal Area | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936837","Primary Vitreoretinal Diffuse Large B-Cell Lymphoma","C157067","An uncommon and potentially fatal diffuse large B-cell lymphoma that involves the uvea, retina, vitreous body, and optic nerve. It is a subset of primary central nervous system diffuse large B-cell lymphoma.","Primary Vitreoretinal Diffuse Large B-Cell Lymphoma | PVR-LBCL | PVRL DLBCL | PVRL Diffuse Large B-Cell Lymphoma | Primary Large B-Cell Lymphoma of the Vitreoretina",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937039","Ondansetron Hydrochloride Anhydrous","C157329","No value exists.","Ondansetron Hydrochloride Anhydrous | 4H-Carbazol-4-one, 1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-, Monohydrochloride, (+-)- | ONDANSETRON HYDROCHLORIDE ANHYDROUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511496","Continuous Chemotherapeutic Hyperthermic Peritoneal Perfusion","C15732","No value exists.","Continuous Chemotherapeutic Hyperthermic Peritoneal Perfusion | CHPP | continuous hyperthermic peritoneal perfusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937040","Unresectable Basal Cell Carcinoma","C157330","Basal cell carcinoma that is not amenable to surgical resection.","Unresectable Basal Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937033","Unresectable Skin Basal Cell Carcinoma","C157331","Basal cell carcinoma of the skin that is not amenable to surgical resection.","Unresectable Skin Basal Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937034","Kidney Transplant Recipient","C157332","An individual who is receiving or has received a transplant of a kidney.","Kidney Transplant Recipient | Kidney Transplantation Recipient",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937035","Inodiftagene Vixteplasmid","C157333","A recombinant DNA plasmid carrying the gene for diphtheria toxin-A (dT-A) chain under the regulation of the H19 promoter, with potential antineoplastic activity. Upon intravesical administration, dT-A chain expression is triggered by the presence of H19 transcription factors that are upregulated in tumor cells. The dT-A chain binds to nicotinamide adenine dinucleotide (NAD) and inactivates the ADP-ribosylation of elongation factor 2 (EF2), resulting in the inhibition of protein synthesis and cell death leading to tumor cell destruction. Inodiftagene Vixteplasmid does not carry the gene for the diphtheria toxin-B (dT-B) chain, thereby preventing the transfer of the toxic dT-A chain between cells. H19, a paternally imprinted, oncofetal gene, is highly expressed in embryonic and certain malignant tissues, but minimally expressed in normal, adult tissues.","Inodiftagene Vixteplasmid | BC 819 | BC-819 | BC819 | Diphtheria-toxin-A-H19 | INODIFTAGENE VIXTEPLASMID | dT-A-H19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937036","Metastatic Extracranial Malignant Solid Neoplasm","C157334","A malignant solid neoplasm that arises from any anatomic site other than the brain and has spread from its original site of growth to another anatomic site.","Metastatic Extracranial Malignant Solid Neoplasm | Metastatic Extracranial Malignant Solid Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937030","Advanced Extracranial Malignant Solid Neoplasm","C157335","A malignant solid neoplasm that arises from any anatomic site other than the brain and has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Extracranial Malignant Solid Neoplasm | Advanced Extracranial Malignant Solid Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937031","Refractory Adenovirus Infection","C157336","An adenovirus infection that does not respond to treatment.","Refractory Adenovirus Infection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3179130","Multidetector Computed Tomography","C157337","A type of computed tomography that uses a two-dimensional detector array, allowing for the acquisition of multiple slices simultaneously. This results in an increase in imaging acquisition speed, more coverage of the patient, and high spatial resolution. MDCT acquires volume data instead of individual slice data.","Multi-detector Computed Tomography | MDCT | Multidetector CT | Multidetector Computed Tomography",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937032","Multi-detector Computed Tomography Angiography","C157338","Angiography that uses multi-detector computed tomography.","Multi-detector Computed Tomography Angiography | MDCT Angiography | MDCTA | Multidetector Computed Tomography Angiography",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511886","Diagnostic Trial","C15733","Clinical evaluation of the utility of diagnostic procedures.","Diagnostic Trial | Clinical Trials, Diagnosis | diagnostic trial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937098","CPTAC Stomach Adenocarcinoma Baseline Form","C157532","Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on Stomach Adenocarcinoma Baseline Form data.","CPTAC Stomach Adenocarcinoma Baseline Form | CPTAC STAD Baseline Form Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516278","Carcinogenesis Reversion","C15781","No value exists.","Carcinogenesis Reversion | Carcinogenesis, Reversion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937525","Cognitive Behavior Therapy for Insomnia","C157821","A structured program that helps the patient identify and replace thoughts and behaviors that cause or worsen sleep problems with habits that promote sound sleep. Techniques include stimulus control therapy, sleep restriction, sleep hygiene, sleep environment improvement, relaxation training, remaining passively awake, and biofeedback.","Cognitive Behavior Therapy for Insomnia | CBT-I | CBTI | Cognitive Behavioral Therapy for Insomnia",,,,,,,,,,,,,,,"3663230","Cognitive behavioral therapy for insomnia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0009355","Collis Gastroplasty","C157822","A surgical procedure that lengthens the esophagus with part of the stomach to provide relief from GERD or Barrett's esophagus.","Collis Gastroplasty | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937524","Colon Resection","C157823","A surgical procedure in which part of the colon is removed.","Colon Resection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1456685","Plastic and Cosmetic Surgery","C157827","Surgery to improve the aesthetics of an individual's body.","Cosmetic Plastic Surgery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937519","Cranial Base Surgery","C157828","Surgery to remove tumors that use high powered microscopes with fiberoptic illumination to identify target areas.","Cranial Base Surgery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937520","Cryoablation for Arrhythmia","C157829","The use of cold to freeze heart tissue that is a source of an irregular rhythm. It is administered via a balloon catheter that use advanced radiographic techniques.","Cryoablation for Arrhythmia | cryoablation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516462","Clinical Chemoprevention","C15782","Chemoprevention use in a clinical setting.","Clinical Chemoprevention | Chemoprevention, Clinical",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937517","Double Eyelid Surgery","C157830","Surgery to create an eyelid fold where one does not exist.","Double Eyelid Surgery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950856","Specify Identified Mutation","C158845","A request to enter the specific mutation that was identified in the study.","Specify Identified Mutation | Mutation identified, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950858","Presence of Another Mutation","C158847","A question to determine if another mutation was found in the study.","Presence of Another Mutation | Other Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950859","1p/19q Deletion Analysis Testing Method","C158848","A request to enter the specific molecular analysis method used to determine the 1q/19q deletion status.","1p/19q Deletion Analysis Testing Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937662","PAX5 NM_016734.2:c.547G>A","C158143","A nucleotide substitution at position 547 of the coding sequence of the PAX5 gene where guanine has been mutated to adenine.","PAX5 NM_016734.2:c.547G>A | ALL3 c.547G>A | BSAP c.547G>A | NM_016734.2:c.547G>A | PAX5 c.547G>A | Paired Box 5 c.547G>A | Paired Box Gene 5 c.547G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937663","PAX5 NP_057953.1:p.G183S","C158144","A change in the amino acid residue at position 183 in paired box protein Pax-5 where glycine has been replaced by serine.","PAX5 NP_057953.1:p.G183S | B-Cell Lineage Specific Activator Protein G183S | B-Cell Lineage Specific Activator Protein Gly183Ser | B-Cell-Specific Transcription Factor G183S | B-Cell-Specific Transcription Factor Gly183Ser | BSAP G183S | BSAP Gly183Ser | NP_057953.1:p.G183S | NP_057953.1:p.Gly183Ser | PAX5 G183S | PAX5 Gly183Ser | PAX5 NP_057953.1:p.Gly183Ser | PAX5 p.G183S | PAX5 p.Gly183Ser | Paired Box Protein Pax-5 G183S | Paired Box Protein Pax-5 Gly183Ser",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937660","IKZF1 Protein Variant","C158145","A variation in the amino acid sequence for DNA-binding protein Ikaros.","IKZF1 Protein Variant | DNA-Binding Protein Ikaros Protein Variant | IKAROS Family Zinc Finger 1 Protein 1 Protein Variant | Lymphoid Transcription Factor LyF-1 Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937661","IKZF1 NP_006051.1:p.N159Y","C158146","A change in the amino acid residue at position 159 in DNA-binding protein Ikaros where asparagine has been replaced by tyrosine.","IKZF1 NP_006051.1:p.N159Y | DNA-Binding Protein Ikaros Asn159Tyr | DNA-Binding Protein Ikaros N159Y | IKAROS Family Zinc Finger 1 Protein 1 Asn159Tyr | IKAROS Family Zinc Finger 1 Protein 1 N159Y | IKZF1 Asn159Tyr | IKZF1 N159Y | IKZF1 NP_006051.1:p.Asn159Tyr | IKZF1 p.Asn159Tyr | IKZF1 p.N159Y | Lymphoid Transcription Factor LyF-1 Asn159Tyr | Lymphoid Transcription Factor LyF-1 N159Y | NP_006051.1:p.Asn159Tyr | NP_006051.1:p.N159Y",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937659","Sexual Maturity Status","C158148","An indication of whether an organism is capable of sexual reproduction. The capacity of an organism to reproduce via sexual reproduction.","Sexual Maturity Status | SEXMATS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937656","Recurrent Transformed B-Cell Non-Hodgkin Lymphoma","C158149","The reemergence of B-cell non-Hodgkin lymphoma transformed after a period of remission.","Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513732","Multicenter Hemophilia Cohort Study","C15814","A multi-center study of HIV disease progression and heterosexual transmission begun in 1982.","Multicenter Hemophilia Cohort Study | MHCS | MHCS-I",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937657","Refractory Transformed B-Cell Non-Hodgkin Lymphoma","C158150","An indolent B-cell non-Hodgkin lymphoma which has undergone histologic transformation to an aggressive B-cell non-Hodgkin lymphoma and has become resistant to treatment.","Refractory Transformed B-Cell Non-Hodgkin Lymphoma | Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936830","Recurrent PVRL","C157068","The reemergence of primary vitreoretinal non-Hodgkin lymphoma after a period of remission.","Recurrent Primary Vitreoretinal Non-Hodgkin Lymphoma | Recurrent PVRL | Recurrent Primary Vitreoretinal Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937337","Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1","C157710","A recombinant, replicating oncolytic vesicular stomatitis virus (VSV) carrying the human interferon-beta (IFN-b) gene and the tyrosinase related protein 1 (TYRP1) gene, with potential immunomodulating and antineoplastic activities. Upon intratumoral and intravenous administration, recombinant VSV-expressing IFN-b/TYRP1 preferentially replicates in tumor cells. Due to defective IFN-b-mediated innate antiviral host defense mechanisms in tumor cells, VSV is able to replicate in these cells without interference. This induces VSV-mediated cytolytic activity towards the tumor cells. By expressing human IFN-b, an IFN-b-mediated antiviral immune response in surrounding normal cells is activated which protects normal cells against virus replication and the associated VSV-mediated cell lysis.  Also, the IFN-b produced by VSV may activate an immune response in surrounding normal cells, involving the activation of cytotoxic T-lymphocytes (CTL), dendritic cells (DCs) and natural killer (NK) cells. This induces an anti-tumor immune response against the tumor cells. In addition, the expression of TYRP1 further activates the immune system to induce a CTL-mediated immune response against the TYRP1-expressing tumor cells, thereby further killing TYRP1-expressing tumor cells.  VSV, a single-stranded RNA virus belonging to the genus Vesiculovirus of the family Rhabdoviridae, is relatively nonpathogenic to healthy humans but is able to rapidly replicate in and induce apoptosis of tumor cells. TYRP1, a tumor-associated antigen (TAA), is primarily expressed in melanocytes and melanomas.","Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1 | Recombinant VSV-IFNbetaTYRP1 | Recombinant VSV-expressing IFN-b and TYRP1 | VSV-IFN-b/TYRP1 | VSV-IFNbetaTYRP1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937332","GDC Terminology","C157711","Terminology that supports the Genomic Data Commons (GDC).","GDC Terminology | Genomics Data Commons Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937333","GDC Therapeutic Agent Terminology","C157712","No value exists.","GDC Therapeutic Agent Terminology | AGENT | therapeutic_agents",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0029352","Orthopedic Devices","C157713","No value exists.","Orthopedic Devices | ",,,,,,,,,,,,,,,"4038746|4146959","Orthopedic device|Orthopedic aid",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL937334","Malignant Epithelial Cells with Cytoplasmic Vacuoles or Flocculent Cytoplasmic Inclusions Containing Wispy Eosinophilic Material Present","C157714","A morphologic finding indicating the presence of malignant epithelial cells with cytoplasmic vacuoles or flocculent cytoplasmic inclusions containing wispy eosinophilic material giving a bubbly appearance.","Malignant Epithelial Cells with Cytoplasmic Vacuoles or Flocculent Cytoplasmic Inclusions Containing Wispy Eosinophilic Material Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937330","Total Gut Decontamination","C157715","A process that uses combinations of antibiotics to remove or reduce the gut microbiome.","Total Gut Decontamination | TGD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937331","Dermal Injectable Filler","C157717","A preparation consisting of absorbable or non-absorbable materials, or harvested autologous fat, that may be injected into certain areas of tissue to minimize skin depressions, scars, and signs of aging. Absorbable materials, which include collagen, hyaluronic acid (HA), calcium hydroxylapatite (CaHA), and poly-L-lactic acid (PLLA), tend to have more temporary effects, whereas the effects of non-absorbable materials, such as polymethylmethacrylate (PMMA) microspheres, tend to be more permanent.","Dermal Injectable Filler | Collagen/Fat Injectable Fillers | Soft Tissue Injectable Filler",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511081","Behavior Research, Indirect","C15771","Research concerning any factor or condition, exposure to which is theoretically susceptible to behavioral modification, but in which no actual behavioral work is being done (e.g., experimental studies on tobacco use, consumption of various dietary components, and exposure to many other environmental carcinogens).","Behavior Research, Indirect | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937091","CPTAC Thyroid Carcinoma Baseline Form","C157533","Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on Thyroid Carcinoma Baseline Form data.","CPTAC Thyroid Carcinoma Baseline Form | CPTAC THCA Baseline Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937092","CPTAC Uveal Melanoma Baseline Form","C157534","Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus onUveal Melanoma Baseline Form data.","CPTAC Uveal Melanoma Baseline Form | CPTAC UVM Baseline Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937993","UCHL5 protein, human","C158570","Ubiquitin carboxyl-terminal hydrolase isozyme L5 (329 aa, ~38 kDa) is encoded by the human UCHL5 gene. This protein plays a role in chromatin modification and the removal of lysine-48-linked polyubiquitin chains from substrate proteins.","Ubiquitin Carboxyl-Terminal Hydrolase Isozyme L5 | EC 3.4.19.12 | INO80 Complex Subunit R | UCHL5 | Ubiquitin C-Terminal Hydrolase L5 | Ubiquitin C-Terminal Hydrolase UCH37 | Ubiquitin Carboxyl-Terminal Esterase L5 | Ubiquitin Carboxyl-Terminal Hydrolase L5 | Ubiquitin Thioesterase L5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937990","Months Since Completion of Primary Therapy","C158571","An indication of the number of months that have passed between the completion of primary therapy and the present.","Months Since Completion of Primary Therapy | Months From Completion of Primary Therapy | Months From Completion of Primary Therapy to Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937991","ZNF385B Gene","C158572","This gene may play a role in the cellular tumor antigen p53 (TP53)-dependent apoptosis pathway.","ZNF385B Gene | ZNF385B | Zinc Finger Protein 385B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937988","ZNF385B wt Allele","C158573","Human ZNF385B wild-type allele is located within 2q31.2-q31.3 and is approximately 420 kb in length. This allele, which encodes zinc finger protein 385B, may be involved in the regulation of apoptosis.","ZNF385B wt Allele | FLJ25270 | ZNF533 | Zinc Finger Protein 385B wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937989","Zinc Finger Protein 385B","C158574","Zinc finger protein 385B (471 aa, ~50 kDa) is encoded by the human ZNF385B gene. This protein may play a role in the regulation of cellular tumor antigen p53 (TP53) signaling pathways.","Zinc Finger Protein 385B | ZNF385B | Zinc Finger Protein 533",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937986","CADPS2 Gene","C158575","This gene is involved in the regulation of neurotransmitter and neuropeptide exocytosis.","CADPS2 Gene | CADPS2 | Calcium Dependent Secretion Activator 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937987","CADPS2 wt Allele","C158576","Human CADPS2 wild-type allele is located in the vicinity of 7q31.32 and is approximately 568 kb in length. This allele, which encodes calcium-dependent secretion activator 2 protein, plays a role in the exocytosis of neuropeptides and neurotransmitters. Mutation of the gene may be associated with autism.","CADPS2 wt Allele | CAPS2 | Calcium Dependent Secretion Activator 2 wt Allele | KIAA1591",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937984","Calcium-Dependent Secretion Activator 2","C158577","Calcium-dependent secretion activator 2 (1296 aa, ~148 kDa) is encoded by the human CADPS2 gene. This protein is involved in the secretion of neurotrophins.","Calcium-Dependent Secretion Activator 2 | CADPS2 | CAPS-2 | Ca++-Dependent Activator Protein for Secretion 2 | Ca++-Dependent Secretion Activator 2 | Ca2+ Dependent Secretion Activator 2 | Ca2+-Dependent Activator Protein for Secretion 2 | Calcium Dependent Secretion Activator 2 | Calcium-Dependent Activator Protein for Secretion 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937985","ECPAS Gene","C158578","This gene plays a role in proteasome assembly and localization.","ECPAS Gene | ECPAS | Ecm29 Proteasome Adaptor and Scaffold Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937982","ECPAS wt Allele","C158579","Human ECPAS wild-type allele is located in the vicinity of 9q31.3 and is approximately 124 kb in length. This allele, which encodes proteasome adapter and scaffold protein ECM29, is involved in the assembly and cellular localization of the proteasome.","ECPAS wt Allele | ECM29 | ECM29 Homolog (S. cerevisiae) Gene | ECM29, Yeast Homolog of Gene | Ecm29 Proteasome Adaptor and Scaffold wt Allele | FLJ22036 | Homolog of Yeast Ecm29 Gene | KIAA0368",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950696","Regular Smokeless Tobacco Use for Six Weeks or More","C158796","A question about whether the individual ever used smokeless tobacco regularly for a period of six weeks or more.","Regular Smokeless Tobacco Use for Six Weeks or More | Did the patient ever use smokeless tobacco (including chewing tobacco and snuff) regularly for a period of six weeks or more",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950872","Average Daily Use Smokeless Tobacco after Use for Six Weeks","C158797","A question about how many times per day an individual who has used smokeless tobacco regularly for at least six weeks.","Average Daily Use Smokeless Tobacco after Use for Six Weeks | If the patient used smokeless tobacco (including chewing tobacco and snuff) regularly for at least six weeks, on average how many times per day did they use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950873","Not Applicable - Never Quit","C158798","No value exists.","Not Applicable - Never Quit | Not Applicable - Never quit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937655","Refractory Transformed Chronic Lymphocytic Leukemia","C158152","Chronic lymphocytic leukemia which has undergone histologic transformation to an aggressive diffuse large B-cell lymphoma (Richter's transformation) and has become resistant to treatment.","Refractory Transformed Chronic Lymphocytic Leukemia | Refractory Richter Syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937653","GDS02TS","C158155","Geriatric Depression Scale Short Form total score.","Geriatric Depression Scale Short Form - Total Score for Analysis | GDS02-Total Score - Analysis | GDS02TS | Geriatric Depression Scale Short Form - Total Score",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937650","Treatment Amount","C158156","The concentration or quantity of the medication.","Treatment Amount | TRTAMT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937882","Humanized 3F8 Bispecific Antibody","C158436","A bispecific antibody comprised of a humanized anti-CD3 OKT3 (huOKT3) single chain variable fragment (scFv), linked to the carboxyl end of a humanized anti-GD2 3F8 (hu3F8) immunoglobulin G1 (IgG1) light chain, with potential antineoplastic activity. Upon intravenous administration, nivatrotamab binds to CD3 on T-cells and disialoganglioside GD2 expressed on certain tumor cells, thereby cross-linking T-cells with GD2-expressing tumor cells. This promotes a selective cytotoxic T-lymphocyte (CTL) response against GD2-expressing cells. The Fc region of the anti-GD2 hu3F8/anti-CD3 huOKT3 bispecific antibody has two amino acid substitutions, N297A and K322A, which may prevent cytokine release syndrome and other unwanted side effects including complement-mediated pain. GD2, a disialoganglioside and tumor-associated antigen (TAA), is overexpressed in a variety of tumor cell types. CD3 is part of the functional T-cell receptor (TCR) complex, which is necessary for antigen recognition by T-cells and is required for signal transduction.","Nivatrotamab | Anti-GD2 hu3F8/Anti-CD3 huOKT3 Bispecific Antibody | Humanized 3F8 Bispecific Antibody | Humanized Anti-GD2 x Anti-CD3 Bispecific Antibody | NIVATROTAMAB | hu3F8 x huOKT3 Bispecific Antibody | hu3F8-BsAb",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937879","Recurrent Endometrial Adenocarcinoma","C158437","The reemergence of endometrial adenocarcinoma after a period of remission.","Recurrent Endometrial Adenocarcinoma | Recurrent Endometrial Adenocarcinoma, Not Otherwise Specified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937880","iPSC-derived Natural Killer Cells FT500","C158438","A preparation of off-the-shelf, natural killer (NK) cells derived from a clonal master induced pluripotent stem cell (iPSC) line, with potential antineoplastic and immunostimulatory activities. Upon administration, iPSC-derived natural killer cells FT500 bind to stress-induced ligands on tumor cells, leading to tumor cell lysis and release of tumor neoantigens. Additionally, iPSC-NK cells secrete inflammatory cytokines and chemokines including interferon-gamma (IFN-gamma), tumor necrosis factor-alpha (TNF-alpha), C-C motif chemokines 3, 4, and 22 (CCL3, CCL4, and CCL22), and C-X-C motif chemokine 10 (CXCL10), thereby enhancing T-cell activity and recruitment to the tumor site.","iPSC-derived Natural Killer Cells FT500 | FT 500 | FT-500 | FT500 | Induced Pluripotent Stem Cell-derived Natural Killer Cells FT500 | iPSC-NK Cells FT500 | iPSC-derived NK Cells FT500",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937328","Intra or Intercytoplasmic Lumina Present","C157721","A morphologic finding where the malignant cell has intra or intercytoplasmic lumina thereby imparting a cribriform or sieve-like architecture.","Intra or Intercytoplasmic Lumina Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0868838","Otoplasty","C157723","No value exists.","Otoplasty | ",,,,,,,,,,,,,,,"4203632","Repair of auricle of ear",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937329","High-Dose-Rate Vaginal Brachytherapy","C157724","High dose rate radiation delivered by a radiation source contained in an intra-vaginal cylinder to target neoplasms in or surrounding the vaginal canal.","High-Dose-Rate Vaginal Brachytherapy | HDR-IVB | High-Dose-Rate Intra-Vaginal Brachytherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042381","Vascular Surgical Procedure","C157725","No value exists.","Vascular Surgical Procedure | ",,,,,,,,,,,,,,,"4148948","Vascular surgery procedure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937021","4-[18F]Fluoroglutamic Acid","C157280","A radioconjugate composed of the radionuclide fluorine F 18 conjugated to L-glutamic acid, with potential imaging activity upon positron emission tomography (PET). Upon intravenous administration, the glutamic acid moiety of  4-[18F]fluoroglutamic acid specifically binds to tumor cells and is preferentially taken up by tumor cells due to the higher metabolic activity and enhanced glutaminolytic pathway in these cells compared to normal, healthy cells. Upon internalization and PET, tumor cells can be imaged and assessed. Tumor cells use the amino acid glutamine for nutritional purposes necessary for energy production and growth; as tumor cells proliferate more rapidly than normal healthy cells, glutamine uptake is higher in certain cancer cells.","4-[18F]Fluoroglutamic Acid | (2S)-2-Amino-4-[F-18]-fluoro Pentanedioic Acid | BAY 85-8050 | BAY 858050 | BAY-85-8050 | Fluorine F 18-BAY 85-8050 | [18F] 4-L-fluoroglutamine (2S,4R) | [F-18]BAY 85-8050",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937014","Autologous CLL1-CD33 Compound CAR T Cells","C157281","Autologous T-lymphocytes transduced with a lentiviral vector expressing a compound chimeric antigen receptor (cCAR) containing two CARs, one specific for the CD33 antigen and one specific for the C-type-lectin-like molecule-1 (CLL1; C-type lectin domain family 12 member A; CLEC12A), with potential immunomodulating and antineoplastic activities. Upon administration, the CD33/CLL1-specific CARs lentiviral vector-transduced autologous T-lymphocytes, expressing both the anti-CD33 CAR and the anti-CLL1 CAR on their surfaces, specifically and simultaneously target and bind to CD33- and CLL1-expressing tumor cells, with their anti-CD33 CAR and their anti-CLL1 CAR, respectively. This induces selective toxicity in tumor cells that express the CD33 antigen and the CLL1 antigen. CD33 is expressed on normal non-pluripotent hematopoietic stem cells and is overexpressed on myeloid leukemia cells. CLL1, a member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily, is overexpressed in leukemic stem cells (LSCs) and plays an important role in disease progression and relapse for myeloid malignancies.","Autologous CLL1-CD33 Compound CAR T Cells | Autologous Anti-CLL1/Anti-CD33 CARs-expressing T-lymphocytes | Autologous CLL1-CD33 cCAR | Autologous CLL1-CD33 cCAR T Cells | Autologous CLL1-CD33 cCAR T-lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937016","ADAR Gene","C157283","This gene plays a role in the metabolism of double-stranded RNA.","ADAR Gene | ADAR | Adenosine Deaminase, RNA Specific Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937017","ADAR wt Allele","C157284","Human ADAR wild-type allele is located in the vicinity of 1q21.3 and is approximately 46 kb in length. This allele, which encodes double-stranded RNA-specific adenosine deaminase protein, is involved in ribonucleotide deamination. Mutations in the gene are associated with dyschromatosis symmetrica hereditaria and Aicardi-Goutieres syndrome type 6.","ADAR wt Allele | ADAR1 | AGS6 | Adenosine Deaminase Acting on RNA 1 Gene | Adenosine Deaminase, RNA Specific wt Allele | Adenosine Deaminase, RNA-Specific Gene | Adenosine Deaminase, RNA-Specific, 1 Gene | DRADA | DSH | DSRAD | G1P1 | IFI-4 | IFI4 | K88DSRBP | P136",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937010","adenosine deaminase RNA-specific binding protein, human","C157285","Double-stranded RNA-specific adenosine deaminase (1226 aa, ~136 kDa) is encoded by the human ADAR gene. This protein plays a role in the deamination of adenosine to inosine in double-stranded RNA (A-to-I RNA editing).","Double-Stranded RNA-Specific Adenosine Deaminase | 136 kDa Double-Stranded RNA-Binding Protein | ADAR | DRADA | EC 3.5.4.37 | IFI-4 | Interferon-Induced Protein 4 | Interferon-Inducible Protein 4 | K88DSRBP | RNA-Specific Adenosine Deaminase | dsRNA Adenosine Deaminase | p136",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936822","Transcribe the data from this form into CDR, and record the following","C157111","A directive to transcribe the form data into the Comprehensive Data Resource, and record the following information.","Transcribe Data into CDR and Record the Following | Transcribe the data from this form into CDR, and record the following",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936813","tGLI1 Allele","C157117","Human tGLI1 allele is located in the vicinity of 12q13.3 and is approximately 12 kb in length. This allele, which encodes truncated glioma-associated oncogene homolog 1 protein, is involved in the modulation of transcription by RNA polymerase II. Expression of this allele is associated with glioblastoma multiforme (GBM).","tGLI1 Allele | TGLI1 | Truncated GLI Family Zinc Finger 1 Allele | Truncated GLI1 Gene | Truncated Glioma-Associated Oncogene Homolog 1 Gene | tGLI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936814","GLI1 Gene Product","C157118","A protein encoded by the GLI1 gene.","GLI1 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0679695","Prevention Research","C15711","Studies identifying, testing, and implementing interventions among groups of individuals that are designed to prevent the initiation of a substance, such as tobacco or alcohol.","Prevention Research | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950874","Age When Quit using Smokeless Tobacco after Regular Use","C158799","A question about the age of an individual when they started using smokeless tobacco, once they have been using regularly for six weeks.","Age When Quit using Smokeless Tobacco after Regular Use | If the patient used smokeless tobacco (including chewing tobacco and snuff) regularly for at least six weeks, how old were they when they quit using | smokeless tobacco quit age | smokeless_tobacco_quit_age",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950875","Definitive Therapy Date of Completion","C158800","The date of completion of the curative therapy.","Definitive Therapy Date of Completion | Date of Completion of Definitive (Curative) Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950877","Concurrent Chemotherapy","C158802","No value exists.","Concurrent Chemotherapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950878","Non-Concurrent Chemotherapy","C158803","No value exists.","Non-Concurrent Chemotherapy | Chemotherapy (not given concurrently)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950880","Tumor Progression After Initial Treatment","C158805","A question about whether the tumor progression was present after the initial treatment.","Was Tumor Progression Present After Initial Treatment | Tumor Progression After Initial Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950881","Tumor Reoccurrence After Initial Treatment","C158806","A question whether tumor reoccurrence was present after the initial treatment.","Was Tumor Reoccurrence Present After Initial Treatment | Tumor Reoccurrence After Initial Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950882","Greater than or Equal to 50% Myometrial Invasion","C158807","A response that there is greater than or equal to 50% myometrial invasion.","Greater than or Equal to 50% Myometrial Invasion | >= 50% myometrial invasion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511154","Biology of the Brain Disorders","C15880","NIH Emphasis Area -- New emphasis on the biology of brain disorders reflects the extraordinary rate at which the neurosciences, with strong support from the fields of molecular genetics, imaging, and cell biology, is growing.  Efforts in neural development; neurodegeneration, especially in Alzheimer's disease, Parkinson's disease, mental illness and traumatic injury to the brain and spinal cord are few examples of the promise of this field.","Biology of the Brain Disorders | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950884","At Time of Diagnosis","C158810","A specification that indicates the time to assess is the time of diagnosis.","At Time of Diagnosis | at time of diagnosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937735","RASSF1 Gene Promoter Hypermethylation","C158105","A genetic finding indicating an excess of DNA methylation in the promoter region of the RASSF1 gene.","RASSF1 Gene Promoter Hypermethylation | 123F2 Gene Promoter Hypermethylation | NORE2A Gene Promoter Hypermethylation | RASSF1 Promoter Hypermethylation | RASSF1A Gene Promoter Hypermethylation | RDA32 Gene Promoter Hypermethylation | REH3P21 Gene Promoter Hypermethylation | Ras Association Domain Family Member 1 Gene Promoter Hypermethylation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937877","Autologous Anti-MUC1*-CAR-4-1BB-CD3zeta-expressing T-lymphocytes","C158439","A preparation of autologous T-lymphocytes transduced with a lentiviral vector encoding a human CD8 alpha leader sequence, a humanized MNC2-single chain variable fragment (scFv) targeting the extracellular domain of the cleaved form of mucin-1 (MUC-1), known as MUC1*, portions of human CD8 hinge and transmembrane domains, and human 4-1BB and human CD3-zeta costimulatory domains, with potential antineoplastic and immunostimulating activities. Upon re-introduction into the patient, the autologous anti-MUC1*-CAR-4-1BB-CD3zeta-expressing T-lymphocytes specifically recognize and induce selective toxicity in MUC1*-expressing tumor cells. MUC1* is a post-translationally modified form of MUC1, a single pass type I transmembrane protein that is normally expressed in the glandular or luminal epithelial cells of the esophagus, stomach, duodenum, pancreas, uterus, prostate, and lungs, and may be aberrantly expressed in certain tumor types. MUC1* is a growth factor that is activated by ligand-induced dimerization of its extracellular domain, which may stimulate mitogen-activated protein kinase (MAP kinase, MAPK) signaling and promote tumor cell growth. MUC1* is frequently expressed in certain cancer types, with increased expression noted in higher grade lesions and tumor cells resistant to certain chemotherapies.","Autologous Anti-MUC1*-CAR-4-1BB-CD3zeta-expressing T-lymphocytes | Anti-MUC1*-CAR-4-1BB-CD3zeta-expressing Autologous T-lymphocytes | Autologous HuMNC2-CAR44 | Autologous huMNC2-CAR44 CAR T Cells | Autologous huMNC2-CAR44 T-lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937878","KDM7A Gene","C158440","This gene is involved in histone demethylation and brain development.","KDM7A Gene | KDM7A | Lysine Demethylase 7A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937875","KDM7A wt Allele","C158441","Human KDM7A wild-type allele is located in the vicinity of 7q34 and is approximately 92 kb in length. This allele, which encodes lysine-specific demethylase 7A protein, plays a role in brain development and histone modification.","KDM7A wt Allele | JHDM1D | Jumonji C Domain Containing Histone Demethylase 1 Homolog D (S. cerevisiae) Gene | KDM7 | KIAA1718 | Lysine (K)-Specific Demethylase 7A Gene | Lysine Demethylase 7A wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937876","KDM7A protein, human","C158442","Lysine-specific demethylase 7A (941 aa, ~107 kDa) is encoded by the human KDM7A gene. This protein is involved in histone demethylation and brain development.","Lysine-Specific Demethylase 7A | EC 1.14.11.- | Histone Lysine Demethylase JHDM1D | JmjC Domain-Containing Histone Demethylation Protein 1D | Jumonji C Domain Containing Histone Demethylase 1 Homolog D | KDM7A | Lysine Demethylase 7A | Lysine-Specific Demethylase 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937873","KDM7A-DT Gene","C158443","The function of this gene is unknown.","KDM7A-DT Gene | KDM7A Divergent Transcript Gene | KDM7A-DT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950646","CPTAC Questions","C158612","No value exists.","CPTAC Questions | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950647","Was Menopausal Hormone Therapy Ever Used","C158614","A question about whether menopausal hormone therapy was ever used.","Was Menopausal Hormone Therapy Ever Used | Has the patient ever taken menopausal hormone therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950648","Was another Form of Birth Control Ever Used","C158615","A question about whether another form of birth control was ever used.","Was another Form of Birth Control Ever Used | Has the patient ever used another form of birth control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937011","Temporally-Feathered Intensity-Modulated Radiation Therapy","C157286","A modification of intensity-modulated radiation therapy that optimizes the temporal dimension through which radiation therapy is delivered to further reduce radiation-induced toxicity by increasing the time for normal tissue recovery.","Temporally-Feathered Intensity-Modulated Radiation Therapy | TFRT | Temporally Feathered Intensity-Modulated Radiation Therapy | Temporally Feathered Radiation Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937013","ONECUT2 Gene","C157288","This gene is involved in the transcriptional activation of genes affecting melanocyte and hepatocyte differentiation.","ONECUT2 Gene | ONECUT2 | One Cut Homeobox 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937007","ONECUT2 wt Allele","C157289","Human ONECUT2 wild-type allele is located in the vicinity of 18q21.31 and is approximately 56 kb in length. This allele, which encodes one cut domain family member 2 protein, plays a role in DNA binding, transcriptional regulation and organogenesis.","ONECUT2 wt Allele | HNF6B | OC-2 | OC2 | One Cut Domain Family Member 2 Gene | One Cut Domain, Family Member 2 Gene | One Cut Homeobox 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0751715","Reiki Therapy","C15728","An alternative medical practice.  The practitioners of reiki believe that health and disease are a matter of the life force being disrupted.  Reiki healers claim to channel reiki into 'diseased' individuals for 'rebalancing.' (from Skeptic's Dictionary)","Reiki Therapy | Reiki",,,,,,,,,,,,,,,"45766671","Reiki",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937069","MRTX 849","C157493","An orally available, small molecule inhibitor that targets the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration adagrasib covalently binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C, thereby inhibiting mutant KRAS-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.","Adagrasib | ADAGRASIB | KRAS G12C Inhibitor MRTX849 | Krazati | MRTX 849 | MRTX-849 | MRTX849",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937070","Anti-CTLA-4/OX40 Bispecific Antibody ATOR-1015","C157494","A bispecific antibody consisting of a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitory protein fused to an OX40 agonistic human immunoglobulin G1 (IgG1) antibody, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CTLA-4/OX40 bispecific antibody ATOR-1015 simultaneously binds to CTLA-4 and OX40, which may inhibit CTLA-4-mediated downregulation of T-cell activation and induce proliferation of memory and effector T-lymphocytes via OX40 activation. Both CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), and OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), are overexpressed by regulatory T-cells (Tregs) in the tumor microenvironment. ATOR-1015 may reduce the number of Tregs and promote the activation of effector T-cells, thereby enhancing the immune-mediated anti-tumor response.","Anti-CTLA-4/OX40 Bispecific Antibody ATOR-1015 | ADC 1015 | ADC-1015 | ADC1015 | ATOR 1015 | ATOR-1015 | ATOR1015 | CTLA-4 x OX40 Bispecific Antibody ATOR-1015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937071","MIV 818","C157496","A liver-targeting nucleotide phosphoramidate prodrug of troxacitabine monophosphate (TRX-MP), a dioxolane derivative and L-configuration deoxycytidine analogue, with potential antineoplastic activity. Upon oral administration, fostroxacitabine bralpamide is rapidly and specifically hydrolyzed in hepatocytes by liver carboxylesterase 1 (carboxylesterase 1, CE-1), generating high levels of the chain-terminating nucleotide, troxacitabine triphosphate (TRX-TP) in the liver. TRX-TP is then incorporated into tumor cell DNA, leading to termination of DNA synthesis and inhibition of tumor cell proliferation.","Fostroxacitabine Bralpamide | FOSTROXACITABINE BRALPAMIDE | MIV 818 | MIV-818 | MIV818 | Troxacitabine Nucleotide Prodrug MIV-818 | Troxacitabine Prodrug MIV-818",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937064","Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents","C157497","Castration-resistant prostate carcinoma which is refractory to second-generation androgen receptor axis-targeted agents, namely abiraterone and enzalutamide.","Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents | Castration-Resistant Prostate Carcinoma Refractory to Second-Generation ARAT Agents",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937384","AST 008","C157771","A spherical nucleic acid (SN)-based agonist of toll-like receptor 9 (TLR9), with potential immunostimulating activity. Upon administration, cavrotolimod targets and is able to enter various immune cells, including monocytes/macrophages, plasmacytoid dendritic cells (pDCs), natural killer (NK) cells and B cells, through endocytosis. Within the endosome, it binds to and activates TLR9. TLR9 activation induces immune signaling pathways and activates various immune cells, including B-cells, pDCs, NKs, and induces both the production of T-helper 1 cells (Th1) and a Th1-mediated immune response as well as a cytotoxic T-lymphocyte (CTL)-based immune response against tumor cells. This results in an inhibition of tumor cell proliferation. TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate and adaptive immune responses. The SNA is a dense, radial arrangement of nucleic acids (DNA) on the surface of liposomal nanoparticles, providing a 3D-construct, that has a high cellular uptake and an increased presentation of the DNA for TLR9 agonism. It also protects against breakdown by nucleases and increases the half-life of the construct compared to linear oligonucleotides that are not in SNA format.","Cavrotolimod | AST 008 | AST-008 | AST008 | CAVROTOLIMOD | SNA AST-008 | TLR9 Agonist AST-008 | Toll-like Receptor 9 Activator AST-008",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937381","Antibody-drug Conjugate VLS-101","C157772","An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the tumor-associated antigen (TAA) receptor tyrosine kinase-like orphan receptor 1 (ROR1) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of zilovertamab vedotin targets and binds to ROR1 expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the ROR1-expressing cancer cells, through an as of yet unknown mechanism of action. ROR1, also known as neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), is expressed during embryogenesis and by certain leukemias. It plays key roles in tumor cell proliferation and survival.","Zilovertamab Vedotin | Anti-ROR1 ADC VLS-101 | Antibody-drug Conjugate VLS-101 | MK-2140 | VLS 101 | VLS-101 | VLS101 | ZILOVERTAMAB VEDOTIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937382","Cryocompression Therapy","C157773","Therapy that combines compression garments or dressings with cooling of the treated area.","Cryocompression Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937379","Metastatic Malignant Genitourinary System Neoplasm","C157774","A malignant neoplasm that arises from the genitourinary system and has metastasized to other anatomic sites.","Metastatic Malignant Genitourinary System Neoplasm | Metastatic Genitourinary System Malignant Neoplasm | Metastatic Genitourinary Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937380","Botulinum Toxin Therapy","C157775","Treatment by injections of botulinum toxin. This can diminish signs of aging in the face, reduce excessive sweating and muscle spasms, and treat overactive bladder and lazy eye.","Botulinum Toxin Therapy | Botox | Botox Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937424","Maraba Oncolytic Virus Expressing Mutant HPV E6/E7","C157776","A cancer vaccine comprised of a recombinant, attenuated form of the oncolytic rhabdovirus Maraba (MG1) encoding inactive, mutant forms of the human papillomavirus (HPV) transforming proteins E6 and E7, with potential immunostimulating and antineoplastic activities. Upon administration of MG1-E6E7, MG1 preferentially infects tumor cells and induces the expression of the E6 and E7 proteins. The MG1 virus exerts its oncolytic activity, thereby directly lysing tumor cells. Following the lysis of infected cells, the virus is released and can infect adjacent cells, which both induces further tumor cell oncolysis and may activate the immune system to kill the infected tumor cells. The expressed E6 and E7 proteins stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV E6 and E7, thereby further inducing tumor cell lysis. Oncoproteins E6 and E7 play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.","Maraba Oncolytic Virus Expressing Mutant HPV E6/E7 | MG1-E6/E7 | MG1-E6E7 | MG1-expressing Mutant HPV E6/E7 | Oncolytic MG1 Virus-encoding E6E7 | Oncolytic Virus MG1-E6E7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937425","Adenovirus Expressing Mutant HPV E6/E7","C157777","A cancer vaccine comprised of a genetically engineered, replication-deficient adenovirus encoding inactive, mutant forms of the human papillomavirus (HPV) transforming proteins E6 and E7, with potential immunostimulating and antineoplastic activities. Upon administration of adenovirus expressing mutant HPV E6/E7, the adenovirus infects and expresses the E6 and E7 proteins. The expressed E6 and E7 proteins stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV E6 and E7, thereby inducing tumor cell lysis. Oncoproteins E6 and E7 play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.","Adenovirus Expressing Mutant HPV E6/E7 | Ad-E6/E7 | Ad-E6E7 | Adenoviral-HPV E6E7 Vaccine | Adenoviral-expressing Mutant HPV E6/E7 | Adenovirus Vaccine Expressing Mutant HPV E6 and E7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937732","CDH1 Gene Promoter Hypermethylation","C158106","A genetic finding indicating an excess of DNA methylation in the promoter region of the CDH1 gene.","CDH1 Gene Promoter Hypermethylation | Arc-1 Gene Promoter Hypermethylation | CD324 Gene Promoter Hypermethylation | CDH1 Promoter Hypermethylation | CDHE Gene Promoter Hypermethylation | Cadherin 1 Gene Promoter Hypermethylation | Cadherin, Epithelial Gene Promoter Hypermethylation | Calcium-Dependent Adhesion Protein, Epithelial Gene Promoter Hypermethylation | E-Cadherin Gene Promoter Hypermethylation | ECAD Gene Promoter Hypermethylation | LCAM Gene Promoter Hypermethylation | UVO Gene Promoter Hypermethylation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937733","EDNRB Gene Promoter Hypermethylation","C158107","A genetic finding indicating an excess of DNA methylation in the promoter region of the EDNRB gene.","EDNRB Gene Promoter Hypermethylation | EDNRB Promoter Hypermethylation | ET-B Gene Promoter Hypermethylation | ET-BR Gene Promoter Hypermethylation | ETB Gene Promoter Hypermethylation | ETB1 Gene Promoter Hypermethylation | ETBR Gene Promoter Hypermethylation | ETRB Gene Promoter Hypermethylation | Endothelin Receptor Type B Gene Promoter Hypermethylation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937730","VEGF Overexpression Positive","C158108","An indication that overexpression of a member of the VEGF family has been detected in a sample.","VEGF Overexpression Positive | VEGF Family Overexpression Positive | Vascular Endothelial Growth Factor Family Overexpression Positive | Vascular Endothelial Growth Factor Overexpression Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937731","THBS1 Overexpression Positive","C158109","An indication that overexpression of THBS1 has been detected in a sample.","THBS1 Overexpression Positive | TSP Overexpression Positive | TSP-1 Overexpression Positive | TSP1 Overexpression Positive | Thrombospondin 1 Overexpression Positive | Thrombospondin-1 Overexpression Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517709","Laboratory/Correlate Data","C15810","No value exists.","Laboratory/Correlate Data | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937728","E2F3 Gene Amplification","C158110","A molecular genetic abnormality indicating the presence of multiple copies of the E2F3 gene.","E2F3 Gene Amplification | E2F Transcription Factor 3 Gene Amplification | E2F-3 Gene Amplification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937727","CDISC SDTM QRS Method Terminology","C158113","Terminology associated with the QRS method codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM QRS Method Terminology | QRS Method | QRSMTHOD | SDTM-QRSMTHOD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937725","CDISC ADaM Geriatric Depression Scale Short Form Questionnaire Parameter Name Terminology","C158115","Terminology associated with the Geriatric Depression Scale Short Form questionnaire parameter name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Analysis Data Model (ADaM).","CDISC ADaM Geriatric Depression Scale Short Form Questionnaire Parameter Name Terminology | ADaM-GDS02PN | GDS02PN | Geriatric Depression Scale Short Form Questionnaire Parameter Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937722","CDISC SEND Challenge Agent Parameter Code Terminology","C158116","Terminology associated with the challenge agent parameter code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).","CDISC SEND Challenge Agent Parameter Code Terminology | ACPARMCD | Challenge Agent Parameter Code | SEND-ACPARMCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937723","CDISC SEND Challenge Agent Parameter Long Name Terminology","C158117","Terminology associated with the challenge agent parameter long name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).","CDISC SEND Challenge Agent Parameter Long Name Terminology | ACPARM | Challenge Agent Parameter Long Name | SEND-ACPARM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937861","TINAGL1 Gene","C158391","This gene may play a role in the regulation of receptor-mediated signaling.","TINAGL1 Gene | TINAGL1 | Tubulointerstitial Nephritis Antigen Like 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950650","LOXO 305","C158617","An orally available, selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Upon oral administration, pirtobrutinib selectively and reversibly binds to BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, thereby inhibiting the growth of malignant B-cells that overexpress BTK. Reversible binding of LOXO-305 may preserve antitumor activity in the presence of certain acquired resistance mutations, including C481 mutated BTK, and limit toxicity associated with inhibition of other non-BTK kinases. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.","Pirtobrutinib | 5-Amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-((2S)-1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide | BTK Inhibitor LOXO-305 | Jaypirca | LOXO 305 | LOXO-305 | LOXO305 | LY3527727 | PIRTOBRUTINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950651","Have Oral Contraceptives Ever Been Taken","C158618","A question about whether oral contraceptives were ever taken.","Have Oral Contraceptives Ever Been Taken | Has the patient ever taken oral contraceptives",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950652","Was Tamoxifen Ever Taken","C158619","A question about whether Tamoxifen was ever taken.","Was Tamoxifen Ever Taken | Has the patient ever taken Tamoxifen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519573","Trace Element Nutrition, Other","C15861","No value exists.","Trace Element Nutrition, Other | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950653","Endometrioid Tumor, Variant with Squamous Differentiation","C158620","An endometrioid tumor exhibiting squamous differentiation.","Endometrioid Tumor, Variant with Squamous Differentiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950654","Number of Full Term Pregnancies","C158621","The number of full term pregnancies.","Number of Full Term Pregnancies | Number of full term pregnancies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950655","Borderline Serous Cystadenofibroma","C158622","A neoplasm of low malignant potential arising from a site in the female reproductive system. Almost all cases have been reported in the ovary. It is characterized by the presence of cystic spaces which are lined by atypical serous epithelial cells. The surrounding ovarian stroma is fibrotic. There is no evidence of stromal invasion.","Borderline Serous Cystadenofibroma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950656","Greater Than or Equal to Four","C158623","A response indicating that the reported result, quantity or score is greater than or equal to four.","Greater Than or Equal to Four | Greater Than or Equal to 4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950657","Click or Tap Here to Enter Text","C158624","A directive to click or tap to enter text.","Click or Tap Here to Enter Text | Click or tap here to enter text",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950658","Age at Initial Pathologic Diagnosis","C158625","A question about the age of the individual at the time of the initial pathologic diagnosis.","Age at Initial Pathologic Diagnosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950659","Date and Method of Initial Pathologic Diagnosis","C158626","A section header about the date and method of the initial pathologic diagnosis.","Date and Method of Initial Pathologic Diagnosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950660","Date of Tumor Progression After Initial Treatment","C158627","The data of tumor progression after initial treatment.","Date of Tumor Progression After Initial Treatment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950661","Date of Tumor Reoccurrence After Initial Treatment","C158628","The date of  the tumor reoccurrence after the initial treatment.","Date of Tumor Reoccurrence After Initial Treatment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516775","Computers and Advanced Instrumentation","C15884","NIH Emphasis Area -- Recent advances in basic biology, genetics, diagnosis, and health care have all been closely linked to the development of new research instruments and computer hardware and software.  Improvements in the detection of early cancers and technologies to better visualize the living body in health and disease states will provide a wealth of knowledge that can lead to new and improved diagnostics, treatments and prevention strategies.","Computers and Advanced Instrumentation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950861","ALK Rearrangement Testing Method","C158850","A request to enter the specific molecular analysis method used to detect and identify rearrangements involving the ALK gene.","ALK Rearrangement Testing Method | ALK Rearrangement Analysis Testing Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937065","Resistance to Second-Generation Androgen Receptor Axis-Targeted Agents","C157498","A finding indicating that a castration-resistant prostate carcinoma is refractory to second-generation androgen receptor axis-targeted agents.","Resistance to Second-Generation Androgen Receptor Axis-Targeted Agents | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937066","Nanoscale Coordination Polymer Nanoparticles CPI-100","C157499","A preparation of self-assembled core-shell nanoscale coordination polymer (NCP) nanoparticles containing an as of yet undisclosed payload with potential immunostimulating and antineoplastic activities. Upon intravenous administration, NCP nanoparticle formulation CPI-100 delivers its payload to tumor cells, which may lead to enhanced immune-mediated killing and regression of tumor cells.","Nanoscale Coordination Polymer Nanoparticles CPI-100 | CPI 100 | CPI-100 | CPI100 | NCP Nanoparticles CPI-100",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937067","CD56-enriched CD3-positive Donor Lymphocytes","C157500","A population of CD3-positive lymphocytes expressing the CD56 surface antigen, with potential immunomodulating activity. Upon infusion of the CD56-enriched CD3-positive donor lymphocytes, these cells may facilitate the reconstitution of CD4-positive T-cells, regulatory T-cells (Tregs) and natural killer (NK) cells, which may reduce the incidence of post-transplant graft-versus-host disease (GvHD) following haploidentical stem cell transplant (SCT). CD56 is a transmembrane glycoprotein also known as neural cell adhesion molecule 1 (NCAM-1).","CD56-enriched CD3-positive Donor Lymphocytes | CD56+/CD3+ Donor Cells | CD56-enriched Donor Cells | CD56-enriched Donor Lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936831","Refractory PVRL","C157069","Primary vitreoretinal non-Hodgkin lymphoma that does not respond to treatment.","Refractory Primary Vitreoretinal Non-Hodgkin Lymphoma | Refractory PVRL | Refractory Primary Vitreoretinal Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936832","Recurrent Primary Vitreoretinal Diffuse Large B-Cell Lymphoma","C157070","The reemergence of primary vitreoretinal diffuse large B-cell lymphoma after a period of remission.","Recurrent Primary Vitreoretinal Diffuse Large B-Cell Lymphoma | Recurrent PVRL DLBCL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936833","Refractory Primary Vitreoretinal Diffuse Large B-Cell Lymphoma","C157071","Primary vitreoretinal diffuse large B-cell lymphoma that does not respond to treatment.","Refractory Primary Vitreoretinal Diffuse Large B-Cell Lymphoma | Refractory PVRL DLBCL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936796","Recurrent Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","C157073","The reemergence of primary diffuse large B-cell lymphoma of the central nervous system after a period of remission.","Recurrent Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936797","Refractory Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","C157074","Primary diffuse large B-cell lymphoma of the central nervous system that does not respond to treatment.","Refractory Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936799","Circumferential Margin Status by MRI","C157076","The determination by MRI of the presence or absence of neoplastic tissue outside of a circumferential resection margin.","Circumferential Margin Status by MRI | Circumferential Margin by MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937422","Abdominal Aneurysm Open Repair","C157778","A surgical procedure in which the abdomen is surgically incised (as opposed to laparoscopic intervention) and an aneurysm in the abdominal aorta is repaired in open view.","Abdominal Aneurysm Open Repair | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937423","Ablation for Barrett's Esophagus","C157779","Treatment of an area of Barrett's-affected tissue in the esophagus with heat energy that is delivered through an endoscope.","Ablation for Barrett's Esophagus | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936966","Allogeneic CMV Antigen-specific CD4+/CD8+ T-lymphocytes","C157340","A population of allogeneic T-lymphocytes specifically reactive to cytomegalovirus (CMV) with potential antiviral activity. Allogeneic CMV antigen-specific T-cells are prepared via ex vivo stimulation of donor-derived peripheral blood mononuclear cells (PBMCs) with major cytomegalovirus structural protein, pp65 (ppUL83). T-cells that secrete interferon (IFN)-gamma in response to pp65 antigen exposure are selected and expanded for administration. Administration of the CMV antigen-specific CD4+ and CD8+T-lymphocytes into hematopoietic stem cell transplant (HSCT) or immunocompromised patients infected with CMV may potentially reconstitute virus-specific responses, thereby controlling CMV infections.","Allogeneic CMV Antigen-specific CD4+/CD8+ T-lymphocytes | Allogeneic CMV-specific Antigen-selected T-cells | Allogeneic Cytomegalovirus-specific CD4+ and CD8+ T-cells | Allogeneic Cytomegalovirus-specific CD4+ and CD8+ T-lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936967","Allogeneic HAdV Antigen-specific T-lymphocytes","C157341","A population of allogeneic T-lymphocytes specifically reactive to human adenovirus (HAdV) with potential antiviral activity. Allogeneic HAdV antigen-specific T-cells are prepared via ex vivo stimulation of donor-derived peripheral blood mononuclear cells (PBMCs) with HAdV hexon protein. T-cells that secrete interferon (IFN)-gamma in response to HAdV antigen exposure are selected and expanded for administration. Infusion of the HAdV antigen-specific T-lymphocytes into hematopoietic stem cell transplant (HSCT) patients infected with HAdV may potentially reconstitute virus-specific responses, thereby controlling HAdV infections.","Allogeneic HAdV Antigen-specific T-lymphocytes | Allogeneic HAdV Antigen-selected T-cells | Allogeneic HAdV Antigen-selected T-lymphocytes | Allogeneic HAdV Antigen-specific T-cells | Allogeneic Human Adenovirus-specific T-lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936969","Autologous CT-RCC-1 HERV-E-TCR-transduced-HLA-A11-restricted CD8+/CD34t+ T-cells","C157344","A preparation of autologous T-lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) sequence specific for CT-RCC-1, a tumor-associated antigen (TAA) and HLA-A11-restricted peptide encoded by human endogenous retrovirus (HERV) type E as well as a truncated CD34 chain (CD34t), with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo and re-introduction into the patient, the autologous CT-RCC-1 HERV-E-TCR-transduced-HLA-A11-restricted CD8+/CD34t+ T-cells bind to and induce selective toxicity in tumor cells expressing both the HLA-A11 allele and the CT-RCC-1 HERV-E antigen. The CD34t protein allows the transduced cells to be identified with an anti-CD34 antibody, and facilitates monitoring of the genetically modified T-cells following adoptive transfer. CT-RCC-1 HERV-E is a TAA found in a high percentage of clear cell renal cell carcinoma (ccRCC) cells.","Autologous CT-RCC-1 HERV-E-TCR-transduced-HLA-A11-restricted CD8+/CD34t+ T-cells | Anti-CT-RCC-1 HERV-E-TCR-transduced-HLA-A11-restricted Autologous CD8+/CD34t+ T-cells (SY) | Autologous CT-RCC-1 HERV-E-TCR-transduced-HLA-A11-restricted CD8+/CD34t+ T-lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936962","Modified FOLFIRINOX Regimen","C157345","A modified, dose-adjusted regimen consisting of fluorouracil, irinotecan, leucovorin and oxaliplatin (FOLFIRINOX) that can be used for the treatment of colorectal cancers, and occult primary, ampullary, pancreatic, small bowel and appendiceal adenocarcinomas.","Modified FOLFIRINOX Regimen | Dose-adjusted FOLFIRINOX Regimen | Dose-attenuated FOLFIRINOX Regimen | Modified FOLFIRINOX | Modified Fluorouracil/Irinotecan/Leucovorin/Oxaliplatin | Modified Fluorouracil/Irinotecan/Leucovorin/Oxaliplatin Regimen | mFOLFIRINOX | mFOLFIRINOX Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937862","TINAGL1 wt Allele","C158392","Human TINAGL1 wild-type allele is located in the vicinity of 1p35.2 and is approximately 11 kb in length. This allele, which encodes tubulointerstitial nephritis antigen-like protein, may be involved in the modulation of ligand-dependent signaling.","TINAGL1 wt Allele | ARG1 | Androgen-Regulated Gene 1 | GIS5 | LCN7 | LIECG3 | Lipocalin 7 Gene | OLRG2 | Oxidized LDL-Responsive Gene 2 | P3ECSL | PP6614 | PSEC0088 | TINAG-Like 1 Gene | TINAGRP | Tubulointerstitial Nephritis Antigen Like 1 wt Allele | UNQ204/PRO230",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937859","Tubulointerstitial Nephritis Antigen-Like","C158393","Tubulointerstitial nephritis antigen-like (467 aa, ~52 kDa) is encoded by the human TINAGL1 gene. This protein may play a role in the modulation of receptor signaling.","Tubulointerstitial Nephritis Antigen-Like | Glucocorticoid-Inducible Protein 5 | Lipocalin 7 | OLRG-2 | Oxidized LDL-Responsive Gene 2 Protein | TIN Ag-Related Protein | TIN-Ag-RP | TINAG-Like Protein 1 | TINAG-Related Protein | TINAGL1 | Tubulointerstitial Nephritis Antigen-Related Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937860","Marked Thickening of the Bladder Urothelium Present","C158394","A morphologic finding indicating the presence of marked thickening of the urothelium in the bladder.","Marked Thickening of the Bladder Urothelium Present | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937857","NMT1 Gene","C158395","This gene is involved in the myristoylation of proteins.","NMT1 Gene | N-Myristoyltransferase 1 Gene | NMT1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937858","NMT1 wt Allele","C158396","Human NMT1 wild-type allele is located in the vicinity of 17q21.31 and is approximately 57 kb in length. This allele, which encodes glycylpeptide N-tetradecanoyltransferase 1 protein, plays a role in protein myristoylation.","NMT1 wt Allele | Alternative, Short Form NMT-S Gene | Long Form, NMT-L Gene | N-Myristoyltransferase 1 wt Allele | NMT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937855","Glycylpeptide N-Tetradecanoyltransferase 1","C158397","Glycylpeptide N-tetradecanoyltransferase 1 (496 aa, ~57 kDa) is encoded by the human NMT1 gene. This protein is involved in the irreversible transfer of myristoyl groups from tetradecanoyl-CoA to N-terminal glycines of protein substrates.","Glycylpeptide N-Tetradecanoyltransferase 1 | EC 2.3.1.97 | Myristoyl-CoA:Protein N-Myristoyltransferase | Myristoyl-CoA:Protein N-Myristoyltransferase 1 | N-Myristoyltransferase 1 | NMT 1 | NMT-L | NMT1 | Peptide N-Myristoyltransferase 1 | Type I N-Myristoyltransferase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937856","Vaginal Cuff Brachytherapy","C158398","Radiation delivered by a radiation source contained in an intra-vaginal cylinder to target neoplasms of the vaginal cuff.","Vaginal Cuff Brachytherapy | VCB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937853","High-Dose-Rate Vaginal Cuff Brachytherapy","C158399","High dose rate radiation delivered by a radiation source contained in an intra-vaginal cylinder to target neoplasms of the vaginal cuff.","High-Dose-Rate Vaginal Cuff Brachytherapy | HDR-VCB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514411","Prevention and Treatment Evaluation","C15839","No value exists.","Prevention and Treatment Evaluation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937854","Low-Dose-Rate Vaginal Cuff Brachytherapy","C158400","Low dose rate radiation delivered by a radiation source contained in an intra-vaginal cylinder to target neoplasms of the vaginal cuff.","Low-Dose-Rate Vaginal Cuff Brachytherapy | LDR-VCB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937851","Refractory Paraganglioma","C158401","A paraganglioma that does not respond to treatment.","Refractory Paraganglioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950862","Specify Molecular Abnormalities in Study","C158851","A request to enter the specific molecular abnormalities assayed in a study.","Specify Molecular Abnormalities in Study | Molecular Study Abnormalities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950863","ATRX Mutation Analysis","C158852","A procedure used to detect and identify mutations in the ALK gene.","ATRX Mutation Analysis | ATRX Gene Mutation Analysis | ATRX Mutation Status | ATRX, Chromatin Remodeler Mutation Analysis | Alpha Thalassemia/Mental Retardation Syndrome X-Linked Mutation Analysis | RAD54 Homolog Mutation Analysis | RAD54 Mutation Analysis | RAD54L Mutation Analysis | XH2 Mutation Analysis | XNP Mutation Analysis | ZNF-HX Mutation Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950864","ATRX Mutation Analysis Testing Method","C158853","A request to enter the specific molecular analysis method used to detect and identify mutations in the ATRX gene.","ATRX Mutation Analysis Testing Method | ATRX Mutational Analysis Testing Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950865","BRAF Exon 15 Mutation","C158854","A molecular genetic abnormality indicating the presence of a mutation in exon 15 of the BRAF gene.","BRAF Exon 15 Mutation | B-RAF Exon 15 Mutation | B-RAF1 Exon 15 Mutation | BRAF Exon 15 Gene Mutation | BRAF1 Exon 15 Mutation | Exon 15 | v-raf Murine Sarcoma Viral Oncogene Homolog B1 Exon 15 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950866","Neutrophil Recovery Time","C158855","The duration of time it takes for an individual who has had chemotherapy-induced neutropenia to achieve an acceptable numbers of neutrophils.","Neutrophil Recovery Time | Time to Neutrophil Recovery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950869","Time to Platelet Recovery","C158858","The duration of time it takes for an individual who has had chemotherapy-induced low platelets to achieve an acceptable number of platelets in the blood.","Time to Platelet Recovery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950870","Pathologic/Prognostic Information","C158859","A header on a form about the pathologic/prognostic information.","Pathologic/Prognostic Information | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513307","Mind-Body System","C15885","This sub-category of CAM contains numerous specific modalities used in mind-body approaches to health.  Examples are meditation, hypnosis, biofeedback, support groups, etc.  These are often considered conventional practice and become CAM related when applied to conditions for which they are not usually used, such as hypnosis for genetic problems, support groups for cancer survival, meditation to slow aging.  Included are: Psychotherapy, Meditation, Imagery, Hypnosis, Biofeedback, Support groups, Art therapy, Music therapy, Dance therapy, Journalizing, Humor, Body Psychotherapy, Yoga, Qi Gong, and Tai Chi.","Mind-Body System | Mind-Body Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950871","CBFB Gene Rearrangement","C158860","A molecular abnormality indicating rearrangement of the CBFB gene.","CBFB Gene Rearrangement | CBF-Beta Gene Rearrangement | CBFB | CBFB Rearrangement | Core-Binding Factor Subunit Beta Gene Rearrangement | PEBP2B Gene Rearrangement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950815","days to ANC >1000 per mcl","C158861","The number of days to achieve a neutrophil count of greater than 1000 per microliter.","Days to Absolute Neutrophil Count Greater than 1000 per Microliter | days to ANC >1000 per mcl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950816","Days to Platelet Count Greater than 100,000 per Microliter","C158862","The number of days to achieve a platelet count of greater than 100,000 per microliter.","Days to Platelet Count Greater than 100,000 per Microliter | days to platelet count >100,000 per mcl",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0559229","Cytogenetic Abnormalities Absent","C158864","An indication that cytogenetic abnormalities were not detected in a sample.","Cytogenetic Abnormalities Not Detected | Cytogenetic Abnormalities Absent | Cytogenetically Normal | No Cytogenetic Abnormalities Detected | No abnormality detected | None Detected | None detected | Normal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936792","Clear Circumferential Margin by MRI","C157077","The determination by MRI of the absence of neoplastic tissue outside of a circumferential resection margin.","Clear Circumferential Margin by MRI | Negative Circumferential Margin by MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936793","Involved Circumferential Margin by MRI","C157078","The determination by MRI of the presence of neoplastic tissue outside of a circumferential resection margin.","Involved Circumferential Margin by MRI | Positive Circumferential Margin by MRI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936794","Arfolitixorin","C157079","The R-isomer of folitixorin, a reduced folate-based biomodulator and active metabolite of folate drugs leucovorin (LV) and levoleucovorin (l-LV) that can be used to increase the efficacy of certain antimetabolites, such as the cytotoxic agent 5-fluorouracil (5-FU), and reduce as well as protect against certain antimetabolite-associated adverse effects, such as those seen with high-dose (HD) methotrexate. Upon administration of arfolitixorin, 5,10-methylenetetrahydrofolate (MTHF) is a reduced folate substrate for the enzyme thymidylate synthase (TS) and stabilizes, upon co-administration of 5-FU, the covalent binding of the 5-FU metabolite 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP), instead of deoxyuridine monophosphate (dUMP), to its target enzyme TS, which results in an inhibition of TS. This inhibits the synthesis of deoxythymidine monophosphate (dTMP) and leads to the depletion of thymidine triphosphate (TTP), which is a necessary constituent of DNA. This inhibits DNA synthesis, which leads to an inhibition of cellular proliferation and induces tumor cell death. As MTHF is able to stabilize and strengthen the ternary complex, co-administration of arfolitixorin enhances the inhibition of DNA synthesis and increases the cytotoxic effect of 5-FU. As MTHF is the active form of folate and the active metabolite of LV and l-LV, arfolitixorin does not need to be converted to an active metabolite to become activated. In DNA synthesis, a ternary complex is formed between the reduced folate substrate MTHF, the TS enzyme and dUMP in order to convert dUMP to the DNA building block dTMP, which is necessary for DNA synthesis.","Arfolitixorin | (6R)-5,10-Methylenetetrahydrofolate | 6R-5,10-methyleneTHF | 6R-5-10-Methylenetetrahydrofolate | 6R-MTHF | 6R-methylene THF | ARFOLITIXORIN | Methylenetetrahydrofolic Acid, L-(+)- | Modufolin | Rescufolin | [6R] 5,10-methylenetetrahydrofolate | [6R]-5,10-methylene-tetrahydrofolate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936788","MFSD8 wt Allele","C157081","Human MFSD8 wild-type allele is located in the vicinity of 4q28.2 and is approximately 48 kb in length. This allele, which encodes major facilitator superfamily domain-containing protein 8, plays a role in lysosome activity. Missense mutations in the gene are associated with both macular dystrophy with central cone involvement and late infantile-onset neuronal ceroid lipofuscinosis (vLINCL; neuronal ceroid lipofuscinosis type 7; CLN7 Batten disease).","MFSD8 wt Allele | CCMD | CLN7 | Ceroid-Lipofuscinosis, Neuronal 7, Late Infantile Gene | Ceroid-Lipofuscinosis, Neuronal 7, Late Infantile, Variant Gene | MGC33302 | Major Facilitator Superfamily Domain Containing 8 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937325","CDISC Questionnaire PHQ-2 Test Name Terminology","C157726","Test names of questionnaire questions associated with the Patient Health Questionnaire - 2 Item (PHQ-2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PHQ-2 Test Name Terminology | PHQ04TN | Patient Health Questionnaire - 2 Item Questionnaire Test Name | QS-PHQ-2 TEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937326","CDISC Questionnaire PHQ-2 Test Code Terminology","C157727","Test codes of questionnaire questions associated with the Patient Health Questionnaire - 2 Item (PHQ-2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC Questionnaire PHQ-2 Test Code Terminology | PHQ04TC | Patient Health Questionnaire - 2 Item Questionnaire Test Code | QS-PHQ-2 TESTCD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937327","PHQ-2 Questionnaire Question","C157728","A question associated with the PHQ-2 questionnaire.","PHQ-2 Questionnaire Question | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937322","PHQ-2 - Little Interest or Pleasure in Doing Things","C157729","Patient Health Questionnaire - 2 Item (PHQ-2) Over the past 2 weeks, how often have you been bothered by any of the following problems? Little interest or pleasure in doing things.","PHQ-2 - Little Interest or Pleasure in Doing Things | PHQ04-Little Interest/Pleasure in Things | PHQ0401",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936964","Borderline Resectable Mass","C157347","A tumor mass finding that refers to a continuum between resectable and locally advanced unresectable disease.","Borderline Resectable Mass | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796382","Prevention of Gastric Cancer","C15734","No value exists.","Prevention of Gastric Cancer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936960","Borderline Resectable Pancreatic Ductal Adenocarcinoma","C157350","A pancreatic ductal adenocarcinoma term that refers to a continuum between resectable and locally advanced unresectable disease.","Borderline Resectable Pancreatic Ductal Adenocarcinoma | BR-PDAC | BRPC | Borderline Resectable Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Cancer | Borderline Resectable Pancreatic Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937258","HAART with Hydroxyurea and Didanosine","C157540","Treatment for human immunodeficiency virus (HIV) infection that uses a combination of the antiretroviral drugs hydroxyurea and didanosine. The drugs inhibit the ability of the virus to multiply in the body, and they slow down the development of AIDS.","HAART with Hydroxyurea and Didanosine | HAART HU/ddI | HAART using Hydroxyurea and Didanosine | HAART with HU/ddl | HAART with Hydroxyurea Plus Didanosine | Highly Active Antiretroviral Therapy with HU/ddl | Highly Active Antiretroviral Therapy with Hydroxyurea and Didanosine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937252","Ribavirin/Recombinant Interferon alpha-2b","C157542","A fixed combination of ribavirin, a synthetic nucleoside analog of ribofuranose, and a recombinant form of interferon alfa-2b (IFN-a2b), with activity against hepatitis C virus (HCV). Upon oral administration of the ribavirin capsules, ribavirin is incorporated into viral RNA, thereby inhibiting viral RNA synthesis, inducing viral genome mutations, and inhibiting normal viral replication. Upon injection, IFN-a2b binds to specific IFN cell-surface receptors. This activates IFN-mediated signal transduction pathways and induces the transcription and translation of genes with interferon-stimulated response elements (ISREs); the protein products mediate antiviral, antiproliferative and immunomodulating effects. Although it's largely unknown how these two agents work together, in combination, this is used to treat hepatitis C infection by fighting and slowing the spread of the virus, thereby decreasing blood levels of HCV.","Ribavirin/Recombinant Interferon alpha-2b | RTCA/IFN alpha-2b | RTCA/IFN-a2b | Rebetol/Intron A | Rebetron",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937254","ARHGAP45 Gene","C157544","This gene is involved in the activation of Rho-type GTPases.","ARHGAP45 Gene | ARHGAP45 | Rho GTPase Activating Protein 45 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937247","ARHGAP45 wt Allele","C157545","Human ARHGAP45 wild-type allele is located in the vicinity of 19p13.3 and is approximately 22 kb in length. This allele, which encodes Rho GTPase-activating protein 45, plays a role in the positive regulation of Rho family GTPase activity.","ARHGAP45 wt Allele | HA-1 | HLA-HA1 | HMHA1 | Histocompatibility (Minor) HA-1 Gene | KIAA0223 | Rho GTPase Activating Protein 45 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937852","Refractory Adrenal Gland Pheochromocytoma","C158402","A pheochromocytoma that does not respond to treatment.","Refractory Adrenal Gland Pheochromocytoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937849","B4GALT5 Gene","C158403","This gene plays a role in lactosylceramide biosynthesis.","B4GALT5 Gene | B4GALT5 | Beta-1,4-Galactosyltransferase 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937983","Proteasome Adapter and Scaffold Protein ECM29","C158580","Proteasome adapter and scaffold protein ECM29 (1845 aa, ~204 kDa) is encoded by the human ECPAS gene. This protein plays a role in proteasome localization and assembly.","Proteasome Adapter and Scaffold Protein ECM29 | ECPAS | Ecm29 Proteasome Adapter and Scaffold | Ecm29 Proteasome Adaptor and Scaffold | Proteasome-Associated Protein ECM29 Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1960221","Lymphoma in Remission","C158581","A finding of lymphoma that is not growing and responds to treatment.","Lymphoma in Remission | ",,,,,,,,,,,,,,,"4142582","Malignant lymphoma in remission",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937981","Non-Hodgkin Lymphoma in Remission","C158582","A finding of non-Hodgkin lymphoma that is not growing and responds to treatment.","Non-Hodgkin Lymphoma in Remission | Non-Hodgkin's Lymphoma in Remission",,,,,,,,,,,,,,,"603291","Non-Hodgkin's lymphoma in remission",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0281869","Hodgkin Lymphoma in Remission","C158583","A finding of Hodgkin lymphoma that is not growing and responds to treatment.","Hodgkin Lymphoma in Remission | ",,,,,,,,,,,,,,,"4144302","Hodgkin's disease in remission",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL938090","Unresectable Urethral Urothelial Carcinoma","C158585","Urethral urothelial carcinoma that is not amenable to surgical resection.","Unresectable Urethral Urothelial Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938091","Unresectable Bladder Urothelial Carcinoma","C158586","Bladder urothelial carcinoma that is not amenable to surgical resection.","Unresectable Bladder Urothelial Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938088","Unresectable Ureter Urothelial Carcinoma","C158587","Ureter urothelial carcinoma that is not amenable to surgical resection.","Unresectable Ureter Urothelial Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938089","Unresectable Renal Pelvis Urothelial Carcinoma","C158588","A renal pelvis urothelial carcinoma that is not amenable to surgical resection.","Unresectable Renal Pelvis Urothelial Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0920665","Tissue Resources","C15858","No value exists.","Tissue Resources | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513409","Monitoring for Recurrence","C15815","No value exists.","Monitoring for Recurrence | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518299","Neuroscience and Neuropsychiatric Research","C15817","1B; Basic Science Research (includes vaccine and chemotherapy development), Neuroscience And Neuropsychiatric Research","Neuroscience and Neuropsychiatric Research | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511147","Biological Response Modifiers Program","C15772","A program set up to establish cooperative agreements for Clinical Trials of Cancer Therapy with Biological Response Modifiers (CATBRMs) and to develop novel approaches for such therapy.  Funding is provided to foster innovative clinical trials of BRMs by peer-reviewed groups of highly experienced clinical and preclinical investigators who have the unique technical capabilities to study new agents in early clinical trials and to address hypothesis-driven issues of mechanisms of action.","Biological Response Modifiers Program | BRMP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937323","PHQ-2 - Feeling Down, Depressed or Hopeless","C157730","Patient Health Questionnaire - 2 Item (PHQ-2) Over the past 2 weeks, how often have you been bothered by any of the following problems? Feeling down, depressed or hopeless.","PHQ-2 - Feeling Down, Depressed or Hopeless | PHQ04-Feeling Down Depressed or Hopeless | PHQ0402",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937324","ESS - Total Score","C157731","Epworth Sleepiness Scale (ESS) Total score.","ESS - Total Score | ESS01-Total Score | ESS0109",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0396072","Laryngeal Papillomatosis","C157733","Recurrent respiratory papillomatosis that affects the larynx.","Laryngeal Papillomatosis | Recurrent Respiratory Papillomatosis of the Larynx",,,,,,,,,,,,,,,"4048501","Laryngeal papillomatosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL938136","NeuroBlate System","C157734","A proprietary, minimally invasive robotic laser thermotherapy tool, designed specifically for use in the brain, that uses MRI-guided surgical ablation technology. It is designed to provide precise and maximal tumor reduction without the invasiveness of an open neurosurgical procedure.","NeuroBlate System | NBS | NeuroBlate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0565514","Compression Therapy","C157735","The use of compression dressings or garments to prevent or treat any of various conditions.","Compression Therapy | ",,,,,,,,,,,,,,,"4137031","Compression - action",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937461","Compression Therapy for Neuropathy Prevention","C157736","The use of compression garments to prevent the development of peripheral neuropathy.","Compression Therapy for Neuropathy Prevention | Compression Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937459","Kidney Synovial Sarcoma","C157737","A synovial sarcoma arising from the kidney.","Kidney Synovial Sarcoma | Renal Synovial Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937458","Smooth Muscle Metaplasia","C157739","A morphologic finding indicating the transformation of non-smooth muscle cells to smooth muscle cells.","Smooth Muscle Metaplasia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1318456","Cosmetic Surgery","C157741","Procedures and techniques focused on improving an individual's appearance.","Cosmetic Surgery | ",,,,,,,,,,,,,,,"4207050","Cosmetic surgery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937406","Valvular Surgery","C157742","Surgery to repair any of the valves of the heart.","Valvular Surgery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937248","Rho GTPase-Activating Protein 45","C157546","Rho GTPase-activating protein 45 (1136 aa, ~125 kDa) is encoded by the human ARHGAP45 gene. This protein is involved in the activation of Rho family GTPases.","Rho GTPase-Activating Protein 45 | ARHGAP45 | Minor Histocompatibility Antigen HA-1 Precursor | Minor Histocompatibility Protein HA-1 Precursor | Rho GTPase Activating Protein 45",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937249","ARHGAP45 Gene Mutation","C157547","A change in the nucleotide sequence of the ARHGAP45 gene.","ARHGAP45 Gene Mutation | HA-1 Gene Mutation | HLA-HA1 Gene Mutation | HMHA1 Gene Mutation | Histocompatibility (Minor) HA-1 Gene Mutation | Rho GTPase Activating Protein 45 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937250","ARHGAP45 NM_012292.4:c.416G>A","C157548","A nucleotide substitution at position 416 of the coding sequence of the ARHGAP45 gene where guanine has been mutated to adenine.","ARHGAP45 NM_012292.4:c.416G>A | ARHGAP45 c.416G>A | HA-1 c.416G>A | HLA-HA1 Gene c.416G>A | HMHA1 Gene c.416G>A | NM_012292.4:c.416G>A | Rho GTPase Activating Protein 45 Gene c.416G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937244","ARHGAP45 Protein Variant","C157549","A variation in the amino acid sequence for Rho GTPase-activating protein 45.","ARHGAP45 Protein Variant | Minor Histocompatibility Antigen HA-1 Precursor Protein Variant | Minor Histocompatibility Protein HA-1 Precursor Protein Variant | Rho GTPase Activating Protein 45 Protein Variant | Rho GTPase-Activating Protein 45 Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL583648","AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, 1","C157123","An autosomal dominant condition caused by mutation(s) in the STAT3 gene, encoding signal transducer and activator of transcription 3. It is characterized by variable features along a spectrum of autoimmune disorders affecting multiple organs. Common manifestations may include insulin-dependent diabetes mellitus and autoimmune enteropathy, or celiac disease, and autoimmune hematologic disorders. Other features include short stature and nonspecific dermatitis.","Infantile-Onset Multisystem Autoimmune Disease 1 | ADMIO1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4048800","Phelan-McDermid Syndrome","C157124","An autosomal dominant condition caused by mutation(s) and or deletion of the SHANK3 gene, encoding SH3 and multiple ankyrin repeat domains protein 3. It is characterized by variable features, which may include intellectual disability, autism spectrum disorder, developmental delay and mild dysmorphic features.","Phelan-McDermid Syndrome | Chromosome 22q13.3 Deletion Syndrome | PHMDS",,,,,,,,,,,,,,,"44783247","22q13.3 deletion syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL936808","Recurrent Paraganglioma","C157125","The reemergence of paraganglioma after a period of remission.","Recurrent Paraganglioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936809","Unresectable Paraganglioma","C157126","Paraganglioma that is not amenable to surgical resection.","Unresectable Paraganglioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936810","Anti-LAG3 Monoclonal Antibody INCAGN02385","C157127","A Fc-engineered immunoglobulin G1-kappa (IgG1k) monoclonal antibody targeting the co-inhibitory receptor lymphocyte-activation gene 3 protein (LAG-3; LAG3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, tuparstobart targets and binds to human LAG-3 on tumor-infiltrating  lymphocytes (TILs) and blocks the interaction between LAG-3 and major histocompatibility complex class II (MHC II) molecules on the surface of antigen-presenting cells (APCs) and tumor cells. This prevents the negative regulation of T-cell activity that occurs via LAG-3-MHC II binding and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells, which leads to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF), negatively regulates both proliferation and activation of T-cells. Its expression on  TILs is associated with tumor-mediated immune suppression.","Tuparstobart | Anti-LAG-3 Monoclonal Antibody INCAGN02385 | Anti-LAG-3 Monoclonal Antibody INCAGN02385 | Anti-LAG3 Monoclonal Antibody INCAGN02385 | INCAGN 02385 | INCAGN 2385 | INCAGN-02385 | INCAGN02385 | INCAGN2385 | TUPARSTOBART",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936811","Unresectable Adrenal Gland Pheochromocytoma","C157128","Adrenal gland pheochromocytoma that is not amenable to surgical resection.","Unresectable Adrenal Gland Pheochromocytoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936804","Locally Advanced Adrenal Gland Pheochromocytoma","C157129","Adrenal gland pheochromocytoma that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Adrenal Gland Pheochromocytoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938085","Lyophilisate for emulsion for injection","C158596","Solid sterile preparation for veterinary use consisting of a freeze-dried powder intended to be mixed with the specified liquid to obtain an emulsion for injection.","Lyophilisate for Emulsion for Injection Dosage Form | Lyophilisate for Emulsion for Injection | Lyophilisate for emulsion for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938082","Lyophilisate and solvent for emulsion for injection","C158597","Sterile lyophilisate (freeze-dried powder) and sterile solvent intended for the preparation of an emulsion for injection, for veterinary use, by mixing the powder and the solvent.","Lyophilisate and Solvent for Emulsion for Injection Dosage Form | Lyophilisate and Solvent for Emulsion for Injection | Lyophilisate and solvent for emulsion for injection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938083","Effervescent powder and powder for oral suspension","C158598","Effervescent powder and powder intended for the preparation of an oral suspension by dissolving and/or dispersing the effervescent powder and the powder in the specified liquid(s). The effervescent powder contains active ingredient(s); the powder may or may not contain active ingredient(s).","Effervescent Powder and Powder for Oral Suspension Dosage Form | Effervescent Powder and Powder for Oral Suspension | Effervescent powder and powder for oral suspension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950885","Were Routine Cytogenetics Done","C158811","A question about whether routine cytogenetic tests were completed.","Were Routine Cytogenetics Completed | Were Routine Cytogenetics Done",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950886","Total Number of Metaphases","C158812","A section requesting the input of the total number of metaphases.","Total Number of Metaphases | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1450049","Videoconferences","C158813","The use of audio and visual signals to link users at different locations for communication in real-time.","Videotelephony | Video Call | Video Conference | Videoconference",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2749754","Iron Deficiency","C158814","Subnormal concentrations of iron resulting from low iron intake, inefficient iron absorption in the gastrointestinal tract, or increased iron loss.","Iron Deficiency | ",,,,,,,,,,,,,,,"4146209","Iron deficiency",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL950887","Actinium Ac 225-FPI-1434","C158815","A radioconjugate consisting of veligrotug, a humanized monoclonal antibody directed against insulin-like growth factor-1 receptor (IGF-1R) linked, via a bifunctional chelate, to the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic activity. Upon administration of actinium Ac 225-FPI-1434, the veligrotug moiety targets and binds to IGF-1R expressed on tumor cells. Upon binding, the radioisotope moiety delivers a cytotoxic dose of alpha radiation to IGF-1R-expressing tumor cells. Activation of IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by various cancer cell types, stimulates cell proliferation, promotes angiogenesis, enables oncogenic transformation, and suppresses apoptosis.","Actinium Ac 225-FPI-1434 | 225Ac-FPI-1434 | Actinium Ac 225-FPI-1397-FPI-1175 | Actinium Ac 225-labeled FPI-1434 | FPI 1434 | FPI-1434 | FPI1434 | FPX 01 | FPX-01 | FPX01 | [225Ac]-FPI-1434 | [Ac-225]-FPI-1434",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950888","Indium In 111-FPI-1547","C158816","A radioimmunoconjugate composed of FPI-1175 (AVE1642), a humanized monoclonal antibody against insulin-like growth factor-1 receptor (IGF-1R) linked, via the bifunctional chelate FPI-1397, to the radioisotope indium-111 (111In or In-111), with potential imaging activity upon single photon emission computed tomography (SPECT). Upon administration of indium In 111-FPI-1547, the FPI-1547 moiety targets and binds to IGF-1R expressed on tumor cells. Upon uptake and imaging, IGF-1R-expressing tumor cells can be visualized. This allows assessment of IGF-1R expression on tumor cells as well as tumor uptake of the agent. The linker promotes increased clearance of the radioisotope.","Indium In 111-FPI-1547 | Indium In 111-FPI-1397-FPI-1175 | Indium In 111-labeled FPI-1547 | [111In]-FPI-1547",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0340950","Iron Deficiency without Anemia","C158817","Subnormal concentrations of iron resulting from low iron intake, inefficient iron absorption in the gastrointestinal tract, or increased iron loss; occurring in the absence of anemia.","Iron Deficiency without Anemia | Non-Anemic Iron Deficiency",,,,,,,,,,,,,,,"4120446","Iron deficiency without anemia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C4042342","Abaloparatide","C158818","A 34 amino acid synthetic analog of human parathyroid hormone-related protein (PTHrP) (PTHrP(1-34) analog), with bone-growing and bone density conserving activities. Upon subcutaneous administration, abaloparatide acts similar to PTHrP and targets, binds to and activates parathyroid hormone 1 (PTH1) receptor (PTH1R), a G protein-coupled receptor (GPCR) expressed in osteoblasts and bone stromal cells. PTH1R activates the cyclic AMP (cAMP) signaling pathway and the bone anabolic signaling pathway, leading to bone growth, increased bone mineral density (BMD) and volume. This correlates with increased bone mass and strength and prevents or treats osteoporosis and decreases fractures.","Abaloparatide | ABALOPARATIDE | BA058 | BIM-44058 | C2.29-methyl(22-L-glutamic Acid(F>E),23-L-leucine(F>L),25-L-glutamic Acid(H>E),26-L-lysine(H>K),28-L-leucine(I>L),30-L-lysine(E>K),31-L-leucine(I>L))Human Parathyroid Hormone-related Protein-(1-34)-proteinamide | L-Alaninamide, L-alanyl-L-valyl-L-seryl-L-alpha-glutamyl-L-histidyl-L-glutaminyl-L-leucyl-L-leucyl-L-histidyl-L-alpha-aspartyl-L-lysylglycyl-L-lysyl-L-seryl-L-isoleucyl-L-glutaminyl-L-alpha-aspartyl-L-leucyl-L-arginyl-L-arginyl-L-arginyl-L-alpha-glutamyl-L-leucyl-L-leucyl-L-alpha-glutamyl-L-lysyl-L-leucyl-L-leucyl-2-methylalanyl-L-lysyl-L-leucyl-L-histidyl-L-threonyl- | Tymlos",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936863","POLG-Related Spectrum Disorders","C157267","A group of disorders with overlapping phenotypes caused by mutation(s) of the POLG gene, encoding DNA polymerase subunit gamma-1. Phenotypic variations include Alpers-Huttenlocher syndrome (AHS), childhood myocerebrohepatopathy spectrum (MCHS), myoclonic epilepsy myopathy sensory ataxia (MEMSA), ataxia neuropathy spectrum (ANS), autosomal recessive progressive external ophthalmoplegia (arPEO), and autosomal dominant progressive external ophthalmoplegia (adPEO).","POLG-Related Spectrum Disorders | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0032453","Relapsing Polychondritis","C157268","A rare autoimmune disorder characterized by recurrent episodes of inflammation of cartilage and other connective tissues.","Relapsing Polychondritis | ",,,,,,,,,,,,,,,"4216873","Relapsing polychondritis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937026","Aspira Indwelling Catheter","C157269","A proprietary indwelling catheter used to drain accumulated fluid from the pleural or peritoneal cavity to relieve symptoms associated with malignant pleural effusion or malignant ascites. The Aspira system connects to a low-vacuum siphon pump that drains into a bag.","Aspira Indwelling Catheter | Aspira | Aspira Catheter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937027","PHF10 Gene","C157270","This gene is involved in the proliferation of neural progenitor cells and chromatin remodeling.","PHF10 Gene | PHD Finger Protein 10 Gene | PHF10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937028","PHF10 wt Allele","C157271","Human PHF10 wild-type allele is located in the vicinity of 6q27 and is approximately 22 kb in length. This allele, which encodes PHD finger protein 10, plays a role in chromatin remodeling and neural progenitor cell maintenance.","PHF10 wt Allele | BAF45A | BRG1-Associated Factor, 45-kD, A Gene | FLJ10975 | PHD Finger Protein 10 wt Allele | XAP135",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937029","PHD Finger Protein 10","C157272","PHD finger protein 10 (498 aa, ~56 kDa) is encoded by the human PHF10 gene. This protein is involved in SWI/SNF-mediated chromatin remodeling and promotion of neural progenitor cell proliferation.","PHD Finger Protein 10 | BAF45a | BRG1-Associated Factor 45a | PHD Zinc Finger Protein XAP135 | PHF10 | XAP135",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937022","ACTL6A Gene","C157273","This gene plays a role in transcriptional activation and repression of selected genes through chromatin remodeling.","ACTL6A Gene | ACTL6A | Actin Like 6A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937023","ACTL6A wt Allele","C157274","Human ACTL6A wild-type allele is located in the vicinity of 3q26.33 and is approximately 26 kb in length. This allele, which encodes actin-like protein 6A, is involved in chromatin remodeling.","ACTL6A wt Allele | ACTL6 | ARPN-BETA | Actin Like 6A wt Allele | Actin-Related Protein, Beta Gene | Arp4 | BAF53 | BAF53A | BRG1-Associated Factor, 53-kD Gene | INO80K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937024","Actin-Like Protein 6A","C157275","Actin-like protein 6A (429 aa, ~47 kDa) is encoded by the human ACTL6A gene. This protein plays a role in the regulation of both chromatin remodeling and histone acetyltransferase activity.","Actin-Like Protein 6A | 53 kDa BRG1-Associated Factor A | ACTL6A | Actin-Related Protein 4 | Actin-Related Protein Baf53a | ArpNbeta | BAF Complex 53 kDa Subunit | BAF53A | BRG1-Associated Factor 53A | INO80 Complex Subunit K",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937025","ACTL6B Gene","C157276","This gene is involved in chromatin remodeling-dependent transcriptional regulation.","ACTL6B Gene | ACTL6B | Actin Like 6B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937018","ACTL6B wt Allele","C157277","Human ACTL6B wild-type allele is located in the vicinity of 7q22.1 and is approximately 13 kb in length. This allele, which encodes actin-like protein 6B, plays a role in nucleosome remodeling.","ACTL6B wt Allele | ACTL6 | ARPN-ALPHA | Actin Like 6B wt Allele | Actin-Like 6 Gene | Actin-Related Protein, Alpha Gene | ArpNalpha | BAF53B | arpNalpha | hArpN Alpha",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937019","Actin-Like Protein 6B","C157278","Actin-like protein 6B (426 aa, ~47 kDa) is encoded by the human ACTL6B gene. This protein is involved in chromatin remodeling and transcriptional regulation.","Actin-Like Protein 6B | 53 kDa BRG1-Associated Factor B | ACTL6B | Actin-Related Protein Baf53b | ArpNalpha | BAF53B | BRG1-Associated Factor 53B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281606","Recombinant Viral Vaccine","C1572","A vaccine produced from genetically engineered viral vector by introduction of foreign genetic materials to activate immune response in a host.","Recombinant Viral Vaccine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936999","CD96 Gene","C157300","This gene may play a role in T-cell and natural killer (NK) cell adhesion.","CD96 Gene | CD96 | CD96 Molecule Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937000","CD96 wt Allele","C157301","Human CD96 wild-type allele is located within 3q13.13-q13.2 and is approximately 373 kb in length. This allele, which encodes T-cell surface protein tactile, may be involved in immune cell matrix adhesion.","CD96 wt Allele | CD96 Molecule wt Allele | T Cell Activation, Increased Late Expression Gene | T-Cell Activation Antigen, Increased Late Expression Gene | TACTILE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937001","T-Cell Surface Protein Tactile","C157303","T-cell surface protein tactile (585 aa, ~66 kDa) is encoded by the human CD96 gene. This protein may play a role in immunoregulation.","T-Cell Surface Protein Tactile | CD96 | CD96 Antigen | Cell Surface Antigen CD96 | T Cell-Activated Increased Late Expression Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937002","DPF1 Gene","C157304","This gene is involved in the regulation of cell survival.","DPF1 Gene | DPF1 | Double PHD Fingers 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937057","DPF1 wt Allele","C157305","Human DPF1 wild-type allele is located in the vicinity of 19q13.2 and is approximately 19 kb in length. This allele, which encodes zinc finger protein neuro-d4, plays a role in neuronal cell survival and dendrite growth.","DPF1 wt Allele | BAF45B | BAF45b | BRG1-Associated Factor, 45-kD Gene | D4, Zinc and Double PHD Fingers Family 1 Gene | D4, Zinc and Double PHD Fingers Family, Member 1 Gene | Double PHD Fingers 1 wt Allele | NEUD4 | Neuro-D4 Gene | Neuro-D4 Homolog Gene | Neuro-D4, Rat, Homolog of Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937058","Zinc Finger Protein Neuro-D4","C157306","Zinc finger protein neuro-d4 (380 aa, ~43 kDa) is encoded by the human DPF1 gene. This protein is involved in neuronal dendrite growth and cell survival.","Zinc Finger Protein Neuro-D4 | BAF45B | BRG1-Associated Factor 45B | D4, Zinc and Double PHD Fingers Family 1 | DPF1 | Double PHD Fingers 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937060","DPF2 wt Allele","C157308","Human DPF2 wild-type allele is located in the vicinity of 11q13.1 and is approximately 19 kb in length. This allele, which encodes zinc finger protein ubi-d4, is involved in histone binding and modification. Mutation of the gene is associated with Coffin-Siris syndrome 7.","DPF2 wt Allele | BAF45D | BAF45d | CSS7 | D4, Zinc and Double PHD Fingers Family 2 Gene | D4, Zinc and Double PHD Fingers Family, Member 2 Gene | Double PHD Fingers 2 wt Allele | REQ | Requiem, Apoptosis Response Zinc Finger Gene | UBID4 | ubi-d4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0679699","Secondary Prevention","C15712","Procedures or treatment processes designed to prevent complications (e.g., modifying a drug or surgical procedure to prevent complications).","Secondary Prevention | Prevention, Secondary | SECONDARY PREVENTION",,,,,,,,,,,,,,,"4196427","Secondary prevention",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL936805","Recurrent Neuroendocrine Neoplasm","C157130","The reemergence of a neuroendocrine neoplasm after a period of remission.","Recurrent Neuroendocrine Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936806","Refractory Neuroendocrine Neoplasm","C157131","A neuroendocrine neoplasm that does not respond to treatment.","Refractory Neuroendocrine Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516218","Cancer Prevention, Primary","C15777","NIH Emphasis Area -- The term 'prevention' refers to prophylactic and preventative efforts to achieve a significant reduction in cancer incidence, cancer mortality, and cancer morbidity. 'Primary prevention' involves efforts to directly prevent and/or inhibit malignant transformation; to identify, characterize, and manipulate factors that might be effective in achieving that inhibition; and attempts to promote preventative measures, such as appropriate training of scientists and clinicians. Prevention and intervention efforts are biologic activities aimed at the cell - at the genetic and cellular changes that result in the transformation process and that define cancer development","Cancer Prevention, Primary | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937421","Acne Scar Treatment","C157780","Any treatment to minimize acne scars.","Acne Scar Treatment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937418","Ambulatory Anorectal Surgery","C157784","Outpatient surgery on the anus/rectal area.","Ambulatory Anorectal Surgery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518317","New Approaches to Pathogenesis","C15881","NIH Emphasis Area -- Innovative approaches to pathogenesis, resulting from more precise understanding of genes, proteins, and cells, are transforming traditional descriptions of disease processes.  For example, research in this arena will uncover new mechanisms of carcinogenesis and cardiovascular disease and will lead to better understanding of osteoarthritis, birth defects and growth disorders.  These new insights into pathogenesis are, in turn, stimulating new preventive strategies against disease such as the development of new vaccines against a variety of pathogens.","New Approaches to Pathogenesis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950890","Alcohol-free Hypoallergenic Barrier Film Solution","C158820","An alcohol-free, hypoallergenic, polymeric-cyanoacrylate-based solution that provides a barrier film, with potential skin protective and healing activities. Upon topical application of the barrier film solution to intact or damaged skin, the alcohol-free barrier film solution forms a breathable, transparent film over the skin and maintains and enhances skin integrity, provides long-lasting protection against skin injury, infection, and irritation, and maintains moisture to the skin.","Alcohol-free Hypoallergenic Barrier Film Solution | 3M Cavilon Advanced Skin Protectant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937721","CDISC SEND Biological Challenge Agent Category Response Terminology","C158119","Terminology associated with the biological challenge agent category response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).","CDISC SEND Biological Challenge Agent Category Response Terminology | BACAT | Biological Challenge Agent Category Response | SEND-BACAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937718","CDISC SEND Challenge Agent Category Response Terminology","C158120","Terminology associated with the challenge agent category Response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).","CDISC SEND Challenge Agent Category Response Terminology | CAGTCAT | Challenge Agent Category Response | SEND-CAGTCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937719","CDISC SEND Rad/Nuc Agent Ionizing Radiation Type Response Terminology","C158121","Terminology associated with the rad/nuc agent ionizing radiation type Response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).","CDISC SEND Rad/Nuc Agent Ionizing Radiation Type Response Terminology | RNAIOTYP | Rad/Nuc Agent Ionizing Radiation Type Response | SEND-RNAIOTYP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937716","CDISC SEND Rad/Nuc Agent Source Response Terminology","C158122","Terminology associated with the rad/nuc agent source response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).","CDISC SEND Rad/Nuc Agent Source Response Terminology | RNASRC | Rad/Nuc Agent Source Response | SEND-RNASRC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937717","CDISC SEND Restraint Mode Response Terminology","C158123","Terminology associated with the restraint mode response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).","CDISC SEND Restraint Mode Response Terminology | RSTMODRS | Restraint Mode Response | SEND-RSTMODRS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937714","CDISC SEND Sexual Maturity Status Response Terminology","C158124","Terminology associated with the sexual maturity status response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).","CDISC SEND Sexual Maturity Status Response Terminology | SEND-SEXMAT | SEXMAT | Sexual Maturity Status Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937715","CDISC SEND Study Report Status Response Terminology","C158125","Terminology associated with the study report status response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).","CDISC SEND Study Report Status Response Terminology | SEND-STRPSTAT | STRPSTAT | Study Report Status Response",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937712","Seroreactivity","C158126","The presence of a serum antibody that recognizes, binds and reacts to an antigen.","Seroreactivity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937020","ABBV 155","C157279","An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) conjugated, via a solubilizing linker, to a B-cell lymphoma extra long (Bcl-XL) inhibitor, with potential antineoplastic activity. Upon administration of mirzotamab clezutoclax, the anti-B7-H3 monoclonal antibody moiety targets and binds to B7-H3 expressed on tumor cells. Upon binding, internalization and linker cleavage, the Bcl-XL inhibitor targets, binds to and inhibits the activity of the pro-survival protein Bcl-XL. This restores apoptotic processes and inhibits the proliferation of B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It plays a key role in tumor growth and immune responses.","Mirzotamab Clezutoclax | ABBV 155 | ABBV-155 | ABBV155 | ADC ABBV-155 | Antibody-drug Conjugate ABBV-155 | MIRZOTAMAB CLEZUTOCLAX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0198807","Peripheral Nerve Block","C157953","The injection of medications near peripheral nerves to decrease pain and inflammation.","Peripheral Nerve Block | ",,,,,,,,,,,,,,,"4228073","Peripheral block anesthesia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937611","Peritoneal Adhesion Excision","C157954","A surgical procedure to remove peritoneal adhesions.","Peritoneal Adhesion Excision | Excision Peritoneal Adhesions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936535","Peroral Endoscopic Myotomy","C157955","Surgical incisions made in the esophagus via an endoscopic procedure.","Peroral Endoscopic Myotomy | POEM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937609","Physical Therapy for Orthopedics and Sports Medicine","C157956","Physical therapy for injuries seen in the orthopedics and sports medicine departments.","Physical Therapy for Orthopedics and Sports Medicine | Physical Therapy for Orthopaedics and Sports Medicine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937610","Pituitary Tumor Surgery","C157957","A surgical procedure to remove cancer from the pituitary gland.","Pituitary Tumor Surgery | Surgery for Pituitary Tumors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3266857","Positive Airway Pressure Therapies","C157960","A set of therapies that use a stream of compressed air to support the airway during sleep.","Positive Airway Pressure Therapies | PAP Therapies | PAP Therapy | POSITIVE AIRWAY PRESSURE VENTILATION | Positive Airway Pressure Ventilation",,,,,,,,,,,,,,,"607086","Positive pressure ventilation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937606","Prostate Cancer Surgery","C157962","A surgical procedure to remove cancer from the prostate.","Prostate Cancer Surgery | Surgery for Prostate Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525461","Pulmonary Autograft","C157963","A surgical procedure in which the diseased portion of the aortic valve is replaced with the pulmonary valve and the pulmonary valve is replaced by a cadaver valve.","Pulmonary Autograft | Ross Procedure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0190587","Pulmonary Embolectomy","C157964","The removal of a blockage in an artery of the lungs.","Pulmonary Embolectomy | ",,,,,,,,,,,,,,,"4296462","Removal of pulmonary embolus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937605","Pulmonary Metastasectomy","C157965","Removal of metastatic tumors from the lungs.","Pulmonary Metastasectomy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0199529","Pulmonary Rehabilitation","C157966","Treatment programs that use strategies to maintain function, participation and quality of life for individuals with pulmonary disorders.","Pulmonary Rehabilitation | ",,,,,,,,,,,,,,,"4035793","Pulmonary rehabilitation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL1407114","Radioactive Iodine Therapy","C157968","The use of radioactive iodine to treat disease.","Radioactive Iodine Therapy | ",,,,,,,,,,,,,,,"3663192","Radioactive iodine therapy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937645","Reconstructive Plastic Surgery","C157969","A surgical procedure to reconstruct a damaged or deformed part of the body to improve function or aesthetics.","Reconstructive Plastic Surgery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937061","CC 95251","C157501","An immunoglobulin G1 (IgG1) monoclonal antibody targeting signal-regulatory protein alpha (SIRPa; CD172a) with potential immunostimulating and antineoplastic activities. Upon intravenous administration, anzurstobart targets and binds to SIRPa, a cell surface protein expressed on macrophages, thereby blocking the interaction between SIRPa and cluster of differentiation 47 (CD47) expressed on tumor cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47/SIRPa-mediated signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. SIRPa, also known as tyrosine-protein phosphatase non-receptor type substrate 1, mediates negative regulation of phagocytosis, mast cell activation and dendritic cell activation. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","Anzurstobart | ANZURSTOBART | Anti-SIRPa Monoclonal Antibody CC-95251 | Anti-SIRPa Monoclonal Antibody CC-95251 | BMS-986351 | CC 95251 | CC-95251 | CC95251",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937062","HBV Surface Antibody Level Result","C157502","The quantity of hepatitis b virus surface antibody in a sample.","HBV Surface Antibody Level Result | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937063","Feline Histiocytic Sarcoma","C157503","Histiocytic sarcoma occurring in a cat.","Feline Histiocytic Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2931781","Myopathy due to Myoadenylate Deaminase Deficiency","C157504","An autosomal recessive condition caused by mutation(s) in the AMPD1 gene, encoding AMP deaminase 1. The condition is characterized by exercise-induced muscle pain and/or fatigue, which may be associated with rhabdomyolysis and/or increased concentrations of creatinine kinase.","Myopathy due to Myoadenylate Deaminase Deficiency | MMDD",,,,,,,,,,,,,,,"4049856","Deficiency of AMP deaminase",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937119","HBV DNA Level Finding","C157507","The viral load of hepatitis b virus DNA units in a blood sample.","HBV DNA Level Finding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937120","HBV Genotype Finding","C157508","The determination of the genotype of hepatitis b virus in a blood sample.","HBV Genotype Finding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937113","Vinyl Chloride or Derivatives Exposure","C157509","Environmental, occupational, or consumer-based exposure to vinyl chloride or its derivatives during the manufacture or breakdown of polyvinyl chloride (PVC) and other vinyl containing products.","Vinyl Chloride or Derivatives Exposure | Vinyl and/or derivatives",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937115","High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma","C157511","A finding indicating the presence of a high risk bladder urothelial carcinoma that does not invade muscle.","High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma | High Risk NMIBC | High Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma | High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937116","Recurrent High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma","C157512","A finding indicating the reemergence of high risk non-muscle invasive bladder urothelial carcinoma after a period of remission.","Recurrent High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma | Recurrent High Risk NMIBC | Recurrent High Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma | Recurrent High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0188624","Ankle Arthroscopy","C157787","Visualization of the ankle joint with an arthroscope.","Ankle Arthroscopy | ",,,,,,,,,,,,,,,"4279466","Arthroscopy of ankle",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937416","Aortic Valve Surgery","C157788","Surgery on the aortic valve in the heart.","Aortic Valve Surgery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0750934","Arthroscopic Surgery","C157789","Any surgical procedure that involves an arthroscope.","Arthroscopic Surgery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516219","Cancer Prevention, Secondary","C15778","No value exists.","Cancer Prevention, Secondary | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162513","Atherectomy","C157793","The removal of plaque from a blood vessel.","Atherectomy | ",,,,,,,,,,,,,,,"4284964","Atherectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0004708","Balloon Valvuloplasty","C157795","The use of a balloon catheter to improve the patency of a stenotic heart valve by inserting the catheter into the valve and inflating the balloon to compress the sides and widen the opening.","Balloon Valvuloplasty | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937412","Behavioral Measures For Treating Sleep Disordered Breathing","C157796","Any steps taken to modify one's behavior to improve sleep.","Behavioral Measures For Treating Sleep Disordered Breathing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937413","Bladder Cancer Surgery","C157797","Any surgical procedures to treat bladder cancer.","Bladder Cancer Surgery | Surgery for Bladder Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936961","PALB2 Mutation Analysis","C157351","A procedure used to detect and identify mutations in the PALB2 gene.","PALB2 Mutation Analysis | FANCN Mutation Analysis | Fanconi Anemia, Complementation Group N Mutation Analysis | PNCA3 Mutation Analysis | Partner and Localizer of BRCA2 Mutation Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936956","Monomer Deletion","C157353","The physicochemical identity of the repeating monomer unit removed from a polymer.","Monomer Deletion | Deleted Monomer | Monomer Deleted",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936957","Nucleotide Bond Constituents","C157354","The phosphorus (P) and oxygen (O) atoms found in adjacent nucleotides that form a nucleotide bond.","Nucleotide Bond Constituents | Nucleic Acid Bond Constituents",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936958","Colorectal Adenocarcinoma Metastatic in the Liver","C157355","An adenocarcinoma that originates from the colorectal area and has spread to the liver.","Colorectal Adenocarcinoma Metastatic in the Liver | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796409","Prevention of Bladder Cancer","C15735","No value exists.","Prevention of Bladder Cancer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937711","Challenge Agent","C158128","A type of substance that is given to healthy subjects in order to induce a physiological response that the investigational medicinal product is intended to counter or treat.","Challenge Agent | challenge agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0337184","Restraint","C158129","The means or mechanism by which physical movement is reduced or completely impeded.","Restraint | ",,,,,,,,,,,,,,,"4238202","Physical restraint equipment",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1513012","Maternal and Child Health Study","C15812","Studies focusing on the involvement of maternal factors (and efforts to modify these factors) that may affect the health of the child or fetus: smoking or exposure to drugs or toxic chemicals during pregnancy, maternal/fetal immunologic interactions.","Maternal and Child Health Study | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937670","PRMT1 Inhibitor","C158131","Any agent that inhibits protein arginine N-methyltransferase 1 (PRMT1; histone-arginine N-methyltransferase PRMT1; interferon receptor 1-bound protein 4).","PRMT1 Inhibitor | Histone-arginine N-methyltransferase PRMT1 Inhibitor | Interferon Receptor 1-bound Protein 4 Inhibitor | Protein Arginine N-methyltransferase 1 Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978092","Observational Study Protocol Version Specimen Available For DNA Extraction Indicator","C164878","No value exists.","Observational Study Protocol Version Specimen Available For DNA Extraction Indicator | ObservationalStudyProtocolVersion.specimenAvailableForDNAExtractionIndicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937850","B4GALT5 wt Allele","C158404","Human B4GALT5 wild-type allele is located in the vicinity of 20q13.13 and is approximately 81 kb in length. This allele, which encodes beta-1,4-galactosyltransferase 5 protein, is involved in the synthesis of lactosylceramide.","B4GALT5 wt Allele | B4Gal-T5 | BETA4-GALT-IV | Beta-1,4-GalT IV | Beta-1,4-GalT-V | Beta-1,4-Galactosyltransferase 5 wt Allele | Beta-1,4-Galactosyltransferase 5, Polypeptide 5 Gene | Beta-1,4GalT-V | Beta4Gal-T5 | Beta4GalT-V | UDP-Gal:BetaGlcNAc Beta 1,4- Galactosyltransferase, Polypeptide 5 Gene | UDP-Gal:BetaGlcNAc Beta-1,4- Galactosyltransferase, Polypeptide 5 Gene | gt-V",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937847","Beta-1,4-Galactosyltransferase 5","C158405","Beta-1,4-galactosyltransferase 5 (388 aa, ~45 kDa) is encoded by the human B4GALT5 gene. This protein plays a role in the transfer of galactose from UDP-galactose to glucosylceramide to yield lactosylceramide.","Beta-1,4-Galactosyltransferase 5 | B4GALT5 | Beta-1,4-GalT II | Beta-1,4-GalT-V | Beta-1,4-GalTase 5 | Beta-1,4GalT-V | Beta-1.4-Galactosyltransferase V | Beta4Gal-T5 | EC 2.4.1.- | EC 2.4.1.274 | Glucosylceramide Beta-1,4-Galactosyltransferase | LacCer Synthase | Lactosylceramide Synthase | Lactosylceramide Synthase Beta-1,4-GalT-V | UDP-Gal:Beta-GlcNAc Beta-1,4-Galactosyltransferase 5 | UDP-Galactose:Beta-N-Acetylglucosamine Beta-1,4-Galactosyltransferase 5 | b4Gal-T5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937848","CH25H Gene","C158406","This gene plays a role in the metabolism of cholesterol and 25-hydroxycholesterol.","CH25H Gene | CH25H | Cholesterol 25-Hydroxylase Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937845","CH25H wt Allele","C158407","Human CH25H wild-type allele is located in the vicinity of 10q23.31 and is approximately 2 kb in length. This allele, which encodes cholesterol 25-hydroxylase protein, is involved in sterol synthesis.","CH25H wt Allele | C25H | Cholesterol 25-Hydroxylase wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937846","Cholesterol 25-Hydroxylase","C158408","Cholesterol 25-hydroxylase (272 aa, ~32 kDa) is encoded by the human CH25H gene. This protein plays a role in the reversible conversion of cholesterol to 25-hydroxycholesterol.","Cholesterol 25-Hydroxylase | CH25H | Cholesterol 25-Monooxygenase | EC 1.14.99.38 | h25OH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937843","FNDC5 Gene","C158409","This gene may be involved in exercise-dependent metabolic processes.","FNDC5 Gene | FNDC5 | Fibronectin Type III Domain Containing 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514412","Prevention and Treatment of Opportunistic Infection","C15840","Improve understanding of the biology of opportunistic pathogens, identify potential molecular targets for effective therapies, and discover and delineate the structure and function of potential agents for prevention and treatment of HIV-associated OIs and other infections that are modified by HIV infection.","Prevention and Treatment of Opportunistic Infection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937844","FNDC5 wt Allele","C158410","Human FNDC5 wild-type allele is located in the vicinity of 1p35.1 and is approximately 10 kb in length. This allele, which encodes fibronectin type III domain-containing protein 5, may play a role in the cellular response to exercise.","FNDC5 wt Allele | FRCP2 | Fibronectin Type III Domain Containing 5 wt Allele | Irisin Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511801","Developmental Diagnostic","C15796","Refers to diagnostic methods for evaluating developmental problems.","Developmental Diagnostic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937644","Reproductive Surgery","C157970","A surgical procedure in the field of reproductive medicine.","Reproductive Surgery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937642","Sarcoma Surgery","C157975","A surgical procedure to remove sarcoma or repair adjacent areas.","Sarcoma Surgery | Surgery for Sarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937080","Glucagon Receptor","C157480","Glucagon receptor (477 aa, ~54 kDa) is encoded by the human GCGR gene. This protein plays a role in the glucagon-dependent regulation of blood glucose levels.","Glucagon Receptor | GCGR | GL-R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937081","CDK4/6 Inhibitor BPI-16350","C157481","An orally bioavailable inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon administration, CDK4/6 inhibitor BPI-16350 selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S-phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation.","CDK4/6 Inhibitor BPI-16350 | BPI 16350 | BPI-16350 | BPI16350",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937076","Allogeneic Tri-functional Anti-CD19 CAR-NK Cells","C157484","A preparation of allogeneic natural killer (NK) cells transduced with a retroviral vector expressing the immunostimulatory cytokine interleukin-15 (IL-15) and encoding a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19) that is coupled to the co-stimulatory domains cluster of differentiation 28 (CD28, T-cell-specific surface glycoprotein CD28), cluster of differentiation 137 (CD137; 4-1BB), and the zeta chain of the T-cell receptor (TCR)/CD3 complex (TCRzeta; CD247; CD3zeta); and a blocker for the inhibitory T-cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immunomodulating and antineoplastic activities. Upon transfusion, the allogeneic tri-functional anti-CD19 CAR-NK cells recognize, bind to and induce selective cytotoxicity in CD19-expressing tumor cells. IL-15 enhances the cytotoxic effect of the NK cells and the activated anti-tumor T-cells. The PD-1 inhibitory domain targets and binds to programmed cell death-1 ligand 1 (PD-L1) expressed on tumor cells, thereby preventing the binding of the PD-1 on T-lymphocytes to its ligand, PD-L1 on tumor cells. This prevents PD-1/PD-L1-mediated inhibition of T-lymphocytes and leads to the activation and expansion of T-cells resulting in a cytotoxic T-lymphocyte (CTL) response against tumor cells, thereby enhancing the elimination of tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. The co-stimulatory signaling domains enhance both proliferation of T-cells and anti-tumor activity.","Allogeneic Tri-functional Anti-CD19 CAR-NK Cells | Allogeneic CD19-TriCAR SILK Cells | Allogeneic CD19-TriCAR-T/SILK | Allogeneic CD19-TriCAR-T/SILK Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937111","Multiple Agent Therapy","C157515","Pharmacotherapy that uses more than one agent simultaneously.","Multiple Agent Therapy | Multiple Agent Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937112","Unknown Regimen","C157516","An indication that the treatment regimen used is not known.","Unknown Regimen | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2001954","MFSD8 protein, human","C157082","Major facilitator superfamily domain-containing protein 8 (518 aa, ~58 kDa) is encoded by the human MFSD8 gene. This protein is involved in the modulation of lysosomal functions.","Major Facilitator Superfamily Domain-Containing Protein 8 | Ceroid-Lipofuscinosis Neuronal Protein 7 | MFSD8 | Major Facilitator Superfamily Domain Containing Protein 8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936790","BRD9 Gene","C157083","This gene plays a role in binding to acylated histones, chromatin remodeling and the regulation of transcription.","BRD9 Gene | BRD9 | Bromodomain Containing 9 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936791","BRD9 wt Allele","C157084","Human BRD9 wild-type allele is located in the vicinity of 5p15.33 and is approximately 42 kb in length. This allele, which encodes bromodomain-containing protein 9, is involved in chromatin remodeling, transcriptional regulation and acylated histone binding.","BRD9 wt Allele | Bromodomain Containing 9 wt Allele | FLJ13441 | LAVS3040 | PRO9856 | UNQ3040/PRO9856",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936784","Bromodomain-Containing Protein 9","C157085","Bromodomain-containing protein 9 (597 aa, ~67 kDa) is encoded by the human BRD9 gene. This protein plays a role in transcriptional regulation, acylated histone binding and chromatin remodeling.","Bromodomain-Containing Protein 9 | BRD9 | Rhabdomyosarcoma Antigen MU-RMS-40.8 | Sarcoma Antigen NY-SAR-29",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936785","BICRAL Gene","C157086","This gene is involved in chromatin remodeling and transcriptional regulation.","BICRAL Gene | BICRAL | BRD4 Interacting Chromatin Remodeling Complex Associated Protein Like Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936786","BICRAL wt Allele","C157087","Human BICRAL wild-type allele is located in the vicinity of 6p21.1 and is approximately 122 kb in length. This allele, which encodes BRD4-interacting chromatin-remodeling complex-associated protein-like protein, plays a role in SWI/SNF-dependent chromatin remodeling.","BICRAL wt Allele | BRD4 Interacting Chromatin Remodeling Complex Associated Protein Like wt Allele | GLTSCR1 Like Gene | GLTSCR1-Like Gene | GLTSCR1L | Glioma Tumor Suppressor Candidate Region Gene 1-Like Gene | KIAA0240",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936787","BRD4-Interacting Chromatin-Remodeling Complex-Associated Protein-Like","C157088","BRD4-interacting chromatin-remodeling complex-associated protein-like (1079 aa, ~115 kDa) is encoded by the human BICRAL gene. This protein is involved in SWI/SNF-mediated chromatin remodeling.","BRD4-Interacting Chromatin-Remodeling Complex-Associated Protein-Like | BICRAL | BRD4 Interacting Chromatin Remodeling Complex Associated Protein Like | BRD4 Interacting Chromatin Remodelling Complex Associated Protein Like | GLTSCR1-Like | GLTSCR1L | Glioma Tumor Suppressor Candidate Region Gene 1 Protein-Like",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936780","BCL7B Gene","C157089","This gene plays a role in SWI/SNF complex-mediated chromatin remodeling and in the regulation of apoptosis.","BCL7B Gene | BCL7B | BCL7B, BAF Complex Component Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0678094","Prevention of Oral Cancer","C15708","No value exists.","Prevention of Oral Cancer | Oral Cancer Prevention",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936954","Metastatic Lung Non-Small Cell Squamous Carcinoma","C157364","A squamous non-small cell carcinoma that arises from the lung and has metastasized to another anatomic site.","Metastatic Lung Non-Small Cell Squamous Carcinoma | Metastatic Non-Small Cell Squamous Lung  Carcinoma | Metastatic Non-Small Cell Squamous Lung Carcinoma | Metastatic Squamous Non-Small Cell Lung Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936947","Locally Advanced Lung Non-Small Cell Squamous Carcinoma","C157365","A non-small cell squamous carcinoma of the lung that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Lung Non-Small Cell Squamous Carcinoma | Locally Advanced Squamous Non-Small Cell Lung Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937245","ARHGAP45 NP_036424.2:p.R139H","C157550","A change in the amino acid residue at position 139 in Rho GTPase-activating protein 45 where arginine has been replaced by histidine.","ARHGAP45 NP_036424.2:p.R139H | ARHGAP45 Arg139His | ARHGAP45 NP_036424.2:p.Arg139His | ARHGAP45 R139H | ARHGAP45 p.Arg139His | ARHGAP45 p.R139H | HA-1(H) Precursor | Minor Histocompatibility Antigen HA-1 Precursor Arg139His | Minor Histocompatibility Antigen HA-1 Precursor R139H | Minor Histocompatibility Protein HA-1 Precursor Arg139His | Minor Histocompatibility Protein HA-1 Precursor R139H | NP_036424.2:p.Arg139His | NP_036424.2:p.R139H | Rho GTPase Activating Protein 45 Arg139His | Rho GTPase Activating Protein 45 R139H | Rho GTPase-Activating Protein 45 Arg139His | Rho GTPase-Activating Protein 45 R139H | mHag HA-1 Precursor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937246","VLHDDLLEA","C157551","A peptide antigen comprised of 9 amino acids (VLHDDLLEA) that is derived by antigen processing from a variant of Rho GTPase-activating protein 45 where the arginine at amino acid residue 139 is substituted with histidine. This peptide can be presented by MHC class I HLA-A*0201 expressing cells. The complex of this peptide with HLA-A elicits donor-cytotoxic T-lymphocyte (CTL) reactivity following treatment by HLA-identical allogenic bone marrow transplant.","Minor Histocompatibility Antigen HA-1 | HA-1 | HA-1(H) | mHag HA-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937841","FNDC5 Gene Product","C158411","A protein encoded by the FNDC5 gene.","FNDC5 Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937842","Fibronectin Type III Domain-Containing Protein 5","C158412","Fibronectin type III domain-containing protein 5 (212 aa, ~24 kDa) is encoded by the human FNDC5 gene. This protein plays a role in the cellular response to physical reactivity.","Fibronectin Type III Domain-Containing Protein 5 | FNDC5 | Fibronectin Type III Domain Containing Protein 5 | Fibronectin Type III Repeat-Containing Protein 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937839","Irisin","C158413","Irisin (112 aa, ~13 kDa) is encoded by the human FNDC5 gene. This protein may be involved in muscle cell responses to exercise.","Irisin | FNDC5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937840","Translocase Gene","C158414","Genes encoding a class of enzymes that catalyze the movement of ions or molecules across or within membranes.","Translocase Gene | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937834","Translocase","C158419","A class of enzymes that catalyze the movement of ions or molecules across or within membranes.","Translocase | EC 7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514413","Prevention of High-Risk Behavior","C15841","1C2; Basic Sciences Research (includes vaccine and chemotherapy development); Behavioral Research; Prevention of high-risk behaviors (behavioral and pharmacologic interventions)","Prevention of High-Risk Behavior | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938080","Autologous Cytoplasmic Activated PD-1 CAR T-cells","C158599","A preparation of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19), carrying cytoplasmic activated programmed cell death 1 (PD1; PDCD1; CD279; programmed death-1), with potential antineoplastic activity. Upon intravenous administration, autologous cytoplasmic activated PD-1 CAR T-cells target, bind to, and induce selective toxicity in CD19-expressing tumor cells. The cytoplasmic activated PD1, a negative immunoregulatory human cell surface receptor, normally binds to programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) on tumor cells, causing T-cell inactivation. By preventing PD1/PD-L1 signaling, T-cell exhaustion is abrogated, and T-cell activation is enhanced leading to an increased cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. CD19 is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors.","Autologous Cytoplasmic Activated PD-1 CAR T-cells | Autologous CAR19 T-cells Carrying Cytoplasmic Activated PD-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519571","Trace Element Nutrition, Fluorides","C15859","Studies of the role of the trace element fluoride, obtained through diet, on general health","Trace Element Nutrition, Fluorides | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282222","Lubricant","C1585","Any substance that helps to minimize friction and facilitates motion between interacting surfaces.","Lubricant | lubricant",,,,,,,,,,,,,,,"45768409","Lubricant",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL601005","Ocoxin","C158600","A nutritional supplement containing a variety of antioxidants, vitamins, minerals and amino acids, including glycyrrhizic acid, epigallocatechin gallate (EGCG), zinc, vitamins B5, B6 and B12, vitamin C (ascorbic acid), folic acid, malic acid, glucosamine, arginine, and glycine, with potential immunomodulating, anti-inflammatory, protective, and antineoplastic activities. Upon oral administration, the antioxidants in the solution modulate certain enzymes involved in inflammation and oxidative stress and downregulate certain pro-inflammatory mediators. They also scavenge free radicals. This protects against inflammation- and reactive oxygen species (ROS)-induced cellular damage. In addition, this formulation may also inhibit various signal transduction pathways involved in inflammation and cancer, may suppress the growth of susceptible tumor cells, induce tumor cell cycle arrest, induce apoptosis and reduce angiogenesis and metastasis.","Green Tea/Licorice Extract-based Antioxidant Solution | Ocoxin and Viusid | Ocoxin-Viusid | Ocoxin/Viusid | Oral Antioxidant Solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937077","JTX 4014","C157485","A human immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pimivalimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","Pimivalimab | Anti-PD-1 Monoclonal Antibody JTX-4014 | JTX 4014 | JTX-4014 | JTX4014 | PIMIVALIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937078","Fluorine F 18-Active Site Inhibited Factor VIIa","C157486","A radioconjugate containing a tissue factor (TF) tracer, a derivative of activated factor VII (FVIIa), labeled with fluorine F 18, with potential use for TF-expressing tumor imaging using positron emission tomography (PET). Upon administration of fluorine F 18 active site inhibited factor VIIa (18F-ASIS), the active site inhibited factor VIIa (FVIIai) moiety selectively targets and binds, with a much higher binding affinity than FVIIa, to TF. Upon PET imaging, tumor cells expressing TF can be visualized and assessed. TF, a transmembrane glycoprotein, is overexpressed on certain tumor cell types and is correlated with tumor aggression and poor prognosis.","Fluorine F 18-Active Site Inhibited Factor VIIa | 18F-ASIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937072","Therapeutic Ex Vivo-expanded Allogeneic gamma delta T-cells","C157487","An off-the-shelf preparation of a subset of therapeutic, ex vivo-expanded, allogeneic T-lymphocytes that express only gamma chain and delta chain T-cell receptors (TCRs), with potential immunomodulating and antineoplastic activities. Upon administration of the therapeutic ex vivo-expanded allogeneic gamma delta T-cells, these cells secrete interferon-gamma (IFN-g) and exert direct killing of tumor cells. In addition, these cells activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against tumor cells. Gamma delta T-lymphocytes play a key role in the activation of the immune system and do not require major histocompatibility complex (MHC)-mediated antigen presentation to exert their cytotoxic effect.","Therapeutic Ex Vivo-expanded Allogeneic gamma delta T-cells | Ex-vivo Expanded Allogeneic gd T-lymphocytes | OmnImmune | Therapeutic Ex Vivo-expanded Allogeneic gamma, delta T-Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937314","Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma","C157678","T-cell/histiocyte-rich large B-cell lymphoma that is resistant to treatment.","Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937315","Recurrent Primary Effusion Lymphoma","C157679","The reemergence of primary effusion lymphoma after a period of remission.","Recurrent Primary Effusion Lymphoma | Recurrent HHV8-Positive Primary Effusion Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515823","AIDS, Clinical Trials on Children","C15767","AIDS clinical trials related to children 0-18 years of age. These trials include pregnant females, neonates, and infants.","AIDS, Clinical Trials on Children | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937316","Refractory Primary Effusion Lymphoma","C157680","Primary effusion lymphoma that is resistant to treatment.","Refractory Primary Effusion Lymphoma | Refractory HHV8-Positive Primary Effusion Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937317","Recurrent Primary Lymphoma of Bone","C157681","The reemergence of primary lymphoma of bone after a period of remission.","Recurrent Primary Bone Lymphoma | Recurrent Primary Lymphoma of Bone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937311","Recurrent Plasmablastic Lymphoma","C157683","The reemergence of plasmablastic lymphoma after a period of remission.","Recurrent Plasmablastic Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936781","Autologous CD4+/CD8+ 4-1BB-CD3zeta-EGFR806-CAR-EGFRt/4-1BB-CD3zeta-CD19-CAR-HER2tG-expressing CARs T Cells","C157090","A preparation of CD4+ and CD8+ autologous T-lymphocytes transduced with a lentiviral vector that co-expresses two different second generation chimeric antigen receptors (CARs), one composed of a short chain variable fragment (scFv) binding domain derived from depatuxizumab, a human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MAb806; ABT-806), coupled to the zeta chain of the TCR/CD3 complex (CD3-zeta) and the signaling domain of 4-1BB (CD137), and linked to a truncated form of the human epidermal growth factor receptor (EGFRt), and one composed of a short chain variable fragment (scFv) binding domain derived from an anti-CD19 monoclonal antibody, coupled to CD3-zeta) and 4-1BB,  and linked to a truncated form of the human epidermal growth factor receptor 2 (HER2tG), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, the autologous CD4+/CD8+ 4-1BB-CD3zeta-EGFR806-CAR-EGFRt/4-1BB-CD3zeta- CD19-CAR-HER2tG-expressing CARs T-cells are directed to, bind to, and induce selective toxicity in EGFR deletion mutation variant III (EGFRvIII)-expressing tumor cells. The binding of these T-cells to CD19 expressed on B-cells enhances their expansion and prolongs their persistence in vivo, thereby increasing the efficacy of these CAR T-cells. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt and HER2tG facilitate in vivo detection of the administered, transduced T-cells and can promote elimination of these cells through an antibody-dependent cellular cytotoxicity (ADCC) response. HER2tG allows for enhanced binding by trastuzumab. EGFRvIII, an in-frame deletion of exons 2-7 in the EGFR gene, is overexpressed by a variety of cancer cell types but absent in normal, healthy cells. It plays a key role in tumor cell proliferation, tumor angiogenesis and resistance to both radio- and chemotherapy. Depatuxizumab specifically targets abnormal conformational states of EGFR, including EGFRvIII, and activating mutations, with lower affinity for wild-type EGFR. CD19, a transmembrane phosphoglycoprotein is expressed on the surface of cells in the B-lineage.","Autologous CD4+/CD8+ 4-1BB-CD3zeta-EGFR806-CAR-EGFRt/4-1BB-CD3zeta-CD19-CAR-HER2tG-expressing CARs T Cells | Autologous CD4+/CD8+ 4-1BB-CD3zeta-EGFR806-CAR-EGFRt/4-1BB-CD3zeta- CD19-CAR-HER2tG-expressing CARs T Cells | Autologous CD4+/CD8+ T Cells Expressing EGFR806-specific CAR/EGFRt and CD19-specific CAR/HER2tG | Autologous EGFR806-specific CAR T Cells | Autologous EGFR806xCD19 Bispecific CAR T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937404","Kidney Neuroendocrine Neoplasm","C157743","An epithelial neoplasm with neuroendocrine differentiation that arises from the kidney.  It includes neuroendocrine tumor, small cell neuroendocrine carcinoma, large cell neuroendocrine carcinoma, and paraganglioma.","Kidney Neuroendocrine Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937405","Childhood Cystic Nephroma","C157745","A cystic nephroma that occurs in very young children.","Childhood Cystic Nephroma | Pediatric Cystic Nephroma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937402","Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes","C157746","A preparation of autologous T-lymphocytes that have been immunomagnetically depleted of CD14+ myeloid cells and CD25+ regulatory T-cells (Tregs), activated with anti-CD3 and anti-CD28 beads, and transduced with a self-inactivating (SIN) lentiviral vector (LV) encoding a chimeric antigen receptor (CAR) containing a prostate stem cell antigen (PSCA)-specific, humanized and affinity matured A11 single chain variable fragment (scFv), a human immunoglobulin G4 (IgG4) Fc spacer lacking the CH2 domain, a human CD4 transmembrane domain, a costimulatory human 4-1BB (CD137) cytoplasmic signaling domain linked to the zeta chain of the human T-cell receptor (TCR)/CD3 complex (CD3zeta), and a truncated human CD19 sequence (CD19t), with potential immunostimulating and antineoplastic activities. Upon intravenous infusion, the autologous anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes recognize and induce selective toxicity in PSCA-expressing tumor cells. PSCA, a glycosyl-phosphatidylinositol (GPI)-linked cell surface antigen, is uniquely and highly expressed in certain cancers including bladder, pancreatic, and prostate cancers. Co-expression of CD19t provides an inert, non-immunogenic surface marker that allows for measurement of genetically modified cells and tracking of T-cells following adoptive transfer. The costimulatory signaling domains improve T-cell function, selectivity, expansion and survival.","Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes | Autologous Anti-PSCA(dCH2)BBz-CAR T-cells | Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-cells | PSCA(dCH2)BBzeta-CAR T-cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937403","TSC2 Monoallelic Inactivation","C157747","Any gain, loss, or exchange of DNA that results in monoallelic loss of function mutations in the TSC2 gene.","TSC2 Monoallelic Inactivation | Monoallelic TSC2 Gene Inactivation | Monoallelic Tuberin Gene Inactivation | Monoallelic Tuberous Sclerosis 2 Gene Inactivation | TSC2 LOH | TSC2 Loss of Heterozygosity | TSC2 Monoallelic Gene Inactivation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937401","Metanephric Tumor","C157748","A neoplasm arising from the distal convoluted tubule and collecting duct areas of the kidney.","Metanephric Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1285519","Metanephric Stromal Tumor","C157749","A rare benign renal neoplasm composed of moderately cellular spindle cells. It occurs mostly in infancy and childhood.","Metanephric Stromal Tumor | ",,,,,,,,,,,,,,,"4180932","Metanephric stromal tumor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937242","MIR1290 Gene","C157555","This gene may play a role in tumorigenesis and invasion.","MIR1290 Gene | MIR1290 | MicroRNA 1290 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937243","MIR1290 wt Allele","C157556","Human MIR1290 wild-type allele is located in the vicinity of 1p36.13 and is 78 bases in length. This allele, which encodes MIR1290 pre-miRNA, may be involved in tumor cell invasion.","MIR1290 wt Allele | MIRN1290 | MicroRNA 1290 wt Allele | hsa-mir-1290 | mir-1290",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937236","MIR1290 Pre-miRNA","C157557","MIR1290 pre-miRNA (78 bases) is encoded by the human MIR1290 gene. This oligoribonucleotide may play a role in transcriptional silencing and tumorigenesis.","MIR1290 Pre-miRNA | Pre-hsa-mir-1290 | Pre-miR1290 | Pre-mir-1290",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937237","MIR1246 Gene","C157558","This gene may play a role in tumorigenesis and metastasis.","MIR1246 Gene | MIR1246 | MicroRNA 1246 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937238","MIR1246 wt Allele","C157559","Human MIR1246 wild-type allele is located in the vicinity of 2q31.1 and is 73 bases in length. This allele, which encodes MIR1246 pre-miRNA, may be involved in the regulation of gene expression in various cancers.","MIR1246 wt Allele | MIRN1246 | MicroRNA 1246 wt Allele | hsa-mir-1246 | mir-1246",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937239","MIR1246 Pre-miRNA","C157560","MIR1246 pre-miRNA (73 bases) is encoded by the human MIR1246 gene. This oligoribonucleotide may play a role in tumor cell invasion.","MIR1246 Pre-miRNA | Pre-hsa-mir-1246 | Pre-miR1246 | Pre-mir-1246",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937233","MAGT1 wt Allele","C157562","Human MAGT1 wild-type allele is located in the vicinity of Xq21.1 and is approximately 69 kb in length. This allele, which encodes magnesium transporter protein 1, plays a role in magnesium ion transport and protein modification. Mutation of the gene is associated with X-linked intellectual disabilities and X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia.","MAGT1 wt Allele | DKFZp564K142 | IAP | MRX95 | Magnesium Transporter 1 wt Allele | OST3B | Oligosaccharyltransferase 3 Homolog B (S. cerevisiae) Gene | Oligosaccharyltransferase 3 Homolog B Gene | PRO0756 | UNQ628/PRO1244 | XMEN | bA217H1.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936803","PKLR Gene","C157136","This gene plays a role in the production of ATP in glycolysis.","PKLR Gene | PKLR | Pyruvate Kinase L/R Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936912","PKLR wt Allele","C157137","Human PKLR wild-type allele is located in the vicinity of 1q22 and is approximately 19 kb in length. This allele, which encodes pyruvate kinase PKLR protein, is involved in glycolysis.","PKLR wt Allele | PK1 | PKL | PKR | PKRL | Pyruvate Kinase L/R wt Allele | Pyruvate Kinase, Liver Type Gene | Pyruvate Kinase, Liver and RBC Gene | Pyruvate Kinase, Red Cell Type Gene | RPK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936913","PKLR Gene Product","C157138","A protein encoded by the PKLR gene.","PKLR Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936914","Pyruvate Kinase PKLR","C157139","Pyruvate kinase PKLR (574 aa, ~62 kDa) is encoded by the human PKLR gene. This protein plays a role in the transphosphorylation of phohsphoenolpyruvate into pyruvate and ATP in erythrocytes.","Pyruvate Kinase PKLR | EC 2.7.1.40 | PKLR | PKR | Pyruvate Kinase 1 | Pyruvate Kinase Isozyme R | Pyruvate Kinase Isozyme R/L | Pyruvate Kinase Isozymes L/R | Pyruvate Kinase Isozymes R | Pyruvate Kinase Isozymes R/L | Pyruvate Kinase L/R | Pyruvate Kinase PKLR Isoform R-Type | Pyruvate Kinase PKR | Pyruvate Kinase R | R-Type PK | R-Type Pyruvate Kinase | R-Type/L-Type Pyruvate Kinase | Red Cell Pyruvate Kinase | Red Cell/Liver Pyruvate Kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938078","Autologous Cytotoxic T-lymphocytes Exposed to Dendritic Cells loaded with 6B11 Anti-idiotype Minibody","C158601","A preparation of autologous cytotoxic T-lymphocytes (CTLs) that are exposed, ex vivo, to autologous dendritic cells (DCs) loaded with the anti-idiotype minibody 6B11, which mimics the epithelial ovarian tumor-associated antigen (TAA), OC166-9, with potential immunostimulatory and antineoplastic activities. Upon administration, the CTLs exposed to DCs loaded with 6B11 anti-idiotype minibody target and kill autologous ovarian cells expressing the TAA.","Autologous Cytotoxic T-lymphocytes Exposed to Dendritic Cells loaded with 6B11 Anti-idiotype Minibody | 6B11 Anti-idiotype Minibody-pulsed DCs Induced Autologous CTLs | Autologous CTLs Exposed to 6B11-OCIK | Autologous CTLs Exposed to 6B11mini-ovarian-cytokine-induced-killer Cells | Autologous CTLs Induced with 6B11 Anti-idiotype Minibody-pulsed DCs | Autologous Cytotoxic T-cells Induced by Autologous Dendritic Cells Loaded with 6B11 Anti-idiotype Minibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938079","Anti-EGFR CAR-transduced IL-12-expressing T-lymphocytes","C158602","A preparation of human T-lymphocytes transduced with a retroviral vector encoding an anti-epidermal growth factor receptor (EGFR) chimeric antigen receptor (CAR) gene coupled to the signaling domains from CD28, 4-1BB (CD137) and CD3 zeta, and modified to express the cytokine interleukin-12 (IL-12), with potential immunostimulatory and antineoplastic activities. Upon administration, the anti-EGFR CAR-transduced IL-12-expressing T-lymphocytes target and bind to the EGFR antigen on tumor cell surfaces; subsequently, EGFR-expressing tumor cells may be lysed. IL-12 expression activates the immune system by promoting the secretion of interferon-gamma (IFNg), activating natural killer cells (NKs), and inducing cytotoxic T-cell responses, which may result in both decreased cell proliferation and increased cell death for the EGFR-overexpressing tumor cells. EGFR, overexpressed by a variety of cancer cell types, plays a key role in tumor cell proliferation, tumor angiogenesis and radio- and chemoresistance.","Anti-EGFR CAR-transduced IL-12-expressing T-lymphocytes | EGFR-IL12-CAR T-cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938076","CH 5132799","C158603","An orally bioavailable inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) catalytic subunit alpha (PIK3CA), with potential antineoplastic activity. Upon administration, izorlisib selectively binds to and inhibits PIK3CA and its mutated forms in the PI3K/Akt (protein kinase B)/mammalian target of rapamycin (mTOR) pathway. This results in both apoptosis and growth inhibition in PIK3CA-expressing tumor cells. By specifically targeting PIK3CA, izorlisib may be more efficacious and less toxic than pan-PI3K inhibitors. In addition, izorlisib also targets mutated forms of PI3K gamma (PI3Kg). It may also stimulate the immune system to restore CD8+ T-cell activation and cytotoxicity. Dysregulation of the PI3K/Akt/mTOR pathway is often found in solid tumors and results in the promotion of tumor cell growth, survival, and resistance to chemo- and radio-therapy. PIK3CA, one of the most frequently mutated oncogenes, encodes the p110-alpha catalytic subunit of the class I PI3K. In most solid tumors, the activation of the PI3K pathway is induced by mutations of PIK3CA.","Izorlisib | 5-(7-Methylsulfonyl-2-morpholin-4-yl-5,6-dihydropyrrolo[2,3-d]pyrimidin-4-yl)pyrimidin-2-amine | Alpha-selective PI3K Inhibitor MEN1611 | CH 5132799 | CH-5132799 | CH5132799 | IZORLISIB | MEN 1611 | MEN-1611 | MEN1611 | PA 799 | PA-799 | PA799 | PI3K-alpha Inhibitor MEN1611 | PI3K-alpha Inhibitor MEN1611 | PI3Kalpha Inhibitor MEN1611",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950891","4-[4-(4-{[(3R,5R)-5-(2,4-Difluorophenyl)-5-(1H-1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy}-3-methylphenyl)piperazin-1-yl]-N-(4-fluorophenyl)benzamide","C158821","A synthetic triazole antifungal agent, with activity against a variety of pathogenic fungi that can potentially be used against invasive pulmonary aspergillosis. Upon inhalation by nebulizer, opelconazole is delivered in high concentrations to the lungs and resides in the lung tissues for a long period of time with minimal systemic exposure. Opelconazole selectively binds to and inhibits the CYP450-dependent 14-alpha-sterol demethylase in fungi, thereby preventing the production of ergosterol, which is an essential constituent of the fungal cell membrane. This results in fungal cell lysis and inhibits fungal infection in the lungs.","Opelconazole | 4-[4-(4-{[(3R,5R)-5-(2,4-Difluorophenyl)-5-(1H-1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy}-3-methylphenyl)piperazin-1-yl]-N-(4-fluorophenyl)benzamide | Antifungal PC945 | Inhaled Antifungal PC945 | OPELCONAZOLE | PC 945 | PC-945 | PC945 | Triazole Antifungal PC945",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950892","FLT3 NM_004119.2:c.2073T>A","C158822","A nucleotide substitution at position 2073 of the coding sequence of the FLT3 gene where thymine has been mutated to adenine.","FLT3 NM_004119.2:c.2073T>A | CD135 c.2073T>A | FLK2 c.2073T>A | FLT3 c.2073T>A | FMS-Related Tyrosine Kinase 3 c.2073T>A | NM_004119.2:c.2073T>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950893","FLT3 NP_004110.2:p.F691L","C158823","A change in the amino acid residue at position 691 in the receptor-type tyrosine-protein kinase FLT3 protein where phenylalanine has been replaced by leucine.","FLT3 NP_004110.2:p.F691L | CD135 Antigen F691L | CD135 Antigen Phe691Leu | FLT3 F691L | FLT3 F691L Mutation | FLT3 NP_004110.2:p.Phe691Leu | FLT3 Phe691Leu | FLT3 p.F691L | FLT3 p.Phe691Leu | Fetal Liver Kinase-2 F691L | Fetal Liver Kinase-2 Phe691Leu | Flt-3 Receptor F691L | Flt-3 Receptor Phe691Leu | Fms-Related Tyrosine Kinase 3 F691L | Fms-Related Tyrosine Kinase 3 Phe691Leu | NP_004110.2:p.F691L | NP_004110.2:p.Phe691Leu | Receptor-Type Tyrosine-Protein Kinase FLT3 F691L | Receptor-Type Tyrosine-Protein Kinase FLT3 Phe691Leu | Stem Cell Tyrosine Kinase 1 F691L | Stem Cell Tyrosine Kinase 1 Phe691Leu",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937312","Refractory Plasmablastic Lymphoma","C157684","Plasmablastic lymphoma that is resistant to treatment.","Refractory Plasmablastic Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937313","Recurrent HIV-Related Lymphoproliferative Disorder","C157685","The reemergence of HIV-associated lymphoproliferative disorder after a period of remission.","Recurrent HIV-Related Lymphoproliferative Disorder | Recurrent HIV-Associated Lymphoproliferative Disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937306","Refractory Lymphoproliferative Disorder","C157686","Lymphoproliferative disorder that is resistant to treatment.","Refractory Lymphoproliferative Disorder | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937307","Refractory HIV-Related Lymphoproliferative Disorder","C157687","HIV-associated lymphoproliferative disorder that is resistant to treatment.","Refractory HIV-Related Lymphoproliferative Disorder | Refractory HIV-Associated Lymphoproliferative Disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937309","Recurrent NK-Cell Lymphoma, Unclassifiable","C157689","The reemergence of NK-cell lymphoma, unclassifiable after a period of remission.","Recurrent NK-Cell Lymphoma, Unclassifiable | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515824","AIDS, Clinical Trials on Women","C15768","AIDS clinical trials related to females 12 years of age or older. These trials include pregnant women, women at risk of AIDS, female prostitutes, and women who have perinatally transmitted AIDS to a fetus or newborn.","AIDS, Clinical Trials on Women | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937302","Refractory NK-Cell Lymphoma, Unclassifiable","C157690","NK-cell lymphoma, unclassifiable that is resistant to treatment.","Refractory NK-Cell Lymphoma, Unclassifiable | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937303","Refractory T-Cell Prolymphocytic Leukemia","C157691","T-cell prolymphocytic leukemia that is resistant to treatment.","Refractory T-Cell Prolymphocytic Leukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937305","Refractory Aggressive NK-Cell Leukemia","C157693","Aggressive NK-cell leukemia that is resistant to treatment.","Refractory Aggressive NK-Cell Leukemia | Refractory Aggressive NK-Cell Leukemia/Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937298","Refractory Monomorphic Epitheliotropic Intestinal T-cell Lymphoma","C157694","Monomorphic epitheliotropic intestinal T-cell lymphoma that is resistant to treatment.","Refractory Monomorphic Epitheliotropic Intestinal T-cell Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937299","Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma","C157695","The reemergence of subcutaneous panniculitis-like T-cell lymphoma after a period of remission.","Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937300","Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma","C157696","Subcutaneous panniculitis-like T-cell lymphoma that is resistant to treatment.","Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937301","Refractory B-Cell Prolymphocytic Leukemia","C157697","B-cell prolymphocytic leukemia that is resistant to treatment.","Refractory B-Cell Prolymphocytic Leukemia | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511300","Breast Cancer Therapeutic Procedure","C15774","Medical or surgical interventions to eradicate breast tumors and/or their metastases.","Breast Cancer Therapeutic Procedure | Breast Cancer Treatment | Breast Cancer, Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937399","Metastatic Bladder Squamous Cell Carcinoma","C157750","Bladder squamous cell carcinoma that has spread to another anatomical site.","Metastatic Bladder Squamous Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937400","Metastatic Plasmacytoid Urothelial Carcinoma of the Bladder","C157751","Bladder plasmacytoid urothelial carcinoma that has spread to another anatomic site.","Metastatic Bladder Plasmacytoid Urothelial Carcinoma | Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant | Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant | Metastatic Invasive Bladder Urothelial Carcinoma, Plasmacytoid Variant | Metastatic Plasmacytoid Urothelial Carcinoma | Metastatic Plasmacytoid Urothelial Carcinoma of the Bladder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937395","Metastatic Kidney Medullary Carcinoma","C157755","Kidney medullary carcinoma that has spread to another anatomical site.","Metastatic Kidney Medullary Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937393","Metastatic Sarcomatoid Renal Cell Carcinoma","C157757","Sarcomatoid renal cell carcinoma that has spread to another anatomical site.","Metastatic Sarcomatoid Renal Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937053","Zinc Finger Protein Ubi-D4","C157309","Zinc finger protein ubi-d4 (391 aa, ~44 kDa) is encoded by the human DPF2 gene. This protein plays a role in transcriptional regulation and DNA binding.","Zinc Finger Protein Ubi-D4 | Apoptosis Response Zinc Finger Protein | BAF45D | BRG1-Associated Factor 45D | D4, Zinc and Double PHD Fingers Family 2 | DPF2 | Double PHD Fingers 2 | Protein Requiem | UBI-D4/Requiem Homolog",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519011","Chemotherapeutic Peritoneal Perfusion","C15730","No value exists.","Chemotherapeutic Peritoneal Perfusion | peritoneal perfusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937054","DPF3 Gene","C157310","This gene is involved in neuron-specific chromatin remodeling.","DPF3 Gene | DPF3 | Double PHD Fingers 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937055","DPF3 wt Allele","C157311","Human DPF3 wild-type allele is located in the vicinity of 14q24.2 and is approximately 285 kb in length. This allele, which encodes zinc finger protein DPF3, plays a role in chromatin remodeling in differentiated neurons.","DPF3 wt Allele | BAF45C | BAF45c | CER-D4, Mouse, Homolog of Gene | CERD4 | Cerd4 | D4, Zinc and Double PHD Fingers, Family 3 Gene | D4, Zinc and Double PHD Fingers, Family, Member 3 Gene | Double PHD Fingers 3 wt Allele | cer-d4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937056","Zinc Finger Protein DPF3","C157312","Zinc finger protein DPF3 (378 aa, ~43 kDa) is encoded by the human DPF3 gene. This protein is involved in neuron-specific chromatin remodeling.","Zinc Finger Protein DPF3 | BAF45C | BRG1-Associated Factor 45C | D4, Zinc and Double PHD Fingers Family 3 | DPF3 | Double PHD Fingers 3 | Zinc Finger Protein Cer-d4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937355","Pyruvate Kinase PKLR Isoform L-Type","C157140","Pyruvate kinase PKLR isoform L-type (543 aa, ~58 kDa) is encoded by the human PKLR gene. This protein is involved in transphosphorylation of phohsphoenolpyruvate into pyruvate and ATP in the liver.","Pyruvate Kinase PKLR Isoform L-Type | EC 2.7.1.40 | L-Type PK | L-Type Pyruvate Kinase | Liver Pyruvate Kinase | PKL | PKLR | Pyruvate Kinase Isozyme L | Pyruvate Kinase Isozymes L | Pyruvate Kinase L | Pyruvate Kinase PKL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936910","CONNECT Video Doctor","C157143","A multimedia interactive intervention that uses an actor-portrayed Video Doctor and a library of digital video clips, extensive branching logic, and participant input, to provide participants with information tailored to their individual responses. The system establishes proactive outreach using brief telephone calls and text messaging to follow up with smokers, provide motivation enhancement, and refer and engage patients in evidence based smoking cessation interventions. A typical session takes 10-15 minutes.","CONNECT Video Doctor | Video Doctor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2751536","CEREBRAL AMYLOID ANGIOPATHY, APP-RELATED","C157147","An autosomal dominant form of cerebral amyloid angiopathy caused by mutation(s) in the APP gene, encoding amyloid-beta A4 protein. The deposition of amyloid in cerebral blood vessels wall may lead to degenerative vascular changes that may result in cerebral hemorrhage. Mutation(s) in the APP gene may also cause autosomal dominant Alzheimer disease 1.","Cerebral Amyloid Angiopathy, APP-Related | HCHWAD | Hereditary Cerebral Hemorrhage with Amyloidosis-Dutch Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0394697","Brachial Plexus Block","C157799","A regional anesthesia technique that involves injecting local anesthetic agents near the nerves of the brachial plexus to temporarily block sensation and movement of the upper extremity.","Brachial Plexus Block | ",,,,,,,,,,,,,,,"4262378","Injection of anesthetic agent into brachial plexus",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516274","Carcinogen Screening","C15779","In vitro or in vivo testing to give a quantitative measure of tumor-inducing potency of the substance.","Carcinogen Screening | Carcinogenesis, Screening",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1426663","USP46 Gene","C158824","This gene plays a role in both deubiquitination and gamma-aminobutyric acid (GABA) synthesis regulation.","USP46 Gene | USP46 | Ubiquitin Specific Peptidase 46 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950894","USP46 wt Allele","C158825","Human USP46 wild-type allele is located in the vicinity of 4q12 and is approximately 68 kb in length. This allele, which encodes ubiquitin carboxyl-terminal hydrolase 46 protein, is involved in protein modification and neurotransmitter-dependent behavior.","USP46 wt Allele | FLJ12552 | Ubiquitin Specific Peptidase 46 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950897","Premenopausal Greater than 6 months since LMP and no Prior Bilateral Oophorectomy and Not on Estrogen Replacement","C158828","A response that an individual is considered premenopausal, as it has been  longer than 6 months since LMP and there was no prior bilateral oophorectomy and she is not on estrogen replacement.","Premenopausal Greater than 6 months since LMP and no Prior Bilateral Oophorectomy and Not on Estrogen Replacement | Premenopausal: <6 months since LMP AND no prior bilateral oophorectomy AND not on estrogen replacement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950842","Perimenopausal 6 to 12 Months Since LMP","C158829","A time period of 6-12 months since the last menstrual period.","Perimenopausal 6 to 12 Months Since LMP | Perimenopausal: 6-12 months since last menstrual period",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518320","New Prevention Strategies Against Disease","C15882","NIH Emphasis Area: Research in new procedures and approaches to prevent disease.","New Prevention Strategies Against Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950843","Postmenopausal: >12 months since LMP with no prior oophorectomy OR prior bilateral oophorectomy","C158830","A question about whether a patient was postmenopausal at diagnosis for longer than 12 months since the last menstrual period with no prior oophorectomy or prior bilateral oophorectomy.","Postmenopausal with no Prior Oophorectomy Status | Postmenopausal: >12 months since LMP with no prior oophorectomy OR prior bilateral oophorectomy | Was the patient Postmenopausal at diagnosis, where it was >12 months since LMP with no prior oophorectomy OR prior bilateral oophorectomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950845","Yes- Melanoma Related Only","C158832","A response that a melanoma related only event occurred after the initial treatment.","Melanoma Related Only Event Occurred after Initial Treatment | Yes- Melanoma Related Only",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950846","Yes- Non- Melanoma Related Only","C158833","A response that a non-melanoma related only event occurred after the initial treatment.","Non-Melanoma Related Only Event Occurred after Initial Treatment | Yes- Non- Melanoma Related Only",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937671","Anti-CD73 Monoclonal Antibody NZV930","C158132","A fully human monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, anti-CD73 monoclonal antibody NZV930 targets and binds to CD73 on tumor cells, leading to internalization of CD73. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine, thereby preventing adenosine-mediated suppression of lymphocyte activity and increasing the activity of cytotoxic T-lymphocytes (CTLs). This also activates macrophages and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes. By abrogating the inhibitory effect on the immune system and enhancing the CTL-mediated immune response against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, is upregulated in many cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment.","Anti-CD73 Monoclonal Antibody NZV930 | NZV 930 | NZV-930 | NZV930 | SRF 373 | SRF-373 | SRF373",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1504419","Pelvic Hemorrhage","C158133","Bleeding within the pelvic cavity.","Pelvic Hemorrhage | Pelvic Bleeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511071","Basic Behavioral and Social Science Research","C15769","Basic social sciences and behavioral research designed to strengthen the understanding of (a) the determinants and processes that influence HIV-related risk behaviors and (b) the consequences of HIV disease.","Basic Behavioral and Social Science Research | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281727","Sedoxantrone Trihydrochloride","C1576","The trihydrochloride salt of the anthrapyrazole antineoplastic antibiotic sedoxantrone with potential antineoplastic activity. Sedoxantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.","Sedoxantrone Trihydrochloride | 2H-(1)Benzothiopyrano(4,3,2-cd)indazol-8-ol, 5-((2-aminoethyl)amino)-2-(2-(diethylamino)ethyl)-, Trihydrochloride | CI 958 | CI-958 | LEDOXANTRONE TRIHYDROCHLORIDE | Ledoxantrone Trihydrochloride | sedoxantrone trihydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937338","Reticular Growth Pattern","C157705","A morphologic finding where the cells proliferate and give a net-like appearance to the lesion showing multiple spaces of varying sizes in between the cells.","Reticular Growth Pattern | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937335","Microcystic Growth Pattern","C157706","A morphologic finding where cells show numerous small cyst-like spaces that vary in size creating a sieve-like appearance.","Microcystic Growth Pattern | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937336","HIV-Related Lymphoproliferative Disorder","C157709","A lymphoproliferative disorder that develops in an individual with HIV infection.","HIV-Related Lymphoproliferative Disorder | HIV-Associated Lymphoproliferative Disorder | HIV-Associated Lymphoproliferative Disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511080","Behavior Research, Direct","C15770","Research concerning people's behavior in the context of cancer, i.e., how people's behavior affects their chance of developing cancer.","Behavior Research, Direct | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937640","Scoliosis and Kyphosis Deformity Correction","C157976","The correction of a scoliosis or kyphosis deformity of the spine.","Scoliosis and Kyphosis Deformity Correction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0559702","Shoulder Arthroscopy","C157979","A visualization of the shoulder joint via an arthroscope.","Shoulder Arthroscopy | ",,,,,,,,,,,,,,,"4085220","Arthroscopy of shoulder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1511879","Diagnostic Methods and Reagents","C15797","1A4; Basic Science Research (includes vaccine and chemotherapy development), Biomedical Research","Diagnostic Methods and Reagents | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937638","Shoulder Replacement Surgery","C157980","A surgical procedure to replace the shoulder joint.","Shoulder Replacement Surgery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937043","Unresectable Skin Carcinoma","C157324","Skin carcinoma that is not amenable to surgical resection.","Unresectable Skin Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937106","Therapy Used at Visit","C157517","An indication of the type of therapy used during a visit.","Therapy Used at Visit | Type of Therapy Used at Visit | therapy type | therapy_type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937107","Therapy Used Since Last Visit","C157518","An indication of the type of therapy used since the last visit.","Therapy Used Since Last Visit | Type of Therapy Used Since Last Visit | treatment since last contact | treatment_since_last_contact",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937108","Drug Included in Regimen","C157519","A question about whether a specified drug or agent was included in a treatment regimen.","Drug Included in Regimen | Is Drug Included in Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937109","Potent Antiretroviral Therapy","C157520","Antiretroviral therapy using two or more nucleoside reverse transcriptase inhibitors with either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor.","Potent Antiretroviral Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796399","Nolatrexed Dihydrochloride","C1577","The dihydrochloride salt of nolatrexed, a water-soluble lipophilic quinazoline folate analog with antineoplastic activity. Nolatrexed occupies the folate binding site of thymidylate synthase, resulting in inhibition of thymidylate synthase activity and thymine nucleotide synthesis with subsequent inhibition of DNA replication, DNA damage, S-phase cell cycle arrest, and caspase-dependent apoptosis. This agent also exhibits radiosensitizing activity.","Nolatrexed Dihydrochloride | 3,4-Dihydro-2-amino-6-methyl-4-oxy-5-(4-pyridylthio)-quinazoline Dihydrochloride | AG-337 | AG337 | NOLATREXED DIHYDROCHLORIDE | Nolatrexed Hydrochloride | Thymitaq | nolatrexed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937410","Brain Tumor Surgery","C157801","A surgical procedure on the brain to remove a tumor.","Brain Tumor Surgery | Surgery for Brain Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938150","Breast Surgery","C157802","A surgical procedure on the breast.","Breast Surgery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0395122","Brow Lift","C157803","A plastic surgery procedure in which the eyebrows are raised on the forehead to give a more youthful appearance.","Brow Lift | ",,,,,,,,,,,,,,,"4070230","Browlift",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0018821","Cardiac Surgery","C157806","A surgical procedure on the heart.","Cardiac Surgery | Cardiac surgery | Heart Surgery | OR Heart Procedures",,,,,,,,,,,,,,,"4275564","Operation on heart",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0014099","Carotid Endarterectomy","C157807","A surgical procedure to remove plaque from the carotid arteries.","Carotid Endarterectomy | ",,,,,,,,,,,,,,,"4283095","Carotid endarterectomy",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0441308","Casts and Splints","C157808","Orthopedic appliances designed to immobilized bones.","Casts and Splints | ",,,,,,,,,,,,,,,"4129941","Cast splint",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL938102","Cataract Surgery","C157809","A surgical procedure to remove cataracts from the eyes.","Cataract Surgery | CATARACT SURGERY",,,,,,,,,,,,,,,"4004519","Cataract surgery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1516276","Carcinogenesis Inhibition","C15780","Suppression or prevention of the carcinogenic process/development of cancer.","Carcinogenesis Inhibition | Carcinogenesis, Inhibition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937531","Cervical Cancer Surgery","C157810","A surgical procedure to remove cancer from the cervix.","Cervical Cancer Surgery | Surgery for Cervical Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937532","Chemotherapy for Brain Tumor","C157811","The administration of drugs to ameliorate the effects of or shrink a brain tumor.","Chemotherapy for Brain Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937529","Chronic Pain Rehabilitation","C157815","Treatment to assist an individual with longstanding and constant pain.","Chronic Pain Rehabilitation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937669","Nonrandom X Chromosome Inactivation","C158134","An indication that greater than 75% of cells in a sample demonstrate preferential inactivation of the same X chromosome.","Nonrandom X Chromosome Inactivation | Non-Random X Chromosome Inactivation | Non-Random X Inactivation | Non-Random X-Inactivation | Nonrandom X Inactivation | Nonrandom X-Chromosome Inactivation | Nonrandom X-Inactivation | Skewed X Chromosome Inactivation | Skewed X Inactivation | Skewed X-Inactivation | X Chromosome Skewing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3809651","INFANTILE LIVER FAILURE SYNDROME 2","C158135","An autosomal recessive condition caused by mutation(s) in the NBAS gene, encoding neuroblastoma-amplified sequence. It is characterized by recurrent episodes of acute liver failure that begin in infancy.","Infantile Liver Failure Syndrome 2 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1523491","INO80 Complex","C158137","An ATP-dependent chromatin remodeling complex comprised of 15 unique subunits that plays a role in transcriptional regulation, DNA replication and both DNA double-strand break repair and nucleotide-excision repair.","INO80 Complex | INO80 Chromatin Remodeling Complex",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4049489","Thoracic Endometriosis","C158138","A condition characterized by the presence of functioning endometrial tissue in the lung, pleura, chest wall, and/or diaphragm.","Thoracic Endometriosis | ",,,,,,,,,,,,,,,"36713394","Endometriosis of thorax",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937666","PAX5 Gene Mutation","C158139","A change in the nucleotide sequence of the PAX5 gene.","PAX5 Gene Mutation | ALL3 Gene Mutation | BSAP Gene Mutation | Paired Box 5 Gene Mutation | Paired Box Gene 5 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513044","Media Intervention","C15813","An act or ministration that produces an effect to alter the course of a pathologic process through the use of a variety of media, i.e., CD-ROM, Web application, video, telephone.","Media Intervention | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937667","PAX5 Protein Variant","C158140","A variation in the amino acid sequence for paired box protein Pax-5.","PAX5 Protein Variant | B-Cell Lineage Specific Activator Protein Variant | B-Cell Specific Transcription Factor Protein Variant | BSAP Protein Variant | Paired Box Protein Pax-5 Protein Variant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937664","PAX5 NM_016734.2:c.239C>G","C158141","A nucleotide substitution at position 239 of the coding sequence of the PAX5 gene where cytosine has been mutated to guanine.","PAX5 NM_016734.2:c.239C>G | ALL3 c.239C>G | BSAP c.239C>G | NM_016734.2:c.239C>G | PAX5 c.239C>G | Paired Box 5 c.239C>G | Paired Box Gene 5 c.239C>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937665","PAX5 NP_057953.1:p.P80R","C158142","A change in the amino acid residue at position 80 in paired box protein Pax-5 where proline has been replaced by arginine.","PAX5 NP_057953.1:p.P80R | B-Cell Lineage Specific Activator Protein P80R | B-Cell Lineage Specific Activator Protein Pro80Arg | B-Cell-Specific Transcription Factor P80R | B-Cell-Specific Transcription Factor Pro80Arg | BSAP P80R | BSAP Pro80Arg | NP_057953.1:p.P80R | NP_057953.1:p.Pro80Arg | PAX5 NP_057953.1:p.Pro80Arg | PAX5 P80R | PAX5 Pro80Arg | PAX5 p.P80R | PAX5 p.Pro80Arg | Paired Box Protein Pax-5 P80R | Paired Box Protein Pax-5 Pro80Arg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937835","Patidegib Topical Gel","C158420","A topical gel containing patidegib, a cyclopamine-derived inhibitor of the Hedgehog (Hh) pathway, with potential antineoplastic activity. Upon topical application of the patidegib gel, patidegib binds to and inhibits the activity of the G-protein coupled receptor smoothened (SMO), thereby inhibiting Hh pathway signaling. This decreases proliferation and survival in tumor cells in which the Hh pathway is overactivated. Upregulated Hh signaling is associated with uncontrolled tumor cell proliferation. Topical application of patidegib allows for local anti-tumor activity while avoiding systemic exposure and unwanted systemic effects.","Patidegib Topical Gel | IPI-926 Topical Gel | Patidegib Gel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937639","Shoulder Steroid Injections","C157981","A subacromial injection of a steroid to reduce pain or inflammation.","Shoulder Steroid Injections | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937637","Skin Lesion Surgery","C157983","A surgical procedure to remove a skin lesion and a margin around the area.","Skin Lesion Surgery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937635","Skull Base Surgery","C157984","A surgical procedure to treat a disorder or remove a cancer at the base of the skull.","Skull Base Surgery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL382718","Small Bowel Transplantation","C157985","Replacing diseased bowel with healthy bowel tissue.","Small Bowel Transplantation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0037935","Spinal Fusion","C157986","Fusing two or more vertebrae into one.","Spinal Fusion | Spinal fusion",,,,,,,,,,,,,,,"4208113","Spinal arthrodesis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937634","Stabilize Extremity Dislocation","C157987","Immobilization of a dislocated extremity.","Stabilize Extremity Dislocation | Treatment Dislocation of Lower Extremities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937632","Stabilize Femur Fracture","C157988","Immobilization of a broken femur.","Stabilize Femur Fracture | Treatment Femur Fracture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937633","Stabilize Hip Fracture","C157989","Immobilization of a broken hip.","Stabilize Hip Fracture | Treatment Hip Fracture",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511890","Diagnostics Research","C15798","No value exists.","Diagnostics Research | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937630","Stabilize Lower Extremity Fracture","C157990","Immobilization of a dislocated lower extremity.","Stabilize Lower Extremity Fracture | Treatment Fracture of Lower Extremity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937629","Stretta Procedure","C157992","An endoscopic procedure that delivers electromagnetic waves through the end of a catheter to the lower esophageal sphincter and the gastric cardia.","Stretta Procedure | Esophagus Reconstruction (Stretta Procedure)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3665868","Strictureplasty","C157993","Repair of a narrowing in a tubular portion of an organ.","Strictureplasty | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0204097","Stroke Rehabilitation","C157994","Treatment programs that use strategies to maintain function, participation and quality of life for individuals who have had a stroke.","Stroke Rehabilitation | ",,,,,,,,,,,,,,,"4097325","Stroke rehabilitation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937627","Subfascial Endoscopic Perforator Surgery","C157996","A minimally invasive procedure to treat chronic venous ulcers by ligating abnormal perforator veins under the muscle fascia in the legs.","Subfascial Endoscopic Perforator Surgery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937628","Surgery to Improve Sleep","C157997","A surgical procedure to improve breathing during sleep, which improves overall health.","Surgery to Improve Sleep | Sleep Surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937625","Targeted Therapy for Melanoma","C157998","Therapy directed at the precise type of melanoma an individual has based on the results of genetic profiling.","Targeted Therapy for Melanoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937105","CPTAC Bladder Urothelial Carcinoma Baseline Form","C157524","Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on Bladder Urothelial Carcinoma Baseline Form data.","CPTAC Bladder Urothelial Carcinoma Baseline Form | CPTAC BLCA Baseline Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937100","CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form","C157526","Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form data.","CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form | CPTAC CESC Baseline Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937101","CPTAC Esophageal Carcinoma Baseline Form","C157527","Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on Esopohageal Carcinoma Baseline Form data.","CPTAC Esophageal Carcinoma Baseline Form | CPTAC ESCA Baseline Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937102","CPTAC Cholangiocarcinoma Baseline Form","C157528","Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on  Cholangiocarcioma Baseline Form data.","CPTAC Cholangiocarcinoma Baseline Form | CPTAC CHOL Baseline Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937095","CPTAC Liver Hepatocellular Carcinoma Baseline Form","C157529","Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on Liver Hepatocellular Carcinoma Baseline Form data.","CPTAC Liver Hepatocellular Carcinoma Baseline Form | CPTAC LIHC Baseline Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937096","CPTAC Prostate Adenocarcinoma Baseline Form","C157530","Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on Prostate Adenocarcinoma Baseline Form data.","CPTAC Prostate Adenocarcinoma Baseline Form | CPTAC PRAD Baseline Form Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937097","CPTAC Brain Lower Grade Glioma Baseline Form","C157531","Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on Brain Lower Grade Glioma Baseline Form data.","CPTAC Brain Lower Grade Glioma Baseline Form | CPTAC LGG Baseline Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936782","BCL7B wt Allele","C157091","Human BCL7B wild-type allele is located in the vicinity of 7q11.23 and is approximately 22 kb in length. This allele, which encodes B-cell CLL/lymphoma 7 protein family member B protein, is involved in both the promotion of apoptosis and chromatin remodeling. The chromosome region this gene resides in is associated with Williams-Beuren syndrome.","BCL7B wt Allele | B-Cell CLL/Lymphoma 7B Gene | BCL Tumor Suppressor 7B Gene | BCL7B, BAF Complex Component wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936783","Perometer","C157092","A device designed for the measurement of limb volume. It consists of two sets of light-emitting diodes and photosensors arranged as parallel-acting light curtains. The transmitters are set in a frame, perpendicular to each other, so that as the frame passes over the limb the limb is illuminated and its diameter is measured in two planes.","Perometer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936776","Form Directive","C157093","No value exists.","Form Directive | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936778","Confirm AJCC/TNM Cancer Staging Edition","C157095","A directive to confirm the relevant edition of the AJCC/TNM Cancer Staging Edition.","Confirm AJCC/TNM Cancer Staging Edition | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936943","CD45RA-depleted Donor T-lymphocytes","C157369","A preparation of donor lymphocytes that have been depleted of CD45RA-positive cells, that can potentially be used for immune reconstitution purposes. CD45RA depletion results in a cellular product that contains a high amount of memory T-cells (Tm). Upon infusion of the allogeneic CD45RA-depleted T-lymphocytes after a hematopoietic cell transplantation (HCT), these cells provide Tm recovery and are able to prevent viral infections. The depletion of the CD45RA-positive cells reduces the risk of graft-versus-host disease (GvHD) upon infusion. CD45RA is expressed on naive T-cells, whereas Tm cells are CD45RA-negative. Naive T-cells have the potential to induce GvHD.","CD45RA-depleted Donor T-lymphocytes | CD45RA-depleted Allogeneic T-cells | CD45RA-depleted Allogeneic T-lymphocytes | CD45RA-depleted Donor T-cells | Donor CD45RA-depleted (memory) T-cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512916","Intracarotid Infusion Procedure","C15736","No value exists.","Intracarotid Infusion Procedure | Intracarotid Infusion | intracarotid infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936944","TCR alpha/beta/CD19-depleted Allogeneic Hematopoietic Progenitor Cells","C157370","A preparation of hematopoietic progenitor cells (HPCs) from a haploidentical donor that have been depleted of T-cell receptor (TCR) alpha and beta (TCRa/b+) as well as CD19-positive (CD19+) cells, that can potentially be used for immune reconstitution purposes. The TCR alpha/beta/CD19-depleted HPCs contain high amounts of natural killer (NK) cells, gamma/delta T-cells, CD34+ stem cells, monocytes, and dendritic cells (DCs), while devoid of alpha/beta T-cells and CD19-positive B-cells. The TCR alpha/beta/CD19-depleted HPCs are used for allogeneic hematopoietic cell transplantation (HCT) and may allow for rapid and sustained engraftment, rapid immune reconstitution, and may prevent or reduce graft-versus-host disease (GvHD).","TCR alpha/beta/CD19-depleted Allogeneic Hematopoietic Progenitor Cells | Allogeneic TCRab/CD19-depleted Hematopoietic Stem Cells | Allogeneic alpha, beta TCR/CD19-depleted HPCs | Autologous CD34-positive BCL11A-disrupted HPCs ST-400 | TCR alpha/beta+/CD19+ Depleted HPCs | TCR alpha/beta+/CD19+ Depleted Hematopoietic Progenitor Cells | TCR alpha/beta/CD19-depleted HPCs | TCRab+/CD19+-depleted Haploidentical Donor HPCs | TCRab-/CD19-depleted Allogeneic Hematopoietic Progenitor Cells | TCRab-/CD19-depleted Hematopoietic Progenitor Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0162969","Chitosan","C157372","A naturally occurring polysaccharide composed of beta-1,4-linked glucosamine residues with potential antineoplastic activity. Upon administration, poliglusam may, through a not yet fully elucidated mechanism, reduce advanced glycation end product (AGE) levels. This may reduce the interaction between AGEs and the receptor for advanced glycation end products (RAGE, AGER), which is overexpressed in some tumor types and is associated with poor patient outcomes. AGE-RAGE interaction may induce the phosphorylation and subsequent degradation of retinoblastoma protein (Rb), a key cell cycle inhibitor and tumor suppressor, through the phosphoinositide 3-kinase (PI3K)/protein kinase B (PKB, Akt) signaling pathway. Hyperphosphorylation of Rb leads to the dissociation of the Rb-E2F complex, which triggers the activation of genes required for G1/S transition and tumorigenesis. Reducing AGE levels may limit AGE-RAGE interaction and normalize the G1 to S-phase transition, potentially reducing the development and progression of certain cancers. AGEs are non-enzymatic protein modifications produced during the normal aging process that have been shown to play a role in the development and progression of some cancers.","Poliglusam | Chitosan | Deacetylchitin | POLIGLUSAM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936998","Mepolizumab","C157376","A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against interleukin-5 (IL-5) with anti-asthmatic and potential immunosuppressive activity. Upon subcutaneous administration, mepolizumab selectively binds to IL-5, preventing it from associating with interleukin-5 receptor subunit alpha (IL5RA) on the surface of eosinophils and their progenitors. IL-5 plays a role in the regulation of eosinophil development from hematopoietic progenitors as well as eosinophil maturation, differentiation, mobilization, activation, and survival. IL-5 also play a role in the pathogenesis of some phenotypes of hypereosinophilic syndrome (HES).","Mepolizumab | Bosatria | MEPOLIZUMAB | Nucala | SB 240563 | SB-240563 | SB240563",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0862493","Recurrent Endometrioid Adenocarcinoma","C158421","The reemergence of endometrioid adenocarcinoma after a period of remission.","Recurrent Endometrioid Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937895","Sustained-release Mitomycin C Hydrogel Formulation UGN-102","C158422","A sustained-release (SR) reverse thermal (RT) hydrogel formulation containing the antineoplastic antibiotic mitomycin C (MMC), with potential antineoplastic activity. Upon intravesical instillation of the SR MMC hydrogel formulation UGN-102, the liquid converts into gel form and conforms to the bladder wall, allowing MMC to be deposited locally in the bladder to prevent the excretion of this chemotherapeutic agent via urinary flow. In turn, MMC alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis resulting in inhibition of tumor cell proliferation. Due to its reverse thermal-gelation properties, this gel is able to stay in a liquid state at cold temperatures, at 4 degrees Celsius, and transition to a water-soluble gel at body temperature. This allows for increased accumulation of MMC locally in the upper urinary tract which leads to increased efficacy compared to standard intravesical delivery of MMC for bladder cancer. Compared to UGN-101, in UGN-102 the strength of MMC is lower.","Sustained-release Mitomycin C Hydrogel Formulation UGN-102 | Intravesical Mitomycin Gel UGN-102 | MMC + UG-1 Gel | Mitomycin Urothelial Gel UGN-102 | RTGel with Mitomycin C UGN-102 | UGN 102 | UGN-102 | UGN102 | Vesigel",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937893","Chemical Impurity","C158423","Any unwanted organic, inorganic, and residual solvents in drug substances and final products.","Chemical Impurity | Chemical Impurities | Impurities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937894","Physical Property","C158424","Any of the characteristics that define the nature of matter or forces that act upon it.","Physical Property | Physical Properties",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937891","Biological Properties","C158425","Characteristics of biological systems.","Biological Property | Biological Properties",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937892","Recurrent Desmoplastic Small Round Cell Tumor","C158426","The reemergence of desmoplastic small round cell tumor after a period of remission.","Recurrent Desmoplastic Small Round Cell Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937890","Recurrent Fibrosarcoma","C158428","The reemergence of fibrosarcoma after a period of remission.","Recurrent Fibrosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937887","Refractory Fibrosarcoma","C158429","Fibrosarcoma that is resistant to treatment.","Refractory Fibrosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514407","Prevention, Early Detection of Premalignant Lesions","C15842","A procedure that includes screening, diet and behavioral adjustments to prevent and/or detect the transformation of normal cells into cancerous lesions.","Prevention, Early Detection of Premalignant Lesions | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937888","Recurrent Spindle Cell Sarcoma","C158430","The reemergence of spindle cell sarcoma after a period of remission.","Recurrent Spindle Cell Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937885","Refractory Spindle Cell Sarcoma","C158431","Spindle cell sarcoma that is resistant to treatment.","Refractory Spindle Cell Sarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937881","Chemical Identification","C158435","The identification of a chemical based on certain criteria and tests.","Chemical Identification | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562806","Anti-PDL1 Monoclonal Antibody MSB2311","C155931","A second-generation, humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Betifisolimab contains a unique, not as of yet elucidated, pH-dependent antigen binding property allowing the antibody to only bind to PD-L1 within the acidic tumor microenvironment (TME), while it is not able to bind to PD-L1 in normal, healthy tissue. Upon administration, once able to bind to PD-L1 in the TME, betifisolimab blocks the binding of PD-L1 to and activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on activated T-cells suppresses the immune system and results in immune evasion. PD-1 negatively regulates T-cell activation.","Betifisolimab | Anti-PD-L1 Monoclonal Antibody MSB2311 | Anti-PD-L1 Monoclonal Antibody MSB2311 | Anti-PDL1 Monoclonal Antibody MSB2311 | BETIFISOLIMAB | Humanized Anti-PD-L1 Monoclonal Antibody MSB2311 | MSB 2311 | MSB-2311 | MSB2311",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562801","Locally Advanced Digestive System Neuroendocrine Carcinoma","C155934","A neuroendocrine carcinoma that arises from any part of the digestive system and has spread to nearby tissues or lymph nodes.","Locally Advanced Digestive System Neuroendocrine Carcinoma | Locally Advanced Gastrointestinal System Neuroendocrine Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562802","Unresectable Digestive System Neuroendocrine Carcinoma","C155935","A neuroendocrine carcinoma that arises from any part of the digestive system and is not amenable to surgical resection.","Unresectable Digestive System Neuroendocrine Carcinoma | Unresectable Gastrointestinal System Neuroendocrine Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556014","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking Up 10 Stairs","C155516","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking up 10 stairs (1 flight) without stopping.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking Up 10 Stairs | FAC100-Sev: Walking Up 10 Stairs | FAC10035",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556015","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking Up 10 Stairs Why Not","C155517","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking up 10 stairs (1 flight) without stopping. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking Up 10 Stairs Why Not | FAC100-Sev: Walking Up 10 Stairs Why Not | FAC10036",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556020","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking Up 30 Stairs","C155518","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking up 30 stairs (3 flights) without stopping.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking Up 30 Stairs | FAC100-Sev: Walking Up 30 Stairs | FAC10037",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281187","Cervical Cancer Screening","C15551","No value exists.","Cervical Cancer Screening | Cervical Cancer Early Detection | Early Detection of Cervical Cancer | Screening for Cervical Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514235","Population Research","C15878","Research on fertility, contraceptives, transplacental carcinogenesis or other in utero or pre-conception disease induction.","Population Research | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950692","Related to Acute Myeloid Leukemia","C158792","A response that relates an event to acute myeloid leukemia.","Related to Acute Myeloid Leukemia | Related to AML",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950695","Did the patient use smokeless tobacco (including chewing tobacco and snuff) at the time of diagnosis","C158795","A question whether an individual was using smokeless tobacco at time of diagnosis.","Did the Individual use Smokeless Tobacco Use at Diagnosis | Did the patient use smokeless tobacco (including chewing tobacco and snuff) at the time of diagnosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937740","Black Currant Juice","C158098","The juice from the berries of the black currant (Ribes nigrum L.) shrub belonging to the family Grossulariaceae, with potential antioxidant and protective activities. Black currant juice contains a variety of nutrients, including vitamin C, iron, potassium, manganese, anthocyanins, including delphinidin-3-O-glucoside, delphinidin-3-O-rutinoside, cyanidin-3-O-glucoside, and cyanidin-3-O-rutinoside. The antioxidants in black currant juice scavenge free radicals, thereby protecting cells from damage.","Black Currant Juice | BLACK CURRANT JUICE | Ribes nigrum L. Juice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937741","Anti-FL(FITC-E2) CAR T Cells","C158099","A preparation of genetically modified T-cells transduced with a replication incompetent, self-inactivating (SIN) lentiviral vector expressing a second generation chimeric antigen receptor (CAR) consisting of an anti-fluorescein (anti-FL) fluorescein isothiocyanate (FITC)-E2 single chain variable fragment (scFv), that is coupled, via an immunoglobulin G4 (IgG4) hinge-CH2(L295D)-CH3 spacer, to the costimulatory signaling molecules CD28, CD137 (4-1BB), and CD3 zeta, and linked to a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Prior to the administration of anti-FL(FITC-E2) CAR T-cells, the CAR-T adaptor molecule (CAM) EC17 is administered. EC17 is a bispecific molecule that is composed of folic acid conjugated to FITC (folate-FITC). EC17 targets and binds with its folate moiety with high affinity to folate receptor (FR)-expressing tumor cells. Upon administration of the anti-FL(FITC-E2) CAR T-cells, these cells are attracted by and bind to the FITC antigen moiety of EC17. Upon binding to EC17, the T-cells induce specific tumor cell lysis, cytokine secretion, and proliferation, and activate a robust immune response against the EC17-bound, FR-expressing tumor cells. FR is overexpressed in various tumor cell types and is associated with increased leukemic cell proliferation and aggressiveness. The co-stimulatory molecules are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity. EGFRt both facilitates detection of the administered T-cells in vivo and can promote elimination of those cells following a cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) response. The reactivity of the anti-FL(FITC-E2) CAR T-cells is dependent on dosing of EC17, and therefore allows CAR T-cell activity to be controlled by dosing of EC17.","Anti-FL(FITC-E2) CAR T Cells | Anti-FL(FITC-E2) CAR T-lymphocytes | Anti-FL(FITCE2) CAR Expressing T Cells | AntiFL(FITCE2) CAR Expressing T Cells | Fluorescein-specific (FITC-E2)-CAR T Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517707","Laboratory Animal Production and Facilities","C15809","The production of laboratory animals for research.","Laboratory Animal Production and Facilities | Research Animal Facility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938016","Autologous Dendritic Cell/Myeloma Fusion Vaccine","C158480","A therapeutic cancer vaccine consisting of autologous dendritic cells (DCs) fused with patient-derived plasma cell (multiple) myeloma cells with potential immunostimulatory and antineoplastic activities. Upon administration, autologous DC/multiple myeloma fusions stimulate both helper and cytotoxic T-lymphocyte (CTL) responses through the presentation of internalized and newly synthesized tumor associated antigens (TAAs). This may promote cellular and humoral antitumor immune responses in patients with plasma cell myeloma.","Autologous Dendritic Cell/Myeloma Fusion Vaccine | Autologous DC/Multiple Myeloma Fusions | DC/MM Fusion Vaccine | DC/MM Fusions | DC/Multiple Myeloma Fusions | DC/Plasma Cell Myeloma Fusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938013","PALM2 Gene","C158481","This gene may be involved in modeling of the actin cytoskeleton.","PALM2 Gene | PALM2 | Paralemmin 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938014","PALM2 wt Allele","C158482","Human PALM2 wild-type allele is located in the vicinity of 9q31.3 and is approximately 311 kb in length. This allele, which encodes paralemmin-2 protein, may play a role in cell shape.","PALM2 wt Allele | Paralemmin 2 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938011","Paralemmin-2","C158483","Paralemmin-2 (379 aa, ~42 kDa) is encoded by the human PALM2 gene. This protein may be involved in cell shape and cytoskeletal structure.","Paralemmin-2 | PALM2 | Paralemmin 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938012","AKAP2 Gene","C158484","This gene is involved in the regulation of protein kinase A activity.","AKAP2 Gene | A-Kinase Anchoring Protein 2 Gene | AKAP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938071","AKAP2 protein, human","C158486","A-kinase anchor protein 2 (859 aa, ~95 kDa) is encoded by the human AKAP2 gene. This protein is involved in the modulation of protein kinase A activity.","A-Kinase Anchor Protein 2 | A Kinase Anchor Protein 2 | A-Kinase Anchoring Protein 2 | AKAP-2 | AKAP-KL | AKAP2 | PRKA2 | Protein Kinase A Anchoring Protein 2 | Protein Kinase A-Anchoring Protein 2 | Protein Kinase A2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2829990","PALM2/AKAP2 Fusion Gene","C158487","A fusion gene (~7 kb) that results from a read-through of 2 genes in the vicinity of 9q31.3 which fuses the PALM2 gene to the AKAP2 gene. Variation in the fusion gene is associated with the variability in human height.","PALM2/AKAP2 Fusion Gene | PALM2 and AKAP2 Fusion Gene | PALM2-AKAP2 | PALM2-AKAP2 Readthrough Gene | PALM2-AKAP2 Readthrough Transcript Gene | PALM2/AKAP2 | PALM2/AKAP2 Readthrough Gene | PALM2/AKAP2 Readthrough Transcript Gene | PALM2::AKAP2 Fusion Gene | PALM2AKAP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938069","PALM2/AKAP2 Fusion Protein","C158488","PALM2/AKAP2 fusion protein (1103 aa, ~122 kDa) is encoded by the human PALM2/AKAP2 fusion gene. This protein plays a role in the determination of human height.","PALM2/AKAP2 Fusion Protein | PALM2 and AKAP2 Fusion Protein | PALM2-AKAP2 Fusion Protein | PALM2-AKAP2 Protein | PALM2-AKAP2 Readthrough Protein | PALM2/AKAP2 Protein | PALM2/AKAP2 Readthrough Protein | PALM2::AKAP2 Fusion Protein | Paralemmin-2-A-Kinase Anchor Protein 2 Fusion Protein | Paralemmin-2/A-Kinase Anchor Protein 2 Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938066","QSOX2 Gene","C158489","This gene plays a role in extracellular protein modification.","QSOX2 Gene | QSOX2 | Quiescin Sulfhydryl Oxidase 2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514708","Radiology, Treatment Planning","C15848","The creation of a strategy for radiation therapy.","Radiology, Treatment Planning | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969245","New Tumor Event After Initial Treatment Absent","C160286","There is evidence of a new tumor after the initial treatment.","New Tumor Event After Initial Treatment Absent | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL970062","CDISC Ebola Therapeutic Area User Guide Version 1.0","C161442","The 1.0 version of the CDISC Ebola therapeutic area user guide.","CDISC Ebola Therapeutic Area User Guide Version 1.0 | Ebola Therapeutic Area User Guide v1.0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282089","Carubicin Hydrochloride","C1582","The hydrochloride salt of the anthracycline antineoplastic antibiotic carubicin.  Carubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.","Carubicin Hydrochloride | CARUBICIN HYDROCHLORIDE | Carubicin hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937786","Multiple Challenge Agent Same Category Indicator","C158300","An indication as to whether the subject was challenged with more than one challenge agent from the same challenge agent category.","Multiple Challenge Agent Same Category Indicator | MCSCTIND | Multiple Challenge Agent Same Cat Ind",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937783","Challenge Agent Supplier Name","C158301","The name of the person, company, organization, or institution that supplied the challenge agent employed in the study model.","Challenge Agent Supplier Name | CAGTSUPN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937784","Challenge Agent Supplier Address","C158302","The address of the person, company, organization, or institution that supplied the challenge agent employed in the study model.","Challenge Agent Supplier Address | CAGTSUPA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937781","Biological Agent Biovar Name","C158303","The biovar name of the biological challenge agent.","Biological Agent Biovar Name | BABIOVRN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937782","Biological Agent Serovar Name","C158304","The serovar name of the biological challenge agent.","Biological Agent Serovar Name | BASEROVN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937779","Biological Agent Strain Name","C158305","The strain name of the biological challenge agent.","Biological Agent Strain Name | BASTRNN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937780","Biological Agent Engineered Indicator","C158306","An indication as to whether the biological challenge agent is engineered rather than naturally occurring.","Biological Agent Engineered Indicator | BAENGIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937777","Biological Agent Certificate of Analysis Indicator","C158307","An indication as to whether a certificate of analysis exists for the challenge agent.","Biological Agent Certificate of Analysis Indicator | BACOAIND | Biological Agent CoA Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937778","Biological Agent Type","C158308","The type of biological agent employed in the model.","Biological Agent Type | BACAT | Biological Agent Category",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937775","Biological Agent Genus and Species","C158309","The genus and species of the biological challenge agent used in the study.","Biological Challenge Agent Scientific Name | BAGENSPC | Biological Agent Genus and Species | Biological Agent Genus and Species",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518861","Palliative Care, Other Than Pain and Hospice","C15830","Supportive care that is not hospice or pain relief","Palliative Care, Other Than Pain and Hospice | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937776","Master Bank or Seed Stock Immediate Supplier","C158310","The name of the direct supplier of the master bank or seed stock of organisms from which the biological challenge agent came.","Master Bank or Seed Stock Immediate Supplier | BAMBSSDS | Bio Ag Master Bank/Seed Stock Dir Supp | Bio Master Bank or Seed Stock Dir Supp | Bio Master Bank or Seed Stock Direct Supplier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937978","Autologous CMV-pp65-shLAMP-1 mRNA Loaded Dendritic Cell Vaccine","C158522","A cancer cell vaccine consisting of autologous dendritic cells pulsed with mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) as a fusion construct with a short peptide chimeric antigen from lysosome-associated membrane protein 1 (shLAMP-1), with potential antineoplastic and immunostimulatory activities. Upon vaccination, the autologous CMV-pp65-shLAMP-1 vaccine exposes the immune system to the CMV pp65 peptide, which may elicit a cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells. The incorporation of shLAMP-1 may route CMV pp-65 antigens into the lysosomal compartment, resulting in enhanced MHC class II antigen presentation, thereby promoting CD4-positive T-cell responses. The CMV pp65 protein is the primary component of the enveloped sub-viral particle of CMV and is expressed in certain tumor types.","Autologous CMV-pp65-shLAMP-1 mRNA Loaded Dendritic Cell Vaccine | Autologous pp65-shLAMP-1 DC Vaccine | Autologous shLAMP-1-pp65 mRNA-pulsed DC Vaccine | Autologous shLAMP-1-pp65-DC Vaccine | Autologous shLAMP-1-pp65-DCs | pp65-shLAMP-1 mRNA DCs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937973","RFC4 Gene","C158525","This gene is involved in DNA elongation during replication.","RFC4 Gene | RFC4 | Replication Factor C Subunit 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937974","RFC4 wt Allele","C158526","Human RFC4 wild-type allele is located in the vicinity of 3q27.3 and is approximately 17 kb in length. This allele, which encodes replication factor C subunit 4 protein, plays a role in DNA replication.","RFC4 wt Allele | A1 | Activator 1, 37-kD Subunit Gene | RFC2, Yeast, Homolog of Gene | RFC37 | Replication Factor C (Activator 1) 4 (37kD) Gene | Replication Factor C (Activator 1) 4, 37kDa Gene | Replication Factor C Subunit 4 wt Allele | Replication Factor C, 37-kD Subunit Gene | Replication Factor C, Subunit 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950701","Autologous iC9-GD2CAR-CD28-CD3zeta-IL-15-expressing T-lymphocytes","C158732","A preparation of autologous T-lymphocytes that have been transduced with the retroviral vector SFG, a Moloney murine leukemia (Mo-MuLV) virus-based vector, expressing both an extracellular domain consisting of interleukin 15 (IL-15) and a GD2-specific chimeric antigen receptor (CAR) derived from the monoclonal antibody 14G2a, linked to the CD28 and CD3zeta (TCRzeta; CD247) costimulatory signaling domains and containing the suicide gene, inducible caspase 9 (iCasp9 or iC9), with potential immunomodulating and antineoplastic activities. Upon administration, the autologous iC9-GD2CAR-CD28-CD3zeta-IL-15-expressing T-lymphocytes recognize, bind to and induce selective cytotoxicity in GD2-expressing tumor cells. IL-15 is a pro-survival cytokine that promotes T-cell persistence and potentiates the immune response against tumor cells. Incorporation of the costimulatory signaling domains increases T-cell function, expansion, and survival. The iCasp9 safety switch consists of a full-length caspase 9, including its caspase recruitment domain, linked to a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V). If the administered CAR T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903, which binds to the FKBP12-F36V drug-binding domain, activates caspase 9 and results in apoptosis of the administered CAR T-cells, can be administered. GD2, a disialoganglioside and tumor-associated antigen (TAA), is overexpressed on the surface of neuroblastoma cells and other neuroectoderm-derived neoplasms and is minimally expressed on normal, healthy cells.","Autologous iC9-GD2CAR-CD28-CD3zeta-IL-15-expressing T-lymphocytes | Autologous iC9-GD2CAR-CD28-CD3zeta-IL-15-expressing T-cells | iC9.GD2.CAR.IL-15 T-cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950702","Zirconium Zr 89-DFO-REGN3504","C158733","A radioimmunoconjugate consisting of an antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), linked, via the chelator desferrioxamine (DFO), to the radioisotope zirconium Zr 89 (Zr89), with potential diagnostic properties upon positron emission tomography (PET) imaging. Upon administration, the antibody moiety of zirconium Zr 89-DFO-REGN3504 specifically targets and binds to PD-L1. Upon binding, the radioisotope moiety may be detected using PET, thereby allowing the imaging and quantification of PD-L1-expressing tumor cells. PD-L1, a transmembrane protein expressed on activated T-cells, is overexpressed in some cancer types and plays a significant role in immune evasion by tumor cells.","Zirconium Zr 89-DFO-REGN3504 | 89Zr-DFO-REGN3504",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937738","Protein Arginine Methyltransferase 5 Inhibitor PF-06939999","C158100","An orally available inhibitor of protein arginine N-methyltransferase 5 (histone-arginine N-methyltransferase PRMT5; PRMT5) with potential antiproliferative and antineoplastic activities. Although the mechanism of action has not yet been fully elucidated, orally administered PRMT5 inhibitor PF-06939999 inhibits the methyltransferase activity of PRMT5, thereby decreasing the levels of monomethylated and dimethylated arginine residues in histones H2A, H3, and H4, and modulating the expression of genes involved in several cellular processes including cell proliferation. This may increase the expression of antiproliferative genes and/or decrease the expression of genes that promote cell proliferation, and may decrease the growth of rapidly proliferating cells, including cancer cells. PRTM5, an arginine methyltransferase that can catalyze the formation of both omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA) on histones and a variety of other protein substrates, is overexpressed in several neoplasms.","Protein Arginine Methyltransferase 5 Inhibitor PF-06939999 | PF 06939999 | PF-06939999 | PF06939999 | PRMT5 Inhibitor PF-06939999",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937739","Refractory Cholangiocarcinoma","C158101","Cholangiocarcinoma that is resistant to treatment.","Refractory Cholangiocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937737","Dihydroorotate Dehydrogenase Inhibitor AG-636","C158103","An orally available inhibitor of dihydroorotate dehydrogenase (DHODH), with potential antineoplastic activity. Upon administration, AG-636 specifically targets, binds to and prevents the activation of DHODH, thereby preventing the fourth enzymatic step in de novo pyrimidine synthesis. This prevents uridine monophosphate (UMP) formation, DNA synthesis, cell division and cellular proliferation, causes reactive oxygen species (ROS) formation, enables differentiation and induces apoptosis in susceptible tumor cells. DHODH, a mitochondrial enzyme, catalyzes the conversion of dihydroorotate (DHO) to orotate in the endogenous synthesis of UMP.","Dihydroorotate Dehydrogenase Inhibitor AG-636 | AG 636 | AG-636 | AG636 | DHODH Inhibitor AG-636",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937734","Refractory WHO Grade II Glioma","C158104","WHO grade 2 glioma that is resistant to treatment.","Refractory WHO Grade 2 Glioma | Refractory WHO Grade II Glioma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937933","Surgery Patient","C158375","A patient who is undergoing a surgical procedure.","Surgery Patient | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937934","Gynecologic Surgery Patient","C158376","A patient who is undergoing a gynecologic surgical procedure.","Gynecologic Surgery Patient | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937931","Hysterectomy Patient","C158377","A patient who is undergoing a hysterectomy.","Hysterectomy Patient | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937932","Refractory Endometrial Serous Adenocarcinoma","C158378","Endometrial serous adenocarcinoma that is resistant to treatment.","Refractory Endometrial Serous Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937929","Refractory Endometrial Mixed Cell Adenocarcinoma","C158379","Endometrial mixed cell adenocarcinoma that is resistant to treatment.","Refractory Endometrial Mixed Cell Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514232","Population Intervention","C15837","No value exists.","Population Intervention | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937930","Refractory Endometrial Clear Cell Adenocarcinoma","C158380","Endometrial clear cell adenocarcinoma that is resistant to treatment.","Refractory Endometrial Clear Cell Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937927","Refractory Uterine Corpus Carcinosarcoma","C158381","Uterine Corpus Carcinosarcoma that is resistant to treatment.","Refractory Uterine Corpus Carcinosarcoma | Refractory Endometrial Carcinosarcoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950770","Were Immunophenotype and Cytochemistry Analyses Performed on Bone Marrow Aspirate","C158679","A question asking if immunophenotyping and cytochemistry were performed on bone marrow aspirate during the study","Were Immunophenotype and Cytochemistry Analyses Performed on Bone Marrow Aspirate | Were Immunophenotype & Cytochemistry Performed on Bone Marrow Aspirate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519892","Vaccine Development, Other Non-AIDS","C15867","No value exists.","Vaccine Development, Other Non-AIDS | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950771","Check all that Apply","C158680","A directive to check all that apply on the form.","Check all that Apply | Check all that apply | If yes, check all that apply",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950772","Autologous Anti-GD2CAR-CD28-CD3zeta-IL-15-expressing Natural Killer T-cells","C158682","A preparation of autologous natural killer T-lymphocytes (NKTs) that have been transduced with a retroviral vector to express both an extracellular domain consisting of interleukin 15 (IL-15) and a chimeric antigen receptor (CAR) specific for the human tumor associated antigen (TAA) GD2, linked to the CD28 and CD3zeta (TCRzeta; CD247) costimulatory signaling domains, with potential antineoplastic activity. Upon intravenous administration, autologous anti-GD2CAR-CD28-CD3zeta-IL-15-expressing NKTs target, bind to, and induce selective toxicity in GD2-expressing tumor cells. IL-15 is a pro-survival cytokine that promotes T-cell persistence and potentiates the immune response against tumor cells. Incorporation of the costimulatory signaling domains increases T-cell function, expansion, and survival. The CD28 costimulatory molecule signaling domain enhances activation and signaling after recognition of GD2. Additionally, inclusion of the CD28 signaling domain may increase proliferation of T-cells and antitumor activity compared to the inclusion of the CD3zeta chain alone. GD2, a disialoganglioside and tumor-associated antigen (TAA), is overexpressed in a variety of tumor cell types.","Autologous Anti-GD2CAR-CD28-CD3zeta-IL-15-expressing Natural Killer T-cells | Autologous Anti-GD2CAR-CD28-CD3zeta-IL-15-expressing | Autologous Anti-GD2CAR-CD28-CD3zeta-IL-15-expressing NKTs | G28z.15 NKTs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950773","Anti-CD34 Antibody","C158683","Any antibody that recognizes hematopoietic progenitor cell antigen CD34.","Anti-CD34 Antibody | Anti CD34 | Anti-Hematopoietic Progenitor Cell Antigen CD34 | CD34 Antibody | HPCA1 Antibody | gp105-120 Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950774","Anti-CD45RA Antibody","C158684","Any antibody that recognizes receptor-type tyrosine-protein phosphatase C isoform CD45RA.","Anti-CD45RA Antibody | Anti CD45RA | Anti-Receptor-Type Tyrosine-Protein Phosphatase C Isoform CD45RA | CD45RA Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938146","Transcatheter Aortic Valve Replacement","C158018","A minimally invasive procedure in which a replacement aortic valve is guided into proper placement in the aortic valve via a catheter.","Transcatheter Aortic Valve Replacement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2921039","Transcatheter Mitral Valve Repair","C158019","A minimally invasive procedure in which a replacement mitral valve is guided into proper placement in the mitral valve via a catheter.","Transcatheter Mitral Valve Repair | ",,,,,,,,,,,,,,,"36684977","Transcatheter mitral valve repair",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1512070","Drug Development, Preclinical","C15801","Drug development activites focused on preclinical trials and testing.","Drug Development, Preclinical | Drug Testing/Development, Preclinical",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937774","Biological Agent Nucleotide Sequence Indicator","C158312","An indication as to whether the genetic sequence of the challenge agent has been identified.","Biological Agent Nucleotide Sequence Indicator | BANSIND | Biological Agent Nucleotide Sequence Ind",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937771","Biological Agent Nucleotide Sequence Location","C158313","The reference, citation, or database location of the nucleotide sequence of the challenge agent.","Biological Agent Nucleotide Sequence Location | BANSLOC | Biological Agent Nucleotide Sequence Loc",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937772","Working Bank or Primary Stock Characterized Indicator","C158314","An indication as to whether the working bank or primary stock was characterized by molecular or biological techniques.","Working Bank or Primary Stock Characterized Indicator | BWBPSIND | Bio Ag Work Bank/Primary Stock Char Ind | Biological Working Bank or Primary Stock Characterized Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL462175","Chemical Challenge Agent Name","C158315","The name of the chemical challenge agent.","Chemical Challenge Agent Name | CHAGNAM | Chemical Agent Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937770","Chemical Agent CAS Number","C158316","The unique numerical identifier assigned by the Chemical Abstract Service (CAS), a division of the American Chemical Society, to the chemical challenge agent used in the study.","Chemical Agent CAS Number | CHAGCAS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL1659534","VERU 111","C158517","An orally bioavailable, small molecule tubulin inhibitor, with potential antineoplastic, antiviral and anti-inflammatory activities. Upon oral administration, sabizabulin binds to the colchicine-binding site of alpha- and beta-tubulin subunits of microtubules and crosslinks the microtubules, thereby inhibiting microtubule polymerization in tumor blood vessel endothelial cells and tumor cells. This blocks the formation of the mitotic spindle and leads to cell cycle arrest at the G2/M phase. As a result, this agent disrupts the tumor vasculature, tumor blood flow, deprives tumor cells of nutrients, and induces apoptosis. In addition, as microtubules plays an important role in intracellular transport, the inhibition of its polymerization may disrupt the transport of the androgen receptor (AR) into the cell nucleus, as well as virus trafficking around the cell. This may decrease viral replication and assembly. Inhibition of tubulin polymerization may also inhibit the release of pro-inflammatory cytokines and disrupt inflammatory cell activities. Sabizabulin is not a substrate of P-glycoprotein (Pgp), an efflux pump that when overexpressed, may confer resistance to taxane agents.","Sabizabulin | SABIZABULIN | VERU 111 | VERU-111 | VERU111",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938044","RASSF7 wt Allele","C158518","Human RASSF7 wild-type allele is located in the vicinity of 11p15.5 and is approximately 4 kb in length. This allele, which encodes Ras association domain-containing protein 7, is involved in the inhibition of apoptosis.","RASSF7 wt Allele | C11orf13 | Chromosome 11 Open Reading Frame 13 Gene | HRAS1 | HRAS1-Related Cluster 1 Gene | HRAS1-Related Cluster-1 Gene | HRC1 | Ras Association (RalGDS/AF-6) Domain Family (N-Terminal) Member 7 Gene | Ras Association (RalGDS/AF-6) Domain Family 7 Gene | Ras Association Domain Family Member 7 wt Allele | Ras Association Domain Family, Member 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937979","Ras Association Domain-Containing Protein 7","C158519","Ras association domain-containing protein 7 (373 aa, ~40 kDa) is encoded by the human RASSF7 gene. This protein plays a role in the inhibiting the activation of c-Jun N-terminal kinases (JNK) by dual specificity mitogen-activated protein kinase kinase 7 (MAP2K7), which prevents JNK-dependent apoptosis.","Ras Association Domain-Containing Protein 7 | HRAS1-Related Cluster Protein 1 | RASSF7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514807","Redirected Cytolysis","C15851","The killing of target cells by changing the natural specificity of cytotoxic T cells by the use of an antibody or other molecule capable of binding to both the T cell and to the target cell.  Often involves hybrid (bispecific) antibodies having distinct specificities for the T cell and for the target cell. (NCI/OSP)","Redirected Cytolysis | Redirected Cytotoxicity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950703","Lutetium Lu 177-NeoB","C158734","A radioconjugate consisting of the gastrin-releasing peptide receptor (GRPR) antagonist, NeoB, linked via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon administration, lutetium Lu 177 NeoB targets and binds to GRPRs present on certain tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to GRPR-expressing cells. GRPR, also known as bombesin receptor subtype 2, is a G protein-coupled receptor that is overexpressed in some cancer types.","Lutetium Lu 177-NeoB | 177Lu-NeoB | Lutetium 177-NeoB | Lutetium Lu 177 DOTA-NeoBOMB1 | [177Lu]-NeoB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950704","Has the patient ever been diagnosed with diabetes by a physician","C158738","A question whether a physician has diagnosed diabetes.","Did the Physician Diagnose Diabetes | Has the patient ever been diagnosed with diabetes by a physician",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950705","Has the patient had colorectal cancer","C158739","A question whether a physician has diagnosed diabetes.","Is there a History of Colorectal Cancer | Has the patient had colorectal cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519902","Phase III Large Scale Vaccine Trial","C15873","Select suitable vaccine candidates and support efficacy trials when appropriate criteria are met.","Phase III Large Scale Vaccine Trial | Vaccine Trial-Phase III Large Scale",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950706","Measure of Success of Outcome at completion of this Follow-up Form","C158740","A question regarding the success outcome after completion of this form.","What is the Follow-Up Form Completion Outcome Measure of Success | Measure of Success of Outcome at completion of this Follow-up Form",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950707","Specify Other Performance Status Scale: Timing","C158741","A directive to specify a performance status scale other than one listed on the form.","Specify Other Performance Status Scale: Timing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950708","EZH2 Inhibitor SHR2554","C158742","An orally available selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2), with potential antineoplastic activity. Upon oral administration, zeprumetostat selectively targets, binds to and inhibits the activity of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 on lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased proliferation of EZH2-expressing cancer cells. EZH2, an HMT class enzyme and the catalytic subunit of the polycomb repressive complex 2 (PRC2), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation; its expression is correlated with tumor initiation, progression, stem cell self-renewal, migration and angiogenesis.","Zeprumetostat | EZH2 Inhibitor SHR2554 | EZH2 Inhibitor SHR2554 | Enhancer of Zeste Homolog 2 Inhibitor SHR2554 | SHR 2554 | SHR-2554 | SHR2554 | ZEPRUMETOSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937703","Genetically Modified HSV-1 Oncolytic Immunotherapeutic RP1","C158074","A genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic, immunostimulating and antineoplastic activities. Upon administration, vusolimogene oderparepvec specifically targets, infects and replicates in tumor cells only while not infecting normal, healthy cells. This induces tumor cell lysis. The released virus particles, infect and replicate in neighboring tumor cells, thereby further killing tumor cells. The released tumor-associated antigens (TAAs) from the tumor cells activate the immune system to exert an anti-tumor immune response against the tumor cells, thereby further killing the tumor cells. The virus itself also elicits a tumor-specific systemic immune and cytotoxic T-lymphocyte (CTL) response, thereby killing nearby non-infected tumor cells. In RP1, ICP34.5 and 47 proteins of the HSV1 strain have been deleted; RP1 expresses a fusogenic protein for optimal tumor cell infection and killing.","Vusolimogene Oderparepvec | Genetically Modified HSV-1 Oncolytic Immunotherapeutic RP1 | HSV-1 Engineered RP1 | HSV-1 Oncolytic Viral Strain RP1 | HSV-1 RP1 | Oncolytic Virus RP1 | RP-1 | RP1 | VUSOLIMOGENE ODERPAREPVEC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937701","If no, skip to next section","C158076","A directive to move to the next section if the response to the question was no.","Skip to Next Section If No | If no, skip to next section",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937928","Bladder Non-Invasive Papillary Urothelial Carcinoma","C158382","Papillary urothelial neoplastic proliferation in the bladder with some level of cytological and architectural disorder visible at low to intermediate magnification, with no invasion beyond the basement membrane (Ta). (WHO 2016)","Bladder Non-Invasive Papillary Urothelial Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937926","SIGLEC15 Gene","C158384","This gene plays a role in glycan binding and immunity.","SIGLEC15 Gene | SIGLEC15 | Sialic Acid Binding Ig Like Lectin 15 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937923","SIGLEC15 wt Allele","C158385","Human SIGLEC15 wild-type allele is located in the vicinity of 18q21.1 and is approximately 19 kb in length. This allele, which encodes sialic acid-binding Ig-like lectin 15 protein, is involved in both innate immunity and sialylated glycan binding.","SIGLEC15 wt Allele | CD33 Antigen-Like 3 Gene | CD33 Molecule-Like 3 Gene | CD33L3 | HsT1361 | S15 | SIGLEC-15 | Sialic Acid Binding Ig Like Lectin 15 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937924","Sialic Acid-Binding Ig-Like Lectin 15","C158386","Sialic acid-binding Ig-like lectin 15 (328 aa, ~36 kDa) is encoded by the human SIGLEC15 gene. This protein plays a role in both sialylated glycan binding and innate immunity.","Sialic Acid-Binding Ig-Like Lectin 15 | CD33 Antigen-Like 3 | CD33 Molecule-Like 3 | S15 | SIGLEC15 | Sialic Acid Binding Ig Like Lectin 15 | Sialic Acid Binding Ig-Like Lectin 15 | Sialic Acid-Binding Immunoglobulin-Like Lectin 15 | Siglec-15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937921","mSMILE Regimen","C158387","A modified version of the SMILE regimen consisting of dexamethasone, methotrexate, ifosfamide, pegaspargase and etoposide that can be used in the treatment of natural killer (NK)/T-cell lymphoma. Compared to SMILE, in mSMILE the pegylated L-asparaginase is substituted for L-asparaginase and the regimen cycle length is shortened.","mSMILE Regimen | Dexamethasone-Methotrexate-Ifosfamide-Pegaspargase-Etoposide | Dexamethasone/Methotrexate/Ifosfamide/Pegaspargase/Etoposide | Modified SMILE | Modified SMILE Regimen | Modified-SMILE | mSMILE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937922","GSTT2 Gene","C158388","This gene is involved in glutathione conjugation.","GSTT2 Gene | GSTT2 | Glutathione S-Transferase Theta 2 (Gene/Pseudogene) Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937863","GSTT2 wt Allele","C158389","Human GSTT2 wild-type allele is located in the vicinity of  22q11.23 and is approximately 4 kb in length. This allele, which encodes glutathione S-transferase theta-2 protein, plays a role in glutathione metabolism.","GSTT2 wt Allele | Glutathione S-Transferase Theta 2 (Gene/Pseudogene) wt Allele | Glutathione S-Transferase, Theta-2 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514405","Prevent Transmission of HIV/Safety Blood Supply","C15838","Develop and assess multiple and concurrent ethical intervention strategies to reduce or prevent HIV transmission in both domestic and international settings.","Prevent Transmission of HIV/Safety Blood Supply | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937864","Glutathione S-Transferase Theta-2","C158390","Glutathione S-transferase theta-2 (244 aa, ~28 kDa) is encoded by the human GSTT2 gene. This protein is involved in the conjugation of glutathione to hydrophobic electrophiles.","Glutathione S-Transferase Theta-2 | EC 2.5.1.18 | GST Class-Theta-2 | GSTT2 | Glutathione S-Transferase Theta 2 | Glutathione-S-Transferase T2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937997","TSPYL5 wt Allele","C158566","Human TSPYL5 wild-type allele is located in the vicinity of 8q22.1 and is approximately 5 kb in length. This allele, which encodes testis-specific Y-encoded-like protein 5, is involved in inhibiting the deubiquitination of cellular tumor antigen p53 (TP53).","TSPYL5 wt Allele | KIAA1750 | TSPY Like 5 wt Allele | TSPY-Like 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937994","Testis-Specific Y-Encoded-Like Protein 5","C158567","Testis-specific Y-encoded-like protein 5 (417 aa, ~45 kDa) is encoded by the human TSPYL5 gene. This protein plays a role in the inhibition of cellular tumor antigen p53 (TP53) deubiquitination by ubiquitin carboxyl-terminal hydrolase 7 (USP7).","Testis-Specific Y-Encoded-Like Protein 5 | TSPY-Like Protein 5 | TSPYL5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937995","UCHL5 Gene","C158568","This gene plays a role in deubiquitination, regulation of proteasome-mediated protein degradation and chromatin remodeling.","UCHL5 Gene | UCHL5 | Ubiquitin C-Terminal Hydrolase L5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937992","UCHL5 wt Allele","C158569","Human UCHL5 wild-type allele is located in the vicinity of 1q31.2 and is approximately 48 kb in length. This allele, which encodes ubiquitin carboxyl-terminal hydrolase isozyme L5 protein, is involved in proteasome-mediated protein degradation, chromatin remodeling and hydrolysis of polyubiquitin chains.","UCHL5 wt Allele | CGI-70 | INO80R | UCH-L5 | UCH37 | Ubiquitin C-Terminal Hydrolase L5 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1167687","Transmyocardial Revascularization","C158020","The use of a laser to create channels directly into the heart muscle to encourage vascularization and treat severe coronary artery disease in those individuals who are not considered good candidates for standard bypass surgery.","Transmyocardial Revascularization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937557","Transoral Incisionless Fundoplication","C158021","The use of an endoscope passed orally into the esophagus to repair or recreate a more functional barrier to esophageal reflux","Transoral Incisionless Fundoplication | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937556","Transthoracic Myocardial Laser Revascularization","C158023","The use of a laser to create channels directly into the heart muscle to encourage vascularization and treat severe coronary artery disease in those individuals considered good candidates for standard bypass surgery.","Transthoracic Myocardial Laser Revascularization | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556800","Tummy Tuck","C158024","A surgical procedure to remove excess skin and fat from the abdomen.","Tummy Tuck | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937554","Tumor Ablation Therapy","C158025","A minimally invasive surgical procedure to treat a solid cancer that uses a probe in conjunction with radiology guidance to burn a tumor.","Tumor Ablation Therapy | Tumor Ablation Therapies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937553","Valvotomy","C158027","A surgical procedure in which an incision is made in a valve to relieve stenosis.","Valvotomy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937552","Vascular Study","C158028","A test that checks the blood flow in arteries and veins.","Vascular Study | Vascular Studies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0042421","Vasectomy Reversal Procedure","C158029","A surgical procedure to reattach a previously cut vas deferens.","Vasectomy Reversal Procedure | Vasectomy Reversal",,,,,,,,,,,,,,,"4072179|4073019|4073029|4318648|4329023","Reversal of vasectomy|Surgical reanastomosis of vas deferens|Reestablishment of continuity of vas deferens|Vasovasorrhaphy|Reconstruction of surgically divided vas deferens",,,,,,,,,,,,,"--",,,,,,,,,"--|--|--|--|--"
"C0920472","Drug Discovery","C15802","No value exists.","Drug Discovery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938144","Vena Cava Filter Surgery","C158030","A surgical procedure to insert, repair or remove an inferior vena cava filter.","Vena Cava Filter Surgery | Vena Cava Filter",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937603","Cisplatin/Paclitaxel/Pembrolizumab Regimen","C158033","A regimen consisting of cisplatin, paclitaxel, and pembrolizumab that can be used in the treatment of cervical, head and neck, vaginal and metastatic squamous non-small cell lung cancer (NSCLC).","Cisplatin/Paclitaxel/Pembrolizumab Regimen | Cisplatin, Paclitaxel, Pembrolizumab | Cisplatin-Paclitaxel-Pembrolizumab | Cisplatin-Paclitaxel-Pembrolizumab Regimen | Cisplatin/Paclitaxel/Pembrolizumab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937600","CPTAC Causes of Death Codelist","C158034","Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on causes of death.","CPTAC Causes of Death Codelist | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937598","CPTAC Procedures Codelist","C158036","Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on medical procedures.","CPTAC Procedures Codelist | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562702","Autologous Anti-HLA-A*0201/AFP CAR T-cells ET1402L1","C155884","A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) derived from a human monoclonal antibody specific for an immunogenic human tumor-associated antigen (TAA) alpha-fetoprotein (AFP) epitope, AFP158-166, complexed with human leukocyte antigen (HLA)-A*02:01 (HLA-A*0201/AFP), fused to the co-stimulatory domains of CD28 and CD3zeta, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-HLA-A*0201/AFP CAR T-cells ET1402L1 specifically recognize and selectively bind to the AFP158-166 peptide presented by HLA-A*0201. Upon binding to the AFP-MHC complex, the T-cells release cytokines and induce selective toxicity in HLA-A*0201/AFP-positive tumor cells. AFP, an intracellularly expressed fetal glycoprotein rarely expressed in adult tissues, is overexpressed in certain tumors of endodermal origin and plays a key role in tumor cell proliferation and survival. AFP is processed into peptides and presented by class I major histocompatibility complexes (MHCs) on the surface of tumor cells.","Autologous Anti-HLA-A*0201/AFP CAR T-cells ET1402L1 | Autologous AFP-CAR T-cells | Autologous AFP-CAR-transduced T-cells ET1402L1 | Autologous ET1402L1-CAR T Cells | Autologous ET1402L1-CAR T-cells | Autologous T-cells Transduced with ET1402L1-CAR | ET1402L1-CAR T-cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562695","Tegavivint","C155885","A small molecule inhibitor of the Wnt/beta-catenin pathway with potential antineoplastic activity. Upon intravenous administration, tegavivint binds to transducin beta-like protein 1 (TBL1) and disrupts the binding of beta-catenin to TBL1. This promotes beta-catenin degradation, attenuates nuclear and cytoplasmic levels of beta-catenin, and reduces transcriptional activity of transcription factor 4 (TCF4) and expression of its target genes, cyclin D1, c-Myc and survivin. The Wnt/beta-catenin signaling pathway regulates cell morphology, motility, and proliferation; aberrant regulation of this pathway leads to neoplastic proliferation. Beta-catenin is frequently mutated in various tumors.","Tegavivint | 9,10-Anthracenedione, 2,7-bis(((3R,5S)-3,5-dimethyl-1-piperidinyl)sulfonyl)-, 9,10-dioxime, rel- | BC 2059 | BC-2059 | BC2059 | TEGAVIVINT | Tegatrabetan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562697","Gum Arabic Solution","C155887","A solution containing the polymer gum acacia (gum Arabic), exuded from various Acacia trees, especially from Acacia senegal (Leguminosae), with potential protective and anti-mucositis activities. Upon administration of the gum Arabic solution in the oral cavity, the polymer forms a protective barrier over the oral mucosa, which may prevent inflammation of the mucosal membranes and may decrease chemotherapy- and/or radiation-induced oral mucositis.","Gum Arabic Solution | Acacia Gum Solution | Acacia Resin Solution | Acacia Senegal Solution | Acacia Solution | Gum Acacia Solution",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562698","Autologous Anti-CD19 CAR T-cells IM19","C155888","A preparation of autologous T-lymphocytes that have been genetically modified and transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed co-stimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR T-cells IM19 target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.","Autologous Anti-CD19 CAR T-cells IM19 | Autologous Anti-CD19 CAR-T Cells IM19 | Autologous CD19-specific CAR-T Cells IM19 | IM19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937702","Folinic Acid/5-FU/Liposomal Irinotecan","C158077","A regimen consisting of folinic acid (leucovorin), 5-fluorouracil, and liposomal irinotecan that may be used in the treatment of ampullary and pancreatic adenocarcinoma, and biliary tract cancer.","Fluorouracil/Liposomal Irinotecan/Leucovorin Regimen | FULV and nanoliposomal Irinotecan | Fluorouracil/Folinic Acid/Nanoliposomal Irinotecan | Folinic Acid/5-FU/Liposomal Irinotecan | Folinic Acid/Fluorouracil/Liposomal Irinotecan | Folinic Acid/Fluorouracil/Onivyde | Leucovorin-Fluorouracil-Liposomal Irinotecan | Leucovorin-Fluorouracil-Liposomal Irinotecan Regimen | Leucovorin/Fluorouracil/Liposomal Irinotecan Regimen | Leucovorin/Fluorouracil/Onivyde",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937699","Nicotinamide Riboside","C158078","An orally available form of vitamin B3 and precursor of nicotinamide adenine dinucleotide (NAD+) with potential use in the treatment of chemotherapy induced peripheral neuropathy (CIPN). Upon oral administration, nicotinamide riboside (NR) is converted to nicotinamide mononucleotide by the NR kinases, nicotinamide riboside kinase 1 (NRK 1) and nicotinamide riboside kinase 2 (NRK 2), to which a second adenine is transferred by nicotinamide mononucleotide adenylyl transferase to generate NAD+. NAD+, an essential redox coenzyme, may offer protective effects against axonal injury from both mechanical and neurotoxic injury, and maintenance of NAD+ may be protective in mitochondrial disease. NR may help elevate and maintain NAD+ levels, which may ameliorate potential mechanisms implicated in the development of CIPN including mitochondrial dysfunction and peripheral nerve degeneration.","Nicotinamide Riboside | NICOTINAMIDE RIBOSIDE | NR | Niagen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937700","GTP Regimen","C158079","A regimen consisting of cisplatin, gemcitabine, and paclitaxel that may be used in the treatment of certain urothelial and non-small cell lung cancers.","GTP Regimen | Cisplatin-Gemcitabine-Paclitaxel | Cisplatin-Gemcitabine-Paclitaxel Regimen | Cisplatin/Gemcitabine/Paclitaxel | Cisplatin/Gemcitabine/Paclitaxel Regimen | GTP | Gemcitabine/Paclitaxel/Cisplatin | Gemzar-Taxol-Platinol | Gemzar/Taxol/Platinol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937698","Recurrent B-Cell Prolymphocytic Leukemia","C158081","The reemergence of a B-cell prolymphocytic leukemia after a period of remission.","Recurrent B-Cell Prolymphocytic Leukemia | Prolymphocytic leukemia of B-cell type, in relapse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937695","Super Enhancer Inhibitor GZ17-6.02","C158082","A synthetic formulation of the Arum palaestinum plant that has been fortified with the already naturally occurring constituents of isovanillin, linolenic acid, and beta-sitosterol, with potential antineoplastic activity. Upon oral administration, GZ17-6.02 may induce apoptosis through caspase-3 activation and poly(ADP-ribose) polymerase (PARP) cleavage, inhibit tumor cell progression by attenuating macrophage infiltration, and inhibit the phosphorylation of several mediators of tumor cell proliferation including Src kinase, extracellular signal-regulated kinases 1 (ERK1) and 2 (ERK2), epidermal growth factor receptor (EGFR), serine/threonine protein kinase AKT (protein kinase B), signal transducer and activator of transcription 2 (STAT-2), and serine/threonine-protein kinase Chk2 (Chk-2). GZ17-6.02 may also inhibit certain super enhancers (SEs) that play an important role in the regulation of the sonic hedgehog (SHH) pathway and cancer stem cell activity. Super enhancers (SEs) are unique areas of the genome that are densely bound by numerous transcription factors and play a pivotal role in the cell, including tissue specification, identity and maintenance. SEs are known to regulate the expression of associated genes and often drive high-level transcription.","Super Enhancer Inhibitor GZ17-6.02 | GZ17 6.02 | GZ17-6.02 | GZ176.02 | Synthetic Arum palaestinum derivative GZ17-6.02",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937768","Challenge Agent Metabolite Caused Injury Indicator","C158317","An indication as to whether a metabolite of the chemical challenge agent is known to cause or contribute to the injury or condition of interest.","Challenge Agent Metabolite Caused Injury Indicator | CHAMCIND | Chemical Ag Metabolite Causes Injury Ind | Chemical Agent Metabolite Causes Injury Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937769","Radiological/Nuclear Challenge Agent Source Type","C158318","The mode by which the radiological or nuclear challenge agent is delivered to the subject.","Radiological/Nuclear Challenge Agent Source Type | RNASRC | Rad/Nuc Agent Source",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556018","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Lift Less Than 5 Lbs","C155520","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Lifting something weighing less than 5 lbs (about 2 kg, like a houseplant).","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Lift Less Than 5 Lbs | FAC100-Sev: Lift Less Than 5 Lbs | FAC10039",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556019","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Lift Less Than 5 Lbs Why Not","C155521","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Lifting something weighing less than 5 lbs (about 2 kg, like a houseplant). Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Lift Less Than 5 Lbs Why Not | FAC100-Sev: Lift Less Than 5 Lbs Why Not | FAC10040",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556152","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Lifting 5-10 Lbs","C155522","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Lifting something weighing 5-10 lbs (about 2-4.5 kg, like a basket of clothes).","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Lifting 5-10 Lbs | FAC100-Sev: Lifting 5-10 Lbs | FAC10041",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556153","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Lifting 5-10 Lbs Why Not","C155523","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Lifting something weighing 5-10 lbs (about 2-4.5 kg, like a basket of clothes). Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Lifting 5-10 Lbs Why Not | FAC100-Sev: Lifting 5-10 Lbs Why Not | FAC10042",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556150","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Lift More Than 20 Lbs","C155524","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Lifting something weighing more than 20 lbs (about 9 kg, like a medium-sized suitcase).","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Lift More Than 20 Lbs | FAC100-Sev: Lift More Than 20 Lbs | FAC10043",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950662","Iodine I 124 Monoclonal Antibody M5A","C158629","A radioimmunoconjugate comprised of M5A, a humanized monoclonal antibody directed against carcinoembryonic antigen-related cell adhesion molecule 5 (CEA or CEACAM5), labeled with iodine I 124 (I-124) with potential radiolocalization applications. Upon administration, the antibody moiety of iodine I 124 monoclonal antibody M5A specifically binds to cells expressing CEA. Upon binding, the radioisotope moiety can be detected using positron-emission tomography (PET), thereby allowing the imaging and quantification of CEA-expressing tumor cells. CEA, a tumor associated antigen and a member of the CEA family of proteins, plays a key role in cell migration, cell invasion, and cell adhesion and is overexpressed by a variety of cancer types.","Iodine I 124 Monoclonal Antibody M5A | 124I-M5A | 124I-hT84.66-M5A | Iodine I 124 Anti-CEA Monoclonal Antibody M5A | Iodine I 124 Anti-CEA Monoclonal Antibody hT84.66-M5A | Iodine I 124 Monoclonal Antibody hT84.66-M5A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950613","Did a New Event Occur After Initial Treatment","C158633","A question whether a new event occurs after the initial treatment.","Did a New Event Occur After Initial Treatment | New Event After Initial Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518485","Nutrition, Dietary Components","C15824","Role of dietary components in cancer causation or prevention and in general health.","Nutrition, Dietary Components | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518488","Nutrition, Fats, Saturated","C15825","Role of saturated fats in cancer causation or prevention and in general health.","Nutrition, Fats, Saturated | Lipid Nutrition, Saturated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555983","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walk 50 Steps Why Not","C155485","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking 50 steps/paces on flat ground at a normal speed without stopping. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walk 50 Steps Why Not | FAC100-Sev: Walk 50 Steps Why Not | FAC10004",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555988","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walk Up 20 Stairs","C155486","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking up 20 stairs (2 flights) without stopping.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walk Up 20 Stairs | FAC100-Sev: Walk Up 20 Stairs | FAC10005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555989","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walk Up 20 Stairs Why Not","C155487","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking up 20 stairs (2 flights) without stopping. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walk Up 20 Stairs Why Not | FAC100-Sev: Walk Up 20 Stairs Why Not | FAC10006",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555986","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Preparing Meals","C155488","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Preparing meals.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Preparing Meals | FAC100-Sev: Preparing Meals | FAC10007",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555987","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Preparing Meals Why Not","C155489","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Preparing meals. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Preparing Meals Why Not | FAC100-Sev: Preparing Meals Why Not | FAC10008",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281184","Screening for Oral Cancer","C15548","No value exists.","Screening for Oral Cancer | early detection for oral cancer | oral cancer early detection | oral cancer screening",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555992","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Washing Dishes","C155490","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Washing dishes.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Washing Dishes | FAC100-Sev: Washing Dishes | FAC10009",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555993","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Washing Dishes Why Not","C155491","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Washing dishes. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Washing Dishes Why Not | FAC100-Sev: Washing Dishes Why Not | FAC10010",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937766","Radiological/Nuclear Agent Ionizing Radiation Type","C158319","The form of ionizing radiation that is emitted by the radiological/nuclear agent source.","Radiological/Nuclear Agent Ionizing Radiation Type | RNAIOTYP | Rad/Nuc Agent Ionizing Radiation Type | Specify the modality of radiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518906","Pathobiology of Wasting and Growth Retardation","C15831","Elucidate the pathogenic mechanisms of HIV-related opportunistic infections. Enhance a bidirectional flow between basic and clinical observations and intervention programs on HIV-related complications and foster interdisciplinary collaborations.","Pathobiology of Wasting and Growth Retardation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937767","Radiological/Nuclear Agent Irradiation Source Beam Strength","C158320","The energy of the irradiation beam produced by the source.","Radiological/Nuclear Agent Irradiation Source Beam Strength | RNAISBS | Rad/Nuc Agent Irrad Source Beam Strength | Rad/Nuc Agent Irradiation Source Beam Strength",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937764","Challenge Agent Type Mixed Field Indicator","C158321","An indication as to whether there is more than one type of ionizing radiation associated with the rad/nuc challenge.","Challenge Agent Type Mixed Field Indicator | RNAMFIND | Rad/Nuc Agent Mixed Field Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937765","Radioisotope Species Name","C158322","The literal identifier of the radioisotope, usually specified as the name of the chemical element followed by the mass number.","Radioisotope Species Name | RNARADSN | Rad/Nuc Agent Radioisotope Species Name",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0750862","Dental Examination","C158323","A systematic evaluation of the mouth, face, and neck, which may include tooth counting, cleaning and visual assessments for abnormalities such as caries, gum disease, oral cancer, and structural malformations.","Dental Examination | DENTAL EXAM | Dental Exam | Oral Examination",,,,,,,,,,,,,,,"4145111","Dental consultation and report",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937763","Animal Record Information","C158324","Information obtained from medical records, acquisition records, or other official documentation associated with the animal.","Animal Record Information | ANIMAL RECORDS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937920","Chemical Challenge Agent","C158326","A challenge agent comprising a non-radioactive chemical or elemental substance.","Chemical Challenge Agent | CHEMICAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937919","Radiological/Nuclear Challenge Agent","C158327","A challenge agent that emits ionizing radiation.","Radiological/Nuclear Challenge Agent | RADIOLOGICAL/NUCLEAR | Rad/Nuc | Rad/Nuc Challenge Agent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0345397","Supernumerary Rib","C158328","The presence of more than the usual or expected number of thoracic ribs.","Supernumerary Rib | SUPERNUMERARY RIB | Supernumerary Rib, Full",,,,,,,,,,,,,,,"4006445","Accessory rib",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0158779","Cervical Rib","C158329","Presence of rib formation in the cervical region.","Cervical Rib | CERVICAL RIB",,,,,,,,,,,,,,,"37159006|79144","Cervical rib|Cervical rib",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"C0920369","Patient Oriented Research","C15832","Studies of living individuals or groups of subjects (such as families, communities, or populations defined geographically or demographically), or material of human origin (such as tissues, specimens, and cognitive phenomena, etc.), for understanding of their physiologic and pathophysiologic characteristics, mechanisms of human diseases and development of approaches to diseases treatment and prevention. Includes the laboratory-based development of new forms of technology, studies of health-related professions, institutions, and systems, excludes disease-oriented studies of material, obtained from patients who were unknown to investigators.","Patient Oriented Research | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0685628","Lumbar Rib","C158330","Presence of rib formation in the lumbar region.","Lumbar Rib | Bone structure of thirteenth rib (body structure) | LUMBAR RIB",,,,,,,,,,,,,,,"37152603|4246662","Bone structure of thirteenth rib|Full supernumerary rib",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL937918","Increased Alveolar Macrophages","C158332","Increased number of macrophages in the terminal air spaces.","Increased Alveolar Macrophages | ALVEOLAR MACROPHAGES, INCREASED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937915","Increased Granules","C158333","Increased number and/or size of granules in the cytoplasm of cells.","Increased Granules | GRANULES, INCREASED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950616","Bladder Soft Tissue Neoplasm","C158636","A mesenchymal neoplasm that arises from the bladder.","Bladder Soft Tissue Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950618","Number of Days from Date of Initial Pathologic Diagnosis to Date of Tumor Reoccurrence After Initial Treatment","C158638","The number of days from date of the initial cancer diagnosis to the date of tumor reoccurrence after the initial treatment.","Number of Days from Date of Initial Pathologic Diagnosis to Date of Tumor Reoccurrence After Initial Treatment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950619","Number of Discontiguous Lesions (New Tumor Event)","C158639","The number of the discontiguous lesions in a new tumor event.","Number of Discontiguous Lesions (New Tumor Event) | discontiguous lesion count | discontiguous_lesion_count",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950621","Number of Other Lymph Nodes Examined","C158641","A request to specify the number of other lymph nodes that were examined that are not listed on the form.","Number of Other Lymph Nodes Examined | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950818","del(10q23)/PTEN Gene Locus Deletion","C158865","A cytogenetic abnormality that refers to the deletion of the chromosomal band 10q23, which also results in the deletion of the PTEN gene.","del(10q23)/PTEN Gene Locus Deletion | 10q23/PTEN Locus Deletion | Deletion identified | del10q23/Phosphatase and Tensin Homolog Gene Locus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950819","del(10q23)/PTEN Gene Locus Deletion Analysis","C158866","A procedure used to detect and identify deletion of the PTEN gene located in the vicinity of 10q23.","del(10q23)/PTEN Gene Locus Deletion Analysis | 10q23 (PTEN Locus) Deletion | del(10q23)/PTEN Gene Locus Deletion Status | del10q23/Phosphatase and Tensin Homolog Gene Locus Deletion Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950820","Source of Cells used for Analysis","C158867","A question about the source of the cells for analysis.","What is the Cell Source | Source of Cells used for Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0392673","Adaptation","C158868","The alteration or adjustment in structure or habits, often occurring through natural selection, by which a species becomes better able to function in its environment.","Adaptation | Adapt | Adapted | Adaption",,,,,,,,,,,,,,,"4195446","Adaptation",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL950821","del(10q23)/PTEN Gene Locus Deletion Analysis Method","C158869","A request to enter the specific molecular analysis method used to detect and identify deletion of the PTEN gene located in the vicinity of 10q23.","del(10q23)/PTEN Gene Locus Deletion Analysis Method | Chromosome 10q23 (PTEN Locus) Deletion Analysis Testing Method | del(10q23)/PTEN Gene Locus Deletion Analysis Testing Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938064","QSOX2 wt Allele","C158491","Human QSOX2 wild-type allele is located in the vicinity of 9q34.3 and is approximately 40 kb in length. This allele, which encodes sulfhydryl oxidase 2 protein, is involved in disulfide bond formation in secreted proteins.","QSOX2 wt Allele | DKFZp762A2013 | QSCN6L1 | Quiescin Q6-Like 1 Gene | Quiescin Sulfhydryl Oxidase 2 wt Allele | SOXN | Sulfhydryl Oxidase. Neuroblastoma-Derived Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938065","Sulfhydryl Oxidase 2","C158492","Sulfhydryl oxidase 2 (698 aa, ~78 kDa) is encoded by the human QSOX2 gene. This protein plays a role in the oxidation of sulfhydryl groups to disulfides in extracellular peptides and proteins.","Sulfhydryl Oxidase 2 | EC 1.8.3.2 | Neuroblastoma-Derived Sulfhydryl Oxidase | QSOX2 | Quiescin Q6 Sulfhydryl Oxidase 2 | Quiescin Q6-Like Protein 1 | Quiescin Sulfhydryl Oxidase 2 | Thiol Oxidase 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938062","Platinum-Resistant Lung Small Cell Carcinoma","C158493","Lung small cell carcinoma that is resistant to platinum therapy.","Platinum-Resistant Lung Small Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938063","Platinum-Sensitive Disease","C158494","A finding indicating that a cancer responds to platinum therapy initially, but it comes back after a certain period. For ovarian cancer, it refers to cancer relapse at least six months after the end of platinum therapy.","Platinum-Sensitive Disease | Platinum-Sensitive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938060","Platinum-Sensitive Lung Small Cell Carcinoma","C158495","Lung small cell carcinoma that is sensitive to platinum therapy.","Platinum-Sensitive Lung Small Cell Carcinoma | Platinum-Sensitive Small Cell Lung Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938061","RAB6B Gene","C158496","This gene is involved in the regulation of retrograde trafficking.","RAB6B Gene | RAB6B | RAB6B, Member RAS Oncogene Family Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938059","RAB6B wt Allele","C158497","Human RAB6B wild-type allele is located in the vicinity of 3q22.1 and is approximately 72 kb in length. This allele, which encodes Ras-related protein Rab-6B, plays a role in GTPase activity that modulates intracellular transport pathways.","RAB6B wt Allele | RAB6B, Member RAS Oncogene Family wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL446671","tomographic optical breast imaging","C158498","Diffuse optical breast imaging that utilizes near-infrared (NIR) light propagation through breast tissues to assess the optical properties of tissue for the identification of abnormalities.","Tomographic Optical Breast Imaging | TOBI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938058","Ras-Related Protein Rab-6B","C158499","Ras-related protein Rab-6B (208 aa, ~23 kDa) is encoded by the human RAB6B gene. This protein is involved in the regulation of retrograde transport.","Ras-Related Protein Rab-6B | RAB6B | Ras-Associated Protein Rab6B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514710","High-LET Radiotherapy","C15849","Radiotherapy using radioactive particles that deposit a high amount of energy by radiation per unit length of travel.","High-LET Radiotherapy | Radiotherapy, High Linear Energy Transfer | Radiotherapy-High LET | high-dose radiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282221","Loperamide Hydrochloride","C1584","The hydrochloride salt form of loperamide, a synthetic, piperidine derivative and opioid agonist with antidiarrheal activity. Loperamide acts on the mu-receptors in the intestinal mucosa. This leads to a decrease in gastrointestinal motility by decreasing the circular and longitudinal smooth muscle activity of the intestinal wall. This slows intestinal transit and allows for more water and electrolyte absorption from the intestines. Loperamide is not significantly absorbed from the gut and does not cross the blood-brain barrier. Therefore it has no central nervous system effects.","Loperamide Hydrochloride | Imodium | Imodium A-D | LOPERAMIDE HYDROCHLORIDE | loperamide hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555991","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Sweeping/Mopping Why Not","C155493","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Sweeping or mopping. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Sweeping/Mopping Why Not | FAC100-Sev: Sweeping/Mopping Why Not | FAC10012",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555996","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Making a Bed","C155494","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Making a bed.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Making a Bed | FAC100-Sev: Making a Bed | FAC10013",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555997","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Making a Bed Why Not","C155495","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Making a bed. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Making a Bed Why Not | FAC100-Sev: Making a Bed Why Not | FAC10014",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562840","Ovarian Ablation Patient","C156118","A patient who had or will have an ovarian ablation.","Ovarian Ablation Patient | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562842","Frontal Lobe Anaplastic Oligodendroglioma","C156120","An anaplastic oligodendroglioma occurring in the frontal lobe.","Frontal Lobe Anaplastic Oligodendroglioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1566649","RFC4 protein, human","C158527","Replication factor C subunit 4 (363 aa, ~40 kDa) is encoded by the human RFC4 gene. This protein is involved in the elongation of a primed DNA template.","Replication Factor C Subunit 4 | A1 37 kDa Subunit | Activator 1 37 kDa Subunit | Activator 1 Subunit 4 | RF-C 37 kDa Subunit | RFC 37 kDa Subunit | RFC37 | RFC4 | Replication Factor C 37 kDa Subunit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937972","RTN4RL1 Gene","C158528","This gene plays a role in axon migration during brain development and axon regeneration.","RTN4RL1 Gene | RTN4RL1 | Reticulon 4 Receptor Like 1 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937969","RTN4RL1 wt Allele","C158529","Human RTN4RL1 wild-type allele is located in the vicinity of 17p13.3 and is approximately 91 kb in length. This allele, which encodes reticulon-4 receptor-like 1 protein, is involved in the development of neurons.","RTN4RL1 wt Allele | DKFZp547J144 | NGRH2 | NGRL2 | NgR3 | Reticulon 4 Receptor Like 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1258610","RTN4RL1 protein, human","C158530","Reticulon-4 receptor-like 1 (441 aa, ~49 kDa) is encoded by the human RTN4RL1 gene. This protein plays a role in axon migration and regeneration.","Reticulon-4 Receptor-Like 1 | NgR3 | Nogo Receptor-Like 2 | Nogo-66 Receptor Homolog 2 | Nogo-66 Receptor-Related Protein 3 | RTN4RL1 | Reticulon 4 Receptor Like 1 | Reticulon 4 Receptor-Like 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0398689","Immunodeficiency with Hyper-IgM, X-Linked, Type 1","C158531","An X-linked subtype of hyper-IgM caused by mutation(s) in the CD40LG gene, encoding CD40 ligand. It is characterized by normal or elevated IgM concentrations, with markedly decreased concentrations of other immunoglobulins. The clinical course is variable; it manifests as susceptibility to bacterial and opportunistic infections, neutropenia, and increased risk of lymphoma.","Immunodeficiency with Hyper-IgM, X-Linked, Type 1 | HIGM1 | Hyper-IgM Syndrome 1 | X-Linked Hyper-IgM Syndrome",,,,,,,,,,,,,,,"4300463","X-linked hyper-IgM syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937968","PD-L1 Inhibitor INCB086550","C158532","An orally available, small molecule inhibitor of the immunosuppressive ligand, programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, PD-L1 inhibitor INCB086550 specifically targets PD-L1 expressed on tumor cells preventing the binding and subsequent activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1, a transmembrane protein expressed on activated T-cells, is overexpressed in some cancer types and plays a significant role in immune evasion by tumor cells.","PD-L1 Inhibitor INCB086550 | INCB 086550 | INCB 86550 | INCB-086550 | INCB-86550 | INCB086550 | INCB86550 | PD-1 Ligand 1 Inhibitor INCB086550",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937966","PRGN 3005","C158533","A preparation of autologous T-lymphocytes that have been genetically modified to co-express three transgenes using the Sleeping Beauty (SB) transposon system and include a chimeric antigen receptor (CAR) targeting the unshed portion of the tumor-associated antigen (TAA) human mucin 16 (MUC16, cancer antigen 125; CA125; FLJ14303), a membrane-bound IL-15 (mbIL15) and a safety/kill switch, with potential immunostimulating and antineoplastic activities. Upon introduction of the autologous anti-MUC16 CAR-mbIL15-safety switch T-cells PRGN-3005 into the patient, the T-cells target and bind to MUC16-expressing tumor cells, thereby inducing selective toxicity in MUC16-expressing tumor cells. MUC16, a member of the mucin family of glycoproteins, is overexpressed on a variety of cancer cell types. IL-15 is a pro-survival cytokine that is required for the maintenance of long-lived CD8+ memory T-cells and use of mbIL15 preserves T stem-cell memory (TSCM) through sustained IL-15 signaling, improves T-cell persistence and potentiates the immune response against tumor cells. The safety switch can promote selective elimination of the CAR-T cells. The SB system permits integration of the CAR, the IL-15 fusion variant and safety switch transgenes into T-cells without the need for viral vectors and accelerates the manufacturing process.","Autologous Anti-MUC16 CAR-mbIL15-Safety Switch T-cells PRGN-3005 | Autologous Anti-MUC16 CAR-T Cells PRGN-3005 | Autologous CAR-T Cells PRGN 3005 | Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3005 | Autologous PRGN-3005 UltraCAR-T Cells | PRGN 3005 | PRGN-3005 | PRGN-3005 UltraCAR-T Cells | PRGN3005",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937967","RUNDC1 Gene","C158534","This gene may be involved in the regulation of cellular tumor antigen p53 activity.","RUNDC1 Gene | RUN Domain Containing 1 Gene | RUNDC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937964","RUNDC1 wt Allele","C158535","Human RUNDC1 wild-type allele is located in the vicinity of 17q21.31 and is approximately 13 kb in length. This allele, which encodes RUN domain-containing protein 1, may play a role in the negative regulation of cellular tumor antigen p53 activity. Aberrant expression of the gene may be associated with increased susceptibility for glioma.","RUNDC1 wt Allele | DKFZp761H0421 | LP5161 | RUN Domain Containing 1 wt Allele | RUND1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937965","RUN Domain-Containing Protein 1","C158536","RUN domain-containing protein 1 (613 aa, ~68 kDa) is encoded by the human RUNDC1 gene. This protein is involved in the inhibition of cellular tumor antigen p53 activity.","RUN Domain-Containing Protein 1 | RUNDC1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950822","EGFR Amplification Analysis Testing Method","C158870","A request to enter the specific molecular analysis method used to detect and identify amplification of the EGFR gene.","EGFR Amplification Analysis Testing Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950824","EGFR Mutation Analysis","C158872","A procedure used to detect and identify mutations in the EGFR gene.","EGFR Mutation Analysis | EGFR Gene Mutation Analysis | EGFR Mutation Status | Epidermal Growth Factor Receptor Mutation Analysis | HER1 Mutation Analysis | c-erbB1 Mutation Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950825","EGFR Mutation Analysis Testing Method","C158873","A request to enter the specific molecular analysis method used to detect and identify mutations in the EGFR gene.","EGFR Mutation Analysis Testing Method | EGFR Mutational Analysis Testing Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950828","Event During Procedure","C158878","A question about whether there was a notable event during the procedure.","Event During Procedure | Other notable events during the procedure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950829","Percent Blasts in Peripheral Blood at Diagnosis","C158879","A finding of the percentage of blasts in the peripheral blood at the time of diagnosis.","Percent Blasts in Peripheral Blood at Diagnosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519396","Social and Contextual Areas","C15887","Subcategory of Mind-Body Medicine in CAM classification.  This area deals with social, cultural, symbolic and contextual interventions not covered in other areas.  For example, the study cross-cultural explanatory models, placebo or 'meaning response' research, and caring-based approaches to health care fall into this category.  Included are: Placebo, Explanatory models, Caring-based approaches, Community- based approaches, Intuitive diagnosis.","Social and Contextual Areas | Social and Contextual Areas of Mind Body Medicine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950830","Classified by World Health Organization Only","C158880","A response that the bone marrow was classified by the World Health Organization (WHO) only.","Classified by World Health Organization Only | Classified by WHO only",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950832","Epstein-Barr Virus Analysis Method","C158882","A request to enter the specific molecular analysis method used to detect Epstein-Barr Virus.","Epstein-Barr Virus Analysis Method | Epstein-Barr virus (Epstein-Barr virus encoded RNA [EBER], other)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0403825","Globozoospermia","C158500","A rare but severe cause of male infertility. It is characterized by the presence of 100% round headed spermatozoa and lack of acrosomes.","Globozoospermia | ",,,,,,,,,,,,,,,"4032604","Globozoospermia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL950778","Dense Eosinophilic Basement Membrane Deposit","C158688","Accumulation of dense eosinophilic deposits in the basement membrane.","Dense Eosinophilic Basement Membrane Deposit | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519895","Vaccine Related Development, AIDS","C15868","No value exists.","Vaccine Related Development, AIDS | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950784","Neoantigen-based Renal Cell Carcinoma-Poly-ICLC Vaccine","C158694","A peptide-based renal cell carcinoma (RCC) vaccine consisting of neoantigens and peptides derived from immunogenic epitopes identified through DNA and RNA sequencing of a patient's tumor cells, combined with the immunostimulant poly-ICLC with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-based RCC vaccine stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, leading to tumor cell lysis. The adjuvant poly-ICLC, composed of double-stranded RNA molecules of polyinosinic-polycytidylic acid stabilized with poly L-lysine in carboxymethylcellulose, is a ligand for toll-like receptor-3 (TLR3) and induces the release of cytokines which may help to boost the immune response against the selected neoantigens.","Neoantigen-based Renal Cell Carcinoma-Poly-ICLC Vaccine | NeoVax RCC Vaccine | NeoVax Renal Cell Carcinoma Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951701","One Hundred Percent","C158695","All, one hundred percent.","One Hundred Percent | 1 | 100%",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950729","Per 50 High Powered Fields","C158698","A unit of measurement of the number of entities per unit of area equal to fifty high powered fields.","Per 50 High Powered Fields | /50 HPF | Per 50HPF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519896","Vaccine Related Development, Cancer","C15869","No value exists.","Vaccine Related Development, Cancer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562843","TP53 Mutation Carrier","C156121","An individual who carries an inheritable mutation in the TP53 gene, without manifestation of any associated condition.","TP53 Mutation Carrier | P53 Gene Mutation Carrier | Tumor Protein p53 Gene Mutation Carrier | p53 Mutation Carrier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562836","Thyroid Gland Follicular Carcinoma, Encapsulated Angioinvasive","C156122","An encapsulated follicular carcinoma of the thyroid gland which shows angioinvasion.","Thyroid Gland Follicular Carcinoma, Encapsulated Angioinvasive | FTC, Encapsulated Angioinvasive | Follicular thyroid carcinoma (FTC), encapsulated angioinvasive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562837","Thyroid Gland Follicular Carcinoma, Widely Invasive","C156123","A follicular carcinoma of the thyroid gland with extension into surrounding thyroid or extrathyroid tissues.","Thyroid Gland Follicular Carcinoma, Widely Invasive | FTC, Widely Invasive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937962","SERF1A Gene","C158537","This gene may play a role in the development of the spine.","SERF1A Gene | SERF1A | Small EDRK-Rich Factor 1A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937963","SERF1B Gene","C158538","This gene may play a role in nervous system development.","SERF1B Gene | SERF1B | Small EDRK-Rich Factor 1B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950709","Oncolytic Adenovirus CAdVEC","C158743","A genetically modified oncolytic viral strain of human adenovirus (Ad) with potential immunostimulating and antineoplastic activities. Upon intratumoral administration, the oncolytic adenovirus CAdVEC selectively infects and replicates in tumor cells, leading to tumor cell lysis. Additionally, CAdVEC has been genetically modified to express currently undisclosed immunomodulatory molecules that may enhance the anti-tumor effects of endogenous T-lymphocytes as well as adoptively transferred chimeric antigen receptor (CAR) T-cells.","Oncolytic Adenovirus CAdVEC | CAd-VEC | CAdVEC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950710","Autologous HER2-CAR-modified Adenovirus-specific Cytotoxic T-lymphocytes","C158744","A population of autologous cytotoxic T-lymphocytes (CTLs) specifically reactive to human adenovirus (Ad) that have been transduced with a retroviral vector expressing a second-generation human epidermal growth factor receptor type 2 (HER2; EGFR2; ErbB2)-specific chimeric antigen receptor (CAR) comprised of an exodomain based on a anti-CD22 single chain variable fragment (scFv) from the anti-HER2 monoclonal antibody FRP5 that is linked to the costimulatory domains of CD28 and the zeta chain of the TCR/CD3 complex (CD3zeta), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, the autologous HER2-CAR-modified Ad-specific CTLs are directed to and induce selective toxicity in HER2-expressing tumor cells. Additionally, these cells may help reconstitute Ad-specific CTL responses in immunocompromised individuals and others at risk of developing Ad-infection. HER2, a receptor tyrosine kinase (RTK) overexpressed by a variety of tumor cell types, belongs to the EGFR superfamily and plays a key role in tumor cell proliferation.","Autologous HER2-CAR-modified Adenovirus-specific Cytotoxic T-lymphocytes | HER2-AdVST | HER2-CAR-modified Ad-specific CTLs | HER2-CAR-modified Adenovirus-specific CTLs | HER2-CAR-modified Autologous AdVSTs | HER2.CAR.AdVST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950711","Oral Myoma Vaccine V3-myoma","C158745","An orally available therapeutic myoma vaccine containing pooled antigens derived from hydrolyzed, inactivated blood and tumor tissue samples from patients with uterine myoma, with potential antineoplastic and immunomodulatory activities. Upon oral administration, V3-myoma may stimulate the immune system to mount a cytotoxic T-lymphocyte-mediated response against cells expressing myoma-associated antigens. This may reduce the myoma growth and improve myoma-related symptoms.","Oral Myoma Vaccine V3-myoma | V3 Myoma | V3 Myoma Vaccine | V3-myoma | V3-myoma Vaccine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950712","Anti-HER3 Antibody ISU104","C158746","A fully human antibody directed against the receptor tyrosine-protein kinase erbB-3 (ErbB3; HER3) with potential antineoplastic activity. Upon intravenous administration, barecetamab targets and binds to domain 3 and weakly interacts with domain 1 of ErbB3. This prevents heregulin (HRG) binding and blocks dimerization of ErbB3, thereby inactivating ErbB3 downstream signaling. ISU104 may also elicit the internalization of ErbB3 from the plasma membrane and downregulate ErbB3 expression. This inhibits cellular proliferation and survival of ErbB3-expressing tumor cells. ErbB3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in a variety of tumors and its overexpression generally correlates with poor prognosis and tumor resistance.","Barecetamab | Anti-ErbB3 Antibody ISU104 | Anti-HER3 Antibody ISU104 | BARECETAMAB | ISU 104 | ISU-104 | ISU104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950713","TLR Agonist BSG-001","C158747","A toll-like receptor (TLR) agonist with potential immunomodulating and antineoplastic activities. Upon inhalation, TLR agonist BSG-001 activates one or more not yet disclosed TLRs, which may result in macrophage and plasmacytoid dendritic cell (pDC) stimulation, secretion of interferon alpha (IFNa), production of proinflammatory cytokines, upregulation of co-stimulatory molecules, enhanced T- and B-cell stimulatory responses, T-cell proliferation and a T-helper 1 (Th1) immune response. TLRs are transmembrane receptors that recognize structurally conserved microbial molecules such as bacterial cell-surface lipopolysaccharides (LPS), lipoproteins, lipopeptides, lipoarabinomannan and flagellin, among others. Immune responses stimulated by TLR activation may result in immune-mediated tumor cell killing.","TLR Agonist BSG-001 | BSG 001 | BSG-001 | BSG001 | Syngenon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518448","Nucleic Acid Resources","C15819","No value exists.","Nucleic Acid Resources | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282070","Benzydamine Hydrochloride","C1581","An indazole non-steroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic, and anti-edema properties.  Unlike other NSAIDs, benzydamine hydrochloride does not inhibit cyclooxygenases (COX) but stabilizes membranes, resulting in local anesthesia; inhibits the production of pro-inflammatory cytokines; inhibits the generation of reactive oxygen species by neutrophils; inhibits leukocyte aggregation and adhesion; and exhibits antimicrobial properties. (NCI04)","Benzydamine Hydrochloride | BENZYDAMINE HYDROCHLORIDE | Difflam | Tantum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937874","KDM7A-DT wt Allele","C158444","Human KDM7A-DT wild-type allele is located in the vicinity of 7q34 and is approximately 5 kb in length. This allele, which encodes KDM7A divergent transcript long noncoding RNA, has no known function.","KDM7A-DT wt Allele | AI283268 | FLJ22719 | JHDM1D Antisense RNA 1 (Head To Head) Gene | JHDM1D Antisense RNA 1 Gene | JHDM1D-AS1 | KDM7A Divergent Transcript wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937599","CPTAC Treatments Codelist","C158037","Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on medical treatments.","CPTAC Treatments Codelist | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512071","Drug Discovery Groups","C15803","Self-identified projects in the Biochemistry and Pharmacology Cancer Activity.","Drug Discovery Groups | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937593","Lutetium Lu 177 DOTA-N3-CTT1403","C158044","A radioconjucate consisting of CTT1403, a phosphoramidate-based irreversible inhibitor of human prostate-specific membrane antigen with an albumin binding moiety, connected via click chemistry to lutetium Lu 177-dodecanetetraacetic acid-azide (177Lu-DOTA-N3), with potential antineoplastic activity. Upon administration, lutetium Lu 177-DOTA-N3-CTT1403 targets and binds to PSMA expressed on tumor cells via its CTT1403 moiety, and upon internalization, delivers cytotoxic beta radiation directly to PSMA-expressing tumor cells. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on most prostate tumor cells. The albumin binding motif extends circulation half-life thereby improving tumor cell uptake of the radioconjugate.","Lutetium Lu 177 DOTA-N3-CTT1403 | 177Lu-DOTA-N3-CTT1403 | 177Lu-DOTA-azide-CTT1403 | Lutetium Lu 177 DOTA-azide-CTT1403",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937590","NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor","C158045","A finding indicating the presence of a NF1 mutation in a sample from a patient with malignant peripheral nerve sheath tumor.","NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor | MPNST with NF1 Mutation | MPNST with Neurofibromin 1 Mutation | Malignant Peripheral Nerve Sheath Tumor with NF1 Mutation | Malignant Peripheral Nerve Sheath Tumor with Neurofibromin 1 Mutation | NF1 mutant MPNST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556294","KIT NM_000222.2:c.1958T>C","C155685","A nucleotide substitution at position 1958 of the coding sequence of the KIT gene where thymine has been mutated to cytosine.","KIT NM_000222.2:c.1958T>C | CD117 c.1958T>C | KIT Proto-Oncogene Tyrosine Protein Kinase c.1958T>C | KIT c.1958T>C | NM_000222.2:c.1958T>C | c-KIT c.1958T>C | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.1958T>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556292","KIT NM_000222.2:c.1961T>C","C155687","A nucleotide substitution at position 1961 of the coding sequence of the KIT gene where thymine has been mutated to cytosine.","KIT NM_000222.2:c.1961T>C | CD117 c.1961T>C | KIT Proto-Oncogene Tyrosine Protein Kinase c.1961T>C | KIT c.1961T>C | NM_000222.2:c.1961T>C | c-KIT c.1961T>C | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.1961T>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562779","Mps1 Inhibitor BOS172722","C155895","An orally bioavailable, selective inhibitor of the serine/threonine-protein kinase monopolar spindle 1 (Mps1; TTK), with potential antineoplastic activity. Upon administration, the Mps1 inhibitor BOS172722 binds to and inhibits the activity of Mps1, a core component of the spindle assembly checkpoint (SAC). Inhibition of Mps1 activity compromises spindle assembly checkpoint, increases chromosome missegregation errors and decreases cancer cell viability. Mps1, a dual-specificity protein kinase expressed in proliferating normal tissues and aberrantly overexpressed in certain tumor types, is activated during mitosis and is essential in proper SAC function and chromosomal alignment.","Mps1 Inhibitor BOS172722 | BOS 172722 | BOS-172722 | BOS172722 | Monopolar Spindle 1 Inhibitor BOS172722 | TTK Inhibitor BOS172722",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562780","Autologous Anti-CD19CAR-HER2t/CD22CAR-EGFRt-expressing T-cells","C155897","A preparation of autologous human T-lymphocytes engineered to express dual chimeric antigen receptors (CARs) consisting of both anti-CD19 and anti-CD22 binding domains, fused to an as of yet undisclosed co-stimulatory domain, and linked to truncated forms of the human epidermal growth factor receptor 2 (HER2t) and the human epidermal growth factor receptor (EGFRt), respectively with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-CD19CAR-HER2t/CD22CAR-EGFRt-expressing T-cells bind to CD19 and CD22 on the surface of, and induce selective toxicity against tumor cells expressing CD19 and CD22. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt and HER2t facilitate both in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through an antibody-dependent cellular cytotoxicity (ADCC) response. CD19 and CD22, both transmembrane phosphoglycoproteins expressed on the surface of cells in the B lineage, are often overexpressed on malignant B-cells.","Autologous Anti-CD19CAR-HER2t/CD22CAR-EGFRt-expressing T-cells | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950715","Personalized Neoepitope Yeast Vaccine YE-NEO-001","C158749","A cancer vaccine composed of a heat-killed yeast that has been genetically modified to express patient-specific neoantigen epitopes. Upon vaccination, neoepitope yeast vaccine YE-NEO-001 may elicit a targeted CD4+ and CD8+ T-lymphocyte-mediated immune response against tumor cells expressing these specific epitopes.","Personalized Neoepitope Yeast Vaccine YE-NEO-001 | YE-NEO-001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519942","Validation of Clinical Utility of Markers","C15874","No value exists.","Validation of Clinical Utility of Markers | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950716","ONM 100","C158750","A micellar polymer tracer labeled with the near-infrared (NIR) fluorescent imaging dye indocyanine green (ICG), with potential fluorescent imaging activity. Upon administration, pegsitacianine accumulates in tumor tissue. The micelles dissociate and subsequently fluoresce upon exposure to the acidic conditions of the tumor microenvironment (TME), allowing the visualization of tumors using infrared-based cameras.","Pegsitacianine | Indocyanine Green-labeled Polymeric Micelles ONM-100 | ONM 100 | ONM-100 | ONM100 | PEGSITACIANINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937696","Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide (SY)","C158083","A preparation of ethylcellulose polymeric nanoparticles loaded with cetuximab, a recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR), and decorated with the somatostatin analog, octreotide, with potential antineoplastic activity. Upon oral administration, the octreotide moiety directs the nanoparticles, which remain inert until a pH of 6.8 is reached, to somatostatin receptors (SSTRs), which are present on the cell membranes of many neuroendocrine tumor (NET) cells. At this pH, cetuximab is selectively released from the ethylcellulose polymer. Cetuximab may then bind to the extracellular domain of EGFR-expressing tumor cells, thereby preventing the activation and subsequent dimerization of the receptor. This may inhibit signal transduction and inhibit tumor cell proliferation in EGFR-dependent tumor cells. EGFR, a member of the EGFR receptor tyrosine kinase family, may be overexpressed on the cell surfaces of various tumor types.","Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide | Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide (SY) | Cetuximab-loaded Polymeric Nanoparticles Decorated With Octreotide | Polymeric Nanoparticles Loaded With Cetuximab and Decorated With Octreotide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937693","Umbilical Cord Blood-derived CD4+/CD25+ T-regulatory Cells CK0801","C158084","A preparation composed of allogeneic umbilical cord blood (UCB)-derived, ex vivo expanded and enhanced CD4+/CD25+ T-regulatory cells (Tregs) with potential immunomodulatory activity. Upon administration, the UCB-derived CD4+/CD25+ Tregs CK0801 may promote immunologic homeostasis and prevent autoimmunity by suppressing self-reactive T-cells. This may induce tolerance to allogeneic organ transplants, prevent graft-versus-host disease (GvHD), and suppress autoimmune pathology.","Umbilical Cord Blood-derived CD4+/CD25+ T-regulatory Cells CK0801 | CK 0801 | CK-0801 | CK-0802 | CK0801 | UCB-derived CD4+CD25+ Tregs CK0801",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937694","Anti-EGFR/Anti-c-Met Bispecific Antibody EMB-01","C158085","A human, Fabs-in-tandem immunoglobulin (FIT-Ig)-based, tetravalent, bispecific antibody targeting both the epidermal growth factor receptor EGFR and the hepatocyte growth factor receptor (HGFR;; cMet; c-Met), with potential antineoplastic activity. Upon administration, bafisontamab simultaneously targets and binds to wild-type or certain mutant forms of both EGFR and c-Met expressed on cancer cells, thereby preventing receptor phosphorylation. This prevents the activation of both EGFR- and c-Met-mediated signaling pathways and results in the inhibition of tumor cell proliferation. EGFR and c-Met, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation. In bafisontamab, the two antigen-binding fragments (Fabs) are fused directly in a crisscross orientation resulting in four active and independent antigen binding sites.","Bafisontamab | Anti-EGFR/Anti-c-Met Bispecific Antibody EMB-01 | Anti-EGFR/c-Met Bispecific Antibody EMB-01 | Anti-cMET/EGFR Bispecific Antibody EMB-01 | BAFISONTAMAB | Bispecific Antibody EMB-01 | EMB 01 | EMB-01 | EMB01 | FIT-013a",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937691","Pimodivir","C158086","An orally bioavailable non-nucleoside inhibitor of the polymerase basic protein 2 (PB2) subunit of the influenza A virus polymerase complex with potential antiviral activity. Upon administration, pimodivir occupies the 7-methyl GTP (m7GTP) binding site of PB2, thereby blocking the cap-snatching activity of the influenza polymerase complex and inhibiting the synthesis of viral mRNA. PB2 is one of three subunits that make up the influenza A viral polymerase complex, which is responsible for replication and transcription of the viral RNA (vRNA) genome in the nuclei of infected cells.","Pimodivir | JNJ 63623872 | JNJ-63623872 | JNJ63623872 | PIMODIVIR | VX  787 | VX 787 | VX-787 | VX787",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937871","KDM7A Divergent Transcript","C158445","KDM7A divergent transcript (~2 kb) is encoded by the human KDM7A-DT gene. The function of this long noncoding RNA is unknown.","KDM7A Divergent Transcript | JHDM1D Antisense RNA 1 | KDM7A-DT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937872","DHX58 Gene","C158446","This gene is involved in modulation of antiviral response signaling.","DHX58 Gene | DExH-Box Helicase 58 Gene | DHX58",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937869","DHX58 wt Allele","C158447","Human DHX58 wild-type allele is located in the vicinity of 17q21.2 and is approximately 11 kb in length. This allele, which encodes probable ATP-dependent RNA helicase DHX58 protein, plays a role in the regulation of antiviral signaling.","DHX58 wt Allele | D11LGP2 | D11lgp2e | DEXH (Asp-Glu-X-His) Box Polypeptide 58 Gene | DExH-Box Helicase 58 wt Allele | LGP2 | LGP2, Mouse, Homolog of Gene | Ortholog of Mouse D11lgp2 Gene | RLR-3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937870","DHX58 protein, human","C158448","Probable ATP-dependent RNA helicase DHX58 (678 aa, ~77 kDa) is encoded by the human DHX58 gene. This protein is involved in RNA binding and antiviral responses.","ATP-Dependent RNA Helicase DHX58 | DEXH Box Polypeptide 58 | DHX58 | EC 3.6.4.13 | Probable ATP-Dependent Helicase LGP2 | Probable ATP-Dependent RNA Helicase DHX58 | Probable ATP-Dependent RNA Helicase DHX58 | Protein D11Lgp2 Homolog | RIG-I-Like Receptor 3 | RIG-I-Like Receptor LGP2 | RLR | RLR-3 | RNA Helicase LGP2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937867","LIN9 Gene","C158449","This gene plays a role in the cell cycle G1/S transition.","LIN9 Gene | LIN9 | Lin-9 DREAM MuvB Core Complex Component Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514532","Protein/Amino Acid Nutrition, Animal","C15844","Study of dietary animal protein/amino acids in relation to cancer.","Protein/Amino Acid Nutrition, Animal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937868","LIN9 wt Allele","C158450","Human LIN9 wild-type allele is located in the vicinity of 1q42.12 and is approximately 79 kb in length. This allele, which encodes protein lin-9 homolog, is involved in tumor suppression and cell cycle regulation.","LIN9 wt Allele | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937865","Protein Lin-9 Homolog","C158451","Protein lin-9 homolog (542 aa, ~62 kDa) is encoded by the human LIN9 gene. This protein plays a role in the G1/S transition of the cell cycle.","Protein Lin-9 Homolog | Beta Subunit-Associated Regulator of Apoptosis | HuLin-9 | LIN9 | Rb Related Pathway Actor | TUDOR Gene Similar Protein | Type I Interferon Receptor Beta Chain-Associated Protein | hLin-9 | pRB-Associated Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937866","MIR210HG Gene","C158452","The function of this gene is unknown.","MIR210HG Gene | MIR210 Host Gene | MIR210HG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938042","MIR210 Host Gene Long Noncoding RNA","C158454","MIR210 host gene long noncoding RNA (~2 kb) is encoded by the human MIR210HG gene. The function of this long noncoding RNA is unknown.","MIR210 Host Gene Long Noncoding RNA | MIR210 Host Gene Long Non-Coding RNA | MIR210 Host Gene, Long Non-Coding RNA | MIR210HG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938039","MS4A7 Gene","C158455","This gene may play a role in receptor-mediated signaling.","MS4A7 Gene | MS4A7 | Membrane Spanning 4-Domains A7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938040","MS4A7 wt Allele","C158456","Human MS4A7 wild-type allele is located in the vicinity of 11q12 and is approximately 17 kb in length. This allele, which encodes membrane-spanning 4-domains subfamily A member 7 protein, may be involved in the formation and function of a multimeric receptor complex.","MS4A7 wt Allele | 4SPAN2 | CD20L4 | MS4A8 | Membrane Spanning 4-Domains A7 wt Allele | Membrane-Spanning 4-Domains, Subfamily A, Member 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938037","Membrane-Spanning 4-Domains Subfamily A Member 7","C158457","Membrane-spanning 4-domains subfamily A member 7 (240 aa, ~26 kDa) is encoded by the human MS4A7 gene. This protein may play a role in signal transduction as part of a multimeric receptor complex.","Membrane-Spanning 4-Domains Subfamily A Member 7 | CD20 Antigen-Like 4 | CD20/FCER1B Family Member 4 | CD20/Fc-Epsilon-RI-Beta Family Member 4 | Four-Span Transmembrane Protein 2 | MS4A7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938038","MSANTD3 Gene","C158458","This gene may be involved in protein complex formation or DNA binding.","MSANTD3 Gene | MSANTD3 | Myb/SANT DNA Binding Domain Containing 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938035","MSANTD3 wt Allele","C158459","Human MSANTD3 wild-type allele is located in the vicinity of 9q31.1 and is approximately 25 kb in length. This allele, which encodes Myb/SANT-like DNA-binding domain-containing protein 3, may play a role in protein complex formation and DNA binding.","MSANTD3 wt Allele | C9orf30 | Chromosome 9 Open Reading Frame 30 Gene | L8 | MGC17337 | Myb/SANT DNA Binding Domain Containing 3 wt Allele | Myb/SANT-Like DNA-Binding Domain Containing 3 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937591","Kidney Mixed Epithelial and Stromal Tumor Family","C158046","A family of tumors ranging from predominantly cystic tumors (adult cystic nephromas) to tumors that are variably solid (mixed epithelial and stromal tumors) and contain biphasic epithelial and stromal components with spindle stroma, glands, and cysts. Most of these tumors are benign. (WHO 2016).","Kidney Mixed Epithelial and Stromal Tumor Family | MEST Family",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937588","Insect Glycan","C158047","An oligosaccharide protein modification that is synthesized by insect cells.","Insect Glycan | INSECT TYPE GLYCAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937589","Reptilian Glycan","C158048","An oligosaccharide protein modification that is synthesized by reptilian cells.","Reptilian Glycan | REPTILIAN TYPE GLYCAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937586","Mammalian Afucosylated Glycan","C158049","A fucose-free oligosaccharide protein modification that is synthesized by mammalian cells.","Mammalian Afucosylated Glycan | MAMMALIAN AFUCOSYLATED GLYCAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512126","EPS Library","C15804","Library located at Executive Plaza South.","EPS Library | EPS Library (DCPC Plus DCEG)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937587","Molluscan Glycan","C158050","An oligosaccharide protein modification that is synthesized by molluscan cells.","Molluscan Glycan | MOLLUSCAN TYPE GLYCAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937584","PKLR NM_000298.5:c.1436G>A","C158051","A nucleotide substitution at position 1436 of the coding sequence of the PKLR gene where guanine has been mutated to adenine.","PKLR NM_000298.5:c.1436G>A | NM_000298.5:c.1436G>A | PK1  c.1436G>A | PK1 c.1436G>A | PKL c.1436G>A | PKLR c.1436G>A | PKR c.1436G>A | PKRL  c.1436G>A | PKRL c.1436G>A | Pyruvate Kinase L/R Gene c.1436G>A | Pyruvate Kinase, Liver and RBC Gene c.1436G>A | RPK  c.1436G>A | RPK c.1436G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937762","RANO Ellingson 2017 Oncology Response Criteria","C158262","Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials (Benjamin M. Ellingson, Patrick Y. Wen, Timothy F. Cloughesy. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials. Neurotherapeutics (2017) 14:307-320).","RANO Ellingson 2017 Oncology Response Criteria | RANO ELLINGSON 2017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937760","IRANO Okada 2015 Oncology Response Criteria","C158263","Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. (Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope WB, Prins R, Sampson JH, Wen PY, Reardon DA. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015 Nov;16(15):e534-e542.)","IRANO Okada 2015 Oncology Response Criteria | IRANO 2015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518512","Nutritional Anthropometry","C15826","The study of nutritional effects upon the size, weight, and proportions of the human body.","Nutritional Anthropometry | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562773","Gallium Ga 68-NOTA-anti-HER2 Nanobody VHH1","C155898","A radioconjugate composed of a nanobody directed against human epidermal growth factor receptor 2 (HER2, EGFR2, ERBB2) that is linked, through the macrocyclic chelating agent 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA) to the radionuclide gallium (Ga) 68, with potential use in diagnostic imaging using positron emission tomography/computed tomography (PET/CT). Upon administration of gallium Ga 68-NOTA-anti-HER2 Nanobody VHH1, the anti-HER2 antibody moiety targets and binds to HER2-expressing cells. This facilitates both detection of HER2-expressing tumor cells and assessment of responses to HER2-targeted chemotherapeutic agents during PET/CT. HER2, a tyrosine kinase is overexpressed on the cell surfaces of various tumor cell types.","Gallium Ga 68-NOTA-anti-HER2 Nanobody VHH1 | 68Ga-HER2-Nanobody VHH1 | 68Ga-NOTA-2Rs15d | 68Ga-NOTA-anti-HER2 VHH1 | Gallium Ga 68-NOTA-anti-HER2-VHH1 | VHH1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562774","Anti-CD20 Monoclonal Antibody B001","C155899","A recombinant humanized monoclonal antibody directed against human CD20 with potential antineoplastic activity. Upon intravenous administration, anti-CD20 monoclonal antibody B001 specifically binds to CD20 on the surfaces of B-cells. Although the exact mechanisms through which B001 exert its effects have not been elucidated, B001 may induce a B-cell directed cell-mediated immune response against CD20-expressing B-cells and/or prevent CD20-medaited signaling. This induces tumor cell apoptosis and inhibits proliferation. CD20 is a non-glycosylated cell surface phosphoprotein which is exclusively expressed on B-cells during most stages of B-cell development and which is often overexpressed in B-cell malignancies.","Anti-CD20 Monoclonal Antibody B001 | B 001 | B001",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0280049","Extended Spectrum Penicillin Antibiotic","C1558","A group of penicillins with extended gram-negative bacterial coverage, including Ticarcillin, Piperacillin, Carbenicillin, Timentin and Mezlocillin.","Extended Spectrum Penicillin Antibiotic | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562775","APX001","C155900","An orally available small molecule inhibitor of the Gwt1 fungal enzyme with potential antifungal activity. Upon administration, fosmanogepix, a N-phosphonooxymethyl prodrug, is rapidly and completely metabolized by systemic alkaline phosphatases to its active moiety, APX001A (E1210). The active prodrug targets Gwt1, a highly conserved inositol acylase which catalyzes an essential step in the glycosylphosphatidylinositol (GPI)-anchor biosynthesis pathway. Inhibition of Gwt1 prevents localization of cell wall mannoproteins, which compromises cell wall integrity, biofilm formation, germ tube formation, and fungal growth.","Fosmanogepix | (12-Amino-6-oxa-1(3),7(2)-dipyridina-2(5,3)-(1,2)oxazola- 4(1,4)-benzenaheptaphan-11-ium-11-yl)methyl hydrogen phosphate | APX-001 | APX001 | E1211 | FOSMANOGEPIX | Prodrug APX001 | Pyridinium, 2-amino-1-((phosphonooxy)methyl)-3-(3-((4-((2-pyridinyloxy)methyl)phenyl)methyl)-5-isoxazolyl)-, inner salt",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562776","Unresectable Lung Non-Small Cell Carcinoma","C155901","Lung non-small cell carcinoma that is not amenable to surgical resection.","Unresectable Lung Non-Small Cell Carcinoma | Unresectable Non-Small Cell Lung Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562769","Unresectable Lung Carcinoma","C155902","Lung carcinoma that is not amenable to surgical resection.","Unresectable Lung Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562770","Unresectable Digestive System Carcinoma","C155903","Digestive system carcinoma that is not amenable to surgical resection.","Unresectable Digestive System Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555994","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Lifting 10-20 Lbs","C155496","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Lifting something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries).","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Lifting 10-20 Lbs | FAC100-Sev: Lifting 10-20 Lbs | FAC10015",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555995","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Lifting 10-20 Lbs Why Not","C155497","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Lifting something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries). Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Lifting 10-20 Lbs Why Not | FAC100-Sev: Lifting 10-20 Lbs Why Not | FAC10016",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937692","Anti-CD38/BCMA CAR T-lymphocytes","C158087","A preparation of T-lymphocytes that have been genetically modified to express a dual-targeted chimeric antigen receptor (CAR) recognizing the tumor-associated antigens (TAAs), cluster of differentiation 38 (CD38) and B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, the anti-CD38/BCMA CAR T-cells are directed to and induce selective toxicity in both CD38- and BCMA-expressing cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis. BCMA is found on the surfaces of plasma cells and is and overexpressed on malignant plasma cells.","Anti-CD38/BCMA CAR T-lymphocytes | Anti-CD38/Anti-BCMA CAR T-cells | Anti-CD38/Anti-BCMA CAR T-lymphocytes | Anti-CD38/BCMA CAR T-cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937689","Refractory Digestive System Neuroendocrine Neoplasm","C158088","A digestive system neuroendocrine neoplasm that is resistant to treatment.","Refractory Digestive System Neuroendocrine Neoplasm | Refractory Gastroenteropancreatic Neuroendocrine Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937690","Advanced Digestive System Neuroendocrine Neoplasm","C158089","A digestive system neuroendocrine neoplasm that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Digestive System Neuroendocrine Neoplasm | Advanced Gastroenteropancreatic Neuroendocrine Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512822","Intercept Vertical Transmission-Perinatal Transmission of HIV","C15808","Develop, evaluate, and implement strategies for interrupting vertical transmission of HIV from mother to child and extend our understanding of perinatal transmission and the pathogenesis of early infection (treatment of children will be addressed in other objectives). (Note: The OAR Coordinating Committee on Therapeutics feels scientific objectives 3E through 3G are of equal weight in terms of scientific priorities.)","Intercept Vertical Transmission-Perinatal Transmission of HIV | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937916","Decreased Peri-Insular Halos","C158334","Decreased number and/or size of peri-insular halos.","Decreased Peri-Insular Halos | PERI-INSULAR HALOS, DECREASED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937913","Increased Peri-Insular Halos","C158335","Increased number and/or size of peri-insular halos.","Increased Peri-Insular Halos | PERI-INSULAR HALOS, INCREASED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937914","Paneth Cell Reduction","C158336","Decrease in Paneth cell granules and loss of Paneth cells within the small intestine.","Paneth Cell Reduction | PANETH CELL REDUCTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937911","Secretory Depletion","C158337","Decreased secretory content (e.g., mucus or granules) in secretory cells.","Secretory Depletion | SECRETORY DEPLETION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937912","Increased Atretic Follicles","C158338","Increased number of atretic follicles.","Increased Atretic Follicles | ATRETIC FOLLICLES, INCREASED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937909","Decreased or Absent Follicles","C158339","Decreased number or total absence of follicles.","Decreased or Absent Follicles | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937910","Booster Synchrotron","C158340","A type of particle accelerator that can generate ionizing radiation by colliding subatomic particles traveling at high speeds along a curved or circular chamber.","Booster Synchrotron | BOOSTER SYNCHROTRON",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937908","X-Ray Irradiator","C158341","A device that exposes samples to X-ray radiation.","X-Ray Irradiator | X-RAY IRRADIATOR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0028591","Nuclear Reactor","C158342","A device that enables a controlled, self-sustaining nuclear reaction and release of energy.","Nuclear Reactor | NUCLEAR REACTOR",,,,,,,,,,,,,,,"4278826","Nuclear reactor",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1320374","Chemical Restraint","C158343","A chemical substance that is administered in order to restrict movement.","Chemical Restraint | CHEMICAL",,,,,,,,,,,,,,,"4227384","Chemical restraint",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937906","Chemical and Physical Restraint","C158345","A restraint type that includes both chemical and physical restraining methods.","Chemical and Physical Restraint | CHEMICAL AND PHYSICAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937907","Sexual Maturity Status at Neutering","C158346","A description of when the neutering event took place, relative to the subject's sexual maturation status.","Sexual Maturity Status at Neutering | SEXMATSN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950622","Number of Other Lymph Nodes Positive for Tumor by H&E","C158642","A request to specify the number of other lymph nodes that were positive for tumor by H&E that are not listed on the form.","Number of Other Lymph Nodes Positive for Tumor by H&E | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950623","Number of Other Lymph Nodes Positive for Tumor by IHC staining only","C158643","A request to specify the number of other lymph nodes that were positive for tumor by IHC staining that are not listed on the form.","Number of Other Lymph Nodes Positive for Tumor by IHC staining only | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950624","Number of Para-aortic Lymph Nodes Examined","C158644","A request to specify the number of para-aortic lymph nodes examined.","Number of Para-aortic Lymph Nodes Examined | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950625","Number of Para-aortic Lymph Nodes Positive for Tumor by H&E","C158645","A request to specify the number of para-aortic lymph nodes found positive for tumor by H&E..","Number of Para-aortic Lymph Nodes Positive for Tumor by H&E | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950627","Number of Pelvic Lymph Nodes Examined","C158647","A request to specify the number of pelvic lymph nodes that were examined.","Number of Pelvic Lymph Nodes Examined | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950628","Number of Pelvic Lymph Nodes Positive for Tumor by H&E","C158648","A request to specify the number of pelvic lymph nodes found positive for tumor by H&E.","Number of Pelvic Lymph Nodes Positive for Tumor by H&E | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950629","Number of Pelvic Lymph Nodes Positive for Tumor by IHC staining only","C158649","A request to specify the number of pelvic lymph nodes found positive for tumor by IHC staining.","Number of Pelvic Lymph Nodes Positive for Tumor by IHC staining only | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519888","Vaccine Clinical Trial","C15864","No value exists.","Vaccine Clinical Trial | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950630","Prostate Large Cell Neuroendocrine Carcinoma","C158650","An exceptionally rare neuroendocrine carcinoma that arises from the prostate gland. It is characterized by the presence of malignant large cells.","Prostate Large Cell Neuroendocrine Carcinoma | Prostate large cell neuroendocrine carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950636","Usual Prostate Adenocarcinoma with Neuroendocrine Differentiation","C158656","Acinar adenocarcinoma of the prostate gland characterized by the presence of scattered neuroendocrine cells by immunohistochemistry.","Usual Prostate Adenocarcinoma with Neuroendocrine Differentiation | Usual Prostate Adenocarcinoma with Neuroendocrine Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937755","Numerical Rating Scale 11-Point","C158270","A type of numerical rating scale composed of 11 points, ranging from 0-10.","Numerical Rating Scale 11-Point | 11-Point Numeric Rating Scale | 11-Point Numerical Rating Scale | NRS 11-Point | NUMERICAL RATING SCALE 11-POINT | Numeric Rating Scale 11-Point",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937752","Verbal Rating Scale 4-Point","C158271","A type of verbal rating scale composed of 4 items.","Verbal Rating Scale 4-Point | 4-Point Verbal Rating Scale | VERBAL RATING SCALE 4-POINT | VRS 4-Point",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937753","Verbal Rating Scale 5-Point","C158272","A type of verbal rating scale composed of 5 items.","Verbal Rating Scale 5-Point | 5-Point Verbal Rating Scale | VERBAL RATING SCALE 5-POINT | VRS 5-Point",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937751","Verbal Rating Scale 6-Point","C158273","A type of verbal rating scale composed of 6 items.","Verbal Rating Scale 6-Point | 6-Point Verbal Rating Scale | VERBAL RATING SCALE 6-POINT | VRS 6-Point",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518513","Nutritional Biochemistry","C15827","The study of the biochemistry of foods and vitamins as they affect the body","Nutritional Biochemistry | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938057","Anti-BCMA x Anti-CD3 BiTE REGN5458","C158504","A human bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFvs): one directed again the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and another directed against the CD3 antigen expressed on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, linvoseltamab binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, leading to CTL-mediated killing of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.","Linvoseltamab | Anti-BCMA x Anti-CD3 BiTE REGN5458 | Anti-BCMA/CD3 BiTE Antibody REGN5458 | BiTE Antibody REGN5458 | Bispecific BCMA x CD3 T-cell Engaging Antibody REGN5458 | LINVOSELTAMAB | REGN 5458 | REGN-5458 | REGN5458",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938054","Bispecific DART Protein MGD019","C158505","A hinge stabilized immunoglobulin G4 (IgG4) tetravalent bispecific antibody-like protein directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, lorigerlimab specifically binds to both PD-1 and CTLA4 expressed on tumor-infiltrating lymphocytes (TILs) and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. Dual blockade of PD1 and CTLA4 pathways provides enhanced activity against PD1+CTLA4+ double positive cells and may increase T-cell activation and proliferation compared to the blockade of either immune checkpoint alone.","Lorigerlimab | AEX-1344 | AEX1344 | Anti-PD-1/Anti-CTLA4 DART Protein MGD019 | Anti-PD-1/Anti-CTLA4 DART Protein MGD019 | Bispecific DART Protein MGD019 | D-1 x CTLA4 DART Protein MGD019 | Dual-affinity Retargeting Protein MGD019 | LORIGERLIMAB | MGD 019 | MGD-019 | MGD019 | PD-1 x CTLA4 Bispecific DART Molecule MGD019 | PD-1 x CTLA4 DART Protein MGD019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556000","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Carry 10-20 Lbs","C155498","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Carrying something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries) from one room to another.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Carry 10-20 Lbs | FAC100-Sev: Carry 10-20 Lbs | FAC10017",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556001","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Carry 10-20 Lbs Why Not","C155499","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Carrying something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries) from one room to another. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Carry 10-20 Lbs Why Not | FAC100-Sev: Carry 10-20 Lbs Why Not | FAC10018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281185","Screening for Colorectal Cancer","C15549","No value exists.","Screening for Colorectal Cancer | colorectal cancer early detection | colorectal cancer screening | early detection of colorectal cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555998","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walk for 1/2 Mile","C155500","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking (faster than your usual speed) for 1/2 mile (almost 1 km) without stopping.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walk for 1/2 Mile | FAC100-Sev: Walk for 1/2 Mile | FAC10019",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL555999","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walk for 1/2 Mile Why Not","C155501","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking (faster than your usual speed) for 1/2 mile (almost 1 km) without stopping. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walk for 1/2 Mile Why Not | FAC100-Sev: Walk for 1/2 Mile Why Not | FAC10020",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556004","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Bath Without Help","C155502","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Taking a bath without help.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Bath Without Help | FAC100-Sev: Bath Without Help | FAC10021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556005","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Bath Without Help Why Not","C155503","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Taking a bath without help. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Bath Without Help Why Not | FAC100-Sev: Bath Without Help Why Not | FAC10022",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937905","Previous Research Experience Indicator","C158348","An indication as to whether the study subject has been in a previous study.","Previous Research Experience Indicator | PRVRSIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937902","Neutered Indicator","C158349","An indication as to whether the animal(s) has been neutered.","Neutered Indicator | NEUTIND | neutered indicator | neutered_indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519029","Pharmaceutical Resources","C15834","A collection of pharmaceutical substances available for research use","Pharmaceutical Resources | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937900","Sexually Mature","C158351","The life stage at which the organism is capable of reproduction.","Sexually Mature | SEXUALLY MATURE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937901","Sexually Immature","C158352","The life stage before which the organism is capable of reproduction.","Sexually Immature | SEXUALLY IMMATURE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937898","Expiratory Flow 50%","C158353","The rate of gas flow during exhalation, beginning at the point at which tidal volume is decreased by 50%.","Expiratory Flow 50% | EF50",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937899","Apnea Time","C158354","A measurement of the apnea duration determined by total sleep time minus the sum of inspiration time and expiration time.","Apnea Time | AT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937896","Elapsed Time Between Breaths","C158355","The amount of time between one breath to the next breath calculated by inspiration time plus expiration time.","Elapsed Time Between Breaths | ELTMBB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937897","Efficacy Study With Pre-Exposure Prophylaxis","C158356","A study that assesses the efficacy of prophylactic treatment (including radioprotectors) given before exposure to an agent(s).","Efficacy Study With Pre-Exposure Prophylaxis | EFFICACY, PRE-EXPOSURE PROPHYLAXIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937960","SERF1A wt Allele","C158539","Human SERF1A wild-type allele is located in the vicinity of 5q13.2 and is approximately 18 kb in length. This allele, which encodes small EDRK-rich factor 1 protein, may be involved in musculoskeletal development.","SERF1A wt Allele | 4F5 | FAM2A | H4F5 | SERF1 | SMAM1 | Small EDRK-Rich Factor 1A (Telomeric) Gene | Small EDRK-Rich Factor 1A Gene | Small EDRK-Rich Factor 1A wt Allele | Spinal Muscular Atrophy-Related Gene H4F5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514859","Repository Operation, Serum","C15853","No value exists.","Repository Operation, Serum | Culturing, in vitro Repository Operations, Serum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937961","SERF1B wt Allele","C158540","Human SERF1B wild-type allele is located in the vicinity of 5q13.2 and is approximately 18 kb in length. This allele, which encodes small EDRK-rich factor 1 protein, may be involved in the development of the spinal cord and spinal column.","SERF1B wt Allele | FAM2B | H4F5C | SERF1 | SMAM1 | Small EDRK-Rich Factor 1B (Centromeric) Gene | Small EDRK-Rich Factor 1B wt Allele | h4F5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937959","Small EDRK-Rich Factor 1","C158541","Small EDRK-rich factor 1 (110 aa, ~12 kDa) is encoded by the human SERF1A and SERF1B genes. This protein may play a role in the development of the spinal cord, vertebrae and surrounding musculature.","Small EDRK-Rich Factor 1 | Protein 4F5 | SERF1 | SERF1A | SERF1B | SMA Modifier 1 | h4F5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937957","SMIM5 Gene","C158543","This gene encodes a membrane protein of unknown function.","SMIM5 Gene | SMIM5 | Small Integral Membrane Protein 5 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937958","SMIM5 wt Allele","C158544","Human SMIM5 wild-type allele is located in the vicinity of 17q25.1 and is approximately 8 kb in length. This allele, which encodes small integral membrane protein 5, has no known function.","SMIM5 wt Allele | AW024884 | C17orf109 | Chromosome 17 Open Reading Frame 109 Gene | LOC643008 | PP12104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937955","Small Integral Membrane Protein 5","C158545","Small integral membrane protein 5 (77 aa, ~8 kDa) is encoded by the human SMIM5 gene. This protein has no known function.","Small Integral Membrane Protein 5 | SMIM5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519890","Vaccine Design and Animal Testing","C15865","Apply findings from basic, epidemiologic, and clinical research to the design and evaluation of vaccine strategies in laboratory studies and animal models, and foster collaboration with industry in the research and development of candidate vaccines.","Vaccine Design and Animal Testing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950833","ERBB2 NM_004448.2:c.2326_2327insTCT","C158883","An insertion of 3 nucleotides, thymine-cytosine-thymine, between position 2326 and 2327 of the coding sequence of the ERBB2 gene.","ERBB2 NM_004448.2:c.2326_2327insTCT | CD340 c.2326_2327insTCT | ERBB2 c.2326_2327insTCT | Erb-B2 Receptor Tyrosine Kinase 2 c.2326_2327insTCT | Erb-B2 Receptor Tyrosine Kinase c.2326_2327insTCT | HER-2 c.2326_2327insTCT | HER2 c.2326_2327insTCT | HER2/Neu c.2326_2327insTCT | NM_001005862.2:c.2236_2237insTCT | NM_004448.2:c.2326_2327insTCT | Neu c.2326_2327insTCT | c-erbB2 c.2326_2327insTCT | v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 c.2326_2327insTCT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950834","ERBB2 NP_004439.2:p.G776delinsVC","C158884","A deletion of the glycine and insertion of the amino acid sequence valine-cysteine at position 776 of the receptor tyrosine-protein kinase erbB-2 protein.","ERBB2 NP_004439.2:p.G776delinsVC | ERBB2 776_776G>VC | ERBB2 776_776G>VC Insertion | ERBB2 776_776G>VC insertion mutation | ERBB2 776_776GdelinsVC | ERBB2 776_776Gly>ValCys | ERBB2 776_776GlydelinsValCys | ERBB2 G776>VC | ERBB2 Gly776>ValCys | ERBB2 NP_004439.2:p.Gly776delinsValCys | ERBB2 p.776_776G>VC | ERBB2 p.776_776GdelinsVC | ERBB2 p.776_776Gly>ValCys | ERBB2 p.776_776GlydelinsValCys | ERBB2 p.G776>VC | ERBB2 p.Gly776>ValCys | NP_001005862.1:p.G746delinsVC | NP_001005862.1:p.Gly746delinsValCys | NP_004439.2:p.G776delinsVC | NP_004439.2:p.Gly776delinsValCys | Proto-Oncogene Neu G776delinsVC | Proto-Oncogene Neu Gly776delinsValCys | Receptor Tyrosine-Protein Kinase erbB-2 G776delinsVC | Receptor Tyrosine-Protein Kinase erbB-2 Gly776delinsValCys | Tyrosine Kinase-Type Cell Surface Receptor HER2 G776delinsVC | Tyrosine Kinase-Type Cell Surface Receptor HER2 Gly776delinsValCys",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950835","ERBB2 Mutation Analysis Testing Method","C158885","A request to enter the specific molecular analysis method used to detect and identify mutations in the ERBB2 gene.","ERBB2 Mutation Analysis Testing Method | ERBB2 Mutational Analysis Testing Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951730","ERG Gene Mutation","C158886","A change in the sequence of the ERG gene.","ERG Gene Mutation | ERG | ERG Mutation | ETS Transcription Factor ERG Gene Mutation | Erg-3 Gene Mutation | Erythroblastosis Virus E26 Oncogene Like Gene Mutation | p55 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950836","IDH1/2 Mutation Analysis Testing Method","C158887","A request to enter the specific molecular analysis method used to detect and identify mutations in the genes IDH1 and IDH2.","IDH1/2 Mutation Analysis Testing Method | IDH1/2 Mutational Analysis Testing Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950837","Specify Other BRAF Mutation","C158888","A request to enter the specific BRAF mutation that was identified in the study but is not present in the form.","Specify Other BRAF Mutation | If other BRAF mutation, specify | Other BRAF mutation, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950838","Specify Other BRAF Codon 600 Mutation","C158889","A request to enter the specific mutation involving BRAF codon 600 that was identified in the study but is not present in the form.","Specify Other BRAF Codon 600 Mutation | If other BRAF V600 mutation, specify | Specify Other BRAF V600 Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515927","Alternative Medical System","C15888","NIH: Major category of Complementary and Alternative Medicine classification.  This category involves complete systems of theory and practice that are alternatives to the Western biomedical approach.  Includes: Acupuncture and oriental medicine; Traditional Indigenous Systems; Unconventional Western systems; and Naturopathy.","Alternative Medical System | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950840","Specify Other ERBB2 Non-Exon 20 Mutation","C158891","A request to enter the specific EGFR non-exon 20 mutation that was identified in the study but is not present in the form.","Specify Other ERBB2 Non-Exon 20 Mutation | If other ERBB2 mutation (non-exon 20), specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950841","Specify Other NRAS Mutation","C158892","A request to enter the specific NRAS mutation that was identified in the study but is not present in the form.","Specify Other NRAS Mutation | If Other NRAS mutation, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950785","Specify Polysomy/Monosomy","C158893","A request to specify if monosomy or polysomy was present.","Specify Polysomy/Monosomy | If polysomy/monosomy, specify | Specify Polysomy or Monosomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938055","ABX464","C158506","An orally available, small molecule binder of the cap binding complex (CBC) 80/20, with potential antiviral and anti-inflammatory activities. Upon oral administration, obefazimod binds to the CBC, a complex at the 5'-end of the pre-mRNA transcript that promotes the initial interaction with transcription and processing machinery. This leads to a conformational change in the CBC and enhanced splicing of viral RNA variants and upregulation of the anti-inflammatory microRNA, miR-124, via splicing of a long noncoding RNA at the miR-124-1 locus. In human immunodeficiency virus type 1 (HIV-1)-infected cells, obefazimod interacts with the CBC of HIV-1 mRNA and inhibits viral replication by preventing Rev-mediated export of unspliced HIV-1 transcripts to the cytoplasm. Rev facilitates the nuclear export of unspliced or incompletely spliced viral pre-mRNAs, an essential step in HIV-1 replication. In inflammatory conditions, miR-124 reduces the production of various inflammatory mediators, including interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-alpha), and C-C motif chemokine 2 (CCL2; MCP-1.). miR-124 plays a critical role in innate and adaptive immune responses and is a critical mediator of cholinergic anti-inflammatory action.","Obefazimod | 8-Chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine | ABX 464 | ABX-464 | ABX464 | CBC 80/20 Binder ABX-464 | Cap Binding Complex 80/20 Binder ABX-464 | OBEFAZIMOD | Rev Inhibitor ABX-464 | SPL-464",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938052","IBI 101","C158507","An agonistic fully human anti-OX40 (tumor necrosis factor receptor superfamily member 4; TNFRSF4; CD134; OX40L receptor) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, cudarolimab selectively binds to and activates OX40. Receptor activation induces proliferation of memory and effector T-lymphocytes and results in a T-cell-mediated immune response against tumor cells, which leads to tumor cell lysis. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and provides a co-stimulatory signal that promotes both the proliferation and survival of activated T-cells.","Cudarolimab | Anti-OX40 Monoclonal Antibody IBI101 | CUDAROLIMAB | IBI 101 | IBI-101 | IBI101",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938053","YY 20394","C158508","An orally available selective inhibitor of the delta form of phosphatidylinositol 3-kinase (PI3-kinase subunit delta; PI3K-delta; PI3Kdelta), with potential antineoplastic activity. Upon oral administration linperlisib selectively binds to and inhibits PI3K-delta and prevents the activation of the PI3K/AKT signaling pathway. This decreases proliferation of and induces cell death in PI3K-delta over-expressing tumor cells. PI3K-delta also plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of certain hematologic cancer cells. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells, thereby minimizing serious side effects.","Linperlisib | LINPERLISIB | PI3K-delta Inhibitor YY-20394 | YY 20394 | YY-20394 | YY20394",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938050","99mTc-ABH2","C158509","A radioconjugate composed of an optimized affibody labeled with technetium Tc 99m, with potential use as a tracer for human epidermal growth factor receptor type 2 (HER2; ErbB2)-expressing tumors using single photon emission computed tomography (SPECT). Upon administration, the Tc 99m-labeled affibody ABH2 targets and binds to HER2-expressing tumor cells. This facilitates both detection of HER2-expressing tumor cells and assessment of responses to HER2-targeting chemotherapeutic agents using SPECT. HER2, a receptor tyrosine kinase, is mutated in many tumor cell types and plays a key role in tumor cell proliferation and tumor vascularization.","Technetium Tc-99m Anti-HER2 Affibody ABH2 | 99mTc-ABH2 | HER2-targeting 99mTc-labeled Affibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950734","Was Adjuvant Post-Operative Hormone Therapy Administered","C158703","No value exists.","Was Adjuvant Post-Operative Hormone Therapy Administered | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950736","Adjuvant Post-Operative Pharmaceutical Therapy","C158705","A question whether adjuvant post-operative pharmaceutical therapy was administered.","Was Adjuvant Post-Operative Pharmaceutical Therapy Administered | Adjuvant Post-Operative Pharmaceutical Therapy | Adjuvant Post-Operative Pharmacotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562852","Anti-VEGF Monoclonal Antibody hPV19","C156139","A humanized monoclonal antibody directed against human vascular endothelial growth factor (VEGF), with potential anti-angiogenic and antineoplastic activities. Upon administration, anti-VEGF monoclonal antibody hPV19 targets and binds to VEGFR at a unique binding site and inhibits VEGF binding to its receptors, VEGFR1 and VEGFR2, thereby preventing VEGF/VEGFR-mediated signaling. This prevents the growth and maintenance of tumor blood vessels. This decreases nutrient supply to tumor cells, resulting in tumor cell death. Increased VEGF/VEGFR signaling is associated with increased invasiveness and decreased survival.","Anti-VEGF Monoclonal Antibody hPV19 | Anti-VEGF MAb hPV19 | MoAb hPV19 | hPV 19 | hPV-19 | hPV19",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937956","STK32B Gene","C158546","This gene is involved in protein phosphorylation and limb development.","STK32B Gene | STK32B | Serine/Threonine Kinase 32B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937954","STK32B wt Allele","C158548","Human STK32B wild-type allele is located in the vicinity of 4p16.2 and is approximately 450 kb in length. This allele, which encodes serine/threonine-protein kinase 32B protein, plays a role in limb development. Deletion of the gene is associated with the autosomal recessive skeletal dysplasia, Ellis-van Creveld syndrome.","STK32B wt Allele | HSA250839 | STK32 | STKG6 | Serine/Threonine Kinase 32B wt Allele | UNQ3003/PRO9744 | YANK2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937951","STK32B protein, human","C158549","Serine/threonine-protein kinase 32B (414 aa, ~48 kDa) is encoded by the human STK32B gene. This protein is involved in serine/threonine phosphorylation and limb development.","Serine/Threonine-Protein Kinase 32B | EC 2.7.11.1 | STK32B | Yet Another Novel Kinase 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519393","Social Health Service","C15854","No value exists.","Social Health Service | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937952","TMEM65 Gene","C158550","This gene plays a role in gap junction and mitochondrial functions and cardiac development.","TMEM65 Gene | TMEM65 | Transmembrane Protein 65 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938010","TMEM65 wt Allele","C158552","Human TMEM65 wild-type allele is located in the vicinity of 8q24.13 and is approximately 65 kb in length. This allele, which encodes transmembrane protein 65, is involved in mitochondrial functionality, cardiac development and gap junction formation.","TMEM65 wt Allele | AA555029_RC | LOC286052 | Transmembrane Protein 65 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938009","TMEM74B Gene","C158554","This gene may be involved in autophagy.","TMEM74B Gene | TMEM74B | Transmembrane Protein 74B Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950717","Unresectable Inflammatory Breast Carcinoma","C158751","Inflammatory breast carcinoma that is not amenable to surgical resection.","Unresectable Breast Inflammatory Carcinoma | Unresectable Inflammatory Breast Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950718","Unresectable Breast Carcinoma","C158752","Breast carcinoma that is not amenable to surgical resection.","Unresectable Breast Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950719","Post-secondary Therapy","C158753","Therapy administered after the second treatment.","Post-secondary Therapy | Post Secondary Therapy | Post-Secondary Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950720","Progression of Disease at Recurrence","C158754","At the time of the progression or recurrence of a disease.","Progression of Disease at Recurrence | At Recurrence/Progression of Disease | Recurrence/Progression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950721","No Evidence of Disease at Follow-Up","C158755","No evidence of disease at the follow-up assessment.","No Evidence of Disease at Follow-Up | At Follow up/No evidence of Disease | No evidence of disease (NED)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950723","Other Procedure Type for New Tumor Event","C158757","A directive to specify the procedure which is other than is listed on the form.","Other Procedure Type for New Tumor Event | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1521729","Nutritional Study","C15820","Research that focuses on food, the nutrients and other substances contained therein, their action, interaction, and balance in relation to health and disease.","Nutritional Study | Nutrition | Nutrition Research",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518499","Nutrition Research, Applied Clinical Trials","C15821","No value exists.","Nutrition Research, Applied Clinical Trials | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519897","Vaccine Related Development, Non-Cancer; Non-AIDS","C15870","No value exists.","Vaccine Related Development, Non-Cancer; Non-AIDS | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1537892","MIR371A Gene","C158710","This gene may play a role in tumor malignancy.","MIR371A Gene | MIR371A | MicroRNA 371a Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950742","MIR371A Pre-miRNA","C158712","MIR371A pre-miRNA (67 bases) is an oligoribonucleotide that is encoded by the human MIR371A gene. This ribonucleotide may play a role in both the regulation of gene transcription and tumor malignancy.","MIR371A Pre-miRNA | MIR371A Pre-MicroRNA | Pre-MicroRNA 371A | Pre-miRNA 371A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3147814","MIR371B Gene","C158713","This gene may be involved in translational inhibition or mRNA degradation.","MIR371B Gene | MIR371B | MicroRNA 371b Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950743","MIR371B wt Allele","C158714","Human MIR371B wild-type allele is located in the vicinity of 19q13.42 and is approximately 66 kb in length. This allele, which encodes MIR371B pre-miRNA, may play a role in the regulation of gene expression. Alteration in the expression of this gene is associated with malignant germ cell tumors.","MIR371B wt Allele | MicroRNA 371b wt Allele | hsa-mir-371b",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950744","MIR371B Pre-miRNA","C158715","MIR371B pre-miRNA (66 bases) is encoded by the human MIR371B gene. This ribonucleotide may be involved in both the regulation of gene transcription and tumor malignancy.","MIR371B Pre-miRNA | MIR371B Pre-MicroRNA | Pre-MicroRNA 371B | Pre-miRNA 371B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950745","MiRNA 371-373 Overexpression","C158716","An indication that microRNAs found in the miRNA 371-373 cluster are overexpressed in a sample.","MiRNA 371-373 Overexpression | MicroRNA 371-373 Overexpression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1416843","LHCGR Gene","C158717","This gene plays a role in luteinizing hormone and choriogonadotropin-mediated signaling.","LHCGR Gene | LHCGR | Luteinizing Hormone/Choriogonadotropin Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950746","LHCGR wt Allele","C158718","Human LHCGR wild-type allele is located in the vicinity of 2p16.3 and is approximately 69 kb in length. This allele, which encodes lutropin-choriogonadotropic hormone receptor protein, is involved in binding luteinizing hormone and choriogonadotropin and G protein-coupled receptor signaling. Mutation of the gene is associated with luteinizing hormone resistance in females, precocious puberty in males, somatic Leydig cell adenoma with precocious puberty and Leydig cell hypoplasia with either pseudohermaphroditism or hypergonadotropic hypogonadism.","LHCGR wt Allele | HHG | LCGR | LGR2 | LH/CG-R | LH/CGR | LHR | LHRHR | LSH-R | Luteinizing Hormone/Choriogonadotropin Receptor wt Allele | ULG5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3156876","Lutropin-Choriogonadotropic Hormone Receptor","C158719","Lutropin-choriogonadotropic hormone receptor (699 aa, ~79 kDa) is encoded by the human LHCGR gene. This protein plays a role in G protein-coupled receptor signaling mediated by luteinizing hormone and choriogonadotropin binding.","Lutropin-Choriogonadotropic Hormone Receptor | LH/CG-R | LHCGR | LHR | LSH-R | Luteinizing Hormone Receptor | Luteinizing Hormone/Choriogonadotropin Receptor | Lutropin/Choriogonadotropin Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556299","Locally Advanced Unresectable Carcinoma","C155698","A carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.","Locally Advanced Unresectable Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556302","Locally Advanced Unresectable Renal Cell Carcinoma","C155699","A renal cell carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.","Locally Advanced Unresectable Renal Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1268902","Purine Antagonist","C1556","An antimetabolite that affects the metabolism and utilization of purines.","Purine Antagonist | Purine Inhibitors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562650","BCR-ABL Inhibitor","C155700","Any agent that inhibits the tyrosine kinase BCR-ABL.","BCR-ABL Inhibitor | BCR-ABL Tyrosine Kinase Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556300","KIT NM_000222.2:c.2458G>T","C155701","A nucleotide substitution at position 2458 of the coding sequence of the KIT gene where guanine has been mutated to thymine.","KIT NM_000222.2:c.2458G>T | CD117 c.2458G>T | KIT Proto-Oncogene Tyrosine Protein Kinase c.2458G>T | KIT c.2458G>T | NM_000222.2:c.2458G>T | c-KIT c.2458G>T | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.2458G>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556305","KIT NM_000222.2:c.2466T>R","C155703","A nucleotide substitution at position 2466 of the coding sequence of the KIT gene where thymine has been mutated to any purine (adenine or guanine).","KIT NM_000222.2:c.2466T>R | CD117 c.2466T>R | KIT Proto-Oncogene Tyrosine Protein Kinase c.2466T>R | KIT c.2466T>R | NM_000222.2:c.2466T>R | c-KIT c.2466T>R | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.2466T>R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562771","del(3p21-22)","C155904","A cytogenetic abnormality that refers to deletion of chromosome bands 21-22 on the short arm of chromosome 3.","del(3p21-22) | del(3)(p21;p22)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562772","del(3p25-26)","C155905","A cytogenetic abnormality that refers to deletion of chromosome bands 25-26 on the short arm of chromosome 3.","del(3p25-26) | del(3)(p25;p26)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950725","Other Method, Specify Below","C158759","A directive to specify the method below which is other than is listed on the form.","Other Method, Specify Below | Other Method, specify below",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519943","Validation of Technology","C15875","No value exists.","Validation of Technology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950727","Was Additional Treatment Administered for New Tumor Event","C158761","No value exists.","Was Additional Treatment Administered for New Tumor Event | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950666","Were Immunophenotype and Cytochemistry Analyses Performed on Peripheral Blood Samples","C158764","A question asking if immunophenotyping and cytochemistry were performed on peripheral blood samples during the study.","Were Immunophenotype and Cytochemistry Analyses Performed on Peripheral Blood Samples | Were Immunophenotype & Cytochemistry Performed on Peripheral Blood",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950667","Bone Marrow Aspirate Immunophenotype & Cytochemistry","C158765","A section header for lab results related to bone marrow aspirate immunophenotype and cytochemistry.","Bone Marrow Aspirate Immunophenotype & Cytochemistry | Immunophenotype & Cytochemistry for Bone Marrow Aspirate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950669","Is the New Disease Multifocal","C158767","A question about whether the new disease is multifocal.","Is the New Disease Multifocal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950670","Radiologic Tumor Size of New Tumor","C158768","A question about the size of the tumor via a radiologic procedure.","Radiologic Tumor Size of New Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950671","Radiographic Length","C158769","The longest perpendicular diameter of a tumor from the results of an imaging modality.","Radiographic Length | Radiologic Length",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520025","Virus Cancer Research","C15876","Experimental or epidemiological studies of viruses as carcinogens or co-carcinogens.","Virus Cancer Research | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950672","Radiologic Width","C158770","The longest diameter of a tumor from the results of an imaging modality.","Radiographic Width | Radiologic Width",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950673","Radiographic Depth","C158771","The longest front to back measurement of a tumor from the results of an imaging modality.","Radiographic Depth | Radiologic Depth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950674","Pathologic Tumor Size of New Tumor","C158772","A question about the size of a tumor from the pathology examination of a specimen.","Pathologic Tumor Size of New Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950675","Pathologic Length","C158773","The longest perpendicular diameter of a tumor from the pathology examination of a specimen.","Pathologic Length | length of tumor | length_of_tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937687","Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm","C158090","A digestive system neuroendocrine neoplasm that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.","Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm | Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Neoplasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514533","Protein/Amino Acid Nutrition, Non-Animal","C15845","Study of dietary non-animal protein/amino acids in relation to cancer.","Protein/Amino Acid Nutrition, Non-Animal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938036","Myb/SANT-Like DNA-Binding Domain-Containing Protein 3","C158460","Myb/SANT-like DNA-binding domain-containing protein 3 (275 aa, ~32 kDa) is encoded by the human MSANTD3 gene. This protein may be involved in DNA binding and protein complex formation.","Myb/SANT-Like DNA-Binding Domain-Containing Protein 3 | MSANTD3 | Myb/SANT-Like DNA-Binding Domain Containing 3 | UPF0439 Protein C9orf30",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938031","Metastatic Salivary Gland Carcinoma","C158463","A salivary gland carcinoma that has metastasized to another anatomic site.","Metastatic Salivary Gland Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938032","Locally Advanced Salivary Gland Carcinoma","C158464","A salivary gland carcinoma that has spread to nearby tissues or lymph nodes.","Locally Advanced Salivary Gland Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938029","Challenge Agent Treatment Efficacy Study","C158465","A study that assesses the efficacy of treatment given after a protocol-defined manifestation of the challenge agent(s)-induced disease or condition.","Challenge Agent Treatment Efficacy Study | EFFICACY, TREATMENT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938030","Attenuated Live Listeria monocytogenes Encoding KRAS G12D","C158466","An off-the-shelf, plasmid DNA-based cancer vaccine composed of a live-attenuated strain of the Gram-positive bacterium Listeria monocytogenes (Lm) carrying a plasmid vector encoding multiple, not yet disclosed, tumor associated antigens (TAAs) and sequence peptides associated with commonly occurring hotspot mutations, including the aspartic acid substitution for glycine at position 12 (G12D) in KRAS, with potential immunostimulatory and antineoplastic activities. Upon administration, ADXS-503 is taken up by antigen presenting cells (APCs) and the TAAs are processed and presented to immune cells by both major histocompatibility complex (MHC) I and II molecules. This leads to an increase in antigen-specific CD8-positive T-cells and gamma/delta T-cells within the tumor microenvironment (TME) and an inhibition of immunosuppressive tumor-infiltrating T-regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSCs). This may lead to tumor cell death in cells expressing TAAs that are shared across multiple tumor types. The KRAS G12D mutation is thought to drive tumorigenesis and progression in some cancers.","Attenuated Live Listeria monocytogenes Encoding KRAS G12D | ADXS 503 | ADXS-503 | ADXS503 | Lm-Hot KRAS G12D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517006","Experimental Nutrition","C15805","No value exists.","Experimental Nutrition | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937577","Trastuzumab/Hyaluronidase-oysk","C158060","A ready-to-use combination of trastuzumab, a recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2; receptor tyrosine-protein kinase erbB-2), and hyaluronidase-oysk, a recombinant human hyaluronidase PH20 (rHuPH20), that may be used for the treatment of HER2-overexpressing breast cancers. Upon subcutaneous administration, hyaluronidase-oysk temporarily breaks down the hyaluronan barrier, which decreases viscosity of, and allows trastuzumab to spread rapidly through the interstitial space. This improves access to lymphatic and capillary vessels and facilitates the absorption of trastuzumab into the bloodstream. Trastuzumab binds to the extracellular ligand-binding domain of HER2 and mediates the activation of an antibody-dependent cell-mediated cytotoxicity (ADCC) against HER2-expressing tumor cells. HER2 is overexpressed in many adenocarcinomas, particularly breast adenocarcinomas.","Trastuzumab/Hyaluronidase-oysk | Herceptin Hylecta | Trastuzumab and Hyaluronidase | Trastuzumab and Hyaluronidase-oysk | Trastuzumab and Recombinant Human Hyaluronidase PH20 | Trastuzumab and hyaluronidase | Trastuzumab and rHuPH20 | Trastuzumab-Hyaluronidase-oysk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937746","Adhesion Performance Study","C158283","A type of study designed to evaluate the strength of the bond between an adhesive and the application surface.","Adhesion Performance Study | ADHESION PERFORMANCE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562765","del(3p13-14)","C155906","A cytogenetic abnormality that refers to deletion of chromosome bands 13-14 on the short arm of chromosome 3.","del(3p13-14) | del(3)(p13;p14)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562766","Monoclonal Microbial EDP1503","C155907","An orally available preparation derived from a single clone of Bifidobacterium spp. with potential immunomodulatory and antineoplastic activities. Upon oral administration, monoclonal microbial EDP1503 colonizes the gut and may, through a not yet fully elucidated mechanism, promote the activation of dendritic cells (DCs), and enhance the induction and infiltration of cytotoxic T-lymphocytes (CTLs) in the tumor microenvironment (TME). Bifidobacterium is a genus of anaerobic, Gram-positive bacteria, with some species being a commensal part of the human gastrointestinal tract and vaginal flora.","Monoclonal Microbial EDP1503 | BIFIDOBACTERIUM ANIMALIS LACTIS EDP-1503 | BIFIDOBACTERIUM ANIMALIS LACTIS EDP1503 | EDP 1503 | EDP-1503 | EDP1503",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562767","Metastatic Lung Adenocarcinoma","C155908","Lung adenocarcinoma that has spread from its original site of growth to another anatomic site.","Metastatic Lung Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562768","Autologous Anti-mesothelin CAR-CD3zeta-4-1-BB-expressing T-cells","C155909","A preparation of autologous T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-mesothelin M5 single chain variable fragment (scFv) fused to the costimulatory domains of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), with potential immunomodulating and antineoplastic activities. After isolation, transduction, expansion in culture and reintroduction into the patient, the autologous anti-mesothelin CAR-CD3zeta-4-1BB-expressing T-cells specifically target and induce selective toxicity in mesothelin-expressing tumor cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types.","Autologous Anti-mesothelin CAR-CD3zeta-4-1-BB-expressing T-cells | Autologous Anti-mesothelin CAR-CD3zeta-4-1-BB-expressing T-lymphocytes | Hu-CART-meso cells | Mesothelin-specific CAR T-cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562790","Smoldering Waldenstrom Macroglobulinemia","C155910","Waldenstrom macroglobulinemia with serum IgM monoclonal protein equal or more than 3 g/dL and/or at least 10% bone marrow lymphoplasmacytic infiltration but no evidence of constitutional symptoms, symptomatic anemia, or hyperviscosity. (Blood 2008, 112:2709)","Smoldering Waldenstrom Macroglobulinemia | Asymptomatic Waldenstrom Macroglobulinemia | Smoldering (Asymptomatic) Waldenstrom Macroglobulinemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562791","Bone Marrow Lymphoplasmacytic Infiltrate","C155911","A morphologic finding indicating the presence of a lymphoplasmacytic infiltrate in a bone marrow specimen.","Bone Marrow Lymphoplasmacytic Infiltrate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562789","Metastatic Malignant Neoplasm in the Thoracic Cavity","C155919","A malignant neoplasm that has spread to the thoracic cavity from another anatomic site.","Metastatic Malignant Neoplasm in the Thoracic Cavity | Metastatic Malignant Neoplasm in the Thorax",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281659","Prevention of Ovarian Cancer","C15591","No value exists.","Prevention of Ovarian Cancer | Ovarian Cancer Prevention",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937688","Autologous Deep IL-15 Primed T-cells TRQ15-01","C158091","A preparation of genetically modified, multi-antigen-directed autologous T-lymphocytes, that have particles, consisting of multiple chemically crosslinked human cytokine interleukin-15 (IL-15)/IL-15 receptor alpha (IL-15Ra)/Fc heterodimers, attached to their surface, with potential immunostimulating and antineoplastic activities. TRQ15-01 is made from monocyte-derived dendritic cells (moDCs) that are pulsed with peptides from multiple tumor-associated antigens (TAAs) to expand cytotoxic T-lymphocytes (CTLs) that are subsequently loaded with IL-15 particles. Upon administration of the autologous deep IL-15 primed T-cells, the IL-15/IL-15Ra fusion proteins are slowly released in vivo from the T-cells in a controlled manner and induce autocrine cytokine stimulation of the administered T-cells, thereby increasing T-cell division of the administered T-cells. The expanded T-cells target, bind to and kill tumor cells. This increases tumor cell growth inhibition by T-cells. IL-15 is a pro-survival, inflammatory cytokine and causes sustained T-cell expansion and enhanced anti-tumor activity. Compared to systemically delivered IL-15, IL-15 attached to the T-cells greatly increases target CD8 T-cell concentrations in the tumor, without significant systemic effects.","Autologous Deep IL-15 Primed T-cells TRQ15-01 | IL-15 Loaded Autologous T-lymphocytes TRQ15-01 | TRQ15-01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937685","Spirulina-based Dietary Supplement","C158092","A nutritional supplement composed of the blue-green microalgae spirulina. Spirulina is high in protein and contains significant amounts of calcium, niacin, potassium, magnesium, B vitamins, vitamin E, iodine, iron, beta-carotene, phycocyanin and chlorophyll. The spirulina dietary supplement may affect the cardiovascular, digestive and immune systems and may improve diabetes and high cholesterol. In addition, spirulina contains antioxidants and may protect against cellular DNA damage by reactive oxygen species (ROS). As spirulina has a high concentration of iodine and contains the amino acid tyrosine, it may improve thyroid function, and ameliorate the size of benign thyroid nodules.","Spirulina-based Dietary Supplement | Blue-green Algae Supplement | Spirulina-based Supplement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937686","BOS 172738","C158093","An orally bioavailable selective inhibitor of wild-type, fusion products and mutated forms, including gatekeeper mutations, of the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET), with potential antineoplastic activity. Upon oral administration, zeteletinib selectively binds to and inhibits the activity of RET. This results in an inhibition of cell growth of tumors cells that exhibit increased RET activity. RET overexpression, activating mutations, and fusions result in the upregulation and/or overactivation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role in the development and progression of these cancers.","Zeteletinib | BOS 172738 | BOS-172738 | BOS172738 | CAXM-1190B | DS 5010 | DS 5010B | DS-5010 | DS-5010B | DS5010 | DS5010B | RET Inhibitor DS-5010 | ZETELETINIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937683","Cinnamomum cassia Capsules","C158094","A nutritional supplement composed of the blue-green microalgae spirulina. Spirulina is high in protein and contains significant amounts of calcium, niacin, potassium, magnesium, B vitamins, vitamin E, iodine, iron, beta-carotene, phycocyanin and chlorophyll. The spirulina dietary supplement may affect the cardiovascular, digestive and immune systems and may improve diabetes and high cholesterol. In addition, spirulina contains antioxidants and may protect against cellular DNA damage by reactive oxygen species (ROS). As spirulina has a high concentration of iodine and contains the amino acid tyrosine, it may improve thyroid function, and ameliorate the size of benign thyroid nodules.","Cinnamomum cassia Capsules | Cinnamomum aromaticum Bark Capsules",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937681","D3-ENT","C158096","A deuterated form of enzalutamide, an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Upon administration, deutenzalutamide competitively binds to and inhibits the activity of ARs expressed on prostate cancer cells, which impairs nuclear translocation and DNA binding, resulting in apoptosis of prostate cancer cells. This results in a reduction in prostate cancer cell growth. AR overexpression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance. Deuterium incorporation, by replacing the hydrogen atoms of the N-CH3 moiety with deuterium atoms, decreases enzalutamide's metabolism and allows for an increased pharmacokinetic profile, thereby enhancing its anti-tumor efficacy compared to non-deuterated enzalutamide. As the deuterated form can't cross the blood-brain barrier (BBB), the deutenzalutamide form also reduces the unwanted brain-related side effects of enzalutamide and improves its safety profile.","Deutenzalutamide | D3-ENT | DEUTENZALUTAMIDE | Deuterated Enzalutamide | Deuterated Enzalutamide | Enzalutamide Deuterated | HC 1119 | HC-1119 | HC1119 | N-trideuteromethyl Enzalutamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937682","Recombinant Bovine Basic Fibroblast Growth Factor","C158097","A recombinant form of bovine basic fibroblast growth factor (rb-bFGF), with cell growth stimulating activity. bFGF is a multifunctional cell growth factor that stimulates the growth of cells derived from mesodermal and neuroectodermal cells. Upon administration, rb-bFGF induces cellular proliferation and differentiation, promotes tissue repair and reconstruction. rb-bFGF may improve chemotherapy- or radiotherapy-induced oral mucositis.","Recombinant Bovine Basic Fibroblast Growth Factor | rb-bFGF",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938025","OXCT1 wt Allele","C158469","Human OXCT1 wild-type allele is located in the vicinity of 5p13.1 and is approximately 141 kb in length. This allele, which encodes succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial protein, is involved in ketone body metabolism. Loss of function mutations in the gene are associated with succinyl-CoA:3-oxoacid-CoA transferase deficiency (SCOTD).","OXCT1 wt Allele | 3-Oxoacid CoA-Transferase 1 wt Allele | OXCT | SCOT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938026","Succinyl-CoA:3-Ketoacid Coenzyme A Transferase 1, Mitochondrial","C158470","Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial (520 aa, ~56 kDa) is encoded by the human OXCT1 gene. This protein plays a role in the catabolism of ketone bodies.","Succinyl-CoA:3-Ketoacid Coenzyme A Transferase 1, Mitochondrial | 3-Oxoacid CoA Transferase | 3-Oxoacid CoA Transferase 1 | 3-Oxoacid CoA-Transferase 1 | EC 2.8.3.5 | OXCT1 | SCOT-s | Somatic-Type Succinyl-CoA:3-Oxoacid CoA-Transferase | Succinyl CoA:3-Oxoacid CoA Transferase | Succinyl CoA:3-Oxoacid-CoA Transferase | Succinyl-CoA:3-Ketoacid-CoA Transferase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938023","10/10 HLA Match","C158471","Complete HLA matching for HLA-A, -B, -C, -DRB1, and -DQB1 loci.","10/10 HLA Match | HLA Match 10/10 | Match 10/10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938024","12/12 HLA Match","C158472","Complete HLA matching for HLA-A,-B,-C,-DRB1,-DQB1, and -DP loci.","12/12 HLA Match | HLA Match 12/12 | Match 12/12",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950641","Preoperative Karnofsky Performance Status","C158661","The Karnofsky Performance Status Score assessed preoperatively.","Preoperative Karnofsky Performance Status | Performance Status Score Karnofsky Score (Preoperative)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950642","Preoperative ECOG - Performance Status","C158662","The ECOG Performance Status Score assessed preoperatively.","Preoperative ECOG - Performance Status | Performance Status Score: Eastern Cooperative Oncology Group (ECOG) (Preoperative)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950756","Prostate Adenocarcinoma with Paneth Cell-Like Neuroendocrine Differentiation","C158664","A prostate adenocarcinoma characterized by the presence of cells with eosinophilic cytoplasmic granules that are positive for neuroendocrine markers by immunohistochemistry.","Prostate Adenocarcinoma with Paneth Cell-Like Neuroendocrine Differentiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938103","Alcohol Effect Study","C158284","A type of study designed to evaluate the effects of alcohol on drug safety and efficacy.","Alcohol Effect Study | ALCOHOL EFFECT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938153","Device-Drug Interaction Study","C158285","A type of study designed to evaluate the interaction between a device and a drug, where the use of one may affect the disposition, function, efficacy, or safety of the other.","Device-Drug Interaction Study | DEVICE-DRUG INTERACTION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL493279","Drug-Drug Interaction Study","C158286","A type of study designed to evaluate the interaction between drugs, where the use of one may affect the disposition, efficacy, or safety of the other.","Drug-Drug Interaction Study | DRUG-DRUG INTERACTION",,,,,,,,,,,,,,,"4230596","Drug interaction with drug",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937744","Thorough QT Study","C158287","A type of study designed to evaluate the potential for an experimental drug to delay cardiac ventricular repolarization.","Thorough QT Study | THOROUGH QT | TQT Study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937745","Biosimilarity Study","C158288","A type of study designed to evaluate whether a biologic test article is highly similar in function and effect to an existing biologic that has already been clinically tested and approved for use.","Biosimilarity Study | BIOSIMILARITY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937742","Dose Finding Study","C158289","An early phase clinical study with the objective of determining the optimal therapeutic dose of a drug.","Dose Finding Study | DOSE FINDING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518668","Other Resources","C15828","Resources (facilities, collections, software, information sources, etc.) available to researchers that are not listed in other concepts of Research Resources tree of NCI Metathesaurus.","Other Resources | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937743","Dose Proportionality Study","C158290","A type of study designed to evaluate the relationship between dose and resulting exposure.","Dose Proportionality Study | DOSE PROPORTIONALITY",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937788","Challenge Agent Category","C158298","A general classification of the challenge agent used in the study model.","Challenge Agent Category | CAGTCAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937785","Multiple Challenge Agent Different Category Indicator","C158299","An indication as to whether the subject was challenged with more than one challenge agent from a different challenge agent category.","Multiple Challenge Agent Different Category Indicator | MCCATIND | Multiple Challenge Agent Category Ind | Multiple Challenge Agent Category Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518680","Outcomes and Health Services Research","C15829","Research to evaluate the delivery systems, processes, and impacts of evidence-based clinical interventions in communities.","Outcomes and Health Services Research | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556003","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Taking a Shower Why Not","C155505","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Taking a shower. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Taking a Shower Why Not | FAC100-Sev: Taking a Shower Why Not | FAC10024",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556009","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Putting on Socks Why Not","C155507","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Putting on socks or stockings. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Putting on Socks Why Not | FAC100-Sev: Putting on Socks Why Not | FAC10026",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556006","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Standing 5 Minutes","C155508","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Standing for at least 5 minutes.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Standing 5 Minutes | FAC100-Sev: Standing 5 Minutes | FAC10027",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556007","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Standing 5 Minutes Why Not","C155509","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Standing for at least 5 minutes. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Standing 5 Minutes Why Not | FAC100-Sev: Standing 5 Minutes Why Not | FAC10028",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0281186","Screening for Prostate Cancer","C15550","No value exists.","Screening for Prostate Cancer | early detection of prostate cancer | prostate cancer early detection | prostate cancer screening",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556012","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking 10 Steps","C155510","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking 10 steps/paces on flat ground at a normal speed without stopping.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking 10 Steps | FAC100-Sev: Walking 10 Steps | FAC10029",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556013","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking 10 Steps Why Not","C155511","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking 10 steps/paces on flat ground at a normal speed without stopping. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking 10 Steps Why Not | FAC100-Sev: Walking 10 Steps Why Not | FAC10030",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556010","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking 1/2 Mile","C155512","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking 1/2 mile (almost 1 km) on flat ground at a normal speed without stopping.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking 1/2 Mile | FAC100-Sev: Walking 1/2 Mile | FAC10031",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556011","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking 1/2 Mile Why Not","C155513","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking 1/2 mile (almost 1 km) on flat ground at a normal speed without stopping. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking 1/2 Mile Why Not | FAC100-Sev: Walking 1/2 Mile Why Not | FAC10032",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556016","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking Up 5 Stairs","C155514","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking up 5 stairs without stopping.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking Up 5 Stairs | FAC100-Sev: Walking Up 5 Stairs | FAC10033",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937949","Efficacy Study With Post-Exposure Prophylaxis","C158357","A study that assesses the efficacy of prophylactic treatment given after exposure to the agent(s) but before the manifestation of the disease or condition.","Efficacy Study With Post-Exposure Prophylaxis | EFFICACY, POST-EXPOSURE PROPHYLAXIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937950","Efficacy Study With Post-Exposure Radiomitigation","C158358","A study that assesses the efficacy of a radiomitigator given after exposure to the challenge agent(s) but before the manifestation of the disease or condition.","Efficacy Study With Post-Exposure Radiomitigation | EFFICACY, POST-EXPOSURE RADIOMITIGATION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938141","Draft Study Report","C158359","A preliminary version of the final study report.","Draft Study Report | DRAFT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519044","Phase I and II Vaccine Trials","C15835","Select candidate vaccines or concepts suitable for Phase I and Phase II trials and conduct these trials.","Phase I and II Vaccine Trials | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938099","Final Study Report","C158361","A report that is conclusive in its process or progression and which has been signed by the study director.","Final Study Report | FINAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937947","Amended Final Study Report","C158362","A study report that has been signed by the study director and has been changed by correction, addition, substitution or omission.","Amended Final Study Report | AMENDED FINAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937945","Antimicrobial or Acidified/Chlorinated Water During Husbandry Indicator","C158363","An indication as to whether the animal received antimicrobials or acidified/chlorinated water during husbandry.","Antimicrobial or Acidified/Chlorinated Water During Husbandry Indicator | AACHIND | Antimicrobial Acidified/Chlor H20 Ind | Antimicrobial or Acidified/Chlorinated Water At Test Facility Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937946","Study Report Status","C158364","The status of the study report with respect to the completeness and validity/version of the datasets.","Study Report Status | STRPSTAT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937943","Excluded Pathogen","C158365","The type of pathogen that an animal is verified to be free of.","Excluded Pathogen | PATHEX | Pathogen Exclusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937944","Pathogen Exclusion Verification Method","C158366","The technique by which the vendor or sponsor ensures that the animals are free from specified pathogens.","Pathogen Exclusion Verification Method | PATHEXVM",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937941","Qualified Animal Model Use Indicator","C158367","An indication as to whether the study was performed using a qualified animal model.","Qualified Animal Model Use Indicator | AMQPIND | FDA Qualified Animal Model Indicator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937939","Genetically Modified Subject Indicator","C158369","An indication as to whether the study or set contains test subjects that have been genetically modified in some way (e.g., transgenic knock-in, knock-down, etc.).","Genetically Modified Subject Indicator | GMSIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514515","Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial","C15836","The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, or PLCO Trial, is a large-scale study to determine if certain tests will reduce the number of deaths from these cancers.  Sponsored by the National Cancer Institute (NCI), the study will involve 148,000 men and women ages 55 through 74 at medical facilities in 9 geographic areas across the United States.  (Cancer Facts Screening: Questions and Answers About the PLCO Cancer Screening Trial)","Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial | PLCO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937940","Pharmacokinetic Analysis Indicator","C158370","An indication as to whether the study includes a pharmacokinetic assessment.","Pharmacokinetic Analysis Indicator | PKANIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937937","Challenge Agent Multiple Route Indicator","C158371","An indication as to whether the challenge agent is administered by more than one route for any animal(s).","Challenge Agent Multiple Route Indicator | CAMRTIND",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937938","Toxicological Dose Descriptor","C158372","A statistically derived estimate of a dose with a certain toxicological or physiologic effect in a population, based on data from a dose-response study.","Toxicological Dose Descriptor | TDOSD | Toxic/Physiologic Dose Descr | Toxicologic/Physiologic Dose Description",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519891","Vaccine Development, AIDS","C15866","Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent AIDS. Some vaccines containing antigens are recombinantly produced.","Vaccine Development, AIDS | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950764","DCLK1 wt Allele","C158673","Human DCLK1 wild-type allele is located in the vicinity of 13q13.3 and is approximately 363 kb in length. This allele, which encodes serine/threonine-protein kinase DCLK1 protein, plays a role in neuronal development and migration, microtubule polymerization and retrograde vesicle transport.","DCLK1 wt Allele | CL1 | CLICK1 | DCAMKL1 | DCDC3A | DCLK | Doublecortin Like Kinase 1 wt Allele | KIAA0369",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950765","DCLK1 protein, human","C158674","Serine/threonine-protein kinase DCLK1 (740 aa, ~82 kDa) is encoded by the human DCLK1 gene. This protein is involved in neurogenesis, neuronal migration, microtubule polymerization and retrograde transport.","Serine/Threonine-Protein Kinase DCLK1 | CAMK-Like CREB Regulatory Kinase 1 | DCLK1 | Doublecortin Domain-Containing Protein 3A | Doublecortin Like Kinase 1 | Doublecortin and CaM Kinase-Like 1 | Doublecortin- and Calmodulin Kinase-Like 1 | Doublecortin- and Calmodulin Kinase-Like 1 Protein | Doublecortin-Like Kinase 1 | Doublecortin-Like and CAM Kinase-Like 1 | EC 2.7.11.1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937626","Tear Duct Surgery","C157999","A surgical procedure on the tear ducts of the eye.","Tear Duct Surgery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511889","Diagnostics, Cancer","C15799","Reagents and techniques used for the diagnosis of cancer.","Diagnostics, Cancer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0282042","Eflornithine Hydrochloride","C1579","The hydrochloride form of eflornithine, a difluoromethylated ornithine compound with antineoplastic activity.  Eflornithine irreversibly inhibits ornithine decarboxylase, an enzyme required for polyamine biosynthesis, thereby inhibiting the formation and proliferation of tumor cells. Polyamines are involved in nucleosome oligomerization and DNA conformation, creating a chromatin environment that stimulates neoplastic transformation of cells. (NCI04)","Eflornithine Hydrochloride | 2-(Difluoromethyl)-dl-ornithine Hydrochloride, Monohydrate | 2-Difluoromethyl-dl-ornithine, Monohydrochloride, Monohydrate | EFLORNITHINE HYDROCHLORIDE | Eflornithine hydrochloride | Eflornithine.HCl | Iwilfin | MDL 71782 | MDL-71782 | MDL71782 | Ornidyl | RMI 71782 | RMI-71782 | RMI71782 | Vaniqa | alpha-Difluoromethylornithine hydrochloride",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937570","Temporary Epidural Catheter Placement","C158000","The temporary placement of a catheter into the epidural space to deliver medications.","Temporary Epidural Catheter Placement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937571","Therapeutic Breast Surgery","C158001","A surgical procedure to remove treat disorders of the breast.","Therapeutic Breast Surgery | OR Therapeutic Procedures on Breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937569","Therapeutic Mouth Procedure","C158002","A procedure that is done to treat a condition in the mouth.","Therapeutic Mouth Procedure | Therapeutic Procedures on Mouth",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0947825","Therapeutic Muscle Procedure","C158003","A procedure that is done to treat a condition in the muscle.","Therapeutic Muscle Procedure | Therapeutic Procedures on Muscle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937567","Therapeutic Nervous System Procedures","C158004","A procedure that is done to treat a nervous system disorder.","Therapeutic Nervous System Procedures | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937565","Therapeutic Pharynx Procedure","C158006","A procedure that is done to treat a condition in the pharynx.","Therapeutic Pharynx Procedure | Therapeutic Procedures on Pharynx",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937566","Therapeutic Procedures on Bone","C158007","A procedure that is done to treat a condition in the bones.","Therapeutic Procedures on Bone | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514711","Low-LET Radiotherapy","C15850","Radiotherapy using radioactive particles that deposit a low amount of energy by radiation per unit length of travel.","Low-LET Radiotherapy | Radiotherapy, Low LET | Radiotherapy, Low Linear Energy Transfer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938051","S 65487","C158510","An inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon intravenous administration, Bcl-2 inhibitor VOB560 binds to and inhibits the activity of Bcl-2, thereby restoring apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in many cancer types and plays an important role in the negative regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival.","BCL2 Inhibitor VOB560 | Bcl-2 Inhibitor S65487 | S 65487 | S-65487 | S65487 | VOB 560 | VOB-560 | VOB560",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563467","Polidocanol","C158511","An alkyl polyglycol ether of lauryl alcohol with sclerosing and potential antineoplastic activities. Upon intralesional administration, polidocanol induces endothelial cell injury by disrupting calcium signaling and nitric oxide pathways. Following endothelial damage, platelets aggregate at the site of injury and attach to the venous wall, resulting in a dense network of platelets, cellular debris, and fibrin that occludes the vessel. Inducing endothelial cell damage within melanoma metastases may incite an antitumor response in untreated bystander lesions and inhibit the growth of in transit metastases and other cutaneous lesions.","Polidocanol | Aethoxysklerol | Asclera | Dodecylnonaoxyethylene Glycol Monoether | Laureth 9 | Laureth-9 | Lauromacrogol 400 | Nonaethylene Glycol Monododecyl Ether | POLIDOCANOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938049","Radium bromatum","C158512","An orally available homeopathic preparation with potential radioprotective activities. Upon administration, radium bromatum may reduce the occurrence of, and ameliorate the symptoms associated with radiation-induced dermatitis.","Radium bromatum | RADIUM BROMIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938047","Anti-c-Met Antibody-drug Conjugate TR1801","C158513","An antibody-drug conjugate (ADC) consisting of a non-agonizing anti-c-Met humanized monoclonal antibody that is linked in a site-specific manner to a pyrrolobenzodiazepine dimer (PBD) toxin, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety targets and binds to the c-Met protein, which is overexpressed in certain tumor types. Upon antibody/antigen binding and internalization, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of tumor cell DNA. This induces interstrand cross-links in the minor groove of DNA and inhibits DNA replication, which inhibits the proliferation of c-Met-expressing cells. c-Met, also known as hepatocyte growth factor receptor (HGFR), is a receptor tyrosine kinase that is overexpressed or mutated in many tumor cell types and plays a key role in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.","Anti-c-Met Antibody-drug Conjugate TR1801 | Anti-c-Met ADC TR1801 | MT 8633 | MT-8633 | TR 1801 | TR-1801 | TR1801",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938048","Microtransplantation","C158514","A treatment that uses chemotherapy followed by adoptive infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells to boost autologous immune activity.","Microtransplantation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938045","Eicosapentaenoic Acid Monoacylglyceride","C158515","An eicosapentaenoic acid derivative with potential antineoplastic activities. Upon oral administration, eicosapentaenoic acid monoacylglyceride (MAG-EPA) may inhibit epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR) and serine/threonine protein kinase AKT (protein kinase B)-mediated signaling pathways and reduce vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 1-alpha (HIF1-alpha) expression levels in tumor cells. This may promote apoptosis and inhibit tumor cell growth in cells expressing EGFR, AKT, and VEGFR. MAG-EPA may also inhibit androgen-stimulated tumor cell growth and repress androgenic induction of prostate-specific antigen (PSA) expression. PSA, a tumor associated antigen (TAA), is expressed by prostate epithelial cells and is overexpressed in prostate cancer. The AKT signaling pathway is often dysregulated in cancer and is associated with tumor cell proliferation, survival and migration. EGFR and VGFR are receptor tyrosine kinases that are mutated or upregulated in many tumor cell types and play a key role in tumor cell proliferation and tumor vascularization.","Eicosapentaenoic Acid Monoacylglyceride | MAG-EPA | Monoglyceride Eicosapentaenoic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938046","RASSF7 Gene","C158516","This gene plays a role in the negative regulation of stress-induced apoptosis.","RASSF7 Gene | RASSF7 | Ras Association Domain Family Member 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978084","Organization Staff Role Effective Date Range","C164886","No value exists.","Organization Staff Role Effective Date Range | OrganizationStaffRole.effectiveDateRange",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978057","Performed Administrative Activity Variance Reason Code","C164913","No value exists.","Performed Administrative Activity Variance Reason Code | PerformedAdministrativeActivity.varianceReasonCode",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556017","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking Up 5 Stairs Why Not","C155515","Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking up 5 stairs without stopping. Please indicate why you did not do this in the past 7 days.","FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking Up 5 Stairs Why Not | FAC100-Sev: Walking Up 5 Stairs Why Not | FAC10034",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562853","ADC BA3011","C156141","An antibody-drug conjugate (ADC) composed of a conditionally active biologic (CAB) antibody against AXL receptor tyrosine kinase (AXL; UFO) conjugated to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of mecbotamab vedotin, the anti-AXL antibody becomes activated through an as of yet not fully elucidated process only under the unique microphysical conditions that are present in the tumor microenvironment (TME) as a result of the glycolytic metabolism of cancer cells, and not in the microenvironment of normal, healthy tissues. Upon selective binding to AXL-expressing tumor cells and internalization, the cytotoxic agent kills the tumor cells through an as of yet undisclosed mechanism of action (MoA). AXL, a member of the TAM (TYRO3, AXL and MER) family of receptor tyrosine kinases normally expressed on many normal, healthy cells and overexpressed by many tumor cell types, plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance and poor prognosis. The CAB antibody allows for efficient and reversible binding to AXL-expressing tumor cells under conditions that are present only in the TME, thereby maximizing efficacy while minimizing toxicity by avoiding activation and thus binding of the antibody to normal, healthy AXL-expressing cells under normal conditions.","Mecbotamab Vedotin | ADC BA3011 | BA 3011 | BA-3011 | BA3011 | CAB Anti-AXL ADC BA3011 | CAB-AXL-ADC BA3011 | Conditionally Active Biologic Anti-AXL Antibody-drug Conjugate BA3011 | MECBOTAMAB VEDOTIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562876","CREB3L2/PPARG Fusion Gene","C156142","A fusion gene that results from a chromosomal translocation t(3;7)(p25;q34) which fuses exon 1 and 2 of the CREB3L2 gene with exons 1-6 of the PPARG gene. This rearrangement is associated with thyroid follicular carcinoma.","CREB3L2/PPARG Fusion Gene | CREB3L2-PPARG Fusion Gene | CREB3L2-PPARgamma Fusion Gene | CREB3L2/PPARgamma Fusion Gene | CREB3L2::PPARG Fusion Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562877","CREB3L2/PPARG Fusion Protein","C156143","A fusion protein encoded by the CREB3L2/PPARG fusion gene. This protein is comprised of the first 106 amino acids of the N-terminal DNA binding domain of cyclic AMP-responsive element-binding protein 3-like protein 2, including most of the transactivation domain, and the entire peroxisome proliferator-activated receptor gamma protein, including the ligand binding, DNA binding and activation domains.","CREB3L2/PPARG Fusion Protein | CREB3L2-PPARG Fusion Protein | CREB3L2-PPARgamma Fusion Protein | CREB3L2/PPARgamma Fusion Protein | CREB3L2::PPARG Fusion Protein | Cyclic AMP-Responsive Element-Binding Protein 3-Like Protein 2/Peroxisome Proliferator-Activated Receptor Gamma Fusion Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937935","Factor for Toxicological Dose Descriptor","C158373","The quantity given for the multiplier of the toxicological dose descriptor","Factor for Toxicological Dose Descriptor | FTDOSD | Factor for Toxic/Physiologic Dose Descr | Factor for Toxicologic/Physiologic Dose Description",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937936","Bladder Non-Invasive Urothelial Neoplasm","C158374","A non-invasive neoplasm that arises from the urothelial lining of the bladder.","Bladder Non-Invasive Urothelial Neoplasm | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938006","TMEM74B wt Allele","C158555","Human TMEM74B wild-type allele is located in the vicinity of 20p13 and is approximately 8 kb in length. This allele, which encodes transmembrane protein 74B, may play a role in autophagy.","TMEM74B wt Allele | C20orf46 | Chromosome 20 Open Reading Frame 46 Gene | FLJ11190 | Transmembrane Protein 74B wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938007","Transmembrane Protein 74B","C158556","Transmembrane protein 74B (256 aa, ~28 kDa) is encoded by the human TMEM74B gene. This protein may be involved in autophagy.","Transmembrane Protein 74B | TMEM74B | Transmembrane Protein C20orf46",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938004","AGEN 1181","C158557","An Fc-engineered recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA-4 monoclonal antibody  botensilimab binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system. The engineered Fc domain increases the stability and half-life of the antibody.","Botensilimab | AGEN 1181 | AGEN-1181 | AGEN1181 | Anti-CTLA-4 Monoclonal Antibody AGEN1181 | BOTENSILIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938005","Allogeneic Anti-CD19-CAR T-lymphocytes PBCAR0191","C158558","A preparation of allogeneic, off-the-shelf, T-lymphocytes that have been genetically modified using a proprietary synthetic nuclease-based system to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 (cluster of differentiation 19) with potential immunostimulating and antineoplastic activities. Upon administration, azercabtagene zapreleucel specifically recognize and kill CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen, which is expressed in all B-cell lineage malignancies and normal B-cells.","Azercabtagene Zapreleucel | AZERCABTAGENE ZAPRELEUCEL | Allogeneic Anti-CD19-CAR T-cells PBCAR0191 | Allogeneic Anti-CD19-CAR T-lymphocytes PBCAR0191 | Anti-CD19-CAR Allogeneic T-cells PBCAR0191 | PBCAR0191",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938002","MUC6 Gene","C158559","This gene is involved in the lubrication of the gastrointestinal tract.","MUC6 Gene | MUC6 | Mucin 6, Oligomeric Mucus/Gel-Forming Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514956","State Cancer Legislative Database","C15855","The SCLD maintains information about state legislation and regulation addressing cancer-related topics, including tobacco, breast cancer, genetics, cervical cancer, prostate cancer, testicular cancer, colon cancer, ovarian cancer, access to state-of-the-art cancer treatment, cancer registries, and selected issues related to diet and nutrition, employment discrimination, environmental exposure, and occupational exposure.  The purpose of the SCLD is threefold; it provides necessary information: 1) for evaluating the effect of state legislation on public health and on the application of cancer control science, 2) for facilitating the application of cancer control science, and 3) for monitoring legislative trends that may reflect changing public attitudes and practices. (State Cancer Legislative Database Program)","State Cancer Legislative Database | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938003","MUC6 wt Allele","C158560","Human MUC6 wild-type allele is located in the vicinity of 11p15.5 and is approximately 24 kb in length. This allele, which encodes mucin-6 protein, plays a role in the formation of a protective layer of mucus in the gastrointestinal tract.","MUC6 wt Allele | MUC-6 | Mucin 6, Gastric Gene | Mucin 6, Oligomeric Mucus/Gel-Forming wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1742905","MUC6 protein, human","C158561","Mucin-6 (2439 aa, ~257 kDa) is encoded by the human MUC6 gene. This protein is involved in protection of the epithelial surfaces of the gastrointestinal system.","Mucin-6 | Gastric Mucin-6 | MUC-6 | MUC6 | Mucin 6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938001","MUC5B Gene","C158562","This gene is involved in salivary and cervical mucus lubricating activity.","MUC5B Gene | MUC5B | Mucin 5B, Oligomeric Mucus/Gel-Forming Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937564","Therapeutic Skin Surgery","C158008","A surgical procedure to remove treat disorders of the skin.","Therapeutic Skin Surgery | OR Therapeutic Procedures on Skin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0947834","Therapeutic Tendon Procedure","C158009","A procedure that is done to treat a condition in the tendons.","Therapeutic Tendon Procedure | Therapeutic Procedures on Tendon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512068","Drug Development, Clinical","C15800","Drug development activites focused on clinical trials and testing.","Drug Development, Clinical | Drug Testing/Development, Clinical",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937562","Therapeutic Upper Gastrointestinal Procedures","C158010","A procedure that is done to treat a condition in upper gastrointestinal tract.","Therapeutic Upper Gastrointestinal Procedures | Upper GI Therapeutic Procedure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937563","Thoracic Aortic Aneurysm Open Repair","C158011","A surgical procedure to treat a thoracic aortic aneurysm via the traditional open incision method.","Thoracic Aortic Aneurysm Open Repair | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937560","Thyroid Cancer Surgery","C158012","A surgical procedure to remove cancer from the thyroid.","Thyroid Cancer Surgery | Surgery for Thyroid Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937558","Topical Medications for Melanoma","C158014","Medications that are applied to the skin for melanoma.","Topical Medications for Melanoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937559","Topical Medications for Non-Melanoma","C158015","Medications that are applied to the skin for non-melanoma lesions.","Topical Medications for Non-Melanoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C2144940","Total Disc Replacement","C158016","A surgical procedure to replace a vertebral disc.","Total Disc Replacement | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0186657","Total Shoulder Replacement","C158017","Surgical replacement of the shoulder joint with a metal ball attached to a stem and a plastic socket.","Total Shoulder Replacement | ",,,,,,,,,,,,,,,"4172500","Total shoulder replacement",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1518500","Nutrition Research, Applied Non-Clinical Trials","C15822","No value exists.","Nutrition Research, Applied Non-Clinical Trials | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519898","Vaccine Related Non-Development, AIDS","C15871","No value exists.","Vaccine Related Non-Development, AIDS | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950747","LHCGR Gene Mutation","C158720","A change in the nucleotide sequence of the LHCGR gene.","LHCGR Gene Mutation | HHG Gene Mutation | LCGR Gene Mutation | LGR2 Gene Mutation | LH/CG-R Gene Mutation | LH/CGR Gene Mutation | LHR Gene Mutation | LHRHR Gene Mutation | LSH-R Gene Mutation | Luteinizing Hormone/Choriogonadotropin Receptor Gene Mutation | ULG5 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950748","LHCGR Missense Mutation","C158721","A point mutation in the LHCGR gene that encodes an amino acid substitution in the lutropin-choriogonadotropic hormone receptor protein.","LHCGR Missense Mutation | HHG Missense Mutation | LCGR Missense Mutation | LGR2 Missense Mutation | LH/CG-R Missense Mutation | LH/CGR Missense Mutation | LHCGR Missense Gene Mutation | LHR Missense Mutation | LHRHR Missense Mutation | LSH-R Missense Mutation | Luteinizing Hormone/Choriogonadotropin Receptor Missense Mutation | Non-synonymous LHCGR Gene Mutation | ULG5 Missense Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950749","FOXL2 Gene Mutation","C158722","A change in the nucleotide sequence of the FOXL2 gene.","FOXL2 Gene Mutation | BPES Gene Mutation | BPES1 Gene Mutation | Forkhead Box L2 Gene Mutation | PFRK Gene Mutation | PINTO Gene Mutation | POF3 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950750","Brimonidine Tartrate Nanoemulsion OCU-300","C158723","An ophthalmic nanoemulsion consisting of the tartrate salt form of brimonidine, an imidazole derivative and selective alpha-2 adrenergic receptor agonist, with potential anti-inflammatory and vasoconstrictive activities. Upon ophthalmic instillation, brimonidine tartrate nanoemulsion OCU-300 reduces intraocular pressure by promoting the outflow and decreasing the production of aqueous humor and may reduce ocular erythema through direct vasoconstriction. Additionally, brimonidine may disrupt leukocyte extravasation into the ocular tissue, inhibit nociception and reduce inflammation associated with ocular graft-versus-host disease (oGvHD). The nanoemulsion formulation may enhance distribution of brimonidine to target tissues, thereby allowing more of the active drug to reach underlying ocular tissue.","Brimonidine Tartrate Nanoemulsion OCU-300 | OCU 300 | OCU-300 | OCU300",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950751","Other Performance Status Scale: Timing","C158724","A question about what is the other performance status scale about timing.","What is the Other Performance Status Scale: Timing | Other Performance Status Scale: Timing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519899","Vaccine Related Non-Development, Non-AIDS","C15872","No value exists.","Vaccine Related Non-Development, Non-AIDS | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950699","Ocular Graft Versus Host Disease","C158730","Graft versus host disease occurring in the eye.","Ocular Graft Versus Host Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950700","Chronic Ocular Graft Versus Host Disease","C158731","Chronic graft versus host disease occurring in the eye.","Chronic Ocular Graft Versus Host Disease | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556303","KIT NM_000222.2:c.2466T>G","C155705","A nucleotide substitution at position 2466 of the coding sequence of the KIT gene where thymine has been mutated to guanine.","KIT NM_000222.2:c.2466T>G | CD117 c.2466T>G | KIT Proto-Oncogene Tyrosine Protein Kinase c.2466T>G | KIT c.2466T>G | NM_000222.2:c.2466T>G | c-KIT c.2466T>G | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.2466T>G",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556304","KIT NM_000222.2:c.2466T>A","C155706","A nucleotide substitution at position 2466 of the coding sequence of the KIT gene where thymine has been mutated to adenine.","KIT NM_000222.2:c.2466T>A | CD117 c.2466T>A | KIT Proto-Oncogene Tyrosine Protein Kinase c.2466T>A | KIT c.2466T>A | NM_000222.2:c.2466T>A | c-KIT c.2466T>A | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.2466T>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556309","KIT NM_000222.2:c.2464A>T","C155707","A nucleotide substitution at position 2464 of the coding sequence of the KIT gene where adenine has been mutated to thymine.","KIT NM_000222.2:c.2464A>T | CD117 c.2464A>T | KIT Proto-Oncogene Tyrosine Protein Kinase c.2464A>T | KIT c.2464A>T | NM_000222.2:c.2464A>T | c-KIT c.2464A>T | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.2464A>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556307","KIT NM_000222.2:c.2485G>C","C155709","A nucleotide substitution at position 2485 of the coding sequence of the KIT gene where guanine has been mutated to cytosine.","KIT NM_000222.2:c.2485G>C | CD117 c.2485G>C | KIT Proto-Oncogene Tyrosine Protein Kinase c.2485G>C | KIT c.2485G>C | NM_000222.2:c.2485G>C | c-KIT c.2485G>C | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.2485G>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937998","MUC5B wt Allele","C158563","Human MUC5B wild-type allele is located in the vicinity of 11p15.5 and is approximately 39 kb in length. This allele, which encodes mucin-5B protein, is involved in the lubrication of the mouth, airways and cervix. Mutation of the gene is associated with susceptibility to idiopathic pulmonary fibrosis.","MUC5B wt Allele | MG1 | MUC-5B | MUC5 | MUC9 | Mucin 5, Subtype B, Tracheobronchial Gene | Mucin 5B, Oligomeric Mucus/Gel-Forming wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0254452","MUC5B protein, human","C158564","Mucin-5B (5762 aa, ~596 kDa) is encoded by the human MUC5B gene. This protein plays a role in the lubricant activity and viscoelasticity of saliva and cervical mucus.","Mucin-5B | Cervical Mucin | Cervical Mucin MUC5B | High Molecular Weight Salivary Mucin MG1 | MUC-5B | MUC5B | Mucin 5B | Mucin-5 Subtype B, Tracheobronchial | Sublingual Gland Mucin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937996","TSPYL5 Gene","C158565","This gene plays a role in regulating the ubiquitination of cellular tumor antigen p53 (TP53).","TSPYL5 Gene | TSPY Like 5 Gene | TSPYL5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950676","Pathologic Width","C158774","The longest diameter of a tumor from the pathology examination of a specimen.","Pathologic Width | width of tumor | width_of_tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950677","Pathologic Depth","C158775","The longest front to back measurement of a tumor from the pathology examination of a specimen.","Pathologic Depth | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950679","Pathologic Burden of New Tumor","C158777","The estimate of the number of cells, or size of the tumor from the results of a pathology examination.","Pathologic Burden of New Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950680","Well-Differentiated or De-Differentiated New Tumor","C158778","A question about whether a new tumor is well-differentiated or de-differentiated.","Well-Differentiated or De-Differentiated New Tumor | Is the New Tumor Well-Differentiated or De-Differentiated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520161","Worksite Health Service","C15877","Clinical service at the physical site of employment.","Worksite Health Service | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950686","Canine Granular Cell Tumor","C158784","A granular cell tumor occurring in a dog.","Canine Granular Cell Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950687","Canine Langerhans Cell Histiocytosis","C158785","Langerhans cell histiocytosis occurring in a dog.","Canine Langerhans Cell Histiocytosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950688","Canine Nephroblastoma","C158786","A nephroblastoma occurring in a dog.","Canine Nephroblastoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3538946","DEAFNESS, AUTOSOMAL RECESSIVE 4, WITH ENLARGED VESTIBULAR AQUEDUCT","C158787","An autosomal recessive condition caused by mutation(s) in one of several genes, most often SLC26A4 encoding pendrin. It is characterized by  hearing loss and enlargement of the vestibular aqueduct. Mutation(s) in the SLC26A4 gene also cause Pendred syndrome.","Deafness, Autosomal Recessive 4, with Enlarged Vestibular Aqueduct | Autosomal Recessive Deafness-4 with Enlarged Vestibular Aqueduct | DFNB4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950689","Macrothrombocytopenia and Granulocyte Inclusions with or without Nephritis or Sensorineural Hearing Loss","C158788","An autosomal dominant disorder caused by mutation(s) of the MYH9 gene, encoding myosin-9. Clinical features include thrombocytopenia, giant platelets, and characteristic inclusions in peripheral blood leukocytes, and may be associated with other organ dysfunction. It comprises the Epstein syndrome, Fechtner syndrome, May-Hegglin anomaly, and Sebastian syndrome-- all of which were previously believed to be distinct entities.","Macrothrombocytopenia and Granulocyte Inclusions with or without Nephritis or Sensorineural Hearing Loss | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518501","Nutrition Research, Basic Non-Clinical Trials","C15823","No value exists.","Nutrition Research, Basic Non-Clinical Trials | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938021","9/10 HLA Match","C158473","Degree of HLA match is 9/10 for HLA-A, -B, -C, -DRB1, and -DQB1 loci.","9/10 HLA Match | HLA Match 9/10 | Match 9/10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938022","8/10 HLA Match","C158474","Degree of HLA match is 8/10 for HLA-A, -B, -C, -DRB1, and -DQB1 loci.","8/10 HLA Match | HLA Match 8/10 | Match 8/10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938019","7/10 HLA Match","C158475","Degree of HLA match is 7/10 for HLA-A, -B, -C, -DRB1, and -DQB1 loci.","7/10 HLA Match | HLA Match 7/10 | Match 7/10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938020","6/10 HLA Match","C158476","Degree of HLA match is 6/10 for HLA-A, -B, -C, -DRB1, and -DQB1 loci.","6/10 HLA Match | HLA Match 6/10 | Match 6/10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938017","5/10 HLA Match","C158477","Degree of HLA match is 5/10 for HLA-A, -B, -C, -DRB1, and -DQB1 loci.","5/10 HLA Match | HLA Match 5/10 | Match 5/10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938018","6/6 HLA Match","C158478","Complete HLA matching for HLA-A, -B and -DRB1 loci.","6/6 HLA Match | HLA Match 6/6 | Match 6/6",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL938015","Body Mass Index 25 or Greater","C158479","Indicates a body mass index measurement of 25 or higher.","Body Mass Index 25 or Greater | Body Mass Index Greater than or Equal to 25",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514692","Radiation Non-Ionizing, Radiotherapy","C15847","No value exists.","Radiation Non-Ionizing, Radiotherapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978032","Performed Imaging Study Admitting Diagnosis Code","C164938","No value exists.","Performed Imaging Study Admitting Diagnosis Code | PerformedImagingStudy.admittingDiagnosisCode",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978041","Performed Medical Condition Result Occurrence Date Range Validation Code","C164961","No value exists.","Performed Medical Condition Result Occurrence Date Range Validation Code | PerformedMedicalConditionResult.occurrenceDateRangeValidationCode",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL978035","Performed Observation Additional Qualifier","C164967","No value exists.","Performed Observation Additional Qualifier | PerformedObservation.additionalQualifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937710","Anti-FolRa ADC STRO-002","C158067","An antibody drug conjugate (ADC) composed of SP8166 (H01), an anti-folate receptor alpha (FolRa; FOLR1) human immunoglobulin G1 (IgG1) antibody, conjugated to a proprietary cleavable drug linker, SC239, containing a tubulin-targeting 3-aminophenyl hemiasterlin warhead, SC209, with potential antineoplastic activity. Upon intravenous administration, the SP8166 antibody moiety targets and binds to FolRa expressed on certain tumor cells. Upon binding, internalization, and enzymatic cleavage, the cytotoxic SC209 moiety induces tumor cell death in FolRa-expressing cells. FolRa is a glycosylphosphatidylinositol linked cell-surface glycoprotein that is widely expressed in certain cancers including serous and epithelial ovarian cancer, endometrial adenocarcinoma, non-small cell lung cancer and triple negative breast cancer. In contrast, FolRa expression is limited in normal tissues.","Luveltamab Tazevibulin | Anti-FolRa ADC STRO-002 | Anti-FolRalpha ADC STRO-002 | Anti-Folate Receptor-alpha Antibody Drug Conjugate STRO-002 | Anti-Folate Receptor-alpha Antibody Drug Conjugate STRO-002 | LUVELTAMAB TAZEVIBULIN | STRO 002 | STRO-002 | STRO002",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512356","Health and Behavior in Children","C15806","No value exists.","Health and Behavior in Children Study | Health and Behavior in Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0234119","Neuromuscular Blockade","C158070","The use of muscle relaxants to induce muscle paralysis.","Neuromuscular Blockade | NMB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556313","Anti-HER2 Monoclonal Antibody","C155711","Any monoclonal antibody that is directed against human epidermal growth factor receptor 2 (HER2; HER-2; ERBB2).","Anti-HER2 Monoclonal Antibody | Anti-ErbB2 Monoclonal Antibody | Anti-HER-2 Monoclonal Antibody",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556314","Anti-HER2 Antibody-drug Conjugate","C155712","Any antibody-drug conjugate (ADC) that is directed against the human epidermal growth factor receptor 2 (HER2; HER-2; ERBB2).","Anti-HER2 Antibody-drug Conjugate | Anti-ErbB2 ADC | Anti-HER-2 ADC | Anti-HER2 ADC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556311","Anti-CD22 Antibody-drug Conjugate","C155713","An antibody-drug conjugate (ADC) directed against the CD22 antigen.","Anti-CD22 Antibody-drug Conjugate | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556312","KIT NM_000222.2:c.2492T>C","C155714","A nucleotide substitution at position 2492 of the coding sequence of the KIT gene where thymine has been mutated to cytosine.","KIT NM_000222.2:c.2492T>C | CD117 c.2492T>C | KIT Proto-Oncogene Tyrosine Protein Kinase c.2492T>C | KIT c.2492T>C | NM_000222.2:c.2492T>C | c-KIT c.2492T>C | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.2492T>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563224","CYP2C8 Inducer","C155921","Any substance capable of increasing the activity of cytochrome P450 2C8.","CYP2C8 Inducer | Cytochrome P450 2C8 Inducer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL563227","CYP2C19 Inducer","C155922","Any substance capable of increasing the activity of cytochrome P450 2C19.","CYP2C19 Inducer | Cytochrome P450 2C19 Inducer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3850059","CYP2C19 Inhibitor","C155923","Any substance capable of decreasing the activity of cytochrome P450 2C19.","CYP2C19 Inhibitor | Cytochrome P450 2C19 Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562783","ATR Inhibitor","C155926","Any agent that inhibits the serine/threonine protein kinase ATR (ataxia telangiectasia; Rad3-related protein).","ATR Inhibitor | ATR Kinase Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL562784","Chk1 Inhibitor","C155927","Any agent that inhibits the cell cycle checkpoint kinase 1 (Chk1).","Chk1 Inhibitor | CHEK1 Inhibitor | Checkpoint Kinase 1 Inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951426","Anti-CTLA-4/Anti-LAG-3 Bispecific Monoclonal Antibody XmAb22841","C159530","An Fc-engineered bispecific antibody directed against the human negative immunoregulatory checkpoint receptors cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4) and lymphocyte activation gene 3 protein (LAG3; LAG-3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, bavunalimab targets and binds to both CTLA-4 and LAG-3 expressed on T-cells in the tumor microenvironment (TME). Both CTLA-4 and LAG-3 are inhibitory receptors and members of the immunoglobulin superfamily (IgSF); they are overexpressed by regulatory T-cells (Tregs) in the TME where they downregulate T-cell activation and proliferation. Dual checkpoint blockade of CTLA-4 and LAG-3 with XmAb22841 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone. The engineered Fc domain increases the stability and half-life of the antibody.","Pavunalimab | Anti-CTLA-4/Anti-LAG-3 Bispecific Monoclonal Antibody XmAb22841 | Anti-CTLA-4/LAG-3 Bispecific Antibody XmAb22841 | BAVUNALIMAB | Bavunalimab | CTLA-4  x LAG-3 Bispecific Antibody XmAb22841 | CTLA-4 x LAG-3 Bispecific Antibody XmAb22841 | XmAb 22841 | XmAb-22841 | XmAb22841",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951427","BRAF Inhibitor LUT014","C159531","A topically bioavailable small molecule inhibitor of serine/threonine-protein kinase B-raf (BRAF) protein with potential chemoprotective activity. Upon topical administration, BRAF inhibitor LUT014 targets and binds BRAF and, through the paradoxical effect of BRAF inhibition, induces mitogen-activated protein kinase (MAPK) signaling, which leads to the proliferation and migration of healthy human keratinocytes. This decreases dermal toxicities associated with epidermal growth factor (EGFR) inhibitor therapy. BRAF, a member of the raf family of serine/threonine protein kinases, plays a role in the regulation of MAPK/extracellular signal-regulated kinase (ERK) signaling pathways.","BRAF Inhibitor LUT014 | LUT 014 | LUT-014 | LUT014",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951428","Psychomotor Assessment","C159532","Testing designed to evaluate an individual's precision, coordination, control, dexterity, and reaction time in mechanical motor responses.","Psychomotor Assessment | Psychomotor Evaluation | Psychomotor Examination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951429","SMO Protein Inhibitor ZSP1602","C159535","An orally bioavailable small molecule SMO (Smoothened) inhibitor with potential antineoplastic activity. SMO inhibitor BMS-833923 inhibits the sonic hedgehog (SHH) pathway protein SMO, which may result in a suppression of the SHH signaling pathway.  SMO is a G-protein coupled receptor that lies just downstream of the SHH ligand cell surface receptor Patched-1 in the SHH pathway; in the absence of ligand Patched-1 inhibits SMO and ligand binding to Patched-1 results in increased levels of SMO. The SHH signaling pathway plays an important role in cellular growth, differentiation and repair; constitutive activation of this pathway is associated with uncontrolled cellular proliferation and has been observed in a variety of cancers.","SMO Protein Inhibitor ZSP1602 | Smoothened Inhibitor ZSP1602 | ZSP 1602 | ZSP-1602 | ZSP1602",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950790","KIT NM_000222.2:c.1669T>C","C158898","A nucleotide substitution at position 1669 of the coding sequence of the KIT gene where thymine has been mutated to cytosine.","KIT NM_000222.2:c.1669T>C | CD117 c.1669T>C | KIT Proto-Oncogene Tyrosine Protein Kinase c.1669T>C | KIT c.1669T>C | NM_000222.2:c.1669T>C | c-KIT c.1669T>C | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.1669T>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950791","KIT NP_000213.1:p.L576P","C158899","A change in the amino acid residue at position 576 in the mast/stem cell growth factor receptor Kit protein where leucine has been replaced by proline.","KIT NP_000213.1:p.L576P | CD117 Antigen L576P | CD117 Antigen Leu576Pro | KIT L576P | KIT Leu576Pro | KIT NP_000213.1:p.Leu576Pro | KIT p.L576P | KIT p.Leu576Pro | Mast/Stem Cell Growth Factor Receptor Kit L576P | Mast/Stem Cell Growth Factor Receptor Kit Leu576Pro | NP_000213.1:p.L576P | NP_000213.1:p.Leu576Pro | Proto-Oncogene Tyrosine-Protein Kinase Kit L576P | Proto-Oncogene Tyrosine-Protein Kinase Kit Leu576Pro | Proto-Oncogene c-Kit L576P | Proto-Oncogene c-Kit Leu576Pro | Stem Cell Factor Receptor L576P | Stem Cell Factor Receptor Leu576Pro | Tyrosine-Protein Kinase Kit L576P | Tyrosine-Protein Kinase Kit Leu576Pro | c-KIT L576P | c-KIT Leu576Pro | c-KIT p.L576P | c-KIT p.Leu576Pro",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519583","Traditional Indigenous System","C15889","Subcategory of Alternative Medical Systems in CAM. This sub-category refers to major indigenous systems of medicine other than acupuncture and traditional oriental medicine. It includes systems such as Ayurvedic medicine, Native American Medicine, Unani-Tibbi, Kampo, Traditional African systems and community based traditional medical systems. This sub-category may become subdivided further as these systems become better studied and more familiar in the U.S. Included are: Native American Medicine, Ayurvedic Medicine, Unani-Tibbi, SADHU, Kampo Medicine, Traditional African Medicine, Traditional Aboriginal Medicine, Curandersimo, Central and South American practices, Psychic surgery.","Traditional Indigenous System | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539327","EDA Gene","C159356","This gene plays a role in ectodermal structure morphogenesis.","EDA Gene | EDA | Ectodysplasin A Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951335","EDA wt Allele","C159357","Human EDA wild-type allele is located in the vicinity of Xq13.1 and is approximately 423 kb in length. This allele, which encodes ectodysplasin-A protein, is involved in the morphogenesis of ectodermally derived tissues. Mutation of the gene is associated with X-linked hypohidrotic ectodermal dysplasia type 1 and X-linked, selective tooth agenesis type 1.","EDA wt Allele | ECTD1 | ED1 | ED1-A1 | ED1-A2 | EDA | EDA-A1 | EDA-A2 | EDA1 | EDA2 | Ectodermal Dysplasia 1, Anhidrotic Gene | Ectodysplasin A wt Allele | Ectodysplasin Gene | HED | HED1 | ODT1 | Oligodontia 1 Gene | STHAGX1 | TNLG7C | XHED | XLHED",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951336","EDA Gene Product","C159358","A protein encoded by the EDA gene.","EDA Gene Product | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1618095","ectodysplasin A, isoform 1, human","C159359","Ectodysplasin-A1 (391 aa, ~41 kDa) is encoded by the human EDA gene. This protein plays a role in the positive regulation of signaling mediated by tumor necrosis factor receptor superfamily member EDAR.","Ectodysplasin-A1 | ED1-A1 | EDA Protein | EDA-A1 | EDA1 | Ectodermal Dysplasia Protein 4 | Ectodysplasin A | Ectodysplasin A Isoform 1 | Ectodysplasin A1 | Ectodysplasin A1 Isoform | Ectodysplasin-A | Ectodysplasin-A Isoform 1 | Tumor Necrosis Factor Ligand 7C | X-Linked Anhidroitic Ectodermal Dysplasia Protein",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515094","Surveillance Modeling","C15935","No value exists.","Surveillance Modeling | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951337","Ectodysplasin-A2","C159360","Ectodysplasin-A2 (389 aa, ~41 kDa) is encoded by the human EDA gene. This protein is involved in the positive regulation of signaling mediated by tumor necrosis factor receptor superfamily member 27.","Ectodysplasin-A2 | ED1-A2 | EDA-A2 | EDA2 | Ectodysplasin A Isoform 3 | Ectodysplasin A2 | Ectodysplasin A2 Isoform | Ectodysplasin-A Isoform 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1414061","EDAR Gene","C159361","This gene is involved in ectodysplasin-A1-mediated signaling.","EDAR Gene | EDAR | Ectodysplasin A Receptor Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951338","EDAR wt Allele","C159362","Human EDAR wild-type allele is located in the vicinity of 2q13 and is approximately 95 kb in length. This allele, which encodes tumor necrosis factor receptor superfamily member EDAR protein, plays a role in the development of ectodermally derived tissues. Mutation of the gene is associated with hypohidrotic ectodermal dysplasia types 10A and 10B.","EDAR wt Allele | DL | Downless, Mouse, Homolog of Gene | ECTD10A | ECTD10B | ED1R | ED3 | ED5 | EDA-A1R | EDA1R | EDA3 | Ectodysplasin 1, Anhidrotic Receptor Gene | Ectodysplasin A Receptor wt Allele | HRM1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951339","Tumor Necrosis Factor Receptor Superfamily Member EDAR","C159363","Tumor necrosis factor receptor superfamily member EDAR (448 aa, ~49 kDa) is encoded by the human EDAR gene. This protein is involved in signaling that modulates the development of ectodermal structures.","Tumor Necrosis Factor Receptor Superfamily Member EDAR | Anhidrotic Ectodysplasin Receptor 1 | Downless Homolog | EDA-A1 Receptor | EDAR | Ectodermal Dysplasia Receptor | Ectodysplasin A Receptor | Ectodysplasin A1 Isoform Receptor | Ectodysplasin-A Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1539328","EDA2R Gene","C159364","This gene plays a role in ectodysplasin-A2-mediated signaling.","EDA2R Gene | EDA2R | Ectodysplasin A2 Receptor Gene | TNFRSF27",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951340","EDA2R wt Allele","C159365","Human EDA2R wild-type allele is located in the vicinity of Xq12 and is approximately 45 kb in length. This allele, which encodes tumor necrosis factor receptor superfamily member 27 protein, is involved in signaling that modulates the development of ectodermal structures.","EDA2R wt Allele | EDA-A2R | EDAA2R | Ectodysplasin A2 Receptor wt Allele | Ectodysplasin Receptor, X-Linked Gene | TNFRSF27 | UNQ2448/PRO5727/PRO34080 | XEDAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971191","Other Tumor Site","C160159","The site of the tumor was identified in the study but is not present in the form.","Other Tumor Site | Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518504","Nutrition, Vitamin A","C16015","Role of Vitamin A, its precursons, and its analogs in cancer causation or prevention and in general health.","Nutrition, Vitamin A | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969118","Specify Other Tumor Site","C160160","A directive to specify the other tumor site.","Specify Other Tumor Site | If Other, Specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969117","Unknown Supratentorial Localization","C160161","The supratentorial location is unknown.","Unknown Supratentorial Localization | Unknown: Could not be determined or unsure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971151","Therapeutic Ionizing Radiation to Head History Present","C160162","There is a history of the individual receiving therapeutic ionizing radiation to the head.","Therapeutic Ionizing Radiation to Head History Present | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969116","Therapeutic Ionizing Radiation to Head History Absent","C160163","There is no history of the individual receiving therapeutic ionizing radiation to the head.","Therapeutic Ionizing Radiation to Head History Absent | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969361","MSH6 Loss of Nuclear Expression","C160418","An indication that expression of MSH6 was not detected in the nuclei of cells in a sample.","MSH6 Loss of Nuclear Expression | DNA Mismatch Repair Protein Msh6 Loss of Nuclear Expression | G/T Mismatch Binding Protein Loss of Nuclear Expression | G/T Mismatch-Binding Protein Loss of Nuclear Expression | GTBP Loss of Nuclear Expression | GTMBP Loss of Nuclear Expression | Loss of Nuclear MSH6 | Loss of nuclear expression | MutS Homolog 6 Loss of Nuclear Expression | MutS-Alpha 160 kDa Subunit Loss of Nuclear Expression | Sperm-Associated Protein Loss of Nuclear Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969360","PMS2 Nuclear Expression Intact","C160419","An indication that expression of PMS2 was detected in the nuclei of cells in a sample.","PMS2 Nuclear Expression Intact | DNA Mismatch Repair Protein PMS2 Nuclear Expression Intact | Intact nuclear expression | Mismatch Repair Endonuclease PMS2 Nuclear Expression Intact | PMS1 Protein Homolog 2 Nuclear Expression Intact",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969359","PMS2 Loss of Nuclear Expression","C160420","An indication that expression of PMS2 was not detected in the nuclei of cells in a sample.","PMS2 Loss of Nuclear Expression | DNA Mismatch Repair Protein PMS2 Loss of Nuclear Expression | Loss of Nuclear PMS2 | Loss of nuclear expression | Mismatch Repair Endonuclease PMS2 Loss of Nuclear Expression | PMS1 Protein Homolog 2 Loss of Nuclear Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969358","TP53 Nuclear Expression Intact","C160421","An indication that expression of TP53 was detected in the nuclei of cells in a sample.","TP53 Nuclear Expression Intact | Antigen NY-CO-13 Nuclear Expression Intact | Cellular Tumor Antigen p53 Nuclear Expression Intact | Intact nuclear expression | TRP53 Nuclear Expression Intact | Transformation-Related Protein 53 Nuclear Expression Intact | Tumor Protein p53 Nuclear Expression Intact | Tumor Suppressor p53 Nuclear Expression Intact | p53 Nuclear Expression Intact",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969357","TP53 Loss of Nuclear Expression","C160422","An indication that expression of TP53 was not detected in the nuclei of cells in a sample.","TP53 Loss of Nuclear Expression | Antigen NY-CO-13 Loss of Nuclear Expression | Cellular Tumor Antigen p53 Loss of Nuclear Expression | Loss of Nuclear TP53 | Loss of Nuclear p53 | Loss of nuclear expression | TRP53 Loss of Nuclear Expression | Transformation-Related Protein 53 Loss of Nuclear Expression | Tumor Protein p53 Loss of Nuclear Expression | Tumor Suppressor p53 Loss of Nuclear Expression | p53 Loss of Nuclear Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969371","Non-Regional Lymph Node New Tumor Event","C160424","Lymph nodes located outside the region of interest.","Non-Regional Lymph Node New Tumor Event | Non-Regional Lymph Nodes/ Distant Lymph Nodes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969369","NF1 Mutation Analysis Was Performed","C160426","An indication that NF1 mutation analysis was performed during the study.","NF1 Mutation Analysis Was Performed | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969619","Tetrathiomolybdate","C160684","An orally bioavailable metal copper (Cu) chelator, with potential antiangiogenic, anti-metastatic and antitumor activities. Upon oral administration, tetrathiomolybdate (TM) targets and binds to copper and food protein in the gastrointestinal (GI) tract, thereby forming stable complexes and preventing copper uptake and reabsorption. Additionally, absorbed free TM targets and binds to copper and serum albumin in the bloodstream. This depletes systemic copper reserves and deprives the tumor microenvironment (TME) from copper. Chelation of copper by TM downregulates the expression of angiogenic factors of which copper is a cofactor, such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and prevents the production of nuclear factor-kappa B (NF-kB). Copper deprivation also inhibits the activity and levels of copper-dependent angiogenic enzymes, such as vascular endothelial growth factor receptor (VEGFR). This modulates the activity of VEGFR-positive endothelial progenitor cells (EPCs) that are necessary for metastasis. EPC deficiency results in the inhibition of angiogenesis and prevents metastasis. TM also inhibits the activities of other copper-containing metalloenzymes, including superoxide dismutase 1 (SOD1) in endothelial cells, cytochrome C oxidase, vascular adhesion protein-1 (VAP-1), antioxidant 1 copper chaperone (ATOX-1) and matrix metalloproteinase 9 (MMP-9). Inhibition of these enzymes interferes with the activation of several signal transduction pathways required for cellular proliferation and angiogenesis. TM also inhibits the activity and levels of lysyl oxidase-like 2 (LOXL2; lysyl oxidase homolog 2), a copper dependent amine oxidase that is critical for modeling the pre-metastatic niche and promotes metastasis, tumor cell migration and invasiveness. In addition, copper depletion also attenuates the activation of host cells within the tumor microenvironment including cancer-associated fibroblasts (CAFs), modulates tumor associated macrophages (TAMs) and promotes cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses.","Tetrathiomolybdate | CCRIS 9412 | Molybdate(2-), Tetrathioxo-, (T-4)- (9CI) | TIOMOLIBDATE ION | TM | Tetrathioxomolybdate(2-)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969618","Tumor Invasion of the Mucosa","C160685","A finding indicating that a neoplastic cellular infiltrate has broken the basement membrane and invaded the lamina propria.","Tumor Invasion of the Mucosa | Mucosal Invasion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969617","YES Portal","C160686","A web-based research intervention tool designed to collect and assess participants' toxicities and symptoms, as well as informational needs in between visits with their clinician.","YES Portal | YES | Young, Empowered, and Strong | Young, Empowered, and Strong (YES)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969616","Additional Pharmacotherapy for New Tumor Event Absent","C160688","No value exists.","Additional Pharmacotherapy for New Tumor Event Absent | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969615","Additional Pharmacotherapy for New Tumor Event Received","C160689","No value exists.","Additional Pharmacotherapy for New Tumor Event Received | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516228","Cancer Surveillance Project","C16068","Surveillance projects which focus on issues of cancer","Cancer Surveillance Project | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969613","Lysyl Oxidase-like Protein 2 Inhibitor PAT-1251","C160691","An orally available, small-molecule, irreversible inhibitor of lysyl oxidase homolog 2 (lysyl oxidase-like protein 2; LOXL2) with potential antifibrotic activity. Upon oral administration, the aminomethyl pyridine moiety of lenumlostat interacts with the active site of LOXL2 to form a pseudo-irreversible inhibitory complex, thereby inhibiting the catalytic activity of LOXL2. LOXL2, a secreted glycoprotein, catalyzes the post-translational oxidative deamination of lysine residues on target proteins, including collagen and elastin, leading to the formation of deaminated lysine (allysine). Condensation with other allysines or lysines drives the formation of inter- and intramolecular cross-linkages that impact remodeling of the extracellular matrix (ECM), potentially leading to fibrosis. Inhibition of LOXL2, which is often upregulated in fibrotic tissue, may reduce fibrosis in certain chronic fibrotic diseases.","Lenumlostat | GB 2064 | GB-2064 | GB2064 | LENUMLOSTAT | LOXL2 Inhibitor GB2064 | LOXL2 Inhibitor GB2064 | Lysyl Oxidase-like Protein 2 Inhibitor PAT-1251 | PAT 1251 | PAT-1251 | PAT1251",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969627","Tumor Invasion of the Prostatic Ducts and Acini","C160692","A morphologic finding indicating the presence of a malignant cellular infiltrate invading the ductal and acinar structures of the prostate gland.","Tumor Invasion of the Prostatic Ducts and Acini | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969626","Indeterminate Extranodal Tumor Extension","C160693","An indication that the extranodal tumor extension is undetermined.","Indeterminate Extranodal Tumor Extension | Indeterminate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969625","Indeterminate Lymph-Vascular Invasion","C160694","An indication that the lymphatic invasion in a specimen is indeterminate.","Indeterminate Lymphovascular Invasion | Indeterminate | Indeterminate Lymph-Vascular Invasion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950792","KIT NP_000213.1:p.V559A","C158900","A change in the amino acid residue at position 559 in the mast/stem cell growth factor receptor Kit protein where valine has been replaced by alanine.","KIT NP_000213.1:p.V559A | CD117 Antigen V559A | CD117 Antigen Val559Ala | KIT NP_000213.1:p.Val559Ala | KIT V559A | KIT Val559Ala | KIT p.V559A | KIT p.Val559Ala | Mast/Stem Cell Growth Factor Receptor Kit V559A | Mast/Stem Cell Growth Factor Receptor Kit Val559Ala | NP_000213.1:p.V559A | NP_000213.1:p.Val559Ala | Proto-Oncogene Tyrosine-Protein Kinase Kit V559A | Proto-Oncogene Tyrosine-Protein Kinase Kit Val559Ala | Proto-Oncogene c-Kit V559A | Proto-Oncogene c-Kit Val559Ala | Stem Cell Factor Receptor V559A | Stem Cell Factor Receptor Val559Ala | Tyrosine-Protein Kinase Kit V559A | Tyrosine-Protein Kinase Kit Val559Ala | c-KIT V559A | c-KIT Val559Ala | c-KIT p.V559A | c-KIT p.Val559Ala",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950793","KIT NP_000213.1:p.W557R","C158901","A change in the amino acid residue at position 557 in the mast/stem cell growth factor receptor Kit protein where tryptophan has been replaced by arginine.","KIT NP_000213.1:p.W557R | CD117 Antigen Trp557Arg | CD117 Antigen W557R | KIT NP_000213.1:p.Trp557Arg | KIT Trp557Arg | KIT W557R | KIT p.Trp557Arg | KIT p.W557R | Mast/Stem Cell Growth Factor Receptor Kit Trp557Arg | Mast/Stem Cell Growth Factor Receptor Kit W557R | NP_000213.1:p.Trp557Arg | NP_000213.1:p.W557R | Proto-Oncogene Tyrosine-Protein Kinase Kit Trp557Arg | Proto-Oncogene Tyrosine-Protein Kinase Kit W557R | Proto-Oncogene c-Kit Trp557Arg | Proto-Oncogene c-Kit W557R | Stem Cell Factor Receptor Trp557Arg | Stem Cell Factor Receptor W557R | Tyrosine-Protein Kinase Kit Trp557Arg | Tyrosine-Protein Kinase Kit W557R | c-KIT Trp557Arg | c-KIT W557R | c-KIT p.Trp557Arg | c-KIT p.W557R",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950794","KIT Mutation Analysis","C158902","A procedure used to detect and identify mutations in the KIT gene.","KIT Mutation Analysis | CD117 Mutation Analysis | KIT Mutation Status | KIT Proto-Oncogene Tyrosine Protein Kinase Mutation Analysis | c-KIT Mutation Analysis | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Mutation Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950796","KRAS Mutation Analysis Testing Method","C158905","A request to enter the specific molecular analysis method used to detect and identify mutations in the KRAS gene.","KRAS Mutation Analysis Testing Method | KRAS Mutational Analysis Testing Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951601","CST5 wt Allele","C159795","Human CST5 wild-type allele is located in the vicinity of 20p11.21 and is approximately 3 kb in length. This allele, which encodes cystatin-D protein, plays a role in cathepsin inhibition.","CST5 wt Allele | Cystatin 5 Gene | Cystatin D wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951602","Cystatin-D","C159796","Cystatin-D (142 aa, ~16 kDa) is encoded by the human CST5 gene. This protein is involved in the inhibition of cathepsin-mediated proteolysis.","Cystatin-D | CST5 | Cystatin 5 | Cystatin D | Cystatin-5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951341","Tumor Necrosis Factor Receptor Superfamily Member 27","C159366","Tumor necrosis factor receptor superfamily member 27 (297 aa, ~33 kDa) is encoded by the human EDA2R gene. This protein plays a role in the development and maintenance of ectodermally derived tissues.","Tumor Necrosis Factor Receptor Superfamily Member 27 | EDA-A2 Receptor | EDA2R | Ectodysplasin A2 Isoform Receptor | Ectodysplasin A2 Receptor | Ectodysplasin-A2 Receptor | TNFRSF27 | Tumor Necrosis Factor Receptor Superfamily Member XEDAR | X-Linked Ectodysplasin-A2 Receptor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518458","Nucleotide Analog Chemotherapy","C15956","Use of nucleotide analogs in cancer treatment.","Nucleotide Analog Chemotherapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971155","No","C159578","An indication that a history of chemical/occupational exposures does not exist.","Chemical/Occupational Exposure Absent | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971150","Chemical/Occupational Exposure Type Unknown","C159579","The chemical/occupation exposure type is unknown.","Chemical/Occupational Exposure Type Unknown | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511287","Breast Cancer, Basic Research","C15957","Research on the molecular, genetic, biochemical, cellular, structural, immunological, pharmacological mechanisms and factors as they relate to the causation, progression, diagnosis, and treatment of breast cancer.","Breast Cancer, Basic Research | Breast Cancer-Basic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951581","Sleep Diary","C159581","A record of an individual's experiences and observations about their sleeping. This usually includes: time going to bed and time awakening; times awake during the night; and subjective opinion of sleep quality, but can also include information about sleep preparations: time and amount of caffeine or alcohol consumed; food and drink consumed; medications taken; exercise during the day and pre-sleep activities; and emotional or stress status.","Sleep Diary | Sleep Journal | Sleep Log",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969368","NF1 Mutation Analysis Was Not Performed","C160427","An indication that NF1 mutation analysis was not performed during the study.","NF1 Mutation Analysis Was Not Performed | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969367","Not Known if 10q23/PTEN Locus Deletion Analysis Was Performed","C160428","An indication that it is not known whether 10q23/PTEN deletion analysis was performed during the study.","Not Known if 10q23/PTEN Locus Deletion Analysis Was Performed | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969366","Not Known if 1p/19q Deletion Analysis Was Performed","C160429","An indication that it is not known whether 1p/19q deletion analysis was performed during the study.","Not Known if 1p/19q Deletion Analysis Was Performed | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969365","Not Known if ALK Rearrangement Analysis Was Performed","C160430","An indication that it is not known whether ALK rearrangement analysis was performed during the study.","Not Known if ALK Rearrangement Analysis Was Performed | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969364","Not Known if ATRX Mutation Analysis Was Performed","C160431","An indication that it is not known whether ATRX mutation analysis was performed during the study.","Not Known if ATRX Mutation Analysis Was Performed | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969379","Not Known if Bone Marrow Aspirate Immunophenotyping and Cytochemistry Were Performed","C160432","An indication that it is not known if immunophenotyping and cytochemistry were performed on bone marrow aspirates during the study.","Not Known if Bone Marrow Aspirate Immunophenotyping and Cytochemistry Were Performed | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969632","Chemotherapy Was Not Administered as an Additional Treatment for a New Tumor Event","C160638","A response that chemotherapy was not administered as an additional treatment for a new tumor event.","Chemotherapy Was Not Administered as an Additional Treatment for a New Tumor Event | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969631","Unknown if Chemotherapy Was Administered as an Additional Treatment for a New Tumor Event","C160639","A response that indicates it is unknown if chemotherapy was administered as an additional treatment for a new tumor event.","Unknown if Chemotherapy Was Administered as an Additional Treatment for a New Tumor Event | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0870071","Modeling","C16063","The use of statistical analysis, computer analysis, or model organisms to predict outcomes of research. (doegenomes.org)","Modeling | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969629","Immunotherapy Was Not Administered as an Additional Treatment for a New Tumor Event","C160641","A response that immunotherapy was not administered as an additional treatment for a new tumor event.","Immunotherapy Was Not Administered as an Additional Treatment for a New Tumor Event | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969628","Unknown if Immunotherapy Was Administered as an Additional Treatment for a New Tumor Event","C160642","A response that indicates it is unknown if immunotherapy was administered as an additional treatment for a new tumor event.","Unknown if Immunotherapy Was Administered as an Additional Treatment for a New Tumor Event | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969643","Hormone Therapy Was Administered as an Additional Treatment for a New Tumor Event","C160643","A response that hormone therapy was administered as an additional treatment for a new tumor event.","Hormone Therapy Was Administered as an Additional Treatment for a New Tumor Event | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969642","Hormone Therapy Was Not Administered as an Additional Treatment for a New Tumor Event","C160644","A response that hormone therapy was not administered as an additional treatment for a new tumor event.","Hormone Therapy Was Not Administered as an Additional Treatment for a New Tumor Event | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969641","Unknown if Hormone Therapy Was Administered as an Additional Treatment for a New Tumor Event","C160645","A response that it was unknown if hormone therapy was administered as an additional treatment for a new tumor event.","Unknown if Hormone Therapy Was Administered as an Additional Treatment for a New Tumor Event | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969624","Indeterminate Peri-Neural Invasion","C160695","An indication that the perineural invasion in a specimen is indeterminate.","Indeterminate Perineural Invasion | Indeterminate | Indeterminate Peri-Neural Invasion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969623","Indeterminate Tumor Regression","C160696","An indication that the tumor regression is indeterminate.","Indeterminate Tumor Regression | Indeterminate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969869","Refractory Anaplastic Pleomorphic Xanthoastrocytoma","C160905","Anaplastic pleomorphic xanthoastrocytoma that is resistant to treatment.","Refractory Anaplastic Pleomorphic Xanthoastrocytoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1299012","Number of Regional Lymph Nodes Examined","C160906","The number of regional lymph nodes that were removed and examined by the pathologist.","Number of Regional Lymph Nodes Examined | ",,,,,,,,,,,,,,,"4156565","Number of regional lymph nodes examined by microscopy in excised specimen",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL969868","Number of Regional Lymph Nodes Positive","C160907","The number of regional nodes examined by the pathologist and found to contain metastases.","Number of Regional Lymph Nodes Positive | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969867","Sex Code","C160908","A code which indicates the sex of an individual.","Sex Code | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513386","Molecular Classification of Tumors","C16090","Challenge to research community to revolutionize the classification of human tumors, away from classification based on morphology, toward a more clinically predictive and useful classification system based on molecular characterization of tumors.  (Bypass Budget)","Molecular Classification of Tumors | Director's Challenge | Director's Challenge: Towards a Molecular Classification of Tumors | Extraordinary Opportunities: the Director's Challenge: Toward a Molecular Classification of Tumors | Extraordinary Opportunity: Defining the Signatures of Cancer Cells: Detection and Diagnosis | Molecular Fingerprinting Initiative | Molecular Profiling Initiative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969878","Recurrent Anaplastic Ependymoma","C160912","The reemergence of anaplastic ependymoma after a period of remission.","Recurrent Anaplastic Ependymoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969877","Refractory Anaplastic Ependymoma","C160913","Anaplastic ependymoma that is resistant to treatment.","Refractory Anaplastic Ependymoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969876","Recurrent Anaplastic Ganglioglioma","C160914","The reemergence of anaplastic ganglioglioma after a period of remission.","Recurrent Anaplastic Ganglioglioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969875","Refractory Anaplastic Ganglioglioma","C160915","Anaplastic ganglioglioma that is resistant to treatment.","Refractory Anaplastic Ganglioglioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969874","Locally Advanced Liposarcoma","C160916","A liposarcoma that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Liposarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969873","Locally Advanced Leiomyosarcoma","C160917","A leiomyosarcoma that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Leiomyosarcoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517073","Extraordinary Opportunity: Imaging Technologies","C16091","Goal: to develop a comprehensive imaging research program to fit the development of imaging technology with medical needs to create a system to evaluate new imaging technologies rapidly and effectively. (NCI Web)","Extraordinary Opportunity: Imaging Technologies | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969886","Locally Advanced Breast Carcinoma","C160920","A breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Breast Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951603","Tasadenoturev-infected Allogeneic Bone Marrow-derived Mesenchymal Stem Cells","C159798","A preparation of bone marrow-derived allogeneic mesenchymal stem cells (MSCs) infected with tasadenoturev (Ad5-DNX-2401), an adenovirus serotype 5 strain that is selectively replication competent in cells defective in the Rb/p16 tumor suppressor pathway, with potential antineoplastic activity. Upon infusion of the tasadenoturev-infected bone marrow-derived MSCs, these cells target and deliver the adenovirus to tumor cells. The oncolytic virus then selectively transfects and replicates in the tumor cells, eventually leading to tumor cell lysis and the release of virus particles and various tumor associated antigens (TAAs). This may induce a systemic immune response against tumor cells expressing these TAAs and further infection and killing of nearby tumor cells by the released viral particles. Ad5-DNX-2401 contains an integrin binding RGD-4C motif, allowing Coxsackievirus and adenovirus receptor-independent infection of tumor cells, which are often deficient for Coxsackievirus and adenovirus receptors (CARs). As integral components of the late G1 restriction point, the Rb gene product and p16 are negative regulators of the cell cycle and are often defective in certain cancer types.","Tasadenoturev-infected Allogeneic Bone Marrow-derived Mesenchymal Stem Cells | Ad5-DNX-2401-infected Allogeneic Bone Marrow MSCs | Ad5-DNX-2401-infected Allogeneic Bone Marrow Mesenchymal Stem Cells | Allogeneic BM-hMSC-D24 | Allogeneic BM-hMSC-Delta-24-RGD | Allogeneic Bone Marrow Mesenchymal Stem Cells Loaded with Oncolytic Adenovirus DNX-2401 | Allogeneic Bone Marrow Mesenchymal Stem Cells loaded with DNX-2401 | Allogeneic Bone Marrow Mesenchymal Stem Cells loaded with Tasadenoturev | BM-hMSC-D24 | BM-hMSC-Delta-24-RGD | Oncolytic Adenovirus Ad5-DNX-2401-infected Allogeneic Bone Marrow Mesenchymal Stem Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517281","Focused Ultrasound Therapy","C15979","Minimally invasive procedure for ablating tumors.  The primary mechanism of tissue damage is thermal.","Focused Ultrasound Therapy | Focused Ultrasound | Focused Ultrasound Surgery | High Power Focused Ultrasound | Therapy (Focused US) | Therapy, Focused Ultrasound",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951582","Bladder Well-Differentiated Neuroendocrine Tumor","C159582","A well-differentiated neuroendocrine neoplasm arising from the bladder. It is characterized by the presence of uniform cells with stippled chromatin and inconspicuous nucleoli. Mitotic activity is low and tumor necrosis is absent.","Bladder Neuroendocrine Tumor | Bladder Neuroendocrine Tumor | Bladder Well Differentiated Neuroendocrine Neoplasm | Bladder Well Differentiated Neuroendocrine Tumor | Bladder Well Differentiated Neuroendocrine Tumor | Bladder Well-Differentiated Neuroendocrine Neoplasm | Bladder Well-Differentiated Neuroendocrine Tumor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951583","Anti-CD47 Monoclonal Antibody","C159583","Any monoclonal antibody that targets the CD47 antigen.","Anti-CD47 Monoclonal Antibody | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951584","Specify Other Inhalation Anesthesia Agents","C159584","A request to specify inhalation anesthesia that was administered but not included on a list.","Specify Other Inhalation Anesthesia Agents | Other Inhalation Anesthesia Agents (specify)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951586","Preoperative IV Sedation was Not Administered","C159586","A response indicating that preoperative intravenous sedation was not administered.","Preoperative IV Sedation was Not Administered | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951587","Preoperative IV Sedation was Administered","C159587","A response indicating that preoperative intravenous sedation was administered.","Preoperative IV Sedation was Administered | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951018","ROS1 Rearrangement Analysis","C158952","A procedure used to detect and identify rearrangements involving the ROS1 gene.","ROS1 Rearrangement Analysis | MCF3 Rearrangement Analysis | ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Rearrangement Analysis | ROS Rearrangement Analysis | ROS1 Gene Rearrangement Analysis | ROS1 Rearrangement | ROS1 Rearrangement Status | c-ros-1 Rearrangement Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951019","ROS1 Rearrangement Testing Method","C158953","A request to enter the specific molecular analysis method used to detect and identify rearrangements involving the ROS1 gene.","ROS1 Rearrangement Testing Method | ROS1 Rearrangement Analysis Testing Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951020","Specify Molecular Abnormality Analysis Method","C158954","A request to enter the specific molecular analysis method used to detect abnormalities in the study.","Specify Molecular Abnormality Analysis Method | MOLECULAR_ANALYSIS_METHOD | Type of Molecular Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951021","SDH Complex Mutation Analysis","C158955","A procedure used to detect and identify mutations in any gene that encodes one of the proteins in the succinate dehydrogenase (SDH) complex.","SDH Complex Mutation Analysis | Mitochondrial Complex II Mutation Analysis | Mitochondrial Respiratory Chain Complex II Mutation Analysis | SDH Complex Gene Mutation Analysis | SDH Complex Mutation Status | SDH Family Mutation Analysis | SDH Mutation Analysis | SDH Mutation Status | Succinate Dehydrogenase Mutation Analysis | Succinate-CoQ Reductase Mutation Analysis | Succinate-Coenzyme Q Reductase Mutation Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951022","SDH Complex Mutation Analysis Testing Method","C158956","A request to enter the specific molecular analysis method used to detect and identify mutations in any gene that encodes one of the proteins in the succinate dehydrogenase (SDH) complex..","SDH Complex Mutation Analysis Testing Method | SDHA/B/C/D Mutational Analysis Testing Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950962","TP53 Mutation Analysis Testing Method","C158958","A request to enter the specific molecular analysis method used to detect and identify mutations in the TP53 gene.","TP53 Mutation Analysis Testing Method | TP53 Mutational Analysis Testing Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519842","Use of New Techniques","C15895","No value exists.","Use of New Techniques | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950964","Metastatic Pancreatic Ductal Adenocarcinoma","C158960","An adenocarcinoma that arises from the exocrine pancreatic ducts and has metastasized to other anatomic sites.","Metastatic Pancreatic Ductal Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969640","Targeted Molecular Therapy Was Administered as an Additional Treatment for a New Tumor Event","C160646","A response that targeted molecular therapy was administered as an additional treatment for a new tumor event.","Targeted Molecular Therapy Was Administered as an Additional Treatment for a New Tumor Event | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969639","Targeted Molecular Therapy Was Not Administered as an Additional Treatment for a New Tumor Event","C160647","A response that targeted molecular therapy was not administered as an additional treatment for a new tumor event.","Targeted Molecular Therapy Was Not Administered as an Additional Treatment for a New Tumor Event | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969638","Unknown if Targeted Molecular Therapy Was Administered as an Additional Treatment for a New Tumor Event","C160648","A response that indicates it is unknown if targeted molecular therapy was administered as an additional treatment for a new tumor event.","Unknown if Targeted Molecular Therapy Was Administered as an Additional Treatment for a New Tumor Event | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969637","IDH c.394_395CG>GT","C160649","A complex substitution where the nucleotide sequence at positions 394 and 395 of the coding sequence of the IDH1 gene has changed from cytosine-guanine to guanine-thymine.","IDH1 NM_005896.3:c.394_395delinsGT | IDH c.394_395CG>GT | IDH c.394_395delCGinsGT | IDH1 NM_005896.3:c.394_395CG>GT | IDH1 NM_005896.3:c.394_395delCGinsGT | IDH1 NM_005896.3:c.394_395delCGinsGT | IDH1 c.394_395CG>GT | IDH1 c.394_395delCGinsGT | Isocitrate Dehydrogenase 1 (NADP(+)), Cytosolic c.394_395CG>GT | Isocitrate Dehydrogenase 1 (NADP+), Soluble c.394_395delCGinsGT | NM_005896.3:c.394_395CG>GT | NM_005896.3:c.394_395delCGinsGT | NM_005896.3:c.394_395delinsGT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969651","IDH2 NM_002168.3:c.418C>T","C160651","A nucleotide substitution at position 418 of the coding sequence of the IDH2 gene where cytosine has been mutated to thymine.","IDH2 NM_002168.3:c.418C>T | IDH c.418C>T | IDH2 c.418C>T | Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial c.418C>T | Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial c.418C>T | NM_002168.3:c.418C>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971217","Interval Debulking Surgery","C160866","Debulking surgery that is performed after neoadjuvant chemotherapy or induction chemotherapy and is followed by additional adjuvant chemotherapy of the same type.","Interval Debulking Surgery | IDS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969889","Lipid Nanoparticle Encapsulated mRNAs Encoding Human IL-12A/IL-12B MEDI-1191","C160867","A formulation consisting of lipid nanoparticle encapsulated messenger RNA (mRNA) encoding human interleukin-12 subunit beta (IL-12B; IL-12 subunit p40) and interleukin-12 subunit alpha (IL-12A; IL-12 subunit p35) with potential immunomodulatory and antineoplastic activities. Although the exact mechanism of action has not been completely characterized, upon intratumoral injection, the lipid nanoparticle moiety presumably binds to the plasma membrane of nearby cells and releases the IL-12A and IL-12B mRNA into the cell. The mRNA is then translated by the cellular protein translation machinery to produce a single-chain fusion protein of IL-12B and IL-12A subunits, which is secreted into the local tumor microenvironment (TME). Secretion of IL-12 activates the immune system by promoting the secretion of interferon-gamma, activating natural killer cells (NKs), and inducing cytotoxic T-cell responses, which may result in both decreased tumor cell proliferation and enhanced immune-mediated destruction of tumor cells.","Lipid Nanoparticle Encapsulated mRNAs Encoding Human IL-12A/IL-12B MEDI-1191 | LNP Encapsulated Human IL-12A/IL-12B mRNAs MEDI-1191 | MEDI-1191 | MEDI1191",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516209","Cancer Intervention","C16086","No value exists.","Cancer Intervention | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969885","CDISC Protocol Study Population Attribute Terminology","C160921","Terminology associated with the protocol entity study population attribute codelist of the Clinical Data Interchange Standards Consortium (CDISC).","CDISC Protocol Study Population Attribute Terminology | PROT-Att Study Population | Study Population Attribute Terminology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969343","First Degree Family History Thyroid Cancer Negative","C160210","There is no first degree family history of thyroid cancer.","First Degree Family History Thyroid Cancer Negative | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969342","First Degree Family History Thyroid Cancer Positive","C160211","There is a first degree family history of thyroid cancer.","First Degree Family History Thyroid Cancer Positive | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969341","First Degree Family History Thyroid Cancer Unknown","C160212","There is an unknown first degree family history of thyroid cancer.","First Degree Family History Thyroid Cancer Unknown | Unknown: Could not be determined or unsure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969299","Radiation History Unknown","C160213","There is an unknown history of radiation exposure.","Radiation History Unknown | Unknown: Could not be determined or unsure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969298","Radiation History Positive","C160214","There is a history of radiation exposure.","Radiation History Positive | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969297","Radiation History Negative","C160215","There is no history of radiation exposure.","Radiation History Negative | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969296","Adjuvant I-131 Therapy Positive","C160216","Adjuvant I-131 therapy was administered.","Adjuvant I-131 Therapy Positive | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969295","Adjuvant I-131 Therapy Negative","C160217","Adjuvant I-131 therapy was not administered.","Adjuvant I-131 Therapy Negative | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969294","Adjuvant I-131 Therapy Unknown","C160218","Adjuvant I-131 therapy administration is unknown.","Adjuvant I-131 Therapy Unknown | Unknown: Could not be determined or unsure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518495","Nutrition Monitoring","C16021","Any method for determining as accurately as possible total food amount and composition ingested by subjects in dietary studies or amount of specific dietary components.","Nutrition Monitoring | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951162","Other Medications Administered During Surgery Prior to Tumor Tissue Removal","C159292","A header on the form for medications administered during surgery prior to removal of the tumor tissue.","Other Medications Administered During Surgery Prior to Tumor Tissue Removal | Other medications administered during surgery prior to removal of the tumor tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951163","Surgery Information Indicate If any of the Following Medications were Administered During Surgery","C159293","A directive to indicate whether any of the following medications listed on the form were administered during surgery.","Surgery Information Indicate If any of the Following Medications were Administered During Surgery | Surgery information Indicate whether any of the following medications were administered during surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951166","Other Muscle Relaxants (specify)","C159296","A request to specify muscle relaxants that were administered but not included on a list.","Specify Other Muscle Relaxants Administered | Other Muscle Relaxants (specify)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951168","Other Narcotics/Opiates (specify)","C159298","A request to specify narcotics or opiates that were administered but not included on a list.","Specify Other Narcotics or Opiates Administered | Other Narcotics/Opiates (specify)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518508","Nutrition, Vitamin E","C15929","Role of Vitamin E (alpha-tocopherol), its precursons, and its analogs in cancer causation or prevention and in general health.","Nutrition, Vitamin E | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1527035","Recombinant Alpha Chemokine","C1592","One of a number of chemotactic cytokines. Alpha chemokines are small polypeptides released by macrophages, endothelial cells, keratinocytes, fibroblasts, and smooth muscle cells in the presence of infection or physical tissue damage.  In a therapeutic setting, these agents may act as chemoattractants to recruit neutrophils and T cells from the blood to sites of infection or damage and may either promote or inhibit tumor growth by modulating tumor-associated angiogenesis and metastasis. Also known as CXC chemokines. (NCI04)","Recombinant Alpha Chemokine | Alpha Chemokines | C-X-C Chemokines | CXC Chemokines | CXC alpha Chemokine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0398472","Lymphovenous Bypass","C159300","A surgical procedure in which anastomoses are created from lymphatic vessels to veins..","Lymphovenous Bypass | Lymphovenous Anastomosis",,,,,,,,,,,,,,,"4122913","Lymphovenous anastomosis",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0149709","Hepatitis B Virus Surface Antigen Positive","C160372","An indication that the hepatitis B virus surface protein antigen has been detected in a sample.","Hepatitis B Virus Surface Antigen Positive | HBs Antigen Positive | HBs Positive | HBsAg Positive | Hepatitis B Surface Antigen Positive | Hepatitis B Surface Protein Antigen Positive | Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969437","HRAS Gene Mutation Negative","C160373","A genetic finding indicating that HRAS gene mutations have not been detected in a sample.","HRAS Gene Mutation Negative | C-HA-RAS1 Gene Mutation Negative | H-ras Gene Mutation Negative | HRAS Mutation Negative | HRAS Wild-Type | HRAS Wildtype | HRAS wt | HRas Proto-Oncogene, GTPase Gene Mutation Negative | Ha-ras Gene Mutation Negative | Harvey Rat Sarcoma Viral Oncogene Homolog Gene Mutation Negative | Negative | RASH1 Gene Mutation Negative | v-Ha-ras Harvey Rat Sarcoma Viral Oncogene Homolog Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969387","Adjuvant Post-operative Chemotherapy Was Not Administered","C160375","A response indicating that adjuvant post-operative chemotherapy was not administered.","Adjuvant Post-operative Chemotherapy Was Not Administered | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969386","Adjuvant Post-operative Chemotherapy Administration Unknown","C160376","A response indication the administration of adjuvant post-operative chemotherapy is unknown.","Adjuvant Post-operative Chemotherapy Administration Unknown | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969385","Adjuvant Post-operative Hormone Therapy Was Administered","C160377","No value exists.","Adjuvant Post-operative Hormone Therapy Was Administered | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969384","Adjuvant Post-operative Hormone Therapy Was Not Administered","C160378","No value exists.","Adjuvant Post-operative Hormone Therapy Was Not Administered | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969383","Adjuvant Post-operative Hormone Therapy Administration Unknown","C160379","No value exists.","Adjuvant Post-operative Hormone Therapy Administration Unknown | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518611","Organic Synthesis Facility","C16037","A core facility for the preparation and synthesis of organic molecules.","Organic Synthesis Facility | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969382","IDH Family Mutation Analysis Was Not Performed","C160380","An indication that IDH family mutation analysis was not performed during the study.","IDH Family Mutation Analysis Was Not Performed | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969381","IDH Family Mutation Analysis Was Performed","C160381","An indication that IDH family mutation analysis was performed during the study.","IDH Family Mutation Analysis Was Performed | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969380","Immunohistochemistry Was Not Performed","C160382","An indication that immunohistochemical testing was not performed during the study.","Immunohistochemistry Was Not Performed | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969394","Not Known if Mutation Analysis Was Performed","C160384","An indication that it is not known whether mutation analysis was performed during the study.","Not Known if Mutation Analysis Was Performed | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969393","Not Known if Additional Immunohistochemistry Was Performed","C160385","An indication that it is not known whether additional immunohistochemical tests were performed during the study.","Not Known if Additional Immunohistochemistry Was Performed | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969392","Not Known if Additional Molecular Studies Were Performed","C160386","An indication that it is not known whether additional molecular analysis was performed during the study.","Not Known if Additional Molecular Studies Were Performed | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969390","Adjuvant Post-operative Targeted Molecular Therapy Was Administered","C160388","A response indicating that adjuvant post-operative targeted molecular therapy was administered.","Adjuvant Post-operative Targeted Molecular Therapy Was Administered | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0006155","Respiratory Muscle Training","C160870","A series of breathing and other exercises that are performed to improve the function of the respiratory muscles through resistance and endurance training.","Respiratory Muscle Training | RMT",,,,,,,,,,,,,,,"4029804","Physiotherapeutic breathing exercise",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL969898","Respiratory Muscle Training Device","C160871","A handheld breathing device that is used to strengthen the respiratory muscles through resistance training.","Respiratory Muscle Training Device | Power Lung Device",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969896","Platinum-Sensitive Fallopian Tube Carcinoma","C160873","Fallopian tube carcinoma that has a documented response to platinum-based chemotherapy.","Platinum-Sensitive Fallopian Tube Carcinoma | Platinum-Sensitive Fallopian Tube Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969895","Chronic Cutaneous Graft Versus Host Disease","C160874","Chronic graft versus host disease (GvHD) occurring in the skin.","Chronic Cutaneous Graft Versus Host Disease | Chronic Cutaneous GvHD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969894","Head and Neck Survivorship Tool: Assessment and Recommendations","C160876","A modified electronic platform that uses an algorithmic approach that integrates treatment summaries, self-assessments, discussion guides, and survivorship care plans to provide personalized care in cancer survivorship clinics.","Head and Neck Survivorship Tool: Assessment and Recommendations | HN-STAR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969128","First Degree Family History Cancer Positive","C160165","The parents, siblings or children of an individual have a history of cancer.","First Degree Family History Cancer Positive | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969127","First Degree Family History Cancer Negative","C160166","The parents, siblings or children of an individual have no history of cancer.","First Degree Family History Cancer Negative | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969126","First Degree Family History Cancer Unknown","C160167","The history of cancer of the parents, siblings or children of an individual is unknown.","First Degree Family History Cancer Unknown | Unknown: Could not be determined or unsure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969125","First Degree Family History of Primary Brain Tumor Positive","C160168","The parents, siblings or children of an individual have a history of primary brain tumors.","First Degree Family History of Primary Brain Tumor Positive | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969124","First Degree Family History of Primary Brain Tumor Negative","C160169","The parents, siblings or children of an individual have no history of primary brain tumors.","First Degree Family History of Primary Brain Tumor Negative | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969300","First Course Treatment Completion Measure of Success of Outcome Not Applicable","C160228","A response that the first course treatment completion measure of success of outcome is not applicable.","First Course Treatment Completion Measure of Success of Outcome Not Applicable | Not Applicable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969313","Recurrent High Grade B-Cell Lymphoma","C160229","The reemergence of high-grade B-cell lymphoma after a period of remission.","Recurrent High Grade B-Cell Lymphoma | Recurrent High-Grade B-Cell Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL777819","glecaprevir / pibrentasvir","C160484","A fixed dose combination of glecaprevir, an inhibitor of the hepatitis C virus (HCV) NS3/4A serine protease, and pibrentasvir, an inhibitor of the HCV non-structural protein 5A (NS5A), with activity against HCV genotypes 1-6. Upon oral administration of glecaprevir/pibrentasvir, glecaprevir inhibits the HCV NS3/4A serine protease enzyme, thereby disrupting the cleavage of the virally encoded polyprotein into mature proteins and preventing the formation of the viral replication complex. Pibrentasvir inhibits the activity of the NS5A protein, leading to disruption of the viral RNA replication complex, blockage of HCV RNA production, and inhibition of viral replication. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family; HCV infection is associated with the development of certain cancers.","Glecaprevir/Pibrentasvir | ABT-493/ABT-530 | GLE/PIB | Glecaprevir and Pibrentasvir | Glecaprevir-Pibrentasvir | Mavyret",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969545","Peripheral Blood Immunophenotyping and Cytochemistry Were Not Performed","C160486","An indication that immunophenotyping and cytochemistry were not performed on peripheral blood samples during the study.","Peripheral Blood Immunophenotyping and Cytochemistry Were Not Performed | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969544","Peripheral Blood Immunophenotyping and Cytochemistry Were Performed","C160487","An indication that immunophenotyping and cytochemistry were performed on peripheral blood samples during the study.","Peripheral Blood Immunophenotyping and Cytochemistry Were Performed | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969558","PTEN Mutation Analysis Was Not Performed","C160490","An indication that PTEN mutation analysis was not performed during the study.","PTEN Mutation Analysis Was Not Performed | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969557","PTEN Mutation Analysis Was Performed","C160491","An indication that PTEN mutation analysis was performed during the study.","PTEN Mutation Analysis Was Performed | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969556","BCG Failure","C160492","Failure to achieve a disease-free state following BCG treatment.","Intravesical Bacillus Calmette-Guerin Therapy Failure | BCG Failure | BCG Refractory",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951430","Anti-stabilin-1 Monoclonal Antibody FP-1305","C159536","A monoclonal antibody directed against common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1; stabilin-1; FEEL-1), with potential immunomodulatory and antineoplastic activities. Upon administration, bexmarilimab targets and binds to CLEVER-1 that is expressed on tumor endothelial cells. This prevents the recruitment, infiltration and attachment of tumor-associated macrophages (TAMs) at the tumor site. By preventing the binding of TAMs to tumor cells, the infiltration of activated T-regulatory cells (Tregs) to the tumor and the TAM-mediated immune suppression is abrogated, leading to the polarization of TAM from the immunosuppressive M2 macrophages to the anti-inflammatory and immunostimulatory M1 macrophages. This leads to the activation of the immune system, resulting in a cytotoxic T-lymphocyte (CTL)-mediated immune response and inhibition of tumor cell growth and metastasis. CLEVER-1 is an endothelial cell surface molecule involved in immune suppression, cancer growth and metastasis.","Bexmarilimab | Anti-stabilin-1 Monoclonal Antibody FP-1305 | BEXMARILIMAB | Clevegen | FP 1305 | FP-1305 | FP1305",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951431","Radium Ra 224-labeled Calcium Carbonate Microparticles","C159537","A radiopharmaceutical composed of biodegradable calcium carbonate microspheres labeled with the alpha-emitting radioisotope radium Ra 224, with antineoplastic activity. Upon intraperitoneal (IP) administration of the radium Ra 224-labeled calcium carbonate microparticles, Ra 224 kills tumor cells through local emission of high energy alpha particles, causing DNA double-strand breaks. The short range effects of alpha emission allows for localized DNA damage with limited toxicity to nearby healthy tissue.","Radium Ra 224-labeled Calcium Carbonate Microparticles | 224Ra-labeled Calcium Carbonate Micro-particles | Alpha-emitting 224Ra Calcium Carbonate Microspheres | Ra-224 Alpha-emitting Calcium Carbonate Microparticles | Radspherin",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951376","Anti-PD-L1 Monoclonal Antibody GR1405","C159538","A monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-L1 monoclonal antibody GR1405 specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.","Anti-PD-L1 Monoclonal Antibody GR1405 | GR 1405 | GR-1405 | GR1405",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951377","EGFR Amplification Assessed","C159539","A question asking if EGFR amplification was analyzed during the study.","Was EGFR Amplification Assessed | EGFR Amplification Assessed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511507","Cooperative Family Registries for Breast and Colorectal Cancer Studies","C15953","Cooperative family registries specific for breast and colorectal cancer studies.","Cooperative Family Registries for Breast and Colorectal Cancer Studies | CFRBCS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951378","Oral Cancer Vaccine V3-OVA","C159540","An orally available cancer vaccine composed of autologous ovarian cancer antigens obtained from hydrolyzed, inactivated blood and tumor tissue of patients with ovarian cancer, with potential immunostimulatory and antineoplastic activities. Upon oral administration of the oral cancer vaccine V3-OVA, the ovarian cancer antigens stimulate the immune system and activate a cytotoxic T-lymphocyte (CTL) immune response against ovarian cancer cells.","Oral Cancer Vaccine V3-OVA | Cancer Vaccine V3-OVA | Tableted Vaccine V3-OVA | V3 OVA | V3-OVA | V3OVA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969389","Adjuvant Post-operative Targeted Molecular Therapy Was Not Administered","C160389","A response indicating that adjuvant post-operative targeted molecular therapy was not administered.","Adjuvant Post-operative Targeted Molecular Therapy Was Not Administered | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969701","Was ROS1 Rearrangement Analysis Performed","C160594","A question asking if ROS1 rearrangements were analyzed during the study.","Was ROS1 Rearrangement Analysis Performed | ROS1 Rearrangement assessed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969715","Was EGFR Mutation Analysis Performed","C160595","A question asking if EGFR mutations were analyzed during the study.","Was EGFR Mutation Analysis Performed | EGFR Mutation Status assessed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969714","Fluorescence In Situ Hybridization Was Performed","C160596","An indication that fluorescence in situ hybridization was performed during the study.","Fluorescence In Situ Hybridization Was Performed | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969713","Fluorescence In Situ Hybridization Was Not Performed","C160597","An indication that fluorescence in situ hybridization was not performed during the study.","Fluorescence In Situ Hybridization Was Not Performed | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969712","Not Known if Fluorescence In Situ Hybridization Was Performed","C160598","An indication that it is not known whether fluorescence in situ hybridization was performed during the study.","Not Known if Fluorescence In Situ Hybridization Was Performed | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969711","Advanced Esophageal Carcinoma","C160599","Esophageal carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Esophageal Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0212199","Tecogalan Sodium","C1605","A sulfated polysaccharide isolated from various Arthrobacter bacterial species.  Possessing potential antiangiogenic and antineoplastic properties, tecogalan binds to basic fibroblast growth factor (bFGF), thereby preventing bFGF from binding to its receptors.  Disruption of this receptor binding results in the inhibition of bFGF-stimulated endothelial cell growth, proliferation, and migration. (NCI04)","Tecogalan Sodium | DS-4152 | SP-PG | Sulfated Polysaccharide Tecogalan DS-4152",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969710","Unknown Age When Started using Smokeless Tobacco after Regular Use","C160600","A response that the age an individual started using smokeless tobacco after six weeks regular use is unknown.","Unknown Age When Started using Smokeless Tobacco after Regular Use | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969709","Evidence of Disease Present after Completion of Therapy","C160601","A response that evidence of disease was present after completion of therapy.","Evidence of Disease Present after Completion of Therapy | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969708","Evidence of Disease Absent after Completion of Therapy","C160602","A response that evidence of disease was not present after completion of therapy.","Evidence of Disease Absent after Completion of Therapy | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969664","AZD 9833","C160603","An orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon administration, camizestrant binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This prevents ER-mediated signaling and inhibits the growth and survival of ER-expressing cancer cells.","Camizestrant | AZ-14066724 | AZD 9833 | AZD-9833 | AZD9833 | CAMIZESTRANT | N-(1-(3-Fluoropropyl)-3-azetidinyl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo(4,3-f)isoquinolin-6-yl)-3-pyridinamine | SERD AZD9833 | Selective Estrogen Receptor Degrader AZD9833",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969663","Evidence of Disease Unknown after Completion of Therapy","C160604","A response that evidence of disease is unknown after completion of therapy.","Evidence of Disease Unknown after Completion of Therapy | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969123","First Degree Family History of Primary Brain Tumor Unknown","C160170","The history of primary brain tumors of the parents, siblings or children of an individual is unknown.","First Degree Family History of Primary Brain Tumor Unknown | Unknown: Could not be determined or unsure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969122","Was a BRAF Mutation Identified","C160171","A question asking if a BRAF mutation was identified during the study.","Was a BRAF Mutation Identified | BRAF Mutation Identified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969121","Was an IDH Family Mutation Identified","C160172","A question asking if IDH family gene mutations were identified during the study.","Was an IDH Family Mutation Identified | IDH1/2 Mutation Identified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969134","Was an ATRX Mutation Identified","C160174","A question asking if an ATRX mutation was identified during the study.","Was an ATRX Mutation Identified | ATRX Mutation Identified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969133","Was an EGFR Amplification Identified","C160175","A question asking if an EGFR amplification was identified during the study.","Was an EGFR Amplification Identified | EGFR Amplification Identified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969132","Was a PTEN Mutation Identified","C160176","A question asking if a PTEN mutation was identified during the study.","Was a PTEN Mutation Identified | PTEN Mutation Identified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969131","Was a TP53 Mutation Identified","C160177","A question asking if a TP53 mutation was identified during the study.","Was a TP53 Mutation Identified | TP53 Mutation Identified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969130","History of Medical Treatment Present","C160179","An indication that a history of medical treatment is present.","History of Medical Treatment Present | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519574","Trace Element Nutrition, Selenium","C16017","Role of selenium in cancer causation or prevention and in general health.","Trace Element Nutrition, Selenium | Nutrition, Selenium",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969129","History of Medical Treatment Absent","C160180","An indication that a history of medical treatment is absent.","History of Medical Treatment Absent | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969327","History of Medical Treatment Unknown","C160181","The history of medical treatments is unknown.","History of Medical Treatment Unknown | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969324","Cancer History Absent","C160185","An indication that a cancer history is absent.","Cancer History Absent | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969323","UK English","C160186","A form of the English language spoken in the United Kingdom.","UK English | England English | English, UK | United Kingdom English",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969378","Not Known if BRAF Mutation Analysis Was Performed","C160433","An indication that it is not known whether BRAF mutation analysis was performed during the study.","Not Known if BRAF Mutation Analysis Was Performed | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969377","Not Known if BRAF Rearrangement Analysis Was Performed","C160434","An indication that it is not known whether BRAF rearrangement analysis was performed during the study.","Not Known if BRAF Rearrangement Analysis Was Performed | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969555","RET Gene Rearrangement Negative","C160493","A genetic finding indicating that rearrangement of the RET gene has not been detected in a sample.","RET Gene Rearrangement Negative | Negative | No rearrangement detected | RET Rearrangement Negative | RET/PTC Rearrangement Negative | Ret Proto-Oncogene Rearrangement Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969554","RET Rearrangement Analysis Was Not Performed","C160494","An indication that RET rearrangement analysis was not performed during the study.","RET Rearrangement Analysis Was Not Performed | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969553","RET Rearrangement Analysis Was Performed","C160495","An indication that RET rearrangement analysis was performed during the study.","RET Rearrangement Analysis Was Performed | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969552","ROS1 Rearrangement Analysis Was Not Performed","C160496","An indication that ROS1 rearrangement analysis was not performed during the study.","ROS1 Rearrangement Analysis Was Not Performed | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969551","ROS1 Rearrangement Analysis Was Performed","C160497","An indication that ROS1 rearrangement analysis was performed during the study.","ROS1 Rearrangement Analysis Was Performed | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969565","SDH Complex Mutation Analysis Was Not Performed","C160498","An indication that SDH complex mutation analysis was not performed during the study.","SDH Complex Mutation Analysis Was Not Performed | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1524021","Radiotherapy Research","C16049","[Therapeutic implications] Research in radiotherapy using ionizing and non-ionizing radiation and those areas in radiobiology and radiation physics that relate to radiation therapy, including laboratory investigations at the molecular, cellular, tissue, and whole animal levels. (DEA-CAACT)","Radiotherapy Research | Radiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969621","Multiple Known Primary Tumors Present at Initial Melanoma Diagnosis","C160698","A response that multiple known primary tumors were present at the initial melanoma diagnosis.","Multiple Known Primary Tumors Present at Initial Melanoma Diagnosis | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969620","Multiple Known Primary Tumors Absent at Initial Melanoma Diagnosis","C160699","A response that multiple known primary tumors were absent at the initial melanoma diagnosis.","Multiple Known Primary Tumors Absent at Initial Melanoma Diagnosis | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511293","Breast Cancer Prevention Trial","C16069","Part of the National Surgical Adjuvant Breast and Bowel Project, the Breast Cancer Prevention Trial (BCPT) was a clinical trial designed to see whether taking the drug tamoxifen would prevent breast cancer in women who are at an increased risk of developing the disease. The BCPT also looked at whether taking tamoxifen would decrease the number of heart attacks and reduce the number of bone fractures in these women. The study began recruiting participants in April 1992 and closed enrollment in September 1997.","Breast Cancer Prevention Trial | BCPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0289630","Labradimil","C1606","A synthetic analog of bradykinin.  Lobradimil is a potent, specific bradykinin B-2 receptor agonist that stimulates B-2 receptors expressed on the surface of brain capillary endothelial cells, thereby reversibly increasing the permeability of the blood-brain barrier (BBB).  Compared to bradykinin, this agent possesses enhanced receptor selectivity, greater plasma stability, and a longer half-life. (NCI04)","Labradimil | Cereport | DRG-0182 | L-Prolinamide, L-Arginyl-L-prolyl-trans-4- hydroxy-L-prolyl-3-(2- thienyl)-L-alanylglycl -L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1- -carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-, (S-(R*,R*)) | LABRADIMIL | Lobradimil | RMP-7 | lobradimil",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969810","Multiple Known Primary Tumors Unknown at Initial Melanoma Diagnosis","C160700","A response that multiple known primary tumors were unknown at the initial melanoma diagnosis.","Multiple Known Primary Tumors Unknown at Initial Melanoma Diagnosis | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969809","Unknown Clark Level","C160701","A finding of an unknown Clark level.","Unknown Clark Level | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969808","Tumor Necrosis Not Identified","C160702","A response that tumor necrosis has not been identified.","Tumor Necrosis Not Identified | Not Identified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969807","Tumor Necrosis Present","C160703","No value exists.","Tumor Necrosis Present | Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951380","Bladder Endometrioid Adenocarcinoma","C159542","A rare bladder adenocarcinoma with the histologic characteristics of endometrioid adenocarcinoma of the endometrium.","Bladder Endometrioid Adenocarcinoma | Bladder Endometrioid Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950797","Itacitinib Adipate","C158906","The adipate salt form of itacitinib, an orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1) with potential antineoplastic and immunomodulating activities. Upon oral administration, itacitinib selectively inhibits JAK-1, thereby inhibiting the phosphorylation of signal transducer and activator of transcription (STAT) proteins and the production of proinflammatory factors induced by other cytokines, including interleukin-23 (IL-23) and interleukin-6 (IL-6). The JAK-STAT pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","Itacitinib Adipate | INCB-039110 Adipate | INCB039110 Adipate | ITACITINIB ADIPATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950798","List Exons Assessed","C158907","A request to enter the exons assessed for mutations in this section of the form.","List Exons Assessed | Exons assessed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950799","Metastatic Large Cell Neuroendocrine Carcinoma","C158908","A large cell neuroendocrine carcinoma that has metastasized from its original site of growth to another anatomic site.","Metastatic Large Cell Neuroendocrine Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950800","Locally Advanced Neuroendocrine Carcinoma","C158909","A neuroendocrine carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Neuroendocrine Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519771","Unconventional Western System","C15890","NIH: Subcategory of alternative medical systems in CAM.  This sub-category deals with alternative medical systems developed in the West that are not dealt with elsewhere.  This includes systems such as homeopathy, Anthroposophically- extended Medicine, Environmental Medicine, Functional Medicine, Radionics, Cayce-based therapies, etc.  Included are: Homeopathy, Environmental Medicine, Functional Medicine, Anthroposophically-extended medicine, Radionics, Radiesthesia, Psionic medicine, Cayce-based systems.","Unconventional Western System | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950801","Locally Advanced Large Cell Neuroendocrine Carcinoma","C158910","A large cell neuroendocrine carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Large Cell Neuroendocrine Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0748861","Metastatic Small Cell Neuroendocrine Carcinoma","C158911","A small cell neuroendocrine carcinoma that has metastasized from its original site of growth to another anatomic site.","Metastatic Small Cell Neuroendocrine Carcinoma | Metastatic Small Cell Carcinoma",,,,,,,,,,,,,,,"37165127|46271141","Metastatic small cell carcinoma|Metastatic small cell carcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL950803","Metastatic Prostate Neuroendocrine Carcinoma","C158913","A neuroendocrine carcinoma that arises from the prostate gland and has spread to other anatomic sites.","Metastatic Prostate Neuroendocrine Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950804","Locally Advanced Prostate Neuroendocrine Carcinoma","C158914","A prostate neuroendocrine carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Prostate Neuroendocrine Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969662","Anti-PD-1/PD-L1 Bispecific Antibody LY3434172","C160605","A bispecific antibody targeting both the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and its ligand, human programmed death-ligand 1 (PD-L1; CD274), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, reozalimab simultaneously targets and binds to PD-1, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes in the tumor microenvironment (TME), and PD-L1 expressed on tumor cells. This prevents PD-L1 from binding to and activating its receptor PD-1 and inhibits the PD-L1/PD-1-mediated downregulation of T-cell activation and proliferation. This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.","Reozalimab | Anti-PD-1/Anti-PD-L1 Bispecific Antibody LY3434172 | Anti-PD-1/Anti-PD-L1 Bispecific Antibody LY3434172 | Anti-PD-1/PD-L1 Bispecific Antibody LY3434172 | Bispecific Antibody LY3434172 | LY 3434172 | LY-3434172 | LY3434172 | REOZALIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969733","Prostate Acinar Pleomorphic Giant Cell Adenocarcinoma","C160818","An extremely rare prostate acinar adenocarcinoma characterized by the presence of giant, bizarre anaplastic cells with pleomorphic nuclei and lack of a spindle cell component.","Prostate Acinar Pleomorphic Giant Cell Adenocarcinoma | Prostate Acinar Adenocarcinoma, Pleomorphic Giant Cell Variant | Prostate Pleomorphic Giant Cell Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL519416","Metastatic Colon Adenocarcinoma","C160819","An adenocarcinoma that arises from the colon and has metastasized to another anatomic site.","Metastatic Colon Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517711","Laboratory Sensitivity","C16081","No value exists.","Laboratory Sensitivity | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969732","Metastatic Rectal Adenocarcinoma","C160820","An adenocarcinoma that arises from the rectum and has metastasized to another anatomic site.","Metastatic Rectal Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969744","Peritoneal Fluid is Negative for Malignancy","C160821","A result that the peritoneal fluid is negative for malignancy.","Peritoneal Fluid is Negative for Malignancy | Negative for malignancy/normal/benign",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969743","Atypical Peritoneal Fluid","C160822","A result that the peritoneal fluid is atypical.","Atypical Peritoneal Fluid | Atypical and/or suspicious",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969742","Peritoneal Fluid Positive for Malignancy","C160823","A result that the peritoneal fluid is positive for malignancy.","Peritoneal Fluid Positive for Malignancy | Positive for malignancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971218","Peritoneal Fluid Not Examined","C160825","A response that the peritoneal fluid was not examined.","Peritoneal Fluid Not Examined | Not examined",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969740","Is Tumor Cell Necrosis Present","C160826","A question whether tumor cell necrosis is present.","Is Tumor Cell Necrosis Present | Tumor Cell Necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969738","Macroscopic Satellite Nodule Not Identified","C160828","The macroscopic satellite nodule is not identified.","Macroscopic Satellite Nodule Not Identified | Not Identified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969916","Is Microsatellitosis Present","C160829","A question about whether microsatellitosis is present.","Is Microsatellitosis Present | Microsatellitosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512997","Marker Discovery","C16082","Strategies and technologies for molecular phenotyping and biological marker discovery to improve understanding of disease and aid the pharmaceutical industry's ability to develop new therapeutic products efficiently and cost effectively.","Marker Discovery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969915","Microsatellitosis Absent","C160830","An indication that microsatellitosis is absent.","Microsatellitosis Absent | Not identified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969914","Perineural Invasion Absent","C160831","An indication that perineural invasion is absent.","Perineural Invasion Absent | Not identified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512192","Electron Microscopy Facility","C16043","A shared facility which provides services for electron microscopy.","Electron Microscopy Facility | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969573","Ileal Neuroendocrine Tumor G2","C160440","A well-differentiated, intermediate-grade neuroendocrine neoplasm that arises from the ileum. The mitotic count is 2-20 per 2 mm2 and/or the Ki-67 index is 3 to 20%.","Ileal Neuroendocrine Tumor G2 | Ileal NET G2 | Malignant carcinoid tumor of the ileum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969571","Duodenal Neuroendocrine Tumor G2","C160442","A well-differentiated, intermediate-grade neuroendocrine neoplasm that arises from the duodenum. The mitotic count is 2-20 per 2 mm2 and/or the Ki-67 index is 3 to 20%.","Duodenal Neuroendocrine Tumor G2 | Duodenal NET G2 | Malignant carcinoid tumor of the duodenum",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969570","Colon Neuroendocrine Tumor G2","C160443","A well-differentiated, intermediate-grade neuroendocrine neoplasm that arises from the colon. The mitotic count is 2-20 per 2 mm2 and/or the Ki-67 index is 3 to 20%.","Colon Neuroendocrine Tumor G2 | Colon NET G2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969569","Additional Surgery for New Loco-Regional Tumor Event Was Performed","C160444","Additional surgery was performed for a new loco-regional tumor event.","Additional Surgery for New Loco-Regional Tumor Event Was Performed | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969568","Additional Surgery for New Loco-Regional Tumor Event Was Not Performed","C160445","Additional surgery was not performed for a new loco-regional tumor event.","Additional Surgery for New Loco-Regional Tumor Event Was Not Performed | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969567","Additional Surgery for New Loco-Regional Tumor Event Unknown","C160446","It is unknown if additional surgery was performed for a new loco-regional tumor event.","Additional Surgery for New Loco-Regional Tumor Event Unknown | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969566","Additional Surgery for New Metastatic Tumor Event Unknown","C160447","It is unknown if additional surgery was performed for a new metastatic tumor event.","Additional Surgery for New Metastatic Tumor Event Unknown | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511168","Biostatistics Core","C16044","A shared facility providing biostatistical services.","Biostatistics Core | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969580","Additional Surgery for New Metastatic Tumor Event Was Performed","C160450","Additional surgery was performed for a new metastatic tumor event.","Additional Surgery for New Metastatic Tumor Event Was Performed | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969806","Autologous Anti-BCMA CAR T-cells IM21","C160704","A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector (LV) expressing a chimeric antigen receptor (CAR) targeting the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and containing, as of yet undisclosed costimulatory signaling domains, with potential antineoplastic activity. Upon administration, the autologous anti-BCMA CAR T-cells IM21 recognize and induce selective toxicity against BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and is overexpressed on malignant plasma cells.","Autologous Anti-BCMA CAR T-cells IM21 | Autologous BCMA-specific CAR T-cells IM21 | IM21 CAR T-cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969804","HDAC Class I/IIb Inhibitor HG146","C160706","An orally available inhibitor of histone deacetylase (HDAC) classes I and IIb with potential antineoplastic activities. Upon oral administration, HDAC I/IIb inhibitor HG146 selectively inhibits the catalytic activity of class I and IIb HDACs, which results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. This leads to the inhibition of tumor oncogene transcription, and the selective transcription of tumor suppressor genes, which inhibits tumor cell division and induces tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins. Class I HDACs are located in the nucleus and include HDACs 1, 2, 3, and 8; class IIb HDACs include HDAC 6 and 10 and are located in both the nucleus and the cytoplasm.","HDAC Class I/IIb Inhibitor HG146 | Class I/IIb HDACi HG146 | HDAC I/IIb Selective Inhibitor HG146 | HG 146 | HG-146 | HG0146 | HG146 | HG280146 | HG280146-P1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969803","Ulceration is Present","C160707","A result that ulceration is present","Ulceration is Present | Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969818","Ulceration is Absent","C160708","A result that ulceration is absent","Ulceration is Absent | Absent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969817","No Pathologic Findings Identified","C160709","A response that no pathologic findings were identified.","No Pathologic Findings Identified | None Identified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514509","Prostate Cancer Prevention Trial","C16070","A phase III, randomized, placebo-controlled cancer prevention trial of >18,000 men coordinated by the Southwest Oncology Group.  The trial will determine the effect of a daily dose of finasteride taken for seven years on the biopsy-proven prevalence of prostate cancer.  It is scheduled to be completed in 2004.","Prostate Cancer Prevention Trial | PCPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969883","CDISC SDTM Model Version ResponseTerminology","C160923","Terminology associated with the SDTM model version response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM Model Version ResponseTerminology | SDTM Version Response | SDTM-SDTMVRS | SDTMVRS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969880","CDISC SDTM FDA Technical Specification Response Terminology","C160926","Terminology associated with the FDA technical specification response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","CDISC SDTM FDA Technical Specification Response Terminology | FDA Technical Specification Response | FDATSRS | SDTM-FDATSRS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969879","CDISC SEND Body Irradiation Model Response Terminology","C160927","Terminology associated with the body irradiation model response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).","CDISC SEND Body Irradiation Model Response Terminology | BIRRMRS | Body Irradiation Model Response | SEND-BIRRMRS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969836","CDISC SEND Rad/Nuc Targeted Injury Model Response Terminology","C160928","Terminology associated with the rad/nuc targeted injury model response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).","CDISC SEND Rad/Nuc Targeted Injury Model Response Terminology | RNTIMRS | Rad/Nuc Targeted Injury Model Response | SEND-RNTIMRS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950805","Locally Advanced Small Cell Neuroendocrine Carcinoma","C158915","A small cell neuroendocrine carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.","Locally Advanced Small Cell Neuroendocrine Carcinoma | Locally Advanced Small Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950806","MET Mutation Analysis","C158917","A procedure used to detect and identify mutations in the MET gene.","MET Mutation Analysis | HGFR Mutation Analysis | Hepatocyte Growth Factor Receptor Mutation Analysis | MET Gene Mutation Analysis | MET Mutation Status | MET Proto-Oncogene, Receptor Tyrosine Kinase Mutation Analysis | Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Mutation Analysis | c-met Mutation Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950807","MET Mutation Analysis Testing Method","C158918","A request to enter the specific molecular analysis method used to detect and identify mutations in the MET gene.","MET Mutation Analysis Testing Method | MET Mutational Analysis Testing Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950808","MGMT Promoter Methylation Testing Method","C158919","A request to enter the specific molecular analysis method used to detect the methylation of promoter sequences of the MGMT gene.","MGMT Promoter Methylation Testing Method | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519391","Social Aspects of Cancer","C15891","Influence of social factors, such as community, policy, and legislation on cancer control and outcomes","Social Aspects of Cancer | Psychosocial Influences | Psychosocial Issues",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514709","Radiometry (Microwave)","C15980","The measurement of radiation by photography, as in x-ray film and film badge, by Geiger-Mueller tube, and by scintillation counting.","Radiometry (Microwave) | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1275363","Tumor Infiltrating Lymphocyte Absent","C160833","A response that there are no tumor infiltrating lymphocytes.","Tumor Infiltrating Lymphocyte Absent | Not identified | TIL Absent | TIL Negative",,,,,,,,,,,,,,,"4245230","Tumor infiltration by lymphocytes absent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL969913","Is Tumor Regression Present","C160834","A question about whether tumor regression is present.","Is Tumor Regression Present | Tumor Regression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1300740","Tumor Regression Absent","C160835","An indication that tumor regression is not observed.","Tumor Regression Absent | Not identified",,,,,,,,,,,,,,,"4218376","Regression of tumor absent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL969924","Is Extranodal Tumor Involvement Present","C160837","A question about whether extranodal tumor involvement is present.","Is Extranodal Tumor Involvement Present | Extranodal Tumor Extension | Is Extra-nodal Extension Present | Is Extranodal Extension Present | extranodal extension | extranodal_extension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969142","Sorafenib Regimen","C160118","A regimen consisting of sorafenib that may be used in the treatment of soft tissue sarcoma, gastrointestinal stromal and desmoid tumors (aggressive fibromatoses), follicular, medullary, papillary and Hurthle cell thyroid carcinomas, bone, hepatobiliary and kidney cancers, acute myeloid leukemia (AML), angiosarcoma, salivary gland and solitary fibrous tumors, and myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes.","Sorafenib Regimen | Nexavar Regimen | Sorafenib Tosylate Regimen | Sorafenib monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511900","Diet and Nutrition","C16011","Epidemiology studies looking at the role of dietary patterns, foods, and nutrients or other dietary components in cancer incidence and prevention.","Diet and Nutrition | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969140","Talazoparib Regimen","C160120","A regimen consisting of talazoparib that may be used in the treatment of BRCA mutation-positive, HER2-negative advanced breast cancer.","Talazoparib Regimen | Talazoparib Tosylate Regimen | Talazoparib monotherapy | Talzenna Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969139","Tamoxifen Regimen","C160121","A regimen consisting of tamoxifen that may be used in the treatment of breast, endometrial, ovarian, fallopian tube, and primary peritoneal cancer, and malignant sex cord-stromal tumors.","Tamoxifen Regimen | Nolvadex Regimen | Tamoxifen Citrate Regimen | Tamoxifen monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969138","Temozolomide Regimen","C160122","A regimen consisting of temozolomide that may be used in the treatment of soft tissue and uterine sarcoma, cutaneous and uveal melanoma, small cell lung cancer (SCLC), central nervous system (CNS) cancers, mycosis fungoides and Sezary syndrome, and neuroendocrine tumors (NETs), including NETs of the gastrointestinal (GI) tract, lung, thymus and pancreas, pheochromocytoma and paraganglioma, and extrapulmonary poorly differentiated neuroendocrine carcinoma, large or small cell carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm.","Temozolomide Regimen | Temodar Regimen | Temozolomide monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969137","Temsirolimus Regimen","C160123","A regimen consisting of temsirolimus that may be used in the treatment of uterine sarcoma, kidney cancer, endometrial carcinoma, perivascular epithelioid cell tumors (PEComas), angiomyolipomas, and lymphangioleiomyomatosis (LAM).","Temsirolimus Regimen | Temsirolimus monotherapy | Torisel Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969136","Thalidomide Regimen","C160124","A regimen consisting of thalidomide that may be used in the treatment of AIDS-related Kaposi sarcoma and Castleman disease.","Thalidomide Regimen | Thalidomide monotherapy | Thalomid Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969151","Topical Alitretinoin Regimen","C160125","A regimen consisting of topical alitretinoin that may be used in the treatment of AIDS-related Kaposi sarcoma.","Topical Alitretinoin Regimen | Alitretinoin monotherapy | Topical Panretin Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969150","Topical Bexarotene Regimen","C160126","A regimen consisting of topical bexarotene that may be used in the treatment of primary cutaneous B-cell lymphomas, mycosis fungoides, and Sezary syndrome.","Topical Bexarotene Regimen | Bexarotene Topical Regimen | Topical Targretin Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969649","Oligoprogression","C160653","Disease progression at a limited number of anatomic sites, in the context of stable disease at other anatomic sites.","Oligoprogression | Oligoprogressive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969648","IDH2 NM_002168.3:c.419G>T","C160654","A nucleotide substitution at position 419 of the coding sequence of the IDH2 gene where guanine has been mutated to thymine.","IDH2 NM_002168.3:c.419G>T | IDH c.419G>T | IDH2 c.419G>T | Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial c.419G>T | Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial c.419G>T | NM_002168.3:c.419G>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969645","Plutonium-239 Alpha Particle Radiation","C160658","Alpha rays produced by the decay of plutonium-239.","Plutonium-239 Alpha Particle Radiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969644","IDH2 NM_002168.3:c.419G>A","C160659","A nucleotide substitution at position 419 of the coding sequence of the IDH2 gene where guanine has been mutated to adenine.","IDH2 NM_002168.3:c.419G>A | IDH c.419G>A | IDH2 c.419G>A | Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial c.419G>A | Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial c.419G>A | NM_002168.3:c.419G>A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516230","Cancer Surveillance Research Program","C16065","The Surveillance Research Program (SRP) directs a program of cancer surveillance involving the collection and analysis of pertinent data in order to answer key questions about cancer incidence, morbidity, mortality, and cancer-related health status in diverse regions and in general and specific populations of the U.S. defined by sociodemographic measures.","Cancer Surveillance Research Program | CSRP | Surveillance Research Program",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969658","Americium-241 Alpha Particle Radiation","C160660","Alpha rays produced by the decay of americium-241.","Americium-241 Alpha Particle Radiation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4014538","Mental Retardation, Autosomal Dominant 28","C160662","No value exists.","Mental Retardation, Autosomal Dominant 28 | ADNP Syndrome | Autosomal Dominant Mental Retardation 28 | HVDAS | Helsmoortel-Van Der AA Syndrome | MRD28",,,,,,,,,,,,,,,"35624210","ADNP-related multiple congenital anomalies, intellectual disability, autism spectrum disorder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL969656","IDH2 NM_002168.3:c.516G>C","C160663","A nucleotide substitution at position 516 of the coding sequence of the IDH2 gene where guanine has been mutated to cytosine.","IDH2 NM_002168.3:c.516G>C | IDH c.516G>C | IDH2 c.516G>C | Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial c.516G>C | Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial c.516G>C | NM_002168.3:c.516G>C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969655","IDH2 NM_002168.3:c.516G>T","C160664","A nucleotide substitution at position 516 of the coding sequence of the IDH2 gene where guanine has been mutated to thymine.","IDH2 NM_002168.3:c.516G>T | IDH c.516G>T | IDH2 c.516G>T | Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial c.516G>T | Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial c.516G>T | NM_002168.3:c.516G>T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969835","CDISC SEND Expected Onset of Rad/Nuc Targeted Injury Response Terminology","C160929","Terminology associated with the expected onset of rad/nuc targeted injury Response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).","CDISC SEND Expected Onset of Rad/Nuc Targeted Injury Response Terminology | EORNTI | Expected Onset of Rad/Nuc Targeted Injury Response | SEND-EORNTI",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517075","Extraordinary Opportunity: Preclinical Models of Cancer","C16092","Goal: refine current models, create models that more closely parallel human cancers, devise efficient procedures that will make models available to all researchers who need them. (NCI Web)","Extraordinary Opportunity: Preclinical Models of Cancer | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969834","CDISC SEND Chemical Challenge Agent Name Response Terminology","C160930","Terminology associated with the chemical challenge agent name response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).","CDISC SEND Chemical Challenge Agent Name Response Terminology | CHAGNAMR | Chemical Challenge Agent Name Response | SEND-CHAGNAMR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969833","CDISC SEND Genus and Species Response Terminology","C160931","Terminology associated with the genus and species response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).","CDISC SEND Genus and Species Response Terminology | GENUSSPC | Genus and Species Response | SEND-GENUSSPC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1113670","Nerve Agent","C160932","No value exists.","Nerve Agent | ",,,,,,,,,,,,,,,"4180928","Nerve agent",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0324820","Papio hamadryas","C160933","The baboon species, Papio hamadryas.","Papio hamadryas | ",,,,,,,,,,,,,,,"4070778","Papio hamadryas",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0036055","Saimiri","C160934","No value exists.","Saimiri | SQUIRREL | Squirrel Monkey",,,,,,,,,,,,,,,"4180262","Saimiri",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL969841","Latex Safety Information","C160938","No value exists.","Latex Safety Information | Latex Safety",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969840","Implantable Device Status","C160939","The status of the implantable device.","Implantable Device Status | Device Implantable Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516999","Exogenous Hormone Therapy","C16093","No value exists.","Exogenous Hormone Therapy | Exogenous Hormone Use",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516003","Antibody-Directed Enzyme Prodrug Therapy","C16022","A systemic therapy which ensures that a specific prodrug is not converted into the active moiety anywhere but at the sites where the enzyme-linked, tumor-specific antibodies have localized.","Antibody-Directed Enzyme Prodrug Therapy | ADEPT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969311","Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type","C160231","The reemergence of diffuse large B-cell lymphoma activated B-cell type after a period of remission.","Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Recurrent Diffuse Large B-Cell Lymphoma Non-GC/ABC | Recurrent Diffuse Large B-Cell Lymphoma Non-Germinal Center/Activated B-Cell Type | Recurrent Non-GC/ABC DLBCL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969310","Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma","C160232","The reemergence of transformed follicular lymphoma to diffuse large B-cell lymphoma after a period of remission.","Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951617","Outcome Measure of Success at Completion of Initial Treatment Course Not Applicable","C159812","A response that the measure of success of outcome after the completion of the first treatment is not applicable.","Outcome Measure of Success at Completion of Initial Treatment Course Not Applicable | Not Applicable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951618","Not Applicable","C159813","A response that the measure of success of outcome after the completion of the first treatment is unknown.","Outcome Measure of Success at Completion of Initial Treatment Unknown | Not Applicable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971152","Performance Status Scale Timing Unknown","C159815","The timing of the performance scale is unknown.","Performance Status Scale Timing Unknown | Unknown | Unknown: Could not be determined or unsure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951619","Performance Status Scale Timing Not Applicable","C159816","A response that the performance status scale timing is not applicable.","Performance Status Scale Timing Not Applicable | Not Applicable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951353","FEV1/FVC Post-Bronchodilator","C159318","The test for post-bronchodilator forced expiratory volume over the forced vital capacity percentage value.","FEV1/FVC Post-Bronchodilator | FEV1/FVC post- bronchodilator (Post- Bronchodilator FEV1/FVC Percentage Value) | fev1 fvc post bronch percent | fev1_fvc_post_bronch_percent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951363","CPTAC Normal Endometrial Baseline Form","C159329","No value exists.","CPTAC Normal Endometrial Baseline Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951179","Clinical History","C159310","A clinical history section header on a form.","Clinical History | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951349","Pulmonary Function Tests Performed","C159314","A question about which pulmonary tests were performed.","Which Pulmonary Function Tests Were Performed | Pulmonary Function Tests Performed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951350","FEV1% REF Pre-Bronchodilator","C159315","The test for pre-bronchodilator lung forced expiratory volume 1 test lab percentage value.","FEV1% REF Pre-Bronchodilator | FEV1% REF pre-bronchodilator (Pre- Bronchodilator Lung Forced Expiratory Volume I Test Lab Percentage Value) | fev1 ref post bronch percent | fev1 ref pre bronch percent | fev1_ref_post_bronch_percent | fev1_ref_pre_bronch_percent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951351","FEV1% REF Post-Bronchodilator","C159316","The test for post-bronchodilator lung forced expiratory volume 1 test lab percentage value.","FEV1% REF Post-Bronchodilator | FEV1% REF post- bronchodilator (Post - Bronchodilator Lung Forced Expiratory Volume I Test Lab Percentage Value) | fev1 ref post bronch percent | fev1 ref pre bronch percent | fev1_ref_post_bronch_percent | fev1_ref_pre_bronch_percent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951352","FEV1/FVC Pre-Bronchodilator","C159317","The test for pre-bronchodilator forced expiratory volume over the forced vital capacity percentage value.","FEV1/FVC Pre-Bronchodilator | FEV1/FVC pre- bronchodilator (Pre- Bronchodilator FEV1/FVC Percentage Value) | fev1 fvc pre bronch percent | fev1_fvc_pre_bronch_percent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951354","DLCO % REF","C159319","The lung carbon monoxide diffusing capability test assessment predictive percentage value.","DLCO % REF | DLCO % REF (Lung Carbon Monoxide Diffusing Capability Test) Assessment Predictive Percentage Value | dlco ref predictive percent | dlco_ref_predictive_percent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516615","Clinical Management","C15931","No value exists.","Clinical Management | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969149","Topical Fluorouracil Regimen","C160127","A regimen consisting of topical fluorouracil that may be used in the treatment of penile cancer.","Topical Fluorouracil Regimen | Fluorouracil Topical Regimen | Topical 5-FU Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969148","Topical Imiquimod Regimen","C160128","A regimen consisting of topical imiquimod that may be used in the treatment of primary cutaneous lymphomas, AIDS-related Kaposi sarcoma, cutaneous melanoma, penile cancers, mycosis fungoides and Sezary syndrome.","Topical Imiquimod Regimen | Imiquimod Topical Regimen | Topical Aldara Regimen | Topical Zyclara Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969147","Topotecan Daily Regimen","C160129","A regimen consisting of daily topotecan that may be used in the treatment of ovarian, fallopian tube, and primary peritoneal cancers.","Topotecan Daily Regimen | Daily Hycamtin Regimen | Daily Topotecan HCl Regimen | Daily Topotecan Hydrochloride Regimen | Daily Topotecan Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518481","Nutrition, Artificial Sweeteners","C16012","Study of artificial sweeteners as potential carcinogens and in relation to general health.","Nutrition, Artificial Sweeteners | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969146","Topotecan Every 28 Days Regimen","C160130","A regimen consisting of topotecan every 28 days that may be used in the treatment of cervical and vaginal cancer.","Topotecan Every 28 Days Regimen | Every 28 Days Hycamtin Regimen | Every 28 Days Topotecan Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969145","Topotecan Regimen","C160131","A regimen consisting of topotecan that may be used in the treatment of Merkel cell carcinoma; primary central nervous system (CNS) lymphoma, rhabdomyosarcoma, small cell lung cancer (SCLC), and endometrial, ovarian, fallopian tube, and primary peritoneal cancers.","Topotecan Regimen | Hycamtin Regimen | Topotecan HCl Regimen | Topotecan Hydrochloride Regimen | Topotecan monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517585","Investigation of Mechanisms of Drug Resistance","C16038","Basic research to understand the mechanisms that cells use to avoid being killed by cytotoxic drugs.","Investigation of Mechanisms of Drug Resistance | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969388","Adjuvant Post-operative Targeted Molecular Therapy Administration Unknown","C160390","A response indication the administration of adjuvant post-operative targeted molecular therapy is unknown.","Adjuvant Post-operative Targeted Molecular Therapy Administration Unknown | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969403","KIT Mutation Analysis Was Not Performed","C160391","An indication that KIT mutation analysis was not performed during the study.","KIT Mutation Analysis Was Not Performed | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969401","First Course Treatment Completion Measure of Success of Outcome Unknown","C160393","A response that the first course treatment completion measure of success of outcome is unknown.","First Course Treatment Completion Measure of Success of Outcome Unknown | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969400","KIT Negative","C160395","An indication that expression of KIT has not been detected in a sample.","KIT Negative | CD117 Negative | KIT Proto-Oncogene Tyrosine Protein Kinase Negative | Mast/Stem Cell Growth Factor Receptor Kit Negative | Negative | c-KIT Negative | v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969399","KRAS Mutation Analysis Was Not Performed","C160396","An indication that KRAS mutation analysis was not performed during the study.","KRAS Mutation Analysis Was Not Performed | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969398","KRAS Mutation Analysis Was Performed","C160397","An indication that KRAS mutation analysis was performed during the study.","KRAS Mutation Analysis Was Performed | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969397","Lymph Node Dissection Was Not Performed","C160398","An indication that lymph node dissection was not performed during the study.","Lymph Node Dissection Was Not Performed | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969396","Lymph Node Dissection Was Performed","C160399","An indication that lymph node dissection was performed during the study.","Lymph Node Dissection Was Performed | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1418634","PLCB4 Gene","C160883","This gene is involved in the biosynthesis of second messenger molecules.","PLCB4 Gene | PLCB4 | Phospholipase C Beta 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969899","PLCB4 wt Allele","C160885","Human PLCB4 wild-type allele is located within 20p12.3-p12.2 and is approximately 412 kb in length. This allele, which encodes 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-4 protein, plays a role in diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) synthesis. Mutation of the gene is associated with auriculocondylar syndrome 2.","PLCB4 wt Allele | ARCND2 | DJ1119D9.2 | PI-PLC | Phopholipase C, Beta-4 Gene | Phospholipase C Beta 4 wt Allele | Phospholipase C, Beta 4 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1676033","PLCB4 protein, human","C160886","1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-4 (1175 aa, ~134 kDa) is encoded by the human PLCB4 gene. This protein is involved in the synthesis of diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3).","1-Phosphatidylinositol 4,5-Bisphosphate Phosphodiesterase Beta-4 | 1-Phosphatidylinositol 4,5-Bisphosphate Phosphodiesterase Beta 4 | 1-Phosphatidylinositol-4,5-Bisphosphate Phosphodiesterase Beta 4 | EC 3.1.4.11 | PLC-Beta-4 | PLCB4 | Phosphoinositide Phospholipase C-Beta-4 | Phospholipase C Beta 4 | Phospholipase C-Beta-4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969910","Abexinostat Tosylate","C160889","The tosylate salt form of abexinostat, an orally bioavailable hydroxamate-based pan-inhibitor of histone deacetylase (HDAC), with potential antineoplastic and radiosensitizing activities. Upon administration, abexinostat inhibits HDAC, resulting in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling; the selective transcription of tumor suppressor genes; and the tumor suppressor protein-mediated inhibition of tumor cell division and induction of tumor cell apoptosis. In addition, abexinostat decreases the expression of the DNA-repair protein RAD51, thereby reducing the RAD51 protein, preventing repair of DNA double-strand breaks and increasing sensitivity of tumor cells to DNA damaging agents. HDAC, upregulated in many tumor types, is an enzyme that is responsible for the deacetylation of chromatin histone proteins.","Abexinostat Tosylate | 1H-Pyrrolo(2,3-C)pyridine-2-carboxamide, N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(1-hydroxy-1-methylethyl)phenyl)-6,7-dihydro-6-methyl-7-oxo- | ABEXINOSTAT TOSYLATE | PCI-24781 Tosylate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517069","Extraordinary Opportunities for Investment","C16088","Research areas of exceptional promise in the cancer field.  To qualify as extraordinary opportunities these research initiatives must: Respond to important recent developments in knowledge and technology; Offer approaches to cancer research beyond the size, scope, and funding of our current research activities; Be implemented with specific, defined investments; Be described in terms of achievable milestones, with clear consequences for not investing; and Promise advances for making progress against all cancers. (from 2001 Bypass Budget)","Extraordinary Opportunities for Investment | Extraordinary Opportunities in Cancer Research",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969309","Refractory High Grade B-Cell Lymphoma","C160233","High-grade B-cell lymphoma that is resistant to treatment.","Refractory High Grade B-Cell Lymphoma | Refractory High-Grade B-Cell Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969320","Unknown Tumor Infiltrating Lymphocytes","C160237","A finding of an unknown number of tumor infiltrating lymphocytes in a biospecimen.","Unknown Tumor Infiltrating Lymphocytes | Unknown: Could not be determined or unsure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969319","Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","C160238","Diffuse large B-cell lymphoma germinal center B-cell type that is resistant to treatment.","Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969318","Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type","C160239","Diffuse large B-cell lymphoma activated B-cell type that is resistant to treatment.","Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Refractory Diffuse Large B-Cell Lymphoma Non-GC/ABC | Refractory Diffuse Large B-Cell Lymphoma Non-Germinal Center/Activated B-Cell Type | Refractory Non-GC/ABC DLBCL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519607","Transgenic Mouse Facility","C16023","A shared facility for creation and propagation of transgenic mice.","Transgenic Mouse Facility | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969317","Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma","C160240","Transformed follicular lymphoma to diffuse large B-cell lymphoma that is resistant to treatment.","Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969314","Unknown Eye Color","C160243","The eye color is unknown.","Unknown Eye Color | Unknown: Could not be determined or unsure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971190","Other Eye Color","C160244","The color of the eye was identified in the study but is not present in the form.","Other Eye Color | Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969267","BK Virus Reactivation","C160245","The switching of latent BK virus to a lytic infection.","BK Virus Reactivation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969265","Patient was Postmenopausal with no Prior Oophorectomy","C160247","A response that the  patient was postmenopausal at diagnosis for longer than 12 months since the last menstrual period with no prior oophorectomy or prior bilateral oophorectomy.","Patient was Postmenopausal with no Prior Oophorectomy | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951355","Pathologic Findings in Non-Neoplastic Kidney","C159320","A section header requesting results for the pathologic findings in the non-neoplastic kidney.","Pathologic Findings in Non-Neoplastic Kidney | Pathologic Findings in Nonneoplastic Kidney",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951356","Prognostic Features Used for Tumor Prognosis","C159321","A form section header about prognostic features used for tumor prognosis.","Prognostic Features Used for Tumor Prognosis | Prognostic/Predictive/Lifestyle Features Used for Tumor Prognosis or Responsiveness to Treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951357","Renal Vein or Vena Cava Thrombosis or Other Coagulopathies","C159322","A section header for renal vein or vena cava thromboses or other coagulopathies.","Renal Vein or Vena Cava Thrombosis or Other Coagulopathies | Renal vein or vena caval thrombosis or other coagulopathies (specify)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0265050","Vena Cava Thrombosis","C159323","The formation of a thrombus in the vena cava.","Vena Cava Thrombosis | Vena caval thrombosis",,,,,,,,,,,,,,,"4222639","Thrombosis of vena cava",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL951386","Advanced Gastroesophageal Junction Adenocarcinoma","C159548","Gastroesophageal junction adenocarcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Gastroesophageal Junction Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951387","AB 122","C159549","A human immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, zimberelimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; B7-H1; CD274) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","Zimberelimab | AB 122 | AB-122 | AB122 | Anti-PD-1 Monoclonal Antibody GLS-010 | GLS 010 | GLS-010 | GLS010 | Sepalizumab | WBP 3055 | WBP-3055 | WBP3055 | ZIMBERELIMAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517505","Genetic Annotation Initiative","C15954","NCI initiate to explore, develop and then apply technology for identification and characterization of genes important in cancer.  Based on gene discovery program in CGAP, the GAI is currently exploring the application of multiple technological approaches to searching the 3'UTR of genes for sequence variation.  Once identified and confirmed, these variants will be put into public databases maintained by NCIBI's dbSNP and CGAP web resources.  See also Cancer Genome Anatomy Project.","Genetic Annotation Initiative | CGAP Genetic Annotation Initiative | CGAP-GAI | GAI | Genetic Annotation Initiative (GAI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969409","Follow-Up Form Completion Outcome Measure of Success Unknown","C160402","A response that the follow-up form completion  measure of success of outcome is unknown.","Follow-Up Form Completion Outcome Measure of Success Unknown | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969408","Follow-Up Form Completion Outcome Measure of Success Not Applicable","C160403","A response that the follow-up form completion  measure of success of outcome is not applicable.","Follow-Up Form Completion Outcome Measure of Success Not Applicable | Not Applicable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969407","MET Mutation Analysis Was Not Performed","C160404","An indication that MET mutation analysis was not performed during the study.","MET Mutation Analysis Was Not Performed | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969406","MET Mutation Analysis Was Performed","C160405","An indication that MET mutation analysis was performed during the study.","MET Mutation Analysis Was Performed | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969661","Class-1/4 HDACi OKI-179","C160606","The besylate form of bocodepsin, an orally bioavailable inhibitor of the histone deacetylase (HDAC) subtypes 1 and 4, with potential antineoplastic activity. Upon administration,bocodepsin targets, binds to and inhibits the activity of HDAC1/4. This results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. This consequently results in a selective transcription of tumor suppressor genes, tumor suppressor protein-mediated inhibition of tumor cell division and an induction of apoptosis in tumor cells that overexpress HDAC1/4. HDAC, which is upregulated in many tumor cell types, deacetylates chromatin histone proteins and plays a key role in transcriptional regulation and cell cycle progression.","Bocodepsin Besylate | BOCODEPSIN BESYLATE | Class 1/4 Histone Deacetylase Inhibitor OKI-179 | Class 1/4 Histone Deacetylase Inhibitor OKI-179 | Class-1/4 HDACi OKI-179 | HDAC Inhibitor OKI-179 | HDAC1/4i OKI-179 | HDACi 1/4 OKI-179 | HDACi OKI-179 | OKI 179 | OKI-179 | OKI179",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1268129","Urethra Part","C160608","A named segment of the urethra.","Urethra Part | ",,,,,,,,,,,,,,,"4000504","Urethra part",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519327","Single Nucleotide Polymorphism Map","C16060","A diagram of a gene or genome showing the location of known single nucleotide polymorphisms.","Single Nucleotide Polymorphism Map | SNP Map",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969322","Cancer History Unknown","C160187","An indication that a cancer history is unknown.","Cancer History Unknown | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969333","Mexican Spanish","C160190","A form of the Spanish language spoken in Mexico.","Mexican Spanish | Spanish, Mexico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971189","History of Other Medical Treatment","C160191","There is a history of other medical treatment.","History of Other Medical Treatment | Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969332","DNX 2440","C160192","A selectively replication competent oncolytic adenovirus that is engineered to express OX40 ligand (OX40L) with potential oncolytic and immunostimulatory activities. Upon administration, tezemlimogene daxadenorepvec, which contains an integrin binding RGD-4C motif, infects tumor cells in a Coxsackievirus-adenovirus receptor-independent manner and selectively replicates in tumor cells that are defective in retinoblastoma gene (Rb) or cyclin-dependent kinase inhibitor-2A (p16). Tumor cell selectivity is achieved through a 24-base pair deletion in the E1A gene, which renders the oncolytic adenovirus unable to replicate in normal cells that maintain a functional Rb pathway, but fully replication competent in Rb/p16 defective tumor cells.  Active replication of the OX40L-expressing oncolytic adenovirus within tumor cells may induce oncolysis and release of OX40L. OX40L may then bind to and activate signaling pathways downstream of its cognate receptor, tumor necrosis factor receptor superfamily member 4 (TNFRSF4; OX40), which is expressed on activated T-cells. OX40L/OX40 binding promotes increased cytokine production, which can induce proliferation of memory and effector T-lymphocytes and promote the killing of nearby tumor cells. OX40L, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) ligand family, provides a co-stimulatory signal for the proliferation and survival of activated T-cells. The Rb gene product and p16 are negative regulators of the cell cycle and are defective in certain tumor types.","Tezemlimogene Daxadenorepvec | DNX 2440 | DNX-2440 | DNX2440 | OX40L-expressing Oncolytic Adenovirus DNX-2440 | OX40L-expressing Oncolytic Adenovirus DNX-2440 | Oncolytic Adenovirus Armed With OX40L DNX-2440 | TEZEMLIMOGENE DAXADENOREPVEC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969331","Documentation Present","C160193","Documentation is present.","Documentation Present | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969330","Documentation Absent","C160194","Documentation is absent.","Documentation Absent | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969329","CCS 1477","C160195","An orally bioavailable, small molecule inhibitor of the highly conserved bromodomains of the histone acetyltransferase (HAT) paralogs, p300 (E1A-associated protein p300; p300 HAT) and CREB binding protein (CBP), with potential antineoplastic activity. Upon oral administration, inobrodib selectively and reversibly binds to the bromodomains of p300 and CBP. This disrupts the acetylation of histones and other proteins and prevents the co-activation of key transcription factors that contribute to tumor progression including the androgen receptor (AR), androgen receptor splice variants (AR-SV), hypoxia-inducible factor 1-alpha (HIF-1-alpha) and Myc proto-oncogene protein (c-Myc). The HAT paralogs p300 and CBP are key transcriptional co-activators that are essential for a multitude of cellular processes and are implicated in the progression and therapeutic resistance of certain cancers.","Inobrodib | CCS 1477 | CCS-1477 | CCS1477 | INOBRODIB | p300 HAT/CREB Binding Protein Inhibitor CCS1477 | p300/CBP Bromodomain Inhibitor CCS1477",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969328","Documentation Unknown","C160196","Documentation is unknown.","Documentation Unknown | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969340","CALR Exon 9 Mutant Peptide Vaccine/Montanide ISA-51","C160197","A peptide vaccine consisting of a calreticulin (CALR) mutant peptide, CALRLong36, and montanide ISA 51 with potential antineoplastic activity. Upon vaccination, the CALR exon 9 mutant peptide vaccine may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL)-mediated response against tumor cells harboring mutations in exon 9 of the calreticulin gene. CALR, an endoplasmic reticulum chaperone protein that normally facilitates protein folding, immune response, and hematopoiesis, is often mutated in patients with chronic myeloproliferative neoplasms. In its mutant form, CALR is secreted into the plasma, where it binds to and activates the thrombopoietin receptor MPL and initiates downstream JAK/STAT signaling. Montanide ISA-51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil (w/o) emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens.","CALR Exon 9 Mutant Peptide Vaccine/Montanide ISA-51 | CALR Exon 9 Mutant Peptide Vaccine With Montanide ISA-51 | CALRLong36 Peptide Vaccine/Montanide ISA-51",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951203","Satellite Lesion","C159276","Nodules of melanoma located more than 0.05 mm from the primary lesion.","Satellite Lesion | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518505","Nutrition, Vitamin B","C15927","Role of Vitamin B, its precursons, and its analogs in cancer causation or prevention and in general health.","Nutrition, Vitamin B | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951155","Intraoperative Blood Product Administration","C159284","A header for a form section about intraoperative blood product administration.","Intraoperative Blood Product Administration | Intraoperative blood product administration (Optional)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951157","Surgical Procedure Details","C159286","A header for a form section about other surgical procedure details.","Surgical Procedure Details | Surgical procedure details",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968872","Other Medication","C159287","A directive to specify the other medication administered.","Other Medication | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518506","Nutrition, Vitamin C","C15928","Role of Vitamin C, its precursons, and its analogs in cancer causation or prevention and in general health.","Nutrition, Vitamin C | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951389","Two-Stage Clotting Factor Assay","C159551","A two-staged test with purified coagulation factors in the first stage, and a FXa-specific chromogenic substrate in the second stage. In the first stage, diluted sample plasma, which has been treated with Al(OH)3 to remove prothrombin, is mixed with a combined reagent (human serum, factor V, phospholipids and calcium). In the second stage, a subsample from the first stage is mixed with normal plasma, providing prothrombin and fibrinogen, and the clotting time is measured to deduce the amount of FVIII present.","Two-Stage Clotting Factor Assay | Two-Stage Clotting Assay",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950809","MLH1 Gene Promoter Hypermethylation","C158920","A genetic finding indicating that an excess of DNA methylation in the promoter region of the MLH1 gene has been detected in a sample.","MLH1 Gene Promoter Hypermethylation | COCA2 Promoter Hypermethylation | HNPCC2 Promoter Hypermethylation | MLH1 Promoter Hypermethylation | MutL Homolog 1 Promoter Hypermethylation | MutL, E. coli, Homolog of, 1 Promoter Hypermethylation | Present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950810","MN1 Gene Mutation","C158921","A change in the sequence of the MN1 gene.","MN1 Gene Mutation | MGCR Gene Mutation | MGCR1 Gene Mutation | MGCR1-PEN Gene Mutation | MN1 | MN1 Proto-Oncogene, Transcriptional Regulator Gene Mutation | Meningioma Chromosome Region 1 Gene Mutation | Meningioma Chromosome Region Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950811","NF1 Mutation Analysis","C158922","A procedure used to detect and identify mutations in the NF1 gene.","NF1 Mutation Analysis | NF1 Gene Mutation Analysis | NF1 Mutation Status | NFNS Mutation Analysis | Neurofibromin 1 Mutation Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950812","NF1 Mutation Analysis Testing Method","C158923","A request to enter the specific molecular analysis method used to detect and identify mutations in the NF1 gene.","NF1 Mutation Analysis Testing Method | NF1 Mutational Analysis Testing Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1268127","Ureter Part","C160613","A named segment of the ureter.","Ureter Part | ",,,,,,,,,,,,,,,"4001210","Ureter part",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL969669","Upper Ureter","C160614","The segment of the ureter that extends from the renal pelvis to the upper border of the sacrum.","Upper Ureter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969668","Middle Ureter","C160615","The segment of the ureter that extends between the upper to lower borders of the sacrum.","Middle Ureter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969666","Abdominal Ureter","C160617","The segment of the ureter that extends from the renal pelvis to the iliac vessels.","Abdominal Ureter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969665","Pelvic Ureter","C160618","The segment of the ureter that extends from the iliac vessels to the bladder.","Pelvic Ureter | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969677","Recurrent Malignant Ovarian Granulosa Cell Tumor","C160619","The reemergence of malignant ovarian granulosa cell tumor after a period of remission.","Recurrent Malignant Ovarian Granulosa Cell Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1520140","Whitehead Map of the Human Genome","C16061","Comprehensive maps integrating genetic, physical, STS, EST and radiation hybrid data.","Whitehead Map of the Human Genome | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969676","Tumor Reoccurrence Present After Initial Treatment","C160620","A response that the tumor reoccurrence was present after the initial treatment.","Tumor Reoccurrence Present After Initial Treatment | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969675","Allogeneic CD34+-enriched and CD45RA-depleted PBSCs","C160621","A preparation of donor-derived peripheral blood stem cells (PBSCs) that have been enriched with CD34-positive stem cells and have been depleted of CD45RA-positive cells, that can potentially be used for immune reconstitution purposes. CD45RA depletion results in a cellular product that contains a high amount of memory T-cells (Tm). Upon infusion of the allogeneic CD34+-enriched and CD45RA-depleted PBSCs after a hematopoietic cell transplantation (HCT), these cells provide Tm recovery and are able to prevent viral infections. The depletion of the CD45RA-positive cells reduces the risk of graft-versus-host disease (GvHD) upon infusion. CD45RA is expressed on naive T-cells (Tn), whereas Tm cells are CD45RA-negative. Tn cells have the potential to induce more severe GvHD than Tm cells.","Allogeneic CD34+-enriched and CD45RA-depleted PBSCs | Allogeneic Tn-depleted CD34-preserved PBSCs | Allogeneic TnD- CD34+ PBSCs | Donor-derived Tn Cell Depleted CD34-enriched PBSCs | Naive T-cell Depleted CD34+ Allogeneic Peripheral Blood Stem Cells",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969922","Interferon Gamma Treatment was Administered Prior to Specimen Resection","C160839","A response that interferon gamma treatment was administered prior to the specimen resection.","Interferon Gamma Treatment was Administered Prior to Specimen Resection | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514409","Prevention Protocol","C16083","The protocol associated with a clinical trial that is focused on cancer prevention.","Prevention Protocol | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969921","Interferon Gamma Treatment was not Administered Prior to Specimen Resection","C160840","A response that interferon gamma treatment was not administered prior to the specimen resection.","Interferon Gamma Treatment was not Administered Prior to Specimen Resection | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969920","Unknown if Interferon Gamma Treatment was Administered Prior to Specimen Resection","C160841","A response that it is unknown if interferon gamma treatment was administered prior to the specimen resection.","Unknown if Interferon Gamma Treatment was Administered Prior to Specimen Resection | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969919","Interferon Gamma Treatment was Administered 90 Days Prior to Specimen Resection","C160842","A response that interferon gamma treatment was administered 90 days prior to the specimen resection.","Interferon Gamma Treatment was Administered 90 Days Prior to Specimen Resection | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969918","Interferon Gamma Treatment was not Administered 90 Days Prior to Specimen Resection","C160843","A response that interferon gamma treatment was not administered 90 days prior to the specimen resection.","Interferon Gamma Treatment was not Administered 90 Days Prior to Specimen Resection | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969339","Unknown Tumor Zone","C160198","An indication that the tumor zone is unknown.","Unknown Tumor Zone | Unknown zone | Unknown: Could not be determined or unsure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969579","Rectal Neuroendocrine Tumor G2","C160451","A well-differentiated, intermediate-grade neuroendocrine neoplasm that arises from the rectum. The mitotic count is 2-20 per 2 mm2 and/or the Ki-67 index is 3 to 20%.","Rectal Neuroendocrine Tumor G2 | Malignant carcinoid tumor of the rectum | Rectal NET G2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969578","Not Known if EGFR Amplification Analysis Was Performed","C160452","An indication that it is not known whether EGFR amplification analysis was performed during the study.","Not Known if EGFR Amplification Analysis Was Performed | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969577","Not Known if EGFR Mutation Analysis Was Performed","C160453","An indication that it is not known whether EGFR mutation analysis was performed during the study.","Not Known if EGFR Mutation Analysis Was Performed | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969576","Not Known if ERBB2 Mutation Analysis Was Performed","C160454","An indication that it is not known whether ERBB2 mutation analysis was performed during the study.","Not Known if ERBB2 Mutation Analysis Was Performed | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969575","Not Known if IDH Family Mutation Analysis Was Performed","C160455","An indication that it is not known whether IDH family mutation analysis was performed during the study.","Not Known if IDH Family Mutation Analysis Was Performed | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969574","Not Known if KIT Mutation Analysis Was Performed","C160456","An indication that it is not known whether KIT mutation analysis was performed during the study.","Not Known if KIT Mutation Analysis Was Performed | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969589","Not Known if KRAS Mutation Analysis Was Performed","C160457","An indication that it is not known whether KRAS rearrangement analysis was performed during the study.","Not Known if KRAS Mutation Analysis Was Performed | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969588","Not Known if Lymph Node Dissection Was Performed","C160458","An indication that it is not known whether lymph node dissection was performed during the study.","Not Known if Lymph Node Dissection Was Performed | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517289","Food Patterns","C16045","The types of food combinations that are commonly eaten by a population.","Food Patterns | Dietary Patterns | Food Consumption Patterns",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969586","Not Known if MGMT Promoter Methylation Testing Was Performed","C160460","An indication that it is not known whether MGMT promoter methylation analysis was performed during the study.","Not Known if MGMT Promoter Methylation Testing Was Performed | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969585","Not Known if NF1 Mutation Analysis Was Performed","C160461","An indication that it is not known whether NF1 mutation analysis was performed during the study.","Not Known if NF1 Mutation Analysis Was Performed | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969584","Not Known if NRAS Mutation Analysis Was Performed","C160462","An indication that it is not known whether NRAS rearrangement analysis was performed during the study.","Not Known if NRAS Mutation Analysis Was Performed | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969583","Not Known if PDGFRA Mutation Analysis Was Performed","C160463","An indication that it is not known whether PDGFRA mutation analysis was performed during the study.","Not Known if PDGFRA Mutation Analysis Was Performed | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969582","Not Known if Peripheral Blood Immunophenotyping and Cytochemistry Were Performed","C160464","An indication that it is not known if immunophenotyping and cytochemistry were performed on peripheral blood samples during the study.","Not Known if Peripheral Blood Immunophenotyping and Cytochemistry Were Performed | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969597","Not Known if PTEN Mutation Analysis Was Performed","C160465","An indication that it is not known whether PTEN mutation analysis was performed during the study.","Not Known if PTEN Mutation Analysis Was Performed | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969042","Bosutinib Regimen","C160002","A regimen consisting of bosutinib that may be used in the treatment of chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) and myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes.","Bosutinib Regimen | Bosulif Regimen | Bosutinib monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969041","Brentuximab Vedotin Regimen","C160003","A regimen consisting of brentuximab vedotin that may be used in the treatment of diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL), T-cell lymphoma, primary cutaneous CD30+ T-cell lymphoproliferative disorders, and mycosis fungoides/Sezary syndrome.","Brentuximab Vedotin Regimen | Adcetris Regimen | Brentuximab vedotin monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969055","Capecitabine Regimen","C160005","A regimen consisting of capecitabine that may be used in the treatment of anal carcinoma, breast (and its metastases to the central nervous system), bladder, colon, esophageal and esophagogastric junction, gastric, hepatobiliary, ovarian, fallopian tube, primary peritoneal, rectal and head and neck cancers, appendiceal, small bowel, ampullary and pancreatic adenocarcinoma, occult primary and gestational trophoblastic tumors, and neuroendocrine tumors (NETs) of the gastrointestinal (GI) tract, lung, and thymus.","Capecitabine Regimen | Capecitabine monotherapy | Xeloda Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969054","Carboplatin Regimen","C160006","A regimen consisting of carboplatin that may be used in the treatment of certain central nervous system (CNS), breast, cervical, head and neck, including cancer of the nasopharynx, testicular, ovarian, fallopian tube, primary peritoneal, endometrial, and vulvar cancers; and Merkel cell carcinoma.","Carboplatin Regimen | Carboplatin monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969053","Carmustine Regimen","C160007","A regimen consisting of carmustine that can be used in the treatment of anaplastic gliomas and glioblastomas; adult low-grade infiltrative supratentorial astrocytoma/oligodendroglioma (excluding pilocytic astrocytoma); and adult intracranial and spinal ependymomas (excluding subependymomas and myxopapillary ependymomas).","Carmustine Regimen | BiCNU Regimen | Carmustine monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969052","Ceritinib Regimen","C160008","A regimen consisting of ceritinib that may be used in the treatment of inflammatory myofibroblastic tumor (IMT) with ALK translocation, uterine sarcoma, non-small cell lung cancer (NSCLC), T-cell lymphomas and certain histiocytic neoplasms, such as Erdheim-Chester disease.","Ceritinib Regimen | Ceritinib monotherapy | Zykadia Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969050","Chlorambucil Regimen","C160010","A regimen consisting of chlorambucil that may be used in the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL),and follicular lymphoma (grade 1-2).","Chlorambucil Regimen | Chlorambucil monotherapy | Leukeran Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969048","Cladribine Regimen","C160012","A regimen consisting of cladribine that may be used in the treatment of hairy cell leukemia, Waldenstrom's macroglobulinemia (WM), lymphoplasmacytic lymphoma (LPL), systemic mastocytosis, T-cell large granular lymphocytic leukemia and certain histiocytic neoplasms, such as Langerhans cell histiocytosis, Erdheim-Chester disease and Rosai-Dorfman disease.","Cladribine Regimen | Cladribine monotherapy | Leustatin Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969063","Crizotinib Regimen","C160013","A regimen consisting of crizotinib that may be used in the treatment of inflammatory myofibroblastic tumor (IMT) with ALK translocation, non-small cell lung cancer (NSCLC), cutaneous melanoma, T-cell lymphoma and uterine sarcoma.","Crizotinib Regimen | Crizotinib monotherapy | Xalkori Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969061","Cytarabine Intrathecal Regimen","C160015","A regimen consisting of intrathecal cytarabine that may be used in the treatment of acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN), central nervous system (CNS) cancer, and diffuse large B-cell lymphoma.","Cytarabine Intrathecal Regimen | IT Cytarabine monotherapy | Intrathecal Ara-C Regimen | Intrathecal Cytarabine Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL950996","NRAS NP_002515.1:p.G13S","C158928","A change in the amino acid residue at position 13 in the GTPase NRas protein where glycine has been replaced by serine.","NRAS NP_002515.1:p.G13S | GTPase NRas G13S | GTPase NRas Gly13Ser | NP_002515.1:p.G13S | NP_002515.1:p.Gly13Ser | NRAS G13S | NRAS Gly13Ser | NRAS NP_002515.1:p.Gly13Ser | NRAS p.G13S | NRAS p.Gly13Ser | Transforming Protein N-Ras G13S | Transforming Protein N-Ras Gly13Ser",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL763653","Nuclear Expression Intact","C158929","An indication that expression of a nuclear factor is detected in the nuclei of cells in a sample.","Nuclear Expression Intact | Intact nuclear expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516987","Evaluation of Risk Factors","C15892","No value exists.","Evaluation of Risk Factors | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951000","Specify Other KRAS Codon 12 Mutation","C158933","A request to enter the specific KRAS codon 12 mutation that was identified in the study but is not present in the form.","Specify Other KRAS Codon 12 Mutation | Other codon 12 mutation, specify:",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951001","Specify Other KRAS Codon 13 Mutation","C158934","A request to enter the specific KRAS codon 13 mutation that was identified in the study but is not present in the form.","Specify Other KRAS Codon 13 Mutation | Other codon 13 mutation, specify:",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951002","Specify Other KRAS Codon 61 Mutation","C158935","A request to enter the specific KRAS codon 61 mutation that was identified in the study but is not present in the form.","Specify Other KRAS Codon 61 Mutation | Other codon 61 mutation, specify:",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951620","AVID 200","C159817","A fusion protein composed of the ectodomain of the transforming growth factor (TGF) beta (TGF-beta; TGFb) receptor fused to the human immunoglobulin G (IgG) Fc domain, with potential antineoplastic, immunomodulating and anti-fibrotic activities. Upon administration of the TGFb receptor ectodomain-IgG Fc fusion protein BMS-986416, the fusion protein specifically and selectively targets, binds to and neutralizes the TGF ligands TGF-beta isoform 1 (TGFb1) and 3 (TGFb3). This prevents TGF ligands from binding to TGF receptors and prevents TGFb-mediated signaling. This abrogates TGFb1/3-mediated immunosuppression, enhances anti-tumor immunity in the tumor microenvironment (TME) and promotes a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGFb-dependent proliferation of cancer cells. By preventing TGFb1/3-mediated signaling, BMS-986416 also prevents bone marrow fibrosis and promotes the proliferation of normal hematopoietic progenitors. TGFb, overproduced in myelodysplastic syndrome (MDS) and in many other types of cancer, plays a key role in immunosuppression in the TME, enhances tumor cell proliferation, and promotes cancer progression. The TGFb1 and TGFb3 isoforms are negative regulators of hematopoiesis that play key roles in the pathogenesis and progression of fibrotic diseases. By selectively targeting only specific isoforms of TGFb with minimal activity against TGFb2, BMS-986416 minimizes the potential for cardiotoxicity and promotion of metastasis. The TGFb2 isoform promotes hematopoiesis and plays a key role in normal cardiac function while the inhibition of the TGFb2 isoform promotes metastasis.","TGFbeta Receptor Ectodomain-IgG Fc Fusion Protein BMS-986416 | AVID 200 | AVID-200 | AVID200 | BMS 986416 | BMS-986416 | BMS986416 | TGF-beta 1/3 Inhibitor AVID200 | TGFb Inhibitor AVID200 | TGFbeta Ligand Trap AVID200 | TGFbeta-neutralizing Agent AVID200",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515079","Supportive Cancer Chemotherapy","C15981","Treatment designed to improve the health of a chemotherapy patient but that does not directly affect the tumor.","Supportive Cancer Chemotherapy | Chemotherapy, Cancer, Supportive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969930","Are Sarcomatoid Features Present","C160845","A question about whether sarcomatoid features are present in a specimen.","Are Sarcomatoid Features Present | Sarcomatoid Features",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969929","Sarcomatoid Features Absent","C160846","A response that sarcomatoid features are absent in a specimen.","Sarcomatoid Features Absent | Not identified",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969928","Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3006","C160847","A preparation of autologous T-lymphocytes that have been genetically modified to co-express three transgenes using the Sleeping Beauty (SB) transposon system and include a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD33, a membrane-bound IL-15 (mbIL15) and a safety/kill switch, with potential immunostimulating and antineoplastic activities. Upon introduction of the autologous anti-CD33 CAR-mbIL15-safety switch T-cells PRGN-3006 into the patient, the T-cells target and bind to CD33-expressing tumor cells, thereby inducing selective toxicity in CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem cells and overexpressed on a variety of cancer cell types, including acute myeloid leukemia (AML). It plays a key role in tumor initiation, proliferation and progression. IL-15 is a pro-survival cytokine that is required for the maintenance of long-lived CD8+ memory T-cells and use of mbIL15 preserves T stem-cell memory (TSCM) through sustained IL-15 signaling, improves T-cell persistence and potentiates the immune response against tumor cells. The safety switch can promote selective elimination of the CAR-T cells. The SB system permits integration of the CAR, the IL-15 fusion variant and safety switch transgenes into T-cells without the need for viral vectors and accelerates the manufacturing process.","Autologous Anti-CD33 CAR-mbIL15-Safety Switch T-cells PRGN-3006 | Autologous Anti-CD33 CAR-T Cells PRGN-3006 | Autologous CAR-T Cells PRGN 3006 | Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3006 | PRGN 3006 | PRGN-3006 | PRGN3006",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969926","Advanced Paraganglioma","C160852","A paraganglioma that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Paraganglioma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969144","Topotecan Weekly Regimen","C160132","A regimen consisting of weekly topotecan that may be used in the treatment of cervical, vaginal, ovarian, fallopian tube, and primary peritoneal cancers.","Topotecan Weekly Regimen | Weekly Hycamtin Regimen | Weekly Topotecan HCl Regimen | Weekly Topotecan Hydrochloride Regimen | Weekly Topotecan Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969159","Toremifene Regimen","C160133","A regimen consisting of toremifene that may be used in the treatment of breast cancer.","Toremifene Regimen | Fareston Regimen | Toremifene Citrate Regimen | Toremifene monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969158","Trabectedin Regimen","C160134","A regimen consisting of trabectedin that may be used in the treatment of soft tissue and uterine sarcoma, including uterine leiomyosarcoma.","Trabectedin Regimen | Trabectedin monotherapy | Yondelis Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969157","Trastuzumab Regimen","C160135","A regimen consisting of trastuzumab that may be used in the treatment of breast cancer and salivary gland tumors.","Trastuzumab Regimen | Herceptin Regimen | Trastuzumab monotherapy | Trastuzumab-anns monotherapy | Trastuzumab-dkst monotherapy | Trastuzumab-dttb monotherapy | Trastuzumab-herw monotherapy | Trastuzumab-pkrb monotherapy | Trastuzumab-qyyp monotherapy | Trastuzumab-strf monotherapy | Trastuzumab-zerc monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969596","Not Known if RET Rearrangement Analysis Was Performed","C160466","An indication that it is not known whether RET rearrangement analysis was performed during the study.","Not Known if RET Rearrangement Analysis Was Performed | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969595","Use of Smokeless Tobacco at Time of Diagnosis Positive","C160467","A response was that the individual was using smokeless tobacco at the time of diagnosis.","Use of Smokeless Tobacco at Time of Diagnosis Positive | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969593","Use of Smokeless Tobacco at Time of Diagnosis Negative","C160469","A response was that the individual was not using smokeless tobacco at the time of diagnosis.","Use of Smokeless Tobacco at Time of Diagnosis Negative | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969653","Hematologic Malignancy-Associated Skin Squamous Cell Carcinoma","C160666","A squamous cell carcinoma that arises from the skin in a patient with a history of hematologic malignancy, usually non-Hodgkin lymphoma or chronic lymphocytic leukemia.","Hematologic Malignancy-Associated Skin Squamous Cell Carcinoma | HMCSCC | Hematologic Malignancy-Associated Cutaneous Squamous Cell Carcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969652","Melanoma and Non-Melanoma Related Event Occurred after Initial Treatment","C160667","A response that a melanoma and non-melanoma related only event occurred after the initial treatment.","Melanoma and Non-Melanoma Related Event Occurred after Initial Treatment | Yes- Melanoma & Non-Melanoma Related",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969605","Was Additional Pharmaceutical Treatment for New Tumor Event Administered","C160668","No value exists.","Was Additional Pharmaceutical Treatment for New Tumor Event Administered | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969604","Classified by FAB Only","C160669","A response that the bone marrow was classified by the French-American-British (FAB) method only.","Classified by FAB Only | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513490","Mortality Map","C16066","A visual representation of the national cancer burden.  These maps display cancer mortality data by county and state economic regions across the country.  They are color coded to distinguish between regions with high, intermediate, and low rates of cancer mortality.","Mortality Map | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969603","Select One Tumor Site","C160670","A direction to select one of the listed tumor sites.","Select One Tumor Site | Select One",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969599","Unknown Use of Hormonal Contraceptives","C160674","The individual's use of hormonal contraceptives is unknown.","Unknown Use of Hormonal Contraceptives | Unknown: Could not be determined or unsure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969598","Human Immunodeficiency Virus Unknown","C160675","Indicates that human immunodeficiency virus status of a sample is unknown.","Human Immunodeficiency Virus Unknown | Unknown: Could not be determined or unsure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969612","Specify Other Histologic Type","C160676","A directive to specify the other histologic type.","Specify Other Histologic Type | If Other, Specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969610","Chemical/Occupational Exposure History Unknown","C160678","An indication that a history of chemical/occupational exposures is unknown.","Chemical/Occupational Exposure History Unknown | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969060","Cytarabine Subcutaneous Regimen","C160016","A regimen consisting of subcutaneous cytarabine that may be used in the treatment of acute myeloid leukemia (AML).","Cytarabine Subcutaneous Regimen | Subcutaneous Ara-C Regimen | Subcutaneous Cytarabine Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969059","Dabrafenib Regimen","C160017","A regimen consisting of dabrafenib that may be used in the treatment of non-small cell lung cancer (NSCLC), oncocytic, follicular, papillary, and Hurthle cell thyroid carcinomas; cutaneous melanoma, and certain histiocytic neoplasms, such as Erdheim-Chester disease and Langerhans cell histiocytosis.","Dabrafenib Regimen | Dabrafenib Mesylate Regimen | Dabrafenib monotherapy | Tafinlar Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951411","STAB1 wt Allele","C159509","Human STAB1 wild-type allele is located in the vicinity of 3p21.1 and is approximately 29 kb in length. This allele, which encodes stabilin-1 protein, plays a role in cell-cell signaling and binding to both bacteria and acetylated low density lipoprotein particles.","STAB1 wt Allele | CLEVER-1 | FEEL-1 | FEEL1 | FELE-1 | FEX1 | KIAA0246 | SCARH2 | STAB-1 | Stabilin 1 wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510819","Advanced Technology Center","C15950","The concept of the Center was to have a facility whereby individuals (geneticists, cell biologists, and laboratory-based clinicians) could assemble in an arena to review technologies that are mature enough to span both science and clinics. One section of the ATC is the genome's National Institutes Sequencing Center (NISC) where the NCI sequencing and genotyping group will be located, and another part is the array facility.","Advanced Technology Center | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951412","Stabilin-1","C159510","Stabilin-1 (2570 aa, ~275 kDa) is encoded by the human STAB1 gene. This protein is involved in signal transduction mediated by acetylated low density lipoprotein binding.","Stabilin-1 | CLEVER-1 | Common Lymphatic Endothelial and Vascular Endothelial Receptor-1 | FEEL-1 | Fasciclin EGF-Like, Laminin-Type EGF-Like, and Link Domain-Containing Scavenger Receptor 1 | Fasciclin EGF-Like, Laminin-Type EGF-Like, and Link Domain-Containing Scavenger Receptor-1 | Fasciclin, EGF-Like, Laminin-Type EGF-Like and Link Domain-Containing Scavenger Receptor 1 | MS-1 Antigen | STAB-1 | STAB1 | Stabilin 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0577916","Lung Lesion","C159515","A localized pathological or traumatic structural change, damage, deformity, or discontinuity of the lung.","Lung Lesion | ",,,,,,,,,,,,,,,"4116778","Lesion of lung",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0577053","Liver Lesion","C159516","A localized pathological or traumatic structural change, damage, deformity, or discontinuity of the liver.","Liver Lesion | ",,,,,,,,,,,,,,,"4104000","Lesion of liver",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL968999","[Leu15] Gastrin-17","C159822","A C-terminal amidated synthetic gastrin analog with a single amino acid change at position 15, where leucine replaces methionine, with potential hypoglycemic and immunomodulatory activities. Following pancreatic islet cell transplantation, subcutaneous administration of [Leu15] Gastrin-17 (GAST-17) may induce pancreatic beta cell regeneration and expansion and enhance the insulin secretory capacity of islet cell grafts. Additionally, GAST-17 may reduce inflammation within the islet cell environment, which could potentially improve islet graft survival and function. Gastrin, a gastrointestinal peptide, may induce beta cell neogenesis via induction of the duodenal and pancreatic homeobox transcription factor, PDX-1. Gastrin may also promote beta cell proliferation and neogenesis indirectly through increasing the production of clustrin, a beta cell expansion factor.","[Leu15] Gastrin-17 | GAST 17 | GAST-17 | GAST17",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951711","Not Lost to Follow-Up","C159823","The individual was not lost to follow-up.","Not Lost to Follow-Up | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL968997","Describes Very Well","C159825","An indication that something describes the individual's situation very well.","Describes Very Well | Very Well",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512069","Drug Development, Experimental","C15982","Drug development activites focused on the phases preceding preclinical trials and testing.","Drug Development, Experimental | Drug Testing/Development, Experimental",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951364","CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form","C159330","No value exists.","CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951365","CPTAC Sarcoma Follow-Up Form","C159331","No value exists.","CPTAC Sarcoma Follow-Up Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951366","CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form","C159332","No value exists.","CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951367","CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form","C159333","No value exists.","CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951369","CPTAC Glioblastoma Multiforme Follow-Up Form","C159335","No value exists.","CPTAC Glioblastoma Multiforme Follow-Up Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951370","CPTAC Melanoma Follow-Up Form","C159336","No value exists.","CPTAC Melanoma Follow-Up Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951371","CPTAC Renal Cell Carcinoma Follow-Up Form","C159337","No value exists.","CPTAC Renal Cell Carcinoma Follow-Up Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951372","CPTAC Acute Myeloid Leukemia Follow-Up Form","C159338","No value exists.","CPTAC Acute Myeloid Leukemia Follow-Up Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951373","CPTAC Acute Myeloid Leukemia Baseline Form","C159339","No value exists.","CPTAC Acute Myeloid Leukemia Baseline Form | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969155","Triptorelin Regimen","C160137","A regimen consisting of triptorelin that may be used in the treatment of prostate and breast cancers.","Triptorelin Regimen | Trelstar Regimen | Triptorelin Pamoate Regimen | Triptorelin monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969154","Valrubicin Regimen","C160138","A regimen consisting of valrubicin that may be used in the treatment of refractory carcinoma in situ (CIS) of the bladder.","Valrubicin Regimen | Intravesicular Valrubicin monotherapy | Valrubicin monotherapy | Valstar Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969153","Vandetanib Regimen","C160139","A regimen consisting of vandetanib that may be used in the treatment of advanced follicular, medullary, papillary and Hurthle cell thyroid carcinomas.","Vandetanib Regimen | Caprelsa Regimen | Vandetanib monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518480","Nutrition, Antioxidants","C16013","Role of antioxidants in cancer causation or prevention and in general health.","Nutrition, Antioxidants | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969152","Vemurafenib Regimen","C160140","A regimen consisting of vemurafenib that may be used in the treatment of follicular, papillary and Hurthle cell thyroid carcinomas, cutaneous melanoma, hairy cell leukemia, non-small cell lung cancer (NSCLC), and certain histiocytic neoplasms, such as Langerhans cell histiocytosis and Erdheim-Chester disease.","Vemurafenib Regimen | Vemurafenib monotherapy | Zelboraf Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969166","Venetoclax Regimen","C160141","A regimen consisting of venetoclax that may be used in the treatment of hairy cell leukemia, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), mantle cell lymphoma and Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma.","Venetoclax Regimen | Venclexta Regimen | Venetoclax monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969165","Liposomal Vincristine Regimen","C160142","A regimen consisting of vincristine sulfate liposome that may be used in the treatment of acute lymphoblastic leukemia (ALL).","Vincristine Liposomal Regimen | Liposomal Vincristine Regimen | Liposomal Vincristine Sulfate Regimen | Marqibo Regimen | Vincristine liposomal monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969164","Vinorelbine Regimen","C160143","A regimen consisting of vinorelbine that may be used in the treatment of soft tissue and AIDS-related Kaposi sarcoma; soft tissue sarcoma; rhabdomyosarcoma, peritoneal and pleural mesothelioma, breast, cervical, ovarian, fallopian tube, primary peritoneal, and small cell lung cancers.","Vinorelbine Regimen | Navelbine Regimen | Vinorelbine Tartrate Regimen | Vinorelbine monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL525267","Low Anterior Resection Syndrome","C160144","A collection of symptoms following removal of part or all of the rectum that may include frequency or urgency of stools, numerous bowel movements over a few hours, fecal incontinence, constipation alternating with numerous bowel movements, and/or increased intestinal gas.","Low Anterior Resection Syndrome | ",,,,,,,,,,,,,,,"3655999","Low anterior resection syndrome",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL969163","Sacral Nerve Stimulator","C160145","A surgically implanted medical device that sends electrical impulses to the sacral nerve. It is used to treat bladder or bowel dysfunction.","Sacral Nerve Stimulator | Sacral Neuromodulator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969162","Sacral Nerve Stimulator Battery","C160146","A rechargeable battery that powers a surgically implanted sacral nerve stimulator.","Sacral Nerve Stimulator Battery | Sacral Neuromodulator Battery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969405","MGMT Promoter Methylation Testing Was Not Performed","C160406","An indication that MGMT promoter methylation analysis was not performed during the study.","MGMT Promoter Methylation Testing Was Not Performed | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969404","MGMT Promoter Methylation Testing Was Performed","C160407","An indication that MGMT promoter methylation analysis was performed during the study.","MGMT Promoter Methylation Testing Was Performed | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511186","Black/White Cancer Survival Study","C16067","A study designed to investigate the significance of social, behavioral, lifestyle, biological, treatment, and health care factors in relation to the observed differences in cancer survival between African-Americans and white Americans. Data was collected on more than 3,400 patients, focusing on cancers of the breast, colon, uterus, and bladder.","Black/White Cancer Survival Study | BWCSS | Black/White Cancer Study",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969609","Family History of Stomach Cancer Unknown","C160680","There is an unknown family history of stomach cancer.","Family History of Stomach Cancer Unknown | Unknown: Could not be determined or unsure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969608","New Disease is Multifocal","C160681","A response that the new disease is multifocal.","New Disease is Multifocal | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969607","New Disease is not Multifocal","C160682","A response that the new disease is not multifocal.","New Disease is not Multifocal | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969606","Unknown if New Disease is Multifocal","C160683","It is unknown if the new disease is multifocal.","Unknown if New Disease is Multifocal | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969908","Adipose-derived Expanded Mesenchymal Stem Cells SCM-010","C160891","A preparation of human adipose-derived mesenchymal stem cells (MSCs), that can potentially be used for engraftment purposes in certain autoimmune disorders. Upon intrathecal administration, adipose-derived expanded mesenchymal stem cells SCM-010 migrate to the bone marrow. These MSCs are pluripotent and capable of differentiating along specific lineages and may activate the immune system and repair damage to the nervous system.","Adipose-derived Expanded Mesenchymal Stem Cells SCM-010 | ADSCs SCM-010 | Adipose Derived Stem Cells SCM-010 | SCM 010 | SCM-010 | SCM010",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969907","Class of Case","C160892","A designation assigned to a group of cases within a study or trial.","Class of Case | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969906","Date of Last Contact or Death","C160893","The date of the last contact with an individual or the date of their death.","Date of Last Contact or Death | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969905","Diagnostic Confirmation Code","C160894","The code for the method of cancer diagnostic confirmation.","Diagnostic Confirmation Code | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969864","Computed Spanish/Hispanic Ethnicity Code","C160895","Code identifying individuals for which ethnicity was determined by matching Last Name and Maiden Name to a computer list of Spanish/Hispanic names or by a software algorithm.","Computed Spanish/Hispanic Ethnicity Code | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969861","Primary Healthcare Payer at Diagnosis","C160898","Primary payer/insurance carrier at the time of initial diagnosis and/or treatment.","Primary Healthcare Payer at Diagnosis | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969860","SEER Race Code","C160899","Race code in accordance with the SEER Program Coding and Staging Manual.","SEER Race Code | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517071","Extraordinary Opportunity: Cancer Genetics","C16089","No value exists.","Extraordinary Opportunity: Cancer Genetics | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512515","Human Specimen Resources","C15951","No value exists.","Human Specimen Resources | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951418","Patient Case Review","C159520","Analysis of a patient case report to create a knowledge repository.","Patient Case Review | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951420","Undetermined Explanation","C159522","A request to provide an explanation.","Undetermined Explanation | Cannot be determined, explain | Request for Explanation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951623","Anti-CTLA-4 Monoclonal Antibody REGN4659","C159764","A fully human immunoglobulin G1 (IgG1) antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, anti-CTLA-4 monoclonal antibody REGN4659 targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.","Anti-CTLA-4 Monoclonal Antibody REGN4659 | REGN 4659 | REGN-4659 | REGN4659",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951624","Specify Number of Lymph Nodes Positive for Tumor by IHC Staining Only","C159765","A directive to specify the number of lymph nodes found positive for tumor by immunohistochemical (IHC) staining procedures.","Specify Number of Lymph Nodes Positive for Tumor by IHC Staining Only | Specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951625","Specify Number of Lymph Nodes Positive for Tumor by H&E","C159766","A directive to specify the number of lymph nodes positive for tumor by H&E.","Specify Number of Lymph Nodes Positive for Tumor by H&E | Specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3842591","Zero Full Term Pregnancies","C159767","A response indicating there were no full term pregnancies.","Zero Full Term Pregnancies | 0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951700","One Full Term Pregnancy","C159768","A response indicating there was one full term pregnancy.","One Full Term Pregnancy | 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951716","Two Full Term Pregnancies","C159769","A response indicating there were two full term pregnancies.","Two Full Term Pregnancies | 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1513697","Mouse Tumor Gene Index","C15976","A component of CGAP.","Mouse Tumor Gene Index | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971252","Three Full Term Pregnancies","C159770","A response indicating there were three full term pregnancies.","Three Full Term Pregnancies | 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971200","Greater than or equal to Four Pregnancies","C159771","A response indicating there were greater than or equal to four full term pregnancies.","Greater than or equal to Four Pregnancies | >=4 | Greater Than or Equal to 4 Pregnancies",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971172","Unknown: Could not be determined or unsure","C159773","An individual whose use of oral contraceptives is unknown.","Unknown Oral Contraceptive Use | Unknown | Unknown: Could not be determined or unsure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951628","Unresectable Gastric Carcinoma","C159775","A gastric carcinoma that is not amenable to surgical resection.","Unresectable Gastric Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448285","Health Research Service","C15933","No value exists.","Health Research Service | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0230295","Pelvic Peritoneum","C159344","A membranous lining of the pelvic organs.","Pelvic Peritoneum | ",,,,,,,,,,,,,,,"4216534","Pelvic peritoneum structure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1519102","Risk Factor Service","C15934","No value exists.","Risk Factor Service | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951393","Advanced Adenocarcinoma","C159556","An adenocarcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969355","MLH1 Gene Promoter Hypermethylation Negative","C160408","A genetic finding indicating the absence of DNA hypermethylation in the promoter region of the MGMT gene.","MLH1 Gene Promoter Hypermethylation Negative | Absent | COCA2 Promoter Hypermethylation Negative | HNPCC2 Promoter Hypermethylation Negative | MLH1 Negative | MLH1 Promoter Hypermethylation Negative | MutL Homolog 1 Promoter Hypermethylation Negative | MutL, E. coli, Homolog of, 1 Promoter Hypermethylation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969354","MLH1 Gene Promoter Hypermethylation Status","C160409","A procedure used to detect and identify hypermethylation of promoter sequences for the MLH1 gene.","MLH1 Gene Promoter Hypermethylation Status | COCA2 Promoter Hypermethylation Status | HNPCC2 Promoter Hypermethylation Status | MLH1 Gene Promoter Hypermethylation Analysis | MLH1 Promoter Hypermethylation | MLH1 Promoter Hypermethylation Analysis | MLH1 Promoter Hypermethylation Status | MutL Homolog 1 Promoter Hypermethylation Status | MutL, E. coli, Homolog of, 1 Promoter Hypermethylation Status",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512674","Immunooncology","C16040","The study of cell surface markers on tumor cells which can be recognized by antibodies, and the development of diagnostic reagents or therapeutic strategies which rely upon immune recognition.","Immunooncology | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969352","CYSLTR2 Gene Mutation","C160412","A change in the nucleotide sequence of the CYSLTR2 gene.","CYSLTR2 Gene Mutation | CYSLT2 Gene Mutation | CYSLT2R Gene Mutation | Cysteinyl Leukotriene Receptor 2 Gene Mutation | GPCR21 Gene Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969351","MLH1 Loss of Nuclear Expression","C160413","An indication that expression of MLH1 was not detected in the nuclei of cells in a sample.","MLH1 Loss of Nuclear Expression | COCA2 Loss of Nuclear Expression | DNA Mismatch Repair Protein Mlh1 Loss of Nuclear Expression | FCC2 Loss of Nuclear Expression | HNPCC Loss of Nuclear Expression | HNPCC2 Loss of Nuclear Expression | Loss of Nuclear MLH1 | Loss of nuclear expression | Mismatch DNA Repair Protein MLH1 Loss of Nuclear Expression | Mismatch Repair Protein MLH1 Loss of Nuclear Expression | MutL Protein Homolog 1 Loss of Nuclear Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969350","MLH1 Nuclear Expression Intact","C160414","An indication that expression of MLH1 was detected in the nuclei of cells in a sample.","MLH1 Nuclear Expression Intact | COCA2 Nuclear Expression Intact | DNA Mismatch Repair Protein Mlh1 Nuclear Expression Intact | FCC2 Nuclear Expression Intact | HNPCC Nuclear Expression Intact | HNPCC2 Nuclear Expression Intact | Intact nuclear expression | Mismatch DNA Repair Protein MLH1 Nuclear Expression Intact | Mismatch Repair Protein MLH1 Nuclear Expression Intact | MutL Protein Homolog 1 Nuclear Expression Intact",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969349","MSH2 Loss of Nuclear Expression","C160415","An indication that expression of MSH2 was not detected in the nuclei of cells in a sample.","MSH2 Loss of Nuclear Expression | DNA Mismatch Repair Protein Msh2 Loss of Nuclear Expression | Loss of Nuclear MSH2 | Loss of nuclear expression | MutS Homolog 2 Loss of Nuclear Expression | MutS Protein Homolog 2 Loss of Nuclear Expression",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969363","MSH2 Nuclear Expression Intact","C160416","An indication that expression of MSH2 was detected in the nuclei of cells in a sample.","MSH2 Nuclear Expression Intact | DNA Mismatch Repair Protein Msh2 Nuclear Expression Intact | Intact nuclear expression | MutS Homolog 2 Nuclear Expression Intact | MutS Protein Homolog 2 Nuclear Expression Intact",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969362","MSH6 Nuclear Expression Intact","C160417","An indication that expression of MSH6 was detected in the nuclei of cells in a sample.","MSH6 Nuclear Expression Intact | DNA Mismatch Repair Protein Msh6 Nuclear Expression Intact | G/T Mismatch Binding Protein Nuclear Expression Intact | G/T Mismatch-Binding Protein Nuclear Expression Intact | GTBP Nuclear Expression Intact | GTMBP Nuclear Expression Intact | Intact nuclear expression | MutS Homolog 6 Nuclear Expression Intact | MutS-Alpha 160 kDa Subunit Nuclear Expression Intact | Sperm-Associated Protein Nuclear Expression Intact",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969674","Tumor Reoccurrence Absent After Initial Treatment","C160622","A response that tumor reoccurrence was not present after the initial treatment.","Tumor Reoccurrence Absent After Initial Treatment | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1522620","Recombinant Lymphotoxin Beta","C1608","Lymphotoxin is a cytokine that orchestrates lymphoid neogenesis and is present on the surface of activated T-, B-, and LAK cells as a heterotrimer of alpha and beta subunits. It is also secreted as an alpha homotrimer. LT beta glycoprotein is a 33 kD type II membrane protein that anchors LT alpha to the cell surface.","Recombinant Lymphotoxin Beta | LT-beta | LTB Protein | Lymphotoxin Beta | TNFC | Tumor Necrosis Factor C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969859","Rural-Urban Continuum Code 2003","C160900","Codes published by the Office of Management and Budget (OMB) in 2003 that separate counties into four metropolitan and six non-metropolitan categories based on the size their populations and form a classification scheme that distinguishes metropolitan counties by size and non-metropolitan counties by degree of urbanization and proximity to metro areas.","Rural-Urban Continuum Code 2003 | Beale Codes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969858","Rural-Urban Continuum Codes 2013","C160901","Codes published by the Office of Management and Budget (OMB) in 2013 that separate counties into four metropolitan and six non-metropolitan categories based on the size their populations and form a classification scheme that distinguishes metropolitan counties by size and non-metropolitan counties by degree of urbanization and proximity to metro areas.","Rural-Urban Continuum Codes 2013 | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969870","Recurrent Anaplastic Pleomorphic Xanthoastrocytoma","C160904","The reemergence of anaplastic pleomorphic xanthoastrocytoma after a period of remission.","Recurrent Anaplastic Pleomorphic Xanthoastrocytoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969337","Anti-CD47 Monoclonal Antibody SHR-1603","C160202","A monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody SHR-1603 preferentially binds to CD47 on tumor cells. This blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of tumor cells. Additionally, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T-cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.","Anti-CD47 Monoclonal Antibody SHR-1603 | SHR 1603 | SHR-1603 | SHR1603",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969336","PIM Kinase Inhibitor TP-3654","C160203","An orally available, second-generation and selective ATP-competitive inhibitor of proviral integration site for Moloney murine leukemia virus (PIM) kinases, with potential antineoplastic activity. Upon oral administration, nuvisertib selectively binds to and prevents the activation of the PIM kinases. This prevents the activation of PIM-mediated signaling pathways and inhibits proliferation in cells that overexpress PIM. PIMs, constitutively active proto-oncogenic serine/threonine kinases, are upregulated in various types of cancers and play key roles in tumor cell proliferation and survival.","Nuvisertib | 2-((1R,4R)-4-((3-(3-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)cyclohexyl)propan-2-ol | NUVISERTIB | PIM Inhibitor TP-3654 | PIM Kinase Inhibitor TP-3654 | PIM Kinase Inhibitor TP-3654 | SGI 9481 | SGI-9481 | SGI9481 | TP 3654 | TP-3654 | TP3654",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951708","Continuous Glucose Monitoring System","C159776","A system that uses a sensor under the skin to monitor glucose levels at regular intervals, providing real-time, or near real-time, glucose information.","Continuous Glucose Monitoring System | CGM | Continuous Glucose Monitoring",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951636","CST1 wt Allele","C159785","Human CST1 wild-type allele is located in the vicinity of 20p11.21 and is approximately 4 kb in length. This allele, which encodes cystatin-SN protein, is involved in the inhibition of papain, cathepsin C and ficin.","CST1 wt Allele | Cystatin 1 Gene | Cystatin SN wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951637","CST1 protein, human","C159786","Cystatin-SN (141 aa, ~16 kDa) is encoded by the human CST1 gene. This protein plays a role in the inhibition of certain cysteine proteinases in the saliva, tears, urine and seminal fluid.","Cystatin-SN | CST1 | Cystain-SA-I | Cystatin 1 | Cystatin SA-I | Cystatin SN | Cystatin-1 | Salivary Cystatin-SA-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951638","Checkpoint Inhibitor Relapsed Tumor","C159787","A finding indicating the treatment of a relapsed malignant tumor with checkpoint inhibitors to boost the immune response.","Checkpoint Inhibitor Relapsed Tumor | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512360","Heart Research","C15955","No value exists.","Heart Research | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951399","Advanced Clear Cell Renal Cell Carcinoma","C159562","A clear cell renal cell carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Clear Cell Renal Cell Carcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951400","Refractory Adenocarcinoma","C159563","An adenocarcinoma that does not respond to treatment.","Refractory Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951402","Recurrent Adenocarcinoma","C159565","An adenocarcinoma that has recurred after a period of remission.","Recurrent Adenocarcinoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951403","Indeterminate Macroscopic Satellite Nodule","C159566","Unable to determine if a macroscopic satellite nodule exists.","Indeterminate Macroscopic Satellite Nodule | Indeterminate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951404","Other Site of New Distant Metastasis Tumor Event","C159567","A directive to specify the other site of the new distant metastatic tumor event.","Other Site of New Distant Metastasis Tumor Event | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951003","Is Another Non-Exon 20 ERBB2 Mutation Present","C158936","A question to determine if an ERBB2 mutation that is not located in exon 20 and not listed on the form was found in the study.","Is Another Non-Exon 20 ERBB2 Mutation Present | Other ERBB2 mutation (non-exon 20)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951005","Specify Other MET Mutation","C158938","A request to enter the specific MET mutation that was identified in the study but is not present in the form.","Specify Other MET Mutation | Specify other MET mutation:",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969671","Allogeneic CD34-positive Enriched Peripheral Blood Stem Cells","C160626","A preparation of allogeneic CD34+ selected peripheral blood stem cells (PBSCs) that can potentially be used for immune reconstitution purposes. Upon administration of the allogeneic CD34-positive enriched PBSCs after a hematopoietic cell transplantation (HCT), these cells may provide memory T-cell (Tm) recovery and potentially prevent viral infections. They potentially reduce the occurrence of graft-versus-host disease (GvHD) without increasing the risk of graft failure or poor graft function.","Allogeneic CD34-positive Enriched Peripheral Blood Stem Cells | Allogeneic CD34+ PBSCs | Allogeneic CD34+-enriched Peripheral Blood Stem Cells | Donor-derived CD34-positive PBSCs",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516800","Electronic Tracking Database","C16062","No value exists.","Electronic Tracking Database | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969680","Was Hormone Therapy Administered as an Additional Treatment for a New Tumor Event","C160632","A question about whether hormone therapy was administered as an additional treatment for a new tumor event.","Was Hormone Therapy Administered as an Additional Treatment for a New Tumor Event | Additional Treatment for New Tumor Event Hormone Therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969678","Radiation Was Administered as an Additional Treatment for a New Tumor Event","C160634","A response that radiation was administered as an additional treatment for a new tumor event.","Radiation Was Administered as an Additional Treatment for a New Tumor Event | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969635","Radiation Was Not Administered as an Additional Treatment for a New Tumor Event","C160635","A response that radiation was not administered as an additional treatment for a new tumor event.","Radiation Was Not Administered as an Additional Treatment for a New Tumor Event | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969634","Unknown if Radiation Was Administered as an Additional Treatment for a New Tumor Event","C160636","A response that indicates it is unknown if radiation was administered as an additional treatment for a new tumor event.","Unknown if Radiation Was Administered as an Additional Treatment for a New Tumor Event | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969335","Anti-ILT4 Monoclonal Antibody MK-4830","C160204","A human monoclonal antibody directed against the inhibitory immune checkpoint receptor immunoglobulin-like transcript 4 (ILT4; leukocyte immunoglobulin-like receptor subfamily B member 2; LILRB2; lymphocyte immunoglobulin-like receptor 2; LIR2; monocyte/macrophage immunoglobulin-like receptor 10; MIR-10; CD85d), with potential immunomodulating and antineoplastic activities. Upon administration, anti-ILT4 monoclonal antibody MK-4830 targets and binds to ILT4. This prevents the binding of ILT4 ligands to their receptor and prevents ILT4-mediated signaling. This abrogates the immunosuppressive activities of ILT4 in the tumor microenvironment (TME), activates the expression of pro-inflammatory cytokines, including GM-CSF and tumor necrosis factor alpha (TNFalpha), and enhances a cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response. ILT4, plays a key role in tumor immune evasion. ILT4, a transmembrane protein and inhibitory member of the immunoglobulin-like transcript (ILT) family of proteins, is expressed primarily by myeloid cells, including monocytes, macrophages, dendritic cells (DCs) and granulocytes, and certain tumor cells.","Anti-ILT4 Monoclonal Antibody MK-4830 | Anti-LIR2 Monoclonal Antibody MK-4830 | Anti-leukocyte Immunoglobulin-like Receptor 2 Monoclonal Antibody MK-4830 | MK 4830 | MK-4830 | MK4830",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969348","Family History of Stomach Cancer Present","C160205","There is a family history of stomach cancer.","Family History of Stomach Cancer Present | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969347","Family History of Stomach Cancer Absent","C160206","There is no family history of stomach cancer.","Family History of Stomach Cancer Absent | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969346","SHP2 Inhibitor JAB-3068","C160207","An orally bioavailable inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; Src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic activity. Upon oral administration, SHP2 inhibitor JAB-3068 targets, binds to and inhibits the activity of SHP2. This prevents SHP2-mediated signaling, inhibits MAPK signaling and prevents growth of SHP2-expressing tumor cells. SHP2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the Ras-Raf-MEK-ERK signaling pathway. The Ras-MAPK pathway is often hyperactivated in cancer cells due to specific mutations and rearrangements and are dependent on SHP2 for their oncogenic signaling. SHP2 also regulates programmed cell death 1 (PD-1)-mediated signal transduction and is involved in immune checkpoint modulation.","SHP2 Inhibitor JAB-3068 | JAB 3068 | JAB-3068 | JAB3068",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511292","Breast Cancer Prevention, Education, and Diagnosis Program Initiative","C16020","No value exists.","Breast Cancer Prevention, Education, and Diagnosis Program Initiative | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511878","Diagnostic Imaging Program","C16046","(1) Plans and coordinates the development; (2) coordinates the clinical testing of new approaches in academia, industry, or in other parts of the federal government; (3) coordinates the development targeted to specific biochemical or physiological processes in cancer cells for better biologic insight into the physiology of human tumors; (4) encourages industrial commitment to the development and ultimate clinical testing relevant to cancer; (5) coordinates activities with other programs of the Institute, other federal agencies, and outside organizations; (6) coordinates the activities of the branches within the Program for productive interactions and effective technology transfer; and (7) assesses the activities of the Program and advises the Division Director regarding scientific opportunities for the development of new approaches to the diagnosis and treatment of cancer.","Diagnostic Imaging Program | Biomedical Imaging Program | DIP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969592","Use of Smokeless Tobacco at Time of Diagnosis Unknown","C160470","A response was that it was unknown if the individual was using smokeless tobacco at the time of diagnosis.","Use of Smokeless Tobacco at Time of Diagnosis Unknown | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969590","Regular Smokeless Tobacco Use for Six Weeks or More Negative","C160472","A response that the individual did not use smokeless tobacco regularly for six weeks or longer.","Regular Smokeless Tobacco Use for Six Weeks or More Negative | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951639","CST2 wt Allele","C159789","Human CST2 wild-type allele is located in the vicinity of 20p11.21 and is approximately 3 kb in length. This allele, which encodes cystatin-SA protein, plays a role in the regulation of salivary cysteine proteinase activity.","CST2 wt Allele | Cystatin 2 Gene | Cystatin SA wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514860","Repository Operation, Tissue","C15978","No value exists.","Repository Operation, Tissue | Culturing, in vitro Vertebrate Repository Operations, Tissue",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951640","CST2 protein, human","C159790","Cystatin-SA (141 aa, ~16 kDa) is encoded by the human CST2 gene. This protein is involved in salivary cysteine proteinase inhibition.","Cystatin-SA | CST2 | Cystatin 2 | Cystatin S5 | Cystatin SA | Cystatin-2 | Cystatin-S5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951641","CST4 wt Allele","C159792","Human CST4 wild-type allele is located in the vicinity of 20p11.21 and is approximately 3 kb in length. This allele, which encodes cystatin-S protein, is involved in cysteine proteinase inhibition.","CST4 wt Allele | Cystatin 4 Gene | Cystatin S wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951642","CST4 protein, human","C159793","Cystatin-S (141 aa, ~16 kDa) is encoded by the human CST4 gene. This protein plays a role in the inhibition of papain, ficin and several other cysteine proteinases.","Cystatin-S | CST4 | Cystain-SA-III | Cystatin 4 | Cystatin S | Cystatin-4 | Salivary Acidic Protein 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969058","Dacarbazine Regimen","C160018","A regimen consisting of dacarbazine that may be used in the treatment of cutaneous and uveal melanoma; neuroendocrine tumors (NETs) of the gastrointestinal tract, pancreas, lung and thymus; and soft tissue and uterine sarcomas.","Dacarbazine Regimen | DTIC Regimen | Dacarbazine monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969057","Daratumumab Regimen","C160019","A regimen consisting of daratumumab that may be used in the treatment of plasma cell (multiple) myeloma, acute lymphoblastic leukemia (ALL) and systemic light chain amyloidosis.","Daratumumab Regimen | Daratumumab monotherapy | Darzalex Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1512500","Hospice Planning/Development","C16001","No value exists.","Hospice Planning/Development | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969056","Dasatinib Regimen","C160020","A regimen consisting of dasatinib that may be used in the treatment of cutaneous melanoma, bone cancer, chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GISTs), acute lymphoblastic leukemia (ALL), and myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes.","Dasatinib Regimen | Dasatinib monotherapy | Sprycel Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969007","Decitabine Regimen","C160021","A regimen consisting of decitabine that may be used in the treatment of acute myeloid leukemia (AML), myeloproliferative neoplasms, and myelodysplastic syndromes.","Decitabine Regimen | Dacogen Regimen | Decitabine monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969006","Degarelix Regimen","C160022","A regimen consisting of degarelix that may be used in the treatment of advanced prostate cancer.","Degarelix Regimen | Degarelix monotherapy | Firmagon Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969005","Denosumab Regimen","C160023","A regimen consisting of denosumab that may be used in the treatment of giant cell tumor (GCT) of the bone; and bone metastases from solid tumors and bone complications from plasma cell (multiple) myeloma.","Denosumab Regimen | Denosumab monotherapy | Xgeva Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969004","Docetaxel Regimen","C160024","A regimen consisting of docetaxel that can be used in the treatment of breast, bladder, gastric, cervical, head and neck, non-small cell lung, small cell lung, ovarian, fallopian tube, primary peritoneal, prostate, endometrial, esophageal and esophagogastric junction cancers; malignant sex cord-stromal (SCST) and malignant germ cell tumors (GCTs); angiosarcoma and small bowel adenocarcinoma, and anaplastic carcinoma. Docetaxel every 21 days regimen may be used for the treatment of breast cancer.","Docetaxel Regimen | Docetaxel monotherapy | Taxotere Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951006","Specify Other MET Exon 14 Mutation","C158939","A request to enter the specific MET exon 14 mutation that was identified in the study but is not present in the form.","Specify Other MET Exon 14 Mutation | Other MET exon 14 mutation, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0920429","Cell Bank","C15893","Repository of cell samples","Cell Bank | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951007","Specify Other MET Intron 13 Mutation","C158940","A request to enter the specific MET intron 13 mutation that was identified in the study but is not present in the form.","Specify Other MET Intron 13 Mutation | Other MET intron 13 mutation, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951008","Specify Other MET Intron 14 Mutation","C158941","A request to enter the specific MET intron 14 mutation that was identified in the study but is not present in the form.","Specify Other MET Intron 14 Mutation | Other MET intron 14 mutation, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951010","p16 Positive by Immunohistochemistry","C158943","An indication that CDKN2A-p16 expression has been detected in a sample using immunohistochemical techniques.","p16 Positive by Immunohistochemistry | CDKN2A-p16 Positive by Immunohistochemistry | CDKN2A-p16(INK4a) Positive by Immunohistochemistry | Cyclin-Dependent Kinase 4 Inhibitor A Positive by Immunohistochemistry | Cyclin-Dependent Kinase Inhibitor 2A Positive by Immunohistochemistry | p16 Positive (>70% nuclear and cytoplasmic staining) | p16(INK4a) Positive by Immunohistochemistry | p16-INK4 Positive by Immunohistochemistry | p16INK4 Positive by Immunohistochemistry | p16INK4a Positive by Immunohistochemistry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951011","PDGFRA Mutation Analysis","C158944","A procedure used to detect and identify mutations in the PDGFRA gene.","PDGFRA Mutation Analysis | CD140A Mutation Analysis | PDGFR-2 Mutation Analysis | PDGFR2 Mutation Analysis | PDGFRA Gene Mutation Analysis | PDGFRA Mutation Status | PDGFRalpha Mutation Analysis | Platelet-Derived Growth Factor Receptor Alpha Mutation Analysis | RHEPDGFRA Mutation Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951012","PDGFRA Mutation Analysis Testing Method","C158945","A request to enter the specific molecular analysis method used to detect and identify mutations in the PDGFRA gene.","PDGFRA Mutation Analysis Testing Method | PDGFRA Mutational Analysis Testing Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951014","PTEN Mutation Analysis Testing Method","C158947","A request to enter the specific molecular analysis method used to detect and identify mutations in the PTEN gene.","PTEN Mutation Analysis Testing Method | PTEN Mutational Analysis Testing Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951016","Rearrangement Negative","C158949","An indication that cytogenetic rearrangements were not detected in a sample.","Rearrangement Negative | Chromosomal Rearrangement Negative | Chromosome Rearrangement Negative | Cytogenetic Rearrangement Negative | No rearrangement detected | Rearrangement Absent",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0920661","Technique Development","C15894","Develop and evaluate new laboratory assays, behavioral methods, and statistical techniques for epidemiologic studies. (FMB)","Technique Development | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL951017","RET Rearrangement Testing Method","C158950","A request to enter the specific molecular analysis method used to detect and identify rearrangements involving the RET gene.","RET Rearrangement Testing Method | RET Rearrangement Analysis Testing Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969633","Chemotherapy Was Administered as an Additional Treatment for a New Tumor Event","C160637","A response that chemotherapy was administered as an additional treatment for a new tumor event.","Chemotherapy Was Administered as an Additional Treatment for a New Tumor Event | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969925","Advanced Adrenal Gland Pheochromocytoma","C160853","An adrenal gland pheochromocytoma that has spread extensively to other anatomic sites or is no longer responding to treatment.","Advanced Adrenal Gland Pheochromocytoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1511073","Basic Cancer Research","C16085","Fundamental research designed to obtain or increase general knowledge about cancer, performed without the goal of solving or addressing a specific cancer-related issue or condition.","Basic Cancer Research | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969542","Regular Smokeless Tobacco Use for Six Weeks or More Unknown","C160473","A response that it is unknown if the individual used smokeless tobacco regularly for six weeks or longer.","Regular Smokeless Tobacco Use for Six Weeks or More Unknown | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969541","Average Daily Use Smokeless Tobacco after Use for Six Weeks Unknown","C160474","A response that it the daily use of smokeless tobacco after at least six weeks of use is unknown.","Average Daily Use Smokeless Tobacco after Use for Six Weeks Unknown | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969540","Never Quit using Smokeless Tobacco after Regular Use","C160475","A question about the age of an individual when they quit using smokeless tobacco, once they have been using regularly for six weeks.","Never Quit using Smokeless Tobacco after Regular Use | Not Applicable - Never quit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969539","Not Known if SDH Complex Mutation Analysis Was Performed","C160476","An indication that it is not known whether SDH complex mutation analysis was performed during the study.","Not Known if SDH Complex Mutation Analysis Was Performed | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969538","Not Known if TP53 Mutation Analysis Was Performed","C160477","An indication that it is not known whether TP53 mutation analysis was performed during the study.","Not Known if TP53 Mutation Analysis Was Performed | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969537","NRAS Mutation Analysis Was Not Performed","C160478","An indication that NRAS mutation analysis was not performed during the study.","NRAS Mutation Analysis Was Not Performed | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969536","NRAS Mutation Analysis Was Performed","C160479","An indication that NRAS mutation analysis was performed during the study.","NRAS Mutation Analysis Was Performed | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516733","Community Oncology and Rehabilitation","C16047","Introduction, application, and evaluation of effective and practical cancer prevention, control, and rehabilitation intervention programs in community settings.","Community Oncology and Rehabilitation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969535","PAX8 Gene Rearrangement","C160480","A molecular abnormality indicating rearrangement of the PAX8 gene.","PAX8 Gene Rearrangement | PAX8 Rearrangement | Paired Box 8 Gene Rearrangement | Paired Box Gene 8 Gene Rearrangement | Paired Domain Gene 8 Gene Rearrangement | Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969550","PAX8 Gene Rearrangement Negative","C160481","A genetic finding indicating that rearrangement of the PAX8 gene has not been detected in a sample.","PAX8 Gene Rearrangement Negative | Negative | PAX8 Rearrangement Negative | Paired Box 8 Gene Rearrangement Negative | Paired Box Gene 8 Gene Rearrangement Negative | Paired Domain Gene 8 Gene Rearrangement Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969549","PDGFRA Mutation Analysis Was Not Performed","C160482","An indication that PDGFRA mutation analysis was not performed during the study.","PDGFRA Mutation Analysis Was Not Performed | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969548","PDGFRA Mutation Analysis Was Performed","C160483","An indication that PDGFRA mutation analysis was performed during the study.","PDGFRA Mutation Analysis Was Performed | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969003","Doxorubicin Regimen","C160025","A regimen consisting of doxorubicin that may be used in the treatment of soft tissue and uterine sarcomas, rhabdomyosarcomas, anaplastic thyroid, endometrial, breast, bone, ovarian, fallopian tube, and primary peritoneal cancers, and desmoid tumors (aggressive fibromatoses).","Doxorubicin Regimen | Doxorubicin HCl Regimen | Doxorubicin Hydrochloride Regimen | Doxorubicin monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969002","Durvalumab Regimen","C160026","A regimen consisting of durvalumab that may be used in the treatment of non-small cell lung cancer (NSCLC) and hepatobiliary cancers.","Durvalumab Regimen | Durvalumab monotherapy | Imfinzi Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969001","Duvelisib Regimen","C160027","A regimen consisting of duvelisib that may be used in the treatment of T-cell lymphoma, chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).","Duvelisib Regimen | Copiktra Regimen | Duvelisib monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969000","Enzalutamide Regimen","C160028","A regimen consisting of enzalutamide that may be used in the treatment of prostate cancer.","Enzalutamide Regimen | Enzalutamide monotherapy | Xtandi Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969015","Epirubicin Regimen","C160029","A regimen consisting of epirubicin that may be used in the treatment of breast cancer; and soft tissue and uterine sarcomas.","Epirubicin Regimen | Ellence Regimen | Epirubicin monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969014","Eribulin Regimen","C160030","A regimen consisting of eribulin that may be used in the treatment of breast cancer; and soft tissue and uterine sarcomas.","Eribulin Regimen | Eribulin HCl Regimen | Eribulin Hydrochloride Regimen | Eribulin monotherapy | Halaven Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969013","Erlotinib Regimen","C160031","A regimen consisting of erlotinib that may be used in the treatment of kidney, vulvar and bone cancers, and non-small cell lung cancer (NSCLC), including brain metastases from NSCLC.","Erlotinib Regimen | Erlotinib HCl Regimen | Erlotinib Hydrochloride Regimen | Erlotinib monotherapy | Tarceva Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969012","Estradiol Regimen","C160032","A regimen consisting of estradiol that may be used in the treatment of breast cancer.","Estradiol Regimen | Estradiol monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969011","Etoposide Regimen","C160033","A regimen consisting of etoposide that may be used in the treatment of AIDS-related Kaposi sarcoma, thymomas and thymic carcinomas, and Castleman disease.","Etoposide Regimen | Etoposide monotherapy | VP-16 Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0481508","Donor Status","C159525","Vital information about a donor at the time of donation.","Donor Status | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516191","Cancer Control Research Program","C15952","No value exists.","Cancer Control Research Program | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516717","Combined Pharmacological and Behavioral Treatment","C15983","Pharmacological and behavioral interventions, such as the combined use of nicotine replacement and biofeedback, for the treatment of physiological addictions, such as nicotine. (NCI/TRIP)","Combined Pharmacological and Behavioral Treatment | Combined Pharmacological/Behavioral Treatment | Combined Pharmacological/Behavioral Treatments",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969890","Primary Debulking Surgery","C160865","Debulking surgery undertaken as the first treatment modality.","Primary Debulking Surgery | PDS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969161","JNJ 67856633","C160147","An orally bioavailable inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), with potential antineoplastic activity. Upon administration, safimaltib targets, binds to, and prevents the activity of MALT1. This inhibits MALT1-dependent signaling, reduces interleukin-10 (IL-10) and upregulates interferon (IFN). This results in the inhibition of Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling and nuclear factor-kappa B (NF-kB) signaling, induces apoptosis, and inhibits tumor cell growth of MALT1-expressing tumor cells. MALT1 belongs to the caspase family of proteases and is the active component of the CARD11-BCL10-MALT1 (CBM) signaling complex. It plays an essential role in B- and T-lymphocyte activation and is over-activated in certain tumor cells.","Safimaltib | 1-(1-Oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazole-4-carboxamide | JNJ 67856633 | JNJ-67856633 | JNJ67856633 | MALT1 Inhibitor JNJ-67856633 | MALT1 Inhibitor JNJ-67856633 | Mucosa-associated Lymphoid Tissue Lymphoma Translocation Protein 1 Inhibitor JNJ-67856633 | SAFIMALTIB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969114","Refractory EBV-Related Lymphoma","C160149","EBV-related lymphoma that is resistant to treatment.","Refractory EBV-Related Lymphoma | Refractory EBV-Associated Lymphoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518482","Nutrition, Caffeine","C16014","Role of caffeine in cancer causation or prevention and in general health.","Nutrition, Caffeine | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969113","EBV-Related Lymphoproliferative Disease with Primary Immunodeficiency","C160150","An EBV-related lymphoid proliferation that arises in the setting of immune deficiency due to a primary immunodeficiency or immunoregulatory disorder.","EBV-Related Lymphoproliferative Disease with Primary Immunodeficiency | EBV- Associated Lymphoproliferative Disease with Primary Immunodeficiency | Epstein-Barr Virus-Associated Lymphoproliferative Disease with Primary Immunodeficiency | Epstein-Barr Virus-Related Lymphoproliferative Disease with Primary Immunodeficiency | Epstein-Barr Virus-Related Lymphoproliferative Disease with Primary Immunodeficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969112","Recurrent Epstein-Barr Virus-Related Lymphoproliferative Disease with Primary Immunodeficiency","C160151","The reemergence of EBV-associated lymphoproliferative disease with primary immunodeficiency after a period of remission.","Recurrent EBV-Related Lymphoproliferative Disease with Primary Immunodeficiency | Recurrent Epstein-Barr Virus-Associated Lymphoproliferative Disease with Primary Immunodeficiency | Recurrent Epstein-Barr Virus-Related Lymphoproliferative Disease with Primary Immunodeficiency | Recurrent Epstein-Barr Virus-Related Lymphoproliferative Disease with Primary Immunodeficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969110","Specify Other Risk Factor","C160153","A directive to specify the other risk factor.","Specify Other Risk Factor | If Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969109","Unknown New Tumor Event","C160154","The new tumor event is unknown.","Unknown New Tumor Event | Unknown: Could not be determined or unsure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3281169","Bladder Diverticulum","C160155","A pouch or sac-like protrusion in the bladder wall.","Bladder Diverticulum | ",,,,,,,,,,,,,,,"195864","Diverticulum of bladder",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL969120","CPTAC Responses","C160157","No value exists.","CPTAC Responses | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969119","Carcinoma Arising in Bladder Diverticulum","C160158","A carcinoma arising in a bladder diverticulum. Approximately one-third to half of the cases represent non-invasive, low-grade or high-grade urothelial carcinomas. Approximately half of the invasive carcinomas are urothelial. The rest include adenocarcinomas, squamous cell carcinomas, and small cell carcinomas.","Carcinoma Arising in Bladder Diverticulum | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937138","Age When Started using Smokeless Tobacco after Regular Use","C157417","A question about the age of an individual when they started using smokeless tobacco after at least six weeks regular use.","Age When Started using Smokeless Tobacco after Regular Use | If the patient used smokeless tobacco (including chewing tobacco and snuff) regularly for at least six weeks, how old were they when they started using",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796544","Screening for Hepatocellular Cancer","C15741","No value exists.","Screening for Hepatocellular Cancer | hepatocellular cancer, screening for | liver cancer, screening for | screening for liver cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937133","CA19-9 Level Finding","C157420","A finding that indicates the amount of carbohydrate associated antigen (CA19.9) in a sample.","CA19-9 Level Finding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937135","Total Bilirubin Level Finding","C157422","A finding that indicates the amount of total bilirubin in a sample.","Total Bilirubin Level Finding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0428279","Creatinine Level Finding","C157423","A finding that indicates the amount of creatinine in a sample.","Creatinine Level Finding | ",,,,,,,,,,,,,,,"4275203","Creatinine level - finding",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937131","Total Thyroxine Level Finding","C157426","A finding that indicates the amount of total thyroxine in a sample.","Total Thyroxine Level Finding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937127","Serum CEA Level Finding","C157427","A finding that indicates the amount of carcinoembryonic antigen (CEA) in a serum sample.","Serum CEA Level Finding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937128","Serum CA 19-9 Level Finding","C157428","A finding that indicates the amount of carbohydrate associated antigen (CA19.9) in a serum sample.","Serum CA 19-9 Level Finding | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937184","Carboplatin/Nab-Paclitaxel/Pembrolizumab Regimen","C157619","A regimen consisting of carboplatin, nab-paclitaxel, and pembrolizumab that can be used in the treatment of metastatic squamous non-small cell lung cancer (NSCLC).","Carboplatin/Nab-Paclitaxel/Pembrolizumab Regimen | Abraxane/Carboplatin/Keytruda | Albumin-bound Paclitaxel-Carboplatin-Pembrolizumab | Albumin-bound Paclitaxel-Carboplatin-Pembrolizumab Regimen | Carboplatin, nab-Paclitaxel, Pembrolizumab | Nab-Paclitaxel-Carboplatin-Pembrolizumab Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515885","Acustimulation Therapy","C15761","Use of a low intensity electrical current to provide mild stimulation of the body's acupuncture points in order to control symptoms such as nausea and vomiting.","Acustimulation Therapy | Acustimulation | acustimulation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969697","Specify SDH Complex Mutation","C160582","A request to enter the specific SDH complex mutations that were identified in the study.","Specify SDH Complex Mutation | Mutation identified, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969694","TERT Promoter Mutation","C160585","A molecular abnormality indicating mutation in the promoter region of the TERT gene.","TERT Promoter Mutation | EST2 Promoter Mutation | Positive | TCS1 Promoter Mutation | TERT Gene Promoter Mutation | TP2 Promoter Mutation | TRT Promoter Mutation | Telomerase Reverse Transcriptase Gene Promoter Mutation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969693","TERT Promoter Mutation Negative","C160586","A genetic finding indicating that mutations in the promoter of the TERT gene have not been detected in a sample.","TERT Promoter Mutation Negative | EST2 Promoter Mutation Negative | Negative | TCS1 Promoter Mutation Negative | TERT Gene Promoter Mutation Negative | TP2 Promoter Mutation Negative | TRT Promoter Mutation Negative | Telomerase Reverse Transcriptase Gene Promoter Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL607213","Executive Function Disorder","C160587","Cognitive, emotional, and behavioral difficulties that often occur in conjunction with frontal lobe disorders, including traumatic injury and dementia. It is also a feature of attention deficit disorder and other non-trauma-induced conditions.","Executive Function Disorder | EFD | Executive Dysfunction | Executive Functioning Deficit | Impairment of Executive Functions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969707","TP53 Mutation Analysis Was Not Performed","C160588","An indication that TP53 mutation analysis was not performed during the study.","TP53 Mutation Analysis Was Not Performed | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969706","TP53 Mutation Analysis Was Performed","C160589","An indication that TP53 mutation analysis was performed during the study.","TP53 Mutation Analysis Was Performed | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1514788","Recombinant Interval Database","C16058","No value exists.","Recombinant Interval Database | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969705","Was ALK Rearrangement Analysis Performed","C160590","A question asking if ALK rearrangements were analyzed during the study.","Was ALK Rearrangement Analysis Performed | ALK Rearrangement assessed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969704","Was BRAF Rearrangement Analysis Performed","C160591","A question asking if BRAF rearrangements were analyzed during the study.","Was BRAF Rearrangement Analysis Performed | BRAF Rearrangement assessed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969702","Was RET Rearrangement Analysis Performed","C160593","A question asking if RET rearrangements were analyzed during the study.","Was RET Rearrangement Analysis Performed | RET Rearrangement assessed",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969718","Epoetin Alfa Regimen","C160801","A regimen consisting of epoetin alfa that may be used in the management of anemia secondary to chemotherapy, HIV infection, or chronic kidney disease (CKD); and in the prevention of anemia in certain patients undergoing elective non-cardiac surgical procedures.","Epoetin Alfa Regimen | Epogen Regimen | Procrit Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969717","Filgrastim Regimen","C160802","A regimen consisting of filgrastim that may be used in the prevention of febrile neutropenia; in the harvest of peripheral blood stem cells (PBSCs); and in the symptomatic management of neutropenic disorders.","Filgrastim Regimen | Neupogen Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969716","Aldesleukin Regimen","C160804","A regimen consisting of aldesleukin that may be used in the treatment of metastatic melanoma and metastatic renal cell carcinoma (RCC).","Aldesleukin Regimen | IL-2 monotherapy | Proleukin Regimen | Recombinant Human IL-2 Regimen | Recombinant Human Interleukin-2 Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969731","High-dose Methylprednisolone Regimen","C160805","A regimen consisting of high-dose methylprednisolone sodium succinate that may be used in the palliative management of acute lymphoblastic leukemia (ALL); and in the management of severe allergic conditions, hypercalcemia of malignancy, idiopathic thrombocytopenic purpura (ITP), Crohn's disease, and other inflammatory disorders.","High-dose Methylprednisolone Regimen | HDMP | High-dose Solumedrol Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937079","GCGR wt Allele","C157479","Human GCGR wild-type allele is located in the vicinity of 17q25.3 and is approximately 10 kb in length. This allele, which encodes glucagon receptor protein, is involved in hormone-dependent signaling. Mutation of the gene is associated with type 2 diabetes mellitus and glucagon cell hyperplasia and neoplasia.","GCGR wt Allele | GGR | GL-R | Glucagon Receptor wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515822","AIDS, Clinical Trials on Minorities","C15765","AIDS clinical trials related to individuals of non-Caucasian descent.","AIDS, Clinical Trials on Minorities | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937205","Nodule Margin Conspicuity","C157662","A description about the radiologic visiblity of a nodule's margins.","Nodule Margin Conspicuity | Nodule margin conspicuity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1269830","Tumor margin status","C157665","A description about the radiologic type of a nodule's margins.","Nodule Margin Type | Margin | Margin Type",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515821","AIDS, Clinical Trials on Patients with Opportunistic Infections","C15766","Clinical trials related to the development of vaccines and therapeutics directed against opportunistic infections associated with HIV infection. These trials include the following opportunistic infections: pneumocystosis, toxoplasmosis, cryptosporidiosis, candidacies, cryptococcosis, mycobacteriosis, cytomegalovirus, papillomavirus, herpes simplex, JC virus, coccidioides, hairy leukoplakia, and HIV-related periodontal disease.","AIDS, Clinical Trials on Patients with Opportunistic Infections | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969793","Docetaxel/Leuprolide Regimen","C160750","A regimen consisting of docetaxel and leuprolide that can be used for the treatment of prostate cancer.","Docetaxel/Leuprolide Regimen | Docetaxel and Leuprolide | Docetaxel-Leuprolide | Docetaxel/Leuprolide | Leuprolide-Docetaxel | Leuprolide-Docetaxel Regimen | Leuprolide/Docetaxel Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971239","Intimacy Enhancement Intervention","C160751","Phone-based cognitive behavioral couple's therapy and sex therapy designed to help couples cope with sexual concerns and enhance their intimate relationship following breast cancer diagnosis and treatment. The intervention consists of education and skills training to enhance physical and emotional intimacy.","Intimacy Enhancement Intervention | IE | Intimacy Enhancement",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969792","Living Healthy Together","C160752","Intervention that focuses on delivering education and support to breast cancer survivors and their partners across a range of topics including social support, sleep and fatigue, stress and stress management, nutrition, and physical activity.","Living Healthy Together | LHT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969791","Handout","C160753","Printed information provided free of charge, especially that distributed to people attending a speech, lecture, or meeting.","Handout | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969790","Routine Cytogenetics Were Completed","C160754","A response that routine cytogenetic testing was completed.","Routine Cytogenetics Were Completed | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969789","Routine Cytogenetics Were not Completed","C160755","A response that routine cytogenetic testing was not completed.","Routine Cytogenetics Were not Completed | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969801","Favorable CALGB Criteria","C160757","A rating for AML by CALGB which indicates the outlook on the patient recovery is favored towards recovery.","Favorable CALGB Criteria | Favorable",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971180","Poor CALGB Criteria","C160759","A rating for AML by CALGB which indicates the outlook on the patient recovery can be considered poor.","Poor CALGB Criteria | Poor",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518914","Patient-Focused Outcomes","C16075","Traditional methods for evaluating treatment outcome focus on disease state.  Patient-Focused Outcomes places a greater emphasis on quality of life issues.","Patient-Focused Outcomes | Patient-Centered Outcomes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969799","Remission CALGB Criteria","C160760","A rating for AML by CALGB which indicates the patient has met the CALGB criteria for remission.","Remission CALGB Criteria | N/A-Remission",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969798","Other Cytogenetic Analysis Abnormality Type","C160761","A result that is other than those presented in the form.","Other Cytogenetic Analysis Abnormality Type | Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969797","Specify if Other Cytogenetic Analysis Abnormality Type","C160762","A directive to specify if other cytogenetic analysis abnormalities were present.","Specify if Other Cytogenetic Analysis Abnormality Type | If Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969796","Other Molecular Analysis","C160763","A response of a type of molecular analysis other than what is included on the form.","Other Molecular Analysis | Other | specialized molecular test | specialized_molecular_test",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969750","Specify Other Molecular Analysis","C160765","A request to specify the other molecular analysis type.","Specify Other Molecular Analysis | If Other, specify",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969749","Were Molecular Abnormalities Detected","C160766","A question about whether molecular abnormalities were detected.","Were Molecular Abnormalities Detected | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969748","Molecular Abnormalities Detected","C160767","A response that molecular abnormalities were detected.","Molecular Abnormalities Detected | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969747","Molecular Abnormalities Not Detected","C160768","A response that molecular abnormalities were not detected.","Molecular Abnormalities Not Detected | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969198","Interleukin-2 Intralesional Regimen","C160060","A regimen consisting of intralesional aldesleukin (recombinant human interleukin-2) that may be used in the treatment of cutaneous melanoma.","Aldesleukin Intralesional Regimen | Interleukin-2 Intralesional Regimen | Intralesional Aldesleukin Regimen | Intralesional IL-2 Regimen | Intralesional Interleukin-2 Regimen | Intralesional Proleukin Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969213","Intralesional BCG Regimen","C160061","A regimen consisting of intralesional Bacillus Calmette-Guerin (BCG) that may be used in the treatment of cutaneous melanoma.","Intralesional BCG Regimen | BCG Intralesional Regimen | Bacillus Calmette-Guerin Intralesional Regimen | Intralesional Bacillus Calmette-Guerin Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969259","Not Known if Additional Testing Was Performed","C160303","An indication that it is not known whether additional tests were performed during the study.","Not Known if Additional Testing Was Performed | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969258","10q23/PTEN Locus Deletion Analysis Was Not Performed","C160304","An indication that 10q23/PTEN deletion analysis was not performed during the study.","10q23/PTEN Locus Deletion Analysis Was Not Performed | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969257","10q23/PTEN Locus Deletion Analysis Was Performed","C160305","An indication that 10q23/PTEN deletion analysis was performed during the study.","10q23/PTEN Locus Deletion Analysis Was Performed | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3845265","10q23/PTEN Locus Deletion Negative","C160306","A genetic finding indicating that deletion of 10q23/PTEN has not been detected in a sample.","10q23/PTEN Locus Deletion Negative | Negative | None detected | del(10q23)/PTEN Gene Locus Deletion Negative | del(1p/19q) Negative | del10q23/Phosphatase and Tensin Homolog Gene Locus Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969256","Unknown Procedure Type for New Tumor Event","C160307","The surgical procedure for the new tumor event is unknown","Unknown Procedure Type for New Tumor Event | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969255","1p/19q Deletion Analysis Was Not Performed","C160308","An indication that 1p/19q deletion analysis was not performed during the study.","1p/19q Deletion Analysis Was Not Performed | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969254","1p/19q Deletion Analysis Was Performed","C160309","An indication that 1p/19q deletion analysis was performed during the study.","1p/19q Deletion Analysis Was Performed | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516245","Carbogen Breathing","C16030","Increases the oxygenation of tumors thereby enhancing the effect of radiation therapy.","Carbogen Breathing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969448","Additional Immunohistochemistry Was Not Performed","C160310","An indication that additional immunohistochemical tests were not performed during the study.","Additional Immunohistochemistry Was Not Performed | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969447","Additional Immunohistochemistry Was Performed","C160311","An indication that additional immunohistochemical tests were performed during the study.","Additional Immunohistochemistry Was Performed | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969446","Additional Molecular Studies Were Not Performed","C160312","An indication that additional molecular tests were not performed during the study.","Additional Molecular Studies Were Not Performed | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969444","Mutation Analysis Was Not Performed","C160314","An indication that mutation analysis was not performed during the study.","Mutation Analysis Was Not Performed | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969442","ALK Rearrangement Analysis","C160316","A procedure used to detect and identify rearrangements involving the ALK gene.","ALK Rearrangement Analysis | ALK Gene Rearrangement Analysis | ALK Gene Rearrangement Status | ALK Rearrangement | Anaplastic Lymphoma Kinase Gene Rearrangement Analysis | Anaplastic Lymphoma Receptor Tyrosine Kinase Gene Rearrangement Analysis | CD246 Gene Rearrangement Analysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969730","Low-dose Cytarabine Regimen","C160806","A regimen consisting of low-dose cytarabine that may be used in the treatment of acute myeloid leukemia (AML).","Low-dose Cytarabine Regimen | LD-AraC Regimen | LDAC Regimen | LoDAC | Low Dose Ara-C Regimen | Low-dose AraC Regimen | Low-dose Cytarabine monotherapy (LoDAC)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969729","Niraparib Regimen","C160807","A regimen consisting of niraparib tosylate monohydrate that may be used as maintenance therapy in the treatment of certain recurrent ovarian, fallopian tube, or primary peritoneal cancers.","Niraparib Regimen | Niraparib monotherapy | Zejula Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969728","Palbociclib Regimen","C160808","A regimen consisting of palbociclib that may be used in the treatment of well-differentiated/dedifferentiated liposarcoma.","Palbociclib Regimen | Ibrance Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969727","Pegfilgrastim Regimen","C160809","A regimen consisting of pegfilgrastim that may be used in the prevention of febrile neutropenia; in the harvest of peripheral blood stem cells (PBSCs); and in the symptomatic management of neutropenic disorders.","Pegfilgrastim Regimen | Neulasta Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1515089","Surgical Management","C16080","Postoperative care of surgery patients.","Surgical Management | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969726","Pralatrexate Regimen","C160810","A regimen consisting of pralatrexate that may be used in the treatment of T-cell lymphomas, mycosis fungoides/Sezary syndrome, and primary cutaneous CD30+ T-cell lymphoproliferative disorders. Low-dose pralatrexate regimen and standard-dose pralatrexate regimen may be used for the treatment of mycosis fungoides/Sezary syndrome.","Pralatrexate Regimen | Folotyn Regimen | Pralatrexate monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969725","Romidepsin Regimen","C160811","A regimen consisting of romidepsin that may be used in the treatment of T-cell lymphomas, and mycosis fungoides and Sezary syndrome.","Romidepsin Regimen | Istodax Regimen | Romidepsin monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969724","Rucaparib Regimen","C160812","A regimen consisting of rucaparib that may be used in the treatment of uterine sarcoma, pancreatic adenocarcinoma, castration-resistant, metastatic prostate cancer, and recurrent ovarian, fallopian tube, or primary peritoneal cancers.","Rucaparib Regimen | Rubraca Regimen | Rucaparib monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969737","Sipuleucel-T Regimen","C160813","An autologous cellular immunotherapy regimen that may be used in the treatment of metastatic, hormone refractory prostate cancer.","Sipuleucel-T Regimen | Provenge Regimen | Sipuleucel-T monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969736","Talimogene Laherparepvec Regimen","C160814","A regimen consisting of talimogene laherparepvec that may be used in the treatment of recurrent, unresectable, cutaneous, subcutaneous, and nodal melanoma lesions.","Talimogene Laherparepvec Regimen | Imlygic Regimen | T-VEC Regimen | Talimogene laherparepvec monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969734","Prostate Acinar Microcystic Adenocarcinoma","C160817","Acinar prostate adenocarcinoma characterized by the presence of microcystic foci in radical prostatectomy specimens.","Prostate Acinar Microcystic Adenocarcinoma | Prostate Acinar Adenocarcinoma, Microcystic Variant | Prostate Microcystic Adenocarcinoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969184","Peginterferon Alfa-2a Regimen","C160106","A regimen consisting of peginterferon alfa-2a that may be used in the treatment of myeloproliferative neoplasms, primary cutaneous anaplastic large cell lymphoma (ALCL) with multifocal lesions, systemic mastocytosis, hairy cell leukemia, and mycosis fungoides/Sezary syndrome.","Peginterferon Alfa-2a Regimen | Pegasys Regimen | Peginterferon alfa-2a monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937321","Nodule Shape","C157673","A description about the radiologic shape of a nodule.","Nodule Shape | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936875","Endoscope Distal Attachment Cap","C157256","A transparent cap for the end of an endoscope designed to maintain a constant distance between the endoscope and the mucosa to increase the detection of visible lesions.","Endoscope Distal Attachment Cap | Disposable Distal Attachment Cap | Distal Attachment | Distal Attachment Cap | Olympus Disposable Distal Attachment Cap",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936868","Anti-CD123/CD3 Bispecific Antibody APVO436","C157257","An immunoglobulin Fc-modified bispecific monoclonal antibody against the tumor-associated antigen (TAA) CD123 and the human T-cell surface antigen CD3 bispecific monoclonal antibody, with potential immunostimulatory and antineoplastic activities. Upon administration, mipletamig simultaneously binds to both CD3-expressing T-cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This results in the activation and proliferation of T-cells and causes CTL-mediated cell lysis of CD123-expressing tumor cells. CD123, the interleukin-3 receptor alpha chain, is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells. The Fc domain on the antibody prolongs the half-life of the bispecific antibody. Compared to some other CD123 x CD3 targeting bispecific antibodies, mipletamig causes less cytokine release upon T-cell stimulation.","Mipletamig | APVO 436 | APVO-436 | APVO436 | Anti-CD123 x Anti-CD3 Bispecific Antibody APVO436 | Anti-CD123/CD3 Bispecific Antibody APVO436 | Anti-CD123/CD3 Bispecific Antibody APVO436 | Bispecific Anti-CD123 x Anti-CD3 Antibody APVO436 | CD123 x CD3 Targeting Bispecific Antibody APVO436 | MIPLETAMIG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936869","B-Cell CLL/Lymphoma 7 Protein Family Member B","C157258","B-cell CLL/lymphoma 7 protein family member B (202 aa, ~22 kDa) is encoded by the human BCL7B gene. This protein plays a role in chromatin remodeling and apoptotic signaling.","B-Cell CLL/Lymphoma 7 Protein Family Member B | Allergen Hom S 3 | B-Cell CLL/Lymphoma 7B | BCL Tumor Suppressor 7B | BCL7B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936870","BCL7C Gene","C157259","This gene may be involved in apoptosis and nucleosome structure.","BCL7C Gene | BCL7C | BCL7C, BAF Complex Component Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936871","BCL7C wt Allele","C157260","Human BCL7C wild-type allele is located in the vicinity of 16p11.2 and is approximately 61 kb in length. This allele, which encodes B-cell CLL/lymphoma 7 protein family member C protein, may play a role in apoptosis and nucleosome remodeling.","BCL7C wt Allele | B-Cell CLL/Lymphoma 7C Gene | BCL Tumor Suppressor 7C Gene | BCL7C, BAF Complex Component wt Allele",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936864","B-Cell CLL/Lymphoma 7 Protein Family Member C","C157261","B-cell CLL/lymphoma 7 protein family member C (217 aa, ~23 kDa) is encoded by the human BCL7C gene. This protein may be involved in nucleosome remodeling and apoptosis.","B-Cell CLL/Lymphoma 7 Protein Family Member C | B-Cell CLL/Lymphoma 7C | BCL Tumor Suppressor 7C | BCL7C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969746","Molecular Abnormalities Unknown","C160769","A response that it is unknown if molecular abnormalities were detected.","Molecular Abnormalities Unknown | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969027","Histrelin Regimen","C160049","A regimen consisting of histrelin that may be used in the treatment of prostate cancer.","Histrelin Regimen | Histrelin Acetate Regimen | Histrelin monotherapy | Vantas Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969026","Hydroxyurea Regimen","C160050","A regimen consisting of hydroxyurea that may be used in the treatment of myeloproliferative neoplasms, acute myeloid leukemia (AML), and Langerhans cell histiocytosis (LCH).","Hydroxyurea Regimen | Droxia Regimen | HU Regimen | Hydrea Regimen | Hydroxyurea monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969025","Ibrutinib Regimen","C160051","A regimen consisting of ibrutinib that may be used in the treatment of mantle cell lymphoma, Waldenstrom's macroglobulinemia (WM), lymphoplasmacytic lymphoma (LPL), diffuse large B-cell lymphoma (DLBCL), gastric MALT lymphoma, nongastric MALT lymphoma, nodal marginal zone lymphoma, extranodal marginal zone lymphoma of nongastric sites and the stomach, splenic marginal zone lymphoma, hairy cell leukemia, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and central nervous system (CNS) cancers.","Ibrutinib Regimen | Ibrutinib monotherapy | Imbruvica Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969024","Idelalisib Regimen","C160052","A regimen consisting of idelalisib that may be used in the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).","Idelalisib Regimen | Idelalisib monotherapy | Zydelig Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969205","Ifosfamide Regimen","C160053","A regimen consisting of ifosfamide that may be used in the treatment of bladder, bone, cervical, endometrial, ovarian, fallopian tube and primary peritoneal cancers; soft tissue and uterine sarcomas; and malignant thymomas and thymic carcinomas.","Ifosfamide Regimen | Ifex Regimen | Ifosfamide monotherapy | Ifosfamide/Mesna",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969204","Imatinib Regimen","C160054","A regimen consisting of imatinib that may be used in the treatment of bone cancer, acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), pigmented villonodular synovitis (PVNS), dermatofibrosarcoma protuberans (DFSP), AIDS-related Kaposi sarcoma, cutaneous melanoma, systemic mastocytosis, tenosynovial giant cell, gastrointestinal (GI) stromal, and desmoid tumors (aggressive fibromatoses), other myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes, and myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) overlap neoplasms.","Imatinib Regimen | Gleevec Regimen | Imatinib Mesylate Regimen | Imatinib monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969203","Interferon alfa-2b Regimen","C160055","A regimen consisting of interferon (IFN) alfa-2b that may be used in the treatment of bone cancer; AIDS-related Kaposi sarcoma; desmoid tumors (aggressive fibromatoses); neuroendocrine tumors (NET) of the gastrointestinal (GI) tract, lung, and thymus; myeloproliferative neoplasms; and systemic mastocytosis.","Interferon alfa-2b Regimen | IFN alfa-2b Regimen | Interferon alfa-2b monotherapy | Intron A Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969202","Intra-CSF Interferon Alfa-2b Regimen","C160056","A regimen consisting of intra-cerebrospinal fluid (CSF) interferon (IFN) alfa-2b that may be used in the treatment of leptomeningeal metastases.","Intra-CSF Interferon Alfa-2b Regimen | Intra-CSF IFN alfa-2b Regimen | Intra-CSF Intron A Regimen | Intra-cerebrospinal Fluid Interferon alfa-2b Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969201","Intra-CSF MTX Regimen","C160057","A regimen consisting of intra-cerebrospinal fluid (CSF) methotrexate that may be used in the treatment of leptomeningeal metastases.","Methotrexate Intra-Cerebrospinal Fluid Regimen | Intra-CSF MTX Regimen | Intra-CSF Methotrexate Regimen | Intra-cerebrospinal Fluid Methotrexate Regimen | Methotrexate Intra-CSF Regimen | Methotrexate Intra-cerebrospinal Fluid Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969200","Intra-CSF Thiotepa Regimen","C160058","A regimen consisting of intra-cerebrospinal fluid (CSF) thiotepa that may be used in the treatment of leptomeningeal metastases.","Intra-CSF Thiotepa Regimen | Intra-cerebrospinal Fluid Thiotepa Regimen | Intrathecal Thiotepa Regimen | Thiotepa Intra-CSF Regimen | Thiotepa Intrathecal Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969199","Intra-CSF Topotecan Regimen","C160059","A regimen consisting of intra-cerebrospinal fluid (CSF) topotecan that may be used in the treatment of leptomeningeal metastases.","Intra-CSF Topotecan Regimen | Intra-CSF Topotecan HCl Regimen | Intra-CSF Topotecan Hydrochloride Regimen | Intra-cerebrospinal Fluid Topotecan Regimen | Intrathecal Topotecan Regimen | Topotecan Intra-CSF Regimen | Topotecan Intrathecal Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518316","New Agents","C16005","Research into new physical or chemical means to treat disease.","New Agents | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969441","ALK Rearrangement Analysis Was Not Performed","C160317","An indication that ALK rearrangement analysis was not performed during the study.","ALK Rearrangement Analysis Was Not Performed | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969456","ALK Rearrangement Analysis Was Performed","C160318","An indication that ALK rearrangement analysis was performed during the study.","ALK Rearrangement Analysis Was Performed | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969455","ANO1 Negative","C160319","An indication that expression of ANO1 has not been detected in a sample.","ANO1 Negative | Anoctamin-1 Negative | DOG1 Negative | Negative | ORAOV2 Negative | TAOS2 Negative | TMEM16A Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1518989","Perioperative Adjuvant Therapy","C16031","Treatment given at the time of an operation to augment the effects of the operation.","Perioperative Adjuvant Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969454","ANO1 Positive","C160320","An indication that expression of ANO1 has been detected in a sample.","ANO1 Positive | Anoctamin-1 Positive | DOG1 Positive | ORAOV2 Positive | Positive | TAOS2 Positive | TMEM16A Positive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969475","Abiraterone/Goserelin/Prednisone Regimen","C160543","A regimen consisting of abiraterone, goserelin, and prednisone that may be used in the treatment of certain types of prostate carcinoma.","Abiraterone/Goserelin/Prednisone Regimen | Abiraterone-Goserelin-Prednisone | Abiraterone/Goserelin/Prednisone | Zytiga/Zoladex/Deltasone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969474","Abiraterone/Leuprolide/Prednisone Regimen","C160544","A regimen consisting of abiraterone, leuprolide, and prednisone that may be used in the treatment of certain types of prostate carcinoma.","Abiraterone/Leuprolide/Prednisone Regimen | Abiraterone-Leuprolide-Prednisone | Abiraterone/Leuprolide/Prednisone | Zytiga/Lupron/Deltasone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969473","BDR Regimen","C160545","A regimen consisting of bortezomib, dexamethasone, and rituximab that may be used in the treatment of Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma, Castleman disease, and mantle cell lymphoma.","BDR Regimen | BDR | BDR (rituximab-abbs) | BDR (rituximab-arrx) | BDR (rituximab-blit) | BDR (rituximab-pvvr) | BDR (rituximab-rite) | BDR (rituximab-rixa) | BDR (rituximab-rixi) | BORID | Bortezomib-Dexamethasone-Rituximab | Bortezomib/Dexamethasone + Rituximab | Bortezomib/Dexamethasone Plus Rituximab | Bortezomib/Dexamethasone/Rituximab | Bortezomib/Dexamethasone/Rituximab Regimen | Velcade/Decadron/Rituxan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1831652","bortezomib/dexamethasone/thalidomide","C160546","A regimen consisting of bortezomib, thalidomide, and dexamethasone that may be used in the treatment of plasma cell (multiple) myeloma.","VTD Regimen | Bortezomib-Thalidomide-Dexamethasone | Bortezomib/Dexamethasone/Thalidomide | Bortezomib/Thalidomide/Dexamethasone | Bortezomib/Thalidomide/Dexamethasone Regimen | VDT | VTD | Velcade/Immunoprin/Decadron | Velcade/Thalidomide/Dexamethasone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969487","Abemaciclib/Fulvestrant/Leuprolide Regimen","C160547","A regimen consisting of abemaciclib, fulvestrant, and leuprolide that may be used in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer in premenopausal women.","Abemaciclib/Fulvestrant/Leuprolide Regimen | Abemaciclib-Fulvestrant-Leuprolide | Abemaciclib/Fulvestrant/Leuprolide | Verzenio/Faslodex/Lupron",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969486","Ibrutinib-Bendamustine-Rituximab","C160548","A regimen consisting of ibrutinib, bendamustine and rituximab that may be used in the treatment of certain types of relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).","BR-Ibrutinib Regimen | Bendamustine and Rituximab (BR) and Ibrutinib | Bendamustine and Rituximab-abbs (BR) and Ibrutinib | Bendamustine and Rituximab-arrx (BR) and Ibrutinib | Bendamustine and Rituximab-blit (BR) and Ibrutinib | Bendamustine and Rituximab-pvvr (BR) and Ibrutinib | Bendamustine and Rituximab-rite (BR) and Ibrutinib | Bendamustine and Rituximab-rixa (BR) and Ibrutinib | Bendamustine and Rituximab-rixi (BR) and Ibrutinib | Bendamustine/Ibrutinib/Rituximab | Ibrutinib-Bendamustine-Rituximab | Ibrutinib/Bendamustine + Rituximab | Ibrutinib/Bendamustine Plus Rituximab | Ibrutinib/Bendamustine/Rituximab | Ibrutinib/Bendamustine/Rituximab Regimen | Imbruvica/Treanda/Rituxan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969485","Bendamustine/Idelalisib/Rituximab Regimen","C160549","A regimen consisting of bendamustine, idelalisib and rituximab that can be used in the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL).","Bendamustine/Idelalisib/Rituximab Regimen | BR and Idelalisib | Bendamustine and Rituximab (BR) and Idelalisib | Bendamustine and Rituximab-abbs (BR) and Idelalisib | Bendamustine and Rituximab-arrx (BR) and Idelalisib | Bendamustine and Rituximab-blit (BR) and Idelalisib | Bendamustine and Rituximab-pvvr (BR) and Idelalisib | Bendamustine and Rituximab-rite (BR) and Idelalisib | Bendamustine and Rituximab-rixa (BR) and Idelalisib | Bendamustine and Rituximab-rixi (BR) and Idelalisib | Bendamustine/Idelalisib/Rituximab | IBR | IBR Regimen | Idelalisib/Bendamustine/Rituximab | Idelalisib/Bendamustine/Rituximab Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL448309","Drug Synthesis and Chemistry Branch","C16054","A branch of the Developmental Therapeutics Program of the National Cancer Institute. It is responsible for activities that support the discovery and development of novel anti-cancer agents, including management of the storage, inventory, documentation, and distribution of samples for research purposes; and synthesis of cold and radiolabelled compounds for in vivo studies and anti-angiogenesis standards.","Drug Synthesis and Chemistry Branch | Drug Synthesis | Drug Synthesis and Chemistry",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969183","Pegintron Regimen","C160107","A regimen consisting of peginterferon alfa-2b that may be used in the treatment of myeloproliferative neoplasms and systemic mastocytosis.","Peginterferon Alfa-2b Regimen | Peginterferon alfa-2b monotherapy | Pegintron Regimen | Sylatron Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969197","Pemetrexed Regimen","C160109","A regimen consisting of pemetrexed that may be used in the treatment of primary central nervous system (CNS) lymphoma; malignant peritoneal and pleural mesothelioma; bladder, cervical, non-small cell lung, ovarian, fallopian tube, and primary peritoneal cancers; and thymomas and thymic carcinomas.","Pemetrexed Regimen | Alimta Regimen | Pemetrexed Disodium Regimen | Pemetrexed monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519203","Scientist Exchange Program","C16010","Office of International Activities sponsors two international scientist exchange programs: Short-Term Scientist Exchange Program and Oncology Research Faculty Development Program","Scientist Exchange Program | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969196","Pomalidomide Regimen","C160110","A regimen consisting of pomalidomide that may be used in the treatment of Kaposi sarcoma, primary central nervous system (CNS) lymphoma and plasma cell (multiple) myeloma.","Pomalidomide Regimen | Pomalidomide monotherapy | Pomalyst Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969195","Ponatinib Regimen","C160111","A regimen consisting of ponatinib that may be used in the treatment of chronic myeloid leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), gastrointestinal stromal tumors (GIST), and myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes.","Ponatinib Regimen | Iclusig Regimen | Ponatinib HCl Regimen | Ponatinib Hydrochloride Regimen | Ponatinib monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969194","Ramucirumab Regimen","C160112","A regimen consisting of ramucirumab that may be used in the treatment of esophageal, gastric, gastroesophageal junction and hepatobiliary cancers.","Ramucirumab Regimen | Cyramza Regimen | Ramucirumab monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969193","Regorafenib Regimen","C160113","A regimen consisting of regorafenib that may be used in the treatment of appendiceal adenocarcinoma, colorectal and hepatobiliary cancers, bone cancer, central nervous system (CNS) cancers, soft tissue sarcoma, and gastrointestinal stromal tumors (GISTs).","Regorafenib Regimen | Regorafenib monotherapy | Stivarga Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969192","Rituximab and Hyaluronidase Human Regimen","C160114","A regimen consisting of a fixed-dose combination of rituximab and human hyaluronidase that may be used in the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic, follicular, diffuse large B-cell and primary cutaneous B-cell lymphomas, hairy cell leukemia, Waldenstrom macroglobulinemia or lymphoplasmacytic lymphoma, and nodular lymphocyte-predominant Hodgkin lymphoma.","Rituximab and Hyaluronidase Human Regimen | Rituxan Hycela Regimen | Rituximab and Human Hyaluronidase | Rituximab and Human Hyaluronidase Regimen | Rituximab and hyaluronidase monotherapy | Rituximab/Hyaluronidase Human Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969191","Rituximab Regimen","C160115","A regimen consisting of rituximab that may be used in the treatment of acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and hairy cell leukemia, mantle cell, small lymphocytic, diffuse large B-cell, primary cutaneous B-cell, classic follicular, central nervous system (CNS), nodal marginal zone, splenic marginal zone, and mucosa-associated lymphoid tissue (MALT) lymphomas, extranodal marginal zone lymphoma of nongastric sites (noncutaneous) and the stomach, Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma, nodular lymphocyte-predominant Hodgkin lymphoma, and post-transplant lymphoproliferative disorders.","Rituximab Regimen | Rituxan Regimen | Rituximab monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969190","Ruxolitinib Regimen","C160116","A regimen consisting of ruxolitinib that may be used in the treatment of myeloproliferative neoplasms, myelodysplastic/myeloproliferative neoplasm (MDS/MPN), myeloid or lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes, T-cell lymphoma, T-cell prolymphocytic leukemia and T-cell large granular lymphocytic leukemia.","Ruxolitinib Regimen | Jakafi Regimen | Ruxolitinib Phosphate Regimen | Ruxolitinib monotherapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969143","Sirolimus Regimen","C160117","A regimen consisting of sirolimus that may be used in the treatment of Kaposi sarcoma, uterine sarcoma, kidney cancer, perivascular epithelioid cell tumors (PEComas), angiomyolipomas and lymphangioleiomyomatosis (LAM).","Sirolimus Regimen | Rapamune Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936865","pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0","C157262","A whole cell cancer vaccine composed of irradiated autologous whole tumor cells that are transfected, ex vivo, with a plasmid DNA encoding the highly immunogenic Streptococcus pyogenes (S. pyogenes) bacterial antigen Emm55, with potential immunostimulating and antineoplastic activities. Upon intralesional administration of IFx-Hu2.0, the tumor cells expressing the Emm55 bacterial antigen on their cell surface are taken up and processed by antigen-presenting cells (APCs), thereby presenting both the Emm55 and the patient-specific tumor-associated antigens (TAAs) to the immune system. This activates the immune system to elicit a tumor antigen-specific cytotoxic T-lymphocyte (CTL)-mediated immune response against the tumor cells expressing the TAAs.","pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0 | Autologous Cancer Cell-transfected with Plasmid DNA Encoding for Emm55 Streptococcal Antigen IFx-Hu2.0 | IFx-Hu2.0 | ImmuneFx | Plasmid DNA Autologous Cancer Vaccine IFx-Hu2.0 | Plasmid DNA Vaccine Encoding S. pyogenes Emm55 Protein | pDNA Autologous Cancer Cell Vaccine IFx-Hu2.0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936866","BRD7 Gene","C157263","This gene plays a role in SWI/SNF complex-dependent chromatin remodeling, Wnt signaling and p53-mediated cell cycle arrest.","BRD7 Gene | BRD7 | Bromodomain Containing 7 Gene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936867","BRD7 wt Allele","C157264","Human BRD7 wild-type allele is located in the vicinity of 16q12.1 and is approximately 55 kb in length. This allele, which encodes bromodomain-containing protein 7, is involved in Wnt signaling, p53-mediated G1 to S phase arrest and chromatin remodeling.","BRD7 wt Allele | BP75 | Bromodomain Containing 7 wt Allele | Bromodomain Protein, 75-kD Gene | Bromodomain-Containing 7 Gene | CELTIX1 | NAG4",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936862","Bromodomain-Containing Protein 7","C157265","Bromodomain-containing protein 7 (651 aa, ~74 kDa) is encoded by the human BRD7 gene. This protein plays a role in p53-dependent G1/S phase arrest, SWI/SNF-mediated chromatin remodeling and Wnt signaling.","Bromodomain-Containing Protein 7 | 75 kDa Bromodomain Protein | BRD7 | Protein CELTIX-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3554496","LEFT VENTRICULAR NONCOMPACTION 7","C157266","An autosomal dominant sub-type of left ventricular noncompaction syndrome caused by heterozygous mutation(s) of the MIB1 gene, encoding E3 ubiquitin-protein ligase MIB1.","Left Ventricular Noncompaction 7 | LVNC7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969816","Other Pathologic Findings","C160710","A response that indicates pathologic findings were present other than those on the form.","Other Pathologic Findings | Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969815","Autologous Anti-CS1 Hinge-optimized CAR-4-1BB-EGFRt-expressing Memory-enriched T-cells","C160711","A preparation of autologous central memory-enriched T-cells (Tcm) that have been transduced with a self-inactivating (SIN) lentiviral vector expressing a hinge-optimized chimeric antigen receptor (CAR) comprised of a CS1 (CD2 subset 1; SLAM family member 7; SLAMF7; CD319; CRACC)-specific single chain variable fragment (scFV), fused to the costimulatory signaling domain of 4-1BB (CD137), and a truncated human epidermal growth factor receptor (huEGFRt), with potential antineoplastic activity. Upon intravenous infusion, anti-CS1-CAR-4-1BB-CD3z-EGFRt-expressing Tcm-enriched T-lymphocytes target and induce selective toxicity in CS-1-expressing tumor cells. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed huEGFRt facilitates both in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) response. CS1, a cell surface glycoprotein of the signaling lymphocyte activation molecule (SLAM) receptor family, is highly expressed on certain malignant plasma cells.","Autologous Anti-CS1 Hinge-optimized CAR-4-1BB-EGFRt-expressing Memory-enriched T-cells | Anti-CS1 Hinge-optimized CAR-4-1BB-EGFRt-expressing Memory-enriched Autologous T-cells | Anti-CS1 Hinge-optimized CAR-4-1BB-EGFRt-expressing Memory-enriched Autologous T-lymphocytes | Autologous Anti-CS1 Hinge-optimized CAR-4-1BB-EGFRt-expressing Memory-enriched T-lymphocytes | CS1-CAR T-cells | CS1-CAR T-lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969814","Bushen Culuan Decoction","C160712","A traditional Chinese medicine (TCM) decoction containing a mixture of ten Chinese herbs including Tusizi, Yinyanghuo, Xianmao, Xuduan, Gouqizi, Nvzhenzi, Zelan, Shengpuhuang, Xiangfu and Chuanshanlong, with potential to induce ovulation. Upon oral administration, Bushen Culuan decoction may, through a not yet fully elucidated mechanism, depress follicle-stimulating hormone (FSH) levels, elevate anti-Mullerian hormone (AMH) levels, and increase the number of antral follicle counts (AFCs), thereby promoting ovulation.","Bushen Culuan Decoction | Bushen Culuan TCM Decoction | Bushen Culuan Traditional Chinese Medicine Decoction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0198069","Ear Pinning","C157832","Reshaping or suturing of the ear(s) to lie flatter against the head.","Ear Pinning | ",,,,,,,,,,,,,,,"4179780","Setback of ear",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0186599","Elbow Arthroscopy","C157833","A procedure to examine the elbow joint via an arthroscope.","Elbow Arthroscopy | ",,,,,,,,,,,,,,,"4112597","Arthroscopy of elbow",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937516","Endometrial Cancer Surgery","C157835","A surgical procedure to remove or destroy cancer in the endometrium.","Endometrial Cancer Surgery | Surgery for Endometrial Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937515","Endoscopic Sinus Surgery","C157836","A surgical procedure on the nasal sinuses with an endoscope.","Endoscopic Sinus Surgery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1700929","Endoscopic Submucosal Dissection","C157837","A surgical procedure on the gastric tract to remove deep tumors via endoscope.","Endoscopic Submucosal Dissection | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937513","Endourologic Procedure","C157838","The use of an endoscopic scope to visualize and treat issues in the urethra, bladder and ureter.","Endourologic Procedure | Endourology",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517570","Intraventricular Infusion Procedure","C15737","No value exists.","Intraventricular Infusion Procedure | Intraventricular Infusion | intraventricular infusion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936991","Live Animal Dosage Form","C157383","A type of pharmaceutical dose form consisting of a whole, live animal used as a medicinal product, which may have a mechanical function and/or deliver physiologically active substances.","Live Animal Dosage Form | Live animal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0438235","Normal Liver Function Test","C157384","A laboratory test result indicating the results of a liver function test are within normal parameters for the age and population.","Normal Liver Function Test | Liver Function Test Normal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969484","Letrozole/Leuprolide/Palbociclib Regimen","C160550","A regimen consisting of letrozole, leuprolide and palbociclib that can be used in the treatment of estrogen receptor (ER)-positive and HER-2/neu-negative metastatic or advanced breast cancer.","Letrozole/Leuprolide/Palbociclib Regimen | Femara/Lupron/Ibrance | Letrozole-Leuprolide-Palbociclib | Letrozole/Leuprolide/Palbociclib",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969482","Bevacizumab/Carboplatin/Gemcitabine Regimen","C160552","A regimen consisting of gemcitabine, carboplatin, and bevacizumab that may be used in the treatment of ovarian, fallopian tube, or primary peritoneal cancer.","Bevacizumab/Carboplatin/Gemcitabine Regimen | Avastin/Paraplatin/Gemzar | Bevacizumab/Carboplatin/Gemcitabine | Carboplatin and Gemcitabine (GCb) and Bevacizumab | Carboplatin and Gemcitabine (GCb) and Bevacizumab-adcd | Carboplatin and Gemcitabine (GCb) and Bevacizumab-awwb | Carboplatin and Gemcitabine (GCb) and Bevacizumab-aybi | Carboplatin and Gemcitabine (GCb) and Bevacizumab-bvzr | Carboplatin and Gemcitabine (GCb) and Bevacizumab-equi | Carboplatin and Gemcitabine (GCb) and Bevacizumab-maly | Carboplatin and Gemcitabine (GCb) and Bevacizumab-onbe | Carboplatin and Gemcitabine (GCb) and Bevacizumab-tnjn | Carboplatin, Gemcitabine, Bevacizumab | Carboplatin, Gemcitabine, Bevacizumab-adcd | Carboplatin, Gemcitabine, Bevacizumab-awwb | Carboplatin, Gemcitabine, Bevacizumab-aybi | Carboplatin, Gemcitabine, Bevacizumab-bvzr | Carboplatin, Gemcitabine, Bevacizumab-equi | Carboplatin, Gemcitabine, Bevacizumab-maly | Carboplatin, Gemcitabine, Bevacizumab-onbe | GC + Bev | GC Plus Bev | Gemcitabine/Carboplatin/Bevacizumab | Gemcitabine/Carboplatin/Bevacizumab Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969480","CCD Regimen","C160554","A regimen consisting of carfilzomib, cyclophosphamide and dexamethasone that can be used in the treatment of plasma cell (multiple) myeloma.","CCD Regimen | CCD | CCd | CCyd | Carfilzomib-Cyclophosphamide-Dexamethasone | Carfilzomib/Cyclophosphamide/Dexamethasone | Carfilzomib/Cyclophosphamide/Dexamethasone Regimen | KCD | KCD Regimen | KCyd | Kyprolis/Cyclophosphamide/Dexamethasone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516473","Childhood Cancer Survivor Study","C16076","An NCI-funded multi-institution project designed to better understand late effects of cancer upon cancer survivors","Childhood Cancer Survivor Study | CCSS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969745","Vascularized Lymph Node Transfer","C160770","A surgical treatment for lymphedema. This involves the microsurgical transfer of lymph node-containing tissue to a lymphedematous limb, which works based on the movement of lymphatic fluid from the affected limb into the transferred lymph node and drainage via the newly anastomosed venous route.","Vascularized Lymph Node Transfer | VLNT",,,,,,,,,,,,,,,"619600","Transfer of vascularized lymph node",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL971250","Coherent Anti-Stokes Raman Spectroscopy","C160771","A nonlinear Raman spectroscopy technique. It uses two very strong collinear lasers to irradiate a sample, instead of the traditional single laser and is orders of magnitude stronger than spontaneous Raman emission.","Coherent Anti-Stokes Raman Spectroscopy | CARS | Coherent anti-Stokes Raman Scattering Spectroscopy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969758","Anti-PD-L1/CD137 Bispecific Antibody MCLA-145","C160772","A full-length, Fc-silenced immunoglobulin G1 (IgG1) bispecific antibody targeting both the human programmed death-ligand 1 (PD-L1) and CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, anti-PD-L1/CD137 bispecific antibody MCLA-145 simultaneously targets and binds to CD137, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes, and PD-L1 expressed on tumor cells, thereby crosslinking PD-L1-expressing tumor cells and T-lymphocytes. Through CD137 binding, MCLA-145 acts as a conditional CD137 agonist, resulting in T-cell co-stimulation and enhanced anti-tumor activity. At the same time, MCLA-145 prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. Crosslinking of PD-L1-expressing tumor cells and activated T-lymphocytes may enhance T-lymphocyte-mediated lysis of PD-L1-expressing tumor cells.","Anti-PD-L1/CD137 Bispecific Antibody MCLA-145 | Anti-PD-L1/4-1BB Bispecific Antibody MCLA-145 | Anti-PD-L1/Anti-CD137 Bispecific Antibody MCLA-145 | MCLA 145 | MCLA-145 | MCLA145",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971212","Progress Notes","C160773","The part of a medical record where healthcare professionals record details to document a patient's clinical status or achievements. They are meant to facilitate communication and coordination among the team, and as a way to document the goals, objectives and the services being provided.","Progress Notes | Clinical Notes | Clinician Notes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937186","Platinum-Resistant Fallopian Tube Carcinoma","C157621","Fallopian tube carcinoma that progresses between one and six months of completing platinum therapy.","Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Fallopian Tube Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937187","Platinum-Resistant Primary Peritoneal Carcinoma","C157622","Primary peritoneal carcinoma that progresses between one and six months of completing platinum therapy.","Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Primary Peritoneal Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C4087471","Metastatic Cholangiocarcinoma","C157623","A cholangiocarcinoma that has metastasized to other anatomic sites.","Metastatic Cholangiocarcinoma | ",,,,,,,,,,,,,,,"37159784","Metastatic cholangiocarcinoma",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937181","Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma","C157624","Histologic transformation of an indolent chronic lymphocytic leukemia to an aggressive diffuse large B-cell lymphoma.","Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937182","Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma","C157625","Histologic transformation of a small lymphocytic lymphoma to an aggressive diffuse large B-cell lymphoma.","Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937177","Chromosome Arm 5q Loss of Heterozygosity","C157627","A molecular abnormality that results in monoallelic loss of function mutations located within the long arm of chromosome 5 (5q).","Chromosome Arm 5q Loss of Heterozygosity | 5q LOH | 5q Loss of Heterozygosity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937178","Chromosome 6 Loss of Heterozygosity","C157628","A molecular abnormality that results in monoallelic loss of function mutations located within chromosome 6.","Chromosome 6 Loss of Heterozygosity | Chromosome 6 LOH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937179","Chromosome 8 Loss of Heterozygosity","C157629","A molecular abnormality that results in monoallelic loss of function mutations located within chromosome 8.","Chromosome 8 Loss of Heterozygosity | Chromosome 8 LOH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1517722","Laparoscopic Colectomy","C15762","Surgical removal of part or all of the colon, using a laparoscope.","Laparoscopic Colectomy | Laparoscopic-Assisted Colectomy | Laparoscopy-Assisted Colectomy | laparoscopic-assisted colectomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937180","177Lu-DOTA-IPN01087","C157630","A radioconjugate consisting of the neurotensin receptor type 1 (NTR1) antagonist, IPN01087 (3BP-227), that is linked, via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and imaging activity during positron emission tomography/computed tomography (PET/CT). Upon administration, lutetium Lu 177 zalsenertant tetraxetan binds to NTR1 expressed on certain tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to NTR1-expressing cells. NTR1, a G-protein coupled receptor, is highly expressed in ductal pancreatic adenocarcinoma but not in normal pancreatic tissue.","Lutetium Lu 177 Zalsenertant Tetraxetan | 177Lu-3BP-227 | 177Lu-DOTA-3BP-227 | 177Lu-DOTA-IPN01087 | 177Lu-IPN01087 | Lutetium Lu 177 DOTA-3BP-227 | Lutetium Lu 177 DOTA-IPN01087 | ZALSENERTANT TETRAXETAN LUTETIUM LU-177",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0001383","Acylation","C157214","The addition of an acyl group to an acceptor molecule.","Acylation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969812","Anti-PD-1 x TIM-3 Bispecific Antibody RO7121661","C160714","A bispecific antibody directed against both the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, lomvastomig simultaneously targets and binds to both TIM-3 and PD-1 expressed on certain T-cells. This blocks the interaction of TIM-3 with some of its physiologic ligands and prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is often co-expressed with PD-1 on tumor-antigen-specific T-cells. Dual checkpoint blockade of PD-1 and TIM-3 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.","Lomvastomig | Anti-PD-1 x TIM-3 Bispecific Antibody RO7121661 | Anti-PD-1/Anti-TIM-3 Bispecific Antibody RO7121661 | Anti-PD-1/TIM-3 Bispecific Antibody RO7121661 | Anti-PD-1/TIM-3 Bispecific Antibody RO7121661 | LOMVASTOMIG | RO 7121661 | RO-7121661 | RO7121661",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969811","Anti-CD137 Agonistic Monoclonal Antibody ADG106","C160715","A human agonistic monoclonal antibody targeting CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating activity. Upon administration, anti-CD137 agonistic monoclonal antibody ADG106 binds to and activates CD137 expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytokine production and promotes T-cell mediated anti-tumor immune responses. CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.","Anti-CD137 Agonistic Monoclonal Antibody ADG106 | 4-1BB-directed Agonistic Monoclonal Antibody ADG106 | ADG 106 | ADG-106 | ADG106 | Anti-4-1BB Agonistic Monoclonal Antibody ADG106 | CD137-directed Agonistic Monoclonal Antibody ADG106",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969853","Every Evening","C160957","Planned or occurring every evening.","Every Evening | EVERY EVENING",,,,,,,,,,,,,,,"4141103","Every evening",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL971177","Never Used Menopausal Hormone Therapy","C160251","A response indicating menopausal hormonal therapy was never used.","Never Used Menopausal Hormone Therapy | Never | Never Used",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969837","Reduced Device Function","C160942","A decrease in the functionality of a device.","Reduced Device Function | Reduced Function",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL524349","Device Status","C160943","The current status of the device.","Device Status | ",,,,,,,,,,,,,,,"37110035|439388","Device status|Device status",,,,,,,,,,,,,"--",,,,,,,,,"--|--"
"CL969850","Reported in Error","C160944","A report was made erroneously.","Reported in Error | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969849","Device Status Unknown","C160945","The status of the device is unknown.","Device Status Unknown | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969848","UDI Entry Method","C160946","The method in which data was obtained about a device.","UDI Entry Method | UDI Entry Type | Unique Device Identifier Entry Method",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL971175","Data Card","C160947","A card which contains data for automatic processing of an item.","Data Card | Card",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969847","Unknown Data Entry Method","C160948","The method of data entry is unknown.","Unknown Data Entry Method | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969846","AIDC UDI","C160949","A method of encoding a UDI (and possibly other information) on a low cost and portable device that can be detected by a computer system.","AIDC UDI | Automatic Identification and Data Capture Unique Device Identifier",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516291","Cardiac Function Study","C16094","The study and analysis of the normal or abnormal functioning of the heart using methods such as echocardiography, exercise stress cardiography, 24-hour Holter EKG and magnetic resonance imaging.","Cardiac Function Study | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969845","Pharmacotherapy Regimens","C160950","A set of concepts that are used as regimens to treat a disease.","Pharmacotherapy Regimens | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969844","Single-agent Therapeutic Regimens","C160951","A course of drug therapy with one agent.","Single-agent Therapeutic Regimens | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936986","BCR-JAK2 Fusion in Hematologic Malignancies","C157387","An extremely rare finding in hematologic malignancies indicating an association with BCR-JAK2 fusion gene that results from t(9;22)(p24;q11.2). Most cases exhibit chronic myelogenous leukemia-type phenotype.","BCR-JAK2 Fusion in Hematologic Malignancies | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936987","Immunomodulatory Imide Drug","C157388","A class of immunomodulatory drugs containing an imide group.","Immunomodulatory Imide Drug | IMiD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936988","Number Used Since Last Visit","C157389","An indication of the number of drugs used during the time since the last visit.","Number Used Since Last Visit | Number of Drugs Used Since Last Visit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0796462","Dyspnea Management","C15738","Treatment to manage or alleviate difficult or painful breathing or shortness of breath.","Dyspnea Management | management of dyspnea",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936981","Number Used at Visit","C157390","An indication of the number of drugs used during the visit.","Number Used at Visit | Number of Drugs Used at Visit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936982","Drug Used at Visit","C157391","An indication that a specified drug was used during a visit.","Drug Used at Visit | Use of Drug at Visit | Used Drug at Visit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936983","Drug Used Since Last Visit","C157392","An indication that a specified drug was used during the time since the last visit.","Drug Used Since Last Visit | Use of drug Since Last Visit | Used Drug Since Last Visit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0406709","Ankyloblepharon-Ectodermal Defects-Cleft Lip/Palate","C157576","An autosomal dominant condition caused by mutation(s) in the TP63 gene, encoding tumor protein 63. It is characterized by congenital ectodermal dysplasia, ankyloblepharon filiforme adnatum, and cleft lip/palate.","Ankyloblepharon-Ectodermal Defects-Cleft Lip/Palate | ",,,,,,,,,,,,,,,"4184126","Hay-Wells syndrome of ectodermal dysplasia",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C1868681","Dystonia 12","C157577","An autosomal dominant condition caused by mutation(s) in the ATP1A3 gene, encoding sodium/potassium-transporting ATPase subunit alpha-3. It is characterized by abrupt onset of dystonia and parkinsonism in young adulthood, often triggered by physical or psychological stress.","Dystonia 12 | DYT12 | Rapid-Onset Dystonia-Parkinsonism",,,,,,,,,,,,,,,"45765396","Rapid onset dystonia parkinsonism",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937279","Anti-PD1/Anti-ICOS Bispecific Monoclonal Antibody XmAb23104","C157578","A humanized, Fc-engineered bispecific monoclonal antibody directed against both the human negative immunoregulatory checkpoint receptor, programmed cell death protein 1 (PD-1; PCD-1; CD279), and inducible T-cell co-stimulator (ICOS; CD278), with potential immunomodulating and antineoplastic activities. Upon administration, izuralimab targets and binds to both PD-1 and ICOS expressed on certain T-cells, including tumor-infiltrating lymphocytes (TILs). This prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2), and stimulates ICOS-mediated signaling, which promotes the activation of T-cells and enhances T-cell-mediated immune responses against tumor cells. Combined PD-1 blockade and ICOS stimulation may enhance T-cell activation and proliferation more than targeting each receptor individually. The engineered Fc domain increases the stability and half-life of the antibody.","Izuralimab | Anti-PD1/Anti-ICOS Bispecific Monoclonal Antibody XmAb23104 | Anti-PD1/ICOS Bispecific Monoclonal Antibody XmAb23104 | IZURALIMAB | PD1 x ICOS Bispecific Monoclonal Antibody XmAb23104 | XmAb 23104 | XmAb-23104 | XmAb23104",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969754","Autologous Anti-CD19/Anti-CD20-CAR-CD28-4-1BB-CD3zeta-EGFRt+-expressing Tn/mem Cells","C160777","A preparation of genetically modified autologous naive/memory T-cells (Tn/mem),  that have been transduced with a self-inactivating (SIN) lentiviral vector to express a bispecific chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) of anti-CD19, derived from the anti-CD19 monoclonal antibody FMC63, in tandem with an anti-CD20 scFv, derived from the anti-CD20 monoclonal antibody Leu16, and fused to the hinge domain of human immunoglobulin (Ig) G4, the transmembrane domain of human CD28, and the cytoplasmic signaling domains of 4-1BB (CD137) and the T-cell antigen receptor complex zeta chain (CD3-zeta) (BBz), and linked via the T2A sequence to a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon transfusion, autologous anti-CD19/anti-CD20-CAR-CD28-4-1BB-CD3zeta-EGFR+-expressing Tn/mem cells recognize and induce selective toxicity in CD19/CD20-expressing tumor cells, resulting in tumor cell lysis. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, EGFRt both facilitates in vivo detection of the administered T-cells and can promote elimination of those cells upon a cetuximab-induced antibody dependent cellular cytotoxicity (ADCC) response.","Autologous Anti-CD19/Anti-CD20-CAR-CD28-4-1BB-CD3zeta-EGFRt+-expressing Tn/mem Cells | Autologous Anti-CD19/20 Bispecific CAR-CD28-BBz-EGFRt+-expressing Tn/mem Cells | Autologous Anti-CD19/20 CAR-CD28-4-1BB-CD3zeta-EGFRt+-expressing Naive and Memory T-lymphocytes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969212","Intralesional Interferon Alfa-2b Regimen","C160062","A regimen consisting of intralesional interferon alfa-2b that may be used in the treatment of cutaneous melanoma.","Intralesional Interferon Alfa-2b Regimen | Interferon Alfa-2b Intralesional Regimen | Intralesional IFN Alfa-2b Regimen | Intralesional Intron A Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969211","Intralesional Imlygic Regimen","C160063","A regimen consisting of intralesional talimogene laherparepvec that may be used in the treatment of cutaneous melanoma and Merkel cell carcinoma.","Talimogene Laherparepvec Intralesional Regimen | Intralesional Imlygic Regimen | Intralesional Talimogene Laherparepvec Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969210","Intralesional Triamcinolone Regimen","C160064","A regimen consisting of intralesional triamcinolone that may be used in the treatment of primary cutaneous B-cell lymphomas.","Intralesional Triamcinolone Regimen | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969209","Intralesional Vinblastine Regimen","C160065","A regimen consisting of intralesional vinblastine that may be used in the treatment of AIDS-related Kaposi sarcoma and desmoid tumors.","Intralesional Vinblastine Regimen | Intralesional Vinblastine Sulfate Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969208","Intrathecal MTX Regimen","C160066","A regimen consisting of intrathecal methotrexate that may be used in the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute lymphoblastic, chronic lymphocytic and acute myeloid leukemias; and diffuse large B-cell and small lymphocytic lymphomas, with central nervous system (CNS) involvement.","Methotrexate Intrathecal Regimen | Intrathecal MTX Regimen | Intrathecal Methotrexate Regimen | Intrathecal Methotrexate Sodium Regimen | Methotrexate Sodium Intrathecal Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969207","Ipilimumab Regimen","C160067","A regimen consisting of ipilimumab that may be used in the treatment of cutaneous and uveal melanoma.","Ipilimumab Regimen | Ipilimumab monotherapy | Yervoy Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969206","Irinotecan Every 14 Days Regimen","C160068","A regimen consisting of irinotecan every 14 days that can be used in the treatment of colorectal cancer, and appendiceal and small bowel adenocarcinoma.","Irinotecan Every 14 Days Regimen | Camptosar Every 14 Days Regimen | Every 14 Days Irinotecan Regimen | Irinotecan HCl Every 14 Days Regimen | Irinotecan Hydrochloride Every 14 Days Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936855","Epoxidation","C157215","The conversion of a carbon-carbon double bond and oxygen, peroxide or peroxyacid into an a cyclic ether with a three-atom ring (epoxide or oxirane).","Epoxidation | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0014895","Esterification","C157216","The process of converting an alcohol and an acid into an ester and water.","Esterification | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936856","Viral Hemagglutinin Purification","C157217","The process used to isolate hemagglutinin from a viral sample.","Viral Hemagglutinin Purification | Viral hemagglutinin purification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936857","Viral Neuraminidase Purification","C157218","The process used to isolate neuraminidase from a viral sample.","Viral Neuraminidase Purification | Viral neuraminidase purification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936851","Viral Envelope Glycoprotein Purification","C157219","The process used to isolate envelope glycoproteins from a viral sample.","Viral Envelope Glycoprotein Purification | Viral envelope glycoproteins purification",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936852","Antigen Cultivation","C157220","The method used to collect and isolate the antigenic proteins or DNA from a pathogen or pathologic sample.","Antigen Cultivation | Antigen Harvesting | Antigen Purification | Antigen cultivation | Antigen generation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936853","Monomer Deletion Process","C157221","The process of removing one or more monomeric units from a polymer.","Monomer Deletion Process | Monomer deletion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936854","Polymer Branch Connection Points","C157222","The chemical structures that make up the head and branch points found between repeating units in a branched polymer.","Polymer Branch Connection Points | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936848","Nucleotide Bond","C157223","The phosphodiester bonds that are formed between nucleotides in a nucleic acid.","Nucleotide Bond | Nucleic Acid Bond",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL936849","Nucleic Acid Variation Site","C157224","The nucleotide position that is substituted in a nucleic acid variant.","Nucleotide Substitution Site | Nucleic Acid Variation Site | Nucleotide Variation Site | Nucleotide substitution point | Nucleotide substitution site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937349","CBDD Terminology","C157225","The Chemical Biology and Drug Development (CBDD) Terminology is a set of terms used in design, development, and description of drug substances, mainly but not exclusively pertaining to the chemistry (including chemical reactions) of small molecules and polymers. The terminology is intended to support the chemoinformatics community's effort to develop conceptual models for describing modern drug design such as performed by the NCI Computer-Aided Drug Design (CADD) Group (part of the NCI Chemical Biology Laboratory) and collaborators at NIH, academia, and other government agencies.","CBDD Terminology | CBDD | CBDD Vocabulary | Chemical Biology and Drug Development Terminology | Chemical Biology and Drug Development Vocabulary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574362","Malayo-Polynesian Language","C160953","An Austronesian language spoken by the Austronesian people of the island nations of Southeast Asia and the Pacific Ocean, with a smaller number in continental Asia.","Malayo-Polynesian Language | ",,,,,,,,,,,,,,,"4183662","Malayo-Polynesian language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL969855","Northwest Caucasian Language","C160954","A group of languages spoken in the northwestern Caucasus region, chiefly in three Russian republics (Adygea, Kabardino-Balkaria, Karachay-Cherkessia), the territory of Abkhazia, and Turkey, with smaller communities scattered throughout the Middle East.","Northwest Caucasian Language | Abkhazo-Adyghean | Circassic | West Caucasian",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574145","Afroasiatic Language","C160955","A large language family of about 300 languages, including languages spoken predominantly in West Asia, North Africa, the Horn of Africa and parts of the Sahel.","Afroasiatic Language | Afrasian Language | Afro-Asiatic Language | Chamito-Semitic | Hamito-Semitic | Semito-Hamitic",,,,,,,,,,,,,,,"4180041","Afro-Asiatic language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL969854","West Germanic Language","C160956","A group of Germanic languages that developed in the region of the North Sea, Rhine-Weser, and Elbe.","West Germanic Language | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969852","Central Tano Language","C160958","Languages of the Niger-Congo family spoken in Ghana and Ivory Coast by the Akan people.","Central Tano Language | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516639","Clinical Trials: Cancer Control","C16095","No value exists.","Clinical Trials: Cancer Control | Cancer Control Trial",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0574300","Indo-European Language","C160962","A family of languages that developed and spread within the Indian subcontinent in the east to its westernmost reach in Europe.","Indo-European Language | ",,,,,,,,,,,,,,,"4181527","Indo-European language",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL969264","Patient was not Postmenopausal with no Prior Oophorectomy","C160248","A response that the patient was not postmenopausal at diagnosis for longer than 12 months since the last menstrual period with no prior oophorectomy or prior bilateral oophorectomy.","Patient was not Postmenopausal with no Prior Oophorectomy | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969263","Currently Using Menopausal Hormone Therapy","C160249","A response indicating current use of menopausal hormonal therapy.","Currently Using Menopausal Hormone Therapy | Current Therapy | Current User",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1510892","Animal Barrier Facility","C16024","A shared facility which maintains a breeding stock of animals in a disease-free state.","Animal Barrier Facility | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969262","Formerly Used Menopausal Hormone Therapy","C160250","A response indicating former use of menopausal hormonal therapy.","Formerly Used Menopausal Hormone Therapy | Former Therapy | Former User",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969261","Unknown Use of Menopausal Hormone Therapy","C160252","A response indicating unknown use of menopausal hormonal therapy.","Unknown Use of Menopausal Hormone Therapy | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969275","Another Form of Birth Control was Used","C160253","A response indicating that another form of birth control was used.","Another Form of Birth Control was Used | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969274","Another Form of Birth Control was not Used","C160254","A response indicating that another form of birth control was not used.","Another Form of Birth Control was not Used | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969221","Irinotecan Every 21 Days Regimen","C160069","A regimen consisting of irinotecan every 21 days that can be used in the treatment of colorectal cancer, and appendiceal and small bowel adenocarcinoma.","Irinotecan Every 21 Days Regimen | Every 21 Days Irinotecan Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1519889","Vaccine Design","C16006","Determining the antigens (whole virus, parts or crossreacting) to be incorporated in a vaccine","Vaccine Design | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969219","Ixabepilone Regimen","C160071","A regimen consisting of ixabepilone that may be used in the treatment of advanced breast cancer.","Ixabepilone Regimen | Ixabepilone monotherapy | Ixempra Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969218","Ixazomib Regimen","C160072","A regimen consisting of ixazomib that may be used in the treatment of systemic light chain (AL) amyloidosis and multiple myeloma.","Ixazomib Regimen | Ixazomib monotherapy | Ninlaro Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969217","Lapatinib Regimen","C160073","A regimen consisting of lapatinib that can be used in the treatment of bone and breast cancers.","Lapatinib Regimen | Lapatinib monotherapy | Tykerb Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969216","Larotrectinib Regimen","C160074","A regimen consisting of larotrectinib that can be used in the treatment of breast, central nervous system (CNS), cervical, colorectal, endometrial, esophageal and esophagogastric junction, gastric, hepatobiliary, ovarian, fallopian tube, primary peritoneal and vulvar cancers, non-small cell lung cancer (NSCLC), gastrointestinal stromal tumors (GIST), salivary gland tumors, Hurthle cell, papillary and follicular carcinomas, cutaneous melanoma, ampullary, ampullary, appendiceal, pancreatic and small bowel adenocarcinomas, soft tissue and uterine sarcoma, anaplastic, occult primary and oncocytic carcinoma, and extrapulmonary poorly differentiated neuroendocrine carcinoma/large or small cell carcinoma/mixed neuroendocrine/non-neuroendocrine neoplasm.","Larotrectinib Regimen | Larotrectinib monotherapy | Vitrakvi Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969215","Lenalidomide Maintenance Regimen","C160075","A regimen consisting of lenalidomide maintenance that may be used in the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), and plasma cell (multiple) myeloma..","Lenalidomide Maintenance Regimen | Revlimid Maintenance Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969214","Lenalidomide Regimen","C160076","A regimen consisting of lenalidomide that can be used in the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), diffuse large B-cell, follicular, (grade 1-2), Hodgkin, mantle cell, T-cell and central nervous system (CNS) lymphomas, plasma cell (multiple) myeloma, myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) overlap neoplasms, Kaposi sarcoma, and Castleman disease.","Lenalidomide Regimen | Lenalidomide monotherapy | Revlimid Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969229","Lenvatinib Regimen","C160077","A regimen consisting of lenvatinib that may be used in the treatment of hepatocellular carcinoma (HCC), salivary gland tumors, thymic, follicular, medullary, papillary, Hurthle cell thyroid and oncocytic carcinomas.","Lenvatinib Regimen | Lenvatinib Mesylate Regimen | Lenvatinib monotherapy | Lenvima Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969453","ATRX Gene Mutation Negative","C160321","A genetic finding indicating that ATRX gene mutations have not been detected in a sample.","ATRX Gene Mutation Negative | ATRX Mutation Negative | ATRX Wild-Type | ATRX Wildtype | ATRX wt | ATRX, Chromatin Remodeler Gene Mutation Negative | Alpha Thalassemia/Mental Retardation Syndrome X-Linked Gene Mutation Negative | Negative | No | RAD54 Gene Mutation Negative | RAD54 Homolog Gene Mutation | RAD54L Gene Mutation Negative | XH2 Gene Mutation Negative | XNP Gene Mutation Negative | ZNF-HX Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969452","ATRX Mutation Analysis Was Not Performed","C160322","An indication that ATRX mutation analysis was not performed during the study.","ATRX Mutation Analysis Was Not Performed | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969450","BAP1 Gene Mutation Negative","C160324","A genetic finding indicating that BAP1 gene mutations have not been detected in a sample.","BAP1 Gene Mutation Negative | BAP1 Mutation Negative | BAP1 Wild-Type | BAP1 Wildtype | BAP1 wt | BRCA1 Associated Protein 1 Gene Mutation Negative | BRCA1-Associated Protein 1 Gene Mutation Negative | Negative | UCHL2 Gene Mutation Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969449","Bone Marrow Aspirate Immunophenotyping and Cytochemistry Were Not Performed","C160325","An indication that immunophenotyping and cytochemistry were not performed on bone marrow aspirates during the study.","Bone Marrow Aspirate Immunophenotyping and Cytochemistry Were Not Performed | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969464","Bone Marrow Aspirate Immunophenotyping and Cytochemistry Were Performed","C160326","An indication that immunophenotyping and cytochemistry were performed on bone marrow aspirates during the study.","Bone Marrow Aspirate Immunophenotyping and Cytochemistry Were Performed | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969463","Bone Marrow Transplantation Performed","C160327","No value exists.","Bone Marrow Transplantation Performed | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937473","Lap Band Surgery","C157899","A laparoscopic procedure in which a band is placed around the stomach to decrease the size of the stomach, which contributes to a fuller feeling and assists with losing weight.","Lap Band Surgery | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1516647","Clinical Trials, Monitoring","C15789","For clinical decision-making, the purposeful and ongoing acquisition, interpretation, and synthesis of patient data obtained from clinical trials.","Clinical Trials, Monitoring | Trial Monitoring | trial monitoring",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937470","Laparoscopic Nissen Fundoplication","C157900","A surgical procedure in which a portion of the upper stomach is wrapped around the lower esophageal sphincter to reinforce it and prevent reflux.","Laparoscopic Nissen Fundoplication | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937471","Laser Resurfacing","C157901","The use of a laser that vaporizes layers of skin to resurface it and remove imperfections and make it smoother.","Laser Resurfacing | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937468","Laser Tattoo Removal","C157902","The use of a laser to break apart the ink in a tattoo, which is then reabsorbed and the tattoo dissolves.","Laser Tattoo Removal | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937469","Laser Vein Treatment","C157903","The use of a laser beam to destroy a vein, which is done either externally or internally when a laser catheter is passed into the vein.","Laser Vein Treatment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937511","Laser Vision Correction","C157904","The use of a laser to change the shape of the cornea to improve vision.","Laser Vision Correction | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937512","Left Atrial Appendage Closure","C157905","Blocking the flow of blood from the appendage in the left atrium to reduce the risk of clots entering the bloodstream.","Left Atrial Appendage Closure | ",,,,,,,,,,,,,,,"37208174","Left atrial appendage closure",,,,,,,,,,,,,"--",,,,,,,,,"--"
"C0038640","Liposuction","C157908","The removal of excess fat deposits from the body.","Liposuction | ",,,,,,,,,,,,,,,"4118090","Liposuction of subcutaneous tissue",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937509","Liver Disease Prevention","C157909","Steps towards preventing damage to the liver which can include vaccinations against hepatitis A and B, healthy diet, regular exercise, moderate alcohol intake, proper use of medications and avoiding contact with other's blood and body fluids.","Liver Disease Prevention | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL556745","Low FODMAP Diet","C157910","A diet that restricts the consumption of fermentable oligo-, di-, mono-saccharides and polyols, which are short chain carbohydrates that are poorly absorbed in the small intestine.","Low FODMAP Diet | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969273","Unknown if Another form of Birth Control was Used","C160255","A response indicating that use of another form of birth control is unknown.","Unknown if Another form of Birth Control was Used | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969272","Specify Another Form of Birth Control that was Used","C160256","A directive to specify another form of birth control that was used.","Specify Another Form of Birth Control that was Used | Other",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969271","BI 894999","C160257","An orally bioavailable inhibitor of the bromodomain and extra-terminal (BET) family of proteins with potential antineoplastic activity. Upon oral administration, amredobresib binds to bromodomain-containing proteins 2, 3, and 4 (BRD2, BRD3, and BRD4) as well as bromodomain testis-specific protein (BRDT), thereby preventing the interaction between BET proteins and acetylated histones. This disrupts chromatin remodeling and suppresses the expression of certain oncogenes, including Myc and other transcriptional regulators. Preventing the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomains at the N-terminus, BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during cellular development and growth.","Amredobresib | 1,2,4-Triazolo(4,3-a)pyrazin-8-amine, N,3-dimethyl-6-(6-(4-methyl-1-piperazinyl)-1-(phenylmethyl)-1hbenzimidazol-2-yl) | 6-(1-Benzyl-6-(4-methylpiperazin-1-yl)-1H-1,3-benzodiazol-2-yl)-N,3-dimethyl-(1,2,4)triazolo(4,3-a)pyrazin-8-amine | AMREDOBRESIB | BET inhibitor BI 894999 | BET inhibitor BI 894999 | BI 894999 | BI-894999 | BI894999",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969270","TGF-beta Receptor 1 Inhibitor PF-06952229","C160258","An orally bioavailable inhibitor of transforming growth factor-beta receptor 1 (TGFbR1), with potential antineoplastic activity. Upon administration, TGF-betaR1 inhibitor PF-06952229 specifically targets and binds to TGFbR1, which prevents TGFbR1-mediated signal transduction. This abrogates TGFbR1-mediated immunosuppression, enhances anti-tumor immunity in the tumor microenvironment (TME) and promotes a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGFbR1-dependent proliferation of cancer cells. The TGFb signaling pathway is often deregulated in tumors and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, and angiogenesis. It plays a key role in immunosuppression in the TME.","TGF-beta Receptor 1 Inhibitor PF-06952229 | PF 06952229 | PF-06952229 | PF06952229 | TGFbR1 Inhibitor PF-06952229",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969268","Former User Tamoxifen","C160260","A response indicating Tamoxifen was used in the past.","Former User Tamoxifen | Former Therapy | Former User",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969283","Never Used Tamoxifen","C160261","A response indicating Tamoxifen has never been taken.","Never Used Tamoxifen | Never Used",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969282","Unknown Tamoxifen Use","C160262","A response indicating unknown Tamoxifen use.","Unknown Tamoxifen Use | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969281","Unknown Number of Full Term Pregnancies","C160263","A response indicating there an unknown number of full term pregnancies.","Unknown Number of Full Term Pregnancies | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969280","Adjuvant Post-operative Radiation Therapy Was Administered","C160264","A response indicating that adjuvant post-operative radiation therapy was administered.","Adjuvant Post-operative Radiation Therapy Was Administered | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0287294","DC-Cholesterol Liposome","C1604","A cationic cholesterol derivative mixed with dimethylaminoethane-carbamoyl and sonicated to form small unilamellar vesicles that can complex with DNA, DNA/protein complexes and other drug complexes and mediates the delivery into the cytosol from the endosome compartment. (NCI)","DC-Cholesterol Liposome | DC-Chol Liposomes | Dimethylaminoethane-carbamoyl-cholesterol Liposomes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969563","TLR8 Agonist DN1508052","C160500","A small molecule Toll-like receptor 8 (TLR8; CD288) agonist with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, TLR8 agonist DN1508052 binds to TLR8, which is expressed in myeloid dendritic cells (mDCs), monocytes, and natural killer (NK) cells. This may lead to the activation of nuclear factor NF-kappa-B, the release of proinflammatory cytokines and a Th1-weighted anti-tumor immune response. Additionally, activation of TLR8 signaling in tumor cells may block the induction and reverse the suppression of senescent naive and tumor-specific T-cells, resulting in enhanced anti-tumor immunity. TLR8, like other TLRs, recognizes pathogen-associated molecular patterns (PAMPs) and plays a key role in innate and adaptive immunity.","TLR8 Agonist DN1508052 | DN A1 | DN-1508052 | DN-A1 | DN1508052 | DN1508052-01 | DNA1 | TLR8 Agonist DN-A1 | TLR8 Agonist DN1508052-01",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0683225","Cytogenetic Map","C15717","The visual appearance of a chromosome when stained and examined under a microscope. Particularly important are visually distinct regions, called light and dark bands, which give each of the chromosomes a unique appearance. This feature allows a person's chromosomes to be studied in a clinical test known as a karyotype, which allows scientists to look for chromosomal alterations. (NHGRI Glossary of Genetic Terms)","Cytogenetic Map | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937514","Endovascular Aneurysm Repair","C157839","The repair of an aneurysm by deploying a graft into the area of the aneurysm via a special endovascular catheter.","Endovascular Aneurysm Repair | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C3504487","Endovascular Stenting","C157840","The repair of an aneurysm by deploying a stent graft into the area of the aneurysm via a special endovascular catheter.","Endovascular Stenting | Endovascular Stent Graft",,,,,,,,,,,,,,,"37163237","Endovascular stent graft",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL969462","BRAF Gene Rearrangement Negative","C160328","A genetic finding indicating that rearrangement of the BRAF gene has not been detected in a sample.","BRAF Gene Rearrangement Negative | B-RAF Gene Rearrangement Negative | B-RAF1 Gene Rearrangement Negative | BRAF Rearrangement Negative | Negative | No rearrangement detected | v-raf Murine Sarcoma Viral Oncogene Homolog B1 Gene Rearrangement Negative",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969461","Bone Marrow Transplantation Not Performed","C160329","No value exists.","Bone Marrow Transplantation Not Performed | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969459","BRAF Mutation Analysis Was Not Performed","C160332","An indication that BRAF mutation analysis was not performed during the study.","BRAF Mutation Analysis Was Not Performed | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969458","BRAF Mutation Analysis Was Performed","C160333","An indication that BRAF mutation analysis was performed during the study.","BRAF Mutation Analysis Was Performed | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969457","BRAF Rearrangement Analysis Was Not Performed","C160334","An indication that BRAF rearrangement analysis was not performed during the study.","BRAF Rearrangement Analysis Was Not Performed | No",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969472","BRAF Rearrangement Analysis Was Performed","C160335","An indication that BRAF rearrangement analysis was performed during the study.","BRAF Rearrangement Analysis Was Performed | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969471","Chemotherapy Received","C160336","No value exists.","Chemotherapy Received | Yes",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969469","Chemotherapy Status Unknown","C160338","No value exists.","Chemotherapy Status Unknown | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969468","Immunotherapy Received","C160339","No value exists.","Immunotherapy Received | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969467","Immunotherapy Not Received","C160340","No value exists.","Immunotherapy Not Received | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969466","Immunotherapy Status Unknown","C160341","No value exists.","Immunotherapy Status Unknown | Unknown",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969419","Pharmacotherapy Not Received","C160343","No value exists.","Pharmacotherapy Not Received | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969418","Pharmacotherapy Status Unknown","C160344","No value exists.","Pharmacotherapy Status Unknown | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969495","CaRD Regimen","C160555","A regimen consisting of carfilzomib, dexamethasone and rituximab that may be used in the treatment of Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma.","CaRD Regimen | CaRD | CaRD (rituximab-abbs) | CaRD (rituximab-arrx) | CaRD (rituximab-blit) | CaRD (rituximab-pvvr) | CaRD (rituximab-rite) | CaRD (rituximab-rixa) | CaRD (rituximab-rixi) | Carfilzomib/Dexamethasone/Rituximab | Carfilzomib/Dexamethasone/Rituximab Regimen | Kyprolis/Decadron/Rituxan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969494","Cyclophosphamide/Dexamethasone/Rituximab Regimen","C160556","A regimen consisting of cyclophosphamide, dexamethasone and rituximab that may be used in the treatment of Waldenstrom macroglobulinemia.","Cyclophosphamide/Dexamethasone/Rituximab Regimen | Cyclophosphamide-Dexamethasone-Rituximab | Cyclophosphamide/Dexamethasone/Rituximab | Cytoxan/Decadron/Rituxan | DRC | DRC (SC rituximab) (rituximab-abbs) | DRC (SC rituximab) (rituximab-arrx) | DRC (SC rituximab) (rituximab-blit) | DRC (SC rituximab) (rituximab-pvvr) | DRC (SC rituximab) (rituximab-rite) | DRC (SC rituximab) (rituximab-rixa) | DRC (SC rituximab) (rituximab-rixi) | DRC (rituximab-abbs) | DRC (rituximab-arrx) | DRC (rituximab-blit) | DRC (rituximab-pvvr) | DRC (rituximab-rite) | DRC (rituximab-rixa) | DRC (rituximab-rixi) | DRC Regimen | Dexamethasone/Rituximab/Cyclophosphamide | Dexamethasone/Rituximab/Cyclophosphamide Regimen | Oral Cyclophosphamide/Dexamethasone Plus Rituximab | Oral Cyclophosphamide/Dexamethasone/Rituximab",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969493","DPd","C160557","A regimen consisting of daratumumab, dexamethasone and pomalidomide that can be used in the treatment of relapsed/refractory plasma cell (multiple) myeloma.","Dara-Pd Regimen | DPd | DPd Regimen | Dara-Pd | Daratumumab-Dexamethasone-Pomalidomide | Daratumumab/Dexamethasone/Pomalidomide | Daratumumab/Dexamethasone/Pomalidomide Regimen | Darzalex/Decadron/Pomalyst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937508","Lower Gastrointestinal Therapeutic Surgical Procedure","C157911","Any surgical treatments on the bowel, which includes the duodenum, jejunum and the ileum.","Lower Gastrointestinal Therapeutic Surgical Procedure | Lower GI Therapeutic Surgical Procedures | OR Lower GI Therapeutic Procedures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937507","Lung Cancer Surgery","C157912","Surgery to minimize or eliminate a neoplastic process in the lungs.","Lung Cancer Surgery | Surgery for Lung Cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C0375931","Lung Volume Reduction Surgery","C157913","Surgery to remove diseased lung tissue, which is often emphysematous. This reduces the size of the lung, and allows expansion of more healthy lung tissue.","Lung Volume Reduction Surgery | ",,,,,,,,,,,,,,,"4323902","Lung volume reduction surgery",,,,,,,,,,,,,"--",,,,,,,,,"--"
"CL937169","Date of Last Targeted Molecular Therapy","C157445","The date of the last targeted molecular therapy.","Date of Last Targeted Molecular Therapy | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937170","Date of Last Immunotherapy Treatment","C157446","The date of the last immunotherapy treatment.","Date of Last Immunotherapy Treatment | ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL937166","Hybrid Argon Plasma Coagulation","C157448","A modification of argon plasma coagulation ablation (APC) that combines APC with submucosal saline injection. The saline is injected beneath the epithelium to create a cushion that protects the underlying tissue from the ablative procedure.","Hybrid Argon Plasma Coagulation | Hybrid APC | Hybrid Argon Plasma Ablation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969562","Ifex/Mesnex/Taxol","C160502","A regimen consisting of ifosfamide, mesna and paclitaxel that can be used in the treatment of uterine, ovarian, fallopian tube, or primary peritoneal cancer, malignant germ cell tumors, malignant sex cord-stromal tumors, and certain carcinosarcomas, such as malignant mixed Müllerian tumors.","Ifosfamide/Paclitaxel Regimen | Ifex/Mesnex/Taxol | Ifosfamide and Paclitaxel | Ifosfamide-Mesna-Paclitaxel | Ifosfamide/Mesna/Paclitaxel | Ifosfamide/Mesna/Paclitaxel Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969561","Abiraterone/Prednisone Regimen","C160503","A regimen consisting of abiraterone and prednisone that can be used for the treatment of prostate cancer and salivary gland tumors.","Abiraterone/Prednisone Regimen | Abiraterone-Prednisone | Abiraterone/Prednisone | Prednisone-Abiraterone | Prednisone-Abiraterone Regimen | Prednisone/Abiraterone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969560","Apalutamide/Degarelix Regimen","C160504","A regimen consisting of apalutamide and degarelix that can be used for the treatment of prostate cancer.","Apalutamide/Degarelix Regimen | Apalutamide-Degarelix | Apalutamide/Degarelix | Degarelix-Apalutamide | Degarelix-Apalutamide Regimen | Degarelix/Apalutamide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969559","Antithymocyte Globulin Rabbit/Tacrolimus Regimen","C160505","A regimen consisting of rabbit antithymocyte globulin and tacrolimus that can be used for the prevention and treatment of acute rejection following organ transplantation.","Antithymocyte Globulin Rabbit/Tacrolimus Regimen | Antithymocyte Globulin (ATG) Rabbit/Tacrolimus | Antithymocyte Globulin Rabbit/Tacrolimus | Rabbit ATG/Tacrolimus | Rabbit Antithymocyte Globulin/Tacrolimus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"C1541558","everolimus/letrozole","C160506","A regimen consisting of everolimus and letrozole that can be used for the treatment of endometrial cancer.","Everolimus/Letrozole Regimen | Everolimus and Letrozole | Everolimus/Letrozole | Letrozole and Everolimus | Letrozole/Everolimus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969511","High-dose Methylprednisolone/Obinutuzumab Regimen","C160507","A regimen consisting of high-dose methylprednisolone and obinutuzumab that can be used for the treatment of chronic lymphocytic leukemia (CLL).","High-dose Methylprednisolone/Obinutuzumab Regimen | HD Methylprednisolone/Obinutuzumab Regimen | HDMP/Obinutuzumab Regimen | High-dose Methylprednisolone/Obinutuzumab | Obinutuzumab/High-Dose Methylprednisolone | Obinutuzumab/High-dose Methylprednisolone Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969510","Cisplatin/Paclitaxel/Intraperitoneal Paclitaxel Regimen","C160508","A regimen consisting of intravenous (IV) paclitaxel, cisplatin, and intraperitoneal (IP) paclitaxel that can be used for the treatment of ovarian, fallopian tube, and primary peritoneal cancers.","Cisplatin/Paclitaxel/Intraperitoneal Paclitaxel Regimen | Cisplatin/IP Paclitaxel/IV Paclitaxel | Cisplatin/Paclitaxel/IP Paclitaxel Regimen | Cisplatin/Paclitaxel/Paclitaxel IP | Cisplatin/Paclitaxel/Paclitaxel IP Regimen",,,,,,,,,,,,,,,,,,,,,,,,,,,,,"--"
"CL969509","Bicalutamide/Degarelix Regimen","C160509","A regimen consisting of bicalutamide and degarelix that can be used for the treatment of prostate cancer.","Bicalutamide/Degarelix Regimen | Bicalutamide-Degarelix | Bicalutamide/Degarelix | Degarelix-Bicalutamide | Degarelix-Bicalutamide Regimen | Degarelix/B